id|nct_id|intervention_type|name|description
223892032|NCT04049539|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223892033|NCT06847893|OTHER|rebozo technique|In accordance with the 'Rebozo Chart' developed by the researcher, the pregnant women in the experimental group were massaged with 4 different rebozo techniques (rebozo technique in hand-knee position, rebozo technique in knee-chest position, umbilical support with rebozo, rebozo technique applied with Pilates ball) in the active phase of labor. After the application, the duration, frequency and cervical dilatation of the pregnant woman were recorded in the chart.
223939792|NCT06733675|DRUG|Ceftibuten|capsules
223939793|NCT06733675|DRUG|Ceftibuten-ledaborbactam etzadroxil|Fixed Dose Combination (FDC)
224081031|NCT05180786|OTHER|Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned on.
224081032|NCT05180786|OTHER|No Error Fields|Participants will complete a reaching experiment using the robotic arm with error fields turned off.
223515713|NCT05837247|OTHER|Game-based telerehabilitation exercises|online Game-based home exercises are physiotherapy programs that include exercises transformed into game activities to increase the child's participation in the rehabilitation process. The exercises were planned such as; the dwarf camel game as squat exercises; the flamingo balance game as single leg balance exercises and weight-bearing activities etc. The exercise program will be conducted for 6 weeks and 3 sessions in a week.
223515714|NCT05837247|OTHER|Home exercises|The physiotherapist will evaluate the control group patients and monitor them using only a home exercise program.
223515715|NCT06184009|DRUG|ALL, High risk|"Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported."
223515716|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 1
223515717|NCT05883748|DRUG|DISC-1459|DISC-1459 dose level 2
223515718|NCT06540118|OTHER|15 Medically Tailored Meals (MTM) per week|15 heart-healthy medically tailored meals delivered to participants each week. Meals include breakfast, lunch, dinner, and snack to consume Monday-Friday.
223515719|NCT06540118|OTHER|14 Medically Tailored Meals (MTM) per week|14 heart-healthy medically tailored meals delivered to participants each week. Meals include lunch and dinner to consume Monday-Sunday.
223515720|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Electrical stimulation (E-stim)|PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets. For treating left-sided neglect, a person wears the prism lenses that shift the visual field, including the images of the target and of one's own reaching arm, certain degrees to the right depending on the diopter of the lens (e.g., the 20-diopter lens shifts the visual field by 11.4 degrees). The visual system adapts over the repetitive practice of the arm reaching toward the target. The person eventually achieves success with a leftward movement reaching the actual target. Electrical stimulation (E-stim) involves parameters and settings commonly used in clinical practice as well as research for pain relief and other applications, commonly referred to as transcutaneous electrical nerve stimulation (TENS). TENS and E-stim are delivered using FDA-approved, commercially available portable clinical transcutaneous electrical stimulators (e.g. Empi TENS Unit).
223515721|NCT06053320|DEVICE|Prism adaptation therapy (PAT) + Sham Stimulator|Participants in the PAT with sham stim condition group will receive sham electrical stimulation treatment (electrodes will be attached but the stimulator will not be turned on) to the left upper limb with the same placement of electrodes while undergoing PAT.
223515722|NCT06053320|OTHER|Gait Training|After PAT, participants will complete multiple 30-seconds to 4-minute bouts of walking on the treadmill or overground at speeds ranging from self-selected to fast speeds (faster than comfortable self-selected speed), with rest breaks between bouts.
223515723|NCT04548050|OTHER|Nurses training|"* Presentation of the benefits of colostrum and manual expression technique on a slide show and practical workshops for learning the manual expression technique on a fictitious breast.~* Presentation to all staff of a service protocol for early colostrum donation."
223515724|NCT03508440|PROCEDURE|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
223515725|NCT03508440|DRUG|Prednisone|Oral Steroid
223515726|NCT03242031|PROCEDURE|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
223515727|NCT03242031|PROCEDURE|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
223515728|NCT04070040|DRUG|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
223515729|NCT01726608|PROCEDURE|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
223515730|NCT02881216|DEVICE|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
223515731|NCT02881216|DEVICE|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
223515732|NCT03557905|DEVICE|RM 0.5|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
223515733|NCT03557905|DEVICE|RM 0.3|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.3.
223534776|NCT03435380|BEHAVIORAL|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
223703988|NCT01577420|OTHER|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
224081033|NCT06357676|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224081034|NCT06357676|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224081035|NCT06357676|PROCEDURE|Computed Tomography|Undergo CT scan or FDG PET/CT
224081036|NCT06357676|PROCEDURE|Echocardiography|Undergo echocardiography
223892034|NCT06843837|OTHER|Sweet orange essential oil aromatherapy|The sweet orange essential oil used in the study was prepared by the Food Engineering Department of Fırat University. To obtain the essential oil used for aromatherapy in this study, the peels of Citrus sinensis sweet oranges were utilized. The orange peels were cut into small pieces of approximately 3-5 mm in size, placed into a boiling flask, and distilled water was added. Based on the analysis results, the percentage composition of the total essential oil fatty acids was determined. The chemical composition analysis revealed that D-limonene was the major component, comprising 90% of the total oil. The oil is 100% pure essential oil, containing up to 90% D-limonene, along with citral and linalool. A cotton ball infused with three drops of sweet orange essential oil was held 4 to 5 cm away from the student's nose, and they were instructed to breathe slowly for five minutes. After this, the students were asked to perform IV cannulation on the patient.
223892035|NCT05085977|BIOLOGICAL|TARA-002|Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
223892036|NCT05269160|DRUG|Dermaprazole 1%|Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks
223892037|NCT05269160|DRUG|Dermaprazole 2%|Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
223892038|NCT03310957|DRUG|ladiratuzumab vedotin|Given into the vein (IV; intravenously)
223892039|NCT03310957|DRUG|Pembrolizumab|IV infusion every 3 weeks
223892040|NCT05284552|DRUG|Tinzaparin Injectable Solution|Subcutaneous injection
223892041|NCT05813275|DRUG|AD109|Oral administration at bedtime
223892042|NCT05813275|DRUG|Placebo|Oral administration at bedtime
223892043|NCT04927637|PROCEDURE|imaging 24 hours following intravenous administration of ICG|Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
223892044|NCT02754882|DRUG|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
223892045|NCT02754882|DRUG|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
223892046|NCT02754882|DRUG|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
223892047|NCT02754882|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
223892048|NCT06087601|DRUG|0.9% Sodium chloride|us-guided bilateral genicular nerves sham block with 0,5ml 0,9% normal saline
223892049|NCT06087601|DRUG|95% ethanol|us-guided bilateral genicular nerves neurolysis with 0,5ml 95% ethanol
223892050|NCT06541951|OTHER|Services as usual|During this phase of the stepped wedge design, agencies offering prenatal and postnatal care will follow their standard procedures
223892051|NCT06541951|OTHER|Scale-up implementation approach|An implementation approach for scaling up bundled equity-focused maternal health safety guidelines in community care settings county-wide, co-developed with partners. It may involve implementation approaches such as training, facilitation, learning collaboratives, coalitions, and other activities.
223892052|NCT06546982|DIAGNOSTIC_TEST|Surface-enhanced Raman Spectroscopy|The Raman spectra of patient samples will be measured in the presence of gold nanoparticles, which will enhance the spectroscopic characteristics of serum components via near-field enhancements.
223892053|NCT06415370|BEHAVIORAL|Home Delivered Healthy Meals|In-person delivery of HDHM at least one time weekly for 12 weeks.
223892054|NCT06415370|BEHAVIORAL|"In-person friendly visits"|"Friendly visits last approximately 5-10 minutes and include brief wellness check questions such as, How are you doing today? Did you try \[HDHM recipe\] yesterday- how did it taste? Any suggestions for future flavors? What are some of the things you plan to do in the next few days? Is there anything else you want to share with me?"
223892055|NCT06415370|BEHAVIORAL|Student Companion calls|Student Companions call participants at least one time weekly to provide telephone reassurance- i.e., checking on the participant's well-being. These calls may also include referrals to appropriate resources such as NCCARE 360 (statewide network that connects individuals with complex health and social needs, to community resources and service)
223892056|NCT05203341|DRUG|Placebo|Matching placebo tablets
223892057|NCT05203341|DRUG|NBI-1065845|NBI-1065845 tablets
223892058|NCT04833309|PROCEDURE|pharmacopuncture therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
223892059|NCT04833309|PROCEDURE|physical therapy|The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
223892060|NCT05722964|DRUG|SHR-1906|Intravenous injection
223892061|NCT05722964|DRUG|SHR-1906|Intravenous injection
223892062|NCT05722964|DRUG|Placebo|Placebo，Intravenous injection
223892063|NCT03973320|OTHER|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
223892064|NCT05508633|DRUG|Alverine Citrate|Low-dose group: Alverine (60 mg, 1 capsule) High-dose group: Alverine (120 mg, 2 capsules) The drug is orally given with 200 ml warm water after measurement of the baseline portal pressure.
223939794|NCT06733675|DRUG|Esomeprazole|40 mg capsule
223939795|NCT07045311|DRUG|JS207 in combination with 9MW2821|JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 m.g/kg (D1 and D8, Q3W)
223939796|NCT07045311|DRUG|JS207 in combination with Albumin paclitaxel|JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), Albumin paclitaxel will be administered intravenously at a dose of 125 mg/m2 (D1 and D8, Q3W).
223892065|NCT04312308|OTHER|Sample collection|"1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.~2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)~3\. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)~4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.~4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional."
223892066|NCT05076370|DRUG|CBD Day 1|CBD 400mg
223892067|NCT05076370|DRUG|CBD Day 2|CBD 800mg
223892068|NCT05076370|DRUG|CBD Day 3|CBD 1200mg
223892069|NCT04954664|BIOLOGICAL|Allograft particles hydrated with rhPDGF|Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.
223892070|NCT04954664|BIOLOGICAL|Allograft particles hydrated in a conventional way with saline.|Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
223892071|NCT05837221|DIAGNOSTIC_TEST|Metagenomic sequencing|Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.
223939797|NCT06891352|BEHAVIORAL|Dietary Monitoring|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and continue their habitual eating patterns.
223534777|NCT03435380|BEHAVIORAL|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
223534778|NCT03435380|BEHAVIORAL|Control|Mailed educational materials.
223892072|NCT05837221|DIAGNOSTIC_TEST|Metabolic analysis|Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
224081037|NCT06357676|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
224081038|NCT06357676|BIOLOGICAL|Glofitamab|Given IV
224081039|NCT06357676|DRUG|Ibrutinib|Given PO
224287205|NCT02155374|BEHAVIORAL|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
224287206|NCT02155374|DRUG|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
224287207|NCT02155374|DRUG|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
224287208|NCT01368627|DEVICE|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
224287209|NCT01490320|BEHAVIORAL|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
224287210|NCT01490320|BEHAVIORAL|Play Nicely Program|Multimedia program available at www.playnicely.org.
224287211|NCT01490320|OTHER|Control Group|Standard care in primary care clinic.
224287212|NCT04417582|PROCEDURE|bariatric surgey|patients undergone bariatric surgery or prescribed antiobesity drugs
224287213|NCT05676060|COMBINATION_PRODUCT|quasi|block facet joint in back pain due to afacet cause
224287214|NCT02197026|DRUG|Hylan G-F 20|
224287215|NCT02197026|DRUG|Standard treatment|Standard drug treatment at the discretion of the investigator
224287216|NCT02197026|PROCEDURE|Physiotherapy|
224287217|NCT02197026|PROCEDURE|Hydrotherapy|
224287218|NCT00161382|BEHAVIORAL|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
224287219|NCT00161382|BEHAVIORAL|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
224287220|NCT02732691|DEVICE|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
224287221|NCT00847106|DRUG|Daclizumab|
224287222|NCT00847106|BIOLOGICAL|Dendritic cells|
224287223|NCT02162355|DRUG|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
224287224|NCT02162355|DRUG|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
224287225|NCT02162355|DRUG|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
224287226|NCT02162355|DRUG|Placebo|1 or 2 matching placebo tablets once daily for 10 days
224287227|NCT03794518|DRUG|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
224287228|NCT03794518|DRUG|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
224287229|NCT04239118|COMBINATION_PRODUCT|Complex endoscopic treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets|Complex endoscopic bleeding ulcers treatment with the use of granular sorbent aseptisorb-A and autoplasm enriched with platelets
224287230|NCT04239118|PROCEDURE|Traditional methods of endoscopic hemostasis|Traditional methods of endoscopic hemostasis were used without the use of platelet-enriched plasma and granular sorbents
224287231|NCT01473121|OTHER|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
224287232|NCT01158352|DIETARY_SUPPLEMENT|Nutritional supplementation formula|Nutritional supplementation formula
224287233|NCT01158352|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
224287234|NCT06604195|PROCEDURE|Modified sciatic nerve mobility exercises|Each participant was made to lie down in a supine position on the treatment couch. The participant's leg was moved to about 30-45 degrees hip flexion with knee extension. The ankle was then moved to maximum dorsiflexion with inversion and hip internal rotation within the participant's tolerance, and this position was maintained for 30 seconds. While the therapist performed dorsiflexion with inversion and hip internal rotation in the supported straight leg raise position, the participant was instructed to actively flex the cervical spine slowly until they perceived a tolerable stretch sensation in the hamstring muscle and lower leg. The synchronous alternating movements were performed rhythmically for 10-15 repetitions. This maneuver was repeated 3 times in a single session, 3 days per week, and continued for 3 consecutive weeks.
224287235|NCT06604195|PROCEDURE|Dynamic hamstring muscle stretching|"The participant was instructed to stand straight with the unaffected foot supported on the floor and the toes pointing forward. The heel of the testing leg was placed on an 18 high step with the toes directed upwards with knee extension. Once cued, the participant was asked to flex forward at the hip while maintaining the spine in a neutral position and reaching the arms forward. The knee joint remained fully extended as the participant continued to flex the hip until a gentle stretch was felt in the posterior thigh. Once the position was achieved, the participants were asked to hold it for 20-30 seconds. The same procedure was repeated 3 times daily, 3 days a week for three consecutive weeks."
223534779|NCT01103414|DRUG|Mitoglitazone|50 mg capsules, once daily for 84 days
223534780|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
223534781|NCT01103414|DRUG|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
223534782|NCT01103414|DRUG|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
223892073|NCT03376321|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
223939798|NCT06891352|BEHAVIORAL|Time-Restricted Eating (TRE)|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and adhere to a personalized consistent 10-hour time-restricted eating window.
223515734|NCT04869527|DEVICE|BIOTRONIK ICDs with DX Technology|The BIOTRONIK DX system offers a single chamber ICD that enables sensing of atrial signals through floating atrial dipoles, using a single ventricular lead. This technology enables enhanced arrhythmia diagnosis based on atrial and ventricular electrograms and, in addition, early diagnosis and automatic transmission of AF and heart failure (HF) diagnostic data. The DX technology provides several features in a single chamber device that are usually only found in dual chamber devices, including atrial diagnostics and SVT discrimination - early detection of SAF, increased diagnostics accuracy, dual-chamber discrimination. Nevertheless, the benefits of a single chamber device are preserved: reduced lead complications, reduced procedure complexity, elimination of costs for atrial lead. The DX system also integrates with BIOTRONIK Home Monitoring, allowing physicians to remotely follow their patients' clinical and device statuses with daily updates.
223515735|NCT05770245|DEVICE|The novel electrolyzed water spray|The researcher used electrolyzed water or piped water to treat the diseased area two times a day for five days. The trial consists of 7 study visits (day 1-day 7). The reduction in the disease area of discomfort or itching scores and promoting healing of the damaged skin of patients with mild dermatophytosis event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
223515736|NCT02055339|DEVICE|Fisher & Paykel heated humidified high flow nasal cannula|
223515737|NCT02055339|DEVICE|InfantFlow/RAM nasal continuous positive airway pressure|
223515738|NCT06371378|PROCEDURE|PEEP 0|PEEP 0 CMH20 will be used During Surgery
223515739|NCT06371378|PROCEDURE|PEEP 4|PEEP 4 CMH20 will be used During Surgery
223515740|NCT06371378|PROCEDURE|PEEP 8|PEEP 8 CMH20 will be used During Surgery
223515741|NCT01821846|DRUG|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
223892074|NCT03376321|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
223892075|NCT03376321|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
223892076|NCT02671903|DEVICE|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
223892077|NCT05579639|OTHER|Xylitol|Xylitol wipes
223892078|NCT05579639|OTHER|Placebo|Placebo wipes
223892079|NCT04641026|OTHER|Broccoli sprouts|Subjects will consume one serving (about 1 cup) of broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
223892080|NCT04641026|OTHER|Deuterium oxide-labelled broccoli sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled broccoli sprouts with breakfast (bagel, cream cheese, and orange juice).
223892081|NCT04641026|OTHER|Alfalfa sprouts|Subjects will consume one serving (about 1 cup) of alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
223515742|NCT06184087|OTHER|Educational/Instructional|ICAP constructive-interactive engagement mode
223515743|NCT03831776|DRUG|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (\> 300 mg/d \> 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
223515744|NCT03831776|DRUG|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
223515745|NCT05670704|BIOLOGICAL|ARGX-119|Patients receiving ARGX-119 IV or SC
223515746|NCT05670704|OTHER|Placebo|Patients receiving Placebo IV or SC
223515747|NCT04252664|DRUG|Remdesivir|RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
223515748|NCT04252664|DRUG|Remdesivir placebo|RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
223515749|NCT06959121|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Participants will receive cardiac ablation with the CellFX® nsPFA™ Cardiac Clamp
223515750|NCT05272488|OTHER|Manual therapy and vagus nerve stimulation|A neurodinamic intervention of vagus nerve through deep breaths involving diaphragm muscle and manual therapy techniques.
223534783|NCT01103414|DRUG|Placebo|Placebo, once daily for 84 days
223892082|NCT04641026|OTHER|Deuterium oxide-labelled alfalfa sprouts|Subjects will consume one serving (about 1 cup) of deuterium oxide-labelled alfalfa sprouts with breakfast (bagel, cream cheese, and orange juice).
223892083|NCT06163105|PROCEDURE|Meibomian gland expression (MGX)|"The MGX procedure has a standardized protocol in lid spa at Chula's Refractive Surgery Center every 2 weeks (totally 6 sessions). During the study, all MGX procedures will be conducted by the same nurse following these steps:~1. Topical anesthesia by Tetracaine 0.5%~2. Clean the eyelids by gauzes with commercial available foam~3. Warm the eyelids by Blephasteam machine for 10 minutes~4. Instill Tetracaine 0.5% again~5. Use Mastrota paddle and Q-tip to squeeze the gland~6. Clean the lid margin by commercial available foam~7. Use Moxifloxacin 0.5% eyedrop"
223892084|NCT04258709|BEHAVIORAL|AME|Participants receive education on AME and feedback on technique with a remotely-based IBCLC via live streaming video.
223892085|NCT04258709|BEHAVIORAL|Video-based infant care education|Participants view a standard set of web-based streamed videos addressing evidence-based infant care, unrelated to feeding/breastfeeding.
223892086|NCT04337554|DEVICE|Exoskeleton footwear|Assistive footwear
223892087|NCT05963425|OTHER|Physical activity|This physical activity program will be based only on the work of basic physical training, in which specifically and mainly the strength and resistance will be worked, but also flexibility
223892088|NCT05963425|OTHER|usual clinical practice|usual clinical practice
223892089|NCT05972512|OTHER|Placebo|Mode of usage: Two times a day Route of administration: Oral
223892090|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardized biotin|Mode of usage: Two times a day Route of administration: Oral
223892091|NCT05972512|DIETARY_SUPPLEMENT|Botanical extract of standardised biotin with silica|Mode of usage: Two times a day Route of administration: Oral
223892092|NCT05509192|DRUG|MTPI|Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.
223892093|NCT05509192|DRUG|Classic Induction|Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
223892094|NCT05014984|BEHAVIORAL|mental contrasting with implementation intentions|"To deliver MCII, Dr. Oettingen developed a step-wise procedure called WOOP (Wish, Outcome, Obstacle, Plan; Figure 1). In a quiet setting, patients identify an important wish (e.g., losing weight) and then name and vividly imagine the best outcome (e.g., feeling healthier). Next, they name a current internal obstacle (e.g., urge to eat when feeling stressed) and try to vividly imagine their experience when they encounter this obstacle. Finally, they address their obstacle with an if-then plan specifying when, where, and how to overcome it (e.g., If I have the urge to eat when feeling stressed, I will go for a walk) and then imagine themselves experiencing the obstacle and carrying out the action of surmounting it. To facilitate use of the WOOP technique, Dr. Oettingen developed a free, publicly available WOOP app"
223892095|NCT05014984|BEHAVIORAL|telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!|MOVE! is a national VA weight management and health promotion program to improve the quality of life of Veterans.6,75 This effective program encourages healthy eating behavior and increased physical activity. MOVE! will be delivered via telephone (16 sessions) by existing staff consistent with national MOVE! program guidelines. The program has 16 modules and will offered weekly, but Veterans will be able to make up sessions at their own pace if they miss one. MOVE! staff use the MOVE! facilitator guide that provides instruction on delivering the program via telephone. Update as of 11-2023, the New York Harbor VA paused their offering of telephone-delivered MOVE!. Participants in both arms are offered the in-person or video-delivered MOVE! program. For participants who do not want or are unable to attend group-based MOVE!, they are offered TeleMOVE!.
223892096|NCT05014984|BEHAVIORAL|Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All|All participants will receive handouts that they review with a lay educator on weight management, adapted from the educational materials developed for our FIReWoRk Study. Topics include losing weight at a healthy rate, setting a 6-month weight loss goal of 5-10%, limiting sugar-sweetened beverages and portion sizes, making better choices when eating at restaurants, self-monitoring diet and weight, and participating in at least moderate-intensity physical activities.
223892097|NCT05014984|BEHAVIORAL|Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)|The lay educator will review and practice the WOOP technique based on protocols from prior studies. To probe Veterans' comprehension, the lay educator will ask for their four steps and ask about their WOOP use and experiences. If needed, the lay educator will help the Veteran to create a new WOOP for the next month and address any questions and concerns about using WOOP.
223892098|NCT06385925|DRUG|TSN1611|TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
223892099|NCT04814446|BIOLOGICAL|Vaccination|Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
223892100|NCT05447689|BEHAVIORAL|Integrative-Mind-Body Skills Group|Integrative-Mind-Body Skills Group (I-MBS-G) is an 8-week group that teaches skills to build inner resources for effective mood management. This group incorporates a holistic approach to wellness through meditation and mindfulness practices, guided imagery, breath and body awareness, relaxation techniques, self-reflection, and mindfulness-based cognitive-behavioral skills. Mind-body approaches have demonstrated effectiveness in reducing stress mood symptoms and improving quality of life.
223892101|NCT06042387|GENETIC|Blood or saliva sample collection|Blood or saliva sample \& clinical data collection
223892102|NCT02287610|DRUG|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
223892103|NCT06636539|DEVICE|CEM Exam in Investigational Device|All subjects enrolled in this study will undergo a CEM exam using Investigational Device.
224081040|NCT06357676|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223515751|NCT05272488|OTHER|Manual therapy|Manual therapy techniques. Joint manipulation techniques for temporomandibular joints and Soft tissue techniques for the muscles
223515752|NCT05520333|BEHAVIORAL|BIPAS Alcohol|Weekly text messages for three months.
223515753|NCT02500966|DEVICE|DUDA device|Insertion DUDA device
223515754|NCT02500966|PROCEDURE|LEEP|Loop Electrosurgical Excision Procedure
223515755|NCT00071994|DRUG|gefitinib|Given orally
223515756|NCT00071994|OTHER|laboratory biomarker analysis|Correlative studies
223515757|NCT05513573|DRUG|HLX07|1500 mg, D1，Q3W
223515758|NCT05513573|DRUG|HLX10|300 mg, D1, up to 2 years,Q3W
223515759|NCT05513573|DRUG|placebo|1500 mg, D1，Q3W
223515760|NCT05513573|DRUG|chemotherapy|gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles
223515761|NCT01117662|DRUG|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
223515762|NCT01117662|DRUG|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
223515763|NCT00273780|BEHAVIORAL|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
223515764|NCT00273780|DEVICE|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
223515765|NCT02457546|BIOLOGICAL|EVICEL Fibrin Sealant|
223515766|NCT02457546|DEVICE|Hydrogel sealant|
223515767|NCT02473302|OTHER|ham|160g per day during 4 days
223515768|NCT02473302|OTHER|ham + pomegranate extract|160g per day during 4 days
223515769|NCT02473302|OTHER|ham + tocopherol|160g per day during 4 days
223515770|NCT02473302|OTHER|rare sirloin steak|110g per day during 4 days
223515771|NCT02473302|OTHER|marinated rare sirloin steak|110g per day during 4 days
223515772|NCT02473302|OTHER|marinated cooked sirloin steak|110g per day during 4 days
223515773|NCT06413069|DIETARY_SUPPLEMENT|Raw whole almonds|Subjects will be supplemented with 60 grams of almonds (treatment) or left untreated (no-nut group) for 16 weeks. Patients of the no-nut group will receive 6,7 kgs of almonds after finishing the study, supporting their compliance as untreated group.
223515774|NCT04713046|BIOLOGICAL|CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16|Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.
223515775|NCT04713046|BIOLOGICAL|Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16|Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
223515776|NCT01905085|DEVICE|No intervention|
223515777|NCT02667561|DRUG|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
223515778|NCT02667561|DRUG|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
223515779|NCT02667561|DRUG|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
223515780|NCT02667561|DRUG|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
223515781|NCT03236805|DRUG|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
223515782|NCT03236805|DRUG|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
223515783|NCT02056145|PROCEDURE|LFCNB|LFCNB - Normal Saline solution 10 cc
223515784|NCT02056145|PROCEDURE|FNB|FNB - Normal saline solution 10 cc
223515785|NCT02056145|PROCEDURE|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
223515786|NCT02056145|PROCEDURE|FNB|FNB - Chirocaine 0.25%, 20 cc
223515787|NCT03345810|DRUG|Durvalumab|Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
223515788|NCT03345810|DRUG|Vinorelbine|(30 mg/m2 D1 + D8 as infusion) cycle Q3W
223515789|NCT03345810|DRUG|Gemcitabine|(1000 mg/m2 D1 + D8 as infusion) cycle Q3W
223515790|NCT03345810|DRUG|nab-Paclitaxel|(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
223515791|NCT03345810|DRUG|Carboplatin|(AUC = 5 mg•min/mL on Day 1) cycle Q3W
223515792|NCT04053426|OTHER|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
223515793|NCT06570421|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct transcutaneous, electrical stimulation of the peroneal nerve
223515794|NCT01435980|PROCEDURE|Gastric Bypass|basal treatment and Gastric Bypass
223515795|NCT01435980|DRUG|Exenatide|basal treatment and Exenatide
223515796|NCT06571617|PROCEDURE|Mini PCNL (mini percutaneous nephrolithotomy)|half of the cases will be treated using mini PCNL
223515797|NCT06571617|PROCEDURE|RIRS (retrograde intrarenal surgery/ flexible URS)|THE OTHER HALF WILL BE TRAETED USING Flexible URS
223515798|NCT03854435|OTHER|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
223515799|NCT03854435|OTHER|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
223515800|NCT03008096|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
223515801|NCT01121354|DRUG|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
223515802|NCT01121354|DRUG|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
223703989|NCT01577420|OTHER|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
224081041|NCT06357676|BIOLOGICAL|Obinutuzumab|Given IV
223892104|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (MDCK cells)|Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).
223892105|NCT06342349|BIOLOGICAL|Quadrivalent influenza virus split vaccine (Chicken embryo)|Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).
223892106|NCT06342349|OTHER|Phosphate buffer solution|Phosphate buffer solution without vaccine antigen(0.5ml/dose).
223892107|NCT02639026|RADIATION|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
223892108|NCT02639026|DRUG|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
223515803|NCT01793571|PROCEDURE|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
223892109|NCT02639026|DRUG|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
223892110|NCT05935059|DRUG|Pregabalin|Pregabalin 50Mg Oral Capsule. Pre-operative administration of Pregabalin for prevention of Post mastectomy Pain Syndrome (PMPS)
223892111|NCT05935059|DRUG|Tianeptine|Tianeptine 12.5Mg Capsules. Prevention of Post Mastectomy Pain Syndrome
223892112|NCT04573725|DRUG|TS-142|Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)
223892113|NCT04573725|DRUG|Dose-matched Placebo to TS-142|Participants received single dose-matched placebo to TS-142 (oral capsule)
223892114|NCT04639206|BEHAVIORAL|HOBSCOTCH|HOBSCOTCH (Home Based Self-management and Cognitive Training Changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. The HOBSCOTCH intervention consists of 8 weekly sessions conducted in-person, over the telephone, or via video-conferencing. A smart phone application will be used to collect data on seizure frequency, medication adherence, and patient engagement.
223892115|NCT06793891|DIETARY_SUPPLEMENT|ashwagandha root|This substance is extracted from the root of the plant.
223892116|NCT06793891|DIETARY_SUPPLEMENT|ashwagandha root and leaf|This substance is extracted from both the root and leaves of the plant.
223892117|NCT06793891|OTHER|placebo|The inert placebo does not contain any of the plant matter.
223892118|NCT04241068|DRUG|Aducanumab|Administered as specified in the treatment arm.
223892119|NCT04784247|DRUG|Lenvatinib|20mg daily (two 10mg lenvatinib capsules) taken orally
223892120|NCT04784247|DRUG|Pembrolizumab|(200mg) will be administered as a 30-minute IV infusion, Q3W +/-3 days (infusions lasting between 25-40 minutes. Study treatment with pembrolizumab may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
223892121|NCT01413100|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223892122|NCT01413100|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
223892123|NCT01413100|DRUG|Cyclophosphamide|Given IV
223892124|NCT01413100|BIOLOGICAL|Filgrastim|Given SC
223892125|NCT01413100|OTHER|Laboratory Biomarker Analysis|Correlative studies
223892126|NCT01413100|DRUG|Mycophenolate Mofetil|Given PO
223892127|NCT01413100|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
223892128|NCT01413100|DRUG|Plerixafor|Given SC
223892129|NCT01413100|OTHER|Quality-of-Life Assessment|Ancillary studies
223892130|NCT01413100|OTHER|Questionnaire Administration|Ancillary studies
223892131|NCT05257850|DEVICE|High-flow nasal therapy|A high-flow nasal therapy for 30 minutes.
223892132|NCT05257850|DEVICE|Airflow directed to face by a fan|A fan directed to the face for 30 minutes
223892133|NCT06437977|RADIATION|SBRT|SBRT. 24Gy/3fractions Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
223892134|NCT06437977|DRUG|Toripalimab|Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
223892135|NCT06310967|DRUG|IG3018|Oral administration
223892136|NCT06310967|OTHER|Placebo matching IG3018|Oral administration
223892137|NCT05369403|DRUG|Lebrikizumab|Administered SC
223892138|NCT04207814|BIOLOGICAL|biological sample|biological samples will be taken from the subjects included
223892139|NCT05402930|DIAGNOSTIC_TEST|Angiomammography|"Patients will receive their care in a standard manner. Breast MRI is one modality used by physicians to monitor response to neoadjuvant chemotherapy and will therefore be used as standard. A CESM exam will be added at the same time as the MRI.~Patients will have a physical exam, breast MRI and CESM before the start of chemotherapy (less than 2 weeks). These examinations will be repeated after cycle 2 (±1 week) and at the end of chemotherapy. After each cycle of chemotherapy, the tumor will be measured in two axes by the attending physician.~Histological examination of the surgical specimen will be used to determine the pCR. Responses observed on MRI and CESM will be compared to pCR."
223892140|NCT05949658|DRUG|Sirolimus|5mg, 10mg, or 15mg once weekly sirolimus
223892141|NCT05949658|DRUG|Everolimus|5mg, 10mg, or 15mg once weekly everolimus
223892142|NCT05612971|BEHAVIORAL|iAmHealthy Parents First|iAmHealthy Parents first is a 3-month adult obesity treatment program targeting the unique needs of adults with school-age children. Following the iAmHealthy Parents First program, these dyads will take part in a 6-month family-based healthy lifestyles program.
223892143|NCT05612971|BEHAVIORAL|iAmHealthy|The iAmHealthy group will receive newsletters for three months. Following this period, these dyads will take part in a 6-month family-based healthy lifestyles program.
223892144|NCT04750525|DEVICE|BreEStim|120 BreEStim stimuli will applied for about 10-30 minutes.
223515804|NCT03240055|DRUG|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
224268934|NCT05419934|BEHAVIORAL|EMDR therapy|"Children will receive an EMDR psychotherapy comprising 8 treatment phases. As the treatment progresses, the child will proceed to desensitize the events of adversity experienced.~Phase 1 and 2, before the desensitization phases:~1. History of the patient (collection of anamnesis)~2. Securing the patient, preparing for the desensitization phases~   Desensitization phases, to be repeated for each traumatic event to be desensitized:~3. Evaluation of the target to be treated~4. Desensitization~5. Installation of positive beliefs~6. Body scanner (verification of body non-response)~7. Closure, verification that the patient is in a stable emotional state allowing him to leave the session~   Reassessment phase, to be repeated for each traumatic event that has been desensitized:~8. Reassessment of the traumatic target, verification of complete desensitization."
223515805|NCT03240055|OTHER|etomidate|receive etomidate only
223515806|NCT03796975|DRUG|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
223515807|NCT03796975|DRUG|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
224268935|NCT05419934|BEHAVIORAL|CBT Control therapy|Children in the control group receive Cognitive Behavioral Therapy (CBT) administered by the Lenval Foundation (CHU de Nice - France) within the Pediatric Psychotrauma Assessment Center (Centre d'évaluation du psychotraumatisme pédiatrique - CE2P).Cognitive and behavioral therapies are a standard treatment in the care service. Children in the control group will receive CBT specific to the treatment of PTSD in children under 6 years of age. CBT treatments dedicated to early childhood trauma have already been tested in the United States, and have shown evidence of effectiveness in randomized controlled trials (Mc Guire et al., 2021; Scheeringa et al., 2011).
224268936|NCT05638633|DRUG|Prednisolone 20 mg/ 5 mg|Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.
224268937|NCT05638633|DRUG|Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)|Administration of vitamin B compound for 28 days.
224268938|NCT05638633|DRUG|Placebo for Vitamin B compound|Administration of placebo for vitamin B compound placebo for 28 days.
224268939|NCT05638633|DRUG|Placebo for Prednisolon|Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
224268940|NCT05814068|DRUG|antihypertensive drug treatment|Patients with hypertension will be treated for it by their physician
224268941|NCT00310297|DRUG|Insulin Glulisine|
224268942|NCT05269563|OTHER|Surgical intervention|Pars Plana Vitrectomy for Macular Hole Closure
224268943|NCT02634736|DEVICE|Exergame plus usual treatment|An individualised \[i.e. frequency and duration will be set according to each participant's baseline levels\] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
224268944|NCT01109849|BEHAVIORAL|behavior therapy|combination of individual and group parent training plus school consultation
224268945|NCT01109849|DRUG|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
224268946|NCT01109849|OTHER|monitoring|monthly weight, height and BMI checks
224268947|NCT01109849|OTHER|drug holiday|switch from seven day a week dosing to medication only on school days
224268948|NCT01109849|DIETARY_SUPPLEMENT|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
224268949|NCT03004508|DIETARY_SUPPLEMENT|Gingko Biloba Extract|120mg/day, twice a day, 6 month
224268950|NCT03004508|DIETARY_SUPPLEMENT|Placebo|120mg/day, twice a day, 6 month
224268951|NCT03516487|DRUG|SYNB1618|SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
224268952|NCT03516487|DRUG|Placebo|Subjects receive placebo orally in a chilled buffered solution (100 mL).
224268953|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
224268954|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
223515808|NCT02149797|PROCEDURE|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
223718992|NCT02900196|OTHER|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
223718993|NCT05366946|OTHER|Prevalence study|Prevalence study of chronic pain in COPD vs healthy controls
223718994|NCT00393029|BIOLOGICAL|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
223718995|NCT00393029|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
223718996|NCT00393029|BIOLOGICAL|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count \> 1.0 x 10\^9/L x 3 days or \> 5.0 x 10\^9/L.
223718997|NCT00393029|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
223718998|NCT00393029|DRUG|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
223718999|NCT02927730|OTHER|no interventions|no interventions
223719000|NCT03355716|DRUG|bupivacaine|Bupivacaine 25 ml (0.25%)
223719001|NCT03355716|DRUG|morphine|Morphine (3.0 mg)
223719002|NCT03355716|DRUG|fentanyl|fentanyl (30.0 Mc)
223719003|NCT03355716|DRUG|Ketamine:|ketamine (0.5 mg/kg).
223719004|NCT00640991|DRUG|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
223892145|NCT04750525|DEVICE|EStim|120 EStim stimuli will applied for about 10-30 minutes.
223892146|NCT04516772|DEVICE|Visian TICL|The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
223892147|NCT05744869|BEHAVIORAL|SBAT Implementation|Implementation of the SBAT Program
223892148|NCT05744869|BEHAVIORAL|Usual Care|Usual Care for children with asthma
223892149|NCT06281119|BIOLOGICAL|Cervavac as three dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
223892150|NCT06281119|BIOLOGICAL|Cervavac as two dose regimen|Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
223892151|NCT06281119|BIOLOGICAL|Gardasil as three dose regimen|Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.
223534784|NCT02133573|DRUG|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
223892152|NCT05521308|DEVICE|Hearing Aid - Standard Curve|Our current hearing aids which will be programmed to our standard frequency response curve.
223892153|NCT05521308|DEVICE|Hearing Aid - Variation #1|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
223892154|NCT05521308|DEVICE|Hearing Aid - Variation #2|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
223892155|NCT05521308|DEVICE|Hearing Aid - Variation #3|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
223892156|NCT05521308|DEVICE|Hearing Aid - Variation #4|Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
223892157|NCT05337943|BEHAVIORAL|CBT-I|Weekly sessions with a therapist to improve sleep for 8 weeks.
223892158|NCT05337943|DEVICE|Bright Light Therapy|Daily light therapy for 30 minutes for 8 weeks.
223892159|NCT04747496|DRUG|Edoxaban|This is a non-interventional, observational study.
223892160|NCT04059770|DRUG|single dose of L-AmB|(i) single IV dose of 10 mg/kg of L-AmB on day 1;
224268955|NCT00666354|DRUG|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
223892161|NCT04059770|DRUG|2 doses of L-AmB|(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
223892162|NCT04059770|DRUG|2 weeks of L-AmB|(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
223892163|NCT06836973|DRUG|Blinatumomab|Blinatumomab is used at its starting dose of 9 µg per day and administered as continuous infusion for 5 days (total dose of 38.5 µg). After a 1-week pause, the patients receive a second 5-day infusion with blinatumomab of total 38.5 µg of the drug.
223892164|NCT04896476|DEVICE|EchoMark / EchoSure|"The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.~The follow-up EchoSure scans will be conducted by the designated EchoSure user without the investigator and without the sonographer/RVT conducting the Duplex exam in the room, either during the routine work-up prior to the surgeon seeing the patient or after. The EchoSure results for flow, and vessel depth and diameter are shown as numerical values on the screen of the EchoSure device."
223892165|NCT01458782|PROCEDURE|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
223892166|NCT06837662|BEHAVIORAL|"MOUD Plus Intervention (treatment as usual + coordinated counseling and referral to community based peer)"|"In addition to treatment as usual (clinic visits for primary care and MOUD), patients will meet with clinic based addictions counselor who provides 1) rapport building ; 2) brief counseling interventions (e.g. motivational interviewing, change talk/solutions based therapy, harm reduction counseling); 3) referral to community resources. Patients will also be referred to community based peer recovery services who are credentialed and trained to meet the person where they are in the community and provide advocacy and support for client directed goals."
223892167|NCT06837662|BEHAVIORAL|Treatment As Usual (primary care with low threshold MOUD prescribing)|Treatment as usual arm consists of primary care clinical appointments with prescribers who treat medical issues and are trained to diagnosis and treat OUD using low threshold prescribing approaches.
223892168|NCT06029010|DRUG|Regorafenib (Stivarga, BAY73-4506)|Follow clinical administration.
223892169|NCT03836911|OTHER|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
223892170|NCT03836911|OTHER|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
223892171|NCT03476187|DEVICE|µCor|Monitor with µCor
223892172|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule|10 cc of blood is collected at one time point, which is prior to biopsy procedure
223892173|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection|10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery
223892174|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer|10 cc of blood is collected at one time point
223892175|NCT05462795|DIAGNOSTIC_TEST|Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease|30 cc of blood is collected at one time point
223892176|NCT06837025|OTHER|Fascial manipulation|Fascial manipulation once a week
223892177|NCT03924986|DRUG|Tislelizumab|200 mg intravenously (IV) once every 3 weeks (Q3W)
223892178|NCT03924986|DRUG|Placebo|Placebo to match tislelizumab (administered intravenously Q3W)
223892179|NCT03924986|DRUG|Gemcitabine|1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles
224268956|NCT05141786|DRUG|MRG002|Administrated intravenously
224268957|NCT06678295|BEHAVIORAL|Cognitive Behavioral Therapy|Twelve weekly sessions of individual cognitive behavioral therapy
223515809|NCT02149797|PROCEDURE|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
223515810|NCT02149797|PROCEDURE|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
223515811|NCT03346746|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
223515812|NCT03346746|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
223515813|NCT02674763|DRUG|IMGN779|
223515814|NCT01063569|DRUG|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
223515815|NCT01063569|DRUG|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
223515816|NCT04872946|DIETARY_SUPPLEMENT|Tea|Ashwagandha(Withania somnifera) root and leaf extract (32% Withania Oligosaccharides, 10% Withanolide Glycosides, 0.5% Withaferin A) 125 mg Saffron(Crocus Sativus) stigmas extract (3.48% Crocin and 0.03% Safranal) 28mg
223515817|NCT04872946|OTHER|Serum|Aqua/Water/Eau, Glycerin, Propanediol, Diheptyl Succinate, Caprylic/Capric Triglyceride, Lactococcus Ferment Lysate, Sorbitol, Dimethicone, Steareth-21, Octyldodecyl Neopentanoate, Sodium Polyacrylate, Steareth-2, Caprylyl Glycol, Hydrogenated Polydecene, Trideceth-6, Octyldodecanol, Panthenol, Sodium PCA, Azelaic Acid, Bisabolol, Capryloyl Glycerin/Sebacic Acid Copolymer, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Caprylhydroxamic Acid, Phytic Acid, Aminomethyl Propanol, Lactic Acid, Sodium Chloride, Phenoxyethanol, Sodium Benzoate.
223515818|NCT04872946|OTHER|Moisturizer|Aqua/Water/Eau, Glycerin, Diisopropyl Dimer Dilinoleate, Coco-Caprylate, Lactococcus Ferment Lysate, Myristyl Myristate, Dimethicone, Propanediol, Behenyl Alcohol, Glyceryl Stearate SE, Potassium Cetyl Phosphate, Palmitic Acid, Ammonium Acryloyldimethyltaurate/Beheneth-25 Methacrylate Crosspolymer, Myristyl Laurate, Caprylyl Glycol, Hydroxyethylcellulose, Myristic Acid, Tocopherol, Ethylhexylglycerin, Centella Asiatica Leaf Extract, Agastache Mexicana Flower/Leaf/Stem Extract, Helianthus Annuus (Sunflower) Seed Oil, Trisodium Ethylenediamine Disuccinate, Lactic Acid, Sodium Hydroxide, Sodium Phosphate, Disodium Phosphate, Sodium Chloride, t-Butyl Alcohol, Phenoxyethanol, Sodium Benzoate.
223515819|NCT02095457|BEHAVIORAL|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
223515820|NCT01633112|DRUG|fingolimod|capsule
223892180|NCT03924986|DRUG|Cisplatin|80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.
223892181|NCT06836596|DEVICE|Peripheral sensory electrical stimulation via Elettronica Pagani Roland series model: ET 20 S/N: 1907 (Made in Italy)|Sensory electrical stimulation, Transcutaneous electrical nerve stimulation (TENS) involves delivering electrical current through electrodes placed on the skin to manage pain. It can be applied at different frequencies, ranging from low (50 Hz). The intensity can be adjusted from sensory to motor levels. Sensory intensity is when the patient experiences a strong yet comfortable sensation without triggering muscle contraction
223515821|NCT01633112|DRUG|glatiramer acetate|subcutaneous injection
223515822|NCT01908699|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
223892182|NCT06836596|DEVICE|Alternating electromyogram (EMG) neuromuscular electrical stimulation via MyoTrac Infiniti device (T9800, Thought Technology Ltd. Montreal, Quebec, Canada)|the device detects the EMG threshold value (peak muscle torque) of the target muscle and activates stimulation to enhance the patient's voluntary activation of the targeted muscle groups. It is used to assess peak muscle torque and deliver alternating and EMG-triggered stimulation. Surface electrodes are employed to detect electromyography in the affected muscle and administer electrical stimulation to the targeted muscle during treatment. The device stimulates the targeted muscles, after which the patient attempts to replicate the same movement until reaching the preset EMG feedback level
223892183|NCT06365918|DRUG|VG2025|Given by Intraperitoneal
223515823|NCT01908699|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
223515824|NCT01783808|OTHER|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
223534785|NCT02133573|DRUG|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
223534786|NCT00788112|DRUG|vorinostat|
223892184|NCT05523713|BIOLOGICAL|Peripheral venous blood samples|10 ml in a sodium heparin tube and 5 ml in an EDTA tube
223892185|NCT06056518|OTHER|AI-based risk prediction for kidney graft loss|Implementation of AI-based risk prediction tool for the 1-year risk of kidney graft loss.
223892186|NCT06097520|OTHER|VR Intervention|For the VR Intervention a VR head-mounted display, the Pico G2 4K, will be used. This intervention involves wearing VR glasses and experiencing non-interactive videos with sound through a headset. The footage consists of different immersive 360-degree scenarios from natural environments (e.g., forest), while corresponding sounds, meditation or classical music harmoniously tuned to these scenarios and are played through noise-cancelling headphones.
224268958|NCT03969641|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
224268959|NCT03969641|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
223892187|NCT04406857|DRUG|Capecitabine|Given PO
223892188|NCT04406857|RADIATION|Radiation Therapy|Undergo radiation therapy
223892189|NCT04406857|DRUG|Ropidoxuridine|Given PO
223892190|NCT06836843|OTHER|Since this is an observational study rather than an interventional study, the exposure type refers to all potential factors influencing pregnancy both before and during pregnancy|"Since this is an observational study rather than an interventional study or clinical trial, the exposure type refers to all potential factors influencing pregnancy both before conception and during pregnancy. These exposures include:~Lifestyle habits: Such as obesity, smoking and alcohol use before and during pregnancy.~Sociodemographic factors: Such as age, residence, medical insurance. Medications: Any prescription, over-the-counter, or herbal medications used before or during pregnancy.~Past medical history: Pre-existing medical conditions or illnesses, such as hypertension, diabetes, or autoimmune diseases, that could affect pregnancy.~Past surgical history: Previous surgeries, especially those related to the reproductive system or any that may impact pregnancy outcomes.~Previous pregnancies: Information about past pregnancies, including the number of full-term and preterm births, complications, and outcomes.~Abortions: Any history of miscarriages"
223892191|NCT05948670|DEVICE|DISC-MVP|DISC-MVP is a digital program grounded in validated psychotherapies (e.g., cognitive behavioral therapy), that enlists a relational agent (Woebot) to engage users in therapeutic conversations and generates responses through a controlled process using large language models.
223892192|NCT05948670|DEVICE|DISC-CON|DISC-CON is a digital program grounded in validated psychotherapies (e.g., including cognitive behavioral therapy) that uses a virtual relational agent (Woebot) to engage users in therapeutic conversations with responses that are selected from a list based on natural language processing.
223892193|NCT06467227|OTHER|exercise modality|exercise using legs and arms
223892194|NCT04633369|DIETARY_SUPPLEMENT|dietary fibers|during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
223892195|NCT05072340|BEHAVIORAL|Resilience Skills Enhancement (RISE)|The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
223892196|NCT02649790|DRUG|KPT-8602|Participants will receive KPT-8602 oral tablets.
223892197|NCT02649790|DRUG|ASTX727|ASTX727 is a combination drug of 35 mg decitabine and 100 mg cedazuridine.
223892198|NCT02649790|DRUG|Dexamethasone|Participants will receive dexamethasone oral tablets.
223892199|NCT05729399|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
223892200|NCT06831006|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
223892201|NCT03699709|BEHAVIORAL|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
223892202|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction with Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction with (ADM)
223892203|NCT05316324|PROCEDURE|Prepectoral Breast Reconstruction without Acellular Dermal Matrix (ADM)|Prepectoral Breast Reconstruction without ADM
223892204|NCT06838156|DRUG|Bupivacain|Suprainguinal Fascia Iliaca Compartment block was performed with a linear probe placed over the inguinal ligament using a portable ultrasound device. After visualization of the femoral nerve, 30 ml of 0.25% bupivacaine was injected into the fascia iliaca overlying the iliopsoas muscle using an appropriate needle.
223892205|NCT06838156|DRUG|Bupivacain|Quadratus Lumborum Type 3 block was performed using a portable ultrasound device with a linear probe placed between the costal margin and the iliac crest on the lateral abdominal wall. 30 ml of 0.25% bupivacaine was injected between the quadratus lumborum and psoas muscles using an appropriate needle.
223892206|NCT06837675|DEVICE|high tone power therapy|High tone Power therapy (HiToP191-H) device is a new electrotherapy technology. Its primary impact on the body is to provide energy to the body to activate cells and rebuild it. It can cause an oscillation or vibration that promotes metabolism, nand erve regeneration and relieves pain by dispersing pain and inflammation mediators, nutrients, and waste products
223892207|NCT06837675|OTHER|selected physical therapy program|selected physical therapy protocol for 45 minutes 3 times per week for 3 months in form of pelvic floor exercises and core stability exercise
223892208|NCT06832956|PROCEDURE|robotic bronchoscopy system|cryobiopsy with the help of RBS
223892209|NCT06828978|PROCEDURE|Full Pulpotomy|After control of bleeding in teeth allocated to the intervention group, the gel is to be placed into the pulp chamber to a level 3 mm below the cementoenamel junction (CEJ) over the root pulp stumps.
223892210|NCT06752915|BEHAVIORAL|acupressure application|Acupressure massage will be applied to LI4, HT7, LU1 and ST 36 acupuncture points for 2 minutes.
223892211|NCT06819293|BIOLOGICAL|IB-T101 injection|IB-T101 injection to treat advanced clear renal cell carcinoma
223892212|NCT06833528|DEVICE|tooth restoration|restoration of class II cavities
223892213|NCT06833528|DEVICE|tooth restoration|restoration of class II cavities
223892214|NCT00390793|DRUG|Cyclophosphamide|Given IV
223892215|NCT00390793|DRUG|Cytarabine|Given IV or IT
223892216|NCT00390793|DRUG|Dasatinib|Given PO
223515825|NCT04846946|BEHAVIORAL|Hey, Friend|"Intervention in development. However, we will use intervention mapping and the designing for dissemination approach, informed by self-reported qualitative data, to develop the Hey, Friend modules. The mHealth intervention will include three modules that include multiple sub-topics (e.g., What is HIV?; How do I protect myself from HIV?; What is PrEP?, etc.), deliver culturally appropriate counseling content in community settings, juvenile court system, clinics, and schools; will include Motivational Interviewing components that are effective in evoking behavior change while being acceptable to adolescents and parents, and will include ongoing support through a text reminder to maximize the likelihood of initiating HIV prevention through testing and PrEP."
223515826|NCT01582555|DRUG|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
223515827|NCT01582555|DRUG|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
223515828|NCT06154525|OTHER|RO water|Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
223515829|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo Preg-Mom|LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
223892217|NCT00390793|DRUG|Dexamethasone|Given IV or PO
223892218|NCT00390793|DRUG|Doxorubicin|Given IV
223892219|NCT00390793|DRUG|Methotrexate|Given IV or IT
223892220|NCT00390793|DRUG|Prednisone|Given PO
223892221|NCT00390793|DRUG|Vincristine|Given IV
223892222|NCT06126809|DEVICE|Steep-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
223892223|NCT06126809|DEVICE|Flat-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
223892224|NCT06126809|DEVICE|Sham-tRAS|Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
223892225|NCT02945020|DRUG|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
223892226|NCT02945020|DRUG|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
223892227|NCT02945020|DRUG|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
223892228|NCT06827405|DIETARY_SUPPLEMENT|Lactase enzyme|Patients were given 5 drops of lactase enzyme (200 units lactase/drop)/ounce of milk, 5-30 minutes before feeding
223892229|NCT06827405|DIETARY_SUPPLEMENT|Lactose-free formula feed|Patients were advised lactose-free formula milk/diet.
223892230|NCT06837597|DRUG|Jianzhong Qushi Formula|Jianzhong Qushi Formula (A Chinese traditional formula, approved by Chinese Patent, No. ZL202210097886.0)
223892231|NCT06837597|DRUG|Placebo|A simulated Chinese medicine placebo, with similar appearance and smell to Jianzhong Qushi Formula.
223892232|NCT06832397|PROCEDURE|Diagnostic laparoscopy|Diagnostic laparoscopy with peritoneal biopsies
223892233|NCT06325371|DEVICE|Visceral aneurysm stenting|Flow diverter stenting
223892234|NCT06838377|DEVICE|standard Champy mini plate|the operation will under general anesthesia with nasal intubation and oral pack, Injection of 20 cc saline adrenaline 1:00000 to 0 in the sulcus for hemostasis, Vestibular mucosal incision, Reflect the flap to visualize the broken segments. Full thickness mucoperiosteal flaps were then carefully raised to expose enough underlying alveolar bone then mobilize the broken segment , Arch bar was made to achieve proper occlusion put the Champy 2.0 plate on the ventral surface of the external oblique of the mandible and remove it for further bending using plate pliers for further accommodation of the plate then fix it in place using mono cortical screws.
223515830|NCT06154525|DIETARY_SUPPLEMENT|LiveSpo KIDS|LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
223892235|NCT06838377|DEVICE|computer guided screw holes locating guide and Patient Specific Champy plate|"the operation will under general anesthesia with nasal intubation and oral pack, Injection of 20 cc saline adrenaline 1:00000 to 0 in the sulcus for hemostasis, Vestibular mucosal incision, Reflect the flap to visualize the broken segments.~Full thickness mucoperiosteal flaps were then carefully raised to expose enough underlying alveolar bone to accommodate the screw holes locating guide and the custom-made Champy plate.~, Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made Champy plate and fix it with screw for passive reduction of the segments. Then suture the mucosa."
223515831|NCT04635774|DRUG|Insulin|40 IU via four activations of an intranasal spray
223515832|NCT04635774|DRUG|Saline|Four activations of an intranasal spray containing placebo (normal saline).
223515833|NCT05505786|BEHAVIORAL|Normal stance width|Normal self-selected stance width when performing squat exercises.
223892236|NCT06377189|OTHER|Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings|"The CL brief psychiatric intervention (2 months) in the primary setting will consist of 3 different phases:~1. A direct referral of their PCP to the practice's CL psychiatrist will be held directly after the inclusion of the patient to the intervention arm, by conducting a clinical exchange (by oral or by mail) with the latter.~2. The CL psychiatrist will organize rapidly (in a delay of 1-2 weeks) a first session and will perform 1 to 4 psychiatric sessions, depending on the participant's needs. These sessions will take place in his/her consultation room, located in the referring PCP's practice, and will be completed in less than 2 months. No intervention guide will be provided to perform these sessions.~3. A joint feedback session between the PCP, the participant, and the CL psychiatrist will be organized (2 months after the first psychiatric session), during which the CL psychiatrist will make restitution of his/her proposals, from a biopsychosocial perspective."
224099137|NCT04063943|DEVICE|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
224081042|NCT05285501|BEHAVIORAL|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
224081043|NCT05285501|BEHAVIORAL|Group relaxation and psychoeduaction|A single session of relaxation (10 minutes) psychoeducation (10 minutes) will contain minilectures about mental well-being and psychohygiene. In summary 20 minutes.
224081044|NCT05285501|DEVICE|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
224081045|NCT05848934|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
224081046|NCT05848934|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
224081047|NCT04340622|DEVICE|supra-luminous LED|810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.
224081048|NCT04340622|DEVICE|Sham|Light-emitting diode covered with aluminium foil
224081049|NCT05156294|DEVICE|NovoMatrix|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
224081050|NCT05156294|OTHER|Control|Implants of Camlog Conelog Screw-Line Promote Plus will be placed. Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
224081051|NCT06412692|OTHER|The Motivational Interviewing Technique|Motivational interviewing technique applied to adolescents with epilepsy; It is thought that it will be effective in reducing social anxiety and increasing the quality of life of adolesce.
224081052|NCT00022074|DRUG|gabapentin|
224081053|NCT00022074|PROCEDURE|quality-of-life assessment|
224081054|NCT05020379|PROCEDURE|Perioperative and postoperative multimodal analgesia|"Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.~The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day."
224081055|NCT05020379|PROCEDURE|ESP Block|Patients in the ESPB group will be placed in a sitting position. A convex probe ultrasound transducer will be placed in a longitudinal parasagittal orientation approximately 3 cm lateral to the spinous process. Local anesthetic (20 ml 0.25% bupivacaine) will be injected bilaterally into the fascial plane on the deep face of the erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical Rating Scale (NRS). NRS scores for pain and postoperative opioid consumption will be evaluated at 15th and 30th minutes, 1st, 2nd, 6th, 12th, 24th hours, 2nd day.
224081056|NCT01536444|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
224081057|NCT06584409|DEVICE|Laser Pen|Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)
224081058|NCT06584409|OTHER|Observation|"Sham treatment with no laser output, stimulate the same acupoints as laser acupuncture group as follows: 30 seconds at bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3)~After 6 months followed up, the sham group received truely Laser stimulation energy of 4.5 J for 30 seconds at each of the following acupoints: bilateral Cuanzhu (BL2), Fengchi (GB20), Taiyang (EX-HN5), Shuaigu (GB8), Hegu (LI4), Taichong (LR3) and midline Yintang (EX-HN3), and followed up for another 3 months."
224081059|NCT02312024|DEVICE|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
224081060|NCT01583179|DRUG|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
224081061|NCT01097928|PROCEDURE|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
224081062|NCT01211912|DRUG|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
224081063|NCT01211912|DRUG|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
223534787|NCT00788112|GENETIC|protein expression analysis|
223515834|NCT05505786|BEHAVIORAL|Wide stance width|Increased stance with (by 20% over their own self-selected stance width) when performing squat exercises.
223515835|NCT02320071|OTHER|Examination of abdominal wall strength changes over time|
223515836|NCT02133872|DRUG|Minocycline dose escalation|Subjects will receive minocycline 50mg if no mean daytime ABPM SBP decline =/\> 5mm Hg; subjects will receive minocycline 100mg, if no mean daytime ABPM SBP decline =/\> 5mm Hg BP subjects will receive minocycline 200 mg.
223515837|NCT03439072|DRUG|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
223515838|NCT03439072|DRUG|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])
223515839|NCT05299580|DRUG|dabrafenib|Dabrafenib 150 mg bid
223515840|NCT05299580|DRUG|Trametinib|Trametinib 2mg qd
223515841|NCT05001113|PROCEDURE|the subxiphoid approach thoracoscopic thymectomy|A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
223515842|NCT05001113|PROCEDURE|the lateral intercostal approach thoracoscopic thymectomy|"Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces."
223515843|NCT02923167|DEVICE|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
223515844|NCT06232954|DEVICE|Mossie-Go containing treated transfluthrin disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with repellent discs impregnated with transfluthrin and a carrier oil. These discs sit above a fan that is powered by a small motor charged by solar energy. The device is expected to both prevent bites and cause some mortality to mosquitoes when switched on for 8-12 hours overnight for up to 1 calendar month. The discs then need to be replaced.
223515845|NCT06232954|DEVICE|Mossie-Go containing untreated blank disc|The Mossie-GO repellent device is approximately 8 cm3 and can be fitted with a blank untreated disc. These discs sit above a fan that is powered by a small motor charged by solar energy. The device containing the untreated disc is not expected to prevent mosquito bites. The discs will still be replaced monthly for blinding purposes.
223515846|NCT05206045|OTHER|Standard of care|Standard of care for patients with Sezary Syndrome
223515847|NCT01951729|DRUG|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
223515848|NCT01951729|DRUG|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
223515849|NCT01951729|DRUG|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
223515850|NCT01951729|DRUG|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
223515851|NCT01951729|DRUG|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
223515852|NCT01951729|DRUG|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
223515853|NCT01951729|DRUG|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
223534788|NCT00788112|OTHER|immunohistochemistry staining method|
223534789|NCT00788112|OTHER|laboratory biomarker analysis|
223534790|NCT00788112|PROCEDURE|neoadjuvant therapy|
223892237|NCT06377189|OTHER|Control Arm - Treatment As Usual (TAU)|PCPs will explain to the participants that they will treat their psychological suffering, by providing the usual care for patients with psychiatric co-morbidities. Treatment as usual (TAU) by the PCP may involve supportive care (psychoeducation, psychotherapeutic support, social interventions, etc.), referral to a mental health provider (psychotherapist, psychiatrist, psychiatric nurse, etc.), treatment with psychotropic drugs, hypnosis, acupuncture, relaxation, etc. So as to facilitate their task, PCPs participating in this study will be provided with a list of mental health workers that they could contact.
223892238|NCT06833099|DIAGNOSTIC_TEST|VAS Point and Imaging Examination|"This intervention uses a machine learning model to predict the risk of recurrent lumbar disc herniation (rLDH) in patients who have had percutaneous endoscopic interlaminar discectomy (PEID) at the L5-S1 level. The model combines clinical data (e.g., BMI, disease duration, diabetes) and imaging metrics (e.g., posterior disc height index, spinal canal stenosis) to create a personalized risk score, unlike traditional methods that rely on clinical judgment or imaging alone.~Key Features:~Data-Driven Approach: Developed using data from 309 patients for real-world relevance.~Advanced Variable Selection: Identifies eight key predictors using LASSO regression.~Multiple Machine Learning Techniques: Uses algorithms like support vector machine, random forest, and extreme gradient boosting.~Optimized for Clinical Decision-Making: Assists surgeons in personalizing treatment plans to reduce recurrence risk."
223892239|NCT06835634|PROCEDURE|Self reported questionnaires|PROMs and psychological tests submission in patients affected by neurosurgical diseases
223892240|NCT06231108|OTHER|Kinesio Taping|"Three different taping applications will be applied, namely ankle correction, quadriceps facilitation, and gluteus maximus facilitation.~1. Taping: Functional correction technique will be used to facilitate dorsal flexion movement.~2. Taping: Quadriceps Femoris (QF) Facilitation Technique - In taping to activate the QF muscle and regulate muscle tone, the patient will be placed in a supine position with hips and knees in neutral.~3. Taping: Gluteus Maximus (GM) Facilitation Technique - For taping to facilitate the GM muscle, a double-band application will be performed."
223892241|NCT04562649|DEVICE|Wise App with medication adherence reminders|The Intervention group will receive the Wise App that delivers medication adherence reminders.
223892242|NCT04562649|BEHAVIORAL|CHW Sessions|The Intervention group will complete sessions with a community health worker (CHW).
223892243|NCT03505203|BEHAVIORAL|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
224081064|NCT05846880|DRUG|Lenalidomide|For first three cycles, taken orally once daily for 28 days at 10mg/day dose. After cycle 4, taken orally once daily at 15 mg/day dose
223892244|NCT03505203|BEHAVIORAL|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
223892245|NCT06036004|DRUG|Intranasal OXT|"Syntocinon® contains the synthesized peptide OXT in a solution formulated to promote absorption through the nasal mucosa. Additional ingredients are E216 (propyl-4-hydroxybenzoate), E218 (methyl-4-hydroxybenzoate), and chlorobutanol hemihydrate. One bottle contains 5 ml, i.e., 200 IU of OXT in total. Each 0.1 ml nasal insulation delivers 4 IU of oxytocin.~OXT (24 IU twice daily) is given for 28 (± 2) days of treatment."
223892246|NCT06036004|OTHER|Placebo nasal spray|"The placebo will contain no OXT but, otherwise, be identical to the intranasal OXT product with respect to the other ingredients.~Placebo is given twice daily for 28 (± 2) days of treatment."
223892247|NCT06822751|DRUG|Fosfomycun-trometamol|Study of the efficacy and safety of Fosfomycin trometamol as a 14-day treatment using a 3 g sachet every 2 days for 14 days for the treatment of male urinary tract infections in primary care: open-label, non-randomised, multicentre, inter-regional trial.
223892248|NCT00582231|OTHER|Questionnaires.|Questionnaires.
223892249|NCT04942535|BEHAVIORAL|Social Incentive Gamification|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Each participant signs a pre-commitment contract. Participants are entered into a game with their family members. Each family receives 70 points weekly. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family keeps its points; if not, they lose 10 points. The participant is notified the following day if they were the family rep.~At the end of the week, if the family has 40 points or more, they advance 1 level. If they have less than 40 points, the family drops down 1 level. Each family team starts in the middle of 5 levels.~At the end of the intervention, families in the top 2 levels receive a small gift.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
223892250|NCT04942535|BEHAVIORAL|Social Goals through Incentives to Charity|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Families select a charity at the beginning of the intervention. They are informed that $20 is available each week to be donated to a charity of their choice. Each day, a family member is selected at random to represent the family. If that person's step goal was achieved, the family gets credit for meeting their goal; if not, the entire family does not get credit. The participant is notified the following day if they were the family rep.~If the family achieves their goal on at least 4 of 7 days in a week, $20 is donated to charity.~In the 6 month follow-up, participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
223892251|NCT04942535|BEHAVIORAL|Daily Performance Feedback|"Participants enroll as a family team. They are asked to use a Fitbit activity tracker daily. Each participant sets a daily step goal based on their baseline step count.~Participants receive a daily text message stating whether or not they achieved their step goal on the prior day."
223892252|NCT06188026|DRUG|NNC0194-0499|Once a week for 5 weeks as an injection in dose of 30 mg. The injection will be given under the skin
223892253|NCT06188026|DRUG|ethinylestradiol/levonorgestrel|Oral contraceptive is taken as tablet daily composed of 30 μg ethinylestradiol and 150 μg levonorgestrel.
223892254|NCT06832527|OTHER|Rehabilitation treatment|ROM, strength, stretch and proprioception exercises
223892255|NCT06832527|OTHER|Virtual Reality games|Virtual Reality games using META QUEST PRO glasses
223892256|NCT04850274|BEHAVIORAL|Remote Therapy Intervention (RTI)|A single ED session followed by 5 remote therapy sessions
223892257|NCT04850274|BEHAVIORAL|Artificial Intelligence Remote Therapy Intervention|Optimized by reinforcement learning to step up or down the intensity of treatment between three levels based on patient response to daily assessments.
224081065|NCT05846880|DRUG|Maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, will start maintenance therapy with Monthly replacement with 50,000 IU
224081066|NCT05846880|DRUG|No maintenance Vitamin D|After replacement of vitamin D deficiency with weekly cholecalcefirol 50,000 units untill levels are \> 30, stop replacement and continue monitoring levels
223515854|NCT01951729|DRUG|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
223515855|NCT06136299|OTHER|Neuromuscular Training|This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
223515856|NCT04248673|OTHER|carbohydrate reduced bread|Consumption of carbohydrate reduced bread for three months.
223515857|NCT04248673|OTHER|carbohydrate rich bread|Consumption of carbohydrate rich bread for three months.
223892258|NCT06513416|PROCEDURE|Elective upper abdominal surgery|The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
223892259|NCT05977114|BEHAVIORAL|family conflict intervention group|The family conflict preventive intervention includes the introduction to the occurrence of family conflicts, communication skills training, and role play to practice the skills.
223892260|NCT05977114|BEHAVIORAL|handicraft-making group|The group involves handicraft-making.
224081067|NCT05630963|DEVICE|Aversive stimuli|Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
224081068|NCT05630963|DRUG|PET radiotracer|"A Nociceptin/Orphanin FQ (N/OFQ) peptide tracer (\[11C\] NOP-1A) will be used as the PET radiotracer. Approximately 10 mCi of this tracer will be delivered intravenously as a slow bolus over 60 seconds with beginning of the PET imaging acquisition. Approximately 60 ml of blood will be drawn from an artery throughout the dynamic PET acquisition in order to measure the blood N/OFQ levels."
224081069|NCT05946772|DRUG|Cyclosporine A|2.5mg/kg body weight Cyclosporine A as an intravenous bolus
224081070|NCT05946772|DRUG|Placebo|The same amount of 0.9% sodium chloride (NaCl0.9%) will be applied in an indistinguishable package as an intravenous bolus
224081071|NCT02249741|DRUG|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
224081072|NCT00445302|DRUG|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
224081073|NCT00188630|DRUG|N-acetylcysteine|
223892261|NCT06835244|OTHER|68Ga-PSMA-11|All patients with non prostatic neoplasm expressing PSMA undergo 68\[Ga\]Ga-PSMA-11-PET/CT
224081074|NCT00188630|OTHER|5% dextrose solution|
224081075|NCT02055625|BIOLOGICAL|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
223892262|NCT06831708|BEHAVIORAL|Psychoanalytic Psychotherapy|This intervention involves short-term psychoanalytic therapy based on a standardized framework. Although not rigidly manualized, the treatment protocol includes core psychoanalytic concepts (such as transference, resistance, and the exploration of unconscious conflicts). Sessions will be conducted weekly (50 minutes each) for a total of 12 sessions. This intervention is delivered by two study authors who have undergone dedicated training and calibration to ensure consistent application of the framework.
223892263|NCT06831708|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|This intervention consists of a structured and manualized CBT program specifically tailored for individuals with Generalized Anxiety Disorder (GAD). The intervention includes defined session objectives, cognitive restructuring techniques, behavioral experiments, and homework assignments. Participants will receive 12 weekly sessions (50 minutes each), delivered by two study authors who are trained in CBT.
223892264|NCT05562791|DRUG|[68Ga]PSMA|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
223892265|NCT05562791|DIAGNOSTIC_TEST|PET/CT imaging|68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
223515858|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/CT|Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.
223515859|NCT04298112|DIAGNOSTIC_TEST|PSMA PET/MR|Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
223515860|NCT03992872|BIOLOGICAL|Chikungunya|Virus Like Particle
223515861|NCT04907955|PROCEDURE|phacoemulsification with implantation of presbyopia correcting IOL|cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
223515862|NCT04932772|OTHER|Kinesiotaping|Technique: Include Rectus Abdominas Muscles (RAM), Oblique Abdominal Muscles (OAM). Tape will be applied on RAM using muscles technique from origin to insertion of muscle with a tension between15-35%. Band will be start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xyphoid process. Finally will perform on the right and left external oblique muscles the procedure will be start with no tension from bottom and of 6-12 ribs and then the hip will be place in flexion and rotation to opposite direction and the band will tape on pubic bone with tension between 15-35% (Kase et al., 2003).
223534791|NCT00788112|PROCEDURE|therapeutic conventional surgery|
223892266|NCT05891236|BIOLOGICAL|MAM01 1.5 mg/kg|1.5 mg/kg MAM01 will be administered via IV route.
223892267|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via IV route.
223892268|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via SC route.
223892269|NCT05891236|BIOLOGICAL|MAM01 10 mg/kg|10 mg/kg MAM01 will be administered via IV route.
223892270|NCT05891236|BIOLOGICAL|MAM01 40 mg/kg|40 mg/kg MAM01 will be administered via IV route.
223892271|NCT05891236|BIOLOGICAL|MAM01 450 mg|MAM01 will be administered via SC route.
223892272|NCT05891236|BIOLOGICAL|Placebo|Placebo will be administered via SC route.
224081076|NCT00496392|DRUG|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
224099138|NCT02799381|DRUG|Optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications were individually optimized to their maximum therapeutic effect.
223515863|NCT04932772|OTHER|Abdominal Exercises|Women in group B will receive abdominal muscles exercise (2 sessions/ week) for eight weeks. This program will be applied in both group A and B. The women will repeat the same exercise program on other days as home routine. This program is proposed by Kamel and Yousif, 2017, as based on the literature (Kamel and Yousif, 2017), there is no golden standard exercise program for DRAM. Illustrations of the exercises will be provided, so that the women could repeat the same exercise program on other days as a home routine. All the exercises will be performed while the subject tied a scarf around her abdomen. The following proposed one included sit ups, reverse sit-ups, reverse trunk twists, and U-seat exercises (Fig. 5). Each exercise was repeated 20 times and was increased by four repetitions each week throughout the interventions. In addition, a respiratory rehabilitation maneuver to involve the abdominal muscles, especially the transverse abdominis will be performed.
223892273|NCT05891236|BIOLOGICAL|MAM01 5 mg/kg|5 mg/kg MAM01 will be administered via IV route.
223892274|NCT05891236|OTHER|Control|No drug or placebo will be administered.
223892275|NCT05891236|BIOLOGICAL|MAM01 600 mg|MAM01 will be administered via SC route.
223892276|NCT05891236|BIOLOGICAL|MAM01 900 mg|MAM01 will be administered via SC route.
223892277|NCT06836362|OTHER|Acupuncture treatment|"Children will receive 8 acupuncture sessions during 10 weeks (1 session per week during 6 weeks, followed by 1 session every other week during 4 weeks).~At each acupuncture session, the acupuncturist records the patient's bowel habits, gastrointestinal symptoms and the use of escape medication during the period between sessions. After 3, 6 and 8 acupuncture treatments respectively, patients will visit the research team after they receive acupuncture to evaluate adverse events.~After completion of these 10 weeks, an acupuncture-free follow-up period of 4 weeks commences. The follow-up period will be used to investigate if and how long effects of the intervention will persist. During the intervention period and the follow-up period, escape medication (bisacodyl or enemas) is allowed under the same conditions as during the run-in period."
224081077|NCT03646448|BEHAVIORAL|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
223892278|NCT06829394|OTHER|Program Assignment|The intervention group will include People living with HIV who were assigned to the Arms Around You Program in the lottery.
224081078|NCT01029730|DRUG|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
224081079|NCT01029730|DRUG|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
224081080|NCT01029730|DRUG|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
224081081|NCT03242330|DEVICE|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
224081082|NCT02477345|DRUG|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
224081083|NCT01613326|DRUG|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
224081084|NCT01613326|DRUG|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
224081085|NCT01613326|DRUG|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
224081086|NCT01613326|DRUG|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
224081087|NCT01613326|DRUG|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
224081088|NCT02201160|DIETARY_SUPPLEMENT|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
224081089|NCT03370159|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
224081090|NCT03370159|DRUG|Docetaxel|Given IV
224081091|NCT03370159|OTHER|Pharmacological Study|Correlative studies
224081092|NCT05205408|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Administered by intratumoral injection as single agent.
224081093|NCT04181879|BEHAVIORAL|Intervention|"* GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~* The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~* GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste')."
224081094|NCT05331911|DRUG|Propofol|total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
223892279|NCT03861897|OTHER|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
223515864|NCT01940744|PROCEDURE|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
223515865|NCT01940744|PROCEDURE|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
223515866|NCT01537432|DRUG|secukinumab|secukinumab
223515867|NCT01537432|DRUG|placebo|placebo comparator
223515868|NCT01033669|DEVICE|CRC-749|There is no drug being used. This is a device.
223515869|NCT01033669|DEVICE|Diskus|There is no drug being used. This is a device.
223515870|NCT01033669|DEVICE|Twisthaler|There is no drug being used. This is a device.
223515871|NCT01033669|DEVICE|Miat Monohaler|There is no drug being used. This is a device.
223515872|NCT05580679|OTHER|Abdominal massage|"Application time of the massage: 30 minutes after meals, twice a day, at 10:00 in the morning and at 16:00 in the evening.~Application time of the massage: 15 minutes each Materials needed: Gloves, Liquid Vaseline, Paper Towel Massage methods used: Efflorage, Petrissage, Vibration"
223515873|NCT04585581|BEHAVIORAL|time-restricted eating|Participants will be asked to limit the time-window for their daily energy intake to a maximum of 10 hours.
223515874|NCT04585581|BEHAVIORAL|high intensity exercise|Participants will be encouraged to exercise with high intensity 2-3 times per week
223515875|NCT04585581|OTHER|Standard Care|Standard clinical care
223515876|NCT00314977|DRUG|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
223515877|NCT00314977|DRUG|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
223515878|NCT00314977|DRUG|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
223515879|NCT00889005|OTHER|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
223515880|NCT04105283|BIOLOGICAL|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
223515881|NCT03452345|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
223515882|NCT03452345|DRUG|Placebo|Placebo (Normal saline)
223515883|NCT05166902|DEVICE|Lens A (comfilcon A lens)|1 month
223515884|NCT05166902|DEVICE|Lens B (lehfilcon A lens)|1 month
223515885|NCT04935593|OTHER|The RENEW Intervention|An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
223515886|NCT05628571|COMBINATION_PRODUCT|Zinc toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing amine-based zinc lactate (0.1%) and fluoride (1400 ppm F).
223515887|NCT05628571|COMBINATION_PRODUCT|Fluoride Toothpaste|Participants will brush their teeth with a commercially available, soft-bristle adult toothbrush and toothpaste containing fluoride (1450 ppm F).
223515888|NCT03482232|DRUG|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
223892280|NCT03861897|OTHER|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
223892281|NCT06458894|BEHAVIORAL|Prerehabilitation|Home prerehabilitation was performed on the basis of routine preoperative preparation
223892282|NCT06065020|BEHAVIORAL|VIDACTIVA sessions|"Community health workers (CHWs) will delivered VIDACTIVA intervention that consists in 8 home-sessions, one hour duration, within a period of 14 weeks + 2 follow-up calls (monthly). In total, a period of 22 weeks.~The multicomponent intervention consist in the following:~Problem-Solving Exercises: These are basic structured exercises aimed at training older individuals in problem-solving. This activity is centered around the older adult, meaning the older adults guides this activity, and the CHWs is a facilitator.~Physical Activation: This component involves planning and scheduling enjoyable activities (physical or social) that the older adult chooses based on their preferences and capabilities.~Education on Depressive Symptoms (psychoeducation)"
223892283|NCT06065020|BEHAVIORAL|Standard Care|Study fieldworkers will provide 2 educational sessions (45-60 min) about mental health at old age and participant will be guided to mental health community services (primary care centers). One session after the enrolment (week 1) and one at the 14th week.
223892284|NCT06347874|DRUG|Cryoablation|an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves
223515889|NCT03482232|DRUG|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
223515890|NCT03482232|DRUG|paracetamol|paracetamol 1g for more than 3 days
223515891|NCT03482232|DRUG|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
223515892|NCT03482232|DRUG|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
223515893|NCT03482232|DIAGNOSTIC_TEST|Prostate cancer|Screening for prostate cancer in asymptomatic patients
223515894|NCT03482232|RADIATION|Lumbago|image tests in non-specific lumbago
223515895|NCT03482232|DRUG|Antimicrobial agent|antibiotics for pharyngitis (infants)
223515896|NCT03482232|DRUG|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
223892285|NCT06347874|DRUG|ESP Catheter|an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
223892286|NCT06010446|OTHER|No intervention, just retrospective analysis of data.|
223515897|NCT03482232|DRUG|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
223515898|NCT01269775|OTHER|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
223515899|NCT01998477|BIOLOGICAL|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain \[A/H1N1-like, A/H3N2-like, and B-like\]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
223515900|NCT01998477|BIOLOGICAL|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain \[A/ H1N1-like, A/H3N2-like, and B-like\]) IM injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere.
223515901|NCT04843592|DEVICE|SOKARY Mobile|Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
223515902|NCT05044481|PROCEDURE|third molar surgical removal|ambulatory surgical intervention of the maxilla and / or mandible for third molar removal
223515903|NCT04984200|PROCEDURE|Retinal imaging|Subjects will undergo retinal imaging before and/or after administration of mydriatic agent
223515904|NCT04984200|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
223515905|NCT01210781|PROCEDURE|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
223515906|NCT00779909|DRUG|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
223515907|NCT00779909|OTHER|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
223515908|NCT03462602|PROCEDURE|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
223515909|NCT03462602|PROCEDURE|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
223515910|NCT03523585|DRUG|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
223515911|NCT03523585|DRUG|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
223515912|NCT03523585|DRUG|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
223515913|NCT03523585|DRUG|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
223515914|NCT02171728|DRUG|BIBW 2992|
223515915|NCT01799902|DRUG|Solifenacin|Oral
223515916|NCT05129306|OTHER|Observational|In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.
223892287|NCT06826391|DEVICE|Calcium hydroxylapatite|This intervention consists of calcium hydroxylapatite injections into the attached gingiva of a patient who has gingival recession to stabilize, grow and reverse gingival recession. These injections will also reduce tooth hypersensitivty in the affected teeth.
223892288|NCT06198374|DIETARY_SUPPLEMENT|Sodium propionate|The patients will be randomized to PA or placebo intervention (2:1 randomization). After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group). By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function.
223892289|NCT06198374|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
224099139|NCT02799381|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|Dose levels were individually optimized.
223515917|NCT00005940|RADIATION|iodine I 131 monoclonal antibody BC8|Given IV
223515918|NCT00005940|DRUG|busulfan|Given PO
223515919|NCT00005940|DRUG|cyclophosphamide|Given IV
223515920|NCT00005940|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
223515921|NCT00005940|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
223515922|NCT00005940|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
223515923|NCT00005940|DRUG|cyclosporine|Given IV or PO
223892290|NCT05463874|BEHAVIORAL|Mindful Self-Compassion Program|The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
223892291|NCT04505020|OTHER|3D Print + Conventional imaging|This group will have a 3D reconstruction of their hip printed using a 3D printer so that the PI can use it in their pre and intra-operative planning along with traditional imaging.
223892292|NCT04505020|OTHER|Conventional imaging|This group will have CT, MRI and X-Ray imaging completed so that the PI can use it in their pre and intra-operative planning.
223892293|NCT03792282|BEHAVIORAL|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
223515924|NCT00005940|DRUG|methotrexate|Given IV
223515925|NCT00005940|OTHER|laboratory biomarker analysis|Correlative studies
223515926|NCT04870866|DRUG|Nicotinamide ribonucleoside|Two year intervention
223515927|NCT00003053|DRUG|cisplatin|
223892294|NCT03792282|BEHAVIORAL|Usual care|Participants receive a general lifestyle counseling.
223515928|NCT00003053|DRUG|etoposide|
223515929|NCT00003053|PROCEDURE|adjuvant therapy|
223515930|NCT05360225|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The KRAS Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx instrument for the detection of somatic G12C mutations in the human KRAS oncogene using DNA extracted from formalin fixed paraffin-embedded (FFPE) Non-small Cell Lung Cancer (NSCLC) tissue.
223515931|NCT05406726|DIETARY_SUPPLEMENT|palmitoylethanolamide|palmitoylethanolamide is an lipid based endocannabinoid naturally made by the body and is present in several common foods such as eggs
223515932|NCT05406726|DIETARY_SUPPLEMENT|Placebo|a capsule filled only with maltodextrin will be used as a placebo
223515933|NCT05145894|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
223515934|NCT06401109|DEVICE|AquaPass|"The AquaPass system works by activating the body's natural sweating mechanism to remove excess fluid from the interstitial compartment. This process is achieved by wearing a garment that creates optimal microclimate conditions around the skin.~The system is controlled by a portable unit that delivers warm air to the wearable component while ensuring patient safety."
223515935|NCT00635583|OTHER|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~* 8 oz milk~* 6 oz yogurt~* 1.5 oz cheese"
223515936|NCT02166762|PROCEDURE|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
223515937|NCT03704922|BIOLOGICAL|Transfusion|Red cell units for transfusion
223515938|NCT01132690|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
223515939|NCT03148782|BEHAVIORAL|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
223515940|NCT02822690|OTHER|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
223515941|NCT04774562|BEHAVIORAL|Video-Assisted Discharge Education (VADE)|Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.
223515942|NCT04774562|BEHAVIORAL|Physiotherapy (PT) Program|Physiotherapy (PT): Breathing exercises, positioning, hip range of motion and strengthening exercises, and information about walking and ambulation.
223515943|NCT04909411|OTHER|OPHTHALMOLOGICAL ASSESSMENT|assessment of eye mobility (search for heterophoria or strabismus), visual acuity, visual fields, external structures and funduscopic examination
223515944|NCT04909411|OTHER|NEUROPSYCHOLOGICAL ASSESSMENT|completion of WISC-5, Vineland Adaptive Behavior Scale II and Strengths and Difficulties Questionnaire
223515945|NCT00003327|DRUG|paclitaxel|
223515946|NCT03476252|DIAGNOSTIC_TEST|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
223515947|NCT03380988|OTHER|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
223515948|NCT03380988|OTHER|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
223515949|NCT03495895|BEHAVIORAL|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
223515950|NCT03495895|BEHAVIORAL|Usual Care|Usual care condition
223892295|NCT05893082|DEVICE|F2 Filter and Delivery System|Placement of F2 device in aorta to cover the great cerebral vessels.
223892296|NCT05569382|DRUG|Verapamil|"1\. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
223892297|NCT05569382|DRUG|Bisoprolol|"1\. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
223892298|NCT05569382|DRUG|Placebo|"1\. week: uptitration with one capsules per day, until maximum dosage of three capsules/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5\. week: downtitration"
224099140|NCT02799381|DEVICE|CADD-Legacy ambulatory infusion pump|(manufactured by Smiths Medical)
223892299|NCT03025698|DRUG|Eltrombopag|Tablet for oral use, once daily or Powder for oral suspension (PfOS), once daily
224081095|NCT05331911|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
224081096|NCT06499818|PROCEDURE|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
224081097|NCT06499818|PROCEDURE|STABLE-AF|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during Atrial Fibrillation
224081098|NCT06499818|PROCEDURE|CPVI|ablate around the pulmonary vein orifice
224081099|NCT03980938|DRUG|neflamapimod|40 mg neflamapimod capsule
223515951|NCT04629157|DEVICE|Innova Lateral Flow Device|The Innova Lateral Flow Device will be used on anterior nasal swab specimens and RT-PCR will be performed on nose and throat swabs.
223515952|NCT03568786|PROCEDURE|End-inspiratory pause 10%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time
223515953|NCT03568786|PROCEDURE|End-inspiratory pause 30%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
223515954|NCT01795339|DRUG|AZD3293|Oral solution
223515955|NCT01795339|DRUG|Placebo|Oral solution
223515956|NCT02872142|BIOLOGICAL|Albutein 5%|Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the participant.
223515957|NCT02872142|PROCEDURE|Plasma Exchange|Plasma Exchange will be performed using albutein 5% as the replacement solution.
223515958|NCT05243316|PROCEDURE|Clamping|There will be a randomized selection of patients who will have a clamping of the chest tube 6 hours prior to chest tube removal.
223515959|NCT05243316|PROCEDURE|Non Clampling|There will be a randomized selection of patients who wont have chest tube clamping 6 hours prior to chest tube removal.
223515960|NCT00894010|DRUG|carbamazepine 400mg|
223515961|NCT00894010|DRUG|levetiracetam 1000mg|
223515962|NCT02577380|BEHAVIORAL|IPV/GBV HTC|Participants will be interviewed after receiving their services.
223515963|NCT01287429|OTHER|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
223515964|NCT05657171|DRUG|cyproterone Acetate/Ethinyl Estradiol Combination|cyproterone acetate (CPA) 2 mg, combined with EE 35 µg.
223515965|NCT03559686|DRUG|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
223515966|NCT01903720|DRUG|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
223515967|NCT01197274|DEVICE|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
223515968|NCT02002195|DRUG|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
223515969|NCT02002195|DRUG|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
223515970|NCT02977871|PROCEDURE|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
223892300|NCT03025698|DRUG|hATG|Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
223892301|NCT03025698|DRUG|CsA|Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
223892302|NCT06838260|OTHER|24°C Endotracheal tube|A disposable ETT sized appropriately for the age of the patients will be kept in a 40°C incubator (MIR-162) for 30 minutes. An infrared non-contact thermometer will be used to measure the ETT wall temperature. After removal from the incubator, intubation will be performed as soon as the tubes reach a temperature of 24°C for the T1 group by serial measurements. All intubations will be performed by a single anesthesiologist who is not associated with the study.
224081100|NCT03980938|OTHER|Placebo|matching placebo capsule
224081101|NCT02266173|DRUG|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
224081102|NCT02485080|DRUG|Simeprevir|
224081103|NCT02485080|DRUG|Sofosbuvir|
224081104|NCT02244151|DRUG|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
224081105|NCT02244151|DRUG|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
224081106|NCT05030727|DIAGNOSTIC_TEST|record of pNGAL|Preoperative (0.hour baseline), postoperative 24.,48. BUN, Creatinine, Lactate values in the blood of the patients at 1 hour, and for plasma NGAL, blood samples will be taken at the preoperative, postoperative 6th and 24th hours. And the results will be recorded.
224081107|NCT04724148|DRUG|Fentanyl|To assess the accuracy of HVPG in TIPS after injecting a dose of 1\~2 mg/kg fentanyl.
224081108|NCT00840827|DRUG|lenalidomide|Lenalidomide 10mg po daily
224081109|NCT00840827|DRUG|cyclosporine A|CSA 250mg orally twice daily
224099141|NCT02799381|DEVICE|Percutaneous endoscopic gastrostomy tube|(PEG tube)
223515971|NCT00952562|DIETARY_SUPPLEMENT|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
223515972|NCT00952562|DIETARY_SUPPLEMENT|placebo|Empty capsules, 3 capsules per day for 16 weeks
223515973|NCT03479684|OTHER|Gene-directed dosage of warfarin|the first day given model prediction dose \* 1.5 times（\<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
223515974|NCT03479684|OTHER|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
223515975|NCT05186298|DEVICE|AcrySof® IQ PanOptix®|The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL
223515976|NCT05186298|DEVICE|Synergy®|The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.
223515977|NCT05186298|PROCEDURE|Cataract Surgery|IOL implantation will be performed
223515978|NCT00002656|DRUG|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
223515979|NCT01827189|OTHER|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
223515980|NCT02244957|DEVICE|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations \<88% while on stable bi-level settings.
223515981|NCT02244957|DRUG|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
223515982|NCT03136094|BEHAVIORAL|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
224099142|NCT02799381|DEVICE|Jejunal extension tube|(J-tube)
223515983|NCT03136094|BEHAVIORAL|SBIRT+Usual Care|Patients receive usual SBIRT care
223515984|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young men|"Participants in this intervention will be healthy young men. The information of nutritional supplements is below.~Hydrolyzed collagen: 30 grams unflavored hydrolysed collagen (HC) (Myprotein, Cheshire, UK) 30.5 grams unflavored maltodextrin (Myprotein, Cheshire, UK) 50 milligrams vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK) 3 grams non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
223515985|NCT06372080|DIETARY_SUPPLEMENT|Resistance training with hydrolyzed collagen ingestion in healthy young women|Participants in this intervention will be healthy young women. The same nutritional supplements in Arm 1 wil be used in Arm 2.
223515986|NCT03373669|BIOLOGICAL|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
223515987|NCT03373669|BIOLOGICAL|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
223515988|NCT05306015|COMBINATION_PRODUCT|Mindfulness meditation based on brain-computer interface|"Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation."
223892303|NCT06838260|OTHER|37°C Endotracheal tube|A disposable ETT sized appropriately for the age of the patients will be kept in a 40°C incubator (MIR-162) for 30 minutes. An infrared non-contact thermometer will be used to measure the ETT wall temperature. After removal from the incubator, intubation will be performed as soon as the tubes reach a temperature of 37°C for the T2 group by serial measurements. All intubations will be performed by a single anesthesiologist who is not associated with the study.
223892304|NCT04186520|BIOLOGICAL|8/12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
223892305|NCT04186520|BIOLOGICAL|8/12-Day Production of Cryopreserved Car-T Cells|A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
223892306|NCT04186520|BIOLOGICAL|12-Day Production of Car-T Cells|A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
224081110|NCT01445535|BIOLOGICAL|Rituximab|Rituximab will be given with siplizumab and etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin every 21 days
223515989|NCT05306015|COMBINATION_PRODUCT|Routine care|Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
223515990|NCT06003647|OTHER|Educational Intervention|Educational module and video
223515991|NCT02548819|OTHER|MRI|MR imaging of patients with implanted cardiac devices
223515992|NCT04620980|DIAGNOSTIC_TEST|targeted resequencing|The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).
223515993|NCT05600517|OTHER|Fluoride|a patient-centered education on diet, oral hygiene and fluoridated toothpaste 5000ppm with check up´s and topical fluoride application (varnish) every second month.
223515994|NCT02189967|RADIATION|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
223515995|NCT02189967|RADIATION|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
223515996|NCT04709393|OTHER|FRAX+SARC-F questionnaire pre-screening|Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
223515997|NCT06636825|OTHER|Graded hypercapnia|Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
223515998|NCT06636825|DRUG|Caffeine|400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
223515999|NCT06636825|DRUG|Placebo|Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
223516000|NCT06564103|COMBINATION_PRODUCT||
223516001|NCT06551909|RADIATION|Neoaddjuvant Stereotactic Radiotherapy with Simultaneous Integrated Boost|Patients with Glioblastoma will receive neoadjuvant stereotactic radiotherapy to Planning Target Volume (PTV) to 30 Gy in 5 fractions, and a Simultaneous Integrated Boost delivering 35-50 GY to GTV. Patients will be divided into groups of 5 and will receive (in the absence of 2 G4 toxicities per group), the following dose levels: 35-40-42.5-45-47.5 and 50 Gy. Standard Temozolomide chemotherapy will be prescribed after surgery.
223516002|NCT00836901|DRUG|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
224081111|NCT01445535|DRUG|Etoposide|Etoposide will be given with siplizumab and prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
223516003|NCT00836901|DRUG|Augmentin®|400 mg-57 mg chewable tablet
223516004|NCT06639932|BEHAVIORAL|We-INtervention|The We-INtervention focuses on the relationship dynamics of HIV-serodiscordant male couples. In developing the intervention, we reviewed relevant theories and frameworks, such as the cognitive transactional model, the systemic transactional model, the dyadic illness management model, and the intersectional framework of stigma. The three weekly 60-minute sessions are Session 1: We-disease appraisal. Despite stigma related to their dual minority identities, couples develop a perception of HIV as a shared disease, enhancing illness control. Session 2: Couple communication. Couples undertake skill-building exercises on effective communication techniques to strengthen their relationship. Session 3: Dyadic coping. Couples learn to optimize preference and value assessments in HIV management. A few skill-building exercises help them mobilize and maintain mutual support and develop joint problem-solving skills.
223516005|NCT06639932|BEHAVIORAL|Usual Care Group|The participants in the control condition will receive health information pamphlets. The HIV-seropositive partners will receive information on HIV-related knowledge (e.g., symptoms, comorbidity, stages, and opportunistic infection), treatment (e.g., ART and side effects), and management (e.g., nutrition and mental health). The HIV-seronegative partner will receive information on HIV transmission (e.g., risk factors), prevention (e.g., safe sex and PrEP), and testing.
223516006|NCT05694494|BEHAVIORAL|internet-based Lifestyle-integrated Functional Exercise (iLiFE)|receiving internet-based LiFE training and home safety assessment
223516007|NCT05694494|BEHAVIORAL|upper limb exercise training|upper limb exercise training
223516008|NCT00830336|DRUG|Azithromycin|Oral Suspension
223516009|NCT00830336|DRUG|Zithromax®|Oral Suspension
223516010|NCT01565759|DRUG|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
223892307|NCT04876742|OTHER|Beer|"As interventive agent 0.5 L organic alcohol-containing wheat beer produced by the brewery Unser Bier in Basel, Switzerland, is administered once a day at 8pm for 6 consecutive days after enrolment."
224081112|NCT01445535|BIOLOGICAL|Siplizumab|Siplizumab will be given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
224081113|NCT01445535|DRUG|Prednisone|Prednisone will be given with siplizumab and etoposide, vincristine, cyclophosphamide, doxorubicin and rituximab every 21 days
224081114|NCT01445535|DRUG|Vincristine|Vincristine will be given with siplizumab and etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab every 21 days
224081115|NCT01445535|DRUG|Cyclophosphamide|Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
224081116|NCT01445535|DRUG|Doxorubicin|Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
223892308|NCT04876742|OTHER|Water|For the interventional control group 0.5L water is administered once a day at 8pm for 6 consecutive days after enrolment.
223892309|NCT06783205|OTHER|Restriction of the Dominant Hand Due to Splint Use|This study aimed to assess whether the non-dominant hand function changes in patients using splints or casts on their dominant hand during the tissue healing period.
223892310|NCT06830213|OTHER|Questionnaire study|Questionnaire application
223892311|NCT03667196|PROCEDURE|antegrade and retrograde approach|This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
223892312|NCT06836206|DIETARY_SUPPLEMENT|Gum Arabic|Gum Arabic (Acacia seyal and Acacia senegal) 30g powdered GA in 100ml water, consumed daily.
223892313|NCT06836206|OTHER|Water|100ml water, consumed daily
223892314|NCT05650970|OTHER|routine therapy|Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients
223892315|NCT05650970|OTHER|radial nerve mobilization exercise|Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
223892316|NCT05258422|RADIATION|stereotactic body radiotherapy, 20 Gy in 1 fraction|A single dose of focused radiation therapy of 20 Gy in 1 fraction to the PTV of the arrhythmogenic substrate
223892317|NCT06475378|DEVICE|Moonbird|Moondbird is a technology-supported breathing exercise with a tactile breath pacer device
223892318|NCT06475378|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is the recommended, first-line treatment for chronic insomnia, as it is proven to be highly effective in improving sleep quality. It is a multifaceted approach, which includes time-in-bed restriction (i.e., reducing time spent in bed to enhance sleep consolidation), stimulus control (i.e., restricting behaviours incompatible with sleep in the bedroom), and cognitive restructuring (i.e., addressing and altering maladaptive thoughts and beliefs regarding sleep) to reinstate a regular sleep pattern.
223892319|NCT04029688|DRUG|Idasanutlin|Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
223892320|NCT04029688|DRUG|Venetoclax|Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
223892321|NCT04029688|DRUG|Cyclophosphamide|Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m\^2) as an intravenous (IV) infusion.
223892322|NCT04029688|DRUG|Topotecan|Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m\^2 as an IV infusion.
223892323|NCT04029688|DRUG|Fludarabine|Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m\^2 as an IV infusion.
223892324|NCT04029688|DRUG|Cytarabine|Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m\^2 as an IV infusion.
223892325|NCT04029688|DRUG|Intrathecal Chemotherapy|All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
223892326|NCT06837285|DEVICE|mandibular advancement device|Results of clinical trials on MADs are regularly published in the international literature but are generally very strongly controlled studies, still far away from being applied in routine daily clinical practice. The current retrospective study evaluates real-world data to determine the extent to which MAD improves both symptoms in patients with OSA. It is estimated that about 3% of newly diagnosed OSA patients are treated with MAD. In the light of new future treatment conventions, health government departments are increasingly demanding real-world data to stimulate knowledge of the relative effectiveness and value of treatments in the management of patients in routine clinical settings.
223892327|NCT06833515|OTHER|one flare+wave one gold glider+wave one gold|In this clinical study, the teeth will first undergo coronal shaping with the One Flare file. Then, the glide path and final shaping will be performed in reciprocal mode with reciprocal files.
223892328|NCT06833515|OTHER|wave one gold glider+wave one gold|In this group, only the glide path and final shaping will be performed using reciprocal files, without coronal shaping.
223892329|NCT06833515|OTHER|wave one gold|In this group, shaping will be performed using only a reciprocating file, without coronal shaping and glide path preparation.
223892330|NCT06833515|OTHER|15K-type stainless-steel hand file|The operator prepared the glide path using a #15K-type stainless-steel hand file with push-pull motion. On sensing resistance, the file was withdrawn, recapitulation was performed with a #10K-type stainless-steel file, and debris was removed by irrigating the canals with 5% NaOCl. The operator repeated this procedure until the #15K-file reached the complete working length
224081117|NCT01183624|OTHER|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
224081118|NCT01183624|OTHER|Placebo Patch|Control patch with no herbal ingredients
223516011|NCT04138355|OTHER|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
223516012|NCT01127958|DEVICE|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
223516013|NCT01127958|DEVICE|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
224081119|NCT03216382|BEHAVIORAL|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
224081120|NCT03216382|BEHAVIORAL|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
224081121|NCT01283932|DRUG|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
223516014|NCT04873908|OTHER|modified constraint-induced therapy|Patients received conventional rehabilitation and modified constraint-induced therapy schedule
223516015|NCT04873908|OTHER|Proprioceptive Training|Patients received conventional rehabilitation and Proprioceptive Training schedule
223516016|NCT04873908|OTHER|conventional rehabilitation|Patients received conventional rehabilitation schedule
223516017|NCT02599831|DEVICE|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
223516018|NCT02599831|DEVICE|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
223516019|NCT02599831|DEVICE|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
223516020|NCT03376386|RADIATION|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
223516021|NCT01383876|BEHAVIORAL|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
223516022|NCT01383876|BEHAVIORAL|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
223516023|NCT01542944|DRUG|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
223516024|NCT05218707|OTHER|GUEDEL Airway|GUEDEL Airway of size '000,00,0,' and '1' will be used.
223892331|NCT06835205|BEHAVIORAL|Tous Épanouis à l'École (TEAL Program)|The TEAL Program is a structured, five-session behavioral intervention targeting psychosocial skill development in children. Delivered by healthcare students in elementary school classrooms, the program includes interactive activities designed to improve communication, empathy, social proximity, and prosocial behaviors. The intervention aims to reduce bullying behaviors (victims and aggressors) and enhance classroom climate. Each session is guided by a detailed manual and includes active participation from students and their teachers.
224081122|NCT01145937|PROCEDURE|PET|Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
223516025|NCT06160206|BIOLOGICAL|Bevacizumab|Given IV
223516026|NCT06160206|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223516027|NCT06160206|PROCEDURE|Computed Tomography|Undergo CT
223516028|NCT06160206|OTHER|Electronic Health Record Review|Ancillary studies
223516029|NCT06160206|RADIATION|Hypofractionated Radiation Therapy|Undergo radiation therapy
223516030|NCT06160206|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223516031|NCT06160206|BIOLOGICAL|Retifanlimab|Given IV
223516032|NCT03907891|BEHAVIORAL|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
223516033|NCT03907891|BEHAVIORAL|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
223516034|NCT03907891|BEHAVIORAL|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
223516035|NCT03680508|DRUG|TSR-022 and TSR-042|immunotherapy
223516036|NCT03449485|DRUG|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
223516037|NCT04831346|OTHER|Low level laser|940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.
223516038|NCT04831346|DEVICE|Soft occlusive splint|"A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene."
224287236|NCT06824012|BEHAVIORAL|Growth Mindset Intervention|"A structured, daily-activity-based intervention program designed to foster a growth mindset among adolescents in youth custody frameworks and their staff. The intervention involves:~Guided engagement in practical, meaningful daily activities tailored to individual and group needs.~Reflective feedback sessions to reinforce principles of a growth mindset. Pre- and post-intervention assessments using standardized tools, including the Canadian Occupational Performance Measure (COPM) and structured questionnaires."
224081123|NCT01145937|PROCEDURE|DALK|Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
223516039|NCT03760081|DRUG|ASP1650|Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
223516040|NCT00221221|DEVICE|Pedometer|
223516041|NCT00221221|DEVICE|Exercise guidebook|
223534792|NCT02825108|DRUG|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
223534793|NCT02825108|DRUG|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
223534794|NCT02825108|PROCEDURE|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
224081124|NCT00420511|DRUG|Sitagliptin|sitagliptin 100 mg once a day
224081125|NCT00420511|DRUG|Placebo|placebo once a day
224081126|NCT00420511|DRUG|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
224081127|NCT01646099|BEHAVIORAL|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
224081128|NCT01337973|BEHAVIORAL|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
224081129|NCT01337973|BEHAVIORAL|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
224081130|NCT01337973|BEHAVIORAL|E-TAU|Enhanced Treatment as Usual
224081131|NCT04456452|BIOLOGICAL|Ampion|Ampion, administered by intravenous infusion
224081132|NCT04456452|OTHER|Standard of Care|Standard of Care
224081133|NCT00248703|DRUG|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
224081134|NCT01928628|DRUG|Lercanidipine 10mg|
224081135|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg|
224081136|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg|
224081137|NCT01928628|DRUG|Lercanidipin 10mg Placebo|
224081138|NCT01928628|DRUG|Lercanidipine10mg /Valsartan 80mg Placebo|
224081139|NCT01928628|DRUG|Lercanidipine 10mg /Valsartan 160mg Placebo|
224081140|NCT03239431|OTHER|asthmatic exacerbation|evaluate the risk factors, frequency and nature of asthma exacerbations
224081141|NCT02624492|DRUG|BI 836826|
224081142|NCT02624492|DRUG|GemOx|
224081143|NCT02624492|DRUG|Rituximab|
224081144|NCT02624492|DRUG|GemOx|
224081145|NCT03429946|DRUG|Spironolactone|Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
224081146|NCT03429946|DRUG|Placebo|Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
224081147|NCT03429946|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
224081148|NCT03429946|OTHER|Euglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
224081149|NCT01043757|BEHAVIORAL|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
224081150|NCT02876887|DRUG|Cocoa|
224081151|NCT02876887|DRUG|Placebo|
224081152|NCT03972722|DRUG|GLS-010|Patients will be given 240mg GLS-010 every treatment.
224081153|NCT03942315|OTHER|Data collection from standard follow-up after liver transplant|All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
224081154|NCT04137783|OTHER|no intervention|there is no intervention in this study, only observation.
224081155|NCT02103868|BEHAVIORAL|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
223534795|NCT04041193|BEHAVIORAL|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
224081156|NCT02305693|DRUG|Letrozole|
224081157|NCT02305693|PROCEDURE|Laparoscopic ovarian drilling|
224081158|NCT03792074|DRUG|SCT510|SCT510 Injection
224081159|NCT03792074|DRUG|Bevacizumab|Bevacizumab Injection
224081160|NCT03792074|DRUG|Paclitaxel|Paclitaxel Injection
224081161|NCT03792074|DRUG|Carboplatin|Carboplatin injection
224081162|NCT02312947|DEVICE|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
224081163|NCT02312947|DEVICE|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
224081164|NCT01166451|DIETARY_SUPPLEMENT|Low-iron formula|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
224081165|NCT01166451|DIETARY_SUPPLEMENT|High-iron formula|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
223516042|NCT01470820|OTHER|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
223516043|NCT04846699|PROCEDURE|per-cutaneous stone extraction|percutaneous nephrolithotripsy for renal stones by different renal access
223516044|NCT05261490|DRUG|maplirpacept (PF-07901801)|PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.
223516045|NCT05261490|DRUG|Pegylated Liposomal Doxorubicin (PLD)|RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
223516046|NCT01722734|BEHAVIORAL|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
223516047|NCT01837550|BEHAVIORAL|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
223516048|NCT01837550|BEHAVIORAL|Control group|The control group only had access to reading material.
223516049|NCT04425278|DEVICE|transcranial direct current stimulation with real current|transcranial direct current stimulation with real current is a noninvasive technique to activate and modify the activity of the neurons
223516050|NCT04425278|DEVICE|transcranial direct current stimulation with sham current|transcranial direct current stimulation with sham current is a placebo
223516051|NCT01971593|DRUG|Eplerenone|
223516052|NCT05103111|OTHER|No intervention|no intervention
223516053|NCT02316132|DRUG|Stress|Corticotropin-Releasing Hormone
223516054|NCT02316132|DRUG|Control|Saline 0.9%
223516055|NCT04667559|DEVICE|Conformis iTotal Identity Knee Replacement System|The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.
223516056|NCT05938569|DEVICE|Hair restoration|The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
223516057|NCT06047470|BEHAVIORAL|Kangaroo Care|Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.
223516058|NCT06047470|BEHAVIORAL|No Kangaroo Care|Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
223516059|NCT01724307|PROCEDURE|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
223516060|NCT00928720|DEVICE|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
223516061|NCT00928720|DEVICE|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
223516062|NCT06500156|OTHER|Fluid challenge|Rapid infusion (\< 15 minutes) of a fluid bolus of crystalloids (200 to 500cc)
223892332|NCT06835205|BEHAVIORAL|Standard Health Education Sessions|This intervention consists of five sessions on general health topics unrelated to bullying, such as nutrition, sleep hygiene, and physical activity. The sessions are facilitated by healthcare students as part of their Service Sanitaire training. These sessions provide a comparable structure and duration to the TEAL program but do not address bullying prevention.
223892333|NCT06837571|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay
223892334|NCT06837571|DRUG|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
223516063|NCT04167735|DEVICE|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
223892335|NCT06837571|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
223892336|NCT05041023|OTHER|Relative section|"Relatives are assessed by phone calling with an experienced psychologist at 3 and 6 months after patient's death. Relatives answer to self-questionnaire and 3 scales.~Furthermore, 20 of them are offered to participate in a semi-structured interview with an experienced psychologist, within 6 months to 1 year following the patient's death."
223516064|NCT04167735|DEVICE|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
223516065|NCT00237159|DRUG|Zoledronic acid|
223892337|NCT05041023|OTHER|Caregiver section|"Caregivers are self-evaluated within 72 hours after death by questionnaire survey, whose results will remain confidential to the center that included the situation.~Furthermore, 20 of them (10 medical staff and 10 paramedical staff and / or until saturation) are offered to participate in a semi-structured interview with an experienced psychologist."
223892338|NCT06832111|OTHER|Kinesio Taping 1|A specific Kinesio taping technique applied to the ankle to evaluate its effects on joint position sense and balance.
223892339|NCT06832111|OTHER|Kinesio Taping 2|A different Kinesio taping technique applied to the ankle to assess its impact on proprioception and postural stability.
223892340|NCT06832111|OTHER|Sham Kinesio Taping|A placebo taping application that mimics the real Kinesio tape placement but lacks therapeutic tension or functional support, serving as a control condition to evaluate the true effects of the experimental interventions.
223892341|NCT03452111|DRUG|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
223892342|NCT06837428|OTHER|Peer comparison-based Risk Communication (PRICOM)|Based on the Health Belief Model, a risk communication intervention, Peer comparison-based Risk Communication (PRICOM), was developed for primary care physicians to counsel patients with T2DM on their glycaemic control and the complications that could arise, and to recommend ways to improve glycaemic control and prevent complications (or further complications). This will be supported by information from an AI (Artificial Intelligence) based diabetes tool. PRICOM aims to promote health actions in patients with T2DM by increasing their risk perceptions of diabetes complications.
223892343|NCT04666571|DEVICE|TOKA|The device is a digitally planned (using individual CT scan measured anatomic data) personalised opening wedge high tibial osteotomy (HTO) procedure using a custom 3D printed surgical guide and plate.
223892344|NCT04666571|DEVICE|Tomofix or ActivMotion|The comparators, Tomofix and ActivMotion, are the most widely used devices for HTO procedures in the UK. Surgical procedures using the Tomofix and ActiveMotion are similar to TOKA, however, they are not patient specific and do not use custom-made plates.
223892345|NCT05664945|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
223892346|NCT05664945|BEHAVIORAL|home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline)."
223892347|NCT05664945|BEHAVIORAL|Control|"Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation)."
224081166|NCT06503445|OTHER|education video|"the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video."
224081167|NCT04668859|DRUG|Midodrine|Oral vasoactive that is metabolized by the liver an peripheral tissues into desglymidodrine, an active metabolite. It produces arteriolar and venous constriction with a subsequent elevation in blood pressure.
224081168|NCT04668859|DRUG|Methylcellulose|Placebo will consist of inert methylcellulose
224081169|NCT06528886|PROCEDURE|hysterectomy by V-NOTES|V-notes is like laparoscopy via the vaginal route.
224081170|NCT00576173|DRUG|tramadol hydrochloride; acetaminophen|
224081171|NCT06017154|OTHER|Motor-Cognitive Training Program|The training will incorporate cognitive tasks which focus on reaction time, processing speed, working memory, cognitive flexibility, and inhibitory control using visual stimuli on a screen or through sensors which illuminate using LED lights. These cognitive tasks will be performed while also executing physical performance tasks that challenge static and dynamic postural stability, lateral movement, agility, and other movement patterns. The training session will last approximately 30 minutes and participants will complete up to 5 exercises
224081172|NCT03555266|DEVICE|NSS-2 Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.
224081173|NCT03555266|DEVICE|Sham NSS-2 BRIDGE|NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
224081174|NCT01654900|OTHER|No intervention in this study|
223516066|NCT02680496|DEVICE|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
223516067|NCT02680496|OTHER|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
223516068|NCT02680496|OTHER|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
224081175|NCT02167945|DRUG|ABT-450/r/ABT-267|Tablet for oral use
224081176|NCT02167945|DRUG|ABT-333|Tablet for oral use
224081177|NCT02167945|DRUG|Ribavirin (RBV)|Ribavirin was provided as 200 mg tablets, and dosed based on weight, 1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
224081178|NCT00137917|BIOLOGICAL|Meningococcal serogroup B vaccine|
224081179|NCT05788185|BIOLOGICAL|RVM-V001 30 µg|For BNT162b2 subjects
224081180|NCT05788185|BIOLOGICAL|RVM-V002 30 µg|For BNT162b2 subjects
224081181|NCT05788185|BIOLOGICAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BNT162b2 subjects
223516069|NCT02136355|RADIATION|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
224081182|NCT05788185|BIOLOGICAL|RVM-V001 30 µg|For BBIBP-CorV or CoronaVac subjects
224081183|NCT05788185|BIOLOGICAL|RVM-V002 30 µg|For BBIBP-CorV or CoronaVac subjects
224081184|NCT05788185|BIOLOGICAL|RVM-V001 (15 µg) + RVM-V002 (15 µg) co-administration|For BBIBP-CorV or CoronaVac subjects
223516070|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 1|Sulindac (HLX-0201) Capsule
223516071|NCT04823052|DRUG|Sulindac (HLX-0201), dose strength 2|Sulindac (HLX-0201) Capsule
223516072|NCT04823052|DRUG|Placebo|Placebo Capsule
223516073|NCT04823052|DRUG|Gaboxadol (HLX-0206)|Gaboxadol (HLX-0206) Capsule
223516074|NCT05629572|DIAGNOSTIC_TEST|i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity|Paired whole blood and plasma samples collected at multiple time points.
223516075|NCT05211960|BEHAVIORAL|Mindfulness-based meditation|AmDTx is a mindfulness-based meditation app that includes lessons, interactive exercises, and additional in-app features to practice mindfulness.
224081185|NCT05319236|DEVICE|Gabi System|See arm description
224081186|NCT01665963|DEVICE|TopClosure(c) System|
224081187|NCT01665963|DEVICE|Pressure Bandage|
224081188|NCT02328898|DEVICE|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
224081189|NCT02328898|DEVICE|Resolute Integrity stent|
224081190|NCT03437551|OTHER|cross-sectional observation|cross-sectional ophthalmic examination
224081191|NCT02239263|DEVICE|Nucleus 6 Sound Processor|
224081192|NCT00788645|BEHAVIORAL|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
223516076|NCT02269774|PROCEDURE|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
223516077|NCT02842346|OTHER|ultrasonography|
223516078|NCT04411069|DRUG|Droperidol|Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
223516079|NCT04964700|DRUG|Natalizumab|Monthly Infusions
224081193|NCT00788645|BEHAVIORAL|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
223534796|NCT04041193|BEHAVIORAL|Usual Care Program|Usual Care program activities (paper and pencil at home)
224081194|NCT01171456|DRUG|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
224081195|NCT01171456|DRUG|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
224081196|NCT01788007|DRUG|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
224081197|NCT01788007|DRUG|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
224081198|NCT01788007|DRUG|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
224081199|NCT02866825|BIOLOGICAL|IFX-1|
224081200|NCT02866825|BIOLOGICAL|Placebo|
224081201|NCT00822107|DRUG|Hydrochlorothiazide|50 mg one time
224081202|NCT01500356|BEHAVIORAL|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
224081203|NCT01500356|BEHAVIORAL|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
224099143|NCT04556604|BEHAVIORAL|Educational meetings and visual prompts|Information was disseminated to trainees via informal meeting or dedicated audit meetings with the aid of visual prompts
224099144|NCT02214173|DIETARY_SUPPLEMENT|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
224099145|NCT02214173|DIETARY_SUPPLEMENT|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
224099146|NCT03368859|DRUG|Leucovorin|Intravenous
224099147|NCT03368859|DRUG|Fluorouracil - bolus|Intravenous
224099148|NCT03368859|DRUG|Bevacizumab|Intravenous
224099149|NCT03368859|DRUG|Fluorouracil - infusion|Intravenous
224099150|NCT03368859|DRUG|ABT-165|Intravenous
224099151|NCT03368859|DRUG|Irinotecan|Intravenous
224099152|NCT03952130|DRUG|LY900014|Administered SC
224099153|NCT03952130|DRUG|Insulin Lispro|Administered SC
224099154|NCT03952130|DRUG|Insulin Glargine|Administered SC
224099155|NCT03952130|DRUG|Insulin Degludec|Administered SC
224099156|NCT03397186|PROCEDURE|Biopsy|Undergo biopsy
224099157|NCT03397186|OTHER|Laboratory Biomarker Analysis|Correlative studies
224099158|NCT03397186|DRUG|Trabectedin|Given as standard of care
224099159|NCT01713348|DEVICE|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
224081204|NCT01500356|BEHAVIORAL|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
223516080|NCT04090606|OTHER|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
223516081|NCT04090606|OTHER|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
223516082|NCT04090606|OTHER|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
223516083|NCT00970710|BEHAVIORAL|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
223516084|NCT03660449|COMBINATION_PRODUCT|Moderately hypofractionated conformal radiation combined With S-1|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
223516085|NCT00704834|OTHER|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
223516086|NCT01646216|BEHAVIORAL|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
223516087|NCT06446362|BEHAVIORAL|IMCHB-Based Breastfeeding Support Program|"This intervention includes a structured breastfeeding support program based on the Interaction Model of Client Health Behavior (IMCHB). It consists of:~Educational Sessions: Conducted during the last trimester of pregnancy to provide information and prepare mothers for breastfeeding.~Motivational Interviews: Conducted face-to-face at 1-3 days, 15 days, 30 days, 45 days, and 60 days postpartum to address individual challenges and provide personalized support.~Follow-Up Support: Two follow-up sessions via WhatsApp video calls at 4 and 5 months postpartum to reinforce the intervention and provide ongoing assistance."
223516088|NCT06446362|BEHAVIORAL|Standard Breastfeeding Education|Participants receive the standard care provided at Family Health Centers, which includes routine breastfeeding education and support typically offered to new mothers. This standard care does not include the additional structured support interventions provided in the IMCHB-Based Breastfeeding Support Program.
223516089|NCT02587364|DRUG|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
223516090|NCT02587364|DRUG|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
224081205|NCT00005979|DRUG|FOLFIRI regimen|
224081206|NCT00005979|DRUG|fluorouracil|
223516091|NCT02587364|DRUG|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
223516092|NCT02587364|DRUG|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
223516093|NCT02587364|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
223516094|NCT02587364|DRUG|Placebo|Placebo once daily (QD)
223516095|NCT04874961|DIETARY_SUPPLEMENT|Tensiofytol®|standardized olive extract
223516096|NCT04874961|OTHER|Placebo|contains excipients only
223516097|NCT00773591|DRUG|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
223516098|NCT05860244|DRUG|Salbutamol|Salbutamol for 6 months
223516099|NCT05860244|DRUG|Placebo|Placebo Syrup for 6 months
223516100|NCT00461318|PROCEDURE|Individual placement and support (vocational rehabilitation)|
223534797|NCT04494789|DRUG|Fludrocortisone Acetate|50mcg
223534798|NCT04494789|DRUG|Fludrocortisone Acetate|100mcg
223534799|NCT04494789|DRUG|Fludrocortisone Acetate|200mcg
223534800|NCT04494789|OTHER|Standard Therapy|NO Fludrocortisone
224081207|NCT00005979|DRUG|irinotecan hydrochloride|
224081208|NCT00005979|DRUG|leucovorin calcium|
224081209|NCT01058096|DRUG|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
224081210|NCT01058096|DRUG|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
224081211|NCT02916940|DRUG|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
224081212|NCT03253588|PROCEDURE|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
224081213|NCT01328795|OTHER|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
224081214|NCT04276207|DRUG|LY900014|Administered by CSII
224081215|NCT04276207|DRUG|Insulin Lispro|Administered by CSII
224081216|NCT06318845|DRUG|DHP2302R1|75 mg per dose, once daily
224081217|NCT06318845|DRUG|DHP2302R2|50 mg per dose, once daily
224081218|NCT04282005|PROCEDURE|Metabolic/Bariatric surgery|Patients will undergo surgery; 7 RYGB and 7 SG, as planned for their standard care.
224099160|NCT01713348|DEVICE|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
223534801|NCT06486402|OTHER|participation rate|participation rate
223892348|NCT06833177|OTHER|Beautilink SA cement|"According to the manufacturer's instructions (BeautiLink SA - Shofu USA)~* To enhance the adhesion, adhesive bonding agent BeautiBond Xtreme, Shofu will be applied on the tooth and cured according to the manufacturer's instructions.~* Press the plunger of the auto-mix syringe of Beautilink SA to dispence the cement on the adhesive surface of the restoration.~* Seat the restoration in the cavity and apply proper pressure after using Teflon to protect the adjacent teeth and help in the removal of the excess material.~* Light-cure the excess material for 1-2 sec with a light-curing unit followed by removal of the tack-cured material with a probe.~* Using a light-curing unit to cure each surface and marginal areas for 10 seconds. For areas where the light cannot reach, or when using opaque cement, hold the restoration in place for approximately 5 minutes after light-curing to allow for chemical curing."
223892349|NCT06833177|OTHER|RelyX resin cement|"According to the manufacturer's instructions (Espe).~* To enhance the adhesion, adhesive bonding agent 3M™ Scotchbond™ Universal Plus Adhesive will be applied on the tooth and cured according to the manufacturer's instructions.~* Application of 3M™RelyX™ Universal Resin Cement into the cavity~* Seat the restoration in the cavity and apply proper pressure after using Teflon to protect the adjacent teeth and help in the removal of the excess material.~* Light-cure the excess material for 2-3 sec with a light-curing unit followed by removal of the tack-cured material with a probe.~* Using a light-curing unit to cure each surface and marginal areas for 10 seconds. For areas where the light cannot reach, or when using opaque cement, hold the restoration in place for approximately 6 minutes after light-curing to allow for chemical curing."
223892350|NCT05784662|BEHAVIORAL|Social Workers Addressing Firearm Risk|Educational intervention for social workers.
223892351|NCT06642389|OTHER|Sonoanatomical Structure Identification|ChatGPT-4 will analyze the ultrasound images to identify key anatomical landmarks such as nerves, muscles, blood vessels, and fascial planes that are critical for successful regional anesthesia. These structures will be labeled and compared to the expert anesthesiologist's assessment to determine accuracy.
223892352|NCT06642389|OTHER|Block Type Prediction|Based on the ultrasound images and the position of the probe, ChatGPT-4 will predict the type of regional anesthesia block being performed (e.g., supraclavicular block, femoral nerve block). These predictions will be compared to the actual block performed to evaluate the AI's accuracy.
223534802|NCT04088903|DRUG|Daratumumab|\>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
223534803|NCT04859998|BEHAVIORAL|dog-assisted therapy|It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
223516101|NCT05957523|DEVICE|Remote ischaemic preconditioning|The participants rested in the supine position for 5 minutes, then turn on the ischaemic preconditioning apparatus and place the automatically programmed blood pressure cuff on both upper arms of the participant, pressurize to 200 mmHg, pressurize for 5 minutes, rest for 5 minutes, perform 4 cycles for a total of 40 minutes each time. The training for participants in group A will be performed once daily, while for participants in group B the training will be performed twice daily. And heart rate and blood pressure before and after each training will be recorded for 7 days.
223516102|NCT02395627|DRUG|Tamoxifen|
223516103|NCT02395627|DRUG|Vorinostat|
223516104|NCT02395627|DRUG|Pembrolizumab|
223516105|NCT06311513|BIOLOGICAL|Concentrated Bone Marrow Aspirate Injection|Intraoperatively, bone marrow will be harvested from the iliac crest with a commercial kit, it will then be prepared via centrifugation and an injection of the resulting concentrated product (cBMA) will be administered in the operative knee. cBMA is an autologous biologic product.
223516106|NCT06311513|PROCEDURE|Sham Incision|A 2 mm sham incision will be made in the anatomical site where bone marrow would be harvested.
223516107|NCT06311513|PROCEDURE|Revision Anterior Cruciate Ligament Reconstruction|This is the standard-of-care surgical procedure.
223516108|NCT02492776|DRUG|Omeprazole|20 mg oral capsules administered once daily for 8 days
223516109|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
223516110|NCT02492776|DRUG|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
223516111|NCT00372320|GENETIC|Gene Transfer|
223516112|NCT00372320|DRUG|AdhAQP1|
223516113|NCT05112068|OTHER|traditional skin care method|Skin and hair care for critically ill patients will be carried out using traditional means: clean warm water, cotton diapers and napkins, liquid soap, 0.02% aqueous chlorhexidine solution, and regular shampoo.
223516114|NCT05112068|OTHER|method using specialized gloves|"Specialized hygienic gloves soaked in a washing lotion Aqua Total Hygiene (Cleanis, France) for skin care and Aqua Shampoo (Cleanis, France) for hair care will be used.~According to the manufacturer's recommendation, six hygienic gloves should be used for one skin care procedure, and two gloves should be used for hair care. The care method used in the experimental group will not require additional rinsing and drying."
223516115|NCT06375772|DRUG|2-Deoxy-D-glucose|Intranasal administration
224081219|NCT04282005|OTHER|Lifestyle and Diet|Patients will be provided with a lifestyle interventions including dietary counselling choosing between a Low-Calorie Diet or a Meal Replacement Diet.
223516116|NCT06375772|OTHER|Placebo|Intranasal administration
224081220|NCT05812664|OTHER|enteral feeding|The amount of enteral nutrition that should be given daily was calculated by the nutritionist using the Harris-Benedict formula. Formula at room temperature was given with a nasogastric foley catheter and a feeding pump. The position of the nasogastric Foley catheter in the stomach was confirmed by the PAAC graph when it was first inserted, and by listening before each feeding. Feeding was done in a position with the head at 30 degrees.
224099161|NCT02562729|PROCEDURE|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
223516117|NCT01903590|PROCEDURE|TVT surgery TOT surgery|
223516118|NCT04657692|PROCEDURE|Anesthesia; general or regional|General anesthesia: general anesthesia with endotracheal tube Regional anesthesia: spinal anesthesia, epidural anesthesia, combined spinal epidural anesthesia
223516119|NCT02953964|OTHER|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
223516120|NCT02953964|OTHER|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
223892353|NCT06642389|OTHER|Block Success Assessment|After analyzing the ultrasound images from the block application, ChatGPT-4 will assess whether the block was successfully administered. This assessment will be based on the correct placement of the needle, the spread of the anesthetic, and proximity to target structures. The AI's evaluation of block success will be compared to the expert anesthesiologist's judgment.
223516121|NCT02953964|OTHER|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
223892354|NCT05912387|DRUG|Rosuvastatin|Rosuvastatin 20 mg tablet once daily by mouth
223516122|NCT06305858|PROCEDURE|Prosthetic Surgical Procedure|"The population consists of 48 patients divided into two groups:~24 patients Group A experimental group: partial denture surgical procedure~24 patients Group B control group: total denture surgical procedure with patellar resurfacing"
223516123|NCT04768478|DRUG|CBD|25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
223516124|NCT04768478|DRUG|Placebo|Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
223516125|NCT04462250|DEVICE|Prescription Opioid Management App|Smartphone application that provides education and reinforcement of safe opioid use, storage, and disposal
223516126|NCT05547854|BEHAVIORAL|Behavior Therapy Training Institute|In-person therapist training will follow the Tourette Association of America's established Behavior Therapy Training Institute procedures and will consist of 12 hours of in-person training conducted over the course of 2 days. Day 1 will involve standardized didactic lectures on tic disorders and video demonstrations of therapeutic techniques. Day 2 will involve break-out groups and role-play practice of CBIT techniques. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a training instructor while providing CBIT to a study-enrolled patient.
223516127|NCT05547854|BEHAVIORAL|CBIT-Trainer|In the online therapist training condition participants will be provided with access to the CBIT-Trainer program and asked to complete the training over the course of 4 weeks. CBIT-Trainer is designed for the average user to complete in approximately 12 hours. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a CBIT expert while providing CBIT to a study-enrolled patient.
223516128|NCT00514397|DRUG|motexafin gadolinium|
223516129|NCT00514397|DRUG|temozolomide|
223516130|NCT00514397|PROCEDURE|adjuvant therapy|
223892355|NCT02925871|BEHAVIORAL|Co-designed person-centred care transitions|The intervention consists of several elements that aim to meet patients', significant others', and professionals' needs for shared understanding, patient preparedness for homecoming, and coordination.
223892356|NCT02925871|BEHAVIORAL|Current care transitions|Control group participants will receive current care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
223892357|NCT03601728|BEHAVIORAL|personalized prehabilitation|The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.
223516131|NCT00514397|PROCEDURE|quality-of-life assessment|
223516132|NCT00514397|RADIATION|radiation therapy|
223892358|NCT06822036|PROCEDURE|Arm A - Application of 5g of ARISTA™ AH|Perioperative application of 5g of ARISTA™ AH to the prostate bed and neurovascular bundles during and at the end of the surgery to control bleeding and oozing in accordance with labelled directions; no other hemostyptic agent in aforementioned area
223892359|NCT06283082|DIAGNOSTIC_TEST|Lithiasis assessment|Measurement of oxaluria and glycolaturia on 24 h urine collection, identification of lithiasis disease (biological and ultrasound) and search for lithiasis risk factors.
224099162|NCT04425850|COMBINATION_PRODUCT|Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|Topical application in the nose and oral cavity
224099163|NCT01701791|OTHER|Computerized Decision Support System|
223516133|NCT06222333|BEHAVIORAL|Respiratory physiotherapy|In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
223516134|NCT06222333|DRUG|Conservative Treatment|Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
223516135|NCT05615350|OTHER|Meals served during breakfast with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
223516136|NCT05615350|OTHER|Meals served during lunch with a wide range of different food textures|Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
223516137|NCT02633527|DRUG|Placebo|Placebo was administered once daily
223516138|NCT02633527|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
223516139|NCT02633527|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
223516140|NCT02633527|DRUG|300mg SPN-812|300mg SPN-812 was administered once daily and compared to placebo
223516141|NCT02633527|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
223516142|NCT01323543|DEVICE|Elaspine™|Implantation of device
223534804|NCT05162248|DIAGNOSTIC_TEST|Microsatellite instability analysis|Molecular analysis for Microsatellite Instability (MSI) status was performed using immunohistochemistry (IHC). IHC now recognized as an approved method to highly precision predict MSI in colorectal cancer.
224081221|NCT05812664|PROCEDURE|blood glucose measurements|Blood glucose values were measured in all groups at 06:00, 12:00, 18:00 and 24:00, 4 times a day for 7 days. The sample was taken from the patient's cannula and examined in the biochemistry lab. The targeted range in the measurements was accepted as 70-180 mg/dl.
224081222|NCT05812664|PROCEDURE|Evaluation of feeding intolerance with gastric residue|gastric residue assessment; 30 minutes after the feeding was stopped, the N/G tube was drained and the amount coming 30 minutes later was evaluated. Residue positive was defined as the return of more than half of the amount of formula in the last cycle. The same was continued without increasing the amount given. If the incoming amount was less than half, the residue was evaluated as negative and the formula was continued by increasing the predetermined amount.
224081223|NCT01417845|BEHAVIORAL|High Intensity Exercise Training|"* High intensity resistance and aerobic training~* Resistance training is performed 2 days per week for 3 months~* Aerobic training is performed on the same days as resistance training and 1 additional day per week."
224081224|NCT01417845|BEHAVIORAL|Moderate Intensity Exercise Training|"* Moderate intensity resistance and aerobic training~* Resistance training is performed on 2 days per week for 3 months.~* Aerobic training is performed on the same days as resistance training and 1 additional day per week."
224081225|NCT02769624|DRUG|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
224081226|NCT02769624|DRUG|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
224081227|NCT04451330|DRUG|Trifarotene cream|Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
224081228|NCT04451330|DRUG|Doxycycline hyclate|Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
224081229|NCT04451330|DRUG|Trifarotene Vehicle|Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
224081230|NCT04451330|DRUG|Doxycycline Placebo|Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
224081231|NCT05099640|DRUG|PTC923|PTC923 powder for oral use will be suspended in water or apple juice prior to administration.
224081232|NCT05099640|DRUG|Placebo|Placebo matching to PTC923
223516143|NCT03615274|DEVICE|Executive function training|Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).
223516144|NCT03615274|OTHER|Psychoeducation|Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.
224081233|NCT05135832|DEVICE|Electronic patient-reported outcomes regarding symptoms and health-related quality of life|"Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.~The supportive care (including drugs) is similar in the two treatment arms except for the use of electronic patient-reported outcomes."
224081234|NCT04844255|DIETARY_SUPPLEMENT|dietary salt|2 grams of dietary salt
224081235|NCT01443780|DIETARY_SUPPLEMENT|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
224081236|NCT03342950|DRUG|Topical Solution|Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
224081237|NCT03342950|DRUG|Placebos|Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
224081238|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Low dose: 1x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
224081239|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10e7 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
224081240|NCT02474342|BIOLOGICAL|Autologous Adipose Tissue Derived MSCs Transplantation|"1. Study drugs: Autologous adipose tissue derived MSCs~2. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~3. Number of injections : only once during the study period~4. Device: Ultrasound~5. Injection technique: Injection into the lesion by investigator"
224081241|NCT00135460|DRUG|nucleoside analogue sparing HAART regimen|
224081242|NCT00179959|DRUG|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
224081243|NCT00179959|DRUG|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
224081244|NCT00179959|DRUG|Water|Water baths twice weekly for three months
223516145|NCT03615274|DEVICE|Placebo non-adaptive training|Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
223516146|NCT06475495|DRUG|KYV101|an autologous fully-human anti-CD19 CAR T-cell immunotherapy
223516147|NCT06475495|DRUG|Rituximab (active comparator)|anti CD20 monoclonal antibody
223516148|NCT05250557|DIAGNOSTIC_TEST|Fractional flow reserve|Physiologic assessment includes Δ FFR (lesion-specific) and FFR (vessel-specific) measurement. Δ FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).
224081245|NCT00179959|DRUG|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
224081246|NCT00000704|DRUG|Zalcitabine|
224081247|NCT01592201|DRUG|Paliperdidone ER|Form = osmotic release oral system, route = oral
224081248|NCT01592201|DRUG|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
223516149|NCT01992081|DEVICE|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
223892360|NCT06168721|OTHER|Expert survey|The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
223892361|NCT00583349|DRUG|Abraxane|"Abraxane is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Intravesically administered, dose escalation, 6 weekly instillations"
223516150|NCT01992081|OTHER|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
223892362|NCT04755140|BEHAVIORAL|Questionnaires|The patient and an informant will be asked to complete a questionnaire about his or hers current and past physical thinking abilities.
223892363|NCT04755140|BEHAVIORAL|Interviews|Cognition and memory interviews will take place with the patient.
223892364|NCT04755140|DIAGNOSTIC_TEST|Blood Test|Three blood draws will occur to assess patients immune response, metal levels, and cardiac health.
224081249|NCT05590520|PROCEDURE|Botulinum injection|Botox injection to be injected in internal anal sphincter to see the curative response in comparison to gtn cream application
223516151|NCT04254250|DIAGNOSTIC_TEST|Preoperative risk estimation of disc herniation recurrence|Risk estimation of disc herniation recurrence will be evaluated preoperatively, depend on the risk significance each patient will be assigned to one of two groups - with high risk and low risk. Then each patient will undergo conventional one-level microdiscectomy.
223534805|NCT05790694|DRUG|HBM9378 (SKB378) Injection|Strength: 225 mg (1.5 mL)/vial
223534806|NCT05790694|DRUG|Placebo|Strength: 225 mg (1.5 mL)/vial
223534807|NCT03641196|DEVICE|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
224081250|NCT05590520|DRUG|GTN OINTMENT|0.2%GTN applied on anal canal.
223534808|NCT03641196|PROCEDURE|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
223534809|NCT06399055|DRUG|CKD-387|1 Tablet
224081251|NCT04123158|DIAGNOSTIC_TEST|Ultrasound|"Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth \>30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]"
223534810|NCT06399055|DRUG|D484|1 Tablet
223892365|NCT04755140|DIAGNOSTIC_TEST|Echocardiogram|Each echocardiogram takes about 3 hours and 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
223892366|NCT01570998|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
223892367|NCT01570998|OTHER|Laboratory Biomarker Analysis|Correlative studies
223892368|NCT03276832|DRUG|Imiquimod|Applied cutaneously
223892369|NCT03276832|PROCEDURE|Biopsy|Undergo biopsy
223892370|NCT03276832|BIOLOGICAL|Pembrolizumab|Given IV
223892371|NCT03276832|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223892372|NCT03276832|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223516152|NCT06125301|DEVICE|MS Sherpa|MS sherpa® is a medical device, intended to support monitoring of persons with MS in order to give patients and their professional healthcare team(s) insight into the presence and progress of symptoms related to MS. MS sherpa® is a system consisting of a smartphone app for data collection and data presentation, a cloud service for data storage, analysis algorithms, and a clinician or research dashboard for user management and data visualization. The device measures the course of symptoms related to MS with respect to walking speed (average walking speed derived from the distance walked during a 2-minute walk), cognitive processing speed, number of correct answers on a smartphone variant of the symbol digit modalities test (SDMT) and patient reported outcomes, through predefined questionnaires regarding fatigue, amongst others. MS sherpa® measures changes in these parameters over time and shows these on an insights screen in the app and on the clinician dashboard.
223892373|NCT03276832|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223892374|NCT01851694|DRUG|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
223892375|NCT01851694|DRUG|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
223892376|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\] ) and at a higher dose in Cohort 1B (1x10\^9 CFU)
223892377|NCT02592967|BIOLOGICAL|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
223892378|NCT04842890|RADIATION|Pencil Beam Scanning Proton SBRT|The intervention being investigated is ultra-hypofractionated, image-guided, pencil beam scanning proton SBRT directed at the prostate gland and seminal vesicles to 40 Gy equivalent in 5 fractions, delivered every other day.
223892379|NCT06540326|DRUG|irinotecan liposome (II)|irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
223892380|NCT06540326|DRUG|fluorouracil|fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab
223892381|NCT06540326|DRUG|cetuximab|cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
223892382|NCT06540326|DRUG|bevacizumab|bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
223892383|NCT06493045|DRUG|IRL757|IRL757 capsule
223892384|NCT06493045|DRUG|Placebo|Placebo capsule
223892385|NCT04339452|DEVICE|Impella 5.5 with SmartAssist Supported OPCABG|Subjects will undergo insertion of an axillary or ascending aortic Impella 5.5 with SmartAssist, followed by Impella-supported OPCABG using a sternotomy approach with shunting of the coronary arteries to achieve myocardial protection.
223892386|NCT02424929|PROCEDURE|Sedation|Propofol anesthesia administered during entire surgery.
223892387|NCT02424929|PROCEDURE|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
223892388|NCT04021719|OTHER|Stakeholder feedback|Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
223892389|NCT04021719|OTHER|Data infrastructure|Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
223892390|NCT06411639|DRUG|ianalumab|ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.
223892391|NCT05770219|DRUG|TAK-755|TAK-755 as IV injection at dose calculated based on the participant's body weight as measured at each dosing visit. For most participants, the final volume of infusion will be between 5 and 14 mL.
223892392|NCT04739956|OTHER|The Hospital and Anxiety Depression Scale|Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.
223892393|NCT04739956|OTHER|Point of care testing (POCT)|Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
223892394|NCT03167281|COMBINATION_PRODUCT|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
223892395|NCT04566991|DRUG|Deferoxamine|"There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 milligram per kilogram per hour (mg/kg/hr). The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.~Patients will be randomized to 32 mg/kg or 48 mg/kg of Deferoxamine."
223892396|NCT04566991|DRUG|Placebo|There will be 3 doses given to the patients days 1-3. Dose will be given intravenous with a fixed rate of 7.5 mg/kg/hr. The second dose will be given 24 hours after the first dose, and the third dose will be given 48 hours after the initial dose.
223892397|NCT06850012|BEHAVIORAL|Meleis' Transition Theory-Based Educational Program|This intervention is a 7-week online educational program based on Meleis' Transition Theory, aimed at helping immigrant nurses understand and cope with migration challenges, improve social integration, manage stress, and enhance professional self-efficacy. The program will be divided into three groups (12-12-11 participants), and it will include interactive sessions, group discussions, and practical activities such as breathing exercises to promote active participation and engagement.
223892398|NCT03920111|BIOLOGICAL|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
223892399|NCT06848920|DRUG|Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatment|Sinibolimab combined with Lenvatinib in neoadjuvant treatment
223892400|NCT06567496|OTHER|First Resort|First Resort is an 8-week, self-guided, at-home, virtual reality program designed to be navigated via Meta Quest II headset devices and will be used as an intervention.
223892401|NCT05858671|OTHER|Fenugreek Seed Tea|Fenugreek seeds will be delivered at a dose of 5g/day, drunk as a tea (2.5g/per tea bag), p.o. twice a day at a 12-hour interval) for 8 weeks (56 days). The tea bags will be brewed in a cup (200ml) of boiled hot water for 10 minutes before drinking. This will be self-administered by the subjects, twice a day at a 12-hour interval.
223892402|NCT05858671|OTHER|Black Tea|A control black tea (2.5g/bag), self-administered by the subjects, twice in a day at a 12-hour interval.
223892403|NCT06850376|BEHAVIORAL|COVID Feel Good VR Self-Help Protocol|The intervention consists of a 7-day self-help protocol based on daily exposure to 'The Secret Garden' 360° VR video (10 minutes per day) available at www.covidfeelgood.com, combined with different daily cognitive and social exercises. Participants use a smartphone with VR headset compatible with the Cardboard format. Each day's exercise addresses different psychological aspects: fighting rumination, awakening self-esteem, autobiographical memory, sense of community, goals and dreams, empathy, and planning for change. Exercises are designed to be performed individually and then discussed with a partner.
223892404|NCT06850376|OTHER|Waiting Period|Participants in the control group initially undergo a 7-day waiting period before receiving the VR self-help protocol. During this period, they complete the same baseline assessments as the experimental group but do not receive any specific intervention.
223892405|NCT06848309|PROCEDURE|Bronchoscopy|Some participants in all 5 groups may undergo an optional bronchoscopy procedure with bronchoalveolar lavage and endobronchial biopsy collection if they choose.
223892406|NCT06848998|BEHAVIORAL|aerobic exercise|"40 minutes of aerobic exercise, twice per week for six weeks.~Sessions comprised of the following: 10-minute warm-up, 40-minute conditioning period as a circuit, and 10-minute cool-down.~Aerobic exercises (for example, recumbent cycling, stepping, arm crank) commenced at an intensity of 40-50% heart rate reserve (HRR) and increased incrementally by 10% as tolerated, up to a maximum of 70-80%. All sessions were individually tailored as far as possible to participants' needs, abilities, and preferences."
223892407|NCT06848998|BEHAVIORAL|Resistance exercise|"4 x resistance exercises (3 sets of 6 repetitions), twice per week for six weeks.~Strengthening exercises (for example, resistance band work) were prescribed at an intensity that corresponded to 11-12 and incrementally increased to a maximum of 14-15, as tolerated, on the Borg Ratings of Perceived Exertion (RPE) 6-20 Scale. All sessions were individually tailored as far as possible to participants' needs, abilities, and preferences."
223892408|NCT06846840|DIETARY_SUPPLEMENT|Ketone ester|0.29 g per kilogram body mass per hour of ketone monoester (R)-3-hydroxybutyrate (R)-3-hydroxybutyl
223892409|NCT06846840|DIETARY_SUPPLEMENT|Placebo|Medium chain triglycerides and bitter tastant (Bitrex)
223892410|NCT04024917|OTHER|Cardiac coherence|"An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~\- The program cardiac coherence will be performed during 90 days after the surgery"
223892411|NCT04024917|OTHER|Standard care|Standard care
223892412|NCT05341167|DEVICE|HPI algorithm using Edwards device https://www.edwards.com/gb/devices/decision-software/hpi|The HPI algorithm will be used in order to prevent hypotensive episodes. When the HPI is greater than 85%, the anesthesiologist will have to intervene within the next 2 minutes taking the hemodynamic parameters available into consideration, as well as the treatment protocol that has been designed according to current literature
223892413|NCT05341167|DRUG|Vasoactive Agent|Hypotensive episodes will be treated with vasoactive agents and fluids. The HPI algorithm recordings will be blinded and will not be available to the anesthesiologist for the duration of the operation.
223892414|NCT04171661|BIOLOGICAL|SASS|SASS applied on chronic skin wounds as skin graft
223892415|NCT06844435|OTHER|continuous renal replacement therapy|continuous renal replacement therapy during OLT in surgery room
223892416|NCT06845449|PROCEDURE|tenting screw combined with particulate autogenous|In Tenting screw cases, the screws will be placed in suitable positions and depths, blocks will be crushed into particulates which will then be mixed with equal amount of bovine particles. the mixture will be applied to the recipient site all around the tenting screws a resorbable collagen membrane (CM) will be shaped and placed over the graft and fixed using subperiosteal sutures.
223892417|NCT06845449|PROCEDURE|autogenous ring block grafts combined with xenogenic bone|In the non screw group, the blocks will be adapted to fit the recipient sites and secured to the alveolar bone using titanium bone fixation screws. Following the placement of the blocks, bovine particles will be applied over the graft and into any remaining gaps between the block and the recipient site, a resorbable collagen membrane (CM) will be shaped and placed over the graft and fixed using subperiosteal sutures
223892418|NCT05954143|DRUG|BDC-1001|BDC-1001 is an immune-stimulating antibody conjugate (ISAC) designed to be delivered systemically (intravenously) and act locally by targeting HER2-expressing tumors and related metastatic disease for destruction by the innate and adaptive immune systems. BDC-1001 consists of an investigational biosimilar of the humanized monoclonal antibody (mAb) trastuzumab that is chemically conjugated to a toll-like receptor (TLR)7/8 agonist (payload) with an intervening non-cleavable, cell membrane impermeable linker.
223892419|NCT05954143|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody that targets HER2 and prevents dimerization of HER2 with other members of the HER family (HER1, HER3, and HER4), thereby blocking ligand-activated downstream signaling.
223892420|NCT06844942|DIAGNOSTIC_TEST|vessel Fractional Flow Reserve|Optical coherence tomography and vessel fractional flow reserve evaluation of coronary arteries with intermediate to severe stenosis.
223892421|NCT06846788|OTHER|Physical exercise|A traditional sensory relearning rehab session will be performed after our intervention consisting of 30 minutes of physical exercise.
223892422|NCT06841861|GENETIC|Stem cell|Primary cell cultures of tissue cells will be established. Cell cultures will undergo genetic reprogramming to induce the long-term propagation of living cells.
223892423|NCT06841861|GENETIC|Genetic Screening|Serum samples are processed through RNA sequencing to reveal known and novel infertility-related biomarkers and genes.
223892424|NCT06841861|GENETIC|Genetic Reprogramming|Genes or gene products will be reinserted into cells to observe how the cells can be changed, or reprogrammed, into embryonic-like cells or into sperm precursor cells.
223892425|NCT06841861|GENETIC|Cell Maturation|Genetically unmodified and modified cells are placed in a laboratory-based testicular environment to promote spermatogenesis into maturity.
223892426|NCT06841393|OTHER|Biometrological measurements|"Measurements will be taken from the face:~* For acne group: inflammatory lesional area and non-lesional area~* For control group: non-lesional area"
223892427|NCT06841393|OTHER|Biological sampling|"Samples will be taken from the face:~* For acne group: inflammatory lesional area, non-lesional area and retentional area~* For control group: non-lesional area"
223892428|NCT06841393|OTHER|Clinical assessments|Only for acne group: acne scores will be evaluated on the face by the investigator
223892429|NCT06841393|OTHER|Questionnaire|Only for acne group: consumers' perception
223892430|NCT06563245|DRUG|Brentuximab Vedotin for Injection|1.8mg/kg/dose (MAX 180 mg)
223892431|NCT06563245|RADIATION|response-adapted radiation|For patients who did not achieve complete metabolic response at early response assessment based on PET/CT result.
223892432|NCT06563245|DRUG|Doxorubicin|25mg/m2/dose,
223892433|NCT06563245|DRUG|Etoposide|125 mg/m2/dose
223892434|NCT06563245|DRUG|Prednisone|20 mg/m2, BID, orally
223892435|NCT06563245|DRUG|Cyclophosphamide|600 mg/m2/dose
223892436|NCT06563245|DRUG|Dacarbazine|250 mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at early assessment based on PET/CT results.
223892437|NCT06563245|DRUG|Tislelizumab Injection|3mg/kg/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
223892438|NCT06563245|DRUG|Bedamustine|180mg/m2/dose; For patients in intermediate/high risk group who did not achieve complete metabolic response at late assessment based on PET/CT results.
223892439|NCT06843161|DEVICE|The jog or ground go no go task for retraining automatic bias|Recruited participants will be performing the JOGGNG Task on the Kinarm Endpoint Laboratory. This task requires participants to control a robotic handle to manipulate a virtual avatar that looks as if it is jogging across a field. During the jogging, a frisbee will appear and quickly move towards the avatar, eventually tilting clockwise or counterclockwise. Participants are required to either reach quickly to grab the frisbee from the air during clockwise tilts or to not move during counterclockwise tilts. This tilt/movement associated is reversed to control for a potential bias in tilt angle and movement. An image of physical activity or sedentary behaviour will appear inside of the frisbee but participants are not told that it is associated with any of the tilts. Each trial consists of one frisbee and participants will complete a total of 3 blocks of 360 trials each which will take approximately 30 minutes to complete.
223892440|NCT05591196|DEVICE|Non-invasive Electrical Spinal Cord Stimulation|Electrical stimulation of the spinal cord using surface electrodes
223892441|NCT05591196|OTHER|Activity Based Rehabilitation|Exercise therapy targeting paralyzed hand and arm
223892442|NCT06849180|COMBINATION_PRODUCT|Interventional therapies combined with or without systemic drugs|The study will include adult patients with histologically/cytologically confirmed unresectable CHC. Collect patient genomics, proteomics, immune microenvironment, pathology reports, medical images and clinical electronic medical records, etc., to form high-quality and deeply labeled data sets to support the subsequent development and application of AI large models. Based on multi-source heterogeneous data of CHC patients, a large model for comprehensive diagnosis and treatment was constructed. Firstly, multi-modal data of different stages of disease were integrated by using cross-modal multi-course fusion technology to achieve efficient fusion of complex data. Secondly, by fine-tuning the large model, tasks such as CHC classification, prognosis inference and treatment plan recommendation are accurately completed, and potential information in the diagnosis and treatment process is mined.
223892443|NCT06850129|BEHAVIORAL|DIGITAL INTERVENTION|All patients received specific information about DM, treatments and po-tential complications. Then, patients were randomized to the digital interven-tion group or usual care. Those patients randomized to the intervention group were educated in the use of different social networks with access to infor-mation related to healthy lifestyle habits, dietary support, optimization of physi-cal activity, insulin titration, therapeutic targets, self-care, based on validated material from scientific societies and endorsed in diabetes education. Patients also had the valuable resource of a Digital Diabetes Coach: an online expert specializing in therapeutic education. This virtual guide provided patients with the flexibility to interact in both unidirectional and bidirectional ways, using methods such as chat boxes, audio messages, videos, and more. Through this digital medium, patients could seek guidance and have their questions re-solved.
223892444|NCT06848374|DRUG|40 mg Methylprednisolone|Ultrasound guided injection of 40mg methylprednisolone injection
223892445|NCT06848374|DRUG|80 mg Methylprednisolone|Ultrasound guided injection of 40mg methylprednisolone injection
223892446|NCT04691960|OTHER|Ketogenic Diet|Ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis. The diet will begin at an approximately 3:1 fat to carbohydrate + protein ratio for 5 days. If the patient does not show urine ketosis (1.5 mmol/L or 27.0 mg/dL), the ketosis diet will be advanced to approximately 4:1 ratio for 5 days. If the patient still does not attain ketosis a 24 hour fast will be done to promote ketosis. The diet will encourage at least 30 ml per day of Medium Chain Triglycerides (MCT) oil to enhance ketosis.
223892447|NCT04691960|DRUG|Metformin|Metformin will be administered as a single 850 mg dose P.O. at Week 8, then titrated up to 850 mg P.O. BID at Week 10, and then 850 mg T.I.D. at Week 12, as tolerated.
223516153|NCT01681849|DRUG|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
223516154|NCT01681849|DRUG|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
223516155|NCT01681849|OTHER|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
223892448|NCT03514511|DRUG|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
223892449|NCT03514511|DRUG|LEO 138559 placebo|LEO 138559 placebo
223892450|NCT04048278|DRUG|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
223892451|NCT04048278|DRUG|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
223892452|NCT06848270|OTHER|Early palliative care integration|Early follow up by the palliative care team, from diagnosis
223892453|NCT06848777|BEHAVIORAL|Intervention group:|After a 50-meter walk while listening to the sounds of nature, the patient will walk 50 meters again to his/her room and then to his/her bed, where he/she will be seated. Then, the researcher nurse will remove the headphones from the patient's ears and ensure that the patient rests in a comfortable position.
223892454|NCT05614752|DRUG|Fexuprazan|Fexuclue Tablet 40mg
223516156|NCT02465112|DRUG|In111-Pentetréotide|
223516157|NCT02465112|OTHER|simple monitoring without active therapy|
223516158|NCT01950039|DRUG|Betaine|Betaine or placebo administered orally in divided doses over 12 weeks
223516159|NCT01950039|DRUG|Placebo|Placebo administered orally in divided doses over 3 months
223516160|NCT04074837|DRUG|NNI-362|NNI-362 small molecule in liquid suspension.
223516161|NCT04074837|DRUG|Placebo|Placebo liquid suspension
223516162|NCT02957019|DRUG|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
223516163|NCT02957019|DRUG|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
223892455|NCT05694286|PROCEDURE|Juvederm Volbella XC hyaluronic acid dermal filler injection|Infraorbital filler injection
223516164|NCT02957019|DRUG|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
223516165|NCT02852005|BIOLOGICAL|MVA/HIV62B vaccine|1×10\^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
223516166|NCT02852005|BIOLOGICAL|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
223516167|NCT02852005|BIOLOGICAL|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
223516168|NCT00962338|BEHAVIORAL|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
223516169|NCT06571526|BEHAVIORAL|External focus|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to focus on a random series of digits ranging from 0 to 9 displayed on monitors placed at the immediate and future destinations of the walkway. Each number was displayed for at least 2 seconds to allow participants to have sufficient time to read them.
223516170|NCT06571526|BEHAVIORAL|Control|The training phase consisted of 20 consecutive training trials, with a rest interval of at least 30 seconds between trials. All participants had to circumvent an obstacle during each trial on the 8-m level-ground walkway. During each trial, the general instruction was to walk to the end of the walkway at your natural pace.
223516171|NCT05736887|DRUG|N-Acetylcysteine|N-Acetylcysteine in 600mg tablets
223516172|NCT05736887|DRUG|Placebo|Placebo in 600mg tablets
223516173|NCT06113614|PROCEDURE|Physiotherapy|All participants will be treated with the standardized physiotherapy protocol suggested by Ratajczak et al. 2019. To receive physiotherapy treatment, participants will need to attend a 30-minute session, twice a week, for 12 weeks.
223516174|NCT06113614|DEVICE|Photobiomodulation|The PBM will be applied with LED devices in the form of a shoulder brace. The applications will occur every day starting 24 hours after the surgical procedure. The shoulder brace from the brand Cosmedical (Mauá, SP, Brazil) contains 70 red LEDs and 70 infrared LEDs. The area corresponding to the fixation plate will not be irradiated (no LEDs will be placed). PBM will be applied every day for 10 minutes using a device containing 318 light-emitting diodes (LEDs), including 159 LEDs at 660 nm (28.5 mW; 12 J/cm2 to 17 J) and 159 LEDs at 850 nm (23 mW; 10 J/cm2 to 14 J).
223516175|NCT06113614|DEVICE|Simulation of photobiomodulation|The simulation of PBM will use the same LED devices in the form of a shoulder brace but without active light. It will be applied following the same regimen of the Photobiomodulation group.
223516176|NCT03295786|DRUG|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
223516177|NCT03295786|DEVICE|Renishaw Drug Delivery System|Stereotactically implanted device
223516178|NCT04135443|BEHAVIORAL|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-19. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
223516179|NCT04135443|BEHAVIORAL|General Health Materials Website|The control group will receive access to a website containing general health promotion materials.
223516180|NCT05979818|DRUG|Propranolol hydrochloride|10 mg, PO, BID, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
223516181|NCT05979818|DRUG|Sintilimab|intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.
223516182|NCT05979818|DRUG|Chemotherapy|"Platinum-based chemotherapy:~For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1-3, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4-6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent."
223516183|NCT00070083|BIOLOGICAL|oblimersen sodium|
223516184|NCT00070083|BIOLOGICAL|rituximab|
223516185|NCT00070083|DRUG|cyclophosphamide|
223516186|NCT00070083|DRUG|doxorubicin hydrochloride|
223516187|NCT00070083|DRUG|prednisone|
223516188|NCT00070083|DRUG|vincristine sulfate|
223516189|NCT06101485|DEVICE|Telerehabilitation|Telerehabilitation platform: Hjerteportalen, blood pressure monitor (iHealth(neo/BP5s), weight scale (iHealth Lina), Activity tracker (FitBit inspire 3), ECG monitor (AliveCor KardiaMobile), sleep sensor (Emfit QS), video consultation (VDX by MedCom)
223516190|NCT00020007|DRUG|isolated perfusion|
223516191|NCT00020007|DRUG|paclitaxel|
223516192|NCT00020007|PROCEDURE|hyperthermia treatment|
223516193|NCT00178828|DRUG|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
223516194|NCT00178828|DRUG|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
223516195|NCT04939103|DEVICE|TRUS-FNA|Transrectal Ultrasound Guided Fine Needle Aspiration for rectal tumor
223516196|NCT04499001|OTHER|Pharmacist's consultation|Information about bDMARDs management.
223892456|NCT03853746|DRUG|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
223892457|NCT06286254|DRUG|Cycloferone|Cycloferone® is administered according to the instruction for medical use: 600 mg (4 tablets) once daily on day 1, 2, 4, 6 and 8.
223892458|NCT04266951|BEHAVIORAL|Singstrong:|Group singing and breathing control training
223892459|NCT03426579|DEVICE|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
223892460|NCT05681520|BEHAVIORAL|PEEPS|Working with a peer specialist for six 30-minute sessions to enhance engagement in pain management approaches/treatments
223892461|NCT04529993|PROCEDURE|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
223892462|NCT04754945|DRUG|Bortezomib|Given SC
223892463|NCT04754945|DRUG|Cyclophosphamide|Given IV or PO
223892464|NCT04754945|DRUG|Dexamethasone|Given IV or PO
223892465|NCT04754945|BIOLOGICAL|Isatuximab|Given IV
223892466|NCT00999804|DRUG|Lapatinib|1000 mg of Lapatinib by mouth daily
223892467|NCT00999804|DRUG|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
223892468|NCT00999804|DRUG|Trastuzumab|6 mg/kg intravenously, every 3 weeks
223892469|NCT03675815|DRUG|Darunavir (DRV) 800 milligram (MG) Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
223516197|NCT02420314|DRUG|Paclitaxel|"* Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
223892470|NCT03675815|DRUG|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
223892471|NCT03675815|DRUG|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
223892472|NCT03675815|DRUG|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
223892473|NCT03675815|DRUG|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
223892474|NCT03675815|DRUG|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
223892475|NCT03675815|DRUG|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
223892476|NCT06191250|DRUG|Durvalumab|one dose of durvalumab (750 mg IV)
223892477|NCT06191250|RADIATION|Non-ablative oligofractionated radiation (NORT)|12 Gy of Radiation in 3 fractions
223892478|NCT05229146|BEHAVIORAL|Episodic Future Thinking|Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
223892479|NCT03751709|DRUG|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
223892480|NCT03751709|OTHER|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15
223892481|NCT05023369|DRUG|Dexamethasone is a steroid drug and will be administered as an injectable solution (4mg/ml)|Dexamethasone will be administered as an injectable solution (4mg/ml). Every ml of this solution contains 4 mg of dexamethasone sodium phosphate, corresponding to 3 mg of dexamethasone. Thus 3 ml of solution will be injected peri-articularly (arm-A)
223892482|NCT06455553|OTHER|Blood sample|A blood sample will be taken from all patients included in the study. This blood sampling is an added act of the study. It will be performed as soon as possible after inclusion in the study. The total volume of blood drawn will be 12.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen.
223892483|NCT06639204|DEVICE|Electrical stimulation|A removable appliance will be used to accelerate orthodontic tooth movement by emitting electrical stimulation.
223892484|NCT06639204|PROCEDURE|Orthodontic treatment without acceleration|No additional appliances will be used. Only the traditional fixed appliances (braces).
223892485|NCT06367218|DRUG|opioid based strategy|Induction and maintenance of anesthesia with opioids
223892486|NCT06367218|DRUG|opioid-free strategy|Esketamine was used for induction and maintenance of anesthesia
223892487|NCT06367218|PROCEDURE|Laryngeal mask airway; Preserved spontaneous breathing|The patient used a laryngeal mask to maintain spontaneous breathing
223892488|NCT06367218|PROCEDURE|Double lumen tracheal tube; Mechanical ventilation|The patient was mechanically ventilated using a double-lumen tracheal catheter
223892489|NCT04226599|DEVICE|Dissolve AVF|Subjects in the test group will be treated with peripheral scoring drug balloon.
223892490|NCT04226599|DEVICE|Armada 35|Subjects in the test group will be treated with plain balloon catheter.
223892491|NCT00906906|DEVICE|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
223892492|NCT03382977|BIOLOGICAL|VBI-1901|The vaccine is formulated with GM-CSF adjuvant and administered intradermally (ID) or with AS01B adjuvant and administered intramuscularly (IM) to patients with recurrent GBM.
223516198|NCT02420314|DRUG|Carboplatin|"* Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response"
223892493|NCT03382977|DRUG|Carmustine|Treatment with carmustine intravenously at a dose of 150 mg/m² on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
223892494|NCT03382977|DRUG|Lomustine|Treatment with lomustine given orally at a dose of 110 mg/m² (up to a maximum dose of 200 mg) on Day 1 and every 6 weeks until the earlier of disease progression or intolerable toxicity.
223892495|NCT06276894|DEVICE|Motek C-Mill™ treadmill|We will enroll 10 to 15 participants to participate in a VR treadmill training session while wearing an fNIRS cap.
223892496|NCT06276894|OTHER|training session with and without VR wearing the fNIRS cap|training session with and without VR wearing the fNIRS cap
223892497|NCT06553547|DRUG|Tenapanor|Tenapanor 5 mg/mL solution
223516199|NCT02420314|DRUG|Ascorbic Acid|"* Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts"
223892498|NCT06553547|DRUG|Placebo|Matching Placebo solution
223892499|NCT02182245|DRUG|BIBF 1120|
223892500|NCT02182245|DRUG|Paclitaxel|
223892501|NCT02182245|DRUG|Carboplatin|
223892502|NCT05552547|DEVICE|Home Blood Pressure Machine|Participants will be asked to measure blood pressure twice daily for three days in a row at home.
223892503|NCT05552547|DEVICE|24-Hour Blood Pressure Machine|Participants will be asked to wear the machine for 24 hours.
223892504|NCT05256706|DIAGNOSTIC_TEST|SomaSignal Informed Medical Management SSCVD|For participants randomized to the Informed arm, the SSCVD test results will be provided to the participant's clinicians approximately 2-4 weeks after the baseline blood draw. Clinicians will discuss results with the participant and make adjustments to the care plan as needed based on the SSCVD test results within 50 days of receiving results. Clinicians may advise participants to (i) either change the doses of existing medications within existing guidelines, (ii) prescribe additional guideline-based medications, (iii) advise additional lifestyle interventions, or (iv) advise no change. This information will be documented in the case report forms. This test is neither intended to diagnose cardiovascular disease (CVD) nor replace the standard of care protocols for this disease. The physician should not rely solely on this information to make a decision on the best course of action for this patient.
223892505|NCT05256706|OTHER|Standard of Care|Clinicians will provide the standard of care based on routine test results and without the SSCVD results. The SSCVD and SomaSignal Metabolic Factor Panel results from participants from both the baseline and 6-month period will be provided to the study team at the 6-month study visit. The SomaSignal Metabolic Factor tests include evaluation of Liver Fat, Glucose Tolerance, Kidney Function, Alcohol Impact, Cardiorespiratory Fitness/oxygen consumption (VO2) max, Resting Energy Rate, Body Fat Percentage, Visceral Fat, and Lean Body Mass. Any recommendations made to the participant by the physicians, based on obtaining the aforementioned test results will be collected.
223892506|NCT01997840|DRUG|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
223892507|NCT04631094|OTHER|The group holding the serrated ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the serrated ball during the blood draw.
223892508|NCT04631094|OTHER|The group holding the serrated ball in the hand on the opposite side of the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the serrated ball during the blood draw.
223892509|NCT04631094|OTHER|The group holding a smooth ball in the hand on the extremity from which venous blood will be taken|Children in the experimental groups will squeeze the smooth ball during the blood draw.
223892510|NCT04631094|OTHER|The group holding a smooth ball in the hand opposite the extremity from which venous blood will be taken.|Children in the experimental groups will squeeze the smooth ball during the blood draw.
223516200|NCT04797884|DEVICE|TheraBionic Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.
223892511|NCT05956028|PROCEDURE|Ultrasound guided SCV cannulation|receive ultrasound guided SCV cannulation
223892512|NCT05956028|PROCEDURE|Ultrasound guided IJV cannulation|receive ultrasound guided IJV cannulation
223892513|NCT06039865|BEHAVIORAL|Immediate Intervention|Participants will receive customized weekly reports from the pulse oximetry data collected by the consumer wearable.
223892514|NCT06039865|BEHAVIORAL|Waitlist control|Participants only receive usual care from the sleep center.
223892515|NCT04360928|DEVICE|Graymont X ERIS Knee Splint|Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.
223892516|NCT04360928|DEVICE|Standard Hinge Knee Brace|Standard knee brace used postoperatively after ACL reconstruction.
223892517|NCT04014673|BEHAVIORAL|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
223892518|NCT05304936|DRUG|HCW9218|Bifunctional TGF-β antagonist/IL-15 protein complex
223892519|NCT03850678|DEVICE|Hearing Aid|Hearing Aid
223892520|NCT04509102|DRUG|Adderall-XR|Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
223892521|NCT04509102|DRUG|Placebo|Subjects randomized to placebo will take an identical-appearing tablet/capsule and, in order to maintain blinding, will also take one tablet by mouth daily. The placebo substance will be sugar for 21 days.
223892522|NCT05355363|DIAGNOSTIC_TEST|Standard Colonoscopy|Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
223892523|NCT06849453|BEHAVIORAL|Exercise snacks group|Exercise snacks on the stairs for 8 weeks.
223892524|NCT06849453|BEHAVIORAL|Sprint interval training group|Sprint interval training on the stairs for 8 weeks.
223892525|NCT06831201|DEVICE|Flow trigger sensitivity group|1\. Pressure support ventilation will be titrated at a level sufficient to achieve a respiratory rate of 20-30 breath/min and tidal volume 4-6 ml/kg. Pressure support will be reduced by 2 cm H2O every hour to reach pressure support 8 cm H2O. Two exercise sessions will be performed, at 9 AM and 5 PM. Training will be based on decreasing the trigger sensitivity gradually in order to increase muscle endurance. The trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training (In the first session), inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reach 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing trigger sensitivity by 10% of the initial MIP. Patients who could not tolerate IMT with 20% of MIP for 5 min were trained with 10% of MIP. Training consists of 5 to 6 sets of repetitions through the trainer.
224099164|NCT04293848|OTHER|Vibroacoustic therapy|listening to low-frequency sound of 40 Hz with biorhythmic sequential modulation combined to music
224099165|NCT04293848|OTHER|Only music (no vibrations)|listening to music, no vibrations
223516201|NCT04797884|DEVICE|Placebo Device|Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.
223516202|NCT04797884|DEVICE|Quality of Life Assessment|Ancillary services
223516203|NCT05584566|DEVICE|OSSIX Breeze|barrier membrane
223516204|NCT05584566|DEVICE|Jason membrane|barrier membrane
223516205|NCT05370209|DEVICE|Otinova® Ear Spray|Ear spray
223516206|NCT03760068|DRUG|MYL-1601D Product|(100 U/mL)
223516207|NCT03760068|DRUG|FlexPen NovoLog®|(100 U/mL)
223516208|NCT01057940|PROCEDURE|DBE PEJ placement|One time procedure with follow-up telephone call.
223516209|NCT03856177|BEHAVIORAL|Emotion Induction|Described in arm
223516210|NCT01342042|BIOLOGICAL|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
223516211|NCT06195111|DRUG|Trifluridine/Tipiracil|This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription
223516212|NCT04262427|DRUG|Cyclophosphamide 50mg|cytotoxic chemotherapy
223516213|NCT04262427|DRUG|Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]|potent humanized immunoglobulin (Ig) G4 monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor
223516214|NCT04130971|OTHER|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
223892526|NCT06831201|PROCEDURE|Active proprioceptive facilitation technique ( active PNF) technique|"1. patients in this group treated with the rhythmic initiation technique derived from the PNF concept. The RIT will be applied in four manual positions of the therapist's hands: The upper and lower chest wall, the sternum and below the rib cage, so that the patient can learn the correct breathing pattern. Verbal commands will be also used by the PT to reinforce the manual stimulation with each pattern/exercise being performed 10 times.~2. patients treated with the initial stretch technique ,This technique facilitates the initiation of inhalation. The IST was applied to help the patient to initiate the inhalation phase, increase the force developed by the inspiratory muscle, and to enhance the active range of motion of the chest wall and the diaphragm. At the final stage of exhalation, when inspiratory muscles will be elongated optimally, the stretch reflex will be initiated by applying a quick tap to elicit a strong and active inspiratory muscle contraction"
223939799|NCT06891352|BEHAVIORAL|Time-Restricted Eating with a Low-Glycemic Snack (TRE-LGS)|Participants in the group will receive standard advice for a healthy lifestyle, log all food and beverage intake on the myCircadianClock app, and adhere to a personalized consistent 10-hour time-restricted eating window. On nights that participants work night shifts, they will consume a low-glycemic snack provided by the research team.
223516215|NCT04265118|DEVICE|Sidewards Tilting Bed|Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
223516216|NCT02239042|PROCEDURE|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
223516217|NCT01130428|DEVICE|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (\~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading \[38\]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
223516218|NCT05410795|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
223516219|NCT05062772|DIAGNOSTIC_TEST|Ultrasound|Intraoperative ultrasound imaging
223516220|NCT03172559|RADIATION|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
223516221|NCT00846482|DRUG|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
223516222|NCT02088580|PROCEDURE|Triple Chronotherapy|
223516223|NCT04037644|PROCEDURE|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
223516224|NCT04037644|PROCEDURE|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
223516225|NCT04913090|DRUG|XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
223516226|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part A)|Tablet(s) administered orally once daily for 1 Day
223892527|NCT06831201|PROCEDURE|Passive proprioceptive facilitation technique ( passive PNF) technique|"Perioral pressure is provided by applying pressure with the therapist's finger on the top lip between the nose and lip. The pressure is maintained for the length of time that the therapist wishes the patient to breathe in the activated pattern.~Intercostal stretch is provided by applying pressure to the upper border of a rib in order to stretch the intercostal muscle in a downward(not inward) direction. The stretch position is then maintained while the patient continues to breathe in his/her usual manner.~vertebral pressure high - manual pressure applied to thoracic vertebrae in the region T2 - T5.~vertebral pressure low - manual pressure applied to thoracic vertebrae in the region T9 - T10.~Co-contraction of the Abdomen Provided by the therapist by pressing adequate pressure on the lower ribs and pelvis on the same side, so that pressure is applied at right angles to the patient.~Moderate Manual Pressure of the open hand(s) is maintained over the area in which expansion is desired"
223892528|NCT05523154|PROCEDURE|Biospecimen Collection|Undergo collection of bile samples
223892529|NCT05523154|OTHER|Laboratory Procedure|Undergo routine laboratory testing
223892530|NCT05523154|DEVICE|Nanopore Sequencing|Undergo nanopore sequencing
223892531|NCT06838611|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair of the tricuspid valve for the treatment of severe tricuspid valve regurgitation.
223892532|NCT04022616|OTHER|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
224081252|NCT04123158|DIAGNOSTIC_TEST|MRI|"Diagnostic Test: MRI; MRI investigating the following carachteristics:~TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity \[relative to myometrium\] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI \[SItumour - SImyometrium / SImyometrium\]"
223892533|NCT01492751|BEHAVIORAL|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.~Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
223892534|NCT01492751|PROCEDURE|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
224081253|NCT06528275|OTHER|Health promotion intervention|Health promotion intervention with activites linked to nutrition, and distribution of baskets of fresh fruits and vegetables
224081254|NCT02276859|DRUG|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
224081255|NCT02276859|DRUG|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
224081256|NCT02276859|DRUG|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
224081257|NCT03942432|OTHER|Oral Glucose Tolerance Test (OGTT)|Blood samples at T0, T30min, T120min
224081258|NCT03942432|OTHER|Clinical exam|weight, length, waist measurement, cardiac frequency, blood pressure
224081259|NCT03942432|BIOLOGICAL|Blood sample|Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c
223939800|NCT07052032|BIOLOGICAL|CND261|CND261 will be dosed according to the assigned cohort
223939801|NCT07062094|DEVICE|Intragastric Balloon|The Orbera365™ IGB System is to be used in conjunction with a long-term supervised diet and behavior modification program designed to increase the possibility of long-term weight loss maintenance. The IGB is placed in the stomach and filled with sterile saline, causing it to expand into a spherical shape. The filled IGB is designed to occupy space and move freely within the stomach, potentially altering appetite and satiety to achieve weight loss.
223939802|NCT07057258|PROCEDURE|Endoscopic suture repair|Children receiving endoscopic suture repair of laryngeal cleft
224081260|NCT03942432|DEVICE|MRI|3 Tesla abdominal MRI
224081261|NCT03942432|DEVICE|Bioimpedance|Measurement of body composition
224081262|NCT03942432|BEHAVIORAL|Questionnaires|Quality of life, physical activity, alcohol consumption and eating habits
224081263|NCT01564836|BEHAVIORAL|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
224099166|NCT02413983|PROCEDURE|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
224099167|NCT02413983|PROCEDURE|hepatectomy midline incision|
224099168|NCT02413983|PROCEDURE|hepatectomy transverse incision|
224099169|NCT01668082|PROCEDURE|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
223892535|NCT01492751|RADIATION|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
223892536|NCT01492751|RADIATION|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
223892537|NCT04415424|BIOLOGICAL|4CMenB vaccine|A four-component meningococcal B vaccine
223892538|NCT04415424|OTHER|Placebo|0.5 ml of 150 mmol sodium chloride (0.9% saline solution)
223892539|NCT05321056|DEVICE|masks (surgical mask, respirator)|The mask (surgical mask, respirator) will be worn on the face of the in vitro bionic model in the procedure room for measuring droplet exposure.
223892540|NCT04582825|OTHER|N/A - Observational Study|N/A - Observational Study
223892541|NCT05872477|DRUG|Ruxolitinib Topical|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
223892542|NCT05872477|DRUG|Placebo|There will be 2 arms with intra individual comparison. Both groups will receive epidermal cell suspension (provided by Cutiss®). After 7 days the dressing will be removed. Each grafted side of the body will be randomly assigned to receive twice daily application of topical 1.5% ruxolitinib cream (Group A) or twice daily application of placebo cream (Group B). After 3 months, both sides will be treated by twice daily applications of topical ruxolitinib for 3 additional months.
223892543|NCT06373562|OTHER|hypoxia|The athletes were living in hypoxic rooms, which could simulate a selected altitude above sea level.
223892544|NCT05849064|BEHAVIORAL|Behavioral Control|Participants will receive standardized behavioral management strategies for their concussion symptoms including: activity, hydration, nutrition, sleep, and stress management strategies. These strategies provide general methods to manage concussion symptoms and regulate daily activities to assist in the recovery of concussion.
223939803|NCT07057258|PROCEDURE|Injection laryngoplasty|Children receiving injection of the interarytenoid space for laryngeal cleft treatment
223939804|NCT06359041|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
223939805|NCT07076394|BEHAVIORAL|Forgiveness Education|"The curriculum will apply the textbook of Forgiveness is a Choice: A Step-by-Step Process for Resolving Anger and Restoring Hope written by Dr. Robert Enright."
223939806|NCT06896045|BEHAVIORAL|Assess stress levels 4 times a day before meals (morning, noon and evening and at bedtime) using a visual analogue scale|In addition to stress assessment with the stress meter, patients will be fitted with a Continious Glucose Monitoring
223516227|NCT04913090|DRUG|XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
223516228|NCT04913090|DRUG|Placebo to match XZP-5610 Tablet (for Part B)|Tablet(s) administered orally once daily for 14 Days
223516229|NCT04913090|DRUG|"XZP-5610 Tablet （for Part C1）"|Tablet(s) administered fasted orally once daily for 1 Day
223939807|NCT07075237|DRUG|Paliperidone Palmitate Injection (PP1M)|"Day 0: 150 mg deltoid injection; Day 7: 100 mg deltoid injection; Monthly maintenance dose of 75-150 mg (deltoid or gluteal) for 6 months (dose adjusted per investigator's judgment).~To avoid missed doses, administration is permitted ±7 days around the scheduled monthly date."
223516230|NCT04913090|DRUG|"XZP-5610 Tablet for Part C2"|Tablet(s) administered after a high-fat meal orally once daily for 1 Day
223939808|NCT06750913|PROCEDURE|Comparison between PCNL without Catheterization in the Split-leg Prone Position and Traditional PCNL|Before the start of PCNL, one group of patients was placed in the lithotomy position and then converted to the prone position, and one group of patients directly separated from the leg prone position without an external brace
223939809|NCT07079098|OTHER|Simulation-free workflow|Pre-existing diagnostic images (CTs, PET/CTs, or MRIs) will be imported into the online treatment planning system called Ethos. The Ethos platform and online adaptive radiation therapy (ART) will be utilized at the time of treatment planning and the first (of five) fractions. Subsequent fractions will be delivered using standard image-guided radiotherapy (IGRT) or ART; this will be decided by the treating physician and institutional guidelines.
223939810|NCT07079098|RADIATION|SBRT|Participants will receive SBRT per standard of care in up to five fractions. Fractions will be delivered once daily or once every other day over a total period of one to two weeks.
223939811|NCT06905509|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHCT
223939812|NCT06905509|DRUG|Carboplatin|Given carboplatin
223939813|NCT06905509|DRUG|Cytarabine|Given cytarabine
223939814|NCT06905509|DRUG|Dexamethasone|Given dexamethasone
223939815|NCT06905509|BIOLOGICAL|Epcoritamab|Given SC
223939816|NCT06905509|DRUG|Etoposide Phosphate|Given etoposide phosphate
223939817|NCT06905509|DRUG|Gemcitabine|Given gemcitabine
223516231|NCT01906138|DEVICE|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
223892545|NCT05849064|BEHAVIORAL|Targeted Intervention|Participants will be prescribed one or more interventions, tailored to their domains. Anxiety/Mood-Cog beh therapy(CBT) for maladaptive beliefs/avoidance/coping behaviors. Graded exposure/activity/relaxation exercises, cognitive restructuring. Cognitive-Accommodations for reduced work/school time/delayed deadlines, more frequent/longer cognitive rest during symptom-provoking activities. Migraine/Headache: Education, relaxation training/mindfulness based therapy. Ocular-Exercises for ocular symptoms, near point convergence, may include Brock string, pencil push-ups, fixation, saccade tracking, pursuits. Sleep-Sleep regulation/hygiene. Mindfulness-based training, morning physical activity, CBT.Vestibular-Exercises for dizziness, visual motion sensitivity, gait, imbalance that may include gaze stability, visual habituation, static and dynamic balance/gait.
223892546|NCT02158767|BIOLOGICAL|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
223892547|NCT06422390|BIOLOGICAL|Platelet - Rich Plasma|Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
223892548|NCT04101474|DRUG|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
223892549|NCT05826132|OTHER|Adjusted Content Intervention|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, using language that speaks to the specific experience of being a young Latina woman
223892550|NCT05826132|OTHER|Non-Adjusted Intervention Video|2-3-minute video in which an empowered essential worker protagonist shares her COVID-19 related mental health problems and describes how she was able to confront her mental health problems and pursuit of mental health care, without any language alluding to her particular identity characteristics
223892551|NCT06155266|DIAGNOSTIC_TEST|2 additional whole blood samples of 6mL each will be taken|"As part of the initial blood work-up, 2 additional samples of 6mL each of whole blood will be taken, to which 1mL of Cytodelics® Stabiliser will be added. The tubes will be mixed by inverting 10 to 15 times, incubated at +20°C for 10 minutes, then transported within 1 to 2 hours at 4°C by courier to the CRB at Pitié-Salpêtrière for aliquoting and freezing at -80°C . The expression level of cell surface markers will then be measured in series on an Aurora spectral cytometer, after frozen samples (1 to 2 aliquots) have been sent from the CRB-PSL to CIMI (INSERM U1135) at -80°C approximately once a month.~Any remaining samples sent to CIMI will be destroyed once the analyses have been completed."
223892552|NCT06442059|OTHER|Kinesiophobia Level Due to Dyspnea|Kinesiophobia Level Due to Dyspnea
223892553|NCT03656549|DRUG|Pemetrexed + oral folinic acid rescue|3+3 dose escalation study of pemetrexed in patients with impaired renal function in combination with roal folinic acid rescue
223892554|NCT04774003|DRUG|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) in 0.5 mL solution. Subcutaneous administration at Day 1
223892555|NCT04774003|DRUG|Placebo|Inclisiran sodium 0mg (equivalent to inclisiran 0 mg) in 1.5 mL solution. Subcutaneous administration at Day 1
223892556|NCT04774003|DRUG|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) in 1.5 mL solution. Subcutaneous administration at Day 1
223892557|NCT05603234|BEHAVIORAL|Symptom Monitoring|Reporting symptoms each day via a symptom questionnaire
223892558|NCT04522375|DRUG|FP-045|activator of aldehyde dehydrogenase
223892559|NCT01573442|DRUG|testosterone|10.4 mg
223892560|NCT01573442|OTHER|placebo|
223892561|NCT05586763|DRUG|Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)|Each patient with vertigo symptoms will be registered in vertigo list after written consent taken. The ED doctor will take one paper from the vertigo list box and will write the case there including patient ID, date, age and symptoms. Assessment (VAS \& EEV) will be done in the pre- medication 0 min, and at 60 mins posts anti-vertigo medication. The medication will be provided blindly through the pharmacy. Any possible medication side effect and any possible further work up done for patient will be involved in each paper as ED doctor will put a tick near each point. Score will be written in papers as per patient evaluation of their symptoms grade from 1-10. The need for rescue medication ( betahisten or ondansetron ) will be recorded in the paper or is need eply manuver. Principle investigator in each centre will be responsible to collect the papers for analysis by end of each weeks.
223892562|NCT02502435|OTHER|Observation|Observational study
223892563|NCT05896267|DEVICE|Masimo INVSENSOR00061|Masimo INVSENSOR00061 will be used to measure noninvasive SpO2 (Oxygen Saturation )
223892564|NCT05873504|DEVICE|High Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
223892565|NCT05873504|DEVICE|Low Oscillatory Index Device|This device is commonly used to provide assistance with airway secretion clearance.
223892566|NCT04274543|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the meniscal lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
223892567|NCT04274543|DRUG|Normal Saline|"Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions."
223939818|NCT06905509|DRUG|Ifosfamide|Given ifosfamide
223939819|NCT06905509|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223939820|NCT06905509|DRUG|Oxaliplatin|Given oxaliplatin
223939821|NCT06905509|BIOLOGICAL|Rituximab|Given rituximab
223892568|NCT05845918|BEHAVIORAL|PRISEM Remote|"Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another."
223892569|NCT05977270|DEVICE|Lifebloom One|LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
223892570|NCT05710107|OTHER|PENG + LFC Block|Subjects assigned to this group will receive PENG + LFC Block
223516232|NCT03460704|DRUG|CMS|"1 MIU equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%. Investigational Medicinal Product (IMP) glass vials were shrink wrapped in opaque white plastic and provided in boxes of 30 vials (two weeks of b.i.d. dosing).~The 1 MIU/ml CMS/0.45% saline solution was transferred from the glass vial into a specific nebuliser system fitted with a 0.3 mL medication chamber, for administration by inhalation. This delivered a nominal dose of 0.3 MIU/24 mg CMS (11 mg CBA) from the device.~The first dose of the IMP was administered at the site under the supervision of the site staff and subjects were instructed how to prepare and self-administer the IMP at home via a specific nebuliser system, b.i.d. (morning and evening) over aperiod of 12 month.~At least 10 minutes (min) before each administration, an inhaled short-acting bronchodilator (e.g. salbutamol/albuterol), supplied by the Sponsor, could be taken to improve tolerability."
223516233|NCT03460704|OTHER|Placebo|1 mL saline solution 0.45%. The placebo was made up of identical empty glass vials to which the same saline solution diluent was added in exactly the same way as the reconstitution of the active treatment by injecting the diluent through the rubber stopper. The glass vials were shrink wrapped with opaque white plastic to mantain the blind.
223516234|NCT02644057|DRUG|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
223516235|NCT02644057|DRUG|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
223516236|NCT00760305|BEHAVIORAL|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
223516237|NCT01978301|DRUG|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
223516238|NCT01978301|DRUG|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
223516239|NCT05904379|DRUG|AK112|Subjects receive AK112 intravenously.
223516240|NCT05904379|DRUG|AK104|Subjects receive AK104 intravenously.
223516241|NCT05904379|DRUG|Carboplatin|Subjects receive carboplatin intravenously.
223516242|NCT05904379|DRUG|paclitaxel|Subjects receive paclitaxel intravenously.
223892571|NCT05710107|OTHER|QL Block|Subjects randomized to this group will receive a QL Block
223892572|NCT04166773|DRUG|Tirzepatide|Administered SC
223892573|NCT04166773|DRUG|Placebo|Administered SC
223892574|NCT05038332|RADIATION|Ultra-hypofractionated radiation therapy|34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)
223892575|NCT05038332|RADIATION|Moderately Hypo-fractionated Radiation Therapy|55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)
223892576|NCT05858008|BEHAVIORAL|Time-restricted eating|Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
223516243|NCT05904379|DRUG|pemetrexed|Subjects receive pemetrexed intravenously.
223516244|NCT05904379|DRUG|Docetaxel|Subjects receive docetaxel intravenously.
223892577|NCT06469398|DEVICE|Cutera Laser System|Subjects will receive up to 6 laser treatments
223516245|NCT03888287|DEVICE|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
223516246|NCT03888287|OTHER|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
223892578|NCT06212440|DIAGNOSTIC_TEST|Radioactive Isotope (RI) Mapping|Administered via peritumoral or subareolar injection for sentinel lymph node detection.
223892579|NCT06212440|DIAGNOSTIC_TEST|Indocyanine Green Fluorescence (ICG-F) Mapping|Administered via peritumoral or subareolar injection, detected using near-infrared fluorescence imaging.
223892580|NCT06212440|DIAGNOSTIC_TEST|Vital Dye Mapping|Administered via peritumoral or subareolar injection for intraoperative visualization of lymphatic drainage pathways.
223892581|NCT05110443|OTHER|D-WB PET/CT|"Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way."
223892582|NCT04115540|DEVICE|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
223516247|NCT05902975|DEVICE|Fiber reinforced composite resin space maintainer|Bonding of fiber reinforced with composite resin on primary second molar and primary canine under rubber dam isolation
223516248|NCT04160598|DRUG|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
223516249|NCT04160598|DRUG|intrathecal fentanyl|10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
223516250|NCT02913326|DRUG|Dabigatran etexilate|
223516251|NCT02913326|DRUG|Warfarin|
223516252|NCT05600257|DEVICE|DBT|Image with digital breast tomosynthesis
223516253|NCT05600257|DEVICE|DM|Image with digital mammography
223516254|NCT00002515|BIOLOGICAL|filgrastim|
223516255|NCT00002515|DRUG|carboplatin|
223516256|NCT00002515|DRUG|thiotepa|
223516257|NCT00002515|DRUG|topotecan hydrochloride|
223516258|NCT00002515|PROCEDURE|autologous bone marrow transplantation|
223516259|NCT00002515|PROCEDURE|bone marrow ablation with stem cell support|
223516260|NCT00002515|PROCEDURE|in vitro-treated bone marrow transplantation|
223516261|NCT00619398|DRUG|Prograf|Oral
223516262|NCT00619398|DRUG|FK506MR capsule|Oral
223516263|NCT02909257|DRUG|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
223516264|NCT02909257|DRUG|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
223516265|NCT01767857|DRUG|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
223516266|NCT01767857|DRUG|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
223516267|NCT02792946|DRUG|Acebrophylline|
223516268|NCT06468553|BEHAVIORAL|Prediabetes Care Program|Patients are cared for by the medical, nutritionist and psychology team, in a total of 14 individual and group visits, during 12 months of care. The intervention has an initial stage lasting 6 months in which 12 visits will be scheduled and a transition stage lasting 6 more months in which 2 more visits will be scheduled. Patients will be evaluated at 6 months, 12 months and 24 months
223516269|NCT03138382|DEVICE|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
223516270|NCT03138382|DEVICE|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
223516271|NCT03016702|OTHER|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
223516272|NCT03016702|OTHER|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
223516273|NCT00003680|DRUG|CMF regimen|
223892583|NCT04175847|DRUG|RC88|"Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration"
223892584|NCT06282887|OTHER|Music therapy|The intervention has two parts. The first part is an approximately 15-minute music therapy session to induce relaxation and positive memories attached to the relaxing live music provided by a credentialed music therapist. The second part is music listening during the scanning process.
223892585|NCT06483503|DEVICE|EFOV Colonoscope|Routine colonoscopy using the EFOV lens in the colonoscope.
223516274|NCT00003680|DRUG|cyclophosphamide|
223516275|NCT00003680|DRUG|fluorouracil|
223516276|NCT00003680|DRUG|methotrexate|
223516277|NCT00003680|DRUG|tamoxifen citrate|
223516278|NCT00003680|DRUG|thiotepa|
223516279|NCT00003680|PROCEDURE|peripheral blood stem cell transplantation|
223516280|NCT00003680|RADIATION|radiation therapy|
223516281|NCT05208957|OTHER|No intervention|No intervention
223516282|NCT03184025|OTHER|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
223516283|NCT05438771|COMBINATION_PRODUCT|Ankaferd Blood Stopper|mouth wash
223516284|NCT05438771|OTHER|Bicarbonate|mouth wash
223516285|NCT03800901|OTHER|Continuing Medical Education|CME or ABIM MOC credits
223534811|NCT02523950|PROCEDURE|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
223534812|NCT02523950|PROCEDURE|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
223516286|NCT03800901|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control."
223516287|NCT04938531|OTHER|Exercise|Participants will perform an entry passive exercise test within 48 hours of onset of severe sepsis. Patients then will perform 30-60 min supine passive cycle ergometry exercise 5 days/week.
223516288|NCT04526457|OTHER|Standard of Care|Randomized to standard of care with lipid testing only.
223516289|NCT04526457|OTHER|Genetic Testing|Randomized to genetic testing.
223892586|NCT06214949|DEVICE|Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over 3-4 weeks. Specifically, the active or sham treatments will be conducted \~5 times a week during the treatment phase of the study. The treatment protocol parameters (stimulus location, frequency, duration, and intensity) will be derived from the PrTMS software algorithm which incorporates clinical inputs from neurocognitive surveys and quantitative EEG analysis. The mechanical parameters will adhere to the recommended PrTMS parameters for pain treatment: figure of 8 coil that produces biphasic stimulatory pulses to the central zone cortex, frontal zone cortex, Broca's area, and frontal pre-cortex areas at a stimulation depth of 2 cm. Treatment parameters will be unique to each participant but will remain within known ranges. The frequency will be between 8 and 13 Hz, at an amplitude of 20-30% (approximately 30-40% of RMT), and about 3200-7200 pulses per session. Since parameters are specific to each participant, treatment settings will vary.
223892587|NCT06214949|DEVICE|Sham Personalized Repetitive Transcranial Magnetic Stimulation|Treatment will consist of 15 sessions over the course of 3-4 weeks. More specifically, the active or sham treatments will be conducted roughly 5 times a week during the course of the treatment phase of the study. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
223892588|NCT06475222|OTHER|Study 1: Facial serum with alpha albutin|Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.
223892589|NCT06475222|OTHER|Study 1: Facial serum with Tubtim Chumpae rice extract|Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.
223892590|NCT06475222|OTHER|Study 2: Facial mask with Hom Pathum rice extract|Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.
223892591|NCT06475222|OTHER|Study 3: Control jelly|Consumption with control jelly as active comparator at 3.5 g/kg body weight.
223892592|NCT06475222|OTHER|Study 3: Jelly with Tubtim Chumpae rice|Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
223892593|NCT06475222|OTHER|Study 3: Jelly with Hom Pathum rice|Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.
223892594|NCT05182242|OTHER|Collection of clinical data|family history, clinical data, ultrasound and all other data necessary for the study on a e-CRF (CleanWEB), allowing the collection of the family tree, and if necessary photographic elements.
223892595|NCT05182242|BIOLOGICAL|Collection of samples|"Collected during fetal and blood sampling performed as part of care for ACPA:~* 4 Streck tubes maximum for the pregnant woman for NIPD-Exome, collected prior to invasive fetal sampling~* 1 additional vial of fetal sample (amniotic fluid or fetal blood) and 1 EDTA tube for each of the two parents"
223892596|NCT05182242|OTHER|Questionnaires|within the framework of the pilot study (optional): questionnaires (about 20 minutes) for the evaluation of the experience, perceptions, impact of the analyses on the decision, satisfaction and concerns regarding exome sequencing (ES) and its results, opinion on certain types of results currently not reported, anxiety, possible psychological difficulties
223892597|NCT05182242|OTHER|Parent interviews|as part of the pilot study (optional): interview (about 1 hour) with a sociologist to explore perceptions of ES and the impact of the results, expectations about certain types of results that are not currently available, emotional situation, position regarding the continuation of the pregnancy
223892598|NCT05182242|OTHER|Professional interview and focus groups|Interview (approximately 45 minutes) to understand how the decision is formed Focus groups to help clarify whether the Variants of Unknown Significance (VUSs) should potentially be returned to the clinicians, or even the patient via the clinician
223892599|NCT06382727|OTHER|EN will be continued up to extubation (EN will not be withheld prior to extubation)|As per the arm/group descriptions.
223892600|NCT03641092|BEHAVIORAL|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
223939822|NCT06100952|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
223516290|NCT03635879|OTHER|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
223516291|NCT03635879|OTHER|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
223516292|NCT03635879|OTHER|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
223516293|NCT03635879|OTHER|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
223516294|NCT03635879|OTHER|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
223516295|NCT03635879|DRUG|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
223516296|NCT00214526|PROCEDURE|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
223516297|NCT00214526|DRUG|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
223892601|NCT03641092|BEHAVIORAL|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site \[when recruited families will be ineligible for CenteringParenting groups that will start in control sites\]. They will receive anticipatory guidance and handouts that are standard for the clinic.
223892602|NCT05490290|OTHER|Active|In the active intervention condition, decision support is provided during the referral procedure of medical imaging exams.
223892603|NCT06439901|OTHER|Screening|A first step to identify and recruit people eligible for screening,
223892604|NCT06439901|OTHER|Inclusion|A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
223892605|NCT06439901|OTHER|Chest CTscan and follow-up|A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
223892606|NCT04717492|OTHER|Observational|Observational
223892607|NCT06550284|OTHER|Physical Therapy|The intervention will be physical therapy standard care.
223892608|NCT04456517|DRUG|Ranolazine|500 mg tablet
223892609|NCT04456517|DRUG|Placebo|Ranolazine-matched placebo tablet
223892610|NCT03543202|DRUG|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
223892611|NCT03543202|DRUG|local infiltration anesthesia|will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
223892612|NCT03543202|DRUG|Intravenous patient controlled analgesia|will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
223892613|NCT05999084|DRUG|Anti-amyloid Monoclonal Antibodies (mAbs)|Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.
223892614|NCT05999084|COMBINATION_PRODUCT|Standard of Care|The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.
223892615|NCT03485469|BEHAVIORAL|Hypnosis|"There ar 10 hypnosis sessions :~* 1st session of hypnosis : relaxation and orientation towards emotional cleansing.~* 2nd session of hypnosis: oriented towards digestion, physical and psychological~* 3rd session of hypnosis: oriented towards the feeling of security.~* 4th session of hypnosis: self-esteem oriented.~* 5th hypnosis session: oriented towards emotional management.~* 6th hypnosis session: oriented towards self-confidence.~* 7th hypnosis session: oriented towards the completion of the projects.~* 8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
223892616|NCT03485469|BEHAVIORAL|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
223892617|NCT05441501|DRUG|JNJ-80038114|JNJ-80038114 will be administered.
223892618|NCT04367883|DRUG|Antihistamine|No intervention is performed. We propose an observational study.
223892619|NCT04367883|DRUG|Amantadine|No intervention is performed. We propose an observational study
223892620|NCT04367883|DRUG|ACEI|No intervention is performed. We propose an observational study.
223892621|NCT04367883|DRUG|ARB|No intervention is performed. We propose an observational study.
223892622|NCT04367883|OTHER|Influenza vaccine and COVID|No intervention is performed. We propose an observational study.
223892623|NCT06318338|OTHER|Virtual Reality Program|Study participants will be provided a HTC or Pico VR head-mounted device (HTC Flow, HTC Focus or Pico Neo Pro) which will be fitted for comfort. Patients will remain seated for the entirety of the VR program. The program generally takes about ten minutes to complete but may last up to 11 minutes. The program displays a relaxing environmental setting with narration based in mindfulness meditation principles. Subjects will be prompted to practice breathing exercises designed to relax and reduce anxiety.
223892624|NCT06096038|DRUG|Cyclophosphamide|cyclophosphamide 300 mg/meter square IV
223892625|NCT06096038|DRUG|Fludarabine|fludarabine 30 mg/meter square IV × 3 days
223892626|NCT06096038|BIOLOGICAL|Cell Therapy|the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion
223892627|NCT01477957|PROCEDURE|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
223892628|NCT05485090|OTHER|Questionnaire : Adapted Safety Assessment Scale|Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
223892629|NCT05794412|OTHER|No intervention|No intervention
223892630|NCT03927638|BEHAVIORAL|sit/stand|Subjects will be asked to both sit and stand during a single trial.
223892631|NCT05467943|DRUG|Tazemetostat|All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
223892632|NCT05149872|OTHER|Muscle relaxation|Rocuronium will be used to induce partial paralysis
223892633|NCT05149872|OTHER|Reversal|Sugamamdex will be used to reverse muscle relaxation
223892634|NCT05521776|PROCEDURE|First-trimester preeclampsia screening (FMF triple test)|"An algorithm assessing the risk of developing preeclampsia combining maternal parameters, blood pressure measurement, Doppler measurements of the uterine arteries and maternal PlGF concentrations.~For women in the screening group, a Doppler study of the uterine arteries and a blood test to quantify PlGF concentrations will be performed within 2 days of randomization, allowing the risk to be calculated according to the screening test. For women with a positive screening test (i.e. predicted risk\> 1/100), a treatment with aspirin will be prescribed at 160 mg/day, started as soon as possible and before 15 WG, and taken up to 36 WG, in the absence of contraindications. For women with negative screening, usual pregnancy monitoring without aspirin will be offered."
223892635|NCT05597306|DRUG|Bomedemstat|Bomedemstat will be administered orally once daily via capsule.
223892636|NCT05597306|DRUG|Venetoclax|Venetoclax will be administered orally once daily via tablet.
224099170|NCT05882890|OTHER|Craniosacral Therapy|Manual treatment, 5 grams, on the airway system, the throat, the neck, the meninges, the cranial nerve sleeves, the visceral cranium, and the soft tissue in the mouth.
223892637|NCT03888170|OTHER|No intervention|No intervention
223892638|NCT05259072|DIAGNOSTIC_TEST|99m-technetium pyrophosphate scintigraphy|Imaging test
223892639|NCT03903146|BEHAVIORAL|Early Childhood Obesity Risk-Reduction Program in Hispanics|"Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month)."
223892640|NCT04176965|DEVICE|FINEVISION HP IOL|Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
223892641|NCT04176965|DEVICE|Alcon AcrySof SN60AT|Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.
223892642|NCT03861975|OTHER|Breast Cancer-Related Lymphedema Measurements|All patients will receive bilateral arm measurements using the LymphaTech Scanner and the Perometer.
223892643|NCT03808987|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
223892644|NCT03808987|BEHAVIORAL|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
223892645|NCT05261399|DRUG|Savolitinib|300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral
223892646|NCT05261399|DRUG|Osimertinib|"80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral"
223892647|NCT05261399|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) Administrative route : IV infusion
223892648|NCT05261399|DRUG|Cisplatin|Cisplatin (75 mg/m2) or Administrative route : IV infusion
223892649|NCT05261399|DRUG|Carboplatin|Carboplatin (AUC5) Administrative route : IV infusion
223892650|NCT05394818|DRUG|SHR-A2009|The total dosage of SHR-A2009 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
223939823|NCT06100952|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
223939824|NCT06527690|DRUG|Niraparib/Abirate rone acetate fixed-dose combination|Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.
223939825|NCT06527690|DRUG|Prednisone|Participants will receive prednisone 5mg 2 tablets once daily on days 1-28 of each 28-day cycle.
223939826|NCT06902558|DRUG|ABBV-CLS-628|IntraVenous Infusion
223939827|NCT06902558|DRUG|Placebo|IntraVenous Infusion
223939828|NCT06904287|DRUG|Magnesium|Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by magnesium 2 g administered as an intravenous bolus over a period of 20 minutes
223939829|NCT06904287|DRUG|Placebo|Prochlorperazine 10 mg administered as an intravenous push over 2 minutes followed by placebo (normal saline)
223939830|NCT02629120|DRUG|Alemtuzumab|Transplant Conditioning Drug: Monoclonal antibody that targets recipient and donor T-cells to prevent graft verses host disease. Not an IND. This is a well studied drug, and is not under an IND.
224081264|NCT06203301|BEHAVIORAL|resistance exercise and walking|"After receiving the cases, they were divided into 4 groups by random allocation:~1. Control group: No exercise intervention measures are performed, and the patients carry out their daily lives according to their past living habits.~2. Resistance exercise group: Resistance exercise training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. The patients are given resistance exercise training for 45 minutes each time, 3 times a week, for 12 consecutive weeks. Afterwards, the patient is asked to regularly perform resistance exercise on his own for at least 1 year.~3. Walking group: Walking training begins before the patients receive simultaneous radiochemotherapy, radiation therapy, or chemotherapy. They should walk continuously for 15 minutes at least twice a day and continue walking at least 5 days a week. Or walk for at least 150 minutes a week and walk for at least 15 minutes continuously each time for 12 consecutive weeks of walk"
224081265|NCT05169528|OTHER|Colorectal Cancer Prehabilitation Programme|Assessment and Interventions involving the Prehabilitative domains of medical optimisation, exercise prescription, nutrition and mental health optimisation
224081266|NCT04075331|DRUG|Mepolizumab|Mepolizumab 100mg subcutaneous injection
224081267|NCT04075331|DRUG|Placebo|Saline solution for subcutaneous injection
224081268|NCT06356233|OTHER|No intervention will be performed|No intervention will be performed
224081269|NCT05417854|DEVICE|Splenic Ultrasound|Daily ultrasound application to the spleen of approximately 18 minutes per day, 5 days per week for up to 8 weeks, in addition to standard clinical care.
224081270|NCT03220672|BEHAVIORAL|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
224081271|NCT05264220|BEHAVIORAL|ACT Matrix|Participants will receive a 4 session psychological intervention based on the ACT Matrix
224081272|NCT02881034|DRUG|Triple therapy|
224081273|NCT01286246|DRUG|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
224081274|NCT01286246|DRUG|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
224081275|NCT04539093|OTHER|Exposure of interest - Use of left ventricular assist device (LVAD)|Mechanical circulatory support devices such as left ventricular assist device is used as a treatment option for patients with end-stage heart failure.
224081276|NCT01791608|DIETARY_SUPPLEMENT|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
224081277|NCT01791608|DIETARY_SUPPLEMENT|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
224081278|NCT01791608|DIETARY_SUPPLEMENT|Milk without fortification without zinc|Milk without fortification
224081279|NCT02984592|BEHAVIORAL|physical exercise|regular exercise programs in the previous 6 months.
224081280|NCT04663178|OTHER|Warm Salt Water Foot Bath|A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
224081281|NCT00503204|DRUG|Cediranib|oral tablet
223892651|NCT01874769|OTHER|Blood collection|"* 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~* 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~* 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
224081282|NCT00503204|DRUG|Lomustine|oral capsule
224081283|NCT03261531|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
224081284|NCT00416988|OTHER|educational intervention|
224081285|NCT00402441|DRUG|Risedronate (HMR4003)|
224081286|NCT00820755|DRUG|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
224081287|NCT00820755|DRUG|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
224081288|NCT00820755|DRUG|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
224081289|NCT05816863|DRUG|pabolizumab|pabolizumab IV every 3 weeks (q3w)
223516298|NCT03288259|PROCEDURE|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
223892652|NCT01874769|OTHER|Skin biopsies|"* A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~* During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
223892653|NCT04427709|DRUG|Oxytocin|Intramuscular injection of Oxytocin (Pitocin®)
223892654|NCT04427709|DRUG|Placebo|Intramuscular placebo injection
223892655|NCT05614024|OTHER|Real fNIRS Neurofeedback|Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
223892656|NCT05614024|OTHER|Sham-Control fNIRS Neurofeedback|Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
223892657|NCT02919683|DRUG|Nivolumab|
223892658|NCT02919683|DRUG|Ipilimumab|
223892659|NCT02919683|PROCEDURE|Standard of Care Surgery|
223892660|NCT05456165|DRUG|GRT-C901|An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
223892661|NCT05456165|DRUG|GRT-R902|An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
223892662|NCT05456165|DRUG|Atezolizumab|Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
223892663|NCT05456165|DRUG|Ipilimumab|Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
223892664|NCT05456165|DRUG|Adjuvant chemotherapy|Administered according to standard of care.
223892665|NCT05911633|DEVICE|BioPearl™|TACE
223892666|NCT05854251|DRUG|Anakinra|Subjects receive an s.c. injection of 100 mg Anakinra on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
223892667|NCT05854251|DRUG|Placebo|0.67 ml of s.c. injection of saline will be taken on the evening before and on the respective study day 60 minutes before ingestion of the mixed-meal
223892668|NCT06052345|DEVICE|Garmin smartwatch|"* Physical activity (Activity sessions, type and length of activity, activity intensity estimations)~* Meal detection and meal characteristics (accelerometry and gyroscope data)~* Oxygen saturation (pulse oximetry)~* Number of steps (pedometer)~* Stress level indicators (based on heart-rate analytics)~* Sleep patterns (sleep and wake-up time, sleep quality)"
223892669|NCT06052345|OTHER|REBECCA Mobile application|"* GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection)~* Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3~* Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)"
223892670|NCT06052345|OTHER|REBECCA PC plug-in|"* the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram).~* These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites"
223892671|NCT06335589|OTHER|EBP-Massed|CPT or PE will be delivered in a massed format (e.g., sessions at least 3 days per week)
223892672|NCT06335589|OTHER|EBP-TAU|CPT or PE will be delivered treatment as usual, which is typically once per week.
223892673|NCT05619900|OTHER|There is no intervention|This is an observational study. There is no intervention. The purpose of the project is to create a database of patients diagnosed either prenatally or after birth with a lysosomal storage disease. The database will be utilized to assess patient outcomes, build on existing clinical management, improve medical decision making, and improve quality of care.
223892674|NCT05679154|BEHAVIORAL|Team-focused Implementation|CACs randomized to the experimental condition (n = 2) will participate in team-focused implementation. They will receive team development interventions (e.g., goal-setting exercise, training in communication skills) integrated with standard CPM-PTS training and technical assistance strategies.
223892675|NCT05679154|BEHAVIORAL|Standard Implementation|CACs randomized to the comparison condition (n = 2) will receive standard training and technical assistance strategies to support CPM-PTS implementation. They will receive CPM-PTS materials (e.g., manual, REDCap surveys, referral protocols), an interactive training, and six months of technical assistance.
223892676|NCT05690581|DRUG|CM369|Specified dose on specified days.
223892677|NCT04286490|OTHER|Prone position|Abdomen suspension in prone position
223892678|NCT06402721|DRUG|BAY3283142|Single oral dose.
223892679|NCT02742493|OTHER|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
223892680|NCT02742493|OTHER|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
223892681|NCT02742493|OTHER|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
223892682|NCT04187651|OTHER|platelet rich plasma|platelet rich plasma prepared from the patients' own blood will be applied to the fistula tract
223892683|NCT06771180|DRUG|Dara-CyBorD|Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
223892684|NCT04918823|DRUG|Restasis|Subject will use one drop of Restasis in the lens before insertion
223892685|NCT04072380|DRUG|SUVN-G3031|SUVN-G3031 Tablets
223892686|NCT04072380|DRUG|Placebo|Placebo Tablets
223892687|NCT04512547|DRUG|Hyperpolarized 129XeMRI|Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
223892688|NCT04783571|OTHER|Placebo|Auditory stimulation will not be delivered during the nap
224099171|NCT05882890|OTHER|Exercices Targeting Upper Posture and Respiration|Exercises targeting upper posture and breathing exercises. The exercises is given when the therapist has reached some anatomical milestones in the treatment protocol. For example, an exercise with diaphragmatic breathing is given after manual treatment of diaphragma.
223516299|NCT03288259|DRUG|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
223892689|NCT04783571|OTHER|Auditory Stimulation|Auditory stimulation will be delivered during the nap
223892690|NCT03144765|PROCEDURE|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
223892691|NCT05722652|BEHAVIORAL|CONFIDENCE|"This clinic-based, multicomponent intervention consists of 3 parts:~1. Webinar training for clinicians and clinic staff about how to communicate with vaccine-hesitant parents~2. Parent-facing educational materials about COVID-19 vaccination~3. Support in creating a personalized poster campaign featuring providers and clinic staff sharing personal stories about COVID-19 vaccination"
223892692|NCT06259448|OTHER|urine self-sampling|urine self-sampling
223892693|NCT04266080|OTHER|Fitbit Inspire HR|assessing step counts
223892694|NCT04266080|OTHER|Questionaires|Patient-Reported Outcomes Measurement Information System (PROMIS)
223892695|NCT05551637|DIETARY_SUPPLEMENT|Kazu Gain Gold|"Kazu Gain Gold is an Oral Nutritional Supplementation made by AIWAIDO Food Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~User Manual: Mix 6 spoons of Kazu Gain Gold (equal to 49,2 grams) with 180 ml of warm water (The energy density reaches 1kal/ml). Consume 2 glasses per day or follow the directions from the medical staff. The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
223892696|NCT06223854|DIETARY_SUPPLEMENT|Iodized salt|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
223892697|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with lower-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
223892698|NCT06223854|DIETARY_SUPPLEMENT|Experimental: Iodized salt with higher-dose folic acid fortification|Masked, individually labeled 500-g containers of the study salts will be delivered to the participants' homes bi-weekly by field workers who will collect previously delivered salt containers during the same visit. Participants will be counseled to use the study salt for all food preparation and meal-time seasoning for all members of the household and not to share the salt with others or use it for non-food consumption purposes.
223892699|NCT05030155|DRUG|Mepolizumab|300 mg/month subcutaneous
223892700|NCT05030155|DRUG|cyclophosphamide/azathioprine|Patients with FFS≥1 will receive cyclophosphamide then azathioprine
223892701|NCT05030155|DRUG|Placebo|Patients with FFS=0 will receive placebo
223892702|NCT04721912|DRUG|Probiotic dietary supplement|GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
223892703|NCT04740567|BEHAVIORAL|Cognitive Training|The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.
223892704|NCT04740567|BEHAVIORAL|Goal Management Training|"Goal management training will (1) teach patients compensatory strategies such as stop techniques \[e.g., to stop and think about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in sustained and vigilant attention theory and it enables patients to actively attend to higher order goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies."
223892705|NCT02643498|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
223892706|NCT01659411|OTHER|Observational|Yearly clinical visits
223892707|NCT05009264|PROCEDURE|OMT|OMT will be performed on identified areas of trapezius trigger points
223516300|NCT04681313|PROCEDURE|High-risk percutaneous coronary intervention|Percutaneous coronary interventions (PCI) deemed high risk based on patient-related risk features, hemodynamic criteria, clinical presentation and complexity of coronary anatomy.
224081290|NCT04072757|BEHAVIORAL|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~* connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~* seasonal fruits \& vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~* quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~* choose healthier foods Session Five: Taste Bud Rehab~* reduce foods high in sugar and salt.Mind-body connection Session Six: Batch \& One Ingredient Cooking~* making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~* prepare healthier desserts Session Eight: Family Meal Practices~* healthy eating habits in children Session Nine: Snacks as Mini Meals~* make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~* healthy up favorite recipes"
224081291|NCT04072757|BEHAVIORAL|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
224081292|NCT01916629|DRUG|Photocil for Psoriasis|Photocil for Psoriasis
224081293|NCT01916629|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
224081294|NCT02838173|PROCEDURE|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
224081295|NCT02838173|PROCEDURE|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
224081296|NCT02838173|PROCEDURE|serratus plane bloc : placebo|
224081297|NCT02838173|PROCEDURE|tissue infiltration : placebo|
224081298|NCT03308864|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
223516301|NCT03784300|DRUG|50 mg PTI-125|PTI-125 50 mg Oral Solution
223892708|NCT02878915|DEVICE|Ultrasound guided femoral puncture|
223516302|NCT03784300|DRUG|100 mg PTI-125|PTI-125 100 mg Oral Solution
223516303|NCT03784300|DRUG|200 mg PTI-125|PTI-125 200 mg Oral Solution
223892709|NCT03114553|GENETIC|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
224099172|NCT06488755|DRUG|SIM0718 injection|"Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks"
224099173|NCT06488755|DRUG|SIM0718 injection of placebo|"Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks"
224099174|NCT03187561|BEHAVIORAL|Infant sleep-adapted coparenting intervention|The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
223516304|NCT06523816|DIAGNOSTIC_TEST|dermoscopy|Dermoscopy is a fast imaging technique that allows an excellent visualization of non-melanocytic skin tumors to diagnose them without invasive interventon.
223516305|NCT05196724|BEHAVIORAL|Mentalization Based Therapy MBT|The focus is on improving the core components of secure attachment, particularly by developing the reflective functioning for all professionals working with children in out-of-home care, which is subsequently proposed to increase the psychosocial adjustment of the child and decrease emotional and behavioral problems. MBT treatment consists of up to 12 weekly sessions with the foster parents and child covering three core components: 1) psycho-education about mentalizing, trauma, and attachment for foster parents; 2) support for reflective practice in the professional network, and 3) mentalization-based therapy for the foster family \[41\].
223516306|NCT05196724|BEHAVIORAL|Usual care|The control group will receive the usual care offered to foster families such as supervision
223516307|NCT06358703|DRUG|Caplacizumab|Early Caplacizumab use
223516308|NCT02739880|DEVICE|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
223516309|NCT04467853|BIOLOGICAL|LCAR-C18S cells|Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen
223516310|NCT05756556|COMBINATION_PRODUCT|T3011 + Cobimetinib|1e8 plaque-forming units (PFU)/mL (up to 10 mL, every 2 weeks \[Q2W\], 28 days/cycle) T3011 will be administered in combination with 60 mg Cobimetinib (once daily \[QD\] for the first 21 days of each 28-day cycle)
223516311|NCT03241420|DEVICE|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
223516312|NCT06268678|OTHER|Phase of the menstrual cycle|Follicular or luteal phase
223516313|NCT01162785|DRUG|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
223516314|NCT01433861|PROCEDURE|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
223516315|NCT05392751|DRUG|EA-2353|EA-2353 Ophthalmic Suspension
223516316|NCT05930444|DIAGNOSTIC_TEST|Multimodal Machine Learning Program for Auxiliary Diagnosis of Eye Diseases|Patients presenting with eye-related chief complaints initially complete a mobile phone application. This application utilizes patient medical history and relevant images (such as selfies and photos from eye examinations) to provide intelligent diagnosis. The diagnosis remains undisclosed to the patients. Subsequently, patients seek medical attention and undergo clinical examination by a skilled clinician. The clinical diagnosis is subsequently reviewed by a second experienced clinician. If the diagnoses align, it is considered the gold standard. In cases of discrepancy, the consensus reached by the two clinicians becomes the gold standard.
223516317|NCT06563076|OTHER|Vestibular Rehabilitation|supervised vestibular rehabilitation program
223516318|NCT06563076|OTHER|Vestibular Electrical Stimulation|80 Hz high frequency transcutaneous vestibular electrical stimulation (VES)
223516319|NCT02844075|DRUG|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
223516320|NCT06144853|OTHER|scan|Fluorodeoxyglucose (FDG)-positron emission tomography/Computed tomography scan
223516321|NCT06132308|PROCEDURE|PENG Block with 0.25% bupivacaine|Peng block was performed.
223516322|NCT05958225|BEHAVIORAL|SEE Change Business and Personal Agency Training|"A three day residential training based on SEE Change's Empowered Entrepreneur Training curriculum. This training will be led by a certified SEE Change trained facilitator. The workshop will include individual and group exercises that allow participants to increase their self-awareness, build mental tools for resiliency and adaptability in their life, create life visions and key tools to create behavior change. Additional exercises will include specific business related content including record keeping, financial planning and marketing strategies based on the Business Model Canvas tool.~After the 3 day training, the participants will receive a supportive message through an interactive voice recording, once a week for 6 weeks. In addition, they will be contacted once a month, for three months (either by phone or in person) by the trainer to see how they are doing on their goals."
223516323|NCT05544396|OTHER|probiotic|probiotic group give probiotics (2 packs per day) for 6 months.
223892710|NCT03339817|DIAGNOSTIC_TEST|Polysomnography|During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
223892711|NCT05864105|BIOLOGICAL|PM8002|PM8002 20mg/kg Q2W
223892712|NCT05864105|DRUG|FOLFOX regimen|day 1: oxaliplatin \[85 mg/m2, 2-h infusion\] plus leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]; day 2: leucovorin \[200 mg/m2, 2-h infusion\], followed by 5-fluorouracil \[400 mg/m2, intravenous bolus; 600 mg/m2, 22-h infusion\]
223892713|NCT03033576|BIOLOGICAL|Ipilimumab|Given IV
223892714|NCT03033576|BIOLOGICAL|Nivolumab|Given IV
223892715|NCT05179837|DEVICE|Optical coherence tomography probe|The OCT probe is attached to an approximately 3-meter wire that is attached to the OCT fiber probe system setup. This setup consists of a power supply unit, and a control platform that controls fiber probe rotation and retraction. The OCT probe will be advanced through the colonoscope instrument channel
223892716|NCT06237062|OTHER|erenumab|This is an observational study, there is no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients will be directed through a link to the full survey.
223892717|NCT04529031|BEHAVIORAL|Reminder Focused Positive Psychiatry|The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices
223892718|NCT04529031|BEHAVIORAL|attentional control condition (group process)|This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
223892719|NCT06266260|DEVICE|EUS PPG measurement|Direct EUS PPG measurement
223892720|NCT06453083|DRUG|Placebo|Placebo tablets will be dispensed to the participants for 6-days.
223892721|NCT06453083|DRUG|Medrol|Medrol tablets will be dispensed to the participants for 6-days.
223892722|NCT05056129|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
223892723|NCT05056129|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
223892724|NCT06128200|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
223892725|NCT06128200|DEVICE|Sham NEUROMARK System|Sham ablation procedure using the NEUROMARK System
223892726|NCT06255236|DEVICE|Bispectral index (BIS)|"* All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped."
223892727|NCT05410509|PROCEDURE|Trans-arterial embolization (TAE)|Trans-arterial embolization (TAE) is a minimally-invasive procedure in which the tumor-feeding arteries are catheterized under x-ray guidance and therapeutically occluded. TAE of the kidney is routinely performed in clinical practice for traumatic or iatrogenic injury or to de-vascularize tumors such as angiomyolipomas, oncocytomas, and RCC. The procedure has a long clinical history of success with a very low major complication rate. TAE of RCC with or without percutaneous cryoablation (PA) has been described in retrospective case series as a mechanism to destroy the tumor, reduce bleeding complications from PA, or improve symptoms of RCC such as pain or hematuria. However, these findings have yet to be confirmed in a rigorous, prospective fashion.
223892728|NCT05901051|DRUG|vonoprazan|Potassium competitive acid blocker
223892729|NCT05901051|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
223892730|NCT06576622|OTHER|biological sampling|"As part of the health check-up oral, Will be taken:~* Salivary samples by sputum.~* Samples of subgingival plaque in the periodontal sulcus~* A collection of the history and disease risk factors will then be carried out.~* periodontal problems by a routine care interview, the clinical examination and radiological examination."
223939831|NCT02629120|DRUG|Busulfan|Transplant Conditioning Drug: Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under an IND.
223939832|NCT02629120|DRUG|Sirolimus|Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
224081299|NCT03308864|BEHAVIORAL|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
224081300|NCT04000802|BEHAVIORAL|response to questionnary|No intervention. Observational study
224081301|NCT03653598|OTHER|Atrial Fibrillation|Data collection on Atrial Fibrillation
224081302|NCT04267211|OTHER|Illustrated handout at prenatal consult|Illustrated consult group will be given an illustration paper describing the majority of the issues discussed at the prenatal consult
224081303|NCT04267211|OTHER|Standard Prenatal Consult|Standard prenatal consult
224081304|NCT04434352|DEVICE|Storz Duolith Low-Intensity Shockwave Therapy|"A: Sham - the sham uses an attachment on the hand held probe that mimics the shockwave device, however it does not deliver any shockwaves. Sham will be delivered twice weekly for 3 weeks in the same manner as the LiSWT. The sham treatment will take about 20 minutes to complete.~B: LiSWT delivered twice weekly for 3 weeks, comprising of 3000 shockwaves delivered to the distal penis (1000 shockwaves), base of penis (1000 shockwaves), and corporal bodies on the perineum (500 shockwaves to each crura). LiSWT is delivered into the penile tissue by a small hand held probe that produces low intensity shockwaves. A tranducer head is placed on the left and right sides of the penis. Treatment takes about 20 minutes to complete."
224081305|NCT00760981|DRUG|Imatinib|The single cohort for this study will receive 2 dose levels of imatinib, 200 mg orally daily followed by 400 mg orally daily.
224081306|NCT01225562|DRUG|Ticagrelor 90 mg|Oral dose twice a day
224081307|NCT01225562|DRUG|Ticagrelor 60 mg|Oral dose twice a day
224081308|NCT01225562|DRUG|Ticagrelor Placebo|Oral dose twice a day
223892731|NCT06491433|DEVICE|H2-BP|"The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study."
223892732|NCT05195151|DIETARY_SUPPLEMENT|Taking capsule containing probiotics or placebo|The probiotics capsule containing two strains of probiotics.
223892733|NCT06576817|OTHER|High intensity circuit exercise class - Lower and upper extremity|Exercises performed at high intensity effort in the circuit (8 total) will focus on both the lower extremity (4) and upper extremity (4)
223892734|NCT06576817|OTHER|High intensity circuit exercise class - Lower extremity alone|All exercises performed at high intensity effort in the circuit (8 total) will focus on the lower extremity alone
224081309|NCT04336098|DRUG|SRF617|SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
223892735|NCT06033001|DRUG|[Lu-177]-PNT2002|\[Lu-177\]-PNT2002, is a radiopharmaceutical investigational drug. \[Lu-177\]-PNT2002 targets a specific protein that is located on the surface of prostate cancer cells called PSMA. \[Lu-177\]-PNT2002 delivers radiation to your cancer by binding to the PSMA which helps destroy the cancer cells. \[Lu-177\]-PNT2002 is administered intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment.
223892736|NCT05773326|DRUG|Temsirolimus|TORISEL® (temsirolimus) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
223892737|NCT05279690|DRUG|Colchicine|Patients will receive 14 days of colchicine in the absence of prohibitive toxicity of disease progression
223892738|NCT05796583|DEVICE|Active Pulsed Shortwave Treatment|Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse
223892739|NCT05796583|DEVICE|Sham Treatment|Application of 8 days of a nonfunctional sham device
224081310|NCT04336098|DRUG|Gemcitabine|Gemcitabine as an intravenous (IV) infusion
224081311|NCT04336098|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel as an IV infusion
223534813|NCT02523950|DEVICE|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
223892740|NCT06013345|DRUG|Remimazolam|analgosedation without secured airway
224081312|NCT04336098|DRUG|Pembrolizumab|Pembrolizumab as an IV infusion .
224081313|NCT00903279|DRUG|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
224081314|NCT00903279|DRUG|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
223534814|NCT03070626|DIETARY_SUPPLEMENT|PreOp®|No preoperative drink.
223892741|NCT06013345|DRUG|Propofol|analgosedation with secured airway
223892742|NCT06013345|DRUG|Propofol|TIVA with secured airway
223892743|NCT06241651|DEVICE|Conduction system pacing|Firstly, we will attempt LBBP if the patient is allocated to the experimental group. If we can not achieve LBBP successfully, then we will turn to attempt HBP.
223892744|NCT06241651|DEVICE|Biventricular pacing|Implantation of RA lead, RV lead and LV lead are attempted using the standard-of-care technique.
223892745|NCT03377361|BIOLOGICAL|Nivolumab|Specified dose on specified days
223892746|NCT03377361|DRUG|Trametinib|Specified dose on specified days
223892747|NCT03377361|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223892748|NCT03377361|DRUG|Regorafenib|Specified dose on specified days
223892749|NCT05184894|BEHAVIORAL|AKI in Care Transitions (ACT) program|Multicomponent transitional support bundle that includes consultation from nurse educators before discharge to deliver kidney health education and coordination of appointments post-discharge.
223892750|NCT05133479|BEHAVIORAL|Let's Know! small-group or TierL 2 Intervention|Let's Know! is an 22-week intervention spanning 1 school year. Each week features 4-5, 30 minute lessons targeting lower-level and higher-level language skills. There are 2 narrative and 2 expository units. Within units, instructors and children progress through specific types of lessons to meet language-focused learning objectives. Lesson types include (a) Read to Me, designed to engage children with text and promote discussion, inferential language, and comprehension monitoring, (b) Words to Know, designed to unit vocabulary, (c) Integration, to teach and practice retelling, inferencing and comprehension monitoring (d) Show Me What You Know, instructors administer CAMs to monitor children's progress and (e) Stretch and Review, to provide teachers time to review key concepts. Included in the lessons are practice opportunities for students to collaborate with peers with teacher guidance and feedback. A manual provides scope of instruction, teaching strategies, lessons and materials.
223892751|NCT06070194|BEHAVIORAL|Time restricted eating (TRE)|Subjects randomized to this arm will be asked to follow an 8h eating duration/day for 4 weeks. Participants will be asked to continue habitual sleep patterns.
223892752|NCT05980091|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
223892753|NCT05980091|DIAGNOSTIC_TEST|Serum LH, E2, P4|In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels
223892754|NCT05980091|DRUG|Estradiol Valerate 2 MG|"Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)"
223892755|NCT05980091|DRUG|Progesterone 100 Mg Vaginal Insert|The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily
223892756|NCT05980091|DIAGNOSTIC_TEST|Serum P4 day of ET|On the day of embryo transfer (ET), a blood test is taken to measure serum P4
223892757|NCT05980091|PROCEDURE|Embryo transfer|Procedure in which embryo is transferred into the uterus
223892758|NCT04263051|DRUG|UCPVax + Nivolumab|"UCPVax will be administrated at day 1 of week 1 ; 2 ; 3 ; 5 ; 6 ; 7 and then week 13 and every 2 months until months 12.~Nivolumab will be administrated at the dose of 480 mg at day 1 and then every 4 weeks until disease progression or unacceptable toxicity according to label.~At the end of COMBO phase, nivolumab will be continued every 4 weeks for maximum 24 months from the first administration, until disease progression or unacceptable toxicity according to standard of care."
223892759|NCT04263051|DRUG|standard chemotherapy|Second line chemotherapy at the choice of the investigator
223892760|NCT06551090|OTHER|CAMERA (Context-Aware Multimodal Ecological Research and Assessment)|The CAMERA platform is a multimodal, hardware-software framework for measuring brain-behavior interactions in an unstructured environment and predict ecological states. CAMERA will use multimodal, passive sensor data to predict anxiety-memory state in patients undergoing inpatient monitoring with intracranial electrodes for clinical epilepsy. CAMERA consists of: Wristband sensors of autonomic physiologic signals, emphasizing heart rate metrics and electrodermal activity; Smartphone usage, emphasizing natural language processing of text input for linguistic features; Subject-tracking audiovisual array, emphasizing subject vocal activity; Intracranial neural recordings, emphasizing hippocampal theta power and high-frequency activity (\~70-200 Hz).
223892761|NCT05119296|DRUG|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death
223892762|NCT06283758|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
223516324|NCT06315894|DEVICE|SuperCAP Program|"Distance program including tasks and exercises to improve cognitive, emotional, and functional status.~The intervention will be applied via cell phone and will have a duration of 3 months (12 weeks).~Tasks and exercises will be performed 5 days per week. Contents of the program will include daily exercises, daily games, daily videos, and weekly videos.~They will address cognitive functions, daily habits, and lifestyle factors in general.~Compliance will be monitored to control the adherence to the intervention. The program has been designed specifically for people with post-COVID syndrome."
223516325|NCT06332339|BIOLOGICAL|16055 NFL delta Gly4 trimer|200 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.27 mL each)
223892763|NCT06283758|DEVICE|Sham-control group|Participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
223892764|NCT05656794|RADIATION|Radiotherapy|Standard of care radiotherapy administered as per institutional guidelines.
224081315|NCT05436548|OTHER|Supervisor-employee frequent check-ins to identify and address work stressors|Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins
224081316|NCT05436548|OTHER|Usual practice waitlist controls|If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
224081317|NCT06381661|DRUG|Tocilizumab|8 mg per kilogram of body weight enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
224081318|NCT06381661|DRUG|Baricitinib|4mg, enterally (oral or via a gastric tube) once daily for 14 days (or hospital discharge pending which will occur first) (same for adults and children)
224081319|NCT06381661|DRUG|Anakinra|100 mg subcutaneously once daily for 10 days (or hospital discharge pending which will occur first) (same for adults and children)
224081320|NCT06381661|DRUG|Hydrocortisone|50mg (in children: 1-2 mg/kg) IV Q6 for 7 days
223516326|NCT06332339|BIOLOGICAL|Trimer 4571|100 mcg admixed with 3M-052-AF, 5 mcg and Alum, 500 mcg to be administered as 2 separate IM injections (0.2 mL each)
223892765|NCT05184335|DRUG|Brilaroxazine|RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.
223892766|NCT05184335|OTHER|Placebo|RP5063 matching Placebo
223892767|NCT06389032|BEHAVIORAL|Peer Mentor Support and Caregiver Education|12- week modular curriculum with handbook (PDF and Website version), additional resources and weekly phone discussions with Lewy Body Dementia (LBD) peer mentor/mentee.
223892768|NCT06389032|BEHAVIORAL|Caregiver Education|12-weeks of receiving weekly curated list of Lewy Body Dementia (LBD) educational resources based on the weekly topics via email.
223892769|NCT03984097|DRUG|TAK-079|TAK-079 subcutaneously.
223892770|NCT03984097|DRUG|Lenalidomide|Lenalidomide orally.
223892771|NCT03984097|DRUG|Dexamethasone|Dexamethasone orally.
223892772|NCT03984097|DRUG|Bortezomib|Bortezomib subcutaneously.
223892773|NCT03984097|DRUG|Pomalidomide|Pomalidomide orally.
223892774|NCT06190340|DRUG|TNP-2092 capsules|Administration orally.
223892775|NCT06190340|DRUG|Placebo|Administration orally.
223892776|NCT05517434|BIOLOGICAL|Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation|Participants will undergo a bone marrow aspiration. About 10 mL of BMA will be collected from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest using the Cervos Marrow Cellution™ kit. The BMA does not require processing using a centrifuge after collection. 9 mL (or less) of BMA is injected into the osteoarthritic knee joint after collection (Arm A, Study 1).
223892777|NCT05517434|OTHER|Saline (Placebo Comparator for BMA)|Participants will undergo a bone marrow aspiration to collect about 10 mL of BMA from the posterior iliac spine i.e., ipsilateral and/or contralateral iliac crest. However, 0.9% sodium chloride (NaCl) Baxter or equivalent (9 mL) is injected into the osteoarthritic knee joint (Arm C, Study 1).
223892778|NCT05517434|BIOLOGICAL|Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations|Participants will undergo a lipoaspiration. 40 mL of lipoaspirate (LA) will be collected from subcutaneous adipose tissue. LA will be processed using the Cervos LIPO-PRO™ kit and a centrifuge. Participants will also undergo a blood draw. About 30 mL of whole blood will be collected from the antecubital fossa. Whole blood will be processed using the Cervos KEYPRP kit and a centrifuge. After processing, 9 mL (or less) of LAM is injected first followed immediately by 2 mL (or less) of LP-PRP into the osteoarthritic knee joint (Arm B, Study 2).
224081321|NCT06381661|DRUG|Hydrocortisone and fludrocortisone|Hydrocortisone 50mg IV Q6 for 7 days + Fludrocortisone 50mg orally or via gastric tube once a day for 7 days.
223516327|NCT06332339|BIOLOGICAL|Ad4-Env145NFL, 5 x 108 viral particles (vp)|to be administered intranasally (IN) (0.07 mL into 1 nostril)
223892779|NCT05517434|OTHER|Saline (Placebo Comparator for LAM + LP-PRP)|Participants will undergo a lipoaspiration to collect 40 mL of LA and a blood draw to collect about 30 mL of whole blood. However, 0.9% of sodium chloride (NaCl) Baxter or equivalent is injected twice (9 mL + 2 mL) into the osteoarthritic knee joint (Arm D, Study 2).
223892780|NCT06327945|DEVICE|Lung uDCD Protocol|The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.
223892781|NCT05629286|DEVICE|McConnell taping|non-stretch rigid McConnell tape will be applied
223892782|NCT05629286|DEVICE|Patella Stabilizer Brace|An orthotic application that wraps the patellofemoral joint, which has a patellar cavity and supports the patella, and provides stabilization with velcro
223892783|NCT04775719|OTHER|Patient-Specific Prediction of Functional Outcome|Information sheet that describes whether a patient is more likely to improve on or maintain their current preoperative function.
224081322|NCT06381661|DRUG|Heparin|Therapeutic unfractionated heparin (UFH) starting at 400 (in children: 20 IU/kg/h) IU/kg/24h (target between 0.3 and 0.5 IU/ml), adapted to the therapeutic Partial Thromboplastin Time targeting values in the range of 60 to 100 seconds, with lower intensity dosing in the range of 60 to 80 seconds, for 7 days (or ICU discharge, pending which will occur first).
224081323|NCT06381661|DRUG|Low molecular weight heparin|Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in children 100 U/kg) IU/kg/24h, for 7 days (or hospital discharge pending which will occur first).
224081324|NCT06381661|DRUG|Recombinant humanThrombomodulin( rhTM)|Recombinant human thrombomodulin (rhTM) 0.06 mg/kg/j IV, for 7 days (or ICU discharge, pending which will occur first).
224081325|NCT06381661|DRUG|Sivelestat|0.2 mg/kg/h for 7 days (or ICU discharge, pending which will occur first)
224081326|NCT06381661|BIOLOGICAL|Fresh frozen plasma|12 ml/kg/day as long as INR remains \>1.4
223892784|NCT04775719|OTHER|Standard Pre-Operative Total Knee Arthroplasty Information|Standard of care information that is routinely provided at patient preadmission appointments.
223892785|NCT05583448|DEVICE|ExploR Radial Head|Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
223892786|NCT05328635|DRUG|Candesartan|Multdisciplinary approach
223892787|NCT05421416|DRUG|Loratadine|Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
223892788|NCT05421416|DRUG|Placebo|Placebo sugar pill
223892789|NCT05828810|PROCEDURE|Chlorhexidne Gluconate-Alcohol Skin Preparation|"Participants will undergo skin antisepsis with 4% chlorhexidine gluconate pre-wash, followed by 2% chlorhexidine gluconate with 70% isopropyl alcohol skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using a wet chlorhexidine surgical scrub brush followed by immediate drying using towels. The definitive preparation will then be carried out using tinted chlorhexidine gluconate-alcohol sponges applied with forceps. The drying time and the minimum number of sponge packs used will comply with the product 'Instructions for Use'. The drapes can be applied as per the surgeon's usual approach and they will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention."
223892790|NCT05828810|PROCEDURE|Poviodine-iodine Skin Preparation|"Participants will undergo skin antisepsis with 7.5% povidone-iodine detergent pre-wash, followed by 10% povidone-iodine skin preparation.~The surgical field to be sterilized will be at the discretion of the surgical team, but typically includes the distal torso to ankle for patients undergoing hip arthroplasty and proximal thigh to ankle for patients undergoing knee arthroplasty.~Pre-wash of the surgical area will be carried out using iodine detergent soaked gauze pads followed by immediate drying using towels. The definitive preparation will then be carried out using povidone-iodine soaked gauze pads applied with forceps. The drapes can be applied as per the surgical team's usual approach and they otherwise will be treated according to the institution and surgeon's routine practice for draping and surgical site infection prevention."
223892791|NCT01606215|DRUG|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
223892792|NCT01606215|DRUG|Placebo|Placebo
223892793|NCT04592549|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
223892794|NCT04592549|OTHER|Placebo|Placebo
223892795|NCT05184192|DRUG|Gabapentin gelatin capsules 300mg|Gabapentin is an anti-epileptic also used for nerve pain. This study will investigate the efficacy of gabapentin for olfactory nerve recovery and improvement in post-Covid-19 olfactory dysfunction.
223892796|NCT05184192|DRUG|Placebo|lactose monohydrate NF
223892797|NCT03797716|DEVICE|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
223892798|NCT04610710|PROCEDURE|Operation|Operation for deep infiltrating endometriosis
223892799|NCT04610710|PROCEDURE|Fertility treatment|In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
223892800|NCT05257642|OTHER|REThink Game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
223892801|NCT04322357|DRUG|Prednisone|A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
223892802|NCT04322357|BEHAVIORAL|In-home Exercise Training|For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
223892803|NCT04322357|DRUG|Prednisone plus exercise|Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
223892804|NCT03042988|OTHER|Heating pad|Heat stress applied on the trunk for up to 8 hours
223892805|NCT03042988|OTHER|Sham control|heating pad turned off applied on the trunk for up to 8 hours
223892806|NCT05565092|DRUG|ALXN1820|ALXN1820 will be administered subcutaneously.
223892807|NCT04054596|BEHAVIORAL|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
223892808|NCT04823585|DRUG|Mepolizumab|Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
223892809|NCT04823585|DRUG|Placebo|Solution. Subcutaneous.
223892810|NCT06793098|DIAGNOSTIC_TEST|Measurement of kisspeptin concentration|Measurement of kisspeptin concentration in fasting venous blood serum
223892811|NCT06793098|DIAGNOSTIC_TEST|Measurement of ghrelin concentration|Measurement of ghrelin concentration in fasting venous blood serum
223892812|NCT06793098|DIAGNOSTIC_TEST|Measurement of zonulin concentration|Measurement of zonulin concentration in fasting venous blood serum
223892813|NCT03257215|DRUG|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
223892814|NCT03257215|DRUG|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
223892815|NCT03257215|DRUG|Stoss placebo|A single 1.5 mL dose administered on Day 1
223892816|NCT03257215|DRUG|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
223892817|NCT05558813|DIAGNOSTIC_TEST|Cardiac MRI|two cardiac MRIs with Gadolinum injection at 2-year intervals
223892818|NCT05558813|BIOLOGICAL|Blood assays|blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection
224081327|NCT06381661|OTHER|Usual care|Usual care
223892819|NCT04860726|OTHER|Joint mobilization|Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes
223892820|NCT04860726|OTHER|Myofascial Release|"Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min ii. heating pad for 15 minutes"
223892821|NCT04860726|OTHER|Joint mobilization & Myofascial Release|"Maitland Mobilization GIII and GIV i. PA Central and unilateral vertebral pressure ii.Transverse vertebral pressure iii. heating pad for 15 minutes iv. Myofascial release is a hands-on soft tissue technique that facilitates a stretch into the restricted fascia. A sustained pressure is applied into the restricted tissue barrier; after 90-120 seconds the tissue will undergo histological length changes allowing the first release to be felt. The therapist will follow the release into a new tissue barrier and holds. After a few releases the tissue will become softer and more pliable.~The middle point of the Lateral raphae of the Thoracolumbarfascia between the posterior musculofascial junction of the Transversus Abdominis will be identified by ultrasonography. Vertical manual pressure will be applied on the middle point of the thoracolumbarfascia for 1 min"
223892822|NCT06373224|OTHER|Flush|After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
223892823|NCT04184635|DEVICE|VA-ECMO|"* The ECMO device will be the CardioHelp (MAQUET, GETINGE, Orléans, France) using the veno-arterial setting and percutaneous femoro-femoral cannulation with MAQUET GETINGE HLS cannulae.~* Intraortic balloon pump will be MEGA 50 cc or 40cc, (MAQUET, GETINGE, Orléans, France)."
223892824|NCT06822777|BEHAVIORAL|RISE for Nurse Preceptors Program|Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
223892825|NCT03703492|DRUG|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
223892826|NCT03703492|DRUG|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
223892827|NCT06292975|OTHER|Supervised Vigorous intensity aerobic interval exercise|7-weeks course of aerobic and resistance exercise, delivered 2 weeks before neoadjuvant radiotherapy (NART), 1 week of NART and 4 weeks post NART.
223892828|NCT02348749|RADIATION|18F-MFBG (meta-fluoro benzylguanidine)|About 8mCi of 18F-MFBG will be administered to adult patients. Pediatric dose will be based upon adjustment using BSA to the dose of 8 mCi for 1.7m2 BSA ± 10% with maximum activity of 8 mCi. The tracer will be given intravenously.
223892829|NCT02348749|DEVICE|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (\~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (\~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
223892830|NCT02348749|OTHER|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
223892831|NCT06781970|DRUG|Oral Vitamin C|Patients will be given 500 mg of oral vitamin C, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
223892832|NCT06781970|DRUG|Placebo|Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
223892833|NCT06069843|DRUG|IV Ketamine|0.5 mg/kg IV Ketamine
223892834|NCT05794022|OTHER|MRI|1 MRI at 1 month with gadolinium injection
223892835|NCT05794022|BIOLOGICAL|Biocollection|Biocollection from blood (H0, H4, H24, H48, 1 month, 1 year), urine (H48) and faecal (initial hospitalisation) samples.
223892836|NCT05794022|BEHAVIORAL|Quality of life questionaries|EQ-5D-5L and HAD questionaries at 1 month and 1 year.
223939833|NCT02629120|DRUG|Cyclophosphamide|Post transplant cyclophosphamide given to prevent graft verses host disease. This is a well studied drug, and is not under an IND.
223939834|NCT02629120|RADIATION|Total Body Irradiation|Transplant Conditioning Total Body Radiation (300cGy in 2 fractionated doses), given only to patient receiving matched unrelated donor cells, to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow.
223939835|NCT02629120|BIOLOGICAL|Peripheral blood stem cells|Donor Peripheral blood stem cells, either matched unrelated donor or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
224081328|NCT00603135|DRUG|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
224081329|NCT04408807|OTHER|Speculum-free (SpF) fundoscopy|Indirect ophthalmoscopy without the use of eyelid speculum and scleral indentation
224081330|NCT04408807|OTHER|Speculum (Sp) fundoscopy|Indirect ophthalmoscopy with the use of eyelid speculum and scleral indentation
224081331|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
224081332|NCT01463813|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
224081333|NCT01463813|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
224081334|NCT02111733|OTHER|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
224081335|NCT06148961|PROCEDURE|botox prior to modified lip repostioning|"botox injection prior to surgical intervention by 5 to 10 days A surgical marker was used to outline the boundaries of the surgical incision region.~the height of the superior incision was measured as 15 mm within the vestibule. Superior and inferior incisions were made with a scalpel blade number 15 and linked bilaterally by two vertical incisions.~A partial thickness dissection was used to remove the strip of the indicated mucosa, exposing the fascia of the connective tissue beneath. When necessary, all salivary glands and frenal attachments were removed. The surgical site was then properly closed using a periosteal simple interrupted suture was put in place prior to the continuous interlocking sutures. It was placed by commencing the needle 2 mm coronal to Per surgery site, 3 to 4 periosteal sutures were typically The new mucosal boundary to the gingiva was stabilized in its new place using this suture"
224081336|NCT01692808|DRUG|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
224081337|NCT01692808|DRUG|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
224081338|NCT03543085|DEVICE|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (\>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
223892837|NCT05988515|BEHAVIORAL|Speech-Language Pathologist-led Speech Motor Chaining|Sessions begin with Pre-practice to elicit the /r/ sound. During Structured Practice, the same utterance is practiced several times in a row (with systematic increases in difficulty based on performance). Our web-based software manipulates the principles of motor learning, including feedback prompts for the clinician, the complexity of the utterance, and the variability in the practice trial; the software will analyze the clinician's rating to increase the difficulty of practice when the child is more accurate. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order. A trained speech-language pathologist is involved in all practice trials to provide feedback throughout the session.
223516328|NCT03995511|PROCEDURE|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
223516329|NCT06566703|BEHAVIORAL|All Nations Snuff Out Smokeless|All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.
223516330|NCT06566703|BEHAVIORAL|Healthy Living|Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.
223516331|NCT06517927|DIAGNOSTIC_TEST|Clinical and radiographic dental examination|complete clinical oral examination + intra-oral and panoramic x-rays
223892838|NCT05988515|BEHAVIORAL|Artificial Intelligence-led Speech Motor Chaining (CHAINING-AI)|Sessions include Structured Practice and Randomized Practice using our web-based software with an Artificial Intelligence clinician to address the /r/ sound. Within a practice session, participants speak into a microphone, and the audio file is sent to a server to be analyzed by a classifier, which returns a binary accurate/inaccurate rating of productions in a fashion similar to SLP judgment. Our web-based software manipulates the principles of motor learning, including feedback prompts, the complexity of the utterance, and the variability in the practice trial. The software will analyze the child's accuracy as determined by the classifier to increase the difficulty of practice when the child is more accurate.
223892839|NCT05544864|DEVICE|Drug eluting stent (DES)|DES-implantation with an everolimus-eluting stent (Xience, Abbott Vascular)
223892840|NCT05544864|DEVICE|Drug coated ballloon (DCB)|DCB angioplasty with any commercially available drug-coated balloon
223892841|NCT05003258|DEVICE|Intravitreal injection of Dexamethasone implant|Intravitreal injection of Dexamethasone implant
224081339|NCT04617366|OTHER|Individualized rTMS strategy|It will adjust the rTMS parameters based on the results of fNIRS.
224081340|NCT04617366|OTHER|Traditional rTMS strategy|The patients will always be given low-frequency rTMS to contralesional M1.
224081341|NCT00165958|PROCEDURE|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
224081342|NCT00165958|PROCEDURE|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
224081343|NCT04428606|DIETARY_SUPPLEMENT|Metabolic Rheostat|Metabolic Rheostat™ Ingredients: Ginseng extract, Ginseng root extract, berberine chloride, Livaux (gold kiwi powder), MegaSporeBiotic, and MenaquinGold (vitamin K2-7) powder
224081344|NCT04428606|DIETARY_SUPPLEMENT|Butyrate Ultra|An anerobic probiotic supplement that contains butyrate-producing Butyricicoccus pullicaecorum 25-3T, vitamin K2, and fenugreek to maintain healthy glucose balance.
224081345|NCT04428606|DIETARY_SUPPLEMENT|Placebo|Placebo
224287237|NCT06590376|OTHER|midwifery care based on swanson care theory|All stages in the Midwifery Care and Counselling Practitioner Guide for Couples Experiencing Pregnancy Loss, which was developed by the researcher and included care, education and midwife counselling consisting of eight interviews, four of which were face-to-face and four by telephone, were applied.
224287238|NCT03418792|OTHER|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head \& neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
224287239|NCT02194569|DRUG|Citrate|
224287240|NCT00759434|PROCEDURE|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
223516332|NCT05787483|BEHAVIORAL|MindUP group|MindUP is a Collaborative for Academic, Social, and Emotional Learning SELect (CASEL) program, meaning the program is evidence-based and meets the adequate criteria for developing students' social and emotional competence at the highest level. MindUP addresses all five components of the CASEL SEL Framework: self-awareness, social awareness, self-management, responsible decision-making, and relationship skills (CASEL, 2020). Students are taught how the workings of the brain are related to emotions, behaviors, decision making, and learning. MindUP is the first program to provide clear instruction in both SEL and mindfulness.
223892842|NCT04709783|OTHER|3-Step Workout for Life|Participants will receive the modified 3-step Workout for Life program given by their physical therapy or occupational therapy providers. The program includes single-joint and multiple joint progressive resistance exercise and activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and/or lower extremity. During the activities of daily living exercise, participants will practice activities of daily living that they experience difficulty. The intervention volume, duration, and frequency will be modified to enhance practicality in a home health care setting over the implementation phase. In addition to the 3-Step Workout for Life exercise, participants may also receive other routine rehabilitation treatment determined and provided by their therapists to facilitate their functional recovery.
223516333|NCT05787483|BEHAVIORAL|active control group|business as usual; regular wellness or SEL classes
223892843|NCT03682250|DEVICE|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
223892844|NCT03682250|DEVICE|Holter monitor|A Holter monitor will be used to measure heart's activity
223892845|NCT03763604|DRUG|Abemaciclib|Administered orally.
223892846|NCT05935527|DRUG|POLAT-001|Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
223892847|NCT05935527|DRUG|Placebo|Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
223892848|NCT05999565|OTHER|Motor Imagery Exercises|"Lateralization Training: Individuals with cervical discogenic pain will receive lateralization training using a mobile application called Recognize Neck from the Neuro Orthopaedic Institute in Adelaide, Australia.~Kinesthetic Imagery: During this training, individuals will be asked to actively perform exercises and feel the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to imagine the positions of their bodies, the surface they are on, and the desired postures.~Visual Imagery: Individuals will be asked to actively perform exercises and visualize the movements. In a quiet environment, a therapist will verbally describe the exercises, and individuals will be asked to mentally visualize their body positions, the surface they are on, and the exercises.~Mirror-Image Active Exercise: Between weeks 6 and 8 of motor imagery training, the active exercises in front of a mirror."
223892849|NCT05999565|OTHER|Motor Control Exercises|"Stretching Exercises: Stretching exercises will be applied to the cervical muscles, pectoral muscles, back, and shoulder muscles. Individuals will be asked to perform flexion, extension, lateral flexion, and rotational normal joint movements in the cervical region, and hold the end position for a few seconds. All stretching exercises will be performed for 15 repetitions.~Active Exercises: To strengthen the cervical muscle groups, individuals will be taught how to use a mild to moderate resistance theraband for cervical flexion, extension, and lateral flexion, without compromising the chin tuck movement. Each movement will be performed for 10 repetitions, with 5-second rest intervals between exercises.~Endurance Exercises: Before starting the endurance exercises, individuals will be taught the contraction of deep cervical flexors to gain automatic postural stabilization, and they will be instructed to maintain this movement in every exercise and activity."
223892850|NCT06802341|OTHER|Normal protein diet|Animal-based protein meal plan consisted of 60% carbohydrates, 10% proteins and 30% lipids
223892851|NCT06802341|OTHER|Animal protein diet|Animal based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids
223892852|NCT06802341|OTHER|Plant based diet|Plant based high protein meal consisting of 40% carbohydrates, 30% proteins and 30% lipids
223892853|NCT06451848|DRUG|Genakumab Injection (T, Solution for injection)|A single dose of subcutaneous injection of Genakumab（Solution for injection, liquid formulation）200 mg on Day 1
223892854|NCT06451848|DRUG|Genakumab for Injection (R, Powder for solution for injection)|A single dose of subcutaneous injection of Genakumab（Powder for solution for injection, lyophilized formulation) 200 mg on Day 1
223892855|NCT06802250|BEHAVIORAL|RINEW intervention|The intervention included behavioral recommendations and guidance on the topics of Nutrition, WASH, Lead exposure prevention, Mental Health, and child stimulation. The intervention also included the provision of nutritional supplements based on age and nutritional status, low-cost picture books and toys, and soapy water bottles.
223892856|NCT06227182|DIAGNOSTIC_TEST|Muscle ultrasound with surface electromyography and dynamometry|The three procedures are conducted simultaneously for upper and lower extremity muscles. A standard muscle ultrasound preset with a fixed depth of 4 cm or 6 cm will be used, depending on which muscle is visualized in accordance with our routine clinical protocols. During the dynamic approach, the transducer will be placed in a longitudinal fixed position on the muscle using a ProbeFix. All measured contractions in the different muscles will be recorded as short ultrasound videos.
223892857|NCT06227182|DIAGNOSTIC_TEST|MRI scan|In Stage II, all patients and 10 healthy participants will undergo MRI. During the MRI procedure, we evaluate muscle fat fraction, muscle contractile volume, muscle inflammation and edema.
223892858|NCT06519968|DRUG|AZD4604|AZD4604 will be administered as Dry Powder Inhalation (DPI).
223892859|NCT06519968|DRUG|Placebo|Placebo will be administered as DPI.
223516334|NCT06530303|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
223516335|NCT06530303|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223516336|NCT06530303|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
224081346|NCT04323930|DEVICE|eyeWatch|The eyeWatch system will be implanted as per the manufacturer's instruction, and trabeculectomy will be performed using mitomycin C as per standard surgical protocols.
223892860|NCT06304298|DRUG|0.9% Sodium Chloride Injection|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride
223516337|NCT06530303|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
223516338|NCT06530303|DRUG|Pembrolizumab|Intravenous (IV) infusion
224081347|NCT00145990|DRUG|methacholine|
224081348|NCT00145990|DEVICE|KoKo Digidoser|
224081349|NCT00145990|DEVICE|Rosethal Dosimeter|
224081350|NCT05772897|BEHAVIORAL|Circle of Security Parenting program|The Circle of Security Parenting (COSP) program is an 8- week group parenting course that was designed using decades of attachment research to foster a secure attachment by teaching parents to read and respond to infant cues, and to recognize the interplay between their own psychological and emotional experiences and the emotional regulation of their infants. The COSP program provides parents with relationship tools and techniques for understanding their children's needs in new ways that provide lasting security for the child and more satisfaction for the parent. There are two major themes in the program: 1) teaching parents how to read their children's behavior and use it as a guide for meeting their needs and 2) helping parents to understand how their own early attachment relationships have influenced them as a person, and how those influences show up in their parenting and impact their ability to help regulate their child and respond to their needs.
224081351|NCT01682850|BEHAVIORAL|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
224081352|NCT01682850|OTHER|Usual Care|
224081353|NCT01645267|PROCEDURE|Hydroxyapatite|Use of artifical bonegraft material
224081354|NCT02500004|RADIATION|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
224081355|NCT02500004|RADIATION|DXA scanning|Body composition: DXA scanning, D2O and MRI.
224081356|NCT02500004|PROCEDURE|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
224081357|NCT02500004|PROCEDURE|Blood sampling|Systemic inflammatory profile: blood sampling.
223516339|NCT00141193|DRUG|Celecoxib|
223516340|NCT02617212|PROCEDURE|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
223516341|NCT02617212|DEVICE|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
223892861|NCT06304298|DRUG|Ropivacaine 0.2% Injectable Solution|After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacine
224081358|NCT02500004|OTHER|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
224081359|NCT02500004|DEVICE|Accelerometry|Physical activity level: accelerometry.
224081360|NCT02500004|OTHER|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
224081361|NCT03790592|DEVICE|trifocal IOL|intraocular lens
223892862|NCT05982938|DRUG|Danicopan|Participants will receive 150 mg danicopan three times per day (TID) orally as an add-on to a background C5i therapy (SOLIRIS® or ULTOMIRIS®). Participants may be dose-escalated to 200 mg TID based on safety and clinical effect.
224081362|NCT03504202|DRUG|Trimetazidine|After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .
224081363|NCT04478825|DRUG|BBT-401-1S|BBT-401-1S, 8 weeks, once a day
224081364|NCT06446557|DRUG|treatment adaptation guided by ctDNA variation|"after 4 cycles of doublet + TA, non-progressive patients will be allocated to a strategy according to ctDNA value and variation from C1-C3: Arm A1: CT discontinuation (ctDNA normalization \< 0.1 ng/ml or ctDNA not detectable) Arm A2 : maintenance with fluoropyrimidine + TA (ctDNA ≥ 0.1 ng/ml and ∆ctDNA≥ 80%).~Arm A3 : ctDNA non-responders (∆ctDNA \< 80% or increase) : switch of CT +/- TA."
224081365|NCT06446557|DRUG|standard management|At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
224081366|NCT01162421|BIOLOGICAL|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
224081367|NCT01162421|DRUG|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
224081368|NCT02525289|OTHER|Bed Rotation Group|Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.
224287241|NCT00759434|PROCEDURE|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
224081369|NCT02525289|OTHER|Orthostatic Group|Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.
224081370|NCT03611699|DRUG|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
224081371|NCT03611699|DRUG|Placebo|Placebo inhaler
224081372|NCT04568564|OTHER|Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation|The exercise program includes breathing exercises (chest-abdominal-lateral basal breathing; 10 repetitions), use of intensive spirometry (20 repetitions) and assisted coughing. Apart from this, a progressive mobilization program will be applied considering patient tolerance and hemodynamic parameters, starting after the patient is taken to the service room. The teleconference exercise call will be continued from the postop 1st day until discharge, twice a day.
224081373|NCT04568564|OTHER|Exercise booklet|Patients will be interviewed by videoconferencing method at least 1 day before the operation, their first evaluation will be taken and an exercise booklet will be given.
224081374|NCT03603769|DIETARY_SUPPLEMENT|Food supplement capsules containing Salmon-Polar Lipids|Postprandial decreased Platelet activation/aggregation in subjects, after the food supplement capsule consumption
224081375|NCT03603769|DIETARY_SUPPLEMENT|Placebo food supplement capsule|Postprandial unaffected platelet activation/aggregation in subjects, after the food supplement capsule consumption
224081376|NCT05495295|DRUG|PhOx430|"A standard 3 + 3 design will be followed. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.~A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval."
224081377|NCT05495295|DRUG|PhOx430|The implementation of this cohort (Step 3) was decided by the Protocol Steering Committee (PSC) based on clinical and pharmacokinetic data obtained in Steps 1 and 2. Six patients will be enrolled, who will receive PhOx430 orally thrice a day (tid) at a -6-hour interval over 12 hours for 21 days, and then, starting from day 22, four times a day (qid) at a 4-hour interval over 12 hours, continuously in cycles of 21 days. PhOx430 will be taken in single doses of 1,200 mg to patients weighing ≥ 50 kg and of 600 mg to patients weighing \< 50 kg, with no requirement for a full or empty stomach. The first patient will be observed after treatment start for at least 21 days before enrolling the following two. After the third patient is observed for 21 days after treatment start, 3 additional patients will be enrolled without waiting time between them. If the daily dose tested with the tid schedule is not deemed safe, the flat dose will be tested twice a day (bid) at a 12-hour interval.
224081378|NCT03746561|DIAGNOSTIC_TEST|deep learning|detect and classify spinal stenosis by deep learning
224081379|NCT00000927|DRUG|BufferGel|
224081380|NCT05512871|BEHAVIORAL|Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)|The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.
224081381|NCT03538769|OTHER|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
224081382|NCT04301427|OTHER|Bone mineral density|Bone mineral density will be measured twice in all included patients.
224081383|NCT03514927|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
224081384|NCT03514927|DEVICE|High-Intensity Focused Ultrasound|Under go HIFU
224081385|NCT03514927|OTHER|Laboratory Biomarker Analysis|Correlative studies
223516342|NCT02617212|DEVICE|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
223516343|NCT01908387|DRUG|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
224081386|NCT03514927|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
224081387|NCT03514927|PROCEDURE|Radical Prostatectomy|Undergo prostatectomy
224081388|NCT01133340|RADIATION|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
224081389|NCT01054079|OTHER|laboratory biomarker analysis|Correlative study
224081390|NCT01054079|PROCEDURE|quality-of-life assessment|Ancillary study
224081391|NCT01054079|OTHER|questionnaire administration|Ancillary study
224081392|NCT01054079|DRUG|cinacalcet hydrochloride|Given PO
224081393|NCT03522129|DRUG|CT1812|Active Study Drug
224081394|NCT03522129|DRUG|Placebo|Non-active study drug
224081395|NCT03683602|OTHER|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
224099175|NCT06225050|DEVICE|CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)|PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
224081396|NCT03683602|OTHER|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn't used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
224081397|NCT01107444|DRUG|Docetaxel|Administered intravenously
224081398|NCT01107444|DRUG|LY2181308|Administered intravenously
224081399|NCT03567902|DEVICE|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
224081400|NCT03567902|DEVICE|Direct laryngoscope intubation|Direct laryngoscope intubation
224081401|NCT03761329|PROCEDURE|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
224081402|NCT03761329|PROCEDURE|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
224081403|NCT04908839|OTHER|spot-25 questionnaire|spot-25 questionnaire
224081404|NCT05989906|BEHAVIORAL|Sprint Interval Training (SIT)|Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
224081405|NCT05989906|BEHAVIORAL|Usual Care|Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
224081406|NCT05989906|BEHAVIORAL|Home Ergometer (ERGO)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
224081407|NCT05989906|BEHAVIORAL|Motivational Interviewing (MI)|Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
224081408|NCT00956254|DRUG|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
224081409|NCT00836212|DRUG|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
224081410|NCT00836212|DRUG|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (\>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
224081411|NCT00091832|BIOLOGICAL|Denosumab|Denosumab administered by subcutaneous injection
224081412|NCT00091832|DRUG|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
224081413|NCT04823351|BEHAVIORAL|Surgical Mask|The randomized wards will be wearing either FFP2 masks or surgical masks for 8 weeks. Then a cross-over will occur for another 8 weeks.
224081414|NCT03396380|DRUG|Vitamin D with calcium and clomiphene citrate|"1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days ."
224081415|NCT03396380|DRUG|Placebo Oral Tablet with calcium and clomiphene citrate|"1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days"
224081416|NCT00464178|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
224081417|NCT03400722|DRUG|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
223516344|NCT00742742|BEHAVIORAL|healthy life style education|healthy life style education
224099176|NCT06475807|DIETARY_SUPPLEMENT|High-fermented food|Step 1: patients will consume high-fermented food
224081418|NCT03400722|DRUG|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
223516345|NCT06147869|DEVICE|phonophoresis|Phonophoresis is a method of driving topically applied substances across tissues using ultrasound (US) to enhance percutaneous absorption of selected drugs such as corticosteroids, local anaesthetics, and salicylates
223892863|NCT06312696|OTHER|SMT|"SMT will be provided by a licensed chiropractor with at least 5 years' experience.~Treatment will last 15 to 20 minutes each and include a brief history and examination of the cervical spine. SMT will consist of low velocity, variable amplitude spinal mobilization to the cervical spine - Maitland grades 3 or 4. Spinal segments will be determined by the chiropractor using manual palpation and the patients' response to care. Drop-table or instrument-assisted SMT will not be allowed."
223892864|NCT06312696|OTHER|Light Massage|Light Massage will be provided as a pseudo-sham intervention to control for time, attention, and touch by a licensed chiropractor with at least 5 years' experience to control for touch and is intended to be delivered gentler and shorter than recommended for therapeutic massage.
223892865|NCT06282016|OTHER|Case-control study (no intervention)|Observation of risk factors in cases and controls
223892866|NCT04731688|BEHAVIORAL|Weight Maintenance Group|The behavioral program is rooted in social learning theory and based on our existing prenatal intervention but with full food provision to ensure gestational fat mass loss is steady and closely supervised. Brief counseling sessions are designed to review self-monitoring records, reinforce adherence to the structured food provision program, problem-solve barriers, and provide additional support. Individuals will be provided with a structured meal plan designed to promote 25% calorie restriction during the second trimester followed by eucaloric intake during the 3rd trimester. Participants will be provided three meals and two snacks on 7 days at no cost.
223892867|NCT06605937|OTHER|Eustachian milking maneuver with routine postoperative treatment protocol|Eustachian milking maneuver will be applied by the patients parents 3 times a day for 7 days in the post-operative period.
223892868|NCT06605937|OTHER|Routine postoperative treatment protocol|The children adenoidectomy and/or adenotonsillectomy whose parents will not apply eustachian healing maneuvers in the post-operative period.
223892869|NCT06931236|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) can noninvasively modulate cortical activity by delivering a sequence of magnetic pulses.
224081419|NCT05707780|PROCEDURE|Resin-matrix|posterior crowns
224081420|NCT05707780|PROCEDURE|Monolithic zirconia|posterior crowns
223892870|NCT06931236|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham tDCS was delivered using the same protocol and current intensity, but it is carried out as the coil is turned away from the skull at 90°.
223892871|NCT06931249|BEHAVIORAL|The observational study|This study is being conducted to create a Turkish version of the English version of the PAED scale, which did not exist before, and to determine its cultural suitability.
223892872|NCT06933004|DEVICE|Posterior Spinal Fixation System|Using spine implants SmartMIS Spinal Fixation System or ASA Spinal Fixation System.
223892873|NCT02727699|DRUG|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
223892874|NCT02727699|DRUG|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
223892875|NCT04101903|DIAGNOSTIC_TEST|The 6-week Hip Checklist|Comprehensive 9-item structured guide to aid in correct diagnosis of developmental dysplasia of the hip.
223892876|NCT05834608|BEHAVIORAL|Mechanical ventilator-assisted ventilation|After the intravenous anesthesia induction, mechanical ventilator-assisted ventilation with AutoFlow mode of the anesthesia machine (Draeger-Perseus) will be applied before intubation.
223892877|NCT06204913|OTHER|Menu label|Participants will select food items from two restaurant menus, displayed with labels as specified by their assigned group
223892878|NCT04648033|DRUG|Atovaquone Oral Suspension|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
223892879|NCT04648033|DRUG|Standard of care chemotherapy|Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
223892880|NCT04648033|RADIATION|Standard of care radiotherapy|Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
224081421|NCT05707780|PROCEDURE|Metal-ceramic|posterior crowns
224081422|NCT02052557|DRUG|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
224081423|NCT02052557|DRUG|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
224081424|NCT02934438|DIETARY_SUPPLEMENT|Neo40|
224081425|NCT02934438|DIETARY_SUPPLEMENT|Placebo|
224081426|NCT04497025|OTHER|Immersive Virtual-based vestibular rehabilitation|Vestibular rehabilitation based on virtual environment using a head mounted display
224081427|NCT04497025|OTHER|Conventional vestibular rehabilitation protocol|"Cawthorne-Cooksey vestibular rehabilitation exercises."
224081428|NCT03899454|DRUG|Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract|Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
224081429|NCT03899454|DRUG|Placebo Control|Placebo Control
224081430|NCT01557166|DRUG|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
224081431|NCT01557166|DRUG|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
224081432|NCT00946309|DRUG|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
224081433|NCT00946309|DRUG|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
224081434|NCT04724473|DRUG|Tretinoin Cream 0.025%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
224081435|NCT00874250|DEVICE|GORE CTAG Device|Endovascular aortic stent-graft
224081436|NCT01465659|DRUG|temozolomide|Given PO
224081437|NCT01465659|DRUG|pazopanib hydrochloride|Given PO
224081438|NCT00620243|PROCEDURE|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
224081439|NCT02989792|GENETIC|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
224081440|NCT02989792|OTHER|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
224081441|NCT00374244|DRUG|Pimozide|half of the subjects are randomized to the active drug group
224081442|NCT00374244|DRUG|placebo|half of the subjects are randomized to placebo group
224081443|NCT05688787|PROCEDURE|Perineural Injection|".injections are done with a 27 gauge half 1/2 needle directed perpendicular to the skin and going~1/ to the skin surface delivering 1\_2 cc of buffered 5% dextrose solution in the subcutaneous superficial perineural tissue we will be targeting the most triggering points for each patient emphasizing on pain located in thoraco-dorsal fascia, the fascia of the erectorspinae muscles along T10 to L2 dorsal rami, interspinoustenderness from medial branches of dorsal rami, superiorcluneal nerve at 7-8 cm from middle line cross the iliac crest\&amp; T10 cross over iliac crest at a distance 8-10cm"
224081444|NCT01698528|DEVICE|Tablet Computer|
224081445|NCT02445586|DRUG|Docetaxel|Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
224081446|NCT02445586|DRUG|Pertuzumab|Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
224081447|NCT02445586|DRUG|Trastuzumab|Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
224081448|NCT03793387|PROCEDURE|AF-guided endobronchial marking|Bronchoscopic dye marking under CBCT-augmented fluoroscopic guidance
224081449|NCT03793387|DEVICE|ENB-guided endobronchial marking|Bronchoscopic dye marking with ENB system
224081450|NCT00685594|DRUG|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
224081451|NCT00685594|DRUG|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
224081452|NCT04834869|BIOLOGICAL|BNT162b2|Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)
224081453|NCT04834869|BIOLOGICAL|mRNA-1273|Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)
224081454|NCT04834869|BIOLOGICAL|AZD1222|Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)
224081455|NCT04834869|BIOLOGICAL|CoronaVac|Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)
224081456|NCT04834869|BIOLOGICAL|Sinopharm|Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine
224081457|NCT04834869|BIOLOGICAL|Gam-COVID-Vac|Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)
224081458|NCT04834869|BIOLOGICAL|JNJ-78436735|Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)
224081459|NCT04834869|BIOLOGICAL|CVnCoV|Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)
224081460|NCT04834869|BIOLOGICAL|NVX-CoV2373|Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)
224081461|NCT04834869|BIOLOGICAL|BBV152|Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)
224081462|NCT06103903|BEHAVIORAL|Questionnaire|Questionnaire according to age (6-13;14-17); the parents for minors and adults
224081463|NCT02629562|BIOLOGICAL|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
224081464|NCT03657719|BIOLOGICAL|GC3114|High-dose Quadrivalent influenza vaccine
224081465|NCT03657719|BIOLOGICAL|GCFLU Quadrivalent|Quadrivalent influenza vaccine
224081466|NCT03976622|BIOLOGICAL|Blood samples|Blood samples: serum and PBMC
224081467|NCT03976622|BIOLOGICAL|Skin biopsies|These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
224081468|NCT03359876|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
224081469|NCT03359876|DRUG|Warfarin sodium|Individually adjusted dose
223516346|NCT06147869|DEVICE|Low level laser therapy|Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
223892881|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C6 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C6 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
223892882|NCT06015204|PROCEDURE|Interscalene brachial plexus block targeting the C5-to-C8 nerve roots|With the head rotated contralateral to interscalene brachial plexus block (ISBPB), the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery under ultrasound guidance. The linear ultrasound transducer is moved cephalad until the C5-to-C8 nerve roots are visualized between the anterior and middle scalene muscles. A block needle is introduced from lateral to medial direction. A nerve root is blocked by placing at least 5 ml of 0.75% ropivacaine around it. The most caudal cervical nerve root (C8 nerve root) is blocked first, and the most cephalad one (C5 nerve root) is blocked last. Then, 3 ml of 0.75% ropivacaine is placed between the scalene and sternocleidomastoid muscles to block the supraclavicular nerves. An equivalent volume of a standard study drug is planned to be used (A total of 25 ml of 0.75% ropivacaine).
223892883|NCT04088851|DRUG|On Metformin|Oral intake of Metformin (1 g / day) for 2 weeks
223892884|NCT04088851|DRUG|Off Metformin|No oral intake of Metformin (1 g / day) for 2 weeks
223892885|NCT05893498|DEVICE|FFRangio|A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.
223892886|NCT05893498|DEVICE|FFR or NHPR|Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).
223892887|NCT05335967|BEHAVIORAL|Self-management program|The self-management group will receive the self-management program for 12 weeks, including a self-management application, a self-management manual, and Professional support.
223892888|NCT05335967|OTHER|Information package|The patients in this group will receive an information package on a healthy diet.
223892889|NCT03582488|DRUG|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
223892890|NCT03131648|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
223892891|NCT03131648|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
223892892|NCT05324124|DRUG|Selpercatinib|Administered orally.
223892893|NCT00009633|OTHER|No Intervention|No Intervention
223892894|NCT06317350|DRUG|GNS-212-E1|Subjects who are randomized into this group will take GNS-212-E1 from the evening before colonoscopy to the morning of colonoscopy.
223892895|NCT06317350|DRUG|GNS-212-E2|Subjects who are randomized into this group will take GNS-212-E2 from the evening before colonoscopy to the morning of colonoscopy.
223892896|NCT06317350|DRUG|GNS-212-ER|Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
223892897|NCT04354077|DEVICE|DBS of the NAc|Deep Brain Stimulation of the Nucleus Accumbens
223892898|NCT05685927|DRUG|6-months of medically assisted glycemic improvement|Administrated by the clinic at Steno Diabetes Center, Aarhus, Denmark
223892899|NCT05685927|PROCEDURE|Bariatric surgery|Participants are examined prior to and 1 year following bariatric surgery in the Central Region, Denmark
223892900|NCT03946111|DRUG|Naltrexone and Bupropion|Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
223892901|NCT03946111|OTHER|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
223892902|NCT04451044|DEVICE|Philips SyncVision system with Philips pressure wires|Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
223892903|NCT04451044|PROCEDURE|standard of care angiographically-guided PCI|Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
223892904|NCT04058743|DEVICE|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
223516347|NCT03231735|DEVICE|Mid frequency ventilation|Mechanical ventilator used at rates \> 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
223516348|NCT03231735|DEVICE|Standard frequency ventilation|Mechanical ventilator used at rates \< 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
223892905|NCT04058743|DEVICE|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
223892906|NCT03792256|DRUG|Palbociclib|Given PO (or via NG- tube)
223892907|NCT03792256|DRUG|Cytarabine|Given intrathecally (IT)
223892908|NCT03792256|DRUG|Methotrexate|Given intrathecally (IT)
223892909|NCT03792256|DRUG|Hydrocortisone|Given IT
223892910|NCT03792256|DRUG|Doxorubicin|Given intravenously (IV)
223892911|NCT03792256|DRUG|Prednisolone|Either prednisone or prednisolone is given PO
223892912|NCT03792256|DRUG|Vincristine|Given IV
223516349|NCT04824066|DEVICE|Device: Wearable Device|A Wearable Device will be placed on the wrist of the patient \~30 days prior to the patient's scheduled surgery, removed during the operation, and replaced for \~180 days post-operatively. The device will record activity in terms of steps, sleep quality, heart rate, etc.
223516350|NCT03192332|DEVICE|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
223516351|NCT03192332|DRUG|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
223516352|NCT06356350|OTHER|Conventional neuromuscular exercises|Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.
223516353|NCT06356350|OTHER|Core based exercises|Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
223516354|NCT03657407|DRUG|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
223516355|NCT03657407|DRUG|Glycerin Suppository|Glycerine rectal suppository
223516356|NCT02096965|DRUG|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
223516357|NCT02096965|DRUG|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
223516358|NCT04993911|OTHER|Experimental Group|"Assessment will be performed pre and post of intervention. Intervention will be given 3 days a week for 8 weeks. Each session will include a 5-min warm-up on a fitness bike or treadmill before commencement of the program and a 5-min cool period. Participants of this group will receive balance training with conventional treatment. Participants will perform between 2 sets of 5 and 7 repetitions of each exercise.~Single leg balance~* Walking forward~* Walking backward~* Side stepping~* Walk heel to toe~* Static exercises with eyes close or open~CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
223516359|NCT04993911|OTHER|Control Group|"Participants of this group will receive only conventional therapy which will include; before beginning the program, each session will feature a 5-minute warm-up on a fitness bike or treadmill, followed by a 5-minute cool-down. Participants of this group will receive only conventional therapy which will include.~* CONVENTIONAL EXERCISE PROGRAM :~* TENS for 15 minutes~* Hot pack for 15 minutes~* Participants will perform between 2 sets of 7 and 10 repetitions of each exercise:~* Quadriceps/hamstring isometric exercises.~* ROM and active stretching of the hamstring and quadriceps muscle.~* Active ankle pump.~* Squats,step-up, sit to stand, calf raises~* Straigh leg raising exercise in crook lying position"
223516360|NCT06087328|DRUG|Regular Nicotine patch and lozenge dose|1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]
224081470|NCT02031705|PROCEDURE|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
223516361|NCT06087328|DRUG|Augmented Nicotine patch and lozenge dose|21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
223516362|NCT05956535|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
223892913|NCT03792256|DRUG|Pegaspargase|Given IV
223892914|NCT03792256|DRUG|Hydrocortisone|Given intrathecally (IT)
223516363|NCT05956535|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
223516364|NCT05900830|OTHER|play therapy|A combined program based on physical and occupational therapy techniques within a play context
223516365|NCT05900830|OTHER|common educational methods|the child will receive his education in a passive manner
223892915|NCT03792256|DRUG|Prednisone|Either prednisone or prednisolone is given PO
223892916|NCT00579202|DEVICE|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
223892917|NCT05931289|BEHAVIORAL|Enhanced Crisis Response Planning (ECRP)|Using supportive listening, a therapist conducts a brief interview to gather information about lifetime suicide attempt history and recent SI. The therapist then works with the client to identify a) warning signs for being in crisis, b) self-management/distraction strategies, c) reasons for living, d) sources of social support the client could contact in the event of a crisis, and e) crisis resources (e.g., veterans crisis line, contact information for current providers and local emergency resources). Steps for each of these, as well as specific contacts for social support and professional services are written on an index card provided to the patient and the patient is encouraged to keep the card in an accessible place (e.g., wallet) so it can be utilized in the event of a crisis.
223892918|NCT05931289|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT)|This weekly, 12-session intervention involves completion of an enhanced crisis response plan, as well as emotion regulation skills training, learning strategies to identify and challenge thinking patterns that contribute to suicide risk, and increased engagement in personally meaningful activities.
223892919|NCT04606069|DRUG|Regadenoson|Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
224081471|NCT02031705|PROCEDURE|control group|Control group was performed no additional cavotricuspid isthmus ablation.
224081472|NCT00428597|DRUG|sunitinib malate|"* sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
224081473|NCT00428597|DRUG|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
224081474|NCT05149170|DRUG|Anti-PD-1 monoclonal antibody|inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT
224081475|NCT04780542|BEHAVIORAL|Yo Puedo Sentirme Bien- Clinician-Guided version|Internet delivered Cognitive Behavioral Therapy- Guided version
224081476|NCT04780542|BEHAVIORAL|Yo Puedo Sentirme Bien- Self-Guided version|Internet delivered Cognitive Behavioral Therapy- Self-Guided version
224081477|NCT05241327|DIETARY_SUPPLEMENT|Beetroot Juice|Inorganic Nitrate
224081478|NCT06501560|GENETIC|GWAS|In GWAS studies, data are collected to determine common variants in a number of individuals, either with or without a common trait (for example,. disease) across the genome, using genome wide SNP arrays.
224081479|NCT01425112|PROCEDURE|Phacoemulsification|Surgery for complications of trabeculectomy
224081480|NCT00004183|DRUG|capecitabine|
224081481|NCT03775876|PROCEDURE|Shoulder Arthroscopy|patients in both groups are programmed for an elective shoulder arthroscopy surgery
224081482|NCT03775876|PROCEDURE|Regional Block|patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
224081483|NCT03775876|DRUG|Propofol|propofol 10mg/ml was used for sedation as described in the arms section
224081484|NCT03775876|DRUG|Dexmedetomidine|Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
224081485|NCT03775876|DIAGNOSTIC_TEST|BIS|sedation level was monitored using bispectral index to achieve values described in the arms group
224081486|NCT03760497|PROCEDURE|Restorative treatment|For all groups, first the patients will be submitted to the anesthetic technique indicated with Lidocaine + Epinephrine 1: 100,000 (New DFL, Rio de Janeiro, Brazil), followed by absolute isolation with rubber sheet and metal clamp; then prophylaxis of the selected tooth will be performed with Robson's brush and pumice stone and water, surface washing and drying with cotton balls, removal of carious tissue or affected enamel without dentin support with sharp curettes or low-speed spherical drills. Subsequently, each group will follow the treatment protocols suggested by the manufacturer of restorative materials.
223892920|NCT04606069|OTHER|Placebo Control|The same volume of saline will be given intravenously for 6 and half hours.
223892921|NCT05659264|DRUG|mRNA-0184|mRNA-0184 dispersion for intravenous (IV) infusion
224081487|NCT03140904|OTHER|Standard weekly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
224081488|NCT03140904|OTHER|Monthly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
224081489|NCT01284166|DRUG|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
224081490|NCT00983047|DRUG|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\\PR\\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity."
224081491|NCT03607331|DEVICE|Auricular vagus nerve stimulation|Auricular vagus nerve stimulation is a typical representative of TCM modernization.
224081492|NCT03607331|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
224081493|NCT00330473|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
224081494|NCT00330473|DRUG|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
224081495|NCT03668509|DRUG|SHR1459|oral adminstration, single dose
224081496|NCT05192811|DIETARY_SUPPLEMENT|Lactobacillus paracasei K56|probiotic K56 capsule, 1capsule/day (10\^9cfu) ,for 60days
224081497|NCT05192811|DIETARY_SUPPLEMENT|placebo|placebo capsule(maltodextrin) , 1capsule/day ,for 60days
224081498|NCT03923205|OTHER|Dietary Intervention|The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
224081499|NCT02916654|DIETARY_SUPPLEMENT|sucrosomial iron|administration of sucrosomial iron
224081500|NCT02916654|DRUG|Sulphate iron|administration of sulphate iron
224081501|NCT01469000|DRUG|Gefitinib|250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
224081502|NCT01469000|DRUG|Pemetrexed|500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
224081503|NCT03618056|BIOLOGICAL|AIDSVAX® B/E|Administered by intramuscular injection
224081504|NCT02199899|DRUG|BIIF 1149 BS - single rising doses|
224081505|NCT02199899|DRUG|Placebo|
224081506|NCT04479904|DRUG|Famitinib|po
224081507|NCT05296577|DRUG|anlotinib and vinorelbine|anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
224081508|NCT05296577|DRUG|Vinorelbine injection|vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.
224081509|NCT05406856|RADIATION|External beam radiation therapy: IMRT/VMAT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
224081510|NCT05406856|RADIATION|External beam radiation therapy: IMPT|EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
223516366|NCT05586685|OTHER|effect of diaphragmatic release on upper crossed syndrome|"The patients will be positioned in the supine position. The therapist stood at the head of the patient.therapist make manual contact of ribs and ask patient to inspire the move ribs laterally and then expire~conventional exercise Subjects will form the letter 'Y' with their arms then they will flex their elbows and move into a position of shoulder extension, so that their arms will form the letter 'w L to Y Exercise: Subjects will begin with arms abducted to 90° and elbows flexed to 90° Chin tucks : Subjects will length the neck by pushing the chin into the table in an entirely posterior motion stretch pectoral area from supine lying position"
224081511|NCT05406856|DRUG|Cisplatin|The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
223534815|NCT04225858|PROCEDURE|Omission of sentinel lymph node biopsy|No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
223534816|NCT02519842|DRUG|Fosaprepitant|
223534817|NCT02519842|DRUG|Placebo for fosaprepitant|
223892922|NCT05659264|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
223892923|NCT04760678|OTHER|Observational study|No intervention (observational study in human participants)
223892924|NCT05570175|BEHAVIORAL|Mobile application RA joint protection and activity self-management program|The intervention group received a mobile application RA joint protection and activity self-management program based on self-efficacy theory for 6 weeks. The program was based on self-efficacy theory and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
223892925|NCT06836427|BIOLOGICAL|CMTS0929|CMTS0929 is defined as suspension from washed microbiota.
223892926|NCT04195451|OTHER|Live-Video-Supervised Exercise Intervention|The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
223892927|NCT04195451|OTHER|Usual Care then Live-Video Supervised Exercise Intervention|Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
223892928|NCT01748448|DRUG|Vitamin D|"* prospective interventional randomized double blind placebo controlled trail~* clinical setting (tertiary university hospital)~* investigator driven, no pharmaceutical sponsor~* cutaneous malignant melanoma patients~* add- on study (placebo or vitamin D) on top of optimal standard care~* 1:1 inclusion ratio (placebo:Vitamin D)~* randomisation after informed consent and screening"
223892929|NCT01748448|DRUG|Placebo: Oil|
223892930|NCT06836544|BEHAVIORAL|ALL YOU NEED IS LOVE syllabus|"1. Week 1: Introduction to the Kidneys~2. Week 2: Chronic Kidney Disease, Medication Management~3. Week 3: Making Healthy Choices~4. Week 4: Learning about Self-Care~5. Week 5: Becoming Independent~6. Week 6: Review and Self-assessment"
223892931|NCT06836726|DRUG|Evofosfamide|This study is evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.
223892932|NCT06040957|BIOLOGICAL|Bone marrow aspirate concentrate injection|single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
223892933|NCT06040957|BIOLOGICAL|intra-articular injection of Minimally manipulated adipose tissue|single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
223892934|NCT03561805|DEVICE|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
223892935|NCT06446830|DRUG|multimodal analgesia and vitamin B|B1, B6 , B9 , B12 in addition to the routine paracetamol and NSAID
223892936|NCT06446830|DRUG|standard multimodal analgesia|Routine Paracetamol and NSAID
223892937|NCT05803811|DIETARY_SUPPLEMENT|Riboflavin|Colon delivered vitamin B2 (Riboflavin) for 12 weeks
223892938|NCT06838104|DRUG|Melatonin|Participants in this group will receive 6 mg of melatonin orally, administered as two 3 mg tablets 30 minutes before bedtime daily for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).
223892939|NCT06838104|DRUG|Placebo|Participants in this group will receive placebo tablets identical in shape, size, smell, taste, and color to melatonin tablets, administered in the same manner (two tablets 30 minutes before bedtime) for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).
223892940|NCT06438172|DRUG|HCP1803-3|Take it once daily for 8 weeks orally.
223892941|NCT06438172|DRUG|RLD2001-1|Take it once daily for 8 weeks orally.
223892942|NCT06438172|DRUG|HPP2003-3|Placebo drug. Take it once daily for 8 weeks orally.
223892943|NCT06438172|DRUG|HPP2002-1|Placebo drug. Take it once daily for 8 weeks orally.
223892944|NCT06243588|OTHER|clinical records review|review the medical records, radiological imaging, and histological data of these patients
223892945|NCT04528810|OTHER|not applicable (Observational Study)|This is an observational study and does not include interventions.
223892946|NCT06209606|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
224081512|NCT05406856|RADIATION|Brachytherapy|Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2\_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
224081513|NCT00504764|DRUG|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
224081514|NCT00504764|PROCEDURE|Autologous Transplantation|Autologous Transplantation
224081515|NCT00504764|PROCEDURE|Allogenic Transplantation|Allogenic Transplantation
224081516|NCT00504764|DRUG|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
224081517|NCT03122431|DRUG|Thalidomide|Thalidomide 100 mg/day
224081518|NCT03122431|DRUG|Hydroxychloroquine reduced|Hydroxychloroquine 2.5 mg/kg/day
224081519|NCT03122431|DRUG|standard dose of HCQ|Hydroxychloroquine 5.0 mg/kg/day
224081520|NCT04323904|OTHER|Retrospective data collection|Retrospective data collection from patients with hantavirus infection and matching control group patients.
224081521|NCT02558374|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
224081522|NCT02558374|DRUG|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
223892947|NCT06209606|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
223892948|NCT06209606|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
223892949|NCT06562634|PROCEDURE|erector spinea plane block|an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivicaine 0.25%, and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
223892950|NCT06562634|DRUG|Morphine Sulfate|intravenous morphine will be given in a dose of 0.1-0.2mg/kg to maintain intraoperative analgesia.
223892951|NCT06838624|DEVICE|Redcord|"Perticipants will perform exercises in different plank positions using RedCord® while applying local vibration in:~* Supine plank position~* Prone plank position~* Lateral prone plank position"
223892952|NCT06838624|OTHER|Control (Standard treatment)|"Participants will perform exercises in different plank positions:~Supine plank position Prone plank position Lateral prone plank position"
223892953|NCT06837519|DRUG|Lidocaine|Patients will receive lidocaine 0.3 mg/kg over 10 min loading, 0.3 mg/kg/h infusion after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of dexmedetomidine.
223892954|NCT06837519|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine 0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h after induction of anesthesia as maintenance dose till 10 min before the end of the operation plus saline 0.9% with same rate of lidocaine.
223892955|NCT06837519|DRUG|Lidocaine and Dexmedetomidine|Patients will receive lidocaine (0.3 mg/kg in 10 min loading, 0.3 mg/kg/h infusion) and dexmedetomidine infusions (0.5 μg/kg infusion over 10 min as a loading dose then 0.5 μg/kg/h) till 10 min before the end of the operation.
223534818|NCT02519842|DRUG|Ondansetron|
223892956|NCT06836713|PROCEDURE|Surgical Risk Stratification|Database implementation to formulate a regional risk score
223892957|NCT06834841|DRUG|Dexmedetomidine|the preservative-free dexmedetomidine 100 μg/ml will be loaded into a 100-unit insulin syringe (1 μg/unit) and 5 units will be added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine
223892958|NCT06834841|DRUG|Fentanyl|Fentanyl (Fentanyl Hameln® 0.1mg/2ml) 25 mcg will be given intrathecally added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine
223892959|NCT06487741|OTHER|Home-based stretching exercises|The intervention comprises six weeks of daily static stretching exercises (six minutes a day) in accordance with the recommendation of the American College of Sports Medicine. The intervention is self-administered and consists of two bouts of 30-second bilateral static stretches of the knee flexors, hip abductors, and shoulder elevators.
223892960|NCT03337971|DIETARY_SUPPLEMENT|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
224081523|NCT02558374|OTHER|Placebo|1 drop QD, AM, OU
224081524|NCT05751356|DRUG|TR128|TR128 will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Starting dose is 100mg, with escalation to 500mg.
224081525|NCT05218616|DRUG|Aviga, capsules 50 mg / Sutent®, capsules 50 mg|Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
224081526|NCT05218616|DRUG|Sutent®, capsules 50 mg / Aviga, capsules 50 mg|Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
224081527|NCT05642910|DRUG|Azvudine|Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
224081528|NCT05642910|DRUG|Paxlovid group|Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
224081529|NCT02385279|DEVICE|MiStent|Percutaneous Coronary Intervention
224081530|NCT02385279|DEVICE|XIENCE EES|Percutaneous Coronary Intervention
223534819|NCT02519842|DRUG|Dexamethasone|
224081531|NCT00686647|DEVICE|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
224081532|NCT00686647|DEVICE|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
224081533|NCT00632853|RADIATION|Standard Radiation Dose Therapy|45 Gy
223534820|NCT02519842|DRUG|5-HT3 antagonist|
223534821|NCT03928925|OTHER|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
223534822|NCT03928925|OTHER|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
224081534|NCT00632853|DRUG|cisplatin|IV
224081535|NCT00632853|DRUG|etoposide|IV
224081536|NCT00632853|RADIATION|High Radiation Dose Therapy|70 Gy
224081537|NCT00632853|DRUG|carboplatin|IV
224081538|NCT04763070|DRUG|Ciprofloxacin Oral Product|The first stool sample will be taken before treatment and the second one will be taken in day 5 to 7 after treatment initiation. Treatment includes ciprofloxacin tablet 500mg twice a day for 5 days.
224081539|NCT01715584|OTHER|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
224081540|NCT03961711|PROCEDURE|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
224081541|NCT03961711|PROCEDURE|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
224081542|NCT03752645|DEVICE|Transverse Many Channels Laser Instrument|The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
224081543|NCT04161287|PROCEDURE|transcatheter arterial chemoembolization|The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
224081544|NCT04164303|OTHER|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
224081545|NCT02137967|PROCEDURE|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
224081546|NCT02137967|PROCEDURE|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
224081547|NCT02137967|DRUG|2.5% NaOCl|
224081548|NCT02137967|DRUG|20% Formocresol|
224081549|NCT05420389|OTHER|breast massage|Mothers who were included in the breast massage group who met the research criteria were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale was filled out on the first day. These mothers were shown breast massage during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
224099177|NCT06475807|DIETARY_SUPPLEMENT|High fiber supplementation|Step 2: High fiber supplementation
223516367|NCT02628145|BEHAVIORAL|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
223516368|NCT02628145|BEHAVIORAL|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
223516369|NCT00153933|DRUG|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
223516370|NCT00153933|DRUG|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
223516371|NCT03186183|BEHAVIORAL|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
223516372|NCT05262673|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
224099178|NCT06373003|OTHER|Diagnostic accuracy|To assess the diagnostic accuracy of non-criteria aPL (anti-vimentin/cardiolipin and anti-phosphatidylserine/prothrombin) in identifying APS in patients with thrombosis/ recurrent adverse pregnancy outcomes
224099179|NCT02239172|BIOLOGICAL|PA83-FhCMB|
223516373|NCT02339675|OTHER|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
223516374|NCT00049283|DRUG|erlotinib hydrochloride|Given orally
223516375|NCT00049283|DRUG|docetaxel|Given IV
223516376|NCT00049283|RADIATION|radiation therapy|Undergo radiotherapy
223516377|NCT00049283|PROCEDURE|therapeutic conventional surgery|Undergo neck dissection
223516378|NCT00049283|OTHER|laboratory biomarker analysis|Correlative studies
223516379|NCT00049283|OTHER|pharmacological study|Correlative studies
224081550|NCT05420389|OTHER|hot compress|Mothers who were included in the hot application group were informed about the use of milking pumps in the routine application of the hospital and the condition anxiety scale (STAI-I) was filled out on the first day. These mothers were shown the hot application they would make during the use of milking pumps, they were provided with the application and a brochure was given explaining the application.The hot chest compress to be used in this group will be used in the Lansinoh brand Thera°Pearl® Hot Breast Therapy pad, which is sold in medical medicines in pharmacies approved by the Ministry of Health.The breast milk follow-up form, in which they will record the amounts of milk they milk, was explained by the researcher in the hospital and how to fill it out when they were discharged, and they were asked to fill out a last-day anxiety scale.
223516380|NCT06121635|COMBINATION_PRODUCT|Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation|At the robot-assisted gait training, 20-minute gait training for the patient at an appropriate speed with the Locohelp Woodway device. The aim is to re-teach proper walking, gait cycle timing, and create a near-normal gait pattern through multiple repetitions. Robot-assisted gait training will be performed immediately following the stimulation applied to the patients.
223516381|NCT06121635|COMBINATION_PRODUCT|Sham ts-DCS and sham t-DCS|Sham ts-DCS and sham t-DCS
223516382|NCT04098783|OTHER|Home visit, health education|
223516383|NCT05936138|DRUG|LY3502970|Administered orally.
223892961|NCT03337971|DIETARY_SUPPLEMENT|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
224081551|NCT05420389|OTHER|breast massage-hot compress|Mothers who were included in the breast massage and hot application group were informed about the use of milking pumps in the routine application of the hospital, the data collection form and the condition anxiety scale were filled out on the first day. These mothers were shown breast massage and hot application during the use of milking pumps, they were provided with their own application and a brochure was given explaining the application.As long as the breast milk follow-up form to record the amounts of milk they milked was in the hospital, the researcher explained how to fill it out when discharged and was asked to fill out the last-day conditional anxiety scale (SATI-I). Milk amounts are measured in ml.
224081552|NCT00003378|DRUG|carboplatin|
224081553|NCT00003378|DRUG|gemcitabine hydrochloride|
224081554|NCT00003378|DRUG|paclitaxel|
224081555|NCT05268406|DEVICE|C-Scan System|Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion.
224081556|NCT00931489|DRUG|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
223892962|NCT02907099|DRUG|CXCR4 Antagonist BL-8040|Given SC
223892963|NCT02907099|BIOLOGICAL|Pembrolizumab|Given IV
223892964|NCT02907099|OTHER|Pharmacological Study|Correlative studies
223892965|NCT04818632|DRUG|AZD9833|Part A: AZD9833 monotherapy dose escalation.
224081557|NCT04168424|OTHER|no intervention|Completing the questionnaire for health-related resource use in the elderly population (FIMA) by the elderly people
224081558|NCT05501119|BEHAVIORAL|A Program of SUPPORT-D (dementia)|The SUPPORT-D intervention consists educational materials will be presented in a format with enhanced content (face-to-face virtually delivered by nurse interventionist via telehealth (e.g., MS Teams), with printed booklet, and identical digital content (electronic pdf and recorded videos of printed content). The SUPPORT-D intervention will be addressed in four sequential sections including: 1) understanding the disease 2) caring for myself; 3) information for the caregiver; and 4) planning for the future. Within the four sections of the intervention seven topics are addressed included symptom management, understanding your disease, putting safety first, ongoing conversations, respite care, palliative care, and alternative treatments. Participants will attend a total of 4 study visits across 8 weeks (approximately every 2 weeks).
224081559|NCT00955994|DRUG|asimadoline|
224081560|NCT04983160|DRUG|Allopurinol|Allopurinol
224081561|NCT04983160|DRUG|Placebo|Placebo
224081562|NCT01725750|DEVICE|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
224081563|NCT01725750|DEVICE|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
224081564|NCT02542072|DEVICE|comfilcon A|contact lens
224081565|NCT02542072|DEVICE|samfilcon A|contact lens
224081566|NCT06162208|OTHER|Standard exercise program based on telerehabilitation|Exercises included in a standard exercise program based on telerehabilitation; Week 0-3 Patellar mobilization Isometric quadriceps femoris exercise Terminal extension exercise Active assisted knee flexion Straight leg lift Active hip abduction Active assisted knee flexion in sitting SAFTE Cold pack application Week 3-6 Straight leg raises with weights Hip abduction in weighted side lying Knee flexion in the prone position Knee extension in weight-bearing sitting Sliding forward in the chair to increase the knee flexion angle Standing weighted hip abduction Standing knee flexion with weight Squat Walking Climbing stairs Action observation therapy will be practiced by watching videos of all exercises with a focus on close-up action.
223516384|NCT00167531|BEHAVIORAL|treadmill walking with partial weight support|
223892966|NCT04818632|DRUG|AZD9833|Part B: AZD9833 monotherapy dose expansion
223892967|NCT04818632|DRUG|AZD9833 with palbociclib|Part B: AZD9833 with palbociclib dose expansion
223892968|NCT04818632|DRUG|AZD9833 with everolimus|Part B: AZD9833 with everolimus dose expansion
223892969|NCT06823778|DEVICE|Radiofrequency ablation|In this group of patients, epicardial radiofrequency left atrial posterior wall isolation will be performed with AtriCure Isolator Synergy OLL2 bipolar radiofrequency clamp without opening the left atrium.
223892970|NCT06364514|OTHER|Clinical Stability Assessment|Base total days of antibiotics on clinical stability vs utilizing predetermined total days of antibiotics
223892971|NCT06837207|DEVICE|transcranial magnetic stimulation|Individualized transcranial magnetic stimulation of targets based on the association between the orbitofrontal cortex and the functional activity of the habenula .
223516385|NCT00167531|BEHAVIORAL|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
223892972|NCT06836778|DRUG|Carvedilol Tablets|Non-selective beta blocker (Carvedilol 3.125 mg BD for 3 days followed by 6.25 mg BD , maximum dose would be 12.5 mg BD , same shall be switch to maximum tolerable dose if Systolic BP\< 90 , H,R\<55)
223892973|NCT06836778|PROCEDURE|Endoscopic Variceal Ligation|EVL every 3 weeks till eradication of varices followed by every 3 months.
223892974|NCT06087471|DIETARY_SUPPLEMENT|Intervention snack|The intervention snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
223892975|NCT06087471|DIETARY_SUPPLEMENT|Control Snack|The control snack will be consumed by 42 participants for 12-weeks. Snacks will be consumed twice a day (mid-morning and mid afternoon snack).
223892976|NCT05597878|DRUG|Oxycodone|Given after surgery 5 mg every 6 hours as needed for severe pain.
223892977|NCT05597878|DRUG|Acetaminophen|Given after surgery 1000 mg by mouth 4 times daily (every 6 hours)
223892978|NCT05597878|DRUG|Ketamine|Given before and during surgery 1.5 mg/kg intravenously
223892979|NCT05597878|DRUG|Ketorolac|Given during surgery 15 mg or 30 mg intravenously 3 times daily (every 8 hours). After surgery 15 mg IV three times daily (every 8 hours).
223892980|NCT05597878|DRUG|Acetaminophen|Given during surgery 1 mg intravenously 4 times daily (every 6 hours). After surgery 1000 mg by mouth four times daily (every 6 hours)
223892981|NCT06836505|BIOLOGICAL|CART therapy|GD2/B7H3 CAR T-cell therapy
223892982|NCT06248398|PROCEDURE|Surgery with RobOtol®|Patient having cochlear implantation surgery with RobOtol®.
223892983|NCT06248398|PROCEDURE|Conventional manual surgery|Patient having conventional manual cochlear implantation surgery
223892984|NCT06837753|OTHER|Exercise|It consist of traditional exercises.
224081567|NCT00426894|PROCEDURE|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
224081568|NCT00654498|DRUG|Pramipexole|
224081569|NCT00654498|DRUG|Placebo|
224081570|NCT02795078|DRUG|conservative treatment|
224081571|NCT02795078|PROCEDURE|Aneurysms clipping|
224081572|NCT02795078|PROCEDURE|Interventional embolization forAneurysms|
224081573|NCT02795078|PROCEDURE|stenting for stenosis|
224081574|NCT05526027|DIAGNOSTIC_TEST|CFQ-R questionnaire, SNOT-22 questionnaire, fecal elastase measurement|cf supra
224081575|NCT04830267|DRUG|Camrelizumab|Camrelizumab 200mg IV starting day 1 and then every 2 weeks thereafter. Treatment with Camrelizumab will continue until progression or unacceptable toxicity.
224081576|NCT04830267|RADIATION|Stereotactic body radiotherapy|Image guided, stereotactic body radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Camrelizumab).
224081577|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection before vitrectomy
223516386|NCT02056951|PROCEDURE|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~* health education~* exercise therapy~* back school~* physical treatments~* psychological interventions in groups and individual counselling~* rehabilitation/social counselling."
223534823|NCT02234349|PROCEDURE|pancreas kidney transplantation|
223516387|NCT02056951|PROCEDURE|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~* education about low back pain~* behavioural exercise therapy~* coping with pain~* relaxation~* work related informations"
223516388|NCT02303483|DIETARY_SUPPLEMENT|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
223516389|NCT02303483|DIETARY_SUPPLEMENT|Placebo|
223892985|NCT06387108|OTHER|training course|Two-hour online training course for educational professionals at schools on depression and mental health in children and adolescents (including symptoms, causes, comorbidity, prevention) and practical tips for everyday school life to reduce stress.
223892986|NCT05432635|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
223892987|NCT05432635|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autoHSCT
223892988|NCT05432635|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223516390|NCT06456684|DIAGNOSTIC_TEST|Fluoro[18F]promethazine|It is the first F-18-labeled VMAT2 imaging agent for PET imaging that is currently being used in the clinic internationally. In the brains of Parkinson's disease (PD) patients, the target binding of fluoro\[18F\]promethazine was significantly reduced compared with that of normal controls, with an 81% reduction in the posterior region of the nucleus accumbens, a 70% reduction in the anterior region of the nucleus accumbens, and a 48% reduction in the caudate nucleus; the radioactivity uptake in the caudate nucleus of PD patients was correlated with the extent of their disease
223516391|NCT00310141|BEHAVIORAL|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
223516392|NCT00310141|OTHER|Counseling intervention|In-person counseling (5 sessions)
223516393|NCT00310141|DRUG|Nicotine patch|6-week supply of the nicotine patch
223892989|NCT05432635|PROCEDURE|Myeloablative Conditioning|Given standard conditioning regimen
223892990|NCT05525039|DEVICE|Low-magnitude High-frequency Vibration|0.3g, 35Hz, 20mins/day, at least 3 times/week
223892991|NCT05525039|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB) supplement|Oral nutritional HMB supplement at 3g/day
223892992|NCT05525039|DIETARY_SUPPLEMENT|Protein supplement|Daily protein supplement intake
223892993|NCT01480206|OTHER|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
223892994|NCT06835192|OTHER|Experimental group|Initially, the first author presented a 25-minute lecture with a PowerPoint presentation to the nurses of the EG. Following this, each nurse received an IAD directive wheel chart. In the subsequent 25 minutes, the first author presented three clinical cases examples and relevant information, encouraging the nurses to utilize the IAD directive wheel chart in groups. To conclude the session, a 5-minute quiz was conducted, featuring five actual clinical photographs. After the course, the nurses were instructed to take the IAD directive wheel chart back to their clinics for review and use in health education and teaching.
223892995|NCT06835192|OTHER|Control Group|The first author conducted a 25-minute knowledge lecture for the nurses in the CG on the same topics covered in the EG. This lecture included an explanation of IAD, its causes, the latest global classification of IAD, as well as methods for skin prevention and IAD care. Following the lecture, the same three clinical examples presented in the EG were discussed for an additional 20 minutes, during which the nurses were divided into groups for case discussions. Finally, a 5-minute quiz competition was held, featuring the same five actual clinical photographs used in the EG.
223892996|NCT04278157|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.
223892997|NCT04278157|BEHAVIORAL|Treatment as Usual|Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
223892998|NCT03349996|DEVICE|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
223516394|NCT04980963|BEHAVIORAL|Cognitive Support Technology (CST)|Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
223516395|NCT01217515|DRUG|Diltiazem hydrochloride 4% cream|3 times daily
223516396|NCT01217515|DRUG|Diltiazem hydrochloride 2% cream|3 times daily
223516397|NCT01217515|OTHER|Placebo|3 times daily
223516398|NCT04887805|DRUG|Lenvatinib Mesylate|Given PO
223516399|NCT04887805|BIOLOGICAL|Pembrolizumab|Given IV
223516400|NCT05996068|DEVICE|arterial line|insert arterial line for patients who meet major trauma criteria
223516401|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
223516402|NCT03662620|DRUG|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
223516403|NCT06259812|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
223516404|NCT05930067|DEVICE|Pinnacle Gription Acetabular Cup|Pinnacle Gription cup with Corail/ACTIS stem
223516405|NCT05930067|DEVICE|Pinnacle Dual Mobility|Bi-Mentum AltrX liner
223516406|NCT03989674|DIETARY_SUPPLEMENT|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
223516407|NCT03048825|DRUG|Colchicine|Colchicine 0.5 mg once daily
223516408|NCT03048825|DRUG|Spironolactone|Spironolactone 25 mg once daily
223516409|NCT03048825|DEVICE|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
223516410|NCT03048825|DRUG|Colchicine-Placebo|Matching Colchicine-placebo once daily
223516411|NCT03048825|DRUG|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
223892999|NCT06486662|DRUG|OM-85-IN|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of OM-85-IN
223516412|NCT01540539|DRUG|REGN1154 or placebo|Participants will receive active drug or placebo
223516413|NCT00538265|DRUG|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
223516414|NCT00538265|DRUG|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
223516415|NCT00538265|DRUG|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
223516416|NCT02137278|DRUG|Vasoactive drug therapies|Continue current vasoactive therapy
223534824|NCT02234349|PROCEDURE|kidney transplantation|
223893000|NCT06486662|DRUG|Placebo|Participants will receive a Single Ascending Dose (SAD): 1 day single dose treatment and Multiple Ascending Doses (MAD): 16 days multiple dose treatment of Placebo
224081578|NCT01151722|PROCEDURE|bevacizumab injection|bevacizumab injection after vitrectomy
224081579|NCT02004002|BEHAVIORAL|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
224081580|NCT02004002|BEHAVIORAL|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
224081581|NCT00168610|DRUG|Vitamin A|
224081582|NCT04251377|DEVICE|Defensive Antiadhesive Coating DAC®, Novagenit SRL|"DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room.~The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture."
224081583|NCT04758624|DEVICE|Deep Brain Stimulation|Medtronic Activa device will be implanted and administered clinically, except as part of the trial after 24 months of DBS being on it will be turned off for 3 days and will be turned back on.
224081584|NCT05243628|BIOLOGICAL|Afrezza (insulin human) Inhalation Powder|"Pharmaceutical form: powder~Route of administration: inhalation"
224081585|NCT05243628|BIOLOGICAL|insulin degludec|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224081586|NCT05243628|DEVICE|Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)|Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
224081587|NCT05948956|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 2 scoops (=25 g C8-KE) of Qitone Pro-ketone Powder ™ and electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.
224081588|NCT05948956|DIETARY_SUPPLEMENT|Electrolyte Beverage|Participants will consume an electrolyte solution diluted in water, before each of 5 or 12 1-hour sessions of aerobic exercise.
223893001|NCT05570994|DRUG|177Lu HTK03170|Subjects will receive 177Lu HTK03170 treatment over 5 cycles, each cycle occurs every 8 weeks.
224081589|NCT05948956|BEHAVIORAL|Cycling Intervention|"Five or twelve 1-hour sessions of cycling on the ergometer over a 2-6 week period. Sessions will consist of a 10 min warm up followed by 8 intervals consisting of 3 min fast cycling at 80-90 rpm followed by 2 min of slow cycling at ≤60rpm, followed by a 10-minute cool-down."
223534825|NCT04435314|DRUG|Nitazoxanide|Subjects will receive nitazonanide 600 mg TID for 7 days
223893002|NCT05570994|DRUG|68Ga-HTK03149|68Ga-HTK03149 PET/CT imaging; intravenous during screening
223893003|NCT05430360|BIOLOGICAL|GT201|Autologous tumor infiltrating lymphocyte injection
223893004|NCT05491382|PROCEDURE|Uphill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 10 degree (17.6%) incline.
223893005|NCT05491382|PROCEDURE|Flatland running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a 0 degree (0%) incline.
223893006|NCT05491382|PROCEDURE|Downhill running|Participants will run at 70% of their maximal oxygen consumption for 60 min at a -10 degree (-17.6%) decline.
224081590|NCT02353533|DEVICE|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
224081591|NCT02353533|DEVICE|EMR|Standard endoscopic mucosal resection using a resection snare
224081592|NCT01032551|BEHAVIORAL|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
224081593|NCT06508580|BEHAVIORAL|Component 1: Calorie Goal Attainment|On weeks that participants are randomized to receive this component, they will be provided with feedback on the number of days that they met their calorie goal.
224081594|NCT06508580|BEHAVIORAL|Component 2: Diet Quality|On weeks that participants are randomized to receive this component, they will receive three comments regarding specific dietary choices that may impact weight loss success, including reinforcing comments for behaviors consistent with weight loss and potential areas for change.
224081595|NCT06508580|BEHAVIORAL|Component 3: Physical Activity Goal Attainment|On weeks that participants are randomized to receive this component, they will receive feedback related to attainment of that week's physical activity goal.
224081596|NCT06508580|BEHAVIORAL|Component 4: Goal Setting|On weeks that participants are randomized to receive the goal setting component, they will be asked to complete an open-text prompt encouraging them to set a specific weight-related behavior change goal for the next week.
224081597|NCT01657578|DRUG|Omeprazole|administration of Omeprazole
224099180|NCT03370757|OTHER|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
223893007|NCT05368103|BIOLOGICAL|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
223893008|NCT05079256|DEVICE|595 nm Pulsed dye laser (Candela V-beam perfecta)|595 nm pulsed dye laser therapy. 2 treatments Fluence \~ 6 - 9 J/cm\^2 Pulse duration \~ 0.45 - 3.0 ms 33% overlap.
223893009|NCT06829589|OTHER|Removal of economic incentives linked to 7 quality-of-care indicators|"The 7 intervened indicators will be the following:~* Blood pressure (BP) control in type-2 diabetes mellitus.~* BP control in ischemic cardiopathy/cerebrovascular accident.~* Hypertension: BP control in chronic renal insufficiency.~* Hypertension: BP control.~* Diagnostic adequacy of hypertension.~* Correct treatment of atrial fibrillation.~* Inhaler verification.~Professionals randomized to an arm with this intervention will no longer receive an economic reward for reaching a specific goal in the results of these 7 indicators.~The study guarantees no financial loss since the amount of money linked to these incentives will be automatically given to professionals under the concept of participating in the study."
223893010|NCT06829589|OTHER|Removal of information provision linked to 7 quality-of-care indicators|"The 7 indicators will be the same as the previous intervention.~Professionals randomized to an arm with this intervention will no longer see the following in the online platform:~* Numeric result of the indicator.~* Color coding to represent indicator result in relation to the yearly goal.~* 12-month evolution graph.~Next to the 7 indicator names, only the link to a list of patients that are not fulfilling the indicator criteria will be presented (identifying the patients missing a treatment, a control or any other intervention), since this is considered a tool to support clinical practice beyond informing on the result of an indicator."
223893011|NCT06835257|PROCEDURE|Acute normovolemic hemodilutions|Crystalloid infusion throughout the autologous blood collection (3 ml of crystalloid infusion for every 1 ml of blood)
223893012|NCT06835257|DRUG|Vasopressor infusion|Vasopressor infusion throughout the autologous blood collection (according to mean arterial pressure)
223893013|NCT03675282|DRUG|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
223893014|NCT03675282|DRUG|Ioflupane|Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
223893015|NCT05859191|BIOLOGICAL|Blood sample|Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
223893016|NCT06837545|OTHER|No Intervention (Observational Study)|"This study is an observational analysis of preoperative serum uric acid levels and their association with postoperative outcomes. No intervention was administered."
223893017|NCT05501483|DRUG|Pioglitazone 45 mg|Starts with 45 mg
223893018|NCT05501483|DRUG|Empagliflozin 25 MG|Starts with 25 mg
223893019|NCT05501483|DRUG|Semaglutide 7 MG|Starts with 3 mg daily for the first 2 weeks
223893020|NCT05875142|BEHAVIORAL|Behavioral: Digital Tutorial Overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 2 weeks.
223893021|NCT05875142|BEHAVIORAL|Behavioral: Training Materials|10 weeks post-tutorial access to additional digital training materials.
223893022|NCT05875142|BEHAVIORAL|Behavioral: Feedback and Coaching|10 weeks post-tutorial access to additional digital training materials and systematic feedback and coaching.
223893023|NCT06054477|DRUG|ALE.C04|Q3W
223893024|NCT06054477|DRUG|Pembrolizumab|200mg Q3W
223893025|NCT06837883|PROCEDURE|Percutaneous nephrolithotomy through and through guiedwire|In the study group, a modification in percutaneous nephrolithotomy was carried out to have through-and-through guidewire.
223893026|NCT06837883|PROCEDURE|Standard percutaneous nephrolithotomy|Standard percutaneous nephrolithotomy without using through and through guide wire
223516417|NCT02137278|OTHER|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
223516418|NCT02069184|DRUG|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
223516419|NCT02069184|OTHER|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
223893027|NCT06299748|BIOLOGICAL|Efgartigimod|Efgartigimod IV or SC
223893028|NCT03369106|OTHER|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
223893029|NCT05273320|DRUG|Nabilone|Nabilone capsules at a maximum dose of 1 mg twice a day
223893030|NCT00845481|DRUG|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
223893031|NCT00845481|DRUG|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
223893032|NCT00845481|DRUG|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
223893033|NCT00845481|DRUG|Dermovat ointment|Once daily application 6 days a week for 3 weeks
223893034|NCT00845481|DRUG|Elocon ointment|Once daily application 6 days a week for 3 weeks
224099181|NCT03370757|OTHER|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
223516420|NCT04545697|OTHER|Medcorder|Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
223516421|NCT02470377|DEVICE|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
223516422|NCT01907646|DEVICE|bladder training|vescical catheter
223516423|NCT01907646|PROCEDURE|No bladder training|
223516424|NCT05848843|DRUG|Durvalumab|Given by vein (IV)
223893035|NCT00845481|DRUG|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
223893036|NCT03020212|DRUG|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
224081598|NCT04925895|OTHER|Dynamic soft tissue mobilization|Dynamic soft tissue mobilization will be given in the following sequence, In supine position with 90˚ flexion of knee and hip joint deep longitudinal strokes will be applied from distal to proximal direction along with the tightened area of hamstring while passively stretching the hamstring. Total 5 longitudinal strokes will be applied followed by shaking for 20 seconds. Then progressed to the next dynamic technique in the above-mentioned sequence but the patient will be asked to do leg extension actively to achieve reciprocal inhibition of the hamstring muscle. In The next step, the subject will apply a force to the therapist's hand to engage the hamstring eccentrically as the muscle will be lengthened to its end range. In that position, the therapist will apply 5 deep longitudinal strokes from the distal towards the proximal direction on tight hamstring muscles.
224081599|NCT04925895|OTHER|Proprioceptive neuromuscular facilitation stretching|The position of the patient will be supine lying with 90⁰ flexion of hip. Therapist will passively extend the knee joint where patient will feel a mild stretch. Then therapist will ask the patient to do knee flexion in counter resistance applied by the therapist by using about 50% of his maximum strength and isometric contraction of hamstring muscles will be achieved. Patient will maintain that isometric contraction for 8 seconds then relax on therapist command. Just after relaxation therapist will further stretch the hamstring muscle to the point of mild to moderate painless stretch and patient will hold it for 30 seconds. Three repetitions will be applied in each session.
224081600|NCT04925895|OTHER|Cryotherapy|application of cold pack on knee joint for 10 minutes
224081601|NCT04925895|OTHER|Isometric knee strengthening excercises|"i. Isometric hip adductors exercises in crook lying: Two sets of 10 repetitions with a 10-seconds hold will be carried out.~ii. Isometric quadriceps strengthening exercises in supine lying: A towel roll underneath the knee joint will be used to perform this exercise. Two sets of 10 repetitions with a 10-seconds hold will be performed."
224081602|NCT03664375|OTHER|Botulinum toxin type A|All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
224081603|NCT03664375|OTHER|Task Specific Training|Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
224081604|NCT06148038|DRUG|CBD Oral|CBD Oral 350mg twice daily for 28 days
224081605|NCT06148038|OTHER|Control|Placebo Control
224081606|NCT06023732|BEHAVIORAL|Behavioral activation and emotion-focused interventions|Behavioral activation with emotion-focused interventions comprises two consecutive phases. In the first phase, treatment focus is behavioral activation in line with Brief behavioral activation treatment for depression - revised (BATD-R; 11) During the second phase, treatment focus shifts to address participants' emotions. Difficulties in understanding, tolerating, and labeling emotions is addressed by observing and describing emotions (12). Under the guidance of the therapist, participants are instructed to explore emotions normally avoided or ruminated on. This is conceptualized as a form of exposure to aversive emotions, thoughts and memories, to initiate emotional processing (13).
224081607|NCT01462266|DRUG|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
224081608|NCT01462266|DRUG|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
224081609|NCT01462266|BIOLOGICAL|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
224081610|NCT01462266|DRUG|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
224081611|NCT03391947|PROCEDURE|semilunar coronally positioned flap|The description of this intervention has been already given before
223516425|NCT05848843|DRUG|Adagrasib|Given by PO
224081612|NCT03391947|PROCEDURE|coronally advanced flap|The description of this intervention has been already given before
224081613|NCT01106846|DRUG|Group A: Saline Group|Saline continuous infusion
224081614|NCT01106846|DRUG|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
224081615|NCT01119456|BIOLOGICAL|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
224081616|NCT01119456|BIOLOGICAL|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
224099182|NCT00932087|PROCEDURE|Blood sample|Blood sample for lipidomic study
223534826|NCT04435314|DRUG|Placebo|Subjects will receive placebo TID for 7 days.
223534827|NCT02468830|DRUG|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
223534828|NCT00008086|DIETARY_SUPPLEMENT|calcitriol|
223534829|NCT00008086|DRUG|carboplatin|
223893037|NCT04693598|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
223893038|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 6:00-10:00.
223893039|NCT05089448|DRUG|Alisartan, Amlodipine besylate|Drugs will be taken once daily at 20:00-24:00.
223893040|NCT06335524|BEHAVIORAL|Finger puppet|The intervention group will receive finger-puppets and additional training pertaining to infant parent interaction and developmentally appropriate infant communication training.
223893041|NCT06335524|BEHAVIORAL|Bookworm reading intervention training and routine EDI care.|Routine EDI care including Bookworm training.
223893042|NCT04066660|DIETARY_SUPPLEMENT|Oligo Fucoidan|4.4 g oligo fucoidan powder, oral, BID
223893043|NCT04066660|DIETARY_SUPPLEMENT|Placebo|4.4 g placebo powder, oral, BID
223893044|NCT03232138|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
223893045|NCT03232138|DRUG|Placebo|Inactive ingredients
223893046|NCT05477407|DRUG|Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine|Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
223893047|NCT02914535|DRUG|Filgotinib|Tablet(s) administered orally once daily
223893048|NCT02914535|DRUG|Placebo|Tablet(s) administered orally once daily
223893049|NCT06074900|OTHER|prospective cohort study|"This study is observational in nature and does not involve any experimental treatments or additional radiographs, diagnostic tests or clinical interventions beyond what is regularly prescribed within the context of standard of care for each patient.~Outcomes for participants will be measured and captured primarily during regularly scheduled clinic/hospital visits, which include standard of care clinical examinations. Participants will be asked to complete study questionnaires as per the visit schedule and participant data will be recorded on applicable study CRFs at the appropriate time points. CRFs detailing patient, injury, and treatment variables of interested will be collected at the time of recruitment."
223893050|NCT06057649|OTHER|Effleurage Abdominal Massage|perform the effleurage massage by following these steps: Lie in supine position with knee slightly flexed. Start from the right lower quadrant, using gentle pressure, rub in tiny clockwise circular motions using any non-analgesic cream, towards right rib cage then towards upper left side, moving down the left side to hip bone. Keep up the circular massage while moving inward, toward your belly button for three minutes. After three minutes, use a little more pressure, continuing the circular movements for 10 minutes. Massage for 10 minutes a day for two months during the first 3 days of the menstrual cycle.
223893051|NCT06333392|PROCEDURE|Total underwater colonoscopy|one grooup will be randomized to receive a total underwater colonoscopy
223893052|NCT06333392|PROCEDURE|Conventional colonoscopy|one group will be randomized to undergo a conventional colonoscopy with CO2 withdrawal
223893053|NCT03418818|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
223893054|NCT03418818|DRUG|Pimonidazole|Pimonidazole is a drug that will attached to areas in the tumour that are low in oxygen. When this occurs, the areas of the tumour that are low in oxygen can be more easily found and studied after surgical removal.
223893055|NCT05529459|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
223893056|NCT05214092|BEHAVIORAL|Speech sound stimulation|Participants will listen to repetitive speech sound stimuli, presented through headphones, which will induce a neural response (frequency-following response) to be measured via electroencephalography and pupillometry
223893057|NCT04939142|COMBINATION_PRODUCT|SVd (Selinexor+Bortezomib+dexamethasone)|Randomized into two treatment Arms in a 2:1 allocation (SVd Arm or Vd Arm): (1) SVd Arm (\~100): ATG-010 + (Once a week, QW) + bortezomib (QW) + dexamethasone (BIW)
223893058|NCT04939142|COMBINATION_PRODUCT|Vd (Bortezomib+dexamethasone)|Vd Arm (\~50): Bortezomib (Cycles 1-8 \[BIW\], Cycles ≥ 9 \[QW\]) + dexamethasone (Cycles 1-8 \[Four times a week\], Cycles ≥ 9 \[BIW\])
223893059|NCT04852328|DRUG|CUE-101|CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
223893060|NCT03729518|RADIATION|Radiation Therapy (IMRT or IMPT)|"* Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~* Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~* Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
223893061|NCT04700527|DRUG|Short Chain Fatty Acid|Participants will take the supplement as prescribed to determine if it can help with GI toxicity
223893062|NCT04700527|DRUG|Tapioca Flour|Participants taking this will be used as a control group compared to those receiving the SCFA supplement
223893063|NCT06215313|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|In the EMDR condition, the Dutch version of the treatment protocol based on Shapiro's original work (2001) is followed. In the first session, the rationale of EMDR is explained. The patient describes the memory, and identifies the most aversive still image, the associated negative cognition, desired positive cognition, feelings, somatic sensations, and perceived tension, as measured by Subjective Unit of Distress (SUDs). Desensitization then begins by asking patients to focus on the still image while following the movement of a light bar or the therapist's fingers with their eyes (i.e., eye tracking task). Then, in the installation phase, the patient focuses on the positive cognition during the eye tracking task. When the validity of the positive cognition is 6 to 7 on a 7-point Likert scale, a body scan is performed to ensure that no unresolved traumatic material remains. Each session ends with a reflection and debriefing.
223893064|NCT06215313|BEHAVIORAL|Imagery Rescripting|The IR condition, following Arntz and Weertman's (1999) protocol, addresses traumatic or aversive memories by creating alternative scenarios. In the first session, the method is explained. The patient describes their memory in the present tense, from the first-person perspective, and describes associated feelings, thoughts, and emotional needs. The therapist then seeks permission to 'enter' the scene, guiding the patient to visualise an alternative, emotionally satisfying course of events. This may involve the therapist or patient intervening in the situation, ensuring the patient's emotional needs are met. The patient then relives the memory from the point of view of their younger self, with the adult-self intervening in the scene. The process continues until all emotional needs are fulfilled. Generally, one trauma memory is rescripted per session. The initial IR session involves therapist-led rescripting, with subsequent sessions encouraging patient-led rescripting whenever possible.
223893065|NCT05936684|BEHAVIORAL|Breathing with prolonged exhalation (ProlEx) during risky decision-making|20 min divided in 3 blocks of slow, 0.1 Hz breathing (6 cycles per minute) with an inhalation-to-exhalation ratio of 2:8. Cue-assisted breathing (same across participants) and performance of a risky decision-making task (Tom et al., 2007) in the magnetic resonance imaging (MRI) scanner with simultaneous acquisition of physiological and pupil data.
223893066|NCT05936684|BEHAVIORAL|Normal breathing (Eupnea/Control) during risky decision-making|20 min divided in 3 blocks of normal breathing (expected range: 0.16-0.33 Hz, i.e., 10-20 per min), Cue-assisted breathing (individually adapted) and performance of a risky decision-making task (Tom et al., 2007) in the MRI scanner with simultaneous acquisition of physiological and pupil data.
223893067|NCT05340049|PROCEDURE|Academic behavioral intervention of teachers|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
223893068|NCT05340049|PROCEDURE|Therapy sessions|"Seven sessions were given to each of the three groups according to their classification (PCST, PMRT, TMR, TCS), being able to obtain a stable value in each of the treatments carried out. Before each session, the effect of the previous session was explored in order to evaluate its efficacy (from the second session onwards). Each of the therapies had the same number of sessions (1 per week for 7 weeks) in order to have equality in all the parameters evaluated.~The effectiveness values of the cranial blocks and primitive reflexs therapies were expressed as block or normal and active or inactive, depending on what finds the physiotherapist in his evaluation"
223893069|NCT00881920|BIOLOGICAL|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa"
223893070|NCT06351501|DRUG|hormonal treatment with cross sex hormones (testosterone or oestrogenes) started at 14 years old +/- 6 months|4 years of follow up (FU) with evaluation at T0 (14 years old +/- 6 months), T1 (16 years old +/-6 months) and T2 (18 years old+/- 6 months) with eather ANDROGEL® 16.2 mg/g, gel (testostérone) or ESTREVA® 0.1 %, gel ou 1.3 PROVAMES® 1 mg, cp (oestrogenes)
223893071|NCT06351501|DRUG|Cross sex hormones ( œstrogenes or testosterone) started at 16 years old +/- 6 months|2 years of hormonal treatment from 16 old +/- 6 months to 18 years old +/- 6 months
223893072|NCT01440257|DRUG|Placebo|Placebo capsules once daily
223893073|NCT01440257|DRUG|CCX140-B|CCX140-B capsules once daily (Group B)
223893074|NCT04142788|DRUG|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
223893075|NCT05776836|DEVICE|Dermal filler|Subjects will be consecutively included to receive FASY F in nasolabial folds and cheeks and FASY P in periorbital areas.
223893076|NCT06493071|DEVICE|Active Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the auricular branch of the vagus nerve by applying stimulation to the cymba conchae region of the ear using the tVNS R device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Parameters will be set for the duration of the intervention consisting of 4 hours of daily stimulation for a period of 30 days.
223516426|NCT03274089|DEVICE|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~* Collects patient information using patient-specific identification~* Prompts the user for answers to screening questions for acute conditions~* Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~* Triages patients based on responses to screening questions, physiological parameters and blood test results~* Provides recommendations to the patient on the care plan, self management and lifestyle choices"
224081617|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
224081618|NCT01119456|BIOLOGICAL|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
224081619|NCT01119456|BIOLOGICAL|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
224081620|NCT01119456|BIOLOGICAL|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
224081621|NCT01119456|BIOLOGICAL|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
224081622|NCT01119456|BIOLOGICAL|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
224081623|NCT03396094|DEVICE|High-flow nasal cannulae (HFNC) oxygenation|Delivery of 60L/min of supplemental oxygen for pre-oxygenation and apnoeic oxygenation during rapid sequence intubation using the AIRVO™ 2 Humidifier with Integrated Flow Generator (Fisher \& Paykel Healthcare, Auckland, New Zealand)
224081624|NCT03396094|DEVICE|Non-rebreather mask and standard nasal cannula|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
224081625|NCT00146263|BEHAVIORAL|Savyon|Computerized cognitive training
224081626|NCT00146263|BEHAVIORAL|Control|Usual activity
224081627|NCT05223192|BEHAVIORAL|Music Therapy Entrainment with Ocean Disc Intervention|The studied intervention regards live entrainment with the ocean disc. Entrainment involves the use of an external stimulus, in the case of this study, an ocean disc instrument. Motion of the disc creates sounds in synchrony with the breathing of the infant and then in turn can control and influence the infant's regulation of the breath.
223893077|NCT06493071|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation will target the ear lobe using the NEMOS® taVNS device (taVNS Technologies, Erlangen, Germany). To achieve adequate stimulation while avoiding unpleasant or painful sensations, the stimulation intensity will be gradually increased in increments of 0.1mA until the subjective pain threshold is reached, and then reduced to a stimulus intensity just below the individuals pain threshold (expected range based on prior studies 1 - 3.2mA). Pulse width will be set at 100μs and frequency will be set at 25Hz. Participants will perform 4 hours of stimulation per day for a period of 30 days. Stimulation will be applied to the ear lobe in order to ensure participant feel the stimulation while avoiding activation of the vagus nerve.
223893078|NCT06188793|DEVICE|Virtual reality-directed BGBT|Enrolled participants will receive up to 3-days of VR-directed BGBT through several modules including distraction games, mindfulness meditation, breathing exercises, and cognitive behavioral therapy based coaching. Participants will complete questionnaires at various time points and be asked to complete a semi-structured interview post-intervention.
223893079|NCT05260684|DRUG|Encorafenib|450 mg QD
223893080|NCT05260684|DRUG|Binimetinib|45 mg BID
223893081|NCT05260684|DRUG|Vemurafenib|960 mg BID for 28 days/cycle
223893082|NCT05260684|DRUG|Cobimetinib|60 mg QD for 21 days/cycle
223893083|NCT05260684|DRUG|Dabrafenib|150 mg BID
223893084|NCT05260684|DRUG|Trametinib|2 mg QD
224081628|NCT06264700|BEHAVIORAL|Video Directly Observed Therapy (VDOT)|VDOT is an adherence-promoting intervention that involves partnering with an adolescent with SCD (or caregiver of a young patient with SCD) and observing the patient administer their hydroxyurea. In this study, VDOT will be delivered by a small business partner, Scene Health, via a smart phone app.
224081629|NCT06264700|BEHAVIORAL|Health Reminder Tip Alerts|"Participants randomized to this arm will receive an automated, daily, short health or safety tip alert (e.g. Time to get moving! You should be active for at least 30 minutes each day) to receive during the 180-day intervention period on their smartphone. The daily tip will be unrelated to hydroxyurea adherence. After the 180-day intervention period, participants complete a 180-day ongoing monitoring period where they will no longer receive these messages, but they will be reminded to continue to use their electronic adherence monitoring device. All participants will be offered a smart phone with a data plan at enrollment to ensure equal opportunity for participation."
224081630|NCT01528514|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
223893085|NCT05953883|PROCEDURE|Tumor and blood sample|Analyzing proteogenomic profiles in order to find individual platinum-induced modifications on tumor tissue of HGSOC according to chemotherapy response score (CRS). Whole genome sequencing (WGS), transcriptomic (RNAseq) and proteomics analyses on OC tissue samples before and after a standard platinum-based chemotherapy will be carried out and correlated to clinical variables.
224081631|NCT01528514|OTHER|Placebo|Placebo in capsule form, 4 capsules 4 times/day
224081632|NCT02305862|DRUG|Rosuvastatin 5mg|drug intervention
224081633|NCT02305862|DRUG|Rosuvastatin 20mg|drug intervention
224099183|NCT01770184|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|
223893086|NCT04386070|DRUG|RESP301|RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
224081634|NCT04961788|DRUG|Gemox combimed PD1 antibody|"1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses."
224081635|NCT00398463|DRUG|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
224081636|NCT00398463|DRUG|Placebo|Saline infusion will be administered for 14-24 hours
224081637|NCT01380457|DRUG|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
224081638|NCT01380457|DRUG|Marinol|Capsules, 10 mg, single-dose, fasting conditions
224081639|NCT00004001|DRUG|docetaxel|
223893087|NCT02515110|RADIATION|External Beam Radiation Therapy|Undergo hypofractionated RNI
224081640|NCT00004001|DRUG|estramustine|
224081641|NCT00004001|DRUG|mitoxantrone|
224081642|NCT00004001|DRUG|prednisone|
224081643|NCT04124588|DEVICE|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
224081644|NCT04124588|DEVICE|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
224081645|NCT02381119|BEHAVIORAL|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
224081646|NCT02381119|BEHAVIORAL|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
223893088|NCT02515110|OTHER|Questionnaire Administration|Ancillary studies
223893089|NCT02515110|OTHER|Laboratory Biomarker Analysis|Correlative studies
223893090|NCT06324123|OTHER|Peacetil|Nutraceutical supplement Peacetil for a period of 2 months
223893091|NCT06211088|DRUG|famotidine plus10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine
223893092|NCT06211088|OTHER|10ml normal saline|to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by placebo
223893093|NCT06311760|DRUG|AZD0292|AZD0292 will be administered as single dose via IV infusion.
223893094|NCT06311760|DRUG|Placebo|Placebo will be administered as IV infusion.
223893095|NCT03474991|DRUG|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
223893096|NCT04487145|DRUG|Dihydroartemisinin-piperaquine|It is expected that efavirenz (EFV), lopinavir/ritonavir (LPV/r), and/or dolutegravir (DTG) will alter DP exposure.
223893097|NCT06139042|DIAGNOSTIC_TEST|Blood drawing|The participants had their blood drawn.
224081647|NCT05070377|OTHER|Physical activity|"1. structured physical activity sessions by physical education (school), twice a week, with twenty-minute each lesson;~2. self-monitoring plus goal setting by pedometer (out-of-school), progressive goals to achieve weekly;~3. healthy lifestyle guidance ( parents social support)."
224268960|NCT02754128|BEHAVIORAL|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
223893098|NCT03767855|DRUG|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
223893099|NCT03767855|DRUG|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
223893100|NCT03767855|DRUG|CK-3773274 - Tablets|CK-3773274 formulated as tablets
223893101|NCT06543940|DRUG|Vancomycin|vancomycin dose is 7.5 to 10 mg/kg
224081648|NCT05397990|BEHAVIORAL|Exercise|12 weeks of moderate intensity exercise, three times a week.
224081649|NCT03285997|BIOLOGICAL|GC3110A|A single 0.5mL dose intramuscular injection
224081650|NCT03285997|BIOLOGICAL|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
224081651|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
224081652|NCT01332071|DRUG|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
224081653|NCT02280278|PROCEDURE|Radical surgery|
224081654|NCT02280278|DRUG|Adjuvant chemotherapy|
224081655|NCT02280278|BIOLOGICAL|Cytokine-induced killer cell immunotherapy|
224081656|NCT02945631|RADIATION|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
224081657|NCT02945631|RADIATION|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
224081658|NCT03887754|DRUG|Risperidone|It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
224081659|NCT03887754|DEVICE|hyperbaric oxygen therapy|Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
224081660|NCT03887754|DRUG|Non specific Multivitamin|control group received non specific multivitamins as placebo for 8 months.
224081661|NCT04890210|DIETARY_SUPPLEMENT|Early Diet Group|Initiation of clear fluid diet 1 hour after esophageal variceal ligation
224081662|NCT04890210|DIETARY_SUPPLEMENT|Late Diet Group|Initiation of clear fluid diet 6 hours after esophageal variceal ligation
224081663|NCT04934787|DEVICE|ENMS-BSF assisted gait training|"1. ENMS-BSF will correct the foot-drop and foot inversion during post-stroke walking.~2. Each participant will receive 20 sessions device assisted training, with an intensity of 3-5 sessions/week, 1 hr/session.~3. In each session, a participant will complete the device-assisted walking on flat ground with a natural speed and with the aid of a four-pronged cane."
224081664|NCT01318330|DRUG|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
224081665|NCT01625754|BEHAVIORAL|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
224081666|NCT05010356|DRUG|Insulin|Hyperinsulinemic euglycemic clamp
224081667|NCT00643643|DRUG|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
224081668|NCT00643643|DRUG|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
224081669|NCT00643643|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
223893102|NCT06155279|DRUG|Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab|"The neoadjuvant systemic treatment will be based on three cycles of pembrolizumab 200 mg flat dose in combination with standard doses of cisplatin (75 mg/sm) or carboplatin (AUC 5) and pemetrexed (500 mg/sm) administered intra-venous every 3 weeks.~The surgical intervention of pleurectomy/decortication will be planned to occur within 6 weeks after the completion of neoadjuvant treatment.~The adjuvant systemic treatment will be based on 14 cycles of pembrolizumab 200 mg flat dose administered intra-venous every 3 weeks. Patients should be able to start pembrolizumab following surgery as soon as clinically feasible and within 10 weeks from surgery."
223893103|NCT04322643|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV over 30 minutes every 3 weeks
223893104|NCT04322643|DRUG|Atezolizumab|Atezolizumab 1200 mg IV over 60 minutes every 3 weeks. (if first dose is tolerated, all subsequent infusions may be delivered over 30 minutes)
223893105|NCT04322643|DRUG|Durvalumab|Durvalumab 10 mg/kg IV over 60 minutes every 2 weeks.
223893106|NCT04322643|DRUG|Nivolumab|Nivolumab 480mg IV over 30 minutes every 4 weeks
224081670|NCT00643643|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
224081671|NCT00643643|OTHER|Placebo|Matching placebo oral tablet twice daily for 10 days
224081672|NCT05586633|PROCEDURE|deep paravertebral periforaminal ozone injeciton|"Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
224081673|NCT05586633|PROCEDURE|transforaminal steroid injeciton|"Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up."
224081674|NCT04065529|COMBINATION_PRODUCT|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
224081675|NCT04065529|COMBINATION_PRODUCT|placebo + ORS + Zinc supplementation|placebo + ORS + Zinc supplementation
224081676|NCT00494143|DEVICE|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
224081677|NCT00494143|DEVICE|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
224081678|NCT00494143|DEVICE|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
224081679|NCT01738971|OTHER|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
224081680|NCT01738971|OTHER|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
224081681|NCT01088035|DRUG|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
224081682|NCT02542761|DEVICE|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
224081683|NCT02542761|DEVICE|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
224081684|NCT04057339|BEHAVIORAL|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 8-10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
224081685|NCT04057339|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 8-10-hr eating window.
224081686|NCT01393197|OTHER|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
224081687|NCT03439150|DIAGNOSTIC_TEST|Absolute flow and resistance measurement|Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
224081688|NCT01031446|DRUG|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
224081689|NCT01031446|DRUG|everolimus|Taken daily by mouth.
224081690|NCT01031446|DRUG|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
223893107|NCT04322643|DRUG|Avelumab|Avelumab 800 mg IV over 60 minutes every 2 weeks
223893108|NCT06304324|DRUG|0.9% Sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
223893109|NCT06304324|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
223893110|NCT06304324|DRUG|0.05ug/kg Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05ug/kg dexmedetomidine for the popliteal nerve block
223893111|NCT06288191|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
223893112|NCT02801812|DEVICE|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
223893113|NCT04704999|DRUG|Tafenoquine|Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.
223893114|NCT04704999|DRUG|Chloroquine|Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)
223893115|NCT04704999|DRUG|Artemether 20 mg-Lumefantrine 120 mg|Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.
223893116|NCT06346262|BEHAVIORAL|SMART RM|The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).
223893117|NCT06346262|DRUG|Valtoco Nasal Product|Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.
223893118|NCT03584295|DEVICE|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
223893119|NCT03584295|OTHER|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
224081691|NCT01031446|OTHER|laboratory biomarker analysis|Blood collection
223893120|NCT06007651|DRUG|LY3885125|Administered SC
223893121|NCT06007651|DRUG|Placebo|Administered SC
223893122|NCT01524965|PROCEDURE|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
223893123|NCT01524965|PROCEDURE|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
223893124|NCT01524965|DEVICE|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
223893125|NCT05638620|DRUG|stellate ganglion block with 0.5% bupivacaine|"The stellate ganglion block is being done on both sides of the neck. The stellate ganglion block will be performed on the right side at the first visit. The procedure will be repeated on the left side one week after the first injection.~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. Similar to a phase 1 clinical trial, the main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms. As a general rule, phase 1 studies require a low number of patients, typically 12-20 subjects. There is considerable uncertainty regarding long COVID as a disease state, so data from even small numbers of patients in a well-designed clinical trial will make steps towards reducing that uncertainty."
223893126|NCT03891667|DRUG|Disulfiram|Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
224081692|NCT00993746|DRUG|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
224081693|NCT00993746|DRUG|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
223516427|NCT00870155|DRUG|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
224081694|NCT04100330|BIOLOGICAL|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
224081695|NCT04100330|DRUG|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
224081696|NCT00317525|DEVICE|Spectacle Lenses|
224081697|NCT02447848|DRUG|sufentanil sublingual 30 mcg tablet|
224081698|NCT02109341|DRUG|Paclitaxel bound albumine|
224081699|NCT01505998|DRUG|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
224099184|NCT01617486|BEHAVIORAL|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
224081700|NCT06335615|BEHAVIORAL|Brief Acceptance Intervention|The intervention consist of explanations and exercises about acceptance of stress. The intervention starts with a welcome, after which participants do jumping jacks and then breath through a straw to induce an uncomfortable experience. Next, a Chinese finger trap is used to show the automatic, but often not useful, reaction to avoid stress. Participants then watch a short video that introduces the concept of acceptance, and they do a short, guided meditation. Afterwards, they do the straw exercise again, but this time with instruction to examine and allow uncomfortable experiences. The session ends with a recap and the introduction of the home exercise. Participants install an app that reminds them every hour to do a three-second meditation in which they pay attention to their breathing and body in an accepting way.
224081701|NCT06335615|BEHAVIORAL|Psychoeducation|In the psychoeducation, participants learn about the stress response, mindfulness, and acceptance. For this, they are guided through a vignette about a student who struggles with stress and then develops a more accepting stance towards it. The psychoeducation explains how acceptance can help to deal with stress but does not instruct participants to apply this in their own life.
223516428|NCT01280500|BEHAVIORAL|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
223893127|NCT03595293|DEVICE|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
223893128|NCT03595293|DEVICE|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
223893129|NCT02698462|OTHER|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
223893130|NCT02515955|DRUG|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
223893131|NCT02515955|DRUG|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
223893132|NCT02515955|DRUG|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
223893133|NCT02515955|DRUG|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
223893134|NCT02515955|DRUG|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
223893135|NCT05984069|OTHER|observational prospective data collection|Collection of data from medical records.
223893136|NCT05384509|DIAGNOSTIC_TEST|solid organ malignancies treatment|Major inclusion criteria for this cohort of the study included: (1) age above 20 years; (2) presence of solid organ malignancies treated with immunotherapy, chemotherapy, Target therapy irrespective of the treatment phase; and (3) eligibility for vaccination.
224081702|NCT00054977|DRUG|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
224081703|NCT00054977|DRUG|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
224081704|NCT00004260|BIOLOGICAL|recombinant interleukin-12|
224081705|NCT00004260|BIOLOGICAL|rituximab|
224081706|NCT00114062|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
224081707|NCT01617941|DRUG|BGG492|
224081708|NCT01617941|DRUG|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
224081709|NCT05079997|DEVICE|MAGNETIC RESONANCE IMAGING|s a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body. MRI scanners use strong magnetic fields, magnetic field gradients, and radio waves to generate images of the organs in the body. MRI does not involve X-rays or the use of ionizing radiation, which distinguishes it from CT and PET scans. MRI is a medical application of nuclear magnetic resonance (NMR) which can also be used for imaging in other NMR applications, such as NMR spectroscopy.
224081710|NCT03914976|PROCEDURE|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
224081711|NCT03509519|OTHER|NMES-Millicurrent|Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.
224081712|NCT05325320|BEHAVIORAL|SMI/SIA Stigma Reduction Intervention|Online course designed to reduce stigma behaviors towards serious mental illness and suicide ideation and attempt among medical students. It aims to improve medical students' healthcare delivery skills.
223516429|NCT01280500|OTHER|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
223516430|NCT01280500|OTHER|usual care|No EMR
223516431|NCT01280500|OTHER|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
223516432|NCT01280500|OTHER|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
224081713|NCT05325320|OTHER|Disaster Preparedness Course|Online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
224081714|NCT01080885|BEHAVIORAL|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
224081715|NCT01080885|BEHAVIORAL|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
224081716|NCT05982587|OTHER|Survivorship passport (SurPass) delivery|"The Survivorship Passport (SurPass) is a digital tool developed thanks to several EU projects to help Childhood Cancer Survivors (CCS), their families and health care providers (HCPs) in the follow-up process after completion of anticancer treatment. It comprises two main components: Treatment Summary including demographic, diagnosis and treatment data and personalized Survivorship Care Plan providing individual follow-up care recommendations The SurPass assists both CCS and HCPs to improve Long-Term Follow-Up care, in a partnership, supporting CCS empowerment and satisfaction with care, as well as shared decision-making by CCS and HCPs.~The aim of the PCSP implementation study is to evaluate feasibility and outcomes (personal and economic) of implementing the SurPass v2.0 in six clinics located in Austria, Belgium, Germany, Italy, Lithuania and Spain by using interoperability procedures according to Health Level 7- Fast Healthcare Interoperability Resource (HL7-FHIR) standards."
224081717|NCT05081284|DEVICE|Volume-stable collagen matrix Geistlich Fibro-Gide®|"After tooth extraction and implant insertion the Test group will receive a soft tissue augmentation on the buccal side oh the implant. an envelop flap will be raised and a volume-stable collagen graft will be stabilized with sutures.~Control group will not receive soft tissue augmentation."
224081718|NCT03088865|DIAGNOSTIC_TEST|aspirating first blood volume into a regular blood collection tube|order of blood drawing
224081719|NCT02833246|OTHER|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
224081720|NCT02833246|OTHER|usual care|
224081721|NCT06473038|OTHER|Reduction in Salt and Sugar|150 participants who are grouped under interventions, their data will be collected according to the alterations of sodium and sugar intake and then compared with the control group. Instruments include urine analysis, providing two spot urine samples - first-morning void and last void in the evening before leaving campus, at three-time points - at the start of the study, after 3 months, and after 6 months. This will yield a total of 300 × 2 × 3 = 1800 samples. Urine electrolytes (sodium, potassium, chloride) and creatinine will be measured using the potentiometry method (Alinity Abbott) at the laboratory department of Sunway Medical Centre, Bandar Sunway.
224081722|NCT06473038|DEVICE|The potentiometer|The potentiometer is utilized for the quantitative analysis of electrolytes present in urine samples. The potentiometer used for urine electrolytes analysis is a specialized device equipped with electrodes and sensors designed to detect and measure the concentration of specific electrolytes in urine samples. It employs potentiometric principles to generate electrical signals proportional to the concentration of ions present in the sample.
224081723|NCT06473038|DEVICE|Dry Ashing Method Followed by Flame Atomic Absorption Spectrometry (FAAS)|"Dry ashing method involves heating the food samples in a controlled environment to remove organic matter and moisture, leaving behind inorganic residues (ashes) containing the salts and minerals present in the food. Flame Atomic Absorption Spectrometryis utilized to measure the levels of sodium and potassium (components of salt) as well as carbon and hydrogen (components of sugar) in the ashed food samples.~By determining the concentrations of these elements, the salt and sugar content of the food samples can be quantified accurately."
224081724|NCT01967290|DEVICE|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
224081725|NCT01967290|DEVICE|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
224081726|NCT01019785|DIETARY_SUPPLEMENT|Ergocalciferol|100 000 U drops is given once
223516433|NCT01390584|DRUG|Doxorubicin|IV
223516434|NCT01390584|DRUG|Bleomycin|IV
223516435|NCT01390584|DRUG|Vinblastine|IV
223516436|NCT01390584|DIAGNOSTIC_TEST|PET|fludeoxyglucose F 18 Imaging exam
223516437|NCT01390584|RADIATION|INRT|selective external radiation therapy
223516438|NCT01390584|DRUG|Dacarbazine|IV
223516439|NCT01390584|DRUG|Etoposide|IV
223893137|NCT04733950|OTHER|Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm)|"Description:~3-interval, 3-alternative forced choice amplitude modulation detection task using a target sinusoidal carrier and a spectrally distant, interfering (distracting), sinusoidal carrier that may or not be modulated at the same rate as the target."
223893138|NCT04733950|OTHER|Measurement of the pupil diameter for the evaluation of listening effort during speech perception|Pupil diameter is recorded using an eye-tracker device (Tobii Pro TX300) while the subject performs a 16-alternative consonant identification task both in silence and in the presence of interfering speech.
223893139|NCT05937321|BEHAVIORAL|Share plus intervention|"Participants will receive the Share plus intervention:~* Set up Follow app~* Start Share plus intervention~* Communication and problem-solving strategies~* Detailed action plan including glucose targets~* Review communication and problems~* New communication content~* Revise action plan as needed for communication and problem-solving hypo- and hyperglycemia,~* Dyadic glucose pattern management training using Clarity, set automatic Clarity downloads~* Dyad set goals for regular times to discuss glucose trends and problem-solving~* Dyadic review of glucose targets after an in-depth analysis of CGM data and dyadic treatment strategies to improve glucose TIR"
223893140|NCT05937321|BEHAVIORAL|Control group|Diabetes self-management education materials
223893141|NCT05606705|DIETARY_SUPPLEMENT|Baked Milk|Participants to regularly eat a baked milk muffin for 6 weeks
223893142|NCT04145466|BEHAVIORAL|High-fat diet|"The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
223893143|NCT04145466|BEHAVIORAL|High-carbohydrate diet|"The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
224081727|NCT01019785|DIETARY_SUPPLEMENT|Ergocalciferol|500 U drops given once
224081728|NCT02843620|DIETARY_SUPPLEMENT|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
224081729|NCT02843620|OTHER|Placebo|Excipients only
224081730|NCT06264115|PROCEDURE|Laparoscopic Cholecystectomy|Using Three Ports or Four Ports for Laparoscopic Cholecystectomy
224081731|NCT03575715|DEVICE|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
224081732|NCT02793037|DEVICE|Zirconia resin bonded bridge|
224081733|NCT05673941|OTHER|Creative physical training|The intervention will be performed as a group activity twice a week during a 12-week period. Each group will include 4-6 participants under the guidance of two instructors, and a related party if needed or wanted from the participant. The exercise is partly accompanied with calm music and recorded nature sounds and partly made in silence listening to one's own bodily rhythm. The exercise consists of tasks related to cardio and strength training, balance, conscious breathing, body awareness, mental imagery (nature visualizations), flexibility, emotional expression, and movement anticipation together with the facilitator and fellow participants. All the tasks are practiced during a flow of 45- to 60-minute exercise without any major breaks. Complexity and physical intensity of the tasks will gradually increase over the 12-week intervention period.
224081734|NCT05441774|DEVICE|Active transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the active condition, stimulator electrodes deliver a mild electrical current to the tragus. Stimulation parameters: stimulation of left tragus via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
224081735|NCT05441774|BEHAVIORAL|Active self-compassion imagery|Self-compassion imagery is both a meditative technique and a component of compassion-focused cognitive therapy. Here, self-compassionate imagery is delivered as standardized audio-recorded instructions.
224081736|NCT05441774|DEVICE|Sham transcutaneous vagus nerve stimulation|TVNS is a non-invasive counterpart to surgical methods for stimulating the vagus. For the sham condition, stimulator electrodes deliver a mild electrical current to the earlobe. Stimulation parameters: stimulation of left earlobe via two gold-plated electrodes, attached by ear-clip. Waveform: rectangular, frequency: 20 Hz, pulse width: 0.2 ms, individually adjusted intensity based on participant's perceptual threshold.
224081737|NCT05441774|BEHAVIORAL|Sham mental imagery|Draw-a-face-in-imagination is the sham/ control imagery condition. Here, control imagery instructions are delivered as a standardized audio-recording, well-matched to self-compassion imagery for number of words, complexity of language, and duration of the audio instructions.
224081738|NCT05060757|DIAGNOSTIC_TEST|biotax|patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample
224081739|NCT00574574|DIETARY_SUPPLEMENT|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
224081740|NCT02286531|DRUG|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
224081741|NCT04405960|DRUG|Alfacalcidol 1 MCG Oral Capsule|The subjects in the intervention group were given 1 µg oral capsule alphacalcidol once daily Subjects in the control group were given placebo once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
224081742|NCT04405960|DRUG|Sugar pill|The subjects in the control group were given placebo containing simple sugar oral capsule once daily with similar capsule shape and color to the capsule given to the intervention group. The process of alphacalcidol and placebo encapsulation were carried out by pharmacists in the pharmacy depot under the supervision of researchers and CRO Equilab. Alphacalcidol and placebo were put into plastic pots containing 30 capsules for every 4 weeks for each subject. The pot had an etiquette written explaining how to consume the drug (after breakfast between 7 - 10 a.m.). The drugs' packaging and code numbering were carried out by CRO Equilab to ensure a double-blind procedure. As a control, each subject was equipped with a monitoring card. Alphacalcidol and placebo were given for 12 weeks without interruption. Monitoring of compliance and side effects was performed by physicians every 2 weeks.
224081743|NCT06176937|DRUG|Hyaluronic acid|Alveolar ridge preservation by atraumatic tooth extraction and socket curettage then application hyaluronic acid gel after extraction and covering the socket by collagen membrane.
224081744|NCT06176937|OTHER|empty socket|Alveolar ridge preservation by atraumatic tooth socket without application any drug but just covering the socket by collagen membrane.
224081745|NCT05860348|DEVICE|Barostim™ System|Implantation of the Barostim™ System
224081746|NCT00738478|DEVICE|nasogastric tube|insertion of nasogastric tube for 2 days after operation
224081747|NCT00738478|DEVICE|without nasogastric tube|without nasogastric tube after operation
224081748|NCT00396175|DRUG|MK0906, finasteride / Duration of Treatment : 48 Weeks|
224081749|NCT00396175|DRUG|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
224081750|NCT05352581|DIAGNOSTIC_TEST|BD Veritor At-Home|BD Veritor At-Home rapid self testing
224081751|NCT05352581|DIAGNOSTIC_TEST|BD Veritor Professional|BD Veritor Professional rapid test
224081752|NCT00002508|DRUG|carboplatin|
224081753|NCT00002508|DRUG|etoposide|
224081754|NCT00002508|PROCEDURE|autologous bone marrow transplantation|
224081755|NCT00002508|PROCEDURE|peripheral blood stem cell transplantation|
224081756|NCT02486315|DEVICE|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
224081757|NCT03885128|DEVICE|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
224081758|NCT03885128|DEVICE|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
224081759|NCT03344003|DRUG|Wilate or Nuwiq|Wilate or Nuwiq administered via intravenous injection
224081760|NCT06818396|OTHER|US-guided fascia iliaca compartment block (FICB) and spinal anesthesia|US-guided fascia iliaca compartment block (FICB) and spinal anesthesia
224081761|NCT06818396|DRUG|Intrathecal nalbuphine and spinal anesthesia|intrathecal nalbuphine and spinal anesthesia
223516440|NCT01390584|DRUG|Cyclophosphamide|May be given orally, IV push, or by IV infusion
223516441|NCT01390584|DRUG|Vincristine|IV
223516442|NCT01390584|DRUG|Procarbazine|PO
223516443|NCT01390584|DRUG|Prednisone|PO
223534830|NCT02268643|OTHER|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
224081762|NCT06818396|OTHER|Spinal anesthesia|Spinal anesthesia
224081763|NCT02161679|DRUG|IMMU-132 infusion is administered to participants in one arm for the study|
224081764|NCT02161679|DRUG|IMMU-132 plus Carboplatin infusion|
224081765|NCT01493336|DRUG|capecitabine RTD|single oral dose
224081766|NCT01493336|DRUG|capecitabine [Xeloda]|single oral dose
224081767|NCT01493336|DRUG|capecitabine [Xeloda]|standard treatment
224081768|NCT06222151|OTHER|Intervention 1: Mobilization during hospitalization|Surgical ICU Optimal Mobilization Score (SOMS) will be used to initiate early mobilization. SOMS consists of five levels of mobilization reaching from no activity to ambulation. Thirty minutes after PACU-arrival, the patient will be asked to do lower leg exercises. If this is possible, the patient will advance to the next level of mobilization. If not possible, level zero is recorded and the patient rests for another 30 minutes before attempting level one again. This continues until the patient succeeds with level four. Safety criteria for advancing to the next level of mobilization are based on criteria for mobilizing patients in the ICU. The intervention group will receive standard care with additional supervised mobilization while hospitalized. This mobilization consist of walking 1000 steps on postoperative day (POD) 0 and 500 steps on POD1 before discharge. Step counts are measured using pedometers.
224081769|NCT06222151|OTHER|Intervention 2: Mobilization the first 4 postoperative weeks|Intervention 2 will start the first weekday after discharge and continue for 4 weeks. Four supervised physical activity sessions and 8 sessions using telerehabilitation. The activities are low-intensity exercises (walking and lightly strength training using resistance bands) with progressed intensity throughout the weeks. The exercises will be individually progressed to meet the participant's level of activity, as it is important the participants benefit as much as possible from the intervention. The participants will receive information about different possibilities for leisure activities, for motivation to continue physical activity after the first 4 weeks.
224268961|NCT02754128|BEHAVIORAL|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
224081770|NCT06222151|OTHER|Control group|"The control group receives standard care.~Patients are mobilized to sit at the bedside before being transferred to the surgical ward. However, it is not used as prophylactic pain management nor is there a structured evidence based protocol with regard to mobilization. The control group will also be equipped with pedometers. They are encouraged to mobilize, and they receive a form in which they can write down mobilization for each hour. There is no planned supervised mobilization. As patients in the control group are assigned to standard care, they will not receive any supervised physical activity after discharge."
223893144|NCT01623492|OTHER|Subjects with diagnosis of Eisenmenger Syndrome|"1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine~2. Contraception counseling, and recommendations regarding avoidance of pregnancy~3. Documentation and prescription of the specific medications:~   1. Oxygen~  2. Diuretic~  3. ASA, Anticoagulant~  4. CCB, BB, ACEI, ARB~  5. Iron Supplementation~  6. Allopurinol~  7. PAH specific therapy"
223893145|NCT05226598|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
223893146|NCT05226598|DRUG|Carboplatin|Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
224081771|NCT04431830|BEHAVIORAL|Meaning-Centered Pain Coping Skills Training|The goal of this intervention is to help participants manage pain so that they can engage with what gives them a sense of meaning, purpose, and significance in life.
224081772|NCT05455047|DIAGNOSTIC_TEST|PET-CT at 18F-FDG|PET-CT at 18f6FDG in nuclear medicine departement of Nancy's hospital
224081773|NCT01678183|BEHAVIORAL|Monthly Financial Incentive|A cash payment.
224081774|NCT01678183|BEHAVIORAL|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
224081775|NCT02456428|DRUG|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224081776|NCT02456428|DRUG|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224081777|NCT02456428|DRUG|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
224081778|NCT02456428|DRUG|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224081779|NCT02456428|DRUG|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224081780|NCT02456428|DRUG|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
223516444|NCT06438952|PROCEDURE|Transforaminal steroid injection combined with lumbar sympathetic blockade|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance Lumbar sympathetic blockade will be made with 5 ml 0.5% bupivacaine + 6 mg dexamethason + 10 ml NaCl
223893147|NCT05226598|DRUG|Cisplatin|Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
223893148|NCT05226598|DRUG|Paclitaxel|Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
223893149|NCT05226598|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations
223893150|NCT05226598|DRUG|Pemetrexed|Pemetrexed 500 mg/vial administered as IV infusion Q3W until progression, intolerable adverse event (AE), or participant or physician decision
223893151|NCT05226598|BIOLOGICAL|Pembrolizumab|Pembrolizumab 25 mg/mL administered as IV infusion Q3W for up to 35 administrations
223893152|NCT05980806|DRUG|Selinexor 60 mg|Participants will receive selinexor 60 mg oral tablets QW.
224081781|NCT02456428|DRUG|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
223893153|NCT05980806|DRUG|Selinexor 40 mg|Participants will receive selinexor 40 mg oral tablets QW.
223893154|NCT05980806|DRUG|Ruxolitinib|Participants will receive ruxolitinib 5 mg or 10 mg twice daily.
223893155|NCT05980806|DRUG|Pacritinib|Participants will receive pacritinib 200 mg twice daily.
223893156|NCT05980806|DRUG|Momelotinib|Participants will receive momelotinib 200 mg once daily.
223893157|NCT03563144|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
223893158|NCT03563144|DRUG|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
223893159|NCT03563144|DRUG|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
223893160|NCT03563144|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223893161|NCT03563144|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223893162|NCT03563144|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
223893163|NCT03563144|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223893164|NCT03563144|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
223893165|NCT03563144|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
223893166|NCT03563144|BIOLOGICAL|GI-6207|CEA yeast vaccine
223893167|NCT03563144|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223893168|NCT03563144|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\]
223893169|NCT03563144|DRUG|Avelumab|Avelumab
223893170|NCT03563144|DRUG|Bevacizumab|Bevacizumab
223893171|NCT03563144|DRUG|Capecitabine|Capecitabine
224268962|NCT05534048|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
223893172|NCT03563144|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223893173|NCT03563144|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
224081782|NCT02456428|DRUG|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
223893174|NCT03563144|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
223893175|NCT03563144|DRUG|Oxaliplatin|Oxaliplatin
224081783|NCT06183268|RADIATION|Spot Delete|"The treatments plans will utilize the scripted spot delete method to remove spots from the skin rind. To ensure all relevant skin spots are removed, the SkinSpots structure will be a 0.5 cm rind extending inward from the skin contour within 5 cm of the CTV. Spots will be removed from this structure and optimization will continue. Optimization objectives will be utilized to spare the skin rind structure during treatment planning, in addition to deleting spots."
224081784|NCT02065453|DEVICE|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
224081785|NCT02065453|DEVICE|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
224081786|NCT02490293|DRUG|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
224081787|NCT02490293|DRUG|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
224081788|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using closing system|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the SDD group prior to the procedure, the femoral access will be closed with a closure system. Ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
224081789|NCT06598280|PROCEDURE|Atrial Fibrillation with femoral closure using figure-of-eight stitch|The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the ONS group prior to the procedure, the femoral access will be closed with a figure-of-eight suture. The ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
224081790|NCT04899297|OTHER|Questionnaire|All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
224081791|NCT03655418|OTHER|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
223893176|NCT06071312|BIOLOGICAL|single FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through a single infusion of FMT
223893177|NCT06071312|BIOLOGICAL|sequential FMT|This intervention is represented by the administration, in the recipients' gut, of healthy donor microbiota through multiple infusions of FMT (sequential approach)
223893178|NCT03984643|DEVICE|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
223893179|NCT00534469|BIOLOGICAL|aldesleukin|
223893180|NCT00534469|BIOLOGICAL|filgrastim|
223893181|NCT00534469|DRUG|busulfan|
223893182|NCT00534469|DRUG|cytarabine|
223893183|NCT00534469|DRUG|etoposide|
223893184|NCT00534469|DRUG|idarubicin|
223893185|NCT00534469|PROCEDURE|autologous hematopoietic stem cell transplantation|
223893186|NCT00534469|PROCEDURE|bone marrow transplantation|
223893187|NCT00534469|PROCEDURE|peripheral blood stem cell transplantation|
223893188|NCT00534469|RADIATION|total-body irradiation|
223893189|NCT04622943|BEHAVIORAL|firearms safety|interactive and engaging website with videos and educational games to teach children firearms, hunting and shooting safety
223893190|NCT04622943|BEHAVIORAL|nutrition|interactive and engaging website with videos and educational games to teach children about nutrition and wellbeing
224081792|NCT05876052|DEVICE|Hypothermic oxygenated Perfusion - HOPE|HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
224081793|NCT06706661|OTHER|Nutritional treatment|At the day of discharge the intervention group (IG) receives a package containing foods and drinks covering dietary requirements for the next 24 h. Further, a goodie-bag containing samples of protein-rich milk-based drinks is provided. At day 4 after discharge, the IG receives dietetic counselling including a recommendation of daily exercise, and an individual nutrition plan. Information regarding recommendations of nutritional therapy after discharge is systematically and electronically communicated to the municipality. The dietician performes telephone follow-ups on day 30 and a home visit at 12 weeks
224081794|NCT06467773|RADIATION|Radiation: PET-MRI with [18F]-DPA-714|Radiation: PET-MRI with \[18F\]-DPA-714
224081795|NCT01020864|DRUG|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
224081796|NCT01020864|DRUG|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
224081797|NCT01020864|DRUG|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
223893191|NCT05717907|DEVICE|suction catheter|a suction catheter will be first inserted through the ETT so that about 10 cm of the catheter was protruding from the distal end of the tube. The tip of the catheter is then inserted through the selected nostril until it passes to the pharynx. If resistance is felt to the passage of catheter, the other nostril will be tried. The nostril with less resistance to the catheter passage will be chosen for the completion of the procedure. The Endotracheal tube is then advance over the catheter through the nasal passage while holding the catheter proximal to the tube to prevent its advancement with the tube. After the tube tip reach to the pharynx, the suction catheter is withdrawn and tracheal intubation will be completed.
224081798|NCT06883981|BEHAVIORAL|Free and Cued Recall Memory. Temporal Sequence and Spatial Memory|Memory for real-world episodic experiences will be tested in the laboratory first with free recall (spoken narration of their recollections from each environment) and then with cued recall, in which participants will be cued with an event image from the CAPTURE app, a map location, or a relative time and asked to recall the other two non-cued pieces of episodic information (event, place, or time). Because we will know the 'ground truth', the cued recall test will allow us to measure how accurately the participant is able to remember key details of each episode. We will also assess temporal order memory by asking participants to arrange 1st person images in the order in which they occurred, and we will assess spatial memory by asking them to place each image on a schematic map of the venue.
224081799|NCT06715527|DIETARY_SUPPLEMENT|Myo-Inositol and D-Chiro-Inositol (40:1)|Myo-inositol and D-chiro-inositol (40:1 ratio), 2 grams (twice a day) for three months
224081800|NCT06715527|DIETARY_SUPPLEMENT|Myo-Inositol and D-Chiro-Inositol (3.6:1)|Myo-inositol and D-chiro-inositol (3.6:1 ratio), 1.4 grams (once daily) for three months
224081801|NCT06733532|DIETARY_SUPPLEMENT|Berry Propel Fitness Water|Subject will consume 1 Liter of commercially available Berry Propel Fitness Water at a rate of 250 milliliters per 7.5 minutes
224081802|NCT06733532|DIETARY_SUPPLEMENT|Essentia Hydroboost Raspberry Pomegranate|Subject will consume 1 Liter of commercially available Essentia Hydroboost Raspberry Pomegranate at a rate of 250 milliliters per 7.5 minutes
224081803|NCT06733532|DIETARY_SUPPLEMENT|Smart Water|Subject will consume 1 Liter of commercially available Smart Water at a rate of 250 milliliters per 7.5 minutes.
224081804|NCT06729125|DEVICE|transcranial photobiomodulation|Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).
224081805|NCT06729125|OTHER|exercises training|balance exercises and others
224081806|NCT06893679|OTHER|Qigong sensory training|Participants will be received 15 mints massage therapy 2 times in a day and 5 days a week for 8 weeks. Before and after 8 week of intervention, Assessment of sensory modulation scale (ASMS) will be used to check the sensory modulation level and strength and difficulties questionnaire (SDQ) will be used to check the behavior. Data will be collected from Nishtar Hospital Multan. The pre and post intervention assessments will be done.
224081807|NCT06883357|BEHAVIORAL|Graded repetitive arm supplementary program (GRASP)|Graded repetitive arm supplementary program (GRASP) is a self administrated, home-based rehabilitation program. home-based GRASP program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. Participants in experimental group will receive Home GRASP program which will be executed 1hour at home per day. In addition, Participants will be requested to return hospital for follow-up and adjusting the training program in group discussion 3 times per week, lasting 4-6 weeks, and totally 12-18 sessions.
224081808|NCT03631706|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
224081809|NCT03631706|DRUG|Pembrolizumab|Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
223893192|NCT05571878|DRUG|Humalog|All participants will be given an intranasal insulin challenge (80 IU) to assess brain insulin signalling via MRI based assay
223516445|NCT06438952|PROCEDURE|Transforaminal steroid injection only|Transforaminal steroid injection will be made with 2 mg dexamethason + 20 mg lidocaine + 5mg bupivacaine + 5 mcg fentanyl + 100mg magnesium under US-guidance
223516446|NCT00121953|DRUG|Rosiglitazone|
223893193|NCT05571878|DRUG|Saline nasal spray|All participants will be given an intranasal saline placebo (0.8 mL) in order to establish baseline brain insulin signalling via MRI based assay
223893194|NCT05856357|DRUG|Sulfadoxine pyrimethamine|Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
223893195|NCT03952351|RADIATION|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
223893196|NCT05076708|OTHER|IQOS|All participants switch from cigarette smoking to IQOS use for a 14-day phase.
224081810|NCT06915532|BEHAVIORAL|Pain Neurophysiology Education|"The program used for PNE was based on a brochure written in the Tunisian dialect with simple, patient-accessible language. The brochure includes different sections: definition of pain, origin of pain, types of pain, components of pain, role of nervous system in pain modulation and pain management. Thus, all main concepts of the neurophysiology of pain were explained and discussed using visual presentation.~At the end of the sessions, a test was provided to the patient to assess their understanding of the brochure's content.~At the follow-up session a month later, the main ideas taught were reinforced and any questions were answered."
224081811|NCT06915532|PROCEDURE|conventional rehabilitation|"Conventional reeducation focused the first week on analgesic approach including:~* Education and lifestyle: Emphasizing weight management, autonomy in chronic low back pain management, and encouragement of physical activity.~* Massage and electrotherapy: To alleviate pain, enhance circulation, and relax muscles.~* Pelvic and lumbar movement awareness: Exercises focused on improving the control of pelvic movements.~* Breathing exercises: Breathing techniques to reduce tension and improve awareness.~Then in week 2 and beyond, physiotherapist continued analgesic work and physical training:~* Joint mobility and muscle flexibility: Exercises target mobility improvement, muscle strengthening, and stretching, with emphasis on posture control and lumbar mobility.~* Muscle strengthening: Focused on abdominal and spinal muscles, promoting spinal stability and improving trunk control.~* Proprioceptive rehabilitation: Enhancing lumbar-pelvic vigilance to stabilize the spine and prevent further ve"
224081812|NCT06916988|BEHAVIORAL|Sports Stars Brazil|Modified sports interventions promote physical activity participation in individuals with ASD by addressing intrinsic factors, however they do not address contextual barriers, such as environmental and interpersonal factors, which also influence participation. Factors like bullying, parents' perceptions often prioritizing therapy intervention, and challenges faced in community programs (as the lack of adaptations in existing programs to meet their needs) are some of these obstacles, which reduce adherence to physical activities (Jachyra et al., 2021). Therefore, it may be necessary to combine interventions targeting intrinsic factors, such as Sports Stars, with those that address the extrinsic contextual factors impacting the participation of adolescents with ASD in their community.
224081813|NCT06916988|BEHAVIORAL|context-centered therapy|"The complimentary approach of combining intrinsic (Sports Stars) and extrinsic (PREP) interventions aligns with the relationships between the person, their environment, and the quantity and quality of their participation proposed in the family of participation related constructs (Imms et al., 2017). By recognizing that participation depends on both the individual's abilities and the contexts and conditions in which it occurs, professionals can adopt a more holistic and tailored approach to individual needs (Imms et al., 2015)."
223893197|NCT06511752|BEHAVIORAL|Psychosocial educational, support group and implementation of strategies|Psychosocial educational, support group and implementation of strategies
224081814|NCT06917170|BEHAVIORAL|Structured Music Therapy Program|"Description:~Content: Participants engage in passive music therapy sessions where they listen to pre-selected music with smooth rhythms and harmonies (e.g., classical, ambient, or instrumental tracks). The music is chosen to align with evidence-based criteria for promoting relaxation and emotional regulation.~Frequency: Daily (1 session/day).~Duration: 1 hour per session, for a total of 14 sessions over 2 weeks.~Setting: Conducted in a quiet, controlled environment to minimize external distractions.~Goal: To reduce symptoms of psychological distress (depression, anxiety, stress) and enhance self-efficacy through auditory stimulation and emotional engagement."
224081815|NCT06638463|BEHAVIORAL|My Health Coach app|My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
224081816|NCT07076238|BIOLOGICAL|Bacteriophage Treatment|Participants who have a positive match for their NTM isolate will start on mycobacteriophage treatment per prescribed treatment regimen.
224081817|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, low dose|injection
224081818|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, medium dose|injection
224081819|NCT07078994|BIOLOGICAL|anti-TL1A monoclonal antibody, high dose|injection
224081820|NCT07078994|OTHER|Placebo|injection
224081821|NCT05442853|DEVICE|Continuous glucose monitoring|Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.
224081822|NCT05442853|DEVICE|Point of care glucose monitoring|Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.
224081823|NCT06814119|DRUG|MK-1084|Oral tablet
224081824|NCT06902896|BIOLOGICAL|FAP immunosuppressive CAR-DC|Each subject receive FAP immunosuppressive CAR-DC by intravenous infusion
224081825|NCT05007353|BEHAVIORAL|Structured Lifestyle Intervention|Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
223516447|NCT05581888|DEVICE|trifocal intraocular lens|Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
223516448|NCT01399086|DRUG|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
223516449|NCT01720602|DRUG|vorinostat|Given PO
223893198|NCT01544803|BEHAVIORAL|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
223893199|NCT01544803|BEHAVIORAL|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
224081826|NCT05007353|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
223893200|NCT03159702|DRUG|Evomela|140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
223516450|NCT01720602|DRUG|anastrozole|Given PO
223893201|NCT03159702|DRUG|Fludarabine|40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
224081827|NCT04715555|DEVICE|Electrocardiogram monitoring|Continuous monitoring using a wearable, single-lead electrocardiography (ECG) device affixed to the chest.
224081828|NCT04715555|DEVICE|Electrocardiogram recording|Intermittent electrocardiogram (ECG) recordings taken using a wearable device on the wrist.
224081829|NCT04715555|DEVICE|Photoplethysmogram monitoring|Photoplethysmogram monitoring using a wearable device on the wrist.
223893202|NCT03159702|RADIATION|Total Body Irradiation|200 cGy on Day: -1
223893203|NCT03395132|DRUG|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
223516451|NCT01720602|DRUG|letrozole|Given PO
223893204|NCT03395132|DRUG|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
223893205|NCT03395132|DRUG|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
223893206|NCT03395132|DRUG|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
223893207|NCT02524717|DRUG|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
223893208|NCT05759013|DEVICE|Breath synchronized abdominal FES|Active abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), for a minimum of five days per week, for 28 days or ICU discharge, whichever comes first.
223516452|NCT01720602|DRUG|exemestane|Given PO
223516453|NCT01720602|PROCEDURE|positron emission tomography|Correlative studies
223893209|NCT05759013|DEVICE|Sham breath synchronized abdominal FES|Sham abdominal stimulation will be applied for 30 minutes twice per day (minimum of four hours between stimulation sessions), for a minimum of five days per week, for 28 days or ICU discharge, whichever comes first.
223893210|NCT03790787|DRUG|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
224081830|NCT04715555|OTHER|Feedback questionnaire|A questionnaire to collect feedback on participants' experiences of wearing the devices.
224081831|NCT06886802|PROCEDURE|Posterior Uniportal Endoscopic Cervical Decompression|Posterior Uniportal Endoscopic Cervical Decompression
223516454|NCT01720602|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
223516455|NCT01720602|RADIATION|fludeoxyglucose F 18|Correlative studies
223516456|NCT01720602|OTHER|laboratory biomarker analysis|Correlative studies
223516457|NCT01023464|OTHER|FID114657|artificial tears
223516458|NCT01023464|OTHER|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
223516459|NCT00452400|DRUG|BI 1744CL|
223516460|NCT02423720|BEHAVIORAL|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
223516461|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
223516462|NCT01943825|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
223516463|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
223893211|NCT03790787|DRUG|Dorzagliatin|Glucokinase activator currently under development
223893212|NCT01383512|DEVICE|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
223893213|NCT01383512|OTHER|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
224081832|NCT05951075|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm
224081833|NCT06357832|DEVICE|Brainsway Deep TMS System|The BrainsWay Deep TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency.
224081834|NCT05448326|OTHER|Questionnaire to assess expectations of a diagnosis|Duration 45 minutes
223516464|NCT01943825|BIOLOGICAL|Japanese Encephalitis Vaccine|0.5 mL, Intramuscular
223516465|NCT02781701|DEVICE|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
223516466|NCT02767245|DRUG|Thiamine|Thiamine IV 100 mg/day
223516467|NCT00029900|DRUG|ADI PEG|
223516468|NCT05004168|OTHER|Day Gel-0120|Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
223516469|NCT05004168|OTHER|P5 Reference Standard (SPF 35 reference)|The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
223893214|NCT04869670|PROCEDURE|Gastric peroral endoscopic myotomy.|Under propofol anesthesia, EndoFLIP will be used to assess pyloric diameter and distensibility, prior to and after G-POEM, performed by an endoscopist skilled in this technique. After the procedure, the patient will be observed in the hospital for 2 days. Patients will undergo an upper GI series the next day to rule out perforation. If the patient develops a complication from the procedure, he or she will be managed per standard clinical practice by the treating (unblinded) endoscopist.
223893215|NCT04869670|PROCEDURE|Sham Gastric peroral endoscopic myotomy.|Patients assigned to the sham procedure will be treated identically as above, except for the performance of the G-POEM. Endoscopy and EndoFLIP will be performed and sedation will be stopped when the upper endoscopy is completed. Since sham endoscopy is expected to take less time than G-POEM, the patient should remain in the endoscopy procedure room for a minimum of 30 minutes (including the time required to complete the upper endoscopy). After the procedure, the patient will be observed in the hospital for 2 days. All patients will undergo an upper GI series radiographic examination the next day to rule out perforation in order to maintain study blind.
223893216|NCT05517850|BEHAVIORAL|Therapist-guided cognitive behavioral therapy administered online|This intervention consists of 10 modules of education and interventions and lasts 12 weeks. An introduction provides information about CBT and AD. Step by step, the participants are introduced to the proposed active treatment components: mindfulness training, and exposure with response prevention. Through this whole process, the participant is guided by a therapist. The therapist may be contacted through a secure internet platform at any time and responds within 48 hours. Participants reads the education material, construct exercises to perform, describes their progress in homework assignments, and receives feedback from their therapist.
223893217|NCT05517850|BEHAVIORAL|Self-guided digital intervention based on cognitive behavioral therapy|Participants will access a digital platform, read information, and perform exercises in their everyday life. The main treatment components are mindfulness and exposure with response prevention, with a specific focus on itch. Participants will be able to practice mindfulness with the help of instructions and examples. Participants will receive detailed instructions and guidance, and get to choose exposure exercises from a long list of examples. Participants will also be free to create their own relevant exposure situations within the intervention. Digital self-care consists of 8 modules. The only active interventions, mindfulness and exposure are introduced week 1 and 2, respectively. From week 3-7, no new interventions are introduced and participants are advised to continue practicing the interventions, but there is a new theme of education each week, to act as inspiration for exercises. The last 4 weeks, the participant is merely advised to continue practice.
223893218|NCT04063267|OTHER|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
223893219|NCT04063267|OTHER|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
223893220|NCT05774548|OTHER|In-depth interviews (IDI)|In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
223893221|NCT05774548|OTHER|Focus group discussion (FGD)|Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
223893222|NCT03695276|BEHAVIORAL|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
223893223|NCT03695276|BEHAVIORAL|Usual care|The standard of care, which usually means management within primary care.
223893224|NCT04644185|DRUG|SCTA01|SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
223893225|NCT04644185|OTHER|Placebo|all SCTA01 excipients without active component+best supportive care
223893226|NCT03964727|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223893227|NCT05676489|DRUG|[F-18]MeFAMP PET|Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
223893228|NCT05429125|DEVICE|Endotracheal Tube with Stylet|Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
223893229|NCT05429125|DEVICE|Flexible Tip Bougie|Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
223893230|NCT04336644|DEVICE|BodyGuardian Mini Plus|The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.
223893231|NCT05590312|OTHER|general anesthesia|All patients will undergo general anesthesia. Group D will receive fresh gas flow of 1 l/min and Group Y will receive fresh gas flow of 4 l/min.
223893232|NCT03269136|DRUG|PF-06863135 monotherapy IV or SC|PF-06863135 will be administered intravenously or subcutaneously.
223893233|NCT03269136|DRUG|PF-06863135 + dexamethasone|PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.
224081835|NCT05448326|OTHER|Questionnaire to assess understanding of previously reported results and expectations of a diagnosis|Duration 30 minutes
224081836|NCT05448326|BIOLOGICAL|Blood sample +/- skin biopsy|8 ml of blood biopsy: size 3 to 5 mm
224081837|NCT02805205|DRUG|PEG-rhG-CSF|
223516470|NCT01714388|DRUG|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
223534831|NCT05786287|BIOLOGICAL|Conditioned Medium (CM)|Conditioned Medium (CM) injected by peribulbar
223516471|NCT06254690|DRUG|Pyrotinib dose escalation|Pyrotinib: 240mg in the first week, 320mg in the second week, and 400mg in the third week and thereafter, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
223893234|NCT03269136|DRUG|PF-06863135 + lenalidomide|PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally
223893235|NCT03269136|DRUG|PF-06863135 + pomalidomide|PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally
223893236|NCT04956432|DRUG|SHR4640|SHR4640 Dose 1 ,tablets, QD
223893237|NCT04956432|DRUG|Allopurinol|Allopurinol 300mg, tablets, QD
223893238|NCT05632575|BEHAVIORAL|Virtual Promotoras Program|"Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~1. Educational Modules (8 evidence-based educational modules made by the VPs),~2. Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~3. Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider."
223893239|NCT05901519|DRUG|Prednisone|Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day
223893240|NCT06193525|DRUG|Talazoparib|Talazoparib is administered daily as single agent, 1 mg orally until unacceptable toxicity or progression of disease.
223893241|NCT06178354|PROCEDURE|Cryosurgery|Undergo focal cryotherapy ablation
223893242|NCT06178354|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo high intensity frequency ultrasound ablation
223893243|NCT06178354|OTHER|Survey Administration|Ancillary studies
223893244|NCT05342480|OTHER|EMDR and PE combined treatment|Daily program monday to friday with daily PE and EMDR sessions, physical activity between sessions, in vivo exposure treament and psychoeducational groups. Daily rotation of both EMDR and PE therapists. Multidisiplinary team attached to each pati
223893245|NCT05765214|BEHAVIORAL|Intervention Group (IG)|"In general, the education will cover:~(i) Colorectal cancer - knowledge, perceptions, self-care, and social norms (CRC-KPSS): Knowledge; Perceptions (perceived susceptibility, perceived severity, perceived benefits, perceived barriers); Self-care; and Social norms; and information on colorectal cancer screening (ii) Healthy nutrition colorectal for cancer risk reduction and complementary to diabetes guideline (increasing consumption of fiber, fruits, vegetables, whole grains, and calcium; reducing red and processed meat, fat, added sugars and alcohol)"
224081838|NCT06909318|BEHAVIORAL|Asthma Education - Animated Video|"This intervention consists of a 7-minute and 39-second animated video titled Living with Asthma, specifically designed for children aged 7 to 11. The video features two characters, Mert and Robo, who explain asthma, its symptoms, triggers, and correct inhaler techniques in a child-friendly manner. The content is based on the latest GINA (2020) and NHLBI (2020) guidelines. The video is first watched in the clinic setting using a tablet device and then shared with parents via WhatsApp, email, or CD for home viewing. Parents are asked to watch the video with their child at least twice per week for two months and record viewing frequency using a structured observation form. This visual and engaging format distinguishes the intervention from conventional text-based education."
224081839|NCT06909318|BEHAVIORAL|Booklet Group|"This intervention involves the distribution of a 12-page, full-color, illustrated educational booklet titled Living with Asthma, developed for children aged 7 to 11. The booklet covers topics such as asthma symptoms, triggers, medication use, and device techniques using simple language and visual aids. Its content was developed in line with GINA (2020) and National Heart, Lung, and Blood Institute (2020) recommendations. During the initial clinic visit, children and parents are introduced to the booklet and instructed to review it together at least twice per week over two months. Parents are also asked to log reading sessions using a structured observation form. This printed, interactive material offers a visually supported, age-appropriate alternative to standard asthma education methods."
223893246|NCT04376242|BEHAVIORAL|use of virtual reality|The intervention is a virtual reality program designed to immerse participants in a gaming experience to improve anxiety and fear during an oral food challenge.
223893247|NCT04376242|BEHAVIORAL|use of standard technology|the active comparator group will be allowed standard technology for distraction during oral food challenge which can include TV, non-VR gaming, tablets and smart phones.
223893248|NCT04423185|DRUG|Almonertinib 110 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
223893249|NCT04423185|DRUG|Dacomitinib 45 MG|Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
223893250|NCT04423185|DRUG|Alectinib 150 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
223893251|NCT04423185|DRUG|Crizotinib 250 MG|Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
223516472|NCT06254690|DRUG|Pyrotinib dose normal|Pyrotinib: 400mg per week, by mouth(po),once a day(qd) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
223893252|NCT04423185|DRUG|Pyrotinib 160/80 MG|Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
223516473|NCT01835431|DRUG|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
223893253|NCT04423185|DRUG|Imatinib 400 MG|Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
224081840|NCT05738122|OTHER|60-Day self-guided Emotion Regulation Journal|A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
223516474|NCT01835431|DRUG|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
223893254|NCT04423185|DRUG|Niraparib 200/300 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
224081841|NCT05027932|OTHER|IN Placebo|The placebo is normal saline in two syringes administered IN.
224081842|NCT05027932|OTHER|IM Placebo|The placebo is normal saline in a syringe administered IM.
224081843|NCT05027932|DRUG|BPL-1357|BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It is administered either IM or IN depending on the assigned treatment group.
224081844|NCT06910930|DEVICE|DidgeriTU|the study device that immitate the principle of didgeridoo for expiratory muscle exercise
224081845|NCT06910930|DEVICE|Sham device|a device that look alike DidgeriTU but without resistance plate
224081846|NCT06908005|OTHER|CT radiomic analysis|Radiomic features of tumor tissue
223893255|NCT04423185|DRUG|Palbociclib 125mg|Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
223893256|NCT04423185|DRUG|Vemurafenib 240 MG|Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
223893257|NCT04423185|DRUG|Sintilimab 100MG|Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
224081847|NCT06908005|OTHER|Fibrosis assessment|Fibrosis quantification was performed on picrosirius red (PSR)-stained tissue sections using color deconvolution and binarized collagen signal analysis in ImageJ software (v1.5)
224081848|NCT06914752|DEVICE|TENS|transcutaneous electrical nerve stimulation
223893258|NCT04423185|DRUG|Atezolizumab 1680 MG|Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
223516475|NCT01835431|DRUG|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
223516476|NCT01835431|DRUG|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
223516477|NCT03977610|DRUG|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
223516478|NCT02978508|DRUG|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
223516479|NCT02978508|DRUG|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
223893259|NCT05623007|DIETARY_SUPPLEMENT|Probiotics|Combination of 3 probiotic strains: Lactobacillus rhamnosus (LGG), Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (LA-5)
223893260|NCT05623007|BEHAVIORAL|Counselling on healthy eating, physical activity, and psychosocial stimulation|Counselling on healthy eating, physical activity, and psychosocial stimulation.
224081849|NCT02508805|DRUG|Neuromultivit|
224081850|NCT02508805|DRUG|Voltaren|
224081851|NCT02508805|DRUG|Sirdalud|
223893261|NCT05623007|DIETARY_SUPPLEMENT|Placebo probiotics|Maltodextrin
224081852|NCT06916520|DRUG|Prasugrel 5 mg|Prasugrel 5 mg once daily (monotherapy)
224081853|NCT06916520|DRUG|Dual Antiplatelet (DAPT) Therapy|Dual antiplatelet therapy according to guidelines
224081854|NCT06917066|PROCEDURE|TAVR|TAVR procedure using Myval Transcatheter Heart Valve
224081855|NCT06917495|DRUG|Rifampin|Rifampin: once daily, 600 mg.
224081856|NCT06917495|DRUG|Isoniazid|Isoniazid: once daily, 300 mg.
224081857|NCT06917495|DRUG|Rifapentine (RPT)|Rifapentine: once daily with dosage adjusted based on body weight: 750 mg for ≤41.2 kg, 900 mg for \>41.3-48.7 kg, 1050 mg for \> 48.8-56.2 kg, 1200 mg for ≥ 56.3 kg.
224081858|NCT06917495|DRUG|Moxifloxacin|Moxifloxacin: once daily, 400 mg.
224081859|NCT06917495|DRUG|Pyrazinamide|Pyrazinamide: once daily with dosage adjusted based on body weight: 1000 mg for \< 55 kg, 1500 mg for ≥ 55-75 kg, and 2000 mg for \>75 kg.
224081860|NCT06917495|DRUG|Ethambutol|Ethambutol: once daily with dosage adjusted based on body weight: 800 mg for \< 55 kg, 1200 mg for ≥ 55-75 kg, and 1600 mg for \> 75 kg.
223893262|NCT06499740|BEHAVIORAL|Adapted SAFETY-A for PC|This intervention is a suicide prevention intervention that will be adapted from the evidence-based SAFETY-Acute program. The specific intervention components will be determined from information gathered in this study but the investigators anticipate will include components such as safety planning, lethal means restriction, psychoeducation, motivation building, and care linkage.
223516480|NCT04633876|BEHAVIORAL|Individual coaching|Individual coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
223516481|NCT04633876|BEHAVIORAL|Group coaching|Group coaching on lifestyle change, sleep, nutrition, physical activity and stress management.
223516482|NCT04633876|OTHER|Control group|Group receives no lifestyle coaching but did get baseline results from assessments which might motivate for lifestyle change.
223516483|NCT02846727|DEVICE|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
223516484|NCT00562861|DRUG|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
223516485|NCT00562861|DRUG|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
223516486|NCT05023902|OTHER|Pilates|Pilates has been performed to all participants two times a week in order to compare the effects of NIA
223516487|NCT05023902|OTHER|Neuromuscular Integrative Action|NIA was the experimental group of this study.
223516488|NCT04349098|DRUG|Selinexor|Participants will receive 20 mg of selinexor.
223516489|NCT04349098|OTHER|Placebo|Participants will receive 20 mg of placebo matched to selinexor.
223516490|NCT05655988|DIAGNOSTIC_TEST|inguinal ultrasonography|After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
223516491|NCT01703221|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
223516492|NCT01703221|DRUG|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
223516493|NCT01703221|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
224081861|NCT06917339|DEVICE|NeuroStar Advanced TMS Therapy System|non-invasive brain stimulation device
224081862|NCT06915922|DEVICE|Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy|Nd:YAG laser treatment(s) for Vision Degrading Myodesopsia (clinically significant vitreous floaters) in eyes with vitreous opacities due to myopic vitreopathy and posterior vitreous detachment (PVD).
224081863|NCT06915181|DRUG|Pyridostigmine|"Subjects will participate in a double-blind randomized controlled cross-over trial. All patients will receive the study drug and placebo. Subjects and investigators will remain blinded to whether the subject receives active treatment during the first or second treatment period.~Participation in the study will last 10 weeks, with 4 weeks on active treatment and 4 weeks on placebo, with a 2-week wash-out period in between."
224081864|NCT06915818|DEVICE|Ileo-colic and colo-colonic Anastomosis with Flexagon SFM and OTOLoc|This study will investigate two types of intervention: ileo-colic and colo-colonic anastomosis creation in subjects undergoing colon surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically and/or endoscopically into a portion of either the ileum or the colon that are intended to be anastomosed. An OTOLoc device will be deployed into the ileum/colon wall to provide access for the deployment of a Flexagon SFM into the bowel. The process is repeated at an intended section of colon. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two lumens until the anastomosis is fully formed.
224081865|NCT06910449|RADIATION|hemithoracic Volumetric Arc Radiotherapy post Pleural decortication|post operative delivery of hemithoracic Volumetric Arc Radiotherapy
223516494|NCT01703221|DRUG|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
223516495|NCT03505424|OTHER|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
223516496|NCT03505424|OTHER|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
223516497|NCT03505424|OTHER|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
223516498|NCT06608732|BIOLOGICAL|Inaticabtagene autoleucel|CNCT19 combined with autologous hematopoietic stem cell transplantation，Dose: （0.5 -2）x 10\^6/kg CNCT19 Cell Injection via intravenous infusion.
223893263|NCT06499740|BEHAVIORAL|Treatment as Usual|Treatment as usual delivered in participating clinics.
223893264|NCT02378805|DRUG|ACE-inhibitor|observational study
223893265|NCT02378805|DRUG|Angiotensin-receptor blocker (ARB)|observational study
223893266|NCT02378805|DRUG|HMG-Coenzyme inhibitor (statin)|observational study
223893267|NCT02378805|DRUG|Spironolactone or Finerenone|observational study
224081866|NCT06917183|OTHER|Training using the Immersive Multi- player Virtual Surgical Safety Checklist Training Simulator|Training for performing surgical safety checklist for a period of 4 weeks.
224081867|NCT06917261|DIAGNOSTIC_TEST|nasopharyngeal swab.|The only additional procedure related to the study is a nasopharyngeal swab.
224081868|NCT06913062|PROCEDURE|conventional rehabilitation|For control group, the conventional rehabilitation protocol aimed to alleviate muscular and neuropathic pain in the short term, improve cervical mobility, reduce muscle tension, and increase muscle strength in the medium term, and promote a healthy lifestyle along with socio-professional reintegration in the long term. The principles included educating patients about their condition, respecting pain thresholds, and considering fatigue levels. Each patient received treatment for two months, with three sessions per week, each lasting about one hour. The protocol consisted of three phases: the first week focused on relaxation through massage and low-frequency electrotherapy; the second week introduced passive joint mobilizations; and from the third week, muscle stretching and strengthening exercises were incorporated. Additionally, functional exercises targeting daily activities and body awareness techniques are included to maintain proper posture.
224081869|NCT06913062|PROCEDURE|neural mobilisation|The protocol was structured around three main axes: treatment of interfaces (joint mobilizations and traction), direct treatment (using neurodynamic techniques), and indirect treatment (neural self-mobilization and lifestyle advice). The treatment included various stages for each ULNT technique. ULNT1 targeted the median nerve and involved shoulder abduction, elbow extension, and head inclination. ULNT2 focused on scapular depression and targeted cervical roots. ULNT3 emphasized radial nerve tension with internal rotation of the shoulder, while ULNT4 addressed ulnar nerve tension through elbow flexion and shoulder abduction. Each technique was executed with specific movements, maintained for 20 to 30 seconds, and repeated 15 times, followed by gentle scapular mobilizations until pain resolution.
224081870|NCT06914089|DEVICE|The BioMime is an ultra-thin strut (65 µm) SES that uses a cobalt-chromium platform with a unique hybrid design of open cells in the mid segment and closed cells at the edges|testing its safety and efficacy at long term follow up after primary percutaneous intervention
224081871|NCT06916676|DEVICE|Low-Dose High-Intensity Laser Therapy (10 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 10 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
223516499|NCT01312077|DRUG|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
224081872|NCT06916676|DEVICE|Medium-Dose High-Intensity Laser Therapy (15 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 15 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
224081873|NCT06916676|DEVICE|High-Dose High-Intensity Laser Therapy (20 J/cm²)|Application of HILT using an Nd:YAG laser (BTL-6000, 1064 nm). Delivered via continuous scanning technique (1 cm distance) to 5 zones (25 cm² each) covering anterior, medial, and lateral knee aspects. Target dose: 20 J/cm² per zone. Session frequency: 3x/week for 4 weeks (12 total). Session duration: 15-20 min. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
224081874|NCT06916676|DEVICE|Sham High-Intensity Laser Therapy|Sham procedure mimicking active HILT using the same Nd:YAG laser device (BTL-6000). Same setup, patient positioning, scanning technique over identical zones, and session duration/frequency (3x/week, 4 weeks, 15-20 min). Device powered on with visual/auditory cues active, but no laser energy emitted. Administered by trained PTs in outpatient rehab. Skin temperature monitored.
224081875|NCT06915948|PROCEDURE|Macular Hole Surgery|Pars Plana Vitrectomy with ILM peeling with silicone oil tamponade
224081876|NCT06915272|OTHER|Head and Neck Cooling Intervention|Participants received a head and neck cooling intervention involving the daily use (≥2 hours/day) of cooling devices consisting of a cooling cap and cooling towel specifically designed for localized head and neck cooling. Devices were activated by immersing them in cold water maintained at approximately 10°C.
223516500|NCT01312077|DRUG|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
224081877|NCT06916000|DRUG|Pericapsular nerve group (PENG) block|"As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango.~All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points."
224081878|NCT06916000|OTHER|Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.|Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.
224081879|NCT06915870|DRUG|Dapagliflozin 10 mg daily|Dapagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
224081880|NCT06915870|DRUG|Empagliflozin 10 MG OD|Empagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
223516501|NCT05177328|BIOLOGICAL|S. hominis A 9 Product|Commensal staph species, phosphate buffered saline, and glycerol.
223516502|NCT05177328|DRUG|Placebo|Phosphate buffered saline and glycerol
223893268|NCT02378805|DRUG|Paricalcitol|observational study!
223893269|NCT02378805|DRUG|SGLT2 inhibitor|observational study
223893270|NCT05856591|BEHAVIORAL|Food Resources & Kitchen Skills (FoRKS)|Food Resources \& Kitchen Skills (FoRKS) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes with embedded lessons in kitchen organization, tool use, nutrition, budgeting, and shopping.
223893271|NCT05856591|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
223516503|NCT03073070|DRUG|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
223516504|NCT03927846|BEHAVIORAL|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
223516505|NCT03878069|BIOLOGICAL|elapegademase-lvlr|Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
223516506|NCT06674512|BEHAVIORAL|Clinical Pharmacist-led Pharmaceutical Services|Pharmacists developed an intervention plan to reduce DRPs and improve patients' quality of life by assessing patients' medication knowledge, drug-related problems, and adherence problems in the intervention group in the order of urgency, importance, and priority to be addressed. The plan included a list of patients' medication or lifestyle-related problems, a list of programs based on the assessed problems, and other information.
223516507|NCT06541301|DEVICE|PICC-port|Implantation of a PICC-port device by a dedicated PICC team member following predefined evidence-based international guidelines and protocols
223516508|NCT06541301|DEVICE|Chest-port|Implantation of a Chest-port device by expert physicians or certified expert nurses, following predefined evidence-based international guidelines and protocols
223516509|NCT00834587|DRUG|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
223516510|NCT00834587|DRUG|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
223516511|NCT06546735|DRUG|N0728|1 tablet of the test drug (N0728) and 1 tablet of placebo of Vesomni®.
223516512|NCT06546735|DRUG|Vesomni®|1 tablet of the comparator drug Vesomni® and 1 tablet of the placebo of the test drug.
223516513|NCT06674057|PROCEDURE|KinesioTaping|"The experimental group will receive the following treatment for week 1-3 (3 days on alternate days):~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Kinesio tape 3 times per week. (Anchor opposed to effected compartment to provide facilitation and sustained stretch).~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of mediu"
223516514|NCT06674057|PROCEDURE|Control|"The control group will receive the following treatment for week 1-3 on alternate days:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~For week 3-6 the treatment will include:~* Passive and active ROMs 25 repetitions each, 3 times per week.~* PNF stretching (hold relax) for spastic muscles for 20 repetitions with a 10 second hold and 10 second relaxation of the muscle group 3 times per week.~* D1 flexion and extension for 20 repetitions 3 times per week.~* Strengthening affected muscle groups by resistance training, 3 times per week (using a resistance band of medium resistance)."
223516515|NCT06673459|BIOLOGICAL|TBICy|The TBI-Cy group was administered 250 mg/m2/d oral Me-CCNU on day -8. A total of 12 Gy TBI was for each patient and fractionated dose was 2 Gy twice daily or 4Gy once daily on days -8 to -6. Occluding of the lung fields during TBI, the corresponding irradiation dose reduced to a total of 8 Gy. On day -5, the schedule was intravenous 2 g/m2 Ara-C every 12 hours. Then intravenous 1.8 g/m2 CTX once per day from days -4 to -3.
223516516|NCT06673459|BIOLOGICAL|BuCy|The BuCy group received oral Me-CCNU 250 mg/m2/d twice daily on day -8, intravenous cytosine arabinoside (Ara-C) 2 g/m2 twice daily on day -7, intravenous Bu 3.2 mg/kg/d from days -6 to -4, and intravenous cyclophosphamide (CTX) 1.8 g/m2/d from days -3 to -2. There were no patients accepted oral Bu.
223516517|NCT04840875|BIOLOGICAL|chimeric antigen receptor T cell treatment|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
223893272|NCT04322370|PROCEDURE|Standard of Care Surgical Procedure|Zone 2 Flexor Tendon surgical repair will be performed by the principal investigator per standard of care. The same technique of tendon repair will be performed for all patients.
223893273|NCT04322370|DEVICE|VersaWrap Treatment|is intended to manage and protect tendon injuries where there is no significant loss of tendon tissue
223893274|NCT02984852|DRUG|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
223893275|NCT02984852|DRUG|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
223893276|NCT02984852|DRUG|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
223893277|NCT02984852|DRUG|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
223893278|NCT06206343|OTHER|TENS application, Tele-rehabilitation treatment program|Exercise training
223893279|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 135 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
223893280|NCT06552429|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 180 mcg, s.c., once a week, during the targeted treatment period (the first 48 week), peginterferon α-2b dose is depended on the patient's response and tolerability during the extension treatment (week 49 to week 96).
224268963|NCT05534048|BIOLOGICAL|Comirnaty®|0.45 mL concentrate in a 2 mL clear multidose vial (type I glass) with a stopper (synthetic Bromo-butyl rubber) and a purple flip-off plastic cap with aluminum seal. Each vial contains 6 doses.
223516518|NCT06682975|DRUG|ZP9830|Participants will receive 1 single dose of ZP9830 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
224081881|NCT06916390|DRUG|Guselkumab|"All patients will receive guselkumab 400 mg intravenous at week 0, week 4, and week 8, followed by subcutaneous guselkumab 200 mg at week 12, week 16, week 20, week 24, week 28, week 32, week 36, week 40, week 44, and week 48.~All subjects will receive concomitant antibiotic treatment with ciprofloxacin 500mg twice daily from randomization through week 4."
224081882|NCT06916390|OTHER|Diet|Subjects randomized to the group with the dietary intervention will be advised to follow a low-UPF, high-fruit diet. Patients will be instructed to restrict the intake of NOVA 4 food products during the first 16 weeks of the trial, and to increase the intake of fruits (minimum 3 servings per day) during the full trial. Dietary education will be provided by certified IBD dietitians, lists of products to avoid, and week menu's will also be provided to increase dietary adherence. Dietary information will be collected with food records and food frequency questionnaires.
223516519|NCT06682975|DRUG|Placebo|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Volume will be matching the active treatment
223516520|NCT06691295|OTHER|Questionnaires|"This study aims to explore transdiagnostic psychological processes (PP) via the administration of self-reported scales and questionnaires, in a population of newly diagnosed FND patients, prior to any therapeutic management.~The main objective is to describe the psychometric properties (scores on tools measuring psychological processes) of NFT patients (presenting the main phenotypes; sensitivo-motor; and seizures and discomfort)."
223516521|NCT06686589|DIAGNOSTIC_TEST|Intestinal ultrasound|Intestinal ultrasound performed by hand held ultrasound devices
224081883|NCT06915402|DEVICE|"LMW - CL - HA FACE/BODY"|"The dosage to be used for the individual case is at the discretion of the doctor. The periodicity with which to repeat the procedure depends on different factors, concerning both the physiology of the patient (skin type, individual metabolism, anatomy, age) and lifestyle; another element to consider is related to the implantation techniques adopted. After the first treatment, the result can be retouched after 15 days, repeating the treatment after 9-12 months to maintain the results obtained. Local anesthesia for facial treatments can be performed, in order to ensure the necessary comfort for the patient. The area of intervention must be cleaned with antiseptic solutions before proceeding to the implant. Do not use quaternary ammonium-based disinfectants, as they can react with the HA and form precipitates.LMW - CL - HA FACE/BODY is to be used intracutaneously and must not be injected into the blood vessels. Further details on the injection procedure are reported in the IFU."
224081884|NCT06915623|DRUG|Innovative Gel application|Innovative gel application: Gel is applied as an adjunct treatment to cleaning and scaling.
224081885|NCT06915623|PROCEDURE|Mechanical Debridement|Cleaning and scaling of the implant.
224081886|NCT06917053|DEVICE|Ultrasound (including contrast enhanced ultrasound)|Ultrasound measures: contrast enhanced ultrasound (CEUS) of the kidney, venous excess ultrasound (VExUS), echocardiography
224081887|NCT06917053|DEVICE|Sublingual incident dark field videomicroscopy|Sublingual incident dark field (IDF) videomicroscopy
224081888|NCT06917053|DEVICE|Urinary oxygen tension.|Continuous urinary oxygen tension
224081889|NCT06915506|DRUG|Shenfu Injection|"This intervention combines traditional Chinese medicine (TCM) with modern critical care practices to distinguish it from conventional sepsis therapies. Key unique features include:~TCM-Based Intervention:~Shenfu Injection: A standardized herbal extract derived from Panax ginseng and Aconitum carmichaelii , prepared under Chinese Pharmacopoeia guidelines.~Mechanism: Targets mitochondrial dysfunction and endothelial glycocalyx repair, with preclinical evidence of anti-inflammatory, anti-apoptotic, and vasoregulatory effects.~Precision Delivery Protocol:~Dosage: 60 mL (1 mL/kg for patients \<60 kg) administered via syringe pump-controlled continuous infusion over 3 hours, ensuring stable plasma concentrations.~Timing: Initiated only after hemodynamic stabilization (≥1 hour of stable vasopressor requirements post-fluid resuscitation), aligning with the golden window for vascular repair in sepsis."
224081890|NCT00525538|RADIATION|conformal radiotherapy|
224081891|NCT07155239|DEVICE|AviClear Lase Treatment|Three laser sessions at Weeks 0, 4, 8; follow-ups at Weeks 12, 16, 24.
224081892|NCT07155239|DEVICE|Sham (No Treatment)|No active laser treatment
224081893|NCT07179055|DRUG|VSJ-110|ophthalmic solution
224081894|NCT07179055|DRUG|Placebo|ophthalmic solution
224081895|NCT07178990|BEHAVIORAL|Digital Contingency Management Intervention Arm|Participants will use a version of the app for 6-months. Participants in this group may earn rewards for completing recovery-related activities and for abstinence from drugs and alcohol. During the 6 months this will include: random saliva drug tests, breathalyzer tests, and video selfies, completing surveys and questionnaires through the app, and receiving rewards on a debit card for abstinent tests, surveys, and activities. Additionally, participants will complete follow-up at approximately 9 months after randomization.
224268964|NCT01212549|PROCEDURE|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
224268965|NCT01212549|PROCEDURE|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
223516522|NCT06691620|PROCEDURE|Nasal irrigation with isotonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of isotonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
223516523|NCT06691620|PROCEDURE|Nasal irrigation with hypertonic saline|Infants were placed on the examination stretcher in the right or left lateral position. Then, 10 mL of hypertonic saline solution was administered over 5 s into the upper nasal cavity of the infant. The secretion and irrigation solution from the lower nasal cavity were cleaned using gauze. The infant was placed on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
223516524|NCT06691620|PROCEDURE|Nontraumatic nasopharyngeal aspiration|After nasal irrigation, the secretions and saline solution from the underlying nasal cavity were nontraumatically aspirated from the entrance of the nasal cavity after the irrigation. The infant was positioned on the other side, and the same procedure was repeated for the other nasal cavity. The infant was then placed in the prone position, and the tapotement technique was applied. The infant's mouth and nose were cleaned with gauze, completing the procedure.
223516525|NCT06689813|DIETARY_SUPPLEMENT|Vitamin D tablets|Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A
223516526|NCT06689813|OTHER|Ispaghula husk|Ispaghula husk tablets were given to Group B participants
223516527|NCT06689683|DEVICE|Shock wave lithotripsy|SWL works on the principle of focusing on the calculus using fluoroscopy. There has yet to be a consensus on the optimal frequency of fluoroscopic monitoring in the literature.
223516528|NCT06688877|DEVICE|headphones with activated noise cancelling|noise cancelling is new
223516529|NCT06688877|DEVICE|headphones with activated noise cancelling and soft 60 bpm musc|noise cancelling is new
223516530|NCT06688877|DEVICE|heart rate measurement|three times (before, during and after surgery)
223516531|NCT06688877|OTHER|Questionnaire|two times (before and after surgery)
223516532|NCT06683495|OTHER|Mirror Therapy|For mirror therapy, a 50×40 cm mirror will be used
223516533|NCT06685796|DRUG|BEBT-209 capsules|BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.
223516534|NCT06685796|DRUG|Carboplatin injection|Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
223516535|NCT06685796|DRUG|Gemcitabine hydrochloride for injection|Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
223516536|NCT06687499|DRUG|Bismuth-based susceptibility-guided treatment|The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori. A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens.
223516537|NCT06695182|BEHAVIORAL|physical activity|
223516538|NCT06694870|DIAGNOSTIC_TEST|Transcutaneous CO2 monitoring|Transuctaneous CO2 monitoring
223516539|NCT06689345|DEVICE|taVNS - transauricular vagal nerve stimulation|30 minutes of electrical stimulation on the afferent portion of the vagal nerve on the cymba conchae of the ear, in the following configuration: 30 seg ramp up, 30 seg on, 30 seg off in intensity on which the volunteer feels a light tingling.
223516540|NCT06689345|DEVICE|rPMS - repetitive peripheric magnetic stimulation|Magnetic stimulation on the efferent portion of the vagal nerve on the neck, on the following configuration: 20Hz, 25 pulses in the trein, in every inhalation, for 20 inhalations with 50% of machine capacity (500 pulses total).
223516541|NCT06689345|DEVICE|rTMS - repetitive transcranial magnetic stimulation|rTMS intermitent theta- burst on the left DLPFC, on the following configuration: 50 Hz in treins of 5Hz, with 110% of the resting motor limiar and 600 pulses in 3 minutes.
223516542|NCT06689345|DEVICE|taVNS sham|Simulated taVNS (SHAM) on helix left ear, that is the same as taVNS, but during only 1 minute
223516543|NCT04524130|DRUG|Lidocaine Hydrochloride|lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.
223516544|NCT04524130|DRUG|Ketamine|Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.
223516545|NCT04524130|DRUG|Placebo|Normal saline will be given with the same rate of lidocaine or ketamine.
223516546|NCT04095936|DRUG|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
223516547|NCT00294567|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
223516548|NCT04064671|OTHER|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
223516549|NCT01177488|BEHAVIORAL|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
223516550|NCT00527878|DRUG|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
223516551|NCT00527878|DRUG|Placebo|
223516552|NCT04917939|OTHER|RNA sequencing|Samples in both groups will be sequenced by single-cell sequencing and spatial transcription sequencing.
223516553|NCT01671774|DRUG|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
223516554|NCT01671774|DRUG|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
223516555|NCT01671774|DRUG|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
223516556|NCT01671774|DRUG|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
223516557|NCT04210115|BIOLOGICAL|pembrolizumab|IV infusion
223516558|NCT04210115|DRUG|placebo|IV infusion
223516559|NCT04210115|DRUG|cisplatin|IV infusion
223516560|NCT04210115|DRUG|5-FU|IV infusion
223516561|NCT04210115|RADIATION|radiotherapy|external radiation
223516562|NCT04210115|DRUG|leucovorin|IV infusion
223516563|NCT04210115|DRUG|levoleucovorin|IV infusion
223516564|NCT04210115|DRUG|oxaliplatin|IV infusion
223516565|NCT00188435|PROCEDURE|Minimum Dose CT|
223516566|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET|Prostate specific membrane antigen positron emission tomography
223516567|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/MRI|Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging
223893281|NCT05145127|DRUG|PF-06741086|"For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria."
223893282|NCT05326776|DRUG|Pitocin|At each session, 4mcg/2ml oxytocin or 2ml isotonic saline (0.9% sodium chloride; placebo control) will be injected into the middle of the dorsal forearm. Sessions will be separated by at least 48 hours to ensure drug clearance.
223893283|NCT04016818|DRUG|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
223893284|NCT04016818|DEVICE|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
223893285|NCT06442631|BEHAVIORAL|MyStroke|MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.
223893286|NCT06038487|PROCEDURE|Immediate loading of maxillary implant overdenture|The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
223893287|NCT06038487|PROCEDURE|Delayed loading of maxillary implant overdenture|A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
223893288|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 1)|Single dose of AZD3152 300 mg IM on Visit 2 Day 1
223893289|NCT05932641|BIOLOGICAL|Placebo (Cohort 1)|Single dose of Placebo IM on Visit 2 Day 1
223893290|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 2)|Single dose of AZD3152 600 mg IM on Visit 2 Day 1
223893291|NCT05932641|BIOLOGICAL|Placebo (Cohort 2)|Single dose of Placebo IM on Visit 2 Day 1
223516568|NCT04790968|DIAGNOSTIC_TEST|PSMA-PET/CT|Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
223516569|NCT02113878|DRUG|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
223516570|NCT02113878|DRUG|Cisplatin|Cisplatin is a chemotherapy drug
223893292|NCT05932641|BIOLOGICAL|AZD3152 (Cohort 3)|Single dose of AZD3152 1200 mg IV on Visit 2 Day 1
223893293|NCT05932641|BIOLOGICAL|Placebo (Cohort 3)|Single dose of Placebo IM on Visit 2 Day 1
223516571|NCT02113878|RADIATION|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
223516572|NCT06303752|DRUG|ADRC injection|Allocated patients will receive injection of 5 ml suspension including 30 million autologous adipose-derived regenerative cells ADRC and injected at the same site of the lipoaspirate injection.
223516573|NCT06303752|DRUG|ADRC001 injection|Allocated patients will receive injection of 5 ml suspension including 30 million allogenic adipose-derived regenerative cells ADRC001 and injected at the same site of the lipoaspirate injection.
223516574|NCT02999659|DEVICE|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
223516575|NCT04744831|DRUG|DS-8201a 5.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
223516576|NCT04744831|DRUG|DS-8201a 6.4 mg/kg Q3W|DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
223516577|NCT06633991|PROCEDURE|verbal instructions|verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
223516578|NCT04392570|DIAGNOSTIC_TEST|Fasting|blood samplings will be taken 08:00 am and again 2 hours before breaking the fast
223516579|NCT03966118|DRUG|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
223516580|NCT03966118|DRUG|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
223516581|NCT03966118|DRUG|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
223516582|NCT02257138|DRUG|Decitabine|Given IV
223516583|NCT02257138|OTHER|Laboratory Biomarker Analysis|Correlative studies
223516584|NCT02257138|DRUG|Ruxolitinib Phosphate|Given PO
223516585|NCT04775758|BEHAVIORAL|Self-evaluating questionnaires|Patients are asked to describe their disease (gathering of anamnesis) and to categorize their symptoms according to their strength. Furthermore, patients complete self-evaluating questionnaires: Visual analog scale, Hospital anxiety and depression scale, Pittsburgh sleep quality index, Big five personality traits questionnaire.
223516586|NCT04775758|BEHAVIORAL|iMotions analysis platform|While patients' anamnesis and questionnaire indexes are being gathered, iMotions software will gather facial expression analysis, galvanic skin response and heart rate data which will be compared with self-evaluating questionnaires.
223516587|NCT00530257|DRUG|Placebo|Placebo (sugar pill)
224081896|NCT07178990|BEHAVIORAL|Digital Wellness Arm|Participants will use a version of the app for 6-months focussed on wellness. During the 6 months this will include: random requests to do saliva drug tests, breathalyzer tests, and video selfies, complete surveys and questionnaires through the app, and receive rewards on a debit card for completing tests, surveys, and activities. Participants in this group may also earn rewards for completing study activities like tests and surveys. Additionally, participants will complete follow-up at approximately 9 months after randomization.
223516588|NCT00530257|DRUG|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
223516589|NCT00385515|DRUG|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
223516590|NCT00385515|DRUG|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
223516591|NCT03676270|OTHER|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
223516592|NCT00000845|BIOLOGICAL|P3C541b Lipopeptide|
223516593|NCT06570460|DRUG|17-beta estradiol|Treatment with orally administered estrogen for 6 months
223516594|NCT06570460|DRUG|17-beta estradiol|Treatment with transdermally administered estrogen for 6 months
223516595|NCT04951505|DRUG|cefepime-taniborbactam|IV infusion
223893294|NCT03834753|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
223893295|NCT03834753|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
223893296|NCT03432936|DEVICE|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
224081897|NCT07178873|BEHAVIORAL|Psychosocial teleassistance intervention|The teleassistance psychosocial intervention involves 10 weekly 90-minute group sessions, with each group comprising 6 to 7 participants. These sessions are designed to enhance self-concept, self-esteem and social skills, reduce symptoms, and improve overall psychological well-being. Two follow-up sessions will be provided three months after the main program concludes.
223516596|NCT04343833|PROCEDURE|Immediate dental implants|At the time of operation, the tooth was atraumatically extracted, and the implant was immediately placed following the surgical protocol recommended by the manufacturer. A temporary prosthesis was made without occlusal contact.
223516597|NCT04859686|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR program included weekly 2.5-hour sessions in a group format over eight weeks, plus a 1-day retreat. Formal practices included several types of meditation, such as mindful breathing, sitting meditation, walking meditation, gentle hatha yoga, body scan, and mindful awareness. Participants were asked to practice at home for 20 minutes daily, six days a week.
223516598|NCT04859686|PROCEDURE|Acupuncture Treatment|"Participants received two treatments per week over eight weeks, 35-40 minutes each.~At each treatment, participants were treated with 10 body and two ear points: seven major points on either the front or back of the body. The treatment position alternated between sessions, such that the first session was on the back, with the next session on the front, unless a physical limitation prevented alternation."
223516599|NCT02674828|BEHAVIORAL|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
223516600|NCT02674828|OTHER|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it \>2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
223516601|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
223516602|NCT02465814|DRUG|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
223893298|NCT06507462|PROCEDURE|prostate biopsy|All patients were required to underwent transperineal prostate biopsy and have corresponding pathological diagnosis results.
223893299|NCT05706480|DIAGNOSTIC_TEST|colored periodontal probes (CPP)|The CPP will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
223893300|NCT05706480|DIAGNOSTIC_TEST|standard periodontal probes (SPP)|The SPP (William's graduated probe) will be placed with a force of approximately 0.2 N into the sulcus at the mid buccal surface of the tooth and the color that will be apparent from the tissue will be recorded
223893301|NCT05706480|DIAGNOSTIC_TEST|transgingival sounding with an endodontic file|the gingival thickness using the transgingival sounding. After application of local anesthesia gel an endodontic file (ISO 20) with a rubber stopper will be inserted perpendicularly into the buccal aspect of the gingiva (1 mm below the gingival margin) until it touches the tooth surface. The insertion depth will be ensured through placing the rubber stopper in contact with the gingiva and fixing its position and the distance between the tip and the rubber stopper will be calibrated using a manual calibration device (endodontic ruler).
224081898|NCT07178210|DEVICE|Symani Surgical System|Use of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes.
223516603|NCT02465814|DRUG|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
223516604|NCT02465814|DRUG|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
223516605|NCT02465814|DRUG|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
223516606|NCT02465814|DRUG|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
223516607|NCT02465814|DRUG|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
224081899|NCT07179445|OTHER|Not applicable- observational study|Not applicable- observational study
224081900|NCT07178275|BEHAVIORAL|Baduanjin Qigong|A standardized 60-minute Baduanjin Qigong protocol (15 minutes of breathing-focused warm-up, eight movements each lasting 5 minutes, and 10 minutes of breathing-focused closing). The sessions will be conducted by a licensed occupational therapist certified in Qigong.
224081901|NCT07178275|BEHAVIORAL|Passive Rest|Passive rest refers to a condition in which participants remain seated or lying quietly in a calm environment for a specified period of time, without engaging in any structured physical activity, therapeutic exercise, or cognitive tasks. During this period, external stimuli such as phone use, electronic devices, or reading materials are restricted in order to minimize distraction. The purpose of the passive rest condition is to provide a neutral control state that accounts for the passage of time and environmental factors, allowing valid comparison with the active intervention
224081902|NCT07179406|OTHER|H-Reflex|H-reflex - A small electrical stimulus is provided to the leg and foot area and a measurement of the stimulus is taken by the EEG electrodes.
224081903|NCT07179406|OTHER|Somatosensory evoked potential (SSEP)|A small electrical stimulus is provided to a nerve on the body and measured at several places along the nervous system (spinal cord, brain, etc.) with the EMG and EEG electrodes.
224081904|NCT07179406|OTHER|Vibratory Electrophysiological Response Potential (ERP)|stimulation is provided to the ankle with vibration sensations using a device like a buzzer and the recording of the body's responses using the EEG and/or EMG electrodes.
224081905|NCT07179406|OTHER|Transcranial Magnetic Stimulation (TMS)|A small magnetic pulse is used to provide a small amount of electrical stimulation to the nervous system. The EEG and/or EMG electrodes will be used to measure the body's reaction.
224081906|NCT07179406|OTHER|Spinal Cord Stimulator (SCS) manipulation|Spinal cord stimulator will be turned on/off
224081907|NCT07178743|DRUG|Initiation of palbociclib plus letrozole|Initiation of palbociclib plus letrozole described in electronic health records is used as the exposure.
224081908|NCT07178743|DRUG|Initiation of letrozole|Initiation of letrozole described in electronic health records is used as the reference.
224081909|NCT07177872|DRUG|NTQ5082 capsules 200 mg|NTQ5082 capsules 200 mg
224081910|NCT07178678|DRUG|NeuroEPO|0.5 mg of NeuroEPO will be administered intranasally three times a week for 52 weeks.
224081911|NCT07178678|DRUG|Placebo|250 µL of placebo will be administered to intranasally to each nostril three times a week for 52 weeks.
224081912|NCT02453074|OTHER|Online survey - Follow up for Better Care|
223516608|NCT03939065|DEVICE|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
223516609|NCT03939065|DEVICE|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
223516610|NCT00569075|OTHER|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
223516611|NCT02019173|BEHAVIORAL|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
223516612|NCT01897896|DRUG|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
223516613|NCT02002858|DRUG|Nicotine Patch|
223516614|NCT02002858|BEHAVIORAL|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
224081913|NCT03548441|PROCEDURE|Surgery|Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.
224081914|NCT03548441|OTHER|Non-surgical management|Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
224081915|NCT04704934|DRUG|Trastuzumab deruxtecan|6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
224081916|NCT04704934|DRUG|Ramucirumab|8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
224081917|NCT04704934|DRUG|Paclitaxel|80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
223516615|NCT02002858|BEHAVIORAL|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
223516616|NCT03348462|DRUG|ethosomal preparation of anthralin|once daily with short contact topical application
223516617|NCT03348462|DRUG|liposomal preparation of anthralin|once daily with short contact topical application
223516618|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target emmetropia OU.
223516619|NCT05069415|DEVICE|Eyhance IOL|Intraocular lens replaces the natural lens removed during cataract surgery in both eyes. Target mini monovision in the non-dominant eye.
223516620|NCT05708508|DRUG|ROVALCYTE|"Immuno-guided strategy arm"
223516621|NCT00949065|BIOLOGICAL|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
223516622|NCT04519138|DEVICE|Endodrill Model X|The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
223516623|NCT04519138|DEVICE|Fine-needle aspiration/biopsy|The standard method is used for biopsy sampling in the upper gastrointestinal tract
223516624|NCT02584738|DRUG|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
223516625|NCT02584738|DRUG|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
224081918|NCT05142709|DRUG|Anti-PD-1 Immune Checkpoint Inhibitors|used as 1st line treatment for metastatic ESCC.
224081919|NCT03371368|PROCEDURE|Roux-en-Y Gastric Bypass (RYGBP)|This is a standard RYGBP procedure that would be performed clinically and is not research-specific.
224081920|NCT03371368|PROCEDURE|Sleeve Gastrectomy (SG)|This is a standard SG procedure that would be performed clinically and is not research-specific.
223516626|NCT02584738|DRUG|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
223516627|NCT02584738|DRUG|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
223516628|NCT02584738|DRUG|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
223516629|NCT06569472|BIOLOGICAL|CD19-targetd CAR-T|Subjects underwent lymphocyte clearance chemotherapy and then received a single intravenous cell infusion
223516630|NCT06571877|OTHER|Dietary intervention with manipulation of the energy density|Dietary intervention with manipulation of the energy density either during breakfast or during lunch
223516631|NCT06571097|DRUG|Levoﬂoxacin|0.5g/day for 2 weeks
223516632|NCT02749461|PROCEDURE|heel stick|Consecutive routine blood sampling heel sticks
223516633|NCT01830101|DRUG|TMZ plus concurrent re-irradiation|
223516634|NCT01830101|DRUG|Temozolomide|low-dose temozolomide daily for one year
223516635|NCT02796482|DIETARY_SUPPLEMENT|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
223516636|NCT00203242|DRUG|Depacon IV and Depakote ER|
224081921|NCT03371368|BEHAVIORAL|Very Low Calorie Diet (VLCD)|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
224268966|NCT05389670|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
223516637|NCT02167347|BEHAVIORAL|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
223516638|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 14 days before surgery|
223516639|NCT04304287|PROCEDURE|Preoperative autologous blood donation, 72 hours before surgery|
223516640|NCT04304287|PROCEDURE|Without preoperative blood donation|
223516641|NCT00434811|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
223516642|NCT00434811|BIOLOGICAL|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
223516643|NCT00434811|DRUG|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
223516644|NCT00434811|DRUG|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
223516645|NCT00434811|BIOLOGICAL|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
223516646|NCT00434811|PROCEDURE|Islet Transplantation|Transplantation of pancreatic islet cell
223516647|NCT00434811|BIOLOGICAL|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
223516648|NCT06437457|RADIATION|ceus|MRI was performed by using a superconducting magnet scanner operated at 3.0 T (GE discovery MR750w, USA) and the CEUS examination (Mindray, China), ultrasound was performed first in B-mode to identify the suspicious lesions and then switched to contrast mode prior to the injection of the contrast medium.
223516649|NCT05020808|DIETARY_SUPPLEMENT|NEAA|Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
223516650|NCT05020808|DIETARY_SUPPLEMENT|PPI|Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
223516651|NCT00866775|DRUG|Eslicarbazepine acetate|1600 mg QD
223516652|NCT00866775|DRUG|Eslicarbazepine acetate|1200 mg QD
223516653|NCT02973022|OTHER|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC\&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
223516654|NCT00569998|DEVICE|NovoPen™ 4|
223516655|NCT00569998|DEVICE|NovoPen® 3|
223516656|NCT05454007|BEHAVIORAL|Step length asymmetry training|Participants will engage in four, five-minute periods of step symmetry training during session 2. This training uses established sensorimotor adaptation-based methods (e.g. split-belt treadmill walking, walking with unilateral leg weighting) to elicit motor aftereffects of more equal step lengths. Two minute sitting rest breaks will be given between training blocks or at the participant's request. A video recording will be taken of the first and final two minutes of training.
223516657|NCT01500135|DRUG|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
223516658|NCT01500135|DRUG|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
223516659|NCT03708510|DEVICE|Restorative materials- Filtek Silorane|Filtek Silorane
223516660|NCT03708510|DEVICE|Restorative materials-Kalore|Kalore
223516661|NCT03708510|DEVICE|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
223516662|NCT03708510|DEVICE|Preparation- Diamond Bur|Bur
223516663|NCT01952262|OTHER|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
223516664|NCT01872182|DRUG|ALS-L1023|daily twice for 12 weeks
223516665|NCT01872182|DRUG|placebo|daily twice for 12 weeks
223516666|NCT00781664|OTHER|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
223516667|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
223516668|NCT00781664|DRUG|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
223516669|NCT00781664|OTHER|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
223516670|NCT00781664|DRUG|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
223516671|NCT00781664|DRUG|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
223516672|NCT00781664|DRUG|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
224081922|NCT05847686|OTHER|Counseling|Participate in therapy visits
224081923|NCT05847686|DRUG|Psilocybin|Given PO
224081924|NCT05847686|OTHER|Questionnaire Administration|Ancillary studies
223516673|NCT00781664|DRUG|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
223516674|NCT00781664|OTHER|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
224268967|NCT05389670|DEVICE|Sham Continuous Theta-burst stimulation (cTBS)|Sham cTBS, inhibitory-like patterned form of TMS.
223534832|NCT05786287|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
224268968|NCT04168307|DEVICE|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
224268969|NCT04168307|OTHER|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
223516675|NCT03497286|BEHAVIORAL|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
223516676|NCT03497286|BEHAVIORAL|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
223516677|NCT05175001|DRUG|Diprospan|Diprospan combined with ropivacaine in ultrasound-guided thoracic paravertebral nerve block
223516678|NCT05175001|DRUG|Ropivacaine|Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
223516679|NCT03511287|OTHER|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
223516680|NCT02073201|OTHER|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
223516681|NCT02073201|OTHER|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
223516682|NCT02073201|OTHER|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
223516683|NCT02399566|DRUG|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
223516684|NCT00310843|DRUG|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
223516685|NCT03875443|OTHER|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
223516686|NCT03875443|OTHER|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
223516687|NCT02115243|DRUG|Ipilimumab|
223516688|NCT01380132|PROCEDURE|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
223516689|NCT03193138|DRUG|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
223516690|NCT00781898|DRUG|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
223516691|NCT00781898|OTHER|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
223893302|NCT04057924|OTHER|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
223893303|NCT06210958|OTHER|Intertransverse process block|The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
223893304|NCT06112002|OTHER|Educational Intervention|Attend an educational session
223893305|NCT06112002|BEHAVIORAL|Health Education|Receive educational materials
224268970|NCT00697918|DRUG|RWJ-333369|100 mg to 400 mg twice daily
223893306|NCT06112002|OTHER|Survey Administration|Ancillary studies
223893307|NCT06528743|RADIATION|RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.|Patients will receive RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases. Enrolled patients will receive a fractionation scheme with increasing break length.
223893308|NCT04557163|DRUG|TS-142|TS-142 will be given as 1 mg per capsule administered orally with water.
223893309|NCT04557163|DRUG|Itraconazole|Itraconazole will given as 50 mg per capsule administered orally with water.
224081925|NCT06353113|BEHAVIORAL|Down Dog Prenatal Yoga App|"The Down Dog prenatal yoga app launched in 2015 and was designed to align with the changes a pregnant body goes through in each trimester. Users can select a practice by trimester, which will offer modification cues to work with a changing body during pregnancy. Users can also customize their experience by boosting things like Heartburn or Pubic Symphysis so they can continue to practice yoga and omit poses that might be uncomfortable. The app also utilizes user feedback, to continuously implement new practices to better their app for user interface.~All of the prenatal yoga classes were created by a certified and experienced prenatal yoga instructor who has a 200hr yoga certification through Pure Yoga (New York), 80hr prenatal yoga certification through Prenatal Yoga Center (New Yoga), and is Trauma Informed Yoga certified through Exhale to Inhale (New York)."
223893310|NCT06353841|BEHAVIORAL|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week in four weeks.
223893311|NCT06295757|OTHER|Cigarettes|Participants will smoke their own usual brand cigarettes. Cigarette butts will be collected.
223893312|NCT02754765|DRUG|Bedaquiline|
223893313|NCT02754765|DRUG|Delamanid|
223893314|NCT02754765|DRUG|Clofazimine|
223893315|NCT02754765|DRUG|Levofloxacin|
223893316|NCT02754765|DRUG|Moxifloxacin|
223893317|NCT02754765|DRUG|Linezolid|
223893318|NCT02754765|DRUG|Pyrazinamide|
223893319|NCT02754765|DRUG|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
223893320|NCT06391125|DRUG|normal Saline|0.5ml normal saline solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
223893321|NCT06391125|DRUG|Lidocaine|0.5ml 1% lidocaine solution added to prefilled 1.2 million units Benzathine Pencillin G syringe
223893322|NCT05751694|PROCEDURE|Visceral manual treatment|The patient will be placed in a reclining sitting position and triple flexion of the lower limbs to keep the abdominal region relaxed. The therapist will be placed to the right of the patient at the height of the abdomen, with the hands placed in the epigastric area. He will make a skin fold that reduces tension in the area, so that the contact is focused on the visceral tissue of the area. The patient will be asked to take deep breaths, and during the exhalation, the therapist will perform a zigzag movement with vibration of the hands while pulling the tissue caudally. This procedure will be performed for 5 minutes.
223893323|NCT05751694|PROCEDURE|Respiratory listening|The patient and the therapist will be placed in the same position as in the experimental group. The therapist will place his hands in contact with the lower rib cage, and the patient will be asked to take a deep breath. The therapist will not exert any pressure, nor place restrictions on the tissues or movements of the ribcage.
223893324|NCT05770882|DRUG|Chidamide|Subjects will receive a single dose of chidamide. 5mg tablet. One dose every three days.
223893325|NCT05770882|DRUG|Regorafenib|Subjects will receive a single dose of Regorafenib. 40mg tablet. One dose daily.
223893326|NCT06442657|OTHER|Hydrocellular dressing|Application of hydrocellular dressings to at-risk areas prior to prone positioning. Assessment of pressure sores and their stage after prone positioning.
223893327|NCT06442657|OTHER|Hydrocolloids dressing|Application of hydrocolloids dressings to at-risk areas prior to prone positioning.
223893328|NCT04909931|DRUG|Vitamin D 2|Randomized allocation first arm : add on vitamin D supplementation 40,000 iu/week for 12 weeks
223893329|NCT04909931|DRUG|Placebo|Second arm : add on placebo for 12 weeks
223893330|NCT04795843|OTHER|Exercise and patient education|Over a period of 6-months, patients will be offered eight one-to-one supervised training sessions. In these sessions, patients will be instructed in a home-based exercise programme and given patient education. The programme includes four exercises covering strength and stability training. The exercises will be performed in sets of three with a minimum of 5 repetitions, and patients will be instructed to perform a minimum of three training sessions each week. Each of the exercises can be progressed through three levels of difficulty, allowing for individualised treatment with regard to exercise quality and perceived exertion according to the Borg CR10 scale. Exercises will be performed on a perceived exertion level from somewhat hard (level 5) to very hard (level 7). Patient education includes pain management, a focus on exercise adherence and progression, and advice on physical activity.
224081926|NCT03494868|DIETARY_SUPPLEMENT|Carbohydrate Drink|2 - 12 oz drinks
223516692|NCT02090530|OTHER|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
223516693|NCT05513170|PROCEDURE|Use of Densah Burs in closed sinus lift|Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
223516694|NCT05513170|PROCEDURE|Closed sinus lift using osteotomes|Closed sinus lift will be performed using osteotomes. Osteotomes elevate the sinus floor and enhance the bone quality.
223516695|NCT01266200|PROCEDURE|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
223516696|NCT01266200|PROCEDURE|XIA|Treatment of the fracture with Xia and conventional operation technique
223893331|NCT04795843|OTHER|Usual Care|Patients will follow usual care, including an individual consultation on self-management of hip symptoms and general advice on exercise and physical activity.
223893332|NCT04205110|DIAGNOSTIC_TEST|PET-CT|PET-CT compared to intravascular imaging for assessment of atherosclerotic plaques in stable angina patients
223893333|NCT03150810|DRUG|Pamiparib|Administered by mouth as a capsule twice daily
223516697|NCT02542371|OTHER|Arterial Imaging|
223516698|NCT01140932|DRUG|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
223516699|NCT01140932|BEHAVIORAL|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
223893334|NCT03150810|DRUG|Temozolomide|TMZ at various doses administered by mouth as a capsule once daily.
223893335|NCT04759001|BIOLOGICAL|Donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
224268971|NCT03092388|DIAGNOSTIC_TEST|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
223893336|NCT04759001|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
223893337|NCT02285140|DRUG|Cefazolin|administration as outlined
223893338|NCT02285140|DRUG|Vancomycin|administration as outlined
223516700|NCT00698412|DEVICE|Cane|This group use the cane every day since the baseline
223516701|NCT05314387|DEVICE|SMR TT Hybrid Glenoid without Cementless Finned Short Stem|The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
223516702|NCT05314387|DEVICE|SMR TT Hybrid Glenoid with Cementless Finned Short Stem|"The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation."
223516703|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
223893339|NCT05735977|DIAGNOSTIC_TEST|Indocyanine Green (ICG)|Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
223893340|NCT02503709|DRUG|CDK Inhibitor AT7519|Given IV
223893341|NCT02503709|OTHER|Laboratory Biomarker Analysis|Correlative studies
223893342|NCT02503709|DRUG|Onalespib|Given IV
223893343|NCT02503709|OTHER|Pharmacological Study|Correlative studies
223893344|NCT05642715|BEHAVIORAL|EX+|All participants, regardless of study arm, will be offered: BecomeAnEX, an online tobacco treatment with support community PLUS Positively Smoke Free on the Web (an intervention targeting people with HIV who smoke) integrated into the BecomeAnEX site.
223893345|NCT05642715|DRUG|Varenicline|All participants, regardless of study arm, will be offered: A 12-week course of varenicline dosed according to product label.
223516704|NCT06317597|DRUG|Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution|OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
223516705|NCT01879826|DEVICE|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
223516706|NCT01879826|DEVICE|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
223516707|NCT01933555|BEHAVIORAL|Empowerment Program|
223516708|NCT00977444|DRUG|kondrium|intraarticular injections once month
223516709|NCT00977444|DRUG|kondrium f|intraarticular injections once month
223516710|NCT00977444|DRUG|methyl prednisolone (corticosteroid)|intraarticular injections once month
223516711|NCT04714255|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of images attractive that need to be colored, created as a book called TICK-B. This book was created with the instructions and recommendations of a pediatric psychiatrist and a professional drawing teacher at a children's school.Distraction with TICK-B began 1-3 min. before the intravenous cannula procedure and lasted until the end of the procedure.
223516712|NCT06564714|DRUG|Early baclofen Intervention|"Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic."
223516713|NCT06564714|DRUG|Usual routine care|"Baclofen is initiated only when acute spasticity is deemed problematic.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response."
223516714|NCT05665452|PROCEDURE|Patellar mobilization, retinacula release, deep friction message, stretch and strength|"All exercises will be performed for 30 to 45 minutes per session, 3 times per week for 4 weeks (12 sessions). Group (1): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise).~Group (2): stretch exercises are performed for calf, hamstring, iliotibial band and quadriceps. strength exercises consist from open kinetic chain (hip abductors, hip external rotators and quadriceps) and closed kinetic chain exercises (mini wall squat exercise, forward step up exercise, lateral step up exercise and terminal knee extension exercise). manual therapy consists from iliotibial band release, deep friction message for lateral retinacula and medial patella mobilization."
223516715|NCT04632862|DRUG|DWP16001|DWP16001 A mg
223516716|NCT06440837|BEHAVIORAL|IMB stress self-management health education|The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
223516717|NCT04386239|DRUG|Sarilumab Prefilled Syringe|Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
223516718|NCT04854473|DEVICE|Exero Medical Leak Detection System|"the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes."
223516719|NCT05412979|DRUG|ST-1891|ST-1891
223516720|NCT05412979|DRUG|Levothyroxine|Levothyroxine
223516721|NCT01030809|OTHER|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
223516722|NCT02126891|PROCEDURE|Tests|Individual parameters of echocardiography and heart rate variability
223516723|NCT01520103|DRUG|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
224081927|NCT05947513|DRUG|Curcumin|Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
223516724|NCT01520103|DRUG|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
223516725|NCT01993680|DRUG|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
223516726|NCT01993680|DRUG|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
223516727|NCT00589524|DEVICE|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
223516728|NCT01246518|DRUG|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
224081928|NCT05947513|RADIATION|Palliative radiotherapy|As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
224081929|NCT05263076|OTHER|Uterine Transplant|Transplant of a uterus from a live or deceased donor.
224268972|NCT03092388|DIAGNOSTIC_TEST|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
223516729|NCT05131256|BEHAVIORAL|Neurofunctional characterization of emotional regulation (fMRI)|Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
223516730|NCT02003898|DEVICE|Medtronic MiniMed 530G Insulin Pump|
223516731|NCT03930511|PROCEDURE|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
223516732|NCT00273585|DEVICE|Personally-tailored educational software program|
223516733|NCT03590548|DIAGNOSTIC_TEST|gausher disease|lab investigation and radio logical
223516734|NCT01486329|BIOLOGICAL|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
223516735|NCT01486329|BIOLOGICAL|Placebo|Drink solution
223516736|NCT01484756|DIETARY_SUPPLEMENT|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
223516737|NCT01484756|DIETARY_SUPPLEMENT|Placebo|calcium carbonate 500 mg
223516738|NCT01660373|DRUG|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
223516739|NCT01660373|DRUG|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
223516740|NCT05115773|PROCEDURE|Intraligamentary anaesthesia|one tooth anaesthesia by 2 or 4 points intraligamentary injection
223516741|NCT05115773|PROCEDURE|Mandibular anaesthesia|Inferior alveolar nerve block by direct standart method
223516742|NCT05458531|OTHER|Questionnaire|A single questionnaire
223516743|NCT05458531|OTHER|Semi-structured interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
223516744|NCT01539031|DRUG|E2020|"Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
223516745|NCT01539031|DRUG|E2020|"Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
223516746|NCT00663156|PROCEDURE|breast implants|patients will have breast augmentation using implants
223516747|NCT00663156|PROCEDURE|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
224268973|NCT03092388|DIAGNOSTIC_TEST|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
223516748|NCT01987999|DIETARY_SUPPLEMENT|Acetogenins|
223516749|NCT06240676|BEHAVIORAL|AWARENESS-BASED COGNITIVE THERAPY|A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
223516750|NCT03446690|DRUG|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
223516751|NCT03446690|OTHER|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
223516752|NCT00938626|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
223516753|NCT00938626|PROCEDURE|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
223516754|NCT00938626|PROCEDURE|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
224099185|NCT05200988|DRUG|Ipilimumab + nivolumab|"Induction with immune checkpoint blockade: ipilimumab 3mg/kg on day 1, pilimumab 3mg/kg plus nivolumab 1mg/kg on day 22, and nivolumab 3mg/kg on day 43~Response evaluation after the last cycle of checkpoint inhibition.~Chemoradiation will start 10-12 weeks after start of checkpoint inhibition according to the following scheme:~* Mitoycine C (12mg/m2) on the first day of radiotherapy, followed by either 5-fluorouracil intravenously (500mg/m2) five days a week during week one and four of radiation, or oral capecitabin (2x825mg/m2) every day during the radiation period~* Radiation with a preference for a four-week schedule, in which 55 Gy will be administered using intensity modulated radiation therapy"
224099186|NCT04813744|PROCEDURE|Atraumatic restorative treatment|
223893346|NCT05642715|BEHAVIORAL|HR|Participants allocated to the EX+/HR arm will be offered: 30-minute video urging smokers who cannot or will not quit to cut down on cigarettes, and also to control their risk for lung cancer and cardio or cerebrovascular disease by undergoing low-dose CT screening for lung cancer (for those meeting prespecified criteria), and referral to Cardiometabolic Clinic (for those meeting prespecified criteria).
223893347|NCT05642715|BEHAVIORAL|TAU|Participants allocated to the EX+/TAU arm will be offered: Medical treatment as usual from their regular providers after completing Stage 1 of the study
223893348|NCT03884855|OTHER|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
223893349|NCT03884855|OTHER|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
223516755|NCT01266980|DRUG|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
223893350|NCT05287568|DRUG|Venetoclax|Venetoclax is a potent, selective and orally bioavailable small molecule inhibitor of BCL-2 that binds with \> 1,000-fold higher affinity to BCL-2 (Ki \< 0.010 nM) than other apoptotic pathway proteins BCL-XL (Ki = 48 nm) or MCL-1 (Ki \> 444 nM). Leukemia stem cells (LSCs) overexpress BCL-2, and BCL-2 overexpression has been associated with worse outcomes in AML.
223893351|NCT05287568|DRUG|CC-486|An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.
223516756|NCT05954884|OTHER|Telemedicine-based WHO HEARTS package|"Interventions in this study will include-~1. Community- and team-based model of hypertension care delivery~2. Opportunistic hypertension screening at Community Clinic (CC) by Community Health Care Provider (CHCP)~3. Use of a hypertension treatment protocol with amlodipine and losartan and standardized approach to measuring and monitoring BP, retaining participants in care, and promoting adherence~4. Use of Simple App to document BP readings and medications/dosage and to monitor hypertension care delivery at the CC through utilities including dashboards~5. Establishment of telemedicine service between CC and Upazila Health Complex (UHC)~6. Community-based, multi-month prescription refills from CC~7. Training of clinic and research staff on BP measurement following standard techniques~8. Site monitoring and mentorship to ensure screening and patient enrollment/registration~9. Use of text messages to promote follow-up visits and medication adherence"
223516757|NCT04199390|PROCEDURE|total hip arthroplasty|each patient is expected to undergo an anterior total hip arthroplasty procedure and some sort of physical therapy postoperatively
223516758|NCT05941780|DIAGNOSTIC_TEST|Pain classification method|A current clinical algorithm will be used to determine the predominant type of pain in individuals with FMS. The classification to diagnose nociceptive, neuropathic and nociplastic pain will based on a recent method developed by Nijs et al. This method consists of seven steps in total. These steps question the following, respectively: duration of pain, pain distribution, presence of nociceptive pain, presence of neuropathic pain, phenomenon of hypersensitivity, presence of hypersensitization and presence of specific comorbidity. Besides, inter-rater and intra-rater reliability of pain classification algorithm will be determined by two independent researchers.
223516759|NCT01971918|BIOLOGICAL|anti drug antibodies dosage|anti drug antibodies dosage
223516760|NCT01765413|BIOLOGICAL|Varicella-zoster virus|
223893352|NCT05723601|DRUG|Estradiol vaginal cream|Participants will use vaginal estradiol cream for 3 months
223516761|NCT01765413|BIOLOGICAL|Yellow Fever Vaccine|
223516762|NCT01765413|BIOLOGICAL|Placebo|
223516763|NCT01532154|DRUG|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
223516764|NCT02386072|DRUG|mirabegron|oral
223516765|NCT02386072|DRUG|antimuscarinic medication|oral
223893353|NCT05723601|DRUG|Estradiol Vaginal Tablet|Participants will use vaginal estradiol tablet for 3 months
223893354|NCT04898595|PROCEDURE|Discontinuation of CRRT|Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
223893355|NCT05381844|OTHER|Blood sampling|30 ml blood sampling for virological research
223893356|NCT05936099|BEHAVIORAL|E-cigarette & Tobacco Use Treatment Intervention|The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
223893357|NCT03972930|RADIATION|Hypofractionated Radiotherapy|Hypofractionated radiation is delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
223893358|NCT03841305|PROCEDURE|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
223893359|NCT05116787|DRUG|Placebo|Administered orally twice daily
223893360|NCT05116787|DRUG|BCX9930 monotherapy|Administered orally twice daily
223893361|NCT05217420|BEHAVIORAL|Moving Well|Experimental arm
223893362|NCT05217420|BEHAVIORAL|Staying Well|Active comparator arm
224081930|NCT05417490|OTHER|PRADO-IC|"The CAM (Health Insurance Advisor) are part of the staff of the Primary Health Insurance Funds (CPAM). They are physically present in the establishments participating in the PRADO.~They are facilitators between city health professionals and the patient for their return home.~They assist the patient in making appointments with their general practitioner, their cardiologist, and the IDE (general care nurses) trained at PRADO-IC who will make the home visits.~After returning home, the CAM verifies, by two telephone calls at 1 week and 2 months, that the patient has initiated his outpatient follow-up.~IDE, trained in the therapeutic education of the IC patient according to the PRADO-IC device, carry out:~* for NYHA (New York Heart Association) 1-2 patients: 8 home visits in two months.~* for NYHA 3-4 patients: 8 home visits in 2 months, upon confirmation and prescription from the physician, 8 visits in the following 4 months.~The doctor carries out a long consultation at 2 months."
223516766|NCT05454982|DEVICE|Cryocompression|A cryocompression device will be attached to the lower limb of participants using a cuff spanning from the mid-thigh to mid-calf. The device will circulate ice-water at a constant temperature of 8℃ throughout each test session. Depending on the condition, the cuff will also apply varying levels of pressure for the duration of each test. Each test session will last for 30 minutes. Participants will take part in all conditions, with at least 24 hours rest in between test sessions. Skin temperature around the knee will be measured prior to the cryocompression device being applied; every 5 minutes during the 30 minute test; and every 5 minutes after the test until skin temperature \>15℃.
223516767|NCT04614779|DRUG|CN128 Tablets|Iron chelator, oral tablets
223516768|NCT00000340|DRUG|Pemoline|
223516769|NCT03878121|BIOLOGICAL|Ad4-Env145NFL|10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
223516770|NCT03878121|BIOLOGICAL|Ad4-Env150KN|10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
223516771|NCT03878121|BIOLOGICAL|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
223516772|NCT06546527|DRUG|[177Lu]Lu-PSMA-137|\[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
223516773|NCT03940521|OTHER|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
223516774|NCT02217007|DRUG|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
223516775|NCT03309475|BEHAVIORAL|SocialMIND|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
223516776|NCT03309475|BEHAVIORAL|Psychoeducational multicomponent intervention|The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
223516777|NCT03309475|BEHAVIORAL|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
223516778|NCT03309475|DRUG|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
224099187|NCT01986335|BIOLOGICAL|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
224099188|NCT05726695|DIAGNOSTIC_TEST|microRNA test|Laboratory analysis for the detection of microRNA in blood samples.
224099189|NCT05726695|DIAGNOSTIC_TEST|Heart ultrasound examination|Heart ultrasound examination will be performed as a standard cardiology examination.
224268974|NCT03092388|DIAGNOSTIC_TEST|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
223516779|NCT06142591|DRUG|Oxycodone 10mg|10mg of oxycodone was added to Octenisept in the wound dressing.
223516780|NCT06142591|DRUG|Oxycodone 20mg|20mg of oxycodone was added to Octenisept in the wound dressing.
223516781|NCT00744419|DRUG|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose \[0.4 mg/kg (\< 44 wks PMA) or 0.8 mg/kg (44 wks to \< 1 yr)\] and the last 6 subjects in each age group will receive high dose \[0.8 mg/kg(\< 44 wks PMA) or 1.6 mg/kg(44 wks to \< 1 yr)\]
223516782|NCT05345405|BEHAVIORAL|Dyadic CARE|Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
223516783|NCT05345405|BEHAVIORAL|Supporter-Only CARE|Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
223516784|NCT03920020|OTHER|the concentric isokinetic exercise group|concentric isokinetic exercises
223893363|NCT05406817|DRUG|Revumenib|Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
223893364|NCT05159830|DRUG|Cannabidiol oral oil|The CBD dosing used in the CARAMEL study will start at 40mg/d up to 600 mg/d. Oral oil contain 20 mg of CBD. 20 mg because our supplier does not have a more highly dosed oral oil.
223893365|NCT05159830|DRUG|Placebo oral oil|Placebo of similar cannabidiol galenic form
223893366|NCT04516564|DRUG|AK119|Single dose of AK119 is administered via intravenous infusion to healthy subjects
224099190|NCT00775567|DIETARY_SUPPLEMENT|Fructose powder|30g in 250ml water twice a day
224099191|NCT01584024|DEVICE|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
224081931|NCT05417490|DEVICE|Remote monitoring|"Chronic Care Connect is intended for remote medical monitoring of patients suffering from chronic heart failure.~It consists of a web application (named NOMHADChronic™) and non-medical remote human assistance performed by qualified personnel.~Non-medical human assistance allows the following steps to be carried out:~* characterization of alerts~* structured follow-up of remote patients.~This non-medical human assistance is provided by:~* nurses trained in therapeutic education and cardiology, Customer Relations Advisors, and logisticians.~Weight and symptoms (listed in an 8-question questionnaire) are collected respectively using a connected scale and the mobile application.~It allows, via a web browser:~* to the personnel constituting the non-medical human assistance, to have access to the health data of the patients~* remote monitoring doctors, to have access to the health data of each of their own patients, and to carry out medical remote monitoring procedures."
224081932|NCT06272370|OTHER|Asthma Symptom Monitoring online tools|All participants will be provided access to the Asthma Symptom Monitoring tools and 3/4's will be randomized to one of the other three arms above
224081933|NCT06272370|DRUG|Inhaled Steroids|participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice with their current reliever therapy or be converted to budesonide/albuterol as rescue therapy
224081934|NCT06272370|DRUG|Azithromycin Pill|Participants will take 500mg of azithromycin three times a week or 10mg/kg if under 50Kg which may be reduced to 250mg/Kg for side effects
224081935|NCT06083220|BEHAVIORAL|Smart Start - School Readiness Program|Participants will complete 64 hours of intervention focused on goal directed school readiness. Each of the five domains will be addressed in each session, and the activities will be tailored to support the individual goals of the participant using a goal-directed training approach. A goal-directed training approach includes the child, caregiver, and researcher collaboratively setting goals that are meaningful to the child and their family. Intervention strategies for goal attainment will include both remediation of skills (i.e. learning to button a button) or the accommodation of skills (i.e. using Velcro instead of a button) depending on the child's goals and current ability. The primary focus of the intervention will be goal attainment related to school readiness.
224081936|NCT05523973|OTHER|Lingual Endurance Training|Participants will participate in 3 training sessions per day for 8 weeks. Some participants will complete 3 sessions of lingual endurance exercise. For example, if the participant completed 100 repetitions during the baseline measurement, they would complete 75 repetitions during their exercise session. Other participants will complete effortful swallows during their 3rd training session. These participants will complete 30 swallows where they are instructed to press their tongue hard on the bulb and swallow their saliva.
224081937|NCT05301478|DEVICE|standard of care insole|standard of care diabetic insole
224081938|NCT05301478|DEVICE|3D Printed Insole - pressure based|3D Printed Insole - pressure based
224081939|NCT05301478|DEVICE|3D Printed Insole - FEA|3D Printed Insole - FEA
224081940|NCT06519656|DRUG|Mazdutide|In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.
224081941|NCT06787664|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224081942|NCT05888103|DRUG|Inclisiran|Inclisiran s.c
223516785|NCT03920020|OTHER|the eccentric isokinetic exercise group|eccentric isokinetic exercises
223516786|NCT03920020|OTHER|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
223516787|NCT00825448|PROCEDURE|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
224081943|NCT05888103|DRUG|Matching Placebo for Inclisiran|Matching s.c. placebo
224081944|NCT05892614|DRUG|efzofitimod 450 mg|IV infusion over approximately 60 minutes every 4 weeks
223516788|NCT05229367|OTHER|Eccentric isokinetic training|Eccentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
223516789|NCT05229367|OTHER|Concentric isokinetic training|Concentric exercises of the hamstring muscles were performed with the use of an isokinetic dynamometer device.
223516790|NCT06522932|DRUG|64Cu-GRIP B|Given IV
223516791|NCT06522932|PROCEDURE|Positron Emission Tomography (PET)|Undergo imaging procedure
224081945|NCT05892614|DRUG|efzofitimod 270 mg|IV infusion over approximately 60 minutes every 4 weeks
224081946|NCT05892614|DRUG|Placebo|IV infusion over approximately 60 minutes every 4 weeks
224081947|NCT05707884|OTHER|critical care management|The different sedation methods result in considerable differences in terms of set-up costs and the management of the patient, which will be examined in a direct comparison.
224081948|NCT01806311|DRUG|Candesartan32mg|
224081949|NCT01806311|DRUG|Amlodipine10mg|
223516792|NCT06522932|PROCEDURE|Optional tumor biopsy|Undergo optional tumor biopsy
223516793|NCT02416544|OTHER|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
223516794|NCT01690325|DRUG|Docetaxel|
223516795|NCT01690325|DRUG|Trastuzumab|
223516796|NCT01690325|DRUG|Bevacizumab|
223516797|NCT01690325|DRUG|Epirubicin|
224081950|NCT06270784|PROCEDURE|Traditional Extraction|Participants in this group will undergo traditional extraction method. This method involves uncovering the impacted tooth and extracting the tooth with or without dividing it.
224081951|NCT06270784|PROCEDURE|Orthodontic Extraction|"Participants in this group will undergo orthodontic extraction method. In this method, a two-stage surgical procedure will be performed. In the first operation, the impacted tooth will be uncovered, and then a button will be placed on the tooth. For anchorage purposes, orthodontic mini screws will be placed in the mandibular ramus or zygomaticomaxillary buttress area. Elastics and/or ligature wires fixed to the button will be attached to the mini screw to provide force for the traction of the tooth.~Patients will be called for check-up appointments every two weeks, and the movement of the impacted tooth will be monitored with panoramic x-rays. The second operation will be planned when the tooth moves away from the inferior alveolar nerve. In the second operation, the tooth will be extracted in a similar way to the traditional extraction group."
224081952|NCT04528771|DRUG|SNO|Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
224081953|NCT04528771|DRUG|Nitrogen gas|Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
224081954|NCT05959720|DRUG|Prednisone|60 mg/m2 D1 to D21
224081955|NCT05959720|DRUG|Vincristin|1.5 mg/m2 D1, D8, D15 and D22
224081956|NCT05959720|DRUG|Daunorubicin|40 mg/m2 D1, D8, D15 and D22
224081957|NCT05959720|DRUG|Peg-asparaginase|2000 UI/m2 D12 and D26
224081958|NCT05959720|DRUG|Intrathecal Suspension|MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
224081959|NCT05959720|DRUG|Cyclophosphamide|1000 mg/m2 D36 and D64
224081960|NCT05959720|DRUG|Cytarabine|75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60
224081961|NCT05959720|DRUG|Mercaptopurine|30 mg/m2 D36 to D63 and D1 to D56 of consolidation
224081962|NCT05959720|DRUG|Methotrexate|3.000 mg/m2 D8, D22, D36 and D50
224081963|NCT05959720|DRUG|Doxorubicin|30 mg/m2 D1 and D22
224081964|NCT05227105|BEHAVIORAL|Physical Activity|Physical activity will be encouraged up to an amount of 150 minutes per week.
224081965|NCT05227105|BEHAVIORAL|Delayed intervention|Physical activity will be encouraged at the end of the trial.
223516798|NCT01690325|DRUG|Cyclophosphamid|
224081966|NCT05663580|DRUG|Cabotegravir 600mg/3mL, Rilpivirine 900mg/3mL|Initial administration of two separate intramuscolar injection of cabotegravir 400mg/3mL and rilpivirine 600mg/3mL in opposite gluteal muscles, repeated one month later and then every two months.
224081967|NCT06437509|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224081968|NCT06437509|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
224081969|NCT06777420|OTHER|Question prompt list|The question prompt list includes 12 questions related to neoadjuvant therapy. It has been developed by an expert team including breast surgeons, oncologists, nurses, and psychologists and has been refined through focus interview with patient advocates and caregivers.
224081970|NCT05617833|COMBINATION_PRODUCT|MLT+EPO|Melatonin component will be a daily dose of 30 mg/kg enteral administered in the evening in a split dose given at cares/feedings. EPO component is a two-stage regimen with high dose EPO (1000 U/kg/dose q 48 hrs ± 2hr subcutaneously or intravenously) for 10 doses followed by maintenance dose EPO (400 U/kg/dose q Monday, Wednesday, Friday subcutaneously or intravenously) to 33-6/7wk. Maintenance EPO dosing will begin on the day closest to completing the high dose series.
224081971|NCT05617833|OTHER|Placebo|Placebo enteral and IV
224081972|NCT04259125|DIAGNOSTIC_TEST|Blood draw|Evaluation of plasma inflammatory markers including cytokines and micro-RNA.
224081973|NCT04259125|OTHER|Survey|Regarding epilepsy and development.
224081974|NCT05734989|DIAGNOSTIC_TEST|BP|Blood pressure measurements and HbA1c tests will be conducted to identify participants with or at risk for high blood pressure and/or Type 2 Diabetes. Those identified will be referred to PCP for follow up/treatment.
224081975|NCT05734989|DIAGNOSTIC_TEST|HbA1c|HbA1c will screen to identify patients with Type 2 diabetes
224081976|NCT05734989|BEHAVIORAL|PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD|Guidelines will be developed and provided to PCPs to use with their Hispanic/Latinx patients with or at risk for CKD.
224081977|NCT03915145|OTHER|Kinesio tape application|Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
224081978|NCT03915145|OTHER|Sham Kinesio tape application|Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
224081979|NCT03915145|OTHER|No intervention|The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
223516799|NCT01604798|OTHER|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
223516800|NCT06294899|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed to patients with suspected lower respiratory tract infections.
223516801|NCT06294899|DIAGNOSTIC_TEST|C-Reactive Protein Test|C-Reactive Protein Test will be performed to patients with suspected lower respiratory tract infections.
223516802|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
223516803|NCT01482403|DRUG|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
223516804|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 24 weeks
223516805|NCT01482403|DRUG|Pegasys|180 microgram subcutaneous once a week for 48 weeks
224081980|NCT02326519|OTHER|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
223516806|NCT01482403|DRUG|boceprevir|800 mg three times a day for 24 weeks
224081981|NCT00352534|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo radiotherapy
224081982|NCT00352534|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223516807|NCT01482403|DRUG|boceprevir|800 mg three times a day for 48 weeks
223516808|NCT01482403|DRUG|mericitabine|1000 mg twice daily for 24 weeks
223516809|NCT01482403|DRUG|mericitabine placebo|mericitabine placebo
223516810|NCT01482403|DRUG|boceprevir placebo|boceprevir placebo
223516811|NCT01482403|DRUG|boceprevir|800 mg three times a day for 44 weeks
223516812|NCT02236897|OTHER|PET Scanning|
223516813|NCT03232892|DRUG|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
223516814|NCT03766906|BEHAVIORAL|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
223516815|NCT04883749|BIOLOGICAL|Acalabrutinib|Cycle (q28d): Acalabrutinib p.o.100 mg twice daily (BID)
223516816|NCT06379620|DEVICE|Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)|Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
223516817|NCT02035228|DEVICE|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation"
223516818|NCT02035228|DEVICE|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation"
223516819|NCT02035228|DEVICE|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation"
223516820|NCT02035228|DEVICE|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation"
223516821|NCT02035228|DEVICE|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation"
223516822|NCT02035228|DEVICE|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation"
224081983|NCT00352534|PROCEDURE|Chest Radiography|Undergo chest X-ray
224081984|NCT00352534|PROCEDURE|Computed Tomography|Undergo CT
224081985|NCT00352534|BIOLOGICAL|Dactinomycin|Given IV
223516823|NCT02035228|DEVICE|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation"
223893367|NCT04516564|DRUG|Placebo|Single dose of placebo is administered via intravenous infusion to healthy subjects
224081986|NCT00352534|DRUG|Doxorubicin Hydrochloride|Given IV
224081987|NCT00352534|PROCEDURE|Echocardiography Test|Undergo echocardiography
224081988|NCT00352534|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224081989|NCT00352534|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224081990|NCT00352534|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
224081991|NCT00352534|DRUG|Vincristine Sulfate|Given IV
224081992|NCT01836679|DRUG|Chidamide|Given orally
224081993|NCT01836679|DRUG|Paclitaxel|Given IV
224081994|NCT01836679|DRUG|Carboplatin|Given IV
224081995|NCT01836679|DRUG|Placebo|Given orally
224081996|NCT00408863|DRUG|tibolone|tibolone 2.5 mg/day
224081997|NCT00408863|DRUG|placebo|
224081998|NCT02304198|DRUG|Udenafil|Udenafil 50mg tablet
224081999|NCT00783016|DRUG|Morphine|
223516824|NCT02035228|DEVICE|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation"
223516825|NCT02035228|DEVICE|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation"
223516826|NCT03789370|DRUG|Propofol|Maintanance of general anaesthesia with propofol
223516827|NCT03789370|DRUG|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
223516828|NCT05596812|OTHER|New Care Pathway|The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
223516829|NCT01748656|DEVICE|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
223516830|NCT01748656|DEVICE|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
223516831|NCT06308211|OTHER|MOTOR IMAGERY+MIRROR THERAPY+ROUTINE PHYSICAL THERAPY|Subjects will be instructed to watch the video provided and recorded by investigator.In next step participants will be asked to close the eyes to focus and then to imagine how they are doing task they had previously observed 10 times.Participants will be than instructed to carry out the task in verbal commands given whenever necessary.The unaffected limb will be placed in front of the mirror so that the reflected illusion of the limb would be hallucinated to represent the affected limb and routine physical therapy includes passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions).
223516832|NCT06308211|OTHER|MOTOR RELEARNING PROGRAM+ROUTINE PHYSICAL THERAPY|"Motor relearning consists of five components including analysis of task, practice of missing components, practice of task and transference of training. Patient will be asked to practice task in both sitting and standing~* supine to side-lying to sitting~* looking up at ceiling (ensure that centre of body mass does not move back when head is tilted back)~* without moving one's feet, turning to gaze over each other's shoulders and scanning the surroundings for specific items, reaching motions in multiple directions while moving the head and trunk, scooting in bed, altering the base of support (standing with your feet together, in tandem, with one foot on a step, or on one leg)~* squatting to pick up an object and cross over stepping and routine physical therapy includes Passive and active assisted range of motion for the upper and lower extremity including the shoulder, forearm, wrist, hip, knee and ankle will be given (10 - 15 repititions)."
223516833|NCT06641492|BEHAVIORAL|Chatbot-delivered interventions tailored to one's stage of changes|The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
223516834|NCT06641492|BEHAVIORAL|Chatbot-delivered standard interventions|The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
223516835|NCT04118920|DRUG|Topical insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
223516836|NCT04118920|DRUG|Topical insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
223516837|NCT04118920|DRUG|Artificial tears|N=3, 40 microliters per drop
223516838|NCT06636903|OTHER|Acupressure|Before pressing directly on the point for acupressure, a gentle warming, relaxing and preparatory process of approximately 15 seconds should be performed on the point area. In this case, manual pressure with the thumb, index finger and/or middle finger will be applied sequentially (in the rhythm of breathing) without lifting the finger for an average of 1.5 minutes on each point, at a frequency that does not disturb the person, does not cause pain and has a calming effect. Before the suturing procedure, acupressure will be applied to the HT7 and Li4 points by a researcher (EB) who has an acupressure certificate.
223516839|NCT06636903|OTHER|Acupressure|Before and after acupressure, vital signs and before acupressure, anxiety scores will be checked using the Spielger State Anxiety Scale. In addition, vital signs and anxiety scores will be checked again immediately after the stitching procedure.
223516840|NCT05205863|BIOLOGICAL|Cofact|Human prothrombin complex concentrate
223893368|NCT04359108|DEVICE|Navigation system mode: Argus Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Argus mode~* Haptics: none~* Audio: none Since this mode only provides the standard Argus vision, it is equivalent to using the base Argus II system without the navigational aid."
223893369|NCT04359108|DEVICE|Navigation system mode: Depth Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Depth mode (at Argus II resolution and field-of-view)~* Haptics: none~* Audio: none"
224082000|NCT01602341|DRUG|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
224082001|NCT01602341|DRUG|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
224082002|NCT01602341|DRUG|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
224082003|NCT01602341|DRUG|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
224082004|NCT00955435|OTHER|Non-interventional|Patients receive induction hormones\* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.
224082005|NCT00955435|GENETIC|Protein expression analysis|
224082006|NCT00955435|GENETIC|Proteomic profiling|
224082007|NCT00955435|OTHER|Laboratory biomarker analysis|
223516841|NCT06529627|PROCEDURE|Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection|pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
223516842|NCT06501963|BIOLOGICAL|Live Attenuated Influenza Vaccine|The FDA-approved live attenuated seasonal influenza vaccine (LAIV) (FluMist®, AstraZeneca) is licensed in the US for people 2-49 years of age. The approved seasonal LAIV at the time of study enrollment will be obtained from the manufacturer. LAIV will be administered by a study nurse or health care provider at the Hope Clinic as a single 0.2 milliliter (mL) dose given as 0.1 mL spray in each nostril.
223516843|NCT02772302|DEVICE|mindBEAGLE EEG-based brain-computer interface|
223516844|NCT05821894|OTHER|Observational study|
223516847|NCT05917964|DRUG|LP-168 tablet|LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
223516848|NCT05965323|BEHAVIORAL|Health Education|Health education with comic books and videos
223516849|NCT03942653|DRUG|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
223516850|NCT03942653|DRUG|Pembrolizumab|Pembrolizumab, IV, Q3W
223516851|NCT04906187|OTHER|Arm A : intraoperative ANI monitoring of nociception|For the experimental group (arm A), the sufentanil doses are adjusted to maintain an ANI between 50 and 70. Morphine doses are adjusted from 0.05 to 0.05 µg / ml. Intraoperative data will be collected for ANI, TIVA and hemodynamics.
223516852|NCT04906187|OTHER|Arm B : no specific monitoring of nociception|For the control group (arm B), adjustments to the opioid doses are made in relation to the hemodynamic reactions of the patient and the operating times. Intraoperative data will be collected for TIVA and hemodynamics.
223516853|NCT04140344|OTHER|Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
223516854|NCT04970576|DRUG|Rivaroxaban|Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
224082008|NCT01402245|BIOLOGICAL|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
223516855|NCT04970576|DRUG|Warfarin|Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
223516856|NCT06463899|PROCEDURE|multi-perforated catheter|After skin closure, cardiac surgeons place multi-perforated catheters aseptically.
223516857|NCT06463899|PROCEDURE|Classic procedure|opioid analgesia (PCA morphine in bolus mode alone or morphine titration if PCA not available), nefopam, non-steroidal anti-inflammatory drugs, ketamine, pregabalin and paracetamol
223516858|NCT03268499|PROCEDURE|Lipiodol-based transarterial chemoembolization|Arterial catheterization to segmental, subsegmental, or sub-subsegmental level was achieved depending on the tumor size, to gain arterial access as close to the tumors as possible. The formulation was delivered under fluoroscopic control until the vasculature of all tumors was entirely filled, or until the maximum dose was reached.
223893370|NCT04359108|DEVICE|Navigation system mode: Depth Vision with Haptic / Audio|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: Depth mode (at Argus II resolution and field-of-view)~* Haptics: yes~* Audio: yes"
224082009|NCT01402245|BIOLOGICAL|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
224082010|NCT05480969|OTHER|Heart failure educational intervention|Educational intervention constitutes of a face-to-face session delivered before hospital discharge and outpatient sessions on regular intervals for a total of 6 months. Outpatient sessions in Intervention group 1 constitute of two home-based sessions on months 1 and 3, combined with weekly telephone calls during month 1 and bi-weekly calls during months 2-6. Outpatient sessions in Intervention group-2 constitute of weekly telephone sessions during month 1 and bi-weekly calls during months 2-6. The pre-discharge session will address self-monitoring and health awareness. Education will be provided by in-person discussion and through printed supporting material. Caregiver education will include understanding heart failure and advice on how to support their patient, manage their own health and well-being and how to get help when needed. During outpatient sessions, repeat education will be done and evaluation of implementation of self-care activities.
224082011|NCT06265142|PROCEDURE|Bladder catheterization|Participant will undergo the standard bladder catheterization for urine collection
224082012|NCT06265142|PROCEDURE|clean catch urine via bladder massage technique|Participant will undergo clean catch urine via bladder massage technique
224082013|NCT04439279|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
224082014|NCT03521791|DRUG|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
224082015|NCT03521791|OTHER|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
224082016|NCT05046288|OTHER|Virtual guided tours|The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
224082017|NCT04024501|DRUG|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
224082018|NCT04024501|DRUG|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
224082019|NCT04024501|DRUG|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
224082020|NCT04024501|DRUG|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
224082021|NCT04024501|DRUG|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
223516859|NCT06224153|OTHER|3-day dietary record|This is the conventional ingesta assessment. It will be performed twice during the study.
223516860|NCT06224153|OTHER|Food Frequency Questionnaire (FFQ)|This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
223516861|NCT03622905|DEVICE|DBS-f On|Deep Brain Stimulation of the fornix
223516862|NCT03622905|DEVICE|DBS Off|Deep Brain Stimulation of the fornix turned off
223516863|NCT03533491|BEHAVIORAL|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
223516864|NCT04002063|BEHAVIORAL|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
223516865|NCT04002063|BEHAVIORAL|CBT alone|CBT therapy individual
223516866|NCT06464913|RADIATION|With or without chest wall RT|Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
223516867|NCT04508530|BIOLOGICAL|Panzyga|Panzyga 10% IVIG
223516868|NCT04508530|OTHER|Placebo|Placebo
223893371|NCT04359108|DEVICE|Navigation system mode: Haptic / Audio|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: none~* Haptics: yes~* Audio: yes Since this mode does not provide any visual feedback, it is equivalent to using navigational aid completely blind without a visual prosthesis."
223893372|NCT04359108|DEVICE|Navigation system mode: High Field-of-View Depth Vision|"This intervention uses the navigational aid with the output sensory modalities configured as follows:~* Vision: High Field-of-View Depth mode (at twice the Argus II resolution and field-of-view along each dimension)~* Haptics: none~* Audio: none"
224082022|NCT05357131|BEHAVIORAL|Hypnosis without VR (HYP)|"HYP will last for 15 minutes including an induction phase of 5 minutes. The hypnotic audio script Heaven of Peace developped/recorded by Pr. M-E. Faymonville will be used."
224082023|NCT05357131|DEVICE|Hypnosis with VR (VRH)|The VRH intervention will use the Aqua video session developed by Oncomfort.
223516869|NCT05702047|BEHAVIORAL|Nose-only breathing|Participants will breathe only through their nose (mouth closed) during rest and submaximal exercise.
223516870|NCT05702047|BEHAVIORAL|Mouth-only breathing|Participants will breathe only through their mouth (nose clips prevent nose breathing) during rest and submaximal exercise.
223516871|NCT06148948|DRUG|BI 1584862|BI 1584862
224082024|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
224099192|NCT01584024|DEVICE|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
223516872|NCT06148948|DRUG|Placebo|Placebo matching BI 1584862
223516873|NCT04324944|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
223516874|NCT04324944|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation around befriending. Each session is 60 minutes long.
223516875|NCT06175533|PROCEDURE|ultrasound guided 60 degree CRF for plantar fasciitis|ultrasound guided plantar fascia CRF for chronic conditions not responding to treatment
223516876|NCT01725282|DRUG|quetiapine extended release (XR)|Extended release tablets
224099193|NCT05015101|OTHER|Cohort observation|Cohort observation
224082025|NCT00650611|DRUG|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
224082026|NCT00680836|DRUG|Placebo|orally two times per day for 14 days
224082027|NCT00680836|DRUG|Rifaximin|550 mg orally two times per day for 14 days
224082028|NCT02343484|DRUG|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
224082029|NCT02343484|DRUG|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
224082030|NCT03038308|DRUG|Ropinirole|0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
224082031|NCT00145847|DRUG|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
224082032|NCT04607395|RADIATION|pre-operative radiograph|"Three hundred and sixty pre-operative radiographs of deep carious lesions and a contrasted version of the same set have been screened and annotated by 4 evaluators. Annotations were placed at the dentino-enamel junction, at the floor of the carious lesions, and on pulp chamber wall. From these annotations, the ratios residual dentin thickness/ total dentin thickness were derived. First, inter-evaluator agreement and concordance were assessed. A logistic regression that accounted for measurement error was applied to precisely estimate the capacity of the ratio to predict exposure (reported as odds-ratio)."
224082033|NCT03695913|OTHER|Normal Diet|"Phase I (regular diet):~all participants will eat their normal diet and will log their food."
224082034|NCT03695913|OTHER|Low carb diet|"Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food"
224082035|NCT03695913|DEVICE|CGM with no real time feedback|Phase I will collect CGM without real time feedback
224082036|NCT03695913|DEVICE|CGM with real time feedback)|Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.
224082037|NCT03695913|BEHAVIORAL|Education material|"Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make."
224082038|NCT04574596|OTHER|no Intervention|This is an observational study. There is no intervention
224082039|NCT02303431|DRUG|Edoxaban low dose|Edoxaban low dose
223516877|NCT01725282|DRUG|Placebo|matching tablets
224082040|NCT02303431|DRUG|Edoxaban high dose|Edoxaban high dose
224082041|NCT01973309|DRUG|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
224082042|NCT03729778|BIOLOGICAL|Prevnar-13|One time administration of prevnar-13 vaccine
223516878|NCT04064567|BEHAVIORAL|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network \[TCN\]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
223516879|NCT04064567|OTHER|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
223893373|NCT04359108|DEVICE|Distance test vision mode: Low Resolution / Low Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: Low~* Field-of-View: Low"
224082043|NCT01777763|DRUG|Posaconazole 200 mg|
224082044|NCT01777763|DRUG|Posaconazole 300 mg|
224082045|NCT04887571|OTHER|No Intervention - Observational Registry|All consecutive adult patients in the Cape Metropole and the Garden Route Health District with an Acute coronary syndrome (STEMI, NSTEMI, Unstable Angina) will be recruited into the PERFUSION Registry.
224082046|NCT00321165|DRUG|taurolidine|
224082047|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily"
224082048|NCT03054363|DRUG|Tucatinib in Combination with Palbociclib and Letrozole|Subjects Tucatinib 300 mg PO BID Palbociclib 75mg PO daily 21 days on followed by 7 days off Letrozole 2.5 mg PO daily.
224082049|NCT03242954|OTHER|Autonomous minor consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
224082050|NCT03242954|OTHER|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
224082051|NCT03242954|OTHER|Parental permission required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
224082052|NCT04690699|BIOLOGICAL|Lerapolturev|Lerapolturev administered via intravesical instillation once
224082053|NCT04690699|OTHER|5% DDM|5% DDM and saline washes
224082054|NCT05512949|BIOLOGICAL|JYNNEOS|JYNNEOS is FDA-approved and licensed as a smallpox and monkeypox vaccine in the United States. JYNNEOS is a live vaccine produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus. Each 0.5 mL dose is formulated to contain 0.5 x 10\^8 to 3.95 x 10\^8 infectious units of MVA-BN live virus in 10 mM Tris (tromethamine), 140 mM sodium chloride at pH 7.7. Subcutaneous is administered in the deltoid region, intradermal is administered in the volar aspect (inner side) of the forearm.
223516880|NCT04624399|DRUG|Atezolizumab|Patients receive 2 x 3-weekly cycles of Atezolizumab (one infusion on the first day of each cycle) prior to cystectomy surgery.
223516881|NCT05263791|DEVICE|Airmod|Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
223516882|NCT04576481|BEHAVIORAL|Texting|Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.
223516883|NCT04576481|BEHAVIORAL|Regret|Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.
223516884|NCT04576481|BEHAVIORAL|Lottery|Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
223516885|NCT06287853|DEVICE|Tapestry Biointegrative Implant|The Tapestry RC Biointegrative Implant System is an arthroscopic delivery and fixation system intended for tendon augmentation with Tapestry Biointegrative Implant during arthroscopic rotator cuff (RC) repair. The system combines the biointegrative collagen-based implant (Tapestry Biointegrative Implant) with bioabsorbable fixation ( Bioabsorbable Anchors). Tapestry Biointegrative Implant is a collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues.
223516886|NCT04879563|OTHER|ASCAPE-based follow-up strategy|"Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues."
223516887|NCT06642714|PROCEDURE|weaning by early non-invasive ventilation and progressive high flow oxygen therapy|"Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR\>30bpm, HR\>130bpm,SBP\>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh"
223516888|NCT06641544|DRUG|Inetetamab|Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
223516889|NCT06640062|OTHER|Erector spinae plane block|Patients received ultrasound-guided erector spinae plane block.
223516890|NCT06640062|OTHER|Oblique subcostal transversus abdominis plane block|Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
223516891|NCT06637007|DRUG|Chidamide Tablets combined with AK112|Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
223516892|NCT06637033|BEHAVIORAL|Chewing Food|Daily foods like candies and dumplings will be cut into small pieces. Patients will chew them before each feeding and then spit them out, with each training session lasting ten minutes.
223516893|NCT06637033|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
223516894|NCT06637033|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223516895|NCT06639555|PROCEDURE|PRP( platelet rich plasma)|regenerative therapy with PRP for vertical bone defects
223516896|NCT06639555|PROCEDURE|EMD (Enamel Matrix Derivative)|regenerative therapy with EMD for vertical bone defects
223516897|NCT06639555|PROCEDURE|Guided Tissue Regeneration (barrier membrane)|guided tissue regeneration with barrier membrane alone for vertical bone defects
223516898|NCT06639555|PROCEDURE|Guided Tissue Regeneration(barrier membrane and PRP)|guided tissue regeneration with barrier membrane and PRP for vertical bone defects
223516899|NCT04652882|DRUG|Tasimelteon|oral capsule
223516900|NCT04652882|DRUG|Placebo|oral capsule
223516901|NCT04715022|DRUG|Ascorbic acid solution (American Regent Laboratories Inc.)|"Ascorbic acid solution (American Regent Laboratories Inc.) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a drip-infusion of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min."
223516902|NCT04715022|DRUG|Saline|Placebo (saline) will be administered
223516903|NCT03403790|DRUG|Quetiapine|Oral (extended-release tablet)
223516904|NCT03204747|OTHER|Observational study : gait speed|No intervention, only propose water and wait for need to void
223516905|NCT01682720|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
223516906|NCT01682720|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223516907|NCT01682720|DRUG|Placebo to match SOF|Placebo to match SOF administered orally once daily
224082055|NCT01825902|DRUG|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
224082056|NCT01825902|RADIATION|fludeoxyglucose F 18|Undergo 18F-FDG PET
224082057|NCT01825902|PROCEDURE|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
224082058|NCT01825902|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
224082059|NCT01825902|OTHER|laboratory biomarker analysis|Correlative studies
224082060|NCT03156803|BEHAVIORAL|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
224082061|NCT04366999|PROCEDURE|SG|SG involved a vertical gastric resection beginning 4-6 cm from the pylorus and ending 1-2 cm from the His angle, using linear staplers with the guidance of a 36 French intragastric bougie.
224082062|NCT04366999|PROCEDURE|RYGB|RYGB entails the creation of a 15-30 mL (approximate) gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb.
224082063|NCT04366999|PROCEDURE|OAGB|OAGB entails the creation of a long gastric tube by beginning 2 cm below the angular incisure starting from the lesser curvature side and then divided vertically upward by linear cutting staplers as calibrated with a 36 French bougie, followed by the creation of a single gastrojejunal anastomosis with an afferent biliopancreatic limb of 200 cm.
224082064|NCT02135536|BIOLOGICAL|NGM282|NGM282
224082065|NCT06957639|OTHER|Standard physiotherapy intervention and home exercises|Various physical agents such as electrotherapy, hotpack (warm compress) and ultrasound therapy will be used within the standard physiotherapy intervention. These approaches are effective methods to reduce pain, relax muscles and accelerate healing. Home exercises are daily neck exercises recommended by a specialist physiotherapist.
224082066|NCT06957639|OTHER|Trigger point therapy and home exercises|Trigger point therapy is a common method used in patients with myofascial pain syndrome. This method involves manually releasing trigger points. Approaches such as pressure applications and stretching techniques are used. Muscle functions are improved by loosening painful muscle knots. Muscle flexibility and endurance are increased with home exercises.
224082067|NCT06957639|OTHER|Kinesiology Taping therapy and home exercises|"Kinesiology taping is an elastic band technique used for pain management and muscle activity support. It accelerates healing by increasing blood circulation. It supports and protects the muscles in the neck and shoulder area.~It provides supportive stabilization without restricting joint movements. It facilitates movement by reducing pain. It targets muscle strengthening and mobilization with home exercises"
224082068|NCT06957639|OTHER|Cervical - Scapular Mobilization and home exercises|Cervical and scapular mobilization includes manual therapy techniques aimed at increasing the range of motion of the joints in the spine and shoulder area. Mobilization is applied to the cervical spine and shoulder joints. Relaxation is provided in the muscles around the shoulder and neck. Cervical and scapular stability is improved. Postural disorders are corrected and range of motion is increased. Sustainability of mobilization is ensured with home exercises.
224082069|NCT06155175|DRUG|NSAIDs|The exposure to NSAIDs: NSAIDs was used at least once within the first day after surgery
224082070|NCT05839210|BEHAVIORAL|LIFE-L Mediterranean Diet|Mediterranean Diet will include goals of: 4+ vegetable servings (2-4 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week. Limit or avoid highly processed foods, sugar-sweetened beverages and foods, processed meats, red meat, and alcohol.
224082071|NCT05839210|BEHAVIORAL|LIFE-L Home-Based Exercise Program|The Home-Based Exercise Program will include goals of: 150+ minutes moderate or 75+ minutes vigorous exercise per week, completed in sessions of at least 10-minute duration, including daily aerobic exercise plus two resistance-based exercise sessions per week.
224082072|NCT05839210|BEHAVIORAL|Supportive Materials|"Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week."
224082073|NCT05956223|DEVICE|Virtual Reality measurement of essential tremor and dystonia|"1. The virtual reality (VR) platform, which detects whole-of-body movements. The VR environment is a series of sensors in a room that detect whole body motion and a series of sensors worn by the participant. As well the participant dons VR goggles that allows them to see a virtual environment in which they can perform the TETRAS.~   Within the VR platform, an avatar (an electronic image that represents the participant) is produced in the VR environment, and this will be used to review the participant.~2. Sensors for the detection of wrist, head and voice tremor. The sensors are small devices worn on the wrists and head of the participant and are similar to those used in the VR system. A microphone is attached to the participants to detect voice tremor."
224082074|NCT01781221|DEVICE|Alpha-Bio's GRAFT Natural Bovine Bone|
224082075|NCT01781221|DEVICE|Bio-Oss xenograft|
224082076|NCT04609878|DRUG|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
224082077|NCT04609878|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
224082078|NCT04609878|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
224082079|NCT04609878|DRUG|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
224082080|NCT01246206|DRUG|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
224082081|NCT05855265|DEVICE|photon therapy face mask|"In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,"
224082082|NCT04620486|OTHER|Epic Best Practice Alert|This is a customized Best Practice Alert created at Mass General Brigham in the institutional Epic electronic medical record system.
224082083|NCT03194984|DRUG|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
224082084|NCT03194984|DRUG|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
224082085|NCT01775631|BIOLOGICAL|Urelumab|
224082086|NCT01775631|BIOLOGICAL|Rituximab|
224082087|NCT00678145|DRUG|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
223516908|NCT01682720|DRUG|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
223516909|NCT01396785|DRUG|33525|Daily for 14 days
224082088|NCT00678145|DIETARY_SUPPLEMENT|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
223516910|NCT01396785|DRUG|Placebo|Daily for 14 days
224082089|NCT00678145|BEHAVIORAL|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
224082090|NCT00678145|DRUG|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
224082091|NCT00678145|DRUG|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
224082092|NCT02000804|DRUG|darapladib 160mg|drug
224082093|NCT06197061|PROCEDURE|RAMS|The robotic arms were oriented from the caudal direction. Dissection was begun circumferentially at 1.0 cm above the peritoneal reflection. The rectum was mobilized outside the longitudinal muscle layer, with the anatomical plane farther away from Denonvillier's fascia and the nerve plexus anterior or lateral to the rectum. The mobilization of the rectum reached 4-7 cm into the pelvis. After the robot was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the robotic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
224082094|NCT06197061|PROCEDURE|LAMS|The mesentery of the colon was separated by laparoscopy with the vessel of the pull-through bowel preserved. Under the rectal peritoneal reflex, close to the rectal wall separate with the electric hook, the anterior wall of the rectum was separated to the bladder neck or the posterior wall of the vagina. The posterior wall of the rectum can be separated down to 1cm above the dentate line. After the laparoscopy was unlocked, a circular incision was made 0.5-1 cm from the dentate line, dividing the mucosa upward by 0.5-1.0 cm, breaking through the muscular cuff, and exposing the laparoscopic dissection plane in the pelvis. The diseased colon was then gently pulled out through the anus. The posterior wall of the muscular cuff was completely removed along the left and right sides, accounting for two-thirds of the whole circular muscular cuff to 0.5 cm of the dentate line edge. One third of the anterior wall of the muscular cuff was retained,we then performed Soave's anastomosis.
224082095|NCT02452372|DRUG|givosiran (ALN-AS1)|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
224082096|NCT02452372|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
224082097|NCT04147468|OTHER|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
224082098|NCT04147468|OTHER|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
224082099|NCT01288560|OTHER|Advanced cardiac imaging|
224082100|NCT01288560|OTHER|Standard Cardiac Imaging|
224082101|NCT04753398|DEVICE|Blood Pressure Monitor, medication dispenser, telemonitoring technology|The telemonitoring interference in the telemonitoring arm consists of an automatic blood pressure device and medication dispenser that transmit data to a central platform.
224082102|NCT00746967|DRUG|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
224082103|NCT02307916|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
224082104|NCT02307916|OTHER|Placebo|Placebo comparator using a sterile saline solution.
224082105|NCT04273048|OTHER|Diet Intervention - Group 1|They will be provided with a Mediterranean diet plan.
224082106|NCT04273048|OTHER|Exercise Intervention - Group 1|They will be provided with an exercise plan to follow.
224082107|NCT00855660|DRUG|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
224082108|NCT00855660|DRUG|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
224082109|NCT02790866|BEHAVIORAL|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
224082110|NCT02790866|BEHAVIORAL|NCI Website|NCI Website on Lung Cancer Screening
224082111|NCT00568555|DRUG|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
224082112|NCT00568555|DRUG|Placebo - sugar pill|Placebo pill once daily
224082113|NCT03246828|OTHER|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
223516911|NCT01091532|DRUG|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
223516912|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
223516913|NCT01091532|DRUG|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
223516914|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
223516915|NCT01091532|DRUG|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
223516916|NCT01091532|DRUG|placebo|given orally twice daily for 14 days
223516917|NCT01091532|DRUG|UK-396,082|"UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
223516918|NCT01091532|DRUG|placebo|given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
223516919|NCT05541328|OTHER|Tisagenlecleucel|The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
223516920|NCT03791424|DRUG|Midazolam|Administering premedication with sedative drug to relieve anxiety
223516921|NCT03139266|BEHAVIORAL|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
223516922|NCT03139266|BEHAVIORAL|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
223516923|NCT05129735|DIETARY_SUPPLEMENT|Meal replacement shake|Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
223516924|NCT00247039|DIETARY_SUPPLEMENT|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
223516925|NCT00247039|OTHER|Placebo capsules|placebo capsules
224082114|NCT03125278|OTHER|Medication knowledge|Participants will be asked questions over the phone about their medications
224082115|NCT05431257|DRUG|Venetoclax|"Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of low-dose venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia."
223516926|NCT06137092|DRUG|Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)|rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
223516927|NCT02098486|DRUG|Moxifloxacin|
223516928|NCT02098486|DRUG|ceftriaxone|
223516929|NCT04170075|BEHAVIORAL|Whole Body Vibration|Undergo WBV
224082116|NCT01936389|DRUG|AR-12286|
224082117|NCT04227756|DRUG|LSD|LSD 0.1 mg per os, single dose OR Psilocybin 20 mg per os, single dose OR Mescaline 300 mg per os, single dose OR Placebo
224287242|NCT02506608|PROCEDURE|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
224287243|NCT05542979|DRUG|HH-003 injection|HH-003 injection is administrated via I.V. infusion
224082118|NCT04227756|DRUG|Psilocybin|Psilocybin 20 mg per os, single dose
224082119|NCT04227756|DRUG|Mescaline|Mescaline 300 mg or 500 mg per os, single dose
224082120|NCT04227756|OTHER|Placebo|Placebo (Mannitol)
224287244|NCT05542979|DRUG|Placebo|Placebo is administrated via I.V. infusion
224082121|NCT02969902|DEVICE|Buzzy® device|
224082122|NCT02969902|DEVICE|Hand-held computer|
224082123|NCT03329456|DRUG|Ropivacaine|Minimum effective volume
224082124|NCT04214847|PROCEDURE|Ahmed Glaucoma Valve surgery|The surgical procedure was identical for both implant types and was performed as described previously.9,14 All surgical procedures were performed under local anesthesia except for children, general anesthesia was used. The valve plate was primed and placed in the superotemporal quadrant after making fornix-based conjunctival flap. The valve plate was secured to sclera with 10-0 nylon sutures 10 mm posterior to the limbus. Before implantation, applying sponges soaked with Mitomycin- c 0.3 cc for three minutes on bare sclera at this quadrant. The tube was placed in the anterior chamber through a 23-gauge needle tract at the limbus. The tube left patent and viscoelastic substance injected into anterior chamber. A donor scleral graft was secured with interrupted 10-0 nylon sutures over the exposed portion of the tube. Conjunctiva was sutured with 10-0 nylon sutures.
224082125|NCT02668614|DEVICE|WR-22 model microwave sensor|
224082126|NCT06031077|PROCEDURE|cardiac catheterization|An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
224082127|NCT00860158|DRUG|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
224082128|NCT00860158|DRUG|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
223516930|NCT03060265|DRUG|Paracetamol|Administrating Paracetamol IV pre-cesarean section
224082129|NCT00860158|PROCEDURE|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
224082130|NCT06014944|DRUG|Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody|neoadjuvant therapy for short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody for PMMR / MSS type middle and low locally advanced rectal cancer.
224082131|NCT03065179|DRUG|Nivolumab/Ipilimumab|IV immunotherapy
224082132|NCT03065179|RADIATION|SBRT|SBRT will be delivered in conjunction with immunotherapy
224082133|NCT05971966|OTHER|Virtual Reality technique|"They would be receiving treatment as follow:~Specific exercises by using virtual reality with conventional treatment. The VR game included holopoint,hot squat and portal stories that will target the hamstring, quadriceps and gluteas muscles.Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: virtual reality gaming exercises Conventional PT including patellar mobilization+ ultrasound on anterior knee in supine lying + stretching of ITB . Frequency: 10 reps with 5 sec hold for 3 times/week for 4 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
224099194|NCT01217606|DRUG|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
224099195|NCT01217606|DRUG|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
224099196|NCT02677779|PROCEDURE|CO2 laser|Single session of CO2 laser debridement
223516931|NCT03060265|DRUG|PLACEBO|Administrating SALINE IV pre-cesarean section
223516932|NCT06460662|OTHER|Routine Physical Therapy|"Group B: Routine physical therapy Group that includes:~* Calf Stretching~* Hamstring Stretching~* Prone Quadriceps Stretching~* Long-Sitting Knee Flexion and Extension~* Quadriceps setting~* Supine Straight Leg Raises~* Prone Hip Extensions~* Standing Hamstring Curls With Cuff Weights~* Standing Calf Raises~* Treadmill Walking~* Mobilization techniques"
223516933|NCT01254929|DEVICE|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
223516934|NCT01254929|DEVICE|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
223516935|NCT00069953|BIOLOGICAL|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients \>70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
224082134|NCT05971966|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of quadriceps and hamstring muscles. Frequency: 3 times/week for 4 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Muscle energy technique to improve range of motion.~Conventional PT including patellar mobilization + ultrasound on anterior knee in supine lying + stretching of ITB. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
224082135|NCT02799862|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
223516936|NCT00069953|BIOLOGICAL|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
224082136|NCT02799862|DRUG|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
223516937|NCT00069953|DRUG|cisplatin|During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
223516938|NCT00069953|DRUG|fluorouracil|During induction therapy, patients receive 650 mg/m\^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m\^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
223516939|NCT00069953|DRUG|paclitaxel|During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
223516940|NCT00069953|PROCEDURE|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
223516941|NCT00069953|RADIATION|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (\> 6 MV) will be used to deliver multiple (\> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
223516942|NCT02034565|DRUG|Apixaban|
223516943|NCT00000373|DRUG|olanzapine + fluoxetine|
223516944|NCT00000373|DRUG|placebo + fluoxetine|
223516945|NCT06416982|OTHER|Perineal massage|2 minutes of perineal massage as described in arm/group descriptions.
223516946|NCT06569628|COMBINATION_PRODUCT|Envita Stories Methodology in Long-term care Centres for old adults|Collaborative intervention program in long-term care Centres for old adults between professionals, old adults, families and volunteers that aims to foster person-centered care and promote meaningful relationships through the digitization of life stories and life project methodologies in a timeline.
223516947|NCT06569628|BEHAVIORAL|Contact Methodology in Long-term Care Centres for old adults|Professionals know and use Envita Stories Methodology but do not apply it directly with these people.
223516948|NCT05495230|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
223516949|NCT05495230|OTHER|Usual care|See arm description.
223534833|NCT03563547|BEHAVIORAL|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
224082137|NCT00669617|DRUG|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
224082138|NCT00669617|DRUG|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
224082139|NCT00669617|DRUG|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
224082140|NCT00669617|DRUG|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
224082141|NCT00669617|DRUG|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
224082142|NCT00669617|DRUG|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
224082143|NCT05499520|OTHER|Culturally Tailored Anti-Smoking Messages|Anti-smoking messages will be administered online via a Qualtrics survey.
223516950|NCT02808884|GENETIC|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
223516951|NCT00113373|DRUG|lapatinib ditosylate|Given orally
223516952|NCT00113373|OTHER|laboratory biomarker analysis|Correlative studies
223516953|NCT01548885|DEVICE|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223516954|NCT01548885|DEVICE|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223516955|NCT01548885|DEVICE|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223516956|NCT01548885|DEVICE|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223516957|NCT01548885|DEVICE|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223516960|NCT04717479|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
223516961|NCT00236795|DRUG|norelgestromin + ethinyl estradiol; triphasil.|
223516962|NCT00003067|BIOLOGICAL|aldesleukin|
223516963|NCT00003067|BIOLOGICAL|lymphokine-activated killer cells|
223516964|NCT01974479|BIOLOGICAL|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
223516965|NCT06570239|PROCEDURE|intervention group|"Protocol A combines dry physiotherapy and psychological support. It will be organised on an outpatient basis. Weeks 1, 2 and 3: 8 sessions of dry physiotherapy and 3 sessions of psychotherapy. 5 psychotherapy sessions will be given over the following five weeks.~Protocol B combines hydro-physiotherapy and hydro-thermal treatments with psychological support. Protocol B begins with 3 weeks in a spa establishment - Care provided during weeks 1, 2 and 3: 8 hydrokinesitherapy sessions, 32 hydrothermal treatments, 3 psychotherapy sessions. 5 psychology sessions will be given over the following five weeks."
223516966|NCT04525183|BEHAVIORAL|Enhanced Usual Care (EOC)|Educational materials
223516967|NCT04525183|BEHAVIORAL|REVITALIZE ACT Intervention|Six 60-75 minute telehealth sessions approximately once a week for 6-8 weeks
223516968|NCT02408029|OTHER|Observational study - no intervention|
223516969|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
223516970|NCT00979407|BIOLOGICAL|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
223516971|NCT01782274|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
223516972|NCT01782274|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
223516973|NCT01166646|DRUG|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
223516974|NCT01166646|DRUG|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
223516975|NCT05613946|DRUG|Lumason|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
223516976|NCT05613946|DRUG|Optison|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
224082144|NCT03453892|DRUG|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
223516977|NCT05613946|DRUG|Definity|Ultrasound microbubble contrast agent intradermal 0.2-0.3 cc of microbubble suspension per injection, 10-12 total injections per upper extremity
223516978|NCT05996445|BIOLOGICAL|XmAb662|Intravenous (IV) administration
223516979|NCT05996445|BIOLOGICAL|Keytruda® (pembrolizumab)|Intravenous (IV) administration
223516980|NCT05216146|OTHER|Strength and Conditioning|A specially designed strength and conditioning program will be delivered for a period of 6 months from the experienced strength and conditioning coaches. The program will consist of the basic aerobic and anaerobic exercises that could be practiced without additional equipment and with own body weight.
224082145|NCT03453892|DRUG|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
224082146|NCT03453892|RADIATION|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
223516981|NCT02511769|BEHAVIORAL|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
224082147|NCT03453892|DRUG|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
224082148|NCT05719480|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites in different liver diseases during the development of liver cancer by collecting residual blood and urine from routine diagnosis and treatment or physical examination
224082149|NCT00230347|PROCEDURE|Stereotactic radiosurgery|
224082150|NCT02314793|DRUG|ASP2205|oral
224082151|NCT02314793|DRUG|Placebo|oral
223516982|NCT02511769|BEHAVIORAL|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
223516983|NCT05168592|BEHAVIORAL|Threat conditioning|Day 1: The participant is repeatedly shown two stimulus (CS+,CS-), one at a time. CS+ is paired with an electric shock. CS- acts as a control stimulus. The stimuli consist of photos of two different objects. Stimuli will be counterbalanced between participants.
224082152|NCT02494596|DRUG|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m\^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
224082153|NCT02494596|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
224082154|NCT04878367|BEHAVIORAL|Five active practices of living rules for responding to fine dust.|"1. Check the fine dust weather forecast~2. Check the operation time and filter of the air purifier~3. Window ventilation~4. Inhalant is used or not~5. Bad fine dust: Refrain from going out"
224082155|NCT01590147|PROCEDURE|Yoga therapy|receive YST
224082156|NCT01590147|OTHER|questionnaire administration|Ancillary studies
224082157|NCT01590147|PROCEDURE|quality-of-life assessment|Ancillary studies
224082158|NCT01590147|OTHER|laboratory biomarker analysis|Correlative studies
224082159|NCT01590147|OTHER|assessment of therapy complications|Ancillary studies
224082160|NCT01590147|PROCEDURE|management of therapy complications|Receive YST or CE
224082161|NCT01590147|OTHER|educational intervention|Receive CE
224082162|NCT04545489|BEHAVIORAL|Intervention group|This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)
224082163|NCT04545489|BEHAVIORAL|Education control group|This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
224082164|NCT00584194|BIOLOGICAL|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to \< 1:40.
224082165|NCT01397864|DRUG|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
224082166|NCT02238457|DRUG|Low dose losartan|25 mg losartan bid for 10 weeks
224099197|NCT02677779|PROCEDURE|traditional surgery|Single session of traditional debridement
224082167|NCT02238457|DRUG|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
224082168|NCT00769288|DRUG|2'-F-ara-deoxyuridine|Given IV
224082169|NCT00769288|OTHER|positron emission tomography|Correlative studies
224082170|NCT00769288|OTHER|laboratory biomarker analysis|Correlative studies
224082171|NCT00769288|OTHER|pharmacological study|Correlative studies
224082172|NCT00769288|OTHER|pharmacogenomic studies|Correlative studies
224082173|NCT04270929|DRUG|FOLFIRI|During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
224082174|NCT04270929|DRUG|FOLFIRINOX|During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
224082175|NCT04270929|DEVICE|TriSalus Infusion System|The TriSalus Infusion System administers therapeutics using PEDD technology.
223516984|NCT05168592|BEHAVIORAL|Imaginal extinction|Day 1: Participants are repeatedly instructed to produce mental imagery of the two stimuli used during threat conditioning. Imagery is prompted through different written instructions presented in pseudo-randomized order on a screen. No shocks will be delivered.
224082176|NCT02172859|DIETARY_SUPPLEMENT|lumiVida™|
224082177|NCT02172859|DIETARY_SUPPLEMENT|Placebo|
224082178|NCT00471432|DRUG|custirsen sodium|
223516985|NCT04043247|DEVICE|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
223516986|NCT04043247|DEVICE|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
224082179|NCT00471432|DRUG|docetaxel|
224082180|NCT00471432|OTHER|pharmacological study|
224082181|NCT00553046|OTHER|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
224082182|NCT00152152|PROCEDURE|Radiostereometric Analysis beads inserted during surgery|
224082183|NCT01438697|BEHAVIORAL|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
224082184|NCT01438697|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
224082185|NCT02373111|DIETARY_SUPPLEMENT|Isoflavone|
224082186|NCT02373111|DIETARY_SUPPLEMENT|Astaxanthin|
224082187|NCT02373111|DIETARY_SUPPLEMENT|Placebo|
224082188|NCT01207271|BEHAVIORAL|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
224082189|NCT01207271|BEHAVIORAL|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
224082190|NCT06092294|BEHAVIORAL|Tactical training in numerical superiority and numerical inferiority|"In the present study, the SSGs training sessions will be carried out in the following areas:~2c1: length 11.5m and width 9m (total: 103.5m2), equivalent to 34.5m2 for each player.~3c2: length 14m and width 12m (total: 168m2), equivalent to 33.6m2 for each player.~4c3: length 17m and width 14m (total: 238m2), equivalent to 34m2 per each player."
224082191|NCT06092294|BEHAVIORAL|Conventional training in numerical equality|Coach who will run the CG training program will be different from the coach who will run the GE training program. As with the GE, a coach will also be assigned to the CG to record, quantify and monitor the training stimuli of this comparison group, who will record it on forms designed for this purpose.
224082192|NCT02856750|DRUG|Gabapentin|Gabapentin 300 mg three times daily x30 days
224082193|NCT03017560|BEHAVIORAL|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
224099198|NCT03095105|DRUG|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
224099199|NCT05288842|BIOLOGICAL|Lumbar puncture|5 mL of CSF
223516987|NCT01406054|OTHER|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
224082194|NCT01757717|RADIATION|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
223516988|NCT03748212|DRUG|D935 Cap. 1T|single oral administration under fed condition
223516989|NCT03748212|DRUG|CKD-385 Tab. 1T|single oral administration under fed condition
223516990|NCT04286776|DEVICE|Direct electrical stimulation|Stimulation will not exceed 0.75 mA and will be approved prior by study investigators. Each subject will have a safety threshold testing at the beginning of each session and if 'afterdischarges' occur the subject's stimulation threshold will be lowered.
223516991|NCT03019653|DRUG|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
224082195|NCT02597621|OTHER|no intervention|no intervention
224082196|NCT03426020|OTHER|Oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before induction
223516992|NCT03019653|DRUG|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
223516993|NCT00967486|PROCEDURE|Carotid endarterectomy with routine shount|
223516994|NCT00967486|PROCEDURE|Carotid endarterectomy with selective shunt|
223516995|NCT00003192|DRUG|aminocamptothecin|
223516996|NCT00135876|DRUG|dalteparin|
223516997|NCT05814614|OTHER|pelvic physical therapy|Pelvic floor muscle exercises, biofeedback, bladder training
223516998|NCT00274950|BIOLOGICAL|bleomycin sulfate|
223516999|NCT00274950|DRUG|carboplatin|
223517000|NCT00274950|DRUG|cisplatin|
223517001|NCT00274950|DRUG|etoposide|
223517002|NCT00274950|DRUG|ifosfamide|
223517003|NCT00274950|DRUG|vinblastine sulfate|
223517004|NCT00274950|PROCEDURE|adjuvant therapy|
223517005|NCT00274950|PROCEDURE|conventional surgery|
223517006|NCT02163356|DRUG|Fenretinide/LXS Oral Powder|Oral Powder
223517007|NCT02163356|DRUG|Ketoconazole|Oral Tablet
223517008|NCT02163356|DRUG|Vincristine|IV
223893374|NCT04359108|DEVICE|Distance test vision mode: Low Resolution / High Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: Low~* Field-of-View: High"
224082197|NCT03426020|OTHER|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.
224082198|NCT03426020|OTHER|Play game (PC fishing game)|Patients will be played a simple PC game (a fishing game) 20 minutes before induction
224082199|NCT01361997|BIOLOGICAL|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
224082200|NCT01361997|BIOLOGICAL|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
224082201|NCT02685917|PROCEDURE|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
224082202|NCT02685917|PROCEDURE|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
224082203|NCT05299385|BEHAVIORAL|Conventional rehabilition treatment(e.g leaflet) educated by hospital|"Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~* method of the conventional rehabilitation treatment~* intensity for aerobic exercise and anaerobic exercise"
224082204|NCT05299385|DEVICE|Digital treatment based on Respiratory Rehabilitation Software|"Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise."
224082205|NCT03850184|DIAGNOSTIC_TEST|The Exercise in Mental Illness Questionnaire (EMIQ)|Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
223517009|NCT01813227|DRUG|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
223893375|NCT04359108|DEVICE|Distance test vision mode: High Resolution / Low Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: High~* Field-of-View: Low"
224082206|NCT03440359|DRUG|Progesterone Vaginal Gel 8%|progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.
224082207|NCT03440359|DRUG|Letrozole Oral Tablet|letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
223517010|NCT01813227|DRUG|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
223517011|NCT01813227|DRUG|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
223517012|NCT02858778|OTHER|Early order of palliative care consultation|
224082208|NCT03440359|DIAGNOSTIC_TEST|pelvic ultrasound|pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is \>17 mm in diameter
224082209|NCT03440359|DRUG|Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe|ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter
223517013|NCT00833729|DRUG|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
223517014|NCT04063462|DRUG|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
223517015|NCT03804255|OTHER|Survey Administration|Complete surveys
223517016|NCT04672616|BEHAVIORAL|Group psychotherapy|The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
223517017|NCT06304896|DRUG|Carvedilol|Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.
223517018|NCT06304896|DRUG|Ramipril|Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.
223517019|NCT06304896|DRUG|Rosuvastatin|Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.
223517020|NCT06304896|DRUG|Colchicine|Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.
223517021|NCT06304896|DRUG|Placebo|Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
223517022|NCT06036264|OTHER|Collected of Datas|age, sex, mode of dialysis, emergency context, approach, date of creation of the arteriovenous fistula (if concerned), date of start of dialysis, transplant status, date of registration on the renal transplant waiting list (if concerned), nephrologist, date of first consultation with the pre-nurse in advanced practice (APN) (if concerned)
223517023|NCT06036264|OTHER|semi-structured interview|Semi-structured interviews will be realized. The goal is to establish a qualitative analysis of the relevance and organization of pre-transplant assessments, of the reactivity in the adjustment of requests and assessments, and to identify the strong points or areas for improvement.
223517024|NCT01335685|DRUG|Ixazomib|Ixazomib capsules
223517025|NCT01335685|DRUG|Melphalan|Melphalan tablets
223517026|NCT01335685|DRUG|Prednisone|Prednisone tablets
223517027|NCT02542280|PROCEDURE|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
224082210|NCT03440359|OTHER|Intrauterine insemination or timed intercourse|Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
224082211|NCT03675880|DRUG|TAB014|TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
224082212|NCT05068609|BIOLOGICAL|Nivolumab|Participants in this study are being treated with nivolumab for SCCHN
224082213|NCT00140894|DRUG|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
224082214|NCT00140894|DRUG|Comparator: placebo / Duration of Treatment: 24 weeks|
224082215|NCT00173862|DRUG|Gemcitabine, Ifosfamide|
223517028|NCT02542280|PROCEDURE|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
223517029|NCT02542280|DRUG|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
223517030|NCT00127478|DRUG|Atrasentan|
223517031|NCT04951843|DIETARY_SUPPLEMENT|Black soybean koji product|Black soybean koji product
223893376|NCT04359108|DEVICE|Distance test vision mode: High Resolution / High Field-of-View|"This intervention performs the relative distance to two obstacles test with the user's vision output configured as follows:~* Resolution: High~* Field-of-View: High"
224082216|NCT05885581|OTHER|Arm A Grow Well|"1. the preliminary efficacy of the adapted intervention on mothers' and caregivers' infant feeding knowledge, use of recommended feeding practices, and infant anthropometric measurement outcomes.~2. the feasibility of implementing the intervention and its acceptability among mothers and caregivers.~3. the feasibility of collecting infant anthropometric data."
224082217|NCT05885581|OTHER|Arm B Healthy Steps|Group B: Healthy Steps and will receive the Healthy Steps curriculum or treatment as usual as this is the curriculum commonly shared during well baby visits (n= 15 mother-infant-caregiver triad).
224082218|NCT04926935|DIAGNOSTIC_TEST|Microbiological analysis of blood samples.|Microbiological analysis of blood samples collected from the patients with clinically suspected infection.
224082219|NCT01717469|DEVICE|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
224082220|NCT01717469|DEVICE|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
224082221|NCT05389488|DEVICE|OsciPulse system|The OsciPulse system is a pneumatic compression system designed to provide intermittent compression to the limbs to augment venous blood flow.
224287245|NCT03353454|DRUG|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
224287246|NCT03353454|DRUG|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
224082222|NCT05389488|DEVICE|Flowtron ACS900|The Arjo Flowtron ACS900 intermittent pneumatic compression system provides compression the calf to augment venous blood flow.
224082223|NCT04703569|PROCEDURE|Dressing with monolayer high compression elastic bandage|The nurse will be apply the therapy high compression elastic bandage once a week, during 26 weeks
224082224|NCT04703569|PROCEDURE|Dressing with Unna boot|The nurse will be apply the therapy Unna Boot once a week, during 26 weeks.
224082225|NCT00559273|DRUG|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
224082226|NCT00559273|DRUG|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
224082227|NCT01648257|DRUG|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
224082228|NCT01648257|DRUG|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
224082229|NCT01648257|DRUG|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
224082230|NCT05398614|BIOLOGICAL|SENL101|Patients will be treated with CD7 CAR-T cells
224082231|NCT00395967|DRUG|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
224082232|NCT03073746|OTHER|Health Search|
224082233|NCT03073746|OTHER|Standard Search|
224082234|NCT04401033|BEHAVIORAL|Telephonic medical visit|The patient will receive a telephonic call passing a medical visit
224082235|NCT04401033|PROCEDURE|Gastrointestinal endoscopy|Upper or lower GI endoscopy according to clinical practice and current guidelines
224082236|NCT04401033|PROCEDURE|Abdominal ultrasound|Diagnostic abdominal ultrasound according to the current guidelines
224082237|NCT03387787|DEVICE|GlucoTab|"The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days."
224082238|NCT03387787|DRUG|Insulin Degludec|During the study, patients will be treated with basal Insulin degludec
224082239|NCT00506857|DRUG|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
224082240|NCT00506857|DRUG|Fludarabine|30 mg/m\^2 by vein daily x 4 days.
224082241|NCT03118947|DRUG|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
224082242|NCT02953145|DRUG|Tisseel|Tisseel will be applied to open areas lateral to the cleft palate repair
224082243|NCT03031600|DIAGNOSTIC_TEST|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
224082244|NCT03031600|DIAGNOSTIC_TEST|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
224082245|NCT00344097|PROCEDURE|Soy protein|
224082246|NCT05261854|DEVICE|Pressure biofeedback|Deep cervical flexor training by using preesure biofeedback will be given 5 days a week for 6 week Conventional exercise for deep cervical muscle training will be given 5 days a week for 6 weeks
224082247|NCT05261854|OTHER|Conventional exercises for deep cervical muscle training|Conventional exercise for deep cervical muscle training will be given 4 days a week for 6 weeks
224082248|NCT04428801|BIOLOGICAL|autologous adipose-derived stem cells|Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
224082249|NCT02516670|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
224082250|NCT02516670|DRUG|Docetaxel|Given IV
223893377|NCT03983018|DRUG|Rituximab|Infusion
224082251|NCT02516670|OTHER|Laboratory Biomarker Analysis|Correlative studies
224082252|NCT02516670|OTHER|Pharmacological Study|Correlative studies
224082253|NCT02516670|OTHER|Placebo|Given IV
224082254|NCT02516670|OTHER|Quality-of-Life Assessment|Ancillary studies
224082255|NCT01385735|DRUG|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
224082256|NCT01385735|DRUG|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
224082257|NCT05463809|DRUG|Continuous Gastrocnemius plane block with ropivacaine|After extubation, the patient was routinely monitored for his vital signs.The nerve block operation was performed by the same doctor: let the patient take the lateral decubitus position, use the ultrasonic high-frequency array probe under the popliteal socket to scan the sciatic nerve, move the probe down to find the tibial nerve and the common peroneal nerve, and then a single injection of 0.375% Ropivacaine 15milliliters was given into the common peroneal nerve, medial sural cutaneous nerve, and lateral sural cutaneous nerve. Then avoid common peroneal nerve, use the indwelling needle (16GA 3.25 IN), and put the catheter after saline expansion.
224082258|NCT05463809|DRUG|oxycodone|The patient was revived and received intravenous oxycodone titration according to the numerical rating scale (NRS) score, and was treated with no background dose of oxycodone patient-controlled intravenous analgesia (PCIA) pump for analgesia.
224082259|NCT03227367|OTHER|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
224082260|NCT00627237|BEHAVIORAL|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
224082261|NCT00627237|BEHAVIORAL|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
224082262|NCT04417829|DEVICE|Biological prosthesis in the aortic valve|Transcatheter aortic valve implantation of bioprosthesis in patients with severe symptomatic aortic stenosis (clinically indicated)
224082263|NCT00000690|DRUG|Dextran sulfate|
224082264|NCT01017510|DEVICE|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
224082265|NCT01017510|DEVICE|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
224082266|NCT04203485|BIOLOGICAL|Camrelizumab 200mg|Camrelizumab 200mg q2w ivgtt
224082267|NCT04203485|DRUG|Apatinib Mesylate 250mg|Apatinib Mesylate 250mg po qd
224082268|NCT04203485|DRUG|Pemetrexed disodium for injection|Pemetrexed disodium for injection 500 mg/m2 q3w
224082269|NCT04203485|DRUG|Paclitaxel injection|Paclitaxel injection 175 mg/m2 q3w
224082270|NCT04203485|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min q3w
224082271|NCT05048160|DRUG|Intravenous Infusion|Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
224082272|NCT00189462|DRUG|Montelukast|
224082273|NCT00189462|DRUG|Placebo|
224082274|NCT04047901|OTHER|exercise training|Patients undergo 16 weeks of physical training
224082275|NCT05641701|DEVICE|System On|The DBS system will be turned on, and the individual's stutter will be assessed.
223893378|NCT05340270|DRUG|PD-1 inhibitor+GP|PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
224082276|NCT05641701|DEVICE|System off|The DBS system will be turned off, and the individual's stutter will be assessed.
224082277|NCT02986594|DRUG|Aspirin|
224082278|NCT02986594|DRUG|Heparin|
224082279|NCT05752929|DRUG|Insulin|correction scheme with Rapid Acting Insulin Analogs according with the Umpierrez sensitive correction scheme
224082280|NCT05752929|DRUG|insulin|correction scheme with Rapid Acting Insulin Analogs according with the Davidson correction scheme
224082281|NCT04957186|OTHER|Collection of postoperative information|The EORTC BR45 questionnaire will be used to gather information from patients regarding possible post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse.
224082282|NCT04957186|OTHER|Analysis of postoperative information collected from patients|All post-operative complications recorded via electronic patient-reported outcomes (pain, swelling, hypersensitivity etc.) as well as via the interviews with the state-registered coordinating nurse will be analyzed with the aim of proposing an appropriate care pathway.
224082283|NCT00448708|DEVICE|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm\^2 paclitaxel
224082284|NCT00448708|DEVICE|Lifespan® ePTFE Vascular Graft|vascular graft
224082285|NCT00448708|DEVICE|Lifespan® ePTFE Vascular Graft|vascular graft
224082286|NCT00928421|DRUG|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
224082287|NCT05883280|OTHER|Binaural beats|The binaural beat audio file consists of pure tones with a frequency of 432 Hz in the left ear and 420 Hz in the right ear. It is played through headphones starting 30 minutes before the end of the surgery.
224082288|NCT03288909|OTHER|MRI|
224082289|NCT00918151|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study
224082290|NCT02572284|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
224082291|NCT02572284|PROCEDURE|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
224099200|NCT05288842|BIOLOGICAL|blood sample|6x5 mL of blood sample collected :1 dry tube, 2 EDTA tubes, 1 fluoride tube, and 2 polypropylene tubes
224287247|NCT06857058|DEVICE|NOVA DES|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon
224082292|NCT02572284|OTHER|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
224082293|NCT02377895|DRUG|Nasapaque Nasal Solution|
224082294|NCT02377895|DRUG|Placebo Saline Nasal Solution|
224082295|NCT02400255|DRUG|Crenolanib besylate|
224082296|NCT00599417|DRUG|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
224082297|NCT00599417|DRUG|placebo|placebo controlled
224082298|NCT06076668|DRUG|Dexmedetomidine|Patients will receive an intravenous dexmedetomidine infusion of 0.2 mcg/kg/h starting at 9 p.m. The infusion will be halved at 6:00 A.M. and discontinued at 6:15 A.M.
224082299|NCT06076668|DRUG|Melatonin 3 MG|Patients will receive oral melatonin tablet 3 mg 9:00 p.m.
224082300|NCT06076668|DRUG|Saline|Patients will receive saline infusion at the same rate of dexmedetomidine infusion and placebo capsule similar to that of melatonin.
224082301|NCT02697942|OTHER|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
224082302|NCT02697942|OTHER|exercise training|The investigators will provide participants with foot peddlers.
224082303|NCT01423539|DRUG|bendamustine|Intravenous repeating dose\\n
224082304|NCT01423539|DRUG|navitoclax|Oral repeating dose\\n
224082305|NCT01423539|DRUG|rituximab|Intravenous repeating dose\\n
224082306|NCT01653119|DRUG|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
224082307|NCT02159027|DRUG|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
224082308|NCT02159027|DRUG|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
224082309|NCT01868984|DRUG|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
223517032|NCT03116178|OTHER|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi\<4 fluid rate is 50-60ml/hr and pvi\>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
224082310|NCT01868984|PROCEDURE|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
224082311|NCT03244007|PROCEDURE|Vitrectomy|
224082312|NCT02538484|DRUG|Letrozole|Aromatase inhibitor
224082313|NCT02538484|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 free fatty acid
224082314|NCT05491785|DRUG|Cebranopadol 600 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 3 cebranopadol 200 µg tablets and 2 cebranopadol placebo tablets
224082315|NCT05491785|DRUG|Cebranopadol 800 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, 4 cebranopadol 200 µg tablets and 1 cebranopadol placebo tablet
224082316|NCT05491785|DRUG|Cebranopadol 1000 µg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol 200 µg tablets
224082317|NCT05491785|DRUG|Oxycodone 30 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 10 mg capsules, and 5 cebranopadol placebo tablets
224082318|NCT05491785|DRUG|Oxycodone 60 mg|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone 20 mg capsules, and 5 cebranopadol placebo tablets
224082319|NCT05491785|DRUG|Placebo|Participants will be administered a single dose of 8 identically appearing capsules containing: 3 oxycodone placebo capsules, and 5 cebranopadol placebo tablets
224082320|NCT02859155|PROCEDURE|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
224082321|NCT03696992|PROCEDURE|Tandem colonoscopy|Tandem colonoscopy with different image modalities
224082322|NCT02693314|DIETARY_SUPPLEMENT|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
224082323|NCT02693314|DIETARY_SUPPLEMENT|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
224082324|NCT02693314|DIETARY_SUPPLEMENT|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
224082325|NCT01961544|DRUG|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
224082326|NCT04821583|DRUG|Hydrocortisone|Hydrocortisone is orally administered.
224082327|NCT04821583|DRUG|Placebo|Placebo is orally administered.
224082328|NCT05679362|BEHAVIORAL|online brief CBT intervention|Cognitive behavioral therapy
224082329|NCT00269529|PROCEDURE|femoral nerve block|
224082330|NCT00269529|PROCEDURE|knee infiltration and injection via catheter|
224287248|NCT02744131|DRUG|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
224287249|NCT02744131|DRUG|Metformin 1500mgs per day|
224287250|NCT03043560|DRUG|Ezogabine|daily for 5 weeks
224082331|NCT03498274|DEVICE|Fitting System|End users will drive the screening and fitting flow; however, a trained professional is intended to assist them and help with explanations and the actual fitting of the hearing aids on the person. For a first time user the physical act of placing the hearing aid in/on the ear may create confusion. Therefore, the software is designed for an assistant to guide the user through the process and help with specific parts of the fitting or any questions in general.
224082332|NCT03498274|DEVICE|Traditional Fitting System|The trained professional will fit the hearing aids with the traditional software that is currently used on the market. They will not involve the patient except to play demonstration tones.
224082333|NCT00892554|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
224082334|NCT00892554|DIETARY_SUPPLEMENT|Corn/soy oil|Capsules taken once daily
224082335|NCT02300454|DEVICE|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
224082336|NCT02300454|DEVICE|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
224082337|NCT02327091|DRUG|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
224082338|NCT05509478|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
224082339|NCT05509478|DRUG|PD-1 inhibitors|Regular dose intravenously every 3 weeks
224082340|NCT01656902|DRUG|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
224082341|NCT01656902|PROCEDURE|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
224082342|NCT02733874|DRUG|Compound Clobetasol Propionate Ointment|
224082343|NCT02733874|DRUG|Calcipotriol Betamethasone Ointment|
224082344|NCT03665285|DRUG|NC318|NC318 is an experimental antibody drug that may make the immune response more active against cancer.
224082345|NCT02047669|BEHAVIORAL|Biopsychosocial|
224082346|NCT02047669|BEHAVIORAL|Reference|
224082347|NCT04598542|DRUG|Lorecivivint (LOR)|0.07 mg
224082348|NCT04598542|DRUG|Triamcinolone acetonide (TA)|40 mg
224082349|NCT03106532|DRUG|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
224082350|NCT03106532|DRUG|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
224082351|NCT03106532|DRUG|Placebo ophthalmic solution|3 drops daily, 28 days
224082352|NCT01766947|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
224082353|NCT00378170|DEVICE|intubation of patients undergoing elective surgery|
224082354|NCT00354601|DRUG|capecitabine|oral capecitabine twice daily on days 1-21
224082355|NCT00354601|DRUG|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
224082356|NCT01135732|PROCEDURE|brush cytology|brush cytology during ERCP
224082357|NCT04082260|DRUG|Alemtuzumab Injection [Lemtrada]|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
224082358|NCT01554930|DRUG|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
224082359|NCT01554930|DRUG|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
224082360|NCT05935254|DEVICE|Plaque removal efficacy of children's electric toothbrush (Oral-B D100 Vitality; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with an electric toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
224082361|NCT05935254|DEVICE|Plaque removal efficacy of children's soft manual toothbrush (Oral-B Stages 6-12 years; Procter & Gamble, Cincinnati, OH, United States)|At the baseline appointment, Löe-Silness Gingival Index values were recorded in all fully erupted permanent teeth and primary teeth without exfoliation. Mira-2-Ton Plaque Staining Solution was applied to the labial and lingual surfaces of all teeth with a micro brush to determine the amount of dental plaque before the first brushing. After plaque discoloration, the Approximal Plaque Index and the Turesky Modification of Quigley-Hein Plaque Index values were recorded. The children brushed their teeth with a manual toothbrush for 2 minutes, under the supervision of a physician who was not included in the study. Plaque discoloration was performed again to determine the amount of plaque removal after the first brushing. Approximal Plaque Index and The Turesky modification of the Quigley-Hein Plaque Index the measurements were recorded. The same procedures were repeated to evaluate the brushing habits at the 1st-month and 3rd-month, respectively.
224287251|NCT03043560|DRUG|Placebos|placebo pill daily for 5 weeks
224287252|NCT05356143|DRUG|Rupatadine|Oral single dose 10 mg tablet
224287253|NCT00000963|DRUG|Didanosine|
224287254|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
224287255|NCT01644422|BIOLOGICAL|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
224287256|NCT01644422|OTHER|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
224287257|NCT05335083|DEVICE|CPAP|A positive CPAP intervention
223517033|NCT03116178|OTHER|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
223517034|NCT05198661|BIOLOGICAL|Collection of biological sample with sera, CSF, buffy coat, PBMC, plasma.|"Blood is collected only one time by blood sample to obtain serum, buffy coat, plasma and PBMC.~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube If possibility of delivery in 48 hours at the Centre of Biological Resources, 7\*4ml of blood on heparin tube If cerebrospinal fluid has been drawn for diagnosis, remaining sample available will be stored in the collection"
223517035|NCT01588925|DEVICE|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
223517036|NCT01588925|DRUG|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
223517037|NCT01588925|DRUG|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
223517038|NCT04097665|DEVICE|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1\*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
223517039|NCT02732496|BEHAVIORAL|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
223517040|NCT02732496|OTHER|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
223517041|NCT02214628|DRUG|Fovista® (anti-PDGF BB) plus anti-VEGF|
223517042|NCT04054882|BIOLOGICAL|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
223517043|NCT04054882|BIOLOGICAL|Sabin-IPV|administration of Sabin-IPV only
224082362|NCT04732754|DIETARY_SUPPLEMENT|Aerobic exercise + Theobroma cocoa (AETC)|Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
224082363|NCT04732754|DIETARY_SUPPLEMENT|Control Group (CG)|Daily consumption of placebo capsules for 8 weeks
223517044|NCT04054882|BIOLOGICAL|DTaP|administration of DTaP only
223517045|NCT03777020|BEHAVIORAL|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
223517046|NCT03777020|OTHER|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
223517047|NCT01550887|OTHER|No intervention|No intervention will be performed on this study
224082364|NCT04732754|DIETARY_SUPPLEMENT|Aerobic Exercise (AE)|Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.
223517048|NCT02274233|DRUG|SP-420|
224082365|NCT04732754|DIETARY_SUPPLEMENT|Theobroma Cocoa (TC)|Daily consumption of 500mg cocoa in capsules for 8 weeks.
224082366|NCT00022087|DIETARY_SUPPLEMENT|calcium salts|1000 mg PO per day
224082367|NCT00022087|DIETARY_SUPPLEMENT|cholecalciferol|400 IU PO per day
224082368|NCT00022087|DRUG|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
224287258|NCT00465231|DRUG|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
224287259|NCT00465231|DRUG|preservative free saline|10mL saline solution
224287260|NCT01776567|DEVICE|Everolimus eluting stents|
224287261|NCT03490474|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
224287262|NCT03490474|OTHER|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
224287263|NCT03490474|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
224287264|NCT02926781|DEVICE|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
224082369|NCT02371265|OTHER|Adherence and retention package|"Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:~* Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;~* Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision."
224082370|NCT06348381|OTHER|No intervention|No intervention
224082371|NCT03287258|OTHER|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
224082372|NCT03287258|OTHER|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
224082373|NCT00809107|DRUG|HCG|5000IU
224082374|NCT01175291|DRUG|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + MK-0646 (Investigational).
224082375|NCT01175291|DRUG|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
224082376|NCT03603652|DEVICE|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
224082377|NCT03228368|DRUG|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
224082378|NCT05684640|DRUG|Rodatristat Ethyl|Tablets, Oral, 600mg, QD
224082379|NCT05684640|DRUG|Placebo|Tablets, Oral, 0mg, BID
224082380|NCT04431115|OTHER|Interviews|Interviews for stakeholders
224082381|NCT06035822|OTHER|Debriefing with TeamGAINS|The IG debriefings were conducted by the research teacher, who is trained in clinical simulation methodology, is a clinical simulation instructor, and is trained in the use of the TeamGAINS tool, using this tool as a debriefing script, in accordance with the objectives Clinical Simulation Scenario
224082382|NCT02822456|PROCEDURE|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
224082383|NCT03450083|DRUG|Benralizumab|30mg Benralizumab will be delivered subcutaneously
223517049|NCT06391333|DEVICE|laryngeal mask airway and endotracheal tube|The two most commonly used devices for mechanical ventilation.
223517050|NCT06474962|BEHAVIORAL|Pause|7 days of no e-cigarette consumption
224082384|NCT03450083|DRUG|Placebo|Subcutaneous placebo injection
224082385|NCT03076983|DEVICE|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required."
224082386|NCT00943995|DRUG|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
224082387|NCT00454493|DRUG|Omacor (omega-3-acid ethyl esters)|
223517051|NCT06020937|DIAGNOSTIC_TEST|TDI|Sniffin' Sticks Threshold and Identification Test
224082388|NCT01711827|DRUG|Isavuconazole|oral
224082389|NCT01711827|DRUG|Prednisone|oral
224082390|NCT00511680|BEHAVIORAL|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
224082391|NCT02195492|DRUG|Synvisc®|
224082392|NCT02906254|OTHER|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
224082393|NCT02906254|OTHER|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
224082394|NCT04711096|PROCEDURE|Ultrasound-guided transversus abdominis plane (TAP) block 0.25% bupivacaine.|After preparing the skin with antiseptic solution, a linear high frequency ultrasound probe will be placed abdominal wall between the iliac crest and the costal margin. A Spinal needle 22g attached with flexible tubing to a syringe filled with saline will be used to perform the block then introduced through the skin anteriorly in the plane between the internal oblique and transversus abdominis muscles with its tip lying in the mid axillary line. To assist with identifying these structures, The final position of the probe will to be no further anterior than the anterior axillary line. If satisfactory views are not obtained, the TAP block will not be performed. Hydro dissection with saline (2-5 ml) will be used to separate the fascial layers. After aspiration to exclude inadvertent vascular puncture, 20 ml of the 0.25% bupivacaine will be injected . TAP block will be performed in a similar fashion on the opposite side.
224082395|NCT05346107|DRUG|pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage|The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
224082396|NCT00235105|DRUG|Adalimumab 40 mg sc every other week|
224082397|NCT03213366|BEHAVIORAL|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
224082398|NCT03213366|BEHAVIORAL|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
223517052|NCT06020937|DIAGNOSTIC_TEST|Trigeminal Test|Test the trigeminal smell answer by a device that releases air and a substance that stimulates the trigeminal response
223517053|NCT06020937|DIAGNOSTIC_TEST|Cognitive Evaluation by Montreal Cognitive Assessment|Montreal Cognitive assessment
223517054|NCT06020937|DIAGNOSTIC_TEST|Anxiety and Depression questionnaire|Specific test to evaluate patient's mood
223517055|NCT06020937|DIAGNOSTIC_TEST|Visual Analogue Scale Ratings|"* Smell ability (How is your sense of smell right now? 0 cannot smell, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)~* Nasal breathing (How well can you breathe through your nose right now? 0 complete nasal obstruction, 1-3 severe impairment, 4-6 moderate impairment, 7-9 mild impairment, 10 normal)"
223517056|NCT06020937|DIAGNOSTIC_TEST|Quality of smell Questionnaire|Patients will answer to a validated questionnaire
223517057|NCT00489476|DRUG|Staccato Loxapine|
223517058|NCT00489476|DRUG|Staccato Placebo|Placebo aerosol inhalation (0mg)
223517059|NCT03989479|BEHAVIORAL|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
223517060|NCT03989479|BEHAVIORAL|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
223517061|NCT00005839|DRUG|capecitabine|
223517062|NCT00005839|DRUG|oxaliplatin|
223517063|NCT04418154|DRUG|epirubicin hydrochloride|Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
223517064|NCT04418154|DRUG|Cyclophosphamide|Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
223517065|NCT04418154|DRUG|Albumin bound paclitaxel|Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab, following epirubicin hydrochloride and cyclophosphamide.
224082399|NCT02836015|BEHAVIORAL|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
224082400|NCT02286388|PROCEDURE|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~* Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~* Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
224082401|NCT02286388|PROCEDURE|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
224082402|NCT02286388|DEVICE|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
224082403|NCT02286388|DEVICE|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
224082404|NCT02671331|PROCEDURE|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
224082405|NCT01140009|BIOLOGICAL|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
224082406|NCT01140009|BIOLOGICAL|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
224082407|NCT04991337|BEHAVIORAL|Detraining group|Detraining is defined as exercise corresponding to a heart rate ≤75% of maximum heart rate and ≤80% of the self-reported average weekly amount of exercise (hours/week) during the past six months, for a period of 16 weeks.
224082408|NCT04991337|BEHAVIORAL|Control group|At least three weekly sessions of high intensity exercise, corresponding to a heart rate ≥85% of maximum heart rate, and otherwise continue endurance exercise as usual.
224082409|NCT01311466|PROCEDURE|Liver transplantation|
224082410|NCT02532855|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet
224082411|NCT02532855|DRUG|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
224082412|NCT02532855|DRUG|Metformin|This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
224082413|NCT02532855|DRUG|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
224082414|NCT02532855|DRUG|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
224082415|NCT02532855|DRUG|Sulfonylurea|This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
224082416|NCT04981275|OTHER|No intervention study|This observational study will only collect data, not provide any intervention to participants.
224082417|NCT00687284|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224082418|NCT02668367|DRUG|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
224082419|NCT02668367|DRUG|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
224082420|NCT04846361|OTHER|Vaginal hygiene wash|vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash
224082421|NCT04846361|OTHER|placebo wash|placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
224082422|NCT04697329|DRUG|Preincisional infiltration with levobupivacaine|Local, preincisional infiltration of port sites with levobupivacaine 5 mg/ml 20 ml
224082423|NCT00434044|DRUG|Enbrel (etanercept)|
224082424|NCT05252793|BEHAVIORAL|Education based on the health belief model|After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.
224082425|NCT01780792|OTHER|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
224082426|NCT01727258|DEVICE|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
224082427|NCT01727258|DRUG|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
224082428|NCT01727258|DRUG|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
224082429|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
224082430|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
224082431|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
224082432|NCT01225666|DRUG|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
224082433|NCT02567929|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
224082434|NCT02567929|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
224082435|NCT01409603|DRUG|darexaban|oral
224082436|NCT01409603|DRUG|Naproxen|oral
224082437|NCT05616702|OTHER|Pressure Biofeedback Therapy + Progressive Muscles Relaxation + thermotherapy|"Pressure Biofeedback Therapy~* prone position, abdominal drawing in for 10 sec. (PBU inflated to 70 mmHg)~* Supine position with flexed knees, abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~* Progress to leg loading in supine abdominal drawing in for 10 sec. (PBU inflated to 40 mmHg)~Exercising dosage:~* Duration: 15 mins~* Frequency: 3 sessions/ week~* Repetitions: 3 sets of 15 reps~Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
224082438|NCT05616702|OTHER|Progressive Muscles Relaxation + thermotherapy|"Progressive Muscles Relaxation Technique~* Tense =\> five seconds and,~* release =\> ten seconds (Each group of muscle)~* 2 circuits daily~Exercising dosage:~* Duration: 15 mins~* Frequency: weekly 3 sessions; for 6 weeks~* Repetitions: 2 reps (cycles)~Thermotherapy at lumbar region via electrical heating pad Duration: 15 mins"
224082439|NCT01934569|DRUG|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
224082440|NCT02857218|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
224082441|NCT02857218|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
224082442|NCT00142129|DRUG|Bortezomib (Velcade)|
224082443|NCT05848661|DEVICE|AUDISSEE|AUDISSEE is a digital therapy designed specifically to improve the hearing in noise of presbycusis patients by offering a complete cognitive auditory training, with verbal and non-verbal stimuli. The therapy takes place over 10 weeks with 3 sessions of 20 minutes per week.
224082444|NCT05848661|DEVICE|Placebo|The Placebo is a therapy designed within the same frame as the AUDISSEE therapy but with no auditory exercises, instead the patients are listening to audiobook. The therapy takes place over 10 weeks, with 3 sessions of 20 minutes per week.
224082445|NCT02296411|DRUG|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
224082446|NCT02296411|DRUG|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
224082447|NCT01960855|DRUG|ABT-494|ABT-494 capsule administered orally twice daily (BID).
224082448|NCT01960855|DRUG|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
224287265|NCT02624726|DRUG|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
224287266|NCT02624726|DRUG|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
224287267|NCT02624726|DRUG|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
224287268|NCT02624726|DRUG|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
224287269|NCT04325854|PROCEDURE|I and II level ART procedure|I level: Intrauterine insemination II level: Invitro fertilization technique; Intracytoplasmic sperm injection; Embryo transfer
224082449|NCT02328066|DEVICE|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
224082450|NCT04856241|OTHER|Coaching|Physiotherapists (trained by the research team) train the coaches to deliver Prep-to-Play. The Physiotherapists will also provide face-to-face one-to-one support to each coach at their team's training session (two visits), with all their players.
224082451|NCT04856241|OTHER|Peer support|Coaches shed. Coaches provide each other with support and ideas. Strategies to overcome barriers and motivate players.
224082452|NCT04856241|OTHER|Educational materials|Prep-to-Play program resources are available online for coaches and players to view
224082453|NCT06175897|PROCEDURE|Deep Brain Stimulation|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.~Device: STN-DBS devices DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China); Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
224082454|NCT06175897|PROCEDURE|non-Deep Brain Stimulation|Patients with PD were given their original drug dose and did not receive DBS.
224082455|NCT04166279|OTHER|Single rehabilitative treatment|The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
224082456|NCT04166279|OTHER|Group rehabilitative treatment|Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
223893379|NCT05340270|DRUG|GP|Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT and cisplatin (100mg/m2, d1, 22, 43 of RT) during concurrent chemoradiotherapy.
224082457|NCT01305863|DEVICE|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
224082458|NCT01305863|DEVICE|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
224099201|NCT02719054|BEHAVIORAL|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
224082459|NCT02058147|DRUG|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
224082460|NCT02058147|DRUG|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
224082461|NCT02058147|DRUG|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
224082462|NCT02058147|DRUG|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
224082463|NCT04009993|DEVICE|A-BIRTHPERFORM digital tool|use of A-BIRTHPERFORM digital tool
224082464|NCT05236998|DRUG|SID1903 (FDC)|Single oral administration of SID1903 (FDC) after an overnight fast
223893380|NCT06130449|DRUG|Natesto testosterone intranasal gel|A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
223517066|NCT04418154|DRUG|Toripalimab|Take Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles with nanoparticlealbumin-bound paclitaxel, following epirubicin hydrochloride and cyclophosphamide.
224082465|NCT05236998|DRUG|Dapagliflozin and Sitagliptin|Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
224082466|NCT03640832|OTHER|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
224082467|NCT03640832|OTHER|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
224082468|NCT05572463|COMBINATION_PRODUCT|Sintilimab + IBI110|IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule
224082469|NCT02642926|PROCEDURE|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
224082470|NCT02642926|PROCEDURE|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
224082471|NCT05334446|BEHAVIORAL|The Effect of the Mobile Application|"This study was planned to determine the Effect of Mobile Application Use on Treatment Adherence and Self-Care Management in Patients with Hypertension. The study was designed to improve individuals' knowledge about the disease, regular drug use, diet compliance, physical activity level, quitting smoking and alcohol if using, and weight control."
224082472|NCT05537545|PROCEDURE|Soft tissue grafting|A pouch is made in the buccal mucosa using microsurgical instruments. Thereupon, a free gingival graft is harvested from the palatal mucosa in the premolar area and de-epithelialized to arrive at a CTG of about 1 mm thickness. Height and length are tailored to the dimensions of the site. Then, the CTG is brought into the pouch and fixed with two single sutures (Seralon 6/0, Serag Wiessner, Naila, Germany) onto the buccal mucosa.
224082473|NCT04972994|PROCEDURE|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies|laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
224082474|NCT02170116|DRUG|BIBR 1048 MS dose 1|
224082475|NCT02170116|DRUG|BIBR 1048 MS dose 2|
224082476|NCT02170116|DRUG|BIBR 1048 MS dose 3|
224082477|NCT02170116|DRUG|BIBR 1048 MS dose 4|
224082478|NCT02170116|DRUG|BIBR 1048 MS dose 5|
224082479|NCT02170116|DRUG|Placebo to BIBR 1048 MS|
224082480|NCT00784667|DRUG|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
224082481|NCT00784667|DRUG|Erlotinib|100mg orally daily continuously
224082482|NCT03312569|PROCEDURE|Right Colectomy with Intracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. The right mesocolon is mobilized and the ileal mesentery is divided. The transverse colon and ileum are then divided with the stapler. Next, attention is turned to constructing the anastomosis. For this purpose, the terminal ileum and the transverse colon stump are brought together. A colotomy and ileostomy is created to form a common channel. The common enterotomy is then closed as per the surgeon's standard of care. The specimen is extracted through an off-midline incision (muscle splitting transverse incision, Pfannenstiel).
224082483|NCT03312569|PROCEDURE|Right Colectomy with Extracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. Intracorporeal devascularization may be performed at the surgeon's discretion. The gastrocolic ligament is taken down and the hepatic flexure is mobilized. After complete mobilization of the right colon, the midline incision is extended to serve as the extraction site. The specimen is delivered through the midline extraction incision and the anastomosis is conducted in a standard open technique. The two cut ends of the bowels are aligned for extracorporeal anastomosis.
224082484|NCT03556215|DEVICE|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
224082485|NCT03556215|PROCEDURE|Myringotomy|Myringotomy will be performed using a standard procedure.
224082486|NCT06439849|DRUG|S-Gboxin|S-Gboxin (lyophilized form of S-Gboxin) for the treatment diffuse midline glioma with H3 K27M / H3 K28M mutation
224082487|NCT01857609|DRUG|Metformin|
224082488|NCT01857609|DRUG|Metformin and Pantoprazole|
224082489|NCT01857609|DRUG|Metformin and Rabeprazole|
224082490|NCT00820573|DRUG|Sitagliptin|tablet, 100 mg/day, 6 weeks
224082491|NCT00820573|DRUG|Metformin|tablet, 1000 mg/ bid, 6 weeks
224082492|NCT00820573|DRUG|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
224082493|NCT00820573|DRUG|Placebo|Placebo 6 weeks
224082494|NCT01271621|DEVICE|Intubation|Endotracheal intubation
224082495|NCT01756729|DEVICE|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
224082496|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in Healthy Controls|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to healthy controls
224082497|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in NAFLD Participants|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to NAFLD participants (defined as simple steatosis through NASH)
223517067|NCT02098473|DRUG|RPC4046|
223517068|NCT02098473|DRUG|Placebo|
224082498|NCT06348563|DIAGNOSTIC_TEST|AGED Multiple Target Assay in Fibrosis Participants|Analysis of blood based cfDNA/cfRNA biomarkers found at defined concentrations in participant samples that correlates to liver fibrosis stage (F0-F4)
224082499|NCT00211107|DRUG|Dapoxetine|
224082500|NCT00002520|DRUG|nicotine|
224082501|NCT00002520|BEHAVIORAL|Usual Care|
224082502|NCT04676048|BIOLOGICAL|ASC618|ASC618 will be given as a single IV infusion
224082503|NCT06011720|OTHER|Improved transition of care.|Evaluation of how early physiatry consultation after acute stroke affects length of stay and resulting outcomes.
224099202|NCT02755636|BEHAVIORAL|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
224099203|NCT02755636|OTHER|Usual care|Primary care as usual
224099204|NCT03042949|DEVICE|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
224082504|NCT04458844|OTHER|Exercise|Intervention programmes were designed based on previous research (Duncan, et al., 2017; Faigenbaum, et al., 2011; Miller, et al., 2006) to ensure all exercises were developmentally appropriate for the age of the participants (an example session plan can be seen in the supplementary material). Each session consisted of five activities and lasted 50 - 60 minutes. Three out of the five activities were identical for the FMS and FMS+ groups, while two differed focusing on skill development for the FMS group and strength development for the FMS+ group. The FMS and FMS+ group received their sessions twice a week for 4 weeks. The sessions were delivered at least 48 hours apart to allow recovery and to reduce the risk of fatigue effecting performance (Faigenbaum, et al., 1996). All sessions were led by a researcher and a qualified sports coach.
224082505|NCT03728205|BEHAVIORAL|Yoga|Twice weekly yoga sessions for 12 weeks
224082506|NCT02456688|DRUG|Imrecoxib|
224082507|NCT00317213|DRUG|LIBERTAL- a phospholipid mixture|
224082508|NCT02544412|BEHAVIORAL|novel mindfulness-based well-being training|
224082509|NCT06314555|OTHER|Blood sample|Blood sample to analyse the values of sFlt-1 and PlGF
223517069|NCT04795453|OTHER|score system to predict the need for surgery|two and more grades of NEC is assessed using the score system to predict the need for surgery
224082510|NCT06314555|OTHER|Vascular-renal sample|Usual vascular-renal sample to analyse the values of sFlt-1 and PlGF
224082511|NCT02868203|DEVICE|OCT|OCT after stent implantation
224082512|NCT02868203|DEVICE|eLuting stent|
224082513|NCT05863117|DIAGNOSTIC_TEST|Reveal Rapid TP (from MedMira)|Point of care tests for HIV and Syphilis
224082514|NCT01358903|DRUG|RO5429083|Cohorts receiving multiple escalating doses iv
224082515|NCT01358903|DRUG|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
224082516|NCT05087537|PROCEDURE|Valve ablation|Valve ablation
224082517|NCT05087537|PROCEDURE|Valve ablation and bladder neck incision|Valve ablation and bladder neck incision
224082518|NCT03604445|DRUG|BI 905677|Solution for infusion
224082519|NCT00681239|DIETARY_SUPPLEMENT|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
224082520|NCT02840851|DEVICE|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
224082521|NCT02840851|DEVICE|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
224082522|NCT02981069|DRUG|Dapagliflozin|10mg
224082523|NCT02981069|DRUG|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
224082524|NCT02981069|DRUG|Placebo|Placebo for Dapagliflozin
224082525|NCT01267448|DRUG|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
224082526|NCT01267448|DRUG|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
223517070|NCT04795453|OTHER|usual method to predict the need for surgery|two and more grades of NEC is assessed using the usual method to predict the need for surgery
224082527|NCT01267448|DRUG|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
224082528|NCT03198130|DRUG|REGN2810|Intravenous (IV) use
224082529|NCT05618873|DEVICE|Flutter device|The flutter was used as follows. Sitting with a straight back and the elbows supported on the table, the patient held the flutter horizontally. The patient inhaled deeply, held their breath for 2 or 3 s and then took the mouthpiece into the mouth and exhaled quietly yet quickly enough to activate the flutter. The patient had to keep their cheeks as stiff as possible. This procedure was repeated 15 times, following which the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times. The patient obtained the maximal vibration sensation by tilting the flutter upwards or downwards by a few degrees.
224082530|NCT05618873|DEVICE|positive expiratory pressure mask|"The PEP-mask was used as follows. Sitting with a straight back and the elbows supported on the table, the patient pressed the mask against the face with both hands. After a quiet inhalation, a slow active exhalation followed. The exhalation was restricted by a resistance selected to cause a positive expiratory pressure of 8-12 cmH2O. The patient exhaled 15 times through the mask.~Thereafter, the patient huffed three times and evacuated sputum by a voluntary cough. This sequence was repeated five times."
224082531|NCT01014585|DRUG|Placebo|Placebo tablets administered orally twice daily
224082532|NCT01014585|DRUG|Milnacipran|Milnacipran tablets administered orally twice daily
224082533|NCT03459573|BEHAVIORAL|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
224082534|NCT03459573|BEHAVIORAL|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
223517071|NCT00002985|DRUG|daunorubicin hydrochloride|
223517072|NCT00002985|DRUG|pegylated liposomal doxorubicin hydrochloride|
223517073|NCT00803049|DRUG|Teriflunomide (HMR1726)|Tablet, oral administration QD.
223517074|NCT03485885|DIETARY_SUPPLEMENT|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
223517075|NCT00474357|BEHAVIORAL|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
223517076|NCT01707446|DEVICE|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
223517077|NCT01707446|OTHER|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of \< 75% from baseline is reached for \> 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
223517078|NCT04126174|DEVICE|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
223517079|NCT04126174|OTHER|Manual LRI|Manual LRI
223517080|NCT01942460|DRUG|Ferumoxytol|
223517081|NCT01514422|DRUG|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
223517082|NCT02423954|DRUG|Temsirolimus|
223517083|NCT02423954|DRUG|Irinotecan|
223517084|NCT02423954|DRUG|Irinotecan + capecitabine|
223517085|NCT02423954|DRUG|nivolumab|
223517086|NCT04203771|DIETARY_SUPPLEMENT|Probiotic AB-DENTALAC|Orodispersible tablets containing Lactobacillus plantarum \[now Lactoplantibacillus plantarum\] KABP051 (CECT7481) and Lactobacillus brevis \[now Levilactobacillus brevis\] KABP052 (CECT7480) as active ingredients, at a minimum dose of 5x10\^8 cfu each, and sorbitol (E420) and guar gum (E412) as excipients, taken b.i.d. for 7 days.
223517087|NCT04203771|OTHER|Placebo|Orodispersible tablets made of sorbitol (E420) and guar gum (E412), taken b.i.d for 7 days.
223517088|NCT04203771|PROCEDURE|Surgical removal of mandibular third molars at baseline|Surgical removal of both mandibular third molars, performed under intravenous sedation and loco-regional anesthesia (Articaine Hydrochloride 4% with Epinephrine 1:100.000), after having undergone a professional oral cleaning.
223517089|NCT04203771|DRUG|Ibuprofen|Ibuprofen syrup at 20-30 mg/Kg of body weight, orally every 8 hours (t.i.d), for 7 days
223517090|NCT04511741|OTHER|no intervention, it is an observational study.|no intervention, it is an observational study.
223517091|NCT05045417|DIAGNOSTIC_TEST|Serum level of IL-17|"Measurement of serum level of IL-17 :~1. To explore the role of IL-17 in systemic lupus erythematosus~2. To determine the relation between IL-17 and lupus disease activity~3. To analyze the correlation between IL-17 and internal organ affection (lupus nephritis , interstitial lung disease)"
223517092|NCT05181085|DRUG|NST 6179|orally administered, fully synthetic medium chain fatty acid (MCFA) analogue
223517093|NCT05181085|DRUG|Placebo|inactive analogue
223517094|NCT00004665|DRUG|dehydroepiandrosterone|
223517095|NCT03563079|OTHER|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
223517096|NCT03563079|OTHER|Manual Myofascial Release|Myofascial Release Technique
223517097|NCT02203279|OTHER|Rebase II Fast|It is going to be used a direct relining material
223517098|NCT02203279|OTHER|Flexacryl|This is going to be used as a second direct relining material
223517099|NCT02203279|OTHER|Vertex|This is going to be used as an indirect relining material
223517100|NCT01817946|OTHER|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
223517101|NCT03008980|OTHER|Diagnostic Test|
223517102|NCT01373411|DRUG|ticagrelor|ticagrelor 90 mg BID for 90 days
223517103|NCT01373411|DRUG|Placebo|Placebo 1 pill BID for 90 days
223517104|NCT03908294|DIAGNOSTIC_TEST|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
223517105|NCT05214508|DIAGNOSTIC_TEST|interleukin 6|assessment of serum IL-6 by ELISA
223517106|NCT01055119|DIETARY_SUPPLEMENT|Omega-3 fatty acids|duration: 4 month
223517107|NCT05812300|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
223517108|NCT03868280|PROCEDURE|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
223517109|NCT03868280|PROCEDURE|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
223517110|NCT03897881|DRUG|mRNA-4157|Individualized Neoantigen Therapy
223517111|NCT03897881|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223517112|NCT05980403|OTHER|no intervention|no intervention
223517113|NCT04243863|DRUG|VNRX-7145|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
224082535|NCT03459573|BEHAVIORAL|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
224082536|NCT04059744|DEVICE|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
224082537|NCT03287180|BEHAVIORAL|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
224082538|NCT03287180|OTHER|Combination of buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
224082539|NCT02262169|DRUG|Omeprazole|2 Omeprazole capsules 20 mg, once daily
224082540|NCT02262169|DRUG|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
224082541|NCT02262169|DRUG|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
224082542|NCT02262169|DRUG|Placebo capsule of Omeprazole|2 placebo capsules of Omeprazole, once daily
224082543|NCT01324557|PROCEDURE|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
224082544|NCT03418532|COMBINATION_PRODUCT|MP0250 DARPin® drug candidate, Osimertinib|Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
224082545|NCT02580331|DRUG|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
224082546|NCT02580331|DRUG|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
224082547|NCT04278911|DIAGNOSTIC_TEST|MMSE and MoCA|This is an observational study. All the patients evaluate with MMSE (Mini-mental State Examination) and MoCA (Montreal Cognitive Assessment), and investigate the incidence and characteristics of cognitive and MACE
224082548|NCT00773279|DEVICE|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
224082549|NCT00773279|DEVICE|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
224082550|NCT02808390|DRUG|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
224082551|NCT02808390|DRUG|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
224082552|NCT02808390|DRUG|Placebo|Placebo BID for 8 Weeks
224082553|NCT05953792|PROCEDURE|Select the vertebra above sagittal stable vertebra as the distal fusion level|The surgeries were performed by the same surgical team. Multi-level Ponte osteotomies were performed across the apex of the kyphosis after complete exposure of the spine, with resection of supra- and inter-spinous ligaments, ligamentum flavum, and the whole facet joints. After placement of the pedicle screws at the expected fusion levels, pre-contoured rods were attached to the screws followed by segmental compression. During rod placement, two to three rounds of compression in the area with Ponte osteotomies were employed to enhance kyphosis correction. Satellite rods were routinely added to long rods and implanted with duet screws. The final tightening was performed, and the posterior fusion was completed with a mixture of local and allogeneic bone. Due attention was given to preserving the posterior ligamentous structures at the upper and lower junctional areas.
224082554|NCT05537714|BEHAVIORAL|Qualitative interviews/focus groups|We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
224082555|NCT01154933|DRUG|exenatide 5 mcg|exenatide 5 mcg
224082556|NCT01154933|DRUG|exenatide 10 mcg|exenatide 10 mcg
224082557|NCT01154933|DRUG|placebo|saline sq
224082558|NCT04178772|DEVICE|Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens|JJVC Marketed Contact Lens
224082559|NCT03447626|DEVICE|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
224082560|NCT03777683|DIETARY_SUPPLEMENT|Dietary Supplement (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Oligopin supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
224099205|NCT03042949|DEVICE|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
224082561|NCT03777683|OTHER|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
224082562|NCT00155480|PROCEDURE|computed tomography|
224082563|NCT05192369|DRUG|CTP-543|CTP-543 12 mg (1 x 12 mg tablet), dosed with water
224082564|NCT05192369|DRUG|CTP-543|CTP-543 48 mg (4 x 12 mg tablet) dosed with water
224082565|NCT05192369|DRUG|Moxifloxacin|Moxifloxacin (1 x 400 mg tablet) dosed with water
224082566|NCT05192369|DRUG|Placebo|Placebo (1 tablet) dosed with water
224082567|NCT00191516|DRUG|Atomoxetine|
224082568|NCT00308607|DRUG|Bevacizumab (Avastin)|
224082569|NCT00308607|DRUG|dacarbazine|
224082570|NCT00308607|DRUG|interferon-alfa-2a (Roferon-A)|
224082571|NCT01753908|DRUG|Broccoli Sprout Extract|Given PO
223893381|NCT06130449|DRUG|Ayr Saline Nasal Gel|A single dose of Ayr (one spray per nostril) will be administered to each participant.
223893382|NCT04325789|DEVICE|nanofiber scaffold|Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
224082572|NCT01753908|OTHER|Laboratory Biomarker Analysis|Correlative studies
224082573|NCT01753908|OTHER|Pharmacological Study|Urinary ITCs and metabolites measured
224082574|NCT01753908|OTHER|Placebo|Given PO
223517114|NCT04243863|DRUG|Placebo|Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
223893383|NCT04712773|DEVICE|PMD-200 monitor|Patient is connected to non-invasive PMD-200 monitor, measuring Nociception Level
223893384|NCT04712773|DEVICE|Surgical Pleth Index monitor|Patient is connected to non-invasive monitor measuring Surgical Pleth Index
223939836|NCT04625946|DRUG|Metformin|"Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control.~Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout."
223939837|NCT04625946|BEHAVIORAL|Recommendations for lifestyle modification.|All subjects will receive education on lifestyle changes and exercise which are standard of care. This will include discussion with their treating electrophysiologist and a handout.
223939838|NCT04625946|DEVICE|AliveCor|Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
223939839|NCT06731855|PROCEDURE|Abdominal Surgery for congenital gut malformation in the first 5 days of life.|Abdominal Surgery for congenital gut malformation in the first 5 days of life. Procedure will depend on the congenital gut malformation.
223939840|NCT06770764|DRUG|ODC-IL2|ODC-IL2 as a single agent infused IV over 60 minutes on Days 1 and 15 of a 28 day cycle.
223939841|NCT06509191|DRUG|Intervention 1|Melatonin 5mg/day
224082575|NCT03867630|PROCEDURE|Transforaminal Block|Epidural block via neural foramen of lumbar spine
224082576|NCT02012530|PROCEDURE|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
224082577|NCT02012530|PROCEDURE|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
224082578|NCT00713219|RADIATION|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
224082579|NCT01580930|BEHAVIORAL|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
223939842|NCT06509191|DRUG|Intervention 2|Melatonin 8 mg/day
223939843|NCT06509191|OTHER|Control|Placebo
223939844|NCT06926881|DEVICE|BiWaze Clear System|"The BiWaze Clear device includes several components as follows:~1. BiWaze Clear System.~2. BiWaze Clear Dual Lumen Breathing Circuit.~   * Dual Lumen bacterial/viral filter.~  * Dual Lumen breathing tube.~  * Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter).~3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System"
223939845|NCT06355310|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
223939846|NCT06355310|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
223939847|NCT06564038|DRUG|AZD0486|AZD0486 will be administered as either SC injection or IV infusion.
223939848|NCT06564038|DRUG|Prednisone (or equivalent)|Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.
223939849|NCT06564038|DRUG|Rituximab|Rituximab will be administered as IV infusion as per standard of care.
223939850|NCT06564038|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as IV infusion as per standard of care.
223939851|NCT06564038|DRUG|Vincristine|Vincristine will be administered as IV infusion as per standard of care.
223939852|NCT06564038|DRUG|Doxorubicin|Doxorubicin will be administered as IV infusion as per standard of care.
223939853|NCT06564038|DRUG|Acalabrutinib|Acalabrutinib will be administered orally
223939854|NCT06047951|PROCEDURE|Stereotactic RadioSurgery (SRS)|"All treatments will be performed using the Gamma Knife Perfexion or Icon system (Elekta). The following treatment parameters will be used:~* The head will be immobilized using a stereotactic Leksell Model G frame, installed using local protocols~* Targeting will be performed by using a stereotactic CTA. No MRI will be performed.~* Only one aneurysm will be treated per patient~* The aneurysm, including its neck, will be contoured and targeted using a combination of 4mm isocenters as deemed appropriate by the treating team~* A prescription dose of 25 Gy at the margin of the target will be used~* The maximal dose on optic pathways will be kept below 10 Gy~* The brainstem 12-Gy volume will be kept below 1cc"
223939855|NCT05598398|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|"The V.A.C.Ulta™ Negative Pressure Wound Therapy System is a 510(k) - cleared, Class II device (K100657) with the following indication for use: the V.A.C.Ulta™ Negative Pressure Wound Therapy System is an integrated wound management system that provides Negative Pressure Wound Therapy with an instillation option."
223939856|NCT05598398|OTHER|Standard of Care (Wet-to-dry dressings)|Wet-to-dry dressings
223939857|NCT07101926|BIOLOGICAL|blood sampling|One-time peripheral blood draw (10.8 mL total, 4 citrated tubes) collected during a routine clinical visit for thrombin generation testing on platelet-rich and platelet-poor plasma. No additional medical procedures or treatments are involved in the study.
223939858|NCT05774184|BIOLOGICAL|barzolvolimab|subcutaneous administration
223939859|NCT05774184|DRUG|Matching Placebo|subcutaneous administration
223939860|NCT01976260|DEVICE|Fractional Radiofrequency|
223939861|NCT01976260|DEVICE|1550-nm Fractional Photothermolysis|
223939862|NCT05391308|OTHER|Pre-polysomnography mesurement|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner), time spent sitting down (self-reporting)
223939863|NCT05391308|OTHER|Polysomnography measure|Apnea-Hypopnea Index
223939864|NCT05391308|OTHER|Post-polysomnography measurements|Leg fluid volume (bioelectrical impedance), neck circumference (tape measure), neck volume (3D scanner)
223939865|NCT05216276|PROCEDURE|TEP|Laparoscopic totally extra-peritoneal (TEP) inguinal hernia repair
223939866|NCT05216276|PROCEDURE|rTAPP|robotic transabdominal preperitoneal (TAPP) inguinal hernia repair
223939867|NCT03541902|DRUG|Cabozantinib|Given PO
223939868|NCT03541902|DRUG|Sunitinib Malate|Given PO
223939869|NCT04593407|PROCEDURE|Endoscopic mucosal resection (EMR)|"Endoscopic mucosal resection (EMR) is an endoscopic resection technique that allows the removal of large colorectal lesions using a conventional lift-and-cut procedure or an underwater technique"
223939870|NCT04593407|PROCEDURE|Endoscopic submucosal dissection (ESD)|"Endoscopic submucosal dissection (ESD) is an endoscopic procedure that allows dissection of larger colorectal lesions in one piece using endoknives.~The procedure is technically more difficult, much more time-consuming than EMR, mandates multiday hospital admission and has an increased risk of perforation."
223939871|NCT06940427|DRUG|FAPI tracer|"radioactive substance called a tracer injected into the arm"
223939872|NCT06940427|DEVICE|PET/MRI|positron emission tomography (PET) takes pictures of inside of the body
224082580|NCT01580930|BEHAVIORAL|sedentary time reduction|participants provided with strategies to decrease sitting
224082581|NCT01580930|BEHAVIORAL|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
224082582|NCT01409460|PROCEDURE|Oburator Nerve block|Use of selective pain block.
224082583|NCT01409460|PROCEDURE|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
224082584|NCT05410288|DEVICE|Acu-TENS|A TENS stimulator will be used (NeuroTrac TENS; Verity Medical Ltd., Wexford, Ireland). Electrodes will be placed over selected acupoints (i.e., bilateral SP6, PC6 and HT7) and connected to the TENS stimulator. These acupoints are selected according to the traditional Chinese medicine and results of previous studies. The stimulation will be lasted 30-min for each session. The frequency of the stimulation parameter's waveform will be set to 100 Hz and the square pulses will be set to 0.2-ms. The intensity of the stimulation will be below motor threshold and lower than the intolerable level, and hence, participants will feel a pleasant and mild aching sensation.
224082585|NCT05410288|OTHER|acupressure+SHP|Participants in the acupressure group will receive acupressure coupled with SHP. The acupressure protocol was developed based on a protocol recommended by a review and will comprise the following: (1) applying consistent finger-tip pressure of 3-5 kg, with rotational movements; (2) counterclockwise and then clockwise circular motions for 2.5-min each; (3) confirming the precision of the acupressure based on participants feeling pain, numbness, distension, or warmth at the point of application; and (4) an acupoint sequence from the leg to the head, first on the left side of the body and then on the right side of the body; and (5) a 5-min treatment on each acupoint (i.e., bilateral SP6, PC6, and HT7) in each 30-min session. The SHP is the same with Acu-TENS+SHP group.
224082586|NCT05410288|OTHER|placebo stimulation+SHP|Participants in the placebo stimulation + SHP group will receive 30-minute placebo stimulation from identical-looking TENS devices with the electrical circuit disconnected inside.
224082587|NCT05410288|OTHER|sleep hygiene program(SHP)|SHP is a set of instructions designed to help with sleep and promote healthy sleeping habits. The sleep guide contains information on how much sleep is needed by every individual daily, factors that could affect sleep, and risk factors for sleep disorders. It also contains information on the types of sleep disorders, delayed sleep syndrome, insomnia-producing behavior that could affect sleep quality, and suggestions for inducing sleep. The participants will be instructed to read the guide after the baseline assessment (T0). Those instructions will be reinforced by the research practitioner after each treatment session, in order to maintain the healthy sleeping habits.
224082588|NCT00018902|DRUG|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
224082589|NCT00018902|DRUG|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
224082590|NCT00018902|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
223517115|NCT04379271|DRUG|IMU-838|"Tablets will be taken BID with a glass of water (if possible); one tablet each in the morning (15 to 50 min before a meal if applicable), and in the evening (2 hours after any meal if applicable).~If the patient is intubated for ventilation, IMP is to be given via a gastric tube. The tablet has no coating and a homogeneous content and can be crushed into smaller pieces (if necessary) for dosing via gastric tube."
224082591|NCT00018902|DRUG|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
224082592|NCT03718845|BEHAVIORAL|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
224082593|NCT05984563|DEVICE|Cardiopulmonary bypass|CPB will be ensured as usual care: priming volume will be set as 1200 to 1500 mL. Patient blood management and hemodynamic management will be left at the discretion of the anesthesiologist in charge of the patient. Anticoagulation during CPB will be handled through an initial heparin bolus of 300-400 UI/kg followed by additional boluses to maintain ACT above 400 s. Non-heparin-coated bypass circuits incorporating an integrated phosphorylcholine-coated oxygenation system will be used.
224082594|NCT00132067|DRUG|vorinostat|Given orally
224082595|NCT03163654|PROCEDURE|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
224099206|NCT06378710|PROCEDURE|Optimized PEEP|Optimized PEEP
223517116|NCT04379271|OTHER|Placebo|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for IMU-838
223517117|NCT05656274|DRUG|JS1-1-01|Oral tables
223517118|NCT05656274|DRUG|Placebo|Oral tables
223517119|NCT04439903|OTHER|Web-based Simulation Tool|Glucose, insulin and meal data from the participants' insulin pump will be collected and entered into the WST, which will generate personalized models of the participants' glucose metabolism to enable replay simulations.
223517120|NCT06290323|PROCEDURE|Quadratus lumborum block|Posterior quadratus lumborum block
223517121|NCT06290323|PROCEDURE|Placebo|Patients in the first group are the control group and after spinal anesthesia, the sensory block is formed, the lithotomy position will be taken for the surgical procedure.
224082596|NCT03163654|PROCEDURE|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
224082597|NCT02744157|BEHAVIORAL|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
224082598|NCT02817087|DEVICE|repetitive Transcranial Magnetic Stimulation -On|Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
224082599|NCT02817087|DEVICE|repetitive Transcranial Magnetic Stimulation -Off|Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
224082600|NCT03221894|DIETARY_SUPPLEMENT|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
224082601|NCT05857176|OTHER|COVID-19 Vaccine questionnaire|An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).
224082602|NCT02899858|OTHER|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
224082603|NCT02899858|OTHER|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
224082604|NCT02899858|PROCEDURE|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
224082605|NCT02899858|OTHER|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
223517122|NCT05700695|DRUG|Branch Chain Amino Acid|Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm
223517123|NCT05700695|DRUG|Lactulose|Oral lactulose will be given to patients in both arms
223517124|NCT04087655|BEHAVIORAL|Exercise|Eight weeks of interval exercise training
223517125|NCT02901561|DRUG|misoprostol 200|
223517126|NCT02901561|DRUG|misoprostol 400|
223517127|NCT06642688|OTHER|Sacroiliac Joint Manipulation|The patient was asked to tie his arms while he was in the side lying position. The patient's upper knee was flexed and positioned such that it was placed in the popliteal fossa of the lower knee, while the lower knee was in full extension. Pushing maneuver was performed with HVLA from posterior to anterior and from medial to lateral with pelvic rotation. The contact point of the sacroiliac joint was PSIS.
223517128|NCT06642688|OTHER|Cervical Spine Manipulation|Cervical SM was applied supine to restrictions found on motion palpation, according to the technique described by Bergmann and Peterson28 The participant's head and neck were simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7) -to the end of passive ROM. Thereafter, a high-velocity, low-amplitude thrust was delivered in the direction of restricted movement. Participants with more ROM restriction in the lateral plane were given more lateral-to-medial directed thrusts; participants with more restriction in rotation were given thrusts in the direction of restricted axial rotation; and participants with more restriction in extension were given more anteriorly directed thrusts.
223517129|NCT05117125|DIAGNOSTIC_TEST|Heparin-binding protein|Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
223517130|NCT05117125|DIAGNOSTIC_TEST|Interleukin-26|Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
223517131|NCT05117125|DIAGNOSTIC_TEST|Microbiome|Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
224082606|NCT02899858|OTHER|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
224082607|NCT02899858|OTHER|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
224082608|NCT03215784|DIETARY_SUPPLEMENT|Fish Oil|
224082609|NCT03215784|DIETARY_SUPPLEMENT|Probiotic|
224082610|NCT03215784|DIETARY_SUPPLEMENT|Placebo|
224082611|NCT00067704|BEHAVIORAL|Trauma writing|
224082612|NCT00067704|BEHAVIORAL|Writing about daily events|
224082613|NCT05797272|PROCEDURE|in-utero HSCT|Pregnant women who are diagnosed to have BHFS affected fetuses and opt for continuation of pregnancy will undergo in-utero HSCT.
224099207|NCT02864303|OTHER|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
224099208|NCT04419506|DRUG|BI 1015550|18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
224099209|NCT04419506|DRUG|Placebo|placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
224099210|NCT00058799|BIOLOGICAL|Dose Level 1|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
223517132|NCT05117125|DIAGNOSTIC_TEST|Bacterial transcriptome|Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
223517133|NCT05117125|DIAGNOSTIC_TEST|Proteome|Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
223517134|NCT02244788|DEVICE|SR™ PIP|SR™ PIP
223517135|NCT05457140|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
223517136|NCT05457140|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
223517137|NCT05034887|DRUG|Trastuzumab Deruxtecan (T-DXd) monotherapy|T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.
223517138|NCT05034887|DRUG|T-DXd, Durvalumab and Capecitabine Combination|Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
223517139|NCT03978156|DRUG|Dronabinol 2.5 MG|Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
223517140|NCT03978156|DRUG|Microcrystalline cellulose|Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
223517141|NCT05673902|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223517142|NCT01523431|DRUG|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
223517143|NCT01523431|DRUG|5-fluorouracil|The 5-FU dosage will remain the standard.
223517144|NCT01523431|DRUG|Leucovorin|The LV dosage will remain the standard.
223517145|NCT00378287|DRUG|rabeprazole sodium|
224099211|NCT00058799|BIOLOGICAL|Dose Level 2|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 2 x 10\^5
223517146|NCT05019807|OTHER|WhatsApp group|Patients under intervention group will attend an education sessions by structured videos and images with the help of digital tool-WhatsApp group chat administered by the researcher. The group will have the objective interaction with patients and researchers to convey about their view of opinion on sight threatening diabetic retinopathy and management. The structured programme included definition of diabetes mellitus, symptoms, risk factors, awareness of DM and DR, importance of self-care about the disease (eye care and blood glucose monitoring), dietary management and importance of physical activity (Life style modification). The groups will be tracked frequently by WhatsApp/telephonic call and will be documented. Confidentiality of all participants will be maintained.
223517147|NCT05019807|OTHER|Control group|Patient under non-intervention group will not attend or take part in the education sessions or interaction with other patients. Will receive only the general instructions or advises from ophthalmologists about management and follow-up visit.
223703990|NCT01931592|DRUG|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
224099212|NCT00058799|BIOLOGICAL|Dose Level 3|Leukemic Blasts 2 x 10\^7; IL-2 Fibroblasts 2 x 10\^7; CD40L Fibroblasts 4.2 x 10\^7
224082614|NCT04513470|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
224082615|NCT04927728|OTHER|Mental Practice|MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.
223517148|NCT05225012|OTHER|Acceptance and Commitment Therapy|Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
224082616|NCT04927728|OTHER|Repetitive-Task Practice|Repetitive-Task Practice is the repetitive rehearsal of a motor task with the intent to improve motor performance.
223517149|NCT05815784|DRUG|Atropine|0.05% atropine. One drop per eye per day for 2 years.
224082617|NCT04927728|OTHER|Traditional Therapy|Traditional therapy includes traditional interventions completed in occupational therapy for patients following a stroke. These interventions include but are not limited to, range of motion, weight-bearing, massage, modalities, self-care training, and transfer training.
224082618|NCT04052581|PROCEDURE|POEM-TIF|Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
223517150|NCT05815784|DEVICE|MiSight contact lenses|Daily wear for 2 years.
223517151|NCT04722679|DRUG|Non-VKA Oral Anticoagulants (NOAC)|Follow clinical practice.
223517152|NCT04983238|DRUG|BYON5667 & SYD985|Ocular administration: BYON5667, Intravenous administration: SYD985
224082619|NCT03588377|DEVICE|Pulse Oximetry|"Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under \<5 children with symptoms of cough or difficulty breathing~Case definition:~1. Birth - 6 days: Fast breathing +/- Low oxygen in blood \<92% (Hypoxemia)~2. 7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood \<92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor."
224082620|NCT00508391|DEVICE|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
224082621|NCT04285333|PROCEDURE|fascia iliaca block|ultrasound guided block with 20 mL lidocaine 1.5%
224082622|NCT04285333|PROCEDURE|percapsular nerve group block|ultrasound guided block with 20 mL lidocaine 1.5%
224268975|NCT04170452|PROCEDURE|liver biopsy|Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
224268976|NCT00622362|BIOLOGICAL|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
224268977|NCT00622362|BIOLOGICAL|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
224268978|NCT00622362|BIOLOGICAL|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
224082623|NCT01295060|DRUG|Octreotide|84 mg Octreotide Implant
223517153|NCT04983238|DRUG|Placebo & SYD985|Ocular administration: Placebo, Intravenous administration: SYD985
223703991|NCT01931592|DRUG|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
223703992|NCT00055250|DRUG|Gemcitabine|
224082624|NCT05983289|DRUG|HSK7653|HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg
224082625|NCT05983289|DRUG|Placebo|Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg
224082626|NCT01692678|DRUG|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
224082627|NCT01692678|DRUG|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
224082628|NCT03311256|DIAGNOSTIC_TEST|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
224082629|NCT01332682|BEHAVIORAL|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
223517154|NCT06500000|DIAGNOSTIC_TEST|liquid chromatography-mass spectrometry (LC/MS)|Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography- mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and reproducibility.
223517155|NCT02578537|DRUG|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
223517156|NCT02578537|DRUG|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
223517157|NCT05540184|DRUG|Trimetazidine 35 mg|Trimetazidine 35mg twice daily will be given to patients before the procedure and 24 hours after the procedure
224082630|NCT01332682|BEHAVIORAL|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
224082631|NCT05825690|OTHER|Retrospective evaluation of specific brain MRI features|"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
224082632|NCT04405219|OTHER|The Relationship Between Preoperative Smoking Cessation, Anxiety, Pain|Preoperative anxiety high score suggests stress related to surgery and anesthesia. High anxiety scores independent of post-operative pain showed smoking withdrawal.
224082633|NCT02762487|DEVICE|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
224099213|NCT02396862|DRUG|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
224099214|NCT00715715|DRUG|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
224099215|NCT05374941|DEVICE|Injectable and wearable neurostimulator for the hypoglossal nerve|Temporary placement of injectable and wearable neurostimulator for the hypoglossal nerve
224099216|NCT01845025|DRUG|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
224099217|NCT01845025|DRUG|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
223517158|NCT05540184|DRUG|Allopurinol 300 MG|allopurinol 300 mg once daily 5 hours before the procedure and next day of the procedure
224099218|NCT01845025|DRUG|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
223517159|NCT05540184|DRUG|Normal saline|rate of 1 mL/kg per hour (3 to 4 hrs before the procedure and up to 24 hours post-procedure, maximum 100 ml/hr)
223517160|NCT06413875|OTHER|education|Education Specific to Menopause Symptoms
223517161|NCT01878474|DRUG|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
223517162|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
223517163|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25 mg
223517164|NCT01878474|DRUG|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
223517165|NCT01878474|DRUG|Placebo|Single ascending dose in Caucasian men
223517166|NCT01878474|DRUG|Placebo|Age-effect in Caucasian men
223517167|NCT01878474|DRUG|Placebo|Gender-effect in Caucasian women
223517168|NCT01878474|DRUG|Placebo|Single ascending dose in Japanese men
223703993|NCT00055250|DRUG|LY293111|
223703994|NCT00055250|DRUG|placebo|
223703995|NCT00845104|DRUG|fludarabine phosphate|Given IV
223703996|NCT00845104|BIOLOGICAL|rituximab|Given IV
224099219|NCT01845025|DRUG|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
224099220|NCT01845025|DRUG|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
224099221|NCT00089128|DRUG|gemcitabine hydrochloride|
224099222|NCT00089128|DRUG|irinotecan hydrochloride|
223517169|NCT06302985|PROCEDURE|atomized inhalation ICG before thoracoscope pneumonectomy|"Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed."
223517170|NCT01564030|OTHER|Empty|overnight fast
223517171|NCT01564030|OTHER|Fluid|250mL apple juice
223517172|NCT01564030|OTHER|Solid|breakfast
223517173|NCT06239753|BEHAVIORAL|Dynamic Neuromuscular Stabilization|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes. Application of Dynamic Neuromuscular Stabilization (DNS).
223517174|NCT06239753|BEHAVIORAL|Standard Prenatal Education Program Implementation|Conducting routine pregnancy examinations. Measurement of pelvic floor muscle dimensions. Providing education through prenatal classes.
223517175|NCT04003142|DRUG|Fezolinetant|Oral tablet
223517176|NCT04003142|DRUG|placebo|Oral Tablet
223517177|NCT05570318|DRUG|Polyethylene Glycols|To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
223517178|NCT05570318|DEVICE|Low volume trans anal irrigation|To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
223517179|NCT04042311|OTHER|High-intensity interval training|a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
223517180|NCT06535646|OTHER|Home exercise program using Physitrack exercise program and a smart watch|Participants wear a smart watch to monitor activity levels while using a web based exercise program to follow along for 8 weeks.
223517181|NCT03382873|BEHAVIORAL|Group Lifestyle Balance (GLB)|The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
223517182|NCT03382873|BEHAVIORAL|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
223517183|NCT02370342|PROCEDURE|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
223517184|NCT02370342|PROCEDURE|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
223517185|NCT02370342|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
223517186|NCT02370342|DEVICE|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
223517187|NCT05773352|DEVICE|Tornier Perform® Humeral System - Fracture|"A replacement of shoulder joints for anatomic and reverse shoulder arthroplasty.~A replacement of other shoulder joints devices in case of revisions if sufficient bone stock remains."
223517188|NCT06420076|BIOLOGICAL|CD5/CD7 CAR-T|"The intervention in this clinical trial involves a novel approach using CD5/CD7 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD5/CD7 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD5/CD7 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD5/CD7 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
223517189|NCT02554838|OTHER|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
223517190|NCT02554838|OTHER|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
223517191|NCT02554838|BEHAVIORAL|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
223517192|NCT05668507|BEHAVIORAL|REACHOUT Virtual Mental Health Support|"REACHOUT is a mobile app which delivers peer-led mental health support to adults with type 1 diabetes. The mobile app has three support features:~1. One-on-one support delivered by a Peer Supporter. Participants will be able to review Peer Supporter profiles and connect with one of their choosing.~2. Group support delivered via a 24/7 chat room~3. Face to face support delivered via virtual happy hours"
223517193|NCT03324412|DRUG|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
223703997|NCT00845104|BIOLOGICAL|bevacizumab|Given IV
223703998|NCT00845104|OTHER|laboratory biomarker analysis|Correlative studies
223517194|NCT03324412|DRUG|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
223517195|NCT05281458|PROCEDURE|Early drainage of peripancreatic fluid collections|Participants will undergo EUS guided drainage earlier (≤1 weeks) in the disease course.
223517196|NCT05530915|OTHER|Gel capsule|Single capsule per dose
223517197|NCT01205412|PROCEDURE|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
223517198|NCT01460537|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
223517199|NCT01460537|DRUG|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
223517200|NCT01460537|DRUG|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
223517201|NCT01460537|DRUG|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
223517202|NCT01460537|DRUG|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
224082634|NCT04869267|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"Session 1:~This session aims to let the participants get familiar with the interventionist. The interventionist will tell them the purpose of the program and basic rules. And the interventionist will promise their privacy protection.~Session 2:~This session includes how to separate thoughts/feelings/sensations related to diagnose with advanced lung cancer and experience of fatigue with facts and see these feelings in an objective way with observing self.~Session 3:~This session mainly aims to help participants understand the importance of values, differentiate values from goals and clarify their personal values.~Session 4:~This session aims at helping patients practice to engaging in committed action based on chosen values, motivated to change behavior in consistency with life direction and health goal."
224268979|NCT01207479|DEVICE|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
223517203|NCT03976726|DEVICE|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
223517204|NCT05701631|DIAGNOSTIC_TEST|Radiomic model|Radiomic model for PCP diagnosis
223517205|NCT04180423|DEVICE|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
223517206|NCT04180423|DEVICE|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
223517207|NCT05625867|OTHER|Psychological and quality of life questionnaires|At 4/5 months and at 9 months
223517208|NCT05625867|OTHER|Interdisciplinary consultation at 4/5 months|About ten days after the questionnaires were administered
223517209|NCT04409418|DEVICE|Extended dwell catheters|EDCs are generally placed using ultrasound for guidance and are commonly placed in any of 3 veins in the arm. They can be inserted above or below the antecubital fossa (the bend of your elbow). These catheters can be left for up to 30 days and don't fail as quickly when compared to peripheral IVs.
223517210|NCT03066518|DRUG|Melatonin 5 mg|
223517211|NCT03066518|OTHER|Placebo|
223517212|NCT00307580|DRUG|Cathflo Activase (Alteplase)|
223517213|NCT06643962|DRUG|Venetoclax|Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.
223517214|NCT06643962|DRUG|Idarubincin|Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
223517215|NCT06643962|DRUG|Cytarabine|During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age \>55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
223517216|NCT02926196|DRUG|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
223517217|NCT05510934|BEHAVIORAL|Shared-care model|A Shared care follow-up strategy involving patients, PCPs and specialists that uses an automated reminder system (TCARS).
223517218|NCT03153202|DRUG|Ibrutinib|once daily oral intake ibrutinib
223517219|NCT03153202|DRUG|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
224268980|NCT02033902|DRUG|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
223517220|NCT03201094|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
223517221|NCT03201094|DIETARY_SUPPLEMENT|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
223517222|NCT00160875|DRUG|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
223517223|NCT00160875|DRUG|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
223517224|NCT05487391|DRUG|QL1706 injection|QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy
223517225|NCT05487391|DRUG|Vinorelbine Tartrate|Vinorelbine 25mg/m2（D1、D8）Q3W IV, 2-4 cycles
224082635|NCT04869267|OTHER|Usual care|The usual care mainly includes treatments and daily care during admission, medication instructions, diet and exercise advice, retest recommendations when discharge
223517226|NCT05487391|DRUG|Paclitaxel|Paclitaxel 175mg/m2（D1） Q3W IV, 2-4 cycles
224268981|NCT05231603|DRUG|Ivermectin|0.4 mg/kg/day-maximum dose is 24 mg.
224082636|NCT00802360|DRUG|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
224268982|NCT05231603|OTHER|Placebo|Similar to drug in term of tablets
224268983|NCT00354835|DRUG|Cyclophosphamide|Given IV
224268984|NCT00354835|BIOLOGICAL|Dactinomycin|Given IV
223939873|NCT05825482|PROCEDURE|Arm 1 Partial mastectomy with Savi Scout® localization and shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 1 randomization, the surgeons will be instructed to perform a partial mastectomy with routine cavity shave margins using Savi Scout® localization. The lesion will be removed in the routine fashion. The surgeons will use the Savi Scout® to perform routine cavity shave margins by extracting superior, lateral, inferior, medial, anterior, and posterior margins.
223517227|NCT05487391|DRUG|Cisplatin|Cisplatin 75mg/m2（D1）Q3W IV, 2-4 cycles
223939874|NCT05825482|PROCEDURE|Arm 2 Partial mastectomy with Savi Scout® localization and selective shave margins.|Patients will undergo preoperative Savi Scout® reflector placement under image guidance per routine care. Patients will undergo randomization. With Arm 2 randomization, the surgeons will be instructed to perform a partial mastectomy with selective margins shave margins using Savi Scout®. The lesion will be removed in the routine fashion. The Savi Scout® localizer will be utilized to determine selective shave margins by examining the same margins on the excised tissue specimen. The surgeon will obtain selective margins if the margin of the tissue specimen is within 1mm of invasive cancer and 2mm within DCIS.
223517228|NCT05487391|DRUG|Carboplatin|Carboplatin AUC=5（D1） Q3W IV, 2-4 cycles
223939875|NCT06941129|BIOLOGICAL|UCAR T-cell|universal allogeneic anti-CD19/BCMA CAR T-cells
223939876|NCT06941961|DEVICE|intermittent theta burst stimulation|The iTBS delivered to the ipsilesional primary motor cortex (M1) at 80% resting motor threshold (RMT). Each session consists of 600 pulses (3-minute trains of 50 Hz triplets repeated every 10 seconds, twice daily with a 5-minute interval), administered for 7 consecutive days starting within 6 hours post-randomization.
223939877|NCT06941961|DEVICE|sham intermittent theta burst stimulation|Sham-iTBS is performed in the same way as the treatment group but uses 20% RMT.
223939878|NCT07144267|DRUG|Epinephrine|Normal saline bolus over 10 min followed by Epinephrine intravenous infusion of 0.05-0.1 mcg/kg/min.of epinephrine 5-10 minutes before aortic unclamping
223939879|NCT07144267|DRUG|Milrinone Injection|Milrinone initial bolus doses of 50 µg/kg, followed by 0.40 - 0.80 µg/kg/min of milrinone 5-10 minutes before aortic unclamping
223939880|NCT06945198|PROCEDURE|Anatomical reconstruction|Anatomical ligamentoplasty or anatomical reconstruction is performed under arthroscopy. The principle of this method, which lasts around 40 minutes under spinal anaesthetic or general anaesthetic, is to reconstruct the LTFA and sometimes also the LCF, if it has been damaged, using a fragment of the tendon gracilis, located in the thigh, removed through an incision under the knee
223939881|NCT06945198|PROCEDURE|Broström anatomical repair|Broström's anatomical repair is performed under arthroscopy. The principle of this method is to tighten and reattach the LTFA using very small anchors, when it is detached from the fibula but not too retracted and still of good quality. If necessary, this may also be accompanied by ligament reinforcement ('gould'), using a fragment of a fibrous structure in the ankle, the extensor retinaculum
223939882|NCT06341933|OTHER|Duration of Surgery|Total surgery time in minutes
223939883|NCT06341933|OTHER|Volume of Fluid in Surgery|Fluid volume given during surgery in ml
223939884|NCT06341933|OTHER|Blood Loss|Blood loss during surgery in ml
223939885|NCT03255746|BEHAVIORAL|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
223939886|NCT03255746|BEHAVIORAL|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
223939887|NCT04801589|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.2-2.0 mcg/kg/hr. For example, a 10 kg patient on an infusion of 1 mcg/kg/hr of dexmedetomidine would receive 10 mcg of study drug per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
223939888|NCT04801589|DRUG|Midazolam|For patients in the midazolam group, dose will range from 0.025-0.25 mg/kg/hr. For example, a 10 kg patient on an infusion of 0.15 mg/kg/hr of midazolam would receive 1.5 mg of midazolam per hour. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the mini-MENDS study steering committee.
223939889|NCT05672355|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223939890|NCT05672355|BIOLOGICAL|mRNA COVID-19 Vaccine|Given IM
223939891|NCT05672355|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM
223939892|NCT06945172|PROCEDURE|Total prostatectomy|Total prostatectomy is a surgical procedure performed to treat prostate cancer.
223939893|NCT06945172|PROCEDURE|Focal HIFU|Focal HIFU treatment is an innovative technique that consists of destroying prostate tumour cells using high-intensity ultrasound focused exclusively on the affected area of the gland.
223939894|NCT06260293|BEHAVIORAL|exercise|"A total of 4 exercise interventions.~Twice In-patient exercise interventions: exercises on the ward at POD1, and POD2, and Recommended walking and stretching.~Twice home-based exercise interventions: post-discharge, Recommended 30 minutes of low to moderate-intensity walking and daily bodyweight exercises per day(150 minutes each week). and remote exercises 1 per week."
223939895|NCT06411860|OTHER|Placebo|Participants will receive a subcutaneous (SC) injection of placebo.
223939896|NCT06411860|DRUG|Olpasiran|Participants will receive a SC injection of olpasiran at dose level 1 or 2.
223939897|NCT06411860|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.
223939898|NCT07143461|BEHAVIORAL|Faith Healing|In the prayer condition, the participants will engage and vocalize in prayers they are already familiar with and commonly practice at least once, then continue silently for 10 minutes, focusing on the content. If distracted, participants should refocus on the prayer and reflect on its meaning.
224082637|NCT00802360|DRUG|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
224082638|NCT00802360|DRUG|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
224082639|NCT00802360|DRUG|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
224082640|NCT00802360|DRUG|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
223517229|NCT05487391|DRUG|Pemetrexed|Pemetrexed 500mg/m2（D1） Q3W IV, 2-4 cycles
223517230|NCT05487391|DRUG|Placebo|Placebo
223517231|NCT01292538|DEVICE|Erchonia GLS|532 nm green diode low level laser light device
223517232|NCT01292538|DEVICE|Placebo laser|Sham light output with no therapeutic benefit
223703999|NCT00845104|OTHER|flow cytometry|Correlative studies
223704000|NCT00845104|GENETIC|polymerase chain reaction|Correlative studies
223939899|NCT07143461|BEHAVIORAL|Control|In the control condition, participants will read a neutral text with no spiritual or religious content for 10 minutes. If distracted, they should refocus on the text.
223939900|NCT06950281|DRUG|Low Sodium Oxybate|Low sodium oxybate (LXB) will be administered as a twice nightly regimen. All subjects will undergo an 8 week Treatment Titration and Optimization Phase. Titration should proceed in an increment of 1.5g per night each 7 days until a 50% reduction in nocturnal headache frequency is achieved or a maximum dose (9g per night) is reached. If a subject is unable to titrate to a higher dose, they may stay at the highest tolerated dose for the duration of the study. Subjects may stop titration or have dose reduction at any time for safety and tolerability reasons.
223939901|NCT06950281|DRUG|Placebo|Placebo with equal appearance
223939902|NCT06953375|PROCEDURE|NMES|The NMES intervention protocol in this study ensures patients receive NMES intervention that is adequately dosed (dose = treatment minutes x intensity), delivered using evidence-based parameters, and feasible. The investigators will deliver NMES using a portable two-channel stimulator that the investigators have found to produce stronger muscle contractions than other portable NMES units and has been used in previous clinical studies. It also has a built-in compliance meter to monitor patient treatment minutes (adherence) to NMES application. NMES sites will perform routine collection of outcomes as part of standard practice.
223939903|NCT06953375|OTHER|Usual Care|Usual Care clinics will continue with routine collection and documentation of physical performance outcomes as standard practice. A combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Usual Care clinics including the facility, rehabilitation clinicians, and patients will not have access to NMES materials developed for this study.
223939904|NCT07148999|COMBINATION_PRODUCT|Opt-IVF|Opt-IVF provides optimized dosage profile for each patient
223939905|NCT07148999|OTHER|Control|Physicians will decide the dosage for each day for patients
223939906|NCT06948214|DRUG|LUM-201|1.6 mg/kg/day, administered orally once daily
223939907|NCT06948214|OTHER|Matched Placebo (Capsules)|Administered orally once daily
223939908|NCT06951880|DRUG|AZD4916|AZD4916 will be administered as oral solution.
223939909|NCT06951880|OTHER|Placebo|Placebo will be administered as oral solution.
223939910|NCT06950541|PROCEDURE|Myofascial therapy|The myofascial therapy in the form of Fascial Distortion Model (FDM) method is based on the idea that issues within the musculoskeletal system stem from deformations or distortions in the fascia. Once the type of deformation is identified, a specific technique is employed by the physiotherapist using their hands and pressure. FDM identifies six types of fascial distortions that can cause pain and other musculoskeletal issues. These distortions include triggerbands, continuum distortions, cylinder distortions, herniated triggerpoints, tectonic fixations, and folding distortions.
223939911|NCT06950541|PROCEDURE|Deep Tissue Massage|"A deep tissue massage is a therapeutic technique that focuses on realigning deeper layers of muscles and connective tissue. It is particularly beneficial for individuals dealing with chronic pain, muscle tension, or injury recovery.~The physiotherapist uses more intense pressure compared to other massage types, like Swedish massage. The goal is to reach deeper muscle layers to relieve tension and pain. The therapist employs various techniques, including long, slow strokes, deep finger pressure, and friction, also use elbows, knuckles, or forearms to apply pressure to specific areas."
223939912|NCT03857529|DEVICE|transcranial direct current stimulation and electrical stimulator|"Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration."
223939913|NCT05179499|DRUG|Norepinephrine|Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
223939914|NCT05179499|OTHER|Balanced Crystalloid|IV fluids administered as per standard care
223939915|NCT07153250|BEHAVIORAL|Project EMPOWER|Project EMPOWER is a web-based, self-administered program for parents that takes about 20 minutes to complete.
223939916|NCT07153250|BEHAVIORAL|Being Brave Parent Education|Being Brave Parent Education is an online, self-guided program which consists of three brief video-recorded lessons (approximately 20 minutes each) with accompanying knowledge checks and workbook on implementing parent-directed cognitive-behavioral therapy.
223939917|NCT07153250|BEHAVIORAL|Sharing Feelings|A self-guided 20-minute educational control, that teaches parents about the importance of sharing feelings and about helpful versus unhelpful expression of emotion.
223517233|NCT00907088|OTHER|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
223517234|NCT00907088|OTHER|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
223517235|NCT00347087|DRUG|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
224082641|NCT01418495|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224082642|NCT01418495|OTHER|Pharmacological Study|Correlative studies
224082643|NCT02041962|BEHAVIORAL|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
224082644|NCT02041962|OTHER|Educational Control|
224082645|NCT00189644|PROCEDURE|6 FEC 100|
224082646|NCT00189644|PROCEDURE|4 FEC 100 followed by 4 Taxol|
224082647|NCT01799057|DRUG|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
224082648|NCT01799057|DRUG|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
224082649|NCT01812967|DIETARY_SUPPLEMENT|Milk Fat|
224082650|NCT01812967|DIETARY_SUPPLEMENT|Milk Protein|
224082651|NCT01812967|DIETARY_SUPPLEMENT|Lactose|
224082652|NCT01812967|OTHER|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
224082653|NCT01812967|DIETARY_SUPPLEMENT|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
224082654|NCT05644171|DEVICE|RESToration Of Rehabilitative function with Epidural spinal Stimulation|Three patients with chronic motor SCI will be recruited in total for this study. The recruited patients will not be randomized nor blinded due to the nature of this study. Pre-op rehabilitation session will take place over 4 weeks. 1 month post-surgical implants, patients will undergo 24 weeks of rehabilitation. The training sessions may continue to take place after the stipulated 24 weeks as long the electrode remains implanted, and the patient is available.
224082655|NCT05443204|OTHER|Fortimel energy|Standard nutritional oral supplement
224082656|NCT05443204|OTHER|Nutrision Advanced Diason Energy HP|Specifc nutritional oral supplement in diabetics patients
224082657|NCT05242770|OTHER|Control Arm|Participants randomized to this arm will only receive educational pamphlets with resources for sexual dysfunction and will not participate in physical therapy. Participants will be contacted at 3 months and 6 months to fill out two questionnaires about sexual function and quality of life. After 6months, if participants desire a referral to physical therapy, investigators will provide a referral.
224082658|NCT05242770|OTHER|Physical Therapy Arm|Participants will receive a referral to begin a pelvic physical therapy regimen. Participants will complete the sexual function and quality of life questionnaires after completion of the physical therapy regimen and again 3 months after. There will be a brief exit interview.
224082659|NCT05242770|OTHER|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Questionnaire designed to measure cancer patients' physical, psychological and social functions
224082660|NCT05242770|OTHER|Female Sexual Function Index (FSFI)|19-item self-report inventory designed to assess female sexual function.
224082661|NCT05242770|OTHER|Exit Interview|11-item questionnaire for participants to give feedback to investigators about teir experience with the intervention.
224082662|NCT03488160|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
224082663|NCT02765451|BEHAVIORAL|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
224268985|NCT00354835|DRUG|Irinotecan Hydrochloride|Given IV
224268986|NCT00354835|OTHER|Laboratory Biomarker Analysis|Correlative studies
224268987|NCT00354835|OTHER|Questionnaire Administration|Ancillary studies
224268988|NCT00354835|RADIATION|Radiation Therapy|Undergo radiotherapy
224268989|NCT00354835|DRUG|Vincristine Sulfate|Given IV
224268990|NCT02112123|DRUG|Icariin|
224268991|NCT02112123|DIETARY_SUPPLEMENT|Matching placebo|
223704001|NCT00845104|GENETIC|fluorescence in situ hybridization|Correlative studies
223517236|NCT00986895|DRUG|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
223517237|NCT05249400|PROCEDURE|Off-site assistance|The trainer supervised the trainee's cannulation operation outside the procedure room through a high-definition screen displaying the endoscopic and fluoroscopic view. The trainer was allowed to provide unlimited verbal instructions to the trainee by an intercom.
223517238|NCT00804479|OTHER|No intervention.|
223517239|NCT00775086|DRUG|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
223517240|NCT02034266|DIETARY_SUPPLEMENT|Omega-3 supplementation|5 mL twice daily, administered under the tongue
224099223|NCT02783560|BEHAVIORAL|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
223517241|NCT03109769|BEHAVIORAL|Mobile phone application|
223517242|NCT03109769|BEHAVIORAL|Verbal oral hygiene instructions|
224099224|NCT02783560|BEHAVIORAL|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
224099225|NCT00275080|DRUG|vorinostat|Given orally
224099226|NCT00275080|DRUG|decitabine|Given IV
224099227|NCT02966314|DRUG|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
224099228|NCT02966314|DRUG|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
223517243|NCT03179709|BEHAVIORAL|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
223517244|NCT03673722|OTHER|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
223517245|NCT03673722|OTHER|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
223517246|NCT03673722|OTHER|Control|Participants will be given generic healthy eating advice based
223517247|NCT02301793|BEHAVIORAL|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
223517248|NCT02301793|BEHAVIORAL|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
224082664|NCT00816374|OTHER|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~* The American Cancer Society~* The American Academy of Dermatology~* The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~* Sun protection practices~* Risk factors for melanoma~* Information about what melanoma looks like~* How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
223517249|NCT04281771|PROCEDURE|cardiac MRI|"Patients are studied on a clinical 1.5 Tesla scanner with cardiac radiofrequency receiver coil centered over the heart, and ECG monitoring. The following parameters are assessed:~Functional imaging: ECG-gated cine Steady-state free precession (SSFP) MRI images are obtained during repeated breath holds in long axis and short axis orientations covering the entire left ventricle. Global systolic and diastolic function are assessed, and left ventricular mass is calculated.~Flow imaging: ECG-gated 2D flow measurements are assessed above the prosthetic valve, and at the level of the pulmonary trunk."
223517250|NCT00544687|DRUG|CRx-191|topical (mometasone furoate + nortriptyline HCl)
223517251|NCT00544687|DRUG|mometasone furoate|topical mometasone furoate
223517252|NCT00544687|DRUG|nortriptyline HCl|topical nortriptyline HCl
223517253|NCT00544687|DRUG|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
224082665|NCT00816374|OTHER|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~* Melanoma and skin cancer protection guidelines~* The benefits of skin screening practices~* Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
224082666|NCT00816374|OTHER|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~* knowledge of melanoma~* current and past skin cancer screening practices~* current and past sun protection practices~* attitudes about skin cancer and sun protection~* feelings about relative's melanoma diagnosis and treatment"
224082667|NCT00874302|DRUG|Proellex|One 25mg capsule taken orally once every day.
223517254|NCT00544687|DRUG|Vehicle|topical (placebo)
223517255|NCT02477046|BIOLOGICAL|tOPV|administered per protocol
223517256|NCT02477046|BIOLOGICAL|bOPV|administered per protocol
223517257|NCT02477046|BIOLOGICAL|IPV|administered per protocol
223517258|NCT01435746|BEHAVIORAL|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
223517259|NCT04023474|PROCEDURE|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
223517260|NCT01885338|DRUG|N-acetylcysteine (NAC)|
223517261|NCT01885338|DRUG|Inactive placebo capsule|
223517262|NCT04978831|DEVICE|PEP Device|The breathing exercise device is a device that simulates pursed-lip breathing by creating positive expiratory pressure (PEP). Before starting to use the device, it will be explained that they need to put the mouthpiece on the device and put the nose clip on their nose, and the participants will be shown how it is done. The device will be used at 5 cmH2O pressure. A single exercise session consists of 3 exercise cycles, and a single exercise cycle consists of 15 breathing-exhalation activities. Participants will complete 3 cycles (a total of 45 inhales and exhales) in a single session. 1 loop lying on the left side, 1 loop lying on the right side, and 1 loop in sitting upright position. Participants held these sessions in the morning, afternoon, and evening. After completing each cycle, the participants will remove their nose clips and cough 2-3 times. Each participant will perform a total of 135 breathing exercises in one day.
223517263|NCT04978831|OTHER|Reading Aloud|"The patients in this group were given a book that they chose from among the book types within the scope of the study, according to their wishes. For the selection of books, opinions were taken from the experts in the education faculty of the same university and it was stated that any book separation was not important. The books that the participants wanted to read were provided by the researcher. They were asked to read this book aloud during the day, sitting upright on a chair or sofa, for 15 minutes, three times a day.~They were able to stop reading when the participant was tired or felt too short of breath to continue reading."
223517264|NCT02261142|DEVICE|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
223517265|NCT01062295|DEVICE|Siesta-System|
223517266|NCT01062295|DEVICE|Standard headrest|
223517267|NCT02472951|OTHER|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
223517268|NCT02472951|OTHER|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
223719005|NCT01872377|RADIATION|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
223517269|NCT06469580|OTHER|NPLUS (neonatologist performed lung ultrasound)|"NPLUS is conducted with an ultrasound scanner using a high-frequency (12-15 MHz) linear transducer probe (scanning depth approximately 4-5 cm). The neonate is placed in a supine position. The anterior, lateral and posterior chest areas are scanned using the presets lung or small parts. Landmarks are the anterior and posterior axillary line (longitudinal) on each hemithorax. A sequential scan from right to left, anterior to posterior is performed. (6 lung areas). In the study NPLUS is performed to quantify the lung ultrasound score at time points T0, T1 and T2. Sequences of 3-5 seconds are saved and assessed according to the lung ultrasound score adapted by Rodriguez-Fanjul et al. (0- to 3 point score for each area, resulting in a total score ranging from 0 to 18). To ensure inter-observer reliability the anonymous video sequences are then rated by two independent neonatologists."
223517270|NCT02980185|PROCEDURE|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
223517271|NCT06255340|DRUG|BI 3031185|BI 3031185
223517272|NCT06255340|DRUG|Placebo matching BI 3031185|Placebo
223517273|NCT01433003|PROCEDURE|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
223517274|NCT05200780|DEVICE|ultrasound|All subjects will undergo the tests with the same machine. Transverse ultrasound images were obtained using the Philips HD with a 4-12 MHz probe. in neurosonology unit in neurology department.
223517275|NCT02473263|DRUG|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
223517276|NCT02473263|DRUG|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
223517277|NCT02473263|DRUG|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
223517278|NCT02473263|DRUG|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
223517279|NCT02838706|PROCEDURE|Surgery for hip fracture|
223517280|NCT00648713|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
223517281|NCT00648713|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fed
223517282|NCT01292993|DRUG|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
223517283|NCT01292993|DRUG|1000 mg metformin|1000 mg metformin given as a solid oral dose form
224082668|NCT00874302|DRUG|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
223517284|NCT01446510|OTHER|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
224082669|NCT01549548|DRUG|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
224082670|NCT01196559|DRUG|Vinorelbine and Gemcitabine|Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
223517285|NCT05510973|OTHER|Enhanced package for AHD care|The enhanced package of AHD care includes CD4 and tuberculosis lipoarabinomannan (TB-LAM) tests and the initiation of patients on TB prophylaxis \[TPT and CPT\], offered through a hub-and-spoke facility system, with continuous quality improvement (QI)
223517286|NCT05127785|PROCEDURE|LVAD or Heart Transplant|Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
224099229|NCT01998607|OTHER|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
223517287|NCT01044459|DRUG|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
223517288|NCT01044459|DRUG|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
223517289|NCT01029964|BEHAVIORAL|Individually and in groups|During three year in a clinical setting.
223517290|NCT05154929|BEHAVIORAL|Dietary and physical activity JITAI delivered through the myBPmyLife app|A Fitbit smartwatch and home blood pressure monitor will be mailed to participants (in both the experimental and control arms). Participants in the intervention arm then will set up and utilize the myBPmyLife app. This app includes push notifications to promote increased physical activity and improve low-sodium food choices, establish goal setting for weekly step count and low sodium food choices, and deliver feedback on achieving the goals using a dashboard visualization within the mobile application.
223517291|NCT05154929|OTHER|Control Group|Participants will receive the myBPmyLife app, a smartwatch, and blood pressure cuff. The myBPmyLife app will not be fully activated (as they are in the control arm). They will be provided with the option of downloading and installing a mHealth app that is publicly available. In this arm they will also perform the blood pressure monitoring, but do not receive the intervention components through the myBPmyLife app.
223517292|NCT02856373|PROCEDURE|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
224099230|NCT01242111|DRUG|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
223517293|NCT04582643|BEHAVIORAL|6P intervention|6P assessment targeting on diet, activity and mentality, along with education provided based on the 6P components. The 6P tool serves the functions to help the women to self-monitor and be aware of their negative lifestyle choices.
223517294|NCT01095965|BEHAVIORAL|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
223517295|NCT04105725|BEHAVIORAL|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
223517296|NCT04105725|OTHER|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
223517297|NCT04195256|DRUG|IN Ketodex (D4K2)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
223517298|NCT04195256|DRUG|IN Ketodex (D3K3)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
223517299|NCT04195256|DRUG|IN Ketodex (D2K4)|Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
224082671|NCT04301141|OTHER|Virtual Reality Assisted Cognitive Behavioural Therapy|The intervention will be delivered in NHS services and will involve using VR to assist the delivery of conventional CBT for the treatment of social anxiety in autistic adolescents. Social situations that are commonly anxiety-evoking for this patient group will be simulated in VR and used for exposure (a typical component of CBT for social anxiety). Therapists will use a modular approach involving optional modules such as psychoeducation on anxiety in the context of ASD, managing expectations of outcome and emotional literacy training. Essential modules include rapport building, introducing the use and purpose of VR, and exposure (incorporating VR). Because CBT is delivered in routine clinical practice, the VR exposure sessions will be the main subject of interest.
224082672|NCT00838019|PROCEDURE|Intrabone administration of umbilical cord blood|Single administration
224082673|NCT03856151|DEVICE|"HEALTHY BOX Powered heating pad (electronic moxibustion)"|Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
224082674|NCT03183544|COMBINATION_PRODUCT|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
224082675|NCT05057455|PROCEDURE|cytokine hemadsorption|the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
224082676|NCT01481896|DEVICE|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
224082677|NCT03152240|OTHER|Non intervention|Non intervention
224082678|NCT03871114|DRUG|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
224082679|NCT06388902|DRUG|BR115 for injection|BR115 for injection will be administered by subcutaneous injection, two doses at the first week of treatment, followed by once per week until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data.
224082680|NCT05176912|OTHER|Exercise|Reformer Pilates exercises will given for 8 weeks, 3 days in a week
224082681|NCT01990261|DRUG|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
224082682|NCT05618366|DRUG|Venetoclax|Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
224082683|NCT05618366|DRUG|Tazemetostat|Tazemetostat 800mg taken orally, twice daily.
224082684|NCT01509352|PROCEDURE|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
224082685|NCT01509352|PROCEDURE|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
224082686|NCT00324285|DRUG|Amylase resistant starch added ORS|
224082687|NCT04263831|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
224082688|NCT04147351|DRUG|Atezolizumab Injection; bevacizumab Injection|a PD-L1 inhibitor; anti-angiogenesis
224082689|NCT00954109|BEHAVIORAL|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
224082690|NCT03929887|OTHER|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
224082691|NCT00599495|PROCEDURE|allogeneic HSCT|dose-reduced conditioning regimen
224082692|NCT01910714|BEHAVIORAL|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
224082693|NCT01910714|BEHAVIORAL|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
224082694|NCT02721537|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Three capsules, twice per day for 84 days
224082695|NCT02721537|OTHER|Matching placebo|Three matching capsules, twice per day for 84 days
224082696|NCT04299295|DEVICE|YVOIRE Y-Solution 360|Hyaluronic acid dermal filler
224082697|NCT04299295|DEVICE|Juvéderm VOLBELLA|Hyaluronic acid dermal filler
224082698|NCT04003688|DRUG|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
224082699|NCT04003688|DRUG|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
224082700|NCT04003688|DRUG|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
224082701|NCT01845038|DRUG|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
224082702|NCT01845038|DRUG|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
224082703|NCT01845038|DRUG|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
224082704|NCT03302273|OTHER|Corneal Epithelial Stem Cell Transplant|Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
224082705|NCT06176157|DIETARY_SUPPLEMENT|vitamin D2, vitamin D3|comparing parentral D2, D3, to oral D2, D3
224082706|NCT05821140|PROCEDURE|dental treatment for global oral rehabilitation|dental treatment can include conservative, orthodontic, prosthetic or surgical procedures
224082707|NCT05821140|OTHER|oral health check up|regular preventive follow-up visit (every 6 months)
224082708|NCT02482584|DEVICE|CPAP|CPAP intervention
224082709|NCT02482584|OTHER|Control|Control
224268992|NCT05722080|OTHER|Eyesi simulator|Eyesi simulator learning curve for new ophthalmology residents
224268993|NCT05722080|OTHER|Sleep deprivation|See how experienced residents perform after sleep deprivation using the Eyesi simulator
224287270|NCT00562120|DRUG|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
224287271|NCT00562120|DRUG|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
224287272|NCT00562120|DRUG|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
224287273|NCT00562120|DRUG|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
224287274|NCT05598164|OTHER|Botulinum toxin type A|"Patients of main group are treated with injection in internal sphincter botulinum toxin type A.~In the control group, the fissure is excised in combination with a injection in internal sphincter botulinum toxin type A."
223517300|NCT04195256|DRUG|IV Ketamine|Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
223517301|NCT00185055|DRUG|Olmesartan medoxomil|
223517302|NCT00185055|DRUG|Irbesartan|
223517303|NCT00185055|DRUG|Valsartan|
223517304|NCT01498380|DRUG|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease \< 20% or blood pressure decrease/increase \< 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease \>/= 20% or SBP/DBP/MAP decrease or increase \>/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
223517305|NCT02322931|PROCEDURE|Intra-operative C-arm CT imaging|"1. Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~2. Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~3. One Cine loop C-arm scan in the sagittal plane while retracting the probe.~4. One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
223517306|NCT04712227|OTHER|intubation|intubation
223517307|NCT04712227|OTHER|mask ventilation|mask ventilation
223517308|NCT04879485|BIOLOGICAL|Blood products|Compare two different transfusion strategies against standard transfusion regimen
223517309|NCT06491576|DRUG|BGT-002|taking the study drug orally
223517310|NCT06491576|DRUG|Placebo|taking the placebo orally
223517311|NCT04365270|DRUG|Glass Ionomer|Glass ionomer filling material would be modified accordingly or used as is
224082710|NCT02667080|OTHER|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
224082711|NCT02667080|OTHER|2 hours of sexual abstinence|2 hours of sexual abstinence
224082712|NCT04320407|DEVICE|Osia 2 System|The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
224082713|NCT06152822|DRUG|pyrotinib+capecitabine+bevacizumab|pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w
223517312|NCT04365270|DRUG|Chitosan Low Molecular Weight (20-200 Mpa.S)|deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying
223517313|NCT04365270|DRUG|Chlorhexidine Diacetate|Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716
223517314|NCT04365270|DRUG|Titanium Dioxide|Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
223517315|NCT05864716|BIOLOGICAL|Colonscopic probiotics spray|20g of multi-strain probiotics powder via colonoscopic spray. The probiotic used in this study is SynPro-15G, which has 15 probiotics, including Bacillus coagulans BC1031, Bifidobacterium bifidum BB14, Bifidobacterium breve BR18, Bifidobacterium animalis subsp. lactis BAL06, Bifidobacterium longum (B. longum) BL986, Lactobacillus acidophilus LA1063, Lactobacillus casei LC122, Lactobacillus delbrueckii subsp. lactis LDL114, Lactobacillus fermentum LF26, Lactobacillus helveticus LH43, Lactobacillus paracasei LPC12, Lactobacillus plantarum LP198, Lactobacillus reuteri LR21, Lactobacillus rhamnosus LRH10, and Streptococcus thermophilus ST37 at a concentration of 2x1010 CFU/g (Synbiotech Corp., Kaohsiung, Taiwan). SynPro-15G is made either as a vial of powder (2x1011 CFU /vial) for colonoscopic spray or as a capsule (2x1010 CFU/capsule) for oral intake.
223517316|NCT05346640|DEVICE|Cionic Neural Sleeve|Adaptive, functional electrical stimulation
224082714|NCT02878980|BEHAVIORAL|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
224082715|NCT02878980|OTHER|Laboratory Biomarker Analysis|Correlative studies
223517317|NCT03818971|OTHER|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
223517318|NCT00480025|BIOLOGICAL|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
223517319|NCT00480025|BIOLOGICAL|Placebo Control|Intramuscular administration, 13 doses
224082716|NCT02878980|OTHER|Quality-of-Life Assessment|Ancillary studies
224082717|NCT02878980|OTHER|Questionnaire Administration|Ancillary studies
224082718|NCT00004156|BIOLOGICAL|MUC1-KLH vaccine/QS21|
223517320|NCT04190771|BEHAVIORAL|TAU + multicomponent treatment NAT-FM|"Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
223517321|NCT04190771|BEHAVIORAL|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients with fibromyalgia.
223517322|NCT04920825|DIETARY_SUPPLEMENT|Sacha Inchi Oil softgel supplement|A twice daily supplementation of Sacha Inchi Oil softgel for 12 weeks
223517323|NCT04920825|DIETARY_SUPPLEMENT|Corn oil softgel|A twice daily supplementation of Corn Oil softgel for 12 weeks (Placebo)
223517324|NCT01310114|BIOLOGICAL|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
223517325|NCT01310114|DRUG|Placebo|Thawed placebo
223517326|NCT05940649|PROCEDURE|Continuous norepinephrine administration|In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure \< 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
223517327|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
223517328|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
223517329|NCT02425176|DRUG|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
224082719|NCT05154292|BEHAVIORAL|Serious Game: Emotional Health Island (SAEM)|This intervention aims to aim to develop competencies for emotional regulation through exposure and acceptance strategies. This intervention is applied through a serious game developed for this purpose. the adolescent will complete a series of missions aimed at developing skills related to psychological flexibility, namely, greater psychological acceptance, mindfulness in the present moment, and committed actions in the direction of personal values. This serious game is guided by a therapist.
223517330|NCT04131894|BIOLOGICAL|autogenous dentin graft|
223517331|NCT04131894|BIOLOGICAL|platelet rich fibrin (PRF)|
223517332|NCT04831619|DRUG|PET scanner with injection of 18 FDG (18F-2-fluoro-2-deoxy-D-glucose) (radiolabel)|A PET scan will be performed in the patients included, in addition to the conventional imaging workup (MRI, endovaginal and pelvic ultrasound).
224082720|NCT06419764|DRUG|Spleen Invigorating and Weight Reducing Decoction|"Composition: Raw Astragalus (Huang Qi) 5g, Cang Zhu 5g, Fructus Aurantii Immaturus (Zhi Shi) 3g, Prepared Rhubarb (Shu Jun) 3g, Red Peony Root (Chi Shao Yao) 3g, Crataegus (Shan Zha) 3g, Tribulus (Bai Jie Li) 2g, Cimicifuga (Sheng Ma) 1g.~Granule form, for oral administration. Take 1 dose daily (2 bags, once in the morning and once in the evening, dissolved in water), for a course of 1 month."
223517333|NCT06480461|DRUG|VGN-R09b|This is a Phase I/II trial, with safety as the primary measure. Sample size is not determined through statistical justification. There will be 3 subjects in each dose cohort in the dose escalation part. In the dose expansion part, a sham surgery group and 2 dose groups will be designed; 10 subjects will be enrolled in each group.
223517334|NCT00966446|DRUG|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
223517335|NCT00966446|DRUG|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
223517336|NCT02601365|DRUG|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
223517337|NCT02601365|DRUG|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
224082721|NCT06419764|OTHER|Diet and meal replacements|The dietitian provides recommended meal plans based on body weight, and meal replacements are used postoperatively.
224082722|NCT03652142|OTHER|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
224082723|NCT03652142|DRUG|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
224082724|NCT01382693|BEHAVIORAL|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
223517338|NCT02601365|DRUG|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
223517339|NCT00103701|DRUG|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
223517340|NCT01392066|BEHAVIORAL|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
223517341|NCT02189629|DRUG|CD5789 (trifarotene)|
223517342|NCT01043029|DRUG|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
223517343|NCT01043029|DRUG|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
224082725|NCT01382693|BEHAVIORAL|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
224082726|NCT00883532|DRUG|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 \< 30% or is extubated
223517344|NCT04634331|BEHAVIORAL|Augmented Reality Multi-Modal Training|Training administered via an augmented reality headset.
223517345|NCT04634331|BEHAVIORAL|Traditional Multi-Modal Training|Training administered via a 1:1 physical therapy session
223517346|NCT03726879|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
224082727|NCT00883532|DRUG|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
224099231|NCT01232725|DIETARY_SUPPLEMENT|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
224099232|NCT04006769|DRUG|Entacapone|Entacapone tablet
224099233|NCT04006769|DRUG|Imatinib Mesylate|Imatinib Mesylate tablet
224082728|NCT04686630|OTHER|Video based observational gait analysis and SCALE Test|Twenty-four spastic diparesis and eighteen spastic hemiparesis cases were included in the study. Data was collected from 84 lower extremities. There were 22 female and 20 male patients aged between 4-18 years. Personal and disease-related information of 42 individuals with diplegic or hemiparetic CP were recorded by using the data collection form. Information collection form; The patient's name-surname, age, gender, height, weight, history, gestational age, birth weight, SCALE Test, GMFCS, Modified Ashworth Scale (MAS), Range of Motion (ROM), EVGS, affected side and previous surgical histories were recorded and their functional levels were determined and recorded.
224082729|NCT00030342|BIOLOGICAL|recombinant interferon alfa|
224082730|NCT00030342|BIOLOGICAL|sargramostim|
224082731|NCT00030342|BIOLOGICAL|therapeutic autologous lymphocytes|
224082732|NCT00030342|DRUG|fluorouracil|
224082733|NCT06909435|OTHER|PEEK dental bar|"the master stone cast is scanned with external desktop scanner to produce an STL (Standard Tesellation Language) file for a virtual model using the CAD/CAM software (Medit 500i.). The design of the multiunit abutment and bar (Rhein Bar )was selected from the library of the CAD software. The bar dimensions were selected according to the study bar design .~After the data acquisition, the STL file was imported to the CAM part of the CAD/CAM system to mill PEEK bar from biological high-performance polymer (Bio-HPP) (BreCAM. BioHPP, Bredent GmbH \& Co.KG, Senden, Germany) block PEEK type. Multi-unit abutments were screwed to the implants and the PEEK bar was screwed to the abutments ."
224082734|NCT06909435|OTHER|Metal bar attachment|Co-Cr metal bar group, in the master cast , the multiunit abutment were attached to the implant analogues and plastic abutments were adjusted , prepared and then wax pattern coping was customized on each abutment and was connected to a preformed castable bar 2.4mm Height, (Rhein 83) The bar was placed to be away from the anterior ridge by about 2-3 mm for proper hygiene measures. The wax pattern was then sprued and casted into cobalt- chromium alloy.
224082735|NCT06912243|OTHER|Educational animation about the process of ear tube surgery|A nurse will explain the process of ear tube surgery to children in an educational video. This educational video scenario includes information about a child's fears before surgery, the structure of the ear, what they are most curious about, what an ear tube is, what happens during and after surgery. The educational video will be made by a person specialized in computer technologies. Artificial intelligence will be used in the vocalization of the educational video. Expert opinion will be taken for the instructional video. The duration of the educational video is planned to be in the range of 3-4 minutes in total.
224082736|NCT06912243|OTHER|Control-Standard Care|The standard information given to all children who had ear tube surgery in the relevant ward will be given to the children in the control group.
224082737|NCT00874211|PROCEDURE|assessment of therapy complications|By dental and medical assessments.
224082738|NCT02514512|DEVICE|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
224082739|NCT03883516|OTHER|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
224082740|NCT03883516|OTHER|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
224082741|NCT03883516|OTHER|No Pre-briefing|no instruction of the study participants prior to the simulation training
224082742|NCT06912074|DRUG|Induction chemoimmunotherapy|All patients will receive two cycles of induction therapy with albumin-bound paclitaxel and cisplatin combined with toripalimab.
224082743|NCT06912074|RADIATION|Hypofractionated Radiation Therapy|"All patients will receive hypofractionated radiotherapy once daily, five days per week, followed by a boost. Three weeks after the completion of the first phase of hypofractionated radiotherapy, tumor response and cardiopulmonary function will be evaluated. For patients who achieve a partial response, have no deep esophageal ulcers on endoscopy, and have cardiopulmonary function tolerating the radiotherapy boost, a second phase of radiotherapy will be planned using a new CT simulation and radiotherapy design.~First Phase of Radiotherapy: Total dose of 2500 cGy in 5 fractions (500 cGy per fraction) Second Phase of Radiotherapy: Total dose of 2500 cGy in 10 fractions (250 cGy per fraction) The interval between the two phases of radiotherapy will be 28 days."
224082744|NCT06912074|RADIATION|Conventional Fractionated Radiation Therapy|Patients will receive a total dose of 5000 cGy in 25 fractions, with 200 cGy per fraction.
224082745|NCT06912074|DRUG|Concurrent Chemotherapy|Capecitabine oral administration, 1000 mg/m², twice daily
224082746|NCT06910644|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of 0.5 μg/kg/h.
223517347|NCT03726879|DRUG|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
223517348|NCT03726879|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
223517349|NCT03726879|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
223517350|NCT03726879|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
223517351|NCT03726879|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
223517352|NCT03726879|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
223517353|NCT03726879|DRUG|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
224082747|NCT06910644|DRUG|Lidocaine|Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5mg/kg/h.
224082748|NCT06910644|DRUG|Isotonic saline|Patients will receive intravenous isotonic saline 0.9% in the same volume and manner as the study drugs.
224082749|NCT06913712|OTHER|Weight loss without pharmacotherapy|The study will record the weight of the patients with Idiopathic Intracranial Hypertension every three months. It will correlate with the response to the different treatment modalities (weight loss with no other intervention, diuretic drugs (acetazolamide), lumboperitoneal shunt, or ventriculoperitoneal shunt). No medication will be provided to help lose weight.
224082750|NCT06913959|DIAGNOSTIC_TEST|Prospective|Blood samples will be collected in order to meet the objectives of this substudy and possibly for complementary research
224268994|NCT05150223|OTHER|traditional strength training|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband). Participation in the traditional strength training group will complete these exercises with a load and without time limitations and speed.
223517354|NCT02766478|DRUG|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
223517355|NCT02766478|DRUG|Placebo|A placebo pill will be taken orally for 12 weeks.
224268995|NCT05150223|OTHER|Power training|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
224082751|NCT06917573|DRUG|Cemiplimab|"Patients will receive Cemiplimab administered by IV infusion over 30 minutes every 28 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a high affinity hinge-stabilized IgG4P human antibody to the PD-1receptor (PDCD1, CD279) that blocks PD 1/PD L1 mediated T cell inhibition. Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.~Route of administration: Intravenous infusion."
224082752|NCT06917573|DRUG|Carboplatin|"Patients will receive Carboplatin administered by IV infusion for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin.~Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion."
223517356|NCT05626686|DEVICE|CLINY catheter|Subjects using a single use catheter for bladder management at inclusion. During the study period, subjects will use the reusable CLINY catheter for 28 test-days
223893385|NCT05090540|DEVICE|Trancatheter Edge to Edge Repair|TEER is performed by apposing the edges of the anterior and posterior leaflet (edge-to-edge) of prolapsed MV. The patient may be under conscious sedation or general anesthesia, depending on hospital standard practice. The procedure is performed through femoral venous access and the inter-atrial septum is crossed using standard techniques. Trans-septal puncture allows MitraClip Steerable Guide Catheter (Guide) to advance so that the guide is positioned over the mitral valve. The MitraClip delivery catheter is advanced to the MitraClip device and emerges from the tip of the guide into the left atrium. The MitraClip device can now be opened and advanced through the MV in the LV. Once in the LV, it is pulled back to grasp the leaflets. Two-dimensional and/or 3-dimensional echocardiography and color Doppler are useful for evaluating the anatomical features of the mitral valve and directing the procedure until the double orifice is formed alongside evaluating residual mitral regurgitation
223517357|NCT01093573|DRUG|midostaurin|Given orally
224082753|NCT06917573|DRUG|Paclitaxel|"Patients will receive Paclitaxel administered by IV infusion for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20- epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately).~The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
224082754|NCT06917612|PROCEDURE|Normal diagnostic laparoscopy|The appendix is left in situ e.g., not resected and no other surgical resection is needed to treat other diseases
224082755|NCT06917612|PROCEDURE|Negative appendectomy|The appendix is resected but is without histopathological-confirmed inflammation and no other surgical resection is needed to treat other diseases
224082756|NCT06916013|PROCEDURE|Focal laser ablation|Targeted focal laser ablation
224082757|NCT06916013|PROCEDURE|Focal laser ablation|Targeted focal laser ablation of localized intermediate-risk prostate cancer
224082758|NCT06915428|BEHAVIORAL|Care coordination|"Research team members will serve as research assistants and will also function as perinatal care coordinators.~In the care coordination role, team members will provide emotional support, liaise with clinical staff, and execute regularly scheduled check-ins with each study participant. Team members also assist with helping participants with logistics, obtaining and remembering to take prescribed medications, and other similar related activities. Participants receive access to contact the research assistant / care coordinator by text, email, phone, or through the electronic medical record participant portal.~\- Per protocol, the research staff will meet in person with participants at least twice (visit 1, visit 2) during pregnancy and once postpartum (0-10 weeks after delivery, for most participants).~Research staff may also meet in person with participants prior to visit 1 for recruitment/enrollment purposes."
224082759|NCT06915428|BEHAVIORAL|Electronic massage|"Participant is given the option to receive a 15-minute electronic massage / relaxation session in clinic via (a) a specialized massage chair or (b) a massage pad that is placed on top of a standard recliner chair.~* the electronic massages provide gentle massages and are safe for most people to use throughout pregnancy.~* participants are always be in control of the massage experience and will be given instructions on how to stop the massage at any time.~* participants are advised to consult the primary obstetric provider before using the massage chair regarding any specific concerns or questions~* during the session, participants may view relaxation videos (from free, publicly available sites online).~  * participants may choose to sign up for massage(s) at any obstetric visit in the clinic between visit 1 and delivery."
223517358|NCT01093573|DRUG|azacitidine|Given IV
223517359|NCT01093573|OTHER|bone marrow aspiration|Correlative study: Pretreatment bone marrow aspirates or blood \[(3 ml in EDTA tube (purple top)\] will be analyzed according to local institution guidelines to determine whether blasts contain wild type Flt3, ITD, or Flt 3 mutations.
223517360|NCT01093573|OTHER|mutation analysis|Correlative study
223517361|NCT01093573|OTHER|Pharmacokinetic study|Correlative study: Concentrations of unchanged midostaurin and its major metabolites, CGP52421 and CGP62221 in plasma samples will be determined using a validated liquid chromatography / mass spectrometry method.
223517362|NCT02577575|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
223517363|NCT02577575|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
223517364|NCT05705804|DRUG|Pitavastatin|Pitavastatin 4 mg will be given.
223517365|NCT05705804|DRUG|Pitavastatin plus Ezetemibe|Pitvastatin 4 mg plus ezetemibe 10 mg will be given.
223517366|NCT05705804|DRUG|Atorvastatin|Atorvastatin 40 mg will be given.
223517367|NCT00944840|DRUG|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
223517368|NCT00944840|DRUG|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
223517369|NCT06290037|DEVICE|VR Driving Simulator|Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
223517370|NCT06290037|OTHER|Computerized Neurocognitive Function Test|Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
223517371|NCT06290037|OTHER|Driver Test Station|Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
223517372|NCT06290037|OTHER|Short Physical Performance Battery|Evaluation of functional capability and provide a measure of the biological age of an older individual by measuring lower extremity physical performance status(standing balance, walking speed, and chair stand tests).
223517373|NCT06290037|OTHER|On-road field driving Test|Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
223517374|NCT00023972|DRUG|exatecan mesylate|
223517375|NCT00023972|DRUG|gemcitabine hydrochloride|
223893386|NCT05090540|PROCEDURE|Mitral Valve Replacement|Mitral valve replacement is performed using mechanical or biological prosthesis while preserving the subvalvular apparatus to avoid dilation of the left ventricle over time.
224082760|NCT06915428|BEHAVIORAL|support gift #1|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 14+0 and 23+6 weeks gestation at time of routine prenatal appointment"
224082761|NCT06915428|BEHAVIORAL|Support gift #2|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 18+0 and 27+6 weeks gestation at time of routine prenatal appointment"
224082762|NCT06915428|BEHAVIORAL|Support gift #3|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 22+0 and 29+6 weeks gestation at time of routine prenatal appointment"
224082763|NCT06915428|BEHAVIORAL|Support gift #4|"* Small gift packet with encouraging items (example of items = coloring kit, tea lights, stickers, bookmarks, keychain fidget toy, printed support index cards, and other similar items).~* Given between 26+0 and 33+6 weeks gestation at time of routine prenatal appointment"
224082764|NCT06915428|BEHAVIORAL|Additional PTBCARE+ support|"Additional benefits / support items and support elements are provided to some participants on an as needed basis, per study protocol.~* Information / details intentionally withheld and not made public in order to preserve the scientific validity of the study and protect the rights of the research participants~* participant eligibility for additional resources as a part of the PTBCARE+ program will be determined by the research staff on the day of Visit 1 after initial set of surveys are completed, and is per protocol"
223517376|NCT06354842|DIAGNOSTIC_TEST|pilocarpine iontopheresis|Application of pilocarpine on the skin of the patients/subjects to induce sweat production to analyse sweat sodium concentration via flame photometry
223517377|NCT06644404|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
223517378|NCT06644404|DRUG|DWC202407 1,000mg|1 tablet, Orally, Twice daily
223893387|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie|Mitral valve repair consists of a restrictive mitral annuloplasty (RMA) using a prosthetic ring
223893388|NCT05090540|PROCEDURE|Restrictive Mitral Annuloplastie/Subvalvular Repair|RMA may be associated with the use of a subvalvular repair (SR). The SR permits the approximation or the relocation of papillary muscles which is displaced by post infarction scar formation.
223517379|NCT06644404|DRUG|DWC202408 2mg|1 tablet, Orally, Once daily single dose
223517380|NCT03708770|DEVICE|everlinQ endoAVF System|
223517381|NCT00901095|BEHAVIORAL|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
223517382|NCT06673199|DIETARY_SUPPLEMENT|Washoku diet|The Washoku diet will consist of following the principles of a healthy eating plate, which will be supplemented with elements of the Washoku diet (30g of roasted black soybeans and 5g of wakame). Food products will be given to women on the day of the first meeting. The Washoku diet will be used for 7 days a week for a period of 1 month (4 weeks).
223517383|NCT06674772|DIAGNOSTIC_TEST|Saliva test|Sampling of CGRP in saliva and DNA blood test and sex hormones blood test.
223517384|NCT06673953|OTHER|Respiratory Muscle Training by (The Breather)|Patients are instructed to inhale deeply and forcefully (at non fatigable resistance) for 2-3 seconds, slight pause, and then exhale forcefully for 2-3 seconds for 10 repetitions with 2 sets.
224082765|NCT06915428|BEHAVIORAL|Stress reduction toolkit - Visit 1 (V1)|"In person check-in with research team member re: participant's needs; research team member provides support.~Physical items that are included as part of this visit include:~Tote bag with the following stress reduction items or similar:~* eye mask~* set of pocket index cards, printed back and front, on a variety of topics that influence pregnancy health, ranging from physical to emotional/mental~* water bottles~* small notebook~* pill minder case~* magnet and business card for Health Resources and Services Administration (HRSA) national maternal mental health hotline~* log in codes for electronic resources~* initial handouts with self care plan, introduction to stress reduction toolkit, etc."
224082766|NCT06915428|BEHAVIORAL|PTBCARE+ mobile application (app) and website|"Comprehensive, study-specific app that is available as a website or as a downloadable application that includes personalized, interactive modules and resources~* no study related materials are available without a password~* goal is to collate reputable sources of information to make investigating things online easier~* includes optional educational modules for participants~* also includes option of entering stress, well-being, blood sugar, blood pressure, etc. values with option to easily download recorded values for patient's clinical team~* available online (computer/laptop), tablet, or smart phone. can be downloaded as a progressive web application (PWA) to a local device and used without internet access~* Electronic access to the PTBCARE+ website will continue through 10 weeks postpartum unless the participant delivered \<16+0 weeks gestation in which case access will continue through 4 weeks postpartum"
224082767|NCT06915428|BEHAVIORAL|Sleep, meditation, and Wellness app|"* complimentary one-year subscription to Aura - an 'all-in-one' wellbeing app that contains an enormous library of meditations, stories, breath work, work wellness, music, sounds, and more!~* Participants can access this app as needed throughout pregnancy and beyond, for up to one year after the date of enrollment"
224082768|NCT06915428|BEHAVIORAL|Emergency low blood sugar kit|"Pouch contains:~* printed index card with information about signs and symptoms of low blood sugar~* printed index card with information about what to do if blood sugar is low~* 2-3 non-perishable, individually wrapped over the counter candy / glucose-raising options; use for low blood sugar treatment is described on the card~Only participants who have a diagnosis of diabetes mellitus or glucose intolerance AND have been prescribed an oral medication for blood sugar control or have been prescribed insulin are eligible to receive this.~Each participant can receive a maximum of two kits during pregnancy; first at enrollment, and the other at visit 2 or until delivery"
224082769|NCT06915428|BEHAVIORAL|Low dose aspirin (LDA)|"* Bottle of 90-100 pills (depending on manufacturer)~* Provided at Visit 1 (after randomization)~* Patients who received a bottle of low-dose aspirin at Visit 1 are offered a 2nd bottle at Visit 2.~All patients whose provider recommends or prescribes either 81mg or 162mg of LDA during pregnancy are offered LDA as described herein. LDA must be on the patient's med list or specific notes from the patient's prenatal provider must explicitly note that it is recommended the patient take LDA in pregnancy for it to be offered. Individuals who are receiving LDA due to participation in another study are not eligible to receive LDA from PTBCARE+~Please note that this is listed as a behavioral intervention rather than drug intervention because the rational behind providing this over the counter medication is to help make the participant's life easier, and the focus is not on the efficacy of LDA. As such, it is being provided as a behavioral intervention."
224082770|NCT06915428|BEHAVIORAL|Visit #2 Stress Reduction Toolkit|"In person check-in with research team member re: participant's needs; research team member provides support.~Physical items that are included as part of this visit include the following stress reduction items or similar:~1. Frame + ultrasound photo + certificate of achievement!~   * Picture from anatomy ultrasound (or other subsequent ultrasound) is downloaded, printed, and placed in frame.~  * Certificate of achievement is printed and placed on other side of frame with ultrasound photo~2. other small items including stickers, printed index cards with supportive messaging, etc."
224082771|NCT06916182|OTHER|MRI sequence|This sequence is a 2D spin-echo sequence for the generation of synthetic maps
224082772|NCT06917534|DEVICE|Transcranial direct current stimulation|The participant cohort recruited for this study consists of individuals with drug addiction specifically those addicted to drugs. During the intervention phase, this group will adhere to a strict non-pharmacological intervention protocol, meaning they will not receive any form of pharmacotherapy, neurosurgical intervention, or other neuromodulation-based cognitive interventions, including but not limited to techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). This design aims to ensure the internal validity of the study results and to exclude potential confounding effects of other interventions on neuroplasticity and cognitive function.
223517385|NCT06673953|OTHER|Traditional physical therapy program|Traditional physical therapy program in form of: (TENS / Low-intensity continuous ultrasonic / Infrared radiation application / Cervical Stabilization exercise )
224082773|NCT06916026|PROCEDURE|Xenograft|Gap distance grafting using xenograft
224082774|NCT06916026|PROCEDURE|Xenograft mixed with HAM gel.|Gap distance grafting using xenograft mixed with HAM gel.
224082775|NCT06916897|DRUG|sevasemten|single dose 10mg sevasemten administered orally
223517386|NCT02171208|DRUG|dimethyl fumarate - Reference form|single dose 240 mg
223517387|NCT02171208|DRUG|dimethyl fumarate - Test form|single dose 240 mg
223517388|NCT06673680|DEVICE|Do colposcopy and cervical punch biopsy then compare between findings|The aim of this study is to correlate colposcopy and histopathological findings in early screening of suspicious cervix and cervical cancer. And to do a colposcopic evaluation of all cervical lesions and the early detection of all cervical precancer and invasive lesions of the cervix in symptomatic women.
223517389|NCT06675877|OTHER|virtual reality camera|The virtual reality eyeglasses were placed on the child's head, the child watched 3 D VR kids' cartoons or videos to distract his/her attention during needle insertion. The video was displayed through a smart phone inserted inside the virtual reality headset.
223517390|NCT06674668|OTHER|Vibrotactile stimulation|The intervention includes traditional physiotherapy and 20 minutes of vibrotactile device use. As traditional physiotherapy, 30 seconds of 8 repetitions of passive wrist stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Afterwards, the Intellinetix Elbow Wearable Vibration Device providing vibration will be worn on the affected tissue. The patient will remain in a comfortable position on the treatment table with the affected extremity for 20 minutes (10 minutes × 2).
223517391|NCT06674668|OTHER|Traditional physiotherapy|For traditional physiotherapy, passive stretching exercises, radial head mobilization and deep friction massage will be applied to the affected extremity. Stretching exercises will be performed on the wrist flexor and extensor muscles for 30 seconds and 8 repetitions. Mill's manipulation, described by James Cyriax, will be applied once for radial head mobilization. The treatment will be completed with a 5-minute deep friction massage, affecting the wrist extensor muscle tendons and their ending points.
224082776|NCT06916897|DRUG|Verapamil|multiple doses 240mg verapamil
224082777|NCT06917105|DRUG|CD33/CD123/CLL-1 CAR-T Cells|"Part A: Dose Escalation Phase. Follows a 3+3 dose escalation design with four predefined dose cohorts: 0.2×10⁶, 0.5×10⁶, 1×10⁶, and 2×10⁶ CAR-positive cells/kg.Anticipated enrollment: 12-24 subjects.Primary objectives: Assess safety, tolerability, and determine MTD.Dose-limiting toxicity (DLT) observation period: 28 days post-infusion.~Part B: Dose Expansion Phase.Enrolls 21 additional subjects to receive CAR-T cell infusion at the recommended Phase 2 dose (RP2D) established in Part A.Primary objective: Further evaluate therapeutic efficacy."
224082778|NCT06915688|DRUG|Doxycycline|Doxycycline will be given to COPD group 1
223517392|NCT06690203|COMBINATION_PRODUCT|NRICM102|A traditional Chinese medicine formula
223517393|NCT06687213|BEHAVIORAL|Smoking cessation counselling group|Case group will be counseled to cessate smoking and will be followed up with HbA1c
223517394|NCT06689137|OTHER|mini mental state assessment test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used. With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
223517395|NCT06689137|OTHER|mini-cog test|Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
223517396|NCT06691841|DRUG|Chlorhexidine Gluconate|oral wiping and oral care solution rinsing, oral care solution was 0.12% chlorhexidine gluconate, and the frequency of oral care was 3 times a day.
224082779|NCT06915688|DRUG|Levofloxacin|Levofloxacin given to copd patients
224082780|NCT06916377|BEHAVIORAL|Edutainment Content: Norms Campaign|Soap opera that challenges harmful norms that condone IPV, targeting the belief that violence is an acceptable way to assert control or maintain reputation.
224082781|NCT06916377|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)-based skills|CBT-based skills for stress management and non-violent conflict resolution.
224082782|NCT06916377|BEHAVIORAL|Edutainment Content: Placebo Campaign|Soap opera that features unrelated non-violent content
224268996|NCT05828290|BEHAVIORAL|Child Yoga|The children's yoga consists of compositions such as playing, stories, postures, breathing exercises, imitations things in nature, memory games, music, dance and daydreaming.
224082783|NCT06916299|DIAGNOSTIC_TEST|dental casts|"At the end of the planned expansion, an 8-month retention period was expected. At this time, the expansion device was removed, and impressions were taken in both groups (T1).~At 12-month follow-up (T2), new impressions were taken in both groups to evaluate, at dental level, the relapse in the short term. Fig 1"
224082784|NCT06916299|DEVICE|tooth-borne expander insertion|tooth-borne expander delivery.
224082785|NCT06916299|PROCEDURE|miniscrew and bone-borne expander insertion|Insertion of the paramedian miniscrews in a totally guided procedure, and after was delivered the tooth-borne expander
224082786|NCT04971005|DRUG|Autologous Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
224082787|NCT04971005|DRUG|Ocrelizumab|600 mg every 6 months continuously
224082788|NCT04971005|DRUG|Alemtuzumab|12 mg/day for 5 consecutive days and again after 365 days for 3 days
224082789|NCT06917092|DRUG|QL1706 combined with chemotherapy ± Bevacizumab|"* Drug: QL1706: 5 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first.~* Drug: Chemotherapy: physician's choice chemotherapy for 3-6 cycles.~* Drug: Bevacizumab (optional): 15 mg/kg IV every 3 weeks until progression, unacceptable toxicity, completion of 1 year of treatment, or meeting protocol-defined discontinuation criteria, whichever occurred first."
224082790|NCT00865020|DRUG|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
223517397|NCT06691841|OTHER|normal saline|oral wiping and oral care solution rinsing, oral care solution was 0.9% normal saline, and the frequency of oral care was 3 times a day.
223517398|NCT06689293|DIAGNOSTIC_TEST|Faecal Immunochemical Test|Self-collected sample from stool collected into testing kit
223517399|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Low Dose Radiotherapy|in experimental arm 1
223517400|NCT06688760|PROCEDURE|Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Double upper neck lymph node dissection|in experimental arm 2
223517401|NCT06690619|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224082791|NCT00865020|DRUG|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
224082792|NCT00865020|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
223517402|NCT06690619|DIETARY_SUPPLEMENT|315 mg Alpha-GPC|350 mg of 90% pure alpha-GPC (315 mg)
223517403|NCT06690619|DIETARY_SUPPLEMENT|630 mg Alpha-GPC|700 mg of 90% pure alpha-GPC (630 mg)
223517404|NCT06694376|OTHER|No intervention|No intervention.
223517405|NCT06687707|OTHER|Attitude Scale towards Physiotherapy Profession|It is a questionnaire that evaluates the attitudes of physiotherapists with 35 questions under 3 headings: professional satisfaction, qualifications required by the profession, and concerns about the profession. It was developed in 2018 by Begümhan Turhan. In this scale, which is a Likert-type questionnaire, each question is scored between 0 and 5 points. The minimum score that can be obtained from the scale is 35 and the maximum score is 175. A high score indicates that physiotherapists have a positive attitude towards their profession
223517406|NCT06687707|OTHER|Minnesota Job Satisfaction Scale|It is a 20-item Likert-type questionnaire. Scores less than 3 points indicate low job satisfaction. Turkish validity and reliability studies were conducted. The validity and reliability study in Turkey was conducted by Baycan and the Cronbach's alpha value of the scale was found to be 0.77. It is a tool consisting of 20 items with features that reveal internal and external job satisfaction factors. The neutral satisfaction score of the scale is 3. If the score obtained from the scale is less than 3, job satisfaction is considered low, and if it is greater than 3, job satisfaction is considered high.
223719006|NCT04152278|DIAGNOSTIC_TEST|cervicovaginal culture and qPCR for chlamydial trachomatis and wadallia chondrophila|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic and anaerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
224082793|NCT00865020|DRUG|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
224082794|NCT04129060|DRUG|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
224082795|NCT00910156|DEVICE|Airtraq laryngoscope|Airtraq intubation
224082796|NCT00910156|DEVICE|Glidescope laryngoscope|glidescope intubation
224082797|NCT00910156|DEVICE|Macintosh laryngoscope|Macintosh intubation
224082798|NCT03641560|DRUG|Enzalutamide|Enzalutamide was administered orally
223517407|NCT06687707|OTHER|Maslach Burnout Scale|The Burnout Inventory, which was developed by Maslach and Jackson (1981) and introduced to the literature under Maslach's name, is a seven-point Likert-type scale and consists of a total of 22 items and three subscales. Among these subscales, emotional exhaustion subscale consists of 9 items, depersonalisation subscale consists of 5 items and personal accomplishment subscale consists of 8 items. Scale items are scored as '1 never' and '7 always'. The Turkish validity and reliability of the questionnaire was conducted by Burhan Çapri. It is a 5-point Likert-type scale measured with 0: never 4: always options. High scores are expected
223517408|NCT04951063|RADIATION|Hypofractionated radiotherapy|"Split-course adaptive HRT-CHT is administered at the following three dose levels:~1. Level 1: DT 4500cGy/15 daily fractions/300cGy in the first course，DT 1500cGy/5 daily fractions/300cGy in the second course;~2. Level 2: DT 4000cGy/10 daily fractions/400cGy in the first course， DT 2000cGy/5 daily fractions/400cGy in the second course;~3. Level 3: DT 3000cGy/6 daily fractions/500cGy in the first course， DT 3000cGy/6 daily fractions/500cGy in the second course."
223517409|NCT04951063|DRUG|Concurrent chemotherapy|weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT
223517410|NCT04951063|DRUG|Consolidation immunotherapy|Consolidative immunotherapy (PD-1 or PD-L1 inhibitor) up to 1 year is administered for those without disease progression after HRT-CHT.
223517411|NCT03668340|DRUG|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
223517412|NCT02836795|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
223517413|NCT04681885|DEVICE|Tapered bristles A|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week .
223517414|NCT04681885|DEVICE|Tapered bristles B|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
223517415|NCT04681885|DEVICE|End rounded bristles|Subjects use the toothbrush two times daily with a fluoride toothpaste for 2 minutes with instructed brushing method for one week.
223517416|NCT06003790|DEVICE|MR-001|Use of device 3 times per week for 8 weeks - for a total of 24 sessions.
223517417|NCT05892393|DRUG|Zirconium Zr 89-DFO-YS5|Given IV
223517418|NCT05892393|PROCEDURE|Positron Emission Tomography / Computed Tomography (PET/CT)|Positron emission tomography-computed tomography is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography scanner and an x-ray computed tomography scanner, to acquire sequential images from both devices in the same session, which are combined into a single superposed image
223517419|NCT05892393|PROCEDURE|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI)|Positron emission tomography-magnetic resonance imaging is a hybrid imaging technology that incorporates magnetic resonance imaging soft tissue morphological imaging and positron emission tomography functional imaging.
223719007|NCT06293001|OTHER|No intervention|No intervention
223517420|NCT05892393|OTHER|Fludeoxyglucose F-18|Given IV
223893389|NCT05069077|OTHER|Music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
223517421|NCT01197300|DRUG|Zoledronic acid|intravenous infusion
223517422|NCT02498795|OTHER|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
223719008|NCT05436093|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/CT scan.
223893390|NCT05069077|OTHER|No music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
224082799|NCT03641560|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
224082800|NCT02297802|DRUG|PD-0325901|
224082801|NCT04660643|DRUG|Tirzepatide|Administered SC
224082802|NCT04660643|OTHER|Placebo|Administered SC
224082803|NCT03988907|DRUG|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
223517423|NCT02498795|OTHER|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
223517424|NCT02498795|OTHER|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
223517425|NCT04775979|DRUG|diphenylcyclopropenone (DPCP)|Depigmenting agent
223517426|NCT05775042|BIOLOGICAL|CM338|CM338 injection
223517427|NCT06415240|OTHER|Facilitated Tucking|Facilitated Tucking is a position to be adopted for pain relief in neonates.
223517428|NCT06415240|OTHER|Gentle Human Touch|while gentle human touch is caressing on head for pain relief.
223517429|NCT05515575|DRUG|Niraparib|Each patient will receive niraparib daily in 21-day cycles until disease progression or unacceptable toxicity. Mandatory baseline tumor biopsies will occur during study screening, if feasible.
223517430|NCT02531451|DRUG|Ibuprofen|
224082804|NCT03988907|DRUG|Midazolam|single dose administration of 2 mg midazolam
224082805|NCT06434311|DIAGNOSTIC_TEST|3 meter Backward Test|evaluation
224082806|NCT02810964|DRUG|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
224082807|NCT02810964|DRUG|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
224082808|NCT06434831|DEVICE|Medical device for SNM: Interstim II, Interstim micro|ANI will be used during the SNM (2 hours)
224082809|NCT05588635|OTHER|Identification of predictive factors|Evaluation of the following variables : mother age (years), father age (years), serum progesterone (ng/ml), mother body mass index (kg/m2), serum Antimüllerian hormone (AMH) (ng/ml), infertility etiology (yes/no): 4 categories: idiopathic etiology, mixed origin infertility, male infertility, female infertility; smoker status among mothers (yes/no).
223517431|NCT02531451|DRUG|Acetylsalicylic acid|
224082810|NCT02273583|DRUG|continuous oral cyclophosphamide and methotrexate|
224082811|NCT02975843|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
224082812|NCT03363633|DRUG|sodium tetradecyl sulfate|Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
224082813|NCT03363633|DEVICE|Compression|20-30 mmHg compression stockings
224082814|NCT03266835|DEVICE|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
224082815|NCT03072693|PROCEDURE|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
224082816|NCT03072693|PROCEDURE|Home-based physiological parameter recording only|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
223517432|NCT06060444|OTHER|Telemedicine Consult|Neurological consultation completed remotely
223517433|NCT06060444|OTHER|In-person Consult|Neurological consultation completed in-person
223517434|NCT06479239|DRUG|EGFR FPBMC|Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.
223517435|NCT04818177|DRUG|Institutional standard intravenous immune globulin treatment|No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
223517436|NCT00262613|DRUG|sodium pyruvate in 0.9% sodium chloride solution|
223517437|NCT03741855|DEVICE|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
223893391|NCT04650256|OTHER|Complementary and alternative medicine (CAM)|CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
224082817|NCT01867229|OTHER|observational|standard of care fore patients with non metastatic breast cancer
224082818|NCT05212740|DRUG|Corticosteroid|The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.
224082819|NCT05212740|OTHER|Exercise|The exercise program will be performed two times per week for six weeks for 12 sessions.
224082820|NCT05495204|DRUG|Ibalizumab|Participation in clinical trials vs. routine care in OPERA
224082821|NCT01171820|DEVICE|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
224082822|NCT01171820|DEVICE|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
224082823|NCT04285385|OTHER|Lavender aromatherapy|0.10 ml of lavender essential oil
224082824|NCT04285385|OTHER|Sham aromatherapy|0.10 ml of mineral oil
224082825|NCT06207266|BEHAVIORAL|emotion intelligence program|The programme was established using research that described emotional intelligence components and their applicability to patients suffering from substance abuse. it considers as awareness program.
224082826|NCT03969875|DEVICE|Interscalene catheter|rescue catheters attached to a PCA pump
224082827|NCT03969875|DRUG|Liposomal bupivacaine|10 cc
224082828|NCT03969875|DRUG|Dexamethasone|1 cc of 4mg
224082829|NCT03969875|DRUG|Bupivacaine|0.5% bupivacaine
224082830|NCT03817203|OTHER|Kinesio tape application|Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
224082831|NCT03817203|OTHER|Sham tape application|Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
224082832|NCT02186184|DEVICE|Orthokeratology|
224082833|NCT02186184|DEVICE|Spectacle|
224082834|NCT03513653|DIAGNOSTIC_TEST|Echocardiography with speckle-tracking imaging|"1. Measurement of left ventricular ejection fraction and global longitudinal strain~2. Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~3. Measurement of right ventricular global longitudinal strain"
224082835|NCT05242250|DEVICE|Catheter Ablation|Ablation RF technologies manufactured by Abbott.
224082836|NCT03064672|DEVICE|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
224082837|NCT00657384|DRUG|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
224082838|NCT00657384|DRUG|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
224082839|NCT01307033|DRUG|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
224082840|NCT01307033|DRUG|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
224082841|NCT01307033|DRUG|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
224082842|NCT01307033|DRUG|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
224082843|NCT02208245|DEVICE|Ultrasound: Axillary block|Ultrasound guided axillary block
224082844|NCT02208245|DEVICE|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
224082845|NCT02208245|DRUG|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
224082846|NCT04376437|DRUG|medical cannabis|inhalation by using a Portable Metered-Dose Cannabis Inhaler
224082847|NCT00555087|DRUG|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
224082848|NCT04956900|DRUG|Aurase Wound gel|Aurase Wound Gel is reconstituted from Aurase Component A (a hydrogel) and Aurase Component B (stabilised solutions of Aurase enzyme). By diluting different strengths of Aurase Component B with Component A, specific concentrations of Aurase Wound Gels with differing Aurase contents are yielded.
224082849|NCT01126255|DRUG|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
224082850|NCT01126255|DRUG|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
224082851|NCT01231555|DRUG|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
224082852|NCT01231555|DRUG|GSK2248761 200 mg once daily|2x100 mg capsules
224082853|NCT01231555|DRUG|Efavirenz 600 mg once daily|1x600mg tablet
224082854|NCT03324204|OTHER|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
224082855|NCT03324204|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
224082856|NCT00947531|DRUG|Cerebrolysin|
224268997|NCT00901719|DRUG|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
224268998|NCT00901719|DRUG|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
224268999|NCT00901719|DRUG|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
224269000|NCT00901719|DRUG|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
224269001|NCT03273751|PROCEDURE|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
224269002|NCT03273751|PROCEDURE|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
224269003|NCT03141151|BEHAVIORAL|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
224269004|NCT03141151|BEHAVIORAL|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
224269005|NCT05303441|PROCEDURE|percutaneous coronary intervention|conventional coronary angiography
224269006|NCT04563260|DRUG|Normal saline injection|Normal saline 2 mL, intravenous injection
224269007|NCT04563260|DRUG|Palonosetron Injection [Aloxi]|Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
224269008|NCT01787929|PROCEDURE|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
224269009|NCT04506918|OTHER|IVR survey|Participants will receive an IVR survey
224269010|NCT04506918|OTHER|SMS survey|Participants will receive a SMS survey
224269011|NCT00842127|DRUG|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
224269012|NCT01087567|DRUG|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
224269013|NCT01087567|DRUG|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
224082857|NCT00947531|DRUG|0.9% Saline Solution|
224082858|NCT06018779|OTHER|Cryoultrasound therapy plus high-intensity laser therapy|Group A received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and cryo-sound therapy.
224082859|NCT06018779|OTHER|diathermy plus high-intensity laser therapy|Group B received a daily rehabilitation treatment lasting 10 sessions for 10 consecutive sessions, consisting of high-intensity laser therapy and diathermy.
224269014|NCT06529146|DRUG|BHV-4157|BHV-4157 (troriluzole) 200 mg QD
224269015|NCT05778890|OTHER|Intervention Group: Physiotherapy program + home exercises program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education. In addition to the treatment for control group, intervention group received home exercises program.The intervention group was also taught home exercises program and asked to do 6 repetitions 6 times a day. This exercise program was given to the patients in brochure form.
224269016|NCT05778890|OTHER|Control Group : Physiotherapy program|Physiotherapy program: The physiotherapy program consisted of 1 session per day for 3 weeks, a total of 15 sessions. Treatment for control group included Ultrasound for 5 minutes to both TMJ, TENS on both TMJ for 20 minutes, exercise for 30 minutes and patient education.
224269017|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
224269018|NCT03245333|DRUG|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
224269019|NCT03214237|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
224269020|NCT04997551|DRUG|Colchcine|"In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day"
224269021|NCT01196598|OTHER|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
224269022|NCT04498676|OTHER|CB-0002B|CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
224269023|NCT00273130|PROCEDURE|transnasal endoscopy|
224269024|NCT00273130|PROCEDURE|transoral thin endoscopy|
223893392|NCT06757270|OTHER|Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis|Second arm : aleovera 3 times daily after brushing teeth
224269025|NCT00884390|DRUG|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
224269026|NCT00884390|PROCEDURE|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
224269027|NCT03864458|DRUG|KHK7791|oral administration
224269028|NCT03864458|DRUG|Placebo|oral administration
224269029|NCT03563443|DIAGNOSTIC_TEST|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
224269030|NCT02733211|DEVICE|MD- Logic Closed Loop System|Closed Loop System
224269031|NCT02733211|DEVICE|sensor augmented pump therapy|Sensor augmented pump therapy
224269032|NCT04630795|DEVICE|ViscoTurf insole|Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.
224269033|NCT04630795|DEVICE|Control insole|Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
224269034|NCT06067789|PROCEDURE|neuraxial anesthesia|Intervention arm participants will be allocated to neuraxial anesthesia.
224269035|NCT02582944|DEVICE|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
224269036|NCT02582944|DEVICE|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
224269037|NCT02582944|DEVICE|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
224269038|NCT02582944|PROCEDURE|Biopsy|
224269039|NCT02319850|RADIATION|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
224269040|NCT04727164|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 on Day 1 Cycle 1 and be treated with HBM4003 and Triprilimab during each 21-day cycles from Cycle 2 in part 1.Subjects will be treated with HBM4003 and Triprilimab on Day 1 during each 21-day cycle in part 2.
224269041|NCT05568849|DIAGNOSTIC_TEST|OCTA measurements|OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
224269042|NCT04037488|DIAGNOSTIC_TEST|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
224269043|NCT02979132|DRUG|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
224269044|NCT02979132|DRUG|Ferinject(R)|Single-dose Ferinject(R) administration
224269045|NCT02979132|DIETARY_SUPPLEMENT|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
224269046|NCT03088007|OTHER|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
224269047|NCT05485051|OTHER|2% chlorhexidine digluconate solution with surface-active agents|Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
224269048|NCT05485051|OTHER|Usual Baths|Bathing will be performed at least daily using soap and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.); These areas will be bathed according to each center current practice.
224269049|NCT02670551|DRUG|Cariprazine|
224269050|NCT02670551|DRUG|Placebo|
224269051|NCT00490932|DRUG|Hypo-osmolar ORS|
224269052|NCT05650151|DIETARY_SUPPLEMENT|Vitamin D|576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
224269053|NCT05650151|DIETARY_SUPPLEMENT|Placebo|An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
224269054|NCT04736537|DEVICE|4DCT|CT imaging conceptually similar to time-lapse photography.
224269055|NCT00139815|DRUG|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
223893393|NCT03978689|DRUG|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
224269056|NCT00139815|DRUG|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
224269057|NCT02961205|DIETARY_SUPPLEMENT|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
224269058|NCT03284697|PROCEDURE|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
224269059|NCT03284697|PROCEDURE|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
224269060|NCT01940445|DEVICE|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
224269061|NCT01940445|DEVICE|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
224269062|NCT03840577|DEVICE|Monitorization of sedation by Bispectral Index|The sedative dose administered through a continuous infusion pump will be adjusted based on the BIS value to maintain a target range of 40 to 60. If the BIS value is below the target range, the dose will be increased, and if it exceeds the range, the dose will be decreased, aiming to keep the BIS within the desired range.
224269063|NCT01971645|DRUG|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
224269064|NCT01971645|DRUG|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
224269065|NCT04476277|DRUG|Biotin label|Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival
224269066|NCT03076645|BEHAVIORAL|Facilitator support and education|Group engaged with facilitator support and education
224269067|NCT01962298|DRUG|sugammadex 2mg/kg|
224269068|NCT01962298|DRUG|neostigmine|
224269069|NCT01962298|DRUG|sugammadex 4mg/kg|
224269070|NCT01962298|DRUG|placebo|
224269071|NCT01962298|DRUG|Single rocuronium dose|
224269072|NCT01962298|DRUG|Repeated rocuronium dose|
224269073|NCT01962298|DRUG|Continuous rocuronium infusion|
224269074|NCT04173923|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
224269075|NCT04173923|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
224269076|NCT04173923|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
224269077|NCT04173923|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
224269078|NCT04173923|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
224269079|NCT04173923|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
224269080|NCT04173923|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
224269081|NCT05062564|DEVICE|LipiFlow Thermal pulsation system|Single treatment with LipiFlow thermal pulsation system on the eyelids within two months before surgery
224269082|NCT05062564|PROCEDURE|Eyelid warm compresses plus massages|Eyelid warm compresses plus massages twice a day for the preoperative month
224269083|NCT00533507|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
224269084|NCT00533507|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
224269085|NCT00533507|BIOLOGICAL|Rotarix|Oral, 2 doses.
224269086|NCT02708758|BEHAVIORAL|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
224269087|NCT03783897|DRUG|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
224269088|NCT03783897|DRUG|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
224269089|NCT01022879|PROCEDURE|vitrectomy|
224269090|NCT04955158|DRUG|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack (Group D) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
224269091|NCT04955158|DRUG|Ketamine|50 mg ketamine soaked pharyngeal pack (Group K) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
224269092|NCT04955158|OTHER|saline 0.9%|20 ml 0.9% saline soaked pharyngeal pack (Group C) putted in the posterior pharyngeal wall after induction of anesthesia and ETT.
224269093|NCT00249197|DRUG|levofloxacin|
224269094|NCT04184947|DRUG|SGLT2 inhibitor|New prescription of a SGLT-2 inhibitor (dapagliflozin, empagliflozin or canagliflozin) at any dosage during routine clinical practice
224269095|NCT04184947|DRUG|GLP-1 receptor agonist|New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
224269096|NCT01032590|BEHAVIORAL|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
224269097|NCT03825198|PROCEDURE|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
224269098|NCT03825198|DRUG|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
224269099|NCT03825198|PROCEDURE|spine fusion|fusion of lumbar vertebral body on 1 or two levels
224269100|NCT03825198|DRUG|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
224269101|NCT03825198|DRUG|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
224269102|NCT03825198|DRUG|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
224269103|NCT03825198|DRUG|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
224269104|NCT03825198|DRUG|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
224269105|NCT03825198|DRUG|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
224269106|NCT03825198|DRUG|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
224269107|NCT03825198|DRUG|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
224269108|NCT03825198|DRUG|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
224269109|NCT03825198|DRUG|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
224269110|NCT03917758|DRUG|SGLT2 inhibitor|Start of the treatment with SGLT2i.
224082860|NCT01226290|DEVICE|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
224269111|NCT00213551|DRUG|Glutamine|
224269112|NCT00213551|DRUG|Glucose|
224269113|NCT00213551|DRUG|glutamine-antioxidants containing solution|
224269114|NCT03548480|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo
224082861|NCT04223245|BEHAVIORAL|exercise+multi-modal sensory feedback (MMSF)|home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
224082862|NCT04223245|BEHAVIORAL|Exercise only|3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
224269115|NCT03548480|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic
224082863|NCT05750992|PROCEDURE|surgical TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.
224269116|NCT05002660|BEHAVIORAL|Group 1 (Intervention)|The investigators will evaluate the efficacy of the CC curriculum in a 24-months community-based randomized controlled trial. They will compare changes in CVD-related anthropometric, behavioral, and psychosocial parameters between subjects in intervention and control communities.
224269117|NCT05002660|BEHAVIORAL|Group 2 (Control)|Group 2 will be offered the same activities as Group 1 after the conclusion of the research study.
224269118|NCT03788876|OTHER|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge.
224269119|NCT03788876|OTHER|Conventional care|Physiotherapy protocol will be performed by HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
224269120|NCT04316962|OTHER|Complex cancer rehabilitation|"The program is conducted as group rehabilitation, organized by four hour weekly over 12 weeks (approximately 50 hours) with 8-10 participants in each group over three years. The program is located in Askøy Municipality's 'Health Central' and conducted by a multidisciplinary team.~The content of the program is based on prior research and clinical experience, consisting of five elements:~1. Individual goal-setting~2. Physical activity (2 hours/week) focusing on balance/coordination, cardio and strength.~3. Psychoeducation: Five teaching sessions and discussions focusing on physical activity, fatigue and late-effects, nutrition, coping, social support and work/studies. In addition, two sessions (first and last) will also include next of kin.~4. Individual follow-up: Mandatory session at the start and end of the program, otherwise based on individual request and need.~5. Peer support."
224269121|NCT01083329|BEHAVIORAL|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
224269122|NCT01083329|DRUG|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
224269123|NCT01083329|DRUG|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
224269124|NCT00881426|DRUG|Cefprozil 500 mg Tablets (Sandoz GmbH)|
224082864|NCT05750992|PROCEDURE|US guided TAP block|performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
224082865|NCT00212173|DRUG|Sibutramine|
224082866|NCT00212173|DIETARY_SUPPLEMENT|Slim Fast|
224082867|NCT03856944|DEVICE|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
224082868|NCT03948230|BIOLOGICAL|Salt with / without water|Drinks with and without a salt containing capsule
224082869|NCT04257331|BEHAVIORAL|Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme|The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
224082870|NCT02023658|OTHER|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
224082871|NCT03902678|PROCEDURE|EUS guided fine needle aspiration of portal vein thrombus|endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique
224082872|NCT02835885|DEVICE|Digitmer High Voltage Stimulator model DS7A TENS unit|
224082873|NCT02130713|DRUG|Third generation fluoroquinolone|Prulifloxacin 600 mg
224082874|NCT02130713|DIETARY_SUPPLEMENT|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
224082875|NCT01773421|DRUG|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
224082876|NCT01773421|DRUG|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
224082877|NCT05845359|DRUG|Methadone|One group will receive 10mg of methadone upon induction, while the other will receive a saline solution as placebo. We will see the effectiveness of methadone on postoperative pain management, while monitoring for opioid-related side effects.
224082878|NCT03743831|DEVICE|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
223517438|NCT03741855|DEVICE|Cloud Dx Kit with remote-monitoring|"* Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~* A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~* The RT will also check on patients once a week irrespective of the value of the vitals."
224082879|NCT03743831|DEVICE|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
224082880|NCT03502330|DRUG|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
224082881|NCT03502330|DRUG|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
223517439|NCT06090799|DRUG|SHR-3032|Single dose at varying dosage levels depending on treatment assignment
223517440|NCT06090799|DRUG|SHR-3032 Placebo|Single dose at varying dosage levels depending on treatment assignment
223517441|NCT00581100|DRUG|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
224082882|NCT03502330|DRUG|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
224082883|NCT02265484|DRUG|Lactulose+Rifaximin +Bromocriptine|
224082884|NCT02310048|DRUG|MT-1303-FormA|
224082885|NCT02310048|DRUG|MT-1303-FormB|
224082886|NCT02804763|DRUG|Placebo|Solution for infusion, 0,9% saline
224082887|NCT02804763|DRUG|Dapirolizumab pegol (DZP)|Solution for infusion
224082888|NCT06310148|COMBINATION_PRODUCT|The Chronic Disease Co-Care (CDCC) Pilot Scheme|Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
224082889|NCT02507479|DRUG|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
224082890|NCT01992809|DIETARY_SUPPLEMENT|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA \[α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%\], in 3 capsules/ day
224082891|NCT00067756|DRUG|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
224082892|NCT05513014|DRUG|Secukinumab|Patients with Psoriasis who initiated Secukinumab
224082893|NCT04224935|PROCEDURE|Leukocyte Platelet rich fibrin membrane|the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
224082894|NCT01809548|OTHER|Early intervention group|solid food will be introduced between week 10 and 12
224082895|NCT01809548|OTHER|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
224082896|NCT03371563|DRUG|Antibiotics|Patients were treated with antibiotics for Lyme disease.
224082897|NCT03371563|OTHER|no intervention|controls were not given antibiotics
224082898|NCT04274348|OTHER|Skin biopsies and blood samples|Two skin biopsies and 30 ml of blood will be collected.
223517442|NCT00834574|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
224082899|NCT05246540|OTHER|Data collection|Data collection
224082900|NCT02245048|OTHER|Carotid Intima-Media Thickness (CIMT)|
224082901|NCT02984800|OTHER|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
224082902|NCT02984800|OTHER|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
224082903|NCT02984800|OTHER|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
224082904|NCT03443167|BEHAVIORAL|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
224082905|NCT03443167|BEHAVIORAL|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
224082906|NCT02078479|PROCEDURE|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
224082907|NCT02078479|PROCEDURE|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
223517443|NCT00834574|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
224082908|NCT03105739|OTHER|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
224082909|NCT04172090|OTHER|Control|Normal physical activity and standard energy intake
224082910|NCT04172090|OTHER|SIT+E|Reduced physical activity and standard energy intake
224082911|NCT04172090|OTHER|SIT=E|Reduced physical activity and reduced energy intake
224082912|NCT06005584|DEVICE|Spinal Cord Stimulation - High Frequency SCS|"High Frequency-SCS consists of delivering electrical stimulation at frequencies equal to or greater than 1kHz.~This intervention will last up to 6 weeks."
224082913|NCT06005584|DEVICE|Spinal Cord Stimulation - Burst SCS|"Burst SCS consists of closely spaced, high frequency stimuli delivered to the spinal cord.~This intervention will last up to 6 weeks."
224082914|NCT06005584|DEVICE|Spinal Cord Stimulation - Sham SCS|This intervention will last up to 6 weeks.
224082915|NCT05821361|DRUG|HAIC+Cadonilimab+Bevacizumab|Cadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
224082916|NCT02626676|OTHER|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
224082917|NCT03751267|PROCEDURE|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
224082918|NCT03283202|DRUG|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
224082919|NCT03283202|DRUG|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
224082920|NCT03283202|DRUG|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
224082921|NCT03283202|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
224082922|NCT03283202|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
224082923|NCT04474327|DRUG|Montelukast Sodium|Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
224082924|NCT05034640|PROCEDURE|Conventional multiport thoracoscopic surgery|Use 2 or more incisions for multiple instrument entry during the surgery and chest tube placement at the end of the operation.
224082925|NCT05034640|PROCEDURE|Single port site thoracoscopic surgery|Using only 1 incision for multiple instrument entry during the surgery and chest tube placement at the end of the operation. Single port - GelPOINT Mini® port (Applied Medical, Rancho Santa Margarita, California, USA)
224082926|NCT01487421|DRUG|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
224082927|NCT01487421|DRUG|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
224082928|NCT00875758|PROCEDURE|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
224082929|NCT00875758|PROCEDURE|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
224082930|NCT02472847|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
224082931|NCT02472847|DRUG|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
224082932|NCT05035121|DIETARY_SUPPLEMENT|milk supplement|Intervention groups provided 200 mL long life milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
224082933|NCT05035121|DIETARY_SUPPLEMENT|soy milk supplement|Intervention groups provided 200 mL long life soy milk two times per day at morning and afternoon. The participants joined the resistance exercise training program, three times per week (30 min/time)
224082934|NCT05035121|BEHAVIORAL|resistance exercise|The participants joined the resistance exercise training program, three times per week (30 min/time)
224082935|NCT01113151|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
224082936|NCT01113151|OTHER|Placebo|3 placebo tablets daily for 12 weeks
224082937|NCT04656990|BEHAVIORAL|Integrated Intervention|Gross motor and social-emotional integrated intervention
224082938|NCT03010540|DRUG|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
224082939|NCT03010540|DRUG|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
224082940|NCT03561233|DRUG|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
224082941|NCT01269164|PROCEDURE|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
224082942|NCT02174718|DIETARY_SUPPLEMENT|Transdermal D Patch|
224082943|NCT02174718|DIETARY_SUPPLEMENT|Oral vitamin D3|
224082944|NCT02174718|DIETARY_SUPPLEMENT|Placebo patch|
224082945|NCT02174718|DIETARY_SUPPLEMENT|Oral placebo|
224082946|NCT03657459|BEHAVIORAL|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities) that reflect patient behaviors
224269125|NCT00881426|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
224082947|NCT01693445|DRUG|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
224082948|NCT04833803|BEHAVIORAL|eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed
223517444|NCT03058952|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
223517445|NCT03058952|BEHAVIORAL|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
223517446|NCT06105255|DRUG|D-1553|D-1553 is a novel, targeted KRASG12C inhibitor.
223517447|NCT02256748|DRUG|BIRT 2584 XX|
223517448|NCT02256748|DRUG|Midazolam|
223517449|NCT00590317|DRUG|Prochlorperazine|Patients receiving Prochlorperazine
223517450|NCT00590317|DRUG|Ondansetron|Patients receiving Ondansetron
223517451|NCT05210725|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to acetylsalicylic acid (80-00mg once a day, standard care).
223517452|NCT03837509|DRUG|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.
223517453|NCT03837509|BIOLOGICAL|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.
223517454|NCT02150746|PROCEDURE|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
224082949|NCT01800721|BEHAVIORAL|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
224082950|NCT01800721|BEHAVIORAL|SNAP Control|Behavioral: SNAP control 7 group sessions
224082951|NCT01348230|OTHER|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
224082952|NCT00623831|BIOLOGICAL|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
223517455|NCT02150746|PROCEDURE|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
223517456|NCT03490994|DRUG|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
223517457|NCT03490994|DRUG|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
223517458|NCT05142319|BIOLOGICAL|Homologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
223517459|NCT05142319|BIOLOGICAL|Heterologous mRNA booster vaccine|Single intradermal injection. The vaccine dose will be according to manufacturer's instructions.
223517460|NCT05142319|BIOLOGICAL|COVAXIN|Single intradermal injection at 6ug (0.5ml) per dose.
224082953|NCT02512458|DRUG|Cabazitaxel|
224082954|NCT02562625|DRUG|Pembrolizumab|Powder solution for infusion
224082955|NCT02562625|RADIATION|Radiotherapy|24Gy
224082956|NCT00282243|DRUG|tacrolimus modified release (MR)|Oral
224082957|NCT00282243|DRUG|tacrolimus|Oral
224082958|NCT00700856|DRUG|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
224082959|NCT00700856|DRUG|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
224082960|NCT01383031|PROCEDURE|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
224269126|NCT01589835|BEHAVIORAL|Lifestyle changes|Green prescription with support from facilitator
224082961|NCT01383031|PROCEDURE|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
224082962|NCT01468649|DEVICE|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
224082963|NCT03151889|DEVICE|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
224082964|NCT02773329|OTHER|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
224082965|NCT02773329|OTHER|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
224082966|NCT03724448|DRUG|aleozen|treatment with herbal medicine
224082967|NCT03724448|DRUG|Placebo Oral Tablet|No aleozen treatment
224082968|NCT03242655|BEHAVIORAL|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
224082969|NCT03933943|DRUG|LY3361237|Administered SC
224082970|NCT03933943|DRUG|Placebo|Administered SC
224082971|NCT05422729|BEHAVIORAL|mHealth-supported coaching|The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.
224082972|NCT05422729|BEHAVIORAL|Conventional Health coaching|Three individual consultation sessions delivered by a nurse.
224082973|NCT01067820|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
224082974|NCT01067820|DRUG|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
224082975|NCT01734148|BEHAVIORAL|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
224082976|NCT05381506|DRUG|Orelabrutinib and Gemox|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin"
224082977|NCT01070329|DRUG|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
224082978|NCT01070329|DRUG|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
224082979|NCT02669693|DIETARY_SUPPLEMENT|bread without olives|
224082980|NCT02669693|DIETARY_SUPPLEMENT|bread with olives|
224082981|NCT00492219|DEVICE|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
224082982|NCT00492219|DEVICE|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
224082983|NCT02707770|OTHER|Pulmonary Rehabilitation|
224082984|NCT01504932|DIETARY_SUPPLEMENT|BRB Lozenge|ARM I: Patients will be instructed to begin BRB administration and continue daily for up to 6 months.
224082985|NCT01504932|OTHER|Survey Administration|Patients will complete a baseline survey documenting any family history of cancer. Patients will then provide a history of tobacco, alcohol and mouthwash use, complete the Head and Neck Cancer Inventory Survey (HNCI), the Insomnia Severity Index (ISI) Survey, and the Brief Fatigue Inventory (BFI) Survey. Patients will receive a trial-specific logbook to record their usages.
224082986|NCT01504932|OTHER|Laboratory Biomarker Analysis|Patients will provide blood, urine, saliva, and cheek scrape samples. These biological samples will be evaluated for the presence of BRB components (as a measure of compliance) and assessed for BRB-responsive gene expression, respectively.
224082987|NCT01504932|OTHER|pharmacological study|Correlative studies
224082988|NCT05619965|DRUG|sedative|dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
224082989|NCT05619965|DEVICE|Awake endotracheal intubation by Glidescope videolaryngoscope|Awake endotracheal intubation by Glidescope videolaryngoscope of cervical trauma patient
224269127|NCT06357416|DEVICE|MV-POCT Sub-study|Point of care blood testing
224082990|NCT05619965|DEVICE|Awake endotracheal intubation by Fiberoptic bronchoscope|Awake endotracheal intubation by Fiberoptic bronchoscope of cervical trauma patient
224082991|NCT05424393|DRUG|YISAIPU® ( An etanercept biosimilar)|YISAIPU®, an etanercept biosimilar produced by 3SBio Inc., is a TNF-α inhibitor targeting soluble TNF-α to inhibit its interaction with cell-surface receptors. It has been widely used in clinical practice for 17 years in China. According to the prescription information, YISAIPU should be given as 25mg, biw, pc.
224269128|NCT06357416|OTHER|Main Man Van Group Sub-study (MV-Eco)|Consent for long-term follow-up of patients
224082992|NCT05424393|DRUG|csDMARDs|csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
224082993|NCT02863848|DIETARY_SUPPLEMENT|OraftiR inulin-type fructans|
224082994|NCT02863848|DIETARY_SUPPLEMENT|Placebo|maltodextrin
224082995|NCT00425490|DRUG|sitagliptin|
224082996|NCT02247869|DRUG|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
224082997|NCT03269981|RADIATION|Whole breast irradiation|Radiotherapy to the whole breast alone.
224082998|NCT03269981|RADIATION|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
224082999|NCT05997277|DRUG|Deucravacitinib|Deucravacitinib is a stable deuterium-containing compound (where deuterium is a stable, nonradioactive isotope of hydrogen) and a potent, highly selective small molecule inhibitor of TYK2. Deucravacitinib has a unique mode of binding that provides the high selectivity over the other members of the JAK family of nonreceptor tyrosine kinases. 1 active oral tablet (6mg) in the morning and evening for 16weeks.
224083000|NCT05997277|DRUG|Placebo|Placebo will consist of a tablet (0mg) and will be administered orally BID for 16weeks.
224083001|NCT03790943|DIAGNOSTIC_TEST|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
224083002|NCT06062264|BEHAVIORAL|Portal-based Video Message|Video recorded by physician encouraging patients to receive influenza vaccine. Sent via the patient portal.
224083003|NCT06062264|BEHAVIORAL|Portal-based Infographic Message|Infographic with information about the influenza vaccine and an image of the physician. Sent via the patient portal.
224083004|NCT05294731|DRUG|BGB-16673|Orally administered
224269129|NCT06357416|OTHER|MV-QualQ Sub-study|Qualitative questionnaire and interview sub-study
224269130|NCT06357416|DIAGNOSTIC_TEST|MV-PRS Sub-study|Patients consenting to polygenic risk score testing
224269131|NCT06357416|OTHER|MV-DNA and MV-UctDNA Sub-study|Patients consenting to collection of DNA and urine for further study.
224269132|NCT06357416|OTHER|Man Van patients|All patients seen in Man Van
224269133|NCT06357416|OTHER|MV-SSI Sub-study|Semi-structured interviews will be conducted with stakeholders involved in the running of or recruitment to the project.
224269134|NCT06357416|OTHER|MV-TPP Sub-study|Multi-stage qualitative study comprising of interviews and participatory design focus group workshops.
224269135|NCT05575557|PROCEDURE|Right heart catheterization|All groups were detected with SW catheter by the internal jugular vein before the procedure. After the measurement, the catheter was indwelled, and the pacemaker implantation procedure was started. After ventricular pacing for 5 minutes, the SW catheter measurement was performed again. After the measurement, the SW catheter was withdrawn.
224269136|NCT01062490|DRUG|Treosulfan|14 g/m2/d, day -6 to -4
224269137|NCT01576705|DRUG|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
224269138|NCT01140607|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
224269139|NCT00268216|DRUG|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
224269140|NCT05560139|DEVICE|a-tDCS|Transcranial direct current stimulation
224269141|NCT06297408|DRUG|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
224269142|NCT03021876|DRUG|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
224269143|NCT03021876|OTHER|usual intake|baseliner
224269144|NCT01068704|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, \~ 12 months depending on response
224269145|NCT01068704|DRUG|Lapatinib|Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response
224269146|NCT01068704|DRUG|Letrozole|Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response
224269147|NCT00829894|DRUG|Risperidone|1 mg Tablet
224269148|NCT00829894|DRUG|Risperidone|1 mg Tablet
224269149|NCT03224663|OTHER|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
224269150|NCT03224663|OTHER|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
224269151|NCT06173050|DEVICE|PAP System A (with Amalfi) then PAP System B (with CLA11)|PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
224269152|NCT06173050|DEVICE|PAP System B (with CLA11) then PAP System A (with Amalfi)|PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
224269153|NCT04392934|PROCEDURE|a conservative physiotherapy protocol|5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
224269154|NCT02790658|DIETARY_SUPPLEMENT|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
224269155|NCT02896296|DRUG|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
224269156|NCT01751854|DRUG|SSRI|SSRI alone or with training
224269157|NCT01751854|DRUG|Placebo|Placebo alone or with training
224269158|NCT01385163|BEHAVIORAL|Treatment as usual|Standard psychosocial counseling
224269159|NCT01385163|BEHAVIORAL|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
224269160|NCT01385163|BEHAVIORAL|Cognitive Processing Therapy|group 12 session intervention
224269161|NCT02421653|DIETARY_SUPPLEMENT|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
224269162|NCT02421653|DIETARY_SUPPLEMENT|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
224269163|NCT02421653|DIETARY_SUPPLEMENT|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
224269164|NCT02421653|DIETARY_SUPPLEMENT|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
224269165|NCT02421653|DIETARY_SUPPLEMENT|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
224269166|NCT02421653|DIETARY_SUPPLEMENT|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
224269167|NCT04550013|OTHER|Heavy-Slow Resistance training|Resistance training for knee extensors. The exercise will be performed at 80% of 1 RM and slowly (6 s/repetition).
224269168|NCT04550013|OTHER|Low-Load Blood Flow Restriction training|Resistance training for knee extensors. The exercise will be performed at 30% of 1 RM and with a relative Artery Occlusion Pressure of 80%
224269169|NCT01874535|DRUG|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
224269170|NCT01215721|DRUG|Vesicare|5 mg daily
224269171|NCT00866476|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
224269172|NCT00866476|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
224269173|NCT03949296|BEHAVIORAL|Mindfulness Intervention|"10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends"
224269174|NCT03949296|BEHAVIORAL|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~1. Maintain a regular sleep pattern~2. Only try to sleep when feeling tired or sleepy~3. If unable to sleep, do something calm until feeling tired and returning to bed~4. Avoid caffeine \& nicotine for 4-6 hours before going to bed~5. Avoid alcohol for 4-6 hours before going to bed~6. Use the bed only for sleeping and sex~7. Avoid naps during the day~8. Develop rituals to get relaxed and ready to sleep~9. Try a hot bath prior to bedtime~10. Avoid checking the clock during the night~11. Use a sleep diary for a few weeks to track progress~12. Avoid strenuous exercise before bedtime~13. Avoid a heavy meal before bedtime~14. Create a sleep environment that is quiet, comfortable, and dark~15. Maintain a regular daytime routine"
224269175|NCT02286479|PROCEDURE|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
224269176|NCT02286479|PROCEDURE|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
224269177|NCT01298050|PROCEDURE|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
224269178|NCT02380534|PROCEDURE|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
224269179|NCT00045162|DRUG|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
224269180|NCT00045162|DRUG|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 \& 3. Q 3 weeks x 4 Cycles
224269181|NCT00045162|DRUG|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 \& 15. Q 4 weeks x 4 Cycles
224269182|NCT00096655|DRUG|Infliximab|
224269183|NCT00702793|DRUG|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
224269184|NCT01044433|DRUG|lapatinib ditosylate|Given orally
224269185|NCT01044433|DRUG|capecitabine|Given orally
224269186|NCT03595254|BEHAVIORAL|Thrive|Computerized Cognitive Behavior Therapy program
224269187|NCT06520683|DRUG|Tislelizumab|\- Tislelizumab 200mg (day 1 and day 22), administered after surgery
224269188|NCT06520683|DRUG|Adjuvant chemotherapy|"* Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine."
224269189|NCT00483145|DEVICE|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
224269190|NCT00483145|DEVICE|Long-pulsed dye laser|
224269191|NCT00483145|DEVICE|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
224269192|NCT03882762|DRUG|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
224269193|NCT05341492|BIOLOGICAL|EGFR/B7H3 CAR-T|2 × 10\^6/kg CAR-T cells,For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
224269194|NCT05953987|OTHER|aerobic combined with diaphragmatic breathing exercise (EXDB)|The participant underwent diaphragmatic breathing exercises which were performed in a supine position, gradually in-creasing the weight by 2.5 kg in weeks 1-4 and further increasing to 5 kg in weeks 5-8. After completing the prescribed breathing exercises and taking a 60-second rest, participants proceeded to perform aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added
224269195|NCT05953987|OTHER|aerobic exercise (EX)|The participant underwent aerobic exercises, either by running on a treadmill or on a regular floor surface. Each training session began with a 5-minute warm-up comprising stretching exercises. In weeks 1-4, moderate intensity was maintained, targeting 40-50% of the heart rate reserve (HRR) for a duration of 60 minutes. From weeks 5-8, the intensity increased to the range of 51-60% of the heart rate reserve, and a 5-minute cool down was added.
224269196|NCT05953987|OTHER|sedentary control (CON)|The participant did not engage in the aerobic exercise training protocol or receive any form of supplementation during the study trial.
224269197|NCT02838953|BEHAVIORAL|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
224269198|NCT06445478|OTHER|Blood Flow Restrictive Exercise and Isokinetic Exercise|"Before providing exercise training, the muscle strength, circumference measurement, joint range of motion, agility and quality of life of female football players will be determined. Muscle strength measurements will be evaluated with the Kineo Intelligent Load Isokinetic Device for the BFR-RE and ID-RE groups. Then, both groups will be given 4 weeks of resistance exercise training. After this training, all evaluations will be made again. After this evaluation, another 4 weeks of training will be given and the evaluations will be re-applied at the end of the 8th week.~The Informed Volunteer Consent Form will be read and signed by 30 selected participants."
224269199|NCT01859260|DEVICE|CPAP/autopap|
224269200|NCT02594527|OTHER|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
224269201|NCT02943096|DIETARY_SUPPLEMENT|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
223517461|NCT05142319|BIOLOGICAL|Nuvaxovid|Single intradermal injection at 5mcg (0.5mL) per dose.
224269202|NCT02943096|OTHER|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
224269203|NCT03258996|PROCEDURE|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
224269204|NCT03258996|PROCEDURE|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
224269205|NCT03831490|DIAGNOSTIC_TEST|history|combining these 4 interventions will great an algorithm predicting preeclampsia
224269206|NCT03293719|DEVICE|BPK-S Integration UC|Primary Knee Endoprosthesis
224269207|NCT05065619|BIOLOGICAL|MT-2766 High dose (3.75 µg)|Subjects will receive two doses of MT-2766 high dose (3.75 µg) given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
223893394|NCT03978689|DRUG|KEYTRUDA®, Pembrolizumab|KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
224269208|NCT05065619|DRUG|Placebo|Subjects will receive two doses of placebo given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
223893395|NCT06355778|OTHER|Magnetic Resonance Imaging (MRI)|Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.
223893396|NCT06355778|BEHAVIORAL|Computer Tasks|Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
224269209|NCT05065619|BIOLOGICAL|MT-2766 Low dose|Subjects will receive two doses of MT-2766 low dose given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)
223893397|NCT06393088|DEVICE|IR REHAB|Participants undergo therapy sessions with active, dual frequency, low level laser therapy device
223893398|NCT06393088|DEVICE|Sham|Participants undergo therapy sessions with disabled device producing no laser energy
223517462|NCT01627197|PROCEDURE|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
223517463|NCT03755401|OTHER|TFPP|Trauma-Focused Psychodynamic Psychotherapy
224269210|NCT06168903|PROCEDURE|Ultrasound guided EOI block|"Before receiving general anesthesia, patients will be randomly assigned to one of the two study groups: the EOI block group or the ESPB group.~Using Ultrasound (Siemens ACUSON X300 Ultrasound System), guided blocks will be administered immediately after the induction of anesthesia and prior to surgical incision by consultant anesthesiologists who have experience in regional anesthesia and are familiar with the EOI and ESPB blocks"
224269211|NCT02261181|DEVICE|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
224269212|NCT00709514|DRUG|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
224269213|NCT00709514|DRUG|Placebo|Placebo
224269214|NCT04391517|DIAGNOSTIC_TEST|SpHb measurement|All included patients will have their Hb measured non-invasively by a trained health care provider. SpHb values will be recorded in the documentation software already in use at the clinic.
224269215|NCT04976023|DRUG|Yupingfeng Powder granules|14.5 5 g twice daily for 8 weeks
224269216|NCT04976023|OTHER|Placebo|14.5 5 g twice daily for 8 weeks
224269217|NCT00193323|DRUG|Docetaxel|
224269218|NCT00193323|DRUG|Gemcitabine|
224269219|NCT03614455|DRUG|Milademetan|Milademetan 100 mg capsule for oral administration
224269220|NCT03614455|DRUG|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
224269221|NCT03614455|DRUG|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
224269222|NCT02835755|OTHER|Educational Intervention|Receive standard HPV and HPV vaccine information
224269223|NCT02835755|OTHER|Educational Intervention|Receive mHealth HPV vaccine intervention
224269224|NCT02835755|OTHER|Survey Administration|Ancillary studies
224269225|NCT02970149|OTHER|NA (observational)|
224269226|NCT05418790|DEVICE|TASSO device|During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
224269227|NCT06618638|BEHAVIORAL|Shared decision making model|Shared decision making model for choosing pharmacotherapy in ADPKD patients. This newly developed shared decision making model follows the SHARE approach and includes patient education, identifying values and preferences, reaching a decision and evaluating.
224269228|NCT06618638|BEHAVIORAL|Usual Care|Usual care for ADPKD patients
224269229|NCT04903652|DRUG|Pyrotinib Maleate|Pyrotinib p.o. 400 mg once daily
223517464|NCT03755401|OTHER|TAU|treatment as usual at the VA for PTSD
223517465|NCT05170061|DRUG|Nebivolol|Nebivolol 20 mg daily (1 week) followed by nebivolol 40 mg daily (3 weeks) followed by nebivolol 20 mg daily (1 week)
223517466|NCT05170061|DRUG|Valsartan|Valsartan 160 mg daily (1 week) followed by valsartan 320 mg daily (3 weeks) followed by valsartan 160 mg daily (1 week).
223517467|NCT05170061|DRUG|Nebivolol/valsartan combination|Valsartan/Nebivolol, 160/20 mg daily (1 week) followed by valsartan/nebivolol 320/40 mg daily (3 weeks) followed by valsartan/nebivolol 160/20 mg daily (1 week)
224269230|NCT04903652|DRUG|Vinorelbine|Vinorelbine p.o. 40 mg once every other day
224269231|NCT02026479|DRUG|Dexamethasone Phosphate|5mg; postauricular injection
224269232|NCT02026479|DRUG|Dexamethasone Phosphate|10mg; postauricular injection
224269233|NCT02026479|DRUG|Ginaton|40mg/pill, 3times/day,oral
224269234|NCT06293352|DEVICE|All-cement articulating spacer|Two-stage intervention
224269235|NCT06293352|DEVICE|Durable, real-component articulating spacer|Single stage intervention
224269236|NCT06293352|DEVICE|Rigid Spacer|Observation intervention
224269237|NCT03786770|BIOLOGICAL|DaxibotulinumtoxinA for injection|Intramuscular injection
224269238|NCT05357287|DEVICE|PREVENA incision management system|We will apply Prevena on the surgical wound right after closure of the wound in the operating theater. Prevena will be used for 7 days, unless there is ongoing infection or much wound drainage that requires debridement.
224269239|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation device|PoNS device will be used to deliver trans-lingual electrical stimulation. The stimulation will be delivered while the participants engages in evidence-based physiotherapy for walking and balance.
224269240|NCT05275049|COMBINATION_PRODUCT|PT plus translingual stimulation control device|Control device will be used. Participants will wear device while engaging in evidence-based physiotherapy for walking and balance.
224269241|NCT05364606|DEVICE|Patient Specific Talus Spacer|Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
223517468|NCT04901975|DRUG|Spironolactone|Spironolactone is a mild diuretic. Drug dosage will be those used clinically and per the CHOP formulary: 3 mg/kg/day in divided doses every 6-24 hours; the drug will be weight adjusted every \~0.5 kg with a maximum dosage of 200 mg/24 hours. Maximum single dose is 100 mg. Spironolactone, the aldosterone antagonist to be utilized in Specific Aim 2 of this study, is FDA approved, has been on the market for many years and is routinely administered to all types of children with congenital heart disease including SV patients. The choice of which patient this should be administered to is up to the clinician and their patients and therefore, not all SV patients are on this medication.
223517469|NCT04540380|DRUG|Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab|Conditioning regimen .Patients will receive Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Thymoglobulin
223517470|NCT04540380|PROCEDURE|Combined bone marrow and kidney transplant|Recipients will receive a conditioning regimen that includes rituximab on study days -7 and -2, fludarabine 10mg/m2/day on days -6 to -3 (4 doses), cyclophosphamide (22.5mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumabon days -1, 0, and +1. Combined kidney and bone marrow transplant will be performed on study day 0. Methylprednisolone will be started at 250 mg/day on day 0 and tapered to prednisone 20mg by day 10 after which it will be continued until day 20. Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 52 weeks following transplantation. The proportion of patients successfully weaned off immunosuppression without chimerism transition syndrome (CTS) will be assessed.
223517471|NCT06791044|DIETARY_SUPPLEMENT|DELTIUS|A treatment plan will be implemented, as applicable, consisting of 50,000 I.U of vitamin D weekly for 8 weeks
223517472|NCT06791044|DIETARY_SUPPLEMENT|DELTIUS|A treatment plan will be implemented, as applicable, consisting of 25,000 I.U of vitamin D for 4 weeks followed by 10,000 I.U of vitamin D drops weekly for an additional 4 weeks (totaling 8 weeks)
223517473|NCT02608385|RADIATION|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
223517474|NCT02608385|DRUG|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
223517475|NCT06157983|OTHER|measurement of lipoprotein(a)|Plasma lipoprotein(a) will be measured in the biological relatives group as part of a clinical health care development project
223517476|NCT02531386|DEVICE|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
223517477|NCT05931965|DIETARY_SUPPLEMENT|L-methylfolate|Participants receive L-methylfolate 400µg orally twice daily for 4 weeks
223517478|NCT05931965|DIETARY_SUPPLEMENT|Vitamin B12|Participants receive mecobalamin 500µg intramuscularly stat on alternate days (6 total injections)
223517479|NCT05931965|DIETARY_SUPPLEMENT|magnesium|Participants receive magnesium glycinate 400mg twice daily orally for 4 weeks (elemental 120mg approx.)
223517480|NCT02344472|DRUG|pertuzumab|HER2 targeted Therapy
223517481|NCT02344472|DRUG|Trastuzumab|HER2 targeted Therapy
223517482|NCT02344472|DRUG|Capecitabine|Chemotherapy
223517483|NCT02344472|DRUG|Paclitaxel|Chemotherapy
223517484|NCT02344472|DRUG|Vinorelbine|Chemotherapy
223517485|NCT02344472|DRUG|Docetaxel|Chemotherapy
223517486|NCT02344472|DRUG|Exemestane|endocrine therapy
223517487|NCT02344472|DRUG|Letrozole|endocrine therapy
223517488|NCT02344472|DRUG|Anastrozole|endocrine therapy
223517489|NCT02344472|DRUG|Fulvestrant|endocrine therapy
223517490|NCT02344472|DRUG|Ribociclib|CDK 4/6 inhibitor
223517491|NCT02344472|DRUG|nab-Paclitaxel|chemotherapy
223517492|NCT02344472|DRUG|eribulin|chemotherapy
223517493|NCT02344472|DRUG|leuprorelin|endocrine therapy
223517494|NCT02344472|DRUG|goserelin|endocrine therapy
223517495|NCT01460277|PROCEDURE|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
223517496|NCT01460277|PROCEDURE|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
223517497|NCT01521741|OTHER|Breast Cancer-Related Lymphedema Screening|All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
223517498|NCT03495232|DEVICE|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
223517499|NCT03318627|DEVICE|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
223517500|NCT01458457|OTHER|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
223517501|NCT01458457|OTHER|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
223517502|NCT03816579|OTHER|PRO-A|30 g of beef protein will be consumed at each meal
223517503|NCT03816579|OTHER|PRO-B|30 g of complementary proteins will be consumed at each meal
223517504|NCT03816579|OTHER|PRO-C|30 g of complementary proteins will be consumed over 24 hours
223517505|NCT00292903|BEHAVIORAL|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
223517506|NCT00292903|BEHAVIORAL|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
223517507|NCT04431063|PROCEDURE|Distal Stump Suturing|in ACL Reconstruction case , Group A consist of subject with operation procedure suturing the distal stump peroneus longus against the peroneus brevis in ACL reconstruction using the peroneus longus autograft.
223517508|NCT04781842|OTHER|Boxing exercise program|Participants attended an hour long class once a week for 12 weeks. Included in class was a warm up, boxing activities including weight shifting, kicking, and punching bags, strengthening activities and a cool down.
223893399|NCT06266689|BEHAVIORAL|Personalized Diet Information|These participants will receive a report detailing their genomic food data based on the investigators' DNA metabarcoding technique in addition to standard dietary guidance to see if receiving the report modifies what they choose to feed their infant.
223517509|NCT01630109|DRUG|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
223517510|NCT01630109|DRUG|Placebo|A placebo capsule made to look like the metoclopramide capsule.
223517511|NCT05034081|PROCEDURE|body contouring|any post-bariatric body contouring surgery included
224269242|NCT03790137|DRUG|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
224269243|NCT05819437|OTHER|Balneotherapy program|"Whirlpool bath, bath with immersion showers, poultice application and underwater massage.~The baths were performed in an individual tub in ten-minute sessions. The temperature was set specifically for each patient, on average from 34 to 38°C. These were baths with jets and air diffusion.~The mud was applied as a poultice to the 2 knees and if necessary (duration of application: 10 minutes).~The massages were carried out by qualified physiotherapists under an affusion ramp of thermal water at 38°C for 10 minutes.~The water used is a mixed sulphated Natural Mineral Water, collected by drilling the capuchins at a depth of 975 m. The temperature of the water at the outlet of the borehole is 41.8°C and is lowered to 35°C."
224269244|NCT02069951|OTHER|Practice a procedural module on a simulator|
224269245|NCT00714051|BEHAVIORAL|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
224269246|NCT00714051|BEHAVIORAL|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
224269247|NCT04293354|PROCEDURE|Serratus Plane Block|Serratus Plane Block was performed
224269248|NCT04293354|PROCEDURE|Control|No block was performed
224269249|NCT04552405|DIETARY_SUPPLEMENT|Anti-inflammatory Diet|FAP individuals followed for 3 months a low-inflammatory diet
224269250|NCT00141505|DRUG|Bifeprunox|
224269251|NCT02583698|DRUG|Carvedilol|
224269252|NCT02583698|DRUG|Placebo|
224269253|NCT06324305|PROCEDURE|Pars plana vitrectomy (PPV) and drainage of subretinal fluid|Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
224269254|NCT03727945|OTHER|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
224269255|NCT03727945|OTHER|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
224269256|NCT04474145|PROCEDURE|Comb group|"Patients in the Comb group will receive hydrodilatation of the affected shoulder and subdeltoid bursa injection for 2 times in 2-week interval. Patients also receive mobilization exercise and conventional physical therapy (including physical modalities and stretch exercise), 3 times a week, for 8 weeks.~The injectates for hydrodilation include 10mg triamcinolone, 2cc 1% xylocaine, and 17cc normal saline for both posterior and anterior shoulder joint injection. 10mg triamcinolone and 2cc 1% xylocaine will also be injected into the subdeltoid bursa of the affected shoulder. All injections will be performed under ultrasound guidance. For shoulder joint injection, ａ21 gauge, 3-inch needle will be used; and a 22 gauge, 1.5 inch needle will be applied for subdeltoid bursa injection."
224269257|NCT04474145|PROCEDURE|PT group|The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 8 weeks or until total recovery of the symptoms. The stretching exercise program is similar to the stretching exercise described above. For mimicking injection in the Comb group, patients in the PT group will receive 2cc 1% xylocain injection at the posterior deltoid muscle.
223517512|NCT06541132|OTHER|Observational study without human intervention|Observational study without human intervention
223893400|NCT02515773|DRUG|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
223893401|NCT02515773|BEHAVIORAL|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
224269258|NCT06248645|DRUG|Oxygen|High-flow oxygen (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
223517513|NCT04753359|OTHER|Med|Mediterranean diet
223517514|NCT04753359|OTHER|WL|Measuring change in weight
224269259|NCT06248645|DRUG|Placebo|High-flow medical air (12 L/min) administered with a non-rebreathing facial mask, started as soon as possible after the beginning of the attack and for 15 minutes.
224269260|NCT00907205|DRUG|SF1126|Dose Escalating with 3+ patients in each cohort
224269261|NCT00351117|DRUG|St. John's Wort|SJW in capsule form 300 mg PO TID
224269262|NCT00351117|DRUG|Lactose|lactose in gelatin capsule that same as St. John's wort
224269263|NCT04385745|PROCEDURE|Biodegradable Intramedullary Nailing (BIN)|Unstable forearm shaft fractures are treated by the study method (BIN) or the control method (ESIN).
224269264|NCT03414073|DEVICE|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
224269265|NCT03414073|DEVICE|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
224269266|NCT03414073|DEVICE|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
224269267|NCT03045627|DRUG|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
224269268|NCT03045627|DRUG|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
224269269|NCT03045627|DRUG|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
224269270|NCT03045627|DRUG|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
224269271|NCT03109327|DIAGNOSTIC_TEST|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
224269272|NCT05523960|PROCEDURE|No MBP|No mechanical bowel preparation before operation
224269273|NCT03757468|DEVICE|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
224269274|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
224269275|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
224269276|NCT00758758|DEVICE|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
224269277|NCT06212674|PROCEDURE|PVI + LAAO|Treatment with a complex procedure of PVI + LAAO
224269278|NCT06212674|PROCEDURE|LAAO|Tratment with LAAO procedure
224269279|NCT06212674|DRUG|NOAC|NOAC treatment
224269280|NCT00858416|DEVICE|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
224269281|NCT00858416|DEVICE|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
224269282|NCT05745636|DIETARY_SUPPLEMENT|Broccoli, mustard, vitamin C|2 capsules per day for 4 weeks
224269283|NCT05745636|DIETARY_SUPPLEMENT|Placebo|2 capsules per day for 4 weeks.
224269284|NCT01352052|OTHER|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
224269285|NCT02119936|BEHAVIORAL|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
224269286|NCT03545399|DIETARY_SUPPLEMENT|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
224269287|NCT03545399|DIETARY_SUPPLEMENT|Placebo|The dose was taken with a glass of water during the evening meal once daily
224269288|NCT00570128|DRUG|Donepezil HCl|Blinded donepezil 2.5 milligram per day (mg/day) (2.5 milliliter per day \[mL/day\]) orally for participants with body weight (BW) 20 and less than (\<) 25 kilogram (kg), 5 mg/day (5 mL/day) orally for participants with BW 25 to \<50 kg, and 10 mg/day (10 mL/day) orally for participants with BW greater than or equal to (\>=) 50 kg liquid formulation (1 milligram per 1 milliliter \[1 mg/1 mL\]) (titrated to 0.1 to 0.2 milligram per kilogram per day \[mg/kg/day\] based on BW).
224269289|NCT00570128|DRUG|Placebo|Liquid formulation matched to active treatment for oral administration.
224269290|NCT05886127|DEVICE|A novel hemostatic agent (Purastat®)|A novel hemostatic agent (Purasta®) will be applied on cutted ampulla of Vater
224269291|NCT03868631|DIETARY_SUPPLEMENT|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
224269292|NCT03868631|DIETARY_SUPPLEMENT|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
224269293|NCT05894031|BEHAVIORAL|Wim Hof Method|The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
224269294|NCT01436448|DRUG|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
224269295|NCT01620281|DEVICE|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
224269296|NCT03458364|DEVICE|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
224269297|NCT03458364|DEVICE|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
224269298|NCT04912063|DRUG|Lemzoparlimab|Intravenous (IV) Infusion
224269299|NCT04912063|DRUG|Azacitidine|Subcutaneous Injection or Intravenous (IV) Injection/Infusion
224269300|NCT04912063|DRUG|Venetoclax|Oral Tablet
224269301|NCT03092414|PROCEDURE|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
224269302|NCT03092414|PROCEDURE|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
224269303|NCT01420614|PROCEDURE|Femoral approach|diagnostic and interventional procedures by femoral artery access
224269304|NCT01420614|PROCEDURE|Radial approach|diagnostic and interventional procedures by radial artery access
224269305|NCT02928458|DRUG|Omnipaque|
224269306|NCT02928458|DRUG|MD-Gastroview|
224269307|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
224269308|NCT00564187|DRUG|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP\<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP\<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
224269309|NCT03910361|DRUG|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
224269310|NCT03910361|DRUG|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
224269311|NCT04035954|OTHER|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
224269312|NCT03231345|PROCEDURE|US guided IJ|IV catheter placement
224269313|NCT03231345|DEVICE|Ultrasound|Ultrasound-guided Internal Jugular vein
224269314|NCT01711567|DRUG|tenofovir|tenofovir 300 mg qd
224269315|NCT01711567|DRUG|entecavir|entecavir 0.5 mg qd
224269316|NCT02223169|DIETARY_SUPPLEMENT|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
224269317|NCT00691756|PROCEDURE|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
224269318|NCT00691756|PROCEDURE|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
224287275|NCT03699254|DRUG|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
224269319|NCT03442192|OTHER|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~* On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~* HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
224269320|NCT02725060|DRUG|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every \~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
224269321|NCT02725060|DRUG|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every \~3 min until heart rate increases by 25 bpm. This intervention is optional.
224269322|NCT02725060|RADIATION|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
224269323|NCT02725060|PROCEDURE|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
224269324|NCT02725060|PROCEDURE|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
224269325|NCT02725060|PROCEDURE|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
224269326|NCT02725060|PROCEDURE|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
224269327|NCT02725060|OTHER|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
224269328|NCT02725060|OTHER|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
224269329|NCT02725060|PROCEDURE|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
224269330|NCT00032240|DEVICE|Shoe Insert|
224269331|NCT00652002|DRUG|budesonide/formoterol|
224269332|NCT00652002|DRUG|budesonide|
224269333|NCT00652002|DRUG|formoterol|
224269334|NCT02411149|DRUG|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
224269335|NCT02411149|DRUG|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
224269336|NCT02411149|DRUG|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
224269337|NCT04427033|DEVICE|Bone Conduction Implant|Bonebridge system BCI 602
223517515|NCT03987685|DRUG|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
223517516|NCT03822715|OTHER|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)
223517517|NCT03822715|DRUG|standard of care aromatase inhibitors|standard of care aromatase inhibitors
223517518|NCT01534221|DEVICE|Biomatrix drug eluting stent|Biomatrix drug eluting stent
224269338|NCT05999734|DRUG|Bupivacaine|Before skin incision, under complete aseptic precautions and sterilization, the patient will be placed in a lateral position. The spinous process of the fourth thoracic vertebra will be identified and marked. The ultrasound guided MTP block will be done by high frequency linear transducer will be placed in position just lateral to the spinous processes of thoracic vertebra target of the paravertebral space. A 50 mm 22-gauge echogenic needle will be inserted in an in plane technique from a caudal to a cephalad direction and will be advanced. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml normal saline will be injected. Once the needle tip has been confirmed and after careful aspiration to demonstrate the absence of air or blood, 0.5mL/kg 0.25% bupivacaine will be injected.
224269339|NCT01929681|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
224269340|NCT02218216|DEVICE|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
224269341|NCT06066671|OTHER|GCO (Experimental copaiba oil resin gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the GCO will receive the application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
224269342|NCT02860325|DEVICE|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
224269343|NCT02860325|DEVICE|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
224269344|NCT03111381|DRUG|Toradol|IV toradol
224269345|NCT05320146|OTHER|MRI-PDFF|Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a MRI-based diagnostic imaging biomarker of the liver.
224269346|NCT04499664|DEVICE|Monitoring of the autonomic nervous system|Monitoring of the autonomic nervous system using E-patch, LiDCO and Root-Massimo.
224269347|NCT03332732|DRUG|VNRX-5133|β-lactamase inhibitor
224269348|NCT03332732|DRUG|VNRX-5022|Approved β-lactam antibiotic
224269349|NCT03332732|DRUG|Metronidazole|Approved antibiotic and antiprotozoal medication
224269350|NCT03332732|DRUG|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
224269351|NCT03750448|OTHER|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
223517519|NCT02125422|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
224269352|NCT03750448|OTHER|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
224269353|NCT03750448|OTHER|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
224269354|NCT04962945|PROCEDURE|Oblique-axis approach group|The first two attempts via the oblique-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the long-axis approach.
224269355|NCT04962945|PROCEDURE|Long-axis approach group|The first two attempts via the long-axis approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the oblique-axis approach.
224269356|NCT03147768|DEVICE|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
224269357|NCT02068651|BEHAVIORAL|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
224287276|NCT03699254|DRUG|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
224287277|NCT00260273|BEHAVIORAL|Cognitive Behaviour Therapy|therapy
224287278|NCT04290494|DRUG|IV rtPA (intravenous recombinant plasminogen activator)|intravenous injection
223517520|NCT04952519|DRUG|Amantadine|Patients are treated with high doses of amantadine.
224287279|NCT00176358|DEVICE|PTCA and Stent Implantation|
224287280|NCT00176358|BEHAVIORAL|Exercise Training|
224287281|NCT03366194|DEVICE|SkinStylus Sterilock System|Microneedling device will be used to treat ventral hypertrophic scars.
224287282|NCT01090817|DRUG|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
224287283|NCT04184999|DRUG|dexamethasone intraocular suspension, 9%|single dose intracameral corticosteroid
224287284|NCT04184999|DRUG|Prednisolone Acetate 1% Oph Susp|topical ophthalmic steroid drop
224287285|NCT06396637|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride: 20mg/kg, qd
224287286|NCT00545688|DRUG|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
224287287|NCT00545688|DRUG|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
224287288|NCT00545688|DRUG|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
224287289|NCT02087891|BEHAVIORAL|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
224269358|NCT01582464|BEHAVIORAL|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), \& a demographic \& functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
224269359|NCT01739647|DRUG|AZD3293|Oral solution
224269360|NCT01739647|DRUG|Placebo|Oral solution
224269361|NCT00285961|DEVICE|Cork splint materials (instead of plaster splint)|
224269362|NCT00169364|DEVICE|positron emission tomography|
224269363|NCT02840669|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|
224269364|NCT02840669|PROCEDURE|Exercise-stress test|
224269365|NCT02840669|PROCEDURE|Echocardiography (ECHO)|
224269366|NCT02840669|PROCEDURE|Cardiac-related blood studies|
224269367|NCT03817151|PROCEDURE|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
224269368|NCT05316636|DEVICE|Vibrational forces|
224269369|NCT05316636|PROCEDURE|Orthodontic treatment with clear aligners|
224269370|NCT00794794|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
224269371|NCT00794794|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
224269372|NCT01989884|DRUG|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
224269373|NCT05895435|DEVICE|radiofrequancy|"* Power of device: 150 W~* Duration of the session: 40 minutes~* Frequency: 2 sessions per week for 8 week.~* Heating temperature: According to patient tolerance."
223517521|NCT03127163|DEVICE|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
224269374|NCT05895435|OTHER|aerobic exercise|The program include five minutes for warming-up in the form of range of motion and stretching exercises, thirty minutes of walking on treadmill with high speed (60-70% of maximum heart rate) and five minutes of cooling down (on treadmill with low speed and without inclination
224269375|NCT02452463|BIOLOGICAL|Durvalumab|Given IV
224269376|NCT02452463|DRUG|Nintedanib|Given PO
224269377|NCT02452463|OTHER|Placebo|Given PO
224269378|NCT02452463|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223517522|NCT06054308|OTHER|MSLN CART|Endoscopic ultrasound guided injection of mesothelin-targeted CAR-T cells
224269379|NCT00229944|DRUG|Azithromycin|
224269380|NCT03997799|PROCEDURE|uniportal lobectomy with complete lymphadenectomy|uniportal lobectomy with complete lymphadenectomy
224269381|NCT05740098|BEHAVIORAL|Best Practices|Five As plus referral to a quit line
224269382|NCT05740098|BEHAVIORAL|Financial Incentives|Financial incentives provided contingent on biochemically confirmed smoking abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks following quit date.
224269383|NCT05740098|DRUG|Nicotine Replacement Therapy|Nicotine patches and gum/lozenge provided together for dual therapy
224269384|NCT02421627|DEVICE|moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral). using mild-warm moxibustion，the surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
224269385|NCT02421627|DEVICE|Sham moxibustion|Acupoints: Tianshu (ST25，bilateral), Zusanli (ST36，bilateral); using sham mild-warm moxibustion，the surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint, once every other day, three times a week, a total of six weeks treatment. After the treatment, subjects were followed up at weeks 12, 18 and 24.
224269386|NCT01942616|OTHER|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
224269387|NCT01942616|OTHER|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
224269388|NCT01942616|OTHER|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
224269389|NCT04656938|BEHAVIORAL|Pre-frail intervention|Pre-frail partiipants will undergo 4 month intervention consisted of group-based physical exercise and nutritional classes.
224269390|NCT01073631|DRUG|voriconazole tablet|200 mg PO bid (orally, twice a day)
224269391|NCT04949386|DRUG|S-1226 (8%)|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
224269392|NCT04949386|OTHER|Placebo|Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
224269393|NCT02171988|DRUG|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
224269394|NCT02171988|DRUG|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
224269395|NCT02171988|DRUG|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
223893402|NCT05391971|DRUG|Bupivacaine|At the C6 level, a total of 7cc of 0.5% bupivacaine will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of 0.5% bupivacaine.
223893403|NCT05391971|DRUG|Saline|At the C6 level, a total of 7cc of saline control will be injected slowly at this level, with negative aspiration every 2cc. The same procedure will be repeated at the C4 level directed towards the upper cervical ganglion ventral to the longus colli muscle with a total of 3cc of saline control.
223517523|NCT05053685|DIAGNOSTIC_TEST|Measurement of Urine and plasma metanephrines|Measurement of Urine and plasma metanephrines
223517524|NCT02108808|DRUG|Ticagrelor|
223517525|NCT02108808|DRUG|Prasugrel or Clopidogrel|
223517526|NCT04166747|OTHER|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
223517527|NCT04586751|OTHER|Pecs block|Pecs block under real-time ultrasound guidance after anesthesia induction will be performed.
223517528|NCT04586751|OTHER|no Pecs block|no regional block will be performed in this arm
223517529|NCT04949087|PROCEDURE|Glenohumeral Injection|Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
223517530|NCT04787315|DEVICE|Conventional intensive functional rehabilitation + Workstations|Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
223517531|NCT04787315|BEHAVIORAL|Conventional intensive functional rehabilitation|Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
223517532|NCT03682367|DRUG|Gabapentin|Use of Gabapentin peri- and post-operatively.
223517533|NCT03682367|DRUG|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
223517534|NCT02048007|DRUG|Azithromycin|Biannual mass oral azithromycin to children
223517535|NCT02048007|DRUG|Placebo|Biannual mass oral placebo to children
223517536|NCT06044623|DRUG|CDK 4/6 inhibitors|Either Palbociclib, Ribociclib or Abemaciclib
223517537|NCT06044623|DRUG|Endocrine therapy|Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
223517538|NCT02998307|PROCEDURE|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
223517539|NCT04595292|OTHER|older adults, assessment|Dubousset Function Test, 3-m backwards walk test, timed up and go test,Tinnetti Balance and Gait Test, Berg BalanceTest, Functional Reach Test
223517540|NCT03295344|OTHER|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
223517541|NCT03295344|OTHER|Tissue Doppler|Determine the threshold value for diaphragm mobility
223517542|NCT05424588|DIAGNOSTIC_TEST|clinical evaluation, bioelectrical impedance analysis (BIA), cardiopulmonary exercise testing (CPET) and venipuncture for blood samples collection|Total body dual-energy X-ray absorptiometry (DEXA) was taken BN and AN to measure total (FM) and segmental fat (truncal FM), visceral adipose tissue (VAT) and lean mass (LM). Tetra-polar dual frequency BIA (InBody 120; Cerritos, USA) was used BPP, BN and AN to measure weight and to estimate FM, FFM, and MM. Impedance measurements were performed. CPET was carried out on a cycle ergometer with clip-on pedals. Blood samples were collected in the morning BPP, BN, AN. Biochemical parameters considered in this study were: ALT, AST, creatinine, 25-hydroxy vitamin D, total cholesterol, HDL, LDL, triglycerides concentrations. We isolated CPCs from heparinized blood, as previously reported (14). After the collection of peripheral blood mononuclear cells (PBMCs) by a gradient centrifugation. (15). Differentiating Human Skeletal muscle cells were cultured with or without pooled sera of participants at 5% final concentration. 146b and 34a miRNAs were extracted from PBMCs.
223517543|NCT01582581|BEHAVIORAL|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
223517544|NCT01582581|BEHAVIORAL|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
223517545|NCT04840511|DRUG|lidocaine group|lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)
224269396|NCT02171988|DRUG|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
223517546|NCT04840511|DRUG|control group|normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
223517547|NCT03395093|DRUG|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
223517548|NCT03395093|DRUG|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
223517549|NCT03395093|DRUG|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
223517550|NCT03395093|DEVICE|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
223517551|NCT06288893|DRUG|SHEN211 Tablets|SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.
223517552|NCT06288893|PROCEDURE|Placebo for SHEN211 Tablets|Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5
223517553|NCT00129974|DRUG|pemetrexed and gemcitabine|
223517554|NCT05848570|OTHER|Keeping it LITE|observational cohort only
223517555|NCT00266981|DEVICE|APOS - exercise component|
223517556|NCT01494857|DRUG|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
224269397|NCT01260623|DRUG|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
224269398|NCT02278302|DRUG|Aggrenox®|
224269399|NCT02278302|DRUG|Placebo|
224269400|NCT02278302|OTHER|Ethanol|
224269401|NCT04363359|BIOLOGICAL|0.5ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
224269402|NCT04363359|BIOLOGICAL|0.25ml Quadrivalent influenza vaccine|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2, B/Victoria and B/Yamagata strains
224269403|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/V)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Victoria strains
223517557|NCT03591536|OTHER|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
223517558|NCT03591536|OTHER|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
223517559|NCT04734392|PROCEDURE|TAVR|TAVR implantation in cusp overlay technique
223517560|NCT04633720|OTHER|Changes in positive end-expiratory pressure and tidal volume|"When the patient is in the supine position 10 minutes after induction of anesthesia, the following 4 mechanical ventilator settings are applied to the patients in order.~Positive end-expiratory pressure 8 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 5 ml/kg Positive end-expiratory pressure 10 cmH2O, tidal volume 8 ml/kg Positive end-expiratory pressure 12 cmH2O, tidal volume 5 ml/kg"
223517561|NCT00414609|DRUG|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
223517562|NCT00414609|DRUG|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
223517563|NCT01665794|DRUG|Pomalidomide|Pomalidomide taken orally at assigned dose.
223517564|NCT01665794|DRUG|Carfilzomib|Carfilzomib given by intravenous (IV) infusion at assigned dose.
223517565|NCT01665794|DRUG|dexamethasone|Dexamethasone taken orally of given by IV infusion.
224269404|NCT04363359|BIOLOGICAL|0.25ml Trivalent influenza vaccine(B/Y)|The inactivated split virion vaccines contained 7.5 μg of each hemagglutinin antigen of influenza A/H1N1, A/H3N2 and B/Yamagata strains
223517566|NCT01665794|DRUG|Daratumumab|Daratumumab given by intravenous (IV) infusion at assigned dose.
223517567|NCT00170820|DRUG|Everolimus|
224269405|NCT04437303|DRUG|Continuation of oral anticoagulants|Oral anticoagulant treatment will not be interrupted before the procedure.
224269406|NCT04437303|DRUG|Interruption of oral anticoagulants|"Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician."
223517568|NCT00320320|DRUG|Irinotecan|
223517569|NCT03199534|DRUG|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
223517570|NCT03199534|DRUG|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
223517571|NCT03199534|DRUG|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
224269407|NCT02105220|OTHER|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
224269408|NCT01528735|DRUG|BI 207127 NA|one fix dose
223517572|NCT03470883|OTHER|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (\> 12 months)
223517573|NCT03680521|DRUG|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks in segments 1 and 2.
223517574|NCT03680521|DRUG|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks in segment 2.
223517575|NCT02050399|OTHER|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
223517576|NCT00812539|OTHER|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
223517577|NCT00812539|OTHER|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
223517578|NCT04325607|PROCEDURE|Excision of HS followed by NPWTi|The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
223517579|NCT04325607|PROCEDURE|Excision of HS followed by NPWT|The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
223517580|NCT05175729|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters,corneal topography
224269409|NCT01528735|DRUG|peginterferon|per package insert
224269410|NCT01528735|DRUG|Ribavirin|per weight BID
224269411|NCT01528735|DRUG|Ribavirin|per weight BID
223517581|NCT02534155|DEVICE|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
224269412|NCT01528735|DRUG|BI 207127 NA|one fix dose
224269413|NCT01528735|DRUG|BI 201335 NA|high dose
224269414|NCT01528735|DRUG|BI 201335 NA|low dose
224269415|NCT01528735|DRUG|peginterferon|per package insert
224269416|NCT03354780|OTHER|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
224269417|NCT03354780|OTHER|Survey on first pregnancy|rate of miscarriage was noted
224269418|NCT03112031|DRUG|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
224269419|NCT03112031|DRUG|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
223517582|NCT02534155|PROCEDURE|Mitral valve Surgery|Repair or replace mitral valve
223517583|NCT03194932|DRUG|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
223517584|NCT03194932|DRUG|Cytarabine|Given intravenously (IV) or intrathecally (IT).
223517585|NCT03194932|DRUG|Idarubicin|Given IV.
223893404|NCT06302010|BEHAVIORAL|Stress Ball Intervention|The stress ball has a soft plastic or silicone structure that can be held comfortably. Each ball is approximately 6 cm in diameter, in different colors, and is a soft toy that can be squeezed and manipulated with fingers to relieve stress and muscle tension and exercise the muscles (Apaydin Cirik et al., 2023). Squeezing a stress ball is a distraction and relaxation method. It is thought that squeezing a stress ball may be advantageous for reducing anxiety, considering its reliability, easy accessibility, effectiveness, low cost, sustainability, non-pharmacological and non-invasive properties.
223893405|NCT03836248|OTHER|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
224269420|NCT03112031|DRUG|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
224269421|NCT03709953|DRUG|Apatinib|500 mg，po，QD； 28 days every cycle
224269422|NCT02469480|DRUG|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
223517586|NCT03194932|DRUG|Intrathecal Triple Therapy|Given IT.
223517587|NCT03194932|DRUG|Azacitidine|Given IV.
223517588|NCT05207839|DIETARY_SUPPLEMENT|Milk powder|one sachet per day dissolved in 200 ml of water
223517589|NCT05770180|BIOLOGICAL|Recombinant COVID-19 variant vaccine (Sf9 cell)|WSK-V102
223517590|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (CHO cell)|control 1
223517591|NCT05770180|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cell)|control 2
223517592|NCT03177798|DRUG|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
224269423|NCT02469480|DRUG|Ferro sanol|200 mg ferro sanol per day over 12 weeks
224269424|NCT02161705|DRUG|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
224269425|NCT02161705|DRUG|Saline|Up to 0.8 mL/kg of normal saline administered
224269426|NCT01426854|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
224269427|NCT01426854|OTHER|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
224269428|NCT01971554|DRUG|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
224269429|NCT01971554|DRUG|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
224269430|NCT00438750|OTHER|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
224269431|NCT00438750|OTHER|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
224269432|NCT03803267|OTHER|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38\_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
224269433|NCT03803267|OTHER|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
224269434|NCT03803267|DRUG|Propofol|Propofol (2 mg/kg)
224269435|NCT03803267|DRUG|Fentanyl NCS|Fentanyl (1µg/Kg)
224269436|NCT03803267|DRUG|Atracurium Injectable Product|atracurium (0.5mg/kg)
224269437|NCT03803267|OTHER|Endotracheal intubation|endotracheal intubation
224269438|NCT03803267|DRUG|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
224269439|NCT03803267|DRUG|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
224269440|NCT04627857|DEVICE|Manual toothbrush|Patients in group 1 (''reference procedure'') receive a manual toothbrush with a small compact head to facilitate access to the posterior teeth and soft bristles.
224269441|NCT04627857|DEVICE|Manual toothbrush and water flosser (Philips Sonicare AirFloss)|\- Group 2 patients receive a manual toothbrush with a small, compact head for easy access to the posterior teeth and soft bristles. They also receive a Philips brand interdental microjet (Philips Sonicare AirFloss Ultra) which must be filled with water.
224269442|NCT04627857|DEVICE|Sonic toothbrush|\- Group 3 patients receive a rechargeable sonic electric toothbrush from Philipps with an integrated excess pressure sensor and a compact toothbrush head for easy access to the posterior teeth.
224269443|NCT04627857|DEVICE|Sonic toothbrush (Philips Sonicare) and water flosser (Philips Sonicare AirFloss)|\- Group 4 patients receive a Philips Sonicare ProtectiveClean rechargeable sonic electric toothbrush with an integrated excess pressure sensor and 2 compact toothbrush heads for easy access to the posterior teeth. They also receive an interdental microjet from Philips (Philips Sonicare AirFloss Ultra) which must be filled with water.
224269444|NCT03505151|DRUG|BI 409306 (C-13/N-15)|i.v solution
224269445|NCT03505151|DRUG|BI 409306|Film-coated tablet
224269446|NCT02610647|DRUG|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
224269447|NCT02610647|OTHER|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
224269448|NCT02610647|OTHER|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
224269449|NCT02610647|OTHER|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
224269450|NCT00147134|PROCEDURE|open colectomy|Procedure/Surgery: open colectomy
224269451|NCT00147134|PROCEDURE|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
224269452|NCT01942135|DRUG|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
224269453|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
224269454|NCT01942135|DRUG|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
224269455|NCT01942135|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
224269456|NCT02272335|BEHAVIORAL|Group Sessions|"10 weekly sessions:~* CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~* CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
224269457|NCT06563063|DRUG|Flumazenil|The dose determination for flumazenil followed a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there was an improvement in respiratory distress, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9.
224269458|NCT00950300|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
224269459|NCT00950300|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
224269460|NCT00950300|DRUG|Docetaxel|Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
224269461|NCT00950300|DRUG|Epirubicin|Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
224269462|NCT00950300|DRUG|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
224269463|NCT00950300|DRUG|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
224269464|NCT05008380|PROCEDURE|prone positioning|3-6 hours of prone-positioning twice a day
224269465|NCT01897324|DRUG|Growth hormone (Norditropin, Novo nordisk)|
224269466|NCT01427036|PROCEDURE|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
224269467|NCT01427036|PROCEDURE|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
224269468|NCT00765635|DRUG|drops intilation (Taponoto ® )|four drops, unique doses
224269469|NCT00765635|DRUG|drops intilation (Otocerum®)|four drops, unique doses
224269470|NCT00765635|DRUG|drops intilation (Placebo)|Placebo
224269471|NCT01717040|DRUG|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
224269472|NCT01717040|DRUG|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
223517593|NCT03177798|DRUG|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
223517594|NCT05600751|PROCEDURE|Radiosurgery of ganglion stellatum|Patients will undergo radiosurgery of ganglion stellatum (left one or both)
224269473|NCT00494013|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
223517595|NCT03662529|BEHAVIORAL|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
223517596|NCT03662529|BEHAVIORAL|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
223517597|NCT03713411|PROCEDURE|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
223517598|NCT00398879|DRUG|Perifosine|Perifosine 50 mg/d qd
223517599|NCT00398879|DRUG|Capecitabine|Capecitabine 825 mg/m\^2 BID days 1 - 14 q 3 weeks
223517600|NCT00398879|OTHER|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
223517601|NCT01720836|BIOLOGICAL|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
223517602|NCT06108609|OTHER|Administration of the French version of the COSI and IOI-HA questionnaires|"Inclusion (D0):~* Audiometry (as part of treatment)~* Clinical evaluation (as part of treatment)~* Passing the French version of the COSI and IOI-HA questionnaires Visit 1 (D0 +3±1 week): only for 35 patients Second administration of the French version of the COSI and IOI-HA questionnaires either by telephone, or during a second consultation or hospitalization, if this occurs within a compatible time frame."
223517603|NCT02249520|OTHER|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
223517604|NCT02249520|OTHER|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
224269474|NCT00494013|DRUG|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
223517605|NCT02249520|OTHER|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
224269475|NCT05642949|DRUG|MHB036C|MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
224269476|NCT04544033|DIAGNOSTIC_TEST|interleuken 6 level measurment|Detection of IL6 level using ELISA technique.
224269477|NCT04544033|DIAGNOSTIC_TEST|Interleukin-6 Gene-174C detection|The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
224269478|NCT04174053|DEVICE|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
224269479|NCT06677684|DIETARY_SUPPLEMENT|Vitamin A|the intervention group received standard antibiotics plus adjunctive vitamin A supplementation (25,000 IU daily for two days)
224269480|NCT05913115|DRUG|FPA144|FPA144 will be administered intravenously Q2W.
224269481|NCT05235022|OTHER|Questionnaires|"The participants included in the study will have to answer:~1. a questionnaire created specifically for the study concerning the possible difficulties encountered during their return to work,~2. the Multidimensional Fatigue Inventory (MFI), a questionnaire assessing fatigue through 5 dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation).~These 2 questionnaires will be filled during a 30-minute face-to-face or phone interview."
224269482|NCT05832424|BEHAVIORAL|UPLIFT program|The telehealth group intervention will be delivered using Zoom. Participants will attend facilitated weekly, 1-hour sessions for 8 weeks. The sessions follow a standardized, manualized program based on cognitive-behavioral therapy (CBT) and mindfulness-based practice (MBP)-therapies widely accepted and used by mental health providers for the treatment and prevention of depression and substance use. The study team have tailored this intervention for use in a pregnant population.
224269483|NCT04203823|DEVICE|Cloud-based Digital Twin and Meal Prediction algorithms|Test safety and effectiveness of the Digital Twin and Meal Prediction algorithms
224269484|NCT01682421|DRUG|Weak steroid (Flurolon, Allergan)|
224269485|NCT01682421|DRUG|Potent steroid (Maxidex, Alcon)|
224269486|NCT02609191|DEVICE|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
224269487|NCT02609191|DEVICE|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
224269488|NCT02609191|DEVICE|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
224269489|NCT01499043|DRUG|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
224269490|NCT00538863|DRUG|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
224269491|NCT05724394|OTHER|Culturally Adapted Getting Better Bite By Bite (Ca-GBBB) intervention|The Ca-GBBB strongly focuses on enhancing participant's motivation and belief in their ability to change. The intervention will be comprised of 16-week training program delivered over four months.
224269492|NCT04917393|DEVICE|iRF System Multi-organ Denervation|If assigned to the treatment arm, subjects will remain blinded and recieve angiography prior to catheter based RF ablation to circumferentially disrupt the sympathetic nerves surrounding the target arteries
224269493|NCT04917393|OTHER|Control Procedure|If assigned to the control group, subjects will remain blinded and recieve angiography of the target arteries prior to sheath removal.
224269494|NCT06435793|PROCEDURE|MEP measurement - Surface EMG - IOPI|"Participants will undergo serial expiratory maneuvers using variously-sized circular mouthpieces and a reference ovoid-shaped mouthpiece.~At each maneuver, the maximal expiratory mouth pressure at total lung capacity will be measured, alongside with the degree of neuromuscular activation of the internal oblique and transverse abdominal muscles using surface electromyography.~The Orbicularis Oris strength will also be measured using the Iowa Oral Performance Instrument."
224269495|NCT02070783|DRUG|ARA290|
224269496|NCT02070783|DRUG|Placebo|
224269497|NCT01394094|BEHAVIORAL|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
224269498|NCT04071613|DRUG|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
224269499|NCT04071613|DRUG|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
224269500|NCT04237220|DIAGNOSTIC_TEST|stomach biopsies|To determine the diagnostic performance in the detection of Helicobacter pylori in biopsies taken only from the gastric antrum for the determination of the positive predictive value, the negative predictive value, and sensitivity and specificity.
223517606|NCT05599165|OTHER|signal processing on consonant recognition|Consonant recognition will be measured in noise without any signal processing.
224269501|NCT01316536|OTHER|provide headphones with music playing|Participants will be provided with music through headphones
224269502|NCT01316536|OTHER|Sounds|recorded ICU sounds will be provided to participants through headphones
224287290|NCT02087891|BEHAVIORAL|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
224287291|NCT02087891|BEHAVIORAL|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
224287292|NCT00707421|DRUG|ketorolac acetate|
224287293|NCT00707421|DRUG|fluorometholone|
224287294|NCT00707421|DRUG|artificial lacrimal tears|
224287295|NCT02722252|DEVICE|Embryoscope|
224287296|NCT02722252|DEVICE|Embryo culture system without incorporated camera|
224287297|NCT03123783|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
224287298|NCT03123783|DRUG|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
224287299|NCT00000239|DRUG|Buprenorphine|
224287300|NCT00958802|OTHER|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
223517607|NCT06638255|OTHER|Sequence A involves administering Low PEEP for 12 hours, followed by High PEEP for 12 hours.|"Patients will first receive the Low PEEP protocol for 12 hours, followed by the High PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies.~Description: Patients will first receive the High or LOW PEEP protocol for 12 hours, followed by the Low or HIGH PEEP protocol for 12 hours. This sequence is randomized and part of a crossover trial design to assess the effects of both PEEP strategies."
223517608|NCT06638255|OTHER|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.|Sequence B involves setting High PEEP for 12 hours, followed by Low PEEP for 12 hours.
223517609|NCT06637280|DEVICE|High - flow nasal cannula|"High flow nasal cannula (HFNC), a device first introduced in neonates and pediatric care, is currently used in a wide range of indications in adult respiratory and critical care medicine (5-7). It is a relatively new method in bronchoscopy with several notable theoretical advantages over low flow oxygen via conventional nasal cannula (CNC):~* High flow up to 60 liters per minute ensures a more stable FiO2 and better matches the increased patient's inspiratory flow~* High flow generates a small positive expiratory airway pressure (up to 5 cm H2O) which could stabilize the upper airways during sedation and have a beneficial effect in the lower airways~* High flow reduces dead space in the upper airways and increases alveolar ventilation."
223893406|NCT03836248|OTHER|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
223893407|NCT03836248|OTHER|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
223893408|NCT05280652|BEHAVIORAL|Nutritional and culinary intervention|Participants will attend 6 two-hours nutritional-culinary workshops between May 2022 and February 2023. All of the workshops will be held in a kitchen, and will be given in groups of 2 dyads or parents according to the intervention group. In addition, during the intervention families will be given access to a web page with nutrition and culinary education materials (infographics, videos).
223893409|NCT05280652|BEHAVIORAL|Nutritional intervention|Participants will attend 6 1-hour nutritional workshops between May 2022 and February 2023. The workshops will be held in person, and will be given in groups of 10-12 families. In addition, during the intervention families will be given access to a web page with nutrition education materials (infographics, videos).
223893410|NCT06223035|OTHER|Exercise|Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.
223893411|NCT05435495|PROCEDURE|Single-photon emission computed tomography|Imaging procedure
223893412|NCT05435495|PROCEDURE|Blood Draw|Blood draw for future research tests (45-60 mL).
223893413|NCT05435495|PROCEDURE|Tumor Biopsy|Guided biopsy of lesion
223893414|NCT05051124|BEHAVIORAL|Peer Delivery of Medications|The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities
224287301|NCT00958802|OTHER|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
224287302|NCT00813826|DRUG|SLC022|SLC022 150 mg capsule, 900mg daily dose
224287303|NCT00813826|DRUG|Placebo|Placebo capsule, TID
224287304|NCT05655247|PROCEDURE|Split-thickness non-advanced tunnel (Zabalegui et al. 1999)|A split-thickness non-advanced tunnel will be performed according to Zabalegui et al. (1999).
224287305|NCT05655247|PROCEDURE|Full-thickness coronally-advanced tunnel (Aroca et al. 2010)|A full-thickness coronally-advanced tunnel (Modified Coronally Advanced Tunnel - MCAT) will be performed according to Aroca et al. (2010).
224287306|NCT02664987|OTHER|Patients receiving cancer pain treatment|
224287307|NCT03643926|PROCEDURE|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
224287308|NCT03643926|PROCEDURE|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
224287309|NCT04850248|OTHER|no intervention, this is an observational study|no intervention, this is an observational study
224287310|NCT04678063|OTHER|Exposure to Placebo|Patients are exposed to placebo in the EEC
224287311|NCT04678063|OTHER|Exposure to dose A and dose B of cat allergen|Patients are exposed to dose A and B for successive exposures in the EEC
224287312|NCT04678063|OTHER|Exposure to a single dose of cat allergen|Patients are exposed to a single dose of cat allergen in the EEC according to the dose selected to achieve the main objective (dose A or B)
224287313|NCT06390566|OTHER|calpaïnopathies|Identify and quantify the loss of strength of upper and lower limb muscle groups in patients with LGMD2A
224287314|NCT01182662|OTHER|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
224287315|NCT01182662|OTHER|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
224287316|NCT04299217|DIETARY_SUPPLEMENT|Zynamite®|Zynamite® is a novel mango (Mangifera indica) leaf extract standardized to contain 60% of the polyphenol mangiferin. Zynamite® is classified as a food or food supplement and is available for purchase within the EU. Zynamite® is not associated with any significant deleterious side effects.
224287317|NCT04299217|OTHER|Placebo|Placebo comparator (carrier)
224287318|NCT02681484|BEHAVIORAL|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
223517610|NCT06637280|DEVICE|Standard nasal cannula|Standard method for supplementing oxygen during EBUS bronchoscopy
223719009|NCT04659161|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
223719010|NCT04659161|DRUG|Placebo|Placebo Capsules twice a day (BID)
224269503|NCT01301937|DRUG|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
224269504|NCT06065839|OTHER|non-nutritive sucking 5 minutes|Give pacifier non-nutritive sucking for 5 minutes before feeding
224269505|NCT06065839|OTHER|non-nutritive sucking 15 minutes|Give pacifier non-nutritive sucking for 15 minutes before feeding
224269506|NCT02456285|PROCEDURE|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
224269507|NCT02456285|PROCEDURE|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
224269508|NCT02456285|PROCEDURE|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
224269509|NCT02456285|PROCEDURE|No surgery|Patients who have no surgery.
224269510|NCT00980941|DIETARY_SUPPLEMENT|soup with or without starch|
224269511|NCT01897207|BIOLOGICAL|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
224269512|NCT06559293|DIAGNOSTIC_TEST|laryngeal ultrasound|laryngeal ultrasound with linear probe will be positioned on the patient's neck. A list of anatomical sites to be visualised will be determined beforehand. Once all the pre-determined structures have been visualised, in an axial and sagittal plane, we will note the position of the ultrasound probe and its orientation. This will enable us to determine the ideal position of the ultrasound probe for obtaining all the elements of interest on a section that will be called the reference section.
224269513|NCT03129841|BEHAVIORAL|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
224269514|NCT03129841|BEHAVIORAL|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
224269515|NCT02901028|OTHER|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
224269516|NCT02901028|OTHER|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
224269517|NCT00898664|GENETIC|cytogenetic analysis|
224269518|NCT00898664|GENETIC|gene expression analysis|
224269519|NCT00898664|GENETIC|mutation analysis|
224269520|NCT00898664|GENETIC|polymerase chain reaction|
224269521|NCT00898664|OTHER|immunohistochemistry staining method|
224269522|NCT00898664|OTHER|laboratory biomarker analysis|
224269523|NCT03226613|PROCEDURE|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
224269524|NCT03226613|PROCEDURE|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
224269525|NCT03226613|PROCEDURE|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
224269526|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with explainable AI|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with explainable AI.
224269527|NCT06617468|DIAGNOSTIC_TEST|computer-aided diagnosis with deep learning|Perform a same test to estimate the pathologic diagnosis on 200 NBI still images with computer-aided diagnosis with deep Iearning.
224269528|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
224269529|NCT01023334|PROCEDURE|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
224269530|NCT04345133|DEVICE|Dental Implants Insertion Drilling Sequence|Drilling sequence protocol to insert immediate Dental Implants at the Maxilla.
223719011|NCT03155568|PROCEDURE|sciatic nerve block|sciatic nerve block at popliteal fossa
224269531|NCT04599751|DEVICE|Hair removal treatment|Axilla and bikini line hair removal treatments using the Trio Laser Module (Alma Lasers).
224269532|NCT01604239|DRUG|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
224269533|NCT00582244|BEHAVIORAL|CBT and relaxation|Group A: CBT and relaxation.
224269534|NCT00582244|BEHAVIORAL|Physical activity|Group B: Physical exercise program.
224269535|NCT00582244|BEHAVIORAL|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
224269536|NCT00582244|OTHER|Control group|Waiting list control group
224269537|NCT02818751|DRUG|Escitalopram|Patients being randomized to receive escitalopram.
224269538|NCT02818751|OTHER|Placebo|Patients being randomized to receive placebo.
224269539|NCT06623162|DRUG|gemcitabine + cisplatine|4 cycles
224269540|NCT06623227|DIETARY_SUPPLEMENT|Placebo|Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
224269541|NCT06623227|DIETARY_SUPPLEMENT|Vitamin E and C|Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
224269542|NCT06098313|DRUG|Cyclophosphamide|-Cyclophosphamide 50 mg/kg/day i.v. daily on days 3 and 4 (for 2 days)
224269543|NCT01791686|DRUG|CDX-1135|
223517611|NCT06642194|BEHAVIORAL|Education on sunnah of sleeping|The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
223719012|NCT03155568|PROCEDURE|ankle block|block of major nerves supplying the foot at the level of the ankle
224269544|NCT05011695|OTHER|physiotherapy|The 1st group will be given ESWT therapy, the 2nd group will be given transverse friction massage, and the 3rd group will be given exercises that are used in the treatment of plantar fasciitis and have proven effectiveness
224269545|NCT01881165|DRUG|Cranberry|
224269546|NCT01881165|DRUG|Placebo|
224269547|NCT03299829|DRUG|Trientine|Trientine is a chelating agent for removing the copper from the body
224269548|NCT02517554|BEHAVIORAL|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
224269549|NCT02517554|BEHAVIORAL|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
224269550|NCT02517554|BEHAVIORAL|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
224269551|NCT01152645|DRUG|ARQ 197|Orally twice daily administration of ARQ 197
224269552|NCT01806272|DRUG|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
224269553|NCT01806272|DRUG|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
224269554|NCT02191059|DRUG|Icotinib|
224269555|NCT02191059|DRUG|Docetaxel|
224269556|NCT00000159|DRUG|Sorbinil|
224269557|NCT05748561|DRUG|Recombinant human erythropoietin 4,000 UI and 2,000 UI|Intravenous recombinant human erythropoietin (10,000 IU every 24 hours for 5 days)
224269558|NCT05748561|DRUG|Methylprednisolone succinate 500 mg|Intravenous Methylprednisolone succinate (1 g daily for 5 days)
224269559|NCT05608239|DEVICE|Sculptra aesthetic|The goal of the study is to evaluate the volumizing and bio-stimulatory effects of sculptra injections in the temples with total volume of the diluted product as 9 ml (8 ml of sterile water and 1 ml of Lidocaine).
224269560|NCT02937259|OTHER|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
224269561|NCT05497986|DEVICE|High flow nasal cannula|HFNC with the maximum tolerated flow (up to 60 L/min). Titration of supplemental oxygen to a SpO2 between 88 - 92%.
224269562|NCT05497986|DEVICE|Conventional low flow oxygenation|Conventional oxygenation through nasal prongs or a facemask, with supplemental oxygen titrated to a SpO2 between 88 - 92%.
224269563|NCT06502301|OTHER|Cross-sectional study|This is not intervention study.
224269564|NCT02043522|DRUG|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
224269565|NCT05064917|DIAGNOSTIC_TEST|Blood draw|The burden for child/parents in this study is low as it is limited to a single blood draw, which is already necessary for usual diagnostic care in about 70% of the children
224269566|NCT01243983|DRUG|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~* Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~* Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
224269567|NCT02716311|DRUG|Afatinib|
224269568|NCT02716311|DRUG|Cetuximab|
224269569|NCT03193021|DEVICE|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
224269570|NCT03193021|OTHER|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
224269571|NCT03815903|DRUG|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
224269572|NCT03815903|COMBINATION_PRODUCT|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
224269573|NCT02286466|BEHAVIORAL|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
224269574|NCT02286466|BEHAVIORAL|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
224269575|NCT01276496|DRUG|Cilengitide|Given IV
224269576|NCT01276496|OTHER|Laboratory Biomarker Analysis|Correlative studies
224269577|NCT01276496|DRUG|Paclitaxel|Given IV
224269578|NCT01276496|OTHER|Pharmacological Study|Correlative studies
224269579|NCT03680144|PROCEDURE|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
224269580|NCT03680144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
224269581|NCT05644392|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
224269582|NCT05644392|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
224269583|NCT04681391|DEVICE|transCranial direct current stimulation|In the present study, we applied DC Brain Stimulator Plus to stimulate right temporoparietal junction (rTPJ). The target electrode was placed over the location of rTPJ; on the other hand, the return electrode was placed over the left supraorbital area. That is, during anodal tDCS, the anode was placed over CP6, and the cathode was placed over left supraorbital area; conversely, during cathodal tDCS, the cathode was placed over CP6, and the anode was placed over left supraorbital area. For the active stimulation, which are anodal and cathodal tDCS, a constant current of 1 mA was delivered through 35 cm2 electrode for 20 minutes with fade-in and fade-out of 10 seconds, producing a current density of 0.029 mA/cm2. On the other hand, same fade-in, fade-out, and current density were applied for the sham stimulation, but the duration of current-delivering only last 35 seconds. Therefore, participants could feel the skin sensation but did not have the after-effects of tDCS.
224269584|NCT05244863|OTHER|Test|Measurements
224269585|NCT00835081|DRUG|Cefadroxil 500 mg Capsules|1 x 500 mg
224269586|NCT00835081|DRUG|DURICEF® capsules 500 mg|1 x 500 mg
224269587|NCT00421304|BIOLOGICAL|Motavizumab|A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
224269588|NCT00421304|OTHER|Placebo|A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
224269589|NCT02281253|DIETARY_SUPPLEMENT|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
224269590|NCT02281253|DIETARY_SUPPLEMENT|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
224269591|NCT05870332|DEVICE|GI Genius (GIG)|"GIG is an artificial intelligence unit that assists human colonoscopist in real-time to detect polyps during colonoscopy.~Four months collection period prior to activating GIG, then four months with GIG, and Four months afterwards without GIG"
224269592|NCT05014958|OTHER|Exercise training on whole body vibration|Participants will be included in the 6-week exercise training on whole body vibration
224269593|NCT03196284|DRUG|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
224269594|NCT03196284|DRUG|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
224269595|NCT03911635|PROCEDURE|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
224269596|NCT01139762|DRUG|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
224269597|NCT01139762|DRUG|Placebo|Administered orally, once daily for 26 weeks
224269598|NCT01139762|DRUG|Finasteride|5mg administered orally, once daily for 26 weeks
224269599|NCT05244876|BEHAVIORAL|Back school|Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
224269600|NCT00621660|PROCEDURE|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
224269601|NCT00621660|PROCEDURE|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
224269602|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
224269603|NCT03895879|DRUG|Tocilizumab|Tocilizumab sc (162 mg) once every week
223517612|NCT06639152|DRUG|oil-based contrast medium|In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.
223517613|NCT06639152|DRUG|water-based contrast medium|In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.
223719013|NCT03155568|DRUG|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
224269604|NCT02280707|OTHER|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
224269605|NCT00501735|DRUG|Forodesine 200 mg|2 x 100mg tablets once daily
224269606|NCT01912807|DRUG|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
224269607|NCT01912807|DRUG|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
224269608|NCT04334863|DRUG|WP1066|"WP1066 is an analogue of caffeic acid that is a potent inhibitor of p-STAT3.~It will be taken by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
224269609|NCT04190160|DRUG|IDegLira|A single administration of IDegLira, dose depending on glicaemic control, in place of any pre-existing hipoglycaemic therapeutic scheme
224269610|NCT04750239|DRUG|Nivatrotamab|Anti GD2×CD3 monoclonal bi-specific antibody
224269611|NCT03510260|OTHER|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
224269612|NCT03510260|OTHER|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
224269613|NCT03510260|OTHER|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
224269614|NCT04806035|BIOLOGICAL|TG-1801|It is a bispecific, first-in-class, CD47 and CD19 antibody
224269615|NCT04806035|BIOLOGICAL|Ublituximab|recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks
224269616|NCT02031250|DRUG|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
224269617|NCT02031250|DRUG|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
224269618|NCT02031250|RADIATION|IMRT (Intensity-Modulated Radiation Therapy)|
224269619|NCT02031250|RADIATION|Boost Radiation to Hypoperfused Volumes|
224269620|NCT00919711|DRUG|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
224269621|NCT00919711|DRUG|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
224269622|NCT02489864|DRUG|Terlipressin|
224269623|NCT00903877|DRUG|T3|Patients receive T3 in a dose of 25mcg and 50mcg
224269624|NCT04667390|OTHER|total knee arthroplasty|total knee arthroplasty
224269625|NCT02965261|DRUG|Torrent's Fluoxetine Tablets|
224269626|NCT02965261|DRUG|Warner Chilcott LLC Sarafem Tablets|
224269627|NCT03018925|DRUG|Golimumab|The treatment followed was an induction of 200 mg of Golimumab at week 0, and 100 mg at week 2. Under 70 Kg, the follow-up treatment dose would be 50 mg/month, and 100 mg/month in patients above 70 Kg asindicated in standard clinical practice.
224269628|NCT01262235|DRUG|TKM-080301|Repeat dose IV infusion.
224269629|NCT02756858|DRUG|ANAVEX2-73|
224269630|NCT01137864|OTHER|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
224269631|NCT00922896|DRUG|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"* Erlotinib 100 mg po q d daily AND~* Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~* Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
224269632|NCT00107263|DRUG|letrozole|
224269633|NCT00107263|DRUG|zoledronic acid|
224269634|NCT00163345|DRUG|Ciclesonide|
224269635|NCT02409797|OTHER|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
224269636|NCT00087529|DRUG|placebo|Intravenous repeating dose
224269637|NCT00087529|DRUG|rituximab|Intravenous repeating dose
223517614|NCT05888922|DRUG|Minoxidil Tablets|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
224269638|NCT03503435|BEHAVIORAL|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
224269639|NCT00163319|DRUG|Ciclesonide|
224269640|NCT05583162|BEHAVIORAL|Healthy Sport Project|2 interactive information lectures (given per class of 30 pupils), and 4 interactive workshops (given to sex-homogenous groups of 10 pupils). One per week, a total of 6 weeks with intervention.
224269641|NCT01126762|BEHAVIORAL|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
224269642|NCT01126762|BEHAVIORAL|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
224269643|NCT02665780|PROCEDURE|Periodontal debridement|teeth cleaning
224269644|NCT02665780|OTHER|Cetylpyridium chloride|mouthrinse
223517615|NCT05888922|DRUG|Minoxidil Topical|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
223517616|NCT05888922|DRUG|Placebo oral tablet|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
224269645|NCT03747107|BEHAVIORAL|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
224269646|NCT05389813|DRUG|Oxycodone 20 Mg Oral Tablet|Oxycodone is a semi-synthetic, morphine-like opioid alkaloid with analgesic activity. Oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Binding of the opiate receptor stimulates the exchange of GTP for GDP on the G-protein complex and inhibits adenylate cyclase, thereby preventing cAMP production. Subsequently, the release of nociceptive neurotransmitters, such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, and noradrenaline, is inhibited. Oxycodone also inhibits the release of vasopressin, somatostatin, insulin, and glucagon. In addition, oxycodone closes N-type voltage-gated calcium channels and opens G-protein-coupled inwardly rectifying potassium channels resulting in hyperpolarization and reduction of neuronal excitability.
224269647|NCT05389813|DRUG|Pregabalin 150mg|Pregabalin is a gabapentinoid and acts by inhibiting certain calcium channels. Specifically it is a ligand of the auxiliary α2δ subunit site of certain voltage-dependent calcium channels (VDCCs), and thereby acts as an inhibitor of α2δ subunit-containing VDCCs. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and pregabalin shows similar affinity for (and hence lack of selectivity between) these two sites. Pregabalin is selective in its binding to the α2δ VDCC subunit. Despite the fact that pregabalin is a GABA analogue. r synthesizing GABA, and hence may have some indirect GABAergic effects by increasing GABA levels in the brain. In accordance, inhibition of α2δ-1-containing VDCCs by pregabalin appears to be responsible for its anticonvulsant, analgesic, and anxiolytic effects.
224269648|NCT05389813|DRUG|Multivitamin with Minerals|Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
224269649|NCT01368380|BEHAVIORAL|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
224269650|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
224269651|NCT02407548|DIETARY_SUPPLEMENT|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
224269652|NCT02407548|DIETARY_SUPPLEMENT|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
224287319|NCT06734728|DEVICE|Profilm Cold Sores|The treatment will consist of daily applications of the product as soon as the first symptoms of an outbreak appear, and until the outbreak subsides, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
224287320|NCT02642237|BIOLOGICAL|Fluenz|intranasal inoculation with Fluenz
224287321|NCT02642237|OTHER|placebo|
224287322|NCT02642237|OTHER|LPS|
223893415|NCT05051124|BEHAVIORAL|Health Information Technology (HIT) Platform|To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.
223893416|NCT04782973|OTHER|AMAZE (TM) Disease Management Platform|Providing patients with smartphone app that will integrate with provider facing dashboard within electronic medical record.
223893417|NCT06637787|OTHER|Pads|A specially desigend pad is used to collect information about leakage and body movement at night.
223893418|NCT05068648|OTHER|Manual Wheelchair (MWC) backrest configuration|Wheelchair backrest fitting, postural and functional assessment
223893419|NCT06637592|OTHER|Calcaneal taping|Calcaneal taping is a method employed to offer assistance and relieve discomfort in the heel and ankle area. Start with a clean surface and apply first tape from lateral malleolus, pulling calcaneus in medial direction and attach to medial malleolus. Apply two more tapes in the same manner going distally. Apply an anchor tape at back of heel.
223893420|NCT06637592|OTHER|Windlass taping|Begin by anchoring the tape just above the ball of the foot (metatarsal heads). Tear or cut a strip of tape, approximately 2-3 inches long, and place it horizontally around the foot, securing the starting point. Pull the tape diagonally across the bottom of the foot, aiming to support the arch. The tape should be applied with moderate tension to provide support without causing discomfort. While keeping tension on the tape, extend the big toe (great toe) upward. As the toe extends, the tape should tighten, activating the windlass mechanism and providing additional arch support.
223893421|NCT04422912|BIOLOGICAL|DSG3-CAART or CABA-201|"Intravenous infusions of DSG3-CAART alone at different doses and different fractionations. Subjects may also receive varying doses of DSG3-CAART as part of a sub-study, which will employ pre-treatment with intravenous immunoglobulin, cyclophosphamide, and with or without fludarabine to potentially increase the in vivo expansion, persistence and activity of DSG3-CAART.~OR~CABA-201: Single intravenous infusion of CABA-201."
224269653|NCT02535923|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
224269654|NCT02535923|BEHAVIORAL|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
224269655|NCT05237635|OTHER|descriptive case-scenarios|Each case-scenario will include: (1) a GRADE Summary of Finding (SoF) table providing information about the Population, Intervention, Comparator, Outcome (PICO), the relative and absolute anticipated effects of the intervention, and the certainty in the evidence; (2) a Health Outcome Descriptor describing key attributes of the outcome under consideration including symptoms, time horizon, testing and treatment, and consequences; a measure of the impact on health of the outcome (also known as 'value' of the outcome or 'health utility' in health economics).
224269656|NCT05651958|OTHER|Nebulizer|Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.
224269657|NCT05651958|OTHER|Breathing Technique|15 repeatations of Breathing in morning and evening
224269658|NCT03516058|OTHER|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
224269659|NCT01170741|BEHAVIORAL|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
224269660|NCT01628887|OTHER|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
224269661|NCT03867890|OTHER|no intervention|
224269662|NCT00106886|DRUG|Folic acid, vitamin B6 and B12 or placebo|
224269663|NCT02282722|OTHER|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
224269664|NCT02282722|OTHER|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
224269665|NCT01853722|DRUG|DCN01|Three serial applications per periocular region.
224269666|NCT01853722|DRUG|Unisol|Three serial applications per periocular region.
224269667|NCT00213122|DRUG|miglitol|
224269668|NCT06363799|OTHER|4th ventricle compression technique|"For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards."
224269669|NCT06363799|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.
224269670|NCT06363799|OTHER|Diaphragmatic breathing technique|For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
224269671|NCT01473173|DRUG|CJ-12420|
224269672|NCT01473173|DRUG|Esomeprazole 40mg|
224269673|NCT01664650|DIETARY_SUPPLEMENT|Genistein|
224269674|NCT01664650|DIETARY_SUPPLEMENT|Placebo|
224269675|NCT05668650|DRUG|Pembrolizumab|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
223893422|NCT05694767|DRUG|CM313 Injection|"intravenous CM313 administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (CM 313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
223893423|NCT06008951|OTHER|Listening to music|All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
223893424|NCT06008951|OTHER|Listening to a podcast|ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
223893425|NCT06449742|DIAGNOSTIC_TEST|AI software and automatic 3D reconstruction|Radiological medical evaluation with automatic 3D reconstruction of the thoracic and lumbar spine and through application of the AI software NanoxAIHealthVCF, NANO-X IMAGING LTD on abdomen-chest CT studies.
223893426|NCT05190471|DRUG|BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide|Dose escalation of BP1002 monotherapy
223893427|NCT05190471|DRUG|Decitabine (in combination with BP1002)|Dose expansion of BP1002 in combination with decitabine
223893428|NCT03642665|DRUG|Natural cycle|no medication
223893429|NCT03642665|DRUG|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
223893430|NCT03642665|DRUG|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
223893431|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct external drainage|"Pancreaticojejunostomy:~Assess pancreatic texture and duct diameter, preparing a 2 cm pancreatic remnant, and securing it to the jejunum's muscular layer using 3-0 prolene for U-shaped anastomosis. A patented drainage tube is inserted into the jejunum for effective drainage. Anastomoses are performed with 4-0 prolene between the pancreatic duct and jejunal mucosa, both posteriorly and anteriorly, with additional reinforcement at the pancreas and jejunum's anterior walls. A Fr6 silicone tube is placed in the distal jejunal remnant and secured.~The drainage system, featuring a one-way valve, connects the internal and external silicone tubes to a drainage bag.~Choledochojejunostomy:~The common bile duct's diameter is noted, and an opening in the jejunum is made for hepatobiliary tract formation with 4-0 absorbable sutures. A Fr10 silicone tube is inserted into the afferent limb and secured. This tube, too, connects to the external drainage system with a one-way valve."
223893432|NCT06322680|PROCEDURE|Main pancreatic duct and biliary duct internal drainage|"Pancreaticojejunostomy:~Assess the pancreatic texture and pancreatic duct diameter, and reserve the length of the pancreatic remnant to about 1.5 cm. Open the transverse mesocolon and bring the distal small intestinal remnant to the side of the pancreatic remnant. Perform a 2 cm side-to-side pancreaticojejunostomy with an invagination technique. Use a simple full-layer suturing method, 4-0 PDS plus continuous suturing, insert a plastic strip into the pancreatic duct, and fix the pancreatic duct stent with 3/0 Vicryl.~Choledochojejunostomy:~Record the diameter of the common bile duct, about 10 cm away from the pancreaticojejunostomy, and open the jejunum. Form the hepatobiliary tract and perform interrupted anastomosis with 4-0 absorbable sutures."
223893433|NCT01363921|DEVICE|HCO 1100|Dialysis treatment with HCO1100
223893434|NCT03557697|BEHAVIORAL|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
223893435|NCT03557697|BEHAVIORAL|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content. In addition, participants will receive biweekly phone calls from study community health workers to review the video content and clarify questions, set goals, and problem-solve barriers to achieving the goals.
223893436|NCT04213794|DRUG|Cisplatin|Undergo HIPEC with doxorubicin and cisplatin
223893437|NCT04213794|PROCEDURE|Cytoreductive Surgery|Undergo cytoreduction
223893438|NCT04213794|DRUG|Doxorubicin|Undergo HIPEC with doxorubicin and cisplatin
223893439|NCT04213794|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with doxorubicin and cisplatin
223893440|NCT04213794|DRUG|Sodium Thiosulfate|Given IV
223893441|NCT04213794|PROCEDURE|Computed Tomography|Undergo CT scan
223893442|NCT04213794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223893443|NCT04213794|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223893444|NCT04213794|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223893445|NCT05099705|BEHAVIORAL|Access to a Family Service Navigator and Treatment Support System|An RCT will be conducted. 40 participants will be randomly assigned to the intervention group and 15 participants to the non-personalized comparison group (i.e., information, training, and referral). The intervention group will have access to a navigator and the treatment support system.
223893446|NCT06576882|DRUG|Vonoprazan|Participants will receive Vonoprazan 20 mg tablets twice daily before meals.
223893447|NCT06576882|DRUG|Amoxicillin|Participants will receive Amoxicillin 50 mg/kg/day capsules or suspension \[maximum daily dose: 2 g\].
223893448|NCT06576882|DRUG|Clarithromycin|Participants will receive Clarithromycin 20 mg/kg/day tablets or suspension \[maximum daily dose: 1 g\].
223893449|NCT04711278|DEVICE|Mask-wearing hypnosis|"Virtual mask will be worn by patients before and during surgery of Hallux valgus to realize hypnosis.~Virtual mask with 2 types of voice: female voice and male voice. Several types of image or music to choice by patient."
224269676|NCT05668650|DRUG|Pembrolizumab biosimilar|Study drug administration: intravenous infusion Dosing instructions: 200 mg administered over 30 minutes, every 3 weeks The time for infusion should be closer to 30 minutes. However, considering the variability of the infusion pumps from one center to another, a -5 to +10 minutes window is allowed (ie, the time for infusion is 30 minutes with an allowed range of 25 to 40 minutes).
224269677|NCT04935905|DEVICE|Mechanical Insufflator-Exsufflator|This device augments a cough by applying a positive pressure via the upper airway or tracheostomy to increase lung volume to maximal inspiratory capacity, followed by a rapid and quick change to negative pressure to increase expiratory flow and simulate normal cough mechanism
223893450|NCT04711278|OTHER|Without hypnosis|No hypnosis during surgery of Hallux valgus.
224269678|NCT03173651|DEVICE|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
224269679|NCT03173651|DEVICE|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
224269680|NCT03173651|DEVICE|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
224269681|NCT01698736|DEVICE|Membrane filtration|Membrane filtration (Polysulfone)
224269682|NCT01698736|DEVICE|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
224269683|NCT01090505|DRUG|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
224269684|NCT01954212|OTHER|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~1. Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~2. Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~3. Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
224269685|NCT02427919|DRUG|G-CSF|Comparison of the effect of G-CSF use
224269686|NCT02747680|OTHER|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
224269687|NCT05046340|OTHER|Passive leg raising|We perform the PLR test by adjusting the bed and not by manually raising the patient's legs. Bronchial secretions must be carefully aspirated before PLR. If awake, the patient should be informed of what the test involves. And measure the cardiac output by using certain devices at the bedside. The end-expiratory occlusion consists in interrupting the ventilator at end-expiration for 15-30 s and assessing the resulting changes in cardiac output.
224269688|NCT05319054|DEVICE|Sacral NeuroModulation|Sacral Neuromodulation group will include up-to 20 patients with major LARS. Medtronic Interstim system will be used, including 2 week trial device.
224269689|NCT05319054|DEVICE|Trans-Anal Irrigation|Trans-Anal irrigation group will include up-to 20 patients with major LARS. Specific system will be agreed with the patient, depending on eligibility and preference.
224269690|NCT05319054|OTHER|Optimised Conservative Management|Optimised conservative management will include up-to 30 patients with major LARS. They will be provided with a resource booklet which includes dietary and lifestyle advice as well as exercises that can be undertaken independently.
223893451|NCT06576596|OTHER|apnoeic Oxygenation|One approach to preventing adverse respiratory events due to hypoxaemia during paediatric anaesthesia is the use of apnoeic oxygenation. The principle is to deliver oxygen to the airways of anaesthetised patients via a conventional nasal cannula. As less carbon dioxide is produced than oxygen is consumed during apnoea, the supply of oxygen to the upper airways leads to an 'inward diffusion' of oxygen, which may prolongs the time until desaturation and hypoxaemia occur.
224269691|NCT06366555|PROCEDURE|Manual Acupuncture Twirling,|Manual Acupuncture twirling : using 0.14x 25 mm needle, punctured and penetrated the skin and then a twirling manipulation is carried out, 180 degrees, 3 rad/second, for 30 second each at LU5 and PC2. The needles retained for 20 minutes and manipulated at 0 minutes and 10 minutes.
224269692|NCT06366555|PROCEDURE|Manual Acupuncture Sham|Manual Acupuncture Sham : Using 0.14x25mm needles on plesterin without being penetrated into skin and no manipulation given, retained for 20 minutes
224269693|NCT00873587|PROCEDURE|Chest tube pull on inspiration|Pull chest tube on Inspiration
223893452|NCT05270733|DRUG|Ustekinumab|Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
224269694|NCT00873587|PROCEDURE|Expiration|Pull chest tube on Expiration
224269695|NCT03699930|DEVICE|tDCS|Anodal or sham tDCS will be applied to the scalp.
224269696|NCT03699930|BEHAVIORAL|Speech and language therapy|A trained speech pathologist will administer the speech and language therapy.
224269697|NCT03578497|DRUG|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
224269698|NCT04640129|DRUG|PEG-Interferon Alfa, Tenofovir Disoproxil Fumarate|Combination therapy group was treated with PEG-interferon Alfa in addition to TDF monotherapy
224269699|NCT04640129|DRUG|Tenofovir Disoproxil Fumarate|TDF monotherapy
224269700|NCT02924025|BEHAVIORAL|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
224269701|NCT05471349|BEHAVIORAL|Flyer and video|Participants will view a flyer and video
224269702|NCT03097692|PROCEDURE|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
224269703|NCT03097692|DRUG|Pharmacologic preconditionig|Pharmacologic preconditionig will be attained by sevoflurane anesthesia
224269704|NCT02233751|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
224269705|NCT02725619|BEHAVIORAL|CBT|
224269706|NCT02725619|BEHAVIORAL|PST|
224269707|NCT00475410|DRUG|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
224269708|NCT00475410|DRUG|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
224269709|NCT02713139|DRUG|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
224269710|NCT02713139|DRUG|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
224269711|NCT02713139|DRUG|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
224269712|NCT00685334|DRUG|Olanzapine|Participants will take olanzapine daily for 12 weeks.
224269713|NCT00685334|DRUG|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
224269714|NCT01096329|DRUG|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
224269715|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
224269716|NCT01096329|DRUG|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
224269717|NCT06628154|DRUG|Losartan potassium 50mg|Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
224269718|NCT06628154|OTHER|Placebo|Single tablet encapsulated identically to losartan
224269719|NCT00095537|DRUG|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
224269720|NCT06255145|DEVICE|Bioelectrical Impedance Analysis|"Bioelectrical Impedance Analysis Beurer BF 1000 Super Precision device was used to measure the body composition of the participants. Operating on the principle of BIA, the device allows the body composition to be evaluated by giving an imperceptible electric current to the body.~Fatigue Severity Scale (FSS) Fatigue Severity Scale (FSS) was used to measure participants' fatigue levels. Rivermead Mobility Index Rivermead Mobility Index (RMI) was used to assess the mobility levels of the participants.~Functional Independence Measure Functional Independence Measure (FIM) was used to evaluate the functional status of the participants."
224269721|NCT00964054|OTHER|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
224269722|NCT00964054|OTHER|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
224269723|NCT02288923|PROCEDURE|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
224269724|NCT02288923|PROCEDURE|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
224269725|NCT02288923|PROCEDURE|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
224269726|NCT02288923|PROCEDURE|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
224269727|NCT02288923|DRUG|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
224269728|NCT02288923|DRUG|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
223517617|NCT05888922|DRUG|Vehicle solution|The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.
223893453|NCT05932485|PROCEDURE|Stellate nerve block|Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
224269729|NCT02288923|DRUG|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
224269730|NCT02288923|DRUG|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
224269731|NCT02288923|DRUG|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
224269732|NCT01891357|PROCEDURE|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
224269733|NCT01891357|DRUG|paclitaxel|
224269734|NCT01891357|DRUG|lapatinib|
224269735|NCT01891357|DRUG|trastuzumab|
224269736|NCT06227741|OTHER|Concept Mapping: as a Tool for Problem Based Learning|Concept mapping is a visual representation and organizational tool that illustrates the relationships between concepts, ideas, and information. It involves creating a graphical depiction of knowledge, typically using nodes or boxes to represent concepts and connecting lines or arrows to signify the relationships between them. The central concept or main idea is often positioned in the center of the map, with subsidiary concepts branching out from it. These maps serve as a comprehensive overview of a subject, highlighting the hierarchical structure and interconnectedness of various elements.
224269737|NCT04823091|DRUG|Fludarabine + Cyclophosphamide + CAR7-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 250 mg/kg on day -5, -4, and -3; CAR7-T Cells on day 0.
224269738|NCT00002158|DRUG|Nitazoxanide|
223893454|NCT06263101|OTHER|Biochemical testing of abdominal drainage fluid|Drainage fluid was collected from patients on the first and third postoperative days to test the levels of three biochemical tests (albumin, lactate dehydrogenase \[LDH\], adenosine deaminase \[ADA\]).
224269739|NCT02431949|OTHER|Admission to BCPP|There is no intervention associated with this study.
223893455|NCT06263101|OTHER|Cytological examination of abdominal drainage fluid|Cytological examination of abdominal drainage fluid on the first postoperative day and the third postoperative day, calculation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI)
223893456|NCT06263101|OTHER|Peripheral blood cytology tests|Peripheral blood cytology tests on the first postoperative day and the third postoperative day, calculation of Neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet lymphocyte ratio (PLR), systemic immunoinflammatory index (SII)
224269740|NCT02341547|DRUG|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
224269741|NCT06582264|BIOLOGICAL|MB310|Live bacterial therapeutic for oral administration
224269742|NCT06582264|OTHER|Placebo|MB310-matching placebo for oral administration
224269743|NCT06582264|DRUG|Vancomycin|Antibiotic
224269744|NCT01253564|DRUG|RO5185426|960 mg b.i.d. orally
224269745|NCT06765668|DRUG|CREXONT ER|CREXONT ER capsule.
224269746|NCT04085861|BEHAVIORAL|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
224269747|NCT04085861|BEHAVIORAL|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
224269748|NCT01723202|DRUG|dabrafenib|150 mg orally twice daily given orally
224269749|NCT01723202|DRUG|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
224269750|NCT07070856|DIETARY_SUPPLEMENT|WHO-recommended standard therapeutic milk used for stabilization phase in SAM)|F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.
224269751|NCT07070856|DIETARY_SUPPLEMENT|HO-recommended Rice based therapeutic milk used for stabilization phase in SAM)|Rice based F75 GIVEN INITIALLY 2HOURLY,130 ml per kg than 3 and 4hourly maximum takes 5 to 7 days.
224269752|NCT03694197|DRUG|Praluent|Subcutaneous (SC) administration
224269753|NCT01763554|DRUG|Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
224269754|NCT02552082|DEVICE|Scorpio NRG posterior stabilized (PS)|
224269755|NCT03806257|OTHER|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
224269756|NCT06628297|DIAGNOSTIC_TEST|PET|PET imaging will be performed with a Discovery 710 PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Four 5-minute PET recordings will be performed of each subject within a single scanning session of 70 min. Two consecutive 5-minute scans are conducted of the heart and brain in rest. \[15O\]H2O, is produced on-site (GENtrace, GE, Uppsala, Sweden), and 600 MBq \[15O\]H2O is intravenously injected by an automatic Hidex Radiowater Generator (Hidex, Turku, Finland). To induce heart vasodilation, adenosine is infused (140 g/kg/min) for 6 min and a scan of the heart is repeated. To induce brain vasodilation, 1 g of acetazolamide is infused over 5 min and 15 min later the brain is scanned. Myocardial perfusion is calculated using CarimasCE software version 1.3.1. (Turku, Finland). Cerebral perfusion is calculated using PMOD software (PMOD Technologies, Switzerland).
224269757|NCT07139067|BIOLOGICAL|YK1101 cells|Drug: Fludarabine + Cyclophosphamide
224269758|NCT03506633|DIETARY_SUPPLEMENT|MitoQ|"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each participant in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."
224269759|NCT05695417|DRUG|OTX-TKI|Injection of OTX-TKI
224269760|NCT05695417|DRUG|Sham|Sham Injection of OTX-TKI
224269761|NCT01348958|DEVICE|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
224269762|NCT03944057|DRUG|ATG-010|"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"
224269763|NCT03316222|DRUG|GNS561|Escalating doses to be administered 3 times a week.
224269764|NCT04573309|DRUG|ALXN1840|Administered orally as tablets.
224269765|NCT00260793|DRUG|Ropinirole Hydrochloride|
224269766|NCT00070239|DRUG|alvocidib|Given IV
224269767|NCT00070239|OTHER|pharmacological study|Correlative studies
224269768|NCT00070239|RADIATION|fludeoxyglucose F 18|Correlative studies
224269769|NCT00070239|OTHER|fluorine F 18 fluorothymidine|Correlative studies
224269770|NCT00070239|PROCEDURE|positron emission tomography|Correlative studies
224269771|NCT01465932|OTHER|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
224269772|NCT01465932|OTHER|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
224269773|NCT00368082|BIOLOGICAL|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2"
224269774|NCT02783326|OTHER|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
224269775|NCT04815460|BEHAVIORAL|High intensity-interval training (HIIT)|Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
224269776|NCT04815460|BEHAVIORAL|Moderate intensity-continuous (MICT)|Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
224269777|NCT03391622|DEVICE|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
224269778|NCT06533072|OTHER|The group receiving infrared LED therapy|Patients in this group are the ones who will be exposed to IR LED light therapy, three times in total
223893457|NCT06528964|DIAGNOSTIC_TEST|Immunohistochemistry and immunofluorescence|Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
223893458|NCT05048706|DEVICE|Laser lithotripsy (SP TLF)|Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)
224269779|NCT05659238|BEHAVIORAL|the effect on language development & attention|Tv \& other electronic devices effects onn children's language development \& attention
224269780|NCT00159419|DRUG|Alendronate|
224269781|NCT00159419|DRUG|Pamidronate|
224269782|NCT04042649|BEHAVIORAL|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
224269783|NCT00225849|DRUG|Aspirin|
224269784|NCT00002224|DRUG|Nelfinavir mesylate|
224269785|NCT00002224|DRUG|Stavudine|
224269786|NCT00002224|DRUG|Didanosine|
224269787|NCT02206009|DEVICE|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
224269788|NCT01541215|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
224269789|NCT01541215|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
224269790|NCT01541215|DRUG|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
224269791|NCT05314062|DIETARY_SUPPLEMENT|FeSO4|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
224269792|NCT05314062|DIETARY_SUPPLEMENT|Ao iron|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
224269793|NCT00693589|DRUG|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
224269794|NCT01104948|DRUG|DA-8031|
224269795|NCT01104948|DRUG|Placebo|
224269796|NCT02735330|PROCEDURE|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
224269797|NCT02735330|PROCEDURE|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
224269798|NCT02735330|PROCEDURE|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
224269799|NCT03008538|OTHER|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
224269800|NCT03008538|OTHER|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
224269801|NCT00007787|BIOLOGICAL|Cyclosporine|
224269802|NCT00007787|BIOLOGICAL|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
224269803|NCT00007787|DRUG|Tacrolimus|
224269804|NCT05306600|DIAGNOSTIC_TEST|whole exome and whole genome sequencing analysis|"Somatic and germline whole exome sequencing will be analyzed for prostate and HER2-positive breast cancer~Somatic whole exome and germline whole genome sequencing will be analyzed for triple-negative breast cancer"
224269805|NCT00818220|PROCEDURE|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
224269806|NCT00818220|OTHER|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
224269807|NCT01023776|BIOLOGICAL|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
224269808|NCT02361957|DIETARY_SUPPLEMENT|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
224269809|NCT02361957|DIETARY_SUPPLEMENT|Placebo|Placebo
224269810|NCT05743634|BIOLOGICAL|YY001|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
224269811|NCT05743634|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
224083005|NCT06062394|BEHAVIORAL|Penn Med Healthy Heart Program|Patients randomized to the intervention arm will be assigned a Patient Navigator (Clinical Research Coordinators, with support from Nurse Practitioners and a Medical Director) who will conduct an initial assessment with the patient to determine their main barriers to improving blood pressure and cholesterol control. The Patient Navigators will provide the patient with a home blood pressure cuff for remote monitoring, support from Way to Health text message reminders, referrals to established Penn Medicine smoking cessation programs, and referrals to nutrition and social workers as applicable. The Patient Navigators will help move the patients through four modules: Blood Pressure, Food Insecurity/Nutrition Screening, Statins, and Smoking Cessation. These modules provide patients with the chance to work on blood pressure, cholesterol control, access nutrition resources, and smoking cessation simultaneously or sequentially.
224083006|NCT00083187|DRUG|hydroxyurea|
224083007|NCT00083187|DRUG|laromustine|
224083008|NCT01072409|DEVICE|Nucleus 5 Cochlear implant|Cochlear implant surgery
224083009|NCT01072409|DEVICE|Cochlear implantation|Implantation
224083010|NCT02944916|DEVICE|IryPump R Set|
224083011|NCT03798886|OTHER|natural cycle|When follicle is ready for ovulation, we will use this injection by intra-dermal route
224083012|NCT03798886|OTHER|modified natural cycle|we will use that drug in the natural modified transfer group after embryo transfer
224083013|NCT03798886|OTHER|embryo transfer|we will do transfer when the endometrium is ready
224083014|NCT05464745|DRUG|PERINDOPRES® DUO 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
224269812|NCT05743634|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
224269813|NCT05124496|DEVICE|Screening Device|Screening device comparing Rt-PCR positive and negative results to HyperDetector results
224083015|NCT05464745|DRUG|Noliterax® 10 mg/2.5 mg 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure) and indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure)
224083016|NCT03588741|DRUG|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
224083017|NCT05892887|DRUG|Bupivacaine 0.25% Injectable Solution|Bilateral ultrasound guided in erector spinae plane block by bupivacaine 0.25%
224083018|NCT04547257|DEVICE|Seraph 100|Bloodfiltration with Seraph 100
224083019|NCT05588323|DRUG|Naldemedine|Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
224083020|NCT04925492|RADIATION|Positron Emission Tomography|An imaging method that uses radiotracers to view changes in the metabolic process.
224083021|NCT04925492|DRUG|Cu-64]-LLP2A|A radioactive tracer used in PET imaging.
224083022|NCT06496672|PROCEDURE|Modified long arm cast|A shorter cast that frees the wrist
224083023|NCT06496672|PROCEDURE|Traditional long arm cast|Current standard of care where the cast extends up to the palmar bar
224083024|NCT03416283|BEHAVIORAL|Remote Monitoring|Remote BP monitoring and medication adherence
224083025|NCT03416283|BEHAVIORAL|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
224083026|NCT05364411|RADIATION|HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)|20 daily fractions, 5 times per week
224083027|NCT05364411|RADIATION|conventional fractionated radiotherapy|35 daily fractions, 5 times per week
224083028|NCT02410694|DRUG|Ixazomib|
224083029|NCT02410694|DRUG|Thalidomide|
224083030|NCT02410694|DRUG|Dexamethasone|
224083031|NCT02084446|DRUG|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
224083032|NCT02084446|DRUG|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
224083033|NCT02084446|DRUG|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
224083034|NCT02084446|DRUG|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
224083035|NCT02084446|DRUG|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
224083036|NCT02084446|DRUG|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
224083037|NCT04364204|OTHER|Kangaroo Mother Care and BEMPU bracelet|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. The BEMPU bracelet, also known as the BEMPU Tempwatch, is a silicone band with a thermistor metal cup that emits an audio alarm and flashes an orange light when the body temperature drops below 36.5⁰C, signaling hypothermia and prompting caregiver to provide thermal care.
224083038|NCT04364204|OTHER|Kangaroo Mother Care|Kangaroo mother care involves early, continuous and prolonged skin-to-skin contact between a mother and her newborn, frequent and exclusive breastfeeding and early discharge from hospital. This is the current standard of care for low birthweight/preterm infants.
224083039|NCT05855733|DEVICE|radiofrequency treatment|patient undergoing radiofrequency using the Fistura procedure for treatment of a infected pilonidal sinus
224083040|NCT02522767|DRUG|Mesalamine|
224083041|NCT02522767|DRUG|Placebo|
223517618|NCT06032923|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The dietary supplement Nicotinamide Riboside or a placebo capsule in subjects with SLE. Niagen(R) is a commercially available form of nicotinamide riboside (NR)
223517619|NCT06059001|DRUG|OMO-103|Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
224083042|NCT00705978|DRUG|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
224083043|NCT00705978|DRUG|Placebo|placebo
224083044|NCT03913663|OTHER|vestibuloocular training|using vestibulo ocular training program for training neglect patient
224083045|NCT03913663|OTHER|regular exercise training for hemiplegic patients|Traditional gait training program.
224083046|NCT00548548|DRUG|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
224083047|NCT00548548|DRUG|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
224083048|NCT00548548|DRUG|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
224083049|NCT00548548|DRUG|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
224083050|NCT00548548|DRUG|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
224083051|NCT05657184|DRUG|REGEND001|Transplantation of REGEND001 for dose escalation.
224083052|NCT02664116|DRUG|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
224083053|NCT02664116|DRUG|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
224083054|NCT01260155|DRUG|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
224083055|NCT01260155|DRUG|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
224083056|NCT01260155|DRUG|E5501|Treatment C: 40 mg new tablet formulation administered with food
224083057|NCT01823068|DRUG|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
224083058|NCT01222650|DRUG|KSO-0400|
224083059|NCT01222650|DRUG|KSO-0400|
224083060|NCT01222650|DRUG|Silodosin|
224083061|NCT01222650|DRUG|Placebo|
224083062|NCT02128126|DRUG|ISA101/ISA101b|Four dose levels ISA101/ISA101b
224083063|NCT03082001|DRUG|12% Sucrose|
224083064|NCT03082001|DRUG|24% Sucrose|
224083065|NCT01705691|DRUG|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
224083066|NCT01705691|DRUG|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
224083067|NCT01705691|DRUG|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
224083068|NCT01705691|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
224269814|NCT01135264|BEHAVIORAL|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
224083069|NCT04887402|DRUG|Clomiphene Citrate|"All patients will be treated with CC starting with 50 mg/day on the day 2 of their cycle for 5 days, a transvaginal ultrasound will be done 1 week after the last pill, if all follicles are below 10 mm the dose will subsequently be increased to 100mg/day for 5 days then 150mg/day for 5 days if a transvaginal is done a week from the last pill and showed no response (all follicles being below 10 mm ).Maximum cc dose will be 150 mg (ASRM, 2013). Medroxyprogesterone (10 mg/d Provera for 10 days)will be given to induce withdrawal bleeding to start these steps again in a new cycle. These steps will be repeated for 3cycles before declaring the patient CC resistant.~o Response: Response to CC will be assessed by ovulation. TVS will be done by the same observer using a Samsung ultrasound machine, HS40.~A scan will be done 1 week after the last pill of each dose. No response: if all follicles are below 10 mm (ASRM, 2013), follicles \>10mm, follow up till ovulation"
224287323|NCT01370239|BIOLOGICAL|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
224287324|NCT05488886|DIETARY_SUPPLEMENT|Whole Aronia Berry Powder Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce A will additionally contain whole aronia berry powder (Milne MicroDried, Nampa, ID).
224083070|NCT00078364|PROCEDURE|MRI|
223517620|NCT06059001|DRUG|Nab-Paclitaxel|IV infusion - Standard of Care
224083071|NCT02313740|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
224083072|NCT02446392|OTHER|No intervention.|
224083073|NCT04399382|DRUG|Biologics|The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.
224083074|NCT04997239|BIOLOGICAL|Two doses of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
224083075|NCT04997239|BIOLOGICAL|One dose of quadrivalent influenza vaccine|15ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administation is Intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.
224287325|NCT05488886|DIETARY_SUPPLEMENT|Aronia Berry Extract Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce B will additionally contain aronia berry extract (Artemis International, Fort Wayne, IN).
224287326|NCT05488886|DIETARY_SUPPLEMENT|Phospholipid-Polyphenol Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce C will additionally contain PLP which will be prepared with commercially-available aronia juice concentrate (Greenwood Associates, Niles, IL) and soy lecithin (Whole Foods, Austin, TX).
224287327|NCT05488886|OTHER|Low-Polyphenol Control Applesauce|The food will be designed to be a berry-flavored applesauce. The food will include applesauce, sweeteners, citric acid, natural flavors and food colorants. Applesauce D will not contain additional polyphenol-rich ingredients and is thus considered a low-polyphenol control.
224083076|NCT03640884|DRUG|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
224083077|NCT03492684|PROCEDURE|total hip arthroplasty|total hip arthroplasty and EMG
224083078|NCT02913313|DRUG|BMS-986207|Specified dose on specified days
224083079|NCT02913313|BIOLOGICAL|Nivolumab|Specified dose on specified days
224083080|NCT02913313|BIOLOGICAL|Ipilimumab|Specified dose on specified days
224083081|NCT02970695|DEVICE|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
224083082|NCT02970695|DEVICE|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
224083083|NCT04088409|DRUG|Baricitinib|Administered orally
224083084|NCT04088409|DRUG|Adalimumab|Administered SC
223517621|NCT06059001|DRUG|Gemcitabine|IV infusion - Standard of Care
224083085|NCT03025256|PROCEDURE|Biospecimen Collection|Correlative studies
224083086|NCT03025256|PROCEDURE|Computed Tomography|Undergo CT
224083087|NCT03025256|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture for cerebrospinal fluid collection
224083088|NCT03025256|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of brain and spine
224269815|NCT01135264|BEHAVIORAL|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
224083089|NCT03025256|BIOLOGICAL|Nivolumab|Given IV or IT
224083090|NCT03025256|PROCEDURE|Positron Emission Tomography|Undergo PET
224083091|NCT04233229|DEVICE|t:slim X2 with Control-IQ|closed-loop in patients at home for three months
224083092|NCT04233229|OTHER|home healthcare services|home healthcare services from Air Liquide in patients at home for three months
223517622|NCT04406454|DEVICE|ApolloVue® S100 Image System|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 3 quality OCT images of B-scan (cross-section) and E-scan (en face) with 4 depths for each skin site respectively for each skin site. There is a total of 6 skin sites.
223517623|NCT06176586|OTHER|Mat Pilates Exercises|The intervention will consist of mat Pilates exercises performed twice a week over a duration of 12 weeks, as an adjunct to the routine medical treatment for the patients, under the guidance of a qualified physiotherapist. Each exercise session will last for approximately 60 minutes. The treatment protocol will encompass targeted mobility exercises for the thoracic and lumbar regions, along with strengthening exercises focusing on core activation. The exercise program will be progressed in every four weeks.
223517624|NCT03407950|BEHAVIORAL|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
223517625|NCT03407950|BEHAVIORAL|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
223517626|NCT04098588|BEHAVIORAL|BEAST|See Arm Description
224083093|NCT04233229|OTHER|usual care for daily insulin treatment|multiple daily injection insulin regimen with family nurse's daily assistance at home for performing insulin injections and/or glucose monitoring
224083094|NCT00841763|BIOLOGICAL|Placebo (PL)|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle, preferably of the non-dominant arm.
224083095|NCT00841763|BIOLOGICAL|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
224083096|NCT00841763|BIOLOGICAL|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
224083097|NCT00841763|BIOLOGICAL|Adjuvanted trivalent influenza virus vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
224083098|NCT02505282|OTHER|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
224083099|NCT04628923|OTHER|QUADRATUS LUMBORUM BLOCK|QUADRATUS LUMBORUM BLOCK BY PARASPINOUS SAGITTAL SHIFT APPROACH
224083100|NCT01884831|BIOLOGICAL|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
224083101|NCT01609595|DRUG|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
224083102|NCT01901835|PROCEDURE|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
224083103|NCT01901835|OTHER|survey administration|Ancillary studies
224083104|NCT01901835|PROCEDURE|quality-of-life assessment|Ancillary studies
224083105|NCT03416361|DIETARY_SUPPLEMENT|4000IU Vitamin D3|Chewable blackcurrant flavoured tablets (two per day)
224269816|NCT01985464|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
224083106|NCT00648167|DRUG|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
224083107|NCT04762628|DIETARY_SUPPLEMENT|MAF capsules 148 mg|enteric capsules based on enzymatically treated bovine colostrum
224083108|NCT04762628|DIETARY_SUPPLEMENT|M capsules 148 mg|enteric capsules based on enzymatically treated bovine whey
224083109|NCT04762628|OTHER|Standard of care|Standard of care
224269817|NCT04386408|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP027)|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
224269818|NCT04386408|COMBINATION_PRODUCT|Placebo|Each participant will consume a sachet disolve in water once at day without any restriction in the diet nor in their habits of life.
224269819|NCT00498199|PROCEDURE|visual tests|
224269820|NCT02998606|DRUG|Naloxegol|MOVANTIK™ 25 mg, daily
224269821|NCT02998606|DRUG|Placebo Oral Capsule|Placebo 25 mg, daily
224269822|NCT04201795|OTHER|Laser|laser with no emision will applied
224269823|NCT04201795|OTHER|pressure and traction tecnique|pressure and traction in plantar fascia with hands will be applied
224269824|NCT01847924|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
224269825|NCT01847924|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
223517627|NCT04098588|BEHAVIORAL|Descriptive Feedback|See Arm Description
223893459|NCT05048706|DEVICE|Laser lithotripsy (Ho:YAG)|Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
224083110|NCT03612687|DEVICE|Minimally invasive hemodynamic monitoring|Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
224083111|NCT05254028|PROCEDURE|filiform needle|Manual acupuncture using filiform needles
224083112|NCT05301075|DRUG|Rhomboid Intercostal and Sub-Serratus block|Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
224083113|NCT05410782|DIETARY_SUPPLEMENT|Power Prenatal for Sperm|A prenatal vitamin complex that includes numerous ingredients aim at improving sperm quality (ingredients: https://birdandbe.com/the-power-prenatal-for-sperm)
224083114|NCT03061266|BEHAVIORAL|E-health Education|E-health education on shared care program will be established by different type's professionals including diabetes physicians, pharmacists, dietitians and diabetes health teacher.
224083115|NCT03061266|OTHER|Routine care|Routine care on shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
224083116|NCT00927368|PROCEDURE|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
224083117|NCT00927368|PROCEDURE|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
224083118|NCT00927368|PROCEDURE|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
224083119|NCT05561790|BEHAVIORAL|eCBT-I|Automated digital administration of sleep hygiene, sleep optimization, stimulus control therapy, deactivation/relaxation training, and cognitive therapy modules via mobile or web application, lasting approximately six weeks.
224083120|NCT01079481|DRUG|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
224083121|NCT01747057|BEHAVIORAL|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation\* and with sinus rhythm.~1. PPV \>12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ \[(PPmax+PPmin)/2\] x100 (during 5 respiratory cycles)~2. SVV \> 12% (15). SVV: Stroke volume variation~   * A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV \< 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP\>12).~● Non-preload responsive patients (defined as PPV or SVV \< 12%) will resume the same protocol as responders when fluid response parameters are negative."
224083122|NCT01747057|BEHAVIORAL|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (\> 65mmHg) or CVP \> 12mmHg. If CVP reaches \> 12 mmHg and MAP remains \< 65mmHg, norepinephrine should be started to reach MAP \> 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output \< 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC\>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
224269826|NCT05521022|DRUG|AT-02|AT-02 via IV infusion
224269827|NCT05521022|OTHER|AT-02 (Placebo)|Normal saline solution via IV infusion
224269828|NCT01472432|DRUG|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
224269829|NCT01472432|DRUG|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
224269830|NCT06627556|DRUG|H021|H021 oral tablet.
224269831|NCT06627556|DRUG|H021 Placebo|H021 placebo oral tablet.
224269832|NCT03196557|DRUG|Prenisolone|Specified dose on specified days
224269833|NCT03196557|DRUG|Placebo|Specified dose on dose on specified days
224269834|NCT03755596|DRUG|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
224269835|NCT04438044|DRUG|ICP-022|ICP-022 The drug product is a white, round, uncoated tablet
224269836|NCT06173960|DEVICE|atherectomy|Jetstream atherectomy in combination with Ranger paclitaxel elution balloon (Drug Coated Balloon (DCB))
224269837|NCT04619862|DRUG|Gabapentin|See arm descriptions
224269838|NCT04619862|DRUG|Placebo|See arm descriptions
224269839|NCT02277262|DEVICE|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
224269840|NCT02277262|PROCEDURE|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
224269841|NCT03736460|BEHAVIORAL|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
224269842|NCT03736460|BEHAVIORAL|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
224269843|NCT05462080|DIAGNOSTIC_TEST|Ceraxis product|All patients will have their symptoms evaluated using the Ceraxis product
224269844|NCT05280080|OTHER|Resistance exercise|Do the maximum number of repetitions of externally-resisted (50% 1RM) knee extensions.
224269845|NCT00006262|DRUG|becatecarin|
224269846|NCT03064867|DRUG|Venetoclax|"Beginning with 400mg daily on days 1-10 of cycle 1-3~Phase I dose escalation scheme:~Dose Level -2 (DL-2): 100 mg daily, days 1-10, cycle 1-3~DL-1: 200 mg daily, days 1-10, cycle 1-3~DL1: 400 mg daily, days 1-10, cycle 1-3~DL2: 600 mg daily, days 1-10, cycle 1-3~DL3: 800 mg daily, days 1-10, cycle 1-3~Phase II: Given at a dose of 400mg daily for 5 days"
224269847|NCT03064867|DRUG|Rituximab|"Part of R-ICE treatment:~Rituximab: 375 mg/m\^2 intravenously (IV) on Day 1 of R-ICE every 21 days"
224269848|NCT03064867|DRUG|Ifosfamide|"Part of R-ICE treatment:~Ifosfamide: 5,000 mg/m\^2 mixed together with mesna at a dose of 5,000 mg/m\^2 over 24 hours beginning on Day 2 and completing on Day 3 of each 21-day cycle"
224269849|NCT03064867|DRUG|Carboplatin|"Part of R-ICE treatment:~Carboplatin: At a dose corresponding to an AUC = 5 based on Cockcroft-Gault calculation of GFR using adjusted body weight. Carboplatin is given IV on the Day 2 of RICE of each 21 day cycle"
223517628|NCT06161181|DEVICE|Decision Support System|"TREAT (TREatment Adherence SupporT) is a web-based DSS that comprises four sections:~i) Metastatic Breast Cancer: contains information about MBC and its physical and psychological consequences;~ii) Adherence to Cancer Therapies: contains information about adherence in the cancer population;~iii) Promoting Adherence: contains information about resources, barriers, and available interventions used to foster adherence;~iv) My Adherence Diary."
223517629|NCT04388631|OTHER|Coronavirus Disease 2019|male patients who have developed COVID-19
223517630|NCT01853280|DRUG|L-methylfolate|15mg/day L-methylfolate.
224269850|NCT03064867|DRUG|Etoposide|"Part of R-ICE treatment:~Etoposide: 100 mg/m2by IV daily on 3 consecutive days (Days 1-3) of each 21-day cycle"
224269851|NCT04793633|COMBINATION_PRODUCT|LINFU™ Technique|Non-focused ultrasound excitation of the pancreas with IV Lumason and IV secretin injected during the ultrasound procedure.
224269852|NCT02231957|OTHER|educational text message reminders|
224269853|NCT02231957|OTHER|conventional text message reminders|
224269854|NCT04654429|DRUG|IV Ondansetron 4mg|IV ondansetron 4mg
224269855|NCT04654429|OTHER|Higher OT temperature range|OT temperature set to 19-22 degree celsius
224269856|NCT04654429|DRUG|Placebo|IV Normal Saline 2cc will be given
224269857|NCT04654429|OTHER|Lower OT temperature Range|OT temperature set to 17-19 degree celsius
224269858|NCT01581892|PROCEDURE|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
223517631|NCT01853280|DRUG|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
223517632|NCT01853280|DRUG|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
224269859|NCT02817828|DRUG|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
224287328|NCT06904755|DEVICE|It is loaded with a mesenchymal stem cells reaction device for blood purification|Artificial liver blood purification therapy is performed using a mesenchymal stem cells reactor.
224269860|NCT01470898|DEVICE|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
224269861|NCT02336633|DIETARY_SUPPLEMENT|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
224269862|NCT02336633|OTHER|Placebo|
224269863|NCT02207764|BEHAVIORAL|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
224269864|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
224269865|NCT02093728|DRUG|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
224269866|NCT02093728|DRUG|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
224269867|NCT02093728|DRUG|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
224269868|NCT02093728|DRUG|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
224269869|NCT02093728|DRUG|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
224269870|NCT02093728|DRUG|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
223893460|NCT05662631|DEVICE|BioIntellisense BioSticker|"This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis."
224269871|NCT02093728|DRUG|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
224269872|NCT05545228|BEHAVIORAL|Link work intervention|Intervention from a link worker to support participants to access dental services.
224269873|NCT00616993|DRUG|Difluprednate|Difluprednate
224269874|NCT00616993|OTHER|Placebo|Vehicle
224269875|NCT02651987|DRUG|Lanreotide autogel 120 mg|
224269876|NCT04406545|OTHER|evaluation of skin microvascular flow and reactivity|evaluation of skin microvascular flow and reactivity using laser Doppler perfusion monitoring
224269877|NCT00163124|PROCEDURE|spinal manipulation & patient education/nutrition|
224269878|NCT00759616|DEVICE|Oxford Partial Knee|Oxford Partial Knee
224269879|NCT03685617|DEVICE|Dual Chamber Pacemaker|1\. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
224269880|NCT03685617|DEVICE|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
224269881|NCT04731324|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
224269882|NCT00486434|DRUG|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
224269883|NCT00486434|DRUG|SMC021 Placebo|Placebo orally, twice daily
224269884|NCT00522041|DRUG|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
223517633|NCT05156112|DEVICE|Positive Airway Pressure Device|Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
224269885|NCT00522041|DRUG|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
224269886|NCT02786433|OTHER|conventional physiotherapy|
224269887|NCT02786433|OTHER|Virtual Reality with X- Box Kinect®|
224269888|NCT03318133|PROCEDURE|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
224269889|NCT00279045|DRUG|Rosiglitazone|
224269890|NCT00279045|DRUG|glyburide|
224269891|NCT00279045|DRUG|metformin|
224269892|NCT00860145|PROCEDURE|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
224269893|NCT00860145|PROCEDURE|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
224269894|NCT01083797|DRUG|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
223893461|NCT05743673|DEVICE|Shape II|cardiopulmonary exercise testing apparatus
224269895|NCT01083797|DRUG|Chloral Hydrate|Initial dose=50 mg/kg
224269896|NCT05167149|PROCEDURE|Carbon nanoparticles|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to National Comprehensive Cancer Network (NCCN) guidelines, 1ml diluted ICG solution (25 mg /10 ml) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (2ml totally) with 1ml syringe. ICG should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection under the multimodel observation of fluorescence laparoscopy. Search the fluorescent labeled lymphatics from bilateral parametrium to iliac vessels. The diffusion of ICG is rapid , and it is easy to spread to the next stations lymph nodes. The first fluorescent labeled lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all fluorescent lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
224269897|NCT05167149|PROCEDURE|Indocyanine green|After pneumoperitoneum is established and laparoscopic instruments are prepared, according to NCCN guidelines, 0.5ml(25mg) carbon nanoparticle solution (the dose was from our retrospective study) is injected into the submucosa around tumor at 3 and 9 o'clock of the cervix (1ml totally) with 1ml syringe. Carbon nanoparticle should be slowly injected to avoid drug leakage. Intratumoral and deep cervical stroma injection should be avoided. The retroperitoneum is dissected immediately after injection. Search the black lymphatics from bilateral parametrium to iliac vessels. Because there is no fluorescence penetration as ICG, the black lymphatic vessels should be dissected carefully.The first black lymph nodes on each lymphatic drainage pathway are identified as SLNs, other than all black lymph nodes. All detectable SLNs and enlarged or suspicious nodes regardless of mapping are resected for pathological examination alone.
224269898|NCT00055549|DRUG|Dextromethorphan|
224269899|NCT00055549|DRUG|Lorazepam|
224269900|NCT03957096|DRUG|SGN-CD47M|SGN-CD47M administered intravenously
224269901|NCT01311596|OTHER|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
224269902|NCT01610050|DRUG|LFA102|
224269903|NCT01981044|DEVICE|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
224269904|NCT05092035|DIAGNOSTIC_TEST|single high-fidelity expiratory CO2 analysis|in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
224269905|NCT02832466|OTHER|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
224269906|NCT00968916|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
224269907|NCT04013750|OTHER|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
224269908|NCT00080613|DRUG|exemestane|
224269909|NCT00080613|PROCEDURE|adjuvant therapy|
223893462|NCT03153527|DRUG|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
223893463|NCT03153527|OTHER|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
224269910|NCT00080613|PROCEDURE|aromatase inhibition|
224269911|NCT00080613|PROCEDURE|conventional surgery|
224269912|NCT00080613|PROCEDURE|endocrine therapy|
224269913|NCT00080613|PROCEDURE|hormone therapy|
224269914|NCT00080613|PROCEDURE|neoadjuvant therapy|
224269915|NCT00080613|PROCEDURE|surgery|
224269916|NCT05765617|DRUG|Calcitriol|The treatment group received calcitriol 2x400 iu per day for five days. Calcitriol uses Oscal, obtained from Kalbe Pharma
224269917|NCT05765617|OTHER|Placebo|Placebo give 2x1 per day for five day
224269918|NCT02191124|DRUG|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
224269919|NCT02191124|DRUG|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
224269920|NCT02752334|DRUG|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
224269921|NCT05995990|DEVICE|Raman Spectrometry|Laboratory technique of Raman Spectrometry
224269922|NCT05883397|OTHER|HBOT|Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.
224269923|NCT05883397|OTHER|Hippocampal training|Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
224269924|NCT06260982|RADIATION|18-FDG-PET|18-FDG-PET and neuropsychological tests (language, memory, visuo-spatial tests, etc.).
224269925|NCT00746460|BEHAVIORAL|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
224269926|NCT00686062|OTHER|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
224269927|NCT00686062|OTHER|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
224269928|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
224269929|NCT01418235|BIOLOGICAL|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
224269930|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
224269931|NCT01418235|BIOLOGICAL|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
224269932|NCT00735696|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
224269933|NCT00735696|DRUG|Paclitaxel|200 milligrams per meter squared (mg/m\^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
224269934|NCT00735696|DRUG|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
224269935|NCT05553496|DRUG|Rituximab|Group (1) RTX in Refractory Nephrotic syndrome patients on conventional treatment (20 patients)
224269936|NCT05553496|DRUG|Dexamethasone|Group (2) Refractory Nephrotic Syndrome patients on Conventional therapy (20 patients)
224269937|NCT01969864|BEHAVIORAL|HRSA Video Intervention|
224269938|NCT01969864|BEHAVIORAL|PI Video Intervention|
224269939|NCT01969864|BEHAVIORAL|CDC Health Website Intervention|
224269940|NCT04478708|BIOLOGICAL|maridebart cafraglutide|Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
224269941|NCT04478708|DRUG|Placebo|Participants will receive placebo as a single dose in Part A and multiple doses in Part B.
224269942|NCT05824949|PROCEDURE|osseodensification drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.
224269943|NCT05824949|PROCEDURE|conventional drilling|Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
224269944|NCT06058806|OTHER|Multimodal Physical Therapy|Multimodal Physical Therapy program consisting of electrophysical agents, manual therapy interventions, and core stability exercises
224269945|NCT03609749|BEHAVIORAL|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
224269946|NCT04981457|DRUG|Misoprostol and iso sorbide mononitrates|drug
224269947|NCT00159172|DEVICE|Motor cortex stimulation|
224269948|NCT03624777|BEHAVIORAL|Outdoor Fall prevention brochure|Participants in the wait list control group will initially receive written information only about preventing outdoor falls
224269949|NCT03624777|BEHAVIORAL|Stroll Safe outdoor fall prevention program|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
224269950|NCT05120791|DIETARY_SUPPLEMENT|Placebo vegetable bouillon|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1,3g)
224269951|NCT05120791|DIETARY_SUPPLEMENT|microalgae phaeodactylum|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae Phaeodactylum
224269952|NCT05120791|DIETARY_SUPPLEMENT|From the Microalgae phaeodactylum the extracted beta-Glucan (especially chrysolaminarin)|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), Beta-Glucan (1.8g)
223517634|NCT04702607|PROCEDURE|contrast enhanced 4DCT|Functional Lung Imaging with DECT and 4DCT
223517635|NCT03032484|DRUG|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
224269953|NCT05120791|DIETARY_SUPPLEMENT|A combination of the vegetable bouillon, the microalgae and the beta-Glucan|14 days wahs-out: no fish eating 14 days: no fish eating, the participants eat vegetable bouillon (1.3g), 2.3g Microalgae, Beta-Glucan (1.8g)
223517636|NCT03032484|DRUG|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
223517637|NCT04745806|DEVICE|ActiGraft|Whole blood clot (WBC) gel
223517638|NCT01229111|DRUG|cediranib maleate|Given PO
223517639|NCT01229111|DRUG|oxaliplatin|Given IV
223893464|NCT03189641|DEVICE|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
223517640|NCT01229111|DRUG|leucovorin calcium|Given IV
223517641|NCT01229111|DRUG|fluorouracil|Given IV
223517642|NCT03989908|OTHER|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
223517643|NCT03989908|OTHER|Control noodle|In this intervention arm, subjects will be served with normal noodle.
223517644|NCT04503642|PROCEDURE|Changing the surgical team for wound closure|The intervention consists of the exchange of the primary surgical team with a second surgical team that consists of one surgeon and one student. The first surgical team then may leave the operation theatre but is continuously accessible for questions.
223517645|NCT06158477|DRUG|JYP0035 Experimental Drug Treatment|Single dose intervention
223517646|NCT05796193|OTHER|Alpha-cypermethrin and PBO LLIN|Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO
223893465|NCT04458883|PROCEDURE|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging - Cardiac Scan
223893466|NCT04458883|PROCEDURE|Fast Field Cycling - Magnetic Resonance Imaging|Fast Field Cycling - Magnetic Resonance Imaging Cardiac Scan
224269954|NCT01941069|BEHAVIORAL|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
224269955|NCT01941069|BEHAVIORAL|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
224269956|NCT00623558|DRUG|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
224269957|NCT00623558|DRUG|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
224269958|NCT00623558|DRUG|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
224269959|NCT03484234|DEVICE|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
224269960|NCT03484234|DEVICE|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
224269961|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
224269962|NCT04511611|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|10 mg as 1 x 10 mg film-coated tablet
224269963|NCT02707887|BEHAVIORAL|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
224269964|NCT02707887|BEHAVIORAL|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
224269965|NCT02707887|BEHAVIORAL|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
224269966|NCT00147693|BEHAVIORAL|Diagnosis of caregivers' problems|
224269967|NCT00147693|BEHAVIORAL|Professional service: treatment of problems by counseling or practical support|
224269968|NCT00037752|DRUG|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
224269969|NCT00037752|BEHAVIORAL|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
224269970|NCT05953506|DRUG|HS-10506|HS-10506 will be administered orally once on Day 1.
224269971|NCT05953506|DRUG|HS-10506 Placebo|Matching placebo will be administered orally once on Day 1.
224269972|NCT01406639|DRUG|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
224269973|NCT04846439|BIOLOGICAL|CAR-T infusion|Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
224269974|NCT02591849|DIETARY_SUPPLEMENT|Glucagon-like peptide-1 (GLP-1)|
224269975|NCT02591849|OTHER|Isotonic saline|
223517647|NCT05796193|OTHER|Alpha-cypermethrin and Clorfenapyr LLIN|Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr
224269976|NCT02591849|OTHER|Hyperglycemic clamp|
224269977|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
224269978|NCT00831987|BIOLOGICAL|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
223517648|NCT05796193|OTHER|Alpha-cypermethrin only LLIN|reference: standard pyrethroid LLIN
223517649|NCT04893811|BIOLOGICAL|Trumenba|Bivalent recombinant lipoprotein 2086 vaccine
223893467|NCT04458883|PROCEDURE|Electrocardiogram|Electrocardiogram
223893468|NCT04458883|PROCEDURE|Echocardiogram|Echocardiogram
223893469|NCT04749615|DRUG|Periarticular Injection (PAI)|PAI is a widely-utilized, surgeon-performed, analgesic intervention for TKA patients.
223893470|NCT04749615|DRUG|Saline Control Periarticular Injection (PAI)|equal volume of saline will be used in place of analgesics used in PAI injections
223893471|NCT05686590|BEHAVIORAL|Augmented Reality Headset|The simulation scenario will be a pediatric hypoglycemia-induced seizure case, which will be done through an AR simulation. AR (Augmented Reality) headset, which is a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario.
224269979|NCT03538795|COMBINATION_PRODUCT|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everyday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
224269980|NCT04559841|OTHER|bone substitute; NanoBone®|surgical treatment of peri-implantitis using a regenerative surgical protocol utilizing NanoBone (NB) synthetic bone graft with or without simvastatin.
224269981|NCT06417632|OTHER|Graded Zirconia Crown|monolithic implant supported crown
224269982|NCT06417632|OTHER|Conventional Zirconia Crown|monolithic implant supported crown
224269983|NCT03768817|OTHER|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
224269984|NCT02045355|OTHER|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
224269985|NCT00510419|DRUG|"InvestigationalAuto-injector (sumatriptan succinate)"|
224269986|NCT02998541|DRUG|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
224269987|NCT02998541|DRUG|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
224269988|NCT02998541|OTHER|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
224269989|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
224269990|NCT03147833|DIETARY_SUPPLEMENT|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
224269991|NCT03304782|OTHER|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
224269992|NCT06274424|BEHAVIORAL|The Friends Program|A group CBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
224269993|NCT05770557|BEHAVIORAL|survey|administration of a survey among healthcare workers
224269994|NCT02965872|OTHER|No intervention|
224269995|NCT05069233|OTHER|UGI+SB|Patients who underwent combined upper digestive tract and small intestine examination under MCE.
224269996|NCT06537869|BEHAVIORAL|iCBT for depression|iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
223893472|NCT06491758|DEVICE|ML1101 Stimulus Isolator|Electrical stimulation electrodes will be placed on the ear with the intensity of the current being increased by 10 percent every 60 seconds, the subject will grade the intensity of the current on a scale of 0-10. Increasing of the current will occur until the subject reports a comfortable level. Once the target level has been achieved the stimulation will be delivered for 2 minutes.
224083123|NCT03402997|DIAGNOSTIC_TEST|Resistivity measurement|To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
224269997|NCT06314490|DRUG|nL-SCN2A-002|Personalized antisense oligonucleotide
224269998|NCT03957928|OTHER|Low fat cookie|to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
224269999|NCT03957928|OTHER|Mango fruit|to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
224270000|NCT05696392|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
224270001|NCT06794229|DRUG|Zanzalintinib|Zanzalintinib 100mg orally (PO) once daily for 12 weeks up (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1)
224270002|NCT06794229|DRUG|Nivolumab|Nivolumab will be administered at either 240mg IV every 2 weeks or 480mg IV 4 every weeks for 12 weeks (all subjects) and up to 48 weeks from Cycle 1 Day 1 (Cohort B1).
224270003|NCT06406725|DIAGNOSTIC_TEST|Point-of-Care Ultrasound of the Airway|Patients who are recruited will have an ultrasound performed of their larynx while they are on noninvasive positive pressure ventilation and then a second ultrasound when they are removed from noninvasive positive pressure ventilation. Between the two ultrasounds, the otolaryngology team will perform their fiberoptic nasolaryngoscopy, as per standard unit protocol and patient care.
224270004|NCT01134549|DRUG|Etelcalcetide|Administered as a single intravenous (IV) injection
224270005|NCT01134549|DRUG|Placebo|Administered as a single intravenous (IV) injection
224270006|NCT01929486|BIOLOGICAL|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
224270007|NCT03044873|DRUG|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
224270008|NCT03044873|DRUG|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
224270009|NCT02133638|DRUG|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
224270010|NCT02133638|DRUG|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
224270011|NCT03387462|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
224270012|NCT03387462|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
223517650|NCT05059626|DRUG|simvastatin 10mg|Simvastation acts as a systemic LOX inhibitor.
224083124|NCT00670410|PROCEDURE|Related donor transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
224270013|NCT01884844|DRUG|Vitamin D3, Cholecalciferol|
224270014|NCT01884844|DRUG|Placebo|
223517651|NCT05059626|DRUG|Bazedoxifene 20/Estrogens,Con 0.45Mg Tb|Duavee is a selective estrogen receptor modulator.
224270015|NCT04785053|DEVICE|transcranial alternating current stimulation (tACS)|The tACS intervention (gamma stimulation, theta stimulation and active sham condition) will be administered to the participants over three visits that will be completed within one of the working days (Mon-Fri) at approximately the same time of day for all participants. Participants will be randomized and blinded to the tACS treatment.
223893473|NCT06491758|PROCEDURE|Vagal Maneuver|"Subjects will undergo the following procedures to stimulate the vagus nerve.~* Cough: 6 to 8 forceful coughs~* Cold stimulus: a washcloth soaked in ice water will be placed on the face for 10 seconds.~* Carotid massage~* Gagging: a tongue depressor will be inserted for 10 seconds into the mouth touching the back of the mouth.~* Valsalva maneuver: subjects will will be asked to bear down as if they were having a bowel movement. They will be asked to blow through a mouthpiece that is hooked to a machine that measures how hard they are blowing.~* Eating: Subjects will be asked to drink water ( 8oz or 1 cup) or/ and Ensure Original ( 8 oz or 1 cup) that has 220 calories after fasting overnight to see that effect on vagal activity during eating."
223893474|NCT03611491|DEVICE|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
224270016|NCT04179396|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
224270017|NCT04179396|DRUG|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
224270018|NCT04179396|DRUG|Abiraterone|Abiraterone will be administered once daily with prednisone
224270019|NCT03196817|DRUG|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
224270020|NCT03196817|DEVICE|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
224270021|NCT00890864|OTHER|Invitation for breast screening|Invitation for breast screening to women in different age groups
224270022|NCT00218322|DRUG|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
224270023|NCT00218322|DRUG|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
224270024|NCT01080820|DRUG|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
224270025|NCT01080820|DRUG|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
223893475|NCT06445556|BEHAVIORAL|NatureUplift|a culturally tailored, nature-based program offered at the TRPD. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing). Following week 12, participant dyads who were randomized to the NatureUplift intervention (i.e., delayed intervention arm) will receive access to 4 additional weeks of the NatureUplift+Active intervention.
224083125|NCT00670410|PROCEDURE|Cord blood transplant|Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
224270026|NCT01080820|DRUG|Viread|One single oral dose of 300mg Viread.
224270027|NCT01944722|DEVICE|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
224270028|NCT01944722|PROCEDURE|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
224270029|NCT03539926|DEVICE|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
224270030|NCT03539926|DIAGNOSTIC_TEST|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
224270031|NCT06048848|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
224270032|NCT06048848|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
224270033|NCT06048848|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
224270034|NCT04929821|DEVICE|Biliary Duct Stenting|UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
224270035|NCT04153825|DEVICE|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
224270036|NCT04153825|DEVICE|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
224270037|NCT04153825|OTHER|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
224270038|NCT04153825|DEVICE|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
223719014|NCT03715530|DEVICE|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
223719015|NCT01929343|DRUG|lidocaine following cue-induced craving|as described in Arm Description
223719016|NCT01929343|DRUG|lidocaine following neutral stimulus|as described in Arm Description
223719017|NCT01929343|DRUG|saline|as described in Arm Description
223517652|NCT05991466|DRUG|Dexmedetomidine|"All patients will be assessed clinically and investigated for exclusion of any of the above-mentioned contraindications. The required laboratory work will be: complete blood count (CBC); prothrombin time and concentration (PT\&PC); partial thromboplastin time (PTT); bleeding time (BT); clotting time (CT); liver function tests and kidney function tests.~Before arrival to the operation room (OR), women will be premedicated by metoclopramide 10mg and ranitidine 50 mg intravenous. Intra operatively, hemodynamics will be recorded baseline before spinal anaesthesia , after its performance, every 3 minutes until delivery and then every 10 minutes till the end of the CS. Any change within 20% of baseline will be accepted and any changes more than 20% will be managed according to guidelines. All groups will be anaesthetized to preform CS with conventional spinal anaesthesia. The TAP block group will receive a landmark orientated Ultrasound guided bilateral TAP block."
223517653|NCT04526158|BEHAVIORAL|Mobile+Group LAMP Mindfulness-Based Intervention|The Mobile+Group LAMP Mindfulness-Based Intervention (MBI) condition consists of eight 90-minute weekly group sessions, delivered via secure video-conferencing. The first session is preceded by a 90-minute technical session introducing the video-conference system and other logistics. The program consists of educational and instructional videos presented by a trained mindfulness instructor interspersed with workbook reflections and group discussions, and daily practice exercises that participants do on their own. A trained facilitator (who is not required to be an expert in mindfulness) leads the group. Participants also have access to a mobile app and a study website, with the same educational and instructional videos that are presented in the group sessions, and the accompanying workbook.
224270039|NCT04153825|DEVICE|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
224270040|NCT04386122|DRUG|FABALOFEN 60|Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
224270041|NCT04386122|DRUG|JAPROLOX TABLET|Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
224270042|NCT05788250|PROCEDURE|Subacromial spacer implantation|A biodegradable balloon implanted arthroscopically between the acromion and humeral head with tenotomy of long head of biceps.
224270043|NCT05788250|PROCEDURE|Rotator cuff repair|Rotator cuff repair with tenotomy of long head of biceps.
224270044|NCT02906917|DRUG|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
224270045|NCT02906917|DRUG|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
224270046|NCT02906917|DRUG|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
223704002|NCT01011777|DRUG|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
224270047|NCT02371837|OTHER|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
224270048|NCT02995187|DRUG|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
223893476|NCT06445556|BEHAVIORAL|NatureUplift+Active|NatureUplift plus a supplementary walking/hiking educational component. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing) prescribed during the NatureUplift condition and an additional 60 min/week of supplementary moderate- intensity activities (e.g., walking and hiking) prescribed during the NatureUplift+Active condition. Those who were randomized to the NatureUplift+Active intervention will continue to receive access to 4 additional weeks of the NatureUplift+Active intervention.
224270049|NCT02232945|DRUG|placebo of oseltamivir phosphate|
224270050|NCT02232945|DRUG|oseltamivir phosphate|
224270051|NCT02232945|DRUG|Banlangen (Radix Isatidis) granules|
224270052|NCT02232945|DRUG|placebo of Banlangen(Radix Isatidis) granules|
224270053|NCT02926170|DRUG|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
224270054|NCT02926170|DRUG|acenocumarol|Doses will be adjusted according to INR
224270055|NCT04457115|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block performed at T2-T3 and T4-T5 levels with administration of Ropivacaine 0.7% 8 ml for each level
224270056|NCT04457115|PROCEDURE|Erector spinae plane Block|Erector spinae plane block performed at T2 and T5 levels with administration of Ropivacaine 0.5% 12 ml for each level
224270057|NCT02393560|PROCEDURE|DECT scan|
224270058|NCT01437735|DRUG|QAW039|QAW039 po
224270059|NCT01437735|DRUG|Montelukast|Montelukast 10 mg po
224270060|NCT01437735|DRUG|Placebo|Placebo
224270061|NCT03004157|PROCEDURE|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
224270062|NCT02865148|BEHAVIORAL|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
223704003|NCT01134276|PROCEDURE|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
223704004|NCT01191333|DEVICE|rTMS|Repetitive Transcranial Magnetic Stimulation
223893477|NCT05499897|PROCEDURE|ultrasoud guided interscalene block|Open shoulder surgery by ultrasound guided peripherel block. Observation effect of this peripheral block on immunity and wound healing
223893478|NCT05499897|PROCEDURE|general anesthesia|Open shoulder surgery by general anesthesia. Observation effect of this peripheral block on immunity and wound healing
223893479|NCT03769415|DEVICE|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
223893480|NCT06513936|PROCEDURE|The skin care Bundle|S- Secure device and protect the skin with dressings K- Keep repositioning more frequently than twice daily Inspect the skin under the device more than twice daily N- Nutrition and hydration C- Choose the correct size and type of medical device A- Avoid placing devices over sites of prior or existing pressure injury R- Report MDRPI correctly and immediately E- Educate staff on the correct use of devices and prevention of skin breakdown
223893481|NCT06513936|PROCEDURE|Routine care|Routine care delivered in the unit
223893482|NCT04188470|BEHAVIORAL|person-centered care model|A multidisciplinary team (clinical pharmaceutical, expert physician on chronic management disease, and basic healthcare team) will review the frailty, complexity, the therapeutic goals of the patients to propose changes on the therapeutic plan to improve the appropriateness, these changes will we agreed with the patient or caregiver.
223893483|NCT06425198|DRUG|BMS-986278|Specified dose on specified days
223893484|NCT06050109|DRUG|OFS continues to use group after 5 years use|Patients included in the group continued or discontinued to use goserelin or leuprolide after 5 years use.
223893485|NCT06050109|DIAGNOSTIC_TEST|Immunohistochemical detection of HR status|Enrolled patients must be HR-positive premenopausal breast cancer patients
223893486|NCT03373071|BIOLOGICAL|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
223893487|NCT02235909|DRUG|Azilsartan Medoxomil Low-dose|Azilsartan medoxomil low-dose (AZM-L) 10 mg
223893488|NCT02235909|DRUG|Losartan|
223893489|NCT02235909|DRUG|Placebo for Azilsartan Medoxomil|
223893490|NCT02235909|DRUG|Placebo for Losartan|
223893491|NCT02235909|DRUG|Azilsartan Medoxomil Medium-dose (20 mg)|Azilsartan medoxomil medium-dose (AZM-M) 20 mg
223893492|NCT02235909|DRUG|Azilsartan Medoxomil High-dose (40 mg)|Azilsartan medoxomil high-dose (AZM-L) 40 mg
223893493|NCT05026320|DRUG|Naproxen gel|10%, bid for 5 days (final application on morning of Day 6)
223704005|NCT01191333|DEVICE|Sham Device|Placebo Device that simulates active rTMS treatment
223704006|NCT00036829|PROCEDURE|pain therapy|
223704007|NCT01626456|DRUG|ALKS 9072, Low|IM injection, given monthly
223704008|NCT01626456|DRUG|ALKS 9072, High|IM injection, given monthly
223893494|NCT05026320|DRUG|Diclofenac gel|2.32% bid for 5 days (final application on morning of Day 6)
223893495|NCT05026320|DRUG|Placebo gel|bid for 5 days (final application on morning of Day 6)
223893496|NCT06299137|PROCEDURE|Serratus Anterior Plane Block|Patients who undergo randomization to the intervention arm will undergo the Serratus Anterior Plane Block.
223893497|NCT06299137|DRUG|Ropivacaine injection|For the Serratus Anterior Plane Block, Ropivacaine will be used as the anesthetic.
223893498|NCT02235623|PROCEDURE|Single-stage Fowler-Stephens orchidopexy (FSO)|
223893499|NCT02235623|PROCEDURE|Two-stage Fowler-Stephens orchidopexy (FSO)|
223893500|NCT04930822|OTHER|Table Top Visual Intervention|Table top visual interventions and exercises.
223893501|NCT04930822|DEVICE|Bioness Integrated Therapy System Visual Intervention|Digital visual interventions and exercises.
223893502|NCT05666960|DRUG|R-3750|Probiotic
223893503|NCT06435299|DRUG|Cannabis oil|Patients in this arm will have to take Cannabis oil (50mg/mL) twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
223893504|NCT06435299|DRUG|Placebo|Patients in this arm will have to take Placebo oil twice a day with the daily dose estimated during auto titration phase (from W0 to W2)
223893505|NCT05538533|RADIATION|46 Gy Radiation Therapy|Dose per fraction of 4.6.
223893506|NCT05538533|RADIATION|40 Gy Radiation Therapy|Dose per fraction 5.7.
223893507|NCT05538533|RADIATION|35 Gy Radiation Therapy|Dose per fraction 7.0.
224270063|NCT05863845|DRUG|Venetoclax|100mg day -10, 200mg day -9, 400mg day -8, 800mg day -7 to -1, Given PO
223893508|NCT06082063|DRUG|Aspirin tablet|Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
223893509|NCT06082063|DRUG|Semaglutide|GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.
223893510|NCT06082063|DRUG|Sotagliflozin|SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.
223893511|NCT06082063|DRUG|Finerenone|Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.
223893512|NCT05065970|DRUG|Felzartamab|anti-CD38+ monoclonal antibody
224270064|NCT05863845|DRUG|Carmustine|300mg/m2 day -7, Given IV
223893513|NCT05065970|OTHER|Placebo|Placebo comparator
223893514|NCT05591144|DRUG|Prednisone tablet|The dose selection of oral prednisone is the maximum daily dose based on weight for 4 days, followed by a taper every 2 days, with the maximum duration to 14 days.
224270065|NCT05863845|DRUG|Cytarabine|100mg/m2/d, day -6 to day -3, Given IV
224270066|NCT05863845|DRUG|Etoposide|200mg/m2/d, day -6 to day -3, Given IV
224270067|NCT05863845|DRUG|Melphalan|140mg/m2, day -2, Given IV
224270068|NCT05863845|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
224270069|NCT06338410|BEHAVIORAL|Kangaroo Mother Care|KMC is a care system for LBW and preterm infants at birth, based on skin-to-skin contact between the infant and the mother and exclusive breast feeding. The mother carries her Preterm infant for at least one hour per day. Urine collected before and after skin-to-skin contact.
224270070|NCT05809180|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt d1;
224270071|NCT05809180|DRUG|Orelabrutinib|Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
224270072|NCT05809180|DRUG|Pomalidomide|Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
224270073|NCT05809180|DRUG|Pro-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
224270074|NCT05809180|DRUG|R-miniCHOP-like regimen|rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
223893515|NCT05591144|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extracts are traditional Chinese medicine, which can improve microcirculation and provide good ameliorating effects for the treatment of tinnitus
223893516|NCT03547869|DEVICE|Active tDCS|Active tDCS will be adminestered
224270075|NCT04352062|DRUG|Melatonin|
224270076|NCT04352062|OTHER|placebo|
224270077|NCT04352062|DRUG|Pantoprazole 40mg|pantoprazole 2 x 40mg
224270078|NCT04352062|DRUG|Amoxicillin|Amoxicillin 2 x 1000mg
224270079|NCT04352062|DRUG|Levofloxacin 500mg|Levofloxacin 2 x 500mg
223893517|NCT03547869|DEVICE|Sham tDCS|Sham tDCS will be administered
223893518|NCT05478499|DRUG|Deucravacitinib|Specified dose on specified days
224270080|NCT00210639|DRUG|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
224270081|NCT01242124|PROCEDURE|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
223893519|NCT05478499|OTHER|Placebo|Specified dose on specified days
223893520|NCT05559671|BIOLOGICAL|Herpes Zoster Subunit (HZ/su) Vaccine|Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
223893521|NCT05559671|BIOLOGICAL|Placebo|Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
224270082|NCT01242124|PROCEDURE|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
224270083|NCT04292548|DIAGNOSTIC_TEST|taking saliva samples to determine TAS, TOS and LL-37|
224270084|NCT01067950|PROCEDURE|Isolated Pancreas Transplant|
224270085|NCT01067950|DRUG|Intensive Insulin Therapy|
224270086|NCT04144998|DIAGNOSTIC_TEST|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
224270087|NCT04462198|DRUG|PIPE-505|Intratympanic injection
224270088|NCT04462198|DRUG|Placebo|Intratympanic injection
224270089|NCT05755854|BIOLOGICAL|allogeneic γ9δ2 T Cells|dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)
224270090|NCT05755854|DRUG|Fludarabine|Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition
224270091|NCT05755854|DRUG|Cyclophosphamide|Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
223893522|NCT04266210|DEVICE|Fuji Bulk|Restorative system
223893523|NCT04266210|DEVICE|G-ænial Posterior|Restorative system
224270092|NCT05755854|DRUG|Zoredronic acid|Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
224270093|NCT01202253|DRUG|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
224270094|NCT05252988|DRUG|Neratinib|Neratinib orally once daily for 13 cycles, unless patient discontinues earlier.
224270095|NCT05252988|DRUG|Loperamide|Loperamide orally.
224270096|NCT05252988|DRUG|Colesevelam|Colesevelam capsules orally, 2 times a day for the first month (28 days).
224270097|NCT06731491|OTHER|Concurrent Training|Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes
224270098|NCT06731491|OTHER|Massage therapy and Aromatherapy|Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.
224270099|NCT06849869|BEHAVIORAL|COMPASS+|COMPASS+ is centered around the integration of a care manager (a licensed mental health clinician) who provides mental health supports (e.g. short-term therapy) and symptom monitoring to perinatal patients. The care manager works closely with the patient and obstetric clinician to create a treatment plan based on the patient's preferences and needs. The care manager also utilizes a care registry to send monthly mental health screeners to patients and track their symptoms. The care manger meets weekly with the obstetric clinician and a consulting psychiatrist to review and modify treatment plans as needed. The care manager services are available throughout pregnancy and up to one year postpartum.
224270100|NCT00550329|DRUG|Glipizide GITS|
224270101|NCT05591729|OTHER|Pilates exercises|Each Pilates session will last for one hour. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centering which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the craniocervical junction). A pilates exercise program will consist of 11 levels of treatment program.
224270102|NCT05591729|OTHER|postural correction exercise|the patients will receive postural correction exercises, stretches, and exercises to the pectoralis major, elevator scapulae, upper trapezius, serratus anterior, rhomboids, and deep neck flexors. The stretches included sitting chair stretches, Brugger's, wall angels, and doorway stretches. The exercises included push-up-plus, head-neck-retraction, and Kibler squeeze
224270103|NCT01046097|BIOLOGICAL|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
224270104|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
224270105|NCT00232687|DRUG|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
224270106|NCT05939102|COMBINATION_PRODUCT|v-prep combined with RMGIC for bracket bonding|prepare the tooth surface with the V-prep, then bond a bracket with the RMGIC
223893524|NCT04585035|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
223893525|NCT04585035|DRUG|D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other|Standard treatment of solid tumor, NSCLC or CRC
224270107|NCT05939102|COMBINATION_PRODUCT|Conventional bracket bonding technique|prepare the tooth with acid-etch, then bond a bracket using resin composite
224270108|NCT04411251|BEHAVIORAL|Nature-near integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
224270109|NCT04411251|BEHAVIORAL|Conventional integrative day care unit programme|Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
223893526|NCT06666517|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Routine surgery after neoadjuvant chemotherapy for breast cancer according to current guidelines.
224270110|NCT05429463|BIOLOGICAL|Sintilimab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
224270111|NCT05429463|DRUG|Carboplatin|AUC 5-6 mg/mL/min by IV infusion Q3W, given on cycle day 1.
223517654|NCT04526158|BEHAVIORAL|Mobile LAMP Mindfulness-Based Intervention|The Mobile LAMP MBI consists of 8 self-paced, 30- to 60-minute weekly sessions, delivered on a mobile app and available on the study website, with an accompanying workbook. The program consists of educational and instructional videos presented by a trained mindfulness instructor, with workbook reflections and daily practice exercises that participants do on their own (the same content used in Mobile+Group LAMP). Participants also participate in 3 engagement phone calls with a facilitator. The 1st call (45-60 minutes), held at the beginning of the program, includes technical and logistical information on engaging with mobile app, website, and workbook; and discussion of goals, challenges and plans for practice. The 2nd (middle of program) and 3rd call (end of program) are 25-45 minutes long and address technical/logistical issues and discussion of goals, progress, plans for practice and strategies to address challenges.
223893527|NCT06666517|OTHER|Immunohistochemistry Analysis|Determination of breast cancer subtypes through immunohistochemical analysis, and selection of Luminal B, HER2-positive, and triple-negative groups.
223893528|NCT06666517|PROCEDURE|Second Biopsy|Taking biopsies from the center of the tumor and the peritumoral stroma of the same mass during marking of the mass before neoadjuvant chemotherapy
223893529|NCT02962895|BIOLOGICAL|VAY736|VAY736
223893530|NCT02962895|OTHER|Placebo|Placebo control
223893531|NCT03784248|OTHER|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
224270112|NCT05429463|DRUG|Albumin-Bound Paclitaxel|260 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
224270113|NCT06405815|OTHER|tumor and peritumor radiomic feature|extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
224270114|NCT00362505|DRUG|Clevudine|
224270115|NCT00794053|PROCEDURE|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
224270116|NCT06676618|OTHER|Multimodal Exercise Training|"The exercise training consisting of aerobic, strengthening and balance exercises will be applied for 12 weeks/3days for 1hour. One day of the exercise training will be performed in a clinical environment with a physiotherapist, and the other 2 days of the week, participants will be asked to apply asynchronous video-based telerehabilitation over the internet in their own homes. The asynchronous video-based telerehabilitation application will be performed through an account created specifically for the participant on the www.telenororehab.com website. The exercise program will be created according to the individual's condition and progression will be provided every 3 weeks. Patients who do not attend 3 consecutive sessions will be excluded from the study."
224270117|NCT06676618|OTHER|Control Group|Participants in the control group will be placed on the waiting list after all evaluation methods have been applied and will be re-evaluated at the end of 12 weeks. After the evaluations, individuals in the control group will also be given multimodal exercise training.
224083126|NCT00670410|DRUG|Busulfan|Busulfan (Busulfex) \[4mg/kg/dose for patients \< 4 years; 3.2 mg/kg/dose for patients \> 4 years\] will be given IV in 0.9% sodium chloride or D5W to a final concentration \> 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
224270118|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
224270119|NCT03129061|DRUG|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"* Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
224270120|NCT04141878|BEHAVIORAL|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
224270121|NCT04141878|BEHAVIORAL|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
224270122|NCT04505163|PROCEDURE|Standard Cryoballoon Pulmonary Vein Isolation (PVI)|Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone
224270123|NCT04505163|DEVICE|Cryoballoon PVI + Posterior Wall Isolation|Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component
224270124|NCT02586350|DRUG|Anlotinib|
224270125|NCT02586350|DRUG|Placebo|Placebo p.o. qd
224270126|NCT00343681|BIOLOGICAL|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
224270127|NCT04022122|PROCEDURE|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
224270128|NCT04888039|OTHER|quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)|"Excepted the delivery of quality of life questionnaires (a maximum of 5 times during the course of treatment) specific to this study, only the data available during the course of patient care will be collected.~The quality of life questionnaires and the perceived stress questionnaire will be given to patients :~* At diagnosis (before starting 1st line of treatment),~* after the induction phase (before autologous transplantation for patients who will be transplanted),~* after the consolidation phase,~* after the maintenance phase : 1 year and 2 years after the start of the maintenance."
224270129|NCT02854800|DRUG|varenicline|Participants followed the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
224270130|NCT00973388|DRUG|Telaprevir; Moxifloxacin; Placebo|
224270131|NCT03431961|DRUG|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
224270132|NCT03431961|DRUG|Placebo|twice daily for 14 days
224270133|NCT00000245|DRUG|Desipramine|
224270134|NCT01916239|DIETARY_SUPPLEMENT|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
224270135|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-1|New pomegranate extract formulation-1
224270136|NCT01916239|DIETARY_SUPPLEMENT|Pomegranate extract formulation-2|New pomegranate extract formulation-2
224270137|NCT04546282|OTHER|Description of the molecular alterations detected in blood samples of patients treated by osimertinib|Description of the molecular alterations detected in blood samples of patients treated by osimertinib. This test is usualyy performed routinely to detect conventional mutations including EGFR T790M. We performed panel of genes screeining based on next generation sequencing. Thius, iIn some cases, new mutations can be detected by this assay.
224270138|NCT05833425|DEVICE|Respiratory Pressure Meter (MicroRPM)|Peripheral muscle strength, respiratory muscle strength and postural controls of all adolescents will be evaluated. The values of the scoliotic and healthy groups will be compared.
224270139|NCT03639181|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
224270140|NCT04509648|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral chest wall or whole breast and regional lymph regions and a sequential tumor bed boost of 5.2 Gy in 2 fractions to the conserved breast
224270141|NCT03611335|BEHAVIORAL|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
224270142|NCT05971056|OTHER|Care transition|Cancer care is transitioned to a satellite site.
224270143|NCT05971056|OTHER|No care transition|Cancer care is not transitioned to a satellite site.
224270144|NCT01538459|DRUG|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
224270145|NCT01538459|DRUG|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
224270146|NCT05280288|DEVICE|Bone@BC app|Participants in the intervention group will be asked to use the Bone@BC app daily it will take them 1-3 minutes to answer the daily questions in the app concerning symptoms and physical activity. They will have access to a Questionnaire Prompt List in the app Bone@BC.
224270147|NCT04173611|DRUG|EXPAREL|Injection into the Intrathecal space.
224270148|NCT04173611|DRUG|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
224270149|NCT04173611|OTHER|Placebo|Injection into the Intrathecal space.
223517655|NCT04889950|DEVICE|Tixel C|Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
223517656|NCT04889950|DEVICE|LipiFlow|LipiFlow
224270150|NCT04125186|DIAGNOSTIC_TEST|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
224083127|NCT00670410|DRUG|Thymoglobulin|Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
224270151|NCT04125186|DIAGNOSTIC_TEST|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
224270152|NCT04125186|DIAGNOSTIC_TEST|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
224270153|NCT04125186|OTHER|No other intervention|No other intervention
224270154|NCT01121601|PROCEDURE|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
224270155|NCT01121601|PROCEDURE|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
224270156|NCT05508490|DIAGNOSTIC_TEST|renal chemistry, serum electrolyte,|detection of renal chemistry affection and electrolyte disturbance in diabetic ketoacidosis
224270157|NCT03090282|PROCEDURE|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
224270158|NCT00827463|BIOLOGICAL|dosage of the NFS and iron|a blood test will be made.
224270159|NCT00627731|DRUG|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
224270160|NCT00627731|DRUG|prednisolone (PSL)|PSL 40 mg per day for 10 days
223517657|NCT05389150|DRUG|Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg|Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral
224270161|NCT03648580|DIETARY_SUPPLEMENT|Ensure Complete powder|Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
224270162|NCT03648580|OTHER|verbal nutrition education|give the verbal nutrition education
224270163|NCT05014438|DRUG|BMS-986166|Specified dose on specified days
224270164|NCT05014438|DRUG|Branebrutinib|Specified dose on specified days
224270165|NCT05014438|OTHER|Placebo|Specified dose on specified days
224270166|NCT02509143|PROCEDURE|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
224270167|NCT02509143|DEVICE|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
224270168|NCT02509143|DRUG|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
224270169|NCT03426657|COMBINATION_PRODUCT|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
224270170|NCT04492930|BEHAVIORAL|14:10 Regimen|14 hours of fasting, followed by a 10-h diet regimen that includes a fasting snack at 12 hours from the start of the fasting period
224270171|NCT04492930|BEHAVIORAL|12:12 Regimen|12 hours of fasting, followed by a 12-h diet regimen
224270172|NCT03056144|DEVICE|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~1. st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~2. nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~3. th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~4. th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min \>5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
224270173|NCT00418158|BEHAVIORAL|use of Airlife (therapy)|
224270174|NCT01827696|DIETARY_SUPPLEMENT|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
224270175|NCT01576458|DRUG|ursodeoxycholic acid|450 mg/day for 14 days
224270176|NCT01576458|DRUG|Placebo|placebo
224270177|NCT00486239|BEHAVIORAL|TLE Arm 1|Behavioral/cognitive testing
224270178|NCT00486239|BEHAVIORAL|Emotion Memory Test|Behavioral/cognitive Measure
224270179|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
224270180|NCT00486239|BEHAVIORAL|Emotion Memory Testing|Behavioral/cognitive testing
224270181|NCT02792816|DRUG|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
224270182|NCT06150196|BEHAVIORAL|Mindfulness-based Stress Reduction class|9-week standard Mindfulness-based Stress Reduction class training on mindfulness techniques, medication, and yoga
224270183|NCT06150196|BEHAVIORAL|Brain Health Education class|9-week Brain Health education class that involves lectures/discussion about how the brain works and recovers after brain injury
224270184|NCT02627963|DRUG|Tivozanib hydrochloride|Tivozanib hydrochloride
224270185|NCT02627963|DRUG|Sorafenib|Sorafenib
224270186|NCT02424435|DRUG|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
224270187|NCT01515163|BEHAVIORAL|Exercise training|Aerobic exercise training, two times a week
224270188|NCT02379624|DRUG|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
224270189|NCT01787695|PROCEDURE|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
223517658|NCT05389150|DRUG|Pregabalin 150mg|From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral
224270190|NCT00838838|DRUG|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients \> 18yrs in medical practices fulfilling all criteria for documentation.
224270191|NCT01269658|DRUG|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
224270192|NCT01269658|DRUG|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
223517659|NCT05389150|DRUG|Tramadol 50 mg|From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
223517660|NCT06119321|OTHER|Pentacam, Corvis ST and Scansys|morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST
224083128|NCT00670410|DRUG|Fludarabine|Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients \< 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
224270193|NCT01537718|DEVICE|REPLY 200|REPLY 200 pacemaker
224270194|NCT01904513|DIETARY_SUPPLEMENT|Pasteurized Whole Milk|
224270195|NCT01904513|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1|
224083129|NCT01748604|OTHER|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
224270196|NCT01508065|DEVICE|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
224270197|NCT06628011|OTHER|Intervention group/training group|We will assess the short-term effects through a 12-week intervention, and its long-term effects after 1-year. Both the intervention group (IG) and control group (CG) will receive two sessions of aerobic interval training at the Exercise Training Clinic, situated at the Department of Psychosis and Rehabilitation, Psychiatry Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. One training session consists of 36 minutes of high intensity training (HIT).
224270198|NCT01291095|DRUG|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
224270199|NCT01291095|RADIATION|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
224270200|NCT06475651|GENETIC|Methylation analysis|Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
224270202|NCT03673267|BEHAVIORAL|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
224270203|NCT04488380|OTHER|dental restoration|Restoration of carious mandibular 2nd molar teeth either with high viscosity glass ionomer or nanohybrid composite resin
224270204|NCT02025660|DRUG|Mw, 0.3ml x three days sc|
224270205|NCT02025660|DRUG|Placebo|
224270206|NCT05971394|DEVICE|Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)|Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
224270207|NCT02344550|DRUG|Everolimus(afinitor)|Everolimus 10mg p.o. daily
224270208|NCT02344550|DRUG|Letrozole|Letrozole 2.5 mg p.o. daily
224270209|NCT02344550|DRUG|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
224083130|NCT01748604|DEVICE|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
224270210|NCT04990648|DEVICE|Buzzy|Buzzy ® device (Buzzy ® Mini Healthcare) has been used to reduce pain by using local cold application and vibration effect. Buzzy ® was developed by Dr. Amy Baxter in 2009. The size of the Buzzy ® device measures 2⅞ꞌꞌ x 1⅞ꞌꞌ x ⅞ꞌꞌ (7,2 cm x 4,8 cm x 2,2 cm). It is a bee-shaped device made of hard plastic with a vibrating motor (2 settings - fixed and pulsed), powered by a 2AAA battery. There are 4 ice packages and elastic fastening strap. On the part where the device touches the skin, there is an ice package in the shape of a wing. When the button on the device is pressed, it vibrates.
224270211|NCT01746550|DEVICE|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
224270212|NCT05649904|DEVICE|IRRAflow with Active Fluid Exchange System|"IRRAflow® Active Fluid Exchange System is an intracranial drainage system intended for use by professional medical hospital personnel, trained and experienced in neurosurgical medical care.~The intracranial pressure is kept at a safe level by draining excessive intracranial fluid. The system incorporates an irrigation support mechanism, used to irrigate the system in a controlled, programmed manner to minimize catheter occlusion. Additionally, a manual bolus can be given to facilitate keeping the catheter clear of occlusion or to clear the catheter of occlusion if one is present. This mechanism works by producing a bolus pulse using short periods of high flow (i.e. flow pulses)."
224270213|NCT05649904|DEVICE|External Ventricular Drain|The External Ventricular Drain (EVD) is used standard of care at the study site for ventricular drainage.
224270214|NCT03586622|DIETARY_SUPPLEMENT|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
224083131|NCT01748604|OTHER|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
224270215|NCT03586622|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum\* BL03, B. infantis\* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus\*\* BD08; \*Recently reclassified as B. animalis subsp. lactis \*\* Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
224270216|NCT06398522|DIETARY_SUPPLEMENT|Food for special medical purposes with calcium butyrate, zinc gluconate and vitamin D3|Food for special medical purposes with functional release containing calcium butyrate, zinc gluconate and vitamin D3
224270217|NCT06398522|OTHER|Placebo|Placebo
224270218|NCT02638922|DRUG|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
224270219|NCT01608646|DRUG|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
224270220|NCT02244190|DRUG|Tipranavir|New oral solution (back up) formulation
223893532|NCT06801431|DEVICE|Transcutaneous spinal cord stimulation|Individuals will receive a 10-day course of daily, 30-minute sessions of transcutaneous spinal cord stimulation to the thoracolumbar spine cord using the Chattanooga Mobile 2 Stim Device. These sessions will be conducted in the morning before bowel care and therapy. Cathode pads will be placed between the T10 and T11 spinous processes and the T12 and L1 spinous processes. Anode pads will be placed over the iliac crests. Stimulation will consist of 1 millisecond duration, biphasic pulses, at 30 Hertz frequency. The intensity of the current, will be adjusted to be suprasensory and sub-motor, and no more than 140 milli-amperes.
224270221|NCT02244190|DRUG|Tipranavir|
223893533|NCT04252781|OTHER|Exhaustive exploration|"* clinical investigations~* imagery~* blood assessment~* functional respiratory investigations~* muscle function / skeletal muscle index"
224270222|NCT02244190|DRUG|Ritonavir|
224270223|NCT03007563|DEVICE|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
224270224|NCT03007563|PROCEDURE|bilirubin concentration measured in standard blood samples|
224270225|NCT03007563|DEVICE|bilirubin concentration measured by transcutaneous device|
224287329|NCT06904170|DRUG|Durvalumab Plus Tremelimumab|"Systemic infusion of :~Tremelimumab 300 mg, single dose at Cycle 1 Durvalumab 1500 mg at Cycle 1 then every 4 weeks until disease progression or unacceptable toxicity.~Durvalumab and Tremelimumab will be delivered during a single angiography. Implantable catheter is also allowed.~Durvalumab infusion will start 1 hour after the end of the tremelimumab infusion."
224287330|NCT06904170|DRUG|HAIC (GEMOX)|"Hepatic Arterial Infusion of Chemotherapy (HAIC) :~Gemcitabine 1000 mg/m² over 30 minutes, followed by Oxaliplatin 100 mg/m² over 2 hours. Administered every 2 weeks for 4 cycles. When a Durvalumab cycle match with an HAIC infusion, HAIC will be delivered on the same day."
224287331|NCT06905314|DRUG|HRS-4029|HRS-4029
224287332|NCT06905314|DRUG|Placebo|Placebo
224287333|NCT06903910|DRUG|Donepezil (Aricept)|Donepezil is a cholinesterase inhibitor tablet taken by mouth once nightly
224287334|NCT06905457|COMBINATION_PRODUCT|Vojta therapy|Vojta therapy, also known as Reflex Locomotion Therapy, is a specialized physiotherapy technique developed by Czech neurologist Václav Vojta, using sensory stimulation to activate innate movement patterns and improve motor skills, posture, and overall function
224287335|NCT06905457|COMBINATION_PRODUCT|Bobath therapy|Bobath therapy, also known as Neurodevelopmental Treatment (NDT), is a problem-solving approach to neurological rehabilitation, focusing on motor learning and efficient motor control to improve function and participation in daily activities
224287336|NCT06905184|BEHAVIORAL|Activity PRN|"An Activity PRN plan will be delivered to consenting patients, as described above. The intervention will be communicated to them as a new approach that 'supports the individual to engage in personalised meaningful activities, which they can engage in as and when required'.~Activity Resources are organised within a suitable, accessible location according with the patient's risk management and support plan. Dependent on the plan, resources may be kept on their person, in their bedroom, in a communal area, or in a locked or unlocked accessible cupboard.~Ward staff will facilitate prn activities on an 'as and when required' basis. This can occur when: 1) a patient requests an activity from their card, 2) the patient appears disengaged, or 3) staff deem that the patient may benefit from participation in an activity for the purpose of engagement or distraction."
224287337|NCT06904430|OTHER|Bucket Group|This Bucket Intervention is behavioral and studies the effect of players limiting their throw count during practice to reduce pain occurrence
224287338|NCT06904430|DEVICE|Brace Group|The Brace intervention studies the use of players using an elbow throwing brace during practice to reduce the occurrence of pain
224287339|NCT06905587|DRUG|Methylphenidate (MPH)|"10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.~For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol."
224287340|NCT06905587|DRUG|Placebo|"10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.~Dosage will follow the exact same principles as for the study drug (methylphenidate)."
224287341|NCT06472180|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
224287342|NCT06472180|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
224287343|NCT05872464|OTHER|Artificial saliva containing cumin and ginger extract|Artificial saliva containing cumin and ginger extract in spray bottle
224287344|NCT05872464|OTHER|Placebo|Placebo containing composition close to the test group without cumin and ginger extract in spray bottle
224287345|NCT05992948|DEVICE|Transanal stapling device|Transanal stapling device used in low anterior- or anterior rectum resection, sigma resection, left hemicolectomy and intestinal reconstruction operations
224287346|NCT00932282|DRUG|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
224287347|NCT00932282|DRUG|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
224287348|NCT02953678|DRUG|Ruxolitinib|
224287349|NCT02953678|DRUG|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
224287350|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
224270226|NCT05278858|COMBINATION_PRODUCT|MedJet Device with intralesional triamcinolone|A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
224270227|NCT05010135|DEVICE|Zebris Gait System assessment for gait weight distribution + EMG evaluation of Quadriceps, Hamstrings, Tib Anterior and Calves + Positional Sense assessment|To measure the above parameters and to compare between the healthy subjects and the vertebral fracture subjects
224270228|NCT04589286|BEHAVIORAL|Pack Health's Digital Life Coaching (DLC)|Pack Health smartphone-based DLC platform
224270229|NCT04589286|OTHER|Electronic Handouts|Generic wellness-related electronic handouts
223893534|NCT06801691|OTHER|Experimental: Intervention group|Educational materials: Iodine Feedback Tool, lecture on the topic of iodine and health, booklet, exercises, group assignments and a webpage This is a pre/post intervention with no control group.
224270230|NCT00362635|DRUG|Clevudine|
224270231|NCT03508596|OTHER|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
224270232|NCT04320563|PROCEDURE|Rexon-eye|This treatment involved the technology known as quantum molecular resonance (QMR) which has emerged as a new treatment for all types of dry eyes.
224270233|NCT00354419|RADIATION|total-body irradiation|Undergo radiotherapy
224270234|NCT00354419|DRUG|cyclophosphamide|Given IV
224270235|NCT00354419|BIOLOGICAL|anti-thymocyte globulin|Given IV
224270236|NCT00354419|DRUG|cyclosporine|Given IV
224270237|NCT00354419|PROCEDURE|umbilical cord blood transplantation|Undergo transplantation
224270238|NCT00354419|DRUG|mycophenolate mofetil|Given IV or orally
224270239|NCT00354419|PROCEDURE|bone marrow aspiration|Correlative study
224270240|NCT00354419|GENETIC|DNA analysis|Correlative study
224270241|NCT00354419|BIOLOGICAL|filgrastim|Given IV or SC
224270242|NCT01932021|PROCEDURE|adipose tissue grafting|
224270243|NCT02265679|DRUG|BIIL 284 BS, low dose, pediatric patients|
224270244|NCT02265679|DRUG|BIIL 284 BS, medium dose, pediatric patients|
224270245|NCT02265679|DRUG|BIIL 284 BS, high dose, pediatric patients|
224270246|NCT02265679|DRUG|BIIL 284 BS, low dose, adult patients|
224270247|NCT02265679|DRUG|BIIL 284 BS, medium dose, adult patients|
224270248|NCT02265679|DRUG|BIIL 284 BS, high dose, adult patients|
224270249|NCT02265679|DRUG|Placebo|
224270250|NCT03315533|DRUG|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
224270251|NCT03315533|DRUG|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
224270252|NCT03315533|DRUG|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
223893535|NCT06801067|BIOLOGICAL|SER-155|SER-155 (Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated) is an experimental designed ecology of 16 unique, human-commensal bacterial strains encapsulated for oral administration and will be provided by Seres as an investigational drug
224083132|NCT01748604|DEVICE|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
224270253|NCT05392959|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg per day
224270254|NCT05392959|DRUG|Placebo|Placebo for dapagliflozin film-coated tablets 10 mg
224270255|NCT03610542|BEHAVIORAL|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
224270256|NCT03610542|BEHAVIORAL|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
224270257|NCT03610542|BEHAVIORAL|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
224270258|NCT03610542|BEHAVIORAL|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
224270259|NCT03610542|BEHAVIORAL|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
224270260|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
224270261|NCT01322633|OTHER|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
224270262|NCT05759715|OTHER|Iris Color Measurement , LF/HF Measurement|Iris Color Measurement (Photos were taken of the iris with a digital camera ) LF/ HF Measurement (Using the three-channel standard ambulatory Holter recording system)
224270263|NCT00983099|DRUG|Neramexane|single and multiple dose, tablets, oral
224270264|NCT02022306|DRUG|TD-6450|
224270265|NCT02022306|DRUG|Placebo|
224270266|NCT00019487|BIOLOGICAL|aldesleukin|
224270267|NCT00019487|BIOLOGICAL|gp209-2M antigen|
224270268|NCT00019487|BIOLOGICAL|incomplete Freund's adjuvant|
224270269|NCT05120388|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil Addition|Daily dietary addition of olive oil (three tablespoons)
224287351|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
224270270|NCT02267707|DRUG|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
224270271|NCT02267707|DRUG|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
224270272|NCT00313937|DRUG|Insulin glargine|
224270273|NCT01545193|OTHER|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
224270274|NCT04579653|DEVICE|transcutaneous electrical nerve stimulation devices|electrical stimulation through surface electrodes
224270275|NCT03574051|DRUG|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
224270276|NCT05862805|PROCEDURE|Sample Collection and Endometrial Biopsy|Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
224270277|NCT03821974|PROCEDURE|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
224270278|NCT03821974|PROCEDURE|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
223517661|NCT06241014|OTHER|Mulligan Mobilization and Sling Exercises|Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
223517662|NCT06241014|OTHER|Mulligan Mobilization|Mulligan Mobilization
224270279|NCT02985060|DEVICE|Arctic Sun|"1. Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~   Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~2. Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~3. Recovery phase:Rewarming velocity: 0.05\~0.1℃ (within 30 hours)"
223517663|NCT03164993|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
223517664|NCT03164993|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
223517665|NCT03164993|DRUG|Cyclophosphamide|Chemotherapy
223517666|NCT03164993|OTHER|Placebo|Placebo
224287352|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
224287353|NCT00952276|BIOLOGICAL|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
224287354|NCT00952276|BIOLOGICAL|Normal saline solution|0.5 mL, Intramuscular on Day 0
224287355|NCT03259685|OTHER|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
224287356|NCT03259685|OTHER|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
224287357|NCT03259685|OTHER|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
224287358|NCT05589038|OTHER|Baby Wash/Shampoo|Parent participant will bathe the baby participant with the baby wash/shampoo at least 3 times per week, but no more than once daily.
224287359|NCT05589038|OTHER|Baby Lotion|Parent participant will use the baby lotion on baby participants at least once daily.
224287360|NCT05329818|DEVICE|high definition transcranial direct current stimulation|"Non-invasive brain stimulation neuromodulation using HD (3,14cm\^2) gel based round electrodes. Scalp electrode locations will be positioned based on a optimized biophysical solution targeting ipsilesional dlPFC and the contralesional anterior cerebellum.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 1.73mA. Patients in the cerebellar stimulation group will receive 20 min of HD-tDCS with 2.0mA.~Patients in the prefrontal stimulation group will receive 20 min of HD-tDCS with 3.73 mA.~Patients in the sham stimulation group will receive 20 min of sham HD-tDCS, with 30 seconds ramp-up and 30 seconds ramp-down."
224287361|NCT02883478|DEVICE|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
224287362|NCT02883478|PROCEDURE|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
224287363|NCT02883478|DRUG|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
224287364|NCT03431064|OTHER|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
224287365|NCT03431064|OTHER|Fluid Administration|Administration of IV Fluid by Anesthesiologist
224287366|NCT05859243|BEHAVIORAL|Traditional concurrent training|The subjects will perform two sessions per week of traditional concurrent training, consisting of strength training followed by aerobic exercise over 12 weeks, with progressive intensities and training volumes. Each traditional concurrent training session will consist of specific warm-up performed on equipment for upper and lower limbs with a load of less than 30% of the training load. Then the bench press, low row, leg press, extension and knee flexion exercises will be performed. Participants will be instructed to perform the concentric phase of the movement in one second and the eccentric phase in two seconds. After strength training, aerobic training (walking outdoors or on a treadmill) will be performed with intensity based on the adapted BORG effort perception scale (ranged to 0 = minimum effort, to 10 = maximal effort).
224287367|NCT05859243|BEHAVIORAL|Concurrent training consisting of strength training combined with dance classes|Each concurrent training session associated with dance classes will consist of the same strength training as the traditional concurrent training group, but the traditional aerobic training will be replaced by a dance class. Each dance class will consist of a 5-minute general warm-up with joint mobility exercises and dynamic stretching. Then the main part will be performed with the elaboration of choreography, lasting approximately 20 minutes. Finally, there will be a 5-minute cool-down with stretching exercises. Classes will be held in four different dance modalities, divided into four modules.
224287368|NCT01343875|PROCEDURE|tear of the distal tendon in the biceps muscle|
224287369|NCT06190886|DRUG|PTX-912|Investigation Product Monotherapy
224287370|NCT05183412|DEVICE|The Sedakit Oncomfort VR glasses (30-minutes Aqua program)|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone. The patients watch a VR underwater view of the ocean while listening to speeches to induce relaxation and meditation.
224287371|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery without VR glasses|During placement of ultrasound-guided regional nerve block (axillary or distal peripheral) and hand surgery, patients are NOT subjected to a 30-minutes VR program (Oncomfort SA, Wavre, Belgium) 'Aqua' via a head-mounted display and headphone.
224287372|NCT05183412|PROCEDURE|Ultrasound-guided regional nerve block and hand surgery with VR glasses|Ultrasound-guided regional nerve block and hand surgery with VR glasses
224270280|NCT02985060|OTHER|Standard treatment|"1. All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~2. In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~3. Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~4. Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
224270281|NCT02985060|DRUG|Saline|
224270282|NCT00503867|DEVICE|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
224270283|NCT05109104|DRUG|CAP UnScented|Sunscreen lip balm.
224270284|NCT05109104|DRUG|CAP Herbal Mint|Sunscreen lip balm.
224270285|NCT05109104|DRUG|CAP Mountain Berry|Sunscreen lip balm.
224270286|NCT05109104|DRUG|SPF Standard Sunscreen|SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
224270287|NCT05705869|DIAGNOSTIC_TEST|NT-proBNP|NT-proBNP will be measured in all participants in the Investigational arm. If the level of the NT-proBNP is elevated (≥125pg/mL) participants will undergo a full cart-based transthoracic echocardiogram along with a clinical examination for signs of HF and a HF symptom assessment. Participants with HF identified will be referred to their local HF clinic for ongoing management.
224270288|NCT01732562|OTHER|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
224270289|NCT00014469|DRUG|busulfan|
224270290|NCT00014469|DRUG|melphalan|
224270291|NCT00014469|DRUG|methotrexate|
224270292|NCT00014469|DRUG|tacrolimus|
224270293|NCT00014469|PROCEDURE|allogeneic bone marrow transplantation|
223517667|NCT06397183|OTHER|Mulligan Strech with Traction (TSLR) Technique|The Mulligan traction straight leg raise (TSLR) technique is a mobilization technique that can increase hamstring flexibility and range of motion.
224270294|NCT00897676|DRUG|Exendin-(9-39)|100-500pmol/kg/min
224270295|NCT00897676|DRUG|placebo|placebo (0.9% NaCl)
224270296|NCT01979146|OTHER|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
224270297|NCT03648931|BEHAVIORAL|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
224270298|NCT03648931|BEHAVIORAL|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~* Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~* Perceptions of HIV risk during pregnancy and breastfeeding~* Perceived role of male partners during pregnancy and breastfeeding~* Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~* Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~* How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
224270299|NCT04697173|OTHER|Single consent|A single consent form for possible procedures the child may undergo while in the PICU
224270300|NCT03028792|BEHAVIORAL|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
224270301|NCT03028792|BEHAVIORAL|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
224270302|NCT03807440|DRUG|Empagliflozin|Empagliflozin
224270303|NCT03807440|DRUG|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
224270304|NCT03807440|DRUG|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
224270305|NCT03807440|DRUG|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
224270306|NCT04207229|DEVICE|CODMAN CERTAS Programmable Valves|Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
223517668|NCT06397183|OTHER|Post-Isometric Relaxation Technique|Post-Isometric Relaxation Technique is a Muscle Energy Technique which increases hamstring flexibility and range of motion.
223517669|NCT03945253|DRUG|ASP8374|Intravenous
223517670|NCT05931718|BIOLOGICAL|cytokine essays|evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples
224270307|NCT04560725|DRUG|11C-Choline|11C-choline (0.05-0.1mCi/kg) was injected intravenously one week before or after the \[68Ga\]P137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
224270308|NCT00448825|DRUG|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
223517671|NCT05931718|BIOLOGICAL|NGS|evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples
223517672|NCT05931718|BIOLOGICAL|Fecal microbiome|evaluation of fecal microbiome on fecal samples
224270309|NCT00448825|DRUG|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
224270310|NCT05208892|PROCEDURE|SZMN block|Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally
224270311|NCT05208892|PROCEDURE|SZMN block with Dexmedetomidine|Suprazygomatic Maxillary Nerve (SZMN) Blocks with local anesthetic and Dexmedetomidine bilaterally
224270312|NCT03905967|PROCEDURE|TACE|TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.
223517673|NCT05931718|DRUG|Erythropoietin|evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
223517674|NCT05931718|DRUG|Luspatercept|evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice
223517675|NCT05931718|DRUG|Thrombopoietin Receptor Agonist|evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice
223517676|NCT05931718|DRUG|G-CSF|evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
223517677|NCT05201495|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
223517678|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with CTG|"An epithelial-connective tissue graft of approximately 2-3 mm of thickness and adequate length will be taken from the palate or retromolar region of the patient and de-epithelialized with a scalpel (ideally a thickness of 1.5-2.0mm).~The connective tissue graft (CTG) obtained will then be positioned buccally to the dental implant and sutured to the internal side of the flap so to provide soft tissue bulk at the level of the neck of the implant and simulate a root prominence for the missing tooth."
224270313|NCT03905967|DRUG|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients \<60kg, and 12 mg qd for patients \>60kg)
223517679|NCT04265768|PROCEDURE|Soft tissue augmentation surgery with Fibro-Gide|Fibro-Gide will be used to obtain buccal soft tissue augmentation. Fibro-Gide will be trimmed with a scalpel and adjusted in size and thickness to better adapt to the area buccal to the implant. In particular, the graft will be shaped in order to obtain a graft of approximately 2-3 mm of thickness and adequate length. Fibro-Gide will then be sutured to the inner side of the buccal flap, before repositioning the flap and suturing it in a tension-free way.
223517680|NCT04265768|PROCEDURE|No soft tissue augmentation|During implant placement surgery, no soft tissue augmentation will be performed
223517681|NCT03315026|DRUG|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
223517682|NCT03315026|BEHAVIORAL|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
223517683|NCT06121284|DRUG|D-Cycloserine|Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
224083133|NCT01499017|DRUG|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
224270314|NCT04584073|PROCEDURE|Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application|Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
223517684|NCT06121284|DEVICE|intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
224270315|NCT06089330|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
224270316|NCT06089330|DRUG|SG001|240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).
224270317|NCT06089330|DRUG|Irinotecan|180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).
224083134|NCT01499017|DRUG|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
224270318|NCT06089330|DRUG|Regorafenib (Stivarga)|160 mg, taken orally once daily for the first 21 days of each 28-day cycle.
224270319|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
224270320|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
224270321|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
224270322|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
224270323|NCT01140672|DRUG|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
224270324|NCT01140672|DRUG|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
224270325|NCT06449534|BEHAVIORAL|Patient Education|It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.
224270326|NCT06449534|BEHAVIORAL|Exercise Therapy|Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.
224270327|NCT06449534|BEHAVIORAL|Cold Application|Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
224270328|NCT00323258|BEHAVIORAL|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
224270329|NCT00323258|DEVICE|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
224270330|NCT00323258|DEVICE|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
224083135|NCT00964431|DRUG|Celecoxib 400 mg|Capsules 2 x 200 mg Single-Dose
224083136|NCT00964431|DRUG|Placebo|Capsules 2 Single-Dose
224270331|NCT00323258|BEHAVIORAL|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
224270332|NCT00323258|BEHAVIORAL|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
224270333|NCT00323258|BEHAVIORAL|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
224270334|NCT00323258|BEHAVIORAL|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
224270335|NCT00323258|OTHER|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
224270336|NCT05649358|DEVICE|Lactate sensor (Lactisense)|Non-invasive monitoring of interstitial lactate levels during and after exercise.
224270337|NCT05782439|OTHER|Manual evaluation of ITB tension|There will be a double evaluation for each sampling session: 1) if there is a uniformity of the tension between the two sides, or if there is a prevalence on one side; 2) quantification of the difference, if present, with a graduation in 3 levels.
223517685|NCT06121284|DRUG|Placebo oral tablet|Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
223517686|NCT04914273|DRUG|Inhalation Spray|400 mcg salbutamol administered per metered dose inhaler
224270338|NCT05201235|DEVICE|MAEVAD|"MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character."
223517687|NCT04914273|DRUG|Tablet|8 mg salbutamol administered per tablet for ingestion
223517688|NCT03984461|BIOLOGICAL|Autologous cell therapy|Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
224083137|NCT00964431|DRUG|Indomethacin Test (lower dose)|20-mg single dose
224287373|NCT05468372|DRUG|Posaconazole 600 mg followed by posaconazole 300 mg once daily|Posaconazole will be given as a delayed release tablet, the dose would be 600 mg in two divided doses on day 1, followed by 300 mg once a day from then on. If a subject vomits within 15 minutes of posaconazole tablet administration, the dosing should be repeated as soon as possible, following appropriate antiemetic treatment. The drug will be administered after a meal.
224287374|NCT05468372|DRUG|Liposomal Amphotericin B|"All study subjects will be administered intravenous liposomal amphotericin B \[5 mg/kg/day infusion in 5% dextrose solution\] over at least 2 hours, as per recommendations. Amphotericin B will be administered for the first seven days in the experimental arm, whereas it will be administered atleast for four weeks in the active comparator arm. Premedication or intravenous hydration will not be routinely administered. For patients experiencing chills, fever, hypotension, nausea, or other non-anaphylactic immediate infusion-related reactions, premedication (acetaminophen, diphenhyramine or hydrocortisone) will be administered 30 to 60 minutes prior to the next dose of amphotericin infusion.~The dose of intravenous amphotericin B will be modified further if required, based on the tolerability, and response to treatment."
224287375|NCT05824819|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
224083138|NCT00964431|DRUG|Indomethacin Test (upper dose)|40-mg single dose
224083139|NCT01497977|DRUG|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
224083140|NCT01497977|DRUG|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
224287376|NCT02682147|DRUG|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
224287377|NCT05535855|DRUG|CD19 Directed CAR T Cell|The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
224287378|NCT00095433|DRUG|rhuFab V2 (ranibizumab)|
224287379|NCT00214331|DRUG|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
223517689|NCT05813093|DEVICE|rTMS|Accelerated iTBS treatment
223517690|NCT05999383|DRUG|Cannabis|Participants will vape marijuana in varying doses from the PAX device
223517691|NCT05999383|DRUG|Nicotine|Participants will vape Regular and Very Low Nicotine content cigarettes from the PAX device
224287380|NCT00214331|DRUG|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
224287381|NCT00214331|DRUG|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
224270339|NCT05201235|DEVICE|DeCaLigne|"DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game."
224270340|NCT02518139|DRUG|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
224270341|NCT02518139|DRUG|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
224270342|NCT01586039|DEVICE|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
224270343|NCT04436198|DEVICE|MORCHER® EYEJET® CTR Types 14, 14A, and 14C|"Intervention. Toric IOL + CTR. Whether the subject receives 14, 14A, or 14C is an either or scenario depending on the eye's axial length and is a single intervention:~Axial length \> 28.0 mm: CTR model 14A Axial length 24.0-28.0 mm: CTR model 14C Axial length \< 24.0 mm: CTR model 14~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
224270344|NCT04436198|DEVICE|Toric IOL Only|"Control. Toric IOL only. Standard of care cataract surgery without placement of a capsular tension ring.~Lens Selection: The patients will undergo standard of care preoperative measurements and planning. The surgeon will evaluate preoperative measurements and use lens calculations, as well as a discussion with the patient, to identify whether a toric lens will be used and to determine the IOL power, cylinder, and target axis (standard of care). Preoperative measurements will be taken using IOL-Master 700, with the addition of the Pentacam and automatic keratometry as needed (standard of care). The toric lens used will be the TECNIS IOL. It will be used on label (standard of care)."
224270345|NCT00873990|OTHER|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
224270346|NCT00873990|OTHER|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
224083141|NCT00440726|DRUG|Bortezomib|Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
224270347|NCT00945490|DRUG|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
224270348|NCT00945490|DRUG|Placebo|Single intraprostatic injection of placebo
224270349|NCT00558402|BEHAVIORAL|Meditation|meditation class 1/week for 8 weeks
224270350|NCT00558402|BEHAVIORAL|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
224270351|NCT00558402|BEHAVIORAL|Respite only|Respite care 90 mins per week for 8 weeks
224083142|NCT00440726|DRUG|Dexamethasone|10 mg/m2/day divided BID, oral administration for 14 days.
224270352|NCT04821232|OTHER|yoga|"Content of education;~1. Breath Awareness Training (10 minutes)~   Students will be checked on a routine basis~2. Asanas (20 minutes) I. Don't bend sideways in Mountain Pose ii. Warrior Pose iii. Bridge Pose iv. Happy Baby Pose~v. Fixed Butterfly / Angel Pose vi. Wide sitting in Angel Pose vii. Cat Pose Tiger Breath viii. Cow-downward dog, ix. Plank x. Cobra c. Mudra and meditation (10 minutes) will be practiced."
224270353|NCT04821232|OTHER|Routin control|Students will be checked on a routine basis
224270354|NCT02372006|DRUG|afatinib|
224270355|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 50 mg QD
223517692|NCT05999383|DEVICE|Pax Loose Leaf Vaporizer|In all arms, participants will be using the PAX Loose Leave Vaporizer.
224270356|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD
224270357|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD
224270358|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
224270359|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
224270360|NCT01316237|DRUG|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
224270361|NCT01316237|DRUG|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
224270362|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900mg , BID
224270363|NCT01316237|DRUG|GS-6620 tablet|GS-6620 tablet, 900 mg
224083143|NCT00440726|DRUG|PEG-asparaginase|2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
224270364|NCT01614288|PROCEDURE|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
224270365|NCT01614288|OTHER|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
224270366|NCT04987645|PROCEDURE|Water-only infusion technique|During a routine colonoscopy, a resident in the study will use water only infusion technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
224270367|NCT04987645|PROCEDURE|Water infusion and air insufflation|During a routine colonoscopy, a resident in the study will use water infusion and air insufflation technique for this intervention. This intervention is used to look at the impact that water assisted colonoscopy has on resident learning.
224270368|NCT04848688|DRUG|Moxidectin 2 mg|Monotherapy, oral administration, single-dose, fixed-dose, 4 tablets of 2 mg each to yield an 8 mg final dose.
224270369|NCT04848688|DRUG|Ivermectin 3 mg|Monotherapy, oral administration, single-dose, weight dependent, The number of tablets will be adjusted according to the patients' weight to yield 200 ug/kg final dose.
224270370|NCT04848688|DRUG|Placebo|Monotherapy, oral administration, single dose, matching number of tablets to either moxidectin or ivermectin
224270371|NCT03161197|BEHAVIORAL|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
224270372|NCT04268797|DEVICE|HR rTMS|high frequency repetitive transcranial magnetic stimulation (HF rTMS) with H7-coil applied once daily during the twenty days
224270373|NCT04268797|DEVICE|sham|SHAM HF rTMS coil once daily x 20 days
224270374|NCT03947905|PROCEDURE|Virtual visit|Type of visit
224270375|NCT05432687|DIAGNOSTIC_TEST|evaluation of deep abdominal wall before surgery|: cough test (L guillarme) + ulstrasonography of transversus abdominis
224270376|NCT04819009|OTHER|the Enhanced Transtheoretical Model Intervention (ETMI)|"ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~1. Creating a therapeutic alliance (communication skills and reassurance)~2. Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~3. Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~4. Postcard with reminder messages on how to self manage the back."
224270377|NCT03306758|DRUG|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
224270378|NCT00603967|PROCEDURE|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
224270379|NCT00603967|PROCEDURE|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
224270380|NCT00603967|BEHAVIORAL|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
224270381|NCT04416750|DRUG|Imatinib Mesylate|Treatment with Imatinib
224270382|NCT05311072|PROCEDURE|pulmonary endarterectomy or balloon pulmonary angioplasty|A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
223517693|NCT05999383|OTHER|Placebo Marijuana|Participants will vape placebo marijuana from the PAX device
223517694|NCT03689179|BEHAVIORAL|Time for Living and Caring (TLC)|"Time for Living \& Caring (TLC) is an online, self-administered intervention. It includes three types of modules: 1) virtual coaching module (defined as a series of prompts, reminders, and suggestions that guide caregivers through assessment, goal setting, and goal review activities) to monitor respite time-use and time-use goals, 2) an interactive calendar that can be used to schedule and track respite time, 3) resource pages (including links, printable forms, video guides) that provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?."
224083144|NCT00440726|DRUG|Doxorubicin|60 mg/m2/day IV over 15 minutes on Day 1
224083145|NCT00440726|DRUG|Cytarabine|"Given intrathecally on Day 1 of course 1 at the dose defined by age below.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age"
224270383|NCT05612958|DEVICE|DKM-410|Injection up to 2.0ml
223893536|NCT06539052|DIAGNOSTIC_TEST|anti-HDV positive with the reflex testing methodology|Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
223893537|NCT06801119|DRUG|HN2301 injection|Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.
223893538|NCT05581745|PROCEDURE|Blood group A2 donor to blood group O recipient lung transplant surgery|Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant
224270384|NCT05612958|DEVICE|Juvederm ULTRA PLUS XC 1.0ml|Injection up to 2.0ml
224270385|NCT04170335|PROCEDURE|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
223893539|NCT05003739|PROCEDURE|Hip arthroplasty with Logica Mirror femoral stem|Total or partial hip arthroplasty with implant of Logica Mirror femoral stem
224270386|NCT03259841|OTHER|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
224270387|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
223893540|NCT05965609|BEHAVIORAL|CBTI|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
223893541|NCT05965609|BEHAVIORAL|MRTI|Intervention includes education about sleep and behavioral and relaxation strategies to improve sleep
224270388|NCT01225510|BIOLOGICAL|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
224270389|NCT03458741|OTHER|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (\~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
224270390|NCT00686764|OTHER|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
224270391|NCT02169323|OTHER|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
224270392|NCT00130949|DRUG|ALGRX 4975|
224270393|NCT05526703|DRUG|D064, D701, placebo of D012|Experimental Group Subjects assigned to this group are treated with D064, D701, placebo of D012
224270394|NCT05526703|DRUG|D012, placebo of D064, placebo of D701|Comparator Group Subjects assigned to this group are treated with D012, placebo of D064, placebo of D701
224270395|NCT03504085|OTHER|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
224270396|NCT03504085|OTHER|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
224270397|NCT00320307|DRUG|abacavir|
224270398|NCT03935815|DRUG|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
224270399|NCT03935815|PROCEDURE|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
224270400|NCT04133311|DRUG|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.
224270401|NCT04133311|DRUG|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.
224270402|NCT04133311|DRUG|DE-130A/DE-130A|After Week 12, received DE-130A continuously.
223893542|NCT05481320|BEHAVIORAL|REACH VN Phone Intervention|4-6 intervention sessions delivered via phone over the course of 1-3 months.
224270403|NCT04133311|DRUG|Xalatan®/DE-130A|From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
224270404|NCT02911909|DEVICE|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
223893543|NCT05481320|BEHAVIORAL|Enhanced Control|A single phone session providing education about dementia.
223517695|NCT06402136|DRUG|83-0060|Oral MPro inhibitor
224270405|NCT02911909|OTHER|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
224270406|NCT01698645|DRUG|PecFent® (fentanyl) nasal spray|
224270407|NCT06069037|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
224270408|NCT04947761|DRUG|modified Tian Wang Bu Xin Dan hydrogel patch|modified Cheonwangbosimdan hydrogel patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
224270409|NCT04947761|OTHER|placebo patch|placebo patch (one patch/24 hours) applied to Shenque point for 4 days (1 patch daily beginning 2 days preoperative, and continued at 1 patch daily until 2 days postoperatively)
224270410|NCT00252161|PROCEDURE|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
224270411|NCT00252161|DRUG|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
224270412|NCT06249451|OTHER|Checklist-based phone calls|"The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.~On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.~The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines."
224270413|NCT00804011|OTHER|ATC|Automatic tube compensation
224270414|NCT00804011|OTHER|PSV|Pressure support ventilation
224270415|NCT00189553|DRUG|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
224270416|NCT00189553|DRUG|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
224270417|NCT00189553|DRUG|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
224270418|NCT00668577|DRUG|Lactic acid (Dermacid)|
224270419|NCT04872777|BEHAVIORAL|Noom Healthy Weight|"Following study group assignment, the following procedures will be completed for the Noom HW mHealth lifestyle intervention:~1. Noom application set-up and troubleshooting on smartphone (license provided)~2. Digital scale provision (subjects may keep the scale)~3. Capture of available clinical information over preceding 28-days."
224270420|NCT00623077|BIOLOGICAL|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) \> 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
224270421|NCT00623077|DRUG|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
224270422|NCT00623077|DRUG|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
223517696|NCT06402136|DRUG|Placebo|Placebo
223517697|NCT04581629|DRUG|Encaleret|Tablets administered orally
224270423|NCT00623077|DRUG|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
224270424|NCT00623077|DRUG|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
224270425|NCT00623077|DRUG|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
224270426|NCT00623077|PROCEDURE|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
224270427|NCT00623077|RADIATION|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
224270428|NCT00623077|RADIATION|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
224270429|NCT00623077|DRUG|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
224270430|NCT00623077|RADIATION|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
224270431|NCT01926119|DEVICE|Transcranial Magnetic Stimulation|
224270432|NCT03762954|OTHER|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
224270433|NCT02832921|BEHAVIORAL|cognitive training by virtual reality|
224270434|NCT02832921|BEHAVIORAL|watching a scientific TV documentary|
224270435|NCT02832921|DEVICE|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking-i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill-places greater demand on cognitive resources than a single task."
224270436|NCT04877145|OTHER|drill|single 3.25 mm stainless steel drill
224270437|NCT05535998|PROCEDURE|TACE-HAIC|The TACE-HAIC which was performed using 30 mg/m2 of epirubicin mixed with 2-5 mL lipiodol, followed by pure lipiodol. Then, a catheter was placed and fixed in the tumor feeding artery for the FOLFOX-based chemotherapy infusion at the following dosage: 85 mg/m2 of oxaliplatin infusion for 2 hours; leucovorin, 400 mg/m2 infusion for 2 hours; 400 mg/m2 of 5-FU bolus; and 2400 mg/m2 of continuous 5-FU infusion for 46 hours or 1200mg/m2 of continuous 5-FU infusion for 23 hours, respectively. Repeated TACE-HAIC was performed at intervals of 3-4 weeks.
224270438|NCT05535998|PROCEDURE|TACE|TACE was performed using 30 mg/m2 of epirubicin, 200 mg/m2 of carboplatin, and 4mg/m2 of MMC, mixed with 2-5 mL lipiodol. Up to 20 mL of additional pure lipiodol were injected into the tumor-feeding artery until stasis of blood flow was observed in the target artery. Repeated TACE was performed at intervals of 3-4 weeks.
224270439|NCT05535998|DRUG|Targeted therapy|The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
224270440|NCT05535998|DRUG|PD-1 inhibitors|PD-1 inhibitors were intravenously administered on the first post-TACE day as follows: camrelizumab 200 mg or sintilimab 200 mg or toripalimab 240 mg or tislelizumab 200 mg, every 3-4 weeks.
224270441|NCT01347749|BEHAVIORAL|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
224270442|NCT01347749|BEHAVIORAL|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
224270443|NCT05609617|DEVICE|injection|Intradermal injection on the face and neck/or décolleté by the NCTF135 HA
224270444|NCT05609617|OTHER|Cream application|Application of hydra filler cream on the face and neck/or décolleté
224270445|NCT00001698|DRUG|Ketorolac Rinse|
224270446|NCT02994147|DRUG|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
224270447|NCT02994147|DRUG|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
224270448|NCT01905605|DRUG|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
224270449|NCT01905605|DRUG|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
224270450|NCT03053245|BEHAVIORAL|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
224270451|NCT03053245|BEHAVIORAL|Attention Control|Patients in this group will receive regular wellness calls from the research team.
224270452|NCT02802852|DEVICE|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
224270453|NCT02802852|DRUG|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
224270454|NCT04303221|OTHER|Exercise|The exercises will be performed three times a week (Mondays, Wednesdays and Fridays), lasting 60 min, 10 minutes of warm-up, 40 min of multisensory exercises, and 10 min of final relaxation, for 12 weeks.
224270455|NCT03369535|OTHER|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
224270456|NCT03369535|OTHER|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
224270457|NCT03369535|OTHER|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
224270458|NCT04211935|DEVICE|Use of PCA|A commercially available PCA pump will be connected to the patient's intravenous line at the end of the MIRPE operation.
224270459|NCT04211935|DEVICE|Use of ESB for postoperative pain control after MIRPE|Pediatric anesthesiologists will place ESB at the time of the MIRPE operation if study participants are randomized into this group.
224270460|NCT04211935|DEVICE|Use of INC for postoperative pain control after MIRPE|Pediatric surgeons will perform INC during the MIRPE operation if they are randomized to this group.
224270461|NCT03896594|DRUG|HL237|Experimental
224270462|NCT03896594|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
224270463|NCT02172781|DRUG|Ipratropium - unit dose vial|
224270464|NCT02172781|DRUG|Tiotropium - inhalation capsule|
224270465|NCT02172781|DRUG|Placebo matching tiotropium|
224270466|NCT02172781|DRUG|Placebo matching ipratropium|
224270467|NCT02607826|PROCEDURE|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
224270468|NCT02666807|DIETARY_SUPPLEMENT|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
224270469|NCT02666807|DIETARY_SUPPLEMENT|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
224270470|NCT00156182|DRUG|Asoprisnil|10mg Tablet, oral Daily for 6 months
224270471|NCT04184167|OTHER|intermittent fasting 4 months before ICSI|women will start intermittent fasting before starting ICSI by 4 months
224270472|NCT00978536|OTHER|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
224270473|NCT00102349|BEHAVIORAL|Behavior Therapy|
224270474|NCT03032536|DRUG|AL-3778|AL-3778 tablets or capsules
224270475|NCT03032536|DRUG|Entecavir|Entecavir once daily for 14 days
224270476|NCT03032536|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
224270477|NCT01728636|DRUG|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
224270478|NCT02226250|DIETARY_SUPPLEMENT|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
224270479|NCT05232539|DEVICE|Intraoperative Optical Coherence Tomography (iOCT)|The use of iOCT during surgery offers the advantage of a new view of the operating field, theoretically allows more precise performance and can also change decision-making mechanisms during surgery with more precise visual control of some surgical steps.
224270480|NCT02740257|OTHER|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
223517698|NCT04360681|DRUG|Lofexidine|BID dosing, and a max daily dose of 1.6 mg/day
223517699|NCT04360681|DRUG|Placebo oral tablet|Placebo
224270481|NCT01326663|DRUG|Medication Trial|
224270482|NCT01373515|BIOLOGICAL|DCP-001|4 bi-weekly vaccinations
224270483|NCT03879187|DIETARY_SUPPLEMENT|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
224270484|NCT05535868|OTHER|SPN3 innoculation|Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
224270485|NCT05515458|DRUG|Chiglitazar|Oral single dose 48 mg
224287382|NCT02919241|BEHAVIORAL|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
224287383|NCT02919241|BEHAVIORAL|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
223517700|NCT05879302|BEHAVIORAL|Kidney Offer Shared Decision Making|The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
223517701|NCT06639243|DEVICE|QYM Technique|"The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out"
224287384|NCT04587102|OTHER|whole body viberation|vibration training in the form of whole body vibration for 20-30 minutes per session, 3 sessions per week for 8 weeks. The vibration training was performed on a whole body vibration platform
224287385|NCT04587102|OTHER|Traditional program(balance exercises and resisted exercises)|balance exercises and resisted exercises
224287386|NCT05218109|DEVICE|tVNS|transcutaneous vagus nerve stimulation
224287387|NCT05218109|BEHAVIORAL|Mindfulness|Brightmind mobile mindfulness application
224287388|NCT05218109|DEVICE|sham tVNS|sham transcutaneous vagus nerve stimulation
224287389|NCT05218109|OTHER|Number Puzzle|Control number puzzle task delivered via mobile device
224287390|NCT05721651|DRUG|Fruquintinib+PD-1|"This is a one-arm, prospective, exploratory clinical study, including patients with advanced HER-2-negative gastric cancer (including gastroesophageal junction adenocarcinoma) who received first-line immunization combined with standard chemotherapy (RECIST 1.1 criteria) and were treated with fruquintinib（4mg orally, once daily for 3 wks on/1 wk off ）combined with PD-1 antibody. Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.~PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;"
224287391|NCT04193319|DRUG|Fluzoparib|PARP inhibitor
224287392|NCT04193319|DRUG|Fluconazole|inhibitor
224287393|NCT06286644|DIETARY_SUPPLEMENT|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo, 0,125 mg, 0,375 mg or 0,75 mg soluble Xanthohumol)
224287394|NCT06286644|DIETARY_SUPPLEMENT|Iso-alpha-Acids|Participants receive a study drink supplemented with Iso-alpha-Acids (0 mg = Placebo, 15 mg, 45 mg or 90 mg Iso-alpha-Acids)
224287395|NCT06286644|DIETARY_SUPPLEMENT|Xanthohumol + Iso-alpha-Acids|Participants receive a study drink supplemented with Xanthohumol + Iso-alpha-Acids (0 mg = Placebo, 0,125 mg + 15 mg , 0,375 mg + 45 mg or 0,75 mg + 90 mg soluble Xanthohumol + Iso-alpha-Acids)
224270486|NCT05532631|PROCEDURE|Percutaneous coronary intervention|The studied intervention will be percutaneous coronary angioplasty with drug eluting stent implantation. Percutaneous coronary intervention may be performed during one single procedure or during staged procedures. The decision will be left at the investigator choice. PCI will be performed using drug eluting stent exclusively. The techniques for bifurcation lesions and chronic total occlusion angioplasty will be left at the operator choice. The choice of the drug eluting stent used will be left at the operator's choice. Anti-platelet therapy will be given to all patients randomized to PCI. The choice of the anti-thrombotic regiment and its duration will be left at the investigator choice (after assessment of initial presentation, bleeding and ischemic risks) but will have to comply with the European Society of Cardiology guidelines.
224270487|NCT05532631|PROCEDURE|Coronary artery bypass grafting|Coronary artery bypass grafting technique will be total arterial revascularization unless internal mammary grafts are unavailable or have inadequate flow. All patients will be treated with anti-thrombotic therapy according to the European Society of Cardiology guidelines
224270488|NCT03255980|DEVICE|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
223517702|NCT06639308|PROCEDURE|Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles|The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel
224270489|NCT03255980|OTHER|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
224270490|NCT02611362|BEHAVIORAL|IMB Gaming Intervention|
223893544|NCT06800742|OTHER|Collection of anthropometric and biochemical parameters|Collection of anthropometric parameters biochemical parameters basal metabolic rate body composition questionnaires
224270491|NCT03146143|PROCEDURE|ultrafiltration|ultrafiltration after cardiopulmonary bypass
224270492|NCT05972590|OTHER|Biological samples collection (blood + feces)|Blood + stools samples will be collected from each volunteer
224270493|NCT00948480|BIOLOGICAL|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
224270494|NCT00948480|DRUG|GM-CSF|500 mcg
224270495|NCT01274143|BEHAVIORAL|TeleCARE|Personalized telephone-delivered cancer risk assessment.
224270496|NCT01274143|BEHAVIORAL|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
224270497|NCT00854126|DRUG|GDC-0980|Escalating repeating dose
224270498|NCT03357380|DRUG|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
224270499|NCT03357380|DRUG|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
224270500|NCT01155531|DRUG|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
224270501|NCT02325180|DRUG|Dihydroartemisinin-Piperaquine|
224270502|NCT02325180|DRUG|Artemether-lumefantrine|
224270503|NCT03103594|DRUG|DMSO|DMSO will be instilled intravesically.
224270504|NCT03103594|DRUG|Botox|Botox will be instilled intravesically with DMSO.
224270505|NCT00464594|BEHAVIORAL|Standard lifestyle guidance|
224270506|NCT00464594|DRUG|Lifestyle guidance and monotherapy with acarbose|
224270507|NCT00464594|DRUG|Lifestyle guidance and monotherapy with metformin|
224270508|NCT00464594|DRUG|Lifestyle guidance and monotherapy with gliclazide|
224270509|NCT05343273|DIAGNOSTIC_TEST|taking a blood sample|blood collection for routine biochemical analysis
224270510|NCT05907694|PROCEDURE|Transcatheter PFO closure|"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."
224270511|NCT05907694|DRUG|Optimal medical treatment|Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
224270512|NCT00354159|DEVICE|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
224270513|NCT02364531|OTHER|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
224270514|NCT02544139|OTHER|Chagas Detect Plus|
224270515|NCT01627639|DRUG|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
224270516|NCT01627639|DRUG|Placebo|Placebo
224270517|NCT01667822|BEHAVIORAL|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
223517703|NCT06639308|PROCEDURE|Open Flexor Hallucis longus transfer to tendon achilles|The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
224270518|NCT01667822|BEHAVIORAL|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
224270519|NCT05419739|OTHER|Glasgow coma scale|This scale, which consists of three parameters, includes the best eye response (1-4 points), the best verbal response (1-5 points), and the best motor response (1-6 points). Total score; It is calculated as Eye Response + Verbal Response + Motor Response and takes a value between 3-15 points. The severity of head trauma is evaluated in three categories: mild (GCS 13-15 points), moderate (GCS 9-12 points), and severe (GCS ≤ 8 points).
224270520|NCT00458822|DRUG|bortezomib|Given IV
224270521|NCT00458822|DRUG|dexamethasone|Given orally
224270522|NCT00048139|DRUG|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
224270523|NCT00048139|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
224270524|NCT05719467|DRUG|Buscopan 20 MG/ML Injectable Solution|1 mL intravenously
224270525|NCT05719467|DRUG|Sodium bicarbonate|4 g orally
224270526|NCT05719467|DRUG|Placebo|4g orally
224270527|NCT05719467|DRUG|Nacl 0.9%|1 mL intravenously
224270528|NCT02017873|DRUG|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
224270529|NCT01653704|BEHAVIORAL|observational role|observational role in crisis scenario
224270530|NCT01653704|BEHAVIORAL|active role|active role in managing crisis scenario
224270531|NCT00694044|DRUG|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
223517704|NCT06637267|DIAGNOSTIC_TEST|Proclarix®|The aim of the study is the implementation of new biomarkers (Proclarix®) in order to increase the sensitivity and specificity of PSA-based Prostate cancer early detection avoiding unnecessary prostate biopsies thus decreasing the associated morbidity (infections, bleeding, urinary retention, etc.). PSA values, Proclarix and mpMRI findings will be correlated with the results of the prostate biopsy in order to improve patient selection for future biopsies in order to avoid unnecessary prostate biopsies, but still be able to detect relevant carcinomas at an early stage. The null hypothesis in our observational study is the lack of superiority in PCa early detection when using the Proclarix over PSA alone.
223517705|NCT05463952|DRUG|vepdegestrant|ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
223517706|NCT06637761|DRUG|NeoMTA2|Bio-active bio-ceramic mineral trioxide aggregate
223517707|NCT06637761|DRUG|WMTA|White Mineral trioxide aggregates
224270532|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
224270533|NCT00694044|DRUG|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
224270534|NCT00694044|DRUG|Placebo|Placebo for 21 days
224270535|NCT00795158|DRUG|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
224270536|NCT01728116|DEVICE|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
224270537|NCT01728116|PROCEDURE|Sham Procedure|Endoscopic evaluation but no device placement
224270538|NCT02928744|OTHER|COPD|Plethysmography
224270539|NCT02928744|OTHER|COPD|Forced oscillations
224270540|NCT06256224|DRUG|Toripalimab|Toripalimab combined with CCRT
224270541|NCT06256224|RADIATION|CCRT|CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx)
224270542|NCT05128058|DRUG|Ritlecitinib 50 mg|50 mg single dose
224270543|NCT05128058|DRUG|Ritlecitinib 200 mg|200 mg single dose
224270544|NCT00867919|BEHAVIORAL|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~* parent-adolescent conflict~* adolescent development~* support and closeness~* behavioral activation~* response to adolescent negative affect~* relapse prevention~* suicide prevention, if necessary"
224270545|NCT00867919|OTHER|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
224270546|NCT03727763|DRUG|Vemurafenib|960mg po bid
224270547|NCT03727763|DRUG|Cetuximab|500mg/m2 iv gtt (14 days per course)
224270548|NCT00646984|DRUG|Standard continuous antiretroviral therapy|
224270549|NCT00646984|DRUG|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
224270550|NCT00646984|DRUG|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
224270551|NCT02533466|OTHER|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
224270552|NCT02533466|OTHER|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
224270553|NCT02480634|DRUG|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
224270554|NCT02480634|RADIATION|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
224270555|NCT05689541|OTHER|Mobile app intervention|"A mobile-based application will be developed to provide parents with a supplemental curriculum that will include games and activities focusing on motor outcomes. The focus of these games and activities will correspond with the adapted horseback riding program's weekly lesson plan. The mobile app will be created with Glide, which allows us to create a mobile application with basic spreadsheet skills.~The mobile app will aim to incorporate 10-12 games and activities designed to improve specific motor outcomes. Parents will be instructed to partake in the app-delivered activities with their children daily for at least 30-45 minutes."
224270556|NCT01885897|BIOLOGICAL|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
223517708|NCT06638983|OTHER|Non-extraction Orthodontic Treatment of Angle Class I Malocclusion|Cephalometric radiographs, and extraoral and intraoral photographs, and cast impressions were collected before and after intervention. The weighted PAR Index (Peer Assessment Rating) employed to determine outcome of orthodontic treatment. Also the following soft tissue and bone indexes were assessed before and after intervention
224270557|NCT00929019|BIOLOGICAL|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
224270558|NCT03811977|DIETARY_SUPPLEMENT|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
224270559|NCT03811977|DIETARY_SUPPLEMENT|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
224270560|NCT00235963|DRUG|Simvastatin|
224270561|NCT03710629|OTHER|Patients with driver genes|Patients with driver genes
224270562|NCT01457092|DEVICE|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
223517709|NCT06641947|PROCEDURE|Whipple procedure|Typically used for treating pancreatic cancer, particularly tumors located in the head of the pancreas.
223517710|NCT06643689|DRUG|Tranilast|Tranilast is an anti-allergic agent that is hypothesized to prevent stricture formation in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive 100 mg orally three times a day for 8 weeks.
224270563|NCT03277248|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
224270564|NCT03277248|DRUG|Teriflunomide|Film coated tablets administered orally.
224270565|NCT03277248|DRUG|Oral Placebo|Administered orally.
224270566|NCT03277248|DRUG|IV Placebo|Administered as an IV Infusion.
224270567|NCT04668820|DIAGNOSTIC_TEST|video Pediatric Gait, Arms, Legs and Spine (V-pGALS)|The Video-pGALS includes maneuvers from pediatric regional examination of the musculoskeletal system (pREMS) and derived from the pediatric gait arms legs spine examination assessment which is a validated simple basic musculoskeletal (MSK) examination for children. V-pGALS offers a structured approach to a cursory overview MSK exam with a focus on range of movement and symmetry. Utilizing the parent or caregiver to feel the joint in question for obvious warmth/ swelling or to palpate for point of maximal tenderness can add important information.
223517711|NCT06643689|DRUG|Dexamethasone|Prednisone is a corticosteroid used to reduce inflammation and prevent stricture in patients undergoing cESD for superficial esophageal tumors. Participants in this group will receive an oral dose of 30 mg once daily for 8 weeks, with a gradual tapering of the dosage as follows: Weeks 1-2: 30 mg daily; Weeks 3-4: 25 mg daily; Weeks 5-6: 20 mg daily; Weeks 7-8: 15 mg daily; and then tapering to 10 mg daily in Week 7 and 5 mg daily in Week 8.
224270568|NCT01458886|DRUG|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
224270569|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
224270570|NCT01458886|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
223704009|NCT06570707|OTHER|Brighter Bites|Families will receive a distribution of fresh fruits and vegetables (FV) (\~20lbs., 50 servings/family/distribution) for \~16 weeks during the school year using primarily donated produce from local food banks. Nutrition education will be implemented for children using the evidence-based Coordinated Approach to Child Health (CATCH) program and for parents using bilingual nutrition handbooks and fun food experiences such as healthy FV recipe tastings for families during produce pick-up time will be conducted.
224270571|NCT01458886|DRUG|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
224270572|NCT04862806|DIAGNOSTIC_TEST|COVID-19 serology|Immune response to BNT162b2 mRNA vaccine is assessed on the basis of anti covid19 IgG levels. A centralized assessment of the serological response for 4 medical centers is performed on serum samples stored at -60 °C using Abbott-SARS-CoV-2 IgG quant (Positive value \> 151; range 0-40.000). The other 4 medical centers performed the test locally using DiaSorins-LAISISON SARS-CoV S1/S2 IgG test (positive value \>15 range 15-400). In the central virus laboratory at the Chaim Sheba Medical center the test was done by Elisa-RDB (positive value \>1.1; range 1.1-10).
224270573|NCT03610607|BEHAVIORAL|Intense education|we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
224270574|NCT02083809|DRUG|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
223704010|NCT02418598|GENETIC|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.
223704011|NCT02418598|GENETIC|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
224270575|NCT02083809|DRUG|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
224270576|NCT02824510|OTHER|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
224270577|NCT02824510|OTHER|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
224270578|NCT02824510|DRUG|Insulin aspart, glargine and detemir|
224270579|NCT05569109|DEVICE|doppler ultrasound|doppler ultrasound on arteriovenous fistula in hemodialysis patients
224270580|NCT03116776|PROCEDURE|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
224270581|NCT03116776|DRUG|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
224270582|NCT05465096|PROCEDURE|Micro-fragmented adipose tissue injection|Intra-articular ultrasound-guided injection of MF-AT
224270583|NCT01152112|DEVICE|Myomectomy|Removal of fibroids and / or polyps
224270584|NCT01691612|BIOLOGICAL|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
224270585|NCT05086913|OTHER|Lifestyle medicine smartphone booklets|Participants will receive a pocket size 6-page booklet weekly over 8 weeks that covers 8 lifestyle medicine, mental health and CBT themes including stress, relaxation, diet, exercise, sleep hygiene, worry management, mindfulness, and positive psychology, and guides participants to set and meet short term and long-term goals.
224270586|NCT05086913|OTHER|Lifestyle medicine smartphone app|The lifestyle medicine app offers 8 modules with identical content as the wellness booklets, in addition to videos, relaxation, exercise and cooking demonstrations, daily challenges, record of goals, and ecological momentary assessments of diet, physical activity, sleep, stress and mood.
224270587|NCT05086913|OTHER|Waitlist control|The waitlist control group will receive access to the lifestyle medicine app and booklets at the end of the study.
224270588|NCT05646238|OTHER|psychoeducation|Students assigned to the experimental group will be divided into groups of 6-9. 3 psychoeducation sessions will be held with each group once a week for a total of 3 weeks. Group sessions are estimated to last between 60-75 minutes. Psychoeducational content based on Leventhal's Self-Regulation Model was prepared. In the first stage, cognitive bases of dysmenorrhea, in the second stage, strategies to cope with dysmenorrhea, and in the third stage, the effectiveness of coping strategies in dysmenorrhea will be discussed. In the second stage, the participants will be taught the progressive muscle relaxation exercise, which is among the strategies to cope with dysmenorrhea. Sessions will be held online.
224270589|NCT05646238|OTHER|training|The control group will be given a online training of 30-45 minutes covering dysmenorrhea and coping in a single session. From the first menstrual cycle after the training session is completed, measurements will be made in 3 consecutive menstrual cycles
224270590|NCT02473237|DRUG|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
224270591|NCT02473237|DRUG|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
224270592|NCT05575245|DEVICE|Drug-eluting Stent|Drug-eluting Stent angioplasty
224270593|NCT05575245|DEVICE|Excimer Laser Ablation Combined Drug-coated Balloon|Excimer Laser Ablation Combined Drug-coated Balloon angioplasty
224270594|NCT03588260|OTHER|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
224270595|NCT00292760|DRUG|Alemtuzumab|
224270596|NCT00292760|DRUG|Methyprednisolone|
224270597|NCT05339191|BEHAVIORAL|Compassionate image workshop|Participants attend a workshop through which they will be supported to develop and use their own compassionate image.
224270598|NCT02711527|OTHER|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
224270599|NCT02711527|OTHER|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
224270600|NCT00171145|DRUG|Darifenacin|Darifenacin 15 mg tablets once daily
224270601|NCT00171145|DRUG|Placebo|Placebo tablets once daily
224270602|NCT05534243|OTHER|Standard neuromuscular blocker practices|Usual care neuromuscular blocker in the ED
223704012|NCT00071474|PROCEDURE|shamanic healing|
223704013|NCT05384574|DIETARY_SUPPLEMENT|cholecalciferol|daily supplementation of cholecalciferol, 10 000 IU, during 14 days
223704014|NCT00497718|PROCEDURE|Chiropractic Manipulation|
224270603|NCT05534243|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of shorter acting neuromuscular blockers, and the objectives of the research. Education will include in-services and lectures focused on the importance of neuromuscular blocker protocols on patient outcome. The use of neuromuscular blokers will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based neuromuscular blocker protocols.
224270604|NCT06543394|BEHAVIORAL|Primer postcard|Mailed primer postcard
224270605|NCT06543394|BEHAVIORAL|Control recruitment letter|Mailed recruitment letter with usual care message framing
224270606|NCT06543394|BEHAVIORAL|Behavioral theory-informed recruitment letter|Mailed recruitment letter with prospect-theory informed message framing
224270607|NCT06543394|BEHAVIORAL|2 phone calls|Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
224270608|NCT06543394|BEHAVIORAL|4 phone calls|Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
224270609|NCT00640341|DEVICE|PureVision Contact Lens|contact lens for daily wear
224270610|NCT00640341|DEVICE|Acuvue Oasys Contact Lens|contact lens for daily wear
224270611|NCT00640341|DEVICE|O2Optix Contact lens|contact lens for daily wear
224270612|NCT00000564|PROCEDURE|oxygen inhalation therapy|
224270613|NCT02761720|OTHER|No Intervention|
224270614|NCT03673514|PROCEDURE|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
224270615|NCT02190318|DRUG|Losartan|
224270616|NCT02190318|DRUG|spirolactone|
224270617|NCT02190318|OTHER|blank control|
224270618|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.
224270619|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - targeted-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.
224270620|NCT06003309|DEVICE|Transcranial Magnetic Stimulation (TMS) - Standard-iTBS|Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
224270621|NCT00591071|OTHER|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
224270622|NCT00591071|OTHER|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
224270623|NCT06090708|DIETARY_SUPPLEMENT|yogurt with probiotic bacteria|Children in probiotic study group were received 15 mg/kg of market available fresh probiotic yogurt after stopping vomiting every four to six hours for three consecutive days beside to the standard hospital care and the prescribed medication for acute gastroenteritis.
224270624|NCT01573819|DRUG|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
224270625|NCT01573819|DRUG|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
224270626|NCT06186219|DRUG|Rituximab|"Rituximab is a monoclonal antibody that targets cluster of differentiate 20 (CD20) present on B-cells and lowers humoral immunity. Rituximab has been used successfully as a desensitization agent to treat Highly Human Leukocyte Antigens (HLA)-sensitized patients planning renal transplant. All cases of antibody-mediated rejection were seen in the placebo group, none in the Rituximab group. Rituximab has been safely used with Methotrexate in the treatment of Rheumatoid Arthritis, where co-administration of Methotrexate and Rituximab results in better outcomes than either medication alone.~We propose this safety and feasibility open-label trial that will examine if Rituximab pre-treatment before Standard-of-Care Methotrexate-Pegloticase will result in recapture of Pegloticase efficacy as measured by serum urate (SU) \< 6 mg/dL throughout the trial and up to 6-months of Methotrexate-Pegloticase administration."
224270627|NCT03900884|DRUG|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
224270628|NCT03900884|DRUG|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
224270629|NCT03900884|DRUG|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
224270630|NCT05610007|DRUG|Prilocaine|Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
224270631|NCT02251509|DRUG|Carvedilol|
223704015|NCT04015336|BIOLOGICAL|E7 T-Cell Receptor (TCR)|The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
223893545|NCT05894577|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
224270632|NCT02251509|DRUG|Metoprolol tartrate|
224270633|NCT02172469|DRUG|Tiotropium inhalation powder capsule|
224270634|NCT02172469|DRUG|Placebo Metered Dose Inhaler|
224270635|NCT02172469|DRUG|Ipratropium Bromide Metered Dose Inhaler|
224270636|NCT02172469|DRUG|Placebo inhalation powder capsule|
224270637|NCT02071368|DRUG|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
224270638|NCT02071368|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
224270639|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
224270640|NCT02071368|DRUG|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
224270641|NCT02980172|OTHER|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
224270642|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization
224270643|NCT01894230|GENETIC|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study
224270644|NCT01894230|GENETIC|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele
224270645|NCT04129255|DRUG|Octreotide Acetate|administration every 28 days
224270646|NCT02178124|DRUG|Donepezil|
224270647|NCT02178124|DRUG|placebo|
224270648|NCT05587023|PROCEDURE|stellate ganglion block|The experimental group was given 6ml ropivacaine for stellate ganglion block. In the control group, 6ml saline was used for stellate ganglion block.
224270649|NCT02480608|DRUG|Imatinib|
224270650|NCT02480608|DRUG|Hydroxyurea|
224270651|NCT04646824|DRUG|Almonertinib Pemetrexed/Cisplatin|Pemetrexed/Cisplatin Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
224270652|NCT00656539|DRUG|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
224270653|NCT02583308|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
224270654|NCT02583308|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
224270655|NCT00137202|DRUG|Ondansetron (Zofran)|
224270656|NCT00137202|DRUG|Diphenhydramine (Benadryl)|
224270657|NCT01096602|BIOLOGICAL|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
224270658|NCT00000708|DRUG|Flucytosine|
224270659|NCT00000708|DRUG|Fluconazole|
224270660|NCT00000708|DRUG|Amphotericin B|
224270661|NCT06491979|DIETARY_SUPPLEMENT|Vitamin A treatment|Vitamin A, 32 microgram per kilograms (of body weight) per day, for three weeks
224270662|NCT06491979|DIETARY_SUPPLEMENT|Monounsaturated fatty acid mixture|Monounsaturated fatty acid mixture (mainly Omega-7, Omega-9), 47 milligrams per kilogram (of body weight) per day, for three weeks
224270663|NCT06491979|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid mixture|Polyunsaturated fatty acid mixture (mainly Omega-3, Omega-6), 6 milligrams per kilogram (of body weight) per day, for three weeks
224270664|NCT06491979|DIETARY_SUPPLEMENT|Fatty acid mixture|Fatty acid mixture (mainly saturated fatty acid, Omega-6, Omega-7, Omega-9), 83 milligrams per kilogram (of body weight) per day, for three weeks
224270665|NCT02300987|DRUG|LEE011|
224270666|NCT02300987|DRUG|LEE011 Placebo|
224270667|NCT03930849|BEHAVIORAL|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
224270668|NCT03930849|BEHAVIORAL|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
224270669|NCT06356987|PROCEDURE|Herniotomy|In Group A Laparoscopic assisted needle herniotomy was done
224270670|NCT02217709|DRUG|phenelzine sulfate|Given by mouth
224270671|NCT02217709|OTHER|laboratory biomarker analysis|Correlative studies
224270672|NCT02217709|OTHER|questionnaire administration|Ancillary studies
224270673|NCT05454085|DIETARY_SUPPLEMENT|Bisphenol-A|measurement of BPA levels in maternal blood and amniotic fluid
224270674|NCT02700971|PROCEDURE|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
224270675|NCT02647515|DRUG|ranibizumab|
224270676|NCT02488109|OTHER|Higher Calorie Refeeding|
224270677|NCT02488109|OTHER|Lower Calorie Refeeding|
224270678|NCT03866928|DRUG|Stiripentol|1500 mg of stiripentol b.i.d.
224270679|NCT00660387|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
224270680|NCT00660387|DRUG|Placebo Gel|
224270681|NCT00660387|DRUG|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
224270682|NCT00660387|DRUG|Placebo (PBO) oral capsules|
224270683|NCT00660387|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
224270684|NCT00660387|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
224270685|NCT00660387|DEVICE|J-tube|jejunal tube
224270686|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation Plus Economic Assistance|The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
224270687|NCT05259852|BEHAVIORAL|Food Assistance and Cessation Resources Navigation|The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
224270688|NCT06226259|DIETARY_SUPPLEMENT|GABA supplement|Oral administration of GABA supplement once daily before sleep for 14 days.
224270689|NCT06226259|DIETARY_SUPPLEMENT|placebo|Oral administration of placebo once daily before sleep for 14 days.
224270690|NCT01251393|DRUG|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
224270691|NCT01251393|DRUG|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
224270692|NCT01495715|DRUG|Idebenone|
224270693|NCT01495715|DRUG|Placebo|
224270694|NCT00110851|DRUG|rosiglitazone|
224270695|NCT00110851|DRUG|metformin|
223517712|NCT06643819|DRUG|sacubitril/valsatran(dose maintenance)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
223517713|NCT06643819|DRUG|sacubitril/valsartan(dose increasing)|"During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day.~After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 CKD-202A(Sacubitril∙Valsartan) 200mg, 1 placebo of D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day."
224083146|NCT00440726|DRUG|Methotrexate|"Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
224270696|NCT00110851|DRUG|PN2034|
224270697|NCT04413461|OTHER|TENS|Transcutaneous Electro Neuro Stimulation
224270698|NCT04413461|OTHER|TENS Sham|placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
224270699|NCT00249717|BEHAVIORAL|Contingency management|Receive rewards (prizes) abstinence and attendance
224270700|NCT01245842|OTHER|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
224270701|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
224270702|NCT05884970|DRUG|"100 mcg Salbutamol Sandoz and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
224270703|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Sandoz"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
224270704|NCT05884970|DRUG|"100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK"|Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
224270705|NCT00785876|OTHER|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
224270706|NCT01954901|DEVICE|Hyperbaric oxygen therapy|
224270707|NCT01954901|DEVICE|Hyperbaric room air|
224270708|NCT04311346|DIAGNOSTIC_TEST|Cardiac MR|Cardiac MR diagnostic tool for detection of acute rejection, double blind comparison with invasive cardiac biopsy
224270709|NCT01948401|DRUG|LABA|long-acting beta-agonist treatment
224270710|NCT01948401|DRUG|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
224270711|NCT01948401|DRUG|prednisolone|additional 0.5 mg/kg orally for 7 days
224270712|NCT05080140|DRUG|Ezetimibe 10mg|Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites
224270713|NCT06678425|DEVICE|Peripheral magnetic stimulator|a non-invasive method of delivering a rapidly pulsed, high-intensity magnetic field to peripheral muscles
224270714|NCT06678425|DEVICE|Peripheral magnetic stimulator|The same coil as real rPMS, but in a position perpendicular to the skin
224270715|NCT06678308|DEVICE|Embolisation with Magic Glue®|Magic Glue® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
224270716|NCT06678308|DEVICE|Embolisation with Embosphere®|Embosphere® will be injected within prostatic arteries, leading to ischaemia and necrosis of part of the adenomatous tissue of the prostate gland
224270717|NCT03037424|DRUG|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
224270718|NCT03037424|DRUG|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
224270719|NCT05740696|PROCEDURE|ALF|Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
224270720|NCT05740696|PROCEDURE|SALF|The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
224270721|NCT05740696|PROCEDURE|ACLF|On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
224270722|NCT03670719|OTHER|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
224270723|NCT03670719|OTHER|Exercise|Exercises for the cervical spine
224270724|NCT03086135|DEVICE|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
224270725|NCT06076941|OTHER|Education|"Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated."
224270726|NCT02971813|BEHAVIORAL|Facebook|"1. Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~2. Participants will be given a baseline BREQ-3 survey and a PNSE scale.~3. Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~4. The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~   1. Educational posts will cover topics that will cover healthcare information.~  2. Provider support will be posted much like the educational posts.~5. The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~6. Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
224270727|NCT00033436|DIETARY_SUPPLEMENT|niacinamide|
224270728|NCT00033436|DRUG|carbogen|
224270729|NCT00033436|RADIATION|radiation therapy|
224270730|NCT02889302|DRUG|KPS-0373|24 weeks
224270731|NCT02889302|DRUG|Placebo|24 weeks
224270732|NCT03888521|BEHAVIORAL|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
224270733|NCT01639664|DEVICE|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization.
224270734|NCT00601406|GENETIC|gene expression analysis|
224270735|NCT00601406|GENETIC|gene rearrangement analysis|
224270736|NCT00601406|GENETIC|polymorphism analysis|
224270737|NCT00601406|OTHER|laboratory biomarker analysis|
223517714|NCT06643819|DRUG|Valsartan|During the 4 weeks of Placebo Run-in Period(Single blind), all participants are treated 1 placebo of CKD-202A(Sacubitril∙Valsartan) 100mg and 1 placebo of D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After Placebo Run-in Period, During the 4 weeks out of 10 weeks of Treatment Period(Double blind), All TEST2 pariticipants are treated 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg and 1 D763(Valsartan 80 mg) each, total of 2 oral doses once a day. After 4 weeks of Treatment Period, During the 6 weeks out of 10 weeks of Treatment Period(Double blind), All TEST1 pariticipants are treateed 1 placebo of CKD-202A (Sacubitril∙Valsartan) 100 mg, 1 placebo of CKD-202A(Sacubitril∙Valsartan) 200mg, 1 D764(Valsartan 160 mg) each, and a total of 3 oral doses once a day.
223517715|NCT06645405|BEHAVIORAL|AI algorithm|Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
223517716|NCT05406453|OTHER|Whole Genome Sequencing testing|Whole Genome Sequencing testing, community-based contact tracing
223517717|NCT03495635|BEHAVIORAL|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
223517718|NCT04577703|DRUG|CT053PTSA|CT053PTSA will be administered daily in fasting state
223517719|NCT01830387|DEVICE|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
224270738|NCT00601406|RADIATION|radiation therapy|
224270739|NCT01023061|DRUG|abiraterone acetate|Given PO
224270740|NCT01023061|DRUG|prednisone|Given PO
224270741|NCT01023061|DRUG|leuprolide acetate|Given via injection
224270742|NCT01023061|OTHER|laboratory biomarker analysis|Correlative study
224270743|NCT01023061|RADIATION|external beam radiation therapy|Undergo radiotherapy
224270744|NCT01023061|DRUG|goserelin acetate|Given via injection
224270745|NCT01119586|GENETIC|DNA analysis|
224270746|NCT01119586|GENETIC|genetic linkage analysis|
224270747|NCT01119586|GENETIC|microarray analysis|
224270748|NCT01119586|GENETIC|nucleic acid sequencing|
224270749|NCT01119586|GENETIC|polymerase chain reaction|
224270750|NCT01119586|GENETIC|polymorphism analysis|
224270751|NCT01119586|OTHER|laboratory biomarker analysis|
224270752|NCT02966340|DRUG|Prazosin|2mg Prazosin
224270753|NCT02966340|DRUG|Placebo|Placebo
224270754|NCT04650750|DRUG|Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin|"Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect."
224270755|NCT04650750|DRUG|Placebo|Similar placebo 4g twice a day for two months
224270756|NCT01245491|OTHER|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
224270757|NCT02822482|DRUG|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
224270758|NCT02822482|DRUG|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
224270759|NCT00203320|DRUG|etanercept given by perispinal administration|
224270760|NCT01853540|DRUG|Sildenafil|
224270761|NCT00187265|DEVICE|Cardiac Resynchronization Therapy|
224270762|NCT01622660|DRUG|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
223517720|NCT01830387|OTHER|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
223517721|NCT04816903|DIAGNOSTIC_TEST|Gyni|Vaginal discharge collection
223517722|NCT01946880|DRUG|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
224083147|NCT00440726|DRUG|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
224270763|NCT01622660|DRUG|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
224270764|NCT06677801|BIOLOGICAL|Telitacicept 160mg|Telitacicept 160mg weekly for 24 weeks, and peripheral subtypes of immune cells will be measured at week 0, 4, 12, and 24.
224270765|NCT04445701|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
224270766|NCT04445701|DRUG|AO-176 + Dex|Humanized mAb targeting CD47 plus dexamethasone
224270767|NCT04445701|DRUG|AO-176 + Dex + Bort|Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
224270768|NCT03538925|BEHAVIORAL|AAC Generative Language Intervention|Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
224270769|NCT03538925|BEHAVIORAL|Standard of Care / Business as Usual|Parent/Caregiver AAC App Operational Training
224270770|NCT06353750|OTHER|Magnesium supplement|Intravenous magnesium supplement (10mmol).
224270771|NCT03791541|BEHAVIORAL|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
223517723|NCT01946880|DRUG|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
224270772|NCT05581134|DEVICE|Virtual Reality intervention|Virtual reality (VR) is a powerful tool to create an illusory state in which the user can feel that they have been transported to a new location (place illusion), that events happening are real (plausibility illusion), and even that bodies have been substituted by an avatar (embodiment illusion). VR illusions are driven by the same neurological mechanisms of everyday perception of the body in the world and induce realistic responses to VR.
224270773|NCT05581134|BEHAVIORAL|Control Group intervention|Treatment will follow general treatment principles in physiotherapy for FMDs: (1) education; (2) exploration of how symptoms affect movement and posture; (3) retraining movement using strategies based on redirection of attention; and (4) development of a self-management plan.
224270774|NCT06099990|DRUG|dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets|dalpiciclib+ abiraterone+ prednisone
224270775|NCT06099990|DRUG|placebo; abiraterone acetate tablets; prednisone tablets|placebo+abirarerone+prenisone
224270776|NCT00504179|PROCEDURE|Osteopathic Manipulative Treatment|
223517724|NCT01946880|DRUG|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
223517725|NCT06571331|OTHER|De-Stress & Snooze Gummies-U001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
223517726|NCT06571331|OTHER|De-Stress & Snooze Gummies-I001|Two gummies daily in sequence 30-45 minutes before bed for 60 days
224270777|NCT05184803|DRUG|Docetaxel injection, oxaliplatin, S-1|As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
224270778|NCT01897987|BIOLOGICAL|Pneumostem®|
224270779|NCT01897987|BIOLOGICAL|normal saline|
224270780|NCT02299687|DRUG|Omeprazole|
224270781|NCT03164187|DRUG|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
224270782|NCT05344287|OTHER|Typical American Diet|Participants self-reported adherence to a typical American diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
223517727|NCT06571331|OTHER|Placebo Gummies 002|Two gummies daily in sequence 30-45 minutes before bed for 60 days
223517728|NCT03329131|DEVICE|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
224270783|NCT05344287|OTHER|Plant-Based Diet|Participants self-reported adherence to a 100% plant-based diet prior to enrolling in the study. This factor determined cross-sectional group allocation.
224270784|NCT03854409|DRUG|Aripiprazole|Injection.
224270785|NCT06407999|DEVICE|Expiratory Pressure Relief|EPR is a function used in CPAP intended to improve comfort by reducing delivered pressure during the expiratory phase. When EPR is not used, the patient receives true CPAP.
224270786|NCT00536588|GENETIC|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
224270787|NCT05418985|BEHAVIORAL|Monthly reminder message about breast self-exam.|Monthly reminder message about breast self-exam.
224270788|NCT03710707|DRUG|DNL201|Oral repeating dose
224270789|NCT03710707|DRUG|Placebo|Oral repeating dose
224270790|NCT03103828|BEHAVIORAL|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
224270791|NCT03103828|BEHAVIORAL|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
224270792|NCT03103828|BEHAVIORAL|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
224270793|NCT01136928|DRUG|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
224270794|NCT01616199|DRUG|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
224270795|NCT01616199|DRUG|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
224270796|NCT00396955|DRUG|PLA-695|
224270797|NCT01015924|PROCEDURE|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
224270798|NCT01015924|PROCEDURE|ESIN|Elastiv stable intramedullary nailing
224270799|NCT00067717|BEHAVIORAL|Distance healing|
224270800|NCT04556734|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily
224270801|NCT04556734|DRUG|Etrasimod|Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
224270802|NCT04556734|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily
224270803|NCT03869424|OTHER|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
224270804|NCT02342041|DRUG|SUVN-G3031|
224270805|NCT02342041|DRUG|Placebo|
224270806|NCT05164835|OTHER|pharmaceutical follow-up|"Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information."
224270807|NCT00526435|BEHAVIORAL|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
224270808|NCT00526435|BEHAVIORAL|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
224270809|NCT00519506|OTHER|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
224270810|NCT00164918|DEVICE|nasogastric tube|
224270811|NCT05287087|BEHAVIORAL|My Symptoms 1 (MySt-1)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~These four provisions are identical to the first part of the MySt-2."
224270812|NCT05287087|BEHAVIORAL|My Symptoms 2 (MySt-2)|"The patients will get access to an eHealth programme consisting of:~1. A questionnaire including the BDS checklist~2. A brief introductory animation about how to understand symptoms in general~3. Basic information on symptom in general and on six common symptoms: headache, fatigue, dizziness, pain, dyspepsia and abdominal unease.~4. A brief animation about the interaction of body and mind.~5. Thorough symptom explanations~6. Physical energy (focus on sleep, diet and activity)~7. Values and choices (focus on meaning and existential issues)~8. Emotional health (focus on emotion regulation)~9. Mental energy (focus on stress regulation and thinking)~After 4-6 weeks, the patient will see the GP for a follow-up consultation."
224270813|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
224270814|NCT01530906|PROCEDURE|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
224270815|NCT05034185|DEVICE|Computer-aided diagnosis (CADx) support tool|"The CADx support tool operates when the Clinician switches the preconfigured CAD EYE function on using a button on the controller while the scope system is in BLI mode. This is performed after the Clinician first makes an optical prediction of polyp histology using IEE as described. The CADx support tool will make a prediction of polyp histology as hyperplastic or neoplastic."
224270816|NCT02466087|DRUG|Mg Cl|Four supplements a day for 6 weeks.
224270817|NCT00063609|DRUG|zoledronic acid|
224270818|NCT03915977|BEHAVIORAL|Post ICU recovery program|Standardized follow up program
224270819|NCT01433887|DRUG|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
224270820|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
224270821|NCT01433887|DRUG|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
224270822|NCT01433887|DRUG|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
224270823|NCT00878787|DEVICE|Transcranial magnetic stimulation|
224270824|NCT06467851|DRUG|Suanzaoren Decoction and Huanglian Wenda Decoction|Twice daily. Chinese herbal medicine includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.
224270825|NCT05392569|OTHER|Deep Brain Stimulation|"In addition to standard micro electrode recordings, we propose to measure:~1. surface potentials at the scalp (EEG) evoked by stimulation at the DBS electrode site~2. micro electrode potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~3. local field potentials at the DBS electrode site evoked by stimulation at the median and tibial nerves~4. surface EMG in the first dorsal interosseus and gastrocnemius muscles during stimulation at the DBS electrode site."
224270826|NCT05767216|OTHER|Biological sampling|Blood, skin and stool samples for laboratory analysis
224270827|NCT03209024|OTHER|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
224270828|NCT03209024|DEVICE|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
224270829|NCT01858350|OTHER|Active Music Therapy|
224270830|NCT01858350|OTHER|Passive Music Therapy|
224270831|NCT01858350|OTHER|Distraction Therapy|
224270832|NCT05950217|OTHER|Education|Nurse-led patient education
224270833|NCT06147414|BIOLOGICAL|Blood sample|"A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing."
224270834|NCT04509050|DRUG|Ivacaftor or elexacaftor/tezacaftor/ivacaftor|In Part B, approved CFTR modulator as prescribed at the discretion of the treating physician -not dictated by the BEGIN investigators
224270835|NCT02930135|PROCEDURE|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
224270836|NCT01632163|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
224270837|NCT01632163|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
224270838|NCT04633616|OTHER|Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be tailored as the mode of weblink delivery will be customized to patient preference. Patients can choose messages to be delivered via e-mail, SMS, WhatsApp, or Facebook. For example, if one patient determines SMS messaging as their preferred communication mode, then this patient will receive a weblink via SMS directing the patient to customized educational videos and questionnaires. Weblinks delivered via tailored patient-provider communication will be enabled by Wecudos.
224270839|NCT04633616|OTHER|Non-Tailored Patient-Provider Communication|Every 1.5 months, patients randomized to the non-tailored patient-provider communication model will receive weblinks directing patients to disease-specific educational videos and associated questionnaires. Communication will be non-tailored such that patients will not be able to choose their preferred mode of communication and will receive hardcopy. Patients will receive hardcopy on how to access psoriasis education. Weblinks delivered via non-tailored patient-provider communication will be enabled by Wecudos.
224270840|NCT04433494|DRUG|TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg|TY-302 is taken orally. Tamoxifen is taken orally.
224270841|NCT01623804|DEVICE|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
224270842|NCT01623804|DEVICE|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
224270843|NCT06210204|OTHER|Telehealth follow-up|Patients to follow-up via phone after surgery
224270844|NCT03191838|OTHER|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
224270845|NCT05452434|DRUG|mirabegron|mirabegron 50mg QD for 12 weeks.
224270846|NCT03498924|DIAGNOSTIC_TEST|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
224270847|NCT00402519|RADIATION|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
224270848|NCT00402519|RADIATION|External beam whole breast irradiation|Standard Whole breast irradiation
224270849|NCT02827396|BEHAVIORAL|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
224270850|NCT06678958|PROCEDURE|Reconstruction of acetabular defect by trabecular metal augment|The augments were used in the flying buttress position
224270851|NCT01891058|DEVICE|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
224270852|NCT06214637|DRUG|Melissa|The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
224270853|NCT06214637|DRUG|Placebo|It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
224270854|NCT01120899|DRUG|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
224270855|NCT01989299|DEVICE|ILR implantation|
224270856|NCT04810533|DRUG|[14C] SH-1028|Volunteer will receive a single oral dose of 200 mg/88 uCi \[14C\]SH-1028 as a solution on Day 1
224270857|NCT00820599|DEVICE|Sapien XT™ transcatheter heart valve and delivery system|
224270858|NCT03065699|DEVICE|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
224270859|NCT06083987|BEHAVIORAL|Intersectionality and Identity|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of intersectionality and identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
224270860|NCT06083987|BEHAVIORAL|Confidentiality|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on Confidentiality for caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
224270861|NCT06083987|BEHAVIORAL|Educating Your Community|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of the education of family and friends about identity. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
224270862|NCT06083987|BEHAVIORAL|How to find Affirming Caregivers|"Participants will use the computer application, Discord, a social media site that allows for sharing of content and interaction with other people in a variety of forms (video chat, direct messaging, and talking in group chat areas). We will be using the group chat function to set up discussion forums where there will be video and text resources focused on matters of finding affirming caregivers. Participants will do at least one activity from three types each week for four weeks. The three activity types will have the participants engage with the content and then either discuss it in the forum (Talk about it), write a review about the content discussing why/why not they like it (Rate it), or Attempt to use the knowledge or skills to accomplish a task offline (Try it)."
224270863|NCT06083987|BEHAVIORAL|Control Group - No Interventions|Control Group - Will be given no interventions
224270864|NCT04374188|DRUG|Ciprofloxacin|drug adminstration to ameliorate sepsis incidence
224270865|NCT04374188|DRUG|Levofloxacin|levofloxacin pill
224270866|NCT02377388|DRUG|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
224270867|NCT02377388|DRUG|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
224270868|NCT01717937|PROCEDURE|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
224270869|NCT02806609|OTHER|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
224270870|NCT02806609|OTHER|immersion in water at room temperature|immersion in water at room temperature
224270871|NCT02806609|OTHER|active recovery - running|active recovery
224270872|NCT02806609|OTHER|rest in the chair|rest in the chair
224270873|NCT00997477|DRUG|Foradil Combi (Formoterol-budesonide)|
224270874|NCT00387205|DRUG|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
224270875|NCT00271557|DRUG|nesiritide|
224270876|NCT01999088|OTHER|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
224270877|NCT01999088|OTHER|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
224270878|NCT06519760|DRUG|68Ga-C1|68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
224270879|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
224270880|NCT00202839|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
224270881|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
224270882|NCT00202839|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
224270883|NCT05945810|DRUG|TLL-018 extended-release tablet|50mg TLL-018 extended-release tablet QD
224270884|NCT05945810|DRUG|TLL-018 immediate-release tablet|20mg TLL-018 immediate-release tablet BID
224270885|NCT04986124|OTHER|treatment as usual|No inervention. Treatment regime remains unchanged.
224270886|NCT01133236|DIETARY_SUPPLEMENT|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
224270887|NCT00565513|PROCEDURE|blood test|cord blood and maternal milk test
224270888|NCT04618484|OTHER|Biomodulation (non-pharmacological)|cryo-, photo- and electro-biomodulation
224270889|NCT06617663|BEHAVIORAL|EMDR|Eye Movement Desensitization and Reprocessing (EMDR) is a therapy designed to alleviate the distress associated with traumatic memories.
224270890|NCT06617663|BEHAVIORAL|ACT|Acceptance and Commitment Therapy (ACT) is an action-oriented approach to psychotherapy that stems from traditional behavior therapy and cognitive behavioral therapy. Clients learn to stop avoiding, denying, and struggling with their inner emotions and, instead, accept that these deeper feelings are appropriate responses to certain situations and should not prevent them from moving forward in their lives. The ACT Your Way method is specifically designed for young people.
224270891|NCT06298565|BIOLOGICAL|efgartigimod|efgartigimod
224270892|NCT03436953|DRUG|CX-8998|T-type calcium channel blocker
224270893|NCT03436953|DRUG|Placebo|Placebo comparator
224270894|NCT00559598|GENETIC|proteomic profiling|
224270895|NCT00559598|OTHER|medical chart review|
224270896|NCT06678126|RADIATION|Prostate and Pelvic Nodes Radiotherapy|60 Gy prostate and 44 Gy pelvic nodes with 20 fractions
224270897|NCT05053724|OTHER|Star to move Protocol|"Progressive physical therapy according to the Gosslink protocol called Start to move."
224270898|NCT01784016|RADIATION|[11C]-PHNO|\[11C\]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
224270899|NCT03244605|OTHER|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
224270900|NCT03244605|OTHER|Rehabilitation Education|General health education
224270901|NCT03244605|DRUG|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
224270902|NCT03244605|DRUG|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
224270903|NCT00442351|DRUG|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
224270904|NCT00442351|OTHER|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
224270905|NCT04647734|BEHAVIORAL|High intensity interval training|12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week
224270906|NCT04647734|BEHAVIORAL|Standard care|standard care after discharge from hospital (control group)
224270907|NCT04768634|DIAGNOSTIC_TEST|Provocative electrophysiology study|Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
224270908|NCT06793592|BEHAVIORAL|Behaviorally informed recruitment message|Study participants will receive a behaviorally informed recruitment message that highlights an employer value proposition.
224270909|NCT06793592|BEHAVIORAL|Simplified direct message with no employer value proposition|Study participants will receive a simplified message that does not highlight any specific employer value proposition.
224270910|NCT06793592|BEHAVIORAL|No message|Study participants will not receive a recruitment message.
224270911|NCT06094842|DRUG|Bendamustine|Given IV
224270912|NCT06094842|PROCEDURE|Biopsy|Undergo tissue biopsy
224270913|NCT06094842|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224270914|NCT06094842|PROCEDURE|Bone Scan|Undergo bone scan
224270915|NCT06094842|PROCEDURE|Bridge Therapy|Undergo bridging therapy
224270916|NCT06094842|PROCEDURE|Computed Tomography|Undergo CT
224270917|NCT06094842|DRUG|Cyclophosphamide|Given IV
224270918|NCT06094842|PROCEDURE|Echocardiography|Undergo ECHO
224270919|NCT06094842|DRUG|Fludarabine|Given IV
224270920|NCT06094842|PROCEDURE|Leukapheresis|Undergo leukapheresis
224270921|NCT06094842|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224270922|NCT06094842|BIOLOGICAL|T-cell Receptor-engineered T-cells|Given autologous L1CAM-specific CAR+EGFRt+ T cells IV
224270923|NCT06094842|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
224270924|NCT05565690|DEVICE|MRS|It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain
224270925|NCT01206803|DRUG|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg \& daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
224270926|NCT02160613|PROCEDURE|Open flap debridement|an access flap
224270927|NCT06283888|DRUG|CYP2C19 Genotype Guided DAPT|Patients with \*2 or \*3 carrier will be received ticagrelor 60mg or 45mg bid (if \<50 kg, ≥75 years) + aspirin 100 mg qd; Patients with \*2 or \*3 non-carrier will be received clopidogrel 75mg qd + aspirin 100 mg qd
224270928|NCT06283888|DRUG|Conventional DAPT|Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd
224270929|NCT03522649|DRUG|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8\~12 hours.
224270930|NCT03522649|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m\^2/day (total 2400 mg/m\^2) continuous infusion.
224270931|NCT03522649|DRUG|Leucovorin|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
224270932|NCT03522649|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 followed by or concurrent with leucovorin 400 mg/m\^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
224270933|NCT01634685|RADIATION|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
224270934|NCT01634685|DRUG|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
224270935|NCT01634685|DRUG|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
224270936|NCT04837456|DIETARY_SUPPLEMENT|Calorie restricted diet and exercise intervention|the calorie restricted diet were prescribed a balanced diet that provided an energy deficit of 800 kcal/day from their daily energy requirement.Macronutrient content of low caloric diet, expressed as percentage of ingested energy with carbohydrates 45-65%; fat 20-35%; and protein 10- 35%\[36\]. Participants were guided by a dietitian for adjustments of their caloric intake weekly for six months.Participants performed 1 or 2 sets at a resistance of approximately 65% of their one-repetition maximum, with 8 to 12 repetitions of each exercise; they gradually increased the intensity to 2 to 3 sets at a resistance of approximately 80% of their one-repetition maximum, with 6 to 8 repetitions of each exercise.
224270937|NCT04837456|PROCEDURE|libitum diet and waiting list control group|libitum diet and waiting list control group, participants then underwent a calorie of 2000 calorie above based on libitum free diets recommended to adults and normal physical activity without exercise during the program.
224270938|NCT04837456|PROCEDURE|Early arthroscopic partial menisectomy group|Early APM group participants received APM with syndrome within 3 to 6 months
224270939|NCT04837456|PROCEDURE|delayed APM group recruit participants with symptoms lasting for more than 6 months|delayed APM group recruit participants with symptoms lasting for more than 6 months
224270940|NCT06383130|DIAGNOSTIC_TEST|Oscillometry with reversibility testing|Oscillometry is a test that uses sound waves to measure the mechanical properties in the lungs during tidal breathing
224270941|NCT06383130|DIAGNOSTIC_TEST|Breath volatile testing|We will be optimising and evaluating the sensitivity and specificity of a novel breath volatile organic compound test of a combination of reactive aldehydes using a gas chromatography-ion mobility spectrometry device
224270942|NCT06383130|DIAGNOSTIC_TEST|Nasal eosinophil peroxidase|We will be evaluating the sensitivity and specificity of a novel nasal swab test for eosinophil peroxidase
223517729|NCT05504746|DRUG|SHEN26 capsule|"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
224270943|NCT06383130|DIAGNOSTIC_TEST|Handheld capnometry|We will be evaluating handheld capnometry (carbon dioxide breath testing) to diagnose adult asthma
224270944|NCT02532192|DRUG|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
224270945|NCT02532192|DRUG|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
224270946|NCT02532192|DRUG|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
224270947|NCT02532192|DRUG|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
224270948|NCT02532192|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
224270949|NCT02532192|DRUG|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
224270950|NCT02532192|DRUG|Fluconazole|100 mg by mouth daily for 10 days.
224270951|NCT03192813|DEVICE|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
224270952|NCT03192813|DEVICE|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
224270953|NCT04182555|DEVICE|Bilirubin estimates from Smartphone Application|Bilirubin estimates through color analysis of digital images obtained through smartphone application.
224270954|NCT04182555|DIAGNOSTIC_TEST|Bilirubin concentration measured in standard blood samples|Bilirubin measured in total serum bilirubin.
224270955|NCT04182555|DEVICE|Bilirubin estimates from standard transcutaneous device|Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
224270956|NCT04182555|OTHER|Visual assessment of jaundice|Degree of jaundice will be assessed by Kramer scale
224270957|NCT00072514|DRUG|gemcitabine hydrochloride|Given IV
224270958|NCT00072514|DRUG|carboplatin|Given IV
224270959|NCT00072514|DRUG|dexamethasone|Given PO
224270960|NCT00072514|BIOLOGICAL|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
224270961|NCT06447753|PROCEDURE|Direct pulp capping|after caries excavation, the pulp will be inspected visually. If bleeding present, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Cases in which bleeding will not stop within 6 minutes will be excluded from the study and further managed by RCT. The exposed pulp will be capped with MTA which will be freshly mixed according to manufacturer's instructions and placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier following which the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. Then tooth will be restored using composite resin following etch and rinse technique.
223517730|NCT05504746|DRUG|SHEN26 capsule|Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
223517731|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
223517732|NCT05504746|DRUG|SHEN26 placebo|"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
223517733|NCT06225544|DRUG|Lumasiran|Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
224270962|NCT06447753|PROCEDURE|Complete Pulpotomy|exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant 28to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 6 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 6 minutes. After hemostasis, ProRoot MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using an amalgam carrier. After placement, the cavity floor will be dabbed with moist sterile cotton pellet to ensure the setting of MTA, followed by application of a layer of light-cure RMGIC over MTA and light-curing for 20s. The tooth then will be restored using composite resin following etch and rinse technique.
224270963|NCT00544167|DRUG|Doxorubicin|
224270964|NCT00544167|DRUG|Cyclophosphamide|
224270965|NCT00544167|DRUG|Paclitaxel|
224270966|NCT00544167|DRUG|Sorafenib|
224270967|NCT04323215|DEVICE|Support system|A support system named Provement will be used to provide behavioral treatment.
224270968|NCT01085981|DRUG|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
224270969|NCT01085981|DRUG|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
224270970|NCT01085981|DRUG|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
224270971|NCT03887598|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
224270972|NCT01388998|OTHER|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
224270973|NCT03857724|PROCEDURE|prolapse surgery|prolapse surgery
224270974|NCT02413034|DRUG|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
224270975|NCT02413034|OTHER|Control group|no antibiotic prophylaxis
224270976|NCT02370836|OTHER|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
224270977|NCT03824834|DRUG|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
224270978|NCT03824834|OTHER|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
224270979|NCT04918992|DIAGNOSTIC_TEST|Artificial Intelligence|investigators utilize a Artificial Intelligence (AI) supportive system to predict radiation proctitis for patients with pelvic cancers underwent radiotherapy
224270980|NCT04583150|PROCEDURE|Bariatric surgery|Bariatric surgery : sleeve gastrectomy or Roux-en-Y gastric bypass (RYGB)
224270981|NCT05910294|OTHER|questionnaires|Vaginal Assessment Scale (VAS) \& Vulvar Assessment Scale (VuAS) Breast Clinical Care and Symptom Survey (BCCSS) Female Sexual Function Index (FSFI) Sexual Activity Questionnaire (SAQ) Female Sexual Distress Scale Revised (FSDS-R) Menopausal Symptom Check List (MSCL) Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF) Weekly Non-Hormonal Moisturizer Diary
224270982|NCT05910294|OTHER|moisturizers|Patients will be provided a list of recommended moisturizers by the female sexual medicine and women's health program (FSMWHP), but will purchase the moisturizers themselves at their local pharmacy.
224270983|NCT05910294|OTHER|moisturizers|potential vaginal moisturizers include Hyalogyn, Replens, Liquibeads, or Vitamin E capsules
224270984|NCT06093893|DRUG|Dexmedetomidine|1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
224270985|NCT06093893|DRUG|Nicardipine|1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or
224270986|NCT06093893|DRUG|Labetalol|20 - 80 mg will be administered intravenously at 10-minute intervals to maximum of 300 mg;
224270987|NCT06743269|BEHAVIORAL|High-Resistance Inspiratory Muscle Strength Training|Performs inspiratory maneuvers at 55% maximal inspiratory pressure (PIMAX) during week 1, 65% PIMAX during week 2, and 75% PIMAX during weeks 3-6.
224270988|NCT06743269|BEHAVIORAL|Low-Resistance Inspiratory Muscle Strength Training|Performs inspiratory maneuvers at 15% maximal inspiratory pressure (PIMAX) for all 6 weeks.
224270989|NCT06743269|DEVICE|POWERbreathe K3 device|Inspiratory muscle training device
224270990|NCT06130956|DIETARY_SUPPLEMENT|Vegan diet|Vegan diet for 2 weeks before surgery
224270991|NCT06130956|DIETARY_SUPPLEMENT|Omnivorous diet|Omnivorous diet for 2 weeks before surgery
224270992|NCT05639036|DEVICE|Image Guided External Ventricular Drain Placement Using the NAV3 System|Nav3 image guidance system used to assist with external ventricular drain placement
224270993|NCT05639036|PROCEDURE|Free Hand External Ventricular Drain Placement|External ventricular drain will be placed with the standard free-hand technique
223517734|NCT06225544|DRUG|0.9% Sodium Chloride (placebo)|Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
224270994|NCT03320863|DEVICE|Enso device|An active Enso device that delivers neuromodulation therapy.
224270995|NCT02153203|BEHAVIORAL|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
223517735|NCT04477837|DRUG|Apixaban 5 MG|frequency of heavy menstrual bleeding
223517736|NCT04477837|DRUG|Rivaroxaban 20 MG|frequency of heavy menstrual bleeding
224270996|NCT02153203|OTHER|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
224270997|NCT02856594|DRUG|Dexmedetomidine|Dexmedetomidine
224270998|NCT02856594|DRUG|Placebo|Placebo
224270999|NCT04709757|DEVICE|Intermittent Dosing HF10 30/90|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 120 seconds OFF
224271000|NCT04709757|DEVICE|Intermittent Dosing HF10 30/360|10kHz frequency spinal cord stimulation delivered at 30 seconds ON and 360 seconds OFF
224271001|NCT05651698|DEVICE|HeartMan Intervention group|The system uses wrist-band sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
224271002|NCT03170739|DRUG|Dexmedetomidine|Dexmedetomidine given during surgery.
224271003|NCT03170739|DRUG|Dopamine|Dopamine given during surgery.
224271004|NCT01887158|DRUG|Polyethylene glycol|
224271005|NCT01887158|DRUG|Bisacodyl|
224271006|NCT02926040|PROCEDURE|Irreversible electroporation|
224271007|NCT02233374|OTHER|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
224271008|NCT02233374|OTHER|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI \& ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
224271009|NCT01591720|BEHAVIORAL|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
224271010|NCT05281120|DEVICE|Low-level mechanical vibrations WITH vertical sinusoidal acceleration|Small platform designed to induce vertical, sinusoidal acceleration.
224271011|NCT05281120|DEVICE|Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration|Small platform designed to NOT induce vertical, sinusoidal acceleration
224271012|NCT05445180|BEHAVIORAL|Contingency management|Contingency management will be used to encourage abstinence
223517737|NCT04477837|DRUG|Edoxaban 60 MG|frequency of heavy menstrual bleeding
224271013|NCT02622867|OTHER|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
224271014|NCT02622867|DIETARY_SUPPLEMENT|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
224271015|NCT05136001|DEVICE|polysomnography|Duration of sleep was collected with polysomnography on second postoperative night. (from 20:00pm to 06:00am).
224271016|NCT01977521|DEVICE|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
224271017|NCT01977521|DEVICE|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
223517738|NCT04477837|DRUG|Dabigatran 150 Mg Oral Capsule|frequency of heavy menstrual bleeding
223517739|NCT02758626|DRUG|ataluren|Powder formulation
223517740|NCT02758626|DRUG|Placebo|Powder formulation
223517741|NCT04833738|DRUG|Hyaluronic acid|
223517742|NCT04833738|DRUG|Corticosteroids Triamcinolone Acetonide|triamcinolone acetonide, 40 mg/ml, single dose
223517743|NCT04833738|OTHER|Electrotherapy|electrotherapy
223517744|NCT04025957|DRUG|SHR-1501|Administered subcutaneously
224271018|NCT02805764|DEVICE|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
224271019|NCT02156453|PROCEDURE|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
224271020|NCT02582554|BEHAVIORAL|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
224271021|NCT05588063|DEVICE|Transcutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
224271022|NCT05588063|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
224271023|NCT03492138|DRUG|ONC201|625mg
224271024|NCT03492138|DRUG|Ixazomib|Dose to be determined in Phase 1 of study
224271025|NCT03492138|DRUG|Dexamethasone|40mg
224271026|NCT04879927|OTHER|Resource Matching|Resource staff involved in the customized resource matching arm of the intervention will include staff from DFCI Patient Services and DFCI Financial Counseling. Financial counseling will support patients with financial resource needs. DFCI Patient Services will provide assistance for all other patient Social Determinants of Health needs.
224271027|NCT04879927|OTHER|Usual Care|Patients randomized to the control group will receive a pre-existing pamphlet detailing DFCI resources.
224271028|NCT04392999|DRUG|Intraarticular platelet rich plasma cervical facet injection|Injection of PRP into the cervical facet joints.
224271029|NCT04392999|DRUG|Corticosteroid injection|Injection of corticosteroid into the cervical facet joints.
224271030|NCT03204851|DEVICE|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
224271031|NCT00001191|DRUG|Pantoprazole|
224271032|NCT00001191|DRUG|Omeprazole|
224271033|NCT03797248|COMBINATION_PRODUCT|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
223517745|NCT04543786|DEVICE|Transcutaneous spinal cord stimulation|Neuromodulation with transcutaneous spinal cord stimulation applied on lower back adjacent to spine for 30-60 minutes for 5 consecutive days.
223517746|NCT04806399|OTHER|Educational Materials and Decision Counseling|Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
223517747|NCT04880356|OTHER|collection of data|collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
224271034|NCT05722496|OTHER|Aerobic pedaling exercise|aerobic exercise in the form of leg pedaling exercise in semi-supine position using leg ergometer by different intensities
224271035|NCT00377117|PROCEDURE|Management|
224271036|NCT00377117|PROCEDURE|Screening|
224271037|NCT03108235|BEHAVIORAL|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse.
224271038|NCT03108235|BEHAVIORAL|HOM-HEMP with smartphone app|"a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed HF education and self-management toolkit, three biweekly home visits by the research nurse. In addition, participants will receive a smartphone app.~The smartphone will be used to monitor their health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference."
224271039|NCT03108235|BEHAVIORAL|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
224271040|NCT05072535|DRUG|HA121-28 tablet B|HA121-28 tablet B 200 mg
224271041|NCT05072535|DRUG|HA121-28 tablet A|HA121-28 tablet A 200 mg
224271042|NCT05954663|OTHER|Basic demographic information|"Basic demographic information: age, sex, weight, height, BMI. Comorbidities: history of major bleeding, cardiovascular comorbidities, diabetes mellitus, renal failure, smoking, hormone therapy Anticoagulant and antiplatelet therapy (molecule, duration and indication, before and after intervention) Procedure data: number and type of stents implanted, diameters and lengths, name of stented venous segments Postoperative complications: bleeding complications, pelvic pain, early thrombosis, early pulmonary embolism~* Clinical examination carried out 1 month after the operation and more than 6 months after the operation~* Data from the control ultrasound performed 1 month after the operation and more than 6 months after the operation"
224271043|NCT02315963|OTHER|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
224271044|NCT00408018|DRUG|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
224271045|NCT05191238|OTHER|IUD self-removal education|Two part educational intervention (watching IUD self-removal video and practicing IUD removal on two simulation models)
224271046|NCT06245928|DEVICE|Individualized Respiratory Exercise Device|The Individualized Respiratory Exercise device will include both inspiratory muscle training, expiratory muscle training, and intensive spirometer features.
224271047|NCT06245928|DEVICE|Threshold® IMT + Threshold™ PEP|The Threshold® IMT device allows inspiratory muscle training and the Threshold™ PEP device allows expiratory muscle training.
224271048|NCT00006153|BIOLOGICAL|HIV-1 Immunogen|
224271049|NCT00259896|DRUG|exenatide|
224271050|NCT04281472|BIOLOGICAL|efgartigimod PH20 SC in stage B|Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC
224271051|NCT04281472|OTHER|placebo in stage B|Stage A: N/A, stage B: placebo
224271052|NCT06561269|PROCEDURE|Multifidus plane block|"Using the in-plane technique,The fascial plane between the multifidus muscle and the median sacral crests of S2 and S3, will be injected by bupivacaine."
224271053|NCT06561269|PROCEDURE|caudal block|"The ultrasound transducer will first be placed transversely at the midline to obtain the transverse view of sacral hiatus. At this level, the ultrasound transducer is rotated 90 degrees to obtain the longitudinal view of sacral hiatus. The block needle is inserted using the in-plane technique."
224271054|NCT04261374|DIAGNOSTIC_TEST|Measurement of sublingual microcirculation|Measurement of sublingual microcirculation
224271055|NCT01884701|DEVICE|ENABLER-P Catheter System|
224271056|NCT00774540|DRUG|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
224271057|NCT00774540|DRUG|Placebo|Saline
224271058|NCT03680001|BEHAVIORAL|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
224271059|NCT04122950|BEHAVIORAL|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
224271060|NCT03811158|DEVICE|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
224271061|NCT03811158|DEVICE|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
224271062|NCT00731458|DEVICE|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
224271063|NCT05493163|DRUG|Thrombolytic|Local, catheter-directed thrombolysis with a total dose of 10mg per affected lung administered over 9 hours.
223517748|NCT01142570|OTHER|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
223517749|NCT01142570|OTHER|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
224271064|NCT05493163|DRUG|Standard anticoagulation|Standard anticoagulation therapy of acute pulmonary embolism.
224271065|NCT05308186|BEHAVIORAL|Auditory stimulation|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report) through headphones. In case no report is given, nature (brook) sounds will be streamed.
224271066|NCT05308186|BEHAVIORAL|Auditory and tactile stimulations|The patient will be exposed to music that he used to enjoy (from the family's or guardian's report, otherwise nature (brook) music will be streamed) through headphones combined with deep tissue massage will be given on the upper limbs.
224271067|NCT04883996|DRUG|1% EXP039|1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),
224271068|NCT04883996|OTHER|Saline control|Saline
224271069|NCT03558295|DRUG|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
224271070|NCT03850938|DEVICE|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
224271071|NCT03850938|DEVICE|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
224271072|NCT02095613|OTHER|traditional food|
224271073|NCT02095613|OTHER|food that is nutrient dense|
224271074|NCT00042835|DRUG|cisplatin|Given IV
224271075|NCT00042835|DRUG|etoposide|Given IV
224271076|NCT00042835|DRUG|erlotinib hydrochloride|Given orally
224271077|NCT00042835|RADIATION|radiation therapy|Undergo radiotherapy
224271078|NCT00042835|DRUG|docetaxel|Given IV
224271079|NCT00042835|DRUG|paclitaxel|Given IV
224271080|NCT00042835|DRUG|carboplatin|Given IV
224271081|NCT00042835|OTHER|laboratory biomarker analysis|Correlative studies
224271082|NCT05137093|DEVICE|Actigraphy Device|Patients will wear actigraphy device which detects scratching events.
224271083|NCT03862547|DIAGNOSTIC_TEST|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
224271084|NCT06001463|DRUG|CSMed Dressing|Half of the irradiated area was covered with CSMed® and the other half was under routine treatment. An irradiated area of 11cm\*14cm with best fit or easy accessibility was chosen for CSMed® dressing application. The area without dressing was treated with routine skin care in each patient.
224271085|NCT03056547|OTHER|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
224271086|NCT00152451|DRUG|Seletracetam (ucb 44212)|"* Pharmaceutical form: oral capsules~* Concentration: 10 and 50 mg~* Route of administration: oral administration"
224271087|NCT05456451|DEVICE|noninvasive vagus nerve srimulation|Non-invasive Vagus nerve stimulation (VNS) stimulates the vagus nerve through the ear via a headset. VNS is a non-pharmacological intervention with the potential to improve walking, cognition, fatigue, and autonomic functions in the treatment of Parkinson's disease.
224271088|NCT03766360|BEHAVIORAL|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
224271089|NCT05053360|BEHAVIORAL|Healing Touch|"Healing Touch (HT), with a foundation in holistic nursing, is a gentle therapy that uses touch to promote health and well-being by balancing the human energy system. Healing Touch (HT) is a biofield therapy in which practitioners use their hands in a heart-centered and intentional way to provide energetic balance to support physical, emotional, mental and spiritual health. It is safe for all ages and works in harmony with, is complementary to, and may be integrated with standard medical care. Healing Touch is a collection of standardized, noninvasive techniques that clear, energize, and balance the human and~environmental energy fields."
224271090|NCT05053360|OTHER|Control|Quiet Time (QT) session is when a subject is provided with quiet for 15 minutes
224271091|NCT00155220|DEVICE|Low Stretch Bandage and Kinesio Tape|
224271092|NCT05645120|OTHER|Education|All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
223517750|NCT01142570|DIETARY_SUPPLEMENT|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
224271093|NCT05995769|DRUG|Psilocybin|Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing
224271094|NCT04468880|OTHER|Group (A1 → A2)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A1A2 milk for 2 weeks (period 1), then they will consume A2A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
224271095|NCT04468880|OTHER|Group (A2 → A1)|"Before each start of consumption of the products under study, a wash-out period of 2 weeks (no consumption of milk) must be observed by the subjects.~25 subjects will consume A2A2 milk for 2 weeks (period 1), then they will consume A1A2 milk for 2 weeks (period 2).~During each consumption period, various questionnaires will be completed by the subjects: frequency and consistency of stool, analog visual scales on digestive comfort and dietary surveys. Stool collections will also be carried out."
224271096|NCT00254280|PROCEDURE|Intense Pulsed Light + paring versus paring alone|
224271097|NCT03711591|DEVICE|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
224271098|NCT02604680|DRUG|BLI1100-1|BLI1100-1 Topical gel
224271099|NCT02604680|DRUG|BLI1100-2|BLI1100-2 Topical gel
224271100|NCT02604680|DRUG|BLI1100-3|BLI1100-3 Topical gel
224271101|NCT02604680|DRUG|BLI1100-4|BLI1100-4 Topical gel
224271102|NCT02604680|DRUG|Placebo|Placebo - Topical gel
224271103|NCT00620880|BEHAVIORAL|Blood sample|
224271104|NCT05863026|BEHAVIORAL|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)|THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
224271105|NCT05031455|DRUG|Aspirin Challenge|"Dupilumab is a fully human monoclonal antibody that blocks the receptor component for IL-4 and IL-13, which are key drivers of type 2 inflammation. All subjects will be prescribed this at standard 300mg subcutaneous dosing every 2 weeks. The intervention will be the response to aspirin challenge.~All 16 subjects will receive dupilumab. All subjects will undergo an aspirin challenge/desensitization procedure. It is estimated that 50% of subjects will have a respiratory reaction to aspirin and 50% will not. There will not be any randomization."
224271106|NCT06348888|DRUG|BAY2927088|Oral
224271107|NCT06348888|DRUG|Itraconazole|Capsule, 100 mg, oral.
224271108|NCT06348888|DRUG|Carbamazepine|Tablet, 100 mg, 200mg and 300mg, oral.
224271109|NCT05643105|PROCEDURE|Any kind of colectomy|This is a registry of surgical patients with colon cancer that are managed following current clinical practice in each participating center. The aim of this research is studying anastomotic leak rates and posible risk factors.
224271110|NCT00582205|DRUG|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
223893546|NCT05894577|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
224271111|NCT02107469|DRUG|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
224271112|NCT02107469|DRUG|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
224271113|NCT02107469|DRUG|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
224271114|NCT02107469|DRUG|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
224271115|NCT02107469|OTHER|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
224271116|NCT02107469|OTHER|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
224271117|NCT00981344|OTHER|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
224271118|NCT05104996|BEHAVIORAL|Telephone Counseling|The form was used for weekly follow-up of the patients included in the experimental group. Headings were created according to the topics in the training form and/or for other problems and the problems stated by the patients were marked every week. Ongoing or eliminated problems of each patient until the time of next telephone counseling were indicated in the form. General problems in the form included drugs, pain, exercise, wound care, edema, compression socks, corset, nutrition, constipation, bathing, sleep, emergencies, back to work, sexual life, travel, visitors, climbing stairs, alcohol use/smoking, stress/anxiety, check-ups, and other issues.
224271119|NCT02016235|DRUG|Phosphorus Supplement|250 mg po qid
224271120|NCT02016235|OTHER|Observation|Baseline blood and urine measurements only
224271121|NCT00198835|BEHAVIORAL|Maternal nutrition and infant feeding advice|
224271122|NCT01756716|DRUG|MT-3995 Low|MT-3995 Low dose for 8 weeks
224271123|NCT01756716|DRUG|MT-3995 High|MT-3995 High dose for 8 weeks
224271124|NCT01756716|DRUG|Placebo|Placebo for 8 weeks
224271125|NCT01055834|DRUG|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting \>=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast \& the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
224271126|NCT01055834|DRUG|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
224271127|NCT03528486|BEHAVIORAL|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
223893547|NCT05876598|DRUG|antibiotic treatments|The outcome of the study will be to implement Prediction Models to support clinicians for the assessment of risk of having a bloodstream infection.
223893548|NCT05784584|PROCEDURE|Blood samples collection|The study population will take blood samples for virological and immunological measurements.
223893549|NCT06323408|DIAGNOSTIC_TEST|Tissue, blood, cerebrospinal-spinal fluid|Processing, analysis
223517751|NCT01142570|DIETARY_SUPPLEMENT|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
223517752|NCT01142570|DIETARY_SUPPLEMENT|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
224271128|NCT03333863|OTHER|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
224271129|NCT02754219|DRUG|Evogliptin|DPP4-inhibitor, Evogliptin
224271130|NCT04303208|PROCEDURE|Blood sample|Blood sample ( 5 ml venous blood ) will be obtained under complete aseptic conditions from all eligible participants , using serum separator tube and allow samples to clot for 30 minutes before centrifugation for 15 minutes to obtain clear serum . Separated serum will be stored at \< - 20c ( avoid repeated freeze - thaw cycles ) till assessment of Sirt 3 and Sirt 7 levels using Enzyme- linked immunosorbent assay (ELISA) method .
223517753|NCT04850599|DRUG|Carfilzomib|Given IV
223517754|NCT04850599|BIOLOGICAL|Isatuximab|Given IV
223517755|NCT04850599|DRUG|Pomalidomide|Given PO
223517756|NCT05960201|DRUG|[18F]fluoroestradiol (FES)|F-18 FES 111\~222 MBq(megabecquerel) injection
223893550|NCT05093478|DRUG|Intranasal capsaicin|Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.
223893551|NCT05093478|DRUG|topical lidocaine|The nose will be pre-treated with topical lidocaine 15 minutes before each application
223534834|NCT03563547|BEHAVIORAL|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
223893552|NCT06800937|OTHER|Determination of sphingolipidomic profile|The plasma/serum levels of the following sphingolipids will be measured: ceramides and dihydroceramides from C16 to C24, including 2 unsaturated ones (C18:1 and C24:1), sphingomyelins (those from C16 to C24 and the one C24:1), sphingosine, sphinganine, sphingosine-1-phosphate and sphinganine-1-phosphate.
223893553|NCT06800807|OTHER|Observation of several factors involved in eating and nutrition disorders|Observation of symptomatology of eating and nutrition disorders, metacognitive beliefs, brooding and rumination.
223517757|NCT05617196|BEHAVIORAL|Virtual PREHAB|The Virtual PREHAB program begins with a virtual health care team assessment. The physiotherapist will support patients in identifying ways to safely engage in home-based physical activities and in their neighborhoods. Additional weekly 30-minute telephone consultations with the physiotherapist, nurse, and dietitian are provided as well as three 30-minute online consultations are provided; telephone calls will replace these online consults if the patient does not have internet access. Telephone and/or online consults with participants will monitor the progression of the individual through the program, review patient materials, review medication changes, as well as provide recommendations to adopting a physically active lifestyle, diet, well-being, smoking, or other supports available to the patient. Medication changes are monitored by a nurse and any necessary medication recommendations involve the program's medical director, the patient's family physician, and TAVI team.
223517758|NCT05617196|BEHAVIORAL|Standard care|In Nova Scotia, patients are referred to the TAVI program. The TAVI health care team, consisting of a cardiac surgeon, cardiologist, nurse, and geriatric team conduct patient assessments and provide guidance and resources on self management.Once patient assessments are completed, patients are discussed at a multidisciplinary team meeting. When a patient is accepted for TAVI, they are placed on a waiting list which lasts for 3-6 months depending on urgency.
223517759|NCT06484543|OTHER|Maslinic Acid|Consumption of Maslinic Acid for 12 weeks
223517760|NCT06484543|OTHER|Placebo|Consumption of Placebo for 12 weeks
223517761|NCT06547996|DEVICE|tES-tDCS group|2mA/20mins/session
223517762|NCT06547996|DEVICE|tES-tACS group|2mA/40Hz/20mins/session
223517763|NCT06547996|DEVICE|tES-sham group|0mA/20mins/session
223517764|NCT05830097|DRUG|CBP-1019|Light yellow to yellow loose lumps or powder；50mg/vial; Infusion for 90 minutes (± 10 minutes), once every 2 weeks.
223517765|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
223517766|NCT00720811|DRUG|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
223517767|NCT00720811|DRUG|paracetamol|paracetamol 500mg tablet \<36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
223517768|NCT00720811|DEVICE|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
223517769|NCT00720811|DRUG|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
223517770|NCT03197272|PROCEDURE|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
223517771|NCT01204281|OTHER|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
223517772|NCT04616235|DRUG|Tocilizumab Injectable Product|The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.
223517773|NCT04616235|OTHER|Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour|The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
223517774|NCT04355689|DRUG|NPI-001|oral tablet
223517775|NCT04355689|OTHER|Placebo|Placebo tablets
223517776|NCT06404554|OTHER|without any intervention|without any intervention
224271131|NCT05004649|BEHAVIORAL|Psychophysical task|A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
224271132|NCT01717313|DRUG|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
223517777|NCT05358782|DEVICE|Dental implant positioning|observational study of the effect of implant malposition
223517778|NCT06197516|OTHER|Integrated Neuromuscular Inhibition Technique|After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.
223517779|NCT06197516|OTHER|Neuromuscular Reeducation Technique|Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required
223517780|NCT01766843|DRUG|Seretide Diskus and charcoal|2 inhalations as a single dose
223517781|NCT01766843|DRUG|Seretide Diskus|2 inhalations as a single dose
223517782|NCT01766843|DRUG|SF Easyhaler and charcoal|2 inhalations as a single dose
223517783|NCT01766843|DRUG|SF Easyhaler|2 inhalations as a single dose
224271133|NCT01717313|DRUG|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
223517784|NCT02626351|OTHER|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: \[1\] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; \[2\] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; \[3\] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; \[4\] Follow up.
224271134|NCT01717313|DRUG|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
224271135|NCT01717313|DRUG|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
224271136|NCT01717313|DRUG|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
224271137|NCT02134821|PROCEDURE|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
224271138|NCT00276536|BIOLOGICAL|recombinant interferon alpha-1b|interferon
224271139|NCT00276536|DRUG|IFN|IFN daily
224271140|NCT02063815|PROCEDURE|Fissure sealant application|
224271141|NCT03522532|PROCEDURE|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
224271142|NCT03522532|PROCEDURE|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
224271143|NCT03522532|PROCEDURE|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
223517785|NCT02626351|OTHER|Baseline data collection (active comparator)|Endpoint data collection only
223517786|NCT05105971|DRUG|BAT6026|Phase 1 dose titration study from BAT6026 0.01mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
223517787|NCT02922712|DRUG|NISE|Nise 200mg Max per day in 2 divided doses
224271144|NCT03522532|PROCEDURE|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
224271145|NCT03522532|PROCEDURE|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
224271146|NCT03522532|PROCEDURE|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
224271147|NCT00091377|DRUG|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
224271148|NCT00091377|DRUG|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
224271149|NCT00091377|DRUG|phenoxodiol|IV 3 mg/kg
224271150|NCT02987153|RADIATION|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
223517788|NCT04476680|DIETARY_SUPPLEMENT|Vitamin D|Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
224271151|NCT00728754|DEVICE|Dental implant Osseotite Prevail|Root form titanium dental implant
223517789|NCT03370835|DRUG|Metoprolol succinate ER|Cardioselective beta-blocker
223517790|NCT03370835|DRUG|Carvedilol|Non-cardioselective beta-blocker
223517791|NCT00663195|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
223517792|NCT04204902|DRUG|Tepotinib 100 mg|Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
223517793|NCT04204902|DRUG|Tepotinib 250 mg|Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
223517794|NCT03101670|DRUG|filgotinib|one filgotinib oral tablet q.d.
223517795|NCT03101670|DRUG|Placebo Oral Tablet|one placebo oral tablet q.d.
223534835|NCT03745950|DRUG|Olaparib Oral Capsule|\- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
224271152|NCT00728754|DEVICE|Dental implant Osseotite|root form titanium dental implant
224271153|NCT03948854|OTHER|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
224271154|NCT03948854|OTHER|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
224271155|NCT03948854|OTHER|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
224271156|NCT03948854|OTHER|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
224271157|NCT04464005|DRUG|Magnesium sulfate 33% solution|Topical pads with cold magnesium sulfate 33% solution will be given 5 times/day for 15 minutes
224271158|NCT04464005|OTHER|Cold water|Topical pads with cold water will be given 5 times/day for 15 minutes
224271159|NCT02155153|OTHER|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
224271160|NCT00002253|DRUG|Octreotide|
224271161|NCT00009945|DRUG|clodronate|1600 mg PO daily
224271162|NCT00009945|DRUG|placebo|2 pills PO daily
224271163|NCT02654145|DRUG|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
224271164|NCT02654145|DRUG|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
224271165|NCT02654145|DRUG|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
224271166|NCT01800838|DRUG|silicon phthalocyanine 4|Given topically
224271167|NCT01800838|DRUG|photodynamic therapy|Undergo PDT
224271168|NCT01800838|OTHER|pharmacological study|Correlative studies
224271169|NCT01800838|OTHER|laboratory biomarker analysis|Correlative studies
224271170|NCT00955838|OTHER|Rehabilitation technique|12 therapy session
224271171|NCT01769898|DRUG|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
224271172|NCT01769898|DRUG|Theophylline|Theophylline 0.1 Q12H
224271173|NCT01769898|DRUG|Placebo|Placebo for theophylline 0.1 Q12H
224271174|NCT03304223|DIAGNOSTIC_TEST|[18F]FB-IL2 PET scan|\[18F\]FB-IL2 PET scan procedure
224271175|NCT02569138|DEVICE|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
224271176|NCT02569138|DEVICE|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
224271177|NCT03344120|OTHER|Administration of USSQ Symptoms questionnaire after stent positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of stents after ureteroscopy
224271178|NCT06360887|PROCEDURE|Conservative|Conservative treatment
224271179|NCT06360887|PROCEDURE|ORIF|Open surgery
224271180|NCT06360887|PROCEDURE|CRPP|Minimal invasive surgery
224271181|NCT05553444|BEHAVIORAL|Self-management intervention|"The procedure will be based on the A - B - A'/B' design. After recruitment, patients will attend an initial session with CLS where written and oral information about the study will be provided. In this study, the A phase will serve as baseline to establish fluctuation in pain intensity prior to initiating the treatment.~During phase A, patients will be assessed every day for a minimum of 8 days and maximum of 14 days.~During phase B, CLS will facilitate the intervention based on the initial session, pain levels during phase A and the patients' goals. During phase B, patients will attend a 1-hour weekly session over 6 weeks.~During phase A', the participants will be followed weekly for 12 weeks. During the phase A', participants will not receive treatment.~Phase B' contains 3 x 1 hour criterion-based booster sessions which are delivered over 3 consecutive weeks."
223517796|NCT04539431|GENETIC|validation of new technologies|Development of a new molecular assay on tissue as well as on liquid biopsies (plasma and CSF), based on a single, open, real-time PCR platform with unprecedented sensitivity
223517797|NCT05900401|OTHER|Bone Marrow Transplant|Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)
223534836|NCT03745950|DRUG|Placebo oral capsule|\- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
223893554|NCT05582746|BEHAVIORAL|Tri-City COVID Attitudes Study|We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
224271182|NCT05140759|DEVICE|automated continual water removal system|The device removes excess fluids in heart failure patients with diuretic resistance
224271183|NCT00835588|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
224271184|NCT00835588|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
224271185|NCT01991548|DEVICE|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
224271186|NCT01943435|DRUG|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
224271187|NCT01943435|PROCEDURE|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
224271188|NCT01943435|OTHER|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
224271189|NCT01943435|OTHER|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
224271190|NCT01943435|OTHER|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
224271191|NCT02382224|BEHAVIORAL|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
223517798|NCT05900401|PROCEDURE|Peripheral Blood Stem Cell Collection|PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.
223517799|NCT05900401|DRUG|Fludarabine|Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
223517800|NCT05900401|DRUG|Cyclophosphamide|Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
223517801|NCT05900401|DRUG|Rituximab|Rituximab on study day -6
223517802|NCT05900401|DRUG|Siplizumab|Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.
223517803|NCT03876808|DEVICE|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
223517804|NCT03876808|DEVICE|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
223517805|NCT03098706|PROCEDURE|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
223517806|NCT03098706|PROCEDURE|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
223517807|NCT03165695|DRUG|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
223517808|NCT03165695|DRUG|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
223517809|NCT05187988|PROCEDURE|supraclavicular brachial plexus block|group will receive brachial plexus block above clavicle,Injection of anaesthetic will be done in brachial plexus around subclavian artery
223517810|NCT05187988|PROCEDURE|Retroclavicular brachial plexus block|group will receive brachial plexus block inferior to the clavicle,injection of anaesthetic will be done around axillary artery
223517811|NCT01545310|DRUG|SLV354|One dose of ABT-354
223517812|NCT00154245|DRUG|Enteric-Coated Mycophenolate sodium (EC-MPS)|
223517813|NCT02868931|BEHAVIORAL|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
223517814|NCT00456365|DRUG|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
223517815|NCT00456365|DRUG|Placebo|Placebo daily
223517816|NCT00870324|DEVICE|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
223517817|NCT00870324|DEVICE|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
223517818|NCT00706537|DRUG|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
223517819|NCT00706537|DRUG|Placebo|Placebo as two tablets once daily for three weeks
223517820|NCT02704000|BEHAVIORAL|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
223517821|NCT04873193|DEVICE|Leo device|Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
223517822|NCT02124005|DRUG|Bupivacaine|
223517823|NCT04797390|DEVICE|Advanced Pneumatic Compression Device (APCD)|Once daily treatment with Flexitouch Plus.
223517824|NCT04797390|OTHER|Usual Care|Usual care consists of a two-phase CDT. Phase 1 includes consultation with a lymphedema therapist, patient education, MLD, compression garments or bandages, skin care techniques, and a program of exercises and postural recommendations. Phase 2 consists of ongoing self-care, where patients conduct a life-long program of disease management that mimics the program in phase 1.
223517825|NCT01930708|DRUG|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
223517826|NCT00347971|DRUG|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
223517827|NCT04634136|DIAGNOSTIC_TEST|Lab tests|CBC and differential counts, blood electrolytes, magnesium, calcium, phosphorus, urea \& creatinine, liver enzymes (AST, ALT, gGT)
223517828|NCT04634136|DIAGNOSTIC_TEST|ECG|Electrocardiogram
224271192|NCT02382224|BEHAVIORAL|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
223517829|NCT04634136|DIAGNOSTIC_TEST|Cannabinoid Levels|Determination of levels of cannabidiol (CBD) and delta-9-tetrahydrocannbinol (THC) for determination of levels at following time(s) after ingestion: 0, 1, 2, 4, 8 and 24 hours.
223517830|NCT04634136|DRUG|Full-spectrum Medical Canabis Product (HemPhar)|Active substance
223517831|NCT04634136|DRUG|Placebo|Placebo
223517832|NCT04634136|DIAGNOSTIC_TEST|Spasticity level according to modified Ashworth scale (Bohannon)|"A trained physiotherapist will assess spasticity level according to modified Ashworth scale (Bohannon), which is 6-level scale for assessment of spasticity.~Modified Ashworth/Bohannon Scoring Scale (Bohannon and Smith, 1987):~0 No increase in muscle tone~1. Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension 1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of movement (ROM )~2. More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved~3. Considerable increase in muscle tone, passive movement difficult~4. Affected part(s) rigid in flexion or extension~Best score is 0 (no spasticity), worst score is 4 (severe spasticity)."
223517833|NCT04634136|DIAGNOSTIC_TEST|Gross Motor Function Measure|"A trained physiotherapist will assess Gross Motor Function Measure (GMFM-88) which is commonly used in the evaluation of gross motor function in children with cerebral palsy~The Gross Motor Function Measure-88 (GMFM-88) is a standardized observational instrument developed to measure change in gross motor function over time. The test consists of 88 items categorized in five dimensions (Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing and Dimension E: walking, running and jumping). The test was conducted as described in the GMFM-88 manual . A percentage score as compared to maximum is calculated for each dimension and for the total score of the five dimensions.~Reference curves exist for GMFM-88 for each age group.~Floor score is 4 (minimum score / worst), ceiling score (maximum score / best) is 75."
224271193|NCT00295490|DRUG|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
224271194|NCT00295490|DRUG|Placebo|Placebo has same dosing freq as for active intervention and for same time period
224271195|NCT04254315|BEHAVIORAL|Group based cognitive therapy|"Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising."
224271196|NCT03181386|DRUG|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
224271197|NCT03181386|DRUG|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
224271198|NCT03181386|DRUG|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
224271199|NCT05054777|PROCEDURE|oncoplastic breast-conserving surgery|The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
224271200|NCT05054777|PROCEDURE|conventional breast-conserving surgery|conventional breast-conserving surgery without any oncoplastic operations
224271201|NCT03921801|OTHER|Gait retraining|"Gait retraining using real-time electromyography biofeedback performed once per week for eight weeks.~During the gait retraining session the participant is walking on a treadmill while receiving information on calf muscle activation. A single session includes five bouts of walking each lasting for 5 minutes. During the first bout, the participant is receiving feedback (visual and auditive) on soleus muscle activation with the aim to increase it by 20% from their normal walking. During the second bout, the participant is receiving feedback (visual and auditive) on medial gastrocnemius muscle activation with the aim to decrease it by 20% from their normal walking. During the last three bouts, the participant is receiving feedback (visual and auditive) on the soleus to medial gastrocnemius muscle activation ratio with the aim to increase it by 20% from their normal walking. If hitting the target, the aim is increased by 5% for the subsequent bout."
223517834|NCT04634136|DIAGNOSTIC_TEST|Borg rating of perceived exertion scale|Borg rating of perceived exertion scale
223517835|NCT04634136|DIAGNOSTIC_TEST|Edmonton symptom assessment system|Edmonton symptom assessment system and general impression scale (1 - very much improved; 7 - very much worse).
223517836|NCT02826785|BEHAVIORAL|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
223517837|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.02%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
223517838|NCT05451329|DRUG|VVN539 Ophthalmic Solution 0.04%|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
223517839|NCT05451329|DRUG|VVN539 Ophthalmic Solution Vehicle|Once a day \[q.d.\] in the morning, q.d. in the evening and twice a day \[b.i.d.\]) will be tested for 7-9 days
223517840|NCT00832026|DEVICE|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
223517841|NCT00133432|DRUG|Zinc|
224271202|NCT03921801|OTHER|Gait retraining + strength training|"Gait retraining using real-time electromyography biofeedback performed once per week and home-based calf muscle strength training performed three times per week for eight weeks.~The gait retraining is identical to the one intervention described for the intervention group Gait retraining.~The strength training is performed three times per week except for the first week in which it is performed two times. The session contained a warm-up (3x10 repetitions of two-legged heel raises) and maximal isometric calf muscle contractions. The maximal contractions are performed using a custom device with the ankle in dorsiflexion and the knee flexed by 100-120 degrees. Three sets of 10 repetitions (3-second contraction and 3-second rest) are performed with both legs and with maximal effort and 1-minute rest between the sets."
224271203|NCT01617096|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
224271204|NCT01617096|COMBINATION_PRODUCT|Placebo Ring|Vaginal ring containing no drug substance
223517842|NCT02714842|DRUG|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
223517843|NCT02714842|DRUG|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
224271205|NCT03612973|DIAGNOSTIC_TEST|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
224271206|NCT03612973|DIAGNOSTIC_TEST|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
224271207|NCT03612973|DIAGNOSTIC_TEST|fibro scan|liver stiffness by fibro scan before and after treatment
224271208|NCT03892343|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
224271209|NCT00893919|DRUG|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
224271210|NCT03921762|PROCEDURE|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
224271211|NCT03921762|PROCEDURE|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
224271212|NCT03040895|OTHER|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
224271213|NCT03040895|OTHER|Treatment as usual|Treatment as usual through the data collection period (6 months)
224271214|NCT01485068|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
224271215|NCT05535920|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Patients will use Lokelma supplementation on off-dialysis days (4 days/week) while receiving hemodialysis with 3.0 K+/2.5 Ca++ mEq dialysate bath. The individual starting dose will be 5.0 grams, and may be titrated weekly in 5.0 gram increments up to 15.0 grams to maintain K+ between 4.0 and 5.5 mEq/L.
224271216|NCT00005873|DRUG|rubitecan|
224271217|NCT03029364|BEHAVIORAL|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
224271218|NCT03795441|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
224271219|NCT00397657|DRUG|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
224271220|NCT00397657|DRUG|ezetimibe|Ezetimibe 10mg once daily
224271221|NCT04132063|DRUG|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
224271222|NCT03825562|BEHAVIORAL|acceptance and commitment therapy, ACT|
224271223|NCT00400634|DRUG|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10\^11 vg
224271224|NCT00400634|PROCEDURE|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
224271225|NCT01196390|DRUG|Carboplatin|Given IV
224271226|NCT01196390|OTHER|Laboratory Biomarker Analysis|Correlative studies
224271227|NCT01196390|DRUG|Paclitaxel|Given IV
224271228|NCT01196390|OTHER|Quality-of-Life Assessment|Ancillary studies
224271229|NCT01196390|RADIATION|Radiation Therapy|Undergo radiation therapy
224271230|NCT01196390|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224271231|NCT01196390|BIOLOGICAL|Trastuzumab|Given IV
224271232|NCT04646603|DRUG|MRG-001|Subjects will receive subcutaneous MRG-001 injections.
224271233|NCT04646603|DRUG|Placebo|Subjects will receive subcutaneous placebo injections.
224271234|NCT05702255|OTHER|Active acupressure|Participants will receive training (2 sessions, 2 days a part) by a training researcher. Patients will be taught on the acupoints location and the acupressure technique. Participants will be verified for the correct location of the acupoints, acupressure technique and strength. Participants will be instructed to use thumb or middle finger to self- press each acupoint using circular movements. The force of pressing must be sufficiently strong but still within a comfortable range. A lubricant will be uses to decrease friction between the acupoints and the finger. Follow up evaluation will be at the end of the week 2 and week 4 .The training researcher will make weekly calls to remind participants to perform acupressure and to answer questions
224271235|NCT05702255|OTHER|Sham acuptressure|The same protocol as the active acupressure group.
224271236|NCT06348979|PROCEDURE|Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns|restoration of endodontically treated teeth by endocrowns
224271237|NCT06348979|PROCEDURE|all ceramic Endocrowns (emax)|restoration of endodontically treated teeth by endocrowns
224271238|NCT03526484|BEHAVIORAL|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
224271239|NCT03526484|BEHAVIORAL|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
224271240|NCT04051307|DRUG|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
224271241|NCT04051307|DRUG|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
224271242|NCT06232837|DEVICE|Direct laryngoscopy using Macintosh blade|Patients in operative room requiring direct laryngoscopy for endotracheal intubation
224271243|NCT02588911|PROCEDURE|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
224271244|NCT02588911|PROCEDURE|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
224271245|NCT01876758|BEHAVIORAL|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
224271246|NCT01876758|BEHAVIORAL|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
224271247|NCT03256149|DRUG|Dexamethasone|
224271248|NCT03256149|DRUG|Placebo|Normal saline (IV placebo)
224271249|NCT01894009|PROCEDURE|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
224271250|NCT01894009|PROCEDURE|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
224271251|NCT00513253|DRUG|lapatinib|
224271252|NCT01720953|OTHER|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
224271253|NCT01257451|DRUG|Vildagliptin|vildagliptin 50mg bid
223517844|NCT02714842|DRUG|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
224271254|NCT01257451|DRUG|Placebo|Placebo 50mg bid
224271255|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
224271256|NCT03307551|DRUG|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
224271257|NCT02725996|BIOLOGICAL|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
224271258|NCT02725996|OTHER|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
224271259|NCT04055233|DRUG|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
224271260|NCT04055233|DRUG|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
224271261|NCT02519153|DRUG|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
224271262|NCT04766905|PROCEDURE|Mini Lateral Shoulder Approach (MLSA)|"The skin incision is about 4 to 5 cm made by the distal acromial edge in sagittal plane, The dissection takes place slightly over the acromial edge proximally and over the origin of the acromial deltoid part (the middle part of deltoid origin) distally.~After clearly revealing the region of the medial deltoid origin on the acromion, the acromionic deltoid origin is skinned only; of the edge of the acromion, and that maybe accrued by electric knife pen or periosteal elevator, without exposure the clavicular deltoid origin in the front and the deltoid origin on the spine of scapula in the back, the origin of the acromial deltoid is distanced laterally and distally, where the lateral edge, the lower surface of the acromion, under acromial bursa and the rotator cuff are exposed clearly."
224271263|NCT00273013|DRUG|GW274150|GW274150 will be available as 30 mg white oval tablets.
224271264|NCT00273013|DRUG|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
224271265|NCT00273013|DRUG|Placebo|Matching placebo for Singulair and GW274150 will be available.
224271266|NCT02218398|DRUG|Albuterol|
224271267|NCT04651335|DEVICE|afferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The concentric direction moves the ball from the left to the center of the body.
224271268|NCT04651335|DEVICE|efferent virtual reality program|When visual gaze training is applied to the left unilateral neglected patient, the gaze direction can be divided into an afferent direction closer to the body and an efferent direction away from the body. The efferent direction moves from the center to the right.
224271269|NCT04610580|DRUG|ALXN1840|ALXN1840 will be administered orally.
224271270|NCT04122027|OTHER|Cerebral oximeter|Near infra-red spectroscopy, NIRS
224271271|NCT03787017|DRUG|FDC(MP-513 20mg/Metformin XR 1000mg)|
224271272|NCT03787017|DRUG|MP-513 20mg|
224271273|NCT03787017|DRUG|Metformin XR 1000mg|
224271274|NCT01097694|DRUG|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
224271275|NCT01097694|DRUG|Placebo|Placebo
224271276|NCT05586386|OTHER|Cherry group|200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
224271277|NCT05586386|OTHER|Placebo group|200 mL of placebo juice twice/day
224271278|NCT03067935|DRUG|glembatumumab vedotin|
224271279|NCT05901116|OTHER|Serratus posterior superior intercostal plane block (SPSIPB)|Serratus posterior superior intercostal plane block is the intervention used in this study. It was performed when the patient is in lateral decubitis position. A high frequency (7-12 MHz) linear transducer of the ultrasound device is placed at the spinae scapula level in the transverse plane, and the upper medial border of the scapula, the trapezius muscle, rhomboid muscle, serratus posterior superior muscle (SPSM) and the second and third ribs are visualized. The sonovisible needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs in order to reach the fascial plane between the SPSM and intercostal muscles. After contact of the needle with the rib gently, 1-2mL of saline is used to confirm the correct plane, and a total of 30 mL of 0.25% bupivacaine is administered to the superficial to the intercostal muscle.
224271280|NCT01861990|DRUG|Valproic Acid|All participants enrolled on valproic acid arm.
224271281|NCT02179190|DEVICE|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
224271282|NCT03937206|DIETARY_SUPPLEMENT|NutriterraTM|Nutriterra 1000mg
224271283|NCT03937206|DIETARY_SUPPLEMENT|Placebo|Corn Oil 1000mg
224271284|NCT03213548|PROCEDURE|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
224271285|NCT03213548|PROCEDURE|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
224271286|NCT06220526|DEVICE|endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Transbronchial biopsy with Menghini-type or Franseen type Needle
224271287|NCT01552330|DRUG|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~\- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~\- Dosage: 3 tablets"
224271288|NCT01552330|DRUG|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~\- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~\- Dosage: 3 tablets"
223517845|NCT02714842|DRUG|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
224271289|NCT02377349|BIOLOGICAL|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
224271290|NCT02377349|DRUG|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
224271291|NCT04809844|OTHER|Concurrent chemoradiation|concurrent Paclitaxel and radiation therapy after Adjuvant doxorubicin and Cyclophosphamide chemotherapy for stage ll or lll breast cancer .
224271292|NCT05983523|DRUG|PEP07|PEP07 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
224271293|NCT03506841|DRUG|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
224271294|NCT05414695|DEVICE|real acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle penetrates the skin 4 mm
224271295|NCT05414695|DEVICE|Placebo acupuncture|Device with acupuncture needles 25 × 0.22 mm, Cloud \& Dragon Medical Device Co, Ltd, China. Needle does not touch the skin.
224271296|NCT03770793|PROCEDURE|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
224271297|NCT00384592|DRUG|Esomeprazole|
224271298|NCT00384592|PROCEDURE|Physical exam|
224271299|NCT00384592|PROCEDURE|Pregnancy test if applicable|
223517846|NCT05152485|DRUG|BIIB104 Reference Formulation|Administered as specified in the treatment arm
223517847|NCT05152485|DRUG|BIIB104 Test Formulation|Administered as specified in the treatment arm
223517848|NCT00020176|BIOLOGICAL|filgrastim|
223517849|NCT00020176|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223517850|NCT00020176|DRUG|cyclophosphamide|
223517851|NCT00020176|DRUG|cyclosporine|
223517852|NCT00020176|DRUG|fludarabine phosphate|
223517853|NCT00020176|PROCEDURE|peripheral blood stem cell transplantation|
224271300|NCT03504020|DEVICE|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
224271301|NCT01323062|DRUG|Bavituximab|Administered 3 mg/kg weekly
224271302|NCT04288076|OTHER|PEEP Titrated Mechanical Ventilation|Subjects will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O and back down to 5 cmH20. Pleural pressure and intracranial pressure will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. At the completion of the study patients will be returned to the PEEP level they were on prior to titration of the ventilator.
224271303|NCT04714060|BIOLOGICAL|UB-621|mAb by SC administration
224271304|NCT05517096|OTHER|E-Health|In the intervention phase asthma care is provided on an at-needed-basis via online communication and is always available during working hours.
224271305|NCT04863131|BIOLOGICAL|EXG-5003|COVID-19 self-replicating mRNA vaccine
224271306|NCT04863131|BIOLOGICAL|Placebo|placebo solution
224271307|NCT05305586|DEVICE|Splint retained by Bulk-fill flowable|Luxated teeth were splinted with bulk-fill flowable composite
224271308|NCT05305586|DEVICE|Splint retained by Packable Composite|Luxated teeth were splinted with packable composite
224271309|NCT01993940|DRUG|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
224271310|NCT01993940|DRUG|Placebo|Placebo tablet taken orally once a day
224271311|NCT05193734|DRUG|Pertagen®|"Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
224271312|NCT05193734|DRUG|Revaxis®|"Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle."
223517854|NCT03484195|DRUG|FOLFOXIRI|Irinotecan 150 mg/m\^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m\^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m\^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m\^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
223517855|NCT02202577|DRUG|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
224271313|NCT06288217|DEVICE|NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)|Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements
224271314|NCT06288217|OTHER|Upper Limb Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
224271315|NCT06288217|OTHER|Sham Stimulation|Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.
224271316|NCT04986098|DEVICE|TurboHawk|Directly remove the diseased plaque in the blood vessel to increase the effective lumen in the blood vessel
224271317|NCT04986098|DRUG|Paclitaxel|Paclitaxel
224271318|NCT00001763|DRUG|Interleukin-12|
223517856|NCT02202577|DRUG|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
223893555|NCT06598930|OTHER|Routine follow-up|As recommended: a vascular doctor exclusively, face-to-face consultations.
224271319|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo|Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
224271320|NCT04238195|DRUG|Moxifloxacin 400mg|Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
223893556|NCT06598930|OTHER|Intensive follow-up|a vascular physician and an IPA, with alternating face-to-face and remote consultations.
224271321|NCT04238195|OTHER|Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
224271322|NCT04238195|DRUG|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Treatment B: Subjects receive TBPM-PI-HBr.
224271323|NCT03621046|DRUG|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
224271324|NCT03621046|OTHER|Placebo|Placebo
224271325|NCT01204138|DRUG|Apremilast|Apremilast 30mg BID
224271326|NCT01204138|DRUG|Placebo|Placebo BID
224271327|NCT00096850|DRUG|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
224271328|NCT00096850|DRUG|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
224271329|NCT00096850|DRUG|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
224271330|NCT05450549|DRUG|DNL919|Single doses
224271331|NCT05450549|DRUG|Placebo|Single doses
224271332|NCT00314288|DRUG|Sarizotan HCl|
224271333|NCT00441961|DRUG|methotrexate|methotrexate
224271334|NCT03650751|OTHER|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
224271335|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal Plus (SC+)|
224271336|NCT02077907|DIETARY_SUPPLEMENT|Super Cereal (SC), fortified oil, sugar|
224271337|NCT02077907|DIETARY_SUPPLEMENT|Plumpy Sup|
224271338|NCT02077907|DIETARY_SUPPLEMENT|Corn Soy Blend 14 (CSB14) and fortified oil|
224271339|NCT05016427|BIOLOGICAL|VT301|VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
224271340|NCT05536960|OTHER|68Ga-Dotatate PET/CT|One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
224271341|NCT05414162|DIAGNOSTIC_TEST|Cardiac MRI|Hematooncology patients under CAR T-cell therapy will receive 3 MRI examinations: at baseline, within 2 weeks of start of CAR T-cell therapy, and at 6 months follow-up.
224271342|NCT00405262|DRUG|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
224271343|NCT00405262|DRUG|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
224271344|NCT00405262|DRUG|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
224271345|NCT00629057|BIOLOGICAL|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
224271346|NCT00629057|BIOLOGICAL|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
224271347|NCT00629057|BIOLOGICAL|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
224271348|NCT06241157|OTHER|Pediatric Quiz Game|"Investigator will start interacting with children upon their arrival and during their presence in the waiting room before entering the operating room. This will help to obtain better cooperation (frankl scale) and anxiety reductions (FIS and VPT) at different stages of the dental examination (e.g., entering the clinic, sitting on the dental chair, opening mouth, examination with mirror, probe, use of low-high-speed handpieces, ITR restoration). Pediatric Quiz is actually an ice-breaking quiz game developed for children, with the promise of a surprise gift at the end. It can be defined as asking children basic questions on colors, animals, fruits and/or cities depending on the age of the child among which the child would choose him/herself and answer the question easily."
224271349|NCT03259165|DRUG|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~2. SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to \< 120 mmHg)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
224271350|NCT03259165|DRUG|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~1. Patients receive 1 inch topical nitropaste~2. IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~3. Reassessment every 2 hours. If LUS B-lines \>15, repeat step 2. If \< 15, stop algorithm."
224271351|NCT01198392|DRUG|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
224271352|NCT01198392|DRUG|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
224271353|NCT05203692|DRUG|DS-7011a|Intravenous or subcutaneous administration, single dose
224271354|NCT05203692|DRUG|Placebo|Intravenous or subcutaneous administration, single dose
224271355|NCT02822716|PROCEDURE|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
224271356|NCT02822716|DEVICE|Ultrasound|
224271357|NCT03039816|DEVICE|Nasaleze|Nasaleze cellulose powder
224271358|NCT03039816|DEVICE|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
224271359|NCT04483895|PROCEDURE|Endotracheal tube insertion|ETT was inserted and the depth was estimated by either OHL method or 7-8-9 method
224271360|NCT04817995|BEHAVIORAL|FOREST|Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
224271361|NCT00785603|DRUG|Paroxetine|tablets of 20 mg paroxetine
224271362|NCT00785603|DRUG|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
224271363|NCT00785603|DRUG|Tramadol|Capsules of 50 mg tramadol
224271364|NCT01609270|DEVICE|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
224271365|NCT01949532|DRUG|Carfilzomib|Carfilzomib was administered by IV injection.
224271366|NCT02037854|OTHER|Nutrient formulation|
224271367|NCT04995354|DRUG|EGF loaded Hydrogel|Patients will receive 25 Ug/day of EGF. This is the estimated daily dose that will be obtained when the patient applies the gel thrice daily. Patients will receive the treatment for one week
224271368|NCT04995354|DRUG|Hydrogel|Non-medicated self-healing hydrogel to be applied three times a day for 1 week
223517857|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
224271369|NCT00003795|PROCEDURE|quality-of-life assessment|
224271370|NCT01127776|DEVICE|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
224271371|NCT01127776|OTHER|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
224271372|NCT02298387|DRUG|OMP-305B83|intravenous (in the vein) infusions
224271373|NCT02498938|GENETIC|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
224271374|NCT03141580|DIAGNOSTIC_TEST|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
224271375|NCT00236886|DRUG|topiramate|
224271376|NCT05921812|DIAGNOSTIC_TEST|real time pcr|evaluate the expression of certain circulating microRNAs by real time pcr
224271377|NCT02413008|DRUG|estriol|0.005% estriol vaginal gel
224271378|NCT02413008|DRUG|Placebo|placebo vaginal gel
224271379|NCT04387617|DRUG|Cannabidiol|The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.
224271380|NCT04387617|DRUG|Placebo|The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days
224271381|NCT02707016|OTHER|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
224271382|NCT02707016|OTHER|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
224271383|NCT06361355|BIOLOGICAL|Post-change CMAB807|for subcutaneous injection only
224271384|NCT06361355|BIOLOGICAL|Prolia|for subcutaneous injection only
224271385|NCT03483350|DRUG|Granisetron|Ampoule
224271386|NCT03483350|DRUG|Midazolam|Ampoule
224271387|NCT00939523|DRUG|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
224271388|NCT05074706|BIOLOGICAL|IgG antibodies to Sars-Cov-2|Samples will be collected between 30 and 60 days after second vaccine dose.
224271389|NCT05074706|BIOLOGICAL|QuantiFERON SARS-CoV-2 test|Samples will be collected within 9 months after completion of the vaccination series
224271390|NCT04733313|PROCEDURE|ultrasound guıded quadratus lumborum block|Administering local aneshtetic agent with a block needle using the in-plane technique, bilaterally. Lumbar interfascial triangle, where the middle lumbar fascia joins the deep lamina of the posterior layer on the lateral border of the erector spinae was targeted as the optimal point of injection.
224271391|NCT00024258|DRUG|arsenic trioxide|
224271392|NCT00870935|PROCEDURE|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
224271393|NCT00870935|PROCEDURE|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
224271394|NCT04520243|DIAGNOSTIC_TEST|Visual acuity assessment by ETDRS charts|All participants must complete VA measurement of both eyes using 2 charts including the ETDRS letters chart and ETDRS numbers chart.
224271395|NCT01050764|DRUG|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg"
224271396|NCT01050764|DRUG|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
224271397|NCT01050764|DRUG|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
224271398|NCT01050764|DRUG|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
224271399|NCT01050764|DEVICE|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
224271400|NCT01050764|DRUG|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
224271401|NCT01050764|DRUG|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
224271402|NCT02697708|DIETARY_SUPPLEMENT|Potassium control diet|No additional potassium.
224271403|NCT02697708|DIETARY_SUPPLEMENT|Potassium gluconate diet|1000 mg K from potassium gluconate.
224271404|NCT02697708|DIETARY_SUPPLEMENT|Potato Diet|1000 mg K from potatoes.
224271405|NCT02697708|DIETARY_SUPPLEMENT|French Fries Diet|1000 mg K from French Fries.
224271406|NCT02312037|BIOLOGICAL|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~1. Mylotarg \<=9 mg/m2 as a single agent on Day 1 \& 14 of a 28-day cycle for a total of two cycles~2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
224271407|NCT00943865|BEHAVIORAL|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
224271408|NCT00943865|BEHAVIORAL|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
224271409|NCT00943865|BEHAVIORAL|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
224271410|NCT00943865|BEHAVIORAL|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
224271411|NCT00943865|BEHAVIORAL|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
223893557|NCT03530306|DEVICE|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
224271412|NCT05191745|DRUG|Parasternal blocks|Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg
224271413|NCT05191745|DRUG|Standard of care|All standard management of postoperative pain, as per local protocols
224271414|NCT03711396|BEHAVIORAL|Advance Care Planning Group Visits|Pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences.
224271415|NCT01144845|PROCEDURE|Thoracic surgery|Thoracoscopy or anterior thoracotomy
224271416|NCT03363555|DRUG|SHR-1210|A humanized monoclonal immunoglobulin.
224271417|NCT00461435|PROCEDURE|hyperbaric oxygen therapy|
224271418|NCT01226953|BIOLOGICAL|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
224271419|NCT05546060|DRUG|Venetoclax|Venetoclax 100mg qd d1，200mg qd d2，400mg qd d3-56
224271420|NCT05546060|DRUG|Dexamethasone|Dexamethasone 10mg/m2 qd d1-14, 5mg/m2 qd d15-28, 2.5 mg/m2 qd d29-42, and 1.25mg/m2 qd43-56
224271421|NCT05546060|DRUG|Etoposide|Etoposide 75mg/m2 qw d1-56
224271422|NCT02614196|DRUG|Galcanezumab|Administered SC
224271423|NCT02614196|DRUG|Placebo|Administered SC
224271424|NCT03790163|DRUG|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
224271425|NCT05965908|DRUG|liraglutide|glucagon-like peptide 1 receptor agonist
224271426|NCT05965908|DRUG|Metformin|biguanide antihyperglycemic
224271427|NCT05437068|OTHER|Oral Nutritional Supplement (ONS)|ONS plus dietary counseling
224271428|NCT02179788|BEHAVIORAL|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
224271429|NCT02179788|DRUG|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~* Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~* Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~* Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
224271430|NCT02179788|DRUG|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
224271431|NCT03302598|DIAGNOSTIC_TEST|serum C-reactive protein|
224271432|NCT01750827|DRUG|SB659032|single dose
224271433|NCT00789776|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
224271434|NCT00789776|DRUG|Cyclophosphamide|Given IV
224271435|NCT00789776|DRUG|Fludarabine Phosphate|Given IV
224271436|NCT00789776|OTHER|Laboratory Biomarker Analysis|Correlative studies
224271437|NCT00789776|DRUG|Mycophenolate Mofetil|Given PO
224271438|NCT00789776|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
224271439|NCT00789776|DRUG|Tacrolimus|Given IV or PO
224271440|NCT00789776|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
224271441|NCT02627001|DEVICE|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
224271442|NCT02627001|DEVICE|Bag Valve Mask|Conventional bag valve mask
224271443|NCT06374654|OTHER|Home-based Exercise Protocol|The home-based eccentric exercise protocol is a do-as-tolerated variation on the protocol described by Alfredson et al. in 1998. The protocol includes doing a series of heel raises, twice daily. No equipment is necessary. Patients will be given handouts and video links that depict and describe the exercises and their prescribed frequency.
224271444|NCT06374654|OTHER|Formal Physical Therapy|Patients will be given a prescription for physical therapy consisting of 1-2 sessions per week for 6 weeks, with a renewal for another 6 weeks to be executed at the physical therapists' discretion. If an in-person visit is necessary for the renewal, or is requested by the physical therapist, the patient will be seen again in the office. Each patient will be given a release form to provide to his or her physical therapist. The release form will request a written record of all the treatment methods used by the physical therapist. Physical therapists who participate in the care of patients in this study will treat each patient using any and all methods that their professional experience deems clinically necessary.
224271445|NCT04637139|DRUG|Vebicorvir (VBR)|300mg Vebicovir containing 2 µCi \[14C\]VBR.
224271446|NCT05770011|DEVICE|intraoral scanner of nonsplinted scan bodies|scanning of non splinted scan bodies
224271447|NCT05770011|DEVICE|impression material|conventional recording
224271448|NCT05770011|DEVICE|intraoral scanner of splinted scan bodies|scanning of splinted scan bodies
224271449|NCT04317664|COMBINATION_PRODUCT|In-vehicle device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smartphone app (downloaded on the teen's smartphone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data; and 3) A customized biweekly driving summary report.
224271450|NCT04317664|BEHAVIORAL|Parent Communication|An individualized virtual training in communication strategies about driving safety along with a booster session will be delivered by a traffic safety communication specialist to subjects in the Feedback and Parent Communication Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
224271451|NCT02973269|BIOLOGICAL|daxibotulinumtoxin type A|Intramuscular injection
224271452|NCT02973269|BIOLOGICAL|Placebo|Intramuscular injection
224271453|NCT05829239|BIOLOGICAL|ADI-PEG20|Intramuscular injection weekly for 8 weeks
224271454|NCT05829239|OTHER|Placebo|Intramuscular injection weekly for 8 weeks
224271455|NCT00466479|DRUG|brimonidine|
224271456|NCT00466479|PROCEDURE|laser trabeculoplasty|
224271457|NCT01085890|BEHAVIORAL|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
224271458|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
224271459|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
224271460|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
224271461|NCT00258856|BIOLOGICAL|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
224271462|NCT05590390|DIAGNOSTIC_TEST|DXA|bone densitometry at lumbar and femoral site+ morphometry (DXA),
224271463|NCT05590390|DIAGNOSTIC_TEST|serum sample|serum samples for bone biomarkers ( eg. P1NP, CTX, Dkk-1, etc)
224271464|NCT05590390|DIAGNOSTIC_TEST|PROs|questionnaires to investigate patients reported outcome on quality of life
224271465|NCT03436316|DRUG|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
224271466|NCT04598958|OTHER|IMPROVE|Health system interventions that include: (1) Multidisciplinary integrated management teams to coordinate patient-focused and outcome-oriented PMTCT and MCH services; (2) Enhanced Positive Health, Dignity, and Prevention (PHDP)-focused counseling and skills-building training and job aids; and (3) Increased early community-based counseling and support for first (antenatal care clinic) ANC attendees
224271467|NCT00250315|DRUG|Dobutamine|
224271468|NCT03157349|OTHER|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
224271469|NCT03157349|OTHER|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
224271470|NCT00000449|DRUG|naltrexone (Revia)|
223517858|NCT01504360|GENETIC|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
223517859|NCT06569641|DEVICE|Neoneur Feeding System|The Neoneur Feeding System is placed between a nipple and a bottle, and used to measure feeding skill patterns.
223517860|NCT03442972|DRUG|Teduglutide|Teduglutide
223517861|NCT03442972|DRUG|Placebo|Placebo
223517862|NCT00829868|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg
223517863|NCT00829868|DRUG|SONATA® 10 mg capsules|1 x 10 mg
223517864|NCT04452370|DRUG|oral etoposide + anlotinib|anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
223517865|NCT05809154|DIAGNOSTIC_TEST|Video-Urodynamics|Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
223517866|NCT05042466|DRUG|Trauma|0.15g. thru 0.33g., M/W/F and monthly 1 time a dose of 1g. to 1.5g monthly. 8 week trial.
223517867|NCT00529815|DEVICE|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
223517868|NCT00529815|DEVICE|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
224271471|NCT00000449|BEHAVIORAL|cognitive behavioral therapy|
224271472|NCT00000449|BEHAVIORAL|cue exposure treatment|
224271473|NCT04902911|DEVICE|COVID-19 SARS-CoV IgG/IgM antibody rapid test|Needle stick point of care and 3mL vial of blood will be collected and tested for individual without history of COVID-19 and immunization as well as a second group composed of individuals with history of COVID-19
224271474|NCT03756701|BEHAVIORAL|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~1. Introduction and Drawings~2. Autogenic Training and Biofeedback~3. Guided Imagery~4. Meditation~5. Mobilizing, Transforming, and Celebrating Emotion~6. Genograms part 1~7. Genograms part 2~8. Mindful Eating and Healthy Nutrition~9. Spirituality~10. Closing Drawings and Ritual"
224271475|NCT01691430|DIETARY_SUPPLEMENT|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
224271476|NCT01691430|DIETARY_SUPPLEMENT|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
224271477|NCT01763255|BIOLOGICAL|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
224271478|NCT02805413|OTHER|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10…). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9…). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
224271479|NCT05659758|PROCEDURE|Head up positioning during preoxygenation|patients will be preoxygenated in head up position
224271480|NCT02756949|OTHER|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
224271481|NCT02756949|DEVICE|Smartphone|
224271482|NCT01758406|BIOLOGICAL|Intracoronary injection|stem cell transplantation
224271483|NCT01758406|BIOLOGICAL|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
224271484|NCT02573285|PROCEDURE|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
224271485|NCT02573285|PROCEDURE|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
224271486|NCT02219009|DEVICE|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
224271487|NCT01510509|DEVICE|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
224271488|NCT01510509|DEVICE|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
224271489|NCT01463709|DEVICE|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
224271490|NCT01944553|DEVICE|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
224271491|NCT00762411|DRUG|LY450139|Administered orally once daily.
224271492|NCT00762411|DRUG|Placebo|Administered orally once daily.
224271493|NCT05157048|OTHER|Charcoal-filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
223517869|NCT00831155|DRUG|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
224271494|NCT05157048|OTHER|Non-charcoal filtered cigarette|Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
224271495|NCT02259348|DRUG|Cyclophosphamide|Given intravenously (IV)
224271496|NCT02259348|DRUG|Fludarabine|Given IV
223704016|NCT02082275|OTHER|OB Nest|"* Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires."
224271497|NCT02259348|BIOLOGICAL|G-CSF|Given IV or subcutaneously (SQ)
224271498|NCT02259348|BIOLOGICAL|Interleukin-2|Given SQ
224271499|NCT02259348|DRUG|Melphalan|Given IV
224271500|NCT02259348|DRUG|Thiotepa|Given IV
224271501|NCT02259348|DRUG|Rituximab|Given IV
224271502|NCT02259348|BIOLOGICAL|Natural killer cell therapy|Given IV
224271503|NCT02259348|BIOLOGICAL|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
224271504|NCT02259348|BIOLOGICAL|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
224271505|NCT01094262|DRUG|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
224271506|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
224271507|NCT01094262|DRUG|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
224271508|NCT01094262|DRUG|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
224271509|NCT01663467|DRUG|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
224271510|NCT01663467|BEHAVIORAL|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
224271511|NCT04211766|DIETARY_SUPPLEMENT|Dietary Fiber|Given fiber supplement
224271512|NCT04211766|DIETARY_SUPPLEMENT|Fish Oil|Given fish oil supplement
224271513|NCT04211766|OTHER|Comparator|Given fiber supplement placebo
224271514|NCT04211766|OTHER|Comparator|Given fish oil supplement placebo (corn oil)
224271515|NCT00545116|OTHER|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
224271516|NCT00929981|DRUG|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
223534837|NCT01362101|BEHAVIORAL|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
224271517|NCT02769650|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
224271518|NCT02769650|DRUG|Optimal medicamentous treatment|
224271519|NCT02769650|PROCEDURE|Stress-MRI|A standard stress-MRI test with adenosine
224271520|NCT05648539|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
224271521|NCT04590781|BIOLOGICAL|XmAb18087|Monoclonal bispecific antibody
224271522|NCT04590781|DRUG|XmAb18087 ± Pembrolizumab|XmAb18087 ± Pembrolizumab
224271523|NCT00006034|BIOLOGICAL|keyhole limpet hemocyanin|Given intradermally and IV
224271524|NCT00006034|DRUG|doxorubicin hydrochloride|Given IV
224271525|NCT04449458|BEHAVIORAL|Positively Me|12 session smoking cessation intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
224271526|NCT04449458|BEHAVIORAL|Positively Living|12 session healthy living intervention based on Social Cognitive Theory, designed for people with certain health conditions (8 primary sessions, followed by 4 booster sessions)
224271527|NCT01291641|DRUG|HMG-CoA Reductase Inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
224271528|NCT01291641|DRUG|Probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
224271529|NCT01291641|DRUG|Cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
224271530|NCT02247518|DRUG|Cialis Tab. 5mg|
224271531|NCT02247518|DRUG|Harnal-D Cap. 0.2mg|
224271532|NCT04313296|DEVICE|Unique measurement (AutoSTRAIN) by a commercial software program (TOMTEC-ARENA)|The historic echocardiograms from patients who meet the study inclusion criteria will be uploaded into this software, which was newly acquired by the PBMC Cardiology Department. MaineHealth Information Services are currently working with study staff to assure appropriate security compliance within the network. LA GLS has not been routinely collected previously from echocardiograms performed at PBMC because of a lack of such technology.
224271533|NCT00459823|DRUG|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
224271534|NCT02400463|DRUG|Ruxolitinib|
224271535|NCT00359671|DRUG|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
224271536|NCT00359671|DRUG|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
224271537|NCT02400515|OTHER|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
224271538|NCT03205501|DRUG|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
224271539|NCT03205501|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
224271540|NCT05437406|BEHAVIORAL|Parent-based treatment- All caregivers (PBT-AC)|PBT-AC provides all the elements of FBT, including nutrition and physical activity education, behavior therapy skills, and parenting skills.
224271541|NCT05437406|BEHAVIORAL|Health Education (HE)|The HE arm will provide information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
224271542|NCT05402917|PROCEDURE|Erector Spinae Plane Block|Interfascial plane (area) blocks are blocks in which the local anesthetic agent is injected into the potential area between the two fasciae. The ESPB we used in our study is a member of interfascial plane blocks. The erector is applied between the spinal muscle and the transverse process, spreading the drug from the injection site to both cranial and caudal. Unlike other defined interfascial plane blocks, ESPB can show paraspinal block characteristics since the injection site is above the transverse process.
224271543|NCT04556916|DIAGNOSTIC_TEST|Blood sample|"Per patient 49 ml of peripheral blood sample :~* 21ml divided into 3 TransFix or EDTA 7ml tubes will be sent to Hamburg for subsequent CTCapture analysis;~* 28ml divided into 4 EDTA 7ml tubes will be sent to Montpellier for subsequent EPIDROP analysis (21 ml), PHI analysis (7 ml) and plasma isolation."
224271544|NCT01680016|BIOLOGICAL|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
224271545|NCT01680016|BIOLOGICAL|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
224271546|NCT04130217|PROCEDURE|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
224271547|NCT04130217|PROCEDURE|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
224271548|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.
224271549|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
224271550|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
224271551|NCT01156896|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
224271552|NCT05192096|BEHAVIORAL|Train-the-trainer workshop|To deliver health-related information to trainees, which facilitate improving their knowledge, confidence, and ability to share and discuss health-related information with others, including service users, families and friends.
224271553|NCT06504303|DEVICE|3D-printed socket|During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
224271554|NCT03512249|BIOLOGICAL|H56:IC31|5ug H56/500 nmol IC31
224271555|NCT03512249|BIOLOGICAL|Placebo|Sterile saline for injection
224271556|NCT00089167|BIOLOGICAL|filgrastim|
224271557|NCT00089167|DRUG|dexamethasone|
224271558|NCT00089167|DRUG|melphalan|
224271559|NCT00089167|DRUG|thalidomide|
224271560|NCT02335372|PROCEDURE|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
224271561|NCT02335372|DRUG|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
224271562|NCT02335372|DRUG|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
224271563|NCT02335372|PROCEDURE|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
223534838|NCT00700206|DRUG|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
224271564|NCT01200017|BIOLOGICAL|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
224271565|NCT03686215|COMBINATION_PRODUCT|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
224271566|NCT02653729|BEHAVIORAL|cognitive behaviour therapy|
224271567|NCT02653729|DRUG|Espidone|
224271568|NCT02653729|DRUG|Olepra|
224271569|NCT02653729|DRUG|Donu|
224271570|NCT01273857|PROCEDURE|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
224271571|NCT01273857|PROCEDURE|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
224271572|NCT02396290|PROCEDURE|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
224271573|NCT02396290|PROCEDURE|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
224271574|NCT06002178|DIAGNOSTIC_TEST|Neck ultrasound|A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
224271575|NCT04125615|BEHAVIORAL|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
224271576|NCT05518227|DEVICE|The Clareon™ PanOptix™ Trifocal (toric and non-toric models)|Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
224271577|NCT01883791|BEHAVIORAL|SBIRT|See above Arm description.
224271578|NCT01883791|BEHAVIORAL|Health Education|See Arm Description.
224271579|NCT00962494|BEHAVIORAL|Cancer: Thriving and Surviving Online Workshop|
224271580|NCT02485158|DRUG|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
224271581|NCT02485158|DRUG|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
224271582|NCT02485158|DRUG|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
224271583|NCT02485158|DRUG|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
224271584|NCT02485158|DRUG|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
224271585|NCT05916716|PROCEDURE|Restorative procedure|Under local anesthesia, a rubber dam isolation will be placed at the site and a coronal bevel will be performed at the incisal margin of the NCCL allowing a correct tooth emergence profile. In sequence, acid etching with 35% phosphoric acid will be applied to the area and washed for 30 seconds with a water-air jet. The lesion will be dried with sterile cotton pellets to prevent dehydration. Active application of the adhesive will be performed for 20 seconds, followed by light curing for 30 seconds. The apical margin of the restoration will be placed 1 mm beyond the estimated position of the cementoenamel junction(CEJ) in order to rebuild only the anatomical part of the crown destroyed by the NCCL and 1 mm of the root surface to give the appropriate emergence profile. After rubber dam removal, the restoration will be finished with ultrafine-grained burs, and 48 hours after the restoration procedure, polishing will be completed with diamond paste and felt discs.
224271586|NCT05916716|PROCEDURE|Coronally Advanced Flap (CAF).|Two horizontal incisions will be performed at the papilla base united by an intrasulcular incision around the tooth. In sequence, releasing incisions will be designed and a split-full-split flap will be raised beyond the mucogingival junction. Then, sling sutures will be placed to stabilize the flap margin 2 mm coronal to CEJ, followed by interrupted sutures to close the releasing incisions.
224271587|NCT05916716|DEVICE|Volume-stable collagen matrix (VCMX)|VCMX will be cut according to the recession defect and moistened with saline solution. The biomaterial will be placed at the cementoenamel junction (CEJ) level and stabilized in the adjacent surgical papillae by interrupted sutures.
224271588|NCT05916716|DRUG|Amoxicillin 500mg|Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
224271589|NCT05916716|DRUG|Sodium dipyrone|All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
224271590|NCT04282239|PROCEDURE|PECS2 block|Superficial peripheral nerve block placed at the interfascial plane between the pectoralis major and minor muscles and the plane between the pectoralis minor and serrates anterior muscles. Targeted nerves include the lateral and medial pectoral nerves in addition to the long thoracic nerve, thoracodorsal, and thoracic intercostal nerves from T2 to T6.
224271591|NCT04282239|DRUG|Ropivacaine 0.5% Injectable Solution|15 mL on each side of anterior chest for a total of 30mL
224271592|NCT04282239|DRUG|Lidocaine Epinephrine|10 mL on each side of anterior chest for a total of 20mL
224271593|NCT04282239|DRUG|Dexmedetomidine 0.004 MG/ML|10 mL
224271594|NCT04086524|OTHER|Binocular cartoon treatment at home|see arm description.
224271595|NCT04086524|OTHER|Patching|see arm description
224271596|NCT04086524|OTHER|Binocular cartoon treatment in office|see arm description.
224271597|NCT03001024|BEHAVIORAL|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
224271598|NCT03001024|BEHAVIORAL|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
224271599|NCT02793713|PROCEDURE|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
224271600|NCT03710096|DEVICE|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
224271601|NCT03710096|DEVICE|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
224271602|NCT05416099|PROCEDURE|laser|grid vs micropulse laser
224271603|NCT01034852|PROCEDURE|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
224271604|NCT05987085|OTHER|Diet and exercise|Routine intervention included diet control and exercise
224271605|NCT00002228|DRUG|Enfuvirtide|
224271606|NCT02846883|BIOLOGICAL|1 million MSCs/kg|Intravenous infusion of 1 million allogeneic MSCs/kg.
224271607|NCT02846883|BIOLOGICAL|3 million MSCs/kg|Intravenous infusion of 3 million allogeneic MSCs/kg
224271608|NCT02846883|DRUG|Placebo|Intravenous infusion of Plasmalyte A (placebo)
224271609|NCT01134198|DRUG|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
224271610|NCT01134198|DRUG|placebo|placebo
224271611|NCT01417351|DIETARY_SUPPLEMENT|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
224271612|NCT01417351|DIETARY_SUPPLEMENT|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
224271613|NCT00927251|DEVICE|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
224271614|NCT06136416|OTHER|Questionnaire for Non-dystrophic myotonias|Patients will have to complete the questionnaire created specifically for their pathology, as well as an evaluation grid of the same questionnaire to assess its relevance and good understanding
224271615|NCT06677788|DRUG|Roflumilast 500 Mcg Oral Tablet|Patients in this group received roflumilast 500 μg once daily for three months.
224271616|NCT06677788|DRUG|Vitamin E capsule|vitamin E group or control group (n=24) which received vitamin E 1000 mg once daily
224271617|NCT04066920|DRUG|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) \[ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 \], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
224271618|NCT04934020|OTHER|Pre-pandemic stroke related metrics|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
224271619|NCT04934020|OTHER|Stroke related metrics during the pandemic|De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.
224271620|NCT01911104|BEHAVIORAL|Exercise|10 weeks of aerobic exercise
224271621|NCT03825367|DRUG|Nivolumab|"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
224271622|NCT03825367|DRUG|5-azacytidine|75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
224271623|NCT06679166|OTHER|No intervention|No intervention
224271624|NCT05229055|DRUG|Ketamine|giving ketamine intranasal
224271625|NCT03966950|DIETARY_SUPPLEMENT|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
224271626|NCT03966950|DRUG|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
224271627|NCT03818295|DRUG|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
224271628|NCT06679023|DIAGNOSTIC_TEST|MolecuLight i:X and Wound blotting and Alcian blue biofilm detection kit|we will enroll patients with chronic wounds and quantify the biofilm severity by staining color of Wound blotting and Alcian blue biofilm detection kit, and by non-touched flourescent intensity of MolecuLight i:X.
223893558|NCT03530306|DEVICE|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
223893559|NCT03530306|DEVICE|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
224271629|NCT00003850|DRUG|thalidomide|
224271630|NCT05093881|BIOLOGICAL|Cellgram-LC|Patients who had administered Cellgram-LC in PMC-P-07 study
224271631|NCT05867524|OTHER|Oral Glucose Tolerance Test|75g oral glucose tolerance test, sampled over three hours
224271632|NCT05867524|OTHER|Cycling test|2 hours of moderate activity level cycling
224271633|NCT01477424|DRUG|PA21|The maximum dose of PA21 will be 15.0 g/day.
224271634|NCT01477424|DRUG|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
224271635|NCT01636817|DRUG|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
224271636|NCT01636817|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
223893560|NCT03530306|DEVICE|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
224271637|NCT06679335|OTHER|Lateralization Imagery Training|"Lateralization Imagery Training (LIE) is a form of implicit motor imagery that involves determining as accurately and quickly as possible whether an image of a body part belongs to the left or right side. It has been assumed that LIE performance differences reflect changes in central nervous system functioning, errors in judgment, and changes in bodily representations. It has been shown that LIE is a complex mental task that includes cognitive, sensory, motor and behavioral processes and can be associated with them. A study showed that there was a strong correlation between LIE and proprioception.~Within the scope of our study, 3 weeks of training will be provided; Lateralization imagery training will be given every day for the first 2 weeks, and imagery training will be given 3 days a week in the 2nd and 3rd weeks. A total of 20 sessions of treatment will be applied, including 14 sessions of lateralization and 6 sessions of visualization training."
224271638|NCT02432118|PROCEDURE|Lumpectomy|Undergo lumpectomy
224271639|NCT02432118|OTHER|Questionnaire Administration|Ancillary studies
224271640|NCT02432118|PROCEDURE|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
224271641|NCT03003364|DRUG|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
224271642|NCT03003364|DRUG|Placebo|Placebo in a blinded syringe
224271643|NCT06616103|DIAGNOSTIC_TEST|computerized tomography|noncontrast abdominal CT
224271644|NCT01065116|DRUG|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
224271645|NCT01065116|DRUG|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
224271646|NCT04492397|DEVICE|Test Contact Lens|Subjects will be randomized to wear test lenses.
224271647|NCT04492397|DEVICE|Control Contact Lens|Subjects will be randomized to wear control lenses.
224271648|NCT00006228|BIOLOGICAL|trastuzumab|Given IV
224271649|NCT00006228|BIOLOGICAL|aldesleukin|Given SC
224271650|NCT00006228|OTHER|laboratory biomarker analysis|Correlative studies
224271651|NCT00006228|OTHER|pharmacological study|Correlative studies
224271652|NCT01275976|DRUG|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
224271653|NCT01275976|OTHER|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
224271654|NCT04119557|DRUG|Placebo|Administered SC
224271655|NCT04119557|DRUG|LY3471851|Administered SC
224271656|NCT04239495|OTHER|Observational study: range of clinical and lifestyle factors|Medical conditions and medications. Educational and occupational history. Lifestyle exposures, assessed using reduced Food Frequency Questionnaire, Rapid Assessment of Physical Activity questionnaire and objectively-measured physical activity levels over 7 days using a GeneActiv wrist-worn accelerometer (Activinsights, Cambridge, UK).
224271657|NCT03514186|BEHAVIORAL|Speech and Language Therapy|"Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication"
224271658|NCT01863186|DRUG|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
224271659|NCT01863186|DRUG|Placebo|Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
224271660|NCT01863186|DRUG|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
223893561|NCT05252962|DIETARY_SUPPLEMENT|Collagen Peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
224271661|NCT06787716|DEVICE|The whole body vibration|Patients in the study group will receive the traditional physical therapy program first (passive and active ROM exercises, stretching and strengthening exercises) for 60 minutes, 3 days/ week for 12 weeks.This will be followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program will be three sessions a week for 12 weeks. WBV duration started with 10 min at the 1st week up to 35 min at the 12th week, with a regular increase of five minutes every two successive weeks.
224271662|NCT06787716|OTHER|The traditional physical therapy program|The traditional physical therapy program will be three days a week for 12 weeks. The program will include 60 minutes of a supervised and individualized exercise program including passive and active exercises of the hip, knee, and ankle joints, stretching exercises for the Calf and hamstring muscles followed by strengthening exercises of the hip, knee, ankle, and foot muscles. To improve the strength, free weights will be used for all exercises. During the first week, 50 to 60% of the repetitions maximum test will be set as the starting weight. Then, from the second week to the sixth, the weight will be increased to 70%-75% of three repetitions maximum (3 sets, 4-10 repetitions). The training amplitude then will be raised to 80%-85% of the three-repetition maximum (3 sets, 8-12 repetitions) that will be continued through weeks 7 to 12, holding 5 seconds at the end of the range.
224271663|NCT06355830|DIAGNOSTIC_TEST|Orthoptic assessment (Outcome measure)|The protocol image assessment is non-invasive and includes retinal imaging by Color Fundus photography (CFP), Spectral Domain Optical Coherence Tomography (SD-OCT), OCT-Angiography (OCT-A) using Spectralis OCT, with OCT Angiography Module (Heidelberg Eng. GmbH, Germany).
224271664|NCT00069030|BIOLOGICAL|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
224271665|NCT05353036|OTHER|Survey|Survey assessing incidence, frequency, and type of illicit substance use
224271666|NCT04386109|OTHER|No intervention - exposure is to COVID-19|No intervention - exposure is to COVID-19
224271667|NCT05659329|DEVICE|Simplex HV|Simplex HV bone cement is a fast-setting acrylic resin for use in bone surgery. Mixing the two separate sterile components produces a ductile bone cement which, after hardening, fixes the implant and transfers stresses produced during movement evenly to the bone.
224271668|NCT01242618|BIOLOGICAL|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
224271669|NCT06368024|OTHER|This is a retrospective analysis study of data collected with a diagnostic medical device|Transcranial Magnetic stimulation and Electroencephalogram
224271670|NCT01813435|DRUG|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
224271671|NCT01813435|DRUG|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
224271672|NCT01813435|DRUG|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
224271673|NCT01497119|DRUG|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
224271674|NCT01497119|DRUG|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
224271675|NCT01497119|DRUG|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
224271676|NCT06081361|DRUG|Bedaquiline|Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week
224271677|NCT06081361|DRUG|Delamanid|Oral, 100mg bid
224271678|NCT06081361|DRUG|Contezolid|Oral, 800mg bid
224271679|NCT06081361|DRUG|Levofloxacin|Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg
224271680|NCT06081361|DRUG|Moxifloxacin|Oral, 400mg qd
224271681|NCT06081361|DRUG|Clofazimine|Oral, 100mg qd
224271682|NCT06081361|DRUG|Linezolid|Oral, 600mg qd
224271683|NCT06081361|DRUG|Cycloserine|Oral, 250mg bid
224271684|NCT06081361|DRUG|Prothionamide|Oral, 600mg qd for weight \<50kg, 600-800mg qd for weight ≥50kg
224271685|NCT06081361|DRUG|Pyrazinamide|Oral, 1500mg qd for weight \<50kg, 1750mg qd for weight ≥50kg
224271686|NCT06081361|DRUG|Para-Aminosalicylic Acid|8000mg qd for weight \<50kg, 10000mg qd for weight ≥50kg
224271687|NCT06081361|DRUG|Ethambutol|750mg qd for weight \<50kg, 1000mg qd for weight ≥50kg
224271688|NCT03474809|DEVICE|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
224271689|NCT05583097|DIAGNOSTIC_TEST|Non-selective cytology|All noduleas are evaluated according to EU-TIRADS. Cytology performed on all nodules larger than 1 cm regardless of ultrasonographic features. Nodules 1 cm or smaller evaluated as EU-TIRADS 5 undergo cytologic examination if possible.
224271690|NCT06530745|PROCEDURE|Hyaluronic acid (HA) injection|2% hyaluronic acid Synocrom Forte (Croma-Pharma GmbH, Leobendorf, Austria) injection
224271691|NCT06530745|PROCEDURE|Platelet-rich plasma (PRP) injection|PRP from peripheral venous blood of the elbow bend centrifuged at 160 revolutions per minute for 5 minutes with iFuge D06 (Neuation Technologies Pvt. Ltd, Gujarat, India) injection
224271692|NCT00399724|DRUG|Insulin glargine|
224271693|NCT03035890|RADIATION|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
223534839|NCT02922946|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
223534840|NCT02319486|DRUG|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
223534841|NCT02319486|DRUG|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
223534842|NCT02220634|DRUG|Regadenoson|Injection for intravenous administration
224271694|NCT03035890|DRUG|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~* Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~* Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~* Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
224271695|NCT05940987|BEHAVIORAL|Phone-based smoking cessation intervention|Participants who allocate to the intervention group will receive regular phone-based smoking cessation intervention by professional team.
224271696|NCT04394390|DIETARY_SUPPLEMENT|vitamin d|vitamin D levels
224271697|NCT04375943|DRUG|Antidiabetic|Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
224271698|NCT02012335|DRUG|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
224271699|NCT06298877|OTHER|Frailty and Quality of Life evaluation|Frailty and Quality of Life evaluation after surgery
224271700|NCT06187701|BEHAVIORAL|Co-Active Therapeutic Theatre (Co-ATT)|There will be one group drama therapy session per week, for a total of twelve weeks (i.e., total twelve sessions) followed by a single performance (with composition of the audience determined by unanimous agreement of the participants) of the dramatic work (script) produced by the participants during the course of the drama therapy intervention.
223893562|NCT05655078|RADIATION|Proton beam therapy|5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).
224271701|NCT00343720|DRUG|VELCADE|
224271702|NCT00343720|DRUG|Alimta|
224271703|NCT00989053|DRUG|escitalopram|10 mg/d for a duration of 8 weeks
224271704|NCT00989053|DRUG|placebo|1 pill per day for 8 weeks
224271705|NCT00496990|BEHAVIORAL|Enhanced care|this group received counseling, contingency management and methadone or detoxification
223893563|NCT04872790|DRUG|Dasatinib|Given PO
223893564|NCT04872790|DRUG|Methotrexate|Given IT
223893565|NCT04872790|DRUG|Prednisone|Given PO
224271706|NCT00496990|BEHAVIORAL|control|this group receives the opportunity to participate in a support group
224271707|NCT00452348|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
224271708|NCT00452348|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
224271709|NCT05073523|OTHER|Diet|All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
224271710|NCT06278090|DRUG|Ursodeoxycholic Acid Only Product|Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
224271711|NCT00275249|DRUG|levorphanol|
224271712|NCT02275403|PROCEDURE|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
224271713|NCT02275403|OTHER|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
224271714|NCT01490190|DRUG|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
224271715|NCT04750590|PROCEDURE|en bloc resection, morcellation|Laser en bloc resection with subsequent tumor morcellation will be performed. This tissue will be sent for histology in order to estimate the histological subtype and differentiation grade. Next stage laser resection of the tumor basis will be performed with subsequent histology to determine the depth of invasion and the status of surgical margin.
224271716|NCT04750590|PROCEDURE|piecemeal resection, tissue removal by loop|Tumor piecemeal resection will be performed with electric loop. Then fragments of the tumor will be removed by the loop or Janet's syringe. Fragments from the base of the tumor will be sent separately in order to assess which stage the tumor is at and its surgical margin status.
224271717|NCT02560051|DRUG|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
224271718|NCT02560051|DRUG|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
224271719|NCT02560051|DRUG|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
224271720|NCT02560051|DRUG|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
224271721|NCT02560051|DRUG|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
224271722|NCT04152356|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
224271723|NCT04152356|DRUG|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
224271724|NCT05856799|DEVICE|Leadless Micra AV Transcatheter Pacing System|Patients are implanted with a leadless Micra AV TPS
224271725|NCT05856799|DEVICE|Transvenous Azure XT DR dual chamber pacemaker|Patients are implanted with a transvenous Azure XT DR pacemaker
224271726|NCT03469960|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
224271727|NCT03469960|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
224271728|NCT02545530|DRUG|transdermal clonidine|2.5mg/patch per week
224271729|NCT04345822|PROCEDURE|Decompression surgery|The surgeries aim to relieve the myelopathy from cord compression
224271730|NCT04467619|DEVICE|Functional Proprioceptive Stimulation|Functional Proprioceptive Stimulations (FPS) are applied on the musculo-tendinous junction. FPS mechanically stimulate the muscle spindles, mimicking the sensory signals - Ia fibers of functional movements. This neurosensory trick activates related sensory-motor areas allowing patients to feel natural movements. Because sensory \& motor systems are interdependent, the central nervous system then reacts by initiating corresponding movements.
224271731|NCT04883164|OTHER|Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples|Cellular immunity will be assessed with T-cells and other immune cells that express CD154 or other inflammatory or other markers after stimulation with spike antigens. Antibody immunity will be measured with binding and neutralizing activity of antibodies to spike antigens.
224271732|NCT04459754|DRUG|Fuzheng Yiliu Formulation|"The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption."
224271733|NCT00250354|DRUG|Risperidone oral solution|
224271734|NCT02752854|OTHER|pain threshold measurement|pressure algometer
223534843|NCT04904835|DIAGNOSTIC_TEST|Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|All samples will be tested with both CE-marked HBV serological predicate assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) and Access HBV serological assays (HBsAg, HBsAb, HBcT, HBc IgM, HBeAb, and/or HBeAg assays) according to respective Instructions For Use to determine non-reactive (NR), initially reactive (IR), repeatedly reactive (RR), or confirmed or not confirmed Positive.
223534844|NCT00413348|DRUG|Lactobacillus acidophilus NCFM|
223534845|NCT04089514|DRUG|Adalimumab|Administered as specified in the treatment arm
224271735|NCT05174754|BEHAVIORAL|Physician-prescribed Exercise Programme|A 20-week structured exercise programme derived and supervised by a Sports Medicine Physician following the FITT Principles
224271736|NCT05174754|DRUG|Best Medical Therapy|Best medical therapy with biologic agent or small-molecule therapy
224271737|NCT02161263|OTHER|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
224271738|NCT00307541|BIOLOGICAL|Pneumococcal (vaccine)|
224271739|NCT04632641|DEVICE|Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES|The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
223893566|NCT04872790|BIOLOGICAL|Rituximab|Given IV
223893567|NCT04872790|DRUG|Venetoclax|Given PO
223893568|NCT04872790|BIOLOGICAL|Blinatumomab|Given IV
224271740|NCT04632641|OTHER|Figure 8 Suture - LARGE-BORE PROCEDURES|A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.
224271741|NCT02559843|DIETARY_SUPPLEMENT|pomegranate juice|
224271742|NCT02559843|BEHAVIORAL|lifestyle modification|
224271743|NCT06200376|DRUG|T3011|T3011 will be administered intraperitoneally twice a week.
224271744|NCT01072162|DRUG|Eltrombopag|25 mg tablet
224271745|NCT01072162|DRUG|Eltrombopag|25 mg powder for oral suspension
224271746|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing native palm olein|
224271747|NCT01710280|DIETARY_SUPPLEMENT|High-fat meal containing interesterified palm olein|
224271748|NCT03673592|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
224271749|NCT00960154|DEVICE|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
224271750|NCT00960154|PROCEDURE|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
224271751|NCT02931630|OTHER|Whey protein powder|60 g of whey protein powder
224271752|NCT02931630|OTHER|Maltodextrin powder|60 g of Maltodextrin powder
224271753|NCT02931630|OTHER|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
224271754|NCT02931630|OTHER|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
224271755|NCT01380613|BEHAVIORAL|Workshop|10 session intervention
224271756|NCT01380613|BEHAVIORAL|Workshop control|1 session intervention on standard HIV/STD information
224271757|NCT00377156|RADIATION|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
224271758|NCT00377156|RADIATION|stereotactic radiosurgery|
224271759|NCT03283748|DEVICE|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
224271760|NCT02407496|OTHER|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
224271761|NCT02156219|OTHER|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~1. Control: Surveillance that men do not use cars corresponding to women.~2. Dosage: Regulation of entry women.~3. Assignment: Of the women, to the part of the platform where the first wagons stop."
224271762|NCT01494090|DRUG|Rosuvastatin|5 or 20 mg per day during 6 months
224271763|NCT01494090|DRUG|Placebo|5 or 20 mg per day during 6 months
224271764|NCT00125541|DRUG|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
224271765|NCT00856349|BEHAVIORAL|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
224271766|NCT02725515|BIOLOGICAL|XmAb5871|
224271767|NCT02725515|BIOLOGICAL|Placebo to match XmAb5871|
224271768|NCT00353535|PROCEDURE|Total Lymphoid irradiation|
224271769|NCT00056433|DRUG|Hydroxyurea|
224271770|NCT00056433|DRUG|L-Arginine|
224271771|NCT00056433|DRUG|Sildenafil|
224271772|NCT00874549|BIOLOGICAL|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
224271773|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224271774|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
224271775|NCT00874549|BIOLOGICAL|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224271776|NCT02898740|BEHAVIORAL|Structural exercise|Exercise instruction and encouragement
224271777|NCT02898740|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
224271778|NCT01415596|DRUG|salbutamol|
224271779|NCT01415596|DRUG|Placebo|
224271780|NCT02383706|DEVICE|ApneaLink Air|Overnight, home polysomnography device
224271781|NCT02383706|BEHAVIORAL|Berlin Quesionnaire|OSA screening questionnaire
224271782|NCT02383706|BEHAVIORAL|Epworth Sleepiness Scale|OSA screening questionnaire
224271783|NCT02383706|BEHAVIORAL|STOP-BANG questionnaire|OSA screening questionnaire
224271784|NCT02383706|OTHER|Physical exam|Physical exam of neck, mouth and upper airway
224271785|NCT02036749|PROCEDURE|nerve block|quadratus lumborum block
224271786|NCT06175741|PROCEDURE|erector spinae plane block|The ultrasound (US)-guided ESP block will be provided while the patient be in a seated position according to surgical site (right or left). Using high-frequency linear US transducer , the probe is placed in the longitudinal orientation lateral to thoracic third and six spinous processes ,then the trapezius muscle ,rhomboids major muscle and erector spinae muscle are identified and we will inject 20ml of 0.25% bupivacaine into interfacial plane below erector spinae muscle in one level (between T3and T6) ,alone in 1st group,with 3 mg morphine in 2nd group and 5 mg morphine in 3rd group
224271787|NCT05981716|OTHER|No intervention|This is an observational study. There is no intervention.
224271788|NCT00432705|PROCEDURE|Checking stability of ankle|Flexing and walking
224271789|NCT03971734|DRUG|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
224271790|NCT03971734|DRUG|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
224271791|NCT03971734|DRUG|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
224271792|NCT03971734|DRUG|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
224271793|NCT03971734|DRUG|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
224271794|NCT03971734|DRUG|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
224271795|NCT03971734|DRUG|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
224271796|NCT04402606|OTHER|Evaluation on skin toxicities|Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
224271797|NCT06677736|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
224271798|NCT06677736|RADIATION|Diode laser as adjunctive to conventional scaling and debridement|Diode laser as adjunctive to conventional scaling and debridement
224271799|NCT01812629|OTHER|Experimental Infant Formula|Infant formula to be fed ad libitum
224271800|NCT04922294|OTHER|Clinical decision support system|To develop a clinical decision support system based on a published cardiometabolic disease staging system.
224271801|NCT02279784|DEVICE|Freeway PTA|angioplasty with Freeway drug-eluting balloon
223704017|NCT06793540|BEHAVIORAL|SELF POSTUROTHERAPIE|a simplified posturotherapy protocol that can be carried out by the patient himself. This protocol is based on the same principles as posturotherapy carried out by a physiotherapist by combining inclined positioning, percussion and diuresis.
223893569|NCT04872790|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223893570|NCT04872790|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224271802|NCT02279784|DEVICE|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
224271803|NCT03008941|BIOLOGICAL|FMT|Capsules with fecal microbiota from healthy donors
224271804|NCT03008941|OTHER|Placebo|Placebo capsules
224271805|NCT06579417|DIAGNOSTIC_TEST|RSI MRI|In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients' images are read separately by two expert radiologists at the center, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients' future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.
224271806|NCT01712568|DRUG|Test Product (Ropinirole)|"one Tablet at 0 hour"
224271807|NCT01712568|DRUG|Reference Product (REQUIP )|"one Tablet at 0 hour"
224271808|NCT05799235|DEVICE|Telerehabilitation TAR program using a mobile application|Participants in this study arm will use a mobile application which allows participants to perform their home exercises with real-time feedback given, allowing for proper execution of exercises, on top of standard care.
224271809|NCT05799235|OTHER|Standard rehabilitation sessions|Participants in this control group will attend standard in person rehabilitation sessions with home exercise program given as per standard care.
224271810|NCT00970788|BEHAVIORAL|Video intervention|Video of goals of care
224271811|NCT02753465|PROCEDURE|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
224271812|NCT02753465|PROCEDURE|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
224271813|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
224271814|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
224271815|NCT01091766|DRUG|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
224271816|NCT03865225|OTHER|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
224271817|NCT03865225|OTHER|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
224271818|NCT00158535|PROCEDURE|liver transplantation|
224271819|NCT04924699|DRUG|MRG002|Administrated intravenously
224271820|NCT04924699|DRUG|Trastuzumab Emtansine for Injection|Administrated intravenously
224271821|NCT00556699|DRUG|rituximab|Escalating intravenous repeating dose
224271822|NCT00556699|DRUG|SGN-40|Escalating intravenous repeating dose
224271823|NCT02212106|BIOLOGICAL|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
224271824|NCT02212106|BIOLOGICAL|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
224271825|NCT05544656|DRUG|Tolperisone Hydrochloride|Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
224271826|NCT05544656|DRUG|Placebo|matching placebo administered three times a day
224271827|NCT06113913|DRUG|Infliximab|Weekly administration of subcutaneous infliximab.
224271828|NCT06113913|DRUG|Infliximab|Bi-weekly administration of subcutaneous infliximab.
224271829|NCT06113913|DRUG|Infliximab|Optimized dosing schedule of intravenous infliximab.
224271830|NCT01151449|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
224271831|NCT01151449|OTHER|laboratory biomarker analysis|Correlative studies
224271832|NCT03537911|BEHAVIORAL|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
224271833|NCT01027767|DEVICE|Molecular Breast Imaging|Molecular Breast Imaging
224271834|NCT00517192|DRUG|Tipranavir|
224271835|NCT00517192|DRUG|Darunavir|
224271836|NCT00517192|DRUG|Ritonavir|
224271837|NCT01324544|DRUG|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
224271838|NCT00757991|GENETIC|polymorphism analysis|
224271839|NCT00757991|OTHER|laboratory biomarker analysis|
224271840|NCT00757991|OTHER|questionnaire administration|
224271841|NCT00117182|DRUG|Dry powder mannitol|
224271842|NCT00117182|DRUG|Budesonide 400mcg administered via turbuhaler|
224271843|NCT00117182|DRUG|Ipratropium bromide 80mcg|
224271844|NCT00117182|DRUG|Salbutamol 400mcg|
224271845|NCT02941588|PROCEDURE|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
224271846|NCT01480895|BEHAVIORAL|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
224271847|NCT03992651|DEVICE|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
224271848|NCT01486108|PROCEDURE|dorsal column stimulator|test different settings of stimulation
224271849|NCT02318550|OTHER|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~* Normal operating mode~* SAR ≤ 2.0 W/kg per patient."
224271850|NCT06198647|PROCEDURE|Tui-na massage|Using Tui-na massage for the back muscles
224271851|NCT06198647|PROCEDURE|positional release technique|using positional release manual technique to relax the back muscles
224271852|NCT05341856|DRUG|isosorbide mononitrate|insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
224271853|NCT05341856|DRUG|Placebo|insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
224271854|NCT06674135|DRUG|biosimilar insulin glargine|Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
224271855|NCT00476437|DRUG|biphasic insulin aspart|
224271856|NCT00476437|DRUG|biphasic human insulin|
224271857|NCT00804245|PROCEDURE|needle biopsy|Biopsy of positive findings found on CT scan
224271858|NCT00804245|DRUG|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
224271859|NCT00230594|DRUG|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
224271860|NCT00230594|DRUG|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
224271861|NCT03730740|DRUG|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
224271862|NCT02809768|DRUG|Avatrombopag|
224271863|NCT02809768|DRUG|Fluconazole|
224271864|NCT02809768|DRUG|Itraconazole|
224271865|NCT02809768|DRUG|Rifampin|
224271866|NCT02007668|OTHER|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
224271867|NCT05190432|DIETARY_SUPPLEMENT|Taxifolin|A naturally occurring polyphenol found in apples, onions and other fruits and bark extracts.
224271868|NCT05190432|DIETARY_SUPPLEMENT|Ergothioneine|An amino acid found in mushrooms, oats and some bean varieties.
224271869|NCT05190432|DIETARY_SUPPLEMENT|Control|Microcrystalline cellulose.
224271870|NCT03635268|OTHER|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
224271871|NCT03085368|DRUG|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
224271872|NCT02849236|DRUG|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
224271873|NCT02849236|DRUG|Placebo|20 mL saline 0.9%
224271874|NCT02733627|DRUG|BI 1467335|
224271875|NCT02733627|DRUG|Placebo|
224271876|NCT06472323|PROCEDURE|PRF+PRP, PRF|Under CT guidance, the trocar then was inserted through the ipsilateral foramen ovale to the Gasserian ganglion of the patient. After puncturing the foramen ovalis, remove the cannula needle core and connected with RF electrode (PMK-21-100, Baylis, Canada) and the RF generator. Electrical stimulation was carried out at 50 Hz to determine the sensory threshold and at 2 Hz to determine the motor threshold. The RF generator was set to the manual PRF mode with a standard setting of 42°C, the UP knob was turned to increase the output voltage until the maximum voltage (bearable without causing pain in conscious patients)was reached; 120 s, 2 times. After removing the RF electrode in the combined treatment group, 2ml of LP-PRP mixture was injected slowly into the Gasserian ganglion and mandibular nerve and PRF group only receive PRF treatment.
224271877|NCT00183196|DRUG|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
224271878|NCT00183196|DRUG|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
224271879|NCT00183196|OTHER|Inactive Placebo|Placebo
224271880|NCT06548243|BEHAVIORAL|Act with Nature Programme|The participants in the intervention group are offered a 12-week nature-based programme, which includes independent exercises and information on an online learning environment, as well as online or in-person group meetings.
224271881|NCT06323070|OTHER|Low-fat cookies|To determine the effects of low-fat cookie consumption on physiological indicators of wellness regarding sexual, skin, and gut health
224271882|NCT06323070|OTHER|Watermelon|To determine the effects of watermelon consumption on physiological indicators of wellness regarding sexual, skin, and gut health
224271883|NCT03375866|OTHER|Pretzels|Subjects consume 240 kcal of pretzels daily for 16 weeks.
224271884|NCT03375866|OTHER|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
224271885|NCT03796572|DRUG|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
223893571|NCT04872790|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223893572|NCT05282173|BEHAVIORAL|Siyakhana CHW Training|Please see arm description.
223893573|NCT05891353|OTHER|Cold Water Immersion|Cold Water Immersion task of hand
224271886|NCT03796572|OTHER|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
224271887|NCT06624735|DIAGNOSTIC_TEST|psychometry|ADHD test and measurement of IQ level
224271888|NCT01961817|OTHER|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack \& Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
224271889|NCT01961817|OTHER|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack \& Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
224271890|NCT01513239|BIOLOGICAL|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
224271891|NCT01513239|BIOLOGICAL|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
224271892|NCT01513239|BIOLOGICAL|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
224271893|NCT01513239|DRUG|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
224271894|NCT04005222|DRUG|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
224271895|NCT04005222|DRUG|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
224271896|NCT02873260|BIOLOGICAL|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^4.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10\^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10\^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10\^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
224271897|NCT02873260|BIOLOGICAL|rDEN3Δ30|Administered at a dose of 10\^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
224271898|NCT02873260|BIOLOGICAL|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
224271899|NCT00842062|DEVICE|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
224271900|NCT01327976|DEVICE|vBloc (Active Device)|Active device will deliver vBloc Therapy
224271901|NCT01327976|DEVICE|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
224271902|NCT03582423|OTHER|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
224271903|NCT06423014|BEHAVIORAL|Wearable devices only|self-monitoring
224271904|NCT06423014|BEHAVIORAL|Wearable devices with the 1st behavior change technique|reminder
224271905|NCT06423014|BEHAVIORAL|Wearable devices with the 2nd behavior change technique|social support
224271906|NCT06423014|BEHAVIORAL|Wearable devices with the 3rd behavior change technique|Competition
224271907|NCT06423014|BEHAVIORAL|Wearable devices with the 4th behavior change technique|Goal-setting
224271908|NCT06423014|BEHAVIORAL|Wearable devices with the 5th behavior change technique|health coach
224271909|NCT06423014|BEHAVIORAL|Wearable devices with all behavior change techniques|Self-monitoring, health coach, goal-setting, competition, social support, and reminder
224271910|NCT03390790|DRUG|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
224271911|NCT03390790|OTHER|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
224271912|NCT03167606|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
224271913|NCT00059332|DRUG|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
224271914|NCT00059332|DRUG|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
224271915|NCT03483818|PROCEDURE|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
223517870|NCT06289283|OTHER|Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera|"Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for"
224271916|NCT01239303|DIETARY_SUPPLEMENT|Citrulline|single dose
224271917|NCT01239303|DIETARY_SUPPLEMENT|alanine|single dose
224271918|NCT04142996|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
224271919|NCT05214677|DRUG|DW1809|pelubiprofen 30mg
224271920|NCT05214677|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
224271921|NCT01404351|DEVICE|PEAK PlasmaBlade|
223517871|NCT00272805|DRUG|carvedilol|
223893574|NCT05891353|OTHER|Pain Inducing Stretch|Moderately painful stretch of the neck
224271922|NCT01404351|PROCEDURE|Scalpel and Traditional Electrosurgery|
224271923|NCT01476358|DIETARY_SUPPLEMENT|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
224271924|NCT04097041|PROCEDURE|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
223893575|NCT05891353|OTHER|Pain Free Stretch|Pain free stretch of the neck
224271925|NCT04097041|PROCEDURE|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
224271926|NCT04484090|DEVICE|Vertica RF device|The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
224271927|NCT04808908|BIOLOGICAL|N-803|N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
224271928|NCT01812603|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
224271929|NCT00413049|DRUG|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
224271930|NCT00413049|DRUG|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
224271931|NCT04546412|DEVICE|Vitrification and thawing|Vitrification using the Cryotop® - Open System followed by thawing
224271932|NCT01460628|DRUG|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
224271933|NCT04038866|OTHER|rehabilitation gait with dual task|
224271934|NCT04038866|OTHER|rehabilitation gait without dual task|
224271935|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 1)|"* 3 additional tubes of blood sample (cohort 1), at diagnosis and upon relapse if relapse occurs~* Bone marrow aspirate : 3 additional tubes (cohort 1), at diagnosis and upon relapse if relapse occurs"
224271936|NCT05772559|OTHER|Collection of blood sample of bone marrow (cohort 2 and 3)|"* 1 additional tube of blood sample (cohort 2 and 3 at inclusion)~* Bone marrow aspirate: 1 additional tube (cohort 2 and 3 at inclusion)"
224271937|NCT02587143|DRUG|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
224271938|NCT02587143|DRUG|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
223517872|NCT05102461|DIETARY_SUPPLEMENT|Florajen Digestion Supplementation|Subjects will take the placebo starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
223517873|NCT05102461|DIETARY_SUPPLEMENT|Placebo Supplementation|Subjects will take Florajen Digestion starting from Week 3 post-transplant until 180 days after transplant. Compliance will be measured through the return of empty packs and urinalysis for riboflavin during follow-up visits in clinic.
224271939|NCT02128516|OTHER|oral powder in sachet|
224271940|NCT03670758|DIAGNOSTIC_TEST|Protein S activity|Intravenous blood sample
224271941|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Rockwood Clinical Frailty Scale
224271942|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Frail NonDisabled Questionnaire (FiND)
224271943|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Clinician's subjective 'end-of-bed' test
223517874|NCT00667979|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
223517875|NCT00667979|DRUG|Placebo|Matching placebo
223517876|NCT04591587|PROCEDURE|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery|Lenticule Implantation in Keratoconus Disease with RELEX Smile Surgery using VisuMax Femtosecond laser- Smile module surgery with primary objective to increase central corneal thickness and secondary objective to improve visual acuity and reduces K-values
223517877|NCT02029612|DRUG|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
223517878|NCT02029612|BEHAVIORAL|Phone Counseling|Each participant counseled on quitting smoking at baseline.
223517879|NCT02029612|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
223517880|NCT02029612|BEHAVIORAL|Breath Test|Breath test performed at 3 month and 6 month visit.
223517881|NCT02029612|BEHAVIORAL|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
224271944|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|Healthcare Improvement Scotland FRAIL Scale
224271945|NCT06040658|DIAGNOSTIC_TEST|Frailty assessment|11-item modified Frailty Index (mFI-11)
224271946|NCT01675739|BEHAVIORAL|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
224271947|NCT01675739|DRUG|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
224271948|NCT02837913|DEVICE|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
224271949|NCT03373630|DEVICE|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
224271950|NCT00165919|OTHER|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
224271951|NCT05024487|DIAGNOSTIC_TEST|Clinical Examination|Given the most frequent causes of AD, the above-mentioned trigger stimuli will be used. All these procedures are commonly used in SCI people.
224271952|NCT02557464|BEHAVIORAL|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
224271953|NCT02557464|BEHAVIORAL|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
224271954|NCT06378320|OTHER|App access and Text message|Access to App and Text messages with app related breastfeeding related question
224271955|NCT06378320|OTHER|App access only|Access to App without Text messages with app related breastfeeding related question
224271956|NCT03314857|DEVICE|SAPIEN XT THV with the NovaFlex+ delivery system|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
224271957|NCT02230930|DRUG|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
224271958|NCT02230930|DEVICE|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
224271959|NCT02230930|DRUG|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
224271960|NCT02230930|DRUG|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
224271961|NCT00753350|DEVICE|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
224271962|NCT06331650|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
223893576|NCT06018454|OTHER|Handout on PGT-A|Educational handout on PGT-A
223893577|NCT06018454|OTHER|Handout on PGT-A and genetic counseling|Handout on PGT-A and genetic counseling session with a genetic counselor on PGT-A
223893578|NCT03364647|OTHER|Arm A - blood flow restriction training|Group receive standard of care plus blood flow restriction training
224271963|NCT06353724|DEVICE|conventional oral positioning stent were used during radiation planning and the PTV will be defined and contoured in computed tomography pre irradiation planning|"Dosimetric analysis: the maxilla (area of the teeth), both parotid glands (ipsilateral and contralateral), the mandible, and the PTV were defined and contoured in computed tomography pre irradiation planning. The mean corresponding dose of each structure were acquired using a dose-volume histogram.~All patients will complete the radiotherapy sessions using the positional radiation prosthesis.~Mucositis assessment: The severity of mucositis will be assessed weekly from the beginning of RT to the end of the treatment (mean time, 7 weeks). It will be scored in accordance with the classification criteria of the National Cancer Institute.~PH of saliva measurement: Collection of saliva sample were done from each patient to measure salivary PH by digital PH meter before beginning of radiotherapy and the measurement will be continued weekly till the end of the treatment."
224271964|NCT06353724|DEVICE|Digital positioning stent|Digital positioning stent
224271965|NCT01119625|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
224271966|NCT01119625|BIOLOGICAL|Infanrix-IPV/Hib|Intramuscular injection, one dose
224271967|NCT01706809|OTHER|blood sampels from vena rectalis superior and vena cubiti|
224271968|NCT04499209|DRUG|XG005|XG005 Capsule
224271969|NCT04499209|DRUG|Combination of Naproxen and Pregabalin|Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
224271970|NCT04499209|DRUG|Placebos|Placebo Capsule
224271971|NCT03237156|DRUG|TAK-906|TAK-906 capsules.
224271972|NCT03237156|DRUG|TAK-906 Placebo|Placebo capsules.
224271973|NCT01286805|PROCEDURE|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
224271974|NCT01286805|PROCEDURE|Control|The control group will receive only a combined spinal-epidural.
223517882|NCT02029612|BEHAVIORAL|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
223893579|NCT03364647|OTHER|Arm B - standard of care|Group will receive standard of care plus a sham version of blood flow restriction training
223893580|NCT04842253|DEVICE|High flow nasal cannula|HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation.
224271975|NCT03447691|DRUG|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
224271976|NCT03447691|DRUG|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
224271977|NCT01721772|BIOLOGICAL|BMS-936558 (Nivolumab)|
224271978|NCT01721772|BIOLOGICAL|Placebo matching BMS-936558 (Nivolumab)|
224271979|NCT01721772|DRUG|Dacarbazine|
224271980|NCT01721772|DRUG|Placebo matching Dacarbazine|
224271981|NCT01095887|DRUG|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
224271982|NCT02213887|DRUG|Pantoprazole|40 mg PO QAM
224271983|NCT02213887|DRUG|Pantoprazole|0 mg PO QAM
224271984|NCT00422253|BEHAVIORAL|dietary intervention|
224271985|NCT05530291|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
224271986|NCT06581120|DRUG|Glucagon-Like Peptide-1 receptor agonists|GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
224271987|NCT06581120|DIAGNOSTIC_TEST|Point of Care Gastric Ultrasound|A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
224271988|NCT00796874|OTHER|active surveillance|Correlative Study
224271989|NCT00796874|OTHER|imaging biomarker analysis|Correlative Study
224271990|NCT00796874|PROCEDURE|biopsy|Tissue Removal
224271991|NCT00796874|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
224271992|NCT00796874|PROCEDURE|magnetic resonance imaging|Radiolical Medical Imaging
224271993|NCT00796874|PROCEDURE|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
224271994|NCT04620941|DIAGNOSTIC_TEST|reticulocyte/hemoglobin (Ret-He) ratio|Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.
224271995|NCT00973050|DRUG|Bicalutamide|50 mg Tablet
224271996|NCT00973050|DRUG|Casodex®|50 mg Tabelt
224271997|NCT02465684|PROCEDURE|unicondylar knee arthroplasty|
224271998|NCT05638035|DIAGNOSTIC_TEST|Ultrasonografi, Sarcopenia measurement, Zebris|"The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2."
224271999|NCT00005668|DRUG|Itraconazole oral solution|
224272000|NCT02146690|OTHER|osteopathic manipulative treatment|
224272001|NCT02146690|OTHER|sham therapy|
224272002|NCT02146690|OTHER|usual care|
224272003|NCT06106152|DRUG|WTX212A injection|The WTX212A infusion is given every 21 days
224272004|NCT06106152|DRUG|PD -1/PD-L1 monoclonal antibody|The PD -1/PD-L1 monoclonal antibody is given every 21 days
224272005|NCT00352807|DRUG|Brimonidine Purite|
224272006|NCT06440278|BEHAVIORAL|Behavioral Activation for Health and Depression (BA-HD)|BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
224272007|NCT06440278|OTHER|Enhanced Usual Care|Patients will receive depression and heart disease education, as well as a list of local mental health resources.
224272008|NCT00287053|DRUG|divalproex sodium|Divalproex sodium vs. placebo
224272009|NCT00234780|PROCEDURE|pediatric nursing used in home to avoid hospitalization|
224272010|NCT05156086|DRUG|COVID-19 vaccine, booster|Additional dose of COVID-19 vaccine (booster shot)
224272011|NCT03547414|OTHER|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2\*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
224272012|NCT04604210|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive FDA-approved technique that is commonly used as a treatment for depression. It has been shown to focally activate specific brain regions that are believed to be underactive in patients suffering from depression. In this study, TMS will be administered within FDA-approved guidelines under the supervision of a physician with experience in administering the treatment and monitoring for complications.
224272013|NCT04831138|PROCEDURE|MRI with ASL|"T0 (Week 0): MRI with ASL will be performed either for research alone or along with patient's standard of care imaging session including contrast-enhancement.~T1 (Day 7+-2): contrast-enhanced research MRI with ASL T2 (Day 14+-2): contrast-enhanced research MRI with ASL T3: MRI with ASL will be performed along with patient's standard of care imaging session.~T4: MRI with ASL will be performed along with patient's standard of care imaging session.~T5: MRI with ASL will be performed along with patient's standard of care imaging session."
224272014|NCT00497250|DRUG|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
224272015|NCT00497250|DEVICE|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
224272016|NCT04646356|DRUG|Tacrolimus capsule (low-dose)|low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months
224272017|NCT03960801|DRUG|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
224272018|NCT03960801|DRUG|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
224272019|NCT05823662|PROCEDURE|DJ stent|A 5 Fr DJ stent will be inserted and then removed after three weeks.
224272020|NCT05823662|DRUG|Silodosin|Patients will be given one capsule of silodosin 8 mg at the night for three weeks.
224272021|NCT02542462|DRUG|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
224272022|NCT02542462|DRUG|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
224272023|NCT02542462|DRUG|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
224272024|NCT02542462|DRUG|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
224272025|NCT06236100|BEHAVIORAL|Strengthening Families Program + Family Advocate|This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.
224272026|NCT06236100|BEHAVIORAL|Strengthening Families Program|This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.
224272027|NCT06244420|OTHER|Clinical data review|review the medical records, radiological imaging, and histological data of these patients
224272028|NCT04096586|OTHER|Red juice|To determine the effects of red juice on satiety and gut health
224272029|NCT04096586|OTHER|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
224272030|NCT01146080|DEVICE|Promus Element|Promus Element implanted to treat coronary artery lesions.
224272031|NCT01146080|DEVICE|Promus|Promus stent implanted to treat coronary artery lesions
224272032|NCT01899833|DIAGNOSTIC_TEST|99mTc-Sestamibi|An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
224272033|NCT02779933|OTHER|Epidemiology od HAP|no intervention
224272034|NCT05266287|DIETARY_SUPPLEMENT|a supplement containing 2'-fucosyllactose (2'-FL)|Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
224272035|NCT05266287|DIETARY_SUPPLEMENT|Placebo Supplement|Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
224272036|NCT05904639|GENETIC|Decoding Your Diet|We will collect information from cardiac patients on their genes at baseline and then expose them to a diet intervention and collect genetic information after the intervention.
224272037|NCT00397254|DRUG|rizatriptan|10mg ODT 27 tablets
224272038|NCT00397254|DRUG|rizatriptan|10mg ODT 9 tablets
224272039|NCT02374216|PROCEDURE|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
224272040|NCT01531816|DEVICE|Early Rehabilitation intervention|"1. Passive mobility: cycle ergometer~2. Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
224272041|NCT00493883|DEVICE|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
224272042|NCT05214144|OTHER|PRO Instruments assessment questionnaire|"Patient Reported Outcome (PRO) questionnaire consisting of:~* PRO-CTCAE (approximately 11 questions plus free text)~* Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form (version 8c) (8 questions)~* PRO ECOG question (1 question)~* EORTC Quality of Life questionnaire (QLQ)-F17 questions (17 questions)~* Functional Assessment of Cancer Therapy-General version, rated on a 5-point Likert scale, (FACT-GP5) (single item global side effect bother question) (1 question)~* The Patient Global Impression (PGI)-C and PGI-S items (anchors for physical function) (2 questions)"
224272043|NCT05214144|OTHER|Baseline Survey Clinician- reported (ClinRO) ECOG|Baseline Survey completed prior to initiation of chemotherapy
224272044|NCT05214144|DEVICE|Fitbit|wearable device
224272045|NCT05214144|OTHER|"Hugo Health (Hugo)"|an electronic platform that aggregates real world EHR data with patient's wearable and PRO data
224272046|NCT05214144|OTHER|6 Minute Walk Test (6MWT)|A comprehensive performance measure of exercise capacity, encompassing components of mobility, endurance, and functional capacity measure (PerfO)
224272047|NCT04153318|DEVICE|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
224272048|NCT06075849|DRUG|PB101|"Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator."
224272049|NCT01632449|DRUG|Test product|Dimethyl Fumarate (BG00012)
224272050|NCT01632449|DRUG|Reference product|Dimethyl Fumarate (BG00012)
224272051|NCT04881188|DIAGNOSTIC_TEST|Survey|Patients with chronic low back pain in in-patient multimodal pain therapy. Three survey times, questionnaires
224272052|NCT02212236|OTHER|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
224272053|NCT02102815|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
223517883|NCT02799043|PROCEDURE|Standard PVI|Standard PVI procedure without FIRMap.
223893581|NCT05994924|BEHAVIORAL|Educational Handout|Educational handout describing responsive feeding practices.
223893582|NCT05994924|BEHAVIORAL|Video Series|Videos geared toward responsive feeding practices.
224272054|NCT02102815|DRUG|Normal saline|NSS 50 mL IV slowly push over 5 minutes
224272055|NCT05857345|OTHER|Collection of breastmilk|Collection of breastmilk and other information about the participant
224272056|NCT00310492|BIOLOGICAL|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
224272057|NCT02340780|DRUG|Buparlisib|
224272058|NCT02924649|PROCEDURE|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
224272059|NCT01733576|DEVICE|HD-tDCS|
224272060|NCT03109041|DEVICE|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
224272061|NCT02593019|DRUG|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
224272062|NCT05311150|DEVICE|Narrow band imaging bronchoscopy guided endobronchial biopsy|Examination of the airways will be performed with the narrow band imaging mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
224272063|NCT05311150|DEVICE|White light bronchscopy guided endobronchial biopsy|Examination of the airways will be performed with the white light bronchoscopy mode using a flexible video-bronchoscope (BF-1T 180, Olympus Medical, Japan). Endobronchial biopsies will be performed from the abnormal areas as deemed by the operator.
224272064|NCT02798406|BIOLOGICAL|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
224272065|NCT02798406|BIOLOGICAL|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
224272066|NCT02671877|PROCEDURE|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
224272067|NCT03212378|OTHER|percutaneous coronary interventions|Percutaneous coronary intervention.
224272068|NCT04273438|DEVICE|Visual field testing using Oculus Rift and Humphrey Visual Field Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
224272069|NCT04273438|DEVICE|Visual Field Testing using HUmphrey 24-3 Perimeter|Glaucoma patients at Queen's University, Belfast, will be invited to undergo both Visual field testing using the Oculus Rift and the gold-standard Humphrey 24-2 (Carl Zeiss Meditec, Dublin, CA) at two visits, and evaluating consistency for detecting visual field impairments.
224272070|NCT01516762|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
224272071|NCT00066391|DRUG|cisplatin|
224272072|NCT00066391|DRUG|irinotecan hydrochloride|
224272073|NCT00066391|PROCEDURE|neoadjuvant therapy|
224272074|NCT02181140|DEVICE|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
224272075|NCT06283823|DEVICE|Thermoformed orthodontic retainer|compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
224272076|NCT04251091|OTHER|Treadmill walking|Up to 5 bouts of 6 minutes walking on the treadmill with rest breaks allowed between sets
224272077|NCT04251091|OTHER|Overground Walking|Up to 5 bouts of 6 minutes walking overground with rest breaks allowed between sets
224272078|NCT05753995|DIAGNOSTIC_TEST|PET imaging|The evaluation of PET imaging using PET ligand \[18F\]JNJ-64413739 or a \[18F\] labeled equivalent in vivo in patients.
224272079|NCT04711824|DRUG|Olaparib|Olaparib 100-300 mg twice daily up to 28 days concurrently with stereotactic radiosurgery. Three dose levels of olaparib will be explored in the Phase I portion. Olaparib will start one week prior to SRS and continue during and following SRS for up to 28 days total. One cycle will be given.
224272080|NCT04711824|RADIATION|Stereotactic Radiosurgery|SRS 1-5 fractions will be given per institutional standards
224272081|NCT04711824|DRUG|Durvalumab|Durvalumab 1120 mg IV over 60 minutes Day 1 of each cycle 21 day cycle.
224272082|NCT04711824|DRUG|Physicians Choice systemic chemotherapy|Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
224272083|NCT03449680|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
224272084|NCT03449680|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
224272085|NCT05284877|OTHER|No intervention|The study is an observational study without intervention.
224272086|NCT01221051|PROCEDURE|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
224272087|NCT01221051|PROCEDURE|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
224272088|NCT05626023|DRUG|Human TH-SC01 cell injection|Single injection of human TH-SC01 cell injection
224272089|NCT01006954|DRUG|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
224272090|NCT01006954|DRUG|Flare up|Flare up protocol in poor responders for IVF/ICSI
224272091|NCT04809662|DRUG|Imiquimod|"Patients with a diagnosis of actinic keratosis or warts that would be prescribed imiquimod as standard of care will be asked to apply 2 packets (or 2 full pumps) of imiquimod once daily before bedtime for two weeks and then leave on overnight for \~8 hours.~(a) A biopsy will be performed at the baseline visit on the pre-treatment skin and the skin where the medication will not be applied. The skin where the medication will not be applied will act as the negative control. A biopsy will then again be performed on day 10 of imiquimod treatment on the treated skin only, where the study drug was applied."
224272092|NCT05887687|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
224272093|NCT02902133|DRUG|Acetazolamide|Acetazolamide 500 mg by mouth twice per day for 5 days
224272094|NCT06385548|DRUG|Lurbinectedin|participants will receive intravenous infusions of lurbinectedin at a dose of 2.6 mg/m², diluted in a minimum of 100 mL of either 5% glucose solution or 0.9% sodium chloride solution. The infusion will last for one hour and will be administered every three weeks.
224272095|NCT06385548|DRUG|Dostarlimab|participants will receive intravenous infusions of dostarlimab at a fixed dose of 500 mg, administered over 30 minutes on Day 1 of each three-week cycle.
224272096|NCT05426200|BEHAVIORAL|Health Coaching|Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
224272097|NCT04710823|PROCEDURE|Thoracic paravertebral block|A bolus dose of 0.25% bupivacaine (0.3 ml/kg) will be injected slowly over 3-5 minutes. At 30 minutes after injection of the loading dose, the dermatomal loss of sensation to pinprick was tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion will be continued for 4 days.
224272098|NCT04710823|PROCEDURE|Serratus anterior plane block|A bolus of 30 ml of 0.25% bupivacaine will be injected slowly over 3-5 minutes between latissmus dorsi muscle and serratus anterior muscle (Figure 15). Then a catheter was inserted through the Tuohy needle and advanced 3cm into the space and secured in place. At 30 minutes after injection of a loading dose, the dermatomal loss of sensation to pinprick will be tested. Patients who reported pain to pinprick will be considered to have a failed block and were excluded from the study. The block will be maintained by continuous infusion of bupivacaine 0.25% at a rate of 0.1 ml/kg/h via a syringe pump. The infusion was continued for 4 days.
224272099|NCT04301258|OTHER|Articular cartilage repair|Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
224272100|NCT03956758|OTHER|Semi-directed interview|Semi-directed interview on ChemSex practice
224272101|NCT04703933|OTHER|EVALUATION OF THE LEVEL OF KNOWLEDGE AND ATTITUDE OF THE OPERATING ROOM NURSES|This descriptive study was conducted with 100 nurses working in the operating room of two university hospitals in Istanbul
224272102|NCT03736577|OTHER|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants' drug charts
224272103|NCT03232450|DRUG|Aspirin|Subjects will receive 81 mg enteric coated aspirin
224272104|NCT03232450|DEVICE|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
224272105|NCT03232450|DEVICE|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
224272106|NCT03768635|OTHER|necrotizing external otitis|description of necrotizing external otitis
224272107|NCT06626906|DIAGNOSTIC_TEST|Echocardiography, Blood sampling for biomarker assays|
224272108|NCT02637141|BIOLOGICAL|AMG 714|AMG 714 administered by subcutaneous injection
223517884|NCT02799043|PROCEDURE|FIRM-Guided Procedure and PVI|
223517885|NCT01326897|BEHAVIORAL|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
223517886|NCT01326897|BEHAVIORAL|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
223893583|NCT05994924|BEHAVIORAL|Group Discussion Sessions|Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
224272109|NCT02637141|BIOLOGICAL|Placebo|Matching placebo to AMG 714 administered by subcutaneous injection
224272110|NCT02637141|OTHER|Placebo Gluten Challenge|Gluten-free cookies (Finnish rusks)
224272111|NCT02637141|OTHER|Gluten Challenge|Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
224272112|NCT02606032|DRUG|Metronidazole|active comparator
224272113|NCT02606032|DRUG|Doxycycline|active comparator
224272114|NCT02606032|DRUG|Terbinafine|active comparator
224272115|NCT02606032|DRUG|Placebo|identical placebos to all antibiotics
224272116|NCT04143607|DRUG|ASK120067|ASK120067 (80 mg orally twice daily) . A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
224272117|NCT04143607|DRUG|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
224272118|NCT04143607|DRUG|Gefitinib|Gefitinib (250 mg orally, once daily) , A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit acording to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
223517887|NCT03352180|PROCEDURE|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
223517888|NCT03352180|PROCEDURE|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
223517889|NCT04142723|BIOLOGICAL|blood withdraw|venous blood sampling
224272119|NCT04143607|DRUG|Placebo ASK120067|Placebo ASK120067orally 80mg twice daily . A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit according to RECIST 1.1, as judged by the Investigator, and in the absence of discontinuation criteria.
223517890|NCT03981198|DEVICE|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
223893584|NCT02751762|OTHER|Observation Only|No Intervention
223893585|NCT06302946|OTHER|neuromuscular stimulation and mindfulness breathing|Receive neuromuscular stimulation and mindfulness breathing; the experimental group participants will receive neuromuscular electrical stimulation with Mindful breathing.
224272120|NCT04605211|BEHAVIORAL|Online Mindfulness Meditation|Complete online audio-based mindfulness meditation exercises
223893586|NCT06302946|OTHER|neuromuscular electrical stimulation|participants in the control group perceived neuromuscular electrical stimulation
224272121|NCT04605211|OTHER|Internet-Based Webinars|Attend webinars
224272122|NCT04563481|OTHER|Hand Therapy via Telerehabilitation|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
224272123|NCT04563481|OTHER|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~* 3 days / week with physiotherapist~* 2 days / week as home program 30 minutes / day 12 repetitions"
224272124|NCT01282736|BEHAVIORAL|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
224272125|NCT01282736|BEHAVIORAL|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
224272126|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
224272127|NCT01412281|BIOLOGICAL|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
224272128|NCT00097734|DRUG|ertapenem|
224272129|NCT01662050|DRUG|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
224272130|NCT06563193|DIAGNOSTIC_TEST|NERVE GROWTH FACTOR|urinary neurotrophins
224272131|NCT03885934|BIOLOGICAL|V114|V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
224272132|NCT03885934|BIOLOGICAL|Prevnar 13®|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
224272133|NCT00370851|DRUG|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
224272134|NCT03849547|OTHER|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
224272135|NCT03849547|OTHER|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
224272136|NCT01167439|PROCEDURE|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
224272137|NCT06301386|DRUG|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
223517891|NCT01313533|DRUG|Polyarginine|Vein soak treated with polyarginine
223517892|NCT01313533|DRUG|Vein soak treated with Lactated Ringers Solution|Vein soak
223517893|NCT02665650|BIOLOGICAL|AFM13|
224272138|NCT06301386|DRUG|PD-1|200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
224272139|NCT06422286|DEVICE|low-level laser|children will be allocated to the device then the gag reflex will be re-evaluated
224272140|NCT06422286|BIOLOGICAL|microcurrent stimulation|children will be allocated to the device then the gag reflex will be re-evaluated
224272141|NCT06422286|DEVICE|placebo|children will be allocated to a deactivated meridian pen
224272142|NCT03472196|DEVICE|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
224272143|NCT06347627|BEHAVIORAL|Group 1 (I x S x S x F)|Experimental message: Individual x Safety x Storytelling x Factual
224272144|NCT06347627|BEHAVIORAL|Group 2 (O x S x S x F)|Experimental message: Organization x Safety x Storytelling x Factual
224272145|NCT06347627|BEHAVIORAL|Group 3 (I x E x S x F)|Experimental message: Individual x Effectiveness x Storytelling x Factual
224272146|NCT06347627|BEHAVIORAL|Group 4 (O x E x S x F)|Experimental message: Organization x Effectiveness x Storytelling x Factual
224272147|NCT06347627|BEHAVIORAL|Group 5 (I x S x S x M)|Experimental message: Individual x Safety x Storytelling x Misinformation
224272148|NCT06347627|BEHAVIORAL|Group 6 (O x S x S x M)|Experimental message: Organization x Safety x Storytelling x Misinformation
224272149|NCT06347627|BEHAVIORAL|Group 7 (I x E x S x M)|Experimental message: Individual x Effectiveness x Storytelling x Misinformation
224272150|NCT06347627|BEHAVIORAL|Group 8 (O x E x S x M)|Experimental message: Organization x Effectiveness x Storytelling x Misinformation
224272151|NCT06347627|BEHAVIORAL|Group 9 (I x S x D x F)|Experimental message: Individual x Safety x Scientific data x Factual
224272152|NCT06347627|BEHAVIORAL|Group 10 (O x S x D x F)|Experimental message: Organization x Safety x Scientific data x Factual
223517894|NCT02665650|BIOLOGICAL|Pembrolizumab|
224272153|NCT06347627|BEHAVIORAL|Group 11 (I x E x D x F)|Experimental message: Individual x Effectiveness x Scientific data x Factual
224272154|NCT06347627|BEHAVIORAL|Group 12 (O x E x D x F)|Experimental message: Organization x Effectiveness x Scientific data x Factual
224272155|NCT06347627|BEHAVIORAL|Group 13 (I x S x D x M)|Experimental message: Individual x Safety x Scientific data x Misinformation
224272156|NCT06347627|BEHAVIORAL|Group 14 (O x S x D x M)|Experimental message: Organization x Safety x Scientific data x Misinformation
224272157|NCT06347627|BEHAVIORAL|Group 15 (I x E x D x M)|Experimental message: Individual x Effectiveness x Scientific data x Misinformation
224272158|NCT06347627|BEHAVIORAL|Group 16 (O x E x D x M)|Experimental message: Organization x Effectiveness x Scientific data x Misinformation
224272159|NCT01307358|OTHER|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
224272160|NCT00662272|BIOLOGICAL|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
224272161|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
224272162|NCT00662272|BIOLOGICAL|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
224272163|NCT01291862|DEVICE|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
224272164|NCT01753362|DRUG|liraglutide|
224272165|NCT01753362|DRUG|placebo|
224272166|NCT01826760|OTHER|Using training and testing groups to construct ANN based on laboratory tests|
224272167|NCT03202927|DRUG|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
224272168|NCT01936662|DEVICE|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
224272169|NCT01936662|DEVICE|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
224272170|NCT04473326|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
224272171|NCT04233060|DRUG|CS3005|CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
223517895|NCT03796221|BEHAVIORAL|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
224272172|NCT02840162|DRUG|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
224272173|NCT02840162|DRUG|Placebo|
224272174|NCT02046122|DRUG|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
224272175|NCT02046122|DRUG|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
224272176|NCT02046122|BIOLOGICAL|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10\^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
224272177|NCT05428696|DRUG|ALXN2080|Powder-in-capsule
224272178|NCT05428696|DRUG|Placebo|Powder-in-capsule
224272179|NCT06287216|BEHAVIORAL|Mental Hygiene|Mental hygiene are daily evidence based practices that support mental wellbeing.
224272180|NCT06287216|BEHAVIORAL|Self-Care|Instructed to do 10 minutes of self-care daily.
223704018|NCT03792191|RADIATION|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
223704019|NCT03792191|RADIATION|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
224272181|NCT02135991|BEHAVIORAL|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
224272182|NCT02135991|BEHAVIORAL|Project CHOICE|Sites will receive standard training for Project CHOICE.
224272183|NCT03347019|OTHER|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
224272184|NCT03347019|OTHER|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
224272185|NCT06449703|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
224272186|NCT06449703|DRUG|Xultophy®|Xultophy®
224272187|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
224272188|NCT01559116|DRUG|tiotropium|low dose
224272189|NCT01559116|DRUG|olodaterol|one dose only
224272190|NCT01559116|DRUG|tiotropium|high dose
224272191|NCT01559116|DRUG|tiotropium + olodaterol|low dose + one dose only
224272192|NCT01559116|DRUG|Placebo|placebo matching tiotropium+olodaterol FDC
224272193|NCT01559116|DEVICE|Respimat|Respimat inhaler
224272194|NCT01532908|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
224272195|NCT01532908|DRUG|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
224272196|NCT01532908|DRUG|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
224272197|NCT04728750|PROCEDURE|Enucleation of a tumor of the pancreas|Enucleation of a tumor in the pancreas is feasible and safe, as it offers a minimally invasive approach, and morbidities are fewer than open or conventional approach
224272198|NCT00857779|BIOLOGICAL|subcutaneous immunotherapy|7 injections
224272199|NCT03312894|DRUG|TAK-653|TAK-653 tablets
224272200|NCT03312894|DRUG|Placebo|Placebo-matching tablets
224272201|NCT03336788|DEVICE|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
224272202|NCT03336788|DEVICE|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
224272203|NCT06074328|DEVICE|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset|Virtual Reality Neurocognitive Exercises administered through an Oculus Headset as a form of neurorehabilitation in patients who suffer a traumatic brain injury.
224272204|NCT05123885|OTHER|Study on Data|Study on Data
224272205|NCT02096484|BEHAVIORAL|Group Metacognitive Therapy|
224272206|NCT02096484|BEHAVIORAL|Mindfulness Meditation Therapy|
224272207|NCT05324891|DRUG|Dexmedetomidine|Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
224272208|NCT05324891|DRUG|Fentanyl|Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
223893587|NCT03476460|DRUG|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
223893588|NCT03476460|DRUG|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
224272209|NCT00625339|DRUG|Entecavir|entecavir 0.5 mg QD
224272210|NCT00625339|DRUG|Lamivudine|lamivudine 100 mg QD
224272211|NCT05078827|DRUG|Test Product (A): Fluorouracil Cream, 5% topical cream|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
224272212|NCT05078827|DRUG|Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
224272213|NCT05078827|DRUG|Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India|Apply cream twice daily in an amount sufficient to cover the lesions. Fluorouracil should be applied preferably with a nonmetal applicator or suitable glove. If Fluorouracil is applied with the fingers, the hands should be washed immediately afterward.
224272214|NCT02330016|DEVICE|Voluma XC|Voluma XC
224272215|NCT00021541|DRUG|tipifarnib|Given orally, 200 mg/m\^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
224272216|NCT00021541|OTHER|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
224272217|NCT01927016|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
224272218|NCT05440305|PROCEDURE|surgery type/exstirpation/debulking|Evaluation of benefit according to surgery
224272219|NCT05471687|DEVICE|dual-energy dual-layer spectral scanner|Realization of dual-energy dual-layer spectral scanner with stress protocol
224272220|NCT05471687|DRUG|Stress protocol with adenosin during dual-energy dual-layer spectral scanner|Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
224272221|NCT05183282|DEVICE|Tarsus Patch|The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
224272222|NCT02570854|BIOLOGICAL|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
224272223|NCT02570854|DRUG|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
224272224|NCT06127186|DIAGNOSTIC_TEST|Swab test for viral antigens|No intervention except for a routine examination and viral testing is planned.
224272225|NCT01173536|DRUG|GDC-0449|Oral repeating dose
224272226|NCT01173536|DRUG|moxifloxacin|Oral single dose
224272227|NCT01173536|DRUG|placebo|Oral repeating dose
224272228|NCT00826241|DRUG|Temozolomide|Starting dose 125 mg/m\^2 daily by mouth on days 1-7 \& 15-21 of a 28 day cycle.
224272229|NCT00826241|DRUG|Lapatinib|Starting dose 1250 mg daily by mouth.
224272230|NCT01145157|DEVICE|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
224272231|NCT01145157|DEVICE|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
224272232|NCT01145157|DEVICE|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
224272233|NCT06202534|OTHER||radiotherapy
224272234|NCT05772858|OTHER|Training on CIFFTA competencies using Family Therapy Training and Implementation Platform (FTTIP)|An Innovative Web-based Tool to train mental health therapists in family therapy competencies with animated families and provided recorded video responses to receive feedback from trainers.
224272235|NCT05772858|OTHER|Training on CIFFTA competencies using Training and Coaching as Usual (TCAU).|Therapists receive training using the traditional face to-face training method for 2.5 days followed by coaching.
224272236|NCT05772858|OTHER|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA).|CIFFTA has three major components: Family Therapy, Individual Therapy, and Psycho-educational Modules, delivered over 16 weeks in a two session (60 minutes each) per week format. One session will typically be a family session which may include Family Therapy or Psychoeducational modules designed for the family or parents alone. The other session is typically with the adolescent alone which may include individual treatment or Psycho-educational modules designed for the adolescent.
224272237|NCT05772858|OTHER|Agency Readiness Consultation- Family Therapy Training and Implementation Platform (FTTIP)|The FTTIP agency readiness work begins with a pre-recorded FTTIP introduction webinar presented separately to each agency which presents overall goals of the project and the different FTTIP components, and key decisions agencies often make when seeking to sustain a new EBT.
224272238|NCT05772858|OTHER|Agency Engagement and Orientation as Usual|Work with the agency leaders will consist of the traditional engagement of the leadership so that they agree to collaboration with the study team, with the training team, and with the study procedures.
224272239|NCT04409379|DIAGNOSTIC_TEST|Relative telomere length|Relative telomere length in peripheral blood cell
224272240|NCT05940259|DRUG|[68Ga]P3|68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
224272241|NCT01985724|DRUG|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
224272242|NCT01985724|DRUG|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
224272243|NCT01985724|DRUG|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
224272244|NCT01985724|DRUG|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
224272245|NCT01985724|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
224272246|NCT05008120|OTHER|No intervention|No intervention
224272247|NCT02589067|DRUG|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
224272248|NCT02589067|DRUG|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
224272249|NCT01675596|DEVICE|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
224272250|NCT02313545|DRUG|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
224272251|NCT01539239|DEVICE|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
224272252|NCT01539239|PROCEDURE|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
224272253|NCT05597631|DEVICE|G-IVF PLUS|Experimental
224272254|NCT00987480|DRUG|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
224272255|NCT00987480|DEVICE|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
224272256|NCT03201003|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
224272257|NCT03201003|OTHER|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
224272258|NCT00843089|OTHER|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
224272259|NCT01715077|DRUG|Ipilimumab at 3 mg/kg dose|
224272260|NCT00834613|DRUG|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
224272261|NCT00834613|DRUG|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
224272262|NCT04112199|DRUG|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
224272263|NCT00748137|DEVICE|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
224272264|NCT00748137|OTHER|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
224272265|NCT01368354|BEHAVIORAL|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
224272266|NCT00079287|DRUG|carboplatin|
224272267|NCT00079287|DRUG|docetaxel|
224272268|NCT00079287|DRUG|gemcitabine hydrochloride|
224272269|NCT00079287|DRUG|paclitaxel|
224272270|NCT00079287|DRUG|vinorelbine tartrate|
224272271|NCT01693809|DRUG|Caffeine|
224272272|NCT02293928|PROCEDURE|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
224272273|NCT06375915|RADIATION|radioembolization with Y-90|Radioembolization with Y-90 will be performed in nominal day 0
224272274|NCT06375915|DRUG|Durvalumab|Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
224272275|NCT06375915|DRUG|Cisplatin|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
224272276|NCT06375915|DRUG|Gemcitabine|Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
224272277|NCT02379533|OTHER|Aerobic exercise|
224272278|NCT01751087|OTHER|Mifepristone|oral mifepristone 200 mg on Day 1.
224272279|NCT01751087|DRUG|misoprostol|buccal misoprostol 400 mcg on Day 2
224272280|NCT01751087|DEVICE|Osmotic dilators|osmotic dilators on Day 1
224272281|NCT01751087|OTHER|placebo|placebo for mifepristone, on day 1
224272282|NCT01751087|OTHER|placebo|placebo for misoprostol, on day 2
224272283|NCT04872231|DRUG|Voriconazole Inhalation Powder|"PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID."
224272284|NCT04872231|DRUG|Placebo|"PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses."
224272285|NCT00681486|DRUG|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
224272286|NCT00681486|DRUG|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
224272287|NCT04682327|OTHER|Response to anti-PD-1/PD-L1|Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
224272288|NCT04682327|OTHER|Non-response to anti-PD-1/PD-L1|Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
224272289|NCT04042415|OTHER|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
224272290|NCT04042415|OTHER|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
224272291|NCT05628311|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
224272292|NCT05628311|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
224272293|NCT00697619|DRUG|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
224272294|NCT03711448|DRUG|prednisone treatment|tapering prednisone regimen
224272295|NCT03711448|DRUG|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
224272296|NCT03711448|OTHER|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
223893589|NCT02766231|DEVICE|Physica CR|Cruciate retaining total knee replacement
223893590|NCT02766231|DEVICE|Physica PS|Posterior Stabilized total knee replacement
223893591|NCT06626672|BEHAVIORAL|Digital Health Intervention|Access to a digital platform including weekly workout videos, live workouts, recipes, study summaries, and a consultation hour.
223893592|NCT05059041|DEVICE|Dilated Refraction|The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.
224272297|NCT03711448|BIOLOGICAL|Blood samples|Additional blood samples for immunomonitoring
224272298|NCT00471510|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
224272299|NCT05462548|DRUG|Luspatercept Injectable Product|1-1.25mg/kg every 3 weeks subcutaneous injection
224272300|NCT01664169|OTHER|laboratory biomarker analysis|
224272301|NCT03093025|DRUG|TS-121 10 mg|Orally taken once daily
224272302|NCT03093025|DRUG|TS-121 50 mg|Orally taken once daily
224272303|NCT03093025|DRUG|Placebo|Orally taken once daily
224272304|NCT01869556|DRUG|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
224272305|NCT01869556|DRUG|Ergot|Ergot 0.25mg IV
224272306|NCT01869556|DRUG|Carboprost|Carboprost 0.25mg IM
224272307|NCT01591915|OTHER|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
224272308|NCT05191511|RADIATION|Far- infrared|safety of far- infrared
224272309|NCT02559219|OTHER|Questionniares|
224272310|NCT03017352|DRUG|Exenatide|
224272311|NCT03017352|DRUG|Placebos|
224272312|NCT05735028|DRUG|Centipeda minima+PD-1/PD-L1 inhibitor|Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
224272313|NCT05735028|DRUG|PD-1/PD-L1 inhibitor|PD-1/PD-L1 inhibitor
224272314|NCT04997720|OTHER|Training|"Each course will consist of:~1. Initial evaluation~2. Theoretical tutorial~3. Training with exercises of increasing complexity.~4. Final evaluation."
224272315|NCT02005562|DRUG|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
224272316|NCT02005562|DRUG|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
224272317|NCT02005562|DRUG|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
224272318|NCT02005562|DRUG|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
224272319|NCT02005562|DRUG|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
224272320|NCT03241186|DRUG|Ipilimumab|1mg/kg
224272321|NCT03241186|DRUG|Nivolumab|3mg/kg
224272322|NCT03241186|DRUG|Nivolumab|480mg
224272323|NCT03091868|DRUG|Placebo oral capsule|Matching placebo capsules. Oral administration.
224272324|NCT03091868|DRUG|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
224272325|NCT03091868|DRUG|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
224272326|NCT03091868|DRUG|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
224272327|NCT03091868|DRUG|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
224272328|NCT03274037|DIAGNOSTIC_TEST|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
224272329|NCT06433193|DEVICE|PAK HD Sorbent Therapy|"Study Period 1:~Subjects will receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, one 4h CHD therapy will be performed at a dialysate flow rate (QD) of 300mL/min, identical to the dialysate flow rate of the PAK HD sorbent therapy. Blood and dialysate samples will be collected during treatment and sent for analysis, for comparison with PAK HD sorbent treatment.~Study Period 2:~Subjects will again receive their normal prescribed 4h CHD treatments Monday or Tuesday. On Wednesday or Thursday, a 2h PAK HD +/- 2h CHD therapy will be performed. Blood and dialysate samples will again be collected during treatment and sent for analysis, for comparison with the CHD therapy of the first period. After completion of study period 2 (PAK HD +/- CHD), subjects will be observed for a minimum duration of 1 h in the hospital after which they may go home if the post-dialysis period was uneventful."
224272330|NCT04068818|DEVICE|ANTERION|Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
224272331|NCT04238962|DRUG|Semaglutide (administered by DV3396 pen-injector)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
224272332|NCT04238962|DRUG|Semaglutide (administered by PDS290 pen-injector)|Increasing doses of semaglutide given sc in the stomach for 7 weeks
223893593|NCT05059041|DEVICE|Non-Dilated Refraction|The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.
223893594|NCT06249191|PROCEDURE|Biopsy|Undergo tumor biopsy
223893595|NCT06249191|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224272333|NCT04092595|DRUG|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
224272334|NCT04092595|DRUG|Rosuvastatin|10 mg oral tablet
224272335|NCT01528293|DEVICE|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
224272336|NCT01528293|OTHER|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
224272337|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
224272338|NCT00288704|DRUG|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
224272339|NCT00288704|DRUG|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
224272340|NCT01579006|DRUG|Tocilizumab|
224272341|NCT01937806|DRUG|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
224272342|NCT01937806|DRUG|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
224272343|NCT06259968|DEVICE|Neuromuscular electrical stimulation|Patients in the neuromuscular electrical stimulation group will receive neuromuscular electrical stimulation without the concomitant execution of voluntary quadriceps contraction
224272344|NCT06259968|DEVICE|Neuromuscular electrical stimulation with superimposed voluntary contraction|Patients will be instructed to perform maximum voluntary contractions superimposed on neuromuscular electrical stimulation
224272345|NCT00324896|DRUG|eszopiclone|eszopiclone
224272346|NCT00324896|OTHER|placebo|matching placebo administered at night
224272347|NCT01960608|OTHER|24_hours_urine_sodium|
224272348|NCT00799708|DRUG|Comparator: placebo|placebo capsule once daily for 7 days.
224272349|NCT00799708|DRUG|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
224272350|NCT02853916|DIETARY_SUPPLEMENT|500 mg InSea2®|
223517896|NCT03796221|BEHAVIORAL|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
223517897|NCT01674361|DRUG|Bitopertin|Bitopertin once daily orally.
223517898|NCT01674361|DRUG|Placebo|Placebo matched to bitopertin once daily orally.
223517899|NCT01674361|DRUG|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
223517900|NCT06091956|DRUG|Deucravacitinib|6 milligram (mg) orally administrated, twice daily
223517901|NCT05944393|DRUG|Ropivacaine 0.2% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.5% ropivacaine
223517902|NCT05944393|DRUG|Normal saline 0.9% Injectable Solution|Ultrasound-guided Erector Spine Plane block with 10 mL 0.9% normal saline
223517903|NCT02608086|BEHAVIORAL|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
223893596|NCT06249191|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223893597|NCT06249191|PROCEDURE|Computed Tomography|Undergo CT scan
223893598|NCT06249191|DRUG|Cyclophosphamide|Given IV
223893599|NCT06249191|DRUG|Doxorubicin|Given IV
224272351|NCT02853916|DIETARY_SUPPLEMENT|250 mg InSea2®|
224272352|NCT02853916|DIETARY_SUPPLEMENT|Placebo|
224272353|NCT04346563|OTHER|Kinesio tape, functional correction technique|According to Kinesio Taping, functional correction technique could use for correcting shoulder, scapular alignment and decrease pain.
224272354|NCT04346563|OTHER|Elastic band strengthening shoulder exercise|"The exercise in which both groups will receive Introduction of exercise with rubber bands (Elastic band) It is a home exercise (Home base exercise program) for patients to do with appropriate resistance. Which can be done at least 10 times and not more than 20 times continuously,will be asked to do all 3 positions.~1\) Shoulder external rotation in shoulder abduction 90 degrees 2) Shoulder horizontal abduction in shoulder abduction 90 degrees 3) Seated bend row, which will be done 15 times, each hold for 10 seconds, do 3 sets, each set rest 2 minutes, 2 times a day ( Morning-evening) consecutively for 1 week"
224272355|NCT03343639|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
224272356|NCT03343639|DRUG|Matching Placebo Tablets|Placebo Tablets
224272357|NCT00859040|DRUG|SOM230C|Injection in the buttocks every 28 days
224272358|NCT03264716|DEVICE|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
224272359|NCT04212819|OTHER|Before Erythrocyte Suspension (ES)|ES transfusion needs of the patients were determined according to clinical signs and symptoms. Vital signs were closely monitored and recorded before, during and after transfusion. Infusion was performed slowly for the first 15 minutes in terms of allergic reaction, and then the transfusion rate was adjusted according to the patient's clinic.
224272360|NCT04212819|OTHER|After Erythrocyte Suspension (ES)|Venous blood samples were obtained from patients who needed ES transfusion before transfusion. Control venous blood samples were obtained from the patients who did not develop any complications for 24 hours after starting of the transfusion and became hemodynamically stable.
224272361|NCT05253430|PROCEDURE|Lymphadenectomy type|D1 vs D2 lymph node dissection
224272362|NCT05546242|DRUG|Cabotegravir/Rilpivirine|injectable long-acting cabotegravir 600mg + long-acting rilpivirine 900mg administered every 2 months
224272363|NCT05546242|DRUG|Antiretroviral|Oral antiretroviral therapy in the form of 2NRTIs + dolutegravir 50mg administered daily
224272364|NCT04838379|DRUG|Dexmedetomidine|Ninety patients were randomized to receive ultrasound-guided RSB\&tap block After the induction of anesthesia and patient stabilization, the abdomen was sterilized and draped. Then, under complete aseptic conditions, ultrasound-guided Bilateral Rectus Sheath Block \& tap block was performed
224272365|NCT05592483|OTHER|None (Observational Study)|Not Applicable since observational study
224272366|NCT06459960|GENETIC|Hydrotherapy|Heated pool (32°C); Convention rehabilitation + Hydrotherapy
224272367|NCT06459960|GENETIC|Convention|Convention rehabilitation only
224272368|NCT06031337|DIAGNOSTIC_TEST|ELISA|quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
224272369|NCT04386213|DEVICE|coronary artery in-stent restenosis|treat the petients with coronary artery in-stent restenosis
224272370|NCT01713166|DRUG|plasmalyte solution|plasmalyte solution
224272371|NCT01713166|DRUG|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
224272372|NCT04262739|DRUG|NYH817G|Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
224272373|NCT04262739|DRUG|NYH100P|Subject will orally administer NYH100P (100 mg) during the cycles(21 days)
224272374|NCT04262739|DRUG|NYH817G and NYH100P|Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
223517904|NCT02608086|BEHAVIORAL|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
224272375|NCT02077881|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
224272376|NCT02077881|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
224272377|NCT02077881|DRUG|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
224272378|NCT04566549|COMBINATION_PRODUCT|Test group Probiotic Shampoo|Probiotic Shampoo
224272379|NCT04566549|COMBINATION_PRODUCT|Placebo group|Shampoo base
224272380|NCT02310841|DEVICE|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
224272381|NCT05766956|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
224272382|NCT05766956|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
224272383|NCT05385900|DRUG|Penpulimab combination with anlotinib and chemotherapy|Penpulimab: fixed dose of 200 mg, administered on day 1 of each cycle, repeated every 3 weeks; Anlotinib: 12 mg, administered on days 1-14 of each cycle, orally once a day, about half an hour before breakfast (the time of daily administration should be the same as possible), with warm water, every 3 weeks Repeat 1 time
224272384|NCT05880888|BIOLOGICAL|Renuva|Renuva® (MTF Biologics) is an injectable decellularized allograft adipose matrix (AAM) used to increase volume in adipose tissue.
224272385|NCT02874950|OTHER|office exercise training|The exercise group, did 6 months office exercise training.
224272386|NCT02874950|OTHER|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
224272387|NCT02874950|OTHER|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
224272388|NCT02874950|OTHER|Control|Control group did not do any exercise and did not follow any ergonomic modification.
223517905|NCT00896844|BEHAVIORAL|emotional disclosure|writing about emotional events from the past
223517906|NCT00896844|BEHAVIORAL|placebo writing|writing about how they spent their time the previous day
224272389|NCT01112891|DRUG|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
224272390|NCT01112891|DRUG|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
224272391|NCT01112891|DRUG|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
224272392|NCT02153723|DRUG|Glatiramer Acetate|
224272393|NCT02697617|DRUG|Pioglitazone|Pioglitazone
224272394|NCT02697617|DRUG|Placebo|Placebo
224272395|NCT01149434|DRUG|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
224272396|NCT01149434|DRUG|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
224272397|NCT04580186|PROCEDURE|bladder exstrophy repair|primary complete bladder exstrophy repair
224272398|NCT01058122|PROCEDURE|Collection of adverse drug events|
224272399|NCT06535763|OTHER|professional caregiver|"Care professionals will be questioned using a self-administered Quality of Life at Work scale, as well as a second scale (before and after training, with one test per day for 3 consecutive working days) asking about the number of work situations involving behavioral disorders in the residents under their care, and how they use the HAPNeSS method to deal with these situations.~The effects of the HAPNeSS method on caregivers' professional practices (actions taken, performance of tasks, relations with residents, etc.) and their feelings on the subject, will be collected in two semi-structured interviews (with half the participants selected at random) conducted before and after the training course by the research team's occupational psychologist."
224272400|NCT02460835|RADIATION|Adaptive Radiation Therapy|
224272401|NCT03141216|DEVICE|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
224272402|NCT03141216|DEVICE|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
224272403|NCT06222658|DEVICE|pharmaco-mechanichal thrombectomy|pharmaco-mechanichal thrombectomy in acute limb ischemia
224272404|NCT01157234|DRUG|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of \< 140/ 90.
224272405|NCT01157234|DRUG|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure \< 140/90.
224272406|NCT03033134|DEVICE|BSJ003W|BSJ003W implant
224272407|NCT02531490|DRUG|Labetalol|
224272408|NCT02531490|DRUG|Nifedipine|
224272409|NCT02531490|DRUG|Methyldopa|
224272410|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
224272411|NCT00999284|DRUG|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
224272412|NCT00999284|DRUG|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
224272413|NCT01876953|DRUG|cytarabine|Given IV
224272414|NCT01876953|DRUG|idarubicin|Given IV
224272415|NCT01876953|DRUG|dasatinib|Given PO
224272416|NCT01876953|OTHER|laboratory biomarker analysis|Correlative studies
223517907|NCT02191995|BEHAVIORAL|yoga|
224272417|NCT00099580|DRUG|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
224272418|NCT00099580|DRUG|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
224272419|NCT04559750|BEHAVIORAL|Internet delivered behavior therapy (I-BT)|10 weeks of I-BT
224272420|NCT06300827|OTHER|Structured digital-based training|The eight week intervention will be delivered in 15 different sessions, each session lasting 40 minutes. It is expected that the seventh week session will last approximately 150 minutes. The control group is expected to continue with their daily lives.
223517908|NCT01586897|DEVICE|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
223517909|NCT01586897|OTHER|Usual Care|
223517910|NCT04710303|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|The hAd5-S-Fusion+N-ETSD vaccine is a hAd5 \[E1-, E2b-, E3-\] vector-based targeting vaccine encoding the SARS-CoV-2 S and N proteins. The hAd5-S-Fusion+N-ETSD vaccine is designed to induce both humoral and cellular responses even in individuals with pre-existing adenoviral immunity.
224272421|NCT02073006|DIETARY_SUPPLEMENT|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
224272422|NCT02877017|BEHAVIORAL|Family safety reporting intervention|family safety reporting intervention for families and providers
224272423|NCT05843890|BEHAVIORAL|Structured and tailored PainGuide|"Participants will receive specific instruction to complete one module a week over the first 4 weeks. Participants will then receive tailored messaging using scores from the assessments completed during T1(baseline visit) from the PROMIS 29+2.~The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks.~The NPP Participants will be asked to complete surveys for 52 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
224272424|NCT05843890|BEHAVIORAL|Standard PainGuide|"Participants in the control group will not receive any messaging once enrolled. The initial group of participants (prior to AME00158411) will complete surveys for 24 weeks.~The NPP Participants will be asked to complete surveys for 52 weeks.~All participants will also be registered with a Fitbit device that is linked to the PainGuide to capture movement data (daily step counts)."
224272425|NCT06059872|OTHER|High Intensity Interval Training (HIIT)|HIIT consists of three weekly 25-60 minute cycling sessions for 12 weeks at the Atlanta VA, administered by a trained exercise physiologist, for a total of 36 HIIT sessions.
224272426|NCT06321276|DEVICE|extracorporeal shockwave therapy|Extracorporeal shock wave therapy (ESWT) is a non-invasive procedure that uses single-pulse acoustic waves generated outside the body and focused on a specific area of the body. Shock waves promote axonal regeneration of peripheral nerves through various molecular reactions. Although the anti-nociceptive mechanisms of ESWT have not yet been elucidated, ESWT may produce analgesia through biochemical changes in the nerve fiber itself and reduce inflammation of soft tissues.
224272427|NCT06377683|DRUG|177Lu-Dansyl-PSMA radioligand therapy|Radioligand therapy using 177Lu-Dansyl-PSMA 50mCi (1.85GBq) will performed 6-weekly. A maximum of 2 cycles will be administered, and subsequent cohorts receive an incremental 50% dose increase until dose-limiting toxicity (DLT) was observed.
224272428|NCT06221670|DRUG|Toripalimab|This is a prospective, open, single-center, single-arm phase II clinical study with no driver mutations identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Toripalimab therapy in completely resected stage IA2-IB non-squamous NSCLC with high-risk factors.
224272429|NCT06559202|DIAGNOSTIC_TEST|chest and abdominoplevic CT|chest and abdominopelvic computed tomography on the same day for health screening purposes
224272430|NCT03690063|OTHER|Follow up|Follow up of treatment, behavior, co-morbidity
224272431|NCT01635582|OTHER|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
224272432|NCT01635582|OTHER|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
224272433|NCT02075645|OTHER|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
224272434|NCT04175158|BIOLOGICAL|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
224272435|NCT04175158|BIOLOGICAL|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is \> 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
224272436|NCT06209034|OTHER|Optic nerve sheath measurement|ONSD was measured bilaterally 3 mm posterior to the papilla. Transverse measurements were made for each optic nerve.
224272437|NCT02930876|BEHAVIORAL|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
224272438|NCT00504634|DRUG|Bortezomib|1 mg/m\^2 IV On Days 1, 4, 8, and 11.
224272439|NCT00876265|DEVICE|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
224272440|NCT00876265|DEVICE|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
224272441|NCT04517526|DRUG|pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT|pemetrexed (500 mg/m2/d1) + cisplatin/carboplatin (20-25 mg/m2 × 3 days/AUC 5) + bevacizumab (7.5 mg/kg) + durvalumab (10 mg/kg) every 3 weeks for 4 to 6 cycles after informed consent, followed by bevacizumab and/or durvalumab anti-maintenance therapy until the emergence of what the investigator considers to be treatment-related toxicity or disease progression in the patient, followed by stereotactic radiotherapy to appropriate oligometastatic or oligoprogressive sites.
224272442|NCT06010823|DEVICE|PlaXtreme|"A robotic device capable of applying motor error enhancement forces during upper limb practice in a virtual environment. The forces stimulate the body's instinctive adaptive response, which does not require the use of cognition to correct the patients hand movement.~The device consists of a controller and specifically designed games projected on a screen requiring 3D active reaching movements. During the treatment sessions, the device will be operated by a trained occupational therapist."
224272443|NCT02458391|OTHER|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
224272444|NCT03160079|DRUG|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
224272445|NCT03160079|DRUG|pembrolizumab|"Cycle 1 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembrolizumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
224272446|NCT03490916|DRUG|Acetazolamide|Administration of Acetazolamide
224272447|NCT03490916|DRUG|Placebo|Administration of Placebo
224272448|NCT04022824|OTHER|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
224272449|NCT04022824|OTHER|Non-OSA|Patients without OSA (apnea hypopnea index \<15) based on sleep study
224272450|NCT05690815|DRUG|Descovy|Descovy is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex. In this study, patients at risk of acquiring HIV will be screened for HIV and those that are HIV-negative will be initiated on PrEP within 24 hours.
224272451|NCT05897385|DRUG|Lignocaine|Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
224272452|NCT05897385|DRUG|Normal Saline|Intraperitoneal 20ml of 0.9% normal saline
224272453|NCT05633186|BEHAVIORAL|Moodbuster Life|All participants get access to the Moodbuster Life intervention. Moodbuster Life is an online self-help intervention that contains 5 web-based modules focusing on lifestyle and coping: psycho-education, behavioral activation, physical activity, problem-solving, and worrying. All participants start with module 1, psycho-education. Next, participants can choose what module they wish to continue with. All modules take about 45 minutes to complete and contain text, exercises, video clips and preparing the home-work assignments. Executing the home-work assignments may take 20 minutes each week.
224272454|NCT05633186|BEHAVIORAL|Mobile application|The participants randomized to receive this component will receive access to a mobile application. The aim of this app is two-folded, (1) used for diary ratings, (2) sending out personalized automated messages. First, the participants will rate their mood, sleep and related factors on a daily basis. The participants are prompted to rate the diary ratings three times a day (morning, afternoon, evening). Moreover, the application graphically pictures progression over time. Second, the application will send personalized automated messages. The content of the messages is informative, affirmative or encouraging. The investigators will use reinforcement learning (RL) to find so-called policies that show best long-term engagement and most sustained improvement of participants' mood. To drive choices, the investigators will use the data mentioned in the advising for the modules as well as behavioral data (mood ratings), data across all users is exploited.
224272455|NCT05633186|BEHAVIORAL|Guidance by a coach|A coach will provide support once per week at a scheduled time to participants who are allocated to receive support. The coaches are psychologists who are not part of the research team. The support will be provided via the Moodbuster Life messaging system and is focused on helping the participant work through the modules, showing empathy and motivating the participants to continue with the modules. The coaching is not aimed at developing a patient-therapist relationship.
224272456|NCT05633186|BEHAVIORAL|Motivational Content|Participants who are randomized to this component, receive access to extra content that is based on the principles of motivational interviewing. This includes an extended first module that contains psychoeducation on the importance of motivations and on how persons can motivate themselves to engage with the interventions. Participants are asked about their life goals (long term) and intervention goals (short time) and are guided in how they should formulate these goals to increase the chance of success. Moreover, in each of the 4 modules a short exercise aimed at increasing motivation is included.
224272457|NCT06677619|DEVICE|intrusion by reverse curve wire in cervical position of twin slot bracket|intrusion of anterior teeth by putting reverse curve wire in incisal slot of twin slot bracket
224272458|NCT05066568|DEVICE|Active Tracranial Direct Current Stimulation|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
224272459|NCT05066568|OTHER|Hypnotic analgesia suggestion|The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
224272460|NCT05066568|BEHAVIORAL|Rest|The patient is asked to remain seated still for 20 minutes.
224272461|NCT05066568|OTHER|Active tDCS + Hypnotic analgesia suggestion|"Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Intervention time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.~The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance."
224272462|NCT05066568|OTHER|Sham tDCS + Hypnotic analgesia suggestion|Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 0mA Intervention time: 20 min The current is turned off after 30 seconds. The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
224272463|NCT06033313|BEHAVIORAL|Negatively Framed text messages|Negatively Framed text messages delivered to participants three times per week for 8 weeks.
224272464|NCT06033313|BEHAVIORAL|Positively Framed text messages|Positively Framed text messages delivered to participants three times per week for 8 weeks.
224272465|NCT03433703|DRUG|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
223517911|NCT00801255|DRUG|RO5024048|500mg po bid/100mg po q8h for 7 days
223517912|NCT00801255|DRUG|danoprevir|500mg po bid/100mg po q8h for 14 days
223517913|NCT00801255|DRUG|danoprevir|1000mg po bid/100mg po q8h for 14 days\\n500mg po bid/200mg po q8h for 14 days
223517914|NCT00801255|DRUG|danoprevir|1000mg po bid/200mg po q8h for 14 days
223517915|NCT00801255|DRUG|danoprevir|1000mg/600mg po twice daily for 14 days
223517916|NCT00801255|DRUG|danoprevir|1000mg/900mg po twice daily for 14 days
223517917|NCT03154567|DRUG|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
223517918|NCT03813121|DRUG|midazolam intravenous infusion|Participants will receive a single drug infusion
223517919|NCT03813121|DRUG|placebo intravenous infusion|Participants will receive a single placebo infusion
223517920|NCT03813121|DRUG|ketamine intravenous infusion|Participants will receive a single drug infusion
224272466|NCT02997878|BIOLOGICAL|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human umbilical cord
224272467|NCT03782493|BEHAVIORAL|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
224272468|NCT04195828|DRUG|Camrelizumab|Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.
224272469|NCT04195828|DRUG|Apatinib Mesylate|Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。
224272470|NCT04195828|DRUG|nab-paclitaxel|nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.
224272471|NCT04195828|DRUG|S1|S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time
224272472|NCT00000136|DRUG|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
224272473|NCT00000136|DRUG|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
224272474|NCT04851067|OTHER|Dry Needling and Therapeutic Exercises (DNTEx)|Already included in arm/group descriptions.
224272475|NCT04851067|OTHER|Manual Therapy and Therapeutic Exercises (MTTEx)|Already included in arm/group descriptions.
224272476|NCT04435249|OTHER|BPF-001|Expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold
224272477|NCT05139238|DRUG|Labetalol|Intravenous labetalol, a short acting ant-hypertensive
223517921|NCT06307366|OTHER|No intervention will be used|This is a qualitative study, no intervention will be used
224272478|NCT05139238|DRUG|Nifedipine|Oral nifedipine, a short acting ant-hypertensive
224272479|NCT00620958|BEHAVIORAL|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
224272480|NCT00620958|BEHAVIORAL|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
224272481|NCT00620958|BEHAVIORAL|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
224272482|NCT02786953|BEHAVIORAL|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
224272483|NCT01897077|DRUG|Peanut Dissolving Film|
224272484|NCT02241798|OTHER|oxygen|O2 by nasal prongs
224272485|NCT01745068|OTHER|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
224272486|NCT05746377|DRUG|Metoclopramide 10mg|IV Metoclopramide
224272487|NCT05746377|DRUG|Saline|Placebo
223517922|NCT06131112|DIAGNOSTIC_TEST|64Cu-DOTATATE PET/CT scan|Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
223517923|NCT00153790|DRUG|PhosphoLean|
223517924|NCT00196612|DRUG|emtricitabine, FTC (drug)|
223517925|NCT00196612|DRUG|didanosine, ddI (drug)|
223517926|NCT00196612|DRUG|efavirenz (drug)|
223704020|NCT03792191|PROCEDURE|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient's skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
224272488|NCT06641037|DRUG|LY3866288|Administered orally
224272489|NCT06560866|BEHAVIORAL|Just Care for Families|Just Care for Families is a behavioral intervention to address the needs of families involved in or at-risk for involvement with the child welfare system. Just Care involves treatment components, supported by ongoing purposeful engagement: (1) Substance use treatment including contingency management and positive reinforcement, day planning, healthy environments and peer choices, and refusal skills; (2) Mental health treatment including cognitive behavioral therapy, developing healthy coping skills, emotion regulation skills, exposure therapy, and referral for medication management; (3) Parent management training including parenting skills, nurturing and attachment, reinforcement, emotion regulation, supervision, structure, non-harsh discipline, and nutrition; (4) Community building including indigenous and external social supports; (5) Systems navigation; and (6) provision of assistance with basic needs including assistance with housing and employment.
224272490|NCT05597228|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
223893600|NCT06249191|PROCEDURE|Echocardiography|Undergo echocardiography
224272491|NCT01264523|OTHER|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
224272492|NCT01852721|BEHAVIORAL|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
224272493|NCT01852721|BEHAVIORAL|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
224272494|NCT02671630|OTHER|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
224272495|NCT04425031|DRUG|Low oxygenation target|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
224272496|NCT04425031|DRUG|High oxygenation target|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
224272497|NCT01859637|BIOLOGICAL|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
224272498|NCT00820885|DRUG|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
224272499|NCT00820885|DRUG|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
224272500|NCT00820885|DRUG|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
224272501|NCT01698554|DRUG|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
223517927|NCT01215331|DRUG|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
223704021|NCT03792191|PROCEDURE|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
223704022|NCT03792191|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
223704023|NCT03792191|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
223893601|NCT06249191|DRUG|Etoposide|Given IV
223893602|NCT06249191|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224272502|NCT01698554|DRUG|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
224272503|NCT01698554|DRUG|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
224272504|NCT01698554|DRUG|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
224272505|NCT03453554|OTHER|Digital Notebook app|Training in use of Digital Memory Notebook app
224272506|NCT03453554|OTHER|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
224272507|NCT02694653|DRUG|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
224272508|NCT02694653|DRUG|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
224272509|NCT02042547|OTHER|Tissue samples from the right atrium|
224272510|NCT02042547|OTHER|Blood samples|
224272511|NCT03715751|OTHER|ASV|Adaptive Support Ventilation
224272512|NCT03715751|OTHER|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
224272513|NCT06626854|DEVICE|RF-PNS|Noninvasive peripheral nerve stimulator using interferential multi source radio frequency
224272514|NCT00004105|DRUG|estramustine phosphate sodium|
224272515|NCT00004105|DRUG|paclitaxel|
224272516|NCT00004105|DRUG|vinorelbine ditartrate|
224272517|NCT03026153|BEHAVIORAL|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
224272518|NCT03026153|BEHAVIORAL|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
223517928|NCT01215331|DRUG|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
223517929|NCT01448304|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
223517930|NCT04652297|DRUG|HS-10356|Single dose of HS-10356
223517931|NCT04652297|DRUG|Placebo|Single dose of Placebo
223517932|NCT04652297|DRUG|HS-10356|Multiple doses of HS-10356
223517933|NCT04652297|DRUG|Placebo|Multiple doses of Placebo
224272519|NCT03192397|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
224272520|NCT03192397|DRUG|Cyclophosphamide|Given IV
224272521|NCT03192397|DRUG|Fludarabine Phosphate|Given IV
224272522|NCT03192397|OTHER|Laboratory Biomarker Analysis|Correlative studies
224272523|NCT03192397|DRUG|Melphalan Hydrochloride|Given IV
224272524|NCT03192397|DRUG|Mycophenolate Mofetil|Given IV
224272525|NCT03192397|DRUG|Sirolimus|Given IV and PO
224272526|NCT03192397|RADIATION|Total-Body Irradiation|Undergo TBI
224272527|NCT06159647|BEHAVIORAL|Mouth cancer warning|Participants will view messages about the risk of mouth cancer from alcohol consumption.
224272528|NCT06159647|BEHAVIORAL|Throat cancer warning|Participants will view messages about the risk of throat cancer from alcohol consumption.
224272529|NCT06159647|BEHAVIORAL|Voice box (larynx) warning|Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
224272530|NCT06159647|BEHAVIORAL|Esophagus cancer warning|Participants will view messages about the risk of esophagus cancer from alcohol consumption.
224272531|NCT06159647|BEHAVIORAL|Liver cancer warning|Participants will view messages about the risk of liver cancer from alcohol consumption.
224272532|NCT06159647|BEHAVIORAL|Colon and rectum cancer warning|Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.
224272533|NCT06159647|BEHAVIORAL|Breast cancer|Participants will view messages about the risk of breast cancer from alcohol consumption.
224272534|NCT06159647|BEHAVIORAL|Cancer (generic, not site-specific)|Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
224272535|NCT06159647|BEHAVIORAL|Addiction and neurological changes|Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
224272536|NCT06159647|BEHAVIORAL|Hypertension|Participants will view messages about the risk of hypertension from alcohol consumption.
224272537|NCT06159647|BEHAVIORAL|Liver damage|Participants will view messages about the risk of liver damage from alcohol consumption.
224272538|NCT06159647|BEHAVIORAL|Harm to fetus|Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
224272539|NCT06159647|BEHAVIORAL|Dementia|Participants will view messages about the risk of dementia from alcohol consumption.
224272540|NCT06159647|BEHAVIORAL|Impaired sleep|Participants will view messages about the risk of impaired sleep from alcohol consumption.
224272541|NCT06159647|BEHAVIORAL|Drinking guidelines|Participants will view messages about guidelines for alcohol consumption.
224272542|NCT06159647|BEHAVIORAL|Control|Participants will view neutral messages unrelated to the harms of alcohol consumption.
224272543|NCT06159647|BEHAVIORAL|Road injuries|Participants will view messages about the risk of road injuries from alcohol consumption.
224272544|NCT02923336|DRUG|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
224272545|NCT00414479|DRUG|praziquantl, iron, ACT|
224272546|NCT02229084|BIOLOGICAL|P10s-PADRE/ MONTANIDE™ ISA 51 VG|Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions concurrent with chemotherapy.
224272547|NCT02229084|DRUG|Doxorubicin|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
224272548|NCT02229084|DRUG|Cyclophosphamide|Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
224272549|NCT02229084|DRUG|Docetaxel|"Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.~If docetaxel is not tolerated, paclitaxel (175mg/m2) may be used in its place."
224272550|NCT02774018|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR) program|
224272551|NCT05290519|OTHER|plant and animal protein|plant protein: 2 bottle of black soy milk (400 mL/bottle) for 4 weeks animal protein: pork dished for 4 weeks
224272552|NCT04417348|DRUG|Retinoic acid|To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
224272553|NCT04244643|OTHER|data collection|"Data collected from patient records~* Demographic data: date of birth, sex, city of birth~* Contact lenses: laboratory, brand, model, wearing time before the exam, opening date of the blister, solution of contact lenses, material, renewal time~* Refraction~* Dry eye disease: Ocular Surface Disease Index (OSDI) score~* LACRYDIAG data: Non-Invasive Break-Up Time (NIBUT), interferometry and tears meniscus height"
224272554|NCT02809196|BEHAVIORAL|1: Tailored SMS program implicating friend and mother|
224272555|NCT02809196|BEHAVIORAL|2: Standardized SMS program implicating friend and mother|
224272556|NCT02809196|BEHAVIORAL|3: Tailored SMS program implicating friend, not mother|
224272557|NCT02809196|BEHAVIORAL|4: Standardized SMS program implicating friend, not mother|
224272558|NCT02809196|BEHAVIORAL|5: Tailored SMS program implicating mother, not friend|
224272559|NCT02809196|BEHAVIORAL|6: Standardized SMS program implicating mother, not friend|
224272560|NCT02809196|BEHAVIORAL|7: Tailored SMS program not implicating mother or friend|
224272561|NCT02809196|BEHAVIORAL|8: Standardized SMS program not implicating mother or friend|
224272562|NCT02809196|BEHAVIORAL|9: No SMS program|
224272563|NCT01096641|BEHAVIORAL|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
224272564|NCT01096641|BEHAVIORAL|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
224272565|NCT01874041|OTHER|Massage|
224272566|NCT01874041|OTHER|Occlusal splint|
224272567|NCT00106106|PROCEDURE|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
224272568|NCT00106106|DRUG|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
224272569|NCT00746486|DRUG|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
224272570|NCT00746486|DRUG|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
224272571|NCT00630253|BIOLOGICAL|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
224272572|NCT00630253|DRUG|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
224272573|NCT00630253|DRUG|Fludarabine|35 mg/m\^2 intravenously (IV) on days -6 through -2.
224272574|NCT00630253|PROCEDURE|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
224272575|NCT00630253|DRUG|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
224272576|NCT00630253|DRUG|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count \> or = 2.5 x 10\^9/L
224272577|NCT00630253|DRUG|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
224272578|NCT00630253|DRUG|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] \> 0.5 x 10\^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
224272579|NCT01328782|DRUG|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
224272580|NCT01328782|DRUG|Bupivacaine 0.25%|"* Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~* Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
224272581|NCT01328782|DRUG|Ropivacaine 0.20%|"* Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~* Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~* All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
224272582|NCT04535986|DRUG|Ensifentrine|Dosage Formulation: Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks or 48 weeks
224272583|NCT04535986|DRUG|Placebo|Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
224272584|NCT03210363|OTHER|Human Biological samples|Blood sample
224272585|NCT02964663|DEVICE|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
224272586|NCT00905541|DRUG|simvastatin|40 mg/day
224272587|NCT00905541|DRUG|simvastatin|80 mg simvastatin acute-on-chronic
224272588|NCT04174118|DRUG|belcesiran|belcesiran will be administered subcutaneously (SC) at dose levels planned.
224272589|NCT04174118|DRUG|Placebo|Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
224272590|NCT03066479|DEVICE|Fitbit|Wearable activity \& sleep tracker.
224272591|NCT03066479|OTHER|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
224272592|NCT03066479|DIAGNOSTIC_TEST|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
224272593|NCT02004769|DRUG|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
224272594|NCT02004769|DRUG|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
224272595|NCT02004769|DRUG|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
223517934|NCT02890160|DEVICE|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
224272596|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: excitatory iTBS|600 pulses (3 pulses at 50 Hz given every 200 milliseconds in 2-second trains at 10-second intervals, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 Device: Magstim Co., Wales, UK.
224272597|NCT05303649|DEVICE|Noninvasive transcranial brain stimulation: inhibitory cTBS|600 pulses (3 pulses at 50 Hz, repeated at 5 Hz, delivered at 80% of active motor threshold) generated by Magstim Super Rapid2 stimulator equipped with a figure-of-eight coil applied over BA 45 homologue Device: Magstim Co., Wales, UK.
224272598|NCT05303649|BEHAVIORAL|Individual speech-language therapy (SLT)|45 minutes training tailored to every patient's deficits, abilities and needs. Exercises used during each therapeutic session include: expressions tasks (naming and sentence building), complex utterances comprehension tasks, reading and writing exercises. Training is administered using paper-and-pencil tasks and computerized aphasia therapy program AfaSystem (Harpo sp.zoo, Poznań, Poland).
224272599|NCT05303649|DEVICE|Sham TBS simulating left hemispheric iTBS|Sham TMS coil positioned exactly like an active TMS coil resulting in a very good approximation of the auditory effects Device: Magstim Co., Wales, UK.
224272600|NCT04333264|PROCEDURE|suction drainage|After primary total hip arthroplasty closed suction drainage will be used.
224272601|NCT04333264|PROCEDURE|no suction drainage|After primary total hip arthroplasty closed suction drainage won't be used.
224272602|NCT01223755|DRUG|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
223517935|NCT02890160|DEVICE|XIENCE|Everolimus Eluting Coronary Stent System
223517936|NCT06414031|DRUG|Tranexamic Acid|Intravenous administration
223517937|NCT06414031|DRUG|Placebo|Intravenous administration
223517938|NCT05282407|DRUG|Tenofovir disoproxil 245mg|1 tablet q.d. for 48 weeks
224272603|NCT01223755|DRUG|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
224272604|NCT00135187|DRUG|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
224272605|NCT00135187|DRUG|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
224272606|NCT00135187|DRUG|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
224272607|NCT05625607|PROCEDURE|Transcatheter mitral valve-in-valve implantation|Transcatheter transfemoral mitral valve-in-valve implantation is an alternative for surgery redo in high-surgical-risk patients with bioprosthetic valve failure. The procedure is performed via femoral vein access. By the transseptal puncture (in the postero-inferior part of the interatrial septum) and balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle. The valve is expanded in the mitral position during rapid ventricle pacing.
224272608|NCT00680498|DRUG|Ranibizumab|Ranibizumab 0.5 mg
224272609|NCT00680498|DRUG|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
224272610|NCT00456898|DRUG|desvenlafaxine sustained release (DVS SR)|
224272611|NCT00456898|DRUG|Paroxetine|
224272612|NCT00456898|DRUG|Codeine|
224272613|NCT06083623|BIOLOGICAL|TNM001|single dose intramuscular injection
224272614|NCT06083623|BIOLOGICAL|placebo|single dose intramuscular injection
224272615|NCT02284139|DRUG|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
224272616|NCT02284139|DRUG|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
224272617|NCT02284139|DRUG|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
224272618|NCT01632215|DRUG|Gabapentine|Gabapentine 600 mg 01 dose
224272619|NCT01632215|OTHER|Sugar pill|Sugar pill 01 dose
224272620|NCT04943887|BEHAVIORAL|eSupport Health Weekly Group Sessions for PwMS|A formal semi-structured program of psychoeducational support delivered in an online weekly small group format by health coaches (licensed therapists) who specialize in MS.
224272621|NCT03513549|DRUG|Loxapine 10 MG|
224272622|NCT05086653|PROCEDURE|Surgery|Sutured by Prolene 3-0 with two layers of pledge
224272623|NCT00041860|PROCEDURE|Controlled Exposure to Environmental Contaminant|
223517939|NCT05282407|DRUG|Tenofovir disoproxil fumarate 300mg|1 tablet q.d. for 48 weeks
223517940|NCT02429167|DEVICE|Cranial nerve non-invasive neuromodulation via PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
223893603|NCT06249191|BIOLOGICAL|Mosunetuzumab|Given IV
224272624|NCT03997253|OTHER|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
224272625|NCT02637180|DRUG|anti-osteoporotic medication|check previous information
224272626|NCT06380387|DIETARY_SUPPLEMENT|Meal|Liquid meal
224272627|NCT02720549|PROCEDURE|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
224272628|NCT02720549|PROCEDURE|valvular surgery with bypass|valvular surgery with bypass
224272629|NCT04561115|BIOLOGICAL|Gamunex-C|Intravenous infusion.
224272630|NCT04561115|BIOLOGICAL|IVIG-PEG|Intravenous infusion.
224272631|NCT00212654|DRUG|ONO-1101|
224272632|NCT02528019|DRUG|DPP-4 inhibiotors|
224272633|NCT02528019|DRUG|SGLT2 inhibitors|
224272634|NCT02528019|DRUG|Glimepiride|
224272635|NCT00743145|DRUG|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
224272636|NCT00743145|DRUG|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
224272637|NCT00743145|DRUG|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
224272638|NCT00743145|DRUG|Naltrexone|Naltrexone (12mg/70kg)
224272639|NCT00743145|DRUG|Placebo naltrexone|Naltrexone (0mg)
224272640|NCT03786705|OTHER|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
224272641|NCT03786705|OTHER|Non-Massive Transfusion|Trauma patients who had received blood transfusion\<10 U
224272642|NCT03153605|OTHER|Common toothpaste|different toothpaste
224272643|NCT06840470|DRUG|Imiquimod 5% Topical Cream|Participants will apply this cream to one side of the face 3 times a week for up to 8 weeks. The cream will be applied before bedtime. The imiquimod should be washed off with mild soap and water after 6-10 hours. Participants will have baseline and follow-up visits that will include photographs of the lesions.
224272644|NCT05909436|DRUG|GLS-012|"In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
223517941|NCT02429167|DEVICE|Sham PoNS device|The PoNS is a medical device worn around the neck. The controller contains the pulse generator and a user interface. The mouthpiece, held to the top of the tongue, contains 143 circular gold electrodes that deliver a mild, controlled electric stimulation to the subject. The sham control device is physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, minimizing any neuromodulatory effect. While the subject is receiving stimulation, they will perform increasingly difficult balance, posture, gait, and movement control tasks designed to challenge existing abilities. Each training session takes approximately one hour to complete, and is separated by an interval of 2-2.5 hours.
223517942|NCT01641055|DIETARY_SUPPLEMENT|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
224272645|NCT05909436|DRUG|GLS-010|"In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W."
224272646|NCT03368482|BEHAVIORAL|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
224272647|NCT03368482|BEHAVIORAL|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
224272648|NCT01745094|DRUG|mirabegron|oral
224272649|NCT01745094|DRUG|solifenacin|oral
224272650|NCT02416180|DEVICE|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
224272651|NCT02416180|DEVICE|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
224272652|NCT02416180|DEVICE|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
224272653|NCT04566497|OTHER|No stress testing|No stress testing during the patient follow up (up to 48 months) if the patient remains asymptomatic
224272654|NCT04566497|PROCEDURE|stress testing|Systematic annual stress testing during the patient follow up (up to 48 months)
224272655|NCT00939380|BEHAVIORAL|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
224272656|NCT00939380|OTHER|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
224272657|NCT00939380|OTHER|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
224272658|NCT00939380|OTHER|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
224272659|NCT03645616|DIAGNOSTIC_TEST|6-minute walk test|"First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires."
224272660|NCT03645616|DIAGNOSTIC_TEST|10 meters walk test|"First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test."
224272661|NCT03645616|DIAGNOSTIC_TEST|30 Second Sit to Stand Test|At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
224272662|NCT05795296|DRUG|Fruquintinib|Fruquintinib: 5mg po, d1-d14, q3w
224272663|NCT05795296|DRUG|Sintilimab|Sintilimab: 200mg ivgtt, d1, q3w
224272664|NCT04432077|BEHAVIORAL|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)|DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
223517943|NCT01641055|DIETARY_SUPPLEMENT|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
224272665|NCT03936894|DRUG|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
224272666|NCT00522223|BEHAVIORAL|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
224272667|NCT05757609|DEVICE|Anodal tDCS combined with active physiotherapy|anodal tDCS over prefrontal cortex combined with active physiotherapy
224272668|NCT05757609|DEVICE|Sham anodal tDCS combined with active physiotherapy|Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
224272669|NCT00004906|BIOLOGICAL|filgrastim|
224272670|NCT00004906|DRUG|anastrozole|
224272671|NCT00004906|DRUG|carboplatin|
224272672|NCT00004906|DRUG|cisplatin|
224272673|NCT00004906|DRUG|cyclophosphamide|
223517944|NCT01641055|DIETARY_SUPPLEMENT|Cod protein|2.5g cod protein per day for 8wk.
224272674|NCT00004906|DRUG|docetaxel|
223517945|NCT01641055|DIETARY_SUPPLEMENT|Milk protein|2.5g milk protein per day for 8wk.
223517946|NCT01396876|BEHAVIORAL|clown|a distraction technique is performed by a clown during venipuncture
223517948|NCT03493893|DEVICE|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
223517949|NCT01983670|OTHER|Temporal electrical stimulation|
223517950|NCT05626335|DIAGNOSTIC_TEST|Intraoral scan|On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
223893604|NCT06249191|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224272675|NCT00004906|DRUG|doxorubicin hydrochloride|
224272676|NCT00004906|DRUG|etoposide|
224272677|NCT00004906|DRUG|pamidronate disodium|
224272678|NCT00004906|DRUG|thiotepa|
224272679|NCT00004906|PROCEDURE|peripheral blood stem cell transplantation|
224272680|NCT05874648|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
224272681|NCT01170715|DRUG|Etanercept|self-administered for 52 weeks
224272682|NCT05585489|OTHER|Gait training with musical cue|Entraînement de 20 minutes de marche à vitesse confortable sur un parcours ovale de 20 mètres au laboratoire ARM avec la technique d'indiçage musical personnalisé de la longueur de pas.
224272683|NCT01505049|DRUG|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
224272684|NCT02571634|DRUG|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
224272685|NCT04162171|RADIATION|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
224272686|NCT02725645|OTHER|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
224272687|NCT00590694|DRUG|ranibizumab|0.5mg injection monthly according to protocol for one year
224272688|NCT06679725|DIETARY_SUPPLEMENT|Wild ginseng extract|This ginseng extract was manufactured and provided by the Korea Food Research Institute (sponsor). It is extracted from red ginseng. Red ginseng is generally considered to have greater biological effects and fewer side effects than white or fresh ginseng.
224272689|NCT06679725|DIETARY_SUPPLEMENT|Placebo|The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring
224272690|NCT04338334|OTHER|Manual drainage & arm therapeutic exercise|See arm/group descriptions.
224272691|NCT04338334|OTHER|Cohesive bandaging & arm therapeutic exercise|See arm/group descriptions.
224272692|NCT00460850|DRUG|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
224272693|NCT00881569|DRUG|CS-7017|CS-7017 administered orally, twice daily continuously for 6 weeks
224272694|NCT01333917|DRUG|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
224272695|NCT03655860|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
224272696|NCT06053840|DRUG|Chloral Hydrate|Participants will be involved in the trial for approximately 7-8 weeks, the first week to collect baseline data and complete screening and eligibility confirmation, the following two weeks they will administer IMP, and there will be a further 4 week observation period. All trial recruitment and follow-up procedures will be conducted remotely via telephone/video calls.
224272697|NCT02948426|BIOLOGICAL|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
224272698|NCT03565562|OTHER|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
224272699|NCT03565562|OTHER|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
224272700|NCT05155293|DRUG|AVT06 (proposed aflibercept biosimilar)|Patients will receive IVT injections of AVT06
224272701|NCT05155293|DRUG|Eylea® (Aflibercept)|Patients will receive IVT injections of Eylea®
224272702|NCT03078257|DRUG|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
224272703|NCT03078257|DRUG|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
224272704|NCT03078257|DRUG|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
224272705|NCT03078257|DRUG|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
224272706|NCT03078257|DRUG|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
224272707|NCT03078257|DRUG|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
223517951|NCT04096235|OTHER|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
223893605|NCT06249191|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224272708|NCT03078257|DRUG|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
224272709|NCT04391829|DIAGNOSTIC_TEST|Ejaculated semen sample|SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
224272710|NCT00180401|BEHAVIORAL|CRT-P and CRT-D devices|
224272711|NCT03515044|DRUG|40 mg Rifaximin SSD once daily|SSD once daily (QD)
224272712|NCT03515044|DRUG|40 mg Rifaximin SSD twice daily|SSD twice daily (BID)
224272713|NCT03515044|DRUG|80 mg Rifaximin SSD once daily|SSD once daily (QD)
224272714|NCT03515044|DRUG|80 mg Rifaximin SSD twice daily|SSD twice daily (BID)
224272715|NCT03515044|DRUG|Placebo|Administered twice daily (BID)
224272716|NCT04225065|OTHER|Chlorhexidine|Chlorhexidine prep prior to surgery
224272717|NCT04225065|OTHER|Betadine|Betadine prep prior to surgery
224272718|NCT02101073|BIOLOGICAL|ALX-0061|single dose, intravenous
224272719|NCT02101073|BIOLOGICAL|ALX-0061|single dose, subcutaneous
224272720|NCT02149394|OTHER|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
224272721|NCT02149394|OTHER|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
224272722|NCT05735626|COMBINATION_PRODUCT|Piperine 150μM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).
224272723|NCT05735626|COMBINATION_PRODUCT|Piperine 1mM + tDCS 2mA|2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).
224272724|NCT05735626|COMBINATION_PRODUCT|Capsaicin 10μM + tDCS 2mA|2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
224272725|NCT05072119|DEVICE|Device implantation|Implantation of single chamber, dual chambers or triple chambers PM/ICD
224272726|NCT01599689|OTHER|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
224272727|NCT04186286|DRUG|Ivabradine 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
224272728|NCT04186286|DRUG|Propranolol 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
224272729|NCT04186286|DRUG|Placebo 4-week course|After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
224272730|NCT02052817|DEVICE|Optimal Medical Therapy Debridement + Toad Brace|
224272731|NCT02052817|OTHER|Optimal Medical Therapy - Debridement|
224272732|NCT01799850|DRUG|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
224272733|NCT01799850|DRUG|placebo|placebo assigned randomly, double blind
224272734|NCT03313713|DIETARY_SUPPLEMENT|Beta-glucans|Placebo consumption at breakfast (3 g per day)
224272735|NCT03313713|DIETARY_SUPPLEMENT|Placebo|Placebo consumption at breakfast (3 g per day)
224272736|NCT04759989|PROCEDURE|Actual Body Weight Dosing|30cc/kg initial bolus calculated using Actual Body Weight
224272737|NCT04759989|PROCEDURE|Adjusted Body Weight Dosing|30cc/kg initial bolus calculated using Adjusted Body Weight
224272738|NCT04759989|PROCEDURE|Ideal Body Weight Dosing|30cc/kg initial bolus calculated using Ideal Body Weight
224272739|NCT01812239|DRUG|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
224272740|NCT01812239|PROCEDURE|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
224272741|NCT01812239|DRUG|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
224272742|NCT04693221|OTHER|Choice of VNS set of parameters based on the lowest PLI|Vagal nerve stimulation according to PLI results.
224272743|NCT04693221|OTHER|EEG|Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
224272744|NCT06628349|DIETARY_SUPPLEMENT|Whey Protein Isolate 90%|Commercially available animal based protein powders
224272745|NCT06628349|DIETARY_SUPPLEMENT|Soy Protein Isolate (90% Protein)|Commercially available plant based protein powders
224272746|NCT06628349|DIETARY_SUPPLEMENT|Organic Pea Protein Isolate|Commercially available plant based protein powders
224272747|NCT06628349|DIETARY_SUPPLEMENT|Placebo (Water)|Normal drinking water
223893606|NCT06249191|DRUG|Prednisone|Given PO
223893607|NCT06249191|DRUG|Vincristine|Given IV
224272748|NCT00486993|BEHAVIORAL|Dietary and nutritional modification|
224272749|NCT00486993|BEHAVIORAL|Stop smoking|
224272750|NCT00486993|BEHAVIORAL|Regular physical activities|
224272751|NCT00486993|BEHAVIORAL|Weight reduction to normal ranges|
224272752|NCT00486993|BEHAVIORAL|Regular intake of polyphenols, esp. from Ilex paraguayensis|
224272753|NCT02247037|OTHER|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
224272754|NCT01415245|DEVICE|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
224272755|NCT00695045|DRUG|intra thecal morphine|100 mcg intrathecal morphine given once .
224272756|NCT00695045|DRUG|intra thecal morphine|200 mcg intrathecal morphine given once
224272757|NCT00695045|DRUG|intra thecal morphine|300 mcg intrathecal morphine given once
224272758|NCT00521573|OTHER|Dark chocolate|
224272759|NCT00095160|DRUG|852A|
224272760|NCT01567527|DRUG|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
224272761|NCT01567527|DRUG|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
224272762|NCT06368076|BEHAVIORAL|Exercise|High intensity interval training on a bike or pedaltrainer from the wheelchair.
224272763|NCT02004691|DRUG|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion"
224272764|NCT02004691|DRUG|Olipudase alfa|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to olipudase alfa, and during the extension treatment period for all participants.~Route of administration: intravenous infusion"
224272765|NCT00509301|DRUG|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
224272766|NCT01391650|PROCEDURE|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
224272767|NCT02623218|DEVICE|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
224272768|NCT02623218|DEVICE|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
224272769|NCT01726803|OTHER|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
224272770|NCT01726803|OTHER|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
224272771|NCT02816684|BEHAVIORAL|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
224272772|NCT02816684|BEHAVIORAL|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
224272773|NCT04334837|DIAGNOSTIC_TEST|Copper Cu 64 Dotatate|The drug product contains Copper Cu 64 Dotatate filled in a glass vial, closed with butyl rubber stopper secured with an aluminum crimp seal. The drug product will be delivered by Curium to the clinical site. The EAP drug will be administered as an intravenous bolus injection. The dose will be administered according to the schedule detailed in the protocol.
224272774|NCT01449409|OTHER|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
224272775|NCT00759707|DRUG|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein \[arterial\] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
224272776|NCT03084562|OTHER|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
224272777|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
224272778|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
224272779|NCT02244762|DRUG|20 mg HC-ER|1-72 hours
224272780|NCT00005967|DRUG|tipifarnib|
224272781|NCT05626348|DRUG|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
224272782|NCT05626348|DRUG|Methotrexate|Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
224272783|NCT05626348|DRUG|Adalimumab Injection|Adalimumab Injection，40mg，iH，every two weeks (q2w) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
224272784|NCT05626348|DRUG|Leflunomide|Leflunomide，20mg, po, quaque day (qd) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
224272785|NCT05626348|DRUG|Hydroxychloroquine|Hydroxychloroquine，200mg, po, twice per day (bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
224272786|NCT00691470|DRUG|ATI-5923|Dose Adjusted based on INR.
224272787|NCT00691470|DRUG|Coumadin (warfarin)|Dose adjusted based on INR.
224272788|NCT03369496|OTHER|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
224272789|NCT02702635|PROCEDURE|DCE MRI of the brain|An MRI of the brain including a DCE sequence
223517952|NCT01821014|OTHER|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
224272790|NCT06110819|OTHER|control|Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.
224272791|NCT06110819|OTHER|Workgroup|"Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health."
224272792|NCT05317806|DRUG|Metformin Extended Release Oral Tablet|daily metformin treatment vs. no treatment with metformin
224272793|NCT01685008|DRUG|MOR00208 (formerly Xmab 5574)|
224272794|NCT05881733|DEVICE|POLARx FIT cryoballoon|Patients will undergo cryoablation with the 31 mm balloon size of the POLARx FIT cryoballoon.
224272795|NCT03454490|PROCEDURE|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
224272796|NCT05055687|DRUG|FL058|2500mg、3000mg
224272797|NCT05055687|DRUG|Placebo|empty bottle
224272798|NCT05055687|DRUG|FL058|500mg、1000mg、2000mg
224272799|NCT05055687|DRUG|Placebo|empty bottle
224272800|NCT00204451|DRUG|0.75 levonorgestrel|
224272801|NCT00204451|DRUG|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
224272802|NCT05219734|DIAGNOSTIC_TEST|Personalized Cancer Monitoring (PCM)|personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease
224272803|NCT03492476|DEVICE|Circaid|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
224272804|NCT03492476|DEVICE|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
224272805|NCT05869162|DRUG|SY-3505|A Third-generation ALK TKI
224272806|NCT03138044|PROCEDURE|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (\> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
224272807|NCT02712294|OTHER|Neuromuscular Electrical Stimulation|
224272808|NCT00009776|BIOLOGICAL|monoclonal antibody Lym-1|
224272809|NCT00009776|DRUG|cyclosporine|
224272810|NCT00009776|DRUG|paclitaxel|
224272811|NCT00009776|RADIATION|indium In 111 monoclonal antibody Lym-1|
224272812|NCT00009776|RADIATION|yttrium Y 90 monoclonal antibody Lym-1|
224272813|NCT00908180|BIOLOGICAL|alemtuzumab|
224272814|NCT00908180|BIOLOGICAL|donor lymphocytes|
224272815|NCT00908180|DRUG|carmustine|
224272816|NCT00908180|DRUG|cyclosporine|
224272817|NCT00908180|DRUG|cytarabine|
224272818|NCT00908180|DRUG|etoposide|
224272819|NCT00908180|DRUG|melphalan|
224272820|NCT00908180|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224272821|NCT04541680|DRUG|Nintedanib 150 MG [Ofev]|Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
224272822|NCT04541680|OTHER|Placebo|Placebo
224272823|NCT00592579|DRUG|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
224272824|NCT01970592|BEHAVIORAL|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be \~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
224272825|NCT03757520|DIAGNOSTIC_TEST|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
224272826|NCT03757520|DIAGNOSTIC_TEST|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
224272827|NCT00499473|DRUG|sunitinib malate|Given orally
224272828|NCT00499473|OTHER|pharmacological study|Correlative studies
224272829|NCT00642057|DRUG|tetrabenazine|25 mg titrated to optimal dose per patient
224272830|NCT03706508|PROCEDURE|Robot-assisted laparoscopic radical prostatectomy|Patients with localized prostate cancer underwent transperitoneal robot-assisted laparoscopic radical prostatectomy
224272831|NCT02373839|OTHER|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
224272832|NCT01320722|DRUG|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
224272833|NCT01320722|DRUG|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
224272834|NCT01320722|DRUG|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
224272835|NCT01320722|DRUG|Placebo|Placebo soft gel once per week for 8 weeks
224272836|NCT01320722|DRUG|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
224272837|NCT01182792|DIETARY_SUPPLEMENT|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
224272838|NCT01182792|DIETARY_SUPPLEMENT|Placebo|1 month Placebo
224272839|NCT01603667|DRUG|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
224272840|NCT01603667|DRUG|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
224272841|NCT02581917|OTHER|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
224272842|NCT02581917|OTHER|Laboratory Biomarker Analysis|Undergo metabolic analysis
224272843|NCT01970917|DEVICE|Olixia pure eye drops|
224272844|NCT01970917|DEVICE|Placebo|0.9% physiological saline solution
224272845|NCT00245986|PROCEDURE|Blood draw|
224272846|NCT02586324|BIOLOGICAL|global medium|
224272847|NCT02586324|BIOLOGICAL|SSM|
224272848|NCT01268839|DRUG|TMC278|25mg tablet once daily for 28 days
224272849|NCT01268839|DRUG|TMC278|25mg tablet once daily for 14 days
224272850|NCT01268839|DRUG|Efavirenz|600mg tablet once daily for 14 days
224272851|NCT03595241|DEVICE|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
224272852|NCT00160524|BIOLOGICAL|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
223517953|NCT01821014|OTHER|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
223517954|NCT01421459|DRUG|LY2963016|Administered subcutaneously
223517955|NCT01421459|DRUG|Lantus|Administered subcutaneously
223517956|NCT01421459|DRUG|OAMs|Administered orally
224272853|NCT03687619|OTHER|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
223517957|NCT06284122|DRUG|Mosunetuzumab|5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21
223517958|NCT06284122|DRUG|Lenalidomide|20 mg/day Day 1 to Day 21 from C2 to C12
224272854|NCT03687619|OTHER|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
224272855|NCT01377441|DRUG|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
224272856|NCT01377441|DRUG|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
224272857|NCT02806063|PROCEDURE|intraoperative samples|
224272858|NCT02398734|DEVICE|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
224272859|NCT06369935|DRUG|Equecabtagene Autoleucel|Equecabtagene Autoleucel (CT103A) is a novel fully human BCMA-targeting CAR-T therapy
224272860|NCT00112216|BIOLOGICAL|Melan-A analog peptide|
224272861|NCT00112216|BIOLOGICAL|FluMa peptide|
224272862|NCT00112216|BIOLOGICAL|Mage-A10 peptide|
224272863|NCT00112216|BIOLOGICAL|SB AS-2 adjuvant|
224272864|NCT00112216|BIOLOGICAL|Montanide adjuvant|
224272865|NCT04003441|DRUG|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
224272866|NCT04003441|DRUG|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
224272867|NCT00784095|OTHER|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
224272868|NCT00784095|OTHER|Attention Control|Subjects will listen to a non-guided relaxation CD.
224272869|NCT04642781|DIAGNOSTIC_TEST|reading of a text|Reading of 2 IRest Texts presented on a laptop in randomized order while eye movements are recorded with a tracking bar.
223517959|NCT06284122|DRUG|Rituximab|when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20
224272870|NCT02392858|OTHER|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
224272871|NCT04817514|OTHER|Shoulder rehabilitation exercises and aerobic exercises|"SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines."
224272872|NCT01816230|DRUG|NiCord®|
224272873|NCT01497743|DRUG|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
224272874|NCT06390813|BEHAVIORAL|Otago Exercise Training|A total of 18 sessions of Otago Training were conducted 3 days a week for 6 weeks, each session lasting 60 minutes in total, including 5 minutes of warm-up and cool-down periods.
224272875|NCT06390813|BEHAVIORAL|Square Stepping Exercise Training|A total of 18 sessions of SSE were performed 3 days a week for 6 weeks, each session lasting 40 minutes.
223517960|NCT06284122|DRUG|Obinutuzumab|when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18
223517961|NCT06284122|DRUG|Cyclophosphamide|750 mg/m2 Day 1 from C1 to C6
223517962|NCT06284122|DRUG|Doxorubicin|50 mg/m2 Day 1 from C1 to C6
223517963|NCT06284122|DRUG|Vincristin|1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
224272876|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 6(Draf III).|Patients will receive endoscopic frontal sinus surgery grade 6(Draf III).
224272877|NCT05979662|PROCEDURE|Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)|Patients will receive endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).
224272878|NCT04475315|DEVICE|Papillary Muscle Sling|The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.
223517964|NCT06284122|DRUG|Prednisone|100 mg/day Day 1 to Day 5 from C1 to C6
223517965|NCT06284122|DRUG|Rituximab|when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
223517966|NCT06284122|DRUG|Obinutuzumab|when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
223517967|NCT06284122|DRUG|Bendamustin|90 mg/m2 Day 1 and Day 2 from C1 to C6
223517968|NCT05408260|PROCEDURE|Ultrasonography|Undergo HHUS
223517969|NCT05408260|PROCEDURE|Automated Breast Ultrasound|Undergo ABUS
224272879|NCT04475315|PROCEDURE|CABG surgery|Standard of care Coronary Artery Bypass Grafting (CABG) surgery will be performed to improve blood flow to the heart by bypassing the narrowed segment of a severely diseased coronary artery
224272880|NCT02731781|OTHER|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
224272881|NCT04491838|DRUG|Pozelimab|Single subcutaneous (SC) injection
224272882|NCT04123587|DRUG|discontinuation of Sulfonylureas|"1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
224272883|NCT02177552|DRUG|Carboplatin|
224272884|NCT02177552|DRUG|Docetaxel|
224272885|NCT02177552|DRUG|Capecitabine|
224272886|NCT02177552|DRUG|Epirubicin|
224272887|NCT02177552|DRUG|Oxaliplatin|
224272888|NCT05365698|BEHAVIORAL|Community Health and Nutrition Program|"The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods."
224272889|NCT00245882|BEHAVIORAL|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
224272890|NCT00245882|BEHAVIORAL|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
224272891|NCT03955276|OTHER|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
224272892|NCT04485806|OTHER|GPS/LM|Media microdroplet geometry (3D dishes) in combination with light mineral oil overlay
224272893|NCT04485806|OTHER|SPL/LM|Media microdroplet geometry (2D dishes) in combination with light mineral oil overlay
224272894|NCT04485806|OTHER|GPS/PO|Media microdroplet geometry (3D dishes) in combination with Paraffin oil overlay
224272895|NCT04485806|OTHER|SPL/PO|Media microdroplet geometry (2D dishes) in combination with paraffin oil overlay
224272896|NCT06678711|PROCEDURE|minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion|Make a 4.5 cm incision along the median line and then dissect the trapezius, splenius capitis, and semispinalis capitis muscle laterally 1.5 cm off the median line. Retract the obliquus capitis inferior muscle to expose the C1-C2 intra-articular space. Remove the articular cartilage, insert allogenic granular bone and 3D-printed cage. Place the screws and rod in the same positions as conventional surgery, and the operation is completed.
224272897|NCT06678711|PROCEDURE|Open atlantoaxial fixation and fusion|The Goel-Harms procedure will be used in the control group. Screws and rods are placed in the same position as in the experimental group, and a negative-pressure drain was placed until daily drainage was \<50 mL.
224272898|NCT00936351|BEHAVIORAL|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
224272899|NCT00936351|BEHAVIORAL|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
224272900|NCT02032316|DEVICE|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
224272901|NCT03234127|GENETIC|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
224272902|NCT02667951|OTHER|A home-based caregiver-training program|A home-based caregiver-training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
224272903|NCT04960761|OTHER|İntervention Group|"In the experimental group, pre-operative anxiety and quality of life scales will be applied to the child and their parents before and after the operation with audio and picture books, the preoperative quality of life scale will be made, the postoperative anxiety and quality of life scale will be repeated and the early mobilization scale will be made.~The control group will be routinely informed before the operation, an anxiety scale will be given to the child and their parents before the operation, a quality of life scale will be given to the child, the postoperative anxiety and quality of life scale will be repeated, and early mobilization form will be applied."
224272904|NCT01547728|DRUG|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
224272905|NCT00966628|DRUG|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
223517970|NCT06522503|BEHAVIORAL|stress ball|The intervention group was provided with a stress ball to be held in both hands for a period of five minutes prior to the insertion of the port catheter needle. They were instructed to squeeze the ball in their hands at regular intervals until the conclusion of the procedure.
223517971|NCT02899754|BEHAVIORAL|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
223517972|NCT02899754|BEHAVIORAL|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
224272906|NCT00966628|DRUG|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
224272907|NCT05397444|OTHER|No intervention|This is an observational study with no intervention.
224272908|NCT03202251|OTHER|It's is a cohort|It is a prospective, observational, cohort study
224272909|NCT06340698|BEHAVIORAL|Resilience intervention|"Contents of the first session include:~1. Resilience. Know the concept of resilience.~2. Stigma management. Discuss stigma experience and learn stigma management strategies such as normalizing the disease.~3. Self-efficacy. Learn ways of improving self-efficacy, such as experience of success and social support.~Contents of the second session include:~1. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions. Learn effective communication skills.~2. Acquiring social support. Know people and resources that could provide support when having HIV-related difficulties and mental health problems.~3. Emotional regulation. Understand the physiological responses to emotions. Know a range of emotional regulation strategies, such as cognitive reappraisal and deep breathing."
224272910|NCT06340698|BEHAVIORAL|Adherence intervention|"Contents of the first session include:~1. Adherence behavioral skills. Identify barriers to optimal HAART adherence. Know behavioral skills that can deal with these barriers, such as forgetting, afraid of others' questioning and side effects.~2. Adherence information and motivation. Know how the HIV virus attack human body and the mechanisms of HAART medication. Understand the influence of adherence level on health outcomes.~Contents of the second session include:~1. Adherence motivation. Discuss possibilities and hope of future life, intimate relationship and career.~2. Mother-child interaction skills. Identify speaking styles that have a negative influence on mother-child interactions concerning HAART medication. Learn effective communication skills.~3. Acquiring social support. Know people and resources that could provide support when having HAART-related difficulties and problems."
224272911|NCT04416854|PROCEDURE|resection of primary tumor|resection of primary lesion with unresectablely metastatic colon cancer
224272912|NCT04416854|DRUG|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
224272913|NCT04416854|DRUG|mFOLFOX6|Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
224272914|NCT03893617|DRUG|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
224272915|NCT03893617|DRUG|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
224272916|NCT03893617|BEHAVIORAL|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
224272917|NCT03893617|BEHAVIORAL|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
224272918|NCT03025451|BEHAVIORAL|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
224272919|NCT04664751|OTHER|Nil-per-Oral|NPO details
224272920|NCT03828539|BIOLOGICAL|Erenumab|70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
224272921|NCT03828539|DRUG|Topiramate|"Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase."
224272922|NCT03828539|BIOLOGICAL|Erenumab matching placebo|Erenumab matching placebo pre-filled syringue administered every 4 weeks
224272923|NCT03828539|DRUG|Topiramate matching placebo|Topiramate matching placebo administered daily
224272924|NCT06677697|DRUG|Ropivacaine 0,5%|Group B 30 patients recive 0.5% ropivacine
224272925|NCT01341405|DRUG|CG100649|once daily for 28 days
224272926|NCT01341405|DRUG|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
224272927|NCT06103760|DRUG|Esketamine Nasal Spray [Spravato]|This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
224272928|NCT00057941|DRUG|anastrozole|Given orally
224272929|NCT00057941|DRUG|gefitinib|Given orally
224272930|NCT00057941|DRUG|fulvestrant|Given intramuscularly
224272931|NCT00057941|OTHER|laboratory biomarker analysis|Correlative studies
224272932|NCT04211480|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression
224272933|NCT00913536|OTHER|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
224272934|NCT04443049|DRUG|Lenvatinib|Lenvatinib will be given once a day(OD) orally at dose of 8 mg if body weight is \< 60 kg and 12 mg if body weight is \> 60 kg
224272935|NCT04443049|DRUG|Mebendazole|mebendazole will be given at dose of 100 mg orally twice a day (BD) daily
224272936|NCT04443049|OTHER|Placebo|Placebo (Tab Mecovit) orally twice a day (BD) daily
224272937|NCT04721145|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
224272938|NCT06017427|OTHER|Questionnaires|Submission of several questionnaires (Quality of Life and clinical scores) at three time points: before initiation of Dupilumab, after 6 months of Dupilumab treatment, and 6 months after stopping Dupilumab treatment
224272939|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
224272940|NCT02600676|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
224272941|NCT02103101|OTHER|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
224272942|NCT02103101|GENETIC|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
224272943|NCT05028140|DRUG|PIEMONTE|Piemonte association 1 coated tablet once a day
224272944|NCT05028140|OTHER|PIEMONTE PLACEBO|Placebo of Piemonte association 1 coated tablet once a day
224272945|NCT05028140|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg 1 coated tablet once a day
224272946|NCT05028140|OTHER|PLACEBO EMPAGLIFLOZIN|Placebo of empagliflozin 25 mg 1 coated tablet once a day
224272947|NCT05028140|DRUG|PIOGLITAZONE|Pioglitazone 30 mg 1 tablet once a day
224272948|NCT05028140|OTHER|PLACEBO PIOGLITAZONE|Placebo of pioglitazone 30 mg 1 tablet once a day
224272949|NCT00002367|DRUG|Saquinavir|
224272950|NCT00002367|DRUG|Lamivudine|
224272951|NCT00002367|DRUG|Zidovudine|
224272952|NCT03252990|DIAGNOSTIC_TEST|PET-MRI|Additional 18F-choline PET-MRI examination
224272953|NCT03252990|PROCEDURE|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
224272954|NCT04142658|DRUG|Apixaban 5 MG|"For patients that do NOT meet the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
224272955|NCT04142658|DRUG|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~* age ≥ 80 years~* weight ≤ 60 kilograms~* creatinine ≥ 1.5 mg/dL (133 micromol/L)"
224272956|NCT04142658|DRUG|Warfarin|Active Control Intervention
224272957|NCT04142658|DEVICE|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
224272958|NCT00201136|BEHAVIORAL|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
224272959|NCT00201136|BEHAVIORAL|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
224272960|NCT01625390|DRUG|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
224272961|NCT01625390|DRUG|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
224272962|NCT01625390|DRUG|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
224272963|NCT01216254|DEVICE|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
224272964|NCT05543551|OTHER|Diaphragmatic breathing with Resistance Training|"Wall press-up:~Stand arm's length from the wall. Place your hands flat against the wall at chest level, with your fingers pointing upwards. With your back straight, slowly bend your arms, keeping your elbows by your side.~Dumbbell biceps curls:~Hold a pair of light weights and stand with your feet hip-width. Keeping your arms by your side, slowly bend them until the weight in your hand reaches your shoulder. Slowly lower again.~Back squats:~Place barbell with weights onto the squat rack. Bring your body under the bar. Rest barbell over your traps and shoulders. Make sure hands are even on each side of the bar. Keep your feet in the same position as they would be for an air squat. Brace your midline and keep your chest up.~Leg press:~Position feet about shoulder width apart. Try to push through your heels, keeping the knees lined up over the toes. Extend the legs until nearly straight, avoiding locking the knees."
224083148|NCT00440726|DRUG|Triple IT Therapy|"Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg~Cytarabine:~* \<2 years: 16 mg~* 2 - \<3 y: 20 mg~* 3 - \<9 y: 24 mg~* \>=9 y: 30 mg~Hydrocortisone:~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg"
224272965|NCT05543551|OTHER|diaphragmatic breathing with out resistance training|"Diaphragmatic Breathing:~1. Lie on your back on a flat surface (or in bed) with your knees bent. You can use a pillow under your head and your knees for support if that's more comfortable.~2. Place one hand on your upper chest and the other on your belly, just below your rib cage.~3. Breathe in slowly through your nose, letting the air in deeply, towards your lower belly. The hand on your chest should remain still, while the one on your belly should rise.~4. Tighten your abdominal muscles and let them fall inward as you exhale through pursed lips. The hand on your belly should move down to its original position. You can also practice this sitting in a chair, with your knees bent and your shoulders, head, and neck relaxed"
224272966|NCT00924053|DRUG|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
224272967|NCT00924053|DRUG|Placebo|Placebo capsules to match EGT0001474
224272968|NCT04833205|DRUG|Nimotuzumab|Nimotuzumab 200 mg was diluted in 250mL 0.9% sodium chloride injection, intravenously dripping, the duration of administration was controlled over 60 min), and the drug was used continuously for 8 weeks
224272969|NCT03434145|OTHER|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
224272970|NCT05821608|OTHER|Message variation 1|Message before call letting member know they will be called (variation 1)
224272971|NCT05821608|OTHER|Message variation 2|Message before call letting member know they will be called (variation 2)
224272972|NCT01346644|OTHER|Infant formula|Powder infant formula
224272973|NCT01346644|OTHER|Infant formula|Powder infant formula
224272974|NCT04804839|OTHER|First research arm|Patients in this group were given 8-week PFMT (including knack maneuver) and lifestyle recommendations for the treatment of urinary incontinence symptoms.
224272975|NCT04804839|OTHER|Second research arm|Patients in this group were given only 8-week PFMT (including knack maneuver) for the treatment of urinary incontinence symptoms.
224272976|NCT04804839|OTHER|Third research arm|It is the control group and patients in this group were given alone8-week PFMT (without knack maneuver).
224272977|NCT02176616|PROCEDURE|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
224272978|NCT02176616|PROCEDURE|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
224272979|NCT00830167|DRUG|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
224272980|NCT00830167|DRUG|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
224272981|NCT02738216|BEHAVIORAL|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
224272982|NCT02738216|BEHAVIORAL|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
224272983|NCT03168035|DRUG|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
224272984|NCT04287608|DRUG|dupilumab|No investigational agents will be provided to study patients, and no specific treatment is required during the study. DUPIXENT®-treated patients will receive DUPIXENT as standard of care for the treatment of their AD, as prescribed by their physician. However, continuous treatment with dupilumab for at least 8 weeks is required as a condition for eligibility.
224272985|NCT00892749|DRUG|ASP1585|oral
224272986|NCT00869115|DRUG|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
224272987|NCT00869115|DRUG|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
224272988|NCT00869115|DRUG|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
224272989|NCT00869115|DRUG|Istaroxime|Placebo continuous i.v. infusion for 24 hours
224272990|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
224272991|NCT02224053|DRUG|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
224272992|NCT02224053|DRUG|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
224272993|NCT02224053|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
224272994|NCT04720547|DRUG|Zolpidem|A nonbenzodiazepine hypnotic
224272995|NCT04720547|OTHER|No Treatment|The Control condition in which participants do not receive medication.
224272996|NCT01876745|DRUG|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
224272997|NCT01898598|DRUG|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
224272998|NCT01898598|DRUG|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
224272999|NCT04513327|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery."
224273000|NCT04513327|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
224273001|NCT02894827|BIOLOGICAL|Blood sample|
224273002|NCT02894827|OTHER|Flow cytometry|
224273003|NCT02894827|OTHER|western blot|
224083149|NCT00331409|DRUG|Everolimus|2.5 mg by mouth daily
224083150|NCT00331409|DRUG|imatinib mesylate|600 mg by mouth daily
224273004|NCT04320576|DEVICE|Bulk-fill|Bulk-fill resin composite (bulk technique)
224273005|NCT04320576|DEVICE|Nano-fill|Nano-fill resin composite (layering technique)
224273006|NCT03526562|BEHAVIORAL|Exercise|Exercise according to dose escalation
224273007|NCT03930069|DRUG|Misoprostol|prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
224273008|NCT03930069|DRUG|Vasopressin|one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
224273009|NCT04194008|DEVICE|Nerivio|A remote electrical neuromodulation (REN) device for the acute treatment of migraines.The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
224273010|NCT03096067|OTHER|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
224273011|NCT03096067|OTHER|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
224273012|NCT02828631|DEVICE|Macintosh laryngoscope|
224273013|NCT02828631|DEVICE|McGrath videolaryngoscope|
224273014|NCT02828631|DEVICE|Pentax videolaryngoscope|
224273015|NCT04789330|DRUG|Norepinephrine|Norepinephrine administered during anesthesia
224273016|NCT04789330|DRUG|Phenylephrine|Phenylephrine administered during anesthesia
224273017|NCT00279760|DRUG|Belatacept|
224273018|NCT00279760|DRUG|Abatacept|
224273019|NCT02962180|DEVICE|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
224273020|NCT05702762|DRUG|Gentamicin|5 mg/kg intramuscular injection
224273021|NCT05702762|DRUG|Standard of Care|Usual oral antibiotic multi-day dosing based on local antibiogram
224273022|NCT00860262|DRUG|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
224273023|NCT00860262|DRUG|telmisartan|telmisartan 80mg for the 8w, no titration required
224083151|NCT00305942|DRUG|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
224273024|NCT00860262|DRUG|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
224273025|NCT00348517|OTHER|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
224273026|NCT00348517|OTHER|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
224083152|NCT00305942|DRUG|carboplatin|Carboplatin AUC=5 IV day 1 only .
224273027|NCT04980105|BIOLOGICAL|Platelet-rich plasma|Two intra-articular injections of autologous platelets-rich plasma (PRP) in two weeks intervals between the first and the second injection.
224273028|NCT04980105|DRUG|Hyaluronic acid|Two intraarticular injections of hyaluronic acid (60 mg) in two weeks intervals between the first and the second injection
224273029|NCT04980105|DRUG|Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)|Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
224273030|NCT00124618|BIOLOGICAL|cetuximab|
224273031|NCT00124618|RADIATION|radiation therapy|
224273032|NCT02117141|DRUG|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
224273033|NCT02117141|DRUG|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
224273034|NCT05736250|DIAGNOSTIC_TEST|biopsie|gingival biopsie
224273035|NCT01116505|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-containing cereals removed from diet
224273036|NCT00899951|DRUG|fentanyl citrate|
224273037|NCT00899951|OTHER|pharmacological study|
224273038|NCT01401296|BEHAVIORAL|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
224083153|NCT04992143|PROCEDURE|TACE|TACE first ,and more TACE could be performed when it is necessary.
224083154|NCT04992143|DRUG|Tilelizumab|Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
224273039|NCT01401296|BEHAVIORAL|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
224273040|NCT04349696|DRUG|Mitiglinide|"Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)"
224273041|NCT05589636|DIETARY_SUPPLEMENT|Bergamot Juice|Bergamot Juice (35% in water)
224273042|NCT04384289|PROCEDURE|Nursing care based on the Transitonal Care Model|Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
224273043|NCT00882245|OTHER|Vehicle ointment|Topical vehicle cream
224273044|NCT00882245|DRUG|Ointment|SRD441 Ointment
224273045|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
224273046|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
224273047|NCT01102660|DRUG|Placebo|Tablet, 0 mg once daily for 2 weeks
224273048|NCT01102660|DRUG|PH-797804|Tablet, 6 mg once daily for 2 weeks
224273049|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
224273050|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
224273051|NCT01102660|DRUG|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
224273052|NCT01102660|DRUG|Naproxen|Tablet, 500 mg twice daily for 2 weeks
224273053|NCT05033145|DRUG|AZVUDINE|AZVUDINE 5 tablets QD + standard treatment, for up to 14 days
224273054|NCT05033145|DRUG|AZVUDINE placebo|5 tablets QD + standard treatment, for up to 14 days
224273055|NCT02977416|OTHER|anti-TNFα|
224273056|NCT03001934|OTHER|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
224273057|NCT03161236|OTHER|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
224083155|NCT04992143|DRUG|Sorafenib|Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
224083156|NCT01482910|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
224273058|NCT03161236|OTHER|non exercise program|continue usual lifestyle
224273059|NCT06276153|OTHER|no interventions|retrospective registry cohort with no other specific interventions
224273060|NCT02691676|DRUG|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
224273061|NCT02691676|DRUG|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
224273062|NCT01037231|BIOLOGICAL|Oxalobacter formigenes|NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks
224273063|NCT01037231|DRUG|Placebo|placebo
224273064|NCT01596127|DRUG|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
224273065|NCT01875887|PROCEDURE|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
224273066|NCT00141258|DRUG|pregabalin|
224273067|NCT01573663|DRUG|Ambroxol and Levodropropizine|Ambroxol HCl 30mg \& Levodropropizine 60mg, PO, Single dose
224273068|NCT01573663|DRUG|Ambroxol|Ambroxol HCl 30mg, PO, single dose
224273069|NCT01573663|DRUG|Levodropropizine|Levodropropizine 60mg, PO, single dose
224273070|NCT05796843|PROCEDURE|360 Degrees virtual reality-based mirror therapy|Participants will receive mirror therapy using a virtual reality device (Pico G2 VR 4K, Pico, China). They will be asked to follow tasks that are played in HMD using their paralyzed hand. The video played using HMD will be video taped using 360 degree camera prior to the treatment. The 360MT will last 30 minutes/session, 3 sessions a week for 4 weeks. The tasks are finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions.
224273071|NCT05796843|PROCEDURE|Traditional mirror therapy|Participants will receive mirror therapy using an acrylic mirror (40cm x 40cm x 3cm) that reflects unparalyzed side of them. They will be asked to perform tasks including finger flexion-extension, wrist flexion-extension and pronation-supination, and elbow flexion-extension for ten repetitions. They will be asked to follow the reflection on mirror using their paralyzed limb. The TMT will last 30 minutes/session, 3 sessions a week for 4 weeks.
224273072|NCT05796843|PROCEDURE|Conventional Physical Therapy|Participants will receive conventional physical therapy including neurodevelopmental therapy, muscle strengthening exercises, and joint mobilization which will be provided 60 minutes per day, 5 sessions a week, for 4 weeks. The therapy will follow upper extremity rehabilitation protocol which consists of three phases of warm up, circuit, and cool down exercises
224273073|NCT00637533|PROCEDURE|Lumbar sympathetic block with Botulinum Toxin type A|
224273074|NCT03748251|OTHER|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
224273075|NCT03748251|OTHER|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
224273076|NCT05958433|BEHAVIORAL|Rehabilitation with stoma appliance|The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
224273077|NCT06623695|OTHER|Exercise|SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
224273078|NCT06623695|OTHER|Exercise|USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
224273079|NCT03311061|OTHER|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
224273080|NCT03149900|DRUG|Secukinumab|See Arm Description
224273081|NCT03721718|BIOLOGICAL|GLS-5300|\[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
224273082|NCT03721718|DEVICE|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
224273083|NCT02542254|DRUG|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
224273084|NCT02542254|DRUG|Ipratropium|40 micrograms ipratropium administered using a pMDI
224273085|NCT02542254|DRUG|RPL554|6 mg RPL554 administered using a nebuliser
224273086|NCT02542254|DRUG|Salbutamol matched placebo|Placebo pMDI
224273087|NCT02542254|DRUG|Ipratropium matched placebo|Placebo pMDI
224273088|NCT02542254|DRUG|RPL554 matched placebo|Nebulised placebo
224273089|NCT04816396|BEHAVIORAL|reminiscence Therapy|Application Stages of Reminiscence Therapy Based on Roy Adaptation Model Week 1 (Session 1):Introduction-Meeting-Infancyand Family Life Week 2 (Session 2):Childhood and School Years Week 3 (Session 3):Unforgettable Historical Periods,Old movies, Old Songs Week 4 (Session 4):Loved, meals,Desserts and Recipes,Nutrition Style Week 5 (Session 5):Work and Marriage Week 6 (Session 6):Home and Garden Works,Animals, Plants Week 7 (Session 7): Travels, Vacation Memories Week 8 (Session 8): Celebration Memories, Evaluation Posttest Closing.
224273090|NCT03069963|DRUG|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
224273091|NCT03069963|DRUG|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
224273092|NCT03275363|DIAGNOSTIC_TEST|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black \& white), verbal fluency, digit forward and backward span."
223517973|NCT05898334|DEVICE|Active Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.
224273093|NCT03275363|DIAGNOSTIC_TEST|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
224273094|NCT03275363|BIOLOGICAL|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
224273095|NCT03275363|DIAGNOSTIC_TEST|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
224273096|NCT03275363|DIAGNOSTIC_TEST|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
224273097|NCT04205539|DRUG|Dexmedetomidine|This medication will be administered sublingually using an LMA Intranasal Mucosal Atomization Device, which allows the medication to be administered in the form of a spray. Patients will be instructed to keep the medication in their mouth for about 2 minutes, or until fully absorbed. Pulse oximetry and blood pressure will be monitored throughout the duration of treatment. After the subject is asleep, the second DTI scan will be done.
224273098|NCT06246591|OTHER|Extracorporeal Shockwave Therapy (Group A)|Each patient was evaluated before treatment for trigger points; patients underwent focal ESWT (PulseWave 2 - Mectronic Medicale s.r.l.) with a specific program for muscle contractures and myofascial pain (80-100 mJ with 2250 pulses of 5-10 Hz).
224273099|NCT06246591|OTHER|Mesotherapy (Group B)|Each patient was evaluated before treatment for trigger points; after disinfection with Chlorhexidine 2% and sterile gauze, Thiocolchicoside fl 4mg/2ml, and a local anesthetic, Mepivacaine fl 10mg/1ml, diluted in 0.9% NaCl saline, for a final volume of 10 ml, were inoculated mesodermally; 6 to 12 microinjections with needle 26G 0.40x4mm, were performed.
224273100|NCT05290896|DEVICE|Phacoemulsification|Phacoemulsification for senile cataract.
224273101|NCT06467032|OTHER|superficial CO2 laser resurfacing|Application of the tested product and comparators on the laser treated side of the back
224273102|NCT06467032|OTHER|Laser untreated side|Application of the tested product and comparators on the laser untreated (control) side of the back
224273103|NCT00266487|DRUG|Folic acid|
224273104|NCT00266487|DRUG|Vitamin B12|
224273105|NCT00266487|DRUG|Vitamin B6|
224273106|NCT02786784|OTHER|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
224273107|NCT02246348|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
224273108|NCT01235260|OTHER|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
224273109|NCT01235260|DRUG|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
224273110|NCT05878899|DRUG|Enoxaparin|Prophylactic dose of enoxaparin once daily for 10 days after delivery.
224273111|NCT04895553|OTHER|Observation of ICH and VTE|The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.
224273112|NCT00633022|DRUG|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
224273113|NCT00633022|DRUG|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
224273114|NCT04483596|DRUG|melatonin effect on the Abbreviated Mental Test|"Questionnare~1. Age~2. Time (to nearest hour)~3. Address for recall at end of test (Ask patient to repeat the address to ensure it has been heard correctly)~4. Year~5. Name of hospital~6. Recognition of two persons (e.g. doctor, nurse)~7. Date of birth~8. Year of any famous event e.g: the last Egyptian revolution~9. Name of the present monarch~10. Count backwards from 20 to 1"
224273115|NCT04388787|DEVICE|Stochastic resonance (SR) wraps|SR wraps will be applied to the one or both wrists depending on whether the impairment is unilateral or bilateral. Two additional actuators will be secured around the shoulder. The threshold for detection of SR will be determined by the examiner prior to initiating the test condition. The intensity of the stimulation is adjustable with a scroll bar on the app and ranges from a 0 - 100. The examiner will gradually increase the stimulus intensity until the participant reports being able to feel it. This will set the participant's detection threshold.
224273116|NCT04327401|DRUG|Dexamethasone|Dexamethasone administration for 10 consecutive days after randomization.
224273117|NCT03698357|BEHAVIORAL|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
224273118|NCT03698357|BEHAVIORAL|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
224273119|NCT04541264|DIAGNOSTIC_TEST|radiomic of chest CT|radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.
224273120|NCT02279277|BEHAVIORAL|Supervised physical therapy program prior to total knee replacement surgery|
224273121|NCT06447285|DIAGNOSTIC_TEST|SensoDetect BERA technology|"All recruited participants are to be tested using SensoDetect's patented technology. All tests shall be performed in a quiet and darkened room. Participants will be asked to be comfortably seated in an armchair in a resting position (part 1 only). Surface electrodes will then be attached to the skin over the mastoid bones behind the left and right ear, with a ground electrode on one arm. Two reference electrodes will also be placed on the forehead. Before each test session, the procedure shall be fully explained to the test subject or parents.~The subjects will then be instructed to relax with their eyes closed and are permitted to fall asleep (with modifications in part 3). The test will require no active participation other than being subjected to sound stimulation. The subjects will be tested one at a time, and the duration of the testing procedure will be 15 min."
224273122|NCT00989716|DRUG|Transdermal glyceryl trinitrate patch|5mg per day
224273123|NCT00989716|DRUG|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
224273124|NCT01855880|BIOLOGICAL|AbGn-168H|
224273125|NCT01855880|BIOLOGICAL|placebo|
224273126|NCT01232244|OTHER|GLP-1 infusion|1 pmol/kg/min
224273127|NCT01232244|OTHER|Glucagon infusion|3ng/kg/min
224273128|NCT01232244|OTHER|Oxyntomodulin infusion|3 pmol/kg/min
224273129|NCT01232244|OTHER|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
224273130|NCT01232244|OTHER|Placebo|NaCl 9 g/L infusion
224273131|NCT03045198|DRUG|Azithromycin|
224273132|NCT00688844|DRUG|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
224083157|NCT01482910|DRUG|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
224273133|NCT00174980|DRUG|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
224273134|NCT01287351|DRUG|extra-fine hydrofluoroalkane beclometasone dipropionate|
224273135|NCT01287351|DRUG|Fluticasone propionate|
224273136|NCT01721551|OTHER|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
224273137|NCT01721551|OTHER|Usual Treatment|The CON group received no intervention but the usual treatment
224273138|NCT05511662|OTHER|PRO follow up|On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
224273139|NCT02803879|DEVICE|Cardiogoniometry|
224273140|NCT04196296|BEHAVIORAL|Psychoeducation|Online psychoeducation about social anxiety, evidence-based treatments that target social anxiety, and treatment referral/resource information.
224273141|NCT04196296|BEHAVIORAL|Motivation|Online exercises/activities regarding social anxiety (and treatment thereof) based in principles from Acceptance and Commitment Therapy (ACT) and Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET).
224273142|NCT01374451|DRUG|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
224273143|NCT01374451|DRUG|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
224273144|NCT00259194|BEHAVIORAL|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
224273145|NCT00259194|BEHAVIORAL|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
224273146|NCT04876716|DRUG|Azole|Dosing according to the SPC
224273147|NCT04876716|DRUG|Anidulafungin|200mg loading dose on day 1 and 100mg QD thereafter
224273148|NCT01360216|BEHAVIORAL|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
224273149|NCT01223027|DRUG|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
224273150|NCT01223027|DRUG|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
224273151|NCT01282450|RADIATION|Radiotherapy|Radiotherapy
224273152|NCT04651816|BEHAVIORAL|Financial Incentives|Participants will be entered into a lottery to receive a gift card for class attendance.
224273153|NCT04651816|BEHAVIORAL|Motivational Message|Participants will be sent motivational messages through out their participation in the PSH DPP program.
224273154|NCT04651816|BEHAVIORAL|DPP Program|All Participants will be enrolled in the DPP program.
224273155|NCT00685854|DRUG|Ranibizumab|
224273156|NCT00704249|DRUG|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
224273157|NCT00704249|DRUG|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
224273158|NCT01656876|BEHAVIORAL|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
224273159|NCT01656876|OTHER|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
224273160|NCT01656876|BEHAVIORAL|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
224273161|NCT02946255|BEHAVIORAL|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
224273162|NCT02946255|BEHAVIORAL|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
224273163|NCT02946255|BEHAVIORAL|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
224273164|NCT00540358|DRUG|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
224273165|NCT00540358|DRUG|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
224273166|NCT04618172|OTHER|Exercise|30 minute long exercises twice a week
224273167|NCT06249113|DRUG|NaCl 0.9%|NaCl 0.9% continous intravenous on tumor craniotomy surgery
224273168|NCT06249113|DRUG|Adjuvant lidocaine continous|Adjuvant lidocaine continous intravenous on tumor craniotomy surgery
224273169|NCT05013619|OTHER|Circumstances of pain|It will be questioned in which situations the pain occurred in the previous week (at rest from spasms, at rest from splints, on feeding, on moving, on dressing, at night, on exercise, on other treatments, on botulinum toxin application) and record as yes/no.
224273170|NCT05013619|OTHER|Pain Questionnaire|"Participants will be asked to respond to the initial question Over the past month, have you experienced physical pain? (yes or no). Those responding yes will be asked Please indicate how severe your pain was over the past month, on average, with response options from 1 (very little pain) to 10 (extremely painful). They will be also asked to indicate How much the pain gets in the way of your daily activities over the past month from a low of 1 (does not get in the way at all) to 10 (unable to carry out activities because of the pain). Finally, they will be asked to indicate the body regions in which they experienced pain."
224273171|NCT05013619|OTHER|Gross Motor Functional Classification System|Severity of CP will be determined based on the Gross Motor Functional Classification System (GMFCS). GMFCS is a standardised measure that classifies gross motor functions in children with CP. Children in level I are very independent in motor functions while those in level V are the least independent
224273172|NCT05013619|OTHER|The subtypes of Cerebral palsy|The subtypes of CP will be classified, using the Swedish classification, into spastic (tetraplegia, diplegia and hemiplegia), ataxic, dyskinetic and mixed
224273173|NCT01121744|DEVICE|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
224273174|NCT04169815|DIAGNOSTIC_TEST|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
223517974|NCT05898334|DEVICE|Inactive Biophoton Generators|The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
224273175|NCT03572582|DRUG|Nivolumab|Nivolumab therapy combined with standard TACE treatment
224273176|NCT03572582|DRUG|TACE|TACE is performed by using drug eluting beads
224273177|NCT01131091|DRUG|SK-0403|SK-0403 400 mg
224273178|NCT00724958|BIOLOGICAL|Infliximab|Not specified in the protocol.
224273179|NCT06028477|DEVICE|Stanford Glove|The non-invasive neuromodulation hardware system comprises two wireless controllers/battery packs which are fastened to the top of each hand via an adjustable elastic strap. Each controller is equipped with four vibrotactile fingertip stimulators, also known as tappers. There is a total of eight tappers (for index, middle, ring and pinkie of each hand) per system.
224273180|NCT06622239|DRUG|Naltrexone|naltrexone 50mg for 6 weeks
224273181|NCT06622239|DRUG|Placebo|placebo for 6 weeks
224273182|NCT05957159|OTHER|Detoxification Program|Patients will begin inpatient or outpatient detoxification prior to completing imaging
224273183|NCT05957159|RADIATION|PKAB|90 PET Imaging Scan using \[11C\]LY2795050 (AKA \[11C\]PKAB)
224273184|NCT05957159|RADIATION|CFN|90 Pet Imaging Scan using \[11C\]-Carfentanil
224273185|NCT05522244|DIAGNOSTIC_TEST|extended CTA|Extending the standard CTA 6 cm below the carina.
224273186|NCT06111534|BEHAVIORAL|Holding|Holding is an effective non-pharmacological method for reducing procedural pain. Minor painful procedures, such as heel pricks, are easy to use, practical, non-invasive, and affordable procedures when performed when the neonate is held/cuddled by one of its parents. Neonates held/cuddled by their mothers are likely to experience less pain and cry less during heel pricks. The MHC and PHC methods help neonates experience tactile, auditory, visual, and olfactory sensory inputs that can enhance analgesic effects. These multisensory methods can alleviate the pain experienced by the infant during minor painful procedures and shorten the crying time. This type of analgesia may be mediated by multisensory stimulation associated with the mother/father-infant attachment.
224273187|NCT00150683|DEVICE|vibration and passive standing versus passive standing alone|
224273188|NCT03908307|DRUG|OZURDEX|Implant 700 μg
224273189|NCT01520987|DRUG|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
224273190|NCT01520987|DRUG|Placebo|once-daily
224273191|NCT02301533|BEHAVIORAL|Shikamana Intervention|See arm description
224273192|NCT02301533|BEHAVIORAL|Standard Care|See arm description
224273193|NCT05109520|DRUG|Insulin Glargine 300 UNT/ML [Toujeo]|Switch during standard routine care to Gla-300.
224273194|NCT03567460|BEHAVIORAL|Exercise|Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
224273195|NCT02919020|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
224273196|NCT02919020|OTHER|Resistance exercise|resistance exercise to strengthen lower limbs
224273197|NCT01479062|BEHAVIORAL|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
224273198|NCT01479062|BEHAVIORAL|Usual Care|Placebo Control
224273199|NCT05721469|BEHAVIORAL|Art therapy|Determining the mothers of children with eating disorders with the data obtained from the questionnaires and scales and separating them into randomized experimental and control groups, 8-12 sessions of 90 minutes of music, painting, ceramics, etc. were given to the mothers participating in the experimental group. Art Therapy Studies
223517975|NCT01188993|COMBINATION_PRODUCT|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
223517976|NCT05444088|DRUG|Adebrelimab|intravenous infusion
223517977|NCT05444088|DRUG|Bevacizumab|intravenous infusion
224273200|NCT04171401|OTHER|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
224273201|NCT00636324|DEVICE|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
224273202|NCT00636324|DEVICE|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
224273203|NCT04729101|DRUG|Vonoprazan|Oral tablet
224273204|NCT04729101|DRUG|Lansoprazole|Oral capsule
224273205|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
224273206|NCT02940522|DRUG|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
224273207|NCT00274625|DEVICE|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
224273208|NCT00274625|PROCEDURE|Control|Incision is closed without the placement of a graft material (standard of care control)
224273209|NCT03845816|BEHAVIORAL|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
224273210|NCT06677723|BEHAVIORAL|physical activity|moderate-intensity running
224273211|NCT05060458|OTHER|No intervention|No intervention
224273212|NCT00388219|DRUG|Transtec (R) PRO (buprenorphine)|
224273213|NCT02959840|DEVICE|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
224273214|NCT02959840|DRUG|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
224273215|NCT02959840|DRUG|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
224273216|NCT02802462|BEHAVIORAL|HIT|3-minute intervals at 40% and 80%VO 2max
224273217|NCT02802462|BEHAVIORAL|MCT|sustained 60%VO 2max
224273218|NCT00003387|DRUG|carboplatin|
224273219|NCT00003387|DRUG|chemotherapy|
224273220|NCT00003387|DRUG|paclitaxel|
224273221|NCT00003387|RADIATION|radiation therapy|
224273222|NCT04022031|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
224273223|NCT05746507|BEHAVIORAL|Night Respite Care|(see description above)
224273224|NCT02795026|PROCEDURE|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
224273225|NCT02795026|PROCEDURE|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
224273226|NCT00497679|DRUG|AZD1152|7-day continuous intravenous infusion
224273227|NCT06375187|BIOLOGICAL|Engineering Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC203 TIL followed low-dose PD-1 antibody.
224273228|NCT01762228|DEVICE|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
224273229|NCT01762228|DIETARY_SUPPLEMENT|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
224273230|NCT03348488|PROCEDURE|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
224273231|NCT06628609|OTHER|Passive recovery|Volunteers laid in supine position resting for 30 minutes.
224273232|NCT06628609|DEVICE|PBMT-sMF|PBMT-sMF applied in the lower limbs with different doses per muscle group.
224273233|NCT06628609|DEVICE|Shock wave|Shock wave therapy applied in the lower limbs for 30 minutes.
224273234|NCT06628609|DEVICE|Pneumatic compression|Pneumatic compression applied in the lower limbs for 30 minutes.
224273235|NCT06677983|OTHER|Bioflex Crowns|A preformed crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area.
224273236|NCT06677983|OTHER|Stainless steel crown|An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur ) to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement. Any excess cement will be removed, and proper occlusion will be verified.
224273237|NCT01355328|PROCEDURE|laser and radiofrequency|different laser and radiofrequency with different fluences
224273238|NCT05122351|DRUG|Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries|Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
224273239|NCT04414137|OTHER|Description of eosinophilic pneumonia due to daptomycine|Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
224273240|NCT05550831|PROCEDURE|Radiofrequency|Peripheral ablation of affected Morton´s Neuroma nerve endings by thermal dissipation by an electrode.
224273241|NCT04397640|DIAGNOSTIC_TEST|Sonovue|Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
224273242|NCT01754376|DRUG|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
224273243|NCT01754376|DRUG|Vemurafenib|Tablets given twice daily.
224273244|NCT04931160|OTHER|Blood, fluid, sells and urine samples|Blood, fluid, sells and urine samples will be collected.
224273245|NCT01735786|DEVICE|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
224273246|NCT02502968|DRUG|Cytarabine|
224273247|NCT02502968|DRUG|BL-8040|
224273248|NCT02502968|DRUG|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
224273249|NCT01056926|BEHAVIORAL|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
224273250|NCT01056926|DRUG|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
224273251|NCT01056926|DRUG|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
224273252|NCT03098186|BEHAVIORAL|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
224273253|NCT03098186|BEHAVIORAL|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
224273254|NCT00071539|DRUG|TP-38|Recombinant chimeric protein
224273255|NCT00071539|DRUG|TP38|recombinant chimeric protein
224273256|NCT01737255|OTHER|Whole body MRI|Individuals will undergo whole body and brain MRI
224273257|NCT01737255|OTHER|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
224273258|NCT01386034|DRUG|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-\[1-13C\]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
224273259|NCT04264819|DRUG|RTH258/Brolucizumab|Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.
224273260|NCT06535490|PROCEDURE|EUS-FNA|Puncture of pancreatic cystic lesion with a fine needle under EUS guidance
224273261|NCT06535490|DRUG|ATBp|Antibiotic prophylaxis consists of a single intravenous administration before or at the beginning of the procedure according to the common practices of each practitioner or unit
224273262|NCT03336879|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
224273263|NCT05302479|OTHER|COMPASS 31 questionnaire|A 31 question questionnaire that measures autonomic symptoms.
224273264|NCT02136706|PROCEDURE|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
224273265|NCT04502706|DRUG|GS-0189|GS-0189 will be administered intravenously.
224273266|NCT04502706|DRUG|Rituximab|Rituximab will be administered intravenously.
224273267|NCT01159106|OTHER|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
224273268|NCT01159106|OTHER|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
224273269|NCT05393349|BEHAVIORAL|Empowering the patient and caregiver for early and safe discharge of patients with geriatric hip fractures|Orthopaedic surgeon, geriatrician, physiotherapists, occupational therapists, and nurses will make videos (each 3-5 minutes long) which are available to the patients and caregivers during both the hospitalization period and after discharge. They will complement the therapists' training sessions and allow revision of the contents by the patients and caregivers anytime. The patients and caregivers will be asked to complete an assessment after they view the videos to reinforce the knowledge they learn in the videos. Caregivers can be patient's relatives, friends or domestic helper who can commit to visiting the patient at least two days per week during the early discharge period.
224273270|NCT00602615|DRUG|Torsemide|
224273271|NCT03481855|DEVICE|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
223517978|NCT05444088|DRUG|SHR-8068|intravenous infusion
223517979|NCT04130867|PROCEDURE|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
223517980|NCT04130867|PROCEDURE|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
224273272|NCT00856622|DRUG|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
224273273|NCT00856622|DRUG|timolol 0.5% ophthalmic solution|one drop in the morning and evening
224273274|NCT00856622|DRUG|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
224273275|NCT00817141|OTHER|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
224273276|NCT00549341|DRUG|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
224273277|NCT00549341|OTHER|Physiologic saline|Single injection.
224273278|NCT01267916|DEVICE|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
224273279|NCT01267916|DEVICE|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
224273280|NCT01267916|DEVICE|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
224273281|NCT01267916|DEVICE|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
223517981|NCT01512251|DRUG|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
224273282|NCT01267916|DEVICE|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
224273283|NCT01267916|DEVICE|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
224273284|NCT02371928|OTHER|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
224273285|NCT02371928|OTHER|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
224273286|NCT05120687|DRUG|noncorticosteroid systemic immunomodulatory therapy (NCSIT)|Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.
224273287|NCT01590251|OTHER|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
224273288|NCT01590251|BEHAVIORAL|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
224273289|NCT01520545|DRUG|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
224273290|NCT01520545|DEVICE|SynchroMed® II Programmable Pump|Intrathecal programmable pump
224273291|NCT01866176|DEVICE|Stabilizing Knee Brace|Brace with no valgus action
224273292|NCT01866176|DEVICE|Valgus Knee Brace|Valgus brace with traditional three point bending system
224273293|NCT01866176|DEVICE|New Knee Brace|Brace with new mechanism to decrease the knee loading.
224273294|NCT04564404|OTHER|Survey|Questionnaire to ask about the willingness-to-buy applications in neuromuscular monitoring.
224273295|NCT02111434|DRUG|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
223517982|NCT05065671|DRUG|Tolcapone 100 MG|Tolcapone 100 mg by mouth once
223893608|NCT06225245|DEVICE|Epidural Spinal Stimulation (ESS)|ESS will be delivered using The CoverEdgeX 32 Surgical Lead at frequencies of 0.2 to 60 Hz with intensity up to 10 mA, adjusted to induce motor threshold responses in the target muscle for the above motor task (e.g., biceps brachii for elbow flexion) \[31-33\]. The ESS controller will only be operated by trained study team members. Therefore, stimulation will only be delivered during study visits. Stimulation will be administered for a maximum duration of 1 hour total per visit, varying according to the individual's tolerance and fatigue levels, with 5 - 10 minutes breaks interspersed between intervals of stimulation.
223893609|NCT05193149|BEHAVIORAL|Inspiratory muscle training|Training of respiratory muscles
223893610|NCT05193149|BEHAVIORAL|Exercise training|Supervised aerobic exercise intervention
223517983|NCT05065671|DRUG|Duloxetine 20 MG|Duloxetine 20 mg by mouth once
223517984|NCT04356378|OTHER|Data record|Data record
223517985|NCT06644027|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
223517986|NCT06644027|DEVICE|Molicare Premium Bed Mat|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
223517987|NCT06252987|OTHER|routine treatment|Routine medical treatment, basic rehabilitation training and individualized cognitive training
223517988|NCT06252987|OTHER|Non-invasive brain stimulation|tDCS\&rTMS
223517989|NCT04246749|DRUG|[14C]-CRN00808|Investigational drug
223517990|NCT04246749|DRUG|CRN00808|Investigational drug
223893611|NCT04123366|DRUG|Olaparib|Oral tablet
224273296|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
224273297|NCT04768296|DRUG|Berzosertib|Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
224273298|NCT04768296|DRUG|Topotecan|Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
224273299|NCT00919334|DEVICE|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
224273300|NCT04999696|PROCEDURE|radical hysterectomy|To compare disease-free survival and overall survival of patients with early stage cervical cancer undergoing total laparoscopic radical hysterectomy versus total abdominal radical hysterectomy
224273301|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate|1.2 g/kg/h
224273302|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
224273303|NCT00975390|DIETARY_SUPPLEMENT|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
224273304|NCT00646503|DRUG|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
224273305|NCT06675890|DIAGNOSTIC_TEST|serum homocysteine|serum homocysteine is associated with atherosclerosis and vascular diseases.
224273306|NCT01910337|DEVICE|Use the Polar Cardiac rate meter|
224273307|NCT05333315|DIETARY_SUPPLEMENT|IP1|"IP1: 2 softchews 3 times a day before meals with 1-2 glasses of water for eight weeks.~OTHER: Placebo"
224273308|NCT05333315|DIETARY_SUPPLEMENT|IP2|"IP2: One bag per day mixed in 200 mL of cold water or tea and consumed immediately, on an empty stomach, half an hour before breakfast for eight weeks.~OTHER: Placebo"
224273309|NCT05333315|DIETARY_SUPPLEMENT|IP3|"IP3: One bag per day in the morning, dissolved in a glass of warm water and three capsules per day with a glass of water or tea (one capsule at breakfast, one at lunch and one at dinner) for eight weeks.~OTHER:Placebo"
223893612|NCT04123366|BIOLOGICAL|Pembrolizumab|Intravenous infusion
224273310|NCT05333315|DIETARY_SUPPLEMENT|IP4|"IP4: Twice a day 20 mL half an hour before breakfast and half an hour before dinner for eight weeks.~OTHER:Placebo"
224273311|NCT05333315|DIETARY_SUPPLEMENT|IP5|"IP5: Formula 1: One capsule per day at breakfast with a glass of water for eight weeks and Formula 2: Two capsules a day at breakfast and at dinner with a glass of water for eight weeks.~OTHER:Placebo"
224273312|NCT00658957|DRUG|gentamicin-collagen sponge|5 × 5 cm sponge
224273313|NCT00658957|DRUG|placebo collagen sponge|5 × 5 cm sponge
224273314|NCT03798340|OTHER|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
224273315|NCT03798340|OTHER|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
224273316|NCT03798340|OTHER|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
224273317|NCT00491257|BIOLOGICAL|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
224273318|NCT01618630|DIETARY_SUPPLEMENT|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
224273319|NCT01618630|DIETARY_SUPPLEMENT|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
224273320|NCT06236412|BEHAVIORAL|Health education|Health education about the contents listed under each arm will be provided for the participants.
224273321|NCT03087786|DRUG|Nicotine Bitartrate Lozenge 4mg|Test Product
224273322|NCT03087786|DRUG|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
224273323|NCT04383717|DRUG|Levamisole and isoprinosine|oral tablets levamisole 50 mg 3 times daily every other day for 2 weeks Isoprinosine oral tablets 1 g 4 times daily for 2 weeks
224273324|NCT04383717|DRUG|Azithromycin and hydroxychloroquine|oral tablets daily 500 mg azithromycin Oral tablets daily 200 mg hydroxychloroquine twice daily
224273325|NCT02145624|DRUG|Repevax|vaccine
224273326|NCT02145624|DRUG|Boostrix-IPV|vaccine
224273327|NCT06616883|DRUG|DA-5221_01|single dose administration (DA-5221\_01 one tablet once a day)
224273328|NCT06616883|DRUG|DA-5221_01-R1 + DA-5221_01-R2|single dose administration (DA-5221\_01-R1 one tablet once a day + DA-5221\_01-R2 one tablet once a day)
224273329|NCT00122447|DRUG|Aspirin|325 mg PO QD
224273330|NCT00122447|DRUG|Alpha lipoic acid|600 mg PO BID
224273331|NCT00122447|DRUG|Olmesartan|40 mg PO QD
224273332|NCT00122447|DRUG|Placebo|"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
224273333|NCT02574715|DRUG|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
224273334|NCT03885869|OTHER|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
224273335|NCT03885869|OTHER|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
224273336|NCT03885869|OTHER|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
224273337|NCT03885869|OTHER|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
224273338|NCT03885869|OTHER|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
224273339|NCT03885869|OTHER|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
224273340|NCT05103709|OTHER|MULTI-FORTIFIED|Treatment with multifortified bread for 120 days
224273341|NCT05103709|OTHER|FORTIFIED|Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
224273342|NCT02775578|PROCEDURE|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
224273343|NCT02775578|PROCEDURE|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
224273344|NCT02775578|PROCEDURE|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
224273345|NCT06461793|RADIATION|Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients|this researcher performed biodegradable material injection during radical radiotherapy in combination with hormone therapy in high - risk prostate cancer patients. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.
224273346|NCT00458107|DRUG|SCA-136|
223517991|NCT03564067|DEVICE|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
224273347|NCT03983798|OTHER|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
224273348|NCT00030524|DRUG|gefitinib|
224273349|NCT01453153|DRUG|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
224273350|NCT01453153|DRUG|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
223517992|NCT03564067|BEHAVIORAL|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
223517993|NCT02598973|BEHAVIORAL|Exercise|Aerobic walking
223517994|NCT01790191|BEHAVIORAL|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
224273351|NCT01453153|DRUG|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
224273352|NCT03662724|DRUG|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
224273353|NCT05472896|PROCEDURE|cTACE|transcatheter arterial chemoembolization with
224273354|NCT05472896|DRUG|Dicycloplatin (TP21)|the dosage of dicycloplatin was based on the body surface area (550 mg/m2) according to previous research. The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
224273355|NCT05472896|DRUG|Epirubicin|the dosage of epirubicin was determined according to the tumor size, and the maximum dose was limited to 40 mg. The volume ratio of lipiodol to epirubicin aqueous solution was 2:1. The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL.
224273356|NCT06073899|OTHER|Leg Extension Exercise|Participants will perform a concentric quadriceps contraction into terminal knee extension with weight equivalent to 65% of a1-repetition maximum.
224273357|NCT02711033|PROCEDURE|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
224273358|NCT02711033|PROCEDURE|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
224273359|NCT04735107|PROCEDURE|colorectal anastomosis reinforcement and trans-anal drainage|Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
224273360|NCT06013930|BEHAVIORAL|External Qigong|External Qigong will be facilitated by a seasoned Qigong practitioner. The Qigong practitioner will assist participants in learning how to use the healing powers of their bodies to decrease feelings of anxiety and/or depression
224273361|NCT06013930|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a meditation designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
224273362|NCT06013930|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to managing anxiety and/or depression through a recorded presentation. Participants will learn about stress-management techniques to help reduce symptoms of anxiety and/or depression. They will also receive information on resources that could be helpful in treating anxiety and/or depression.
224273363|NCT04582799|DEVICE|ECCO2R|Extracorporeal CO2 Removal
224273364|NCT04582799|DEVICE|NIV|Non-invasive ventilation
224273365|NCT05113563|DEVICE|Transcranial Electric Stimulation Therapy|TEST is a form of brain stimulation.
224273366|NCT03055871|BEHAVIORAL|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
224273367|NCT03055871|BEHAVIORAL|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
224273368|NCT05720663|OTHER|Standard of care|Participants will receive the standard of care for their condition
224273369|NCT04140929|OTHER|Oral Health Tool Box|Please see, description of the intervention group
224273370|NCT00361049|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
224273371|NCT00361049|GENETIC|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
224273372|NCT00361049|OTHER|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
224273373|NCT00361049|OTHER|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
224273374|NCT00361049|OTHER|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
223893613|NCT05207202|DEVICE|electrical impedance tomography|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to zero every 2min.
223893614|NCT06480448|OTHER|Traditional physical herapy|core stability, strengthening exercises, stationary bicycle training and sustained strechinng exercises.
223893615|NCT06480448|OTHER|Treadmill training|Treadmill training for 20 minutes three time a week.
224273375|NCT00361049|PROCEDURE|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
224273376|NCT00361049|PROCEDURE|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
224273377|NCT04657315|DRUG|MSC11FCD|"Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration"
224273378|NCT02751866|DIETARY_SUPPLEMENT|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
224273379|NCT02751866|DIETARY_SUPPLEMENT|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
224273380|NCT05146024|BEHAVIORAL|Way To Serve Plus: Improving Responsible Alcohol Service|Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
224273381|NCT03379636|DEVICE|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
224273382|NCT03379636|DEVICE|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
224273383|NCT01802216|PROCEDURE|Scaling and root planing|non-surgical periodontal disease treatment
224273384|NCT01802216|DRUG|Minocycline|antibiotic microspheres
224273385|NCT00880334|DRUG|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
224273386|NCT00880334|DRUG|vandetanib|taken orally once a day, every day
224273387|NCT00880334|DRUG|Placebo|Taken orally once a day every day
224273388|NCT03523546|OTHER|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
224273389|NCT04408534|OTHER|mode of noninvasive ventilation|administration of during 3 hours each 4 cycles
224273390|NCT00076245|BEHAVIORAL|Light Therapy|Light therapy will involve exposure to bright light twice a day.
224273391|NCT00076245|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
224273392|NCT03368027|BEHAVIORAL|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
224273393|NCT03368027|OTHER|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
224273394|NCT06358027|DIAGNOSTIC_TEST|lung ultrasound|The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
224273395|NCT05061992|DRUG|Lactulose|"Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28."
224273396|NCT01738217|PROCEDURE|Fluobeam|
224273397|NCT06616181|DEVICE|Anodal tDCS over M1|The anode will be placed over the left M1 (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
224273398|NCT06616181|DEVICE|Anodal tDCS over DLPFC|The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC) (C3 according to the International 10-20 system), and the cathode will be positioned over the right supraorbital area (FP2). Once the electrodes are positioned, continuous stimulation at 2mA will be applied for 20 minutes per session, with 30-second initial and final ramp-ups. One session will be administered per week for 12 weeks.
224273399|NCT06616181|BEHAVIORAL|Exercise telerehabilitation|Two weekly 50-minute sessions of mixed exercise, including both aerobic and resistance components, will be performed. Aerobic exercises will involve large muscle groups, and resistance training will be performed through elastic bands of varying intensity will be used for strengthening exercises. Exercise intensity will be regulated using the modified Borg Rating of Perceived Exertion scale (0-10), with participants maintaining between 4 and 7 points on this scale. The exercises will be monitored through video and weekly phone contact.
224273400|NCT02473393|DRUG|OPS-2071 tablet|
224273401|NCT00040794|DRUG|paclitaxel|Given IV
224273402|NCT00040794|DRUG|carboplatin|Given IV
224273403|NCT00040794|DRUG|gefitinib|Given PO
224273404|NCT00040794|RADIATION|radiation therapy|Undergo radiotherapy
224273405|NCT00040794|OTHER|laboratory biomarker analysis|Optional correlative studies
224273406|NCT04274829|PROCEDURE|Thyroidecomt and lymphectomy|Patients underwent total thyroidectomy or lobectomy associated to lymph node sampling or neck lymphectomy
224273407|NCT00616096|PROCEDURE|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
224273408|NCT01751633|PROCEDURE|Surgical|
224273409|NCT01751633|PROCEDURE|Conservative treatment|
224273410|NCT02658435|DRUG|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
224273411|NCT02658435|DRUG|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
224273412|NCT00458159|DRUG|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, \& 50mg, taken once daily, orally.
224273413|NCT00297141|DRUG|Capecitabine|chemotherapy oral use
223704024|NCT01306396|BEHAVIORAL|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
224273414|NCT00297141|DRUG|Oxaliplatin|chemotherapy intravenous use
224273415|NCT00891098|BEHAVIORAL|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
224273416|NCT00891098|BEHAVIORAL|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
224273417|NCT04224948|DEVICE|PET MRI scan|"Standard of care includes a baseline PET-CT and conventional CT after 2 cycles of neoadjuvant chemotherapy, and after 5-6 cycles, of neoadjuvant chemotherapy, as per current practice/ standard of care.~Patients that enroll in the trial will receive two additional PET MRI scans- one at baseline and one after 1 cycle of chemotherapy"
224273418|NCT03316157|DIETARY_SUPPLEMENT|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
224273419|NCT03316157|BEHAVIORAL|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
224273420|NCT03874026|DRUG|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
224273421|NCT00481026|DEVICE|transcranial direct current stimulation (tDCS)|tDCS
224273422|NCT00481026|DEVICE|active tDCS|Active tDCS
224273423|NCT02899312|DRUG|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
224273424|NCT01677650|DRUG|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
224273425|NCT02684539|DEVICE|tilt table Erigo®|tilting table with onset of syncope
224273426|NCT06004934|DRUG|Avacopan|Administered orally.
224273427|NCT02274558|DRUG|NBI-98854|NBI-98854 40 mg capsules
224273428|NCT02274558|DRUG|Placebo|NBI-98854 placebo capsules
224273429|NCT06143462|DRUG|Usual care|Include anti-dizziness medications, diuretics, or hormone therapy.
224273430|NCT06143462|OTHER|Health Education|Include comprehensive health education, fall prevention and lifestyle adjustments.
224273431|NCT06143462|BEHAVIORAL|vestibular rehabilitation|Encompass office-based sessions of vestibular rehabilitation treatment once weekly, supplemented by home-based exercises conducted two or three times daily for the remaining duration of the study.
224273432|NCT04479735|DEVICE|Virtual Reality Goggles|Virtual reality goggles will placed at least 2 min prior to venipuncture to deteremine if it mitigates perceived anxiety or perceived pain scores.
224273433|NCT02964390|PROCEDURE|Balloon Pulmonary Angioplasty|
223704025|NCT06792721|GENETIC|Mutation Burden cfMB analysis|Blood samples will be collected (one time only)
224273434|NCT05296941|PROCEDURE|Brush sampling|Brush sampling instead of surgical biopsy for control of reaccurance
224273435|NCT05603936|OTHER|Questionnaire|"The original QOLISSY questionnaire was first developed in 2011, it is available as a patient reported and a parent reported instrument. It includes:~* QoLISSY questionnaire for children and adolescents (8-12, 13-18 yrs)~* QoLISSY questionnaire for parents of children with short stature (4-7, 8-12 and 13-18 yrs) The QoLISSY instrument can be used to assess the health-related quality of life in short stature youth regardless of its cause; however it was specifically developed for patients with GHD and ISS and their parents.The aim of the current study is the adaption, implementation and validation of the instrument for the investigation of the short stature specific quality of life (QoLISSY) for children (age 0-4 years) with achondroplasia (ACH), Small for Gestational Age (SGA) and Growth Hormone Deficiency (GHD) from a parental perspective."
224273436|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
224273437|NCT01191606|PROCEDURE|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
224273438|NCT05333653|OTHER|Continouse supportive care|"Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic."
224273439|NCT05333653|OTHER|routine care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
224273440|NCT02509260|DEVICE|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
224273441|NCT02509260|OTHER|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
224273442|NCT01775722|DEVICE|Pulsed Dye Laser|port wine stain
224273443|NCT01775722|DEVICE|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
224273444|NCT00964353|DRUG|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
224273445|NCT03389763|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
224273446|NCT03135340|PROCEDURE|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
224273447|NCT03135340|PROCEDURE|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
224273448|NCT03135340|DRUG|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
224273449|NCT03135340|DRUG|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
224273450|NCT01782755|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
224273451|NCT01782755|OTHER|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
223704026|NCT00277836|DRUG|MST-997|
224273452|NCT03278158|DRUG|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
224273453|NCT03278158|DRUG|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
224273454|NCT03278158|DRUG|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
224273455|NCT03278158|DRUG|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
224273456|NCT03278158|DRUG|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
224273457|NCT03658148|PROCEDURE|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
224273458|NCT06277050|DRUG|Maintenance Therapy with Toripalimab and Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. Maintenance therapy of Toripalimab (240 mg, every 3 weeks). The total treatment time of oral chemotherapy is 12 months.
224273459|NCT06277050|DRUG|Maintenance Therapy with Capecitabine|Capecitabine maintenance therapy (1000 mg/m2 orally twice daily on days 1-14) every 3 weeks. The total treatment time of oral chemotherapy is 12 months.
224273460|NCT03994536|BEHAVIORAL|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
224273461|NCT03994536|OTHER|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
224273462|NCT01708655|OTHER|Sweat Evaporimeter measurement|"1. The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~2. intracutaneous injection of 0.2 ml of atropine~3. Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~   1. Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~  2. intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~  3. intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
224273463|NCT06628999|OTHER|Visual Training|16-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness
224273464|NCT06628999|OTHER|Control Group|16-week of active lifestyle based on healthy habits
224273465|NCT06628999|OTHER|Visual Training-detraining|8-week training protocol focused on visual training designed for ameliorating cognitive performance and physical fitness, followed by 8 week with no specific training protocol
224273466|NCT05393271|DRUG|VH4011499|VH4011499 will be administered.
224273467|NCT05393271|DRUG|Placebo|Placebo will be administered.
224273468|NCT05393271|DRUG|Midazolam|Midazolam will be administered
224273469|NCT02943993|DRUG|Edoxaban|Prescribed according to approved label
224273470|NCT04178096|OTHER|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
224273471|NCT03759236|BEHAVIORAL|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
224273472|NCT03759236|BEHAVIORAL|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
224273473|NCT04317820|BEHAVIORAL|Deep Brain Reorienting (DBR)|Trauma processing through DBR involves bringing up a traumatic memory and encouraging the client to focus on tensions arising in the muscles of the shoulders, neck, head and face (i.e., those involved in orienting toward a threatening person/event). The rationale is as follows: Physiologically, orienting to a stimulus, whether external or in the mind's eye, comes before any affective response to it. Here, it is hypothesized that there is activity in certain midbrain structures , i.e.,Superior Colliculi (SC) and Periaqueductal Gray (PAG). The deep layers of the SC bring on a brief (orienting) tension in the neck as well as preparing for eye movements, which is later followed by the processing of raw affect in the PAG. In session, if we can attend to this tension - even if we have to backtrack from the emotion that follows - we can establish an anchor in the body that precedes the affect and is hypothesized to protect against emotional overwhelm.
224273474|NCT06486506|OTHER|Analysis|Analysis and review of imaging and clinical data
224273475|NCT06430463|DIAGNOSTIC_TEST|pure tone audiometry levels|The patient will be examined by ENT physician on the morning of the operation, otoscopic examination will be performed, pure tone audiometry, speech audiometry and tympanometric examination will be performed and recorded.The same tests will be performed at the next day after the surgery but before the discharge and also when he/she applies for the first week check-up.
224273476|NCT03946995|OTHER|Dry Needling Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week."
224273477|NCT03946995|OTHER|Graston Technique Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week."
224273478|NCT04968925|DEVICE|ACUVUE Oasys 1-Day|TEST
224273479|NCT04968925|DEVICE|Precision 1|CONTROL
224273480|NCT02829684|OTHER|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
224273481|NCT00033150|BEHAVIORAL|Fast ForWord|
224273482|NCT00033150|BEHAVIORAL|Computer Assisted Language Intervention|
224273483|NCT00033150|BEHAVIORAL|Individual Language Intervention|
224273484|NCT00033150|BEHAVIORAL|Academic enrichment|
224273485|NCT03408730|BIOLOGICAL|Hepatitis B Vaccination|Hepatitis B Vaccination
224273486|NCT05682963|OTHER|Square Step Exercises Program|Intervention description: patient will be treated for eight weeks, two days a week, one session a day, and total 16 session. Each session will be 45 minute.
224273487|NCT05682963|OTHER|Home Exercise Program|Frenkel's coordination exercises will be applied as a home program for 8 weeks, 2 days a week, with each exercise session 15-30 minutes excluding rest periods.
224273488|NCT02625311|PROCEDURE|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
224273489|NCT05077501|DRUG|ACD856|Multiple daily oral doses of ACD856 will be administered for 7 days in an escalation scheme of dose 1, dose 2 and dose 3. The escalation schedule may be adapted based on evaluation by the internal Safety Review Committee.
224273490|NCT05077501|DRUG|Placebo|Placebo oral solution
224273491|NCT01566994|BEHAVIORAL|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
224273492|NCT01566994|BEHAVIORAL|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
224273493|NCT01566994|BEHAVIORAL|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
224273494|NCT02360007|DRUG|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad"
224273495|NCT04284007|DRUG|Perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
224273496|NCT04284007|DRUG|Perineural dexamethasone in addition to levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 4mg dexamethasone diluted in 2 ml saline in interscalene brachial plexus block plus 10 ml intravenous saline.
224273497|NCT04284007|DRUG|Intravenous dexamethasone with perineural levobupivacaine|Patients will receive 20 ml of 0.25% levobupivacaine plus 2ml saline in interscalene brachial plexus block plus 4 mg intravenous dexamethasone diluted in 10 ml saline.
223704027|NCT03499704|DRUG|Pioglitazone + Alogliptin|Pioglitazone and Alogliptin FDC tablets
224273498|NCT00487695|DEVICE|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
223704028|NCT03499704|DRUG|Alogliptin|Alogliptin tablets.
224273499|NCT00487695|DEVICE|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
224273500|NCT05916248|BIOLOGICAL|Personalized neoantigen tumor vaccine|Neoantigen tumor vaccine
224273501|NCT05916248|BIOLOGICAL|PD-1 inhibitor|pembrolizumab
224273502|NCT06166264|OTHER|Progressive resistance training|It consists of patients who will receive both Resistance exercise training sessions and aerobic training 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercises used in the resistance exercise 1)Standing chess press;(2)Strengthening back muscles in sitting position;(3)Standing strengthening abduction of both shoulders;(4)Standing strengthening flexion of both shoulders;(5)Standing strengthening flexion of both forearms;(6)Standing strengthening extension of both forearms;(7)Strengthening extension of both knees in sitting position;(8)Strengthening flexion of both knees in sitting position;(9)Strengthening dorsiflexion of both ankles in sitting position.
224273503|NCT06166264|OTHER|Control group|The participants will receive information regarding health education.
224273504|NCT04542694|DRUG|Favipiravir|200 mg coated tablets
224273505|NCT04542694|DRUG|Standard of care|"Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc."
224273506|NCT03677219|OTHER|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
224273507|NCT00969124|DEVICE|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
224273508|NCT05344716|DEVICE|Laser|Intraurethral and vaginal laser treatment
224273509|NCT03859128|BIOLOGICAL|TORIPALIMAB INJECTION(JS001 )|Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
224273510|NCT05824494|DRUG|Cadonilimab|Cadonilimab 10mg/kg,every 3 weeks,IV infusion
224273511|NCT05824494|DRUG|Nab paclitaxel|Nab paclitaxel ≤260mg/m2,every 3 weeks,IV infusion
224273512|NCT06103279|DRUG|Empagliflozin 10 MG|1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
224273513|NCT00687739|DRUG|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
224273514|NCT00687739|DRUG|Estradiol Transdermal|0.075 mg patch per day for 5 months
224273515|NCT00687739|BEHAVIORAL|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
224273516|NCT05431777|DRUG|Avelumab|As provided in real world setting
224273517|NCT04650243|DRUG|ursodeoxycholic acid|The two experimental groups will receive reduced dosage of UDCA at 10mg/Kg and 5mg/Kg everyday respectively, while the control group will receive standard dosage of UDCA.The treatment duration will be at least one year.
224273518|NCT05479448|OTHER|Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness)|Biological material will be sampled at three time-points. The first time-point will be when patients have been treated with 15 mg of prednisone per day for at least 5 days. A second time-point will be after prednisone was successfully tapered and maintained at 5 mg per day for at least 5 days, a third time point will be 4 weeks after the stop of prednisone. Biosampling is done for cellular analyses, pharmacokinetics and hormone measurements.
224273519|NCT05479448|OTHER|Data collection for exploratory analyses of endogenous steroid hormones|Concentrations of GC, MC, androgens and progestins will be determined and the suppression of cortisol and cortisone upon prednisone treatment will be analyzed.
224273520|NCT05479448|OTHER|Data collection for correlation between clinical defined and lab defined GC responsivness|The time to first relapse, the cumulative steroid dose at 1 year after diagnosis, the need for treatment with steroid sparing agents and the GTI after 1 year will be correlated to the percentage of in vitro inhibition of cytokine concentration by dexamethasone treatment, to the prednisone/prednisolone ratio in plasma, to the percentage of endogenous GC suppression (plasma and urinary cortisol and cortisone) by prednisone treatment. Furthermore, correlations of steroid sensitivity with Mineralocorticoid (MC) and androgens will be investigated.
223704029|NCT03499704|DRUG|Metformin|Metformin tablets.
224273521|NCT05479448|OTHER|Data collection for Prednisone metabolism|Plasma concentrations of prednisone and its active metabolite prednisolone will be quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). If changes on prednisone/prednisolone are observed, the quantification of the 6-hydroxylated prednisone/prednisolone metabolites in 24 h urine samples will be performed to estimate their metabolism as well as the ratio of inactive to active GC.
224273522|NCT04237350|BEHAVIORAL|Video recording for behaviors|"A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded."
224273523|NCT01069614|DEVICE|TopClosure 3S System|
224273524|NCT04413968|DIAGNOSTIC_TEST|Rapid detection test|Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff
223704030|NCT03499704|DRUG|Dapagliflozin|Dapagliflozin tablets.
223704031|NCT03695744|DRUG|Daratumumab|Daratumumab
223704032|NCT03695744|DRUG|Bortezomib|Bortezomib
224273525|NCT04413968|DIAGNOSTIC_TEST|Nasopharyngeal swab|Posterior nasopharyngeal swabbing in children
224273526|NCT04413968|DIAGNOSTIC_TEST|Stool collection|Stool collection in children
223704033|NCT03695744|DRUG|Dexamethasone|Dexamethasone
223517995|NCT01790191|BEHAVIORAL|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
223517996|NCT01790191|BEHAVIORAL|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
223517997|NCT05810467|OTHER|Active Surveillance|"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."
223517998|NCT03707392|OTHER|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
223517999|NCT03707392|OTHER|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
223518000|NCT04222504|BEHAVIORAL|Provision of sexual health preventative services in the salon setting|"Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services."
223518001|NCT05607589|DRUG|DWP213388|immunosuppressant
223893616|NCT05545761|OTHER|music therapy|Feedback will be received via WhatsApp that the participants have listened to the maqam conveyed to them.Before applying music therapy in the experimental group, they will be asked to fill out the questionnaires.At the end of the music therapy application, the questionnaires made at the beginning will be applied to the experimental group again.No application will be made to the control group, and data collection forms will be applied twice with an interval of 4 weeks.
223893617|NCT05538754|DEVICE|EVO ICL|The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
223893618|NCT03420508|DRUG|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
223893619|NCT03420508|DIAGNOSTIC_TEST|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
223893620|NCT04471038|BIOLOGICAL|SAB-176|Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
223893621|NCT04471038|OTHER|Normal Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
223893622|NCT06126198|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS induces local electrical currents in the stimulated neurons and has been shown to induce long-term inhibition or excitation of groups of neurons in treated cortical areas
223893623|NCT03576248|DEVICE|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
223893624|NCT03576248|DEVICE|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
223893625|NCT03576248|DEVICE|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
223893626|NCT03576248|DEVICE|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
223893627|NCT06807294|BEHAVIORAL|Tai Chi Program|12-week virtual Tai Chi program with experienced Tai Chi instructor. Sessions will be conducted via the HIPPA-compliant teleconference platform, Zoom.
223893628|NCT06210633|OTHER|medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
223893629|NCT06210633|OTHER|endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
223893630|NCT05732428|DRUG|ARV-471|ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
223893631|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars. They will then have a Virtual Reality Avatar experience, where they will see an avatar resembling themselves in a park setting.
223893632|NCT06302413|DEVICE|Virtual Reality|They will receive a Virtual Reality Park experience, which is an empty park with no avatars.
224273527|NCT01957150|DRUG|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
224273528|NCT01957150|DRUG|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
224273529|NCT06476106|DEVICE|Venoconstrictive Thigh Cuff (VTC)|The VTC is an adjustable fabric cuff that is worn on the upper thighs to retain some fluid in the legs. It consists of wide straps and a buckle which allow it to be tightened, then velcro to secure the strap in the tightened position. There is also lacing that can be tightened for micro adjustments. Imbedded within the fabric strap is a bladder that is not used for increasing tightness but allows the pressure of the cuff to be measured and tracked.
224273530|NCT01207752|DRUG|Systane Balance|Artificial tear emulsion drop
224273531|NCT01207752|DRUG|Optive Lubricant Eye Drops|Artificial tear eye drop
224273532|NCT03394833|OTHER|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
223518002|NCT05607589|OTHER|Placebo|Placebo
223518003|NCT03434301|DEVICE|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
223893633|NCT06484569|OTHER|Control|The content of ergonomics training will include the definition of ergonomics, ergonomic positions and arrangements. Postural arrangements will be explained to patients individually and supported by a brochure.
223893634|NCT06484569|OTHER|exercise and cranio sacral therapy|Posture exercises Stretching exercises Strengthening Exercises In addition, deep tissue massage will be applied to increase blood circulation and cranio-sacral therapy will be applied to increase cerebrospinal fluid circulation.
224273533|NCT02088333|BEHAVIORAL|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
224273534|NCT02088333|BEHAVIORAL|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
224273535|NCT05399056|BEHAVIORAL|Telephonic Peer Coaching|Telephonic Peer Coaching from an individual with lived experience with COPD and Pulmonary Rehabilitation trained in motivational interviewing
224273536|NCT05399056|BEHAVIORAL|Storytelling|Video narratives of an individual with lived experience with COPD and Pulmonary Rehabilitation describing their journey through Pulmonary Rehabilitation
224273537|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
224273538|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
224273539|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
224273540|NCT02451358|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
224273541|NCT05673707|DIAGNOSTIC_TEST|Thyromental Height|its measure between thyroid and mentum
224273542|NCT02483507|OTHER|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
224273543|NCT05539937|OTHER|Quality of life questionnaire|Before TAVI, 30 days, 6 months and twelve months after TAVI, patients will answer TASQ questionnaire,
224273544|NCT01662011|DEVICE|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
223518004|NCT03434301|DEVICE|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
223518005|NCT02725606|BIOLOGICAL|Pegylated Recombinant Human G-CSF|subcutaneous
223893635|NCT04550468|OTHER|Low-Carb High-Fat breakfast|Participants will receive 8 low-carb high-fat breakfast meal recipes to follow daily during 3 months.
224273545|NCT01662011|DEVICE|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
224273546|NCT03701451|DRUG|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
224273547|NCT02429583|DRUG|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
224273548|NCT01341951|DRUG|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
224273549|NCT00960414|BEHAVIORAL|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detailed nutritional education.
224273550|NCT03303781|OTHER|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
224273551|NCT00314834|DRUG|Intradialytic parenteral nutrition|
224273552|NCT02375750|DEVICE|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
224273553|NCT02375750|OTHER|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
224273554|NCT00252564|DRUG|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
224273555|NCT00252564|DRUG|Oxaliplatin|85 mg/m2 on Days 1 and 15
224273556|NCT00252564|DRUG|Leucovorin|400 mg/m2 on Days 1 and 15
224273557|NCT00252564|DRUG|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
224273558|NCT00252564|DRUG|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
224273559|NCT02173964|DRUG|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
224273560|NCT02173964|DRUG|water|same amount of water for pinverin administration
224273561|NCT00994604|DRUG|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
224273562|NCT05530811|DRUG|Dexamethasone|The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
224273563|NCT05530811|DRUG|Bupivacaine|0.5% bupivacaine
223518006|NCT02725606|BIOLOGICAL|GW003|subcutaneous
223704034|NCT03423082|DRUG|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
224273564|NCT02836587|BEHAVIORAL|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
224273565|NCT04508205|DRUG|CGB-400|BID application
224273566|NCT04219527|PROCEDURE|Dual-target injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid) + 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
224273567|NCT03645876|DRUG|SHR-1210|200mg
224273568|NCT03645876|DRUG|BP102|7.5mg/kg
224273569|NCT03645876|DRUG|oxaliplatin|130mg/m2
224273570|NCT03645876|DRUG|capecitabine|1000mg/m2
224273571|NCT01842555|OTHER|Registry|Registry
224273572|NCT02319603|DRUG|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
224273573|NCT02319603|DRUG|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
223704035|NCT03423082|DEVICE|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
224273574|NCT00610506|DRUG|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
224273575|NCT05951751|OTHER|TRI-MOM intervention|"The TRI-MOM strategy includes 4 main activities:~1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services)~2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests~3. Assessment and treatment of women positive for any of the 3 targeted infections~4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections"
224273576|NCT02687789|OTHER|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
224273577|NCT02687789|OTHER|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
224273578|NCT03095950|OTHER|News items with spin|Interpretation of news items with spin
224273579|NCT03095950|OTHER|News items without spin|Interpretation of news items without spin
224273580|NCT03486938|DRUG|Placebo Oral Tablet|Placebo oral tablet
224273581|NCT03486938|DRUG|AGB101 220 mg tablet|220 mg AGB101 active compound
224273582|NCT03414034|DRUG|Onvansertib|Onvansertib orally
224273583|NCT03414034|DRUG|Abiraterone|Abiraterone orally
224273584|NCT03414034|DRUG|Prednisone|Prednisone orally
224273585|NCT03368391|DRUG|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
224273586|NCT03368391|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
224273587|NCT03368391|DRUG|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
224273588|NCT03368391|DRUG|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
224273589|NCT03368391|DRUG|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
224273590|NCT01093560|DIETARY_SUPPLEMENT|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
224273591|NCT01332968|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
224273592|NCT01332968|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
224273593|NCT01332968|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
224273594|NCT01332968|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
224273595|NCT01332968|DRUG|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
223704036|NCT05340023|BIOLOGICAL|blood sample|to realize proteomic analysis.
223704037|NCT06549790|DRUG|NMS-03597812|Route of Administration: Oral
224273596|NCT01332968|DRUG|Bendamustine|Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
224273597|NCT01332968|DRUG|Rituximab|Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
224273598|NCT05029427|OTHER|High molecular weight β-glucan oat cookies|Two cookies that contains 4g beta glucan made from oats will be consumed per day.
224273599|NCT05029427|OTHER|Control wheat based cookies|Two cookies that made from cream of wheat without beta glucan will be consumed per day.
224273600|NCT06315660|BEHAVIORAL|Cognitive Miljeu Therapy|TAU is an integrated voluntary inpatient treatment based on the principles of CBT, lasting between 12-20 weeks. This treatment includes exercise, close medical monitoring, group-based CBT for SUD, planning with social services, and is called Cognitive Milieu Therapy.
224273601|NCT06315660|BEHAVIORAL|Virtual Reality based CBT for Anxiety|The experimental intervention is a manualized add-on to TAU and comprises eight sessions of 60 minutes over a period of four weeks. Of these eight sessions, six will include 30 minutes of VR-based behavioral experiments targeting agoraphobic and social fear.
224273602|NCT02664792|OTHER|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
224273603|NCT04002869|DIAGNOSTIC_TEST|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
223704038|NCT05723302|DIAGNOSTIC_TEST|MIP/MEP|MIP/MEP
223704039|NCT04149626|DRUG|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
223704040|NCT04149626|DRUG|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
224273604|NCT03232762|DIETARY_SUPPLEMENT|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
224273605|NCT03232762|DIETARY_SUPPLEMENT|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
224273606|NCT03480022|DRUG|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
223704041|NCT04149626|DRUG|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
223704042|NCT01965821|DEVICE|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
223704043|NCT01965821|DEVICE|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
224273607|NCT03480022|DRUG|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
224273608|NCT04784169|DEVICE|free middle turbinate flap|Repairing low flow leak using free middle turbinate flap
224273609|NCT04784169|DEVICE|vascularized nasoseptal flap|Repairing low flow leak using fascia lata
224273610|NCT05429944|OTHER|Motor Relearning Program|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
224273611|NCT05429944|OTHER|Proprioceptive Neuromuscular Facilitation|"The techniques administered included Rhythmic Initiation, Slow Reversal and Agonistic Reversal.~The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks."
224273612|NCT05429944|OTHER|Conventional Physical Therapy|The exercise will be performed for approximately 30 minutes, 3 times a week for 6 weeks.
224273613|NCT01087034|DEVICE|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
224273614|NCT01087034|RADIATION|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
224273615|NCT01087034|OTHER|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
224273616|NCT05139394|PROCEDURE|emergency pancreaticoduodenectomy|Emergency pancreaticoduodenectomy (EPD) is a complex surgical procedure, that can be performed for complex pancreaticoduodenal injuries, that cannot be controlled through less invasive procedures. EPD can be performed either as a classical Whipple procedure, or as a pylorus-preserving procedure. A one stage procedure implies the reconstruction step being done in the same surgical intervention, while a two step procedure implies the reconstruction being done in a later stage, through a second surgical intervention.
223893636|NCT04550468|OTHER|"Low fat standard care control breakfast"|Participants will receive 8 low-fat breakfast meal recipes to follow daily during 3 months.
224273617|NCT04811729|BEHAVIORAL|Motivational interview|The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
224273618|NCT04811729|BEHAVIORAL|Medical advice|Usual care
224273619|NCT04636450|PROCEDURE|Rotatory technique pulpectomy|Primary mandibular molars treated with a rotatory technique pulpectomy and a K3 system or a Kedo-S system.
224273620|NCT04636450|PROCEDURE|Manual pulpectomy|Primary mandibular molars treated with a manual pulpectomy and a K-file system or a Kedo-SH system.
224273621|NCT06016582|DEVICE|Use of virtual reality hypnosis headset during frozen embryo transfer|"The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study."
224273622|NCT06679322|DRUG|Androtriol Injection (High-dose group)|Participants will receive 30 mL of Androtriol Injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
224273623|NCT06679322|DRUG|Androtriol Injection (Low-dose group)|Participants will receive 10 mL of Androtriol Injection combined with 20 mL of placebo (Hydroxypropyl Beta-Cyclodextrin Injection) per dose, administered every 12 hours for 7 consecutive days. Each infusion will be administered over a period of 30±5 minutes.
224273624|NCT06679322|DRUG|Hydroxypropyl-β-cyclodextrin injection|Participants will receive 30 mL of Hydroxypropyl-β-cyclodextrin injection per dose, administered every 12 hours for 7 consecutive days. Each infusion will be completed within 30±5 minutes.
224273625|NCT00640926|DRUG|Radezolid|300 mg/day, orally for 7-10 days
224273626|NCT00640926|DRUG|Radezolid|450 mg/day orally for 7-10 days
224273627|NCT00640926|DRUG|Radezolid|900 mg/day orally for 7-10 days
224273628|NCT01968369|DIETARY_SUPPLEMENT|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
224273629|NCT02321839|DRUG|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
224273630|NCT06207669|OTHER|Music therapy|Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
224273631|NCT03922750|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
224273632|NCT03922750|DRUG|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
224273633|NCT02828566|DRUG|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
224273634|NCT02828566|DRUG|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
224273635|NCT02828566|DRUG|IN saline 0.9%|Intranasal 0.9% normal saline
224273636|NCT02828566|DRUG|IV saline 0.9%|Intravenous 0.9% normal saline
224273637|NCT05158660|DEVICE|transcranial duplex sonography|it is an imaging device that will measure the intracerebral hematoma expansion
224273638|NCT00163969|DRUG|ketamine|
224273639|NCT02387034|BEHAVIORAL|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
224273640|NCT02387034|OTHER|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
224273641|NCT01992341|DRUG|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
224273642|NCT01992341|DRUG|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
224273643|NCT06228196|DEVICE|Simultaneous cortico-spinal magnetic resonance imaging, Serum|Simultaneous cortico-spinal magnetic resonance imaging data were collected in a strong magnetic field and collected the serum of participants.
224273644|NCT02985398|BIOLOGICAL|ALD403 (Eptinezumab)|
224273645|NCT01471951|OTHER|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
224273646|NCT01172912|BIOLOGICAL|filgrastim|
224273647|NCT01172912|BIOLOGICAL|pegfilgrastim|
224273648|NCT01172912|DRUG|carboplatin|
224273649|NCT01172912|DRUG|cisplatin|
224273650|NCT01172912|DRUG|dexamethasone|
224273651|NCT01172912|DRUG|etoposide|
224273652|NCT01172912|DRUG|ifosfamide|
224273653|NCT01172912|OTHER|high-dose chemotherapy with autologous stem cell rescue|
224273654|NCT01172912|OTHER|laboratory biomarker analysis|
224273655|NCT01172912|PROCEDURE|autologous hematopoietic stem cell transplantation|
224273656|NCT01172912|PROCEDURE|peripheral blood stem cell transplantation|
224273657|NCT04257695|BEHAVIORAL|TapPro|Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
224273658|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. I|Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
224273659|NCT05827263|DEVICE|Usage of the hydrostatic appliance|The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
224273660|NCT05827263|DIAGNOSTIC_TEST|T-Scan occlusal recording No. II|The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
224273661|NCT06000163|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the skin, which is non-invasive, and skin thickness and blood flow parameters will be measured.
224273662|NCT05447416|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
224273663|NCT05447416|DEVICE|Intermittent Hypoxic Training - IHT|Each session lasts 60 minutes of 15.2% oxygen at 1.0 ATA. Subjects will be training according to individualized training protocol.
224273664|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
224273665|NCT01225523|DRUG|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
224273666|NCT03660787|DRUG|Seroguard|Seroguard 0.41 g/L solution
224273667|NCT03660787|DRUG|Placebo|Saline
224273668|NCT03195387|DRUG|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
224273669|NCT06149949|OTHER|Observational study|the aim of the study is to define the prevalence of rhinosinusitis cronic in intestinal bowel disease patients, to assess how it affects the patient's quality of life, and any correlations between these two entities
224273670|NCT02941159|BIOLOGICAL|SF2000SD|This is an intergrase inhibitor
224273671|NCT02941159|BIOLOGICAL|Placebo|
224273672|NCT04164758|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
224273673|NCT04164758|OTHER|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
224273674|NCT04164758|DRUG|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
224273675|NCT01909115|DRUG|1000 IU of Vitamin D3|1000 IU of Vitamin D will be administered in capsule form, once daily.
224273676|NCT01909115|DRUG|4000 IU of Vitamin D3|4000 IU of Vitamin D will be administered in capsule form, once daily.
224273677|NCT00467805|PROCEDURE|Light therapy|
224273678|NCT06478745|OTHER|Retrospective and prospective cohort|"* Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia."
224273679|NCT06478745|OTHER|Focus group, semi-structured interviews and Photovoice|The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
224273680|NCT06478745|OTHER|Systematic review|No patient recruitment required
224273681|NCT01670097|DRUG|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
224273682|NCT01670097|DRUG|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
224273683|NCT01670097|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
224273684|NCT01670097|DEVICE|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
224273685|NCT01670097|OTHER|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
224273686|NCT00143273|DRUG|lasofoxifene|0.05 mg tablets
224273687|NCT00143273|DRUG|Placebo|0 mg
224273688|NCT00143273|DRUG|Lasofoxifene|0.25 mg tablets
224273689|NCT00143273|DRUG|Lasofoxifene|0.5 mg tablets
223893637|NCT06211634|DRUG|HMB-001|HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
223893638|NCT04015167|DEVICE|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
224273690|NCT03417427|DRUG|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
224273691|NCT03417427|DRUG|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
223704044|NCT05626426|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
224273692|NCT00697827|DEVICE|Interspinous Spacer device|Device: In-Space
224273693|NCT00697827|DEVICE|Interspinous Process Distraction Device|Device: X STOP
224273694|NCT01917227|BEHAVIORAL|Video|
224273695|NCT00377039|DRUG|AD 337|
223893639|NCT03640312|DRUG|QUARTET LDQT|Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
223893640|NCT03640312|DRUG|Candesartan|Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
224273696|NCT01847950|DIETARY_SUPPLEMENT|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
224273697|NCT01847950|DIETARY_SUPPLEMENT|Maltodextrin|
224273698|NCT01915641|DEVICE|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
224273699|NCT00247013|BEHAVIORAL|Breast Cancer Screening Compliance|
224273700|NCT00768352|OTHER|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
224273701|NCT06040606|PROCEDURE|In-Hospital COVID-19 Omicron Infection after surgery|Thoracic Surgery Patients with In-Hospital COVID-19 Omicron Infection after surgery
224273702|NCT03910049|DRUG|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
224273703|NCT05248399|BEHAVIORAL|COVID-19 Group Problem Solving|The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
224273704|NCT05248399|BEHAVIORAL|Standard of Care|The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
224273705|NCT02386007|DRUG|DW-3101_150mg|
224273706|NCT02386007|DRUG|DW-3101_300mg|
224273707|NCT02386007|DRUG|DW-3101_600mg|
224273708|NCT02386007|DRUG|Placebo|
224273709|NCT03994952|DEVICE|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
224273710|NCT03994952|DEVICE|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
224273711|NCT05686993|DRUG|Cinnarizine|Cinnarizine oral 30mg TDS
224273712|NCT05686993|DRUG|NIFEdipine ER|Nifedipine oral 60mg daily extended release
224273713|NCT05665387|DRUG|0.1% STN1013600 ophthalmic solution|0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
224273714|NCT05665387|DRUG|0.3% STN1013600 ophthalmic solution|0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
224273715|NCT05665387|DRUG|Placebo|Placebo ophthalmic solution 1 drop BID for 2 months
224273716|NCT04021511|OTHER|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
224273717|NCT05068661|DRUG|Ropivacaine 0.1% Injectable Solution|DPE
224273718|NCT05068661|DRUG|Bupivacaine 0.25% Injectable Solution|CSE
224273719|NCT03732833|DRUG|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
224273720|NCT03732833|DRUG|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
224273721|NCT03151954|PROCEDURE|functional endonasal sinus surgery|collect nasal polyps from patients
224273722|NCT03151954|PROCEDURE|nasal septal construction|collect inferior turbinates from patients as control arm
223893641|NCT06168253|BEHAVIORAL|Safety Behavior Fading for Social Anxiety|Participants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
224273723|NCT04780451|DIETARY_SUPPLEMENT|Omega-3 supplementation in recreational runners|Male recreational runners participated in 12 weeks of endurance training combined with omega-3 fatty acids supplementation. Before starting and at the end of the 12-week cycle, the runners performed an increasing intensity treadmill test where oxygen uptake and VO2 peak were assessed.
224273724|NCT03493633|DEVICE|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (\<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
224273725|NCT00550147|DRUG|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~* Visit 2 dose of 18 mg QAM~* Visit 3 dose of 36mg QAM~* Visit 4 dose of 54mg QAM."
224273726|NCT00550147|DRUG|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~* Visit 5 dose of 25mg BID~* Visit 6 dose of 50mg BID~* Visit 7 dose of 100mg BID~* Visit 8 dose of 200mg BID~* Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
224273727|NCT04124354|BEHAVIORAL|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
224273728|NCT00325780|DRUG|Pitavastatin|Pitavastatin 4 mg once daily
224273729|NCT02966860|DRUG|Oral solution OC/APAP|
224273730|NCT02856776|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D provided in capsule form
224273731|NCT01919827|BIOLOGICAL|Endobronchial infusion of adult mesenchymal stem cells|
224273732|NCT01919827|BIOLOGICAL|Autologous mesenchymal stem cells derived from bone marrow|
224273733|NCT02311894|DRUG|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
224273734|NCT04221048|OTHER|Retrospective observational|Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
224273735|NCT03965065|DEVICE|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
224273736|NCT03965065|DEVICE|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
223893642|NCT06168253|BEHAVIORAL|Unhealthy Behavior Fading|Participants are asked to reduce or eliminate unhealthy behaviors via text message reminders and checklists to monitor progress.
223893643|NCT05733975|OTHER|Decision Making Guide|The tool includes a brief introduction to the tool and decision-making, a values clarification exercise, and a question prompt list.
224273737|NCT03770130|DRUG|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
224273738|NCT03770130|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment
224273739|NCT04756739|DEVICE|Clearblue Connected Ovulation Test System|Clearblue Connected Ovulation Test System which is a CE marked device used for tracking the menstrual cycle
224273740|NCT00617825|OTHER|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
224273741|NCT00005958|BIOLOGICAL|filgrastim|
224273742|NCT00005958|DRUG|docetaxel|
224273743|NCT00005958|DRUG|gemcitabine hydrochloride|
224273744|NCT03634735|DRUG|Thiamine|Vitamine B1
224273745|NCT03634735|OTHER|Placebo|Placebo tablets
223704045|NCT05265039|BEHAVIORAL|Cognitive Processing Therapy|An evidence-based treatment for posttraumatic stress disorder (PTSD)
224273746|NCT03797196|DRUG|low dose tacrolimus in combination with everolimus|a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
224273747|NCT03797196|DRUG|standard dose tacrolimus with mycophenolate mofetil|A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
224273748|NCT01426334|DRUG|dasatinib|Given PO
224273749|NCT01426334|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
224273750|NCT01426334|OTHER|pharmacological study|Correlative studies
224273751|NCT01426334|DRUG|cyclosporine|Given PO
224273752|NCT02118324|BEHAVIORAL|Exergaming Program|Participants will exercise through exergaming play.
224273753|NCT00269386|DRUG|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
224273754|NCT00269386|DRUG|Placebo|
224273755|NCT00662896|DRUG|naproxcinod 375 mg bid|naproxcinod 375 mg bid
224273756|NCT00662896|DRUG|naproxcinod 750 mg bid|naproxcinod 750 mg bid
224273757|NCT00662896|DRUG|naproxen 250 mg bid|naproxen 250 mg bid
224273758|NCT00662896|DRUG|naproxen 500 mg bid|naproxen 500 mg bid
224273759|NCT00662896|DRUG|ibuprofen 600 mg tid|ibuprofen 600 mg tid
224273760|NCT00751023|DRUG|Modafinil|400 mg daily for four weeks
224273761|NCT00751023|DRUG|Placebo|Placebo 2 tablets daily for 4 weeks
224273762|NCT04685681|BEHAVIORAL|Hiking challenge|The main intervention of interest is the provision of free access to a local hiking challenge (which is provided following baseline assessments in the experimental group and after the conclusion of the study in the control group; $20 value). If participants choose to sign up for the free hiking challenge, they receive a list of local hikes/nature walks, accompanying maps, scavenger-hunt-like activities (finding a certain landmark on each hike), and the opportunity to earn prizes and engage with other hikers on social media.
224273763|NCT04685681|OTHER|Activity list|The control group will receive a list of CDC-recommended activities following the baseline survey and will receive the hiking challenge as a delayed intervention following post-test.
223518007|NCT03182556|BEHAVIORAL|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
223704046|NCT05265039|BEHAVIORAL|Relaxation Training|Guided relaxation
224273764|NCT03548155|DRUG|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
224273765|NCT03548155|DRUG|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
224273766|NCT03548155|DRUG|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
224273767|NCT03617419|DEVICE|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
224273768|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
224273769|NCT03617419|DEVICE|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
224273770|NCT04609397|DRUG|Hemay005|Hemay005 tables 60mg bid p.o;
224273771|NCT04609397|DRUG|Hemay005|Hemay005 tables 45mg bid p.o
224273772|NCT04609397|OTHER|Placebo|placebo to Hemay005 tables bid p.o
224273773|NCT00382083|DRUG|1000 mg acetaminophen|
224273774|NCT00382083|DRUG|800 mg ibuprofen|
224273775|NCT00382083|DRUG|1 oz 4% lidocaine gel|
224273776|NCT06352762|OTHER|Conventional physiotherapy|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.
224273777|NCT06352762|OTHER|Robotic Rehabilitation|Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions. An additional 30 minutes of robotic rehabilitation was applied to the conventional physiotherapy program. Robotic rehabilitation was applied after each session of conventional physiotherapy applications.
224273778|NCT03350191|DRUG|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
224273779|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
224273780|NCT03350191|DRUG|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223704047|NCT06391840|OTHER|Airway ultrasound|Pre-operative airway ultrasound
224273781|NCT01875055|DEVICE|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
224273782|NCT01875055|DEVICE|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
224273783|NCT02473055|OTHER|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
224273784|NCT06625255|BEHAVIORAL|Parent Education - Promoting Playfulness|Parents will participate in 2, 45 minute parent education sessions promoting playfulness through information about child development, parent stressors, and parent advocacy.
224273785|NCT01689155|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224273786|NCT03610555|OTHER|new patient centered website|
224273787|NCT00070759|DRUG|Daclizumab|
224273788|NCT00003906|DRUG|Raloxifene|60 mg/day plus placebo for 5 years
224273789|NCT00003906|DRUG|Tamoxifen|20 mg/day plus placebo for 5 years
224273790|NCT04598607|DRUG|Hypidone Hydrochloride tablets|30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
224273791|NCT04598607|DRUG|Placebo|3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
224273792|NCT04568707|OTHER|blood sample|blood sample for serum (serology, biomarkers) and DNA
224273793|NCT03290807|DEVICE|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
224273794|NCT04919785|DEVICE|Deep brain stimulation|Stereotactic functional neurosurgery was first developed in 1947 and is today an established treatment for movement disorders. The surgical procedure is initiated by mounting a stereotactic frame on the head of the patient and a magnetic resonance image (MRI) is performed. Using a computerized navigational system the target structure is identified on the MRI and a trajectory chosen. In the operating theatre a burrhole is made on each side of the midline for the implantation of two electrodes. The electrodes are about 1.3 mm in diameter with several contacts at their distal end. An extension cable is tunneled under the skin, connecting the electrodes with a neuropacemaker placed below the clavicle in a subcutaneous pocket. The hospitalization time after surgery is dependent on the time needed for programming of the device, but the patients can usually return home within 3-5 days.
224273795|NCT06678451|DRUG|Sugammadex|When T2 appeared, the sugammadex group was given 2mg/kg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
224273796|NCT06678451|DRUG|Neostigmine|When T2 appeared, the neostigmine group was given 0.04mg/kg of neostigmine + 0.02mg/kg of atropine intravenously (adjusted body weight).
224273797|NCT04522245|BEHAVIORAL|Noom Healthy Weight; mobile behavior change program for weight loss.|"The mobile cognitive behavior change program follows guidelines from the Obesity Society's 2013 Guidelines for the Management of Overweight and Obesity in Adults NIH Practical Guide on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.~There are 52 weeks of curriculum with 1-3 articles to read per day. Users are requested to perform weight logging once daily and food logging after each meal. Users are assigned human coaches and are able to interact with them via in-app messaging or phone communication. Users are also assigned to support groups via in-app messaging."
224273798|NCT04522245|OTHER|Matched Control|Matched control group (Noom-branded 'healthy eating' short guide on weight loss).
224273799|NCT00619853|BEHAVIORAL|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
224273800|NCT00619853|BEHAVIORAL|treatment approach - HABIT|HABIT-2 months, 2Hr per day
224273801|NCT03637127|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
224273802|NCT03637127|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
224273803|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil|9-cis Rich Powder
224273804|NCT01256697|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawill|9-cis Rich Powder
224273805|NCT01256697|OTHER|Sugar pill|Sugar pill
224273806|NCT02092701|DRUG|Cholecalciferol|
224273807|NCT04912206|DIAGNOSTIC_TEST|Point-of-Care Ultrasound|Abdominal clinician-performed Ultrasound
224273808|NCT03261817|BEHAVIORAL|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
224273809|NCT03261817|BEHAVIORAL|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
224273810|NCT01591824|OTHER|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~* general column.~* lumbar muscles, and paraspinal muscles,~* sacral decompression oscillatory~* Opening by lateral vertebral lumbar rhythmic swing.~* Balancing and pelvic decompression~* Swing-lumbar vertebral rotation."
224273811|NCT01591824|OTHER|column exercise group|"* paraspinal muscle stretching exercises~* postural correction~* mobilization exercises thoracic and lumbar~* Motor control exercises"
224273812|NCT04956848|DEVICE|iDAScore®|Images of all the embryos reaching at least developmental stage of 3BB will be analyzed by iDAScore®. The embryo with the highest iDAScore® will be proposed for transfer.
224273813|NCT03266276|OTHER|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
224273814|NCT05590676|DRUG|Metformin Hydrochloride|"Infants will receive 14 consecutive doses, once daily, of metformin, with two dose cohorts.~Arm 1: Five infants with HIE will be enrolled on the first dose cohort of 20 mg/kg. Once complete, another five infants will be enrolled on the second dose cohort of 25 mg/kg.~Arm 2: Five preterm infants will be enrolled on the first dose cohort of 15 mg/kg. Once complete, another five preterm infants will be enrolled on the second dose cohort of 20 mg/kg."
224273815|NCT03407729|OTHER|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
224273816|NCT03407729|OTHER|Cognitive Performance Testing|For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots.
224273817|NCT02775058|DEVICE|synergoss Pxx|dental grafting
224273818|NCT03950674|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
223518008|NCT03182556|BEHAVIORAL|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
223893644|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (face-to-face care)|A Program structured in 28 visits (in group and individual) and 21 contacts (through phone calls or video calls) to guide the improvement of diet quality, self-care, and regular practice of physical activity
223893645|NCT06426277|BEHAVIORAL|Diet|Hypocaloric diet prescription
224273819|NCT03950674|DRUG|Cisplatin|IV infusion
224273820|NCT03950674|DRUG|Carboplatin|IV infusion
224273821|NCT03950674|DRUG|Pemetrexed|IV infusion
224273822|NCT03950674|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
224273823|NCT03950674|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
224273824|NCT03950674|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
224273825|NCT03950674|DRUG|Saline solution|IV infusion
224273826|NCT04970862|PROCEDURE|reversion surgery|reversion surgery
224273827|NCT06120660|OTHER|Music Therapy|Music Therapy
224273828|NCT04394130|DRUG|ropivacaine 0.2%|continuous peripheral nerve local anesthetic infusion (ropivacaïne 0.2 %) for 48 hours postoperative.
224273829|NCT05361057|DRUG|Venetoclax, Azacitidine|The patients were administrated with azacytidine 75 mg/m2 d1-7，venetoclax: 100mg d1, 200mg d2, 400mg d3-21;
224273830|NCT05361057|DRUG|Venetoclax, daunorubicin, cytarabine|The patients were administrated with daunorubicin：45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14
224273831|NCT00193492|DRUG|Bevacizumab|
224273832|NCT00193492|DRUG|Rituximab|
224273833|NCT00379158|DRUG|Micronutrient supplements|
224273834|NCT03886363|BEHAVIORAL|MBSR|Described previously
224273835|NCT05619796|PROCEDURE|pulpectomy procedure|single visit pulpectomy was performed under strict aseptic conditions by a single operator. Peri-operative evaluation was done using intraoral digital senso. The teeth were anesthetized with 2% mepivacaine with 1:20,000 levonordefrin \& isolated using rubber dam. caries was removed using no. 330 round carbide burs in high-speed contra angle headpiece. Access opening was gained \& the roof of the pulp chamber was removed. Working length was determined by apex locator, then confirmed by periapical radiograph. Working length will be determined 1 mm shorter than apex. mechanical preparation was done using the tested files according to each group. Then, canals were irrigated with 1% sodium hypochlorite between each file followed by irrigation with normal saline. The root canals were dried using paper points \& root canals were filled with Metapex. Intermediate restorative material was placed, and the tooth was restored with a preformed stainless-steel crown in the same appointment.
224273836|NCT05619796|RADIATION|Post-operative Cone Beam Computed Tomography|"post-operative CBCT image was taken after completing the procedure with fixed exposure parameters (120 Kv, 5mA and 0.125mm voxel size) using smallest field of view (8D, 8Hcm) to improve spatial resolution. The CBCT images were obtained by using 3D module of On Demand Dental software (version 1.0 (build 1.0.10.7462),× 64 Edition, copyright 2004-2017 Cybermed, Korea and license key 670094709).~The Immediate post-operative CBCT was taken to evaluate the quality of root canal filling by two trained pediatric dentists, blinded to instrumentation technique ."
223704048|NCT06103539|DEVICE|Cardiac catheterization and evoked response to cardiac stimulation|Cardiac catheterization with a combined elecrtophysiology and pressure sensing catheter to perform multisite stimulation and measure the evoked pressure response in a connected software.
223893646|NCT06426277|BEHAVIORAL|Brazilian Diabetes Prevention Program (remote care)|A Program structured in 49 contacts delivered through telehealth (through phone calls or video calls between professional and participant) to guide the improvement of diet quality, self-care, and regular practice of physical activity
223893647|NCT05231837|BEHAVIORAL|Experimental: Fee Waiver|Fees are waived for youth sports programs at the park and recreation center
223893648|NCT05231837|BEHAVIORAL|Fee Waiver Plus Intensive Outreach|Fees are waived for youth sports programs at the park and recreation center and intensive outreach is conducted in the neighborhood through community advisory boards and partner engagement.
224273837|NCT05619796|OTHER|Post-operative pain assessment|The parents of the children were given a questionnaire to record the intensity of postoperative pain at six, twelve, twenty-four and forty-eight hours after the pulpectomy procedure. A nursing officer who was blind to the study groups, had trained all parents on how to record the postoperative pain. The four-point pain intensity scale was used to record postoperative pain (figure 5). This scale categorizes pain as follows: (1) no pain; (2) slight pain; (3) moderate pain; and (4) severe pain. To ensure standardization, the same parent was asked to record the child's pain intensity at all time intervals. To reduce the possibility of the parents failing to record the pain at a given time, the investigator also recorded findings via telephonic conversation with the parents. The children returned to the department two days after the pulpectomy procedure with their completed questionnaire form.
224273838|NCT03347058|OTHER|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
224273839|NCT04315779|PROCEDURE|Salpingectomy|Patients will undergo removal of the affected tube
224273840|NCT04033484|PROCEDURE|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
224273841|NCT04805385|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
224273842|NCT06679387|DRUG|Memantine-HCl|Memantine hydrochloride 20 mg once daily for 12 weeks.
224273843|NCT06679387|DRUG|Placebo Oral Tablet|A once daily matched tablet of placebo for 12 weeks
224273844|NCT00609154|DRUG|glucagon like peptide-1|GLP-1 1 pmole/kg/min
224273845|NCT00609154|DIETARY_SUPPLEMENT|glucose control|glucose without GLP-1
224273846|NCT02650973|DRUG|CHS-1701|
223893649|NCT06473961|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.
223893650|NCT02848040|OTHER|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
223893651|NCT05407129|BEHAVIORAL|Family safety reporting intervention|Family safety reporting intervention for patients/families
224273847|NCT02650973|DRUG|Pegfilgrastim|
224273848|NCT05983627|BIOLOGICAL|Human Umbilical Cord Mesenchymal Stem Cells|The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
224273849|NCT03833427|DRUG|Selumetinib|Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle.
224273850|NCT03833427|DRUG|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
224273851|NCT02069262|OTHER|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
224273852|NCT03059329|DRUG|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
224273853|NCT02707276|DEVICE|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
224273854|NCT02707276|DEVICE|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
224273855|NCT01499160|DRUG|letrozole|Drug is are to be taken orally. 2.5 mg once daily
224273856|NCT01499160|DRUG|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
224273857|NCT01499160|DRUG|everolimus|Drug is to be taken orally. 5 mg once daily.
224273858|NCT03212820|PROCEDURE|Drilling at low speed|
224273859|NCT03212820|PROCEDURE|Drilling at conventional or high speed|
224273860|NCT02319057|DRUG|ORM-12741 MR A|Modified release formulation of ORM-12741
224273861|NCT02319057|DRUG|ORM-12741 IR|Immediate release formulation of ORM-12741
224273862|NCT02319057|DRUG|ORM-12741 MR B|Modified release formulation of ORM-12741
224273863|NCT03448692|DRUG|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
224273864|NCT06581601|OTHER|physiotherapy, exercises|An author's questionnaire will be used for participant selection, asking about the number and course of deliveries. Additionally, participants will log daily activities to calculate the physical activity level coefficient. Weight and height will be measured using a Tanita device to calculate BMI. The posture type and pelvic type will be assessed. Participants will be asked to complete the following questionnaires before and after the intervention: Pelvic Floor Disability Index (PFDI-20), Pelvic Floor Impact Questionnaire Short Form (PFIQ-7 SF), Sexual Satisfaction Scale (SSS-W-R15), Neck Disability Pain Index, Revised Oswestry Low Back Pain Disability Scale, Migraine Disability Assessment (MIDAS), Hospital Anxiety and Depression Scale (HADS), Short Form McGill Pain Questionnaire, CRANIA (Integrated Approach to Cranio Mandibular Neuroscience) questionnaire, IPAQ (International Physical Activity Questionnaire). Modified 1-Hour Pad Test. Execution of the Author's Training Program.
224273865|NCT00222040|RADIATION|Ultrasound|2-MHz, low intensity transcranial ultrasound
224273866|NCT00222040|DRUG|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
224273867|NCT04155840|DRUG|Copanlisib|Given IV
224273868|NCT04155840|BIOLOGICAL|Rituximab|Given IV
224273869|NCT04155840|DRUG|Bendamustine|Given IV
224273870|NCT01763658|DRUG|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
224273871|NCT01763658|OTHER|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
224273872|NCT04411017|PROCEDURE|Endoscopy|Colonoscopy
224273873|NCT02339363|BEHAVIORAL|Sitting Meditation|4 weeks Sitting Meditation
224273874|NCT02339363|BEHAVIORAL|Hatha yoga|4 weeks of Hatha yoga
224273875|NCT05533151|DEVICE|Respiratory muscle training|All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
224273876|NCT03789630|DEVICE|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 55 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
224273877|NCT04361838|BEHAVIORAL|prayer|receive prayers daily while in ICU
224273878|NCT02344849|DRUG|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
224273879|NCT06149962|PROCEDURE|FLEXOR TENDON REPAIR|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture under WALANT technique and brachial plexus block.
224273880|NCT00526136|DRUG|Placebo|
223518009|NCT06567262|DEVICE|CAD/CAM metallic removable partial denture|"Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework."
224273881|NCT00526136|DRUG|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
224273882|NCT03951727|DEVICE|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
224273883|NCT03261843|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
223893652|NCT03891576|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
224273884|NCT03261843|PROCEDURE|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
224273885|NCT00935805|DRUG|Metformin|850 mg TID
224273886|NCT00935805|DRUG|Glybenclamide|10 mg BID
224273887|NCT00935805|DRUG|NPH insulin|Variable SC dose
224273888|NCT00935805|DRUG|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
224273889|NCT00935805|DRUG|Propranolol|40 mg BID
224273890|NCT00935805|DRUG|Captopril|50 mg TID
224273891|NCT00935805|DRUG|Amlodipine|10 mg QD
224273892|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
224273893|NCT00593827|DRUG|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
224273894|NCT05692115|DIAGNOSTIC_TEST|stress ECG|stress ECG to patients suspected to be ischemic patients .
224273895|NCT04099433|DIETARY_SUPPLEMENT|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
224273896|NCT04099433|OTHER|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
224273897|NCT00240734|DRUG|Epoetin alfa|
224273898|NCT01118767|OTHER|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
224273899|NCT04876001|BEHAVIORAL|Brief Behavior Therapy for Insomnia|"The BBTI consists of two in-person sessions on week 1 and 3 and two sessions on week 2 and 4 as the booster delivered by phone call."
224273900|NCT01071551|BEHAVIORAL|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
224273901|NCT01071551|BEHAVIORAL|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
224273902|NCT05748938|BIOLOGICAL|RD14-01|ROR1 Targeted CAR-T cells
224273903|NCT02269735|DRUG|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
224273904|NCT02269735|BIOLOGICAL|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
224273905|NCT02269735|DRUG|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
224273906|NCT02269735|BIOLOGICAL|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
224273907|NCT02269735|DRUG|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
224273908|NCT06177405|DRUG|genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors|drug therapy
224273909|NCT05806177|DRUG|AD16 30mg、40mg|AD16 was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
224273910|NCT05806177|DRUG|AD16 Placebo 30mg、40mg|AD16 placebo was taken continuously.Firstly, a 30 mg (bid) multiple dose study was conducted, followed by a 40 mg (bid) multiple dose study
224273911|NCT02993562|DRUG|Levothyroxine|Normal treatment with levothyroxine.
224273912|NCT00663234|DRUG|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
224273913|NCT02643407|DRUG|Docetaxel|60mg/m2
224273914|NCT02643407|DRUG|Nedaplatin|80mg/m2
224273915|NCT02643407|DRUG|Cisplatin|75mg/m2
224273916|NCT02188407|DRUG|Sevoflurane|MAC 3-5 V% during surgery
224273917|NCT02188407|DRUG|Propofol|Propofol group (P group)- The group anaesthesied with propofol
224273918|NCT01888107|DRUG|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
224273919|NCT01888107|DRUG|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
224273920|NCT01888107|DRUG|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
224273921|NCT01994980|DRUG|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
224273922|NCT00065962|DRUG|secretin, synthetic porcine|
224273923|NCT00065962|DRUG|secretin, biologically derived porcine|
224273924|NCT00382187|BIOLOGICAL|MF59 adjuvanted H5N1 influenza vaccine|"* MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1"
223704049|NCT04785248|PROCEDURE|Three-step disinfection|"Three step disinfection method can be divide in three part. The first step of disinfection: scalp dandruff removal + disinfection The second step of disinfection: whole head Use 2% iodine tincture to smear the whole head skin, the assistant helps to lift the head to expose the surgical field, from both eyebrows to the occipital hairline, from both sides to the neck, after the iodine tincture dry out, use 75% alcohol to deionize. Then placing more than 4 layers of operation towel under the head.~The third step of disinfection: neck chest abdomen disinfection."
224273925|NCT03332433|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
224273926|NCT04164706|DEVICE|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
224273927|NCT04164706|OTHER|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
224273928|NCT01889758|DRUG|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
224273929|NCT01889758|DRUG|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
224273930|NCT01889758|DRUG|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
224273931|NCT05259657|BEHAVIORAL|Lymfit Intervention|"Participants will be allocated a pre-registered Inspire II / Charge IV model Fitbit. The research team will reach out to the participant via videoconferencing and help them to: download the Fitbit smartphone application; log-in using the anonymous study identification information; and pair their Fitbit with their smartphone application.~A kinesiologist of the study will meet with the participants for a baseline fitness assessment. The kinesiologist will examine the baseline physical activity levels, fitness level and sedentary behaviours of the participants, to design a personalized exercise prescription. Within one week after the baseline fitness assessment, the kinesiologist will contact the participants to discuss the exercise prescription. Every two weeks there-after, the kinesiologist will follow up with the participants via videoconferencing to discuss their progress and to modify or advance their exercise prescriptions as needed, plus an acceptability assessment survey."
224273932|NCT05259657|BEHAVIORAL|Wait-list control|Participants will be contacted by the study kinesiologist for a baseline fitness assessment 3 months after they consent, participants will be given a Fitbit, a personalized exercise prescription and receive bi-weekly follow-ups for 12 weeks.
224273933|NCT01581164|BIOLOGICAL|Influenza vaccine|Influenza vaccine: Injection, post transplant
224273934|NCT01581164|BIOLOGICAL|Varicella vaccine|Varicella vaccine: Injection, post transplant
224273935|NCT01709903|DRUG|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
224273936|NCT01709903|DRUG|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
224273937|NCT01709903|DRUG|Placebo to QVA149|Placebo to QVA149 with SDDPI
224273938|NCT01709903|DRUG|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
224273939|NCT03613038|BEHAVIORAL|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
223704050|NCT05049681|DRUG|Camrelizumab|SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
223704051|NCT05049681|DRUG|Apatinib|Apatinib 250mg, q.d.po
224273940|NCT06405854|OTHER|Exercise|Children in the coordinative exercise intervention group will be encouraged to participate in sessions twice a week, each lasting 20 minutes. The foundational movement patterns tailored to the specific purpose were organized in a game format suitable for preschool-aged children. These foundational movement patterns comprise open-ended tasks progressing from simple to complex, with motor planning as a prerequisite. As the exercise intervention was game-based, the sessions were maintained as a fun, active, and social learning environment for the children. Duration of the intervention is eight weeks,
224273941|NCT02061280|DRUG|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
224273942|NCT02061280|DRUG|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
224273943|NCT02061280|DRUG|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
224273944|NCT02258035|OTHER|Blood draw|Sampling of 100-150 ml of blood
224273945|NCT00271115|BEHAVIORAL|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
224273946|NCT04728828|BIOLOGICAL|Serological COVID-19 vaccine immunogenicity|Serological test
224273947|NCT00096460|DRUG|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
224273948|NCT00096460|DRUG|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
224273949|NCT00096460|RADIATION|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of \< 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC \> 500/mm3 x 3 days."
224273950|NCT00096460|DRUG|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
224273951|NCT00096460|PROCEDURE|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
224273952|NCT00096460|PROCEDURE|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
224273953|NCT00096460|DRUG|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
223704052|NCT02528604|PROCEDURE|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
224273954|NCT00096460|DRUG|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
224273955|NCT04164030|BEHAVIORAL|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
224273956|NCT04164030|BEHAVIORAL|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
223518010|NCT06567262|DEVICE|Conventional metallic removable partial denture|"Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally."
223518011|NCT06567301|COMBINATION_PRODUCT|Ultrasound therapy combined with Chitosan nanoparticles gel|Gymna - Belgian
223518012|NCT02592655|DEVICE|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
223518013|NCT02592655|DEVICE|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
223518014|NCT02592655|DEVICE|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
223518015|NCT02592655|DEVICE|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
223893653|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored protonated e-liquid
224273957|NCT06485284|BEHAVIORAL|El Camino|"El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships."
224273958|NCT06485284|BEHAVIORAL|Life skills program|Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
223893654|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unflavored protonated e-liquid
223893655|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of tobacco flavored unprotonated cigarette
223893656|NCT05455086|BEHAVIORAL|Cigarette Smoking|Receive 1 puff of unfavored unprotonated cigarette
223893657|NCT05455086|PROCEDURE|Computed Tomography|Undergo PET/CT
223893658|NCT05455086|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224273959|NCT03961828|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
224273960|NCT01756885|DRUG|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
224273961|NCT01756885|DRUG|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
224273962|NCT01756885|BEHAVIORAL|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
224273963|NCT02812381|PROCEDURE|KT|to aplicate neuromuscular bandage technique(KT)
224273964|NCT02812381|PROCEDURE|SCS|To aplicate strain-counterstrain above trigger point
224273965|NCT03643731|DEVICE|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
224273966|NCT02575651|DRUG|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
224273967|NCT00333450|BIOLOGICAL|Pneumococcal vaccine|
224273968|NCT02722421|DRUG|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
224273969|NCT02722421|DRUG|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
224273970|NCT03641222|DEVICE|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
224273971|NCT06082505|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include 1 hour breast and cervical cancer prevention education session delivered with support of electronic presentations. For phone education, trained project staff or Community Health Workers (CHWs) will deliver telephone-based education as an alternative to group education session for women who missed scheduled session twice (education materials would be printed and mailed).
224273972|NCT06082505|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
224273973|NCT05605652|PROCEDURE|microosteoperforations|"Flapless micro-osteoperforations will be performed interproximally on the alveolar bone equidistant between upper right canine to upper left canine at every interdental alveolar bone except at the midline~alveolar bone to prevent trauma to the soft tissue frenum before placing the initial leveling archwire."
224273974|NCT04247841|OTHER|Visual Aid|The visual aid will include a graphic display of 100 individuals with number of individuals anticipated to suffer a myocardial injury highlighted by being filled in in red. There will also be a textual discription stating the anticipated risk. For example in a patient with an rCRI score = 2 the text will state 10 out of 100 patients will have a myocardial injury (MINS) and 90 out of 100 patients will have no myocardial injury and 10 of the patients will be shaded red on the visual aid. The patients in this intervention will also received the scripted discussion of perioperative risk of MINS.
224273975|NCT04247841|OTHER|Scripted Risk Discussion|The patients seen in PSS will have a standardized discussion of perioperative risk of myocardial injury read to them by the anesthesiologist in the PSS clinic.
224273976|NCT01374945|DEVICE|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
224273977|NCT05215496|DIAGNOSTIC_TEST|[18F]fluoro-PEG-folate PET/CT scan|A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
224273978|NCT04162197|DEVICE|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
224273979|NCT04162197|DEVICE|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
223893659|NCT05455086|OTHER|Questionnaire Administration|Ancillary studies
224083158|NCT00783393|DRUG|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
223518016|NCT02592655|DEVICE|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
223518017|NCT00890656|DRUG|Cyclophosphamide (CTX)|300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
223518018|NCT00890656|DRUG|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
223518019|NCT00890656|DRUG|Doxorubicin|50 mg/m\^2 by vein (IV) over 24 hours
224273980|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
224273981|NCT01234324|DRUG|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
223518020|NCT00890656|DRUG|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
223518021|NCT00890656|DRUG|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
223518022|NCT00890656|DRUG|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
223518023|NCT00890656|DRUG|Ara-C|3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
223518024|NCT00890656|DRUG|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
223518025|NCT06308965|PROCEDURE|Vessel sparing technique|Vessel sparing
223518026|NCT06308965|PROCEDURE|Vessel ligation technique|Vessel ligation
223518027|NCT03436849|DRUG|ESN364|ESN364 will be administered orally.
224273982|NCT05595616|DEVICE|Insertion of tracheal thermometer and pulmonary artery catheter|Endotracheal intubation of endotracheal tube with thermometer (Human Endotracheal Tube, Insung Medical Co., Korea) and insertion of Swan-Ganz catheter
224273983|NCT05194202|BEHAVIORAL|ED-HEART|Behavioral intervention that assesses 1) healthy and unhealthy relationship behaviors, 2) conversation with partners around boundaries within relationships, 3) harm reduction strategies, and 4) resources for Adolescent Relationship Abuse (ARA) and related concerns, including Point of Care (POC) Reproductive and Sexual Health (RSH) harm reduction resources.
224273984|NCT06679426|DRUG|Conestat Alfa|See arm/group descriptions
224273985|NCT05135273|BIOLOGICAL|Pfs230D1-EPA/Matrix-M Vaccine|Each single-use vial of Pfs230D1M-EPA contains 160 µg/mL of conjugated Pfs230D1M and 124 µg/mL or 143 µg/mL of conjugated EPA in 4 mM phosphate-buffered saline (PBS), in a volume of 0.5 mL. Each vial of Matrix-M1 contains saponin content of 0.375 mg/mL in PBS, at a pH of 7.2, in a final volume of 0.75 mL. Components will be combined in volumes defined in the protocol at point of use.
224273986|NCT05135273|BIOLOGICAL|Verorab Rabies Vaccine|Verorab Rabies Vaccine is a purified inactivated rabies vaccine (Wistar rabies PM/WI 38 1503-3M strain) prepared on Vero cells. It is supplied as a powder and solvent for suspension for injection in a prefilled syringe. Before reconstitution, the powder is a white and homogeneous pellet. The solvent is a limpid solution.
224273987|NCT02710214|DRUG|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
224273988|NCT02710214|DRUG|Placebo|Once-daily dosing of placebo for 8 weeks
224273989|NCT04273087|OTHER|Observation|Clinical signs and symptoms
224273990|NCT01485471|DEVICE|Diffuse optical spectroscopy imaging|ear exam imaging
224273991|NCT04544852|BEHAVIORAL|Current practice|"Intervention A depicts current practices by informing the participants that FIT kits can be obtained from from the Singapore Cancer Society (SCS) or one of their collection point free of charge. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test."
224273992|NCT04544852|BEHAVIORAL|Targeted intervention programme|The targeted intervention programme includes participants undergoing a structured educational program regarding colorectal cancer and the importance of screening in its prevention. The details will be explained to them using the pamphlet from MOH on Colorectal Cancer Screening. They will also be offered two FIT kits free of charge. Research team will educate participants on how to perform the FIT test. A detailed information guide on how to collect stool samples for FIT kit and how to return the completed FIT kit to the NUH Colorectal Centre will be given to them. Participants will be contacted at 3 months after enrollment to determine whether they have completed the FIT test.
224273993|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
224273994|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
224273995|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
224273996|NCT00131482|DRUG|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
224273997|NCT00131482|DRUG|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
224273998|NCT05373667|PROCEDURE|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) - High Frequency at 10 kHz
223518028|NCT03436849|DRUG|Placebo|Placebo will be administered orally.
223518029|NCT03554330|OTHER|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
223518030|NCT03554330|OTHER|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
223704053|NCT02528604|PROCEDURE|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
224273999|NCT02868723|OTHER|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
224274000|NCT04711317|DEVICE|Nasal high flow oxygen|Pregnant women scheduled for cesarian section in general anaesthesia will be preoxygenated using nasal high flow oxygen
224274001|NCT03031834|DRUG|Quinapril|
224274002|NCT01345734|DRUG|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
224274003|NCT03084458|BEHAVIORAL|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
224274004|NCT02497235|DRUG|TAK-935|TAK-935 oral solution.
224274005|NCT02497235|DRUG|[18F]MNI-792 (tracer)|\[18F\]MNI-792 injection.
224274006|NCT05722249|BEHAVIORAL|Mindfulness and Sleep Hygiene|Participants will experience demonstrations and explanations regarding sleep hygiene, mindfulness alerts for at work and mindfulness rest for at home.
223518031|NCT06094855|OTHER|20 minutes of biking on a stationary recumbent bicycle with and without a cooling vest|2 bouts of 20 minutes of pedaling on a stationary recumbent bicycle, 1-2 weeks apart. Subjects will be cooled for one of the bouts and uncooled for the other.
223518032|NCT06468930|DEVICE|Low-level light therapy (LLLT)|LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.
224274007|NCT05722249|BEHAVIORAL|Phyical activity and Sleep Hygiene|All enrolled participants in the inpatient units randomly assigned to Arm B during Study Period 1 will receive written guidelines about physical activity during the nightshift (please see Appendix V). These guidelines will instruct them to achieve the goal of up to 15 minutes of physical activity between midnight and 0500 each nightshift during the 8-week study period. Each enrolled participant will view a video with voice over of the study team physical therapist demonstrating the methods
224274008|NCT03712202|DRUG|Bleomycin|Given IV
224274009|NCT03712202|DRUG|Brentuximab Vedotin|Given IV
224274010|NCT03712202|DRUG|Dacarbazine|Given IV
224274011|NCT03712202|DRUG|Doxorubicin|Given IV
224274012|NCT03712202|BIOLOGICAL|Nivolumab|Given IV
224274013|NCT03712202|OTHER|Quality-of-Life Assessment|Ancillary studies
224274014|NCT03712202|DRUG|Vinblastine|Given IV
224274015|NCT05954819|OTHER|Planned patient education|Patients in the experimental group will be given about 30 minutes of patient education. After the training, a Patient Education Booklet containing Myocardial Infarction and Diabetes Education will be presented to the patients. Control group patients will not be given any training other than the hospital routine.
224274016|NCT02503813|PROCEDURE|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
224274017|NCT00290264|DRUG|Budesonide/formoterol|
224274018|NCT00313508|BIOLOGICAL|Autologous Dendritic Cells (DC)|Given intranodally
224274019|NCT00313508|DRUG|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
224274020|NCT00313508|BIOLOGICAL|Autologous Lymphocyte Infusion (ALI)|Infusion
224274021|NCT00458445|DRUG|SPD465|
224274022|NCT00458445|OTHER|Placebo|Placebo is a material that may look similar to SPD465, however, contains no active drug.
224274023|NCT00374049|DRUG|MUC_1|Pretreatment with Poly-ICLC alone week 1 \&2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
224274024|NCT04688372|OTHER|Surge Index|See study description above
224274025|NCT00377572|BIOLOGICAL|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
224274026|NCT00377572|BIOLOGICAL|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
224274027|NCT02937506|DRUG|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
224274028|NCT02937506|DRUG|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
224274029|NCT04522999|DEVICE|Photobiomodulation|The Valeda™ Light Delivery System
224274030|NCT04602585|BEHAVIORAL|Psycho-education|Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
224274031|NCT02456987|DEVICE|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
224274032|NCT06424691|DIETARY_SUPPLEMENT|Tailored Recommendations|Based on the microbiome analysis, participants will receive personalized action plans. These plans include dietary, lifestyle, and supplemental suggestions to improve their infant's gut health.
224274033|NCT06424691|BEHAVIORAL|Consult Call|Participants will have seven consult calls with a Gut Health Coach over the course of the study. These calls will provide guidance on the gut health reports, action plans, and any questions or concerns parents may have.
224274034|NCT06424691|BEHAVIORAL|Email Series|Parents will receive a series of educational emails covering topics such as the importance of gut health, breastfeeding benefits, the impact of C-section delivery on the microbiome, and tips for introducing solid foods.
224274035|NCT02978651|DRUG|Pitolisant (BF2.649)|
224274036|NCT02978651|DRUG|Placebo Oral Tablet|
224274037|NCT02749591|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
224274038|NCT02749591|OTHER|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
224274039|NCT02749591|OTHER|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
224274040|NCT02749591|OTHER|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
224274041|NCT05962268|OTHER|Video based education|The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
224274042|NCT05962268|OTHER|Face to face education|The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
224274043|NCT06237101|DRUG|High dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
224274044|NCT06237101|DRUG|Medium dose of remifentanil|The dose of remifentanil will be changed to determine the concentration of propofol at which burst suppressions are generated
224274045|NCT03977168|PROCEDURE|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
224274046|NCT00769314|DRUG|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
224274047|NCT00769314|DRUG|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
224274048|NCT03393481|DRUG|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
224274049|NCT03393481|DRUG|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
223704054|NCT02528604|PROCEDURE|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
224274050|NCT04360408|OTHER|Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis|The total program consisting of three educational sessions (at Week -1, week -3 and week -5) and one booster session (week -10) over a period of 12 weeks. Participants will receive individual, face to face education during their regular HD session. Education will be provided over 30-45 minutes for the first session, 30 minutes in the next two sessions and 30-45 minutes for the booster session. The lead researcher, who is a nurse, will deliver the entire intervention to avoid information bias. The simple language will be used, and emphasis will be given on the objectives of each session.
224274051|NCT06381687|BEHAVIORAL|A multi-component, multi-level programme (MoviMusi)|"The MoviMusi program will be designed and implemented in each city by the 12 ECEC centres in the intervention group. In addition, the intervention programme will aim to address the main barriers and facilitators identified during the first year (baseline assessment) in relation to movement and music curricular practices. The programme will have three axes:~(1) Training. Educators and families will actively participate in a series of seminars and training workshops on the promotion of PA as a healthy behaviour and the use of music as a didactic resource to strengthen holistic education both inside and outside ECEC. (2) Participation. Each ECEC institution will be supported as they design a movement and music programme to offer children better opportunities to learn about the body, its possibilities of action, and musical skills.(3) Implementation. The specific actions of the MoviMusi Programme will be put into practice in each ECEC institution."
224274052|NCT04157452|PROCEDURE|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
224274053|NCT05922488|PROCEDURE|Umbilical cord milking|Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
224274054|NCT05922488|PROCEDURE|delayed cord clamping|delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
224274055|NCT03224078|OTHER|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
224274056|NCT03908528|DIETARY_SUPPLEMENT|Alpha-lipoic acid Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies) with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks..
224274057|NCT03908528|OTHER|Placebo Plus Chemotherapy (doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by taxol)|Placebo with four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
224274058|NCT00497588|PROCEDURE|surgery|
224274059|NCT00497588|RADIATION|radiotherapy|
224274060|NCT06678815|OTHER|Emergency response|Those delivering or receiving emergency care from a CFR.
224274061|NCT03480685|DEVICE|IVUS and OCT Imaging|Use of an imaging catheter
224274062|NCT03701126|PROCEDURE|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
223518033|NCT06468930|DEVICE|Intense pulsed light (IPL)|The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim
223518034|NCT05857878|DRUG|BI 1815368|BI 1815368
223518035|NCT05857878|DRUG|Matching placebo|Matching placebo
224274063|NCT03701126|PROCEDURE|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
224274064|NCT03701126|DRUG|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
224274065|NCT03701126|DEVICE|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
224274066|NCT05535660|DIAGNOSTIC_TEST|Lipid panel|fasting blood draw to examine concentrations of lipids in maternal blood during pregnancy
224274067|NCT03217526|OTHER|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
224274068|NCT05316389|PROCEDURE|Breast reconstruction|Muscle sparing Latissimus Dorsi Flap or prothesis
224274069|NCT06148662|OTHER|No intervention (negative control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds."
224274070|NCT06148662|OTHER|Water (positive control)|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds. Then, participants will to rinse their mouth with tap water 60 seconds."
224274071|NCT06148662|DRUG|"Dental foam Biorepair PERIBIOMA"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam Biorepair PERIBIOMA to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
223704055|NCT02528604|DEVICE|Implantable loop recorder|
224274072|NCT06148662|DRUG|"Dental foam WATER:DENT"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental foam WATER:DENT to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
224274073|NCT06148662|DRUG|"Dental spray BUCCOTHERM"|"The participants will be asked to hold 20 ml of coca-cola in their mouth for 30 seconds.~Then, participants will use a dental spray BUCCOTHERM to rinse their mouth. They should rinse their mouth for 60 seconds and then spit out the foam."
223518036|NCT05272579|OTHER|Fecal Filtrate Transfer|Treatment with donated fecal samples filtered to contain practically no bacteria and mainly viruses, including bacteriophages
223518037|NCT05272579|OTHER|Placebo|Saline solution
223518038|NCT03228043|DRUG|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
223518039|NCT03228043|DRUG|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
224274074|NCT02838940|PROCEDURE|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
223518040|NCT05378529|OTHER|Lp(a) Screening|Participants will provide demographic information and have a blood draw for Lp(a) levels if they are unknown.
223518041|NCT05306574|BIOLOGICAL|Telitacicept|Subcutaneous injection weekly for 52 weeks
223518042|NCT05306574|BIOLOGICAL|Placebo|Subcutaneous injection weekly for 52 weeks
223518043|NCT03717454|OTHER|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
223518044|NCT03717454|DRUG|Drug treatment|The medication will continue if DA causes tumors to shrink.
223518045|NCT06439927|DEVICE|Polycaprolactone nasal mesh|a 3-dimensional fabricated Polycaprolactone nasal mesh
223518046|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
223518047|NCT00392288|DRUG|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
224274075|NCT02838940|DRUG|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
224274076|NCT02853539|DRUG|Denosumab|Subcutaneous injection of Denosumab
224274077|NCT00704496|DRUG|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
224274078|NCT05845957|OTHER|Digital Education Group|Providing training on safe pediatric intravenous drug administration with digital storytelling method
224274079|NCT01069796|DRUG|Paclitaxel|80 mg/m² weekly
224274080|NCT01069796|DRUG|Bevacizumab|10 mg/kg d1 d15
224274081|NCT01069796|DRUG|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
224274082|NCT01188226|DEVICE|Denture teeth|Denture teeth made of nano hybrid composite material
223518048|NCT00392288|DRUG|Placebo|Placebo MDI over twelve weeks
223518049|NCT01127204|DRUG|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
223518050|NCT01127204|DRUG|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
223518051|NCT02544763|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
224274083|NCT04920045|OTHER|Red blood cell transfusion|All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
224274084|NCT04622124|DRUG|Placebo|
224274085|NCT04622124|DIETARY_SUPPLEMENT|fasted vs. high-fat meal|
224274086|NCT04622124|DRUG|Placebo|
224274087|NCT00804024|DEVICE|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
224274088|NCT01662024|DEVICE|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
224274089|NCT05127135|BIOLOGICAL|ThisCART7 cells|0.5-6 x 10\^6 CAR T cells per kg body weight
223518052|NCT02544763|DRUG|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
224274090|NCT00304434|DRUG|Oseltamivir|
224274091|NCT00304434|DRUG|Probenecid|
223704056|NCT03375008|DIAGNOSTIC_TEST|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
224274092|NCT04916613|DRUG|Darolutamide 300 mg|600 mg po, b.i.d.
224274093|NCT04916613|DRUG|Placebo|po, b.i.d.
224274094|NCT04916613|DRUG|Androgen deprivation therapy|Use according to local standard of care
224274095|NCT04888949|BIOLOGICAL|Mesenchymal stem cell|1\*10\^8 cells are administered once a week, total four times intravenously.
224274096|NCT04888949|BIOLOGICAL|Placebo|Commercially available saline.
224274097|NCT05105659|DIAGNOSTIC_TEST|Wechsler IQ for Adults|IQ test that measures the cognitive functions and intelligence using a scale and consists of many subtests assessing verbal and non-verbal performance.
224274098|NCT05105659|DIAGNOSTIC_TEST|MAS (Memory assessment scale)|tool that uses verbal and the visual tasks to assess memory, recall and cognition. The MAS consists of 12 subtests based on the following 7 memory tasks: Verbal Span, List Learning, Prose memory, Visual Span, Visual Recognition, Visual Reproduction and Names-Faces.
224274099|NCT05105659|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL)|measures multiple aspects of the individual's life and the impact of the disease and treatment on the individual's life. It does so by assessing the individual's own views and perspective of the care and treatment they are receiving and whether consider it satisfactory or not.
224274100|NCT05105659|DIAGNOSTIC_TEST|Symptom check list 90|a well-known scale that is used to identify and assess psychological symptoms. It consists of a 90-item checklist having a 5-point rating scale.
224274101|NCT05105659|DIAGNOSTIC_TEST|Socioeconomic level|scale for measurement of socioeconomic status in health research in Egypt. The new socioeconomic status scale has 7 domains with a total score of 84. Intra-and inter-observer variability and the internal consistency of the scale were assessed.
224274102|NCT03616002|OTHER|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
223518053|NCT03940157|BEHAVIORAL|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
223704057|NCT01865188|DRUG|LCZ696|Experimental monotherapy doses
224274103|NCT04977596|OTHER|No intervention|Retrospective study without intervention
223704058|NCT01865188|DRUG|Amlodipine|Active comparator monotherapy doses
223704059|NCT01865188|DRUG|LCZ696 and amlodipine combination|Experimental combination doses
223704060|NCT01865188|DRUG|Placebo|Placebo comparator dose
224274104|NCT05116137|BEHAVIORAL|Circuit-based resistance exercise (CRT)|CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
224274105|NCT04980456|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
224274106|NCT04980456|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
224274107|NCT04980456|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
224274108|NCT04832971|DRUG|ARO-ANG3|ARO-ANG3 Injection
224274109|NCT04832971|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
224274110|NCT03296813|DRUG|Torsemide|Loop diuretic
224274111|NCT03296813|DRUG|Furosemide|Loop diuretic
224274112|NCT01324856|PROCEDURE|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
224274113|NCT01324856|PROCEDURE|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
224274114|NCT04648007|DIAGNOSTIC_TEST|Kaihani Score|Assessment of neuromodulatory chemicals in peripheral blood plasma samples.
224274115|NCT00030407|DRUG|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
224274116|NCT00030407|DRUG|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
224274117|NCT00000745|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
224274118|NCT00000745|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
224274119|NCT03440333|DRUG|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
224274120|NCT05531851|OTHER|Instrument Assisted Soft Tissue Mobilization|"For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin."
224274121|NCT03623893|PROCEDURE|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
224274122|NCT06226025|DRUG|Melatonin|Participants randomized to this intervention will take 1 oral pill (0.5 milligrams (mg)) daily. They will attend 4 weekly behavioral sleep intervention sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
224274123|NCT06226025|OTHER|Placebo|Participants randomized to this intervention will take 1 oral placebo pill daily. They will attend 4 weekly behavioral sleep control sessions with a therapist. In addition, participants will complete questionnaires (MyDataHelp app), monitor sleep, collect saliva samples, and wear the Fitbit Device.
224274124|NCT06226025|BEHAVIORAL|Behavioral sleep intervention|An active intervention that is typically paired with melatonin to maximize treatment effects.
224274125|NCT06226025|BEHAVIORAL|Behavioral sleep control|A behavioral placebo (which does not improve sleep in delayed sleep-wake phase disorder) to control for social/interpersonal effects of behavioral sleep intervention sessions.
224274126|NCT05808166|BIOLOGICAL|Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).|Hecolin® will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 1), and 0, 1 and 6 months for the non-pregnant participant (arm 3).
224274127|NCT05808166|OTHER|Isotonic Sodium Chloride injection|Placebo will be administered 2 doses administered 4 weeks apart during pregnancy and 1 dose administered after delivery at least 20 weeks following the second dose for the pregnant participants (arm 2)
224274128|NCT01185860|DRUG|danoprevir|oral doses
224274129|NCT01185860|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
224274130|NCT01185860|DRUG|placebo|oral doses
224274131|NCT01185860|DRUG|ribavirin|1000-1200mg/day po
224274132|NCT01185860|DRUG|ritonavir|oral doses
224274133|NCT02523794|OTHER|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
224274134|NCT02523794|OTHER|Placebo|Purified Drinking Water
223518054|NCT01337310|DRUG|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
223518055|NCT01887197|OTHER|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
223518056|NCT01887197|DRUG|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
223518057|NCT01887197|DRUG|mannitol inhalation powder|mannitol inhalation powder
223518058|NCT05270031|DEVICE|Balloon dilation of the eustachian tube|Balloon dilation of the eustachian tube
223518059|NCT03233971|OTHER|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
223704061|NCT01422460|BIOLOGICAL|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
224274135|NCT02293460|DRUG|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
224274136|NCT06617624|OTHER|MRI|Healthy volunteer will have a non-injected cardiovascular MRI
224274137|NCT06617624|OTHER|MRI Contrast|Patients will have the gadolinium injected cardiovascular MRI
224274138|NCT00706719|DRUG|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
224274139|NCT00706719|DRUG|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
224274140|NCT05196100|DEVICE|Amparo confidence socket|Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
224274141|NCT05696509|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.
224274142|NCT05696509|DRUG|Isoflurane|Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC
224274143|NCT05696509|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
224274144|NCT02676245|BEHAVIORAL|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
224274145|NCT02676245|BEHAVIORAL|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
224274146|NCT06615778|BEHAVIORAL|Motivated Social Emotional Learning|"MSEL arm consists of three intervention components: 1) CSEL, 2) the meaningful role tasks, and 3) the Secret Angel activity. First, participants in the MSEL arm will receive the same 6-session SEL as participants in the Curriculum-based Social-Emotional Learning arm.~Second, other than the CSEL, the second component is the Class Diploma tasks adopted from the pupil responsibilities intervention developed by Ellies et al. (2016). Participants will be provided with a list of meaningful roles and select the role they are willing to take based on their talents and interests. Each participant will take the role for two weeks, fulfilling the related duties and responsibilities. The third component is the Secret Angel, in which participants will anonymously recognize each other via the appraisal notes on Shout Out for Your Board."
224274147|NCT06615778|BEHAVIORAL|Curriculum-based Social Emotional Learning|"In the CSEL arm, 6-session SEL training will be delivered as the experimental component. The primary goal of the SEL training is to reduce traditional bullying and cyberbullying perpetration and victimization by enhancing students' social-emotional competence, which has been examined to be the protective factor for bullying-related behaviors.~Each session lasts 40 minutes and is delivered by the headteacher in each class weekly as an after-school workshop. The SEL curriculum is tailored to the social-emotional needs of primary school students, as suggested by CASEL (2013). Also, building on past literature highlighting the lack of SEC as a risk factor linked to bullying behaviors both in the physical and cyber world, specific topics such as self-appreciation (self-awareness), stress management (self-management), respect and acceptance (social awareness), and conflict resolution (relationship skills) incorporated into the curriculum design."
224274148|NCT04502498|DIAGNOSTIC_TEST|Lower limb duplex & doppler|Lower limb duplex and doppler one week before radical cystectomy
224274149|NCT00159835|DRUG|atorvastatin|
224274150|NCT00159835|DRUG|simvastatin|
224274151|NCT05310825|OTHER|Dry Wiping Bath with Single-Use Wipes|Cleaning wipes will be used in the bathing process which do not contain alcohol, paraben or latex. These wipes are a product routinely used in patient hygiene procedures in the intensive care unit where the study is to be conducted. Before taking them out of the packet, the wipes to be used in the bathing will be heated according to usage instructions at 850W for 50 seconds in a microwave oven which will be brought by the researcher The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated.
224274152|NCT05310825|OTHER|Traditional Body Wiping Bath|"The rubbing cloth to be used with both the soapy and the rinsing water in the routine procedure will have an inner layer of pure cotton with an outer layer of hydrophilic gauze. The patient's body wash will be performed with this cloth, using foam from the soapy water. As soon as the bathing procedure is commenced, a chronometer will be started by another nurse who is independent of the study.~The steps to be followed in the wiping procedures of bath will be, in order, cleaning the patient's face area (the eyes will only be cleaned with rinsing water), the ears on each side, the arms, the hands, the breast and chest area, the legs on each side, the feet, the back, and finally, the perineum and anal area, after which the washing procedure will be terminated"
224274153|NCT03749707|DIAGNOSTIC_TEST|HPV analysis|HPV analysis of SLNs with an in-house targeted Next Generation Sequencing assay
224274154|NCT02957760|DRUG|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
224274155|NCT02583191|DRUG|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
224274156|NCT02583191|DRUG|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~* Enoxaparin 1 mg/kg BW twice daily~* Tinzaparin 175 I.E./kg BW once daily~* Dalteparin 200 I.E./kg BW once daily"
224274157|NCT05001698|BIOLOGICAL|Anifrolumab|intravenous infusion (IV)
223704062|NCT01801826|DEVICE|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
224274158|NCT00735319|DEVICE|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
224274159|NCT04282694|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|Early detection of lung cancer by LDCT and smoking cessation counselling
224274160|NCT05490095|DRUG|SVG101 (T)|5mg of SVG101
224274161|NCT05490095|DRUG|Afinitor (R)|5mg of Afinitor
224274162|NCT05048862|DIAGNOSTIC_TEST|Neuromuscular ultrasound|Ultrasound will be performed with the Affiniti 70 (Philips Medical Instruments, Bothell, WA). all patients following standardized methods of our hospital. All the patient would be checked the skin surface temperature before the ultrasound examination. The image would be exported from the echo machine as DICOM format.
223704063|NCT02007616|OTHER|Non-action video game training|Based on cognitive training Lumosity
223704064|NCT04500730|DRUG|Shaoyao Gancao Decoction Jiawei|"Study herb will be prescribed for 28 consecutive days. Study follow up will be offered every 7 days till 56th day after enrolment.~Daily leg cramps log will be filled in by each individual everyday from day 0 to day 56."
224274163|NCT05048862|DIAGNOSTIC_TEST|Muscle MRI|Muscle MRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject will lie in a supine position comfortably, supplied with ear plugs. A high resolution T1 weighted scan and Short-T1 Inversion Recovery series (STIR) of the four limbs muscle were obtained in axial and coronal plane. MR spectroscopy in interested muscle was also sampled to evaluate the composition of fat, water, lactate, and other studied molecules.
223704065|NCT00357357|DRUG|HF0220|comparison of different dosages of drug
223704066|NCT01636531|DRUG|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
223704067|NCT01636531|DRUG|gantenerumab|Lyophilized formulation (LyoF), single dose sc
223518060|NCT06230341|OTHER|Health Services Research|MSPs benefit from a learning system. The learning system combines an individualised support programme provided by a regional support structure for quality and safety in health care (QualiREL Santé) and the provision of a web platform. Based on the 4 dimensions of the Shortell model, the support programme includes initial training (6 months) and personalised methodological support (18 months) for each MSP. A web platform is provided to MSPs to enable them to implement the full approach of the Risk Management Support Programme. It provides support for reporting, analysis and management of PSIs.
223518061|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
223518062|NCT05490472|DRUG|JAB-2485 (Aurora A inhibitor)|Administered orally
223518063|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
223518064|NCT00656643|DRUG|Placebo|Two subconjunctival injections of placebo.
223518065|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
223518066|NCT00656643|DRUG|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
223518067|NCT00299715|DRUG|Paliperidone extended-release|
223518068|NCT04990947|OTHER|lifestyle / RYGB|No intervention, just 2 different groups will be included
223518069|NCT02462629|DRUG|BLZ-100|
223518070|NCT01336699|OTHER|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
223518071|NCT01336699|BIOLOGICAL|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
223518072|NCT01336699|BIOLOGICAL|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10\^3 colony-forming units (cfu) to 1x10\^7 cfu.
223518073|NCT02097225|DRUG|Dabrafenib|Given PO
223518074|NCT02097225|OTHER|Laboratory Biomarker Analysis|Correlative studies
223518075|NCT02097225|DRUG|Onalespib|Given IV
223518076|NCT02097225|OTHER|Pharmacological Study|Correlative studies
223518077|NCT02097225|DRUG|Trametinib|Given PO
223518078|NCT06357078|OTHER|Art Therapy|Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
223518079|NCT02074839|DRUG|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
223518080|NCT06037083|DEVICE|Oxygen saturation probe|The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).
223518081|NCT06037083|DEVICE|Near infrared spectroscopy sensors|The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).
223518082|NCT06037083|DEVICE|Electrical impedance tomography|"The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)"
224274164|NCT05048862|DIAGNOSTIC_TEST|Nerve conduction studies and autonomic function tests|Nerve conduction study will be performed with a Nicolet Viking IV Electromyographer (Madison, WI) in all patients following standardized methods recommended by the Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. Studied nerves include sural, peroneal, tibial, median and ulnar (motor and sensory) nerves.Autonomic functions will be assessed by the SSR and RRIV with established protocol by using Nicolet Viking IV Electromyographer (Madison, WI).
223518083|NCT05135754|DEVICE|Heylo|Test of the supporting product (test product) for a 12 weeks period. No additional intervention will be conducted. A few follow up nurse calls to assess few endpoints together with subject. All remaining endpoints are captured via surveys send to the subjects every 14 days.
224274165|NCT05048862|DIAGNOSTIC_TEST|Quantitative sensory test|Quantative sensory test will be performed with a Thermal Sensory Analyzer and Vibratory Sensory Analyzer (Medoc Advanced Medical System, Minneapolis, MN). The procedure is the same as previously described 25. Briefly, the machine delivers to the patient a stimulus of constant intensity which is pre-set by the algorithm. By adjusting the intensity of stimulus (increase or decrease the intensity by a fixed ratio) according to the response of the subject (i.e. whether the subject perceives the stimulus or not), sensory thresholds of the warm, cold and vibratory modalities will be measured.
224274166|NCT05048862|DIAGNOSTIC_TEST|Skin biopsy|A skin specimen of 3 mm in diameter will be taken with a biopsy punch from the lateral side of the distal leg under 2% lidocaine local anaesthesia 26. No suturing is required, and the wounds are covered with a piece of gauze. Wound healing takes 7\~10 days, similar to a typical abrasion wound. Informed consent will be obtained from each patient before the skin biopsy. The intraepidermal nerve fiber density and sweat gland nerve innervation will be examined.
224274167|NCT05048862|DIAGNOSTIC_TEST|Muscle and nerve biopsy|Two muscle specimens with 5 x 5 x 5 mm were collected in an open muscle biopsy or needle biopsy at studied muscles under 2% lidocaine local anaesthesia. The wound was about 2-3 cm long, and suture was required. Would healing usually takes 10-14 days. First specimen was undergoing snap freezing fixation in a longitudinal axis perpendicular to the cork with the liquid nitrogen and isopentane. The second specimen was divided into two equiponderous tissues, and one was freezed in liquid nitrogen for DNA and protein analysis. The another one was treated with RNAlater solution in 4°C overnight for RNA analysis. Sural nerve biopsies or superficial peroneal nerve were obtained from a standard site posterior to the lateral malleolus under local anesthesia. The nerves were then fixed in 5% glutaraldehyde in 0.1 M phosphate buffer (PB) at 4 °C overnight. All samples were stored in the -80°C refrigerator for further analysis.
224274168|NCT05048862|DIAGNOSTIC_TEST|Genomics, transcriptome, and proteomics|The DNA, RNA, and protein of the tissues (blood, muscle, nerve and skin) were retrieved and stored in the -80°C refrigerator. The next generation sequencing (whole exon sequencing or whole genome sequencing) and RNA-seq would be performed by NGS \& Microarray Core lab in National Taiwan University or another professional team. The protein analysis would be performed by the Proteomics \& Protein Function Core Lab in National Taiwan University.
224274169|NCT05048862|DIAGNOSTIC_TEST|Laboratory of blood chemical substances, metals and endocrine profiles|The methods of the measurement will follow the standards set by Department of Laboratory Medicine of National Taiwan University Hospital.
223518084|NCT02685852|DRUG|Exenatide|Exenatide at a dose of 5 mcg
223518085|NCT02685852|DRUG|Acarbose|Acarbose at a dose of 25 mg
223518086|NCT02685852|DRUG|Exenatide Placebo|Placebo for Exenatide
223518087|NCT02685852|DRUG|Acarbose Placebo|Placebo for Acarbose
223518088|NCT02993666|DEVICE|Bair Hugger|forced air warming with Bair Hugger air warmer
223518089|NCT01764932|PROCEDURE|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
223518090|NCT00181545|PROCEDURE|escalation of dose (radiotherapy treatment)|
223518091|NCT00674063|DRUG|alefacept|IV
223518092|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
223518093|NCT01027351|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
223518094|NCT05856760|DRUG|Sparsentan|Target dose of 400 mg daily
223518095|NCT02505074|PROCEDURE|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
223518096|NCT02757963|OTHER|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score \>=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
223518097|NCT02757963|OTHER|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score \>=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
223518098|NCT02971137|BEHAVIORAL|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
223518099|NCT02971137|BEHAVIORAL|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
223518100|NCT01877057|DIETARY_SUPPLEMENT|Saturn|
223518101|NCT03696693|DEVICE|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
223518102|NCT05259098|DRUG|Sufentanil Sublingual Tablet System|Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
223518103|NCT05259098|DRUG|Intravenous Patient-Controlled Analgesia with morfine|Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
223518104|NCT00911157|DRUG|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (\< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
223518105|NCT00911157|DRUG|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
223518106|NCT03689088|DEVICE|Goldfish|Goldfish will be placed in the eye for 24h monitoring
223518107|NCT03689088|DEVICE|Tonometry|Fellow eye will be measured by tonometry
224274170|NCT05048862|DIAGNOSTIC_TEST|Contact heat evoked potentials|A contact heat evoked potential stimulator (Medoc, Ramat Yishai, Israel) will be used for delivering heat stimulation. Stimuli will be delivered repeatedly to the same stimulation site and the inter-stimulus interval will be randomly set to around 18\~22 s. CHEP will be recorded using a Nicolet Bravo evoked potential system (Nicolet Biomedical, Madison, WI). The recording electrode was placed at the Cz and P3 of international 10-20 system. The impendence of all recording electrodes was kept below 3 kΩ. The evoked potentials were filtered with a bandpass filter at 0.1\~30 Hz. Recording was triggered by the onset of each stimulus, and the sweep time was 1500 ms.
224274171|NCT05048862|DIAGNOSTIC_TEST|Nerve excitability study|Nerve excitability studies will be undertaken on the median, tibial, peroneal and sural nerves as per previously detailed protocols. Skin temperature will be monitored at the site of stimulation and was maintained at \>32°C. Stimulation and recording will be controlled by automated computerized system (QTRAC; Institute of Neurology, London, U.K.) and the stimulus current will be administered using an isolated linear bipolar constant-current stimulator (DS5; Digitimer, Welwyn Garden City, U.K.). Responses will be amplified (ICP511 AC amplifier, Grass Technologies, West Warwick, USA) with electronic noise removed (Hum Bug 50/60 Hz Noise Eliminator, Quest Scientific Instruments, North Vancouver, Canada).
224274172|NCT05048862|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|In simple rTMS protocols, individual stimuli are spaced apart by identical interstimulus intervals (ISI). The stimulation protocol was in accordance with published safety recommendations. The patterned rTMS protocols included (1) Theta burst stimulation, (2) Repetitive paired-pulse TMS. All the above stimulation protocols or paradigms will follow the international guideline of the use of TMS in clinical practice and research (Rossi et al., 2009; Fitzgerald and Daskalakis, 2012; Groppa et al., 2012; Steeves et al., 2012).
224274173|NCT05048862|DIAGNOSTIC_TEST|fMRI acquisition and image analysis|fMRI will be performed on a 3-T MR machine (Trio; Siemens, Erlangen, Germany). Each subject's head will be positioned comfortably inside a receive-only 8-channel birdcage head coil, supplied with ear plugs, heavily padded and secured with a strap across the forehead in order to minimize head motion. All data will be processed using SPM2 (Wellcome Department of Cognitive Neurology, London UK) 36 implemented on MATLAB (Mathworks Inc. Sherborn, MA).
224274174|NCT05702021|BEHAVIORAL|Science to Service Laboratory|The Science of Service Laboratory implementation strategy consists of: didactic training (contingency management workshops; monthly contingency management coaching calls), performance feedback (practice sessions and electronic medical record feedback); and facilitation (monthly facilitation calls).
224274175|NCT00613041|PROCEDURE|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
223518108|NCT04755231|DEVICE|AcrySof IQ PanOptix Presbyopia Correcting IOL|UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.
223518109|NCT04755231|PROCEDURE|Cataract surgery|Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL
223518110|NCT02088086|BEHAVIORAL|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
223518111|NCT02088086|BEHAVIORAL|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
223518112|NCT02088086|BEHAVIORAL|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
223518113|NCT06577948|DEVICE|Single vision spectacle lens|Standard single vision spectacle lens
223518114|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 1|P.A.U.S.E. spectacle lens 1
223518115|NCT06577948|DEVICE|P.A.U.S.E. spectacle lens 2|P.A.U.S.E. spectacle lens 2
223518116|NCT06554899|OTHER|Clinician-led intervention to address fear of cancer recurrence (CIFeR)|The intervention includes five components informed by theoretical models and existing interventions for FCR: 1) FCR normalization: reassurance that FCR is a common and normal phenomenon after treatment for cancer, 2) Providing prognostic information: asking patients whether they would like information about their risk of recurrence and, if yes,providing this information, 3) Providing education and take-home information on red-flag recurrence symptoms, 4) Brief advice on managing worry: distraction, meditation, mindfulness, reassurance, and links to online resources to manage FCR, and 5) referral to a psychologist if FCR is high (FCRI-SF \>= 22), or if deemed helpful by the patient or clinician. Access will be provided to ConquerFear-Group delivered online by trained psychologists.
223704068|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
224274176|NCT05361343|OTHER|1. Nutrition; 2. Physical activity; 3. Hypoxic training; 4. Menthal heals improvement|"1. Nutrition: intermittent fasting;~2. Physical activity: medium-intensity or high-intensity physical activity;~3. Hypoxic training (at least three per visit to the center);~4. correction of hygiene and sleep duration, relaxation techniques, cognitive behavioral therapy for insomnia.~5. Individual motivational counseling."
224274177|NCT03860025|OTHER|No intervention.|No intervention.
224274178|NCT04592419|DRUG|KSI-301|Intravitreal Injection
223518117|NCT06642948|OTHER|Motor rehabilitation based on ai visual recognition|Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance. Initially, patients will be provided with exercise materials developed by the intervention team, one-on-one guidance via the AI rehabilitation platform, and a detailed explanation of the exercise intervention program (including its components, foundational knowledge, and benefits).The aerobic warm-up routine includes activities such as marching in place, full-body stretches, jumping jacks, side steps with arm circles, and squats with alternating punches. For the elderly, the warm-up routine is similar but also incorporates chest expansion exercises, abduction exercises, overhead reaches, lateral movements, hip extension exercises, calf raises, and additional full-body stretches.Functional training should be done 3 to 5 times per week at an intensity of RPE 3 to 4, with each session lasting 15 to 30 minutes.
223518118|NCT06637618|BEHAVIORAL|up front use of mineralocorticoid receptor antagonist|the sequence of which the four drug classes are prescribed will differ, where the intervention is early use of MRA, where the control group will receive standard care, where MRA are usually prescribed last
223518119|NCT06644885|PROCEDURE|TIVAD implantation complications|Follow up and post operative outcome of patients with devices implantation
223518120|NCT06643104|PROCEDURE|Tuina|X-ray mapping guides three days of tailored exercises, including 3D therapy, breathing techniques, and spinal manipulation.
223518121|NCT06535893|DRUG|TN|Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab
223518122|NCT06535893|DRUG|TN-1|Carboplatin + paclitaxel + pembrolizumab followed by niraparib + pembrolizumab Niraparib Pembrolizumab AC
223518123|NCT06179004|DRUG|Liposomal bupivacaine|133mg Liposomal bupivacaine plus 10mL 0.5% bupivacaine administered in a supraclavicular single shot perineural injection
223518124|NCT06179004|DRUG|Bupivacaine Hydrochloride|20mL 0.25% bupivacaine administered in a supraclavicular single shot perineural injection
223518125|NCT06221813|BIOLOGICAL|PHV02|Nipah virus vaccine
223518126|NCT06221813|BIOLOGICAL|Lactated Ringer's|Placebo
223518127|NCT02016599|OTHER|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
223518128|NCT06479863|COMBINATION_PRODUCT|Pozelimab/Cemdisiran|Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks
223518129|NCT04650893|DRUG|Intravenous Ketorolac|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
223518130|NCT04650893|DRUG|Intravenous Dexamethasone|To assess the efficacy of the meds for dysphagia and dysphonia following ACDF
223518131|NCT04650893|DRUG|Placebo|Control
223518132|NCT05919030|RADIATION|Intensity-modulated radiotherapy (IMRT)|Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy
223518133|NCT05919030|DRUG|Tislelizumab|200 mg IV Q3W
223893660|NCT05764863|RADIATION|fMRI|The participant will then complete a series of working memory tasks under three distinct conditions as described above (visual spatial, visual non-spatial, auditory). The instructions and tasks will be administered via an MRI compatible monitor and headset system (NordicNeuroLab). During the tasks, the participant's brain activity will be recorded. Finally, at the end of the experiment, a high-resolution anatomical image of the brain will be acquired in order to facilitate the subsequent data processing steps and to define the position of the interparietal sulcus for each subject. The visit will be completed by a visual imaging questionnaire.
224274179|NCT04592419|DRUG|Aflibercept|Intravitreal Injection
224274180|NCT04592419|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
224274181|NCT06678321|BEHAVIORAL|Mobil game|Participants in the intervention group will be asked to play the game and complete all parts.
224274182|NCT01264913|BEHAVIORAL|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
224274183|NCT01853371|PROCEDURE|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
224274184|NCT01853371|OTHER|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
223518134|NCT05919030|DRUG|Cisplatin|During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W
223518135|NCT05919030|DRUG|Nab paclitaxel|During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
223518136|NCT00298155|DRUG|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
223518137|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
223518138|NCT00298155|DRUG|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
223518139|NCT00250575|DRUG|Clozapine|
223518140|NCT06151665|PROCEDURE|single file rotary|Kedo-S plus file is the fifth generation of pediatric files will be used in pulpectomy of primary molars
223518141|NCT06151665|PROCEDURE|Conventional Manual K files|Stainless-steel K files is the golden standard files used in pulpectomy of primary molars
223518142|NCT00912873|DRUG|0.1% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
223518143|NCT00912873|DRUG|0.4% Ropivacaine|Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
223518144|NCT02142829|DRUG|EXPAREL|
223518145|NCT02142829|DRUG|On-Q Pain Ball|bupivacaine HCl 0.25%
224274185|NCT00057967|BIOLOGICAL|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
223518146|NCT02714543|DRUG|aloevera juice|aloevera juice to drink twice daily for 3 months.
223518147|NCT02714543|DRUG|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
223518148|NCT02714543|DRUG|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
223518149|NCT02714543|DRUG|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
223518150|NCT02714543|DRUG|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
223518151|NCT00189878|DRUG|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
223518152|NCT00189878|DRUG|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
223518153|NCT00313521|DRUG|thiotepa|
223518154|NCT00313521|PROCEDURE|adjuvant therapy|
223518155|NCT00313521|RADIATION|radiation therapy|
223518156|NCT03075436|BEHAVIORAL|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
223518157|NCT03075436|BEHAVIORAL|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
223518158|NCT05394051|BEHAVIORAL|Positive Affect Regulation sKills (PARK)|"The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up."
224274186|NCT00808262|BIOLOGICAL|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
224274187|NCT04129944|DRUG|UBX0101|Investigational drug intra-articular injection
224274188|NCT04129944|OTHER|Placebo|Placebo intra-articular injection
224274189|NCT04158778|DRUG|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
224274190|NCT04158778|OTHER|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 \& 7) within the 10 week course of psychotherapy.
224274191|NCT02690051|DEVICE|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
224274192|NCT02419573|DEVICE|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
223518159|NCT00761137|DRUG|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
223518160|NCT00761137|DRUG|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
223518161|NCT00761137|DRUG|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
223518162|NCT00761137|DRUG|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
223518163|NCT03468465|DRUG|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
223518164|NCT03468465|DEVICE|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
223518165|NCT01561612|BEHAVIORAL|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
223518166|NCT04548219|DRUG|Mirikizumab|Reference and test formulations of mirikizumab administered as a SC injection.
223518167|NCT05039489|DRUG|Antipsychotic drugs|Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs
223518168|NCT05039489|DEVICE|cTBS（the left temporoparietal cortex as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
223518169|NCT05039489|DEVICE|cTBS （the left cerebellum Crus II as the stimulation target）|Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks
223518170|NCT05253326|OTHER|Progressive Muscle Relaxation Exercises|It is among the relaxation techniques that require the active participation of the individual.
223518171|NCT04875845|BEHAVIORAL|Fasting for elective surgery|6-hours and 8-hours fasting before elective surgery
223518172|NCT04924452|PROCEDURE|Laser conditioning and Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; laser conditioning of the occlusal enamel surface. The parameter settings used will be: tip-to-tissue distance 1.5mm from the tooth surface; tip diameter 600 µm; laser energy 70 mJ; pulse frequency 10 Hz; water spray level 8; average power 0.7 W; energy density 67 J/cm2; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
223518173|NCT04924452|PROCEDURE|Sealant application|Sealant application protocol includes: a low-speed rubber cup and pumice paste (CleanPolish, Kerr) will be used for 30 seconds for cleaning and polishing of the occlusal surface of the chosen permanent molar; tooth surface will be washed for debris and organic residue removal and dried with air spray; isolation; tooth surface will be etched with 35% phosphoric acid gel (Etching gel, DMP Ltd) for 30 seconds and rinsed for the same time; reisolation; tooth surface will be dried with air spray for 15s; fissure sealant application (Pit\&Fissure Sealant, DMP Ltd); light cured for 20 seconds.
223518174|NCT04924452|DEVICE|Er:YAG laser therapy|Er:YAG laser (LiteTouch, Light Instruments LTD), emission wavelength 2940 nm will be used for caries removal - parameters: enamel removal - energy 100-200mJ; density 9.84-13.03 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface; dentin removal - energy 100mJ; density 9.84 J/cm2, pulse frequency 20Hz; tip diameter 800 μm; water spray level 8; tip-to-tissue distance 0.5÷1 mm form the tooth surface. Restoration with compomer.
223518175|NCT04924452|PROCEDURE|Conventional therapy|Conventional rotary instruments will be used for caries removal - high-speed and low-speed dental handpieces. Restoration with compomer.
223518176|NCT00098761|DRUG|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
223518177|NCT04444297|OTHER|3D Telemedicine|A consultation performed with a 3D form of telemedicine
223518178|NCT04444297|OTHER|2D Telemedicine|A consultation performed with 2D (standard) telemedicine
223518179|NCT06189872|DEVICE|Attune Cementless|"* Attune AFFIXIUM Cementless Tibial Baseplate, Fixed Bearing~* Attune POROCOAT Cementless Femoral Component, Cruciate Retaining~* Attune AOX Antioxidant Polyethylene Tibial Insert, Cruciate Retaining~* Attune AOX Patellar Button, Domed or Medialized Dome, Cemented or Cementless (surgeon preference for resurfacing)"
223518180|NCT03224377|DIAGNOSTIC_TEST|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
223518181|NCT00072579|BIOLOGICAL|sargramostim|
223518182|NCT06660030|OTHER|No intervention|No intervention
224274193|NCT02419573|DEVICE|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
224274194|NCT00493792|DEVICE|X3 Polyethylene|Highly cross-linked polyethylene (HXLPE).
224274195|NCT00493792|DEVICE|N2Vac Polyethylene|Ultra-high-molecular-weight polyethylene (UHMWPE).
224274196|NCT00004416|DRUG|botulinum toxin type A|
224274197|NCT01811368|BIOLOGICAL|rituximab|Given IV
224274198|NCT01811368|BIOLOGICAL|ibritumomab tiuxetan|Given IV
224274199|NCT01811368|BIOLOGICAL|anti-thymocyte globulin|Given IV
223518183|NCT04816292|PROCEDURE|Active Comparator: Hot Snare Polypectomy|Hot Snare Polypectomy with the use of electrocautery for the resection of polyps.
223518184|NCT04816292|PROCEDURE|Experimental: Cold Snare Polypectomy|Cold Snare Polypectomy without the use of electrocautery for the resection of polyps.
223518185|NCT05238220|DRUG|Valganciclovir|continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity
223704069|NCT02231632|BIOLOGICAL|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
223893661|NCT06803095|BEHAVIORAL|free walking with dog and diet restriction|the total participants of tinnitus (chronic subjective form) and obstructive sleep apnea (mild degree) in this group will be 20. This group will follow low calorie diet.. this diet will be applied for 12 weeks.. during this period the study, this group will receive free walking (30 min) with dog three timmes weekly.
224274200|NCT01811368|RADIATION|total nodal irradiation|Undergo TLI
224274201|NCT01811368|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
224274202|NCT01811368|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
224274203|NCT01811368|DRUG|cyclosporine|Given PO or IV
224274204|NCT01811368|DRUG|mycophenolate mofetil|Given PO or IV
224274205|NCT02964650|DEVICE|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
224274206|NCT05002881|OTHER|Moringa oleifera (E-HS-01)|One capsule to be taken stat
224274207|NCT05002881|OTHER|Placebo|One capsule to be taken stat
224274208|NCT00793234|DRUG|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
224274209|NCT00793234|DRUG|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
224274210|NCT03052855|OTHER|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
224274211|NCT01848717|DEVICE|MINTLIFT®|
224274212|NCT02951195|DRUG|VX-152|Tablet for oral administration.
224274213|NCT02951195|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
224274214|NCT02951195|DRUG|IVA|Tablet for oral administration.
224274215|NCT02951195|DRUG|Placebo|Placebo matched to VX-152.
224274216|NCT02951195|DRUG|Placebo|Placebo matched to VX-152/TEZ/IVA triple combination (TC).
224274217|NCT06260501|OTHER|super-wet technique|Liposuction with super-wet technique using wetting-solution containing 0.5 gr lidocaine and 0.5 mg epinephrine in each liter
223518186|NCT06311331|DEVICE|Total Talus Replacement (TTR)|The restor3d patient-specific TTR Implant and Instrumentation System is designed to replace a native talus bone that has been affected by a disease state or injury. The implant is an additively manufactured Cobalt Chromium alloy (ASTM F3213) construct produced by laser powder bed fusion. The data-driven design of the implant enables the patient to salvage their joint while maintaining ankle range of motion, reducing pain and improving physical function.
224274218|NCT00810706|DRUG|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
223518187|NCT06673641|DRUG|Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
223518188|NCT06673641|DRUG|CABTREO Topical Gel|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
223518189|NCT06673641|DRUG|Placebo Control|The study medication was applied once daily to cover the entire face after washing, avoiding the eyes, lips, angles of the nose, and mucous membranes for 84 consecutive days.
223518190|NCT04604093|DEVICE|SMBG Meter|Self Monitoring Blood Glucose Meter
223518191|NCT04604093|DEVICE|FreeStyle Libre 2 System|The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
223518192|NCT06673797|OTHER|Effects of Swiss Ball exercises|"Effects of Swiss ball exercises along with stretching as baseline treatment.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times.~2. Swiss ball exercises. a.Sitting on the Swiss ball with the trunk straight, arms by the sides, and eyes opened progressed towards eyes closed for 10 seconds, then rest. b.Sitting on the Swiss ball with trunk straight and arm by the sides. The therapist would assist the patient to engage the patient in shifting the body's weight to one side and the other side sideways as well as anterior and posterior and up and down alternatively. Start with 10 repetitions. c. Standing with gym ball in front. The therapist would stand behind the patient to provide support and ask the patient to lean forward on the gym ball with both hands via outstretched arms. Start with 10 repetitions d. One leg weight bearing on a gym ball with the therapist behind the patient, gripping the patient's pelvis to provide support. Start with 10 repetitions"
223518193|NCT06673797|OTHER|EFFECTS OF FRENKEL EXERCISES ON STATIC AND DYNAMIC BALANCE IN ATAXIC CHILDREN WITH CEREBRAL PALSY|"Frenkel Exercises along with stretching as baseline treatment. The second intervention group would participate in Frenkel Exercises along with stretching as baseline treatment. The exercises would be performed 3 times per week for four weeks.~1. Stretching of hamstrings, calf, and quads for 10 seconds hold 5 times. (11)~   a. Calf stretching. b. Hamstring stretches. c. Quads stretching~2. Frenkel\&#39;s lower limb exercises are the exercises listed below. The time of each session was set to be 10 minutes in the first week and then raised by 5 minutes every week. The patients were given 5 minutes to relax after 10 minutes of practice. (12)~   1. Supine lying~  2. While sitting~  3. Stride standing"
223518194|NCT06675981|OTHER|Real Acupuncture|Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
223518195|NCT06675981|OTHER|Non-acupuncture at real-acupoint|The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
223518196|NCT06675981|OTHER|Shallow acupuncture at real-acupoint|At the same acupoint in the acupuncture group, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
223518197|NCT06675981|OTHER|Shallow acupuncture at non-meridian and non-acupoint|At non-meridian and non-acupoint, the subcutaneous puncture is only 1-2 mm, no manipulation will be applied
223518198|NCT06535321|OTHER|vibration training|After modelling, when the vibration platform is closed, all participants of the control group completed the same action as vibration training.
223518199|NCT06535321|OTHER|vibration training|For the vibration group, vibration training was performed immediately after DOMS modelling.
223518200|NCT06535321|OTHER|Y-shaped kinesio taping|For the kinesio group, Y-shaped kinesio taping was performed 30 min before DOMS modelling.
223518201|NCT06535321|OTHER|Combined vibration training and Y-shaped kinesio taping|For the combined group, the vibration group and kinesio group interventions were performed simultaneously.
223518202|NCT00176254|RADIATION|Radiotherapy|80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy
223518203|NCT00176254|DRUG|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
223518204|NCT00176254|DRUG|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
223518205|NCT06678997|DEVICE|Zinc-L carnosine/Polaprezinc|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
223518206|NCT06678997|OTHER|Thickened formula|This will be a randomised, single blind, controlled, multicenter study, designed to evaluate efficacy and safety of Zinc-L carnosine/Polaprezinc in infants (1-12 months of age) with symptoms suggestive of GER. This study will include a 2-week screening period, and a 8-week treatment period. After the screeing phase, eligible patients will be randomly assigned to either Zinc-L carnosine/Polaprezinc (Hepilor Liquido, Azienda Farmaceutica Italiana, Italy) twice a day or thickened formula, in a 1:1 ratio, for 8 weeks. Study visits will be conducted every 4 weeks during the treatment period.
223518207|NCT06678503|OTHER|balance exercise|Balance exercises are physical activities designed to improve stability, coordination, and posture by challenging the body's ability to maintain an upright position. These exercises target the muscles and systems involved in balance, particularly the core, legs, and the sensory systems (like vision and proprioception).
224274219|NCT05838456|DEVICE|Viz.AI software|Viz.AI software performs artificial intelligence-based automated detection of large vessel occlusions and alerts the AIS care team.
224274220|NCT00423709|PROCEDURE|Allogeneic Blood Stem Cell Transplantation|
224274221|NCT00423709|DRUG|Fludarabine|
224274222|NCT00423709|DRUG|Melphalan|
224274223|NCT01559558|PROCEDURE|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
224274224|NCT04767958|DIAGNOSTIC_TEST|Spartan COVID-19 Platform|Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
224274225|NCT03558035|DRUG|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
224274226|NCT03558035|RADIATION|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
224274227|NCT02900053|DEVICE|tDCS|tDCS for transcranial Direct-Current Stimulation
224274228|NCT02900053|DEVICE|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
224274229|NCT03448276|OTHER|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
224274230|NCT03448276|OTHER|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
224274231|NCT02719704|BEHAVIORAL|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
223518208|NCT06678503|OTHER|Core stability exercises|"Core stability exercises are physical activities designed to improve the strength, endurance, and coordination of the muscles that support and stabilize the spine, pelvis, and torso. These exercises specifically target the muscles of the abdomen, lower back, hips, and pelvis, collectively referred to as the core. The goal is to enhance overall posture, prevent injury, and improve performance in daily activities or sports by increasing the body's ability to stabilize itself during movement."
223518209|NCT06618534|DRUG|Azithromycin|A standard dose of azithromycin (500 mg) will be delivered by oral route.
223893662|NCT06803095|BEHAVIORAL|diet restriction|the total participants with tinnitus (chronic subjective form) and obstructive sleep apnea (mild degree) in this group will be 20. This group will follow low calorie diet only .. this diet will be applied for 12 weeks..
224274232|NCT02719704|BEHAVIORAL|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
223893663|NCT06441422|OTHER|Blood flow restriction training|Participants randomized to blood flow restriction training will complete low load resistance training exercises while the limb is occluded at 80% arterial occlusion pressure.
224274233|NCT02128152|DEVICE|Ekso exoskeleton|
224274234|NCT03934827|DRUG|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
224274235|NCT03934827|DRUG|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
224274236|NCT05693831|OTHER|Cellworks Report|Survey physicians and molecular tumor board perspectives of the benefit of Cellworks Singula™ and Ventura™ reports in facilitating treatment decisions in pan-cancer patients.
224274237|NCT05719831|DRUG|vonoprazan fumarate + high dose amoxicillin（H-10d）|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
224274238|NCT05719831|DRUG|vonoprazan fumarate + low dose amoxicillin（L-10d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin1000mg/ time, 2 times/day, oral, for 10d
224274239|NCT05719831|DRUG|vonoprazan fumarate + amoxicillin（H-14d)|vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 14d
224274240|NCT06615804|BIOLOGICAL|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It's primarily used to treat depression, especially in patients who haven't responded well to traditional treatments like medications or psychotherapy. The most common target is the dorsolateral prefrontal cortex, a region often underactive in people with depression. The magnetic pulses stimulate or inhibit brain activity in the targeted area. This is believed to help reset or correct patterns of neural activity associated with depression and other psychiatric disorders. TMS represents an alternative for those struggling with depression, offering a non-invasive approach with relatively few side effects and significant potential benefits
224274241|NCT00217334|BEHAVIORAL|Volunteer-led pharmacy sessions with feedback to physicians|
224274242|NCT02001155|PROCEDURE|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
224274243|NCT04871009|BEHAVIORAL|Neurofeedback Intervention|"InteraXon, Inc. produces the MUSE 2 wearable neurofeedback device and mobile application (heretofore referred to as the MUSE app), respectively comprising the electroencephalogram (EEG) hardware and interactive software components that will be used in this intervention. The MUSE 2 is an adjustable headband that is placed across the forehead and over and behind the ears. It contains EEG sensors for active sites across the forehead and behind the ears, and an additional reference site behind the ear. These sensors use EEG technology to passively record children's brainwaves. During a session, caregivers will help children place the MUSE 2 on their heads and connect it to the app on their personal device. Children's brain activity is recorded by the MUSE 2 and is represented on the app through audio-based feedback that children will listen to with earbuds, and use their volition to influence in real time, with the goal of gaining increased control over their own brain activity."
224274244|NCT04871009|BEHAVIORAL|standard of care|trauma focused cognitive behavioral therapy or other behavioral therapy at the discretion of therapist
223518210|NCT06674876|BEHAVIORAL|Blog writing|Participants were asked to write 2blogs online for four weeks and attend a 4hours wellness workshop
223704070|NCT01001013|DRUG|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
223704071|NCT00489060|PROCEDURE|Cryoablation and External Beam Radiation|
223704072|NCT01868503|DRUG|lapatinib ditosylate|Given PO
223893664|NCT06441422|OTHER|No blood flow restriction training|Participants randomized to no blood flow restriction training will complete low load resistance without occlusion.
223518211|NCT06623266|PROCEDURE|Neck management|"In the experimental arm: the neck management is neck observation, simultaneous elective neck dissection is not performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions.~In the control arm: the neck management is elective neck dissection. Simultaneous elective neck dissection is performed during the surgical resection of primary lesion. The patients will be followed up every two months for at least two years, focusing on the lymph node metastasis and local recurrence. Ultrasonography, CT scan, and/or MRI will be used to detect lesions."
223518212|NCT06679660|OTHER|inferior alveolar nerve block with 4% articaine|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Inferior Alveolar Block anesthesia via the mandibular foramen.
223518213|NCT06679660|OTHER|Mental/Incisive Nerve Block (%4 Articaine)|A single ampoule of 4% articaine was administered to a cohort of patients presenting with irreversible pulpitis in the first or second mandibular premolars, designated for Mental or Incisive Nerve Block anesthesia via the mental foramen.
223518214|NCT06679452|OTHER|Emotion-Focused Therapy|This feasibility protocol is a two-arm, parallel, double-blinded, RCT aimed at informing a future trial assessing the effectiveness of EFT in resolving emotional injuries in older adults in the context of interpersonal offenses.
223518215|NCT07009756|DIETARY_SUPPLEMENT|Cricket Powder|"The intervention product is each serving of cricket powder, which contains 21.5 grams of house cricket (Acheta domesticus) powder blended with pumpkin powder, packed in a sachet. The powder is prepared under sterile conditions and heat-treated to ensure microbiological safety, in compliance with Thai public health regulations.~Each serving of cricket powder will be consumed together with 32 grams of instant pork-flavored congee, serving as the food base.~This intervention is distinguished by its use of whole cricket powder as a natural, food-based source of protein, chitin, and bioactive compounds, rather than isolated nutrients or supplements. Unlike many clinical studies that use encapsulated insect protein, purified chitin, or insect extracts, this study utilizes a whole-food approach, incorporating cricket powder into a culturally relevant format, congee, to reflect real-life dietary practices."
223518216|NCT07009756|OTHER|Placebo|32 grams of instant pork-flavored congee that does not contain cricket powder
223518217|NCT06691607|OTHER|Serum NGAL level|serum NGAL level
223518218|NCT06690021|DRUG|Dexmedetomidine|Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
223518219|NCT06691347|BEHAVIORAL|Eye movement desensitization and reprocessing|Psychotherapy with EMDR. A therapist guides the client in recalling distressing events while simultaneously following a stimulus, like a moving light or tapping. The idea is that this bilateral stimulation helps reduce the intensity of the traumatic memory, allowing clients to gain perspective and lessen emotional distress associated with it. The standard treatment protocol includes up to 24 weekly sessions.
223518220|NCT06691347|BEHAVIORAL|Cognitive therapy for PTSD|"Psychotherapy with CT-PTSD. A therapist works with the client to understand how they interpret their trauma and identify distorted thinking patterns that fuel their PTSD symptoms. Through guided discussions, written exercises, and sometimes re-living the trauma in a controlled way, clients learn to reshape these beliefs, gain a more balanced perspective, and reduce symptoms like hypervigilance, flashbacks, and avoidance behaviors. The standard treatment protocol includes up to 24 weekly sessions."
223518221|NCT00941421|DEVICE|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
223518222|NCT06694116|DIAGNOSTIC_TEST|sentinel lymph node biopsy using carbon dye|Sterile Charcoal carbon dye peritumoral injection will be performed around vulvar tumor and inguinofemoral lymph node dissection will be done 20 min later (unilateral or bilateral)
223518223|NCT06694909|DEVICE|tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
223518224|NCT06694909|DEVICE|sham tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
224083159|NCT00308763|DRUG|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
224083160|NCT00308763|DRUG|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
224274245|NCT05505760|BEHAVIORAL|Quality-Based Digital Messaging|"The impact of MomConnect's models will be evaluated using a randomized controlled trial (RCT). Randomization will be at the individual level, where an individual refers to the unique user, which is defined by the unique phone number used at the time of registration to MomConnect at health facilities. Randomizing control and treatment allocations ensures that the study groups will be comparable in terms of observable and unobservable characteristics in expectation. Therefore, statistical inference can shed light on the likelihood that any differences in outcome variables at the end of the intervention were caused by the intervention as compared to chance. We will also study the treatment effects on different outcomes between the different arms of the experiment - comparing outcomes across different treatment arms or outcomes in the control to outcomes in treatment arms will help us answer the aforementioned research questions."
223518225|NCT06694909|DEVICE|tDCS + PNS without action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
223518226|NCT06694909|DEVICE|sham tDCS + PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
223518227|NCT06694909|DEVICE|tDCS + sham PNS with action observation|tDCS: transcranial direct current stimulation; PNS: peripheral nerve stimulation
223518228|NCT06686823|BEHAVIORAL|Health Education Program|n informative leaflet will promote a healthy lifestyle with WHO guidelines to reduce cognitive decline, recommending a balanced diet, physical activity, social engagement, cognitive games, good sleep, stress management, hydration, and avoiding smoking and excessive alcohol.
223518229|NCT06686823|BEHAVIORAL|Cognitive Training Program|The cognitive training program (CT) on everyday cognition (EC) will be individualized, with each participant receiving a tailored dossier. The intervention includes four 1-month training periods (P1-P4), each featuring 20 activities, conducted at a rate of 5 activities per week over 4 months.
223518230|NCT06689709|OTHER|Serum Alkaline Phosphatase Levels|Venous blood was drawn from the patients
223518231|NCT06687486|BEHAVIORAL|relaxin|caregivers relaxing and care burden
223518232|NCT06687486|OTHER|kontrol|no intervention
223518233|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using flower configuration of the Farapulse catheter|catheter ablation
223518234|NCT06691074|PROCEDURE|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter|Catheter ablation of cavotricuspid isthmus using basket configuration of the Farapulse catheter
223704073|NCT01868503|RADIATION|radiation therapy|Undergo radiation therapy
223704074|NCT01868503|OTHER|laboratory biomarker analysis|Correlative studies
224274246|NCT00971919|OTHER|questionnaire administration|
224274247|NCT00971919|PROCEDURE|assessment of therapy complications|
224274248|NCT00971919|PROCEDURE|psychosocial assessment and care|
224274249|NCT00971919|PROCEDURE|quality-of-life assessment|
224274250|NCT06616090|BEHAVIORAL|Nurse Implemented Infant-Mother Attachment Security Program|The intervention will draw on video-feedback of mother-infant interactions during the well-child visit. Nurses will videotape the dyad during routine visit in the Family Health Center and show short clips to mothers during the session in order to provide mother positive feedback on their sensitive caregiving. Additionaly, intervention mothers will be exposed to the reminders (e.g., pictures, posters, short film screenings) reflecting maternal sensitivity and secure attachment in the waiting rooms of the intervention Family Health Centers.
224274251|NCT04684680|DIETARY_SUPPLEMENT|zamzam water|will receive the normal need of daily requirement of water (2.5 liter) in form of zamzam water till patients deliver or till term
223518235|NCT06689306|BEHAVIORAL|7E learning model|7E learning model7E learning cycle is a teaching model that encourages students to be active, to think about the findings they obtain, to interpret their findings according to their initial plans and to predict them in new situations. This model provides students with opportunities for discussion and interaction. The model is designed based on constructivist theory. The guiding concept of constructivism is that later learning is greatly influenced by previous knowledge; therefore, learning should be based on the interaction of old and new knowledge. 7E learning cycle model consists of seven steps: Reveal, Participate, Explore, Explain, Elaborate, Evaluate and Extend. According to past studies, 7E model is more effective in developing students than traditional learning models.
223518236|NCT06691152|BIOLOGICAL|CD19 Universal CAR-T cells|Three dose groups (1×10\^7/kg, 3×10\^7/kg, 6×10\^7/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
223518237|NCT06686719|OTHER|Post Facilitation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed to mid- range. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 30 % of the strength for 15 seconds by attempting to push the leg back toward the therapist and relax. The therapist then passively stretched the muscle until a mild stretch sensation was reported. The stretch was held for another 10 seconds. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
223518238|NCT06686719|OTHER|Post Isometric Relaxation|"For hamstring muscle, the patient positioned in supine with hip and knee flexed. For calf muscle, the patient positioned in supine with straight leg. Now therapist ask the subjects to isometrically contract the hamstring and calf using 25 % of the strength for 7-10 seconds by attempting to push the leg back toward the therapist and relax.After relaxation, the therapist further extends the knee for 3 to 5 seconds.. This sequence will repeat 5 times on each subject in the group.~Stretching of the hip flexors, adductors and plantar flexors. Functional training includes bridging, kneeling and sit to stand."
223518239|NCT06686719|OTHER|Myofascial Release|"MFR for Hamstring muscle will be given with patient in prone position with 120 second hold. For giving the MFR, the thumb of the therapist will be allowed to sink in to the central portion of the hamstring. It will held for 120 seconds to allow the tissue to soften and then myofascial structures will spread in a lateral direction until feeling of first fascial barrier. MFR will be performed for 15 mins.~Stretching of the hip adductors, hip flexors and plantar flexors. Functional training includes kneeling, bridging and sit to stand."
223518240|NCT06690645|OTHER|Exposure: psychological stress status|The assessment of depressive, anxiety or perceived Stress was conducted using PHQ-9, GAD-7 or PSS scale. Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 or a PSS score ≥ 20 were categorized as the stressed group.
223518241|NCT06687577|BEHAVIORAL|DBT-C|Tobacco cessation treatment adapted for high risk population.
223518242|NCT06687577|BEHAVIORAL|Treatment as usual|Standard behavioral tobacco cessation treatment.
223518243|NCT06633042|DRUG|Universal BCMA-CD19 CART|1.0-4.0×10\^6 CAR-T cells/kg
223518244|NCT03454347|DIETARY_SUPPLEMENT|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
223518245|NCT03454347|OTHER|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
223518246|NCT01260831|OTHER|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
223518247|NCT01260831|OTHER|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
223518248|NCT06694506|OTHER|Biological Sample|Clinical examination and blood test. The clinical examination and blood test are considered standard-of-care as they could be performed annually or bi-annually as part of an adult GHD follow-up. Subsequently, the data will be collected directly from the patient's chosen physician.
223518249|NCT06694818|BEHAVIORAL|trauma film paradigm|Use the trauma films as stressors to induce stress and evaluate how it affects sleep reactivity in healthy subjects with insomnia symptoms compared to healthy subjects without insomnia symptoms
223518250|NCT06689904|DEVICE|Nanodropper|One eye is randomly selected to be dilated with the nanodropper
223518251|NCT06689904|DEVICE|Standard eye drop bottle|eye is dilated with the standard eye drop bottle
223518252|NCT06687720|OTHER|MetBroma|Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day
223518253|NCT06695234|BEHAVIORAL|Meditation Awareness Training|A second-generation mindfulness-based intervention that reincorporates Buddhist wisdom concepts into mindfulness-based intervention.
223518254|NCT06690047|BIOLOGICAL|Ruconest|recombinant human C1-esterase inhibitor
223518255|NCT06627595|DRUG|Immunotherapy|Patients will be treated in accordance with the guidelines for melanoma treatment.
223518256|NCT06687005|PROCEDURE|non-surgical periodontal therapy|non-surgical periodontal therapy
223518257|NCT06695559|OTHER|Labrida Bioclean|Debridement on the active comparator group will be implemented on the implant surface with Labrida Bioclean (i.e. the chitosan brush).
223518258|NCT06695559|COMBINATION_PRODUCT|Labrida Bioclean and tetracycline slurry|On the experimental group debridement of the implant surface will be carried out with Labrida Bioclean and thereafter irrigation of the periimplant sulcus with tetracycline slurry will take place.
223518259|NCT06695468|DRUG|Levobupivacaine|40-ml mixture of 20 ml of 0.5% levobupivacaine diluted with 20 ml of 0.9% N.S. (20 ml to be injected on each side
223518260|NCT06695468|DRUG|Levobupivacaine + Dexmedetomidine|60 ml mixture of 1.5 mic/kg dexmedetomidine added to 30 ml of 0.5% levobupivacaine diluted with 30 ml of 0.9% N.S. (30 ml to be administered on each side, divided into 15 ml for the upper segment and 15 ml for the lower segment).
223518261|NCT06694064|PROCEDURE|Pulpotomy|Pulpotomy will be done for mta group
223518262|NCT06694064|PROCEDURE|extraction for histologic examination|after pulp therapy the teeth exrtracted for histologic examination
223518263|NCT06691711|BEHAVIORAL|ASPIRE support package|The ASPIRE support package has a modular structure with core modules that all participating families are encouraged to complete initially, followed by optional modules which the family is supported to select from according to their strengths and needs. Core modules provide psychoeducation for the caregiver and optional modules contain information on the selected positive psychology topic together with instructions for suggested activities to be completed by the caregiver with their child to implement evidence-based positive psychology strategies. All resources can be accessed both electronically via an online portal or via the printed resource pack. Each caregiver is supported through the programme by a trained practitioner who offers regular support sessions (up to 8 in total) to provide information, advice and encouragement. Support sessions can take place face-to-face, by video call or over the phone according to participant preference.
223518264|NCT05004987|DRUG|Escitalopram Oxalate|The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.
223518265|NCT05004987|DRUG|Placebo|Daily dose of placebo will mimic that of ESC.
223518266|NCT06686069|DIETARY_SUPPLEMENT|bioarginina zero|treatment
223518267|NCT06686069|DIETARY_SUPPLEMENT|Placebo|absence of treatment
223518268|NCT01851226|PROCEDURE|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
223518269|NCT02841631|GENETIC|HPV status and typing of tissue|HPV status and typing of tissue
223518270|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
223518271|NCT00280488|BEHAVIORAL|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
223518272|NCT00280488|BEHAVIORAL|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
223518273|NCT02736812|BIOLOGICAL|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of FLYP"
223518274|NCT02736812|BIOLOGICAL|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~* Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~* Usual pre-hospital care according to recommendations in best practices~* Administration of Normale Saline Solution"
223518275|NCT01718106|DEVICE|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
223518276|NCT05561985|DRUG|Itacitinib|
223518277|NCT06055569|OTHER|Rehabilitation protocol: AOT+NMES|Action observation and neuromuscular electrical stimulation followed by motor execution
223518278|NCT06055569|OTHER|Rehabilitation protocol: Action Observation Therapy (AOT)|Action observation followed by motor execution
223518279|NCT06055569|OTHER|Observation of motor-neutral stimuli (MNO)|Motor-neutral observation followed by motor execution
223518280|NCT02168699|OTHER|Ultrasound examination of the axilla|
223518281|NCT06402487|DIETARY_SUPPLEMENT|Propionic acid 1000 mg capsule|Patients will be assigned to propionic acid or placebo as add on MS treatment.
223518282|NCT06402487|DIETARY_SUPPLEMENT|Placebo|Patients will be assigned to propionic acid or placebo as add on MS treatment.
223518283|NCT03461120|DRUG|Experimental continuous peripheral nerve blocks|Bupivacaine 0.3% \[or ropivacaine 0.5%\] infusions for 7 days via femoral and sciatic perineural catheters
223518284|NCT03461120|DRUG|Control continuous peripheral nerve blocks|Bupivacaine 0.1% \[or ropivacaine 0.2%\] infusions for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
223518285|NCT01639690|GENETIC|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
223518286|NCT05715320|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
223518287|NCT05584137|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
223518288|NCT05584137|DRUG|HLX10|Humanized Anti-Programmed Death-1 Monoclonal Antibody
223518289|NCT04208256|DIETARY_SUPPLEMENT|Energy Stimulus|Energy stimulus (energy surplus v. energy neutral) will be randomly assigned at the first brain imaging visit. At the second brain imaging visit, the participant will receive the alternate stimulus from what they received at the first brain imaging visit.
223518290|NCT06062472|DIETARY_SUPPLEMENT|Probiotics|Lactobacillus paracasei PS23 will be used in this study
223518291|NCT06062472|DIETARY_SUPPLEMENT|heat-treated of Lactobacillus paracasei HT-PS23|heat-treated probiotic capsule contain 10 billion of Lactobacillus paracasei, 2 caps daily use
223518292|NCT06062472|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose, 2 caps daily use
223518293|NCT01251965|DRUG|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
223704075|NCT01457222|BEHAVIORAL|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
223704076|NCT01457222|BEHAVIORAL|Music relaxation|Music relaxation 10 minutes daily
223704077|NCT05515471|DRUG|SHR8058 eye drops|SHR8058 eye drops
223518294|NCT00945542|OTHER|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
223518295|NCT00945542|OTHER|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR\>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
223518296|NCT06099366|DRUG|induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate|vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
223518297|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
223518298|NCT06099366|DRUG|Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
223518299|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
223518300|NCT06099366|DRUG|Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
223518301|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 Dexamethasone 10mg/m2 Intrathecal Methotrexate
223518302|NCT06099366|DRUG|Delayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 L-asparaginase 6,000IU/m2 Doxorubicin 25mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 100mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
223518303|NCT06099366|DRUG|Maintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate|Vincristine 1.5mg/m2 Mercaptopurine 50mg/m2 Methotrexate 20mg/m2 Dexamethasone 6mg/m2 Intrathecal Methotrexate
223518304|NCT03191734|DEVICE|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
223518305|NCT06439784|OTHER|whole body SPECT/CT|Patient will unergo a whole body SPECT/CT in treatment position
224274252|NCT04684680|DIETARY_SUPPLEMENT|tap water|will receive the normal need of daily requirement of water (2.5 liter) in form of tap water
224274253|NCT01333202|OTHER|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
224274254|NCT03405857|OTHER|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
224274255|NCT05230602|DIETARY_SUPPLEMENT|opuntia (tzabar fruit)|consuming of the tzabar fruit twice a day
224274256|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
224274257|NCT02246764|DRUG|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
224274258|NCT02246764|DRUG|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
224274259|NCT02246764|OTHER|Placebo|1 drop QD, AM, OU
224274260|NCT06204016|DRUG|Estradiol Valerate|To elevate estradiol levels each woman will receive 12mg on two consecutive days (total 24mg) of estradiol valerate (Progynova21©)
223518306|NCT04802590|DRUG|Ibrutinib 560 mg|560mg/d continuously from C1D2 to end C24
223518307|NCT04802590|DRUG|Venetoclax 10 MG Oral Tablet [Venclexta]|20mg/d from C2D1 to C2D7
223518308|NCT04802590|DRUG|Venetoclax 50 MG Oral Tablet [Venclexta]|50mg/d from C2D8 to C2D14
223518309|NCT04802590|DRUG|Venetoclax 100 MG Oral Tablet [Venclexta]|100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
223704078|NCT05515471|DRUG|saline eye drops.|saline eye drops.
224274261|NCT06204016|DRUG|Placebo|Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
224274262|NCT05477849|DRUG|Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection|"1. Dose level 1~2. Dose level 2~3. Dose level 3~4. Dose level 4~5. Dose level 5"
224274263|NCT04658238|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
224274264|NCT04658238|OTHER|Ocular immune system|Functional characterization of the tear fluid proteome, histology of conjunctival tissue and molecular assays
224274265|NCT05809466|OTHER|Vegan diet|A self-composed 12 week fully plant-based diet
224274266|NCT05809466|OTHER|Resistance exercise|Biweekly resistance exercise for 12 weeks
224274267|NCT05809466|OTHER|Omnivorous diet|Habitual diet containing both animal- and plant-based food products
224274268|NCT06838026|OTHER|External Intercostal Nerve Block|External ICNB: A mixture of analgesics will be given through a needle inserted in the intercostal space from outside the chest wall.
224274269|NCT06838026|OTHER|Internal Intercostal Nerve Block|Internal ICNB: A mixture of analgesics will be given through a needle inserted in the intercostal space inside the chest wall under direct thoracoscopic vision.
223893665|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
224274270|NCT06838026|OTHER|Intercostal Catheter|Intercostal Catheter: it will be put 1-2 intercostal spaces above the VATS incision, and the participant will receive the 15 cc of the previously mentioned mixture every 8 hours for two to three days.
223518310|NCT02375711|BIOLOGICAL|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
223518311|NCT03261375|DEVICE|Renal Artery Radiofrequency Ablation System (Generator and Catheter )|A renal denervation system with a mesh 6-electrode radiofrequency ablation catheter and multi-channel radiofrequency generator
223518312|NCT03261375|DRUG|Antihypertensive Agents|Calcium channel blocker, Diuretic
223518313|NCT03261375|DEVICE|Sham Procedure|Catheterization without renal denervation
223518314|NCT05867888|OTHER|conventional therapy|conventional therapy ( instructions, ice application, deep tissue massage, stretching exercises, joint mobilization and isometric exercises )
223518315|NCT05867888|OTHER|shock wave therapy|Acoustic waves (shock waves) that can carry energy and can propagate through tissues promote healing effects.
223518316|NCT05867888|OTHER|low level laser therapy|The application of light to a biologic system to promote tissue regeneration, reduce inflammation and relieve pain.
223518317|NCT06057025|BIOLOGICAL|"Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition"|"Single intramuscular injection of Sputnik Lite vaccine for the prevention of COVID-19 with altered antigenic composition."
223518318|NCT00216385|DRUG|Gatifloxacin combined regimen|
223518319|NCT05603780|BEHAVIORAL|exploratory protocol|physiological and cognitive evaluations
223518320|NCT04616196|DRUG|NKTR-255|NKTR-255 IV every 21 days
223518321|NCT04616196|DRUG|Cetuximab|Cetuximab will be given at specified doses on specified days
223518322|NCT00467493|DRUG|Anastrozole|
223518323|NCT06062355|DRUG|HRS-9815 injection|HRS-9815 injection
223518324|NCT05463419|BIOLOGICAL|PIKA COVID-19 vaccine|"SARS-CoV-2 spike subunit protein (Also called Recombinant SARS-CoV-2 S-trimer protein), PIKA adjuvant."
223518325|NCT05463419|BIOLOGICAL|Inactivated Covid-19 vaccine|Inactivated SARS-CoV-2 virus
223518326|NCT06365502|DEVICE|Drug-coated balloon|Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed.
223518327|NCT06365502|DRUG|Guideline-directed medical treatment|All individuals will receive guideline-directed medical treatment.
223518328|NCT03428347|BIOLOGICAL|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
223518329|NCT03457662|COMBINATION_PRODUCT|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
223518330|NCT03457662|COMBINATION_PRODUCT|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
223518331|NCT05401409|DIETARY_SUPPLEMENT|Beetroot juice|70mls beetroot juice (400mg nitrate) given daily for 4 weeks
223518332|NCT05401409|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
223518333|NCT02371889|DRUG|Topiramate|Max therapeutic dose of 200mg/day
223518334|NCT02371889|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
223518335|NCT02371889|DRUG|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
223518336|NCT02741050|BEHAVIORAL|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
223704079|NCT03286738|DRUG|FOLFIRI, target agent|"* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
223704080|NCT00810914|DRUG|bupivicaine epidural|bupivicaine continuous epidural infusion
223704081|NCT00810914|DRUG|bupivicaine epidural infusion patient epidural|bupivicaine
223893666|NCT06470139|DRUG|Ropivacaine 0.2% Injectable Solution + 4mg Dexamethasone|20ml 0.2% Ropivacaine + 4mg Dexamethasone
223893667|NCT05926934|DEVICE|Experimental: Single strand β-Ti fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
224274271|NCT06176612|PROCEDURE|total hip arthroplasty|Patients with Crowe type 3 or Crowe type 4 hip dysplasia who underwent hip replacement
224274272|NCT05223725|BIOLOGICAL|AdKCNH2-G628S|adenovirus containing the transgene KCNH2-G628S
223518337|NCT02741050|BEHAVIORAL|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
223518338|NCT00571714|DRUG|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
223518339|NCT00571714|DRUG|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
223518340|NCT06380907|DRUG|ZL-1102 1% w/w gel BID for 16 weeks|"ZL-1102~1% w/w gel BID for 16 weeks"
223518341|NCT06380907|DRUG|ZL-1102 3% w/w gel BID for 16 weeks|ZL-1102 3% w/w gel BID for 16 weeks
223518342|NCT06380907|DRUG|ZL-1102 3% w/w gel QD for 16 weeks|ZL-1102 3% w/w gel QD for 16 weeks
223518343|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel BID for 16 weeks|Vehicle 0% w/w gel BID for 16 weeks
223518344|NCT06380907|DRUG|Placebo ZL-1102 0% w/w gel QD for 16 weeks|Vehicle 0% w/w gel QD for 16 weeks
223518345|NCT06630689|OTHER|Dry Full Body Massage|Applying massage after phototherapy
223518346|NCT06630689|OTHER|Oil Full Body Massage|Oil Full Body Massage
223518347|NCT05976633|OTHER|Whole white rice (control)|One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
223518348|NCT05976633|OTHER|Whole brown rice|One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
223518349|NCT05976633|OTHER|Whole wild rice|One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
223518350|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Stovetop|One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
223518351|NCT05976633|OTHER|15% Wild rice and 85% Brown rice blend - Microwaved|One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
224274273|NCT06850103|RADIATION|short-course radiotherapy|Neoadjuvant short-course radiotherapy (SCRT) will be administered at a total dose of 25 Gy, delivered in 5 fractions of 5 Gy each.
224274274|NCT06850103|DRUG|CAPEOX/XELOX|Capecitabine: 1000 mg/m² BID, D1-14, Q3W × 4 cycles Oxaliplatin: 130 mg/m² IV, D1, Q3W × 4 cycles
224274275|NCT06850103|DRUG|Serplulimab|Serplulimab: 300 mg IV, D1, Q3W × 4 cycles
223518352|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection
223518353|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
223518354|NCT04904549|BIOLOGICAL|Placebo|Pharmaceutical form: liquid. Route of administration: intramuscular administration.
223518355|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
223518356|NCT04904549|BIOLOGICAL|SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination|Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
223518357|NCT05359718|OTHER|Questionnaire|Questionnaire
223518358|NCT06284278|OTHER|Diaphragmatic breathing retraining|8 weeks diaphragmatic breathing training
223518359|NCT06284278|OTHER|Pelvic stabilization exercise|8 weeks pelvic stabilization exercise training
223518360|NCT06284278|OTHER|pelvic anatomy education|pelvic anatomy education
223518361|NCT05822817|DRUG|sevoflurane|Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
223518362|NCT05822817|DRUG|propofol|Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
223518363|NCT00614341|DEVICE|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
223518364|NCT05363930|DEVICE|Novel motorized spiral enteroscopy|Novel motorized spiral enteroscopy (Olympus Medical Systems Corporation, Tokyo, Japan) procedures would be performed under general anaesthesia with nasotracheal intubation under fluoroscopic guidance. Four litres of PEG was given to all patients with at least 8 hours of fasting prior to NMSE. Initially antegrade enteroscopy would be performed failing which retrograde enteroscopy would be done to reach the lesion. If the desired lesion is not reached via antegrade/retrograde route, hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anesthesia using the same overtube. The time of procedure will be calculated from insertion of NMSE to its withdrawal. The depth of insertion would be measured by sequential withdrawal technique.
223704082|NCT00810914|DRUG|bupivicaine|patient controlled anesthesia only
223704083|NCT00547573|DRUG|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
223704084|NCT00547573|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
223704085|NCT00547573|DRUG|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
223704086|NCT01890941|DRUG|KCT-0809 ophthalmic solution|
223704087|NCT01890941|DRUG|Placebo|
223518365|NCT05363930|DEVICE|Single balloon enteroscopy|Single balloon enteroscopy will be performed with single balloon video-enteroscope (Olympus Medical Systems, Tokyo, Japan) under monitored anaesthesia (deep sedation with propofol). Initially antegrade/retrograde enteroscopy would be performed based on pre-procedure localization failing which enteroscopy would be done from opposite route to reach the lesion. Hemoclips would be applied or tattooing would be done followed by enteroscopy from opposite direction on the same day under the same anaesthesia using the same overtube. Duration of procedure would be calculated from the time of introduction of the enteroscope to time of removal. The depth of insertion would be measured using the push and pull technique.
224274276|NCT06850103|PROCEDURE|surgery|Primary tumor: Total Mesorectal Excision (TME) Metastatic lesions: Local therapeutic intervention
224274277|NCT06247241|DRUG|VMB-100|VMB-100 is administered as intrasphincteric injection in the urethra sphincter
224274278|NCT04937543|DRUG|inhaled beclametasone|Adding belcamethasone to standard of care for Covid 19 positive patients
224274279|NCT04937543|DRUG|Inahaled beclomethasone / formoterol / glycopyrronium|Adding belcametasone/ formoterol / glycopyrronium to standard of care for Covid 19 positive patients
224274280|NCT05753007|DRUG|Cannabidiol (CBD)|Custom-formulated full-spectrum solution high in cannabidiol
224274281|NCT05753007|DRUG|Placebo|Placebo solution
224274282|NCT03945695|PROCEDURE|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"1. Appropriate anesthesia and antiseptic preparation of the surgical field~2. Prophylactic paracentesis of the anterior chamber~3. One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~4. Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
224274283|NCT05851898|DRUG|Duloxetine 30 mg|Duloxetine 30mg daily prescribed at discharge
224274284|NCT01491464|DEVICE|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
224274285|NCT01491464|DEVICE|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
224274286|NCT05714787|OTHER|Chest CT Scan examination|Double examination of chest CT scan on sagittal section after multiplanar reconstruction
224274287|NCT05884957|DIAGNOSTIC_TEST|Nitric oxide synthase gene|Biochemical assessment of serum nitric oxide level pre and post 5 mg tadalafil therapy in diabetic patients with erectile dysfunction and in normal healthy controls.
224274288|NCT01707316|DRUG|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
224274289|NCT01707316|DRUG|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
224274290|NCT01707316|OTHER|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
224274291|NCT01767753|DEVICE|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
223518366|NCT06548672|DRUG|BC3195|BC3195 is a novel antibody drug conjugate (ADC) targeting CDH3 (calcium-dependent adhesion 3). The payload, monomethyl auristatin E (MMAE), is a microtubule disrupting agent covalently attached to the antibody via a cleavable dipeptide linker Val-Cit (vc).
223518367|NCT02579759|DRUG|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
223518368|NCT02579759|DRUG|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
223518369|NCT02579759|DRUG|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
224274292|NCT01021657|PROCEDURE|trabeculectomies, non penetrating deep sclerectomies|
224274293|NCT00397696|DRUG|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of \[123I\] 5-IA followed by SPECT imaging as described below. A second \[123I\] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial \[123I\] 5IA imaging session.
224274294|NCT04875585|DRUG|neoadjuvant therapy with Pembrolizumab/Lenvatinib|Neoadjuvant therapy for 6 weeks
224274295|NCT04875585|PROCEDURE|Surgery|surgical resection of primary tumor and lymph-node-dissection.
224274296|NCT04875585|DRUG|Adjuvant Treatment Phase|Adjuvant treatment with 15 cycles of Pembrolizumab
224274297|NCT00555893|DRUG|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight \<=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
224274298|NCT00555893|DRUG|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: \<=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
223704088|NCT01228643|BIOLOGICAL|Pancreatic enzimes|\- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
224274299|NCT02015351|DRUG|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
224274300|NCT03914898|OTHER|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
224274301|NCT00326326|DRUG|CP-778,875|
224274302|NCT06399445|PROCEDURE|conventional cold tonsillectomy and curettage adenoidectomy|After entering the operating room, the children will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths, then we will set 4 % concentration of Sevoflurane. After loss of consciousness, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, Fentanyl 1 mcg/kg iv. and Propofol 2 mg/kg. During stage III of anesthetic depth, we will perform orotracheal intubation.
224274303|NCT06399445|DRUG|Rocuronium Bromide|After entering the operating room, chlidren will be monitored (electrodes for ECG, blood pressure cuff and pulse oximeter). We will use gas mixture of O2/N20 50/50% and concentration of Sevoflurane set between 5% and 6 % with a dose of 6 L/min (1.0 -1.3 MAC) for 10 breaths. After loss of consciousness, we will turn off Sevoflurane, intravenous line 22 G will be obtained and 0.9 % saline infuse with a dose of 4 ml/kg/hr, 1 mcg/kg Fentanyl, 2.5 mg/kg Propofol and 0.6 mg/kg Rocuronium bromide (esmeron). After 2 min, orotracheal intubation will be performed.
224274304|NCT00260026|DRUG|Docetaxel|
224274305|NCT00260026|DRUG|Jin Fu Kang|
224274306|NCT02336906|DRUG|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
224274307|NCT02336906|BEHAVIORAL|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
224274308|NCT02336906|BEHAVIORAL|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
224274309|NCT02563249|OTHER|Parabolic flight|
224274310|NCT02563249|OTHER|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
224274311|NCT02881359|DEVICE|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
224274312|NCT01003951|PROCEDURE|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
224274313|NCT01092169|OTHER|No intervention|
224274314|NCT02179151|DRUG|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
224274315|NCT02179151|DRUG|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
224274316|NCT04880954|PROCEDURE|Soft Tissue Mobilization|Soft Tissue Mobilization will be provided to participants by Licensed Chiropractor focusing on structures of the lower and upper leg. This will be provided for 20 minutes, once per week for 12 weeks.
224274317|NCT04880954|OTHER|Rehabilitation|Participants will engage in 20 minutes of prescribed at-home exercise 5 times per week, for 12 weeks.
224274318|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care)|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days.
224274319|NCT05006560|OTHER|Pulmonary Rehabilitation (usual care) + familiarization with components of the aftercare program|Participants receive the standard inpatient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention implemented by an interdisciplinary rehabilitation team. PR is based on a patient assessment followed by a combination of patient-tailored therapies. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current guidelines; physical training (endurance training, strength training, whole body vibration muscle training); structured education; respiratory physiotherapy. PR lasts on average 25 days. Additionally, participants use several functions of the aftercare program's mobile application. This includes using the application during endurance and strength training (as part of usual care) and using a consumer activity monitor to count daily steps.
223704089|NCT01228643|DEVICE|Creon ®|\- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
223704090|NCT02836392|BEHAVIORAL|Questionnaire|
224274320|NCT05006560|OTHER|After care: Exercise and physical activity promotion|"Participants will agree with their therapist on an exercise plan (endurance and resistance training) that are made available for participants through the study's mobile app. Frequency and duration of endurance and strength training are prescribed in accordance with exercise guidelines for persons with COPD. However, they can be adjusted according to participants needs.~Next to the exercise, participants receive physical activity counseling. This consists of phone or video calls with a therapist, group video calls with a therapist, a complementary e-learning course as well as complementary functions of the study's mobile app."
224274321|NCT05647291|DEVICE|extracorporeal Shock wave therapy|Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week, for two weeks, adding up to a total of 4 sessions.
224274322|NCT05647291|DRUG|Corticosteroid injection|40mg/1ml methylprednisolone, two sessions once a week
224274323|NCT05647291|DEVICE|Kinesiotaping|The first strip was adhered along the plantar fascia from the calcaneus to the toes using maximum stretch. The other four strips of tape were attached medially and laterally to support the medial longitudinal arch with a 45° inclination. While maximum stretching was applied to the middle 1/3 of all bands, no stretching was applied to the ends. Once a week, three times
224274324|NCT01671592|BIOLOGICAL|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
224274325|NCT02754492|DEVICE|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
224274326|NCT01956565|OTHER|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
224274327|NCT05363241|PROCEDURE|Cooled radiofrequency in classical targets (CRF-CT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
224274328|NCT05363241|PROCEDURE|Cooled radiofrequency in revised targets (CRF-RT)|Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
224274329|NCT04423003|PROCEDURE|Endoscopic intervention|All endoscopic interventions in COVID-19 positive tested patients were included
223518370|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
223518371|NCT02735642|BEHAVIORAL|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
224274330|NCT05701124|DRUG|Ranibizumab (0.25 mg/0.025 mL)|Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
224274331|NCT01702415|DRUG|Zoledronic acid|Single dose, intravenous solution 5mg
224274332|NCT01702415|DRUG|Placebo|
224274333|NCT01408888|BIOLOGICAL|LY2189265|Administered subcutaneously
224274334|NCT01408888|DRUG|Sitagliptin|Administered orally
224274335|NCT06249893|OTHER|Point-of-care vascular ultrasound|Point-of-care ultrasound will be used to image the femoral vessels and to perform a pulsed-wave doppler measurement of blood flow during chest compressions and during pauses for rhythm and manual pulse checks.
224274336|NCT01990807|DRUG|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
224274337|NCT04425577|DIAGNOSTIC_TEST|Transabdominal Ultrasound|Transabdominal Ultrasound
224274338|NCT03700398|DEVICE|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
223518372|NCT02735642|BEHAVIORAL|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
224274339|NCT03700398|DEVICE|first WLI|the routine in the clinical practice
224274340|NCT03166904|DRUG|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
224274341|NCT06070545|OTHER|Modified Supine Position|Among the patients in the control group, for whom consent was obtained, the standard clinical procedure including supine after percutaneous coronary intervention (0 degrees flat on the back) will be provided, and for the patients in the experimental group, care including the modified supine position will be provided. The modified supine position is a position in which patients lie on their back with the head of the bed elevated at a 20-degree angle, with a pillow between the soles of their feet and the end of the bed. Both study groups will be required to lie supine in bed for 6 hours and stay in bed for 12 hours before ambulation is allowed in order not to increase the risk of local bleeding, as required by the clinical procedure.
224274342|NCT03209167|BEHAVIORAL|Questionnaire|Two study-specific questionnaires
224274343|NCT00264381|DRUG|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
223518373|NCT02735642|BEHAVIORAL|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
223518374|NCT02735642|BEHAVIORAL|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
223518375|NCT02735642|OTHER|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
223518376|NCT02410200|DRUG|dimethyl fumarate|
223518377|NCT03517800|OTHER|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
223518378|NCT06548516|PROCEDURE|Control group (conventional scalpel surgery)|The patients in the control group will undergo frenectomy using conventional scalpel surgery.
223518379|NCT06548516|PROCEDURE|Diode laser group|The patients in the laser group will undergo frenectomy using a diode laser.
223518380|NCT04804436|GENETIC|Genetic analysis|he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
223518381|NCT04850963|DEVICE|Transcranial direct current stimulation (Anodal tDCS) + dual-task training|"anodal tDCS 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
223518382|NCT04850963|DEVICE|Transcranial direct current stimulation (tDCS dualsite) + dual-task traning|"tDCS dualsite 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
223518383|NCT04850963|DEVICE|Transcranial direct current stimulation sham + dual-task training|"tDCS sham 837 / 5.000 Resultados de tradução Simultaneously with the tDCS sessions, participants will be submitted to a physical therapy protocol based on motor and cognitive dual-task training, which will include: (1) walking repeating phrases spoken by the researcher; (2) walking counting numbers in ascending order; (3) walk while counting the numbers in descending order; (4) walking during the execution of a string of words; (5) Walking while listening to a list of fruits and saying YES when hearing the word strawberry and (6) walking reciting a phrase backwards. Each task will have a duration of 3 minutes, followed by a rest period of 30s.~The tasks will be performed performing forward, side and back march. Subjects will be instructed to focus on both tasks. The training will have a total duration of 20 minutes in each session."
223518384|NCT00461890|DRUG|Injectable Naltrexone|
223518385|NCT04279769|DRUG|CB-280|CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
224274344|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)|Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
223518386|NCT04279769|DRUG|Placebos|Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
223518387|NCT02510742|DEVICE|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
223518388|NCT02510742|DEVICE|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
223518389|NCT04722809|DRUG|Botulinum toxin injection|Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
223518390|NCT04722809|OTHER|QOL-Brux|Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
223518391|NCT04722809|OTHER|Muscular strength of the jaw|"Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection."
223518392|NCT04722809|OTHER|Intensity and frequency of episodes of nocturnal bruxism|Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
223518393|NCT04722809|OTHER|visual analogue pain scale|Evaluation of jaw pain. At inclusion and 3 months post-injection
223518394|NCT04722809|OTHER|Endobuccal and linea alba photographs|"anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion"
223518395|NCT06571604|DIAGNOSTIC_TEST|Dislocation|One episode of total hip dislocation diagnozied on Xray within 2 years of surgery
223518396|NCT06571604|DIAGNOSTIC_TEST|No dislocation|No experience of dislocation within two years post-surgery
223518397|NCT06570226|DIETARY_SUPPLEMENT|hibiscus tea|Some cell and animal experiments have pointed out that drinking tea may be related to hypotension, body composition and vision problems, and there are more and more related advertisements, especially for hibiscus tea, which is rich in anthocyanins.
223518398|NCT00526851|OTHER|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
223518399|NCT05490056|OTHER|no intervention|the study will not apply on intervention
223518400|NCT05305573|BIOLOGICAL|COVID-19 Vaccine HIPRA 40 ug/dose|Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)
224274345|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)|Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.
224274346|NCT00695110|DRUG|Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)|Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.
224274347|NCT00695110|DRUG|Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)|Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
224274348|NCT04395196|DIETARY_SUPPLEMENT|Choline bitartrate|Provided in beverage form
224274349|NCT04395196|DIETARY_SUPPLEMENT|Placebo|Provided in beverage form
224274350|NCT05746819|OTHER|Aggressive antipyretics therapy of fever vs usual care in the Malaria RCT study|After clinical trial of the Malaria RCT study, this study will compare children allocated to aggressive antipyretic therapy vs. usual care on the prevalence of structural brain abnormalities after recovery from CNS malaria.
224274351|NCT02672540|DRUG|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
223518401|NCT05305573|BIOLOGICAL|Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection|Subjects will receive one injection of Comirnaty Vaccine
223518402|NCT04245605|PROCEDURE|Coronary angiography|Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
223518403|NCT06029166|DEVICE|Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)|Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
224274352|NCT02672540|DRUG|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
224274353|NCT02866240|DEVICE|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
224274354|NCT04746079|BEHAVIORAL|Positive Imagery Therapy|Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
224274355|NCT00217724|DIETARY_SUPPLEMENT|glutamine|Given orally
224274356|NCT00217724|OTHER|placebo|Given orally
224274357|NCT05081336|DRUG|Statin|Statin +/- ezetimib +/- Alirocumab
224274358|NCT04438850|DRUG|Ivermectin|Patients will be administered a single oral daily dose of approximately 600 μg/Kg (486-679 μg/Kg as rounded to a whole number of tablets), or 1200 μg/Kg (1098-1286 μg/Kg).
224274359|NCT04438850|OTHER|Placebo|Patients should take placebo orally on an empty stomach with water
223518404|NCT03895476|DIAGNOSTIC_TEST|palatal wound will be cover with collagen and sutures|after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
223893668|NCT05926934|DEVICE|Experimental: SS fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
223893669|NCT05926934|DEVICE|Experimental: Twisted fixed retainer|All 90 patients between 13-30 y.o. treated with fixed orthodontic appliances (Roth 0.018'' slot at their final finishing stage) on at least between their lower first premolars and with no lower anterior teeth crowding (total irregularity index score = 0) and no need of removable retention appliances on their lower teeth, were randomly assigned to one of the three experimental groups.
223893670|NCT04499053|DRUG|Durvalumab|durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)
223893671|NCT04499053|DRUG|Tremelimumab|tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
223893672|NCT03618199|DEVICE|Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing|"Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testing stimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified."
223893673|NCT06105060|DRUG|Rosuvastatin 20mg|to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
223893674|NCT05465616|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
223893675|NCT06408597|PROCEDURE|Nitroglycerin Infusion|"Nitroglycerin prepared using a vial (50 mg nitroglycerin) transferred into a 500 ml glass bottle of sodium chloride injection (0.9%), this yields a concentration of 100 mcg/ml.~Patients in the nitroglycerin group will receive nitroglycerin infusion at a rate of 0.25 mic/kg/min all through the surgery, to be discontinued in the PACU."
223893676|NCT06408597|PROCEDURE|Mannitol Infusion|"Mannitol will be prepared through diluting 100 ml of the 20% solution with 180 ml of sodium chloride injection (0.9%).~Patients in the mannitol group will receive an infusion bolus of mannitol 20% 0.5gm/kg added to the standard fluid chart via centeral line.~Mannitol intake will be started directly after induction of anaesthesia and before intra-peritoneal gas insufflation, as an infusion over 15 minutes."
223893677|NCT06408597|PROCEDURE|Fluid Regimen|"Patients will take the standard fluid chart, as the patient will receive the estimated maintenance \& deficit requirements according to 4/2/1 rule.~In case of hypotension, (defined as 20% decrease from the baseline), administration of a fluid bolus of 200 ml ringer will be done.~Blood loss more than 10% of estimated blood volume will initiate blood transfusion using 1:1 ratio. Additional fluids may be administered postoperatively according to the patient's volume status."
223893678|NCT06570447|DRUG|Glofitamab|For Glofitamab Injection solution, after Obinutuzumab pretreatment on Day 1 of Cycle 1, patients followed a step-dose escalation regimen.
223893679|NCT06570447|DRUG|Chidamide|Chidamide: 30 mg/d orally twice a week for 21 days as a treatment cycle.
224274360|NCT06183450|DIAGNOSTIC_TEST|auditory level|"* Evaluation of auditory thresholds through audiometric tests.~* Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix).~* Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality."
224274361|NCT06183450|DIAGNOSTIC_TEST|cognitive level|"* Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test.~* Evaluation of inhibition capacities using the Stroop Test.~* Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test."
224274362|NCT06183450|DIAGNOSTIC_TEST|quality of life level|\- Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.
224274363|NCT04862962|DRUG|Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose|Oral Tablets 10 mg/10 mg or 20 mg/10 mg
224274364|NCT00346892|BIOLOGICAL|Rotavirus (vaccine)|
224274365|NCT05727449|PROCEDURE|General Anesthesia|General Anesthesia was intruduced for Cesarean Delivery
224274366|NCT05727449|PROCEDURE|Spinal Anesthesia|Spinal Anesthesia was intraduced for Cesarean Delivery
224274367|NCT05255952|PROCEDURE|Electrical stimulation|Electrical stimulation of the cardiac plexus
224274368|NCT05424133|OTHER|High frequency chest wall oscillation|High frequency chest wall oscillations at 13-15Hz oscillating frequency for 20 minutes twice a day for 4 weeks.
224274369|NCT05424133|OTHER|Active cycle of breathing|Active cycle of breathing technique and it will performed twice a day for 4 week intervention period for 20 minutes
224274370|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
224274371|NCT00865007|DRUG|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
223518405|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
223518406|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
223518407|NCT03895476|DIAGNOSTIC_TEST|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
223518408|NCT01050218|DRUG|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
223518409|NCT05510167|BEHAVIORAL|Study arm|Participants will be asked to completely abstain from drinking or consume 2 or less drinks per week for 8 months following catheter ablation
223518410|NCT06498180|OTHER|Periodontal initial treatment under local anesthesia|Removal of plaque retention factors, supragingival scaling and subgingival scraping under local anesthesia with articaine (combined with manual and ultrasound methods), and polishing
223518411|NCT06498180|DRUG|Glucocorticoid Therapy|Local blockade therapy with Betamethasone Sodium Phosphate Injection (containing 1.4mg Betamethasone equivalent), local use of 1% Triamcinolone Acetate Ointment, and rinsing with 1% Sodium Bicarbonate (avoiding systemic use during visits)
223518412|NCT06498180|BEHAVIORAL|oral hygiene instruction|Instructions and demonstrations for using manual toothbrushes Instructions and demonstrations for using dental floss or interdental brushes
223518413|NCT06238973|OTHER|Group Low|In order to maintain arterial blood pressure within the range of 50-57 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
223518414|NCT06238973|OTHER|Group Middle|In order to maintain arterial blood pressure within the range of 58-65 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
223518415|NCT05231252|PROCEDURE|Cyclophotocoagulation|Transcleral cyclophotocoagulation is used to treat glaucoma secondary to silicone oil.
223518416|NCT01149460|DRUG|Valacyclovir|Test 1000 mg Tablet
223518417|NCT01149460|DRUG|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
223518418|NCT00077285|BIOLOGICAL|filgrastim|
224083161|NCT04519996|PROCEDURE|US Internal Jugular Vein Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A curvilinear USG probe for IVC imaging (1-5 MHz, 21 mm).~The US transducer will be placed on the right side of the neck in the transverse plane over RIJV 2 cm above the sternoclavicular joint. The IJV will be identified by the color flow Doppler and compressibility. Care will be taken not to compress or obliterate the vein by applying minimal pressure. When the whole circumference of the vein will be visible the measurements were done. The recordings will be done for four respiratory cycles. The maximum, minimum AP diameters, and cross-sectional area will be estimated and, from this, corresponding CI will be derived (Maximum diameter or cross-sectional area (CSA)-minimum diameter or CSA/maximum diameter or CSA) ×100%. All the above measurements will be repeated with the head end of patients elevated to 30° position."
224274372|NCT04815694|RADIATION|RT Dose escalation in LARC patients with an Early Regression Index > 13.1 at second week on nCRT|The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously. A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated. If ERI will be inferior than 13.1 the patient will continue the original treatment. If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
224274373|NCT00611884|DRUG|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
224274374|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
224274375|NCT00611884|DRUG|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
223518419|NCT00077285|DRUG|carboplatin|
223518420|NCT00077285|DRUG|cyclophosphamide|
223518421|NCT00077285|DRUG|dexrazoxane hydrochloride|
223518422|NCT00077285|DRUG|doxorubicin hydrochloride|
223518423|NCT00077285|DRUG|etoposide|
223518424|NCT00077285|DRUG|ifosfamide|
223518425|NCT00077285|DRUG|irinotecan hydrochloride|
223518426|NCT00077285|DRUG|vincristine sulfate|
223518427|NCT00077285|PROCEDURE|conventional surgery|
223518428|NCT00077285|RADIATION|radiation therapy|
223518429|NCT03673930|DIETARY_SUPPLEMENT|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
223518430|NCT03673930|DIETARY_SUPPLEMENT|Placebo|sunflower oil matched for appearance
223518431|NCT05059665|DIAGNOSTIC_TEST|Helio Liver Test|De-identified whole blood and serum samples are collected for the purpose of evaluating the performance (sensitivity/specificity) of the HelioLiver Test for the detection of hepatocellular carcinoma (HCC).
223518432|NCT01985282|BEHAVIORAL|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
223518433|NCT03020316|BEHAVIORAL|Peer Mentor|A volunteer with a similar disease as the subject
223518434|NCT03020316|BEHAVIORAL|Transcendental Meditation|A meditation technique
223518435|NCT03412552|DRUG|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
223518436|NCT06540014|OTHER|No intervention|No intervention is made, groups are formed just due to the races.
223518437|NCT05226052|DIETARY_SUPPLEMENT|Saccharomyces boulardii (Floratil 600mg)|PGIC and PGIS assessment
223518438|NCT05226052|DIETARY_SUPPLEMENT|3 capsules of placebo|PGIC and PGIS assessment
223518439|NCT01791179|BEHAVIORAL|Comprehensive substance abuse services|
223518440|NCT03151668|DRUG|Dexmedetomidine|
223518441|NCT00459550|DRUG|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
223518442|NCT00459550|DRUG|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
223518443|NCT05315778|BIOLOGICAL|autologous anti-BCMA chimeric antigen receptor T cells|Lymphoadenodepletion chemotherapy with FC (fludarabine 30mg/ m2 for 3 consecutive days and cyclophosphamide 300mg/m2 for 3 consecutive days) will be given at day -5, -4 and -3 before CAR T-cells infusion. A total of 1.0-2.0×10e7/Kg autologous anti-BCMA CAR T-cells will be infused by dose-escalation after the lymphoadenodepletion chemotherapy. Dose of CAR T-cells are allowed to be adjusted according to the severity of cytokine release syndrome.
223518444|NCT04359329|DRUG|Estradiol patch|Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
223518445|NCT00057798|DRUG|gemcitabine hydrochloride|
223518446|NCT00057798|DRUG|vinorelbine ditartrate|
223518447|NCT00057798|GENETIC|cytogenetic analysis|
223518448|NCT00057798|GENETIC|loss of heterozygosity analysis|
223518449|NCT00057798|GENETIC|microarray analysis|
223518450|NCT00057798|PROCEDURE|conventional surgery|
223518451|NCT00057798|PROCEDURE|neoadjuvant therapy|
224274376|NCT00611884|DRUG|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
224274377|NCT00611884|DRUG|metformin|Tablets, 1500-2000 mg/day
224274378|NCT00981799|DRUG|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
223518452|NCT02512939|PROCEDURE|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
223518453|NCT03053232|DEVICE|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
223518454|NCT03053232|DEVICE|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
223518455|NCT02315950|OTHER|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
223518456|NCT04501822|DIAGNOSTIC_TEST|Evaluation of clinical, instrumental and laboratory diagnostics tests|During follow-up visits patients undergo clinical, instrumental and laboratory diagnostics tests
224274379|NCT00981799|DRUG|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
224274380|NCT00981799|DRUG|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
224274381|NCT00981799|DRUG|Methotrexate|"Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age"
224274382|NCT00981799|DRUG|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.
224274383|NCT05728645|DRUG|Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg|Intravenous Hydroxyethyl Starch 130/0.4 and Electrolyte injection of 5ml/kg before induction of general anesthesia
224274384|NCT05728645|DRUG|Multiple Electrolytes injection of 5 ml/kg|Intravenous Multiple Electrolytes injection of 5ml/kg before induction of general anesthesia
223518457|NCT04198649|DRUG|Non-surgical periodontal treatment and azithromycin treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
223518458|NCT04198649|OTHER|Non-surgical periodontal treatment and placebo treatment|Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
224274385|NCT01190930|DRUG|Cyclophosphamide|Given IV
224274386|NCT01190930|DRUG|Cytarabine|Given IT, IV, or SC
224274387|NCT01190930|DRUG|Dexamethasone|Given orally (PO) or IV
223518459|NCT05286112|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
224274388|NCT01190930|DRUG|Doxorubicin Hydrochloride|Given IV
224274389|NCT01190930|OTHER|Laboratory Biomarker Analysis|Correlative studies
224274390|NCT01190930|DRUG|Leucovorin Calcium|Given PO
223518460|NCT05286112|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
223518461|NCT00839930|DRUG|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
223518462|NCT00839930|DRUG|Pletal®|1 x 50 mg, single-dose tablet
223518463|NCT05313373|OTHER|Virtual Reality|In addition to the routine procedure, virtual reality glasses will be applied to the women in the virtual reality group of the research. Virtual reality glasses is a device that works on compatible smart mobile phones. After being taken to the gynecological table for the HSG procedure, the women included in the experimental group will be made to watch a video lasting an average of 10 minutes with virtual reality glasses until the procedure is completed. While watching the video, the relaxing music of the video will be played.
223518464|NCT00809588|BIOLOGICAL|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
223893680|NCT01898754|OTHER|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
224274391|NCT01190930|DRUG|Mercaptopurine|Given PO
224274392|NCT01190930|DRUG|Methotrexate|Given IT, PO, or IV
224274393|NCT01190930|DRUG|Pegaspargase|Given IV
224274394|NCT01190930|OTHER|Quality-of-Life Assessment|Ancillary studies
224274395|NCT01190930|OTHER|Questionnaire Administration|Ancillary studies
224274396|NCT01190930|DRUG|Thioguanine|Given PO
224274397|NCT01190930|DRUG|Vincristine Sulfate|Given IV
224274398|NCT02095808|PROCEDURE|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
224274399|NCT03203239|DEVICE|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
224274400|NCT03203239|DRUG|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
223518465|NCT03692169|PROCEDURE|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
223518466|NCT00228956|DRUG|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
223518467|NCT04085731|PROCEDURE|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
223518468|NCT03594474|OTHER|Intravenous lipid emulsion|using higher dose of IV lipids after birth
223518469|NCT00859885|DRUG|Antithrombotic treatment|antiplatelets, anticoagulants
223518470|NCT00859885|DEVICE|percutaneous device closure of PFO|umbrella device for PFO closure
223518471|NCT05777863|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
223518472|NCT02790736|DRUG|propranolol|active treatment
223518473|NCT02790736|DRUG|Placebo|inactive pill
223518474|NCT04545892|DRUG|Capsaicin|One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
223518475|NCT04306120|OTHER|Traditional Rehabilitation Therapy|The protocol included range of motion, ambulation, endurance, strengthening, reconditioning exercise, and home program education according to therapists' plans and the patients' ability.
223518476|NCT01427673|PROCEDURE|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
223518477|NCT02273427|DRUG|BIIL 284 BS|
223518478|NCT02273427|OTHER|high fat meal|
223518479|NCT02273427|OTHER|low fat meal|
223518480|NCT04818710|PROCEDURE|skin incision with a scalpel|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)"
223518481|NCT04818710|PROCEDURE|skin incision with diathermy|"A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)"
223518482|NCT02801578|DRUG|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
223518483|NCT03484897|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
223518484|NCT01839409|BEHAVIORAL|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
223893681|NCT06161337|DIETARY_SUPPLEMENT|Meals|"Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning or evening consumption of either a standardized mixed meal of containing 600 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition."
224274401|NCT03145688|BEHAVIORAL|Family Physical Activity Planning|"Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed \& then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions"
223518485|NCT02154230|DIETARY_SUPPLEMENT|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
223518486|NCT02154230|DIETARY_SUPPLEMENT|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
223518487|NCT00668642|DRUG|Dutasteride|0.5 mg capsule given orally on daily basis
223518488|NCT00668642|DRUG|Placebo|Identical placebo
223518489|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
223518490|NCT03938740|DRUG|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
223518491|NCT04639791|OTHER|No intervention|Observation only, no intervention
223704091|NCT02359422|BEHAVIORAL|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
223704092|NCT02995031|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
223893682|NCT05841212|OTHER|DBT for ADHD|See information included in arm/group description.
223893683|NCT02921581|RADIATION|FDG-PET guided dose painting|
223518492|NCT02192476|OTHER|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
223518493|NCT02192476|OTHER|California tri-pull taping (CTPT)|"Two types of tape was used, a self-adhesive 1.5 cotton undercover tape and a 1 rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape."
223518494|NCT03412591|DRUG|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
223518495|NCT06015009|OTHER|Symptom management mobile health application with personalised support|"Other: Symptom management mobile health application with personalised support Child-caregiver dyads in the intervention group will use the mHealth app for 12 weeks with personalised nurse support via interactive communication technologies. The design of the app will be guided by the theory of unpleasant symptoms.~The app will comprise several interactive elements to provide children and their caregivers with real-time symptom management support. Comprehensive educational materials regarding cancer and its treatment side effects, including possible symptoms, functional limitations, and psychological responses, will be provided in the app for the children and their caregivers to gain a thorough understanding of the potential symptom burden that they may experience."
223518496|NCT05403866|DRUG|LT3001 Drug Product|Administered by intravenous infusion
223518497|NCT05403866|DRUG|Placebo|Administered by intravenous infusion
223518498|NCT02272985|OTHER|[15O]H2O PET-CT scan|All participants will undergo 3 \[15O\]H2O PET-CT scans during the hemodialysis study session
223518499|NCT02272985|OTHER|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
223518500|NCT02458027|DIETARY_SUPPLEMENT|Hemp Shake|Hemp Protein
223518501|NCT02458027|DIETARY_SUPPLEMENT|Hemp|Hemp Protein Shake
223518502|NCT02458027|DIETARY_SUPPLEMENT|Soybean Shake|Soybean Protein
223518503|NCT02458027|DIETARY_SUPPLEMENT|Soybean|Soybean Protein Shake
223518504|NCT02458027|DIETARY_SUPPLEMENT|Control|Non-Protein Shake
224274402|NCT03145688|BEHAVIORAL|Family Physical Activity Habit Formation|Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
223518505|NCT00124358|DRUG|Buprenorphine|
223518506|NCT00124358|BEHAVIORAL|Integrated HIV care and office-based opioid dependence treatment|
223518507|NCT00960245|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
223518508|NCT00960245|DRUG|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
223518509|NCT02921867|OTHER|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
223518510|NCT03119129|BEHAVIORAL|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
223518511|NCT02738619|DRUG|Vitamin D3|1600 UI
223518512|NCT02738619|DRUG|placebo|placebo
223518513|NCT01751880|BEHAVIORAL|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
223518514|NCT00497497|DRUG|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
223518515|NCT00497497|DRUG|cetuximab|Intravenous repeating dose
223518516|NCT00497497|DRUG|FOLFIRI regimen|Intravenous repeating dose
223518517|NCT00497497|DRUG|irinotecan|Intravenous repeating dose
223518518|NCT00497497|DRUG|PRO95780|Intravenous repeating dose
223518519|NCT05775939|OTHER|Fludeoxyglucose F-18|Given FDG
223518520|NCT05775939|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223518521|NCT05775939|PROCEDURE|Computed Tomography|Undergo PET-CT
223518522|NCT05775939|OTHER|Questionnaire Administration|Ancillary studies
223518523|NCT06547320|BEHAVIORAL|Eat Less Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the amount of food eaten.
223518524|NCT06547320|BEHAVIORAL|Eat Slower Intervention|A sensor worn on eyeglasses monitors eating and provides messages to a smartphone when eating occurs to prompt small reductions in the rate of eating.
223518525|NCT02567903|DEVICE|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
223518526|NCT02567903|PROCEDURE|Knee arthroscopy|Knee arthroscopy
223518527|NCT02676037|DEVICE|foot pressure plate form|
223518528|NCT00615888|PROCEDURE|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
223518529|NCT00615888|PROCEDURE|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
223518530|NCT05755581|DRUG|Hormonal Antineoplastics|the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
224274403|NCT01207856|BEHAVIORAL|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
224274404|NCT01207856|BEHAVIORAL|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
224274405|NCT01207856|OTHER|no intervention|no intervention
224274406|NCT02167594|DRUG|Flortaucipir F18|IV injection, 370 megabecquerel (MBq) (10 mCi)
224274407|NCT02167594|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
223518531|NCT05755581|DRUG|Chemotherapy drug|the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.
223518532|NCT01069757|DRUG|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
223518533|NCT05815264|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive one dose of 23-valent pneumococcal polysaccharide vaccine administered by intramuscular injection.
223518534|NCT05815264|BIOLOGICAL|pneumococcal vaccine polyvalent|This vaccine（0.5ml） is produced by Merck Sharp \& Dohme Corp. Subjects will receive one dose of pneumococcal vaccine polyvalent administered by intramuscular injection.
223518535|NCT02463435|BEHAVIORAL|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
223518536|NCT02463435|OTHER|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
223518537|NCT02463435|DIETARY_SUPPLEMENT|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
223518538|NCT00770679|DRUG|lipitor|80 mg everyday (QD) for 3 weeks
223518539|NCT06022640|BEHAVIORAL|Educational and supportive care|The trial had a total of 75 participants assigned to the intervention group, whereby they were provided with an educative and supporting program specifically developed by a clinical pharmacist. The intervention group was provided with assistance via a series of five visits, which included an initial visit upon admission, subsequent visits for monitoring medication, ovulation, and negative effects, as well as visits dedicated to giving emotional support. Additionally, a follow-up visit was conducted after the egg collecting process and embryo transfer.
223518540|NCT06490666|DEVICE|femoral artery doppler|femoral artery pulse wave doppler to measure both pulsatility and resistive indices
223518541|NCT01577316|BIOLOGICAL|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus;~* a B/Wisconsin/1/2010-like virus."
223518542|NCT04940078|DRUG|Cagrilintide|Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
223518543|NCT04940078|DRUG|semaglutide|Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
223518544|NCT04940078|DRUG|Cagrilintide and semaglutide|Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
223518545|NCT03064009|OTHER|Infection|This is an observational trial
223518546|NCT04759287|DEVICE|C-MAC VS|The first group (VS group) will include patients undergoing awake intubation using the C-MAC VS
223518547|NCT04759287|DEVICE|flexible fibreoptic bronchoscope|The second control group (FOB group) will include patients undergoing awake intubation using the flexible fibreoptic bronchoscope.
223518548|NCT00296712|DRUG|escitalopram + bupropion|same dosing as for monotherapy arms
223518549|NCT02494492|OTHER|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
223704093|NCT02995031|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
223704094|NCT01127035|BIOLOGICAL|sublingual immunotherapy|
223704095|NCT01127035|BIOLOGICAL|placebo|
223704096|NCT02371304|RADIATION|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
223704097|NCT02371304|PROCEDURE|Additional TME surgery|
224274408|NCT02161549|DEVICE|Motus Gl CleanUp System|
224274409|NCT02404558|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
224274410|NCT02404558|DRUG|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
224274411|NCT01535911|OTHER|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
224274412|NCT02926651|DRUG|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
224274413|NCT02926651|DRUG|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
223518550|NCT03709667|BEHAVIORAL|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
223518551|NCT03709667|BEHAVIORAL|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
223518552|NCT00441324|PROCEDURE|recombinant human LH|
223518553|NCT05277935|DEVICE|Use of the WeCancer app combined with the smartwatch.|To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
223518554|NCT06220110|DIETARY_SUPPLEMENT|Probiotic|Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
223518555|NCT06220110|DIETARY_SUPPLEMENT|Placebo|Capsules containing dextrose (1 capsule per day)
223518556|NCT00380926|DRUG|polyunsatturated fatty acids (fish oil)|
223518557|NCT05096130|BEHAVIORAL|Lifestyle Medicine Strategies|"LM addresses health risk factors in primary, secondary, and tertiary prevention of developing disease rather than limiting resources and medical expenditures on acute care and reacting to illness, injury, and disease.~The intervention will target the four pillars of the LM approach including physical activity, diet, stress, and sleep. Certified in LM strategies professionals will consult participants from the LM group in a biweekly base in order to improve their lifestyle habits."
223518558|NCT01988077|BIOLOGICAL|Adoptive cell transfer|Adoptive cell transfer
223518559|NCT01988077|DRUG|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
223518560|NCT00610038|DRUG|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
223518561|NCT01955551|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
223518562|NCT01955551|BEHAVIORAL|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
223518563|NCT01759641|DEVICE|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
223518564|NCT03735914|OTHER|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
223518565|NCT04877379|DRUG|VNRX-7145|β-lactamase inhibitor
223518566|NCT04877379|DRUG|VNRX-5024 (ceftibuten)|β-lactam antibiotic
223518567|NCT04877379|DRUG|Placebo|Placebo
223518568|NCT04063202|OTHER|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
223518569|NCT06216262|OTHER|Control group|Brushing teeth twice a day for 8 weeks
223518570|NCT06216262|OTHER|Arginine|Brushing teeth twice a day for 8 weeks
223518571|NCT06216262|OTHER|Novamin|Brushing teeth twice a day for 8 weeks
223518572|NCT06216262|OTHER|Propolis|Brushing teeth twice a day for 8 weeks
223518573|NCT06216262|OTHER|Casein Phosphopeptide Amorphous Calcium Phosphate|Following the procedure in the control group, it is applied to the tooth surface once a day for 3 minutes before going to bed at night for 8 weeks
223518574|NCT06216262|OTHER|Potassium Nitrate|Following the procedure in the control group, mouthwash twice a day in the morning and evening for 8 weeks
223518575|NCT04759170|OTHER|Music therapy|The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
223518576|NCT00487630|DRUG|recombinant alpha-galactosidase A|
223518577|NCT01819480|PROCEDURE|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
223518578|NCT04250792|DRUG|Naltrexone Pill|role of low dose naltrexone in patients affected with psoriasis
223518579|NCT00002480|RADIATION|radiation therapy|
223518580|NCT00944021|DRUG|PA-824|50mg
223518581|NCT00944021|DRUG|PA-824|100mg
223518582|NCT00944021|DRUG|PA-824|150 mg
223518583|NCT00944021|DRUG|Rifafour e-275 mg|275 mg
223518584|NCT00944021|DRUG|PA-824|200 mg
223518585|NCT01496859|DEVICE|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
223518586|NCT00266032|DRUG|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
223518587|NCT00266032|DRUG|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
223518588|NCT00266032|DRUG|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
223518589|NCT00204581|DRUG|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
223518590|NCT05736913|BIOLOGICAL|ID BNT162b2 vaccine|intradermal BNT162b2 vaccine
223518591|NCT05736913|BIOLOGICAL|IM BNT162b2 vaccine|intramuscular BNT162b2 vaccine
223518592|NCT03318393|DRUG|Bivalirudin|Continuous infusion
223518593|NCT03318393|DRUG|Unfractionated heparin|Continuous infusion
223518594|NCT06110871|OTHER|inhaled lavender|They will be asked to inhale deeply 10 times. Then, a total of 30 minutes in the waiting room where aromastone is located and in the IA application room.
223518595|NCT06110871|OTHER|Working Group 2: Focusing|During IUD application
223518596|NCT06110871|OTHER|Working Group 3 music|for a total of 30 minutes
223518597|NCT00188032|PROCEDURE|Computer-Assisted diagnostic Decision Support|
223518598|NCT00188032|PROCEDURE|written diagnostic guidelines|
223518599|NCT00188032|PROCEDURE|electronic therapeutic reminders|
223518600|NCT00814983|PROCEDURE|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
223518601|NCT00814983|PROCEDURE|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
223518602|NCT00814983|DEVICE|Isolex device from Baxter|
223518603|NCT03627468|DRUG|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
223518604|NCT03627468|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
223518605|NCT02796456|OTHER|blood sample|
223518606|NCT00326014|DEVICE|iStent|Glaucoma Surgery
223518607|NCT04157738|DRUG|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
223518608|NCT04157738|DRUG|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
223518609|NCT00160563|DRUG|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
223518610|NCT00160563|OTHER|Placebo|Oral drops, bid for 18 months
223518611|NCT04205916|DRUG|Dexamethasone|Drugs to be administer during cataract surgery to experimental group
223518612|NCT04205916|OTHER|Standard of care surgery|Standard method used for surgery and the use of post operative drops
223518613|NCT00363363|BEHAVIORAL|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
223518614|NCT00363363|BEHAVIORAL|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
223518615|NCT01730573|PROCEDURE|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
223518616|NCT01730573|PROCEDURE|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
223518617|NCT01991873|DRUG|Maintenance Chemotherapy|
223518618|NCT01991873|DRUG|Panitumumab (Within maintenance phase)|
223518619|NCT01991873|DRUG|mFOLFOX6 (Within re-induction phase)|
223518620|NCT01991873|DRUG|Panitumumab (Within re-induction phase)|
223518621|NCT03721458|OTHER|Sequence|Potentially identifying genetic defects that could have clinical significance
223518622|NCT02118831|BIOLOGICAL|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
223518623|NCT02118831|DRUG|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
223518624|NCT02118831|DRUG|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
223518625|NCT02118831|DRUG|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
223518626|NCT04874597|DRUG|Ocrelizumab|Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
223518627|NCT04491110|OTHER|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be done by using mobile telephones.
223518628|NCT04491110|OTHER|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through mobile phones.
223518629|NCT03587090|DIAGNOSTIC_TEST|echocardiography|echocardiography by subcostal and transhepatic views
223518630|NCT03190876|PROCEDURE|Variable drain usage|Influence of drain usage on seroma formation rate
223518631|NCT03070834|DEVICE|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
223518632|NCT02302326|DRUG|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
223518633|NCT02302326|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
223518634|NCT05737680|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg daily
223518635|NCT05737680|DRUG|Colchicine|Colchicine continued
223518636|NCT01514357|DRUG|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
223518637|NCT01514357|DRUG|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
223518638|NCT04280380|DIAGNOSTIC_TEST|Real time PCR|At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with \>500 copies/mL of plasma will be considered positive.
223518639|NCT04801901|PROCEDURE|dTRA|Subjects randomized to the experimental arm will undergo left heart catheterization, coronary angiography and/or percutaneous coronary intervention using distal transradial access (dTRA)
223518640|NCT04801901|PROCEDURE|fTRA|Left heart catheterization, coronary angiography and/or percutaneous coronary intervention using the left forearm radial artery.
223518641|NCT05730660|DIETARY_SUPPLEMENT|Quercetin group|2 capsules a day of Quercetin Fitosoma® of 250 mg each
223518642|NCT05730660|DIETARY_SUPPLEMENT|Placebo group|2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
223518643|NCT00752219|DRUG|ceftazidime/NXL104 + metronidazole|IV TID
223518644|NCT00752219|DRUG|meropenem|IV TID
223518645|NCT04642209|DEVICE|Aggregometry|"After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation."
223518646|NCT04072939|OTHER|Patients having had a lens surgery|Dilated fundus exam
223518647|NCT03905239|DIAGNOSTIC_TEST|algorithm|clinical examination and procalcitonin assessment
223518648|NCT04309266|DEVICE|Amadeo by Tyromotion|Distal upper extremity/hand robot for robot-assisted therapy
223518649|NCT04309266|BEHAVIORAL|Active Learning Protocol for Stroke|Metacognitive approach involving active problem solving for using the affected upper extremity in motoric activities. Also includes a home program.
223518650|NCT03576651|BIOLOGICAL|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
223518651|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
223518652|NCT03576651|BIOLOGICAL|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
223518653|NCT02811419|DEVICE|i-scan|examination will be performed with i-scan digital enhancement
223518654|NCT02811419|DEVICE|standard high-definition white light|examination will be performed with high-definition white light
223518655|NCT02695186|PROCEDURE|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
223518656|NCT05598515|BEHAVIORAL|Time-Restricted Feeding|Participants will be asked to eat for only 8 hours out of 24 hours in a day.
223518657|NCT03604744|DRUG|LSD|LSD 0.1 mg per os, single dose
223518658|NCT03604744|DRUG|LSD|LSD 0.2 mg per os, single dose
223518659|NCT03604744|DRUG|Psilocybin|Psilocybin 15 mg per os, single dose
223518660|NCT03604744|DRUG|Psilocybin|Psilocybin 30 mg per os, single dose
223518661|NCT04211948|PROCEDURE|robotic surgery|Pancreatectomy with robotic assisted system
223518662|NCT04211948|PROCEDURE|open surgery|Traditional open pancreatectomy
223704098|NCT02371304|DRUG|capecitabine|
223518663|NCT03058887|OTHER|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
223518664|NCT03058887|OTHER|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
223704099|NCT03898258|OTHER|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
223704100|NCT03898258|OTHER|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
224274414|NCT04785963|BEHAVIORAL|Music with Suggestion|A nonpharmacological, short-term treatment that poses minimal risk and places very limited burden on patients seems ideal for this population, and music with suggestions is one such treatment option.
224274415|NCT04785963|BEHAVIORAL|Pain Information|The comparison condition of informational recordings about chronic pain are structured to account for non-specific effects of general time and attention and to evaluate whether the treatments of music alone, and music in combination with suggestion are effective in the reduction of pain intensity more than an appropriate control group.
224274416|NCT04785963|BEHAVIORAL|Music|The comparison condition of the music only is structured to account for the effect of music listening, and to evaluate whether the addition of suggestion optimizes its effectiveness in the reduction of pain intensity.
224274417|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
224274418|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
224274419|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
224274420|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
224274421|NCT00585741|PROCEDURE|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
224274422|NCT01185158|DRUG|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
224274423|NCT00067327|DRUG|Inosine|
224274424|NCT02039635|DIETARY_SUPPLEMENT|Korean Red Ginseng|Given Orally
224274425|NCT02039635|DIETARY_SUPPLEMENT|Placebo|Given Orally
224274426|NCT02093377|DEVICE|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
224274427|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
224274428|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
224274429|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
224274430|NCT01583530|BIOLOGICAL|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
224274431|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
224274432|NCT01583530|BIOLOGICAL|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
224274433|NCT01460030|DRUG|Cinacalcet HCl|Oral administration
224274434|NCT02647853|DRUG|TAT4 Gel concentration A|
224274435|NCT02647853|DRUG|TAT4 Gel concentration B|
224274436|NCT02647853|DRUG|Placebo|
224274437|NCT04771767|DRUG|Ketamine|Patients will receive 6 sub-anesthetic IV ketamine infusions over 8 weeks, each one lasting 40 minutes.
224274438|NCT04771767|BEHAVIORAL|Online Trauma-Focused Cognitive Behavioural Therapy|Participants will enrol in a 12-week online CBT program mirroring in-person trauma-focused CBT.
224274439|NCT03904836|DRUG|Tobramycin|5 milligrams per kilogram intravenous for one dose
224274440|NCT03933267|OTHER|Cervical sensorimotor control training exercises|"Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions \* 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility."
224274441|NCT03933267|OTHER|Conventional Exercises|conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
224274442|NCT00162968|DRUG|escitalopram|
224274443|NCT00893776|OTHER|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
224274444|NCT04010227|BEHAVIORAL|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants receive handouts on session topics and a compact disc (CD) that we developed to guide mindfulness practices.
223704101|NCT00446615|BEHAVIORAL|computer decision support tool|
223704102|NCT00446615|BEHAVIORAL|audit and feedback|
223704103|NCT00446615|BEHAVIORAL|group learning session|
223704104|NCT04042181|DIETARY_SUPPLEMENT|Placebo|standard food grade excipients
223518665|NCT06020079|OTHER|laughter yoga|"According to the literature and the training received on laughter yoga, the time required for the treatment of depression is 50 minutes. The first 10 minutes includes relaxation, stretching and warm-up exercises. The next 30 minutes includes laughing exercises, and finally, the last 10 minutes includes relaxation exercises.~Steps of laughter yoga sessions:~1. Clapping hands and warm-up exercises: Participants clap their hands, fingers and palms. Then, sounds like ho-ho and ha-ha are added to the clapping exercises along with the rhythm.~2. Deep breathing exercises: Breathing exercises should be repeated 3-4 times while standing~3. Childlike games: Arms are raised, imitating the funny and clumsy behavior of a child.~4. Laughter exercises: The researcher names the exercise, explains how to do it, and the group performs the exercise together.~Dance and Relaxation"
223518666|NCT01514279|BEHAVIORAL|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
223518667|NCT01514279|BEHAVIORAL|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
223518668|NCT05139095|DRUG|Camrelizumab plus apatinib CohortA|Cohort A: Camrelizumab (200 mg q2w iv) concomitantly with apatinib (250 mg qd po) and EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\] every 2 weeks. For certain patients with high tumor burden, 1-2 cycles of low-dose chemotherapy (actinomycin D 500 ug and etoposide 100mg/m2, D1-3) will be administered, then followed by EMA/CO. The observation period is 14 days.
223518669|NCT05139095|DRUG|Camrelizumab plus apatinib Cohort B|Cohort B: Camrelizumab (200 mg q3w iv) concomitantly with apatinib (250 mg qd po) and multi-drug chemotherapy. The multi-drug chemotherapy regimen will be chosen by the investigator (chemotherapy regimen: EMA/CO \[etoposide, methotrexate, actinomycin D/cyclophosphamide, vincristine\]; or EMA/EP \[etoposide, methotrexate and actinomycin-D/etoposide, cisplatin\]; or FAEV \[floxuridine, actinomycin-D, etoposide, vincristine\]). The observation period is 21 days.
223518670|NCT04383639|OTHER|No product (A)/mixture of coca and carob together with breakfast (B)/mixture of coca and carob 10 h before breakfast (C)|The subjects will receive, after overnight fasting, a high-fat high-sugar breakfast. In treatment A, they will not receive any additional product; in treatment B, they will receive at the same time a mixture of coca and carob; in treatment C, they will receive the mixture of coca and carob 10 h before breakfast. A total of 6 blood samples will be collected during each visit: 0-30-60-120-180-240-270 min. Urine samples will be collected during the permanence of the subjects in the Unit of Human Nutrition. Feces will be collected the first time they are generated after treatments A and C. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
223518671|NCT05149768|DRUG|Brentuximab vedotin|Dose 0.6mg/kg will be given every 3 weeks for 16 cycles (48 weeks), in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil (MMF, cellcept) and mycophenolic acid (myfortic)
223518672|NCT05801887|DEVICE|Extracorporeal shockwave device|"Extracorporeal shockwave device generates true shock waves which are characterized by a sudden rise in pressure followed by an exponential decay.~This is different from the commercially available shockwave devices in which they use piezoelectric based mechanisms which generate high frequency waves."
223518673|NCT05801887|DEVICE|No ESWT|the osteoblast like cells are not exposed to shockwaves
223518674|NCT06641674|DRUG|18F-LF13|18F-LF13 PET/CT: after intravenous injection of 1.85 - 3.7 MBq/kg body weight of quality-controlled 18F-LF13, a Siemens Biograph PET/CT scan will be applied within 0.5 h, and the scan range will be from the top of the head to 1/3 of the upper thigh, 2 h to 4 h delayed scanning can be added if necessary.
223518675|NCT06126172|DIAGNOSTIC_TEST|Multiparametric magnetic resonance imaging (mpMRI)|Detecting and localizing prostate cancers and using radiomics extracted from prostate mpMRI for risk stratification patients of histological aggressiveness as well as to predict very early recurrence of PCA patients within 6 months after radical prostatectomy.
223518676|NCT06638593|PROCEDURE|MIRRORS-FROZEN Protocol.|Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
223518677|NCT06638593|PROCEDURE|Standard open surgery|A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
223518678|NCT06637228|BEHAVIORAL|Move Your Hands, Feet, and Brain: Integrated Exercise Intervention Based on Taipei City Elderly Physical Activity Guidelines|"This video is tailored for fitness exercises for both healthy and sub-healthy elderly individuals and features various physical activity themes, including warm-up routines, balance and coordination drills, aerobic coordination exercises, strength training using chairs and water bottles, and cool-down routines. We selected a 3-month duration with sessions held three times a week to align with established effective intervention periods and to ensure participant adherence.~Integrated exercise sessions were conducted by the staff at the dementia care centers/service bases and lasted 50 minutes. Considering the impact of dementia and aging on the ability of older adults to engage in physical activities, the staff provided simple instructions, and participants performed the exercises while seated to prevent falls. Meanwhile, the control group continued with their usual treatment and daily activities."
223518679|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
223518680|NCT06642961|DRUG|GR1802 injection|GR1802 will be administered SC.
223518681|NCT06642961|OTHER|Placebo|The placebo will be administered SC.
223518682|NCT03424343|OTHER|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
223518683|NCT03424343|OTHER|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
223518684|NCT03162211|OTHER|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
223518685|NCT03438032|DIAGNOSTIC_TEST|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
223518686|NCT00168376|DEVICE|Transcranial Magnetic Stimulation|
223518687|NCT03405350|PROCEDURE|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
223518688|NCT03405350|PROCEDURE|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
223518689|NCT03405350|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
223518690|NCT03405350|PROCEDURE|Terrain Therapy|walking, outdoors physical activities,
223518691|NCT03405350|PROCEDURE|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
223518692|NCT03405350|PROCEDURE|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
223518693|NCT03405350|PROCEDURE|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
223518694|NCT03405350|PROCEDURE|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
223518695|NCT03405350|PROCEDURE|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
223518696|NCT03405350|PROCEDURE|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
224274445|NCT04010227|BEHAVIORAL|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers are directed to resources for practical and health information and contact information for psychosocial services. Sessions include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist also describes resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants receive handouts summarizing session topics and are asked to review them as homework.
223518697|NCT03405350|PROCEDURE|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
223518698|NCT03007433|OTHER|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
223518699|NCT00651287|DRUG|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
223518700|NCT00651287|DRUG|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
223518701|NCT00651287|DRUG|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
223518702|NCT06044792|OTHER|differences in CD4 reconstruction|Differences in the increase in CD4 lymphocyte count and CD4:CD8 ratio between patients with primary drug resistance mutations and those without these mutations.
223518703|NCT03893357|OTHER|Data extraction from medical files|Retrospective data extraction from the medical files
223518704|NCT00781261|DRUG|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
223518705|NCT00781261|DRUG|Placebo|Subjects in the control group will receive a placebo drug for a similar period
223518706|NCT05056857|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223518707|NCT05056857|OTHER|Electronic Health Record Review|Medical charts are reviewed
223518708|NCT01047540|DRUG|AIC316|Oral administration
223518709|NCT01047540|DRUG|AIC316|Oral administration
223518710|NCT01047540|DRUG|AIC316|Oral administration
223518711|NCT01047540|DRUG|AIC316|Oral administration
223518712|NCT01047540|DRUG|Placebo|Oral administration
223518713|NCT05212909|BEHAVIORAL|General Anxiety Disorder-7 scale|The General Anxiety Disorder-7 scale was used to evaluate the level of anxiety in anesthesiology providers.
223518714|NCT06320990|DRUG|Tamoxifen 20mg|Tamoxifen is a nonsteroidal antiestrogen for oral administration.
223518715|NCT00005980|DRUG|pegylated liposomal doxorubicin hydrochloride|
223518716|NCT04250207|DRUG|K-321 Solution|K-321 solution drops
223518717|NCT04250207|DRUG|Placebo Solution|Placebo solution drops for K-321
223704105|NCT04042181|DIETARY_SUPPLEMENT|Bifidobacterium longum|Target dose of 1x10\^10 CFU/day, plus standard food grade excipients
223518718|NCT02344355|DRUG|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
223518719|NCT02344355|RADIATION|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
223518720|NCT02344355|DRUG|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
223518721|NCT02081703|DRUG|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
223518722|NCT02081703|DRUG|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
223518723|NCT02081703|DRUG|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
223518724|NCT02081703|DRUG|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
224274446|NCT04752527|DRUG|venetoclax combined with decitabine|combination of venetoclax plus decitabine, and sorafenib for patients with high FLT3-ITD allelic ratio. (On day 1 of cycle 1, decitabine 20 mg/m2 will be given intravenously, and will continue for 5 days. Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 28 day cycle is finished. For patients with high FLT3-ITD allelic ratio, sorafenib was administered at a dose of 400mg orally twice daily, on days 3 through 28.
224274447|NCT03051776|OTHER|Kinesio Taping|
224274448|NCT03051776|OTHER|Compression Garment|
224274449|NCT04842435|DRUG|COVID-globulin|"In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study."
224274450|NCT04842435|DRUG|Placebo|"In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose."
224274451|NCT00197834|DRUG|Depakote|
224274452|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
223518725|NCT01437189|DRUG|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
223518726|NCT05603676|OTHER|Intermittent hypoxia-hyperoxia conditioning|The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.
223518727|NCT05603676|OTHER|Placebo intervention|Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
223518728|NCT03308279|DIAGNOSTIC_TEST|Ultrasound|Ultrasound and Anthropometric meassures
223518729|NCT00347269|BEHAVIORAL|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
223518730|NCT00347269|DRUG|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
223518731|NCT00347269|BEHAVIORAL|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
223518732|NCT00376103|DRUG|temozolomide|75 mg/m2/day
223518733|NCT00376103|PROCEDURE|Brachytherapy|60 Gy to 1 cm
223518734|NCT00376103|PROCEDURE|External Beam Radiation Therapy|60 Gy
224274453|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
224274454|NCT01841073|DIETARY_SUPPLEMENT|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
223704106|NCT03650556|DEVICE|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
224274455|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
224274456|NCT01841073|DIETARY_SUPPLEMENT|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
224274457|NCT01841073|DIETARY_SUPPLEMENT|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
224274458|NCT03210038|DRUG|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
224274459|NCT03210038|DRUG|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
224274460|NCT00091195|DRUG|romidepsin|
224274461|NCT03946436|DEVICE|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
224274462|NCT03946436|OTHER|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
224274463|NCT00286533|PROCEDURE|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
224274464|NCT00286533|PROCEDURE|Questionnaires|Questionnaires are used.
224274465|NCT04808388|OTHER|MRI|Using MRI for fat fraction and Biodex for isometric strength
224274466|NCT01189656|BIOLOGICAL|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
224274467|NCT04184206|BEHAVIORAL|attention training intervention 1|14-day smartphone-based audio-guided attention training program with heavy mindfulness component
224274468|NCT04184206|BEHAVIORAL|attention training intervention 2|14-day smartphone-based audio-guided attention training program with moderate mindfulness component
223518735|NCT02735460|DEVICE|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
223518736|NCT01878448|DRUG|Anlotinib|
223518737|NCT06518369|OTHER|Prehabilitation|"Prehabilitation program for 4-6 weeks before surgery will include:~* Review of the frailty risk analysis calculator score obtained in the frailty study (#2212-74)~* Review of lab results including complete blood count, creatinine, albumin, and prealbumin~* Review of chronic conditions.~* An office visit or telehealth visit to review instructions on instructions on nutrition, exercise, smoking cessation, and optimization of chronic disease.~* Drinking surgery immunonutrition drinks twice daily for 5 days before surgery.~* Educational information and video instruction~* Weekly phone calls to motivate, ensure adherence, and assess progress.~* Measurements of hand grip strength and body weight"
223518738|NCT06168968|BEHAVIORAL|Life and Medication Recommendations|Based on obtained subjective and objective data from patient-filled questionnaire and laboratory testing respectively, lifestyle and medication recommendations will be provided for secondary prevention of cardiovascular and cerebrovascular diseases
223518739|NCT03654326|DRUG|Gefapixant|Gefapixant tablet 45 mg taken orally
223518740|NCT03654326|DRUG|Placebo|Placebo matching gefapixant tablet taken orally
223518741|NCT03654326|DRUG|Naproxen|Naproxen sodium 275 mg tablets taken orally as needed, at dose prescribed by sites' principal investigator
223518742|NCT06399107|GENETIC|Drug Product is administered by IV infusion following myeloablative conditioning with busulfan|An autologous CD34+ cell-enriched population from patients with sickle cell disease (SCD), which includes hematopoietic stem cells (HSCs) that have been transduced with the BAH243 lentiviral vector (LVV) carrying the βA-T87Q-globin gene, is preserved in a cryopreservation solution.
224274469|NCT04184206|BEHAVIORAL|attention training intervention 3|14-day smartphone-based audio-guided attention training program without mindfulness component
224274470|NCT01424020|OTHER|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
224274471|NCT00301327|DRUG|Summers 5% L.A.|
224274472|NCT03240991|OTHER|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
224274473|NCT03550196|OTHER|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
224274474|NCT03174158|DRUG|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
224274475|NCT03174158|BEHAVIORAL|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
224274476|NCT03174158|BEHAVIORAL|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
224274477|NCT01652638|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
224274478|NCT00403806|DRUG|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
224274479|NCT00403806|DRUG|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
224274480|NCT00403806|DRUG|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
224274481|NCT00403806|DRUG|Saline|Intravenous saline
224274482|NCT00283842|DRUG|DVS SR|
224274483|NCT00283842|DRUG|Placebo|
224274484|NCT04777552|OTHER|diazepam (or equivalence if other benzodiazepine)|
224274485|NCT01326351|PROCEDURE|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
224274486|NCT01326351|PROCEDURE|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
224274487|NCT01326351|BEHAVIORAL|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
224274488|NCT01824498|OTHER|Low Fat diet|Low fat diet = 20% fat
223518743|NCT06404450|BEHAVIORAL|Digital CBT|The digital CBT program is called Daylight (Big Health, Ltd). The program employs a virtual therapist to guide individuals through interactive exercises and animations to facilitate the learning and implementation of CBT techniques. The program focuses on four modules (10-20 minutes each) which address specific CBT principles: stimulus control, applied relaxation, cognitive restructuring (decatastrophizing), and imaginal exposure. Daylight is designed to be self-paced, with the app encouraging users to practice techniques both within the app and in real-life situations on a daily basis. Users receive reminders and motivational messages via emails, push notifications, and text messages tailored to participant progress.
223518744|NCT05501522|BIOLOGICAL|GBP510 adjuvanted with AS03|injection volume of 0.5mL on Day 0
223518745|NCT05501522|OTHER|Placebo (Normal Saline)|injection volume of 0.5mL on Day 0
223518746|NCT05424315|DRUG|Dapagliflozin 10mg|10mg Tab once daily
223518747|NCT05424315|DRUG|Glucose Tab|Placebo Oral Tablet
223518748|NCT01628770|DRUG|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
223518749|NCT01628770|DRUG|Ferrous sulphate|200mg twice daily
223518750|NCT05872516|DEVICE|Chang Gung Atrial Fibrillation Detecting Software|This software is expected to be used in clinical testing to interpret the static 12-lead ECG of adults who are over 20 years old and suspected of having atrial fibrillation, detect whether there is a signal of atrial fibrillation, and output the results for clinicians Near-instant auxiliary diagnostic use.
223518751|NCT04472468|DEVICE|Percutaneous Balloon Pericardiotomy|"* Subxiphoid approach under fluoroscopic guidance is used.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is advanced into the pericardial space.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections."
223518752|NCT04573478|DRUG|Atrasentan|Film-coated tablet
223518753|NCT04573478|DRUG|Placebo|Film-coated tablet
223518754|NCT00936650|DRUG|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
223518755|NCT00936650|DRUG|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
223518756|NCT04129021|DEVICE|High-resolution retinal imaging through adaptive optics|The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
223518757|NCT04129021|DEVICE|High-resolution retinal imaging through holographic systems|The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
223518758|NCT05853406|DIAGNOSTIC_TEST|Functional Reach test|"The determination by statistical research is carried out during a usual physiotherapy assessment of the volunteers. Data patient demographics and standard tests (FRT, Tinetti test, Timed Up and Go test, unipodal station) will be noted.~A satisfaction questionnaire inspired by Patient rating of change will be sent to participants for the determination of the MCID by ANCHOR method.~Concerning the Delphi method, a questionnaire will be sent to physiotherapists with proven geriatric activity."
224274489|NCT01824498|OTHER|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
224274490|NCT01824498|OTHER|High Fat Diet|High Fat Diet = 40% fat
224274491|NCT04262245|PROCEDURE|Traditional Irrigation|irrigation with syringe
224274492|NCT04262245|DEVICE|Xp-endo Finisher (XPF)|irrigation activation file
223518759|NCT05763303|OTHER|educational program|interventional program consists of educational part and training part in case of agreement of participants
223518760|NCT00281437|BEHAVIORAL|choice of exercise program|
223518761|NCT05181475|DRUG|Sodium Oligomannate Capsules (GV-971)|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
223518762|NCT04157465|OTHER|Treatment strategy trial|"Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan\>150 pg/ml, Galactomannan index\>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures."
223518763|NCT05435859|BEHAVIORAL|Speech Tasks|Listen to 25-minutes of speech sounds in English.
224274493|NCT04262245|DEVICE|Passive Ultrasonic Irrigation|irrigation activation method
223518764|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.4 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
223518765|NCT04424251|DRUG|Experimental: stage I：HSK21542 1 μg/kg|Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
223518766|NCT04424251|DRUG|Experimental: stage I：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
224274494|NCT04262245|DEVICE|EndoActivator|irrigation activation method
224274495|NCT04320745|DRUG|Androderm®|Androderm® transdermal dose.
224274496|NCT04358627|DRUG|Dexmedetomidine Injectable Product|continuous intravenous infusion of dexmedetomidine
223518767|NCT04424251|DRUG|Experimental: stage I：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
223518768|NCT04424251|DRUG|Experimental: stage II：HSK21542 0.5μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
223518769|NCT04424251|DRUG|Experimental: stage II：HSK21542 1μg/kg|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
223518770|NCT04424251|DRUG|Placebo|once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
223518771|NCT04102514|BEHAVIORAL|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
223704107|NCT00325702|BEHAVIORAL|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
224083162|NCT04519996|PROCEDURE|US Inferior Vena Cava Collapsibility Index measurment|"Machine~A sonosite M-Turbo ultrasound machine will be used for all the examinations. A linear vascular transuder for IJV imaging (7-13 MHz, 38 mm) will be used.~The transducer will be placed in the subxiphoid region in a longitudinal position. IVC measurements will be made just distal to the IVC-hepatic vein junction, approximately 3 to 4 cm distal to the right atrium. The IVC will be identiﬁed by Doppler waveform, compressibility and phasic collapse with respiration. The maximum (IVCD) and minimum (IVCD) internal anteroposterior (AP) diameters of the IVC at the end of expiration and inspiration respectively over the same respiratory cycle will be measured. The IVCCI is derived from the equation, IVCCI= (IVCD max -IVCD min)/IVCD max × 100."
224083163|NCT01872338|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
224083164|NCT01872338|BEHAVIORAL|Treatment as usual|VA standard care for suicide prevention
224083165|NCT05586126|DRUG|Sevoflurane|sevoflurane inhalation
224083166|NCT03455699|DEVICE|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
224083167|NCT03455699|DEVICE|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
224083168|NCT03455699|DEVICE|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
224083169|NCT04733547|PROCEDURE|Placement of a central venous catheter|The right internal jugular vein is located at the first rib level under ultrasound-guidance. Using an out-of-plane technique, a needle is introduced into the lumen of the vessel. The aspiration of blood into the syringe connected to the hub of the needle confirms the placement of the needle tip in the lumen. After the syringe is detached from the needle, a guidewire is advanced into the vessel lumen through the needle. A dilator is introduced over the guidewire and subsequently is removed. Then, a central venous catheter is introduced over the guidewire into the vessel lumen through the pathway expanded by the dilator. The catheter tip is placed in the superior vena cava by inserting the catheter as far as the distance between the edge of the right transverse process of the first thoracic vertebra and the carina, which is preoperatively measured on a posteroanterior chest radiograph.
224274497|NCT01220960|OTHER|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
224274498|NCT00231582|DRUG|epirubicin|epirubicin
224274499|NCT00231582|PROCEDURE|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
224274500|NCT00231582|DRUG|paclitaxel|paclitaxel
224274501|NCT00231582|DRUG|etoposide|etoposide
224274502|NCT00231582|DRUG|ifosfamide|ifosfamide
224274503|NCT00231582|DRUG|carboplatin|carboplatin
224274504|NCT05063591|OTHER|Transfusion support|Patients will be offered symptom-driven transfusion support in addition to standard hospice care
224274505|NCT06476782|OTHER|Motor Relearning Program(MRP) and aerobic exercise|Participants of this group received training for a total of 8 weeks in the form of 3 sessions per week each session of 40 minutes, with a total of 24 sessions.
223518772|NCT04102514|BEHAVIORAL|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
223518773|NCT06432322|DRUG|Esketamine nasal spray|Nasal spray solution, 56mg (28mg per nostril), intranasal
223518774|NCT06432322|OTHER|Placebo|Nasal spray solution, 0.9% NaCl, intranasal
223518775|NCT02383823|DRUG|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
223518776|NCT02383823|OTHER|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
223518777|NCT03761641|OTHER|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics \& eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face \&cushion between the skin \& eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, \& dilation velocity. Total pupil dilation testing time is \< 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position \& movement velocity during these tests. Total saccade-tracking testing takes \< 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
223518778|NCT06035094|BEHAVIORAL|Exercise Intervention to improve overall Brain Health|"During each exercise session, the participant will be assigned to the HIIT or MIT exercise group and asked to ride the stationary bicycle for approximately 30-40 minutes, while wearing the heart rate monitor and recording the session on their smart phone application. For each exercise session, the Polar Beat application will record the time in each of four intensity zones. The participant will receive training on how to use the outlined schedule during the initial supervised training session."
223518779|NCT01689649|DRUG|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
223518780|NCT00835549|DRUG|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
223518781|NCT00835549|DRUG|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
223518782|NCT03298334|BIOLOGICAL|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
223518783|NCT03298334|OTHER|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
223518784|NCT05078710|DRUG|Telitacicept|160mg once a week for 24 weeks
223518785|NCT04360330|RADIATION|Stereotactic Ablative Breast Radiotherapy|"Preoperative SABER: Participants will be treated with an assigned dose level of preoperative SABER, delivered in once a day, 5 fractions given on non-consecutive days, over a period of 2 weeks. In this phase I study, starting with dose level II, a dose level of preoperative SABER will be assigned per study dose-escalation design, treating 2 to 6 patients per dose level. The tested doses are the following:~* Dose Level I: 35 Gy (5 fractions of 7 Gy)~* Dose Level II (Starting Dose): 40 Gy (5 fractions of 8 Gy)~* Dose Level III: 45 Gy (5 fractions of 9 Gy)~* Dose Level IV: 50 Gy (5 fractions of 10 Gy)"
223518786|NCT00835042|DRUG|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
224274506|NCT06476782|OTHER|Motor Relearning Program(MRP)|the week 8 session was held in which patients were involved in 60-minute activities that involved practicing functional tasks without explicitly giving any type of relationship between those learned skills and the remedial tasks.
224274507|NCT00221520|DRUG|midazolam with 2 different levels of sedation scores|
224274508|NCT02759380|OTHER|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
224274509|NCT01021501|DRUG|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
223518787|NCT00835042|DRUG|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
223518788|NCT00619918|DRUG|Nebulized 3% saline|4 ml inhaled q8h
223518789|NCT00619918|DRUG|Nebulized 0.9% saline|normal saline
223518790|NCT06140420|DRUG|Naltrexone Oral Product|Generic, oral tablet.
224274510|NCT00000562|PROCEDURE|extracorporeal membrane oxygenation|
223518791|NCT06140420|DRUG|Placebo|Oral Placebo
223518792|NCT04169009|BIOLOGICAL|Zostavax|Intradermal injection of Zostavax
223518793|NCT04169009|BIOLOGICAL|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
223518794|NCT03492385|DRUG|PB2452 Infusion|30 minute - 12 hour infusion
223518795|NCT03492385|DRUG|Placebo - Sodium Chloride|30 minute - 12 hour infusion
224274511|NCT04285073|DEVICE|Paclitaxel-eluting graft|Implantation of e-PTFE Grafts inner surface-treated with paclitaxel as access for hemodialysis
223518796|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
223518797|NCT03492385|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
223518798|NCT05041699|COMBINATION_PRODUCT|IPM Ring-105|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
223518799|NCT05041699|COMBINATION_PRODUCT|IPM Ring-106|DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
223518800|NCT03617939|PROCEDURE|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
223518801|NCT03617939|OTHER|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
223518802|NCT03617939|OTHER|Medical Chart Reviews|Data taken directly from the patients' medical charts.
223518803|NCT06138158|PROCEDURE|Exercise and Education Group|Physical exercise and pain education
223518804|NCT03118505|DEVICE|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
223518805|NCT03118505|DEVICE|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
223518806|NCT02891954|DRUG|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
223518807|NCT05700721|DRUG|Niraparib|Given by PO
223518808|NCT05700721|DRUG|Dostarlimab|Given by IV (vein)
223518809|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF5993 pMDI
223518810|NCT05018598|DRUG|Administration via pressurized metered dose inhaler (pMDI)|CHF1535 pMDI or CHF5993 pMDI
224274512|NCT01577173|DRUG|MEHD7945A|1100 mg iv every 2 weeks
224274513|NCT01577173|DRUG|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
224274514|NCT03792139|DRUG|LY3200882|Administered orally.
224274515|NCT03792139|DRUG|Itraconazole|Administered orally.
224274516|NCT01380522|DRUG|Metronidazole|Capsules, single-dose, fed
224274517|NCT01380522|DRUG|Flagyl|Capsules, single-dose, fed
224274518|NCT00046839|DRUG|celecoxib|
224274519|NCT00046839|RADIATION|radiation therapy|
224274520|NCT02472639|DEVICE|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
224274521|NCT02472639|OTHER|No Ostom-i Alert Sensor|Patient will not use device
224274522|NCT00496067|DEVICE|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
223518811|NCT03920982|DIAGNOSTIC_TEST|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
223518812|NCT05829330|OTHER|Outpatient|Outpatient Initiation of noninvasive mechanical ventilation
223518813|NCT05829330|OTHER|Hospitalization|Initiation of non-invasive mechanical ventilation during hospitalization
223518814|NCT04989218|DRUG|Novel combination of chemotherapy and immunotherapy|This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
223518815|NCT06076213|DRUG|Artesunate-amodiaquine|Tablets
223518816|NCT06076213|DRUG|Artemether-lumefantrine|Tablets
223518817|NCT03415048|OTHER|No Intervention|
223518818|NCT05662722|OTHER|percutaneous needle electrolysis|It´s an intervention of physiotherapy. It´s an invasive technique.
223518819|NCT05662722|OTHER|Dry needling|It´s an intervention of physiotherapy. It´s an invasive technique.
223518820|NCT05662722|OTHER|Sham needling|It´s an intervention of physiotherapy. It´s an invasive technique simulation.
223518821|NCT06215508|OTHER|Questionnaires|Questionnaires participants fill out at different study visits
223518822|NCT04724252|DRUG|Gabapentin|Determine if the peri and post operative use of gabapentin in children reduces the need for narcotics after surgery.
223518823|NCT04724252|OTHER|Placebo|Control Arm
223518824|NCT03702738|DRUG|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
223518825|NCT05158699|DRUG|Bromfenac|Bromfenac topical eye drops (Yellox)
223518826|NCT05158699|DRUG|Dexamethasone|Dexamethasone topical eye drops
223518827|NCT05158699|DRUG|Triamcinolone Acetonide|0.25ml of 40mg/ml (10mg) triamcinolone acetonide (Triesence/Vistrec) will be injected subconjunctivally
224274523|NCT02918058|OTHER|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
224274524|NCT03542734|OTHER|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
224274525|NCT03867916|BEHAVIORAL|Patient Navigation Program|Use patient navigation program
224274526|NCT03867916|OTHER|Quality-of-Life Assessment|Ancillary studies
224274527|NCT03867916|OTHER|Survey Administration|Ancillary studies
224274528|NCT04645186|DEVICE|bone graft substitute|Filling bone defects in current clinical practice
224274529|NCT05975112|DIAGNOSTIC_TEST|Coagulation tests (TEG, Levels of F1, F2, hs-D-dimer, Plasminogen, PAI 1+2), SpHb before discharge|Coagulation tests named earlier as well as SpHb
224274530|NCT02339038|DRUG|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
224274531|NCT00999115|DRUG|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
224274532|NCT00702507|DRUG|0.25 % Miconazole Nitrate Ointment|Topical Application
224274533|NCT04848207|DEVICE|Digital impression technique|3D printed generic Scan bodies with unified shape and length replacing the traditional transfer copings will be press fitted on the trans-mucosal abutments and pickup cylinders that are screwed on the implants to capture their position and intra-oral scanning will be done.
223518828|NCT05158699|DRUG|Ketorolac-Phenylephrine Ophthalmic 0.3%-1% Intraocular Solution|Omidria is added to the irrigation fluid used during cataract surgery. At the end of surgery, the anterior chamber will be filled with the ketorolac solution.
223518829|NCT05531149|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
223518830|NCT05531149|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
223518831|NCT06451458|BEHAVIORAL|ECHO program for DMMC|For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
223518832|NCT06451458|BEHAVIORAL|Usual care|The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
223518833|NCT03100461|OTHER|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
223518834|NCT03100461|OTHER|Health Education|Standard of care approach that will provide basic information on CRC screening.
223518835|NCT06316999|DIAGNOSTIC_TEST|Intestinal Ultrasound|Transabdominal and trans perineal ultrasound of the pouch
223518836|NCT05632601|DIAGNOSTIC_TEST|PET scan|PET scan
223518837|NCT05995600|DRUG|Antiplatelet Drug|Clopidogrel ± other antiplatelet drug
223518838|NCT05995600|DRUG|Warfarin|Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
223518839|NCT03042975|OTHER|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
223518840|NCT03042975|PROCEDURE|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
223518841|NCT06449547|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
223518842|NCT03168529|DRUG|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
223518843|NCT03168529|DRUG|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
223518844|NCT04522739|DRUG|Spironolactone|Study participants will receive a 25 mg dose of spironolactone. Participants will take one capsule by mouth per day for 12 months.
223518845|NCT04522739|DRUG|Placebo|A placebo to match spironolactone will be taken orally once per day for 12 months.
223518846|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
223518847|NCT04463914|BEHAVIORAL|Behavioral Activation Therapy app + EHR|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
223518848|NCT04463914|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
223518849|NCT03396861|DRUG|Aflibercept|Subconjunctival aflibercept
223518850|NCT06640504|DIAGNOSTIC_TEST|serum albumin|Serum albumin ratios were calculated as the ratio between the estimated blood lactate, and serum levels of CRP and PCT divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR), CRP-to-albumin ratio (CAR) and procalcitonin (PCT)-to-albumin ratio (PAR).
223518851|NCT06640504|DIAGNOSTIC_TEST|C-Reactive Protein|The serum levels of C-reactive protein (CRP) are divided by the estimated serum albumin level to get the CRP-to-albumin ratio (CAR).
223518852|NCT06640504|DIAGNOSTIC_TEST|Serum procalcitonin|The serum levels of procalcitonin (PCT) are divided by the estimated serum albumin level to get the PCT-to-albumin ratio (PAR).
223518853|NCT06640504|DRUG|Blood Lactate|The serum levels of blood lactate are divided by the estimated serum albumin level to get the lactate-to-albumin ratio (LAR).
223518854|NCT06637644|DEVICE|Right-sided ventricular assist device|Percutaneous device for right heart support
223518855|NCT05524948|OTHER|Experimental Dentifrice|Dentifrice containing 0.454% stannous fluoride with 0.3% zinc chloride.
223518856|NCT05524948|OTHER|Reference Dentifrice|Standard fluoride dentifrice containing 0.243% sodium fluoride.
223518857|NCT05155085|DRUG|AK002|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
223518858|NCT05155085|OTHER|Placebo|Placebo
224083170|NCT04733547|DEVICE|Monitoring of central venous pressure|Following the placement of a central venous catheter, a fluid-filled system for monitoring central venous pressure is connected to the proximal lumen of the catheter. The reference transducer is placed at the level of 4/5 of the anteroposterior diameter of the thorax.
224274534|NCT04848207|OTHER|Open tray impression technique|"Transfer copings will be screwed to the multiunit abutments on the existing implants, and splinted together using pre-cured printed resin splinting framework that will be fixed to the copings using flowable composite .~A one step impression technique using putty and light addition silicon will be made, where light impression material will be injected all around transfer copings and putty silicon will be loaded in tray and then will be seated intra-orally making sure to fully expose the screws of transfer copings through the impression material."
224274535|NCT01213407|DRUG|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
224274536|NCT01213407|DRUG|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
224274537|NCT03599583|BEHAVIORAL|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
224274538|NCT04385511|DEVICE|supraglottic jet ventilation|patients who were randomized into supraglottic jet ventilation group would be placed Wei Nasal Jet Tube after conducted. Then they will get the supraglottic jet ventilation to make sure their pulse oximetry is over 95%. After 3 minutes, endotracheal intubation was performed via mouth approach.
224274539|NCT01534754|DRUG|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
224274540|NCT01534754|DRUG|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
224274541|NCT01534754|DRUG|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
224274542|NCT01534754|DRUG|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
224274543|NCT01199653|PROCEDURE|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
224274544|NCT01199653|PROCEDURE|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
224274545|NCT00082160|BEHAVIORAL|Meditation|
224274546|NCT00082160|PROCEDURE|Functional Magnetic Resonance Imaging|
224274547|NCT05390255|DRUG|Mometasone furoate nasal spray hormone|This group of patients received mometasone furoate nasal spray hormone treatment throughout the study.
224274548|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + oral hormone|The patients in this group were given oral hormone therapy for 14 days in the first month and the fourth month under the background of mometasone furoate nasal spray hormone treatment throughout the course.
224274549|NCT05390255|DRUG|Mometasone furoate nasal spray hormone + omalizumab|The patients in this group were injected with omalizumab once a month under the background of mometasone furoate nasal spray hormone treatment, for a total of 6 times.
224274550|NCT00960596|BEHAVIORAL|Health promotion and health education for smoking habits|We provide the education to intervention group.
224274551|NCT02308696|BEHAVIORAL|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
224274552|NCT02308696|BEHAVIORAL|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
224274553|NCT01176981|DRUG|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
224274554|NCT00013364|BEHAVIORAL|Talker variability|
224274555|NCT02201316|DRUG|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
224274556|NCT02201316|DRUG|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
224274557|NCT02201316|DRUG|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
223518859|NCT06639373|OTHER|Specialized clinical service access|A new model of addiction care that will offer comprehensive and coordinated service delivery
223518860|NCT06640348|OTHER|No intervention|No intervention
223518861|NCT06640686|OTHER|Exercise training|Inspiratory muscle training for increase strength of inspiratory muscle.
223518862|NCT06643078|DRUG|HL231 Solution for Inhalation|HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
224274558|NCT06533215|OTHER|antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.|"The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml)."
224274559|NCT02805517|DEVICE|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 12 mm trocars.
224274560|NCT03969108|DRUG|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
224274561|NCT04806763|DEVICE|Menicon Z Night|To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
224274562|NCT04806763|DEVICE|Control|Distance, single-vision glasses were used as control
224274563|NCT05529576|DRUG|Omega 3 fatty acid|Omega-3 fatty acids complementation according to the patient's CRP level
224274564|NCT06180395|OTHER|Group 1|"consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
224274565|NCT06180395|OTHER|Group 2|"consisted of 38 children with CP classified to level IV and V according to GMFCS. then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL)."
224274566|NCT01211262|DRUG|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
224274567|NCT04965233|BEHAVIORAL|DNA reports|The personalized DNA lifestyle reports cover the following topics: Healthy weight, Vitamin D, Alcohol, Lactose, Injuries, Caffeine, Fitness, Carbohydrates, The mind, Vitamin B, The senses, and Omega.
224274568|NCT04965233|BEHAVIORAL|Information reports|Reports containing general information on eczema
224274569|NCT04207333|BEHAVIORAL|Mental Arithmetic Test|The researcher will call out a four-digit number and ask the participant to subtract either 7 or 13. Each minute, a new four-digit number will be called out and the participant must subtract the 7 or 13 from the number. The test will last approximately 5 minutes
224274570|NCT04702789|DRUG|Dorzolamide-timolol-brimonidine and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
224274571|NCT04702789|DRUG|Dorzolamide-timolol and latanoprost|Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
224274572|NCT04396392|BEHAVIORAL|VR-based training|"All interventions will be home-based and self-guided. The participants will work on the interventions after school hours at home.~All participants will be randomized into four groups (see Figure 1). All participants will receive an introduction module, with information tailored to their study group. Parents will receive an introduction module with information about the study group their adolescents belong to."
224274573|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
224274574|NCT02346825|BEHAVIORAL|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
224274575|NCT02346825|BEHAVIORAL|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
224274576|NCT03619330|DRUG|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
224274577|NCT03619330|DRUG|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
224274578|NCT05456022|DRUG|Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one|"Appearance (Color) Conforms Yellow Appearance (Form) Powder~1H NMR Spectrum Conforms to Structure Loss on Drying \< 4 % \_ Purity (HPLC) \> 95 %"
224274579|NCT05456022|DRUG|Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT)|Nano QUT will prepared by PLGA-PEG nanocomposites that will be prepared by an oil-in-water (O/W) single emulsion solvent evaporation method
224274580|NCT05456022|DRUG|Doxorubicin chemotherapeutic drug as a positive control|Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2
224274581|NCT04989244|BEHAVIORAL|Weight loss program|Women with obesity were included to the weight loss program which included physical exercise and dietary guidelines
224274582|NCT02382601|RADIATION|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
224274583|NCT02382601|RADIATION|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
224274584|NCT02382601|PROCEDURE|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
224274585|NCT02382601|BEHAVIORAL|Neurological Function Assessment|Neurological development tests including a Bayley exam, Mullen exam, Developmental Profile-3, Child Behavior Checklist, and Pediatric Stroke Outcome Measure (PSOM) will be performed.
224274586|NCT02382601|PROCEDURE|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
224274587|NCT02382601|PROCEDURE|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
224274588|NCT02382601|RADIATION|Pediatric heart ultrasound|Children will have ultrasounds of their hearts during follow-up visits.
224274589|NCT02584166|BEHAVIORAL|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
224274590|NCT06213792|OTHER|Adaptation of the VOR|Subjects will undergo adaptation of their VOR in virtual reality in two different conditions. The side on which the adaptation will take place and the type of condition with which the patients will start will be randomized. Subject will undergo passive rapid head movements done by an experienced examinator whilst fixing a target in front of them. The movement of the target relative to the movement of the head will increase every 90 seconds by 10% until the movement of the visual scene is twice that of the head movement. In one condition the visual scene will be only a target in a grey void. In the other condition the visual scene will be more complex and represent a target in the room in which the subject is seated. Subjects will undergo both conditions at least 7 days apart.
224274591|NCT03057535|DRUG|Sodium Bicarbonate|
224274592|NCT03057535|DRUG|Sodium Chloride|
223518863|NCT06643078|DRUG|Ultibro 110μg/50 μg|Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
223518864|NCT06640205|PROCEDURE|pulpotomy|Removal of coronal pulp tissue and then placing pulpotomy agent
223518865|NCT06640777|DRUG|LEAF-4L6715|LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
223518866|NCT06640777|DRUG|Supportive Care|Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
224274593|NCT01740934|OTHER|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
224274594|NCT01740934|OTHER|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
224274595|NCT00421863|DRUG|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274596|NCT00421863|DRUG|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274597|NCT00421863|DRUG|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274598|NCT00421863|DRUG|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274599|NCT00421863|DRUG|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274600|NCT00421863|DRUG|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
223518867|NCT06638554|BEHAVIORAL|Active Choice|The participant will be send a letter inviting them to complete a SDM visit either in-person or via telehealth.
223518868|NCT06638554|BEHAVIORAL|Telehealth Only|The participant will be send a letter inviting them to complete a SDM visit via telehealth only.
223518869|NCT06638554|BEHAVIORAL|Low Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging.
224274601|NCT00421863|DRUG|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274602|NCT00421863|DRUG|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274603|NCT00421863|DRUG|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
224274604|NCT05260203|DEVICE|RITA (App)|"The RITA Remote Intelligence for Therapeutic Adherence application was designed, on the doctor's side, as a support for the management of the onco-hematological patient and, on the patient's side, as a first aid tool for the management of the most common problems, as well as an efficient and non-invasive means of communication with the doctor. The system also allows the caregiver and general practitioner to be included in the communication group.~The added value of the app consists in improving the relationship between the patient and the doctor, creating an effective communication channel, increasing the safety the patient has when facing his difficult path, reducing the number of visits to the facility and, in general, making those visits more efficient, thus creating savings both in terms of time and resources."
224274605|NCT01277510|DRUG|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
224274606|NCT01277510|DRUG|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
224274607|NCT01277510|DRUG|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
223518870|NCT06638554|BEHAVIORAL|High Touch Strategy|Patient will be sent asynchronous text messaging reminders encouraging SDM for LCS using framed messaging in combination with synchronous telephone-based digital care coordination.
224274608|NCT04768114|BEHAVIORAL|Genetically-Informed RiskProfile|"* Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing."
224274609|NCT04768114|OTHER|Brief Cessation Advice|"* Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing."
224274610|NCT03941795|BIOLOGICAL|JS001(Toripalimab Injection)|"Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years."
224274611|NCT03941795|DRUG|Axitinib 1 MG [Inlyta]|Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
224274612|NCT03941795|OTHER|JS001 and Axitinib|"Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years"
224274613|NCT01194908|DRUG|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
224274614|NCT01151696|DRUG|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
224274615|NCT01151696|DRUG|Placebo|Placebo
224274616|NCT02768974|DRUG|OPRX-106|Oral delivery, once daily.
224274617|NCT02143596|OTHER|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
223518871|NCT06642844|DRUG|Avastin, 25 Mg/mL Intravenous Solution|"Experimental group/ Patients randomized to the experimental group of the trial will receive bevacizumab as an IV infusion at a dose of 10 mg/kg, administered in 2 preparations of 5 mg/kg, every 2 weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity.~Control group: Patients randomized to the control group of the trial will receive bevacizumab at a dose of 5 mg/kg and placebo (NaCl) every two weeks. Patients will receive treatment until progression, patient refusal, or unacceptable toxicity."
224274618|NCT05079555|DEVICE|Robotic rehab|Patients using the robotic platform SWalker
224274619|NCT00000623|DRUG|Deferoxamine|
224274620|NCT00000623|DRUG|Deferiprone|
224274621|NCT00000623|DRUG|Arginine|
224274622|NCT00000623|DRUG|Sildenafil|
224274623|NCT00000623|DRUG|Decitabine|
224274624|NCT02323555|OTHER|Paramedic telephone consultation|
224274625|NCT02810223|BIOLOGICAL|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
224274626|NCT05727579|OTHER|Salt-Diet and/or Ertugliflozin|The interventions consist of an determined amount of dietary sodium intake in combination with either Ertugliflozin 15mg once daily or placebo
224274627|NCT03144479|PROCEDURE|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
224274628|NCT06348277|BEHAVIORAL|Mindfulness plus mood monitoring|mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
224274629|NCT06348277|BEHAVIORAL|Mood monitoring|mobile app that prompts for mood monitoring three times per day
224274630|NCT03710551|OTHER|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
224274631|NCT03710551|OTHER|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
224274632|NCT01321177|BEHAVIORAL|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model"
224274633|NCT01321177|BEHAVIORAL|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management"
224274634|NCT02686567|PROCEDURE|with TDT|After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
224274635|NCT02686567|PROCEDURE|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
224274636|NCT02086838|DRUG|Theragran Hematinic|
223518872|NCT06637982|PROCEDURE|ridge splitting with the use of allograft and pericardium membrane|ridge splitting with the use of allograft and pericardium membrane
224274637|NCT02086838|DRUG|low molecular weight iron dextran|
223518873|NCT06637982|PROCEDURE|ridge splitting with the use of extended platelet rich fibrin|ridge splitting with the use of extended platelet rich fibrin
223518874|NCT06638086|DRUG|Acetaminophen Suppositories|Per rectal suppositories
223518875|NCT06638086|DRUG|Acetaminophen Injection|Intra-venous injection
223518876|NCT06645392|DEVICE|visual transparent bladed trocar of|visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm
223518877|NCT06645392|DEVICE|Ternamian bladeless trocar|Ternamian bladeless trocar of diameter 10 mm
223518878|NCT06644105|DRUG|cefditoren pivoxil tablets|took cefditoren pivoxil tablets 200mg after
223518879|NCT06643221|BEHAVIORAL|Exercise|After an initial maximal graded exercise test to determine maximal oxygen uptake and peak cycling power, healthy participants will undergo a 20-minute graded exercise test at intensities corresponding to 50, 60, 70 and 80% VO2max (5-minutes per stage)
223518880|NCT06643221|DRUG|Isoproterenol|To determine if pharmacological activation of beta-adrenergic receptors evokes an immune respponse akin to exercise, healthy participants will receive an intravenous infusion of isoproterenol (50ng/kg/min)
223518881|NCT06643221|DRUG|Placebo|Healthy participants will consume the placebo 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
223518882|NCT06643221|DRUG|Bisoprolol Fumarate Tablet 10 mg|Healthy participants will consume a 10mg Bisoprolol Fumerate tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
223518883|NCT06643221|DRUG|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|Healthy participants will consume a 80mg Nadolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
223518884|NCT06643221|DRUG|Carvedilol 50 mg|Healthy participants will consume a 50mg Carvedilol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
223518885|NCT06643221|DRUG|Roflumilast 500 Mcg Oral Tablet|Healthy participants will consume a 500mcg Roflumilast tablet and a 10mg Bisoprolol tablet 2-3h prior to completing a 20-minute graded exercise test at intensities ranging from 50-80-% of the maximal oxygen uptake
223518886|NCT06643182|OTHER|Back Support|When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
223518887|NCT06643806|BEHAVIORAL|CHAI dyad study|In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
223518888|NCT06644313|DRUG|Vebreltinib|Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
223518889|NCT04878471|DRUG|Pudexacianinium chloride|Intravenous
223518890|NCT04878471|DRUG|Placebo|Intravenous
223518891|NCT06527872|OTHER|None (Observational study)|Not Applicable since Observational Study
223518892|NCT02914886|DRUG|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
223518893|NCT02914886|DRUG|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
223518894|NCT00595075|DRUG|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
223518895|NCT00595075|DRUG|placebo|placebo identical in appearance to active experimental drug x 1 dose
223518896|NCT06560346|OTHER|Geneticlly confirmed disease causing FXN mutatuion|No intervention in this observational Natural History Study
223518897|NCT06560346|OTHER|Healthy Control|No intervention in this observational Natural History Study
223518898|NCT03060707|DRUG|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
223518899|NCT00607477|DRUG|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
223518900|NCT00607477|DRUG|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
223518901|NCT03884920|DIETARY_SUPPLEMENT|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
223518902|NCT01156467|DEVICE|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
223518903|NCT01156467|DEVICE|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
223518904|NCT00248235|BEHAVIORAL|Exercise|
223518905|NCT04246944|PROCEDURE|harvesting induced membrane|The induced membrane will be harvested during the second step of the bone reconstruction.
223518906|NCT01462747|DEVICE|KULIST|Twice daily dosing for 8 weeks
223518907|NCT02228330|PROCEDURE|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
223518908|NCT05429411|OTHER|Silicone gel|At the selected treatment sites the participants will wear the gels for 4 hours for the first 2 days, 8 hours for the second 2 days with a gradual increase of at least 2 hours/day until they reach \>21 hours/day. Once the graduate progression has been completed the gel sheet will be applied daily by the subjects for as close to 21+ hours as possible. The gel will be removed for exercise and treatment interventions as well as personal hygiene
223518909|NCT02489487|DRUG|VM-1500|VM-1500 40 mg
223518910|NCT02489487|DRUG|Darunavir|Darunavir 600 mg
223518911|NCT02489487|DRUG|Ritonavir|Ritonavir 100 mg
223518912|NCT02489487|DRUG|Raltegravir|400 mg Raltegravir
223518913|NCT06063681|DRUG|SR-8541A|orally administered ENPP1 inhibitor
223518914|NCT06063681|DRUG|Immune checkpoint inhibitor (ICI)|The ICI will be either nivolumab or pembrolizumab.
223518915|NCT03864328|DRUG|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
224274638|NCT06678594|PROCEDURE|Calcium modification|"Patients will undergo one or more of the following procedures, subject to the algorithm:~Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy"
224274639|NCT04526080|DEVICE|TheraBionic Device|Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 6-week treatment period will be considered a cycle of treatment. For subjects who are randomized to the active arm, the device will be programmed with hepatocellular carcinoma-specific modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
224274640|NCT04526080|DEVICE|Placebo Device|Subjects who are randomized to receive placebo, will receive the same instructions and a similar device. The placebo device will look and sound the same as the active device, but will not deliver the modulation frequencies. For subjects randomized to the placebo arm, the device will not emit any hepatocellular carcinoma-modulation frequencies and will be activated for more than 200 one-hour treatment sessions.
224274641|NCT03750591|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
224274642|NCT03750591|PROCEDURE|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
224274643|NCT03750591|PROCEDURE|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
224274644|NCT03750591|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
224274645|NCT03750591|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
224274646|NCT03750591|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
224274647|NCT03750591|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
224274648|NCT03750591|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
224274649|NCT03711357|RADIATION|980 nm diode laser|980 nm high power diode laser device.
224274650|NCT03711357|OTHER|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
224274651|NCT01711801|DRUG|Placebo|Single ascending dose
224274652|NCT01711801|DRUG|RO5545965|Single ascending dose
224274653|NCT01711801|DRUG|RO5545965|Single dose, in fed and fasted state
224274654|NCT03407222|OTHER|Text messages|Text messages which encourage the increment of daily step count
224274655|NCT03980522|DRUG|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult participants (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as 2 subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric participants (6 to \<18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as 2 subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL.~Participants considered to be 'treatment responders' will be offered participation in an optional 18-week extension period (EP) in which KPL-914 can be continued for a total duration of KPL-914 treatment of up to 24 weeks."
224274656|NCT03335241|DRUG|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
224274657|NCT03335241|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
224274658|NCT05721092|OTHER|Pre and Post Education on practice of pneumococcal vaccination|A cross-sectional study will be conducted among 25 diabetologists in each of the four zones in India representing all directions - North, East, West and South. Diabetologists will be selected through purposive sampling. A semi-structured questionnaire (study tool) is designed based on the existing literature that addresses our objectives. An education session on Pneumococcal vaccination will be conducted for the diabetologists through webinar after completing the survey. A post assessment will be done using the same questionnaire among the study participants after the education session in order to see an increase in the knowledge of pneumococcal vaccination.
223518916|NCT03864328|DRUG|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
223518917|NCT05739162|DEVICE|Apollo Endoscopic Suture System|Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.
223518918|NCT05739162|BEHAVIORAL|Lifestyle Intervention|Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
223518919|NCT05848232|DEVICE|coraFlex Catheter|The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
223518920|NCT05848232|DEVICE|coraForce Catheter|The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
223518921|NCT05848232|DEVICE|coraCross Catheter|The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
223518922|NCT06253312|PROCEDURE|Open surgery|Patients with complex TASC C and D aortoiliac occlusive disease undergoing open surgery: aortobifemoral bypass, crossover bypass, axillobifemoral bypass, aortoiliac endarterectomy, iliofemoral bypass
223518923|NCT06253312|PROCEDURE|Hybrid repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing simultaneous open surgical femoral artery reconstruction (endarterectomy, bypass, profundoplasty) and stenting of the iliac axis
223518924|NCT06253312|PROCEDURE|Endovascular repair|Patients with complex TASC C and D aortoiliac occlusive disease undergoing total endovascular repair using different material: bare metal stents (self and balloon expandable), stent-grafts (self and balloon expandable), covered endovascular reconstruction of aortic bifurcation (CERAB), simple plain old balloon angioplasty (POBA)
223518925|NCT00408174|DRUG|Balsalazide disodium|
223518926|NCT00413712|DRUG|Calcium Channel Blocker & Adenosine|
223518927|NCT00718731|DRUG|GSI-136|
223518928|NCT00718731|OTHER|Placebo|
223518929|NCT02372357|DRUG|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
223518930|NCT02372357|PROCEDURE|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
223518931|NCT02524899|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
223518932|NCT02524899|DRUG|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
223518933|NCT02524899|DRUG|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
223518934|NCT01171079|DEVICE|application of oxidized regenerated cellulose|
223518935|NCT02096354|DRUG|RRx-001|
224274659|NCT00769496|DRUG|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
224274660|NCT05654363|PROCEDURE|Administration of morphine by intrathecal route|Lumbar puncture was performed before the induction of general anesthesia, in the operating room. Spinal anesthesia was performed in sitting position using a midline approach into the L3-L4 or L4-L5 interspaces with a 25ga pencil-point spinal needle administering 75-100 mcg morphine, with or without local anesthetic (levobupivacaine 0,5% 10-15 mg or bupivacaine 0,5% 10-15 mg or ropivacaine 0,5% 10-15 mg), depending on the anesthesiologist's preference. General anesthesia was then conducted according to clinical practice. All patients were transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery. Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
223518936|NCT02096354|DRUG|Regorafenib|
223518937|NCT02096354|DRUG|Irinotecan|To be dosed after RRx-001 or regorafenib
223518938|NCT03715829|DRUG|PF-06651600|Induction dose 1. Oral tablet taken QD
223518939|NCT03715829|DRUG|PF-06651600|Induction dose 2. Oral tablet taken QD
223518940|NCT03715829|DRUG|PF-06651600|Maintenance dose A. Oral tablet taken QD
223518941|NCT03715829|DRUG|PF-06651600|Maintenance Dose B. Oral tablet taken QD
223518942|NCT03715829|DRUG|PF-06651600|Maintenance Dose C. Oral tablet taken QD
223518943|NCT03715829|DRUG|placebo|placebo
223518944|NCT03715829|DRUG|PF06700841|Oral tablet taken QD
223518945|NCT03715829|DEVICE|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
223518946|NCT06538350|OTHER|Telemedicine Consultation|Telemedicine intervention will be delivered via Zoom and Video WhatsApp platforms via a secure internet connection.
223518947|NCT06538350|OTHER|Face-to-Face Consultation|Face-to-Face consultation according to the standard of care.
223518948|NCT00764426|DRUG|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
223518949|NCT00764426|DRUG|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
223518950|NCT04106635|PROCEDURE|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
223518951|NCT04106635|PROCEDURE|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
223518952|NCT01338597|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
223518953|NCT00001784|DRUG|Mexiletine|
223518954|NCT01800110|DIETARY_SUPPLEMENT|pomegranate juice|
223518955|NCT05032222|OTHER|Uroflowmetry|Diagnostic test
223518956|NCT03422887|DRUG|Nalbuphine|Nalbuphine administration during surgery
223518957|NCT03422887|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
223518958|NCT03422887|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
223518959|NCT04903769|BEHAVIORAL|Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)|SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
223518960|NCT04593745|DEVICE|Intraocular pressure measurment|Intraocular pressure measurmentt using iCare devise: TONOPEN
223518961|NCT03579719|DRUG|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
224274661|NCT05654363|PROCEDURE|Administration of morphine by intravenous route|General anesthesia was conducted according to clinical practice and a morphine bolus was administered before emergence from anesthesia according to clinical needs. All patients were then transferred in the Post-Anesthesia Care Unit (PACU) at the end of surgery and received Patient-Controlled Analgesia (PCA) with morphine 1mg/mL (CADD®-Solis 2110 Infusion System, Smiths Medical ASD, Inc., USA, 1 mL bolus on demand, no background infusion, 7 minute lockout, max 8 mg/h). Throughout the first 48 postoperative hours, all patients were regularly evaluated in the hospital ward by a member of the Acute Pain Service Team.
223518962|NCT03579719|DRUG|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
223518963|NCT00202241|PROCEDURE|testosterone injection|
223518964|NCT03747237|OTHER|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
223518965|NCT01173003|DRUG|Mifepristone, misoprostol|
223518966|NCT05295953|DEVICE|TBS|Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
223518967|NCT05295953|DEVICE|Sham TMS|Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
223518968|NCT05313958|DRUG|Cladribine|5mg/㎡/day d1-5 in 2 hours, before the use of Cytarabine
223518969|NCT05313958|DRUG|G-CSF|5ug/kg/day d0-5,if Peripheral blood leukocytes\<20,000/ul
223518970|NCT05313958|DRUG|Cytarabine|2g/㎡/day d1-5 in 4 hours, after the use of Cladribine
223518971|NCT05313958|DRUG|Idarubicin|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
223518972|NCT05313958|DRUG|Mitoxantrone|Idarubicin 10mg/m2/day or mitoxantrone 10mg/m2/day on day 1-3 in the induction therapy II
223518973|NCT05313958|DRUG|Sorafenib|200mg/m2/day was taken orally until molecular biology remission for 2 years
223518974|NCT03576820|DRUG|Lidocaine|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
223518975|NCT03576820|DRUG|Placebo|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
223518976|NCT04407117|BEHAVIORAL|Lock-down and social distancing|Lock-down and social distancing during COVID-19 pandemic
223518977|NCT05459779|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.
223518978|NCT05459779|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
223518979|NCT06214325|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, a minimum of 24 hours apart, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
223518980|NCT01455844|DRUG|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
223518981|NCT01455844|OTHER|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
223518982|NCT01455844|DRUG|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
223518983|NCT05720351|PROCEDURE|Lachmann maneuver|Patients undergone the Lachmann recruitment maneuver (30 CmH2O PEEP for 30 seconds)
223518984|NCT05720351|PROCEDURE|Staircase maneuver|Patients undergone Undergone staircase recruitment maneuver (stepped increase in PEEP by 2 CmH2O every five breaths until reach upper deflection point
223518985|NCT05249660|OTHER|Soft tissue release technique|Patient sat on a chair. The therapist stood behind the participant and held one hand over head as the support, with the thumb of the other hand scan to detect the painful area of the latent TP of the upper trapezius muscle along the fibers. Then, pressure was applied by the thumb and the participant was asked to simultaneously actively change the muscle from shorted position to elongated state (ipsilateral side flexion of the cervical to the opposite side). This technique was repeated 3-5 times per session, and each repetition was maintained for 40-60 s till release is felt, with a 15-second rest interval. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
223518986|NCT05249660|OTHER|Comparator: Instrument assisted soft tissue mobilization|Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
223518987|NCT00400322|DRUG|Valganciclovir (Valcyte)|
223518988|NCT00400322|OTHER|Placebo|
223518989|NCT03071302|OTHER|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
223518990|NCT01071785|DIETARY_SUPPLEMENT|guar gum|guar gum 10g/day for six weeks
223518991|NCT01917370|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
223518992|NCT00389480|DRUG|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
224274662|NCT02077335|RADIATION|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~* V100 \> 95%~* V150 30-35%~* V200 \< 15%~* D90 \> 90% (12,15Gy)~Bladder~• V75 \< 1cc~Rectum~• V75 \< 1cc~Urethra~V125 = 0cc D10 \< 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
224274663|NCT06447441|OTHER|Placebo|Enteral supplementation of placebo in 3 consecutive days within 96 hours after ICU admission.
224274664|NCT06447441|OTHER|Cholecalciferol|Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
224274665|NCT04641403|PROCEDURE|The surgeon performed Laparoscopic-assisted TAP (LTAP) block|After the induction of anesthesia, the first port will be inserted through the umbilicus and a 12 mmHg pneumoperitoneum will establish as a standard. Under the direct view of the laparoscopic camera, the block will be performed by inserting a 22-G needle just above the iliac crest through the midclavicular line posteriorly into the triangle of Petit and then inserting the needle below the costal arch through the midclavicular line towards the anterior axillary line into the subcostal plane. The block needle will be advanced under direct view until the two pops were felt and the extraperitoneal space will reach without puncturing the parietal peritoneum, and pulling back the needle 0.5 cm, the area of the thin transversus abdominis muscle fibers wiil be infiltrated. In this area, the correct plane of the needle tip will confirm by observing Doyle's bulge and the spread of the local anesthetic.
224274666|NCT04892147|BEHAVIORAL|Mobility-Oriented Behavioral Activation|12-weeks of mobility-oriented behavioral activation group
224274667|NCT06403150|DRUG|Levetiracetam Injection|Levetiracetam at 60 mg/kg (max dose 4500 mg) will be intravenously administered in 100mL of normal saline at an administration rate of 2-5mg/kg/min or over 10 minutes. After 30 minutes following Levetiracetam needle time reassessment of the patient will be done to determine the outcomes.
224274668|NCT06403150|DRUG|Fosphenytoin Injection|Fosphenytoin at 20 mg/kg (Phenytoin equivalent dose of 15 mg/kg) will be intravenously administered in 100mL of normal saline at an administration rate not exceeding 3mg/kg/min or 150 mg/min. After 30 minutes following the Fosphenytoin needle time reassessment of the patient will be done to determine the outcomes.
224274669|NCT00498264|BEHAVIORAL|walking program, resistance muscular exercise|
224274670|NCT06627985|DIAGNOSTIC_TEST|GPT-4o|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
224274671|NCT06627985|DIAGNOSTIC_TEST|GPT-4o mini|Input all patient medical records, including text, examination reports, and imaging data, into GPT-4o mini. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
224274672|NCT06627985|DIAGNOSTIC_TEST|MedicalGPT|Input all patient medical records, including text, examination reports, and imaging data, into MedicalGPT. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
224274673|NCT06627985|DIAGNOSTIC_TEST|Claude-3.5 Sonnet|Input all patient medical records, including text, examination reports, and imaging data, into Claude-3.5 Sonnet. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
223518993|NCT00855166|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
223518994|NCT00855166|DRUG|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
223518995|NCT00855166|DRUG|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
223518996|NCT00855166|DRUG|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
223518997|NCT01269437|DRUG|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
223518998|NCT04942327|BEHAVIORAL|Interview|This will be evaluated through a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phases.
223518999|NCT01422382|DRUG|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
224274674|NCT06627985|DIAGNOSTIC_TEST|Claude 3 Haiku|Input all patient medical records, including text, examination reports, and imaging data, into Claude 3 Haiku. Use pre-tested prompts to establish department roles, enabling it to provide diagnostic and treatment recommendations pertinent to the respective department.
224274675|NCT06627985|DIAGNOSTIC_TEST|Real Doctors|Retrospectively collect the diagnostic and treatment recommendations from the corresponding departments involved in the multidisciplinary treatment of past patients, as well as the overall recommendations.
224274676|NCT00111696|BIOLOGICAL|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
223519000|NCT01422382|DRUG|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
223519001|NCT04115254|RADIATION|MR-guided Linac|Radiation will be delivered on an MR-guided Linear Accelerator
223519002|NCT06190236|BEHAVIORAL|Stand-alone web-based cognitive behavioral therapy (CBT4CBT) for alcohol use disorder|CBT4CBT is a 7-module web-delivered program based on CBT, an evidence-based behavioral treatment for alcohol use disorder (AUD).
223519003|NCT03917498|RADIATION|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
223519004|NCT03286569|DEVICE|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
223519005|NCT01854762|DRUG|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
223519006|NCT01854762|DRUG|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
223519007|NCT04818229|DRUG|CBP-307|CBP-307 capsules oral administration.
223519008|NCT04818229|DRUG|Placebo-matched CBP-307|Placebo-matched CBP-307 capsules oral administration.
223519009|NCT04818229|DRUG|Moxifloxacin (Avelox)|Moxifloxacin tablets oral administration。
223519010|NCT04818229|DRUG|Placebo-matched Moxifloxacin|Placebo-matched Moxifloxacin tablets oral administration.
223519011|NCT04082364|BIOLOGICAL|margetuximab|margetuximab: Fc-modified anti-HER2 monoclonal antibody: 15 mg/kg IV, Day1 of each 3-week cycle
223519012|NCT04082364|BIOLOGICAL|Retifanlimab|Retifanlimab: anti-PD-1 checkpoint inhibitor 375 mg IV, Day 1 of each 3-week cycle.
223519013|NCT04082364|BIOLOGICAL|Tebotelimab|Tebotelimab: anti PD-1, anti-LAG3 bispecific DART (R) molecule 600 mg IV, Day 1 of each 3-week cycle.
223519014|NCT04082364|BIOLOGICAL|Trastuzumab|Anti-HER2 monoclonal antibody 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3-week cycle
223519015|NCT04082364|OTHER|Chemotherapy|"Investigator choice of 1 of 2 chemotherapy regimens: XELOX or mFOLFOX6~Chemotherapy~XELOX chemotherapy Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion~mFOLFOX6 chemotherapy: Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion."
223519016|NCT03186378|COMBINATION_PRODUCT|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
223519017|NCT02486770|BIOLOGICAL|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
223519018|NCT02486770|BIOLOGICAL|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
223519019|NCT02486770|BIOLOGICAL|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
223519020|NCT06199999|PROCEDURE|Erector Spinae Block|General anesthesia with Erector Spinae Plane Block
223519021|NCT06199999|PROCEDURE|Local infiltration with local anesthetic|General anesthesia with local infiltration of local anesthetic:
224274677|NCT04542746|PROCEDURE|Minimally invasive surgical technique|After local anesthesia , for the sites of test group , a minimally invasive surgical technique (MIST) will be performed. The defects associated inter-dental papilla will be surgically approached with a diagonal incision following the pattern of the simplified papilla preservation flap. Flap elevation was to the buccal and oral aspect in the interdental space, An enamel matrix derivative (EMD) was applied into the defect.f A primary closure of the interdental papillae will be achieved using a 5-0 monofilament non resorbable suturing material.
223519022|NCT00265642|DRUG|Irbesartan|one tablet of 150 mg/d during 2 years
223519023|NCT00265642|DRUG|placebo|one tablet per day during 2 years
223519024|NCT00045331|GENETIC|proteomic profiling|
223519025|NCT06229873|DEVICE|App-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by a smartphone application. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. All training sessions will be guided by the smartphone application.
223519026|NCT06229873|DEVICE|Clinic-Based Inspiratory Muscle Strength Training|Participants will perform inspiratory muscle strength training guided by researchers. Participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, 6 days a week, for 6 weeks. One training session each week will be performed in the research clinic.
223519027|NCT02181413|DRUG|Ixazomib Citrate|Ixazomib citrate capsules
223519028|NCT02181413|DRUG|Placebo|Ixazomib citrate placebo-matching capsules
223519029|NCT02514746|BIOLOGICAL|Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine|0.5 mL subcutaneous injection
223519030|NCT06048497|DEVICE|Corrected carotid flow time measurement guided fluid preload|Preoperative FTcs of pregnant women who underwent C/S operation were measured, and those below the cut-off value (327 ms) determined in previous studies were preloaded with Ringer Lactate until FTc was \> 327 ms.
223519031|NCT04669093|BEHAVIORAL|"Placebo cream- promotion suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a promotion approach (promoting good feelings)."
223519032|NCT04669093|BEHAVIORAL|"Placebo cream- prevention suggestion"|"Over-the-counter hand cream will be applied to participants' skin, but they will be told that they are given a highly efficient topical analgesic cream. The suggestion will be based on a prevention approach (preventing pain)."
223519033|NCT04669093|BEHAVIORAL|Control cream|In a control condition, with the same cream as in the placebo interventions, participants will be instructed that the cream is a control cream with no effects.
223519034|NCT01375140|DRUG|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
223519035|NCT01375140|DRUG|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
223519036|NCT01375140|DRUG|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
223519037|NCT00772525|DRUG|Nerispirdine|"form: tablet~Route: oral"
223519038|NCT00772525|DRUG|Placebo|"form: tablet~Route: oral"
223519039|NCT01924065|PROCEDURE|Cardioversion|Electrical cardioversion
223519040|NCT01924065|DRUG|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
223519041|NCT05838716|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223519042|NCT05838716|DIETARY_SUPPLEMENT|D Vitamin|Given PO
223519043|NCT05838716|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
223519044|NCT05838716|DRUG|Placebo Administration|Given PO
223519045|NCT05838716|OTHER|Quality-of-Life Assessment|Ancillary studies
223519046|NCT05838716|OTHER|Questionnaire Administration|Ancillary studies
224274678|NCT01554111|DRUG|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
224274679|NCT01554111|DRUG|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
224274680|NCT01554111|DRUG|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
224274681|NCT00338390|DRUG|Abacavir|Change tenofovir to abacavir
224274682|NCT00338390|DRUG|Didanosine|Increase didanosine dose to 400 mg/day if weight is \> 60 Kg. or to 250mg/day if weight is \< 60 kg.
224274683|NCT00338390|DRUG|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
224274684|NCT05263505|DRUG|Baricitinib 2 MG [Olumiant]|Two tabs daily
224274685|NCT05263505|DRUG|Methotrexate|Target dose: 20mg weekly
224274686|NCT05263505|DRUG|Azathioprine|Target dose: 2mg/kg daily
224274687|NCT05263505|DRUG|Mycophenolate|Target Dose: 1g twice daily
224274688|NCT03501420|OTHER|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
224274689|NCT03501420|OTHER|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
224274690|NCT03501420|OTHER|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
223519047|NCT06645600|DIAGNOSTIC_TEST|Fracture risk|To calculate fracture risk, the percentages for major and hip fracture risks will be calculated using the Fracture Risk Assessment Tool (FRAX®). The one-leg stance test, used to assess static posture and balance, and the 30-second sit-to-stand test, used to evaluate endurance and lower extremity strength, will be applied to the patients.
223519048|NCT03984578|DRUG|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
223519049|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
223519050|NCT03984578|DRUG|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
223519051|NCT03984578|DRUG|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
223519052|NCT03984578|DRUG|CAPEOX/Pembrolizumab|"* Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle.~* IV Oxaliplatin: 130mg/m2 on Day 1 of a 3-week cycle.~* Pembrolizumab: IV infusion of 200mg on Day 1 of a 3-week cycle."
223519053|NCT03984578|DRUG|Pembrolizumab alone|IV infusion of 200mg 21 days from the last CAPEOX/Pembrolizumab combination dose.
223519054|NCT03984578|PROCEDURE|Surgical resection|Performed after all medical intervention.
223519055|NCT06308770|BEHAVIORAL|Standard Care|Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.
223519056|NCT06308770|BEHAVIORAL|4 week FMP|Participants attend 3 once weekly live online group interventions with a final intervention 8 weeks later.
223519057|NCT06308770|BEHAVIORAL|7 week FMP|Participants attend 6 once weekly live online group interventions with a final intervention 8 weeks later.
223519058|NCT03555994|DRUG|MEDI0382|MEDI0382 administered subcutaneously
223519059|NCT03555994|DRUG|Placebo|Placebo administered subcutaneously
223519060|NCT03555994|DRUG|Liraglutide|Liraglutide administered subcutaneously
224274691|NCT05826301|OTHER|Percutaneous neuromodulation in tibial nerve|The procedure consisted in the application of a square wave biphasic electrical current, with 2-4 Hz frequency, 450 μs pulse during 25 minutes with a needle (0.30mm x 40 mm) inserted proximal to the surface on the tibial nerve.
224274692|NCT05826301|OTHER|Percutaneous electrolysis|"The procedure consist on placed a needle (0.30mm x 40 mm) on the most hyperalgesic plantar fascia location with a galvanic current of 3mA, 3 times during 3 seconds.~1 time per weeK"
224274693|NCT05568758|OTHER|Thoracic lymphatic pump technique|The subject lies in the supine position; the therapist stands at the patient's head, facing the subject. The therapist then, places the thenar eminence of each hand to the pectoral region inferior to the clavicle and the other fingers are spread around the thoracic cage and angled toward the body's side to create a consistent, compressive force across the thoracic cage. The subject is then asked to breathe in deeply and breathe out. While breathing out, rhythmic oscillatory compression in the posterior and caudal direction is applied to the chest wall. By the end of the expiratory phase, the compressive force is maintained, and the subject is asked to take another deep breath. In this way, the subject encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver is repeated for five respiratory cycles, after that the therapist slowly reduces the compressive force and withdraws his hands.
224274694|NCT05568758|OTHER|Exercises (stretching and strenghtening )|"stretching exercises include: Hamstring stretching exercises~Lower back stretching exercises :~strenghtening exercises include:~Abdominal curl up exercises :~Supine bridging exercises. Trunk extension exercises"
224274695|NCT06662617|OTHER|modified thoracoabdominal nerve block through perichondrial approach|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
223519061|NCT05035628|OTHER|Cardiopulmonary exercise training|"Participants will follow a 2-month exercise training program, thrice-weekly trainings. The training sessions will start with a 5-min warmup, followed by an aerobic training (20 min) after which 20-min of resistance/muscular training will take place. The program will end with respiratory exercises and cool down period (10 min). Training will be adapted to individuals' baseline capacity as measured by the baseline cardiorespiratory test.~A certified kinesiologist will supervise trainings. Heart rate, oxygen saturation and rating of perceived exertion (Borg Scale, 6-20) will be measured during training sessions."
223519062|NCT06123468|DRUG|Sacituzumab govitecan|10 mg/kg i.v. at day 1 and day 8 of each 21-day cycle (Q3W) for max 17 cycles (max. 12 months treatment)
224274696|NCT06662617|OTHER|Transversus Abdominal Plane block|After the patient fell asleep, surgery was not yet started. Following sterile conditions for bilateral TAP block application, USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline . After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
224274697|NCT01157598|DEVICE|bispectral index monitoring|parameter monitoring of bispectral index
224274698|NCT00176891|PROCEDURE|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
224274699|NCT00176891|DRUG|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
224274700|NCT01085669|DEVICE|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
224274701|NCT03439995|OTHER|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
224274702|NCT03439995|OTHER|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
224274703|NCT02459886|DRUG|BIIB054|IV infusion
224274704|NCT02459886|DRUG|Placebo|IV infusion
224274705|NCT00862212|BEHAVIORAL|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
224274706|NCT00001217|DRUG|pre-surgical chemotherapy|
224274707|NCT02825316|BEHAVIORAL|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
224274708|NCT02825316|BEHAVIORAL|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
224274709|NCT04436718|DIAGNOSTIC_TEST|Daily pocus exam|Daily evaluation of lung ultrasound for B line artifacts plus IVC assessments
224274710|NCT04554264|OTHER|questionnaire|Inventory of Complicate Grief (ICG) score in relative from patients who died in ICU after SARS-Cov2 infection. This is the most commonly used assessment tool for complicated grief which focuses on different symptoms than depression or anxiety. A score \> 25 indicate complicated grief.
224274711|NCT04987749|DEVICE|intermittent theta burst stimulation|stimulatory protocol
224274712|NCT03041532|PROCEDURE|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
224274713|NCT03041532|PROCEDURE|Frontal view|The investigator explore twice right colon with frontal viewing
224274714|NCT00730652|BIOLOGICAL|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
224274715|NCT03428945|DRUG|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
224274716|NCT03428945|DRUG|Placebo|Placebo tablet identical to active drug
224274717|NCT03827005|DIETARY_SUPPLEMENT|L-arginine|NOW Foods, Bloomingdale, IL
224274718|NCT03827005|DIETARY_SUPPLEMENT|Placebo|InHealth Specialty Pharmacy, Fargo, ND
224274719|NCT01953172|DIETARY_SUPPLEMENT|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
224274720|NCT01953172|OTHER|Placebo|Placebo
224274721|NCT04753541|OTHER|no intervention|this is not an interventional study
224274722|NCT03455036|OTHER|Whole body vibration training|10 x 1 min whole body vibration exposure
224274723|NCT04883788|OTHER|Pandemic period|Perioperative care (nursing and physiotherapy) provided to patients treated with hip and knee replacement during the pandemic period
224274724|NCT02672761|BEHAVIORAL|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
223519063|NCT03724097|OTHER|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
223519064|NCT03724097|OTHER|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
223519065|NCT03724097|DRUG|target drug with the score above 0,1|target drug with the score above 0,1
224274725|NCT02672761|BEHAVIORAL|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
224274726|NCT02672761|BEHAVIORAL|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
224274727|NCT02672761|BEHAVIORAL|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
224274728|NCT02086617|OTHER|ultrasound of aorta|
224274729|NCT03432273|DRUG|Nicotine lozenge|Nicotine mint lozenge, 2 mg
224274730|NCT03432273|DRUG|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
224274731|NCT05380050|BEHAVIORAL|Goal Management Training plus Attention Training|GMT is a Power Point directed interactive group training to use a five point strategy to plan and execute complex tasks. Attention Training utilizes Brain HQ attention modules and individualized attention goals.
224274732|NCT05380050|BEHAVIORAL|Brain Health Workshop and National Geographic Movies|BHW is a Power Point directed interactive training to learn about the brain and cognitive components. National Geographic Movies, participants select movies to watch with the therapists and answers questions regarding the content.
223519066|NCT03724097|DRUG|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
223519067|NCT03724097|DRUG|non-target drug|non-target drug
223519068|NCT03724097|DRUG|palliative care|palliative care
223519069|NCT00112307|PROCEDURE|Brachytherapy|
223519070|NCT05399433|OTHER|Biopsy and venous blood|"A skin biopsy will be performed under local anesthesia in diabetic and non-diabetic psoriatic patients (25 per group) in the injured area (joint extension) and in the non-injured area more than 2 cm from any lesion in the same area. In patients in the diabetic or non-diabetic control group (25 per group) only one biopsy will be performed.~Peripheral venous blood will be collected in heparin tubes for metabolic parameter analysis and blood CD analysis"
223519071|NCT06541249|DRUG|Methotrexate (MTX)|MTX has recently been identified as a dose-dependent JAK/STAT pathway inhibitor. 15mg will be given once a week orally.
223519072|NCT05346809|DRUG|Isatuximab|Isatuximab in IV form 10 mg/kg doses
223519073|NCT05346809|OTHER|Standard Procedures|Standard procedures (standard of care) for transplant
223519074|NCT05967455|BIOLOGICAL|Dengue virus 1 Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
223519075|NCT05967455|BIOLOGICAL|Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)|Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489
224274733|NCT02311517|DRUG|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
224274734|NCT02311517|DRUG|Normal Saline|
224274735|NCT05107739|BIOLOGICAL|Drug Product De-TIL-0255|Autologous tumor-infiltrating lymphocytes
224274736|NCT03888534|DRUG|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
224274737|NCT05377294|OTHER|Method of Levels therapy|MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
224274738|NCT01597349|DRUG|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
224274739|NCT03900039|DEVICE|Highly Cross Linked Polyethylene and oxidized zirconium femoral head|"Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads"
224274740|NCT02571257|DRUG|Gemcabene|1-300 mg tablet, QD, 56 days
224274741|NCT02571257|DRUG|Gemcabene|3-300 mg tablets, QD, 56 days
224274742|NCT02571257|DRUG|Placebo|
223519076|NCT03973489|BEHAVIORAL|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
223519077|NCT03973489|DRUG|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
223519078|NCT03973489|DRUG|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
223519079|NCT02113813|DRUG|naquotinib|oral
223519080|NCT02113813|DRUG|midazolam|oral
223519081|NCT06308237|OTHER|RESISTED EXERCISES|"Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions."
223519082|NCT06308237|OTHER|BALANCE EXERCISES|"Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes."
223519083|NCT05135260|BEHAVIORAL|Virtual reality therapy|Participants will watch a video allowing them to view nature, dinosaurs, animals, and human interactions in three dimensions during a session lasting 11 minutes.
223519084|NCT05135260|BEHAVIORAL|Questionnaires|Questionnaires will be completed regarding stress, pain and affect
223519085|NCT05135260|PROCEDURE|Measure heart rate|To be measured prior to starting treatment and halfway through the 11 minute Video
223519086|NCT05135260|BEHAVIORAL|Cyber sickness measurement|To be measured using the fast motion sickness scale
223519087|NCT04012710|PROCEDURE|Laparoscopy|Conventional abdominal laparoscopy
223519088|NCT04012710|PROCEDURE|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
223519089|NCT05936736|RADIATION|prostate SBRT|Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
223519090|NCT06168734|DRUG|Cefepime-taniborbactam|Cefepime-taniborbactam administered 2.5g q8h intravenously (IV) over a 4-hour period for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
223519091|NCT06168734|DRUG|Meropenem|Meropenem will be administered 2g q8h IV over 4 hours for 7 days to 14 days at the investigator's discretion. Dose adjustments for renal function may apply.
223519092|NCT06137807|DEVICE|TricValve® Transcatheter Bicaval Valve System|The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The system is a single use, sterile device compatible with all the valve sizes. The valves are premounted in the TricValve® Delivery System. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system available in sizes 25 and 29 for superior vena cava and 31 and 35 for inferior vena cava. The valve is implanted percutaneously by the transfemoral approach. The valves are supplied already premounted into the TricValve® Delivery System.
223519093|NCT06472791|DIETARY_SUPPLEMENT|Centella Asiatica|Centella Asiatica is a perennial, herbaceous plant that is sold as a dietary supplement in the United States under the name Gotu Kola. It has been used for centuries in Ayurvedic and Chinese medicine. Evidence suggests it may help with resilience to aging and cognitive decline. The product for this study will be produced by Arjuna Natural.
223519094|NCT06472791|DIETARY_SUPPLEMENT|Placebo Comparator|The comparator will contain microcystalline cellulose in matched capsules. The comparator product for this study will be produced by Arjuna Natural.
223519095|NCT04105634|DRUG|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
223519096|NCT04105634|DRUG|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
223519097|NCT06381791|DRUG|Epidiolex|150mg of Epidiolex
223519098|NCT06381791|DRUG|Placebo oral solution|150mg of Placebo oral solution
223519099|NCT04046419|OTHER|Turkish validity and reliability|"1. Explanation of the Turkish version of the scale.~2. Translating the Turkish version of the scale into English to ensure consistency with the original scale.~3. First application of scales to participants.~4. Second application of the scales to the participants.~5. Statistical analysis and scaling"
223519100|NCT01635530|DRUG|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
223519101|NCT01635530|DRUG|Ceftriaxone|2 g intravenous once a day, three weeks
223519102|NCT03301415|DRUG|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
223519103|NCT03247673|DRUG|CT-P16|CT-P16 is a biosimilar product for Avastin
223519104|NCT03247673|DRUG|EU-approved Avastin|EU-approved Avastin
224274743|NCT02287220|DEVICE|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
223519105|NCT03247673|DRUG|US-licensed Avastin|US-licensed Avastin
223519106|NCT04912518|DRUG|Dexmedetomidine (DEX)|The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
223519107|NCT04912518|DRUG|Placebo (Saline)|The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
223519108|NCT02113280|PROCEDURE|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
223519109|NCT02113280|PROCEDURE|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
223519110|NCT01111552|DRUG|Escitalopram|Escitalopram oral capsules.
223519111|NCT01111552|DRUG|Aripiprazole|Aripiprazole oral capsules.
223519112|NCT01111552|DRUG|Placebo|Study drug matching placebo capsule.
223519113|NCT00919360|PROCEDURE|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
224274744|NCT02050165|DIETARY_SUPPLEMENT|KIND Bars|Consumption of KIND Bars for 12 weeks
224274745|NCT02050165|DIETARY_SUPPLEMENT|Typical American Snack|Consumption of typical American snacks for 12 weeks
224274746|NCT00000380|DRUG|GHRH|
224274747|NCT01598896|DRUG|Dronabinol|Dronabinol titrated to 5 mg three times daily
223519114|NCT00919360|PROCEDURE|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
223519115|NCT00919360|PROCEDURE|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
223519116|NCT00919360|PROCEDURE|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
223519117|NCT05584631|DRUG|Intravenous immune globulin G|Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.
223519118|NCT05584631|DRUG|Subcutaneous immune globulin G|Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.
223519119|NCT03434886|OTHER|CFView|Registry patient portal
223519120|NCT03434886|OTHER|CF educational videos|CF educational videos
223519121|NCT04670315|DIAGNOSTIC_TEST|Telematic evaluation of motor function|Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
223519122|NCT06083571|DRUG|Ketorolac|Non-inferiority
223519123|NCT06083571|DRUG|Prochlorperazine|Adjunct
223519124|NCT06083571|DRUG|Diphenhydramine|Adjunct
223519125|NCT04071535|DEVICE|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
223519126|NCT00345280|PROCEDURE|impression cytology, obtain the tear fluid|Vitamin A
223519127|NCT06641258|OTHER|Control Group (Standard Procedure)|"Application in Control Group: After the theoretical lesson, the nurses in the control group determined and classified the pressure injuries in their patients using the  Braden Risk Assessment Scale, which has been accepted as valid and reliable. The nurses in the control group, who determined the pressure injuries using the scale, were given training on the determination and classification of pressure injuries using written material, the content of which was prepared by the researchers. After the training, the Satisfaction with the Training Method Survey was applied to the nurses. One week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied. After the completion of the application, volunteer nurses from the control group were subjected to pressure injury detection and classification with the deep learning model and trained with the mobile application."
223519128|NCT06641258|OTHER|Experimental Group|"Application in the Experimental Group: After the theoretical course, the nurses in the experimental group detected and classified pressure injuries in their patients with the Deep Learning Model. In the experimental group, a mobile application developed by the researchers was installed on the phones of the nurses who detected pressure injuries using the deep learning model and training was applied. Thus, the nurses were provided with the patient's care and treatment according to the developed mobile application according to the pressure injury stage detected by the deep learning model. After the training, the Satisfaction Survey with the Training Method was applied to the nurses. 1 week after the training, the nurses were given the Post-Test ( Modified Pieper Pressure Sore Knowledge Test) was applied"
223519129|NCT02976688|OTHER|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
223519130|NCT04743063|DRUG|sacubitril/valsartan|Initiation of sacubitril/valsartan, identified using prescription fill in pharmacy claims
223519131|NCT04743063|DRUG|Angiotensin II Receptor Blockers|Initiation of ARBs, identified using prescription fill in pharmacy claims
223519132|NCT06085638|DRUG|Azacitidine|Given by SC (under the skin) or IV (vein)
223519133|NCT06085638|DRUG|Tamibarotene|Given by PO
223519134|NCT06085638|DRUG|Venetoclax|"Given by PO~TAMIBAROTENE Azacitidine Azacitidine, 5-azacytidine, 5-aza, Vidaza™, 5-AZC, AZA-CR, Ladakamycin, NSC-102816, Azacytidine Venetoclax ABT-199, GDC-0199, Venetoclax"
223519135|NCT06563830|OTHER|educational application|The content of the training to be applied to nurses will include: definition of MDRPI, etiology, prevalence and cost, staging, risk factors, nursing initiatives to be implemented to prevent MDRPI.
223519136|NCT00005931|DRUG|SU5416|
223534846|NCT05589987|DEVICE|power mobility|"Sessions of adjustment, adaptation and choice of the device for training will be carried out. Once the cars are fully adapted and conditioned to the environment and needs of the family and the child, the intervention will begin.~The study will take place in the child's natural environment for 12 weeks. Three 40-minute sessions per week will be held, each session includes: 1) configuration of the environment (families will be instructed by the therapists to adapt the environment to the child's situation and their conditions for driving the car): 5 min ; 2) natural play as a warm-up activity: 5 min; and 3) mobility and social training with cars: 30 min. The 30-minute driving session will involve participants learning cause and effect concepts by driving the toy car (press the button to move and release to stop). The therapist and caregivers will use verbal cues to encourage children to drive and explore the environment. All sessions will be video and audio recorded."
223534847|NCT04794933|OTHER|Conventional therapy|
224274748|NCT01598896|DRUG|Clonidine|Clonidine 0.1 mg twice daily
224274749|NCT01598896|DRUG|Placebo|One placebo capsule by mouth twice daily
224274750|NCT02833181|DEVICE|BIS monitor|Monitoring circadian variation of EEG
224274751|NCT05198973|BEHAVIORAL|Bumblebee Breath|"Bumblebee Breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). With the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. Next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. The result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face.~this will applied half an hour daily for ( 1 month)"
223519137|NCT05444439|GENETIC|detection of vacuolating cytotoxin A (Vac A) and cytotoxin-associated gene A (Cag A) virulent H.Pylori genotypes by polymerase chain reaction amplification(PCR) in gastric biopsies :|Extraction of DNA, using Wizard® Genomic DNA Purification Kit (Promega-USA), will be done following the manufacturer instructions. For detection of vacuolating cytotoxin A and cytotoxin-associated gene A gene, polymerase chain reaction amplification will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 60˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. For detection of vacuolating cytotoxin A (S1/S2, m1, m2), PCR will be performed with a 9 minutes' initial denaturation at 94˚C, followed by 35 cycles of 1 minute at 94˚C, 45 seconds at 56˚C, and 45 seconds at 72˚C. Final extension will be performed for 5 minutes at 72˚C. Amplified DNA will be analyzed by agarose gel electrophoresis. A positive sample will give bands at DNA fragment 138-bp for cytotoxin-associated gene A, at 259/286-bp for vacuolating cytotoxin A s1/s2, and 290-bp and 352-bp for m1 \& m2, respectively
223519138|NCT05444439|DIAGNOSTIC_TEST|Culture and sensitivity of endoscopic gastric biopsies:|During endoscopy, three biopsies will be taken from antrum and/or corpus of and will be examined by rapid urease test also known as Campylobacter-like organism test (Kimberly-Clark,USA). Culture of the bacterium on Columbia agar plus 5-7% defibrinated horse or sheep blood and selective Dent supplement under microaerophilic condition at 37degree Celsius for 3-5days.
223519139|NCT05444439|OTHER|Histopathological examination endoscopic gastric biopsies:|Histological sections from the antrum and body regions will be stained with Giemsa stain. Giemsa stain working solution was prepared as follows: 40 ml Giemsa stock solution with 60 ml of distilled water. Giemsa stock solution will be prepared as follows: Giemsa powder 4 g, glycerol 250 ml and methanol 250 ml. Histological sections will be examined by a gastrointestinal pathologist to standardize the classification of gastritis. Histopathological classification will be recorded as following (acute gastritis, mild-moderate- severe chronic gastritis, Glandular atrophy or Intestinal metaplasia).
223519140|NCT05444439|PROCEDURE|Upper endoscopy|it will be done patient before start empirical therapy and multiple antrum and/or corpus biopsies will be taken . Patient will be fasting at least 8 hours.Upper and findings will be recorded in the report as presence of gastroesophageal reflux disease, diffuse or localised gastric and/or duodenal redness, mucosal swelling, atrophy of mucosa, nodularity, intestinal metaplasia, erosions or ulcers.
223519141|NCT05444439|DRUG|empirical H.pylori regimens|Start empirical antibiotics regimens patient triple therapy ((levofloxacin 400 mg once , amoxicillin 1000 mg twice for 2 weeks) and (Proton pump inhibitor twice for 1 month)). Follow up after 2 weeks after finishing regimen by Stool Ag in stool
223519142|NCT05444439|DIAGNOSTIC_TEST|H.Pylori Ag in stool|"Any symptomatic patient is above 18 years old with H pylori infection patients diagnosed by positive H pylori Ag in stool will be included.~assessment of laboratory response, 2 weeks after finishing empirical therapy."
223519143|NCT03680131|DRUG|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
223519144|NCT03680131|DRUG|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
223519145|NCT03680131|DRUG|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
223519146|NCT03680131|DRUG|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
223519147|NCT06673771|OTHER|Vestibular Rehabiliation Therapy|"Moving the eye horizontally between two stationary target while keeping the head still Moving the eye vertically between two stationary target while keeping the head still Moving the target horizontally and tracking it with the eye while keeping the head still Moving the target vertically and tracking it with the eye while keeping the head still Moving the head horizontally while a keeping a look on stationary target Moving the head vertically while a keeping a look on stationary target Moving the head and target in opposite direction horizontally while tracking the target with eyes Moving the head and target in opposite direction vertically while tracking the target with eyes.~Sit down and stand up, sit down and stand up with eye open and eye close Stand up, but turn to the right while standing Stand up, but turn to the left while standing Place an object on the floor. Take it and bring it above your head and place it on the floor again"
223519148|NCT06673771|OTHER|Conventional treatment|Standing balance training, weight shifting training, walking training, muscle strength training, step-up-and-down training.
223519149|NCT06675448|DEVICE|MitraClip|Participants will undergo the Mitraclip procedure according to current standards of practice
223519150|NCT06675448|OTHER|Moderate MR|Patients who present with moderate MR (Mitral regurgitation) will serve also as an internal control against which the outcomes of Mitraclip treated patients)
223519151|NCT07010536|BEHAVIORAL|VR-Based Music Therapy|"VR-Based Music Therapy Protocol:~Participants undergo immersive VR sessions twice weekly for 6 weeks, each lasting 30 minutes, supervised by a physiotherapist. Each session includes three 10-minute activities with 2-minute breaks:~Rhythm Exercises: Participants follow tempo by clapping on a table while watching Brooklyn Music Factory YouTube videos played within the VR headset (levels 1-4), progressing weekly.~Ocean Rift: Exploration of calming underwater environments with marine life to enhance relaxation, attention, and cognition.~PianoVision: Virtual piano exercises using hand tracking with the unaffected hand; difficulty increases from levels 0 to 4."
223519152|NCT07010536|BEHAVIORAL|Conventional Physiotherapy and Rehabilitation|"Participants will receive conventional physiotherapy and rehabilitation exercises as follows:~Upper and lower extremity strengthening exercises~Resistance training exercises~Aerobic exercises~Basic and assisted parallel bar walking~Skill courses on various surfaces~Training on stable and unstable surfaces~Static and dynamic balance exercises~Fine motor skill exercises~Weight transfer exercises to improve postural stability~Exercises will be performed according to the patient's condition in standing, sitting, four-point kneeling, supine, and prone positions.~Exercise difficulty will be adjusted based on the patient's performance and functional level.~Sessions will be 60 minutes long, 5 days per week, for 6 weeks."
223519153|NCT06687239|DIAGNOSTIC_TEST|Blinded estimation of fetal weight|Blinded ultrasound-based estimation of fetal weight
223519154|NCT06687239|DIAGNOSTIC_TEST|Non blinded estimation of fetal weight|Non-blinded ultrasound-based estimation of fetal weight
223519155|NCT06695962|DRUG|Domperidone 10mg|30 mg per day for 21 days
223519156|NCT06695962|DRUG|Placebo|3 per day for 21 days
223519157|NCT06695962|DIAGNOSTIC_TEST|gastric emptying test|gastric emptying test
223519158|NCT06690697|DRUG|JS004|200 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
223519159|NCT06690697|DRUG|Toripalimab|240 mg, ivdrip, D1, Q3W, each 21 days as a treatment cycle
223519160|NCT06690697|DRUG|Axitinib|5 mg, po, bid, each 21 days as a treatment cycle
223519161|NCT06690697|DRUG|Sorafenib|0.4 g, po, bid, each 21 days as a treatment cycle
223519162|NCT03227575|BEHAVIORAL|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
223519163|NCT06694519|DEVICE|manometry through the PHENIX series device (model: PHENIX LIBERTY; manufacturer: ELECTRONIC CONCEPT LIGNON INNOVATION, Montpelier, France).|For this manometry the air probe, connected to the Phenix biofeedback system, covered by a latex probe cover lubricated with gel, will be used. In the procedure, the labia majora are opened with one hand and slowly rotated into the vagina while holding the back of the manometric probe with the other hand. Basal tone in g will be measured prior to pelvic floor muscles force measurements. The manometry probe will extract pelvic floor pressure signals by measuring both your basal tone and the maximum pressure held for 10 seconds in three measurements, the average of the three being calculated at the command, 'contract as hard as you can for as long as possible'.
223519164|NCT06694519|DIAGNOSTIC_TEST|PFIQ-20 questionnaire (Pelvic Floor Impact Questionnaire Short Form)|This questionnaire allows assessment of the impact of urinary symptoms, colo-rectal-anal symptoms and genital prolapse symptoms. This questionnaire will also be used as an inclusion criterion, to homogenise the characteristics of the population in terms of pelvic dysfunction prior to the intervention, as indicated above.
224274752|NCT04202484|DRUG|Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules|Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
224274753|NCT04231292|DRUG|RD01|RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
224274754|NCT04231292|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
224274755|NCT04231292|DRUG|placebo|placebo
223519165|NCT06694519|DIAGNOSTIC_TEST|ICIQ-SF (International Consultation on Incontinence Questionnaire - Short Form)|a four-question self-administered questionnaire that identifies individuals with urinary incontinence by assessing frequency, severity and impact on quality of life. It is composed of five questions assessing frequency, severity and impact of UI, plus a set of eight self-diagnostic items related to UI situations experienced by patients. The maximum sum of the response values indicates a score of 21 points, referring to the high impact of UI on an individual's life.
223519166|NCT06694519|DIAGNOSTIC_TEST|Sandvik's test|It provides information on the severity of the UI by means of two questions. The interpretation based on the score is classified as: 1-2 mild UI, 3-6 moderate UI, 8-9 severe UI, 12 very severe UI.
223519167|NCT06694519|DIAGNOSTIC_TEST|vaginal health index (VHI)|this index consists of a graduated scale from 1 to 5 for each item (vaginal elasticity, fluid volume, pH, epithelial integrity and moisture).Vaginal elasticity ranges from 1 (no elasticity) to 5 (excellent elasticity), assessed by distension of the mucosa on palpation and speculum placement. The volume of fluid, assessed during inspection, varies between 1 (no discharge) and 5 (normal discharge) (white flocculent). The integrity of the epithelium varies between 1 (petechiae already detected on inspection) and 5 (non-friable tissue and normal mucosa). Moisture ranges from 1 (no moisture detected on inspection and presence of inflamed mucosa) to 5 (normal moisture). The pH will be quantified using a pH indicator strip between 0 and 14 (MColorpHast™-PH indicator strips) to be placed directly on the right lateral vaginal wall for one minute, giving 1 point for pH 6.1, 2 for pH 5.6-6.0, 3 for pH 5.1-5.5, 4 for pH 4.7-5.0 and 5 for pH ≤ 4.6. The sum of all items represents the vaginal health
223519168|NCT06694519|DIAGNOSTIC_TEST|Visual analogue scale (VAS)|This scale allows the intensity of pain described by the patient to be measured with maximum reproducibility between observers. It consists of a horizontal line of 10 centimetres, at the ends of which are the extreme expressions of a symptom. At the left end is the absence or lowest intensity and at the right end the highest intensity. The patient is asked to mark on the line the point that indicates the intensity of the pain during sexual intercourse and it is measured with a millimetres ruler. The intensity is expressed in centimetres or millimetres. The rating will be: 1 Mild pain if the patient scores the pain as less than 3; 2 Moderate pain if the rating is between 4 and 7; 3 Severe pain if the rating is equal to or greater than 8.
223519169|NCT06694519|DIAGNOSTIC_TEST|Body Image Scale (S-BIS)|It consists of 10 items assessing various dimensions of body image in cancer patients, evaluating: affective, behavioural and cognitive. The items are scored on a four-point scale (0: not at all; 1: a little; 2: quite a lot; 3: a lot) with a maximum possible score of 3 points. The higher the score, the higher the body image problem. Its brevity facilitates rapid assessment in both clinical and research settings. It shows a stable factor structure between samples, and good psychometric properties with high reliability (Cronbach's alpha=0.93), suggesting that it is a suitable and useful measure for assessing body image in breast cancer patients.
223519170|NCT06694519|DIAGNOSTIC_TEST|Likert's scale questionnaire|five-point Likert scale for satisfaction with treatment to be classified as: 1 (very dissatisfied), 2 (dissatisfied), 3 (no change), 4 (satisfied), 5 (very satisfied). Women who miss any of the RF sessions and/or whose attendance at the face-to-face physiotherapy sessions (RF and/or PFMT) does not reach 80% will be considered as not complying with the study protocol and their participation will be terminated, although they will be included in the analysis (by intention to treat).
223534848|NCT04794933|OTHER|CT+ PNF in extremity pattern|
223534849|NCT04794933|OTHER|CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns|
223534850|NCT00401076|DRUG|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
224274756|NCT01715779|DRUG|Eltrombopag|Eltrombopag exposure
224274757|NCT06265038|DEVICE|ReSpace TiCell Cage|"ReSpace TiCell Cages are anatomically shaped interbody spacer implants with curved contour. These implants intended to be inserted into the intervertebral disc space for intervertebral body fusion. The interbody spacers are designed to restore height and lordotic angle in the spine. The spacers have teeth on the endplate-engaging surfaces to provide stability, resist shear and rotational forces, and to help prevent migration of the spacer within the disc space. The open central cavity on them allows for placement of graft material allowing for subsequent bone growth through the interior of the devices.~ReSpace TiCell Cages are indicated for lumbar spine stabilization (between L.I.-S.I. segments). TLIF spine surgery will be combined with posterior fixation using pedicle screws and rods."
223519171|NCT06694519|DIAGNOSTIC_TEST|Oxford's Scale|It allows the contractile capacity of the pelvic floor muscles to be assessed. It scores from 0 to 5, as follows: if there is no contraction it is 0, if the contraction is very weak it is 1, if the contraction is weak it is 2, if the contraction is moderate/with tension/and maintained it is 3, if the contraction is good and maintains tension with resistance it is 4, and if the contraction is strong and maintains tension against a resistant force it is 5.
223519172|NCT06694519|DIAGNOSTIC_TEST|Sexual function and self-esteem|The Female Sexual Function Index (FSFI) questionnaire consists of 19 items that assess sexual function over the past 4 weeks and performance in six domains: sexual desire, arousal, lubrication, orgasm, satisfaction and pain. A cut-off point ≤ 26.5 is considered sexual dysfunction and an increase in score is considered an improvement.
223519173|NCT02169258|PROCEDURE|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis \> 70% of the major epicardial vessels and bypass graft vessel or their major branches (\> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (\<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
223519174|NCT04017455|DRUG|Atezolizumab|3 cycles of atezolizumab 840 mg
223519175|NCT04017455|DRUG|Bevacizumab|3 cycles of bevacizumab 5mg/kg
223519176|NCT05145387|BEHAVIORAL|Transitioning Emotionally and Academically to Middle School Successfully (TEAMSS)|Students randomized to TEAMSS will receive reading materials on transitioning to middle school and a a school tour with the middle school clinician (in 5th grade) and the TEAMSS group sessions (in 6th grade) delivered over 10 weeks. During the 10 weeks of TEAMSS, parents of students will attend two group meetings and clinicians will consult with at least one teacher (usually the advisory/homeroom teacher).
223519177|NCT04507581|OTHER|electrical impedance tomography during anaesthesia|Before induction of the anaesthesia, before the radiological procedure when the induction is terminated, after the termination of the radiological procedure, before transport to the Post anaesthesia Care Unite (PACU), and before the discharge from the PACU after 2 hours of monitoring ventilation distribution changes by thoracic electrical impedance tomography are measured (each measurement will last 1 min). For this, resulting potential differences are measured, and impedance distribution sampled at 30 Hz will be calculated by an automated linearized Newton-Raphson reconstruction algorithm (9). Relative change in poorly ventilated lung regions (silent spaces) and end-expiratory lung impedance (EELI) and measures of ventilation inhomogeneity such as the global inhomogeneity index will be calculated as described previously, using customised software (Matlab R2013a, The MathWorks, Nattick, Massachusetts, USA)(10-12).
223519178|NCT06438003|BEHAVIORAL|Special Services|Community members will complete data collection at the extension office or community partner location. Extension cooking classes and helping to make raised bed gardens along with other area happenings will be offered to participants throughout the year with check-ins and reminders. Data will be collected from study participants (regardless of the intervention decided) , at two time points, to include survey, dietary recall, and carotenoid scanner.
223519179|NCT06438003|OTHER|Services as Usual|Community members will receive extension services as usual with Data collection on participants at two time points to assess changes in rates of food insecurity, dietary quality, and overall health conditions.
223519180|NCT06538012|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
223519181|NCT06538012|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223519182|NCT06538012|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223519183|NCT06538012|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
223519184|NCT06538012|DRUG|Pembrolizumab|Intravenous (IV) infusion
223519185|NCT05597397|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
223519186|NCT05720091|DRUG|ZX-7101A 80mg|a drug to treatment influenza in Chinese adults
223519187|NCT03682744|BIOLOGICAL|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
223519188|NCT04021368|DRUG|RVU120(SEL120)|RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
223519189|NCT06334146|OTHER|Tap dance program|Participants will take part in a weekly adapted tap dance class, for one hour per week, for eight weeks.
223519190|NCT04679987|DIAGNOSTIC_TEST|Holter ECG|all patients will be monitored for paroxysmal Af by holder ECG
223519191|NCT06124924|DRUG|SGLT2 inhibitor|a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
223519192|NCT02811614|PROCEDURE|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
223519193|NCT02811614|PROCEDURE|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
223519194|NCT02811614|PROCEDURE|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
223704108|NCT03253575|DIAGNOSTIC_TEST|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
223704109|NCT00691301|DRUG|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
223704110|NCT00691301|DRUG|pemetrexed disodium|
223704111|NCT01823146|DRUG|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
223519196|NCT06640153|DIAGNOSTIC_TEST|mpMRI|Gastroesophageal junction or upper gastric adenocarcinoma patients undergo mpMRI at siewert classification, length of esophageal involvement, primary staging and restaging
223519197|NCT02988076|DEVICE|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
223519198|NCT02686775|BEHAVIORAL|Patient coach|
223519199|NCT02686775|BEHAVIORAL|Standard care|
223519200|NCT06160167|DRUG|IMiD treatment|Participants with MM treated with IMiDs
223519201|NCT06160167|DRUG|No IMiD treatment|Participants with MM not treated with IMiDs
223519202|NCT06160167|DRUG|Systemic therapy|Participants with MM treated with systemic therapy
223519203|NCT06813378|BEHAVIORAL|(Neuro)Cognitive Remediation|(Neuro)Cognitive remediation is an intervention for people experiencing cognitive impairments that interfere with their daily functioning. Attention, memory, abstract reasoning, and processing speed are all examples of cognitive skills. By focusing on improving these underlying skills, the overall aim of cognitive remediation is to improve the client's daily satisfaction and success. Although cognitive remediation programs and strategies have been studied with other populations, it has not been sufficiently evaluated from a mental health trans-diagnostic perspective for military Veterans and police officers and retirees who this research will study.
223519204|NCT05633927|BIOLOGICAL|SARS-CoV-2 Vaccine|Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
223519205|NCT00297791|PROCEDURE|surgery|randomized to open or laparoscopic technique
223519206|NCT00431379|DRUG|Tenecteplase|
223519207|NCT03850067|DRUG|CC-90011|CC-90011
223519208|NCT03850067|DRUG|Cisplatin|Cisplatin
223519209|NCT03850067|DRUG|Carboplatin|Carboplatin
223519210|NCT03850067|DRUG|Etoposide|Etoposide
223519211|NCT03850067|DRUG|Nivolumab|Nivolumab
223519212|NCT00817609|DRUG|Angongniuhuang Pill|7 days of Angongniuhuang Pill
223519213|NCT00817609|DRUG|placebo|7 days of placebo
223519214|NCT05388487|DRUG|HF1K16 /Arm 45 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
223519215|NCT05388487|DRUG|HF1K16 /Arm 90 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
223519216|NCT05388487|DRUG|HF1K16 /Arm 120 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
223519217|NCT05388487|DRUG|HF1K16 /Arm 160 mg/m²|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
223519218|NCT05388487|DRUG|HF1K16 /Arm 120 mg or 180 mg|HF1K16 is a liposome suspension containing encapsulated ATRA. Drug concentration is 2mg/ml, and infusion should be completed between 60 minutes and 90 minutes
223519219|NCT04129398|DRUG|Letermovir tablet|A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
223519220|NCT04129398|DRUG|Letermovir IV|IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
223519221|NCT06274177|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
223519222|NCT00198900|BEHAVIORAL|survey of information|
223519223|NCT05711797|DRUG|ZX-7101A 80mg|ZX-7101A a drug to treatment influenza in Chinese adults
223519224|NCT02376010|DRUG|rivaroxaban|
223519225|NCT02376010|DRUG|Warfarin|
223519226|NCT01428635|DRUG|Eltrombopag Olamine|Given PO
223519227|NCT04473196|OTHER|weightbearing|immediate weightbearing
223519228|NCT05615883|OTHER|AEP Group Walking Sessions|The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
223519229|NCT05615883|OTHER|CEP Group Walking Sessions|The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
223519230|NCT05186233|BEHAVIORAL|Phototherapy|Light exposure recommendations provided by SHIFT mobile application
223519231|NCT04732806|BEHAVIORAL|Mightier video games|Biofeedback video game play in home
223519232|NCT02363283|DRUG|Glembatumumab Vedotin|Given IV
223519233|NCT02363283|OTHER|Laboratory Biomarker Analysis|Correlative studies
223519234|NCT02363283|OTHER|Pharmacological Study|Correlative studies
223519235|NCT03163329|PROCEDURE|TAVR|Transcatheter Aortic Valve Replacement
223519236|NCT03163329|PROCEDURE|SAVR|Surgical Aortic Valve Replacement
223519237|NCT06296355|BEHAVIORAL|Health Warning Label|"Message displayed on warning label is: WARNING: Consuming ultra-processed food and drinks can cause weight gain, which increases the risk of obesity and type 2 diabetes."
223519238|NCT06296355|BEHAVIORAL|Identity Warning Label|"Message displayed on warning label is: WARNING: Ultra-processed food."
223519239|NCT06296355|OTHER|Barcode Label|Barcode is displayed.
223519240|NCT05802836|OTHER|no interventions|no intervention, only 3 different patients groups
223519241|NCT01965951|OTHER|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
223519242|NCT01965951|OTHER|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, \~30 mins each session.
223519243|NCT02117271|DEVICE|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
223519244|NCT02117271|OTHER|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
223704112|NCT01823146|DRUG|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
223519245|NCT01254214|BEHAVIORAL|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
223519246|NCT01254214|BEHAVIORAL|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
223519247|NCT04883203|DRUG|Vit-D 0.2 MG/ML Oral Solution [Calcidol]|ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
223519248|NCT04883203|DRUG|Physiological Irrigating Solution|ARM 2 : placebo
223519249|NCT05708690|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
223519250|NCT05708690|DRUG|normal saline|Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances
223519251|NCT03743519|DIETARY_SUPPLEMENT|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
223519252|NCT03743519|DIETARY_SUPPLEMENT|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
223519253|NCT02895984|BEHAVIORAL|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
223519254|NCT04802109|DEVICE|wearing level D personal protective equipment|rubber gloves + surgical face mask + general isolation clothing
223519255|NCT04802109|DEVICE|wearing Level C personal protective equipment with N-95|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing"
223519256|NCT04802109|DEVICE|wearing Level C personal protective equipment with Powered Air-Purifying Respiratory|"C-level protective clothing+ N95 mask + disposable protective clothing (Ten Quin Medial Apparel) + foot cover + rubber gloves + mask + general isolation clothing+Powered Air-Purifying Respiratory"
223519257|NCT03362632|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
223519258|NCT04622267|DEVICE|Barbed suture|to close a C-section incision
224274758|NCT03828435|DEVICE|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
223519259|NCT04622267|PROCEDURE|Standard antimicrobial suture|to close a C-section incision
223519260|NCT06570876|PROCEDURE|Surgery|The decision between RS and CS depended on the patient's performance status; on the cyst's main characteristics and contact with liver structures; and on intraoperative findings.
223519261|NCT06569225|DRUG|Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig|: Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
223519262|NCT06569732|OTHER|Homemade oral nutrition supplements|The homemade oral nutrition supplement is made of soy milk, whey protein powder, vegetable oil, and fruit juices
223519263|NCT06569732|OTHER|Commercial oral nutrition supplements|The commercial oral nutrition supplement is kidney-specific oral nutrition supplement that is high in energy and protein, but low in electrolytes and fluid
224274759|NCT06071338|DIAGNOSTIC_TEST|Clinical Periodontal Examination|No details will be published from the clinical assessment.
223519264|NCT06565676|DIETARY_SUPPLEMENT|Bread with whey protein powder added|Volunteer participants will consume bread with and without whey powder added and its effect on blood sugar will be examined.
223519265|NCT06151418|DRUG|Novel hormonal therapy|As provided in real-world setting
223519266|NCT06230913|DEVICE|Kinesiotape|To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
223534851|NCT02507986|DEVICE|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
223519267|NCT06230913|DEVICE|Pressure garment|The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
223519268|NCT02174237|DRUG|LNP1892|Tablets of two strengths (5 and 25 mg)
223519269|NCT02174237|DRUG|Placebo|Matching placebo
223519270|NCT03829514|DRUG|Fenofibrate|40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
223519271|NCT04174482|PROCEDURE|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
223519272|NCT01339091|DRUG|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
223519273|NCT01339091|DRUG|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
223519274|NCT00661180|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
223519275|NCT03923088|BEHAVIORAL|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
223519276|NCT03923088|BEHAVIORAL|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
223519277|NCT00302822|DRUG|enfuvirtide|from week 0 to 24
223519278|NCT00302822|DRUG|emtricitabine/tenofovir|1 pill/day
223519279|NCT00302822|DRUG|lopinavir or efavirenz|investigator choice
223519280|NCT02788292|DRUG|Acetylcysteine|See arm description
224274760|NCT05276986|OTHER|DOMS protocol|For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
224274761|NCT00804999|DRUG|Clear Care|neutralized Clear Care
224274762|NCT00804999|DRUG|ReNu|overnight soak in solution
224274763|NCT00804999|DRUG|OPTI-FREE|overnight soak in solution
223519281|NCT00844220|PROCEDURE|CT/MR|CT/MRI-directed clinical management strategy
223519282|NCT00844220|PROCEDURE|Catheterization|Standard clinical management directed by conventional coronary angiography
223519283|NCT03607110|DRUG|Ketamine|sedation drugs
224274764|NCT03546738|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
223519284|NCT03607110|DRUG|fentanyl|sedation drugs
223519285|NCT03607110|DEVICE|patient control analgesia|patient control analgesia
223519286|NCT00108563|DRUG|Citalopram or Placebo|
223519287|NCT05051410|PROCEDURE|intracanal cryotherapy using needle irrigation and EndoVac system|a cold saline will be used as final irrigant in two groups but with different irrigation systems.
223519288|NCT05646173|DEVICE|vagus stimülation device|Vagustim is a wearable medical technology device that focuses on non-invasive bilateral auricular vagus nerve stimulation (VNS). VNS is a clinically approved, safe and effective neuromodulation method.
223519289|NCT05646173|DEVICE|Electrophysical agents|Electrophysical agents (EPAs) are those modalities that administer thermal, mechanical, electrical or light energy to the patient to provide physiological effects and therapeutic benefits.
223519290|NCT05646173|OTHER|home exercise program|The home exercise program will be explained to the patients by the physiotherapist and will also be given to the patient in the form of a brochure. Patients will be instructed to do the exercises regularly, three times a day for ten repetitions each day. The content of the exercises is updated weekly.
223519291|NCT01775345|PROCEDURE|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
223519292|NCT01775345|PROCEDURE|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
223534852|NCT02507986|DEVICE|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
223534853|NCT05746858|OTHER|no intervention (observational study)|No intervention (observational study)
224274765|NCT03546738|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
223519293|NCT01775345|PROCEDURE|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
223519294|NCT01775345|PROCEDURE|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
223519295|NCT04414943|DRUG|S-ketamine|For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
223519296|NCT04414943|DRUG|Placebo|For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
223519297|NCT05273736|BEHAVIORAL|5 Behavioral Change Techniques|"1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon."
223519298|NCT02779231|OTHER|Bi-directional texting|
223519299|NCT02593630|DEVICE|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
223519300|NCT01321684|OTHER|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
223519301|NCT01321684|OTHER|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
224274766|NCT03546738|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Boston Scientific will be implanted: Precision NoviTM implantable pulse generator and InfinionTM CX 16-contact lead or LinearTM ST 8-contact lead."
224274767|NCT04444141|BIOLOGICAL|AK104|The subjects will receive AK104 till disease progression or for a maximum of 24 months.
224274768|NCT03391505|BEHAVIORAL|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
224274769|NCT03391505|BEHAVIORAL|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
224274770|NCT03391505|BEHAVIORAL|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
224274771|NCT03924154|DRUG|RVT-1201|RVT-1201 600 mg immediate-release tablet
223519302|NCT00625105|BEHAVIORAL|Biofeedback|
223519303|NCT04437745|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
223519304|NCT01108874|DRUG|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
223519305|NCT00003907|DRUG|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
223519306|NCT00003907|DRUG|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
223519307|NCT00003907|DRUG|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
223519308|NCT00003907|PROCEDURE|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
223519309|NCT02649309|PROCEDURE|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
224274772|NCT03924154|DRUG|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
224274773|NCT04438434|DRUG|Filming Formulation of Hydrogen Peroxide and Hyaluronic Acid|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~The treatment to be evaluated involves mouth rinsing with 10 ml of BMG0703 three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
223519310|NCT02649309|PROCEDURE|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
223519311|NCT02649309|PROCEDURE|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
223519312|NCT02649309|PROCEDURE|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
223534854|NCT05584579|PROCEDURE|laparoscopic surgery|laparoscopic surgery
223519313|NCT04520230|DRUG|Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid|inhaled corticosteroid (ICS)plus long acting B2-agonist (LABA) (Budesonide/Formoterol combination 160/4.5 mcg, 2 inhalations bid ).
223519314|NCT04520230|DRUG|Tiotropium 18 mcg capsule inhaled once daily + Budesonide|inhaled corticosteroid (ICS) plus long acting anticholinergic (LAAC) (Tiotropium 18 mcg capsule inhaled once daily + Budesonide ).
223519315|NCT04520230|DRUG|Formoterol/Tiotropium|long acting B2-agonist (LABA) plus long acting anticholinergic (LAAC).
223519316|NCT01517178|DEVICE|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
223519317|NCT01517178|DEVICE|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
223519318|NCT01573429|OTHER|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
223519319|NCT06502028|DEVICE|Video laryngeal mask airway|The airway is secured with a video laryngeal mask airway.
223519320|NCT06502028|DEVICE|Endotracheal tube|The participant is intubated with an endotracheal tube via direct laryngoscopy.
223519321|NCT00273663|DEVICE|TCES|
223519322|NCT05529602|OTHER|conventional physical therapy|"core stability exercises~A total of 3 sessions per week were given for 15-20 minutes"
223519323|NCT05529602|OTHER|relaxation exercise|"the experimental group was given Post-isometric relaxation exercise along with core stability~A total of 3 sessions per week were given for 15-20 minutes"
223519324|NCT05249855|BEHAVIORAL|Psychological measurement|Psychological assessment
223519325|NCT04162158|BIOLOGICAL|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10'9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
223519326|NCT05663554|BEHAVIORAL|WW Intervention|The core of the WW food program is the SmartPoints® system. Briefly, the SmartPoints® system assigns each food and beverage a SmartPoints® value per volume based on four components: calories, sugar, saturated fat, and protein. Certain foods have a SmartPoints® value of zero (ZeroPoint foods). These foods (e.g., lean sources of protein such as skinless chicken breast and vegetables) form the basis of a healthy eating pattern, are at low risk for overconsumption and do not have to be weighed, measured or tracked. Participants were assigned a personalized SmartPoints® Budget, based on reported food and lifestyle preferences, and designed to create an energy deficit, using the Mifflin St-Jeor formula, which uses age, sex, height, and weight to estimate resting energy expenditure.
223519327|NCT05663554|OTHER|Usual Care|The Usual Care group will continue to receive routine medical care by their provider, in addition to receiving one 50-minute virtual on-line session of nutrition counseling with a registered dietitian, with additional materials at the time of their 6- and 12-month follow-up assessments.
223519328|NCT02553473|DRUG|Doxycycline|
223519329|NCT02553473|DRUG|Placebo|
223519330|NCT02999997|BEHAVIORAL|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
223519331|NCT00234793|BEHAVIORAL|Problem-Solving Skills Training|
223519332|NCT01557569|DRUG|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
223519333|NCT01557569|DRUG|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
223519334|NCT02256033|DRUG|Istradefylline|One 40 mg-tablet administered on Day 1
223519335|NCT04883047|OTHER|holistic birth support strategies|"Holistic Birth Support Strategies are composed of birth-supporting practices that were created by Horn and D'Angelo (2017) within the scope of the Algorithm for Coping with Birth Pain and recommended for coping with labor pain. Holistic Birth Support Strategies; It includes four parameters: physical comfort, emotional comfort, informative support and advocacy."
223519336|NCT00002171|DRUG|Nelfinavir mesylate|
223519337|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
223519338|NCT05980702|DRUG|Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses|"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
223519339|NCT00433186|DRUG|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
223519340|NCT02772120|DRUG|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
223519341|NCT02772120|DRUG|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
223519342|NCT05845892|OTHER|stress ball|The use of the stress ball by the experimental group patients will be reminded by a hemodialysis nurse who was not involved in the study.
223534855|NCT05739266|BEHAVIORAL|3 minutes step test|3 minutes step test- Stair hight:20 cm, Pace: 96 steps per minute
223519343|NCT04098913|BEHAVIORAL|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
223519344|NCT02869009|DRUG|clopidogrel|
223519345|NCT02869009|DRUG|Aspirin|
223519346|NCT05527769|PROCEDURE|mastectomy + immediate breast reconstruction|pre- or retro pectoral prosthesis
223519347|NCT00353119|DRUG|Placebo comparator|Patients received placebo subcutaneously twice weekly
223519348|NCT00353119|DRUG|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
223519349|NCT04096677|PROCEDURE|hysteroscpy|
223519350|NCT02970058|OTHER|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
223519351|NCT02970058|OTHER|Control|The control group will receive saline as a placebo
223519352|NCT02771327|DEVICE|CPAP plus Gas|
223519353|NCT02771327|DEVICE|ventimask plus gas|
223519354|NCT05560113|OTHER|Continuous theta burst stimulation (cTBS)|cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
223519355|NCT05560113|OTHER|Sham continuous theta burst stimulation (cTBS)|This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
223519356|NCT02500836|DRUG|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
223519357|NCT02500836|DRUG|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
223519358|NCT02500836|DRUG|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
223519359|NCT02475356|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|The treatment of Mirena should comply with the local product information.
223519360|NCT02644304|DRUG|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
223519361|NCT02644304|DRUG|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
223519362|NCT02644304|OTHER|Placebo|placebo(half tablet) every 3 days (4 doses).
223519363|NCT05158010|OTHER|HELIX's follow-up|"* Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples."
223519364|NCT02974192|OTHER|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
223519365|NCT02538796|OTHER|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
223519366|NCT02538796|OTHER|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
223519367|NCT02538796|OTHER|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
223519368|NCT02538796|OTHER|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
223519369|NCT03009292|DRUG|lenvatinib|once daily continuous dosing
223519370|NCT06264544|DIETARY_SUPPLEMENT|zinc, selenium, and L-tyrosine in SEPP1|zinc, selenium, and L-tyrosine in SEPP1 polymorphism
223519371|NCT06264544|OTHER|Placebo|placebo comparator in SEPP1 polymorphism group
223519372|NCT04695366|OTHER|No intervention|No intervention
223519373|NCT03751982|DEVICE|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
223519374|NCT05263167|DRUG|Sodium Aescinate|sodium Aescinate 10mg in 250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
223519375|NCT05263167|DRUG|Placebo|250ml sodium chloride 0.9% infusion bag intravenously once daily for 10 days.
223519376|NCT04691115|DRUG|AM1476|AM1476 Capsules
223519377|NCT04691115|DRUG|Placebo|Placebo Capsules
223519378|NCT00323245|BEHAVIORAL|Physiotherapy for urinary incontinence|See Detailed Description.
224274774|NCT04438434|DRUG|Chlorhexidine mouthwash|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use Chlorhexidine 0.2% mouthwash as an active comparator; 10 ml three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to Chlorhexidine will be advised to discontinue its use, and seek medical advice."
224274775|NCT04438434|OTHER|Placebo product|"The enrolled subjects will be examined and treated by specialized medical personnel.~The extraction will be carried out by an experienced operator and will follow the standard guidelines for the extraction of impacted teeth. Once the tooth has been removed, a suture with detached stitches using silk thread 3/0 will be applied.~From a pharmacological point of view, the patient will be prescribed antibiotic therapy (Amoxicillin 1g) to be administered twice daily for seven days, analgesic/anti-inflammatory therapy with NSAIDs (e.g. Synflex 550 mg/Brufen 800 mg) are to be used for a maximum of twice daily.~Subjects in this group are to use a placebo product, and will be instructed to use 10 ml for mouth rinsing three times daily, after meals and after normal oral hygiene procedures, for one week (date of the follow-up visit).~Patients with allergic reactions or hypersensitivity to the product will be advised to discontinue its use, and seek medical advice."
223519379|NCT00832013|DRUG|Propofol|See detailed description
224274776|NCT04121533|DIETARY_SUPPLEMENT|Placebo|Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
224274777|NCT04121533|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
224274778|NCT04121533|DIETARY_SUPPLEMENT|Glucosamine sulfate and omega-3 fatty acids|Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
224274779|NCT04640194|PROCEDURE|Standard of care|Standard of Care (SOC) includes any supportive measures applied in hospital, specifically on an intensive care unit (ICU), such as for example the use of non-invasive or invasive ventilation, oxygen masks, haemodynamic support, if needed, sedation, as well as medical therapies commonly used in patients suffering from acute respiratory distress syndrome (ARDS) or its complications. SOC should include best possible treatment regimen established locally and should be in line with current guidelines for ARDS treatment.
224274780|NCT04640194|DRUG|Alteplase low dose|0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
224274781|NCT04640194|DRUG|Alteplase high dose|0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
224274782|NCT03945916|DIETARY_SUPPLEMENT|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
224274783|NCT03945916|DIETARY_SUPPLEMENT|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
224274784|NCT06391450|DRUG|Empagliflozin 10 MG|Oral
224274785|NCT06391450|DRUG|Placebo|Oral
224274786|NCT00545428|PROCEDURE|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
224274787|NCT02061358|DRUG|UV-4B 3 mg|Oral solution, single dose
224274788|NCT02061358|DRUG|UV-4B 10 mg|Oral solution, single dose
224274789|NCT02061358|DRUG|UV-4B 30 mg|Oral solution, single dose
224274790|NCT02061358|DRUG|UV-4B 90 mg|Oral solution, single dose
223519380|NCT00832013|DRUG|Propofol|See detailed description
224274791|NCT02061358|DRUG|UV-4B 180 mg|Oral solution, single dose
224274792|NCT02061358|DRUG|UV-4B 360 mg|Oral solution, single dose
224274793|NCT02061358|DRUG|UV-4B 720 mg|Oral solution, single dose
223519381|NCT05898178|OTHER|Experimental intervention: 8-5-2% oxygen gradient concentration in the incubator|After oocyte retrieval and insemination, half of a given patient's embryos will be randomly allocated in an incubator set at a gradient of oxygen tension (8-5-2%). The embryos will remain in the incubator until their developmental assessments on day 5.
223519382|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed|"Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
223519383|NCT05849246|DRUG|Sintilimab+Carboplatin or Cisplatin+Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
224274794|NCT02061358|DRUG|UV-4B 1000 mg|Oral solution, single dose
224274795|NCT02061358|DRUG|Placebo|Oral solution, single dose
224274796|NCT01071876|DRUG|BF2.649|1 capsule in the morning before breakfast
223519384|NCT05849246|DRUG|Tusamitamab ravtansine+Sintilimab|"Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous.~Other Name: Tusamitamab ravtansine. Other Name: Tyvyt®"
223519385|NCT06451146|PROCEDURE|PCI Facilitated with Orbital Atherectomy Device|Percutaneous coronary intervention for coronary artery disease supported by the Orbital Atherectomy Device
223519386|NCT06565013|DRUG|Cabenuva 600/900|Participants will switch to Cabenuva at baseline. The visit schedule, the product administration and the clinical follow-up will be done according to standard of care.
223519387|NCT06565013|OTHER|Self administered questionnaires|Questionnaires on treatment satisfaction (HIVTSQs), quality of life (WHOQoL-HIV-BREF) and drug use assessment (DEBA-D) will be administered at baseline, M5 and M11
223519388|NCT06565013|OTHER|Semi-directed interview|At baseline and M11, participants will conduct a semi-directed interview about the perception of their HIV treatment and the global care they receive as a person living with HIV who is practicing chemsex.
223704113|NCT02698878|DIETARY_SUPPLEMENT|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
223519389|NCT06560788|OTHER|collection of cerebrospinal fluid|CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
223519390|NCT02331303|OTHER|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
223519391|NCT01220687|DRUG|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
223519392|NCT01220687|OTHER|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
223519393|NCT04694287|DIAGNOSTIC_TEST|Percutaneous DUS volume flow measurements|Volume flow measurements of the AFV will be obtained using intraprocedural DUS just prior to sheath insertion and at the end of the final balloon dilation, before sheath removal.
223519394|NCT03242447|BEHAVIORAL|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
223519395|NCT03242447|BEHAVIORAL|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
223519396|NCT03586921|BEHAVIORAL|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
223519397|NCT03586921|OTHER|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
223519398|NCT03622983|OTHER|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
223519399|NCT05597124|BEHAVIORAL|Cardio-Dance Fitness|This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).
223519400|NCT05597124|BEHAVIORAL|Strength, Flexibility & Balance|This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
223519401|NCT04204616|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.
223519402|NCT06352463|OTHER|Denken + Doen = Durven|DDD is an evidence based cognitive behavioural therapy (CBT)-treatment protocol for children with anxiety. This research will use the modular version of DDD, which means that the therapist will decide which modules she will use based on the specific symptoms and needs of the child. DDD consists of four parts. First, there will be psycho education in which the child learns about how anxiety can arise, when anxiety is normal, and how thoughts, emotions, and behaviour are linked. Second, the child will learn coping strategies for dealing with anxiety. Third, there will be cognitive restructuring by which that the child will learn skills to deal with anxious and negative thoughts, through challenging and experimenting. Finally, there will be exposure. In the exposure sessions, the child will face their fears step by step.
223519403|NCT06352463|OTHER|Supportive Parenting for Anxious Childhood Emotions|Parents will follow the SPACE program. SPACE is a theory driven, evidence-based treatment program of 12 sessions. In a structured way, parents are trained to change their own behaviour as a reaction to the symptoms of their child. First, they are trained to recognise family accommodation and slowly reduce this. Second, this program focuses on the increase in supportive reactions from parents. They are taught to accept the child's feelings, fears, and problems and to trust in the ability of the child to cope with and tolerate anxiety-related problems. These two goals are attained via a sequence of steps in the SPACE manual. Furthermore, SPACE includes additional modules that can be implemented if needed. These provide tools for conquering communal challenges that can arise during the treatment process, including dealing with extremely disruptive behaviour of children and improving parental collaboration.
223519404|NCT04616781|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|nutritional ketone ester
223519405|NCT04616781|DRUG|Isocaloric dextrose placebo|Drink indistinguishable from ketone ester
224274797|NCT01071876|DRUG|Placebo|1 capsule in the morning before breakfast
224274798|NCT06366113|OTHER|Pulmonary rehabilitation|"Pulmonary rehabilitation includes :~* Exercise re-training with resumption of physical activities~* therapeutic patient education"
224274799|NCT02213705|BIOLOGICAL|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
224274800|NCT03850522|BIOLOGICAL|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
224274801|NCT01209988|DRUG|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
224274802|NCT01209988|OTHER|No medication|No medication
223519406|NCT04616781|OTHER|Alcohol drinks|drink an alcohol priming dose to produce a 0.03 g/dl breath alcohol concentration (BrAC) followed by a choice paradigm in which subjects receive 2 trays of 4 min-drinks each beverages Each min-drink would achieve 0.015 g/ld BrAC over a 1 hour period to achieve a max 0.1 g/dl BrAC.
223519407|NCT06038214|OTHER|core exercises|"1.5 minutes walking 2. Stretching exercise~* hallowing in supine and side lying position~* Bracing in supine and side lying position~* Bracing on the prone and forearms~* Bracing in the crawling position~* Bracing in laptop, half-lap and standing position~* Heel slide exercise~* Bridge building exercise~* Unilateral limb flexion exercise in crawling position~* Reciprocal heel slide exercise in supine position~* Bilateral lower extremity lifting exercise~* Unilateral lower extremity flexion in bridging position~* Side bridging exercise with knees extended~* Unilateral lower extremity extension in crawling position~* Contralateral lower and upper extremity lift in the crawling position~* Straight and oblique trunk flexion~* Straight and oblique trunk flexion with hip and knee flexed to 90°~* bracing on the ball~* squat~* bracing while walking"
223519408|NCT06038214|OTHER|home exercises|"Right and left rotation of the head~* lateral flexion of the head~* Flexion and extension of the head~* Stretching the neck extensors~* pectoral stretch~* Stretching the hip extensors~* Hamstrig stretching~* Stretching the lumbar extensors~* Abdominal strengthening~* bridging~* Hip abduction strengthening~* hip extension strengthening~* Upper extremity resistant flexion~* Upper extremity resistant abduction~* Upper extremity relaxation exercise~* Capsule stretching~* Stretching the hip flexors~* Stretching the lower extremity adductors~* relaxation exercise"
223519409|NCT05035927|DRUG|TRYP-0082|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
223519410|NCT05035927|BEHAVIORAL|Psychotherapy|A single (1) 25 mg oral dose of TRP 8802 will be administered in a carefully monitored setting following 6 to 8 hours of preparatory psychotherapy. Subjects will be in the study for 12 weeks following the dose of TRP 8802 (until Week 14), approximately 5 months from initiation of screening through the last follow-up.
223519411|NCT06641167|PROCEDURE|Shoulder surgery|shoulder surgery by arthroscopic approach under locoregional anesthesia combining an interscalene block and a superficial cervical plexus block
223519412|NCT06642857|OTHER|Peripheral blood, tougue coating, saliva, and feces|Peripheral blood, coating, saliva, and feces on the tongue and clinical data of patients with advanced gastric cancer patients who received chemotherapy combined with immunotherapy will be collected.
223519413|NCT06641206|DRUG|Triamcinolone Acetonide|1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
223519414|NCT06641206|DRUG|Bupivacaine Hydrochloride|20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
223519415|NCT06641206|DRUG|Dexmedetomidine|Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
223519416|NCT06644001|DIETARY_SUPPLEMENT|Bacillus coagulans GBI-30,6086 (BC GBI-30)|2g powder/sachet, consists of bacillus coagulans at a dose of 1x10\^9 CFU, taken once daily before a meal.
223519417|NCT06644001|DIETARY_SUPPLEMENT|Placebo|2g powder/sachet, consists of maltodextrin only, taken once daily before a meal.
223519418|NCT04981145|DRUG|Iguratimod Tablets|Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
223519419|NCT04981145|DRUG|Hydroxychloroquine Sulfate Tablets|Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
223519420|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
223519421|NCT02242656|DRUG|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
223519422|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
223519423|NCT05109559|BIOLOGICAL|Half dose of Ad26.COV2. 2.5x10^10vp|A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
223519424|NCT05109559|BIOLOGICAL|Full dose of Ad26.COV2. 5x10^10vp|A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
223519425|NCT03318874|DEVICE|Blephasteam|Steam delivery goggles, once daily
223519426|NCT03318874|DEVICE|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
223519427|NCT03318874|DRUG|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
223519428|NCT02518698|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
223519429|NCT04067622|DEVICE|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
223519430|NCT02219100|DRUG|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
223519431|NCT03288857|DEVICE|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
223519432|NCT04661839|BIOLOGICAL|COVID-HIGIV|COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion.
223519433|NCT04661839|OTHER|Placebo (saline)|The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion.
223519434|NCT02928822|BEHAVIORAL|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
223519435|NCT02928822|BEHAVIORAL|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
223519436|NCT00610220|DEVICE|Fiberglass short arm cast|Cast will be applied for a 4-week period
223519437|NCT00610220|DEVICE|Prefabricated wrist splint|Splint will be applied for a 4-week period
223519438|NCT06634771|DEVICE|10 Hz transcranial alternating current stimulation (tACS)|10 Hz bi-frontal tACS: Alternating current stimulation is delivered by an XCSITE 100 device (Pulvinar Neuro, Chapel Hill, NC), through three conductive carbon-rubber electrodes. Electrodes are placed over the apex of the head (Cz) and the prefrontal cortex bilaterally (F3 and F4). Stimulation is delivered during the second half of the HABIT Test session. Stimulation parameters: 2mA peak-to-peak 10Hz sine-wave flanked by 10 second linear envelope ramps in and out for a total duration of 30 min and 20 seconds.
223519439|NCT06634771|DEVICE|sham transcranial alternating current stimulation (tACS)|Sham tACS: The procedure for sham stimulation will be identical, but it will last for 2 minutes instead of 30 minutes.
223519440|NCT04025320|OTHER|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
223519441|NCT04025320|OTHER|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
223519442|NCT04373551|BEHAVIORAL|Cultural adaptation of a patient-provider communication tool|Adaptation of a patient-provider communication tool for PrEP uptake utilized among AA women and their providers in a pilot pre/post-intervention design.
223519443|NCT04660682|OTHER|Modified static cross-body posterior shoulder stretching|For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
223519444|NCT04660682|OTHER|Traditional static cross-body posterior shoulder stretching|For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
223519445|NCT04660682|OTHER|Control Group|In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
223519446|NCT06042491|BEHAVIORAL|Prehabilitation intervention|The intervention consists of exercise, nutritional support and breathing techniques. The exercise component consists of 1) strength training; 2) cardio and 3) stretching. Participants will be encouraged to complete self-directed and/or group sessions \>= 3 times per week. Each intervention participant will be provided a unique login to the virtual prehabilitation platform, which is the STRIVE Trial website. The nutrition component includes: 1) protein supplementation; 2) nutrition advice to support healthy eating. For the breathing component, participants will be encouraged to watch the video on Inspiratory Muscle Training (IMT) which involves diaphragmatic breathing and coughing/huffing. They will also be provided with an instruction booklet to take to hospital with them to support postoperative conduct of IMT during early recovery.
223519447|NCT04677361|COMBINATION_PRODUCT|MILs™ in Combination with Pembrolizumab|Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC
223519448|NCT00332566|BIOLOGICAL|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
223519449|NCT00332566|BIOLOGICAL|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
224274803|NCT05590039|DEVICE|MyEllevate Procedure|"The defined study area will be identified and may be marked with a surgical marker.~A local tumescent anesthetic, such as lidocaine, will be injected to the area prior to the procedure. The MyEllevate® device will be used in accordance with the Instructions for Use (IFU) manual for soft tissue approximation and elevation of sub dermis and underlying muscle of the submentum and jawline."
223519450|NCT03647137|OTHER|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
224274804|NCT05594095|DRUG|PIK3CA inhibitor|PIK3CA inhibitor
224083171|NCT04733547|DRUG|Furosemide-induced hypovolemia before graft procurement|Patients fast from 10 pm the day before surgery. On the arrival at the operating room, an intravenous catheter for Plasmalyte infusion is placed into the right cephalic or basilic vein. The distal lumen of the central venous catheter is used for the infusion of 6% hydroxyethyl starch. Fluid requirements due to anesthesia, surgery, and no per os intake are not replaced by minimizing the administration of the fluids. Five minutes after the collection of the baseline data, 20 mg of furosemide is administered to promote diuresis for facilitating the venous outflow of the liver. An additional dose of furosemide 20 mg is given if the urine output is \<1 ml/kg within 30 minutes after the first dose. Unless the second dose of furosemide produces \>1 ml/kg of urine within 30 minutes, 40 mg of furosemide is administered. In the absence of effective diuresis (1 ml/kg within 30 minutes after each dose), the use of furosemide is abandoned and the patients are excluded from the study.
224083172|NCT04733547|DRUG|Replacement of fluid loss after graft procurement|Immediately after the graft procurement, 500 ml of 6% hydroxyethyl starch are infused over 25 minutes. Afterward, Plasmalyte is infused at a rate of 10 ml/min until the end of surgery.
224083173|NCT04733547|DEVICE|Monitoring of stroke volume variation|Following anesthesia induction, the right radial artery is catheterized. The catheter is connected to the EV1000 monitor (Edwards Lifesciences, Irvine, CA) through the FloTrac transducer (Edwards Lifesciences). The transducer is level with the one for central venous pressure monitoring. Using pulse contour analysis without external calibration, the stroke volume for each heartbeat is measured. At a 20-second interval, stroke volume variation is calculated as (maximum stroke volume - minimum stroke volume)/mean stroke volume.
224083174|NCT03658369|DIETARY_SUPPLEMENT|Lanconone®|2 capsules
224083175|NCT03658369|DIETARY_SUPPLEMENT|Methyl crystalline cellulose|2 Capsules
224083176|NCT06549140|OTHER|Augmented reality exercise program|Participants enrolled in an organized exercise program based on two weekly sessions of 45 to 60 minutes each for 12 weeks: one traditional session (group session) and one augmented reality (AR) session (individual session), both supervised by sports and exercise professionals. The AR session was designed to provide an entire exercise session targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time, decision-making, and memory).
224083177|NCT06549140|OTHER|Traditional exercise program|Participants enrolled in a traditional organized exercise program (group sessions) based on two weekly sessions of 45 to 60 minutes each for 12 weeks. These sessions are supervised by sports and exercise professionals, targeting physical fitness components (cardiorespiratory capacity, strength, balance, agility, and flexibility) and cognitive function (reaction time and decision-making).
224083178|NCT02614079|DEVICE|DSSEP|Collision testing after the placement of SCS leads
224083179|NCT03544073|DRUG|Saline Solution for Injection|Placebo arm will receive a saline injection
224083180|NCT03544073|DRUG|Leuprolide Acetate|Treatment arm will receive a Leuprolide injection
224083181|NCT03370770|DRUG|Afatinib|GILOTRIF, GIOTRIF, XOVOLTIB
224083182|NCT03370770|DRUG|Osimertinib|on T790M resistance mutation was developed
224083183|NCT02814149|PROCEDURE|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
224083184|NCT02814149|PROCEDURE|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
224083185|NCT03729947|DEVICE|Subfascial closed suction drain|Ch 14 closed suction drain
224083186|NCT00524160|DRUG|Fentanyl transdermal patch|
224083187|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
224083188|NCT06452264|BEHAVIORAL|game-like computerized activities|game-like computerized activities
224083189|NCT03175341|DRUG|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
224083190|NCT03175341|DRUG|Placebos|100 ml normal saline 0.9%
224083191|NCT03881969|BEHAVIORAL|Financial Payment of £100|No financial payment
224083192|NCT04305015|DEVICE|NOL Guided Analgesia|NOL values exceeding 25 will typically be treated with boluses of fentanyl 50 µg at roughly 5-minute intervals. The target will be maintained until surgery ends
224083193|NCT04305015|OTHER|Routine opioid management|Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 50 µg can be given per clinical judgement
224083194|NCT00234039|DRUG|gemcitabine hydrochloride|
224083195|NCT03558347|DEVICE|short implants with splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns
224083196|NCT03558347|DEVICE|short implants with non-splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
224083197|NCT01284504|DRUG|Celecoxib|200 mg tablet oral
224083198|NCT01284504|OTHER|placebo|Placebo, tab
224083199|NCT00518479|DRUG|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
224083200|NCT00518479|DRUG|Valsartan 160mg OD; Moxonidine 400mcg OD|
224083201|NCT03683394|BEHAVIORAL|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
224083202|NCT03683394|BEHAVIORAL|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
224083203|NCT02279030|OTHER|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
224083204|NCT00110019|DRUG|Carboplatin|Given IV
224083205|NCT00110019|OTHER|Laboratory Biomarker Analysis|Correlative studies
224083206|NCT00110019|DRUG|Paclitaxel|Given IV
223519451|NCT02105480|DEVICE|Computer aided auscultation (CAA)|
223519452|NCT05116345|DRUG|DEXTENZA|Intracanalicular Dexamethasone ophthalmic insert (0.4mg)
223519453|NCT05116345|DRUG|Topical Dexamethasone|topical dexamethasone drops
223519454|NCT06417788|DEVICE|Dental implant placement|Dental implant placement guided by Navident® (ClaroNav Inc., Toronto, Canada)
223519455|NCT06417788|PROCEDURE|Static guided implant placement|Dental implant placement guided by a stereolithographic pilot drill guide.
223519456|NCT03220256|DRUG|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
223519457|NCT06220253|PROCEDURE|vaginal hysterectomy by bipolar vessels sealing|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be coagulated and cut by a bipolar vessel sealing instrument
224083207|NCT00110019|OTHER|Pharmacological Study|Correlative studies
224083208|NCT00110019|OTHER|Placebo|Given PO
223519458|NCT06220253|PROCEDURE|vaginal hysterectomy by traditional technique|The surgery will take place according to the canonical times of vaginal hysterectomy and all the support structures will be sutured by absorbable threads
223519459|NCT06569940|DEVICE|Sleepiz One+|In this study Sleepiz One+ will measure heart rate and respiration rate of a participant sitting or lying in different positions (right and left side, back, abdomen) on a bed. The recording will take around 42 minutes.
223519460|NCT01000116|PROCEDURE|Fibrin glue|Tissucol 2 ml
224274805|NCT05594095|DRUG|AKT inhibitor|AKT inhibitor
223519461|NCT01000116|PROCEDURE|Tacks|Protacks
223519462|NCT04957472|DEVICE|fabian HFO, fabian +nCPAP evolution and fabian Therapy evolution with PRICO function|24 hours of automated control of FiO2
223519463|NCT04957472|OTHER|Manual Control|24 hours of manual control of FiO2
223519464|NCT03277872|DEVICE|Laryngoscopy with GlideScope (GVL) Blade|"1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
223519465|NCT03277872|DEVICE|Laryngoscopy with MacIntosh (MAC) Blade|"1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
223519466|NCT01518179|DEVICE|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
223519467|NCT01518179|OTHER|Routine follow up and treatment|Control
223519468|NCT04598087|BEHAVIORAL|Prehabilitation|The multi-phasic prehabilitation intervention involves three phases: Phase 1: Before surgery (typically \~25 days); Phase 2: The in-hospital phase (typically 10-14 days); Phase 3: Discharge to 6-weeks after surgery.
224083209|NCT00110019|DRUG|Sorafenib Tosylate|Given PO
224083210|NCT02224131|DRUG|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
224083211|NCT02224131|DRUG|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
224083212|NCT03897751|DEVICE|ABT12 Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
224083213|NCT03897751|DEVICE|COMPLETE Multi-Purpose Solution|Contact lens cleaning and disinfecting solution
224083214|NCT03897751|DEVICE|Sensitive Eyes® Rewetting Drops|For use as needed during the study.
224083215|NCT02455635|PROCEDURE|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath \& 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
224083216|NCT04299100|BEHAVIORAL|Sleep Health Program for Participants with No/Mild Sleep Apnea|Participants randomized to the Sleep Health Program will receive the Self-Management for Sleep Care videos and digital materials.
224083217|NCT04299100|BEHAVIORAL|Sleep Health Program for Participants with Moderate/Severe Sleep Apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea will receive the Self-Management for Sleep Care videos and digital materials, and be recommended for referral to a sleep clinic as part of standard of care.
224083218|NCT03229720|DEVICE|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
224083219|NCT01906125|DRUG|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
224083220|NCT01906125|DRUG|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
224083221|NCT01906125|DRUG|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
224083222|NCT03649399|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
224083223|NCT04426695|DRUG|REGN10933+REGN10987 combination therapy|Administered intravenously (IV) single dose
224083224|NCT04426695|DRUG|Placebo|Placebo IV Single Dose
224274806|NCT05594095|DRUG|Carrelizumab|Pd-1 mab
223519469|NCT00517114|DRUG|Rabeprazole 20mg twice daily|
223519470|NCT05651490|BEHAVIORAL|Problem Solving Treatment for Diabetes|"In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~1. Clarifying and defining the problem~2. Setting a realistic goal~3. Brainstorming multiple solutions~4. Generating pros and cons for each solution~5. Evaluating and choosing a preferred solution~6. Developing a specific action plan to implement the solution~7. Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants."
223519471|NCT05651490|BEHAVIORAL|Attention Control Group|During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
223519472|NCT02615613|OTHER|Low Acceptability Meal|
223519473|NCT02615613|OTHER|High acceptability meal|
223519474|NCT02800785|DRUG|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
223519475|NCT02800785|PROCEDURE|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
223519476|NCT01974947|OTHER|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
223519477|NCT03523663|OTHER|no intervention. measure eye movement data|
223519478|NCT00002759|DRUG|cyclosporine|
223519479|NCT00002759|DRUG|irinotecan hydrochloride|
223519480|NCT00002759|DRUG|phenobarbital|
223519481|NCT04753567|DEVICE|nCap pain relief patch|Each participant will be randomly assigned to sham or actual patch. Patches will be worn for 3 weeks. Pain and quality of life will be assessed and compared between groups
223519482|NCT04753567|DEVICE|Sham Patch|Sham patch will be worn for 3 weeks exactly like actual pain patch
223519483|NCT02446509|BEHAVIORAL|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
223519484|NCT02446509|BEHAVIORAL|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
223519485|NCT06198777|DEVICE|Magnetometer|Inspection equipment for magnetocardiography
223519486|NCT05902858|DEVICE|Conventional intubation with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo conventional intubation with hyperangulated videolaryngoscope
223519487|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with hyperangulated videolaryngoscope
223519488|NCT05902858|DEVICE|Intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope|After the induction of general anesthesia, the patient will undergo intubation with ProVu TM video stylet combined with standard Macintosh laryngoscope
224274807|NCT05594095|DRUG|Famitinib|VEGFR inhibitor
223519489|NCT02261610|PROCEDURE|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
223519490|NCT03253627|BEHAVIORAL|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
223519491|NCT03253627|BEHAVIORAL|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
223519492|NCT05197374|DRUG|Estradiol Valerate 4mg|Estradiol valerate 2 mg (two tablet once daily) started 5 days before expected menses (or 7 days after ovulation of previous cycle). After start of menses, estradiol pretreatment was stopped and controlled ovarian stimulation started.
223519493|NCT01603368|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
223519494|NCT01603368|DIETARY_SUPPLEMENT|Placebo|Oil drops without Lactobacillus reuteri
223519495|NCT03079778|PROCEDURE|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
223519496|NCT03079778|RADIATION|TACE plus RT|radiobiologically guided radiation
223519497|NCT00394225|DRUG|Oxygen|
223519498|NCT00394225|DRUG|Helium|
223519499|NCT06124300|DIETARY_SUPPLEMENT|Female Hormone Balance Supplement|The product contains: Myo-Inositol D-Chiro Inositol Folic Acid Vitamin D Vitamin B12
223519500|NCT05187910|BEHAVIORAL|Speech Therapy|Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
223519501|NCT05187910|BEHAVIORAL|Swallowing Therapy|Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
224083225|NCT03142698|PROCEDURE|Quantification of hepatic steatosis|Quantification of hepatic steatosis (histology, and in MRI)
224274808|NCT05594095|DRUG|Fluzoparib|PARP inhibitor
224274809|NCT05594095|DRUG|Dalpiciclib|CDK4/6 inhibitor
224274810|NCT05594095|DRUG|SHR-A1811|HER2 ADC
223519502|NCT05187910|BEHAVIORAL|Upper Airway Therapy|Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
223519503|NCT00498966|DRUG|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
223519504|NCT01082458|DRUG|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
223519505|NCT05725434|BIOLOGICAL|CT-P47 AI (tocilizumab)|CT-P47 (162 mg/0.9 mL) by subcutaneous (SC) injection via autoinjector (AI) at Week 0 and Week 2
223519506|NCT05725434|BIOLOGICAL|CT-P47 PFS (tocilizumab)|CT-P47 (162 mg/0.9 mL) by SC injection via pre-filled syringe from Week 4 every other week or weekly (based on the clinical response by investigator's discretion) up to Week 10
223519507|NCT05116644|OTHER|NONE - this is a cross-sectional survey design|NONE - this is a cross-sectional survey design
223519508|NCT00606099|DRUG|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
223519509|NCT00606099|DRUG|adefovir dipivoxil|Active Comparator
223519510|NCT03829683|DRUG|Vitamin C|200mg/kg/24hours
223519511|NCT03829683|DRUG|Dextrose 5% in water|50mL intravenously every 6 hours
223519512|NCT00742157|DRUG|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
223519513|NCT03539640|OTHER|PEEP: 5 cmH2O|During second part of the study (MRI)
223519514|NCT03539640|OTHER|PEEP: 10 cmH2O|During second part of the study (MRI)
223519515|NCT03539640|OTHER|PEEP: 15 cmH2O|During second part of the study (MRI)
223519516|NCT03890107|DEVICE|OtoSight Middle Ear Scope|OtoSight imaging using a near-infrared laser
223519517|NCT02511743|OTHER|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
223519518|NCT04010838|PROCEDURE|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
223519519|NCT05807945|DRUG|Ropivacaine 0.75% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.75%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
223519520|NCT05807945|DRUG|Ropivacaine 0.2% Injectable Solution|The patients receive 10 ml of intraarticular solution in the knee (at the anatomical point at the level of the upper pole of the ball joint, under the iliotibial band), with different content of ropivacaine 0.2%; the vehicle for application presents the same physical appearance for all patients and is applied by previously standardized treating physicians.
224274811|NCT05594095|DRUG|Everolimus|mTOR inhibior
223519521|NCT06468943|DRUG|Polatuzumab Vedotin|1.8mg/kg/21d（d0） Intravenous infusion
224274812|NCT05594095|DRUG|Aromatase Inhibitors or Fulvestrant|Letrozole/Anastrozole/Exemestane or Fulvestrant
224274813|NCT05594095|DRUG|Goserelin|For premenopause
223519522|NCT06468943|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
223519523|NCT06468943|DRUG|Rituximab|375mg/㎡/21d（d0） Intravenous infusion
223519524|NCT06468943|DRUG|Cyclophosphamide|750mg/㎡/21d（d1） Intravenous infusion
223519525|NCT06468943|DRUG|Doxorubicin|50mg/㎡/21d（d1） Intravenous infusion
223519526|NCT06468943|DRUG|Prednisone|100mg PO （d1-d5）/21d
224274814|NCT05594095|DRUG|TPC|Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
224274815|NCT05594095|DRUG|Sorafenib|RTK Inhibitor
224274816|NCT05594095|DRUG|Apatinib|Apatinib 250mg po qd
224274817|NCT05594095|DRUG|SHR-A1921|TROP2 ADC
223519527|NCT05043831|DEVICE|DSLT|Direct-SLT is applied via the limbus to the trabecular meshwork
223519528|NCT04348630|OTHER|Simulated heatwave exposure|Older adults are exposed to a 8-hour simulated exposure
223519529|NCT02980458|DRUG|Deferiprone 500Mg Tablet|
223519530|NCT02980458|DRUG|Deferiprone 500 MG Oral Tablet [Ferriprox]|
223519531|NCT05952375|DRUG|Chimeric antigen receptor T cell preparation targeting Claudin18.2|Chimeric antigen receptor T cell preparation targeting Claudin18.2
224274818|NCT05594095|DRUG|SHR-A2102|NECTIN4 ADC
224274819|NCT05594095|DRUG|SHR-A2009|HER3 ADC
223519532|NCT01922895|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
224274820|NCT05594095|DRUG|SHR-1167|PARP1i
224274821|NCT05594095|DRUG|SHR-6209|CDK4i
224274822|NCT05594095|DRUG|bevacizumab|bevacizumab
223519533|NCT01922895|DRUG|Placebo for Probiotic|Capsule manufactured without active ingredients.
223519534|NCT01916226|DRUG|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
223519535|NCT01916226|DRUG|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
223519536|NCT01916226|DRUG|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
223519537|NCT01916226|DRUG|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
223519538|NCT03163667|DRUG|Placebo|oral tablets
223519539|NCT03163667|DRUG|CB-839|oral tablets
223519540|NCT03163667|DRUG|everolimus|oral tablets
223519541|NCT02121639|DRUG|Placebo|
223519542|NCT02121639|DRUG|AZD5363|
223519543|NCT01686321|DRUG|Bendamustine and subcutaneous rituximab|
224274823|NCT04773600|DRUG|Roflumilast Cream|Roflumilast cream 0.15% for topical application
224274824|NCT04773600|DRUG|Vehicle cream|Vehicle cream for topical application
223519544|NCT04005326|PROCEDURE|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
224274825|NCT04070222|OTHER|Hysteroscopy|"1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
224274826|NCT03157869|DEVICE|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
224274827|NCT03157869|OTHER|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
224274828|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
224274829|NCT02666417|DIETARY_SUPPLEMENT|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
224274830|NCT05700396|BEHAVIORAL|Breast Cancer Survivor Education Program|Weekly sessions via Zoom platform with study staff.
224274831|NCT05582109|DRUG|Envafolimab, Lenvatinib Combined With TACE|PD-L1 inhibitor
224274832|NCT02413528|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
224274833|NCT02413528|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
224274834|NCT04522804|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
224274835|NCT00282581|BIOLOGICAL|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
224274836|NCT00269334|DRUG|Using Citalopram(drug) or Paroxetine(drug)|
224274837|NCT03395015|OTHER|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
224274838|NCT01427881|DRUG|cyclophosphamide|Given IV
224274839|NCT01427881|DRUG|cyclosporine|Given IV
224274840|NCT01427881|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
224274841|NCT01427881|RADIATION|total-body irradiation|Undergo TBI
224274842|NCT01427881|DRUG|fludarabine phosphate|Given IV
224274843|NCT01427881|DRUG|busulfan|Given IV
224274844|NCT01427881|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
224083226|NCT04303000|DRUG|Opioid Overdose Education with Naloxone Distribution|Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with a naloxone kit.
224274845|NCT05656690|OTHER|Exposure to disability|Disability status assessed by functional measures
224274846|NCT02361814|PROCEDURE|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
224274847|NCT01062334|PROCEDURE|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
224274848|NCT00500318|DRUG|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
224274849|NCT00500318|DRUG|Placebo|Dose matched placebo, once daily oral inhalation.
224274850|NCT00535041|DRUG|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
224274851|NCT06535035|DEVICE|laser therapy After implant surgery, laser therapy (LLLT) was applied|After implant surgery, laser therapy (LLLT) was applied a single session with an EPIC X Biolase diode laser (BIOLASE, Inc., USA)
224274852|NCT06535035|DEVICE|SHAM|After implant surgery, After implant surgery, laser therapy (LLLT) was applied in the same manner but without activating it
224274853|NCT05752435|PROCEDURE|COMPARISON OF THERAPEUTIC EFFICACY BETWEEN INTRALESIONAL BLEOMYCIN AND CRYOTHERAPY IN PLANTAR WARTS|comparison of therapeutic efficacy between intralesional bleomycin and cryotherapy in plantar warts
224274854|NCT03497819|BIOLOGICAL|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
224274855|NCT05391659|DEVICE|deep learning|a form of artificial intelligence (AI), has been introduced for automated analysis of images
224274856|NCT05391659|DIAGNOSTIC_TEST|remote grading of fundus images|referrable cases identified by DR AI tool will be remotely graded by a human
224274857|NCT05391659|DIAGNOSTIC_TEST|gold standard|examination by ophthalmologist
223519545|NCT04005326|PROCEDURE|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
223519546|NCT04005326|PROCEDURE|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
223519547|NCT06541587|BEHAVIORAL|mindfulness based virtual reality|mindfulness based virtual reality
224274858|NCT03842852|PROCEDURE|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
223519548|NCT06541587|BEHAVIORAL|mindfulness based audio practice|mindfulness based audio practice
223519549|NCT04448847|DIETARY_SUPPLEMENT|Bif195|Active trial product with minimum 100 billion CFU daily dose
223519550|NCT04448847|OTHER|Placebo|Placebo similar to trial product but without Bif195
223519551|NCT06014801|DRUG|Dialysate fluid, Filtration replacement fluid|Dose of continuous hemodialysis and/or hemofiltration
223519552|NCT05701345|DEVICE|OMNIFIT DTx-MDD|This software medical device consists of multifaceted interventions (breathing training, cognitive rehabilitation training, binaural beat training, concentration training) that help improve depressive disorder, and is automatically executed for 35 minutes per session
223519553|NCT05701345|OTHER|standard treatment|"It is based on the Korean Medical Association's clinical treatment guidelines for depression or the Korean Medical Association's Korean Medical Association/Korean Depression Management Association's 2021 guidelines for drug treatment for depression disorders.~Standard treatment will be performed according to the judgment of the attending physician reflecting the clinical situation based on these treatment guidelines."
223519554|NCT06211218|DIAGNOSTIC_TEST|Cornea diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose cornea diseases from slit-lamp images.
223519555|NCT03779620|DEVICE|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
223519556|NCT06332755|DRUG|LB-LR1109|intravenous administration
223519557|NCT05430919|DRUG|REGN5713|Administered subcutaneously (SC)
223519558|NCT05430919|DRUG|REGN5714|Administered SC
224274859|NCT04554706|BEHAVIORAL|Mobile-phone delivered Treatment for Excessive Rumination|This is a one-month three-arm clinical control trial to reduce the rumination and interpersonal impairment link.
224274860|NCT06433206|OTHER|no intervention|no intervention
224274861|NCT02993705|DRUG|Trabectedin|Chemotherapy drug
224274862|NCT03574337|DRUG|Sugammadex|No additional information
223519559|NCT05430919|DRUG|REGN5715|Administered SC
223519560|NCT05430919|OTHER|Placebo|Administered SC
223519561|NCT03098927|BEHAVIORAL|Motor imagery training|Motor imagery training
223519562|NCT02594579|DRUG|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
223519563|NCT02594579|DRUG|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
224274863|NCT03574337|DRUG|neostigmine/glycopyrolate|No additional information
224274864|NCT06678685|DRUG|.spironolactone|In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
224274865|NCT03023709|BIOLOGICAL|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
224274866|NCT03023709|BIOLOGICAL|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
224274867|NCT05567887|DRUG|maplirpacept (PF-07901801)|maplirpacept (PF-07901801)
223519564|NCT05627986|OTHER|No intervention|No intervention
223519565|NCT02644070|DEVICE|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
223519566|NCT02644070|DEVICE|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
223519567|NCT02644070|DEVICE|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
223519568|NCT03663023|PROCEDURE|Intestinal obstruction|
224083227|NCT04303000|DRUG|Opioid Overdose Education|Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
224083228|NCT02590484|PROCEDURE|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
223519569|NCT02594943|DEVICE|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
223519570|NCT02594943|DEVICE|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
224274868|NCT00095862|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|
223519571|NCT03320993|OTHER|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
223519572|NCT03282994|DEVICE|Dermal Cooling System|Cryotherapy
223519573|NCT02407938|OTHER|Rice meal|
223519574|NCT02887794|OTHER|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
223519575|NCT02478749|PROCEDURE|arm retraction|gently pulling through the ipsilateral arm to the knee
223519576|NCT02702999|DEVICE|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
223519577|NCT02702999|DEVICE|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
224274869|NCT00095862|BIOLOGICAL|recombinant interferon alfa|
224274870|NCT00095862|DRUG|cyclophosphamide|
224274871|NCT00699244|PROCEDURE|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
224274872|NCT00699244|PROCEDURE|Central placement of local anesthesia|Central placement of local anesthesia
223519578|NCT05391958|BEHAVIORAL|base on Lean Body Mass Pattern|PTC(post-tetanic count) was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on lean body weight mass pattern once when PTC \> 2.
223519579|NCT05391958|BEHAVIORAL|base on Actual Body Weight|PTC was measured every 6min during the operation, and single injection of 0.05 (1ED95) mg/kg cisatracurium that was calculated based on actual body weight once when PTC \> 2.
223519580|NCT05391958|GENETIC|obese patients|obese patients with elective laparoscopic colorectal surgery were selected，and the inclusion criteria were as follows: age 18-65, body mass index (BMI) 30-35, waist circumference (WC) : female ≥80cm, male ≥90cm, and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
223519581|NCT05391958|GENETIC|normal patients|normal patients with elective laparoscopic colorectal surgery whose body mass index (BMI) 18-24 were selected,and American Society of Anesthesiologists (ASA) grade Ⅰ \~ Ⅲ.
223519582|NCT01848457|DRUG|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
223519583|NCT01848457|DRUG|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
223519584|NCT04104477|OTHER|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
223519585|NCT04104477|OTHER|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
223519586|NCT01566565|DRUG|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
223519587|NCT02940223|DRUG|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
223519588|NCT02940223|BEHAVIORAL|Exercise Intervention|Complete resistance exercises and undergo walking program
223519589|NCT02940223|BEHAVIORAL|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
223519590|NCT02940223|OTHER|Laboratory Biomarker Analysis|Correlative studies
223519591|NCT02940223|OTHER|Placebo|Given PO
223519592|NCT02940223|BEHAVIORAL|Quality-of-Life Assessment|Ancillary studies
223519593|NCT02940223|OTHER|Questionnaire Administration|Ancillary studies
223519594|NCT04846998|DRUG|BR9003|"Treatment group B:~Once-daily oral administration of one BR9003 2mg tablet in the fasting state.~Treatment group C:~Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it."
224274873|NCT03028064|OTHER|blood taking|in this cohort study, we will take blood to examine the platelet function
223519595|NCT04846998|DRUG|BR9003A|"Treatment group A:~Twice-daily oral administration of one BR9003A 1mg tablet in the fasting state"
223519596|NCT06497673|OTHER|sample collection|New collected samples, as well as surplus surgical and diagnostic samples.
223519597|NCT01485367|DRUG|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand \& extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand \& extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right \& left forearms.
224274874|NCT06679491|OTHER|Resistance periodized training program (N-PF)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the follicular phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated based on the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are performed at a higher training load during both early and late follicular phases. The increased intensity leverages higher estrogen levels, which may support greater muscle strength and recovery during this phase.~Luteal Phase (Days 15-28): Training sessions are conducted at a lower training load during both early and late luteal phases to accommodate the hormonal shifts associated with elevated progesterone."
223519598|NCT00245154|DRUG|carboplatin|Given IV
223519599|NCT00245154|DRUG|cediranib maleate|Given orally
223519600|NCT00245154|DRUG|paclitaxel|Given IV
223519601|NCT00245154|OTHER|placebo|Given orally
223519602|NCT00521352|DEVICE|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
223519603|NCT00521352|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
223519604|NCT04314973|DEVICE|Active Pelvis Orthosis|Walking with the robotic device providing the assistive protocol.
223519605|NCT04314973|OTHER|Walking exercises|Walking exercises without wearing the robotic device.
223519606|NCT06501352|DRUG|Dexmedetomidine|Additive to Local anesthetic mixture
223519607|NCT06501352|DRUG|Neostigmine|Additive to Local anesthetic mixture
223519608|NCT06501352|DRUG|Saline|Control
223519609|NCT01813357|DRUG|Rosuvastatin|encapsulated tablet 20mg daily
223519610|NCT01813357|OTHER|Placebo|Placebo arm included to maintain blinding
223519611|NCT01962753|DRUG|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
223519612|NCT06192966|DIETARY_SUPPLEMENT|Food supplement|Probiotic formulation containing Lactobacillus plantarum, cranberry and vitamine C for 6 months 1 capsule/day
223519613|NCT06192966|DIETARY_SUPPLEMENT|Placebo|Placebo composed of maltodextrin for 6 months 1 capsule/day
223519614|NCT01271231|DRUG|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
223519615|NCT01271231|DRUG|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
223519616|NCT01271231|DRUG|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
223519617|NCT05560880|BEHAVIORAL|High Intensity Interval Gait training|Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
223519618|NCT05560880|BEHAVIORAL|Moderate Intensity Interval gait training|subjects will walk for 20 minutes at theri best comfortable pace
223519619|NCT03773562|DRUG|Erenumab|Erenumab will be used per label instructions.
224274875|NCT06679491|OTHER|Resistance peioridized training program (N-PL)|"This intervention consists of a 13-week structured resistance training program tailored to align with the natural menstrual cycle, focusing on intensified training during the luteal phase. Participants perform two resistance training sessions per week, each lasting 90 minutes, with intensity modulated according to the participant's menstrual phase.~Intensity Modulation:~Follicular Phase (Days 1-14): Training sessions are conducted at a lower training load during both early and late follicular phases to accommodate the hormonal environment of this phase.~Luteal Phase (Days 15-28): Training sessions are performed at a higher training load during both early and late luteal phases. The increased intensity leverages the hormonal environment associated with elevated progesterone, which may affect muscle endurance and neuromuscular adaptations during this phase."
223519620|NCT02825563|DRUG|Anlotinib|in the fasting state
223519621|NCT02825563|DRUG|Anlotinib|in the high fat diet
223519622|NCT03317873|DIETARY_SUPPLEMENT|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
223519623|NCT03317873|DIETARY_SUPPLEMENT|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
223519624|NCT03131479|DRUG|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
223519625|NCT01272219|DRUG|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
223519626|NCT01272219|DRUG|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
223519627|NCT01272219|DRUG|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
223519628|NCT01272219|DRUG|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
223519629|NCT01906320|BEHAVIORAL|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
223519630|NCT02009449|DRUG|Pegilodecakin|Daily subcutaneous injections of pegilodecakin up to 12 months
223519631|NCT02009449|DRUG|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
223519632|NCT02009449|DRUG|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
223519633|NCT02009449|DRUG|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
223519634|NCT02009449|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
223519635|NCT02009449|DRUG|Pazopanib|Pazopanib will be administered orally daily continuously
223519636|NCT02009449|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
223519637|NCT02009449|DRUG|Paclitaxel|"Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
223519638|NCT02009449|DRUG|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
223519639|NCT02009449|DRUG|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
223519640|NCT06087289|DRUG|KAND567|"KAND567 is a drug in capsule and is intended to be orally administered approximately every 12 hours (±1 hour) with an initial loading dose on Day 2 of two times the dose specified for that dose group (e.g., 2 x 250, 2 x 375, 2 x 500, or 2 x 625 mg KAND567, depending on the dose group; in Part 2, this is the RPIID), followed by a KAND567 dose (Day 2, evening dose) that corresponds to the given dose level. On Days 3 to 7, the subjects will be orally administered the specified KAND567 dose (e.g., 250, 375, 500, or 625 mg BID, depending on the dose group; in Part 2, this is the RPIID).~During the second week of dosing (Days 8 to 14) in Part 1 and Part 2, the subjects will be orally administered KAND567 at a dose of 250 mg BID. One treatment cycle is defined as a 21-day period, and each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression)."
223519641|NCT06087289|DRUG|Carboplatin|Carboplatin will be administered i.v. according to standard of care at a dose of AUC 5. One cycle is defined as a 21-day period with chemotherapy given on Day 1. Each subject will receive up to 6 treatment cycles (or until unacceptable toxicity or disease progression). The carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC 5 × (GFR + 25). GFR should be calculated using the Cockcroft-Gault formula. The maximum carboplatin dose is based on a calculated GFR that is capped at 125 mL/min for subjects with normal renal function.
223519642|NCT02365688|PROCEDURE|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
223519643|NCT04487821|OTHER|Cawthorne Cooksey Exercises|"Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing"
223519644|NCT00050011|DRUG|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
223519645|NCT00050011|DRUG|Letrozole|Participants received Letrozole 2.5 mg daily.
223519646|NCT05607472|OTHER|blood sampling|blood samples for bio collection
223519647|NCT05607472|OTHER|questionnary of health estate during 18 month|clinical exam Charlson comorbidity classification questionaries : SHERE and EHAD (emotional evaluation), SF-12, EQ-5D-5L, MFIS-5 (Fatigue evaluation) during 18 months
223519648|NCT03035097|OTHER|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
223519649|NCT05939544|DIETARY_SUPPLEMENT|Experimental: Milk Fat Globule Membrane-enriched Powdered Ingredient|Milk Fat Globule Membrane-enriched Powdered Ingredient
223519650|NCT05939544|DIETARY_SUPPLEMENT|Placebo Comparator: Control (Placebo) Powdered Ingredient|Placebo Comparator: Control (Placebo) Powdered Ingredient
223519651|NCT06362629|BEHAVIORAL|Artificial Intelligence assistant decision-making system (AIADMS) App|Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
223519652|NCT04806373|DRUG|Cathflo Activase|Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
223519653|NCT04806373|DRUG|Talc Slurry Pleurodesis|Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
223519654|NCT05449873|PROCEDURE|Radiofrequency ablation using combined bipolar and monopolar energy deliver with Triple Cooled-Wet electrodes|Radiofrequency ablation will be performed by using triple cooled-wet electrodes. Two or three electrodes will be places around the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF, bipolar mode and switching monopolar mode) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C.
223519655|NCT00423865|DRUG|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
223519656|NCT00423865|DRUG|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
223519657|NCT00423865|GENETIC|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
223519658|NCT00423865|OTHER|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
223519659|NCT00423865|OTHER|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
223519660|NCT00423865|OTHER|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
223519661|NCT00423865|PROCEDURE|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
224274876|NCT06679491|OTHER|Continuous resistance training program (C)|"This intervention consists of a 13-week structured resistance training program with a continuous training intensity maintained throughout the menstrual cycle. Participants perform two resistance training sessions per week, each lasting 90 minutes, with a consistent training load applied across all phases.~Intensity Modulation:~All Phases: Training sessions are conducted at a steady training load regardless of menstrual phase. This continuous approach is designed to provide a baseline for assessing neuromuscular adaptations without the influence of phase-specific intensity adjustments."
223519662|NCT05513508|PROCEDURE|Protocolized rotational use of interfaces|The NIV mask will be changed every 6 hours, alternating two different interfaces between the two most used in that center among those available i.e., oro-nasal, total face or hybrid mask.
223519663|NCT05513508|PROCEDURE|Standard of care|Mask will be chosen according to the standard of care of the participating centers among the three types of masks available i.e., oro-nasal, total face or hybrid mask. Interface will be changed in case of discomfort judged by the patient as unbearable or in case of the presence of a pressure sore.
223519664|NCT06566300|PROCEDURE|injection of autologous nanofat grafting|Injection of nanfat graft
223519665|NCT06566300|PROCEDURE|microneedling with autologus nanofat graft|delivery of nanofat graft with microneedling
223519666|NCT06568796|OTHER|randomize controlled study|eswt treatment
223519667|NCT05810597|DRUG|Tirzepatide|Administered SC
223519668|NCT05810597|DEVICE|Single Dose Pen|Used to administer tirzepatide SC
223519669|NCT05810597|DEVICE|Multi-use Prefilled Pen|Used to administer tirzepatide SC
223519670|NCT02866331|DRUG|G-CSF (Leucostim)|
223519671|NCT02866331|BIOLOGICAL|CB (autologous cord blood)|
223519672|NCT02866331|DRUG|Placebo (Normal saline)|
223519673|NCT05899959|DEVICE|Corsano CardioWatch 287-2|Patients receive either an EKG holter or an automatic blood pressure cuff, as prescribed by their cardiologist. The readings from these devices (atrial fibrillation detection and blood pressure) will be compared to the readings from the CardioWatch 287-2.
223519674|NCT03845166|DRUG|XL092|oral doses of XL092
223519675|NCT03845166|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)
224274877|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 subcutaneously.
223519676|NCT03845166|DRUG|Avelumab|Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)
223519677|NCT02913846|OTHER|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
224274878|NCT05848440|DRUG|AZD9550|Participants will be administered AZD9550 intravenously.
224274879|NCT05848440|DRUG|Placebo|Participants will be administered matching volumes of placebo subcutaneously or intravenously.
223519678|NCT02913846|OTHER|Muscular assessment|An assessment of muscular force will be performed once a week.
223519679|NCT02913846|OTHER|Pre-albumine dosage|Dosage performed once a month.
223519680|NCT02214212|DEVICE|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
223519681|NCT02214212|DEVICE|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
223519682|NCT06025708|DEVICE|Diagnostic Test: Quantra QStat Cartridge|Whole blood coagulation testing system
223519683|NCT06362889|COMBINATION_PRODUCT|Microneedling with CBD|Cannabidiol (CBD) Isolate- 90-100mg / 1mL of carrier oil Organic Hemp Seed Oil- used as carrier oil for CBD isolate in Combination with Microneedling Device
223519684|NCT05944237|DRUG|HTL0039732 Capsules|HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
223519685|NCT05944237|DRUG|HTL0039732 Capsules and atezolizumab infusion|HTL0039732 Capsules will be administered orally on a QD schedule to participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
223519686|NCT01285232|DRUG|Anakinra|150 mg sc once daily during four weeks
223519687|NCT04354857|OTHER|olfactory and gustatory tests|"Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste"
223519688|NCT04065334|BEHAVIORAL|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
223519689|NCT04065334|BEHAVIORAL|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
223519690|NCT05021224|BEHAVIORAL|Caring Contacts|Non-demanding message sent from the care team
223519691|NCT05021224|BEHAVIORAL|Reminders|Appointment reminders sent electronically
223519692|NCT05021224|BEHAVIORAL|Informational Poster|An informational poster linking to an infographic
223519693|NCT05021224|BEHAVIORAL|Motivational Interviewing|Motivational interviewing training for intake coordinators
223519694|NCT06468865|DEVICE|Continuous glucose monitor (Dexcom® G7)|Continuous glucose monitors measures glucose levels in the interstitial fluid every 5 minutes
223519695|NCT06171737|BEHAVIORAL|Decision Aid|The American College of Cardiology decision aid: Treatment Options for Severe Aortic Stenosis for patients deciding between Tavi and Surgery
223519696|NCT06171737|BEHAVIORAL|Shared Decision Making Skills Training|60-minute online training session that will provide practical tips, interactive case studies and tools for conducting shared decision making conversations covering core competencies
223519697|NCT03535987|DEVICE|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
224274880|NCT00098891|DRUG|entinostat|Given orally
224274881|NCT00098891|DRUG|isotretinoin|Given orally
224274882|NCT04124250|OTHER|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
223519698|NCT05966675|DEVICE|conduction system pacing|Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).
223519699|NCT05966675|DEVICE|right ventricular or biventricular pacing|Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
223519700|NCT03223987|DIETARY_SUPPLEMENT|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
223519701|NCT06047717|OTHER|Virtual Reality Driving Task|"Participants will steer a virtual car with the goal of staying in the center of a single-lane roadway while traveling at a constant speed of 26.6 m/s (approximately 60 miles/hr). The roadway alternates between a series of straights and turns of different radii to both the left and the right. This allows for careful control of task difficulty, and for the repeated presentation of specific conditions across multiple trials (i.e. turns in the road) in a randomized order. In addition, the density of the visual texture elements in the virtual environment that provide optic flow (OF) signal is also varied. The low-density OF condition has no road texture or foliage, and only the solid road edges on a flat-black ground plane. The medium-density OF condition has sparse textural elements distributed on the ground plane, and the high-density OF condition has high density road texture and a canopy of road-side trees that provide texture extending far above the horizon."
223519702|NCT02061085|DRUG|Eribulin|
223519703|NCT05861752|BEHAVIORAL|Treatment as usual|both groups will undergo a psychiatric assessment including interviews, impulsivity tests and fill out questionnaires and leave blood samples. The clinical population will be followed regarding treatment as usual
223519704|NCT06289062|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery
223519705|NCT06289062|DRUG|Cisplatin|75-80mg/m2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg/min.
223519706|NCT06289062|DRUG|Nab paclitaxel|260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
223519707|NCT06289062|PROCEDURE|biopsy|cone biopsy + pelvic lymphadenectomy or Cervical biopsy + pelvic lymphadenectomy
223519708|NCT03503331|DRUG|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
223519709|NCT02118246|DEVICE|Dry Needling|Dry needling was performed for one week, three times a week.
223519710|NCT02118246|DEVICE|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
223519711|NCT03538808|DRUG|Varenicline|Participants will be provided varenicline medication
223519712|NCT03538808|OTHER|Placebo|Participants will be provided placebo medication
224083229|NCT01243736|DRUG|Combination Prep|"combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
223519713|NCT04903093|DRUG|Abrocitinib tablet|Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.
223519714|NCT04903093|DRUG|Abrocitinib Suspension F1|Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.
223519715|NCT04903093|DRUG|Abrocitinib Suspension F2|Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.
223519716|NCT04903093|DRUG|Abrocitinib Suspension F3|Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.
223519717|NCT04903093|DRUG|Abrocitinib Suspension F4|Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.
223519718|NCT04903093|DRUG|Abrocitinib Suspension F5|Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.
223519719|NCT04903093|DRUG|Abrocitinib Suspension F6|Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.
223519720|NCT04903093|DRUG|Famotidine|Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.
223519721|NCT01097681|DRUG|ASP1941|oral
223519722|NCT01417988|DRUG|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
223519723|NCT01417988|DRUG|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
223519724|NCT04236154|OTHER|Pedometer|Participants will wear a pedometer for 4 days at baseline, and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
223519725|NCT04236154|OTHER|Actigraph|Participants will wear a Actigraph for 4 days at baseline and 4-6 weeks later. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
223519726|NCT04236154|OTHER|Perturbation Treadmill|Participants will walk on an instrumented treadmill while wearing a safety harness at baseline and 4-6 weeks later. The perturbation treadmill will assess an individual's risk for falling. Baseline readings will be used to derive an individualized exercise program for each participant based on the assigned experimental arm.
223519727|NCT03774121|DEVICE|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve \& anterior femoral cutaneous nerve) guided by ultrasound visualization.
223519728|NCT03774121|OTHER|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
223519729|NCT03774121|DEVICE|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
223519730|NCT00515229|DRUG|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
223519731|NCT02392728|BEHAVIORAL|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
223519732|NCT02392728|BEHAVIORAL|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
223519733|NCT02412436|DRUG|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
223519734|NCT06077279|BEHAVIORAL|Horticultural Therapy Program|Horticultural Therapy Program Is selected plant therapy
223519735|NCT06026696|OTHER|follow-up|Long term follow-up
223519736|NCT06019832|PROCEDURE|Total Knee Arthroplasty (TKA)|Both study arms will undergo TKA
223519737|NCT06019832|DEVICE|Stemmed Tibial Implant|A stemmed tibial implant
223519738|NCT06019832|DEVICE|Non-stemmed tibial implant|non-stemmed tibial implants
223519739|NCT06481813|OTHER|Blood Sampling (2*8mL Tubes)|Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)
223519740|NCT06481813|OTHER|PBMC Sampling (1*8mL Tubes)|Patients will be sampled from 1 x 8 mL PBMC
223519741|NCT06481813|OTHER|Paxgene Sampling|Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube
223519742|NCT06481813|PROCEDURE|Extended biopsies of tumor lesions|"Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.~The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.~For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.~In the case of a complex biopsy, no additional sampling related to the research will be performed."
223519743|NCT04002934|DRUG|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
223519744|NCT02102802|DRUG|Midomafetamine|125, 75, or 30 mg midomafetamine HCl followed 1.5 to 2 hours later by a supplemental dose of midomafetamine HCl half the initial dose
223519745|NCT02102802|BEHAVIORAL|Therapy|Manualized therapy
223519746|NCT04926285|DRUG|Omacetaxine|Escalating doses of Omacetaxine 0.625 mg/m2 q12h, 1.25 mg/m2 q12h, 2.0 mg/m2 q12h, and 2.5 mg/m2 q12h
223519747|NCT04926285|DRUG|Venetoclax|Venetoclax at 400mg
223519748|NCT00622843|BIOLOGICAL|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
223519749|NCT00622843|BIOLOGICAL|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
223519750|NCT05649540|DRUG|Vonoprazan|Potassium-competitive acid blocker
223519751|NCT05649540|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223519752|NCT04233385|OTHER|Myofascial Massage|The myofascial protocol outlines techniques, areas of the body, as well as time to be spent for each technique for a total of 25 minutes. The remaining 5 minutes of the massage are for the massage therapist to tailor myofascial massage to the needs and circumstances of each participant. In order to provide some level of customization, the therapist will determine the impact of massage on the participant's pre-existing pain and/or mobility limitations. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will use effleurage and petrissage techniques to gently massage the identified locations to soften and release the tissues. Techniques used will include deep friction of muscles, sustained compression, and fascial stretch.
223519753|NCT04233385|OTHER|Light Touch|Participants randomized to this group will receive 30 minutes of light touch to their affected breast, chest, and shoulder areas twice a week for 2 months. Therapists will follow a detailed light touch protocol for each of the 16 sessions. In addition, the therapist will inquire about the participant's response to the previous light touch treatment. Second, the therapist will assess the soft tissues around the affected breast, chest, and shoulder to determine the locations of pain, tissue firmness, and restricted mobility. Third, the therapist will place both hands on the participant for 3 minutes at each identified location. Pressure will be very light and consistent, with no side-to-side movement.
223519754|NCT04516213|OTHER|Enteral Formula With (PHGG)|Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)
223519755|NCT05107271|DIAGNOSTIC_TEST|COVID-19 serosurvey|COVID-19 related antibody testing to assess immunogenicity of COVID-19 vaccines or post natural infection acquired immunity
223519756|NCT01812941|OTHER|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
223519757|NCT01812941|OTHER|healthy volunteers: blood collection|blood collected at designated time intervals
223519758|NCT01812941|OTHER|Burn: blood collection|blood collected at designated time intervals
223519759|NCT00306098|DRUG|islets|Intraportal infusion of islets
223519760|NCT00608790|DRUG|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
223519761|NCT00608790|DRUG|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
223519762|NCT04418505|DEVICE|Vielight RX Plus|The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
223519763|NCT06375863|DIAGNOSTIC_TEST|QT and QTc interval|measuring of QT and QTc on ECG
223519764|NCT00842803|DRUG|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
223519765|NCT02017834|PROCEDURE|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
223519766|NCT05558085|BEHAVIORAL|Expanded Food and Nutrition Education Program (EFNEP)|Subjects will participate in nine hands-on EFNEP lessons to teach nutrition, healthy lifestyle choices, physical activity, food preparation, food safety, and food resource management.
223519767|NCT01515215|DEVICE|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
223519768|NCT01323374|DRUG|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
223519769|NCT01323374|DRUG|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
223519770|NCT01323374|DRUG|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
223519771|NCT01323374|DRUG|Placebo|Oral, placebo TID
223519772|NCT02120248|OTHER|Telephone-based breastfeeding peer counseling|
223519773|NCT01407341|PROCEDURE|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
223519774|NCT01407341|PROCEDURE|bone graft|Receive beta tricalcium-phosphate bone graft
223519775|NCT01407341|PROCEDURE|quality-of-life assessment|Ancillary studies
223519776|NCT01407341|OTHER|questionnaire administration|Ancillary studies
223519777|NCT00586937|BEHAVIORAL|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
223519778|NCT05179915|OTHER|Therapeutic Touch focused on sacral region|In the latent phase of labor, the field energy of the sacral region will be cleared for an average of 15 minutes.
223519779|NCT00236665|DRUG|topiramate|
223519780|NCT03487510|OTHER|NO interventions apply|does not apply
223519781|NCT06487286|OTHER|observational study|observational study
223519782|NCT04825262|DRUG|Tacrolimus|Starting dose based on CYP3A5 genotype
223519783|NCT00410436|BEHAVIORAL|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
223519784|NCT00057577|BEHAVIORAL|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
223519785|NCT00057577|DRUG|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
223519786|NCT04090749|BEHAVIORAL|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
223519787|NCT04351672|BEHAVIORAL|Early Time-Restricted Feeding|Eat between 8 am and 4 pm for two weeks
223519788|NCT04351672|BEHAVIORAL|Late Time-Restricted Feeding|Eat between 1 pm and 9 pm for two weeks
223519789|NCT05004298|OTHER|Animal Assited therapy|The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
223519790|NCT05389371|BEHAVIORAL|Alberta Healthy Living Program|Weight management services
223519791|NCT05389371|BEHAVIORAL|Alberta Obesity Centre Program|Multi-disciplinary obesity management
223519792|NCT05389371|BEHAVIORAL|Osteoarthritis advice|Living Your Best Life with Osteoarthritis Handbook
223893684|NCT06037369|BEHAVIORAL|customized standardized educational program sent by LINE software.|At each visit of the research subjects to plastic clinic, the research team record the attending prescriptions and patient educations given by the medical team members, and evaluate whether the research subjects and caregivers need additional mental support or not. Then, according to the above evaluation and records, items of a designed patient education menu will be selected, and the selected patient education messages will be sent according to the transmission frequency and time period proposed by the research object.
223519793|NCT05389371|BEHAVIORAL|Physiotherapy|GLA:D physiotherapy programs.
223519794|NCT02272010|OTHER|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
223519795|NCT02272010|OTHER|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
223519796|NCT03094221|DEVICE|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
223519797|NCT03915756|PROCEDURE|Drainage of surgical wound|Introduction of a drain before full fascial closure
223519798|NCT03424980|COMBINATION_PRODUCT|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
223519799|NCT02577302|DEVICE|CAN-Stim - Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
223519800|NCT02577302|DEVICE|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
224274883|NCT04299776|DEVICE|CirQPOD|CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.
224274884|NCT04299776|DEVICE|Standard airway management|Standard airway management during surgery (PEEP of +5 cmH2O)
224274885|NCT05955469|DEVICE|FS4 then TFS4 (cochlear implant)|Cochlear implant with default fitting then with tonotopy-based fitting
224274886|NCT05955469|DEVICE|TFS4 then FS4 (cochlear implant)|Cochlear implant with tonotopy-based fitting then with default fitting
224274887|NCT00001108|DRUG|Ritonavir|
224274888|NCT00001108|DRUG|Nelfinavir mesylate|
224274889|NCT00001108|DRUG|Saquinavir|
224274890|NCT00001108|DRUG|Nevirapine|
224274891|NCT00001108|DRUG|Lamivudine|
224274892|NCT00001108|DRUG|Stavudine|
224274893|NCT00001108|DRUG|Didanosine|
224274894|NCT03965624|DRUG|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
224274895|NCT01940302|DIETARY_SUPPLEMENT|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
224274896|NCT00136890|PROCEDURE|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
224274897|NCT04890964|DEVICE|Transcranial Direct Current Stimulation (tDCS)|A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
224274898|NCT01121107|DEVICE|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
224274899|NCT01121107|DEVICE|Patient Advisory Module|Handheld device that provides medication reminders
224274900|NCT06617507|OTHER|Group 1|The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
224274901|NCT05372497|OTHER|Intervention group (IG)|"Participants randomized to this treatment will receive a central nervous system-focused intervention consisting of a 20-session treatment program delivered in 30-45-minute sessions scheduled 5 days a week over a 4-week period and standard physical therapy will be continued.~* Chronic pain training will be given according to the needs of the person and 5-10 minutes will be allocated every day for the first week and chronic pain education will be divided into modules.~* Right / Left Discrimination Training~* Localization Training Level 1- Level 2 Training~* Visual imagination Training~* Visual Imagery Training~* Mirror Therapy~* Isometric and functional exercises"
224274902|NCT05372497|OTHER|Control group (CG)|"The control group will receive only conventional physiotherapy. Conventional physiotherapy will be 5 days a week.~The conventional physiotherapy treatment session will take place as follows.~* Electrotherapy~* Scapular mobilization~* Passive stretches~* Stick Exercises~* Pendulum Exercises~* Shoulder flexion, extension, internal rotation, external rotation, horizontal abduction/ adduction strengthening exercises~Conventional physiotherapy intervention is planned for 45-60 minutes a day, five days a week for both groups."
224274903|NCT03263078|DRUG|Propofol|For the maintenance of anesthesia, we used 2% propofol (Fresofol®, Fresenius Kabi, Germany) administered by the target controlled infusion (TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) in Schnider mode with an effect concentration (Ce) of 2.5-3.5 µg ml-1
224274904|NCT03263078|DRUG|Sevoflurane|Anesthesia was maintained using 1-3% sevoflurane (ULTANE®, AbbVie Inc., USA) in the Sevoflurane group.
224274905|NCT00317434|DRUG|lapatinib|
224274906|NCT04372134|DEVICE|repetitive transcranial magnetic stimulation therapy|A sham-controlled double-blind randomized study was undertaken. 28 patients with chronic (\>1 year) motor incomplete traumatic SCI were randomized into real rTMS group (n=14) or sham rTMS group (n=14). Real rTMS (20 Hz, a total of 1600 stimuli) or sham r TMS were applied in the motor cortex area of lower extremities during 3 weeks (15 sessions). In addition to rTMS sessions, patients underwent a rehabilitation program including exercises for strengthening, walking and balance.
224274907|NCT00814606|DRUG|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
224274908|NCT00814606|DRUG|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
224274909|NCT00814606|DRUG|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
223893685|NCT03411083|PROCEDURE|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery including same day surgery
223519801|NCT03361007|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
223519802|NCT05983900|PROCEDURE|BRIX3000|chemo-mechanical caries removal agent
223519803|NCT05983900|PROCEDURE|papacarie|chemo-mechanical caries removal agent
223519804|NCT05983900|PROCEDURE|hand excavation|mechanical caries removal
223519805|NCT02416388|DRUG|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~\+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
223519806|NCT02416388|DRUG|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~\+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
224274910|NCT03084809|DRUG|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
224274911|NCT03084809|DRUG|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
224274912|NCT06532409|DRUG|Amoxicillin/CA|Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
224274913|NCT06532409|DRUG|IV ceftriaxone|Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
224274914|NCT03243396|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
224274915|NCT05623046|BEHAVIORAL|Treatment|8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes
224274916|NCT03687242|DRUG|SPR001|Open label SPR001
224274917|NCT04111705|DRUG|Lorlatinib|100 mg once daily
224274918|NCT04489225|OTHER|Observational|Observational only without any intervention
224274919|NCT03759028|DRUG|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
224274920|NCT03759028|DRUG|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
224274921|NCT03759028|DRUG|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
224274922|NCT02697227|BEHAVIORAL|Behavioral Intervention|Receive BATS counseling
223519807|NCT02416388|DRUG|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
223519808|NCT02416388|DRUG|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
223519809|NCT02416388|DRUG|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
223519810|NCT02416388|DRUG|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
224274923|NCT02697227|OTHER|Laboratory Biomarker Analysis|Correlative studies
224274924|NCT02697227|DRUG|Nicotine Patch|Receive nicotine patch
224274925|NCT02697227|OTHER|Questionnaire Administration|Ancillary studies
224274926|NCT02697227|BEHAVIORAL|Smoking Cessation Intervention|Receive standard smoking cessation counseling
224274927|NCT04857593|BEHAVIORAL|Melodies for Mums|"Classes start with a chat between mothers and the artist. The singing session will include welcome songs, introducing the babies and mothers to one another, and then involve a range of singing and music activities. These will include learning songs from around the world, ranging from short vocal exercises that use motherese style noises and sound effects (including sound baths where the mothers sang a sustained note providing a relaxation technique), to simple lullabies that can be picked up very quickly and sung in basic harmonies or rounds, to longer or more complex songs that will be learnt gradually over the weeks. Instruments such as guitar and ukulele will also be used by the artist for a small number of songs. Mothers will also work to write some of their own songs over the weeks, developing lyrics together about their babies or experiences of motherhood and creating simple melodies. Classes will be led by workshop leaders trained by Breathe, with support of assistants."
224274928|NCT02148744|BIOLOGICAL|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
223519811|NCT02416388|DRUG|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
223519812|NCT02416388|DRUG|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
223519813|NCT02416388|DRUG|Dexamethasone|"Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5"
223704114|NCT02698878|OTHER|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
224274929|NCT02148744|BIOLOGICAL|Placebo|
224274930|NCT03772756|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
223519814|NCT02416388|DRUG|Venetoclax|"Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)"
223519815|NCT03765021|DRUG|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
223519816|NCT03765021|DEVICE|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
223519817|NCT02184442|DEVICE|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
223519818|NCT02184442|DEVICE|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
223519819|NCT03307590|DRUG|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
223519820|NCT03307590|DRUG|Bupivacaine|Caudal block by bupivavaine alone
223519821|NCT05318560|DRUG|Lidocaine 2% Injectable Solution|for MPS
223519822|NCT05318560|DRUG|Ozone|for MPS
223519823|NCT05318560|OTHER|stretching exercise|for MPS
223519824|NCT04918914|DRUG|Dapsone 100 MG|Dapsone 100-200 md orally daily, along with Cimetadine 400 mg PO TID
223519825|NCT00010907|DRUG|NPI-028|
223519826|NCT00233961|BIOLOGICAL|filgrastim|
223519827|NCT03644758|DIAGNOSTIC_TEST|socio-demographic data and personal medical history|Socio-demographic data and personal medical history is a self-administered questionnaire.
223519828|NCT03644758|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
223519829|NCT03644758|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
224274931|NCT03772756|RADIATION|chemoradiotherapy|Receive chemoradiotherapy
223519830|NCT03644758|DIAGNOSTIC_TEST|Insomnia Severity Index (ISI)|Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
223519831|NCT03644758|DIAGNOSTIC_TEST|stop-BANG questionnaire|Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
223519832|NCT03177915|DRUG|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
223519833|NCT03177915|DRUG|Saline|median nerve hydro-dissection using 10 cc saline injection
223519834|NCT01852214|DRUG|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
223519835|NCT01852214|DRUG|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
224274932|NCT05811819|DEVICE|Treatment using the MyHand System|Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
223519836|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
223519837|NCT02853773|OTHER|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
223519838|NCT02853773|OTHER|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
223519839|NCT04091438|DRUG|TAK-925|TAK-925 IV infusion.
223519840|NCT04091438|DRUG|TAK-925 Placebo|TAK-925 placebo-matching IV infusion.
223519841|NCT00421408|DIETARY_SUPPLEMENT|Whey protein supplement|40-g whey protein supplement daily for 18 months
223519842|NCT00421408|DIETARY_SUPPLEMENT|Placebo|Placebo supplement daily for 18 months
223519843|NCT03643588|DEVICE|HYAJOINT Plus|Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
223519844|NCT03643588|DEVICE|Hyalgan|Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
223519845|NCT05530538|BEHAVIORAL|BrainWeighve App|46 total adolescents (14-18 years old) with %BMIp95 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll two successive groups of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually).
223519846|NCT03088111|OTHER|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
223519847|NCT03088111|BIOLOGICAL|Obiltoxaximab|Obiltoxaximab standard of care
224083230|NCT03671928|OTHER|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
224274933|NCT02655224|DRUG|Relugolix|Relugolix Tablets
224274934|NCT02655224|DRUG|Relugolix placebo|Relugolix placebo-matching tablets
224274935|NCT01257581|DRUG|creatine|creatine monohydrate powder
224274936|NCT01257581|DRUG|tamoxifen|Tamoxifen citrate capsules
223519848|NCT02370693|DRUG|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
223519849|NCT02370693|DRUG|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
223519850|NCT02370693|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
223519851|NCT02691494|DRUG|Elagolix|Film-coated tablets
223519852|NCT02691494|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
223519853|NCT02691494|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
223519854|NCT02691494|DRUG|Placebo for Elagolix|Film-coated placebo tablets
223519855|NCT02390999|PROCEDURE|48 hours of therapeutic hypothermia|
223519856|NCT02557165|PROCEDURE|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
223519857|NCT01955265|BEHAVIORAL|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
223519858|NCT01955265|BEHAVIORAL|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
224274937|NCT06137781|BEHAVIORAL|Six weeks of digital prehabilitation|All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
224274938|NCT06148779|BEHAVIORAL|Digitally delivered first-line treatment for osteoarthritis|Digitally delivered first-line for osteoarthritis through the caregiver Joint Academy.
223519859|NCT00677300|DRUG|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
223519860|NCT00677300|DRUG|Darunavir|800 mg P.O. (orally) once daily
223519861|NCT00677300|DRUG|Ritonavir|100mg once daily
223519862|NCT00677300|DRUG|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
224274939|NCT06148779|BEHAVIORAL|Face-to-face first-line treatment for osteoarthritis|First-line for osteoarthritis delivered at a primary care clinic face-to-face with reported data to the BOA registry.
223519863|NCT02157337|DRUG|Atorvastatin|80 mg (PO) once daily for 6 days
223519864|NCT02157337|DRUG|placebo|80 mg (PO) once daily for 6 days
223519865|NCT02481141|DRUG|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
223519866|NCT02481141|DRUG|Placebo|
223519867|NCT06105398|OTHER|clinical evaluation|clinical evaluation tests
223519868|NCT00557739|DRUG|mometasone furoate|Topical 0.1% mometasone furoate
223519869|NCT00557739|DRUG|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
223519870|NCT00557739|DRUG|Vehicle (placebo)|Topical placebo
223519871|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through single incision|Group I: experimental - single incision The surgical technique chosen for thumb basal join was trapeziectomy with ligamentous reconstruction and tendon interposition (LRTI), using flexor carpi radialis (FCR). Through a dorsal approach over trapeziometacarpal joint, the entire trapezium was excised. Volar traction of FCR allowed us to longitudinally incise the deep leaflet of FCR tendon until flexor pollicis longus (FPL) tendon was clearly visualized. Then, ulnar half of FCR tendon was harvested proximally through a second transverse incision in middle third of the forearm and split all the way to its insertion on the index metacarpal. A hole was placed in the base of the first metacarpal and FCR tendon was routed through the bone canal and then fixed with non-reabsorbable sutures. Finally, the tendon remanent was rolled up and placed into the trapezial void to act as a spacer.
223519872|NCT04391751|PROCEDURE|Carpal tunnel release and basal joint arthroplasty through double incision|Group II: active comparator - double incision Trapezial excision and ligament reconstruction were performed in the same way as in group I, except that FCR deep leaflet was not incised. After radial incision wound closure, carpal tunnel release was performed through a second separate longitudinal palmar incision.
223519873|NCT01014312|BEHAVIORAL|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
223519874|NCT01014312|BEHAVIORAL|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
223519875|NCT00400088|DRUG|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
223519876|NCT00400088|DRUG|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
223519877|NCT04778709|DEVICE|Puros allograft|"Bilateral sinus augmentation procedure using the lateral window technique. Graft material combination A or B will be randomly assigned to right and left sinus.~Each subject will receive the following bone allograft material:~Four to six grams of commercially available human donor bone allograft (Puros Allograft Bone Particles, Zimmer Biomet, Palm Beach Gardens, FL USA) consisting of Graft A cortical and cancellous bone chips of both 250-1000 microns and 1000-2000 microns size, or Graft B for contralateral sinus: cancellous 1000-2000 microns size alone."
223519878|NCT02197988|DRUG|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
223519879|NCT02197988|DRUG|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
223519880|NCT02842242|DRUG|MYK-461|
223519881|NCT06609057|OTHER|Nutritional Intervention|Receive Cooking for Your Health in Southern New Mexico intervention
223519882|NCT06609057|OTHER|Questionnaire Administration|Ancillary studies
223519883|NCT06609057|OTHER|Survey Administration|Ancillary studies
223519884|NCT06609057|OTHER|Discussion|Ancillary studies
223519885|NCT03249558|DRUG|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
223519886|NCT03249558|DRUG|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
223519887|NCT03249558|DRUG|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
223519888|NCT06670521|DRUG|Methylprednisolone|50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
223519889|NCT06670521|DRUG|Normal Saline|Normal Saline placebo IV every 6 hours for 4 doses
223519890|NCT05032911|DIAGNOSTIC_TEST|sensorimotor control analysis using inertial sensor technology|Inertial Measurement Unit (IMU) sensors will measure sensorimotor control variables including active range of motion, movement speed, acceleration, smoothness of motion, head repositioning accuracy and motion coupling patterns
223519891|NCT06407401|DRUG|Duloxetine 60 MG|"Patients randomized to the duloxetine arm will take duloxetine orally daily, with or without food, on a continuous dosing schedule.~Initial dose is 30 mg daily for 1 week, followed by 60 mg daily for a total of 6 months of treatment, followed by a taper off the medication of 30 mg daily for 1 additional week."
223519892|NCT06407401|DRUG|Furosemide 40 mg|Patients randomized to the furosemide arm will take furosemide 40 mg orally daily, on an empty stomach with plenty of liquid, on a continuous dosing schedule.
223519893|NCT06407401|BEHAVIORAL|Booklet for healthy behaviors|All patients will receive usual care, including a booklet focused on healthy behaviors, particularly physical exercise, to manage endocrine therapy side-effects.
223519894|NCT05290298|DIETARY_SUPPLEMENT|NITRATE|Multi-component nutritional formula
223519895|NCT05290298|DIETARY_SUPPLEMENT|PLACEBO|Placebo
223519896|NCT05483140|OTHER|Option 1|Partial meal replacement to achieve 900-1000 kcal/day (4 meal replacement products per day combined with 150-200 kcal from vegetable meals (recipes provided))
223519897|NCT05483140|OTHER|Option 2|Partial meal replacement to achieve 900-1000 kcal/day (2 meal replacement products per day combined with one balanced meal (recipes provided))
223519898|NCT05483140|OTHER|Option 3|A real food low energy diet to achieve 800-1000 kcal/day (recipes provided)
223519899|NCT03549507|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
223519900|NCT02613507|DRUG|Nivolumab|
223519901|NCT02613507|DRUG|Docetaxel|
223519902|NCT03941093|DRUG|Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
223519903|NCT03941093|DRUG|Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion.~Drug: FOLFIRINOX is a combination of several agents administered on Days 1 and 15 of each 28 day treatment cycle via IV infusion. The specific agents are Oxaliplatin, Folinic Acid, Irinotecan, and Fluorouracil."
223519904|NCT03918031|BEHAVIORAL|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
223519905|NCT03918031|BEHAVIORAL|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
224274940|NCT01536249|DRUG|Dexpramipexole|Single Oral Dose
224274941|NCT01536249|DRUG|Cimetidine plus Dexpramipexole|Multiple Oral Doses
223519906|NCT07011095|DRUG|VKA|Warfarin
223519907|NCT07011095|DRUG|Direct Oral Anticoagulant (DOAC)|Locally approved DOACs
223519908|NCT07010679|OTHER|Patient Centered CRS Treatment Decision Support|"The intervention is a web-based tool that includes:~* Educational content and Frequently Asked Questions (FAQ) about CRS and treatment options~* Patient stories from CRS patient interviews with artificial intelligence-assisted narrative writing~* A communication tool to support discussions between patients and their doctors~* Culturally tailored components, including Chinese language options and culturally relevant narratives Participants will be introduced to the PC CDS during a routine clinic visit or through a scheduled virtual meeting. They will use the tool before making treatment decisions. The tool is designed to be user-friendly and accessible across devices."
223519909|NCT06688669|OTHER|Fabrication of suitable complete or removable partial dentures for the patient|Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.
223519910|NCT06690723|DRUG|Dapagliflozin (Forxiga)|Dapagliflozin plus lifestyle modification
223519911|NCT06690723|DRUG|Vitamin D3 ( Colecalciferol)|Vitamin D3 plus lifestyle modification
223519912|NCT06690723|DRUG|Vitamin D3 plus Dapagliflozin|Vitamin D3 plus Dapagliflozin plus lifestyle modification
223519913|NCT06690723|BEHAVIORAL|Lifestyle modification|Lifestyle modification alone
224083231|NCT03671928|OTHER|additional blood sample|for le group control, another blood sample is taken outside the usual care.
223519914|NCT06690268|DIAGNOSTIC_TEST|Multimodal AI-driven predictive model|This intervention involves a multimodal artificial intelligence (AI) model that integrates clinical data, imaging results, and pathology findings to predict the risk of postoperative recurrence in patients with locally advanced gastric cancer. Unlike traditional methods that may rely on single data sources, this AI-driven model synthesizes multiple types of patient information, offering a comprehensive and personalized prediction of recurrence risk. This approach aims to improve accuracy in identifying high-risk patients, allowing for more tailored follow-up and treatment planning to enhance patient outcomes.
223519915|NCT06689111|DEVICE|Left bundle branch pacing lead|Use of LBBp Vs the standard method of BiVp in resynchronization therapy
223519916|NCT06689111|DEVICE|CRT with the standard method through cs|standard CRT procedure
223519917|NCT06690944|OTHER|Proprioceptive Neuromuscular Facilitation|The following basic principles and procedures were emphasized when applying the techniques: manual contact, resistance, approximation, verbal commands, and therapist's body mechanics. During stages 1 and 2 of the intervention, the amount of PNF optimal resistance used was necessary to maintain a stable and safe position, with good body alignment, in a manner that produced coordinated movements to generate appropriate motor learning.
223519918|NCT06690944|OTHER|Physical exercise without proprioceptive neuromuscular facilitation control group|The physical exercise without proprioceptive neuromuscular facilitation control group (CG) intervention consisted of the same activities carried out in the proprioceptive neuromuscular facilitation (PNF) group during Stages 1 and 2, during the same amount of minutes, sessions, and weeks; however, CG intervention did not include specific techniques and basic principles (i.e. approximation and optimal resistance) and procedures of the PNF concept. The activities were instructed and supervised by a trained professional through verbal command. The professional was at stand-by assistant position to prevent accidents.
223519919|NCT06686043|DRUG|HPV vaccine, Imiquimod, and metformin combination therapy|Participants in the treatment arm will have visits during the 2nd and 4th weeks of radiation, and then at weeks 8, 10, 12, and 16 after radiation. At each visit, a blood sample will be taken, and tumor cells collected using a cytobrush (or directly from the tumor for vulvar cancer). An HPV vaccine will be injected into the tumor, imiquimod cream will be applied topically, and participants will receive a subcutaneous vaccine shot. They will also take metformin tablets twice daily for two weeks and apply imiquimod cream at home three nights per week. Follow-up PET/CT scans will occur at week 20 and two years post-treatment, with exams every three months for two years.
223519920|NCT06686407|PROCEDURE|Open lumbar decompression ± fusion|"Open lumbar decompression by laminectomy and transpedicular screw fixation using screws and rods ± interbody cage device"
223519921|NCT06686407|PROCEDURE|"Minimally invasive lumbar foraminal decompression using unilateral biportal endoscopy device"|A new endoscopic technique that uses a Unilater Biportal Endoscopy for lumbar foraminal decompression
223519922|NCT07011498|OTHER|Dementia choir|Music therapy informed dementia choirs will be delivered once a week. Rehearsals last app. 2 hours, including a social break. Each choir will be led by 1 conductor and 1 accompanist. The choir leaders will have relevant professional qualifications that supplement each other, such as a music therapist, music pedagogue, conductor, singer, singing teacher, or health care professional with additional music competence. They will be trained by the research team to deliver the choirs in a dementia friendly and music therapy informed way. In addition, the choir leaders will receive supervision from the research team throughout the intervention periods. The choirs will involve volunteers to assist during rehearsals and breaks. The volunteers will also receive training on how to support the choir participants in a dementia friendly way.
223519923|NCT06141460|DRUG|RRG001|Administered via Subretinal injection. Dosage form: injection solution.
223519924|NCT06693141|OTHER|ESP block|ESP block was applied to the patients.
223519925|NCT06693141|OTHER|ITM|ITM was applied to the patients.
223519926|NCT06694467|BEHAVIORAL|Education program|An official diabetes education program designed to provide people with diabetes and their families the information and abilities they need to manage their condition effectively. Diabetes kinds, blood sugar control, self-monitoring methods, nutrition, meal planning, physical activity recommendations, medication management, and problem-solving approaches are all included in these programs. Additionally, they offer psychological assistance to help people manage the emotional challenges of having diabetes.
223519927|NCT06694532|DRUG|Hyaluronic acid|Comparative study between Hyalgan and Hyorth injectable products in TMJ Disorders by arthrocentesis of 2 syringes device
223519928|NCT06694532|DEVICE|Syringes|Whilst you are asleep, two small needles will be inserted into the TMJ / Jaw Joint. One of these needles allows sterile saline to be pumped into the joint under pressure whilst the other needle allows the saline to drain out of the joint then injection of the HA injectiable products .
224274942|NCT04327336|DEVICE|Manual Non invasive ventilation titration|Manual Group: during a complete polysomnography, adding transcutaneous capnography and the basic ventilators curves, the ventilators setting will be adjusted in order to correct respiratory events and patient-ventilator asyncrony. A 10 hours face-to-face investigator training meeting is programmed before opening the inclusion period.
223519929|NCT06695052|DEVICE|multi modal Us|Greyscale US: grey scale ultrasound Color Doppler US: Color Doppler ultrasound Elastography US: Elastography ultrasound
223519930|NCT06688643|DEVICE|ITM group|Patients in the ITM group underwent intrathecal injection with 0.2 mg morphine after admission to the operating room.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
223519931|NCT06688643|DEVICE|EA group|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.Mechanical ventilation was initiated in pressure-regulated volume control (PRVC) mode after induction. Ventilator settings (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) were as follows: tidal volume 6-8 ml kg-1, positive end-expiratory pressure (PEEP) 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 beats per minute (BPM), and inspired oxygen concentration 41%.
224083232|NCT03618745|DEVICE|CT brain|noninvasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body.
223519932|NCT06695000|DEVICE|digital CBT-I|The intervention is a digital Cognitive Behavioral Therapy for Insomnia (CBT-I) program, delivered via a mobile application. The program includes structured, self-guided modules focusing on sleep hygiene education, cognitive restructuring, stimulus control, bed time restriction, and relaxation techniques. Each module offers interactive exercises and weekly assignments designed to support behavior change and improve sleep. Participants will receive app-based reminders to encourage regular engagement, with features for tracking progress and adherence throughout the 6 week program.
223519933|NCT06687512|OTHER|SaaTwae Bio-Natural Moisturizing Cream|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
223519934|NCT06687512|OTHER|Placebo|"Mode of Usage: Apply a generous amount of the test product to the affected areas of atopic dermatitis. Gently massage the product into the skin until fully absorbed. Ensure that the application is consistent, especially after bathing or during flare-ups.~Frequency: Twice a day (Once before going to the bed and once after bathing and drying off and during flare ups/itching) Route of Administration: Topical"
223519935|NCT06685939|PROCEDURE|LPD|The patients who received the LPD
223519936|NCT06689124|DRUG|Nebulized fentanyl|After the enrollment process, the main research assistant will take a brown envelope containing the randomization and hand it to the principal investigator in numerical order. The principal investigator will then open the envelope to determine the group assignment for the patient, revealing which fentanyl nebulization dosage group (2 mcg/kg, 3 mcg/kg and 4 mcg/kg) the patient will be placed in. In this study, participants will be divided into three groups as previously described. We evaluate pain score at 0, 15, 30, 45, 60, 75, 90, 105 and 120 minutes after receiving nebulized fentanyl by a train research assistance who is blind from the treatment dosage.
223519937|NCT06690866|BEHAVIORAL|Stress|Montreal Imaging Stress Task is a stress paradigm in the scanner to examine neuronal correlates of acute psychosocial stress.
223519938|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Groin Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
223519939|NCT06685926|PROCEDURE|Supermicrosurgical LVA, Conventional Multiple Access Approach Only (lymphatic vessel to recipient vien lumen-to-lumen anastomosis)|
223519940|NCT06686199|DIETARY_SUPPLEMENT|steamed potato|135 g per day 4-5 times per week for 8 weeks
223519941|NCT06686199|DIETARY_SUPPLEMENT|fried potato|135 g per day 4-5 times per week for 8 weeks
223519942|NCT06689670|DEVICE|Needle based delivery of INT001 into liver tumors under real-time image guidance|Using ultrasound or CT imaging, the liver tumor is located. Under local anesthesia or, if necessary, intravenous sedation, the needle is inserted through the skin and the needle tip is brought to the center of the liver tumor using image guidance. 1-2 ml of the INT-001 is injected. The needle is removed and a bandaid is applied to the skin entry site. Right after, or as soon as MRI becomes available, MRI is performed to show that the entire tumor has been treated.
223519943|NCT06691009|PROCEDURE|Group 1 (mechanical pleurodesis)|pleural abrasions will be done by scrubbing the parietal and visceral pleura until a uniform aspect of bloody pleura by a piece of gauze attached to the end of a holding forceps , intercostal tube will then placed and monitoring of lung expansion will be done through serial CXR and chest ultrasound follow up and when the lung is fully expanded the tube will be clamped for two hours and follow up CXR will be done for follow up and then the tube removed
223519944|NCT06691009|PROCEDURE|Group 2 chemical pleurodesis by bleomycin)|Those Patients will have indwelling pleural catheter through which pleural fluid will be drained until dryness and then pleurodesis will be done by 60 mg bleomycin dissolved in 50 ml 0.9% saline and 10 ml 2% xylocaine solution then the catheter will be clamped for 6 hours
223534856|NCT00713011|DRUG|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
223534857|NCT00713011|DRUG|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
223534858|NCT05407701|DIETARY_SUPPLEMENT|Cranberry Juice|100% cranberry juice
223534859|NCT05407701|DIETARY_SUPPLEMENT|Placebo|Placebo juice
223534860|NCT00551083|OTHER|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
223704115|NCT02698878|DEVICE|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
223534861|NCT00551083|OTHER|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
223534862|NCT00794092|DRUG|Sinerem administration|Single dose
223534863|NCT02115321|DRUG|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
223534864|NCT02115321|DRUG|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
223534865|NCT02115321|DRUG|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
223519945|NCT06686095|PROCEDURE|Group Adductor canal block|Adductor canal block procedure: The patient will be informed about the technique and consent will be obtained. The patient's hip will be slightly externally rotated, and an ultrasonography linear probe will be placed on the medial thigh, at the midpoint of the patella and vastus medialis. After locating the femoral artery at approximately 3-4 cm depth, if not visible, the artery can be traced distally from the inguinal region using Doppler mode. Once the vastus medialis and sartorius muscles are identified, the superficial femoral artery is centered at the midpoint of the sartorius muscle. The adductor canal roof, along with the saphenous and vastus medialis nerves, appears as hyperechoic structures. A needle is inserted in-plane, advancing toward the anterolateral femoral artery aspect, and 5-20 mL of LA is injected.
223519946|NCT06686095|PROCEDURE|Group Genicular Nerve Block|Genicular Nerve Block: The patient is informed and consent is obtained. With a pillow in the popliteal fossa, the knee is slightly flexed. For the superior lateral genicular nerve, a linear USG probe is positioned on the lateral femoral epicondyle, moving proximally to visualize the bone metaphysis. The superolateral artery is seen between the vastus lateralis fascia and the femur. Using in-plane or out-of-plane technique, the needle is guided to the bone, and 4-5 mL of LA is injected. For the superior medial nerve, the probe is placed on the medial epicondyle and moved proximally to visualize the bone near the adductor tubercle. The artery lies between the femur and vastus medialis fascia. For the inferomedial artery, the probe is placed on the tibial medial condyle, moving distally. A negative aspiration test is conducted before each LA injection.
224274943|NCT04327336|DEVICE|Automatic Non invasive ventilation titration|Automatic Group: the A40 ventilator in the automatic AVAPS mode will be adjusted in order to achieve 8-10 ml/kg of ideal weight.
224274944|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
224274945|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
224274946|NCT02937207|DRUG|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
223519947|NCT06686095|PROCEDURE|Group IPACK Block|IPACK Block: Before the procedure, the patient is informed about the technique and written consent is obtained from the patient. The patient lies in the prone position. The linear USG probe is placed approximately 2-3 cm above the popliteal fossa and scanned distally to identify the femoral shaft and popliteal artery. If the femoral condyles are initially visualized, the probe is moved until the condyles disappear and the femoral shaft is identified as a straight line and hyperechoic. Color doppler can be used to identify the popliteal vessels. The peripheral block needle is advanced between the femoral shaft and the popliteal artery. After negative aspiration control, 15-20 mL of LA medication is injected here.
223519948|NCT06688526|OTHER|Quiet Sounds|Quiet sounds are played during sleep
223519949|NCT06688526|OTHER|Sham sounds|No sounds are played during sleep
223519950|NCT06688591|OTHER|Intervention programme to optimise medication management and prevent MRPs|The intervention is based on a four-step patient empowerment process: 1) the patient understands their role; 2) the patient acquires sufficient knowledge to be able to engage with their healthcare professionals; 3) the patient improves their skills; and 4) there is a facilitating environment (30). Each older adult participant's plan will be unique and consider their preferences, medication literacy and treatment adherence.
223519951|NCT06689280|BEHAVIORAL|Video-supervised home-based exercise training|12 weeks of patient-centered video-supervised home-based exercise training that will be kick-started during hospitalization and continued for 12 weeks after discharge, followed by 12 weeks of self-directed maintenance exercise.
223519952|NCT06685991|DRUG|Dexamethasone|Dexamethasone will be administered intravenously at varying times during anesthesia induction to assess the impact of timing on postoperative outcomes. Participants will be randomized into one of three groups: one group will receive dexamethasone before the administration of fentanyl, a second group will receive it after the administration of a muscle relaxant, and a third control group will not receive dexamethasone. This timing variation aims to determine the optimal administration point to improve outcomes, including postoperative nausea, pain, glycemic stability, and hemodynamic response.
223519953|NCT06688825|BEHAVIORAL|Education regarding Weight loss|Per American Association of Clinical Endocrinology (AACE) guidelines
223519954|NCT06688825|BEHAVIORAL|Lifestyle tools for weight loss|Calorie App, Continuous GlucosWe Monitor (CGM), Weight Scale, Food Scale
223519955|NCT06688825|BIOLOGICAL|Blood draw|Per American Association of Clinical Endocrinology (AACE) guidelines
223519956|NCT06691139|PROCEDURE|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia graft in patients ages from 12 years to 40 years|Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia
223519957|NCT06691139|OTHER|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft|Group (A) Myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft
223704116|NCT03490708|DRUG|Tranilast|Subjects will be treated with tranilast
224083233|NCT04803760|OTHER|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
224274947|NCT02937207|DRUG|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
224274948|NCT02937207|DRUG|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
224274949|NCT02937207|DRUG|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
224274950|NCT02937207|DRUG|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
224274951|NCT02937207|DRUG|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
224274952|NCT02937207|DRUG|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
224274953|NCT02937207|DRUG|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
224274954|NCT02937207|DRUG|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
224274955|NCT02937207|DRUG|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
224274956|NCT04172545|PROCEDURE|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
223519958|NCT06691139|PROCEDURE|Myringoplasty operation using periosteal graft and myringoplasty using Temporalis fascia graft|Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft in age from 12years to 40 years
223519959|NCT06691139|PROCEDURE|Group (A) myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft|Myringoplasty operation using Temporalis fascia graft and Myringoplasty using periosteal graft in patients from 12 years to 40 years
223519960|NCT06688513|DEVICE|Carealth Phone App|The goal for this study is to assess Carealth app's ability to connect patients to resources to meet patient's identified SDH needs, with the end goal of assessing reduction in 30-day readmission and missed visits by connecting patients to resources to meet their social needs in a way that enables them to receive care earlier or avoid complications.
223519961|NCT06688513|BEHAVIORAL|Let's Talk: Sharing information about Family Cancer Risk|An interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk
223519962|NCT06632873|DRUG|177Lu-TATE-RGD|accepted intravenous injection of 177Lu-TATE-RGD
223519963|NCT02251470|OTHER|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
223519964|NCT02251470|OTHER|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
223519965|NCT06686160|OTHER|Plyometrics Training|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise, Plyometrics are primarily used by athletes to improve performance and are used in the fitness field to a much lesser degree. This training focuses on learning to move from a muscle extension to a contraction in a explosive way, for example repeated jumping.
223519966|NCT06686160|OTHER|Theraband Resistance Exercise|Patient will be given baseline treatment that includes thermotherapy+ TENS+ low intensity high repetition exercises. After we will apply our basic intervention exercise Therabands is a Set of bands which are primarily use for resistance Training for strength and Power.
223519967|NCT06686940|DEVICE|intervention group|The monitoring effect of a smart electrocardiogram watch based on the PPG algorithm on atrial fibrillation burden.
223519968|NCT06686706|OTHER|IASTM|"Graston therapy-8 min per session~Procedure:~The patient will be lying down with their knee bent 30 degrees. After a 5-minute ultrasound treatment and static stretching exercises.Treatment will be administered using the Graston tool (using the sweep approach). Applying a moderate amount of effort from the medial side of the heel to the metatarsals and from the metatarsals to the medial side of the heel, to-and-fro stroking at a 60° angle will be done on the sole of the foot for approximately eight minutes (60-70 strokes per minute with a 5- to 10-second rest interval. A cold pack will be used for five minutes after therapy. The GT session will last approximately 30 minutes.~Conventional Therapy:~Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min Functional status and Quality of Life (QOL) will be assessed before and after treatment of 4 weeks using using tools.~Intervention will be conducted once a week for 4 weeks."
223519969|NCT06686706|OTHER|KT group|"Kinesio tapping (left there for 3 days)~Procedure:~We will use a standard 2 (5 cm) kinesiology tape. Fascia tape will be applied to the plantar fascia, and it will be left there for three days. For four weeks, it will be applied once a week. The patient will be in a prone position, lying with the ankle joints in a neutral position while applying tape. With the toes extended against the bed or ground. The tape will be marked on the Achilles tendon. It will be cut longitudinally into five slices of equal width. It will be applied to the forefoot by stretching it by 25%. The last strap will be applied with gentle compression across the bases of the five slices beneath the foot and wrapped around the rear foot.(5) Conventional Therapy Therapeutic ultrasound for 5 min Stretching of plantar fascia 5 reps with 10 sec hold) Cold therapy for 5 min"
223519970|NCT06689514|DRUG|alpha receptor antagonist|Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)
223519971|NCT06689514|DRUG|Low dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID
223519972|NCT06689514|DRUG|High dose Tranilast|Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID
223519973|NCT06695481|PROCEDURE|Conventional RF|The conventional RF group consists of patients who received medial branch RF with a duration of 2 minutes, at 80̊ C temperature, and 7 Volts.
223519974|NCT06695481|PROCEDURE|Combined RF|In the combined RF group, treatment was initiated first with a conventional RF duration of 2 minutes at a temperature of 80̊ C at 7 Volts. Then, pulsed RF duration was applied for 6 minutes at a temperature of 42 C at 45 Volts, with a pulse frequency of 2 Hz and a width of 20 ms.
223519975|NCT06691412|DRUG|Obeticholic Acid 5 mg|\- Patients will be randomly divided into two groups , the first will receive obeticholic acid at a dose of 5 mg once daily and antiviral drug ,and the other will receive the antiviral drug only for six months
223519976|NCT06720259|DRUG|Oxantel Pamoate|Tablets containing 250 mg oxantel pamoate
223519977|NCT06720259|DRUG|Mebendazole|Tablets containing 500 mg mebendazole
223519978|NCT05103735|DRUG|Propofol|awake neurosurgery under propofol-remifentanil sedation
223519979|NCT06359626|DRUG|YHP2205|Test drug: YHP2205
223519980|NCT06359626|DRUG|YHR2401|comparator: YHR2401
223704117|NCT02213640|DEVICE|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
223704118|NCT02213640|DEVICE|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
223704119|NCT05729230|BEHAVIORAL|Questionnaire|"Physician/data nurse and the patients will complete a questionnaire. The physician or data nurse must complete a descriptive form including the patient's age and gender as well as some information about the tumour and the underlying liver disease.~Based on the 4 open questions, patient will be classified into 2 groups after assessment of his answers by a group of digestive oncologists and psychologists. Group A includes patients with an accurate perception of the disease whereas group B will gather patients with unrealistic expectations. Psychosocial aspect, quality of the physician's communication, comprehension of the disease and treatment expectations are assessed by multiple-choice questions (Liker scale evaluation). Depression and anxiety were evaluated by the Hospital Anxiety and Depression Scale (HADS) that has been validated as a good scale with a high sensitivity and specificity for depression and anxiety for cancer patients."
223519981|NCT04912531|DEVICE|Virtual Realty using a Microsoft Hololens, Empatica HR wristband, and EEG|The investigators will use a DeepReality VR with biofeedback using a Microsoft Hololens, Empatica HR wristband and EEG. The Empatica HR wristband will measure HR and the EEG will measure alpha and theta brain waves. To monitor the physiologic data in real-time, data from the EEG and heart rate monitor will be streamed and processed in an Android Application that the investigators previously developed. During data collection, the Android app sends data via OSC to a specific IP and port, which is then collected in the game engine, Unity 3D and processed to adapt the virtual environment. Importantly, each device is inexpensive and can be sanitized and reused by multiple patients.
223519982|NCT04912531|DEVICE|Essence Olfactory Necklace|The Essence Olfactory Necklace holds a small, lightweight 7 ml capsule that contains an essential oil. Within the capsule is a piezo electric transducer which allows us to control the release of scent via Bluetooth using a smartphone app. Each Essence Necklace will be paired with a google phone that the investigators will use to control the frequency and intensity of scent for each patient. The investigators will limit the frequency to one burst of scent every 20 seconds to avoid habituation. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water). The investigators chose lavender because in our previous studies, \>97% of users enjoyed the lavender scent. The Essence Necklace is powered with a 3.7V Lithium Battery and has a battery lifetime of approximately 6 hours. The RC can easily recharge the Essence Necklace through a USB micro connector. Additionally, the Essence Necklace can be easily sanitized and reused by multiple patients.
223519983|NCT04912531|DEVICE|Bedside Olfaction Device|The bedside olfaction device can be clipped on to the side of the patient's bed or beside table. The RC will turn on the night-time olfactory device at 7 pm and will turn off the device at 7 am. When turned on, the device releases scent once every 60 seconds. However, the frequency and intensity of the scent will be adjusted to the patient's preferences. For the scent, the investigators will use diluted lavender essential oil (10% essential oil: 90% water).
223519984|NCT06687473|DRUG|Bismuth-based susceptibility-guided treatment|"The investigators design four regimes for H. pylori eradication and participants receive one of the regimens based on susceptibility test. The four regimens are PBAT for those with both amoxicillin and tetracycline susceptible H. pylori; PBAM for those with amoxicillin susceptible but tetracycline resistant H. pylori; PBMT for those with amoxicillin resistant but tetracycline susceptible H. pylori; PBMR for those with both amoxicillin and tetracycline resistant H. pylori.~A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily), R is rifabutin (150 mg twice daily), and T is tetracycline (500 mg thrice daily). The treatment duration is 14 days for all regimens."
223519985|NCT02620865|BIOLOGICAL|Aldesleukin|Given SC
223519986|NCT02620865|BIOLOGICAL|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
223519987|NCT02620865|DRUG|Fluorouracil|Given IV
223519988|NCT02620865|DRUG|Gemcitabine Hydrochloride|Given IV
223519989|NCT02620865|DRUG|Irinotecan Hydrochloride|Given IV
224274957|NCT06030856|DEVICE|STI test kits (NG, CT and TV) for home use|The adolescent randomized to the at-home STI testing arm will be provided with in-person instruction at enrollment and flyers (in English and isiZulu) with printed step-by-step instructions for kit use. Information will include details on how to store the kits, criteria for adequate specimen collection and preparation, how to run the test, and how to interpret the test results. Video-based instructions with accompanying text subtitles and audio options may also be provided for home use.
223519990|NCT02620865|OTHER|Laboratory Biomarker Analysis|Correlative studies
223519991|NCT02620865|DRUG|Leucovorin Calcium|Given IV
223519992|NCT02620865|DRUG|Oxaliplatin|Given IV
223519993|NCT02620865|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223519994|NCT02620865|BIOLOGICAL|Sargramostim|Given SC
223519995|NCT03838328|DRUG|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
223519996|NCT06070532|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
223519997|NCT03189953|RADIATION|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
223519998|NCT03033693|OTHER|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
223519999|NCT03033693|OTHER|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
223520000|NCT01724385|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
223520001|NCT00561821|DRUG|Esmirtazapine|one tablet daily
223520002|NCT00561821|DRUG|Placebo|one tablet daily
223520003|NCT06690437|DEVICE|Galaxy Fixation System and Orthofix implantable devices|"It is planned to include 118 patients in 3 sites in Italy treated with GALAXY FIXATION™ System and Orthofix implantable devices for the following indications:~* fractures of the long bones or;~* Vertically stable pelvic fractures or vertically unstable pelvic fractures as a treatment adjunct Clinical data will be collected only from patients with a regular indication for GALAXY FIXATION™ System and Orthofix implantable devices as per IFUs (no off-label use will be included) and who underwent surgery performed with the specific devices."
223520004|NCT06686524|DRUG|Anti-CD19 UCAR-T cells|A single infusion of CD19 UCAR-T cells will be administered intravenously after lymphodepletion chemotherapy.
223520005|NCT06380686|OTHER|data collection|Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
223520006|NCT06438250|DRUG|68Ga-JH04|The dose will be 148-222 MBq given intravenously.
223520007|NCT01720563|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
223520008|NCT01720563|DRUG|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
223520009|NCT01720563|PROCEDURE|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
223520010|NCT04634617|OTHER|Questionnaire Administration|Complete questionnaires
223520011|NCT05670756|OTHER|Survey|Parents/guardians will complete a survey about when the medication allergy was identified and the exact symptomatology that resulted in determination of the allergy.
223520012|NCT04089111|OTHER|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
223520013|NCT04089111|OTHER|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
223520014|NCT05972681|DRUG|Bupivacaine|10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
223520015|NCT05972681|DRUG|Epinephrine|Epinephrine (1:200,000) injected to the vaginal laceration site.
223520016|NCT05972681|OTHER|Sham normal saline arm|10 milliliter (ml) of normal saline injected to the vaginal laceration site.
223520017|NCT06423794|DRUG|BHV-7000|BHV-7000 75 mg taken once daily
223520018|NCT03263533|DRUG|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
223520019|NCT03263533|DRUG|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
223520020|NCT06154824|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
223520021|NCT06154824|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
223520022|NCT06018519|OTHER|Clinical endpoints|"1. Number of epileptic seizures~2. Change in antiepileptic treatment (increase or decrease)~3. Visual analogical scale on a target symptom defined with the parents,~4. CGI,~5. Actimetry data over 24 hours,~6. Podometry data over 24 hours,~7. 6 minutes' walk test,~8. Clinical examination~9. Feasibility of performing an MRI without any anesthesia on a mock scanner"
223520023|NCT06018519|OTHER|Parental questionnaires|"10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)"
223520024|NCT06018519|OTHER|Quality of life scale|18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
224274958|NCT06030856|BEHAVIORAL|Self Administered Behavioural Risk Assessment|Self Administered assessment to determine risk of HIV, STIs and pregnancy
223520025|NCT06018519|OTHER|Cognitive assessments|"19- Leiter 3 scale (4 cognitive sub-tests to be able to compute the non-verbal IQ and 2 non-verbal memory sub-tests) or Bayley 4 if Leiter 3 is not possible~20- CPM-BF~21- Simple reasoning task on tablet (match-to-sample task)~22- Implicit rules learning (modified Brixton),~23- 4 sub-tests from the WPPSI-IV (zoo location to assess spatial memory, block design to assess visuo-constructive abilities, bug search , cancellation),~24- Attention assessment (4 sub-tests from KITTAP: alert, go/no go, flexibility, divided attention),~25- Elementary visuo-spatial perception (on tablets)"
223520026|NCT06018519|OTHER|Language assessments|"26- EXALANG 3-6 (10 sub-tests testing for expressive and receptive language assessments),~27- PPVT-5 (receptive vocabulary), EVT-3 (expressive vocabulary),~28- Automatic language analysis (during a 10 minutes interaction, play)."
223520027|NCT06018519|OTHER|Motor assessments|"29- Kinematic task (specifically designed),~30- Purdue-Pegboard test,~31- Renzi test"
223520028|NCT06018519|OTHER|Social assessments|"32- Eye-tracking analysis of social visual scenes and social preference index (movies),~33- theory of mind assessment,~34- ADOS scale (Autism Spectrum Disorder),~35- sensitivity to inequality,~36- pro-social behaviors (help of the psychologist)"
223520029|NCT06018519|OTHER|3T MRI|37- Structural, metabolic and functional data
223520030|NCT06018519|OTHER|Cardiac assessments|"38- ECG~39- Ultrasound"
223520031|NCT06018519|OTHER|Biological collection|"40- Blood sample~41- Urinary sample~42- Superficial skin biopsy"
223520032|NCT06095037|BEHAVIORAL|Mindful yoga|12 week mindful yoga intervention
223520033|NCT06095037|BEHAVIORAL|Psychoeducation|12 week psychoeducation sessions
223520034|NCT02965313|PROCEDURE|SSLS Procedure|Synthetic suture repair
223520035|NCT02965313|PROCEDURE|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
223534866|NCT02785328|OTHER|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
223534867|NCT02785328|OTHER|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
224274959|NCT02394288|PROCEDURE|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
224274960|NCT01728740|DRUG|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
224274961|NCT01728740|DRUG|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
224274962|NCT01728740|DRUG|Metformin|Metformin 500mg, oral, single dose
224274963|NCT04933240|DRUG|Tamoxifen Citrate 10Mg Tab|nonsteroidal antiestrogen for oral administration in 10 mg tablets. Each tablet contains 15.2 mg of tamoxifen citrate which is equivalent to 10 mg of tamoxifen.
224274964|NCT04933240|DRUG|Estradiol|estradiol tablets for oral administration contains 1 mg of micronized estradiol per tablet.
223520036|NCT04684862|DEVICE|Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)|This infusion system is composed of a Medtronic SynchroMed II programmable pump connected to a Intera tapered catheter. Specifically, the Medtronic pump comes with a small connector that ends in a metal flange. During the operation, under sterile conditions, the distal 1 cm of the flange is severed using a scissor. Then, using a Intera connector pin, the end of the Medtronic catheter is connected to the Intera catheter . Two 2-0 silk ties secure the catheters to the pin. The pump and catheter are then inserted into the patient into the abdominal wall or into the chest wall. The catheter is inserted into an artery within the abdomen (usually the gastroduodenal artery but it depends on the exact arterial branching in the individual patient) that feeds the liver.
223520037|NCT00410657|BIOLOGICAL|alemtuzumab|
223520038|NCT00410657|DRUG|methylprednisolone|
223520039|NCT00410657|DRUG|prednisone|
223520040|NCT00410657|OTHER|flow cytometry|
223520041|NCT00410657|OTHER|immunologic technique|
223520042|NCT00410657|OTHER|pharmacological study|
223520043|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using Memsorb|Sevoflurane administration at 0.2L.min-1 (minimal gas flow)
223520044|NCT04539405|DEVICE|To evaluate sevoflurane consumption when using classical Dräegersorb|Sevoflurane administration at 2L.min-1 (classical gas flow)
223520045|NCT05299190|OTHER|Yoga intervention plus TAU|The yoga intervention consists of 8 weekly group sessions. The intervention is based on hatha yoga system. TAU is usual care participants receive from their health care provider
223520046|NCT05299190|OTHER|Clinical Monitoring plus TAU|clinical monitoring includes bi-weekly 15-20 minute telephone contact with participants. TAU is usual care participants receive from their health care provider.
223520047|NCT03849144|BEHAVIORAL|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
223520048|NCT03849144|BEHAVIORAL|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
223520049|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Electric-acoustic stimulation fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
223520050|NCT03379870|DEVICE|Electric Acoustic Speech Processor: Full-electric stimulation fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
224274965|NCT04933240|DRUG|Placebo|A sugar tablet that does not contain any active medicine
223520051|NCT00667043|DRUG|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
223520052|NCT00667043|DRUG|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
223520053|NCT04215458|OTHER|sample collection (swap or tape strip)|collection of swap or tape strip to determine yeast colonization in skin
223520054|NCT02562703|DEVICE|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
223520055|NCT05988281|PROCEDURE|Type I Dental implant placement.|Placement of dental implant.
223520056|NCT05988281|PROCEDURE|Type II Dental implant placement.|Placement of dental implant.
223520057|NCT05988281|PROCEDURE|Type III/IV dental implant placement.|Placement of dental implant.
223520058|NCT05281575|BEHAVIORAL|Baby Friendly Spaces (BFS)|Designed to meet the unique needs of populations living in humanitarian contexts, BFS focus on two domains: psychosocial support that targets maternal wellbeing and childcare practices that target caregiver functioning to also address child wellbeing and development. In so doing, BFS strengthens mothers' internal resources and skills in caring for their children both in quantity (time spent caring for the child) and quality (responsiveness), to positively impact the health status and wellbeing of their children. In BFS, the following activities are delivered by trained psychosocial workers: counselling for infant and young child feeding practices; hygiene education and promotion; mother-child bonding activities that provide psychosocial stimulation essential for children at risk of, or experiencing, malnutrition; and provision of maternal psychosocial support (i.e. psychoeducation, stress management).
223520059|NCT05157997|DRUG|Casirivimab and Imdevimab Antibody Cocktail|The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
223704120|NCT00463580|DRUG|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
223704121|NCT00463580|DRUG|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
224274966|NCT02824640|BEHAVIORAL|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
224274967|NCT02824640|BEHAVIORAL|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
223520060|NCT05996653|DIAGNOSTIC_TEST|Saturation Transfer (ST)-MRI|"Non-contrast magnetic resonance imaging Saturation Transfer scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)"
223520061|NCT05550428|OTHER|home-based-exercise|"All the participants were instructed on the proper performance of the exercise regimen by a senior physiotherapist before the commencement of the intervention. Subjects were then instructed to perform the home-based exercises on their own twice a week for eight weeks. One dedicated research assistant kept a weekly record of the participants' physical activity.~sessions."
223520062|NCT05550428|DEVICE|active pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 PEMF sessions per participant, each leg receiving 8 exposures.
223520063|NCT05550428|DEVICE|shame pulsed electromagnetic field（PEMF）therapy|Alternating legs on consecutive visits were exposed to either PEMF or sham therapy for eight weeks for a total of 16 sham PEMF sessions per participant, each leg receiving 8 exposures.
223520064|NCT04229017|PROCEDURE|Anterior Cervical Discectomy and Fusion|Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
223520065|NCT04229017|DEVICE|Posterior Cervical Stabilization System (PCSS)|Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
223520066|NCT00153231|DEVICE|IVS|Infracoccygeal sacropexy
223520067|NCT00153231|PROCEDURE|Sacrospinofixation|
223520068|NCT06168344|OTHER|Web-Based Education Program|This study was assessed the impact of a web-based education program provided to mothers of infants with congenital heart diseases on their quality of life and self-efficacy levels
223520069|NCT04083027|DEVICE|MRI|Breast MRI
223520070|NCT03858868|BEHAVIORAL|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
223520071|NCT03858868|BEHAVIORAL|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
224274968|NCT05830682|DEVICE|using a walking aid|The walking aid utilized for mobilizing patients in the intervention group during the study is a four-wheeled device that allows for movement in all directions. The height of the device can be adjusted according to the patients' height. It features a seat for resting when needed and a braking system that is controlled from the hand grips.
223520072|NCT06135090|BEHAVIORAL|Trauma Recovery Program (official title TBD)|See arm description
223520073|NCT01394185|DRUG|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
223520074|NCT01394185|DRUG|Placebo|Participants receive placebo
223520075|NCT01394185|DRUG|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
223520076|NCT00633958|DRUG|18F-FLT|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
223520077|NCT00633958|RADIATION|PET Imaging|
223520078|NCT00953628|DRUG|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
223520079|NCT00953628|DRUG|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
223520080|NCT02875418|DEVICE|EUM|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
224274969|NCT01504711|DRUG|fosaprepitant dimeglumine|Given IV
224274970|NCT00416468|DRUG|Aliskiren|
224274971|NCT00416468|DRUG|Valsartan|
224274972|NCT04487288|DIAGNOSTIC_TEST|SONAZOID|CEUS using SONAZOID with fusion technique
223520081|NCT02875418|DEVICE|Tocodynamometry|"STUDY DESIGN~1. Explanation regarding the study and assessing eligibility criteria.~2. Signing an informed consent.~3. Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
223520082|NCT05040386|BEHAVIORAL|EPIC|Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
223520083|NCT05040386|OTHER|Usual COPD Care|Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.
223520084|NCT04050839|OTHER|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
223520085|NCT04050839|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
223520086|NCT05781308|DRUG|Paclitaxel|Paclitaxel 200 mg/m² every 3 weeks
223520087|NCT05781308|DRUG|Bevacizumab|Bevacizumab 15 mg/kg every 3 weeks
223520088|NCT05781308|DRUG|Atezolizumab|1200 mg every 3 weeks
224274973|NCT03547830|DRUG|Plerixafor|Plerixafor for Conditioning before HSCT.
223520089|NCT05817175|PROCEDURE|pre-pectoral breast reconstruction|to prospectively evaluate the utilization of the pre-pectoral approach, and evaluate oncological and aesthetic outcomes related to each type of surgical technique and the use of postmastectomy radiation therapy
223520090|NCT05338320|PROCEDURE|Ultrasound Guided Erector Spinae Plane Block|General anesthesia and Ultrasound Guided Erector Spinae Plane Block
223520091|NCT05338320|DRUG|Intrathecal morphine|General anesthesia and intrathecal morphine
223520092|NCT05338320|OTHER|General anesthesia using intravenous fentanyl (1µg/kg)|General anesthesia using intravenous fentanyl (1µg/kg)
223520093|NCT05670184|DRUG|LSD|Single dose of LSD (50 µg) will be administered in a small amount of alcohol (ethanol, 2ml/95% Vol.) orally.
223520094|NCT05670184|DRUG|Ethanol|Identical ampules containing pure ethanol without the investigational product will be used (1mL ethanol, 95% Vol.).
223520095|NCT05250934|DEVICE|Robotic rehabilitation|The upper limb rehabilitation will be carried out with the planar rehabilitation robot Icone (a CE Class IIA medical device manufactured by Heaxel). The proposed exercises require the patient to move a cursor on the screen using the end-effector of the robot to reach specific points (planar reaching exercises). When the patient is able to perform these exercises independently, the robot assists the movement by minimizing the interaction force applied to the hand and limiting itself to acquiring the kinematic and dynamic parameters of the exercise, which are useful in determining the state of motor skills. Icone assist the subject by applying a force to his hand that helps him complete the task in the phases where the patient plans the movement correctly but is unable to complete it. As a result, the system will enable you to perform planar elbow and shoulder movements in active, passive, or active-assisted modes, with visual and acoustic feedback.
223520096|NCT05067842|DIAGNOSTIC_TEST|Circulating tumor DNA(ctDNA) level measurement|The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
223520097|NCT00100893|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
223520098|NCT02364895|OTHER|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
223520099|NCT02364895|OTHER|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
223520100|NCT02364895|OTHER|Males Group 2: New letter with neutral gender content|Unisex letter
223520101|NCT02364895|OTHER|Males Group 3: New letter with male-specific content|New letter tailored for men
223520102|NCT02364895|OTHER|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
223520103|NCT02364895|OTHER|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
223520104|NCT02364895|OTHER|Females Group 2: New letter with neutral gender content|Unisex letter
223520105|NCT01713244|PROCEDURE|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
223520106|NCT01713244|PROCEDURE|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
223520107|NCT05267600|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
223520108|NCT05267600|OTHER|placebo|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
223520109|NCT05267600|DRUG|Prednisone|Oral Prednisone
223520110|NCT03026777|DRUG|intravenous crystalloid fluid, 500 mL|
223520111|NCT06472024|PROCEDURE|Verum Acupuncture|Acupuncture therapy uses filiform needles at a perpendicular angle at acupuncture points to produce a therapeutic effect.
223520112|NCT06472024|PROCEDURE|Sham Acupuncture|Sham Acupuncture therapy uses filiform needles but is only attached with tape to acupuncture points
223520113|NCT03615131|DIAGNOSTIC_TEST|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
223520114|NCT04255381|DEVICE|Zone-Model Predictive Control Artificial Pancreas (ZMPC_AP)|Zone-Model Predictive Control Artificial Pancreas (ZMPC\_AP)
223520115|NCT05559047|DEVICE|Eclipse novel CPAP mask|"Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly."
223520116|NCT05559047|DEVICE|Phillips Respironics Nuance|Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
223520117|NCT03871504|OTHER|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
223520118|NCT00779610|PROCEDURE|Vibration with flexion|Vibration with forearm flexion (active contraction)
223520119|NCT00779610|PROCEDURE|Vibration without flexion|Vibration without forearm flexion (passive)
223704122|NCT06068023|DRUG|Folfirinox|"Patients meeting the criteria of post-operative adenocarcinoma of the ampulla of Vater will be enrolled, with adjuvant chemotherapy commencing within 8 weeks of recovery from surgery. Those undergoing palliative intent surgery or palliative chemotherapy are ineligible for the ADAPTA study.~The ADAPTA study's adjuvant chemotherapy involves 8-12 FOLFIRINOX cycles (Arm 2) repeated 2 weeks. Given patient outcomes, 8 cycles of FOLFIRINOX are deemed sufficient due to completion challenges in prior research. FOLFIRINOX regimen mirrors the modified version from the ACCORD/PRODIGE trial for metastatic pancreatic cancer. This trial adapts mFOLFIRINOX for standard practice."
223520120|NCT00945880|DRUG|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
223520121|NCT03914833|OTHER|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
223520122|NCT03914833|OTHER|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
223520123|NCT05985174|DIAGNOSTIC_TEST|CD64 , HLA-DR|"CD64 is atype of integral membrane glycoprotein , when activated , it increases the neutrophils' potential for phagocytosis and bacterial killing .~HLA-DR is on the surface of monocyte\\macrophages , dendritic cells and plays a crucial role in adaptive immune response"
223520124|NCT00601445|BEHAVIORAL|Amount of sleep and wake|4 groups with different patterns of sleep and wake
223520125|NCT06004583|DIAGNOSTIC_TEST|Biochemical blood analysis|Serum CRP and albumin levels
223520126|NCT05269797|BEHAVIORAL|Nurse-led health coaching re: heart failure self-care management|A focus group meeting will be arranged with the nurse participants to provide training on the study intervention specific to the Nurse-led health coaching intervention. The intervention involves identifying barriers and finding strategies and solutions to self-care management, while employing a self-care HF management tool of adjusting diuretic dosing (ADD) according to the congestive cardiac calendar (designed in collaboration with nurses in Phase 1). It will be essential for the nurses to document key information pertaining to the rationale for these decision-making strategies or solutions. This is in comparison to the standard of care in primary health care of nurses not taking a standardize approach towards health coaching and the patient being instructed by the practitioner to take a set diuretic dosing (SDD).
223520127|NCT06228937|OTHER|analysis of a sample of stool|typing of the gut microbiota from a stool sample
223520128|NCT05645887|DRUG|Human albumin|Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
223520129|NCT05645887|OTHER|Saline solution|Saline solution from day 0 to day 7.
223520130|NCT03999073|OTHER|Ultrasound measurement|Ultrasound measurement
224274974|NCT03547830|DRUG|Gcsf|GCSF for Conditioning before HSCT.
223520131|NCT06286072|OTHER|Education and message|COPD general education content and fatigue-specific coping strategies. Messages sent to phones
223520132|NCT06549907|OTHER|Multi-omics testing|Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.
223520133|NCT06549907|OTHER|MRI|MRI will be conducted to investigate image characteristics during treatment
223520134|NCT04505787|DRUG|Esflurbiprofen hydrogel patch 165 mg (EFHP)|patch application with PK blood sampling
223520135|NCT04505787|DRUG|Froben 100 mg comprimidos revestidos|tablet administration with PK blood sampling
224274975|NCT05008562|OTHER|COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|there is no interventions to the patients.
224274976|NCT00523289|DRUG|Bupivacaine|Dosage: 150mg at once for anesthesia induction
224274977|NCT00523289|DRUG|Ropivacaine|Single dose of ropivacaine, 150mg
224274978|NCT03889691|PROCEDURE|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
224274979|NCT00891072|DRUG|R-(-)-gossypol acetic acid|Given orally
224274980|NCT00891072|DRUG|paclitaxel|Given IV
224274981|NCT00891072|DRUG|carboplatin|Given IV
224274982|NCT00891072|OTHER|pharmacological study|Correlative studies
223520136|NCT02264756|OTHER|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
223704123|NCT06068023|DRUG|Capox|or 8 CAPOX cycles (Arm 1) every 3 weeks.
223704124|NCT05875571|DRUG|Ketorolac|Patients will get IV ketorolac during IUD placement under sedation
223704125|NCT05875571|DRUG|Placebo|Patients will get IV placebo during IUD placement under sedation
224274983|NCT02102269|DEVICE|actimove sling|
223520137|NCT05704803|DIAGNOSTIC_TEST|Diagnostic Test: IN Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
223534868|NCT02785328|OTHER|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
223534869|NCT00248924|BEHAVIORAL|Social Services|
223534870|NCT02999607|OTHER|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
224274984|NCT02102269|DEVICE|shoulderlift|
224274985|NCT02104817|DRUG|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
224274986|NCT02104817|DRUG|corn oil control|corn oil control arm
224274987|NCT02587312|OTHER|Very low nicotine content cigarettes|
224274988|NCT02587312|OTHER|Standard nicotine content cigarettes|
224274989|NCT00111566|DRUG|eptifibatide|
224274990|NCT03211039|GENETIC|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
224274991|NCT06001827|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.
224274992|NCT06001827|PROCEDURE|Untreated AVF Control|AVF creation surgery without any intervention
224274993|NCT02575339|DRUG|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
224274994|NCT02575339|DRUG|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
224274995|NCT02575339|DRUG|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
223520138|NCT06062485|DRUG|Surufatinib+Toripalimab+AG|"This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）"
223520139|NCT04535115|PROCEDURE|Starting LRM (Lung Recruitment Maneuver)|The LRM is performed first for 30 seconds (an insufflation pressure of 30 cmH2O for 30 seconds is applied). After a free interval of 3 minutes, the VtC is done during 1 minute. For VtC, tidal volume is increased from 6 to 8 ml.kg-1 of predicted body weight. Finally, after a new free interval of 3 minutes, the fluid challenge (consisting in fluid administration of 250 ml of Ringer Lactate) is started for 10 minutes (in aim to determine which patients are responders). This sequence is repeated every 30 minutes (maximum four times).
223520140|NCT04535115|PROCEDURE|Starting VtC (Tidal Volume Challenge)|The VtC is performed first for 1 minute. After a free interval of 3 minutes, the LRM is done for 30 seconds. Finally, after another free interval of 3 minutes, the fluid challenge is started for 10 minutes. This sequence is repe-tead every 30 minutes (maximum four times).
223520141|NCT00974597|DEVICE|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
223520142|NCT05327569|OTHER|Myofascial Chain Release Techniques|Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
223520143|NCT05006040|DEVICE|Hybrid Closed Loop System|Participants will utilize the Tandem Control-IQ Professional Hybrid Closed Loop artificial pancreas system \[25, 26\]. This device consists of the Dexcom G6 Continuous glucose monitor (or a more recent interoperable CGM), the Tandem t:slim X2 continuous subcutaneous insulin infusion pump, and the Control-IQ professional hybrid closed loop control algorithm. The CGM is generally replaced by parents or patients and then replaced after sensor expiration or if it falls off. This CGM, like all future iCGMs, is factory calibrated and approved for direct dosing of insulin. In addition, while the system is in use, patients will conduct blood glucose level checks at least four times a day with a fingerstick and calibrate the CGM if the measurements differ by more than 20 mg/dL of fingerstick blood glucose level. The t:slim X2 insulin pump delivers rapid acting insulin via a subcutaneous cannula which is placed by parents or patients and then replaced every 3 days \[30\].
223520144|NCT04046744|PROCEDURE|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 15-30 ml Ropivacaine 0,5%.
223520145|NCT04046744|PROCEDURE|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 15-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%.
223520146|NCT04046744|DRUG|Ropivacaine|axillary block with 15-30 ml Ropivacaine 0,5%
223520147|NCT04046744|DRUG|Ropivacaine|radial and medial nerve block at the elbow with 3-7 ml Ropivacaine 0,5%
223520148|NCT04046744|DRUG|Lidocaine|axillary block with 15-30 ml Lidocaine 1,5%
223520149|NCT05196529|OTHER|Inspiratory muscle training|All participants will undergo inspiratory muscle training.
223520150|NCT00267488|DRUG|topotecan|
223520151|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
223520152|NCT00803374|DRUG|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
223520153|NCT00803374|DRUG|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
223520154|NCT00803374|DRUG|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
223520155|NCT00803374|DRUG|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
223520156|NCT00803374|DRUG|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
223520157|NCT04628208|DIAGNOSTIC_TEST|Spartan COVID-19 v2 System|A nasopharyngeal swab sample analyzed on the Spartan COVID-19 v2 System for the detection of SARS-CoV-2.
223520158|NCT00055887|DRUG|carboplatin|
223520159|NCT00055887|DRUG|cisplatin|
223520160|NCT00055887|DRUG|efaproxiral|
223520161|NCT00055887|DRUG|gemcitabine hydrochloride|
223520162|NCT00055887|DRUG|paclitaxel|
223520163|NCT00055887|DRUG|vinorelbine ditartrate|
223520164|NCT00055887|PROCEDURE|radiation therapy|
223520165|NCT05222711|DEVICE|Use of the PICO(TM) monitoring device|The aim is to record if the outcome (referral or not) is influenced by the results of the parameters and/or the ECG.
223520166|NCT05388825|DRUG|TPN171H 2.5mg|TPN171H 2.5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
223520167|NCT05388825|DRUG|TPN171H 5mg|TPN171H 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
223520168|NCT05388825|DRUG|TPN171H 10mg|TPN171H 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
223520169|NCT05388825|DRUG|Placebo 5mg|Placebo 5mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
223520170|NCT05388825|DRUG|Placebo 10mg|Placebo 10mg is recommended to take warm water on an empty stomach (2 hours or more after dinner)
224274996|NCT04633642|PROCEDURE|Ultrasound group|Every week during a six-week treatment period
223520171|NCT01596023|DEVICE|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
223520172|NCT05997901|OTHER|Varenicline healthbot|The intervention is a healthbot that will provide information, reminders, answers to questions, and support to participants using varenicline for smoking cessation.
224274997|NCT04633642|PROCEDURE|Surgical group|Every week during a six-week treatment period
224274998|NCT01888341|DRUG|Isotretinoin|Isotretinoin Capsules,20 mg
224274999|NCT03836924|DRUG|Perampanel|Perampanel tablets.
223520173|NCT03171948|BEHAVIORAL|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
223520174|NCT03171948|BEHAVIORAL|Nut Free group|continue their diet without any nut consumption.
223520175|NCT06528080|GENETIC|LY-M001|LY-M001 Injection by Single Intravenous Infusion
223520176|NCT00831389|DEVICE|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
223520177|NCT00278161|BIOLOGICAL|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
223520178|NCT00278161|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52.
223520179|NCT00278161|DRUG|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
223520180|NCT01993082|BEHAVIORAL|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
223520181|NCT04382092|DIAGNOSTIC_TEST|FilmArray Pneumonia|Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
223520182|NCT02644551|DRUG|CELEXT07|
223520183|NCT02644551|DRUG|Penlac|
223520184|NCT02644551|OTHER|vehicle solution|
224275000|NCT06807541|BEHAVIORAL|Exercise intervention|45 minute exercise classes. Twice per week for 12 weeks.
223520185|NCT02998099|DRUG|Rivipansel|A single dose of IV rivipansel over 20 minutes.
223520186|NCT01912235|OTHER|2-15N glutamine|Glutamine with N15 isotope tracer
223520187|NCT01912235|OTHER|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
223520188|NCT01912235|OTHER|1-13C glutamine|Glutamine carbon isotope tracer
223520189|NCT02256878|DRUG|BIRT 2584 XX|
223520190|NCT02256878|DRUG|Amitriptyline|
223520191|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
223520192|NCT01592747|DRUG|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
223520193|NCT01592747|DRUG|Placebo capsules|Once daily, oral administration.
223520194|NCT02118415|OTHER|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
223520195|NCT00124657|DRUG|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
223520196|NCT06276140|DIAGNOSTIC_TEST|Laboratory analyses for the detection of iron deficiency anaemia|"Erythrocyte indices based on the preoperative complete blood count results will be calculated for each patient one day prior to surgical treatment.~Overall morbidity of each patient during hospital stay will be scored using the Comprehensive Complication Index (CCI). Intraoperative complications will be graded according to the ClassIntra classification of intraoperative adverse events. The quality of postoperative recovery of each observed patient will be scored on the first, second and fifth postoperative day, using the 15-item quality of recovery scale (QoR-15).~Data about red blood cell transfusion rate, all-cause infection rate, number of days when antibiotics were administered and the number of different antibiotics administered during hospital-stay will be collected."
223520197|NCT03410771|DRUG|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
223520198|NCT03410771|DEVICE|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
223520199|NCT00205959|DEVICE|Locking proximal humerus plate|
223520200|NCT00205959|DEVICE|Proximal Humerus Internal Locking System|
223520201|NCT00205959|DEVICE|Proximal Humerus Nail|
223520202|NCT02576626|DRUG|indacaterol/glycopyrronium 110/50 Breezhaler®|
223520203|NCT02576626|DEVICE|Placebo by Breezhaler®|
223520204|NCT02576626|DRUG|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
223520205|NCT02576626|DEVICE|Placebo by nebulisation|
223520206|NCT00681070|OTHER|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
223520207|NCT00681070|OTHER|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
223520208|NCT01935947|DRUG|Azacitidine|Given SC
223520209|NCT01935947|DRUG|Azacitidine|Given PO
223520210|NCT01935947|DRUG|Docetaxel|Given IV
224275001|NCT04892316|DIAGNOSTIC_TEST|Diagnostic test|The training dataset was used to train the model, which was validated and tested by the other two datasets.
223520211|NCT01935947|DRUG|Entinostat|Given PO
223520212|NCT01935947|DRUG|Gemcitabine Hydrochloride|Given IV
223520213|NCT01935947|DRUG|Irinotecan Hydrochloride|Given IV
223520214|NCT01935947|OTHER|Laboratory Biomarker Analysis|Correlative studies
223520215|NCT01935947|DRUG|Pemetrexed Disodium|Given IV
223520216|NCT00156195|DRUG|Asoprisnil|10 mg Tablet, oral Daily for 12 months
223520217|NCT00156195|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
223704126|NCT06043882|PROCEDURE|flexible bronchoscopy|fiberoptic bronchoscopy was done where biopsies were taken either by conventional TBNA (c-TBNA) , EBUS-TBNA or direct forceps biopsies and sent for histopathological examination
223704127|NCT03431870|OTHER|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
223704128|NCT04216966|DEVICE|Control group|No intervention was given
223520218|NCT04696003|COMBINATION_PRODUCT|Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter|The amniotic cavity will be punctured with a 18 gauge needle under ultrasound control. The intraamniotic catheter (0.65 mm Diameter, CE 0481, PakuMed GmbH, Essen, Germany) will be placed under local anesthesia with Xylocaine 1% 10 ml. and the amnioinfusion (about 100 ml/h, 2400 ml/day) with artificial amniotic fluid (Amnion Flush Solution, CE 0483, Serumwerk AG Bernburg, Germany) will be carried out with an infusion rate of 100 ml/h under periodic ultrasound using the standard i.v. pump.
223520219|NCT01275378|BEHAVIORAL|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
223520220|NCT01275378|BEHAVIORAL|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
223520221|NCT03064607|OTHER|Fluid collection|Fluids tested for biomarker S100beta
223520222|NCT04709523|PROCEDURE|bovine-derived xenograft with i-PRF|Bovine-derived xenograft was mixed with i-PRF and was placed in the augmentation site.
223520223|NCT04709523|PROCEDURE|bovine-derived xenograft alone|Bovine-derived xenograft was placed in the augmentation site.
223520224|NCT02957240|BEHAVIORAL|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
223520225|NCT02957240|BEHAVIORAL|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
223520226|NCT06639893|PROCEDURE|Telescopic overdenture|Telescopic overdenture with two dental implants in intraforaminal area for mandible.
223520227|NCT06562829|DEVICE|Virtual reality technology|Group B (Lidocaine injection after puncture): ①Download games in the VR headset in advance,The games last approximately 10-15 minutes. Games were selected based on children's preferences, and the VR headset was worn in the optimal state 5 minutes before catheterization.②Sterilized skin -maximum sterile barrier-ultrasound-guided puncture insertion of guidewire -local infiltration anesthesia with 2% lidocaine -broad skin, insertion of skin expansion sheath -insertion of catheter.
223520228|NCT06562829|OTHER|different timing of lidocaine injection|Group C (Lidocaine injection before puncture): Steps①was the same as in group B, After disinfecting the skin, local infiltration anesthesia was administered at the prepuncture site under ultrasound guidance using 0.5ml of 2% lidocaine. Approximately 2 minutes later, a skin puncture was performed and a guidewire was inserted. A broad incision was made to accommodate the torn vascular sheath for delivering the catheter to the predetermined length.
223520229|NCT00655655|DRUG|everolimus|Given orally
223520230|NCT00655655|DRUG|vatalanib|Given orally
223520231|NCT00655655|OTHER|pharmacological study|Correlative study (Cohort IIA only)
223520232|NCT00655655|OTHER|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
223520233|NCT00655655|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
223520234|NCT00655655|PROCEDURE|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
223520235|NCT06565039|DEVICE|Supira System|The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
223520236|NCT01532739|BEHAVIORAL|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
223520237|NCT01148771|DRUG|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
223520238|NCT01148771|DRUG|ertapenem|1 gram 30 minute infusion q24h for 3 days
223520239|NCT01847014|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
223704129|NCT04216966|DEVICE|Gracey Curette|Lingual surface of tooth was debrided by Gracey Rigid curette
223704130|NCT04216966|DEVICE|After Five|Lingual surface of tooth was debrided by After Five Rigid curette
223520240|NCT03563001|DRUG|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
223520241|NCT04049214|OTHER|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
223520242|NCT04375826|DEVICE|Epidural patient controlled analgesia|The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.
223520243|NCT04375826|DEVICE|Preperitoneal analgesia and IV-PCA|During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
223520244|NCT06644794|DRUG|Progesterone-modified natural cycle preparation for frozen embryo transfer|A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
224275002|NCT04306640|OTHER|Sagittal Cervical Posture Corrective Orthotic Device|The subjects in the traction group will receive the deneroll extension traction. The subjects will be asked to lie supine on the ground with their legs straight, upper arms by their sides and forearms gently folded across their trunk. The therapist will place the apex of the denneroll either in the mid cervical region or the lower cervical region depending on the apex of cervical curvature deformity of each subject. Initially, participants begin with three minutes of sustained denneroll extension traction and progressed to the goal of 20 min per session with one to two additional minutes per session
223520245|NCT06644794|DRUG|Hormone replacement therapy cycle preparation for frozen embryo transfer|A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
223520246|NCT04606290|DEVICE|O2matic HOT|Automated oxygen titration with O2matic HOT
223520247|NCT04606290|DEVICE|Oxygen concentrator|Fixed dose oxygen flow from concentrator
223520248|NCT06636799|DEVICE|Microneedling only|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left.
223520249|NCT06636799|OTHER|Microneedling and actives|In this procedure, a derma roller composed of 1.5 mm microneedles from the Smart Derma Roller brand with 540 titanium needles was used. The protocol was performed by passing the derma roller ten times in the following directions: horizontal, vertical, and diagonal right and left. Group G3 received microneedling associated with active ingredients. This manipulated active ingredient was composed of growth factors (EGF Factor, TGFß3 Factor, and IDP-2 Peptide), Hydroxyprolisilane, and hyaluronic acid.
223520250|NCT06638008|DRUG|perineural injection|perineural intervention of placental growth factor in one group and PRP in other group
223520251|NCT06638827|PROCEDURE|Thoracic Sympathectomy|"Bilateral thoracoscopic sympathectomy will be performed with general anesthesia, using single lung ventilation and monopolar cautery for transection of the sympathetic chain.~Persons with PFH who underwent the BTS were classified into three groups, depending the level of transaction of sympathetic chain:~1. transection at the level from the second to the forth thoracic sympathetic ganglion (T2- T4);~2. transection at the level from the third to the forth thoracic sympathetic ganglion (T3-T4)~3. transection at the level from the second to the third thoracic sympathetic ganglion (T2-T3).."
223520252|NCT06645067|BEHAVIORAL|Measuring energy balance|"The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA."
223520253|NCT06643520|DEVICE|19-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 19 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
223520254|NCT06643520|DEVICE|22-gauge|"All procedures will be performed under monitored endoscopist- directed anesthesia. Patients will be placed in a semi-prone position and oxygen at a rate of 3 L/min will be administered routinely.~All procedures will be performed by the same endoscopist, who performed \> 500 diagnostic and interventional EUS procedures annually. A standard linear echoendoscope (EG34-J10U, Pentax Medi- cal, Hoya Corp, Japan) will be used. The patients are going to be followed up until the Modified Aldrete Score \> 9 after the procedure, and then they will be discharged.~All biopsies will be performed with a standard 22 gauge FNA needle (Trident, Micro-Tech (Nanjing) Co., Ltd, Nan) with wet suction technique. Biopsy needles will be used without stylets and primed with diluted heparin (1:1 ratio) to obtain samples by wet-suction technique to prevent clot formation. All the biopsies will be performed from the left lobe of the liver as one pass and five actuations."
223704131|NCT04216966|DEVICE|Mini Five|Lingual surface of tooth was debrided by Mini Five Rigid curette
223520255|NCT06645288|OTHER|Emergency Reflex Action Drill|Emergency Reflex Action Drill in performing Emergency Surgical Airway
223520256|NCT06644586|OTHER|videolaryngoscopy|The patients intubated with video laryngoscopy
223520257|NCT06644586|OTHER|Direct Laryngoscopy|The patients intubated with direct laryngoscopy
223520258|NCT06643533|OTHER|Fecal Microbiota Transplantation|The FMT capsules will be prepared by matching the gut microbiome profiles of healthy donors with those of patients who achieved a complete response to the triple therapy. The FMT capsules will be taken orally at a dosage of 30 capsules per day for the first 3 days of each treatment cycle. The FMT intervention will be administered in 6 cycles, with each cycle lasting for 21 days (Q3W). The duration of the treatment will be determined by the response to therapy, with a maximum of 6 cycles or until disease progression, intolerable toxicity, or participant withdrawal of consent. The FMT capsules are intended to modify the gut microbiome to reverse the resistance to the triple therapy and enhance the therapeutic response.
223520259|NCT06371352|DEVICE|iTBS|Active iTBS over the left DLPFC to induce the long term potentiation of stimulated area.
223520260|NCT06371352|DEVICE|cTBS|Active cTBS over the right DLPFC to induce the long term potentiation of stimulated area.
223520261|NCT06371352|DEVICE|Sham|Sham iTBS or cTBS over the left or right DLPFC respectively for placebo.
223520262|NCT04287829|DRUG|Pembrolizumab|Infusion
223520263|NCT04287829|DRUG|Lenvatinib|Capsule
223520264|NCT06276335|OTHER|Immediate implant placement and guided bone regeneration (Test)|In this group, immediately after tooth extraction, a tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. A prefabricated surgical template based on 3D pre-extraction planning will be used to place the implant. The jumping distance between the implant and the residual buccal bone will be measured and filled with slow resorption bone graft material (Bio-Oss®, Geistlich, Wolhusen, Switzerland) as per standard of practice.
223520265|NCT06276335|OTHER|Late implant placement and guided bone regeneration (Control)|A tapered bone level implant (Straumann BLX Implant System, Roxolid, Straumann AG, Basel, Switzerland) will be placed after complete bone healing (4 - 6 months after tooth extraction) in an ideal prosthetically oriented position to achieve primary stability following the manufacture's guidelines. Guided bone regeneration (GBR) will be performed simultaneously with the aim to re-establish the bone contour and treat any fenestration/dehiscence if needed. A bovine osteoconductive graft (Bio-Oss®, Geistlich, Wolhusen, Switzerland) will be loosely compacted on the buccal aspect of the implant and covered with a collagen membrane (Bio-Gide®, Geistlich, Wolhusen, Switzerland).
223520266|NCT02826187|OTHER|Early complications data|"Early complications of interest are :~* New arthroplasty for any reason~* Related to the implant :~  * Wrong position of the implant~ * Early displacement of the implant~* Related to the intervention :~  * Hematoma~ * Dislocation (or not causing the resumption of joint replacement)~ * Deep vein thrombosis~ * Pulmonary embolism~ * Acute Infection"
224275003|NCT04811183|BEHAVIORAL|Pharmaceutical consultation|"Selection of patients for a pharmaceutical consultation with collection of non-opposition and scheduling of telephone interviews or by teleconsultations at one week after hospitalization.~Data collection through interviews using a telephone questionnaire (or by teleconsultation) one week after consultation. Elements on knowledge and adherence of treatment will be collected."
223520267|NCT02826187|OTHER|Late stage complications data|"Late complications taken into account are:~* New arthroplasty for any reason~* Aseptic loosening~* Delayed hypersensitivity reaction type IV~* Solid Tumors~* Recurrent dislocation (causing or not the resumption of joint replacement)~* Allergic reactions of any kind~* Chronic infection"
223520268|NCT02826187|OTHER|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
224275004|NCT05629923|DRUG|tixagevimab-cilgavimab(AZD7442, AstraZeneca)|In the case of antibody level \<100 IU/ml, patients were invited to prophylaxis with tixagevimab-cilgavimab(AZD7442, AstraZeneca).
224275005|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
224275006|NCT01656798|DRUG|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
224275007|NCT05120817|BEHAVIORAL|"Personal intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
224275008|NCT05120817|BEHAVIORAL|"Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
224275009|NCT05120817|BEHAVIORAL|"Personal + Social intervention"|Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
224275010|NCT03223909|DRUG|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
223520269|NCT02826187|OTHER|Efficacity|Efficacity as evaluated by Harris HIP score
223520270|NCT02826187|OTHER|Radiographic evaluation|Bone reaction visible in radiography
223520271|NCT06628986|BEHAVIORAL|MBSR|20 minutes once a week for 8 weeks
223520272|NCT06628986|BEHAVIORAL|NLP|NLP Neurolinguistic programming, 20 minutes once a week for 8 weeks
223520273|NCT06628986|BEHAVIORAL|control|control group, no practice,
223520274|NCT06630130|DRUG|Trastuzumab deruxtecan|"* Neoadjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W for 3 cycles~* Adjuvant; Trastuzumab Deruxtecan(T-DXd) 5.4mg/kg IV on D1, Q3W 16 cycles (up to 12 months)"
223520275|NCT06630130|DRUG|Capecitabine|"* Neoadjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 3 cycles~* Adjuvant; Capecitabine 1000mg/m2 PO BID on D1-D14, Q3W for 4 cycles (up to 3 months)"
223520276|NCT06630130|DRUG|Rilvegostomig|"(Only Cohort B)~* Neoadjuvant; Rilvegostomig 750mg IV on D1, Q3W for 3 cycles~* Adjuvant; Rilvegostomig 750mg IV on D1, Q3W for 16 cycles (up to 12 months)"
224275011|NCT03223909|DRUG|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
224275012|NCT03223909|DRUG|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
223520277|NCT04103814|DRUG|magnesium-cannabidiolic acid cream|Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
223520278|NCT04103814|DRUG|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
223520279|NCT06293287|DRUG|Subcutaneous enoxaparin sodium|Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily
223520280|NCT06293287|DRUG|Placebo|placebo (0.9% saline solution)
223520281|NCT04812483|DRUG|Eltrombopag (Revolade®)|Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
223520282|NCT04812483|DRUG|standard therapy (without eltrombopag): HD-DXM|standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
223520283|NCT06301815|DIAGNOSTIC_TEST|Scale for Contraversive Pushing|Lateropulsion will be assessed using the Scale for Contraversive Pushing (SCP). It involves observation of the posture of the participant in sitting and standing. Scores are assessed in sitting and standing giving a maximum score of 6.
223520284|NCT06301815|DIAGNOSTIC_TEST|Catherine Bergego Scale|Neglect will be assessed using the Catherine Bergego Scale. The scale is a 10-point scale with each item scored between 0 (no neglect) and 3 (severe neglect). It involves observation of a participant completing daily activities such as eating, dressing and walking.
223520285|NCT06301815|DIAGNOSTIC_TEST|Bucket Test|"The bucket test involves the patient being sat upright and looking into a translucent bucket with the bucket covering their complete field of vision. On the inside of the bucket on the bottom is a dark straight line. On the outside of the bottom of the bucket is a matching dark line, the bottom of the bucket is divided into degrees with the zero-degree line being equivalent to the line inside the bucket. For measurement the bucket will be randomly rotated right or left by the examiner to 45 degrees and then slowly rotated back to the zero-degree position. Patients will signal when they estimate the inside bottom line to be truly vertical by saying stop or by raising their non-paretic hand."
223520286|NCT01384045|OTHER|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
223520287|NCT01893099|DRUG|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
223520288|NCT01893099|DEVICE|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
223520289|NCT05318443|DRUG|SIBP04|SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
223520290|NCT05318443|DRUG|Avastin|Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
223520291|NCT05318443|DRUG|Paclitaxel|Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
223520292|NCT05318443|DRUG|Carboplatin|Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
223520293|NCT02395328|BEHAVIORAL|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
223520294|NCT02951819|DRUG|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
223520295|NCT02951819|DRUG|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m\^2 ) on Days 1, 8, 15, and 22 for every 28 days.
223520296|NCT02951819|DRUG|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
223520297|NCT02951819|DRUG|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
223520298|NCT05273437|BEHAVIORAL|System identification experiment for physical activity|The system identification experiment in Just Walk JITAI study has two key components that are the focus of the system identification experiment: daily adaptive step goal recommendations and within-day suggestions to either plan a bout of walking or to inspire reflection and, by extension, an increased urge to go for a walk.
223520299|NCT03173378|OTHER|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
223520300|NCT02440165|BEHAVIORAL|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
223520301|NCT04877366|DIETARY_SUPPLEMENT|Dietary Supplement: Sprinkled Format REDUCOSE.|2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate
223520302|NCT04877366|OTHER|Reference control|A placebo matching to the test product will be used as control
223520303|NCT04877366|OTHER|Active comparator|Acarbose 100 mg tablet (provided in open-label format)
223520304|NCT01176500|DRUG|(18)Fluciclatide|
223520305|NCT03116022|DRUG|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
223520306|NCT03116022|DRUG|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
223520307|NCT03116022|DRUG|Vaginal Gel|Women using a base water gel lubricant during intercourse
223520308|NCT05274698|BEHAVIORAL|muscle energy technique|It is a manual treatment in which a patient produces a contraction in a precisely controlled position and direction against a counterforce applied by a manual therapist .Muscle energy techniques (MET) were originally developed to treat soft tissue, mobilize joints, stretch tight muscles and fascia, reduce pain and to improve circulation and lymphatic drainage.
223520309|NCT05274698|BEHAVIORAL|conventional physical therapy program (Mobilization exercises, Posterior capsule stretching, and Range of motion exercises) 1 session per day, 5 days a week for 8 weeks.|"Joint mobilization, specifically glenohumeral joint distraction, glenohumeral joint caudal glide, glenohumeral joint posterior glide, and glenohumeral joint anterior glide, will be applied with patients.~Posterior capsule stretching will be applied with patients in side lying position. The scapula will be stabilized at the lateral side with the arm at 90° flexion. Stretching will be applied from the elbow with a downward force. The stretch will be repeated 10 times for 20 s each. A 30-s break will be given between each stretching .~Range of motion exercises:~Codman/ pendulum exercise ,Wall climbing exercise and Shoulder wheel exercise Circumduction of the shoulder joint clockwise and anticlockwise using shoulder wheel"
223520310|NCT02103179|PROCEDURE|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
223520311|NCT04569825|DRUG|Ophtamesone|local application intranasally as drops
223520312|NCT01390103|OTHER|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
223520313|NCT01443026|DRUG|Lycopene 30mg|Lycopene 30 mg.
223520314|NCT01443026|DRUG|Placebo|Placebo
223520315|NCT06046378|OTHER|Digital Story Group Prepared With Digital Audio File (Podcast)|"The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application."
223520316|NCT06046378|OTHER|Control Group|After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
223520317|NCT00581919|DRUG|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
223520318|NCT00738660|DRUG|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
223520319|NCT06569745|OTHER|Verbal Explanation|In the verbal explanation group, a researcher wearing white coat provided oral and dental health education for 3 minutes using a jaw model
223520320|NCT06569745|OTHER|Animation Video Display|"In the animation group, oral and dental health education was presented to the children in the form of a cartoon lasting 1 minute and 17seconds. The animation video was created by the researcher using the test version of www.vyond.com. The animation featured a character voiced by one of the researchers, informative texts, and background music. The character conveyed information about oral and dental health education, using both voice and text content."
223520321|NCT06569745|OTHER|Peer-Led Reels Video Display|In the peer-led reels group, oral and dental health information was presented for 1 minute using a video created on the Instagram platform. The video showed oral hygiene information being provided to a child of a similar age to the target audience with the child then demonstrating the behaviour with music in the background. The video included some text, but did not feature the child's voice or information.
223520322|NCT02655601|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
223520323|NCT02655601|RADIATION|Radiation Therapy|RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.
223520324|NCT02655601|DRUG|Temozolomide|Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
223534871|NCT05098314|OTHER|Personalized interventions regarding the Cicat-Occitanie network|"First of all, healthcare professionals from EHPAD in the intervention arm were invited by email to answer a closed questionnaire. It was built by the authors, on Google forms, and consisted of 11 questions divided into 2 sections.~Section 1 collected data about the participants. In section 2, they were asked to score from 0 to 4 (ranging from not at all to a lot ) the various obstacles to teleconsultations reported by the literature."
223534872|NCT00512564|OTHER|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
224275013|NCT03397004|DRUG|Doxycycline Hyclate|Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
224275014|NCT03397004|DRUG|Placebo|Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
223520325|NCT00916526|PROCEDURE|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
223520326|NCT01600651|OTHER|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
223520327|NCT01600651|OTHER|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
223520328|NCT02398799|BEHAVIORAL|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
223520329|NCT00778401|DRUG|Gabapentin tablets 800 mg|
223520330|NCT02209675|OTHER|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
223520331|NCT00200746|DRUG|Arginine|Amino Acid Arginine
223520332|NCT00802503|DIETARY_SUPPLEMENT|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is \< 60% of energy target in order to reach 100% of energy target by peripheral or central line.
223520333|NCT01177358|DRUG|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
223520334|NCT01177358|DRUG|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
223520335|NCT05029388|OTHER|Aerobic Exercise|The participants will complete three training sessions per week over 10 weeks. The aerobic training program will last for one hour. The session will include a 10-minute warm-up period, followed by a 45-minute aerobic workout, wherein the participants can choose to use either a treadmill, a cycle ergometer, or a rowing ergometer. After the workout, a five-minute period of stretching will be provided for cooling down. The intensity during the workout will be set at 40%-55% of the individual's maximum heart rate.
223520336|NCT05029388|OTHER|High Intensity Interval Training|The intervention will be conducted over a period of 10 weeks, while the participants will complete three training sessions per week. The HIIT training program will last for 30 minutes. The session will include a 10-minute warm-up period, followed by a 15-minute HIIT workout, and a 5-minute period of stretching to cool down. The exercises will include repeated, high-intensity intermittent bursts of vigorous activity at maximal effort. The HIIT will mainly include bodyweight exercises (e.g., push-ups, squats, lunges) that disregards equipment usage. The intensity during the workout will be set to 85%-95% of the individual's maximum heart rate. A half-day training workshop will be provided to the personal trainer to ensure that he/she knows the exercises and can demonstrate them to the participants.
223520337|NCT03697447|PROCEDURE|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
223520338|NCT06152926|OTHER|Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions|"People diagnosed with a urological cancer receiving Immune checkpoint inhibitor treatment at a single centre trust will be invited to either face to face or online video-conference individual interviews (Microsoft teams) according to participant preference.~Consenting participants will be interviewed via semi-structured interview methods round a topic guide and audio-recorded. Inductive thematic analysis will be conducted to explore participant experiences and perceptions of physical activity and exercise."
223520339|NCT05630365|DIAGNOSTIC_TEST|Panbio™|The Panbio™ COVID-19/Flu A\&B Rapid Panel device, hereafter referred to as the Panbio™ Rapid Panel, is a visual lateral flow assay for the rapid immuno-chromatographic qualitative detection of COVID-19 antigen, Influenza A antigen, and Influenza B antigen in mid-turbinate nasal swabs
223520340|NCT06019494|PROCEDURE|Oocyte retrieval with low aspiration flow rate|All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.42 ml/sec.
223520341|NCT06019494|PROCEDURE|Oocyte retrieval with high aspiration flow rate|High aspiration flow rate All follicles will be aspirated with the addition of follicular flushing if necessary (up to 5 times per follicle) with an aspiration flow rate of 0.62 ml/sec.
223520342|NCT05102448|DRUG|Tofacitinib|"1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
223520343|NCT05102448|DRUG|Methotrexate|"1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria."
223534873|NCT04528589|OTHER|prenatal psychotherapy|Prenatal psychotherapy to break intergenerational risk of adverse childhood events
224275015|NCT05689333|DEVICE|Vista Vitrectomy Probe|Vitrectomy will be performed through 27 GA Vista Ophthalmics vitrector
223520344|NCT02510248|DRUG|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
223520345|NCT02510248|DRUG|Placebo|Placebo to match AL-704
223520346|NCT03770611|DIETARY_SUPPLEMENT|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
223520347|NCT03770611|DIETARY_SUPPLEMENT|Prebiotic|The prebiotic fiber is Agave inulin
223520348|NCT03770611|DIETARY_SUPPLEMENT|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
223520349|NCT03770611|DIETARY_SUPPLEMENT|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
223520350|NCT03741842|BEHAVIORAL|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
223520351|NCT06395220|OTHER|Detection of donor-specific anti-HLA antibody (DSA)|"Detection methods~1. . Morphology: using microscope to observe the morphology of bone marrow.~2. . Immunophenotyping: using multi-color flow cytometry (MFC) to detect immunophenotype of leukemia cells and leukemia-associated immunophenotype of bone marrow samples.~3. . Cytogenetics analysis: G-band and/or fluorescence in situ hybridization (FISH) analysis are used in this study~4. . Molecular detection: Real-time quantitative RT-PCR (RQ-PCR) and/or next generation sequencing techniques are used to detect the molecular marker, such as: PML/RARA, AML-ETO, BCR/ABL, and WT1.~5. . HLA-Typing: HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 alleles were determined according to the literatures published by our group \[Huo MR, et al. Bone Marrow Transplant. 2018;53(5):600-608\]..~6. . Other analyses: Detection of minimal residual diseases were performed using MFC and RQ-PCR according to the methods reported by our group \[Li SQ, et al. Blood,2022;140(5):516-520\]."
223520352|NCT03445442|PROCEDURE|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
223520353|NCT03445442|PROCEDURE|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
223520354|NCT03445442|PROCEDURE|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
223520355|NCT05937802|DIETARY_SUPPLEMENT|Osmotin|Oral administration for 6 months of 7 capsules per day (4 in the morning and 3 in the evening) for a daily dosage of 5 grams.
223520356|NCT00143845|PROCEDURE|Reduced intensity conditioning|Busulfan and Fludarabine regimen
223520357|NCT00143845|PROCEDURE|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
223520358|NCT00143845|PROCEDURE|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
223520359|NCT03758846|BEHAVIORAL|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
223520360|NCT03758846|BEHAVIORAL|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
223520361|NCT03758846|BEHAVIORAL|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
223534874|NCT01307449|BIOLOGICAL|PNEUMOVAX|1 dose of PNEUMOVAX
223534875|NCT01307449|BIOLOGICAL|Prevnar|1 dose of Prevnar
223534876|NCT03218917|DRUG|Brensocatib 10 mg|Administered once per day for 24 weeks
223534877|NCT03218917|DRUG|Brensocatib 25 mg|Administered once per day for 24 weeks
223534878|NCT03218917|DRUG|Placebo|Administered once per day for 24 weeks
223704132|NCT03917459|DRUG|LCZ696|sacubitril/valsartan 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
224275016|NCT04507828|RADIATION|Treatment Planning using the DIBH Technique|Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours. The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan. Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
223520362|NCT03758846|BEHAVIORAL|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
223520363|NCT03758846|BEHAVIORAL|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
223520364|NCT05032352|DRUG|Adjuvant|Adjuvant treatment with a standard NSCLC platin-based doublet, 4 cycle (21-day) regimen of the investigator's choice (Arm 1) or other adjuvant therapy (Arm 1a) which can include combination of chemotherapy and targeted therapy, immunotherapy or other.
223520365|NCT05032352|OTHER|Observation|All patients will be observed for progression free survival and overall survival to the end of study or death, whichever occurs first.
223520366|NCT00240019|DRUG|Addition of furosemide 20 mg oral bid to baseline regimen|
223520367|NCT03615768|COMBINATION_PRODUCT|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
223520368|NCT03615768|DRUG|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
223520369|NCT03615768|DRUG|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
223520370|NCT03376529|DRUG|SPR741|400 mg IV over 1 hour
223520371|NCT03376529|DRUG|Ceftazidime|1.0 gram IV over 1 hour
223520372|NCT03376529|DRUG|Piperacillin/tazobactam|4.5 grams IV over 1 hour
223520373|NCT03376529|DRUG|Aztreonam|1.0 gram IV over 1 hour
223520374|NCT00323986|DRUG|azithromycin (drug)|
223520375|NCT02658188|DRUG|ASP8825|Oral
223520376|NCT04504136|PROCEDURE|Serial Biopsy|"During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach."
223520377|NCT00666341|DRUG|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
223520378|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
223520379|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
223520380|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
223520381|NCT00666341|BIOLOGICAL|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
223520382|NCT02528305|OTHER|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
223520383|NCT01044043|PROCEDURE|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
223520384|NCT05333588|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|The autologous TILs will be intravenous infused into patients.
223520385|NCT01299532|DEVICE|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
223520386|NCT02285959|DRUG|Bevacizumab|
223520387|NCT04256837|DEVICE|Transcutaneous electrical auricular vagus nerve stimulation (VNS)|Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
223520388|NCT01789502|DEVICE|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
223520389|NCT01789502|DEVICE|Plastic stents|Plastic stents were inserted by ERCP
223520390|NCT02268487|DRUG|Sertraline|Treatment
223520391|NCT01954511|OTHER|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
223520392|NCT01954511|OTHER|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
223520393|NCT01954511|DEVICE|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
223520394|NCT00872287|PROCEDURE|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
223520395|NCT00872287|PROCEDURE|SILS|Single transumbilical incision laparoscopic cholecystectomy
223520396|NCT02522221|DRUG|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
223520397|NCT02522221|DRUG|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
223520398|NCT04168411|PROCEDURE|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
223520399|NCT03357497|OTHER|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
223520400|NCT02438397|DRUG|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
223520401|NCT02438397|DRUG|metformin|500 mg tid by Merck
223520402|NCT02438397|DRUG|Acarbose|100mg tid by Bayer
223520403|NCT00005880|DRUG|budesonide|
223520404|NCT06234475|BEHAVIORAL|Mobile health support|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months"
223520405|NCT06234475|BEHAVIORAL|Financial incentive|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
223520406|NCT06234475|BEHAVIORAL|Combine intervention|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months~6. Acceptance and Commitment Therapy based real-time Chat-based support for 3 months~7. An escalating incentive scheme for smoking abstinence: HK$500 for using any SC services within 6 months, and HK$1000, 1500 and 2000 for biochemically validated abstinence at 3-, 6- and 12-month, respectively."
223520407|NCT06234475|BEHAVIORAL|Control group|"1. Brief smoking cessation advice~2. Health warning leaflet~3. Smoking cessation information booklet~4. Referral card~5. E-messages on SC-related information and details on community SC services for 3 months for those without abstinence at 12-month follow-up after follow-ups ending~6. Acceptance and Commitment Therapy based rear-time Chat-based support for 3 months for those without abstinence at 12-month follow-up after follow-ups ending"
223520408|NCT02627638|OTHER|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
224275017|NCT04311944|OTHER|Early fast-track care|Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.
224275018|NCT04311944|OTHER|Standard (deferred fast-track) care|Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
224275019|NCT01628549|DRUG|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
224275020|NCT01628549|DRUG|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
224275021|NCT01628549|DRUG|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
224275022|NCT05212038|PROCEDURE|iliopsoas plane block group|Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
224275023|NCT05212038|PROCEDURE|sham block group|Ultrasound-guided iliopsoas plane block with normal saline 10 ml
224275024|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to continue on receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
224275025|NCT04543968|DIETARY_SUPPLEMENT|hydroxytyrosol (HT) intake and withdraw|MD patients will receive hydroxytyrosol (HT) daily as dietary supplements for 12 months. After that, patients will be randomly assigned in 1:1 ratio to withdraw from receiving hydroxytyrosol (HT) as their dietary supplements for another 6 months.
223520409|NCT01961180|DRUG|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
223520410|NCT01961180|DRUG|Placebo|Placebo
223520411|NCT03956108|DIAGNOSTIC_TEST|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
223520412|NCT03956108|DIAGNOSTIC_TEST|PSA + systematic biopsies|Systematic biopsies and PSA test
223520413|NCT05420337|PROCEDURE|Group ıntramuscular|Group I will be applied 20 ml of % 0.25 bupivacain internal oblique and transversus abdominis muscle and 0.1 mg/kg morphine ıntramuscular. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
223520414|NCT05420337|PROCEDURE|Group TAP|Group T will be applied 20 ml of % 0.25 bupivacain and 0.1 mg/kg morphine internal oblique and transversus abdominis muscle. The blocks will be administered under general anesthesia in supine position by the same anesthesiologist.
223520415|NCT00441935|DEVICE|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
223520416|NCT03737890|OTHER|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
223520417|NCT03737890|OTHER|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
223520418|NCT02397369|OTHER|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
223534879|NCT00427193|BEHAVIORAL|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
223534880|NCT00427193|BEHAVIORAL|Control|Participants continue their current diet for 24 months
224275026|NCT02988882|DRUG|Dexamethasone|
224275027|NCT02988882|OTHER|Placebo Vehicle|
223520419|NCT02397369|BEHAVIORAL|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
223520420|NCT02397369|BEHAVIORAL|Tobacco users:Behavioural therapy Only|"1. Focus Group discussion:~   This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~2. Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
223520421|NCT02397369|OTHER|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
224275028|NCT01405469|OTHER|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
224275029|NCT06404463|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
224275030|NCT06404463|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
224275031|NCT06404463|DRUG|Doxorubicin|Doxorubicin, a widely used chemotherapy drug, belongs to the anthracycline class and is effective against various cancers, including breast cancer, leukemia, and sarcomas. It works by intercalating with DNA and inhibiting topoisomerase II, leading to DNA damage and disruption of DNA replication and transcription processes within cancer cells. Despite its efficacy, doxorubicin may cause side effects such as cardiotoxicity and bone marrow suppression, limiting its long-term use in some patients.
224275032|NCT06404463|DRUG|Cyclophosphamide|Cyclophosphamide is a chemotherapy medication commonly used to treat various types of cancers, including lymphoma, leukemia, and breast cancer. It belongs to the class of alkylating agents and works by crosslinking DNA strands, which prevents cell division and leads to cell death. While effective in treating cancer, cyclophosphamide can also cause side effects such as nausea, vomiting, and suppression of the immune system.
224275033|NCT06404463|DRUG|Epirubicin|Epirubicin, a chemotherapy medication, is part of the anthracycline class and is used in the treatment of various cancers, including breast cancer, ovarian cancer, and soft tissue sarcoma. It functions by interfering with DNA replication and RNA synthesis within cancer cells, ultimately leading to cell death. Despite its efficacy, epirubicin can cause side effects such as nausea, hair loss, and bone marrow suppression.
224275034|NCT06009796|DEVICE|Tooth Tissue Borne Rapid Palatal Expansion|In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
224275035|NCT06009796|DEVICE|Tooth Bone Borne Rapid Palatal Expansion|After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
224275036|NCT00177164|DRUG|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
223534881|NCT06544915|DIETARY_SUPPLEMENT|Synbiotic, Probiotic, Placebo|Use of dietary supplements to improve gut microbiome and cardiometabolic health
223534882|NCT05194150|DEVICE|non-diffractive monofocal IOL|Rayone EMV
223893686|NCT05795842|DEVICE|wearable wristband model|MOTO 360 smartwatch: is a specific consumer wearable wristband model (Motorola: MOTO 360), fitted with proprietary firmware (LifeQ) to collect continuous biometric signals, including PPG signals and 3-axis accelerometers in an ambulatory setting. The device is not a medical or diagnostic device, but rather a photoplethysmography (PPG) data collection device. PPG is a non-invasive technology that uses light to measure the change in the volume of blood beneath the skin that occurs as the heart beats. LifeQ has developed software that enables the collection of vital signs data from PPG technology.
223520422|NCT00787800|DEVICE|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
223520423|NCT00787800|DEVICE|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
223520424|NCT00373360|DRUG|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
223520425|NCT04228003|DIETARY_SUPPLEMENT|Pendulum Glucose Control formulation for T2D|"All bacteria contained in the study product formulation are commensal organisms that have been repeatedly documented to inhabit the human GI tract under normal circumstances. Pendulum's Glucose Control Formulation consists of five human commensal microbial strains including butyrate producing and mucin-degrading strains. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS).~The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃."
223520426|NCT05297019|PROCEDURE|Hyperbaric Oxygen Therapy|hyperbaric oxygen therapy
223520427|NCT00090675|DRUG|ZD1839|
223520428|NCT01431547|DRUG|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
223520429|NCT01431547|DRUG|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
223520430|NCT01431547|DRUG|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
223520431|NCT00027300|DRUG|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
223520432|NCT00027300|DRUG|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
223520433|NCT04309500|BEHAVIORAL|Personalized DAT Risk Disclosure Protocol|Individual participants and their co-participants will receive information about the participant's DAT risk based on their clinical history, structural magnetic resonance imaging, apolipoprotein-E (APO-E) genotype, and amyloid and tau burden on positron emission tomography (PET) scanning. This session will include consent, psychoeducation, re-consent, personal risk feedback, action suggestions, participant/caregiver resources, and a written summary of results. Risk assessment and safety planning will be applied if needed.
223520434|NCT00047580|DRUG|tizanidine hydrochloride capsule|
223520435|NCT01081574|DRUG|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
223520436|NCT01568229|DRUG|AMG 747|Three dose levels once-daily oral administration
223520437|NCT01568229|DRUG|Placebo|Once-daily oral administration
223520438|NCT00498407|DRUG|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
223520439|NCT00773461|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
223520440|NCT00773461|DRUG|Placebo|iv every 4 weeks for 24 weeks
223520441|NCT00913835|BIOLOGICAL|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
223520442|NCT00913835|DRUG|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
223520443|NCT06548347|DRUG|Linperlisib|Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
223520444|NCT06127901|PROCEDURE|Any surgery under any type of anaesthesia.|Any surgery under any type of anaesthesia.
223520445|NCT00833274|BEHAVIORAL|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
223520446|NCT06366165|PROCEDURE|seemingly irrelevant funny videos and memes in teaching|linking funny videos and memes to special care dentistry curriculum lectures
223520447|NCT00637156|DEVICE|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
223520448|NCT00637156|DEVICE|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
223534883|NCT05194150|DEVICE|standard EDOF IOL|Acrysof IQ Vivity
223534884|NCT00337038|DRUG|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
223704133|NCT03917459|DRUG|Enalapril matching placebo|Placebo to Enalapril 10 mg film-coated tablets
223704134|NCT03917459|DRUG|Enalapril|Enalapril 10 mg film-coated tablets
223704135|NCT03917459|DRUG|LCZ696 matching placebo|Placebo to LCZ696 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
223520449|NCT05930535|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens|"PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other."
223520450|NCT01407887|DRUG|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
223520451|NCT02340546|DEVICE|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
223520452|NCT00000501|BEHAVIORAL|diet, sodium-restricted|
223520453|NCT00000501|BEHAVIORAL|diet, reducing|
223520454|NCT00000501|DRUG|potassium|
223520455|NCT02431026|DEVICE|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
223520456|NCT05648747|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Italy's government rapidly established diverse public actions, which helped maintain the medical supply. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether pelvic inflammatory disease rates were affected by the COVID-19 pandemic.
223520457|NCT00461812|DRUG|Mometasone|
223520458|NCT00461812|DRUG|Advair|
223520459|NCT03757663|BEHAVIORAL|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
223520460|NCT01793233|OTHER|Laboratory Biomarker Analysis|Correlative studies
223520461|NCT01793233|OTHER|Questionnaire Administration|Ancillary studies
223520462|NCT01503177|BIOLOGICAL|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
223520463|NCT01503177|OTHER|laboratory biomarker analysis|Correlative studies
223520464|NCT01503177|PROCEDURE|single photon emission computed tomography|Correlative studies
223520465|NCT01503177|PROCEDURE|computed tomography|Correlative studies
223520466|NCT05914129|OTHER|Diaphragm, Stomach and Liver techniques|"Diaphragm Stretching:~The participant is seating down and the researcher will be behind, placing their hands on the inferior costal border. Cephalic traction is performed during inhalation, remaining during exhalation. Procedure is repeated 2 times, for 10 respiratory cycles, with 1-minute intervals.~Inferior Mobilization of the Stomach:~The participant is seating down with slight flexion of the torso, while the investigator stands behind them, placing the thumbs on the epigastric region. The volunteer will extend their body while the researcher performs a caudal traction. This procedure lasts 5 minutes.~Liver Pump:~Participant is laying on their back, and the investigator is standing on the participants side. The researcher places one hand on the right side inferior costal border posteriorly and the other one bellow the costal border anteriorly. Researcher compresses during exhalation and releases their hands abruptly during inhalation. This procedure lasts 5 minutes."
223520467|NCT05914129|OTHER|Stomach and Liver techniques|In this group, techniques are the exact same as described previously but only liver and stomach ones will be performed.
223520468|NCT05914129|OTHER|Sham technique|In the sham group, manual contact without any therapeutic intention will be performed in the same regions as the experimental groups. This contact will be maintained during the same amount of time as for the experimental group A.
223520469|NCT03193437|DRUG|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
223520470|NCT02067598|OTHER|scapular exercise|
223520471|NCT04868357|BEHAVIORAL|Hypnosis|Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.
223520472|NCT04868357|BEHAVIORAL|Relaxation|Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
223520473|NCT03856918|PROCEDURE|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
223520474|NCT03856918|PROCEDURE|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
223520475|NCT03856918|PROCEDURE|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
223520476|NCT05348122|DRUG|TG103,Q2W|TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
223520477|NCT05348122|DRUG|TG103,QW|TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
223520478|NCT05348122|DRUG|Placebo,Q2W|Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.
223520479|NCT05348122|DRUG|Placebo,QW|Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
223520480|NCT05348122|DRUG|Dulaglutide,QW|Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.
223520481|NCT04083079|DRUG|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
223520482|NCT04083079|DRUG|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
223520483|NCT05487378|DIETARY_SUPPLEMENT|PKU GOLIKE|AA protein Substitute for the dietary management of PKU, PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
223520484|NCT04907084|DIETARY_SUPPLEMENT|Serine|Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally)
223520485|NCT04907084|DRUG|Fenofibrate|Fenofibrate 160mg pill, taken orally
223520486|NCT06644352|PROCEDURE|different thoracic surgical approaches|Right Versus Left Thoracic Surgical Approaches
223520487|NCT03918408|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
223520488|NCT03486470|DIAGNOSTIC_TEST|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
223520489|NCT05003336|DRUG|Xiangshao Granules|dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
223520490|NCT05003336|DRUG|Xiangshao Granules Placebo|Xiangshao Granules Placebo
223520491|NCT01509456|DIETARY_SUPPLEMENT|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
223520492|NCT04948268|BEHAVIORAL|Adaptive messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Content and messages will be tailored using machine learning.
223520493|NCT04948268|BEHAVIORAL|Non-personalized messaging intervention|Psychological content and messages delivered regularly over an 8-week period via interactive SMS messages. Psychological content will center on a single psychological strategy each week. There will not be any tailoring of messaging and content based on group or individual level data.
223520494|NCT04948268|BEHAVIORAL|Coaching|Human coaching to support intervention use and engagement via telephone calls, text or email
223520495|NCT04948268|BEHAVIORAL|Psychoeducational links|SMS messages with URLs containing brief psychoeducational information.
223520496|NCT01778621|DEVICE|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
223520497|NCT02414841|DRUG|Vonapanitase|
223520498|NCT02414841|DRUG|Placebo|
223520499|NCT05212337|DRUG|Denosumab|Subcutaneous injection with 60 mg Denosumab once
223520500|NCT05212337|DRUG|Sodium chloride|Subcutaneous injection with NaCl once
223520501|NCT06602817|OTHER|Exposure: prone position|Exposure: surgery in prone position
223520502|NCT06602817|OTHER|Exposure: Supine position|Exposure: Surgery in supine position
223520503|NCT04658368|PROCEDURE|Primary TMR|TMR procedure as part of the primary major limb amputation surgery
223520504|NCT04658368|PROCEDURE|Secondary TMR|TMR procedure subsequent to major limb amputation surgery
223520505|NCT03053362|DRUG|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
223520506|NCT03053362|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
223520507|NCT05553210|BEHAVIORAL|FOREST+|The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
223520508|NCT06569433|PROCEDURE|THERAPEUTIC EXERCISE AND MOBILISATION OF THE FEMORAL NERVE|"the control group that will perform only therapeutic exercise will perform a specific exercise programme for knee tendinitis under the supervision of a physiotherapist, while the intervention group that will perform therapeutic exercise plus femoral nerve mobilisation will receive therapeutic exercise sessions and femoral nerve mobilisations performed by a trained physiotherapist.~The intervention will last for 6 weeks, during which 60-minute sessions will be held at the centre, measurements will be taken during the six weeks, using standardised questionnaires to evaluate the variables (set out below) and always measuring the range of movement and femoral nerve mobility with the Slump Test on the same day of the week and at the same time of treatment."
223520509|NCT06603311|OTHER|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection|Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.
223704136|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
223704137|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
223704138|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
223704139|NCT00491764|DRUG|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
223704140|NCT00491764|DRUG|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
223704141|NCT00491764|DRUG|Placebo|Placebo for 24 weeks.
224275037|NCT03314376|DEVICE|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
224275038|NCT03776344|DEVICE|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
224275039|NCT03946462|DRUG|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
224275040|NCT03946462|OTHER|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
224275041|NCT00965757|DRUG|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
224275042|NCT00965757|DRUG|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
224275043|NCT01572857|BIOLOGICAL|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~* Of the 24-hour urine~* at 8 AM~* at 12 AM~* at 4 PM~On each of these urine samples, the following analysis will be performed:~* Proteinuria~* Albuminuria~* Urinary FLC (Freelite ™)~* Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
224275044|NCT02689817|DEVICE|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
223520510|NCT05251805|PROCEDURE|Blood, bone marrow and lung tumor tissue collection|"Blood sampling: 12ml of blood will be collected during the routine pre-operative blood collection~Bone marrow aspiration during thoracic surgery: following the surgical intervention, bone marrow aspiration will be performed through the incisions made for the thoracic procedure. The ribs lying directly above and below the trocar incision will be exposed. A bone marrow needle will be advanced into the periost until the needle tip reaches the bone marrow. After removing the stylet a 2ml syringe will be attached to the aspiration needle and 0.5ml to 2ml of bone marrow will be aspirated before removing the needle. This procedure will be repeated twice for every trocar site, for a maximum of 3 trocar sites, or until 5ml of bone marrow aspirate is obtained.~Lung tumor collection: all surgical samples will be analyzed by our anatomopathological department. Viable and fresh material, not used for the diagnostic purposes, will be sent to the LMCT."
223520511|NCT06656221|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 2000mg on Cycle 1 Days 1-2
223520512|NCT06656221|DRUG|Glofitamab|Glofitamab is given intravenously at a dose of 2.5mg on Cycle 1 Day 8. Glofitamab is given intravenously at a dose of 10mg on Cycle 1 Day 15. Glofitamab is given intravenously at a dose of 30mg on Day 1 of Cycles 2-6
223520513|NCT06656221|DRUG|Bortezomib|Bortezomib is given intravenously at a dose of 1.6 mg/m² on Days 1, 8, and 15 of Cycles 1-12.
223520514|NCT06656221|DRUG|Orelabrutinib|Orelabrutinib is given orally at a dose of 150 mg daily on Days 1-21 of Cycles 1-12.
223520515|NCT04846868|DRUG|Iclepertin|Iclepertin
223520516|NCT04846868|DRUG|Placebo|Placebo
223520517|NCT06670586|PROCEDURE|conventional in vitro fertilization|Fertilization via conventional In Vitro Fertilization
223520518|NCT06670586|PROCEDURE|intracytoplasmic sperm injection (ICSI)|Fertilization via intracytoplasmic sperm injection
223520519|NCT03422731|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow and blood samples
223520520|NCT03422731|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
223520521|NCT03422731|DRUG|Fluorothymidine F-18|Undergo FLT PET
223520522|NCT03422731|OTHER|Laboratory Biomarker Analysis|Correlative studies
223520523|NCT03422731|PROCEDURE|Magnetic Resonance Imaging|Undergo water-fat MRI
223520524|NCT03422731|PROCEDURE|Positron Emission Tomography|Undergo FLT PET
223520525|NCT06992089|DEVICE|Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®)|"Dual-chamber cardiac pacemaker (Essentio MRI L111 Boston Scientific®), with rate-adaptive pacing of the right atrium. There will be an associated right atrial lead (INGEVITY™ MRI Pacing Lead Boston®) and right ventricular lead (INGEVITY™ MRI Pacing Lead Boston®).~Single-chamber cardiac pacemaker (Essentio MRI L110 Boston Scientific®), with rate-adaptive pacing of the ventricles. There will be a right ventricular lead (INGEVITY™ MRI P Boston®)."
223520526|NCT06671301|BEHAVIORAL|PSAI|Holistic stress management program implementing the pillars of Lifestyle Medicine
223520527|NCT06671301|OTHER|Usual Care|Usual care without specific treatment
223520528|NCT06673914|BEHAVIORAL|Control Group: Diet Group|"Patient in Diet Group and Oleuropein and Diet Group will be given a personalized diet and be followed up by a dietician."
223520529|NCT06673914|DIETARY_SUPPLEMENT|Oleuropein and Diet Group|"Dietary Supplement: Oleuropein (Olive Leaf Extract) Patients in Oleuropein and Diet Group will receive 200 mg/day oleuropein supplement and personalized diet followed up by a dietician."
223520530|NCT03535701|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
223520531|NCT03535701|OTHER|Laboratory Biomarker Analysis|Correlative studies
223520532|NCT03535701|DRUG|Paclitaxel|Given standard of care therapy with paclitaxel
223520533|NCT03535701|OTHER|Quality-of-Life Assessment|Ancillary studies
223520534|NCT03535701|OTHER|Questionnaire Administration|Ancillary studies
223520535|NCT06998927|OTHER|Application of Proportional Assist Ventilation Plus (PAV+) at three support levels (20%, 50%, 70%) to assess ventilator-displayed work of breathing and its correlation with physiologic measures.|This intervention is distinguished by applying Proportional Assist Ventilation Plus (PAV+) at three support levels (20%, 50%, 70%) within the same patient, allowing a stepwise analysis of its effect on work of breathing. It uses real-time ventilator-displayed work of breathing, a noninvasive and underexplored tool, correlated with multiple physiological parameters such as esophageal pressure, Pocc, and P0.1. This within-subject design controls for interindividual variability, improving the precision of the analysis. Focusing on patients with spontaneous respiratory effort facilitates clinical application to optimize personalized ventilatory support. Thus, the study provides novel data to adjust support levels according to the patient's actual effort and to validate ventilator measurements against reference physiological indicators.
223520536|NCT06675058|PROCEDURE|Indirect Pulp Treatment|Indirect pulp treatment is considered one of the most conservative pulp therapies, which preserves the pulp's vitality in teeth with reversible pulpitis. It has been chosen to be the intervention in both groups as the aim of this study is to assess the impact of caries location (proximal vs. occlusal caries) in influencing the success rate of IPT.
223520537|NCT06674200|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery is shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Separate the mesentery around the stoma and shape it into a sturdy support structure.~Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
223520538|NCT06674200|PROCEDURE|Regular|"The stoma surgery is performed using conventional non-molding suturing techniques. The specific steps include:~Select an appropriate stoma site, typically within the rectus abdominis muscle. Perform routine suturing around the stoma without additional mesentery shaping. Form the stoma, ensuring a tight fit of the surrounding tissues."
223534885|NCT00748631|DEVICE|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
223520539|NCT07004712|DRUG|Adebelizumab combined with irinotecan liposome as second-line therapy|Adebellizumab: intravenous drip, 1200mg, the infusion time is controlled between 30-60 minutes, and the infusion is completed within 2 hours at most. It is administered on the first day of each cycle and repeated once every 3 weeks.Irinotecan liposome: intravenous drip, 80mg/m2, infusion time of 30 minutes, the first dose of each cycle, repeated once every 3 weeks.After 4-6 cycles of adebelizumab combined with irinotecan liposome treatment, the subjects who did not develop the disease continued to use adebelizumab (1200mg, D1, Q3W) for maintenance treatment until the disease progressed, the toxicity was intolerable, the subjects voluntarily asked to withdraw and the researchers judged that the subjects needed to withdraw from the study.
223520540|NCT05893732|DEVICE|High-Intensity Laser Therapy (HILT)|Participants will undergo HILT treatment using a diode laser device (wavelength: 1064 nm; power: 12 W; peak power: 50 W; energy density: 600 J/cm²; spot size: 1 cm²; pulse duration: 200 μs; pulse frequency: 10 Hz) applied in continuous mode. The laser probe will make contact with the skin over the LFCN entrapment site at three specific points: (a) the inguinal ligament, (b) the point of maximum tenderness along the nerve pathway, and (c) the mid-point between the ASIS and the lateral border of the patella. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
223520541|NCT05893732|DEVICE|Sham High-Intensity Laser Therapy (Sham HILT)|Participants will undergo sham HILT treatment using an identical laser device with no active laser output, following the same treatment protocol as the HILT group. The laser probe will make contact with the skin over the LFCN entrapment site at the same three specific points as the HILT group. Each point will be treated for 1 minute and 40 seconds, totaling a 5-minute session. Participants will undergo 12 sessions in total, with three sessions per week for four weeks.
223520542|NCT03048682|DEVICE|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
223520543|NCT03048682|DEVICE|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
223520544|NCT04331769|DEVICE|AccuCinch Ventricular Restoration System|AccuCinch Ventricular Restoration System
223520545|NCT04331769|DRUG|Guideline-Directed Medical Therapy|Guideline-Directed Medical Therapy
223520546|NCT06158438|DEVICE|BTL-754-4 Treatment|Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
223520547|NCT07010367|PROCEDURE|Acupuncture|Patients will be instructed to lie in the supine position. After strict disinfection of the acupoints area, acupuncture needles will be inserted into the Baliao points (inserted at the surface projections of the first, second, and third pairs of sacral foramina, with a depth of 3-4 cm). The treatment will be administered five times per week, with each session lasting 30 minutes, for a total of two weeks.
223520548|NCT07010367|PROCEDURE|Sham acupuncture|Patients will be instructed to lie in the supine position. After strict disinfection of the sham acupoints area, acupuncture needles will be inserted lateral to the surface projections of the first, second, and third pairs of sacral foramina, with a depth of 1 cm.The treatment will be administered five times per week, with each session lasting 30 minutes, for a total of two weeks.
223520549|NCT07010328|PROCEDURE|Neurorehabilitation|4-8 weeks of inhospital Neurorehabilitation
223520550|NCT07010328|DEVICE|AI-based home rehabilitation for postural disorders|AI-based home rehabilitation for postural disorders by means of the Kemtai platform.
223520551|NCT07011251|BEHAVIORAL|Food as Medicine Program|Grocery Prescription - participants will receive a card loaded with $100 per month to be used on the Instacart Fresh Funds program website/app or a SodaHealth grocery prescription card to be used inside a Kroger or Food City stores. Patients who select grocery delivery where Instacart is not available will receive Food City meals for the same value. or 2) Medically Tailored Meals (MTM) - participants receive approximately 5 frozen meals per week from Mom's Meals that follow an approved diet for those with hypertension. Participants will complete screening questions (screening decision tree attached) after informed consent to determine which food package the participant will receive. The screening decision tree is a tool that asks about kitchen availability for preparing foods, skills, and access to transportation. Depending on how the patient answers they will receive either grocery prescription or MTM for 3-months or 12-weeks.
223520552|NCT07011251|OTHER|Survey|"Participants answering no to assistance but agreeing to the 20-30 minute survey will receive a direct link to a survey related to reasons for not wanting assistance to answer questions at one time point."
223520553|NCT06626347|OTHER|TREAT-ED Virtual Group Diabetes Self-Management Education and Support|TREAT-ED is an innovative group telehealth delivery model designed to engage emerging adults in DSMES services. TREAT-ED sessions are facilitated by a Diabetes Care and Education Specialist and include content centered around the ADCES7 Self-Care Behaviors and applied learning strategies, e.g., case scenarios integrating glucose monitoring, and group discussions to drive knowledge transfer and skill development for diabetes self-care behaviors within the context of issues that are salient to the target population.
224275045|NCT01140438|DRUG|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
224275046|NCT01140438|DRUG|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
224275047|NCT03074799|OTHER|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
224275048|NCT03074799|OTHER|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
224275049|NCT00296270|BEHAVIORAL|Memory for truth|
223520554|NCT07010757|BEHAVIORAL|HARPP|In HARPP, MOVE! and CPT are delivered in up to 16 individual psychotherapy sessions. While all CPT content is included, it is slightly tailored to address factors that interfere with health behavior change (e.g., hypervigilance that hinders community-based physical activity). All MOVE! materials are included; MOVE! uses cognitive-behavioral techniques and autonomy-supporting counseling to promote physical activity and healthy eating. HARPP targets other PTSD-related barriers to recovery and healthy lifestyles by promoting sleep and relationship quality, and community engagement. HARPP participants receive at least one medication management consultation (review by clinician and telephone session) focused on currently may cause weight gain and AOM options. When relevant and based upon Veteran interest, medications are changed or prescribed, in coordination with the Veteran's psychiatric and primary care teams.
223520555|NCT07010757|BEHAVIORAL|control arm for HARPP trial|"Participants in the control condition will receive the following:~1. Referral to MOVE!; they will select a MOVE! that fits their schedule (at VAPS MOVE! is a 12-week group).~2. Standard CPT in 60-minute individual sessions, delivered by 4 CPT-trained psychotherapists (different therapists than intervention arm therapists to avoid contamination).~3. One non-visit consult medication review using the same procedures and template outlined above. After the non-visit consult, the Dr. will alert the Veteran's relevant usual care team member(s) via the non-visit consult template in the medical record. They will not have direct contact with control participants, but the study team will monitor for safety following any medication changes."
223520556|NCT07011186|DRUG|TQB3909 Tablets + Azacitidine|TQB3909 is a protein inhibitor; Azacitidine is a cytidine nucleoside analogue
223520557|NCT07010926|BIOLOGICAL|L2-01 adipose-derived mesenchymal stem cells (MSC)|L2-01 is a biological product consisting of human mesenchymal stem cells isolated from adipose tissue of the patient or a first-degree relative. The MSCs are expanded under Good Manufacturing Practice (GMP) conditions and suspended in 10 ml of lactated Ringer's solution. The product is administered as a single intravenous infusion at a dose of 1 × 10\^6 cells per kilogram of body weight, diluted in 100 ml of saline, infused over approximately 30 minutes. The infusion is closely monitored for safety.
223520558|NCT07010926|OTHER|Placebo saline solution|Placebo consists of 10 ml of lactated Ringer's solution mixed with 100 ml of saline. It is administered as a single intravenous infusion over approximately 30 minutes. The placebo is packaged identically to the active product to maintain study blinding.
223520559|NCT06088563|OTHER|Vaccine injection|Injection of the vaccine in renal transplant patients.
223520560|NCT06683898|OTHER|External Focused Pilates|Pilates training was implemented with an external focus (EF).
223520561|NCT06683898|OTHER|Internal Focused Pilates|Pilates training was implemented with an internal focus (IF).
223520562|NCT06685016|DIAGNOSTIC_TEST|Evaluation of Dentin hypersensitivity with VAS scale|Dentin hypersensitivity and periodontal indices evaluation are performed after and before IPR, at 1 week, 1 month and 3 months
223520563|NCT06685380|OTHER|Not applicable- observational study|For observational studies, participants are not assigned an intervention as part of the study
223520564|NCT07010003|PROCEDURE|Acupressure|Ear acupressure following the NADA Protocol is carried out using special acupuncture patches that press a small bead onto defined points on the ear: Shen Men, kidney, lung, liver, and vegetative. NADA ear acupressure is a non-invasive and low-risk intervention. In addition, the protocol is carried out exclusively by NADA-certified doctors, medical assistants, or nursing staff.
223520565|NCT06689176|DEVICE|Irrisept® Antimicrobial Wound Lavage|Irrisept® Antimicrobial Wound Lavage is a single-use, manual, self-contained irrigation device comprised of a 450mL bottle of 0.05% Chlorhexidine Gluconate (CHG) in 99.95% Sterile Water for Irrigation, United States Pharmacopeia (USP) and an applicator (labeled Irriprobe®). The solution is aseptically filled in a Blow-Fill-Seal (BFS) bottle. The CHG acts as a preservative to inhibit microbial growth in the solution.
223520566|NCT06691789|OTHER|Social support|This intervention includes a social support given to the students during COVID-19 pandemic
223520567|NCT06686732|OTHER|Multimodal physiotherapy|Experimental group included cold pack over lateral epicondyle. Passive stretching exercises in trapezius and levator scapulae and upper ECRB,ECRL,ECU,Extensor Digitorum, Extensor Digiti Minimi. Eccentric exercise of the extensor muscles associated with mobilization with movement. Neuromusclar Rehabilitation Excersise. In the region of origin of the tendons of the extensor muscles of the wrist and fingers for 2 min and inhibition of points of tension in the belly of the extensor region. Early mobilization with movement with the wrist in extension. Lateral sustained glide will be give at humeroradial joint during movement.
223520568|NCT06686732|OTHER|Conventional physiotherapy|Control group included Cold pack for 10 mins on the lateral epicondylitis, Extensor carpi radialis brevis stretching (hold for 15 seconds x 4 reps) Active ROM of wrist flexion and extension (10 reps x 3 sets) Active ROM of elbow flexion, extension, supination and pronation (10 reps x 3 sets) . Manually resisting wrist extensors (10 second hold x 5 reps x 3 sets) 4 sets of Maitland elbow joint mobilization with 1 min of rest between sets. Baseline Dynamometer for grip strength and VAS for pain. These pre and post intervention values were mentioned in questionnaire. The participants were administered with the protocol and data was collected again immediately after the interventions without any delay.
223520569|NCT06689319|BEHAVIORAL|Assessment of Artificial Intelligence Literacy|The Artificial Intelligence Literacy Scale will be used to determine the level of AI literacy.. The scale is a 12-item instrument designed to measure individuals' knowledge and skills in AI awareness, usage, evaluation, and ethical considerations. Items are rated on a Likert scale from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree), with some items reverse-coded (items 2, 5, and 11). The minimum possible score on the scale is 12, and the maximum score is 84; a higher score indicates a higher level of AI literacy. The Turkish version of the scale will be used in this study.
223520570|NCT06687811|OTHER|preoperative carbohydrate loading|Patients receive 200 ml drink containing Maltodextrin 12.5%, 2 hours prior to surgery
223520571|NCT06687811|OTHER|Placebo|Patients receive 200 ml regular drinking water with zero-calorie sweetener, 2 hours prior to surgery
224275050|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER-Bupivacaine/Once
224275051|NCT00974350|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER-Bupivacaine/Once
224275052|NCT00974350|DRUG|SABER-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER-Placebo/Once
224275053|NCT01214980|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
223520572|NCT06690853|OTHER|Experimental Coordinative training|The warm-up protocols of the Experimental Group included four types of upper and lower limb coordination exercises using different-sized balls, with intensity increasing week by week.
223520573|NCT06690853|OTHER|Traditional training (control group)|The Control Group warm-up protocol only involved joint mobility exercises and muscle activation, as used in their regular training activities.
223520574|NCT06688487|OTHER|early extubation of hypoxemic patients|patient extubated after the spontaneous ventilation trial despite the presence of hypoxemia defined by SpO2 ≤ 90% either in T-piece under 6 L/min, or under FiO2 = 40% if SBT is performed in spontaneous ventilation with minimal inspiratory assistance.
223520575|NCT06688565|DEVICE|Hativ® electrocardiogram monitoring|Using Hativ®, a currently commercially available class II medical device, ECGs are measured every day at home and before and after dialysis
223520576|NCT06689631|PROCEDURE|Respiratory Physiotherapy|Mucociliary clearance techniques (prolonged slow expiration and provoked cough), bronchodilator when prescribed and nebulisation with 3% hypertonic saline.
223520577|NCT06681727|OTHER|Accessible Video Mental Healthcare Triage and Assessment (IP)|Patients aged 18 years and older who were registered at participating primary care centers were eligible to access the IP through a regional healthcare app. IP comprised a brief digital screening followed by a 45-minute video consultation with a mental health professional. Eligible patients could thereafter schedule appointments at cooperating healthcare centers and clinics through the app used for video consultations.
223520578|NCT05970939|OTHER|Development of the Telerehabilitation Usability Questionnaire|This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
223520579|NCT05612750|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.
223520580|NCT05612750|BEHAVIORAL|Empowered Relief|A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
223520581|NCT05965479|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate that contains trastuzumab covalently linked to deruxtecan, a topoisomerase I inhibitor. It is given by intravenous infusion.
223520582|NCT04037397|DRUG|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
223520583|NCT04037397|PROCEDURE|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
223520584|NCT05520736|BEHAVIORAL|Appointment reminders, motivational interviewing and targeted vaccine drives|Automated and real time phone call reminders, motivational interviewing and targeted vaccine drives applied in sequence
223520585|NCT06694987|OTHER|Non-Physician Health Worker|"NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months.~Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals."
223520586|NCT06695143|DRUG|Fusidic Acid|Fusidic acid 2% cream
223520587|NCT06695143|OTHER|Vehicle cream|Cetomacrogol cream
224275054|NCT01214980|OTHER|Standard of care|Standard of care provided per site-specific protocol
223534886|NCT06021808|PROCEDURE|Thoracoscopic LAA clipping|The surgeons measured the length of the base of the LAA, an appropriately sized LAA clip is then inserted with the aid of a thoracoscope and placed parallel to the base of the LAA.
224275055|NCT02933892|PROCEDURE|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
224275056|NCT01344018|PROCEDURE|therapeutic conventional surgery|
224275057|NCT01344018|RADIATION|3-dimensional conformal radiation therapy|
224275058|NCT02044939|OTHER|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
224275059|NCT05070754|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
224275060|NCT05070754|DEVICE|Cryotherapy|Cryotherapy refers to the application of liquid nitrogen using a cryospray device in order to freeze a lesion of interest. Treatment is repeated every few weeks until the lesion of interest has disappeared. It is considered SOC for the treatment of warts.
224275061|NCT05070754|DRUG|Canthardin Collodion|Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
224275062|NCT03127241|DEVICE|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
223520588|NCT06695715|BEHAVIORAL|Mindfulness Training Program|This mindfulness training program is based on the Mindfulness-Based Stress Reduction (MBSR) model developed by Jon Kabat-Zinn, incorporating elements of self-compassion and acceptance. What sets this program apart is its integration of both formal and informal practices. Participants engage in 45-minute guided sessions focused on breath awareness and the observation of thoughts, emotions, and physical sensations. Additionally, informal practices include brief daily moments of present-moment awareness. Participants will also receive 10 audio recordings for at-home practice, enhancing the program's accessibility and supporting consistency.
223520589|NCT06695715|BEHAVIORAL|HRV Biofeedback|This HRV biofeedback training program is distinguished by its combination of advanced technology and a novel at-home methodology. Participants will engage in five weekly sessions, with four conducted at home using a heart rate sensor and the EliteHRV mobile app, which provides real-time feedback on heart rate variability. One session per week will take place in the lab, utilizing the Procomp Infiniti biofeedback system. The at-home approach is based on recent research (Schumann et al., 2021), offering participants a flexible yet structured method to practice biofeedback and improve heart rate variability over the six-week program.
223520590|NCT06695715|BEHAVIORAL|Interoception Training|The interoception training program stands out by its focus on developing internal body awareness through structured guided sessions. Participants will engage in weekly 45-minute formal sessions at the university, where they will learn to focus on internal sensations like breath and muscle tension using specific techniques. Additionally, participants will receive 10 guided interoceptive exercises to practice at home, four times a week. This program not only focuses on the physical sensations but also integrates these practices into daily life, aiming to improve self-care and self-regulation over the six weeks, with personalized feedback provided.
223520591|NCT06694207|DRUG|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl|Intraperitoneal Bupivacaine with Dexmedotomidine or Fentanyl for Post-Operative Analgesia Following Laparoscopy in Pediatric Patients
223520592|NCT06695039|DIAGNOSTIC_TEST|Fluoroestradiol (18F)|images for 90 minutes after F-18 FES injection
223520593|NCT06694129|DRUG|Entrectinib|Patients in each cohort were treated with Entrectinib.
223520594|NCT06695091|PROCEDURE|Monolithic zirconia crown|All-ceramic crown
223520595|NCT06695091|PROCEDURE|Monolithic lithium disilicate crown|All-ceramic crown
223520596|NCT06694220|OTHER|Tailored preventive exercises|Players in the experimental group will be asked to perform the tailored preventive program 2-3 times per week for 1 hour for at least 6 weeks preseason which includes warming up for 10 mins, flexibility exercises, strengthening exercises, core and lower body stability and balance exercises and drills all these exercises for 1-4 sets x 10-20 reps and cooling down stretches for the last 10 mins.
223520597|NCT06694220|OTHER|Traditional exercises|The players will be warmed up as usual, with jogging and ball-based exercises following FIFA 11+ warming up program which consist of three steps with 15 specific exercises running exercises for 8 mins, starting warming up in pairs; Path consists of 6-10 pairs of parallel cones: (Running Straight Ahead, Running Hip Out, Running Hip In, Running Circling Partner, Running Shoulder Contact, Running Quick Forwards and Backwards, Rep. x2). Strength, plyometric, balance for 10 minutes (The Bench, Sideways Bench, Single-leg Stance, Squats, Jumping Rep. 2x 30 sec each side). Running Exercises for 2 minutes (End of heating): (running across the pitch, running bounding, running plant, and cut. Rep x 2). Techniques need to be performed correctly and with an emphasis on maintaining the correct posture of the body. This exercise program should be done at least twice a week
223520598|NCT06689254|DRUG|Mifepristone 1200 mg daily|Oral tablets
223520599|NCT06689254|DRUG|Placebo|Oral tablet
223520600|NCT06690684|BIOLOGICAL|Hematological indicators|This project is a retrospective clinical cohort study. STEMI patients undergoing PCI were selected to explore whether hematological indicators such as PIV, SHR, and Lp(a) can improve the accuracy of predicting short-term MACE events in STEMI patients.
223520601|NCT06690684|BIOLOGICAL|Serological indicators in patients with myocardial infarction|This study selected STEMI patients who underwent PCI and collected their hematological indicators to explore the value of PIV, SHR, Lp(a) and other indicators in improving the accuracy of predicting MACE in STEMI patients in the short term.
223520602|NCT06690684|BIOLOGICAL|Levels of biomarkers in blood of patients with acute myocardial infarction|Hemoglobin, neutrophil count, lymphocyte count, monocyte count and platelet count values, N-terminal pro-B type natriuretic peptide (NT-proBNP), peak creatine kinase isoenzymes (CK-MB), peak troponin T levels, total cholesterol (TC), fasting blood glucose (FBG), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and blood urine nitrogen, blood creatinine (Cr) and other indicators
223520603|NCT06695624|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganglion block group 4cc (80mg) 2% lidocaine + 1cc (4mg) dexamethasone in total 5cc volume will be prepared under sterile conditions before the procedure, 2.5 cc will be given to both nostrils. Sphenopalatine ganglion block will be applied by transnasal endoscopic method.
223520604|NCT06694636|PROCEDURE|endovascular radiofrequency ablation and desympathetic nerve surgery|endovascular radiofrequency ablation and desympathetic nerve surgery
223520605|NCT06689384|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Trios 3, 3Shape; Primescan, Dentsply; Element 5D, iTero; Lumina, iTero) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
223719018|NCT00901316|PROCEDURE|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
223520606|NCT06689384|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|"The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth.~A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology."
223520607|NCT06688110|DEVICE|Gixam System|Jubaan's Gixam System is designed to predict the likelihood of colorectal adenomas or SSL by using white light in the 400 to 720 nm range to capture ultra-high-definition images of the of the tongue and analyzing the spectral signature of the oral microbiome to predict the presence of colorectal adenomas or SSL with help of artificial intelligence (AI).
223520608|NCT06690827|DRUG|Anti-CD123 CAR NK cells|Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.
223520609|NCT05954494|BIOLOGICAL|BPAN Patients|Patients, children or adults with a neurological impairment (epilepsy, dystonia, cognitive impairment...) related to a pathogenic variant of the WDR45 gene
223520610|NCT06691646|BEHAVIORAL|Gaze-control training game|An eyetracker-controlled computer game designed to improve attentional control by training inhibitory control over direction of gaze. It includes six mini-games, each designed to train different aspects of oculomotor control, including selective attention, motor inhibition, motor timing, and spatial working memory.
223520611|NCT06690463|DIAGNOSTIC_TEST|sacroiliac joint injection|"The procedure involves the administration of a 2.5 cc injection of 2% lidocaine to the sacroiliac joint, targeting the articular or periarticular areas. The injection is performed under real-time ultrasound guidance to ensure accurate placement of the needle.~The 2% lidocaine solution is injected into both the joint space (articular area) and the surrounding soft tissues (periarticular area), which may include ligaments, capsules, and adjacent muscles. The goal is to temporarily anesthetize the joint and surrounding structures to assess the contribution of the sacroiliac joint in the patient's pain, as well as to provide therapeutic pain relief. The use of ultrasound ensures minimal risk of injury to surrounding structures and enhances the accuracy of the injection.~This intervention is commonly used in both diagnostic and therapeutic settings, helping to confirm the role of the sacroiliac joint in a patient's symptoms and providing relief in cases of sacroiliac joint dysfunction."
223520612|NCT06689358|DRUG|0.4 ml/kg of 0.5% bupivacaine|0.4 ml/kg of 0.5% bupivacaine injected into the thoracic paravertebral space
223520613|NCT06689657|BEHAVIORAL|Cognitive behavioral group therapy for adolescents and non violent resistance group for parents|"In the adolescents group, this cognitive-behavioral group therapy will include emotion regulation skills, distress tolerance skills, cognitive strategies, work on values and problem-solving strategies~Those sessions will include psychoeducation about adolescents, about suicidal ideation and suicidal behavior, coping with adolescent emotional distress, support on how to be a parent today (screen regulation...) and manage daily life"
223520614|NCT06689657|OTHER|Adolescent group therapy (CARES) and parent group therapy (RNV)|"In the adolescent group, they will attend 8 group sessions during 1 month (2 sessions/week). There also will be a boost session 3 month after the last session. Parents will attend 4 group sessions during 1 month too (1 session/week). There will be 2 boost sessions : 1 month and 3 month after the last session Patients will be randomized in each group with blinded assessment"
223520615|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A|0,5 ml DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses. Vaccine is injected intramuscularly in left anterolateral thigh.
223520616|NCT06690515|BIOLOGICAL|DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B|0,5 ml injected of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B three-dose regimen with 28 days interval between doses. Injected intramuscularly in left anterolateral thigh.
223520617|NCT06690515|BIOLOGICAL|Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®|The control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml IPV (Sinovac)® injected in three-dose regimen with 28 days interval between doses. Registered DTwP-Hepatitis B-Hib Vaccine are injected intramuscularly into the left antero-lateral thigh region. IPV (Sinovac)® vaccine are injected intramuscularly into the right mid-lateral thigh region
223520618|NCT06688149|DIAGNOSTIC_TEST|Derivation algorithms|Derivation algorithm based on non-invasive methods, to standardise the continuum of care for diabetic patients with NAFLD from primary care and endocrinology settings to NAFLD specialised units (NSU)
223520619|NCT06687200|OTHER|Setup with neutral pelvic positioning technique|Setup with neutral pelvic positioning technique (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT Mega Voltage Computed Tomography)
223520620|NCT06687200|OTHER|Standard setup|Standard setup (from dosimetry onward and at each session) and daily IGRT (CBCT or MVCT)
223520621|NCT06687187|DRUG|Neostigmine|two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
224275063|NCT03127241|DEVICE|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
223520622|NCT06691477|OTHER|No Interventions|No intervention required. Subjects accepted regular medical treatment
223534887|NCT06021808|DRUG|Novel oral anticoagulant|For patients with creatinine clearance ≥50 ml/min, oral rivaroxaban 20 mg daily was administered, whereas for patients with creatinine clearance between 30-49 ml/min, oral rivaroxaban 15 mg daily was administered.
223534888|NCT00051077|DRUG|Adefovir dipivoxil|
223534889|NCT00051077|DRUG|Peginterferon-alfa-2A|
223534890|NCT00051077|DRUG|Ribavirin|
223534891|NCT00051077|PROCEDURE|Liver Biopsy|
224275064|NCT00789464|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10\^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
223520623|NCT06688773|BEHAVIORAL|Progressive relaxation exercise|In this study, the relaxation exercises CD, which is a material created by the Turkish Psychological Association, was used. This CD consists of three parts. The first part consists of 10 minutes and this part explains the definition and purpose of deep relaxation exercise and the points to be considered during the exercise. The second part of the CD consists of 30 minutes of verbal explanation of the items of relaxation exercises accompanied by the sound of a stream. The third part consists of 30 minutes and includes only relaxation music.
223520624|NCT06688773|OTHER|Control group: Standart nursing care group|Routine postoperative patient care in the clinic was applied.
223520625|NCT06686550|OTHER|This is a observational study and there is no intervention.|This is a observational study and there is no intervention.
223520626|NCT06689020|PROCEDURE|Continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP) therapy|During application of CPEP and CHFO, EIT is monitored.
223520627|NCT06686186|OTHER|No Intervention: Observational Cohort|There were no interventions in our cohort. The subjects of our cohort were and will be followed up at the regular intervals.
223520628|NCT06690476|DRUG|Dose escalation(IPM514 monotherapy)|Drug：IPM514 Intramuscular Injection A total of 7 administrations, including 2 cycles of vaccination with each cycle at QW × 3 doses; there is a 2-weeks interval between the two cycles, then followed by a boost dose 3 weeks after the 2'nd cycle.
223520629|NCT06690476|DRUG|Dose expansion (IPM514 combined with tislelizumab)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration The usage and dosage of the tislelizumab will be based on the drug instructions. IPM514 administration is planned to be concomitant with PD-1 antibody and to be stopped after 9 doses of treatment, while the PD-1 antibody will be continuously administered for a maximum of 1 year.
223520630|NCT06690476|DRUG|Neoadjuvant therapy cohort(IPM514 combined with tislelizumab, cisplatin and paclitaxel)|Drug：IPM514 Intramuscular Injection Drug：tislelizumab intravenous administration Drug：cisplatin intravenous administration Drug：paclitaxel intravenous administration In this stage, subjects will receive the treatment of IPM514 combined with Tislelizumab, cisplatin and paclitaxel. All four drugs will be administered once every 3 weeks (± 1 day). IPM514 will be administered for the first time on D0, and Tislelizumab, cisplatin and paclitaxel will be administered for the first time on D3 (the administration order: Tislelizumab - paclitaxel - cisplatin). IPM514 will be administered a total of 3 times, and PD-1 antibody, cisplatin and paclitaxel will all be administered a total of 2 times (that is, IPM514 is administered on D0/D21/D42, and Tislelizumab, paclitaxel and cisplatin are administered on D3/D24).
223520631|NCT06689930|OTHER|PDSA Cycles|Conduct PDSA cycle and follow-up interviews and surveys for patients (5 per cycle, 10 total) and CBO staff (no less than 2)
223520632|NCT06688682|OTHER|PRP joint injection combined with acupoint injection|PRP acupoint injection
223520633|NCT06686836|PROCEDURE|Sinus lift augmentation with bone substitute (Bio-Oss)|A maxillary sinus lift augmentation was performed with a lateral window approach that was filled with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®).At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically.
223520634|NCT06686836|PROCEDURE|Open sinus lift surgery lift using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®(Geistlich AG, Wolhusen, Switzerland)) - L-PRF Block|"A maxillary sinus lift augmentation was performed with a lateral window approach that was filled using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®) (L-PRF block).~L-PRF block will be performed as described by Cortellini et al. 2018. L-PRF membranes are cut into small pieces and mixed with Bio-Oss® at a ratio of 2 membranes / 0.5 g biomaterial. Pieces of the block will be removed and compacted in the sinus cavity until it is filled.~At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically."
224275065|NCT00789464|DRUG|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
223520635|NCT06690541|DRUG|Lorlatinib 100 mg|Patients received continuous daily PO dosing of lorlatinib 100mg QD from the date of first dosing (per the current protocol) or until one of the following criteria were met (whichever occurred first): disease progression; initiation of a new anticancer therapy; unacceptable toxicities; global deterioration of health-related symptoms; pregnancy; withdrawal of consent; loss to follow-up; death; investigator decision dictated by protocol non-compliance; or study termination.
223520636|NCT06687083|DEVICE|nasal high frequency oscillatory ventilation mode|"Preterm neonates who will be allocated will start nHFOV: (CNO, Medin, Germany). nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart; Medin, Germany).~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter."
223520637|NCT06687083|DRUG|nasal continuous positive pressure ventilation mode|Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
223520638|NCT06688656|DRUG|Pemetrexed 500 mg/m2|1\. Pemetrexed: 500mg/m² on Day 1, Q3W, administered via intravenous infusion for a total of 3 cycles.
223520639|NCT06688656|DRUG|carboplatin|AUC=5 on Day 1, Q3W，administered via intravenous infusion for a total of 3 cycles.
223520640|NCT06688656|DRUG|Sintilimab|Sintilimab, 200mg, administered via intravenous infusion on the 3rd day of each cycle, Q3W, for a total of 3 cycles.
223520641|NCT06687993|DRUG|Donepezil 2.5 mg|2.5 mg daily oral intake for 90 days
223520642|NCT06687993|DRUG|Donepezil 5 mg|5 mg daily oral intake for 90 days
223520643|NCT06687993|DRUG|Placebo Comparator|daily oral intake for 90 days
224275066|NCT00307723|DRUG|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
224275067|NCT00307723|DRUG|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
223520644|NCT06501339|PROCEDURE|maintenance ECT|Frequency of weekly sessions for 1 month, then fortnightly for 5 months
223520645|NCT06501339|DRUG|Aripiprazole tablet|Aripiprazole 10 mg in the morning throughout the study period
223520646|NCT06355284|OTHER|Functional MRI|While in the MRI scanner, participants will complete several classic experimental tasks designed to capture brain activity related to core cognitive features of overcontrol that impact social functioning. Tasks include the Stop Signal Task (error monitoring), Delay Discounting Task (valuation, impulsivity), and Reversal Learning (cognitive flexibility).
223520647|NCT06699134|DEVICE|Total knee arthroplasty|Primary total knee replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
223520648|NCT06699134|DEVICE|Total Hip arthroplasty|Primary total hip replacement using Hi-Fatigue G Bone Cement and a Zimmer Biomet implant
223520649|NCT06694740|DRUG|Interferon Gamma 1-b|interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
223520650|NCT06694740|DRUG|Placebo|Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
223520651|NCT06694597|DRUG|Astragalus Membranaceus Root|Astragalus tablets 15g, warm water to drink, once a day, take for 1 year, during which routine treatment should also be carried out.
223520652|NCT06695455|BEHAVIORAL|Swallowing rehabilitation by rhythmic auditory cue|"Three assessments, each spread over two days, will be administered at three different time points during the study: before the experiment (T0), after 7 weeks of the experiment (T1), and 3 months after the intervention (T2). The evaluation will include a pharyngography as well as a clinical assessment of swallowing and rhythmic abilities.~Each subject will be invited to participate in 3 individual rehabilitation sessions per week for 7 weeks, conducted by a speech therapist at La Musse Hospital. Each session will be structured similarly: the subject will be asked to swallow their saliva, followed by a nectar-like texture (IDDSI 2) and a pudding-like texture (IDDSI 4), timed to the rhythm of a metronome. The rhythm will vary throughout the sessions. The goal will be to get as close as possible to the rhythm of a healthy swallow."
223520653|NCT06695403|PROCEDURE|Pilates Exercise|"1. Pilates Exercise: The Pilates method is a low-intensity form of movement based on body control, which works the body in a complete way, promoting physical and mental health. PET is different when compared to traditional exercises, which, in turn, tend to isolate the working muscles and have specific training approaches using repetitive motions.~2. Telerehabilitation: Telehealth is emerging as a key method for delivering essential healthcare. Primary care research suggests that telehealth is acceptable and has potential to overcome geographical barriers for individuals needing many times rehabilitation by eliminating the need for extensive and costly travel~3. Diet approach: A customized low-carbohydrate high-fat (LCHF) restricted caloric diet in women with lipedema will be used for 12 weeks. The LCHF diet may be a valuable nutritional strategy for lipedema and overweight/obese women, reducing inflammatory status with a beneficial effect on weight, glucose profile the concentration of"
223520654|NCT06694896|DIAGNOSTIC_TEST|Microarray Application|Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.
223520655|NCT06689787|OTHER|Self-Guided STAIR Coach with Real-Time Assessment|Two mobile apps to be used as one intervention package to support participants in their progress through STAIR (Skills Training in Affective and Interpersonal Regulation) with self-monitoring of symptoms and functioning
223520656|NCT06689787|OTHER|Real-Time Assessment|One mobile app to support participants in self-monitoring of symptoms and functioning
223520657|NCT06695871|OTHER|Patient navigation-based health management|A patient navigation-based health management model for individuals with cervical lesions post-LEEP procedure, encompassing healthcare consultation services, personalized health guidance, and routine follow-up assessments.
223520658|NCT06689332|OTHER|Comprehensive Geriatric Assessment|Comprehensive geriatric assessment (CGA) is performed by a geriatrician and a geriatric nurse. CGA in this study includes: Assessment of coexisting diseases and treatments. Review of medications and adjustments as needed. Assessment of symptoms and health related issues including screening for depression, dementia, delirium, nutritional problems, falls, polypharmacy and fatigue. Objective examination including blood tests and electrocardiogram. Assessment of activities of daily living and instrumental activities of daily living through standardized questionnaires. Assessment of domestic conditions, including need for assistance from community-based health care services. Assessment of physical function through history and physical tests. Based on the CGA findings, the geriatrician will initiate relevant interventions (including investigations or treatments) and follow-up as required.
223520659|NCT06686225|OTHER|Bowen's technique.|"This group will receive 20 mint per session for 6 weeks of bowen's technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 20 mints~* Type: Bowen's technique"
223704142|NCT05455268|OTHER|eHOPE|"e-Haematological Oncology Parents Education (eHOPE) consists of caregiving information for parents of children with leukaemia and lymphoma, presented in multimedia format through an online learning platform. The contents are developed in Malay language, encompassing basic information on disease and treatment, medical caregiving, emotional caregiving, appraising information, communication and self-care. Parents will be able to access multimedia information designed to support them in the care of their sick child. There are 4 self-paced activities in eHOPE with the following objectives:~1. Parents should be able to outline key tasks related to care for their child at home.~2. Parents should be able to outline strategies to initiate discussions with their child's healthcare providers.~3. Parents should be able to appraise reliability of information sources.~4. Parents should be able to identify coping strategies that they can use when faced with stressful situations."
223704143|NCT05455268|OTHER|Usual care|Face-to-face verbal discussions and caregiver training will be provided as deemed necessary by the clinicians.
223704144|NCT01253473|DRUG|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
223704145|NCT01253473|DRUG|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
223704146|NCT01253473|DRUG|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
224275068|NCT00307723|DRUG|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
223520660|NCT06686225|OTHER|Mulligan bent leg raise technique|"This group will receive 15 mints per session for 6 weeks of mulligan's bent leg raise technique.~* Frequency: 3-5 days per week for 6 days~* Intensity: moderate to high intensity of soft tissue mobilization~* Time: 15 mints~* Type: Mulligan bent leg raise technique"
223520661|NCT06690073|OTHER|Motor Relearning Program|"Total duration of the intervention is 45 minutes per session (30 minutes of CPT treatment followed by 15 minutes MRP), three sessions per week.~MRP of sitting and standing activities: The physical therapist will instruct the participant, who will be seated in an armrest-equipped chair, to keep their feet back and position their trunk forward.. The participant will then be guided to press down through the affected foot, stand up quickly, and move their hips forward. The therapist will suggest pressing down through the participant's knee along the leg while moving it forward through the affected foot.~MRP of standing to sitting: The participant will stand while the physiotherapist assists with anterior shoulder movement and knee bending at the start of the transition. The therapist will then help maintain weight on the affected leg while sitting. The participant will progress by standing and sitting at different seat heights, stopping at various points in the ROM, and changing speed."
223520662|NCT06690073|OTHER|Conventional Physical Therapy|Conventional Physical Therapy (CPT) will be administered to the control group three times per week for six weeks (45 minutes per session). CPT treatments such as mat activities, assisted movements, weight-bearing strategies, and gymnasium training will be given to the control group.
223520663|NCT06687863|OTHER|Exercise training|Includes aerobic exercise, strength training, streching
223520664|NCT06686290|OTHER|Post-Isometric Relaxation Technique|Post isometric relaxation will be performed with the frequency of 5 times, such that it includes 30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold.
224275069|NCT00307723|DRUG|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
224275070|NCT00307723|PROCEDURE|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
224275071|NCT02349854|PROCEDURE|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm \& 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
224275072|NCT06627374|DIAGNOSTIC_TEST|Patent Ductus Arteriosus in neonates|Neonates admitted to Neonatal care Unit after birth, undergoing hsPDA (hemodynamically significant Patent Ductus Arteriosus) closure according to standard clinical practice, will be included.
224275073|NCT01398787|DEVICE|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
224275074|NCT01398787|DEVICE|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
224275075|NCT03289260|DRUG|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
224275076|NCT03289260|DRUG|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
224275077|NCT03289260|PROCEDURE|Fulguration|Surgical Excision and Fulguration of condyloma
224275078|NCT01067794|DRUG|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
224275079|NCT00514150|DRUG|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
224275080|NCT00514150|DRUG|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
224275081|NCT01658358|DRUG|Lapatinib|"* dose level I, II 1000mg po daily~* dose level III, IV 1250mg po daily"
223520665|NCT06686290|OTHER|Static Stretching|Static Stretching
224275082|NCT01658358|DRUG|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
224275083|NCT02351167|DRUG|Combination NRT (Nicotine patch, Nicotine lozenge)|
224275084|NCT02351167|DRUG|Varenicline|
224275085|NCT02351167|DRUG|Placebo|
224275086|NCT02351167|BEHAVIORAL|Intensive smoking counseling|
224275087|NCT02608424|DEVICE|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
224275088|NCT03521362|DEVICE|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
224275089|NCT03521362|DEVICE|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
224275090|NCT04933357|RADIATION|Dose escalation|Dose escalation to poor responders to achieve dose equivalent more than 80 Gy using SBRT boost
224275091|NCT04933357|RADIATION|Standard dose|Standard dose to good responders to achieve dose equivalent of 70 Gy.
224275092|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
224275093|NCT02406287|DRUG|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
224275094|NCT01954030|DRUG|CTO and Bevacizumab|
224275095|NCT01954030|DRUG|CTO alone|
224275096|NCT03714373|DRUG|DCCR|Once daily oral administration of open-label DCCR tablet(s) during the OLE Period
223520666|NCT06697951|DEVICE|bilevel ventilation with the Neovent|Newborn infants with respiratory distress will be placed on the Neovent and we will see if study staff set up, use, and trouble shoot the Neovent correctly and see if study staff can monitor for safety problems in lower-resourced nurseries and to determine if the infants have any more problems than seen with bubble CPAP or Neovent in a higher resourced nursery including any more nasal irritation, abdominal distention, or clinically important amount of air around the lung (pneumothorax)
223520667|NCT05720936|PROCEDURE|Percutaneous stellate ganglion block (PSGB)|"Both the two approaches present in literature and commonly used for this technique are allowed for the study:~* The anatomical approach which consist in the identification of the Chassaignac's tubercle that represents the point of needle insertion~* The echo-guided approach"
223520668|NCT06695884|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized. Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
223520669|NCT06694038|PROCEDURE|Needle Knife Fistulotomy|Biliary access using needle knife fistulotomy technique
223520670|NCT06694038|PROCEDURE|standard biliary cannulation|standard biliary cannulation
223520671|NCT06693973|DRUG|AcNK-Sup003 cell injection solution|The AcNK technology has successfully achieved the direct, covalent, and directional conjugation of intact antibodies which includes the Fc domain to the surface of NK cells via a one-step enzymatic reaction. This novel approach yields a non-genetically modified NK cell that is conjugated with dual-targeting antibodies, referred to as AcNK. Specifically, AcNK-Sup003 cells are cryopreserved NK cells that have been conjugated with bispecific antibodies target both CD20 and CD19.
223520672|NCT06695273|DIAGNOSTIC_TEST|AI-derived probability of coronary heart disease.|Physician readers will be assisted with AI-derived probability of coronary heart disease. The AI tool provides individualized obstructive CHD probabilities and diagnosis, leveraging retinal biomarkers associated with cardiovascular risk.
223520673|NCT06695273|DIAGNOSTIC_TEST|PCEs derived ASCVD risk|Physicians use a PCEs to calculate the probability of 10 year ASCVD risk. This approach aligns with current clinical guidelines to assist in decision-making.
223520674|NCT06688604|BEHAVIORAL|skin contact|Ensuring mother-infant skin-to-skin contact by the researcher within the first 5 minutes after birth
223520675|NCT06688019|DEVICE|conventional oxygenation (nasal cannula)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
223520676|NCT06688019|DEVICE|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|conventional oxygenation arm will receive oxygen at 2 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
223520677|NCT06686212|OTHER|Sensory re-education+ strengthening exercises+ kinesio taping|"Sensory re-education. Splinting: as constant maintained touch with wrist holding in neutral position for 15 minutes.~Topical anesthesia spray on affected area for 10 minutes. Massage: apply massage over sensitive areas with same speed and pressure, then the light pressure with cotton, velvet, terry cloth, polyester and wool over sensitive area for 10 minutes.~PNF using upper extremity (D2) pattern including shoulder extension, adduction, internal rotation, wrist and fingers flexed and wrist ulnar deviated. 10-15 repetitions for 5 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions of each exercise for 20 minutes.~Kinesio taping: Taping will be applied twice a week for 12 weeks."
223520678|NCT06686212|OTHER|Neural mobilization+ Strengthening exercises+ Kinesio taping.|"The median nerve is mobilized through wrist flexion and extension with elbow straight and palm facing up.~Wrist flexion and extension with elbow flexed to 90 degrees with palm facing up 10-15 repetitions.~Wrist flexors stretch with extended arm and palm facing down 10-15 repetitions. Straight fist: hold your hand up with fingers straight. Full fist: bend your fingers to form a full fist. Median nerve stretch and wrist extension exercises for 30 minutes. Free the bird exercises, busy bee flexion shape of Z exercises and wall stretch exercise. (10-15 repetitions) for 10 minutes.~Strengthening exercises: wrist flexion and extension, supination and pronation, opposition, gripping, ball squeeze and fingers pinching against resistance. 10-15 repetitions each for 20 minutes.~Kinesio taping: The taping will be applied twice a week for 12 weeks."
223520679|NCT06688045|DRUG|Nemtabrutinib|Oral administration
223520680|NCT06688045|DRUG|Itraconazole|Oral administration
223520681|NCT06691061|DRUG|Vedolizumab|UC patients treated with vedolizumab
223520682|NCT06691061|DRUG|Ustekinumab - Standard Dosage|UC patients treated with ustekinumab
223520683|NCT06691061|DRUG|JAK Inhibitor|UC patients treated with JAK inhibitors
223520684|NCT06687109|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty
223520685|NCT06687109|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty
223520686|NCT06690528|PROCEDURE|Surgical resection of both the primary tumor and liver metastases|Surgical resection of both the primary tumor and liver metastases. The surgical approach, extent of resection, and perioperative management will follow the standard protocols at each participating center. Venous vascular resections might be performed to reach radicality. Either standard or parenchyma sparing liver resections might be performed for resection of the liver metastases. Alternatively, needle ablation/microwave on the liver lesions is possible for lesions \<20 mm if technically feasible. Post-operative chemotherapy and/or radiotherapy could be administered as per multi-disciplinary decision based on case-by-case evaluation.
223520687|NCT06686966|DIAGNOSTIC_TEST|gastric cancer|be diagnosed as gastric cancer
223520688|NCT06689969|PROCEDURE|conventional implant placement method|Site marking was the first step in preparing the place for implantation. Subsequently, using a high speed surgical handpiece and a surgical motor, a pilot drill was revolved at 1200 RPM in a clockwise rotation to the desired depth, creating a 1.5 mm first pilot osteotomy. An X-ray was obtained using paralleling pins to validate the angle between the surrounding teeth and the implants. Eventually the implant's precise placement was established. To prepare the osteotomy site to the desired diameter, drills are used sequentially at 1200 RPM in a clockwise motion. Gradually bigger drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes were utilized in ascending order
223534892|NCT03167138|BIOLOGICAL|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
223520689|NCT06689969|PROCEDURE|Osseodensification to implant placement using densah bur kit|"Beginning with site marking, the area was prepared for implantation. A high speed surgical handpiece and a surgical motor (surgic pro® NSK, Japan) were then used to construct a 1.5 mm initial pilot osteotomy using a pilot drill spun at 1200 RPM in a clockwise rotation to the desired depth. In order to verify the angle between the surrounding teeth and the implants, paralleling pins were used to capture an X-ray.~After it was determined that the implant was in the proper location, OD was used to extend the osteotomy using a Densah® Bur VT1525 2.0-mm (VersahTM, LLC, USA) in non-cutting anticlockwise rotation at 1200 RPM (Densifying Mode). The osteotomy was expanded to the desired diameter by repeatedly using a DensahTM Bur operating in a non-cutting anticlockwise (CCW) direction at 1200 RPM (Densifying Mode). Gradually increasing drill diameters were used for incremental drilling. Based on the diameter of the desired implant, bur sizes (diameters) were utilised in ascending order"
223520690|NCT06691048|OTHER|Description of an adult population diagnosed late with a neurodevelopmental disorder|Clinical description during diagnostic interview
223520691|NCT06686810|PROCEDURE|Endoscopic Retrogradade CholangioPancreatography (ERCP)|ERCP is an endoscopic therapeutic procedure to drain the bile ducts in case of stones or biliary strictures that can be treated by balloon dilatation or stents (plastic or metal) insertion
223520692|NCT06694103|OTHER|Reverse Kangaroo Care Position|"* Babies will be taken to the examination table and their clothes other than diapers will be removed.~* Mothers will take off their upper clothes and lie on the examination table and position their babies in the reverse kangaroo care position, with the baby's back against the mother's bare chest.~* Babies will be monitored with disposable probes from their right feet.~* Video recording will be started. -While the position applied to the babies is maintained, the speculum will be placed in the eye by the ophthalmologist and the examination will be recorded on video from the beginning to end.~* After the completion of both eye examinations, the position of the babies whose monitoring continues will be maintained while the video recording will be taken for another 1 minute. The SPO2, HR, PIPP-R score at the end of the 15th second before the examination, the first minute during the examination and the 30th second after the examination will be evaluated."
223520693|NCT06694103|OTHER|ROP Position|"* Babies will be taken to the examination table and monitored with disposable probes from their right feet.~* The nurse will place the infant's own palms on the temporal region and hold them with her hands to support their head, while the mother will also support the infant by holding their legs.~* The video recording will be started.~* SPO2, HR, PIPP-R values will be recorded on video for one minute.~* While the ROP position applied to the babies is maintained, the speculum is placed in the eye by the ophthalmologist and the examination begins.~* SPO2, HR, PIPP-R evaluation at the 1st minute of the examination.~* After the completion of both eye examinations, the babies whose monitoring continues will be kept in their positions and a video recording will be taken for another 1 minute.~* The SPO2, HR values and PIPP-R pain score at the end of the 30 seconds after the examination will be evaluated."
223520694|NCT06689371|OTHER|Group A (Dry Needling)|The patient will receive dry needling on suboccipital, upper trapezius and SCM muscles with conventional therapy 3 sessions per week for 4 weeks.
223520695|NCT06689371|OTHER|Group B (Dry cupping)|Patients will receive dry cupping on suboccipital, upper trapezius and SCM muscles weeks with conventional therapy 3 sessions per week for 4 weeks.
223520696|NCT06689371|OTHER|Group C (control)|will receive standard exercise three sessions per week for four weeks. This standard regimen consists of the same exercises as group A and B.
223520697|NCT06688097|BEHAVIORAL|Compression of esophageal|Before the start of FMV, ultrasound is used to locate the esophagus, and pressure is applied to the esophagus at the cricoid level to collapse the esophageal lumen. Esophageal pressure is released just before tracheal intubation following 4 minutes of ventilation.
223520698|NCT06686563|OTHER|Intervention Group: Gamma stimulation|Participants in this group be stimulated with gamma frequency (39-42 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
223520699|NCT06686563|OTHER|Control Group: Theta stimulation|Participants in this group will be stimulated with theta frequency (4-7 Hz). The frequency of the intervention will be 5 times a week, with the AVNS being used twice a week for 20 minutes (a minimum of 20 sessions - 8 to 12 weeks) and the other 3 days being spent at home with 20 minutes of audio frequency stimulation.
223520700|NCT00690352|BEHAVIORAL|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
224275097|NCT03714373|DRUG|DCCR|Once daily oral administration of double-blind (DCCR) tablet(s) during the RW Period
223520701|NCT06694844|PROCEDURE|Socket preservation with M1|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M1 membrane (peramem membrane).
223520702|NCT06694844|PROCEDURE|Socket preservation with M2|Following extraction, socket will be filled with the combination of bovine xenograft and autograft and then covered with d-PTFE M2 membrane (Cytoplast membrane).
223520703|NCT06729996|DRUG|Pioglitazone (PIO)|Subjects will take 30 mg tablet, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 45 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food till 24 weeks.
223520704|NCT06729996|DRUG|Empagliflozin (EMPA)|Subjects will start with 10 mg dose, once daily in the morning, taken with or without food for 12 weeks and after 12 weeks dose will be escalated to 25 mg based on Hemoglobin A1c (HbA1c) levels (HbA1c \>7.0% at 12 weeks, escalate the dose) once daily in the morning, taken with or without food.
223520705|NCT00028288|DRUG|Daclizumab|
224275098|NCT03714373|DRUG|Placebo for DCCR|Once daily oral administration of double-blind (placebo for DCCR) tablet(s) during the RW Period
224275099|NCT01341678|DRUG|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
224275100|NCT01341678|DIETARY_SUPPLEMENT|NeutraPhos|Diet will be supplemented with NeutraPhos
224275101|NCT01341678|OTHER|Diet Only|Diet containing 1500mg of phosphorus
223520706|NCT06113302|DRUG|Luspatercept|Given by SC or (Injection)
223520707|NCT06742684|PROCEDURE|PCI with following SSO2 Therapy|SSO2 Therapy
223520708|NCT00972257|DRUG|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
223520709|NCT00972257|DRUG|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
223520710|NCT01511237|DRUG|Nevirapine, zidovudine, lamivudine|"* Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~  * NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~ * AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~ * 3TC syrup 2 mg/kg every 12 hours for four weeks."
223520711|NCT03607058|OTHER|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
223520712|NCT03607058|OTHER|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
223520713|NCT00152958|DRUG|Pramipexole|
223520714|NCT03595722|DEVICE|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
223520715|NCT04231565|DRUG|Tenofovir alafenamide Fumarate|Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.
223520716|NCT02194686|DRUG|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
223520717|NCT02194686|DRUG|Dummy Placebo|One tablet twice per day for 12 weeks
223520718|NCT00908661|DEVICE|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
223520719|NCT05459714|DEVICE|MCE for obese patients|Sequence of stomach examination: The stomach examination is performed sequentially according to the order of fundus, cardia, gastric body, angulus, antrum, and pylorus, which should ensure the integrity of the observation of each part of the stomach and achieve the purpose of comprehensive observation by means of different observation distances such as distant view and close view, and different observation angles such as front and side.
223520720|NCT02946411|PROCEDURE|Cardiac surgery|Glucose level will be measured after cardiac surgery.
223520721|NCT03800628|OTHER|qualitative study|semi-structured interviews
223520722|NCT03621215|DIETARY_SUPPLEMENT|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
223520723|NCT03621215|OTHER|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
223520724|NCT00821821|DRUG|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
223520725|NCT00821821|DRUG|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
223520726|NCT04632030|BEHAVIORAL|Tobacco power wall size and tobacco products displayed|The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
223520727|NCT03220555|DEVICE|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
223520728|NCT03220555|DRUG|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
223520729|NCT00964678|DRUG|Carvedilol|twice daily oral treatment in escalating dose
223520730|NCT04380025|DIETARY_SUPPLEMENT|Experimental: Oral Mirtogenol|The experimental arm is Oral Mirtogenol dietary supplement, one capsule daily in addition to bimatoprost ophthalmic drops with primary open angle glaucoma
223520731|NCT04380025|DIETARY_SUPPLEMENT|Placebo of oral Dietary supplement|This is the oral placebo of the supplement (control) un daily capsule in addition to the bimatoprost ophtalmic drops
223520732|NCT02292355|OTHER|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
223520733|NCT04081012|DRUG|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
223520734|NCT04081012|DRUG|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
223520735|NCT05202171|OTHER|Cervical Stabilization Exercise|Exercise group will be performed cervical stabilization exercise training applied with telerehabilitation and standard treatment ( preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine) for 8 weeks
223520736|NCT05202171|OTHER|Standard treatment|standard treatment will include preventive/symptomatic oral drug therapy routinely in the clinic and suggestions for triggering factors in migraine for 8 weeks
223520737|NCT05362799|DRUG|Letrozol (Femara, Novartis)|Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
223520738|NCT05362799|DRUG|Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)|Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
223520739|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
223520740|NCT05362799|DRUG|highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin|Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
223520741|NCT06144658|DEVICE|Augmented Reality Headset / Hololens 2 or Varjo XR3|Augmented Reality Headset
223520742|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and driver ablation.
223520743|NCT05153486|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with vein of Marshall ethanol infusion.
223520744|NCT05153486|PROCEDURE|Surgical ablation|Patients receive surgical ablation.
223520745|NCT02605616|DRUG|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
223520746|NCT02605616|OTHER|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
223520747|NCT03359395|DRUG|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
223520748|NCT03359395|DRUG|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
223520749|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
223520750|NCT02986438|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
223520751|NCT01306994|OTHER|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
223520752|NCT01306994|PROCEDURE|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
223520753|NCT01306994|OTHER|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
223520754|NCT01306994|OTHER|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
223520755|NCT01306994|OTHER|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
223520756|NCT01306994|OTHER|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
223520757|NCT01306994|OTHER|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
223520758|NCT05339659|DEVICE|mHealth Intervention|Mobile health (mHealth) app to motivate and support quitting smoking.
223520759|NCT03164356|DEVICE|Bioimpedance monitor|Participant in aim 1 will be monitored using the bioimpedance monitor. Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
223520760|NCT03377998|OTHER|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
223520761|NCT03151603|DRUG|Arctuvan|application of a herbal drug
223520762|NCT03151603|DRUG|Fosfomycin|application of an antibiotic drug
223520763|NCT03151603|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan
223520764|NCT03151603|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin
223520765|NCT02712216|PROCEDURE|Laparoscopy|Determine best port sites to insert bariatric trocars
223520766|NCT00100477|DRUG|Topotecan|
223520767|NCT00100477|DRUG|Mitozantrone|
223520768|NCT00100477|DRUG|Etoposide|
223520769|NCT02868879|OTHER|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
223520770|NCT03189927|DEVICE|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
223520771|NCT01415453|PROCEDURE|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
223520772|NCT06688318|BIOLOGICAL|Intra-articular secretome injection therapy|Intra-articular secretome injection therapy from hypoxic umbilical cord mesenchymal stem cell conditioned media
223520773|NCT02288962|DRUG|cabergoline|
223520774|NCT04695119|OTHER|Exposure is septic shock (defined according to Sepsis-III) and standard treatment according to departmental protocols.|Collection of data, biomarker and echocardiography analysis will be centralized and blinded. Assessment of endpoints will be blinded.
223520775|NCT00335426|PROCEDURE|Spinal manipulative therapy|
223520776|NCT05943990|DRUG|GSK3845097|GSK3845097 was administered.
223520777|NCT05943990|DRUG|Cyclophosphamide|Cyclophosphamide was administered as lymphodepleting chemotherapy.
223520778|NCT05943990|DRUG|Fludarabine|Fludarabine was administered as lymphodepleting chemotherapy.
223520779|NCT03407833|OTHER|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
223520780|NCT03407833|OTHER|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
223520781|NCT03407833|OTHER|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
223520782|NCT03407833|OTHER|Excised Liver Tissue Sampling|Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
223520783|NCT01258985|BEHAVIORAL|Tai Chi|12 weeks of Tai Chi
223520784|NCT01258985|BEHAVIORAL|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
223520785|NCT06470919|OTHER|SMS reminders for upcoming vaccination(s)|All parents/caregivers of children in participating villages will receive access to a digital vaccine card. This will be used for record-keeping application (digital vaccine registry). Selected parents/caregivers of children will receive SMS messages and reminders related to vaccination.
223520786|NCT05998564|DEVICE|Connecting patients to both non-invasive monitors to observe and compare the monitor's capabilities.|All patients will be connected to the NOL monitor and the SCA monitor during general anesthesia.
223520787|NCT02657356|DRUG|Placebo capsules|
223520788|NCT02657356|DRUG|Bardoxolone methyl capsules|
223520789|NCT04526925|DEVICE|Respiratory filter in-line placed with the standard mouthpiece|The respiratory filter is a device that removes solid/large particles from gas
223520790|NCT04526925|OTHER|Standard mouthpiece|The mouthpiece is the interface that is placed on participant's face in order to measure all the breathing physilogic responses
223520791|NCT05193383|BEHAVIORAL|Imaginal exposure|Session 1 (Day 1): Participants receive repeated exposure to mental imagery of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
223520792|NCT05193383|BEHAVIORAL|Exposure|Session 2 (Ca one week): Participants receive both imaginal and in vivo exposure to fear-provoking stimuli and neutral stimuli (both arms are exposed to both video clips (in vivo exposure) and mental imagery (imaginal exposure). Session 2 is conducted in the laboratory, i.e., no brain imaging.
223520793|NCT05193383|BEHAVIORAL|Approach-avoidance conflict|Session 2 (Ca one week): Spider fear is probed by an approach-avoidance conflict task. Participants can receive varying small rewards for watching pictures of spiders, or avoid the spider pictures at the cost of not receiving a reward (neutral pictures are shown instead).
223520794|NCT05193383|BEHAVIORAL|In vivo exposure|Session 1 (Day 1): in vivo exposure. Participants receive repeated exposure to film clips of fear-provoking stimuli (spiders) and neutral stimuli (leaves) while undergoing brain imaging med fMRI.
223520795|NCT04354233|DEVICE|Physical activity intervention with connected devices|"Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team."
223520796|NCT05187650|DEVICE|Ekso (EksoNR, Ekso Bionics)|The EksoNR is a powered exoskeleton designed to be used in a rehabilitation setting. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices and is used for gait training in neurorehabilitation.
223520797|NCT05187650|DEVICE|FES (RehaMove2, Hasomed)|RehaMove 2 sends electrical impulses via electrodes to nerves to evoke muscle contraction. The device meets the provision of the Council Directive 93/42/EEC concerning medical devices.
223520798|NCT04876287|DRUG|Radioiodine|cancer therapy
223520799|NCT03864848|DEVICE|Mitral Touch Implant|The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.
223520800|NCT04744103|DRUG|TCA|Patients will receive a TCA peel as a treatment for their actinic cheilitis.
223520801|NCT04580550|OTHER|Axial length variability|Biometry (axial length measurement)is performed using the IOL Master 700 (Carl Zeiss Meditec AG, Jena, Germany) and Heidelberg Anterion (Heidelberg Engineering, Germany) pre and postoperatively.
223520802|NCT00214565|DRUG|Galida|
223520803|NCT04745780|DIETARY_SUPPLEMENT|Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin|Myo-inositol (1950 mg), D-chiro-inositol (50 mg), Gymnema sylvestre (250 mg), Zinc (7,5 mg) and Alpha-lactalbumin (50 mg) - Two-times daily on an empty stomach, for 6 months
223520804|NCT04745780|DIETARY_SUPPLEMENT|Placebo|Placebo - Two-times daily on an empty stomach, for 6 months
223520805|NCT04164186|OTHER|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
223520806|NCT01204385|PROCEDURE|Sample collection|Middle ear fluid and urine
223520807|NCT02569008|DRUG|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
223520808|NCT01558258|BEHAVIORAL|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
223520809|NCT00991978|OTHER|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
223520810|NCT03795519|DRUG|[14C]-olinciguat|oral capsule
223520811|NCT05553236|DIAGNOSTIC_TEST|Targeted next-generation sequencing|During intervention periods, an additional patient sample derived from routinely collected specimens will be processed by a local technician. Extracted DNA extracted from these samples will be batched on a regular basis for targeted deep sequencing. Sequencing results will be regularly transmitted to a clinical advisory committee.
223520812|NCT00088699|DRUG|Ketamine|
223520813|NCT00088699|DRUG|Placebo|
223520814|NCT01756742|OTHER|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
223520815|NCT01756742|OTHER|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
223520816|NCT02244398|OTHER|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
223520817|NCT02244398|OTHER|FP services|VHTs in the control arm only provide family planning services
223520818|NCT04347109|DIAGNOSTIC_TEST|Non invasive epicardial mapping|Non invasive mapping using Cardio Insight system is performed in all included patients.
223520819|NCT06461494|OTHER|baseline treatment|hot pack will be applied for 10 minutes
223520820|NCT01524744|DRUG|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
223520821|NCT01524744|DRUG|Adcortyl|triamcinolone acetonide 0.1% in orabase
223520822|NCT02326584|DRUG|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
223520823|NCT02326584|DRUG|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
223520824|NCT02326584|DRUG|Daunorubicin|60 mg/m2/day Days 1-3
223520825|NCT02326584|DRUG|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
223520826|NCT03416816|DRUG|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
223520827|NCT01556334|DRUG|Azithromycin|Azithromycin 1g po
223520828|NCT01556334|DRUG|Erythromycin|Erythromycin IV then PO
223520829|NCT06515613|DRUG|CTIM-76|Claudin 6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28 day treatment cycle until disease progression.
223520830|NCT06145711|OTHER|hiPSC-DAP|Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
223520831|NCT05679622|OTHER|Fecal Microbiota Transplantation|In the induction stage of UC, FMT group received FMT and PEN intervention, and FMT group are given for at least one course of FMT treatment. If repeated FMTs are received, it is usually at a 2 month interval. All the participants received PEN (80% of total calories as a polymeric diet, Peptamen, Nestle, Vevey, and Switzerland) intervention to help induce and maintain clinical remission.
223520832|NCT06132204|DRUG|HRS-7535 Tablets|HRS-7535 Tablets
223520833|NCT04874194|DRUG|Omacetaxine Mepesuccinate|Given SC
223520834|NCT04874194|DRUG|Venetoclax|Given PO
223520835|NCT02615275|PROCEDURE|Bioelectric Impedance Analysis|Undergo BIA with seca mBCA
223520836|NCT02615275|PROCEDURE|Computed Tomography|Undergo CT
223520837|NCT02615275|PROCEDURE|Positron Emission Tomography|Undergo PET
223520838|NCT02615275|OTHER|Quality-of-Life Assessment|Ancillary studies
223520839|NCT02615275|OTHER|Questionnaire Administration|Ancillary studies
223520840|NCT02615275|RADIATION|Radiation Therapy|Undergo RT
223520841|NCT03443401|PROCEDURE|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
223520842|NCT03753516|PROCEDURE|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
224275102|NCT04744467|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
224275103|NCT06561581|BEHAVIORAL|Acuity|Enhancement to Motivity product for clinical decision support
223520843|NCT03753516|PROCEDURE|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
223520844|NCT06060509|DIETARY_SUPPLEMENT|Phytosterol-rich Wheat and Corn Germ Blended Oil|Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.
223520845|NCT06060509|DIETARY_SUPPLEMENT|Peanut oil|Participants in the control group consumed peanut oil daily for cooking.
223520846|NCT04272034|DRUG|INCB099318|INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
223520847|NCT06448351|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223520848|NCT06448351|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
223520849|NCT06448351|OTHER|Vaping session|Sample study e-liquids in vaping sessions at research lab with e-cig study device
223520850|NCT06448351|OTHER|Survey Administration|Ancillary studies
223520851|NCT06446037|DEVICE|Non-invasive EMG band instrumentation|The sensed EMG signals from the subjects will be decoded by Phantom X algorithm and used to drive various gestures in a desk-mounted hand prosthesis
223520852|NCT03302663|DIAGNOSTIC_TEST|MRI scan|Addition of advanced imaging sequences for fetal MRI
223520853|NCT02209987|DRUG|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
223520854|NCT02209987|DRUG|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
224275104|NCT03334045|RADIATION|PET/MR scans|Observations of glucose metabolism and dopamine binding potential
224275105|NCT05655429|PROCEDURE|physical therapy|The exercise intervention included aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for ≥2 day per week.
223520855|NCT01823055|PROCEDURE|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
223520856|NCT02016521|OTHER|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
223520857|NCT02016521|OTHER|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
223520858|NCT04767321|DRUG|LTX-109 gel, 3% w/w|LTX-109 gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
223520859|NCT04767321|DRUG|Placebo|Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
223520860|NCT04500145|RADIATION|SIB-IMRT|60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
223520861|NCT04500145|RADIATION|routine IMRT|patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
223520862|NCT00980044|DRUG|Tramadol|Oral Medication
223520863|NCT00980044|DRUG|Placebo|Oral Medication
223520864|NCT00175279|BEHAVIORAL|Opinion leader generated and endorsed evidence summaries|
223520865|NCT04287959|DEVICE|High flow nasal cannula support|airvo2 highflow devices will be used.
223520866|NCT06635863|DRUG|Prednisone 40mg|Prednisone 40mg x 8weeks
223520867|NCT00000305|DRUG|Dextroamphetamine|
223520868|NCT05544487|PROCEDURE|Colorectal Anastomosis|Differences in intra-operative techniques and surgeon grades
224275106|NCT05655429|PROCEDURE|arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy surgery procedure
224275107|NCT03638063|DIAGNOSTIC_TEST|Adenosine Triphosphate|Adenosine Triphosphate aerosol
223520869|NCT04868032|BEHAVIORAL|Positive Psychology-Motivational Interviewing|Participants will receive a written treatment manual with detailed information about each topic. The intervention consists of 10 weekly phone sessions (30 minutes each). Each session includes a new psychological skill designed to increase positive emotions experienced during physical activity, a motivational skill designed to boost physical activity, and setting a physical activity goal for the next week using information from the Fitbit. A motivational interviewing approach will be used for all topics.
223520870|NCT04868032|BEHAVIORAL|Physical Activity Education Control|Participants randomized to this condition will be provided with a Fitbit, and will be mailed educational materials about physical activity at 4 time points throughout the intervention period. They will not receive a manual or phone calls with an interventionist.
223520871|NCT05572736|DEVICE|Conduction system pacing|Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).
223520872|NCT05572736|DEVICE|Biventricular pacing|Pacing from the coronary sinus and right ventricular leads.
223520873|NCT05811013|DEVICE|Transcranial static magnetic field stimulation (tSMS)|Patients will be randomly assigned to either real or sham tSMS. Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Patients will choose whether to undergo stimulation at home or in the hospital on an outpatient setting. Real tSMS will be delivered with two cylindrical neodymium magnets (grade N45) of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), applied with south polarity, each pointing toward the motor cortex. To discharge the weight of the helmet from the head during the sessions, patients will be instructed to rest the back of head and helmet on an inclined surface in a comfortable position. They will be also instructed to rest, minimizing movement, and not to watch audiovisuals during the stimulation sessions.
223520874|NCT05811013|DEVICE|Sham Transcranial static magnetic field stimulation (tSMS)|Real or sham tSMS will be performed daily without any interruption during each session of 60 min. Each patient will be instructed to self-administer tSMS, two sessions per day (AM and PM, 6-10 hours apart), sequentially for 60 minutes each, for 6 +6 months. Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain).
224275108|NCT03638063|DIAGNOSTIC_TEST|capsaicin|capsaicin aerosol
224275109|NCT04791956|DIETARY_SUPPLEMENT|Prebiotic|Daily intake of Inulin-type fructans from chicory
224275110|NCT04791956|DIETARY_SUPPLEMENT|Placebo|Daily intake of maltodextrin
224275111|NCT02564016|DRUG|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
223520875|NCT05146778|PROCEDURE|Opioid-free anesthesia|OFA group will be sedated using dexmedetomidine and lidocaine.
223520876|NCT05146778|PROCEDURE|Conventional opioid-based anesthesia|Conventional opioid-based anesthesia group will be sedated using remi-fentanyl
223520877|NCT05799092|DIAGNOSTIC_TEST|Invasive coronary angiography|As alternative to non-invasive functional testing, invasive coronary angiography will be performed.
224275112|NCT02564016|OTHER|Capped Epidural|epidural will be capped with no saline infusion.
224275113|NCT05663255|DRUG|Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)|Discontinuation or reduction of at least one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)
224275114|NCT00668395|DRUG|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
224275115|NCT06094764|DEVICE|Group A|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group A will be fitted with a cooling and bio-harness. At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
224275116|NCT06094764|DEVICE|Group B|The intervention will take place after lunch for about 2-3 hours in regular working conditions. Group B will wear a bio-harness and no cooling vest.At the end of each workday, participants will return the monitors and vests will be removed and returned to the research station. The biomonitor's battery will be recharged and data downloaded. The ice vests will be placed in a freezer.
224275117|NCT01249014|OTHER|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
224275118|NCT01249014|OTHER|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
224275119|NCT01249014|DEVICE|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
224275120|NCT01249014|DEVICE|Bair hugger warming blanket|Bair hugger warming blanket laid on body
224275121|NCT05396417|PROCEDURE|cesarean delivery|Cesarean delivery under any form of anesthesia for any reason and for any indication
224275122|NCT01325038|PROCEDURE|Isometric exercise|Isometric exercise several times/week for three months
224275123|NCT00306306|DEVICE|Reprieve Endovascular Temperature Therapy System|
224275124|NCT04404907|OTHER|no intervention|This is a secondary analysis of registry data.
224275125|NCT02970188|BEHAVIORAL|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
224275126|NCT02858037|COMBINATION_PRODUCT|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
224275127|NCT00624351|BIOLOGICAL|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
224275128|NCT00624351|OTHER|Placebo|Phosphate-buffered Saline (PBS) infusion.
224275129|NCT03031951|BEHAVIORAL|Lifestyle Intervention Group|The intervention group will start the lifestyle intervention with a 60-minute nutrition appointment given by a certified dietitian. This meeting is intended to provide a well-balanced personalized diet plan, calculated to create a moderate reduction from \~300 to 500kcal/day according to each participant's energy requirements and preferences. Two additional follow-up appointments are also planned to adjust the individual energy requirements throughout the intervention. Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Weight will be monitored weekly.
224275130|NCT03298516|DRUG|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
224275131|NCT03298516|DRUG|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
224275132|NCT02249117|DRUG|BIWH 3|
224275133|NCT02249117|DRUG|Placebo|
224275134|NCT02771392|DRUG|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
224275135|NCT02771392|OTHER|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
224275136|NCT05770804|BEHAVIORAL|Face to face education|Face-to-face training was provided and supported by booklets.
223520878|NCT05799092|DIAGNOSTIC_TEST|Non-invasive functional test|Standard non-invasive functional testing will be performed.
223520879|NCT05044871|DRUG|Pamiparib|40mg PO. bid.
223520880|NCT05044871|DRUG|Bevacizumab|7.5mg/kg IV. D1 (q3w.)
223520881|NCT05044871|DRUG|Tislelizumab|200mg IV. D1
223520882|NCT05044871|DRUG|Nab paclitaxel|125mg / m2 IV. D1, 8 (q3w).
223520883|NCT05044871|DRUG|Bevacizumab + Nab paclitaxel (intense dose-dense)|Bevacizumab 7.5mg/kg IV. D1, 15 (Q4w). + Nab paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
223520884|NCT04878718|BIOLOGICAL|Fecal Microbiota Transplant; Vancomycin|Subject will be treated with vancomycin followed by fecal microbiota transplant
223520885|NCT02466997|DRUG|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
224275137|NCT05157750|OTHER|Recording of major clinical events|During follow-up, major clinical events, defined as (i) disease flare; (ii) IBD-related hospitalization, (iii) IBD-related surgery, (iv) necessity for initiation of systemic steroids, immunosuppressants or biologics; (v) necessity for escalation of an existing biological therapy, will be recorded.
224275138|NCT06650189|OTHER|Music intervention|Recorded music created by a certified music therapist
224275139|NCT01101386|DRUG|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
224275140|NCT02099318|OTHER|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
224275141|NCT02099318|OTHER|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
224275142|NCT00584103|DEVICE|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
224275143|NCT00584103|DEVICE|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
224275144|NCT02417428|DIETARY_SUPPLEMENT|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
224275145|NCT02417428|OTHER|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
223520886|NCT02466997|DRUG|Placebo|
223520887|NCT01257243|DRUG|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
224275146|NCT02417428|BEHAVIORAL|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
224275147|NCT02417428|OTHER|without exercise|No exercise program will be assigned to participants.
224275148|NCT05909696|DRUG|rocuronium|Advanced intravenous injection of rocuronium before the succinylcholine injection
224275149|NCT01937767|DRUG|Remimazolam|
224275150|NCT01937767|DRUG|Propofol|
224275151|NCT01937767|DRUG|Sevoflurane|
224275152|NCT01937767|DRUG|Remifentanil|
224275153|NCT01937767|DRUG|Fentanyl|
224275154|NCT01937767|DRUG|Rocuronium|
224275155|NCT06486389|DEVICE|reading fairy tales|Reading fairy tales during inhaler medication administration.
224275156|NCT06486389|DEVICE|painting|painting during inhaler medication administration
224275157|NCT06317584|OTHER|Experimental: Empowerment Application for CAM Health Education|Using empowerment software application for complementary and alternative therapy education, explaining the risk factors that need to be considered, and teaching the use of assistive tool of the empowerment software application
224275158|NCT06317584|OTHER|Written Paper for CAM Health Education|Using written paper for complementary and alternative therapy education and explaining the risk factors that need to be considered
224275159|NCT00461669|PROCEDURE|ultrasound examination of the hip|
224275160|NCT06223490|PROCEDURE|Cryolipolysis|To investigate the Effect of Cryolipolysis On insulin resistance and In adult type 2 female patients.
224275161|NCT03117244|OTHER|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
224275162|NCT03117244|OTHER|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
224275163|NCT01476904|DRUG|Placebo|0 mcg/inhalation, 2 inhalations QID
224275164|NCT01476904|DRUG|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
224275165|NCT01476904|DRUG|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
224275166|NCT02070523|DRUG|VDCLD regimen|
224275167|NCT00052923|BIOLOGICAL|filgrastim|
224275168|NCT00052923|BIOLOGICAL|rituximab|
224275169|NCT00052923|DRUG|carmustine|
224275170|NCT00052923|DRUG|cyclophosphamide|
224275171|NCT00052923|DRUG|etoposide|
224275172|NCT00052923|PROCEDURE|peripheral blood stem cell transplantation|
224275173|NCT00052923|RADIATION|radiation therapy|
224275174|NCT02121717|DRUG|Chiglitazar|Take orally
224275175|NCT02121717|DRUG|Placebo|Take orally
224275176|NCT05810636|DEVICE|Garmin Vivosmart wearable device|Wearing smartwatches to collect data
224275177|NCT00594503|DRUG|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
224275178|NCT01647321|BEHAVIORAL|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
224275179|NCT01647321|BEHAVIORAL|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
224275180|NCT05529238|BEHAVIORAL|biofeedback training|participants received biofeedback training for kegel exercises in the supervised group. the unsupervised group practised their Kegel exercises at home
224275181|NCT03428542|BEHAVIORAL|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
224275182|NCT03428542|BEHAVIORAL|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
224275183|NCT04985149|OTHER|Electromyographic measurement:|"Nerve conduction studies; assesses nerve function and includes motor, sensory, and mixed nerve tests.~Micromed (Italy 2020) EMG device will be used in the electrophysiological examination. Sensory and motor conduction studies will be performed in the lower and upper extremities by paying attention to the extremity temperatures of the cases.~Nerve conduction studies will be performed by another physician who is unaware of the diagnosis of the patients. Bilateral lower extremity sural sensory responses of the patients will be taken.~In the antidromic method in sural nerve conduction examination, the bipolar superficial electrode is placed behind the lateral malleolus; stimulation will be made with bipolar surface electrodes 12-15 cm proximal to the recording site. Initial latency should be \< 3.8 ms, amplitude \> 10 Mv, and conduction velocity \> 36 m/sec in sensory response of the sural nerve."
223520888|NCT01257243|DRUG|Syrup of guaifenesin|5ml each 4 hours
223520889|NCT04105361|PROCEDURE|Posterior neurectomy|Cut of posterior nasal nerve
223520890|NCT02904265|DRUG|Diazepam|
223520891|NCT02904265|DRUG|Acetazolamide|
223520892|NCT02346812|OTHER|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
223520893|NCT02346812|OTHER|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
223520894|NCT01337505|DRUG|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
224275184|NCT04985149|OTHER|Ultrasonographic measurement:|Sural nerve ultrasonography (US) will be performed by another clinician (Merve Akdeniz leblebicier) who is experienced in musculoskeletal ultrasonography and unaware of clinical evaluation, using a 6-18 Mhz linear probe. (Mindray -UMT 200, United States) Both sural nerve joints of the patients will be evaluated. The patient will lie on the stretcher in the prone position, the ankle will be out of the bed. The 14 cm above the malleolus will be marked as the main line, the nerve will be detected in the lateral of the tendon of the gastrocnemius muscle and the proximal of the saphenous vein. Nerve diameter measurement will be measured 3 times in mm2 and the average will be taken. Then, possible inflammatory pathologies will be ruled out by providing clinical confirmation using the Doppler mode (11).
224275185|NCT00068042|DRUG|Pegvisomant|
224275186|NCT00068042|DRUG|Sandostatin LAR|
224275187|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
224275188|NCT01749085|DRUG|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
224275189|NCT01633307|OTHER|Education|Teaching program
224275190|NCT05633251|BEHAVIORAL|Variable (random) interval|Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
224275191|NCT05633251|BEHAVIORAL|Variable (non-random) interval|Using Variable (Non-random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
224275192|NCT05633251|BEHAVIORAL|Variable (random) interval with table tents|Using Variable (Random) Interval Reinforcement Schedules and Table Tents with Health-related Messages to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
224275193|NCT05633251|BEHAVIORAL|Control|No intervention
224275194|NCT06361654|OTHER|The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer|"The measurements will be taken during different climbing sessions, after the warm-up.~The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer."
224275195|NCT04049097|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily during breakfast, early afternoon, and at bedtime
223520895|NCT04384497|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (200ml, up to a maximum of 7 CP infusions). Plasma from consenting individuals who have recovered from SARS-CoV-2 infection.
223520896|NCT02115672|DRUG|BL-8040|BL-8040 will be added to imatinib to improve CML response.
223520897|NCT03448835|DRUG|Atezolizumab|atezolizumab 1200 mg 5 cycles
223520898|NCT03448835|DRUG|Capecitabine|capecitabine 850 mg /m2 4 cycles
223520899|NCT03448835|DRUG|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
223520900|NCT03448835|DRUG|Docetaxel|docetaxel 50 mg/m2 4 cycles
223520901|NCT05787782|DEVICE|Masimo INVSENSOR00063|Masimo INVSENSOR00063 will be used to measure temperature
223520902|NCT05841667|DRUG|Remimazolam besylate|"This is an observational study, meaning that no interventions are actually administered to the participants. However, blood and urine samples will be collected for research purposes.~Participants will receive remimazolam besylate for at least 2 hours during anesthesia and surgery. Blood will be drawn to determine the concentration of remimazolam in the blood at the following time points: (1) before remimazolam administration, (2) after remimazolam administration has lasted at least 2 hours without a change in concentration, (3) immediately before discontinuation of remimazolam if there has been a change in concentration since the second blood draw, (4) within 5 minutes of discontinuation, (5) within 15-60 minutes of discontinuation, and (6) 90 minutes after discontinuation. Urine will also be collected after the end of anesthesia to check for metabolites of remimazolam."
223520903|NCT02832531|DRUG|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
223520904|NCT02832531|DRUG|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~1. Left atrial enlargement ≥ 5.5 cm, OR~2. Left atrial spontaneous echo contrast OR~3. Left atrial thrombus OR~4. Frequent ectopic atrial activity (\>1000/24 hours) on Holter ECG."
223520905|NCT04804345|OTHER|standard of care|retrospective study: standard of care
223520906|NCT02416479|BEHAVIORAL|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
223520907|NCT02416479|BEHAVIORAL|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
223520908|NCT00205322|DRUG|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
223520909|NCT06571643|OTHER|Lower Abdomen MRI|The patients will undergo a lower abdomen MRI to assess the size of the psoas muscle and derive the PMI
223520910|NCT06570538|DRUG|Ropivacaine|300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
223520911|NCT06570538|DRUG|Sufentanil|Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
223520912|NCT06570564|DEVICE|The arm crank ergometer|Before starting the program, patients will perform an adaptation session for familiarization with the ergometer and also to identify the training load. For this, patients will perform 10 bouts of two minutes of exercising with a minimum load and two minute passive intervals between bouts. Patients will be instructed to maintain 50 revolutions per minute (RPM) during the exercise. Subsequently, to determine the training load for each session, patients will perform a progressive test where the load will be increased by 10 watts every minute of the test, following the protocol of two minutes of exercise with two minutes of interval
223520913|NCT06570564|DEVICE|bicycle ergometer|bicycle ergometer program will consist of a bicycling exercise 3 days per week. Exercise intensity was set at 70% of maximal load with 30 minutes per session. The exercise protocol also incorporated warm-up and cool-down sessions that involved stretches of the major lower limb muscle groups (total exercise time, 40-60 minutes)
223520914|NCT06570564|DEVICE|treadmill|Supervised treadmill exercise as routine physiotherapy program
223520915|NCT06569862|PROCEDURE|Postoperative day 1 dressing|The patient's dressing will be removed on the first day after surgery, leaving the incision exposed to air, with daily cleaning.
223520916|NCT06569862|PROCEDURE|Postoperative day 6+/-1 dressing|The patient will have a daily dressing change according to the usual nursing procedures, including saline serum washing, until the sixth day (+/- 1 day) after surgery. This will be done while the patient is in hospital, or at home if discharged before the sixth day.
223520917|NCT06572020|OTHER|education|simulation-based training on blood pressure and ECG measurement
223520918|NCT03827317|RADIATION|[18F]GE-226|\[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
223520919|NCT06122597|OTHER|ConcenTrace|The product contains concentrated seawater from Utah's inland sea.
223520920|NCT05552365|BEHAVIORAL|Adapted Cognitive Behavioural|8-session cognitive behavioural intervention adapted for children indicated to have developmental language disorder. Intervention includes psychoeducative, bodily relaxation, graded exposure, cognitive restructuring and brainstorming. Adaptations include increasing the number of visual supports, use of physical objects to illustrate concepts in addition to language.
223520921|NCT05552365|OTHER|Treatment as Usual|Participants given a mental health brochure with contact information, where they can access services provided by mental health support service providers.
223520922|NCT05067985|PROCEDURE|covid 19 spinal anesthesia|this group description covers that all the covid 19 pregnant women which we gave spinal anesthesia for cesarean section procedures. The investigators analyzed them retrospectively.
223520923|NCT03193580|DEVICE|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
223520924|NCT03193580|DEVICE|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
223520925|NCT03193580|DEVICE|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
223520926|NCT03942744|DEVICE|on-line hemodiafiltration|on-line postdilutional hemodiafiltration with high convective transport above 21 liters
223520927|NCT05704088|DRUG|Dapagliflozin tablet|randomized control trial, study group will receive dapagliflozin tablets
223520928|NCT05704088|DRUG|placebo|randomized control trial, control group will receive placebo tablets
223520929|NCT03463681|DRUG|Cabometyx|cabozantinib 60 mg orally once daily
224275196|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
224275197|NCT01742208|DRUG|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
224275198|NCT01742208|DRUG|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
224275199|NCT01924247|BEHAVIORAL|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
224275200|NCT01924247|BEHAVIORAL|Standard treatment by family physician|Standard treatment by family physician.
224275201|NCT04417959|PROCEDURE|Phaco-DSAEK|The intervention will be performed as a DSAEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DSAEK.
224275202|NCT04417959|PROCEDURE|Phaco-DMEK|The intervention will be performed as a DMEK triple-procedure with phacoemulsification and intraocular lens implantation prior to DMEK.
224275203|NCT06109337|DIAGNOSTIC_TEST|drow blood|Participants will be taken peripheral blood about 5 ml
224275204|NCT02013050|DRUG|SGX942|
224275205|NCT02013050|DRUG|Placebo|
224275206|NCT03386461|BEHAVIORAL|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
224275207|NCT03386461|DIETARY_SUPPLEMENT|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
224275208|NCT03386461|DIETARY_SUPPLEMENT|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
224275209|NCT02565836|DRUG|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
224275210|NCT02565836|DRUG|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
224275211|NCT00032227|PROCEDURE|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
224275212|NCT00032227|OTHER|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
224275213|NCT00271973|DRUG|Oxycodone|
224275214|NCT00002976|DRUG|conjugated estrogens|
224275215|NCT01285076|OTHER|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
224275216|NCT04117880|DRUG|Ataluren|Oral
224275217|NCT06236880|DRUG|GM-2505|IV
224275218|NCT02737462|DRUG|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
224275219|NCT01690260|DRUG|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
224275220|NCT01690260|PROCEDURE|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
224275221|NCT05100680|OTHER|Multicomp|Daily dietary supplementation over 12 weeks with test product: food supplement - 2 capsules / day containing together: 20 mg coenzyme Q10,500 mg methyl sulfonyl methane (MSM), 100 mg L-proline, 10 mg L-cysteine (as HCl monohydrate), 2 mg thiamine , 2.4 mg riboflavin, 19 mg niacin, 8.5 mg pantothenic acid, 2.3 mg vitamin B6, 0.15 mg, biotin, 0.0125 mg vitamin B12, 80 mg vitamin C, 5.5 mg vitamin A , 22 mg vitamin E, 10 mg zinc, 0.07 mg selenium, 1.1 mg copper.
224275222|NCT05100680|OTHER|Placebo|Daily dietary supplementation over 12 weeks with placebo product: dietary supplement - 2 capsules / day, containing only modified starch.
224275223|NCT06677762|PROCEDURE|Irreversible electroporation|Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.
224275224|NCT03087162|DRUG|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
224275225|NCT05257694|PROCEDURE|Surgery|hepatectomy
224275226|NCT05257694|PROCEDURE|Ablation (Microwave ablation or Radiofrequency ablation)|image-guided ablation
224275227|NCT01963260|DRUG|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
224275228|NCT01963260|DRUG|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
224275229|NCT00660491|OTHER|exercise training|moderate intensity exercise group, and high intensity exercise group
224275230|NCT04595591|DRUG|2mg/kg/min|titration dosing speeds of propofol at 2mg/kg/min
224275231|NCT04595591|DRUG|1mg/kg/min|titration dosing speeds of propofol at 1mg/kg/min
224275232|NCT04595591|DRUG|0.5mg/kg/min|titration dosing speeds of propofol at 0.5mg/kg/min
224275233|NCT03807830|PROCEDURE|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
223520930|NCT06389123|DRUG|[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.|Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.
223520931|NCT00027599|BIOLOGICAL|bevacizumab|
223520932|NCT00027599|BIOLOGICAL|prostatic acid phosphatase-sargramostim fusion protein|
223520933|NCT00027599|BIOLOGICAL|sipuleucel-T|
223520934|NCT00027599|BIOLOGICAL|therapeutic autologous dendritic cells|
223520935|NCT00027599|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223520936|NCT05908760|DEVICE|CO2 ReHaler|The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
223520937|NCT01917032|DIETARY_SUPPLEMENT|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
223520938|NCT01917032|DIETARY_SUPPLEMENT|placebo|
223520939|NCT01161966|DRUG|Zonisamide|Zonisamide capsules 100 mg
223520940|NCT01161966|DRUG|Zonegran|Zonegran Capsules 100 mg of EISAI INC
223520941|NCT00833703|DRUG|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
223520942|NCT00833703|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
223520943|NCT03960346|PROCEDURE|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
223520944|NCT04822883|DRUG|RL-007|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
223520945|NCT04822883|DRUG|RL-007 Matching Placebo|Cohorts are 10 mg, 20 mg, 40 mg, and 80 mg with TID dosing
223520946|NCT00122473|DRUG|Imatinib (Glivec)|
223520947|NCT06304012|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
223520948|NCT06304012|DEVICE|Intermittent Oro-esophageal Tube Feeding|The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
223520949|NCT06304012|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
223520950|NCT03368144|DEVICE|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
223520951|NCT01993550|BEHAVIORAL|Telephone counseling|
223520952|NCT01993550|BEHAVIORAL|Education|
223520953|NCT02615288|DIETARY_SUPPLEMENT|Vitamin D3|
223520954|NCT00675233|DRUG|HPPH|Given IV
223520955|NCT00675233|PROCEDURE|laser therapy|Escalating light doses with 665 nm light
223520956|NCT05538728|DEVICE|poly-l-lactic acid (Sculptra)|Sculptra
223520957|NCT05536791|DRUG|Dabigatran Etexilate (DE)|Dabigatran Etexilate (DE)
223520958|NCT01784484|OTHER|No intervention|
223520959|NCT00233246|PROCEDURE|FFP Infusion|
223520960|NCT02695888|BEHAVIORAL|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
223520961|NCT02695888|BEHAVIORAL|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
223520962|NCT04706325|OTHER|ACUTE KIDNEY INJURY|KDIGO LEVELS
223520963|NCT02254460|DIETARY_SUPPLEMENT|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
223520964|NCT02254460|OTHER|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
223520965|NCT01655056|DRUG|YM150|oral
223520966|NCT01655056|DRUG|Placebo|oral
223520967|NCT05559385|DEVICE|Robot-Assissted Therapy|Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
223520968|NCT05559385|PROCEDURE|Conventional Rehabilitation|It is an upper extremity rehabilitation program prepared in line with individual needs.
223520969|NCT03706066|DEVICE|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
223520970|NCT03706066|PROCEDURE|Cataract surgery|Per investigator's standard of care
223520971|NCT03308773|OTHER|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
223520972|NCT00583531|DRUG|AST-120|Oral, 2 grams TID in sachets for 4 weeks
223520973|NCT04369612|PROCEDURE|Standard follow-up|Standard post-transplant follow-up
223520974|NCT04369612|PROCEDURE|Home-based monitoring|Patients take capillary blood sample by finger-prick and send to lab for analyses. Telecom follow-up that day by treating physician
223520975|NCT01827020|DRUG|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
223520976|NCT01827020|DRUG|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
223520977|NCT01827020|DRUG|Saline|12 mL saline (0.9% isotonic solution)
223520978|NCT04649749|DIAGNOSTIC_TEST|MRI|MRI scan
223520979|NCT05634200|PROCEDURE|Bronchoscopy|During bronchoscopy endobronchial biopsy, transbronchial biopsy, transbronchial needle aspiration, bronchial washing, bronchoalveolar lavage, EBUS-TBNA and EUS-B-FNA may be performed
223520980|NCT03269266|DIAGNOSTIC_TEST|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
224275234|NCT02202057|OTHER|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
224275235|NCT02202057|OTHER|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
223520981|NCT02640131|BEHAVIORAL|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
223520982|NCT02640131|BEHAVIORAL|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
223520983|NCT02640131|BEHAVIORAL|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
223520984|NCT01808170|PROCEDURE|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
223520985|NCT01808170|PROCEDURE|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
223520986|NCT02572648|OTHER|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
223520987|NCT02572648|OTHER|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
223520988|NCT04377776|OTHER|Practice details|Questionnaire
223520989|NCT03345082|BIOLOGICAL|OPT-302|Intravitreal injection
223520990|NCT03345082|BIOLOGICAL|ranibizumab|Intravitreal injection
223520991|NCT03345082|OTHER|sham intravitreal injection|Sham (mock) intravitreal injection
223520992|NCT01655446|BEHAVIORAL|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
223520993|NCT01655446|BEHAVIORAL|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
223534893|NCT03167138|DEVICE|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
223534894|NCT00005590|DRUG|levofloxacin|
223534895|NCT02129712|BEHAVIORAL|Cognitive training|
223534896|NCT01119287|DRUG|Dexamethasone 0.1% ophthalmic suspension|Maxidex
223534897|NCT01119287|DRUG|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
224275236|NCT04470739|DIAGNOSTIC_TEST|chest x-ray|First Chest X-ray in the first 6 hours of infants
224275237|NCT02403973|OTHER|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
224275238|NCT01675973|DRUG|RANEXA|500mg BID up to 1000mg BID
223520994|NCT01655446|BEHAVIORAL|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
223520995|NCT01655446|BEHAVIORAL|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
223520996|NCT01655446|BEHAVIORAL|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
223520997|NCT04133038|OTHER|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
223520998|NCT00583154|DRUG|BLI-801|Dose 1
223520999|NCT00583154|DRUG|BLI-801|Dose 2
223521000|NCT00583154|DRUG|BLI-801|Dose 3
223521001|NCT00583154|DRUG|BLI-801|Dose 4
223521002|NCT02943499|BEHAVIORAL|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
223521003|NCT02943499|BEHAVIORAL|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
223521004|NCT02943499|DEVICE|Smartphone|
223521005|NCT04016610|DEVICE|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
223521006|NCT01904279|DRUG|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
223521007|NCT05276856|DRUG|Levothyroxine|"Step 1:~* Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~* If serum T4 is normal, go to step 2.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~* Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~* If serum T4 is normal, go to step 3.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~* Recheck serum TSH and T4 after 8 weeks.~* If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~* If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure)."
223521008|NCT05450237|BEHAVIORAL|Psychometric Evaluations|"The main evaluation scales we will use are the Beck Depression Inventory-II (BDI II), the State-Trait Anxiety Inventory (STAI), The twenty-item Toronto Alexithymia scale- I (TAS-20), The fatigue severity scale (FSS), Modified Fatigue Impact Scale (MFIS), The Multiple Sclerosis Impact Scale (MSIS-29), The Epworth Sleepiness Scale (ESS) (Johns MW. 1991), The Pittsburgh Sleep Quality Index (PSQ1), The Multiple Sclerosis quality of life Inventory (MSQOLI), The work productivity and activity impairment instrument (WPAI), Frailty Index.~These rating scales will be administered in person, by telephone and / or by sending them electronically."
223521009|NCT06565351|OTHER|eGFR estimated from creatinine and cystatin C|eGFR estimated from creatinine and cystatin C was compared to GFR measured by 99mTc-DTPA clearance (gold standard)
223521010|NCT00629603|GENETIC|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
223521011|NCT00629603|GENETIC|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
223521012|NCT00629603|GENETIC|cytokine polymorphism|fibrosis-relating cytokine polymorphism
223521013|NCT03056469|OTHER|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
223521014|NCT04124419|DEVICE|Treatment with Evolve System|EMS and RF Treatment
223521015|NCT03583294|OTHER|MRI pelvic|Pelvic MRI
223521016|NCT02758730|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
223521017|NCT02758730|BIOLOGICAL|Adjuvant without active component|s.c. injection
223521018|NCT03562156|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
224275239|NCT02629640|OTHER|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
224275240|NCT02629640|OTHER|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
224275241|NCT02629640|OTHER|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
223521019|NCT03562156|DRUG|Placebo|matching placebo capsule
223521020|NCT05095285|OTHER|Swaddling|"* Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded."
223534898|NCT01119287|OTHER|Inactive ingredients, used as placebo|Tears Naturale II
223534899|NCT04086355|OTHER|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
223521021|NCT05095285|OTHER|Oropharyngeal colostrum|"* Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue."
223521022|NCT02963818|OTHER|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
223521023|NCT02963818|OTHER|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
224275242|NCT02629640|OTHER|Blood or buccal sample|Codon-129 genotyping; storage for future research.
223521024|NCT02963818|OTHER|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
223521025|NCT05341843|DRUG|sertraline|sertraline at the intended dose of 50 mg twice daily for 8 weeks.
223521026|NCT05341843|DRUG|placebo|a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
223521027|NCT03926013|DRUG|JNJ-63898081|JNJ-63898081 will be administered.
223521028|NCT03514940|DIAGNOSTIC_TEST|ultrasound|second trimester us scan will be made to pregnant women
223521029|NCT01356940|DRUG|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
223521030|NCT01356940|DRUG|placebo|identical placebo tablet administered bid for four weeks
223521031|NCT06478524|BEHAVIORAL|Live music|Patients will have baseline data collection in the first week, followed by live music sessions and data collection during dialysis in the second week. The live music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
223521032|NCT06478524|BEHAVIORAL|Pre-recorded music|Patients will have baseline data collection in the first week, followed by pre-recorded music sessions and data collection during dialysis in the second week. The pre-recorded music will be played for 45 minutes to one hour per dialysis session, and will be played during each of patients' three dialysis sessions in week 2 of this arm of the study.
223521033|NCT02400684|BIOLOGICAL|blood samples|Evolution of AMH before and after deep endometriosis surgery
223521034|NCT06367101|OTHER|AR training with gait and HRV feedback|Use projection-based AR system to train gait and HRV. To give gait and HRV feedback for subjects after AR training.
223521035|NCT05888064|DIAGNOSTIC_TEST|diffusion MRI sequences|Diffusion MRI sequences will be optimized to derive more accurate estimates of microstructure and microvasculature of tumour and healthy organs: multiple b-values will be acquired and advanced diffusivity models considered. MRI sequences to derive tumour hypoxia (i.e. indicative of radioresistance) will be also considered along with MR spectroscopy to evaluate tumour microenvironment.
223521036|NCT05558579|OTHER|No sling use|Patients will not use standard of care sling
224275243|NCT02629640|OTHER|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
223521037|NCT05323344|OTHER|Neuro-physiotherapy|Neuro-Physiotherapy will be done in Intervention group I
223521038|NCT05323344|OTHER|Combination of metacognitive behavioral therapy and Neuro-physiotherapy|Combination of metacognitive behavioral therapy and Neuro-physiotherapy will be done in intervention group II
223521039|NCT00853684|DRUG|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
223704147|NCT03888586|DEVICE|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
224275244|NCT05616455|DRUG|Propionibacterium Acnes|Application of the gel every 12 hours for 40 days
224275245|NCT05616455|DRUG|glyceryl trinitrate|Application of the gel every 12 hours for 40 days
223521040|NCT00853684|DRUG|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
223521041|NCT00685295|DRUG|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
223521042|NCT00685295|DRUG|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
223521043|NCT00685295|DRUG|Oxycodone|Oxycodone 5/325 mg tablet
223521044|NCT05409794|BIOLOGICAL|Blood sample|Blood sample for the determination of plasma lithium levels
223521045|NCT01076699|DRUG|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
223521046|NCT01076699|DRUG|0.125 mg RVX-100|This group is taking an average dose of RVX-100
223704148|NCT03888586|OTHER|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
223704149|NCT06409936|DRUG|Asciminib|both arms will include asciminib treatment
223704150|NCT06409936|DRUG|Nilotinib|in the arm B the nilotinib will be added on in all patients
223704151|NCT01282632|DRUG|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
223704152|NCT01282632|DRUG|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
223704153|NCT04824950|OTHER|Circulating tumor DNA monitoring|Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy
223521047|NCT01076699|DRUG|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
224275246|NCT01256996|PROCEDURE|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
224275247|NCT00131716|DRUG|sulfadoxine-pyrimethamine|
223521048|NCT01076699|DRUG|placebo|This group is taking a placebo
223521049|NCT00245479|DRUG|Primary nocturnal enuresis|Desmopressin
223521050|NCT01900184|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
223521051|NCT01900184|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
223521052|NCT04720807|DRUG|Letrozole combined with anlotinib hydrochloride|Letrozole combined with anlotinib hydrochloride in the treatment of platinum-resistant recurrent ovarian cancer.
223521053|NCT00973128|DRUG|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
223521054|NCT00973128|DRUG|Meglumine antimoniate|20mg/daily for 20 days
223521055|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
223521056|NCT01282541|DRUG|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
223521057|NCT04862494|OTHER|clinical surveillance|regular clinical follow up including chest X-rays, pulmonary investigations, etc...
223521058|NCT04862494|PROCEDURE|diaphragmatic plication|plication of a hemidiaphragm, performed via laparoscopy, thoracoscopy (including robot-assisted surgery), or classical thoracotomy
223521059|NCT04448379|DRUG|JMT101|IV infusion Q2W for 4 weeks (28-day cycles)
223704154|NCT04333550|DRUG|Deferoxamine|Intravenous infusion of Deferoxamine
224275248|NCT01091363|BEHAVIORAL|Standard|10 minute brief cessation counseling
223521060|NCT01344356|RADIATION|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
223521061|NCT01344356|RADIATION|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
223521062|NCT00095576|BIOLOGICAL|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10\^10 adenovirus genomes \[ad-vg\]/dose).~This dose is equivalent to 3x10\^10 vp/dose used in study V520-016."
223521063|NCT00095576|DRUG|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
223521064|NCT03889379|DRUG|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
223521065|NCT03287986|OTHER|MRI|Structural and functional sequences
223521066|NCT04277247|DRUG|Botulinum toxin type A|A standardized dose will be injected in each muscle: 25 Units of BTXA in the extensor hallucis longus in 1 site, 50 Units of BTXA in the flexor digitorum brevis in 2 sites and 25 Units of BTXA in the tibialis posterior in 1 site.
223521067|NCT04277247|DRUG|Placebo|0.9% saline placebo injection
223521068|NCT02911727|PROCEDURE|Fast-track discharge|As described above
223521069|NCT05858931|PROCEDURE|vaginal repair|vaginal repair
223521070|NCT01138722|RADIATION|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
223521071|NCT06456892|DRUG|Pucotenlimab|Pucotenlimab Combined with Standard Chemotherapy Regimen
223704155|NCT03720353|DRUG|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
224275249|NCT01091363|BEHAVIORAL|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
223521072|NCT04927702|DEVICE|Synthetic Hybrid-Scale Fiber Matrix|A synthetic absorbable skin substitute indicated for use in the local management of wounds. It is made of small synthetic fibers that are designed to be similar to the structure of human skin.
223521073|NCT04927702|DEVICE|Standard of Care|To ensure off-loading, each patient will be fitted with an off-loading device based on the investigator's decision, e.g. a boot for forefoot and a heel protector for hindfoot. Patients is instructed on how to care for the surgical site, utilize an off-loading device, and keep the surgical site moist and clean. If the wound is dry, a hydrogel category dressing type should be used. If the wound has exudate, an alginate or foam dressing is recommended.
223521074|NCT04927702|DEVICE|Living Cellular Skin Substitute|An absorbable skin substitute comprised of human and bovine (cow) tissues indicated for use in the local management of wounds.
223521075|NCT05880524|DRUG|Dornase Alfa|Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
223521076|NCT05880524|DRUG|Isotonic Saline Solution|Patients will receive an intravenous dose of Isotonic saline solution twice within within 24±6 hours after symptom onset, administered as a bolus.
223521077|NCT02692534|OTHER|Urine cocaine negative|Preoperative urine cocaine negative
223521078|NCT02692534|OTHER|Urine cocaine positive|Preoperative urine cocaine positive
223521079|NCT02673021|PROCEDURE|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
223521080|NCT00121979|DRUG|Racivir, a non-nucleoside reverse transcriptase inhibitor|
223521081|NCT03088683|DEVICE|Nathanson Retractor|Liver will be retracted with Nathanson retractor
223521082|NCT03088683|DEVICE|Reveel Retractor|Liver will be retracted with Reveel retractor
224275250|NCT04302935|OTHER|Global pain-assessment|Global pain-assessment, based on the ICF framework
224275251|NCT00397735|PROCEDURE|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
223521083|NCT03235804|DIETARY_SUPPLEMENT|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
223521084|NCT00674102|DRUG|ASA404|
223521085|NCT00772057|DRUG|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
223521086|NCT00772057|DRUG|Placebo|Placebo tablets given two times daily.
223521087|NCT04408612|DIAGNOSTIC_TEST|Scales for assessment of symptoms|"Medical Research Council Dyspnea scale, the visual analogue scale of dyspnea, Borg scale, modified dictionary of dyspnea, G. Rose questionnaire, Seattle Angina Questionnaire, Framingham criteria for chronic heart failure, the SHOCK scale."
223521088|NCT04729439|BEHAVIORAL|Homework Organization and Planning Skills (HOPS) Intervention|A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills
223521089|NCT04729439|DEVICE|Digital Health Application (Online Platform) for Encouraging Skills Practice|This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
223534900|NCT03859037|OTHER|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
224275252|NCT00397735|DRUG|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
224275253|NCT02343796|OTHER|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
224275254|NCT02343796|DEVICE|everStick|GC, Belgium
224275255|NCT01299779|DRUG|PEG-SD|"PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients."
224275256|NCT01299779|DRUG|PEG-ELS|"* 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
224275257|NCT06185244|BEHAVIORAL|Therapist-supported internet-delivered trauma-focused CBT|12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.
224275258|NCT06185244|BEHAVIORAL|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.|12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
224275259|NCT04576936|OTHER|AIRVO|Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
224275260|NCT05917262|BEHAVIORAL|Mindfulness-based breathing|The 20-minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experiences in a non-judgmental fashion.
224275261|NCT05917262|BEHAVIORAL|HRV biofeedback|The 20-minute HRV biofeedback is based on the resonant frequency breathing with an external pacemaker. Generally, the breath rhythm is between 4.5 and 6.5 times per min.
224275262|NCT05917262|BEHAVIORAL|cognitive-behavioral pain psychoeducation|The 20-minute psychoeducation session is a supportive session where behavioral coping strategies for pain management are discussed.
224275263|NCT03023189|DRUG|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
224275264|NCT03023189|DRUG|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
224275265|NCT00248092|DRUG|NRP104|
224275266|NCT01781234|DRUG|Intranasal Insulin|
224275267|NCT01781234|DRUG|Placebo|
224275268|NCT03099590|DIETARY_SUPPLEMENT|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
224275269|NCT03099590|DIETARY_SUPPLEMENT|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
224275270|NCT01236495|DRUG|spinal morphine 0.3 mg|spinal morphine 0.3 mg
224275271|NCT01236495|DRUG|spinal morphine 0.2 mg|spinal morphine 0.2 mg
224275272|NCT04096547|DRUG|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
224275273|NCT01931345|BEHAVIORAL|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
224275274|NCT01931345|BEHAVIORAL|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
224275275|NCT02357927|BEHAVIORAL|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
224275276|NCT02357927|BEHAVIORAL|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
223534901|NCT03612024|BEHAVIORAL|questionnaire|a standardized questionnaire was sent to all participants
223534902|NCT05203380|DRUG|dupilumab|Weight based dosing for 16 weeks in accordance of United States prescribing information (USPI)
223534903|NCT00041028|DRUG|EF5|
223521090|NCT00642291|DRUG|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if \<30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if \>=7 to \<15kg; 10/2.5 mg/kg BID if \>=15 to \<=40 kg)
223521091|NCT00642291|DRUG|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
223521092|NCT06192420|DRUG|Traumeel®|3g of gel three times daily for 7days (+1 day visit window)
223521093|NCT06192420|DRUG|Diclofenac sodium gel 1%|3g of gel three times daily for 7days (+1 day visit window)
223521094|NCT06192420|DRUG|Placebo|3g of gel three times daily for 7days (+1 day visit window)
223521095|NCT06340867|DEVICE|CEREC primescan intra-oral scanner|intra-oral scanner
223521096|NCT00505687|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
223521097|NCT04305210|DRUG|F-18 PMPBB3|In this study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients (aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan, and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical evaluation.
223521098|NCT04305210|DRUG|18F-florbetapir|18F-florbetapir
223521099|NCT05598788|OTHER|Measurement of drug concentrations|Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample
223521100|NCT01290991|DEVICE|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
223521101|NCT04608708|OTHER|The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions|lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
223521102|NCT00654602|DRUG|Rosuvastatin|
223521103|NCT00654602|BEHAVIORAL|Maintenance of specific diet|
223521104|NCT00006427|DRUG|Amitriptyline|
224275277|NCT02929927|PROCEDURE|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
224275278|NCT02929927|DEVICE|aPDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60 s,then irradiation 120 s.
223521105|NCT00145730|DRUG|Ibuprofen|
224275279|NCT02929927|DRUG|1% iodine tincture|use 1% iodine tincture to disinfect the crown of the teeth.in order to avoid the outside microbe
224275280|NCT02929927|DRUG|2.5%NaClO|use 2.5% NaClO as irrigants
223521106|NCT04618094|OTHER|bicycle ergometer training with different intensities|Following a 10-min warm-up phase at a constant work load below ventilatory threshold, participants of the high intensity interval group perform repeated high intensity exercise bouts, followed by an active recovery on a bicycle ergometer. The comparative group perform a constant moderate intensity with the same mean workload. The cool-down phase is 5 min with a constant work load for both groups.
223521107|NCT00000600|DRUG|Vitamin E|
223521108|NCT00000600|DRUG|Vitamin C|
223521109|NCT03626233|OTHER|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
223521110|NCT03116126|DRUG|Guanfacine|2mg oral daily tablet
223521111|NCT03116126|DRUG|Placebo|inactive oral daily tablet
223521112|NCT03205267|DRUG|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to \<G2.
223521113|NCT01712373|DRUG|Ginseng|it is kind of drug
223521114|NCT01712373|DRUG|Placebo|it is placebo
223521115|NCT02177162|OTHER|Education to physiotherapists|
223521116|NCT01027676|DRUG|Study treatment|Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
224275281|NCT02929927|PROCEDURE|root canal preparation|mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer
223521117|NCT01631266|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
223521118|NCT01631266|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
223521119|NCT04509388|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
223521120|NCT02001792|PROCEDURE|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
223521121|NCT02001792|DEVICE|pulse oximeter|
223521122|NCT02510924|DEVICE|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
223521123|NCT04409444|DIAGNOSTIC_TEST|Lung Cancer Screening|The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model)
223521124|NCT04409444|DIAGNOSTIC_TEST|Biomarkers|This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers.
223534904|NCT00041028|OTHER|flow cytometry|
223534905|NCT00041028|OTHER|immunohistochemistry staining method|
223534906|NCT00383071|BIOLOGICAL|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
223534907|NCT00383071|PROCEDURE|Apheresis|Once subjects achieved a high antibody titer (\>1:160), they could begin apheresis to collect plasma.
223521125|NCT03947463|PROCEDURE|PECS block|After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
224275282|NCT02929927|PROCEDURE|root canal obturation|filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation
224275283|NCT04189120|PROCEDURE|Thoracic epidural analgesia , superficial serratus plane block and deep serratus plane block|neuroaxial thoracic epidural analgesia and regional analgesia supeficial and deep serratus plane blocks
223521126|NCT00740675|OTHER|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~1. Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~2. Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~3. Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
223521127|NCT01737905|DRUG|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
223521128|NCT01737905|DRUG|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
223521129|NCT00480532|DRUG|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
223521130|NCT00480532|DRUG|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
223521131|NCT00480532|DRUG|Oracea|40-mg tablet daily for 84 days
223521132|NCT00480532|DRUG|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
223521133|NCT00480532|DRUG|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
223521134|NCT00480532|DRUG|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
223521135|NCT00480532|DRUG|placebo daily|Placebo daily for the first 84 days of the study
223521136|NCT04826302|OTHER|Myofascial treatment|"40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
223521137|NCT04826302|OTHER|Sham myofascial treatment|"40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area"
223521138|NCT00448513|DIETARY_SUPPLEMENT|catechin extracts|comparison with placebo
223521139|NCT04893525|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is a first line, evidence-based opioid agonist therapy that improves mortality for people with opioid use disorder, and that has been demonstrated to be effective at retaining people in addictions care and decreasing illicit opioid use when initiated from EDs.
223521140|NCT03223675|RADIATION|hippocampal-sparing WBRT|
223521141|NCT03409198|DRUG|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
223521142|NCT03409198|DRUG|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
223521143|NCT03409198|DRUG|Pegylated liposomal doxorubicin|Chemotherapy
223521144|NCT03409198|DRUG|Cyclophosphamide|Chemotherapy
223521145|NCT01817777|DRUG|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
223521146|NCT01817777|DRUG|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
223521147|NCT05655767|OTHER|4D-flow MR & CT-scan|4D-flow MR and CT-scan after cardiac surgery (until 12 months afterwards), for the purpose of obtaining more precise data on (hemo)dynamic processes within the cardiovascular system, in combination with data extraction from the established biobank and databank (FIBAA-bank).
223521148|NCT00443456|DRUG|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
223521149|NCT05107076|DIAGNOSTIC_TEST|2D Echocardiography with color Doppler assessment & Galactin-3 level in blood|"* Measurements will be~  1. Pulsed wave (PW) Doppler~ 2. E (early diastolic)/A (late diastolic) - Using PW Doppler~ 3. IVRT (isovolumic relaxation time)~ 4. Deceleration time (DT) - from the peak of E wave to baseline.~ 5. E/e'- PW tissue Doppler imaging (TDI)~ 6. Left atrial volume and left atrial volume index (LAVI)~* Peripheral blood samples will be obtained within 48 hours after acute MI, and the serum will be frozen at -70°C until tested for Galactin-3 level."
223704156|NCT03720353|DRUG|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
223704157|NCT03720353|DRUG|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
223704158|NCT00001963|PROCEDURE|hemoglobin-transported nitric oxide|
224275284|NCT03960762|OTHER|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
223521150|NCT05517408|DRUG|ciprofol|The first patient received Ciprofol 0.3mg/kg (actual body weight) at a rate of 1 mg/s. If the desired depth of sedation/anesthesia reached, then it was judged as negative, and the dose of Ciprofol in next patient would be decreased by one concentration gradient (the difference between two adjacent drugs was 1:1.1); If the desired sedation/anesthesia depth was not achieved, then it was judged as positive. And the dose of Ciprofol in next patient would be increased by one concentration gradient. Patients were enrolled consecutively until the trial was terminated at the eighth crossing point (positive to negative or negative to positive).
223521151|NCT02587455|DRUG|Pembrolizumab|Pembrolizumab - Trial Treatment
223521152|NCT02587455|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
223521153|NCT04768244|OTHER|maternal SARS-CoV-2 infection|positive PCR in nasopharinx and/or presence of antibodies in serum
223521154|NCT03733327|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
223521155|NCT03733327|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223521156|NCT03733327|DRUG|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days -3 to -2.
223521157|NCT00756340|DRUG|Bevacizumab|"* Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg"
223521158|NCT00756340|DRUG|Everolimus|"* Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2"
223521159|NCT03538847|OTHER|Numerical rating scale|Measure of postoperative pain
223521160|NCT03057184|BEHAVIORAL|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
223521161|NCT00557440|DRUG|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
223521162|NCT00557440|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
223521163|NCT00557440|DRUG|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
223521164|NCT00557440|DRUG|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
223521165|NCT00664222|DRUG|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
223521166|NCT01309061|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
223521167|NCT05724030|DEVICE|integrated pulmonary index|integarted pumobary index monitoring
223521168|NCT05724030|DEVICE|saturation|saturation monitorization
223521169|NCT03524157|DRUG|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
223521170|NCT03524157|DRUG|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
223521171|NCT03524157|DRUG|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
223521172|NCT04389060|DIETARY_SUPPLEMENT|Grape seed extract|Two capsule grape seed extract (total 600 mg)
223521173|NCT05913167|PROCEDURE|laparoscopic nephrectomy|laparoscopic nephrectomy
223521174|NCT04626934|OTHER|specific cognitive intervention|The intervention will include all together 12 sessions, each being 45 minutes, for a total of 3 weeks. The intervention will include: 4 treatments in the area of memory and attention, 4 treatments in the area of problem solving, 4 treatments in the area of planning and analysing.
223521175|NCT04626934|OTHER|conventional occupational therapy treatment|The intervention will include all together 12 sessions of conventional occupational therapy treatments, each being 45 minutes, for a total of 3 weeks.
223521179|NCT01001689|BEHAVIORAL|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
223521180|NCT04629430|OTHER|Pre-biotic foods/drinks|2 servings per day
223521181|NCT00520338|DRUG|celecoxib|"1. placebo~2. celecoxib 400 mg oral single dose"
223521182|NCT00490711|DRUG|gemcitabine|
223521183|NCT00490711|DRUG|carboplatin|
223521184|NCT00490711|DRUG|paclitaxel|
223521185|NCT04669795|DRUG|Cissus Quadrangularis|Drug with osteogenic potential given to the patients after consolidation period. dose was two capsules once /day with meals for 6 weeks
223521186|NCT05648708|PROCEDURE|Combine Adductor Canal & Sciatic Nerve Block|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia
223521187|NCT05648708|PROCEDURE|Combine Femoral & Sciatic Nerve Block|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia
223521188|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined adductor canal \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
223521189|NCT05648708|DRUG|Bupivacaine and prilocaine hydrochloride|The investigators will perform a combined femoral \& sciatic nerve block on that patient group for postoperative analgesia with bupivacaine and prilocaine hydrochloride
223521190|NCT00319189|DRUG|Nateglinide|
223521191|NCT03066375|DEVICE|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
223521192|NCT04826614|OTHER|optimized treatment|early adjust dose or change drug
223521193|NCT03527667|BEHAVIORAL|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
223521194|NCT02695654|DRUG|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
223521195|NCT02695654|DRUG|Clonidine|Clonidine 100 mcg
223521196|NCT05904483|OTHER|PFA|PFA
223521197|NCT00850187|BIOLOGICAL|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
223521198|NCT01596426|DRUG|Sancuso|granisetron transdermal system
223521199|NCT01596426|DRUG|IV granisetron|IV granisetron
223521200|NCT02157610|BEHAVIORAL|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
223521201|NCT02157610|DRUG|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke \>10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
223521202|NCT02157610|BEHAVIORAL|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
223521203|NCT02157610|PROCEDURE|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
223521204|NCT02157610|BEHAVIORAL|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
223521205|NCT02157610|DRUG|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
223521206|NCT01705392|DRUG|Bevacizumab|Bevacizumab 10 mg/kg q3w
223521207|NCT01705392|DRUG|Propranolol|Propranolol 80 mg x 1
223521208|NCT01705392|DRUG|Enalapril|Enalapril 5 mg x 1
223521209|NCT01705392|DRUG|Dacarbazine|dacarbazine 1000 mg/m2 q3w
223521210|NCT01577407|DRUG|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
223521211|NCT06200948|OTHER|Aerobic Exercise|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
223521212|NCT06200948|OTHER|Complete Decongestive Treatment|While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
223521213|NCT03235492|DEVICE|SmartAlbu|"Plan:~1. Consent an individual~2. Measure and record temperature, blood pressure, heart rate, height and weight~3. Obtain two samples of saliva for the SmartAlbu portable salivary sensor~4. Take a venous blood sample for HbA1c and~5. Glycated albumin~6. Obtain blood sample from a finger stick for point of care HbA1c device"
223521214|NCT04503421|OTHER|Blood Flow Restriction Therapy|Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
223521215|NCT05732870|PROCEDURE|Relevant orthopaedic surgery|Inclusion criteria is purposefully broad to examine a range of discarded bone waste. Therefore, a large number of surgical interventions are relevant.
223521216|NCT00338611|BEHAVIORAL|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
223521217|NCT00338611|BEHAVIORAL|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
223521218|NCT00338611|BEHAVIORAL|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
223521219|NCT00338611|BEHAVIORAL|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
223521220|NCT01740518|DRUG|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
223521221|NCT01378195|BEHAVIORAL|CBT-based program for dementia caregivers|Participants will receive a CBT-based program \[Cognitive Behavioral Therapy\], containing videos, workbook, and website.
223521222|NCT01378195|BEHAVIORAL|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
223521223|NCT03868696|PROCEDURE|MUA with sham ultrasound|Standard MUA with sham ultrasound
223521224|NCT03868696|PROCEDURE|MUA with active ultrasound|Standard MUA guided by ultrasound
223521225|NCT00425555|DRUG|Panobinostat|
223521226|NCT00684684|DEVICE|Chartis System|Assessment of airway flow and pressure
223521227|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Microencapsulated Magnesium|Volunteers will be provided with the product Microencapsulated Magnesium. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
223521228|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Oxide|Volunteers will be provided with the product Magnesium Oxide. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
223521229|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Citrate|Volunteers will be provided with the product Magnesium Citrate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
223521230|NCT06225349|DIETARY_SUPPLEMENT|Dietary supplementation with Magnesium Bisglycinate|Volunteers will be provided with the product Magnesium Bisglycinate. For each volunteer, a blood sample from digital puncture will be obtained before (0 hour) and 1, 2, 4, 6, and 8 hours after oral intake of the product, and magnesium levels in plasma will be quantified by ICP-MS.
223521231|NCT06561776|OTHER|Physical Evaluations of individuals|Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
223521232|NCT06638684|OTHER|Exercise|Subjects in the two groups preformed 90-100 minutes of exercise at different intensities.
223521233|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+8Gy x 3f|Radiotherapy: 8Gy x 3f, once every other day; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
223521234|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+16Gy x 1f|Radiotherapy: 16Gy x 1f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
223521235|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+2.67Gy x 15f|Radiotherapy: 2.67Gy x 15f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
223521236|NCT06639672|DRUG|Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f|Radiotherapy: 0.5Gy x 12-18f; Chemotherapy: Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle. Cycles 5-8: Epirubicin: 90-100 mg/m², IV, administered on day 1 of each cycle; Cyclophosphamide: 600 mg/m², IV, administered on day 1 of each cycle; Immunotherapy: PD-1 inhibitor, once every three weeks
223521237|NCT06434493|RADIATION|Proton Beam Therapy|All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy)
223521238|NCT06434493|DRUG|Concurrent oral capecitabine chemotherapy|All patients to be offered concurrent oral capecitabine 625mg/m2 twice daily on radiation days
223521239|NCT06434493|DRUG|Cisplatin & Gemcitabine intravenous chemotherapy|Following chemoradiotherapy (PBT + capecitabine), and whilst on the liver transplant waiting list, patients will be offered up to 6 cycles of standard chemotherapy with cisplatin and gemcitabine.
223521240|NCT06434493|PROCEDURE|Orthotropic Liver Transplant|If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.
223521241|NCT06639048|BEHAVIORAL|Questionnaire|Questionnaire including demographic characteristics, social media usage habits, body weight, height, effects of social media on eating behavior scale and eating disorder fear questionnaire.
223521242|NCT05210543|OTHER|not applicable, observational study|Patients do not receive intervention; observational study
223521243|NCT04409431|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol
223521244|NCT03730350|BEHAVIORAL|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
223521246|NCT06636695|DEVICE|Cellular Matrix|Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.
223521247|NCT06636695|DEVICE|Orthovisc|Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
223521248|NCT06638047|PROCEDURE|robotic-assisted TKA|Robotic-assisted TKA means that TKA surgery is operated with the guidance of robotic system.
223521249|NCT06638047|PROCEDURE|CI-TKA|TKA operated with conventional instruments
223521250|NCT06644664|BEHAVIORAL|Health Education|Receive control MMS messages
223521251|NCT06644664|OTHER|Interview|Ancillary studies
223521252|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive AR MMS messages
223521253|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive RR MMS messages
223521254|NCT06644664|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resources
223521255|NCT06644664|OTHER|Survey Administration|Ancillary studies
223521256|NCT06644664|OTHER|Text Message-Based Navigation Intervention|Receive check-in text message
223704159|NCT05140785|DIAGNOSTIC_TEST|Advanced MRI sequences|Advanced MRI sequences which look to a) determine structure of a primary brain tumour and b) metabolism within a primary brain tumour
224275285|NCT03960762|OTHER|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
224275286|NCT05449080|DIAGNOSTIC_TEST|Karyotype|Patients were subjected to karyotype to determine their genotype
224275287|NCT00216060|DRUG|Risedronate|Daily oral risedronate combined with androgen deprivation
224275288|NCT00216060|DRUG|Placebo|Daily oral placebo combined with androgen deprivation
224275289|NCT02834962|PROCEDURE|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
224275290|NCT02834962|PROCEDURE|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
224275291|NCT03949062|DRUG|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
224275292|NCT03949062|DRUG|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
224275293|NCT03949062|DRUG|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
224275294|NCT02476331|BEHAVIORAL|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
224275295|NCT03755739|DRUG|Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy|vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.
224275296|NCT05889039|DEVICE|BEMER|Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.
224275297|NCT05889039|PROCEDURE|OMT|Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
224275298|NCT05889039|PROCEDURE|Sham OMT + Sham BEMER|Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
224275299|NCT02661022|DRUG|SL-401 7 µg/kg/day|SL-401 7 µg/kg/day in combination with pom/dex
224275300|NCT02661022|DRUG|SL-401 9 µg/kg/day|SL-401 9 µg/kg/day in combination with pom/dex
224275301|NCT00131092|BEHAVIORAL|The Stanford Active Choices program|
224275302|NCT00131092|BEHAVIORAL|The TLC system|
224275303|NCT04440696|DRUG|Lanthanum Polystyrene Sulphonate Powder|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
224275304|NCT04440696|DRUG|Lanthanum Carbonate 500 MG|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
224275305|NCT04440696|DRUG|Placebo|D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
224275306|NCT00604916|OTHER|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
224275307|NCT00604916|OTHER|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
224275308|NCT04681586|DEVICE|bright light therapy|using a bright light therapy device (10.000 lux) for 30min every morning for two weeks
224275309|NCT04681586|DEVICE|dim red light|using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
224275310|NCT03976934|DRUG|Tamsulosin|administration of tamsulosin tablets
224275311|NCT03976934|DRUG|Placebo oral tablet|sugar pills
224275312|NCT01138345|GENETIC|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
224275313|NCT01138345|GENETIC|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
224275314|NCT01138345|OTHER|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
224275315|NCT01138345|OTHER|medical chart review|perform medical chart review for all subjects
224275316|NCT01138345|OTHER|questionnaire administration|each cohort will be given the same questionnaire
224275317|NCT04000776|DIAGNOSTIC_TEST|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
224275318|NCT04000776|DIAGNOSTIC_TEST|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
223704160|NCT02704260|GENETIC|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
224275319|NCT04000776|DIAGNOSTIC_TEST|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
224275320|NCT04000776|OTHER|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
224275321|NCT02445846|DEVICE|dual HIV/syphilis rapid diagnostics tests|
224275322|NCT02742701|OTHER|diagnosis|Measurement of glycosuria
224275323|NCT03702816|DRUG|GE180 PET Scan|GE180 PET Scan
224275324|NCT01478516|PROCEDURE|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
224275325|NCT05900323|COMBINATION_PRODUCT|enteral nutrition guidelines|The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
224275326|NCT02361736|DRUG|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
224275327|NCT02361736|DRUG|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
224275328|NCT04509232|PROCEDURE|Silver diamine fluoride|"Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately ."
224275329|NCT04509232|PROCEDURE|Silver diamine fluoride and glass ionomer|"* 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration."
224275330|NCT01984606|DRUG|Empagliflozin|Empagliflozin once daily
224275331|NCT01984606|DRUG|Placebo|Placebo matching empagliflozin
224275332|NCT01984606|DRUG|Sitagliptin|Sitagliptin once daily
224275333|NCT01984606|DRUG|Placebo|Placebo matching sitagliptin
224275334|NCT01785615|DRUG|Atorvastatin|80mg
224275335|NCT01785615|OTHER|Placebo|80mg
224275336|NCT01881737|DRUG|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
224275337|NCT01562132|DRUG|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
224275338|NCT01562132|DRUG|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
224275339|NCT05926245|DIETARY_SUPPLEMENT|Glutaryl Solution|Glutathione, ascorbic acid, cyclodextrin, potassium sorbate and radish root extracts
224275340|NCT05926245|DIETARY_SUPPLEMENT|Placebo Solution|Empty nanoparticles
224275341|NCT01746654|DRUG|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
224275342|NCT01746654|DRUG|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
224275343|NCT01746654|DRUG|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
224275344|NCT01746654|DRUG|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
223521257|NCT05014126|BEHAVIORAL|Pain, Stress and Emotions|2-hour, zoom-delivered, group intervention focused on teaching patients how pain is processed in their brain and learning about the role of psychosocial factors in their pain conditions.
223704161|NCT05687175|OTHER|Questionnaire|Questionnaire administration (PDQ-M, NRS, SF-36)
224275345|NCT02474654|DRUG|Bupivicaine|15mg
224275346|NCT02474654|DRUG|Fentanyl|15mcg
224275347|NCT02474654|DRUG|Epimorphine|150mcg
224275348|NCT02474654|DRUG|Normal Saline|0.3 ml
224275349|NCT02474654|DRUG|Normal Saline|30ml
224275350|NCT02474654|DRUG|Normal Saline|100 ml
224275351|NCT02474654|DRUG|Ropivicaine|100 ml
224275352|NCT02474654|DRUG|Epinephrine|600 mcg
224275353|NCT02474654|DRUG|Ketorolac|30 mg
224275354|NCT02474654|DRUG|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
224275355|NCT03837405|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
224275356|NCT03837405|BEHAVIORAL|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
223521258|NCT06643559|OTHER|cognitive rehabilitation|Cognitive rehabilitation started to one group at the beginning of the antiseizure medicine. Participants underwent computer-based cognitive rehabilitation for 3 sessions per week, with each session lasting an average of 60 minutes. Before the sessions, all participants were given detailed information about the programme and its use. The rehabilitation process was carried out in three areas of cognitive functions: memory, executive functions, and language skills.
223521259|NCT06643624|OTHER|Vision Training Program|Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.
223521260|NCT06643624|OTHER|Routine Training Program|All athletes performed their routine training for wrestling 6 days a week.
223521261|NCT06644677|DIAGNOSTIC_TEST|HPV integration|Collect late-stage cervical cancer (Stage IIIB and beyond) and post-treatment recurrence and metastasis specimens (TCT, tissue) associated with HPV infection. Utilize third-generation nanopore technology to detect the integration sites of HPV DNA based on the principle of probe hybridization capture. Obtain information on HPV integration and hot spot genes in the samples. By analyzing the integration of HPV in primary and recurrent/metastatic tissues, identify insertions and gene alterations associated with recurrence/metastasis, and develop a predictive formula.
223521262|NCT06644547|BEHAVIORAL|Gezond en goed met elkaar|"The intervention 'Gezond en goed met elkaar' focuses on improving (positive) health literacy and literacy. The six domains of positive health are the focus of the intervention meetings. This intervention has been made available for citizens of Almere, Zwolle, Gouda, Nunspeet and Leusden through collaboration with these municipalities. Lifestyle coaches working in these municipalities implement the intervention."
223521263|NCT05418426|DEVICE|IVR Dose 1|Estradiol 80 ug/progesterone 4 mg
223521264|NCT05418426|DEVICE|IVR Dose 2|Estradiol 160ug/progesterone 8 mg
223521265|NCT05418426|DRUG|Oral Reference|estradiol 1mg/progesterone 100 mg
223521266|NCT01713829|OTHER|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
223521267|NCT01713829|OTHER|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
223521268|NCT01674062|DRUG|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
223521269|NCT01674062|DRUG|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
223521270|NCT04620668|DEVICE|Wysa|Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.
223521271|NCT01397591|BIOLOGICAL|Ofatumumab|Given intravenously
223521272|NCT01397591|DRUG|Bortezomib|Given intravenously
223521273|NCT02315976|DRUG|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
223521274|NCT01881932|DEVICE|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
223704162|NCT05276037|OTHER|Liver transplantation|Both groups will receive the same advantages on the LT waiting list (SE points)
223521275|NCT01881932|DEVICE|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
223521276|NCT01248819|DRUG|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
223704163|NCT02451111|DRUG|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
223704164|NCT02451111|DRUG|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
223704165|NCT04312581|DEVICE|Extracorporeal shock wave therapy|3 sessions of radial- extracorporeal shock wave therapy rESWT one week apart, 2000-3000 impulses at 0.25-0.84 millijoule /mm2with a pressure 2.8 bar and 15 Hz frequency.
223704166|NCT04312581|OTHER|Conventional rehabilitation|physical \& occupational therapy
223704167|NCT00419276|PROCEDURE|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
223704168|NCT05347277|DIAGNOSTIC_TEST|Kappa Free Light Chain (K-FLC)|A biochemical test measured on CSF sample via nephelometry on Beckman Immage-800 analyzer using kits from Freelite, The Binding Site, according to the manufacturer's instructions.
223704169|NCT01479478|DRUG|Placebo|One placebo capsule daily.
223704170|NCT01479478|DIETARY_SUPPLEMENT|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
223704171|NCT01142271|PROCEDURE|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
223521277|NCT01248819|DRUG|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
223521278|NCT04956016|DEVICE|classic rTMS using the 8-shaped coil|20 rTMS sessions are planned (5 sessions per week)
223521279|NCT04956016|DEVICE|deep rTMS using the H1-shaped coil|20 rTMS sessions are planned (5 sessions per week)
223521280|NCT01873508|DRUG|RO4917523|Fast release MR capsule, single dose
223521281|NCT01873508|DRUG|RO4917523|Target release MR capsule, single dose
223521282|NCT01873508|DRUG|RO4917523|Slow release MR capsule, single dose
223521283|NCT01873508|DRUG|RO4917523|\[13C\]-labeled tracer dose i.v.
223521284|NCT06099639|DRUG|HER3-DXd|5.6 mg/kg Q3W \[on Day 1 of each 21-day cycle\]) infused IV over approximately 90 minutes
223521285|NCT04546243|PROCEDURE|resection group|patients received VATS
223521286|NCT04546243|RADIATION|radiotherapy group|patients received radiotherapy
223521287|NCT01251757|OTHER|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
223521288|NCT01251757|OTHER|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
223521289|NCT04450212|GENETIC|Phase I, Buccal Swab Collection for DNA Isolation|Buccal swab will be taken from study participants for DNA isolation.
223521290|NCT04450212|DIETARY_SUPPLEMENT|Phase II, Vitamin K (Vitacost) Supplementation|1-mg/day phylloquinone (Vitacost; Natures Life K-1 Phylloquinone) for 10 consecutive days. Each dose will be taken in the morning (\~ 8 am), with one half pint of 2% milk to facilitate absorption. Blood and urine samples collection before and during the vitamin K supplementation period.
223521291|NCT03419624|DRUG|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
223521292|NCT03419624|DRUG|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
223521293|NCT03419624|DRUG|Placebo Oral Tablet|Placebo oral tablet once daily
223521294|NCT03419624|DRUG|Placebo injection|Placebo injection once weekly
223521295|NCT03419624|DRUG|Insulin|daily Insulin injections
223521296|NCT03419624|DRUG|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
223521297|NCT02529956|DRUG|UCB4940|"* Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use"
223521298|NCT02529956|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use"
223704172|NCT01142271|PROCEDURE|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
223704173|NCT06295302|DRUG|HWH486|HWH486 capsule was administrated orally
223521299|NCT00837135|OTHER|Screening|"A. SCREENING~1. Consent~2. Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~3. Physical Exam, History, Blood Tests~4. Skin Test (for allergy to saccaromyces cerevisiae) yeast.~5. Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~1. Consent~2. Chemotherapy~3. GI-4000 Vaccine #1 + Prevnar + Activated T Cells~4. GI-4000 Vaccine #2~5. Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
223521300|NCT00837135|BIOLOGICAL|GI-4000 Vaccine|"1. Chemotherapy and Radiation~2. GI-4000 Vaccine #3~3. GI-4000 Vaccine #4"
223521301|NCT00837135|BIOLOGICAL|GI-4000 Vaccine + Activated T Cells|"1. Apheresis #2~2. Chemoradiation~3. Activated T Cells + GI-4000 Vaccine #3~4. GI-4000 Vaccine #4"
223521302|NCT00837135|BIOLOGICAL|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
223521303|NCT05554731|DEVICE|a New Balloon Catheter for Intraairway Hemostasis|In the treatment group, the new balloon catheter was inserted in three steps, that is, the tracheoscope was inserted into the airway to remove the blood in the airway and find the target bronchus.The new airway hemostatic balloon catheter was directly inserted through the tracheoscopy biopsy channel, and then directly inflated and fixed after positioning.Then exit the tracheoscope directly to complete.
223521304|NCT05554731|DEVICE|Traditional Therapy|A six-step technique was adopted to place the traditional balloon catheter, that is, the tracheoscope was entered to find the target bronchus, the guide wire was inserted through the biopsy channel, the tracheoscope was exchanged to exit the tracheoscope, the catheter was entered through the guide wire exchange, the tracheoscope was re-entered, the catheter was positioned, inflated and fixed, and the tracheoscope was withdrawn.
223521305|NCT02709707|DEVICE|Blood glucose monitor|
223704174|NCT06295302|DRUG|Placebo|Matching placebo was administrated orally
224275357|NCT05380726|BEHAVIORAL|Patient education|The intervention received will be a specific patient education for each subject depending on the parameters assessed by the electronic wrist device in real-time. The recommendation are related to different educational topics as hygienic-dietary measures and sleep related habits, or physical activity.
224275358|NCT01376544|DEVICE|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
224275359|NCT01489930|BEHAVIORAL|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
224275360|NCT01489930|BEHAVIORAL|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
224275361|NCT01489930|BEHAVIORAL|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
224275362|NCT04841967|BEHAVIORAL|TELL Tool Intervention|A 60-minute session with decision support information delivered digitally to parents at their homes or other private, quiet location.
224275363|NCT04841967|BEHAVIORAL|eBook Attention Control|A 60-minute session with good parenting principles delivered digitally to parents at their homes or other private, quiet location.
224275364|NCT00776867|DRUG|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
224275365|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gelatin capsule|Participants will intake one gelatin capsule with 75 mg of Pterostilbene cocrystal (ccPT).
224275366|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene free form (PT)|Participants will intake one capsule with 50 mg of Pterostilbene free form (PT)
224275367|NCT06289140|DIETARY_SUPPLEMENT|Pterostilbene cocrystal (ccPT) - Gastro-resistant capsule|Participants will intake one gastro-resistant capsule with 75 mg of Pterostilbene cocrystal (ccPT).
224275368|NCT01896492|DRUG|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
224275369|NCT00337558|DRUG|Solifenacin succinate|tablet
224275370|NCT00337558|BEHAVIORAL|Simplified bladder training|Instructions
224275371|NCT05603858|PROCEDURE|Tenodesis by end button|open reduction of the dislocated hip and stabilization by end button
224275372|NCT03793296|DEVICE|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
224275373|NCT04106817|BIOLOGICAL|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
224275374|NCT02260635|DRUG|Evacetrapib|Administered orally
224275375|NCT02260635|DRUG|Placebo|Administered orally
224275376|NCT00006124|DRUG|celecoxib|Given orally
224275377|NCT00006124|DRUG|placebo|Given orally
224275378|NCT00000516|DRUG|enalapril|
224275379|NCT02798419|DRUG|DFD05 Cream|
224275380|NCT02798419|DRUG|Active01 Cream|
224275381|NCT05167617|DRUG|Vit D|Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
224275382|NCT03201341|OTHER|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
224275383|NCT03201341|OTHER|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
224275384|NCT03201341|OTHER|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
224275385|NCT03201341|OTHER|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
224275386|NCT03201341|OTHER|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
224275387|NCT03201341|OTHER|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
224275388|NCT03201341|OTHER|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (\~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
224275389|NCT03201341|OTHER|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
224275390|NCT06471179|DEVICE|Functional MRI|Functional Magnetic Resonance Imaging during rest for minutes and analysis of data obtained from resting fMRI
223521306|NCT03097640|OTHER|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
223521307|NCT04426357|DRUG|JNJ-64417184|Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1.
223521308|NCT05753228|OTHER|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)|MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
223521309|NCT05753228|OTHER|Chalder Fatigue Scale|The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
223521310|NCT05753228|OTHER|Health Questionnaire (EQ-5D-5L)|"The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems."
223521311|NCT05753228|OTHER|Hamilton Depression Rating Scale|The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
223521312|NCT06558435|OTHER|FEES|Single group
223521313|NCT06563778|DRUG|Chidamide; Decitabine; Anti-PD-1 Antibody|Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
223521314|NCT06563778|DRUG|Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody|Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
223521315|NCT00691509|GENETIC|gene expression analysis|
223521316|NCT00691509|GENETIC|polymorphism analysis|
223521317|NCT00691509|OTHER|high performance liquid chromatography|
223521318|NCT00691509|OTHER|laboratory biomarker analysis|
223521319|NCT00691509|OTHER|mass spectrometry|
223521320|NCT00691509|OTHER|questionnaire administration|
223521321|NCT05105620|DIAGNOSTIC_TEST|Fluorescein Angiography|Fluorescein Angiography for pateints with diabetes using fundus camera (TRC-NW8F retinal camera; Topcon Corporation, Tokyo, Japan).
224275391|NCT00152516|DRUG|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
224275392|NCT03011879|OTHER|clinical pathway|
224275393|NCT00630903|DRUG|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
224275394|NCT00630903|DRUG|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
224275395|NCT00360490|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
224275396|NCT00360490|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
224275397|NCT00451490|DRUG|Agomelatine|
224275398|NCT00451490|DRUG|Fluoxentine|
224275399|NCT03563885|PROCEDURE|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
223521322|NCT05105620|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography for pateints with diabetes using • Topcon DRI OCT Triton device (ver.10.13; Topcon Corporation, Tokyo, Japan).
223521323|NCT02796651|DRUG|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
223521324|NCT02796651|DRUG|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
223521325|NCT02796651|DRUG|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
223521326|NCT02796651|DRUG|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
223521327|NCT02796651|DRUG|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
223521328|NCT04331951|DIAGNOSTIC_TEST|Targeted biopsy within Sydney protocol|Biopsy at suspicious GIM lesions at any area of antrum (both lesser and greater curvature site), body (both lesser and greater curvature site) and incisura. If there is no abnormal mucosa seen at any site, random biopsy will be performed.
224275400|NCT04130685|DIAGNOSTIC_TEST|Allosure Test|Venous Blood Draw
223521329|NCT01013259|DRUG|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
223521330|NCT01013259|DRUG|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
223521331|NCT05014919|DRUG|Vortioxetine|Tablets
224275401|NCT01611415|DRUG|Ipragliflozin|Oral
224275402|NCT01611415|DRUG|Furosemide|Oral
224275403|NCT03749915|DEVICE|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
224275404|NCT03749915|DRUG|Ametop|Tetracaine Hydrochloride Gel 4%
224275405|NCT02476305|DEVICE|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
224275406|NCT03117205|OTHER|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
224275407|NCT03117205|OTHER|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
224275408|NCT03211351|DRUG|Liposic|one eye of the participant recieved Lipoic
224275409|NCT03211351|DRUG|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
224275410|NCT03562845|OTHER|NA-Observational only|NA-Observational only
223521332|NCT05014919|DRUG|Placebo|Tablets
223521333|NCT04684212|DEVICE|LAmbre PlusTM Left Atrial Appendage Closure System|The LAmbre Plus device is a self-expanding occluder, composed of a distal Umbrella and a proximal Cover laser welded together, delivered percutaneously via femoral venous access and trans-septal puncture. The distal Umbrella consists of an elastic nitinol frame and outer PET membrane, and has circumferential anchors to secure the occluder to the left atrial appendage (LAA) wall. The proximal Cover is a disc of elastic nitinol mesh, which seals the orifice of the LAA and minimizes thrombus formation, and includes a PET membrane to prevent the passage of blood into the LAA after implantation.
223521334|NCT04684212|DRUG|Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)|Continuation of market approved OAC drug.
223521335|NCT00680914|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
223521336|NCT00680914|BIOLOGICAL|Prevenar|3 doses administered intramuscularly.
223521337|NCT00680914|BIOLOGICAL|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
223521338|NCT05721729|DRUG|Mizagliflozin|Encapsulated
223521339|NCT05721729|DRUG|Placebo|Encapsulated
223521340|NCT01321905|DIETARY_SUPPLEMENT|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
223521341|NCT05745961|RADIATION|TSPO PET scan (11C-PBR28)|PET scan
223521342|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
223521343|NCT03851666|DIETARY_SUPPLEMENT|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
223521344|NCT03851666|OTHER|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
223521345|NCT02971163|BEHAVIORAL|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
223521346|NCT05698498|OTHER|Guaranteed Income|Guaranteed income payments will be disbursed monthly for a total of 24 months to participants who are randomized to the guaranteed income intervention group. Participants will be given the choice to select from one of two different payment strategies (equal monthly payments of $1,000/month vs hybrid payment schedule with initial amount of $6,500 the first month followed by $500/month x 11 months); payment strategy preferences will be re-assessed after 12 months. The choice of payment strategy will be strictly left to participants to specify.
223521347|NCT05698498|OTHER|Public Benefits Information Session|All participants (both the control and intervention groups) will be offered the option of attending a Public Benefits Information Session during which they will receive a comprehensive resource directory of public benefit, assistance, and social service programs available to residents of Santa Clara County, have the opportunity to ask questions about enrolling in those programs, and also have the opportunity to seek additional benefits navigation assistance from our community partner, Sacred Heart Community Service. This session is intended to be optional, with the decision to attend and participant to be left to the discretion of each study participant. Attendance is not required for study participation.
223521348|NCT02959346|PROCEDURE|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
223521349|NCT02959346|PROCEDURE|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
223534908|NCT04795375|BEHAVIORAL|Physical Activity counseling|"The Physical activity counseling techniques will be based on the Self Determination Theory and Five A's (Assess, Advise, Agree, Assist, Arrange). Guidelines for physical activity will include combined aerobic and resistance exercises.~Each participant in the intervention group will receive personal exercise prescriptions in accordance the post-surgical statues and exercise recommendations after bariatric surgery. Participants will receive long term follow-up and accompaniment during the first six months after the surgery, through Personal meetings with a certified nurse, Phone-calls, motivational massages, and Exercise Videos."
223521350|NCT04868071|BEHAVIORAL|Physical Exercise|Exercise interventions were carried out over a total of 16 weeks in the mornings (08:00 am-12:00 am) under the supervision of at least two fitness instructors. Participants performed four exercises for lower limbs (Figure 9): 1st) squat on the chair, 2nd) seated unilateral hip flexion, 3rd) seated unilateral knee extension, and 4th) bilateral calf raise with 12-15 submaximal repetitions avoiding fatigue (i.e., inability to complete a repetition in a full range of motion). The number of sets was increased linearly during the first month, such that one set was performed in the 1st week, two sets in the 2nd week, 3 sets in the 3rd week, and 4 sets in the 4th week. Subsequently, participants performed the main exercise period. After a brief warm-up, participants performed the same exercises that were performed during the familiarization period using an adjustable weight vest and ankle weights (DOMYOS®, Shangai, China).
223521351|NCT00539500|DRUG|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
223521352|NCT00539500|DRUG|Etoposide|300 mg/m\^2 by vein over 24 hours for 4 days
223521353|NCT00539500|DRUG|Melphalan|70 mg/m\^2 Intravenous Bolus for 3 Days
223521354|NCT00539500|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.
223521355|NCT00539500|DEVICE|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
223521356|NCT00804232|BEHAVIORAL|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
223521357|NCT03376282|OTHER|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
223521358|NCT04910165|DRUG|Exparel|Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
223521359|NCT04910165|DRUG|Ropivacaine|Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
223521360|NCT01287208|DEVICE|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
223521361|NCT01287208|DEVICE|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
223521362|NCT02252510|OTHER|HALOSPERM|
223521363|NCT06395766|DIAGNOSTIC_TEST|BREF,MSPSS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL )~2. the Zimet Multidimensional Scale of Perceived Social Support -. The original version on the MSPSS"
223521364|NCT04037137|OTHER|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
223521365|NCT01586715|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
223521366|NCT00104403|DRUG|GW679769|
223521367|NCT00104403|DRUG|Dexamethasone|
223521368|NCT00104403|DRUG|Ondansetron Hydrochloride|
223521369|NCT05531942|DRUG|Ginkgo Diterpene Lactone Meglumine Injection|The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
223521370|NCT05531942|DRUG|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
223521371|NCT01855503|PROCEDURE|Core Biopsy|
224275411|NCT04763447|OTHER|Attempt to withdrawal OMA treatment|Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
223521372|NCT03828526|OTHER|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
223521373|NCT03828526|OTHER|Traditional teaching strategy|Classroom-based strategy
223521374|NCT03073512|OTHER|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
223521375|NCT02054728|OTHER|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
223521376|NCT04007731|DIETARY_SUPPLEMENT|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
223521377|NCT04007731|DIETARY_SUPPLEMENT|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
224275412|NCT04763447|DRUG|Continuation of OMA treatment|"Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care."
223521378|NCT02392169|DRUG|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
223521379|NCT00559039|OTHER|questionnaire administration|
223521380|NCT00559039|PROCEDURE|evaluation of cancer risk factors|
223521381|NCT01491919|DRUG|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
224275413|NCT02999698|OTHER|Observational|Observational
224275414|NCT00508898|DRUG|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
224275415|NCT00508898|DRUG|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
224275416|NCT03518723|OTHER|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
224275417|NCT03518723|OTHER|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
224275418|NCT01257191|DRUG|Carbon Black|source: commercial
224275419|NCT01257191|DRUG|Diesel Exhaust Particles|source: diesel engine
223521382|NCT04905641|PROCEDURE|Bilateral intermediate cervical plexus block|Bilateral intermediate cervical plexus block was performed under ultrasound guidance.
223521383|NCT04003389|DRUG|fezolinetant|administered orally
223521384|NCT04003389|DRUG|placebo|administered orally
223521385|NCT04986189|DIAGNOSTIC_TEST|Low dose CT thorax|A low dose CT scan of the thorax to screen for lung cancer
223521386|NCT05642975|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
223521387|NCT03833583|DEVICE|Soterix Medical mini-CT tDCS stimulator|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
223521388|NCT06536972|OTHER|knowledge|"Develop an instrument to evaluate knowledge about humidification systems among different health professionals in intensive care units (ICU).~Describe the knowledge about humidification systems among different health professionals in intensive care units (ICU)."
223521389|NCT06064162|DRUG|ketamine|60mg (.5mg/kg over 40 minutes intravenously)
223521390|NCT05377723|DEVICE|Neodyne Device|See Arm Description: Neodyne Device
223521391|NCT03996018|OTHER|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
223521392|NCT02871219|DRUG|Lenalidomide|Given PO
223521393|NCT02871219|BIOLOGICAL|Obinutuzumab|Given IV
223521394|NCT05156203|DRUG|T-1301 Capsules|T-1301 Capsules, 10 and 50 mg, are opaque hard gelatin capsules for oral administration.
223704175|NCT00435864|PROCEDURE|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
223521396|NCT04255043|DEVICE|IVUS guidance|IVUS (Boston Scientific®) guidance + DCB (Sequent® Please) treatment
223521397|NCT04255043|DEVICE|Angiography guidance|DCB (Sequent® Please) treatment
223521398|NCT04725071|DIETARY_SUPPLEMENT|Impact Advanced Recovery|L-arginine and omega-3 rich supplement
223521399|NCT04725071|DIETARY_SUPPLEMENT|Boost High Protein|conventional supplement
223521400|NCT06002152|DRUG|Bupivacaine|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of 0.25% bupivacaine on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
223521401|NCT06002152|DRUG|Placebo|After anesthesia induction and prior to the start of surgery, the superficial cervical plexus block will be performed according to standard protocol by an experienced blinded clinician. In this arm, participants will receive 10 milliliters of saline on both sides of their neck for this block. This will be the only intervention administered for purposes of this study.
223521402|NCT06324695|BEHAVIORAL|HautKompass|The HautKompass program is a structured self-guided online psychosocial intervention designed to reduce self-stigma in people with visible chronic skin diseases. It combines educational content and practical exercises based on cognitive-behavioral therapy (CBT), namely cognitive restructuring of negative automatic thoughts and cultivating self-compassionate thinking and behavior. The program consists of eight skin-generic modules (on average, 15-20 minutes per module, one module per week).
223521403|NCT02081768|RADIATION|90yttrium colloid|90yttrium colloid will be inserted into a sellar/parasellar cyst
223521404|NCT06296706|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
223521405|NCT06296706|DRUG|Taxotere (docetaxel)|Taxotere, by intravenous infusion, every 3 weeks.
223521406|NCT03196089|PROCEDURE|Oxygen application|Supplemental oxygen via mask
223521407|NCT03004807|DIETARY_SUPPLEMENT|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
223521408|NCT03004807|OTHER|Control|A matching tablet to the dietary supplement, but without any active ingredients
223521409|NCT06642623|DRUG|Enavogliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
223704176|NCT03473535|COMBINATION_PRODUCT|BEACON + Problem Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application.
223704177|NCT03473535|BEHAVIORAL|Problem-Solving Therapy|Six sessions of face-to-face PST delivered by a trained Research Therapist.
224275420|NCT01257191|DRUG|Fine Concentrated Ambient Particles|source: concentrated ambient air
224275421|NCT01257191|DRUG|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
224275422|NCT01257191|DRUG|Saline|Saline solution
224275423|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 25 gauge spinal needle|the investigators performed spinal anesthesia with 25 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
224275424|NCT05777694|PROCEDURE|Patients who underwent cesarean section under spinal anesthesia with 26 gauge spinal needle|the investigators performed spinal anesthesia with 26 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
224275425|NCT05777694|PROCEDURE|Patients who underwent cesarean section operation under spinal anesthesia with 27 gauge spinal needle|the investigators performed spinal anesthesia with 27 gauge pencil point spinal needle to that patient group for prevent postdural puncture headache
224275426|NCT04228627|DRUG|Parentral Iron|Correction of Iron stores without anaemia
223521410|NCT06642623|DRUG|Dapagliflozin or Empagliflozin|The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.
223521411|NCT06643013|DRUG|XBD173|4 weeks treatment
223704178|NCT00697788|DRUG|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine \[in ug/kg/hr\], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
223704179|NCT02432742|DEVICE|Restylane Perlane|Intradermal injection
223704180|NCT02432742|DEVICE|Restylane|Intradermal injection
223521412|NCT06638580|DIAGNOSTIC_TEST|Clinical Periodontal Measurements (plaque index, gingival index, bleeding index, clinical attachment level), Optical Coherence Tomographic Measurements, Serum IL1-β, TNF-α, IL-10, TAS, TOS, OSİ levels|"Probing pocket depth (PPD) was measured as the distance between the deepest point of the sulcus (or pocket) and the gingival margin, and clinical attachment level (CAL) was measured as the distance between the base of the pocket and the cementoenamel junction. PPD and CAL were measured at six different points (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) in each tooth, and other index scores were taken at four different points (mesial, distal, vestibular and palatinal).~Serum IL1-β, TNF-α, and IL-10 levels were measured via immunosorbent assay method using human-specific kits according to the kit manufacturer's instructions.~Serum total antioxidant status (TAS) and total oxidant status (TOS) levels were mea-sured by a spectrophotometric method using specific kits.~Retinal and choroidal imaging and measurements were performed with optical coherence tomography (SS-OCT) with swept-source (SS) technology and non-invasive OCT angiography."
223521413|NCT06642805|PROCEDURE|duodenal atresia|surgery for duodenal atresia
223521414|NCT03248661|BEHAVIORAL|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
223521415|NCT05841771|DRUG|Venetoclax|"Participants will receive maintenance therapy with venetoclax and azacitidine or decitabine after allogeneic stem cell transplantation.~Azacitidine will be administered once daily subcutaneously (32mg/m2/d) on days 1-5, and venetoclax will be administered once daily orally (400mg/day) on days 1-7. If the patient is refractory or allergic to azacitidine, they will receive decitabine. Decitabine will be administered intravenously (5mg/m2/d) on days 1-5. If the patient is treated with CYP450 inhibitors(such as posaconazole or voriconazole), the dose of venetoclax will reduce to 100 mg once daily on days 1-7. Maintenance therapy will start from the 60th to 120th days after allogeneic hematopoietic stem cell transplantation and repeat every 28 days for up to 10 cycles within the first year after transplantation."
223521416|NCT05841771|DRUG|Azacitidine or decitabine|azacytidine 32mg/m2 or decitabine 5mg/m2
223521417|NCT03975660|DEVICE|Pain Measurement Device|When participants request labor analgesia, the sensors of the pain measurement device (ROPA System \[CereVu Medical, Inc. San Francisco, CA\] and Edwards Foresight device) will be applied to the forehead and connected to the device. Data recording is then started.
223521418|NCT05494073|PROCEDURE|ACL Reconstruction with Hybrid Remnant Repair|The intervention includes the incorporation of the host ACL remnant into the graft. The intervention hopefully
223521419|NCT05494073|PROCEDURE|ACL Reconstruction without Hybrid Remnant Repair|ACL reconstruction without preservation or incorporation of host ACL remnant
223521420|NCT04678544|DEVICE|Scalp cooling system 2|"The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.~After the RCT, 34 patients who were expected to receive 4, 6, or 8 cycles of chemotherapy with an anthracycline regimen were further enrolled in the intervention group as a single-arm trial."
223521421|NCT04511468|DIETARY_SUPPLEMENT|Zinc, Chromium, Vitamin C, and Copper Supplementation|Combination of mineral and vitamin supplementation that consist of Zinc, Chromium, Vitamin C, and Copper
223521422|NCT04511468|BEHAVIORAL|Standard healthy lifestyle intervention|Standard healthy lifestyle intervention will follow the Guidelines on the Management and Prevention of Prediabetes by the Indonesian Ministry of Healthy and the Indonesian Diabetes Association.
223521423|NCT04511468|OTHER|Placebo|Placebo with inactive ingredients
223521424|NCT06185803|PROCEDURE|anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction
223521425|NCT06477094|DEVICE|Stratus Nimbus Electrosurgical RF Multi-Tined Expandable Electrode|Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stratus Nimbus Electrode
223521426|NCT06477094|DEVICE|Stryker Venom Radiofrequency Cannula|Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stryker Venom Cannula
223521427|NCT06335706|BEHAVIORAL|Fit of underpants worn|Tight or loose-fitted underpants
223521428|NCT02389517|DRUG|Ixazomib Citrate|Given PO
223521429|NCT02389517|DRUG|Lenalidomide|Given PO
223521430|NCT02389517|DRUG|Dexamethasone|Given PO
223521431|NCT04437823|BIOLOGICAL|Intravenous Infusions of Stem Cells|Cultured stem cells will be injected at days 1, 3 and 5 intravenously. While patients will be monitored and evaluated for various hematological and organ functions at baseline (day 0) and days 1, 3, 5, 7, 14, 21 and 30
223521432|NCT05309746|PROCEDURE|Laparoscopic surgery|Surgery used to remove the child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into the child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of the child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
223521433|NCT04283279|OTHER|Virtual reality exercise|"Participants will do exercises in a virtual environment, solving tasks that require cognitive efforts and motor/balance efforts. The virtual environment/tasks will be delivered through a head-mounted display (goggles). Difficulty will progress from standing/sitting, to walking on a treadmill. The environments that will be used will be both over-the-counter environments, as well as in-house designed environments."
223704181|NCT05374733|DIAGNOSTIC_TEST|Coronary Physiology assessment|"1. Pd/Pa, diastolic pressure ratio (dPR), resting full cycle ratio (RFR), FFR, coronary flow reserve (CFR), and index of microvascular resistance (IMR) measurements in the coronary of interest before the valvular intervention.~2. Pd/Pa, dPR, RFR, FFR, vFFR, CFR and IMR measurements in the coronary of interest after the valvular intervention."
224275427|NCT01517867|BEHAVIORAL|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
223704182|NCT06277596|OTHER|Exercise|Clinical Pilates exercises (basic and advanced stabilization exercises)
223704183|NCT05521620|BEHAVIORAL|The father-friendly NICU|"* Fathers have skin-to-skin contact with their infants~* Fathers participate in important situations~* Fathers receive information and guidance directly~* Both parents participate in meaningful conversations~* The department organize mother and father groups~* The families have the opportunity to have a close family member to support them~* Older siblings have the opportunity to stay overnight.~* The department offer counseling by a social worker"
223521434|NCT04283279|OTHER|Vestibular rehabilitation exercise|Vestibular rehabilitation exercises focus on head and eyes movements, as well as whole-body movements. The aim is to facilitate the use of other sensory organs than the vestibular organs, which will also be relevant to persons who are not receiving sufficient sensory information from the auditory system. The exercises will progress as tolerated, under careful supervision of trained therapists.
223704184|NCT04496700|PROCEDURE|Whole blood donation and transfusion|"The effect of whole blood donation on physical performance:~Donation of 450 ml whole blood - one time only."
223704185|NCT00594048|DEVICE|Resperate|Use of the device 15 minutes a day for 9 weeks
223704186|NCT00594048|DEVICE|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
223521435|NCT04283279|OTHER|Control|Participants will not be randomised to either of the exercise interventions, but will be adviced to stay active
223521436|NCT03622515|COMBINATION_PRODUCT|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
223521437|NCT00117442|DRUG|carboplatin|Chemotherapy
223521438|NCT00117442|DRUG|paclitaxel|chemotherapy
223521439|NCT00117442|DRUG|pegfilgrastim|Growth factor for mobilization
223521440|NCT03105765|DRUG|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
223521441|NCT03105765|DRUG|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
223521442|NCT06127771|OTHER|Programming DBS using Percept PC neurostimulator's full potential|This study aims to enroll patients who previously had Activa PC neurostimulator and underwent a battery change to Medtronic PerceptTM PC as standard-of-care. However, in this study, the investigators intent to fully utilize the programming potential of Medtronic PerceptTM PC to optimize treatment outcome.
223521443|NCT00257933|DRUG|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
223521444|NCT00257933|DRUG|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
223521445|NCT02821650|OTHER|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
223521446|NCT01627106|DRUG|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
223521447|NCT01627106|DRUG|Amiodarone|Administered IV as per product label
223521448|NCT02019836|OTHER|Determining maternal and neonatal vitamin D levels|
223521449|NCT06239285|DEVICE|Brief Violence Intervention VR (BVI-VR)|BVI-VR is being developed as a hospital-based brief gun violence intervention program founded on the principles of positive psychology, motivational goal setting (via gameplay), psychoeducation, cognitive-behavioral therapy, and dialectical behavioral therapy. All steps of the BVI-VR emphasize being in control of making positive choices, and how to locate and leverage opportunities within their communities to improve their well-being. BVI-VR empowers patients to be the driver of their well-being
223521450|NCT06239285|OTHER|Treatment as Usual (TAU)|group will receive a community resource brochure (the same one that is provided at the end of BVI-VR). This brochure provides contact detail for services in the local area. These include organizations that provide mental health counseling, mentorship services, career development programs, organized community activities and sports, educational support, financial support, substance abuse programs, and resource assistance (e.g., food, housing, etc.).
223521451|NCT05302609|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in reinforcement of scleral thinning.
223521452|NCT06496659|PROCEDURE|Segmentectomy|A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
223704187|NCT05527197|DEVICE|Lapiplasty|The Lapiplasty® System instruments and implants will be retrospectively evaluated in patients previously surgically treated with the Lapiplasty® Procedure for Triplane MTP and TMT joint arthrodesis.
223704188|NCT06315348|PROCEDURE|flapless alveolar decortication with augmentation|piezocision-assisted orthodontics, concomitant to soft tissue grafting (volume-stable collagen matrix), with piezocision-assisted orthodontics, concomitant to bone grafting with a xenograft and a native collagen membrane. Piezocisions will be performed using a piezoelectric device.
223704189|NCT03005145|OTHER|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
223704190|NCT03005145|OTHER|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
223704191|NCT00689078|DRUG|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
223704192|NCT00689078|DRUG|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
223704193|NCT00689078|DRUG|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
223704194|NCT00689078|DRUG|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
223704195|NCT00385710|DRUG|valproic acid|Depakine
223521453|NCT05114018|DIETARY_SUPPLEMENT|Pasteurized A. muciniphila|Daily oral dose
223521454|NCT05114018|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
223521455|NCT06431919|DRUG|Simvastatin 20mg|Simvastatin fixed dose of 20 mg per day
223521456|NCT06431919|DRUG|Carvedilol 3.125 mg|Carvedilol: Starting dose of 3.125 mg twice daily targeted upwards q 7 days to achieve target heart rate
223521457|NCT05824702|BEHAVIORAL|Peer education & communications|The intervention trains peer educators to promote medication-assisted drug treatment among peer who inject drugs and are living with HIV.
223521458|NCT05824702|BEHAVIORAL|Standard of care educational|This is an educational equal attention control group
223521459|NCT04737603|DRUG|ED-Initiated treatment with buprenorphine / naloxone|A Clinical Opiate Withdrawal Score (COWS) score will be administered, and an induction dose of buprenorphine when COWS scores \>=8. Participants who weigh \> 70 kg and/or reported using ≥ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg. After 1 hour an additional 4 mg will be administered for a total of 8 mg. Participants who weigh \<= 70 kg and/or reported using ≤ 3 bags of heroin/day or its prescription opioid equivalent will receive 4 mg of buprenorphine. After 1 hour, an additional 2 mg will be administered for a total of 6 mg. Patients will be prescribed sufficient take-home daily doses (one-week supply) to ensure that the patient has adequate medication to receive 12-16 mg buprenorphine sublingual once daily. Parents of adolescents will also receive appropriate education on how to administer medication. Home induction instructions will be provided to patients and parents that arrive to the ED after an opioid overdose.
223521460|NCT06477016|DEVICE|OsciPulse|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
223521461|NCT06477016|DEVICE|Intermittent Pneumatic Compression|Non-invasive device that provides rapid pulses of compression of the calves to modify venous blood flow patterns in immobilized persons.
223521462|NCT06585384|COMBINATION_PRODUCT|etanercept and repeated contrast ultrasound|Strategy combining 9 weeks of etanercept administration (50mg/week) with 5 weeks of repeated contrast ultrasound of 2 sessions per day, 5 days per week (from the fifth week of etanercept treatment)
223521463|NCT01597700|DRUG|10mg Ezetimibe|1 tablet taken by mouth
223521464|NCT01597700|DRUG|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
223521465|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/100|5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
223521466|NCT03213405|BIOLOGICAL|rBCG-N-hRSV 1/10|5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
223521467|NCT03213405|BIOLOGICAL|rBCG-N-hRSV full dose|1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
223704196|NCT00385710|DRUG|Placebo|Placebo
223704197|NCT01188421|DRUG|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
223704198|NCT01188421|DRUG|Clonidine|up to 0.8 mg per day (oral)
223704199|NCT01188421|DRUG|Tramadol ER|up to 600 mg per day
223704200|NCT06036823|DRUG|Insulin regular|Intravenous insulin
223704201|NCT06036823|DRUG|Dextrose 50|to be given to both arms
223704202|NCT06036823|DRUG|salbutamol|to be given to all patients
223704203|NCT05536583|PROCEDURE|Laparoscopic sleeve Gastrectomy|Laparoscopic sleeve Gastrectomy
223704204|NCT00075218|DRUG|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
223704205|NCT00075218|DRUG|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
223704206|NCT03401593|DRUG|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
223521468|NCT03213405|BIOLOGICAL|Conventional BCG full dose|2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
223704207|NCT05043909|BEHAVIORAL|VR-based training|Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
223704208|NCT06292234|DEVICE|PSI|Fabrication of PSI implants using virtual surgical planning
223704209|NCT06292234|DEVICE|Conventional miniplates|Ready made miniplates
223704210|NCT03840174|BIOLOGICAL|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
223704211|NCT03840174|OTHER|Placebo|Saline solution (0.9% sodium chloride \[NaCl\] administered as a 0.5 mL IM injection
223704212|NCT05203640|BEHAVIORAL|High repetition (HI)|Participants will perform 15 to 20 repetitions of 7 different exercises at 50% of their one repetition maximum
223704213|NCT05203640|BEHAVIORAL|Moderate repetition (MOD)|Participants will perform 8 to 10 repetitions of 7 different exercise at 75-80% of their one repetition maximum
223704214|NCT00131508|DRUG|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
223704215|NCT00131508|DRUG|Placebo|Placebo
223704216|NCT00171483|DRUG|Tegaserod|
223704217|NCT04269707|DRUG|Ferric carboxymaltose|IV iron
223704218|NCT03922126|OTHER|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
223704219|NCT03922126|DIAGNOSTIC_TEST|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
223704220|NCT05393011|DRUG|human chorionic gonadotropin|10000 IU when at least three follicles become more than 16 mm
223704221|NCT00250120|DRUG|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
223521469|NCT04426591|DRUG|Biotin Labeled Red Blood Cells|On the day of transfusion, a 20 mL aliquot will be sterilely withdrawn from each RBC unit, washed and labeled with sulfo-NHS-biotin for 30 minutes, washed to stop the labeling reaction, then resuspended in plasma to a hematocrit of \~60%. The biotin-labeled RBC (BioRBC) will be transfused along with the remainder of the RBC unit (unlabeled volume). Standard blood bank and CTT protocols and minor antigen matching for SCD patients will be followed. Exact transfusion volume will be determined based on pre-transfusion hemoglobin (Hb), sickle cell hemoglobin (HbS), and body weight, per clinical protocol.
223521470|NCT04426591|DEVICE|INTERCEPT Blood System|In addition to the blood drawn for the main study, individuals participating in this optional intervention will have additional tubes of peripheral venous blood will be drawn for evaluating treatment-emergent antibodies specific to INTERCEPT RBCs and acridine surface label monitoring. Tests for treatment-emergent antibodies specific to INTERCEPT RBCs will be performed according to procedures developed by Cerus Corporation.
223521471|NCT05375929|DRUG|Abrocitinib 100 mg|Orally administered, abrocitinib 100 mg tablets QD
223521472|NCT05375929|DRUG|Abrocitinib 200 mg|Orally administered, abrocitinib 200 mg tablets QD.
223521473|NCT02873962|DRUG|Bevacizumab|"* Bevacizumab will be given intravenously at a pre-determined dosage~* One dose reduction will be allowed for Bevacizumab"
223521474|NCT02873962|DRUG|Nivolumab|"* Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~* No dose reductions or escalations will be allowed for Nivolumab"
223521475|NCT02873962|DRUG|Rucaparib|"* Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~* Up to three dose reductions will be allowed for Rucaparib (depending on cohort)."
223521476|NCT06549647|OTHER|low caloric diet|A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
223521477|NCT06549647|OTHER|Placebo laser acupoint stimulation|Placebo laser acupoint stimulation will be used for all participants in group (A).
223704222|NCT01880281|OTHER|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
223521478|NCT06549647|OTHER|Laser Acupuncture|Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
223704223|NCT03555734|OTHER|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
223704224|NCT02371148|DRUG|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22\* Rituximab: 375 mg/sqm i.v. day 1\*\* Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles \*In case of toxicity is omitted~\*\*In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
223521479|NCT03916419|DEVICE|ViewRay MR-Linear Accelerator|-Radiation will be delivered by this machine
223521480|NCT03916419|RADIATION|Radiation therapy|-60Gy in 15 fractions
223521481|NCT03916419|DRUG|Paclitaxel|-50 mg/m\^2 intravenous
223521482|NCT03916419|DRUG|Carboplatin AUC|-2 mg/mL/min intravenous over 30 minutes
223704225|NCT03214315|PROCEDURE|Visceral adipose tissue specimen|specimen
223704226|NCT01830231|DRUG|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
223704227|NCT01830231|DRUG|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years."
223521483|NCT03916419|BIOLOGICAL|Durvalumab|-10 mg/kg
223521484|NCT02941055|OTHER|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
223521485|NCT02941055|OTHER|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
223521486|NCT06636916|PROCEDURE|Short Intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
223521487|NCT06636916|PROCEDURE|Long intervals HIIT|Participants will undergo different high-intensity interval training (HIIT) protocols, which involve repeated bouts of exercise at an intensity above 90% of VO2max, followed by recovery periods. The work and rest durations will vary across the protocols to assess the impact on the total time spent at or above 90% of VO2max.
223704228|NCT02322476|OTHER|No intervention will be performed|No intervention will be performed
223704229|NCT00618683|PROCEDURE|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
223704230|NCT01195246|BIOLOGICAL|HEPLISAV|Intramuscular (IM) injection on Day1
223704231|NCT01195246|BIOLOGICAL|Engerix-B|Intramuscular (IM) injection on Day 1
223704232|NCT01195246|BIOLOGICAL|Fendrix|Intramuscular (IM) injection on Day 1
223704233|NCT06437496|DRUG|68Ga-AAZTA-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.
223704234|NCT06437496|DRUG|68Ga-PSMA-11//68Ga-PSMA-617|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
223704235|NCT00298584|PROCEDURE|Percutaneous Suprapubic Aspiration|
223521488|NCT03926247|BEHAVIORAL|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
223521489|NCT05718531|DRUG|Rivaroxaban 2.5 Mg Oral Tablet twice daily|effect of rivaroxaban 2.5 mg twice daily on MACE and quality of life in coronary artery ectasia patients.
223521490|NCT05718531|DRUG|Clopidogrel 75 Mg Oral Tablet|Used as control group in 2nd arm and 5th arm
223521491|NCT05718531|DRUG|Aspirin tablet 75 mg|Used as control group in 2nd arm and 5th arm
223704236|NCT00298584|PROCEDURE|Urethral Catheterization|
223704237|NCT06632002|OTHER|DSF1|220 mL
223704238|NCT06632002|OTHER|DSF2|220 mL
223704239|NCT06632002|OTHER|Standard of Care (SOC)|Standard of care
224275428|NCT01517867|BEHAVIORAL|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
224275429|NCT02613286|PROCEDURE|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
224275430|NCT02613286|PROCEDURE|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
224275431|NCT02033317|DRUG|patiromer|15 grams/day (5 grams 3 times daily) administered orally
224275432|NCT01266603|DRUG|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
224275433|NCT01266603|BIOLOGICAL|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
224275434|NCT05746143|DRUG|Zolpidem Tartrate 10 mg|two days preoperatively and five days postoperatively
224275435|NCT05746143|DRUG|Placebo|two days preoperatively and five days postoperatively
224275436|NCT03901690|DRUG|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
224275437|NCT03901690|DRUG|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
223521492|NCT01603251|DRUG|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
223521493|NCT01603251|DRUG|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
223521494|NCT01603251|DRUG|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
223521495|NCT03708809|DEVICE|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
223521496|NCT03708809|OTHER|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
223521497|NCT05142293|OTHER|Ambulatory procedure|In the same-day hospitalization group, some patients will be hospitalized on an ambulatory process
223521498|NCT01348581|DEVICE|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
224275438|NCT04621656|COMBINATION_PRODUCT|January Mobile Application (Sugar AI)|Sugar AI is a mobile health and fitness app the allows participants to log and record health-related data through Continuous Glucose Monitors, Heart Rate Monitors, and manual food, water, and activity logging. Using machine learning data science techniques, the Sugar AI App integrates the data collected to personalize lifestyle recommendations and help individuals optimize their health and wellness.
224275439|NCT04731493|OTHER|Therapeutic Education Program|"* needs assessment~* educational group workshop~* specialized workshops by age group: child / adolescent / transition / adult / entourage / separated parents and in parallel~* socio-administrative workshop~* individual summary (accompanied or not by his entourage / family)~* satisfaction questionnaire"
224275440|NCT00011063|DRUG|Ginkgo Biloba|
224275441|NCT04789187|PROCEDURE|High-Intensity-Interval-Training|Defined exercise program up to four times per week including high-intensity-interval-training for one year of active study intervention.
223521499|NCT03767387|OTHER|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
223521500|NCT00178139|BEHAVIORAL|Music Therapy|Music Therapy
223521501|NCT03405753|DIETARY_SUPPLEMENT|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
223704240|NCT06297902|RADIATION|Dose painting|Dose painting
223704241|NCT04596514|PROCEDURE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)
223704242|NCT04596514|PROCEDURE|usual procedure according to guidelines|Treatment as described in the guidelines from the European Resuscitation Council, the Norwegian Resuscitation Council, and other local national guidelines
223704243|NCT03983824|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223704244|NCT03983824|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224275442|NCT04789187|PROCEDURE|General Physical Activity Recommendations|Patients will be given general physical activity recommendations during chemotherapy.
224275443|NCT03639220|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
224275444|NCT02466386|DRUG|SPD489|Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
224275445|NCT04330495|DRUG|Hidroxicloroquina|Chemoprophylaxis with hydroxychloroquine at a dose of 200 mg twice a day for 6 months.
224275446|NCT04330495|DRUG|Control group|Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
224275447|NCT04799223|OTHER|Four-foods eating guidelines|To follow a healthy eating pattern and consume four (4) foods designed for the study (extra virgin olive oil with olive leaf extract, chickpea dish with spinach, vegetable cream dish, and olive fiber) and to follow a healthy eating pattern.
224275448|NCT04799223|OTHER|No designed-foods eating guidelines|To follow a healthy eating pattern. Their diet is not accompanied by the four newly designed foods of the other group.
224275449|NCT05072821|DRUG|Botulinum Toxin Type A Injection [Botox]|After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.
224275450|NCT05072821|DRUG|0.9% Sodium Chloride Injection|After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
224275451|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes."
224275452|NCT04556123|OTHER|Measurement of the hydration state and decongestive treatment according to clinical judgement alone|Clinical judgement will be performed in each center by a reference physician or nurse
224275453|NCT04487964|DIETARY_SUPPLEMENT|Licorice extract|"LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour"
223521502|NCT03405753|DIETARY_SUPPLEMENT|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
223521503|NCT03191032|OTHER|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
223521504|NCT05081271|BIOLOGICAL|Homologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
223521505|NCT05081271|BIOLOGICAL|Heterologous booster|Group 1 will receive a booster dose of a homologous vaccine and Group 2 a heterologous vaccine. This means Ad26.COV2.S if they originally received BNT162b2 or mRNA-1273 or vice versa
223704245|NCT03983824|DRUG|Cytarabine|Given IV
224275454|NCT00367536|DRUG|bazedoxifene/conjugated estrogens combination tablet|
224275455|NCT05377606|PROCEDURE|Pars plana vitrectomy with silicone oil|Silicone oil will be used at the end of primary vitrectomy. OCT, OCTA and microperimetry will be done 2 months later. Silicone oil will be removed at 3 months. Finally, the OCT, OCTA, and microperimetry will be repeated once more after 4 months from the vitrectomy.
224275456|NCT05377606|PROCEDURE|Pars plana vitrectomy with SF6|Sulfur hexafluoride (SF6) will be used at the end of primary vitrectomy. OCT, OCTA, and microperimetry will be done 2 months and 4 months after surgery.
224275457|NCT00120315|DRUG|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
224275458|NCT00120315|PROCEDURE|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
223521506|NCT04691492|BEHAVIORAL|Friend-Based Motivational Interview|The intervention will use Motivational Interviewing's (MI) collaborative conversation style for strengthening commitment to change, to motivate and prepare women to work together to reduce Sexual Assault (SA) risk. This intervention will target ways that the friend dyad may support, encourage, and share responsibility with one another in protecting against SA. The Friend-based MI (FMI) will then use the responsibility and relationship of friends as a framework to foster collaborative efforts to increase readiness and decrease barriers to helping behavior. As part of this, the FMI will focus on the identification and implementation of skills friends can use to help one another prevent sexual assault. FMI will include a focused discussion of the ways drinking may impede helping efforts. Moreover, the FMI will encourage women to identify personal, specific strategies for reducing the effects of alcohol on helping.
223521507|NCT04310774|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug)|CCRT followed by Tegafur, Gimeracil and Oteracil Potassium Capsules consolidation chemotherapy
223521508|NCT01724814|DRUG|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
223521509|NCT01724814|DRUG|Placebo|Singe dose SC administration of Placebo
223521510|NCT01788774|DRUG|Risperidone ISM 50 mg|
223521511|NCT01788774|DRUG|Risperidone ISM 75 mg|
223521512|NCT01788774|DRUG|Risperidone ISM 100 mg|
223521513|NCT04192838|PROCEDURE|Laparoscopic incisional ventral hernia repair|Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
223521514|NCT04192838|PROCEDURE|Open incisional ventral hernia repair|Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
223704246|NCT03983824|PROCEDURE|Echocardiogram Recording|Undergo ECHO
223704247|NCT03983824|DRUG|Etoposide Phosphate|Given IV
223704248|NCT03983824|DRUG|Mitoxantrone Hydrochloride|Given IV
223704249|NCT03983824|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223704250|NCT03983824|DRUG|Peposertib|Given PO
223704251|NCT05962216|DRUG|Brexpiprazole|Brexpiprazole as treatment for psychosis and schizophrenia, and/or as augmentation treatment for depressive disorders
223704252|NCT05224141|BIOLOGICAL|Pembrolizumab/Vibostolimab Co-Formulation|Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
223704253|NCT05224141|DRUG|Saline placebo|Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
223704254|NCT05224141|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
223704255|NCT05224141|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
223704256|NCT05224141|BIOLOGICAL|Atezolizumab|Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
223521515|NCT01270555|DRUG|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
223521516|NCT01754740|DRUG|Uréia|"The subjects were randomly divided into two groups:~1\. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
223521517|NCT01754740|DRUG|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
223521518|NCT04674319|BEHAVIORAL|external cues and cogntive movement strategies|"external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing).~In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task.~During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section."
223521519|NCT01827306|DRUG|Biofreeze|
223704257|NCT05224141|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
223704258|NCT05139004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo AHSCT
223704259|NCT05139004|BIOLOGICAL|Basiliximab|Given IV
223704260|NCT05139004|DRUG|Fludarabine Phosphate|Given IV
223704261|NCT05139004|DRUG|Indium In 111-DOTA-Basiliximab|Given IV
223704262|NCT05139004|DRUG|Melphalan|Given IV
223704263|NCT05139004|BIOLOGICAL|Palifermin|Given IV
223704264|NCT05139004|RADIATION|Total Lymphoid Irradiation|Undergo TMLI
223704265|NCT05139004|RADIATION|Total Marrow Irradiation|Undergo TMLI
223704266|NCT05139004|BIOLOGICAL|Yttrium Y 90 Basiliximab|Given IV
223704267|NCT05744232|BEHAVIORAL|Low calorie total diet replacement|"Summary~1. Weeks 1-12: TDR phase~2. Weeks 13-14: Food reintroduction phase I~3. Weeks 15-16: Food reintroduction phase II~4. Weeks 17 till 20: Food reintroduction phase III~5. Weeks 21 till 24: Maintenance phase"
223704268|NCT05744232|OTHER|Usual care|Participants allocated to the control group will be offered and continue benefiting from standard care. Participants will not be stopped from pursuing any behavioural weight management programme but if they do, this will be recorded.
223704269|NCT03901547|BEHAVIORAL|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
223704270|NCT03901547|BEHAVIORAL|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
223704271|NCT03901547|OTHER|Maslach burnout inventory|Maslach burnout inventory
223521520|NCT02018679|PROCEDURE|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
223521521|NCT02018679|PROCEDURE|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
223521522|NCT01407614|PROCEDURE|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
223521523|NCT00322218|DRUG|Zevalin|"Zevalin study treatment regimen consisted of 2 rituximab i.v. infusions (Day 1 and Day 7-9) and one \[90Y\]-ibritumomab tiuxetan infusion in connection with the second rituximab infusion.~The core treatment regimen in the Zevalin arm was:~Day 1: Rituximab i.v. infusion 250 mg/m\^2~Day 7-to 9: Rituximab i.v. infusion 250 mg/m\^2 immediately followed by \[90Y\]-ibritumomab tiuxetan 14.8 MBq/kg (0.4 mCi/kg) with a maximum dose of 1184 MBq (32 mCi),administered as slow intravenous push over 10 minutes."
223521524|NCT00000709|DRUG|Zidovudine|
223521525|NCT06326541|BEHAVIORAL|music therapy|Listening to the Holy Quran.
223521526|NCT03928015|DRUG|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
223521527|NCT03928015|DRUG|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
223704272|NCT03901547|OTHER|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
223704273|NCT03901547|OTHER|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
224275459|NCT06341504|BEHAVIORAL|Prevention pop-up messages|"Messages are shown full screen on the EGM's play screen on a fixed presentation schedule. Clock of the gambling session starts the first time the participant puts money in the EGM. From this event, messages are shown at those timepoints: \[1\] +10 minutes; \[2\] +40 minutes; \[3\] +70 minutes; \[4\] +100 minutes. Messages block the screen for 15 seconds before automatically closing. Up to 4 different messages are presented during the gambling session. Order is determined by sortition without replacement.~Messages have a warning heading Caution!. Content is, from top to bottom: (a) time spent gambling from beginning; (b) warning that gambling could lead to serious monetary loss; (c) 1 of 4 self-appraisal phrases about current gambling behaviour; (d) advice to the participant that a break could help choose what is best for them; (e) countdown before the message closes itself; (f) Health department logo is shown in the lower right corner as a more neutral endorsement of the messages."
224275460|NCT06341504|BEHAVIORAL|Mandatory time limit|Activated either when (a) the previous time limit is up; or (b) the player bank meter reaches $0. When the previous time limit is up, a pop-up takes up the upper third of the play screen and requires the player to set a new time limit using one of five choice buttons (four firsts buttons: 15, 30, 45 or 60 minutes; fifth button: cash out, which prints a receipt and ends the gambling session). As the EGM cannot track who is playing, there are no limits on consecutive gambling sessions. When the player's bank meter reaches $0, the the pop-up described above appears as soon as new money is inserted in the EGM, no matter if the previous time limit is up or not.
224275461|NCT06341504|BEHAVIORAL|Responsible gambling information|Located in a submenu accessed through a button on the main touch screen. This open a window which contains basic information on randomness and responsible gambling advice. The information is presented in small white font on a black background.
223521528|NCT06209450|PROCEDURE|Ventral hernia repair with mesh fixation|Sutured versus suturless mesh fixation
223521529|NCT03631511|PROCEDURE|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
223521530|NCT05730478|DEVICE|ASOCT&UBM|glaucoma assesment by ASOCT \&UBM
223521531|NCT05730478|DRUG|Glaucoma therapy|ASOCT and UBM parameters Comparison
223521532|NCT05730478|DRUG|Glaucoma therapy|Comparison
223521533|NCT00982579|BIOLOGICAL|MVA.HIVA|1 dose of 5 x 10\^7 pfu of MVA.HIVA administered intramuscularly
223521534|NCT06672133|DRUG|Adebrelimab|Given：IV
223521535|NCT06672133|RADIATION|Radiation Therapy|Undergo radiation therapy
223521536|NCT06613139|DRUG|YHP2305|Test drug: YHP2305 Comparator: YHR2404
223521537|NCT06613139|DRUG|YHR2404|Test drug: YHP2305 comparator: YHR2404
223521538|NCT06673849|OTHER|Rhythmic Stabilization|"Rhythmic Stabilization Program for Children with Cerebral Palsy Objective: Enhance upper extremity strength and stability through rhythmic stabilization exercises.~Program Overview:~Duration: 30-minute sessions Frequency: Once per week for 6 weeks~Exercise Steps:~Positioning: The child positions their upper extremity within their available range of motion.~Isometric Contraction: The child holds an isometric contraction, maintaining the position without movement.~Therapist's Role: Apply resistance that is sufficient to elicit a reaction but not enough to disrupt the isometric contraction.~Progression: Gradually increase the duration of the isometric hold. Increase the amount of resistance applied. Decrease the contact area between the therapist's hands and the child's upper extremity to enhance stability challenges. Monitoring and Adjustments: Assess the child's ability to maintain the contraction and adapt the resistance and support as needed. Encourage the child's engagement."
223521539|NCT06673849|OTHER|Ball Balancing|"Ball Balancing Program Objective: Improve balance and stability. Equipment: 48-inch gymnastic ball~Program Details:~* Duration: 6 weeks~* Frequency: As needed~Steps:~1. Initial Balance:~   * Eyes Open: Balance on hands for 10 seconds.~  * Progression: Increase to 3-5 repetitions of 60 seconds.~2. Eyes Closed: Repeat the above exercise with eyes closed.~3. Variations:~   * Both Hands on One Ball~  * Each Hand on Separate Balls~  * Weaker Arm on One Ball~4. Body Positions: Progress through four body positions with eyes open, then closed.~5. Correction: If the child misses a position, they open their eyes and reposition actively."
223521540|NCT06675396|OTHER|Antidepressants|control
223521541|NCT07009938|DEVICE|Drug-Coated Balloon (DCB)|Following lesion preparation (usually with a standard balloon), a drug-coated balloon is advanced to the target lesion. The balloon is inflated and maintained to allow effective drug transfer to the vessel wall.
223521542|NCT07009938|DEVICE|Drug-Eluting Stent (DES) implantation|After coronary angiography identifies the target lesion, a DES is selected based on the vessel size. Post-deployment angiography is performed to confirm the result and check for complications.
223521543|NCT07011238|DIAGNOSTIC_TEST|Patients meeting HLA immunization criteria|At enrollment visit, a single sample of a volume of 50 ml of blood will be taken as part of routine care in order to directly and simultaneously explore the clonality (BCR repertoire), the phenotype of membrane markers and the transcriptome of Bmem alloreactive with respect to a restricted panel of HLA alleles chosen according to the HLA antibody reactivity profile of the patients analyzed
223521544|NCT07011485|DRUG|Minoxidil 5% Topical Solution|Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
223521545|NCT07011485|DRUG|PDFE-2304 Topical Solution|Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.
223704274|NCT03901547|BEHAVIORAL|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
223704275|NCT04448938|OTHER|MRI|"The MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.~A consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation.~The subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO."
223704276|NCT04448938|OTHER|visual acuity|Patients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital
223704277|NCT06051422|DEVICE|three dimensional formetric system|A three-dimensional computer program that automatically detects pelvic torsion, surface rotation, and anatomical landmarks. Aesculap-Meditec GMBH, based in the Netherlands, creates the Formetric Instrument System. Different subject heights could be accommodated by adjusting the scanner.
223704278|NCT04432259|DRUG|Dexamethasone|4 mg bid for 4 days
223704279|NCT04432259|DRUG|Placebo|oral placebo
223704280|NCT05335629|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor) which is a new class of hypoglycemic drugs, and they can block sodium-dependent glucose transporter-2 (SGLT2) located in the early proximal renal tubule to increase urinary glucose excretion and decrease the concentration of blood glucose
223704281|NCT01479127|DRUG|ABT-SLV187|
223521546|NCT06690177|DRUG|EscharEx (EX-03)|a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
223521547|NCT06690177|DRUG|Placebo (Gel vehicle)|A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
223521548|NCT00908141|BIOLOGICAL|sargramostim|Given subcutaneously on varying schedule
223521549|NCT02207101|DIETARY_SUPPLEMENT|E-OJ-01 (OXYJUN)|
223521550|NCT02207101|DIETARY_SUPPLEMENT|Placebo|
223704282|NCT01479127|DRUG|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
223704283|NCT01479127|DEVICE|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
223704284|NCT01479127|DEVICE|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
223704285|NCT01479127|DEVICE|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
223521551|NCT06752499|DEVICE|Online stimulation|5 Hz rTMS is applied to the primary motor cortex on the affected hemisphere when the patients are performing motor tasks.
223521552|NCT06752499|DEVICE|Offline stimulation|After 5 Hz rTMS is applied to the primary motor cortex on the affected hemisphere, the patients perform motor tasks.
223521553|NCT06752499|DEVICE|Sham stimulation|Sham rTMS is applied to the primary motor cortex on the affected hemisphere when the patients are performing motor tasks.
223521554|NCT06687135|OTHER|KOKU|"KOKU is a digital strength and balance programme designed to prevent physical decline and frailty KOKU provides access to personalised, progressive strength and balance exercises.~More information can be found at: https://kokuhealth.com/"
223521555|NCT06687135|OTHER|FaME / OTAGO leaflet and AGE UK Stay Steady Leaflet|"A leaflet with information on a combination of strength and balance exercises and walking programs, performed on a weekly basis by older adults at home, or community settings. The exercises can be done individually or in a group setting and are aimed at reducing falls in older adults.~More information can be found at: https://fameexercise.com/ and https://www.livestronger.org.nz/assets/Uploads/acc1162-otago-exercise-manual.pdf https://www.ageuk.org.uk/information-advice/health-wellbeing/exercise/staying-steady-download-page/#:\~:text=This%20guide%20outlines%20things%20you%20can"
223521556|NCT06929936|DRUG|Trilaciclib combined with Docetaxel|"Trilaciclib: 240 mg/m2 as a 30-min iv. infusion, completed ≤4h prior to chemotherapy.~Docetaxel: 75mg/m2, iv. infusion for 1 hour on days 1 of each 21-day cycle, totaling 4 cycles of medication."
223521557|NCT02520154|DRUG|Carboplatin|Given IV
224275462|NCT06341504|DEVICE|Electronic gambling machine (model IGT GL20)|"EGM model currently in use in Quebec, Canada, the location where this study is conducted. The EGMs used in this study are fully functional and unaltered except for the presentation of prevention pop-up messages in the experimental arm of this study. These machines are equipped with basics responsible gambling features, the two main ones described in this section (i.e. Mandatory time limit; Responsible gambling information). Wins/losses sequence is fully randomized and not determined beforehand."
224275463|NCT06341504|DEVICE|Square terminal|This terminal allows for buying non-alcoholic beverages (soft drinks or coffee) and chips during the experimentation. This is done to enhance the realism of the bar setting. It also allows for real cash withdrawal from bank account during gambling session. Quebec's code of conduct for EGMs commercialization prohibits retailers from having an ATM near their EGMs, and prohibits them from lending money to consumers or withdrawing cash for them to gamble. However, this rule is not always followed in practice. For this study, participants will be allowed to withdraw from their bank account, at the bar counter, if they ask for it. However, this will not be offered to them upfront.
223521558|NCT02520154|OTHER|Laboratory Biomarker Analysis|Correlative studies
223521559|NCT02520154|DRUG|Paclitaxel|Given IV
223521560|NCT02520154|BIOLOGICAL|Pembrolizumab|Given IV
223521561|NCT02520154|OTHER|Pharmacological Study|Correlative studies
223704286|NCT00531973|DRUG|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
223704287|NCT00531973|DRUG|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
223704288|NCT00004431|DRUG|L-baclofen|
223704289|NCT02707939|OTHER|Observation|Patients will be observed before and after they receive anesthesia
223704290|NCT00242437|DEVICE|Hemostatic matrix|
223704291|NCT00242437|DEVICE|bovine thrombin|
223704292|NCT05176743|BEHAVIORAL|Unconditional Cash Transfer (UCT)|The UCT consists of three $100 VISA merchandise cards provided monthly via mail to participants randomized to the intervention arm. Merchandise cards can be used anywhere that VISA is accepted. Participants in the UCT arm will also receive Usual Care, including referral to the patient support services team and nutritional pamphlets.
223704293|NCT06429111|PROCEDURE|Epidural analgesia|Consists of a central nerve block by injecting a local anesthetic near the nerves that transmit pain, in the lumbar region, for pain relief during labor.
223704294|NCT06429111|PROCEDURE|Immersion water|Consists of the use of hot water immersion in a birthing tub during labor and/or delivery.
223704295|NCT05454280|PROCEDURE|Intensified post-discharge surveillance|"* TCC Nurse Televisit at post-discharge day 1 and 7~* Televisit with APP/Resident/Fellow between post-discharge day 3-5~* Referral for home health nursing evaluation upon discharge"
223704296|NCT05454280|PROCEDURE|Standard post-discharge surveillance|Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.
223704297|NCT02272660|DRUG|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
223704298|NCT02272660|DRUG|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
223704299|NCT05595941|OTHER|tele-yoga|"Each session will include postural exercises (asanas), standing, sitting and lying down, in order to work on balance, muscular strength and endurance, as well as flexibility. They will be adapted to the physical possibilities of the patients with the help of accessories such as chairs, straps, cushions, blocks (provided free to each participant). In addition, breathing work will accompany these postures. A relaxing passive meditation is practiced at the end of each session, in a lying posture called Savasana. The complexity of the postures, their holding time, or the number of repetitions will increase as the program progresses, relative to the abilities of each participant."
223704300|NCT06544889|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
223521562|NCT01812746|DRUG|BIND-014|
223704301|NCT01205204|DRUG|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
223704302|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
223704303|NCT01205204|DRUG|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
223521563|NCT05448313|BEHAVIORAL|Dyadic intervention|Dyads comprising a Veteran and cohabitating support person will participate in the 16-week VA MOVE! weight loss program delivered by video platform. They will then participate in 6 group sessions focused on weight maintenance skills. Communication skills will be taught throughout the intervention.
223521564|NCT05448313|BEHAVIORAL|Veteran-only intervention|Veterans will participate in a 72-week weight management program delivered by video platform. 16 sessions will address weight loss, with 6 additional ones addressing weight loss maintenance.
223521565|NCT03927079|BIOLOGICAL|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
223521566|NCT03927079|PROCEDURE|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
223521567|NCT03927079|BIOLOGICAL|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
223521568|NCT02441400|DEVICE|EndoStim LES Stimulation System|
223521569|NCT04946123|DIETARY_SUPPLEMENT|L-carnitine+Selenium|Supplementation with L-carnitine and Selenium
223521570|NCT06047587|BEHAVIORAL|VR-TrAC|Virtual Reality Training for Aggression. The training consists of 16 twice-weekly sessions, with a duration of 60 minutes each.
224275464|NCT01102452|DIETARY_SUPPLEMENT|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
223521571|NCT06047587|OTHER|Care as Usual|Care as usual as provided in prison.
223521572|NCT04410796|DRUG|Osimertinib|80mg orally daily
223521573|NCT04410796|DRUG|Carboplatin|Carboplatin (AUC 5 IV q 3 weeks)
223521574|NCT04410796|DRUG|Pemetrexed|Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles
223521575|NCT00826293|PROCEDURE|Stabilization belt|Patients receive true stabilization.
223521576|NCT00826293|PROCEDURE|Stabilization belt|Patients receive sham stabilization.
223521577|NCT05381753|DRUG|Avapritinib|Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.
223521578|NCT05381753|DRUG|Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )|Investigators will decide which TKI to use as well as the dosage, frequency, and duration.
223521579|NCT04619147|OTHER|No intervention|This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
223521580|NCT00385489|DRUG|LXR-623|
223521581|NCT05301972|DRUG|BET Inhibitor|Bromodomain and Extra-Terminal Inhibitor
223521582|NCT04097860|BEHAVIORAL|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
223521583|NCT05964166|DEVICE|TetraGraph NMT Monitor|TetraGraph is a unique, EMG=based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
223521584|NCT03571633|DRUG|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
223521585|NCT03571633|DRUG|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
223521586|NCT05712538|DRUG|ARCT-032|ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
223521587|NCT05712538|OTHER|Placebo|Normal saline
223521588|NCT02041793|PROCEDURE|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
223521589|NCT02041793|PROCEDURE|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
223521590|NCT01990690|DRUG|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
223521591|NCT05697640|DRUG|Vericiguat Oral Tablet|The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
223521592|NCT05544695|DEVICE|intravesical sodium hyaluronate (Cystistat®)|Cystistat will be instilled into the bladder according to the instructions for use and in line with the routine clinical practice.
223521593|NCT01781988|DRUG|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
223521594|NCT02875535|BEHAVIORAL|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
223521595|NCT04280783|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
223521596|NCT04280783|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
223521597|NCT00499447|PROCEDURE|radiofrequency ablation|
223704304|NCT01205204|DRUG|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
223704305|NCT06445881|DRUG|Modified Si Jun Zi Tang|Modified Si Jun Zi Tang is a classic formula in traditional Chinese medicine, known for its benefits in unifying and strengthening the spleen.
223521598|NCT00499447|RADIATION|radiation therapy|
223521599|NCT01657981|DRUG|YM150|14C-labeled YM150, oral solution
223521600|NCT06959537|DRUG|Cyclophosphamide|Given by mouth
223704306|NCT03050099|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
223704307|NCT04887844|DRUG|Lidocaine injection|Lidocaine injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
223704308|NCT04887844|DRUG|Corticosteroid injection|Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
223704309|NCT04887844|OTHER|Conventional Physical therapy|The study participants underwent a physiotherapy program that included a one-time 15-minute cold therapy using ice packs and closed-kinetic chain quadriceps strengthening program as follows; isometric quadriceps exercise, isokinetic concentric, and eccentric quadriceps exercises with heel slides and squads. These exercises were repeated ten times a day, seven days per week, for eight weeks in total
223704310|NCT02967731|DRUG|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
223704311|NCT05331651|DRUG|Glycopyrronium in Combination With Tropisetron|Glycopyrronium (0.2mg) in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
223704312|NCT05331651|DRUG|Normal Saline in Combination With Tropisetron|Normal Saline in Combination With Tropisetron (4mg) intravenously given at the ending of the surgery.
223704313|NCT03434197|DRUG|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
224275465|NCT01102452|DIETARY_SUPPLEMENT|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
223704314|NCT03434197|DRUG|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
223704315|NCT04707508|DRUG|Valsartan 80 mg and metformin|Valsartan 80 mg once daily in addition to metformin monotherapy
223704316|NCT04707508|DRUG|Metformin|Metformin monotherapy
223704317|NCT01259596|BEHAVIORAL|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
223704318|NCT01259596|BEHAVIORAL|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
223704319|NCT06201520|PROCEDURE|manual acupuncture|manual acupuncture
223704320|NCT06201520|DEVICE|laser acupuncture|laser acupuncture therapy
223704321|NCT06201520|DEVICE|sham laser acupuncture|sham laser acupuncture
223704322|NCT06201520|DEVICE|wrist splint|wear wrist splint at night
223704323|NCT03469934|BIOLOGICAL|Etokimab|Administered on Day 1 over 1 hour by IV infusion
223704324|NCT03469934|DRUG|Placebo|Administered on Day 1 over 1 hour by IV infusion
223704325|NCT04405583|DEVICE|Occlutech Atrial Flow Regulator|The Occlutech Atrial Flow Regulator is an interatrial shunt device for transcatheter delivery.
223521601|NCT06959537|DRUG|Axatilimab (SNDX-6352)|Given by IV
223521602|NCT06959537|DRUG|Retifanlimab|Given by IV
223521603|NCT05967754|DIAGNOSTIC_TEST|polysomnography|polysomnography and serum uric acid measurement
223521604|NCT02254291|DRUG|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
223521605|NCT02254291|DRUG|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
223521606|NCT02254291|DRUG|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
223521607|NCT02078869|DRUG|Progesterone in oil|Daily administration of 50 mg of IM Progesterone
223521608|NCT02078869|DRUG|vaginal progesterone suppositories|Vaginal Promterium 200 mg , 3 times a day
223521609|NCT06419348|DRUG|99mTc-QULIC-5-P1|Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
223521610|NCT05813418|BIOLOGICAL|blood retriewal|blood retriewal for cytokine concentration measurement
223521611|NCT05937048|BIOLOGICAL|Albumin|20% human albumin solution infusion, to raise and maintain serum albumin levels above 3.0 g/dl. Human albumin solution will be given to those enrolled in the study having serum albumin levels ≤ 3 g/dl to maintain the serum albumin levels above 3 g/dl.
223521612|NCT05937048|OTHER|Standard of Care|Standard treatment that the patient would receive had they not been included in the trial.
223521613|NCT06844916|OTHER|AI-Assisted PEEP Optimization|"In this study, three artificial intelligence (AI) models (ChatGPT, DeepSeek, and Gemini) will analyze mechanical ventilation data, including compliance, elastance, auto-PEEP, time constant, and pressure-volume (P-V) curves, to generate patient-specific PEEP recommendations.~These AI-generated recommendations will be compared with manual PEEP titration performed by experienced ICU specialists. The AI models will also provide abnormal ventilation parameter detection, diagnostic suggestions, and treatment recommendations. The study aims to evaluate the reliability, accuracy, and clinical applicability of AI-generated outputs in optimizing PEEP settings for mechanically ventilated ICU patients."
223521614|NCT04636073|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
223704326|NCT00876746|PROCEDURE|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
223704327|NCT00183820|DRUG|paclitaxel, gemcitabine, and oxaliplatin|"1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days"
224275466|NCT04395599|OTHER|Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.|Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
224275467|NCT05202288|BIOLOGICAL|Ervebo|Administration of r-VSV-ZEBOV vaccine
224275468|NCT05202288|DRUG|Inmazeb|Administration of Inmazeb
224275469|NCT03919695|BEHAVIORAL|Kisoboka: Behavioral and Structural Intervention|"The intervention has two components; a structural component and a behavioral component. The intervention draws from behavioral economics and motivational interviewing.~Structural component: This component is about receiving work payments via mobile money instead of cash.~Behavioral component: This component includes feedback on alcohol screening, counseling, client-centered goal setting, self-monitoring, financial literacy training, and text message reminders of life/savings and healthy living goals."
224275470|NCT03919695|BEHAVIORAL|Screening and Referral|Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
224275471|NCT04496518|DEVICE|Intrinsic Antitachycardia Pacing (iATP) Therapy|iATP is a fully automated ATP therapy for monomorphic ventricular tachycardia (MVT).
224275472|NCT00834158|PROCEDURE|TACE|1 time
224275473|NCT00834158|PROCEDURE|PVE|1 time
224275474|NCT01961245|DEVICE|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
224275475|NCT01774630|DRUG|Nilotinib|300 mg/twice a day
224275476|NCT01688882|DRUG|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
224275477|NCT01688882|DRUG|Placebo|Placebo will be used to control for normal variability in disease severity.
224275478|NCT05997940|DRUG|PENG block|The PENG block was performed with the patient in the supine position at preoperative waiting room. A curvilinear low-frequency ultrasound probe (2-5 MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22 gauge, 100 mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5 mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL
224275479|NCT00267358|DRUG|RC-1291 HCl|
224275480|NCT00267358|DRUG|Placebo|
224275481|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
224275482|NCT01706263|DRUG|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
224275483|NCT01706263|DRUG|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
224275484|NCT05776381|OTHER|Shared Decision Making using a Patient Decision Aid.|The intervention comprises the surgeon actively using the tailored PtDA and SDM with the patient when deciding on the management of an unexpected malignant colorectal polyp.
224275485|NCT00574769|DRUG|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days"
224275486|NCT05307562|OTHER|Interval training + analytical strength|Patients will receive a training program
224275487|NCT05307562|OTHER|Interval training + analytical strength and IMT|Patients will receive a training program + IMT
224275488|NCT01514123|DRUG|VGX-100|VGX-100 will be administered by IV infusion once every week
224275489|NCT01514123|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
224275490|NCT03978416|BEHAVIORAL|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
224275491|NCT04614584|DRUG|Mirtazapine|Mirtazapine 30 mg PO daily x 4 days
224275492|NCT04614584|DRUG|Methamphetamine|Methamphetamine 30 mg IV once
224275493|NCT04013074|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
224275494|NCT04013074|OTHER|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
224275495|NCT02387762|DRUG|acalabrutinib|
224275496|NCT02387762|DRUG|Placebo|
224275497|NCT00608634|DRUG|perillyl alcohol|Applied as topical cream
223521615|NCT06277115|DEVICE|Continuous positive airway pressure (CPAP)|Nocturnal continuous positive airway pressure therapy is the gold standard treatment for symptomatic OSA. It provides positive pressure via a nasal or oronasal mask to prevent upper airway collapse during sleep.
223704328|NCT00765557|DRUG|MiraLAX|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
223704329|NCT00765557|DRUG|Placebos|Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
223704330|NCT05945628|BEHAVIORAL|Different cognitive and memory demands during the memory experiment|Study conditions will involve attempting to memorize visual scenes, attempting to memorize arrays of visual objects, viewing in a self-directed manner, viewing in a passive other-directed manner, and making memory judgments about whether stimuli are studied versus novel.
224275498|NCT00608634|OTHER|placebo|Applied as topical cream
224275499|NCT01918813|DRUG|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
224275500|NCT02641873|DRUG|BBI608|240 mg twice daily (480 mg total daily dose)
224275501|NCT02641873|DRUG|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
224275502|NCT02641873|DRUG|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
224275503|NCT02641873|DRUG|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
224275504|NCT02641873|DRUG|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
224275505|NCT00914654|DRUG|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
224275506|NCT02698345|DEVICE|drug-eluting balloon (In.PACT Admiral, Medtronic)|
224275507|NCT03061903|DEVICE|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
224275508|NCT03061903|DEVICE|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
224275509|NCT00272272|BEHAVIORAL|Music Therapy|Listening to Music while standing
224275510|NCT04315272|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
224275511|NCT04315272|DRUG|Placebo|Placebo
223704331|NCT05945628|OTHER|Different electrical stimulation parameters during cognitive and memory demands|Study conditions will involve different parameters for electrical stimulation delivered through iEEG electrodes, including the presence of stimulation (no stimulation versus stimulation) and the location of stimulation (hippocampus versus amygdala).
224275512|NCT04175860|BEHAVIORAL|The intervention with the patient (Chronic Patient Care Group and his family.)|"* Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~* Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~* Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
223704332|NCT01949831|OTHER|Assessment of functional ability in combination with follow-up at home|
224275513|NCT06382896|OTHER|No intervention|This was an observational study
224275514|NCT03534531|PROCEDURE|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
223521616|NCT02759809|OTHER|Pasteurized donor human breastmilk|
223521617|NCT02759809|OTHER|Preterm formula|
223521618|NCT06311734|DRUG|LW231 tablets|P.O.
223521619|NCT06311734|DRUG|Placebo|P.O.
223704333|NCT01630642|DRUG|Torrent's Clopidogrel Tablets USP 75 mg|
223704334|NCT03062982|DRUG|Fluzoparib|2 doses separated by 7 days.
224275515|NCT03005366|DRUG|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
224275516|NCT03005366|DRUG|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
224275517|NCT03319394|BEHAVIORAL|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
224275518|NCT03319394|BEHAVIORAL|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
224275519|NCT03346902|DRUG|EB-001|Injection of EB-001 into area of scarring (forehead)
224275520|NCT03346902|DRUG|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
224275521|NCT02450058|DRUG|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
223704335|NCT05085574|DRUG|Famotidine|80 mg tablet, QID for 14 days
223521620|NCT00592280|DRUG|Two-Layer Method pancreas preservation system drug|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
223521621|NCT00592280|DEVICE|Two-Layer Method pancreas preservation system device|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
223521622|NCT04839926|DRUG|0.5mg CY150112|single oral CY150112 while fasting on day 1.
223521623|NCT04839926|DRUG|1.5mg CY150112|single oral CY150112 while fasting on day 1.
223521624|NCT04839926|DRUG|4.5mg CY150112|single oral CY150112 while fasting on day 1.
223521625|NCT04839926|DRUG|10mg CY150112|single oral CY150112 while fasting on day 1.
223521626|NCT04839926|DRUG|18mg CY150112|single oral CY150112 while fasting on day 1.
223521627|NCT04839926|DRUG|24mg CY150112|single oral CY150112 while fasting on day 1.
223521628|NCT04898309|DRUG|GNR-038, 50 МЕ/ kg|A single intravenous infusion of GNR-038, 50 МЕ/ kg less than 5 hours after the onset of edema.
223704336|NCT05085574|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
223704337|NCT05085574|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
223704338|NCT03092271|BEHAVIORAL|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
223704339|NCT03092271|BEHAVIORAL|Zero Suicide Quality Improvement|ZSQI
223704340|NCT04305418|OTHER|Mindfulness- Based Intervention|"Mindfulness- Based Intervention in a psychological intervention, based on mind- body connection.~The protocol includes a 10- weeks program, with weekly group sessions of 2 hours and one all-day session after seven weeks. The intervention have standardized core elements consisting of different mental and physical mindfulness exercises: 1) body-scan exercises (paying close attention to all body parts, from the feet to the head), 2) mental exercises focusing one's attention on breathing, 3) physical exercises with focus on being aware of bodily sensations and one's own limits during the exercises, and 4) practicing being fully aware during everyday activities by using the breath as an anchor for attention. Essential to all parts of the program is developing an accepting and non-reactive attitude to what one experiences in each moment."
224275522|NCT02450058|DRUG|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
223704341|NCT02314234|DRUG|sugammadex (Bridion)|single dose of sugammadex at skin incision
223704342|NCT05231681|DIETARY_SUPPLEMENT|Saie Beauty's Hydrabeam Sheer Brightening Under Eye Concealer|Eye Concealer
224275523|NCT02450058|DRUG|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
223521629|NCT04898309|DRUG|GNR-038, 100 МЕ/ kg|A single intravenous infusion of GNR-038, 100 МЕ/ kg less than 5 hours after the onset of edema.
223521630|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
223521631|NCT04898309|DRUG|Placebo|A single intravenous infusion of Placebo less than 5 hours after the onset of edema.
223521632|NCT04898309|DRUG|GNR-038. The dose will be selected according to results of stage 1 clinical trial.|A single intravenous infusion of GNR-038 less than 5 hours after the onset of edema.
223521633|NCT04898309|DRUG|Berinert®, 20 МЕ/ kg|A single intravenous infusion of Berinert®, 20 МЕ/ kg less than 5 hours after the onset of edema.
223521634|NCT06193239|DIAGNOSTIC_TEST|OWL-EVO1|EVOC probe
223521635|NCT01881958|DRUG|DiaPep277®|
223521636|NCT05030389|BEHAVIORAL|Adapted Physical Activity (APA)|The APA program lasts 12 weeks and consists in three one-hour at-home sessions a week (total of 36 sessions), including two aerobic dominant web-based sessions and one muscle strengthening self-guided session.
223521637|NCT05030389|BEHAVIORAL|Bright Light Exposure (BLE)|Bright light exposure (BLE) consists in using lamps for light therapy during 12 weeks, at the rate of five one-hour at-home sessions a week.
223521638|NCT05030389|BEHAVIORAL|Galvanic Vestibular Stimulation (GVS)|The GVS program lasts 2 weeks and consists in five 20-minutes at-home sessions a week (total of 10 sessions), using a portable galvanic stimulator.
223521639|NCT05030389|BEHAVIORAL|Health Education program (HE)|The HE program lasts 14 weeks and consists in one one-hour at-home session a week (total of 14 sessions). This web-based intervention includes courses on general health (sleep habits, diet, physical activity, cardiovascular diseases, etc.).
223521640|NCT01334567|DRUG|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
223521641|NCT00747201|BEHAVIORAL|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
223704343|NCT05288413|DEVICE|3-compression Ultrasound scan with AutoDVT software integrated Ultrasound probe|The study coordinator, Miss Kerstin Saupe will perform a three-point compression ultrasound scan (USS) of the upper leg with the AutoDVT software. The AutoDVT software will store the results of the scan for retroperspective analysis and review. Effectiveness of AutoDVT as diagnostic tool will be evaluated in perspective to different patient groups, eg. patients with adipositas or maligner disease,
224275524|NCT02450058|DRUG|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
224275525|NCT02450058|DRUG|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
224275526|NCT05564845|DIAGNOSTIC_TEST|MR scan of the brain|Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
224275527|NCT05564845|DIAGNOSTIC_TEST|Blood work|Lab work for current lab values and biobanking
223521642|NCT00747201|BEHAVIORAL|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
223521643|NCT00963638|DIETARY_SUPPLEMENT|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
223521644|NCT00963638|DIETARY_SUPPLEMENT|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
223521645|NCT03453242|OTHER|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
223521646|NCT00488293|PROCEDURE|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
223521647|NCT02093273|BIOLOGICAL|tOPV pilot batch|the tOPV vaccine is given orally
223521648|NCT02093273|BIOLOGICAL|tOPV commercial batch|tOPV vaccine is given orally
223704344|NCT03590873|DRUG|Vasopressin|Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
223704345|NCT04576624|BEHAVIORAL|Lifestyle Intervention|A combined approach of a lifestyle structuring intervention to improve the general health and quality of life of persons with cognitive impairments. The investigators propose to combine a multi-modal cognitive intervention and lifestyle redesign approach to improve the cognitive health of older persons with cognitive impairments.
223704346|NCT04576624|BEHAVIORAL|social activity|24 social gathering events
224275528|NCT05564845|DIAGNOSTIC_TEST|Neurological examination|Classical neurological examination
224275529|NCT05564845|DIAGNOSTIC_TEST|Neuropsychological assessment|"Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox"
224275530|NCT05717673|DEVICE|Specular microscopy|Specular microscopy is a noninvasive photographic technique that analyze the corneal endothelium. Using computer-assisted morphometry, modern specular microscopes analyze the size, shape and population of the endothelial cells. The instrument projects light onto the cornea and captures the image that is reflected from the optical interface between the corneal endothelium and the aqueous humor. The reflected image is analyzed by the instrument and displayed as a specular photomicrograph
223521649|NCT05802134|DIETARY_SUPPLEMENT|Fruit and vegetable supplement|Weekly food kits including culturally-appropriate fruits and vegetables (to achieve 8-10 servings per day) and staple items to support DASH diet compliance
223521650|NCT05802134|BEHAVIORAL|Dietary and chronic disease management education|Intensive education for chronic disease management: participants will receive education on hypertension management, which will include an interprofessional health appointment with a medical professional to discuss medication compliance, and resources from an occupational therapist for chronic disease management strategies, and 2 nutrition appointments with a Registered Dietitian regarding the DASH Diet (initial education and follow-up at 2 weeks)
223521651|NCT04775108|DEVICE|Epygon™ Transcatheter Mitral Valve System|"The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.~The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent."
224275531|NCT05215873|DRUG|Misoprostol|a synthetic prostaglandin E1 analogue
224275532|NCT05215873|DRUG|Syntocinon|synthetic oxytocin
224275533|NCT00642811|DRUG|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
224275534|NCT00642811|DRUG|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
224275535|NCT00642811|DRUG|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
224275536|NCT01120691|DRUG|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
224275537|NCT01120691|DRUG|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
224275538|NCT01120691|DRUG|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
223521652|NCT03919019|OTHER|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
223521653|NCT03919019|OTHER|Placebo Group|oral placebo 2 capsules per day for 6 months
223521654|NCT00500331|DRUG|GSK189075|Experimental Drug
223521655|NCT00500331|DRUG|pioglitazone|Active Control
223521656|NCT00500331|OTHER|Placebo|Placebo Comparator
223521657|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
223521658|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
223521659|NCT02150993|DRUG|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
223521660|NCT05192070|OTHER|Percussive Massage Group|Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
223521661|NCT05192070|OTHER|Dynamic stretching group|Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
223704347|NCT00914485|BEHAVIORAL|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
223704348|NCT04889222|DEVICE|INVSENSOR00050|Noninvasive pulse oximeter sensor
223521662|NCT05192070|OTHER|Static stretching group|Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
223521663|NCT00057512|DRUG|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
223521664|NCT03436732|DRUG|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
223521665|NCT03436732|DRUG|SEL-110|administered on day 1 of each cycle for up to 4 cycles
223521666|NCT03345550|DRUG|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
223521667|NCT03345550|DRUG|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
223521668|NCT05179577|DRUG|Arbaclofen|Arbaclofen Extended Release Tablets
223521669|NCT05179577|DRUG|Placebo|Placebo tablets
223521670|NCT04502108|BEHAVIORAL|Covid19|Impact of the COVID19-pandemic on physical activity, nutritional habits and sleeping behavior during an extraordinary period of confinement and social distancing, during the loosening phase and social distancing and the phase after the pandemic.
223521671|NCT01760863|OTHER|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
223521672|NCT03464552|DRUG|Celecoxib 200mg|oral capsule 3 hours before procedure
223521673|NCT03464552|PROCEDURE|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
223521674|NCT03464552|DRUG|Placebo oral capsule|oral capsule 3 hours before procedure
223704349|NCT04889222|DEVICE|RD SET SpO2|Noninvasive pulse oximeter sensor
223704350|NCT06275568|BEHAVIORAL|Usual Care Fresh Connect cardholder engagement|"Fresh Connect, a Food as Medicine product of the non-profit organization About Fresh, Inc., consists of a pre paid, programmable debit card, a cloud-based cardholder success platform, and an analytic engine designed to illuminate the healthcare value of improved food access and nutritional security.~This arm receives:~* About Fresh Food Rx debit card ($100 per month from enrollment until 2 months post-partum)~* Texts for all cardholders per month (1-2 outbound texts)~* Welcome call from About Fresh cardholder engagement team~* 1 text - notification that Fresh Connect funds have been reloaded~* As-needed program updates (e.g. new retailers), inactivity outreach~* Additional texts that would be ad hocs: texts with food experiences (cooking videos), produce how-tos, and fun engagement; and satisfaction surveys - e.g. feedback on the Fresh Connect program, feedback on retailers, satisfaction with cardholder success, etc."
223704351|NCT06275568|BEHAVIORAL|Enhanced engagement communication|Enhanced engagement involves additional outbound texts per month and additional ad hoc bi-monthly or quarterly texts, as well as tailored reminder text to use funds before the end of the month.
223704352|NCT05352178|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
224275539|NCT01120691|DRUG|Salbutamol/albuterol|As needed throughout the study
224275540|NCT00938782|DEVICE|Sedline|
223521675|NCT01631500|BEHAVIORAL|Conventional treatment|Conventional treatment
223521676|NCT01631500|OTHER|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
224275541|NCT04553406|DRUG|SPR720|Capsules for oral administration
223521677|NCT01631500|OTHER|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
223521678|NCT00814736|DRUG|UK369,003|oral tablet, once a day
223521679|NCT00814736|DRUG|sildenafil|single oral dose on day 14 or day 17
223521680|NCT00814736|DRUG|sildenafil matching placebo|single oral dose on day 14 or day 17
223521681|NCT03158246|DRUG|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
223521682|NCT03158246|DRUG|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
223521683|NCT03158246|DIETARY_SUPPLEMENT|calcium|600mg/d calcium for oral daily
223521684|NCT03158246|DIETARY_SUPPLEMENT|vitamin D|925IU/d vitamin D for oral daily
223521685|NCT02862262|DEVICE|ARIES Bordetella Assay|
223704353|NCT05352178|DRUG|Androgen deprivation therapy|Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
224275542|NCT04553406|DRUG|Placebo|Capsules for oral administration
224275543|NCT04553406|DRUG|Open-label Standard of Care|"Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days."
223521686|NCT06363708|DRUG|Tislelizumab|Tislelizumab 200mg D1 ,Q3W
223521687|NCT06363708|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 ) D1,Q3W
223521688|NCT06363708|DRUG|Carboplatin|Carboplatin(AUC=5) D1,Q3W
223521689|NCT05100992|PROCEDURE|Percutaneous Coronary Interbention|Percutaneous Coronary Interbention
223521690|NCT06327425|DEVICE|Magnetocardiography|Magnetocardiography
223521691|NCT03616340|DRUG|Shoulder injection|intra articular or subacromial shoulder injection
223521692|NCT03616340|DRUG|knee injection|intra-articular knee injection
223521693|NCT06142305|PROCEDURE|DDH surgery and casting|DDH surgery and casting
223521694|NCT04861701|BEHAVIORAL|Static stretching exercise|The intervention of this study is home-based stretching exercise. The experimental group will receive 6 stretching exercises which stretch 60 seconds for each side (left or right) of each movement, and relax for 10-20 seconds between the movements. It will take 10-15 minutes every day for continuous 4 weeks. The 6 stretching exercises include : (1) pectoral muscles + calf muscles ; (2) quadriceps ; (3) levator scapulae ; (4) gluteal muscles ; (5) hamstrings ; (6) trunk side-flexors.
223521695|NCT00388609|DRUG|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
223521696|NCT00388609|DRUG|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
223521697|NCT03599076|OTHER|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
223521698|NCT01481103|PROCEDURE|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
223521699|NCT02208167|BIOLOGICAL|HXTC infusion|
223521700|NCT04463927|OTHER|non-nutritive sucking|intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
223521701|NCT00726479|DRUG|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
223521702|NCT00959049|BIOLOGICAL|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
223704354|NCT05352178|DRUG|Androgen receptor targeted therapy|Enzalutamide
223704355|NCT06293131|DRUG|Ciprofol|Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
223704356|NCT01539798|OTHER|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
223704357|NCT01539798|OTHER|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
223704358|NCT02740439|OTHER|Avocado|The intervention meals will contain 1 large avocado.
223704359|NCT02740439|OTHER|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
223704360|NCT06282393|DEVICE|FibriCheck recordings|PPG and single-lead ECG measurements
223704361|NCT00439023|PROCEDURE|dialysis with glucose in dialysis water|
223704362|NCT02639546|DRUG|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
223521703|NCT00959049|BIOLOGICAL|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
223521704|NCT01661673|DRUG|EVP-0962|Arms: 1,2,3,4
223521705|NCT01661673|DRUG|Placebo|Arm 5
223521706|NCT03575598|DRUG|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
223521707|NCT03575598|BIOLOGICAL|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
223521708|NCT00137449|DRUG|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
223521709|NCT01498809|DRUG|Midodrine|Single 10 mg dose
223521710|NCT03218475|OTHER|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
223521711|NCT02772692|BEHAVIORAL|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
223521712|NCT04835259|DRUG|Selenium Amino Acid Chelate (Selenium ACE cream)|application of a topical agent over the whole face for 6 months
223521713|NCT02704884|DIETARY_SUPPLEMENT|probiotic soy milk|
223704363|NCT01147588|DRUG|lansoprazole|60 mg (2x30-mg capsule), once daily
223704364|NCT01147588|DRUG|omeprazole|80 mg (2x40-mg capsule), once daily
223704365|NCT01147588|DRUG|esomeprazole|40 mg (1x40-mg capsule), once daily
223704366|NCT01147588|DRUG|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
223704367|NCT04670055|DRUG|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
223704368|NCT06324331|PROCEDURE|Decidual sparing|Endometrial free uterine closure technique
223704369|NCT06324331|PROCEDURE|Non decidual sparing|Routine uterine closure technique including endometrium
223704370|NCT00113087|DRUG|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
223704371|NCT00113087|DRUG|Placebo|Participants will receive placebo
223704372|NCT03508375|BIOLOGICAL|blood samples|blood samples
223704373|NCT04997915|OTHER|Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU|Critical COVID-19 patients admitted to the ICU
223704374|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct At Home Virtual Reality Vestibular Rehabilitation|The virtual reality intervention will involve standard vestibular rehabilitation as described above and adjunct at home virtual reality video game. This video game will be projected on an android or apple device accommodated into a VR headset for 20 minutes daily until the vestibular rehabilitation is complete. This video will be congruent to current vestibular rehabilitation program exercises. Point-of-view games compatible with both Android and iOS devices will be evaluated by professionals to determine the game that is most representative of current evidence based exercises.
223704375|NCT05424302|BEHAVIORAL|Standard Vestibular Rehabilitation with Adjunct Auditory Intervention|The control intervention will involve standard vestibular rehabilitation as described above and adjunct audio intervention while wearing the VR headset for 20 minutes daily until the vestibular rehabilitation is complete.
223521714|NCT01752179|PROCEDURE|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~1. stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~2. puts the base of tape over the contralateral of sacrum with no tension.~3. attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~4. attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
223521715|NCT00829465|DRUG|Licartin|Licartin
223521716|NCT00829465|PROCEDURE|Transcatheter arterial chemoembolization|TACE
223521717|NCT01078532|OTHER|SMART PHR|Patient receives an active PHR
223521718|NCT01078532|OTHER|usual care|Usual passive PHR
223521719|NCT03512730|DEVICE|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
223521720|NCT03512730|OTHER|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
223521721|NCT05952310|OTHER|Natural Killer (NK) cells (a new immunotherapy)|"It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease.~The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands.~The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect.~In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells."
223521722|NCT05886764|OTHER|Digital Intervention|Digital messages (email, text, etc.) which include general educational information about clinical trials and available resources.
223521723|NCT05886764|OTHER|Community Outreach|Invitation to contact a Community Ambassador for further information and support in the decision to participate in a clinical trial.
223521724|NCT06336564|OTHER|Pelvic floor muscle training|"Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days."
223521725|NCT06336564|DEVICE|Microablative Radiofrequency|Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
223521726|NCT02552264|BEHAVIORAL|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
223521727|NCT03683979|BEHAVIORAL|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
223521728|NCT03683979|BEHAVIORAL|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
223521729|NCT00078260|DRUG|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
223521730|NCT05167708|PROCEDURE|Micro-osteoperforation|flapless small punctures in the bone at direction of tooth movement to accelerate the movement.
223534909|NCT06084351|DRUG|Convalescent Plasma|"Class: Blood product Physical Description: Opaque yellow fluid within a container labelled with the statement Caution: New Drug - Limited by Federal (or United States) law to investigational use). Container will also be labelled with the International Society of Blood Transfusion format for Blood Components. Label will contain the expiration date and the donor identification number. Label will also contain information pertaining to the ABO typing of the plasma. A copy of the IBST identifier will be placed with the patient chart.~Manufacture: Plasma will be collected via apheresis via collaboration with American Blood Bank Corporation, a FDA-registered blood establishment. The donors will be screened in accordance with the FDA guidance for donor eligibility for COVID-19:"
223534910|NCT06084351|OTHER|Standard of Care|Standard of care treatment for hospitalized COVID-19 patients
223704376|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
223704377|NCT02127593|DRUG|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
223521731|NCT06112015|OTHER|Bulgarian split squat exercise variations|The participants performed 4 different sessions of Bulgarian split squat exercises-Bulgarian split squat with trunk flexion (BSS flexion), Bulgarian Split squat with trunk neutral (BSS neutral), suspension based Bulgarian split squat with trunk flexion (SBSS flexion), suspension based Bulgarian split squat with trunk neutral (SBSS neutral)-with EMG recordings being taken from the dominant extremity throughout each session. For each exercise, participants were instructed to perform three successful repetitions. Between each repetition, there was a 30-second break, and there was at least 10 minutes in between each of the 4 exercises. The movement was standardized by a metronome. The modified Borg scale was used to ensure that fatigue did not occur before each exercise since it was believed that fatigue could affect exercise performance. When scores reported using the modified Borg scale were 1 or lower, exercise recording was started.
223521732|NCT06149169|BIOLOGICAL|CD19-targeted Chimeric Antigen Receptor(CAR) T Cells|Relma-cel be administered at one dose level:1×10\^8 CAR+T cells
223521733|NCT01137084|DRUG|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
223521734|NCT01137084|DRUG|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
223521735|NCT05903079|DEVICE|s-Tdcs|Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
223521736|NCT00712283|DRUG|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
223521737|NCT05308810|PROCEDURE|Major Gynecologic- oncologic Surgery|Major Gynecologic-Oncologic surgery between january 2020 - january 2022
223521738|NCT03709017|DRUG|Ponatinib|Iclusig 45mg, 15mg
223521739|NCT02373657|BEHAVIORAL|instruction in soap-making and hygiene education|
223521740|NCT03514576|DRUG|Pasireotide 0.3 MG/ML|See arm description
223521741|NCT03514576|DIAGNOSTIC_TEST|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
223521742|NCT02489279|BEHAVIORAL|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
223521743|NCT02489279|BEHAVIORAL|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
223521744|NCT05613127|BIOLOGICAL|Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Dosage and administration: pre-iflled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
223521745|NCT05613127|BIOLOGICAL|HAVRIX 720 Junior 0.5 mL|Dosage and administration: pre-filled syringe, IM injection of 0.5mL will be given for 2 times with 6-months interval.
223521746|NCT02892279|OTHER|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
223521747|NCT01055951|DEVICE|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
223521748|NCT02263547|DRUG|teriflunomide|
223521749|NCT02263547|DRUG|Colestipol|
223521750|NCT00038935|DRUG|ReFacto AF|
223521751|NCT05751109|PROCEDURE|ipack+adduktor kanal|nerve block
223521752|NCT04519333|PROCEDURE|drug(intradermal injection)|"The mesotherapy was performed by an experienced and trained physician using a disposable 4 mm and 6 mm long, 30 Gauge needles. Initially, a pharmacological mixture of 1 cc (2 mg) thiocolchicoside, 1 cc (16.2 mg) lidocaine and 1 cc (5 mg) tenoxicam was prepared for each treatment session, and 0.1-0.2 cc of this mixture was applied to each injection point with a depth of 1-3 mm using point by point intradermal method without causing papules.~In the systemic therapy group, we applied a 50 mg dexketoprofen (Revafen, Haver Pharma Pharmaceutical Co., Turkey) in 100 cc isotonic solution intravenously for 5 minutes."
223521753|NCT02033408|DRUG|AB (antibiotics)|"1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
223521754|NCT02033408|DRUG|CS (corticosteroids) Only|"1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
223521755|NCT04967456|DIAGNOSTIC_TEST|Measurement of pulpal blood flow of traumatised tooth|"Measurement of the blood flow of the dental pulp will be performed, using a laser doppler flow monitor mVMS-LDF2TM (Moor Instruments Ltd Millwey Axminster Devon, UK), emission wavelength 785nm±10nm, dual-channel laser Doppler monitoring option. Two probes will be used, each consisting of one afferent and one efferent optic fiber to conduct the light to and from the tooth surface. The probe is stainless steel needle-like tube, which is 10-80 mm long and 1.5 mm in the diameter. The utilised parameter settings will be: Average power - 1.0 mV; Diameter of the probe - 1.5 mm; Frequency - 40 Hz; Monitoring time-180 seconds (sec)"
223521756|NCT05876520|PROCEDURE|Total pulpotomy with I-prf mixed with Nano-bioactive glass|Total pulpotomy is done in mature permanent molars followed by I-prf mixed with Nano-Bioactive glass application. Topped with BC putty for coronal seal, RMGI and restored with composite as final restoration
223521757|NCT04908228|DRUG|Ibrutinib and obinutuzumab|Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
223521758|NCT02156947|PROCEDURE|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
223521759|NCT06392425|OTHER|caspase 3 and ADAM 17 biomarkers|Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
223521760|NCT00924092|BIOLOGICAL|GI-6207 [Recombinant Saccharomyces Cerevisia|
223521761|NCT00924092|DRUG|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
223521762|NCT00000684|DRUG|Dextran sulfate|
223534911|NCT03240107|PROCEDURE|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
223521763|NCT01128517|BEHAVIORAL|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --\> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session --\>breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --\> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
223521764|NCT01128517|BEHAVIORAL|Education|Maternal education on complementary food
223521765|NCT01910155|DRUG|Ciprofloxacin/Dexamethasone|
223521766|NCT01910155|DRUG|Ciprodex (R)|
223521767|NCT01910155|DRUG|Placebo|
223521768|NCT00586157|DRUG|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
223521769|NCT00586157|DRUG|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
223521770|NCT01537328|OTHER|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
223521771|NCT05149729|PROCEDURE|Shortened hip arthroplasty|Crowe type 3 and 4 patients who underwent shortened hip prosthesis
223521772|NCT00062764|DRUG|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
223521773|NCT01318681|DRUG|cetirizine 10 mg|cetirizine 10 mg over encapsulated
223521774|NCT01318681|DRUG|fluticasone furoate|nasal spray 25ug per dose
223521775|NCT01318681|DRUG|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
223521776|NCT01183351|BEHAVIORAL|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
223704378|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
223704379|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of saline via MicronJet600 microneedle device|Intradermal administration of 100 µL saline (registration number РN002134/01 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the right arm, followed by the insertion of 18G catheter in a cubital vein immediately after the saline administration.
223704380|NCT05108714|DEVICE|Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (2)|Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
223704381|NCT05108714|PROCEDURE|Intravenous cannulation after without prior interventions|insertion of 18G catheter in a cubital vein without prior interventions.
223521777|NCT02378480|DRUG|Omadacycline|Injection for IV dosing; Tablets for oral dosing
223521778|NCT02378480|DRUG|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
223521779|NCT01916031|BEHAVIORAL|Education|
223521780|NCT02302287|DIETARY_SUPPLEMENT|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
223521781|NCT02302287|OTHER|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
223521782|NCT02302287|OTHER|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
223521783|NCT04556006|OTHER|Patient education|"The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated."
223521784|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
223521785|NCT01189760|BIOLOGICAL|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
223521786|NCT01189760|DRUG|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
223521787|NCT02014467|DRUG|Denosumab|Injection
223521788|NCT02014467|DRUG|Placebo|Injection
223521789|NCT02014467|DIETARY_SUPPLEMENT|Elemental Calcium|Oral, at least 600 mg
223521790|NCT02014467|DIETARY_SUPPLEMENT|Vitamin D|Oral, at least 400 IU
223521791|NCT01230060|DEVICE|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
223521792|NCT05963126|OTHER|No intervention.|No intervention.
223521793|NCT04373200|BIOLOGICAL|Blood samples collection|Blood sample collection at Day 1, day 7, day 14 for all patients. At month 4 for 25 survivors COVID-19 patients
223521794|NCT04373200|OTHER|Saliva collection|Saliva collection at Month 4 for 25 survivors COVID-19 patients
223521795|NCT05006248|DEVICE|Conventional robotic continuous passive movement training|The participants will be single-blinded and wear the M1 robotic device on their affected/weaker foot, and complete up to 30 minutes of continuous passive movement per training session. The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session.
223521796|NCT05006248|DEVICE|Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in transparency mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The transparency mode of the robotic device compensates for its weight and friction so that the participant does not feel weight while moving the device.
223521797|NCT05006248|DEVICE|Haptic and Visual Feedback|The participants will be single-blinded and wear the M1 robotic device in assistance mode on their affected/weaker foot, and complete up to 30 minutes of training with visual biofeedback (games). The participants will complete 12 training sessions. Clinical assessments will be performed at baseline, immediately before the 6th training session, and immediately after the 12th training session. The assistance mode of the robotic device applies assistive/resistive torque based on muscle activity.
223521798|NCT00213525|OTHER|Questionnary for environmental factors research|Questionnary for environmental factors research
223521799|NCT03901586|OTHER|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
223521800|NCT03901586|OTHER|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
223521801|NCT03901586|OTHER|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
223521802|NCT06312215|OTHER|Closed-system catheter|Closed-system catheters was applied
223521803|NCT04642976|DEVICE|Ganglionated Plexi mapping and ablation using Natus Cortical Stimulator and standard ablation catheters|Ganglionated plexi will be mapped using high frequency stimulation with standard ablation catheters attached to a Natus Cortical Stimulator for high frequency stimulation. Vagal innervation to the heart will be assessed with non-invasive Parasym tragal stimulation.
223521804|NCT00931281|DRUG|ABT-450|capsules, QD or BID, 14 days, ascending doses
223521805|NCT00931281|DRUG|ritonavir|capsules, QD or BID, 14 days, ascending doses
223521806|NCT00931281|DRUG|Placebo for ABT-450|capsule, QD or BID, 14 days
223521807|NCT00931281|DRUG|Placebo for ritonavir|capsule, QD or BID, 14 days
223521808|NCT03197519|BEHAVIORAL|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
223521809|NCT03197519|BEHAVIORAL|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
223521810|NCT01217892|DRUG|dapagliflozin|2.5 mg tablet, taken orally, twice daily
223704382|NCT02810522|DEVICE|OneTouch Select® Plus Glucose Test Strips|
223704383|NCT01667692|DRUG|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
223704384|NCT01667692|DRUG|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
223704385|NCT02272478|DRUG|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
223704386|NCT02272478|DRUG|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
223704387|NCT02272478|DRUG|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
223704388|NCT02272478|DRUG|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
223521811|NCT01217892|DRUG|dapagliflozin|5 mg tablet taken orally, twice daily
223521812|NCT01217892|DRUG|dapagliflozin|10 mg tablet taken orally, once daily
223521813|NCT01217892|DRUG|metformin|\>/= 1500 mg total daily dose, tablets taken orally, twice daily
223521814|NCT01217892|DRUG|placebo|placebo
223521815|NCT04053504|BEHAVIORAL|Family Teamwork-Peer Delivery|Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
223521816|NCT00839501|DIETARY_SUPPLEMENT|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
223521817|NCT00839501|DRUG|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
223521818|NCT02059447|OTHER|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
223521819|NCT02059447|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
223521820|NCT02059447|BEHAVIORAL|Relaxation Therapy|
223521821|NCT01052779|DRUG|Ferumoxytol|IV Ferumoxytol
223521822|NCT01052779|DRUG|Iron Sucrose|IV Iron Sucrose
223521823|NCT00243035|DRUG|bortezomib|Given IV
223521824|NCT00243035|DRUG|tipifarnib|Given orally
223521825|NCT00243035|OTHER|laboratory biomarker analysis|Correlative studies
223521826|NCT05385107|DIAGNOSTIC_TEST|Serum procalcitonin concentration|
223521827|NCT04932148|OTHER|Incremental HD|Starting haemodialysis at twice weekly frequency
223521828|NCT04932148|OTHER|Conventional HD|Starting haemodialysis at thrice weekly frequency
223521829|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
223521830|NCT03802916|DRUG|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
223521831|NCT01459120|OTHER|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
223521832|NCT01459120|OTHER|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
223521833|NCT00088946|DIETARY_SUPPLEMENT|Polyphenon E|4-200mg capsules PO daily for 12 months
223521834|NCT00088946|DRUG|erlotinib hydrochloride|100 mg PO daily for 12 months
223521835|NCT00088946|OTHER|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
223521836|NCT00088946|OTHER|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
223521837|NCT03663582|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
223521838|NCT03663582|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
223521839|NCT03663582|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
223521840|NCT03663582|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
223521841|NCT04388228|OTHER|Extended audit and feedback in GPs electronic health record|"The intervention consists of an extended electronically delivered feedback with multiple components which will be delivered 4 times electronically into general practices over 12 months.~This extended feedback report consists of:~* Benchmarking of the results of the audit versus peers, versus guidelines and versus disease specific laboratory results.~* A low cognitive load of the feedback where the results will be presented with the help of graphs.~* Action plans to improve the quality of registration~* A push system to minimize the effort the GP must make to consult the feedback."
223521842|NCT03694028|OTHER|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
223521843|NCT03694028|OTHER|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
223521844|NCT02648360|BEHAVIORAL|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
223521845|NCT00780585|DRUG|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
223521846|NCT03505060|BIOLOGICAL|DNA CON-S env|Administered by intramuscular injection in the deltoid.
223521847|NCT03505060|BIOLOGICAL|IHV01|Administered by intramuscular injection in the deltoid.
223521848|NCT03505060|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
223534912|NCT03240107|PROCEDURE|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
223534913|NCT05321329|DRUG|Capecitabine|Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
223534914|NCT03027674|DRUG|10% nifedipine cream|Topical treatment for Raynaud
223534915|NCT03027674|DRUG|5% sildenafil cream|Topical treatment for Raynaud
223534916|NCT00000389|DRUG|Fluvoxamine|
223534917|NCT02743741|DRUG|Lutetium-177 Octreotate|Radiopharmaceutical
223534918|NCT03679104|PROCEDURE|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
223534919|NCT03679104|PROCEDURE|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
223521849|NCT02069847|DRUG|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
223521850|NCT03638375|DRUG|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10\^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
223521851|NCT04433195|DIAGNOSTIC_TEST|Xpert MTB/RIF test|Xpert MTB/RIF performed as the initial diagnostic test for the diagnosis of pulmonary TB
223521852|NCT04931576|PROCEDURE|no drainage tube applied|No drainage tube implacement after TOETVA
223521853|NCT05994430|OTHER|End-of-life care awareness training in intensive care|End-of-life care awareness training in intensive care
223521854|NCT05126420|PROCEDURE|biopsy|biopsy to identify the lesion in the oral mucosa
223521855|NCT03797937|OTHER|Magnetic resonance imaging (MRI)|MRI scanner
223521856|NCT06318546|DRUG|Dexmedetomidine Injection [Precedex],,,|patients will receive 0.5ml (10 µg) Dexmedetomidine as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
223521857|NCT06318546|DRUG|Fentanyl|will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric Bupivacaine hydrochloride 0.5%
223521858|NCT05348941|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
223521859|NCT03350945|PROCEDURE|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
223521860|NCT00470522|DRUG|Methotrexate and folic acid|
223521861|NCT05333926|DEVICE|MHNA-001|3-month digital therapy program designed to reduce the severity of IBS symptoms
223521862|NCT04774666|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening|Oral fluid-based HIV test
223521863|NCT02191163|DRUG|Antistax®|
223521864|NCT02191163|DRUG|Placebo|
223521865|NCT03242434|OTHER|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose \[5 grams (g)\]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
223521866|NCT03242434|OTHER|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
223521867|NCT00784017|DRUG|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
223704389|NCT02272478|DRUG|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
223704390|NCT02272478|DRUG|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
223704391|NCT02215096|DRUG|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
223704392|NCT02215096|DRUG|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
223521868|NCT00784017|DRUG|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
223521869|NCT02228928|DRUG|CAPNP, 50 ug/cm2 capsaicin patch|
223521870|NCT02228928|DRUG|CAPNP, 100 ug/cm2 capsaicin patch|
223521871|NCT02228928|DRUG|0.075% capsaicin cream|
223521872|NCT02228928|OTHER|Placebo patch|
223521873|NCT05212207|OTHER|CGM, smartwatch, and electronic diary|Participants wear a CGM and a smartwatch while keeping an electronic diary with information such as meals, sleep, and activity.
223521874|NCT01769027|DRUG|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
223521875|NCT01769027|DRUG|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
223521876|NCT01769027|BIOLOGICAL|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
223521877|NCT02477748|DRUG|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
223521878|NCT02477748|DRUG|Placebo|Tablet PO, taken once daily for 10 weeks.
223521879|NCT05775250|DRUG|giomer varnish|Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
223521880|NCT03862417|OTHER|Schroth exercises|An exercise program begun individually and then continued in groups.
223521881|NCT01779414|OTHER|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
223521882|NCT00694863|DRUG|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
223704393|NCT04313842|DEVICE|AVATAMED|tumor specimen will be sent for in vitro drug screening experiment and the result will be analyzed by 'AVATAMED' to predict the clinical response
223521883|NCT00855361|DRUG|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
223521884|NCT04785209|OTHER|Mean platelet volume, lymphocyte number, STEMI clinical risk scores|Lab parameters
223521885|NCT02348021|PROCEDURE|Percutaneous coronary intervention (PCI)|
223521886|NCT02348021|DRUG|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
223521887|NCT02190500|OTHER|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
223521888|NCT02230982|DRUG|nintedanib|soft gelatin capsule
223521889|NCT04507763|DRUG|Etanercept|Patients with ankylosing spondylitis as provided in real world practice
223521890|NCT00626951|DEVICE|LMA Supreme|Extraglottic airway devices
223521891|NCT00626951|DEVICE|LMA ProSeal|
223521892|NCT05684302|OTHER|The free-toroidal design lenses|Participants were asked to wear the new design lenses (the free-toroidal design lenses) for 1 week
223521893|NCT04120870|DRUG|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
223521894|NCT04120870|DRUG|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
223521895|NCT05059275|PROCEDURE|modified ostium obstruction surgery|An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
223521896|NCT00004103|DRUG|cisplatin|
223521897|NCT00004103|DRUG|floxuridine|
223521898|NCT00004103|DRUG|irinotecan hydrochloride|
223521899|NCT00004103|PROCEDURE|adjuvant therapy|
223521900|NCT00004103|PROCEDURE|conventional surgery|
223521901|NCT00004103|PROCEDURE|neoadjuvant therapy|
223521902|NCT04183686|DRUG|ACT-1014-6470 (SAD)|Single dose of ACT-1014-6470; soft capsules for oral use.
223521903|NCT04183686|DRUG|ACT-1014-6470 (MAD)|Multiple doses of ACT-1014-6470; soft capsules for oral use.
223521904|NCT04183686|DRUG|Placebo (SAD)|Single dose of matching placebo; soft capsules for oral use.
223521905|NCT04183686|DRUG|Placebo (MAD)|Multiple doses of matching placebo; soft capsules for oral use.
223521906|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer|Single dose of 14C-ACT-1014-6470 microtracer; soft capsules for oral use.
223521907|NCT04183686|DRUG|14C-ACT-1014-6470 microtracer placebo|Single dose of matching placebo; soft capsules for oral use.
223521908|NCT00000307|DRUG|Naltrexone|
223521909|NCT01146002|DRUG|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
223521910|NCT05593939|BEHAVIORAL|Exercise|Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Participants randomized to the EXE group will perform aerobic exercise five days per week, totaling 150-300 min/week, at moderate to vigorous intensities i.e., \~60-90% heart rate (HR) max. Exercise intensity and duration will gradually increase up until week 3 to habituate the participants to the exercise. The training modality will change to reduce the risk of injuries and may be impacted by individual preferences to increase adherence. The training can be performed individually or in groups of 4-6 participants, depending on the geographical locations of the participants home address, and on the current recruitment rate.
223521911|NCT05593939|BEHAVIORAL|Time restricted feeding|Participants randomized to the time restricted feeding group will be instructed to abstain from any caloric intake during the targeted fasting window of 16 continuous hours and consume ad libitum during the eating window of 8 hours.
223521912|NCT05593939|DIETARY_SUPPLEMENT|Nicotinamide riboside|Participants randomized to the NR group will be instructed to take the administered tablets once in the morning (1 g) and once in the evening (1 g), in both cases with a meal.
223521913|NCT01259531|DRUG|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
223521914|NCT00744614|PROCEDURE|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
223521915|NCT06488833|BEHAVIORAL|Komtü Programme (Komtü)|"Mainly, 4 actions will take place:~* Training with reflective practice exercises. This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~* Healing spaces to generate a collective restorative experience, offering tools that facilitate emotional management~* Individual support for teachers to offer them resources, tools, and intervention strategies to help improve educational practice and the emotional and relational well-being of the school community~* Coaching for the school management team to help them establish some objectives together and offer them the necessary resources and tools so that they can achieve them successfully."
223521916|NCT06488833|BEHAVIORAL|Komtü Training and Reflective Practice|"This is a 32-hours group training involving 21 sessions that last 60 minutes and 11 hours of inter-sessions work. The contents of the training will be 5 of the 10 total blocks of Komtü training: Block 1: Meeting, observing and listening; Block 2: Neuroscience applied in the educational context; Block 3: High- quality relationships; Block 4: Conflict management; Block 5: Boundary management~No other actions will take place in this group."
223704394|NCT03204201|DRUG|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
223521917|NCT04619849|DIAGNOSTIC_TEST|EMG|Electromyography (EMG) is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles.
223521918|NCT04619849|DIAGNOSTIC_TEST|Palmaris Longus Test|Schaffer test will be done to understand the presence of palmaris longus. 4 different tests will be done to prove its absence.
223521919|NCT04118426|RADIATION|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
223521920|NCT02346669|PROCEDURE|gastroscopy|as detailed in arm description
223521921|NCT02346669|DRUG|Fecal Microbiota Transplantation|as detailed in arm description
223521922|NCT02346669|OTHER|high fat low fiber diet|as detailed in arm description
223521923|NCT02346669|OTHER|sham diet|as detailed in arm description
223521924|NCT02346669|OTHER|low fat high fiber diet|as detailed in arm description
223521925|NCT04427345|OTHER|Predictive factors for clinical response in patients with COVID-19.|Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .
223521926|NCT00710619|DRUG|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
223521927|NCT00710619|DRUG|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
223704395|NCT01126970|DRUG|Velneperit 400 mg|Velneperit 400 mg q.d.
223704396|NCT01126970|DRUG|Orlistat 120 mg|Orlistat 120 mg t.i.d
223521928|NCT01021527|OTHER|Comparator: Treatment A|No Treatment
223521929|NCT01021527|DRUG|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
223521930|NCT01021527|DRUG|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
223521931|NCT01021527|PROCEDURE|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
223521932|NCT02174770|OTHER|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
223704397|NCT01126970|DRUG|Orlistat Placebo|Orlistat Placebo t.i.d.
223704398|NCT01126970|DRUG|Velneperit Placebo|Velneperit Placebo q.d
223704399|NCT01126970|OTHER|Reduced Calorie Diet|Reduced calorie diet
223521933|NCT02174770|OTHER|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
223521934|NCT03209765|OTHER|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
223521935|NCT04824677|OTHER|Hospital treatment of COVID disease|Hospital treatment of COVID disease
223521936|NCT00406926|DRUG|Somatropin|
223521937|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
223521938|NCT01047995|DRUG|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
223521939|NCT03427619|DRUG|OK432|OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
223704400|NCT01139489|OTHER|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
223704401|NCT05069610|BIOLOGICAL|AD17002|A recombinant protein
223704402|NCT05069610|BIOLOGICAL|Placebo (Formulation buffer)|Formulation buffer
223704403|NCT04401826|PROCEDURE|Tunneling micro-surgical crown lengthening approach using piezo-surgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling
223704404|NCT04401826|PROCEDURE|Micro-surgical crown lengthening approach using Piezosurgery|excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
223704405|NCT04597229|DIETARY_SUPPLEMENT|Instant multigrain supplement|A twice daily instant multigrain supplementation for 12 weeks
223704406|NCT00472719|BIOLOGICAL|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
223704407|NCT00472719|BIOLOGICAL|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
223704408|NCT00472719|BIOLOGICAL|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
223704409|NCT03948243|DIETARY_SUPPLEMENT|Licorice|Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
223704410|NCT03948243|DRUG|Alprazolam 2 MG|probe substrate
223704411|NCT03948243|DRUG|Caffeine 100 MG|probe substrate
223704412|NCT03948243|DRUG|Tolbutamide 250 mg|probe substrate
223704413|NCT03948243|DRUG|Dextromethorphan 30mg|probe substrate
223704414|NCT04406220|OTHER|Small clog size|Participants will be randomized to run in small clogs
223704415|NCT04406220|OTHER|Large clog size|Participants will be randomized to run in large clogs
223704416|NCT01997853|DRUG|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
223521940|NCT01355666|DEVICE|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
223521941|NCT03070067|OTHER|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
223521942|NCT03781063|DRUG|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
223521943|NCT03781063|DRUG|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
223521944|NCT02196974|PROCEDURE|cryobiopsy|
223521945|NCT02248233|DRUG|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
223521946|NCT02248233|DRUG|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
223521947|NCT03712761|DIETARY_SUPPLEMENT|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
223704417|NCT01997853|DRUG|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
223704418|NCT02840721|DRUG|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
223704419|NCT03005418|BIOLOGICAL|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) - the Human Acellular Vessel (HAV) is a sterile acellular tubular graft composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin which can be used for arterial bypass or reconstruction in patients with life or limb threatening vascular trauma. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
223704420|NCT03636165|DRUG|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
223704421|NCT03636165|DRUG|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
223704422|NCT05342935|DEVICE|Inteligent Dialysis Assistant (IDA)|The IDA is a small dialysis system that allows a higher level of freedom to the patients, permitting them to perform the PD exchange while continuing to do their everyday activities
223704423|NCT04127942|PROCEDURE|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
223704424|NCT05363410|DIETARY_SUPPLEMENT|MagnéVie B6®|micronutrient supplement
223704425|NCT05363410|OTHER|Placebo|placebo supplement
223521948|NCT04605250|OTHER|Respiratory variability before and after surgery|The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
223521949|NCT03017001|DIETARY_SUPPLEMENT|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
223521950|NCT03017001|DRUG|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
223521951|NCT03017001|OTHER|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
223521952|NCT03113344|DRUG|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
223521953|NCT00003451|BIOLOGICAL|recombinant interferon alfa|
223521954|NCT00003451|BIOLOGICAL|recombinant interleukin-12|
223521955|NCT02998866|PROCEDURE|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI \[means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
223521956|NCT02003703|BIOLOGICAL|Recombinant Hepatitis B Virus Vaccine|
223521957|NCT02500108|DRUG|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
223704426|NCT05531331|BEHAVIORAL|At home education via video conferencing|Educational booklets are given according to the type of stoma. The individual with the stoma was told that the researcher was always reachable by phone and could communicate if he had any problems. The individuals with stoma in the experimental group received the training of the company representative that sells stoma materials, which is routinely given in the hospital. After discharge, training was given by the researcher via video conference in a total of four interviews. The first interview was done on the 5th day after discharge, the second on the 10th day, the third on the 15th day, and the fourth on the 2nd month. A post-test was conducted at the end of the 4th training interview, which was administered via video conferencing.
223704427|NCT01479023|DRUG|64Cu-DOTA-U3-1287|
223521958|NCT01968278|OTHER|Baked milk|
223521959|NCT02624856|DRUG|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
223521960|NCT02624856|DRUG|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
223521961|NCT04467255|OTHER|Rehabilitative training|4 weeks aerobic treadmill training compared to endurance training with elastic thera band
223521962|NCT03208790|DRUG|Nigella sativa buccal tablets 10mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 10mg
223521963|NCT03208790|DRUG|Nigella sativa buccal tablets 5mg|thymoquinone will be extracted from Nigella Sativa and packed in buccal tablets of 5mg
223521964|NCT03208790|DRUG|Placebo buccal tablets|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
223521965|NCT03988218|BEHAVIORAL|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
223521966|NCT06642701|DEVICE|Electrical Impedance Tomography|According to the results of traditional assessment, physiotherapists and clinicians discussed the EIT results to give respiratory rehabilitation chest physiotherapy
223521967|NCT06642701|BEHAVIORAL|chest physiotherapy|Conventional assessment by physical therapists was followed by respiratory rehabilitation chest physiotherapy.Chest physical therapy for respiratory rehabilitation includes postural drainage, cough technique, forced expiratory technique, positive expiratory pressure, high-frequency chest wall compression, chest tapping, vibration, active breathing cycle technique, etc. All chest physiotherapy was performed by 1 therapist.
223521968|NCT03215160|BEHAVIORAL|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
223521969|NCT02150707|DRUG|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
223521970|NCT02150707|DRUG|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
223521971|NCT06167148|DEVICE|Biolase Epic X 940nm wavelength Diode laser|Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).
223521972|NCT06167148|DEVICE|Doctor smile simpler 980nm wavelength Diode laser|Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
223521973|NCT06638749|DRUG|Tranexamic Acid|Administration of tranexamic acid
223521974|NCT06638749|DRUG|Normal Saline|Administration of normal saline
223521975|NCT01997164|DRUG|REGN910-3|
223521976|NCT01997164|DRUG|REGN910|
223521977|NCT01997164|DRUG|Intravitreal Aflibercept Injection (IAI)|
223521978|NCT05763381|DEVICE|Photobiomodulation Therapy (PBMT)|Participants will receive PBMT with the PBM device over the course of three consecutive weeks (three treatments per week). PBM treatments will take approximately 5-10 minutes to administer at each session. Specific treatment parameters will be based on measurements of calf, ankle, and foot using pre-calculated treatment tables; participants will receive 10 J/cm2, 25W output power, and the length of the treatment will be dependent on treatment area (size). PBMT will be administered by a trained member of the study team using the LightForce® XPi therapy laser, provided by LiteCure, LLC/DJO Global (New Castle, DE). The LightForce® XPi therapy laser is an FDA cleared device for the treatment of pain. The trained team members will use the Smart Hand Piece technology, which achieves effective treatments and improves dosing accuracy by assessing the operator's speed and providing real-time visual (red - amber - green light) and sensory feedback.
223521979|NCT05763381|DEVICE|Sham-Photobiomodualtion Therapy (Sham-PBMT)|Sham-PBM treatment time will be calculated in the same way as the PBM treatment group, with the time of treatment dependent on the size of the treatment area. The sham-PBMT will be administered by rolling the massage ball over the plantar surface of the foot and dorsal aspect of the calf in contact with the participants' skin. Because emission of photons at the selected treatment parameters may cause participants in the treatment group to feel warmth, the massage ball will be warmed in the sham-PBMT. The device will be turned on, so the red aiming beam will be visible, but the operator will not activate the switch to emit photons.
223521980|NCT06638359|BEHAVIORAL|moderate exercise|moderate exercise for 47 minutes
223521981|NCT06638359|BEHAVIORAL|interval exercise|interval exercise for 28 minutes
223521982|NCT06638359|BEHAVIORAL|Control (placebo) group|without exercise
223521983|NCT06001255|DRUG|HS-20093|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223521984|NCT06564350|DEVICE|IMU (Inertial Measurement Unit) sensors|IMU sensors track an object's acceleration and angular velocity over time and do not emit any electromagnetic fields or radiation. They use tiny masses and springs to measure the acceleration, as well as Hall effect materials to measure the magnetic fields. The force sensor changes its electric resistor value based on the force applied to the sensor surface.
223521985|NCT06639802|OTHER|Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)|HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
223521986|NCT06637202|RADIATION|postoperative radiotherapy|50 Gy in 25 fractions
223704428|NCT01479023|DRUG|U3-1287 (unlabeled)|
223704429|NCT03523130|DIAGNOSTIC_TEST|Imaging|Macrophage-specific inflammation
223704430|NCT00156897|DRUG|ATL-962|
223704431|NCT00156897|DRUG|Orlistat|
223704432|NCT05143281|DRUG|Dexamethasone 0.4 MG [Dextenza]|Ophthalmic Intracanalicular Insert
223704433|NCT00423514|BIOLOGICAL|filgrastim|
223521987|NCT06640621|DRUG|Different concentration of ropivacaine for single brachial plexus block|40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
223521988|NCT01464606|DRUG|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
223521989|NCT01464606|DRUG|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
223521990|NCT01464606|DRUG|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
223521991|NCT01464606|DRUG|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
223521992|NCT01464606|DRUG|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
223521993|NCT06639139|BEHAVIORAL|CogFun RG occupational therapy|21 weekly, online group sessions (4-6 participants in each group), lasting 90 minutes. Sessions are structured, comprising opening, collaborative learning, and summary. Session topics include learning about ADHD as a biological disorder of executive functioning, understanding the impact of ADHD on daily life, discovering strategies for coping with ADHD through exploration of life experiences, and preparing for future self management
223521994|NCT06639763|DIAGNOSTIC_TEST|Questionnaire|Questionnaire containing a combination of basic epidemiological questions, questions regarding recent sexual activity, questions regarding sexual preference and sexual activity, questions regarding the use of different types of erectile aids, questions regarding satisfaction with the use of these different erectile aid and questions regarding the satisfaction with sexual functioning and the partner relation. Al patients at least 6 months after primary genital gender-affirming surgery and who are sexually active are eligible.
223521995|NCT06222684|OTHER|Music therapy|Women applying for mammography screening will receive music therapy for 5 minutes before the procedure, during the mammography scan and for 5 minutes after the procedure.
223521996|NCT06561243|DRUG|BTK inhibitor (Ibrutinib or Acalabrutinib)|Adult patients with a chronic B-cell malignancy included in this study will be separate into 2 groups according to the BTK inhibitor (ibrutinib and acalabrutinib)
223521997|NCT06439810|DIAGNOSTIC_TEST|Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)|Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
223521998|NCT06197581|RADIATION|Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)|Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
223521999|NCT05905146|OTHER|personalized pharmaceutical plan|multi-professional intervention around strong opioid treatment with targeted pharmaceutical interview
223522000|NCT06642493|BIOLOGICAL|Fresh frozen plasma|"Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion."
223522001|NCT06564922|OTHER|Counselling|Counselling was given for treatment group.
223522002|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave once a week
223522003|NCT06563739|PROCEDURE|Divergent low energy shock wave|Receive divergent low energy shock wave twice a week
223522004|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave once a week
223522005|NCT06563739|PROCEDURE|Divergent medium and low energy shock wave|Receive divergent medium and low energy shock wave twice a week
223522006|NCT06563739|PROCEDURE|Focused low energy shock wave|Receive focused low energy shock wave once a week
223522007|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave once a week
223522008|NCT06563739|PROCEDURE|Divergent medium energy shock wave|Receive divergent medium energy shock wave twice a week
223522009|NCT06563739|PROCEDURE|Non-exposed group|Traditional rehabilitation assessment and training guidance
223522010|NCT06642064|BEHAVIORAL|Intervention group|"• Intervention group:~Participants were invited to participate in a 20-minute interactive learning course (PPT lecture) and a 25-minute physical activity.The intervention lasted for 12 weeks, twice a week, 45 minutes each time, for a total of 1080 minutes."
223522011|NCT03535129|BEHAVIORAL|Real time fMRI neurofeedback|During fMRI study, display feedback of brain activity to practice and reinforce control of alcohol craving.
223522012|NCT06641921|DEVICE|Seerlinq haemodynamically-guided heart failure treatment|Heart failure treatment of participants in the Seerlinq intervention arm will be haemodynamically-guided based on the results from the Seerlinq telemedical monitoring system.
223522013|NCT02853136|DRUG|Fluvoxamine|Fluvoxamine
223522014|NCT02853136|DRUG|BI 409306 - Powder for oral solution (PfOS)|BI 409306 - Powder for oral solution (PfOS)
223522015|NCT02853136|DRUG|BI 409306 - film coated tablet|BI 409306 - film coated tablet
223522016|NCT06642740|OTHER|Platelet count|divide into two groups based on platelet count
223522017|NCT06642272|DRUG|Empagliflozin 10 MG|Once daily
223522018|NCT06642272|DRUG|Dapagliflozin 10 MG|Once daily
223522019|NCT05231915|GENETIC|HOXB13 c.853delT mutation|Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
223522020|NCT00841815|DRUG|Amlodipine Besylate|10 mg Tablet
223522021|NCT00841815|DRUG|Norvasc®|10 mg Tablet
223522022|NCT04805593|DEVICE|WaveLight EX500 excimer laser system|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the Wavefront Optimized (WFO) Ablation profile of the WaveLight EX500 excimer laser system will be used for bilateral LASIK treatment of hyperopia with and without astigmatism.
223704434|NCT00423514|DRUG|clofarabine|
223704435|NCT00423514|DRUG|melphalan|
223522023|NCT04805593|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system.
223522024|NCT04540471|OTHER|music|MT group receives additional music therapy
223522025|NCT04540471|OTHER|comprehensive in-patient education program|comprehensive in-patient education program
223522026|NCT05098821|OTHER|not applicable, observational study|Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study
223522027|NCT06641700|DIAGNOSTIC_TEST|diagnosed with gastric cancer|Pathological biopsy confirmed the diagnosis of gastric cancer.
223522028|NCT06637085|DEVICE|LLLT|low level laser therapy Probe laser device: (Laserklasse2M, EN60825-1, +A2:2002, W.L= 635-670nm, P\<6mW, German):low level laser therapy It will be used to stimulate vagus nerve .
223522029|NCT06637085|OTHER|traditional physical therapy|traditional physical therapy include (phase I cardiac rehabilitation, breathing exercises, modified postural drainage, percussion and vibration)
223522030|NCT06637085|DEVICE|ACU TENSE|Acu-TENS device (Digital TENS, EAF20, JERF20BD0604, add manufacturing country): It will be used to stimulate vagus nerve throug h the acupoint PC6 .
223522031|NCT06565286|PROCEDURE|inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias|compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
223522032|NCT00867334|DRUG|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
223522033|NCT00867334|DRUG|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
223522034|NCT00901914|BIOLOGICAL|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
223522035|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
223522036|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
223522037|NCT00901914|BIOLOGICAL|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
223522038|NCT03787615|DEVICE|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
223522039|NCT05516875|DRUG|JM-010|JM-010
223522040|NCT02129972|DEVICE|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
223522041|NCT03031626|BIOLOGICAL|Medical Air vs Oxygen|Medical Air/Oxygen will be given
223522042|NCT06539442|DEVICE|Versius Surgical System|Urological minimal access surgery performed with Versius Surgical System
223522043|NCT04427670|OTHER|Group intervention|Group intervention programme designed for stroke survivors with dysarthria and their carers. The programme was eight weeks long, with weekly two sessions, each session lasting for two hours, lead by speech language therapist and was comprised of activities which addressed participants education about their dysarthria and stroke. The role of family , peer and professional was to provide support and communication practice.
223522044|NCT04427670|OTHER|Regular speech therapy|Regular speech therapy will be provided to the controlled group.Regular speech therapy is one to one speech therapy session,conducted twice a week for the duration of eight weeks.This intervention is implemented to patients with dysarthria following stroke in a format of one patient and one therapist per session.
223522045|NCT06487936|DEVICE|TransLoc 3D SI Joint Fusion System|Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
223522046|NCT02697448|DRUG|propofol|Participant receives propofol as anesthetic for cardiac ablation.
223704436|NCT00423514|DRUG|mycophenolate mofetil|
223522047|NCT02697448|DRUG|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
223704437|NCT00423514|DRUG|tacrolimus|
223704438|NCT00423514|DRUG|thiotepa|
223704439|NCT00423514|PROCEDURE|allogeneic bone marrow transplantation|
223704440|NCT00423514|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223704441|NCT00423514|PROCEDURE|peripheral blood stem cell transplantation|
223704442|NCT06213246|BEHAVIORAL|Sleep Hygiene Strategies|"The sleep hygiene strategies will be applied for all seven days of Week 3 and will involve the following guidelines recommended by the National Sleep Foundation~* Maintain a consistent wake-up and bedtime schedule during workdays.~* Do not delay/advance excessively (no more than 2 hours) the wake-up and bedtime - schedule during weekends.~* Keep the bedroom temperature below 22°C.~* Avoid sources of light and noise in the bedroom.~* Use the bed only for sleeping, avoiding other activities before bedtime.~* Avoid daytime naps during workdays.~* Refrain from using electronic devices (PC, laptop, cellphone, television) at least 30 minutes before bedtime.~* Expose yourself to natural light in the morning and reduce artificial lights in the evening.~* Avoid consuming alcoholic beverages and caffeine in the afternoon.~* Have a moderately sized dinner at least 3 hours before bedtime."
223522048|NCT06078930|DIAGNOSTIC_TEST|Tongue imaging, tougue coating, saliva, gastric juice, and feces|Tongue images, coating, saliva, gastric juice, and feces on the tongue and clinical data of patients with gastric cancer and healthy participants will be collected.
223522049|NCT04550728|COMBINATION_PRODUCT|Ankle robot training group|Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
223522050|NCT04550728|COMBINATION_PRODUCT|Ankle robot training and functional electrical stimulation(FES) group|Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
223522051|NCT02994719|DRUG|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
223522052|NCT02994719|DEVICE|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
223522053|NCT06554639|DRUG|MK-5684|Administered via oral tablet per dosing regimen.
223522054|NCT06554639|DRUG|Prednisone|Administered at a dose of 2.5 mg or 5 mg dependent on HRT dosing regimen via oral tablets.
223522055|NCT06554639|DRUG|Fludrocortisone acetate|Administered at a dose of 0.05 mg per HRT dosing regimen via oral tablets.
223522056|NCT06554639|DRUG|Diltiazem hydrocholoride|Administered at a dose of 240 mg per dosing regimen via oral capsule (extended-release).
223522057|NCT03464461|DRUG|Ketorolac|IV drug
223704443|NCT02623140|DEVICE|Biofreedom|PCI with Biofreedom stent
223704444|NCT02623140|DEVICE|Orsiro|PCI with Orsiro stent
223522058|NCT06771024|BEHAVIORAL|Physical Exercise|The intervention include a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. International/national exercise prescription guidelines will be applied for each clinical condition (cardio/cerebrovascular disease/risk, diabetes mellitus and osteoarthritis).
223522059|NCT06642467|DEVICE|BGEM|BGEM is an ai driven model to predict blood glucose using ppg sensor
223522060|NCT06640283|DIAGNOSTIC_TEST|ctDNA test|ctDNA involves the collection of peripheral blood samples for the analysis of circulating tumor DNA (ctDNA). The samples are processed using next-generation sequencing (NGS) and/or digital polymerase chain reaction (PCR) techniques to detect specific genetic alterations related to the tumor. The objective is to assess the presence and quantity of ctDNA, providing information on tumor burden and treatment response.
223522061|NCT06640283|DRUG|Pembrolizumab|Participants will receive the institution's standard treatment during Phase I. If ctDNA remains positive between 8 and 12 weeks after the standard treatment, the participant will be invited to proceed to Phase II, which will consist of intravenous immunotherapy for up to 12 months, or until disease progression or unacceptable toxicity occurs. Continuous monitoring with ctDNA testing will be performed during Phase II.
223522062|NCT06637397|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
223704445|NCT00003591|DRUG|paclitaxel|
223704446|NCT00003591|RADIATION|radiation therapy|
223522063|NCT06637397|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
223522064|NCT06639529|DIAGNOSTIC_TEST|Tests of the expression of CXCL3 in various tissues|1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.
223522065|NCT06643429|DIAGNOSTIC_TEST|colorectal cancer|Patients diagnosed with colorectal cancer by pathological biopsy.
223522066|NCT06643429|DIAGNOSTIC_TEST|colorectal neoplasm|Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
223522067|NCT06644365|OTHER|Acupresure mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.This practice will continue for three menstrual cycles.
223704447|NCT04111575|BEHAVIORAL|Music Therapy|Music Therapy
223704448|NCT00310648|BIOLOGICAL|Influenza vaccine|
223704449|NCT06201663|DRUG|Romiplostim|Weekly subcutaneous injections
223704450|NCT03729466|OTHER|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
223704451|NCT05929157|DRUG|artesunate-pyronaridine|Pyronaridine and Artesunate are antimalarial agents with a history of clinical use, and Artesunate has been used clinically in combination with other drugs also. The action of Artesunate is a rapid knock down of the parasites, after which, the drug is quickly cleared as it has a short systemic half-life. Pyronaridine is also rapidly effective in the short term but has a long blood half-life thus providing a more sustained schizonticidal effect.
223704452|NCT02587884|PROCEDURE|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
223704453|NCT01008176|BEHAVIORAL|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
223704454|NCT02418078|PROCEDURE|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
223704455|NCT04786938|DRUG|Saccharomyces Boulardii-Containing Product in Oral Dose Form|S. boulardii CNCM I-745 (approximately 22.5 x109 CFU)
223704456|NCT02837146|BIOLOGICAL|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
223522068|NCT06644365|OTHER|Basic mat|The Premenstrual Syndrome Scale will be applied and the scale results will be evaluated. Participants who score 132 and above on the scale will be considered to be experiencing PMS. The intervention will be made in the second phase of the study.Participants in this group will also be sent a reminder message similar to the intervention group. This practice will continue for three menstrual cycles.
223522069|NCT06644807|PROCEDURE|Motor Cortex Stimulation|Motor Cortex Stimulation (MCS) is a neuromodulation technique that involves the surgical implantation of electrodes over the motor cortex, typically targeting the precentral gyrus, to deliver electrical stimulation. The procedure involves placing an electrode grid or strip on the dura mater overlying the motor cortex, which is identified via neuroimaging techniques such as functional MRI or neuronavigation. Once implanted, the electrodes are connected to an implanted pulse generator (IPG), which delivers adjustable electrical impulses.
223522070|NCT06644807|PROCEDURE|Spinal cord stimulation|Spinal Cord Stimulation (SCS) is a neuromodulation that involves the implantation of a device that delivers electrical impulses to the spinal cord through an electrode placed in the epidural space. The stimulation alters pain signals before they reach the brain, effectively masking or reducing the sensation of pain.
223522071|NCT06644807|PROCEDURE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation (PNS) is a neuromodulation technique used to treat chronic pain. The procedure starts with a preoperative assessment, including imaging to identify the target peripheral nerve. Under local anesthesia, a thin, insulated electrode is implanted near the nerve, usually with the help of fluoroscopic or ultrasound guidance for precision.
223522072|NCT06644807|PROCEDURE|Dorsal Root Ganglion Stimulation|Dorsal Root Ganglion Stimulation (DRGS) is a targeted neuromodulation technique for managing chronic pain. The procedure begins with a thorough preoperative assessment, including imaging to locate the specific dorsal root ganglion (DRG) associated with the pain. Under local anesthesia, a small electrode is implanted near the DRG. This is done through a minimally invasive procedure, often guided by fluoroscopy or CT imaging to ensure precise placement.
223522073|NCT03658304|DRUG|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
223522074|NCT05773482|BEHAVIORAL|Breathing and Attention Training (BAT)|BAT is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
223522075|NCT05773482|BEHAVIORAL|Breathing Control|Controlled Breathing (without mindfulness) is an instructor guided breathing technique over 20 min that will be applied once in a training session and approximately one week later in a testing session.
223522076|NCT06571890|DEVICE|Narcotrend bispectral index anaesthesia monitor|A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal
223522077|NCT06571890|DEVICE|Mdoloris Anaesthesia Nociception Monitor|A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
223522078|NCT03685149|DRUG|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
223522079|NCT03685149|DRUG|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
223522080|NCT01628952|DRUG|Transversus Abdominis Plane|PIA coelioscopic
223522081|NCT01628952|DRUG|Curare|IAP coelioscopic
223522082|NCT04148209|DRUG|PF-07081532|Participants will receive single ascending doses PF-07081532
223522083|NCT04148209|DRUG|Placebo|Participants will receive placebo
223522084|NCT01344655|DRUG|Atimos®|Formoterol 12 μg pMDI
223522085|NCT01344655|DRUG|Serevent™|Salmeterol 25 µg pMDI
223522086|NCT01344655|DRUG|Placebo|placebo
223522087|NCT05258292|DEVICE|Continuous glucose monitoring|Glucose levels will be measured using continuous glucose monitoring
223522088|NCT05258292|DRUG|Insulin|Insulin doses will be retrieved from insulin pump reports (for insulin pump users) or journals for (for multiple daily injections users)
223522089|NCT05258292|OTHER|Premenstrual symptoms|Premenstrual symptoms will be assessed using the Premenstrual symptoms screening tool
223522090|NCT05258292|OTHER|Ovulation kits|Ovulation testing will be done using ovulation kits
223522091|NCT05258292|DEVICE|Fitbit Inspire 2|Physical activity will be assessed using the Fitbit Inspire 2
223522092|NCT05258292|OTHER|Keenoa|Food intake will be assessed using the Keenoa phone application
223522093|NCT05258292|OTHER|Menstrual cycle|The application My Calendar will be used to record information on the menstrual cycle
223522094|NCT03191331|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
223522095|NCT05395312|OTHER|Online blended stepped-care mental well-being platform|"Participants in experimental group will be stratified according to their level of anxiety and/or depressive symptoms.~Level 2 (normal range)~* Topic-based personal growth articles, exercises, and chatbots~* Webinars and talks on varied mental health related topics~* Virtual support community~Level 3 (mild to moderate)~* Online self-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online skills-based workshops, questions-and-answers sessions, retreats~Level 4 (severe)~* Online coach-guided mental well-being training programs, such as mindfulness-based intervention, rumination-focused cognitive behavioural therapy, and transdiagnostic cognitive behavioural therapy~* Offline/online group therapy, 4-week group cognitive behavioural therapy or 8-week group mindfulness-based cognitive therapy"
223522096|NCT00260338|BIOLOGICAL|stem cell|mesenchymal stromal cell
223522097|NCT05844319|OTHER|tele-education|The treatment of the patients will be carried out by tele-education method.
223522098|NCT01522274|BEHAVIORAL|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
223522099|NCT01522274|BEHAVIORAL|Health education|Videos
223704457|NCT02837146|DRUG|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
223522100|NCT06570317|DRUG|Nintedanib|For patients with unresectable NSCLC, nidanib is administered during sequential radiotherapy
223522101|NCT04876391|DRUG|Spesolimab 1200 mg|Participants in the 1368-0052 PoCC trial's placebo arm received a 1200 mg intravenous (i.v.) loading dose at Visit 1, then 600 mg s.c. every two weeks for 12 weeks.
223522102|NCT04876391|DRUG|Spesolimab 600 mg|Participants in the 1368-0052 PoCC trial's active arm received a 600 mg subcutaneous (s.c.) loading dose of spesolimab at Visit 1, followed by 600 mg s.c. every two weeks for 12 weeks.
223522103|NCT04876391|DRUG|Placebo matching 600 mg Spesolimab|Participants from the placebo arm of the 1368-0052 PoCC trial will receive a subcutaneous (s.c.) administration of placebo matching 600 mg spesolimab at Visit 1.
223522104|NCT04876391|DRUG|Placebo matching 1200 mg Spesolimab|Participants from the active arm of the 1368-0052 PoCC trial will receive an intravenous (i.v.) infusion of placebo matching 1200 mg spesolimab at Visit 1
223522105|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
223522106|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
223522107|NCT01822327|BEHAVIORAL|Contingency Management|CRA plus Vouchers earned independent of cocaine use
223522108|NCT01743144|DRUG|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
223522109|NCT01743144|DRUG|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
223522110|NCT01257750|DRUG|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
223522111|NCT04717739|DEVICE|TTFields|Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
223522112|NCT01310751|DRUG|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
223522113|NCT01310751|DRUG|distilled water|2 ml per session
223704458|NCT02807519|GENETIC|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
223704459|NCT01462643|DRUG|LAS41004|once daily, topical ointment, 100 microgram per day
223704460|NCT03098121|DRUG|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
223704461|NCT03569085|DRUG|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
223522114|NCT03524066|DRUG|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
223522115|NCT03524066|DRUG|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
223522116|NCT03524066|OTHER|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
223522117|NCT06196034|GENETIC|No intervention|No intervention
223522118|NCT06186284|DIAGNOSTIC_TEST|nerve conduction study|sensory and motor nerve conduction study of both median nerves and ulnar nerves
223522119|NCT06186284|DIAGNOSTIC_TEST|ultrasonography wrists|assess the cross-sectional area of the median nerves and the ulnar nerves
223704462|NCT03569085|DRUG|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
223704463|NCT00607984|DRUG|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
223522120|NCT06186284|DIAGNOSTIC_TEST|Boston carpal tunnel questionnaire|assess the severity of symptoms and the functional impact related to carpal tunnel syndrome
223522121|NCT06186284|DIAGNOSTIC_TEST|clinical provocative tests for carpal tunnel syndrome|Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
223522122|NCT02871440|DRUG|Omega 3|
223522123|NCT02871440|DRUG|Optive Advanced|
223522124|NCT02871440|DRUG|Optive|
223522125|NCT00159445|DRUG|gemcitabine, capecitabine|
223522126|NCT06407011|OTHER|Control|The CON group did not have any intervention but usual care.
223522127|NCT06407011|OTHER|Swedish massage prior circuit breathing training group (SBT)|Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
223522128|NCT06407011|OTHER|Circuit breathing training group (CBT)|Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
223522129|NCT04647357|DRUG|SHR-1316|Anti-PD-L1 antibody，Maintenance therapy, The drug was administered every three weeks
223522130|NCT04481841|DRUG|oryzanol + vitamin B2 (riboflavin) + vitamin E|"1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.~2.Therapeutic regimen of experimental group On the basis of classical Gu-Nucleus-E triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment."
223522131|NCT00255502|DRUG|metoprolol succinate|
223522132|NCT03925467|OTHER|Acupuncture|"Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21."
223704464|NCT04433663|OTHER|Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis|"To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome."
223704465|NCT04330274|OTHER|Bipedal with open eyes|Standing bipedal with open eyes on force platform
223522133|NCT00209131|DRUG|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
223522134|NCT00209131|DRUG|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
223522135|NCT04347967|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
223522136|NCT05360784|DRUG|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation|Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
223522137|NCT05360784|DRUG|Lumify® (brimonidine tartrate ophthalmic solution 0.025%)|Lumify® (brimonidine tartrate ophthalmic solution 0.025%). Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
223522138|NCT04248153|DRUG|BR55|BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
223522139|NCT05218083|BEHAVIORAL|REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)|"REmotely Monitored, Mobile health-supported, High Intensity Interval Training consists of remotely monitored tailored, structured, progressive multidomain physical rehabilitation \& personalized instruction \& coaching.~Patients complete 3 structured exercise sessions/week consisting of HIIT, strength, balance, and mobility exercises. Following warmup, patients increase workload at a heart rate corresponding to 95% VO2peak for 1-minute before returning to warm-up speed for 1-minute at a heart rate corresponding to 60% VO2peak.~Strength includes functional strengthening exercises for lower extremities \& general resistance exercises for major muscle groups.~Balance incorporates static \& dynamic exercises, including progressively narrowing base of support with eyes open or closed, reaching forward \& backward starting within base of support \& progressing to outside base of support.~Mobility rehabilitation includes dynamic start/stop while walking and changing direction while walking."
223522140|NCT05142306|BIOLOGICAL|COVID-HIG|Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation
223522141|NCT01143441|BIOLOGICAL|DAC-HYP|
223704466|NCT04330274|OTHER|Bipedal with closed eyes|Standing bipedal with closed eyes on force platform
223704467|NCT04330274|OTHER|Bipedal with open eyes and with platform|Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
223704468|NCT04330274|OTHER|Bipedal with closed eyes and with platform|Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
223704469|NCT00951444|BIOLOGICAL|dalotuzumab|Given IV
223704470|NCT00951444|DRUG|carboplatin|Given IV
223704471|NCT00951444|DRUG|gemcitabine hydrochloride|Given IV
223704472|NCT05727436|DIETARY_SUPPLEMENT|Dentoblis|Dissolve the tablets in the mouth once a day for 4 weeks
223704473|NCT05727436|DIETARY_SUPPLEMENT|Placebo|Dissolve the tablets in the mouth once a day for 4 weeks
223704474|NCT02437812|DRUG|Metformin|Metformin with standard chemotherapy
223704475|NCT02437812|DRUG|Paclitaxel|Standard chemotherapy
223704476|NCT02437812|DRUG|Carboplatin|Standard chemotherapy
223704477|NCT04872400|DRUG|Vancomycin|1 vial of Vancomycin 1g powder applied topically to the open fracture wound injury.
223704478|NCT04872400|DRUG|Tobramycin|1 vial of Tobramycin 1.2g powder applied topically to the open fracture wound injury.
223522142|NCT02251041|DRUG|Antithrombin-III|
223522143|NCT02251041|DRUG|Infliximab|
223522144|NCT02251041|DRUG|Apotransferrin|
223704479|NCT01132365|DEVICE|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
223704480|NCT03596008|DIETARY_SUPPLEMENT|Active drink|The freeze-dried strawberry powder (25 g) in active drink
223704481|NCT03596008|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink
223704482|NCT03685123|BEHAVIORAL|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
223704483|NCT03685123|BEHAVIORAL|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
223704484|NCT03685123|BEHAVIORAL|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
223522145|NCT02251041|DRUG|Human recombinant erythropoietin|
223522146|NCT02251041|DRUG|C1-Inhibitor|
223522147|NCT02251041|DRUG|Glutathione|
223522148|NCT02251041|DRUG|Alfa-tocopherol|
223522149|NCT02251041|DRUG|Melatonin|
223522150|NCT02251041|DRUG|Epoprostenol|
223522151|NCT02251041|DRUG|Sodium chloride solution|
223522152|NCT05681078|BEHAVIORAL|A Matter of Balance: Managing Concerns about Falls|A Matter of Balance is an evidence-based program targeting physical activity and fall prevention for adults 60 years of age and older. This program incorporates active learning discussions and activities along with exercise training to reduce the fear of falling, improve fall efficacy and management, and increase physical activity levels in older adults.
223522153|NCT04918771|DRUG|Raphamin|"Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days."
223522154|NCT04918771|DRUG|Placebo|Oral administration - not with food. Placebo using Raphamin scheme.
223522155|NCT01046669|DEVICE|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
223522156|NCT01046669|OTHER|Standard medical care for septic shock|Standard medical care for septic shock
223522157|NCT02062684|DRUG|Blisibimod|
223522158|NCT02062684|DRUG|Placebo|
223522159|NCT03434899|BEHAVIORAL|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
223522160|NCT03434899|BEHAVIORAL|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
223522161|NCT00200239|BEHAVIORAL|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
223522162|NCT02915601|DRUG|Sodium bicarbonate|
223522163|NCT02915601|DRUG|Placebo|
223522164|NCT03794726|PROCEDURE|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
223522165|NCT03794726|PROCEDURE|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
223522166|NCT01469156|DRUG|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
223522167|NCT02848027|BIOLOGICAL|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
223522168|NCT05385289|BEHAVIORAL|A cognitive-behavioral approach of rumination as intervention for overgeneral mode of processing in perfectionism|"The B-experimental phase consists in a 6-session intervention targeting rumination and lasting for 3 weeks. The intervention was derived from 3 manuals: Rumination-Focused Cognitive-Behavioral Therapy for Depression (Watkins, 2016), Overcoming Perfectionism (Shafran et al., 2010), and Cognitive-Behavioral Treatment of Perfectionism (Egan et al., 2014). Participants will attend 2 sessions per week at home. Each week will end with an individual 30 minutes-debriefing session with an experimenter, to ascertain understanding of session content and homework.~Intervention sessions will be given in paper format to participant after the A-baseline-phase. A paper diary was also provided for homework, in addition to the session content caneva. Each session contains (a) theoretical content on ruminations linked to perfectionism, (b) exercises to create alternative habits to ruminations, and (c) homework to become aware of ruminations and to experiment with alternatives."
223522169|NCT04832152|OTHER|OT4ASD|Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
223522170|NCT04297774|BEHAVIORAL|virtual reality treatment|18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
223522171|NCT04297774|BEHAVIORAL|standard treatment|18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
223704485|NCT01823302|DIETARY_SUPPLEMENT|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
223704486|NCT01823302|OTHER|nutritional counseling|nutritional counseling
223704487|NCT03555760|BEHAVIORAL|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
223704488|NCT02416219|PROCEDURE|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
223704489|NCT02416219|DEVICE|Ultrasound|
223704490|NCT02702453|BEHAVIORAL|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
223522172|NCT04297774|BEHAVIORAL|balance training|18 balance training sessions (30 minutes a time, 2-3 times a week) (1) Facilitated the balance reaction through weight shifting exercise with standing on even surface to uneven surface, such as tilting board.(2) Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. (3) Changed the standing requirement, such as single legged stance or lunge stance. (4) Increased perception complications through cognition or upper extremity task to improve dual task attention.
223522173|NCT05570162|OTHER|Diabetes educational program|30-minute long diabetes educational program
223522174|NCT03918291|OTHER|Addition of whole-body vibration to squat training|
223522175|NCT03918291|OTHER|Squat training|squatting exercises for 12 weeks, 3x/week
223522176|NCT04564014|BEHAVIORAL|ISSS|The ISSS aims to help participants acquire problem-solving (e.g., interpersonal problems) and time management based on the treatment manual of the therapy. Video introductions for each session and example teacher characters who depict the targeted problems and demonstrate implementation of coping/management techniques in a variety of situations. ISSS will use metaphors, daily examples, and lively narrative stories to enhance motivation for participation and understanding of the intervention contents. Session 2-5 will assign exercise and homework. Within 48 hours, participants will receive personalized written feedback (e.g., suggestions) from an e-Coach on the exercises they have completed. Participants can contact e-Coaches via the online system if they have any questions regarding the contents. Questions that beyond the contents will be referred to the health psychologist (PI) by e-Coaches.
223522177|NCT04564014|OTHER|Education Materials|Participants will recieve education materials addressing the following issues: (1) introduction to mental health and mental illness; (2) signs and symptoms of depression; (3) treatment of depression and available community resources; (4) signs and symptoms of anxiety; (3) treatment of anxiety and available community resources. The education materials will be carefully developed by the health psychologists and clinical psychologist of the research team who are very experienced in education intervention for mental and emotional health.
223522178|NCT00003158|DRUG|carboplatin|
223522179|NCT00003158|DRUG|etoposide|
223522180|NCT00003158|DRUG|paclitaxel|
223522181|NCT00003158|RADIATION|radiation therapy|
223522182|NCT02839928|DRUG|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
223522183|NCT02839928|DEVICE|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
223522184|NCT02839928|DRUG|EMLA|
223522185|NCT04898179|OTHER|Telecare Group|"Home-based telehealth program: telenursing and specialist teleconsultation~Telemonitoring with a new pulse oximeter and specific App~E-health platform~Videoconference"
223522186|NCT04898179|OTHER|Control group|Usual care
223704491|NCT00611507|DRUG|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
223704492|NCT00400764|DRUG|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
223704493|NCT00400764|DRUG|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m\^2 weekly for up to eight doses.
223704494|NCT03404232|DEVICE|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
223704495|NCT05475561|PROCEDURE|Ultrasound guided Pecto-intercostal- fascial plane block|The probe of the ultrasound will be placed at 2 cm lateral to the lateral sternal border at 5th and 6th rib. On the surface plane subcutaneous tissue is identified, while Pectoralis major muscle, Intercostal muscles and ribs are seen in intermediate plane and lung along with pleura are identified in deep plane. A 22-gauge, 80-mm short bevel echogenic needle is used and advanced in in-plane manner, in a caudal-to-cranial direction, until the tip of the needle is located in the fascial plane between the pectoralis major and internal intercostal muscle, where the local anesthetic will be injected.
223704496|NCT05475561|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. Three muscles trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process.Local infiltration with 2% of lignocaine at the site of needle insertion will be done. Using in-plane approach a 22 G short bevel needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro dissection below the muscle plane. A 20 ml of 0.25% plain bupivacaine will be injected on each side.
223704497|NCT05475561|DRUG|Bupivacain|local anesthetic
223704498|NCT05351021|DRUG|Metformin|cidophage 850 gm twice daily
223522187|NCT01299961|DRUG|abatacept|125 mg once a week up to 12 months.
223704499|NCT05351021|DRUG|Placebo|placebo twice daily for treatment period
223704500|NCT05095038|DIETARY_SUPPLEMENT|Appethyl®|Spinach extract, capsules, 5g/day, 26 weeks.
223704501|NCT05095038|DIETARY_SUPPLEMENT|Placebo|Pea protein, capsules, 5g/day, 26 weeks.
223704502|NCT04042896|BEHAVIORAL|exergame|Exergame is 'exercise + game'.
223522188|NCT02904096|DEVICE|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
223522189|NCT05143411|OTHER|PRE-test|we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
223522190|NCT04403685|DRUG|Tocilizumab|Single-dose infusion of 8 mg/kg. Maximum dose of 800 mg.
223522191|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) Low Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)\_Low Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -Low Dose :~   7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
223522192|NCT05887466|BIOLOGICAL|Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC) High Dose|"Biological/Vaccine: Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)\_High Dose~1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC -High Dose :~   1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3#)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
223522193|NCT02860403|PROCEDURE|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
223704503|NCT04042896|BEHAVIORAL|treadmill exercise|traditional aerobic exercise
223704504|NCT03439917|DIETARY_SUPPLEMENT|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
223704505|NCT03439917|DIETARY_SUPPLEMENT|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
223704506|NCT03439917|DIETARY_SUPPLEMENT|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
223704507|NCT02195336|DEVICE|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
223704508|NCT02195336|DRUG|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
223704509|NCT02195336|DRUG|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
223704510|NCT05263375|DEVICE|Innovalve TMVR system|Innovalve TMVR system
223704511|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
223704512|NCT01156259|RADIATION|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
223704513|NCT02058173|DRUG|150 mg/daily chloroquine compare to placebo for 12 week|
223704514|NCT02058173|DRUG|Chloroquine|
223704515|NCT02058173|DRUG|placebo|
223704516|NCT03308955|DRUG|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
223704517|NCT03308955|PROCEDURE|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
223704518|NCT03308955|PROCEDURE|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
224275544|NCT04380233|DRUG|Investigational drug for Functional Dyspepsia-Postprandial Distress Syndrome|The investigational drug is a new pure type of gastrointestinal function modulator traditional Chinese medicine, composed of 4 kinds of Chinese herbs: Rhizoma Atractylodis Macrocephalae, Fructus Aurantii Immaturus, Radix Bupleuri and Fructus Crataegi. The preliminary clinical trial showed that it has a good therapeutic effect on FD patients, its Fructus Aurantii Immaturus promotes gastric emptying by stimulating the cells to release motilin, thereby significantly improving patients' symptoms of fullness, epigastric pain, eructation, and nausea and vomiting.
223704519|NCT00270335|DRUG|Propofol|
223704520|NCT02628938|OTHER|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
223704521|NCT02628938|OTHER|Miswak stick|Miswak stick twice a day for 7 days
223704522|NCT02628938|OTHER|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
223704523|NCT04234360|DRUG|5 days of systemic corticotherapy (prednisone)|Patients randomized to this arm will receive 40 mg prednisone per os per day for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
223704524|NCT04234360|DRUG|5 days of placebo|Patients randomized to this arm will receive an appropriate placebo per os for 5 days. Other aspects of standard, recommended care (e.g. antibiotherapy) are respected.
223704525|NCT00529334|RADIATION|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
223704526|NCT03064750|BEHAVIORAL|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
223704527|NCT03064750|OTHER|Waiting list|patients wait as usual until surgery without special treatment.
224275545|NCT04380233|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
224275546|NCT03370510|DRUG|Oxytocin|Oxytocin nasal spray.
224275547|NCT03370510|BEHAVIORAL|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
224275548|NCT03370510|DRUG|Placebo|Placebo nasal spray.
224275549|NCT04044573|PROCEDURE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
224275550|NCT00772148|DRUG|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
224275551|NCT00772148|DRUG|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
224275552|NCT06063590|BIOLOGICAL|StromaForte|100 millions allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
224275553|NCT01234961|BEHAVIORAL|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
224275554|NCT01234961|OTHER|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
224275555|NCT00749658|DRUG|Bupropion|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
224275556|NCT00749658|DRUG|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
224275557|NCT04884022|PROCEDURE|Miniplates in mandibular symphysis & infrazygomatic|Fixed functional appliance (pushing orthopedic force) in conjunction with direct skeletal anchorage
223522194|NCT04719312|PROCEDURE|Y modification of transconjunctival approach|"Section of the orbital septum is done at the Arcus Marginalis and subperiosteal dissection done to expose the infraorbital rim and orbital floor.~Subsequently, canthotomy of the superficial limb of the lateral canthal ligament is performed and subperiosteal dissection is carried out to expose the fracture at the frontozygomatic region.~The cutaneous Y will transform into a box when retracting its corners, increasing the working area and allowing access of the frontozygomatic (FZ) suture, lateral orbital wall, body of the zygoma, infraorbital rim, and floor of the orbit with a single approach.~A small upper vestibular incision is placed to expose the fracture at the zygomatic buttress. Reduction and fixation of fractures in a regular fashion are accomplished."
223522195|NCT05679557|OTHER|Perioperative geriatric assessment and intervention|The intervention will comprise a preoperative, thorough geriatric, multidisciplinary assessment (CGA) and tailored interventions, focused on optimizing health issues of expected importance in further course of surgery. Furthermore, postoperative ward rounds by a geriatric team will be conducted. Thus, the course of treatment for each patient will be a close interdisciplinary collaboration.
223522196|NCT03898973|BIOLOGICAL|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
223522197|NCT00191698|DRUG|atomoxetine hydrochloride|
223522198|NCT00191698|DRUG|placebo|
223522199|NCT01442610|DRUG|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
223522200|NCT01442610|DRUG|Placebo|Placebo 1tablet once daily for 8 weeks
223522201|NCT02082379|BEHAVIORAL|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
223522202|NCT00006377|DRUG|carboplatin|
223522203|NCT00006377|DRUG|doxorubicin hydrochloride|
223522204|NCT00006377|DRUG|paclitaxel|
223522205|NCT03366831|BEHAVIORAL|Thirty Million Words Initiative Newborn Intervention|The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
223522206|NCT06501976|DRUG|Lurbinectedin|2.6 mg/m2 , Given IV, every 21 days
223522207|NCT06501976|RADIATION|Radiation Therapy|Thoracic radiotherapy
223534920|NCT05214352|OTHER|co-design in the intervention manual elaboration to increase the participation in the community|"It will co-design an intervention manual between all participants (families, young people with cerebral palsy and therapists) and researchers, using the involvement matrix to increase the participation of young people in the community.~Different focus grous will be created to work together and various online meetings, masterclass, workshops to increase the knowlodge in all groups."
223534921|NCT03147183|DRUG|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
224275558|NCT04884022|PROCEDURE|Miniplates in external oblique ridge & anterior maxillary region|Coil spring (pulling orthopedic force) in conjunction with direct skeletal anchorage
224275559|NCT02766257|PROCEDURE|Anesthesia for ambulatory paediatric surgery|
224275560|NCT01525628|DRUG|midazolam|CYP3A probe drug
224275561|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
223522208|NCT01182246|DRUG|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
223522209|NCT05305651|DRUG|Sotrovimab|Sotrovimab dose and administration per standard of clinical care
223522210|NCT05751304|DRUG|Dexmedetomidine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 5μg Dexametomidine.
223522211|NCT05751304|DRUG|Ketamine|(50 patients) will receive calculated dose of intrathecal hyperbaric bupivacaine 0.5 % according to body weight and 0.1 mg/kg ketamine.
223522212|NCT00526799|DRUG|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
224275562|NCT01525628|DRUG|tenofovir|nucleoside analogue
224275563|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
224275564|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
224275565|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
224275566|NCT01525628|DRUG|midazolam|CYP3A probe drug
224275567|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
224275568|NCT01525628|DRUG|pegylated interferon|HCV treatment
224275569|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
223522213|NCT00526799|DRUG|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
223522214|NCT06459778|DEVICE|Piezo-ICSI|Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
223522215|NCT01352455|PROCEDURE|Hemodialysis|5 days per week hemodialysis
223522216|NCT06250257|DRUG|Bromocriptine mesylate plus standard GDMT|The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
223522217|NCT05049824|DEVICE|Self Forming Magnetic (SFM) Anastomosis System|The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact metabolic disease indicators
224275570|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
224275571|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
224275572|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
224275573|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
224275574|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
223522218|NCT05427201|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique designed to alter network function
223522219|NCT05427201|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a mindfulness-based cognitive behavioral intervention that has demonstrated efficacy for chronic pain.
223522220|NCT04275518|DRUG|APG-115|APG-115 orally once daily from Days 1 to 7 every 28 days.
223522221|NCT04275518|DRUG|Azacitidine|75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
223704528|NCT03585062|DRUG|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
224275575|NCT01525628|DRUG|ribavirin|HCV treatment
223522222|NCT04275518|DRUG|Cytarabine|1g/m\^2 IV QD on Days 3-7 (28-day cycle)
224275576|NCT01525628|DRUG|ribavirin|HCV treatment
224275577|NCT01525628|DRUG|ribavirin|HCV treatment
224275578|NCT01525628|DRUG|pegylated interferon|HCV treatment
224275579|NCT01525628|DRUG|ribavirin|HCV treatment
224275580|NCT01525628|DRUG|caffeine|CYP1A2 probe drug
224275581|NCT01525628|DRUG|tolbutamide|CYP2C9 probe drug
224275582|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
224275583|NCT01525628|DRUG|midazolam|CYP3A probe drug
224275584|NCT01525628|DRUG|BI 201335|HCV protease inhibitor
224275585|NCT01525628|DRUG|BI 207127|HCV polymerase inhibitor
224275586|NCT01525628|DRUG|ribavirin|HCV treatment
224275587|NCT03573336|DRUG|Vilaprisan (BAY1002670)|Intake orally, once daily
224275588|NCT03573336|DRUG|Matching Placebo|Intake orally, once daily
224275589|NCT05723796|PROCEDURE|nasal endoscopy|nasal endoscopy and mucosal biopsy
224275590|NCT03959150|DRUG|Capecitabine|Oral fluorouracil
224275591|NCT00239005|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
224275592|NCT00239005|DRUG|Mycophenolate Mofetil (MMF)|
224275593|NCT00957762|OTHER|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
224275594|NCT02614898|OTHER|Eculizumab|This study was an observational study. Therefore, the study drug was not provided as part of this study, and the dosing regimen was based solely at the discretion of the treating physician.
224275595|NCT04202757|BIOLOGICAL|[21CFR640.30] Plasma from 18 - 25 year old volunteer donors|12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
224275596|NCT04202757|OTHER|Saline|12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
224275597|NCT03382041|DEVICE|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
224275598|NCT03382041|DEVICE|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
224275599|NCT06468904|PROCEDURE|cervical stabilization exercises and integrated neuromuscular technique.|"Patients received cervical stabilization exercises and integrated neuromuscular inhibition technique. Cervical stabilization protocol included strengthening exercises of deep cervical flexors muscles which included chin tucks, isometric holds, ball squeeze, as well as deep cervical extensors muscles which included cranio-cervical flexion from neutral, upper cervical rotation and extension of cervical spine.~integrated technique includes ischemic compression, muscle energy technique and strain counter strain."
224275600|NCT00787605|DRUG|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
224275601|NCT00787605|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
224275602|NCT00787605|DRUG|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
224275603|NCT02075385|PROCEDURE|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
224275604|NCT04107064|BEHAVIORAL|NaW|Participants will receive assistance with finding employment, onboarding, training, and so on.
224275605|NCT04107064|BEHAVIORAL|NaW-DS|Participants will receive assistance with onboarding and training 6 months after the initiation of their employment.
224275606|NCT00606658|PROCEDURE|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
224275607|NCT02127216|BEHAVIORAL|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
224275608|NCT06095180|OTHER|corticosteroid injection|In the steroid group, 4 mL lidocaine 2% + 1 mL betamethasone injection will be administered under ultrasound guidance and conventional treatment will be given (conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
224275609|NCT06095180|OTHER|dry needling|In the dry needling group, a total of 3 sessions of dry needling will be performed once a week using a 0.60×100 mm sterile needle under ultrasound guidance and conventional treatment will be given ((conventional treatment includes piriformis stretching exercises. It will be stated that patients should do 2 sets a day and each set should be 10 repetition)
224275610|NCT06095180|OTHER|exercise|The conventional treatment group (control group) will be given piriformis stretching exercises including hip and knee flexion, hip abduction and external rotation in the supine position. It will be stated that patients should do 2 sets a day and each set should be 10 repetitions.
224275611|NCT03298880|DEVICE|Supine VM VAD|Valsalva strain delivered using VAD
224275612|NCT03298880|DEVICE|Supine VAD manometer|supine Valsalva strain delivered using manometer
224275613|NCT03298880|OTHER|Modified VM VAD|modified VM using VAD
224275614|NCT03298880|OTHER|Modified VM Manonmeter|Postural modified position VM using manometer
224275615|NCT05762016|PROCEDURE|Bedside Mini-Incision and Self-Express (MISE)|To perform bedside mini incision and encourage patients to self express the pus following the intervention
224275616|NCT02299869|DEVICE|Verde (Competitor-control)|contact lens
224275617|NCT02299869|DEVICE|Green (CVI-test)|contact lens
224275618|NCT02299869|DEVICE|Cinza (Competitor-control)|contact lens
224275619|NCT02299869|DEVICE|Grey (CVI-test)|contact lens
223522223|NCT04581083|DIAGNOSTIC_TEST|RT-PCR|RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.
223522224|NCT04581083|DIAGNOSTIC_TEST|LAMP|LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.
224275620|NCT02299869|DEVICE|Esmeralda (Competitor-control)|contact lens
224275621|NCT02299869|DEVICE|Jade (CVI-test)|contact lens
224275622|NCT02299869|DEVICE|Azul (Competitor-control)|contact lens
224275623|NCT02299869|DEVICE|Blue (CVI-test)|contact lens
224275624|NCT00563394|DRUG|ofloxacin|400 mg twice a day for 14 days
224275625|NCT00563394|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
223534922|NCT05124730|DRUG|Metformin 500mg prolonged release tablets (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
224275626|NCT03345615|DIAGNOSTIC_TEST|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
224275627|NCT02144805|PROCEDURE|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
224275628|NCT02144805|PROCEDURE|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
224275629|NCT06126939|BEHAVIORAL|Educational training based on the Denver model|In addition to routine health guidance, one-to-one parent classes were conducted to guide parents to interact with children once a week for 1h each time; A group leader was assigned to supervise the formulation of the intervention plan and ensure the quality of the intervention. The intervention lasted for 3 months
224275630|NCT02484508|DRUG|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
224275631|NCT02484508|DRUG|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
223704529|NCT03585062|DRUG|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
223522225|NCT04581083|DIAGNOSTIC_TEST|POOL RT-PCR|POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.
223522226|NCT04581083|DIAGNOSTIC_TEST|POOL LAMP|POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
223522227|NCT05431556|OTHER|Virtual mind-body group exercise classes|"Pre-operative period (baseline/intake day to day before surgery): mid- to high intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)~* Immediate post-operative period (post-operative hospitalization to 2 weeks after surgery): low- to mid-intensity classes focusing on relaxation, stress management and low-impact physical activity (classes: Chair Yoga, Dance Therapy, Meditation, Music Therapy)~* Late post-operative period (3-12 weeks after surgery): mid- to high-intensity classes focusing on aerobic physical activity, relaxation, and stress management (classes: Fitness for Everyone, Tai Chi, Mat Yoga, Dance Cardio, Meditation, Core Strength, Music Therapy)"
223522228|NCT05431556|OTHER|Enhanced usual care|EUC arm will be referred to MSK's multimedia page on the Integrative Medicine website to access pre-recorded mind-body videos on their own time. These videos are 15-60 minutes in duration and consist of educational and self-care videos, including guided meditation and Tai Chi.
223522229|NCT02603497|DRUG|ASP015K|oral
223522230|NCT00532415|DRUG|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
223704530|NCT03015857|DRUG|phenylephrine|\- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
223522231|NCT02298946|DRUG|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
223522232|NCT02298946|RADIATION|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
223522233|NCT02298946|DRUG|Cyclophosphamide|200mg/m(2) IV on day 0.
223704531|NCT03015857|DRUG|Norepinephrine|\- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
223522234|NCT03847818|DRUG|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
223522235|NCT03044899|PROCEDURE|All surgeries in adult patients|All surgeries in adult patients
223522236|NCT01514578|DRUG|TRV130A|Intravenous infusion of 1 hour duration
223522237|NCT01514578|DRUG|Dextrose in Water|Intravenous infusion of 1 hour duration
223522238|NCT02510274|DRUG|ASP3325|oral
223522239|NCT05933603|DRUG|Atomoxetine and Oxybutynin (ato-oxy)|0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly
223522240|NCT00140920|DRUG|MK0966; rofecoxib|
223522241|NCT00140920|DRUG|Comparator: diclofenac 2x 75 mg|
223522242|NCT03096431|BEHAVIORAL|Physical Activity|"* Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~* One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
223522243|NCT03096431|BEHAVIORAL|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
223534923|NCT05124730|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of Reference (R) Product was administered orally with 240 mL of water.
223534924|NCT00024934|DRUG|B-Lymphocyte Stimulator (BLyS)|
223534925|NCT05697718|BIOLOGICAL|MSC|a single injection dose i.v.
223534926|NCT05525962|BEHAVIORAL|questionnaries, scales, cognitive tests|"A first interview is planned with a psycholgist in the weeks following the minor arrival in the structure (M0)~* M0: cognitive test, psychiatric classification and psychologic assessments~* M12 and M24: psychiatric classification and psychologic assessments"
223534927|NCT03892317|BEHAVIORAL|Pharmacist led medication adherence interventions|Medication adherence interventions which will be tailored to individual patient need
223534928|NCT05880147|DEVICE|Consent App|Family will receive their study information and consent form in an app on a tablet
223534929|NCT05880147|OTHER|Traditional paper-based consent|Patient/family will receive their study information and consent on a traditional paper form
223534930|NCT05242601|OTHER||no intervention
223534931|NCT01554098|PROCEDURE|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
223534932|NCT01554098|PROCEDURE|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
223534933|NCT00082121|DRUG|TP10|
223534934|NCT06568419|BEHAVIORAL|Transdiagnostic, work-focused Cognitive Behavioural Therapy|Transdiagnostic, work-focused Cognitive Behavioural Therapy focuses on core mechanisms that creates and maintain illness in depression and anxiety. Namely reducing avoidance and/or suppression of unwanted thoughts, avoidance of meaningful activity and increase cognitive flexibility while under psychological stress.
223534935|NCT02049411|DRUG|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
223534936|NCT02049411|DRUG|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
223704532|NCT03015857|DRUG|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
223704533|NCT03015857|DRUG|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
223704534|NCT03015857|DRUG|Placebo (normal saline)|
223704535|NCT02932202|OTHER|Longitudinal Nutritional Counseling|
223704536|NCT02932202|OTHER|Standard Care|
223704537|NCT03113916|BEHAVIORAL|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
223704538|NCT02029170|PROCEDURE|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
223704539|NCT02029170|PROCEDURE|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
223704540|NCT02398396|BIOLOGICAL|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
223704541|NCT02486523|BEHAVIORAL|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
224275632|NCT04485819|OTHER|Cleavage stage transfer|transferring embryos through ICSI procedures for poor responders on cleavage stage of embryonic development.
224275633|NCT04485819|OTHER|Blast stage transfer|transferring embryos through ICSI procedures for poor responders on blast stage of embryonic development.
223522244|NCT06309719|COMBINATION_PRODUCT|Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)|A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). A PNHA gel will be placed on the root surfaces and supra-bony defects, followed by a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
223522245|NCT06309719|PROCEDURE|Periodontal Access Flap (AF)|A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). No gel will be placed before suturing the flap by tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
223522246|NCT06035510|DIETARY_SUPPLEMENT|whey protein supplement|Participants are given Isolated whey protein supplement in evening before surgery and first day of post operation to compare with standard operative care on postoperative outcomes after gynecological cancer surgery
223522247|NCT04809714|DEVICE|Blood Flow Restriction with Delfi Tourniquet System Cuff|Postoperative rehabilitation will occur up to twice a day for 5 days a week for 2 weeks using a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of 60-100%. For each physical therapy session, participants will undergo therapy following a standardized protocol of 3-5 difference exercises each with 4 sets total in addition to NMES.
223522248|NCT04809714|OTHER|Routine Post-operative Physical Therapy|The control group with undergo a post-op therapy protocol that mirrors that of the intervention group except that they will use a Delfi tourniquet system blood pressure cuff with a limb occlusion pressure (LOP) of only 10%. Participants will use a neuromuscular electrical stimulation device operating at a sub-therapeutic level.
223522249|NCT05286619|DRUG|Pembrolizumab|Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
223522250|NCT05286619|DRUG|Cisplatin|Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
223522251|NCT05286619|DRUG|Carboplatin|Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
223522252|NCT05286619|DRUG|Gemcitabine|Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
223522253|NCT05250583|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
223522254|NCT06106568|PROCEDURE|EOB-MRI|Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan
223522255|NCT06106568|PROCEDURE|Surgery|Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan
223704542|NCT02486523|DEVICE|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
223704543|NCT02486523|BEHAVIORAL|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
223704544|NCT02486523|BEHAVIORAL|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
223704545|NCT02486523|PROCEDURE|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
223704546|NCT00041288|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223704547|NCT00041288|DRUG|cyclophosphamide|
223704548|NCT00041288|DRUG|cyclosporine|
223704549|NCT00041288|DRUG|fludarabine phosphate|
223704550|NCT00041288|DRUG|methotrexate|
223704551|NCT00041288|DRUG|mycophenolate mofetil|
223704552|NCT00041288|DRUG|tacrolimus|
223522256|NCT06106568|PROCEDURE|Open-close Laparotomy|Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
223522257|NCT05003700|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.
223522258|NCT05003700|DRUG|Lenvatinib|8 mg once daily (QD) oral dosing.
223522259|NCT05003700|DRUG|Camrelizumab|200mg intravenously every 3 weeks.
223522260|NCT03340935|OTHER|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
223522261|NCT04391608|DRUG|Switching to Tenofovir Alafenamide|Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
223522262|NCT00337597|OTHER|Glucose 5%|
223522263|NCT00337597|OTHER|NaCl 0.9%|
223522264|NCT03238547|DIAGNOSTIC_TEST|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
223522265|NCT03238547|DIAGNOSTIC_TEST|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
223522266|NCT00190528|DRUG|neoadjuvant chemotherapy + radical hysterectomy|
223522267|NCT00190528|PROCEDURE|radical hysterectomy|
223522268|NCT00958425|DEVICE|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
223522269|NCT00958425|DEVICE|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
223522270|NCT05472870|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
223522271|NCT05414942|BEHAVIORAL|Opioid Reduction Program|Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
223522272|NCT03118895|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
223522273|NCT04881097|BEHAVIORAL|no intervention|no intervention
223534937|NCT06642727|BEHAVIORAL|laughter yoga|Laughter yoga reduces stress levels through sessions lasting approximately 40 minutes without any invasive or pharmacological interventions. It regulates breathing, relaxes muscles, stimulates circulation, increases pain thresholds, strengthens immunity, lightens the mind, enhances social relationships, promotes mental balance, and boosts self-esteem, hope, energy, and quality of life. The content of a session includes deep breathing exercises, warm-up exercises, childlike games, and laughter exercises.
223534938|NCT06191445|PROCEDURE|Conventional Landmark Technique|The investigator will perform spinal anesthesia using the conventional landmark technique.
223534939|NCT06191445|PROCEDURE|Ultrasound Assisted Technique|The investigator will perform spinal anesthesia using the ultrasound assisted technique.
223534940|NCT06191445|PROCEDURE|Real-Time Ultrasound Guided Technique|The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
223534941|NCT05276674|DEVICE|ZNN Bactiguard Retrograde Femoral Nail|Femoral fracture internal fixation.
223534942|NCT06117059|RADIATION|3 fractions of prostate SBRT|Radical radiotherapy using only 3 fractions of prostate SBRT over 3 consecutive days
223534943|NCT03811470|OTHER|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
223534944|NCT04562311|DRUG|Chidamide|Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.
223534945|NCT06557759|BEHAVIORAL|Listening to Calming Music|Participants will listen to calming music, which may enhance health and wellness by reducing autonomic reactivity and improving bodily awareness, brain-body connection, and emotional wellbeing.
223534946|NCT05891899|OTHER|observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
223534947|NCT04087356|GENETIC|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
223534948|NCT01503320|DIETARY_SUPPLEMENT|Enteral glutamine|Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets
223534949|NCT01503320|DIETARY_SUPPLEMENT|Placebo|Similar appearing nutritional supplement without glutamine.
223534950|NCT02711501|PROCEDURE|Laser-assisted surgery.|laser-assisted surgery
223534951|NCT02711501|PROCEDURE|conventional surgery by blade|conventional surgery
223534952|NCT02622191|DEVICE|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
223534953|NCT02341066|DEVICE|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
223534954|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
223534955|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
223534956|NCT00565409|DRUG|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
223534957|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
223534958|NCT00565409|DRUG|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
223534959|NCT00565409|DRUG|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
223704553|NCT00041288|PROCEDURE|peripheral blood stem cell transplantation|
223704554|NCT00041288|RADIATION|radiation therapy|
223704555|NCT01363648|DRUG|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
223704556|NCT01363648|DRUG|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
223704557|NCT03417323|OTHER|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
224275634|NCT05978791|PROCEDURE|collection of venous blood or arterial blood|"1. Partial CAD patients were collected 20 mL arterial blood samples 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor. The blood samples were divided into 2 mL centrifuge tubes, with each containing 1.0 mL (for preparation of blood clots).~2. Partial CAD patients were collected 40 mL blood samples into sodium citrate anticoagulant tubes 12 hours after the last intake of 100mg aspirin and 2 hours after intake of 90mg ticagrelor (for preparation of platelet-poor plasma, PPP).~3. Healthy volunteer (group 1) collected 40 mL blood samples into sodium citrate anticoagulant tubes (for preparation of PPP).~4. Healthy volunteer (group 2) collected 9 mL venous blood samples (for platelet aggregation assay)."
224275635|NCT03345043|BIOLOGICAL|VAL-339851|Escalating dose levels
224275636|NCT03345043|OTHER|Placebo|Saline
224275637|NCT06626542|OTHER|resistance and aerobic training exercises|resistance and aerobic training exercises
224275638|NCT04620057|DIETARY_SUPPLEMENT|butyrate|sodium butyrate (20 mg/kg body weight/day)
224275639|NCT04620057|OTHER|placebo|cornstarch
224275640|NCT03297541|BEHAVIORAL|m-health approach|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981). Anthropometric and demographic data collected on children in the dyad only.
223704558|NCT02964975|PROCEDURE|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
224275641|NCT01506349|DIETARY_SUPPLEMENT|gluten|4 grams of gluten.
224275642|NCT01506349|DIETARY_SUPPLEMENT|Placebo|
224275643|NCT01859936|DEVICE|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
223704559|NCT02964975|DRUG|Optimal medical therapy|Medical threatment according to guidelines
223704560|NCT05303181|DEVICE|Russian Current|"The patient will be placed in sitting position, hip at 90-degree flexion, knee at 60°, the upper body supported by the backrest, cross belt support the trunk and cross belt support the pelvis. The dynamometer rotating axis will be aligned with knee joint axis and the resistance lever arm will place in the distal leg above the malleolus. The angle of the joints adjustment considering the joint's range of motion and the device's user's manual, any movement other than the range of motion determined by the mechanical limit will be not allowed~All electrical induced contraction will last 4 second each, with characteristics of 75 bursts; 4 second time on, 400 μs pulse width and 10 second time off. The greatest electrically induced torque by the quadriceps muscle at the maximum current output from the stimulator will be recorded for each subject to be used in data analysis. The same procedure will be done on the 3rd week and after 6th week."
224275644|NCT03493919|BIOLOGICAL|rMenB+OMV NZ vaccine|Two doses of rMenB+OMV NZ vaccine were administered intramuscularly at Day 1 and Day 61.
224275645|NCT03493919|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|One dose of MenACWY vaccine were administered intramuscularly at Day 1.
223534960|NCT00294034|DEVICE|Pacemaker|
223534961|NCT02832570|DRUG|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
223534962|NCT02832570|DRUG|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
223704561|NCT01354587|DRUG|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
223704562|NCT04094129|DIETARY_SUPPLEMENT|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
223704563|NCT04094129|DIETARY_SUPPLEMENT|Placebo|placebo
224275646|NCT01781312|DIETARY_SUPPLEMENT|ProTectis|
224275647|NCT01781312|DIETARY_SUPPLEMENT|Gastrus|
224275648|NCT00080795|BIOLOGICAL|filgrastim|
224275649|NCT00080795|DRUG|cisplatin|
224275650|NCT00080795|DRUG|doxorubicin hydrochloride|
224275651|NCT00080795|DRUG|gemcitabine hydrochloride|
224275652|NCT00080795|DRUG|ifosfamide|
224275653|NCT00080795|PROCEDURE|conventional surgery|
224275654|NCT00080795|PROCEDURE|neoadjuvant therapy|
224275655|NCT02512328|DEVICE|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
224275656|NCT04045015|DIETARY_SUPPLEMENT|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
224275657|NCT04587245|OTHER|Online questionnaire and interviews|Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview
224275658|NCT03867773|BEHAVIORAL|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
224275659|NCT01402934|PROCEDURE|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
224275660|NCT04218994|OTHER|Flossing technique|Subjects instructed on flossing technique
224275661|NCT00344643|DEVICE|Silicone Hydrogel Soft Contact Lenses|
224275662|NCT01777815|DEVICE|NeoChord DS1000 Artificial Chordae Delivery System|
224275663|NCT04894409|DEVICE|Mouthwash and nose rinse with the AgNPs solution|"The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers"
224275664|NCT04894409|DEVICE|Mouthwashes and nose rinse in a conventional way|The control group was instructed to do mouthwashes and nose rinse in a conventional way
224275665|NCT00801515|DRUG|Maraviroc|150 mg twice per day
224275666|NCT02895841|OTHER|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
224275667|NCT02934334|OTHER|Observational|
224275668|NCT01107028|OTHER|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
224275669|NCT01132417|DRUG|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
224275670|NCT01686217|DRUG|ASP015K ER|oral extended release (ER) at three dosing levels
224275671|NCT01686217|DRUG|ASP015K IR|oral immediate release (IR)
224275672|NCT03646162|DRUG|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
224275673|NCT03646162|DRUG|Placebo|Placebo
224275674|NCT00809705|DRUG|Placebo|sc once weekly for 12 weeks
224275675|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
224275676|NCT00809705|DRUG|taspoglutide|10mg sc once weekly for 12 weeks
224275677|NCT01461785|BIOLOGICAL|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
224275678|NCT01461785|PROCEDURE|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
224275679|NCT02849951|DRUG|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
224275680|NCT02849951|DRUG|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
224275681|NCT06179641|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anesthetics around the nerve.
224275682|NCT06179641|PROCEDURE|IPACK block|The IPACK (Infiltration of local anesthetic between the Popliteal Artery and Capsule of the Knee) will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where nineteen mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anesthetics will be observed above the posterior capsule.
224275683|NCT02681588|PROCEDURE|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
224275684|NCT05862987|DIETARY_SUPPLEMENT|Hydrogen rich water|Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
223534963|NCT05414799|OTHER|figure eight vision exercise|figure 8 vision exercise is performed in sitting position focus on a point 10 feet away, trace an imaginary horizontally figure 8 with eyes. keep tracing figure eight.
223534964|NCT05414799|OTHER|chin nodding|chin nodding performed in sitting for keeping head placed straight over spine, place finger on chin and tuck-in the chin while head straight back until a stretch is felt at base of head.
223534965|NCT05414799|OTHER|neck stretching|"trapezius : neck flexion with opposite side bending and same side rotation for both sides.~sternocleidomastoid : neck extension with opposite side bending and same side rotation for both sides."
223534966|NCT00476645|DRUG|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
223522274|NCT06602180|OTHER|Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).|"Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,"
223522275|NCT06602180|OTHER|Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))|"Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
223522276|NCT06602180|OTHER|Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)|"Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments"
223704564|NCT01630057|DRUG|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
223522277|NCT06593665|DRUG|Inrathecal Morphine|Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
223522278|NCT06593665|DRUG|Intravenous Methadone|Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
223522279|NCT05947890|BIOLOGICAL|MTBVAC|The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.
223522280|NCT05947890|BIOLOGICAL|BCG|The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.
223704565|NCT01630057|DRUG|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
223704566|NCT02056977|OTHER|Titration|Individualized PEEP according to PEEP titration monitored by EIT
224275685|NCT05862987|DIETARY_SUPPLEMENT|Placebo|Tap water with molecular hydrogen concentration 0.0 ppm.
224275686|NCT02671474|OTHER|4-dimensional volume-rendered computed tomography|
223522281|NCT01688791|DRUG|Vintafolide|
223522282|NCT01688791|DRUG|Carboplatin|
223522283|NCT01688791|DRUG|Paclitaxel|
223522284|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
223704567|NCT02056977|OTHER|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
223704568|NCT06419738|BEHAVIORAL|Cognitive behavioral treatment (CBT)|Cognitive behavioral treatment includes education about the disorder, proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients are also consulted on changing habits, adjusting behavior, exercising. Patients are instructed to adjust their behavior: quit harmful habits to limit pain in daily functional activities, maintain scientific sleep, maintain good head, neck and shoulder activities, soft diet and avoid hard foods, do exercises twice a day: open mouth wide combined with cool compresses and warm compresses.
223893687|NCT05795842|OTHER|Samsung Galaxy Watch 6|"The Samsung Galaxy Watch6 will collect study data on physiological signals with a compatible Samsung Galaxy phone S21. The Samsung Galaxy Watch6 will include various models, the difference being the size of the watch face or the analog front end of the device.~The software device is installed on the Samsung Galaxy Watch. The app on the watch continuously records PPG and/or ECG data and transmits it. The phone app allows study staff to enter the subject ID, initiate data collection, and stop data collection sessions on the watch. It also receives and stores PPG and ECG data from the paired watch. The PPG app used in the study does not trigger irregular rhythm notifications or display rhythm classification. The data collected using the PPG app will support algorithm development."
224275687|NCT00965731|DRUG|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
224275688|NCT00965731|DRUG|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
224275689|NCT00965731|DRUG|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
224275690|NCT03035643|DEVICE|AMDS|The device will be implanted during an already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
223704569|NCT06419738|RADIATION|Low level laser therapy combined with CBT (LLLT+CBT)|LLLT may facilitate the release of endogenous opioids, tissue repairment and cellular respiration, increase vasodilatation and pain threshold, and decrease inflammation. Diode low-energy laser machine (Sirolaser blue, Dentsply) are set the default mode according to the correct parameters before use: wavelength 660nm, energy level 2.5 J/cm2, power source 100mW. The projection head is placed perpendicular to the muscle being projected. The laser light is shined on the pain point at the beginning of the treatment, then it will shine on muscle points in turn: temporal muscle (anterior, middle, posterior), masseter muscle (upper, middle, lower), 5 points around the temporomandibular joint area (superior, anterior, lateral, posterior, posterior subcondylar). Each masticatory muscle area is treated for 20 seconds, 3 sessions /week (different days), 10 sessions total. In addition, patients are still instructed CBT as group 1.
223704570|NCT06419738|DEVICE|Occlusal Splint combined with CBT (OS+CBT)|Maxillary occlusal splints are made of hard acrylic after taking impressions of the upper dental arches, recording of centric relation (Okeson). Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night at least 8 hours/day for a period of 8 weeks.In addition, patients are still instructed CBT as group 1.
223704571|NCT06097169|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
223704572|NCT06097169|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
223704573|NCT00846235|OTHER|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
223522285|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
223522286|NCT02343250|DRUG|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
223522287|NCT02343250|DRUG|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
223522288|NCT05700422|DRUG|Varenicline Nasal Spray|OC-01 (varenicline solution) 0.03 mg nasal spray
223522289|NCT06674707|OTHER|Agility Training with Foot mobilization.|Agility training with foot mobilization with the frequency of 3 sets of 10 repetitions thrice per week for a total six weeks. Pre and post intervention values will be taken on 1st day and after six weeks. Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. TJM is a grade III Maitland technique and is applied with a high amplitude from the end range and 1s of vibration in the middle range of the joint through a linear motion to where tissue resistance is felt in the prone position, the patient is supported by a towel placed under the foot. Two sets of 5 min total were performed for 6weeks.
223522290|NCT06674707|OTHER|Agility Training without Foot mobilization|Agility training includes side stepping, braiding activities, and front and back crossover steps during forward ambulation, shuttle walking, multiple changes in direction during walking on therapist command. Comprising of Hot pack and TENS for 10 minutes and Ultrasound for 5 minutes . Comprising of conventional exercises were given for 3 sessions per week for 6 weeks. It includes semi squat, quadriceps isometric, terminal knee extension with elastic band, terminal knee extension in supine position, and adductor squeeze in crook lying (squeeze the ball).
223522291|NCT06673940|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS is applied on the acupuncture points Intervention arm
223522292|NCT06673940|OTHER|Physical Therapy program|Physical therapy methods
223522293|NCT06673836|DEVICE|DYNAMIC CYCLING|"Balance Training: Exercises focused on improving coordination and balance, such as standing on one leg, walking on uneven surfaces, or using balance boards.~Core Strengthening: Strengthening core muscles helps children maintain stability during dynamic movements, such as walking or running.~Proprioceptive Training: Exercises that improve awareness of the body's position in space, such as obstacle courses or activities that challenge movement coordination."
223522294|NCT06673836|DEVICE|INCLINED TREAD MILL|Dynamic Cycling: Refers to the fluctuating nature of movement patterns, often used in therapies like stationary biking or recumbe.nt cycling, where the intensity and resistance vary. Dynamic cycling can also refer to training that involves alternating between high and low-intensity phases or cycling between different positions (sitting, standing) or speeds during the activity
223522295|NCT06675279|OTHER|Survey-based study|The demographic information of individuals with migraines, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
223522296|NCT06674798|OTHER|School-based eHealth NCD Prevention Program|Students will participate in health-promoting sessions delivered by trained facilitators, with each session lasting 30 to 40 minutes. There will be a total of six health-promoting sessions conducted in the classroom for the intervention group, spanning two months with three sessions per month. The health-promoting videos from the school-based eHealth NCD prevention program will be shown in the classroom using multimedia. The drama-based videos will be developed in Urdu Language with English subtitles and will be based on based on contextually relevant content for the Pakistani secondary and higher secondary school students of age 13 to 18 years old. The content of these six sessions will be focused on the leading risk factors associated with NCDs as reported by different studies such as physical inactivity, unhealthy diet and overweight, obesity, harmful alcohol consumption and tobacco use.
223704574|NCT01131611|BEHAVIORAL|CBPT|Cognitive-Behavioral Based Physical Therapy
223704575|NCT01131611|OTHER|Control-Attention|Standard of Care + weekly phone calls
223704576|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Doppler ultrasound at 13, 16, 20 and 26 weeks for assessment of uterine arteries according to ISUOG criteria.
223704577|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at 13, 16, 20, 26 weeks of gestation to determine the sFlt-1/PlGF ratio
223704578|NCT05720169|DIAGNOSTIC_TEST|Blood sample|Blood sampling at week 13 for DNA extraction for genomic studies
223704579|NCT05720169|DIAGNOSTIC_TEST|Doppler ultrasound|Fetal morphological ultrasound at 13, 16 and 20 weeks.
224275691|NCT06531122|DRUG|Apixaban 5MG|100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
224275692|NCT06531122|DRUG|Rivaroxaban 20 MG Oral Tablet|100 CVT patients will receive Rivaroxaban 20mg daily for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire
224275693|NCT03380195|OTHER|Watermelon juice|Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
224275694|NCT03380195|OTHER|Sport drink|Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
223522297|NCT06674187|PROCEDURE|Regular|"The stoma surgery will be performed using conventional non-molding suturing techniques. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Perform routine suturing around the stoma without additional mesentery shaping.~3. Form the stoma, ensuring a tight fit of the surrounding tissues."
223522298|NCT06674187|PROCEDURE|Mesenteric Molding Suturing Group|"During the stoma surgery, the mesentery will be shaped and sutured to enhance the support around the stoma and reduce the risk of hernia formation. The specific steps include:~1. Select an appropriate stoma site, typically within the rectus abdominis muscle.~2. Separate the mesentery around the stoma and shape it into a sturdy support structure.~3. Use non-absorbable sutures to fix the shaped mesentery to the abdominal wall, forming a sturdy support structure.~4. Form the stoma on the support structure, ensuring a tight fit of the surrounding tissues."
223522299|NCT06675682|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|Player randomization was performed using an online tool (https://www.randomizer.org/). An independent researcher assigned alphanumeric codes to each sequence to ensure blinding of both sprint athletes and researchers during the trials. Each player participated in two identical experimental trials separated by one week to allow physical recovery between testing occasions and washout from the beetroot juice treatment.
223522300|NCT06674941|DRUG|Teprotumumab|Administered as an SC injection.
223704580|NCT02067130|PROCEDURE|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
224275695|NCT03380195|OTHER|Sugar water|Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
224275696|NCT03380195|OTHER|Water|Subject drinks 355ml of water 1 hour prior to submaximal exercise
224275697|NCT05672173|PROCEDURE|Biopsy|Undergo tumor biopsy
224275698|NCT05672173|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
224275699|NCT05672173|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
224275700|NCT05672173|PROCEDURE|Computed Tomography|Undergo PET/CT
224275701|NCT05672173|DRUG|Cyclophosphamide|Given IV
224275702|NCT05672173|DRUG|Fludarabine|Given IV
224275703|NCT05672173|DRUG|Ibrutinib|Given PO
224275704|NCT05672173|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
224275705|NCT05672173|BIOLOGICAL|Nivolumab|Given IV
223522301|NCT07010744|DRUG|Triple drug regimen|Amoxicillin 1000mg at 12 hourly for 14 days Clarithromycin 500mg at 12 hourly for 14 days Esomeprazole 20 mg at 12 hourly for 14 days
223522302|NCT07010744|DRUG|Quadruple therapy|Bismuth subsalicylate 300mg at 6 hourly 14 days Metronidazole 400mg at 8 hourly 14 days Tetracycline 500mg at 6 hourly 14 days Esomeprazole 20 mg 12 hourly for 14 days
224275706|NCT05672173|PROCEDURE|Pheresis|Undergo apheresis
224275707|NCT05672173|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224275708|NCT05645224|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
224275709|NCT03388008|DRUG|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
224275710|NCT03388008|DRUG|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
224275711|NCT03388008|DRUG|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
224275712|NCT03388008|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
224275713|NCT03388008|DRUG|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
224275714|NCT03388008|DRUG|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
223704581|NCT01372592|PROCEDURE|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
223704582|NCT00370071|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
223704583|NCT03348137|OTHER|Questionnaire Administration|Ancillary studies
223704584|NCT04308096|DRUG|KRN23|The starting dose of KRN23 will be the dose used for the last administration in the preceding studies. The dose may be modified subsequently in accordance with the criteria for dose and dose adjustment.
223704585|NCT02351999|DEVICE|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
223704586|NCT02701023|DRUG|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
223704587|NCT01196507|DRUG|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
223704588|NCT01196507|DRUG|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
223522303|NCT07011225|DIETARY_SUPPLEMENT|Verisol Collagen 2,5 g/day|Patients allocated to this group will consume Verisol Collagen 2,5 g/day for 90 days.
223522304|NCT07011225|DIETARY_SUPPLEMENT|Peptech Collagen 2,5 g/day|Patients allocated to this group will consume Peptech Collagen 2,5 g/day for 90 days.
223522305|NCT07011225|DIETARY_SUPPLEMENT|Peptech Collagen 10 g/day|Patients allocated to this group will consume Peptech Collagen 10 g/day for 90 days.
223522306|NCT07011225|OTHER|Pulmonary rehabilitation with aerobic and resistance training.|Patients enroled in this group will be submitted to Pulmonary rehabilitation with aerobic and resistance training.
223522307|NCT07011225|DIAGNOSTIC_TEST|Cardiorespiratory test|The patients allocated to this group will be submitted to initial and final evaluations only.
223522308|NCT07009808|DRUG|Nalbuphine 0.20mg/ml(total 30 mg)|In this group, participants will receive an intravenous infusion of Nalbuphine at a concentration of 0.20 mg/ml, which delivers a total of 30 mg over the course of 48 hours. Additionally, 10 mg of Metoclopramide will be administered to manage potential postoperative nausea. This intervention aims to assess the analgesic efficacy and its subsequent effect on psychological outcomes, specifically anxiety and depression, in patients undergoing surgery for ectopic pregnancy.
223522309|NCT07009808|DRUG|Nalbuphine 0.27mg/ml(total 40 mg)|Participants assigned to this group will be treated with an intravenous infusion of Nalbuphine at a concentration of 0.27 mg/ml, resulting in a total dosage of 40 mg administered during the 48-hour postoperative period. They will also receive 10 mg of Metoclopramide to mitigate nausea and vomiting. This intervention is designed to evaluate the effectiveness of this dose in pain management and its influence on anxiety and depression levels post-surgery.
223522310|NCT07009808|DRUG|Nalbuphine 0.33mg/ml(total 50 mg)|In this group, subjects will receive Nalbuphine at a concentration of 0.33 mg/ml, totaling 50 mg, delivered through intravenous infusion for 48 hours. Along with this, 10 mg of Metoclopramide will be included to address potential postoperative discomfort. This intervention seeks to explore how this higher concentration impacts pain relief and subsequent psychological effects, specifically targeting anxiety and depression following ectopic pregnancy surgery.
223522311|NCT07010016|DEVICE|NaviFus Model101|FUS Neuromodulation
223522312|NCT07009873|OTHER|This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.|This study is designed to assess the non-inferiority of a novel ultrasound imaging technique, rather than to evaluate a therapeutic intervention.
223522313|NCT06686641|DRUG|Local and systemical treatment|Evaluating the management of the edema including topical/local treatment (dexamethasone and NSAID, periocular injections, and dexamethasone intravitreal implant) and systemic treatment (prednisolone, DMARD, and biological agents, for example TNF-alpha inhibitors and interleukin-6 inhibitors). Moreover, the duration of any treatment as well as numbers of injections or implants.
223522314|NCT06689761|DIETARY_SUPPLEMENT|ColCT|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
223522315|NCT06689761|DIETARY_SUPPLEMENT|ColET|Dietary Supplement: Collagen Participants ingest 15 grams of specific collagen peptides daily
223522316|NCT06689761|DIETARY_SUPPLEMENT|PlaCT|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
223522317|NCT06689761|DIETARY_SUPPLEMENT|PlaET|Dietary Supplement: Placebo. Participants ingest 15 grams of placebo daily
223522318|NCT04857528|RADIATION|Radiation Treatment With or Without Chemotherapy|Standard care radiation treatment.
223522319|NCT04857528|OTHER|Blood Sample Collection|Researchers will collect blood samples from participants before, during and after radiation treatment. Approximately 6 teaspoons of blood will be collected each time blood is drawn.
223522320|NCT04857528|DIAGNOSTIC_TEST|HPV Genotyping (HPV DNA Test)|A test used to detect the type of HPV DNA found in the participant's blood and tumor tissue samples.
223522321|NCT04857528|DIAGNOSTIC_TEST|Testing Archival Tumor Tissue|Tumor tissue will be tested in a lab for all cervical cancer participants and some participants with anal cancer as assessed by the lead study doctor. This tumor tissue sample will be from a previous biopsy that the participant received before the study per standard care; no new biopsy will be required for this study.
223704589|NCT02399553|OTHER|Soccer boot intervention|
223704590|NCT03175978|DRUG|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
223704591|NCT01999868|BIOLOGICAL|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh \<= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh \> 100 kg at study entry will receive 90 mg of ustekinumab."
223522322|NCT04857528|OTHER|Physical Exam|A physical exam will be given 12 months after radiation treatment. This physical exam may also include an anoscopy (a procedure to examine the anus using a device inserted into the anus) or sigmoidoscopy (a procedure that looks at the rectum and lower part of the colon using a device inserted into the anus).
223704592|NCT01999868|BIOLOGICAL|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
224275715|NCT04323722|PROCEDURE|Empty Bladder planning CT scan and CBCTs|Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
223522323|NCT04857528|DIAGNOSTIC_TEST|Positron Emission Tomography Scan (PET Scan)/ Computed Tomography Scan (CT Scan)|Tests that use computers and/or rotating x-rays to scan/create images of the body.
223522324|NCT07010549|DEVICE|Hyaluronic Acid injections|Among treatments today available, bio-revitalization is a process which triggers the skin's own, natural collagen production and cell rejuvenation through the injection of hyaluronic acid serums. This substance is hydrophilic, drawing many times its weight in water. As we age, we have less naturally produced HA in our tissues and skin dehydration becomes a telltale sign of aging. The HA owns a great hydrating power, due to this property is widely used in the biorevitalization treatments. Its use results in supple, younger-looking skin with reduced wrinkles and improved elasticity.In bio-revitalization procedures that involve intradermal micro-injections of natural HA, with a molecular weight close to the endogenous one, carried out in correspondence with the imperfections, the viscoelastic properties of HA allow to rehydrate the tissues, allowing to prevent and contrast the aging process skin and promote their remodeling.
223522325|NCT07011303|PROCEDURE|H-PRF|Blood will be taken from the patient before the surgical procedure is started. The blood sample will be placed in the H-TZF device for centrifugation and the sample will be horizontally centrifuged (2200 RPMx8 min, 700g). After the blood is processed for centrifugation, the surgery will begin. Surgery will be performed under local anesthesia with articaine 2 ml 4% and epinephrine 1:100,000. All patients will be operated by the same surgeon. After local anesthesia is achieved, tooth extraction will be started. After tooth extraction, the surgical field will be washed with sterile 0.9% saline, and H-PRF material will be placed in the area and primarily sutured with a 3.0 silk suture. All patients will be given postoperative instructions by the surgeon. Patients will be prescribed mouthwash (0.12% chlorhexidine mouthwash twice daily for 7 days).
223522326|NCT07011303|PROCEDURE|L-PRF|Blood will be taken from the patient before the surgical procedure is started. The blood sample will be placed in the L-PRF device for centrifugation and the sample will be centrifuged. (2700M x 12 min, 700g) After the blood is processed for centrifugation, the surgery will begin. Surgery will be performed under local anaesthesia with articaine 2 ml 4% and epinephrine 1:100,000. All patients will be operated by the same surgeon. After local anaesthesia is achieved, tooth extraction will be started. After tooth extraction, the surgical field will be washed with sterile 0.9% saline, and L-PRF material will be placed in the area and primarily sutured with a 3.0 silk suture. All patients will be given postoperative instructions by the surgeon. Patients will be prescribed mouthwash (0.12% chlorhexidine mouthwash twice daily for 7 days).
223522327|NCT06690229|DRUG|glass ionomer cement|A cement used for crown cementation
223522328|NCT06690229|DRUG|self-adhesive resin cement|A cement used for crown cementation
223522329|NCT06690229|DRUG|resin modified glass ionomer cement|A cement used for crown cementation
223522330|NCT01647256|DRUG|Nikkomycin Z|Capsule, 500 mg, single-dose
223522331|NCT03907566|OTHER|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
223522332|NCT04732468|BIOLOGICAL|hAd5-S-Fusion+N-ETSD (Suspension for injection)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
223522333|NCT04732468|DRUG|hAd5-SFusion+ N-ETSD (Oral capsule)|The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
223534967|NCT05944692|DEVICE|Tripolar electroencephalography|We will record physiological signals with the tripolar electroencephalography
223534968|NCT02257684|DRUG|pegcrisantaspase|
223534969|NCT02128776|OTHER|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
223534970|NCT02128776|OTHER|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
223534971|NCT04361279|DRUG|SIBP-02|Injection，100mg/10ml
223534972|NCT04361279|DRUG|Rituximab|Injection，100mg/10ml
223534973|NCT04313582|BEHAVIORAL|SmartPrompt smartphone application|The SmartPrompt is a smartphone application designed specifically for older adults with difficulties remembering to do daily tasks due to cognitive difficulties.
223534974|NCT05478278|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains psilocybin (API only in a capsule).
223534975|NCT05478278|DRUG|Moxifloxacin|The positive comparator used in this study is a 400 mg moxifloxacin tablet.
223534976|NCT05478278|DRUG|Micro-Crystalline Cellulose|The placebo used in this study is encapsulated using a HPMC capsule and contains micro-crystalline cellulose.
223534977|NCT04434755|OTHER|health care professionals' exposure to bioethical issues|health care professionals were differentiated considering the work context and the type of patients cured
223522334|NCT01594372|PROCEDURE|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
223522335|NCT01594372|PROCEDURE|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
223522336|NCT06695585|DRUG|Lidocaine 2% without vessel constrictor|different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared
223522337|NCT06689774|BEHAVIORAL|Cognitive-Motivational Feedback|Salvation Army personnel will be trained to offer adult consumers who use tobacco cognitive-motivational feedback about tobacco use via a no-cost, web-based Qualtrics survey that assesses participant knowledge, beliefs, and priorities and provides feedback to promote knowledge of the costs and risks of smoking and knowledge of the costs and benefits of tobacco use treatment options, including Wisconsin Tobacco Quit Line services. The survey is also designed to help participants weigh the importance of the pros and cons of continuing to use tobacco, and the pros and cons of trying to change their tobacco use.
223522338|NCT06689774|BEHAVIORAL|Staff Tobacco Quit Line Referral Implementation Support|Salvation Army personnel will receive training and will be engaged in efforts to plan, evaluate, adapt, and sustain tobacco treatment referral as part of the social services they provide to adult Salvation Army service consumers who use tobacco. Implementation support will take the form of ongoing engagement of an outreach specialist with a team of Salvation Army personnel and consumers who lead Quit Line referral efforts in the Salvation Army.
223522339|NCT06689774|BEHAVIORAL|Consumer Incentives for Immediate Referral to a Tobacco Quit Line|Salvation Army personnel will offer an incentive to adult consumers who use tobacco to encourage immediate acceptance of a live call with the Wisconsin Tobacco Quit Line. The incentive will be designed by Salvation Army personnel to fit the local context and to be sustainable over time, such as extra access to existing support or resources.
223522340|NCT06688188|DRUG|68Ga-JH12|The dose will be 148-222 MBq given intravenously.
223522341|NCT06690125|DIAGNOSTIC_TEST|Classical and computerized assessment|"Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)"
223522342|NCT06686628|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
223522343|NCT06686628|DRUG|Midazolam|Pharmaceutical form: Solution Route of administration: Oral
223704593|NCT01999868|DRUG|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
223522344|NCT06686628|DRUG|Caffeine|Pharmaceutical form: Tablet Route of administration: Oral
223522345|NCT06686628|DRUG|Metoprolol|Pharmaceutical form: Tablet Route of administration: Oral
223522346|NCT06686628|DRUG|Omeprazole|Pharmaceutical form: Capsule Route of administration: Oral
223522347|NCT06686628|DRUG|Warfarin|Pharmaceutical form: Tablet Route of administration: Oral
223522348|NCT05868655|OTHER|Exercise with Video-Based|A program of stability and balance exercises will be provided
223704594|NCT01999868|DRUG|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
223522349|NCT05868655|OTHER|Standart exercise-Home-Based|Participants will be asked to take the final measurements after the exercises have been monitored by a physical therapist for eight weeks.
223522350|NCT06695741|DRUG|Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy|Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.
223522351|NCT06695611|OTHER|Increase systolic blood pressure|"To increase systolic blood pressure, treating physicians can consider the following options:~1. Withdraw blood pressure medications, reducing dose of medications that are not indicated for other reasons, or down titrate medication.~2. Increase estimated dry weight (EDW) by 0.5 kg increments if the participant is hypovolemic or euvolemic"
223704595|NCT00761631|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
223522352|NCT06695611|OTHER|Decrease systolic blood pressure|"To decrease SBP, treating physicians can consider the following options:~1. Adjust blood pressure medications. This could be accomplished by increasing the dose of current medications, and/or adding an additional medication class. Choice of medication will be dependent on current medications, contraindications, age, comorbidities, and cardiovascular indications. Adherence to blood pressure medications should be reviewed.~2. Reduce EDW by 0.1 - 0.5 kg~3. Reduce sodium levels. This could be accomplished through a reduction in dietary sodium intake to \<2 gm/day and fluid intake to \<1.5 L per day. Adherence to dietary sodium restrictions should be reviewed with the participant~4. Extend dialysis time or adding an additional dialysis session if needed to achieve target dry weight"
223522353|NCT06695338|PROCEDURE|Guided Bone Regeneration (Submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (submerged approach)
223522354|NCT06695338|PROCEDURE|Guided Bone Regeneration (Non-submerged)|Guided Bone Regeneration by means of bone xenograft and collagen membrane (Non submerged Approach)
223522355|NCT06689150|DRUG|Drospinetta|To evaluate the three different types of POPs, the new POPs Drosperinon 4 mg, Desogestrel 75 pg, and Levonorgestrel 30 pg in healthy female subjects as regard to the contraceptive efficacy, bleeding pattern, acceptability and safety
223522356|NCT06688305|DRUG|68Ga-NI-FAPI|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
223704596|NCT00502944|BEHAVIORAL|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
223522357|NCT04340258|DEVICE|Cesium-131|Cs-131 brachytherapy seed is a low-energy-gamma isotope that is contained in a titanium capsule. Dosing will be determined by a radiation oncologist study team member based on CT scan and intraoperative findings. The number of seeds and spacing will be outlined preoperatively based on the proposed square area of exposure in the resection bed. The plan is to deliver a total of 60-70Gy of radiation to the site.
223522358|NCT04340258|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute IV infusion every 3 weeks. The drug will be infused through a peripheral line or an indwelling catheter. The first dose will be given 2 weeks prior to surgery. Post-surgery, pembrolizumab will be started between 2 and 6 weeks and will continue every 3 weeks for a duration of 6 months. Study Drug may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. The Investigator's Brochure contains specific instructions for the preparation of the standard of care pembrolizumab infusion fluid.
223522359|NCT06742762|DRUG|AZD5004|Dose 1
223522360|NCT05995665|DEVICE|EsoGLOVE with Trigno Biofeedback (EMG sensors)|The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVETM with Trigno Biofeedback (EMG sensors) training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day. A total of 15 sessions (5 session per week for a total of 3 weeks) of a minimum of 30 mins. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).
223522361|NCT05995665|OTHER|Graded Repetitive Arm Supplementary Program (GRASP)|Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.
223522362|NCT03094273|PROCEDURE|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
223522363|NCT01423890|GENETIC|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
223522364|NCT03780322|DEVICE|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
223522365|NCT03780322|OTHER|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
223522366|NCT02541201|DIETARY_SUPPLEMENT|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
223522367|NCT02541201|DIETARY_SUPPLEMENT|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
223522368|NCT04279093|OTHER|No intervention, but participants will use a smartphone app daily to complete the EPDS|No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
223522369|NCT04635982|OTHER|Kinesiotape of the physical performance|It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
223522370|NCT00223379|PROCEDURE|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
223522371|NCT02144818|DRUG|Ovitrel|Triggering of ovulation with Ovitrel
223522372|NCT02144818|DRUG|Decapeptyl|Triggering with GnRH agonist
223522373|NCT05902442|DEVICE|3DxSPLINT|Routine immobilization procedure with a patient-specific 3D printed splint instead of the use of a conventional forearm splint after one week of conventional immobilization.
223522374|NCT06686368|DEVICE|I-DROP MGD|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
223522375|NCT06686368|DEVICE|Theloze Duo|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
223522376|NCT06686368|DEVICE|Systane Complete PF|All drops are to be used for 28-30 days, twice daily with assessment done at Day 0, 30 minutes post-installation at day 0, day 7 and day 28/30
223522377|NCT06686901|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
223522378|NCT06686901|BEHAVIORAL|Smartphone-delivered inactive Therapeutic Evaluative Conditioning|Therapeutic Evaluative Conditioning (inactive TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair positive and negative stimuli (pictures, words) with each other.
223522379|NCT05833945|DEVICE|Large Vessel Occlusion Biomarkers Test|Duplex Point of Care test to measure the concentration of biomarkers associated to Large Vessel Occlusion in blood samples used in combination with an APP.
223704597|NCT00502944|BEHAVIORAL|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
223704598|NCT00239109|DRUG|Ziprasidone|
223704599|NCT00239109|DRUG|Olanzapine|
223704600|NCT00239109|PROCEDURE|Scales|
223704601|NCT00239109|PROCEDURE|measures of the body (Weight...)|
223704602|NCT00239109|PROCEDURE|Serum analysis|
223522380|NCT06905340|PROCEDURE|NOL (Nociception Level Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by NOL during general anesthesia in the experimental arm.
223522381|NCT06905340|OTHER|Control (Standard treatment)|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist
223522382|NCT05365880|DRUG|Liquid Lidocaine|The investigational treatment is 2 mL of aqueous 2% lidocaine.
223522383|NCT05365880|DRUG|Placebo|The active placebo comparator will be provided to participant.
223522384|NCT04943341|PROCEDURE|Eco-guided Triamcinolone-Acetonide injection|"The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with in plane technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed."
223522385|NCT03648372|DRUG|TAK-981|Intravenous infusion.
223522386|NCT04211870|RADIATION|LED clusters|Each LED board contains six (6) LEDs with a wavelength of 660nm and a duration of seven (7) minutes in each muscle. The treatment was carried out in a total of four (4) sessions, one (1) session per week.
223522387|NCT06349304|DIETARY_SUPPLEMENT|Freeze-dried table grape powder|Consumption of grape powder as part of daily diet
223522388|NCT06349304|DIETARY_SUPPLEMENT|Placebo grape powder|Consumption of placebo grape powder as part of daily diet
223522389|NCT06950606|DEVICE|Pneumatic leg compression|Patients assigned to the PLC group will receive a pneumatic leg compression sleeve encompassing the calf and thigh, with sleeve size adjusted according to thigh circumference and manufacturer recommendations. The compression pump will be activated before the start of surgery. After surgery, the responsible trial personnel will deactivate the pump and remove the compression sleeves in the PLC group. There will be no standardized anesthesia management protocol; all decisions regarding hemodynamic management will be made at the discretion of the treating anesthesiologist
223522390|NCT06188975|DRUG|DRUG: ABBV-CLS-484|
223522391|NCT06295471|DEVICE|DFG Laser|Laser treatment to the upper thigh
223522392|NCT06295471|DEVICE|CO2 Laser|Laser treatment to the upper thigh
223522393|NCT06295471|DEVICE|Optical coherence tomography (OCT)|Angiographic OCT imaging at areas of interest
223522394|NCT02546232|DRUG|Carboplatin|Chemotherapy
223522395|NCT02546232|DRUG|Paclitaxel|Chemotherapy
223522396|NCT05845580|OTHER|Red yeast rice extract initial therapy followed later on by statin therapy|Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
223522397|NCT05845580|OTHER|Statin therapy|Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
223522398|NCT06319053|DEVICE|Turbine-based insufflator|The use of a turbine-based insufflator instead of a conventional insufflator
223522399|NCT06209372|PROCEDURE|Group PENG|Pericapsular Nerve Group Block (PENG)
223522400|NCT06209372|DRUG|Group C|Tramadol infusion
223522401|NCT06534723|DRUG|Wujia Yizhi granules|Drug: Wujia Yizhi granuless
223522402|NCT06534723|DRUG|Placebo|Placebo
223522403|NCT01888016|OTHER|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
223522404|NCT01888016|OTHER|standard physiotherapies treatment|"10 standard treatments in 2 weeks~* Deltoid and infraspinatus muscles electrotherapy~* Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~* Scar massage~* Upper limb, cervical spine and scapula massages~* Passive and assisted/active shoulder mobilization exercises~* Scapula micro-mobilizations~* Gleno-humeral decoaptation~* Elbow, wrist and hand active mobilization~* Proprioceptive exercise with and without the aid of the mirror"
223522405|NCT03296982|OTHER|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
223522406|NCT03296982|DRUG|edoxaban|
223704603|NCT03999177|BEHAVIORAL|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
223522407|NCT03296982|DRUG|Enoxaparin|
223522408|NCT03296982|DRUG|Saline sham|
223522409|NCT05937243|BEHAVIORAL|Base self-help CBT program|"The self-help app will deliver 12 modules that will be based on Chris Fairburn's Overcoming Binge Eating self-help book, the most widely used self-help resource for binge eating over 12 weeks. Treatment modules will aim to 1) provide psychoeducation on maintenance factors for binge eating, 2) teach CBT skills designed to interrupt these maintenance factors, and 3) coach participant to set personalized goals each week. Modules will be completed in succession over the course of 12-weeks and a new module will be made open each week. In addition, participants will track their eating and eating disorder behaviors using the self-help app."
223522410|NCT05937243|BEHAVIORAL|Just-in-time, adaptive intervention (JITAIs) system|When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.
223704604|NCT05073601|DIAGNOSTIC_TEST|ELISA,DNA extraction|quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)\& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (\< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (\> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested \[Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)\] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
223704605|NCT01590459|DRUG|VX-509|50 mg oral tablet
223704606|NCT01590459|DRUG|VX-509 matching placebo|0 mg oral tablet
223704607|NCT00417118|DRUG|Saredutant|oral administration (capsules)
223704608|NCT00417118|DRUG|Escitalopram|oral administration (capsules)
223704609|NCT00417118|DRUG|Placebo|oral administration (capsules)
223704610|NCT01242462|PROCEDURE|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 \& Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
223704611|NCT01242462|OTHER|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is \>/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH \>/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
223704612|NCT00037804|DRUG|Irinotecan|
223704613|NCT03820271|OTHER|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
223704614|NCT03925857|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
223704615|NCT03585231|BEHAVIORAL|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
223704616|NCT03585231|BEHAVIORAL|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
223704617|NCT03585231|BEHAVIORAL|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
223704618|NCT00289016|DRUG|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
223704619|NCT05462483|OTHER|Rice Sock and Instructions to heat the quadriceps.|A rice sock will be provided to the experimental group to heat the quadriceps 3x per day for six weeks. The participants will be encouraged to heat before and after rehabilitation exercises as well.
223704620|NCT04209192|DRUG|Fosfomycin Tromethamine 3G Sachet|Is the prophylactic drug which will be used in the intervention group.
223522411|NCT05937243|BEHAVIORAL|Advanced Digital Data Sharing (ADDS) with Coaches|When Advanced DDS with Coaches is turned ON, coaches having a bachelor's degree in health-related fields will have access to a secure web portal called the clinical portal. The portal will also mimic four key behavior change techniques typically employed by an expert clinician including 1) gather data on target behaviors from the base self-help app (i.e., uptake of weekly module, self-monitoring compliance, and skills use), 2) synthesize participants' behavioral data on treatment targets, 3) flag data to indicate behaviors needing improvement and 4) use sophisticated algorithms to generate recommendations for intervening on identified data patterns. Using this information, the coaches will send one weekly email to facilitate improvement in treatment targets over 12 weeks. When Advanced DDS with Coaches is turned OFF, participants' will not have their data shared and will not receive emails from the coaches.
223522412|NCT03375437|GENETIC|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2\*10mL EDTA)"
223522413|NCT04847687|DRUG|methylprednisolone|Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
223522414|NCT03637816|DRUG|Anamorelin Hydrochloride|Given PO
223522415|NCT03637816|OTHER|Placebo|Given PO
223522416|NCT03637816|OTHER|Questionnaire Administration|Ancillary studies
223704621|NCT04209192|DRUG|Amikacin|Is the prophylactic drug which will be used in the control group.
223704622|NCT02298530|OTHER|Combination of caffeine and theanine|Beverage containing caffeine and theanine
223704623|NCT02298530|OTHER|Caffeine|Beverage containing caffeine
223704624|NCT03097913|DEVICE|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
223704625|NCT01264783|DRUG|RNS60|RNS60 for intravenous administration
223704626|NCT01264783|DRUG|Placebo|0.9% normal saline for injection
223704627|NCT00003433|BIOLOGICAL|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
223704628|NCT06254651|OTHER|High resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's xiphoid process in a neonatal manikin.
223704629|NCT06254651|OTHER|Low resuscitation table|Participants will be invited to administer face-mask ventilation setting the table height to the operator's superior anterior iliac spines in a neonatal manikin.
223704630|NCT06045884|PROCEDURE|Sono-guided injection|After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
223704631|NCT06045884|DRUG|Ropivacaine injection|After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
223522417|NCT05703126|DIAGNOSTIC_TEST|History taking|Careful history taking, including using questionnaires, to identify risk factors for the development of cardiovascular diseases using the SCORE scale.
223522418|NCT05703126|DIAGNOSTIC_TEST|Anthropometry|Anthropometry: measurement of body weight and height. Calculation of body surface area using the Du Bois formula.
223704632|NCT06045884|DRUG|Saline injection|After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
223704633|NCT03572972|DRUG|Apixaban|Treatment for NVAF patients
223704634|NCT03572972|DRUG|Dabigatran|Treatment for NVAF patients
223704635|NCT03572972|DRUG|Rivaroxaban|Treatment for NVAF patients
223704636|NCT03572972|DRUG|warfarin|Treatment for NVAF patients
223704637|NCT03572972|DRUG|Antiplatelets|Treatment for NVAF patients
223704638|NCT06409923|DEVICE|Stimulation of mandibular growth.|orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
223704639|NCT05768919|DRUG|Treatment Period 1|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 1,2, 3,4,5,6 Cycle length: 6 weeks~Agent: TMZ Premedications/Precautions No food 2 hr before and after dosing Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener PRN. Dose: 75 mg/m2 Route: Oral Schedule: Daily during term of RT Cycle Length: 6 weeks~Agent: Radiotherapy Premedications/Precautions: n/a Dose: 2 Gy Route: External beam therapy Schedule: Monday-Friday Cycle Length 6 weeks"
223704640|NCT05768919|DRUG|Treatment Period 2|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Weeks 7,8,9,10 Cycle length: 4 weeks
223704641|NCT05768919|DRUG|Treatment Period 3|"Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: Adjuvant Cycles 11-34 Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks~Agent: TMZ Premedication/Precautions: No food 2 hr before and after dosing. Antiemetic (eg, ondansetron, prochlorperazine) 30 minutes before dosing Stool softener prn Dose: 150-200 mg/m2 (Cycles 1-6) Route: Oral Schedule: Daily Cycle Length: 4 weeks"
223704642|NCT05768919|DRUG|Treatment Period 4a|Agent: LipoCurc Premedication/Precautions: Dexamethasone 4 mg IV Diphenhydramine 25 mg IV Dose: Per treatment assignment Route: IV over approximately 3 hours Schedule: Weekly: 35+ Weeks 1, 2, 3, 4 of each cycle Cycle Length: 4 weeks
223704643|NCT04376463|DIETARY_SUPPLEMENT|Branched Chain Aminoacid|It is an experimental design, controlled with 8 months of supplementation combined with exercise and washout 2 months, totalling 10 month intervention.
223704644|NCT04899102|BEHAVIORAL|Time-Restricted, Intermittent Fasting|A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
223704645|NCT01441180|DRUG|GS7977|drug intervention
223704646|NCT01441180|DRUG|RBV|drug intervention
223704647|NCT01267045|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
223704648|NCT01801878|BIOLOGICAL|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
223704649|NCT01801878|BIOLOGICAL|Normal saline|Normal saline inject to the half of irradiated breast
223704650|NCT00507923|DEVICE|Actigraph|Wear actigraph
223704651|NCT00507923|OTHER|Best Practice|Receive usual care
223704652|NCT00507923|OTHER|Quality-of-Life Assessment|Ancillary studies
223704653|NCT00507923|OTHER|Questionnaire Administration|Ancillary studies
223704654|NCT00507923|OTHER|Sleep Diary|Complete sleep diary
223522419|NCT05703126|DIAGNOSTIC_TEST|Complete blood count|Before and after each course of chemotherapy: Complete blood count with counting the number of erythrocytes, leukocytes, leukocyte formula, platelets, erythrocyte sedimentation rate.
223522420|NCT05703126|DIAGNOSTIC_TEST|Biochemical blood test|Before and after each course of chemotherapy: Biochemical blood test with the determination of the amount of total protein, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, urea, AlAT, AsAT, LDH, glucose, C-reactive protein, troponin T, proBNP.
223522421|NCT05703126|DIAGNOSTIC_TEST|Coagulogram|Before and after each course of chemotherapy: Coagulogram parameters (fibrinogen, APTT, INR).
223522422|NCT05703126|DIAGNOSTIC_TEST|Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine|Before the start of the treatment and after each course of chemotherapy: Immunoenzymatic analysis of the level of endothelin-1, asymmetric dimethylarginine.
223704655|NCT00507923|OTHER|Stretching|Participate in stretching sessions
223704656|NCT00507923|PROCEDURE|Yoga|Participate in Tibetan yoga
223704657|NCT01402011|PROCEDURE|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
223704658|NCT01402011|PROCEDURE|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
223704659|NCT01402011|PROCEDURE|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
223704660|NCT00797771|DEVICE|"Adi Insulin pump"|insulin delivery will be defined by the physician
223704661|NCT01918384|DRUG|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
224275716|NCT03915561|DRUG|Parecoxib Injectable Product|Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
223522423|NCT05703126|DIAGNOSTIC_TEST|Stress echocardiography with the definition of global longitudinal deformation of the myocardium|Before the start of the treatment and after each course of chemotherapy: Stress echocardiography with the definition of global longitudinal deformation of the myocardium.
223522424|NCT05703126|DIAGNOSTIC_TEST|Triplex scanning of neck vessels|Before the start of the treatment and after each course of chemotherapy: Triplex scanning of neck vessels.
223522425|NCT05703126|DIAGNOSTIC_TEST|Electrocardiography|Before and after each course of chemotherapy: Electrocardiography.
223522426|NCT05703126|DIAGNOSTIC_TEST|Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes|Before the start of the treatment and after each course of chemotherapy: Ultrasound of the abdominal cavity (with calculation of the area of the spleen) and lymph nodes.
223522427|NCT05703126|DIAGNOSTIC_TEST|Cytogenetic examination of the bone marrow to determine genetic abnormalities.|Before the start of the treatment: Cytogenetic examination of the bone marrow to determine genetic abnormalities.
223522428|NCT05703126|DIAGNOSTIC_TEST|Cytological examination of bone marrow cells with cytochemical examination|Before the start of the treatment and after each course of chemotherapy: Cytological examination of bone marrow cells with cytochemical examination.
223522429|NCT05703126|DIAGNOSTIC_TEST|Immunophenotypic examination of the bone marrow by flow cytometry|Before the start of the treatment: Immunophenotypic examination of the bone marrow by flow cytometry.
223522430|NCT05703126|DIAGNOSTIC_TEST|Determination of the presence of a FLT3 mutation using the PCR Method|Before the start of the treatment: Determination of the presence of a FLT3 mutation using the PCR Method.
223522431|NCT05703126|DIAGNOSTIC_TEST|laser Doppler flowmetry|Before the start of the treatment and after each course of chemotherapy: Examination of microcirculation by laser Doppler flowmetry using the LAKK-OP apparatus (NPP Lazma, Moscow, 2011) with respiratory and occlusion tests.
223522432|NCT04605276|OTHER|No intervention|No intervention
223522433|NCT01696565|DRUG|PG2|Injectable
223522434|NCT05284617|DRUG|HU6|HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
223704662|NCT01918384|DRUG|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
223704663|NCT05026008|DRUG|SR1375|The subject will be orally administered by single and multiple doses of SR1375 capsules with 240 ml water
224275717|NCT03915561|DRUG|Normal saline|Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
224275718|NCT06081140|DIETARY_SUPPLEMENT|Standard Process Hemp Oil Complex|10 days of supplementation to determine the tolerance and palatability of Standard Process Hemp Oil Complex.
223522435|NCT05284617|DRUG|Placebo|Placebo
223522436|NCT01802346|DIETARY_SUPPLEMENT|dietary intervention|Consume a low-calorie diet
223522437|NCT01802346|PROCEDURE|nutritional support|Receive dietary advice
223522438|NCT01802346|OTHER|laboratory biomarker analysis|Correlative studies
223522439|NCT05253196|DEVICE|Use of the foley catheter assistive device|All participants will use the foley catheter assistive device when performing their daily enema
223522440|NCT03037749|DRUG|Alcohol beverage|Alcohol beverage measured to have participant achieve a BAC of 0.08%
223522441|NCT03037749|DRUG|Placebo beverage|Placebo beverage measured to mimic the smell and taste of the alcohol beverage.
223522442|NCT01953159|OTHER|Blood Collection|
223522443|NCT01953159|OTHER|Patient Questionnaires|
223522444|NCT03314428|BEHAVIORAL|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
223522445|NCT05421494|BEHAVIORAL|written exposure therapy-revised version|WET-R is a manualized exposure-based therapy program consisting of 5-7 sequential individual sessions. The interval between every 2 consecutive sessions is 0-3 days. There will be 5-7 one to one online sessions in total (only one index trauma will be discussed), and 1-3 weeks to complete. Sessions are scheduled to last for 1 hour in the first session and 50 minutes in other sessions.
223704664|NCT05026008|DRUG|Matching placebo|The subject will be orally administered by single and multiple doses of matching capsules with 240 ml water
223522446|NCT05421494|BEHAVIORAL|minimal contact control|Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
224275719|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
224275720|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
224275721|NCT01273480|DRUG|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
223522447|NCT05550727|OTHER|PorchLight|The PorchLight Project intervention consists of three components: 1) CARES® Dementia Care Specialist online training modules; 2) a PorchLight Project training course; and 3) monthly check-in sessions.
224275722|NCT01273480|DRUG|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
224275723|NCT00000243|DRUG|Buprenorphine|
224275724|NCT02651064|OTHER|HIP|
223522448|NCT06535100|BEHAVIORAL|Art therapy|artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
223522449|NCT05053555|DEVICE|high dose rate brachytherapy|diagnostic workup, staging, and treatment per the institution standard of care
223522450|NCT05053555|DEVICE|high dose rate brachytherapy|reviewing historical patients who meet the above criteria for group A but did not receive HDRBT between 01/01/2000 and 1/01/2021
223522451|NCT06451497|BIOLOGICAL|ZM008|Intravenous delivery
223522452|NCT05654181|DRUG|PF-07328948|investigational drug administered orally
223522453|NCT05654181|DRUG|Placebo|Placebo matching active drug administered orally
223522454|NCT05918029|DRUG|Potassium Citrate Extended Release Oral Tablet|Oral potassium citrate extended-release tablet
223522455|NCT05918029|OTHER|Placebo|Placebo capsule identical to active ingredient
223522456|NCT05918029|DRUG|Potassium Citrate and Citric Acid Oral Solution|Oral potassium citrate and citric acid
223522457|NCT05714748|BIOLOGICAL|EBV mRNA vaccine|With 25ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1 month interval
223522458|NCT05763849|BEHAVIORAL|Interoceptive Exposure Treatment (IE)|Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
223522459|NCT05763849|BEHAVIORAL|Family-Based Treatment (FBT)|Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
223522460|NCT06429332|OTHER|Reversal of Oral anticoagulation within 30 minutes|In situations of either an elevated INR with the use of warfarin - treatment with either 3- or 4-factor prothrombin complex concentrate (PCC) or fresh frozen plasma (FFP) within 30 minutes of ICH diagnosis on NCCT to reach and maintain an INR target \<1.3; or where there has been recent use (\<48 hours) of a direct oral anticoagulant (DOAC), use of an appropriate reversal agent within 30 minutes, where available, and according to local approvals.
223522461|NCT06429332|OTHER|Early intensive blood pressure lowering|A systolic blood pressure (BP) target of 130-140 mmHg within 30 minutes of ICH diagnosis on NCCT is strived for, and to maintain this BP level for the first 7 days (for patients presenting with blood pressure \<200 mmHg). If blood pressure ≥200 and \<220, a target BP of 160 mmHg should be targeted at 30 minutes, and 130-140 mmHg should be achieved in 60 minutes. If BP ≥220, target BP of 160 mmHg and should be achieved in 60 minutes.
223522462|NCT06429332|OTHER|Treatment of pyrexia|To achieve a body temperature target \<37.5 °C within the first 24h following ICH diagnosis on NCCT
223522463|NCT06429332|OTHER|Hyperglycemia treatment|To maintain a blood glucose level 7-10 mmol/L within the first 24h following ICH diagnosis on NCCT
223522464|NCT06429332|OTHER|Do-not-resuscitate (DNR) or withdrawal of care|Refrain from the use of DNR or withdrawal of care orders for 48 hours
223522465|NCT06429332|OTHER|Referral to Intensive Care|Immediate (\<30 min) referral to intensive care if airway, breathing and/or circulation are compromized
223522466|NCT06429332|OTHER|Referral to Neurosurgery|"Immediate (\<30 min) referral to neurosurgery if any of the following criteria are fulfilled:~* Large and/or rapidly evolving supratentorial ICH (\>20 ml volume)~* Any intraventricular extension~* Posterior fossa bleed, irrespective of volume~* Suspicion of a vascular malformation, independent of volume or location~* Reduction in reaction to sensory stimulation or drowsiness"
223522467|NCT06429332|DIAGNOSTIC_TEST|Repeat brain imaging|Repeat 6-12-hour brain imaging with the physicians choice of modality, preferably computed tomography (CT), if clinical deterioration or the patient received OAC reversal treatment
223522468|NCT06429332|OTHER|Standard care|For patients in the usual-care group, decisions about the location of care delivery, investigations, monitoring, and all treatments are made by the treating clinical team. Data will be collected regarding the management of patients, including insertion of invasive monitoring devices, intravenous fluid resuscitation, BP lowering, vasoactive support, glycemic control, mechanical ventilation, neurosurgery, and other supportive therapy.
223522469|NCT04101331|DRUG|AFM13|weekly intravenous infusions of 200mg
223522470|NCT04943757|DRUG|Bendamustine Hydrochloride|50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
223522471|NCT04943757|DRUG|Cyclophosphamid|25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
223522472|NCT00214669|BEHAVIORAL|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
223522473|NCT00214669|BEHAVIORAL|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
223522474|NCT00214669|BEHAVIORAL|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
223704665|NCT02890095|PROCEDURE|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~* 1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* 1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
223704666|NCT02890095|PROCEDURE|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~* measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~* to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
223522475|NCT04762368|DEVICE|Active anodal tDCS|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
223522476|NCT04762368|DEVICE|Sham anodal tDCS|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
223704667|NCT04589325|DRUG|Ixekizumab|"Ixekizumab will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Ixekizumab will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
223522477|NCT05811949|DRUG|Dimethyl Fumarate 240 MG [Tecfidera]|DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
223522478|NCT01189851|DEVICE|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
223522479|NCT03889015|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
223522480|NCT03889015|DIETARY_SUPPLEMENT|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
223522481|NCT00195728|DRUG|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
223522482|NCT03208179|DRUG|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
223522483|NCT03208179|DRUG|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
223522484|NCT03208179|DRUG|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
223522485|NCT05706831|OTHER|Combinatory effect of music stimulation and neurostimulation|music
223522486|NCT05521178|DIAGNOSTIC_TEST|Electrocardiogram|ECG to monitor electrical activities of the heart on each visit
223522487|NCT05521178|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 6 months
223522488|NCT05521178|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac MRI at baseline and 6 months
223522489|NCT05521178|DEVICE|Mobile cardiac telemetry|Mobile cardiac telemetry at baseline and 6 months
223522490|NCT05521178|DIAGNOSTIC_TEST|Blood pressure monitoring|Home blood pressure monitoring three times per week
223522491|NCT05521178|DIAGNOSTIC_TEST|Blood draw|Blood draw at baseline, 3 and 6 months
223522492|NCT05494619|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
223522493|NCT05494619|DRUG|Placebo|Placebo will be administered IV on Day 1 at a dose of 1000 mg for participants with body weight ≥ 40 kg to \< 100 kg, or 1500 mg for participants with body weight ≥ 100 kg. It will be administered SC on Days 2, 8, 15, and 22 at a dose 340 mg in all participants.
223704668|NCT04589325|DRUG|Placebo|"Placebo will be available at a concentration of 80 mg solution for injection in pre-filled syringes.~Placebo will be administrated by the patient via subcutaneous (s.c.) injections for a total treatment period of 12 months. Two s.c. injections (160 mg) will be administrated at week 0, one dose (80 mg) at week 2, 4, 6, 8, 10 and 12 and continue with a maintenance dose (80 mg) every 4th week for a total treatment period of 12 months."
223704669|NCT05847283|PROCEDURE|Dydrogesterone priming ovarian stiumulation protocol|Patients will be co-administered with oral DYG (Duphaston) 30mg/d and Human Menopausal Gonadotrophin (hMG) 225 IU/day (IU/d) via intramuscular injection from menstrual cycle day 2 - 4 (CD2 - CD4) to the day of final oocyte maturation.
223704670|NCT05847283|PROCEDURE|GnRH antagonist protocol|In the fixed GnRH antagonist protocol, hMG 225 IU will be administered daily from menstrual cycle day 2 - 4 (CD2 - CD4) and s.c. administration of GnRH antagonist (Ganirelix 0.25 mg) will be initiated daily on the 5th day of stimulation. Treatment with hMG and GnRH antagonist will be continued until the day of final oocyte maturation triggering.
223704671|NCT04910945|DEVICE|VENUS AIME (RoboCor)|VENUS AIME is a micro-coring device of the skin that can potentially help to reduce visible skin scarring, improve skin laxity and reduce wrinkles.
223522494|NCT05494619|DRUG|Intravenous immunoglobulin therapy|All participants will receive background therapy of IVIg at a dose of 400 milligrams/kilograms (mg/kg) QD for 5 days.
223522495|NCT06342609|DRUG|Colchicine 0.5 MG|0.5mg per day of Colchicine orally administered
223522496|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor+Regorafenib|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
223704672|NCT06974097|OTHER|blood sampling|blood sampling
223522497|NCT06558773|DRUG|Eliglustat+Immune checkpoint inhibitor|"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) ."
223704673|NCT05048459|OTHER|Standard surveillance|Participant coming to the clinic for in-person follow-up visits and having routine endoscopy and cancer imaging procedures as needed
223704674|NCT05048459|OTHER|Telemedicine surveillance (tele-surveillance)|The tele-surveillance visit occurs annually after completion of therapy and consists of a phone call with or without video conferencing between the patient and the treatment team (physician, nurse, and/ or nurse practitioner). The use of video conferencing is strongly encouraged. Clinic visits, endoscopies, and imaging studies can be performed at the discretion of the treatment team for concerning patient symptoms.
223522498|NCT06558773|DRUG|Regorafenib+Immune checkpoint inhibitor|"Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."
223522499|NCT04110145|DRUG|Linaclotide|Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.
223522500|NCT04110145|DRUG|Placebo|Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
223522501|NCT05205837|DRUG|Letrozole 2.5mg, hCG|Drug -Treatment Intramuscular injektion - Treatment
223522502|NCT05205837|DRUG|Placebo|Drug - Placebo Intramuscular injektion - placebo
223522503|NCT00861887|DRUG|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
223704675|NCT05048459|OTHER|Questionnaires|EORTC QLQ-C30 and EORTC QLQ-HN43 at 12 and 24 months, FACE-Questionnaire Module, Telehealth Usability Questionnaire, Telehealth Usability Questionnaire, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction -Patient Satisfaction inventory
223704676|NCT05627765|BEHAVIORAL|Standard treatment (ST) arm|"participants who are ready to quit smoking: a brief smoking cessation intervention based on the 5A models and STAR method as quitting skills.~participants who are not yet ready to quit smoking: a brief smoking cessation intervention based on the 5R models."
223522504|NCT00861887|DRUG|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
223522505|NCT01128478|PROCEDURE|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
223522506|NCT02172729|DRUG|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
223522507|NCT05576064|DIAGNOSTIC_TEST|Gait analysis|Analysis of gait profile and measures by gait laboratory on patients with suspected lower limb rotational deformities and anterior knee pain
223704677|NCT05627765|BEHAVIORAL|Integrated Intervention (II) arm|"brief advice on alcohol use based on the FRAMES model and the brief smoking cessation intervention based on the 5A and 5R models."
223522508|NCT04518501|DRUG|Arsenic trioxide Tablet +Fuzuloparib Capsules|Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
223522509|NCT06298058|DRUG|SIBP-A13 formulation for injection|"SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a 3+3 dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks."
223522510|NCT04717258|OTHER|Fire and Rescue Service Safe and Well Visit|Safe and Well Visits by the Fire and Rescue Service to prevent falls and improve quality of life in an older population
223522511|NCT04717258|OTHER|Self-Determination Theory informed trial invitation letter|Invitation letter to take part in the FIREFLI study informed by Self-Determination Theory
223522512|NCT04717258|OTHER|Pen included with reminder questionaire|A pen will be included with the four-month reminder questionnaire.
223522513|NCT03988933|DRUG|Rifampin double dose|Double dose of rifampin for 2 months.
223522514|NCT03988933|DRUG|Rifampin triple dose|Triple dose of rifampin for 2 months.
223522515|NCT03988933|DRUG|Rifampin standard dose|Standard dose of rifampin for 4 months.
223522516|NCT03705234|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
223522517|NCT03705234|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
223522518|NCT04179084|DRUG|fruquintinib|5mg qd, 2weeks on, 1week off
223522519|NCT04179084|DRUG|Sintilimab|200mg q3w
223704678|NCT03739502|DRUG|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
223704679|NCT06271733|DEVICE|TMS|2 sessions of iTBS per day for 5 days
223704680|NCT06271733|DEVICE|Sham|2 sessions per day for 5 days of sham condition
223704681|NCT05727904|BIOLOGICAL|Lifileucel plus Pembrolizumab|A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
223704682|NCT05727904|BIOLOGICAL|Pembrolizumab with Optional Crossover Period|"Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria.~Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2."
223704683|NCT04028778|DRUG|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
223522520|NCT00233168|BEHAVIORAL|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
223704684|NCT04028778|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
223704685|NCT04028778|OTHER|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
223704686|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
223522521|NCT00233168|BEHAVIORAL|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
223522522|NCT06405529|OTHER|Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge|"During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto."
223522523|NCT04200963|DRUG|IK-175|Subjects will be administered IK-175 PO daily for every 21-day treatment cycle during the Single Agent Treatment dose escalation or for every 28-day treatment cycle during the Single Agent dose expansion.
223522524|NCT04200963|DRUG|IK-175 and nivolumab|Subjects will be administered IK-175 PO daily and administered a single dose of nivolumab IV on Day 1 for every 28-day treatment cycle during the Combination Treatment dose escalation and expansion.
223522525|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
223522526|NCT02221726|DRUG|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
223704687|NCT02569671|DEVICE|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
223704688|NCT06385522|BIOLOGICAL|BITR2101|TNFR2 monoclonal antibody
223893688|NCT05795842|DEVICE|Standard of care extended ECG monitoring|Participants enrolled in the study are prescribed ambulatory ECG monitoring (Mobile Cardiac Outpatient Telemetry, Biotel e-Patch, or LINQ insertable cardiac monitor). If the patient is negative for Afib during their time wearing an ECG monitoring patch, then patients may proceed with LINQ insertable cardiac monitor, as part of their standard of care. These are standard-of-care FDA-approved devices and detection software. Researchers will rely on the final ECG report to identify arrhythmic events to use as a golden standard to evaluate the algorithm findings. Specifically, the raw data will be used for establishing and getting an accurate ground truth for the algorithm.
223522527|NCT05380700|DEVICE|Virtual Reality Stimulation|Participants in the intervention group will be provided with up to 30 minutes of relaxing, 360-degree virtual reality (VR) stimulation and corresponding sounds, twice in 24 hours during their stay on the intermediate care unit.
223522528|NCT06055283|OTHER|Aerobic exercise|The training group will receive aerobic exercise and the intensities will be controlled considering the percentage of estimated maximum heart rate. The training will be performed with a cycle ergometer with a total of 40 minutes of intradialytic aerobic exercise in the training group. To reduce the effects of intolerance to aerobic exercise, a week of adaptation will be performed, with a frequency of three sessions, in the first two hours of hemodialysis, lasting 40 minutes at maximum heart rate intensity of up to 74% and BORG up to 4 (low intensity). Afterwards, the patients will perform the prediction training for 12 weeks, at the frequency of three training sessions per week in the first two hours of hemodialysis. Each training session will start with a 5-minute warm-up at low intensity, 30 minutes of main training with maximum heart rate intensity 55% to 74% and BORG 5 to 7 (moderate intensity) and will end with a 5-minute cool-down at low intensity.
223522529|NCT00203606|DRUG|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
223522530|NCT05274477|DRUG|Fampridine SR|Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
223522531|NCT05274477|DRUG|Placebo|no active component
223522532|NCT06564090|OTHER|robot assisted gait training|Morning Walk® is a new end-effector type robot developed by Hyundai Heavy Industries and Taeha Mechatronics for lower limb rehabilitation in the patients with gait disturbance.The RAGT group received RAGT with robot training for 30 minutes and conventional physiotherapy for 30 minutes per session.
223522533|NCT06564090|OTHER|conventional gait training|The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
223522534|NCT04120987|DRUG|Lifitegrast 5% Ophthalmic Solution|BID OU
223522535|NCT04078867|PROCEDURE|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
223522536|NCT05797623|DRUG|Trappa ethanolamine tablets ; ciclosporin|Trappa ethanolamine tablets combined with ciclosporin
223522537|NCT05797623|DRUG|Placebo ; ciclosporin|Placebo combined with ciclosporin
223522538|NCT02595515|OTHER|Chiropractic treatment|Procedure: chiropractic treatment.
223522539|NCT02595515|OTHER|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
224275725|NCT00559637|DRUG|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
224275726|NCT04684511|DRUG|TRM-201 (Rofecoxib)|Eligible patients will be randomized to receive TRM-201 or placebo
223522540|NCT05930639|OTHER|Surgical Site Infection (SSI) prevention package|"Care package components to be applied to the intervention group; identification of risk factors, antibiotic prophylaxis, normothermia, normoglycemia and patient education.~Risk factors will be evaluated when the patient is admitted to the clinic. Antibiotics (imipenem + cilastatin sodium) routinely administered by the institution before surgery will be administered in both groups.~Passive heating methods will be used to maintain body temperature for the first 24 hours after surgery.~In the perioperative period, the blood glucose level will be kept below 200mg/dl for 48 hours.~Before the operation and before discharge, the patient is educated about infection prevention measures."
223522541|NCT01280669|DRUG|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
223522542|NCT01280669|DRUG|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
223522543|NCT03409809|BEHAVIORAL|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
223522544|NCT03409809|BEHAVIORAL|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
223522545|NCT03409809|BEHAVIORAL|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
223522546|NCT02415114|DIETARY_SUPPLEMENT|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
223522547|NCT02568319|DRUG|LIPO-202|
223522548|NCT02568319|DRUG|Placebo|
223522549|NCT00337168|DRUG|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
223522550|NCT00337168|DRUG|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
223522551|NCT02407119|DRUG|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
223522552|NCT02407119|DRUG|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
223522553|NCT00421564|DRUG|DBT-Danggui Buxue Tang|
223522554|NCT02179034|DRUG|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
223522555|NCT02179034|OTHER|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
223522556|NCT02179034|OTHER|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
223893689|NCT03993509|DEVICE|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
223522557|NCT05903703|DRUG|Canagliflozin and Gemcitabine|"on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle"
223522558|NCT05903703|DRUG|Gemcitabine|on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
223704689|NCT04885192|OTHER|Stepped-Care Model|"Step 0: Screening via Manage My Pain (MMP) App. Patients using MMP will be prompted to complete questionnaires on pain catastrophizing, depressive symptoms, anxiety, suicide risk and opioid risk. Those scoring above clinical risk cut-offs will be referred to Step 1.~Step 1: Acceptance and Commitment Therapy (ACT) Workshop. Patients will be offered a virtual ACT workshop focusing on practical coping skills for dealing with pain, emotional dysregulation, and disability, while maximizing functioning and quality of life with chronic pain. Thirty days later, patients will be prompted to complete all questionnaires through MMP again; those who score above clinical risk cut-offs will be referred to Step 2.~Step 2: Dialectic Behavior Therapy (DBT) group. A 6-week DBT-based skills group will cover topics such as self-compassion, radical acceptance, distress tolerance, and mindfulness, among others. Thirty days later, patients will be prompted to complete questionnaires through MMP."
223522559|NCT03253237|DEVICE|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
223522560|NCT01490021|PROCEDURE|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
223704690|NCT02612129|DRUG|arimoclomol|
223704691|NCT02612129|DRUG|Placebo|
223704692|NCT06388291|DEVICE|Deep Brain Stimulation|ON/OFF stimulation vs OFF/ON stimulation
223704693|NCT05705648|DIETARY_SUPPLEMENT|medium chain triglyceride oil|Medium chain triglyceride oil
223704694|NCT05705648|DIETARY_SUPPLEMENT|Safflower oil|Safflower oil
223704695|NCT04225507|BEHAVIORAL|Diet and exercise coaching|All participants will receive diet and exercise goals and coaching.
223704696|NCT04225507|OTHER|CPAP Treatment|CPAP treatment for sleep apnea and CPAP education and adherence coaching.
223704697|NCT02649088|DEVICE|Microscan|It allows to look at sublingual microcirculation
223522561|NCT01490021|PROCEDURE|rTMS/Placebo TBS|rTMS/Placebo TBS
223522562|NCT03901040|DEVICE|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
223522563|NCT01347814|DRUG|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
223522564|NCT01347814|DRUG|Placebo|Homeopathic (Sugar) pill-Placebo
223522565|NCT00760760|DRUG|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
223522566|NCT00760760|DRUG|control|equivalent amount of fat as butter
223704698|NCT02649088|DEVICE|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
223704699|NCT04122690|BEHAVIORAL|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
223704700|NCT04122690|BEHAVIORAL|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
223704701|NCT05911321|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
223704702|NCT05911321|DRUG|Pomalidomide|Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
223704703|NCT05911321|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
223704704|NCT06601751|OTHER|Neurobic Exercise Program|6 weeks to improve cognitive function, memory and overall brain health by introducing non-routine activities that require participants to utilise their multiple senses and remember sequences and patterns. Each activity would be performed 2-3 times/ session, for recalling the observation period set at 1 minute and at the end of the 9th week, the memory retention effect will be measured.
223704705|NCT06601751|OTHER|Traditional Brain Exercise|activities like calculation or memory games. These exercises will be conducted in 2 days/week for 60-minute sessions in 6 weeks. The memory retention effect will be measured at the end of the 9th week. It is intended to be the baseline for comparing the effectiveness of a neurobic exercise program.
223704706|NCT04332133|PROCEDURE|laser interference,INTRAVITREAL INJECTION|sub threshold micro pulse laser for DME for group 1 and intravitreal injection of Ranibizumab for group 2
223522567|NCT03283241|DEVICE|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
223522568|NCT03283241|DEVICE|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
223522569|NCT00666263|BIOLOGICAL|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
223522570|NCT00666263|BIOLOGICAL|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
223522571|NCT03091855|OTHER|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
223522572|NCT03091855|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
223522573|NCT04908644|DRUG|MS-20 oral solution|Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans
223522574|NCT04908644|OTHER|Placebo|Placebo
223522575|NCT00273884|DRUG|Amonafide L-Malate|
223522576|NCT00273884|DRUG|Cytarabine|
223522577|NCT02691156|DIAGNOSTIC_TEST|Bilirubin Binding Capacity|Research laboratory assay of bilirubin binding capacity
223522578|NCT02691156|DIAGNOSTIC_TEST|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
223522579|NCT02691156|DIAGNOSTIC_TEST|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
223522580|NCT00212004|DRUG|pioglitazone|
223522581|NCT00212004|OTHER|control|
223522582|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) \[Original\], single dose
223522583|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
223522584|NCT01067807|DRUG|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
223522585|NCT01067807|DRUG|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) \[Blended\], single dose
223522586|NCT04191226|DIAGNOSTIC_TEST|Multi-gene panel testing|A multi-gene panel, which consists of more than 500 hundred genes will be provided for mutation analysis
223522587|NCT02288130|DRUG|GnRHa|
223522588|NCT02288130|DRUG|Ulipristal|
223522589|NCT01225952|DEVICE|Crystalens AO|Bausch \& Lomb model silicone multi-piece accommodating IOL.
223522590|NCT01225952|DEVICE|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
223522591|NCT01225952|DEVICE|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
223704707|NCT02923596|PROCEDURE|History of prior Surgery|History of prior Surgery will be reviewed
223522592|NCT00286286|DEVICE|Intraperitoneal Aerosolization System, IntraMyst|
223704708|NCT02923596|RADIATION|History of Radiation Therapy|History of prior radiation therapy will be reviewed
223704709|NCT05514340|DRUG|Normal Saline along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
223522593|NCT02573064|DRUG|Colistin|
223522594|NCT02573064|DRUG|Tigecycline|
223522595|NCT02573064|DRUG|Vancomycin|
223522596|NCT05825040|BEHAVIORAL|Online guided transdiagnostic cognitive behavioural therapy|The contents of guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. Customized guidance will be provided by coaches once a week based on participants' performance
223522597|NCT05825040|BEHAVIORAL|Online self-guided transdiagnostic cognitive behavioural therapy|The contents of self-guided transdiagnostic cognitive behavioural therapy are developed by clinical psychologists and psychological well-being officers. The intervention consists of 8 modules. Contents include emotional awareness, physical sensation, emotion-driven behavior, behavioral activation, worry, cognitive restructuring, behavioral experiment, and relapse prevention. No customized guidance will be provided to participants in the self-guided group.
223522598|NCT05825040|BEHAVIORAL|Online self-guided mindfulness-based intervention|The contents of online self-guided mindfulness-based intervention are developed by clinical psychologists and psychological well-being officers. The intervention consists of 6 modules. Contents include mindfulness and auto-pilot, react and respond, aversion, craving, equanimity, and 'suffering', thoughts and letting go, starting with loving kindness, and mindfulness in life.
223522599|NCT00916487|DIETARY_SUPPLEMENT|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
223522600|NCT00003794|PROCEDURE|psychosocial assessment and care|
223522601|NCT00003794|PROCEDURE|quality-of-life assessment|
223522602|NCT00269581|OTHER|Educational CD-rom|Educational CD-Rom
223522603|NCT00269581|OTHER|Headstrong CD-rom|Headstrong CD-rom
223522604|NCT03226691|DRUG|Plerixafor|Single-dose subcutaneous administration of plerixafor (Mozobil®) at 240 μg/kg
223522605|NCT00900614|DRUG|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
223522606|NCT03594708|DIETARY_SUPPLEMENT|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
223522607|NCT03594708|DIETARY_SUPPLEMENT|Placebo supplement|rice starch, light olive oil, vegetable oil
223522608|NCT01205516|DRUG|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
223522609|NCT01205516|DRUG|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
223522610|NCT04125602|OTHER|High fat low carbohydrate diet|Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
223704710|NCT05514340|DRUG|Sovateltide along with standard treatment|Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
223704711|NCT00169793|OTHER|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
223704712|NCT00169793|OTHER|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
223704713|NCT06857383|OTHER|Fremantle Headache Awareness Questionnaire|"It is a simple Likert-type questionnaire that evaluates individual-specific altered perception (0 = Never/Never feel like this, 1 = Rarely feel like this, 2 = Sometimes or sometimes feel like this, 3 = Often feel like this, 4 = Always or most of the time feel like this). The questionnaire asks individuals 9 questions about how they perceive their heads and headaches in relation to their bodies. The questionnaire was developed by Wand et al. in its first version as The Fremantle Back Awareness Questionnaire. With permission from the author, the questionnaire was created by adapting the questions of the Fremantle Back Awareness Questionnaire to headache."
223522611|NCT04125602|OTHER|Low fat high carbohydrate diet|Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
223522612|NCT01401673|DRUG|Indantadol|Titration
223522613|NCT05326295|DIAGNOSTIC_TEST|CTC detection|CTCs separation and enrichment technology. Combined with the prognosis of patients with recurrence and survival time, we explored the evaluation of CTC number, cell phenotype distribution, PDL1 and FOXC2 expression on the prognosis of early stage breast cancer patients. The research results are expected to provide a new effective index and theoretical basis for evaluating the treatment efficacy of breast cancer patients.
223522614|NCT04118101|DRUG|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
223522615|NCT04118101|OTHER|control|no ESPB will be given.
223522616|NCT00336206|DRUG|Alemtuzumab|
223522617|NCT06467188|OTHER|Validity and reliability|"In order to evaluate the content validity of the Turkish version of the scale, 12 expert researchers in the field of gynecology and obstetrics were consulted. The experts were asked to evaluate the items as 1-Not Appropriate, 2-Somewhat Appropriate, 3-Reasonably Appropriate, and 4-Very Appropriate. Experts were asked to suggest items not evaluated as very appropriate. In the Davis technique, the content validity index which is calculated by dividing the number of experts who marked the options a (The item is appropriate) and b (The item needs minor revision) for each item by the total number of experts providing opinions is expected to be over 0.80 \[30\]. Based on expert opinions, the content validity index (CVI) value of the scale was calculated to be 96%, meaning that content validity was ensured. The items were reorganized by considering the experts' suggestions. The scale was administered to 252 women over 18 who were included in the study sample after scoring."
223522618|NCT05280054|DRUG|AV-101|360 mg capsules
223522619|NCT05280054|DRUG|Probenecid|1000 mg oral
223522620|NCT04628806|DIAGNOSTIC_TEST|CTC isolation by HSP70|patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
223522621|NCT01285102|COMBINATION_PRODUCT|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
223522622|NCT01285102|PROCEDURE|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
223522623|NCT06183970|DEVICE|AssistI patients|The AsistI software package rehabilitation involves tailored upper limb exercises under an individual program. The regimen consists of 10-12 sessions, each lasting 30 minutes. Patients execute 10 exercises sequentially with their unaffected and affected limbs, involving tasks like touching mouth, forehead, and trunk parts with hand's brush, and amplitude movements in upper limb joints. AsistI assesses exercise accuracy, prevents unfavorable patterns, and logs target achievement, considering speed, accuracy, and repetitions.
223704714|NCT00987545|DRUG|QAX576|QAX576 injection
223704715|NCT00987545|DRUG|QAX576 placebo|Placebo to QAX576 injection
223704716|NCT01984983|BIOLOGICAL|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
223704717|NCT01984983|OTHER|0.9% saline placebo|
223704718|NCT06608472|DRUG|N0877|1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®
223704719|NCT06608472|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|1 tablet of Benicar HCT® and 1 tablet of Placebo of N0877
223704720|NCT00892242|DRUG|Zoledronic acid|
223893690|NCT04605679|PROCEDURE|Kidney Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive kidney graft
223522624|NCT06183970|DEVICE|Habilect patients|The Habilect rehab program involves 10-12 sessions using software and hardware. Patients perform upper limb exercises for 30 minutes individually, focusing on specific movements. They repeat 10 exercises, first with the healthy limb, then the affected one. Tasks include touching mouth, forehead, and trunk, along with joint movements like shoulder flexion. Habilect assesses exercise accuracy, preventing wrong moves, and tracks progress, considering speed, accuracy, repetitions.
223522625|NCT06465238|DRUG|SHR-A2009|Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
223522626|NCT06465238|DRUG|SHR-A1921|Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
223522627|NCT05860985|DEVICE|ZEISS disposable|a comparison will be done between the present lenses used (reusable RESIGHT lenses and disposable Vitreq contact lens) and the new disposable RESIGHT lenses.
223522628|NCT01040247|OTHER|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
223522629|NCT02988908|DRUG|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
223522630|NCT02988908|DRUG|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
223522631|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 21 mg administered SC
223522632|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 35 mg administered SC
223522633|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 70 mg administered SC
223522634|NCT04189484|BIOLOGICAL|Evolocumab|Evolocumab 140 mg administered SC
223522635|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 15 mg administered SC
223704721|NCT00904397|DRUG|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
223522636|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 25 mg administered SC
223522637|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 50 mg administered SC
223522638|NCT04189484|BIOLOGICAL|Alirocumab|Alirocumab 100 mg administered SC
223522639|NCT04189484|BIOLOGICAL|Placebo|Placebo administered SC
223522640|NCT02972645|DRUG|LY3305677|Administered SC
223522641|NCT02972645|DRUG|Placebo|Administered SC
223522642|NCT06495606|DIAGNOSTIC_TEST|Voice sample; Recording with microphone + Questionnaire|Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD
223704722|NCT00904397|DRUG|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
223704723|NCT06162429|PROCEDURE|Flexible Bronchoscopy|Subjects with pleural effusion who underwent medical thoracoscopy using flexible bronchoscopy
223522643|NCT06187389|OTHER|1 Grups|This methodological study was conducted using a cross-sectional observational approach at a leading teaching and research hospital. The study duration was from March to June 2023
223704724|NCT06162429|PROCEDURE|Semi-Rigid Pleuroscopy|Subjects with pleural effusion who underwent medical thorascopy using semi-rigid pleuroscopy
223704725|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
223704726|NCT03487549|COMBINATION_PRODUCT|VP-102 Cantharidin, topical film forming solution|VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
223522644|NCT05241366|DEVICE|Transcranial Magnetic Stimulation|"The TMS group will be comprised of 10 patients, each subject will receive 12 sessions of low frequency (1 Hz) rTMS over the right dorsolateral prefrontal cortex with a total of 1500 pulses in each session. Each session will last approximately 30 minutes. There will be one session per day, five sessions per week. The total duration of the treatment will be four weeks.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
223522645|NCT05241366|DEVICE|Sham Transcranial Magnetic Stimulation coil|"Simulated TMS stimulation will be performed with a Sham TMS coil, which has a sound and scalp contact similar to those experienced during active stimulation. The duration of the treatment will be the same as in the experimental arm.~All patients will continue with the usual treatment established by their treating physician. Those who do not have a previous pharmacological treatment will start a protocol with sertraline, which should be started at a 50 mg/day dosage."
223522646|NCT02169596|DRUG|Ticagrelor|Blood tests taken for flow cytometry
223522647|NCT02169596|OTHER|EndoPAT - endothelial assessment|
223522648|NCT04477616|DRUG|Day 7 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
223522649|NCT04477616|DRUG|Day 3 regimen|patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
223704727|NCT03105583|DRUG|Medication use during pregnancy|
223704728|NCT03105583|DIETARY_SUPPLEMENT|Supplement use during pregnancy|
223522650|NCT02714348|OTHER|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
223522651|NCT01907282|BEHAVIORAL|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
223522652|NCT01907282|BEHAVIORAL|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
223522653|NCT02119273|DRUG|Prednisone|See arm description
223522654|NCT02119273|DRUG|Placebo|See arm description
223522655|NCT03629704|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
223522656|NCT00876941|BEHAVIORAL|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
223522657|NCT00876941|BEHAVIORAL|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
223522658|NCT00876941|BEHAVIORAL|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
223522659|NCT04946214|BEHAVIORAL|Smart Water Bottle|Patients will be given a smart water bottle and coached on its use. The device is a 24 oz non-bisphenol A acrylic water bottle with the ability to track water consumption from the bottle, alert its users via a smartphone-based notification system, as well as visually remind patients with a light-emitting diode in the device. Participants will be alerted to drink patient-specific volumes of room temperature water 45 minutes prior to daily standard of care radiotherapy.
223522660|NCT04936555|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
223522661|NCT01066845|DRUG|tadalafil|prescribed in accordance with usual clinical practice
223522662|NCT04020640|OTHER|no intervention|Measure human intake using stable isotope technique
223522663|NCT00659022|PROCEDURE|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
223522664|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
223522665|NCT00659022|DRUG|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
223522666|NCT00659022|DRUG|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
223522667|NCT05321602|DRUG|LY03010 156 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
223522668|NCT05321602|DRUG|LY03010 156 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
223522669|NCT05321602|DRUG|LY03010 351 mg treatment group, deltoid|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
223522670|NCT05321602|DRUG|LY03010 351 mg treatment group, gluteal|LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.
223522671|NCT01554709|DEVICE|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
223522672|NCT01101776|DRUG|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
223704729|NCT03105583|OTHER|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
223522673|NCT01716637|BIOLOGICAL|Etanercept|
223522674|NCT01716637|DIETARY_SUPPLEMENT|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
223522675|NCT00451737|DEVICE|Isokinetic test|
223522676|NCT03574363|DRUG|KBP-5074 0.25 mg tablet|Oral administration, QD, 84 days
223522677|NCT03574363|DRUG|KBP-5074 0.5 mg tablet|Oral administration, QD, 84 days
223704730|NCT06668649|DIAGNOSTIC_TEST|Testing with Questionnaires|Testing with following Questionnaires: pFSS, Polish-language version of Modified Fatigue Impact Scale, Visual Analogue Scale of Fatigue, EQ-5D-5L (EuroQol-5 dimension) questionnaire, Beck Depression Inventory II. In randomly selected 30 patients and 20 controls questionnaires will be administered twice with two weeks interval to assess the test-retest reliability.
223704731|NCT06681597|DIETARY_SUPPLEMENT|Raspberry ketone|Human consumed 500mg of raspberry ketone
223704732|NCT06680505|DRUG|YZJ-1139 10mg|YZJ-1139 10mg tablets
223704733|NCT06680505|DRUG|YZJ-1139 20mg|YZJ-1139 20mg tablets
223704734|NCT06680505|DRUG|YZJ-1139 40mg|YZJ-1139 40mg tablets
223704735|NCT06680505|DRUG|YZJ-1139 60mg|YZJ-1139 60mg tablets
223704736|NCT06680505|DRUG|Placebo|Match placebo tablets
223704737|NCT06680557|BEHAVIORAL|Aerobic and resistance exercises|"* Aerobic exercise session: A 30-minutes of brisk walking exercise on an indoor track without speed walking or running .~* Resistant exercise session: A 30-minutes of resistance exercise using rubber bands including warm-up and cool-down periods. Rubber band exercises are composed of seven exercises: squat, leg extension, pull apart, seated row, standing biceps curl, overhead press and lateral raise. Each exercise consists of three sets of 10 repetitions with 1 minute rest between each exercise set."
223704738|NCT03919162|DRUG|PQ912|PQ912 150 mg tablets
223704739|NCT03919162|OTHER|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
223522678|NCT04023045|DEVICE|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
223522679|NCT04023045|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
223522680|NCT03277599|DRUG|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
223522681|NCT03277599|DRUG|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
223522682|NCT03277599|DRUG|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
223522683|NCT06641596|DIETARY_SUPPLEMENT|Placebo|2 capsules of Placebo, once daily after breakfast for 12 weeks
223522684|NCT06641596|DIETARY_SUPPLEMENT|Cr-400|1 capsule of Cr-400 + 1 capsule of Placebo, once a day after breakfast for 12 weeks
223522685|NCT06641596|DIETARY_SUPPLEMENT|Cr-800|2 capsules of Cr-400, once a day after breakfast for 12 weeks
223704740|NCT05730699|BIOLOGICAL|divozilimab|anti-CD20 monoclonal antibody
223704741|NCT02585622|BIOLOGICAL|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10\^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
223704742|NCT02585622|OTHER|Placebo|Volume total of fluid infused: 40 ml
223704743|NCT06190977|OTHER|Otago Exercise Program|Exercises will include Intensity: 10 repetitions of each set for the first two weeks and 15 repetitions of each set for the last two weeks, Frequency 3 sessions per week for 4 weeks. Time= 40-45 minutes
223704744|NCT06190977|OTHER|General TKR pprotocol|Exercises will include Intensity: 10 repetitions of each set, Frequency 5 sessions per week for 4 weeks. Time= 30 minutes
223704745|NCT05041426|DRUG|Letermovir|Participants who are CMV R+ will receive LET prophylaxis for 6 months, and participants who are CMV D+/R- will receive LET prophylaxis for 12 months. The duration of prophylaxis is per current standard of care. LET will be administered at a dose of 480 mg IV or oral once daily. IV administration will occur only for those patients unable to swallow tablets. If LET is co-administered with cyclosporin A (CsA), the dosage of LET should be decreased to 240 mg once daily. All patients will be followed for 12 weeks after completion of LET for the occurrence of CMV infection or disease after prophylaxis. Participants on this protocol will receive acyclovir 400 mg orally BID for the duration of LET therapy for herpes simplex virus and varicella zoster virus prophylaxis.
223704746|NCT05041426|DRUG|Valganciclovir|Historical controls will have received CMV prophylaxis with valganciclovir for 6 months for CMV R+ and for 12 months for CMV D+/R-.
223704747|NCT06086353|DRUG|Tafamidis|Patients on tafamidis will be observed
223522686|NCT06641596|DIETARY_SUPPLEMENT|PE-500|1 capsule of PE + 1 capsule of Placebo, once a day after breakfast for 12 weeks
223704748|NCT07016802|DRUG|GenSci134|only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
223704749|NCT07016802|DRUG|GenSci134 Placebo|only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
223522687|NCT06641596|DIETARY_SUPPLEMENT|PE-1000|2 capsules of PE-500, once a day after breakfast for 12 weeks
223522688|NCT05236023|BEHAVIORAL|Zero separation and couplet care|"The essence of the intervention is that treatment-requiring mother-infant dyads are admitted together and receives couplet care provided by neonatal nurses.~The nurses will be educated for the intervention by participating in a two-day course about postpartum observations, treatment and care; and participate in education about family-centred care and family-focused nursing."
223704750|NCT07016802|DRUG|Recombinant Human Growth Hormone Injection (Norditropin®)|A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.
223704751|NCT00391820|DRUG|TD-5108|
223704752|NCT06708780|BIOLOGICAL|Ex vivo Expanded Human Autologous Regulatory T Cells|Peripheral blood component donation is used to collect Treg cells for ex vivo expansion, with technical guidance provided by the Center for Biotechnology Drug Development at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
223522689|NCT06642259|RADIATION|Echocardiography|ECHO
223522690|NCT06563570|OTHER|yoga (online)|8-week online yoga practices, 2 days a week
223522691|NCT06216288|OTHER|Repeated back extension exercise (McKenzie)|repetitive back extension exercises in prone position with 1 minute hold on maximal back extension. 3 sets of 10 repetitions with 1 minute break between sets. The intervention was done 3 times per week for 6 weeks.
223522692|NCT06216288|DEVICE|Mechanical traction|The traction was applied using a 3D ActiveTrac table. This motorized split table applied static traction to the lumbar spine with the participant in a prone position. The intensity of the force of traction was 40% to 60% of the participant's body weight applied for 15 minutes. The intervention was done 3 times per week for 6 weeks.
223704753|NCT06708780|OTHER|Routine Care|Routine care is provided to all participants according to clinical guidelines for T1DM.
223704754|NCT06708676|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
223704755|NCT06710782|DRUG|Hyaluronic acid|Patients underwent intra-articular hyaluronic acid injection.
223704756|NCT06710782|DEVICE|Transcutaneous pulsed radiofrequency|Patients underwent transcutaneous pulsed radiofrequency application plus genicular nerve block.
223704757|NCT06709417|DRUG|Sintilimab|Sintilimab 200mg iv Q3W
224275727|NCT04684511|DRUG|Placebo|Matching Placebo
224275728|NCT00029211|DRUG|Echinacea|
223522693|NCT06639776|DIAGNOSTIC_TEST|Questionnaire|"All erection prosthesis placements in post-phalloplasty transgender and gender non-conforming individuals at Ghent University Hospital from start of the gender clinic until June 2023 will be evaluated. All patients that are at least 6 months after erection prosthesis placement and currently have a functioning prosthesis in place are eligible and will be contacted. Upon inclusion and informed consent, the patient's medical files will be used to gather all necessary underlying medical information that is relevant to this study. will receive an email asking them to complete a questionnaire for themselves. At the end of this questionnaire the patient will be asked if they have a sexual partner and if this partner is willing to participate as well. After affirmation, the partner will be contacted in the same way.~Patients will receive a series of questionnaires reviewing recent sexual activity, sexual preference, satisfaction with the erectile prosthesis and quality partner relationship."
223522694|NCT03729609|DRUG|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
223522695|NCT05264454|DEVICE|high flow nasal cannulae|The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
223522696|NCT06638697|OTHER|Free walking|The free walking training program will last 32 weeks. The intensity of the training will be controlled by the scale of perceived exertion (Borg). The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522697|NCT06638697|OTHER|Nordic walking|The Nordic walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
223522698|NCT06638697|OTHER|Dance|The Dance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
223522699|NCT06638697|OTHER|Physical exercise for cognition|The Physical exercise for cognition training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
223522700|NCT06638697|OTHER|Balance|The Balance training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial and final stretching will last five minutes.
223522701|NCT06638697|OTHER|Aquatic physiotherapy|The Aquatic Physiotherapy training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223704758|NCT06709417|DRUG|Chemotherapy|Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )
223704759|NCT06709417|RADIATION|radiotherapy|The total dose is 5040cCy in 28 fractions (5 days per week, 1.8 Gy/day).
223704760|NCT06707649|OTHER|Self Management Education|Patients in this group will receive self-management education during the 3 days when they are in the hospital. On the first day of the training, COPD disease, causes of the disease, symptoms, reasons for alleviating complaints, practical information for living comfortably with COPD will be given. On the second day, emergency situations in COPD, what is an exacerbation and prevention suggestions and diaphragmatic breathing-cough exercises will be taught. On the last day, training will be given on pursed lip breathing, medication use, oxygen and nebulizer treatments. The education will be accompanied by a educational booklet prepared by researchers and expert opinion.
223704761|NCT06707649|OTHER|Telephone Follow-up|Patients will receive their first call one week after discharge. The calls will be scheduled weekly during the first month, biweekly in the second month, and monthly starting from the third month. During the calls, it is planned to repeat the educational content and answer the patient's questions.
223704762|NCT06709885|DRUG|Chidamide + Tislelizumab + chemotherapy (CapeOX )|Chidamide + Tislelizumab + chemotherapy (CapeOX regimen): 4 cycles of combination therapy (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; tislelizumab, 200mg/m2 iv.gtt; Day1,4,8,11Chidamide 20 mg BIW,PO; Day1-Day14, capecitabine 850-1000mg/m2, BID, PO) ；After completing the surgery, Post-operation 4 cycles of Capeox
223704763|NCT06709885|DRUG|CapeOX|4 cycles (q3w; Day1 Oxaliplatin, 130mg/m2, iv.gtt; Day1-Day14, capecitabine, 850-1000mg/m2, BID, PO. ） Post-operation 4 cycles of Capeox
223704764|NCT06707428|OTHER|compression stockings|compression stockings used during cesarean section
223704765|NCT06708637|DRUG|FYB203 2 mg (0.05 mL of 40 mg/mL)|IVT administration of FYB203 in a PFS
224275729|NCT01104571|BIOLOGICAL|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 \& 8 pre-surgery \& one dose of 2mg/kg iv between days 15-19 post surgery
224275730|NCT01104571|DRUG|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
224275731|NCT01104571|OTHER|laboratory biomarker analysis|
224275732|NCT01104571|PROCEDURE|adjuvant therapy|
224275733|NCT01104571|PROCEDURE|neoadjuvant therapy|
224275734|NCT01104571|PROCEDURE|therapeutic conventional surgery|therapeutic conventional surgery
224275735|NCT00510003|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
223522702|NCT06638697|OTHER|Multicomponent gymnastics|The Multicomponent Gymnastics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522703|NCT06638697|OTHER|Water aerobics|The Water Aerobics training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522704|NCT06638697|OTHER|Hydroposture|The Hydroposture training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522705|NCT06638697|OTHER|deep water walking|The deep water walking training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522706|NCT06638697|OTHER|Weight training|The weight training program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522707|NCT06638697|OTHER|Mat pilates|The MAt pilates program will last 32 weeks. The intensity of the training will be controlled by the Borg scale of perceived exertion. The training program will have a frequency of two sessions per week, lasting 60 minutes and will be divided into three parts: a) stretching, joint mobility and warm-up; b) main part (according to the objectives of each modality); c) cool-down and final stretching. Both the initial stretching and the final stretching will last five minutes.
223522708|NCT03794947|PROCEDURE|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
223522709|NCT03794947|PROCEDURE|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
223522710|NCT04869384|OTHER|Reminders and feedback to improve adherence|Subjects will receive reminders and feedback to improve their adherence.
223522711|NCT04869384|OTHER|No reminders and feedback to improve adherence|Subjects will not receive reminders and feedback to improve their adherence.
223522712|NCT06160245|OTHER|exercise therapy|core stabilization exercises
223522713|NCT05789251|DIAGNOSTIC_TEST|Standardized breakfast|Standardized breakfast to replace in fine oral induced hyperglycemia test
223522714|NCT03421353|DRUG|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
223522715|NCT03421353|DRUG|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
223522716|NCT03421353|DRUG|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
223522717|NCT03421353|DRUG|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
223522718|NCT03421353|DRUG|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
224275736|NCT03876028|BIOLOGICAL|Tisagenlecleucel|Infusion
224275737|NCT03876028|DRUG|Ibrutinib|Oral (tablets or capsules)
223522719|NCT03421353|DRUG|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
223522720|NCT03421353|DRUG|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
223522721|NCT02754297|DRUG|177Lu-Octreotate|"* The induction course will consist in 4 cycles at 8-10 weeks intervals.~* Concomitant amino acids will be administered for renal protection.~* Intra-arterial LuTate administration will be allowed in suitable cases.~* Dosimetry will be based on quantitative SPECT/CT imaging.~* In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
224275738|NCT02832167|BIOLOGICAL|Nivolumab|Specified dose on specified days
224275739|NCT05780450|DEVICE|Transcranial Direct Current Therapy (tDCS)|"Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential.~Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA.~The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment."
223704766|NCT06708195|DEVICE|Group experimental|Type: Inactive TENS (placebo) Frequency: 1 session Session duration: 15 minutes Application area: Skin over the bilateral parotid glan
223522722|NCT06268847|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo."
223522723|NCT06268847|DIETARY_SUPPLEMENT|ACT01|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
223522724|NCT06268847|DIETARY_SUPPLEMENT|ACT02|2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
223522725|NCT06040255|DRUG|methylprednisolone, prednisolone, prednisone|Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
223522726|NCT02997085|DEVICE|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
223522727|NCT02997085|DEVICE|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
223522728|NCT01809769|BIOLOGICAL|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
223522729|NCT01809769|BIOLOGICAL|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
223522730|NCT01809769|BIOLOGICAL|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
223522731|NCT03528733|DEVICE|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
223522732|NCT01829451|OTHER|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~\--------------------------------------------------------------------------------"
223522733|NCT02510586|DRUG|Sevoflurane|administer 1.0 MAC (1.7\~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
223522734|NCT00784615|PROCEDURE|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
223522735|NCT03982173|DRUG|Tremelimumab|tremelimumab 75mg
223704767|NCT06709755|BEHAVIORAL|Supporting Teen Problem Solving|STePS is a group-based, teen-focused intervention aimed at reducing diabetes-specific emotional distress and building diabetes resilience. STePS is grounded in both cognitive-behavioral and social problem-solving theories, which recognize the interrelationships among difficult situations, beliefs related to the cause and consequences of those situations, and the emotional and behavioral consequences of those beliefs, and which addresses problem solving strategies that influences ones' adaptive functioning in real-life social settings, distinguishing between problem solving and solution implementation. STePS reduces distress by teaching: 1) emotion regulation, helping teens learn to link beliefs, emotions, and behaviors; to challenge negative thinking by evaluating the accuracy of one's beliefs; and learning new coping skills.2) perspective taking, helping teens learn to identify their own thinking style.
223522736|NCT03982173|DRUG|Durvalumab|Durvalumab 1500mg
223522737|NCT01869673|DEVICE|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
223522738|NCT01869673|DEVICE|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
223522739|NCT01533987|DIETARY_SUPPLEMENT|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
223522740|NCT04687930|DRUG|genicular nerve block|nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.
223522741|NCT04687930|DRUG|intra-articular steroid injection|Triamcinilone injection into the knee joint under ultrasound guidance.
223522742|NCT04311307|BIOLOGICAL|[6,6-2H2]glucose|Each subject will be administered two oral \[6,6-2H2\]glucose loads (pre-prandial, fed) in the hospital setting and one oral \[6,6-2H2\]glucose load at home setting (random time). Capillary blood samples will be collected on filter paper 10 times at specific time points after each oral \[6,6-2H2\]glucose load.
223522743|NCT06042816|PROCEDURE|Free-opioid anesthesia|Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors
223704768|NCT06709755|BEHAVIORAL|Diabetes Education|Arm Description: The Participants will receive diabetes education directed toward adolescents matching time, group experience and homework assignments, delivered virtually
223704769|NCT06709664|BEHAVIORAL|Questionnaire|Questionnaire study
223704770|NCT06708403|OTHER|Judo-Specific Injury Prevention Exercise Program|The intervention includes a structured program designed specifically for judo athletes to prevent injuries and enhance performance. The program consists of warm-up exercises, strength and conditioning drills, balance improvement exercises, agility training, and sport-specific movements. It is delivered over six weeks, with participants completing three sessions per week. Each session is progressively tailored to improve overall motor skills, prevent overuse injuries, and enhance judo-specific abilities.
223522744|NCT06042816|PROCEDURE|opioid anesthesia|Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
223522745|NCT01704157|DEVICE|Cryo-Touch III|Study treatment at Day 0.
223522746|NCT04853121|PROCEDURE|Tapered Implants|Tapered Implants are placed in fresh socket via dynamic navigation
223522747|NCT04853121|PROCEDURE|Straight Implants|Straight Implants are placed in fresh socket via dynamic navigation
223522748|NCT01683812|DEVICE|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
223522749|NCT06094738|DRUG|Relacorilant under fasted conditions|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
223522750|NCT06094738|DRUG|Relacorilant after a high-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
223522751|NCT06094738|DRUG|Relacorilant after a low-fat meal|Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
223522752|NCT04357470|OTHER|Hand Therapy|The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
223522753|NCT00141011|DRUG|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
223522754|NCT00141011|DRUG|Placebo|0.6 mL/kg/hr
223522755|NCT01623947|DIETARY_SUPPLEMENT|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
223522756|NCT01623947|DIETARY_SUPPLEMENT|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
223522757|NCT01623947|DIETARY_SUPPLEMENT|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
223522758|NCT01505855|DRUG|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
223522759|NCT00605189|DEVICE|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
223522760|NCT00605189|DEVICE|Powered Suction Pump|continuous gauze based negative pressure wound therapy
223522761|NCT00605189|DEVICE|MWT|moist wound therapy
223522762|NCT03176927|DIAGNOSTIC_TEST|magnetogastrogram|
223522763|NCT04381806|DRUG|5-ALA|Patients enrolled in this study will receive 3 doses of ALA and fractions of radiation therapy during the course of one 21day cycle. Only one cycle per patient is allowed. Patients are followed through day 56 for adverse event and efficacy measures.
223522764|NCT05544760|OTHER|CatchU Intervention|The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
223522765|NCT02919618|RADIATION|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
223522766|NCT02592863|DRUG|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
224275740|NCT00950716|BEHAVIORAL|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
224275741|NCT00950716|BEHAVIORAL|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
224275742|NCT04687241|DRUG|Almonertinib|The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
224275743|NCT04687241|DRUG|Placebo Almonertinib|Placebo Almonertinib
223522767|NCT02592863|DRUG|Placebo|Patients will take placebo 3 times per day for 12 weeks
223522768|NCT02743221|DRUG|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
223522769|NCT02743221|DRUG|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
223522770|NCT04962113|OTHER|TUBE BATH|Wrap Tube Baht (immersion)
223522771|NCT04503616|DRUG|Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention|Cyclophosphamide 50 mg/kg IV over 2 hours on Day +3 and +4 Abatacept 10 mg/kg IV on days +5, +14, and +28 Tacrolimus 0.02 mg/kg IV by continuous infusion, starting on day +5. May switch to oral when tolerated, adjusted to maintain a drug level between 5-12ng/mL. Treatment is discontinued on day +60 after a 4 week-taper
223522772|NCT04100993|OTHER|No intervention used|No intervention used
223522773|NCT03411044|DEVICE|Fitmore Hip Stem|
223522774|NCT03453541|DRUG|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
223522775|NCT03453541|DRUG|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
223522776|NCT04978467|DEVICE|Exoskeleton|Participants will receive assistance to move finger joints away from the compensatory coordination (compensation avoidance), toward the desired trajectories (task assistance), both, and none in different days.
223522777|NCT05325242|DEVICE|Embozene particles|Embozene particles are FDA approved for the embolization of hypervascular tumors and arteriovenous malformations. Several studies have shown excellent safety and efficacy with regards to tumor control and objective response in liver cancer. It has been used extensively for the treatment of symptomatic uterine fibroids, where Embozene embolization of the uterine arteries results in necrosis of uterine fibroids and cessation of abnormal vaginal bleeding. Other proven uses include embolization of arteriovenous malformations and fistulas.
223522778|NCT06264596|DRUG|Epinephrine|The epinephrine group will have two 3-L normal saline solution bags prepared for each case with 1 mL of 1:1000 epinephrine in each bag
223522779|NCT06264596|PROCEDURE|Normal Saline irrigation fluid|The control group will have two 3-L normal saline solution bags prepared with no additive
223522780|NCT04726527|DRUG|Florbetapir F 18|A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
223522781|NCT04726527|DEVICE|Positron Emission Tomography|PET Scan for brain imaging
223522782|NCT04458766|BEHAVIORAL|Monetary incentives|This intervention will assess the efficacy of subjects using the Wellth mobile phone application to provide reminders to take their statin medication, and receiving monetary incentives for taking their medication as prescribed.
223522783|NCT05665751|DRUG|TLC-3595 Dose 1|Tablets administered orally
223522784|NCT05665751|DRUG|TLC-3595 Dose 2|Tablets administered orally
223522785|NCT05665751|DRUG|Placebo|Tablets administered orally
223522786|NCT05811832|OTHER|Evaluation|Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
223522787|NCT06639646|DIETARY_SUPPLEMENT|Probiotics supplements|"A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration."
223522788|NCT06639646|DIETARY_SUPPLEMENT|Health diet|A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated
223522789|NCT06639867|DEVICE|VR-based home physiotherapy|VR-based home physiotherapy
223522790|NCT06639867|OTHER|Standard physiotherapy care|Standard physiotherapy care as prescribed by the treating physiotherapist
223522791|NCT06642285|PROCEDURE|Non Invasive Respiratory Support bundle|premature neonates who will receive evidence-based guidelines for prevention of nasal pressure injuries associated with non invasive respiratory support till weaning
223522792|NCT06638788|OTHER|Knee extension|Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
223522793|NCT06638437|BEHAVIORAL|Cognitive-behavioral therapy|"The mobile application will include the following modules:~1. Psychoeducation: information about what to expect from each phase of the surgical process (i.e., pre-operative, the surgery itself and the post-operative).~2. Activation control techniques: to teach different activation control techniques such as relaxation, breathing techniques and mindfulness training.~3. Cognitive restructuring and problem solving: to teach how to change maladaptive pain-related beliefs for more adaptive ones and how to better cope with pain.~4. Exercises and tasks: to encourage the use of the learning strategies we will offer a number of exercises and tasks~5. Parent's module: to teach parents about the surgical process and how they can help their children during the process"
223522794|NCT06637579|OTHER|universal exercise unit therapy with task oriented strength training|Leg press, Sit to stand, Half knee rise, Lateral step up, Forward step up.
223522795|NCT06637579|OTHER|Task-oriented training for gross motor functioning|Standing transfer (hip abduction/adduction), Stair climbing (hip extension, calf raise), Walking and gait training, Reaching and grasping activities.
223522796|NCT06641648|DRUG|NK cell|Drug: Donor NK cells injection is a non-genetically modified natural killer cells therapy derived from a healthy donor.
223522797|NCT06637696|OTHER|Blood Culture Bundle|In this pre and post intervention study investigators aimed to evaluate the impact of a blood culture bundles on the incidence of blood culture contamination rates in NICU.
223522798|NCT06640270|DEVICE|Diabetes Treatment|Lucie™ is an innovative medical device for measurement by bio-impedancemetry. It has been developed specifically to meet medical needs in nephrology. The aim of the study is to compare its performance with a reference device validated in nephrology nephrology, the Body Composition Monitor® (BCM) from Fresenius.
223522799|NCT06637683|COMBINATION_PRODUCT|LiveSpo COLON|LiveSpo® COLON has a registration number: 10401/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
223522800|NCT06637683|OTHER|Routine treatment|The standard internal medicine treatment protocol of the hospital
223522801|NCT06644508|OTHER|Strict adherence to European guidelines|"The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met."
224275744|NCT01093196|DRUG|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or \>75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
223522802|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of nano-crystalline putty hydroxyapatite.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
223522803|NCT06643468|PROCEDURE|participants will receive immediate implant with nano-crystalline putty hydroxyapatite as bone graft and ALB- PRF as membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade without vertical releasing incision.~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of nano-crystalline putty hydroxyapatite..~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
223522804|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and collagen membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: collagen followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing abutment."
223522805|NCT06643468|PROCEDURE|participants will receive immediate implant with beta-tricalcium phosphate + calcium sulphate bone graft and ALB-PRF membrane.|"1. Injection of local anesthetic Articaine hydrochloride 4% with Epinephrine (1:100,000).~2. Atraumatic removal of remaining root or tooth then implant will be placed according to the standard protocol.~3. Sulcular incision with be made 15c blade .~4. Implant placement with copious irrigation.~5. Membranes placement: ALB-PRF followed by insertion of eta-tricalcium phosphate + calcium sulphate bone graft.~6. Customized healing abutment application.~7. Suturing of wound edges with 0.5 suture around the customized healing"
223522806|NCT05935150|PROCEDURE|Omit SLNB|All patients enrolled have to receive two or more imaging tests including axillary ultrasound assessed as axillary lymph node negative, and other tests including MRI, PET-CT, \[18F\]-FDG PET-MRI, axillary surgery will be omitted for eligible patients, and BCS or mastectomy (allowing breast reconstruction) will be chosen voluntarily by the patient under the premise of ensuring therapeutic efficacy, patients receiving BCS must undergo whole breast irradiation (WBI) after surgery, and the radiotherapy target area does not include the axillary region.
223522807|NCT06643949|DIAGNOSTIC_TEST|Echocardiography|The registry will focus on the diagnostic and prognostic value of of echocardiographic features of patients with takotsubo syndrome
223522808|NCT06645301|BIOLOGICAL|Group A|BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
223522809|NCT06645301|BIOLOGICAL|Group B|BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled
223522810|NCT02873052|DEVICE|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
223522811|NCT04886856|BEHAVIORAL|Mindful Moms|Twelve 75 minutes weekly group sessions involving gentle yoga practices designed for pregnant women, led by experienced yoga teachers.
223522812|NCT04886856|BEHAVIORAL|Prenatal Education|Twelve 75 minutes weekly group sessions involving prenatal education (for example, what to expect during your pregnancy, during labor and delivery, and after the delivery of your child).
223522813|NCT05176665|DRUG|EMB-01|EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
223522814|NCT04904913|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
223522815|NCT04904913|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
223522816|NCT00803855|DRUG|AZD1446|oral, single dose
223522817|NCT00979758|DRUG|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
223522818|NCT04318938|DRUG|Brigatinib|Treatment with Brigatinib
223522819|NCT04318938|DRUG|Tyrosine kinase inhibitor|Treatment with any TKI
223522820|NCT02609503|DRUG|Pembrolizumab|Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
223522821|NCT02609503|RADIATION|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
223522822|NCT06162507|BIOLOGICAL|CM310|CM310 injection
223522823|NCT02808611|DRUG|propranolol|Reduction of the ANS response
223522824|NCT02808611|DRUG|Placebo|
223522825|NCT01810172|DEVICE|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
223522826|NCT01810172|DEVICE|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
223522827|NCT01555424|DIETARY_SUPPLEMENT|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
223522828|NCT01555424|DIETARY_SUPPLEMENT|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
223522829|NCT05713838|DRUG|Durvalumab|1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)
223522830|NCT05713838|DRUG|FLOT|50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles
223522831|NCT05713838|DRUG|mFOLFOX-6|85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles
223522832|NCT05713838|RADIATION|Radiotherapy|5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
223522833|NCT00938080|BIOLOGICAL|AG013|Mouth rinse once a day for 14 days
223522834|NCT00938080|BIOLOGICAL|AG013|Mouth rinse three times a day for 14 days
223522835|NCT00938080|BIOLOGICAL|AG013|Mouth rinse six times a day for 14 days
223522836|NCT00938080|OTHER|Placebo|Mouth rinse once a day for 14 days
223522837|NCT00938080|OTHER|Placebo|Mouth rinse three times a day for 14 days
223522838|NCT00938080|OTHER|Placebo|Mouth rinse six times a day for 14 days
223522839|NCT02306252|OTHER|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
223522840|NCT02671292|BEHAVIORAL|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
223522841|NCT02671292|OTHER|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
223522842|NCT02262663|DRUG|Vilaprisan (BAY1002670)|
223522843|NCT01531335|DIETARY_SUPPLEMENT|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
223522844|NCT01531335|DIETARY_SUPPLEMENT|Standard care|25 kcal per kg of body weight
223522845|NCT06563869|DRUG|PEG-rhG-GSF|Polyethylene glycolylated recombinant human granulocyte stimulating factor （6mg）will be given 24 hours after the end of chemotherapy.
223522846|NCT04363892|OTHER|Optical and infrared imaging|Acquiring images (photographs) of the skin
223522847|NCT06195007|BEHAVIORAL|Motivational Interview|"The motivational interview (MI) is a 10-15 minute patient-centered conversation which will focus on tobacco use. Multiple communication strategies can be employed during the MI, including open-ended questions, affirmative statements, reflective listening, use of a 'confidence ruler', and summarizing. The 'confidence ruler' technique in this patient population involves asking the patient On a scale of zero to ten, how confident are you that you can stop using tobacco?, and then requesting further information about why they selected a certain number. These communication strategies and techniques are designed to uncover and foster a patient's own internal motivations to change the target behavior."
223522848|NCT01969409|DRUG|Rituximab|i.v. rituximab given on two occasions 14 days apart.
223522849|NCT01969409|DRUG|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
223522850|NCT01446523|DRUG|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
223522851|NCT01446523|DRUG|Lactulose|Syrup 30 ml BD for 12 weeks
223522852|NCT06564935|DRUG|Heptaminol Hydrochloride|heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
223522853|NCT06564935|DRUG|Placebo|Placebo drops (identical to heptaminol drops, prepared by the hospital pharmacy) will be administered 1.5 to 2 hours before spinal anesthesia.
223522854|NCT06172023|DRUG|Silver Nanoparticles Irrigant|Nanosilver irrigant solution
223522855|NCT06172023|DRUG|Chitosan Nanoparticles Irrigant|Chitosan nanoparticles irrigant solution
223522856|NCT05727501|OTHER|Post isometric relaxation|post isometric relaxation in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
223522857|NCT05727501|OTHER|Post facilitation stretching|post facilitation stretching in which 3-5 repetitions for 7-10 seconds hold in each session for three sessions per week in alternate days for four weeks.
223522858|NCT01929694|DIETARY_SUPPLEMENT|Berocca Boost|
223704771|NCT06707532|DRUG|Propofol|"Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~\- In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v.~Elimination of neuromuscular blockade:~\- To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v."
223704772|NCT06707532|DRUG|Rocuronium|"Induction of anaesthesia:~* Fentanyl 1-3ug/kg/m.c i.v.~* Ketamine 50mg i.v.~* Propofol 1.5-2mg/kg/m.c i.v.~* Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation~* Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation~Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA:~\- rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2~Abolition of neuromuscular blockade:~\- Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v."
223704773|NCT06707480|DRUG|Taurolidine and Heparin|Catheter Lock Solution
223704774|NCT06710665|DRUG|Chemotherapy|Chemotherapy
223522859|NCT01929694|DIETARY_SUPPLEMENT|Placebo|
223522860|NCT03000881|OTHER|standard adhesive|This is a standard adhesive (hydrocolloid)
223522861|NCT03000881|OTHER|New adhesive strip|This is a newly developed adhesive strip
223522862|NCT00718185|PROCEDURE|Obtain blood specimens|Obtain blood samples at multiple timepoints.
223522863|NCT00001854|DRUG|Ribavirin|
223522864|NCT04873557|OTHER|Copper-based surfaces plus copper-enriched linen|We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
223522865|NCT01833078|DRUG|ghrelin|ghrelin administration subcutaneously for 7 days
223522866|NCT05623605|DRUG|Moringa mouthwash|using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
223522867|NCT05623605|DRUG|star anise mouthwash|using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
223522868|NCT05623605|DRUG|Indian costus mouth wash|using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
223522869|NCT05532800|DRUG|JS002|JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
223522870|NCT05532800|DRUG|Placebo|JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
223522871|NCT02531256|DEVICE|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
223522872|NCT00854737|DIETARY_SUPPLEMENT|cytidine|cytidine (2g po daily for 4 months)
223522873|NCT00854737|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
223522874|NCT00854737|DRUG|placebo|sugar pill
223522875|NCT01840072|OTHER|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
223522876|NCT02946983|OTHER|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
223522877|NCT02946983|OTHER|Control|Intragastric administration of distilled water
223522878|NCT04077320|BEHAVIORAL|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
223522879|NCT04077320|BEHAVIORAL|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
223522880|NCT02226653|DRUG|Evacetrapib|Administered orally
223522881|NCT05007639|OTHER|Public Health intervention programme|The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
223522882|NCT05007639|OTHER|No public Health intervention programme|
223522883|NCT01832194|DRUG|Botox|
223522884|NCT03078868|DEVICE|Magnetic Resonance Scanner|MRI
223522885|NCT05208437|BEHAVIORAL|Complete oral feeding intervention|Premature infants will be assessed 12 times a day before feedings using the Feeding Preparation Scale by trained nurses. Assess the premature infants by using the Feeding Preparation Scale. If the premature infant does not meet the oral feeding standard, let the premature infant use the non-nutritive sucking for 3 minutes before the nasal feeding. If the premature infant meets the oral feeding standard, use the non-nutritive sucking for 3 minutes, and refer to the feeding schedule for the premature infant.
223522886|NCT05208437|BEHAVIORAL|Routine nursing care group|Pre-feeding assessments will be performed from premature infants corrected for gestational age at 34 weeks. If the baby's vital signs are stable, the method of oral feeding and then nasal feeding is used, and feeding 8 to 12 times a day until the baby reaches complete oral feeding.
223522887|NCT00767208|OTHER|oral glucose load|oral ingestion of 13C labeled glucose
223704775|NCT06733038|DRUG|Atezolizumab|840 mg iv over 30 minutes (60 minutes at first infusion) day 1
223704776|NCT06733038|DRUG|Bevacizumab|5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1
223522888|NCT03314896|PROCEDURE|Laparoscopic surgery|
223522889|NCT03170986|BEHAVIORAL|Multisectoral agriculture and Microfinance Intervention|
223522890|NCT04007549|BEHAVIORAL|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
223704777|NCT06733038|DRUG|Irinotecan (CPT-11)|165 mg/sqm iv over 60 minutes day 1
223704778|NCT06733038|DRUG|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
223704779|NCT06733038|DRUG|Leucovorin|200 mg/sqm iv over 2 hours day 1
223522891|NCT03285360|COMBINATION_PRODUCT|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
223704780|NCT06733038|DRUG|Fluorouracil (5-FU)|3200 mg/sqm 48 h-continuous infusion, starting on day 1
223704781|NCT07041294|DEVICE|7 mm Diameter Dental Implant|To evaluate immediate post-extraction implants with different diameters (7 vs. 5 mm)
223522892|NCT03285360|COMBINATION_PRODUCT|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
223704782|NCT07041294|DEVICE|5 mm Diameter Dental Implant|To evaluate immediate post-extraction implants with different diameters (5 vs. 7 mm)
223704783|NCT06709144|PROCEDURE|SMA lymph node dissection|The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)
223704784|NCT06709144|PROCEDURE|SMV lymph node dissection|The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)
223522893|NCT01706315|DRUG|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
223522894|NCT01706315|DRUG|Placebo|Matching placebo will be available
223522895|NCT05781685|DRUG|Testosterone|Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
223522896|NCT05781685|OTHER|Placebo Syrup|Oil-based sublingual product.
223522897|NCT00099905|DRUG|vildagliptin|
223522898|NCT05949892|BEHAVIORAL|Expanded Health Belief Model-Based Intervention|A healthy Diet Healthy Weight Physical Activity Stress Management Smoking Cessation and Avoidance
223522899|NCT00855101|DRUG|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
223522900|NCT01019915|DEVICE|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
223522901|NCT00967499|DRUG|Ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
223522902|NCT00967499|DRUG|Palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
223522903|NCT05846893|DEVICE|SeQuent® Please NEO drug-coated balloon catheter|Treatment of coronary artery disease with SeQuent® Please NEO for de novo lesions in native large coronary arteries
223522904|NCT05846893|DEVICE|Current-generation drug-eluting stent|Treatment of coronary artery disease with current-generation drug-eluting stent for de novo lesions in native large coronary arteries
223522905|NCT05070819|DIAGNOSTIC_TEST|pro-ANP|pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
223522906|NCT06117540|DRUG|WX390|WX390 tablet, 1.1 mg once a day
223522907|NCT04147286|DRUG|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
223704785|NCT07049978|OTHER|Observational follow-up of standard Dupilumab treatment|Patients undergoing Dupilumab treatment for N-ERD will be observed after three to four years of treatment to assess long term changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
223522908|NCT04147286|DRUG|Placebo oral tablet|Identical placebo
223522909|NCT05069740|DRUG|Salsalate Pill|Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
223522910|NCT05069740|DRUG|Placebo|Placebo for the salsalate intervention
223522911|NCT03206450|PROCEDURE|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
223522912|NCT03206450|OTHER|Laboratory Biomarker Analysis|Correlative studies
223522913|NCT03206450|OTHER|Questionnaire Administration|Ancillary studies
223522914|NCT04414930|DRUG|d-amphetamine|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive amphetamine 5 mg po 1 hour prior to each training.
223522915|NCT04414930|DRUG|Placebo|Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
223522916|NCT03865355|OTHER|Non- interventional|Translational, observational study
223522917|NCT05229705|BEHAVIORAL|Resistance exercise|Participants in this exercise group will receive progressive resistance training.
223522918|NCT04869514|PROCEDURE|spinal manipulation|intervention will consist of either lumbar manipulation, thoracic manipulation or lumbar mobilisation
223522919|NCT03673072|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
223522920|NCT03673072|DRUG|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
223522921|NCT03673072|PROCEDURE|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
223522922|NCT03673072|DRUG|Adjuvant chemotherapy|Can be selected by Investigator's Choice
223522923|NCT05422482|BIOLOGICAL|GC1123|ICV-administered Hunterase, Idursulfase-ß
223522924|NCT01681875|OTHER|very low nicotine content cigarettes|
223522925|NCT00022854|PROCEDURE|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
223522926|NCT00022854|PROCEDURE|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
223522927|NCT00022854|PROCEDURE|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
223522928|NCT03377322|DRUG|Probiotic Capsule|Probiotic - one capsule a day for four weeks
223522929|NCT03377322|DRUG|Placebo Capsule|Placebo - one capsule a day for four weeks
223522930|NCT06637566|OTHER|Brandt Daroff exercises along with Cawthorne Cooksey exercises|"Brandt Daroff exercises along with Cawthorne Cooksey exercises. The Cawthorne Cooksey exercises include eye and head movements, coordination of eye and head movements (visual-vestibular interaction), postural control exercises, and progressively more difficult balance tasks (eyes open, eyes closed, large base support, uneven base support, while walking, in high visual or noisy environments). Exercises should be done three times a day, with 5 repetitions of each. The exercises will be performed in three sessions per week with 60 minutes each session for eight weeks. The cawthorne Cooksey exercises includes the following:~A: Eye and head movement~B: Head and body movement, sitting down:~C: Standing up exercises:"
223704786|NCT06285461|BEHAVIORAL|Non-palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with low hedonic reward.
223522931|NCT06637566|OTHER|Brandt Daroff exercises|brandt daroff exercises without cawthorne Cooksey exercises. To begin the Brandt-daroff exercise, the patient will sit and swivel the head 45 degrees to one side (left), then instantly lie down on the other shoulder (right). The patient should be instructed to maintain this posture for 30 seconds or until the vertigo subsides. The patient then gradually returns to the starting position, maintaining the left ear rotation until sat upright. Following the same 30 second time limits, the patient turns his head in the opposite way (right) and rests down on the opposite shoulder (left). These exercises will be instructed to perform at home for 3 sets (morning, afternoon and evening) with 5 repetitions approximately for 30 minutes in each session for five weeks
223522932|NCT06638762|PROCEDURE|surgery|We recruited patients diagnosed with oral squamous cell carcinoma who had received surgical treatment, collected patient follow-up information and postoperative pathological images, enhanced and standardized pathological images, and extracted pathological features through visual transformation model.
223522933|NCT06639880|OTHER|usual care exercise|the usual care for the lumbar spine which includes TENS, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise
223522934|NCT06639880|OTHER|triple attack protocol|a modified P-A mobilization, manipulation, and stabilization program (Active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine
223522935|NCT05335057|BEHAVIORAL|VR Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with the friend or family member who accompanied them to the lab
223522936|NCT05335057|BEHAVIORAL|VR Alone|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments alone
223522937|NCT05335057|BEHAVIORAL|VR Stranger|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience one of four randomly assigned virtual environments while chatting with a stranger
223522938|NCT05335057|BEHAVIORAL|Video Close Other|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they chat with the friend or family member who accompanied them to the lab using a video-conferencing tool
223522939|NCT06125405|DRUG|Telitacicept|The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
223522940|NCT06096363|DIAGNOSTIC_TEST|Transthoracic Echocardiography|Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
223522941|NCT06320782|BEHAVIORAL|Calorie restriction and balanced distribution of macronutrients|Progressive reduction of 500 to 1000 calories from the usual food intake or the recommendation of 20 calories/kg of current weight/day and distribution of macronutrients: 5% of carbohydrates, 2% of proteins and 3% of fats
223522942|NCT06320782|BEHAVIORAL|Calorie restriction and low-carbohydrate diet|Reduction in carbohydrate consumption and an increase in fat and protein intake, with the following proportions: 45% fat, 20% protein and 35% carbohydrate
223522943|NCT06320782|BEHAVIORAL|Calorie restriction and low-fat diet|Restriction of fat consumption and an increase in carbohydrate consumption, with the following proportions: 20% fat, 15% protein and 65% carbohydrate
223522944|NCT06320782|BEHAVIORAL|Collective nutritional guidance|Recommendations of the Food Guide for the Brazilian Population: limitation of the intake of foods with high energy density from fats and simple carbohydrates; substitution of saturated fats for unsaturated fats; exclusion of trans fat from the diet; increasing fruit and vegetable consumption to a daily minimum of 400g; increased consumption of high-fibre foods and limiting the consumption of sugars and salt.
223522945|NCT05923099|DRUG|LEO 138559|LEO 138559 given by injection just under the skin
223522946|NCT05923099|DRUG|Placebo|Placebo given by injection just under the skin
223522947|NCT03947385|DRUG|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
223522948|NCT03947385|DRUG|Binimetinib|Binimetinib dosed orally, twice daily for each 28-day cycle
223522949|NCT03947385|DRUG|Crizotinib|Crizotinib dosed orally, twice daily for each 28-day cycle
223522950|NCT00272246|PROCEDURE|deep brain stimulation of the internal globus pallidus|
223522951|NCT06215157|DEVICE|Flotrac Group|Haemodynamic parameters were collected simultaneously by the Flotrac monitoring.
223522952|NCT06215157|DEVICE|BioZ Group|Haemodynamic parameters were collected simultaneously by the thoracic bioimpedance (BioZ.com™)monitoring.
223522953|NCT05535972|DRUG|FF/UMEC/VI|FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
223522954|NCT05767086|DRUG|Gonadotropin releasing hormone antagonist (Cetrotide)|clinical pregnancy rates
223522955|NCT05767086|DRUG|Medroxyprogesterone Acetate (Tarlusal)|clinical pregnancy rates
223522956|NCT05767086|DRUG|Dydrogesterone|clinical pregnancy rates
223522957|NCT03340779|DRUG|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
223522958|NCT06641661|DRUG|Hybutimibe 10mg QD|Hybutimibe was added to the conventional treatment
223522959|NCT04102566|DRUG|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
223522960|NCT04102566|BEHAVIORAL|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
223522961|NCT01549015|OTHER|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
223522962|NCT05724771|DRUG|Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)|OnabotulinumtoxinA + Fremanezumab 225mg/1.5mL
223522963|NCT04476147|OTHER|Diagnostic Test: CHA2DS2-VASc, HAS-BLED and Fried Scale.|This is an observational study. All the patients evaluate with CHA2DS2-VASc, HAS-BLED and Fried Scale, and observe the incidence of thrombotic events and the influence of frailty on thrombotic events in elderly patients with NVAF.
223704787|NCT06285461|BEHAVIORAL|Palatable meal|Participants will consume a meal that corresponds to 40% of their daily resting metabolic rate and balanced diet but with high-hedonic reward.
223522964|NCT03589833|DRUG|Tripterygium Wilfordii|Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
223522965|NCT03589833|DRUG|Methotrexate|Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
223704788|NCT07053124|OTHER|Hand-drawn navigation|Hand-drawn navigation employed for diagnosing patients with PPN in Hand-drawn group.
223704789|NCT07053124|OTHER|Virtual bronchoscopy navigation|Virtual bronchoscopy navigation employed for diagnosing patients with PPN in VBN group.
223704790|NCT07054112|OTHER|Mindfulness-Based Stress Reduction (MBSR) meditation program|"The sessions of the meditation program (Mindfulness on Stress Reduction) will be delivered online, outside of the dialysis sessions. They will receive standard care during their hemodialysis sessions.~The program is composed of 8 sessions of 2h30 + 1 day of mindfulness, during 2 months."
223704791|NCT07054112|OTHER|Control group|Patients in the control group will be in a wait list group. They will receive standard care during their hemodialysis sessions. they will receive the MBSR meditation program between M8 and M10.
223522966|NCT03589833|DRUG|Yisaipu|Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
223704792|NCT07054203|DEVICE|Water Flosser|Participants in this Arm used a powered oral irrigator delivering a pulsed water stream at 50-90 psi. The intervention consisted of once-daily full-mouth irrigation, added to routine tooth brushing, for a duration of six months.
223704793|NCT07054203|DEVICE|Interdental Brush|Participants in this Arm used cylindrical, color-coded interdental brushes matched to individual embrasure sizes. The intervention involved once-daily cleaning of all interproximal spaces for six months, in addition to routine twice-daily tooth brushing.
223522967|NCT06258382|OTHER|Questionnaires and functional test|Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
223522968|NCT05881798|DEVICE|Celect Platinum Vena Cava Filter|Inferior vena cava filter
223522969|NCT03213951|OTHER|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
223522970|NCT03213951|DIAGNOSTIC_TEST|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
223522971|NCT05467098|OTHER|Dry Needling|A sterile, disposable, solid filament needle (Seirin Corp., Shizuoka, Japan) will be inserted manually into the MTrP of the infraspinatus muscles. Once the needle has been inserted, the technique described by Hong (1994) will be used. The needle will be pistoned in an up and down motion within the infraspinatus muscle at approximately 1Hz for 10 seconds with the aim of eliciting local twitch responses.
223522972|NCT05144737|BEHAVIORAL|The Diabetes Prevention Program|The multicomponent intervention will focus on intensive lifestyle modification delivered by the Lifestyle Coach. The Lifestyle Coach of African origin will be responsible for delivering the intensive lifestyle intervention and implementing the adapted diabetes prevention program (DPP) curriculum.
223522973|NCT04769986|BEHAVIORAL|Mobile Mindfulness-Relapse Prevention (mMBRP)|Mindfulness Coach 2.0 is a mobile application designed by the VA's National Center for PTSD. The app provides: (a) psychoeducational topics related to mindfulness; (b) audio-guided mindfulness exercises; (c) self-assessment using the Five Facet Mindfulness Questionnaire (d) a journal to track mindfulness practice sessions; (e) goal setting and tracking; (f) personal, customizable reminders; and (g) immediate access to support and crisis resources. We will enhance Mindfulness Coach with MBRP content by adding information about the triangle of awareness to understand connections among thoughts, sensations, and emotions, and specific meditations of sober breathing space and urge surfing to deal with cravings. We will add additional MBRP-specific modules. Participants will be asked to complete the intervention during 8 weeks, with two to three modules per week. After a beta test with 20 veterans, feedback will be used to refine the app for the national randomized clinical trial (RCT).
223522974|NCT04769986|BEHAVIORAL|Exercise/healthy eating mobile app|Participants in the control condition will be asked to download an exercise/healthy eating mobile app and use it for 8 weeks. Similar to Mindfulness Coach, the app will have specialized self-management guides that follow a guide-per-week format, educational videos that teach diet and exercise strategies, and a diary to track diet and exercise progress.
223704794|NCT07054372|DIAGNOSTIC_TEST|Titres on conventional test tube method with different diluent|Titres on conventional test tube method with different diluent
223704795|NCT07053072|DRUG|Low Dose PD-1 mRNA LNP Vaccine|Patients will receive PD-1 mRNA LNP vaccine at 50 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
223704796|NCT07053072|DRUG|Medium dose PD-1 mRNA LNP vaccines|Patients will receive PD-1 mRNA LNP vaccine at 75 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
223704797|NCT07053072|DRUG|High dose PD-1 mRNA LNP vaccines|Patients will receive PD-1 mRNA LNP vaccine at 100 mcg weekly for the first 4 doses and a 5th dose 1 month after the 4th dose.
223704798|NCT07055100|DIAGNOSTIC_TEST|Needle stick injuries|A descriptive cross-sectional study design will be employed, and data will be collected from all staff working in the trauma center through census sampling. A structured questionnaire will capture demographic data, occupational risk factors, and KAP regarding bloodborne pathogens. Blood samples will be collected to screen for HBV, HCV, and HIV infections.
223704799|NCT07055074|DIAGNOSTIC_TEST|Low Pressure Pneumoperitoneum|Low Pressure Pneumoperitoneum (8-10 mmHg) Details: CO₂ insufflation to 8-10 mmHg IAP, continuous monitoring, measurement at baseline, insufflation, and desufflation.
223704800|NCT07055074|DIAGNOSTIC_TEST|Medium Pressure Pneumoperitoneum|Medium Pressure Pneumoperitoneum (12-14 mmHg) Details: CO₂ insufflation to 12-14 mmHg IAP, parameters measured at key intervals, standard general anesthesia used. High Pressure Pneumoperitoneum (15-20 mmHg) Details: Standard high-pressure technique, monitoring of hemodynamic and respiratory parameters.
223704801|NCT05870189|BEHAVIORAL|Remote CMR|12 weeks of remote CMR is done 3x/week, 45 min/session.
223704802|NCT05870189|BEHAVIORAL|Remote Exercise|12 weeks of remote exercise is done 3x/week, 45 min/session.
223704803|NCT06403228|OTHER|Mindfulness Based Structured Nursing Interventions|In the study, 8 days of mindfulness-based structured nursing interventions were applied to high-risk pregnant women. The program lasts 60 minutes each day. The program includes short body scanning meditation, breath awareness meditation, sitting meditation, compassion meditation.
223522975|NCT03285893|OTHER|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
223522976|NCT06384625|OTHER|AIRWISE|AIRWISE (Air Improvement and Real-time Monitoring for Wellness through Interactive Strategies and Education) utilizes personal air cleaners (PACs) to filter indoor air, while enhanced aspects focus on improving compliance to PAC use. Key components include low-cost sensors (PurpleAir, Inc, USA) that change color according to air quality index (AQI) and behavioral recommendations that correspond to varying AQI levels.
223522977|NCT05299424|DRUG|CM336_group 1|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.04mg on C1D8, 0.04mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522978|NCT05299424|DRUG|CM336_group 2a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.04mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522979|NCT05299424|DRUG|CM336_group 2b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 0.2mg on C1D8, 0.2mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522980|NCT05299424|DRUG|CM336_group 3a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 0.2mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 5.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522981|NCT05299424|DRUG|CM336_group 3b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 1.0mg on C1D8, 1.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522982|NCT05299424|DRUG|CM336_group 4a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 1.0mg of CM336 on the first day of first cycle (C1D1), 5.0mg on C1D8, 15.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522983|NCT05299424|DRUG|CM336_group 4b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 2.0mg on C1D8, 2.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522984|NCT05299424|DRUG|CM336_group 5|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 8.0mg on C1D8, 24.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522985|NCT05299424|DRUG|CM336_group 6a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 2.0mg of CM336 on the first day of first cycle (C1D1), 10.0mg on C1D8, 40.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522986|NCT05299424|DRUG|CM336_group 6b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522987|NCT05299424|DRUG|CM336_group 7|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522988|NCT05299424|DRUG|CM336_group 8a|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522989|NCT05299424|DRUG|CM336_group 8b|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223522990|NCT05299424|DRUG|CM336_group 9|CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
223704804|NCT06454435|DRUG|Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: Fruquintinib Fruquinitinib 4mg/d, QD, PO, D1-D14, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
223704805|NCT06454435|DRUG|Sintilimab + S-1 plus nab-paclitaxel|"Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles."
223522991|NCT05299424|DRUG|CM336_RP2D|CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
223704806|NCT03009409|DRUG|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
223704807|NCT03009409|OTHER|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
223704808|NCT06000111|BEHAVIORAL|3 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 3-days and nights of face-down positioning post-operatively.
223704809|NCT06000111|BEHAVIORAL|7 Days of face-down positioning|Following surgical repair, patients in the intervention group will maintain 7-days and nights of face-down positioning post-operatively.
223704810|NCT02280538|DEVICE|Intra-Articular Hyaluronic Acid|
223704811|NCT02280538|DEVICE|Placebo|
223704812|NCT04639700|BEHAVIORAL|Psycho-educational intervention|"Participant will be sent a baseline survey, and will then be contacted by the interventionist to complete 4 sessions, which feature the following areas:~Session 1: Identifying CG Needs for Information \& Support, Communication with Healthcare Team~Session 2: Communication with Patient and Family~Session 3: Self-care: Emotional \& Spiritual Needs, Self-care: Physical Needs~Session 4: Re-Assessing Needs, Planning for the future"
223704813|NCT06933589|OTHER|Test meal with plant protein|The plant protein blend is made up of 5 protein ingredients for which the food grade is guaranteed: a rice protein isolate, a potato protein isolate, a lupin protein isolate, a corn protein isolate.
223704814|NCT06933589|OTHER|Test meal with milk protein|The milk protein product is a food-grade protein isolate.
223704815|NCT06933121|DEVICE|Digital twin for personalized recommendations|"The intervention is the developed eHealth solution, i.e. the healthy lifestyle recommender system. It is based on a previously developed meal recommender system, but will be much extended, resulting in a multilevel portfolio intervention regarding:~1. Suggesting personalized meal recommendations,~2. Proposing physical activities tailored to the individuals' capabilities and preferences,~3. Measuring and considering emotional and psychological parameters,~4. Proposing additional healthy life-style patterns regarding e.g. sleeping patterns, alcohol and tobacco consumption, engaging in social activities etc.~The detailed nature of the interventions will first be developed during co-creation and then targeted to the participating individual. Moreover, particular attention will be given, since this needs to be a eHealth solution easy to be used by children. The intervention will include collecting urine and saliva samples, as well as measuring anthropometrics and collecting data (persona"
223704816|NCT06934954|BEHAVIORAL|EASE|This is the first time EASE is being used in New York to support youth community mental health.
223704817|NCT06933251|DRUG|Neoadjuvant Chemoradiotherapy Combined with PD-1 inhibitor Immunotherapy and PCSK9 Inhibitor Therapy|"1. Neoadjuvant Treatment 1.1 Short-Course Radiotherapy (SCRT) Total Dose: 25 Gy in 5 fractions over 5 days. Interval: 1-week rest before the next stage. 1.2 Chemotherapy and Immunotherapy Regimen: Start 1 week after SCRT with 6 cycles of CAPOX chemotherapy combined with PD-1 inhibitor immunotherapy (3 weeks per cycle).~   1.3 PCSK9 Inhibitor Administration: Subcutaneous injection every 4 weeks during neoadjuvant therapy (6 cycles total).~2. Multidisciplinary Team (MDT) Discussion Timing: 2 weeks after completing neoadjuvant therapy.~Approach:~Patients achieving clinical complete response (cCR): Watch-and-wait strategy. Others: Surgery based on MDT evaluation."
223704818|NCT06933316|OTHER|the intervention group|the intervention group received additional FIC-based care, including individualized health plans, education, daily care guidance, dietary recommendations, micronutrient supplementation, early intervention, growth monitoring, and vaccination support.
223704819|NCT06933316|OTHER|the control group|Infants receive routine healthcare guidance provided by pediatric healthcare professionals. This includes regular check-ups scheduled via phone appointments, general health consultations, vaccinations according to regulations, and tailored feeding and parenting guidance based on examination results.
223704820|NCT06933862|DIETARY_SUPPLEMENT|Striatin|striation or placebo given for 90 days assigned to striatin
223704821|NCT06933862|DIETARY_SUPPLEMENT|Placebo|placebo
224275745|NCT01093196|DRUG|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
223522994|NCT04235062|DRUG|Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution|A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
223522995|NCT04235062|DRUG|Intravenous Bolus Furosemide|Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.
223522996|NCT02456883|DRUG|gilteritinib|oral
223522997|NCT02456883|DRUG|14C-labeled gilteritinib|oral
223522998|NCT00059267|DRUG|HBIG, Epivir, Hepsera|
223704822|NCT06934109|OTHER|Narrative Exposure Therapy (NET)|NET is a psychological talking therapy that has been designed for people who have experienced multiple and prolonged traumatic experiences. It is typically 12-sessions, involving first a psychoeducation session, then laying a lifeline where stones are lain to represent traumatic events, and flowers positive life events. The following sessions the person is asked to talk through their life, going into detail on the traumatic memories that they have experienced.
223704823|NCT06934434|OTHER|FMF Study Group|In the study group consisting of children with FMF, DMFT, dft, bruxism, tooth wear due to bruxism, gingival index (MGI), plaque index (OHI-S), salivary pH, salivary flow rate, salivary buffering capacity, dental age, chronological age difference, mesio-distal dimensions of the teeth, and the presence of aphthous lesions were determined.
223704824|NCT06934434|OTHER|control group|In the control group consisting of healthy children, DMFT, dft, bruxism, tooth wear due to bruxism, gingival index (MGI), plaque index (OHI-S), salivary pH, salivary flow rate, salivary buffering capacity, dental age, chronological age difference, mesio-distal dimensions of the teeth, and the presence of aphthous lesions were determined.
223704825|NCT06067204|DEVICE|Automatic ventilation|"The FDA-approved device used is Meditech MICROVENT RESUSCITATOR, which is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. It is powered by the airflow from the oxygen tank and provides ventilation in fixed interval. It has a pressure valve which will release the pressure once the airway pressure exceeds its threshold. In the current study, the threshold is set at 60 mmH2O. The tidal volume is set at 500-600 ml."
223704826|NCT06067204|DEVICE|Manual ventilation|The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.
223704827|NCT02675114|PROCEDURE|SAVR|SAVR with a commercially available bioprosthetic valve.
223522999|NCT06565663|BEHAVIORAL|MaPGAS Decision Aid|This intervention involves a novel, web-based decision aid tool specifically designed to support transgender and non-binary individuals assigned female at birth in making informed decisions about Metoidioplasty and Phalloplasty Gender Affirming Surgeries (MaPGAS). The tool includes comprehensive information on surgical options, risks, benefits, and medical illustrations to aid in aligning surgical decisions with the individual's personal values and goals.
223523000|NCT05644132|DEVICE|InDx Implant for the carpometacarpal joint|Treatment of thumb base joint arthritis with the InDx Implant
223523001|NCT06043154|OTHER|Patients with severe to extreme anorexia nervosa admitted to hospital for refeeding|Clinical and biological measurements, blood and stool sample collection
223523002|NCT06568393|OTHER|Calisthenic exercise|Calisthenic exercise program was included: jumping jack, burpee, mountain climber, squat thrust, squat, squat jump, split and alternate exercises.
223523003|NCT05475171|DRUG|Lorigerlimab|Given by vein (IV)
223523004|NCT06541964|OTHER|Parent-Provide Distraction|The children will be asked riddles by their parents for 5 seconds before and during the blood collection procedure.
223523005|NCT06541964|OTHER|Windmill Toy Blowing|The children will blow on the windmill toy for 5 seconds before and during the blood collection procedure.
223523006|NCT06541964|OTHER|Control|No intervention will make on the children.
223523007|NCT05360602|DIETARY_SUPPLEMENT|Alpha Lipoic Acid plus the standard care for post-PCI MI|Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
223704828|NCT02675114|DEVICE|SAPIEN 3 THV|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
223704829|NCT06071845|DEVICE|Cytosponge Procedure|Investigators will follow the Cytosponge Cell Collection Kit Instructions for Use to administer and retrieve the Cytosponge device.
223704830|NCT06071845|DIAGNOSTIC_TEST|Endoscopic Assessment|Participants will undergo a diagnostic clinically indicated sedated endoscopy with standard endoscopic equipment.
223704831|NCT06218563|OTHER|vibration-induced illusion of movement|Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same.
223523008|NCT05360602|DRUG|The standard care for post-PCI MI|will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
223523009|NCT04629196|DRUG|Ustekinumab|A second IV weight-based induction dose of Stelara at week 8
223523010|NCT04629196|DRUG|Ustekinumab|A standard 90mg subcutaneous dose of Stelara at week 8
223523011|NCT04629196|DRUG|Ustekinumab|All patients will receive IV ustekinumab weight-based dose at 260mg (55kg or less), 390mg (more than 55kg to 85kg), or 520mg (more than 85kg) at time point 0
223704832|NCT02780375|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
223704833|NCT00239538|DRUG|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
223523012|NCT03792737|DEVICE|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
223523013|NCT03792737|DEVICE|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
223523014|NCT03792737|DEVICE|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
223523015|NCT03792737|DEVICE|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
223523016|NCT03792737|DEVICE|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
223523017|NCT02344927|OTHER|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
223523018|NCT02344927|OTHER|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
223523019|NCT06189612|OTHER|Clinical reasoning based physiotherapy + cervical movement control training|An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
223523020|NCT06189612|OTHER|Clinical reasoning based physiotherapy + orofacial movement control training|An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
223523021|NCT06189612|OTHER|Clinical reasoning based physiotherapy + standard exercises|A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
223523022|NCT05572073|OTHER|Natural History Study|Natural History Study
223523023|NCT01450631|DEVICE|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
223523024|NCT01450631|DEVICE|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
223523025|NCT04738266|DIAGNOSTIC_TEST|Amyloid Cardiomyopathy|Echocardiographic red flags of Amyloid Cardiomyopathy to guide the suspicion of disease and to proceed with second level diagnostic work up including cardiac scintigraphy with bone tracers and search of monoclonal component in serum and urine
223523026|NCT02333292|DRUG|Telaprevir|Initiation of a regimen containing TVR
223704834|NCT00239538|DRUG|valsartan combined with hydrochlorothiazide (160/12.5mg)|
223704835|NCT03971097|BEHAVIORAL|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
223704836|NCT03971097|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
223704837|NCT06090331|DIAGNOSTIC_TEST|89Zr-DFO-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
223704838|NCT03395210|DRUG|Rilzabrutinib|BTK inhibitor
223704839|NCT00106197|DRUG|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
223523027|NCT02333292|DRUG|Boceprevir|Initiation of a regimen containing BOC
223523028|NCT02333292|DRUG|Sofosbuvir|Initiation of a regimen containing SOF
223523029|NCT02333292|DRUG|Simeprevir|Initiation of a regimen containing SMV
223523030|NCT02333292|DRUG|Daclatasvir|Initiation of a regimen containing DCV
223523031|NCT02333292|DRUG|Ledipasvir|Initiation of a regimen containing LDV
223523032|NCT02333292|DRUG|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
223523033|NCT02333292|DRUG|Dasabuvir|Initiation of a regimen containing DBV
223523034|NCT02333292|DRUG|Velpatasvir|Initiation of a regimen containing VPV
223523035|NCT02333292|DRUG|Elbasvir|Initiation of a regimen containing EBV
223523036|NCT02333292|DRUG|Grazoprevir|Initiation of a regimen containing GZR
223704840|NCT02614092|BEHAVIORAL|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
223704841|NCT00717093|DRUG|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
223704842|NCT00717093|DRUG|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
223523037|NCT00835354|DRUG|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
223523038|NCT00835354|DRUG|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
223523039|NCT04450550|DEVICE|VeNS device|VeNS treatment
223523040|NCT04450550|DEVICE|Sham VeNS device|Sham treatment of VeNS
223523041|NCT05478265|DEVICE|RS-4i Plus|RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.
223523042|NCT04766684|DEVICE|J-Tip with Xylocaine MPF with placebo cream|J-Tip with 0.25mL of 1% Xylocaine MPF with placebo cream
223523043|NCT04766684|DRUG|L.M.X.4 cream with J-Tip saline injection|L.M.X.4 cream with J-Tip saline injection
223523044|NCT04194697|BEHAVIORAL|Exercise|Exercise program
223523045|NCT04194697|BEHAVIORAL|No exercise|No exercise program
223523046|NCT06568575|BEHAVIORAL|experiment of music|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by exercise program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes.
223704843|NCT00531934|DRUG|Doxycline|100mg po daily
223704844|NCT00531934|DRUG|erlotinib [Tarceva]|150mg po daily
223523047|NCT06568575|BEHAVIORAL|experiment of exercise|Participants in this study were randomly divided into a control group and an experimental group. The control group did not intervene, and they continued their normal routine. Participants in the control group were asked not to participate in additional physical activity or sports during the study period. The experimental group was intervened by music program. During the experimental experiment phase, all participants were asked to be in similar environments as possible: sports environment, living environment, and disturbed environment. The exercise experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time and a total experiment time of 1420 minutes. The music experiment was 3 times a week with a period of 12 weeks. The length of time was 40 minutes each time, and a total experiment time of 1420 minutes. Examples of songs：Everytime We Touch- Cascada (115 bpm), Beat It - Michael Jackson (120 bpm), Viva La
223523048|NCT06559241|DEVICE|14-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.
223523049|NCT06559241|DEVICE|30-day remote ischemic conditioning|RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.
223523050|NCT06559241|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.
223523051|NCT06559241|DRUG|Best medical management|Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.
223523052|NCT02106546|DRUG|Carboplatin|Carboplatin administered intravenously over approximately 15 to 30 minutes at (AUC 6 mg/mL/min) immediately following paclitaxel infusion.
223523053|NCT02106546|DRUG|Veliparib|Capsules taken orally twice a day, 12 hours apart.
223523054|NCT02106546|DRUG|Paclitaxel|Paclitaxel administered intravenously over 3 hours at a dose of 200 mg/m².
223523055|NCT02106546|DRUG|Placebo to veliparib|Capsules taken orally twice a day, 12 hours apart.
223523056|NCT03110510|DRUG|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
223523057|NCT03110510|DRUG|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
223523058|NCT03110510|DRUG|leucovorin calcium|Leucovorin 200 mg/m2
223523059|NCT03204812|BIOLOGICAL|Durvalumab|Given IV
223523060|NCT03204812|BIOLOGICAL|Tremelimumab|Given IV
223523061|NCT02399852|DRUG|Lomitapide|
223523062|NCT03990987|OTHER|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
223523063|NCT06560736|BEHAVIORAL|Show Me FIRST coping skills intervention|Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
223523064|NCT05682677|DEVICE|iTBS|iTBS over the left dorsolateral prefrontal cortex
223523065|NCT05682677|DEVICE|sham iTBS|sham iTBS over the left dorsolateral prefrontal cortex
223523066|NCT05682677|BEHAVIORAL|Personalized, Augmented Cognitive Training (PACT)|6 sessions of PACT
223523067|NCT05024786|OTHER|continuous quality improvements|We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
223523068|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
223523069|NCT00728533|DRUG|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
223523070|NCT03194529|BIOLOGICAL|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
223523071|NCT01190371|DRUG|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
223523072|NCT01432431|PROCEDURE|spiritual therapy|Undergo palliative spiritual care
223523073|NCT01432431|OTHER|questionnaire administration|Ancillary studies
223523074|NCT01432431|OTHER|survey administration|Ancillary studies
223523075|NCT01432431|OTHER|counseling intervention|Undergo palliative spiritual care
223523076|NCT01432431|OTHER|psychosocial support for caregiver|Undergo palliative spiritual care
223523077|NCT01432431|PROCEDURE|psychosocial assessment and care|Undergo palliative spiritual care
223523078|NCT01126398|PROCEDURE|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
223523079|NCT05278715|DRUG|Carboplatin|Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
223523080|NCT05278715|DRUG|Vincristine|Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
223523081|NCT05278715|DRUG|Recombinant human endostatin|Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
223523082|NCT03094377|OTHER|Multisensory therapy|Sensory stimulation, motor training and ADL training
223523083|NCT03094377|OTHER|Conventional training|Motor training and ADL training
223523084|NCT01385995|DEVICE|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
223523085|NCT01385995|DEVICE|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
223523086|NCT05162794|OTHER|Laparoscopy with excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. Then, the relevant tissue will be excised and a histology will be performed.
223523087|NCT05162794|OTHER|Laparoscopy without excision|Diagnostic laparoscopy will be performed to visually confirm endometriosis in the peritoneum. However, no tissue will be excised and histology will not be performed.
223523088|NCT05162794|OTHER|Medical treatment-as-usual|Patients continue their hormonal and analgesic treatment-as-usual.
223523089|NCT05328167|DRUG|Perflutren Protein-Type A Microspheres|Given IV
223523090|NCT05328167|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
223523091|NCT00112385|DRUG|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
223523092|NCT00112385|DRUG|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
223523093|NCT02361697|OTHER|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
223523094|NCT03686189|DEVICE|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
223523095|NCT04136288|DEVICE|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
223523096|NCT06003829|DRUG|Sinsunatovir|Single dose, to be spit out after tasting
223523097|NCT06003829|OTHER|Bitrex|Single dose, to be spit out after tasting
223523098|NCT06677086|DEVICE|Treatment with BTL-899|The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 device will be applied over the designated area. Each treatment session will last 30 minutes.
223523099|NCT03682146|PROCEDURE|Prostatectomy|Comparison of robotic-assisted and conventional laparoscopic radical prostatectomy
223523100|NCT02006290|DRUG|PF-06412562|single oral split dose 30+20 mg QD
223523101|NCT02006290|DRUG|Placebo|tablet, matching placebo, QD
223523102|NCT05148663|DIAGNOSTIC_TEST|CCM Hemorrhagic Panel|Biomarker
223523103|NCT05248009|DEVICE|Semi-Permanent Tattoo Ink|Subjects will receive semi-permanent tattoo ink in place of the permanent ink utilized in the standard of care. Subjects will be monitored during their treatment course and for 15 months following treatment completion.
223523104|NCT06658756|BEHAVIORAL|internet-CBT|10 modules on line of I-CBT for OCD
223523105|NCT06011889|DRUG|Etanercept|treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
223523106|NCT06011889|DRUG|Placebo|treatment with placebo in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
223523107|NCT05669027|DEVICE|Neurofeedback|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The experimental condition involves a mobile app that provides auditory feedback signaling EEG alpha power above a threshold level, denoting a physiologically relaxed state.
223523108|NCT05669027|DEVICE|Sham (Placebo Control)|Participants will be asked to complete 10-minute sessions at least 4 days per week for 12 weeks. Participants will be asked to report their current level of pain, stress, and anger before and after each session. The control condition involves a visually identical mobile app yoked to a pre-recorded set of actual neurofeedback sessions (i.e., placebo).
223523109|NCT06612281|DEVICE|colorectal cancer (CRC) screening|Gixam test
223523110|NCT06612281|DIAGNOSTIC_TEST|colorectal cancer screening|Fecal Immunochemistry Test (FIT)
223523111|NCT06612281|PROCEDURE|Colonoscopy after bowel cleansing|Standard of care optical colonoscopy for colorectal cancer screening
223523112|NCT05566236|BEHAVIORAL|board game|A board game was designed based on situated learning theory and the results of relevant studies. This board game contains a summary, answer booklet, and multiple card game tasks including situations of interpersonal interaction. The participants must discuss, share personal experiences, and find the answer together.
223523113|NCT06671665|DRUG|calcium supplementation|Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
223523114|NCT06671665|OTHER|Manual therapy|Manual therapy treatment will be in the form of craniosacral techniques and visceral manipulation techniques for 8 sessions in 12 weeks. Sessions will be divided into one session per week for the first 4 weeks then one session every two week for the next 8 weeks. Each session lasts for 45 minutes.
223523115|NCT06675045|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
223523116|NCT02397720|DRUG|Azacitidine|Given SC or IV
223523117|NCT02397720|DRUG|Ipilimumab|
223523118|NCT02397720|DRUG|Venetoclax|Given Orally
223523119|NCT02397720|DRUG|Nivolumab|Given IV
223523120|NCT06543589|DEVICE|High-flow-nasal-cannula|Respiratory support will be provided by devices that deliver a blend of heated and humidified gas mixture of air and oxygen at gas flows exceeding 8 L/ min via binasal cannula.
223523121|NCT06674070|GENETIC|Valproic Acid|syrup/ tablet EPIVAL (250mg
223523122|NCT06675474|OTHER|Clinical periodontal measurements|Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.
223523123|NCT06675474|OTHER|Saliva sampling|The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.
223523124|NCT06675474|OTHER|Serum Sampling|5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.
223523125|NCT06675474|OTHER|GCF sampling|GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.
223523126|NCT06675474|OTHER|Subgingival plaque sampling|Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
223523127|NCT03646357|OTHER|Non-betablocker|No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
223523128|NCT03646357|DRUG|Betablocker|"A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~* Metoprolol succinate up to a total dose of 200mg daily~* Bisoprolol up to a total dose of 10mg daily~* Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care."
223523129|NCT06673589|BEHAVIORAL|Transcendental Meditation|meditation practice
223523130|NCT06675773|OTHER|Conscious Awareness Development Psychoeducation Program|The Conscious Awareness Development Psychoeducation Program consists of nine sessions. The sessions will be applied once a week and last 90 minutes. The psychoeducation program is prepared based on conscious awareness. Conscious awareness and self-compassion techniques will be used in the sessions. Homework will be given to the participants in each session.
223704845|NCT01998529|DRUG|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
223523131|NCT06673485|PROCEDURE|Patients received vitamin D and calcium supplementation during the healing period|"The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill, maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paralling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement.~During the healing period, the patients recieved Vitamin D and Calcium Supplements."
223523132|NCT06673485|PROCEDURE|Patients have not received any nutritional supplementation during the healing period.|The proposed implant site and adjacent tissues were disinfected using betadine mouthwash, and standard infiltration anesthesia was administered both buccally and palatally. A paracrestal incision was then made over the intended implant location, and the mucoperiosteal flap was elevated to expose the underlying bone. Subsequently, an osteotomy was prepared using a 2.0 mm pilot drill while maintaining irrigation with sterile saline. The osseodensification protocol was employed with Densah burs in increasing diameters (2 mm, 3 mm, 4 mm) under copious irrigation. Throughout the osteotomy preparation, implant angulation was regularly checked using a paraling pin. Upon encountering haptic feedback, pressure was modulated to achieve the desired depth. The implant was then installed using a surgical handpiece, and the final insertion torque was recorded using a torque wrench, ensuring successful placement. During the healing period, the patients did not receive vitamin or calcium supplements.
223523133|NCT07010666|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate|25 grams of BHB
223523134|NCT07010666|DIETARY_SUPPLEMENT|Carbohydrate|25 grams of carbohydrate
223523135|NCT07010666|DIETARY_SUPPLEMENT|Caffeine|4 mg/kg of caffeine
223523136|NCT07010263|DRUG|AK112|AK112 20mg/kg, intravenous \[IV\]),Q3W
223523137|NCT07010263|OTHER|Placebo|Placebo, intravenous \[IV\]),Q3W
223523138|NCT07010991|OTHER|AI based clinical problem solving education|This direct involvement of AI and educators aims to improve learning outcomes by leveraging the scalability of AI and the expertise of educators. The question sets created by students and the answers obtained from ChatGPT are discussed within the group and prepared for class presentation, and the instructor provides feedback on accuracy, timeliness, and scientific relevance. This process aims to support students' participation as active questioners and analyzers, rather than passive consumers of information. Intervention will last for 2 weeks, 2 hours of courses each week, in total 4 hours of education will be given. First 2 hours will be the usage parameters and the knowledge about the ChatGPT system and the 2nd week's 2 hours of education will include the presentations and interactive discussion about the case.
223523139|NCT07010991|OTHER|Traditional Low Back Pain Education|The first session will be given by an independent/different instructor about the definition, reasons, evaluation and the treatment of low back pain for 2 hours. Afterwards the students will be informed about the content of the next week's interactive course and supplied with the study sources like book, articles by the other lecturer. A week will be given to the students to study and the other week they will meet with the lecturer to discuss over a specific case. At the beginning and end of the courses, outcome measures will taken from the both groups.
223523140|NCT07009925|DRUG|Ivonescimab 20mg/kg intravenous every 3 weeks|Ivonescimab(20mg/kg) combined with paclitaxel polymeric micelles (≤300mg/㎡) and platinum(cisplatin 75mg/㎡or carboplatin AUC5) IV every 3 weeks for 4 cycles.If patient assessment is of clinical benefit, maintenance therapy with ivonescimab or plus polymeric micelles paclitaxel(≤230mg/m\^2) can be continued based on investigator's evaluation and patient's own choice until disease progression or unacceptable toxicity. Ivonescimab is administered first, followed by paclitaxel polymeric micelles and platinum.The maximum treatment duration of ivonescimab and polymeric micelles paclitaxel is 24 months.
223523141|NCT07010523|BIOLOGICAL|Anti-mesothelin CAR-T cells|D0: 0.1×10\^6/Kg\~1.0×10\^6/Kg; cells will be infused intravenously.
223523142|NCT07010523|DRUG|Fludarabine|D-7 to D-3: Fludarabine (25 mg/m\^2/day) will be administered intravenously for 5 days.
223523143|NCT07010523|DRUG|Cyclophosphamide|D-7 to D-3: Cyclophosphamide (300 mg/m\^2/day) will be administered intravenously for 5 days.
223523144|NCT06679907|DEVICE|WaveLinQ® device|The WaveLinQ® system employs a dual catheter technique to establish communication between deep arteries and veins, typically using a ulnar or radial artery and vein. This procedure necessitates fluoroscopic guidance to position the catheters correctly, a control angiogram, and potential embolization to enhance blood flow.
223523145|NCT06679907|DEVICE|Ellipsys® device|The Ellipsys® system enables the entire AVF creation process to be conducted under ultrasound guidance without the need for fluoroscopy or contrast media. It uses a single needle to puncture the superficial vein, the perforator and the artery and potential balloon angioplasty to enhance blood flow.
223523146|NCT06679907|DEVICE|No device|Surgical AVF creation will involve a direct approach to the proximal radial, ulnar, or brachial artery to create a 4-6 mm longitudinal arteriotomy. An oblique incision will be made at the elbow crease. The cephalic, basilic, or perforating vein may be used for the side-to-end anastomosis. If a transposition is required due to adiposity, it will be performed either during the same procedure or at a later time through tunneling or lipectomy.
223523147|NCT07009977|BEHAVIORAL|self-guided mHealth app only|Mindfulness based stress reduction
223523148|NCT07009977|BEHAVIORAL|self-guided mHealth app + 'real-time' feedback|Mindfulness based stress reduction with mobile app feedback
223523149|NCT07010900|PROCEDURE|Injection|patients randomized in intervention group will use also penile extender
223523150|NCT07011199|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|Intraoperative trans-portal vein injection of 20 million mesenchymal stem cells derived from umbilical cord tissue, suspended in 5 mL autologous plasma.
223523151|NCT07011199|PROCEDURE|Kasai Portoenterostomy|Surgical procedure to create a portoenterostomy for biliary drainage in infants with biliary atresia.
223704846|NCT01998529|DRUG|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
223704847|NCT00527501|DRUG|Travoprost/brinzolamide|
223704848|NCT00721500|DEVICE|etafilcon A|contact lens
223704849|NCT00721500|DEVICE|narafilcon A|contact lens
223704850|NCT02704715|PROCEDURE|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
223704851|NCT01543698|DRUG|LGX818|
223523152|NCT07009743|DIAGNOSTIC_TEST|MRI contrast-enhancing agents|All patients underwent standard pelvic MRI examinations (1.5T or 3T) with the following sequences: T2-weighted imaging (T2WI), T1-weighted imaging (T1WI) with and without fat suppression; axial, sagittal, and coronal post-contrast T1WI following intravenous administration of gadolinium-based contrast agents (GBCA); functional sequences including dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging MRI (DWI-MRI). Enhancement sequences may be omitted if no adnexal masses were identified on T2WI, T1WI, or DWI sequences.
223523153|NCT06691438|DEVICE|prostate biopsy|prostate biopsies with virtual reality hypnosis headset
223523154|NCT04581577|OTHER|Semi-structured telephone questionnaire|Semi-structured telephone questionnaire
223704852|NCT01543698|DRUG|MEK162|
223523155|NCT06690840|DRUG|Atezolizumab in combination with Cyclophosphamide and Vinorelbine|Patients will receive Atezolizumab in combination with Cyclophosphamide and Vinorelbine in 28-day cycles
223523156|NCT07010198|DIAGNOSTIC_TEST|Quantitative HBeAg Testing|Quantitative HBeAg Testing in Population-Based Primary Screening
223523157|NCT07010198|BIOLOGICAL|Measurement Indicators Required for Risk Scoring in HCC Screening Strategies|REACH-B: Age, Sex, HBeAg status, ALT levels, and HBV DNA load; AGED: Age, Sex, HBeAg status, HBV DNA load; aMAP: Age, Sex, Albumin, Total Bilirubin, Platelet Count; aMAP 3.0: Age, Sex, Albumin, Total Bilirubin, Platelet Count, AFP and PIVKA-II.
223523158|NCT07010198|BIOLOGICAL|Follow-Up Monitoring Parameters|AFP, Liver Ultrasound
223704853|NCT01543698|DRUG|LEE011|
223704854|NCT00217620|DRUG|sorafenib|800 mg per day, daily until progression
223704855|NCT05113420|DRUG|Detralex|Diosmin+ Hesperidin
223523162|NCT05064540|DEVICE|Alto Abdominal Stent Graft System|Endovascular Abdominal Aneurysm Repair (EVAR) using commercially available, FDA approved endovascular graft systems implanted.
223523163|NCT05064540|DEVICE|FDA Approved EVAR AAA Graft Systems|FDA approved comparator of choice
223523164|NCT06694077|DRUG|Bupivacaine with Dexamethasone|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
223523165|NCT06694077|DRUG|Bupivacaine only|bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
223523166|NCT06694142|BEHAVIORAL|Rosy app|Participants will be provided a six-month membership subscription to the mobile application ROSY. ROSY will recommend pathways for addressing issues through 1) coaching by board certified coaches or 2) joining a completely anonymous community with other people where they can share experiences and get help as new members of the community to overcome sexual health challenges .Users will work towards their health goals each day using tools from medical and mental health experts . Tools used include 1) virtual workshops and 2) coaching sessions which will provide the opportunity to a) Have an authentic and relatable conversation with an expert b) Explore new pathways to better health experience c) Improve their relationship with themselves, partner, and healthcare providers d) Learn fun ways to improve their everyday wellness e) Access live events from anywhere.
223523167|NCT06691555|DEVICE|Suprachoroidal silicone tube (SST) shunt|This intervention involves implanting a modified suprachoroidal silicone tube (SST) shunt, derived from the Aurolab Aqueous Drainage Device (AADI), to lower intraocular pressure in patients with primary open-angle and pseudoexfoliative glaucoma. The SST shunt, measuring 13.0-15.0 mm with a 0.3 mm inner and 0.6 mm outer diameter, is designed to reach the posterior suprachoroidal space. Six slits near the distal end aid aqueous outflow. Implantation involves creating a scleral flap, accessing the SCS, and placing the distal end in the SCS and proximal end in the anterior chamber (AC). The shunt is secured with sutures, and viscoelastic is injected into the AC to prevent hypotony. No antimetabolites or cautery are used.
223523168|NCT06687096|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
223523169|NCT06687096|OTHER|standart diet list|patients prepared with a routine colonoscopy preparation scheme
223704856|NCT05113420|DRUG|Troxevasin|Troxerutin
223704857|NCT02077244|BEHAVIORAL|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
223523170|NCT06691178|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|The OCT device with cover will be used to take measurements at four areas in the vaginal canal: the proximal posterior aspect, proximal anterior, distal anterior, and distal posterior. The proximal and distal points will be marked on the OCT cover during the first set of measurements. Markings will be used to guide measurements during subsequent visits.
223523171|NCT06690567|DEVICE|Impella implantation|To implante Impella
223523172|NCT02434614|DRUG|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
223704858|NCT04307784|DIETARY_SUPPLEMENT|VD3|VD3 (50.000 IU/week) for 8 weeks
223704859|NCT04307784|DIETARY_SUPPLEMENT|Omega-3FA|Omaga-3FA (300 mg/day) for 8 weeks
223704860|NCT04307784|DIETARY_SUPPLEMENT|VD3 and Omega-3FA|VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
223704861|NCT04307784|OTHER|Control|No intervention is given
223704862|NCT01429415|DRUG|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
223704863|NCT01429415|DRUG|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
223704864|NCT00150709|DRUG|Levetiracetam|"* Pharmaceutical form: Oral tablets and oral solution~* Route of administration: Oral use"
223704865|NCT06000332|DEVICE|InogenOne Rove 6 Portable Oxygen Concentrator|overnight use of Portable Oxygen Concentrator, 6 hours minimum
223704866|NCT05032664|OTHER|Home-based aromatherapy programme|1 hour individualised face-to-face training to family caregivers, and 3 weeks aromatherapy intervention delivered by family caregivers (aromatherapy inhalation 2 times per day, each for 1 hour, using 2 drops of Lavandula angustifolia essential oil.
223523173|NCT02434614|RADIATION|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
223523174|NCT02434614|DRUG|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
223523175|NCT02471677|DRUG|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
223523176|NCT02471677|DRUG|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
223523177|NCT05952323|OTHER|Teach-back|According to the prepared educational materials for medical devices, students will be trained using the teach-back method.
223523178|NCT05952323|OTHER|Video-assisted teaching|Students will be sent educational videos related to medical devices and asked to watch them.
223523179|NCT06368193|DEVICE|Neuralert Monitor|Device to identify upper extremity asymmetry in patients who are high risk for stroke.
223523180|NCT06694363|BIOLOGICAL|Blood samples|A maximum of 27 ml of blood collected at each visit for metabolic markers analysis
223523181|NCT06694363|BIOLOGICAL|Urine samples|One urine sample collected at each visit for enteric virus infection research
223523182|NCT06694363|BIOLOGICAL|Stool samples|One stool sample collected at each visit for enteric virus infection research
223523183|NCT05461326|PROCEDURE|Quad tendon|quadriceps tendon autograft
223523184|NCT05461326|PROCEDURE|BTB|patellar tendon autograft
223523185|NCT04614272|BEHAVIORAL|Prayer|Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
223523186|NCT04614272|BEHAVIORAL|Reading a poem|Reading is a distraction tool for pain management
223523187|NCT03780712|OTHER|Non applicable|No intervention as it is an observational study
223523188|NCT00736151|DRUG|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
223523189|NCT00177632|BEHAVIORAL|behavioral weight loss|
223523190|NCT05345314|PROCEDURE|Narrow-band imaging endoscopy|During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.
223523191|NCT04849507|DEVICE|transcutaneous auricular vagus nerve stimulation|Stimulation of the auricular branch of the left vagus nerve paired with oromotor feeding.
223523192|NCT06769750|OTHER|leg-lift maneuver|"Patients will be monitored as usual using an SpO2 sensor placed on the index finger of the limb contralateral to the pressure cuff, giving the PI value, a tensiometer taking blood pressure (systolic, diastolic and mean) every 2 minutes, and an ECG.~A transthoracic cardiac echocardiogram will be performed with measurement of the sub-aortic time-velocity integral, and the same measurement will be performed 1 min after a passive leg-lift to see if this maneuver significantly increases systolic ejection volume. The PI value and blood pressure will be measured at each of these maneuvers."
223523193|NCT06769750|OTHER|leg-lift maneuver|The perfusion index (PI) value and arterial pressure will be measured at each of manoeuvre
223523194|NCT04376008|PROCEDURE|Standard prostate biopsy|Transperineal TRUS guided standard prostate biopsy (SB).
223523195|NCT04376008|PROCEDURE|Targeted and standard prostate biopsy|Transperineal Image fusion-guided targeted and standard prostate biopsy (TB+SB).
223523196|NCT00969085|DRUG|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
223523197|NCT00969085|BEHAVIORAL|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
223523198|NCT00969085|OTHER|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
223523199|NCT00543127|DRUG|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
223523200|NCT00543127|DRUG|Anastrozole|1 mg oral Anastrozole per day during 5 years.
223523201|NCT03193385|PROCEDURE|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
223523202|NCT02513641|DEVICE|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of \~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
223523203|NCT02853084|DRUG|HL2351|The dose will be adjusted based on disease activities
223523204|NCT05528445|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
223523205|NCT02122185|DRUG|metformin hydrochloride|Given PO
223523206|NCT02122185|DRUG|placebo|Given PO
223523207|NCT02122185|DRUG|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
223523208|NCT02235688|DRUG|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
223523209|NCT02235688|DRUG|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
223523210|NCT02235688|DRUG|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
223523211|NCT02235688|DRUG|gemcitabine|
223523212|NCT03807648|OTHER|Data Inclusion|Patients in this group will be included in the project
223704867|NCT05032664|OTHER|Control Group|Wait-list control, no intervention for 3 weeks, then provide home-based aromatherapy
223704868|NCT01628978|OTHER|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
223704869|NCT01628978|OTHER|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
223704870|NCT04053439|OTHER|Blood test for determination of CHIP|Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
223704871|NCT06057844|OTHER|Additional blood sampling|Once you have been informed and have given your consent, 2 tubes of venous blood (citrated tubes of approximately 5 milliliters (ml) each) will be taken after the blood donation to enable in vitro thrombus formation. The entire sample will be used, and no surplus will be kept in the bank.
223704872|NCT06202430|PROCEDURE|High Thoracic Erector Spinae Plane Block|High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.
223704873|NCT06202430|PROCEDURE|Shoulder Block|"Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus."
223704874|NCT05715697|PROCEDURE|Sham procedure and maintenance of heart failure medications|Sham intervention, maintenance of heart failure medications
223704875|NCT05715697|PROCEDURE|Renal denervation and maintenance of heart failure medications|Renal denervation and maintenance of heart failure medications
223704876|NCT02809404|DRUG|Everolimus|
223704877|NCT02975336|DRUG|Placebo|Participants received placebo matched to M2951 orally for 52 weeks.
224275746|NCT01093196|DRUG|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
223523213|NCT00131885|DIETARY_SUPPLEMENT|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
223523214|NCT00131885|DIETARY_SUPPLEMENT|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
223523215|NCT00131885|DRUG|Levonorgestrel|Levonorgestrel in a single oral dose
223704878|NCT02975336|DRUG|M2951|Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
223704879|NCT02975336|DRUG|M2951|Participants received 75 mg of M2951 orally QD for 52 weeks.
223704880|NCT02975336|DRUG|M2951|Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
223704881|NCT02975336|DRUG|M2951|Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
223704882|NCT00808860|DIETARY_SUPPLEMENT|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
223704883|NCT00808860|DIETARY_SUPPLEMENT|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
223704884|NCT06540729|DRUG|Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer|Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer
223704885|NCT05517551|PROCEDURE|robotic assisted radical prostatectomy|Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery
223704886|NCT05988008|DRUG|CCX168|Administered orally.
223704887|NCT05988008|DRUG|Placebo|Administered orally.
223704888|NCT05108662|PROCEDURE|Surgery method|Patients were subdivided into two groups according to their prostate volume
223523216|NCT04266912|DRUG|Avelumab|Given IV
223523217|NCT04266912|DRUG|Berzosertib|Given IV
223523218|NCT06858683|OTHER|Time-restrictred feeding|Time-restricted feeding pattern consisting of an 8 h eating window (from 6-8 am to 14-16pm) followed by a 16 h fasting period.
223523219|NCT06858683|OTHER|Non-time restricted feeding|14h eating window (from 6-8 am to 8-10 pm), followed by a 10 h fasting period.
223523220|NCT06667869|DRUG|Sedative|Patients admitted to intensive care units who require sedation and mechanical ventilation for more than 24 hours.
223523221|NCT02953457|BIOLOGICAL|Durvalumab|Given IV
223523222|NCT02953457|OTHER|Laboratory Biomarker Analysis|Correlative studies
223523223|NCT02953457|DRUG|Olaparib|Given PO
223523224|NCT02953457|BIOLOGICAL|Tremelimumab|Given IV
223523225|NCT05134883|OTHER|PNF|A PNF stretching protocol will be performed with each participant assuming a long sitting position on a plinth with the knee maintained as extended as possible. At this moment, the participant will be asked to perform a maximum isometric hamstring muscle contraction for 5 seconds followed by 5 seconds of relaxation and 20 seconds of stretching. The therapist will show the participant how to maintain this isometric contraction with the flexion of the hip and ankle. Each participant will undergo 4 repetitions of PNF stretching (30 seconds/rep).
223523226|NCT05134883|OTHER|SMR|For the application of self-myofascial release, the subjects will assume a long sitting position on a firm and even surface by placing the arms backward and transferring their body weight to their palms. The roller foam, applied bilaterally, will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa by applying pressure for 2 minutes.
223523227|NCT05690204|DRUG|SAP-001|Test the efficacy and safety of SAP-001 versus placebo
223523228|NCT05978128|BEHAVIORAL|Health Education|Access electronic patient portal with educational material
223523229|NCT05978128|OTHER|Health Promotion and Education|Receive materials on breast/lung cancer screening
223523230|NCT05978128|BEHAVIORAL|Patient Navigation|Interact with a patient navigator
223523231|NCT05978128|OTHER|Survey Administration|Ancillary studies
223523232|NCT04003402|DRUG|ASP8062|oral
223523233|NCT04003402|DRUG|Alcohol|oral
223523234|NCT04003402|DRUG|ASP8062 Placebo|oral
223523235|NCT04003402|DRUG|Alcohol Placebo|oral
223523236|NCT04191135|BIOLOGICAL|Pembrolizumab|intravenous (IV) infusion
223523237|NCT04191135|DRUG|Olaparib|oral tablets
223523238|NCT04191135|DRUG|Carboplatin|IV infusion
223523239|NCT04191135|DRUG|Gemcitabine|IV infusion
223523240|NCT06921499|BEHAVIORAL|Va Meh Du (Mental Health Education)|Participants randomized to Va Meh Du (mental health education) will receive 20-30 minutes of mental health education each week for roughly 5 weeks. Mental health education will be evidence-based, using sports psychology practices, and culturally targeted toward Karenni refugees.
223523241|NCT06921499|BEHAVIORAL|Active Compartor|Participants randomized to comparison will receive 20-30 minutes of team-building activities each week for roughly 5 weeks.
223523242|NCT06931639|BEHAVIORAL|Safe Alternatives for Teens and Youth (SAFETY)|Please see description of experimental arm (arm one)
223523243|NCT06931639|BEHAVIORAL|Enhanced Treatment As Usual|Please see description of active comparator arm (arm two).
223523244|NCT05884528|BIOLOGICAL|CC BoNT/A|Complex-containing BotulinumtoxinA (BoNT/A) formulations
223523245|NCT05884528|BIOLOGICAL|CF BoNT/A|Complex-free BotulinumtoxinA (BoNT/A) formulation
223523246|NCT05884528|BIOLOGICAL|CF to CC BoNT/A|Switch from complex-free to complex-containing BoNT/A formulations
223523247|NCT05884528|BIOLOGICAL|CC to CF BoNT/A|Switch from complex-containing to complex-free BoNT/A formulations
223523248|NCT06933043|DRUG|NAV-240|Three doses of intravenous (IV) low dose, medium dose or high dose NAV-240 will be administered to participants.
223523249|NCT06933043|DRUG|Placebo|Three doses of matching placebo will be administered to participants.
223523250|NCT06688890|OTHER|Surgical hand rub with the reference product; n-propanol 60%.|Propanol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
223523251|NCT06688890|OTHER|Surgical hand rub with the product P1; Sorbectol for 1 min.|Sorbectol hand rub for 1 min. The applied volume of product is sufficient to keep the hand moist for a total time of 1 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
223523252|NCT06688890|OTHER|Surgical hand rub with the product P2; Sorbectol for 3 min.|Sorbectol hand rub for 3 min. The applied volume of product is sufficient to keep the hand moist for a total time of 3 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
223523253|NCT06688890|OTHER|Surgical hand rub with the product P3; Sorbectol for 5 min.|Sorbectol hand rub for 5 min. The applied volume of product is sufficient to keep the hand moist for a total time of 5 min, adding as many 3 ml portions as necessary according to EN 12791. According to the EN 1279, the role assigned to each hand (immediate or 3h effect) in the first run is swapped in the subsequent runs.
223523254|NCT06943378|BIOLOGICAL|Monoclonal antibody JST-010|Active study drug
223523255|NCT06943378|DRUG|Placebo|Placebo
223523256|NCT06951620|OTHER|HIIT|Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to High intensity training (HIIT)
223523257|NCT06951620|OTHER|MICT|Patients who recently experienced a myocardial infarction (MI) or percutaneous intervention (PCI; angioplasty, stent placement or valve replacement) and enroll in Phase 2 Cardiac Rehabilitation (CR) may be randomized to Moderate intensity training
223523258|NCT05690464|DIETARY_SUPPLEMENT|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
223523259|NCT05690464|DIETARY_SUPPLEMENT|placebo|placebo
223523260|NCT04188548|DRUG|LY3484356|Administered orally
223523261|NCT04188548|DRUG|Abemaciclib|Administered orally
223523262|NCT04188548|DRUG|Everolimus|Administered orally
223523263|NCT04188548|DRUG|Alpelisib|Administered orally
223523264|NCT04188548|DRUG|Trastuzumab|Administered intravenously
223523265|NCT04188548|DRUG|Aromatase Inhibitor (AI)|Anastrozole or Exemestane or Letrozole administered orally (physician choice)
223523266|NCT04188548|DRUG|Pertuzumab|Administered intravenously
223523267|NCT04464733|DRUG|HRS9950|HRS9950
223523268|NCT04464733|DRUG|Placebo|Placebo
223523269|NCT05583890|DEVICE|Continuous glucose monitors|Participants will wear continuous glucose monitors for a 7 day period.
223523270|NCT05583890|DEVICE|Activity tracker|Participants will wear the activity tracker for a 7 day period.
223704889|NCT04888468|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223704890|NCT02680717|DRUG|Clobetasol|ointment, twice daily (alternating weeks)
223704891|NCT02680717|DRUG|Calcipotriene|ointment, twice daily
223704892|NCT02680717|DRUG|Tacrolimus|ointment, 0.1%, twice daily
223704893|NCT00297583|DRUG|Insulin Glulisine|
223704894|NCT02160535|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
224275747|NCT05632796|PROCEDURE|Adjusting the Pfannenstiel skin incision according to the occipitofrontal diameter (OFD) of the fetal head.|All women will be subjected to regional spinal anesthesia. Pfannenstiel incision will be made according to the fetal occiputofrontal diameter, marked on the skin (Pfannenstiel incison with Kaya modification) Following blunt entry to the abdominal cavity, the uterine lower segment Kerr incision will be performed. Folllowing delivery of the baby, umblical cord will be cut and an arterial umblical cord blood sample will be taken. Placenta will be removed. 1st and 5th min. Apgar scores will be noted. Uterine incison will be sutured double-layer with 1 polyglactin 910 suture . Peritoneum and fascia, will be closed with 2-0 and 1 polyglactin 910 suture respectively. Skin incision will be sutured with continuous 3-0 rapid polyglactin 910 suture and measured with flexible ruler in centimeters following completing the skin incision closure.
223523271|NCT05583890|BEHAVIORAL|Food Diary|Participants will complete a food diary of everything they eat for 7 days.
223523272|NCT05583890|BEHAVIORAL|Questionnaires|Participants will complete FACT-Hep, DiPcare-Q and health inequality related questions.
223523273|NCT05753683|BEHAVIORAL|mHealth-Women's CoOp|The mHealth-Women's CoOp, was developed and tested in a previous randomized trial, is a human immunodeficiency virus (HIV) risk-reduction intervention that addresses the intersection of substance use, sexual risk and violence through education, skills-building, and role-play and rehearsal via a mobile app. The mHealth-Women's CoOp app is also used to help participants monitor progress toward their goals throughout the study period. Specifically, the app is programmed to prompt the user, to visit the app and participate in several activities, including health and behavior check-in and revisiting aspects of the mHealth-Women's CoOp educational content to sustain risk reduction.
223523274|NCT05753683|BEHAVIORAL|Virtual Group|The enhanced online group component will be available to be accessed using the mHealth-Women's CoOp platform for participants in the enhanced arm. The purpose of this component is to allow for young women who use alcohol to interact with young women like them and also discuss issues related to substance use and sexual risk-taking via a guided conversation to allow for motivational and informational support. The virtual group component will include online live discussions moderated and monitored by a trained online facilitator.
223523275|NCT05496972|BEHAVIORAL|Survey Administration|Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
223523276|NCT00468247|DEVICE|Navigator|Navigator circulatory mgt system
223523277|NCT00468247|OTHER|Conventional care|Conventional haemodynamic care
223523278|NCT06040788|PROCEDURE|immediate implant placement with customized healing abutment|immediate implant placement with customized healing abutment
223523279|NCT05354219|OTHER|Imaging|Imaging with 3 iris cameras
223523280|NCT02115087|PROCEDURE|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
223523281|NCT02115087|DRUG|Morphine|
223523282|NCT02323711|DEVICE|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
223704895|NCT06327035|OTHER|Gait rehabilitation|"Assessment of gait and balance abilities after stroke during neurorehabilitation from the subacute phase of stroke to 6 months after stroke.~The assessments will be carried out on entrance to the neurological center, then at 1 ,3 and 6 months and on hospital discharge."
223704896|NCT00794378|DRUG|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
223704897|NCT00794378|DRUG|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
223704898|NCT03019575|DRUG|Corifollitropin alfa|CFA administered 100 μg (if body weight ≤60 kg) or 150 μg (if body weight \>60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1, Week 0 through Week 64).
224275748|NCT03801317|DIETARY_SUPPLEMENT|BC/ egg|4.3 egg powder + 5.7 g bovine colostrum
224275749|NCT03801317|DIETARY_SUPPLEMENT|Control|15 grams corn-soya blend
224275750|NCT03801317|DIETARY_SUPPLEMENT|multiple micronutrient|multiple micronutrient sprinkle powder
224275751|NCT05058768|DIAGNOSTIC_TEST|The lungs causes and extrapulmonary factors|Acute lung injury due to internal and external pulmonary causes can be used as intervention items in this study, and intervention items can be excluded according to inclusion criteria and exclusion criteria.
224275752|NCT04021758|BEHAVIORAL|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
224275753|NCT04916275|OTHER|Cognitive tests|Optional tests: Corsi block-tapping task, Stroop test and Iowa gambling task
224275754|NCT05671952|OTHER|Application of integrated intervention system programs|Application of integrated intervention system programs
224275755|NCT00792441|DEVICE|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
223704899|NCT03019575|DRUG|hCG|hCG 500-5000 IU reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64).
223704900|NCT00533897|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
224275756|NCT06036550|DIAGNOSTIC_TEST|Doppler ultrasound measurement|Doppler sonographic assessment of the uterine artery was performed transabdominally. Patients underwent six sets of Doppler ultrasounds measurements of both right and left uterine artery.
223704901|NCT00533897|DRUG|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
223704902|NCT00426790|PROCEDURE|Positive end-expiratory pressure|
224275757|NCT02781935|PROCEDURE|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
223523283|NCT03514134|BEHAVIORAL|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
223523284|NCT03514134|BEHAVIORAL|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
223523285|NCT02471144|BIOLOGICAL|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
223523286|NCT02471144|BIOLOGICAL|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
223523287|NCT02471144|BIOLOGICAL|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
223523288|NCT02471144|BIOLOGICAL|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
223523289|NCT05880212|OTHER|Usual physiotherapy care|In Phase 1, physiotherapists will provide treatment for participants with chronic low back pain in accordance with their current standard physiotherapy practice. Physiotherapists will be free to choose the treatment approach they wish to.
223523290|NCT05880212|OTHER|Individualized (STOPS) physiotherapy|In Phase 3, participants will receive individualized physiotherapy in accordance with the Specific Treatment of Problems of the Spine (STOPS) approach modified for chronic low back pain. Treatment will be individualized on the basis of biopsychosocial assessment findings including dominant pain type (nociceptive, neuropathic or nociplastic), pathoanatomical subgroups (if any), and other barriers to recovery (eg. inflammation, depression, anxiety, stress, catastrophising, pain self-efficacy, and unhelpful motor control strategies). Available treatment strategies will include individualized education/advice, exercise, manual therapy, activity modification/facilitation, goal setting, motor control optimisation, cognitive-behavioural strategies, inflammation management, pain management strategies, sleep management, work management, and relaxation approaches.
223523291|NCT04271800|BIOLOGICAL|CD19 CAR-T cells|A single infusion of CD19-CAR-T cells will be administered intravenously.
223523292|NCT02311803|PROCEDURE|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
223523293|NCT02311803|PROCEDURE|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
224275758|NCT00731224|DRUG|Rivastigmine transdermal patch|
224275759|NCT04702035|DEVICE|Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)|All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
224275760|NCT00224484|BIOLOGICAL|GSK208141|3 intramuscular doses
224275761|NCT00224484|BIOLOGICAL|Havrix (investigational formulation)|3 intramuscular doses
224275762|NCT00224484|BIOLOGICAL|Placebo|3 intramuscular doses
224275763|NCT02805309|BEHAVIORAL|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
223523294|NCT02572531|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
224275764|NCT02805309|BEHAVIORAL|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
223704903|NCT05955261|DRUG|Venetoclax|Venetoclax will be given with each course of therapy. Patients with low-risk AML will receive four courses of therapy, intermediate-risk patients will receive five courses of therapy, and high-risk patients will receive two or three courses of therapy followed by hematopoietic stem cell transplantation.
223704904|NCT05955261|DRUG|Azacitidine|Given IV over 30 minutes on days 1-5
223704905|NCT05955261|DRUG|Cytarabine|Given IV over 30 minutes q12 hours on days 1-8 (16 doses)
224275765|NCT02805309|BEHAVIORAL|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
223523295|NCT02572531|DIETARY_SUPPLEMENT|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
223523296|NCT04883476|OTHER|Observation study only|
223523297|NCT01809665|DEVICE|ICD/CRT-P therapy|
223523298|NCT01809665|OTHER|MRI|
223523299|NCT00003645|DRUG|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
223523300|NCT00003645|DRUG|Leuprolide Acetate|50 mg tablet orally daily for 12 months
223523301|NCT03199183|RADIATION|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
223523302|NCT03199183|OTHER|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
223523303|NCT03199183|GENETIC|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
223523304|NCT04402307|OTHER|Chin Tuck Against Resistance|Training in 6 weeks 3 times a day.
223523305|NCT01888861|DIETARY_SUPPLEMENT|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
223523306|NCT01888861|DRUG|placebo|the patients in this arm were received 900mg placebo through NG tube.
223523307|NCT02574793|DEVICE|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
223523308|NCT06800209|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain.
223704906|NCT05955261|DRUG|Gemtuzumab Ozogamicin|Given IV
223704907|NCT05955261|DRUG|Daunorubicin Hydrochloride|IV over 1 hour on days 1, 3, and 5
223704908|NCT05955261|DRUG|Fludarabine Phosphate|Given IV over 30 minutes on days 1-5
223704909|NCT05955261|DRUG|Idarubicin Hydrochloride|Given IV over 15 minutes on days 3-5
223704910|NCT05955261|DRUG|Mitoxantrone Hydrochloride|IV over 1 hour on days 2-4
223704911|NCT05955261|DRUG|Etoposide|Given IV over 1 hour on days 1-5
223704912|NCT05955261|DRUG|Gilteritinib|PO on days 8-28 (21 doses)
223704913|NCT03921073|DRUG|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
223704914|NCT01884532|DEVICE|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
224275766|NCT04489303|BEHAVIORAL|Caring Response App|Participants will receive the Caring Response mobile app containing the Virtual Patient Behavioral Response Training.
223523309|NCT06800209|OTHER|Usual care|Participants will be asked to continue to do whatever they are currently doing to manage their pain.
223523310|NCT02199912|PROCEDURE|Biopsy of adipose and muscular tissue|
223523311|NCT02199912|OTHER|Blood sampling|
223523312|NCT02199912|OTHER|Calorimetry|
223523313|NCT02199912|OTHER|Impedance measure|Evaluation of physical composition (non-invasive method)
223523314|NCT02199912|OTHER|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
223523315|NCT02199912|OTHER|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
223523316|NCT02199912|OTHER|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
223523317|NCT02199912|OTHER|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
223523318|NCT02199912|OTHER|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
223523319|NCT00943137|DRUG|5-Fluorouracil|"Chemotherapy will be one of the following:~1. de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~2. FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~3. Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
223704915|NCT01816074|DRUG|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
223704916|NCT01816074|BEHAVIORAL|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
223704917|NCT02993393|OTHER|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
223704918|NCT02993393|OTHER|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
223704919|NCT02171377|DEVICE|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
223704920|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
223704921|NCT02171377|DEVICE|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
223704922|NCT02171377|OTHER|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
224275767|NCT04489303|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
223704923|NCT02737696|BEHAVIORAL|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
223704924|NCT02737696|BEHAVIORAL|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
223704925|NCT03826589|DRUG|Avelumab|an anti-programmed cell death ligand 1
223704926|NCT03826589|DRUG|Axitinib|a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
223704927|NCT02563015|DIETARY_SUPPLEMENT|cholecalciferol|liquid drops
223704928|NCT02563015|DIETARY_SUPPLEMENT|Reference 400|liquid drops
223704929|NCT05812755|DRUG|Vericiguat|Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery
223704930|NCT05812755|DRUG|Placebo|Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery
224275768|NCT03064243|DRUG|apatinib|apatinib 500mg po. qd.
224275769|NCT02629588|BEHAVIORAL|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
223704931|NCT00628056|DRUG|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
223704932|NCT04756843|DEVICE|Quad-helix|Fixed orthodontic appliance
223704933|NCT05849129|DRUG|Ascorbic acid|High dose ascorbic acid delivered intravenously
223704934|NCT05849129|OTHER|Normal Saline|0.9% NaCl solution
223704935|NCT03659539|DRUG|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
223704936|NCT03659539|DRUG|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
223704937|NCT00645385|OTHER|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
223704938|NCT05388929|DRUG|Methocarbamol|Methocarbamol after surgery
223704939|NCT05388929|DRUG|Standard Opioid|Standard opioid after surgery or at discharge
224275770|NCT04683588|OTHER|Nursing Coaching|Different strategies, methods and training techniques are used in the implementation of preoperative and postoperative nursing care of surgical patients scheduled for total knee arthroplasty surgery. One of them is patient coaching. Coaching is a method that increases the quality of nursing care.While the coaching strategy contributes more to the recovery process of the patient with the role of the case manager of the nurse, it provides a reduction in the problems related to surgery (pain, nausea-vomiting, mobilization problems), reduction in repeated hospitalizations and positive contributions to the cost.
224275771|NCT00026923|PROCEDURE|Laparoscopic surgery|
224275772|NCT02302937|PROCEDURE|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
224275773|NCT02302937|PROCEDURE|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
224275774|NCT04661449|OTHER|Comprehensive lifestyle intervention|Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
224275775|NCT04204226|BEHAVIORAL|Social Worker|The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.
224275776|NCT04204226|BEHAVIORAL|Autism Behavioral Health Navigation (ABHN)|The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.
224275777|NCT04204226|BEHAVIORAL|Social work + ABHN|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN
224275778|NCT04204226|BEHAVIORAL|Social work + ABHN + CAP|After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
224275779|NCT04313426|OTHER|Integrative Yoga Therapy|Integrative Yoga Therapy included personalised yoga therapy sessions including their standard care, yoga movements, relaxation, meditation, breathing practices and yoga counselling sessions.
224275780|NCT03361124|DRUG|Oxytocin|Administration of additional 20 mU Oxytocin
223704940|NCT05388929|DRUG|Standard opioid plus methocarbamol|Standard opioid plus methocarbamol after surgery or at discharge
223523320|NCT01927614|RADIATION|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~1. Prospectively gated calcium scoring.~2. Stress-myocardial CT perfusion.~3. Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
223523321|NCT03929679|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
223704941|NCT03500757|DEVICE|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
223704942|NCT06562725|OTHER|specific ventilator settings|The special ventilator settings used in the intervention group - aimed at reducing airway pressure - include inspiratory flow \<25 L/min, tidal volume = 5m L/Kg, inspiratory time = 1 sec, respiratory frequency \<20 c/min, PEEP = 5 cmH2O, and FiO2 = 100%
223893691|NCT03937050|BEHAVIORAL|Intervention|"Three film-based components:~1. Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric care, and lifestyle counselling. The films will be screened at professional development meetings.~2. Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The film will be culturally tailored and will be screened in waiting areas of antenatal clinics/electronic versions of the films will be made available for viewing on mobile devices.~3. Structured diabetes self-management programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at group sessions/viewed on mobile devices."
223523322|NCT01357681|DRUG|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
223523323|NCT01357681|DRUG|Placebo|Placebo
223523324|NCT01788878|BEHAVIORAL|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
223523325|NCT00410579|OTHER|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
223523326|NCT04284111|DEVICE|Orthokeratology lenses|Orthokeratology lenses
223523327|NCT05024344|PROCEDURE|Erector Spinae Plane Block|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
223523328|NCT05024344|DRUG|Ropivacaine 0.5% Injectable Solution|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
223523329|NCT05024344|DRUG|Dexamethasone|The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
223523330|NCT00107575|BEHAVIORAL|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
223523331|NCT00107575|OTHER|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
223523332|NCT05725031|DRUG|Ephedrine|70 μg/kg as pretreatment
223523333|NCT05725031|DRUG|Rocuronium 0.6|0.6 mg/kg
224083234|NCT04658394|OTHER|Reminiscence therapy|Intervention group will receive two RT sessions per week for 13 weeks. RT sessions will last approximately 50 minutes and will be developed according to the following structure: · Welcome to the patient and reality orientation therapy (7 minutes) · Conducting the main activity of reminiscence (40 minutes) · Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of RT. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of the Past and the Present.
224083235|NCT01207557|BEHAVIORAL|Standard Education Only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
224083236|NCT01207557|BEHAVIORAL|Standard Education Plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
223523334|NCT05725031|DRUG|Rocuronium 0.8|0.8 mg/kg
223523335|NCT05725031|DRUG|Rocuronium 1.2|1.2 mg/kg
223523336|NCT03768336|OTHER|Waitlist control|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
223523337|NCT03768336|OTHER|3RP-AYA|The 3RP is a group program that-through a variety of mind-body approaches, such as imagery, relaxation, and yoga-seeks to buffer stress and promote psychological resiliency and physical well-being.
223523338|NCT06263816|DRUG|Experimental group: Patients will be treated with carvedilol.|Patients will receive the number of pills of carvedilol corresponding to the dose determined during the titration period (either one pill of 6.25 mg in the morning or 1 pill of 6.25 mg twice a day, 1 in the morning and 1 in the evening.
223523339|NCT06263816|OTHER|Control group: Patients will receive a placebo.|Patients will receive the number of pills of placebo corresponding to the dose determined during the titration period (either one pill in the morning or 1 pill twice a day: 1 in the morning and 1 in the evening).
223893692|NCT05724264|DIAGNOSTIC_TEST|Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays|"LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery."
224275781|NCT06093789|OTHER|PBQ-S1|All patients will fill out Personality Belief Scale-Short Form (PBQ-S1) and Beck Anxiety Scale one day before the procedure and they will be registered.
224275782|NCT02340689|OTHER|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
223523340|NCT06004232|BEHAVIORAL|Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention|The PRY-D curriculum is a mindfulness-based prenatal yoga intervention which utilizes techniques to build both embodiment and mindfulness, and has previously been shown to reduce depression in a small sample of pregnant women with clinical depression.
223523341|NCT06004232|BEHAVIORAL|Treatment as Usual (TAU)|TAU involves routine prenatal care, during which time all patients are given information on the importance of physical activity during pregnancy.
223523342|NCT01697371|RADIATION|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
223523343|NCT01697371|RADIATION|Proton Radiation|
223523344|NCT04551495|DRUG|Entrectinib|Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
223523345|NCT04551495|DRUG|Letrozole|Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
223523346|NCT04551495|DRUG|Goserelin|Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
223523347|NCT05894629|BEHAVIORAL|Pain Neuroscience Education (PNE)+ Therapeutic Exercise (TE)|12-week program consisting of PNE and TE
223523348|NCT05894629|BEHAVIORAL|Active Comparator: Usual treatment|12-week program consisting of home exercises, performed 3 days/week.
223523349|NCT01224288|PROCEDURE|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
223523350|NCT05109325|BEHAVIORAL|IntERact|The IntERact intervention includes: (1) three remotely delivered Health Coach therapist sessions that integrate behavioral therapy (motivational interviewing \[MI\] + cognitive behavioral therapy \[CBT\] and strengths-based care management (CM); as well as, (2) an APP supporting and enhancing the therapist intervention by: (a) conducting automated daily assessments; (b) delivering daily MI/CBT messages tailored by the daily surveys; (c) delivering GPS-enabled alert notifications and immediate one-touch pro-social support; (d) providing access to reminders regarding goals/strengths from the ED session, CBT tools/skills (e.g., infographics, coping strategies, harm reduction strategies), and other psychoeducation (e.g., safe storage); (e) facilitating one-touch contact with pro-social support, including the health coach and others; (f) providing easy linkage to care management resources (web links, phone numbers, contact information).
223523351|NCT05125172|OTHER|Focus of Attention|Focus of attention instruction and feedback. Focus of attention refers to what people are thinking about during motor tasks. An external focus refers to thinking about an outside outcome or target. An internal focus of attention refers to thinking about how someone is moving their body.
223523352|NCT04245098|PROCEDURE|Carpal tunnel syndrome surgery|Biopsy
223523353|NCT03977155|DRUG|BOS-589|oral tablets
223523354|NCT03977155|DRUG|Placebo|oral tablets
224275783|NCT01225055|DRUG|Teriparatide|20 ug daily over 12 months
224275784|NCT01225055|DEVICE|vibration|10 min/day for 12 months
223523355|NCT06252584|DRUG|Vaccines, Peptide|Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
223523356|NCT03620396|PROCEDURE|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
223523357|NCT00010478|PROCEDURE|Acupuncture|
223523358|NCT02829372|DRUG|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
223523359|NCT03943277|OTHER|No intervention, observational study|No intervention observational study
223523360|NCT04667689|BEHAVIORAL|CAMPFIRE Online Cognitive Assessment for Cancer Patients|Subjects will complete PROMIS Cognitive Function/Anxiety/Depression survey assessments and a short neuropsychological battery (NIH Toolbox) on an iPad while in clinic prior to beginning chemotherapy, again before a clinic visit scheduled between 6 - 9 weeks and, lastly, before a post-chemotherapy follow-up clinic visit. Within two weeks of their post-chemotherapy assessment, subjects will be asked to complete a feedback survey. The physician providers and/or their clinical team (e.g., nurse practitioners, registered nurses) will be asked to review subjects' cognitive assessment results and discuss referrals and/or recommendations, if appropriate.
224275785|NCT00717782|PROCEDURE|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
224275786|NCT00717782|PROCEDURE|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
224275787|NCT03968926|OTHER|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
223523361|NCT06959342|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS sessions on five consecutive days for 20 minutes.
223523362|NCT06959342|BEHAVIORAL|Inhibition Training|Computerized Training of inhibitory control (Go-/No-Go task with pictures of preferred alcohol) on five consecutive days.
223704943|NCT06507358|BEHAVIORAL|Parent-Child Interaction group|The intervention for the Parent-Child Interaction group consists of a 6-week program involving weekly 40-minute sessions of therapeutic horticulture in a group setting, with 4-6 participants per group. The sessions focus on sensory-motor activities aimed at helping children engage in daily tasks and activities. Various sensory stimuli are provided through different materials used in gardening activities, including visual, auditory, gustatory, tactile, and olfactory stimuli. The program encourages mutual support and sharing among group members, showcases different outcomes, and emphasizes a sense of responsibility for home care. With a family-centered approach, parental involvement serves as a mediator to promote children's overall development and abilities. Participants are required to complete homework assignments and maintain activity records, including documentation of the 6 sessions through photos and written records.
223704944|NCT05194566|DEVICE|tACS|Neurostimulation will be done using the Neuro Device tCS (Neuro Device tCS), which is a certified transcranial electrical stimulator. The device consists of a stimulator with a touch screen, two electrodes and a soft, flexible cap to ensure stability of the electrodes on the head.
223523363|NCT00775658|DRUG|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
223523364|NCT00775658|DRUG|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
223523365|NCT03502681|DRUG|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2"
223523366|NCT03502681|DRUG|Avelumab|Days 1, 15 Avelumab (10mg/kg)
223523367|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
223523368|NCT01444781|BIOLOGICAL|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
223523369|NCT01444781|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
223523370|NCT06333106|OTHER|POCUS diagnostic value|Evaluation of the diagnostic value of clinical ultrasound in the diagnosis of fecal impaction in the emergency room
223523371|NCT03720366|DRUG|enasidenib|enasidenib
223704945|NCT05826561|OTHER|Childhood Asthma Passive Digital Marker|"A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing passively collected mother/child dyad prognostic data in digital electronic health record (EHR) to provide an objective and quantifiable marker of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care."
223704946|NCT05451771|DRUG|Venetoclax Oral Tablet, 200 mg|200 mg oral tablet daily
223704947|NCT05451771|DEVICE|FISH assay|Cytogenetic analysis is intended for evaluation of relapsed/refractory AL amyloidosis using fluorescence in situ hybridization (FISH) using known translocation probes. Bone marrow aspirate (BMA) samples are collected in lavender top (Ethylenediaminetetraacetic acid (EDTA)) or green top (Sodium heparin) tubes. Specimen tubes shall be transported at room temperature to the laboratory on the same day of collection.
223523372|NCT03720366|DRUG|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
223523373|NCT03720366|DRUG|Arm 2 Probes|digoxin and rosuvastatin
223523374|NCT03720366|DRUG|Arm 3 probes|pioglitazone
223523375|NCT05495438|OTHER|Hypothetical AI|n/a - There is no intervention. Clinicians will review the suggestions of a hypothetical AI
223523376|NCT01331759|DEVICE|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
223523377|NCT02724241|OTHER|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
223523378|NCT02724241|OTHER|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
223704948|NCT05451771|DRUG|Venetoclax Oral Tablet, 400 mg|400 mg oral tablet daily
223704949|NCT05451771|DRUG|Dexamethasone Oral, 10 mg|10 mg oral tablet weekly
223704950|NCT05451771|DRUG|Dexamethasone Oral, 20 mg|20 mg oral tablet weekly
223523379|NCT02724241|OTHER|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
223523380|NCT04371055|OTHER|7-day Holter ECG|7-day Holter ECG at baseline and after 3 and 12 months and then annually until the end of the study or the first (in patients with low risk of atrial fibrillation)
223523381|NCT04371055|OTHER|Implantable cardiac monitor|Continuous rhythm monitoring using an implantable cardiac monitor
223523382|NCT04371055|OTHER|Standard of care|Usual care according to current guidelines (in patients with low and high risk of atrial fibrillation)
223523383|NCT06790303|DRUG|Feladilimab|Feladilimab will be administered.
223523384|NCT06790303|DRUG|Ipilimumab|Ipilimumab will be administered
224083237|NCT05781828|DIAGNOSTIC_TEST|Detailed abdominal ultrasound|size of the liver and architecture, size of the spleen, presence or absence of ascites
223523385|NCT05311397|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
223523386|NCT06497140|DRUG|Ethiodized Oil-based emulsion|Embolization of genicular arteries
223523387|NCT06497140|PROCEDURE|Sham-operation|Mimicked catheterization and embolization of genicular arteries
223523388|NCT03413995|DRUG|Rucaparib|Continuous dosing
223523389|NCT06481423|BEHAVIORAL|dCBT-I|A digital cognitive behavioral intervention course that addresses multiple aspects such as basic sleep knowledge, sleep hygiene, sleep behaviors, improving negative cognition, and improving emotions. The intervention is delivered through video, audio, and text formats.
223523390|NCT06481423|BEHAVIORAL|Relaxing music|Participants can freely listen relaxing music
223523391|NCT05845307|DRUG|Control Group|Given by PO
223523392|NCT05845307|DRUG|TTI-101|Given by PO
223704951|NCT05451771|DRUG|Daratumumab Injection|Daratumumab will be administered at a dose of 16 mg/kg by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter for a maximum of 6 months of therapy. If subcutaneous formulation is available, participants can also receive subcutaneous daratumumab (1800 mg in 15 ml) in the same schedule.
223704952|NCT05451771|DRUG|Bendamustine|Bendamustine will be given at an initial dose of 100 mg/m\^2 intravenously on days 1 and 2 in each 28-day cycle.
223523393|NCT04721691|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is a schedule 5 controlled substance that is a colorless to yellow oral liquid solution that is prepackaged into 100mL vials with 5mL syringes for use. It is typically used for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome in patients 2 years of age and older.
223523394|NCT04721691|OTHER|Placebo|Placebo is composed of dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose.
223523395|NCT02007161|DRUG|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
223523396|NCT05268861|BEHAVIORAL|Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. Subjects will receive an elbow flexion error of 15 degrees to encourage elbow extension.
223523397|NCT05268861|BEHAVIORAL|No Error Augmentation Feedback|Error augmentation (EA) is a feedback modality that provides subjects with magnified motor errors. In our intervention, subjects are provided with an elbow angle error that will encourage subjects to use more elbow extension during reaching. Thus, subjects are provided with feedback that their elbow has extended less than it actually has and will compensate by extending the elbow further to successfully reach a target. In this case, subjects that do not receive EA feedback will act as sham comparators.
223523398|NCT03907202|DRUG|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
223523399|NCT06549777|BEHAVIORAL|SE-group|Psychoeducation and information about treatment possibilities + SE-treatment
223523400|NCT06549777|BEHAVIORAL|Control|Psychoeducation and information about treatment possibilities + Phone
223523401|NCT06518928|OTHER|Artificial Intelligence assisted sperm selection|SiD software for sperm selection
223523402|NCT00991640|BEHAVIORAL|2-day preceptorship on obesity management|
223523403|NCT02144532|DEVICE|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
223523404|NCT02098603|BEHAVIORAL|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
223523405|NCT04744116|OTHER|Cellular Therapy|Given ds-MSCs IV
223523406|NCT04744116|DRUG|Ruxolitinib|Given PO
223704953|NCT05451771|DRUG|Pomalidomide|Pomalidomide will be administered at an initial dose of 2 mg per days on days 1-21 every 28 days.
223704954|NCT05451771|DRUG|Ixazomib|Ixazomib will be administered at an initial dose of 4 mg per days on days 1, 8, and 15 every 28 days.
223704955|NCT05451771|DRUG|Venetoclax MTD with Dexamethasone|Venetoclax MTD (200 mg or 400 mg) with Dexamethasone (10 mg or 20 mg) as determined by the phase I results
223704956|NCT04638296|OTHER|Interviews|The investigators designed 3 versions of the semi structured interview guide for each of the surgeons/anesthesiologists (Appendix A.1), residents (Appendix A.2) and nurses (Appendix A. 3). All versions were subdivided into 3 general categories: 1) participant demographics such as participant's age, years of experience, specialty, years of employment at the institution 2) participant's perceptions of noise in the OR, what they considered as sources of noise, the loudness level, whether they thought this impacted their concentration, performance, communication, whether this was distracting or helpful in different stages of the operation, and 3) perceptions on music.
223704957|NCT05561205|DEVICE|rTMS|repetitive transcranial magnetic stimulation
223523407|NCT02759510|DRUG|Norepinephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
223523408|NCT02759510|DRUG|Phenylephrine|Hypotension (systolic BP \<80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
223704958|NCT05561205|DRUG|methylphenidate|methylphenidate
223704959|NCT00817544|DRUG|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
223704960|NCT06113016|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223704961|NCT06113016|OTHER|Educational Intervention|Receive handout on physical activity
223704962|NCT06113016|OTHER|Exercise Intervention|Receive individually tailored exercise intervention
223704963|NCT06113016|DRUG|Fisetin|Given PO
223704964|NCT06113016|OTHER|Physical Performance Testing|Ancillary studies
223704965|NCT06113016|DRUG|Placebo Administration|Given PO
223704966|NCT06113016|OTHER|Quality-of-Life Assessment|Ancillary studies
223523409|NCT02593214|DEVICE|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
223523410|NCT05061823|DRUG|Bintrafusp alfa|Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
223523411|NCT04661488|DEVICE|AI driven triage-system|AI driven triage-system
223704967|NCT06113016|OTHER|Questionnaire Administration|Ancillary studies
224083238|NCT01717131|PROCEDURE|Surgery for standard axillary node dissection|
224083239|NCT01717131|OTHER|No axillary lymph node dissection|No surgery on axillary lymph node
223523412|NCT05328622|BEHAVIORAL|Aqueduct Contingency Management Platform|"All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care."
223523413|NCT04999267|OTHER|INVEST|The intervention will consist of 3 primary components: 1) school nurse training and technical support for promoting adolescent vaccination (Tdap, MenACWY, HPV) and strengthening existing school nursing vaccination programming, 2) caregiver-targeted educational materials that are disseminated via school nurses, and 3) tools and resources to facilitate linkage to vaccination providers in the local community. Existing materials will be used in the intervention such as resources available from the Centers for Disease Control and Prevention and Middle School Health Starts Here tool kit from the National Association of School Nurses and the National HPV Roundtable. Technical support includes the study team working with local school nurses to identify educational materials available from national and statewide sources.
223523414|NCT06572774|BEHAVIORAL|C3Link Strategies|Education sessions and community liaison support to link to services
223523415|NCT01520441|DRUG|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
223523416|NCT03182855|DRUG|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
223523417|NCT03182855|DRUG|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
223523418|NCT02310269|DRUG|Pasireotide|
223523419|NCT06402305|DIAGNOSTIC_TEST|Lipid profile|Abdominal ultrasound and lipid profile will be done
223523420|NCT00321932|DIETARY_SUPPLEMENT|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
223523421|NCT00321932|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
223523422|NCT00321932|DRUG|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
223523423|NCT00157872|DRUG|MK0966; rofecoxib|
223523424|NCT00157872|DRUG|Comparator: naproxen tablet 500 mg|
223704968|NCT04319991|DIETARY_SUPPLEMENT|Probiotics product|This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
223704969|NCT00258284|DRUG|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
223704970|NCT00258284|DRUG|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
224275788|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
223704971|NCT04811378|OTHER|HaemoCer|Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
224275789|NCT06412926|DRUG|BAY 44-4400|Film-coated tablet, oral use
224275790|NCT00021216|DRUG|bortezomib|Given IV
224275791|NCT00021216|OTHER|laboratory biomarker analysis|Correlative studies
224275792|NCT00021216|OTHER|pharmacological study|Correlative studies
224275793|NCT00799942|DRUG|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
224275794|NCT04915911|OTHER|cross-sectional study|cross-sectional study
223523425|NCT05787041|OTHER|high-fat diet group（AD16 20mg）|AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.
223523426|NCT05787041|OTHER|fasted group（AD16 20mg）|Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.
223523427|NCT06247748|DRUG|Exendin-4 Fc fusion protein (JY09) injection|D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
224275795|NCT04675775|OTHER|Medically-tailored meals (MTM)|After the run-in baseline period participants will be expected to consume the meals and protein supplements meals between approximately Weeks 4 - 11 of the study. Additionally, participants will complete surveys before, during and after the meals.
224275796|NCT04675775|DIETARY_SUPPLEMENT|Protein supplements|"A daytime and nighttime protein supplement will be provided after the baseline visit and should be consumed daily at home during the same study days as MTM. The daytime protein supplement is a protein bar (ZonePerfect or Perfect Bar). The nighttime supplement is a protein powder or liquid that can be dissolved in either water or milk.~This is provided to participants with ProCel Vanilla Whey Protein powder which provides 15 grams of protein per serving or the ProCel LiquaCel liquid protein supplement mango, grape, watermelon and/or lemon flavors which provides 16g of protein per serving."
224275797|NCT04675775|BEHAVIORAL|Nutrition education handout|A standardized nutrition education handout containing instructions on following a high-protein and sodium restricted diet (depending on the presence of ascites) will be given as part of Standard of Care.
223523428|NCT06247748|DRUG|Metformin Hydrochloride tablet|D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
223523429|NCT06247748|DRUG|Rosuvastatin calcium tablets|D8 received a single oral administration of 10 mg of Rosuvastatin calcium tablets in the morning, with a washout period of 168 h,and 10 mg Rosuvastatin calcium tablets orally at 72 h ± 0.5 h (D95) after JY09 administration.
223523430|NCT06247748|DRUG|Digoxin tablet|D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
223523431|NCT05495568|BIOLOGICAL|CT-P17|CT-P17 40mg will be subcutaneous administered
223523432|NCT05495568|BIOLOGICAL|EU-approved Humira|subcutaneous administration
223523433|NCT03809000|RADIATION|Radiation Therapy|daily fractions
223523434|NCT03809000|DRUG|Enzalutamide|tablet
223523435|NCT03809000|DRUG|Bicalutamide|tablet
223523436|NCT03809000|DRUG|GnRH analog|Injection
223523437|NCT03360344|DEVICE|Kinesio 12 inch Tape|Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
223523438|NCT03360344|DEVICE|Kinesio 4 inch Tape|Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
223523439|NCT03360344|DEVICE|Cock up Splint and Lumbrical exercises|A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
223523440|NCT01145183|DRUG|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
223523441|NCT01145183|DRUG|Placebo|Matched placebo daily dosing
223523442|NCT01993732|PROCEDURE|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
223523443|NCT03906409|OTHER|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
223523444|NCT03906409|OTHER|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
223523445|NCT03257657|BEHAVIORAL|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
223523446|NCT03257657|BEHAVIORAL|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
223523447|NCT05410314|DRUG|Myo-Inositol and D-Chiro-Inositol (MIC)|Both groups were followed up for 12 months, in T0 (during first evaluation), and T12 (after twelve months) with blood test for AMH (ng/ml).
223523448|NCT01855984|DIETARY_SUPPLEMENT|Oral mixed tocotrienols|200mg per day
223523449|NCT01855984|DIETARY_SUPPLEMENT|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
223523450|NCT01828060|DIETARY_SUPPLEMENT|Jobelyn™|Sorghum bicolor leaf sheath extract
223523451|NCT01828060|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
223523452|NCT01085903|DRUG|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
224275798|NCT05357079|DRUG|Tranexamic Acid|Topical application
224275799|NCT05357079|DRUG|Normal saline|Topical application
223704972|NCT03225729|DEVICE|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots \<6 mm which are previously selected by the investigator team.
223704973|NCT03225729|DEVICE|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots \<6 mm a small amount of nitrogen liquid.
223704974|NCT03183531|DIAGNOSTIC_TEST|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
223523453|NCT01085903|DRUG|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
223523454|NCT01085903|BEHAVIORAL|Baseline|Observations made at baseline before any intervention
223523455|NCT01085903|BEHAVIORAL|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
223523456|NCT01085903|BEHAVIORAL|Post CPS|20 minutes following the CPS condition.
223523457|NCT01085903|BEHAVIORAL|Follow up|Follow up testing occurred at 3 months
223523458|NCT06240286|BEHAVIORAL|Sitting workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.
223523459|NCT06240286|BEHAVIORAL|Standing workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.
223523460|NCT06240286|BEHAVIORAL|Stepping workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.
223704975|NCT00261118|DRUG|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
223523461|NCT06240286|BEHAVIORAL|Walking workstation|Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
223704976|NCT01612104|BEHAVIORAL|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
223704977|NCT03824184|PROCEDURE|manipulation of endometrium|Manipulation of endometrium with saline
223523462|NCT02971839|DRUG|VX-561|
223523463|NCT02971839|DRUG|Placebo|
223523464|NCT02971839|DRUG|IVA|
223523465|NCT04744792|OTHER|Short Form - 36|"Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients"
223523466|NCT04744792|OTHER|WHODAS-II|"The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients."
223523467|NCT00002035|DRUG|Zidovudine|
223523468|NCT00002035|DRUG|Didanosine|
223523469|NCT05334797|OTHER|hot application|a thermophore filled with hot water will be placed on the patient's shoulder according to the presence of shoulder pain and it will be ensured that he stays for 15 minutes.
223523470|NCT04622930|DEVICE|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
223523471|NCT04904302|BIOLOGICAL|Nivolumab|Given IV
223523472|NCT04904302|OTHER|Quality-of-Life Assessment|Ancillary studies
223523473|NCT04904302|OTHER|Questionnaire Administration|Ancillary studies
223523474|NCT04904302|DRUG|Sitravatinib|Given PO
223523475|NCT06563921|BEHAVIORAL|physical exercise programme|resistance/hypertrophy-oriented resistance programme
223523476|NCT06563921|DIETARY_SUPPLEMENT|probiotics supplementation|probiotics supplementation
223523477|NCT06563921|DIETARY_SUPPLEMENT|placebo|placebo
223523478|NCT02399293|BEHAVIORAL|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
223523479|NCT02399293|BEHAVIORAL|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
223523480|NCT06396559|BEHAVIORAL|pre test-post test|The mobile application will be installed on the mobile devices of student nurses and its effectiveness will be tested.
223523481|NCT01688804|BEHAVIORAL|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
223523482|NCT04503369|BEHAVIORAL|Non-technical skills|"Teamwork The work of the team consists of information exchange and coordination of all activities performed. In-team communication is always calm and assertive, and team members support each other.~Task management With the right planning and preparation of individual activities, the likelihood that all standards of care and best practices will be followed increases.~Situational awareness Situational awareness refers primarily to the collection of information, its understanding and, on that basis, prediction of direction into which the situation will develop. Maintaining situational awareness is crucial in order to move towards the right goal.~Decision-making With good situational awareness, one is able to keep in mind all information needed to make the correct decision at the right time. In some cases, it is advisable to consult with other team members or to verify their consent to the proposed procedure.~Communication Communication is a vital tool when working in a team."
223523483|NCT00690339|DEVICE|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
223704978|NCT02616848|DRUG|Everolimus|
223704979|NCT02616848|DRUG|Eribulin|
223704980|NCT00418249|DRUG|AS101|
223704981|NCT04120441|BEHAVIORAL|Group Mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
223704982|NCT00095992|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
223893693|NCT06465225|DEVICE|Use of a powered alternating pressure air mattress|Patients with a medium to high risk of developing pressure injury, without pressure injury, up during the day and lying between 15 and 20 hours per day will ly a on a R'GO Soins overlay mattress
223893694|NCT04946734|DEVICE|PFO closure device|Device PFO closure.
223704983|NCT06078410|PROCEDURE|Cardiac surgery|The TA-BSM group will undergo transapical beating-heart septal myectomy and the group of cardiac surgery involving left heart operation will udergo patients received cardiac surgery involving left heart operation, such as valvuloplasty, valve replacement, repair of auricular septal defect, repair of auricular/ventricular septal defect.
224275800|NCT02864004|DRUG|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
223523484|NCT04057157|DEVICE|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
223523485|NCT04085250|OTHER|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 60 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
223523486|NCT04085250|OTHER|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)
223523487|NCT04085250|RADIATION|Radiotherapy|Hypofractionated radiation technique was used to deliver a definitive radiation dose
223523488|NCT04085250|DRUG|Nivolumab|Nivolumab consolidation (360 mg) via iv infusion once every 3 weeks (Q3W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q3W schedule for a maximum duration of 12 months.
223523489|NCT04085250|OTHER|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
223523490|NCT05393492|BEHAVIORAL|Dialectical Behavior Therapy and Radically Open dialectical behavior therapy|"Dialectical Behavior Therapy is a third wave cognitive-behavioral therapy. It focuses on emotional dysregulation and interactions between the patient and his family in genesis and maintenance of challenging behaviors. It is used here in an adapted form for cognitive problems.~Delivered in a group format of 19 weeks + individual sessions."
223523491|NCT02000102|DRUG|Intravitreal Injection of Aflibercept|
223523492|NCT03713450|DEVICE|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
223523493|NCT03713450|DEVICE|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
223523494|NCT05994287|DRUG|Aspirin|The patients received aspirin in a dose of 100 mg orally daily.
223523495|NCT05994287|DRUG|Ketorolac|The patients received ketorolac in a dose of 90 mg mg orally daily.
223523496|NCT05994287|DRUG|Celecoxib|The patients received celecoxib in a dose of 400 mg orally daily.
223523497|NCT00057148|PROCEDURE|massage treatment|
223523498|NCT03999476|DEVICE|ambu ascope|nasal route intubation by the device in fixed cancer tongue patients
223523499|NCT03999476|DEVICE|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
223523500|NCT01943227|OTHER|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
223523501|NCT01943227|OTHER|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
223523502|NCT03372616|DIAGNOSTIC_TEST|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
223523503|NCT03372616|DIAGNOSTIC_TEST|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
223523504|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
223523505|NCT03372616|DIAGNOSTIC_TEST|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
223523506|NCT05370092|OTHER|Percutaneous needle electrolysis|Electrolysis is the process by which water (H2O) and sodium chloride (NaCl) molecules, which are present in the biological tissues and body compartments of our organism, are organically broken down into their constituent chemical elements, regrouping to create entirely new substances such as sodium hydroxide (NaOH), hydrogen gas (H2) and chlorine gas (Cl2). This process occurs thanks to the passage of a flow of direct electric current, also known as galvanic current, which is a totally athermal process. The passage of this current allows a local inflammatory response to occur (increase in lymphocytes and macrophages) as well as an increase in vasodilatation, inducing phagocytosis and biological stimulation of tendon repair.
223704984|NCT06261918|PROCEDURE|Influence of metabolic syndrome on the achievement of pathological complete response|The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
223704985|NCT02519218|DEVICE|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
223704986|NCT04835480|DRUG|OrsHSA|OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa
223704987|NCT04835480|DRUG|HSA|Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
223704988|NCT04668807|DEVICE|Connected Medical Device|Monitoring of three simple physiological parameters (SpO2, heart rate and respiratory rate) with a Connected Medical Device (DMC) in the operating room
224275801|NCT02864004|OTHER|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
223523507|NCT05370092|OTHER|Therapeutic exercise|The first exercise they will perform will be the Short-Foot Exercise holding the position 5 seconds isometrically. The second exercise will be plantar flexion of the ankle with adduction of the foot and inversion with elastic band in its concentric and eccentric phase
223704989|NCT04668807|DEVICE|Traditional transmission system|Monitoring of physiological parameters with a traditional wired transmission system between the sensor and the data processing device in the operating room
223523508|NCT05370092|OTHER|Manual therapy|The manual therapy (TM) treatment for tendinopathies is mainly focused on soft tissue mobilization and deep transverse friction massage (Cyriax).
223523509|NCT00392574|DRUG|Prulifloxacin|Tablet
223523510|NCT00392574|DRUG|Placebo|Tablet
223523511|NCT03981510|DIAGNOSTIC_TEST|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
223523512|NCT03723473|DEVICE|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
223523513|NCT00303407|DRUG|nadroparin|
223523514|NCT01468064|GENETIC|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
223523515|NCT01468064|GENETIC|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
223523516|NCT01468064|GENETIC|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
223523517|NCT00800826|DRUG|dexmedetomidine|
223523518|NCT03984279|OTHER|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
223523519|NCT00213070|DRUG|Miglitol|
223523520|NCT02321475|DRUG|EGb761®|
223523521|NCT02896205|DRUG|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
223523522|NCT02896205|DRUG|Placebo|Subjects will be given matching placebo for 6 months
223523523|NCT06541119|OTHER|Selective Peroneus longus excercise|Weight bearing peroneus longus exercise
223523524|NCT06541119|OTHER|Conventional physical therapy programme|"* Passive abduction of the Hallux with traction~* short foot exercise~* toe spread outs"
223523525|NCT02104934|PROCEDURE|Adductor Canal Block|
223523526|NCT02398019|DEVICE|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
223523527|NCT04076332|OTHER|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
223523528|NCT01668680|DRUG|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
223523529|NCT06489366|DEVICE|Thulium Fiber laser (TFL) lithotripsy|Patients with proximal ureteral stones undergoing ureteroscopic lithotripsy using thulium laser lithotripsy.
223523530|NCT06489366|DEVICE|Ho: YAG lithotripsy|Ho:YAG laser lithotripsy was used in patients with proximal ureteral stones undergoing ureteroscopic lithotripsy.
223523531|NCT01905540|DRUG|SSP-004184AQ|Magnesium salt
223523532|NCT01905540|DRUG|SSP-004184SS|Disodium salt
223523533|NCT00000395|DRUG|Methotrexate|
223523534|NCT00000395|DIETARY_SUPPLEMENT|Folinic acid|
223704990|NCT02777710|DRUG|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
223523535|NCT00000395|DIETARY_SUPPLEMENT|Folic acid|
223523536|NCT02367885|DRUG|TAK-850 0.5 mL injection|TAK-850 injection
223523537|NCT02367885|DRUG|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
223523538|NCT06059950|BEHAVIORAL|Mindfulness Flow Program|The mindfulness flow program (MFP) consisted of eleven 60-minute sessions via Zoom, with one session per week. Additionally, a 120-minute in-person sport-specific session were conducted.
223523539|NCT01602484|DEVICE|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
223523540|NCT01602484|DEVICE|Bulk splint supplies|Applying splint by using the bulk splint supplies
223523541|NCT03842280|DEVICE|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
223523542|NCT04326738|DRUG|Midazolam|M group received intravenous injection of 0.03mg·kg-1 (1mg·ml-1) midazolam, After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg (injection was completed in 2s)
223523543|NCT04326738|DRUG|normal saline|N group received corresponding intravenous normal saline of1ml·kg-1 .
223523544|NCT03910595|OTHER|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
223523545|NCT00011635|DRUG|Silymarin (milk thistle)|
223523546|NCT00498628|DRUG|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
223523547|NCT00498628|OTHER|Placebo|Placebo
223523548|NCT00967252|DRUG|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
223523549|NCT00967252|DRUG|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
223523550|NCT00967252|DRUG|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
223523551|NCT00967252|DRUG|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
223523552|NCT00967252|OTHER|Control|No statin being taken
223523553|NCT01322152|DRUG|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
223523554|NCT02743962|DEVICE|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
223523555|NCT02743962|OTHER|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
223523556|NCT03526666|OTHER|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
223523557|NCT04656912|PROCEDURE|Hyperbaric oxygen therapy|Patients with any symptoms and signs were treated with HBO2. During the first HBO2, initial compression was performed to 2.8 atmospheres absolute (ATA) for 45 min, followed by 2.0 ATA for 60 min. If an additional HBO2 was possible within 24 h, then 2.0 ATA was administered for 90 min. Moreover, if necessary, patients were treated with HBO2, even after 24 h, until all symptoms resolved.
223523558|NCT02132260|DRUG|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
223523559|NCT02132260|DRUG|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
223523560|NCT02132260|DRUG|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
224275802|NCT03857672|BEHAVIORAL|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
224275803|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.
223523561|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
223523562|NCT06563934|DRUG|Lenvatinib + PD-1 monoclonal antibody|"Lenvatinib 8mg (≤60 kg body weight) or 12 mg (\> 60 kg body weight) orally once a day.~PD-1 monoclonal antibody 200mg i.v. once every 3 weeks."
223523563|NCT06563934|BIOLOGICAL|Oral enterobacterium capsules placebo|Enterobacterium capsules placebo (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
223523564|NCT06642129|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
224275804|NCT00071084|DRUG|HuMax-CD4|HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
224275805|NCT03566407|PROCEDURE|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
224275806|NCT00348816|DRUG|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
223523565|NCT06640660|DEVICE|Mindlenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
224275807|NCT00348816|DRUG|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
224275808|NCT00348816|PROCEDURE|Radical prostatectomy|Radical prostatectomy as part of standard care
223523566|NCT06640660|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
223523567|NCT06639685|DIAGNOSTIC_TEST|MRI|MR Fingerprinting and ASL
223523568|NCT06049160|DRUG|Misoprostol|All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
223523569|NCT04692922|DIAGNOSTIC_TEST|MRI|MRI will include structural sequences (e.g., T1 weighted imaging, T2 weighted imaging, T2 FLAIR, diffusion weighted imaging with apparent diffusion coefficient, susceptibility weighted imaging, and diffusion tensor imaging). Using the structural sequences we will make note of the types of brain lesions (e.g., ischemic stroke, hemorrhage, hypoxic-ischemic brain injury), and the locations of these brain lesions. MRI will also include fMRI under three conditions: while the patient is at rest (to evaluate resting state functional connectivity), while the patient is exposed to auditory stimuli (to evaluate passive fMRI responses to stimuli), and while the patient is asked to follow commands (to evaluate active fMRI responses to tasks).
223523570|NCT04692922|DIAGNOSTIC_TEST|EEG|The EEG will include resting, stimulus-based, and task-based assessments of brain function.
223704991|NCT02777710|DRUG|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
223523571|NCT06642597|OTHER|Incremental PD|Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.
223523572|NCT06642597|OTHER|Full dose PD|Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
223523573|NCT06564363|DIAGNOSTIC_TEST|IUrisure test|Postoperative patients are followed up every three months on average, and IUrisure test was performed at each follow-up visit.
223523574|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy with use of Emdogain|Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.
223523575|NCT05964699|PROCEDURE|Minimally invasive periodontal therapy without the use of Emdogain|Scaling of root with assisted use of the Videoscope.
223523576|NCT04998513|DRUG|Medical Management Alone Arm|"The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group."
223523577|NCT04998513|PROCEDURE|Surgical Arm|"Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm."
223523578|NCT03003663|DEVICE|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
223523579|NCT06033560|DEVICE|High flow nasal oxygen (HFNO, more than 15 L/min)|Non-invasive respiratory support strategy
223523580|NCT03592355|OTHER|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
223523581|NCT01661283|DRUG|everolimus|10 mg tablet once daily
223523582|NCT01661283|DRUG|bevacizumab|10 mg/kg dose every 14 days
223523583|NCT01656122|DRUG|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
223523584|NCT01656122|DRUG|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
223523585|NCT02327169|DRUG|MLN2480|MLN2480 tablets.
223523586|NCT02327169|DRUG|MLN0128|MLN0128 capsules.
223523587|NCT02327169|DRUG|Alisertib|Alisertib tablets.
223523588|NCT02327169|DRUG|Paclitaxel|Paclitaxel IV infusion.
223523589|NCT02327169|DRUG|Cetuximab|Cetuximab IV infusion.
223523590|NCT02327169|DRUG|Irinotecan|Irinotecan IV infusion.
223523591|NCT02626884|DRUG|Ibrutinib|
223523592|NCT04998630|DEVICE|Extracorporeal shockwave therapy|Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
223523593|NCT05575102|OTHER|Walking Football|"Walking Football (Soccer): Typical football rules apply but without running.~Participants will play at a local sports hall for 6-weeks, (2-hour per week). Time will be split between warm-up, football practice drills, and small-sided games."
223523594|NCT06192563|DRUG|Dupilumab|Subcutaneous injection, standard of care as prescribed by treating physician (no investigational drug provided)
223523595|NCT00492544|BIOLOGICAL|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223523596|NCT05206370|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
223523597|NCT05206370|DRUG|Placebo|film-coated oral tablets containing matched placebo
223523598|NCT05206370|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
223523599|NCT02947971|DEVICE|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
223523600|NCT01920113|DRUG|Dexmedetomidine - remifentanil group|
223523601|NCT01920113|DRUG|Propofol - remifentanil group|
223523602|NCT03132142|DRUG|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
223523603|NCT03132142|DRUG|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
223704992|NCT01582568|DRUG|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
223893695|NCT04946734|DRUG|Aspirin and clopidogrel|Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.
223893696|NCT04946734|DRUG|Triptans|If migraine recurred, Triptans would be administered during the acute phase.
223893697|NCT04876118|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
223523604|NCT03132142|DRUG|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
223523605|NCT03132142|DRUG|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
223523606|NCT05910346|BEHAVIORAL|education and counseling based on maternal role theory|Pregnant women in the experimental group will be given training and counseling based on the maternal role theory, starting at 32 weeks of gestation (1 week in total, 2 days a week, 3 sessions every day, 6 sessions in total, 8 hours in total). After the training and counseling program given to the pregnant women in the experimental group according to the motherhood role theory is completed, a training booklet will be prepared so that they can repeat the information they have learned until birth (for improving the motherhood role). It is planned to give the training booklet at the end of the training in order to ensure continuity in the program.
223523607|NCT00952692|BIOLOGICAL|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~* One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~* One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
223523608|NCT00952692|DRUG|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
223523609|NCT02878863|DRUG|Paeoniflorin + phosphatidylcholine or silymarin|
223523610|NCT02878863|DRUG|Phosphatidylcholine or silymarin|
223523611|NCT04548960|OTHER|cancer patients|Blood sample RNA\_seq at time of diagnostic, best response and relapse ; Biopsy Exom\_seq and RNA\_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
223523612|NCT05503277|DEVICE|LTSD|measuring seal pressure
223523613|NCT05503277|DEVICE|i-gel|measuring seal pressure
223523614|NCT02002325|DRUG|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
223523615|NCT02002325|OTHER|Standard care|Standard treatment for acute stroke without intravenous alteplase.
223523616|NCT03715907|BEHAVIORAL|Financial Incentives|Incentives for gap closure.
223704993|NCT04001933|OTHER|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
223704994|NCT03285854|DIAGNOSTIC_TEST|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
223704995|NCT06450080|OTHER|MRI and MRS acquisitions|All MRI and MRS acquisitions for this study will be carried out on the GIE Faire Faces ACHIEVA 3T TX DStream Philips® Research MRI using a 32-channel head antenna located at the Amiens-Picardie University Hospital .
223704996|NCT06540027|PROCEDURE|rectal cacer surgery|minimally invasive surgery
223523617|NCT03715907|BEHAVIORAL|Information|Information on care gap and closure process.
223523618|NCT00849992|DRUG|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
223523619|NCT00849992|PROCEDURE|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
223523620|NCT04879407|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
223523621|NCT04879407|DRUG|Warfarin|Any warfarin dispensing claim is used as the reference group
223523622|NCT05399173|DEVICE|infrared (gallium aluminum arsenide laser)|Patient Position will be in supine \& prone position, the area of these points is resolved utilizing anatomical landmarks and an arrangement of length measurements whose units are in respect to the physical extents of the individual patient. Acupuncture points used to treat nighttime enuresis are situated in regions that coincide with innervation by spinal sacral segments S2 through to S4 and expressed in the treatment conventions. The points of BL 23, BL 28, BL 32, RN 3, RN 4, RN 6, RN 12 impact the spinal micturition centers and parasympathetic innervation to the urinary tract, while excitement on scalp acupoints of DU 20 and DU 14 change cerebrum function through inner temporal, thalamencephalon and prefrontal cortical frameworks. Excitation of acupoints UB 20, UB 13, SP 6, ST 36, KI 3 and LU 9 are considered to strengthen spleen, vital energy and blood which encourage standardized bladder capacity
223523623|NCT05399173|DRUG|medical treatment(desmopressin acetate)|participants will receive medical treatment (desmopressin acetate) per-night dose of 120 g (for 6 weeks) \& advice
223704997|NCT02624674|DEVICE|Multi-spectral Imaging Device (MSID)|
223704998|NCT05600803|PROCEDURE|Single-operator cholangioscopy|SpyGlass (Boston Scientific Co, Marlborough, USA) which enabled the direct visualization of the pancreaticobiliary system for the evaluation of intraductal lesions
223704999|NCT03363269|DRUG|ID1201|
223523624|NCT03755193|DRUG|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
223523625|NCT03755193|DRUG|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
223523626|NCT03755193|DRUG|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
223523627|NCT00187109|DRUG|Recombinant Human Thrombopoietin|
223523628|NCT02094235|DRUG|E6005 0.05%|
223523629|NCT02094235|DRUG|Placebo|0.5 g placebo ointment
223523630|NCT02094235|DRUG|E6005 0.2%|
223523631|NCT03962647|DIETARY_SUPPLEMENT|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
223523632|NCT03962647|DRUG|Letrozole|2.5 mg taken once daily by mouth
223523633|NCT00818194|DRUG|extended release tacrolimus|oral
223523634|NCT00818194|DRUG|cyclosporine A microemulsion|oral
223523635|NCT06365463|BEHAVIORAL|Telerehabilitation|The training will last for 6 weeks, with two 60-minute sessions of balance and mobility training per week. Two consecutive groups will participate.
223523636|NCT04330859|OTHER|NeoRehab Bundle|The NICU rehabilitation program includes six multimodal, GA appropriate, parent-administered interventions (vocal soothing, scent exchange, comforting touch, kangaroo care, infant massage and physical therapy)
223523637|NCT04330859|OTHER|Routine care|Routine NICU care including talking, touching and holding the participant per unit guideline as well as physical therapy, occupational therapy, and speech therapy per unit guideline
223523638|NCT02878395|PROCEDURE|Ileocolic resection|
223523639|NCT06186518|OTHER|PİKSEÇ|"In designing the PİKSEÇ application, the Turkish validity and reliability version of the 'Difficult Intravenous Access Score' and a literal translation of the miniMAGIC instructions were utilized. The application serves as a guideline for nurses during peripheral intravenous catheter insertion, taking into account parameters such as the patient's age, urgency status, anxiety, and vein characteristics, providing tailored suggestions.~By utilizing the application, nurses can follow evidence-based guidelines more efficiently, ensuring a faster and more practical adherence to the PIVC intervention procedure, ultimately contributing to a safer peripheral intravenous catheter insertion process."
223523640|NCT06186518|OTHER|Routine care|The pediatric unit's PIVC insertion process will be routinely performed in routine care.
223523641|NCT05718739|DEVICE|AX6 6-axis logging accelerometer|The device is collecting longitudinal movement data.
223523642|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 100 and 150
223523643|NCT00420537|DRUG|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
223523644|NCT00420537|DRUG|Mycophenolate mofetil|mycophenolate with low doses
223523645|NCT00420537|DRUG|Everolimus|
223523646|NCT03129906|DIETARY_SUPPLEMENT|Gluten|
223523647|NCT03129906|DIETARY_SUPPLEMENT|Rice protein|
223705000|NCT05942560|BEHAVIORAL|Cognitive behavioural therapy-based intervention|"A specifically designed CBT-based intervention consisting of 8 weekly sessions with group format.~Each group will be comprised of 4-10 participants, and each session will last 1.5 hours.~The content of the weekly sessions will be based on Beck's cognitive theory and the cognitive therapy in groups guidelines.~The framework of every session will follow a pre-determined structure."
223705001|NCT05942560|BEHAVIORAL|Educational group|The educational sessions are consisting of 8 weekly sessions with a group format. These sessions will focus on cancer-related information and care knowledge which will be delivered in daily routine care.
223705002|NCT03266731|DRUG|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
223705003|NCT05956691|DIETARY_SUPPLEMENT|AllerPops|Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.
223705004|NCT02675985|OTHER|Physical Therapy|Early Intensive Physical therapy in the ICU
223705005|NCT06314308|BEHAVIORAL|CATCHES|At the baseline visit (T0), informed consent will be obtained, and baseline questionnaires and measurements completed. A physical activity monitor will be provided. After discharge, Task Specific Training guided by Cognitive Behavioral Therapy with Exposure delivered over 7 one-hour sessions including two intake sessions by specialists and five follow up sessions delivered by CHWs individually at home over 3 months. After the final session at 12 weeks (about 3 months), participants will complete a study end visit (T1) which will include follow up questionnaires and measurements.
223523648|NCT02106806|DIETARY_SUPPLEMENT|Zinc|35 mg of elemental zinc twice daily for 16 weeks
223523649|NCT02106806|OTHER|Placebo|One capsule, twice daily for 16 weeks
223523650|NCT03982810|DRUG|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
223523651|NCT01381679|DRUG|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
223523652|NCT00270556|DRUG|tenofovir disoproxil fumarate|
223523653|NCT00270556|DRUG|Abacavir|
223523654|NCT04758988|OTHER|DermLoop Learn|DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
223523655|NCT06640790|OTHER|Case Group|Root canal treated were categorized based on the AAE case difficulty assessment form. Endodontic mishaps investigated included over-instrumentation, working length loss, underfilling, overfilling, apical transportation, instrument fracture, and perforation.
223523656|NCT05546307|OTHER|SSEP|Every patient presenting for a SSEP will be offered to participate to the study. If accepted, a randomization will determine whether the examination will be preceded by a relaxation session (Relax Group) or not (control group)
223523657|NCT05546307|OTHER|relaxation session|The relaxation session will be performed by one of the 5 nurses trained in relaxation
223523658|NCT05473715|DRUG|Aflibercept(BAY86-5321, Eylea)|2mg, intravitreal (IVT) injection
223523659|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Active Treatment questionnaire|Electronic questionnaire to be administered to patients in active treatment.
223523660|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Survivors questionnaire|Electronic questionnaire to be administered to cancer survivors.
223523661|NCT05947903|OTHER|Administration of the EUonQoL-Kit - Palliative Care questionnaire|Electronic questionnaire to be administered to patients in palliative care.
223523662|NCT06511024|OTHER|Blood sample|Serial blood sampling to monitor immune cells in patient with COVID 19 infection and compare with control group who have no evidence of COVID-19 infection
223705006|NCT03532958|DRUG|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
223705007|NCT03532958|DRUG|Normal saline|Dose volume consistent with weight-based dosing of BNZ-1
223523663|NCT02886962|BIOLOGICAL|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
223523664|NCT02886962|DRUG|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
223523665|NCT06043011|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
223523666|NCT05277532|BEHAVIORAL|High intensity interval training (HIIT)|HIIT performed either in the morning or in the afternoon
223523667|NCT03577470|DRUG|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
223523668|NCT04965064|DRUG|Capecitabine and Neratinib.|Neratinib 240 mg PO QD Daily On-going Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going
223523669|NCT05498870|DRUG|Adductor Canal Block (ACB) Only|Patients will receive an ACB with lidocaine skin wheal
223523670|NCT05498870|DRUG|Adductor Canal Block (ACB) + iPACK Block|Patients will receive an ACB with iPACK block
223523671|NCT06045273|BEHAVIORAL|Elders' Resilience Curriculum|The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
223523672|NCT01690533|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
223523673|NCT06639191|DRUG|[177Lu]Lu-AKIR001|"Patient cohorts of a minimum of three and a maximum of 12 evaluable participants will be opened according to the decision tree defined in the protocol and will be consecutively completed. When one cohort has been completed and fully evaluated, the next cohort will be opened after all participants in the previous cohort have received at least one dose of the IMP without dose-limiting toxicities during a follow-up period of at least six weeks.~The \[177Lu\]Lu-AKIR001 protein mass dose and activity are predefined for each cohort, and could be adjusted according to the results of previous cohort(s) to ensure the safety of participants. The initial design of the trial encompasses five cohorts to escalate both \[177Lu\]Lu-AKIR001 pmd, from 50 mg to 100 mg, and activity, from 0.75 to 3.0 GBq."
223705008|NCT00826046|DRUG|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
223705009|NCT05817318|DEVICE|Renal Denervation|Arrhythmia burden pre-to-post renal denervation as assessed by an implantable cardiac monitor
223705010|NCT01024335|DRUG|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
223705011|NCT01024335|DRUG|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
223705012|NCT02761070|DRUG|Temozolomide|
223705013|NCT02761070|DRUG|Bevacizumab|
223705014|NCT05058235|OTHER|Active Release Technique|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Active release Technique 5 reps/ 1 set/ (6 days/ week)~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
223705015|NCT05058235|OTHER|Bent leg raise|"Moist Hot pack 10 mins/1 set/ (6 days/ week), TENS 20 mins/1 set/ (6 days/ week), Quadriceps Isometric Strengthening 5 sec hold, 10 reps/ 1 set/(6 days/ week), Bent leg raise 5 sec hold/ 5 sec stretch/ 3 reps/ 1 min rest interval/ 1 set/ (6 days/ week).~A total of 2 weeks (12 sessions, 6 sessions/ week) were given each consisting of 40 mins."
223705016|NCT06125561|OTHER|Probing depth and Clinical attachment loss|CPTIN probe will be used for the clinical examination
223523674|NCT06640127|PROCEDURE|Sinus lifting and implant placement with osteotomes|Osteotomes with increasing diameters were used for sinus membrane elevation and implant insertion
223523675|NCT06640127|PROCEDURE|Sinus lifting and implant placement with specifically designed drills|Sequential drills were used for sinus membrane elevation and implant insertion
223523676|NCT06641960|DRUG|Probiotics|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction with probiotic lozenges.
223523677|NCT06641960|PROCEDURE|Traditional treatment|In this group, the patients will undergo orthodontic treatment with metallic appliances and receive oral hygiene instruction without probiotic lozenges.
223523678|NCT06639022|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223523679|NCT06639022|PROCEDURE|Erector spinae plane block|"Erector spinae plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223523680|NCT06639022|PROCEDURE|Group without peripheral nerve block|In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
223534978|NCT06133023|PROCEDURE|Plastic stent|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed."
223705017|NCT00362557|DEVICE|MRI|Magnetic resonance imaging
223705018|NCT00515489|DRUG|Risperidone|as prescribed
223705019|NCT02472873|PROCEDURE|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
223523681|NCT06641583|BEHAVIORAL|LEGO|"The LEGO Therapy intervention in this clinical trial is designed to enhance social skills in children with high-functioning Autism Spectrum Disorder (ASD). The intervention involves the following components:~Group Sessions: The therapy will be conducted in small groups of three children of the same age (10-14 years) with a diagnosis of high-functioning ASD. The sessions are designed to foster collaboration and social interaction between the participants.~Duration: The intervention will last for 3 months, consisting of 12 sessions, with each session lasting 90 minutes. Sessions will take place once a week at the IRCCS Fondazione Stella Maris.~Supervision: The groups will be supervised by trained professionals specializing in neurodevelopmental disorders, ensuring that the therapy is structured and supportive of each child\&amp;amp;amp;#39;s individual needs.~Therapy Structure: During the sessions, children will engage in LEGO-based tasks, where they collaborate to build LEGO models."
223523682|NCT06641583|OTHER|Controllo|This group will also consist of children aged 10-14 diagnosed with high-functioning ASD. However, these children will not receive LEGO therapy. Instead, they will continue their usual treatments in their local settings without participating in the LEGO therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of LEGO therapy.
223523683|NCT06644339|DEVICE|Voice assistant|"Robotic remote monitoring of patients using unique algorithms developed for virtual operator speech technology and a BI system by voice commands on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) depending on disease.~Follow-up and management of disease provided by specialists at participating institutions."
223523684|NCT06644859|DEVICE|Daily Activity Patterns Using Wearable Tri-Axial Sensors|This intervention uniquely focuses on the prediction of injurious falls by combining daily life gait (DLG) measures (e.g., gait speed, cadence, variability) with daily life physical activity (DLPA) measures (e.g., activity levels, activity fragmentation). Unlike other studies, this analysis leverages data from a large cohort of older women (n=17,466) enrolled in the Women's Health Study (WHS), where participants wore a tri-axial accelerometer for 1 week. Additionally, the study links accelerometer data to long-term health outcomes, specifically fall-related injuries from Centers for Medicare \&amp; Medicaid Services (CMS) records. This is the first study to explore whether combining DLG and DLPA measures, derived from wearable technology, can predict fall-related injuries in an aging population, applying advanced machine learning techniques to this large, anonymized dataset.
223523685|NCT06505395|DRUG|SYHX2008 injection|The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
223523686|NCT06505395|DRUG|Sandostatin LAR@|The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
223523687|NCT06232993|OTHER|Kinesio taping|Kinesio taping is a technique that involves the application of a special elastic tape to the skin to provide support to muscles and joints without restricting the body's range of motion. This method is designed to facilitate the body's natural healing process and improve muscle function while providing support and stability to muscles and joints. Kinesio tape is believed to help reduce pain, support muscles during movement, and aid in rehabilitation. It is commonly used in sports medicine and physical therapy to address a variety of musculoskeletal conditions and injuries.
223523688|NCT06232993|OTHER|Occlusal Splinting|Occlusal splinting, also known as a bite guard or night guard, is a removable dental appliance typically made of plastic that is custom-fitted to a patient's upper or lower teeth. It is primarily used to address issues related to teeth grinding (bruxism) or temporomandibular joint (TMJ) disorders. The splint is designed to fit over the teeth, creating a barrier between the upper and lower teeth to prevent grinding and clenching during sleep. Occlusal splints aim to reduce the impact of bruxism on the teeth and jaw, alleviate associated pain, protect the teeth from wear, and promote relaxation of the jaw muscles.
223523689|NCT06232993|OTHER|Exercises|For patients with bruxism, exercises can be beneficial in managing symptoms and promoting relaxation of the jaw muscles. These exercises aim to reduce the frequency and intensity of bruxism, alleviate associated pain, and improve overall jaw function and comfort. It's important for patients to consult with healthcare professionals to determine the most appropriate exercises for their individual needs.
223523690|NCT04506437|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
223523691|NCT04506437|BEHAVIORAL|Standard of care engagement practices|Standard of care engagement practices and services-as-usual
223523692|NCT01787747|DRUG|AVP-786 Dose 1|
223523693|NCT01787747|DRUG|AVP-786 Dose 2|
223523694|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 1|
223523695|NCT01787747|DRUG|AVP-786 Dose 1/Q Dose 2|
223523696|NCT01787747|DRUG|AVP-786 Dose 2/Q Dose 2|
223523697|NCT01787747|DRUG|AVP-923|
224275809|NCT00348816|RADIATION|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
223523698|NCT05919498|OTHER|Individual semi-directive interview|"This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour."
223705020|NCT02472873|PROCEDURE|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
223705021|NCT02472873|DRUG|Ethanol|
223705022|NCT02123342|BEHAVIORAL|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
223705023|NCT05490784|OTHER|Lee Silverman Voice Treatment BIG|Patients assigned to experimental group will get Lee Silverman Voice Treatment BIG along with conventional treatment.
223705024|NCT05490784|OTHER|conventional treatment|patients in this group will get conventional treatment program encompassing set of exercises such as complex motor sequences, stretching, dual tasking, mental imagery and core stability.
223705025|NCT00227448|DRUG|intravenous saline|
223705026|NCT00227448|DRUG|intravenous phenylephrine|
223523699|NCT05919498|OTHER|Focus groups|"This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours."
224275810|NCT02288351|OTHER|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
223523700|NCT06017557|DIAGNOSTIC_TEST|Artificial Intelligence|With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.
223523701|NCT06315998|DEVICE|Magnetocardiography|Magnetocardiography
223523702|NCT00748774|BEHAVIORAL|Questionnaire|Two questionnaires taking about 10 minutes to complete.
223523703|NCT03508583|OTHER|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
223523704|NCT05994300|RADIATION|Moderately hypofractionated adaptive radiotherapy (ART)+ High-dose rate (HDR) Brachytherapy|"Experimental: 43.35Gy/17F external beam radiotherapy (EBRT) with adaptive radiotherapy (ART) + HDR-Brachytherapy~Drug: Concurrent Chemotherapy~Weekly cisplatin 40 mg/m2"
223523705|NCT00370578|DEVICE|repeated thrombus aspiration during primary PCI|
223523706|NCT00427700|DRUG|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
223523707|NCT00427700|DRUG|raloxifene|100mg PO on days 5-9 of the menstrual cycle
223523708|NCT02014376|DRUG|SD-101 dermal cream (3%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
223523709|NCT02014376|DRUG|SD-101 Dermal Cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
223523710|NCT02014376|DRUG|Vehicle (SD-101 0%)|A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.
223705027|NCT00227448|DRUG|intravenous levophed|
223523711|NCT04017312|DEVICE|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
223523712|NCT04017312|DEVICE|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
223523713|NCT05681949|OTHER|ADBoard|Utilizing the clinical decision support system 'ADBoard' for therapy selection in participants with hepatobiliary tumors
223523714|NCT04656561|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT
223523715|NCT04656561|OTHER|Sham comparator|Form and Route of Administration: pressure to mimic IVT injection
223523716|NCT06519526|DRUG|SHR-0302|SHR-0302 will be administered orally as tablets.
223523717|NCT06519526|DRUG|SHR-2554|SHR-2554 will be administered orally as tablets.
223523718|NCT06563687|DEVICE|Dexcom ONE+|In all the neonates recruited CGM sensor and transmitter will be placed soon after study enrollment. The sensors will be inserted in the lateral thigh and continuous measurements will be recorded for all the duration of therapeutic hypothermia.
223523719|NCT00843960|BEHAVIORAL|behavioral adaptation and symptom management|behavioral adaptation and symptom management
223523720|NCT06059898|DEVICE|GBR surgery including membrane placement|After the application of local anesthesia, an incision of the mucosa will be performed and the flap will be elevated. The flap closure line should not be directly over the defect, but away from the defect site to prevent wound dehiscence. The bony defect will be thoroughly cleaned and, in some cases, activated by drilling small holes in the cortical bone to increase blood flow into the bone graft. Bone substitute will be inserted, the membrane will be adapted and fixed, and the flap will be sutured
223705028|NCT00227448|DRUG|oral midodrine|
223705029|NCT04746248|OTHER|Outpatient labor induction|The participants stay at home during til labor induction process and are admitted to hospital at the onset of labor or if a complication occur. Outpatient consultations once a day.
224275811|NCT02288351|OTHER|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
223523721|NCT06059898|PROCEDURE|Biopsy|After a healing period of 6 months, at the implantation site, a biopsy is taken from the site of dental implant insertion for further analysis of bone regeneration
223705030|NCT04746248|OTHER|Inpatient labor induction|The participants are induced following standard inpatient care
224083240|NCT02663739|DEVICE|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
223523722|NCT04539288|OTHER||There is no intervention in this study.
223523723|NCT06003504|OTHER|First aid training with blended learning approach|"The content of the first aid blended learning training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of 2 consecutive parts:~1. First aid theory is learned independently in a mobile application followed by an online test to ob-tain an admission ticket for the subsequent in-class training;~2. First aid skills are practiced during a 1-day in-class training facilitated by a certified first aid instructor of the Rwanda Red Cross.~Participants get at least 10 days to learn in the mobile application and obtain the admission ticket."
223523724|NCT06003504|OTHER|First aid training with face-to-face approach|"The content of the first aid face-to-face training is standardised and based on the 2021 edition of the Basic First Aid in Africa manual from the Belgian Red Cross, covering first aid general principles and instructions for:~* emergencies (i.e. choking, unconsciousness with and without normal breathing, chest discomfort and stroke, poisoning, and severe external bleeding);~* injuries (i.e. skin wounds, burns, and injuries to muscles, joints, limbs, head, neck, and back);~* illnesses (i.e. fainting, fever, fits, and diarrhoea).~The training consists of a 3-days in-class training with lectures and practical exercises on first aid the-ory and skills, facilitated by a certified first aid instructor of the Rwanda Red Cross."
223523725|NCT02264366|BEHAVIORAL|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
223523726|NCT02266771|DEVICE|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
223523727|NCT02266771|DEVICE|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
223523728|NCT05177380|PROCEDURE|Personalized rehabilitation program of facial involvement in systemic sclerosis|Personalized rehabilitation program of facial involvement in systemic sclerosis
223523729|NCT05177380|OTHER|Delivery of a standard prescription for facial rehabilitation|Delivery of a standard prescription for facial rehabilitation
223523730|NCT02951481|BEHAVIORAL|Systematic evaluation by an ID expert.|"Specific bundle of measures:~1. Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~2. To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
223523731|NCT00007774|DRUG|Haloperidol|
223523732|NCT00007774|DRUG|Olanzapine|
223705031|NCT05195190|OTHER|Clinical test|The 2 minutes walking test, the time up and go test and the 30 second sit and stand test will be applied to the patients in order. Each test will be repeated 2 times after the familiarization test and the average of the tests will be taken. There will be a 10-minute rest period between tests. For the re-test, the tests will be repeated after the patients are given a rest period of 2 hour. Testing will be conducted by a single therapist with at least 5 years of experience blinded to the study.
223705032|NCT03228433|DRUG|TAK-418|TAK-418 Capsule.
223705033|NCT03228433|DRUG|TAK-418 Placebo|TAK-418 placebo-matching capsules.
223705034|NCT06558097|DRUG|XXB750|Single SC dose of XXB750 (administered by single or multiple injections)
223705035|NCT06558097|OTHER|Placebo|Single SC dose of matching placebo (administered by single or multiple injections)
223705036|NCT03913988|BEHAVIORAL|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
223523733|NCT05504434|DEVICE|Single-use gastroscope|Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
223523734|NCT02699411|DEVICE|Dry needling|dry needling Travell and Simons
223523735|NCT02699411|OTHER|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
223523736|NCT04962516|DEVICE|single-use precision filtered infusion sets|single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)
223523737|NCT04962516|DEVICE|single-use precision filter infusion set with needle|single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)
223705037|NCT03913988|BEHAVIORAL|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
223705038|NCT03913988|BEHAVIORAL|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
223705039|NCT03268993|DIETARY_SUPPLEMENT|Avmacol|Avmacol is a dietary supplement available over the counter
223705040|NCT03985254|OTHER|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]), and in subsequent weeks the goal will be the development of muscle strength (load\> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
223523738|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
223523739|NCT01051661|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
223523740|NCT01051661|BIOLOGICAL|Placebo|Intramuscular injection, one dose
223523741|NCT05929313|DEVICE|OrbusNeich Scoreflex TRIO|To dilate coronary arteries during the subject's index procedure with Scoreflex TRIO Scoring PTCA catheters
223523742|NCT05929313|DEVICE|OrbusNeich Scoreflex NC|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
223523743|NCT03809533|DRUG|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
223523744|NCT02881827|RADIATION|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
223523745|NCT02881827|OTHER|Placebo|Simulation of treatment with the device switched off
223523746|NCT02881827|OTHER|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
223523747|NCT04642079|BIOLOGICAL|20vPnC|20-valent pneumococcal conjugate vaccine
223523748|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
223523749|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
223523750|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
223523751|NCT01350323|PROCEDURE|Aqueous sample|Aqueous sample (0.1ml)
223523752|NCT05632393|DRUG|Daridorexant|Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
223523753|NCT05931822|OTHER|Silver Diamine Fluoride 38%|silver diamine fluoride 38% brushed on the cavity for 1 minute before adding high viscosity glass ionomer restoration in one molar
223523754|NCT05931822|OTHER|fluoride varnish|fluoride varnish brushed after adding the high viscosity glass ionomer restoration in the contralateral molar
223523755|NCT02412982|DRUG|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
223523756|NCT02412982|DRUG|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
223523757|NCT03097978|DEVICE|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
223523758|NCT03097978|DEVICE|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
223523759|NCT03097978|OTHER|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
223523760|NCT03097978|OTHER|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
223523761|NCT01172392|DRUG|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
223523762|NCT01172392|DRUG|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
223523763|NCT04486677|BEHAVIORAL|Caring Cards Group|Group of Veteran card-makers.
223523764|NCT04486677|BEHAVIORAL|Caring Cards Recipients|Group of Veteran card-recipients.
223523765|NCT06341335|DRUG|cadonilimab|iv, q3w
223523766|NCT06341335|DRUG|pulocimab|iv, q3w
223523767|NCT06341335|DRUG|paclitaxel|iv, q3w
223523768|NCT06341335|DRUG|placebo|iv, q3w
223523769|NCT03030534|COMBINATION_PRODUCT|Educational package and software package|Using Information and communication technology to deliver health promoting activities
223705041|NCT03985254|OTHER|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load \<50% of the one repetition maximum test \[1RM\]). However, in subsequent weeks the goal will be to develop strength (load\> 70% 1RM) and muscle power (load between 40-60% 1RM).
223705042|NCT04261036|DRUG|Ascorbic Acid 1000 mg|1000 mg ascorbic acid (Vitamin C) for 14 days post-op after an elective gynecological surgery.
223523770|NCT03030534|OTHER|Health promotion tips|Give general information on health promotion
223523771|NCT02668757|BEHAVIORAL|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
223523772|NCT04547387|DEVICE|Trans-carotid access revascularization with MicroNET covered stent implantation|Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
223705043|NCT04261036|OTHER|Placebo|Placebo pills for 14 days post-op after an elective gynecological surgery.
223705044|NCT03677427|RADIATION|Radiation|Radiation in breast cancer
223523773|NCT04270019|DRUG|Polyethylene Glycol 3350|In order to prepare PEG 3350 50% weight/volume, 25 grams of the sterilized PEG 3350 will be measured out and placed into a sterilized glass bottle then 25 mL of sterile water will be added. The solution will be allowed to rest for 10 minutes so that dissolution may occur. More sterile water will then be added so the total volume is 50mL. This solution will then be sterilized by the Halifax Health Infirmary pharmacy department using a liquid autoclave cycle of 120 degrees Celsius for 20 minutes in a glass vial. The 50 mL solution will be portioned into 2mL sterilized glass vials using a standard aseptic technique. The solutions will be kept at a solid frozen state between negative 25 degrees Celsius and negative 10 degrees Celsius for a maximum of 45 days. The solutions will be removed from storage on the day of surgical utilization in order to ensure storage guidelines are kept to the highest standards.
223523774|NCT04270019|DRUG|Normal Saline|Standard solution of sterile normal saline.
223523775|NCT01526200|PROCEDURE|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
223523776|NCT00635050|DRUG|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience \<pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
223523777|NCT06116097|BEHAVIORAL|Nutrition education|Fifty participants took 6 physical nutrition education lectures and the other group (n=33) didn't have any nutrition education. Nutrition education was comprimised of 6 physical face to face 60 minutes sessions which was given every week in a school class. Each session was consisted of a different subject including energy metabolism in sport, energy balance, nutrition before and after training, low energy availability, macro and micronutrients, hydration and supplements. Participants also got written information as a printed booklet in order to be able to take notes under sessions and review after the sessions.
223523778|NCT06489509|DEVICE|Positive End Expiratory Pressure 5 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
223523779|NCT06489509|DEVICE|Positive End Expiratory Pressure 10 H2O|Positive End Expiratory Pressure 5 H2O from CPAP apparatus
223523780|NCT00386581|DRUG|atomoxetine|
223523781|NCT00386581|DRUG|placebo|
223523782|NCT03038620|DRUG|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
223523783|NCT03038620|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
223523784|NCT00176748|DRUG|AG 6013736|5 mg po bid
223523785|NCT00473174|DRUG|Ramipril|Dosing on awakening versus bedtime
223523786|NCT00473174|DEVICE|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
223523787|NCT01711099|DEVICE|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
223523788|NCT04011241|DRUG|BI 1323495|Tablet
223523789|NCT04011241|DRUG|Itraconazole|Oral solution
223523790|NCT01871922|DRUG|Placebo|Saline
223523791|NCT01871922|DRUG|Atropine|Atropine
223523792|NCT03653819|OTHER|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
223523793|NCT03653819|OTHER|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
223523794|NCT04817956|DRUG|Atezolizumab|drugs used outside indication, based on biomarker
223523795|NCT03196778|RADIATION|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
223523796|NCT01648322|DRUG|F-627|subcutaneous injection given 1 per chemotherapy.
223523797|NCT01648322|DRUG|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
223523798|NCT00759395|DRUG|AZD2327|Tablet, Oral, Daily
223523799|NCT00759395|DRUG|Placebo|Tablet, Oral, Daily
223523800|NCT00157261|DRUG|tenecteplase|
223523801|NCT00165607|DRUG|MENATETRANONE|
223523802|NCT02304185|BIOLOGICAL|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
223523803|NCT02304185|BIOLOGICAL|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
223523804|NCT02304185|BIOLOGICAL|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
223705045|NCT05081765|DRUG|Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)|correlation between C through and taken drug
223523805|NCT02304185|BIOLOGICAL|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
223523806|NCT02304185|DRUG|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
223523807|NCT03983239|DRUG|Fedratinib|Fedratinib
223523808|NCT03983239|DRUG|Rifampin|Rifampin
223523809|NCT03983239|DRUG|Efavirenz|Efavirenz
223523810|NCT01233947|DRUG|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
223523811|NCT01233947|DRUG|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
223523812|NCT01842347|OTHER|Fecal microbiota|
223523813|NCT02290912|BEHAVIORAL|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
223523814|NCT04244734|OTHER|Usual care treatment|"All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
223523815|NCT04244734|OTHER|New Treatment Protocol-MotoMED®|"Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment: A daily session from Monday to Friday of 40 minutes (5 minutes of warm-up, 30 of training and 5 of cooling). Combined quadriceps / biceps femoris electrotherapy: at 200-350μs intensity. Respiratory physiotherapy with the objectives: Airway permeabilization and inspiratory muscle training at 60% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)"
223523816|NCT04233892|DRUG|CBD-bFGF|CBD-bFGF will be injected into the endometrium after hysteroscopy under the guidance of ultrasound
223523817|NCT04233892|DRUG|Collagen/BMMNCs|A collagen scaffold loaded with BMMNCs will be transplanted into the uterine cavity after hysteroscopy under the guidance of ultrasound
223523818|NCT04233892|DRUG|Estrogen|Patients will receive regular estrogen therapy
223523819|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
223523820|NCT02041273|DRUG|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
223523821|NCT02041273|DRUG|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
223523822|NCT00421967|DRUG|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
223523823|NCT00421967|DRUG|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
223705046|NCT05081765|DEVICE|Lynparza|correlation between C through and taken drug
223705047|NCT06095804|DEVICE|Percutaneous Ultrasound Jejunostomy|Placement of a jejunostomy tube using the PUMA-J System
223705048|NCT02292121|PROCEDURE|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
223523824|NCT02009787|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
223523825|NCT02009787|DRUG|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
223523826|NCT01535482|BEHAVIORAL|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
223523827|NCT01535482|BEHAVIORAL|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
223523828|NCT01758120|DRUG|prednisone plus cyclophosphamide|"1. prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day\*6 months) plus cyclophosphamide(1g intravenous use,per 1 month\*6months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
223523829|NCT01758120|DRUG|Prednisone alone|"1. prednisone alone: prednisone(0.5mg/kg/day\*6 months);~2. supportive care,including ACE-I or ARBs and blood pressure control"
223705049|NCT02292121|OTHER|a solution of mannitol and lactitol|
223705050|NCT01033760|DRUG|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
223705051|NCT01033760|DRUG|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
223705052|NCT04988139|OTHER|individualized educational training|50 min per session, one session per week, 4 sessions per month, of individualized educational training to preschool children with developmental delays under traditional rehabilitation programs
223523830|NCT01652404|BEHAVIORAL|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
223523831|NCT01652404|BEHAVIORAL|Conventional treatment|The antibiotics duration will be determined by treating physician.
223523832|NCT04519567|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
223523833|NCT04519567|BIOLOGICAL|Placebo|Placebo Comparator
223523834|NCT03327129|PROCEDURE|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
223523835|NCT02311504|DEVICE|OCT examination|
223523836|NCT01648933|RADIATION|Rubidium PET|Myocardial Perfusion Imaging
223523837|NCT02071732|DEVICE|real repetitive Transcranial Magnetic Stimulation|
223523838|NCT02071732|DEVICE|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
223523839|NCT05536115|DEVICE|Alveogyl|"The patients will be treated by Alveogyl. Global treatment protocol (curettage, cleaning, local anaesthesia etc.) of the dry socket is at the discretion of the Investigator.~Alveogyl is used as an alveolar dressing. Placement of Alveogyl (about 0.2 g of paste) into the dental socket is done according to its instruction for use by a dental professional only."
223523840|NCT01435356|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
223523841|NCT01435356|BIOLOGICAL|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
223523842|NCT00265499|PROCEDURE|Skeletonization of the internal thoracic artery|
223523843|NCT06205693|PROCEDURE|Fast Degradable, Biodegradable ARCHEMEDES stent|Fast Degradable, Biodegradable ARCHEMEDES stent. Placed in the pancreaticojejunostomy.
223523844|NCT03196479|DRUG|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
223523845|NCT03196479|DRUG|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
223523846|NCT00205985|DEVICE|Scaphoid screw|Conservative treatment versus application of scaphoid screw
223705053|NCT06445296|OTHER|High-fat meal containing beef|High-fat meal (eggs cooked in butter, croissant) with 80% ground beef.
223705054|NCT06445296|OTHER|High-fat meal containing Beyond Meat|High-fat meal (eggs cooked in butter, croissant) with Beyond Meat Cookout Classic.
223523847|NCT03236545|OTHER|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).
223523848|NCT03236545|OTHER|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
223523849|NCT03270228|OTHER|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
223523850|NCT03855540|DIAGNOSTIC_TEST|ECHOcardiography|"ECHO parameters~1. LA diameter~2. LVEDD~3. LVEF~4. Diastolic dysfunction~5. Valvular disease"
223705055|NCT03872154|OTHER|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
223523851|NCT03855540|DIAGNOSTIC_TEST|Peripheral blood samples for plasmatic biomarkers|"1. Coagulation~   * D - dimer~  * Fibrinogen~2. Inflammation and fibrosis~   * Hs - CRP~  * AGEs~  * Soluble RAGE~3. Hemodynamics (LA stretch)~   * Apelin~  * NT - proBNP~  * Hs - troponin~4. MiRNA~   * miRNA - 1~  * miRNA - 133~  * miRNA - 29b~  * miRNA - 208a~  * miRNA - 208b~  * miRNA - 499"
223523852|NCT03855540|DIAGNOSTIC_TEST|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
223523853|NCT03855540|DIAGNOSTIC_TEST|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
223523854|NCT03855540|DIAGNOSTIC_TEST|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
223523855|NCT01481610|DRUG|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
223523856|NCT01481610|DRUG|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
223523857|NCT02386956|OTHER|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
223523858|NCT02386956|OTHER|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
223523859|NCT02386956|OTHER|Control|10 minutes with the patient lying on a machine off of magnetotherapy
223523860|NCT02318433|DRUG|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
223523861|NCT02318433|DRUG|Saline|
223523862|NCT00860496|DRUG|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
223523863|NCT00860496|DRUG|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
223523864|NCT00437073|DRUG|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
223705056|NCT05100459|DIETARY_SUPPLEMENT|Pasture-raised whey protein|25 grams of protein delivered 3 times daily
223705057|NCT05100459|DIETARY_SUPPLEMENT|Conventional whey protein|25 grams of protein delivered 3 times daily
223705058|NCT05100459|DIETARY_SUPPLEMENT|Placebo|Iso-caloric placebo taken 3 times daily like the protein supplementation
223705059|NCT02662829|BEHAVIORAL|Community-based intervention|
223705060|NCT02662829|OTHER|Standard of care|
223523865|NCT00437073|DRUG|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
223523866|NCT00437073|DRUG|lapatinib|lapatinib administered 1250mg once daily orally
223523867|NCT00020683|DRUG|incyclinide|High dose given orally
223523868|NCT00020683|DRUG|incyclinide|Low dose given orally
223705061|NCT02765269|DEVICE|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
223705062|NCT01030536|DRUG|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
224275812|NCT02288351|OTHER|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
223523869|NCT00020683|OTHER|laboratory biomarker analysis|Correlative studies
224275813|NCT02288351|OTHER|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
224275814|NCT02288351|OTHER|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
224275815|NCT02288351|DEVICE|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
224275816|NCT04440709|DEVICE|Brain/neural hand exoskeleton (B/NHE)|The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
223523870|NCT03774381|DIETARY_SUPPLEMENT|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
223523871|NCT03774381|DIETARY_SUPPLEMENT|Control group|160 mg of placebo is orally administered per day for 12 weeks.
223523872|NCT06473714|DEVICE|tDCS|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will be made at 1,5mA
223523873|NCT06473714|DEVICE|SHAM|Transcranial direct current stimulation of the dorsolateral prefrontal cortex will not be made. The electrodes are placed on the skull and a slight but non-continuous intensity is applied.
223523874|NCT03123679|RADIATION|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"1. Patient referred to radiotherapy treatment are evaluated with a baseline PFT \[Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)\].~2. RT simulation at the radiotherapy department and treatment planning.~3. Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~4. Radiotherapy."
223523875|NCT05321745|OTHER|Standardized FMT|Fecal microbiota transplantation of fresh bacteria from healthy donor to the whole colon
223523876|NCT03731572|OTHER|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
223705063|NCT01030536|DRUG|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
224275817|NCT03186716|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
224275818|NCT03186716|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
224275819|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
224275820|NCT02483936|DRUG|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
224275821|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
224275822|NCT02483936|DRUG|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
223523877|NCT03731572|OTHER|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
223523878|NCT04875533|BIOLOGICAL|20vPnC|20vPnC
223523879|NCT04875533|OTHER|Saline|Saline
223523880|NCT04875533|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
223523881|NCT04875533|BIOLOGICAL|PPSV23|Pneumococcal polysaccharide vaccine
223705064|NCT01030536|DRUG|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
223705065|NCT01030536|DRUG|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
223705066|NCT01030536|DRUG|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
223705067|NCT02121431|BEHAVIORAL|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
223705068|NCT05792501|DEVICE|Mechanical ventilation|type of therapy that helps you breathe or breathes for you when you can't breathe on your own
223893698|NCT02986698|BIOLOGICAL|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
224275823|NCT06434324|PROCEDURE|Saline Irrigation|250 cc waves of warmed saline irrigation (up to 2000 cc) through thoracostomy tube on a daily basis
223523882|NCT01275300|DRUG|Aspirin|
223523883|NCT01275300|DRUG|Placebo|
223523884|NCT01275300|DRUG|Niacin|
223523885|NCT03227549|PROCEDURE|Direct Superior Approach|Total hip arthroplasty using direct superior approach
223523886|NCT03227549|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
223523887|NCT03227549|PROCEDURE|Posterior Approach|Total Hip Arthroplasty using posterior approach
223523889|NCT04751357|DIAGNOSTIC_TEST|ECA-Test (Clot-Pro)|Thrombelastometric ECA-Test performed on Clot-Pro
223523890|NCT02657343|DRUG|Ribociclib|
223523891|NCT02657343|DRUG|T-DM1|
223523892|NCT02657343|DRUG|Trastuzumab|
223523893|NCT02657343|DRUG|Fulvestrant|
223523894|NCT03416387|DEVICE|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
223523895|NCT00811850|DRUG|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
223523896|NCT00811850|DRUG|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
223523897|NCT00044733|DRUG|Mylotarg (gemtuzumab ozogamicin) Injection|
223523898|NCT01333787|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
223523899|NCT02011542|DRUG|VSL#3|This is a probiotic mixture
223523900|NCT02011542|DRUG|Placebo|This is a pill with inactive ingredients.
223523901|NCT05713292|DRUG|Pirfenidone Oral Product|Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
223523902|NCT05713292|DRUG|Pirfenidone placebo|Pirfenidone placebo
223523903|NCT06312059|OTHER|Advance Infant Formula Powder|Sole source infant nutrition for the control arm.
223523904|NCT06312059|OTHER|"Kendamil Cow milk test product"|Sole source infant nutrition for the cow milk test arm.
223523905|NCT06312059|OTHER|"Kendamil goat milk test product"|Sole source infant nutrition for the goat milk test arm.
223523906|NCT03988205|BEHAVIORAL|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
223523907|NCT03988205|DRUG|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
223523908|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin)|Kit to test the concentration of Immunoglobulin G anti-SARS-CoV-2 in the plasma of included patients
223523909|NCT05338736|DIAGNOSTIC_TEST|LIAISON SARS-CoV2-IgM (DiaSorin)|Kit to test the concentration of Immunoglobulin M anti-SARS-CoV-2 in the plasma of included patients
223523910|NCT05338736|DIAGNOSTIC_TEST|Human IFN-g ELISpot PLUS (ALP) (AUROGENE)|Kit to test the cellular immunity response by measuring the Interferon gamma released by mononuclear cells (PBMCs)
223523911|NCT00951639|DIETARY_SUPPLEMENT|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
223523912|NCT00951639|PROCEDURE|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
223523913|NCT00951639|DIETARY_SUPPLEMENT|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
223523914|NCT04412746|DRUG|MANAGEMENT OF COVID-19|"MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient."
223523915|NCT06549231|DRUG|Rituximab|one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
223523916|NCT06549231|DRUG|Placebo|one course of intravenous placebo of rituximab consisting of an infusion of 500 mL of saline (0.9% sodium chloride) infusion will be given at day 1, day 15 and week 24;
223523917|NCT00072995|BEHAVIORAL|Four Diets Differing in Macronutrient Composition|
223523918|NCT00072995|BEHAVIORAL|Diets Low in Saturated Fat|
223523919|NCT00330733|DRUG|Salsalate|Participants were randomized to 12-week treatment with up to 4 g/day.
223523920|NCT00330733|DRUG|Placebo|Participants were randomized to 12-week treatment matching the active salsalate arm.
223893699|NCT01703806|PROCEDURE|Early Surgery|MItral valve surgery
223893700|NCT01703806|PROCEDURE|Watchful Observation|Watchful observation
223893701|NCT06354010|GENETIC|Genotyping|Genotyping to determine if patients present mutations to the gene GJB2.
223893702|NCT06354010|OTHER|Audiological assessments|Audiological assessments
223523921|NCT01836354|BEHAVIORAL|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
223523922|NCT03014115|DIETARY_SUPPLEMENT|combination ARA + DHA|combination ARA + DHA supplemented infant formula
223523923|NCT03014115|DIETARY_SUPPLEMENT|DHA|DHA supplemented infant formula
223523924|NCT00751985|OTHER|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
224275824|NCT05932810|BEHAVIORAL|Behavioral Activation Therapy app|Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
223523925|NCT00751985|OTHER|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
223523926|NCT00751985|OTHER|Control|The participant is being informed about their allocation to the control group.
223523927|NCT05226195|OTHER|Sterile Kinesio Taping|The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
223523928|NCT00982280|DRUG|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
223523929|NCT00146822|DEVICE|ENDOTAK RELIANCE G lead|
223523930|NCT01979185|DRUG|Simvastatin|
223523931|NCT01979185|DRUG|SSP-004184SS|
223523932|NCT02941029|OTHER|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
223523933|NCT00980798|DRUG|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
223523934|NCT00980798|DRUG|Placebo|placebo tablet once daily for 16 weeks
223523935|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
223523936|NCT03966547|PROCEDURE|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
223523937|NCT03074669|BEHAVIORAL|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
223523938|NCT02522273|DEVICE|EKF Diagnostics 'SensPoint' Lactate Meter|
223523939|NCT01422577|DEVICE|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
223523940|NCT01422577|DEVICE|White light Endoscopy|White light Endoscopy
223523941|NCT05611164|DEVICE|Software assisted selection of individual spermatozoa for intracytoplasmic sperm injection|Half of the oocytes will be injected with a sperm selected with SiD's assistance
223523942|NCT03283956|DEVICE|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
223523943|NCT05562856|COMBINATION_PRODUCT|surface pre-reacted glass filler coating material|the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
223523944|NCT05706350|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
223523945|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (2g per day)|Participants have to consume 4 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 2g daily
223523946|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (3g per day)|Participants have to consume 6 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 3g daily
223523947|NCT05706350|DIETARY_SUPPLEMENT|Plant stanol soft chews (4g per day)|Participants have to consume 8 soft chews per day containing 0.5g plant stanols each (delivered as plant stanol esters), corresponding to a total plant stanol intake of 4g daily
223523948|NCT05706350|DIETARY_SUPPLEMENT|Control soft chews|Participants have to consume 6 control soft chews per day that does not contain plant stanols
223523949|NCT04221438|DRUG|Binimetinib|Given PO
223523950|NCT04221438|PROCEDURE|Conventional Surgery|Undergo surgery
223523951|NCT04221438|DRUG|Encorafenib|Given PO
223523952|NCT04221438|OTHER|Fluorothymidine F-18|Given IV
224275825|NCT05932810|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
223523953|NCT06325410|PROCEDURE|resection of colorectal cancer|resection of bowel segment and re-anastmosis or stoma formation
223523954|NCT03749239|DIETARY_SUPPLEMENT|Collagen protein|Collagen protein
223523955|NCT05007704|BEHAVIORAL|Global Experts Consensus opinion using Delphi Methodology|The Investigators will conduct iterative Delphi Rounds with Global experts to achieve consensus on Competencies required for Anesthesiologists to manage critically ill medical and surgical patients in ICU
223523956|NCT01441492|PROCEDURE|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
223523957|NCT01441492|PROCEDURE|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
223523958|NCT03510533|OTHER|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
223523959|NCT04724837|DRUG|Zibotentan|Participants will receive zibotentan as per the arms they are randomized.
223523960|NCT04724837|DRUG|Dapagliflozin|Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
223523961|NCT04724837|DRUG|Placebo|Participants will receive placebo as per the arms they are randomized to.
223523962|NCT05962736|DEVICE|Mirror therapy|The patients received a total of 24 sessions of treatment for 8 weeks, 3 sessions a week, starting from the postoperative 1st day after thorakaotomy. Each treatment session lasts between 60 and 90 minutes.
223523963|NCT05018728|DRUG|Voxelotor|Voxelotor is taken orally once a day. Participants 12 years or older will take 1500 mg/day. Participants younger than 12 years of age will receive a dose based on their body weight to provide exposure corresponding to the adult dose of 1500 mg/day.
223523964|NCT04375358|BIOLOGICAL|Blood and urine samples|To measure the clearance of creatinine, urea, potassium, magnesium, sodium, chlorine...
223705069|NCT06395545|DEVICE|Electronic injector|At room temperature, 1% lidocaine combined with 1:100,000 epinephrine was used as a local anesthesia. The electronic constant-speed injector, i-JECT® (MediHub Inc., Gyeonggi-do, Korea) (Figure 1) was used, and the injection speed of the injector was set at level 1 (0.25 mL/s) or level 2 (0.4 mL/s). The injection site in a patient was divided into two sides (left and right). The method of local infiltration (manual or using the electronic injector) was randomly assigned to each side of the surgical field, and 2.5 cc (0.5 cc at five separate areas) of local anesthetic was injected individually using a 5 cc syringe with a 31-gauge needle. All injections were administered by a single surgeon (Sung Joo Tommy Hwang) to reduce inter-operator variation.
223705070|NCT00324909|DRUG|Hyperbaric Oxygen Therapy|
223705071|NCT03847246|DRUG|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
223705072|NCT03847246|DRUG|Entecavir tablets,1.0 mg|oral,once,under fasting condition
223705073|NCT03218644|OTHER|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
223705074|NCT03218644|OTHER|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
223523965|NCT00522379|DRUG|Rotigotine|2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
223705075|NCT03242889|DRUG|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
223523966|NCT00522379|DRUG|Rotigotine|4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
223523967|NCT00522379|OTHER|Placebo|Placebo transdermal patch applied daily
223523968|NCT00522379|DRUG|Rotigotine|6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
223523969|NCT00522379|DRUG|Rotigotine|8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
223523970|NCT03901365|OTHER|Neuroscience pain education|In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
223523971|NCT03901365|OTHER|Traditional patient education|In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
223523972|NCT03901365|OTHER|Manual therapy|Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
223523973|NCT01613586|DRUG|ASP3652|Oral
223523974|NCT01613586|DRUG|Placebo|Oral
223523975|NCT04198402|BIOLOGICAL|Biological sampling|Blood sample (5mL) for metabolomic dosage and Fecal sample for ARN16s sequencing
223523976|NCT03135067|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
223523977|NCT05196620|OTHER|Endoanal Ultrasound (EAUS)|Endoanal Ultrasound pre- and postpartum
223523978|NCT02100826|DRUG|Cephalexin|Administered orally.
223893703|NCT06109753|PROCEDURE|Robotically Assisted Laparoscopic Surgery|robotically assisted surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
223523979|NCT05348421|PROCEDURE|FTPB|A 22-gauge needle will be advanced from anterior using an in-plane technique and passed through the posterior 'tail' of the transversus muscle. the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg will be injected to separate the transversalis fascia from the transversus muscle.
223523980|NCT05348421|PROCEDURE|PENG Block|A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly where the local anesthetic solution of 0.25% bupivacaine will be injected for a total volume of 0.5 ml/kg
223523981|NCT00877656|BIOLOGICAL|HuMax-CD4|Active treatment
223523982|NCT01676870|BEHAVIORAL|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
223523983|NCT01676870|BEHAVIORAL|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
223523984|NCT01676870|BEHAVIORAL|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
223523985|NCT00894881|PROCEDURE|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
223523986|NCT03429088|BEHAVIORAL|Motivational interviewing telephone counseling|
223523987|NCT06466642|BEHAVIORAL|Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©|The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.
223523988|NCT05189678|OTHER|No intervention|No intervention
223523989|NCT00019448|DRUG|gp100 antigen|
223523990|NCT00019448|DRUG|interleukin-2|
223523991|NCT05105724|BIOLOGICAL|PRP|PRP was prepared using double centrifugation of the patient's autologous whole blood, and 400 µL of PRP was injected via vaginal puncture into the ovarian parenchyma.
223523992|NCT06048042|BIOLOGICAL|Autogenous Demineralized Dentin Graft|The participant's own freshly extracted tooth will be cleaned from periodontal ligaments, cementum, soft tissue attachment, caries, or restorations (if present) and have their crown decapitated, using a high- speed fine finishing stone and saline irrigation. The pulp chamber and root pulp will be cleaned by split opening the root and cleaning it out using a high-speed diamond bur. Subsequently, teeth will be ground, and demineralized using a hand bone mill. Then the particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid5 for 30 min then washed twice in saline and dried with sterile gauze. Then it will be used as a graft for the intra-bony defect after modified minimally invasive surgical technique.
223523993|NCT06048042|BIOLOGICAL|Autogenous Bone Graft|Modified minimally invasive surgical technique (M-MIST) will be performed in the intra-bony defects, with autogenous bone graft placement. The graft will be harvested from the retromolar area using automatic chip maker (ACM) bur and a hand bone mill will be used to grind the chips into particles, then it will be placed in the defect.
223523994|NCT03316430|OTHER|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
223523995|NCT00091975|DRUG|Zemplar Capsule|
223523996|NCT05920252|BEHAVIORAL|Vira|"Intensive outpatient DBT supported by the Vira platform. The Vira app is installed on the patient's smartphone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Patients will be asked to use Vira for the duration of their intensive outpatient treatment. Patients' use of the Vira app is supported by practitioners, who can schedule just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan and DBT treatment. The Vira Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the practitioner's workflow."
223523997|NCT05920252|BEHAVIORAL|Treatment as Usual (TAU)|Intensive outpatient DBT + EARS app (passive data monitoring software)
223523998|NCT05697224|DIAGNOSTIC_TEST|urinary micro RNA detection|Urinary Sha-miR-71a gene expression analysis Total RNA extraction and purification Sha-miR\_71a gene expression analysis MAPK-3 gene expression analysis
223523999|NCT05838248|OTHER|antibiotic duration|Duration of antibiotic treatment post appendectomy
223524000|NCT06468176|OTHER|Cognitive Behavioral Therapy (CBT) neuropsychologist|"* CBT: at least 3 teleconsultations by the neuropsychologist (up to 1/week maximum)~* Brain Head Quarters (BrainHQ) Digital program: 4 sessions of 40 minutes / week"
223524001|NCT03763370|DRUG|Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)|"Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles"
223893704|NCT06109753|PROCEDURE|Conventional Laparoscopic Surgery|conventional surgeries of about 60-minute duration with additional 30 min for preparing with the measurement equipment before surgery and 15 post evaluation of the corresponding surgery
224083241|NCT01897467|BEHAVIORAL|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
224275826|NCT02046317|DRUG|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
223524002|NCT03763370|DRUG|Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)|"Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information"
223524003|NCT06548971|DRUG|Aspirin|Patients in the interventional group will chew 300mg of aspirin enteric-coated tablets as soon as possible after randomization. If swallowing difficulties arise, the tablets can be crushed and administered via a nasogastric tube.
223524004|NCT06548971|DRUG|Placebo|Patients in the control group will chew 300mg of placebos as soon as possible after randomization. If swallowing difficulties arise, the placebo can be crushed and administered via a nasogastric tube.
223524005|NCT06548971|OTHER|Best medical management|Patients in both groups will receive the best medical management according to the guidelines.
223524006|NCT02954562|OTHER|fMRI|Participants will undergo two to three fMRI scans
223524007|NCT05189860|DEVICE|C-MIC system|This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.
223524008|NCT06036368|DEVICE|Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)|This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve
223524009|NCT05766254|DEVICE|Active 10-Hz TMS to the DLPFC|The active group will receive 10hz TMS stimulation. Participants in the active stimulation group will receive10-Hz TMS to left DLPFC. The LDLPFC will be based on 4 targeting neuroimaging methods (cortical thickness, fMRI, diffusion imaging, functional connectivity). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
223524010|NCT05766254|DEVICE|Sham TMS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223524011|NCT05789290|DEVICE|Hilotherm cryocompression device|An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
223524012|NCT04344912|OTHER|Data collection|Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
223524013|NCT04498767|RADIATION|Stereotactic body radiotherapy|Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
223705076|NCT04767620|DRUG|Rugdenzengsheng No. 1 prescription|The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
223705077|NCT02509481|DRUG|Ivermectin|
223705078|NCT02509481|DRUG|Albendazole|
223705079|NCT05938062|PROCEDURE|the group without fibrinogen concentrate (GNF) , the group with fibrinogen concentrate (GF)|the group without fibrinogen concentrate (GNF, ) the group with fibrinogen concentrate (GF)
223705080|NCT03289858|DRUG|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
223705081|NCT03289858|DRUG|Sodium Chloride|Saline Injection
223705082|NCT03226860|DEVICE|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
223705083|NCT03226860|OTHER|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
223705084|NCT01549678|OTHER|Total contact insole|EVA insole shaped on patient´s foot.
223705085|NCT01549678|OTHER|placebo insole|EVA insole flat
223705086|NCT01760720|BEHAVIORAL|MMT CARE|
223705087|NCT05587803|DEVICE|Neurowave and Sedline indices in view|3 additional electrodes are attached on the patients forehead. After electrode placement, the indices of both the SEDLINE device and the NEUROWAVE device are noted every 5 seconds for 1 minute
223705088|NCT03617497|DIAGNOSTIC_TEST|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
223705089|NCT03617497|DIAGNOSTIC_TEST|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
223705090|NCT03154164|DEVICE|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
223705091|NCT03918473|OTHER|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
224083242|NCT01897467|BEHAVIORAL|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
223524014|NCT04498767|RADIATION|Palliative RT|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
223524015|NCT05855993|OTHER|Nerve Glide Exercise with Ultra Sound|A brief demonstration will be given to perform the nerve glides exercises to both group. The duration of exercise programmed is 15 minutes every 3 to 5 times per day for 4 weeks. Group A will perform exercise with ultrasound
223524016|NCT05855993|OTHER|Nerve Glide Exercise without Ultra Sound|Group B will perform exercise for 10 minutes every 3 to 5 times per day without ultrasound.
223524017|NCT06638775|OTHER|Fesia Grasp|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
223524018|NCT06638775|OTHER|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
223524019|NCT06637670|OTHER|Kinesiology taping|'Y shaped' kinesiology taping was applied on quadriceps femoris muscle, based on facilitation technique with 25-50% stretching.
223524020|NCT06637670|OTHER|Placebo taping|A tape without tension was applied perpendicular on the quadriceps femoris muscle.
223524021|NCT06253767|PROCEDURE|Endodontic Treatment|Conventional endodontic treatment will be performed equally on all participants.
223524022|NCT06253767|DEVICE|Low Level Laser Therapy|Treatment Group (TG) will receive photobiomodulation for molars with 808nm application (AsGaAl), infrared, equipment with a power of 100 mW, and an exit beam area of 1 cm² perpendicular in contact with the mucosa at the level of the root apices at two vestibular points and one complementary palatal point, with 3J of energy per point (30s per point), totaling 9J of total delivered energy and 90 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 9J/cm² overall. To premolars the parameters will be 808nm application (AsGaAl), infrared, Laser Duo® equipment with a power of 100 mW and an exit beam area of 1cm² perpendicular in contact with the mucosa at the level of the root apices at one vestibular point and one complementary palatal point, with 3J of energy per point (30s per point), totaling 6J of total delivered energy and 60 seconds of application time. The Radiant Exposure is 3J/cm² per point, totaling 6J/cm² overall
223524023|NCT06253767|DEVICE|Simulation Low Level Laser therapy|A simulation of low-level laser therapy was performed on the control group starting from patient preparation (placement of glasses) and the reproduction of device sounds without activation.
223524024|NCT05949385|DRUG|ZX-7101A|Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules
223524025|NCT05706740|OTHER|Physician survey on antithrombotic medication during end-of-life care in cancer patients|"Participating healthcare professionals will be asked to complete the survey electronically within seven days. The survey will consist of general questions (i.e., Have you ever considered deprescribing antithrombotic medicine?), a discrete choice experiment (DCE), and questions involving actual decision-making in patients.~For the DCE, participants will be presented a sequence of choice sets with (hypothetical) scenarios that vary along several characteristics (attributes; e.g., bleeding risk, thrombotic risk). Attributes will be further specified by varying choice levels (attribute levels; e.g., low or high bleeding risk). Participants will be asked to select the healthcare intervention with the highest benefit for the patient according to their opinion.~Finally, participants will be asked to describe actual decisions they made in max. three consecutive patients with active cancer, who were considered to receive end-of-life care."
223524026|NCT00684580|OTHER|Data Collection|Continuing review of outcomes and late toxicities
223524027|NCT04859075|OTHER|Bifidobacterium longum 35624|1 capsule daily
223524028|NCT05790031|DEVICE|Intelligent Nighttime Brace|Participants will be invited to undergo a fitting session of intelligent nighttime brace. After the fitting, participants will join a 6-month wear trial of the intelligent nighttime brace. Participants are required to wear the intelligent nighttime brace for 8 hours a day during sleeping and compliance will be recorded by an intelligent monitoring system. Participants will be invited to undergo assessments before the wear trial, after the trials of 3 months and after the trial of 6 months. The measure outcomes of the assessment include 1)ultrasound scanning image, 2)3D body scanning, 3)garment pressure, 4) questionnaires
223524029|NCT02614248|OTHER|Organic, Unrefined Coconut Oil|
223705092|NCT03918473|OTHER|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
223705093|NCT05397964|DEVICE|Radiopaque Calcium Hydroxide Composition|Treatment of exposed pulp tissue with radiopaque calcium hydroxide composition as a direct pulp capping material
223524030|NCT02614248|OTHER|Medline Remedy Phytoplex Z-Guard Skin Protectant|
223705094|NCT03433157|DEVICE|Hall technique|Metal Stainless stain crown placed with Hall technique
223705095|NCT03433157|DEVICE|Traditional technique|Metal Stainless stain crown placed with Traditional technique
223705096|NCT04007926|BEHAVIORAL|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
224083243|NCT02798926|DEVICE|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
224083244|NCT00732745|DRUG|docetaxel|Given IV
224083245|NCT00732745|DRUG|oxaliplatin|Given IV
224083246|NCT00732745|DRUG|vandetanib|Given orally
224083247|NCT00732745|OTHER|placebo|Given orally
223524031|NCT06265415|DRUG|Labetalol|it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
223524032|NCT06265415|DRUG|Nitroglycerine|a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
223524033|NCT06265415|DRUG|Nifedipine|dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
223524034|NCT02694263|DRUG|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
223524035|NCT02694263|DRUG|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
223524036|NCT02694263|DRUG|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
223524037|NCT02694263|DRUG|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
223524038|NCT02694263|DRUG|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
223524039|NCT02402647|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Treatment (CREST)|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
223524040|NCT02402647|BEHAVIORAL|Exposure Therapy (ET)|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
223524041|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
223524042|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
223524043|NCT06124404|DRUG|Remimazolam besylate|After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
223524044|NCT06484881|DIETARY_SUPPLEMENT|Daniel Alain Probiotic Treatment for Androgenetic Alopecia|Probiotic
223705097|NCT04007926|BEHAVIORAL|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
223705098|NCT02354495|DIETARY_SUPPLEMENT|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
223705099|NCT05896397|PROCEDURE|Endovascular Aortic Treatments|Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.
223705100|NCT04116788|DEVICE|Artefact IRM assessment|IRM
223705101|NCT04742959|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
223705102|NCT04742959|COMBINATION_PRODUCT|Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle
223524045|NCT06484881|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
223524046|NCT01374854|BIOLOGICAL|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10\^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
223524047|NCT01374854|DRUG|traditional therapy|exogenous insulin injection daily
223524048|NCT04197583|DEVICE|Boston Scientific Ureteral Stents, Urinary Diversion Stent|A BSC Ureteral Stent is an implantable device that is used to restore flow of urine from the kidney to the bladder in obstructed ureters. A BSC Urinary Diversion Stent is an implantable device that is used to restore flow of urine from the kidney.
223524049|NCT03637348|DEVICE|TrueTear|Ues of TrueTear neurostimulator
223524050|NCT06564597|OTHER|Patient education|Patient education and counseling are offered one-on-one at the bedside during discharge and are also provided in the second week after discharge in an outpatient clinic setting.
223524051|NCT06446648|DRUG|ICG|Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
223524052|NCT01381887|DRUG|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
223524053|NCT01381887|DRUG|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
223524054|NCT01381887|DRUG|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
224083248|NCT06547983|OTHER|Personalized nutritional advice|Participants in the intervention group received personalized nutrition advice based on their dietary habits, weight, anthropometric data and physical activity.
223524055|NCT01381887|DRUG|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
223524056|NCT03345225|DEVICE|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
223524057|NCT03345225|DEVICE|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
223524058|NCT01040026|OTHER|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at \<1x10e5/kg
223524059|NCT00242892|PROCEDURE|Intra coronary measures of pressure|Intra coronary measures of pressure
223524060|NCT02793050|DRUG|Trabectedin|Collection of data on the clinical use of Trabectedin
223524061|NCT05498909|OTHER|Multidisciplinary joint diagnosis and treatment mode|Multidisciplinary joint diagnosis and treatment mode,break down barriers and treat the heart and brain together
223524062|NCT04600089|DRUG|Saline|Saline infusion
223524063|NCT04600089|DRUG|Ketamine|Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
223524064|NCT05938946|DRUG|L608 Inhalation Solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
223524065|NCT05938946|DRUG|Placebo solution|subjects will be randomized at a ratio of 1:1 (for Sentinel dosing) followed by 5:1 for rest of the cohort to receive the assigned dose of L608 or placebo
223524066|NCT05294523|PROCEDURE|Rocuronium priming dose|Add the priming dose of rocuronium after the first supramaximal stimulation data measured
223524067|NCT00323622|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
223524068|NCT00323622|BIOLOGICAL|Engerix™-B|IM injection in the deltoid muscle
223524069|NCT00323622|BIOLOGICAL|Hiberix®|IM injection in the deltoid muscle
223524070|NCT00323622|BIOLOGICAL|Prevnar™|IM injection in the deltoid muscle
223705103|NCT01419626|DEVICE|Interdental cleaning device with water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
223705104|NCT01419626|DEVICE|Interdental cleaning device with essential-oil mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
223705105|NCT04020380|DRUG|Azithromycin 250Mg Capsule|250 mg OD
223524071|NCT00323622|DRUG|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
223524072|NCT00323622|DRUG|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
223524073|NCT00622206|DRUG|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
223524074|NCT04954989|BIOLOGICAL|Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
223524075|NCT04954989|BIOLOGICAL|Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU|Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
223524076|NCT06016244|OTHER|Oxygen saturation threshold|Oxygen saturation threshold on which supplemental oxygen is decided
223524077|NCT06567392|DRUG|[14C] HRS-5965|Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
223524078|NCT05280145|DEVICE|EchOpen ultra-portable ultrasound device|Depending on the clinical picture, the patient is examined with EchOpen to detect the presence or absence of pyelocaliceal dilatation or hepatic steatosis
223524079|NCT05280145|DEVICE|Ultrasound device routinely used in the department|Patient who was first examined with EchOpen, is secondarily examined with an ultrasound probe used routinely in the department to detect pyelocaliceal dilatation or hepatic steatosis
223524080|NCT05280145|PROCEDURE|Ultrasound examination by an independent referent radiologist|In a case of discordance between the assessments made with echOpen and the usual ultrasound device, an independent referent radiologist will use a standard ultrasound machine to constitute the gold standard (GS) rating. If the latter is not available to carry out the third ultrasound scan within a timeframe deemed clinically acceptable, then the evaluation will be carried out in a delayed manner, using the video loops and image captures saved during the two initial ultrasound scans.
223524081|NCT04977349|OTHER|Manual Therapy|This group will be treated by manual therapy: suboccipital inhibition, myofascial extracavitary treatment in (superior trapezius fibers, ECOM, masseter and temporalis) and intracavitary muscles (medialis and lateral pterygoid muscles).
223524082|NCT04977349|OTHER|Exercise program|Isometric exercises for: cranial protrusion, mouth opening, laterality cervical movement and cervical coordination by laser assessment. And the manual therapy from the Active Comparator group.
223524083|NCT05430321|OTHER|Assessment of physiological parameters|FT implementation begins 3 minutes before the procedures and 10 minutes continuous. After the end of the procedures further 3 minutes was given . Physiological parameters were simultaneously recorded on the registration form
223524084|NCT05430321|OTHER|Assessment of Stress|Newborn Stress Scale (NSS) was used end of the all procedures which means 13th minute.
223524085|NCT05430321|OTHER|Assessment of Comfort|Neonatal Comfort Behavior Scale (NCBS) was used end of the all procedures which means 13th minute.
223524086|NCT00009542|DRUG|kava (Piper methysticum)|
223524087|NCT06637553|COMBINATION_PRODUCT|Adlay formula|The extract will be administered at a dose of 20 grams dissolved in 200cc of hot water once daily
223524088|NCT06637553|COMBINATION_PRODUCT|Placebo|Same weight as the adlay formula but did not include the active compound
223524089|NCT03133377|BEHAVIORAL|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
223524090|NCT06658249|OTHER|Core Stabilization Exercises with Foot-Ankle Strengthening Program|Core Stabilization Exercises and Foot-Ankle Strengthening Program with the frequency of 3 sets of 10 repetitions 3 times per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
223524091|NCT06658249|OTHER|Foot-Ankle Strengthening Program|Foot-Ankle Strengthening Program along with common conventional treatment with the frequency of 3 sets of 10 repetition thrice per week for a total duration of 6 weeks. Core Stabilization Exercises include : Double leg Abdominal Press, Single Leg Abdominal Press, Abdominal crunches, Side-lying Hip Abduction, Bridging Exercise, Wall Squats Exercise. Foot-Ankle Strengthening Program include : Step ups Exercise, Heel Raises in standing/sitting, Toe Raises in standing/sitting, Foot-Ankle isometrics with theraband, One leg balance with chair support. Pre and Post intervention values will be taken on 1st day and after 6 weeks. Simple Conventional treatment will also given that include Hot Pack and TENS for 10 minutes and Ultrasound for 5 minutes and Knee Isometric exercises with the frequency of 1 set of 10 repetitions with 5 sec hold with the ratio of 3 times per week for a total duration of 6 weeks.
223524092|NCT03255395|DEVICE|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
223524093|NCT05319197|OTHER|No Interventions|No Interventions
223524094|NCT07003841|DEVICE|Surgical navigation system with stereotactic guidance|This investigational medical software device utilizes CT imaging data to project the scanned anatomy onto the patient's body, enabling augmented reality-based visualization of the lesion site before surgery
223524095|NCT07003841|DEVICE|General ultrasound imaging system|A general diagnostic ultrasound imaging device that transmits ultrasound energy to the lesion for diagnostic purposes and visualizes the reflected signals. It supports various types of transducers and associated application software packages used for acquiring, displaying, and analyzing ultrasound data.
223524096|NCT07006883|OTHER|Therapeutic exercise|Therapeutic exercise focused on muscle strengthening, balance, and functional performance.
223524097|NCT07006883|OTHER|Yoga therapeutic exercise|Yoga is a mind-body practice that integrates physical postures, breathing techniques, and mindfulness with the aim of improving physical function, balance, strength, mobility, and psychological well-being. I
223524098|NCT04420923|OTHER|Observe and Plan|First the individual interval between the injections of anti-VEGF (vascular endothelial growth factor) is established by observing the time from the loading dose to recurrence of the disease. The patient will come to control every four weeks to establish this interval. Second, the patient will receive injections at intervals that are two weeks shorter than the observed period. 2-3 injections are given before the next control. The control should be no later than six months ahead.
223705106|NCT03703622|BEHAVIORAL|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, \& OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
223524099|NCT04420923|OTHER|Treat-and-Extend|"At the first control 4 weeks after the loading dose, the ophthalmologist assesses whether the macula is still wet or whether the macula is dry. In case of wet macula, the patient receives a new injection on the same day and a new control in 4 weeks. If the macula is dry, the patient will return in 2 weeks for the next injection, ie the injection interval is extended from 4 to 6 weeks.~Patients will be controlled every time they are to receive an intravitreal injection. If the macula is dry, the injection interval will be extended by 2 weeks and if the macula is wet the interval is shortened by 2 weeks. The shortest interval will be 4 weeks."
223524100|NCT07010042|OTHER|The Beck Anxiety Inventory (BAI) of adult patients|Postoperative 0,5,10,15 minutes , RSAS and NRS values
223524101|NCT07010419|DRUG|Firmonertinib|Firmonertinib: 240 mg, QD, orally
223524102|NCT07010419|DRUG|Placebo|Placebo: 240 mg, QD, orally
223524103|NCT07011160|BEHAVIORAL|Transcutaneous electrical nerve stimulation (TENS)|Force-steadiness training will be performance either without (sham) or paired with TENS.
223524104|NCT07011160|BEHAVIORAL|Familiarization|Participants will perform 25 trials of the Grooved Pegboard Test
223524105|NCT06685770|OTHER|Mini mental state assessment test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini mental state assessment test and Mini-cog test will be used.With mini mental state assessment, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
223524106|NCT06685770|OTHER|Mini-cog test|Breast cancer is a very common and important disease in the female population around the world. Anesthesia management during surgery for this disease in the postoperative period should be carefully planned. It will be important to examine the neurocognitive effects of anesthesia management in the postoperative period in this patient group. Today, inhaler and total intravenous anesthesia have advantages as well as disadvantages. It would be valuable to examine its neurocognitive effects in this patient group. In this study, the frequently used Mini-cog test will be used.With Mini-cog test, the patient is asked a number of simple questions to evaluate cognitive functions and each question has certain points. Changes in these score levels preoperatively and postoperatively will be compared within each patient. At the end of the study, preoperative and postoperative changes will be compared statistically between the groups.
223524107|NCT06694051|PROCEDURE|marking|axis marking
223524108|NCT06905223|DIETARY_SUPPLEMENT|MQU10|MQU10 consists of a blend of food-grade probiotic strains (20 billion CFU daily) and prebiotic compounds.
223524109|NCT04945681|BIOLOGICAL|Pneumococcal conjugate vaccine|Mass campaign offering simultaneous pneumococcal conjugate vaccination to all children aged below 5 years of age living in Digaale camp, Somaliland. Children aged below 12 months receive 2 doses of vaccine, spaced 4 weeks apart. All other children receive one dose.
223524110|NCT05855044|OTHER|Rosemary oil application|Application of Rosemary oil (10%) to both hands and both feet once a day for 24 weeks
223524111|NCT06336213|DRUG|Ampicillin-sulbactam|If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
223524112|NCT05144191|DEVICE|Insignia uncemented Hip Stem|Device: Replacement of arthritic hip with Insignia uncemented Hip Stem
223524113|NCT05851417|DEVICE|Fast Field-Cycling (FFC) imaging|FFC scan
223524114|NCT04060238|DIAGNOSTIC_TEST|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
223524115|NCT04725838|DEVICE|Medtronic Intellis™ and Vanta™|Differential Target Multiplexed (DTM®) programming using Medtronic's Intellis™ or Vanta™ Spinal Cord Stimulation systems
223524116|NCT03830437|OTHER|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
223524117|NCT03830437|OTHER|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
223524118|NCT03769350|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
223524119|NCT02882347|DRUG|Somatostatin|
223524120|NCT04596722|DIETARY_SUPPLEMENT|Pomella|"Pomella® Pomegranate Whole Fruit Extract containing 75 mg punicalagin in white/white HPMC size 1 capsules packed in white color HDPE bottle of 30 counts"
223524121|NCT04596722|OTHER|Placebo|"White/white HPMC size 1 capsules each containing 97.67% Maltodextrin, 0.10% Tartrazine color, 0.22% Brown Color, 2.01% Aerosil packed in white color HDPE bottle of 30 counts"
223705107|NCT00180544|DEVICE|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
223705108|NCT04153942|BEHAVIORAL|Mobilization|Any movement out of bed
223705109|NCT03123367|DEVICE|Group 1: Nella VuSleeve|Sleeve
223705110|NCT03123367|DEVICE|Group 2: Nella NuSpec|Speculum
223524122|NCT03525262|RADIATION|30Gy (Gray) planning target volume (PTV)|PTV1\_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
223524123|NCT05634174|DRUG|Mirabegron|Single dose, 100mg oral mirabegron
223524124|NCT03514368|OTHER|Patients treated with immune checkpoint blockade|"Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"
223524125|NCT06429930|DRUG|L608 Liposomal inhalation solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
223524126|NCT06429930|DRUG|Placebo Solution|Participants will be randomized at a ratio of 1:1 (for sentinel dosing) followed by 5:1 for the rest of the cohort to receive the assigned dose of L608 or placebo.
223705111|NCT03123367|DEVICE|Group 3: NellaSpec|Speculum
223705112|NCT03123367|DEVICE|Group 4: Nella Insert|Sleeve
223705113|NCT04609761|DRUG|Privigen Injectable Product (Intravenous Immunoglobulin)|Privigen, 2 g/kg BW every 4th week for 6 months (= 6 infusions).
223705114|NCT00562835|DRUG|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
224083249|NCT06547983|OTHER|Personalized nutritional advice and food boxes|Participants in the intervention plus group received the personalized nutrition advice while also receiving food boxes which are composed based on the personalized nutritional advice.
223524127|NCT04531579|DRUG|Valproic Acid Solution|Valproate sodium in 5-ml single-dose vials containing 100 mg/ml of VPA. The appropriate dose of 140 mg/kg, based on the subject's weight at study entry, will be diluted in isotonic saline solution to a final volume of 300 ml for administration
223524128|NCT04531579|DRUG|Isotonic saline solution|Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
223524129|NCT06477770|PROCEDURE|Clorhexidine soap|surgical wound will be washed with saline solution and 10 ml of chlorhexidine soap
223524130|NCT06477770|OTHER|Sucrose|75 g of sucrose will be administered to the surgical wound at 8:00 am every day, once a day, and then it will be covered with sterile gauze.
223524131|NCT04974476|OTHER|HIIT Exercise Training|The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, \>80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
223524132|NCT05604586|DIETARY_SUPPLEMENT|N-acetylcysteine|100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
223524133|NCT05604586|DIETARY_SUPPLEMENT|Placebo|100 women and men supplementing 1200 mg of placebo daily in three equal doses. Supplementation will last for 7 days.
223524134|NCT06565312|DIETARY_SUPPLEMENT|Flora Power Probiotic Vaginal Suppository|The suppository contains Microcrystalline Cellulose, Ascorbic Acid, Vitamin C, Gelatin Capsule, Vaginal Probiotic Blend (Lactobacillus fermentum LF61, Lactobacillus acidophilus LA85, Lactobacillus plantarum Lp90), Magnesium Stearate, and Silicon Dioxide.
223524135|NCT04185779|DIAGNOSTIC_TEST|Colonoscopy|Diagnostic colonoscopy
223705115|NCT00562835|OTHER|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
223705116|NCT01365052|DRUG|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
223705117|NCT01365052|DRUG|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
223705118|NCT01146912|OTHER|Text Message|Text message vaccine reminders
223705119|NCT01146912|OTHER|automated call|Automated call
223705120|NCT03342677|DIAGNOSTIC_TEST|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
223893705|NCT05992220|RADIATION|Atezolizumab plus bevacizumab, combined EBRT to vascular invasion|"The external beam radiotherapy will commence after day 2 of the first cycle of atezolizumab+bevacizumab, and will be delivered in accordance with institutional protocol.~3D-conformal radiotherapy technique is used to determine target volumes, radiation ports, and dose prescriptions by using a 3D radiotherapy planning system.~The gross tumor volume (GTV) includes vascular invasion and a 2-cm margin into the contiguous HCC. The GTV can consist of the entire HCC and vascular invasion at the discretion of the investigator.~The target dose is 45 Gy, however, the total dose can be reduced as low as 30 Gy according to the liver function, liver volumes, or the maximum dose to the stomach/duodenum during the planning process according to the judgment of the radiation oncologist of each participating sites."
223524136|NCT02733094|DRUG|Secukinumab|
223524137|NCT02771301|BIOLOGICAL|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
223524138|NCT03262961|DRUG|Sildenafil 20 MG|
223524139|NCT03262961|DRUG|Placebo Oral Tablet|
223524140|NCT05791344|DEVICE|ECG monitoring|Intra-procedural ECG changes during TAVR
223524141|NCT05334238|DRUG|Orelabrutinib|oral administration of Orelabrutinib 150mg daily for 1 year, beginning 8 weeks after autologous transplantation
223524142|NCT02804620|BEHAVIORAL|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
223524143|NCT01395134|DEVICE|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
223524144|NCT00621283|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
223524145|NCT02433964|OTHER|Grupo LED|
223705121|NCT02462252|DRUG|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
223524146|NCT02433964|OTHER|Placebo|ledterapia off + price
223524147|NCT06318676|DRUG|Mezigdomide|Specified dose on specified days
223524148|NCT06579508|OTHER|Cycle ergometer|"The initial part will last 5 minutes at low intensity, corresponding to easy by the RPE.~The main part will be performed at the intensity of training zone 3 (100-110% of the Lan), lasting 5 minutes with a rest of 2.5 minutes between exercises. The intensity will be controlled by HR and RPE.~The final part will last 3 minutes at low intensity, corresponding to easy by the RPE.~The load progression occurred during the first four weeks, starting with 3 sets and adding 1 set per week.~The intensity of each effort is 100-110%HRAnTh."
223705122|NCT02462252|DRUG|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
223893706|NCT05992220|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab q3w
223893707|NCT05948267|DRUG|ketamine- dexmeditomidine admixure|ketamine in anesthetic dose mixed with two different doses of dexmeditomidine
223524149|NCT04523519|BEHAVIORAL|Video directly observed therapy with contingency management|PrEP adherence will be assessed by visual recognition software during video capture and reviewed for confirmation by study staff, ensuring that videos demonstrate study medication dosing by participant. Participants will receive small financial incentives upon confirmation of dosing.
223524150|NCT04523519|BEHAVIORAL|Integrated Next-Step Counseling|Integrated Next-Step Counseling combines support for behavioral strategies that reduce sexual and injection-related HIV risk and do not involve PrEP, with strategies to support PrEP adherence in brief, client-centered conversations.
223524151|NCT04336566|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg
223524152|NCT04336566|DIETARY_SUPPLEMENT|Placebo|Comparable Good Neighbor Pharmacy placebo tablet
223524153|NCT00889330|DRUG|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
223524154|NCT00889330|DRUG|Placebo|Vehicle without active, one drop in each eye at each of two visits.
223524155|NCT05537389|DEVICE|In-line filter|"All infusions, with the exception of some solutions (eg blood products), will be subjected to filtration. The aqueous solutions (parenteral therapy and drugs) will be administered through 0.2 μm filters which will be replaced every 96 h; the lipid emulsions will be administered through 1.2 μm filters which will be replaced every 24 h.~In case of emergency, life-saving drugs will be administered with bolus modality though the infusion line closer to the patient without the need for filtration.~In case of drugs/solutions not supported by filtration (eg blood products), they will be administered through a dedicated unfiltered access, which will be removed as soon as the drug is no longer needed."
223524156|NCT02346279|OTHER|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
223524157|NCT02167776|BEHAVIORAL|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
223524158|NCT06420700|PROCEDURE|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty|Combined gastric mucosal ablation with endoscopic sleeve gastroplasty in the treatment of adults with obesity
223524159|NCT02075060|PROCEDURE|IPOI (pre-operative)|
223524160|NCT02075060|PROCEDURE|IPOP (post-operative)|
223524161|NCT02956473|DEVICE|Supine MRI|
223524162|NCT02956473|OTHER|Neoadjuvant Therapy (NAT)|
223524163|NCT02956473|DEVICE|Ultrasound|
223524164|NCT02956473|DEVICE|Mammography|
223524165|NCT02956473|PROCEDURE|Standard of Care|
223524166|NCT02956473|DEVICE|Standard MRI|
223524167|NCT05750784|PROCEDURE|Total knee arthroplasty using the active robotic surgical system|Total knee arthroplasty using the active robotic surgical system TSolution One TCAT, and system for planning TPlan
223524168|NCT05175157|OTHER|Gut Fellings questionnaire|Answer the Gut Fellings questionnaire
223524169|NCT06100120|PROCEDURE|Implant placement|Placement of osteointegrated implants
223524170|NCT03898011|DRUG|Lamotrigine|Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
223524171|NCT03898011|DRUG|Lamictal|Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
223524172|NCT02494115|PROCEDURE|subcutaneous drainage|
223524173|NCT03842397|DEVICE|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
223524174|NCT03033784|DRUG|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
223524175|NCT03033784|DRUG|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
223524176|NCT03033784|DRUG|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
223524177|NCT03033784|DRUG|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
223524178|NCT00568009|DRUG|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
223524179|NCT05786326|DEVICE|group 1|Insertion of fully covered self-expanding metallic stents with multi-holes (FCSEMS- MH) Biliary stent HANAROSTENT® CCC (M.I.Tech Co., Ltd, pyeongtaek, Korea) in a biliary tree through endoscopic retrograde cholangiopancreatography (ERCP) under general anesthesia by expertise in patients with malignant biliary obstruction
223524180|NCT05786326|DEVICE|group 2|Insertion of partially covered self-expanding metallic stents HANAROSTENT® Biliary (NCN) in the biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
223524181|NCT05786326|DEVICE|group 3|Insertion of uncovered self-expanding metallic stents (Biliary stent HANAROSTENT® NNN) (M.I.Tech Co., Ltd. Pyeongtaek, Korea) in a biliary tree through ERCP under general anesthesia by Expertise in patients with malignant biliary obstruction.
223524182|NCT01058746|OTHER|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
223705123|NCT02462252|DRUG|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
223705124|NCT02462252|DRUG|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
223524183|NCT01058746|OTHER|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
223524184|NCT02085980|DEVICE|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
223524185|NCT02987140|BEHAVIORAL|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
223524186|NCT02424162|DEVICE|+2.75 diopters multifocal intraocular lens|
223524187|NCT02424162|DEVICE|+3.25 diopters multifocal intraocular lens|
223524188|NCT02465008|DRUG|Levobupivacaine|
223524189|NCT02465008|DRUG|Placebo|
223524190|NCT02485184|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
223524191|NCT02485184|DRUG|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
223524192|NCT02485184|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
223524193|NCT02485184|DRUG|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
223524194|NCT03129997|DIETARY_SUPPLEMENT|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
223524195|NCT00684385|DRUG|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H\&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H\&NC will take two tablets at each dose administration.
223524196|NCT03295942|DRUG|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
223524197|NCT03332056|DRUG|Belladonna and Opium|
223524198|NCT03332056|OTHER|Placebo suppository|
223524199|NCT02374255|BEHAVIORAL|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
223524200|NCT03106714|DIAGNOSTIC_TEST|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
223524201|NCT01817400|OTHER|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
223705125|NCT02577549|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
223705126|NCT02577549|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
223893708|NCT05948267|DRUG|Propofol, Lidocaine and fentanyl|Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml
223893709|NCT01189786|DEVICE|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
223524202|NCT01817400|DIETARY_SUPPLEMENT|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
223524203|NCT01817400|DRUG|Aspirin|
223524204|NCT01817400|DRUG|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
223524205|NCT06344247|DRUG|RAS inhibitors：Losartan®️/Valsartan®️|Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
223524206|NCT06344247|DRUG|dapagliflozin：Forxiga®️|Forxiga®️ : titrated to the target dose (10 mg qd).
223524207|NCT06344247|DRUG|simagliptin：Forxiga®️|Semaglutide®️ : titrated to the target dose (1 mg qw).
223524208|NCT04132297|BEHAVIORAL|Asthma Academy|The Asthma Academy is a one hour virtual training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
224083250|NCT01016873|DEVICE|IRay|Low voltage stereotactic radiotherapy system
224083251|NCT01109940|BIOLOGICAL|AIN457A|
223524209|NCT04132297|BEHAVIORAL|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through zoom on the participant's smart phone or computer. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
223524210|NCT02093520|PROCEDURE|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
223524211|NCT02093520|DRUG|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
223524212|NCT00525863|DRUG|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to \~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
223524213|NCT03014089|BIOLOGICAL|mRNA-1325|Escalating dose levels
223524214|NCT03014089|OTHER|Placebo|
223524215|NCT05310357|DIAGNOSTIC_TEST|Testing for chromosomal instability (CIN)|The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.
223524216|NCT02792322|DEVICE|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
223524217|NCT00434941|DRUG|Capecitabine|
223524218|NCT00434941|RADIATION|Radiotherapy|
223524219|NCT02995200|BEHAVIORAL|Accelerometer Based Feedback|
223524220|NCT01342055|DRUG|Apetrol ES|sequences of administered drugs
223524221|NCT03618069|DIAGNOSTIC_TEST|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
223524222|NCT01969929|PROCEDURE|20G Vitrectomy|
223524223|NCT01969929|PROCEDURE|23G vitrectomy|
223524224|NCT00797303|DRUG|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
223524225|NCT05516173|DIAGNOSTIC_TEST|Blood Pressure Monitoring, Ambulatory|To monitor the blood pressure during 24 hours.
223524226|NCT03487133|DRUG|bortezomib/dexamethasone|"Induction therapy -\>1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy -\>1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
223524227|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
224083252|NCT03653390|BEHAVIORAL|EnhanceWellness for Disability (EW-D)|Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.
223524228|NCT02711098|BIOLOGICAL|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
223524229|NCT06559319|DIAGNOSTIC_TEST|blood sampling|Venous blood is collected, and sIgE and BAT will be detected using whole blood and serum, respectively.
223524230|NCT06563648|OTHER|shotblocker|A ShotBlocker was placed on the arm of the patients in the ShotBlocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection.
223524231|NCT06563648|OTHER|local cold application|Local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed.
223524232|NCT06563648|OTHER|ShotBlocker placebo group|During the injection, the back side of the ShotBlocker was placed on the arm of the patients in the ShotBlocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection.
223524233|NCT04144920|BEHAVIORAL|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
223524234|NCT04144920|BEHAVIORAL|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
223524235|NCT04144920|BEHAVIORAL|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
223524236|NCT04196621|DEVICE|High viscous artificial tears|Instillation of one drop high viscous artificial tears
223524237|NCT04196621|DEVICE|Low viscous artificial tears|Instillation of one drop low viscous artificial tears
223524238|NCT04576754|DEVICE|WB001|The WB001 treatment consists of PPD-specific psychoeducational lessons and CBT-specific skills or tools. The lessons teach PPD-specific information to normalize and contextualize postpartum experiences, as well as provide information on effective mood management and mental health promotion in the context of having recently given birth. Patients complete up to 30 psychoeducational lessons. In addition, patients access and apply core CBT-based tools upon endorsing a negative mood. These tools are core to CBT and are considered transdiagnostic. Examples include thought challenging, behavioral activation, mindfulness, and self-care.
223524239|NCT04576754|DEVICE|Educational|The Comparison Condition provides educational only material about various mental and physical topics, delivered in an interactive smartphone application that is accessible anytime of day.
223524240|NCT03388827|DEVICE|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
223524241|NCT03388827|DRUG|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
223524242|NCT01418105|PROCEDURE|Videofluroscopic swallow study (VFSS)|Barium, radiation
223524243|NCT01418105|PROCEDURE|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
223524244|NCT01418105|PROCEDURE|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
224083253|NCT03653390|BEHAVIORAL|Wellness Education|Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
223524245|NCT04164719|DRUG|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
223524246|NCT02331758|BEHAVIORAL|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
223524247|NCT03840967|DRUG|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
223524248|NCT03320005|OTHER|Resistance training group|Resistive exercises for legs and arms
223524249|NCT04023058|PROCEDURE|Mitral surgery|Guidelines approved mitral surgery
223524250|NCT04260958|OTHER|Exercise-based cardiac rehabilitation|The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
223524251|NCT05077423|DRUG|CD33*CD3 BsAb|CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
223524252|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
223524253|NCT02523027|DIETARY_SUPPLEMENT|Oral nutritional supplement|(List No- P968/Z0)
223524254|NCT02523027|OTHER|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
223524255|NCT04809337|OTHER|Exercise|After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
223524256|NCT02014987|BEHAVIORAL|Training programmes|"Runners with a high body mass index follow two types of training programmes:~1. a running programme of 3 kilometres per week~2. a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
223524257|NCT01342666|DIETARY_SUPPLEMENT|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
223524258|NCT01342666|DIETARY_SUPPLEMENT|Cucumber consumption|Daily consumption of 300g of cucumber.
223524259|NCT02296099|DRUG|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
223524260|NCT02296099|DRUG|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
223524261|NCT01678742|DIETARY_SUPPLEMENT|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
223524262|NCT01678742|DIETARY_SUPPLEMENT|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
223524263|NCT04945837|OTHER|self administered questionnaire|longitunidal descriptive study
223524264|NCT03220633|DRUG|ATB-346|
223524265|NCT03220633|DRUG|Placebo|
223524266|NCT04707209|DRUG|Sirolimus|"An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months."
223524267|NCT00375232|DRUG|Administration of montelukast or placebo|
223524268|NCT02194179|DRUG|NVP XR 400 mg (KCR 25%)|
223524269|NCT02194179|DRUG|NVP XR 400 mg (KCR 20%)|
223524270|NCT02194179|DRUG|NVP XR 300 mg (KCR 25%)|
223524271|NCT02194179|DRUG|NVP XR 300 mg (KCR 20%)|
223524272|NCT02194179|OTHER|high-fat breakfast|
223524273|NCT02194179|DRUG|NVP IR 200 mg (Viramune®)|
223524274|NCT05012579|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
223524275|NCT04033640|DIAGNOSTIC_TEST|SD Biosensor STANDARD G6PD Test|"The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care (POC) setting. The test is intended to aid in the identification of people with G6PD deficiency.~The test is currently not licensed for use in Brazil and is considered an investigational product."
223524276|NCT04033640|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
224275827|NCT02046317|DEVICE|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
223524277|NCT04033640|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
223524278|NCT04033640|DIAGNOSTIC_TEST|Complete blood count (CBC)|In Manaus, hemoglobin concentration was determined by CBC using an automated hematology analyzer (Sysmex KX-21N).
223524279|NCT05425121|PROCEDURE|Core stability exercises|The intervention in the control group will core stability exercises for different back muscles and strengthening exercises of Gluteal Muscles.
223524280|NCT05425121|DEVICE|Biofeedback training|EMG biofeedback training will be administered to the participants in combination with core stability exercise training.
223524281|NCT06254833|OTHER|micro dosing of ICG|smaller dose of injection of ICG. All devices used are FDA approved in clinical use.
223524282|NCT06560190|OTHER|Orthopaedic Manual Physical Therapy|Individualized Treatment
223524283|NCT04225767|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.
223524284|NCT02811887|BEHAVIORAL|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
223524285|NCT02811887|OTHER|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
223524286|NCT02811887|BEHAVIORAL|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
223524287|NCT00808873|OTHER|socio-educational intervention|brief mental health education and 6 follow-up visits
223524288|NCT02485886|DRUG|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
223524289|NCT04921267|BEHAVIORAL|training|training with filtered speech
223524290|NCT05737979|OTHER|Study chart review|Evaluation of the IVF cycle using the prescribed medication
223524291|NCT03412955|DRUG|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
223524292|NCT00691626|BEHAVIORAL|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
223524293|NCT00691626|BEHAVIORAL|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
223524294|NCT01519479|OTHER|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
223524295|NCT01519479|OTHER|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
223524296|NCT04978415|PROCEDURE|peribulbar block versus subtenon's block|"Sixty patients undergoing vitreoretinal surgery were randomized to receive either peribulbar or sub-Tenon's capsule injection of 8 ml of a 20:80 mixture of 2% lidocaine and 0.75% bupivacaine with 60 IU hyalouronic acid.~two groups 30 patient each (group p and group s) after connecting the patient to the monitor, we give him sedation 50 mg propofol, apply a nasal cannula group P: receives 2 injection peribulbar block group S: receives single injection subtenon Patients rate their pain sensation in both groups using an 11-point (0-10) numerical visual analogue scale immediately after surgery."
223524297|NCT02167711|DRUG|SIRT Yttrium-90|
223524298|NCT02427490|BEHAVIORAL|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
223524299|NCT02427490|OTHER|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
223524300|NCT00688740|DRUG|Docetaxel|intravenous
224083254|NCT05429567|DRUG|Fentanyl|All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
223524301|NCT00688740|DRUG|5-fluorouracil|intravenous
223524302|NCT00688740|DRUG|Doxorubicin|intravenous
223524303|NCT00688740|DRUG|Cyclophosphamide|intravenous
223524304|NCT05688085|DRUG|Irbesartan High/Amlodipine FDC|Irbesartan High/Amlodipine FDC
223524305|NCT05688085|DRUG|Irbesartan High|Co-administration of Irbesartan High and Amlodipine
223524306|NCT05688085|DRUG|Amlodipine|Co-administration of Irbesartan High and Amlodipine
223524307|NCT04505800|DIETARY_SUPPLEMENT|Tryptophan supplement|"* Pure L-tryptophan in capsules (500mg/capsule)~* 3g tryptophan per day (2 capsules, t.i.d.), at 8AM, 4PM, and 0AM (± 1 hour)"
223524308|NCT04505800|DIETARY_SUPPLEMENT|Maltose|Maltose
223524309|NCT05416814|DIETARY_SUPPLEMENT|Kefir|Oral route (via feeding tube in intubated patients). Serving size 240mL to be given in an ascending dosing regimen if tolerated starting at 60 mL/day, 120 mL/day until single 240 mL/day; if evidence of intolerance, dose will be reduced to previously tolerated dose.
223524310|NCT02676180|OTHER|Group|
223524311|NCT02499614|DRUG|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
223524312|NCT01096004|DRUG|AZD4017|oral suspension, 1200mg, once daily, for 10 days
223524313|NCT01096004|DRUG|Placebo|
223524314|NCT03859219|DRUG|Rozanolixizumab|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
223524315|NCT03859219|DRUG|Placebo|"* Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion"
223524316|NCT03463655|DIAGNOSTIC_TEST|cirrhotic albumin|Ascites puncture
223524317|NCT03463655|DIAGNOSTIC_TEST|serum albumin|blood punctures
223524318|NCT03796104|OTHER|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
223524319|NCT04746755|DEVICE|Orthotic Insole: Lower Back|This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.
223524320|NCT04746755|DEVICE|Orthotic Insole: Heel|This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.
223524321|NCT04746755|DEVICE|Orthotic Insole: Knee to Heel|This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.
223524322|NCT04746755|DEVICE|Orthotic Insole: Arch|"This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes."
223524323|NCT02341274|DRUG|Tacrolimus|Bioequivalence study
223524324|NCT01434940|OTHER|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
223524325|NCT06376955|OTHER|High intensity interval exercise|HIIT is a type of interval training exercise. It incorporates several rounds that alternate between several minutes of high intensity movements followed by short periods of lower intensity movements 2 times per week for 4 months.
223524326|NCT06376955|OTHER|Focused ultrasound|Focused ultrasound will be applied over the anterior abdominal, two sessions per week for 4 months, each session 40 minutes.
223524327|NCT00856557|BEHAVIORAL|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
223524328|NCT00239915|DRUG|Pagoclone|
223524329|NCT06101420|DRUG|Vonoprazan|Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
223524330|NCT01432444|DRUG|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
223524331|NCT01502527|DIETARY_SUPPLEMENT|Femarelle|Twice daily oral treatment with Femarelle
223524332|NCT03673176|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
223524333|NCT02301897|DRUG|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
223524334|NCT02301897|DRUG|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
223524335|NCT02518529|BIOLOGICAL|G17DT|
223524336|NCT02015130|OTHER|Individual treatment|See detailed description
223524337|NCT01353729|DRUG|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
223524338|NCT01353729|DRUG|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
223524339|NCT01353729|DRUG|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
223524340|NCT01353729|DRUG|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
223524341|NCT02675400|DRUG|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
223524342|NCT02675400|BEHAVIORAL|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
223524343|NCT02675400|DRUG|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
223524344|NCT02439957|DRUG|Brincidofovir|
223524345|NCT02439957|DRUG|Valganciclovir|
223524346|NCT03532347|DEVICE|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
223524347|NCT03497377|DRUG|18F-DCFPyL Injection|
223524348|NCT03497377|DRUG|18F-NaF|
223524349|NCT03770702|DRUG|Angiotensin receptor blockers|Candesartan
223524350|NCT03770702|DRUG|Statins|Atorvastatin
223524351|NCT01831908|OTHER|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
223524352|NCT05606107|DRUG|Tofacitinib|Tofacitinib combined with other csDMARDs, but no glucocorticoids.
223524353|NCT05606107|DRUG|Glucocorticoid|Glucocorticoid
223524354|NCT05879029|DRUG|Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.|Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
224083255|NCT05479292|OTHER|Sars-CoV-2 outbreak|Sars-CoV-2 pandemic's impact on provision of healthcare for cancer patients
224083256|NCT04765605|DEVICE|WeFlow-Tbranch Stent Graft System|The single-embedded branch thoracic aorta stent graft system consists of the thoracic aorta stent graft system and the branch stent system. The main chest embedded stent graft system consists of the main chest embedded stent graft and its system conveyor, and the branch stent system consists of branch stents and its conveyor. The main chest embedded stent graft and the branch stent are pre-installed in the conveyor
224083257|NCT01261819|DEVICE|cystoscopy|
224083258|NCT05901467|DRUG|kisspeptin 112-121|One IV bolus of kisspeptin 112-121
223524355|NCT05879029|DRUG|Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.|Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
223524356|NCT03377751|PROCEDURE|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
223524357|NCT03377751|PROCEDURE|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~1. Proportion of low voltage area to area of left atrium body \<10% : PVI only~2. Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~   * Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
223705127|NCT02806245|OTHER|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
223705128|NCT04794309|OTHER|Circuit training exercise|"circuit training exercise start with 5 minutes of warming-up then followed by a 30-minute conditioning protocol formed 20 minutes of aerobic exercise and 10 minutes of resisted exercise. The cool-down period is doing in form of walking on a treadmill in low intensity for 5 minutes.~Aerobic exercise will be performed on an electronically-braked cycle ergometer (Quinton Excalibur, QuintonInstrument Company, Bothell, WA). resistance exercise (RT) in the form of eight different exercises will be performed during each workout: military press, leg extension, bench press, standing leg curl (ankle weights), lateral pull-down, dumbbell triceps push-down, dumbbell seated biceps curl, and sit-ups (abdominal curls).~The participant will do 10 minutes for Aerobic exercise followed by 10 minutes of resistance exercise then 10 minutes for Aerobic exercise. This cycle training will perform five days per week for eight weeks."
223705129|NCT04794309|DIETARY_SUPPLEMENT|Healthy high Fiber diet|The diet will be tailor-made for the individual for the body type and obesity in consultation with the nutritionist.
223705130|NCT00731068|BIOLOGICAL|PRGF|injection of 6cc into injured area of tendon
223705131|NCT00731068|BIOLOGICAL|placebo|injection of 6 cc of saline into injured area
223705132|NCT01935297|BEHAVIORAL|Exercise|endurance and resistance exercise 3x/week for 8 weeks
223705133|NCT03074955|DEVICE|leg wrapping with tension|"1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages."
223705134|NCT03074955|PROCEDURE|Trendelenburg position|"1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position"
223705135|NCT03074955|DEVICE|leg wrapping without tension|"1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages"
223705136|NCT03074955|PROCEDURE|supine position|1.maintain supine position
223705137|NCT03393130|DIAGNOSTIC_TEST|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
223705138|NCT04337801|OTHER|Acupressure|The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
223705139|NCT04337801|OTHER|Placebo|The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
223705140|NCT05825339|DIAGNOSTIC_TEST|Coronary Flow Reserve|Diagnostic of Microvascular Coronary Dysfunction using continuous thermodilution flow reserve
223705141|NCT01524731|DRUG|Saline|Normal Saline
223705142|NCT01524731|DRUG|Dexamethasone|4 mg
223705143|NCT01524731|DRUG|Dexamethasone|8 mg
223705144|NCT01145625|DRUG|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
223705145|NCT01145625|DRUG|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
223705146|NCT02680535|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
223705147|NCT02518074|OTHER|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
223705148|NCT05648578|OTHER|Reiki attempt|Four reiki sessions were applied twice a week, on the same days of the week, lasting 25-35 minutes each.
223705149|NCT03979612|GENETIC|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
223705150|NCT04184544|OTHER|Improving of quality of care at health facility and outreach level|Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
223524358|NCT03377751|PROCEDURE|PVI only group|PVI will be performed in this arm.
223524359|NCT04143776|PROCEDURE|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
223524360|NCT04608058|BEHAVIORAL|Digital storytelling training|"The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes."
223524361|NCT04608058|BEHAVIORAL|Routine training|The control group received the clinics' routine training include face to face class education.
223524362|NCT02666053|DRUG|BMS-663068|BMS-663068
223524363|NCT01734044|DRUG|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
223524364|NCT01734044|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
223524365|NCT02246491|OTHER|A-T iPS cell line|Reprogramming A-T patients iPS cell line
223524366|NCT02246491|OTHER|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
223524367|NCT00890500|DRUG|Fludarabine|30mg/m2/day IV x 6 days
223524368|NCT00890500|DRUG|Melphalan|100 mg/m2/day IV x 1 day
223524369|NCT00890500|DRUG|Antithymocyte Globulin|1mg/kg/day x 4 days
223524370|NCT00890500|DRUG|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
223524371|NCT00890500|DRUG|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
223524372|NCT06272604|BEHAVIORAL|Personalized Exercise Rehabilitation|The experimental group will participate in a 12-week exercise intervention program, carefully transitioning from moderate-intensity interval training to high-intensity interval training. The progression of exercise intensity will be regularly adjusted based on each child's tolerance, ensuring a personalized approach to the regimen. The exercise program is structured into three phases: an adaptation phase, an intensification phase, and a consolidation phase. For each participant, the intensity of the exercises is calculated based on their reserve heart rate, allowing for a tailored and scientifically-grounded progression. This approach aims to optimize the exercise program's effectiveness while maintaining safety and adaptability to individual fitness levels and asthma conditions.
223524373|NCT02354521|OTHER|NO INTERVENTIONS|
223524374|NCT02884453|DRUG|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research \& Development, LLC and Pharmacyclics Inc.
223524375|NCT06375148|OTHER|Enteral nutrition|prone position ventilation
223524376|NCT06062303|OTHER|Usual care (UC)|\- Patients allocated to the UC group will be managed by the clinical staff according to usual practice at their sites including decisions about hemodynamic and perfusion monitoring, and all treatments, but should follow general recommendations of the Surviving Sepsis Campaign to avoid extremes of clinical practice. This includes basic hemodynamic targets such as a MAP \>65 mmHg, heart rate (HR) \<120 beats per minute (BPM), arterial oxygen saturation (SaO2) \>94%, Hb \> 7 gr/dl, and the use of NE as the first vasopressor and crystalloids as the fluid of choice.
223524377|NCT04419246|OTHER|interscalene block|ultrasound guided ultrasound guided interscalene block 30 minutes before operation. 30 minutes before operation.
223524378|NCT04419246|DRUG|tranexamic acid|10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
223524379|NCT04419246|OTHER|general anesthesia|general anesthesia will be applied in accordance with standard procedures
223524380|NCT05892107|PROCEDURE|Toy Group|After meeting the children in the toy group, the toy will be given to the children to play 1 minute before the procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
223524381|NCT05892107|PROCEDURE|Mask group with cartoon characters|The nurse who will open the vascular access with the children in the cartoon character mask group will meet the child 1 minute before the procedure with a cartoon character mask on his/her face.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
223524382|NCT05892107|PROCEDURE|Control group|In the control group, the nurse who will open the vascular access will meet the child 1 minute before the procedure with a white mask on her/his face. Children in the control group will be subjected to routine procedures before blood collection.In all groups, the mother will be present with the child during the blood collection procedure. Before nonpharmacological interventions in all groups and 2 minutes before the procedure in the control group, the child's pre-procedural pain will be evaluated by explaining the Wong-Baker Faces Pain Rating Scale to the child.
223524383|NCT04243486|DRUG|UHE-105|Topical shampoo containing active drug
223524384|NCT04243486|DRUG|Vehicle|Topical shampoo containing no active drug
223524385|NCT03716596|RADIATION|SBRT|SBRT radiation dose is 40-50 Gy in total.
223524386|NCT03716596|DRUG|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
223524387|NCT04999410|BEHAVIORAL|High Intensity Interval Training|Interventions will contrast alternative training protocols
223524388|NCT05104060|PROCEDURE|pectoralis minor intervention group|The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.
223524389|NCT05104060|PROCEDURE|shoulder strengthening group|The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
223524390|NCT04923997|BEHAVIORAL|Health Coaching|6 months of integrative health coaching, goal setting, survey administration and physical assessments.
223524391|NCT00841139|DRUG|Perhexiline|100mg o bd
223524392|NCT00841139|DRUG|Placebo|1 tablet bd
223524393|NCT01569412|BIOLOGICAL|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
223524394|NCT01252680|BIOLOGICAL|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
223524395|NCT01252680|BIOLOGICAL|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
223705151|NCT05405868|DRUG|Nicotinomide|Nicotinamide tablets (750mg)
224275828|NCT02046317|DEVICE|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
223524396|NCT01252680|BIOLOGICAL|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
223524397|NCT01252680|BIOLOGICAL|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
223524398|NCT01370148|DRUG|conivaptan hydrochloride|Intravenous
223524399|NCT05872412|DRUG|Doxorubicin|60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
223524400|NCT05872412|DRUG|Cyclophosphamide|600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
223524401|NCT05872412|DRUG|Paclitaxel|80 mg/m2 IV over 1 hour weekly for 12 weeks
223524402|NCT05872412|DRUG|Carboplatin|Area under the curve: 6 mg/ml/min, i.v. every 3 weeks for four cycles
223524403|NCT00600340|BIOLOGICAL|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
223524404|NCT00600340|BIOLOGICAL|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
223524405|NCT06549335|DRUG|Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)|"Induction therapy:~The ZGR regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 28 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-28;~2. Obinutuzumab, 1000mg, ivgtt, day 1/8/15 (C1), day1 (C2-6);~3. Lenalidomide, 25 mg qd, po, day 2-11.~Maintenance therapy:~1. Obinutuzumab, ivgtt,1000mg, every 3 months for 2 years;~2. Lenalidomide, 25mg, PO, during 1-10 days in every 28 days for 6 cycles."
223705152|NCT05405868|DRUG|Matching placebo|Matching placebo
224083259|NCT05901467|DRUG|GnRH|One IV bolus of gonadotropin-releasing hormone
224083260|NCT03983395|BIOLOGICAL|ISB 1302 250 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
224275829|NCT02046317|DEVICE|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
223524406|NCT05754125|DIETARY_SUPPLEMENT|Di-Leucine Supplement|Participants will consume a amino acid supplement containing Di-Leucine following resistance exercise and their whole body anabolism will be determined over the subsequent 6 hours
223524407|NCT05754125|DIETARY_SUPPLEMENT|BCAA Supplement|Participants will consume a amino acid supplement containing branched chain amino acids (BCAA) following resistance exercise and their whole body anabolism will be determined over the subsequent hours
223524408|NCT05754125|DIETARY_SUPPLEMENT|Collagen Supplement|Participants will consume a amino acid supplement containing Collagen protein following resistance exercise and their whole body anabolism will be determined over the subsequent hours
223524409|NCT05530304|DEVICE|Triple inner branched arch stentgraft|New findings regarding treatment planning and management of patients with aortic arch pathologies.
223524410|NCT00181246|DRUG|Transdermal Fentanyl|
223524411|NCT00850330|OTHER|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
223524412|NCT02137343|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
223524413|NCT02137343|DRUG|Placebo|Placebo
223524414|NCT02137343|DRUG|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
223524415|NCT02137343|DRUG|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
223524416|NCT06230146|DRUG|Insulin group|"Fractional ablative laser followed by Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution).~Dose: injection of 0.1 ml\\cm3 of the lesion avoiding subcutaneous injection as much as possible especially in fatty areas."
223524417|NCT06230146|DRUG|Botulinum toxin group|Fractional ablative laser followed by intralesional Botox-A (100 U vacuum-dried powder in a single-use vial for reconstitution diluted in 2 mL of sterile, preservative-free 0.9% saline to constitute a solution at a concentration of 5 U/0.1 mL),It will be injected into the body of the keloid with the help of a 24gauge needle at a distance of 1 cm apart until slight blanching is visible. The dose will be adjusted to 2.5 U/cm3 of the lesion, not exceeding 100 units per session.
223705153|NCT01065259|DRUG|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
224275830|NCT03622359|DIAGNOSTIC_TEST|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
224275831|NCT03622359|DIAGNOSTIC_TEST|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
223524418|NCT06230146|DRUG|Triamcinolone acetonide group|Fractional ablative laser followed by Triamcinolone acetonide injection. TAC 40 mg/ml will be diluted with normal saline solution 0.9% to the concentration of 20 mg/ml .Maximum drug injected during each session will be 40 mg triamcinolone.
223524419|NCT01224314|OTHER|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
223524420|NCT01232140|OTHER|CRP-guided antibiotic treatment|If CRP\> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =\< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
223524421|NCT06642766|DIETARY_SUPPLEMENT|Fiber supplement|"Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary."
223524422|NCT04993196|DIAGNOSTIC_TEST|T1rho imaging|Magnetic Resonance Imaging using T1rho
223524423|NCT03578315|DEVICE|HGM|To Study the Efficacy and safety of QSRL and PSNYL in the Treatment of target: A nonrandomized, controlled, split-face comparative study
223524424|NCT01980264|DEVICE|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
223524425|NCT06034340|DEVICE|LET Gel after STAR Particle Application (Right or Left Arm)|STAR particles are made of titanium dioxide, a widely used and safe ceramic material found in sunscreens, cosmetics, and paint. The particles vary in concentration and length in order to find the optimal concentration and length. Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying a STAR particle preparation to the volar surface of the antecubital fossa.
223524426|NCT06034340|OTHER|LET Gel Application without STAR Particle Application (Contralateral Arm)|Topical lidocaine (0.5 gm of Lidocaine in LET gel) will be applied immediately after applying aloe gel (control condition) to the volar surface of the antecubital fossa of the contralateral arm to the one receiving the STAR particle preparation.
223524427|NCT06639178|OTHER|DECLARAN cream|Patients will apply 1 mL of DECLARAN cream, as a single pressure dispensing (1 for hands, 1 for feet), 2 times/day on hands and feet, starting 3 days before the beginning of treatment with capecitabine and for the first 24 consecutive weeks of treatment.
223524428|NCT06455033|OTHER|Manual Diaphragm Release Technique|The participant will assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. During exhalation, the therapist deepens their contact towards the inner costal margin while maintaining resistance. As the respiratory cycles continues, the therapist progressively increases the depth of their contact within the costal margin.
223524429|NCT06455033|OTHER|Breathing Exercise|"Sit up straight in a chair lengthen the distance between your navel and sternum. Keep your shoulders relax.~Keep the pelvis in neutral position (Sit on your sitting bones). Place your hands at either side of your lower ribs. Breath in slowly through your nose. As you inhale feel your ribs expanding outwards and upwards. During inhalation is generated expansion of the trunk in three directions front , sides and back.~Breath out from your nose. As you exhale feel your lower ribs moving inwards."
223524430|NCT03544463|DEVICE|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
223524431|NCT00478257|DEVICE|bright white light|Intervention: Bright white light administered for 30 minutes each morning
223524432|NCT00478257|DEVICE|comparator red light treatment|dim red light administered for 30 minutes every morning
223524433|NCT06419881|BEHAVIORAL|Tele-drama therapy|A 12-week tele-drama therapy group intervention integrating Playback Theater and Life Review Therapy
223524434|NCT06419881|OTHER|Usual Care|This arm continued to receive the routine activities provided by Uniper Care
223534979|NCT06133023|PROCEDURE|LAMS|"EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed."
224083261|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
224083262|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
224083263|NCT03983395|BIOLOGICAL|ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
223524435|NCT03981640|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
223524436|NCT03981640|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
223524437|NCT03981640|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
223524438|NCT00809822|DRUG|NPB-01|Intravenous immunoglobulin
223524439|NCT00809822|DRUG|Placebo|Physiological saline
223524440|NCT05389072|DEVICE|control contact lens|control CRT lens
223524441|NCT05106556|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, pursed lip breathing exercise, thoracic expansion exercises, upper and lower extremity exercises, stretching the pectoral muscles, posture exercises, walking training and teaching respiratory control.
223524442|NCT05106556|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure with the threshold loading method.
223524443|NCT03470025|OTHER|Psychological Intervention|"1. F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~2. TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~3. CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
223524444|NCT02294864|DEVICE|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
223524445|NCT02294864|PROCEDURE|Physical Therapy|
223524446|NCT03931330|DEVICE|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
223524447|NCT03412929|DEVICE|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
223524448|NCT06052553|DEVICE|TopSpin360|Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
223524449|NCT04897568|OTHER|Patient decision aid|Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
223524450|NCT05480007|DRUG|sitagliptin and metformin|sitagliptin plus metformin group who received sitagliptin (100mg per day) and metformin (500 mg three times per day) (20 patients)
223524451|NCT05480007|DRUG|Sitagliptin|sitagliptin treatment (100mg per day)
223524452|NCT05480007|DRUG|Metformin|metformin group who received metformin (500mg three times per day)
223524453|NCT02474173|OTHER|Laboratory Biomarker Analysis|Correlative studies
223524454|NCT02474173|DRUG|Onalespib|Given IV
223524455|NCT02474173|DRUG|Paclitaxel|Given IV
223524456|NCT02474173|OTHER|Pharmacological Study|Correlative studies
223524457|NCT06564987|DRUG|4% Articaine with 1:200,000 epinephrine|Inferior Alveolar Nerve Block with 4% articaine
223524458|NCT06564987|DRUG|2% lidocaine with 1:100,000 epinephrine|Inferior Alveolar Nerve Block with 2% lidocaine
223534980|NCT01495013|DRUG|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
223534981|NCT01495013|DRUG|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
223534982|NCT01495013|DRUG|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
223534983|NCT01495013|DRUG|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
223534984|NCT01495013|DRUG|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
223534985|NCT01495013|DRUG|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
223534986|NCT01495013|DRUG|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
223534987|NCT01495013|DRUG|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
223534988|NCT01495013|DRUG|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
223534989|NCT01495013|DRUG|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
223524459|NCT04023487|BEHAVIORAL|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
223524460|NCT03947619|DEVICE|Impella CP® placement prior to reperfusion with Primary PCI|Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
223524461|NCT05076110|DRUG|Oxycodone|5 mg tablets every 4 hours postoperatively as needed for pain control
223524462|NCT05076110|DRUG|Ibuprofen|800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day
223524463|NCT05076110|DRUG|Gabapentin|300 mg three times a day for 5 days then wean off by day 10 postoperatively
223524464|NCT05076110|DRUG|Acetaminophen|1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day
223524465|NCT05076110|DRUG|Methocarbamol|500 mg three times a week for 2 weeks postoperatively
223524466|NCT00361712|PROCEDURE|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
223893710|NCT03854214|DEVICE|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 revolutions per minute (RPM). Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
223524467|NCT00361712|DRUG|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS \>5)
223524468|NCT06527430|PROCEDURE|4 mg bupivacaine|Spinal anesthesia was applied to the patients with 4 mg bupivacaine in the lateral decubitus position.
223524469|NCT06527430|PROCEDURE|6 mg bupivacaine|Spinal anesthesia was applied to the patients with 6 mg bupivacaine in the lateral decubitus position.
223524470|NCT05141149|DRUG|PBP1510 (400mg/16mL)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion
223524471|NCT05141149|DRUG|Gemcitabine (1000 mg/m^2)|Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.
223524472|NCT03157128|DRUG|LOXO-292|Oral LOXO-292
223524473|NCT06165107|OTHER|No intervention|No intervention
223524474|NCT06257277|DRUG|GBCAs|GBCAs are given per routine clinical practice.
223524475|NCT06067516|OTHER|Fluid resuscitations|In line with the recommendations in the Surviving Sepsis Guide, fingertip capillary refill time (CRT) will be measured by applying pressure to the index finger for 15 seconds in the T1 time period after 30 mL/kg/3 hours crystalloid infusion.
223524476|NCT06134401|DEVICE|saline|nebulised
223524477|NCT04770285|DEVICE|CT-152 - Digital Therapeutic|CT-152 mobile app was used by the participants as per the schedule specified in the respective arm.
223524478|NCT04770285|DEVICE|Sham|Sham mobile app was used by the participants as per the schedule specified in the respective arm.
223524479|NCT05943496|DRUG|Acalabrutinib|Given PO
223524480|NCT05943496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223524481|NCT05943496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
223524482|NCT05943496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
223524483|NCT05943496|PROCEDURE|Computed Tomography|Undergo CT scan
223524484|NCT05943496|PROCEDURE|Echocardiography|Undergo ECHO
223524485|NCT05943496|BIOLOGICAL|Obinutuzumab|Given IV
223524486|NCT05943496|OTHER|Questionnaire Administration|Ancillary studies
223524487|NCT05943496|BIOLOGICAL|Tafasitamab|Given IV
223524488|NCT03766399|DRUG|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
223524489|NCT03766399|DRUG|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
223524490|NCT05809583|DRUG|Ozanimod|Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care
223524491|NCT01179880|DRUG|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
223524492|NCT01179880|DRUG|Placebo|Matching placebo for each step
223524493|NCT06445439|DEVICE|Pacing rate of 80 bpm|Pacing rate of 80 bpm
223524494|NCT06445439|DEVICE|Pacing rate of 60 bpm|Pacing rate of 60 bpm
223524495|NCT03981055|DEVICE|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
223534990|NCT01495013|DRUG|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
223534991|NCT01495013|DRUG|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
223534992|NCT01495013|DRUG|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
223534993|NCT01495013|DRUG|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
223524496|NCT03981055|DEVICE|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
223524497|NCT03981055|OTHER|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable. (And during the biweekly sessions for Phase II)
223524498|NCT06012084|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF.
223524499|NCT00645658|DRUG|Testim, 1% testosterone gel|Subjects apply contents of gel packet (Testim, 1% testosterone gel) to skin daily.
223524500|NCT03276273|DEVICE|recording of Bispectral Index|recording of Bispectral Index
223524501|NCT05026723|BEHAVIORAL|MTM + ILI|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 20-session telephone lifestyle intervention change program
223524502|NCT05026723|BEHAVIORAL|Standard MTM|Weekly home meal delivery; an explanation of the medical tailoring of the meals; and an initial consultation with a dietitian
223524503|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 400 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
223524504|NCT06269406|DIETARY_SUPPLEMENT|ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg|The combination of ibuprofen 200 mg and Curcumin covered with liquorice root 100 mg in patients after 2-4 molars procedure
223524505|NCT06269406|OTHER|The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure|The combination of ibuprofen 400 mg and placebo 100 mg in patients after 2-4 molars procedure
223524506|NCT00523107|DRUG|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
223524507|NCT00523107|DRUG|Placebo|500 ml normal saline t.i.w. per week
223524508|NCT06291987|DRUG|Ivosidenib|Ivosidenib will be given at assigned dose once daily.
223524509|NCT06291987|DRUG|Ruxolitinib|Ruxolitinib will be given at assigned dose twice daily.
223524510|NCT06129877|DEVICE|CHAMP App|CHAMP App software platform will have been used in other research studies to be included in the Feeding difficulties repository
223524511|NCT06639581|DEVICE|20 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute
223524512|NCT06639581|DEVICE|30 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute
223524513|NCT06639581|DEVICE|40 per minute stimulus|crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
223524514|NCT06637748|PROCEDURE|Echocardiography|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening)"
223524515|NCT06637748|PROCEDURE|Electrocardiography|"Standard 12-lead ECG recording~• Parameters assessed:~* Heart rate and rhythm~* P-wave morphology~* PR interval~* QRS complex duration and morphology~* ST-segment changes~* T-wave abnormalities~* QT interval"
223524516|NCT06639295|DRUG|611|611 subcutaneous (SC) injection.
223524517|NCT06639295|DRUG|Placebo|Placebo subcutaneous (SC) injection.
223524518|NCT06638034|DRUG|68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy|Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
223524519|NCT06641024|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
223524520|NCT06640218|DEVICE|sealer activation with Eddy sonic and AF max|activation of sealer after cleaning and shaping, before the obturation
223524521|NCT06640218|OTHER|without AF max or Eddy sonic sealer activation|sealer without activation
223524522|NCT06640309|DRUG|Nicotinamide Tablet|Nicotinamide is anti-inflammatory and antioxidant.
223524523|NCT06640309|DRUG|conventional synthetic antirheumatic drugs|methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
223524524|NCT06638515|OTHER|Walking apnea at Low Lung Volume|Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
223524525|NCT06638515|OTHER|Walking at normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
223524526|NCT06638528|OTHER|Walking apnea at High Lung Volume|Walking apnea at High Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
223524527|NCT06638528|OTHER|Walking normal breathing|Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
223524528|NCT02003313|BIOLOGICAL|Group T|0.5ml, Intramuscular
223524529|NCT02003313|BIOLOGICAL|Group C|0.5ml, Intramuscular
223524530|NCT05653999|DEVICE|Hearing Aids|Hearing aids will be used by infants with a diagnosed sensorineural hearing loss.
223893711|NCT03854214|DEVICE|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
223524531|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and PRGF ENDORET (PRGF ENDORET®-KMU16)|"A simplified papilla preservation flap (SPPF) will be performed. The clot phase of PRGF ENDORET (F2) will be placed in the defect, while the fibrin membrane phase (F1) will cover it.~Blood will be extracted and collected in dedicated tubes and then centrifuged. Up to 8 tubes of 9ml will be extracted. The time from the start of the extraction to the start of the centrifugation of the tubes must not exceed 4mins.~After centrifugation, the blood is separated into three components: Plasma rich in growth factors, White cells or leukocytes, red blood cells: this is the red column occupying the bottom of the tube.~Following BTI's instructions, fractioning of the centrifuged blood will be performed in order to separate Fraction 2 (F2), which contains a greater number of platelets and growth factors and will be used as a clot inside the periodontal defect from Fraction 1 (F1), which will be used as a fibrin member to cover the clot. The flaps will be repositioned and sutured."
223524532|NCT04254861|PROCEDURE|Simplified Papilla Preservation Flap (SPPF) and GTR|A simplified papilla preservation flap (SPPF) will be performed. The defect will then be treated according to the guided tissue regeneration (GTR) principle (control group). A deproteinized bovine bone mineral (DBBM) graft will be placed in the defect and covered by a collagen membrane.
223524533|NCT01467856|PROCEDURE|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP \> 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
223524534|NCT01066299|DRUG|Syntocinon®|single dose of OXT (24 IU)
223524535|NCT01066299|DRUG|inactive nasal spray|single dose (24 IU)
223524536|NCT04258631|DRUG|Hydromorphone|Given IT
223524537|NCT04258631|PROCEDURE|Laparotomy|Undergo laparotomy
223524538|NCT04258631|DRUG|Liposomal Bupivacaine|Drug
223524539|NCT04258631|OTHER|Questionnaire Administration|Ancillary studies
223524540|NCT03895372|DRUG|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
223524541|NCT03895372|DRUG|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
223705154|NCT01065259|DRUG|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
223705155|NCT04711434|DRUG|PD-1 Antibody|Toripalimab: 240mg IV every 3 months for a year
223524542|NCT01179555|BEHAVIORAL|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
223524543|NCT01179555|BEHAVIORAL|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
223524544|NCT06441305|BEHAVIORAL|SWITCH intervention package|"* Addition of digital monitoring \& supervision by CHA~* Digitized registration of households by CHPs every 6 months~* Digital reminders to CHP to conduct home visit if a child has never been visited in 3 mo.~* Digital reminder for timely training to family MUAC of all family members through home visit by CHP when child turns 6 months of age.~* Platform for 2-ways messaging: biweekly SMS reminders to caregivers through the CHP's app; feedback by caregiver~* Community level screening based on weight and weight-for-age (WAZ) led by CHP every other month (aligned with Community Action Days),~* Digital calculation of WAZ.~* CHP and Growth Monitoring and Promotion refer to health facility if WAZ\<-3 to check on WHZ eligibility~* At the end of every wasting treatment consultation, compilation of the list of defaulters and non-respondents, for immediate transmission by CHA to relevant CHP through digital task of an instruction for immediate follow-up."
223524545|NCT04466839|OTHER|Questionnaire and interview|The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
223524546|NCT03119220|DEVICE|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
223524547|NCT04316416|PROCEDURE|T7 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T7 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T7 spinous process.~After imaging of erector spina musceles and transvers process of 7 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
223705156|NCT03533296|PROCEDURE|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
223705157|NCT02017418|DIETARY_SUPPLEMENT|zeaxanthin|softgel
223705158|NCT02017418|DIETARY_SUPPLEMENT|combinatory supplement|softgel
223705159|NCT01095926|DRUG|doxorubicin|blood sampling before, during and after doxorubicin administration
223524548|NCT04316416|PROCEDURE|T9 Level Erector Spinae Plane Block|"ESP block is planned after the completion of surgery and before the extubation. Its application will be planned from the T9 level bilaterally when the patients are turned to the right lateral position. A linear ultrasound probe will be placed in the longitudinal parasagittal orientation 3 cm to lateral of T9 spinous process.~After imaging of erector spina musceles and transvers process of 9 th trorocal vertebrae, an ultrasound-guided local anaesthetic mixture ( 0.5% bupivacaine 15 cc + 2% lidocaine 5 cc) will be applied to the region between spinae muscles and transverse process using a needle of 22 gauge \& 8cm directed from cranial to caudal.~After application of the same procedure to the other side, the patients will be woken-up and patient-controlled analgesia consisting of intravenous morphine will be planned for all of them.~Additionally, at postoperative 1.,4.,8.,12.,24. hours, NRS scales and morphine consumption will be recorded."
223524549|NCT04316416|DRUG|control group|24 hours morphine consumption will be recorded using the patient controlled analgesia device with intravenous morphine.
223524550|NCT06089993|OTHER|Exercise|"The total volume of exercise is 40 repetitions of each of the 4 exercises. The participant is instructed to perform a maximum of 10 repetitions each set, with 1'30'' rest between sets and between exercises. The researcher provides instructions and verbal encouragement. The total duration of the exercise bout is between 1 hour and 1 hour and 15 minutes.~Part 1: Before and after the exercise condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
223524551|NCT06089993|OTHER|Rest|"The participant remains in sedentary activities such as reading or using a laptop.~Part 1: Before and after the rest condition the participant is sampling 8 different samples: (1) sucrose (2) umami (3) soy protein (4) pea protein (5) hemp protein (6) brown rice (7) whey protein and (8) apple juice.~All protein sources are 3 grams dissolved in 20ml apple juice. Sucrose is 1.66g in 20ml water and umami tastant is 0.09g in 20ml water.~Part 2: a 30g soy protein bolus in 200ml apple juice is given to the participant. After 1 hour energy intake is assessed with an ad libitum lunch meal."
223524552|NCT01206127|OTHER|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
223524553|NCT01206127|OTHER|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
223524554|NCT06634784|OTHER|Bone Conduction Implant (BCI)|Improvement in hearing using BCI.
223524555|NCT03896633|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
223524556|NCT03896633|DRUG|Azopt 1%|Azopt 1%, RLD
223524557|NCT06271057|DRUG|golcadomide|golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
223524558|NCT05687578|DIAGNOSTIC_TEST|Measurements Only|This is an observational study only using biospecimen and imaging-based measurements only
223524559|NCT01722643|BEHAVIORAL|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
223534994|NCT01570387|DRUG|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle
223705160|NCT03361163|BIOLOGICAL|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
223893712|NCT04354480|BIOLOGICAL|RSV Vaccine|Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
223893713|NCT04354480|OTHER|Placebo|Participants will receive a single IM injection of matching placebo on Day 1.
223893714|NCT04263467|OTHER|Exercise intervention|The exercise intervention will consist a intermediate to high aerobic exercise training program.
223534995|NCT01570387|DRUG|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
223534996|NCT02499744|DEVICE|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
223534997|NCT02499744|DEVICE|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
223534998|NCT04204824|OTHER|Ultrasound and exercise|"The control group's ultrasound will be set at an intensity of 0 w/cm2. The first 3 treatments to the experimental group will be continuous ultrasound with an intensity of 1.0w/cm2 for 7 minutes. The next 6 treatments for the experimental group (2 times a week for 3 weeks) will have pulsed ultrasound at an intensity of 1.0w/cm2 with a 50% (1:1) duty cycle for 10 minutes. All will have a frequency of 3 MHZ.~All participants in each group will be given specific exercises targeting intrinsic and extrinsic muscles of the foot and ankle. Exercises will be performed with a level of thera-band that is challenging to the individual participant in each plane of motion without increased pain for 3 sets of 10 repetitions each and one time each day independently at home during the duration of the treatment protocol (4 weeks) and recorded in an exercise log diary Specific stretches for the plantar fascia and Achilles tendon will be performed 3 times each for 30 second intervals and at home"
223534999|NCT03325231|OTHER|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
223524560|NCT01722643|BEHAVIORAL|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
223524561|NCT05423613|PROCEDURE|Microneedling|A 5% lidocaine anesthetic cream will be applied to the scar to be treated and will be wrapped with an occlusive dressing (saran wrap) for 30 minutes prior to the procedure. The same scar will be subjected to the ACS-Pen treatment at a depth of 1.5 mm or less depending on the results of the thickness measurement performed prior to treatment. Within 5 minutes after the microneedling treatment, a thin layer of triamcinolone acetonide and 2% xylocaine (1:3 ratio) suspension will be spread over the scar. The physician will then gently massage the product into the microneedling columns. The same amount will be used for each subsequent treatment. The patient will also be given a small amount of hydrocortisone 2.5% (low potency corticosteroid) to be applied to the treated site at 12 hours and 24 hours post-treatment.
223524562|NCT04289493|OTHER|Language and functional communication therapy|17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
223524563|NCT04283175|OTHER|Posturological examination on KPlates and AMTI platforms|By an unique evaluator
223524564|NCT04283175|OTHER|Berg Balance Scale (BBS)|Falls and fera of falling, motor and sensory impairments
223524565|NCT04639726|DIETARY_SUPPLEMENT|Whey Protein Micro Gel|The test product is whey protein microgels 10g, reconstituted in 125ml water.
223524566|NCT04639726|OTHER|Water without Whey Protein.|A matching placebo (125ml of water without whey protein) will be used as control.
223524567|NCT01472185|DRUG|Ranolazine|Ranolazine tablets administered orally twice daily.
223524568|NCT01472185|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily.
223524569|NCT01472185|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
223524570|NCT01472185|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
223524571|NCT06501105|DEVICE|WOUNDCHEK Bacterial Status|Lateral flow point of care test for the qualitative detection of bacterial protease activity in wound fluid.
223524572|NCT01443312|GENETIC|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
223524573|NCT05870072|OTHER|Dual task training|In addition to balance exercises, random name-word generation, counting the days of the week forward and backward, counting the months of the year forward and backward, subtracting 3 by 3 numbers from 300 to 900 starting from a random number, adding 7 from 1 to 100 and adding 100 Cognitive tasks such as counting tasks by subtracting 7 will be given. While testing dual-task performance, subjects will be asked to perform both tasks without prioritizing and do their best, and will be warned not to stop thinking. In dual-task training, the additional task to be assigned to the motor task will initially be of low complexity and novelty, and will progress to a high degree of complexity and novelty in the training process.
223524574|NCT05870072|OTHER|Kinesthetic motor imagery training|Kinesthetic motor imagery training will be planned according to the PETTLEP model. In our study, a single standard motor imagery frame will be created for the subjects. Before starting the motor imagery sessions, individuals will be given an introductory motor imagery session. How to visualize from first-person and third-person perspectives will be explained practically. Motor imagery training will be done in a quiet environment with the door and window closed in order to minimize the external factors that will distract the individual and prevent him from focusing, and the individual will be asked to sit in the motor imagery training sessions. a comfortable chair in the position they feel most comfortable in. Individuals will have their eyes closed throughout the entire motor imagery training. At the beginning of the session, approximately 5 minutes of relaxation exercise will be performed to maximize attention during motor imagery.
223524575|NCT05870072|OTHER|Balance exercises|Balance exercises will begin with approximately 5 minutes of warm-up exercises and will end with approximately 5 minutes of cool-down exercises at the end of each session. Balance exercises; Static standing on flat ground for 30 seconds with feet together, standing in tandem position for 30 seconds, standing on one leg for 30 seconds, and toes for 30 seconds, one foot airborne backwards, one foot airborne knee flexion slightly squat, one foot airborne knee extension slightly squat, going on the toes, turning with the heel, and multi-directional stretching exercises with eyes open and closed on one leg on the balance board. Each exercise will be performed with 10 repetitions for both lower extremities. Exercises will be applied once a day, 3 days a week for 6 weeks. The exercise program will be accompanied by a physiotherapist and groups of 6-10 people with similar suitability will be formed for the session hours.
223524576|NCT05889468|DRUG|Aspirin 81Mg Ec Tab|Participant may be provided with a 6-week supply of 81 mg of aspirin prior to discharge from the delivery admission.
223524577|NCT05889468|DRUG|Placebo|Participant may be provided with a 6-week supply of placebo to discharge from the delivery admission.
223524578|NCT01309230|BIOLOGICAL|Vigil™|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
223705161|NCT01068834|GENETIC|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
223705162|NCT03663946|OTHER|Non-Interventional|Non-Interventional
223705163|NCT02430623|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
223705164|NCT02430623|DEVICE|NanoKnife|
223705165|NCT01907243|PROCEDURE|spreader flap|producing of upper lateral cartilage flap as a spreader flap
223705166|NCT02479607|DEVICE|Smartphone or tablet|
223705167|NCT00547235|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223705168|NCT00547235|PROCEDURE|allogeneic bone marrow transplantation|
223705169|NCT00547235|RADIATION|total-body irradiation|
223705170|NCT02241252|DEVICE|iPhone ECG|Please see detailed description for additional information.
223524579|NCT05985135|PROCEDURE|Muscle Biopsy|Needle muscle biopsy of the outer thigh muscle
224275832|NCT03681028|DRUG|Individualized therapy|"1. For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~2. When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~3. When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."
224275833|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
223524580|NCT05985135|OTHER|Jell-O with Amino acids|An amino acid mixture containing 13C6 Lysine isotope label
223524581|NCT05985135|DIETARY_SUPPLEMENT|Dextrose|Intravenous form of sugar
223524582|NCT05468918|DEVICE|Phonak Audeo previous generation hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
223524583|NCT05468918|DEVICE|Phonak Audeo Lumity hearing aids|Receiver-in-canal (RIC) hearing aids with universal earpieces
223524584|NCT04481685|DRUG|ATI-450|50 mg (as determined from Phase I study) per dose. (100 mg per day). Up to a maximum of 14 days while inpatient. Patients discharged home or transferred to the intensive care unit (ICU) will be discontinued off drug permanently.
223524585|NCT04481685|DRUG|Placebo|Placebo pill will be taken twice daily preferably spaced 12 hours apart.
223524586|NCT03941561|DRUG|S-1 for 9 months|S-1 for 9 months after D2 resection
223524587|NCT03941561|DRUG|S-1 for 1 year|S-1 for 1 year after D2 resection
223524588|NCT06337214|BEHAVIORAL|Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy|Comparing cancer patients who have participated in the program with those who have not, this study will examine differences in two types of quality of life questionnaires and constitution between the two groups.
223524589|NCT04240509|DRUG|Emtricitabine / Tenofovir|Incarcerated men identified at high risk for HIV transmission will be given a 30-day supply of the study drug and will be provided with patient navigation to follow up care upon release.
223524590|NCT04611243|BIOLOGICAL|third dose vaccination with CoronaVac vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine
223524591|NCT04611243|BIOLOGICAL|third dose vaccination with BionTech vaccine|Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine
223524592|NCT04611243|BIOLOGICAL|Vaccination with Coronavac vaccine|Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart
223524593|NCT04611243|BIOLOGICAL|Vaccination with BionTech Vaccine|Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
223524594|NCT06570746|DRUG|Sedative|Sedation is applied before the procedure
223524595|NCT06570174|DIETARY_SUPPLEMENT|oral protein supplements|Participants in this group received an oral protein supplement providing 18g of protein per day. The supplement was administered postoperatively and continued throughout the study period. The goal was to assess the impact of protein supplementation on protein intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed. These outcomes were measured at three specific time points: before surgery, at discharge, and during the outpatient visit.
223524596|NCT06570174|GENETIC|placebo|Participants in this group received a placebo supplement containing carbohydrates instead of protein, which was identical in appearance and taste to the protein supplement to maintain the study's double-blind design. The placebo was administered postoperatively and continued throughout the study period. The aim was to serve as a control to evaluate the effects of the protein supplement on outcomes including nutrient intake, nutritional status, quality of life, muscle mass, muscle strength, and 10-meter gait speed, measured at three key time points: before surgery, at discharge, and during the outpatient visit.
223524597|NCT06557811|DRUG|Semaglutide|After randomization, each patient will receive four blisters of 3 mg tablets (semaglutide or placebo) and four blisters of 7 mg tablets (semaglutide or placebo), to be taken before breakfast. After 60 days, the patient will receive a 14 mg dose (a total of 16 blisters with 7 tablets each). The possibility of maintaining the 14 mg dose of the study drug or reducing it to 7 mg will be evaluated depending on side effects and tolerability.
223524598|NCT02891356|DEVICE|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
223524599|NCT00823797|DRUG|Bendamustine Hydrochloride|Given IV
223524600|NCT00823797|OTHER|Quality-of-Life Assessment|Ancillary studies
223524601|NCT02899403|OTHER|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
223524602|NCT04279587|BEHAVIORAL|Residential camp|Intensive education at a residential camp.
223524603|NCT05417906|OTHER|Standard care|Oral prednisolone for 5 days
223524604|NCT05417906|OTHER|Eosinophil-directed care|Oral prednisolone for 5 days if eosinophil count is ≥ 0.300 x 10\^3/µL, or 3 days if eosinophil is \< 0.300 x 10\^3/µL
223524605|NCT06252415|BIOLOGICAL|foetal amniotic fluid sample|At the inclusion visit, during the foetal samples taken for the CMA/ES as part of the care.
223705171|NCT02445508|DRUG|Sevelamer|
223705172|NCT02445508|DRUG|Cholecystokinin|
223705173|NCT02445508|DRUG|Sevelamer placebo|
223705174|NCT02445508|DRUG|Isotonic saline|
223705175|NCT01573260|OTHER|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
223524606|NCT06252415|BIOLOGICAL|blood samples|2 x 5ml blood EDTA tubes for both parents
223524607|NCT06252415|OTHER|semi-structured online interviews|25 included couples will be invited to take part in 2 semi-structured online interviews (by telephone or videoconference)
223524608|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection (prefilled syringe)|MG-K10 Humanized Monoclonal Antibody Injection
223524609|NCT06277284|DRUG|MG-K10 humanized monoclonal antibody injection（Penicillin bottle）|MG-K10 humanized monoclonal antibody injection (single injection)
223524610|NCT06563817|DRUG|Rapamycin|All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
223524611|NCT04541927|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
223524612|NCT03049644|PROCEDURE|Mechanical Diagnosis and Therapy|Identification of directional preference.
223524613|NCT03049644|PROCEDURE|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
223524614|NCT00356187|DRUG|Propranolol|
223524615|NCT05226338|DRUG|D-0502|Formulation 1 Formulation 2 Formulation 3
223524616|NCT03104920|PROCEDURE|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
223524617|NCT03104920|PROCEDURE|Traditional treatment|A traditional perioperative management for HCC.
223524618|NCT01459627|OTHER|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
223524619|NCT01459627|OTHER|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
223524620|NCT03517605|OTHER|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
223524621|NCT01146821|DIETARY_SUPPLEMENT|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care
223524622|NCT01146821|DIETARY_SUPPLEMENT|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight \[IBW\] fish oil in addition to standard care.
223524623|NCT05272280|OTHER|External oblique intercostal (EOI) block|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
223524624|NCT05272280|OTHER|Erector spinae plane block (ESPB)|A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of Local Anesthetic mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
223524625|NCT03986892|BEHAVIORAL|Physical Activity|Physical Activity
223524626|NCT03032809|OTHER|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
223524627|NCT04584723|OTHER|Observation of flap survival and complications|We will report the flap survival and complications in this population group underwent to microsurgical procedures in a private practice setting
223524628|NCT05699057|BEHAVIORAL|Suicide GROUP|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains. Finally, we will To document the prevalence of tendency to suicide among medical students in the Egyptian Universities and analyse associated risk factors and any correlated determents.
223524629|NCT04913116|DIAGNOSTIC_TEST|Comparison of antigen tests with RT-PCR as reference method|Antigen tests are performed locally including sampling from multiple anatomical testing sites. A reference oropharyngeal swab is always send for RT-PCR for SARS-CoV-2 at DTU to verify the status of the patient. RT-PCR samples from other anatomical test locations may be included.
223524630|NCT00725855|DRUG|MEM 3454|1 mg dose
223524631|NCT00725855|DRUG|MEM 3454|5 mg dose
223524632|NCT00725855|DRUG|MEM 3454|15 mg dose
223524633|NCT00725855|DRUG|MEM 3454|50 mg dose
223524634|NCT00725855|DRUG|Placebo for MEM 3454|Placebo dose
223524635|NCT01156350|DRUG|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained \< 2.5 x 104 CD3+ cells/kg
223524636|NCT00672035|BIOLOGICAL|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
223524637|NCT00892866|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223524638|NCT00892866|OTHER|Laboratory Biomarker Analysis|Correlative studies
223524639|NCT04150445|BEHAVIORAL|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
223524640|NCT03063645|DRUG|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
223524641|NCT03063645|DRUG|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
223524642|NCT03063645|DRUG|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
223524643|NCT03728686|OTHER|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
223705176|NCT01573260|OTHER|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
224275834|NCT02414464|OTHER|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
223705177|NCT02202980|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223524644|NCT05612945|OTHER|High-intensity interval training group (HIIT)|"Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
223705178|NCT02202980|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223705179|NCT02202980|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
223524645|NCT05612945|OTHER|Low-to-moderate intensity training group (LowMod group)|"Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland)."
223524646|NCT01256047|DIETARY_SUPPLEMENT|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
223705180|NCT02202980|DRUG|VOX|100 mg tablet administered orally once daily with food
223705181|NCT00006477|DIETARY_SUPPLEMENT|mistletoe extract|
223705182|NCT05200832|OTHER|Online questionnaire|Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
223705183|NCT05200832|OTHER|Semi-structured interview|20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
223705184|NCT00763529|DRUG|Mometasone|Mometasone furoate cream 0.1% applied once daily
223705185|NCT00763529|DRUG|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
223705186|NCT00001688|DRUG|Ritonavir|
223705187|NCT00001688|DRUG|Nevirapine|
223705188|NCT00001688|DRUG|Stavudine|
223705189|NCT03026322|OTHER|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
223705190|NCT03026322|OTHER|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
223705191|NCT05456269|DRUG|Bisantrene Dihydrochloride (high dose)|Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2
223705192|NCT05456269|DRUG|Bisantrene Dihydrochloride (low dose)|IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached.
223705193|NCT05456269|DRUG|Cytarabine Hydrochloride|Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5
223705194|NCT05456269|DRUG|Decitabine and cedazuridine|PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion
223705195|NCT02328300|DRUG|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
223705196|NCT01676571|DRUG|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
223524647|NCT06040398|BEHAVIORAL|JUMPSTART exercise program|The intervention is an early mobilization protocol (JUMPSTART). Four interactive exercise videos, at different intensity levels, include a variety of stretches and exercises designed to improve the full body mobilization of post-TAVR patients. Videos have been developed in consultation with a physiotherapist and cardiac rehabilitation specialist and have been piloted for initial acceptability by patients at the Hamilton General Hospital. The videos will be freely accessible to all eligible patients and their caregivers (regardless of participation in the research study) online (www.hhscebi.ca/projects/jumpstart). A written version of the exercise program, with photographs and detailed instructions, will also be made available. Additional exercise videos will be developed based on patients' needs and feedback received.
223524648|NCT02082977|DRUG|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
223524649|NCT03185026|BEHAVIORAL|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~1. Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~2. Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~3. and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5\) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
223524650|NCT03185026|OTHER|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
223524651|NCT01331655|DRUG|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
223524652|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
223524653|NCT01331655|DRUG|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
223524654|NCT00382226|DRUG|Azopt|
223524655|NCT00001382|BIOLOGICAL|PROSTVAC|
223524656|NCT00049543|DRUG|gefitinib|Given PO
223524657|NCT00049543|OTHER|placebo|Given PO
223524658|NCT00049543|OTHER|laboratory biomarker analysis|Correlative studies
223524659|NCT03045952|PROCEDURE|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
223524660|NCT02053155|BEHAVIORAL|Computer based patient education|
223524661|NCT06332157|DRUG|Remimazolam besylate|In Remimazolam group, anesthesia was induced with remimazolam besylate at a rate of 6mg/min and maintained with 1.0-2.0mg/min until the end of surgery.
223524662|NCT06332157|DRUG|Propofol Injection Emulsion|In Propofol group, anesthesia was induced with propofol injection emulsion at a rate of 2mg/kg and maintained with 6-8mg/kg/h until the end of surgery.
223524663|NCT03464201|DRUG|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
223524664|NCT01048957|BEHAVIORAL|Real Time Feedback Training|
223893715|NCT04263467|OTHER|Standard oncological treatments|Standard oncological treatments
223893716|NCT04255615|OTHER|AI to analyze 3 D ultrasound|AI to assess 3 D ultrasound to assess antral follicle count
223524665|NCT06218602|DRUG|Fecal Microbiota Transplantation|Given by PO
223524666|NCT06218602|PROCEDURE|Chemotherapy|Given by Infusion
223524667|NCT06218602|PROCEDURE|CAR-T Therapy|Given by Infusion
223524668|NCT03485157|BIOLOGICAL|Micronized dHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
223524669|NCT03485157|DRUG|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
223524670|NCT00422487|DRUG|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
223524671|NCT00422487|DRUG|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
223524672|NCT00422487|DRUG|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
223524673|NCT00422487|DRUG|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
223524674|NCT00422487|DRUG|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
223524675|NCT00422487|DRUG|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
223524676|NCT00422487|DRUG|Placebo for MBX-2044|Placebo Intervention
223524677|NCT02386241|OTHER|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
223524678|NCT00770393|PROCEDURE|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
223524679|NCT00770393|PROCEDURE|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~\- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
223524680|NCT01460615|DRUG|Hydrocortisone|
223705197|NCT05562414|BEHAVIORAL|HIIT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will perform six high-intensity intervals (95% HRmax) at high pedalling rates of 80-100 rounds per minute (rpm) for 60-90 seconds each. Intervals are interspersed by active breaks of unloaded pedalling (20 watts, 60-80rpm) aimed to return to 60% HRmax (approximately 1.5-2 min). The duration of the HIIT bout is approximately 21 minutes."
223705198|NCT05562414|BEHAVIORAL|MCT|"Exercise intensity will be regulated and heart rate controlled based on the age-predicted heart rate (HRmax), as calculated by the formula 220 minus age in years.~Participants will continuously train at 60% HRmax and pedal at 60-80 rounds per minute. The duration of the MCT bout is 26 minutes."
223705199|NCT01418170|OTHER|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
223705200|NCT04715633|DRUG|PD-1 inhibitor plus VEGF inhibitors|Camrelizumab 200mg IV every 3 weeks; Apatinib 250mg QD day 1-14. Rescue chemotherapy: Oxaliplatin 130mg/m2 IV drip Q3W d1+Capecitabine 1000mg/m2 QD d1-d14 Rescue chemoradiotherapy: Long-course radiotherapy +Capecitabine 825mg/m2 QD d1-d14
223524681|NCT06537687|OTHER|Control|A standardized handout on HPV and vaccine education will be given
223524682|NCT06537687|OTHER|Intervention|A video about HPV and vaccines on a tablet provided by a research assistant
223705201|NCT05789160|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
223705202|NCT02343679|DRUG|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
223705203|NCT01101880|BIOLOGICAL|filgrastim|Given SC
223705204|NCT01101880|DRUG|clofarabine|Given IV
223705205|NCT01101880|DRUG|cytarabine|Given IV
223705206|NCT01399814|BEHAVIORAL|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000\~1500ml crystalloid was administered on the days following operation
223524683|NCT03358173|PROCEDURE|Conservative Treatment|Conservative Treatment
223524684|NCT03358173|PROCEDURE|Operative Plate Fixation|Operative Plate Fixation
223524685|NCT03531541|DEVICE|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
223524686|NCT03531541|DEVICE|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
223705207|NCT01399814|BEHAVIORAL|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000\~2500ml crystalloid was administered on the days following operation
223705208|NCT01302756|OTHER|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
224275835|NCT02414464|OTHER|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
224275836|NCT05771051|DEVICE|Headpulse measurements|Placement of headset on subject
223524687|NCT03531541|DEVICE|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
223524688|NCT03531541|DEVICE|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
223524689|NCT00660231|DRUG|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
223524690|NCT00660231|DRUG|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
223524691|NCT05050669|OTHER|No Intervention for this observational study|No Intervention for this observational study
223524692|NCT05021848|OTHER|partnered multicomponent exercises program|aerobic,strength, flexibility and balance exercises and game
223524693|NCT00003670|DRUG|arzoxifene hydrochloride|
223524694|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
223524695|NCT02233569|PROCEDURE|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
223524696|NCT02233569|DEVICE|Ventralight ST implant|
223524697|NCT02233569|DEVICE|ETHICON PHYSIOMESH®|
223524698|NCT00538447|OTHER|Database|data base for CML
223524699|NCT04379830|DIETARY_SUPPLEMENT|Very Low Energy Diet|Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
223524700|NCT01522872|DRUG|TH-302|
223524701|NCT01522872|DRUG|TH-302 and Dexamethasone|
223524702|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
223524703|NCT01522872|DRUG|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
223524704|NCT04021745|BEHAVIORAL|App-based mindful eating|This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
223524705|NCT04785638|COMBINATION_PRODUCT|INL-001 (bupivacaine hydrochloride) implant|INL-001 (bupivacaine hydrochloride) implant
223524706|NCT05295472|BEHAVIORAL|Grapholearn|GL is a computer game based on the phonics-method (i.e., graphem-phoneme correspondence). It was developed at Jyväskylä University in Finland, in several languages, among others also for Swedish.
223524707|NCT05295472|BEHAVIORAL|Vector|A computer game focusing on children's development of mathematic skills
223524708|NCT05295472|BEHAVIORAL|Usual schooling|No GL or Math computer games, only the usual schooling
223524709|NCT02129621|PROCEDURE|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
223524710|NCT02129621|DRUG|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
223524711|NCT05810480|DIAGNOSTIC_TEST|polyreactive immunoglobulin G|Polyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.
223524712|NCT01793389|PROCEDURE|Subepithelial connective tissue graft|
223524713|NCT01793389|PROCEDURE|Platelet Rich Fibrin|
223524714|NCT05238740|OTHER|ViviGen®|It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
223524715|NCT05238740|OTHER|rhBMP-2|It will investigate the radiological and clinical outcome of ALIF procedure L5/S1 and XLIF L4/L5 procedure using two arms/ treatments, namely either ViviGen® Bone Matrix (intervention group) or rhBMP-2 (control group). ViviGen®/ rhBMP-2 ratio will be 1:1.
223524716|NCT06638723|BEHAVIORAL|Balance and fall recovery training|Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
223524717|NCT06642051|DEVICE|High Intensity focused ultrasound|Sonablate High Intensity Focused Ultrasound system to ablate incompetent veins of the periphery
223524718|NCT06641453|BIOLOGICAL|GPC3-CART cells|"Phase 1: Dose escalation (3+3): Dose 1 (1 × 10\^6 cells/kg) with or without FC regimen, Dose 2 (3 × 10\^6 cells/kg), Dose 3 (6 × 10\^6 cells/kg).~Phase 2: Dose at RP2D."
223524719|NCT06641453|DRUG|Fludarabine Phosphate for Injection|Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
223524720|NCT06641453|DRUG|Cyclophosphamide for Injection|Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
223705209|NCT01302756|DIETARY_SUPPLEMENT|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
223705210|NCT06511830|DIAGNOSTIC_TEST|Dental Monitoring images|Dental Monitoring is a series of intraoral photos that will be taken and assessed to determine the subject's dental plaque levels.
223705211|NCT02072083|DRUG|Dexmedetomidine|via intranasal route 1 mcg/kg
223705212|NCT02072083|DRUG|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
224275837|NCT06012578|DRUG|ISM5411|Investigational Drug
223705213|NCT02130570|OTHER|Multi-Model Intensive Discharge Intervention|"1. Inpatient medication safety interventions~2. Inpatient discharge advocate~3. Structured visiting nurse (VNA) appointments~4. Post-discharge phone call by primary care personnel within 2 business days of discharge~5. Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~6. Improved communication between inpatient and primary care teams~7. High-risk patients will receive additional interventions as needed:~   1. Home pharmacist visit~  2. Enrollment in the Partners integrated Care Management Program (iCMP)~  3. Enrollment in telemedicine programs for patients with CHF~  4. Palliative care consultation regarding goals of care~8. Novel health information technology to facilitate communication and transfer of clinical information"
223524721|NCT04562090|DRUG|mirabegron|Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet
223524722|NCT06643247|DRUG|Drug|1\) Valacyclovir Hydrochloride tablets, 0.3 g per dose, twice daily; 2) Mecobalamin tablets, 0.5 mg, three times daily. Taken continuously for 7 days.The affected skin is kept clean and protected to maintain lesion integrity.
223524723|NCT06643247|PROCEDURE|Electroacupuncture|Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
223705214|NCT00512005|DEVICE|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
223705215|NCT05224986|BEHAVIORAL|Fixed Schedule|Participants will be asked to maintain a fixed schedule for 12 weeks.
223705216|NCT04424888|OTHER|WB-011|WB-011 medical food product.
223705217|NCT04424888|OTHER|Placebo|Placebo Capsules identical to those containing WB-011.
223705218|NCT04424888|DEVICE|Continuous Glucose Monitor|Abbott Freestyle Libre(™) Glucose Sensors were used throughout the study.
223705219|NCT05839600|DRUG|BI 1821736|Solution for infusion
223705220|NCT01008592|DRUG|levocetirizine or placebo|oral administration, single tablet, 5 mg.
223705221|NCT06221462|DRUG|Sintilimab|200mg, every 3 weeks, 3 cycles, in the neoadjuvant setting, and adjuvant 200mg,every 3 weeks no more than one year
223705222|NCT06221462|DRUG|Anlotinib|8mg, orally, D1-14, every 3 weeks, 2 cycles in only neoadjuvant setting
223705223|NCT01696695|DRUG|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
223705224|NCT01696695|DRUG|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
223705225|NCT05346874|DRUG|Oxaliplatin|"The first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1.~The second and fourth cycles: intra-venous oxaliplatin 135mg/m2, day 1."
223705226|NCT05346874|DRUG|Teysuno|Oral S-1, 40mg-60mg, day 1-14 for four 21-day cycles.
223705227|NCT05346874|PROCEDURE|Transarterial chemoembolization (TACE)|In the first and third cycles : transcatheter arterial infusion of oxaliplatin 85mg/m2, day 1; transcatheter arterial embolism of tumor feeding arteries, day 1.
223705228|NCT06088875|DRUG|Nebulization|Patients will be nebulized with mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg by using wall nebulizer for 15 min before awake fiberoptic intubation. Patients in group S will receive saline 10 ml nebulization
223705229|NCT06088875|DRUG|Spray-as-you-go|Patients will receive a mixture of 2% lidocaine 10 ml and dexmedetomidine 1 μg/kg via spray-as-you-go technique + saline 10 ml nebulization. Patients in group N will receive saline via spray-as-you-go technique
223705230|NCT01322659|DEVICE|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
223705231|NCT01322659|DEVICE|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
223705232|NCT05788120|OTHER|Follow up by phone call|Centralized review of ECGs by the Pitié-Salpêtrière rhythmology department and collection of vital status at 12 months (if information not available, telephone call to the patient)
223705233|NCT00766025|DRUG|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
223705234|NCT00443092|OTHER|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
223705235|NCT00443092|OTHER|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
223705236|NCT03881670|DEVICE|Lotrafilcon B|commercially available contact lens
223705237|NCT03881670|DEVICE|lotrafilcon B with Hydraluxe|commercially available contact lens
223705238|NCT04342377|DIAGNOSTIC_TEST|Selective Targeted Sampling|Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.
223705239|NCT04342377|DIAGNOSTIC_TEST|Systematic Sampling|All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
223705240|NCT04326075|DEVICE|CPAP treatment|CPAP should be performed as soon as possible and only with a helmet, using a positive end-expiratory pressure (PEEP) between 8 and 14 cmH2O and an inspired oxygen fraction (FiO2) between 40 and 60%.
223705241|NCT01180647|DRUG|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
223705242|NCT01180647|BEHAVIORAL|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
223705243|NCT02243969|DIETARY_SUPPLEMENT|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
223705244|NCT02243969|DIETARY_SUPPLEMENT|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
223705245|NCT00386607|DRUG|Aliskiren|Aliskiren 300 mg
223705246|NCT00386607|DRUG|Valsartan|Valsartan 320 mg
223705247|NCT00386607|DRUG|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
223705248|NCT00147212|DRUG|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
223705249|NCT04264338|DIAGNOSTIC_TEST|Thyromental height test|Assessment of difficult airway
223705250|NCT02976922|DIETARY_SUPPLEMENT|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
223705251|NCT03358797|BEHAVIORAL|Attention-control|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
223705252|NCT03358797|BEHAVIORAL|Community based intervention with resilience training|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
223705253|NCT03358797|BEHAVIORAL|intervention-HPP|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
223705254|NCT03358797|BEHAVIORAL|Pilot|Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
223705255|NCT01844557|OTHER|Swallowing Exercises|Participants perform 3 swallowing exercises.
223705256|NCT01844557|BEHAVIORAL|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
223705257|NCT01844557|BEHAVIORAL|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
223705258|NCT02059252|DEVICE|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
223705259|NCT00833716|DRUG|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
223705260|NCT01927627|DRUG|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
223705261|NCT02212470|DEVICE|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
223705262|NCT02212470|DEVICE|Nitinol stenting|Nitinol stent deployment
223705263|NCT04032548|DRUG|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
223705264|NCT04032548|DRUG|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
223705265|NCT04032548|DRUG|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
223705266|NCT02744703|DRUG|total-etch adhesive|comparator use of total-etch adhesive
223705267|NCT02744703|DRUG|CAPE-T|experimental group
223705268|NCT02744703|DRUG|self-etch adhesive|comparator use of total-etch adhesive
223705269|NCT02744703|DRUG|CAPE-S|experimental group
223705270|NCT00467857|PROCEDURE|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal\* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
223705271|NCT00467857|OTHER|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
223524724|NCT06639009|OTHER|940nm diode laser photobiomodulation|"The surgical handpiece (diameter 0.6cm) will be used without the fibre optic tips in defocused mode and head sanitized before therapy.~Peak Power : 0.3Watts Power density: 1 Watt/cm2 Fluence: 4J/cm2 per cycle Spot size : 0.28cm2 Distance : 2mm from surface Mode: Continuous, Non- contact mode, circular motion, overlapping, in clockwise concentric manner with laser handpiece perpendicular to surface Duration of cycle : 25 seconds with interval of 30 seconds alternating with other side Cycles per sitting: Four for each side Four Sittings: Day 0,3, 7, and 15 Area of intervention: Bilateral buccal mucosa and masseter muscle Total treatment time per day: 430 seconds/ approx 7 minutes Total treatment time for 4 sittings: approx 28 minutes"
223705272|NCT02701699|BIOLOGICAL|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
223705273|NCT00586651|DRUG|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
223705274|NCT00989157|DRUG|Duloxetine|Single dose of 60 mg of duloxetine
223705275|NCT02058472|DRUG|G3041|
223705276|NCT02058472|DRUG|SEVIKAR®|
223705277|NCT02547675|DRUG|Rociletinib|Rociletinib will be administered to patients orally
223705278|NCT06449417|BEHAVIORAL|Experimental Aurora Training|Patients will be asked to record their physical activity in the logbook every week, at the end of the intervention, each patient will have to dedicate a letter to another patient who will receive the same Aurora Kit.
223705279|NCT01154829|DRUG|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
223705280|NCT01154829|DRUG|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
223705281|NCT05235087|DEVICE|Bovine atelocollagen intradermal injection|Intradermal skin test injection
223705282|NCT06557018|DRUG|liposomal bupivacaine|liposomal bupivacaine group
223705283|NCT06557018|DRUG|traditional peri-articular injection|traditional peri-articular injection group
223705284|NCT04977674|DRUG|Naltrexone|Pre-treatment with naltrexone 45 min before the ketamine infusion.
223705285|NCT04977674|DRUG|Placebo|Pre-treatment with placebo 45 min before the ketamine infusion.
223705286|NCT04977674|DRUG|Ketamine|Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
223705287|NCT00446056|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
223705288|NCT00446056|DRUG|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
223705289|NCT02633813|DRUG|Naftifine hydrochloride 2%|Topical application for two weeks
223893717|NCT06407713|OTHER|Intrinsic foot muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with intrinsic foot muscle training
223524725|NCT06639009|OTHER|Conventional non -Invasive management in Oral Submucous fibrosis|"Brief behavioral Tobacco, areca nut and alcohol habit cessation counseling as per WHO 5As and 5Rs technique at baseline and each follow up.~Oral prophylaxis Removal of oral irritational factors like sharp teeth, appliances or prosthesis, impacted buccoverted third molars, parafunctional habits Oral hygiene maintenance instructions Oral physiotherapy Control of systemic conditions Removal of all predisposing factors for oral candida infection Advocacy for safe sexual practices Nutrition and diet counseling( seasonal and regional food rich in nutrients, vitamins, antioxidants avoidance of spicy /sour/ hot foods and drinks) Regular surveillance for malignant transformation"
223524726|NCT04782180|DRUG|Descovy 200Mg 25Mg Tablet|daily Descovy tab by mouth
223524727|NCT04782180|BEHAVIORAL|PrEP|PrEP will be provided in a community setting by community-based harm reduction program.
223524728|NCT04672681|BEHAVIORAL|Play-based physical activity intervention|The intervention group will participate in a six-month play-based physical activity intervention starting from their initiated treatment. The intervention combines hospital and home-based physical activity. Three days a week, there will be 45 minutes of group-based physical activity at the hospital during admissions or appointments at the outpatient clinic, supervised by an exercise professional or pediatric physiotherapist. Children who are isolated during treatment are offered supervised individual 45 min. training sessions 3 times a week as a substitute. During the other four days a week, or on days where the family is at home, the parents administer the play-based physical activity. At inclusion, the parents receive education and supervision on conducting play-based physical activity with their child in the hospital room or at home. They will receive inspiration material containing numerous different plays, games, and activities in different intensities.
223524729|NCT04662879|OTHER|Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score|ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.
223524730|NCT04662879|OTHER|Abdominal imaging|Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.
223524731|NCT06161493|DRUG|ZEN003694|A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.
223524732|NCT06161493|DRUG|Niraparib|An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
223524733|NCT03886636|OTHER|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
223524734|NCT03886636|OTHER|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
223524735|NCT03886636|OTHER|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
223524736|NCT05253131|DRUG|Selumetinib|"* Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low grade gliomas, and NF1-associated plexiform neurofibromas.~* BI is a potent and selective inhibitor of BRD4/BET bromodomain currently in development for adult malignancies.~* Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that is currently indicated for patients with advanced urothelial carcinoma and unresectable non-small cell lung cancer."
223524737|NCT06064318|PROCEDURE|Revision|Any type of knee revision, excluding knee arthrodesis and femur amputation
223705290|NCT02633813|DRUG|Placebo|Topical application for two weeks
223705291|NCT02633813|DRUG|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
223705292|NCT01561729|DEVICE|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
223893718|NCT06407713|OTHER|Hip abductor muscle training|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with hip abductor muscle training
223893719|NCT04857164|DRUG|Pembrolizumab combined with Chemotherapy|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
224083264|NCT03983395|BIOLOGICAL|ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
223705293|NCT01561729|RADIATION|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
223705294|NCT02637154|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing method
223705295|NCT02637154|BEHAVIORAL|Standard Education|Standard Education material will be used
223705296|NCT00456157|DRUG|Intra-articular Injection of OP-1 to affected knee|
223705297|NCT04599829|DEVICE|AnkleSTRONG100/500/900|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (3 device types: Ankle STRONG 100/500/900) totalling 90 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use an ankle support device.
223705298|NCT04842734|OTHER|Physical exercise|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
223705299|NCT04842734|OTHER|Physical exercise and computerized cognitive training|SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
223705300|NCT03610360|DRUG|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
223705301|NCT05366517|DEVICE|Dornier Aries 2 device|For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
223705302|NCT02296073|DRUG|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
223705303|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
223705304|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
223705305|NCT02296073|DRUG|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
223705306|NCT02296073|DRUG|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
223705307|NCT02296073|OTHER|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
223705308|NCT04977557|DIETARY_SUPPLEMENT|Thiamine|Injection Thiamine 200 mg daily intravenously for 1 week followed by Tablet Thiamine 100mg bid for remaining 11 weeks
223705309|NCT03208127|DRUG|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
223705310|NCT05913258|DEVICE|Er:YAG laser system (Doctor smile, Pluser, Italy)|The Er:YAG laser offers a virtually painless alternative to conventional methods of caries removal, and its adoption in clinical practice could greatly reduce children's fear of going to the dentist. Caries removal is one of the leading reasons for dentist visits among children, and many children become fearful at the mere thought of a drill touching their teeth, before they even hear the sound. Laser caries removal could go a long way toward eliminating children's fear of going to the dentist; it is virtually painless, and most children are able to get through the entire procedure without needing local anesthesia.
223705311|NCT05913258|DEVICE|Master Torque high/low-speed air rotor handpiece (KaVo Dental, Charlotte, North Carolina, USA)|Mechanical removal of carious lesions with a rotating handpiece and bur instruments is the most often used approach for treating dental caries because it is cost-effective, timesaving, and simple. However, these procedures have many drawbacks, including the potential for removing healthy tooth structures, vibration and noise, which can cause the patient anxiety and pain, thus necessitating local anesthesia.
223705312|NCT01713608|DRUG|OZ439|OZ439 x mg once daily for 3 days with milk
223705313|NCT00579098|DRUG|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
223705314|NCT00579098|DRUG|Placebo|Placebo tablet taken by mouth once daily for 90 days
223705315|NCT02273232|OTHER|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
223893720|NCT05056727|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.~During Initiation Phase:~* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.~* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.~During Run-in and Maintenance Phases:~\- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water."
224275838|NCT06012578|DRUG|Placebo|ISM5411 Matching Placebo
223705316|NCT02273232|OTHER|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
223705317|NCT02273232|OTHER|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
223705318|NCT03349697|DIETARY_SUPPLEMENT|Phyllantus amarus|
223705319|NCT03349697|OTHER|Placebo|
223705320|NCT02121522|DRUG|BI 144807|twice daily
223705321|NCT03081975|DEVICE|HD white light or NBI|Use of NBI or HD white light
223705322|NCT06232694|DRUG|Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;|Induction Phase Regimen
223705323|NCT06232694|DRUG|Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;|Consolidation therapy after remission
223705324|NCT06232694|OTHER|utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).|Four cycles in total.Patients who meet the criteria for autologous stem cell transplantation (ASCT) during the treatment process can undergo ASCT.Patients who meet the transplantation criteria and have a suitable donor can undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).
223705325|NCT00098956|DRUG|topotecan hydrochloride|Given IV
223705326|NCT00098956|DRUG|7-hydroxystaurosporine|Given IV
223705327|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
223705328|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
223705329|NCT00338104|DRUG|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
223705330|NCT05254808|DRUG|Fosfomycin|Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
223705331|NCT05254808|DRUG|Nitrofurantoin|Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
223705332|NCT03476278|OTHER|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
223705333|NCT06426433|OTHER|Proprioceptive Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.
223705334|NCT06426433|OTHER|Upper Extremity Exercises|In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
223705335|NCT01141452|DRUG|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
223705336|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
223705337|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
223705338|NCT01141452|DRUG|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
223705339|NCT01141452|DRUG|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
223705340|NCT01141452|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
223705341|NCT01331122|DRUG|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
223705342|NCT00152620|DRUG|Dexamethasone|
223705343|NCT00152620|DRUG|Methylprednisolone|
223705344|NCT05997550|OTHER|Pursed Lip Breathing Exercise|Pursed Lip Breathing Exercise for The COPD
223705345|NCT05997550|OTHER|Laughter Therapy|Laughter Therapy for the COPD
223705346|NCT05997550|OTHER|the control group.|Attention-match training is given to the patients in the control group.
223705347|NCT00633750|DRUG|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
223705348|NCT00633750|GENETIC|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
223705349|NCT00633750|GENETIC|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
223705350|NCT00633750|OTHER|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
223705351|NCT00633750|OTHER|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
223705352|NCT00633750|OTHER|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
223705353|NCT00633750|OTHER|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
223705354|NCT00633750|OTHER|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
223705355|NCT00633750|PROCEDURE|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
223705356|NCT04544085|BEHAVIORAL|noise management|The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
223705357|NCT00934479|DRUG|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
223705358|NCT02096679|DRUG|AZD9291|Volunteer will receive a single oral dose of 20 mg \[14C\]-AZD9291 as a solution on Day 1
223705359|NCT04015492|BIOLOGICAL|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
223705360|NCT04015492|BIOLOGICAL|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
223705361|NCT04057508|OTHER|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
223705362|NCT02502175|DRUG|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
223705363|NCT02502175|DRUG|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
223705364|NCT02002832|DRUG|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
223705365|NCT02002832|DRUG|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
223705366|NCT01330784|DRUG|hMG-HP|
223705367|NCT03623555|BEHAVIORAL|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
223705368|NCT03623555|BIOLOGICAL|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
223705369|NCT03666624|BEHAVIORAL|Personalized care network|The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
223705370|NCT03329508|DRUG|P2B001 0.6/0.75 mg|Fixed low dose extended release combination capsule of pramipexole and rasagiline
223705371|NCT03329508|DRUG|Rasagiline 0.75 mg|Rasagiline 0.75 mg oral extended release capsule, component
223705372|NCT03329508|DRUG|Pramipexole 0.6 mg|Pramipexole 0.6 mg oral extended release capsule, component
223705373|NCT03329508|DRUG|Marketed Pramipexole ER|Marketed Pramipexole ER titrated to optimal dose of 1.5, 3 or 4.5 mg tablet
223705374|NCT01497457|PROCEDURE|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
223705375|NCT00546559|DRUG|statins (simvastatin, pravastatin)|
223705376|NCT05384678|DRUG|N,N-Dimethyltryptamine (54 mg)|A dose rate of 0.6 mg/min will be administered
223705377|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg)|A dose rate of 1.2 mg/min will be administered
223705378|NCT05384678|DRUG|N,N-Dimethyltryptamine (162 mg)|A dose rate of 1.8 mg/min will be administered
223524738|NCT04625660|DEVICE|PQ Bypass System|Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
223705379|NCT05384678|DRUG|N,N-Dimethyltryptamine (216 mg)|A dose rate of 2.4 mg/min will be administered
223705380|NCT05384678|DRUG|Placebo|A Placebo (saline infusion) will be administered.
223705381|NCT05384678|DRUG|N,N-Dimethyltryptamine (108 mg) + dose titration|A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration
223705382|NCT03021304|DRUG|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
223705383|NCT03166059|DEVICE|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
223705384|NCT05767125|DEVICE|APRV|Patients with moderate-to-severe ARDS were supported with APRV.
223705385|NCT05767125|DEVICE|LTV|Patients with moderate-to-severe ARDS were supported with LTV.
223705386|NCT01868464|BIOLOGICAL|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
223705387|NCT00669656|DRUG|Prostate Health Cocktail|3 capsules daily PO up 12 months
223524739|NCT03633058|DRUG|Ketamine|oral ketamine dosed twice daily for 5 days
223524740|NCT05474859|DRUG|XT-0528|Once Daily
223524741|NCT04858997|DRUG|Palbociclib|Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223524742|NCT04858997|DRUG|AI|AI, orally once daily (continuously)
223524743|NCT03312543|DEVICE|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
223524744|NCT03312543|DEVICE|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
223524745|NCT05362305|BEHAVIORAL|Essential Coaching for Every Mother|Daily text messages for the first six-weeks postpartum.
223524746|NCT01568879|OTHER|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
223705388|NCT04108871|PROCEDURE|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
223705389|NCT06161272|DRUG|Fluzoparib|single
223705390|NCT06161272|DRUG|Fluzoparib+Apatinib|combination
223705391|NCT00569270|DRUG|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
223705392|NCT03918161|DEVICE|MRE exam|Magnetic Resonance Elastography
223705393|NCT01555450|OTHER|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
223705394|NCT01811680|DEVICE|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
223705395|NCT03524742|OTHER|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
223705396|NCT03524742|OTHER|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
223705397|NCT05744284|DEVICE|electrocautery|advantages reported in this study in terms of wound infections, healing time, postoperative pain and cosmetic results in association with economic gain for saving in the purchase of scalpels, represent a formidable motivation for the surgeons to abandon the scalpel in favors of diathermy
223705398|NCT05646095|BEHAVIORAL|Bolstering Sleep and Adjustment in Foster Environments (B-SAFE)|We will adapt CBT for insomnia for children in foster care using a trauma-informed approach that considers the child's individual history, unique family environment, and child welfare policies regarding safe sleep practices.
223705399|NCT02037360|BEHAVIORAL|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
223705400|NCT02037360|BEHAVIORAL|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
223705401|NCT00860288|DRUG|Vildagliptin|
223705402|NCT00860288|DRUG|Metformin|
223705403|NCT00860288|DRUG|Placebo|
223705404|NCT00860288|DRUG|Sitagliptin|
223705405|NCT00001067|DRUG|Lamivudine|
223705406|NCT00001067|DRUG|Stavudine|
223705407|NCT00001067|DRUG|Zidovudine|
223705408|NCT00492531|DRUG|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
224275839|NCT04908540|PROCEDURE|Mini-screw Assissted Rapid Palatal Expansion|Mini-screw assissted RPE will be the main intervention in the two comparative groups. In the control (group A) will be used with its conventional activation protocol. While in experimental (group B) will be used with ALT-RAMEC protocol.
224275840|NCT05489497|PROCEDURE|Primary closure with or without omental grafting|Primary closure with or without omental grafting
223705409|NCT00492531|DRUG|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
223705410|NCT00842582|DRUG|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
223705411|NCT00842582|DRUG|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
223705412|NCT00842582|DRUG|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
223705413|NCT02857582|BIOLOGICAL|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
223705414|NCT02857582|DRUG|Vancomycin|Active comparator to treatment with ACHIM
223705415|NCT02857582|DRUG|Metronidazole|Primary treatment for C diff in all treatment arms
223705416|NCT03822182|DRUG|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
223705417|NCT03822182|DRUG|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
223705418|NCT03814083|DEVICE|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
223705419|NCT03814083|DEVICE|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
223705420|NCT03814083|OTHER|Wait-list|No intervention
223705421|NCT02772887|DIETARY_SUPPLEMENT|L-Citrulline|amino acid supplement
223705422|NCT02772887|OTHER|Placebo|placebo
223705423|NCT00810355|BEHAVIORAL|Support Group|General support and problem solving for work activity
223705424|NCT00810355|BEHAVIORAL|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
223524747|NCT01568879|OTHER|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
223524748|NCT06355297|BEHAVIORAL|Education about pelvic floor|The three educational sessions will last 60 minutes, as follows: session1, anatomy of pelvic floor; session2, function and dysfunction of pelvic floor; session3, risk factor for pelvic floor dysfunctions.
223524749|NCT03754361|PROCEDURE|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
223524750|NCT03754361|PROCEDURE|IHD|HD 4hour 2-3times per week
224275841|NCT03525340|BEHAVIORAL|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
224275842|NCT06193187|DRUG|Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg|Test (T)
223524751|NCT04134936|DRUG|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
223524752|NCT04134936|DRUG|Tafasitamab plus lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
223524753|NCT06124313|DIETARY_SUPPLEMENT|Vaginal Probiotic|"This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei"
223524754|NCT01717274|PROCEDURE|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
223524755|NCT02170519|DRUG|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
223524756|NCT01430715|OTHER|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
224275843|NCT06193187|DRUG|Entresto 50 mg|Reference (R)
223524757|NCT06265441|PROCEDURE|Group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance in which the adductor canal is identified and 20 ml of 0.25% bupivacaine will be injected|The patients in group A will receive adductor canal block after spinal anesthesia under a high-frequency ultrasound guidance (SonoSite™, Inc., Bothell, WA 98021, USA) in which the patients are placed in the supine position with the arms resting comfortably across the chest and the affected lower extremity is externally rotated. Adductor canal was identified beneath the sartorius muscle and 22-gauge 90-mm spinal needle is inserted from anterolateral to posteromedial direction at a point approximately at the junction between the middle and distal third of the thigh on the anteromedial femur, this location is called mid adductor canal, then 20 ml of 0.25% bupivacaine is injected in the canal
223524758|NCT06265441|PROCEDURE|Group B will receive adductor canal block under ultrasound guide 20 ml bupivacaine 0.25% and IPACK block under direct visualization of ultrasound of 20 ml bupivacaine 0.25%|The patients in Group B will receive adductor canal block as described in group A then IPACK block, in which the patients are placed in a supine position and knee is placed in position of 90° flexion. A low-frequency ultrasound probe is positioned in the popliteal crease 1 finger breadth above the patella, and a spinal needle is inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle is placed 1-2 cm beyond the lateral edge of the artery, and 20 ml of 0.25% bupivacaine is injected while the needle is being withdrawn after negative aspiration.
223524759|NCT02420717|DRUG|Cyclophosphamide|Given IV
223524760|NCT02420717|DRUG|Cytarabine|Given IV
223524761|NCT02420717|DRUG|Dasatinib|Given PO
223524762|NCT02420717|DRUG|Dexamethasone|Given PO or IV
223524763|NCT02420717|DRUG|Doxorubicin|Given IV
223524764|NCT02420717|OTHER|Laboratory Biomarker Analysis|Correlative studies
223524765|NCT02420717|DRUG|Leucovorin|Given IV or PO
223524766|NCT02420717|DRUG|Mercaptopurine|Given PO
223524767|NCT02420717|DRUG|Methotrexate|Given IV and PO
223524768|NCT02420717|DRUG|Prednisone|Given PO
223524769|NCT02420717|BIOLOGICAL|Rituximab|Given IV
223524770|NCT02420717|DRUG|Ruxolitinib Phosphate|Given PO
223524771|NCT02420717|DRUG|Vincristine|Given IV
223524772|NCT01123187|PROCEDURE|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
223524773|NCT06644963|DEVICE|Impella (5, 5.5 or CP)|Impella (5, 5.5 or CP) as an isolated circulatory support or combined with others Temporary Mechanical Circulatory Support
223524774|NCT04983979|DRUG|Sodium Zirconium Cyclosilicate|sachets of 5g or 10g given OD titrated to serum potassium
223524775|NCT04983979|DRUG|Placebo|matched placebo given titrated according to potassium at a dose to 5 or 10g
223524776|NCT04144517|DRUG|Nemvaleukin Alfa|Nemvaleukin alfa IV infusion.
223524777|NCT04144517|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
223524778|NCT03292978|DIETARY_SUPPLEMENT|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
223524779|NCT03292978|DIETARY_SUPPLEMENT|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
223524780|NCT04928638|BEHAVIORAL|Virtual educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
223524781|NCT04928638|BEHAVIORAL|Written educational intervention|Educational intervention about the disease, the use of medication and the context of pandemic
223524782|NCT01003964|DRUG|IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
223524783|NCT01003964|DRUG|GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
223524784|NCT06238856|DRUG|SLIT™ Amikacin|Amikacin administered via the Pari LC STAR™ nebulizer.
223524785|NCT06238856|DRUG|Placebo|Nebulized saline.
223524786|NCT05307094|BEHAVIORAL|Improving Parents as Communication Teachers|A parent-mediated naturalistic developmental behavioral intervention delivered 2-times per week with a primary caregiver and the child.
223524787|NCT03067636|BEHAVIORAL|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
223524788|NCT03067636|BEHAVIORAL|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
223524789|NCT03067636|BEHAVIORAL|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
223524790|NCT06267417|DEVICE|Laser therapy|\- Laser will be applied with the specified wave length using Diode laser (Sirrolaser Blue ™, USA) device over 5 consecutive days from start of chemotherapy cycle beside the standard preventive protocol applied in the hospital
223524791|NCT06267417|DEVICE|Mock treatment|The exact repetition of the treatment modality but without any laser emission beside the standard preventive protocol applied in the hospital
223524792|NCT06656572|GENETIC|Genetic: Genomic sequencing and molecular diagnostic results, if any.|Genomic sequencing results may be used for diagnosis and treatment of participants.
223524793|NCT06656572|DIAGNOSTIC_TEST|Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)|Whole Proteome programmable phage display immunoprecipitation sequencing will be used to diagnose known and novel autoantibodies.
223524794|NCT06658977|DRUG|Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)|One Triumeq tablet per day
223524795|NCT06658236|OTHER|Proprioceptive Neuromuscular Facilitation|Group A will follow a PNF-based training protocol to enhance strength, flexibility, and coordination. The exercises include two main movement patterns: flexion-abduction-external rotation with the elbow extended and extension-adduction-internal rotation with the elbow extended. These patterns target the muscles around the shoulder and upper chest. A yellow Thera-Band adds light resistance, increasing muscle engagement. The protocol also employs the reversal of antagonists technique, alternating between opposing muscle groups for balanced development and improved coordination. Participants will complete three sets of ten repetitions per session, with a 60-second rest between sets. The program spans 12 weeks, with three weekly sessions, allowing for consistent progress and muscle recovery. This structured approach aims to improve functional mobility and the performance of activities involving similar movements, offering a comprehensive training strategy through PNF and resistance.
223524796|NCT06658236|OTHER|Chest Expansion Exercises|Group B participants followed a breathing-coordinated exercise protocol using a yellow Thera-Band to improve upper extremity function. The protocol began with subjects breathing generally at rest. They were then instructed to synchronize their movements with their breathing: performing upper extremity flexion, abduction, and external rotation during inhalation, followed by extension, adduction, and internal rotation during exhalation. This coordination between breathing and movement aimed to enhance muscle activation and control. Each session included three trials of ten repetitions for each exercise, with a 1-minute rest between trials. The protocol was conducted three times per week over 12 weeks. This approach was designed to promote strength, flexibility, and coordination in the upper body while integrating breath control, which may also support relaxation and better movement efficiency. The structured schedule ensures consistent practice and gradual improvement over the 12 weeks
223524797|NCT06824493|OTHER|no interventions|no intervention as this is an observational studies
223524798|NCT06824493|OTHER|None-placebo|Observational study with no interventions
223705425|NCT00810355|BEHAVIORAL|Cognitive Remediation|Computerized training to enhance cognitive functioning.
223524799|NCT06824493|OTHER|No Intervention: Observational Cohort|no intervention because of observational studies
223524800|NCT05472818|DRUG|[11C]APP311|For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
223705426|NCT01346579|OTHER|laboratory biomarker analysis|Correlative sciences
223705427|NCT04584970|DEVICE|Applied VR|The Applied VR device is a lightweight mobile virtual reality headset with embedded software, creating an immersive experience. The Applied VR is specifically designed for medical use.
223705428|NCT04584970|DEVICE|Apple iPad|The Apple iPad is a tablet device controlled by touch screen with a variety of games and applications.
223705429|NCT01790854|DRUG|Prasugrel dose 5 mg/day|
223705430|NCT01790854|DRUG|Prasugrel dose 10 mg/day|
223705431|NCT06260215|OTHER|ST|Participants will perform a soccer training (ST) session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
223705432|NCT00246623|DRUG|Exubera (inhaled insulin)|
223705433|NCT00246623|PROCEDURE|8-point glucose diary (to assess pre- and post prandial glucoses)|
223705434|NCT00246623|PROCEDURE|Meal Tolerance Test|
223705435|NCT00246623|PROCEDURE|24-hour continuous glucose monitoring (at select sites)|
223524801|NCT06605820|OTHER|None - Interview Only|None - Interview Only
223524802|NCT05336357|DEVICE|Goal-Directed Therapy|"Patients will be monitored by the ClearSight™ System (Edwards Life Sciences, Irvine, CA, USA) in the first 24 hours, where the parameters Cardiac Index (CI), Stroke Volume (SV), Systolic Blood Pressure (SBP) and Mean Arterial Pressure (MAP) will be acquired continuously. The treatment goal will be to keep the CI greater than or equal to 2.2 L/min/m2, the SV greater than or equal to 35 mL/beat, and the SBP greater than or equal to 90 mmHg and/or the MAP greater than or equal to 65 mmHg.~If the CI is below 2.2 L/min/m2 and the SV less than 35 mL/beat, an aliquot of 500 mL of crystalloid solution will be administered; if there is not an increase by 10% in the CI and SV values, a new aliquot of 250 mL may be administered; if this 10% increase does not occur for at least 20 minutes, inotropic medications will be started, with doses titrated periodically. If the pre-established goal is not reached, it is suggested to consider transfusion of a concentrated red blood cell."
223524803|NCT06183593|OTHER|Radiofrequency application|Radiofrequency stimuli will be applied at pain threshold intensity. Arm and leg will be stimulated.
223524804|NCT06183593|OTHER|Pinprick stimuli|Pinprick stimuli will be administered at varying speeds and forces using an automated device
223524805|NCT05697380|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted.
223524806|NCT01622478|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
223524807|NCT01622478|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
223524808|NCT01622478|PROCEDURE|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
223524809|NCT01622478|PROCEDURE|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
223524810|NCT05293314|DIAGNOSTIC_TEST|An exhaled breath test|All exhaled breath samples were collected by trained investigators following the same protocol. All participants fasted for at least 6 hours before breath collection. To reduce potential confounding factors, all participants were asked to not ingest spicy food, alcohol, or coffee the night before exhaled breath collection. Exhaled breath was collected in Tedlar air bags (DuPont de Nemours). The night before breath collection, the Tedlar bags were baked at 60 °C for 3 hours to fully release possible contaminants and continuously purged with high-purity nitrogen 4 times. Participants first gargled with pure water and then performed a single deep nasal inhalation followed by complete exhalation via their mouth into Tedlar bags. A total of 1000 mL of exhaled breath was collected from each participant. Breath sample detection was based on the HPPI-TOFMS platform.
223524811|NCT06248710|DRUG|Oxytocin nasal spray|Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
223524812|NCT06248710|OTHER|Animal-Assisted Intervention|The dogs involved in the study are trained and used to work with different people in animal-assisted interventions. The dog will be familiarized with the room and the material as well as the staff of the study. The dog will be specifically trained for this study. The dog will be involved for a maximum of 3 sessions per day (approx. 20 minutes in total) and 2 days per week.
223524813|NCT06248710|DRUG|Placebo|The placebo nose spray contains a saltwater solution and will be applied like the Syntocinon nose spray containing oxytocin.
223524814|NCT06611306|RADIATION|DE-iPTV|Dose-escalated VMAT-based radiotherapy, as previously described in our planning study
223524815|NCT06257394|DRUG|Dasatinib(Sprycel) arm|"▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib."
223524816|NCT06257394|DRUG|Non-Dasatinib(Sprycel) arm|"▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab"
223524817|NCT00835367|DRUG|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
223524818|NCT00835367|DRUG|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
223524819|NCT06606158|OTHER|Exercises program|Strength, mobility, and balance exercises described within the standardized Physiotherapy plan.
223524820|NCT06606158|OTHER|App exercises program|A strength, mobility, and balance exercise program delivered through a mobile app.
223524821|NCT06606275|DRUG|Apixaban|Apixaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa, playing a crucial role in preventing blood clot formation. It is commonly prescribed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) and for treating and preventing venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
223705436|NCT00246623|PROCEDURE|Pulmonary Function Testing|
223705437|NCT00246623|PROCEDURE|Hypoglycemic Event Monitoring|
223705438|NCT00246623|PROCEDURE|Laboratory Assessments|
223705439|NCT00246623|BEHAVIORAL|Nutritional Counseling and Diabetes Education|
224083265|NCT03983395|BIOLOGICAL|ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
223524822|NCT06606275|DRUG|Warfarin|Warfarin is a vitamin K antagonist widely used as an anticoagulant to prevent thromboembolic events, particularly in conditions like atrial fibrillation, venous thromboembolism, and in patients with mechanical heart valves. It inhibits the enzyme vitamin K epoxide reductase, thereby reducing the activation of vitamin K-dependent clotting factors (II, VII, IX, X) and regulatory proteins C and S. Due to its narrow therapeutic index, warfarin requires regular monitoring of the International Normalized Ratio (INR) to optimize anticoagulation while minimizing the risk of bleeding. Warfarin's pharmacokinetics and pharmacodynamics can be influenced by genetic polymorphisms, diet, and drug interactions, necessitating individualized dosing strategies.
223524823|NCT06121856|DEVICE|VerioVue Enhancements BGMS|Blood glucose monitoring system
223524824|NCT05145816|DRUG|Belantamab mafodotin 2.5 mg/kg (8 weeks)|2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
223524825|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (8 weeks)|1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
223524826|NCT05145816|DRUG|Belantamab mafodotin 1.4 mg/kg (12 weeks)|1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
223524827|NCT05145816|DRUG|Belantamab mafodotin 1.9 mg/kg (12 weeks)|1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
223524828|NCT05145816|DRUG|Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages|Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
223524829|NCT05145816|DRUG|Belantamab mafodotin 1.0 mg/kg (12 weeks)|1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
223524830|NCT06617806|OTHER|Follow-up by the Advanced Practice Nurse|"At each follow-up (FU), the recommendations of an APN may include :~* Referral to a specialized memory assessment in case of cognitive impairment~* Psychological FU in the event that APN detects any mood complaints~* Ophthalmological and/or ear, nose, and throat consultation if any auditory or visual difficulties is observed~* Compression stockings use if orthostatic hypotension is present~* Nutritional counseling, with particular emphasis on the intake of protein, in combination with long-term assessment of weight~* Supplementation with vitamin D and calcium based to prevent osteoporosis in older adults, especially those at risk of recurrent falls~* Proposal of a standardized and personalized physical activity program~* Evaluation of medication therapies, especially antipsychotics, blood pressure medication or broad anticholinergics. The STOPPFall tool will be also proposed and coordinated by APN in accordance with the patient's physician~* A comprehensive social evaluative approach"
223524831|NCT06665555|DRUG|ledaborbactam etzadroxil|Five doses of ledaborbactam etzadroxil will be administered orally every 12 hours
223705440|NCT05252455|BEHAVIORAL|pelvic and abdominal mechanics exercise|"starting from 24 weeks of pregnancy, participate in the pelvic and abdominal mechanics exercises offered by the Good Pregnancy College of Shanghai Tongren Hospital once a week. Each class lasts one hour until the 38th week of pregnancy (attend at least 10 times)"
223705441|NCT00843856|DRUG|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
223705442|NCT00843856|DRUG|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
223705443|NCT04575623|DIAGNOSTIC_TEST|Duration Pattern test (DPT) /Dichotic Digits Test (DDT) /Auditory fusion test-revised (ART-R)/|"Central auditory function evaluation including:~* Duration Pattern test (DPT) designed to test temporal ordering abilities.~* Dichotic Digits Test (DDT) it assesses binaural integration skills.~* Auditory fusion test-revised (ART-R) to measure temporal resolution.~* speech in test to assess central auditory function."
223705444|NCT04575623|DEVICE|Dual band pure tone audiometer (Orbiter 992). -Impedance audiometer (AT 235h). -Sound treated booth (industrial acoustic company IAC model 1602-A-t) -Panasonic stereo CD player SA-AK 240.|"Cognitive function evaluation including:~-Recording of event-related potentials (ERPs) by using odd ball paradigm auditoryP300 wave in evaluating cerebral information processing.~Equipment:~* Dual band pure tone audiometer (Orbiter 992).~* Impedance audiometer (AT 235h).~* Sound treated booth (industrial acoustic company IAC model 1602-A-t)~* Panasonic stereo CD player SA-AK 240."
223705445|NCT04296110|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to practice breathing at their resonance frequency using the Inner Balance device daily for 5-15 mins for the duration of the 12-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the intervention.
223705446|NCT04296110|OTHER|Music Relaxation Therapy|We will determine what genre of music is most relaxing to them and ask them to listen to this type of music using the spotify app for 5-15 mins a day for 12 weeks. If they do not have access to a device that they can listen to spotify on, an ipod will be provided. They will be asked to complete a 2-question survey via Redcap daily that asks them if they have listened to the designated music that day and for how long.
223705447|NCT06021288|OTHER|Effluent dose of CRRT|The effluent dose of the CRRT will be performed according to study group for 7 days or up to the end of CRRT, whatever occurs first.
223705448|NCT00635375|DEVICE|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
224275844|NCT00412204|DRUG|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
223524832|NCT06665555|DRUG|ceftibuten|Five doses of ceftibuten will be administered orally every 12 hours
223524833|NCT06675409|OTHER|Education|The effectiveness of two different training methods with virtual patients for improving the critical decision-making skills of paramedic students will be compared between two groups: one receiving expert-guided training and the other following a self-directed approach
223893721|NCT05056727|DRUG|Placebo|"Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~\- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water."
223893722|NCT05056727|DRUG|Lisinopril|Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.
223524834|NCT06674317|BEHAVIORAL|Internet Delivered Cognitive Behavioral Therapy for Insomnia in Persons with Inflammatory Rheumatic Diseass|"Cognitive behavioral therapy for insomnia (CBTi) is considered a first-line treatment for insomnia. Access to this treatment option is limited therefore we have been developing an internet delivered cognitive behavioral therapy for insomnia (I-CBTi) to help overcome accessibility barriers.~The purpose of this study is to pilot test a tailored internet-delivered cognitive behavioral therapy for insomnia (I-CBTi) intervention for persons with Inflammatory Rheumatic Diseases showing symptoms of insomnia."
223524835|NCT06674005|OTHER|Cucurbita pepo L. Flowers Extract|2 mg twice per day for 1 month
223524836|NCT06674005|OTHER|Placebo|2 mg twice per day for 1 month
223524837|NCT03790956|PROCEDURE|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
223524838|NCT04112368|DRUG|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
223524839|NCT04112368|DRUG|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
223524840|NCT04112368|DRUG|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
223524841|NCT04112368|DRUG|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
223524842|NCT04501718|DRUG|Apatinib Combined With Temozolomide and Etoposide Capsules|"Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator."
223524843|NCT06598761|COMBINATION_PRODUCT|Immunotherapy+radiotherapy|"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."
223524844|NCT06598761|OTHER|surveillance alone|Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
223524845|NCT02549820|DEVICE|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
223524846|NCT06266351|DEVICE|This is observational IOP measurement|IOP measurement of patients having LASIK with both CATS and GAT
223524847|NCT06676085|DRUG|Nafamostat|Nafamostat combined with unfractionated heparin for anticoagulation
223524848|NCT06676085|DRUG|Heparin|unfractionated heparin for anticoagulation
223524849|NCT06609304|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel at 2.0×10\^6/Kg
223524850|NCT06279130|DRUG|botensilimab|Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)
223524851|NCT06279130|DRUG|balstilimab|Anti programmed cell death protein-1 (anti-PD1)
223524852|NCT07004296|DRUG|HDM2005|HDM2005 will be administered via IV infusion.
223524853|NCT03592264|DRUG|OBI-3424|liquid formulation for Intravenous infusion
223524854|NCT07004608|BEHAVIORAL|Aalana Palana|Alan Palana is a facilitated video viewing intervention which promotes responsive and sensitive parenting, early learning opportunities and desired nutritional practices for young children and pregnant women. The content not only describes 'WHAT' behaviours caregiver should adopt, 'HOW' they could include these behaviours in their routines but also 'WHY' a particular behaviour is important for their child's development.
223524855|NCT06919471|OTHER|Fitbit|Wear it on wrist
223524856|NCT06919471|OTHER|MySnackTracker App|App to track your dietary intake
223524857|NCT06679478|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Early Mobilization Protocol|The intervention is applied from the first day after surgery until discharge. (including the day of discharge).
223524858|NCT07006025|DRUG|Decitabine|Oral tetrahydrouridine and oral decitabine capsule
223524859|NCT06675032|BIOLOGICAL|PCV24 formulation 1|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
223524860|NCT06675032|BIOLOGICAL|PCV24 formulation 2|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
223705449|NCT00635375|DEVICE|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
223705450|NCT00635375|DEVICE|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
223705451|NCT00635375|DEVICE|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
223524861|NCT06675032|BIOLOGICAL|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine:Dosage form: Injection Specification:0.5 mL/strip Dosage: The preferred site for infants is the anterolateral thigh (lateral femoral muscle), and for toddlers and children, the deltoid muscle of the upper arm.~Dosing schedule:6 weeks months: 4 doses, one dose each of basic immunization at 2, 4, and 6 months of age, and one dose of booster immunization at 12-15 months of age, with the earliest of the first dose being given at 6 weeks of age. The first dose should be given at 6 weeks of age at the earliest."
223524862|NCT06675032|BIOLOGICAL|Sodium Chloride Injection|"24-Valent Pneumococcal Polysaccharide Conjugate Vaccine formulation 1：Dosage form: Injection Specification:0.5 ml/strip Dosage: The preferred site is the anterolateral thigh (lateral femoral muscle) in infants and the deltoid muscle of the upper arm in infants and children. The preferred dosage for infants is 0.5 ml per dose.~Dosing schedule:24 months old-17 years old group: 1 dose.12-23 months old group: 2 doses, each dose at least 2 months apart.7-11 months old group: 2 doses of basic immunization, the first two doses at least 1 month apart, and a booster dose after 12 months of age.6 weeks months: 1 dose of basic immunization at each of the ages of 2, 4, and 6 months, and 1 dose of booster immunization at the age of 12-15 months, with the earliest of the first dose at the age of 6 weeks. The first dose is given at 6 weeks of age at the earliest."
223524863|NCT06675266|DIAGNOSTIC_TEST|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester screening scan|Development of AI algorithm for early detection of fetal brain anomalies in the second trimester of pregnancy
223524864|NCT06675318|OTHER|Cross training for quadriceps muscle of contralateral lower limb|An isokinetic exercise program consisting of 20 sessions conducted five days a week. The program begins with five repetitions at a speed of 60°/s, followed by sets of 5-15 repetitions with incremental increases of 30°/s. Rest periods of 30 seconds were included between sets.
223524865|NCT06675318|OTHER|Quadriceps isometric exercises, along with hot pack and TENS for painful knee|10 repetitions of quadriceps isometric exercises in 3 sets, along with hot pack and TENS treatments for painful knee
223524866|NCT06674434|OTHER|Mobilization with Movement|Mobilization with Movement (MWM) is a manual therapy technique that combines active, patient-directed movements with passive joint mobilization to treat tennis elbow. To find joint restrictions or dysfunctions, a comprehensive patient assessment is the first step in the process. While the patient was in a supine position with the elbow fully extended and the forearm pronated, the therapist applied a sustained lateral glide of the forearm and stabilized the distal portion of the arm. While the patient asked to make a fist, the therapist kept up the lateral glide. Each session included three sets of movement-based mobilizations, each with ten repetitions. The entire course of treatment consists of twelve sessions.
223524867|NCT06674434|OTHER|Sustained Stretch|The basic concept of stretching involves lengthening the tendon during a state of relaxation. To stretch the Extensor Carpi Radialis Brevis tendon, the following position should be adopted: the elbow should be extended, the forearm in a pronated position, the wrist flexed, and the wrist should also be ulnar deviated, based on the patient's comfort level. This position should be maintained for 30 to 45 seconds and repeated three times before and after exercises in each treatment session, with a 30-second rest period in between.
223524868|NCT06674239|BEHAVIORAL|Patient Follow-up and Evaluation Form, Patient Information Form Healthy Lifestyle Behaviors Scale Education Booklet|"In the experimental phase of the study, an informed consent form, patient information form, healthy lifestyle behaviors scale, patient follow-up and evaluation form and education booklet were used.~Patient Information Form: This form was developed by the researchers. Healthy Lifestyle Behaviors Scale: The scale, which measures the health-promoting behaviors associated with the individual's healthy lifestyle, consists of a total of 52 items.~Patient Follow-up and Evaluation Form: Metabolic value tests are routinely requested in the institution.~Education Booklet: An education booklet was created based on the literature and the opinions of three experts.~Data collection method: Individualized education was given to the experimental group. Then, the Patient Information Form and the Healthy Lifestyle Behaviors Scale were applied as pre-test and post-test. The laboratory values of the patients were examined and recorded in the Patient Follow-up and Evaluation Form."
223524869|NCT02323620|PROCEDURE|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
223524870|NCT07010874|OTHER|REMOTE NURSING INTERVENTIONS BASED ON THE EMPOWERMENT PROCESS MODEL|"The duration of the intervention is determined as 10 weeks. Distance nursing interventions based on the model will be carried out through a web page called Take Care of Yourself. Each participant will have a unique username and password while using the website, so that login information and the frequency of visiting the website will be recorded. During the 10-week intervention period, caregivers will be provided with 8 modules of training content. In the first session of the intervention, the website will be introduced, personal goals will be set and the session will be completed with the planning of the next week. personal goals will be set, and in the last session of the intervention, feedback will be given to the individuals by the researcher regarding the achievement of their personal goals and their ability to cope with future difficulties."
223524871|NCT06631534|DRUG|Dexmedetomidine|Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr
223524872|NCT06631534|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline (placebo)
223524873|NCT06688253|DRUG|IV efgartigimod|IV efgartigimod
223524874|NCT06687850|BEHAVIORAL|animal assisted therapy|The canine was included in therapy sessions to determine the effect of the canine on prosocial behavior and emotional regulation in autistic children with varying verbality.
223524875|NCT06132789|BIOLOGICAL|Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried|This vaccine（1.0ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
223524876|NCT03267849|OTHER|wearing swimming goggles or having laser suturelysis|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the interventions
223524877|NCT05156528|BIOLOGICAL|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine|Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
223524878|NCT05156528|BIOLOGICAL|Placebo|Single intramuscular dose contains 0.15\~0.25 mg of aluminum ion
223893723|NCT05056727|DRUG|Valsartan|Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.
223893724|NCT05056727|DRUG|Irbesartan|"Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved."
223893725|NCT05846620|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
224275845|NCT00412204|OTHER|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
224275846|NCT00006467|DRUG|ISIS 2503|
223524879|NCT06687447|OTHER|Oxycotin Massage Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. At this stage, the patient will receive an oxytocin massage for 10 minutes while in a sitting position. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
223524880|NCT06687447|OTHER|Reflexology Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed women who want to participate in the study, and pre-test data will be collected. The pre-test data of the research were it will be collectedapproximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured. In practice; The foot is first relaxed and warmed up with passive movements, then the sole of the foot is scanned with the thumb walking crawling technique. The application will be applied first to the right foot for 10 minutes and then to the left foot for a total of 20 minutes. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again and uterine involution and physiological parameters will be evaluated.
223524881|NCT06687447|OTHER|Control Group|Primiparous women will be visited 12 hours after cesarean delivery, women will be informed, verbal and written consent will be obtained from women who want to participate in the study, and pre-test data will be collected by the researcher. The pre-test data of the research were it will be collected by face-to-face interview technique in approximately 25 minutes. The height of the fundus part of the uterus will be measured with a tape measure. The woman's physiological parameters will be measured by the researcher. Patients in the control group will not undergo any intervention and will receive their routine care. One hour after the application (13th hour after cesarean section), the physiological parameters of the patients will be measured again by the researcher. 24 hours after the application (36 hours after cesarean section), the data of the patients will be collected again by the researcher and uterine involution and physiological parameters will be evaluated.
223524882|NCT03035214|DRUG|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
223524883|NCT03436667|DIAGNOSTIC_TEST|Spirometry|Lung volumes will be measured using spirometry.
223524884|NCT03436667|DIAGNOSTIC_TEST|Reaction Time|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
223524885|NCT05950438|PROCEDURE|Esophagectomy|Esophagectomy is a complex surgical procedure performed to treat various esophageal disorders. The surgery involves the removal of all or part of the esophagus and reconstruction using other parts of the gastrointestinal tract.
223524886|NCT05898594|PROCEDURE|Low-dose Computed Tomography|Per standard care
223524887|NCT01263210|BIOLOGICAL|Prevenar|
223524888|NCT04361500|DEVICE|Seraph 100|Seraph 100 therapy during a COVID-19 infection
223524889|NCT02953431|DEVICE|CPAP|CPAP will be administered with a CPAP machine
223524890|NCT00936936|DRUG|Gemcitabine|1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.
223524891|NCT00936936|DRUG|Docetaxel|Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.
223524892|NCT00936936|DRUG|Melphalan|50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.
223524893|NCT00936936|DRUG|Carboplatin|"Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3."
223524894|NCT00936936|DRUG|Mesna|3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
223524895|NCT00936936|DRUG|Ifosfamide|3,000 mg/m\^2 IV over 6 hours on Days -6 to -3
223524896|NCT00936936|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.
223524897|NCT00936936|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
223524898|NCT03670472|OTHER|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
223524899|NCT00931541|DRUG|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
223524900|NCT00931541|DRUG|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
223524901|NCT01714674|DIETARY_SUPPLEMENT|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
223524902|NCT01714674|DIETARY_SUPPLEMENT|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
223524903|NCT06140225|BEHAVIORAL|"PACER Application"|It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.
223705452|NCT05807230|BEHAVIORAL|Three-level network rehabilitation services within the medical alliance|Data of all levels of medical and health institutions in Huzhou region are shared, and advanced rehabilitation technologies are passed down from senior hospitals to grassroots medical institutions. Grassroots medical institutions to patients home for 3 months of rehabilitation training.
223705453|NCT02866708|DEVICE|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
223705454|NCT03042325|DRUG|Alogliptin|Alogliptin tablets
223705455|NCT02318537|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
223705456|NCT02318537|DRUG|Placebo Solution|A matching oral solution containing no cannabidiol.
223705457|NCT02000934|DRUG|TAK-659|TAK-659 tablet
223705458|NCT05592262|DRUG|SHR2554|On an empty stomach - after meals
223705459|NCT05592262|DRUG|SHR2554|After meals - on an empty stomach
223705460|NCT04597775|DRUG|hydroxychloroquine|hydroxychloroquine
223705461|NCT02985437|DRUG|Surfactants|
223705462|NCT02985437|DRUG|Saline Solution|
223705463|NCT01893203|DRUG|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
223705464|NCT01893203|DRUG|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
223705465|NCT00621959|DRUG|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
223705466|NCT00621959|DRUG|placebo|0mg (matching oral tablet)for 14 days
223705467|NCT05522452|OTHER|Telerehabilitation|Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
224275847|NCT00006467|DRUG|gemcitabine hydrochloride|
223705468|NCT05522452|OTHER|Face to face rehabilitation|Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
223705469|NCT01758523|DRUG|Dutasteride|
223705470|NCT01758523|DRUG|sugar pill|
223705471|NCT05101642|PROCEDURE|Guided Creeping Technique (GCT)|Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
223705472|NCT03465358|OTHER|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
223705473|NCT00590135|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
223705474|NCT01847742|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy|
223705475|NCT06263556|BEHAVIORAL|Pelvic floor exercises|"Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day"
223705476|NCT06263556|DEVICE|Transcutaneous posterior tibial nerve stimulation|Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.
223705477|NCT06263556|DEVICE|Sham stimulation|Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
223705478|NCT05100901|DIETARY_SUPPLEMENT|MAG oil oral nutritional supplement (ONS)|The study product is suitable for use as an oral nutritional supplement (ONS).The study product contains MAG oil, hydrolyzed whey protein, simple carbohydrates, vitamins and minerals.
223705479|NCT04729621|COMBINATION_PRODUCT|TVB-009|TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
223705480|NCT04729621|COMBINATION_PRODUCT|Prolia®|Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)
223705481|NCT02652065|OTHER|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
224275848|NCT00133367|DRUG|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
224275849|NCT00133367|DRUG|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
224275850|NCT00133367|DRUG|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
224275851|NCT00133367|DRUG|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
223705482|NCT02652065|OTHER|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
223705483|NCT02652065|OTHER|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
223705484|NCT02652065|OTHER|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
223705485|NCT02592525|BEHAVIORAL|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
223705486|NCT03439657|BIOLOGICAL|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
223705487|NCT03439657|BIOLOGICAL|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
223705488|NCT02245984|OTHER|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
223705489|NCT02245984|OTHER|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
223705490|NCT02489760|BIOLOGICAL|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
223705491|NCT02489760|BIOLOGICAL|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
223705492|NCT03526575|DRUG|Zolpidem|
223705493|NCT04882280|BEHAVIORAL|Light|10 hours of light exposure during the daytime, starting 2 hours after habitual wake time
223705494|NCT05221710|BEHAVIORAL|electroacupuncture|"The acupuncture treatment will be performed by the technique of lifting, thrusting, twirling and rotating the needle until the patient is being De-qi (getting a numbness or other acupuncture feeling).The needle will be kept in place for approximately 30 minutes. The point of acupuncture is determined by a traditional Chinese medicine doctor.~Neuromuscular Electrical Stimulation(NMES) group received consecutive daily sessions of electrical stimulation at specific points.~On the basis of the above acupuncture treatment,two points that do not cross the joint will be chosen for electrical stimulation in electroacupuncture group."
223705495|NCT00065988|DEVICE|Dispersed phase amalgam restoration /composite restoration|
223705496|NCT04980781|BEHAVIORAL|Physical exercise and dietary therapy (PED-t)|Behavioral therapy: Physical exercise and dietary therapy (PED-t) is a treatment of bulimia nervosa and binge eating disorder, relying on guided, progressive resistance exercise therapy and dietary therapy (dietary education and group discussions) following a designed therapy manual.
223705497|NCT04980781|PROCEDURE|Implementation program for PED-t in ERC|Participating in a training program for therapists in PED-t; to increase knowledge of eating disorders and to be able to implement and run the PED-t. Training program consists of a therapy manual, digital lectures, and 3 work shops.
223705498|NCT04153604|DRUG|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
223705499|NCT03894800|DRUG|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
224275852|NCT00133367|DRUG|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
224275853|NCT00133367|DRUG|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
224083266|NCT03983395|BIOLOGICAL|ISB 1302 escalating doses,1200 ng/kg D15,22|ISB 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of ISB 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
224275854|NCT00133367|DRUG|Melphalan|Given intravenously on day 2 before transplant.
224275855|NCT03769636|DEVICE|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
224275856|NCT01206751|OTHER|Chest imaging technique and case presentation|
224275857|NCT01653405|OTHER|Multifaceted behavioral intervention|The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
224275858|NCT05793645|DEVICE|personalized care plan|Algorithm that defines personalized care plan
224275859|NCT00213005|DRUG|Carraguard (PC-515)|
224275860|NCT03993587|OTHER|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
224275861|NCT03092167|OTHER|Physical exercises|Physical exercises
224275862|NCT02018796|DRUG|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
224275863|NCT01546363|OTHER|Blood draw|phlebotomy
224275864|NCT05212116|DRUG|SDI-118|SDI-118 is presented as low dose, and high dose capsules.
224275865|NCT05212116|DRUG|Placebo|The Matching Placebo for SDI-118 is mannitol in capsules.
224275866|NCT02569281|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
224275867|NCT02569281|OTHER|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
223524904|NCT06140225|BEHAVIORAL|"MapMyWalk Application"|It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.
223524905|NCT06140225|BEHAVIORAL|"Strava Application"|It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.
223524906|NCT06140225|BEHAVIORAL|"POKEMON GO APPLICATION"|It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.
223524907|NCT06140225|BEHAVIORAL|"JEFIT APPLICATION"|It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.
223524908|NCT06140225|BEHAVIORAL|"FITBIT-FLEX APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
223524909|NCT06140225|BEHAVIORAL|"MEIZU BONG 2S APPLICATION"|It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
223524910|NCT00913822|DRUG|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
223524911|NCT00913822|DRUG|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
223524912|NCT03733548|BEHAVIORAL|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
223524913|NCT01373281|BIOLOGICAL|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
223524914|NCT01373281|BIOLOGICAL|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
223524915|NCT02101463|DEVICE|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
223524916|NCT04432779|OTHER|no intervention|no intervention
223524917|NCT06571864|DRUG|Anti-CD38 Monoclonal Antibody|Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
223524918|NCT06571539|DEVICE|AR-assisted EVD placement|Cfr. arm description
223524919|NCT06571539|PROCEDURE|Freehand EVD placement|External ventricular drain (EVD) placement using the conventional freehand technique. This intervention covers the matched, non-concurrent control group, retrospectively obtained without active enrollment to receive study treatment.
223524920|NCT01300637|DRUG|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
223524921|NCT01300637|DRUG|placebo|identical-appearing pill of placebo
223524922|NCT04197232|OTHER|clinical evaluation|\- In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
223705500|NCT03894800|DRUG|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
224083267|NCT03983395|BIOLOGICAL|ISB 1302 at the MTD and/or RP2D dose|ISB 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
223524923|NCT04277130|BEHAVIORAL|Intervention with active video games|Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I \& II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
223524924|NCT04253600|BEHAVIORAL|Risk profile screening questionnaire|Families will be asked to complete a LimeSurvey questionnaire that aims at evaluating general risk profiles associated with DLD (e.g., no elevated risk, behavioral risk, environmental risk, familial risk), as well as our exclusion criteria (e.g., hearing deficit).
223524925|NCT04253600|PROCEDURE|Investigation of the neural correlates of DLD using Magnetic Resonance Imagery (MRI)|MRI data acquisition will take place during natural sleep in infants aged from 6 to 12 months. First, families will have to complete a security questionnaire to make sure that neither the children nor the accompanying parent have any known contraindication preventing the MRI session and that none of them is wearing any ferro-magnetic elements. Then, families will be welcomed in a calm and child-friendly environment where we will propose them some preparatory games known to facilitate sleep in children. MRI protocol will comprise structural and functional images and won't exceed 30 minutes.
224083268|NCT04735276|DEVICE|HFNO for 5 min|1st basic MRI then HFNO for 5 min with mouth closed breathing and 2nd MRI. Analysis of the surface of the gastric antrum.
224275868|NCT04898816|PROCEDURE|closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive|Application of cyanoacrylate tissue adhesives over the surgical wound
224275869|NCT04898816|PROCEDURE|closure of wound using braided silk suture|suturing the surgical wound using braided black silk
224275870|NCT02050321|DRUG|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
224275871|NCT02050321|DRUG|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
224275872|NCT06217432|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
224275873|NCT01947738|DRUG|VBY-891|Cathepsin S inhibitor
224275874|NCT01947738|DRUG|Placebo|
223524926|NCT04253600|BEHAVIORAL|Online investigation of predictive factors associated with DLD and LANCOM app development|Parents will be asked to complete a series of online questionnaires every six months. Questionnaires will be created on LimeSurvey and will include different questionnaires, scales, and observations that aim at evaluating children's development, and especially language development, as well as parental and environmental characteristics.
223524927|NCT04253600|BEHAVIORAL|Individual behavioral and cognitive assessment|Individual cognitive and behavioral assessment will be scheduled once a year, around the child's birth date, and will comprise an extensive battery of standardized evaluation appropriate for the child's age. This individual evaluation will focus on several developmental aspects including language, psychomotor, behavioral and cognitive development, as well as executive and socio-emotional functioning, depending on the age of the children. Evaluations will be adapted to each child's specific profile, while respecting the following administration rules: (1) we will prioritize language development testing, (2) testing sessions will be adapted to each child's pace and possibilities, (3) if a child does not want to take part in the assessment, feels tired, or does not seem to be comfortable with the investigator, tests won't be administered.
223524928|NCT04253600|BEHAVIORAL|Automated analysis of language development and environment|"Following the individual assessment, families will be asked to record their child's language environment over a 2-days' timeframe using the LENA® device, a small wearable device allowing for large-scale all-day audio recording and automated vocal analyses of speech segments. An automatic analysis of the recordings, performed by the LENA pro software algorithms, will provide amongst others, a direct and natural measure of the child's number of vocalizations, adult word counts, conversational turns, duration of exposure to electronic media versus to meaningful language. Data acquisition will take place once a year following our sample selection, with a required recording time per day ranging from 12 to 16 hours."
223524929|NCT02722785|BEHAVIORAL|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum \[1-RM\] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
223524930|NCT03934294|OTHER|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
223524931|NCT03934294|DRUG|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
223524932|NCT03934294|OTHER|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
223524933|NCT06378840|RADIATION|Nab-paclitaxel/Platinum, Sintilimab|Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy
223524934|NCT05701826|DRUG|HRS3797|HRS3797 for injection, low dose
223524935|NCT05701826|DRUG|HRS3797|HRS3797 for injection, medium dose
223524936|NCT05701826|DRUG|HRS3797|HRS3797 for injection, high dose
223524937|NCT01302886|DRUG|BHQ880|
223524938|NCT04370886|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
223524939|NCT01312298|PROCEDURE|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
223524940|NCT01312298|PROCEDURE|Regional anesthesia|Patients will receive intrathecal anesthesia
223524941|NCT00851084|DRUG|aflibercept|administration: IV infusion
223524942|NCT00851084|DRUG|oxaliplatin|administration: IV infusion
223524943|NCT00851084|DRUG|5-FU|administration: IV infusion
223524944|NCT00851084|DRUG|Folinic Acid|administration: IV infusion
223524945|NCT02997007|DEVICE|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
223524946|NCT02997007|DEVICE|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
223524947|NCT03236883|DRUG|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
223524948|NCT03236883|OTHER|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)\*10\^8/kg,once a month,repeated every 4weeks,three times in all.
223524949|NCT03650023|DIETARY_SUPPLEMENT|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
223524950|NCT03650023|DIETARY_SUPPLEMENT|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
223524951|NCT00734032|DRUG|SB480848 40mg EC Tablet|1 tablet once a day
223524952|NCT00734032|DRUG|SB480848 80mg EC Tablet|1 tablet once a day
223524953|NCT00734032|DRUG|SB480848 160mg EC Tablet|1 tablet once a day
223524954|NCT00734032|DRUG|SB480848 Placebo Tablet|1 tablet once a day
223524955|NCT04973319|DRUG|Pyrotinib|Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.
223524956|NCT04973319|DRUG|Trastuzumab|Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
223524957|NCT05903235|BEHAVIORAL|Virtual Reality-based Mirror Therapy (VR+MT)|In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.
223524958|NCT05903235|BEHAVIORAL|Mixed Reality-based Mirror Therapy (MR+MT)|In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.
223524959|NCT05903235|BEHAVIORAL|Traditional Mirror Therapy (MT)|In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
223524960|NCT03828604|BEHAVIORAL|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
223524961|NCT03828604|BEHAVIORAL|Placebo Trier Social Stress Task|Active control version of the TSST
223524962|NCT05379530|DIAGNOSTIC_TEST|Thromboelastography (TEG)|Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
223524963|NCT05379530|OTHER|Anesthesia Provider Survey|Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
223524964|NCT04669067|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
223524965|NCT04669067|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
223524966|NCT01798225|DRUG|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
223524967|NCT01798225|DRUG|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
223524968|NCT00751231|DRUG|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
223524969|NCT00751231|DRUG|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
223524970|NCT04446052|DRUG|GM-CSF priming|
223524971|NCT04446052|DRUG|Placebo|Placebo
223524972|NCT02753972|BEHAVIORAL|Mindful Eating and Living|8 week mindfulness skills intervention
223524973|NCT02753972|BEHAVIORAL|Active Weight Loss Control|8 week active weight loss control group
223524974|NCT00133705|DRUG|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
223524975|NCT00133705|DRUG|Inert Capsule|sugar pill
223524976|NCT00824954|PROCEDURE|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
223524977|NCT00400101|BIOLOGICAL|Virosome-formulated synthetic peptides (malaria vaccine)|
223524978|NCT00246103|DRUG|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
223524979|NCT00246103|DRUG|Epirubicin|Beginning Dose, Level 1: 75 mg/m\^2.
223524980|NCT00246103|DRUG|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m\^2.
223524981|NCT00246103|DRUG|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m\^2.
223524982|NCT01795157|DEVICE|CCADSS|Questionnaire is transferred wireless to the physician's PC
223524983|NCT01795157|DEVICE|pen-paper|Questionnaire completed and transferred to the physician using standard methods
223524984|NCT04881058|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the PicoSure device.
223524985|NCT00175500|DEVICE|Large Diameter Femoral Head|
223524986|NCT05481684|OTHER|Normal Progesterone group|No progesterone supplementation
223524987|NCT05481684|OTHER|Low Progesterone group|Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, vaginal pills (Lutinus 2\*1) or SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day. Progesterone supplementation was discontinued if there was no pregnancy. Progesterone supplementation at the same dose was continued until 10 gestational weeks for viable pregnancies.
223524988|NCT04114825|BIOLOGICAL|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
223524989|NCT04114825|OTHER|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
223705501|NCT03894800|DRUG|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
224275875|NCT06257979|OTHER|This study is with minimal risk and minimal constraints due to the addition of questionnaires|"In this study, the specific procedures compared to routine care are :~* Considering the addition of questionnaires, this study will be prospective. Due to the use of bacteriological samples, it is considered as a minimal-risk research.~* The research procedure involves a bacteriological analysis of operative elements (sutures placed during the first intervention, the product of tendon debridement, and the subacromial bursa (cleaning product)) used during the re-intervention. These usually discarded operative samples are collected for bacteriological analysis.~* Antibiotic treatment cannot be prescribed immediately after the surgery and during the first month following this re-intervention (time for biofilm formation). As per the protocol, even a positive sample should not lead to the initiation of systematic antibiotic therapy. In the case of identification of a pathogenic microorganism, antibiotic therapy will be prescribed, leading to discontinuation of the study."
224275876|NCT01228552|DRUG|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
223524990|NCT05938686|OTHER|Home_Based Digital Mindful Dance Program|Home\_Based Digital Mindful Dance Program including warm up, dance and cool down for 60 minute with 12 weeks.
223524991|NCT02295865|DRUG|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
223524992|NCT02295865|DRUG|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
223524993|NCT02295865|DRUG|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
223524994|NCT02295865|DRUG|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
223524995|NCT01651988|DRUG|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures \< 10 minutes~1. Ketamine-Propofol Combination KETOFOL 1:1~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~2. Ketamine-Propofol Combination KETOFOL 1:2~   * Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~  * Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~  * Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures \> 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
223524996|NCT03622606|DIAGNOSTIC_TEST|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
223524997|NCT03247101|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
223524998|NCT03247101|DRUG|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
223524999|NCT03247101|DRUG|Biotase group|Biotase 1# \[Biodiastase 30mg + lipase 65mg + newlase 10mg\]/tab po tid x 6 months
223525000|NCT03960736|OTHER|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
223525001|NCT03960736|OTHER|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
223525002|NCT01110512|DRUG|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
223525003|NCT01110512|DRUG|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
223525004|NCT03362671|DEVICE|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
223525005|NCT03362671|DEVICE|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
223525006|NCT02793960|DRUG|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
223525007|NCT04992273|DRUG|casirivimab+imdevimab|Single dose administered based on weight
223525008|NCT03440411|DRUG|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
223525009|NCT03440411|DRUG|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
223525010|NCT03440411|DRUG|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
223525011|NCT04461886|DRUG|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
223525012|NCT04778202|DIAGNOSTIC_TEST|blood sample collection|blood sample collection by venipuncture four both groups and MRI for breast cancr patient group
223525013|NCT01659294|BEHAVIORAL|Nurse Case Management|
223525014|NCT01659294|BEHAVIORAL|standard diabetologist care|routine care by diabetologist \& team
223525015|NCT05349604|DIETARY_SUPPLEMENT|Garlic extracts|One intake in total
223525016|NCT05349604|DIETARY_SUPPLEMENT|Placebo|One intake in total
223525017|NCT02101255|DEVICE|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
223525018|NCT02101255|DEVICE|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
223705502|NCT03894800|DRUG|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
223705503|NCT04937946|DRUG|Fentanyl|Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
223705504|NCT00000546|BEHAVIORAL|meditation|
223705505|NCT01910948|DRUG|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
223705506|NCT05827731|BEHAVIORAL|cesarean section|According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
223705507|NCT02429843|DRUG|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
223705508|NCT00193258|DRUG|Bevacizumab|10mg/kg IV infusion every 2 weeks
223705509|NCT00193258|DRUG|Erlotinib|150 mg po daily
223705510|NCT00193258|DRUG|Imatinib|400-600mg daily
223705511|NCT02394483|DRUG|F901318 safety|Safety assessments
223705512|NCT02394483|DRUG|F901318 tolerability|Tolerability assessments
223705513|NCT02394483|DRUG|F901318 pharmacokinetics|Pharmacokinetic assessments
223705514|NCT02394483|OTHER|Placebo safety|Safety assessments
223705515|NCT02394483|OTHER|Placebo tolerability|Placebo tolerability
223705516|NCT02394483|OTHER|Placebo pharmacokinetics|Plaacebo pharmacokinetics
223705517|NCT05353179|DRUG|Meperizumab injection|Meperizumab injection is a humanized monoclonal antibody of IgG1 injection
223705518|NCT05353179|DRUG|NUCALA®|NUCALA® is a humanized monoclonal antibody of IgG1 injection
223705519|NCT04273373|BIOLOGICAL|Low Dose Albumin|20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
223705520|NCT04273373|BIOLOGICAL|Standard dose Albumin|20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
223705521|NCT03698409|DRUG|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
223705522|NCT00219973|DRUG|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
223705523|NCT05460260|DEVICE|Cascade CGM|21-days of CGM wear
223705524|NCT01393223|DRUG|LP-08 80mg|Intravesical instillation of 80mg LP08
223705525|NCT01393223|DRUG|Normal saline|Intravesical instillation of normal saline
223705526|NCT01393223|DRUG|LP-08 20mg|Intravesical instillation of 20mg LP08
223705527|NCT02741856|DRUG|Carboplatin|For more information please see the arm descriptions section.
223705528|NCT02741856|DRUG|Paclitaxel|For more information please see the arm descriptions section.
223705529|NCT02741856|DRUG|Cisplatin|For more information please see the arm descriptions section.
223705530|NCT02741856|DRUG|Capecitabine|For more information please see the arm descriptions section.
223705531|NCT02741856|RADIATION|Radiotherapy|For more information please see the arm descriptions section.
223705532|NCT04053231|OTHER|liver resection|all type of liver surgical procedures
223705533|NCT00229073|DRUG|dapoxetine|
223705534|NCT06556901|OTHER|retrospective study about reasons for consultations|retrospective study about reasons for consultations
223705535|NCT00194883|DRUG|Recombinant Human Growth Hormone|
223705536|NCT06142708|DRUG|Dual trigger (human chorionic gonadotropin plus GnRH-agonist)|Human chorionic gonadotropin will be added to GnRH-agonist as a dual trigger in participants previously having had a suboptimal response to GnRH-agonist trigger only
223705537|NCT06142708|DRUG|GnRH-agonist only trigger|GnRH-agonist only will be used for final maturation
223705538|NCT03831789|DEVICE|Cerebellar targeted rTMS|10 Hz cerebellar rTMS (250 pulses)
223705539|NCT00391729|DRUG|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
223705540|NCT00391729|DRUG|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
223705541|NCT05239442|OTHER|Taste Commission|"Evaluation of the daily meal once a week:~Introduction on the different sensory dimensions of the food, hedonic rating for each component, indicate what pleases/what could be improved in the recipe."
223705542|NCT05239442|OTHER|Evaluation of the taste commissions|"At 0, 3, 6 months:~* Food intake measurement, satisfaction measurement, and food waste measurement performed on 2 days (same week but not necessarily consecutive)~* Assessment of nutritional status using the Mini-Nutritional Assessment (MNA)"
223705543|NCT05239442|OTHER|Entretien SWOT|Individual semi-guided face-to-face interview with an experimenter. They will allow us to identify the positive and negative effects of the taste commissions in the establishment as well as the levers and difficulties encountered during the implementation of the taste commissions. These interviews will be recorded using an audio device (dictaphone). Their content will then be transcribed in full.
223705544|NCT02956031|OTHER|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
223705545|NCT02956031|OTHER|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
223705546|NCT02956031|PROCEDURE|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
224275877|NCT01228552|OTHER|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
224275878|NCT00011609|DEVICE|Robotic Arm|
223525019|NCT04480866|DEVICE|Colli-Pee® (FV5000 and Small Volumes)|"Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order."
223525020|NCT00358878|DRUG|Satavaptan|oral administration once daily
223525021|NCT00358878|DRUG|placebo|oral administration once daily
223525022|NCT01093131|OTHER|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
223525023|NCT01093131|DRUG|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
223525024|NCT01093131|OTHER|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
223525025|NCT01093131|DRUG|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
223525026|NCT03974061|BEHAVIORAL|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
223525027|NCT03974061|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
223525028|NCT06188195|DRUG|Dexamethasone|ACS intervention were used in the experimental group
223525029|NCT03641287|OTHER|Exercise Counseling|Meet with exercise physiology
223525030|NCT03641287|OTHER|Aerobic Exercise|Receive prescription for moderate aerobic exercise
223525031|NCT03641287|OTHER|Physiological Support|Receive motivational support via telephone care
223525032|NCT03641287|OTHER|Quality-of-Life Assessment|Ancillary studies
223525033|NCT03641287|OTHER|Questionnaire Administration|Ancillary studies
223525034|NCT03641287|OTHER|Best Practice|Undergo habitual level of physical activity
223525035|NCT06487520|OTHER|group watching hot environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Peaceful mountain snow image was shown. This image includes a cold winter day.~Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
223525036|NCT06487520|OTHER|group watching cold environment image|"In this study, Sony playstation VR (Virtual Reality) glasses with LCD (Liquid Crystal Display) screen with OLED (Organic Light-Emitting Diode) technology and 1080P resolution integrated on the device were used. These glasses work integrated with the processor box. The processor box, which provides communication with the Sony playstation VR glasses, can also be connected to the computer with HDMI (High Definition Multimedia Interface) output. Within the scope of the study, the licensed Deep space relaxation image was shown. This image contains a hot environment image with explosions in space.Following the completion of every VR session, the removable face pad was replaced and the goggles and headsets were wiped down with alcohol-based sanitary wipes. Preventing infection via the sharing of the technology was a paramount issue with the study patients."
223525037|NCT05187234|OTHER|Education|Experimental: intervention group Education and training booklet based on the Roy adaptation model was given to the patients. The training was repeated at the first welcome and after the first month.
223525038|NCT05375630|DIETARY_SUPPLEMENT|Placebo|Placebo
223525039|NCT05375630|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
223525040|NCT05809700|DRUG|Freshly manufactured 35 kDa hyaluronan fragment|"This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded."
223525041|NCT06329219|DEVICE|water-filtered Infrared-A radiation|The water-filtered Infrared-A radiation device is designed for self-administered home treatments. The regimen prescribes 30-minute sessions, five times weekly, spanning 12 weeks.
223525042|NCT00722670|BEHAVIORAL|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
223525043|NCT00722670|BEHAVIORAL|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
223705547|NCT04734938|DIETARY_SUPPLEMENT|Huel Powder|Huel is made of an ultra-fine blend of sustainable ingredients. Oats, rice, peas, coconut, flaxseed, and our unique mix of vitamins and nutrients to provide you a meal with all the carbohydrates, protein, essential fats, fibre, and all the 26 essential vitamins and minerals your body needs to thrive. Volunteers will consume only Huel as their food source for the final four weeks of the study.
223705548|NCT02921542|DEVICE|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
223705549|NCT00310401|DRUG|Albuterol|5 mg nebulized q4h
223705550|NCT00310401|DRUG|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
223705551|NCT02028819|DRUG|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
223705552|NCT02028819|DRUG|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
223705553|NCT00760422|DEVICE|NIR|Thermometer
223705554|NCT01203631|DRUG|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
224275879|NCT04821388|DEVICE|Rontis DCB|"The Rontis DCB is intended for use as a percutaneous transluminal angioplasty (PTA) catheter to dilate stenotic or obstructive vascular lesions in the lower extremities for the purpose of improving limb perfusion and decreasing the incidence of restenosis.~In this study, it is intended to use Rontis DCB for treatment of lesions in the femoropopliteal arteries"
223705555|NCT01203631|DRUG|Placebo|A single dose administered subcutaneously (s.c., under the skin)
223705556|NCT00319501|DRUG|Placebo|Intramuscular autoinjector; administered at onset of an episode
223705557|NCT00319501|DRUG|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
223705558|NCT00561457|DEVICE|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
223705559|NCT03360604|DIETARY_SUPPLEMENT|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
223705560|NCT03360604|DIETARY_SUPPLEMENT|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
224275880|NCT03486496|DRUG|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
224275881|NCT03486496|DRUG|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
223525044|NCT04087642|DIAGNOSTIC_TEST|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
223525045|NCT04087642|DIAGNOSTIC_TEST|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if an anti-incontinence procedure should be performed concomitantly. If the test is positive, it will be performed. If the test is negative, it will not be performed.
223705561|NCT01951937|DIETARY_SUPPLEMENT|Fish Meals|Meals containing salmon
223705562|NCT01951937|DIETARY_SUPPLEMENT|Placebo|No fish meals
223705563|NCT06068608|DRUG|TNM005|single,intramuscular injection
223705564|NCT06068608|DRUG|Placebo|single,intramuscular injection
223705565|NCT06068608|DRUG|VariZIG|a single dose of VARIZIG 625 IU,intramuscular injection
223705566|NCT04412434|DIAGNOSTIC_TEST|Electroencephalography (EEG)|"Electroencephalography (EEG) is a painless and harmless method to record the bioelectric activity of the brain. Clinically, EEG refers to the recording of the brain's spontaneous electrical activity over a period of time, as recorded from multiple electrodes placed on the scalp This method can be helpful in the diagnosis of many various brain diseases and pathological conditions.~For the examination, electrodes are placed on the head, using a special harmless gel, similar to gel, used in ultrasonographic studies."
223705567|NCT05393674|DRUG|Fedratinib Oral Capsule [Inrebic]|400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
223705568|NCT05393674|DRUG|Nivolumab|240 mg every 2 weeks i.v. from cycle 2-n
224275882|NCT00113919|DRUG|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin\* 10 mg/m, Continuous infusion 1-4 Adriamycin\*\* 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
224275883|NCT02305407|PROCEDURE|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
224275884|NCT02305407|OTHER|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
223525046|NCT03748550|BEHAVIORAL|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
223705569|NCT01214343|DRUG|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
223705570|NCT01214343|DRUG|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
223705571|NCT00555451|DRUG|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~1. HE3286 5 mg or placebo QD for 28 days;~2. HE3286 10 mg (5 mg BID) or placebo BID for 28 days~3. HE3286 20 mg (10 mg BID) or placebo BID for 28 days~4. HE3286 40 mg (20 mg BID) or placebo BID for 28 days~5. HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~6. HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
223705572|NCT05491720|DRUG|RisperiDONE 1 MG/ML|Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
223705573|NCT05491720|DEVICE|transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
223705574|NCT05491720|DRUG|Placebo|Patients will receive placebo tablet (Galenus pharmaceutical company)
223705575|NCT05491720|DEVICE|sham transcranial direct current stimulation|Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
223705576|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
224275885|NCT04283851|DIAGNOSTIC_TEST|testing functional haemodynamic parameters for preload assessment|dynamic testing of preload responsivity plus echocardiography
223525047|NCT06637410|DEVICE|High intensity laser therapy|HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.
223525048|NCT06637410|DEVICE|Ultrasound therapy|US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
223525049|NCT06637410|OTHER|Therapeutic Exercise|ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
223525050|NCT03963284|PROCEDURE|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
223525051|NCT03963284|DEVICE|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
223525052|NCT02589288|PROCEDURE|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
223525053|NCT02589288|PROCEDURE|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
223525054|NCT01943760|DRUG|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
223525055|NCT01943760|DRUG|0.9% saline|
223525056|NCT06638489|OTHER|High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)|The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.
223525057|NCT06638489|OTHER|Pelvic-Floor-Muscle-Training (PFMT)|The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
223525058|NCT06640673|DIAGNOSTIC_TEST|Hd-EEG|Subjects undergo a clinical and neuropsychological assesment, then a Hd-EEG both during resting state and execution of tasks, and structural Magnetic Resonance Imaging
223525059|NCT06641531|OTHER|Screening pap smear test|"The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain"
223525060|NCT04789941|DRUG|Cis Platinum + Irinotecan|Studying the efficacy and safety of neoadjuvant cisplatin and irinotecan use in treatment of locally advanced cancer cervix.
223525061|NCT06015516|DRUG|Minoxidil Tablets|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
223525062|NCT06015516|DRUG|Minoxidil topical solution 20 mg/ml|"Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period."
224275886|NCT01292668|DRUG|methyl-5-aminolevulinate hydrochloride cream|Applied topically
224275887|NCT01292668|DRUG|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
224275888|NCT01292668|PROCEDURE|laser therapy|Undergo laser light photodynamic therapy
224275889|NCT05696327|OTHER|Tyler Twist Exercises|Tyler twist exercises are the group of exercises which are used to strengthen wrist ex tensors.The protocol consists of several steps using colored twist-able bands and patients are guided to actively perform the steps for their grip strength development.
224275890|NCT05696327|OTHER|conventional physical therapy|Conventional physiotherapy (Ultrasound + Cross Friction Massage for 10 minutes + Wrist extensor stretching and Isotonic wrist extensor strengthening.)
223525063|NCT06639230|DEVICE|laser therapy|Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.
223525064|NCT06639230|DRUG|Sclerotherapy|Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
223525065|NCT05812690|OTHER|This is a non intervention - observation only study|This is non intervention study
223525066|NCT06462404|DRUG|E2086|E2086 oral tablets.
223525067|NCT06462404|DRUG|E2086 Placebo|E2086 matching placebo tablet.
223525068|NCT06462404|DRUG|Active Comparator|Active comparator oral tablets.
223525069|NCT06462404|DRUG|Active Comparator Placebo|Active comparator matching placebo tablet.
223525070|NCT05332704|DRUG|ONO-4685|-Part A: Single ascending doses of ONO-4685 as a single IV dose (Cohort A1-A5).
223525071|NCT05332704|DRUG|Placebo|-Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
223525072|NCT05332704|DRUG|ONO-4685|-Part B: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort B1 and B2)
223525073|NCT05332704|DRUG|Placebo|-Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
223525074|NCT05332704|DRUG|ONO-4685|-Part C: Multiple doses of ONO-4685 as IV doses over a 4-week treatment period (Cohort C1 and C2).
223525075|NCT05332704|DRUG|Placebo|-Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
223525076|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks
223525077|NCT06639399|OTHER|Acupuncture|Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
223525078|NCT06563986|DRUG|Systemic treatment (FTD-TPI and bevacizumab)|"Systemic treatment (FTD-TPI and bevacizumab) administration is according to standard clinical practice. Each treatment cycle will be 28 days in duration.~One treatment cycle consists of the following:~* Days 1-5: oral intake of FTD-TPI and bevacizumab IV infusion on day 1~* Days 8-12: oral intake of FTD-TPI~* Day 15: bevacizumab IV infusion~Bevacizumab 5.0mg/kg i.v. is repeated every 2 weeks. If toxicity occurs, dose modifications and dose delays should be administered and applied according to standard practice."
223525079|NCT06563986|DEVICE|Radioembolization with 166-Ho microspheres|"Individualized 166Ho radioembolization will be performed via a catheter during angiography. Before the treatment, a scout procedure will be performed to determine individualized 166Ho dose of the treatment. Dosimetry-based treatment planning will be individualized using Q- Suite software.~In case of bilateral disease, patients will be treated in two procedures to each hemi-liver, separated by 1 month. Before the first procedure, a scout procedure will be performed in which the individualized 166Ho dose of the first and second procedure will be calculated."
223525080|NCT03413800|DRUG|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
223525081|NCT06561802|DIAGNOSTIC_TEST|GCF and saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Also, 4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips and put into propylene tube. Tubes were stored at -80ºC until the day of analysis.
223525082|NCT06424639|DRUG|Luspatercept|Luspatercept (dose of 1.0 mg/kg, subcutaneous injection every 3 weeks) Cyclosporine (3-5mg/kg/day)
223525083|NCT06424639|DRUG|cyclosporine|Cyclosporine (3-5mg/kg/day)
223525084|NCT00006167|DRUG|oxandrolone|
223525085|NCT00006167|BEHAVIORAL|Progressive Resistance Training|
223525086|NCT00863304|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
223525087|NCT00863304|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
223525088|NCT00863304|DRUG|naproxen|naproxen 1000 mg daily for 16 weeks
223525089|NCT00863304|OTHER|placebo|placebo to match tanezumab and naproxen dosing
223525090|NCT01008826|DIETARY_SUPPLEMENT|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
223525091|NCT03921567|DRUG|Lidocaine Hydrochloride|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
223525092|NCT03921567|DRUG|Lidocaine Hydrochloride and Ketamine|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
223525093|NCT03921567|DRUG|Placebo|will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
223705577|NCT02556554|DEVICE|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
223705578|NCT03549169|BEHAVIORAL|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
223705579|NCT03549169|BEHAVIORAL|Regular attention|Regular attention focused on education for therapeutic adherence
223705580|NCT02242266|DRUG|Tiotropium low dose|inhalation powder, hard PE capsule
223705581|NCT02242266|DRUG|Tiotropium medium dose|inhalation powder, hard PE capsule
223705582|NCT02242266|DRUG|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
223705583|NCT02242266|DRUG|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
223705584|NCT02242266|DRUG|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
223705585|NCT00499499|DRUG|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m\^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
223705586|NCT05805930|DRUG|Anakinra|: Patients will continue daily treatment with anakinra up to week 12. Treatment will be then progressively tapered through the reduction of an administration of the drug per week. Reductions will be performed every 2 weeks up to discontinuation. Therefore, if a relapse does not occur, the treatment will be withdrawn at week 24.
223705587|NCT05805930|DRUG|Prednisone|Steroids will be progressively tapered with a reduction of 0,1-0,15 mg/kg/day of prednisone (or 5 mg in patients in treatment with the maximum dosage of 50 mg/day) from the ongoing treatment every week up to discontinuation. If a relapse does not occur, the treatment will be withdrawn in a period of time of 10 weeks.
223705588|NCT03854188|PROCEDURE|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
223705589|NCT01209728|OTHER|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
223705590|NCT02764697|DRUG|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
223705591|NCT02511990|BIOLOGICAL|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
223705592|NCT02511990|BIOLOGICAL|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
223705593|NCT02511990|BIOLOGICAL|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
223705594|NCT03901885|OTHER|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
223705595|NCT04410029|OTHER|Healthwise Decision Aid|Healthwise, a non-profit company that develops health content and patient information for hospitals, has created a decision aid for EPL management that is available through the EPIC Systems, an electronic medical record. Participants will be given this decision aid after EPL diagnosis and prior to options consultation with a provider.
223705596|NCT04410029|OTHER|Control informational handout|Participants randomized to the control arm will be given an informational handout of treatment options after EPL diagnosis and prior to options consultation with a provider.
223705597|NCT03866460|DIAGNOSTIC_TEST|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
223705598|NCT00302107|DRUG|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
223705599|NCT00302107|DRUG|Placebo|Look-a-like placebo tablets under double-blind conditions
223705600|NCT03550664|DEVICE|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
223705601|NCT03206411|DIAGNOSTIC_TEST|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
223705602|NCT00400283|DRUG|NNC 55-0414|
223705603|NCT04112407|DEVICE|Blue Light Phototherapy|Phototherapy in the blue light spectrum
223705604|NCT04112407|DRUG|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
223705605|NCT04112407|OTHER|Control|Standard surgical site preparation with no P. acnes pretreatment
223705606|NCT01595633|DRUG|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
223705607|NCT00431288|BEHAVIORAL|diet high in fruits, vegetables, and dairy|
223705608|NCT00431288|OTHER|Routine nutrition care|
223705609|NCT01790932|DRUG|BKM120|
223705610|NCT04185064|DEVICE|Game Ready ATX shoulder wrap; Game Ready GRPro 2.1|the Game Ready ATX shoulder wrap that is anatomically engineered for the shoulder joint. The wrap is connected to the Game Ready GRPro 2.1 system enabling the integrated delivery of continuous cold and intermittent pneumatic compression therapy to the shoulder joint and surrounding soft tissues.
223705611|NCT04185064|OTHER|Standard Care|Participants will undergo post-surgical cryotherapy using the treating surgeons preferred method of cryotherapy, which can include rest, ice, and compression using standard ice packs or bag of ice, a cryocuff, or other such device.
223705612|NCT06404671|PROCEDURE|Delayed interval cytoreductive surgery (DICS)|"patients will receive six courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by delayed interval cytoreductive surgery (DICS) within 6 weeks of the last cycle of chemotherapy. After DICS, patients will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
224275891|NCT02699762|OTHER|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
224275892|NCT05103644|DRUG|Atorvastatin 80mg|patients received statin experimental group
224275893|NCT05103644|OTHER|placebo|patients received placebo control group
224275894|NCT00715676|DRUG|Placebo|oral, once daily
224275895|NCT00715676|DRUG|DP001|oral, once daily
224275896|NCT01525680|OTHER|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
224275897|NCT01525680|OTHER|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
224275898|NCT03577561|OTHER|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
224275899|NCT05003882|OTHER|Commercially available, orally ingestible CBD product|botanically-derived CBD extract product
223525094|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
223525095|NCT02670291|DEVICE|MagPro Cool-B65A/P, Magventure|combined active and sham coil
223525096|NCT03578055|DRUG|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
223525097|NCT03578055|DRUG|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
223525098|NCT05393180|DEVICE|Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AF|"Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter.~Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. ."
223525099|NCT05992909|PROCEDURE|Lymphovenous bypass procedure|Participants will return to the clinic 14 days, 6 months, 12 months, 18 months, and 24 months after your surgery for measurements of your legs to see if there are changes over time
223525100|NCT06443853|DIAGNOSTIC_TEST|Dental plaque scoring and dental plaque coated tooth surface measuring|"The Turesky Modified Quigley Hein Plaque Index of anterior teeth of the volunteers' was recorded using clinical visual examination.~Intraoral photographs of the volunteers were taken by using a digital camera and 3D images were recorded by an intraoral scanner. The plaque-covered area and the total surface area of the teeth were marked in the manual mode of the Image J program and the areas were measured in square pixels. The correlation between clinical visual scoring, dental plaque areas on images were compared."
223525101|NCT01930500|BEHAVIORAL|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
223525102|NCT01930500|BEHAVIORAL|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
223525103|NCT02848131|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
223525104|NCT02848131|DRUG|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
223525105|NCT06847256|PROCEDURE|Heat Challenge|Participants will be asked to arrive well-hydrated and to refrain from exercise, alcohol, caffeine, and smoking for 24 hours prior to the visit. Height, weight, blood pressure, and body fat percentage will be measured. Blood (15.5 ml) and urine will be collected. Participants will wear a heart rate monitor and sit in a heat chamber at 62-63 degrees Celsius for 45 minutes. Heart rate will be measured continuously. Body temperature and a self-report of their comfort (1-4 scale) and thermosensation (1-7 scale) will be measured before the challenge, every 15 minutes during the challenge, and after the challenge. During the challenge, a sample of sweat will be collected to measure electrolyte loss. Participants will consume 16 ounces of water at their own pace during the 45 minutes. If they become too uncomfortable to continue or their body temperature rises above 39 degrees Celsius, the challenge will be stopped. All baseline measures except body fat percentage will be measured again.
223525106|NCT06494995|DRUG|Cadonilimab|a PD-1/CTLA-4 dual antibody
223525107|NCT06494995|RADIATION|Low-dose radiotherapy|Low-dose radiation
223525108|NCT06494995|RADIATION|SBRT|selected leisions to treat with stereotactic radiotherapy
223525109|NCT06494995|DRUG|Capecitabine|Capecitabine metronomic chemotherapy
223525110|NCT04511494|DIETARY_SUPPLEMENT|Peanut (bamba)|OIT peanut with slow-updosing for 40-60 weeks followed by maintenance. 3 years treatment.
223705613|NCT06404671|PROCEDURE|Early interval cytoreductive surgery (EICS)|"patients will receive three courses of intravenous carboplatin and paclitaxel every 3 weeks, followed by early interval cytoreductive surgery (EICS) within 6 weeks of the last cycle of chemotherapy. After EICS, patients will receive adjuvant three courses of intravenous carboplatin and paclitaxel every 3 weeks, then will be assessed for the need or not for further adjuvant chemotherapy.~chemotherapy regimen:~* Paclitaxel at 175 mg/m² + carboplatin area under the curve (AUC) 5-6 every 3 weeks.~* Paclitaxel at 60 mg/m² (days 1, 8, and 15), and carboplatin AUC 2 (days 1, 8, and 15) every 3 weeks.~* Paclitaxel at dense dose 80 mg/m² (days 1, 8, and 15) and carboplatin AUC 5-6 (day 1) every 3 weeks."
223705614|NCT04223973|DEVICE|Medtrum A7+ insulin Pump|Use of the Medtrum pump during 3 months in combination with a CGM (Continuous Glucose Measurement)
223705615|NCT04223973|BIOLOGICAL|Lab A1C|Measure of Lab A1C at baseline and end of study
223705616|NCT04665856|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
223705617|NCT04665856|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
223705618|NCT04665856|DRUG|Carboplatin|Carboplatin administered IV to achieve an initial target area under the concentration time curve (AUC) of 5 mg/mL/min, Q3W on Day 1 of each 21-day cycle for 4 cycles.
223705619|NCT04665856|DRUG|Etoposide|Etoposide 100 mg/m\^2, administered by IV infusion, Q3W on Day 1, 2 and 3 of each 21-day cycle for 4 cycles.
223705620|NCT04665856|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
223705621|NCT06966544|OTHER|Conventional Physiotherapy|"All subjects to be included in our study were evaluated before and after treatment by a physiotherapist acting as a blinded evaluator. In the treatment, conventional physiotherapy approaches are applied twice a week for 8 weeks by the physiotherapist conducting the thesis study. In parallel with the initial evaluation, an individualized conventional physiotherapy program is created according to the functional status of the children and the severity and type of the affected area.~The main topics of this program consist of the following: Normal range of motion exercises for shoulder, elbow, wrist and fingers, strengthening exercises for scapulothoracic, shoulder, elbow, hand-wrist joints in all directions, stretching exercises for shoulder, elbow, wrist, fingers (to be selected depending on the patient's involvement), scapulothoracic mobilization, glenohumeral mobilization and elbow according to possible limitations, hand-wrist joint mobilization techniques (myofascial release, gliding"
223705622|NCT06966544|OTHER|Graded Motor Imagery|"All approaches applied to the conventional physiotherapy group are applied to this group in the same manner and duration (8 weeks-twice a week). However, in addition to conventional physiotherapy, progressive motor imagery (AMI) training program is being applied twice a week for 8 weeks.~In the GMI program, in addition to this program, components of GMI training will be applied to sequentially activate cortical motor networks and improve cortical organization. These are;~* Laterality training with the help of visuals selected in the first stage (0-2 weeks)~* In the second stage, motor imagery activities designed in the form of scenarios to be developed specifically for motor activity deficiencies seen in OBPY (2-5 weeks)~* In the third stage, a mirror therapy program will be prepared (5-8 weeks)."
223705623|NCT05456009|OTHER|No intervention|No intervention
223705624|NCT04908709|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo sMRI
223705625|NCT04908709|DEVICE|Proton Therapy|Target volume treatment
223705626|NCT02573688|BEHAVIORAL|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
223705627|NCT05867303|DRUG|RC198 Injection|RC198 injection will be administered subcutaneously on Day 1 of Week 1 to Week 4 (inclusive) of each 6-week (42-day) cycle.
223705628|NCT06826924|BEHAVIORAL|Fasting|7 days of water-only fasting
223705629|NCT01757535|DRUG|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
223705630|NCT01757535|DRUG|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
223705631|NCT02027883|DEVICE|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
223705632|NCT02027883|DEVICE|Educated T shock setting|Experimental Parameter Set 2 Programming Values
224275900|NCT05475392|OTHER|Traditional Physical Therapy|A 2-week physical therapy program will be arranged. Each patient will be given 60 min session , 10 min for neck ROMS (10 reps for each ROM) , 10 min neck Isometrics (5 reps on each side) , 30 sec static gentle stretch of levator scapulae (3reps) , 30 sec static gentle stretch of trapezius (3reps), 5 min Soft tissue manipulation , 5 min Shoulder shrugging (10reps) , 10 min for PIR
223705633|NCT05575531|OTHER|MEWSS and Nursing Guide Application|MEWSS and Nursing Guide application will be used for the patients in the experimental group. According to the Nursing Guide application, patients with MEWS above 4 will be monitored every 5 minutes, while those with a score below 4 will be monitored for 10 minutes. will be followed intermittently. Nursing interventions will be made in accordance with the problems experienced by patients with a score above 4.
223705634|NCT00804674|DRUG|bupivacain|
223705635|NCT00804674|DRUG|placebo|
223705636|NCT00784498|DRUG|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
223705637|NCT00784498|DRUG|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
223705638|NCT00418015|PROCEDURE|Blood Draw|Blood for OPRM1 analysis
223705639|NCT00160485|DRUG|Glyburide|dosage required to obtain adequate glucose control
223705640|NCT00160485|DRUG|Insulin|variable dosage to obtain glucose control
223705641|NCT03948698|OTHER|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
223705642|NCT06007885|OTHER|Pathways and Resources to Engagement and Participation (PREP)|Participants engage in an 8-week community-based activity of their choice (Goal#1). To engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home/community and use the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward). The OT will work with the youth to search for the programs, identify and remove potential environmental barriers for participation (e.g., accessibility, equipment) and educate instructors regarding the youth's specific needs. This process, which includes up to 9 hours of OT support, will set the stage for enrolment of the youth in a community activity for a period of 8 weeks. The intervention will be repeated for a new goal (Goal#2). However, for Goal#2, youth will have the opportunity to select and pursue their new goal (#2) for 8 weeks without OT support first. Then, the OT will provide the PREP intervention for up to 6 weeks to achieve Goal #2.
223525111|NCT04547556|DIAGNOSTIC_TEST|BioFire|"A molecular rapid syndromic testing platform, using the following panels:~* BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus)~* BioFire FilmArray Pneumonia Panel plus (PP)"
223525112|NCT03528902|DRUG|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
223525113|NCT03528902|DRUG|Placebo Oral Tablet|Placebo
223525114|NCT06469021|OTHER|Conservative Approach|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the individuals. In a one session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises and 10 minutes of balance training will be applied. The exercises will start from an easy level and the level of difficulty will be gradually increased. The assessments will be evaluated in three stages: at the beginning of treatment, at the third month of treatment and at the end of treatment (sixth month).
223525115|NCT06469021|OTHER|Rehabilitative Game Therapy|Structured scoliosis exercises will be prescribed by the physiotherapist according to the severity of the curvature and cosmetics of the patients and will be applied to the patients with a conventional approach. In a one-session period, 5-minute warm-up and cool-down periods, 20 minutes of scoliosis exercises, 10 minutes of core stabilization exercises, and 10 minutes of balance training will be applied in the clinical setting. Home exercises will be performing with the SmartPose system differently from the control group. The SmartPose system is a special software system that enables the user to perform movements with a tablet or phone without the need for any sensors.
223525116|NCT06035562|BEHAVIORAL|PVSET|6, one-hour sessions of individual therapy, consisting of Positive Valence System Enhancement Treatment for Anxiety and Depression (PVSET), which will consist of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
223525117|NCT06367413|DIETARY_SUPPLEMENT|Placebo|Participants will receive three servings of carbohydrate per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of maltodextrin per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of maltodextrin per kg of body weight in the pre-sleep serving (1.1 gr maltodextrin/kg BW/day).
223525118|NCT06367413|DIETARY_SUPPLEMENT|NAC|Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).
223525119|NCT06367413|DIETARY_SUPPLEMENT|NAC + Whey Protein|Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
223525120|NCT05499702|BEHAVIORAL|Caloric Restriction|"Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake"
223525121|NCT05499702|DRUG|Hyperglycemic clamp|Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
223525122|NCT05030766|DRUG|Nicotine Replacement Therapy|6 weeks of Nicotine replacement patches
223525123|NCT05030766|BEHAVIORAL|Mindfulness Training Smoking Cessation Intervention|Mindfulness Training Smoking Cessation Intervention administered online via Zoom. Each session lasts 60-90 minutes, twice weekly for 4 weeks for a total of 8 sessions.
223525124|NCT05030766|BEHAVIORAL|Contingency Management Smoking Cessation Intervention|Contingency Management Smoking Cessation Intervention includes one orientation session lasting about 60-90 minutes administered via Zoom. Participants will then be required to contact the research associate about their quitting progress three times a week for 4 weeks also by zoom.
223525125|NCT05059327|DRUG|Basimglurant with crossover to Placebo|Basimglurant with crossover to Placebo
223525126|NCT05059327|DRUG|Placebo with crossover to Basimglurant|Placebo with crossover to Basimglurant
223525127|NCT01405664|OTHER|Weight-Bearing as Tolerated|WBAT immediately after surgery
223525128|NCT03008408|DRUG|Everolimus|Given PO
223525129|NCT03008408|DRUG|Letrozole|Given PO
223525130|NCT03008408|DRUG|Ribociclib|Given PO
223525131|NCT03044054|DEVICE|ECHOPULSE|HIFU Under ultrasound guidance
223525132|NCT05805800|DRUG|5HT3RA+Olanzapine|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner."
223705643|NCT05747820|OTHER|Observational study|This is an observational study designed to assess the evolution of multiple markers of congestion over 4 weeks after a WHF event treated in an outpatient unit
223705644|NCT03868020|PROCEDURE|Computed Tomography|Undergo PET/CT
223705645|NCT03868020|RADIATION|Fluciclovine F18|Given IV
223705646|NCT03868020|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223705647|NCT00825682|OTHER|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
223705648|NCT04961307|DRUG|Trastuzumab|30 female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase
223705649|NCT00079248|BIOLOGICAL|therapeutic progesterone|
223705650|NCT00079248|DRUG|conjugated estrogens|
223705651|NCT03680560|BIOLOGICAL|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
223705652|NCT03680560|DRUG|Trastuzumab|monoclonal antibody targeting HER2
223705653|NCT02557711|DEVICE|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
223705654|NCT05190588|OTHER|Mesotherapy|Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
223705655|NCT01509365|DRUG|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
223705656|NCT01509365|DRUG|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
223893726|NCT03428763|DEVICE|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~* Joint score by the patient~* Patient global disease activity measured on a 0-100 mm visual analogue scale.~* CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
223525133|NCT05805800|DRUG|5HT3RA+Olanzapine+Dexamethasone|"Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered."
223525134|NCT06138782|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Our protocol consists of five treatments of inhibitory continuous TBS (cTBS) to the R OFC lasting three minutes delivered every hour over the course of 10 days (2 weeks) for a total of 50 treatments.
223525135|NCT00023595|PROCEDURE|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
223525136|NCT00023595|DRUG|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
223525137|NCT00023595|PROCEDURE|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
223525138|NCT01277185|DIETARY_SUPPLEMENT|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
223525139|NCT01277185|DIETARY_SUPPLEMENT|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
223525140|NCT04817436|OTHER|physical activity program (APA)|adapted physical activity program (APA)
223525141|NCT00796263|DRUG|HAART|"1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily~plus~dolutegravir(DTG) 50 mg orally once daily"
223525142|NCT02565394|OTHER|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
223525143|NCT06006286|DRUG|Atezolizumab|Given by IV (vein)
223525144|NCT06006286|DRUG|Bevacizumab|Given by IV (vein)
223525145|NCT06006286|DRUG|ADI-PEG 20|Given by Injection (inj)
223525146|NCT06569459|DRUG|Trilaciclib Injection [Cosela]|Chemoradiotherapy and immunotherapy with Trilaciclib in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
223525147|NCT06569459|DRUG|Placebo|Chemoradiotherapy and immunotherapy in the treatment of patients with unresectable locally advanced esophageal squamous cell carcinoma
223525148|NCT05513365|DRUG|Goserelin 10.8 mg|Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
223525149|NCT05513365|DRUG|Bicalutamide 50 mg|Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
223525150|NCT05513365|DRUG|Dutasteride 0.5 mg|Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
223525151|NCT01074346|DRUG|Interferon-β-1a|Interferon-β-1a according to the standard practice
223525152|NCT04535297|OTHER|exposure|Exposure to social distancing due to COVID-19
223525153|NCT03900650|BEHAVIORAL|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
223525154|NCT03900650|BEHAVIORAL|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
223705657|NCT01952925|PROCEDURE|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
223705658|NCT05768217|BEHAVIORAL|Community Resiliency Collective Efficacy Intervention (CRCEI)|The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
223705659|NCT05768217|BEHAVIORAL|Health Education Sessions|Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
223705660|NCT05570292|DRUG|Domperidone|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of domperidone tablet
223705661|NCT05570292|DRUG|Folic acid|ultrasound guieded assesment of gastric residual volume will be done 2 h after oral injestion of folic acid tablet
223705662|NCT06349330|DEVICE|Test: 3D intra-oral scanner|"3D intra-oral scanner will be used to scan the subjects after plaque staining is performed. Subsequently, a 3D rendered image will be produced. Participants will be given oral hygiene education and instruction before being instructed to brush.~A cooling-off period of 30 minutes is given before participants are instructed to brush."
223705663|NCT06349330|OTHER|Control: Standard oral hygiene|Standard oral hygiene instructions will be delivered using a hand mirror. No 3D intraoral scanner will be used.
223705664|NCT02086292|PROCEDURE|2 ml 1% Lidocaine|
223705665|NCT02086292|PROCEDURE|1 ml 2% Lidocaine|
223705666|NCT02903355|DRUG|D-methionine|D-methionine, oral liquid suspension
223705667|NCT02903355|DRUG|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
223705668|NCT03712956|DRUG|Caelyx®|Caelyx® every two weeks for 8 courses
223705669|NCT05689476|DEVICE|NAVA GROUP|NAVA ventilation: Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
223705670|NCT02318147|PROCEDURE|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
223705671|NCT02318147|DRUG|The traditional treatment|the traditional treatments according to associated guidelines
223705672|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
223705673|NCT01644565|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|
223705674|NCT01644565|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|
223525155|NCT03900650|BEHAVIORAL|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
223525156|NCT03900650|BEHAVIORAL|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
223525157|NCT02835105|DRUG|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
223525158|NCT02835105|DRUG|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
223525159|NCT02577809|DRUG|Morphine100|100mcg added to the spinal anaesthetic
223525160|NCT02577809|DRUG|Morphine50|50mcg added to the spinal anaesthetic
223525161|NCT02577809|DRUG|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
223525162|NCT02577809|DRUG|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
223525163|NCT02577809|DRUG|Indomethacin|100mg Indomethacin suppository
223525164|NCT02507726|DEVICE|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
223525165|NCT03403179|OTHER|Functional Remediation|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
223525166|NCT05664529|DIAGNOSTIC_TEST|Chatoor Feeding Scale|Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
223705675|NCT03478332|DRUG|Yangxinshi pill|0.6g/tablet
223705676|NCT03478332|DRUG|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
223705677|NCT03478332|DRUG|Placebos|Yangxinshi simulant
223705678|NCT05984056|BEHAVIORAL|Multidisciplinary lifestyle interventions|Multidisciplinary lifestyle interventions (Brain health training, Yoga, Music therapy, and the MINDS diet education)
223705679|NCT02036697|DRUG|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
223705680|NCT02036697|DRUG|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
223705681|NCT02036697|DRUG|Morphine|morphine 150 mcg.
223705682|NCT02036697|DRUG|Fentanyl|15 mcg
223705683|NCT06467461|DIAGNOSTIC_TEST|Skin biopsy|Skin biopsy to detect systemic alpha-synuclein pathology in 5-HT RBD
223705684|NCT06467461|DIAGNOSTIC_TEST|Speech testing|Speech Testing to quantify evolving signs of 5-HT RBD
223705685|NCT06467461|DIAGNOSTIC_TEST|Ultra high field 7T MRI|7T MRI to examine 5-HT RBD for evidence of brainstem neurodegeneration
223705686|NCT02043171|DIETARY_SUPPLEMENT|Placebo|A Placebo comparator
223705687|NCT02043171|DRUG|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
223705688|NCT02043171|BEHAVIORAL|Non-Exercise|This group will not participate in 3 times per week strength training
223705689|NCT02043171|BEHAVIORAL|Exercise|This group will participate in a supervised 3 times per week strength training program
223705690|NCT01550289|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
223705691|NCT01550289|BIOLOGICAL|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
223525167|NCT03560388|OTHER|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
223525168|NCT05910424|OTHER|collection of saliva, gum fluid and/or dental plaque samples|Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs
223525169|NCT06268106|BEHAVIORAL|Graphic novel visualization|Patients in interventional group do receive and visualize graphic novel, which is more informative than standard informed consent.
223525170|NCT01516372|DRUG|GEn 1200mg|1200 mg of Gen administered as a single dose
223525171|NCT01516372|DRUG|Gen 6000 mg|6000 mg of Gen administered as a single dose
223525172|NCT01516372|DRUG|GEn Placebo|Placebo to match GEn Tablets
223525173|NCT01516372|DRUG|Moxifloxacin Placebo|Placebo to match Moxifloxacin
223525174|NCT01516372|DRUG|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
223525175|NCT01933763|DRUG|REGN1193|
223525176|NCT01933763|OTHER|Placebo|
223525177|NCT00086515|DRUG|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
223525178|NCT00086515|DRUG|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
223525179|NCT00086515|DRUG|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
223525180|NCT00086515|DRUG|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
223525181|NCT00506766|BEHAVIORAL|Bladder Health Class consisting of 6 weekly group sessions|1 time
223525182|NCT00506766|BEHAVIORAL|Practice PFMT and BT|As needed for 4 years
223525183|NCT00506766|BEHAVIORAL|Clinic examination for pelvic muscle function|1/year for 4 years
223525184|NCT00506766|BEHAVIORAL|Record keeping in 3-day voiding diary|Every 6 months for 4 years
223525185|NCT04986150|OTHER|Resistance exercise|Acute leg-based resistance exercise bout performed at 80% 1RM (4 sets to volitional failure on leg extension and leg curl machines)
223525186|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
223525187|NCT00498212|BIOLOGICAL|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
223525188|NCT00400140|DEVICE|Hyperopic lens|+3 D glasses
223525189|NCT01188187|DRUG|Custirsen|
223525190|NCT01188187|DRUG|Docetaxel|
223525191|NCT01188187|DRUG|Prednisone|
223525192|NCT01188187|DRUG|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
223525193|NCT00945087|OTHER|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
223525194|NCT00236041|DRUG|ACTIQ®|
223525195|NCT02714751|BEHAVIORAL|Daily asynchronies information|
223525196|NCT06565182|OTHER|Exercise|The intervention consists of two different types of moderate intensity exercise: Continuous aerobic and resistance exercise.
223525197|NCT04637061|COMBINATION_PRODUCT|intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis|Extra-luminal (serosa) and Endo-luminal (mucosal) evaluation of the proximal colon and distal rectal stump perfusion based on a semi-quantitative NIR-ICG-induced FA. This will be conducted administering IV a bolus of 3.75 to 7.5 mg of ICG and evaluated using a Fluorescence Imaging System; following after completion of the anastomosis a second bolos of 3.75 to 7.5 mg of ICG will be administered IV and the anastomosis will be visualized by insertion of the system trans-anally. Colon and rectal segments and quadrants will be scored for any defect of perfusion.
223525198|NCT04637061|DIAGNOSTIC_TEST|Air Leak test|This will be conducted insufflaying air in the anastomosis through a proctoscope, tube or a flexible endoscope, after filling of the pelvis with saline solution and luminal occlusion of the intestine proximal to the anastomosis. Also, the anastomosis will be checked transanally for the presence of air leak.
223525199|NCT04637061|DIAGNOSTIC_TEST|Evaluation of the anastomotic rings|The assessment of the anastomotic rings following mechanical anastomosis will be recorded as complete/incomplete
223525200|NCT04839640|OTHER|Bredent denture teeth|composite resin denture teeth
223525201|NCT03321942|DRUG|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
223525202|NCT03321942|DRUG|Control group|Conventional treatment were used to treat patients with chronic renal failure.
223525203|NCT00541424|PROCEDURE|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
223525204|NCT02480049|DRUG|Asmakast|1 tablet contains 10 mg of montelukast
223525205|NCT02480049|DRUG|Singulair|1 tablet contains 10 mg of montelukast
223525206|NCT01489137|DRUG|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
223525207|NCT00741377|DRUG|BHQ880|
223525208|NCT00741377|DRUG|Zoledronic acid|
223525209|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
223525210|NCT02106832|DRUG|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
223525211|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
223525212|NCT02106832|DRUG|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
223705692|NCT03959943|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
223705693|NCT04962178|PROCEDURE|Primary PCI|The patients assigned to early invasive strategy group will receive the primary PCI.
223705694|NCT04962178|OTHER|Optimal medical therapy with primary PCI not performed|The patients assigned to conservative strategy group will receive optimal medical therapy before primary endpoint accomplished.
223525213|NCT04192708|PROCEDURE|intercostal nerve block under direct vision|When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
223525214|NCT04192708|PROCEDURE|intercostal nerve block under ultrasound guidance|After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
223525215|NCT04192708|PROCEDURE|paravertebral block under ultrasound guidance|"Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist"
223525216|NCT00706173|DRUG|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
223525217|NCT00706173|DRUG|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
223525218|NCT04434183|DEVICE|Exercises of rehabilitation|Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
223525219|NCT00767780|DEVICE|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
223525220|NCT00219414|DEVICE|Adacolumn Apheresis System|
223525221|NCT05325684|DRUG|PD-L1 inhibitor|Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
223525222|NCT03088033|DEVICE|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
223525223|NCT03088033|OTHER|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
223525224|NCT06083454|DRUG|Durvalumab|Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
223525225|NCT06083454|DRUG|Pharmacological ascorbate|Given intravenously in combination with Durvalumab
223525226|NCT06083454|PROCEDURE|Surgery (SOC)|Surgery SOC
223525227|NCT00375258|DRUG|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
223525228|NCT00375258|DRUG|Sodium Chloride 0.9%|Visual matched placebo
223525229|NCT02692027|OTHER|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
223525230|NCT02692027|OTHER|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
223525231|NCT00319007|DRUG|Sulindac (drug)|
223525232|NCT00319007|DRUG|VSL#3 (probiotic)|
223525233|NCT00319007|DRUG|Inulin (probiotic)|
223525234|NCT05764928|DRUG|BLEX 404|BLEX 404 Oral Liquid, PO, BID
223525235|NCT05808712|OTHER|validation|Translation and validation design
223705695|NCT02418702|DRUG|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
223705696|NCT02418702|OTHER|placebo|20 patients will randomly be assigned a placebo
223705697|NCT01929096|DRUG|Compound Edaravone Injection|
223705698|NCT01929096|DRUG|Edaravone Injection|
223525236|NCT02394574|OTHER|Clean Cookstove|Ethanol
223525237|NCT02394574|OTHER|Traditional Cookstove|Firewood / Kerosene
223525238|NCT05871060|DIETARY_SUPPLEMENT|Whey Protein Concentrate|Whey protein concentrate consumed 30 minutes prior to breakfast and lunch meals
223525239|NCT05871060|DIETARY_SUPPLEMENT|Placebo|Flavoured water consumed 30 minutes prior to breakfast and lunch meals
223525240|NCT05871060|DIETARY_SUPPLEMENT|Whey hydrolysate|Whey hydrolysate consumed 30 minutes prior to breakfast and lunch meals
223525241|NCT02115529|DRUG|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
223525242|NCT02115529|DRUG|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
223525243|NCT04892589|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
223525244|NCT02710032|BEHAVIORAL|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
223525245|NCT02710032|BEHAVIORAL|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
223525246|NCT00265122|DRUG|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
223525247|NCT00265122|DRUG|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
223525248|NCT00265122|DRUG|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
223525249|NCT00265122|DRUG|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
223525250|NCT01429688|DRUG|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
223525251|NCT01146145|DRUG|Ketamine|intravenous morphine titration combined to ketamine
223525252|NCT04582591|DRUG|Cannabidiol 100 MG/ML|Patients receive cannabidiol before and after treatment with chemotherapy
223525253|NCT04744584|OTHER|Medication reconciliation|MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
223525254|NCT04744584|OTHER|Medication reconciliation|After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
223525255|NCT02873728|PROCEDURE|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
223525256|NCT02873728|OTHER|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
223525257|NCT05509660|BEHAVIORAL|PUMA+|Transdiagnostic CBT
223525258|NCT05509660|BEHAVIORAL|PUMA|Transdiagnostic CBT
223525259|NCT03198403|DRUG|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
223525260|NCT00608062|DRUG|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
223705699|NCT05477693|BIOLOGICAL|Experimental 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
223705700|NCT05477693|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Merck Sharp \& Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.
223705701|NCT02119481|BEHAVIORAL|Mindfulness-based stress reduction|
223525261|NCT00608062|DRUG|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
223525262|NCT00608062|DRUG|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
223525263|NCT04349683|DRUG|Jinshuibao|6 capsules at a time, 3 times a day (tid).
223525264|NCT04349683|DRUG|Placebo|6 capsules at a time, 3 times a day (tid).
223525265|NCT02695277|DEVICE|AtriCure Bipolar System|
223525266|NCT02695277|DEVICE|Standard Endocardial Ablation with Catheter|
223525267|NCT02695277|DEVICE|AtriClip® PRO LAA Exclusion System|
223525268|NCT02695277|DEVICE|Endocardial Ablation with Catheter|
223525269|NCT02695277|DEVICE|Repeated Endocardial ablation(s)|
223525270|NCT01728103|DEVICE|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
223525271|NCT05205616|DEVICE|Sonopet ultrasonic saw|Ultrasonic saw to be used on a randomized side of the mandible, reciprocating saw will be used on other side
223525272|NCT05205616|DEVICE|Reciprocating saw|See above description
223705702|NCT02119481|BEHAVIORAL|Expressive writing condition|
223705703|NCT06963463|BEHAVIORAL|TranS-C|This intervention includes participants attending 6-8 sessions with a Sleep Therapist.
223705704|NCT06963463|BEHAVIORAL|Sleep Feedback|Participants are provided with an actigraphy watch that is used to monitor their sleep and activity throughout the day and complete a sleep diary daily. Along with wearing the watch they also will be provided access to their actigraphy and sleep diary graphs that document their data.
223705705|NCT02092493|DEVICE|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
223705706|NCT06465290|DEVICE|Motor relearning training with wearable ankle robot|Ankle motor control relearning training under real-time feedback
223705707|NCT06465290|DEVICE|Passive stretching with wearable ankle robot|Passive stretching under intelligent robotic control
223705708|NCT06465290|DEVICE|Gamed-based active movement training with wearable ankle robot|Active movement training through movement games with robotic assistance
223705709|NCT06465290|DEVICE|Passive movement with limited wearable ankle robot|Passive movement in the joint middle range of motion
223705710|NCT06465290|DEVICE|Active movement training with limited wearable ankle robot|Active movement training without robotic assistance
223705711|NCT06465290|DEVICE|Ankle torque and motion measurement with limited wearable ankle robot|Ankle torque and motion measurement with no real-time feedback
223705712|NCT03152318|DRUG|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
223705713|NCT03152318|DRUG|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
223705714|NCT03152318|PROCEDURE|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
223705715|NCT05313555|DEVICE|Ultraviolet Light (UV-B)|This control group will receive a UV-B exposure as a positive control. Participants will have punch biopsies after exposure.
223705716|NCT05313555|DEVICE|Ultraviolet lights (UV-C)|Violet is tabletop device that emits filtered UV-C (200nm-230nm; peak at 222nm). Participants will choose, based on availability, to be in groups that deliver 1 cycle, 10 cycles, 15 cycles or 25 cycles of the Violet. The subject will be exposed for no more than 5 minutes and 20 seconds in total. Participants will have punch biopsies after exposure.
223705717|NCT03821155|OTHER|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
223705718|NCT03821155|DRUG|Corticosteroid|Prednisolone
223705719|NCT03274596|DRUG|Vitamin E|
223705720|NCT03274596|DRUG|Placebo|
223705721|NCT02173223|DRUG|Rho-Kinase Inhibitor|
223705722|NCT03663998|BIOLOGICAL|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
223705723|NCT03663998|BIOLOGICAL|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
223705724|NCT05084131|OTHER|Use of an online questionnaire as follow-up after abdominal colorectal surgery|Patients were asked to complete a questionnaire via the institutional patient portal. Participants were also asked to upload a photo of their respective incisions. Participants then had an in-person follow-up visit.
223705725|NCT03212924|BEHAVIORAL|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
223705726|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
223705727|NCT03212924|BEHAVIORAL|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
223705728|NCT03212924|BEHAVIORAL|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
223705729|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
223705730|NCT03212924|BEHAVIORAL|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
223705731|NCT01897454|DRUG|Fluorouracil|Given IV
223705732|NCT01897454|DRUG|Gemcitabine Hydrochloride|Given IV
223705733|NCT01897454|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223705734|NCT01897454|DRUG|Irinotecan Hydrochloride|Given IV
223705735|NCT01897454|DRUG|Leucovorin Calcium|Given IV
223705736|NCT01897454|DRUG|Oxaliplatin|Given IV
223705737|NCT01467726|DRUG|Velusetrag|Capsules
223705738|NCT01467726|DRUG|Velusetrag|Capsules
223705739|NCT01467726|DRUG|Placebo|Capsules
223893727|NCT03428763|OTHER|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
223525273|NCT03719859|OTHER|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
223525274|NCT03719859|OTHER|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
223525275|NCT03757494|DEVICE|Alpha Stim|Use of Alpha Stim Device
223525276|NCT04492384|OTHER|non-interventional|Interview on health conditions
223525277|NCT02033941|DRUG|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
223525278|NCT02033941|DRUG|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
223525279|NCT01324973|BEHAVIORAL|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
223525280|NCT05430438|OTHER|dialysis with low dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
223525281|NCT05430438|OTHER|dialysis with standard dialysate sodium concentration|Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
223525282|NCT04813120|BEHAVIORAL|Uni-MVF condition and unimanual training mode using the new MT system (UM-UT)|For the UM-UT group, the participants will be seated in front of the new MT system, and will be instructed to watch the real-time image reflection of movements of the non-affected arm and hand on the screen carefully. At the same time, the patients will need to imagine that the movements were performed by their affected arm and hand. In this group, only the non-affected arm and hand will need to perform the movements, but the affected one will not need to move.
223525283|NCT04813120|BEHAVIORAL|Uni-MVF condition and bimanual training mode using the new MT system (UM-BT)|During the UM-BT, as similar as the first group (UM-UT), the participants will be also seated in front of the new MT system, and be instructed to watch the real-time image reflection of the non-affected arm and hand's movements on the screen carefully and imagine that the movements were performed by the affected arm. However, in this UM-BT group, the bilateral training mode is emphasized, and thus both arms and hands will need to move. That is, during therapy, the patient's affected arm and hand will be required to move at his/her best motor ability with the non-affected arm and hand at the same time.
223525284|NCT04813120|BEHAVIORAL|Bi-MVF condition and bimanual training mode using the new MT system (BM-BT)|For the BM-BT group, the participants will be seated in front of this new MT system, and be instructed to observe the real-time image reflection of the non-affected arm and hand's movements transformed and superimposed on both arms and hands (i.e., bi-MVF), and to imagine that the movements were performed by both arms and hands. In this group, bi-MVF and bilateral training mode are emphasized, and thus both arms and hands will also need to move. The patient's affected arm and hand will be required to move as could as possible simultaneously.
223525285|NCT04813120|BEHAVIORAL|Traditional MT using a mirror box|During traditional MT, the participants will be seated in front of a mirror box placed at their mid-sagittal plane. The affected arm and hand of the participants will be placed inside the mirror box, and the non-affected arm and hand will be in front of the mirror. As similar to the UM-UT group, the participants will be instructed to watch the mirror reflection of the movements performed by the non-affected arm and hand carefully and to imagine that the movements were performed by the aﬀected arm and hand. In this group, the patient's affected arm and hand inside the mirror box will not need to move.
223525286|NCT04992065|DRUG|NNC0385-0434 A 15 mg|15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
223525287|NCT04992065|DRUG|NNC0385-0434 A 40 mg|40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
223525288|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 15 mg)|Placebo administered as 1 tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces). placebo tablets are sized match to the active arm within dose level
223525289|NCT04992065|DRUG|NNC0385-0434 A 100 mg|"100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces)."
223525290|NCT04992065|OTHER|Placebo I A (for NNC0385-0434 A 40 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
223705740|NCT05661799|BEHAVIORAL|Intervention Group|The programme is a PA programme consisting of one weekly session for 12 weeks. The one hour of PA is supplemented by two 15-minute periods. At the end of each session, a PA challenge and a positive reinforcement exercise are proposed for the coming week. At the beginning of the next session, the facilitator has a dedicated time to give feedback on these challenges (successes and difficulties encountered). At the end of each session, the facilitator explains the theme of the next challenge and exercise. For the challenge, three options are proposed. Each participant chooses the option he/she prefers. Positive reinforcement exercises are also offered in the same way. They aim to strengthen motivation, hope and the sense of self-efficacy (SEP). In addition to these two 15-minute sessions, participants are offered a one-and-a-half hour group session for information and experience sharing. The aim of this session is to discuss different themes.
223705741|NCT05661799|BEHAVIORAL|Control Group|The programme is a PA programme consisting of one weekly session for 12 weeks.
223705742|NCT06203860|OTHER|Cardio-Metabolic Clinic|"The Cardio-Metabolic Clinic will adhere to a standardized evaluation and treatment program based on the latest treatment guidelines from the European Cardiovascular Society. The assessment will include the following points:~* Lipid management~* Blood pressure management~* Antithrombotic therapy~* Glycemic targets~* Prevention of diabetes-related complications~* Treatment of vascular disease affecting the lower extremities~* Evaluation of cardioprotective drugs~* Counseling on lifestyle factors, including diet, smoking, alcohol, and exercise~* Guidance on vaccinations"
223705743|NCT06298409|DEVICE|CapScan collection capsule|The CapScan collection capsule is a single-use device that collects fluids from the gastrointestinal tract for analysis ex-vivo.
223705744|NCT00025272|DRUG|carboplatin|
223705745|NCT00025272|DRUG|etoposide|
223705746|NCT00025272|DRUG|topotecan hydrochloride|
223705747|NCT00025272|RADIATION|radiation therapy|
223705748|NCT03689114|DRUG|Low dose carbamazepine|Carbamazepine, 300 mg/die
223705749|NCT03689114|DRUG|Standard dose carbamazepine|Carbamazepine 600 mg/die
223705750|NCT03689114|DRUG|Low dose levetiracetam|Levetiracetam 500 mg/die
223705751|NCT03689114|DRUG|Standard dose levetiracetam|Levetiracetam 1000 mg/die
223705752|NCT03689114|DRUG|Low dose valproate|Valproate 300 mg/die
223705753|NCT03689114|DRUG|Standard dose valproate|Valproate 600 mg/die
223705754|NCT03689114|DRUG|Low dose zonisamide|Zonisamide 150 mg/die
223705755|NCT03689114|DRUG|Standard dose zonisamide|Zonisamide 300 mg/die
223705756|NCT03689114|DRUG|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
223705757|NCT03689114|DRUG|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
223705758|NCT03689114|DRUG|Low dose topiramate|Topiramate 100 mg/die
223705759|NCT03689114|DRUG|Standard dose topiramate|Topiramate 200 mg/die
223705760|NCT03689114|DRUG|Low dose lamotrigine|Lamotrigine 100 mg/die
223705761|NCT03689114|DRUG|Standard dose lamotrigine|Lamotrigine 200 mg/die
224275901|NCT05475392|OTHER|Post Isometric Relaxation|The exercise will be combined with the baseline treatment 3 sets PIR will be applied per session.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction, the patient is asked to relax and exhale while doing so. Following this, a gentle stretch is applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times.
223705762|NCT03689114|DRUG|Low dose gabapentin|Gabapentin 450 mg/die
223705763|NCT03689114|DRUG|Standard dose gabapentin|Gabapentin 900 mg/die
223705764|NCT00094172|DRUG|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
223705765|NCT00094172|DRUG|Placebo|tablet form
223705766|NCT02318875|DIETARY_SUPPLEMENT|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
223705767|NCT02318875|OTHER|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
224275902|NCT02571530|DRUG|Intra-arterial Cerebral Infusion of Trastuzumab|
223705768|NCT05231304|PROCEDURE|Total Talus Replacement (TTR)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.
223705769|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement (TATTR)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.
223705770|NCT05231304|PROCEDURE|Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.
223705771|NCT05231304|PROCEDURE|Total Talus Replacement + Subtalar Fusion (TTR + STJ)|Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
223705772|NCT04923061|OTHER|Acupressure|In the acupressure group, heart meridian 7th point (HT7), large intestine meridian 4th point, stomach meridian 36th point (ST36) and spleen meridian 6th point (SP6) will be applied. Tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Subsequently, consecutive (breathing rhythm) compressions will be applied to the acupressure points determined by the researcher, without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief Since the symmetry of the selected four different points will also be applied to the other extremity, a total of 16 minutes of compression will be applied to each point, provided that it is two minutes. Each nurse's session will be approximately 20 minutes, depending on the preparation and compression time on each point.
223705773|NCT04923061|OTHER|Sham acupressure group|In the sham group, acupressure will be applied on the bone region where the meridians do not pass, approximately 1-1.5 cm away from the HT7, LI4, ST36, SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
224275903|NCT06024148|OTHER|phone survey|patients complete a 10-minute telephone questionnaire on their osteoporosis management
224275904|NCT02992548|DRUG|Pravastatin|
223705774|NCT03076320|COMBINATION_PRODUCT|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
223705775|NCT03076320|COMBINATION_PRODUCT|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
223705776|NCT06061536|DRUG|Lipovirtide 10mg|Lipovirtide 10mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
223705777|NCT06061536|DRUG|Lipovirtide 40mg|Lipovirtide 40mg+3TC+TDF（LP-80：once a week；3TC+TDF：once daily）；
223705778|NCT06061536|DRUG|Lipovirtide 60mg|Lipovirtide 60mg+3TC+TDF（LP-80：once every 2 weeks；3TC+TDF：once daily）；
223705779|NCT06061536|DRUG|DTG|DTG +3TC + TDF（once daily）.
223705780|NCT02057731|GENETIC|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
223705781|NCT05236400|DEVICE|unmanned electric phlegm suction system procedure using an investigational device (LMECA.A1000)|Subjects who have passed the screening test will receive the test device (LMECA.A1000) within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through bronchoscopy before application for clinical trials and 72 hours after application.
223705782|NCT05236400|PROCEDURE|Manual phlegm suction system|Subjects who have passed the screening test will receive a manual phlegm suction system procedure using a catheter by professional medical staff within a minimum of 3 days and a maximum of 14 days. Efficacy and safety are checked through a bronchoscopy before application to clinical trials and 72 hours after application.
223705783|NCT00462566|DEVICE|motor cortex stimulation|
223705784|NCT02981017|DEVICE|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
223705785|NCT01839123|DEVICE|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
223705786|NCT01839123|DEVICE|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
223705787|NCT02609204|DIAGNOSTIC_TEST|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
223705788|NCT04862819|DRUG|new local drug delivery|In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp
223705789|NCT04862819|PROCEDURE|scaling root planing|In the second group, on one side of the dental arch srp will be performed
223705790|NCT03642457|DRUG|Bupivacaine|20 cc 0.5%
223705791|NCT03642457|DRUG|Bupivacaine liposome|133mg liposomal bupivacaine
223705792|NCT03095885|OTHER|Test Meal|
223705793|NCT06377475|PROCEDURE|Jaw relation|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
223705794|NCT06377475|PROCEDURE|Questionnaire|The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
223705795|NCT01392443|DRUG|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
223705796|NCT05543967|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
223705797|NCT05543967|OTHER|Olfactory function measurements|Olfactory Threshold, Odor Identification Score, Odor Memory Score.
223705798|NCT05543967|OTHER|Functional magnetic resonance imaging|resting-state fMRI, odor-induced fMRI.
223705799|NCT03307681|OTHER|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
223705800|NCT03307681|OTHER|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
223705801|NCT03307681|OTHER|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
223705802|NCT03307681|OTHER|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
223705803|NCT03307681|OTHER|Meal skipping|No food given
223705804|NCT00917995|DEVICE|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
223705805|NCT01296217|PROCEDURE|lymph nod detection|
223705806|NCT03041883|PROCEDURE|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
223705807|NCT03041883|PROCEDURE|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
223705808|NCT01977794|DRUG|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
223705809|NCT01977794|DRUG|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
223705810|NCT05817643|DRUG|BMS-984923|Oral capsule
223705811|NCT01895062|DEVICE|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
223705812|NCT02649465|DRUG|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
223705813|NCT02649465|DRUG|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
223705814|NCT01100541|DEVICE|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
223705815|NCT00622817|DRUG|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
223705816|NCT00622817|DRUG|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
223705817|NCT06060743|OTHER|INS-MOBILE: Mobile Application Developed for Insulin Use|After determining the application and control groups in the research, the purpose of the research was explained to both groups. Participants were informed that the application would last 1 month. It was explained that data collection forms would be filled out before the application (Z0), on the 14th day of the application (Z1), and on the 28th day of the application (Z2). On the 0th and 28th days of the follow-up, the participants' insulin administration skills were evaluated face-to-face by the researcher using the Insulin Therapy Skill Observation Form. In addition to the standard training given by diabetes training nurses, a mobile application on insulin use was sent to the application group, while the control group was given standard training only by diabetes training nurses.
223705818|NCT03240965|DIAGNOSTIC_TEST|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
223705819|NCT03240965|OTHER|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
223705820|NCT03240965|DIAGNOSTIC_TEST|Taste-/smell-test|Taste-/smell-test
223705821|NCT03240965|DIAGNOSTIC_TEST|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
223705822|NCT05487144|BEHAVIORAL|Learning in a Virtual Environment (LIVE)|Phase 1 of the study will be a one-time meeting, either remote or in-person to complete V.E. training and fill out questionnaires. Phase 2 of the study is the 8 week intervention implementation.Participants will access the V.E. community from their homes on a computer with broadband internet. During the first four weeks of the intervention, participants will be required to come into the V.E. at least once per week for at least one hour. For the last four weeks, V.E. participation is strongly encouraged, but not required. The content in the V.E. will focus on psychosocial health and stroke recovery, and the messaging in the VE will be updated bi-weekly to encourage retention and engagement. Group meetings led by the study PI, a psychologist, or another trained member of the research team at least once a week will be offered. During the intervention period, VE-specific data will be collected continuously. Phase 3, will include a survey and a focus group interview via online platform.
223705823|NCT00187577|DRUG|Latanoprost (Xalatan)|
223705824|NCT00187577|DRUG|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
223705825|NCT00187577|DRUG|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
223705826|NCT04264091|OTHER|Observational|Observational
223705827|NCT03853408|PROCEDURE|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
223705828|NCT06498154|RADIATION|Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy|Neoadjuvant radiotherapy: whole-breast irradiation ( 50 Gy in 25 fractions) plus a mandatory boost (14 Gy in seven fractions, which began on the day following completion of whole-breast irradiation) TCb (HP) \* : Triple negative patients will receive TCb regimens with or without immunotherapy and HER2 positive patients will receive TCb(HP) regimens.
223705829|NCT00281307|DRUG|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
223705830|NCT03591185|OTHER|FallSensing Clinical Tool|"FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise."
223705831|NCT03869983|OTHER|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
223705832|NCT03869983|OTHER|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
223705833|NCT00437177|DRUG|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
223705834|NCT00437177|DRUG|[(123)I] iodobenzamide|\[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
223705835|NCT02398578|DEVICE|Amphora OAB Device|Cystoscopic procedure to treat OAB
223705836|NCT02478632|DRUG|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
224275905|NCT02441322|DEVICE|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
224275906|NCT04994431|DRUG|Tamsulosin Hydrochloride|0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
224275907|NCT00356096|DRUG|pramipexole|
224275908|NCT03672240|DRUG|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
224275909|NCT04654039|OTHER|Other: Non intervention|Non intervention
223525291|NCT04992065|OTHER|Placebo II A (for NNC0385-0434 A 100 mg)|"Placebo administered as one tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).~placebo tablets are sized match to the active arm within dose level"
223525292|NCT04992065|DRUG|Evolocumab 140 mg/mL, Repatha®|"Every 2 weeks subcutaneous (s.c.) injection of 140 mg into areas of the abdomen, thigh, or upper arm that are not tender, bruised, red, or indurated. Administered using a pre-filled SureClick® autoinjector (single-use).~Dose volume: 1 mL"
223525293|NCT04720001|DRUG|Florbetaben F18|A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
223525294|NCT04720001|DEVICE|PET|PET Scan for brain imaging
223525295|NCT02215473|DRUG|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
223525296|NCT02215473|PROCEDURE|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
223525297|NCT02040909|DRUG|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
223525298|NCT02333474|BIOLOGICAL|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
223525299|NCT02333474|OTHER|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
223525300|NCT01003327|DEVICE|I-gel|intubation with I-gel airway
223525301|NCT01003327|DEVICE|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
223525302|NCT04014192|DRUG|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
223525303|NCT04014192|DRUG|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
223525304|NCT04014192|DRUG|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
223525305|NCT04855890|PROCEDURE|Ablation|The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
223525306|NCT01889446|DIETARY_SUPPLEMENT|Calcium propionate|
223525307|NCT03648892|DRUG|[c11] raclopride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
223525308|NCT03648892|DRUG|[18F]fallypride|The present study will attempt to resolve the controversy by measuring D2BP using both \[18F\]fallypride and \[11C\]raclopride in 39 adults, 13 within each of three BMI strata to represent a large BMI range, under controlled overnight fasting conditions following a period of dietary stabilization. The primary aims are to estimate the mathematical relationship between striatal D2BP and BMI and determine the within-subject correlations of D2BP derived from \[18F\]fallypride and \[11C\]raclopride.
223525309|NCT03391791|GENETIC|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
223525310|NCT01955863|PROCEDURE|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
223525311|NCT01955863|PROCEDURE|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
223525312|NCT01955863|PROCEDURE|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
223525313|NCT03338920|DRUG|sumatriptan nasal powder|nasal powder administered via nosepiece
223525314|NCT03338920|DRUG|Placebo|lactose monohydrate powder administered via nosepiece
223525315|NCT04573738|PROCEDURE|Robotic assisted transanal total mesorectal excision|Robotic assisted transanal total mesorectal excision for rectal cancer patients
223525316|NCT04573738|PROCEDURE|Laparoscopic assisted transanal total mesorectal excision|Laparoscopic assisted transanal total mesorectal excision for rectal cancer patients
223525317|NCT05368935|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
223525318|NCT00802906|DEVICE|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
223525319|NCT00802906|DRUG|bevacizumab|1.5 mg initial intravitreal injection
223705837|NCT02958514|DEVICE|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of \*500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
223705838|NCT02958514|DRUG|Tobramycin and Dexamethasone Ophthalmic Ointment|
223705839|NCT06446011|PROCEDURE|root canal treatment in Ckd patients|root canal treatment in teeth with apical periodontitis to observe periapical healing , and change in eGFR ,blood urea and creatinine and HSCRP
223705840|NCT06446011|PROCEDURE|root canal treatment in healthy patients|root canal treatment in teeth with apical periodontitis to observe periapical healing and change in HSCRP
223705841|NCT03019185|DRUG|Placebo Oral Capsule|Capsule containing an inert placebo
223705842|NCT03019185|DRUG|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
223705843|NCT05196646|DEVICE|Respiratory Acoustic Sensors|Wireless sensor that contains a dual microphone and an inertial measurement unit (IMU) will capture the breathing sound and respiratory effect. Two wireless sensors will be used, with one placed on the suprasternal notch and the other placed on the right upper chest of the infant, in order to determine the sensor placement yielding the best respiratory signal. Data will be transmitted in real-time to a research-dedicated tablet using the Bluetooth Communication Controller (ISP1807, Insight SIP) and stored on the same device for future analysis.
223705844|NCT05196646|DEVICE|Nasal thermistor|The nasal temperature probe that detects changes in temperature between inhaled and exhaled gases allows for the surrogate measure of airflow. It will be placed in one naris and secured with tape at the upper lip or cheek. The nasal temperature signal will be acquired using the Power Lab analog-digital acquisition system and stored for later analysis.
223705845|NCT05196646|DEVICE|Respiratory Inductive Plethysmography|Two respiratory bands will be placed circumferentially around the infant's chest (at the level of nipple line) and around the abdomen (just above the level of the umbilicus) in order to measure chest and abdominal wall movements, respectively. These movements will be recorded using Respiratory Inductive Plethysmography (Respitrace QDC®, Viasys® Healthcare, USA). The Respitrace® signals will be acquired using the Power Lab data acquisition system and stored for later analysis.
223705846|NCT05196646|DEVICE|Pneumotachometer|The pneumotachometer is a pressure-differential based flow sensor that is used to measure respiratory flow. It will be connected to a standard face mask that is gently applied to cover the infant's mouth and nose. The face mask will be similar to the masks used as part of standard of care in the NICU for infants who require continuous positive pressure, with or without ventilation. The flow measurements will be recorded using the Power Lab data acquisition system and stored for later analysis.
223705847|NCT05287126|DRUG|Etrasimod|Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
223705848|NCT04949464|PROCEDURE|Computed Tomography|Undergo LDCT
223705849|NCT04949464|BEHAVIORAL|Smoking Cessation Intervention|Use Positively Smoke Free - Mobile
223705850|NCT05408117|DEVICE|5-0 Polypropylene epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
223705851|NCT05408117|DEVICE|5-0 Fast gut epidermal suture|Split-wound, intra-individual comparison - half of wound will receive 5-0 polypropylene epidermal suture and half of wound will receive 5-0 fast gut epidermal suture
223705852|NCT06582225|BEHAVIORAL|Internet-delivered exposure and response prevention (I-ERP)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks."
223705853|NCT06582225|BEHAVIORAL|Internet-delivered stress management (I-SM)|"The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks."
223705854|NCT04062708|DRUG|Durvalumab|"Preoperative Treatment:~* Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~* Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
224275910|NCT00372996|DRUG|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
224275911|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day.
224275912|NCT00372996|DRUG|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
224275913|NCT00372996|DRUG|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
224275914|NCT02818296|BEHAVIORAL|Active IU CBM-I|
224275915|NCT02818296|BEHAVIORAL|Control CBM-I|
223705855|NCT04062708|PROCEDURE|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
223525320|NCT02011529|OTHER|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
223525321|NCT04798820|OTHER|Dietary education(nutritional counselling)|Dietary education provided to gastrectomy patients by dietitian.
223525322|NCT02816112|DRUG|Ciprofloxacin|Antibiotic
223525323|NCT02816112|DRUG|Neupogen|Granulocyte-colony stimulating factor
223525324|NCT06551727|OTHER|Intervention group|"After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database."
223525325|NCT06551727|OTHER|Control group|After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
223525326|NCT03843073|DEVICE|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
223525327|NCT03889535|DEVICE|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
223525328|NCT03889535|DEVICE|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
223525329|NCT00087035|DRUG|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
223525330|NCT00087035|DRUG|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
223525331|NCT04708847|DRUG|GYM329|GYM329 subcutaneous injection
223525332|NCT04708847|DRUG|Placebo|Placebo subcutaneous injection
223525333|NCT05823441|DRUG|Oxytocin nasal spray|Volunteers inhale 24 units of oxytocin spray
223525334|NCT05823441|DRUG|Placebo|Volunteers inhale 24 units of placebo spray
223525335|NCT05823441|BEHAVIORAL|Stranger|Volunteers watch a video of a pain test and attach a photo of a stranger
223525336|NCT05823441|BEHAVIORAL|Acquaintance|Volunteers watch a video of a pain test and attach a photo of an acquaintance
223525337|NCT03085953|BEHAVIORAL|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
223525338|NCT03085953|OTHER|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
223525339|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
223525340|NCT00663260|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
223525341|NCT00663260|DRUG|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
223705856|NCT04062708|RADIATION|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
224275916|NCT04440358|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
224275917|NCT04440358|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
223705857|NCT03355365|BIOLOGICAL|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
223705858|NCT03355365|OTHER|Intrathecal saline injection|Placebo
223705859|NCT05594290|DRUG|Retifanlimab|Retifanlimab i.v. 500 mg day 1
223705860|NCT05594290|DRUG|Cisplatin|Cisplatin 25 mg/sqm i.v. day 1, 2 (recommended platinum agent) or carboplatin AUC 4 i.v., day 1 (in patients unsuited or unfit for cisplatin)
223705861|NCT05594290|DRUG|Etoposide|Etoposide 100 mg/sqm iv. day 1, 2, 3
223705862|NCT03698201|OTHER|Non-interventional|Translational, observational study
223705863|NCT05768074|OTHER|Qualitative Interview|Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
223705864|NCT00002854|BIOLOGICAL|filgrastim|
223705865|NCT00002854|DRUG|carboplatin|
223705866|NCT00002854|DRUG|cisplatin|
223705867|NCT00002854|DRUG|cyclophosphamide|
223705868|NCT00002854|DRUG|etoposide|
223705869|NCT00002854|DRUG|ifosfamide|
223705870|NCT00002854|DRUG|mesna|
223705871|NCT00002854|DRUG|paclitaxel|
223705872|NCT00002854|PROCEDURE|peripheral blood stem cell transplantation|
223705873|NCT06303908|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
223705874|NCT00446862|DRUG|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
223705875|NCT05274061|BEHAVIORAL|Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy|AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
223705876|NCT02110238|DEVICE|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
223705877|NCT02110238|DEVICE|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
223705878|NCT01139983|GENETIC|DNA analysis|
223705879|NCT01139983|GENETIC|RNA analysis|
223705880|NCT01139983|GENETIC|fluorescence in situ hybridization|
223705881|NCT01139983|GENETIC|microarray analysis|
223705882|NCT01139983|GENETIC|polymerase chain reaction|
223705883|NCT01139983|GENETIC|reverse transcriptase-polymerase chain reaction|
223705884|NCT01139983|OTHER|laboratory biomarker analysis|
223705885|NCT00002561|BIOLOGICAL|bleomycin sulfate|10 units/m2
223705886|NCT00002561|DRUG|dacarbazine|375mg/m2
223705887|NCT00002561|DRUG|doxorubicin hydrochloride|25mg/m2
223705888|NCT00002561|DRUG|vinblastine|6mg/m2
223705889|NCT00002561|RADIATION|radiation therapy|35Gy in 20 fractions (daily)
223705890|NCT03273543|DEVICE|Restylane® Defyne|hyaluronic acid filler injection
223705891|NCT02678975|DRUG|Disulfiram|Disulfiram 400 mg daily
223705892|NCT02678975|DIETARY_SUPPLEMENT|Copper|nutritional supplement with copper, 2 mg daily
223705893|NCT02678975|DRUG|Alkylating Agents|Alkylating antineoplastic agent
223705894|NCT04996043|DIETARY_SUPPLEMENT|Collagen Peptide Drink|Testing product
223705895|NCT04996043|DIETARY_SUPPLEMENT|Placebo drink|Blank
223705896|NCT06088108|DEVICE|Cornell treadmill exercise protocol|Study participants are asked to undertake the Cornell treadmill exercise protocol which they complete to voluntary exhaustion.
224275918|NCT04554186|PROCEDURE|Serratus anterior plane block|Injection of bupivacaine between serratus anterior plane and latissimus dorsi muscle using ultrasound
223705897|NCT00673504|DRUG|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
223705898|NCT00673504|DRUG|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
223705899|NCT00115635|DRUG|docetaxel|
223705900|NCT00115635|DRUG|gemcitabine|
223705901|NCT04185311|BIOLOGICAL|Ipilimumab|Given IV
223705902|NCT04185311|BIOLOGICAL|Nivolumab|Given IV
223705903|NCT04185311|BIOLOGICAL|Talimogene Laherparepvec|Given intratumorally
223705904|NCT02170194|BEHAVIORAL|Resilience Enhancement Training via Smart Phone|
223705905|NCT02170194|BEHAVIORAL|Daily Text Messages|
223705906|NCT03949309|OTHER|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
223705907|NCT03421535|PROCEDURE|Sleeper Stretch|Internal Range of motion of dominant shoulder
223705908|NCT03421535|PROCEDURE|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
223705909|NCT01699490|DRUG|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
223705910|NCT01699490|DRUG|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
223705911|NCT05429060|PROCEDURE|Hemorrhoidal surgery|All surgical interventions under general or local anesthesia, either in the office or operation room, including any type of injection, excision, ligation, ablation, mucopexy and suturation.
223705912|NCT00543010|DRUG|MK0767|
223705913|NCT00142935|BEHAVIORAL|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
223705914|NCT00142935|BEHAVIORAL|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
223705915|NCT00142935|BEHAVIORAL|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
223705916|NCT05049616|DRUG|ACE Inhibitors and Diuretics|Hctz/Lisinopril (brand name: Zestoretic)
223705917|NCT05049616|DRUG|NIFEdipine ER|Extended release nifedipine
223705918|NCT03095339|OTHER|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
223705919|NCT01737320|DRUG|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~1. Intervention group - antibiotic treatment stopped on day 7~2. Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
223705920|NCT01737320|DRUG|accepted prolonged antibiotic treatment|
223705921|NCT00003805|DRUG|piperacillin sodium|
223705922|NCT00003805|DRUG|piperacillin-tazobactam|
223705923|NCT00003805|DRUG|tazobactam sodium|
223705924|NCT00003805|DRUG|vancomycin|
223705925|NCT04567498|OTHER|exhaled breath sampling|The participants are requested to quietly sit and breathe to the air collecting bag until the collecting bag is full. The collecting bag is sealed and connected to the e-nose machine via a collecting hose and HEPA-filter. The data are read and stored in the e-nose machine.
223705926|NCT02489162|DEVICE|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
223705927|NCT02489162|DEVICE|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
223705928|NCT03144947|BIOLOGICAL|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
223705929|NCT03144947|BIOLOGICAL|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)\*, every 3 weeks for 4 cycles.~\*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
223705930|NCT03144947|BIOLOGICAL|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
224275919|NCT04554186|PROCEDURE|Thoracic Paravertebral block|Injection of bupivacaine in the thoracic Paravertebral space using ultrasound
223705931|NCT03144947|DRUG|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
223705932|NCT03055156|DEVICE|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
223705933|NCT03055156|DEVICE|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
223705934|NCT06273462|DRUG|Palmitoylethanolamide 600mg twice a day|600mg palmitoylethanolamide twice a day
223705935|NCT06273462|OTHER|placebo|visually identical placebo capsule
223705936|NCT00528177|DRUG|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
223705937|NCT05898360|COMBINATION_PRODUCT|Time Restricted Eating|time restricted eating
223705938|NCT05898360|OTHER|normal diet|normal diet
224275920|NCT04554186|PROCEDURE|Control|Place a fentanyl patch 50 microgram
224275921|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Probiotic|"Oligomeric oral nutritional supplement (Bi1 peptidic) and a mix of probiotics~* Bifidobacterium animalis subsp. lactis BPL1,~* Lactobacillus rhamnosus BPL15,~* Lactobacillus rhamnosus CNCM i-4036~* Bifidobacterium longum ES1"
224275922|NCT04305535|DIETARY_SUPPLEMENT|Peptidic+Placebo|Oligomeric oral nutritional supplement (Bi1 peptidic) and a placebo
224275923|NCT04305535|DIETARY_SUPPLEMENT|Polymeric+Placebo|Polymeric oral nutritional supplement and a placebo
223705939|NCT02234232|BEHAVIORAL|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
223705940|NCT01330030|DRUG|Selegiline|6mg/24 hrs for 8 weeks
223705941|NCT01330030|OTHER|matching placebo|placebo/24hrs for 8 weeks
223705942|NCT06294782|RADIATION|STereotactic Arhythmia Radioablation (STAR)|STereotactic Arhythmia Radioablation (STAR)
223705943|NCT04820166|OTHER|monitoring portal pressure gradient or hepatic venous pressure gradient|measuring portal pressure gradient or hepatic venous pressure gradient regularly
223705944|NCT00132652|DRUG|Lamivudine|
223705945|NCT00132652|DRUG|Telbivudine|
223705946|NCT04579575|DEVICE|Trans-abdominal Ultrasound|"All patients will undergo trans- abdominal and trans-vaginal examination (The trans-abdominal US was performed for virgin patients or patients with large tumors that cannot be completely seen by the TV route) performed on the devices available in South Egypt Cancer Institute in supine position.~The most important b-mode parameters (such as gain, frequency, number of foci and their depth, etc.) of the US machines were manually adjusted to obtain similar image impressions.~* The morphological features of each AM, and independently categorized the US images of each AM according to the O-RADS published by ACR and GI-RADS simple rules . The results of consensus reviewing were used to calculate the validity of each US classification system.~* The definite diagnoses of AM were preferentially established based on~Histo-pathological findings and other modalities."
223705947|NCT04650490|RADIATION|Stereotactic Radiosurgery|Timing of stereotactic radiosurgery relative to immunotherapy
223705948|NCT04650490|DRUG|Immunotherapy|Physician's choice of immunotherapy per standard of care
223705949|NCT05205525|OTHER|Restrictive antibiotic strategy|Implementation of a restrictive (delayed) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
223705950|NCT05205525|OTHER|Aggressive antibiotic strategy|Implementation of an aggressive (immediate) antibiotic strategy in Ventilator Acquired Pneumonia suspicion without severity symptoms.
223705951|NCT05933616|DEVICE|Device: Sokru device|Different induced glycaemic states in people living with diabetes (PwD).
223705952|NCT02980783|DEVICE|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
223705953|NCT00202800|DRUG|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
223705954|NCT04400994|DRUG|Rituximab|"Rituximab would be given intravenously.~* IV Rituximab is prediluted at a dose of 500mg in 500ml of 0.9% normal saline (i.e. 1:1 dilution, 1 mg/ml)~* Initial infusion rate starts at a rate of 50mg/hr (50ml/hr)~* If no hypersensitivity/anaphylaxis reaction occurs, increase infusion rate in 50mg/hr (50 ml/hr) increments every 30 minutes~* Maximum infusion rate is 400 mg/hr (400 ml/hr)~* Subsequent infusion: start at rate of 100mg/hr (100 ml/hr), increase 100mg/hr (100 ml/hr) increments every 30 minutes~* Monitor temperature, BP HR, respiratory rate and SpO2 every 30 minutes"
223705955|NCT04400994|OTHER|IVIg|"IVIg would be given in combination with Rituximab intravenously. Infusion plan of IVIg:~0 min: 50ml/hour 15 min: 75ml/hour 30 min: 100ml/hour 45 min: 125ml/hour 60 min: 150ml/hour 75 min \& beyond: 180ml/hour"
223705956|NCT00562471|OTHER|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
223705957|NCT00562471|OTHER|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
223705958|NCT00822042|OTHER|Samples and procedures|"* Scanner, histomorphometry : at the inclusion and M3 visits~* whole blood samples, cytoponction : at the inclusion and M3 visits"
223705959|NCT03447704|DRUG|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
223705960|NCT03447704|OTHER|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
223705961|NCT05233878|OTHER|Characterization of a population with cervical paragangliomas|Characterization of a population with sporadic or genetically predisposed cervical paragangliomas in order to evaluate : the initial presentation of the PGL, patients management and patients outcome
223705962|NCT05294640|DRUG|0.9% Bacteriostatic Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic corresponding to the study arm (0.9% bacteriostatic saline or 1% lidocaine with 1:100,000 epinephrine). Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
223705963|NCT05294640|DRUG|1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection|Following research and procedural consent, local anesthetic injection will be carried out using a standard 1 cc of local anesthetic consisting of a commercially available mixture of 1% lidocaine with 1:100,000 epinephrine. Prior to anesthetic administration, the procedure site will be cleaned using standard measures. A 30 gauge needle on a 3 centimeter cubed volume syringe will be utilized. Five minutes will be given for local anesthetic to take effect.
223705964|NCT05294640|PROCEDURE|Eyelid Lesion Removal|Following anesthesia administration, patient will proceed with recommended eyelid lesion removal. The procedure site will be cleaned according to standard protocol, and standard technique for lesion removal will be performed, which will vary according to type of lesion but may involve use of Westcott scissors, forceps, #15 or #11 blades or other oculoplastics administration. The exact procedural details will be at the discretion of the surgeon.
223705965|NCT03779711|BIOLOGICAL|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
223705966|NCT03779711|PROCEDURE|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
223705967|NCT03153280|DRUG|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
223705968|NCT03153280|DRUG|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
223705969|NCT03153280|DRUG|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
223705970|NCT05625594|PROCEDURE|Aspiration|Undergo CSF aspiration
223705971|NCT05625594|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223705972|NCT05625594|PROCEDURE|Catheterization|Undergo catheterization
223705973|NCT05625594|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes|Given ICV
223705974|NCT05625594|PROCEDURE|Computed Tomography|Undergo CT
223705975|NCT05625594|DRUG|Cyclophosphamide|Given IV
223705976|NCT05625594|DRUG|Fludarabine|Given IV
223705977|NCT05625594|PROCEDURE|Leukapheresis|Undergo leukapheresis
223705978|NCT05625594|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223705979|NCT05625594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223705980|NCT05625594|PROCEDURE|Positron Emission Tomography|Undergo PET
223705981|NCT05981391|DIAGNOSTIC_TEST|resting-state functional MRI|We will acquire BOLD fMRI images in an unstimulated state using an extended time-series (300 whole-brain volumes over \~ 60-75 min). These data are a main outcome. Data will be processed on an ongoing basis to ensure integrity, and includes controlling for white matter, cerebral spinal fluid, and movement.
224275924|NCT03485716|OTHER|running on a treadmill under normoxia or hypoxia|"* 30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~* 30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
223705982|NCT05981391|DIAGNOSTIC_TEST|Clinician Administered PTSD Scale for the DSM-5 (CAPS-5)|The CAPS-5 is a semi-structured interview, conducted by an independent evaluator, that measures DSM-5 symptoms of PTSD. Presence of at least one intrusion symptom, one avoidance symptom, two cognition and mood symptoms, and two arousal symptoms for 1 month or more are required to reach the diagnostic threshold.
223705983|NCT05981391|DIAGNOSTIC_TEST|Tympanometry|Tympanometry will be conducted to assess ear canal volume (cm cubed), maximum pressure (daPa) peak compliance (ml), and type (A, AD, AS, B, B-High, C) for each ear) at 226-Hz admittance.
223705984|NCT05981391|DIAGNOSTIC_TEST|Tinnitus Assessment|Tinnitus acoustic assessment (for tinnitus participants only): Tinnitus ear (left, right, bilateral), pitch matched frequency (Hz) and loudness matched intensity (dB) will be conducted. When available, the tinnitus acoustic assessment only will be repeated at the RII, on the same day and prior to the fMRI scan, to demonstrate reproducibility of results.
224275925|NCT06678763|PROCEDURE|CRS-HIPEC|Patients with uterine leiomyosarcoma who received unprotected morcellation were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with docetaxel and gemcitabine.
224275926|NCT00890916|DEVICE|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
224275927|NCT02463019|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
224275928|NCT05421195|DRUG|corticosteroids therapy|Oral corticosteroids
223705985|NCT05981391|DIAGNOSTIC_TEST|Otoscopy|Otoscopy is a clinical procedure used to examine structures of the ear, particularly the external auditory canal, tympanic membrane, and middle ear
223705986|NCT05981391|DIAGNOSTIC_TEST|Pure tone air and bone-conduction|Pure tone air- and bone-conduction threshold will be conducted to evaluate audiometry and masking levels in both ears, from 250 Hz. To 16000 Hz.
223705987|NCT05981391|DIAGNOSTIC_TEST|Speech testing|Speech testing will be conducted in both ears, which will include speech reception threshold, speech reception threshold masking level, word recognition presentation level, and word recognition masking level.
223705988|NCT05981391|DIAGNOSTIC_TEST|Loudness Discomfort|Loudness discomfort levels will be tested in both right and left ears, from 500Hz to 4000Hz and speech reception threshold.
223705989|NCT05981391|DIAGNOSTIC_TEST|Quick Speech in Noise Test|Quick Speech in Noise Test (QuickSIN) is a quick method for clinicians to quantify a patient's ability to hear in noise (1 minute).
223705990|NCT05981391|DIAGNOSTIC_TEST|Distortion-Product Otoacoustic Emissions (DPOAE)|Distortion-Product Otoacoustic Emissions (DPOAE) is an automated evaluation of cochlear function. A sensitive microphone is placed in the ear canal via a probe assembly with a disposable ear-tip attached to perform and record the measurements. DPOAEs will be elicited at multiple frequencies in both ears (10 min).
224275929|NCT05421195|OTHER|Olfactory training|repeat and deliberate sniffing of a set of odorants
224275930|NCT04204590|OTHER|Deprescribing algorithm|For this study an implicit, evidence-supported and patient-centred algorithm has been developed. The outcome of the algorithm is an advice to the doctor to deprescribe or not deprescribe the statin and/or PPI.
224275931|NCT05013723|OTHER|Surveys|Mental health validated psychometric surveys: Depression (PHQ-9), Anxiety (GAD-7), PTSD (PC-PTSD-5) Quality of Life surveys: Post COVID-19 Function Status Scale, Quality of life (SF-12)
224275932|NCT03405064|DRUG|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
224275933|NCT03405064|DRUG|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
224275934|NCT01923818|DRUG|rivaroxaban|orally active direct factor Xa inhibitor
224275935|NCT01923818|DRUG|Aspirin|non-steroidal anti-inflammatory drugs
224275936|NCT01923818|DRUG|placebo|
223705991|NCT05793138|BEHAVIORAL|Geriatric Care Model|First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
223705992|NCT05793138|BEHAVIORAL|Usual Care|Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
223705993|NCT04460937|DRUG|Adavosertib|Given PO
223705994|NCT04460937|RADIATION|Radiation Therapy|Undergo radiation therapy
223705995|NCT02750202|BIOLOGICAL|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
223705996|NCT02750202|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
223705997|NCT02586714|OTHER|No intervention|Observation only
223705998|NCT05450224|BEHAVIORAL|VVC-delivered Massed Imaginal Exposure|Consistent with Zoellner et al., (2017), six, 60-minute daily sessions of imaginal exposure will be conducted based on the PE manual (Foa et al., 2007). No in vivo exposure or homework will be included. Session 1 will include rationale for imaginal exposure and common reactions to trauma. Sessions 2-6 will focus on imaginal exposure (45 minutes) and processing (15 minutes), with later sessions focused on the most distressing aspect of the trauma memory. The final session will include relapse prevention. All sessions will be delivered within a 10-day window.
223705999|NCT06070311|COMBINATION_PRODUCT|Thymoquinone (0.5%) and Olive oil ointment|"Preparation of the Thymoquinone and Olive oil ointment:~Thymoquinone Oleaginous base ointment containing olive oil will be prepared for intranasal administration. The ointment will be prepared using the fusion method as follows:~Anhydrous lanolin and white soft paraffin will be melted at 70°C and then olive oil will be added with continuous stirring, Thymoquinone will be added to the congealing mixture as it is being cooled and stirred finally, the congealing mixture is left to cool at room temperature tell solidification and sterilized using UV radiation. The final product will be characterized for spreadability, drug content, drug release and stability."
223706000|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ TNBC patients|"Standard adjuvant chemotherapy + additional chemotherapy:~* BRCA positive patients: standard adjuvant chemotherapy + olaparib~* BRCA negative patients: standard adjuvant chemotherapy + capecitabine~In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once."
224275937|NCT05534113|DRUG|Almonertinib Envafolimab|"Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography."
224275938|NCT00268164|DRUG|lactobacilus acidophilus & bifidobacterium animalis/lactis|
224275939|NCT00722436|DRUG|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
224275940|NCT00722436|DRUG|saline|Placebo
224275941|NCT00681018|OTHER|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
224275942|NCT00681018|OTHER|Powder human milk fortifier|Powder human milk fortifier added to human milk
224275943|NCT04011787|DIETARY_SUPPLEMENT|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
224275944|NCT04011787|DIETARY_SUPPLEMENT|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
224275945|NCT04011787|DIAGNOSTIC_TEST|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
224275946|NCT04011787|DIAGNOSTIC_TEST|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
223706001|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ HER2+ patients|"Standard adjuvant chemotherapy + intensive targeted therapy:~* Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP~* Adjuvant therapy patients: AC-T/TCb + HP~In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once."
223706002|NCT05345860|OTHER|The MRD strategy for high risk or MRD+ ER+ patients|"Standard adjuvant chemotherapy + intensive endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib.~* Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib.~In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once."
223706003|NCT05345860|OTHER|The MRD strategy for low risk and MRD- TNBC patients|"Standard adjuvant chemotherapy: AC-T/TC/TCb/AC.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in The MRD strategy for high risk or MRD+ TNBC patients will be added for at most twice."
224275947|NCT04011787|RADIATION|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
224275948|NCT01067521|DRUG|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
224275949|NCT01067521|DRUG|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
223706004|NCT05345860|OTHER|The MRD strategy for low risk and MRD- HER2+ patients|"Standard adjuvant chemotherapy + standard targeted therapy:~* Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H.~* Adjuvant therapy patients: AC-T/TC/TCb/wP + H.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in The MRD strategy for high risk or MRD+ HER2+ patients will be added for at most twice."
223706005|NCT05345860|OTHER|The MRD strategy for low risk and MRD- ER+ patients|"Standard adjuvant chemotherapy + standard endocrine therapy:~* Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR.~* Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE.~In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in The MRD strategy for high risk or MRD+ ER+ patients will be added for at most twice."
223706006|NCT03317340|OTHER|Background Sounds|Background music or sound of running water
223706007|NCT04390061|DRUG|Tofacitinib|Jak-1/3 inhibitor
223706008|NCT04390061|DRUG|Hydroxychloroquine|Standard Therapy
223706009|NCT01229826|RADIATION|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
223706010|NCT01103336|DRUG|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"* Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
223706011|NCT05667987|DRUG|Intravenous lidocaine administration|General anesthesia with intravenous lidocaine administration
223706012|NCT02390908|BEHAVIORAL|Immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
223706013|NCT02390908|BEHAVIORAL|Wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
223706014|NCT00003831|PROCEDURE|conventional surgery|
223706015|NCT02829073|DEVICE|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
223706016|NCT02829073|DEVICE|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
223706017|NCT00117455|DRUG|pegfilgrastim|
223706018|NCT00117455|DRUG|filgrastim|
223706019|NCT05612711|DRUG|Dronabinol|All participants will take both dronabinol and placebo at different points in the study in this crossover design trial.
223706020|NCT02911220|GENETIC|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
223706021|NCT02579837|DEVICE|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
223706022|NCT02579837|DEVICE|Zeiss Cirrus|optical coherence tomographer (OCT)
223706023|NCT01964833|PROCEDURE|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
223706024|NCT01964833|PROCEDURE|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
223706025|NCT01631773|GENETIC|microRNA|Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
223706026|NCT05832801|OTHER|( Traditional dietary advice )|traditional dietary advice for IBS which is based on guidance provided by the National Institute for Health and Care Excellence (NICE ) and the British Dietetic Association (BDA). Its principles include adopting healthy, sensible eating patterns such as having regular meals, never eating too little/too much, maintaining adequate hydration, and reducing the intake of (1) alcohol/caffeine/fizzy drinks, (2) fatty/spicy/processed foods, (3) fresh fruit to a maximum of 3 per day, (4) fiber and other commonly consumed gas-producing foods (eg, beans, bread, sweeteners, etc), and (5) addressing any perceived food intolerances (eg, dairy).
223706027|NCT05832801|OTHER|(Pilates exercises)|Pilates exercises will be in the form of Swan, One leg up-down, Leg circles, Single leg stretch, Saw, Side kicks, The hundred,. Pelvic lift on the ball, Sit-ups with the ball, Stretching on the ball. exercise Dose will be First month (first- eighth session) composed of one set of eight repetitions Second month (eighth-sixteenth session) composed of two sets of ten repetitions
223706028|NCT01781975|DRUG|Imatinib Mesylate|
223706029|NCT01781975|DRUG|Placebo (For imatinib mesylate)|
223706030|NCT00324792|DRUG|intensive insulin therapy|
223706031|NCT01940601|DRUG|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
223706032|NCT01940601|DRUG|Filgrastim|Filgrastim 5 μg/kg
223706033|NCT04710394|BEHAVIORAL|Smell Training|Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
223706034|NCT06558591|DEVICE|Telerehabilitation intervention|"Inclusion will take place within the framework of routine care for individuals with chronic diseases in rehabilitation services, hospitals, institutions, etc. The study will be offered to patients with chronic illnesses who are being cared for by their therapists. Data collection will be conducted in two sessions. The period between the two sessions will be determined based on the patient's availability, not exceeding a period of 12 weeks:~1. 1st session at 0 week : Conducting activities and initial evaluation at their usual care center. Therapists will perform the various planned tests and evaluations.~2. 2nd session at 12 weeks : This session will take place under the same conditions as the first one and without any potential health risks to the participants.~3. A final evaluation will be carried out at the 18-week follow-up. A telephone call will be made between sessions to check in and assist participants in case of any issues during the study."
223706035|NCT02737397|DRUG|JMI-001 (SJP-304 and SJP-223)|
223706036|NCT02737397|DRUG|SJP-304|
223706037|NCT02737397|DRUG|SJP-223|
223706038|NCT02737397|DRUG|placebo|
223706039|NCT01164930|BEHAVIORAL|Acceptance and Commitment Therapy|8-week ACT group
223706040|NCT05618860|OTHER|Questionnaire|eligible participants in the radiology department waiting rooms will be asked to complete a questionnaire after taking consent.
223706041|NCT00069940|BIOLOGICAL|sargramostim|
223706042|NCT00069940|BIOLOGICAL|telomerase: 540-548 peptide vaccine|
223706043|NCT06557200|BEHAVIORAL|Digital Infant- parents support|A virtual and in-person, personal and group-based intervention will be delivered-educational information on infant behavior and changes in interpersonal dynamics associated with parenting. Modules aimed at understanding and managing infant behavior include information on infant temperament. Personal support will be provided by face-to-face education and WhatsApp messages and videos. Group support will be provided by mothers and their partners or a support person group discussion.
223706044|NCT02404220|DRUG|Entospletinib|
223706045|NCT02404220|DRUG|Vincristine|
223706046|NCT02404220|DRUG|Dexamethasone|
224275950|NCT05659680|DEVICE|WiSE-CRT|Participants undergo pre-procedural CT, implantation of the WiSE-CRT system targeting the left bundle branch area, and post procedural non-invasive electro-anatomical mapping using electrocardiographic imaging and haemodynamic assessment.
223706047|NCT02404220|DRUG|CNS Prophylaxis|
223706048|NCT01622231|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
223706049|NCT02627521|PROCEDURE|PRU guided CABG|Coronary Artery Bypass Surgery
224275951|NCT02169752|DRUG|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
224275952|NCT00055809|BIOLOGICAL|PEG-interferon alfa-2b|Given SC
224275953|NCT00055809|BIOLOGICAL|bevacizumab|Given IV
224275954|NCT00055809|OTHER|laboratory biomarker analysis|Optional correlative studies
224275955|NCT00252447|PROCEDURE|Pre-Operative Conformal Radiotherapy|
223706050|NCT02627521|PROCEDURE|CABG per standard of care|Coronary Artery Bypass Surgery
223706051|NCT02627521|DEVICE|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
223706052|NCT02627521|DRUG|Ticagrelor|Ticagrelor administration prior to randomization
223706053|NCT06257797|DIAGNOSTIC_TEST|Skin prick test|Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
223706054|NCT01984411|PROCEDURE|Radial Technical|Vascular Access for cardiac catheterization
223706055|NCT01984411|PROCEDURE|Femoral Technical|Vascular Access for cardiac catheterization
223706056|NCT01984411|DRUG|Omnipaque|
223706057|NCT01005108|DRUG|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
223706058|NCT03188315|GENETIC|HPV oncogenes|PCR and oncogenes detection
223706059|NCT01015898|RADIATION|photodynamic therapy|treatment of bcc with 5\_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
223706060|NCT06092385|OTHER|Data collection|"Clinical assessment and blood sampling at day of inclusion and in 6- monthly intervals for stable cirrhotic patients; at day of inclusion and on days 3, 7, 14 and 28 for acute decompensation or acute-on-chronic liver failure patients; assessment of clinical, psychosocial/behavioural and patient-reported data in parallel with blood sampling;~* Biobanking of PBMCs and serum/plasma samples~* Biobanking of other biological material if sampled for clinical reasons (liver biopsies, ascites, urine, gut mucosa, lymph nodes)"
223706061|NCT00658008|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
223706062|NCT00658008|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
223706063|NCT00658008|DRUG|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
223706064|NCT00658008|DRUG|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
223706065|NCT00658008|DRUG|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
223706066|NCT02905149|PROCEDURE|Serrato|Serratus plane block.
223706067|NCT02905149|PROCEDURE|Control|Standard anesthesia
223706068|NCT02329080|DRUG|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
223706069|NCT02329080|DRUG|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
223706070|NCT02329080|DRUG|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
223706071|NCT02329080|DRUG|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
223706072|NCT02329080|DRUG|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
223706073|NCT02329080|DRUG|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
223706074|NCT02329080|DRUG|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
223525342|NCT03361631|DRUG|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
223525343|NCT01399645|DRUG|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
223525344|NCT06199752|DIETARY_SUPPLEMENT|probiotic agent 25 Billion CFU (Nowfoods, USA) , ). Inulin capsules 1000mg Herbamama USA|probiotic agent 25 Billion CFU (Nowfoods, USA), composed of ten strains of bacteria (Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus plantaLactobacillus paracasei, Bifidobacterium breve, Streotococcus thermophiles, Lactobacillus salivarius, and Bifidobacterium longum),
223525345|NCT01799135|OTHER|DCE-MRI scan|
223525346|NCT01799135|RADIATION|Stereotactic Body Radiation Therapy|
223525347|NCT01799135|OTHER|4D-CT scan|
223525348|NCT05781451|DRUG|LY3361237|All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
223525349|NCT02678377|DRUG|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
223525350|NCT02678377|DRUG|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
223525351|NCT05497687|OTHER|Resistance exercise|The training schedule for supervised sessions (including community-based and home-based) will last for 60 minutes per session, two sessions per week. From Week 3 and 4, the exercise specialist will deliver supervised home-based training, with one in-person session via home visits and one session to be delivered remotely via an online platform (Zoom). Then the supervision will gradually tail off from Week 5 and onwards, from online supervised sessions, to unsupervised self-practice sessions. An in-person supervised home visit as a booster session will be given at Week 9, the beginning of the habituation phase. Telephone follow-ups will be arranged at Week 10 - 12 by the exercise specialist. All participants in the intervention group will be invited to take part in a qualitative interview to explore the feasibility and acceptability of the intervention.
223525352|NCT02766855|DRUG|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
223525353|NCT03246880|DRUG|Tamsulosin 0.2mg|per oral for 12weeks after 2\~4weeks run-in period
223525354|NCT03246880|DRUG|Tadalafil 5mg|per oral for 12weeks after 2\~4weeks run-in period
223525355|NCT04429763|BIOLOGICAL|Umbilical cord derived mesenchymal stem cells|One dosis of 1\*10\^6 cells/Kg
223525356|NCT04429763|BIOLOGICAL|Placebo|Placebo
223525357|NCT01890031|OTHER|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
223525358|NCT01890031|OTHER|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
223525359|NCT03109457|OTHER|oral squamous cell carcinoma|Histological diagnosis of H\&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
223525360|NCT05851547|RADIATION|Prostate SBRT with Focal Boost|Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions
223525361|NCT05851547|DRUG|Triptorelin Injection|Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
223525362|NCT01940419|DRUG|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
223525363|NCT01940419|DRUG|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
223525364|NCT02362763|PROCEDURE|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
223525365|NCT06010979|PROCEDURE|conventional intrumentation assisted knee arthroplasty|conventional intrumentation assisted knee arthroplasty
223525366|NCT06010979|PROCEDURE|computer navigation assisted knee arthroplasty|computer navigation assisted knee arthroplasty
223525367|NCT06010979|PROCEDURE|robotic system assisted knee arthroplasty|robotic system assisted knee arthroplasty
223525368|NCT06010979|PROCEDURE|patient-spercific assisted knee arthroplasty|patient-spercific assisted knee arthroplasty
223525369|NCT05061836|DRUG|Ringer acetate|Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate
223525370|NCT05061836|DRUG|1.25%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate
223525371|NCT05061836|DRUG|2.5%Dextrose equivalence|5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate
223525372|NCT05061836|DRUG|Dextrose 5|5%dextrose in normal saline (5%DNSS) infused with maintenance rate
223525373|NCT02884479|DRUG|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
223525374|NCT02884479|DRUG|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
223525375|NCT04942847|DEVICE|Sucking trainer|Repeated sucking for tongue flexibility training can improve the tongue muscle's ability to control and transmit food, and improve the swallowing function.
223706075|NCT02329080|DRUG|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
223706076|NCT02329080|RADIATION|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
223706077|NCT03060733|OTHER|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
223525376|NCT04942847|DEVICE|Cognitive card|To measure the patient's ability to focus, to calculate, to remember and to judge
223525377|NCT03292029|DIAGNOSTIC_TEST|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
223525378|NCT04412239|BEHAVIORAL|Patient-centred advice on Telephone Consultation in TB Patients:|The primary aim was to assess the efficiency and the satisfaction of the telephone consultation. The COVID-19 pandemic might be an opportunity to review and refine our practices in TB care. For the follow-up of selected patients, telephone consultations may be efficient and cost effective.
223525379|NCT02231580|DRUG|BN82451B|BN82451B capsule
223525380|NCT02231580|DRUG|Placebo|Placebo capsule
223525381|NCT05787015|BEHAVIORAL|Vaccine Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about vaccination rates and hesitant attitudes.
223525382|NCT05787015|BEHAVIORAL|Alcohol Norms Feedback|Personalized normative feedback pertaining to normative misperceptions about alcohol use.
223525383|NCT04573985|BEHAVIORAL|Serious game Eurekoi intervention|1 session in group using the serious game eurekoi
223525384|NCT02979990|OTHER|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
223525385|NCT02979990|OTHER|Control Video|The control group will have access to a video about the IVF process
223525386|NCT01533415|DEVICE|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of \<1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
223525387|NCT01533415|DEVICE|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
223525388|NCT02843633|DEVICE|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
223525389|NCT02843633|DRUG|Antiplatelet Drug|Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
223525390|NCT05006755|COMBINATION_PRODUCT|Mineral Trioxide Aggregate|Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair
223525391|NCT05006755|COMBINATION_PRODUCT|Biodentine|Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
223525392|NCT04586257|PROCEDURE|Erector spinae plane block|While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.
223525393|NCT04586257|PROCEDURE|Throacolumbar interfacial plane block|USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
223525394|NCT00997659|DIETARY_SUPPLEMENT|chromium picolinate|1000 mg per day
223525395|NCT05199844|DEVICE|Apple Watch|Apple Watch device measures heart rate and oxygen saturation
223525396|NCT00480727|PROCEDURE|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
223706078|NCT00624234|BEHAVIORAL|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
223706079|NCT00624234|BEHAVIORAL|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
223706080|NCT05905900|COMBINATION_PRODUCT|Emergent IV Dye Preparation|Diphenhydramine 50 mg IV once, famotidine 20 mg IV once, and dexamethasone 10 mg IV once
223706081|NCT04612673|DRUG|Sintilimab|immune checkpoint inhibitor, 200mg, iv, d1,Q3W
223706082|NCT02424448|PROCEDURE|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
223706083|NCT00840892|OTHER|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
223706084|NCT05232071|DRUG|IVA337|800 mg
223706085|NCT05232071|DRUG|Placebo|Placebo to match
223706086|NCT05232071|DRUG|Empagliflozin|10 mg
223706087|NCT06556979|RADIATION|Radiotherapy|Review imaging and medical record of head and neck cancer patient who recieve radiotherpy to find out the incidence of ischemic cerebrovascular event and carotid artery stenosis. The risk factor that influence new carotid artery stenosis was claculated
223706088|NCT05248581|PROCEDURE|Liver transplantation|living donor liver transplantation
223706089|NCT01655797|BEHAVIORAL|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
223706090|NCT02922855|BEHAVIORAL|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
223706091|NCT02922855|BEHAVIORAL|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
223706092|NCT02922855|BEHAVIORAL|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
223706093|NCT00881257|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
223706094|NCT00837356|DRUG|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
223706095|NCT00837356|DRUG|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
223706096|NCT00335413|DRUG|Spironolactone|
223706097|NCT01459081|DRUG|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
223706098|NCT01459081|DRUG|Placebo|inhaled by mouth, twice daily, for 5 days
223525397|NCT00480727|PROCEDURE|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
223525398|NCT04980209|DEVICE|ultrasound evaluation|According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.
223525399|NCT04996745|BEHAVIORAL|Tablet-based educational intervention|"POSNA's Orthokids website and the article on pediatric forearm fracture will be provided on a tablet. The article provided has two separate tabs, labeled Condition and FAQs, that caregivers will be able to read through. Those who speak Spanish will have the Spanish translated version of Orthokids."
223525400|NCT03620981|DRUG|Brexpiprazole|Drug: 1 tablet /day Once daily for 10 weeks
223525401|NCT03620981|DRUG|Placebo|Placebo: 1 tablet /day Once daily for 10 weeks
223525402|NCT03286361|DEVICE|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
223525403|NCT04554836|DRUG|Cetuximab|Patients in Arm A will receive FOLFIRI +cetuximab.
223525404|NCT04554836|OTHER|FOLFIRI|Irinotecan, Folinic acid (racemic), Fluorouracil (5-FU)
223525405|NCT06264570|DIETARY_SUPPLEMENT|B-TMG supplementation|B-TMG supplement (B2 riboflavin, B6 pyroxidine, B9 methylfolate, B12 methylcobalamine, S-adenosylmethionine, Trimethylglycerol (TMG), zinc sulfate) for subjects with normal COMT gene and MTHFR gene polymorphism
223525406|NCT06264570|DIETARY_SUPPLEMENT|B-SAM supplementation|B-SAM supplement (B2 riboflavin, B6 pyroxidine, B9 folic acid, B12 adenosylcobalamin, magnesium, S-adenosylmethionine) for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
223525407|NCT06264570|OTHER|B-TMG placebo|B-TMG placebo for subjects with normal COMT gene and MTHFR gene polymorphism
223525408|NCT06264570|OTHER|B-SAM placebo|B-SAM placebo for Subjects with COMT gene polymorphism or normal COMT gene and normal MTHFR gene
223706099|NCT03364790|PROCEDURE|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
223706100|NCT03364790|PROCEDURE|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
223706101|NCT00174811|DRUG|telithromycin (HMR3647)|
223706102|NCT04814732|DRUG|Surufatinib|HMP-012
223706103|NCT01609231|DRUG|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
223706104|NCT01609231|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
223706105|NCT01609231|DRUG|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m\^2 followed by weekly infusions of 250 mg/m\^2. Pre-medication at the discretion of the investigator will follow local or country-specific standard of care.
223706106|NCT04763785|DEVICE|Corneal tomography with Eyestar 900|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
223706107|NCT04763785|DEVICE|Corneal tomography with Pentacam|Non-invasive corneal tomography to develop an imaging analysis algorithm for keratoconus corneas
223706108|NCT04763785|DEVICE|Biometry with IOL-Master|Non-invasive biometry for presurgical intraocular lens calculation
223706109|NCT04763785|OTHER|retrospective analysis, no intervention|retrospective analysis of 4500 existing, fully anonymised picture data
223706110|NCT04288180|OTHER|No intervention|There will be no intervention in this study. Adults with social anxiety disorder will complete research assessments related to fear and safety learning.
223706111|NCT06421207|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
223706112|NCT03530527|PROCEDURE|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
223706113|NCT03530527|PROCEDURE|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
223706114|NCT00912678|DRUG|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
223706115|NCT00912678|DRUG|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
223706116|NCT02100579|DRUG|Bupivacaine|10 ml of 0.25% bupivacaine
223706117|NCT02100579|DRUG|Preservative free normal saline|10 ml of preservative free normal saline
223706118|NCT00040339|PROCEDURE|hypothermia (body temperature lowered to 33°C or 91.4°F)|
223706119|NCT00815399|DRUG|Pioglitazone|15-45 mg/die
223706120|NCT00815399|DRUG|Metformin|500-2000 mg/die
223706121|NCT00152529|BEHAVIORAL|Screening (Behavior)|
223706122|NCT01067066|DRUG|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
223706123|NCT01067066|DRUG|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m\^2 by mouth (PO) daily, Day 1 to 5.
223706124|NCT03783975|GENETIC|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
223706125|NCT00933829|PROCEDURE|Absorbable Suture Arm|use of irradiated polyglactin 910
223706126|NCT00933829|DEVICE|Non-absorbable suture (Prolene)|suture
223706127|NCT00933829|PROCEDURE|suture|non-absorable sutures and absorable sutures
223706128|NCT03143543|DRUG|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
224275956|NCT03784274|BEHAVIORAL|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~* Respondents who consent to participate in the study.~* Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
223706129|NCT03143543|DRUG|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
223706130|NCT03143543|OTHER|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
223706131|NCT03143543|OTHER|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
223706132|NCT00341445|BEHAVIORAL|Effect of Cockroach Allergen|
223706133|NCT00387803|DEVICE|Cardiac Resynchronization Therapy with Defibrillation|
223706134|NCT02842307|PROCEDURE|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
224275957|NCT00024154|BIOLOGICAL|trastuzumab|Given IV
224275958|NCT00024154|DRUG|gefitinib|Given orally
224275959|NCT00024154|OTHER|laboratory biomarker analysis|Correlative studies
223706135|NCT02842307|PROCEDURE|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
223706136|NCT02842307|PROCEDURE|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
223706137|NCT03282370|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
223706138|NCT03282370|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
224275960|NCT03508154|OTHER|Control Meal 1|carbohydrate test meal
224275961|NCT03508154|OTHER|Control Meal 2|carbohydrate test meal
223525409|NCT05642858|BEHAVIORAL|Digital Educational Messaging|Education via mobile phone text messages for up to 6 months.
223525410|NCT06005324|DRUG|Paclitaxel|Given as part of induction chemotherapy.
223525411|NCT06005324|DRUG|Carboplatin|Given as part of induction chemotherapy.
223525412|NCT06005324|DRUG|Cetuximab|Given as part of induction chemotherapy.
223525413|NCT06005324|RADIATION|Standard Dose Radiation|Radiation given once daily for 5 days for 7 weeks as part of CRT regimen.
223525414|NCT06005324|RADIATION|Low Dose Radiation|Radiation given once daily for 5 days for 6.5 weeks as part of CRT regimen.
223525415|NCT06005324|DRUG|Cisplatin|Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
223525416|NCT06005324|DRUG|TFHX Regimen|Chemotherapy with paclitaxel, fluorouracil (5FU), and hydroxyurea given in combination with radiation therapy. Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
223525417|NCT03775837|DIETARY_SUPPLEMENT|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
223525418|NCT03775837|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
223525419|NCT02607722|DRUG|Nintedanib|
223525420|NCT04355832|DRUG|Glucagon-like peptide-1|Infusion of Glucagon-like peptide-1
223525421|NCT04355832|DRUG|Placebos|Infusion of normal saline solution that will mimic Glucagon-like peptide-1
223525422|NCT06507722|DIAGNOSTIC_TEST|Timing of OGTT|In Aim 1, timing of oral glucose tolerance test will be altered.
223525423|NCT06507722|BEHAVIORAL|Timing of Standardized Meal|In Aim 2, timing of a standardized meal will be altered.
223525424|NCT06212687|BEHAVIORAL|Digital pre-therapy patient education program (StartHjelp)|After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.
223525425|NCT06212687|BEHAVIORAL|Comparator intervention|After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
223525426|NCT04347538|OTHER|Saline Nasal Irrigation|Saline nasal irrigation BID
223525427|NCT04347538|OTHER|Saline with Baby Shampoo Nasal Irrigation|Saline with 1/2 teaspoon Baby Shampoo Nasal Irrigation.
223525428|NCT02135133|DRUG|Idelalisib|150 mg BID Oral Daily
223525429|NCT02135133|DRUG|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
223525430|NCT06614543|DIETARY_SUPPLEMENT|Meal Replacement|These meal replacements provide plant-based protein, fibre and fatty acids that have been shown to have health benefits related to chronic disease.
223525431|NCT00471393|DRUG|1.5% diclofenac in 45.5% DMSO (topical treatment)|
223525432|NCT00471393|DRUG|45.5% DMSO (topical placebo)|
223525433|NCT04891198|DRUG|Envafolimab|Subcutaneous injection
223525434|NCT06077357|OTHER|MMSE Test|Mini Mental State Examination (MMSE), is a brief mental test used to assess individuals' cognitive functions. This test evaluates basic cognitive abilities such as memory, attention, calculation, language, orientation, and problem-solving. MMSE is commonly used for monitoring and assessing mild cognitive impairments, dementia, and other neurological conditions. This test is typically scored out of 30, with higher scores indicating better cognitive function.
223525435|NCT06077357|OTHER|PASE Test|"The PASE test stands for Physical Activity Scale for the Elderly. This scale is used to assess the physical activities undertaken by elderly individuals in their daily lives. The PASE test allows for the evaluation of both daily activities such as walking, climbing stairs, and household chores, as well as exercise routines. It is used to determine the level of physical activity in elderly individuals and support the process of healthy aging."
223525436|NCT06077357|OTHER|The PRISMA-7 Frailty Scale|The PRISMA-7 Frailty Scale is a tool used to assess the level of frailty in elderly individuals. This scale evaluates signs of frailty such as physical activity, fatigue, weight loss, and difficulties with vision and hearing. PRISMA-7 is employed in determining the risk of frailty in the elderly and aids in identifying appropriate treatment and support methods.
223525437|NCT06077357|OTHER|TAMPA Test|"The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area."
223525438|NCT06077357|OTHER|(JAMAR) Muscle Test|The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
223525439|NCT06077357|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
223525440|NCT03238196|DRUG|Erdafitinib|4mg - 8mg
223525441|NCT03238196|DRUG|Palbociclib|125 mg
223525442|NCT03238196|DRUG|Fulvestrant|500 mg
223525443|NCT06393738|DRUG|ARV-393|Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
224275962|NCT03508154|OTHER|Experimental Nutritional Product|ready to drink nutritional formulation
223525444|NCT05442879|BEHAVIORAL|Knowledge Translation Intervention|The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.
223525445|NCT05442879|BEHAVIORAL|Educational handout|Educational handout describing a commonly cited ACL-IPP.
223525446|NCT06634303|DEVICE|Brain cooling|Brain cooling intervention in acute ischemic stroke patients post mechanical thrombectomy
223525447|NCT05081843|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
223525448|NCT05081843|BEHAVIORAL|Usual health education curriculum|The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.
223525449|NCT05918354|DEVICE|Skin Prick Automated Test|Detection of sensitisation to specific allergens via the skin prick automated test.
223525450|NCT03985527|DEVICE|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
223525451|NCT04281940|DEVICE|Transcatheter implantation of chordal repair system|Implantation of anchor via transcatheter delivery system to delivery chordal repair system tethering the mitral leaflets to the ventricle
223525452|NCT02531191|DRUG|peficitinib|oral
223525453|NCT02303821|DRUG|Carfilzomib|
223525454|NCT02303821|DRUG|Dexamethasone|
223525455|NCT02303821|DRUG|Mitoxantrone|
223525456|NCT02303821|DRUG|PEG-asparaginase|
223525457|NCT02303821|DRUG|Vincristine|
223525458|NCT02303821|DRUG|Intrathecal (IT) Methotrexate|
223525459|NCT02303821|DRUG|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
223525460|NCT02303821|DRUG|6-Mercaptopurine|
223525461|NCT02303821|DRUG|Cyclophosphamide|
223525462|NCT02303821|DRUG|Cytarabine|
223525463|NCT02303821|DRUG|Daunorubicin|
223525464|NCT01969578|DRUG|bicalutamide + triptorelin|
223525465|NCT01969578|DRUG|Cisplatin + Doxorubicin|
223525466|NCT01969578|DRUG|Carboplatin + Paclitaxel|
223525467|NCT05087342|DRUG|Semaglutide 2.4mg|The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
223525468|NCT05087342|DRUG|Placebo|A placebo will be given to the control group per the schedule outlined in the armed description.
223525469|NCT03551119|BEHAVIORAL|Exercise|See previous description
223525470|NCT03551119|OTHER|Enhanced usual care|See previous description
223525471|NCT06638970|DRUG|Secretome|3 ml Injection of secretome for 4 times two weeks apart
223525472|NCT06636760|OTHER|Placebo|The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
223525473|NCT06636760|DIETARY_SUPPLEMENT|herbal compound|The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
223525474|NCT06644950|OTHER|Efficacy and safety of administering 1 or two cartridges of anesthesia|"The investigator will administer the first anesthesia for NDI block with a cartridge of 4% articaine anesthetic at 1:100,000 . At the end, an envelope containing the assignment to the experimental or control group will be opened.~In the control group, only the first anesthetic (1.8 mL of articaine 4% 1:100,000) will be injected and a second puncture will be simulated, contacting the syringe without the needle, in the same area, counting up to 30 seconds.~In the experimental group two anesthetic cartridges of articaine 4% 1:100,000 will be administered with the direct technique for the inferior alveolar nerve block."
223525475|NCT06644248|DIAGNOSTIC_TEST|Colposcopy|The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
223525476|NCT06643650|DIETARY_SUPPLEMENT|CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML|Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
223525477|NCT04923672|BEHAVIORAL|Moderate continuous exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
223525478|NCT04923672|BEHAVIORAL|High intensity interval exercise|Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
223525479|NCT05191485|OTHER|Qualitative interviews|We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA\_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.
223525480|NCT06845436|BEHAVIORAL|Exercise|Combined exercise group subjects will undergo weekly three sessions of both HIIT and resistance training for sixteen weeks. The HIIT session will involve four four-minute high-intensity intervals with an intensity of at 80-95% of the HRmax interspersed with two-minute active recovery intervals with intensity of 40% to 60% of the HRmax.
224275963|NCT04442854|OTHER|cognitive behavioral group therapy|A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
223525481|NCT06845436|OTHER|routine physical activity|The control group subjects will be instructed not to change their usual daily physical activities routine and instructed to abstain from practicing any exercise regimens during the 12-week study period.
223525482|NCT05736471|DIAGNOSTIC_TEST|Computational dissociation of the causes of cognitive rigidity in depression|involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
223525483|NCT04341012|DIAGNOSTIC_TEST|Collection of breath sample|Analysis of volatile organic compounds in breath
223525484|NCT05826626|DEVICE|MindLenses Professional|MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet
223525485|NCT05826626|BEHAVIORAL|Conventional rehabilitation|Conventional rehabilition consists in computerized exercises focused on the main cognitive domains
223525486|NCT04938427|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
223525487|NCT04938427|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
223525488|NCT05106062|DEVICE|on remote monitoring|This group will turn on the RM function 0 to 45 days after defibrillator implantation. Patient should be seen at clinic once a year, or if there is any adverse event notification
223525489|NCT03408262|BIOLOGICAL|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
223525490|NCT03408262|BIOLOGICAL|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
223525491|NCT03408262|BIOLOGICAL|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
223525492|NCT05625802|PROCEDURE|Erector Spinae Plane Block (ESPB)|Up to 30 Cubic Centimeter (cc) of 0.5% ropivacaine administered by local injection into the erector spinae plane under ultrasound guidance
223525493|NCT05625802|DRUG|Ropivacaine|0.5% ropivacaine
223525494|NCT05974787|BEHAVIORAL|Emergency department cancer patients interview|The interview focuses on several parts of the (pre-)admission process: The first part is regarding the barriers and facilitators encountered during the (pre-)admission process. The second part will focus on the timeline that led to an emergency department (ED) visit. It will be established when and which symptoms were first detected. The third part is regarding the number and type of health care workers that were contacted before visiting the ED. The fourth part will be about the actions and considerations taken before the ED visit.
223525495|NCT04606849|OTHER|Physician Survey|Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
223525496|NCT04606849|DEVICE|ePNa-CheXED|ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
223525497|NCT05499819|OTHER|Canned black beans, drained and rinsed|Canned black beans, drained and rinsed and consumed in a tortilla wrap
223525498|NCT05499819|OTHER|Canned red kidney beans, drained and rinsed|Canned red kidney beans, drained and rinsed, drained and rinsed and consumed in a tortilla wrap
223525499|NCT05499819|OTHER|Extra-lean ground beef|Extra-lean ground beef, pan-fried and consumed in a tortilla wrap
223525500|NCT01456403|OTHER|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
223525501|NCT05080478|DRUG|Clopidogrel, Ticagrelor|P2Y12 inhibitors are prescribed following the PCI procedure in patients. Patients are enrolled on the study before administration of the first dose of the drug. Parameters are measured before and after drug initiation.
223525502|NCT06506513|OTHER|High-intensity interval training|High-intensity interval training
223525503|NCT06506513|OTHER|Moderate intensity exercise training|Moderate intensity exercise training
223525504|NCT06506513|OTHER|Low intensity exercise training|Low intensity exercise training
223525505|NCT00091897|DRUG|Rituximab|
223525506|NCT00091897|DRUG|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
223525507|NCT03989284|BEHAVIORAL|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
223525508|NCT00745667|PROCEDURE|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
223525509|NCT00745667|PROCEDURE|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
223525510|NCT00708981|OTHER|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~1. BP control of \<130/80mmHg and renal protection with reduction of proteinuria to \<0.5g/day using therapy with ACE inhibitors and/or ARBs.~2. Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~3. Use of hypolipidemic therapy to achieve targets of LDL \< 70 mg/dl, HDL \> 40/50 mg/dl (M/F)and TG \< 200 mg/dl.~4. Patient enhanced self-management provided by combined diabetes-renal education curriculum.~5. Behavior and social intervention~6. Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
223525511|NCT05407766|BIOLOGICAL|OSSM-001|Single injection of OSSM-001 at dose of 100M or 300M cells
223525512|NCT05407766|OTHER|Placebo|Single injection of placebo (saline)
223525513|NCT02624479|DRUG|Sodium thiosulfate|oral administration of thiosulfate
223525514|NCT05620134|DRUG|JK08|Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
223525515|NCT05620134|DRUG|Pembrolizumab|Immune checkpoint inhibitor
223525516|NCT05620134|DRUG|Lenvatinib Pill|Multi-kinase inhibitor
223525517|NCT02689557|OTHER|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
223706139|NCT05476458|RADIATION|White Light Imaging|white light imaging is often the preferred option for poem surgery due to its effective results. However, it also comes with some drawbacks that make it difficult to identify areas of bleeding, unlike RDI, WLI cannot enhance the visibility of deep vessels This can lead to longer haemostasis time as the physician must wait for a longer period before stopping the bleeding. This can make it challenging as it may lead to excessive bleeding. This makes RDI a potential solution for those seeking a more accurate approach to treatment.
223706140|NCT05476458|RADIATION|Red Light Imaging|Red dichromatic imaging (RDI) is a next-generation image enhancement technique which works by employing green, amber and red wavelengths. Greenlight(520-550nm) can visualize small blood vessels in superficial tissue without extending deep into the mucosa. Amber(595-610nm) and red light (620-640nm) can penetrate deep into the tissue owing to low scattering property. The blood vessels in the deeper tissues absorb the amber light because of strong affinity with hemoglobin. Even though red light can penetrate deep into the tissue, it is weakly absorbed by hemoglobin. Hence the reflected light contains red light and amber light without attenuation.
223706141|NCT03675620|DEVICE|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
223706142|NCT03675620|OTHER|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
223706143|NCT03146377|DRUG|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
223706144|NCT03146377|DRUG|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
223706145|NCT03146377|DRUG|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
223706146|NCT01514331|OTHER|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
223706147|NCT01514331|OTHER|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
223706148|NCT03724786|DIAGNOSTIC_TEST|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
223706149|NCT03796533|DRUG|Posaconazole|"* PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~* PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~* The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
223706150|NCT00000503|DRUG|nitroglycerin|
223706151|NCT00000503|DRUG|streptokinase|
223706152|NCT00000503|PROCEDURE|heart catheterization|
223706153|NCT03949439|PROCEDURE|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
223706154|NCT04693117|OTHER|Interval Training|All individual of interventional group participated in an interval training program, which comprised of 3 days/week for twelve weeks. A booklet was given to each participant containing instructions and guideline about interval training. The interval training program was introduced as prescribed previously.17 After the workout, a cool down period of 5 minutes was given during which they perform paddling with low speed. All training program was supervised by a qualified physical therapist.
223706155|NCT04295772|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
223706156|NCT01743417|BEHAVIORAL|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
223706157|NCT02846324|DRUG|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
223706158|NCT02846324|DRUG|Placebo|Placebo capsules
223706159|NCT01365065|DRUG|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
223706160|NCT00193531|DRUG|Paclitaxel|
223706161|NCT00193531|DRUG|Carboplatin|
223706162|NCT00193531|DRUG|Etoposide|
223706163|NCT02256371|BEHAVIORAL|Hypnosis sessions|1 session per week during 8 weeks
223706164|NCT02256371|BEHAVIORAL|Relaxation group|1 relaxation session per week during 8 weeks
223893728|NCT04855227|PROCEDURE|robotic-assisted ventral hernia repair|"Laparoscopic ventral hernia repair With the subject under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the repair. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care.~Robotic-assisted ventral hernia repair With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the subject and used to complete the procedure. The retrorectus space is developed for mesh placement to repair the defect. The repair technique will be per the surgeon's standard of care."
224275964|NCT04986254|OTHER|Blood sampling|During a single dosing interval, each participant will have 1 - 8 blood samples taken for each antibiotic. Blood samples (3 mL each) will be drawn from an existing arterial line or central venous catheter. Blood samples will be collected on 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
223706165|NCT01254071|DRUG|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
223706166|NCT06205823|DRUG|Immunotherapy|Immunotherapy
223706167|NCT04069078|DRUG|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
223706168|NCT04069078|OTHER|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
223706169|NCT04718961|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
223706170|NCT04718961|DRUG|Placebo|Capsules matched to study drug minus active substance.
223706171|NCT04203810|DEVICE|Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)|4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.
223706172|NCT04203810|DEVICE|EMSER® Hals-und Rachenspray (throat spray)|1 to 3 puffs to be administered several times a day
223706173|NCT05960942|DRUG|propofol combined with esketamine|In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
223706174|NCT05960942|DRUG|propofol-sufentanil|In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
223706175|NCT03542123|DEVICE|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
224275965|NCT04986254|OTHER|Epithelial lining fluid sampling|Epithelial lining fluid will be sampled using either a bronchoalveolar lavage (BAL) or mini-BAL technique, in accordance with the preferred procedure in participating sites. 3 BAL or mini-BAL samples will be collected over 2 separate occasions; Occasion 1, between Days 1 - 3 of antibiotic therapy and Occasion 2, between Days 3 - 6 of antibiotic therapy.
223706176|NCT04416659|DEVICE|Neuro-vascular access|Adjunctive device providing a conduit for retrieval device during thrombectomy
223706177|NCT03120559|DEVICE|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
223706178|NCT03120559|DEVICE|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
223706179|NCT03781427|DEVICE|Cardiac resynchronization therapy|Left ventricular pacing
223706180|NCT02908451|BIOLOGICAL|AbGn-107|Antibody Drug Conjugate
223706181|NCT02108782|DRUG|dovitinib lactate|Given PO
223706182|NCT02108782|OTHER|pharmacological study|Correlative studies
223706183|NCT02108782|OTHER|laboratory biomarker analysis|Correlative studies
223706184|NCT06556459|PROCEDURE|Bariatric Surgery|"The patient performs:~* psychological clinical interview~* psychodiagnostic examination~* internal medical examination~* blood tests~* electrocardiogram~* bariatric surgery~* surgical visit"
223706185|NCT04203797|DRUG|dupilumab|Pre-filled syringe administered by subcutaneous (SC) injections
224275966|NCT04986254|OTHER|Urine sampling|The total urine volume over the duration of the dosing interval will be collected on the two sampling occasions for a calculated urinary creatinine clearance measurement.
224275967|NCT04986254|DRUG|Study antibiotics include benzylpenicillin, ceftriaxone, meropenem, and piperacillin/tazobactam|Antibiotic dose and dosing interval will be determined by the treating clinician in accordance to standard prescribing practices based on clinical assessment of the patient. This study aims to recruit at least 20 participants per antibiotic.
223706186|NCT04203797|DRUG|Matching placebo|Pre-filled syringe administered by subcutaneous (SC)
223706187|NCT01454960|BEHAVIORAL|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
223706188|NCT01454960|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
223706189|NCT01454960|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
223706190|NCT00092807|DRUG|MK0653, ezetimibe|
223706191|NCT00092807|DRUG|Comparator: placebo|
223706192|NCT00776282|DRUG|loratadine 10 mg orally disintegrating|
223706193|NCT06205966|DIETARY_SUPPLEMENT|BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)|BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
223706194|NCT06205966|OTHER|Placebo|Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
223706195|NCT03867279|OTHER|Flossing|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
223893729|NCT05011305|DRUG|Saroglitazar Magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
223706196|NCT03867279|OTHER|Reeducation exercises|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
223706197|NCT00516074|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
223706198|NCT00516074|DRUG|placebo|subcutaneous injection, volume equivalent to active, twice a day
223706199|NCT05089955|BEHAVIORAL|Ambient Experience|MRI examination with Ambient Experience
223706200|NCT04610970|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
223706201|NCT00591994|DRUG|piribedil|50 mg once a day, after lunch 3 month therapy
223706202|NCT02279446|OTHER|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
223706203|NCT05317624|COMBINATION_PRODUCT|Platelet rich plasma|platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
223706204|NCT05317624|COMBINATION_PRODUCT|Methylprednisolone|1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
223706205|NCT03540030|DRUG|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706206|NCT03540030|DRUG|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706207|NCT03540030|DRUG|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706208|NCT03540030|DRUG|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706209|NCT03540030|DRUG|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706210|NCT03540030|DRUG|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706211|NCT03540030|DRUG|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706212|NCT03540030|DRUG|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706213|NCT03540030|DRUG|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706214|NCT03540030|DRUG|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706215|NCT03540030|DRUG|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
223706216|NCT00087503|DRUG|Edotecarin|
223706217|NCT03225599|OTHER|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
223706218|NCT00027716|DRUG|bortezomib|
223706219|NCT05180617|BEHAVIORAL|Music Therapy|Music therapy participants will interact both musically and verbally with the therapist and will be given a range of both electronic and acoustic instruments to choose from. Music therapy sessions will be based upon music improvisation, and as such participants are not required to have any previous instrument or other music experience and be invited to improvise freely using the instruments. The music therapist will accompany participants in the improvisation. This provides participants with an opportunity to connect with emotions and feelings connected to hidden psychic material. Following improvisations, the therapist and client will identify these moments of interest which can be further explored either verbally or through further improvisation. The music created within sessions will be recorded and participants can take a copy of the recordings home and it will be used in the therapeutic monitoring and analysis of sessions.
223706220|NCT02747290|DRUG|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
223706221|NCT04823182|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
223706222|NCT05446441|PROCEDURE|Endoscopic surgery;|Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.
223706223|NCT06339034|DIETARY_SUPPLEMENT|Lithium|5mg of elemental lithium/capsule
223706224|NCT06339034|OTHER|Placebo|Cellulose-filled capsules
223706225|NCT00003487|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223706226|NCT00237172|DRUG|Imatinib Mesylate|once daily
223706227|NCT04239053|DRUG|Bupivacaine|Measuring the plasma concentration level of bupivacaine after applying ESPB
223706228|NCT05636059|OTHER|Therapeutic exercise|32 sessions in total, 2 times a day, 30 min. one session. Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball.
223893730|NCT05011305|DRUG|Saroglitazar Magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
224275968|NCT01135940|DEVICE|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
223706229|NCT05636059|OTHER|Exercise + cryotherapy|"Exercise program - 16 sessions in total, once a day, 30 min. one session. Cryotherapy - 8 sessions in total, two-three times a week, one session - 2 min. duration, temperature -60 to -140 C degrees.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
223706230|NCT05636059|OTHER|Exercise + joint mobilization|"Exercise program - 16 sessions in total, once a day, 30 min. one session, two-three times a week.~Joint mobilization - 8 sessions in total, anterior - posterior tibia femoral glide, patella motion, lateral and medial movement.~Exercise program consisted of: cycling stationary bike, isometric and isotonic exercise for knee flexion / extension, hip flexion / extension / abduction / adduction, exercise with resistance bands, weights, and gymnastic ball."
223706231|NCT05209269|OTHER|Work of breathing observation|We will place soft elastic bands around the infant's chest and abdomen to assess their work of breathing.
223706232|NCT01888757|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
223706233|NCT01742000|DIETARY_SUPPLEMENT|Karinat|
223706234|NCT01742000|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
223706235|NCT02109211|DEVICE|Intubation with Magill forceps|
223706236|NCT02109211|DEVICE|Intubation with altered Magill forceps|
223706237|NCT02201641|RADIATION|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
223706238|NCT02201641|RADIATION|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
223706239|NCT02201641|DEVICE|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
223706240|NCT02201641|DEVICE|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
223706241|NCT03558087|DRUG|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
223706242|NCT03558087|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four 21-day cycles.
223706243|NCT03558087|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four 21-day cycles.
223706244|NCT03475823|DIETARY_SUPPLEMENT|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
223706245|NCT03475823|DIETARY_SUPPLEMENT|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
223706246|NCT03475823|DIETARY_SUPPLEMENT|Placebo control|An inert encapsulated powder provided by Finzelberg.
223706247|NCT02617043|RADIATION|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
223706248|NCT04555421|DEVICE|Lumen|Subjects will use the Lumen device and mobile phone application, which will guide their diet, sleep, and routines according to their Lumen measurements. In addition, a Lumen coach will be assigned to the subjects, and they will have a 30 minutes video call with the coach during the familiarization stage, in order to acquaint them with Lumen and explain them about the application and the nutritional guidance.
223706249|NCT04437563|BEHAVIORAL|HERMES|Via an app, the caregiver answers 14 questions about his/her need for (more) information. The caregiver presents his/her answers (i.e., need for information) to the health care professionals (HCPs), and the HCPs provide the caregiver with the lacking information.
223706250|NCT03855228|DRUG|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
223706251|NCT03855228|DRUG|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
223706252|NCT03855228|DRUG|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
223706253|NCT03855228|DRUG|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
223706254|NCT03529331|DRUG|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
223706255|NCT03529331|DRUG|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
224275969|NCT01135940|DEVICE|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
223706256|NCT03529331|DRUG|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
223706257|NCT00737243|DRUG|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
223706258|NCT00737243|DRUG|Carboplatin|AUC 6.0 IV Day 1
223893731|NCT05011305|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily in the morning before breakfast without food, for the duration of treatment.
224275970|NCT02760433|DRUG|Olokizumab|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
223706259|NCT00737243|DRUG|Bevacizumab|15 mg/kg IV infusion Day 1
223706260|NCT00737243|DRUG|Erlotinib|150 mg PO
223706261|NCT00737243|OTHER|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
223893732|NCT05945212|DEVICE|Vibration|The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz
223893733|NCT05945212|DEVICE|Sham vibration|The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.
223706262|NCT04275934|BEHAVIORAL|Health Management; Blood Pressure|Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
223706263|NCT04404205|DIAGNOSTIC_TEST|Postural stability measurements by Biodex Balance System|Postural stability measurements will be done by Biodex Balance System. Three preprogrammed main tests will be applied. Postural stability, fall index, sensory integration will be calculated. All tests will be done in four conditions; implant off(1), implant on(2), implant on music on(3), and implant off again(4).
223706264|NCT00092573|DRUG|MK0653, ezetimibe|
223706265|NCT00092573|DRUG|Comparator: fenofibrate monotherapy|
223706266|NCT04534543|RADIATION|MRI/Spectroscopy|Participants will undergo multiple 7T MR imaging sessions which include advanced 31P MRSI techniques, before start of palliative chemotherapy and during treatment until progression of disease or until week 54.
223706267|NCT06323057|DEVICE|Single pulse TMS to the frontal cortex|Single pulse TMS will be delivered to the left frontal cortex, and stimulation intensity will be at 110% of resting motor threshold.
223706268|NCT04108234|DRUG|HR071603|HR071603 monotherapy ,nasal spray
223706269|NCT04108234|DRUG|placebo|placebo,nasal spray
223706270|NCT03943160|DEVICE|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
223706271|NCT00005865|DRUG|vinorelbine tartrate|
223706272|NCT05383521|DRUG|Tinidazole 56|Tinidazole , 2g， twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
223706273|NCT05383521|DRUG|Tinidazole 42|Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.
223706274|NCT02714374|BIOLOGICAL|GL-ONC1|"Dose and Regimen:~1. Single dose group: Cohort 1 dose is 1 × 109 pfu~2. Multiple dose groups:~   * Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~  * Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~  * Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
223706275|NCT01120535|DEVICE|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
223706276|NCT05862142|OTHER|No intervention|No intervention
223706277|NCT00913380|RADIATION|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
223706278|NCT00913380|RADIATION|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
223706279|NCT01597401|DRUG|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
223706280|NCT01597401|DRUG|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
223706281|NCT01597401|DRUG|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
223706282|NCT01597401|DRUG|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
223706283|NCT01597401|DRUG|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
223706284|NCT00601198|DRUG|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
223706285|NCT04111198|RADIATION|Cardiac MRI|Cardiac MRI
223706286|NCT04259320|DEVICE|Beeswax containing barrier|Use beeswax containing barrier on each nipple after each breastfeeding.
223706287|NCT04259320|BIOLOGICAL|Breast milk|Apply breast milk on each nipple and areola after each breastfeeding.
223706288|NCT05749107|DIAGNOSTIC_TEST|Echocardiography|Identify AF patients at risk of developing moderate/severe STR and those who will benefit from restoring the normal sinus rhythm
223706289|NCT05749107|COMBINATION_PRODUCT|Proteomic analyses|To identify the mechanisms leading to moderate/severe STR during AF.
223706290|NCT04775407|PROCEDURE|blood sampling|IgM og IgG analysis
223706291|NCT02643602|OTHER|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
223706292|NCT02643602|OTHER|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
223706293|NCT06090396|DIAGNOSTIC_TEST|cardiac output monitoring with electrical cardiometry|comparison of limits of agreement between the two monitoring modalities
223706294|NCT04623112|DEVICE|Hearing aid feature: Frequency Compression|FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
223706295|NCT06429488|OTHER|no intervention, questionnaires were used|"The following psychological assessment tools were used:~Obsessive-Compulsive Inventory-Revised (OCI-R): An 18-item self-report questionnaire measuring symptoms across six subscales: washing, checking, neutralizing, obsessing, ordering, and hoarding. A score of 21 or higher indicates likely OCD.~Depression Anxiety Stress Scales-21 (DASS-21): A set of three self-report scales assessing stress, depression, and anxiety over 21 items. This shortened version is widely used for research and clinical purposes and is easy to administer.~Patient Health Questionnaire-9 (PHQ-9): A nine-item scale for assessing depressive symptoms. Scores are categorized as: 1-4 (no/minimal), 5-9 (mild), 10-14 (moderate), 15-19 (moderately severe), and 20-27 (severe depression).~Generalized Anxiety Disorder-7 (GAD-7): A seven-item tool measuring anxiety symptoms and the severity of generalized anxiety disorder (GAD)."
224275971|NCT02760433|DRUG|Placebo|sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
224275972|NCT02151149|DRUG|nab-paclitaxel|
223706296|NCT04640857|DEVICE|Silk'n Toothwave|patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
223706297|NCT02421471|DRUG|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
223706298|NCT05247775|PROCEDURE|Profilometry|Profilometry was performed in 43 patients before open retropubic radical prostatectomy.
223706299|NCT04207021|DIETARY_SUPPLEMENT|Experimental: Curcumin derivate|two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
223706300|NCT04207021|DIETARY_SUPPLEMENT|Placebo|two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
223706301|NCT01468675|OTHER|Intervention|risk assessment survey; decision support for providers for prevention based on risk
223706302|NCT03690531|DEVICE|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
223706303|NCT03690531|DEVICE|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
223706304|NCT06129175|BIOLOGICAL|Neuroncell-EX|Intravenous infusion of Neuroncell-EX (2 million UCMSCs per kg body weight) on day 1 and day 14 plus standard medical care.
223706305|NCT06129175|OTHER|Placebo|Intravenous infusion of Placebo (normal saline) on day 1 and day 14 plus standard medical care.
223706306|NCT04336293|DEVICE|sTMS|"sTMS will be delivered following NeoSync guidelines using the device user~manual"
223706307|NCT04336293|DEVICE|sham sTMS|sham sTMS will be delivered following NeoSync guidelines using the device user manual
223706308|NCT05509036|OTHER|No interventions|No interventions
223706309|NCT02004522|DRUG|Duvelisib|PI3K Inhibitor
223706310|NCT02004522|DRUG|Ofatumumab|monoclonal antibody
223706311|NCT04090866|OTHER|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
223706312|NCT01787331|DRUG|Itraconazole|Given PO
223706313|NCT01787331|OTHER|Laboratory Biomarker Analysis|Correlative studies
223706314|NCT01787331|OTHER|Pharmacological Study|Correlative studies
223706315|NCT01186536|DIETARY_SUPPLEMENT|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
223706316|NCT01186536|DIETARY_SUPPLEMENT|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
223706317|NCT01186536|DIETARY_SUPPLEMENT|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
223706318|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL) admixed with 0.47µg of recombinant double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT) adjuvant.
223706319|NCT05327426|BIOLOGICAL|Intradermal fractional dose inactivated polio vaccine (fIPV)|Sanofi's licensed IPOL trivalent inactivated polio vaccine (NDC 49281-860-78) delivered at the dose-sparing fractional volume of 1/5 the full dose (0.1mL).
223706320|NCT05327426|BIOLOGICAL|Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain|Monovalent oral polio vaccine (OPV) challenge administered as a test of mucosal immunity.
223706321|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
223706322|NCT01689103|BEHAVIORAL|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
223706323|NCT00354861|BIOLOGICAL|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
223706324|NCT00354861|BIOLOGICAL|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
223706325|NCT00354861|BIOLOGICAL|Engerix B|20 µg hepatitis B antigen absorbed on alum
223706326|NCT00667875|DRUG|Placebo|placebo
223706327|NCT00667875|DRUG|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
223706328|NCT00667875|DRUG|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
223706329|NCT02426944|DRUG|NOAC|Medical arm, patients will be treated by NOAC.
223706330|NCT02426944|DEVICE|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
223706331|NCT05577780|PROCEDURE|internal fixation|Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
223706332|NCT04789083|OTHER|Propholis extrate|Plassebo
223706333|NCT00450255|BIOLOGICAL|ziv-aflibercept|Given IV
223706334|NCT00450255|OTHER|pharmacological study|Correlative studies
223706335|NCT03247751|DEVICE|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
223706336|NCT01613534|DRUG|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
223706337|NCT01613534|DRUG|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
223706338|NCT02231008|DRUG|tasimelteon|
223706339|NCT02231008|DRUG|placebo|
223706340|NCT02530359|DRUG|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
223706341|NCT02530359|DRUG|Placebo equivalent|Placebo equivalent per mouth
223706342|NCT01696071|DRUG|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
223706343|NCT01696071|DRUG|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
223706344|NCT03709446|DRUG|Leflunomide|Single agent leflunomide
223706345|NCT01275820|DIETARY_SUPPLEMENT|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
223706346|NCT02183142|DRUG|Mobic, China, 7.5 mg|
223706347|NCT02183142|DRUG|Mobic, Germany, 7.5 mg|
223706348|NCT03685695|OTHER|Laboratory Biomarker Analysis|Correlative studies
223706349|NCT03685695|DEVICE|Monitoring Device|Wear Fitbit Charge 2
223706350|NCT03685695|OTHER|Physical Activity|Complete aimed walking steps
223706351|NCT03685695|OTHER|Quality-of-Life Assessment|Ancillary studies
223706352|NCT03685695|OTHER|Questionnaire Administration|Ancillary studies
223706353|NCT02587793|OTHER|not interventional study|
223706354|NCT02255903|OTHER|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
223706355|NCT02972671|DEVICE|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
223706356|NCT02972671|DEVICE|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
223706357|NCT01163331|OTHER|Singing Therapy|Singing therapy as a way to improve voice quality
223706358|NCT00670150|DRUG|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
223706359|NCT00670150|DRUG|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
223706360|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung impedence|the changes of end expiratory lung impedence measured by EIT
223706361|NCT05585060|DIAGNOSTIC_TEST|the changes of end expiratory lung volume|the changes of end expiratory lung volume measured by apnea method
223706362|NCT04993820|BEHAVIORAL|Physical activity|The goal for week one will be to increase moderate-to-vigorous PA (MVPA) by 90 weekly/mins, and by 120 weekly/mins on week two. This amount of time will provide the participant with an adaptation period. The goal for weeks 3-12 will be to increase MVPA by at least 150 weekly/mins. The prescribed aerobic activities can be performed either: 1) outdoors (e.g., walking or cycling), 2) at home (e.g., in-place jogging, dancing, aerobics), or 3) with available exercise equipment if the participant already has this access. Participants will perform a series of 6 to 8 muscle strengthening (MS) exercises for the major muscle groups using elastic bands and their own bodyweight 3 times per week. All MS activities will be depicted in instructional videos available through the app. Participants will be asked to perform 2 sets of 8 to 12 repetitions (reps) per exercise during weeks 1-3, 3 sets of 8 to 12 reps per exercise during weeks 3-7, and 4 sets of 8 to 12 reps per exercise during weeks 8-12.
223706363|NCT04993820|BEHAVIORAL|Education control|Participants in the education CON group will be asked to perform their usual activities and to not engage in additional PA during the intervention. Participants will receive weekly brochures and reading materials including topics related to living with HIV, healthy eating, stress management, and current Federal PA guidelines for Americans. The brochures and reading materials will be available through the BluejayEngage health web-based platform app.
223706364|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract) 1500 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
223706365|NCT05711784|OTHER|Phaseolean (White Kidney Bean Standardized Extract)3000 mg Capsules|"Mode of Usage: 2 capsules each time before 3 daily meals for consecutive 45 days.~Route of Administration: Oral Administration with a glassful (approx. 250 mL) of water."
223706366|NCT05711784|OTHER|Placebo (Resistant Dextrin) Capsules|Resistant dextrin is a soluble fiber, derived from wheat or corn starch and is prepared by highly controlled partial hydrolysis and repolymerization of the dextrinization process
223706367|NCT04960514|DIAGNOSTIC_TEST|KidneyIntelX|KidneyIntelX is a blood-based clinical diagnostic tool that assesses the risk of progressive kidney function decline in chronic kidney disease patients with type 2 diabetes.
223706368|NCT04482257|DRUG|Irinotecan Liposome Injection combined with 5-FU/LV|Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
223706369|NCT01721993|DRUG|T121|
223706370|NCT01721993|DRUG|Zoledronic acid|
223706371|NCT03966144|DEVICE|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
223706372|NCT05678777|DEVICE|Galvanic Skin Response|The probe will be attached to the patient's finger and the Galvanic Skin Response will be measured
223706373|NCT01769807|DEVICE|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
223706374|NCT05510440|DIETARY_SUPPLEMENT|Alpha-amino acid derivatives|Alpha-amino acid derivatives mainly citrulline will be used as a supplement to reduce kidneys and other internal organs damage
223706375|NCT04721171|DEVICE|The Bridge device|he Bridge device is a non-invasive percutaneous electrical nerve field stimulation (PENFS) applied to the external ear. The Bridge device delivers low voltage (3.2), continuous stimulation for 5 days (around the clock) in alternating frequencies (1-10Hz) with an impulse interval of 100ms/2 sec. This is placed on the ear as per standard protocol at the beginning of the study and removed by the patient after 5 days.
223706376|NCT05747430|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
223706377|NCT05747430|DRUG|Providone-Iodine|5% Providone-Iodine
223706378|NCT03233607|PROCEDURE|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
223706379|NCT06505564|BEHAVIORAL|AVATAR therapy|In the initial phase of treatment, patients collaborate with therapists to visualize the source of their auditory hallucinations. Therapists adjust their voice to match the hallucinations, prompting patients to recall key statements for future sessions. Subsequent sessions involve dialogues with a computerized avatar. Using the altered voice, therapists interact in real-time through the avatar, engaging patients in role-playing. They alternate between the avatar and supportive therapist roles to empower patients with positive affirmations and discussions. Sessions last approximately 50 minutes, utilizing Oculus Rift VR headsets and noise-cancelling headphones to enhance immersion. HEKA VR software adjusts avatar proximity, and patients have the option to record dialogues for home use and sharing. Therapists receive bi-weekly supervision from HEKA VR-trained colleagues. Participants continue their regular medication prescribed by their psychiatrists alongside this experimental therapy
223706380|NCT02138682|DRUG|l-123 Ioflupane|5 millicuries of Ioflupane
224275973|NCT02151149|DRUG|Carboplatin|
223706381|NCT06004362|BEHAVIORAL|Complementary and Integrative Medicine online intervention, routine care and book|"The online program takes place in a multiprofessionally guided online group setting once a week for up to 180 minutes (including several breaks) over a period of 10 weeks:~* Basic principles of a plant-based whole-food nutrition~* Procedures of hydrotherapy according to Kneipp~* Self-help strategies (e.g. teas, wraps, compresses etc.)~* Methods of mind-body medicine (mindfulness, meditation, breathing, yoga etc.)~* Methods of extended Complementary and Integrative Medicine (e.g. acupressure)~It is recommended to practice a part of the taught exercises at home for about 30 minutes daily. In addition, the patients receive a book for the treatment of post-covid syndrome complaints. Group 1 additionally uses the already existing routine care (e.g. general practitioner)."
223706382|NCT06004362|BEHAVIORAL|Routine care and book|Participants in the second study arm receive routine care, e.g. from their general practitioner. In addition, the patients receive the same book as group 1 for the treatment of post-covid syndrome complaints. The participants of the second study arm will be offered to participate in the Complementary and Integrative Medicine online intervention after 4 months within the study.
223706383|NCT01457144|DRUG|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
223706384|NCT05121896|DEVICE|MRI Scan|7.0 tesla functional MRI scan
223706385|NCT00142298|DRUG|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
223706386|NCT02996513|OTHER|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
223706387|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
223706388|NCT00608816|DRUG|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
223706389|NCT00300274|DRUG|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
223706390|NCT00300274|DRUG|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
223706391|NCT00300274|DRUG|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
223706392|NCT00300274|DRUG|corticosteroids|Corticosteroids standard dose.
223706393|NCT06252636|OTHER|A2 Milk|Cow's milk that contains only A2 β-Casein.
223706394|NCT06252636|OTHER|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein.
223706395|NCT03439787|DRUG|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
223706396|NCT03439787|OTHER|Sodium Chloride 0.9 %|10 ml
223706397|NCT06668194|DEVICE|Light Force (150g Niti Coil)|Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (150g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
223706398|NCT06668194|DEVICE|Heavy Force (400 g Niti coil)|Patients' participation in the study (T0) will be started at the stage of canine retraction. At this appointment, 0.019 x 0.025-inch stainless steel archwire will be placed; power arms will be fabricated from 17x25-inch stainless steel on the maxillary first molars and canines. The height of the power arm will be matched with the center of resistance of both canines and molars based on the root length measured on the periapical radiographs. The archwire will be engaged in the canine bracket using stainless steel ligature wire. NiTi coil spring calibrated for force magnitude (400g) at oral temperature will be used to deliver the assigned force will be engaged from the first molars to the canine power arms
223706399|NCT05764408|DEVICE|traxi® Panniculus Retractor|traxi® Panniculus Retractor is a disposable adhesive medical device designed for surgical patients with a BMI of at least 30kg/m2, to retract a pannus cephalad and expose the lower abdomen. The device is like a large sticker or bandage, posing no more than minimal risk to participants. The adhesive will be applied to the abdomen according to manufacturer instructions, just prior to a participant's scheduled ultrasound. Once the ultrasound exam has ended, the adhesive will be immediately removed and discarded.
223706400|NCT07000721|DIAGNOSTIC_TEST|Preoperative navigation path planning using the SARS-pro navigation system|The SARS-pro navigation system was used for preoperative navigation path planning for tracheoscopic biopsies in the new navigation system group (patients with suspected lung cancer).
223706401|NCT07000721|DIAGNOSTIC_TEST|Preoperative navigation path planning using the VBN navigation system|The VBN navigation system was used for preoperative navigation path planning for tracheoscopic biopsies in the old navigation system group (patients with suspected lung cancer).
223706402|NCT07011511|DRUG|MMV055 Dose 1|40mg
223706403|NCT07011511|DRUG|MMV055 Dose 2|100mg
223706404|NCT07011511|DRUG|MMV055 Dose 3|200mg
223706405|NCT07011511|DRUG|MMV055 Dose 4|400mg
223706406|NCT07011511|DRUG|MMV055 Dose 5|800mg
223706407|NCT07011511|DRUG|MMV055 Dose 6|TBCmg
223706408|NCT07011511|DRUG|Matching placebo Part A|Part A
223706409|NCT07011511|DRUG|Matching placebo Part B|Part B
223706410|NCT07011511|COMBINATION_PRODUCT|MMV055/MMV371 Combo 1|Combination 1
223706411|NCT07011511|COMBINATION_PRODUCT|MMV055/MM371 Combo 2|Combination 2
223706412|NCT07011511|COMBINATION_PRODUCT|MMV055/MMV371 Combo 3|Combination 3
223706413|NCT06680531|DRUG|YZJ-1139 tablets|YZJ-1139 tablets are administered orally single dose
223706414|NCT06680531|DRUG|Escitalopram oxalate tablets|•oral tablet, QD
223706415|NCT06680531|DRUG|YZJ-1139 simulated tablets|oral tablet, QD
223706416|NCT06681285|DRUG|Cadonilimab ;Anlotinib|Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
223706417|NCT06680570|DIAGNOSTIC_TEST|Pulmonary Function Testing, Carbon Monoxide (CO) Breath Testing|"Pulmonary Function Testing FEV1 and FVC spirometry tests used to measure lung capacity among both smoker and non-smoker students.~Carbon Monoxide (CO) Breath Testing Measurements taken using a CO breath analyzer to assess CO levels in the smoker group.~Physical Activity Assessment (IPAQ-SF) The International Physical Activity Questionnaire Short Form (IPAQ-SF) used to evaluate physical activity levels and sedentary behavior among students.~Headache Impact Test (HIT-6) HIT-6 questionnaire used to assess the impact of headaches on daily life."
223706418|NCT05351905|DRUG|CBD oil ( MPL-001)|MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
223706419|NCT05351905|DRUG|CDB+THC oil (MPL-005)|MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
223706420|NCT05351905|DRUG|Placebo oil|The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
223706421|NCT06680739|DRUG|Durvalumab|Durvalumab 1500 mg IV every 4 weeks
223706422|NCT06680739|DRUG|Tremelimumab|Tremelimumab 300 mg IV as a single dose
223706423|NCT06251544|GENETIC|HTR2 T Cells|"Arm A -- Two dose levels will be evaluated:~Dose level One: 1.00E+06~Dose level Two: 1.00E+07"
223706424|NCT06251544|GENETIC|HTR2 T Cells|"Arm B -- Two dose levels will be evaluated:~Dose level Two: 1.00E+07~Dose Level Three: 1.00E+08"
223706425|NCT06681337|BIOLOGICAL|BCMA CART + CD19 CART|BCMA CART + CD19 CART
223706426|NCT06681025|DIAGNOSTIC_TEST|NeuMoDx EBV Quant 2.0 Assay|The NeuMoDx™ EBV Quant Assay 2.0 is an automated in vitro nucleic acid amplification test for the quantification of Epstein-Barr virus (EBV) DNA in EDTA plasma from immunocompromised transplant patients. Transplant patients are screened for EBV viral load as part of their standard of care. The remaining samples from these in vitro diagnostic nucleic acid amplification tests (NAAT) will be analyzed using the NeuMoDx EBV Quant Assay 2.0 to quantify EBV DNA in EDTA plasma. That result will be compared to a comparator in vitro diagnostic assay to evaluate the performance of the NeuMoDx EBV Quant 2.0 assay.
223706427|NCT06710587|BEHAVIORAL|Voy Program|Voy Program - coaching and access to the Voy app to support behavioural changes
223706428|NCT06708442|BEHAVIORAL|School-based CBT intervention|School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.
223706429|NCT06708442|BEHAVIORAL|Guided Narrative Technique (GNT) Writing|Guided Narrative Technique (GNT) Writing : GNT writing is an intervention through writing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Writing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
223706430|NCT06708442|BEHAVIORAL|Guided Narrative Technique (GNT) drawing|Guided Narrative Technique (GNT) Drawing: GNT drawing is an intervention through drawing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Drawing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
223706431|NCT06710041|DEVICE|Kinesiotape|Kinesiotape, when applied with a specific method and tension, significantly reduces the pressure on the median nerve by extending the transverse carpal ligament. It regulates edema under the skin and improves lymphatic and blood circulation. It reduces muscle spasms, eases the movement of tendons and fascia, and reduces pain through neurological suppression
223706432|NCT06710041|OTHER|Exercise|Tendon and nerve gliding exercise
224275974|NCT05805527|DIAGNOSTIC_TEST|mobile health application named KANOPEE|Volunteers will undergo two clinical interviews, an in person clinician-led interview and a fully-automated interview administered via mobile phone
223706433|NCT06710041|DEVICE|sham taping|In the sham taping group, kinesiotape was applied with two I bands without stretching and without having the proper position. This group was considered as the placebo group.
223893734|NCT05945212|OTHER|10 meters Walk Test|Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.
223893735|NCT05945212|OTHER|2 Minute Walk Test (2MWT)|Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.
224275975|NCT01181830|DRUG|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
224275976|NCT01181830|DRUG|placebo|administration of 8.1 mmol bid of placebo
224275977|NCT04647825|OTHER|Collection of data from non-invasive epilepsy monitoring|Creation of a large long-term EEG database for seizure detection/prediction
224275978|NCT01196949|OTHER|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
223706434|NCT06708078|OTHER|Follow-up according to the Canhope allied health support program|"The Canhope allied health support program consists in:~* providing information tailored to patients' needs, with a dedicated time for patients to ask questions, obtain answers tailored to their needs, and be aware of the resources available to them;~* organizing peer-patient focus groups.~And aims at:~* reducing anxiety and improving patients' quality of life;~* better taking into account the impact of the announcement of intracranial Aneurysm, and to provide them with specific support.~* managing the emotional consequences of the announcement and the uncertainty of living with an intracranial Aneurysm."
223706435|NCT06708728|OTHER|blood samples|blood samples for CBC parameters , peripheral blood smear, bilirubin levels and kidney function tests
223706436|NCT06707571|PROCEDURE|spinal anesthesia|spinal anesthesia after us-assisted technique
223706437|NCT06707571|PROCEDURE|spinal anesthesia|spinal anesthesia using the surface landmark-guided
223706438|NCT07041268|BIOLOGICAL|rituximab|"Rituximab will be administered intravenously in three courses. The 1st course (loading dose) will include six rituximab infusions on days 1, 3, 5, 8, 14, and 21 of the study. On days 1, 3, and 5 rituximab will be infused at doses of 50, 125, and 200 mg per m2 of the participant's body surface area, respectively. On days 8, 14, and 21 rituximab will be infused at doses of 375 mg/m2, but not more than 500 mg total dose.~The 2nd course (maintenance therapy) will include four rituximab infusions on days 63, 70, 77, and 85 at doses of 375 mg/m2, but not more than 500 mg total dose.~The 3rd course (maintenance therapy) will include four rituximab infusions on days 119, 126, 134, and 140 at doses of 375 mg/m2, but not more than 500 mg total dose"
223706439|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with hypertension|Colorectal cancer patients with hypertension
223706440|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with diabetes|Colorectal cancer patients with diabetes
223706441|NCT06710314|DIAGNOSTIC_TEST|Colorectal cancer patients with fatty liver|Colorectal cancer patients with fatty liver
223706442|NCT06708806|PROCEDURE|cataract surgery|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation of a monofocal IOL (XY1) vs. an toric IOL (XY1A)
223706443|NCT06707415|DIAGNOSTIC_TEST|Auditory evoked potentials|Auditory evoked potentials in parallel systems
223706444|NCT06709170|DEVICE|Novel asymmetrical linear stapler|Novel asymmetrical linear stapler
223706445|NCT06709170|DEVICE|Signia™|Signia™
223706446|NCT06707714|DIAGNOSTIC_TEST|hypertension|Gastric cancer patients with hypertension
223706447|NCT06707714|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
223706448|NCT06707714|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver
223706449|NCT07045233|DEVICE|Sentinel® Cerebral Protection System|Deploy a Sentinel cerebral protection device during TAVR for patient with aortic stenosis.
223706450|NCT07045233|DIAGNOSTIC_TEST|MRI|Patients receive head MRI before and after the surgery in order to determine the stroke incidence.
223706451|NCT07054073|OTHER|None - observational study|None - observational study
223706452|NCT07054814|DEVICE|samsung gear VR google|"do some of games based VR exercise Headmaster 3.0 Dream Match Tennis Beat Saber (PSVR) Knockout League Hoops Richie's Plank Experience Pong It VR Egg Time VR Sparc VR plus accelerated functional rehab protocol~General Principles:~Goal: Promote tendon healing while minimizing stiffness, muscle atrophy, and encouraging a faster return to full function.~Approach: Early controlled mobilization, gradual loading based on patient tolerance (without excessive pain or swelling).~Important: Supervised by an orthopedic surgeon and a physical therapist. Device: Start with a walker boot or splint keeping the ankle plantarflexed.~Phases of Rehabilitation:"
223706453|NCT07054814|OTHER|Traditional theraapy|"General Principles: accelerated functional rehab protocol Goal: Promote tendon healing while minimizing stiffness, muscle atrophy, and encouraging a faster return to full function.~Approach: Early controlled mobilization, gradual loading based on patient tolerance (without excessive pain or swelling).~Important: Supervised by an orthopedic surgeon and a physical therapist. Device: Start with a walker boot or splint keeping the ankle plantarflexed.~Phases of Rehabilitation:"
223706454|NCT07055243|DRUG|Mitapivat|Mitapivat will be given to adult patients with erythrocyte membranopathies
223706455|NCT07053501|DEVICE|Urinary Catheter Carrying Bag Use|A wearable catheter carrying bag was provided to participants. It was designed to conceal the urine bag and increase comfort, privacy, and psychosocial well-being. Participants received training on its use and wore it during all daily activities for 21 days.
223706456|NCT07053267|DIETARY_SUPPLEMENT|Funrional Ice Cream|Single 100 g serving of ice cream enriched with 10 g of Cimarrón bean extrudate, administered after an overnight fast to evaluate postprandial metabolic responses.
223706457|NCT07053267|DIETARY_SUPPLEMENT|Placebo Ice Cream|Single 100 g serving of placebo ice cream identical in flavor, texture, and appearance, but without Cimarrón bean extrudate, administered after an overnight fast to evaluate postprandial metabolic responses.
223706458|NCT07053514|BEHAVIORAL|SD-ART|SD-ART protocol for PWH with both patients and their HIV clinicians
223706459|NCT01869881|DRUG|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
223706460|NCT01869881|DRUG|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
223706461|NCT03989414|DRUG|CC-92480|Specified dose on specified days
223706462|NCT03989414|DRUG|Bortezomib|Specified dose on specified days
224275979|NCT01196949|OTHER|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
223706463|NCT03989414|DRUG|Dexamethasone|Specified dose on specified days
223706464|NCT03989414|DRUG|Daratumumab|Specified dose on specified days
223706465|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
223706466|NCT03989414|DRUG|Elotuzumab|Specified dose on specified days
223706467|NCT03989414|DRUG|Isatuximab|Specified dose on specified days
223706468|NCT03989414|DRUG|Carfilzomib|Specified dose on specified days
223706469|NCT06227546|DRUG|MGC018|Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle
223706470|NCT06495021|PROCEDURE|Lymphatic Pump Osteopathic Manipulative Therapy|OMT is a series of manual pressure and physical stimulation among various parts of the body to stimulate fluid movement and immune response in patients with various symptoms and disease. This may help with conditions such as edema, clearance of infections, facilitate healing and circulation, and bolster the immune response. Specifically, the lymphatic pump type of OMT targets the head, neck, thoracic region, lumbar and sacral regions, pelvis, arms, legs, and abdomen.
223706471|NCT06934772|OTHER|M-TAPA|this study will be compare the analgesic efficacy of bilateral subcostal transversus abdominis plane (TAP) and modified thoracoabdominal (M-TAPA) blocks in reducing intraoperative opioid consumption and postoperative analgesic needs in patients undergoing laparoscopic sleeve gastrectomy (LSG).
223706472|NCT06934772|OTHER|Subcostal TAP|this study will be compare the analgesic efficacy of bilateral subcostal transversus abdominis plane (TAP) and modified thoracoabdominal (M-TAPA) blocks in reducing intraoperative opioid consumption and postoperative analgesic needs in patients undergoing laparoscopic sleeve gastrectomy (LSG).
223706473|NCT03969511|PROCEDURE|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
223706474|NCT03969511|PROCEDURE|standard management|Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
223706475|NCT05147428|OTHER|Educational Materials|Educational materials on inappropriate prescribing and deprescribing.
223706476|NCT00060515|DRUG|RG2133 (2',3',5'-tri-O-acetyluridine)|
223706477|NCT02204397|DRUG|INGAP Peptide, Ustekinumab|
223706478|NCT05241912|DRUG|Dobutamine|administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
223706479|NCT01367002|DRUG|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
223706480|NCT01367002|DRUG|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
223706481|NCT02655640|OTHER|Questionnaires|Questionnaires will be provided to patients
223706482|NCT00730145|DRUG|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
223706483|NCT02428270|DRUG|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
223706484|NCT02428270|DRUG|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
223706485|NCT01542320|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
223706486|NCT01542320|OTHER|Placebo|Solution without active Lactobacillus reuteri
223706487|NCT02468674|DRUG|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Patients enrolled prior to the protocol amendment 1 (Population I ), who received bimagrumab in the core study, entered the extension study at Week 25 and were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. Study medication was administered as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
223706488|NCT02468674|DRUG|Placebo|"Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45."
223706489|NCT02145780|DIETARY_SUPPLEMENT|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
223706490|NCT02145780|DIETARY_SUPPLEMENT|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
223706491|NCT00956020|BIOLOGICAL|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
223706492|NCT00666172|BEHAVIORAL|Exercise|
223706493|NCT00666172|BEHAVIORAL|Weight Loss|
223706494|NCT03717818|BEHAVIORAL|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
223706495|NCT03717818|BEHAVIORAL|treatment as usual|non-specific intervention
223706496|NCT01171430|DEVICE|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~* 1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~* 1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~* 1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
223706497|NCT05607615|DRUG|Hydroxypropyl Beta Cyclodextrin|Minimum active dose of 500 mg/kg (equivalent to 18,500 mg/m2) as an intravenous (IV) infusion once every 28 days
223706498|NCT05607615|DRUG|Placebo|0.5N saline as an intravenous (IV) infusion once every 28 days
223706499|NCT01259128|DRUG|SER120 Nasal Spray 500 ng/day|SER120 Level 1
223706500|NCT01259128|DRUG|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
223706501|NCT03190590|PROCEDURE|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
223706502|NCT03190590|PROCEDURE|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry \[this is not repetitive TMS and so does NOT modulate brain excitability
223706503|NCT03190590|PROCEDURE|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
223706504|NCT02846584|BIOLOGICAL|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
223706505|NCT01948297|DRUG|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
223706506|NCT03625622|DRUG|AR1001|AR1001 Active Oral Tablet
223706507|NCT03625622|DRUG|Placebo|Placebo Oral Tablet
223706508|NCT01492985|BIOLOGICAL|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
223706509|NCT01492985|BIOLOGICAL|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
223706510|NCT04021771|OTHER|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
223706511|NCT00763620|DEVICE|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
223706512|NCT01090271|DEVICE|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
223706513|NCT03689530|BEHAVIORAL|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes.~The 95 peer supporters who consented to participate in the study are included in this arm, along with the participants who were randomized to this arm, in the participant flow. The peer supporters were not randomized to the arm; rather, they consented to deliver the intervention. Although 95 consented, only 68 met with at least one peer, the first step in intervention delivery."
223706514|NCT03689530|BEHAVIORAL|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
223706515|NCT06467968|OTHER|Cardiac ECG-gated PET imaging will added|Blood sample will be used to measure troponin, BNP and CRP . After 68Ga-DOTATOC PET/CT whole body recording, a cardiac ECG-gated PET imaging will added
223706516|NCT02821169|DRUG|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
223706517|NCT02821169|DRUG|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
223706518|NCT04702061|OTHER|Erector spina plane block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be directed between the erector spina muscle and the transverse process of the T4 vertebra using the in-plane technique. The location of the needle will be confirmed by hydrodissection with saline after touching the transverse process. After the plan open, 5 ml of 2% lidocaine, 10 ml of 0.5% bupivacaine and 10 ml of saline, including hydrodissection, will be given in a total amount of 25 ml. Then a 20-G epidural catheter will be inserted 3-4 cm and fixed.
223706519|NCT04702061|OTHER|Thoracic epidural block before general anaesthesia|After skin infiltration with 2 ml of 2% lidocaine, an 18 G tuohy needle will be entered through the T4-5 interspinous space (median or paramedian approach). After reaching the thoracic epidural area by loss of resistance method, the epidural catheter will be advanced and fixed to remain 3-4 cm in the epidural area. Following the test dose (2 ml of 2% lidocaine), 3 ml of 2% lidocaine, 5 ml of 0.5% bupivacaine and 5 ml of saline will be administered intermittently in a total volume of 15 ml.
223706520|NCT04144660|DEVICE|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
223706521|NCT02408627|DEVICE|EEG|
223706522|NCT03539471|DIAGNOSTIC_TEST|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
223706523|NCT04194580|BEHAVIORAL|Phisical activity intervention|The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
223706524|NCT06557083|BEHAVIORAL|Polyvagal Breathing Exercises|Breathing exercises provided include, square breathing, modified Qigong breathing, and three step breathing
223706525|NCT06557083|OTHER|No Intervention|The control group will not perform any intervention.
223706526|NCT02154776|DRUG|LEE011|3 weeks on and 1 week off
223706527|NCT02154776|DRUG|Buparlisib|daily
223706528|NCT02154776|DRUG|Letrozole|2.5 mg daily;
223706529|NCT02530060|DRUG|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
223706530|NCT00217061|DEVICE|Decision Aid Statin Choice|
223706531|NCT03109249|DRUG|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
223706532|NCT03109249|DRUG|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
223706533|NCT01501175|OTHER|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
223706534|NCT01991769|BEHAVIORAL|47 min moderate intensity training|
223706535|NCT01991769|BEHAVIORAL|exercise healthy volunteers|
223706536|NCT01991769|BEHAVIORAL|control; no exercise training|
223706537|NCT00989560|PROCEDURE|endoscopy|patients receive best treatment and care with an additional endoscopy
223706538|NCT04177667|DIETARY_SUPPLEMENT|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
223706539|NCT04177667|OTHER|Placebo|Treatment with placebo for Placebo Arm
223706540|NCT02208479|OTHER|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
223706541|NCT01747044|DRUG|Milnacipran|100mg/day
223706542|NCT01747044|DRUG|Placebo|
223706543|NCT01325961|RADIATION|Intensity-Modulated Radiation Therapy|
223706544|NCT05120778|BEHAVIORAL|exercise training|as appear in arm description.
223706545|NCT05120778|OTHER|conventional medical treatment|participants will maintain habitual medical treatment prescribed by primary care and specialized physicians from the public health service.
223706546|NCT00955071|OTHER|Exercise: LVLI|low volume, low intensity
223706547|NCT00955071|OTHER|Exercise: HVLI|high volume, low intensity
223706548|NCT00955071|OTHER|Exercise: LVHI|low volume, high intensity
223706549|NCT03479970|OTHER|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
223706550|NCT03479970|OTHER|GNPT|It's a computeritzed program of cognitive telerehabilitation
223706551|NCT02304679|OTHER|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~* Validate the patient's inclusion and exclusion criteria;~* Obtain informed consent from the patient;~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Prescribe 1 month of PDE5i treatment.~* The next visit will be scheduled"
223706552|NCT02304679|DRUG|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
223706553|NCT02304679|OTHER|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~* The next visit will be scheduled"
223706554|NCT02304679|OTHER|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~* Verify inclusion and exclusion criteria, and proceed with final inclusion~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* Randomize the patient at the end of the visit~* The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
223706555|NCT02304679|DEVICE|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
223706556|NCT02304679|DEVICE|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
223706557|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
223706558|NCT02304679|OTHER|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
223706559|NCT02304679|DEVICE|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
223706560|NCT02304679|OTHER|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
223706561|NCT02304679|OTHER|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
223893736|NCT05945212|OTHER|Fugl-Meyer (FMA-LE)|The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34
223706562|NCT02304679|OTHER|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
223706563|NCT05305820|BEHAVIORAL|Exercise|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing treatment and for a six-week period when deemed fit post-surgery.
223706564|NCT05305820|BEHAVIORAL|Nutrition|Participants will be screened for their nutritional health and tailored advice and education will be provided on an individualised basis. An online dietary recall tool will be used to track patients' dietary habits. This will occur from diagnosis until point of surgery and recommence for 6 weeks post-surgery once deemed physically fit.
223706565|NCT04524897|DRUG|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children|Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation
223706566|NCT01582165|DRUG|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
223706567|NCT01582165|DRUG|Placebo.|Placebo once daily vs rosuvastatin for 6 months
223706568|NCT00569881|DRUG|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
223706569|NCT03986398|OTHER|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
223706570|NCT00814970|DEVICE|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
223706571|NCT05754931|OTHER|Deep neck flexors training + Conventional therapy|Hold for 10 sec and repeated 10 times.Patients will be treated 3 times a week for 4 consecutive weeks
223706572|NCT05754931|OTHER|Muscles energy techniques + conventional therapy|position of patient is in maximal comfort and lengthening After engaging the barrier use of an isometric contraction Feel the release and lengthen the muscle repeated for 4 time per session Patients will be treated 3 times a week for 4 consecutive weeks
223706573|NCT00222443|DRUG|Irinotecan|
223706574|NCT02826902|DRUG|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
223706575|NCT02826902|DRUG|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
223706576|NCT02671175|DRUG|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
223706577|NCT02671175|DRUG|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
223706578|NCT04694742|OTHER|data collecting|"Within 24h from ICU admission, the ventilatory efficiency will be assessed by the following Ventilatory Ratio equation:~Ventilatory Ratio = \[minute ventilation (ml/min) × PaCO2 (mm Hg)\]/(predicted body weight × 100 × 37.5).~Where PaCO2 is the partial pressure of carbon dioxide in mmHg in the arterial blood.~Tha quasi-static compliance will be calculated according to the equation:~C=Tidal Volume/(Paw plateau - PEEP total)~where Paw plateau is the airway pressure measured during 4 seconds of inspiratory pause, PEEP total is the airway pressure measured during 4 seconds of expiratory pause.~In the same time frame, complete blood count, d-dimer, sequential organ failure assessment score, blood gas analysis, haemodynamic and ventilatory parameters will be collected."
223706579|NCT01402414|RADIATION|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
223706580|NCT01402414|RADIATION|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
223706581|NCT01402414|RADIATION|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
223706582|NCT05455697|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223706583|NCT05455697|DRUG|Cyclophosphamide|Given IV
223706584|NCT05455697|DRUG|Doxorubicin|Given IV
223706585|NCT05455697|DRUG|Prednisone|Given PO
223706586|NCT05455697|BIOLOGICAL|Retifanlimab|Given IV
223706587|NCT05455697|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
223706588|NCT05455697|BIOLOGICAL|Tafasitamab|Given IV
223706589|NCT05455697|DRUG|Vincristine|Given vincristine
223706590|NCT05455697|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223706591|NCT05455697|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223706592|NCT05455697|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT
223706593|NCT05455697|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
223706594|NCT05455697|PROCEDURE|Computed Tomography|Undergo FDG-CT
223706595|NCT05455697|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223706596|NCT05455697|DRUG|Polatuzumab Vedotin|Given IV
223706597|NCT05571917|BEHAVIORAL|Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)|This intervention is an integrated psychosocial treatment of two established treatments for chronic pain and Opioid Use Disorder (OUD). This intervention focuses on reducing pain interference and preventing relapse to opioid misuse.
223706598|NCT05571917|BEHAVIORAL|Enhance Usual Care (EUC)|This intervention consists of psychoeducational materials about chronic pain treatment resources, signs and management of opioid overdose and overdose prevention. This intervention also consists of a brief, remote visit with a study therapist, lasting approximately 15 minutes.
223706599|NCT03494543|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
223706600|NCT05676099|PROCEDURE|Phlebotomy|Participants may elect to submit a blood sample to the Biosample Repository.
223706601|NCT05676099|PROCEDURE|Buccal (cheek) swab|Participants may elect to submit a buccal swab sample to the Biosample Repository.
223706602|NCT05676099|GENETIC|Genetic Testing|Biosamples may be processed and analyzed for genetic variants using whole genome sequencing (WGS) or other sequencing methods. Participants whose samples are processed in this manner may be contacted and provided the option to receive TSC1 or TSC2 genetic variant results by opting in using Consent to Return of Genetic Results Form. Participants will be offered a one-time genetic counseling session to review their results, free of charge. CLIA-certified, TSC1 or TSC2 genetic variant results will be returned to participants who opt in to receive such results. Additionally, negative results and results not able to be clinically certified will also be offered to participants with a one-time genetic counseling session to review their results, free of charge using the Return of Genetic Research Results Template Letter. CSS will be responsible for informing clinic participants that their samples have been sequenced and offer to connect participant to the TSC Alliance for further information.
223706603|NCT05676099|OTHER|Tissue donation after routine clinical procedure|Participants may elect to submit a tissue sample to the Biosample Repository following a medical procedure.
223706604|NCT02405273|PROCEDURE|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
223706605|NCT02405273|PROCEDURE|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
223706606|NCT02202187|DRUG|GSK2140944|Investigational Study Drug
223706607|NCT02202187|OTHER|Placebo|Placebo
223706608|NCT06203171|OTHER|Observational|Routine laboratory parameters requested from patients; Direct lung Radiograph and Electrocardiography results were evaluated and preoperative consultations and recommendations requested from the patients were recorded. Type of anesthesia, operation performed, operation duration, intraoperative blood and fluid losses, intraoperative and postoperative complications that develop within the first 24 hours, additional problems that develop (pain, postoperative nausea and vomiting, hypothermia, change of consciousness, bleeding and unplanned transfer to the intensive care unit). postanesthesia recovery The length of stay in the room, length of hospital stay, and method of discharge were recorded. The effects of preoperative laboratory, imaging methods and required consultations on intraoperative and postoperative complications in the first 24 hours were evaluated.
223706609|NCT03260881|DRUG|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
223706610|NCT03260881|DRUG|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
223706611|NCT06474286|DRUG|Prucalopride 1 MG|The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.
223706612|NCT06079658|BEHAVIORAL|Continuous Caloric Restriction versus Intermittent Caloric Restriction on Fat Loss|This intervention seeks to investigate two different caloric restriction protocol on fat mass.
223706613|NCT04622306|DEVICE|Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B|Condom functionality study to determine failure rates
223706614|NCT01050855|DRUG|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
223706615|NCT01050855|DRUG|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
223706616|NCT01050855|DRUG|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
223706617|NCT00282100|DRUG|Gefetinib (Iressa)|
223706618|NCT00003970|DRUG|irinotecan hydrochloride|Given IV
223706619|NCT00736944|DRUG|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
223706620|NCT00736944|DRUG|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
223706621|NCT00736944|DRUG|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
223706622|NCT00736944|DRUG|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
223706623|NCT00736944|DRUG|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
223706624|NCT00736944|RADIATION|Radiation (Post induction)|Monday-Friday, weeks 1-7
223706625|NCT00736944|DRUG|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
223706626|NCT00736944|DRUG|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
223893737|NCT05945212|OTHER|Modified Ashworth scale|The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4
223893738|NCT05945212|OTHER|ABILOCO questionnaire|The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)
223706627|NCT04521660|DEVICE|Virtual reality glasses|Virtual reality (VR) is a new method that can be used to distract and prepare patients for the procedure during medical procedures. It is an advanced technology that allows the individual to move into a virtual environment and focus his attention on other thoughts to less consideration for pain and anxiety. In this study, VR glasses will be worn on the intervention group just before the procedure begins and patients will continue to wear their glasses until the procedure is completed.
223706628|NCT06487416|DRUG|Tiotropium Bromide Inhalation Powder|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
223706629|NCT06487416|DRUG|Spiriva®Handihaler®|By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
223706630|NCT04085393|DRUG|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
223706631|NCT01601132|DRUG|theophylline|300mg (80mg/15ml elixir)
223706632|NCT01601132|DRUG|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
223706633|NCT01902823|BEHAVIORAL|Services from a Nurse Navigator|Services from a Nurse Navigator
223706634|NCT03629431|PROCEDURE|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
223706635|NCT03629431|PROCEDURE|postoperative standard care|Standard care received postoperatively
223706636|NCT01788488|OTHER|Use of procalcitonin as biomarker to guide therapy|
223706637|NCT04808544|DRUG|Dinalbuphine sebacate|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
223706638|NCT04808544|DRUG|Placebo solution|Benzyl benzoate and sesame oil served as placebo solution (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
223706639|NCT01613300|DRUG|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
223706640|NCT03609879|DEVICE|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
223706641|NCT03609879|DEVICE|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
223706642|NCT03609879|DEVICE|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
223706643|NCT03609879|DEVICE|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
223706644|NCT03609879|DEVICE|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
223706645|NCT04812899|BEHAVIORAL|Parental guided self-help version of FBT-pre-recorded videos and readings from the book|"Each participant will receive a series of pre-recorded videos of parental guided self help version FBT. There will be10 videos of about 10 minutes each. The videos will include content on empowering parents to renourish their child and interrupt binge/purge behaviors. Readings will be assigned to each participant from the book Help Your Teenager Beat and Eating Disorder. There will be psychoeducational content on the dangers and medical complications of eating disorders. The readings will also contain content on coping skills for young people including relaxation, mindfulness strategies, and distress tolerance skills."
223706646|NCT04755790|DEVICE|Point Digit|Patient is fit with Point Digit partial hand prosthetic system
223706647|NCT04036903|RADIATION|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
223706648|NCT01512342|BEHAVIORAL|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
223706649|NCT01512342|BEHAVIORAL|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
223706650|NCT05251766|DRUG|Nab paclitaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
223706651|NCT05251766|DRUG|Docetaxel|To analyze and compare the efficacy and safety of epirubicin + cyclophosphamide (EC) followed by docetaxel and EC followed by nab-paclitaxel in neoadjuvant chemotherapy of breast cancer; To analyze and compare the efficacy and safety of nab-paclitaxel combined with epirubicin + cyclophosphamide (EC) chemotherapy regimen in neoadjuvant therapy of breast cancer, so as to provide a new treatment option for patients with HER2-negative breast cancer.
223706652|NCT03783364|RADIATION|Radiotherapy|Pre- or postoperative acellerated irradition in 5 fractions
223706653|NCT00773656|OTHER|Whole blood sample|70 ml per patient for collection of biological sample
223706654|NCT05164796|DEVICE|IVUS assessment of coronary ostia|"For coronary arteries at high-risk of obstruction during TAVI in native valves or valve-in-valve TAVI:~* IVUS analysis before valve implantation (+ coronary angiogram) to detect any leaflet interference with the coronary ostium, existing prior to the transcatheter heart valve (THV) placement~* IVUS analysis (+ coronary angiogram) after valve implantation in absence of acute coronary occlusion, to assess the patency of the ostium at-risk, the presence of native or degenerated surgical leaflet adjacent to the ostium, and the interaction of THV-frame with the coronary ostium.~* In case of CHIMNEY stenting, re-assessment of the stent expansion and coronary ostia patency with IVUS."
223706655|NCT02040948|DEVICE|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
223706656|NCT01952145|DRUG|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
223706657|NCT01952145|DRUG|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
223706658|NCT01216761|DRUG|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
223706659|NCT01216761|DRUG|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
223706660|NCT01216761|DRUG|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
223706661|NCT04138810|OTHER|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
223706662|NCT04138810|OTHER|Survey|Measure of satisfaction regarding post-op visit.
223525518|NCT05852340|DRUG|Ritlecitinib|"ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)"
223525519|NCT05026801|DRUG|Azithromycin plus hydroxychloroquine|All patients will receive active comparator. One group will receive placebo on D1-3 followed by active comparator D4-9, while the other group will receive active comparator D1-6 followed by placebo D7-9.
223706663|NCT04010058|DEVICE|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
223706664|NCT00985478|DRUG|SLV342|25 mg once daily - Maximal Tolerated Dose
223706665|NCT00985478|DRUG|placebo|matching placebo
223706666|NCT05170984|DEVICE|CACIPLIQ20®|Application of CACIPLIQ20® by spray, directly on the wound surface, after wound cleaning and debridement, twice a week, until wound closure (or up to 20 weeks maximum).
223706667|NCT00153907|DRUG|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
223706668|NCT00153907|DRUG|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
223706669|NCT01869439|DEVICE|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
223706670|NCT01869439|DEVICE|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
223706671|NCT01869439|DEVICE|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
223706672|NCT01869439|DEVICE|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
223706673|NCT01024075|DRUG|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
223706674|NCT01024075|DRUG|Saline|8cc of Saline mixed with Sinufoam
223706675|NCT00242320|DRUG|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
223706676|NCT00242320|DRUG|Placebo|
223706677|NCT05280782|DRUG|Ga-68 Galmydar|Single intravenous injection of the PET radiotracer 68Ga-Galmydar.
223706678|NCT03519620|OTHER|SWWSV|Behaviours to prevent child obesity
223706679|NCT04850521|OTHER|Remote monitoring|patient-facing app + connected spirometer + connected pulse oximeter + clinician view portal
223706680|NCT02589405|DRUG|Benzoyl Peroxide|
223706681|NCT02589405|OTHER|Dermotivin® Soft Liquid cleanser|
223706682|NCT02589405|OTHER|Cetaphil® Dermacontrol Moisturizer SPF30|
223706683|NCT06033612|DRUG|RV299|Oral Suspension
223706684|NCT06033612|DRUG|Placebo|matching placebo
223525520|NCT05694611|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
223706685|NCT06033612|DRUG|Midazolam|pre-filled oral syringe
223706686|NCT04208997|DRUG|Antiarrhythmic drug|Continuation of amiodarone or sotalol.
223706687|NCT02368197|DRUG|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
223706688|NCT02368197|DEVICE|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
223706689|NCT03217630|OTHER|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
223706690|NCT06822452|PROCEDURE|radical prostatectomy|Robot-assisted
223706691|NCT06402071|DIAGNOSTIC_TEST|Ascitic fluid study|Ascitic fluid study will be obtained from all participants
223706692|NCT02688478|OTHER|Phthalate|Delivered by inhalation on day 1 of the triad
223706693|NCT02688478|OTHER|Filtered Air|Delivered by inhalation on day 1 of the triad
223706694|NCT02688478|OTHER|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
223706695|NCT03301805|DRUG|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle."
223706696|NCT04920552|DEVICE|Elastic abdominal binder|"The ABDO-SYNCRO 3-BAHNIG is an elastic abdominal binder with a 3-stripes Velcro fastening, capable of developing a 20 ± 2 mmHg pressure on the abdominal wall. This device will be tested as potentially beneficial with respect to the mentioned primary and secondary outcomes. The investigators anticipate to use this elastic abdominal binder, since participants of a previous trial reported this device to be comfortable enough and to have used it regularly during the open-label follow-up phase. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer (SYNCRO-MED GmbH)."
223706697|NCT04920552|DEVICE|Placebo binder|"Clima Care is a simple body warmer, developing maximal 3±2 mmHg pressure on the abdominal wall. This device will be used as placebo comparator of the present clinical trial. Size will be chosen depending on the abdominal circumference of the participant, according to the size tables provided from the manufacturer."
223706698|NCT04545060|BIOLOGICAL|VIR-7831 (sotrovimab)|VIR-7831 (sotrovimab) given by intravenous infusion (single dose)
223706699|NCT04545060|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
223706700|NCT04526860|OTHER|Calibration of infant breast milk and formula milk intake|We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 2 standard deviations of normal WHO weight standards, in order to prevent infant obesity and subsequent childhood obesity.
223706701|NCT01617200|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
223706702|NCT01617200|DRUG|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
223706703|NCT01617200|DRUG|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
223706704|NCT01617200|DRUG|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
223706705|NCT02509767|DRUG|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
223706706|NCT03515278|PROCEDURE|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
223706707|NCT03515278|PROCEDURE|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
223706708|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
223706709|NCT02546453|BIOLOGICAL|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
223706710|NCT02592122|DRUG|Salbutamol Aerosol|
223706711|NCT02592122|DRUG|No drugs|
223706712|NCT02892123|DRUG|ZW25 (Zanidatamab)|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
223706713|NCT02892123|DRUG|Paclitaxel|Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
223706714|NCT02892123|DRUG|Capecitabine|Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
223706715|NCT02892123|DRUG|Vinorelbine|Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
223706716|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
223706717|NCT02892123|DRUG|Tucatinib|Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
223706718|NCT02638701|DRUG|Infliximab|Please see protocol for details.
223706719|NCT00990405|DRUG|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
223706720|NCT03523234|DRUG|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
223706721|NCT03523234|PROCEDURE|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
223706722|NCT03523234|PROCEDURE|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
223706723|NCT03523234|DRUG|Chemotherapy|etoposide with cisplatin/carboplatin
223706724|NCT00348179|PROCEDURE|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
223706725|NCT03391310|OTHER|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
223706726|NCT04727931|BEHAVIORAL|Neuropsychological assessement and questionnaires|Neuropsychological assessement including memory, working memory, executive function, oral naming and speed processing tests. There are questionnaires to assess mood disorders, anxiety and cognitive reserve.
223706727|NCT01899664|PROCEDURE|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
223706728|NCT02143700|OTHER|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
223706729|NCT05868473|DIAGNOSTIC_TEST|Mobilization With Movement|Mobilization With Movement Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
223706730|NCT05868473|DIAGNOSTIC_TEST|Kinesotaping|Kinesotaping Female Of Knee Osteoarthritis To Improve Pain And Functional Mobility
223706731|NCT03404427|BEHAVIORAL|Normal sleep night|Usual hours of sleep
223706732|NCT03404427|BEHAVIORAL|Sleepless night|Total sleep deprivation the first night
223706733|NCT01481181|DIETARY_SUPPLEMENT|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
223706734|NCT04824976|DIETARY_SUPPLEMENT|Blueberry|freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
223706735|NCT04824976|DIETARY_SUPPLEMENT|Placebo|matched powder maltodextrin twice daily = 60kcal
223706736|NCT02676115|OTHER|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
223706737|NCT02676115|OTHER|Medipore Tape|"* One layer of Medipore tape will be placed across the incision.~* Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
223706738|NCT03082261|DEVICE|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
223706739|NCT01820156|DEVICE|Home Respiratory Polygraphy|
223706740|NCT01820156|DEVICE|Standard Polysomnography|
223706741|NCT00549874|DRUG|Rosiglitazone|oral 8 mg/once daily for 6 months
223706742|NCT00549874|DRUG|Glyburide|20 mg/ once daily for 6 months
223706743|NCT04087304|BEHAVIORAL|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
223706744|NCT00524654|PROCEDURE|HVLA chiropractic manipulation|
223706745|NCT02068027|DRUG|Clonidine Gel 0.1%|
223706746|NCT02068027|DRUG|Placebo|
223706747|NCT01704521|DRUG|PegInterferon|
223706748|NCT01704521|DRUG|Ribavirin|
223706749|NCT01704521|DRUG|Telaprevir|
223706750|NCT05473208|DEVICE|Exoskeleton|Lumbar assistive exoskeleton evaluation
223706751|NCT01032174|DRUG|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
223706752|NCT01032174|DRUG|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
223706753|NCT02173873|DRUG|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
223706754|NCT02651350|DRUG|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
223706755|NCT02651350|DRUG|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
223706756|NCT04558684|DRUG|Chemotherapy|CAPOX (6 cycles): Oxaliplatin(130mg/m2) on day 1 of each cylce and Capecitabine: Dose of 2000mg/m2,14 days, q3w
223706757|NCT04558684|DRUG|Immunotherapy|Camrelizumab (6 cycles): 200mg on day 1 of each cycle, q3w
223706758|NCT04558684|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions)
223706759|NCT01845883|PROCEDURE|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
223706760|NCT06238271|DEVICE|Acriva BB UDM 611|Acriva BB UDM 611 intraocular lens will be implanted into the capsular bag in patients who undergo cataract extraction with phacoemulsification.
223706761|NCT02614651|PROCEDURE|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
223706762|NCT02614651|PROCEDURE|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
223706763|NCT02614651|PROCEDURE|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
223706764|NCT02614651|PROCEDURE|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
223706765|NCT02614651|DEVICE|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
223706766|NCT02623478|DRUG|Insulin Lispro|Administered subcutaneously (SC)
223706767|NCT00702689|DRUG|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m\^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m\^2 oral dose daily (increase to 130 mg/m\^2 daily after 28 days if well tolerated)"
223706768|NCT04645420|PROCEDURE|Global gene expression profiles obtained from synovial biopsies.|Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
223706769|NCT02051842|DRUG|Metadoxine|
223706770|NCT04351854|OTHER|Retrospective data collection|Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.
223706771|NCT01833988|DEVICE|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
223706772|NCT01833988|OTHER|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
223706773|NCT01281137|GENETIC|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
223706774|NCT01281137|OTHER|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
223706775|NCT01281137|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
223706776|NCT01837407|PROCEDURE|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
223706777|NCT04550910|RADIATION|Hypofractionation Schedules for Breast Cancer patients after mastecomy|Two Radiotherapy HypoFractionation Schedules will be applied, after randomization, for female breast cancer patients after mastectomy.
223706778|NCT02932423|OTHER|Control product E|Plain water
223706779|NCT02932423|OTHER|Test product A|Beverage with no sugar but sweetener
223706780|NCT02932423|OTHER|Test product B|Beverage with 22 g/L sugar and sweetener
223706781|NCT02932423|OTHER|Test product C|Beverage with 33 g/L sugar and sweetener
223706782|NCT02932423|OTHER|Test product D|Beverage with 47 g/L sugar and sweetener
223706783|NCT02932423|OTHER|Comparative product F|Beverage with 98 g/L sugar
223706784|NCT03697057|PROCEDURE|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
223706785|NCT03316339|DRUG|Dexmedetomidine|Opioid-free anesthesia
223706786|NCT03316339|DRUG|Remifentanil|Opioid anesthesia
223706787|NCT03388437|DEVICE|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
223706788|NCT03388437|DEVICE|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter \& positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
223706789|NCT03682887|PROCEDURE|Cryoballoon PV isolation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
223706790|NCT03682887|PROCEDURE|Cryoballoon PV isolation with Additional RA linear ablation group|"1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate."
223706791|NCT01581710|DRUG|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
223706792|NCT01581710|DRUG|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
223706793|NCT00853034|DIETARY_SUPPLEMENT|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
223706794|NCT00853034|DIETARY_SUPPLEMENT|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
223706795|NCT00673946|OTHER|True saturation values displayed|Physicians will be presented with real saturations.
223706796|NCT00673946|OTHER|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
223706797|NCT02761733|BEHAVIORAL|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
223706798|NCT00904319|OTHER|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
223706799|NCT01649388|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
223706800|NCT01715935|DRUG|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
223706801|NCT03561116|DIETARY_SUPPLEMENT|XAN|Daily intake of a sachet containing 12 mg of XAN
223706802|NCT03561116|DIETARY_SUPPLEMENT|Placebo|Daily intake of a sachet containing excipient
223706803|NCT01222884|DRUG|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
223706804|NCT01222884|DRUG|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
223706805|NCT02380001|DRUG|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
223706806|NCT02380001|DRUG|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
223706807|NCT01986907|DRUG|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
223706808|NCT00969254|DRUG|Pílulas de Lussen|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo."
223706809|NCT00969254|DRUG|Pyridium®|"Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo."
223706810|NCT02725931|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
223706811|NCT04335032|DRUG|Eicosapentaenoic acid gastro-resistant capsules|same as in arm/group description
223706812|NCT04335032|DRUG|Placebo|same as in arm/group description
223706813|NCT00625794|DRUG|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
223706814|NCT00625794|BEHAVIORAL|Smoking cessation counseling|8 weeks or counseling
223706815|NCT00312182|DRUG|Nelfinavir|
223706816|NCT02149719|OTHER|Desensitisation using boiled peanut|
223706817|NCT02149719|OTHER|Desensitisation using boiled peanut (deferred start)|
223706818|NCT04193358|DIETARY_SUPPLEMENT|FERTILIS HOMME®|L-carnitine 220 mg, Zinc 20 mg, Selenium 0.03 mg, L-arginine 125 mg, L-glutathione 40 mg, Folic acid (vitamin B-9) 0.4 mg, Coenzyme Q10 7.5 mg, and Vitamin E 60 mg
223706819|NCT04193358|OTHER|PLACEBO|Sugar pills
223706820|NCT00003821|DRUG|aminopterin|
223706821|NCT03008226|DEVICE|Implementation of 9 mm intrabronchial valves|
223706822|NCT04052282|DEVICE|Mobile Health App|There is no intervention
223706823|NCT03010670|DRUG|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
223706824|NCT03010670|OTHER|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
223706825|NCT05109845|DIAGNOSTIC_TEST|Spheres & Shield Maze Task|"A VR environment that consists of a maze that the user must solve by moving through space. The movement is done by combining a touchpad with front-facing orientation.~Different hazards will present throughout the maze, with time penalty, energy loss, and certain consequences, such as narrow walkways from which the player can fall (Figure 1) lightning clouds that strike in intervals, flying insects (Figure 2), or locked rooms (Figure 3). The user can also make use of a shield that allows moving through lightning and insects without penalty at the cost of being unable to gather green orbs (Figure 2). When used, the shield requires a recharge time, so it is a limited resource that the player must optimize. Hazards may also be avoided completely by choosing another path through the labyrinth, however completion of the maze requires traversal of a minimum number of hazards."
223706826|NCT05887232|PROCEDURE|Fractional CO2 laser|Patient in group A received FCL treatments four sessions with four weeks apart
223706827|NCT05887232|PROCEDURE|Fractional CO2 with Platelet Rich Plasma|Group B received four PRP and FCL sessions 4 weeks apart
223706828|NCT06319261|PROCEDURE|guided biofilm therapy|Removing plaque and calculus by initially detecting it with a disclosing agent followed by the use of air abrasive powder for the removal of supra and subgingival plaque.
223706829|NCT06319261|PROCEDURE|root surface debridement|Removing plaque and calculus by conventional root surface debridement
223706830|NCT02927782|PROCEDURE|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
223706831|NCT02927782|PROCEDURE|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
223706832|NCT05593471|OTHER|high intensity exercises|resistance training progressively increasing according to specific criteria (10 repetitions maximum). for the major muscles of the body
223706833|NCT05593471|OTHER|low intensity aerobic exercises|low-intensity exercises performed using arm or leg ergometer machines
223706834|NCT00469651|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
223706835|NCT00469651|BIOLOGICAL|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
223706836|NCT00469651|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
223706837|NCT00469651|BIOLOGICAL|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
223706838|NCT00469651|BIOLOGICAL|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
223706839|NCT00263770|DEVICE|soft palate implant|
223706840|NCT00263770|OTHER|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
223706841|NCT05218720|DIAGNOSTIC_TEST|EuroSCORE II|"* Euro score II: Predicts risk of in-hospital mortality after major cardiac surgery. Risk category will be defined as very low risk \<1, low risk 1-2.99, moderate risk 3-4.99, high risk \>5.~* CAM- ICU: The Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is a tool used to assess delirium among patients in the intensive care unit. It is an adaptation of the CAM which was originally developed to allow non-psychiatrists to assess delirium at the bedside. It ranges from 0 to 7, score greater to or equal to 3 will be considered positive for delirium, further categorized as 0-2 no delirium, 3-5 mild delirium 6-7 severe delirium with 7 being most severe."
223706842|NCT05690646|DRUG|Nirmatrelvir/ritonavir|nirmatrelvir 300mg q12h and ritonavir 100 mg q12h for 5 days
223525521|NCT05694611|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
223525522|NCT01955356|PROCEDURE|Scratching|Endometrial biopsy
223525523|NCT01765387|BEHAVIORAL|Spa session|
223525524|NCT02210676|OTHER|PROMIS Upper Extremity|
223525525|NCT02210676|OTHER|Likert Pain Scale|
223525526|NCT02210676|OTHER|Mallet Finger Extensor Lag Measurement|
223525527|NCT06114368|PROCEDURE|Surgery for the treatment of Acute Achilles tendon rupture|Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
223525528|NCT02236013|DRUG|Gilteritinib|Oral
223525529|NCT02236013|DRUG|Idarubicin|lyophilized powder administered intravenously
223525530|NCT02236013|DRUG|Cytarabine|solution administered intravenously
223525531|NCT02236013|DRUG|Daunorubicin|solution administered intravenously
223525532|NCT05363683|PROCEDURE|Squat Biofeedback|The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.
223525533|NCT05363683|PROCEDURE|Standard Care|The intervention group will receive standard care post-operative physical therapy.
223525534|NCT05852470|DEVICE|Clareon Vivity/Vivity Toric Extended Vision IOL|Extended vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
223525535|NCT05852470|DEVICE|Clareon Monofocal/Clareon Toric IOL|Single vision intraocular lens implanted in the capsular bag of the eye during cataract surgery. IOLs are intended for long term use over the lifetime of the cataract patient.
223525536|NCT00417287|DRUG|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
223525537|NCT04665895|DRUG|Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals|twice daily inhalation throughout the study
223525538|NCT04665895|DRUG|FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK|twice daily inhalation throughout the study
223525539|NCT04665895|DRUG|Placebo|twice daily inhalation throughout the study
223525540|NCT02513251|OTHER|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
223525541|NCT06350110|BIOLOGICAL|CD19- BCMA CAR-T cells|"The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
223525542|NCT04212923|BEHAVIORAL|Medical Dashboard based self-management intervention|Before the start of the intervention, chronic kidney disease patients and care providers will receive a face-to-face training session on the use of Medical Dashboard. To avoid contamination, Medical Dashboard will only be made accessible for participants in the intervention group via a secure password-protected registration process.
223525543|NCT00123942|DRUG|MEDI-507|
223525544|NCT02542215|DRUG|Cobiprostone|Cobiprostone 30 mcg oral spray
223525545|NCT02542215|DRUG|Placebo|Matching placebo oral spray
223525546|NCT02542215|DRUG|Standard Care - Chemotherapy|Chemotherapy, as given with radiation as standard care for patients with head and neck cancer.
223525547|NCT02542215|RADIATION|Standard Care - Radiation|Radiation, as given with chemotherapy as standard care for patients with head and neck cancer.
223525548|NCT00403052|DRUG|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
223525549|NCT05881291|DRUG|ciprofol|"induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1."
223525550|NCT05881291|DRUG|propofol|"induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1."
223525551|NCT05951101|DEVICE|Zenith LAA Occlusion System|LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 17 mm and 25 mm
223525552|NCT04261985|BEHAVIORAL|healthy weight behaviors supported by web-based mobile phone application|Chorus is a mobile phone platform that provides texting, a web application, and an online community for mHealth interventions.Content is created using existing templates to insert text, images, pictures, audio, video clips, or any combination of these. Users interface with Chorus by clicking a hyperlink embedded in a text message sent to their phone to then access web-based interactions via prompts and clicks. Content was created in English and Spanish.
223525553|NCT04906512|DEVICE|3M™ Tegaderm™ CHG I.V. Securement Dressing|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
223706843|NCT05690646|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 15mg/kg/day bid for5 days
223706844|NCT01761175|PROCEDURE|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
223706845|NCT01761175|PROCEDURE|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
223706846|NCT02851940|PROCEDURE|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
223706847|NCT02851940|PROCEDURE|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
223706848|NCT03414320|OTHER|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
223706849|NCT04801173|COMBINATION_PRODUCT|Very low calorie ketogenic diet|Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
223706850|NCT04801173|BEHAVIORAL|Low calorie standard diet|Low calorie standard diet with no specified dietary supplement addition
223706851|NCT05501223|OTHER|Medication review|30-60 minutes extra consultation regarding the patients drugs
223706852|NCT05501223|OTHER|Standard care|Standard care i.e. visit at the Dept. of Endocrinology.
223706853|NCT00784641|DEVICE|Novel Bausch & Lomb daily disposable contact lenses|Lenses to be worn and replaced daily for 2 weeks.
223706854|NCT00784641|DEVICE|Bausch & Lomb SofLens daily disposable contact lenses.|Lenses to be worn and replaced daily for 2 weeks.
223706855|NCT00784641|DEVICE|Johnson and Johnson 1-Day Acuvue Moist contact lenses|Lenses to be worn and replaced daily for 2 weeks.
223706856|NCT00496509|DRUG|ZD6474 (Zactima) 100mg|
223706857|NCT00496509|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
223706858|NCT00496509|PROCEDURE|Biomarker Draws|
223706859|NCT00496509|DRUG|ZD6474 (Zactima) 300mg|
223706860|NCT04569253|DEVICE|TempSure|Non-invasive radiofrequency treatments
223706861|NCT03014557|DEVICE|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
223706862|NCT00394446|DRUG|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
223706863|NCT05602350|BEHAVIORAL|Self-administered survey|Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
223706864|NCT05602350|BEHAVIORAL|Enumerator-administered survey|Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
223706865|NCT04356742|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg, orally, once daily, up to 24weeks
223706866|NCT04356742|DRUG|Placebo|Dapagliflozin Placebo, orally, once daily, up to 24weeks
223706867|NCT04356742|DRUG|Evogliptin 5mg|Evogliptin 5mg, orally, once daily for background therapy
223706868|NCT04356742|DRUG|Metformin≥1000mg|Metformin≥1000mg, orally, daily for background therapy
223706869|NCT02173938|OTHER|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
223706870|NCT04200573|DRUG|Ampreloxetine|The study drug will be administered orally as a single Dose A tablet
223706871|NCT05264688|DIAGNOSTIC_TEST|68Ga-FAPI-04 imaging agent|1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg) intravenously
223706872|NCT04862377|DRUG|Poractant Alfa Intratracheal Suspension [Curosurf]|"Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg."
223706873|NCT04862377|DRUG|Budesonide 0.5 MG/ML|"Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide."
223706874|NCT00764296|OTHER|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
223706875|NCT00764296|OTHER|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
223706876|NCT02127710|DRUG|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
223706877|NCT02146664|DRUG|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
223706878|NCT02146664|DRUG|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
223706879|NCT02759497|OTHER|serum amyloid A level|serum amyloid A level (SAA)
223706880|NCT01321060|PROCEDURE|Aspiration|
223706881|NCT01321060|PROCEDURE|Catheter drainage|
223706882|NCT01321060|DRUG|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
223706883|NCT01975051|DRUG|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
223706884|NCT05137704|OTHER|No intervention|This is a non-interventional study.
223706885|NCT02605304|DRUG|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
223706886|NCT02605304|DRUG|Ribavirin|"Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
223706887|NCT02727842|DEVICE|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
224275980|NCT04531969|OTHER|Spa therapy and conventional physical therapy|"HP application +deep heater application + TENS. HP application: A hotpack wrapped in a towel for 20 minutes will be placed on the knee and surrounding soft tissues.~Deep heater application: The application will be performed with a therapeutic ultrasound device at a dose of 1.5watt / cm2 for each string for 6 minutes.~TENS application:TENS device with two electrodes surrounding tendon will be performed for 30 minutes at low-frequency current application.~Spa therapy: A conventional water bath water at 38 ° C will be applied in the pool for 20 minutes a day."
223525554|NCT04906512|DEVICE|3M™ Tegaderm™ Transparent Film Dressing 1626W|Subjects eligible for enrollment will be randomly assigned to either the Tegaderm CHG dressing group or the transparent dressing group, and patients in both groups will be given catheterization according to the hospital's standards and nursed according to the catheter maintenance procedure. The investigator would monitor the subjects during dressing changes, observing the subjects' general conditions, skin condition at the DVC site and the dressing condition, and change a dressing or take relevant measures (if applicable), until the end of the trial, i.e. CVC removal or patient transfer out of the ICU.
223525555|NCT06387953|DEVICE|Bridge Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
223525556|NCT06387953|DEVICE|Sham Therapy|After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.
223525557|NCT06570850|DRUG|Colistin Sodium Methanesulfonate|Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
223525558|NCT06570850|DRUG|Colistin Sodium Methanesulfonate plus Fosfomycin|Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
223525559|NCT02248493|DRUG|Paracetamol|
223525560|NCT02248493|DRUG|Placebo (for paracetamol)|
223525561|NCT02248493|DRUG|Ketoprofen|
223525562|NCT02248493|DRUG|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
223525563|NCT02248493|DRUG|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
223525564|NCT05025605|DRUG|BXCL501 80 Micrograms|Sublingual film containing 80 Micrograms BXCL501
223525565|NCT05025605|DRUG|Placebo Film|Matching Sublingual Placebo film
223525566|NCT05025605|DRUG|BXCL501 120 Micrograms|Sublingual film containing 120 Micrograms BXCL501
223525567|NCT05025605|DRUG|BXCL501 60 Micrograms|Sublingual film containing 60 Micrograms BXCL501 Europe Only
223525568|NCT03886857|DEVICE|transcutaneous spinal cord stimulation|noninvasive electrical stimulation of the human lumbar spinal cord
223525569|NCT05803772|DRUG|APHD-012|Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)
223525570|NCT05803772|DRUG|APH-012P|Distal jejunal-release placebo beads
223525571|NCT04862403|PROCEDURE|Umbilical cord clamping distance|Intervention group I: Umbilical cord clamped at a distance of 2cm Intervention group II: Umbilical cord clamped at a distance of 3cm Control group: Usual care (clamped without measurement).
223525572|NCT04796805|OTHER|Topical essential oil application|We applied black pepper essential oil to the participants in experimental group before the catheter insertion procedure
223525573|NCT00723632|BIOLOGICAL|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
223525574|NCT00723632|DRUG|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants \<65 kg, 1000 mg/day for participants \>65 to \<85 kg, and 1200 mg/day for participants \>=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
223525575|NCT04089696|DEVICE|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
223525576|NCT02756585|RADIATION|ct perfusion|computed tomography perfusion of the head
223525577|NCT01678365|DRUG|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
223525578|NCT00311831|BEHAVIORAL|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
223525579|NCT00311831|BEHAVIORAL|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
223525580|NCT03092193|DRUG|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
223525581|NCT03092193|DRUG|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
223525582|NCT03078231|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
223525583|NCT03078231|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
223525584|NCT01346592|BIOLOGICAL|Trivalent split influenza vaccine (TIV)|
223525585|NCT01346592|BIOLOGICAL|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
223525586|NCT01346592|BIOLOGICAL|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
223525587|NCT05686980|DRUG|ABBV-552|Oral Capsule
223525588|NCT02679274|DRUG|Placebo|Intermittent intramuscular injections of saline (males and females).
223525589|NCT02679274|DRUG|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
223525590|NCT03694730|OTHER|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
223525591|NCT03694730|OTHER|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
223525592|NCT06569485|DRUG|Trilaciclib+R-CHOP|This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
223525593|NCT06810440|BEHAVIORAL|Sumadhur|Sumadhur is a 4-month intervention with weekly sessions that last about 1.5 hours. Newly married women, their husbands and mothers-in-law gather with other household triads (5 households per group for a total of 15 people per group).
223525594|NCT06810440|DIETARY_SUPPLEMENT|Multiple micronutrient supplement MMS|Multiple micronutrient supplement MMS provided in 180 pill bottles
223525595|NCT06570356|DIAGNOSTIC_TEST|Geriatric Depression Scale - 15|a validated screening tool designed to identify depression in older adults. It consists of 15 simple yes/no questions that assess depressive symptoms.
223525596|NCT06570980|DRUG|sulfonylurease with metformin, DPP4 inhibitors with Metformin|Oral hypoglycemic agents
223525597|NCT06471673|BIOLOGICAL|BC1 cell line|BC1 cell line is a different experimental, HER-2 positive, allogeneic, whole cell BC cell lines designed to secrete GM-CSF in situ and augment dendritic cell activity. Similar to the SV-BR-1-GM cell line (NCT03328026, IND 10312), the BC cell line is derived from the BC parent cell line, SV-BR-1, which expresses multiple tumor associated antigens (TAAs)
223706888|NCT02727842|DEVICE|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
223706889|NCT00003023|BIOLOGICAL|BCG vaccine|
223706890|NCT00003023|BIOLOGICAL|monoclonal antibody A1G4 anti-idiotype vaccine|
223706891|NCT03576495|OTHER|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
223706892|NCT03576495|OTHER|Standard Residency Curriculum|The standard residency curriculum consists of previously scheduled resident didactic sessions at all academic medical centers that may or may not include topics on cultural competency or cross-cultural care.
223706893|NCT02162316|DRUG|Motilitone®|
224275981|NCT05586724|DRUG|Micronized progesterone in continuous combination with oral estrogen|Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)
223525598|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab)|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
223706894|NCT02162316|DRUG|A-Cilin®, Clari® and Pantoline®|
223706895|NCT01790425|PROCEDURE|to infuse water into colon to open the lumen for water infusion colonoscopy|
223706896|NCT01790425|PROCEDURE|Air colonoscopy|
223706897|NCT02867150|DEVICE|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
223706898|NCT00000304|DRUG|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
223706899|NCT00000304|DRUG|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
223706900|NCT00000304|DRUG|Placebo|Placebo
223706901|NCT05249699|DRUG|Isoniazid|prevent the development of tuberculosis
223706902|NCT05249699|OTHER|without any additional anti-tuberculosis treatment|reduce the number of Participants With Treatment-Related Adverse Events
223706903|NCT03051750|OTHER|Complex Physical Therapy plus Pressotherapy|
223706904|NCT03051750|OTHER|Kinesio Taping|
223706905|NCT00092768|DRUG|MK0663, etoricoxib|
223706906|NCT00092768|DRUG|Comparator: celecoxib|
223706907|NCT01133041|OTHER|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
223706908|NCT01133041|OTHER|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
223706909|NCT03608254|OTHER|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
223706910|NCT01085474|OTHER|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
223706911|NCT01085474|OTHER|2|The best intervention used in the pilot study will be chosen and included in the main study.
223706912|NCT03344133|BEHAVIORAL|Exercise|4-week moderate intensity exercise programme
224275982|NCT05586724|DRUG|Norethisterone acetate in continuous combination with oral estrogen|Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan
224275983|NCT00296530|DRUG|fluticasone propionate/salmeterol|
223706913|NCT03141593|DRUG|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
223706914|NCT03141593|DRUG|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
223706915|NCT03141593|DRUG|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
223525599|NCT06471673|BIOLOGICAL|Bria-OTS regimen and CPI (tislelizumab) expansion cohort|"Biological: BC1~* BC1 inoculation intradermally at 4 sites~Drug: Low dose cyclophosphamide~* Pretreatment with low dose cyclophosphamide 2-3 days prior to BC1 inoculation~Drug: Interferon~* Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.~Drug: Tislelizumab~* CPI treatment will also be given on the same day as cell inoculation."
223525600|NCT03596554|OTHER|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
223525601|NCT02245659|DEVICE|CPAP|Continuous Positive Airway Pressure
223525602|NCT02245659|OTHER|Nasal dilator strip|Nasal dilator strip to be worn nightly
223525603|NCT04154163|DIAGNOSTIC_TEST|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
223525604|NCT04154163|DIAGNOSTIC_TEST|Venous blood sampling|Venous blood
223525605|NCT02208765|DEVICE|Stress Single Photon Emission Computed Tomography|
223525606|NCT03272321|DRUG|Oxytocin|Syntocinon nasal spray
223525607|NCT03272321|DRUG|Placebo|Placebo nasal spray
223525608|NCT05605197|DRUG|U87 CAR-T|Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.
223525609|NCT03519880|DEVICE|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
223525610|NCT02731560|DRUG|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
223525611|NCT04463355|BEHAVIORAL|Video discharge instructions|Short video (2 minutes) including information about clinical features, management and follow up of pediatric patients with acute gastroenteritis
223525612|NCT02659371|DIETARY_SUPPLEMENT|Low energy diet|
223525613|NCT01260779|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
223706916|NCT03141593|DRUG|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
223706917|NCT05890950|DRUG|K-757 and K-833|Both administered orally
223706918|NCT05890950|DRUG|Matching placebo to K-757 and K-833|Both administered orally
223706919|NCT03866954|COMBINATION_PRODUCT|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
223706920|NCT04419675|OTHER|Observational Cohort, usual care = physical therapy|usual care = physical therapy
223525614|NCT05544409|DEVICE|MAKv1|1 hour sessions with the MAKv1 exoskeleton, thrice per week during 1 month
223525615|NCT03249649|BEHAVIORAL|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
223525616|NCT02085720|DEVICE|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
223525617|NCT01737723|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
223525618|NCT05382130|DIAGNOSTIC_TEST|Test all|"In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results."
223525619|NCT06565091|DEVICE|Measurements of physiological parameters of the anterior chamber|Acquisition by the investigational device
223706921|NCT00640861|BIOLOGICAL|CpG oligodeoxynucleotide|
223706922|NCT00640861|BIOLOGICAL|HER-2/neu peptide vaccine|
223706923|NCT00640861|BIOLOGICAL|MUC-1 peptide vaccine|
223706924|NCT00640861|BIOLOGICAL|incomplete Freund's adjuvant|
223706925|NCT00640861|BIOLOGICAL|sargramostim|
223706926|NCT00640861|OTHER|immunoenzyme technique|
223706927|NCT00640861|OTHER|immunologic technique|
223706928|NCT04177121|OTHER|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
223706929|NCT05711394|DRUG|Atogepant|Oral Tablet
223706930|NCT05711394|DRUG|Placebo-Matching Atogepant|Oral Tablet
223706931|NCT04838782|PROCEDURE|Repeat Surgical Management of Recurrent GBM|Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
223706932|NCT05868759|RADIATION|Roentgen Stereophotogrammetric Analysis (RSA)|"Roentgenstereophotogrammetric analysis (RSA) is a radiographic technique, highly accurate both to evaluate the primary stability of the implant, then the micromovements between bone and implant prosthetic, both for the evaluation of the kinematics of the prosthetic components. The RSA technique in dynamics is able to obtain, with patient in motion, a series of radiographic frames in sequence in two projections, which are captured simultaneously. Each pair of orthogonal projections corresponds to a specific moment of the movement carried out by the patient and will be used to obtain, through dedicated software, a reconstruction three-dimensional instant defined RSA scenes."
223893739|NCT05945212|OTHER|Barthel index|The Barthel index measure autonomy in daily life.
223893740|NCT05945212|OTHER|isometric ergometer|Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.
223706933|NCT05868759|DEVICE|Delos Postural Proprioceptive System (computerized oscillating platform)|The Delos Postural Proprioceptive System uses electronic tilting tables (on a single axis or three axes) with high frequency that allows very short stop and reversal times that allow both to study the proprioception and the patient's response to the modification of movement of the inclined plane
223706934|NCT05868759|DIAGNOSTIC_TEST|Modified Star Excursional Balance Tests|The Star Excursional Balance Test (SEBT) is a clinical test designed for the evaluation of dynamic physical performance of the tibiotarsica. The first literary references date back to 1998 and the test, remaining in balance with the ankle in the studio, the achievement of the maximum possible distance with the contralateral foot along well-defined axes.
223706935|NCT05868759|DEVICE|Inertial sensors Xsens MVN|"The inertial motion acquisition system Xsens MVN is easy to use and economic to detect the movement of different anatomical districts. MVN is based on inertial sensors in miniature through communication solutions combined with advanced fusion algorithms sensors, using hypotheses of biomechanical models.~This MVN system is a system of inertial kinematic measurement of the whole body, which incorporates synchronized data. Instant graphic output is provided, including angles of motion articular."
223706936|NCT05868759|OTHER|American Orthopaedic Foot and Ankle Score (AOFAs)|American Orthopaedic Foot and Ankle Score (AOFAs) is a clinical trial commonly used in scientific literature which serves to assess, in terms of value from 0 to 100, the autonomy, pain, stability, ankle alignment and back foot of the patient.
224275984|NCT00296530|DRUG|fluticasone propionate|
224275985|NCT00296530|DRUG|montelukast|
223525620|NCT06565091|DEVICE|Measurements of the Axial biometry|Acquisition by the investigational device
223525621|NCT00220077|PROCEDURE|Endoscopy|
223525622|NCT06565299|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery about congenital heart defects with cardiopulmonary bypass
223525623|NCT06564740|DRUG|Stem Cell|UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
223525624|NCT06564740|OTHER|Control|In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.
223525625|NCT01295047|DRUG|Atenolol|
223525626|NCT01295047|DRUG|VERAPAMIL|240 MG SR
223525627|NCT01295047|DRUG|Perindopril|4 MG
223525628|NCT00689884|DRUG|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
223525629|NCT04648085|DEVICE|Trigeminal Nerve Stimulation|Applied to to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve.The device generates electrical impulses allowing to stimulate the trigeminal nerve.
223525630|NCT02038036|DRUG|Best Available Therapy|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
223525631|NCT02038036|DRUG|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
223525632|NCT05591365|OTHER|Structured In-Patient and Home plan|A patient education session and a protocol comprise of 3 days. It consists of three different levels having progressive activities. The in-patient protocol will start from the day of the procedure. Each level contains 2 to 6 tasks, performed in sets of 5-10 repetitions 3 times a day. Home plan: Walking 3 days a week starting from normal pace ((RPE: 8-9) for10 minutes and progressively increased intensity and duration over the period of 12 weeks (RPE: 13-14).
223525633|NCT05591365|OTHER|Conventional Therapy|"In-Patient: Wound care, Bed mobility:~AROMS (10 Reps\*3sets\*TD), Breathing Exercise (10 Reps\*3sets\*TD), Mobilization (Walk as per patient tolerance) Patient Education: To keep the heart healthy Diet Avoid strenuous exercise and lifting heavy objects Avoid valsalva manure, Quit smoking Lower cholesterol levels, Maintain a healthy weight Control other conditions, such as diabetes and high blood pressure Take medications as prescribed by your doctor Get regular exercise: Walking at a normal pace as per tolerance (RPE up to 10)"
223525634|NCT04029779|BIOLOGICAL|I-PRF|Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
223525635|NCT03463187|BIOLOGICAL|SHR-1314|Administered subcutaneously
223525636|NCT03463187|DRUG|Placebo|Administered subcutaneously
223525637|NCT03352947|DRUG|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
223525638|NCT03352947|DRUG|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
224275986|NCT04181398|DIAGNOSTIC_TEST|Anthropometry|"* Actual Height and weight~* Calculated BMI from measured weight and height.~* Pubertal development (Tanner stage)~* Waist circumference~* Skin fold measurement (Triceps and Subscapular)~* Waist-to-height ratio will be calculated from measured height and waist circumference."
224275987|NCT04181398|DIAGNOSTIC_TEST|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
224275988|NCT04181398|DIAGNOSTIC_TEST|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
224275989|NCT04181398|OTHER|Questionnaire|General questionnaire on cardiovascular risk factors
224275990|NCT04181398|DIAGNOSTIC_TEST|Blood sample|Blood sample for hs-CRP
223706937|NCT05868759|OTHER|Visual Analogue Scale (VAS)|The Visual Analogue Scale (VAS) is a visual representation of the extent of pain that the patient subjectively warns. The VAS is represented by a 10 cm long line in the original version validated, with or without notches at each centimeter. One end indicates the absence of pain and corresponds to 0, the other end indicates the worst pain imaginable and corresponds to 10.
224275991|NCT00766493|DEVICE|GORE® Embolic Filter|Embolic protection during carotid stenting
223706938|NCT05868759|OTHER|12-Item Short Form Survey (SF-12)|The 12-Item Short Form Survey (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
223706939|NCT01216748|OTHER|quiet breathing|Subjects were instructed to breath normally at room air.
223706940|NCT01216748|OTHER|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
223706941|NCT01216748|OTHER|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
223706942|NCT01216748|OTHER|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
223706943|NCT04648228|BEHAVIORAL|ACT+MBRP|Intervention is behavioral treatment group that combines Acceptance and Commitment Therapy (ACT) with Mindfulness-Based Relapse Prevention. The group focuses on living with long-term pain, ways to complete daily living activities when you experience pain, coping with opioid and other drug cravings, and training in mindfulness practices.
223706944|NCT04648228|BEHAVIORAL|Education control|Education control is behavioral treatment group that combines pain patient education with opioid and other drug education. The group focuses on experiences of long-term pain, instructions on how to function with this pain, and facts about opioids and other drugs.
223706945|NCT04896879|BEHAVIORAL|interviews|semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
223706946|NCT04999488|DRUG|BPM31510|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
223706947|NCT04999488|OTHER|Placebo|A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.
223706948|NCT00239590|DRUG|Testosterone undecanoate|Licensed for androgen deficiency
223706949|NCT01817829|DRUG|paracetamol|500 mg oral tablet
223706950|NCT01817829|DRUG|placebo|
223706951|NCT02033187|OTHER|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
223706952|NCT02033187|OTHER|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
223706953|NCT03638622|COMBINATION_PRODUCT|Photodynamic Therapy|Patients receive aminolevulinic acid (ALA) orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
223706954|NCT03993470|BEHAVIORAL|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
223706955|NCT04020588|DRUG|Celecoxib 200mg|Will be administered for 6 weeks
223706956|NCT04020588|DRUG|Placebo oral capsule|Will be administered for 6 weeks
223706957|NCT04020588|DRUG|Minocycline 100mg|Will be administered for 6 weeks
223706958|NCT03311529|BEHAVIORAL|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
223706959|NCT02362269|DIETARY_SUPPLEMENT|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
223706960|NCT06201442|OTHER|Imaging - magnetic resonance imaging (MRI)|MRI knee - not standard of care
223706961|NCT06201442|OTHER|Blood sampling|blood sample taken and analysis - not standard of care
223706962|NCT06201442|OTHER|Assessment of functionality and strength|Movements and posture Analysis Laboratory Leuven measurement (3D motion analysis) and Biodex measurement - not standard of care
223706963|NCT06201442|OTHER|Activity monitoring|Actigraph measurement- not standard of care
223706964|NCT06201442|OTHER|Imaging - x-ray scan (RX)|RX Knee and EOS radiography full leg - not standard of care
223706965|NCT06201442|BEHAVIORAL|Questionnaires|Patient reported outcomes (PROMS)
224275992|NCT02911636|RADIATION|Pelvic SABR with intra-prostatic SABR|described elsewhere
223706966|NCT04043273|BEHAVIORAL|Noninterventional characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on Patients Needs Questionnaire (PNQ). Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
223706967|NCT00122096|DRUG|valdecoxib|
223706968|NCT01903031|DEVICE|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
223706969|NCT01903031|DRUG|EFV|Participants received EFV 600 mg daily with two or more NRTIs
223706970|NCT01903031|DRUG|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
224275993|NCT04993118|OTHER|Integrated Neuromuscular Inhibition technique|Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
223525639|NCT03005886|PROCEDURE|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
223525640|NCT03005886|PROCEDURE|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
223525641|NCT03005886|PROCEDURE|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
223525642|NCT03265184|DIETARY_SUPPLEMENT|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
223525643|NCT02476448|DRUG|Normal saline|Used to distend the bladder for cystoscopic evaluation
223525644|NCT02476448|DRUG|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
223525645|NCT02476448|DRUG|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
223525646|NCT02476448|DRUG|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
223525647|NCT05609825|DRUG|LY3875383|Administered SC.
223706971|NCT01903031|DRUG|TDF|Participants received 300 mg of tenofovir in Arm C
223706972|NCT01903031|DRUG|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
223706973|NCT01515878|DEVICE|Hemocontrol|Blood Volume Tracking system using biofeedback
223706974|NCT06069323|DEVICE|repetitive Transcranial Magnetic Stimulation|Pediatric patients with ASD and ADHD will be randomized both in active and sham groups.
223706975|NCT02560909|BIOLOGICAL|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
223706976|NCT02560909|BIOLOGICAL|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
223706977|NCT05255211|DRUG|Remimazolam tosilate|IV before procedure
223706978|NCT05255211|DRUG|Propofol|IV before procedure
223706979|NCT05255211|OTHER|saline solution|IV before procedure
223706980|NCT01332084|OTHER|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
223706981|NCT01168141|DRUG|ZD4054|10mg ZD4054 daily in tablet form
223706982|NCT00033605|DRUG|octreotide acetate|
223706983|NCT00033605|OTHER|placebo|
223706984|NCT00033605|RADIATION|radiation|
223706985|NCT05096728|DRUG|Nifedipine XL|"Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg"
223525648|NCT05609825|DRUG|Placebo|Administered SC.
223525649|NCT04262479|DRUG|recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel|3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
223525650|NCT04262479|DRUG|Vitamin D|1 tablet/day, total daily dose of 2000 IE given per os from day -30 through day 90. Supplier Meda, Solna, Sweden
223706986|NCT02863744|PROCEDURE|coronally advanced flap with subepithelial connective tissue graft|"* Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~* The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
223706987|NCT05702918|DEVICE|BTL-6000 FSWT|The energy will be set to 0.14 mJ/mm2, frequency 6 Hz, total number of shocks 1800. The application will be semi-static at the location of the largest USG finding. 600 shocks are applied from all three sides (medial, lateral, dorsal).
223706988|NCT05702918|OTHER|Achilles Tendon Loading Exercise Protocol According to Silbernagel|It is a 12-week Silbernagel ankle dorsiflexion resistance training protocol. It is a series of exercises with a gradual progression of load according to defined criteria, which the patient practices every day.
223706989|NCT04436159|PROCEDURE|Addition of 360 fundoplication after crural closure|A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.
223706990|NCT04436159|PROCEDURE|Addition of 180 posterior fundoplication after crural closure|"The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively."
223706991|NCT02620722|DEVICE|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
223706992|NCT02620722|DEVICE|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
223706993|NCT01216670|BEHAVIORAL|remote patient's management|scheduled remote CareLink data transmission
223706994|NCT00768950|PROCEDURE|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
223706995|NCT00768950|PROCEDURE|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
223706996|NCT03373292|PROCEDURE|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
223706997|NCT03373292|PROCEDURE|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
223706998|NCT02489578|OTHER|other|retrospective cohort study
223706999|NCT01126086|DRUG|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
223707000|NCT02551861|DRUG|Daclatasvir|
223707001|NCT02551861|DRUG|Sofosbuvir|
223707002|NCT02551861|DRUG|Ribavirin|
223707003|NCT00366574|DEVICE|Amadeus Microkeratome|
223707004|NCT00366574|DEVICE|IntraLase|
223707005|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 1)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112011), intramuscularly injected into the lateral deltoid muscle of the upper arm.
223707006|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 2)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112012), intramuscularly injected into the lateral deltoid muscle of the upper arm.
223707007|NCT06314867|BIOLOGICAL|23 Valent Pneumococcal Polysaccharide Vaccine (lot 3)|All subjects were vaccinated with 1 dose of 23 Valent Pneumococcal Polysaccharide Vaccine (batch number: Y202112013), intramuscularly injected into the lateral deltoid muscle of the upper arm.
223707008|NCT02256592|DRUG|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
223707009|NCT00447005|DRUG|Axitinib (AG-013736)|AG-013736 5mg twice daily \[BID\]
223707010|NCT00227006|BEHAVIORAL|Behavioral lifestyle/weight-loss intervention|
223707011|NCT01595035|BEHAVIORAL|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
223707012|NCT01469234|DRUG|loratadine|loratadine, one 10 mg tablet, orally
223707013|NCT01469234|DRUG|fexofenadine|fexofenadine, one 180 mg tablet, orally
223707014|NCT01469234|DRUG|placebo to loratadine|one tablet, orally
223707015|NCT01469234|DRUG|placebo to fexofenadine|one tablet, orally
223707016|NCT01942343|DRUG|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
223707017|NCT05961579|DRUG|Barrier Renew|RoC Skincare (New York, New York, USA) has developed a gentle cleanser and moisturizer that are free of exfoliants, astringents, and other abrasive ingredients. The moisturizer contains emollients, humectants, and silicones to improve the functioning of the skin barrier while antioxidants protect against environmental damage and inflammation
223707018|NCT05744011|OTHER|Tango intervention|"The interventions will be implemented by ABB Reportages and will be carried out by nursing staff who had previously received training in therapeutic tango at the University of Burgundy.~A dance movement therapist and a musician will accompany the interventions twice a month.~Participants will attend a 1-hour tango session, twice a week for twelve weeks."
223707019|NCT05744011|OTHER|Adapted Physical Activity|"The intervention will be carried out by an Adapted Physical Activity professor and by nursing staff.~Music is prohibited during the sessions. Participants will attend a 1-hour APA, twice a week for twelve weeks."
223707020|NCT05820607|BIOLOGICAL|Microbiome, metabolome, transcriptome, genome|Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
223525651|NCT06637241|BEHAVIORAL|Risk stratification care|In this group, Taiwanese adolescent baseball players are categorized into high-risk, medium-risk, and low-risk groups based on injury risk from a previous study. High-risk players receive sports protection education and physician referrals for shoulder and elbow assessments, with further imaging if necessary. Common issues like Little League shoulder and elbow are managed with conservative treatments. The sports protection education includes the Modified Yokohama Baseball-9 (mYKB-9), a program that significantly reduces injuries with exercises targeting shoulder and elbow health. Medium-risk players receive mYKB-9 education only, while low-risk players are observed without changes to their training methods.
223525652|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of short term study (7 days) of stevia leave powder 1000 mg/day in diabetic subjects
223525653|NCT06645002|DIETARY_SUPPLEMENT|stevia rebaudiana bertoni|effect of long term study (60 days) of stevia leave powder 1000 mg/day in diabetic subjects
223525654|NCT06641739|DEVICE|laser assisted SPPF|A full-thickness flaps were elevated. In the test sites after the SPPF access will be performed, root surface debridement will be meticulously performed, followed by intra-marrow penetrations (IMPs), on the defect walls using a 0.25 mm wide half round bur, mounted on a slow-speed handpiece. Following this, low-level laser biostimulation of the defect will be effected with an 940 nm diode laser at 3 W power, with an uninitiated 0.6mm optical fiber tip. The defects will be irradiated for 20 seconds in a continuous noncontact mode and then retracted for 8 seconds. This will be repeated for 3 times so that the defects were effectively lased for about 60 seconds.
223525655|NCT06641739|PROCEDURE|Platelet Rich Plasma|In the second group, following the SPPF, the defect will grafted with particulated PRF, which will be overlaid with a PRF membrane, without any adjunctive defect management measures. PRF will be prepared by collecting Intra-venous blood (from the antecubital vein) in a 10-ml sterile glass tube without anticoagulant and immediately centrifuged in a centrifugation machine at 3000 rpm for 10 minutes. It will result in the separation of blood into a structured fibrin matrix in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma (platelet poor plasma) at the top. PPP will be discarded. PRF will be easily separated from the red corpuscles base using sterile tweezers and scissors.
223525656|NCT04174586|BIOLOGICAL|microtransplantation|HLA mismatched donor cord blood infusion
223525657|NCT00937105|DEVICE|lotrafilcon A contact lenses|FDA approved soft contact lenses
223525658|NCT00937105|DEVICE|Renu Multiplus|
223525659|NCT00937105|DEVICE|Clear Care|
223525660|NCT04952714|DEVICE|Oxiris|Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
223525661|NCT00000354|DRUG|Lofexidine|
223525662|NCT02682251|OTHER|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
223525663|NCT00002256|DRUG|Zalcitabine|
223525664|NCT04280588|DRUG|Fingolimod 0.5 mg|Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
223525665|NCT01972659|DRUG|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
223525666|NCT01972659|DRUG|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
223525667|NCT01972659|DRUG|sugammadex|4 mg/kg iv bolus at the end of the surgery
223525668|NCT04470037|DRUG|DAAOI-P|DAAOI-P 250-1500mg
223525669|NCT04470037|DRUG|Placebo|starch pill
223525670|NCT03997500|DRUG|normal saline|a bolus of normal saline was given followed by normal saline infusion
223525671|NCT03997500|DRUG|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
223525672|NCT05849844|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure
223525673|NCT04111601|DEVICE|Blue light imaging|Advanced virtual chromoendoscopy
223525674|NCT06497946|BEHAVIORAL|SlimTrack Plataform|SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
223707021|NCT01484275|DRUG|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
223707022|NCT01484275|DRUG|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
223525675|NCT06497946|BEHAVIORAL|Diet prescription|Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
223707023|NCT02293161|DRUG|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
223707024|NCT02293161|DRUG|Placebo|It is Sodium Chloride Intravenous Infusion
223707025|NCT02949531|DRUG|oxygen|
223535000|NCT01852981|BEHAVIORAL|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
223707026|NCT02552589|OTHER|Amine fluoride|toothpaste
223707027|NCT02552589|OTHER|Placebo|toothpaste
223707028|NCT01681940|DRUG|Lamazym|ERT, i.v. infusions weekly
223893741|NCT05945212|OTHER|Electromyograms (EMG)|Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.
223707029|NCT05352711|DEVICE|active assisted exercise and with fully immersive Head-Mounted Display virtual reality ( Oculus Quest virtual reality (VR) headset with hand con|VR is mainly created by generating visual effects through head-mounted display (HMD) systems. An HMD is a device worn on the head or as part of a helmet with a built-in display and lenses, allowing the user to experience the virtual world with the help of a wide viewing angle, head and hand movements tracking as well as objects interacting by controllers.
224275994|NCT04993118|OTHER|Ischemic Compression,Hotpack,TENS|Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
223707030|NCT05352711|OTHER|active assisted range of motion exercise|Patients were treated active assisted ROM physical therapy 2 sessions per week for 4 weeks.
223707031|NCT03592654|BEHAVIORAL|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
223707032|NCT02515396|DRUG|MMI-0100|
223707033|NCT02515396|DRUG|Placebo|
223707034|NCT02858960|DEVICE|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
223707035|NCT02858960|DEVICE|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
223707036|NCT05182190|DIETARY_SUPPLEMENT|White bread|Toasted white bread
223707037|NCT05182190|DIETARY_SUPPLEMENT|Black beans whole boiled|Whole boiled black beans with spaghetti sauce
223707038|NCT05182190|DIETARY_SUPPLEMENT|Knife Mill pasta|Black bean pasta (KM) with spaghetti sauce
223707039|NCT05182190|DIETARY_SUPPLEMENT|Combo Flour Pasta|Black bean pasta (Combo) with spaghetti sauce (medium protein flour)
223707040|NCT05182190|DIETARY_SUPPLEMENT|Cyclone Flour Pasta|Black bean pasta (Cyclone) with spaghetti sauce (low protein flour)
223707041|NCT04652427|DRUG|Dexmedetomidine Hydrochloride 0.1 MG/ML|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
223707042|NCT04652427|DRUG|0.9% Sodium Chloride Injection|At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
223707043|NCT05578170|DRUG|Pembrolizumab|Participants receive 200 mg pembrolizumab as a neoadjuvant by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles before surgery.
223707044|NCT01227317|OTHER|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
223707045|NCT03407625|OTHER|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
223707046|NCT03407625|OTHER|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
223707047|NCT02021227|PROCEDURE|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for \> 1 hour
223707048|NCT02918201|DRUG|Tranexamic Acid|TXA 25 mg/ml applied topically to moisten the wound
223707049|NCT02918201|DRUG|saline|Saline solution (0.9% NaCl) applied topically to moisten the wound
223707050|NCT02197273|DRUG|Liposomal bupivacaine|
223707051|NCT02197273|DRUG|Standard of care analgesia|
223707052|NCT02776865|DRUG|suprascapular nerve block|4ml 2% xylocaine
223707053|NCT02776865|OTHER|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
223707054|NCT04154930|DEVICE|Restylane-L®|Intradermal injection.
223707055|NCT05654935|RADIATION|Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center."
223707056|NCT05654935|RADIATION|Telerobotic Ultrasound for Carotid Arteries|"Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet)."
223707057|NCT00334321|RADIATION|IMRT|
223707058|NCT00334321|RADIATION|Intracavitary vaginal brachytherapy|
223707059|NCT00334321|DRUG|Paclitaxel|
223707060|NCT00334321|DRUG|Carboplatin|
223707061|NCT02481583|DRUG|Levosulpiride|different formulations of levosulpiride
223707062|NCT06259123|DRUG|[177Lu]Lu-PSMA I&T|2 cycles of 5 GBq \[177Lu\]Lu-PSMA I\&T at 6-week intervals prior radical prostatectomy for patients with oligometastatic prostate cancer
223707063|NCT03842514|DIETARY_SUPPLEMENT|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
223525676|NCT06674252|OTHER|Jiawei Bufei Tang granules|"Jiawei Bufei Tang is a traditional Chinese medicine formula applied by Professor Li Pingping to patients with lung cancer and qi yin deficiency syndrome. It consists of Huangqi, Codonopsis pilosula, Schisandra chinensis, Rehmannia glutinosa, Ziyuan, Mulberry bark, Snake berry, Half branch Lotus, White Hedyotis diffusa, etc. Bu Fei Tang is derived from the Yuan Dynasty's Yong Lei Ling Fang and consists of six ingredients: ginseng, astragalus, schisandra, Radix Rehmanniae, Ziyuan, and mulberry bark. It is mainly used to treat cough caused by lung qi deficiency. Jiawei Bufei Tang adds white Hedyotis diffusa, Scutellaria barbata, and snake berry to the original formula. White Hedyotis diffusa is more effective in dispelling carbuncles and detoxifying, Scutellaria barbata is more effective in dispelling phlegm and diuresis, and snake berry is more effective in dispelling scrofula and dispersing nodules, increasing the effect of clearing heat and detoxifying. This formula is particularly e"
223525677|NCT06674252|DRUG|Placebo|placebo
223707064|NCT01307982|PROCEDURE|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
223707065|NCT01307982|PROCEDURE|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
223707066|NCT03974243|DRUG|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
223707067|NCT03974243|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
223707068|NCT00515411|DRUG|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
223707069|NCT00515411|DRUG|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
223707070|NCT00515411|DRUG|Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
223707071|NCT03451578|DEVICE|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
223707072|NCT05427929|DEVICE|NVR 4mm Edi catheter|Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
223707073|NCT02270008|OTHER|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
223707074|NCT01599195|DEVICE|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
223707075|NCT03602430|DRUG|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
223707076|NCT03602430|DRUG|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
223707077|NCT04634890|BEHAVIORAL|Exercise intervention|Supervised exercise intervention composed of mixed aerobic and strength activities, with the frequency of 3 sessions per week for 12 weeks, for a total number of trainings of 36.
223707078|NCT04032392|BIOLOGICAL|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
223707079|NCT04049864|BIOLOGICAL|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
223707080|NCT04049864|BIOLOGICAL|Salmonella oral vaccine|suspension 10\^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
223707081|NCT04049864|DRUG|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
223707082|NCT04721730|BEHAVIORAL|PLH-YC|There will be 5 weekly 2-hour sessions. The optimised PLH-YC uses a participatory, non-didactic approach to engage parents. Parents learn positive parenting skills and how to manage child behaviour problems. The program includes Session 1: One-on-One Time and Say What You See, Session 2: Praise and Rewards, Session 3: Instructions, Redirect, Rules, and Routines, Session 4: Ignore and Consequences, Session 5: Reflection and Moving On. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
223707083|NCT04721730|BEHAVIORAL|Lecture|Lecture on parenting. This is a 26-slides power-point presentation that was developed by the University of Bremen for the purpose of this study. Duration: 1 to 1.5 hours. Content: 1) Stages of child development; (2) Potential risk factors for child emotional or behaviour problems; (3) Resources and protective factors; (4) Tips: What parents can do to promote children's development.
223707084|NCT00006111|DRUG|cisplatin|
223707085|NCT00006111|DRUG|fluorouracil|
223707086|NCT00006111|PROCEDURE|conventional surgery|
223707087|NCT00006111|RADIATION|radiation therapy|
223707088|NCT04470141|DRUG|SHC014748M treatment|Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
223707089|NCT00722800|DRUG|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
223707090|NCT00722800|DRUG|Placebo|1 tablet daily for 24 weeks
223707091|NCT03808129|DRUG|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
223707092|NCT04798755|DRUG|Methotrexate|Inicial dose 15mg/week increasing up to 25 mg/week
223707093|NCT04798755|DRUG|Adalimumab|At the Baselin visit adalimumab 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.
223707094|NCT04798755|DRUG|Adalimumab+Methotrexate|"Adalimumab: at the Baseline visit 80 mg subcutaneous loading dose followed a week later by 40 mg every-other-week starting at Week 1.~Methotrexate:Inicial dose 15mg/week increasing up to 25 mg/week"
223707095|NCT03148314|DRUG|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
223707096|NCT03148314|DRUG|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
223707097|NCT06026657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223707098|NCT06026657|PROCEDURE|Computed Tomography|Undergo CT scan
223707099|NCT06026657|DRUG|Gemcitabine|Given IV
223707100|NCT06026657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223707101|NCT06026657|BIOLOGICAL|Naxitamab|Given IV
223707102|NCT06026657|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
223707103|NCT01674114|PROCEDURE|TAP block|
223707104|NCT01674114|PROCEDURE|control|
223707105|NCT03104543|BEHAVIORAL|Education|30 minute education session; 15 minute booster session at 4 months
223707106|NCT03104543|BEHAVIORAL|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
223707107|NCT01828736|BIOLOGICAL|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
223707108|NCT01828736|DRUG|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
223707109|NCT01828736|DRUG|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
223707110|NCT01828736|DRUG|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
223707111|NCT00966771|DRUG|Copper T380 IUD|copper T 380 IUD
223707112|NCT00966771|DRUG|Oral levonorgestrel|1.5 mg
223707113|NCT02130297|DEVICE|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
223707114|NCT00252746|DRUG|ZD6474 (vandetanib) 100mg|once daily oral dose
223707115|NCT00252746|DRUG|ZD6474 (vandetanib) 200mg|once daily oral dose
223707116|NCT00252746|DRUG|ZD6474 (vandetanib) 300mg|once daily oral dose
223707117|NCT04209517|OTHER|Filming|Behavioural markers selection from video-recordings of the interview
223707118|NCT01219673|OTHER|Placebo|1 by mouth twice a day.
223707119|NCT01219673|DRUG|Armodafinil|150 mg by mouth once a day.
223525678|NCT06673719|RADIATION|99mTc-pertechnetate SPECT/CT|This procedure is similar to standard Meckel's diverticulum scan, with the addition of SPECT/CT acquisition to measure gastric volume.
223525679|NCT06673719|PROCEDURE|Combined High-Resolution Manometry-Nutrient Drink Test|Proximal gastric high-resolution manometry was done concurrently with nutrient drink test to measure proximal gastric function.
223707120|NCT01219673|DRUG|Minocycline|100 mg by mouth twice a day.
223707121|NCT01219673|DRUG|Bupropion|100 mg by mouth twice a day.
223707122|NCT03259217|DRUG|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
223707123|NCT02564497|BIOLOGICAL|Process E Belatacept|
223707124|NCT02564497|BIOLOGICAL|Process C Belatacept|
223707125|NCT04596800|OTHER|Prehabilitation Program + Enhanced Recovery After Surgery|Prehabilitation Program (nutrition + exercise + psychological counseling) + ERAS protocol
223707126|NCT04596800|OTHER|Enhanced Recovery After Surgery|ERAS
223707127|NCT06253975|BIOLOGICAL|adipose tissue derived extracellular vesicles (AT-EVs)|Extracellular vesicles from patient's adipose tissue together with HA
223707128|NCT06253975|DRUG|Hyaluronic acid|Use HA only as a placebo
223707129|NCT03763175|DRUG|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
223707130|NCT03763175|DRUG|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
223707131|NCT03763175|DRUG|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
223707132|NCT00551447|DRUG|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
223707133|NCT00551447|DRUG|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
223707134|NCT00551447|DRUG|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
223707135|NCT03196856|BEHAVIORAL|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
223707136|NCT03196856|DIETARY_SUPPLEMENT|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
223707137|NCT03196856|DIETARY_SUPPLEMENT|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
223707138|NCT01647646|DRUG|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
223535001|NCT01852981|BEHAVIORAL|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
223535002|NCT05495022|BEHAVIORAL|Mindfulness-based stress reduction (MBSR) program|Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
223535003|NCT01987557|BEHAVIORAL|rate group|walking with a high cadence (steps per minute)
223535004|NCT01987557|BEHAVIORAL|magnitude treadmill group|
223535005|NCT01987557|BEHAVIORAL|regular treadmill walking|
223535006|NCT03164161|DEVICE|Cold pressor test|Described before.
223535007|NCT03164161|OTHER|β-endorphins evaluation in saliva|Described before.
223535008|NCT03164161|OTHER|β-endorphins evaluation in blood plasma|Described before.
223535009|NCT05266547|DEVICE|OCT guided coronary intervention|patients were divided into two groups,on OCT guided coronary group and coronary angiography guided group
223535010|NCT05486767|DIAGNOSTIC_TEST|Transient elastography|Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
223535011|NCT05683366|DEVICE|No Intervention|There is no intervention in this study
223535012|NCT03398330|DRUG|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
223535013|NCT03398330|DRUG|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
223535014|NCT02347605|DRUG|Nicotine lozenge 4 mg|
223535015|NCT02347605|DRUG|Placebo lozenge|
223535016|NCT05732038|BEHAVIORAL|Healthy Minds Program (HMP)|Participants assigned to the HMP group will be asked to complete a minimum of 10 minutes per day of meditation for 12 weeks. For the first four weeks, participants will listen to prescribed meditations that will teach them the foundations of mindfulness. During weeks 5-12, participants will have full access to the HMP meditation library.
223535017|NCT05732038|BEHAVIORAL|Wellness App (WA)|"Participants in the WA group will listen to a minimum of 10 minutes per day of a caregiver specific educational podcast (including topics such as Caring for the Caregiver or Folate and Preventing Alzheimer's) delivered via a mobile app for the 12 weeks. The app contains one podcast per day for twelve weeks."
223535018|NCT02876731|DEVICE|PET-CT|NaF PET-CT
223535019|NCT02876731|DEVICE|MRI|DWMRI
223535020|NCT00317811|DIETARY_SUPPLEMENT|ascorbic acid|
223535021|NCT00317811|DRUG|bortezomib|
223535022|NCT00317811|DRUG|melphalan|
223535023|NCT05515744|PROCEDURE|Childbirth|Induction or planned cesarean
223535024|NCT02759133|DEVICE|Metal wire|Localization technique for breast surgery using metal wire
223535025|NCT02759133|DEVICE|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
223535026|NCT00805584|DRUG|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
223535027|NCT02272127|DRUG|icotinib|
223535028|NCT03961126|DRUG|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
223535029|NCT03961126|DRUG|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
223535030|NCT03179878|DRUG|Placebo|Placebo
223535031|NCT03179878|DRUG|SYNB1020|Investigational Product
223535032|NCT04162834|DRUG|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
223535033|NCT04162834|DRUG|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
223535034|NCT00431964|DRUG|azithromycin 250 mg tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
223535035|NCT00431964|DRUG|placebo tablets|"* One (1) tablet three times weekly for patients who weigh 40-79 lbs~* Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
223535036|NCT06362109|BEHAVIORAL|Routine rehabilitation|"Routine rehabilitation consists of:~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223535037|NCT06362109|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
223535038|NCT03868358|DEVICE|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
223707139|NCT00806351|DRUG|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
223707140|NCT00806351|DRUG|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
223707141|NCT00134030|DRUG|Cisplatin|Given IV
223707142|NCT00134030|DRUG|Doxorubicin Hydrochloride|Given IV
223707143|NCT00134030|DRUG|Etoposide|Given IV
223707144|NCT00134030|DRUG|Ifosfamide|Given IV
223707145|NCT00134030|DRUG|Methotrexate|Given IV
223707146|NCT00134030|BIOLOGICAL|Peginterferon Alfa-2b|Given subcutaneously
223707147|NCT00134030|OTHER|Quality-of-Life Assessment|Ancillary studies
223707148|NCT00134030|OTHER|Questionnaire Administration|Ancillary studies
223707149|NCT00134030|PROCEDURE|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
223707150|NCT04941859|BEHAVIORAL|acupoint massage and application|Patients in the experimental group were treated with acupoint application combined with acupoint massage on the basis of standard treatment for acute poisoning. When the patient began to launder the stomach, the acupoint was applied to Shenque (umbilical). After the end of the gastric launder, Shenque acupoint and Zusanli diarrhea method (referring to counterclockwise and strong stimulation) were massaged for 15 minutes, and the massage frequency was Q8H.
223707151|NCT05157438|BEHAVIORAL|virtual reality device|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, it has been used to manage cases of phobia and extreme fear through the use of exposure-based treatment programs. The virtual reality system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment into which the child can be entirely immersed. It works to distract the brain from the painful procedure and reduce the perception of pain stimuli
223707152|NCT05157438|BEHAVIORAL|screen programs|the screens are used for distraction during dental treatments. they could be on tablets, iPads or televisions.
223893742|NCT05945212|OTHER|Traditional quantified gait analysis|Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.
223707153|NCT02261454|OTHER|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
223707154|NCT05777746|BEHAVIORAL|12-week plant-based dietary program|a 12-week plant-based dietary program consisting of information via an online platform, online guidance by dieticians and in online peer support groups. Patients will aim to maximize their intake of plant-based products while reducing their of animal products as much as possible.
223707155|NCT05777746|BEHAVIORAL|Usual Diet|Patients in the control group continue with their usual diet and/or usual dietary care. Patients in the control group will be offered access to the online platform at 24 weeks.
223707156|NCT03162588|DRUG|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
223707157|NCT03405584|DRUG|Esomeprazole|Proton pump inhibitor
223707158|NCT03405584|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223707159|NCT03405584|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223707160|NCT06319378|DRUG|psilocybin 25 mg sod|psilocybin 25 mg sod
223707161|NCT06319378|DRUG|psilocybin 1 mg sod|active placebo
223707162|NCT06558045|DRUG|Rivaroxaban 20 mg film-coated tablet|One tablet of the test drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
223707163|NCT06558045|DRUG|Xarelto 20 mg film-coated tablet|One tablet of the reference drug was given orally 30 minutes after subjects have consumed a standardized high fat meal as breakfast
223707164|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
223707165|NCT02028143|DEVICE|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
223707166|NCT02028143|PROCEDURE|Pulmonary vein isolation|
223893743|NCT05945212|OTHER|SPM - Statistical Parametric Mapping|Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.
223893744|NCT05945212|OTHER|FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)|A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.
223707167|NCT02028143|PROCEDURE|ICE catheter placed through one of two existing 8F sheaths|
223707168|NCT01932307|PROCEDURE|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
223707169|NCT01088750|DRUG|cyclophosphamide|
223707170|NCT01088750|DRUG|prednisolone|
223707171|NCT01088750|DRUG|vinblastine sulfate|
223707172|NCT01088750|OTHER|watchful waiting|
223707173|NCT01088750|PROCEDURE|therapeutic conventional surgery|
223707174|NCT00855673|DEVICE|Intermittent Mechanical Compression|FM220 device
223707175|NCT00855673|DRUG|Control|Standard medical treatment
223525680|NCT06673732|OTHER|Muscle Energy Technique with Stationary Bi-Cyclying|"MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition.~For PFS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times. Stationary cycling complements the routine."
223525681|NCT06673732|OTHER|Muscle Energy Technique without Stationary Cycling|MET for post-isometric relaxation of the Achilles, calf, quads, hamstrings, and ankle, position each muscle at resistance, just short of pain. The patient contracts (10-20% effort) for 5-10 seconds while the therapist resists. After relaxing and exhaling, the therapist gently stretches the muscle to the new barrier. Repeat this process 2-3 times, gradually increasing the stretch with each repetition. Post FS MET of the Achilles tendon, calf, quads, hamstrings, and ankle, contract the muscle maximally for 5-10 seconds while the therapist resists. Afterward, the muscle is relaxed, and the therapist quickly stretches it to the new barrier, holding for 10 seconds. Following a 20-second rest, repeat the process 3-5 times. For Reciprocal Inhibition MET, the muscle is placed mid-range, the patient pushes against resistance, then relaxes while the therapist stretches the muscle. This is repeated 3-5 times without Stationary Cycling
223525682|NCT06673576|DIAGNOSTIC_TEST|Complete crown technique for superimposition|the complete crown technique, the crown of the tooth corresponding to the gingival margin under evaluation will be selected using the paint method and circular selection tool. The same selection process will be applied to the moving model.
223525683|NCT06673576|DIAGNOSTIC_TEST|Gold standard technique for superimposition|the gold standard technique, adjacent intact teeth and a portion of the palatal gingiva will be selected. Superimpositions will be executed utilizing the software's iterative closest point algorithm (ICP).
223525684|NCT06674343|DRUG|Furmonertinib|Furmonertinib 160mg, once daily, orally. Other Names: AST2818
223525685|NCT04175015|OTHER|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
223525686|NCT06675747|OTHER|Ultrasound imaging|To investigate the mechanism of action of occlusal splints, a routinely applied treatment method for myogenic temporomandibular disorders, ultrasound images will be taken from all patients before and after treatment, and measurements will be conducted based on these images.
223525687|NCT06675851|DRUG|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|Bupropion 150 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
223525688|NCT06675851|DRUG|Cipralex (escitalopram)|Escitalopram 10 mg daily after baseline PET/MRI or MRI/MRS over 6-8 weeks
223525689|NCT03006315|DEVICE|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
223525690|NCT03006315|BEHAVIORAL|Mobile Health quality of life assessements|
223525691|NCT04767048|PROCEDURE|bilateral mucosectomy + tonsillectomy|Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
223525692|NCT04767048|PROCEDURE|tonsillectomy|tonsillectomy (unilateral or bilateral at the choice of the investigator)
223525693|NCT07011394|DIAGNOSTIC_TEST|FeNO|FeNO will be measured before the bronchial provocation test using a FeNO VIOX device
223525694|NCT07011394|DIAGNOSTIC_TEST|Blood eosinophil count|a blood test will be performed om the day of bronchial provocation test
223525695|NCT07010172|DEVICE|cognitive rehabilitation with computer software|3-5 sessions per week, 4 weeks cognitive rehabilitation with computer software
223525696|NCT07011069|PROCEDURE|ESP block group|ESP blocks are performed for patients undergoing VATS.
223525697|NCT07011069|PROCEDURE|RISS block group|RISS blocks are performed for patients undergoing VATS.
223525698|NCT07010640|OTHER|Video Instrctions|Video instructions of rehabilitation techniques and movements to help with adherence and compliance to treatment.
223525699|NCT06674044|GENETIC|Atorvastatin|Atorvastatin 10mg once a day for 1 month
223535039|NCT02108288|DRUG|OPC-1085EL ophthalmic solution|
223535040|NCT02108288|DRUG|Carteolol long-acting ophthalmic solution|
223535041|NCT02108288|DRUG|Latanoprost ophthalmic solution|
223535042|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM)."
223535043|NCT06289868|DIAGNOSTIC_TEST|Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays|"All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT)."
223535044|NCT00987350|DEVICE|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
224275995|NCT01485718|DIETARY_SUPPLEMENT|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
224275996|NCT01485718|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
224275997|NCT03310593|DRUG|Cannabidiol|Cannabidiol as active intervention.
224275998|NCT03310593|DRUG|Placebo|Placebo intervention.
224275999|NCT01640041|DEVICE|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
224276000|NCT04021160|DEVICE|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
223525700|NCT06675214|DRUG|Full course of PD-1/PD-L1 blockades|a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until intolerable toxicity, or disease progression or withdrawal from the treatment.
223525701|NCT06675214|DRUG|Cisplatin-based induction chemotherapy|Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
223525702|NCT06675214|RADIATION|Standard-dose IMRT|GTVnx/nd:69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82y CTV2: 54.12Gy/33Fr/1.64Gy
223525703|NCT06675214|RADIATION|Gradient Fractionated IMRT|GTVresidue: 68Gy/30Fr/2.27Gy GTVmcr: 60Gy/30F/2Gy CTV1:54Gy/30F/1.8Gy CTV2: 48GY/30F/1.60Gy
223525704|NCT06675214|DRUG|Concurrent Chemotherapy|Cisplatin 100mg/m2 every 3 weeks for 2 cycles
223525705|NCT07011134|DRUG|Group (E): receive aminophylline early intraoperatively,|Group E (n=20): patients received aminophylline at an early intraoperative time immediately after fixation of ETT and confirmation of bilateral adequate lung ventilation (EtSevo\< 1)
223525706|NCT07011134|DRUG|Group (L) received aminophylline late intraoperatively|Group L (n=20): patients received aminophylline at late intraoperative time immediately after discontinuation of sevoflurane (EtSevo \< 1).
223525707|NCT07011134|DRUG|Group (C) will receive normal saline post-anesthetic discontinuation.|Group (C) (n=20): patients received normal saline immediately after discontinuation of sevoflurane (EtSevo \< 1).
223525708|NCT07010055|PROCEDURE|Semi-structured interview|A semi-structured interview will be conducted once in-person to each patient after a follow-up consultation in the hospital after their major surgery
223525709|NCT07010445|OTHER|Naïve: epilepsy first diagnosis, anti-epileptic drugs; DRE-surgery: resective surgery; DRE-VNS: vagal nerve stimulation; DRE-KD: ketogenic diet.|Anti-epileptic drugs, resective surgery, vagal nerve stimulation or ketogenic diet.
223525710|NCT07009691|DIETARY_SUPPLEMENT|Hydrogen water which is prepared from an OTC supplement.|The intervention is hydrogen water which is prepared from an OTC supplement. It involves measurement of heart rate variability.
223525711|NCT07010510|DIAGNOSTIC_TEST|CMR, stress ECG, Holter, BnP|"This study involves no experimental intervention. All data were collected retrospectively from patients with repaired Tetralogy of Fallot (TOF) who underwent standard clinical follow-up. As part of routine care, patients received comprehensive multimodal functional assessment, including:~Cardiac Magnetic Resonance Imaging (CMR) with feature-tracking strain analysis~Transthoracic Echocardiography~Exercise stress testing (treadmill ECG using Bruce protocol)~12-lead ECG and 24-hour Holter monitoring~Laboratory evaluation including NT-proBNP levels~NYHA functional class assessment"
223535045|NCT00987350|DEVICE|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
223535046|NCT00987350|BIOLOGICAL|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
223535047|NCT04683705|DIAGNOSTIC_TEST|Ultrasound|"1. High-resolution ultrasound evaluation of the shoulder region to recognize the biceps tendon, subscapularis tendon, supraspinatus tendon, and infraspinatus tendon.~2. High-resolution ultrasound evaluation for the C5, C6 and C7 nerve roots and the suprascapular nerve over the supraclavicular fossa , in the supraspinatus fossa and in the infraspinatus fossa to obtain the nerve cross-sectional image.~3. Collecting the shoulder pain-related information, including physical examination results (bicipital groove tenderness, Speed test, Yergason's test, Empty can test, Neer test, Hawkins-Kennedy test and painful arc test) and status of disability using Shoulder Pain and Disability Index (SPADI)."
223535048|NCT01130792|DIETARY_SUPPLEMENT|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
223535049|NCT01130792|DIETARY_SUPPLEMENT|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
223535050|NCT01991860|DRUG|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
223535051|NCT01991860|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
223535052|NCT00164281|DRUG|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
223535053|NCT01732614|PROCEDURE|Topcon Endpoint Management laser|
223535054|NCT01337570|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
223535055|NCT01337570|OTHER|Placebo|Vaginal Ring containing no drug substance
223535056|NCT01337570|DRUG|Dapivirine|
223535057|NCT05945888|DRUG|BI 3000202|BI 3000202
223535058|NCT05945888|DRUG|Placebo matching BI 3000202|Placebo matching BI 3000202
223535059|NCT02638909|DRUG|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
223535060|NCT03434834|DEVICE|optical coherence tomography|OCT measurements of 5 locations in the esophagus
223535061|NCT04753489|DRUG|Rivaroxaban film-coated tablet 10 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
224276001|NCT04021160|DEVICE|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
224276002|NCT00752076|OTHER|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
223525712|NCT07010731|OTHER|Social support|After adopting the questioner from Oslo-3 -item social support scale, it was translated in to local language (Amharic) and then back to English by another language expert. The data was collected through face-to-face interviews with three BSc nurses. It was supervised by one MSc nurse
223525713|NCT07009912|DEVICE|Total Knee Arthroplasty|Robotic-assisted primary total knee arthroplasty, evaluating updated features for the Zimmer Biomet ROSA® Knee System, v1.5.
223525714|NCT07011355|OTHER|Stress Ball|"Targeted Sensory Stimulus Type - Proprioceptive Input Based Mechanism:~Stress ball application is aimed at regulating the nervous system, especially through proprioceptive and tactile (tactile) stimuli. In this respect, it differs from methods such as aromatherapy, music therapy or breathing exercises, which are more effective through the sensory, emotional or autonomic nervous system."
223525715|NCT07011290|OTHER|Self-paced Walking (W) training sessions|Participants will partake in 2 sessions of self-paced walking (W), each composed by 3x14 min periods interspersed by 2 min breaks, in which the participants will walk at a self-selected speed (without running) along a 38x18 m course.
223525716|NCT07011290|OTHER|Brisk walking (BW) training sessions|Participants will partake in 2 sessions of brisk walking (BW), each composed by 3x14 min periods, interspersed by 2 min breaks, in which the participants will follow a designated instructor who will dictate the walking speed along a 38x18 m course, thus ensuring that the speed of the walking corresponds to a brisk walking speed.
223525717|NCT07011290|OTHER|Recreational running team handball (RTH) training sessions|"Recreational running team handball (RTH):~Participants will partake in 2 sessions of recreational team handball matches (RTH), each composed by 3x14 min periods, interspersed by 2 min breaks on a 40x20m indoor court."
223525718|NCT07011290|OTHER|Recreational walking team handball (WTH) training sessions|"Recreational walking team handball (WTH):~Participants will partake in 2 sessions of recreational walking team handball matches (WTH), each composed by 3x14 min periods, interspersed by 2 min breaks on a 40x20m indoor court."
223525719|NCT06678581|DRUG|SAP-001|Solid Oral Tablet
223525720|NCT06678581|DRUG|Placebo|Solid Oral Tablet
223525721|NCT06678568|OTHER|telemedicine follow-up in 3rd week|Intervention group will be appointed with telemedicine follow-up in 3rd week after injury, instead of hospital follow-up visit.
223525722|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe
223525723|NCT06683807|DRUG|Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule|Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
223525724|NCT06682000|DRUG|DWC202404, DWC202314|\- 2 tablet, Oral, Once a day
223525725|NCT06682000|DRUG|DWC202404, DWC202314P|\- 2 tablet, Oral, Once a day
223525726|NCT06681974|BEHAVIORAL|CONTROL:Information form with hygienic-dietary measures or sleep hygiene guidelines is provided and explained.|"* Establish a regular sleep schedule~* Do not stay in bed longer than our regular sleep schedule.~* Avoid naps during the day~* Do not perform exciting activities and/or activities that demand physical or mental energy in the 3 hours prior to going to bed.~* Avoid the use of mobile screens, as well as exposure to intense light in the 3 hours prior to going to bed.~* Follow a healthy bedtime routine~* Healthy lifestyle habits: avoid tobacco, alcohol and other toxic substances."
223525727|NCT06681974|BIOLOGICAL|EXPERIMENTAL: program of exercises that will be composed of 4 blocks|the first is the work of the soft palate (retropalatine level), the second is the work of the functionality of the tongue (retroglossus level), the third is the work of the position of the hyoid bone (hypopharyngeal level), and the fourth is work on anterior head tilt and craniocervical extension (anterior head posture).
223525728|NCT06683248|OTHER|Investigate sleep deprivation|"Sleep deprivation~Devices used:~Dreem band for EEG Actiheart Tobii Eye tracker Blood glucose monitor Blood pressure cuff Mira fertility tracker Galvanic skin response K5: wearable metabolic system Fitbit: wearable technology Withings sleep analyzer Body composition monitor"
223525729|NCT06682598|OTHER|Multicomponent physical exercise training|The subjects will perform one session per day of multicomponent physical exercise training, consisting of strength, power, balance, and walking exercises. The program will have progressive intensity and volume, adapted to the frailty level of the patient. The frailty level will be screened by the Short Physical Performance Battery. Each session will consist of two strength exercises for the upper limbs and one to three for the lower limbs. Also, one exercise for balance, and walking. Participants will be instructed to perform the concentric phase of the movement as fast as possible, since a good quality of movement is maintained, and the eccentric phase in two seconds. An expert researcher will supervise the entire session.
223525730|NCT06689527|DRUG|Vamorolone|Days 3 to 14: 6 mg/kg vamorolone once daily.
223525731|NCT06689527|DRUG|Midazolam|Day 1 and 14: Single doses of 2.5 mg midazolam
223525732|NCT06692764|DRUG|Placebo|"0 mg (Placebo). Participants will receive three bottles, each containing 35 tablets with placebo tablets.~Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose."
223535062|NCT04753489|DRUG|Xarelto® film-coated tablet 10 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
224276003|NCT04009876|DRUG|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
224276004|NCT04009876|PROCEDURE|Surgical resection|Surgical resection of the tumour
224276005|NCT04009876|OTHER|Watch-and-wait|No surgery approach
223707176|NCT02925520|DRUG|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
223707177|NCT02842359|DRUG|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
223707178|NCT02842359|DRUG|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
223707179|NCT02842359|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
223707180|NCT06194630|DRUG|68Ga-A3|Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
223707181|NCT04690933|OTHER|Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients|Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
223707182|NCT06210607|DRUG|HS-10511 Tablets|HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts
223707183|NCT06210607|DRUG|HS-10511 Tablets Placebo|HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
224276006|NCT04009876|DRUG|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
223707184|NCT00508755|DEVICE|Gait Robot|gait training with the use of a gait robot
223707185|NCT00508755|DEVICE|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
223707186|NCT01765907|DEVICE|HIFU|
223707187|NCT03837860|DRUG|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
224276007|NCT04009876|DRUG|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
224276008|NCT05778760|OTHER|Retinol|Topical retinol (0.5%) applied to the face
224276009|NCT05778760|OTHER|Adapinoid|Topical Adapinoid (0.5%) applied to the face
224276010|NCT02183376|DRUG|BI 1356|
224276011|NCT03993080|DEVICE|Virtual reality relaxation|1-3.5 minute 360° videos
224276012|NCT05653362|DEVICE|Coconut Oil|Coconut oil was applied to the patients' abdomen during the ultrasound to serve as a conducting medium. When applied topically, coconut oil is not absorbed systemically by the subject and will not affect the fetus. There are no studies showing a potential risk of the use of topical coconut oil in pregnancy. Subjects with a coconut allergy will be excluded from this study due to risk of allergic reaction.
223707188|NCT03837860|DRUG|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
223707189|NCT03837860|DRUG|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
223707190|NCT05306392|DEVICE|Moderate Hypothermia|moderate hypothermia will be induced using the heat controller of the VV-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 48 hours followed by a progressive reheating (0.2±0.1°C/h) to reach 36 °C. Temperature at 36°C will be maintained during 48 hours after having reached 36 °C.
223707191|NCT05306392|DEVICE|Normothermia|Temperature at 36°C will be maintained during 48 hours after having reached 36 °C
223707192|NCT03351933|BIOLOGICAL|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
223707193|NCT03812107|OTHER|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
223707194|NCT03812107|OTHER|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
223707195|NCT03975036|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules
223707196|NCT03975036|DRUG|pd-1 antibody|Pembrolizumabinjection
223707197|NCT01435603|BEHAVIORAL|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
223893745|NCT05451940|DRUG|Hydroxyurea|Hydroxyurea is an orally available antimetabolite medication that has been shown to reduce the frequency of painful crises and acute chest syndrome in adults and children with sickle cell disease. Hydroxyurea treats sickle cell disease by a number of different mechanisms, including increasing the expression of fetal hemoglobin (HbF), which reduces sickling of red blood cells.
224276013|NCT05653362|DEVICE|Commercial Ultrasound Gel|Room-temperature Aquasonic 100 (Parker Laboratories, Inc., Fairfield, NJ) applied to patients' abdomen during the ultrasound to serve an another conducting medium.
224276014|NCT03419962|DRUG|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
223707198|NCT01435603|BEHAVIORAL|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
223707199|NCT04512014|DIAGNOSTIC_TEST|serum lactate|perioperative measurement of lactate levels
223707200|NCT02846831|OTHER|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
223707201|NCT02846831|OTHER|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
223707202|NCT02846831|DEVICE|Insulin pump|Tandem Diabetes Care
223707203|NCT02846831|DEVICE|Continuous glucose monitoring system|Dexcom G5 Platinum
223707204|NCT02846831|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
223707205|NCT01784445|DRUG|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
223707206|NCT04352569|DEVICE|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a non invasive brain stimulation technic
223707207|NCT05879679|BEHAVIORAL|Food craving induction|Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
223707208|NCT00821483|DRUG|Frovatriptan|2.5mg, qd
223707209|NCT03734042|BIOLOGICAL|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
223707210|NCT03734042|BIOLOGICAL|Normal saline|Intrauterine infusion of normal saline at day 11
223707211|NCT01682954|BEHAVIORAL|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
223707212|NCT03777488|DRUG|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
223707213|NCT03777488|DRUG|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
223707214|NCT03777488|DRUG|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
223707215|NCT00159120|OTHER|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
223707216|NCT01349179|DEVICE|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
223707217|NCT01773252|DEVICE|Flow Detection System|
223707218|NCT00066352|DRUG|bortezomib|
223707219|NCT00916097|DRUG|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
223707220|NCT03498144|DEVICE|Anterior segment OCT|lower punctum examination by AS-OCT
223707221|NCT05212571|DRUG|S-ketamine infusion inpatient setting|S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
223707222|NCT05212571|DRUG|S-ketamine infusion outpatient setting|S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.
223707223|NCT06016725|OTHER|Exercise Intervention|Participate in online resistance training sessions
223707224|NCT06016725|OTHER|Informational Intervention|Given educational materials
223707225|NCT06016725|OTHER|Nutritional Assessment|Participate in online nutritional counseling
223707226|NCT06016725|OTHER|Physical Performance Testing|Ancillary studies
223707227|NCT06016725|OTHER|Quality-of-Life Assessment|Ancillary studies
223707228|NCT06016725|OTHER|Questionnaire Administration|Ancillary studies
223707229|NCT06109649|DRUG|Afamelanotide and NB-UVB Light|Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.
223707230|NCT06109649|PROCEDURE|NB-UVB Light|Patients will receive NB-UVB light twice per week for 20 weeks. Upon study completion, NB-UVB Light Arm participants will have the opportunity to enroll in an open-label extension phase of the study. In this extension phase, participants will undergo the same evaluations and assessments as the ones performed in the main part of the study under Afamelanotide and NB-UVB Light Arm.
223707231|NCT04439201|DRUG|Palbociclib|Given PO
223707232|NCT05394675|DRUG|DS-9606a|Intravenous infusion
223707233|NCT06464003|OTHER|Questionnaire|Malocclusion impact questionnaire
223707234|NCT06485947|BIOLOGICAL|Dinutuximab beta|Combination of immunotherapy with standard chemotherapy
223707235|NCT06485947|DRUG|chemotherapy treatment called GPOH|chemotherapy treatment called GPOH
223707236|NCT06485947|DRUG|chemotherapy treatment called rapid COJEC|chemotherapy treatment called rapid COJEC
223707237|NCT02989025|DRUG|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
223707238|NCT03651206|DRUG|Niraparib|PARP Inhibitor
223707239|NCT03651206|COMBINATION_PRODUCT|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
223707240|NCT03651206|DRUG|Chemotherapy Drugs|Chemotherapies given in standard of care
223707241|NCT06315673|BEHAVIORAL|Digital Speech and Handwriting Assessment|"Subjects may complete all or some of these tests, depending on functional ability.~* Handwriting battery~* Pattern tracing battery~* Speech Assessment Battery"
223707242|NCT06655285|OTHER|This was a retrospective study and no patient intervention was performed.|This was a retrospective study and no patient intervention was performed.
223707243|NCT04107766|DEVICE|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
223707244|NCT06656494|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
223707245|NCT06656494|DRUG|Azacitidine|Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle.
223707246|NCT04039633|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
223707247|NCT04039633|PROCEDURE|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
223707248|NCT04786977|OTHER|No Intervention, Observational Study|No Intervention
223707249|NCT03451266|DRUG|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
223707250|NCT03451266|DRUG|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
223707251|NCT04845477|DEVICE|Magnetic tape|magnetic tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
223707252|NCT04845477|DEVICE|Kinesiology tape|kinesiology tape is applied without creating any tension over the cutaneous nerves of the groin with less internal hip rotation
223707253|NCT04144972|DEVICE|Medtronic Summit RC+S or Percept RC|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
223707254|NCT06662942|DRUG|StrataMGT|StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
223707255|NCT06662942|DRUG|Placebo|The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
223707256|NCT06666127|OTHER|LONG and SHORT Resistance Training|One side of the body will be randomly assigned to perform exercises in position 3 (LONG) with the other randomly assigned to position 2 (SHORT) of Prime Fitness horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Each exercise will include 1 warm up set at 50% 1RM followed by 4-5 sets of 8-12 repetitions per limb. 2 minutes of rest between sets on the same side of body will be administered as the participant will alternate between the right and left limb. The left and right side limbs will alternate each session in which one starts each exercise, resulting in 10 training sessions each where the left and right limbs starts first on each exercise. All sets will be performed to momentary failure. A Dynamic Double Progression will be employed to ensure intensity is maintained.
223707257|NCT06666127|OTHER|Maximal Isotonic Strength Testing (1RM)|Each limb will perform a 1RM strength test with each Prime Fitness machine training horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension respectively. Each machine will be set to position 1 (maximal load in mid-range). Testing will occur in weeks 1 and 12 of the study with the non-dominant arm and leg tested before the dominant arm and leg in each exercise. Participants self-selects first warm up set with a weight that is performed between 6-10 repetitions on both limbs. Rest for 1 minute between limbs and subsequent set. A weight is then selected by research staff to perform 3 repetitions with based on previous set. Load is now increased until 1RM is achieved. Rest periods should remain at least 1 minute alternating between limbs, with 1RM being complete within 3-5 attempts. Participant will rest 2-5 minutes before starting testing on the next exercise. Repeat for all exercises. Use pre testing data to inform 1RM attempts for post testing.
223707258|NCT06666127|OTHER|Isokinetic Strength Testing|Participants will engage in isokinetic strength testing on the isokinetic dynamometer (Biodex) in weeks 1 and 12 for each of the four movements: Horizontal shoulder adduction, horizontal shoulder abduction, shoulder abduction and hip extension. Participants will perform each movement unilaterally. Participants will start with the non-dominant arm and leg for each movement. Each movement will be tested through A maximal active range of motion. Participants will complete 10 sub-maximal repetitions to allow familiarization each movement. After a 2-minute rest, participants will complete 3 maximal concentric and eccentric repetitions with 30 seconds rest at 30 degrees per second before the Biodex is reset for the next movement.
223707259|NCT06666127|OTHER|Muscle Oxygenation|During the first and last LONG and SHORT training session (visit 5 and visit 24), A near infrared spectroscopy sensor (NIRS device) (Trainred) will be affixed to the muscle belly of the deltoid during the lateral raise exercise to measure muscle oxygenation.
223707260|NCT06605456|OTHER|Proprioceptive neuromuscular facilitation with postural education|"Phase 1: Active Rhythmic Initiation The exercise was demonstrated to the students in a seated position, as sitting is considered the functional position for neck motion and stability. Then, the exercises was passively practiced on the students using tactile input. After passive demonstration, students were asked to perform the same exercise actively and verbal commands were used to guide and correct them.~Phase 2: Resisted Rhythmic Initiation Modified The investigators applied resistance by placing the palm of one hand on the right side of the chin to strengthen the muscles. Then, resisted scapular posterior depression PNF exercise also employed.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
224276015|NCT04450693|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
223525733|NCT06692764|DRUG|AZD0780|"Dose 1 Participants will receive three bottles, each containing 35 tablets:~* 1 bottle of dose a AZD0780 tablets~* 1 bottle of dose b AZD0780 tablets~* 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose."
223525734|NCT03968042|DRUG|Nerve Growth Factor|Intramuscular injection for 2 weeks
223525735|NCT03968042|DRUG|Edaravone|Intravenous injection for 2 weeks
223525736|NCT03968042|DRUG|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
223525737|NCT06695689|DRUG|LM303|Treatment with LM303 injection
223525738|NCT06695975|BEHAVIORAL|Occupational self-analysis|"Occupational self analysis program is delivered in group sessions, each session lasting 45 minutes, twice a week. Also Individual sessions are held throughout the program with each participant, with the intention of clarifying certain concepts and resolving specific difficulties that were occurring.The thematic modules worked are 5; occupation-health and difficulty, occupational balance, adaptation strategies to difficulties, social relationships and knowing other realities.~The methodological strategies used to structure the program were the Model of Human Occupation (MOHO) and the See-Judge-Act methodology"
223525739|NCT06695208|DRUG|Biodentine|biodentine used in socket preservation
223525740|NCT06690450|DRUG|Venofer® 200 mg|A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes
223525741|NCT06690450|DRUG|Venofer® 100 mg|A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
223535063|NCT01082302|DRUG|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
223535064|NCT01082302|OTHER|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
223535065|NCT02098135|DEVICE|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
223535066|NCT01775540|DRUG|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
223535067|NCT01775540|DRUG|Saline solution|Saline solution,1 drop used QID for 4 weeks
223535068|NCT01775540|DRUG|Maxidex|Eyedrop-1 drop QID for 4 weeks
223535069|NCT03281213|OTHER|Thoracotomy|
223535070|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
223535071|NCT01278264|DRUG|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
223535072|NCT05049863|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil is commercially available.
223535073|NCT05049863|DRUG|Allopurinol|Allopurinol is commercially available.
223535074|NCT05049863|DRUG|Irinotecan|Irinotecan is commercially available.
223535075|NCT00172367|DRUG|Lycopene|
223535076|NCT02900014|PROCEDURE|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
223535077|NCT01901692|RADIATION|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
223535078|NCT01901692|DRUG|Sorafenib|Sorafenib 800 mg/day orally
223535079|NCT01731925|DRUG|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
223535080|NCT01731925|DRUG|Placebo (for sunitinib)|
223535081|NCT01731925|DRUG|Sunitinib|Sunitinib 37.5 mg daily
223535082|NCT03026179|BEHAVIORAL|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
223535083|NCT05152602|PROCEDURE|Bilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
223535084|NCT05152602|PROCEDURE|Unilateral Erector spinae plane block|Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
223535085|NCT01126957|DRUG|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
223535086|NCT01126957|DRUG|Placebo|Placebo given as an bolus to control group.
223535087|NCT01126957|DRUG|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
223535088|NCT01126957|DRUG|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
223535089|NCT00116571|DRUG|Lemuteporfin for injection|
223535090|NCT00116571|DEVICE|Transurethral drug delivery system|
223535091|NCT00116571|DEVICE|Transurethral light delivery system|
223535092|NCT05600413|DIETARY_SUPPLEMENT|L-Citrulline|4 weeks of L-Citrulline supplementation (6 grams/day)
223535093|NCT05600413|DIETARY_SUPPLEMENT|Placebo|4 weeks of Placebo (crystalline cellulose)
223535094|NCT04651530|PROCEDURE|Phaco|phacoemulsification of cataract only
223535095|NCT04651530|PROCEDURE|Phaco+ECP|Endoscopic cyclophotocoagulation is done in the same procedure as phacoemulsification of cataract
223535096|NCT03196830|BIOLOGICAL|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
223535097|NCT01129206|DRUG|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
224276016|NCT04450693|OTHER|Standard care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
223535098|NCT01129206|DRUG|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
223535099|NCT01129206|RADIATION|fludeoxyglucose F 18|Correlative studies
223535100|NCT01129206|PROCEDURE|positron emission tomography|Correlative studies
223535101|NCT04165837|DRUG|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
223535102|NCT04165837|DRUG|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
223535103|NCT05260749|PROCEDURE|real-time fMRI neurofeedback training procedure|real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
223535104|NCT05260749|PROCEDURE|real-time fMRI sham-controlled neurofeedback training procedure|real-time fMRI sham neurofeedback training procedure running on the Turbo Brain voyager (TBV) 3.2 software (Brain Innovation, Maastricht, The Netherlands)
223535105|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
223535106|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
223535107|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
223535108|NCT01564017|BIOLOGICAL|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
223535109|NCT01564017|BIOLOGICAL|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
223535110|NCT01564017|BIOLOGICAL|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
223535111|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
223535112|NCT00518180|BIOLOGICAL|Tdap Vaccine|One dose of vaccine administered intramuscularly
223535113|NCT00518180|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
223535114|NCT03166748|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
223535115|NCT02917005|DRUG|Palbociclib|CDK 4/6 inhibitor
223535116|NCT02917005|DRUG|Exemestane|Aromatase inhibitor
223535117|NCT02917005|DRUG|Goserelin|LHRH agonist
223535118|NCT05244161|BEHAVIORAL|RMV-ECD|Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
223535119|NCT03347630|DIAGNOSTIC_TEST|MRI|Thoraco-abominal MRI
223535120|NCT06033625|PROCEDURE|CEMENTLESS TOTAL KNEE REPLACEMENT|CEMENTLESS CRUCIATE RETAINING BICOMPARTMENTAL TOTAL KNEE REPLACEMENT
223535121|NCT00138684|PROCEDURE|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
223535122|NCT04565730|OTHER|Grup I= General anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
223535123|NCT04565730|OTHER|Grup II= Spinal anesthesia group|"Preoperative and postoperative evaluation Pre-operative data will be collected 1 to 2 hrs before operation. Preoperative anxiety level will be assessed by the Hospital Anxiety and Depression Scale (HADS) and Amsterdam Preoperative Anxiety and Information Scale.~Patients will be asked to complete the Edinburgh Postnatal Depression Scale (EPDS) on the morning of discharge, 1 months and 3 months days after delivery. An online survey will be conducted post-Cesarean delivery to investigate the primary outcome of PND using EPDS, and those will not complete the online survey received phone calls to conduct the follow-up surveys."
223535124|NCT02092181|DRUG|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
223535125|NCT02092181|DRUG|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
223535126|NCT00090506|BEHAVIORAL|Yoga|
223535127|NCT01119638|DRUG|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
223707261|NCT06605456|OTHER|Active neck muscle stretching and strengthening exercises|"Phase 1: Active Muscle Stretching In this phase, participants were instructed on performing active muscle stretching exercises for all cervical muscles, including neck flexors, extensors, lateral flexors and neck rotators. Each stretch was held for a period of 25-30 seconds and repeated three times.~Phase 2: Self-Isometric Strengthening Participants were provided with a demonstration of self-isometric strengthening exercise for the neck muscles. The exercises involved six movement patterns: cervical flexion, cervical extension, right/left lateral flexion and right/left rotation. For each exercise the participants were required to apply resistance against the direction of movement using their hand without allowing any motion in the neck.~Also received a comprehensive postural education program to emphasize the importance of proper posture. The program was divided into three sections, which focused on the effects of good and bad posture, as well as practical demonstration."
223707262|NCT06987370|RADIATION|Conventional Radiotherapy (CRT)|The conventional radiotherapy group, that is, the control group, administering conventional external beam radiotherapy with a dose of 30 Gy in 10 fractions to the bone metastasis lesions.
223707263|NCT06987370|RADIATION|SCART (Stereotactic Central Ablative Radiation Therapy ) /SFRT（Spatially Fractionated Radiation Therapy ）|"Stereotactic Central Ablative Radiotherapy (SCART): When using SCART to treat bone metastases with associated soft tissue components, the gross tumor volume (GTV) of the bone metastases must be accurately delineated according to the guidelines. The GTV are contracted to derive the SCART-Treatment Volume (STV). An initial dose of 8-12 Gy in a single fraction is delivered to the STV, followed by a dose of 25-40 Gy in 5 fractions to the clinical target volume (CTV). Spatially Fractionated Radiation Therapy (SFRT): The GTV are reduced to form a LATTICE target area. Several vertices are uniformly contoured along the edges of the LATTICE. A dose of 8-12 Gy in a single fraction is delivered to the vertices, followed by a dose of 25-40 Gy in 5 fractions to the CTV."
223707264|NCT06987071|PROCEDURE|Acupuncture|Insertion of sterile, single-use needles at specific acupuncture points (LI4, PC6, ST36, SP6) for 20 minutes with manual stimulation, administered 30 minutes before the biopsy by a licensed acupuncturist.
223707265|NCT06987071|PROCEDURE|sham acupuncture|Superficial needle insertion at non-acupuncture points without stimulation, administered 30 minutes before the biopsy, mimicking the acupuncture procedure without therapeutic intent.
223707266|NCT04582695|BEHAVIORAL|Written Exposure Therapy Integrated with Cognitive Behavioral Therapy for Alcohol Use Disorder|Participants will receive 5 to 6 weeks of an integrated behavioral therapy that address posttraumatic stress disorder and alcohol use disorder. Sessions will be 60 minutes in length. It will include written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes. In addition, they will receive 20 minutes of intervention focused on cognitive behavioral therapy for alcohol use disorder which involves learning skills to cope with alcohol cravings and behavior (e.g., challenging thoughts, problem solving).
223707267|NCT04582695|BEHAVIORAL|Written Exposure Therapy|Participants will receive 5 to 6 weeks of written exposure therapy, which involves writing about their experience of sexual assault for 30 minutes.
223707268|NCT06992440|DRUG|Empagliflozin 10 MG|10 mg tablet once daily
223707269|NCT06992440|DRUG|Placebo|matching tablet once daily
223707270|NCT01690585|DRUG|Ferinject 1000 mg|
223707271|NCT01690585|DRUG|Sodium chlorure 0,9 %|
224276017|NCT00225329|PROCEDURE|Labour assessment and support|
223707272|NCT01052376|DEVICE|Confocal endomicroscopy|
223707273|NCT06862635|OTHER|Hydrotherapy|Patients will receive hydrotherapy sessions including stretching, resistance, and balance exercises in water
223707274|NCT06862635|OTHER|traditional land-based balance exercises|Patients will receive traditional land-based balance exercises in the form of stretching, strengthening and balance exercises.
223707275|NCT06857357|OTHER|Questionnaires|"The Tampa Kinesiophobia Questionnaire is a 17-question questionnaire that assesses avoidance of injury and fear of movement. The scale is scored using a Likert scale (1 = Strongly disagree, 4 = Strongly agree). Items 4, 8, 12 and 16 are reversed to calculate the total score of the scale. The total score is between 17 and 68. As the score of the person increases, it is understood that their kinesiophobia is high. A total score higher than 37 is considered as high kinesiophobia. However, since not every item of the questionnaire addresses patients with headache in this study, some questions were removed, some questions were edited and some questions were added to create a kinesiophobia questionnaire for headache. The newly created questionnaire consists of 23 items. Again, it is scored using a Likert scale with 1 = Strongly disagree, 4 = Strongly agree. As the score increases, it is understood that the level of kinesiophobia is high."
224276018|NCT02914457|PROCEDURE|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
224276019|NCT06172439|OTHER|acupressure|Women in the intervention group will receive acupressure for 12 minutes.The acupressure pressure points related to the gynecologic surgery to be performed are named as the large intestine (LI4), stomach (ST36) and spleen (SP6) meridians, respectively. These points are determined by expert opinion and are used for pain control.
223707276|NCT06615739|DEVICE|Regenerex Tissue Attachment Augments|Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
224276020|NCT02451644|DEVICE|pedometer|patient will cary pedometer
224276021|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (25 mg/100 kcal )|
224276022|NCT02092857|DIETARY_SUPPLEMENT|Arachidonic acid (34 mg/100 kcal)|
224276023|NCT02092857|DIETARY_SUPPLEMENT|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
224276024|NCT06116396|GENETIC|Genetic analysis on isolated cells|Isolation of cells from blood and urine
224276025|NCT00672217|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
224276026|NCT00672217|BEHAVIORAL|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
224276027|NCT00058435|BIOLOGICAL|abagovomab|
223893746|NCT05451940|DRUG|Epoetin Alfa|Epoetin alfa is a first-generation erythropoiesis-stimulating agent (ESA), which are recombinant versions of erythropoietin (EPO) produced using recombinant DNA technology. Erythropoietin (EPO) is a glycoprotein hormone, naturally produced mainly in the kidneys in response to hypoxia and stimulates red blood cell production (erythropoiesis) in the bone marrow.
223535128|NCT01119638|DRUG|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
223535129|NCT02373904|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
223535130|NCT01800786|DEVICE|CPAP|
223535131|NCT00242606|DRUG|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
223535132|NCT00242606|DRUG|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
223535133|NCT00485173|DEVICE|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
223535134|NCT03006055|DEVICE|Circulating tumor cells|
223535135|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Healthy volunteers will receive AZD4604 administered with a DPI. The dose is expected to be administered between 10 to 45 minutes, depending upon dose. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
223535136|NCT04769869|DRUG|Placebo for AZD4604 for inhalation via DPI|"Part 1a: An additional cohort of healthy volunteers will receive a placebo administered with a DPI.~Part 2: Healthy volunteers will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 6, and a single dose will be administered on Day 7.~Part 3: Patients will receive placebo administered with a DPI. They will receive BID doses on Day 1 to Day 9, and a single dose will be administered on Day 10."
223535137|NCT04769869|DRUG|AZD4604 for IV administration|Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
223535138|NCT04769869|DRUG|AZD4604 for oral administration|Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
223535139|NCT04769869|DRUG|AZD4604 for inhalation via DPI|Patients with mild asthma will also receive AZD4604 administered with a DPI. Patients will receive BID doses on Day 1 to Day 9 (morning and evening with 12-hour intervals between doses), and a single morning dose will be administered on Day 10. On Day 1 and Day 10, the morning dose will be administered after an overnight fast of 10 hours. For all other doses, the dose will be administered after a 1-hour fast.
223535140|NCT05595109|DRUG|Silymarin|"Silymarin administration prevent the neuro-degeneration through inhibiting the activation of microglia, silymarin attenuates the activation of glial cell activation in cellular models possibly through inhibition of inducible nitric oxide synthase (iNOS) production, also reported to protect both microglia and astroglia from oxidative insults induced by peroxide in ex vivo system .~It also significantly reduces doxorubicin-pro-oxidative activity and decreases histological changes in liver and heart tissue . The hepato-protective and cardio-protective effects of silymarin may be attributed to its antioxidant capacity, its ability to prevent lipid peroxidation and its ability to increase glutathione concentration.~silymarin was reported to improve cognitive impairment in mice."
223535141|NCT05595109|DRUG|Placebo|which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
223535142|NCT04887532|DRUG|HR19042 capsule|phase 1 :8mg; phase 2:12mg; phase 3:16mg
223535143|NCT03445312|BEHAVIORAL|not processing urine cultures|microbiology lab will not process culture unless called
223535144|NCT02433938|PROCEDURE|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
223535145|NCT02433938|PROCEDURE|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
223535146|NCT04894682|BIOLOGICAL|Vaccine inoculation against SARS-CoV-2|Inoculation with any type of approved vaccines according to the standard or recommended dose
223535147|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
223535148|NCT00829244|DRUG|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
223535149|NCT04487509|OTHER|THROMBOLYSE|the treatment delivered to the emergency room, in particular the nature of the treatment for obstruction (primary angioplasty or thrombolysis)
223535150|NCT03361878|DRUG|Metformin Hydrochloride|Single dose of 500mg oral metformin
223535151|NCT02623244|PROCEDURE|Laparoscopic oophorocystectomy or oophorectomy|
223535152|NCT01472731|OTHER|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
223535153|NCT01472731|DRUG|GC1008|5 mg/kg intravenous use
223535154|NCT02727608|DRUG|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
223535155|NCT00755170|DRUG|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
223535156|NCT00755170|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
223535157|NCT00404807|DEVICE|CPAP(Continuous Positive Airway Pressure)|
223535158|NCT02575144|DRUG|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
223535159|NCT02575144|DRUG|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of \>60 cc/min
223535160|NCT02575144|DRUG|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
223535161|NCT01742884|OTHER|Thealoz|Instillation of 1 drop of Thealoz
223535162|NCT01742884|OTHER|Vehicle|1 drop of the vehicle will be instillated in the eye
223535163|NCT03342560|DEVICE|Sonographic SWE measurements with 4 different ultrasound systems|Sonographic Shear wave elastography will be performed to quantify liver fibrosis
223535164|NCT05415488|OTHER|Online dietary group treatment|Dietary advice will be given during one 90 minute online group session
223535165|NCT04400825|OTHER|Dry needling|Dry needling of the active MTrPs following the technique described by Hong et al (1994,1995)
223535166|NCT02604511|DRUG|Ibrutinib|
223535167|NCT06305208|DEVICE|Endoscopic gastric suturing|Endoscopic suturing of the stomach to reduce volume and promote weight loss with either the Apollo Overstitch or Overstitch Sx system.
223535168|NCT06305208|DEVICE|Endoscopic gastric plication|Endoscopic plication of the stomach to reduce volume and promote weight loss with either the POSE or Endomina system.
223535169|NCT06305208|DEVICE|Revisional gastroplasty|Endoscopic suturing or plication of the stomach among patients who have previously undergone gastroplasty, sleeve gastrectomy, or Roux-en-Y gastric bypass to restrict the stomach and promote weight loss
223535170|NCT06305208|DEVICE|Transoral outlet reduction endoscopy (TORe)|Reduction of the size of the gastro-jejunal anastomosis among patients who have previously undergone Roux-en-Y gastric bypass to promote weight loss. A variety of techniques may be used alone or in isolation including suturing (Apollo Overstitch), plication (POSE), argon photocoagulation, and endoscopic submucosal resection/dissection.
223535171|NCT06305208|DEVICE|Duodenal mucosal resurfacing (DMR)|Endoscopic ablation of the post-ampullary duodenal mucosal to enhance improvement in glycaemic control among patients with type 2 diabetes.
223535172|NCT06305208|DEVICE|Intragastric balloon(s)|The insertion of an intragastric implant into the stomach, which is subsequently filled with air or water to promote weight loss. Several intragastric balloons are available including Allurion, Heliosphere, Obalon, Orbera, and Spatz.
223535173|NCT03770286|DEVICE|5% Fluoride Varnish|Topical varnish
223535174|NCT03770286|DEVICE|38% Silver diamine fluoride|Topical varnish
223535175|NCT03770286|DEVICE|Super Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
223535176|NCT02297412|DRUG|Minocycline Hydrochloride|Given PO
223535177|NCT02297412|OTHER|Placebo|Given PO
223535178|NCT02297412|OTHER|Quality-of-Life Assessment|Ancillary studies
223535179|NCT02297412|OTHER|Questionnaire Administration|Ancillary studies
223535180|NCT01596114|OTHER|Stopping treatment with TKI|stopping until loss of MMR
223535181|NCT02031302|DEVICE|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] of \<1.0 cm2 or index of \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
223535182|NCT05479370|BIOLOGICAL|Flublok Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223535183|NCT05479370|BIOLOGICAL|Fluarix Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223535184|NCT05479370|BIOLOGICAL|Flucelvax Quadrivalent vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223535185|NCT03050710|DEVICE|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
223535186|NCT03374306|DRUG|Atropine (0.01%)|tropical application
223535187|NCT03374306|DRUG|Artificial tear|tropical application
223535188|NCT04756453|DEVICE|clip-traction|A endoscopic clip with a loop of tied dental floss will be attached to the lesion. The loop will then be caught by another endoscopic clip and attached to adjacent bowel wall, thus creating tension in the tissue, making dissection easier.
223535189|NCT01370551|DRUG|Estriol 0.03 mg, lyophylized lactobacillus|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
223535190|NCT04466358|PROCEDURE|Modified CLOSE protocol|Modified CLOSE protocol guided isolation of pulmonary veins.
223535191|NCT04466358|PROCEDURE|High density mapping guided pulmonary vein isolation|Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
223535192|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Low Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 2 consecutive minutes for each side, only once for the experiment duration.
223535193|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (Intermediate Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 3 sessions of 2 minutes, with 2 minutes of rest for each side. stimulation will be provided only once for the experiment duration.
223525742|NCT06691815|DIAGNOSTIC_TEST|Triptorelin (GnRH agonists)|"1. Triptorelin test. A baseline blood sample will be taken to determine LH, FSH, Estradiol/Testosterone, AMH, and Inhibin B. Then, Triptorelin Acetate 100 ug/m² of body surface area will be administered subcutaneously, maximum dose 0.1 mg (Decapeptyl Daily prefilled syringe of 0.1 mg for subcutaneous administration. Three hours later, a new sample will be taken to determine LH and FSH. The patient may return home and lead a normal life. An appointment will be made the following day to perform the last sample of this test 24 hours after the subcutaneous administration of Triptorelin Acetate, with the determination of LH, FSH, Estradiol/Testosterone, and Inhibin B.~2. GnRH Infusion: This consists of determining LH and FSH in baseline blood samples, 15, 30, 45, 60 and 120 minutes after slow infusion of GnRH. GnRH 0.83 μg/min during the 120 minutes that the study lasts (Luteoliberin 100 μg)"
223525743|NCT00863590|DRUG|odanacatib|\[Intervention Name: odanacatib (Panel A)\] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
223525744|NCT00863590|DRUG|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
223525745|NCT00863590|DRUG|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
223525746|NCT00863590|DRUG|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
223525747|NCT00069550|DRUG|dextromethorphan|
223525748|NCT00069550|DRUG|donepezil hydrochloride|
223525749|NCT01554358|BEHAVIORAL|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake \<30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~\--------------------------------------------------------------------------------"
223525750|NCT02477033|DIETARY_SUPPLEMENT|Butyricicoccus pullicaecorum 25-3T|
223525751|NCT02477033|OTHER|Maltodextrin|
223525752|NCT04848506|DRUG|Aficamten (5 - 20 mg)|Aficamten tablets administered orally. During titration phase, clinic visits will occur approximately every 2-6 weeks. In the maintenance phase clinic visits will occur every 24 weeks, with safety check-in occurring every 12 weeks between visits by phone or, if desirable, in the clinic.
223525753|NCT06308315|OTHER|Rhythmic balance visual auditory exercise + Routine physical therapy|"5 minute warm-up activities.~Bal-A-Vis-X training includes:~1. Ball Rectangle; A and B hold one ball in each hand, simultaneously bounce right balls to patient left hand; while balls bounce, clap left balls on right hand; catch patient ball with left hand; continue pattern. Bounces must be simultaneous. (10 minutes)~2. Ball rectangle in which one hand has to toss a ball to a partner and the other hand catch an incoming bag from the partner and 2 ball drop/pass/catch, two-foot jumping forward, tandem walking on ground. (10 minutes)~Routine Physical therapy treatment includes:~Range of Motion exercises, Stretching, Strength, balance training for 15 minutes~5 minute cool-down activities."
223525754|NCT06308315|OTHER|Strength Training + Routine Physical Therapy|"The expert managed sessions based on:~5 minute warm-up activities. 5 minute cool-down activities. Strength training includes 5 tasks for 20 minutes~1. core strengthening,~2. upper and lower limbs strength in both static positions as well as with dynamic movements~3. standing long jump,~4. knee push-ups,~5. sit-ups~Routine Physical therapy treatment will be given for 15 minutes.~It includes:~Range of Motion exercises, Stretching, Strength, balance training."
223525755|NCT05395338|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
223525756|NCT03533569|PROCEDURE|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
223525757|NCT03449472|DRUG|Quetiapine|Patients are tested for their normal prescription quetiapine medication
223525758|NCT05040776|DRUG|EP-7041 Injection|EP-7041 infusion
223525759|NCT05176587|OTHER|Follow-up of patients undergoing bariatric surgery : integrated pathway|Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
223525760|NCT05785208|DRUG|Osimertinib|Osimertinib will be administered at a dose of 80 mg daily until disease progression
223525761|NCT04030650|OTHER|Functional analyses|2-minute walking test 200-metre walking test
223525762|NCT04030650|OTHER|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
223525763|NCT04030650|OTHER|Functional analyses|400-metre walking test 200-metre walking test
223525764|NCT04472117|OTHER|usual care|Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.
223525765|NCT04472117|OTHER|Educational video|Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
223525766|NCT03491176|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223525767|NCT03491176|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
223525768|NCT03491176|OTHER|Quality-of-Life Assessment|Ancillary studies
223525769|NCT03491176|OTHER|Questionnaire Administration|Ancillary studies
223525770|NCT04227587|OTHER|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
223525771|NCT04227587|OTHER|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
223525772|NCT06141928|OTHER|Functional recovery analysis|Functional recovery analysis with force evaluator \& tester
223525773|NCT01397253|OTHER|Automated communication tools|"Automated communication tools will include:~* PCP notification of patient admission and location~* Data on medications begun on admission~* Automated alerts on changes in patient status and location while the patient is hospitalized~* Links to the EMR and to hospital physician contact information on all email alerts~* Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~* Automatic reporting to PCPs of test results pending at discharge~* Electronic delivery of final discharge summaries"
223525774|NCT00137592|BEHAVIORAL|small media, group education (multicomponent)|
223525775|NCT02550002|DRUG|Aflibercept|Intravitreal injection
223525776|NCT06839053|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223525777|NCT06839053|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223525778|NCT06839053|PROCEDURE|Computed Tomography|Undergo CT
223525779|NCT06839053|PROCEDURE|Gastrointestinal Endoscopy|Undergo endoscopy
223525780|NCT06839053|BIOLOGICAL|Rituximab|Given IV
223525781|NCT06839053|DRUG|Sonrotoclax|Given PO
223525782|NCT06839053|DRUG|Zanubrutinib|Given orally (PO)
223525783|NCT01871649|DRUG|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
223525784|NCT01871649|DRUG|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
223525785|NCT03130049|PROCEDURE|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
223525786|NCT04523025|DIAGNOSTIC_TEST|NLR-ratio|The ratio of neutrophils and lymphocytes in patients blood sample prior to surgical operation
223525787|NCT06500507|DRUG|QLS4131 Injection|Participants confirming to the eligibility criteria will be assigned to 1 of the 9 dose groups (0.06/0.3/1 \~ 600 ug/kg, respectively) based on the sequence of inclusion.
223525788|NCT05640557|OTHER|Physical Exercises|An original, noninvasive exercise program
223525789|NCT00404911|BEHAVIORAL|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
223525790|NCT00404911|BEHAVIORAL|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
223525791|NCT03290521|PROCEDURE|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
223525792|NCT03290521|PROCEDURE|No washing|no washing
223525793|NCT01937702|OTHER|0.9% NaCl (sodium chloride)|
223525794|NCT05585294|BEHAVIORAL|Exercises|Perturbation exercises: A new protocol of perturbation exercises aimed to disturb static and dynamic posture or equilibrium at primarily at body segments at hip and shoulder level were provided. The perturbation was initially started as anticipatory postural adjustment and progressed to compensatory postural adjustment, where stepping on various directions were challenged. The nature of perturbation or push or nudges applied by physiotherapists were progressed from a) self-generated to therapist applied, anticipated to unanticipated, stable to unstable platforms, static to dynamic postural tasks with loaded extremities and at higher level simple to higher cognitive tasks were also incorporated.
223525795|NCT01892189|DRUG|Ketamine|Ketamine intravenous administration.
223525796|NCT01892189|DRUG|TAK-063|TAK-063 tablets
223525797|NCT01892189|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
223525798|NCT05975424|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
223525799|NCT03378960|DRUG|Omeprazole 20mg|
223525800|NCT05549544|DEVICE|Left bundle branch area pacing|Left bundle branch area pacing is a novel physiological pacing modality and is reported to be feasible and safe in patients with heart failure and left bundle branch block.
223525801|NCT05549544|DEVICE|Biventricular pacing|Biventricular pacing is a widely-established modality to treat heart failure in patients with heart failure
223525802|NCT00932607|DRUG|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
223525803|NCT02957838|DIETARY_SUPPLEMENT|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
223525804|NCT02957838|DIETARY_SUPPLEMENT|mock|Low fat banana milkshake without C18:0 supplement.
223525805|NCT04910620|DRUG|Placebo|Placebo only
223525806|NCT04910620|DRUG|TCI378|TCI378 (Lactobacillus plantarum TCI378)
223525807|NCT04910620|DRUG|TCI507|TCI507 (Lactobacillus plantarum TCI507)
223525808|NCT03716648|DIAGNOSTIC_TEST|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
223525809|NCT03716648|DIAGNOSTIC_TEST|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
223707277|NCT06673446|PROCEDURE|vestibular socket therapy|"atraumatic extraction to the hopeless teeth will be performed using periotomes followed by conventional forceps under local anesthesia.~1. Access and Socket Preparation:~   * A small incision (1 cm) is made on (vestibular area) near the base of the extracted teeth, extending slightly towards neighboring teeth. This creates a pouch for accessing the socket and surrounding bone.~  * Using special instruments from the VST kit, the gum tissue is carefully dissected to expose the underlying bone.~2. Immediate Implant Placement with Guide:~   \* A prefabricated surgical guide ensures precise positioning of the implants directly into the socket.~3. Bone Grafting and Membrane:~   * A mixture of bone chips harvested from the surgical site (autogenous bone) and a bone-grafting material (deproteinized bovine bone mineral) is used to fill any gaps and support the implant, especially in the labial bone wall (labial plate).~  * A special 0.6 mm thick membrane is inserted through the access incision. This membra"
223707278|NCT07001605|DRUG|ketamine|after induction of anesthesia, patients will receive ketamine bolus of 0.5 mL/kg followed by continuous infusion of 0.12 mL/k/hr until the end of surgical procedure.
223707279|NCT07001605|OTHER|Erector Spinae Plane Block|after induction of anesthesia, patients will receive ultrasound guided ESPB. A total of 40 mL of 0.25% bupivacaine will be injected bilaterally at the level of transverse process opposing to the mid-point of the planned incision.
223707280|NCT07001605|OTHER|Wound infiltration|wound infiltration at the end of the surgery before the closure of fascia and subcutaneous tissues using a total of 20 ml of 0.25% bupivacaine
223707281|NCT06679413|DRUG|midazolam|Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study
223707282|NCT06679413|DRUG|metformin|Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study
223707283|NCT06679413|DRUG|bupropion|Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study
223707284|NCT06679413|DRUG|fenfluramine HCl|Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
223707285|NCT06681883|BEHAVIORAL|Action group|"A nursing care program based on the Model of Modifiable Factors Specific to Problematic Internet Use in Adolescents (MFPA)~The nursing care program based on the MFPA model is designed for adolescents with problematic internet use. The program is grounded in the concepts of the draft model. It consists of eight sessions, each expected to last 40-50 minutes. One session will be held per week. The first session includes introductions and an overview of the program, the second session aims to strengthen the adolescent's motivation for change, the third session focuses on improving the adolescent's self-control skills, the fourth session aims to enhance family functionality, the fifth session helps develop offline activities to replace internet use, the sixth and seventh sessions work on developing coping skills, and the eighth session includes the evaluation and termination of the program."
223707286|NCT06681168|DEVICE|transcutaneous auricular vagal nerve stimulation|"Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days.~Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20)."
223707287|NCT06681168|DEVICE|Sham (No Treatment)|The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
223707288|NCT06681116|DIETARY_SUPPLEMENT|structured nano-water|Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria
223707289|NCT06681116|DRUG|Hydrochlorothiazide (HCTZ)|hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria
223707290|NCT06681116|OTHER|ordinary bottled drinking water|Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
223707291|NCT06139861|BEHAVIORAL|TranS-C|Transdiagnostic Sleep and Circadian Intervention (TranS-C) is an evidence based cognitive-behavioral sleep therapy.
223707292|NCT06139861|BEHAVIORAL|Psychoeducation|The overarching principle is to provide information about how sleep, stress, diet, health, exercise, accidents and mood are inter-related and have reciprocal effects.
223707293|NCT06681155|DIAGNOSTIC_TEST|Assessment of plaque morphology, structure, and stability in non-culprit lesions|Assessment of plaque morphology, structure, and stability in non-culprit lesions based on intravascular ultrasound and optical coherence tomography-near-infrared spectroscopy imaging technology.
223707294|NCT06680180|DIAGNOSTIC_TEST|Viscoelastometric assessment of fibrinolysis|Viscoelastometric assessment of whole blood fibrinolysis using supplemental tissue plasminogen activator (tPA) and other agents ex vivo to influence fibrinolysis capacity.
223707295|NCT06680609|DRUG|Nefopam 20 MG/ML|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min
223707296|NCT06680609|DRUG|Placebo|The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
223707297|NCT06680986|OTHER|Clinical cardiac parameters (Arterial pressure, number of anti-hypertensive medications, and the NT-proBNP measurements)|The degree of severity of the hypertension will have been previously diagnosed for each patient with the help of the blood pressure measurements, the number of antihypertensive treatments and the NT-proBNP measurement which is correlated with the left intraventricular pressure and the mass of the left ventricle. This information will be used (i) to guide the structuring of the pathology representation space during the learning phase from a sub-population (a portion of the collected database that will be used for training algorithms); (ii) to serve as an endpoint from a test sub-population (the remaining portion of the database collected).
223707298|NCT05065528|DIETARY_SUPPLEMENT|Magnesium|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with 400 mg supplemental magnesium twice daily for 3 days
223707299|NCT05065528|DRUG|Placebo|Will receive symptomatic care (ondansetron 4mg and acetaminophen 500 mg each twice daily) along with placebo pill
223707300|NCT03913468|DRUG|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
223707301|NCT06689917|DRUG|JY231 Injection|"This study employs two pretreatment regimens:~In the lymphodepletion regimen, upon enrollment, subjects undergo leukapheresis followed by 3-5 days of lymphodepleting therapy with fludarabine and cyclophosphamide, culminating in intravenous infusion of JY231 and autologous patient PBMCs via a double-lumen catheter; in the non-lymphodepletion regimen, subjects receive direct intravenous injection of the JY231 preparation immediately after enrollment."
223707302|NCT07050121|DRUG|Ciwujia capsules|Ciwujia capsules for oral use，2-3 capsules per dose, three times daily. 28 days constitute one treatment course; efficacy and safety will be assessed over two courses. Dosage adjustments should follow the physician's instructions.
223707303|NCT07053202|COMBINATION_PRODUCT|Nivolumab|hepatic artery infusion therapy with nivolumab was performed
223707304|NCT07053202|PROCEDURE|Transarterial Chemoembolization (TACE)|Seldinger technique for femoral artery puncture. Catheterization to celiac trunk/hepatic artery. Infusion of a mixture of idarubicin, raltitrexed, iodized oil, and contrast agent (approx. 8 mL). Embolization with microspheres (300-500 μm and 500-700 μm).
223707305|NCT07054346|DRUG|177 Lutetium Prostate-Specific Membrane Antigen 617|Given intravenously (IV) or intra-arterially (IA)
223707306|NCT07054346|DRUG|Actinium-225 Prostate-Specific Membrane Antigen 617|Given IV or IA
223707307|NCT07054346|PROCEDURE|Non-investigational, Prostatectomy|Undergo non-investigational surgical procedure to remove prostate.
223707308|NCT07054346|PROCEDURE|Prostate Tissue Collection|Whole prostate tissue will be collected for correlative research at time of prostatectomy.
223707309|NCT07054346|PROCEDURE|Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)|Imaging procedure
223707310|NCT07054346|PROCEDURE|Blood Sample Collection|Blood samples will be obtained for research purposes
223707311|NCT07054567|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223707312|NCT07054567|DRUG|Pembrolizumab|Administration by intravenous infusion for a cycle of 3 weeks.
223707313|NCT07054567|DRUG|Bevacizumab|Administration for a cycle of 3 weeks.
223707314|NCT07054944|DIAGNOSTIC_TEST|ICG (Indocyanine Green)|Lymphatic mapping
223707315|NCT07053605|PROCEDURE|laparoscopic resection of splenic artery aneurysm with preservation of spleen|The laparoscopic resection of splenic artery aneurysm with preservation of spleen is performed by the same surgical team.
223707316|NCT00014937|DRUG|lopinavir/ritonavir|
223707317|NCT00014937|DRUG|lamivudine/zidovudine|
223707318|NCT00014937|DRUG|efavirenz|
223707319|NCT00014937|DRUG|lamivudine|
223707320|NCT00014937|DRUG|stavudine|
223707321|NCT00014937|DRUG|zidovudine|
223707322|NCT00014937|DRUG|didanosine|
223707323|NCT06681311|OTHER|Exercises|During the research period, all participants will undergo swimming training for 1 hour per day, 3-4 days a week for 6 weeks. The control group will perform a 5-minute land warm-up covering traditional shoulder, torso, and leg areas before their routine swimming training. In addition to the traditional warm-up program and swimming training, the experimental group will also participate in core and shoulder stabilization exercises under the supervision of a physiotherapist.
223707324|NCT03730012|DRUG|gilteritinib|Oral tablet
223707325|NCT03730012|DRUG|atezolizumab|Intravenous infusion
223707326|NCT05471557|PROCEDURE|pain delivery|Experimental pain paradigm delivered that is short-term and painful but not harmful.
223707327|NCT04833465|OTHER|No Intervention|No Intervention
223707328|NCT05123131|DRUG|Isatuximab|Isatuximab (IV): 10 mg/kg on Days 1, 8, 15, 22, 29 in Cycle 1; from Cycle 2 onwards, it will be given on Days 1, 15, 29.
223707329|NCT05123131|DRUG|Bortezomib|Bortezomib (SQ): 1.3 mg/m² on Days 1, 4, 8, 11, 22, 25, 29, and 32.
223707330|NCT05123131|DRUG|Lenalidomide|Lenalidomide (PO): 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 to \<60 mL/min) from Day 1 to Day 14 and from Day 22 to Day 35 of each cycle.
223707331|NCT05123131|DRUG|Dexamethasone (IV)|Dexamethasone (IV on the days of Isatuximab and PO on other days): 20 mg/day on Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23, 25, 26, 29, 30, 32, and 33. If patients are ≥75 years old, dexamethasone will be administered on Days 1, 4, 8, 11, 15, 16, 22, 25, 29 and 32.
223707332|NCT06426316|BIOLOGICAL|Blood test|1 blood test of maximum 40 millilitres per patient
223707333|NCT05222308|OTHER|Post-Mortem Plan|Following the death of the terminally ill participant, investigators will work with networks as the wishes of the deceased are executed. Continued engagement at this point will allow us to provide support to the network during a difficult period or time while also identifying shortcomings in our plans and systemic challenges to postmortem planning. Working with those who are grieving is a delicate proposition, but one with which my students and I have extensive experience.
223707334|NCT04189770|DEVICE|Accelerometer|Wear accelerometer
223707335|NCT04189770|OTHER|Ecological Momentary Assessment|Complete EMA questionnaire
223707336|NCT04189770|OTHER|Questionnaire Administration|Complete questionnaire
223707337|NCT04189770|OTHER|Survey Administration|Complete survey
223707338|NCT06812793|OTHER|Measurement of Core Muscle Endurance|Endurance of the flexor, extensor and lateral trunk muscles will be assessed using the McGill Trunk Endurance Tests.
223707339|NCT06812793|OTHER|Respiratory Muscle Strength|Inspiratory and expiratory muscle strength will be made with a portable, electronic intra-oral pressure measuring device.
223707340|NCT06812793|OTHER|Respiratory Muscle Endurance|Respiratory muscle endurance testing will be measured using an inspiratory muscle training device at increasing threshold load.
223707341|NCT06812793|OTHER|Peripheral Muscle Endurance|Peripheral muscle endurance will be assessed by performing 30 and 60 second sit-to-stand tests.
224276028|NCT05122858|PROCEDURE|EUS guided biliary drainage|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
223707342|NCT06208865|PROCEDURE|lumbar erector spinae plane block|All procedures were performed under ultrasound (US) guidance. The patient was monitored in the operating room and placed in the prone position under a sterile drape. A 2-6 MHz convex US probe was used during the procedure. The transverse processes of the lumbar vertebrae were visualized and then a 22 gauge spinal needle was advanced to the transverse process of the L3 vertebra. After contacting the transverse process, a total of 15 mL of drug consisting of 2 mL of methylprednisolone and 6 mL of 0.025% bupivacaine was injected into this area, and the spread of the drug in the craniocaudal area was visualized. The patients were followed up for possible complications after the procedure.
223707343|NCT04680052|DRUG|tafasitamab|tafasitamab will be administered IV for 12 cycles
223707344|NCT04680052|DRUG|rituximab|Rituximab will be administered IV on cycles 1 - 5
223707345|NCT04680052|DRUG|lenalidomide|Lenalidomide will be administered PO for 12 cycles
223707346|NCT04680052|DRUG|placebo|placebo will be administered IV for 12 cycles
223707347|NCT06083038|DRUG|Alpelisib|Patients will receive standard of care alpelisib
223707348|NCT06083038|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.
223707349|NCT05898971|OTHER|Robotic|Patients receive robotic training (grasp and grip)
223707350|NCT05898971|OTHER|Mirror|Patients receive mirror therapy
223707351|NCT01818921|DRUG|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
223707352|NCT01818921|DRUG|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
223707353|NCT01818921|DRUG|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
223707354|NCT06292286|PROCEDURE|Carboplatin or cisplatin|Carboplatin of cisplatin for 3-6 cycles
223707355|NCT06292286|DRUG|Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar|Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
223707356|NCT06292286|DRUG|Bevacizumab or biosimilar|Optional
223707357|NCT06292286|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery after chemotherapy
223707358|NCT04785521|RADIATION|Stereotactic radiosurgery|Gamma Knife stereotactic radiosurgery (SRS-GK)
223707359|NCT04785521|DIAGNOSTIC_TEST|Blood samples|Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
223707360|NCT05679427|RADIATION|radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively|Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
223707361|NCT05736497|OTHER|Digital Care Plans|Investigators will develop digital care plans for 10 common Cancer Predisposition Syndromes for patients diagnosed within 3 years.
223707362|NCT03320057|DRUG|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
223707363|NCT03320057|OTHER|Training on mifepristone dispensing|Pharmacists were offered a training on medication abortion and mifepristone dispensing
223707364|NCT00841646|BIOLOGICAL|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
223707365|NCT03047915|OTHER|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
223707366|NCT04546061|BEHAVIORAL|Project Uplift|Substance use and mental health treatment for young sexual and gender minorities in Durham and Charlotte, NC in conjunction with intensive wraparound services that address factors that influence substance use and mental health among this population.
223707367|NCT00354536|DRUG|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
223707368|NCT00354536|BIOLOGICAL|placebo injection|placebo injection
223707369|NCT05557708|DRUG|212-Lead Pentixather|Pentixather radiolabeled with 212-lead to target malignant cells with the CXCR4 ligand.
223707370|NCT05557708|DIAGNOSTIC_TEST|203-Lead Pentixather SPECT/CT|Pentixather radiolabeled with 203-Lead to identify the CXCR4 ligand on the malignant lesions for dosimetric analysis and treatment planning.
223707371|NCT02684916|PROCEDURE|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
223707372|NCT02684916|PROCEDURE|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
223707373|NCT06248801|DRUG|Vildagliptin and Metformin-Test product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by Mylan Laboratories Limited, India
223707374|NCT06248801|DRUG|Vildagliptin and Metformin-Reference product|Vildagliptin and Metformin tablets 50/1000 mg manufactured by NOVARTIS PHARMA PRODUKTIONS GmbH, Germany.
223707375|NCT03813849|DIAGNOSTIC_TEST|Sonographic examination of uterus after surgical evacuation|
223707376|NCT06956170|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
223707377|NCT06956170|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
223707378|NCT06956170|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
223707379|NCT06956170|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
223707380|NCT03035604|OTHER|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
223707381|NCT02023567|DRUG|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
223707382|NCT06373627|OTHER|Hypnosis|"A hypnosis session takes place in 3 stages:~* An induction stage, where we move from an ordinary state of consciousness to a modified state of consciousness through dissociation.~* A work phase to deepen the hypnotic trance. This phase is fueled by the construction of suggestions and metaphors, analogous to those of the patient in pain.~* Finally, a return to the ordinary state of consciousness through re-association with the patient."
223707383|NCT06373627|DRUG|Conventional medications used for sedation-analgesia|MEOPA + intravenous ketamine (0.5 mg/kg) + intraveinous midazolam (50µg/kg)
223707384|NCT06373627|DRUG|Medications used in addition to hypnosis|MEOPA + intravenous ketamine (0.3 mg/kg)
223707385|NCT01516437|PROCEDURE|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
223707386|NCT01516437|PROCEDURE|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
223707387|NCT01516437|PROCEDURE|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
223525810|NCT03716648|DEVICE|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
223707388|NCT05981898|DEVICE|OPTIVF dosage|Dosage predicted by Opt-IVf
223707389|NCT05981898|DEVICE|traditional Dosage|Dosage used traditionally by doctors
223707390|NCT03613844|DRUG|DHA|DHA supplementation
223707391|NCT03613844|DRUG|Placebo|Placebo for DHA
223707392|NCT01650844|OTHER|School-Based Telemedicine Enhanced Asthma Management|
223707393|NCT01650844|OTHER|Enhanced Usual Care|
223707394|NCT01006096|DRUG|erlotinib|100mg tablet, once daily for 16 weeks
223707395|NCT01006096|OTHER|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
223525811|NCT03859011|OTHER|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
223525812|NCT03859011|OTHER|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
223525813|NCT05136716|OTHER|Traditional Physical Therapy|Stretching for tight muscles, strengthening for weak muscles, postural reactions training, proprioceptive training, and walking training were all part of the neurodevelopmental treatment plan.
223525814|NCT05136716|DEVICE|Hyperbaric oxygen therapy|HBO2 therapy at a pressure of 1.7 atm For 60 minutes, participants breathed 100% O2.
223525815|NCT02903485|OTHER|nurses perform presurgical assessement and surveillance during surgery|
223525816|NCT02903485|OTHER|the anesthetic team performs presurgical assessement and surveillance during surgery|
223525817|NCT00569179|DEVICE|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
223525818|NCT02834364|DRUG|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
223525819|NCT02834364|DRUG|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
223525820|NCT03146260|PROCEDURE|Conventional TESE|usual procedure for sperm extraction
223525821|NCT03146260|PROCEDURE|Microdissection TESE|Procedure of extraction is performed under the operating microscope
223525822|NCT00005835|DRUG|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
223525823|NCT00005835|DRUG|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
223525824|NCT00005835|PROCEDURE|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
223525825|NCT00005835|OTHER|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC \>/= 1500 mm3 for three consecutive days.
223707396|NCT05770856|DIAGNOSTIC_TEST|Metagenomic sequencing|Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.
223707397|NCT00902915|DRUG|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
223707398|NCT05503615|OTHER|Observational|No application will be made to the control group.
223707399|NCT05503615|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
223707400|NCT05296512|DRUG|Lenvatinib|Lenvatinib is an oral capsule medication that will be taken by mouth once daily, every day of each 21-day treatment cycle. Treatment will be administered on an outpatient basis.
223707401|NCT05296512|DRUG|Pembrolizumab|"Pembrolizumab will be administered intravenously (IV) on Day 1 of every 21-day treatment cycle. Treatment will be administered on an outpatient basis.~Pembrolizumab will be given up to 35 cycles (approximately 24 months). Participants who stop pembrolizumab treatment with SD or better may be eligible for up to an additional 17 cycles (approximately 12 months) of pembrolizumab treatment (Pembrolizumab Re-Treatment) if they progress after stopping pembrolizumab and while receiving lenvatinib."
223707402|NCT01643356|BEHAVIORAL|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
223707403|NCT04432285|DEVICE|DBS-device, implanted in GPi bilaterally|Chronic/continuous bilateral GPi-DBS
223707404|NCT04432285|DRUG|Botulinum toxin|Repeated intramuscular injections at regular intervals of around 3 months
223707405|NCT06343740|BEHAVIORAL|COMET-Y|Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
223707406|NCT02675283|DEVICE|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
223707407|NCT06484738|OTHER|transcriptomic analysis|to use their biological samples from UC and CD patients, already stored at -80°C for transcriptomic analysis through STOmics Stereoseq
223707408|NCT02281201|BIOLOGICAL|BE1116 (Prothrombin Complex Concentrate)|
223707409|NCT05501275|BEHAVIORAL|psychotherapy|Psychotherapy and psychoeducation in patients after stroke.
223707410|NCT04437186|BEHAVIORAL|Recovery program|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
223707411|NCT03400878|BIOLOGICAL|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
223707412|NCT03400878|BIOLOGICAL|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
223707413|NCT00316719|DRUG|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
223707414|NCT00316719|DRUG|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
223707415|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
223707416|NCT04034628|DEVICE|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
223707417|NCT03493399|BEHAVIORAL|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, \& Kavanagh, 2012; May, Andrade, Panabokke, \& Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, \& May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
223707418|NCT02990689|DEVICE|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
223707419|NCT02990689|DEVICE|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
223707420|NCT02990689|DEVICE|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
223707421|NCT00432419|PROCEDURE|autologous peripheral blood cell transplantation|
223707422|NCT01968759|DRUG|Sevelamer|
223707423|NCT01968759|DRUG|Ramipril and Irbesartan|
223707424|NCT03064984|OTHER|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
223707425|NCT03064984|OTHER|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
223707426|NCT04453371|DRUG|Tissue plasminogen activator|"In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
223707427|NCT04453371|DRUG|Ringer solution|"In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level."
223707428|NCT01212523|DRUG|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
223707429|NCT01559467|OTHER|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
223707430|NCT01559467|OTHER|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
223707431|NCT00134459|DRUG|Bifeprunox|
223707432|NCT00134459|DRUG|Placebo|
223707433|NCT04336306|OTHER|virtual reality-based therapy (VRBT)|"The warm-up was performed using the Just Dance 2015 game, in a sequence previously defined in a pilot study, aiming to increase HR progressively. A multimedia projector (Epson Power Life, H309A, China) connected to a console (Xbox One KinectTM, Microsoft, Redmond, WA) was used to project the game onto a white wall.The conditioning phase was performed using the Shape Up exercise game, in which patients perform exercises following a virtual therapist."
223707434|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 1
223707435|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 2
223707436|NCT02092831|DRUG|GDC-0941|Single dose market image tablet of hardness 3
223707437|NCT02092831|DRUG|GDC-0941|Single dose Phase 2 tablet formulation
223707438|NCT00005073|DRUG|zoledronic acid|
223707439|NCT02099578|DIETARY_SUPPLEMENT|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
223707440|NCT02099578|DIETARY_SUPPLEMENT|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
223707441|NCT02099578|DIETARY_SUPPLEMENT|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
223707442|NCT01925534|DEVICE|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
223707443|NCT01925534|DEVICE|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
223707444|NCT02095977|PROCEDURE|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
223707445|NCT02095977|PROCEDURE|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
223707446|NCT02095977|PROCEDURE|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
223707447|NCT05112471|DEVICE|Airflow, Perioflow and Erythritol powder and ultrasonic debridement|Airflow and Perioflow combined with Erythritol powder will be used as an adjunct therapy
223707448|NCT05112471|DEVICE|Ultrasonic debridement and curettes|traditional Scaling and Root Planing with curettes and ultrasonic scaler
223707449|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
223707450|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
223707451|NCT02400333|DRUG|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
223525826|NCT03022721|OTHER|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
223525827|NCT02323048|DRUG|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
223525828|NCT02323048|DRUG|placebo|Placebo (sugar pill)
223525829|NCT03906214|OTHER|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
223525830|NCT01447992|DEVICE|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
223525831|NCT03359161|COMBINATION_PRODUCT|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
223525832|NCT04101773|PROCEDURE|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
223525833|NCT00757016|DRUG|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
223525834|NCT00757016|DRUG|Saline solution|Saline solution
223525835|NCT00738127|PROCEDURE|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
223525836|NCT05858814|BIOLOGICAL|RC1012 injection (allo-DNT cells)|RC1012 injection (allo-DNT cells) are from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
223525837|NCT01892566|OTHER|mHealth Intervention|See arm description
223525838|NCT06397092|PROCEDURE|transapical beating-heart septal myectomy|The patients with hypertrophic cardiomyopathy undergoing TA-BSM
223525839|NCT00732888|DRUG|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
223525840|NCT00732888|DIETARY_SUPPLEMENT|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
223707452|NCT02400333|DRUG|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
223525841|NCT01195597|DEVICE|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
223525842|NCT06228950|BEHAVIORAL|Mindfulness-Based Stress Reduction|A therapeutic approach called mindfulness-based stress reduction, or MBSR, aims to reduce emotional and behavioral problems by fostering mindfulness, which is an impartial awareness of the present moment. MBSR will be an 8-week training course for students with visual impairment. MBSR training, translated and adapted in Urdu language that includes 8 audios and worksheets corresponding to each week. Worksheets to record home practice will be filled upon receiving oral feedback from the students with visual impairment. Face-to-face group-based sessions will be conducted weekly.
223707453|NCT02738060|DIETARY_SUPPLEMENT|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
223707454|NCT03646318|DRUG|Ketanserin|"The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours"
223707455|NCT03646318|OTHER|Placebo|Glucose 5% solution
223707456|NCT06385639|DIETARY_SUPPLEMENT|Probiotic|This clinical trial will last for 10 days, and each subject will have 4 follow-up visits (Day -1, Day 0, Day 10, Day 20).
223707457|NCT04460638|BIOLOGICAL|Saliva collection|Saliva samples are regularly collected over a period of up to 30 consecutive days.
223707458|NCT04460638|OTHER|Clinical assessment|The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
224276029|NCT05122858|PROCEDURE|ERCP|A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
223525843|NCT03322566|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
223525844|NCT03322566|DRUG|Epacadostat|Epacadostat administered orally twice daily.
223525845|NCT03322566|DRUG|Platinum-based chemotherapy|Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
223525846|NCT03322566|DRUG|Placebo|Matching placebo administered orally twice daily.
223525847|NCT00603681|DRUG|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
223525848|NCT00603681|DRUG|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
223525849|NCT00986882|DRUG|SAF312A|
223525850|NCT00986882|DRUG|Placebo|
223525851|NCT00986882|DRUG|Ibuprofen|
223525852|NCT00164580|BEHAVIORAL|Community-Level Intervention|
223525853|NCT02736071|DRUG|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
223525854|NCT02736071|DRUG|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
223525855|NCT02736071|DRUG|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
223525856|NCT02736071|DRUG|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
223525857|NCT03656354|DEVICE|Seismocardiography|Seismocardiography recording
223525858|NCT00679614|DRUG|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
223525859|NCT00679614|DRUG|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
223525860|NCT00679614|DRUG|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
223525861|NCT03884673|DRUG|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
223525862|NCT01524406|DRUG|HPP593|Oral, twice a day.
223525863|NCT01524406|DRUG|Placebo|Oral, twice a day.
223707459|NCT00962910|OTHER|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
223707460|NCT05036824|DRUG|tinzaparin|Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
223707461|NCT03924453|DIAGNOSTIC_TEST|Pearl Powered by Proov|Participants self test in their homes and report back data via uploading onto an app and taking surveys.
223707462|NCT01866696|DEVICE|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~* Clinical examination~* Radiological examination~* Guided oral implants insertion~* Immediate Prosthetic loading~* Follow-up"
223707463|NCT05343598|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses."
223707464|NCT05343598|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~The rTMS pulses will be delivered in a pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz every 10s for 600 total pulses.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
223707465|NCT02280304|BEHAVIORAL|Inner Resources for Veterans (IRV)|Mindfulness and breath-focused mantra therapy which uses techniques that encourage present moment attention for the purpose of improving self-monitoring and self-regulation
223707466|NCT02280304|BEHAVIORAL|Essential Skills therapy|This active comparator is adapted from a therapy utilized at multiple VAs as a psychoeducational AND symptom management treatment for PTSD. In it, participants learn about mTBI and PTSD symptoms and coping information for PTSD.
223707467|NCT05572320|DIAGNOSTIC_TEST|Platelet Aggregometry Testing|1.6 ml of blood collected in hirudin-coated tubes before the surgery
223707468|NCT03323541|DRUG|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils \>1 giga/l)
223707469|NCT01952405|BEHAVIORAL|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
223707470|NCT00875875|DRUG|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
223707471|NCT03200405|DEVICE|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
223707472|NCT03200405|DEVICE|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
223707473|NCT01910857|BEHAVIORAL|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
223707474|NCT01354340|DIETARY_SUPPLEMENT|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
223525864|NCT03847519|DRUG|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
223525865|NCT03847519|DRUG|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
223707475|NCT01354340|DIETARY_SUPPLEMENT|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
223707476|NCT01354340|OTHER|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
223707477|NCT00185939|DRUG|Augmentin|
223707478|NCT03920033|RADIATION|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
223525866|NCT04403776|DRUG|tofacitinib MR 11 mg|Single oral dose of tofacitinib MR 11 mg, administered as 1 x MR 11 mg tablet, in a fasting state on Day 1 followed by once daily dosing (QD) on Days 3, 4, 5, 6 and 7.
223525867|NCT04403776|DRUG|tofacitinib IR 5 mg|Two separate oral doses (12 hours apart) of tofacitinib IR 5 mg, administered one in the morning in a fasting state and one in the evening at least 2 hours after dinner on Day 1 followed by 5 mg IR every 12 hours on Days 3, 4, 5, 6 and 7.
223525868|NCT05827341|OTHER|No intervention|No intervention needed
223525869|NCT00376558|BEHAVIORAL|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
223525870|NCT01228032|OTHER|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
223525871|NCT03787147|DEVICE|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
223707479|NCT05963659|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|nitrate-rich beetroot juice, \~750 mg NO3- /d
223707480|NCT05963659|DIETARY_SUPPLEMENT|nitrate-depleted beetroot juice|nitrate-depleted beetroot juice, \~1 mg NO3- /d
223707481|NCT03275454|DRUG|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
223707482|NCT03275454|DRUG|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
223707483|NCT04753645|BEHAVIORAL|Handwashing stations at the public places and no soap|BRAC has built 1000 handwashing stations in 20 sub-districts from 3 divisions (out of a total of 8 divisions), namely Dhaka, Mymensingh and Khulna, to increase the access of communities to handwashing facilities. In addition to these handwashing stations, there are other supports available in the intervention areas i.e. in-person demonstration, hygiene meetings, and soap distribution from BRAC. However, this group did not receive any soap from the research team.
223707484|NCT04753645|BEHAVIORAL|No activities of the HBCC project and also no soap (Pure Control)|In these randomly selected villages, BRAC did not implement any activity of its HBCC project. Also, the research team did not distribute soap to these households
223525872|NCT03787147|DEVICE|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
223707485|NCT04753645|BEHAVIORAL|Soap distributed but no activities of the HBCC project|In these randomly selected villages, BRAC did not implement any activity of its HBCC project but the research team randomly selected this group for soap distribution.
223707486|NCT04753645|BEHAVIORAL|HBCC project and Soap|These households belong to those villages where the HBCC project has been implemented and also received the soap from the research team.
223707487|NCT00874107|BIOLOGICAL|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
223525873|NCT03787147|DRUG|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
223525874|NCT03787147|DRUG|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
223525875|NCT01652157|BIOLOGICAL|ULTRESA|pancreatic enzyme replacement therapy
223525876|NCT01652157|BIOLOGICAL|PANCREAZE|pancreatic enzyme replacement therapy
223525877|NCT01652157|BIOLOGICAL|CREON|pancreatic enzyme replacement therapy
223525878|NCT01652157|BIOLOGICAL|ZENPEP|pancreatic enzyme replacement therapy
223525879|NCT01652157|BIOLOGICAL|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
223525880|NCT01652157|BIOLOGICAL|PERTZYE|pancreatic enzyme replacement therapy
223525881|NCT01652157|OTHER|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
223525882|NCT02712203|BIOLOGICAL|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
223525883|NCT03347669|DEVICE|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
223707488|NCT00874107|BIOLOGICAL|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
223707489|NCT00874107|DRUG|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
223707490|NCT00874107|DRUG|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
223707491|NCT05420597|DRUG|Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w. Then a total dose of 70Gy in 35 fractions was administered, with concurrently weekly cisplatin (30mg/m2 qw).~At 3-6 weeks post-radiotherapy, maintenance Toripalimab was administered for 8 cycles (240mg d1 q3w, in total 8 cycles)."
223707492|NCT06240871|OTHER|Pulmonary artery pressure measurements|The investigators will compare noninvasive measurements of right sided pressure measurements with invasive RHC performed in 3 steps:at rest, with agitated saline and with agitated echo contrast, Optison. This was not a clinical trial and there were no intervention arms per se. All patients received agitated saline and echocardiographic contrast.
223707493|NCT04667481|OTHER|Aerobic Exercise Intervention|Participate in aerobic exercise intervention
223707494|NCT04667481|OTHER|Resistance Exercise Intervention|Participate in resistance exercise intervention
223707495|NCT04667481|OTHER|Exercise Intervention: Digital copies and outline of sessions|Receive digital copy of AE and RE sessions and an outline of sessions
223707496|NCT04667481|OTHER|Questionnaire Administration|Ancillary studies
223707497|NCT04667481|OTHER|Quality-of-Life Assessment|Ancillary studies
223525884|NCT06334796|DIAGNOSTIC_TEST|Virtual Assistant|Stage 1 focused on safety, using only medical information from clinical records for the virtual assistant. In Stage 2, which evaluated accuracy, participants interacted with the virtual assistant post-medical stabilization. Additionally, participants also provided initial symptom details for Chat-GPT input. Nine neurologists specializing in emergency participated in the study. In Stage 1, they assessed the virtual assistant's performance using clinical history information. In Stage 2, they analyzed the results from participant interactions with the assistant and performed a comparative evaluation of Chat-GPT. The virtual assistant functioned as a chatbot on WhatsApp and Telegram, using Spanish and incorporating advanced algorithms, decision trees, and large language models for interaction. For comparison, we utilized Chat-GPT versions 3.5 and 4, employing two prompt types in natural Spanish: one incorporating clinical record data and the other based on participant narratives.
223525885|NCT00798408|DIETARY_SUPPLEMENT|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
223525886|NCT00798408|DIETARY_SUPPLEMENT|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation\*1.5 activity factor, volume, and amount and type of macronutrients
223525887|NCT01687062|OTHER|FeSO4|
223525888|NCT01687062|OTHER|reduction of phytate|
223525889|NCT01687062|OTHER|NaFeEDTA|
223525890|NCT01928056|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
223525891|NCT01238887|DIETARY_SUPPLEMENT|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
223525892|NCT01238887|DIETARY_SUPPLEMENT|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
223525893|NCT01238887|DIETARY_SUPPLEMENT|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
223525894|NCT01738412|DEVICE|Neurokeeper stroke detector|Monitoring stroke patients
223525895|NCT05255666|DRUG|Pembrolizumab|400 mg intravenously
223525896|NCT05255666|DRUG|Liposomal Irinotecan|Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
223525897|NCT02314923|BIOLOGICAL|V920 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.
223525898|NCT02314923|OTHER|Placebo|0.9% Saline
223525899|NCT03419819|DIETARY_SUPPLEMENT|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
223525900|NCT00725985|DRUG|Cladribine|Cladribine tablets were administered until CDMS conversion, whichever occur first.
223525901|NCT00725985|DRUG|Placebo|Placebo matched to cladribine tablets were administered.
223525902|NCT00725985|DRUG|Rebif® new formulation (RNF)|Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
223525903|NCT02546323|DRUG|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
223525904|NCT02546323|DRUG|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
223525905|NCT03765931|DRUG|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
223525906|NCT03765931|DRUG|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
223525907|NCT03548129|DRUG|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
223525908|NCT03548129|DRUG|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
223525909|NCT03548129|DIAGNOSTIC_TEST|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
223525910|NCT03548129|DIAGNOSTIC_TEST|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
223525911|NCT03548129|DIAGNOSTIC_TEST|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
223525912|NCT04476784|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
223525913|NCT04476784|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
223525914|NCT04476784|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting solution
223525915|NCT02020226|DRUG|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
223525916|NCT02578082|DRUG|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
223525917|NCT02551783|PROCEDURE|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
223525918|NCT02551783|PROCEDURE|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
223525919|NCT00195780|DRUG|Divalproex Sodium (Depakote ER)|
223525920|NCT03323255|DEVICE|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
223525921|NCT03323255|DEVICE|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
223525922|NCT04957589|DIETARY_SUPPLEMENT|Very Low Calorie Diet|"A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day."
223707498|NCT05580393|DIAGNOSTIC_TEST|RFLP analysis of SSU rRNA|"1. Genomic DNA will be extracted from Blastocystis-positive fecal samples using a specific DNA Stool Mini Kit according to the manufacturer's instructions and will be stored at -20°C until use.~2. PCR will be used to amplify a region of Blastocystis small subunit ribosomal RNA (SSU rRNA) gene.~3. The amplified products for the SSU rRNA gene will be digested to determine the strain subtype of Blastocystis spp. using specific restriction enzymes."
223707499|NCT00539656|BIOLOGICAL|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
223707500|NCT06350396|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
223707501|NCT06350396|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223707502|NCT00313261|DRUG|Clevudine|
223707503|NCT01431170|DRUG|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
223707504|NCT01431170|DRUG|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
223707505|NCT04987775|DRUG|N-Acetyl Cysteine|900mg 2x daily
223707506|NCT04987775|DRUG|Placebo|Matching placebo bid
223707507|NCT03651544|BIOLOGICAL|GamFluVac|1 dose (0,5 ml)
223707508|NCT01890473|DRUG|Abatacept|
223707509|NCT00353665|DRUG|Memantine (Ebixa)|10 mg bid
223707510|NCT00353665|DRUG|riluzole|riluzole 50 mg bid
223707511|NCT00353665|DRUG|Placebo|
223707512|NCT06139965|OTHER|Validity and Reliability|Assessment study
223707513|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
223707514|NCT00934089|DRUG|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
223707515|NCT00934089|DRUG|PF-04217329|Topical ocular solution, once-daily for 14 days
223525923|NCT04957589|OTHER|High Intensity Interval Training|The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
223707516|NCT00934089|DRUG|latanoprost|Topical ocular solution, once-daily for 14 days
223707517|NCT00261274|BIOLOGICAL|A-ECO|
223707518|NCT00261274|BIOLOGICAL|Saline|
223707519|NCT00003473|DRUG|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
223707520|NCT00003473|DRUG|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
223707521|NCT02363842|DEVICE|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
223707522|NCT02363842|OTHER|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
223707523|NCT00725374|DRUG|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
223707524|NCT00725374|DRUG|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
223707525|NCT03352297|BIOLOGICAL|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
223707526|NCT03416725|DEVICE|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
223707527|NCT01842321|DRUG|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
223707528|NCT02982668|OTHER|Initial enteral feeding|
223707529|NCT02982668|DRUG|metoclopramide or mosapride|gastrointestinal (GI) motility improving
223707530|NCT03476993|BIOLOGICAL|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
223707531|NCT06352489|PROCEDURE|Posterior component separation technique.|By dividing the posterior rectus sheath, a posterior plane is reached which can be advanced by dividing the transversus abdominis muscle with reinforcement of the midline with synthetic mesh.
223707532|NCT02998944|OTHER||not any intervention for this study
223707533|NCT04893044|BEHAVIORAL|Video|"The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all."
223707534|NCT00793091|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
223707535|NCT00793091|DRUG|Placebo|4 drops applied daily for 120 days
223707536|NCT02515825|DEVICE|CADence|
223707537|NCT06497998|DEVICE|Mechanical characterization|"The oocyte is placed in a culture dish with IVF culture medium. This procedure is similar to that used in the ICSI procedure, except that the injection pipette is replaced by a glass indenter. The indenter (sterile, single-use, blunt-edged glass cylinder, L:16mm, ø:0.85mm, mass:8mg) is completely decoupled from the micromanipulation and microinjection platform and driven by the principle of a magnetic spring with negative stiffness.~The oocyte is immobilized using a restraining pipette to prevent unwanted movement during measurement.~The main objective is to investigate the prognostic value of parameters derived from kinetic measurements of microforces on mature human oocytes in the context of IVF with ICSI.~On each oocyte the mechanical testing is divided in 4 successive loading unloading phase to measure:~* global elasticity of the oocyte.~* global viscosity behaviour of the oocyte.~* local elasticity of the oocyte.~* local viscosity behaviour of the pellucid membrane."
223707538|NCT02994992|DRUG|BAY 987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
223707539|NCT02994992|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
223707540|NCT04754152|OTHER|θ burst transcranial magnetic stimulation|In addition to drug therapy, TBS supplementary therapy was given every 3 months.The TBS parameters were as follows: 3 pulses, 50 Hz bursts given every 200 ms (at 5 Hz), and an intensity of 70% of the resting motor threshold, as measured from the right first dorsal interosseous muscle using a handheld 70 mm figure-of-eight coil. Take a course every 10 weeks .
223707541|NCT04754152|DRUG|Pharmacotherapy|Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
223707542|NCT02650674|OTHER|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
223707543|NCT02650674|OTHER|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
223707544|NCT02650674|OTHER|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
223707545|NCT02650674|OTHER|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
223707546|NCT02650674|OTHER|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
223707547|NCT02650674|OTHER|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
223707548|NCT04234191|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
223707549|NCT04234191|DRUG|Hydromorphone|Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
223707550|NCT05697315|PROCEDURE|Control|No block was performed
223707551|NCT05697315|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed, tramadol was administered with patient-controlled analgesia (PCA) and all patients were followed in the ward.
223707552|NCT06259721|DRUG|Anti-PD1 antibody, nimotuzumab and capecitabine|"Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment."
223707553|NCT01546207|PROCEDURE|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
223707554|NCT04475991|DRUG|Maraviroc + Currently used therapy|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
223707555|NCT04475991|PROCEDURE|Curently used therapy for COVID-19 non-critical patients|"Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga"
223707556|NCT04475991|DRUG|Favipiravir + Currently used therapy|"Favipiravir tablets 200 mg. given orally for a 7 day period. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)."
223707557|NCT04475991|DRUG|Maraviroc+Favipiravir+CT|"Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)"
223707558|NCT00020904|DRUG|ixabepilone|
223707559|NCT02299830|PROCEDURE|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
223707560|NCT02299830|PROCEDURE|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
223707561|NCT02299830|PROCEDURE|stent placement|use stent placement to open the airway compressed by out neoplasm
223707562|NCT02299830|PROCEDURE|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
223707563|NCT02646137|DRUG|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
223707564|NCT02646137|PROCEDURE|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
223525924|NCT04621578|DEVICE|HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)|"Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point."
223525925|NCT06637189|DRUG|Ganirelix|Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
223525926|NCT06637189|DRUG|Medroxyprogesterone Acetate 10 MG|Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
223525927|NCT01515371|DRUG|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
223525928|NCT01515371|DRUG|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
223525929|NCT00054262|DRUG|T900607|
223525930|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
223525931|NCT04483778|BIOLOGICAL|second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG|Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
223525932|NCT04483778|DRUG|Pembrolizumab|SCRI-CARB7H3(s)x19 plus pembrolizumab
223525933|NCT06252077|DIETARY_SUPPLEMENT|very low ketogenic diet|1 month of active phase of very low ketogenic diet
223525934|NCT01419730|DRUG|Vitamin D3|Vitamin D3 50,000 IU
223525935|NCT01419730|BEHAVIORAL|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
223525936|NCT06004063|DIETARY_SUPPLEMENT|Enteral nutrition (EN)|Given by Nasogastric Tube
223525937|NCT06004063|OTHER|Standard care parenteral nutrition (PN)|Given by PO or Given by IV (vein)
223525938|NCT02947048|DRUG|L1-79|
223525939|NCT02947048|DRUG|Placebo|
223525940|NCT00518869|DRUG|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
223525941|NCT06636955|OTHER|biobank|"* nasopharyngeal swab collection~* nasopharyngeal nasal washes collection, during hospitalization, if any"
223525942|NCT06636955|OTHER|follow up|\- one year follow up: after 1 month, 3 months, 6 months et 12 months
223525943|NCT06637046|DIAGNOSTIC_TEST|Diagnostic procedures|A 30-gauge 1-inch needle was inserted adjacent to, but not within, the CFN. The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus. This was immediately adjacent to the first known anatomical site of compression of the CPN. 0.3cc of the drug was delivered.
223525944|NCT06637046|DIAGNOSTIC_TEST|Lidocaine HCl|This study compares the vasodilatory effects of lidocaine to papaverine after diagnostic infiltration of the Common Peroneal Nerve in patients with demonstrated motor weakness of the EHL (extensor hallucis longus).
223525945|NCT06642025|BIOLOGICAL|CAR-T Cell Injection|"Conditioning chemotherapy: Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before intraperitoneal infusion.~On the day of administration, premedication with 500mg of acetaminophen orally and 20mg of promethazine intramuscularly or intravenously (or other non-steroidal anti-inflammatory drugs and antihistamines) should be given 30 minutes before intraperitoneal infusion.~The therapeutic dose of CAR-T cells is defined as intravenous injection of 1.0E6 CAR-T cells/kg as the initial standard dosage."
223525946|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
223525947|NCT06641388|DRUG|Ebronucimab|Ebronucimab subcutaneous injection
223525948|NCT06644703|OTHER|Cryotherapy|The pulpotomy area was irrigated with 2 °C saline solution for 5 minutes in cryotherapy group.
223525949|NCT06413914|BEHAVIORAL|Cognitive behavioral Therapy|"Cognitive behavioral therapy is the psychological approach in this study. It is associated with better outcomes of rehabilitation for long-term pain in general, reduced pain intensity and less use of medication and health services, sustaining factors that provide an understanding of how thoughts and feelings affect the experience of pain. An important aim is also a reduction in pain-related rumination and worry and changed metacognition that maintains inhibiting behavior and thought patterns.~A workbook for pain has been developed. It contains knowledge about pain and pain management, describes measures and homework from session to session. The treatment consists of 8 sessions with 7 weekly sessions + 1 booster session 2 months after the end of treatment.~."
223525950|NCT03605693|BEHAVIORAL|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
223707565|NCT02646137|PROCEDURE|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
223707566|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
223707567|NCT00724022|DRUG|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
223707568|NCT00724022|DRUG|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
223707569|NCT01394432|PROCEDURE|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
223525951|NCT03047044|OTHER|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: \~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours \~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
223525952|NCT03047044|OTHER|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
223525953|NCT06289764|OTHER|Bergamot Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
223525954|NCT06289764|OTHER|Grapefruit Essential Oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles.
223525955|NCT06289764|OTHER|Sweet almond oil|Selected women will be smelled 3 times a day, at the same time every day, for 4 days, within 7 days before menstruation. Application will be repeated for 3 cycles
223525956|NCT03093415|DRUG|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
223525957|NCT05805189|PROCEDURE|pulmonary vein (PV) isolation|The settings used during ablation will be for both groups: 15W, unipolar; 5ml/min baseline irrigation, 35ml/min irrigation during inflation/RF application; 55°C target electrode temperature; RF application time 60s for anterior electrodes, 20s for posterior electrodes. The catheter insertion in Pulmonary vein and ablation workflow will be different for two groups.
223525958|NCT00304161|DRUG|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
223525959|NCT00304161|DRUG|Placebo|40 to 80 mg orally once daily for 8 weeks
223525960|NCT06296225|DEVICE|Vibration|"Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol."
223525961|NCT05342168|DIAGNOSTIC_TEST|Using a swallowed expanding sponge (Cytosponge TM) to obtain sampling of the esophageal musosa|A gelatin capsule containing the collapsed mesh sponge is swallowed with an attached string fixed to the cheek. After 8 minutes the gelatin capsule will have dissolved and the expanded soft mesh sponge can be with drawn sampling the surface of the esophagus on the way out. The sponge then will be spun and the supernant fixed, processed and stained.
223525962|NCT05593289|OTHER|telerehabilitation|Physical activity that is planned, structured with repeated muscle movements with the aim of relearning motor skills, resistance of neck muscles and postural correction.
223525963|NCT01655277|PROCEDURE|Ultrasound Guided Adductor Canal Block|
223525964|NCT01655277|PROCEDURE|Ultrasound Guided Femoral Nerve Block|
223525965|NCT04552054|DEVICE|Mixed Reality+ 3D printing guided localization|Researchers project a three-dimensional reconstructed image of the patient's chest through MR glasses, then overlay the virtual chest with the actual chest. Finally, researchers put the three-dimensional printing navigational template on the surface of the body to guide for percutaneous lung puncture localization.
223525966|NCT04552054|DEVICE|Computerized Tomography guided localization|CT-guided percutaneous lung puncture staining marker localization.
223525967|NCT00796458|DRUG|docetaxel|Given IV
223525968|NCT00796458|DRUG|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
223525969|NCT04331275|BIOLOGICAL|Viral Specific T-cells (VSTs)|VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
223525970|NCT01968122|DEVICE|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (\<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
223525971|NCT05071326|BEHAVIORAL|Nurse-led health coaching|This project is an 6-month program providing an initial 2-month intensive evaluation and personalized virtual individual health coaching experience that is designed to prepare and equip the participant for improved self-care capacity, motivational insight, health-related problem solving and decision-making. This intensive period will then be followed by monthly 30-minute Nurse Coach assessment and individual coaching 'check-in' virtual visits, continued use of the electronic platform tools and health tracking system, and access to group 'virtual coaching' on tailored topics of interest to the cohort.
223525972|NCT05150678|PROCEDURE|removal of ceserean section scar|we will remove the previous scar in group A
223525973|NCT05150678|PROCEDURE|non removal of cesearean section scar|we will open in the previous cesearean scar in group B
223707570|NCT05081154|OTHER|Product A|P1012915, a nicotine pouch with 8 mg nicotine
223707571|NCT05081154|OTHER|Product B|P1013018, a nicotine pouch with 10 mg nicotine
223707572|NCT05081154|OTHER|Product C|P1013015, a nicotine pouch with 8 mg nicotine
223707573|NCT05081154|OTHER|Product D|P1012815, a nicotine pouch with 8 mg nicotine
223707574|NCT05081154|OTHER|Product E|P1013315, a nicotine pouch with 8 mg nicotine
223707575|NCT05081154|OTHER|Product F|P1013115, a nicotine pouch with 8 mg nicotine
223707576|NCT05081154|OTHER|Product G|P1013215, a nicotine pouch with 8 mg nicotine
223525974|NCT06636578|DRUG|dexmedetomidine|will receive 30 ml of 0.25% of ropivacaine + dexmedetomidine 0.5 μg/kg for each side.
223525975|NCT06636578|DRUG|ropivacaine|will receive 30 ml of 0.25% of plain ropivacaine for each side.
223525976|NCT06636578|DRUG|fentanyl|will not receive any regional anesthesia and only will receive I.V. fentanyl 1μg/kg/hr.
223525977|NCT06635122|PROCEDURE|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. The TIPS-dedicated stent (Gore, Arizona, USA)was emplaced within the liver and gradually expanded utilizing a balloon with a diameter ranging from 6 to 10 millimeters, aiming for a decrease in portal-venous pressure gradient to less than 12 mmHg or achieve a reduction of 25 to 50% relative to the baseline pressure.
223525978|NCT06635122|PROCEDURE|Endoscopic treatment|Endoscopic variceal ligation, endoscopic injection sclerotherapy, endoscopic variceal histoacryl injection therapy , or a combination of several methods were selected according to the location, size, and shape of the patient's varicose veins.Treatment failure can be transferred to TIPS therapy.
223525979|NCT06632171|BEHAVIORAL|Cognitive Behavioral Therapy- Based and Motivational Interviewing-Supported Psychoeducation|The aim of this study is to examine the effects of cognitive-behavioral-based and motivational interview-supported psychoeducation on emotional eating and psychological resilience in obese individuals. The study will be conducted in a randomized controlled experimental design. The sample of the study will consist of 102 obese individuals in total, 51 in the experimental group and 51 in the control group, who meet the inclusion criteria. A cognitive-behavioral and motivational interview-supported psychoeducation program will be applied to the experimental group. All patients will be evaluated at three time points: pretest (baseline), posttest (8 weeks), and follow-up test (3 months after the posttest). No intervention will be applied to the control group.
223525980|NCT06632080|DRUG|Substance P|The participants will receive a continuous intravenous infusion of 20 mL of substance P (1.5 pmol/kg/min) over 20 minutes.
223525981|NCT06632080|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
223525982|NCT06519565|DRUG|PRG-1801|PRG-1801 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA. Participants will undergo leukapheresis to collect mononuclear cells for PRG-1801 manufacturing. Prior to infusion, patients receive lymphodepletion with cyclophosphamide (250-300 mg/m2/day) and fludarabine (25-30 mg/m2/day) for 3 days. PRG-1801 is then administered as a single intravenous infusion at one of three dose levels: 35×10\^6, 100×10\^6, or 300×10\^6 CAR-T cells. Premedication with antipyretics and antihistamines is given 30-60 minutes before infusion. The infusion rate is 2-5 ml/min. Patients are monitored for safety and efficacy for up to 24 months post-infusion. Some patients may be eligible for a second infusion if they respond initially but later relapse.
223525983|NCT02420509|DRUG|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
223525984|NCT04047355|DRUG|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
223525985|NCT04315922|DIAGNOSTIC_TEST|Microbiome and Plasma Characterisation|Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing
223525986|NCT04320199|DIETARY_SUPPLEMENT|Fermented Protaetia brevitarsis seulensis powder group|This group takes Fermented Protaetia brevitarsis seulensis powder for 8 weeks
223525987|NCT04320199|DIETARY_SUPPLEMENT|Placebo group|This group takes placebo for 8 weeks
223525988|NCT05617326|OTHER|AAA screening by a GP|The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..
223525989|NCT05617326|OTHER|AAA screening by a radiologist|General practitioners in the control group will refer their patients to the radiologist for AAA screening.
223525990|NCT06680661|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) is one part of the conditioning regimen. 50 mg/kg beginning on day -6.
223525991|NCT06680661|DRUG|Fludarabine|Fludarabine (Flu) is one part of the conditioning regimen. 150 mg/m2 (30 mg/m2 per day on days -6 to -2)
223525992|NCT06680661|DRUG|Thiotepa|Thiotepa (Thio) is one part of the conditioning regimen.10 mg/kg (5 mg/kg per day on days -5 and -4)
223525993|NCT06680661|RADIATION|Total Body Irradiation|400 cGy (200 cGy per day on days -2 and -1).
223525994|NCT06680661|BIOLOGICAL|Double Umbilical Cord Transplant|Cord blood is a regulated biologic. Selection of cord blood units will be based on published guidelines.
223525995|NCT06680661|DRUG|Tacrolimus|Tacrolimus will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. Tacrolimus will continue at least until day 180 and then be tapered off.
223525996|NCT06680661|DRUG|Mycophenolate Mofetil|MMF will be administered post transplant. Graft-versus-host disease prophylaxis will consist of tacrolimus and mycophenolate mofetil (MMF), starting on day-5. MMF will continue until day 30.
223525997|NCT06680661|DRUG|Abatacept|Abatacept at a dose of 10mg/kg will be given on days T-1, T+5, T+14 and T+28.
223525999|NCT06235801|DRUG|Gilteritinib|Given by PO
223526000|NCT06235801|DRUG|Momelotinib|Given by PO
223526001|NCT03090165|DRUG|ribociclib|400mg PO
223526002|NCT03090165|DRUG|ribociclib|600mg PO
223526003|NCT03090165|DRUG|Bicalutamide|150mg PO
223526004|NCT01928537|DRUG|rigosertib sodium|
223526005|NCT05269082|OTHER|No intervention|This is a non-interventional study.
223526006|NCT01657331|DRUG|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
223526007|NCT01657331|DRUG|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
223526008|NCT01657331|DRUG|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
223526009|NCT01664715|BEHAVIORAL|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
223526010|NCT01664715|BEHAVIORAL|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
223526011|NCT01664715|BEHAVIORAL|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
223526012|NCT04924933|DIAGNOSTIC_TEST|Computerised associative memory task using abstract words and landscape photographs|Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
223526013|NCT06802809|DIETARY_SUPPLEMENT|Lactobacillus crispatus M247 (Crispact®)|Crispact® is a probiotic food supplement containing Lactobacillus crispatus M247.
223526014|NCT06802809|OTHER|Placebo|The placebo does not contain the active probiotic strain and consists of inactive excipients.
223526015|NCT05530655|DRUG|Lisinopril Tablets|This is a dose escalation study of 5 mg, 10 mg and 20 mg doses given once a day.
223526016|NCT03275831|DEVICE|PluroGel|Surfactant based gel
223526017|NCT03275831|DEVICE|Intrasite gel|Hydrogel
223526018|NCT00997763|DEVICE|XIENCE V|everolimus-eluting stent
223526019|NCT00997763|DEVICE|CYPHER|sirolimus-eluting stent
223526020|NCT05444387|OTHER|Upper limb loading|1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
223526021|NCT03477422|DRUG|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
223526022|NCT03477422|DRUG|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
223526023|NCT02423694|DEVICE|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA"
223526024|NCT02423694|DRUG|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
223526025|NCT01379690|OTHER|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
223526026|NCT06388629|DEVICE|Rook Epicardial Access Kit|Access the epicardial surface of the heart via a subxiphoid approach with the subject device to facilitate guidewire placement into the pericardium.
223526027|NCT04581395|OTHER|non-pretreated Succinylcholine|no pretreatment
223526028|NCT04581395|DRUG|succinylcholine 1 minute after rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 1 min +/- 10 sec after pretreatment
223526029|NCT04581395|DRUG|succinylcholine 2 minutes following rocuronium pretreatment|0.05 mg/kg up to 5 mg of rocuronium pretreatment followed by 1.0 mg/kg succinlycholine t = 2 min +/- 10 sec after pretreatment.
223526030|NCT06119217|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
223526031|NCT06119217|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
223526032|NCT06119217|COMBINATION_PRODUCT|Nab-Paclitaxel and gemcitabine|Dose and schedule per protocol
223526033|NCT05945225|DEVICE|Sonicare DiamondClean 9000 Philips®|Brush teeth with the electric toothbrush daily during 3 months
223526034|NCT05945225|DEVICE|HydroSonic Easy Curaden®|Brush teeth with the hydrosonic toothbrush daily during 3 months
223526035|NCT05945225|DEVICE|Manual toothbrush Oral-B 123|Brush teeth with the manual toothbrush daily during 3 months
223526036|NCT05945225|DEVICE|Manual toothbrush Curaprox CS 5460|Brush teeth with the manual toothbrush daily during 3 months
223526037|NCT06272578|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
223526038|NCT06564688|DIAGNOSTIC_TEST|Swallowing function test|"The oral function score assesses the oral functional performance of chewing in all participants.~The Functional oral feeding Scale (FOIS) was used to assess the ability of all participants to eat.~The standardized swallowing assessment (SSA) was used to assess the global swallowing function of all participants."
223526039|NCT04452916|OTHER|Buchinger fasting|Caloric intake of \< 250 kcal/d for 5 days
223707577|NCT01694472|BIOLOGICAL|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
223707578|NCT04218825|DRUG|chlormethine gel|Gel to be applied to all skin areas affected by MF-CTCL
223707579|NCT02079545|DRUG|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
223707580|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
223707581|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
223707582|NCT02079545|DRUG|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
223707583|NCT02079545|DRUG|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
223707584|NCT06136832|BEHAVIORAL|Pneumococcal Vaccine Education|Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia
223707585|NCT00713323|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
223707586|NCT06158373|OTHER|infant massage practice|infant massage practice
223707587|NCT06158373|OTHER|Safe Swaddling|Safe Swaddling
223707588|NCT06158373|OTHER|Control|Control
223707589|NCT01925677|DEVICE|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
223707590|NCT03513328|DRUG|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
223526040|NCT05634343|OTHER|experimental group 1|Laughter therapy, also called therapeutic laughter, is used to relieve pain and stress and to promote a general sense of well-being. Laughter therapy is simply a method of 'laughing for no reason' in which the person interacts in a group setting with improvisation or pantomime-like exercises and childish games without humour, jokes or funny events. The aim is thus to benefit from laughter.
223526041|NCT05634343|OTHER|experimantal group 2|Mindfulness is purposefully drawing attention in the desired direction so that we can stay in the present moment without judgment. It is also defined as a conscious understanding of what is happening in the moment we live in with an open and loving attitude. According to another definition, mindfulness includes paying attention to what is happening in the present moment, noticing the quality of this attention, and accepting what is noticed without judgment. With conscious awareness, the individual discovers how to live in harmony with all the events that take place in the present moment, place and time, without any evaluation, rather than the sorrows and regrets of the past, the anxieties and worries of the future. Mindfulness helps us to relate to our experiences by enabling us to see the positive-negative, good-bad experiences we have had objectively.
223707591|NCT03513328|DRUG|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
223707592|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
223707593|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
223707594|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
224276030|NCT05714241|OTHER|Data extraction|"After routine coronary function testing using a diagnostic pressure-temperature sensor guidewire in order to assess Coronary Flow Reserve (CFR) and the Index of Microvascular Resistance (IMR); and/or the acetylcholine (Ach) provocative test to assess the presence of coronary vasomotion disorders, patients will be stratified, accordingly to coronary function testing and Ach provocative test, in four groups/endotypes:~1. MVA (evidence of CMD defined as any of abnormal CFR \[\<2.0\], IMR \[≥25\], or microvascular spasm);~2. VSA (CFR ≥2.0, IMR \<25 and epicardial spasm);~3. both MVA and VSA (evidence of CMD and epicardial spasm);~4. none/non-cardiac chest pain (CFR ≥2.0 and IMR \<25 and neither microvascular nor epicardial spasm)."
223526042|NCT05500521|DIAGNOSTIC_TEST|Caloric irrigation|In a healthy ear irrigation with warm and cold water should give rise to an intense sensation of vertigo and involuntary eye movements called nystagmus. This nystagmus can be measured and thereby give an indication of the vestibular function in that ear.
223526043|NCT05500521|DIAGNOSTIC_TEST|vHIT|This test measures the vestibular ocular reflex in all six semicircular canals (three in each ear). By performing a fast head thrust in the direction of the canal the eye response can be detected by a high-velocity video camera. A slower response indicates impaired function in that canal.
223707595|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
223707596|NCT00631995|BIOLOGICAL|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
223707597|NCT00631995|DIETARY_SUPPLEMENT|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
223707598|NCT01245660|DRUG|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
223707599|NCT02949037|OTHER|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
223707600|NCT03142087|OTHER|exercises|exercise
223707601|NCT00883805|BIOLOGICAL|Blood draw|Subjects will give blood for analysis of metal ion concentrations
223707602|NCT00883805|RADIATION|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
223707603|NCT04195087|DEVICE|Masimo Radical-7® Pulse CO-Oximeter®|The perfusion index and Pleth variability index will be recorded from the device monitor.
223707604|NCT04942444|OTHER|Dry needling|One-hour weekly session of DN in the 18th tender points during 6 weeks in the DNG, apart from continuing their medical treatment. The CG continue with the habitual medical treatment.
223707605|NCT01947582|DEVICE|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
223707606|NCT04070430|OTHER|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
223707607|NCT04070430|OTHER|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
223707608|NCT02949869|OTHER|Spinal Sonography|As described previously
223707609|NCT03098953|DRUG|Loteprednol Etabonate|one drop per eye for each eye
223707610|NCT01826604|DEVICE|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
223707611|NCT01826604|OTHER|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
223707612|NCT05633823|OTHER|Mobile Application Game Training|"Mobile application game training can be used interactively with smartphones and tablets.~* A user account will be created after the application is downloaded to the mobile phone/tablet.~* After logging into the application, the map of the game will be displayed.~* The game will start with the first level of the game consisting of 5 levels.~* At each level, first of all, educational videos prepared in the form of short (1-2 minutes) animations will be watched. The number of videos varies between 1 and 3.~* After watching the videos, interactive games will be played.~* Children are required to complete each stage in the game, and each stage is planned to take approximately 7-10 minutes.~* After passing the first level, children will be able to move on to the next level of games and will not be able to move on to the next level until the previous level is finished."
223707613|NCT06383221|COMBINATION_PRODUCT|"Mental Fitness Boot Camp - Advanced Counseling Step-by-Step Care"|Simple and scientific advice
223707614|NCT00491075|DRUG|Pemetrexed|500 mg/m\^2 IV Over 10 Minutes on Day 1.
223707615|NCT00491075|DRUG|Gemcitabine|1500 mg/m\^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
223707616|NCT04316065|DRUG|YHP1906|YHP1906 Tab. 5 mg
223526044|NCT05500521|DIAGNOSTIC_TEST|VEMP|Utricular and saccular function can be measured by VEMP. Sound is presented in one ear at a time and the evoked myogenic potential in the sternocleidomastoid and the superior oblique muscles can be measured respectively. This gives a measurement of the function of the sacculus (cVEMP) and utriculus (oVEMP).
223707617|NCT04316065|DRUG|YHR1902|Comparator. YHR1902 Tab. 5 mg
223707618|NCT03660540|DIETARY_SUPPLEMENT|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
223707619|NCT01603355|DRUG|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
223707620|NCT03177694|DEVICE|Wireless bed sensor|Remote data collection
223707621|NCT01911078|PROCEDURE|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
223707622|NCT01911078|DEVICE|EnligHTN™ Renal Denervation System.|
223707623|NCT05746312|BEHAVIORAL|healing attempt|The intervention consists of pre-composed and pre-recorded guided meditations, songs, and poems that total 25 minutes in duration. The elements of the intervention were set to background music tracks that were informed by Black diasporic music traditions and anxiety reduction principles from the music therapy literature.
223526045|NCT04049513|BIOLOGICAL|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
223707624|NCT04798924|DEVICE|Subacute Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the intact field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
223707625|NCT04798924|DEVICE|Subacute Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each subject to be used at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least one and up to 6 months.
223707626|NCT04798924|DEVICE|Chronic Training in the blind field|After the initial training period of one to six months, the same computer software will continue to be used for all subjects. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a predetermined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. Subjects will train daily (about 40-60 minutes total), 5 to 7 days per week for at least 6 months.
223707627|NCT02981121|BEHAVIORAL|Exercise and Diet remedies|
223526046|NCT04049513|DRUG|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m\^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m\^2 IV on days -5 to -3, inclusive
223707628|NCT02981121|DRUG|Metformin|
223707629|NCT06113744|BIOLOGICAL|Placebo|saline
223707630|NCT06113744|BIOLOGICAL|COVID-19 Vaccine (Vero Cell) ,Inactivated|COVILO
223707631|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg|Low-dose
223707632|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg|Mid-dose
223707633|NCT06113744|BIOLOGICAL|COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg|High-dose
223707634|NCT05751928|BIOLOGICAL|BCD-217|BCD-217 (anti-CTLA4 agent nurulimab + anti-PD1) once every 3 weeks in the neoadjuvant setting
223707635|NCT05751928|BIOLOGICAL|anti-PD1|anti-PD1 agent in the adjuvant setting
223707636|NCT05751928|PROCEDURE|Excision of the primary lesion|Excision of the primary lesion will be performed per standard of care.
223707637|NCT05751928|PROCEDURE|Regional lymphadenectomy|Regional lymphadenectomy will be performed per standard of care.
223707638|NCT00716703|OTHER|CT Scan using IV contrast alone|CT scan using IV contrast alone
223707639|NCT02911857|BIOLOGICAL|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
223707640|NCT00380822|DRUG|miglitol|
223707641|NCT03670888|BIOLOGICAL|JHL1101|100 mg/10 mL solution in a single-use vial
223707642|NCT03670888|BIOLOGICAL|Rituximab|100 mg/10 mL solution in a single-use vial
223707643|NCT06177938|DIETARY_SUPPLEMENT|Lactose solution/Glucose solution|Single ingestion of a lactose/glucose solution.
223707644|NCT05971160|BEHAVIORAL|Financial education videos|Brief videos providing structured information on managing one's money
223707645|NCT05971160|OTHER|Microgrant|$150 stipend
223707646|NCT05971160|BEHAVIORAL|Peer mentoring|One-on-one structured mentoring sessions with a trained peer
223707647|NCT05711849|BIOLOGICAL|Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.|Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
224276031|NCT05714241|OTHER|Blood sampling|At the time of this coronary angiography, arterial blood samples through the radial sheath will be collected. If collected at the time of any follow-up visit, venous blood samples will be collected by venipuncture with the same modalities to obtain whole blood, serum and plasma samples after centrifugation.
224276032|NCT05714241|OTHER|Clinical Follow-up|"All patients will undergo a final follow-up visit at 12 months from the date of enrollment.~During the visit, the incidence of MACE in the past months will be investigated, the Seattle Angina Questionnaire (SAQ) will be administered and the SAQ summary score will be collected."
224276033|NCT06613334|BIOLOGICAL|Blood test: measurement of plasma antipsychotic concentration|Four blood tests are prospectively realized per patient during the study to measure the plasma concentration of antipsychotics (primary treatment: risperidone/paliperidone, olanzapine or aripiprazole). These blood samples are taken at the inclusion visit, at the follow-up visits 2 and 4 months after the inclusion visit, then at the end-of-study visit 6 months after the inclusion visit.
223526047|NCT06417060|DRUG|Caudal block anesthesia|Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
223526048|NCT06417060|DRUG|Dorsal penile block anesthesia|Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
223526049|NCT01296204|DRUG|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
223526050|NCT05313490|DIETARY_SUPPLEMENT|Beetroot Juice|7 days of 140 mL per day of beetroot juice
223526051|NCT05313490|OTHER|Placebo Beetroot Juice|7 days of 140 mL per day of placebo beetroot juice
223526052|NCT04597801|DRUG|Alcon|Fluorescein sodium is administered intravenously with a bolus injection of 5 mg per kg of bodyweight 20-40 minutes prior to the planned tumor resection.
223526053|NCT04794504|DRUG|Botox 100 UNT Injection|Botox will be injected intramuscularly into the masseter and temporalis muscles bilaterally to investigate if it can supplement postoperative analgesia in orthognathic surgery patients
223526054|NCT04794504|OTHER|0.9% Saline Injection|As a placebo control to the 100 UNT Botox injection, 0.9% saline will be injected intramuscularly into the masseter and temporalis muscles bilaterally
223526055|NCT02731482|OTHER|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~* Aerobic training in stepping training.~* Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~* Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
223707648|NCT05711849|PROCEDURE|Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).|These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
223707649|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 6 weeks.|
223707650|NCT02785263|RADIATION|2.15 gray and 1.8 gray. Max. 5 weeks.|
223707651|NCT05706701|OTHER|Nicotine vaping visit 1 (free-base nicotine)|Participants will receive the free-base form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at one of their two visits. Participants will use the ENDS device with free-base nicotine and four fluxes in random order.
223707652|NCT05706701|OTHER|Nicotine vaping visit 1 (protonated nicotine)|Participants will receive the protonated form of four nicotine fluxes: 9, 18, 27, 35 μg/sec at the other study visit. Participants will use the ENDS device with protonated nicotine and four fluxes in random order.
223707653|NCT05706701|OTHER|Nicotine vaping visit 2 (free-base nicotine)|Participants who received protonated nicotine during visit 1 will now receive free-base nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
223707654|NCT05706701|OTHER|Nicotine vaping visit 2 (protonated nicotine)|Participants who received free-base nicotine during visit 1 will now receive protonated nicotine fluxes for visit 2: 9, 18, 27, 35 μg/sec.
223707655|NCT05827952|BEHAVIORAL|behavior modification-Atomic Habit by hybrid|Atomic Habits (20-minute audiobook format), a role structure, and a game structure, online schedule reminders more than twice a week, and individual counseling sessions (online and physical) with one to two total interventions. The content of the online schedule reminders consisted of a total of four concepts for each of the four major habits, and a total of 16 sessions of the online audiobook interventions were adapted for the caregivers' relationship-building habits with the children.
223707656|NCT03641404|DRUG|L-ergothioneine|Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.
223707657|NCT03641404|DRUG|Placebo|Placebo. Study control (99% microcrystalline cellulose, 1% magnesium stearate)
223707658|NCT01734863|RADIATION|External Beam Radiotherapy|
223707659|NCT06129422|DRUG|NMK89|Route of administration: intravenous infusion
223707660|NCT05700617|DRUG|1:1 Randomization to receive milrinone|Randomized to receive either inotropic agent: milrinone or no agent
223707661|NCT05578326|DRUG|Trilaciclib|240 mg/m2 intravenous, over 30 minutes at day 1 of each cycle
223707662|NCT05578326|DRUG|Lurbinectedin|3.2 mg/m2, over 60 minutes at day 1 of each cycle
223707663|NCT05880862|BEHAVIORAL|Pelvic Floor Muscle Training|A 12-week, 6 visit, outpatient program of physical therapist delivered behavioral and pelvic floor muscle training (PFMT)
223707664|NCT05880862|DRUG|Mirabegron|Individually titrated Mirabegron, starting at 25 mg daily and increased to 50 mg daily at 6-weeks, during the 12-week intervention period.
223707665|NCT05880862|DRUG|Trospium Chloride|A 12-week course of Trospium XL -extended release, 60mg once daily.
223707666|NCT04252066|DRUG|migalastat|This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
223707667|NCT05488171|DRUG|Methylone|Single oral dose of 200 mg of methylone.
223707668|NCT05488171|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose of 100 mg of MDMA.
223526056|NCT02731482|OTHER|Control Group|"* The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~* Participants will not receive any supervised physical training.~* Once a week, patients will receive a phone call to provide support and general advice."
223526057|NCT05358223|OTHER|Music|A standard music determined by us for the 1st and 4th groups will be played during the process.
223526058|NCT05358223|DEVICE|TENS|TENS device will be connected to the 3rd and 5th groups during the process and the process will be done in this way.
223526059|NCT03960944|OTHER|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
223526060|NCT04190472|DIAGNOSTIC_TEST|IOP HPV test|Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
223526061|NCT03898427|DEVICE|Wrist Actigraphy Devices|A watch-like wearable sensor
223526062|NCT03898427|DEVICE|Polysomnography|Sleep Monitor
223526063|NCT03898427|DEVICE|Videography|Thermal Camera
223526064|NCT00815633|DRUG|Alefacept|15mg intramuscular injection weekly for 12 weeks
223526065|NCT02978495|DRUG|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
223526066|NCT02978495|DRUG|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
223526067|NCT02978495|DRUG|Paclitaxel|80mg/m2 weekly for 12 weeks
223526068|NCT02978495|DRUG|Cyclophosphamide|600mg/m2 4 cycles each 21 days
223526069|NCT00721110|DRUG|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
223526070|NCT00721110|DRUG|Placebo|Placebo boluses and infusions will be substituted
223526071|NCT00721110|DRUG|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
223526072|NCT00721110|DRUG|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
223526073|NCT00416507|DRUG|fluorouracil|
223526074|NCT00416507|DRUG|gemcitabine hydrochloride|
223526075|NCT00416507|DRUG|liposomal cisplatin|
223707669|NCT05488171|DRUG|Placebo|Single oral dose of placebo.
223707670|NCT03665454|DRUG|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
223707671|NCT03665454|DRUG|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
223707672|NCT05589766|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside supplementation up to 3000mg daily in total.
223707673|NCT05589766|OTHER|Placebo|Placebo tablet identical in taste, form and appearance to NR tablets, administered twice daily for a total of 12 weeks.
223707674|NCT02130232|BEHAVIORAL|Lifestyle Intervention|
223707675|NCT02130232|OTHER|Usual Care|
223707676|NCT06258785|DRUG|Tizanidine|Tizanidine 2mg will be given preoperatively prior to scheduled sacrospinous ligament suspension
223707677|NCT05999799|DRUG|GSK1070806|GSK1070806 will be administered.
223707678|NCT05999799|DRUG|Placebo|Placebo will be administered.
223707679|NCT06344104|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"
223707680|NCT06344104|DRUG|Placebo|Placebo tablet administered orally, once daily (QD).
223707681|NCT04417803|BIOLOGICAL|Blood sampling|plasmatic sampling
223707682|NCT05299606|DEVICE|Transbronchial Microwave Ablation|Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
223707683|NCT06961214|DRUG|Depemokimab|Depemokimab as a sterile liquid formulation will be administered.
223707684|NCT06961214|DRUG|Placebo|Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered
223707685|NCT04689269|OTHER|"The simulated easy airway"|A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create an easy airway situation by adjusting the manikin until it becomes in a neutral position
223707686|NCT04689269|OTHER|"The simulated difficult airway"|"A high-fidelity simulator (Airway Management Trainer, model AA-3100, Laerdal Medical Ltd., Orpington, England, UK) will be equipped to create a difficult airway scenario will be established by placing the occiput on an Oasis Elite™ Prone Head Rest, Adult (140 mm in height) (Covidien, Mansfield, MA, USA), and inhibiting head and neck movement by securing the head with an adhesive tape, simulating the effect produced by a cervical-collar."
223707687|NCT04689269|DEVICE|King Vision Laryngoscope|Using a King Vision Laryngoscope for placement of the DLT
223707688|NCT04689269|DEVICE|MacGrath Laryngoscope|Using a MacGrath Laryngoscope for placement of the DLT
223707689|NCT05661110|OTHER|Observational|All patients will be treated with standard of conversion treatment with HIPEC combined PD1/PDL1 inhibitor. After obtaining written informed consent, participants will have serial blood, tumor tissue collection. The blood collection (10 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. Participants will remain on the study for as long as they are being followed or treated at Affiliated Cancer Hospital \& Institute of Guangzhou Medical University. Participants can withdraw from the study at any time.
223707690|NCT04752683|OTHER|MyBuddy Employee Wellbeing App|"The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data)."
223707691|NCT04763668|OTHER|Pregnant HIV positive women on ARTs|Cardiovascular disease risk in pregnant HIV positive women on ARTs
223707692|NCT04763668|OTHER|Babies born to HIV positive mothers on ARTs|cardiovascular disease risk in the offspring of HIV positive mothers on ARTs
223707693|NCT00876057|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy
223707694|NCT00876057|PROCEDURE|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
223707695|NCT05350410|BEHAVIORAL|HALT-AD|HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
223707696|NCT02025322|BEHAVIORAL|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
223707697|NCT04776109|PROCEDURE|erector spinae block|"Bilateral erector spinae catheters will be placed at T8 level. an ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the midline to identify the back muscles and the transverse Processes. Next, 2-3 ml of 2% lidocaine will be infiltrated .~A 16-G, 8-cm Tuohy needle will be then introduced medially in the plane of the ultrasound beam and directed towards the transverse process. Once the needle is underneath the anterior fascia of the erector spinae muscle, 10 ml of saline 0.9% will be injected lifting the muscle of the transverse process. A catheter will be inserted into the newly formed space underneath the ES muscle and secured. The procedure will be repeated on the contralateral side. bupivacaine (20 ml of bupivacaine 0.25%) solution will be injected immediately into each catheter then infusion of bupivacaine 0.125% 0.1 ml/kg/h will be continued for 48 hours."
223707698|NCT05001256|OTHER|questionnaire study|Participants will be surveyed through face-to-face interviews.
223707699|NCT04516174|PROCEDURE|Transversus abdominis plane block using ropivacaine|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using 0.25% ropivacaine was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
223707700|NCT04516174|DRUG|Dexmedetomidine|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of dexmedetomidine.
223707701|NCT04516174|PROCEDURE|Transversus abdominis plane block using saline|Before anesthesia, the ultrasound-guided bilateral transversus abdominis plane block using saline was perdormed by anesthesiologist who is not involved in intraoperative management and postoperative follow-up and evaluate the effect after the block completed.
223707702|NCT04516174|DRUG|Saline|After finished the transversus abdominis plane block, then perform tracheal intubation and start the infusion of saline, dosage and infusion method of saline are consistent with dexmedetomidine.
223707703|NCT03760978|DRUG|Dexmedetomidine|
223707704|NCT04969575|OTHER|Insemination and culture|All MII oocytes will be inseminated by ICSI 39-41 hours post final oocyte maturation trigger.
223707705|NCT04969575|OTHER|Media refreshment Group 1|Zygote scoring on day 1 (18-20hpi). Culture medium refreshment will be done 67-69 hours post insemination (Day3).
223707706|NCT04969575|OTHER|Culture media preparation and refreshment|"30µL of culture medium (Global total LP is added to each well of the 8 wells of LifeGlobal GPS Dish (EGPS-010) and 50µL to the center 3 drops.~Dishes will be equilibrated overnight in a CO2 incubator."
223707707|NCT04969575|OTHER|Embryo grading|Should be done prior to media refreshment. For group 2, embryo grading and media refreshment is done prior to blastocyst biopsy.
223707708|NCT04969575|OTHER|Media refreshment Group 2|Zygote scoring on day 1 (18-20hpi). Culture media refreshment will be done 114-118 hours post insemination (Day5).
223707709|NCT06065397|PROCEDURE|Goal setting improvement program|A improvement program how to optimalize patient-centered goal setting in rehab care is being implemented.
223707710|NCT04447300|PROCEDURE|high power application|Radiofrequency delivery was performed in a point-by point fashion and continuously (an inter-lesion distance of 6 mm) with 50 W and 70 W and the ablation time for each point is limited to 7s and repeated if needed till the Unipolar signal modification turn to complete positive R wave.
223707711|NCT04447300|PROCEDURE|Standard power application|Standard power application
223707712|NCT05821400|OTHER|observational study|observational study
223707713|NCT03543150|DRUG|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
223707714|NCT02211040|BEHAVIORAL|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
223707715|NCT06462885|BEHAVIORAL|home support, hiving alone|Home support: living alone
223707716|NCT06462885|BEHAVIORAL|home support, living with others|Home support: living with others
223707717|NCT01131156|BEHAVIORAL|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
223707718|NCT05024201|BEHAVIORAL|THERAPEUTİC TOUCH FOR HEMODİALYSİS PATİENTS|Therapeutic touch was applied to hemodialysis patients for 3 days every other day.
223707719|NCT03929510|DRUG|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
223707720|NCT03929510|DRUG|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
223707721|NCT03929510|DRUG|PF-06651600|Oral solution 200mg
223707722|NCT00753766|OTHER|Multifactorial Intervention|
223707723|NCT00839852|DRUG|Cariprazine|Cariprazine was supplied in capsules.
223707724|NCT01518023|OTHER|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
223707725|NCT01863420|RADIATION|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
223707726|NCT00494299|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
223707727|NCT00494299|DRUG|Placebo|Placebo: matching placebo
223707728|NCT03333304|DIAGNOSTIC_TEST|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
223707729|NCT05907590|OTHER|Interoceptive accuracy measurement|Interoceptive accuracy will be measured using the Respiratory Occlusion Discrimination Task (ROD task; Van Den Houte et al., 2021). The ROD task measures how good subjects are at distinguishing the lengths of short (max 620 milliseconds) inspiratory occlusions (or respiratory interruptions).
223707730|NCT05907590|OTHER|Interoceptive sensibility measurement|Interoceptive sensibility will be measured using two self-report questionnaires, the Interoceptive Sensitivity and Attention Questionnaire (ISAQ; Bogaerts et al., 2022) and the the Three-domain Interoceptive Sensations Questionnaire (THISQ; Vlemincx et al., 2021)
223707731|NCT05907590|OTHER|Interoceptive awareness measurement|Interoceptive awareness will be measures using a visual analogue scale (VAS)
223707732|NCT05907590|OTHER|Proprioceptive accuracy measurement during postural control|"The effect of muscle vibration on center of gravity displacement (center of pressure or COP) will be examined. Muscle vibration of the m. triceps surae (ankle muscles) and the lumbar multifidus (back muscles) (Johanson et al., 2011; Brumagne et al., 2008; Claeys et al., 2011; Cleays et al., 2015) will be used to examine the role of proprioception during postural control."
224276034|NCT06613334|OTHER|Voice interviews and questionnaires carried out via the CALLYOPE application|"Voice interviews carried out via the Callyope application: they consist of a series of tests, divided into two parts: Structured tasks (same content for each participant) and Semi-structured tasks (content varies for each participant).~The simultaneous analysis of several speech tasks allows us to break down the different stages of speech production and the important factors that influence its achievement.~In addition, patients will complete self-questionnaires via the application. Finally, lifestyle habits (sleep duration and number of steps) will be recorded via the application.~These different tests will be carried out on the application at the inclusion visit (M0), then every month (M1, M2, M3, M4, M5) until the end of study visit (M6)."
223707733|NCT05907590|OTHER|Proprioceptive accuracy measurement of the neck|The head reposition accuracy task will be carried out to assess proprioceptive accuracy of the neck. The most commonly used procedure is the head repositioning accuracy to neutral head position (HRA-to-NHP), first described by Revel and colleagues (1991).
223707734|NCT04198597|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
223707735|NCT04198597|BEHAVIORAL|Process-based Cognitive Behavioral Therapy|Please see arm/group descriptions
224276035|NCT05594641|OTHER|Remote ischaemic preconditioning|A tourniquet will be applied to the right arm and it will be inflated (3 cycles, each lasting 5 minutes, at a pressure of 200 mmHg); each cycle is followed by 5 minutes of resting
223526076|NCT03801590|DEVICE|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
223526077|NCT00000222|DRUG|Buprenorphine|
223526078|NCT05793502|DEVICE|Solia S and Selectra 3D Developed by BIOTRONIK|LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK
223526079|NCT02652247|PROCEDURE|molecular analysis of exhaled breath condensate|
223526080|NCT02652247|PROCEDURE|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
223526081|NCT02652247|PROCEDURE|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
223526082|NCT03380273|BEHAVIORAL|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~1. Antibiotic prophylaxis~2. Perioperative antibiotics~3. Oxygen administration~4. Patient temperature~5. Surgeon protective wear~6. Patient operative skin preparation~7. Suction drains~8. Blood glucose level~9. Red cell transfusion~10. Dressing changes"
223526083|NCT01362790|DRUG|Pentostatin|Regimen A: Cycle 1: 4 mg/m\^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m\^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m\^2 or 2 mg/m\^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m\^2 on days 1 and 5 of 25 day cycle
223526084|NCT01362790|DRUG|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
223526085|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
223526086|NCT01362790|BIOLOGICAL|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
223526087|NCT03452930|RADIATION|Radiation Therapy|Undergo RT
223526088|NCT03452930|DRUG|Tinostamustine|Given IV
223526089|NCT02457065|BEHAVIORAL|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
223526090|NCT04830085|PROCEDURE|Hysterectomy|Hysterectomy (abdominal, vaginal or laparoscopic)
223526091|NCT05896241|OTHER|non-interventional study|non-interventional study
223526092|NCT01554904|DEVICE|Facial-Flex|Oral exercise device
223526093|NCT00517790|DRUG|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
223526094|NCT00517790|DRUG|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
223526095|NCT01969214|DEVICE|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
223526096|NCT01940055|BEHAVIORAL|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
223526097|NCT01940055|BEHAVIORAL|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
223526098|NCT06131190|BEHAVIORAL|mindfulness training|it focuses on attention and has gained empirical support as a complementary or alternative intervention
223526099|NCT05044767|DEVICE|total hip arthroplasty|hip replacement surgery
223526100|NCT05417178|OTHER|myStrength Macropersonalization Enginge|An onboarding process that utilizes the PHQ-9, GAD-7, and WHO-5 that leads to a user of the digital program's clinical focus and primary, secondary, and tertiary intervention recommendations.
223526101|NCT00279695|PROCEDURE|high frequency ultrasound examination|high frequency ultrasound examination of the eye
223526102|NCT02162173|PROCEDURE|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
223526103|NCT03965117|DRUG|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is \> 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
223526104|NCT02553096|DEVICE|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
223526105|NCT03429140|DRUG|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
223526106|NCT03429140|OTHER|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
223526107|NCT01605097|RADIATION|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
223526108|NCT00924274|DIETARY_SUPPLEMENT|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
223526109|NCT00924274|DIETARY_SUPPLEMENT|sunflower oil|sunflower oil
223526110|NCT02554955|DRUG|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
224276036|NCT05594641|OTHER|Control|The tourniquet will be applied to the right arm but the cuff will be not inflated
223707736|NCT02409212|BEHAVIORAL|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
223526111|NCT02554955|DRUG|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
223526112|NCT02554955|DRUG|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
223526113|NCT00763828|DEVICE|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
223526114|NCT03531580|DEVICE|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
223526115|NCT02305992|PROCEDURE|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
223526116|NCT02305992|PROCEDURE|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
223526117|NCT02305992|PROCEDURE|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
223526118|NCT04250701|OTHER|Body Posture Assessment|Application of three evaluations above at a one time.
223526119|NCT02786329|DRUG|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
223526120|NCT02786329|DRUG|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
223526121|NCT02786329|DRUG|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
223526122|NCT02786329|DRUG|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
223526123|NCT04190264|DEVICE|Thermal Rehabilitation Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
223526124|NCT04190264|OTHER|Cold Water Immersion|Whole-body immersion in cold water.
223526125|NCT06486220|DRUG|Intestinal bacteria freeze-dried powder capsules|Oral healthy intestinal bacteria freeze-dried powder capsules, tid
223526126|NCT03256487|DRUG|Buprenorphine|buprenorphine 0.3mg IV
223526127|NCT03256487|DRUG|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
223526128|NCT04179617|OTHER|5% nicotine content JUUL pod|JUUL pods that contain 5% nicotine
223526129|NCT04179617|OTHER|3% nicotine content JUUL pod|JUUL pods that contain 3% nicotine
223526130|NCT04831229|OTHER|Children will perform activities on interactive tablet|AIMG will actively perform activities with user interaction with the equipment through touch or verbal response. Both groups will have a total of 48 intervention sessions.
223526131|NCT04831229|OTHER|Children will perform passive on interactive tablet|"The PIMG is just a spectator, having contact with the equipment only when switching on / off, play / pause . Both groups will have a total of 48 intervention sessions."
223526132|NCT01715116|DEVICE|Enhanced ICD programming|"* VT monitor: \> 166/min~* fVT: \> 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~* VF: \> 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~* SVT/VT discrimination is turned on, high rate time out is OFF~* SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~* SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~* T wave-oversensing and lead noise discrimination is turned on in all devices."
223526133|NCT03107845|BEHAVIORAL|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
223526134|NCT03107845|BEHAVIORAL|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI \& OQ-30), interpersonal functioning (IIP-32 \& OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
223707737|NCT02409212|BEHAVIORAL|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
223707738|NCT00216710|BEHAVIORAL|Home Visiting|
223707739|NCT00801320|PROCEDURE|Tumor collection|Tumor collected at the time of planned surgery
223707740|NCT00120523|DRUG|Pimecrolimus|Pimecrolimus cream 1 %
223707741|NCT00120523|DRUG|Topical corticosteroids|TCS
223707742|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (T4030)|Eye drop
223707743|NCT04898387|COMBINATION_PRODUCT|Bimatoprost Timolol (Ganfort)|Eye drop
223707744|NCT03178331|OTHER|Study questionnaires|filled by parents, school nurse and teacher
223707745|NCT04299542|PROCEDURE|Percutaneous lung biopsy using conventional MDCT|Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
224276037|NCT05965986|OTHER|Experimental: PREPS only|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative."
223526135|NCT03107845|BEHAVIORAL|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
223526136|NCT02038647|DRUG|Alisertib|Alisertib tablets
223526137|NCT02038647|DRUG|Placebo|Placebo matching tablets
223526138|NCT02038647|DRUG|Paclitaxel|Paclitaxel intravenous injection
223526139|NCT02259803|DRUG|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
223526140|NCT02259803|DRUG|Telmisartan|
223526141|NCT02259803|DRUG|Amlodipine|
223526142|NCT02962661|OTHER|Best Practice|Given standard of care
223526143|NCT02962661|OTHER|Laboratory Biomarker Analysis|Correlative studies
223526144|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given IV
223526145|NCT02962661|DRUG|Mesenchymal Stem Cell Transplantation|Given transendocardially
223526146|NCT05887336|DEVICE|Walther System|Walther System providing INMEST treatment
223526147|NCT05887336|DEVICE|Sham Walther System|Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
223526148|NCT05887336|DRUG|Non preserved ocular lubricants|"* Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)"
223526149|NCT05887336|PROCEDURE|Eye lid procedure|Lid hygiene, warm eye bag, lid massage and Omega 3
223526150|NCT01173744|DEVICE|Gamma-3 Nail|Gamma-3 Nail (stryker)
223526151|NCT01173744|DEVICE|DHS|DHS (Zimmer)
223526152|NCT05576649|OTHER|Task difficulty adaptation according to Arvaneh et al. (2019)|The task difficulty in the P300 speller training will be adapted according to Arvaneh et al. (2019).
223526153|NCT05576649|OTHER|Random task difficulty|The task difficulty in the P300 speller training is chosen randomly.
223526154|NCT05576649|OTHER|Task difficulty adaptation according to iterative learning controller|The task difficulty in the P300 speller is determined by an iterative learning controller.
223526155|NCT02757430|PROCEDURE|Cardiac Ablation|
223526156|NCT00261339|DRUG|Pantoprazole|
223526157|NCT06570265|DEVICE|GBR membrane|GBR procedure is a technique often used in conjunction with dental implants to enhance the success and stability of the implant. This technique involves using barrier membranes to protect the bone graft or defect site from the rapid proliferation of surrounding soft tissues. In this clinical investigation resorbable, collagen membrane will be used.
223526158|NCT01809431|BEHAVIORAL|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
223526159|NCT02130037|BEHAVIORAL|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
223526160|NCT02130037|OTHER|psychotherapy|standard psychotherapy for eating disorders
223526161|NCT05755750|DRUG|Genipin|Intratendinous genipin injection
223526162|NCT00044785|DRUG|triacetyluridine|
223526163|NCT00044785|DRUG|fluorouracil|
223526164|NCT00044785|DRUG|leucovorin|
223526165|NCT00044785|DRUG|camptosar|
223526166|NCT01862354|PROCEDURE|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
223526167|NCT01862354|PROCEDURE|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
223526168|NCT04544631|OTHER|Virtual reality game as adjunctive pain management tool|A smart phone virtual reality-based pain alleviation tool (VR-PAT).
223526169|NCT06013852|DIAGNOSTIC_TEST|"processing the radiography with the Boneview software"|all X-Rays will be analysed with and without the software
223526170|NCT00670644|OTHER|questionnaire administration|Completed self-report form
223526171|NCT00670644|OTHER|survey administration|Completed self-report form-other
223526172|NCT00670644|PROCEDURE|quality-of-life assessment|Completed self-report form qol
223526173|NCT03598348|DRUG|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
223526174|NCT03598348|DRUG|Apatinib|Apatinib 250mg po Qd
223526175|NCT06052592|OTHER|Milk|Newborns will be fed with breast milk, formula milk or postbiotic formula milk
223526176|NCT05006664|DRUG|Adcetris 50 MG Injection|Treatment by study drug Brentuximab Vedotin (Adcetris) in combination with CHEP.
223526177|NCT05006664|DRUG|Endoxan|Treatment by study drug Cyclophosphamide (Endoxan) in combination.
223526178|NCT05006664|DRUG|Doxorubicin|Treatment by study drug Doxorubicin in combination.
223526179|NCT05006664|DRUG|Etoposide|Treatment by study drug Etoposide in combination.
223526180|NCT05006664|DRUG|Prednisone tablet|Treatment by study drug Prednisone in combination.
223707746|NCT04299542|PROCEDURE|Percutaneous lung biopsy CBCT|CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
223707747|NCT00245661|DRUG|Temazepam|
223526181|NCT00002930|PROCEDURE|positron emission tomography|
223526182|NCT00002930|RADIATION|fludeoxyglucose F 18|
223526183|NCT06571435|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST), and Posterior Shoulder Endurance Test|"The modified closed kinetic chain upper extremity stability test is reliable and is performed in an individualized manner by placing the hands on the floor at shoulder level. The evaluation process is the same as the original test; the total number of touches in 15 seconds is noted by lifting one hand, touching the other and placing it back. A total of 3 measurements are taken with a 45-second rest interval. The endurance capacity of the muscle group is an important factor for sports performance as it requires specific sports movements repeated in a certain period of time.~For posterior shoulder endurance test participants will lie with their face down. While the shoulder is hanging from the stretcher, individuals will be asked to lift the dumble calculated with the weight appropriate for their weight to 90 degrees abduction in accordance with the 60 bpm metronome. Their duration in seconds will be noted. 1 measurement will be made with each arm."
223526184|NCT03903783|OTHER|Cefotaxime|"Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
223526185|NCT03903783|OTHER|Ceftriaxone|"Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
223526186|NCT05454865|DIETARY_SUPPLEMENT|Jin Si Herbal Tea|Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)
223526187|NCT05454865|DIETARY_SUPPLEMENT|Placebo|Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
223526188|NCT03469895|DRUG|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
223526189|NCT00693147|PROCEDURE|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
223526190|NCT03935347|DRUG|Cyclophosphamide|Given IV
223526191|NCT03935347|DRUG|Fludarabine|Given IV
223707748|NCT00200642|DEVICE|Stretta® System|
223707749|NCT02890927|OTHER|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
223707750|NCT02850354|OTHER|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
223526192|NCT03935347|DRUG|Fludarabine Phosphate|Given IV
223526193|NCT03935347|BIOLOGICAL|Pembrolizumab|Given IV
223526194|NCT03935347|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
223526195|NCT03935347|BIOLOGICAL|Aldesleukin|Given IV
223526196|NCT03817580|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
223526197|NCT03817580|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
223526198|NCT03817580|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
223707751|NCT04151173|PROCEDURE|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
223707752|NCT04151173|PROCEDURE|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
223707753|NCT03993132|DRUG|Empagliflozin|new users (initiators) of Empagliflozin
223707754|NCT03993132|DRUG|Liraglutide|initiators of Liraglutide
223707755|NCT00907712|OTHER|cardiac echo examination|cardiac echo examination - before and after the surgery
223707756|NCT01880619|DRUG|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
223707757|NCT01880619|DRUG|Solifenacin|Patients in the arm will receive Solifenacin
223707758|NCT01880619|DRUG|Control|Patients in this are will receive placebo
223707759|NCT01034189|DRUG|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
223707760|NCT01034189|DRUG|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
223707761|NCT01034189|DRUG|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
223707762|NCT01034189|RADIATION|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
223707763|NCT02326662|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
223707764|NCT05424523|DRUG|Omalizumab|Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
223707765|NCT02549534|PROCEDURE|Axon Reflexes|"\*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~* Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33\*C.~* Heat Ramp: Increasing the heat in the heat probe to 42\*C at approx. 0.1\*C/10 sec.~* Skin Heating: Heating the skin of the toe for 30 minutes 42\*C.~* Heat Ramp: Increasing the heat in the heat probe to 44\*C at 0.1\*C/10 sec..~* Skin Heating: Heating the skin for an additional 5 minutes at 44\*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
223707766|NCT02549534|PROCEDURE|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
223707767|NCT02549534|PROCEDURE|Self-Reported Signs & Symptoms of CIPN|Self-reported signs \& symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
223707768|NCT01578070|BIOLOGICAL|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
223707769|NCT01578070|BIOLOGICAL|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
223707770|NCT01578070|BIOLOGICAL|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
223707771|NCT01578070|BIOLOGICAL|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
223707772|NCT01578070|BIOLOGICAL|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
223707773|NCT02805972|DRUG|Naloxone|4 mg / 0.1 ml
223707774|NCT02805972|DRUG|Placebo|0.1 ml
223707775|NCT04685967|DEVICE|Glass ionomer|Equia Forte HT, GC, Tokyo, Japan
223707776|NCT04685967|DEVICE|Bulk-fill composite|SonicFill2, Orange, CA, USA
223707777|NCT02640573|DRUG|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
223707778|NCT01206166|DRUG|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
223707779|NCT00407329|PROCEDURE|transurethral resection of the prostate|resection of prostate
223707780|NCT05392257|DRUG|Rituximab + zanubrutinib + lenalidomide|Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
223707781|NCT02716805|DRUG|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
223707782|NCT02716805|DRUG|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing \> 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
223707783|NCT02716805|BIOLOGICAL|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
223707784|NCT02716805|DRUG|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
223707785|NCT00932126|DRUG|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
223707786|NCT03239600|DRUG|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
223707787|NCT03239600|DRUG|Placebo|Placebo solution will be administered by IV infusion.
223707788|NCT03239600|DRUG|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
223707789|NCT00066365|BIOLOGICAL|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
223707790|NCT00066365|PROCEDURE|conventional surgery|thoracotomy
223707791|NCT02713373|BIOLOGICAL|Cetuximab|Given IV
223707792|NCT02713373|OTHER|Laboratory Biomarker Analysis|Correlative studies
223707793|NCT02713373|BIOLOGICAL|Pembrolizumab|Given IV
223707794|NCT03815474|DRUG|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
223707795|NCT03062007|DRUG|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
223707796|NCT04288752|DEVICE|VR101 Lubricating Intravaginal Ring|VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
223707797|NCT04288752|DEVICE|Sham Ring|Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
223707798|NCT01807039|PROCEDURE|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
223707799|NCT03939754|BEHAVIORAL|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
223707800|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
223707801|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
223707802|NCT04495933|BIOLOGICAL|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg|MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
223707803|NCT04495933|OTHER|Placebo|sterile saline
223707804|NCT02063711|BEHAVIORAL|Yoga intervention|
223707805|NCT00005017|DRUG|Ritonavir|
223707806|NCT00005017|DRUG|Abacavir sulfate|
223707807|NCT00005017|DRUG|Amprenavir|
223707808|NCT00005017|DRUG|Efavirenz|
223707809|NCT00005017|DRUG|Lamivudine|
223707810|NCT00005017|DRUG|Stavudine|
223707811|NCT00000488|DRUG|cholestyramine|
223707812|NCT00000488|BEHAVIORAL|diet, fat-restricted|
223707813|NCT05034562|PROCEDURE|Computed Tomography|Undergo PET/CT
223707814|NCT05034562|DRUG|Gallium Ga 68-labeled PSMA-11|Given IV
223707815|NCT05034562|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223707816|NCT05034562|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
223707817|NCT00787761|BIOLOGICAL|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains \> 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
223707818|NCT00787761|DRUG|busulfan|"Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
223707819|NCT00787761|DRUG|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume)."
223707820|NCT00787761|DRUG|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes."
223707821|NCT00787761|DRUG|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push."
224276038|NCT05965986|OTHER|Experimental: PREPS and therapy|"Participants will be guided through an education program and exercise program that will cover topics. Participants will have flexibility as to when and how often then need to review material. Participants will be directed to completed on-screen interactive quizzes to re-enforce learning. Participants are encouraged to pose any questions regarding the material they are learning within the education modules to the research team for further clarification.~The intervention group will be asked to participate in the program (6 weeks), but after their surgery, they will not be asked to continue the education or exercise program. However, they will be tracking their activity and adherence to physical therapy through a log for one year post-operative. In addition, participants will have a therapist call on week 2 and 4 of the program and then one week after surgery to check in and ensure the patient is meeting all milestones and answer any questions."
223707822|NCT00787761|DRUG|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
223707823|NCT00787761|PROCEDURE|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
223707824|NCT01934881|DEVICE|voltage adjustment only|Only voltage will be adjusted in all programming sections.
223707825|NCT01934881|DEVICE|Multiple parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
223707826|NCT02635776|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
223707827|NCT02635776|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
223707828|NCT00788073|DRUG|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
223707829|NCT00788073|DRUG|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
223707830|NCT05856188|DIETARY_SUPPLEMENT|Glutamine|Biologic
223707831|NCT00375037|BEHAVIORAL|feedback|
223707832|NCT00375037|BEHAVIORAL|Education|
223707833|NCT00375037|OTHER|usual care|
223707834|NCT05649566|DEVICE|Virtual Reality game|"The game consists of cutting mobile targets, using lightsabers while avoiding obstacles that approach the user. This game is a reference for immersive play since, while distracting, it recreates a physical activity similar to what would be done in reality. It has been shown that the same energy expenditure, on the part of the user, practicing tennis in real life, is what he does playing Beat Saber playing the same period of time."
223707835|NCT06557928|OTHER|measurement|Measurement of multiple physiological indicators and psychological status and multi-omics study
223707836|NCT00376883|DRUG|pamidronate|
223707837|NCT03873025|COMBINATION_PRODUCT|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
223707838|NCT03527030|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
223707839|NCT03527030|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
223707840|NCT01669135|OTHER|Spinal Anesthesia with cerebral oxygen saturation monitoring|
223707841|NCT00499239|DRUG|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
223707842|NCT03412526|DRUG|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
223707843|NCT03412526|RADIATION|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
223707844|NCT03412526|BIOLOGICAL|TIL administration|TIL Administration
223707845|NCT03412526|DRUG|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
223707846|NCT00119431|DRUG|C1 inhibitor concentrate|
223707847|NCT02388919|DRUG|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
223707848|NCT02388919|DRUG|Placebo|Basic dosage, take once when limosis in the morning.
223707849|NCT04234074|DEVICE|Volusense paediatric monitoring device|Comparison of Volusense paediatric monitoring device to full cardiorespiratory polysomnography.
223707850|NCT02058693|DRUG|mixed salts amphetamine|adjunctive to ADT
223707851|NCT02898805|OTHER|Placebo|
223707852|NCT02898805|OTHER|Prescribed Diet|
223707853|NCT02898805|DIETARY_SUPPLEMENT|LopiGLIK®|
223707854|NCT02898805|DIETARY_SUPPLEMENT|Armolipid Plus|
223707855|NCT02056938|DRUG|Anti-Thymocyte Globulins treatment|
223707856|NCT02056938|DRUG|Basiliximab treatment|
223707857|NCT00532558|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
223707858|NCT00532558|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
223707859|NCT03668275|PROCEDURE|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
223707860|NCT00677131|OTHER|Reading the package insert of the drug|package insert of the drug
223707861|NCT00677131|OTHER|Reading the education information provided by the Pharmacy of NTUH|education information
223707862|NCT00677131|OTHER|Oral education provided by the pharmacist|Oral education provided by the pharmacist
223707863|NCT02418650|DRUG|ODM-201 300 mg tablet|
223707864|NCT02418650|DRUG|intravenous14C-ODM-201|
223707865|NCT02418650|DRUG|300 mg 14C-ODM-201 oral solution|
223707866|NCT00316992|DRUG|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
223707867|NCT02827227|BIOLOGICAL|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
223707868|NCT03864978|DRUG|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
223707869|NCT03864978|DRUG|Placebo|Placebo
223707870|NCT02850601|DRUG|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
223707871|NCT04783818|RADIATION|Adjuvant Radiotherapy|PMRT
223707872|NCT02925117|DRUG|Upadacitinib|Tablet for oral use
223707873|NCT02925117|DRUG|Placebo|Tablet
223707874|NCT05582473|BEHAVIORAL|LST-LC Education|"Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain"
223707875|NCT03658239|OTHER|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
223707876|NCT05212922|DRUG|YH001 + Toripalimab|YH001 + Toripalimab
223707877|NCT04067674|BIOLOGICAL|Blood sampling|Blood sampling for biomarker measurement
223707878|NCT00456248|DRUG|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
223707879|NCT04341077|DRUG|SHR3162|A single oral dose of fluzoparib on Day 1
223707880|NCT01446315|BEHAVIORAL|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
223707881|NCT01446315|BEHAVIORAL|Asthma APGAR tools|Usual care
223707882|NCT02027207|BIOLOGICAL|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
223707883|NCT02027207|BIOLOGICAL|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
223707884|NCT03117920|DRUG|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
223707885|NCT02235805|DIETARY_SUPPLEMENT|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
223707886|NCT02235805|DIETARY_SUPPLEMENT|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
223707887|NCT03717246|BEHAVIORAL|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
223707888|NCT03717246|BEHAVIORAL|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
223707889|NCT01853423|DRUG|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
223707890|NCT03504254|DIAGNOSTIC_TEST|MRI examination|Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
223707891|NCT04035109|DRUG|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
223707892|NCT04035109|DRUG|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
223707893|NCT04035109|BIOLOGICAL|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
224276039|NCT05915923|PROCEDURE|1 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)
224276040|NCT05915923|PROCEDURE|10 Hz Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)
224276041|NCT05915923|PROCEDURE|Sham Repetitive transcranial magnetic stimulation|After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
223526199|NCT02852707|BEHAVIORAL|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
223526200|NCT02852707|BEHAVIORAL|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
223526201|NCT02852707|BEHAVIORAL|Not exposed|People not engaged in regular sports competition/exercise training.
223526202|NCT06322901|PROCEDURE|Flap|Different flap designs for implant placement
223526203|NCT03880357|DRUG|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
223526204|NCT03880357|DRUG|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
223526205|NCT03880357|DRUG|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
223526206|NCT00184392|PROCEDURE|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
223526207|NCT02421094|DRUG|GR-MD-02|GM-MD-02 active
223526208|NCT02421094|DRUG|Placebo|Placebo
223526209|NCT01139151|DRUG|3 Day Thiarabine|Starting dose 70 mg/m\^2 IV over 1 hour (±15 minutes) daily x 3
223526210|NCT01139151|DRUG|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
223526211|NCT02320656|OTHER|Blood sampling|Longitudinal (3 stages of the disease)
223526212|NCT02320656|OTHER|Bone marrow aspirate|Longitudinal (3 stages of the disease)
223526213|NCT02320656|OTHER|Skin biopsy|Single biopsy (optional)
223526214|NCT02320656|OTHER|Buccal swab|Single sampling.
223707894|NCT04035109|BIOLOGICAL|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
223707895|NCT01533077|DRUG|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
223707896|NCT01533077|DRUG|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
223707897|NCT00002688|DRUG|cyclosporine|
223707898|NCT00002688|DRUG|etoposide|
223526215|NCT06408376|PROCEDURE|Physiological cord clamping|Immediately after birth, the newborn with prenatal diagnosis of CDH will be placed on a mobile table, made to receive these patients in the delivery room, at the level of the mother's womb, leaving the umbilical cord intact and intubated. The patient will be gently ventilated (PIM 15/25 - PEEP 4 - Fio2 50%), until saturation \>85% and HR\>100 or 10 timed minutes have elapsed, whichever occurs first, the umbilical cord will be clamped.
223526216|NCT03430999|DRUG|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
223526217|NCT03430999|DRUG|Placebo|Placebo
223526218|NCT02774694|DEVICE|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
223526219|NCT02878785|DRUG|Decitabine|DNA methyltransferase inhibitor
223526220|NCT02878785|DRUG|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
223526221|NCT03820076|OTHER|AZT-04|Staphylococcus epidermidis
223526222|NCT01483560|DRUG|Metformin|3 years treatment duration
223526223|NCT01483560|DRUG|Placebo|3 years duration
223526224|NCT05759403|DIAGNOSTIC_TEST|Cortical excitability using transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive neurophysiological technique for assessing human motor cortical function. With TMS, the underlying motor cortex is stimulated by an electric current induced by a transient magnetic field, generated in response to the passage of a large current through the stimulating coil located on the patient's scalp.
223526225|NCT00749346|DEVICE|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
223526226|NCT00460213|DRUG|Valsartan 80mg daily|
223526227|NCT00460213|DRUG|Valsartan 160mg daily|
223526228|NCT06254625|OTHER|Fecal Microbiome|Fecal microbiome transplantation from a healthy donor.
223526229|NCT06254625|OTHER|Placebo|Place capsules
223526230|NCT04870047|DEVICE|Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device|Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.
223526231|NCT00874601|DRUG|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
223526232|NCT03254810|BIOLOGICAL|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
223526233|NCT03254810|BIOLOGICAL|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
223526234|NCT03254810|BIOLOGICAL|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
223526235|NCT06310486|OTHER|Drowning-related OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) and experienced out-of-hospital cardiac arrest (OHCA), defined as being unconscious and not breathing normally at any time in the prehospital setting. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
223707899|NCT00002688|DRUG|mitoxantrone hydrochloride|
223707900|NCT06005350|DIETARY_SUPPLEMENT|Niagen|Nicotinamide-Riboside-Chloride Preparation 1000mg/day
223707901|NCT06005350|OTHER|Placebo|Placebo Preperation
223707902|NCT02904993|OTHER|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
223707903|NCT02904993|OTHER|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
223707904|NCT03989895|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
223707905|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
223707906|NCT02487433|DRUG|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
223707907|NCT00921401|BEHAVIORAL|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
223707908|NCT01593085|BEHAVIORAL|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~\--------------------------------------------------------------------------------"
223526236|NCT06310486|OTHER|Drowning-related non-OHCA|These patients were involved in a drowning incident (submersion or immersion in liquid) but did not experience an OHCA. Some of these patients may die as a consequence of the submersion injury (fatal drowning), while others may survive (non-fatal drowning).
223707909|NCT03598543|OTHER|no intervention|no intervention, this is an obervational study.
223707910|NCT00347360|DRUG|lisinopril|
223707911|NCT00347360|DRUG|carvedilol controlled release formulation|
223707912|NCT01449539|DRUG|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
223707913|NCT02850107|DEVICE|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
223707914|NCT02850107|DEVICE|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
223526237|NCT04716894|DRUG|BI 474121|BI 474121 oral solution
223526238|NCT04716894|DRUG|Itraconazole|Itraconazole oral solution
223526239|NCT04715126|OTHER|Oxyjun|One capsule to be taken after breakfast with water.
223526240|NCT04715126|OTHER|Placebo|One capsule to be taken after breakfast with water.
223526241|NCT03156114|DRUG|BI 754111|Day 1 of 3 week cycle
224276042|NCT06679595|OTHER|Pilot project paediatric transmural care|The implementation of pilot projects for transmural care for chronically ill children
224276043|NCT05611723|OTHER|Exposure to disability|Disability status assessed by functional measures
223526242|NCT03156114|DRUG|BI 754091|Day 1 of 3 week cycle
223526243|NCT01378143|DRUG|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
223526244|NCT00822380|DIETARY_SUPPLEMENT|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
223526245|NCT00822380|DIETARY_SUPPLEMENT|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
223526246|NCT00822380|DIETARY_SUPPLEMENT|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
223526247|NCT00822380|DIETARY_SUPPLEMENT|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
223526248|NCT00822380|DIETARY_SUPPLEMENT|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
223526249|NCT00000884|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
223526250|NCT00000884|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
223707915|NCT02850107|DEVICE|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
223707916|NCT02850107|DEVICE|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
223707917|NCT02850107|DEVICE|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
223707918|NCT04340648|DEVICE|Vital GlucoseDetect|11 time points for blood glucose measurements over 210 min including the ingestion of a standardized meal 30 min after the first blood glucose measurement.
223707919|NCT03398044|DRUG|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
223526251|NCT00000884|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
223707920|NCT03398044|DRUG|Placebo|Placebo will be administered to patients randomised into the control group arm.
223707921|NCT01462487|DRUG|Treatment with zanamivir|Subjects treated with zanamivir
223707922|NCT05004077|DRUG|AMIODARONE|Assess the effectiveness of different dosing strategies of amiodarone.
224276044|NCT02199379|DRUG|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
224276045|NCT03439085|BIOLOGICAL|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
224276046|NCT03439085|BIOLOGICAL|Durvalumab|Given IV
224276047|NCT04192032|OTHER|Preferred Juul pod flavor (5% nicotine)|Preferred Juul pod flavor (5% nicotine)
223526252|NCT05271006|BEHAVIORAL|Exercise|The mHealth platform to be used by the exercise group is Down Dog, which has a suite of apps for yoga, HIIT, barre, and running workouts. Down Dog has agreed to provide free memberships for one year to all participants in the study. To ensure participant de-identification on the Down Dog platform, each participant will receive a Participant ID which will be pre-registered by the study coordinator on the Down Dog platform. Randomized participants will be provided instructions for downloading the apps onto their phone or a link to the website to be used on their computer. Following randomization, participants in the exercise group will be asked to engage in physical activity (using any if the Down Dog apps), 4 days a week for 20 minutes a day for 12 weeks.
223526253|NCT04172220|DRUG|Midazolam|1-2 mg of Midazolam as premedication.
223707923|NCT06015464|DRUG|Orelabrutinib|Addition of novel BTK inhibitor, Orelabrutinib，150 mg qd, to standard treatment regimens, which include R-CHOP and Pola-R-CHP
223707924|NCT02009306|DRUG|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
223707925|NCT02009306|DRUG|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~* Opioids for pain or dyspnoea~  * Diamorphine~ * Oxycodone~ * Fentanyl~* Benzodiazepine and / or anti-psychotic for agitation~  * Midazolam~ * Levomepromazine~ * Haloperidol Anti-emetic for nausea~* Cyclizine~* Metoclopramide~* Haloperidol~* Levomepromazine~* Anti-secretory drug for respiratory secretions~* Glycopyrronium~* Hyoscine butylbromide~* Hyoscine hydrobromide"
223707926|NCT02009306|DRUG|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
223707927|NCT01269411|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223707928|NCT01269411|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223707929|NCT01269411|OTHER|pharmacological study|Correlative studies
223707930|NCT01269411|OTHER|laboratory biomarker analysis|Correlative
223707931|NCT04793087|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis
223707932|NCT02651818|PROCEDURE|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
223707933|NCT02259101|BEHAVIORAL|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
223526254|NCT04172220|PROCEDURE|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
223526255|NCT04172220|PROCEDURE|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
223526256|NCT04172220|PROCEDURE|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase \>20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
223526257|NCT04172220|PROCEDURE|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS\>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
223526258|NCT05202782|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given IV
223526259|NCT05202782|OTHER|Quality-of-Life Assessment|Ancillary studies
223526260|NCT05202782|OTHER|Questionnaire Administration|Ancillary studies
223526261|NCT05202782|DRUG|Zanubrutinib|Given PO
223707934|NCT02259101|BEHAVIORAL|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
223707935|NCT03506789|DRUG|Dexamethasone|Dexamethasone 24 mg
223707936|NCT03506789|DRUG|Placebos|Isotonic saline
223707937|NCT00423904|BEHAVIORAL|Brief intervention|
223707938|NCT04821648|DRUG|RJV001|Subcutaneous injection in the abdomen
223707939|NCT04821648|DRUG|Placebo|The placebo formulation has the same shape, color, and qualitative composition as the RJV001 freeze dried powder, with the exception that RJV001 drug substance has been removed. For each cohort group, a placebo will be injected in a single site in the same area as the treatment.
223707940|NCT04271527|PROCEDURE|cognitive fusion targeted biopsy|A cognitive fusion targeted biopsy
223707941|NCT02819739|DRUG|medical oxygen|
223707942|NCT02187744|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
224276048|NCT04192032|OTHER|Classic Tobacco Juul pod flavor (5% nicotine)|Classic Tobacco Juul pod flavor (5% nicotine)
224276049|NCT04192032|OTHER|Preferred flavor with HWL|Preferred flavor (5% nicotine) with HWL
224276050|NCT04192032|OTHER|Preferred flavor, 3% nicotine|Preferred flavor, 3% nicotine
224276051|NCT04192032|OTHER|Preferred flavor, 0% nicotine|Preferred flavor, 0% nicotine
223526262|NCT05713266|DEVICE|MouthLabTM|Aidar Health's MouthLab device is a non-invasive, hand-held, home monitoring tool that measures multiple clinically meaningful parameters such as temperature, blood pressure, heart rate, heart rate variability, pulse rate, SpO2, single-lead ECG, respiratory rate, breathing pattern, and basic lung functions in 60 seconds.
223526263|NCT01720550|DRUG|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
223526264|NCT01720550|DRUG|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
223526265|NCT03248752|BEHAVIORAL|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
223526266|NCT03248752|BEHAVIORAL|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
223526267|NCT02001519|DRUG|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
223526268|NCT02009826|RADIATION|[18F]-PBR111 Positron Emission Tomography (PET)|\[18F\]-PBR111 radioligand to assess binding to TSPO
223526269|NCT02009826|BEHAVIORAL|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
223526270|NCT02009826|BIOLOGICAL|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
223526271|NCT01468155|DRUG|dabigatran|30 days pre ablation and 90 days post ablation
223526272|NCT04017858|BEHAVIORAL|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
223526273|NCT04017858|BEHAVIORAL|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
223526274|NCT05176067|RADIATION|Thoracic Three-dimensional Radiotherapy|Drug Therapy Combined With Thoracic Three-dimensional Radiotherapy
223526275|NCT00616720|BIOLOGICAL|aldesleukin|
223526276|NCT00616720|BIOLOGICAL|idiotype-pulsed autologous dendritic cell vaccine APC8020|
223526277|NCT00616720|BIOLOGICAL|recombinant interferon gamma|
223526278|NCT00616720|GENETIC|polymerase chain reaction|
223526279|NCT00616720|GENETIC|reverse transcriptase-polymerase chain reaction|
223526280|NCT00616720|OTHER|flow cytometry|
223526281|NCT00616720|OTHER|laboratory biomarker analysis|
223526282|NCT00661856|DIETARY_SUPPLEMENT|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
223526283|NCT06563557|OTHER|Hemodynamic changes between epidural and paravertebral during esophagectomy|The thoracic epidural technique remains the gold standard for perioperative pain management for this procedure. The placement of a paravertebral catheter homolateral with the thoracic incisions is strongly recommended. A goal directed fluid therapy is proposed to guide fluid management and limit postoperative complications. Few studies suggested less side effects in the paravertebral group. The vasoplegia due to the epidural can cause significant hypotension especially as reverse Trendelenburg position is required during surgery. The aim is to bring more light to the hemodynamic changes caused by two different locoregional techniques. An algorithm for fluid and vasopressor management has been proposed. We defined hypotension as 20% of decrement of the median arterial pressure during anesthesia. To reduce bias, the locoregional techniques is performed by an experienced anesthesiologists and the rest of the perioperative management is conducted by another blinded anesthesiologist.
223526284|NCT05279560|BIOLOGICAL|autologous PRP (platelet rich plasma)|The required volume of PRP will be extracted from 60 ml of the patient's peripheral blood. Injecting PRP into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. After centrifugation of the whole blood, 5ml PRP will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
223526285|NCT05279560|OTHER|Saline solution (NaCL) Injection|Injecting NaCL into the ovaries will be performed likewise to the standard operating procedure of oocyte retrieval. NaCL will be injected in each ovary intra-medullar and subcortical using a 17-gauge single lumen needle under sedation und under transvaginal ultrasound monitoring.
223526286|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (25 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
223526287|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (40 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
223526288|NCT06473246|DIETARY_SUPPLEMENT|CBD Isolate (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
223526289|NCT06473246|DIETARY_SUPPLEMENT|CBD Broad Extract (50 mg/0.5 ml)|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
223707943|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
224276052|NCT01872507|OTHER|Biofeedback training|usual treatment +12 biofeedback training
223526290|NCT06473246|DIETARY_SUPPLEMENT|Placebo|0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
223526291|NCT06052891|DEVICE|CHAMP Application|Children's Mercy Kansas City's CHAMP application was developed for data transfer of pediatric cardiac population vitals from home to the healthcare team in March 2014. CHAMP provides families and the clinical team with a new model of care leveraged by a remote patient monitoring (RPM) platform. CHAMP has been used in over 1000 patients, 28 states, and across 12 pediatric hospitals in pediatric cardiology. The CHAMP application is available in 11 languages for families to use on mobile devices (Apple and Android).
223526292|NCT03271775|OTHER|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
223526293|NCT03271775|OTHER|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
223526294|NCT04883138|DRUG|GIGA-2050|Recombinant Hyperimmune Polyclonal Antibody
223526295|NCT03863574|DRUG|Saroglitazar Magnesium 2mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
223526296|NCT03863574|DRUG|Saroglitazar Magnesium 4mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
223526297|NCT03863574|DRUG|Placebos|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
223526298|NCT05712681|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet after the meal
223526299|NCT05712681|DRUG|JP-1366 20mg tablet|R : JP-1366 20mg tablet under fasting condition
223526300|NCT03884257|DEVICE|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
223526301|NCT03884257|DEVICE|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
223526302|NCT06162351|DRUG|PLX038|"Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death."
223526303|NCT06065046|DRUG|Baricitinib 4 MG|Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
223526304|NCT06065046|OTHER|Standard treatment|Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
223526305|NCT05795764|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.
223526306|NCT05795764|BEHAVIORAL|Treatment as Usual|Standard care provided for patients at risk for suicide
223526307|NCT06475820|DRUG|Baricitinib|"GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day."
223526308|NCT03701334|DRUG|Ribociclib|Ribociclib orally taken at 400 mg on days 1 to 21 of a 28-day cycle
223526309|NCT03701334|OTHER|Endocrine Therapy|ET will be administered according to the local clinical guidelines and current local prescribing information
223526310|NCT00005626|DRUG|Irinotecan|Irinotecan as outlined in treatment arm
223526311|NCT05132491|OTHER|TECH-Prep Intervention|Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
223526312|NCT02070211|DIETARY_SUPPLEMENT|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
223526313|NCT02070211|OTHER|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
223526314|NCT02070211|DIETARY_SUPPLEMENT|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
223526315|NCT04507269|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
223526316|NCT04507269|DRUG|Placebo|Saline given by subcutaneous injection
223526317|NCT01080235|OTHER|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
223526318|NCT01080235|OTHER|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
223526319|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
223707944|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
223707945|NCT02187744|BIOLOGICAL|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
223707946|NCT02187744|DRUG|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
223707947|NCT02187744|DRUG|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
223707948|NCT05182866|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed approximately 24 hours later by photoimmunotherapy
223707949|NCT01972568|DRUG|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
223707950|NCT01972568|DRUG|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
223707951|NCT01972568|DRUG|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
223707952|NCT05409248|OTHER|Personalized cognitive stimulation|Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
223707953|NCT05409248|OTHER|Sham cognitive stimulation|Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
223707954|NCT02358681|DRUG|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
223707955|NCT02358681|DRUG|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
223707956|NCT02358681|DRUG|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
223707957|NCT02358681|DRUG|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
223707958|NCT00748735|PROCEDURE|Implantation of a cardiac resynchronization therapy device|
223707959|NCT00748735|PROCEDURE|Echocardiography (myocardial deformation imaging)|
223707960|NCT06005480|DRUG|Mepivacaine|Injection of 1.5% Mepivacaine in nerve block
223707961|NCT05106517|DRUG|Denosumab|Denosumab 60mg/6 months subcutaneously + placebo iv
223707962|NCT05106517|DRUG|Zoledronic acid|Iv zoledronic acid and placebo /6 months subcutaneously
223707963|NCT06391320|OTHER|other|Observational studies do not involve intervention
223707964|NCT00306189|DRUG|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
223707965|NCT00306189|DRUG|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
223707966|NCT00306189|DRUG|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
223707967|NCT00306189|DRUG|Placebo|Placebo SC every 6 months
223707968|NCT01223131|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
223707969|NCT01223131|DRUG|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
223707970|NCT02572401|BEHAVIORAL|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
223707971|NCT02572401|BEHAVIORAL|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
223707972|NCT06050148|BIOLOGICAL|Feacal microbial transplantation (FMT)|Feacal microbial transplantation (FMT)
223707973|NCT06050148|OTHER|Placebo transplantation (PT)|Transplantation with coloured 0,9% NaCl-solution
223707974|NCT01538511|DRUG|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
223707975|NCT01538511|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
223707976|NCT01821196|PROCEDURE|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
223707977|NCT00270439|PROCEDURE|removal of omentum|patients with type 2 diabetes had their omentum removed
223707978|NCT01215565|DRUG|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
223707979|NCT04084431|RADIATION|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
223707980|NCT04084431|OTHER|OSC|optimal supportive Care (OSC) alone
224276053|NCT01863433|BIOLOGICAL|Trivalent Influenza Vaccine|
224276054|NCT00111137|DRUG|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
223893747|NCT01396655|DRUG|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
223893748|NCT05709223|DEVICE|Categorical loudness scaling based fitting using the Nexus Research System.|The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.
223526320|NCT05410223|DRUG|IIaprazole, Amoxicillin/Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
223526321|NCT05410223|DRUG|Yolk antibody and IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline|"Yolk antibody: 7g\*10 board/box, produced by Beijing Yucheng Health Technology Co., Ltd.~Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd."
223526322|NCT05410223|DRUG|IIaprazole, Amoxicillin/ Clarithromycin/Furazolidone, Doxycycline, Bismuth|"Ilaprazole: 5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc. Amoxicillin: 250mg\*50 capsules/box, produced by Hainan General Sanyo Pharmaceutical Co., Ltd.~Clarithromycin: 500mg\*6 capsules/box, produced by Henan Fusen Pharmaceutical Co., Ltd.~Furazolidone: 0.1g\*28 pieces/bag, produced by Tianjin Lisheng Pharmaceutical Co., Ltd.~Doxycycline: 0.1g\*10 capsules/box, produced by Jiangsu Yongxin Pharmaceutical Co., Ltd.~bismuth :55mg\*36 capsules/box, produced by Shanxi Xinbaoyuan Pharmaceutical Co.,Ltd"
223526323|NCT06463730|BEHAVIORAL|Serious games|Custom games played using the Equio system, non-custom Wii Fit games played using the Nintendo Wii Balance Board
223526324|NCT06129955|DRUG|Pucotenlimab Combined With Lenvatinib|Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
223526325|NCT03662451|PROCEDURE|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
223526326|NCT03246412|DIAGNOSTIC_TEST|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
223526327|NCT05051228|DEVICE|CardioFlux|Magnetocardiography (MCG) is a noninvasive method that measure the magnetic field that arises from the electrical activity of the heart cycle.
223526328|NCT02120261|DRUG|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
223526329|NCT02120261|DRUG|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
223893749|NCT05709223|DEVICE|Behavioural fitting using Custom Sound Suite (CSS 6.3) Software|The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
223526330|NCT02120261|DRUG|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
223526331|NCT06570070|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
223526332|NCT06570070|OTHER|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include the absolute risk of smoking, diseases caused by active and second-hand smoking, horrible pictorial warnings of the health consequences of active and second-hand smoking, and the benefits of quitting.
223526333|NCT06570070|OTHER|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, methods to quit, how to handle withdrawal symptoms, misperceptions of quitting, etc.
223526334|NCT06570070|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
223526335|NCT06570070|BEHAVIORAL|Counselor individual support|Participants will receive three months of counselor-led individual support via WeChat. The regular messages and instant messaging on psychosocial support aim to provide cessation advice, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
223893750|NCT05351554|DRUG|Namilumab|Specified dose on specified days
224276055|NCT00111137|DRUG|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
224276056|NCT04674228|OTHER|Electronic Health Record Review|Review of medical records
224276057|NCT02381197|DEVICE|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
224276058|NCT01070745|DRUG|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
223707981|NCT04691271|PROCEDURE|Stellate ganglion block|"After the patient entered the operating room, early SGB will be performed by a designated experienced anesthesiologist using the B-ultrasound visualization technique. The intervention site is the ipsilateral side of the planned craniotomy site. After routine disinfection, 0.5% ropivacaine 8-10 mL will be injected into the surface of the longus colli muscle on the medial side of the prevertebral fascia at the level of the C6 anterior tubercle, and then the puncture point will be covered with sterile dressings. The success criteria of e-SGB are Horner's syndrome, which is characterized by a miosis, ptosis, enophthalmos, conjunctival hyperemia and facial reddishness without sweating. For the camouflaging arm, the anesthesiologist only covered the corresponding part of the patient with sterile dressings to confuse the follow-up, without any puncture. All patients will be admitted to the ICU after the operation and then receive the standard of care."
223707982|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
223707983|NCT04548583|DRUG|Remestemcel-L|adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
223707984|NCT04548583|OTHER|Placebo|Normal saline
223707985|NCT00828412|DEVICE|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
223707986|NCT00828412|DRUG|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
223707987|NCT00853775|OTHER|No intervention, observational study|
223707988|NCT05596344|OTHER|Hospital Anxiety and Depression Scale|The basic information, anxiety and depression, treatment and prognosis of these patients were collected.
223707989|NCT05072704|DRUG|Sufentanil|Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.
223707990|NCT05072704|DRUG|Dexmedetomidine|Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.
223707991|NCT01406743|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
223707992|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
223707993|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
223707994|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
223707995|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
223707996|NCT00957580|DRUG|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
224276059|NCT01070745|DRUG|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
224276060|NCT01292837|DRUG|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
223526336|NCT05143814|DEVICE|3D Printed Mask Adapter Designed from Facial 3D scans for Fit testing.|Given the high level of fit test failures, without the provision of improved fits of masks, patient care will be highly curtailed for frontline staff at risk of SARS-CoV-2. Therefore, a reusable bespoke mask adapter used with a soft FFP3 disposable mask might be an economical solution to address the passing of fit testing. Currently, this is a major challenge in delivery of healthcare and urgent action is needed.
223526337|NCT04245189|OTHER|Endoscopic ultrasound for detection of Chronic pancreatitis|Presence of Chronic pancreatitis in alcoholic cirrhosis patients.
223526338|NCT04103931|BEHAVIORAL|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
223526339|NCT02071589|DRUG|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
223526340|NCT02071589|DRUG|Nifedipine oral solution|6 mL of Nife Par solution
223526341|NCT06064617|DEVICE|Contact Lens|Coopervision Biofinity Multifocal Lens
223707997|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
223707998|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
223707999|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
223708000|NCT01090492|DRUG|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
224276061|NCT05493566|BIOLOGICAL|Aldesleukin|Given SC
224276062|NCT05493566|BIOLOGICAL|Pembrolizumab|Given IV
224276063|NCT05332691|PROCEDURE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricle outlet tract gradient and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient relief of left ventricle outlet tract obstruction and mitral regurgitation, while preventing iatrogenic injuries.
223526342|NCT03070665|DRUG|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
223526343|NCT01013571|DRUG|insulin glargine|pre-filled disposable pen, in package of 5.
223526344|NCT01013571|DRUG|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
223526345|NCT00071032|BIOLOGICAL|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
223526346|NCT00071032|BIOLOGICAL|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
223526347|NCT02784587|PROCEDURE|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
223526348|NCT02903147|BEHAVIORAL|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
223526349|NCT02903147|BEHAVIORAL|The employer's training|
223526350|NCT05752032|GENETIC|ICM-203|Long term follow-up
223526351|NCT05752032|DRUG|Placebo|Long term follow-up
223526352|NCT05580705|OTHER|Routine Physical Therapy|The Routine Physiotherapy treatment will include Transcutaneous Electrical Nerve Stimulation, Hot pack, Range of Motion (ROM) Exercises and Muscle Strengthening Exercises
223526353|NCT05580705|OTHER|Vibration Therapy|Vibration Therapy will include a vibration device of brand Manipol, model number RK-001. It has 360 degree off-centered axis with a frequency of 2500 times per minute. It will be applied on sole of the foot for about 15 mins.
223526354|NCT01907893|BEHAVIORAL|Trauma Collaborative Care Plus Treatment as Usual|
223526355|NCT04104789|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
223526356|NCT04104789|DRUG|Articaine Injection|Local anesthetic
223526357|NCT05561387|DRUG|Bortezomib|Given SC
223526358|NCT05561387|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
223526359|NCT05561387|DRUG|Dexamethasone|Given PO
223526360|NCT05561387|DRUG|Lenalidomide|Given PO
223526361|NCT05561387|OTHER|Quality-of-Life Assessment|Ancillary studies
223526362|NCT05561387|OTHER|Questionnaire Administration|Ancillary studies
223526363|NCT06196138|OTHER|Gum|In the postoperative period, starting from the 4th hour, chewing gum is done 3 times a day, morning, noon and evening, for 30 minutes each, until the patient passes the first flatus.
223526364|NCT06196138|OTHER|Hot Compress|Starting from the 1st postoperative day, patients will receive hot application (to the lumbar region) for 10 minutes in the morning and evening. The hot application is applied by wrapping 2 towels in a water bag containing 55 ± 2 °C hot water. The water bag is applied to the lumbar region for 10 minutes with the patient in the supine position. The application is continued until the patient passes the first flatus.
223526365|NCT06071104|PROCEDURE|Anterior segment ophthalmic surgery|Cataract surgery during which the crystalline lens (often cloudy) is broken into small pieces and gently removed from the eye with suction (phacoemulsification)
223526366|NCT06071104|DEVICE|UNITY VCS|UNITY Vitreoretinal Cataract System (VCS) with console, remote control, foot controller, UNITY Cataract FMS Pack, and UNITY Anterior Vitrectomy Kit
223526367|NCT05866081|DEVICE|Standard of care stent placement|Participants will have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
223526368|NCT05866081|OTHER|No stent placement|Participants not have a stent placed per randomization assigned if there are no complications (per protocol) during ureteroscopy that excludes the participant.
223526369|NCT05866081|OTHER|Surveys|"All participants in the trial cohort and observational arms will be asked to complete survey instruments (evaluating their pain, quality of life, and experiences following ureteroscopy, as well as surveys evaluating their opinions and preferences around ureteral stenting, etc.).~Participants will also have routine clinical data (preoperative, perioperative, and postoperative) to be collected and analyzed for research purposes."
223526370|NCT03518060|DRUG|JULUCA|JULUCA is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
224276064|NCT04162327|DRUG|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
224276065|NCT04162327|DRUG|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
223526371|NCT05078112|DEVICE|Sleep sensor technology|Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
223526372|NCT05136846|DRUG|Carboplatin|Given IV
223526373|NCT05136846|BIOLOGICAL|Durvalumab|Given IV
223526374|NCT05136846|DRUG|Paclitaxel|Given IV
223526375|NCT05136846|DRUG|Papaverine|Given IV or SC
223526376|NCT05136846|RADIATION|Radiation Therapy|Undergo RT
223526377|NCT05136846|DRUG|Pemetrexed|Given IV
223526378|NCT05136846|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
223526379|NCT05136846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223526380|NCT05136846|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223526381|NCT05136846|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
223526382|NCT05136846|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
223526383|NCT05136846|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223526384|NCT03241615|OTHER|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
223526385|NCT04766567|PROCEDURE|Cesarean section with cesarean myomectomy (serosal)|Serosal or endometrial myomectomy performed during cesarean section
223526386|NCT04766567|PROCEDURE|Cesarean section without myomectomy|Cesarean delivery without performing myoemctomy
223526387|NCT05942040|OTHER|Tailored Palliative Care Information|This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
223526388|NCT06113367|OTHER|Evaluation of anti-PD-(L)1 immunotherapy efficacy|Non Applicable, research on data
223526389|NCT01903863|BIOLOGICAL|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
223526390|NCT00553969|DRUG|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
223526391|NCT00553969|DRUG|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
223526392|NCT00553969|DRUG|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
223526393|NCT00553969|DRUG|placebo and placebo|capsule once daily for 9 months; dosage unknown
223526394|NCT04614532|DIAGNOSTIC_TEST|cognitive assessment|"global cognitive assessment :~* Mini Mental State~* Evaluation of manual laterality~* Hospital Anxiety and Depression scale~* 5 words of Dubois~* Trail Making Test~* short battery of the praxies~* neuropathic pain scale (DN4 in french)~* Analog Visual Scale for pain~* Fast Front End Efficiency Battery"
223526395|NCT04614532|OTHER|Cold Pressor Test|"consists of the complete immersion of the participant's arm in a basin of cold water maintained at a temperature.~The test will be divided into two conditions (pain, no pain). In the first, the container will be filled with cold water. In the second, the water in the container will be at room temperature. The investigators will test each arm. During the immersion of the arm, participants will have to remain silent and remove their arm when the ordeal becomes too painful for the painful condition.~For the non-painful condition, the immersion time will be determined according to the results of the pre test."
223526396|NCT04614532|OTHER|digital sensor of Nociception Level Index|placed on the contralateral index finger with the arm immersed in the tank to measure the variation of physiological parameters.
223526397|NCT00220792|BEHAVIORAL|Brief supportive-expressive group therapy|
223526398|NCT05242367|DEVICE|Modius Spero active device|Battery powered non-invasive neurostimulation device
223526399|NCT05242367|DEVICE|Sham device|Placebo comparator sham device (no active stimulation)
223526400|NCT03458572|DEVICE|Seirin Pyonex press needle acupuncture|Acupuncture
223526401|NCT06431581|BEHAVIORAL|m-Health intervention (educational video, SMS and reminder phone call)|Pregnant women meeting the inclusion criteria and assigned to the intervention group will receive m-health intervention that includes a tailored educational video regarding perinatal care targeting positive birth outcomes and infant health, SMS messages, and reminder phone calls for follow-up
223526402|NCT05678465|PROCEDURE|Non-fixation of the mesh|3D-shaped, anatomical, standard, polypropylene mesh without fixation.
223526403|NCT05678465|PROCEDURE|Fixation of the mesh|Glue fixation of lightweight, macroporous, polypropylene mesh.
223526404|NCT04727151|BIOLOGICAL|TAC01-HER2|"TAC01-HER2 and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
223526405|NCT04727151|BIOLOGICAL|TAC01-HER2 plus pembrolizumab|"TAC01-HER2 plus pembrolizumab and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide"
223526406|NCT01969058|DRUG|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
223526407|NCT05478876|RADIATION|carbon ion radiation therapy CIRT|"CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.~The expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.~Immunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and/or up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol."
223526408|NCT03797807|PROCEDURE|MINST|A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
223526409|NCT03797807|PROCEDURE|MIST|A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
223526410|NCT03797807|DIAGNOSTIC_TEST|GTI subgroup (Geometrical/Thermal Imaging)|Geometrical/Thermal Imaging
223526411|NCT04305756|DRUG|Enoxaparin|Low molecular weight heparin
223526412|NCT03924284|DIAGNOSTIC_TEST|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
223526413|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
223526414|NCT03910972|BIOLOGICAL|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
223526415|NCT03910972|BIOLOGICAL|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
223526416|NCT04964752|DEVICE|continuous glucose-monitoring|Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
223526417|NCT03207347|DRUG|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
223526418|NCT00974272|DRUG|Exenatide|Single subcutaneous injection (10 μg)
223526419|NCT00974272|OTHER|Normal Saline|Single subcutaneous injection
223526420|NCT05905198|DEVICE|Programming|programming the implanted DBS device to adjust the parameter and switch stimulation mode between Variable-Frequency settings and High-Frequency settings.
223526421|NCT03290677|PROCEDURE|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
223526422|NCT03290677|PROCEDURE|Biopsy|Removing a small piece of the affected area to confirm cancer
223526423|NCT05594186|DRUG|Tranexamic acid, Oral contraceptive pills and the Levonorgestrel-releasing intrauterine system.|Comparing three different nonsurgical management options for abnormal uterine bleeding caused by cesarean scar niche.
223526424|NCT04431284|OTHER|Questionnaires|The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
223526425|NCT05119868|OTHER|Nutritional intervention based on Mediterranean Diet|A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
223526426|NCT02330003|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
223526427|NCT02330003|BIOLOGICAL|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
223526428|NCT06205069|DEVICE|Tissue flossing|While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
223526429|NCT04977232|DRUG|Escitalopram|Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.
223526430|NCT04977232|BEHAVIORAL|Game intervention|Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.
223526431|NCT06398184|OTHER|Exercise + motor imagery and action observation|A total of 8 sessions of 4 sets of knee extension exercises will be performed. During the breaks between each series, participants will perform a progressive protocol of action observation and motor imagery.
223526432|NCT06398184|OTHER|Exercise|A total of 8 sessions of 4 sets of knee extension exercises will be performed.
223526433|NCT03661099|DIAGNOSTIC_TEST|colonoscopy|endoscopists' performance outcome
223526434|NCT06053372|DEVICE|Apple Watch|Wearable monitor for heart rate and arrhythmia detection
223526435|NCT04976855|DRUG|INDV-2000|Capsule for oral administration
223526436|NCT04976855|DRUG|Placebo|Capsule for oral administration
223526437|NCT04976855|DRUG|SUBOXONE® sublingual film|Administered either under the tongue (sublingual) or between the gum and cheek (buccal)
223526438|NCT03275337|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
223526439|NCT05493410|OTHER|TREATMENT GROUP (TG)|In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
223708001|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
223526440|NCT05493410|OTHER|CONTROL GROUP (CG)|"For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate."
223526441|NCT05095467|PROCEDURE|HIPEC|The abdominal cavity will be filled with paclitaxel 120mg/m2 heated at 43℃ for 1 hour with a hyperthermic circulation machine.
223526442|NCT05095467|DRUG|Paclitaxel-albumin|albumin paclitaxel D1, D8; S-1: D1-D14
223526443|NCT05095467|DRUG|Tegafur-gimeracil-oteracil potassium|40mg bid(BSA\<1.5 m2) ，60mg bid(BSA\>=1.5 m2); D1-D14, po, bid.
223526444|NCT05095467|PROCEDURE|Surgery+HIPEC|gastrectomy with D2 lymphadenectomy+HIPEC procedure
223526445|NCT03940248|RADIATION|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
223526446|NCT02334657|OTHER|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
223526447|NCT01766687|DIETARY_SUPPLEMENT|Hydration|
223526448|NCT06195956|OTHER|exercise|Exercises done 3 times per weeks, 3 repetitions per exercise for 3 months
223526449|NCT05318287|BEHAVIORAL|Walk with Me|Walk with Me is a perinatal grief mobile application to provide supportive care to bereaved parents. The application includes modules to guide bereaved parents through strategies to help support them through their grieving.
223526450|NCT03100279|BEHAVIORAL|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
223526451|NCT03100279|BEHAVIORAL|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
223526452|NCT01606241|DRUG|Cyclophosphamide|Given PO
223526453|NCT01606241|OTHER|Laboratory Biomarker Analysis|Correlative studies
223526454|NCT01606241|BIOLOGICAL|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
223526455|NCT02394067|OTHER|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
223526456|NCT05315752|PROCEDURE|Bariatric surgery|"Bariatric surgery includes (but is not limited to)~* Gastric bypass: surgical bypass of the entire stomach, duodenum and approximately 1 m of the proximal small intestine~* Sleeve: a large part of the stomach is removed laparoscopically, the open vertical edges are put back in place to leave a sleeve-like tube.~Bariatric surgery is considered a treatment option~* for patients with a BMI \>40 kg/m 2 , assuming the patient has previously participated successfully in a group weight management programme (weight loss \>7%) or~* for patients with a BMI of 35-40 kg/m 2 when the obesity is associated with type 2 diabetes or hypertension, or OAS (with CPAP therapy) or severe musculoskeletal disease"
223526457|NCT03537508|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
223526458|NCT03537508|BIOLOGICAL|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
223526459|NCT03537508|BIOLOGICAL|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular
223526460|NCT03537508|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular
223526461|NCT03537508|BIOLOGICAL|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age, oral solution
223526462|NCT03537508|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age, Intramuscular
223526463|NCT03537508|BIOLOGICAL|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age, Subcutaneous
223526464|NCT03537508|BIOLOGICAL|Varicella vaccine|Varicella vaccine at 12 months of age
223526465|NCT03537508|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
223526466|NCT02516813|DRUG|M3814 100 mg|Participants received 100 mg of M3814 as capsule or tablet orally once daily.
223526467|NCT02516813|DRUG|M3814 200 mg|Participants received 200 mg of M3814 as capsule or tablet orally once daily.
223526468|NCT02516813|DRUG|M3814 300 mg|Participants received 300 mg of M3814 as capsule or tablet orally once daily.
223526469|NCT02516813|DRUG|M3814 400 mg|Participants received 400 mg of M3814 as capsule or tablet orally once daily.
223526470|NCT02516813|DRUG|M3814 50 mg|Participants received 100 mg of M3814 as capsule orally once daily.
223708002|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
223708003|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
223708004|NCT01090492|DRUG|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
223708005|NCT00731627|DRUG|placebo|one tablet a day for up to 21 days
223708006|NCT00731627|DRUG|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
223708007|NCT00945893|BIOLOGICAL|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
223708008|NCT00945893|OTHER|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
223708009|NCT02518256|PROCEDURE|Lavage of the Cavum uteri and proximal fallopian tubes|
223708010|NCT03538002|DEVICE|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
223708011|NCT03766074|DIETARY_SUPPLEMENT|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
223708012|NCT03766074|DIETARY_SUPPLEMENT|Placebo|placebo
223708013|NCT01752270|DRUG|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
223708014|NCT01752270|DRUG|Diane-35 pretreatment|
223708015|NCT02447939|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
223708016|NCT02447939|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
223708017|NCT01160315|DRUG|Triptorelin|Triptorelin: intramusculAR injection every 3 months
223708018|NCT01160315|DRUG|Norethisterone acetate|5 mg/day per os until during chemotherapy
223708019|NCT01796509|OTHER|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
223708020|NCT03113071|DRUG|Decitabine|Decitabine will be administered in combination with Digoxin
223526471|NCT02516813|RADIATION|Fractionated RT|Participants received fractionated palliative RT (3 Gray \[Gy\] \* 10 in Arm A and 2 Gy \* 33 to 35, 5 fractions per week \[F/W\]) in Arm B and received a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2 in ancillary CPoP part.
223526472|NCT02516813|DRUG|Cisplatin|Participants received Cisplatin twice at a dose of 100 mg/m\^2 or weekly at a dose of 40 mg/m\^2.
223526473|NCT02399228|DRUG|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
223708021|NCT03113071|DRUG|Digoxin|Decitabine will be administered in combination with Digoxin
223708022|NCT00567372|DRUG|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
223708023|NCT01602120|DRUG|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
223708024|NCT02866916|DRUG|SXL01|Treatment will be administered continuously over 24h through the subcutaneous route.
223708025|NCT00991731|BEHAVIORAL|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
223708026|NCT00991731|BEHAVIORAL|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
223708027|NCT04997083|DEVICE|Maxillary Expander with Differential Opening (EDO)|The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
223708028|NCT04997083|DEVICE|Petit face mask|The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
223708029|NCT01540266|PROCEDURE|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
223708030|NCT01540266|PROCEDURE|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
223708031|NCT03454542|DEVICE|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
223526474|NCT06597513|DRUG|auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab|"Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision."
223526475|NCT06596525|OTHER|Conventional physical therapy|"Conventional physical therapy program will include:~1. Stretching exercises (forearm pronators, ulnar deviators, shoulder internal rotators, hip flexors and adductors, and hamstring muscle groups)~2. Strengthening exercises (ankle dorsiflexors, knee extensors, and hip flexor muscle groups)~3. Posture exercises~4. Balance and proprioception exercises~5. Walking training, obstacle crossing training, stair climbing and descending exercises"
223526476|NCT06596525|OTHER|Barefoot Whole Body Vibration Training (WBVTb)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will be barefoot. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
223526477|NCT06596525|OTHER|Shod Whole Body Vibration Training (WBVTs)|"Each WBVT session will consist of the following schedule: 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest- 3 minutes of WBVT- 2 minutes rest. Thus a treatment session will last 15 minutes in total. The participants will wear everyday sports shoes. A specially designed walker will be used to provide support during WBVT for children who are unable to stand independently on the platform and. All exercises and WBVT sessions will be performed under the supervision of a physiotherapist and postural correction will be encouraged through visual feedback (the platform will be placed in front of a mirror) and verbal cueing. One set of WBVT along with the dynamic exercise program to be implemented on the platform is summarized below.~Stage 1: Semi-squat (knees flexed 10-45º) for 1 minute~Stage 2: Semi-squat +Calf raise for 1 minute~Stage 3: Triceps surae stretch for 1 minute"
223526478|NCT06596525|OTHER|Sham Whole Body Vibration Training (WBVTsh)|"During Sham WBVT; the same exercises that the intervention groups will receive on the vibration platform will be performed on the platform for the same duration (3 days per week for 15 minutes each session, over a period of 4 weeks) without the platform being activated."
223526479|NCT06811285|OTHER|Kinesiological Taping|The Kinesiological Taping group will receive two parallel I-shaped kinesiological taping applications.
223526480|NCT06811285|OTHER|Foot Massage Group|The Foot Massage Group will receive foot massage for 20 minutes.
223526481|NCT01200134|OTHER|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
223526482|NCT04652765|DRUG|Camostat Mesilate|Camostat 600mg by mouth four times a day, for a total of 7 days
223526483|NCT04652765|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg by mouth once daily, for a total of 7 days
223526484|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread mixed with fermented brown seaweed|5-day intake period
223526485|NCT06418763|DIETARY_SUPPLEMENT|Baobab spread|5-day intake period
223526486|NCT05639725|PROCEDURE|maxillary Ist premolar extraction|Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.
223526487|NCT05639725|PROCEDURE|SURGICAL|Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
223526488|NCT06570005|OTHER|Water Quality Assurance Fund|"* At the water system level: Written legal agreements between water systems, centralized laboratories, and the organization facilitating the Assurance Fund will provide water systems with regular water quality testing and provide laboratories a guarantee of payments if water systems fail to pay for testing services on time (for up to three concurrent unpaid invoices). Regular debrief meetings will be held with water operators and local government authorities to discuss test results and water treatment options, and to encourage water systems to share water quality information with their consumers. Technical guidance to improve water treatment will be provided, if requested by water system operators or local government authorities.~* At the community level: Community engagement, primarily at the onset, to inform the community about the water quality testing program and answer questions."
223526489|NCT03403738|BEHAVIORAL|Bounce Back Now|web/smartphone-based intervention for disaster victims
223526490|NCT03403738|BEHAVIORAL|enhanced usual care|enhanced usual care with list of resources
223526491|NCT06183021|PROCEDURE|Vital pulp cryotherapy|Shaved ice made from sterile distilled water will be applied around the treated tooth especially in contact with amputated pulp tissue until totally dissolves.
223526492|NCT06183021|PROCEDURE|Intracanal cryotherapy|After mechanical preparation, a 5-minute final irrigation with 20 mL cold saline (2.5 Centigrade degrees) will be applied using a negative pressure irrigation technique per canal.
223526493|NCT04497155|DRUG|Norepinephrine|Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
223526494|NCT00391716|DRUG|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
223526495|NCT00391716|BEHAVIORAL|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
223526496|NCT00391716|DRUG|placebo|lactose capsule compounded to mimic gabapentin capsules
223708032|NCT03844100|DRUG|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
223708033|NCT04442113|PROCEDURE|Pulmonary vein isolation plus ablation guided by novel STAR mapping™|Catheter ablation for persistent AF consisting of pulmonary vein isolation plus additional ablation guided by the novel STAR mapping™ software on a computer device.
223708034|NCT04442113|PROCEDURE|Pulmonary vein isolation|Catheter ablation for persistent AF consisting of pulmonary vein isolation (the standard treatment for AF)
223708035|NCT02944032|OTHER|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
223708036|NCT02944032|OTHER|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
223708037|NCT06499649|DIETARY_SUPPLEMENT|IBSA Probiotics|Dietary supplement base on probiotic strains.
223708038|NCT06499649|DIETARY_SUPPLEMENT|Placebo|The placebo does not contain functional components, and the appearance is indistinguishable from the comparison product.
223708039|NCT03318510|DEVICE|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
223708040|NCT00209534|DRUG|fospropofol disodium|
223708041|NCT01187433|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
223708042|NCT01187433|BIOLOGICAL|NaCl 0.9%|0.5 mL, Subcutaneous
223708043|NCT01187433|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
223708044|NCT01187433|BIOLOGICAL|Meningococcal A+C vaccine|0.5 mL, Intramuscular
223708045|NCT03748108|DRUG|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
223708046|NCT03748108|DRUG|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
223708047|NCT00526942|BEHAVIORAL|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
223708048|NCT02236442|OTHER|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~1. Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~2. Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~3. Provide a sound-proof helmet to the patient.~4. Provide a light-blocking google to the patient.~5. If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~6. If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
223708049|NCT00547547|DIETARY_SUPPLEMENT|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
223708050|NCT00547547|DRUG|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
223708051|NCT00547547|DRUG|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
223708052|NCT00074269|BIOLOGICAL|anti-thymocyte globulin|
223708053|NCT00074269|BIOLOGICAL|filgrastim|
223708054|NCT00074269|BIOLOGICAL|graft-versus-tumor induction therapy|
223708055|NCT00074269|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223708056|NCT00074269|DRUG|cyclosporine|
223708057|NCT00074269|DRUG|fludarabine phosphate|
223708058|NCT00074269|DRUG|melphalan|
223708059|NCT00074269|DRUG|methotrexate|
223708060|NCT00074269|PROCEDURE|peripheral blood stem cell transplantation|
223708061|NCT00437983|DIETARY_SUPPLEMENT|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
223708062|NCT00437983|DIETARY_SUPPLEMENT|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
223708063|NCT04495270|DIAGNOSTIC_TEST|"Analysis of treatment outcomes of teeth with apical periodontitis based on cone-beam computed tomography and estimated by means of Periapical and Endodontic Status Scale"|Patients were examined by cone-beam computed tomography at baseline and in 24 months after endodontic treatment. Treatment outcome was evaluated using estimates of periapical radiolucencies in size, relation with anatomical structures and location.
223708064|NCT00144391|DRUG|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
223708065|NCT04647864|DEVICE|Transcatheter Aortic Valve Implantation|Replacement of the aortic valve of the heart through the blood vessels, delivered via one of several access methods.
223708066|NCT00672646|DRUG|AZD1386|95mg, oral solution, single dose
223526497|NCT00391716|DRUG|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
223526498|NCT01045733|DEVICE|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
223526499|NCT01045733|DEVICE|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
223526500|NCT01045733|PROCEDURE|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
223526501|NCT02410187|RADIATION|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
223526502|NCT02410187|DRUG|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
223526503|NCT02410187|RADIATION|palliative RT|fraction size of RT = \< 3 Gy
223526504|NCT05147142|DEVICE|Low Intensity Focused Ultrasound|Brainsonix BX Pulsar 1002
223526505|NCT00349986|DRUG|Insuline glargine|
223526506|NCT05434468|OTHER|Sustained neutral apophyseal glides|gong mobilization
223526507|NCT03664544|DRUG|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
223526508|NCT02755350|DRUG|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
223526509|NCT03331887|PROCEDURE|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
223526510|NCT03331887|PROCEDURE|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
223526511|NCT00414154|BEHAVIORAL|Group based multidisciplinary patient education programme|
223526512|NCT05361798|DRUG|M9241|In the safety lead in, M9241 will be given in de-escalating doses (starting dose 16.8 mcg/kg, and de-escalated if needed to 12 mcg/kg, or 8 mcg/kg) every 4 weeks for 3 doses. Within 4 weeks after completing SBRT, those participants receiving immunotherapy agents will receive M9241 by subcutaneous injection at dose determined during the safety lead in every 4 weeks for 3 doses.
223526513|NCT05361798|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the prostate will be delivered in 5 fractions of radiation each of 7.25-8.0 Gy, every other day over the course of 10 business days (2-3 weeks). The total dose will be 36.25-40 Gy
223526514|NCT06001723|BEHAVIORAL|Forest Therapy|Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
223526515|NCT06816823|BIOLOGICAL|CL-NK-001|Dose level 1 (5 × 10\^8 cells); dose level 2 (15 × 10\^8 cells); dose level 3 (30 × 10\^8 cells); additional dose levels (investigator's discretion).
223526516|NCT04556045|BEHAVIORAL|Exercise therapy|The exercise therapy intervention will last 4 weeks. Each participant assigned to this intervention will receive a personalized ET regimen, including in-person, supervised exercise sessions; other activities to be followed at home. Participants will exercise between one and seven times per week depending on their tolerance to the treatment and exercise program.
223526517|NCT06303453|OTHER|Balance exercises|Balance exercises includes active movements (flexion, extension, abduction, adduction) of one upper extremity and lower extremity, trunk movements (bending forward and rotation), raising heel, raising toes and raising heel. Every move in each session will be hold for 30 seconds. The part B comprises of training i.e., holding positions in standing posture which include moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand and throwing the ball against the wall with foot.
223526518|NCT06303453|OTHER|Resisted exercises|"The resistance training protocol include shoulder flexion and extension with 1 kg weight, shoulder pulley with 2 kg weight, arm curls with 1 kg weight, wall push-ups, bridging, hip abduction and adduction against resistance band, knee extensions and flexion in sitting position with resistance applied by contralateral limb, knee adduction and abduction with resistance band, mini squats, strengthening exercise for toes flexor and extensor (22), resisted inversion and eversion and straight leg raise (SLR) with 1 kg ankle weight (10).~Every move in each session comprises of 2 sets of 3 reps each and 1 set will be added at 4th and 8th week."
223526519|NCT05607849|OTHER|The decidons ensemble (let's decide together) leaflet and the discutons-mammo.fr (let's talk about breast cancer screening) online tool.|"The leaflet will include a link to access the discutons-mammo.fr DA aid tool, and will inform women about shared decision-making.~The GPs of women who are sent the leaflet will also be sent a letter encouraging shared decision-making. This material will be sent 3 months after women have received their breast cancer screening invitation letter.~Data related to primary and secondary objectives will be collected by questionnaire from the 2 groups. The questionnaire will be sent 2 months after participants are informed about the tool."
223526520|NCT06239649|PROCEDURE|Genicular nerve Radiofrequency Ablation block|Genicular nerve Radiofrequency Ablation block
223526521|NCT06662513|OTHER|No Intervention: Observational Cohort|No intervention - retrospective observational study
223526522|NCT06658067|DEVICE|Continuous Glucose Monitor (CGM)|The first CGM sensor will be applied as directed during the first visit with a brief training by staff. Participant will be instructed to remove and replace the device every 14 days for the remainder of the 3-month trial period. Participant will also be instructed to scan the sensor three times daily. Compliance may be tracked via remote accessing of the blood glucose log on the online FreeStyle portal. CGM models used will include the Abbott FreeStyle Libre 2 and 3 and Dexcom G5, G6 and G7.
223526523|NCT05218434|DRUG|AX-158|Oral administrations of AX-158
223526524|NCT06669039|DEVICE|Computer-controlled Local Anesthetic delivery system|Local anesthesia will be delivered using Computer-controlled Local Anesthetic delivery system.
223526525|NCT06669039|PROCEDURE|Inferior Alveolar Nerve Block|Local anesthesia will be delivered using the conventional syringe
223526526|NCT06503510|OTHER|Histamine|A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
223526527|NCT06503510|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
223526528|NCT06503510|OTHER|bovine adrenal medulla (BAM8-22)|A small drop of BAM8-22 solution will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
223526529|NCT02322840|DEVICE|Twelve TMVR Implant|Implantation of the Twelve TMVR System -Apical
223526530|NCT02322840|DEVICE|Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System|Implant of Intrepid valve -Transfemoral
223526531|NCT00934180|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
223526532|NCT00934180|DRUG|Zofran®|1 x 8 mg ODT
223526533|NCT05497934|DRUG|Glycerol|In this study, 99.5% pure glycerol will be used as an optical clearing agent. The glycerol will be applied topically to the tympanic membrane.
223526534|NCT00835172|DRUG|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
223526535|NCT00835172|DRUG|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
223526536|NCT06669702|BEHAVIORAL|12-week home based exercise|"Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an rating of perceived exertion in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.~Participants can break down the exercise time in a way that suits their time, i.e., they can do 3 × 10 minutes, 2 × 15 minutes, etc."
223526537|NCT06669702|BEHAVIORAL|Routine care|Participants in this group will continue with their current routine care and will be given a diary of exercises that they can do, which are usually given to them as part of their health care routine by physiotherapists or consultants. The diary has information about yoga-like stretching practices.
223526538|NCT02625428|DRUG|Optison|
223526539|NCT02625428|DIAGNOSTIC_TEST|Ultrasound (US)|A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.
223526540|NCT02625428|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
223526541|NCT06675916|PROCEDURE|PENG Block with lidocaine hydrochloride|Intervention is ultrasound-guided PENG block analgesia with lidocaine hydrochloride
223526542|NCT06675916|PROCEDURE|Intra-articular infiltration with lidocaine hydrochloride|Intervention is intra-articular analgesia with lidocaine hydrochloride
223526543|NCT06673888|OTHER|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) is utilized for a variety of purposes, as luting agents, liners/bases, and restorative materials. The RMGI is more aesthetically pleasing than the conventional glass ionomer while maintaining the clinical benefits of the former, such as the release of fluoride, recharging capabilities, prevention of decalcification of hard tooth tissue, inhibition of bacterial acid metabolism, and ease of clinical operation.
223526544|NCT06673888|OTHER|alkasite based restorative material|Cention forte is bioactive restorative material which has the ability to remineralize hard dental tissues through calcium and fluoride release and can also neutralize bacterial acids through hydroxide ions release.
223526545|NCT06674148|DRUG|Qifangfeixian granules|The experimental group was treated with Qifangfixian granules
223526546|NCT06674148|OTHER|Placebo|The control group was treated with placebo
223526547|NCT06674551|PROCEDURE|Suprascapular nerve block and Axillary nerve block|A linear ultrasound probe will be placed in a sagittal plane at the superior medial border of the scapula. The probe will be moved laterally and then placed parallel to the scapular spine. when the needle tip contacts the bone just medial to the spinoglenoid notch and after confirmation of absence of vascular structure by color Doppler, 10 ml of 0.5% bupivacaine will be injected with aspiration every 3 ml to avoid intravascular injection and the spread of the local anaesthetic
223526548|NCT06674551|PROCEDURE|Interscalene Nerve Block|The ultrasound probe will be placed in the supraclavicular fossa in a transverse orientation, aimed caudad into the thoracic cavity, to visualize the brachial plexus near the subclavian artery. Once identified, the plexus will be followed cephalad where it is found within the brachial plexus fascial sheath in the interscalene groove.
223526549|NCT06673654|DRUG|Ruxolitinib Topical Cream 1.5%|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
223526550|NCT06673654|DRUG|OPZELURA (Ruxolitinib) Cream|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
224276066|NCT04989569|DIETARY_SUPPLEMENT|Nutritional intervention|In the intervention group, the body composition data (of day 1, 3, 8) will be given to the dietitians for adjusting the diet formula. The diet formula will be adjusted on the discretion of the dietitian caring for the septic patients based on clinical judgement. The policy adopted by the dietary treatment guidelines for sepsis is to adjust the dietary concentration when there is too much extracellular water under the premise of gastrointestinal tolerance. When the skeletal muscle mass loss is too fast, the dietitians will increase the protein intake by 1.2g/kg of body weight. For patients with acute renal failure and excess extracellular water accumulation and muscle loss, the dietitians will adjust the protein, sodium, potassium, calcium and phosphorus content in the formula. The dietitians will give appropriate nutrition prescriptions based on clinical signs, disease diagnosis and biochemical values.
224276067|NCT04370444|DEVICE|Phallus Length Reducer|Phallus Length Reducer
224276068|NCT04370444|OTHER|Self-assessment of dyspareunia|Use of a vaginal insert to self assess dyspareunia
224276069|NCT01456260|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
224276070|NCT01456260|DRUG|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
224276071|NCT01456260|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
224276072|NCT01456260|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
224276073|NCT01456260|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
224276074|NCT01456260|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
224276075|NCT01206439|DRUG|nebivolol|nebivolol 5 or 10 mg oral, daily
224276076|NCT03680716|DRUG|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
224276077|NCT03680716|DRUG|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
224276078|NCT00388063|DRUG|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
224276079|NCT06428955|DEVICE|CT LUCIA 621P|The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
224276080|NCT04188808|OTHER|Bypass surgery|All patients scheduled for elective surgery of PAA and PAD.
224276081|NCT01462578|DRUG|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
223526551|NCT06673654|DRUG|Placebo|The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
223526552|NCT03598829|DIAGNOSTIC_TEST|Tryptase, Serum test|Blood draw lab test which measures concentration of Tryptase in the sample. Tryptase is the one of the primary secretions of active mast cells and is used as a measure of inflammatory activity. Normal Reference Value: \&lt;11.5 ng/mL
223708067|NCT00672646|DRUG|Naproxen|500mg, capsule, single dose
224276082|NCT06163937|OTHER|Glucose as reference food|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224276083|NCT06163937|OTHER|Orange juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from orange juice, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224276084|NCT06163937|OTHER|Mixed fruit juice|Ten healthy, normal-weight subjects after 10-14 hours of fasting, consumed 50g available carbohydrates from mixed fruit juice (consisted of apple, orange, grape, and pomegranate), tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224276085|NCT04531527|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 60 μl of Butenafine HCl 1% applied twice to the treated irradiated site and to the treated non-irradiated site for a total application of 240 μl of Butenafine HCl 1%.
224276086|NCT04736862|DEVICE|Continuous non-invasive blood pressure monitoring|In patients randomized to the continuous monitoring group, continuous non-invasive finger-cuff blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
224276087|NCT04736862|DEVICE|Intermittent non-invasive blood pressure monitoring|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring using upper-arm cuff oscillometry will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous non-invasive finger-cuff blood pressure monitoring.
224276088|NCT00142116|DRUG|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
224276089|NCT00142116|DRUG|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
224276090|NCT03514355|BEHAVIORAL|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
224276091|NCT05717387|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
224276092|NCT05717387|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
224276093|NCT02797379|OTHER|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
223708068|NCT00672646|DRUG|Placebo|AZD1386 Placebo oral solution
223708069|NCT05223933|BEHAVIORAL|Proactive community case management|CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
223708070|NCT05499000|BEHAVIORAL|Emotional freedom technique|"Emotional freedom technique will be applied online with the researcher in 2 sessions, 3 days apart.~KBF, SUE, PMSS tests will be applied before the intervention, SUE will be applied before and after each session, At the end of the 2nd session, post-test data will be taken with SUE, PMSS."
223708071|NCT03883711|OTHER|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
223708072|NCT02269306|DRUG|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
223708073|NCT04760821|DRUG|Trimetazidine|Trimetazidine 35mg bid in patients with GFR above 60mL/min. Trimetazidine 35mg od in patients with GFR between 30 and 60mL/min.
223708074|NCT01269632|BIOLOGICAL|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~1. clinical and therapeutic evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~1. clinical evaluation by physician~2. biological: blood sampling, specific biological exams and biobank~3. self administered questionnaires"
223708075|NCT05497583|OTHER|Acetone based HEMA -free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. Bioactive composite ( beautifill II ) will be used.
223708076|NCT05497583|OTHER|Isopropanol based HEMA- free universal Adhesive|Teeth that meet the inclusion criteria will be selected. the operator will prepare incisal bevel. Rubber dam isolation will be used .apply etchant (phosphoric acid etching gel 37 %) only on enamel for 15 s Rinse, for 10 s Air dry to remove excess water then will apply Universal adhesive to the entire bonding surface according to manufacture instructions. resin composite (Neo Spectra™ ST) will be used.
223708077|NCT00242216|DRUG|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
223708078|NCT00242216|DRUG|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
223708079|NCT01786941|OTHER|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
223708080|NCT01786941|OTHER|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
223708081|NCT00678080|DRUG|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
223708082|NCT00678080|DRUG|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
223708083|NCT00214760|DEVICE|PGET|resolbable liner
223708084|NCT00214760|DEVICE|PMMA|cement liner
223708085|NCT03950011|PROCEDURE|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
223708086|NCT00981240|DRUG|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
223708087|NCT02597231|DIETARY_SUPPLEMENT|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
223708088|NCT02597231|OTHER|Placebo|Patients in this group will receive a matching placebo pill.
223708089|NCT06183177|OTHER|Whole-Body Vibration|10 minutes of whole-body vibration when performing semi-squatting or forward lunges (12-16 Hz, varying intensity from low to high depending on patients' tolerance
223708090|NCT06183177|OTHER|Exercise|Four to five sessions of a physiotherapist-led exercise program with education talk (20 minutes), group exercises (30 minutes) and individual exercises (30 minutes) per week supplemented with home exercises
223708091|NCT00069056|PROCEDURE|Laser Treatment|
223708092|NCT02872493|PROCEDURE|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
223708093|NCT05472779|DRUG|Periurethral application of estradiol cream|The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.
223708094|NCT05472779|DRUG|Intravaginal application of estradiol cream|The control group will apply 1 gram estradiol cream intravaginally using an applicator.
223708095|NCT06973746|OTHER|sitting out of bed in an arm-chair position|"Once the patient has been awake with a RASS score between -1 and +1 for more than 12 hours, he or she must be placed in a chair (by any means) every day for a minimum of 30 minutes until discharge from intensive care (or until D28, depending on which comes first), unless there are transient contraindications. If the patient is unable to signal his or her wish to stop the chair session, the criteria for intolerance will be sought and the patient placed in the chair, but in all cases the chair session will not exceed 4 hours."
223526553|NCT04180722|DEVICE|aTouchAway™ platform|Participants will receive multi-component Virtual Transition Intervention. The four components of the intervention comprise: (1) routine virtual clinic visits scheduled at the same frequency as usual care; (2) virtual care plan and action plan for respiratory infection/deterioration and management of ventilator issues; (3) remote, weekly and monthly monitoring of ventilator and cough assist metrics, VAI symptoms, and oxygen saturations; and (4) as needed clinical consultations triggered by identification of abnormal parameters or requested by the VAI or family caregiver.
223526554|NCT07011212|DIAGNOSTIC_TEST|BL-Predicter|To Clinically validate the BL-Predictor toll by a randomised conytrolled ttrial
223526555|NCT06674291|DRUG|No intervention (observational study)|This is an observational registry conducted in the real world clinical setting and there is no intervention in this study. Treatment of MDR-END Regimen and the follow-up of subjects will be conducted in the clinical judgment of the investigator.
223526556|NCT07009795|BEHAVIORAL|Rise & Renew Hybrid Grief Support Program|"The Rise \& Renew Hybrid Grief Support Program is a culturally responsive, multi-component behavioral intervention designed specifically for Black women aged 40 and older who have experienced the loss of a spouse, parent, or child. It integrates wellness practices, grief support, spiritual care, and community healing in a hybrid format that includes both an in-person and virtual component.~This intervention is distinguished by its cultural tailoring for middle-aged and older Black women, co-facilitation by both a trained facilitator and a faith-based leader, and its combination of expressive arts, spiritual guidance, and practical wellness strategies delivered in a hybrid format. It addresses grief holistically through emotional, physical, spiritual, and social dimensions, and emphasizes culturally relevant healing practices often overlooked in conventional grief programs."
223526557|NCT06674330|OTHER|concentration of teicoplanin|post analysis of concentration of teicoplanin
223526558|NCT06675669|OTHER|Reflective thinking method|It will be applied to students in the initiative group for 1 hour per week for 7 weeks.
223526559|NCT07010588|DEVICE|non-contrast abbreviated MRI (NC-AMRI)|Non-contrast abbreviated MRI (NC-AMRI) examination include T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI), which takes 10 minutes approximately.
223526560|NCT07010588|DEVICE|enhanced abbreviated MRI (E-AMRI)|E-AMRI examination (using gadoxetic acid disodium) including T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI)and hepatobiliary phase (HBP) images, which takes 15 minutes approximately.
223526561|NCT07010237|DRUG|Dose-attenuated IST and Hetrombopag|Porcine-ATG : 15 mg/kg/day IV ×5 days. Cyclosporine : 3-5 mg/kg/day (adjusted to trough 100-200 μg/L). Hetrombopag: 15 mg daily for 24weeks.
223708096|NCT06150924|DRUG|Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD|Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks
223526562|NCT07010211|OTHER|Gait Video Recording and Analysis|Participants undergo a 6-minute walk test (6MWT) while being recorded on video. The footage is later analyzed using artificial intelligence algorithms to assess gait parameters.
223526563|NCT07010848|OTHER|Core stability training|Core stability Training consists in the activation of trunk.
223526564|NCT07010718|DRUG|Scented Oil|inpatient-safe aromatherapy (scented oil)
223708097|NCT06150924|DRUG|Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD|Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks
223708098|NCT04651296|BEHAVIORAL|compassion meditation|manualized compassion meditation training
223708099|NCT04651296|BEHAVIORAL|health education|manualized health education group
223708100|NCT06975072|DRUG|Magnesium sulfate administration|A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min).
223708101|NCT06576466|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine monohydrate. Guinama brand with CE marking. Code 89823.
223708102|NCT06576466|OTHER|Placebo|Dextrinomaltose. Guinama brand with CE marking. Code 91146.
223708103|NCT06640530|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
223708104|NCT06640530|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
223708105|NCT01072383|DRUG|BT061|administration of BT061 either intravenous or subcutaneous
223708106|NCT01072383|DRUG|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
223708107|NCT06873113|DEVICE|Active BFRT|The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains 50% of participants limb occlusion pressure for the duration of each strengthening exercise.
223708108|NCT06873113|DEVICE|Sham BFRT|The BFR device is applied unilaterally on participants involved upper extremity. The BFR device maintains a pressure of 20mmHg for the duration of each strengthening exercise.
223708109|NCT06873113|BEHAVIORAL|Strengthening Exercises with BFRT|Participants perform 4 strengthening exercises while using the BFR device: seated scapular plane elevation, prone horizontal abduction, side-lying external rotation, and prone scapular plane elevation. Each exercise is performed unilaterally. Participants perform 1 set of 30 repetitions followed by 3 sets of 15 repetitions (4 total sets, 75 total repetitions). Participants are given 30 seconds rest between sets and 2 minutes of rest between strengthening exercises. Selected resistance for each strengthening exercise is equal to 20% of the participant's maximal force production as measured by handheld dynamometry. Resistance is adjusted weekly.
223708110|NCT06873113|BEHAVIORAL|Skilled Physical Therapy Care|Participants perform non-strengthening interventions as part of skilled physical therapy care. Non-strengthening interventions include an upper arm ergometer for warm-up, active assisted range of motion of the shoulder, shoulder stretching, shoulder joint mobilizations, and cryotherapy. Non-strengthening interventions are prescribed at the discretion of the treating physical therapist. Participants are enrolled in physical therapy for a minimum of 4 weeks. After 4 weeks, the treating physical therapist can discharge a participant based on their progress in meeting their rehabilitation goals. Participants discharged from skilled physical therapy care will continue to complete strengthening exercises with BFRT until the end of the trial period (8 weeks).
223526565|NCT07010718|DEVICE|Ear Plugs|ingestible-safe ear plugs (noise blocking)
223526566|NCT07010718|DEVICE|Eye Mask|inpatient-safe eye mask (light blocking).
224276094|NCT05086770|DEVICE|Gelatin microsphere (Nexsphere™)|Gelatin microsphere (Nexsphere™) is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications for gelatin microsphere are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.
223526567|NCT07010718|BEHAVIORAL|Video based safety check|video based safety checks will be conducted as long as participants are in bed and asleep
223526568|NCT07010718|BEHAVIORAL|In person safety check|In person safety checks will be conducted every 30 minutes
223526569|NCT07010185|BEHAVIORAL|home based exercise|warm-up Exercises (5 minutes), dynamic Stretching (5 to 10 repetitions), strengthening exercises focused on lower limb muscles, such as bridging, clamshells, and various leg exercises (5-10 repetitions across 2-3 sets, based on patient tolerance)
223526570|NCT06690879|DEVICE|Smartphone application AI Posture Evaluation and Correction System (APECS)|Mobile application APECS v. 6.2.0. is used to assess upper body posture during standing from back side and right side.
223526571|NCT06691360|DRUG|AK137|IV infusion, specified dose on specified days.
223526572|NCT06690320|BEHAVIORAL|IMPLEMENTATION OF A PLANNED EDUCATION PROGRAM ON HEALTH BELIEF MODEL AND FATUALIST TENDENCIES IN WOMEN AT HIGH RISK OF BREAST CANCER|Description: By examining the parameters of the health belief model and fatalism scales, 6 targets were determined for these scale parameters. The targets were prepared to gain early diagnosis behaviors in breast cancer. By using the breast model, the behavior will be demonstrated in practice
223526573|NCT06607770|DRUG|Karelizumab+Apatinib|Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
223526574|NCT06626126|OTHER|ApoB-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets
223526575|NCT06626126|OTHER|LDL-C-guided-LLT|Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
223526576|NCT06418282|DEVICE|Dayspring|NPCD
223526577|NCT06630767|PROCEDURE|ERAS|Enhanced recovery after surgery (ERAS) programs are a combination of evidenced-based perioperative care approaches that work synergistically to improve recovery after surgery. The core elements of ERAS protocols are preoperative advice, optimization of diet, systematic analgesic and anesthetic regimes, and early mobilization.
223526578|NCT06630767|PROCEDURE|Conventional|Conventional care for patients subjected for laparoscopic common bile duct exploration
223526579|NCT06686472|DRUG|TL-925|TL-925 is an eye drop.
223526580|NCT06686472|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
223526581|NCT06690671|DRUG|Golidocitinib in combination with anti-PD-1|Golidocitinib 150/75 mg once daily (QD) with anti-PD-1 （200 mg IV Q3W），21 days in one cycle.
223526582|NCT06691737|OTHER|Whole Body Vibration|"Whole body vibration consists of 3-minute vibrations with a 30-second break. Participants were asked to step onto the platform barefoot and position their feet 3 from the center of the platform, with feet pointing forward, knees slightly bent, and upper limbs along the body. The training was divided into two parts: week 1 with a frequency of 20 Hz, and a constant amplitude of 3 mm."
223526583|NCT04275284|BIOLOGICAL|PCV10|0.5 ml injection
223526584|NCT04275284|BIOLOGICAL|PCV13|0.5 ml injection
223526585|NCT02495883|OTHER|Ethanol|50ml of 40% Ethanol
223526586|NCT02495883|DRUG|Propranolol|Beta blocker
223526587|NCT00470223|DRUG|cisplatin|
223526588|NCT00470223|DRUG|doxorubicin hydrochloride|
223526589|NCT00470223|DRUG|etoposide|
223526590|NCT00470223|DRUG|ifosfamide|
223526591|NCT00470223|DRUG|methotrexate|
223526592|NCT00470223|DRUG|zoledronic acid|
223526593|NCT00470223|PROCEDURE|conventional surgery|
223526594|NCT05039307|BEHAVIORAL|Educational and motivational strategy|The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.
224276095|NCT05086770|DEVICE|Embosphere|Tris-acryl gelatin microspheres (Embosphere Microspheres) are biocompatible and nonresorbable with cell adhesion properties for complete and durable mechanical occlusion.
223708111|NCT06680700|DEVICE|Perin Health Patch|The Perin Health Patch (PHP) is a non-invasive, chest-worn device designed to monitor blood oxygen saturation (SpO2) and additional vital signs, including heart rate, respiratory rate, ECG, and bioimpedance (BioZ). Unlike traditional fingertip pulse oximeters, the PHP integrates multi-wavelength photoplethysmography (PPG) sensors with ECG and BioZ technology, allowing for continuous SpO2 tracking even during movement and daily activities.
224276096|NCT04162587|OTHER|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
224276097|NCT04162587|OTHER|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
223526595|NCT06257420|DRUG|Rapamycin|Once weekly oral rapamycin
223526596|NCT06691568|DEVICE|Air purifier|Purifiers were turned on for the active group and off for the placebo
223526597|NCT06690632|OTHER|water preparation|ingestion of 1.5L of water 30min prior MRE acquisition
223526598|NCT06690632|OTHER|polyethylene glycol preparation|ingestion of 1.5L of water diluted PEG 45 min prior MRE acquisition (standard protocol)
223526599|NCT00666042|DRUG|Vigamox - administration in spray form|Vigamox will be administered in a spray form
223526600|NCT00666042|DRUG|Vigamox eye drops|Vigamox eye drops
223526601|NCT05505500|BEHAVIORAL|Interview|Concept Elicitation Interviews are used to create tools followed by Cognitive Debrief Interviews that are used to review created tools.
223526602|NCT03085290|OTHER|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
223708112|NCT06681298|DRUG|The experimental group received Nivolumab|Trastuzumab and the FLOT chemotherapy regimen are clearly recommended by guidelines, whereas Nivolumab is currently requiring further research validation.
223708113|NCT07012876|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|The intervention is a guided mental health chatbot - STARS - developed by the World Health Organization (WHO). It consists of 10 sessions which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Supportive Self-talk (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained and supervised non-specialists (called e-helpers) provide weekly calls (five calls lasting approximately 15 minutes) to support participants individually and increase motivation and adherence to the intervention.
223708114|NCT07012876|BEHAVIORAL|Basic psychoeducation|The control group will receive basic psychoeducation. The content of the psychoeducation is very similar to the content of session 2 of the STARS chatbot and includes psychoeducation about emotions, a personal story about a fictional character who talks about her emotions, and information about where to access mental health support. It also includes a list of organizations and clinics providing mental health care in Lithuania.
223526603|NCT03085290|OTHER|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
223526604|NCT04293432|DRUG|Drugs, Generic|All drugs having ≥10 TdP cases reported in the FAERS database
223708115|NCT07008417|DRUG|Cabergoline tablets test formulation|Single oral administration
223708116|NCT07008417|DRUG|Cabergoline tablets reference formulation|Single oral administration
223708117|NCT05215886|BEHAVIORAL|Surgery|Study subjects scheduled for or have already completed weight loss surgery and have already completed psychological screening as part of their pre-surgery work up
223708118|NCT06684964|OTHER|asciminib|This is an observational study. There is no treatment allocation. The decision to initiate asciminib will be based solely on clinical judgement.
223708119|NCT06684457|BEHAVIORAL|Atrial Fibrillation Education|Atrial fibrillation education rendered through a generative AI chatbot, using an iPAD. The intervention itself is an approximately 1 hour long interaction with the chatbot or approximately 10 questions about atrial fibrillation, for 1 single interaction.
223708120|NCT05000723|OTHER|Standard of care|"Standard of care consisting of~* clearance of infection~* treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~* Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip"
223708121|NCT06680882|OTHER|Auricular Acupoint Stimulation +prucapride|The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
224276098|NCT04162587|OTHER|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
223526605|NCT04809805|DRUG|BAY2666605|One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
223526606|NCT03268278|DRUG|Buprenorphine|Buprenorphine plus local anesthetic
223526607|NCT03268278|DRUG|Sterile saline|Placebo 1,8 ml
223526608|NCT03268278|DRUG|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
223526609|NCT01442571|DEVICE|Hyaluronic Acid Injection|
223526610|NCT01442571|DRUG|Saline Injection|
223708122|NCT06680882|DRUG|prucapride|was administered prucapride as a monotherapy
223708123|NCT06680960|OTHER|Trunk stabilisation exercises|This exercise program includes aerobic exercise, resistance exercise and trunk stabilisation training for eight weeks.
223708124|NCT06680960|OTHER|Respiratory exercises|This exercise program includes aerobic exercise, resistance exercise and respiratory exercise training for eight weeks.
223708125|NCT06873841|BEHAVIORAL|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
223708126|NCT06873841|BEHAVIORAL|Cognitive psychophysiological and Biofeedback|Biofeedback refers to visual exercises that help improve movement control.
223893751|NCT06926335|PROCEDURE|Breast consevative surgery|plastic surgery principles within the context of sound oncological resection. Volume-reducing or volume- replacing methods are utilised to optimise postoperative appearances whilst prioritizing negative margin resection, supported by prompt adjuvant therapy
224276099|NCT04162587|OTHER|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
224276100|NCT02876133|DEVICE|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
223526611|NCT05046730|DEVICE|Ileostomy Reversal using Self Forming Magnets (SFM)|The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
223526612|NCT04699877|DRUG|Gilteritinib|Oral
223526613|NCT02776735|DRUG|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
223526614|NCT06032390|OTHER|AI assisted mammography screening interpretation|Screening examinations will be analyzed by the AI system (Transpara, ScreenPoint Medical, Nijmegen, The Netherlands) that assigns each examination a cancer risk score 1-10. Examinations with a score 1-7 will be single read and examinations with score 8-10 will be double read. Examinations selected by one or two readers will be discussed in a consensus meeting. Examinations with an AI score of \>9.8 will be selected for the consensus meeting by default. AI risk scores and image markings are provided to the readers only in the consensus meetings. The readers will decide whether to recall the woman for further assessment in consensus (standard procedure).
223526615|NCT06032390|OTHER|Standard mammography screening interpretation|Screening examinations will be assessed according to standard of care: independently double read, examinations selected by one or two readers will be discussed in a consensus meeting, and the radiologists will decide whether to recall the woman for further assessment. Screening examinations will be analyzed by the AI system retrospectively but the results will not be made available to the radiologist, only used for comparison to the intervention group in results analyses.
224276101|NCT02876133|DEVICE|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
224276102|NCT03045133|DRUG|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
223708127|NCT07020052|DRUG|temozolomide/anlotinib/pembrolizumab|"Starting from 30 days after radiotherapy, adjuvant temozolomide was orally administered at a dose of 150mg/m2. The dosage of temozolomide was adjusted to 200mg/m2 starting from the second cycle, with continuous use for 5 days per week and a 23 day hiatus. Oral administration for a total of 6 cycles.~The start time of oral administration of anlotinib after radiotherapy follows the cycle of radiotherapy, with continuous oral administration for 2 weeks and cessation for 1 week. Until the side effects are intolerable or the tumor progresses. The maximum duration shall not exceed 24 months.~Begin treatment with bemarituzumab 24 hours after radiotherapy, with a body weight of\>=45kg, intravenous injection of 200mg, once every 3 weeks. Weight\<45kg, 100mg intravenous injection, once every 3 weeks. Until the side effects are intolerable or the tumor progresses. The maximum duration shall not exceed 24 months."
223708128|NCT06229210|DRUG|Lumateperone|Lumateperone 5 mg - 42 mg capsules or orally disintegrating tablets administered orally, once daily based on age and indication
223708129|NCT03389230|BIOLOGICAL|HER2(EQ)BBζ/CD19t+ T cells|Given via catheter
223708130|NCT03389230|OTHER|Laboratory Biomarker Analysis|Correlative studies
223708131|NCT03389230|PROCEDURE|Leukapheresis|Undergo leukapheresis
223708132|NCT02039336|DRUG|Dacomitinib|
223708133|NCT02039336|DRUG|PD-0325901|
223708134|NCT02039336|DRUG|Docetaxel|
223708135|NCT06704776|PROCEDURE|"The medially pedicled IPFP flap group"|"In the The medially pedicled IPFP flap group, the IPFP was exposed and separated, and the lateral side was left intact and the medial side was tipped to form a complete medially tipped IPFP flap, and the IPFP flap was clipped and draped over the medial side to avoid interference of the IPFP with the operative field. After successful implantation of the prosthesis, the IPFP was fixed with in situ sutures."
223708136|NCT06704776|PROCEDURE|"Complete IPFP removal group"|The entire IPFP was resected from below the patellar tendon prior to femoral preparation.
223708137|NCT06706271|DRUG|Vitamin D|2000 IU of Vitamin D
223708138|NCT07028619|DEVICE|Bimodal Streaming Configuration|Participants' devices are configured for bimodal streaming. Participants complete a survey following a trial with the new bimodal streaming feature.
223708139|NCT07039838|DIAGNOSTIC_TEST|3D print of coronary arteries|Based on a pre-surgical cardiac CT the optimal graft insertions points on the target coronary arteries wil be marked and a patient-specific model of the coronary arteries will be 3D-printed and sterialized to be available during CABG to guide the placement of the distal graft anastomosis.
223708140|NCT05213338|DEVICE|Wear-documentation microchip|Microchip embedded in the appliance
223708141|NCT01332500|DRUG|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
223708142|NCT01332500|DRUG|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
223708143|NCT05038189|DIAGNOSTIC_TEST|Gait parameters|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
223708144|NCT05038189|DIAGNOSTIC_TEST|Spine posture|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
223708145|NCT05038189|DIAGNOSTIC_TEST|Trunk position sense|Trunk position sense as indicated by trunk reposition errors (TRE) and spine posture (thoracic and lumbar curvature) will be measured with a digital inclinometer. Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated.
223708146|NCT05812456|OTHER|Estimation of Shear Bond Strength|"Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure."
223708147|NCT02364479|DRUG|50mg Yisaipu|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
223708148|NCT02364479|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
223708149|NCT02364479|DRUG|Placebo|The injection method and frequency of placebo is the same as the other arms.
223708150|NCT01728064|DRUG|Placebo|Placebo capsules
223708151|NCT01728064|DRUG|EPI-743 400 mg|
223708152|NCT01728064|DRUG|EPI-743 200 mg|
223708153|NCT05004103|OTHER|Cosmetic products application|Female healthy volunteers applied cosmetic products (cleanser and moisturizer) in the morning and afternoon for 1 month. Seven days wash out period will be conducted prior study starts. The evaluation will be conducted before, two weeks after treatment starts, and at the end of the study.
223708154|NCT00791570|BIOLOGICAL|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
223708155|NCT01225432|OTHER|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
223708156|NCT02509247|DEVICE|Telemonitoring|Wireless telemonitoring
223708157|NCT04445311|DRUG|Ivermectin|3 successive days ttt of ivermectin started within 48 hours of symptoms
223708158|NCT01034631|DRUG|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
223708159|NCT01034631|DRUG|BNC105P|BNC105P, up to 16 mg/m\^2
223708160|NCT01292746|DEVICE|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
223708161|NCT02348905|DRUG|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
223708162|NCT02348905|DRUG|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
223708163|NCT03426813|OTHER|Historical control group for early mobilization|
223708164|NCT05089149|PROCEDURE|Clinical examination centered on congestion|Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
223708165|NCT05089149|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
223708166|NCT05089149|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation
223708167|NCT05089149|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)
223708168|NCT05089149|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
223526616|NCT06262659|OTHER|Doppler Ultrasonography Assessment|"Preoperative data will be collected from the latest available data within the last month. Preoperative Doppler ultrasonography venous mapping for all patients will be performed by experienced Radiology Specialists.~AVF flow measurement will be performed intraoperatively and at the 6th week postoperatively using Doppler ultrasonography (B-Mode and duplex ultrasound on the LOQIC; GE Healthcare Technologies, Milwaukee, Wisconsin, United States). For each patient, AVF flows will be recorded by taking at least 3 measurements of AVF flow, depth, and vascular diameters at 2, 5, 10, and 15 cm proximal to the AVF anastomosis, and arithmetic averages will be calculated. AVF flow will be expressed in ml/min, and the vascular structure diameters and the distance of AVF from the skin will be indicated in mm. AVF depth will be calculated as the distance from the skin to the anterior wall of the AVF."
223526617|NCT04070209|DRUG|Darolutamide (BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
223526618|NCT04070209|RADIATION|SBRT|SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.
223526619|NCT02639689|DEVICE|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
223526620|NCT04410861|PROCEDURE|Micropulse laser photostimulation|In this treatment invisible, non-damaging laser shots are delivered to the affected area which are believed to lead to absorption of accumulated retinal fluid. Contact lens will be used along with topical anesthesia.Following the procedure eye will be washed with balanced salt solution.
223526621|NCT06193707|OTHER|the Remote Intervention|Remote health intervention refers to the use of big data, artificial intelligence and 5G technology to provide healthcare services and interventions to individuals at a distance. This approach allows healthcare providers to deliver medical care, monitor patients' health, offer consultations, provide education, and offer support without the need for in-person interaction.
223526622|NCT06193707|OTHER|the Traditional Intervention|Ultrasound follow-up review is recommended. If there is suspicious change in the lesion during follow-up, biopsy should be considered to clarify the nature of the pathology.
223526623|NCT02185183|DRUG|Alequel|Alequel
223526624|NCT05928988|DRUG|SHR8554；Itraconazole|Drug: SHR8554 Administered as specified in the treatment arm Drug: Itraconazole Administered as specified in the treatment arm
223526625|NCT04164381|DEVICE|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
223526626|NCT05702307|OTHER|Glucose as reference food|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223526627|NCT05702307|OTHER|Tagliatella control|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from tagliatella control, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223526628|NCT05702307|OTHER|5% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 5% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223526629|NCT05702307|OTHER|16% sunflower tagliatella|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower tagliatella, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223708169|NCT00828932|DRUG|Lorcaserin|
223708170|NCT06505421|BEHAVIORAL|Resistance training|Eccentric resistance training and tradional resistance training
223708171|NCT00194597|DRUG|Viagra (sildenafil citrate)|
223708172|NCT02946944|DRUG|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \\ g + 10 mg apixaban 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
224276103|NCT03045133|DRUG|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
224276104|NCT02102932|DRUG|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
223526630|NCT05702307|OTHER|16% sunflower penne|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower penne, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and samples from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223526631|NCT05702307|OTHER|16% sunflower fusilli|Fifteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from 16% sunflower fusilli, tested once, in different visits, within 10min. Fingertip capillary blood glucose samples and measurements from continuous glucose monitoring system were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223526632|NCT03589274|BEHAVIORAL|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
223526633|NCT03589274|BEHAVIORAL|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
223526634|NCT00791648|DRUG|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
223526635|NCT00791648|DRUG|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
223526636|NCT00317265|PROCEDURE|Coronary bypass surgery|
223526637|NCT05209035|DRUG|Trazodone|Trazodone 50mg daily
223526638|NCT05209035|OTHER|Placebo|Starch 50mg
223526639|NCT04976777|DEVICE|Updated DEX PS DDS Applicator|Intravitreal Administration
223526640|NCT04976777|DEVICE|Approved DEX PS DDS Applicator|Intravitreal administration
223526641|NCT04976777|DRUG|Dexamethasone|Dexamethasone 0.7 mg in a solid polymer drug delivery system
223526642|NCT05114928|PROCEDURE|Transepithelial Corneal Collagen Cross-linking|Bilateral Transepithelial Corneal Collagen Cross-linking was done for all subjects using power of 9mW/cm2 at 55mm from the cornea for 10 minutes, with a total energy of 5.4j/cm2 using the (CCL VARIO, PESCHKE Trade GmbH, Huenenberg Switzerland), in the period between January 2016 to August 2016.
223526643|NCT05114928|DIAGNOSTIC_TEST|Scheimpflug camera|Pentacam (OCULUS Optikgeräte GmbH, Wetzlar, Germany) was done for all subjects at baseline and annually after TE-CXL till 5 years of follow-up.
223526644|NCT03944395|OTHER|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
223526645|NCT00462826|BIOLOGICAL|ziv-aflibercept|
223526646|NCT03983330|BEHAVIORAL|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
223526647|NCT03983330|BEHAVIORAL|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
223526648|NCT04319757|DRUG|ACE1702|ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously
223526649|NCT04319757|DRUG|Cyclophosphamide|Lympho-conditioning agent
223526650|NCT04319757|DRUG|Fludarabine|Lympho-conditioning agent
223526651|NCT05291650|DRUG|Glucocorticoids|The product of the glucocorticoid is betamethasone injectable suspension and the dosage is 1 ml. To alleviate the discomfort on local tissues, the suspension injected into the infrapatellar fat pad will be pre-mixed with 0.5 ml saline and 0.5 ml lidocaine. That is, the total amount of the drug injected into the infrapatellar fat pad for the glucocorticoid group will be 2.0 ml.
223526652|NCT05291650|DRUG|Saline|A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
223526653|NCT05291650|DRUG|Hyaluronic acid|After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
223526654|NCT06789588|DRUG|pharmacogenetic algorithm|The dose predictor algorithm proposed in this work aims to maintain and quality treatment in an individualized and effective manner. In the routine use protocol, warfarin is prescribed based only on the INR collected within 5 days. The proposed intervention protocol is based on the patient's clinical and genetic factors, such as genetic polymorphisms, age, weight, height, race, use of amiodarone, statins, antifungals or antibiotics, tobacco use, clinical indication and what the RNI target.
223526655|NCT06789588|DRUG|Clinical treatment|Patients with AF indicated for OAC therapy guided by institutional protocol.
223526656|NCT05975242|BEHAVIORAL|Smartphone diabetes management application|The intervention is a smartphone diabetes management application that is combined with structured blood glucose testing.
223526657|NCT06441162|DRUG|Nebulized 3% sodium chloride solution|Standardized dose of nebulized 3% sodium chloride will be provided from 4 mL vial and administered be every 6 hours.
223526658|NCT06441162|DEVICE|Chest percussion cups|The chest percussion cup is a small, flexible cup made of vinyl that is used to provide gentle chest wall vibrations to assist with airway clearance and is utilized in patients of all ages with sputum production, such as those with acute bronchiolitis. Administered every 6 hours while on supplemental oxygen therapy.
223708173|NCT02946944|DRUG|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \\ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
223708174|NCT04621630|DRUG|PN-235|Active Drug
223708175|NCT04621630|DRUG|Placebo|Matching Placebo
223708176|NCT03372096|DEVICE|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
223708177|NCT00329004|DRUG|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
223708178|NCT00680017|DRUG|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
223708179|NCT00680017|DRUG|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
223708180|NCT00057317|DRUG|Ro 205-2349|
223708181|NCT01861964|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
223708182|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
223708183|NCT01861964|DIETARY_SUPPLEMENT|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
223708184|NCT02072018|DRUG|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
223708185|NCT02072018|DRUG|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
223708186|NCT04313218|DRUG|Carbetocin|iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
223708187|NCT05074667|DEVICE|Continuous Glucose Monitor|Participants will be provided a continuous glucose monitor for use in self-glucose monitoring as per standard clinical care
223708188|NCT05074667|OTHER|Patient Reported Outcome Questionnaires|Participants and their parents will be asked to complete patient reported outcome questionnaires at 3 study time points.
223708189|NCT01587820|DRUG|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
223708190|NCT01587820|DRUG|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
223708191|NCT05303857|DRUG|Semaglutide Pen Injector|Injection of the semaglutide once weekly
223708192|NCT05303857|DRUG|Placebo|Injection of placebo once weekly
223708193|NCT04717791|DEVICE|Vivaer® ARC Stylus|The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
223708194|NCT06846996|DRUG|Trastuzumab deruxtecan (T-DXd)|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd (starting dose 6.4 mg/kg IV Q3W) will be enrolled in this study as part of clinical routine or the clinical judgement of physician.
223708195|NCT05672836|DRUG|Enavogliflozin|0.3 mg 1 tablet once daily
223708196|NCT05672836|DRUG|Standard-of-Care|Standard-of-Care medical therapy plus Enavogliflozin matching placebo
223708197|NCT06480708|OTHER|Ketogenic diet|The ketogenic diet consisting of fats (70%), protein (20%) and carbohydrates (10%) will be consumed for 14 days prior to undergoing open-heart surgery, and up to 6 days postoperatively or until discharge (if within 6 days postoperatively).
223708198|NCT06480708|OTHER|Control diet|The control diet consisting of a Mediterranean diet, at 25% fat, 20% protein and 55% carbohydrates will be consumed for 14 days prior to undergoing open-heart surgery, and up to 6 days postoperatively or until discharge (if within 6 days postoperatively).
223708199|NCT05320757|DRUG|Olaparib|a PARP inhibitor
223708200|NCT03385902|OTHER|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
223708201|NCT03385902|OTHER|late start time|patients will start hemodialysis when their DIFE less than 30
223708202|NCT05402345|DRUG|GlcNAc-GlcN|GlcNAc powder - weight-dependent dose
223708203|NCT05402345|OTHER|Placebo|Placebo xylose
223708204|NCT03821649|BEHAVIORAL|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
223708205|NCT03821649|BEHAVIORAL|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
223708206|NCT00144690|DRUG|E2007 (perampanel)|
223708207|NCT00144690|DRUG|Placebo|
223708208|NCT06428422|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis Bl-04|4 x 10\^9 cfu/g/day Bifidobacterium animalis subsp. lactis Bl-04 for 12 weeks
223708209|NCT06428422|OTHER|Plasebo|1 g/day maltodextrin for 12 weeks
223708210|NCT04766060|OTHER|Fluorescent Imaging|Fluorescense imaging used to evaluate blood perfusion
223708211|NCT00899574|DRUG|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
223708212|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-active|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type，participants receive 20 min sessions of 2 mA direct current delivered over the dorsolateral prefrontal cortex, 5 days per week, for 4 weeks
223708213|NCT04497493|DEVICE|Transcranial Direct Current Stimulation (tDCS)-sham|Transcranial direct current stimulation (TDC) is a non-invasive neuromodulation technique of the brain with a DC microelectrical stimulator, a cathode electrode and an anode electrode, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min 5 days per week, for 4 weeks
223708214|NCT02614586|DRUG|TAK-058|TAK-058 oral solution.
223708215|NCT02614586|DRUG|Ondansetron|Ondansetron capsule.
223708216|NCT02614586|DRUG|TAK-058 Placebo|TAK-058 placebo-matching, solution.
223708217|NCT02614586|DRUG|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
223708218|NCT05059470|DRUG|Pembrolizumab|Given by IV
223708219|NCT05248685|BIOLOGICAL|Dual CD33/CLL1 CAR T|Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion chemotherapy (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day) will be administrated for 3 days. Then this study will be using BOIN1/2 approach from starting dose 1: 1×10\^6 (±20%) to dose 2: 5×10\^6 (±20%). If the manufactured cells were not sufficient to meet the preassigned standard dose criteria, patients are given infusion at a low dose of 5×10\^5 (±20%)
223708220|NCT05154578|BIOLOGICAL|GBS-NN/NN2 Vaccine|0.5 mL GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS-NN2 and 0.5 mg of aluminium, given by intramuscular injection.
223708221|NCT05154578|BIOLOGICAL|Placebo|0.5 mL normal saline given by intramuscular injection
223708222|NCT03930680|DRUG|Dexrazoxane|One dose of dexrazoxane
223708223|NCT05880251|BEHAVIORAL|Operant Conditioning with Peripheral Stimulation|This is a training intervention to strengthen the weakened sensorimotor responses and reduce pain, after a limb amputation. Non-painful peripheral stimulation will be applied to elicit a response.
223708224|NCT05880251|BEHAVIORAL|Control Group with Peripheral Stimulation Only|This is a control intervention in which the non-painful peripheral stimulation will be applied, same as the operant conditioning group, but no training feedback will be provided.
223708225|NCT06090604|OTHER|High intensity gait training in a balance challenging Movement amplification environment|For Aim 2, each participant will engage in ten 45-min high-intensity gait training sessions performed in a Movement Amplification Environment (MAE). Training sessions will occur 2x/week and led by a licensed Physical Therapist. The goal of each training session is to achieve 40-min of stepping practice within a targeted range of heart rate (HR) of 70 to 80% of estimated age-predicted HR max and perceived excursion (RPE) in a MAE. Each session will begin and end with a 2.5-min warm-up and cool down, with 40-min of training using two 10-min Speed-training blocks and two 10-min Balance-training blocks. Balance training activities will include lateral maneuvers, head turns, obstacle negotiation, and backward walking. The MAE gain, training speeds and balance activities will be progressively increased within and across sessions to challenge the participant.
223708226|NCT03631745|BEHAVIORAL|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~1. NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~2. NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
223526659|NCT05939141|DEVICE|Genio System|"All participants have previously been implanted with a Genio® system implantable stimulator. This research is observational in nature (long term safety follow-up) and participants will not be exposed to additional procedures.~The Genio System comprises of a bilateral Implantable Stimulator (IS), which is implanted via a minimally invasive surgery procedure and positioned over the genioglossus muscle with its electrodes positioned over both the left and right hypoglossal nerve branches. Stimulation of the hypoglossal nerve causes the tongue muscles to contract with the intention to maintain an open airway. The Implantable Stimulator receives energy pulses transmitted via the DP placed under the patient's chin and connected to the Activation Chip (AC), which contains the patient's stimulation parameters and contain a battery that provides energy."
223526660|NCT01701388|DEVICE|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
223526661|NCT05503082|DRUG|Ubrogepant 50 MG [Ubrelvy]|Ubrogepant 50 MG \[Ubrelvy\]
223708227|NCT01832649|BEHAVIORAL|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
223708228|NCT01832649|BEHAVIORAL|Health education|Supervised groups 2 times per week during 8 weeks.
223708229|NCT06105151|DRUG|VV119(SAD)|VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
223708230|NCT06105151|DRUG|VV119 Placebo(SAD)|VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
224276105|NCT02102932|DRUG|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
224276106|NCT02102932|DRUG|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
223526662|NCT05503082|DRUG|Ubrogepant 100 MG [Ubrelvy]|Ubrogepant 100 MG \[Ubrelvy\]
223526663|NCT06177431|DRUG|Monepantel|Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
223708231|NCT06105151|DRUG|VV119(FE)|A：2 mg VV119, following an overnight fast of at least 10 hours for Period 1; 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2; B: 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1;2mg VV119, following an overnight fast of at least 10 hours for Period 2；
223708232|NCT00935090|DEVICE|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
223708233|NCT00443027|DEVICE|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
223708234|NCT02043314|DRUG|Isoniazida|
223708235|NCT02499276|DEVICE|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
223708236|NCT03897023|BIOLOGICAL|Gut Microbiota|Status of microbiota
223708237|NCT06000397|OTHER|Enhanced reminders|"The intervention is sending enhanced (modality and frequency) of reminders to CANImmunize App users, in addition to the standard notifications. Specifically:~* Deliver reminders and recall emails to parents or guardians of infants waiting for their 12-month dose of pneumococcal vaccine,~* Add additional information about the benefits, safety and effectiveness of the pneumococcal vaccine to support increased uptake, and~* Provide tips to improve parents' or guardians' self-efficacy in circumventing barriers to timely immunization of children at the 12-month's visit"
223708238|NCT06000397|OTHER|Standard CANImmunize notifications|"Push notifications at two time points:~* two weeks prior to the immunization due date~* one week after the immunization due date"
223708239|NCT00864721|DRUG|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
223708240|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Colonic-Delivery capsule)|250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)
223708241|NCT06097182|DIETARY_SUPPLEMENT|Post-biotic (Regular Administration capsule)|250mg post-biotic once daily in a regular uncoated vegan gelatine capsule
223708242|NCT06097182|OTHER|Placebo|250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
223526664|NCT05264727|DRUG|Dextrose|Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
223708243|NCT05825781|DRUG|Pertuzumab|i.v.
223708244|NCT05825781|DRUG|Perjeta®|i.v.
223708245|NCT04521374|BEHAVIORAL|Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein|Immediately after consuming the preload meal, volunteers will use a 100mm visual analogue scale (VAS) to rate their liking towards the meal, their hunger, fullness, desire to eat and prospective food intake. Subsequently, they will record these every 30 minutes until they consume their ad-libitum dinner
223708246|NCT00223015|DRUG|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
223708247|NCT03128827|DEVICE|RAM sensor|Acoustic Respiration Monitor
223708248|NCT02154737|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
223708249|NCT02154737|DRUG|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
223708250|NCT04121923|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
223526665|NCT05264727|DRUG|Clinisol 15%|Intravenous infusion 0.003ml/kg/min infused from 0 to 240 minutes
223526666|NCT04996667|DRUG|inhaled nitric oxide (iNO)|"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
223526667|NCT05153772|DRUG|AlphaMedix|212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
223526668|NCT06627049|OTHER|Focus group|Focus group to evaluate the facilitators and barriers to the use of virtual reality.
223708251|NCT00354887|DRUG|Capecitabine|Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
223708252|NCT00354887|DRUG|Oxaliplatin|130 mg/m\^2 by vein Day 1 over 2 hours in 21 Day Cycle
223708253|NCT03875365|PROCEDURE|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
223708254|NCT03258931|DRUG|Crenolanib|Crenolanib will be administered orally
223708255|NCT03258931|DRUG|Midostaurin|Midostaurin will be administered orally
223708256|NCT03258931|DRUG|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
223708257|NCT03258931|DRUG|Duanorubicin|90 mg/m2 IV
223708258|NCT01705730|DRUG|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
223708259|NCT05875428|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Be given intravenously at 20 mg/m\^2 on days 1 of each treatment cycle.
223708260|NCT05344365|DRUG|Iloperidone|oral tablet
223708261|NCT04217330|BEHAVIORAL|Choice of home-based or centre-based pulmonary rehabilitation|Participants will be offered the choice of HomeBase, a home-based pulmonary rehabilitation program, or the traditional centre-based pulmonary rehabilitation program.
223708262|NCT04217330|BEHAVIORAL|Centre-based pulmonary rehabilitation|Participants will be offered a traditional centre-based pulmonary rehabilitation program
223708263|NCT01570088|DIETARY_SUPPLEMENT|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
223708264|NCT01570088|DIETARY_SUPPLEMENT|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
223708265|NCT01570088|OTHER|Placebo|Placebo contains no folic acids
223708266|NCT00705289|BIOLOGICAL|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
223708267|NCT02721160|OTHER|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~* nb of cases screened and referred to HC for acute malnutrition (AM)~* nb of classes promoting good nutrition~HC level~* nb of cases screened and cared for severe and moderate AM~* nb of growth follow-ups~Hospital level~* nb of treated severe AM cases with complications~* length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
223708268|NCT04167982|PROCEDURE|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
223708269|NCT04167982|DRUG|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
223708270|NCT04167982|DRUG|Oral low-dose isotretinoin|low-dose isotretinoin
223708271|NCT05459272|DIETARY_SUPPLEMENT|Aquilea Sueno Forte|"The test product consists of a dietary supplement in the form of tablets with three layers containing: melatonin (1.95 mg/tablet) and herbal products (extracts from Griffonia, Passiflora, California poppy, Valerian, Melissa).~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
223708272|NCT05459272|OTHER|Placebo|"The placebo will consist of tablets with three layers and with the same appearance as the dietary supplement under study, but containing no active ingredients.~Patients should take one tablet daily 30 min before go to bed during 7 days (from day 7 to day 14)."
223708273|NCT05845736|DRUG|Antihypertensive Agents|number of hypertensive drugs
223708274|NCT02601027|PROCEDURE|Transversus Abdominis Plane (TAP) block|
223708275|NCT02601027|DEVICE|Nimbus Infusion Pump IV Administration|
223708276|NCT02601027|DRUG|Bupivacaine infusion|
223708277|NCT02601027|DRUG|Acetominophen|
223708278|NCT02601027|DRUG|Hydromorphone|
223708279|NCT02601027|DRUG|Oxycodone|
223708280|NCT02601027|DRUG|Ondansetron|
223708281|NCT03532841|DRUG|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
223708282|NCT03532841|DRUG|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
223708283|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation A
223708284|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
223708285|NCT01427257|DRUG|Single Dose PB1023|Single Dose PB1023 Formulation B
223708286|NCT05490407|DRUG|Carboplatin|Patients will receive neoadjuvant chemotherapy according to ESGO guidelines
223708287|NCT01744873|DRUG|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
223708288|NCT01744873|DRUG|Bisoprolol|10 mg tablet once a day
223708289|NCT00495365|DRUG|Epoetin alfa|
223708290|NCT06463405|OTHER|Splinted|The investigators will compare splinted versus non-splinted crowns in a randomized design. Whether the crowns will be splinted or not are decided by distant randomization separate from clinicians conducting the trial. Twenty sealed envelopes will be opened where its stands whether the crowns has to be splinted crowns or non-splinted crowns. The implants in the splinted side will have an intermediate titanium abutment and impression will be taken at abutment level, whereas impressions in the non-splinted side will be taken directly at the fixture level. The splinted as well as the non-splinted crowns will be screw-retained and produced in monolithic zirconia. An open-tray technique / (scanning) will be used for both reconstructions.
223708291|NCT02548533|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
223708292|NCT02548533|DRUG|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
223708293|NCT02548533|DRUG|EMLA cream|Topical application 2 hours prior to the treatment.
223708294|NCT05707767|PROCEDURE|Resection surgery|Patients undergo resection surgery in our hospital.
223708295|NCT01227759|DRUG|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
223708296|NCT01227759|DRUG|Placebo|Placebo containing no active ingredient
223708297|NCT02609828|DRUG|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
223708298|NCT01034150|DEVICE|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
223708299|NCT01034150|DEVICE|Placebo stimulation|Placebo stimulation
223708300|NCT02098967|DRUG|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
223708301|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
223708302|NCT02098967|DRUG|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose \</= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
223708303|NCT02164214|DRUG|etanercept Treatment|
223708304|NCT04966832|DRUG|XW10508|XW10508 capsules or tablets
223708305|NCT04966832|OTHER|Placebo|Placebo capsules or tablets
223708306|NCT01286233|DRUG|Metformin|
223708307|NCT01286233|DRUG|Placebo|
223708308|NCT03187275|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
223708309|NCT03187275|OTHER|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
223708310|NCT04465110|DIETARY_SUPPLEMENT|Grape Seed Extract|Subjects took a single dose of 600 mg GSE in capsule form through ingestion 2 hours prior to testing Dietary Supplement: Grape seed extract Two capsule grape seed extract (total 600 mg) per day
223708311|NCT03758066|DEVICE|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
223708312|NCT01500577|DRUG|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
223708313|NCT01500577|DRUG|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
223708314|NCT01500577|OTHER|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
223708315|NCT05014789|DEVICE|Control-IQ technology 2.0|All subjects wearing the t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor
223708316|NCT03019783|DRUG|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
223708317|NCT03019783|OTHER|Placebo|The control group will stay on their baseline regimen
223708318|NCT02407860|OTHER|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
223708319|NCT02407860|OTHER|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
223708320|NCT03874637|DEVICE|Treament|Placement of the FemPulse System with therapy delivery
223708321|NCT03874637|DEVICE|Sham Control|Placement of the FemPulse System without therapy delivery
223708322|NCT00762385|DEVICE|galyfilcon A|galyfilcon A
223708323|NCT00762385|DEVICE|comfilcon A|comfilcon A
223708324|NCT02787096|DEVICE|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
223708325|NCT03129750|DEVICE|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
223708326|NCT00398580|DRUG|Nanomilled testosterone|
223708327|NCT00398580|DRUG|Nanomilled dutasteride|
223708328|NCT00398580|DRUG|commercially available dutasteride|
223708329|NCT06271122|OTHER|Voluntary activation assessed by magnetic stimulation|"Visits V1 (Day 1) and V2 (Day 28) are identical. The dominant leg will be tested, the patient positioned on the ergometer and EMG electrodes placed on the quadriceps.~The familiarization for femoral magnetic stimulation (FMS) will begin, the stimulation site identified and the supramaximality verified.~After a warm up, the subject will perform 3 maximal voluntary isometric contractions (MVIC; 5s, rest = 30s), 3 MVIC reaching maximal force as quickly as possible, and 4 MVIC during which magnetic stimulation (intensity = 100%) will be applied during the contraction and 2 seconds after the contraction ends.~For transcranial magnetic stimulation, the stimulation area and intensity will be determined. After that, the patient will perform 3 CMIV at 100%, 75%, 50% and 35% of CMIV. During each contraction, magnetic stimulation will be delivered during the force plateau."
223708330|NCT01936805|DRUG|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
223708331|NCT01540838|DRUG|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
223708332|NCT01540838|DRUG|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
223708333|NCT00404937|DRUG|Tobradex (Antibiotic steroid combination)|
223708334|NCT01816204|BEHAVIORAL|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
223708335|NCT01816204|BEHAVIORAL|face-to-face individual therapy|weekly individual counseling as usual.
223708336|NCT05700448|BIOLOGICAL|Sugemalimab|IV infusion
223708337|NCT05700448|DRUG|Placebo|IV infusion
223708338|NCT05700448|DRUG|Pegaspargase|Intramuscular injection
223708339|NCT05700448|DRUG|Gemcitabine|IV infusion
223708340|NCT05700448|DRUG|Oxaliplatin|IV infusion
223708341|NCT04007081|PROCEDURE|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
223708342|NCT04007081|DIAGNOSTIC_TEST|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
223708343|NCT04007081|OTHER|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
223708344|NCT04007081|OTHER|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
223708345|NCT04891978|BEHAVIORAL|AIRQ|A validated tool designed to identify patients who may be at risk for adverse outcomes from uncontrolled asthma.
223708346|NCT04891978|BEHAVIORAL|Asthma Checklist|A validated, 3-page tool, based on GINA and NAEPP guidelines to assist providers with recognition, evaluation, and optimization of all patients with asthma. In this study, healthcare providers will be required to complete the assess component (page 1) of the Asthma Checklist .
223708347|NCT04891978|BEHAVIORAL|PRECISION Program (Educational Resources)|Educational resources accessible to all providers in the study. There are provider-facing and patient-facing educational materials that can be accessed during the patient visit or as resources for before/after visits. Resources can be downloaded and sent to patients per the discretion of providers.
223708348|NCT06125522|DRUG|vepdegestrant|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
223708349|NCT06125522|DRUG|Samuraciclib|Daily oral dosages of Samuraciclib continuously, dose escalation/de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days
223708350|NCT02570360|BEHAVIORAL|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
223708351|NCT02570360|BEHAVIORAL|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
223708352|NCT03120234|DRUG|Dexmedetomidine|
223708353|NCT03120234|DRUG|Ketamine|
223708354|NCT03120234|DRUG|Fentanyl|
223708355|NCT03120234|DRUG|Placebos|o.9% normal saline will be used instead of ketamine
223708356|NCT02107404|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
223708357|NCT00871533|DRUG|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
223708358|NCT00871533|DRUG|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
223708359|NCT00871533|DRUG|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
223708360|NCT00871533|DRUG|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
223708361|NCT04912193|DRUG|Antithrombin III|In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
223708362|NCT03641339|OTHER|One vector feeding|Participants will undergo one feeding by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies)
223708363|NCT03641339|OTHER|Four vector feeding|Participants will undergo four feedings by one of three colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies), each about 2 weeks apart, with the same vector type.
223708364|NCT02126995|DRUG|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
223708365|NCT01934946|OTHER|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
223708366|NCT01934946|OTHER|home rehabilitation|6 times home rehabilitation services within 3 months
223708367|NCT06032468|DEVICE|ARC Intellicare|wearable devices to guide rehabilitation exercise
223708368|NCT06032468|OTHER|Rehabilitation sheets|rehabilitation exercise sheets to guide rehabilitation exercise
223708369|NCT04603456|DRUG|Lacteol fort|Lacteol fort is a drug containing lactobacilli
223708370|NCT04603456|DRUG|Standardized Timothy Grass Pollen|SLIT includes 2 phases build up and maintenance phases. (Jubilant HollisterStier LLC 14110 Collections Drive, Chicago USA) .
223708371|NCT04603456|DRUG|Lacteol fort and Standardized Timothy Grass Pollen|Lacteol fort is a drug containing lactobacilli and the Standardized Timothy Grass Pollen includes 2 phases build up and maintenance phases.
224276107|NCT02102932|DRUG|850 mg metformin|850mg metformin tablet
223708372|NCT05596760|BEHAVIORAL|Jumpstart Guide|The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families in the outpatient setting. The intervention's goal is to prompt clinicians to provide, during a scheduled (non-urgent) clinic visit, standard of care which includes a discussion with patients (and/or their LNOKs) about their goals of care. It is designed to promote and guide these discussions for older adults with memory problems through suggestions and tips on the Jumpstart Guide.
223708373|NCT03863197|BEHAVIORAL|Progressive strength training|Progressive Supervised Home-based Strength Training
223708374|NCT03832036|DIAGNOSTIC_TEST|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
223708375|NCT02275637|DEVICE|implantable cardioverter defibrillator|
223708376|NCT05188014|BEHAVIORAL|Luteal Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer during the last week of active pill consumption.
223708377|NCT05188014|BEHAVIORAL|Follicular Phase Aerobic Exercise|Participants will perform 45 minutes of moderate (60% VO2peak) aerobic exercise on a cycle ergometer within 5 days of starting their menses.
223708378|NCT05338216|BEHAVIORAL|Traditional EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name 9 pictures back-to-back four times/day."
223708379|NCT05338216|BEHAVIORAL|Micro-Interaction EMA|"Participants will wear a smartwatch for three weeks. Throughout the day (10am-8pm), the watch will vibrate and a written alert will appear on the screen asking participants if they are ready to name some/a picture(s). Once the picture appears, the participant will attempt to name the picture aloud while the watch records audio. The participants will have up to five seconds to name the picture before a Thank You! screen appears. In this arm, participants will name one picture at a time, 36 times/day."
223708380|NCT03891953|DRUG|DKY709|Novel immunomodulatory agent
223708381|NCT03891953|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
223893752|NCT06786247|BEHAVIORAL|ActivaTeen|"The ActivaTeen app is built on HIPAA-compliant instance of a popular messaging software. Participants in the treatment group can access the app at any time via desktop or mobile, where they can find features designed to enhance their receipt of BA therapy.~These features include: weekly BA skills and homework completion support, in-app messaging with their BA therapist, mood and activity tracking and data visualizations, chatbot check-ins on progress and guided problem-solving around barriers, and moderated peer support using the ActivaTeen app. The app will have a moderator, who is part of the study team, to manage peer-to-peer interactions within ActivaTeen."
224276108|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
224276109|NCT02102932|DRUG|5 mg empagliflozin|5 mg empagliflozin
224276110|NCT02102932|DRUG|850 mg metformin|850 mg metformin
224276111|NCT02102932|DRUG|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
224276112|NCT02102932|DRUG|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
224276113|NCT02102932|DRUG|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
224276114|NCT02102932|DRUG|500 mg metformin|500 mg metformin
223708382|NCT06390397|OTHER|Produce prescription program|"Boxes of fresh fruit and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks. Participants will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
223708383|NCT06390397|OTHER|Standard of care|Standard of care includes routine lab work collection and weight and diet counseling for overweight or obese children. Additionally, referrals placed to community resources for those identified with Social Determinants of Health(SDOH) needs.
223708384|NCT06015451|OTHER|Sub-symptom threshold exercise|Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
223708385|NCT06174649|DIAGNOSTIC_TEST|Reveal|Reveal is a rapid AST method, which uses small molecule sensor technology to detect growth of bacterial populations by measuring volatile metabolites, and provides AST results in \~5 hours. Reveal™ is approved for clinical use in the European Union (EU) and Israel and approval is in process in India, and provides minimum inhibitory concentrations (MICs) for 28 antibiotics and 9 Gram negative species, that together account for \~90% of organisms causing Gram negative blood stream infections (BSI).
223708386|NCT06113003|DIETARY_SUPPLEMENT|Prebiotic|Wheat dextrin fiber
223708387|NCT06113003|DIETARY_SUPPLEMENT|Probiotic|Probiotic packet
223708388|NCT06195605|DEVICE|Restylane-L|Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
223708389|NCT06195605|DEVICE|Vehicle|Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
223708390|NCT05803785|DRUG|BBC1501|BBC1501 solution for Intravitreal injection
223708391|NCT04616248|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IT
223708392|NCT04616248|DRUG|Poly ICLC|Given IT
223708393|NCT04616248|RADIATION|Radiation Therapy|Undergo radiation therapy
223708394|NCT04616248|BIOLOGICAL|Recombinant Flt3 Ligand|Given IT
223708395|NCT04616248|DRUG|Pembrolizumab|Given IV
223708396|NCT04616248|DRUG|Tocilizumab|Given SC
223708397|NCT00550121|DRUG|vitamin C|
223708398|NCT00550121|DRUG|placebo|
223708399|NCT06025825|DRUG|Articaine Hydrochloride + Epinephrine|"Buccal infiltration anesthesia + palatal infiltration anesthesia (with articaine HCl) was applied for first group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction.~Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction."
223708400|NCT06025825|DRUG|Lidocaine Hydrochloride + Epinephrine|Buccal infiltration anesthesia + palatal infiltration anesthesia (with lidocaine HCl) was applied for second group Buccal infiltration anesthesia was applied and 5 minutes was waited before extraction for fourth group Buccal infiltration anesthesia was applied and 8 minutes was waited before extraction for sixth group
223708401|NCT05904912|DRUG|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
223708402|NCT05904912|DRUG|PENG-Bupivacaine|The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.
223708403|NCT05904912|DRUG|Local infiltration-Bupivacaine|Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
223708404|NCT00411528|DRUG|Patupilone|
223708405|NCT00411528|DRUG|prednisone|
223708406|NCT00411528|DRUG|docetaxel|
223708407|NCT01610531|OTHER|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
223708408|NCT01212458|DRUG|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
223708409|NCT01596478|BEHAVIORAL|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
223708410|NCT01596478|BEHAVIORAL|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
223708411|NCT01596478|BEHAVIORAL|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
223708412|NCT01065597|DEVICE|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
223708413|NCT02081287|DRUG|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
223708414|NCT02081287|DRUG|Lamotrigine|Dose up to 200 mg per day over 10 weeks
223708415|NCT00734175|BIOLOGICAL|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
224276115|NCT02102932|DRUG|500 mg metformin|500 mg metformin
224276116|NCT04518553|DRUG|active comarator using antiviral drug of nucleoside analogues|using antiviral drug of nucleoside analogues without additional active interference to control Hepatitis B virus.
224276117|NCT04518553|DEVICE|HA+purification|Based on antiviral drug of nucleoside analogues, plasma purification is added to control hepatitis B virus every three months. After three months, plasma purification will continue if hepatitis B virus DNA titer is still higher than cut-off normal value. plasma purification process lasts 2.5-3 hours each session.
224276118|NCT00982228|DRUG|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
223526669|NCT06627049|OTHER|Implementing facilitating strategies|Implement strategies to facilitate the integration of virtual reality into rehabilitation sessions.
223526670|NCT06627049|OTHER|Focus group|Evaluate the strategies used to facilitate VR implementation.
223526671|NCT06627049|OTHER|Interviews|Interviews to evaluate the facilitators and barriers to the use of virtual reality.
223526672|NCT06627049|OTHER|Interviews|Evaluate the strategies used to facilitate VR implementation.
223526673|NCT06571682|DEVICE|Target Controlled Infusion|TCI (Target Controlled Infusion) is a method used to maintain the dose and rate of anesthesia drugs within a target concentration range set by the anesthetist. This system delivers drugs intravenously to the patient using a computer-controlled pump. The anesthetist adjusts the drug concentration to achieve the desired depth of anesthesia. This method provides more precise control over anesthesia and facilitates maintaining the depth of anesthesia within the desired range.
223526674|NCT06571682|DRUG|Inhalation anesthetic|In the inhalation anesthesia group, maintenance sevoflurane anesthesia will be applied after routine induction.
223526675|NCT05861843|DIAGNOSTIC_TEST|Virtual Reality-based cue exposure paradigm|Virtual Reality (VR) cue exposure to alcohol-associated cues using head-mounted displays (HMD)
223526676|NCT04555759|OTHER|2-minute walk test|The patients will do a 2-minute walk test, using their walking aids or braces
223526677|NCT06116123|DEVICE|Massage mattress with cube/block system|Patients with an odd number were assigned to group I, while those with an even number were allocated to group II. Patients in group I were provided with a pressure sore prevention bed featuring a support surface with vibration (massage) capabilities, a cube/block system creating a low-pressure area, and a ventilation system, routinely utilized in the unit. For group II patients, a viscoelastic pressure sore prevention mattress with an orthopedic support surface, routinely employed in the unit, was used.Within the first six hours after admission, patients in both groups underwent initial assessments using the Braden Scale to determine their pressure sore risk. Both groups were monitored for a maximum of four weeks, with daily pressure ulcer assessments conducted using the Pressure Ulcer Observation Form. Pressure sore area in both groups was calculated in square centimeters (cm2) using the Wound Measurement Ruler.
223526678|NCT05425160|OTHER|Progressive lower limb activities (Chair rise and Step ups)|Progressive lower limb activities (Chair rise and Step ups) were be carried out weekly for upto 6 weeks. Before initiation, cardiopulmonary parameters i.e. Heart rate, oxygen saturation, cardiac output and stroke volume were measured at baseline and later at the termination of activity on each week. Initially, five repeated chair rise were conducted through SPPB and the time was noted to complete the task and step ups through 6MWD for a total period of 30 min. Lastly, fatigue component was assessed via FAS.
223526679|NCT05425160|OTHER|Standard aerobic exercise i.e. low intensity walking|Standard aerobic exercise i.e. low intensity walking were conducted in both the groups. Follow up phone calls and 1 OPD visit were scheduled accordingly
223526680|NCT02947984|RADIATION|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
223526681|NCT02947984|RADIATION|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
223526682|NCT03738917|DRUG|Dextromethorphan 15 milligrams|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
223526683|NCT03738917|DRUG|Ipratropium Bromide 20Micrograms Inhaler|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
223526684|NCT03738917|DIETARY_SUPPLEMENT|Honey 30 g (full tablespoon)|This study product will be provided free to the participants by the sponsor.
223526685|NCT03738917|OTHER|Usual clinical practice|Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
223526686|NCT04636632|DRUG|fosaprepitant|fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
223526687|NCT00247546|BEHAVIORAL|Multifactorial prevention|
223526688|NCT03174327|DIAGNOSTIC_TEST|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
223526689|NCT02649764|DRUG|Cytarabine|Given IV
223526690|NCT02649764|DRUG|Fludarabine Phosphate|Given IV
223526691|NCT02649764|OTHER|Laboratory Biomarker Analysis|Correlative studies
223526692|NCT02649764|DRUG|Prexasertib|Given IV
223526693|NCT03253081|BEHAVIORAL|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
223526694|NCT03253081|BEHAVIORAL|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
223526695|NCT05594875|DRUG|SHR-1921|Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
223526696|NCT05260242|OTHER|Disparities Conversation|The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
223526697|NCT04161482|DRUG|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
223526698|NCT05569317|OTHER|primary nursing|The primary responsibility of one nurse for the planning, evaluation, and care of a patient throughout the course of illness, convalescence, and recovery.
223526699|NCT02898688|BEHAVIORAL|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
223526700|NCT02898688|BEHAVIORAL|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
223526701|NCT02898688|BEHAVIORAL|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
223526702|NCT02898688|BEHAVIORAL|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
223526703|NCT02356237|OTHER|No episiotomy|Avoidance of episiotomy
223526704|NCT01444105|DEVICE|iStent|Implantation of two iStent devices
223526705|NCT01444105|OTHER|SLT|Laser treatment
223526706|NCT04243265|PROCEDURE|MPFL reconstruction with fascia lata allograft|Reconstruction of MPFL using a fascia lata allograft. The rationale for this technique is to stabilize the patella and limit medium to long-term patellofemoral arthritic degeneration by restoring the MPFL in the most anatomical way possible, not using a tubular graft but an aponeurosis with biomechanical characteristics similar to the native MPFL. The MPFL reconstruction can be used alone or in association with the realignment of the extensor apparatus by transposition of the anterior tibial tuberosity, managing to correct most of the recurrent patellofemoral instabilities. Only in very serious particular cases is it necessary to perform more invasive additional procedures with a more uncertain clinical result (such as Trocleoplasty).
223526707|NCT02332928|DRUG|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
223526708|NCT02332928|DRUG|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
223526709|NCT02491879|DRUG|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
223526710|NCT02491879|OTHER|Placebo|Placebo gel with a 2 g local use
223526711|NCT04484857|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
223526712|NCT00614224|BEHAVIORAL|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
223526713|NCT03855904|DEVICE|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
223526714|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
223526715|NCT03404882|BEHAVIORAL|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
223526716|NCT03404882|BEHAVIORAL|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
223526717|NCT01822925|DRUG|DA-9801 300mg|300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
223526718|NCT01822925|DRUG|DA-9801 600mg|600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
223526719|NCT01822925|DRUG|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
223526720|NCT01822925|DRUG|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
223526721|NCT02300545|DRUG|Pazopanib|
223526722|NCT01731782|DRUG|bupivacaine|
223526723|NCT01731782|DRUG|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
223526724|NCT02295462|OTHER|Person-centered Care|Medication Review + Person-centered Care
223526725|NCT02295462|OTHER|Optimised Treatment|Medication Review only
223526726|NCT05890209|DEVICE|Continuous Glucose Monitoring device|A small wearable transdermal sensor that tracks glucose levels in interstitial fluid by taking measurements at regular and frequent intervals throughout the day and night.
223526727|NCT04542681|DRUG|Placebo - 1st Cycle|Subjects will receive a single SQ injection of placebo/normal saline
223526728|NCT04542681|DRUG|MANP - 1st Cycle|Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
223526729|NCT04542681|DRUG|MANP - 2nd Cycle|Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
223526730|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(RESTORE DEB）|
223526731|NCT02944890|DEVICE|Drug Eluting Balloon Catheters(SeQuent® Please）|
223526732|NCT02476227|PROCEDURE|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
223526733|NCT06412887|DEVICE|Virtual reality headset|Meta-Quest 2 virtual reality headset was used in this study
223526734|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
223526735|NCT03044145|BEHAVIORAL|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
223526736|NCT03044145|BEHAVIORAL|Treatment as usual|Standard mental health treatment at FHMC
223526737|NCT02196532|DEVICE|Device: Optical coherence tomography|
223526738|NCT05870345|DEVICE|Butterfly IQ|Butterfly IQ is a pocket sized ultrasound device. Each participant will undergo a ultrasound exam of both elbows using a pocket sized ultrasound device.
223526739|NCT04585178|DEVICE|Biobeat patch|"The Biobeat device (BB-613WP) is a class IIa medical device and is a non-invasive patch used for monitoring vital signs in clinical and non-clinical settings. The sensor continuously records the photoplethysmographic waveform that allows the calculation of several physiological parameters: heart rate (HR), SPO2, systolic blood pressure (SBP) and change in SBP, diastolic blood pressure (DBP) and change in DBP, stroke volume (SV), cardiac output (CO), cardiac index (CI), systemic vascular resistance (SVR), and respiration rate (RR).~Translated with www.DeepL.com/Translator (free version)"
223526740|NCT05291910|DRUG|Inetetamab|Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
223526741|NCT05291910|DRUG|Toripalimab|240mg intravenously every 3 weeks
223526742|NCT05291910|DRUG|Albumin-Bound Paclitaxel|130mg/m2, IV , D1, D8, q3w
223526743|NCT03551093|DEVICE|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
223526744|NCT02089204|RADIATION|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
223526745|NCT02089204|RADIATION|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
223526746|NCT02089204|RADIATION|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
223526747|NCT02937571|DRUG|Carfilzomib|
223526748|NCT02937571|DRUG|Lenalidomide|
223526749|NCT02937571|DRUG|Dexamethasone|
223526750|NCT06236646|OTHER|Thai dance with twenty-five squares (TDT)|The participants received a Thai dance with twenty-five squares (TDT) program 3 days/week, 12 weeks. This training comprises 10 minutes of warm up, following by 40 minutes of exercise at 40-50% of heart rate reserve at week 1-4, 50-60% of heart rate reserve at week 5-8, and 60-70% of heart rate reserve at week 9-12, 5 minutes of cool down.
223526751|NCT06236646|OTHER|Control (CON)|The CON group did not have any intervention but usual care.
223526752|NCT05384483|DRUG|Cariprazine|Cariprazine 1.5 to 3 mg per day
223526753|NCT05384483|DRUG|Placebo|Matching placebo
223526754|NCT04617860|DRUG|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
223526755|NCT05533840|DIAGNOSTIC_TEST|ultra-high-resolution computed tomography exams|Participants in the age groups undergo ultra-high-resolution computed tomography exam
223526756|NCT05819957|OTHER|Therapeutic Education Program (TEP)|the TEP lasts 12 months, being structured into 6 modules.
223526757|NCT00009178|DRUG|Fluoxetine|
223526758|NCT00009178|BEHAVIORAL|Guided Self-Help|
223526759|NCT00453492|DRUG|risedronate sodium|
223526760|NCT01505088|DRUG|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
223526761|NCT01505088|DRUG|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
223526762|NCT01505088|DRUG|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
223526763|NCT01505088|DRUG|Placebo Eyedrops|Placebo Eyedrops
223526764|NCT01055028|DRUG|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
223526765|NCT01055028|DRUG|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
223708416|NCT05075460|DRUG|Tucidinostat, Azacitidine combined with CHOP|"Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.~CHOP chemotherapy:~* Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;~* Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;~* Vinoresin (VDS) 4mg intravenous infusion, day 1;~* Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment"
223708417|NCT03947892|DIAGNOSTIC_TEST|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
223708418|NCT00397345|BIOLOGICAL|Trovax|1ml IM injection 2-8 weeks apart.
223708419|NCT00397345|BIOLOGICAL|Placebo|Placebo
223708420|NCT00397345|BIOLOGICAL|Standard of care therapy|subcutaneous low dose IL-2, interferon-α or sunitinib
223708421|NCT02985372|DRUG|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
223708422|NCT02985372|DRUG|Cytarabine|
223708423|NCT03875404|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
223708424|NCT03725137|OTHER|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding the development of cognitive function after stroke
223708425|NCT01284101|DEVICE|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
223708426|NCT01284101|DEVICE|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
223708427|NCT01685944|DIETARY_SUPPLEMENT|Live Pediococcus pentosaceus LP28|
223708428|NCT01685944|DIETARY_SUPPLEMENT|Heat-killed Pediococcus pentosaceus LP28|
223708429|NCT01685944|DIETARY_SUPPLEMENT|Placebo|
223708430|NCT04067882|OTHER|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
223708431|NCT01197261|DRUG|Oxycodone naloxone prolonged release tablets|2 tablets/ day
223708432|NCT01197261|DRUG|Placebo tablets|2 tablets/ day
223708433|NCT05013489|BEHAVIORAL|Mindfulness and intercare based intervention|"Eight week online program based on mindfulness, compassion and intercare intervention. A two hour synchronic online session every week plus daily homework based on meditation and journaling exercises.~The topics covered in the program are mindfulness meditation, cognitive behavioral therapy exercises, gratitude and acceptance, compassion and self compassion exercises, conservation of resources theory and intercare."
223708434|NCT01319890|PROCEDURE|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
223708435|NCT01597960|OTHER|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
223708436|NCT04526431|DRUG|Dosage Forms Oral|Dosage form of tacrolimus (extended release tacrolimus or immediate release tacrolimus)
223708437|NCT04099147|OTHER|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
223708438|NCT02898883|BEHAVIORAL|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
223708439|NCT01116115|OTHER|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
223708440|NCT01116115|OTHER|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
223708441|NCT02000479|OTHER|training|
223708442|NCT01417442|GENETIC|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
223708443|NCT05738954|OTHER|Ultrasound|"Collect patient data, anonymize and label it. Written informed consent or verbal recorded consent (if the participant lacks the ability to write or sign) will be obtained before performing the MS. In the unlikely event that some of the participants will withdraw their consent after the ultrasound has been performed, the data collected will not be used in the project. Data for publications and dataset will be previously made anonymous following standard practices. The participants will sign a GDPR form.~The DL/SL algorithms will work in a competitive/collaborative way. Following the 'no-free-lunch' theorem, we shall use the competitive phase to establish the most suitable DL/SL technique for the identification and anomaly detection of each organ, and the collaborative phase to make all the algorithms work together in providing a 'second' opinion."
223708444|NCT00999232|DRUG|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
223708445|NCT00999232|DRUG|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
223708446|NCT01457573|DRUG|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
223708447|NCT01457573|DRUG|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
223708448|NCT02332668|BIOLOGICAL|Pembrolizumab|IV infusion
223708449|NCT05962346|DEVICE|BALT GOLDBALL 2 detachable latex ballon|Inflated with fluid in the fetal trachea and provide with the occlusion necessary to promote lung growth.
223708450|NCT05962346|DEVICE|BALTACCIBDPE100 Microcatheter|Used to deliver the detachable balloon
224276119|NCT00982228|DRUG|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
223526766|NCT05769114|PROCEDURE|Surgical stabilization|Anterior-posterior stabilization (360°) with pedicle screws and an expandable cage
223526767|NCT04755647|DRUG|Nitric Oxide-Releasing Solution|Active antimicrobial
223526768|NCT04755647|DRUG|Saline solution, hypotonic|Placebo
223526769|NCT03586531|PROCEDURE|renal biopsy|Renal biopsy samples will be obtained by a percutaneous method using a spring-loaded Trucut® biopsy needle under real time ultrasound guidance. Biopsy samples will be processed for light microscopy with special staining will be done: Schiff periodic acid, Masson trichrome and methenamine silver.and immunofluorescence studies to evaluate IgA, IgG, IgM, complement C1q and C3, fibrin, and kappa and lambda light chain deposits.
223526770|NCT00173719|DEVICE|Standard cane|
223526771|NCT01349478|DEVICE|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
223526772|NCT05181345|OTHER|Sleep recording (at home)|Before both heat exposures, the sleep-wake rhythm will be measured at home for 7 days using actigraphy and a sleep diary that will have been given to him/her during the inclusion visit.
223526773|NCT05181345|OTHER|Heat exposure|"The subjects will be exposed twice (2 different visits) to heat (45°C; 60-70% humidity rate) for 3 hours in a climate chamber.~The subjects will be equipped with various external sensors allowing the continuous recording of core temperature, mean skin temperature (9 skin measurement points), heart rate, cerebral electrical activity, cerebral oxygenation, skin vascular conductance (blood flow by laser-doppler), blood pressure and skin conductance.~Neurophysiological and cognitive exploration (NPCE) includes the Stroop test, the Psychomotor Vigilance Task (PVT) and the odd-ball test."
223526774|NCT05181345|OTHER|Normal sleep|"The night before one of the two heat exposures (first visit for the Normal sleep first group and second visit for the Reduced sleep first group), the participants will have a normal night at home. The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
223526775|NCT05181345|OTHER|Sleep restriction|"The night before one of the two heat exposures (first visit for the Reduced sleep first group and second visit for the Normal sleep first group), the participants' sleep will be restricted. The sleep restriction will correspond to a reduced sleep period with a bedtime of 3 hours (04:00 - 07:00). This night of sleep restriction will be carried out in a sleep apartment (at the lab). The duration and quality of sleep will be measured using a connected headband (Dreem®) allowing for polysomnography."
223526776|NCT04871620|DIAGNOSTIC_TEST|>15% SV increase during fluid challenge|The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
223526777|NCT01868412|DEVICE|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
223526778|NCT01868412|DEVICE|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
223526779|NCT00285051|DRUG|inhaled delta-8-THC 300mcg or 600mcg per dose|"drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC"
223526780|NCT02806661|PROCEDURE|Vagus nerve-preserving Robot-assisted Gastrectomy|
223526781|NCT02806661|PROCEDURE|Conventional Robot-assisted Gastrectomy|
223526782|NCT00000628|DRUG|L-697,661|
223526783|NCT00000628|DRUG|Zidovudine|
223526784|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 12|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
223526785|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 3|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
223526786|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 6|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
223526787|NCT06582732|DRUG|Travoprost Intracameral Implant exchanged at Month 24|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24
223526788|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 21|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21
223526789|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 18|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18
223526790|NCT06582732|DRUG|Travoprost intracameral implant exchanged at Month 15|intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15
223526791|NCT04670809|DRUG|Clevidipine Butyrate Injection|Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
223526792|NCT04670809|DRUG|Ncardipine Hydrochloride Injection|Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
223708451|NCT05962346|DEVICE|Storz fetoscopic operating sheath and miniature telescope/fetoscope|Used to percutaneously enter though the maternal abdominal wall, uterus and into the amniotic cavity, fetal mouth, pharynx, larynx, into the trachea where the delivery catheter will be used to deliver the detachable balloon that will provide with the tracheal occlusion.
223708452|NCT03285984|OTHER|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
223708453|NCT03285984|OTHER|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
223708454|NCT03285984|OTHER|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
223708455|NCT03285984|OTHER|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
223708456|NCT00413244|DRUG|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
223708457|NCT00413244|DRUG|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
223708458|NCT00136123|PROCEDURE|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
223708459|NCT03821909|PROCEDURE|Endoscopic ultrasound-guided protal venous blood sampling|We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
223708460|NCT05373277|DRUG|Placebo|one tablet of placebo twice daily for two days
223708461|NCT05373277|DRUG|Ticagrelor|Intervention Description: 90 mg tablet twice daily for two days
223708462|NCT05373277|DRUG|Rosuvastatin|10 mg tablet, single dose
223708463|NCT00446251|DRUG|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
223708464|NCT00446251|DRUG|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
223708465|NCT00770939|DEVICE|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
223708466|NCT04474158|BEHAVIORAL|Creating Peace|Creating Peace is a 12 session curriculum designed to support youth ages 14-19 in healing from experiences of trauma by restoring social connections, strengthening positive coping strategies that exclude all forms of violence, challenging gender norms that foster violence perpetration, and practicing positive bystander intervention skills to intervene safely with peers' disrespectful and harmful behaviors. Through 12 sessions (3 hours/session) over a 4 to 12 week period, Creating Peace offers gender transformative content combined with youth leadership development. Near program conclusion, youth will offer guidance to law enforcement on interacting with youth in a process of social restoration.
223708467|NCT04474158|BEHAVIORAL|Job Readiness|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
223708468|NCT01021722|PROCEDURE|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
223708469|NCT04083196|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
223708470|NCT04083196|BIOLOGICAL|Placebo|Placebo
223708471|NCT05916027|BEHAVIORAL|The 15-Method|The 15-Method is a Screening and Brief Intervention method for identifying and treating alcohol problems in primary care. The method combines evidence-based approaches from specialized addiction treatment with screening and readily available treatment options in general practice to help identify and treat alcohol problems. The 15-method is based on Motivational Interviewing, Cognitive Behavioral Therapy and utilizes the Alcohol Use Disorder Identification Test (AUDIT) as a screening tool. The 15-Method contains three flexible steps: Identification of clinical problem related to alcohol; feedback and clinical work-up as needed; treatment. Treatment includes structured consultations (maximum of four) with patient home-work assignments, and can be combined with pharmacological treatment for alcohol problems.
223708472|NCT03185871|DRUG|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
223708473|NCT03694587|DRUG|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
223708474|NCT03694587|DRUG|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
223708475|NCT00203073|DRUG|glatiramer acetate 20 mg|glatiramer acetate 20 mg
223708476|NCT00203073|DRUG|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
224276120|NCT00982228|DRUG|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
224276121|NCT06016153|OTHER|Software based feedback|Feedback is given by the data of a software (InnoMed CardioAid-1 Trainer AED, Innomed Inc., Budapest, Hungary).
224276122|NCT06016153|OTHER|Instructor feedback|Feedback is given by the opinion and observation of an experienced instructor.
224276123|NCT02250651|DRUG|Bimatoprost SR|Bimatoprost SR administered in the study eye on Day 1, Week 16, and Week 32.
224276124|NCT02250651|OTHER|Sham: Applicator Without Needle|Sham administered on Day 1, Week 16, and Week 32.
224276125|NCT02250651|DRUG|Active Comparator: Timolol 0.5%|Timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
224276126|NCT02250651|DRUG|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months.
223526793|NCT06121752|PROCEDURE|Endoscopic submucosal dissection|Endoscopic resection is recommended for the management of small DNETs measuring ≤10 mm. Various endoscopic techniques have been utilized for the resection of DNETs including endoscopic mucosal resection (EMR), band ligation assisted EMR, endoscopic submucosal dissection (ESD). However, the published studies report a high rate of histologically incomplete resection even with ESD. More recently, device assisted endoscopic full thickness resection (EFTR) has emerged as a safe and effective resection modality in cases with upper and lower gastrointestinal (GI) mucosal as well as submucosal lesions. There is limited data on the outcomes of EFTR in cases with DNETs.
223526794|NCT06121752|DEVICE|EFTR|"Initially, the lesion will be marked circumferentially using the FTRD probe available with the device (Forced Coag, E1, 20W). Subsequently, wire guided balloon dilatation of the pyloric channel will be performed.~The device will be mounted over a therapeutic channel gastroscope and negotiated across the cricopharynx over the guidewire with or without assistance of dilating balloon available with the device.~After reaching the target site, the lesion will be pulled withing the FTRD cap with the help of grasping forceps and gentle suctioning.~The clip will be fired after ensuring the entry of the lesion inside the cap, the premounted snare closed and electrocautery activated to cut the grasped tissue (HighCut 200W, Effect 4)."
223526795|NCT06464770|DRUG|Chlorhexidine Gluconate|Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
223526796|NCT05882370|DRUG|Cadonilimab|Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
223526797|NCT05882370|PROCEDURE|transjugular intrahepatic portosystemic shunt (TIPS)|transjugular intrahepatic portosystemic shunt (TIPS)
223526798|NCT03763630|DRUG|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
223526799|NCT03763630|DRUG|Normal saline|Normal saline administered in same frequency and manner as intervention
223526800|NCT02800733|DIETARY_SUPPLEMENT|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
223526801|NCT02800733|DIETARY_SUPPLEMENT|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
223526802|NCT01182350|DRUG|Bevacizumab|
224276127|NCT04913545|DIAGNOSTIC_TEST|using salivary miRNA (412,512)|quantitative real time polymerase chain reaction to detect the salivary miRNAs 412,512) to indicate the malignant transformation in potientially malignant oral lesions.
224276128|NCT06458751|OTHER|electrophysiological study|Antidromic sensory nerve conduction studies of median and ulnar nerves will be performed on both hands of 30 healthy subjects with no history of previous neuromuscular disease and no abnormalities on neurological examination., by using surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
223526803|NCT01182350|DRUG|Erlotinib|
223526804|NCT01182350|DRUG|Temozolomide|
223526805|NCT01182350|RADIATION|Radiation|
223526806|NCT05987137|OTHER|No intervention is being administered.|No intervention is being administered.
223526807|NCT04002375|OTHER|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
223526808|NCT03898180|BIOLOGICAL|Pembrolizumab|IV infusion
223526809|NCT03898180|DRUG|Lenvatinib|oral capsule
223526810|NCT03898180|DRUG|Placebo for lenvatinib|oral capsule
223526811|NCT02472249|RADIATION|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
223526812|NCT02472249|DRUG|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds..
223526813|NCT02423486|DEVICE|Electromagnetic stimulation therapy (BIOCON-2000)|
223526814|NCT02423486|DEVICE|Electromagnetic stimulation therapy with biofeedback|
223526815|NCT06130540|DRUG|Secukinumab|Intravenous (i.v.) doses of Secukinumab at Week 0, Week 4 and Week 8
223526816|NCT05147220|DRUG|Remibrutinib|tablet taken orally
223526817|NCT05147220|DRUG|Teriflunomide|capsule taken orally
223526818|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
223526819|NCT03618381|BIOLOGICAL|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
223526820|NCT02507934|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
223526821|NCT02507934|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
223526822|NCT05463133|DRUG|Sirolimus|Post transplant drug - Immunosuppressant to prevent donor peripheral blood stem cell rejection and graft versus host disease. This is a well studied drug, and is not under an IND.
223708477|NCT00046878|DRUG|O6-benzylguanine|
223708478|NCT00046878|DRUG|carmustine|
223708479|NCT00408460|DRUG|imatinib mesylate|Given PO
223708480|NCT00408460|DRUG|paclitaxel|Given IV
223708481|NCT04125888|DRUG|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
223708482|NCT06009692|OTHER|Upper limb Neuro-dynamics (Slider/ Tensioner Technique)|The experimental group will receive neuro-dynamic mobilization techniques along with task oriented training. Slider versus tensioner technique will be applied according to each patient's need. Session time will be 25-30 minutes. Four series of 10 tensioning movements at a rhythm of ∼6s per cycle and 1 min rest between each series will be performed. After each cycle of 10 repetitions, the position will hold for 10s.
223708483|NCT06009692|OTHER|Conventional Therapy for Upper limb|Conventional treatment will include therapeutic ultrasound for 4 min, TENS for 10 min. Task oriented training will be designed according to patient's functional outcomes. Sessions will be given for 6 days a week, 25-30 minutes per day.
223708484|NCT06558461|DRUG|3% Sodium Chloride|4ml nebulized three times daily
223708485|NCT06558461|OTHER|Standard care|Standard care
223708486|NCT00311844|DRUG|desloratadine|
223708487|NCT06362577|DIAGNOSTIC_TEST|EQ-5D-5L IPSS IIEF-5 EPIC-26 ECOG|Diagnostic Test were collected at before surgery, during surgery,2 months, 6 months, 9 months, 12 months, 18 months and 24 months after radical surgery
223708488|NCT02264639|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
223708489|NCT00003661|BIOLOGICAL|anti-thymocyte globulin|
223708490|NCT00003661|DRUG|busulfan|
223708491|NCT00003661|DRUG|cyclosporine|
223708492|NCT00003661|DRUG|melphalan|
223708493|NCT00003661|DRUG|methylprednisolone|
223708494|NCT00003661|PROCEDURE|umbilical cord blood transplantation|
223708495|NCT00003661|RADIATION|radiation therapy|
223708496|NCT04188587|DRUG|177 Lu-PSMA-I&T|All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
223708497|NCT01058655|DRUG|Everolimus|
224276129|NCT06458751|DEVICE|electromyograph|surface electrical stimulation at wrist and surface digital recording electrodes on both sides of D4.
223708498|NCT01058655|DRUG|Tivozanib|
223708499|NCT05617950|OTHER|salicylic acid|Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.
223708500|NCT05617950|OTHER|cryotherapy|Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
223708501|NCT04472429|DRUG|carboplatin|carboplatin will be administered intravenous on Day 1 of each 28 day cycle
223708502|NCT04472429|DRUG|paclitaxel|paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle
223708503|NCT04472429|DRUG|retifanlimab|retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
223708504|NCT02154074|DRUG|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
223708505|NCT02154074|DRUG|Isoflurane|inhale Isoflurane 1.5MAC
223708506|NCT02154074|DRUG|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
223708507|NCT02154074|DRUG|normal saline|the same volume of saline + Isoflurane during operation
223708508|NCT01477593|PROCEDURE|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
223708509|NCT01477593|PROCEDURE|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
223708510|NCT01477593|PROCEDURE|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
223708511|NCT04759573|BEHAVIORAL|Early Vocal Contact|Mothers will be asked to speak and sing to their infants continuously over a 10-min period for each type of intervention (20 min in total). Mothers will be asked to talk in their native language and to sing familiar songs, while observing their infant's reactions. The order of the two vocalizations, speaking and singing, will be reversed in the next intervention.
223708512|NCT04759573|BEHAVIORAL|Behavioral Observation|Mothers in the active control group will be encouraged to spend the same amount of time next to the incubator, observing the infant's behaviours through a standard cluster of indicators.
223708513|NCT03917238|RADIATION|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
223708514|NCT01172522|DRUG|Fexofenadine|Fexofenadine 1%
223708515|NCT01172522|DRUG|Placebo|Placebo
223708516|NCT00927602|DRUG|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
223708517|NCT01902199|BEHAVIORAL|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
223708518|NCT01416272|DEVICE|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
223708519|NCT03295084|DRUG|Irinotecan|Dose Escalation
223708520|NCT03295084|DRUG|Capecitabine|Dose Escalation
223708521|NCT00913172|OTHER|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
223708522|NCT04258163|DRUG|Capecitabine|1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
223708523|NCT04258163|DRUG|Liposomal doxorubicin|50 mg/m 2 IV day 1, cycled every 28 days
223708524|NCT04258163|DRUG|Gemcitabine|800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
223708525|NCT04258163|DRUG|Fulvestrant|500mg IH Days 0, 14, 28, then every 28 days
223708526|NCT04258163|DRUG|Anastrozole|1mg PO qd
223708527|NCT04258163|DRUG|Letrozole|2.5mg PO qd
223708528|NCT05968339|OTHER|Survey|"The survey will be distributed via scientific anesthesiology societies and will be open for a total of 12 consecutive months.~Participation in the survey will be voluntary and anonymous - individual consent will be implied by willingness to complete the survey.~The survey will be conducted via SurveyMonkey. SurveyMonkey allows Health Insurance Portability and Accountability Act (HIPAA)(12) compliant surveys to be created. These follow strict rules around the protection of health information. Of note, SurveyMonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored. Access to the database will be password protected and only the authors will have access for the purpose of data analysis at the end of the survey period. Analysis using chi squared tests and logistic regressions will be performed by trained statisticians."
223708529|NCT01095055|BIOLOGICAL|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly
223708530|NCT01095055|BIOLOGICAL|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
223708531|NCT06058702|DRUG|Delta-9-THC Very Low Dose|Active Delta-9-THC administered intravenously over 20 minutes.
223708532|NCT06058702|DRUG|Placebo|Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
223708533|NCT06058702|DRUG|Delta-9-THC Medium Dose|Active Delta-9-THC administered intravenously over 20 minutes.
223708534|NCT06180720|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
223708535|NCT06180720|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
223708536|NCT05938491|DIAGNOSTIC_TEST|OCT and OCT-A|OCT and OCT angiography for the macula
223708537|NCT03195764|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
223708538|NCT05036759|DRUG|68Ga-FAPI|intravenously injected with 68Ga-FAPI
223708539|NCT02319837|DRUG|Enzalutamide|
223708540|NCT02319837|DRUG|Placebo (No longer applicable in Open Label study period)|Sugar pill to mimic enzalutamide
223708541|NCT02319837|DRUG|Leuprolide Open Label|
223708542|NCT04741607|DEVICE|Implant placement (BLX implant system, Straumann, Basel, Switzerland)|Implants are placed after a healing period of 4 months (delayed implant placement, control group) or immediately after tooth extraction and ridge preservation (immediate implant placement, test group).
223708543|NCT04741607|PROCEDURE|Ridge preservation (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland)|Ridge preservation is performed by inserting a collagen-enriched DBBM (Bio-Oss Collagen 250 mg, Geistlich Pharma AG, Wolhusen, Switserland) in the empty extraction socket (delayed implant placement, control group) or by filling the gap between the implant and buccal bone wall (immediate implant placement, test group).
223708544|NCT04741607|PROCEDURE|Socket seal (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switserland)|The occlusal aspect of the grafted socket in the delayed implant placement/control group is closed with a collagen matrix.
223708545|NCT00003052|DRUG|doxorubicin hydrochloride|
223708546|NCT00003052|DRUG|etoposide|
223708547|NCT00003052|DRUG|ifosfamide|
223708548|NCT00003052|PROCEDURE|conventional surgery|
223708549|NCT00003052|PROCEDURE|hyperthermia treatment|
223708550|NCT00003052|RADIATION|radiation therapy|
223708551|NCT05767320|PROCEDURE|open repair(exploration)|repair of defect of perforated peptic ulcer and peritoneal decontamination by exploration
223708552|NCT05767320|PROCEDURE|abdominal laparoscopy|repair of defect of perforated peptic ulcer and peritoneal decontamination by laparoscopy
224276130|NCT03496298|DRUG|Efpeglenatide (SAR439977)|"Pharmaceutical form: Solution for injection,~Route of administration: SC"
223708553|NCT01790776|RADIATION|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
223708554|NCT01790776|RADIATION|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
223708555|NCT00810472|OTHER|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial \[8\]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method \[6\]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
223708556|NCT00810472|PROCEDURE|Penetrating keratoplasty|Corneal transplantation.
223708557|NCT03865771|BEHAVIORAL|Neuropsychological testing|memory, executive testing, behaviour questionnaire, visual attention,
223708558|NCT03865771|BEHAVIORAL|Neuropsychological procedure|Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
223708559|NCT03865771|OTHER|Video EEG and polysomnography|Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
223708560|NCT00620347|DRUG|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
223708561|NCT06481839|OTHER|Starting dose of NE|Patients will be randomized to either low-dose (5mcg/min) or high-dose (15mcg/min) norepinephrine (NE) for their first vasopressor in shock.
223708562|NCT02872207|DRUG|BAY 987516 (Y65-122)|5 µL in one eye
223708563|NCT02872207|DRUG|BAY 987516 (Y65-118)|5 µL in one eye
223708564|NCT02872207|DRUG|Control|5 uL in other eye
223708565|NCT05191173|PROCEDURE|Cardiac Surgery|No intervention, just observation is performed.
223708566|NCT03422042|OTHER|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
223708567|NCT03422042|OTHER|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
223708568|NCT04709354|DIAGNOSTIC_TEST|Dermoscopic examination|The periungual area, nail plate, subungual area of the patients' fingernails will be examined and images of the lesional nails or target nails will be recorded for comparison.
223708569|NCT02438657|PROCEDURE|median nerve block|
223708570|NCT03264313|DEVICE|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
223708571|NCT00294801|DRUG|flex-a-new (food supplement)|
223708572|NCT03011619|BEHAVIORAL|Usual Standard of Care|medication management, group therapy, and individual therapy.
223708573|NCT03011619|BEHAVIORAL|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
223708574|NCT01440452|DEVICE|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
223708575|NCT01440452|DEVICE|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
223708576|NCT01440452|PROCEDURE|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
223708577|NCT01440452|BEHAVIORAL|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
223708578|NCT01689168|BEHAVIORAL|Counseling|Tobacco cessation counseling
223708579|NCT01689168|PROCEDURE|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
223708580|NCT05693883|OTHER|Pilates training|Subject participating in 60-min sessions for 10 weeks and Each session consisted of a 10-min warm up (Breathing, Imprint \& release, Hip release, Spine rotation, Hip rolls, Scapula isolation, Arm circle, Elevation \& depression scapulae, Head nod, Cat stretch), Pilates program 40-min (Toe tap, Ad prep, Breast stroke preps, Heel squeeze prone, Side leg lift, Single leg extension, One leg circle, Shoulder bridge prep, Four point, kneeling, Spine twist, Hundred prep, Roll up prep, shoulder bridge prep2, Breast stroke, Swimming, Half roll back) and 10-min cool down (Spine stretch forward, Shell stretch, Side bending, Cat stretch, Roll down)
223708581|NCT04545554|DRUG|Romosozumab|Participants will receive multiple doses of romosozumab via a SC injection.
223708582|NCT04545554|DIETARY_SUPPLEMENT|Calcium|All participants will receive daily supplements of elemental calcium.
223708583|NCT04545554|DIETARY_SUPPLEMENT|Vitamin D|All participants will receive daily supplementation with vitamin D.
223708584|NCT05623839|DRUG|LY3305677|Administered SC
223708585|NCT05623839|DRUG|Placebo|Administered SC
223708586|NCT01313312|BIOLOGICAL|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
223708587|NCT00563355|DRUG|erythropoietin|
223708588|NCT03890315|DIAGNOSTIC_TEST|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
223708589|NCT00671333|PROCEDURE|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
223708590|NCT00671333|PROCEDURE|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
223708591|NCT00299351|DRUG|Depsipeptide|
223708592|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
223708593|NCT00975325|DRUG|Yohimbine|yohimbine 5 mg, one tablet, single dose only
223708594|NCT05763212|OTHER|Reverse Walking+Baseline treatment|Reverse Walking+Baseline treatment
223708595|NCT05763212|OTHER|Whole Body Vibration + Reverse Walking+Baseline treatment|Whole Body Vibration + Reverse Walking+Baseline treatment
223708596|NCT03427671|DEVICE|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
223708597|NCT05613400|DRUG|Simvastatin 10mg|One simvastatin 10mg-tablet
223708598|NCT05613400|DRUG|Ezetimibe 10mg|One ezetimibe 10mg-tablet
223708599|NCT00004307|BEHAVIORAL|Protein and calorie controlled diet|
223708600|NCT00004307|GENETIC|Ornithine transcarbamylase vector|
223708601|NCT04859673|DEVICE|radial extracorpeal shock wave|Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
223708602|NCT06043726|DIAGNOSTIC_TEST|Laboratory testing: D-dimeer and astrup|Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
223708603|NCT03041987|OTHER|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
223708604|NCT04853030|DRUG|Fiasp|Advanced closed-loop insulin therapy with Faster acting insulin Aspart (Fiasp)
223708605|NCT04853030|DRUG|Novorapid|Advanced closed-loop insulin therapy with Standard acting insulin Aspart (Novorapid
223708606|NCT00660673|DRUG|Levodopa-Carbidopa Intestinal Gel (LCIG)|LCIG for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa (5 mg/mL) in an aqueous gel that is dispensed in a medication cassette reservoir containing 100 mL of LCIG.
223708607|NCT00660673|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|Portable infusion pump (CADD-Legacy Pump Model 1400) connected to the LCIG medication cassette reservoir.
223708608|NCT00660673|DEVICE|Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)|All participants previously had a PEG-J placed in one of the prior LCIG studies.
223708609|NCT05534685|OTHER|intratracheal administration of surfactant/budesonide|328 patients will be included from Group A: 164 patients, from Group B: 164 patients who meet the selection criteria within the first 4 hours of hospital stay, after the authorization of the parents or guardian signing the informed consent. According to the assigned group, the preparation of surfactant or surfactant/budesonide in the syringe will be carried out, prior to performing the tracheal cannulation procedure. Group A will be given surfactant (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) at a dose of 100mg/kg or 4ml/kg and budesonide (budesonide, nebulized suspension 2ml contains 0.500mg) at a dose of 0.250 mg/kg or 1 ml/kg. Group B will receive surfactant alone (beractant, lung phospholipids of bovine origin. Injectable suspension 1ml contains 25mg) administered at a dose of 100mg/kg or 4ml/kg.
223708610|NCT05534685|OTHER|incidence of bronchopulmonary dysplasia|. Subsequently, follow-up will be carried out at 12 hours to assess the administration of the second dose of surfactant, type of mechanical ventilation, inspired fraction of oxygen (Fi02), arterial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2 ), mean airway pressure (PMVA), oxygen index (IO), oxygen saturation by pulse oximetry, weekly follow-up of the patient will continue for 28 days, evaluating the same parameters to make a diagnosis of bronchopulmonary dysplasia and finally at 36 postmenstrual weeks of gestation in those under 32 SDG or at discharge and at 56 postmenstrual days of life in those over 32 SDG or at discharge, allowing the severity of the disease to be determined
223708611|NCT03884959|BIOLOGICAL|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
223708612|NCT03023787|DRUG|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
223708613|NCT03023787|DRUG|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
223708614|NCT02808793|DRUG|AK002|
223708615|NCT04730687|DEVICE|Traditional non surgical mechanical therapy|Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).
223708616|NCT04730687|DEVICE|Diode laser assisted non-surgical mechancal therapy|One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).
223708617|NCT04730687|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.
223708618|NCT06114225|COMBINATION_PRODUCT|metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy|participants first receive concurrent SBRT and penpulimab (PD-1 blockade) and two cycles of GP regimen (gemcitabine d1,d8 and Penpulimab d8 per a 21-day cycle), followed by complete pulmonary metastasectomy. After surgery, participant receive another 4 cycles of GP regimens followed by Penpulimab monotherapy maintenance. The rationale is that pre-operative SBRT could boost the immune microenvironment, leading to a long-term effect of immunotherapy post-metastasectomy and eventually resulting in better long-term survivorship compared to the histological control for pulmonary resectable recurrence of osteosarcoma .
224276131|NCT03496298|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: SC"
223708619|NCT00627185|BEHAVIORAL|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
223708620|NCT00627185|OTHER|No intervention arm|
223526823|NCT05463133|DRUG|Cyclophosphamide|Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
223526824|NCT05463133|DRUG|Alemtuzumab|Transplant Conditioning Drug - Monoclonal antibody that targets recipient and donor T-cells to prevent graft versus host disease. Not an IND. This is a well-studied drug, and is not under an IND.
223526825|NCT05463133|DRUG|Busulfan|Transplant Conditioning Drug - Chemotherapy to create space in the patient's bone marrow so that the donor peripheral blood stem cells can repopulate in the patient's bone marrow. This is a well studied drug, and is not under IND.
223526826|NCT05463133|BIOLOGICAL|Pheripheral blood stem cells|Donor peripheral blood stem cells either matched unrelated donors or matched related relative to replace the patient's immune cells with functional immune cells. The peripheral blood stem cells are not regulated by the FDA.
223526827|NCT05463133|DRUG|Emapalumab-Izsg|Transplant conditioning drug for High Risk Group only - An interferon gamma blocking antibody used to prevent inflammation/engraftment syndrome post HSC transplant.
223526828|NCT05463133|DRUG|Tociluzumab|Transplant Conditioning Drug - An interleukin-6 (IL-6) receptor antagonist used to decrease Chronic Granulomatous Disease (CGD) inflammation during the HSC transplant process.
223526829|NCT05463133|DRUG|Total Body Irradiation|Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
223526830|NCT05719246|BEHAVIORAL|Yoga|The yoga video set that the participants will follow is a brief, at-home, 6-week twice per week Standardized Yoga \& Meditation Program for Stress Reduction (SYMPro-SR) program. The videos feature Sydney Topfer guiding the participants through different yoga poses.
223526831|NCT05368883|OTHER|Exercise- One-Legged|The exercise program consisted of a 5-minute warm-up, followed by 10 minutes of cycling for each leg during the first 2 weeks, increasing to 15 minutes for each leg in the subsequent weeks (with a 5-10 minute rest period between switching legs), and concluded with a 5-minute cool-down period. During the exercise, the inactive leg was kept stationary and in contact with the ground . In the one-legged cycling exercise training, whether patients started with the dominant or non-dominant leg was determined randomly
223526832|NCT05368883|OTHER|Exercise-Two-Legged|The exercise program consisted of a 5-minute warm-up, followed by 20 minutes of cycling during the first 2 weeks, increasing to 30 minutes in the subsequent weeks, and concluded with a 5-minute cool-down period.
223526833|NCT06637930|OTHER|Edentulous Alveolar Ridge In Mandible|"implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray"
223526834|NCT06640140|BEHAVIORAL|Supervised aerobic plus strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.
223526835|NCT06637956|DRUG|Nitroglycerin (NTG)|Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
223526836|NCT06642883|DIETARY_SUPPLEMENT|Prolife|randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.
223526837|NCT06642883|DIETARY_SUPPLEMENT|Placebo|Placebo: 1 vial/day for 60 days.
223526838|NCT06644053|BEHAVIORAL|Quantified analysis of walking during a crossing task through different horizontal openings|Functional test that reproduce a task of daily living
223526839|NCT06643325|DIAGNOSTIC_TEST|Gastric ultrasound|Serial, gastric sonography
223526840|NCT06567782|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223526841|NCT06567782|DRUG|CAPEOX|CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.
223526842|NCT05406401|BIOLOGICAL|Zilovertamab Vedotin|IV infusion
223526843|NCT05406401|DRUG|Cyclophosphamide|IV infusion
223526844|NCT05406401|DRUG|Doxorubicin|IV infusion
223526845|NCT05406401|BIOLOGICAL|Rituximab|IV infusion
223526846|NCT05406401|BIOLOGICAL|Rituximab Biosimilar|IV infusion
223526847|NCT05406401|DRUG|Prednisone|IV or oral administration (per local guidelines)
223526848|NCT05406401|DRUG|Prednisolone|IV or oral administration (per local guidelines)
223526849|NCT06152835|OTHER|Data and breast milk samples collection|Breast milk samples and, clinical, anamnestic and lifestyle data collection
223526850|NCT06800846|PROCEDURE|Intraosseous Morphine|Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg (totally 22 ml) which divided by 12 ml inject into intramedullary canal before bone plug impaction to close the canal and 10 ml inject into metaphysis of tibia before cementation and implantation
223526851|NCT06800846|PROCEDURE|Periarticular Injection|Participants received combinations of 0.5% bupivacaine 100 mg + 0.1% adrenaline 0.6 mg + Morphine 5mg + Ketorolac 30 mg and mix with normal saline solution for totally 75 ml which divided by 25 ml inject into medial gutter and 25 ml inject into lateral gutter before cementation and implantation. And the last 25 ml of multimodal analgesic drugs were injected into quadriceps.
223526852|NCT02063256|DIETARY_SUPPLEMENT|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
223526853|NCT02063256|OTHER|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
223526854|NCT04753619|DRUG|Niclosamide Oral Tablet|"* NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding."
223526855|NCT01851798|OTHER|Home sleep test administered to all enrolled subjects|
223708621|NCT05446896|DEVICE|AR guidance with Hololens 2|The AR instructions were developed as a step-by-step guide with the same text and images as in the printed manual, utilizing the dynamic 365 Guide (Software, Microsoft Corporation, Redmond, WA, USA). The AR instructions were delivered using the Microsoft HoloLens 2.
223708622|NCT04088942|OTHER|High-intensity smoking cessation intervention|"1. Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~2. Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~1. A hotline is established which the high-intensity group can call.~2. Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~   d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
223708623|NCT04088942|DRUG|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
223708624|NCT02083614|PROCEDURE|to clamp or release the catheter for 2 days before removal|
223708625|NCT01268020|DRUG|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
223708626|NCT03315546|RADIATION|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
223708627|NCT01589978|DEVICE|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
223708628|NCT01589978|DRUG|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
223708629|NCT01589978|DRUG|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
223708630|NCT05901454|DRUG|Yellow Fever Vaccine|vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
223708631|NCT05890339|PROCEDURE|Laparoscopic Proximal Gastrectomy With Double-flap Technique|Patients in this group receive laparoscopic proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9, 11p and 11d). The double-flap technique is used for the esophagogastric reconstruction.
223708632|NCT05890339|PROCEDURE|Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction|Patients in this group receive laparoscopic total gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p；D2 for stage IB: Nos.1, 2, 3, 4, 5, 6, 7, 8a, 9, 11p and 11d, 12a). The Roux-en-Y esophagojejunostomy method is used for the esophagojejunal reconstruction.
223708633|NCT00506337|DRUG|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
223526856|NCT05793086|DIAGNOSTIC_TEST|Ultrasound|Using shear wave elastography and gray scale analysis of ultrasound.
223526857|NCT05793086|DIAGNOSTIC_TEST|Electrical impedance myography|Measurement of localized bioimpedance of muscle
223526858|NCT05793086|DIAGNOSTIC_TEST|Excitability testing|Electrical studies of myofiber excitability
223526859|NCT05731245|DRUG|Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
223526860|NCT03112928|DEVICE|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~1. Pain evaluation~2. Placement of the electrodes and fiducial marker~3. Practice of motor execution in Augmented Reality (AR)~4. Gaming using phantom movements~5. Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
223526861|NCT03112928|DEVICE|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
223526862|NCT05689099|DRUG|Semaglutide B, 1.34 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
223526863|NCT05689099|DRUG|Semaglutide B, 0.68 mg/mL|Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
223708634|NCT01500889|PROCEDURE|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
223708635|NCT01500889|PROCEDURE|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
223708636|NCT01500889|PROCEDURE|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
223708637|NCT01471678|DRUG|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
223708638|NCT01471678|DRUG|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
223708639|NCT01471678|DRUG|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
223708640|NCT01014000|DEVICE|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
223708641|NCT01014000|DEVICE|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
223708642|NCT03881475|OTHER|questionnaire|"During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes."
223708643|NCT05306977|DEVICE|Open-label accelerated 1 Hz repetitive transcranial magnetic stimulation|Patients will receive a 5-day course of accelerated 1 Hz rTMS (8x session x 600 pulses/session) to the right intraparietal sulcus. Subjects will receive a continuous train of 1 Hz stimulation. They will receive a total of 600 pulses per train. Trains will be separated by \~50 min rest intervals.
223708644|NCT05075902|BEHAVIORAL|Aerobic training|The program consists of aerobic exercise performed three times a week on non-consecutive days for 12 weeks at an intensity of 65% to 75% of the reserve heart rate. During the first 4 weeks of training, the exercise duration was 40 minutes (5' warm up + 30 minutes in the intensity zone + 5' cool down). From the fifth week onwards, there was only an increase in volume to 50 minutes in duration (5'warm-up + 40 minutes in the intensity zone + 5'warm-up). The aerobic fitness assessment was performed on a maximal effort ergospirometric treadmill under the supervision of a qualified physician, using the Bruce protocol (adapted) to assess cardiopulmonary capacity (to assess possible cardiovascular capacity that prevents the proposed training) and for individualized training prescription.
223708645|NCT03267017|OTHER|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
223708646|NCT02628470|PROCEDURE|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
223708647|NCT02628470|PROCEDURE|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
223708648|NCT02628470|PROCEDURE|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
223526864|NCT05883709|DRUG|Tafasitamab Injection|The combination of Tafasitamab and lenalidomide based treatment was selected according to the specific conditions of patients
223526865|NCT05589025|PROCEDURE|pulpotomy technique with formocresol|The pulpotomy procedure performed was a modification of that described by Pinkham et al; 2005 where pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. After the completion of the access cavity, coronal pulp was extirpated using a sharp excavator. Any residual coronal pulpal tissue was removed using a sterile round bur in a slow-speed handpiece to a depth of few millimeters below the free gingival margin. Hemostasis was achieved with a water-dampened cotton pellet. If hemostasis was not achieved after the initial application of the cotton pellet, the case was eliminated from the study. Following hemostasis, a cotton pellet, moistened with formocresol was applied for 3 minutes and removed. A zinc- oxide and eugenol base was placed over the amputation site. Thereafter, a glass ionomer base was applied.
223526866|NCT05589025|PROCEDURE|pulpectomy technique with zinc oxide and eugenol|The pulpectomy procedure used herein was a modification of that described by Payne et al;1993 Pulp chamber was unroofed using a no. 330 sterile bur in a water-cooled high-speed handpiece. The entire roof of pulp chamber and overhanging dentinal remnants over the pulp horns were removed. An initial endodontic K-file fitting snugly in the canal was introduced inside it. In most cases, the pulp tissue was removed completely on the first attempt. If the first attempt was unsuccessful, the procedure was repeated and canals were generally enlarged three sizes past the initial file to eliminate the organic remnants. Copious irrigation with a light flow of sterile 0.9% NaCl-solution was used throughout the procedure. At the end, the canals were dried and filled with zinc-oxide \& eugenol.
223708649|NCT02260544|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
223708650|NCT04158752|DRUG|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
223708651|NCT03026361|GENETIC|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
223708652|NCT03867344|OTHER|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
223708653|NCT03867344|OTHER|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
223708654|NCT05213481|DRUG|Tepotinib|Participants received Tepotinib hydrochloride hydrate film-coated tablet once daily with food on Day 1 and Day 26 in the morning.
223708655|NCT05213481|DRUG|Carbamazepine|Carbamazepine 100 mg twice daily at Day 8 and 9, 200 mg twice daily at Day 10 and 11, 300 mg twice daily from Day 12 to 32.
223708656|NCT06220773|DRUG|BR1019A|Subjects take the investigational products once a day for 12 weeks.
223708657|NCT06220773|DRUG|BR1019B|Subjects take the investigational products once a day for 12 weeks.
223708658|NCT06220773|DRUG|BR1019C|Subjects take the investigational products once a day for 12 weeks.
223708659|NCT06220773|DRUG|BR1019A-1|Subjects take the investigational products once a day for 12 weeks.
223708660|NCT06220773|DRUG|BR1019B-1|Subjects take the investigational products once a day for 12 weeks.
223708661|NCT06220773|DRUG|BR1019C-1|Subjects take the investigational products once a day for 12 weeks.
223708662|NCT06284655|BEHAVIORAL|group-based combined with innovative technology education|The intervention combines brief group-based psychoeducation, and digital video- and written information, to deliver an early self-management educational program. The intervention introduces a group-breaking approach, featuring a self-managed peer co-led educational group, in collaboration with user representatives from Vårres and the ADHD organisation. This patient-centred educational programme covers crucial topics such as self-help tools, treatment options and experiences, patients' rights, and self-management, in addition to treatment as usual.
223526867|NCT03559530|DRUG|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
223526868|NCT06109324|OTHER|Robotic Rehabilitation of the upper limb|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
223526869|NCT06109324|OTHER|Conventional Rehabilitation of the upper limb|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
223526870|NCT06565117|DRUG|White yu green skin lotion|Group A: Systemic emollient was applied twice daily for 8 weeks Group B: Continue applying skin lotion twice daily in locally affected skin areas or in areas previously affected by AD for 8 weeks
223526871|NCT03058874|DEVICE|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
223526872|NCT03058874|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
223526873|NCT03331354|BEHAVIORAL|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
223526874|NCT03331354|OTHER|Basic vocational services|self-help manual
223526875|NCT06435026|DRUG|FTC/TDF 200mg/300mg|Standard Dose
223526876|NCT06435026|DRUG|FTC/TDF 300mg/450mg|150% Standard Dose
223526877|NCT06435026|DRUG|FTC/TDF 400mg/600mg|200% Standard Dose
223526878|NCT01370044|DRUG|Carbogen|3 minutes administration of carbogen
223526879|NCT01370044|DRUG|Placebo|3 minutes administration of oxygen
223526880|NCT01646827|DRUG|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
223526881|NCT02816814|OTHER|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
223526882|NCT02816814|OTHER|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
223526883|NCT04626726|DRUG|CD19 CAR-T|CD19 CAR-T infusion for patients with CD19 positive tumor cells
223526884|NCT04626726|DRUG|CD22 CAR-T|CD22 CAR-T infusion for patients with CD22 positive tumor cells
223526885|NCT04626726|DRUG|CD19+CD22 CAR-T|CD19+CD22 CAR-T infusion for patients with CD19 positive and CD22 positive tumor cells
223526886|NCT04626726|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
223526887|NCT04626726|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
223708663|NCT06284655|OTHER|Standard treatment|Treatment as usual.
223708664|NCT04189575|OTHER|SMS Intervention|Delivery of text messages will use the Rip Road Mobile platform.
223708665|NCT03115086|DRUG|Cholbam|Cholbam prescribed according to the approved label.
223708666|NCT01216631|DRUG|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
223708667|NCT01216631|DRUG|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
223708668|NCT01216631|DRUG|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
223708669|NCT05433012|DEVICE|Ultrahigh Field MRI at 7T|Assessment of the micro-anatomy of the menisci and cartilage in patients with presumed Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T
224276132|NCT05207605|OTHER|Rhythmic Stabilization (RS)|Group A includes rhythmic stabilization technique. The patient is in sitting position and faces the physical therapist. The RST program consisted of alternating (trunk flexion-extension) isometric contractions against resistance for 10 seconds, with no motion intended. Subjects performed 3 sets of 15 repetitions at maximal resistance provided by the same physical therapist. Rest intervals of 30 seconds and 60 seconds were provided after the completion of 15 repetitions for each pattern and between sets, respectively. The total duration of RS will be of approximately 33 minutes
224276133|NCT05207605|OTHER|McKenzie technique|McKenzie technique will be guided to conduct four extension exercises and three flexion exercisesAll flexion exercises will be repeated for ten repetitions for two sets. There are three minutes for resting intervals in every set. The McKenzie treatment will lasted for 20-40 minutes.
224276134|NCT01792453|OTHER|Spring water|
224276135|NCT00850447|OTHER|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
224276136|NCT00850447|OTHER|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
224276137|NCT01658995|DRUG|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
224276138|NCT01658995|DRUG|Placebo|Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
224276139|NCT05798637|OTHER|Standard of care|No treatment other than clinical standard therapy is provided. Each subjects will perform a blood draw at enrollment and after 24 months of follow-up. Subjects will also be given a frailty status assessment questionnaire (according to the criteria of Fried)
224276140|NCT00465660|BEHAVIORAL|Progressive resistance training|
224276141|NCT00875082|DRUG|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
224276142|NCT00875082|DRUG|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
224276143|NCT04832776|DRUG|Cetuximab|one group plus cetuximab
224276144|NCT04832776|DRUG|Bevacizumab|one group plus bevacizumab
224276145|NCT04832776|DRUG|FOLFOXIRI|FOLFOXIRI
224276146|NCT01438476|PROCEDURE|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
223526888|NCT04618276|OTHER|Photodynamic Therapy|PDT with two different photosensitizers
223526889|NCT05941429|DRUG|Nano-Silver Fluoride|NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
223526890|NCT05941429|DRUG|Silver diamine fluoride|38% silver diamine fluoride
223526891|NCT00928668|DRUG|Placebo|Placebo device for comparison
223526892|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
223526893|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
223526894|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
223526895|NCT00928668|DRUG|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
223526896|NCT02992730|BEHAVIORAL|No Intervention|No Intervention
223526897|NCT01208766|DRUG|Bortezomib, Melphalan, Prednisone (VMP)|"* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11,22,25,29,32~* Melphalan \_ 9 mg/m² \_ p.o. \_ days 1-4~* Prednisone \_ 60 mg/m² \_ p.o. \_ days 1-4"
224276147|NCT01438476|PROCEDURE|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
224276148|NCT01438476|BEHAVIORAL|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
224276149|NCT01438476|BEHAVIORAL|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
224276150|NCT01186562|DRUG|Sitagliptin|100 mg PO daily
224276151|NCT01186562|DRUG|Placebo|Placebo
224276152|NCT03316976|DRUG|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
224276153|NCT00530660|BIOLOGICAL|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
224276154|NCT01165476|DRUG|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
224276155|NCT01274962|DRUG|FOLFOX|"* Oxaliplatin\* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~* Folinic Acid (Leucovorin)\* 400 mg/m2 IV in 250 ml D5W over 120 minutes~* 5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~* 5-Fluorouracil\*\* 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~* Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
224276156|NCT01274962|RADIATION|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
223708670|NCT05114070|OTHER|Decision of hypothermia|Decision of hypothermia thanks to EEG signal
223708671|NCT02882412|OTHER|observational|
223708672|NCT02505906|RADIATION|Simultaneous Integrated Boost Technique|
223708673|NCT05837585|DEVICE|Air quality sensors|The air quality sensors detect air quality, including temperature, humidity, carbon dioxide, respirable suspended particulates (PM10 or PM2.5), total volatile organic compounds (TVOC) and formaldehyde (HCHO), which may influence health of residences. The managers of the service unit will decide the changes of activities to improve air quality and long-term measures based on the detected air quality indexes. The care staff will follow these decisions.
223708674|NCT03382275|DRUG|Iron Supplement|any oral or intravenous prescription iron supplement
224276157|NCT04099680|PROCEDURE|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
223708675|NCT06132295|OTHER|Nursing care|"1. Consistent Schedule for the Replacement of Positioning Line Pens~2. Tailored Educational Content~3. Hypoallergenic Adhesive Patches~4. Enriched Treatment Care Platform~5. Participants with BMI \> 25 and an education level of high school or below, without specific caregivers, were identified by placing a red dot on the treatment record and on the patient's happiness card. Patients with BMI \< 25 and an education level of high school or above, with specific caregivers, were identified by placing a green dot on their records.~6. Individual interventions, educational pamphlets prepared in-house were added, to assess the maintenance status of the positioning marks."
223708676|NCT03791138|OTHER|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
223708677|NCT00415168|DRUG|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
223708678|NCT00415168|DRUG|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
223708679|NCT06405958|OTHER|gut microbiome|Obtaining new gut microbiome data in organ transplantation
223708680|NCT03273270|RADIATION|transcranial magnetic stimulation|transcranial magnetic stimulation
223708681|NCT00332280|DRUG|AMT2003|
223708682|NCT05353361|DRUG|SHR-A1811：Pyrotinib|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
223708683|NCT05353361|DRUG|SHR-A1811；Pertuzumab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
223708684|NCT05353361|DRUG|SHR-A1811；Adebrelimab|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip
223708685|NCT05353361|DRUG|SHR-A1811；Albumin paclitaxel|SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
223708686|NCT03623841|OTHER|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
223708687|NCT03623841|OTHER|Treadmill training|Participants in control group will do treadmill training only
223708688|NCT06044389|DEVICE|Fructosin|"Fructosin® is a CE marked medical device. The capsules with 30.23 mg xylose isomerase are taken as recommended. This means that, depending on the total intake, 1-2 capsules are to be taken with water 15 minutes before meals containing fructose, a maximum of 3 times a day.~Use as needed during the 4-week intake phase."
223708689|NCT04765982|DIAGNOSTIC_TEST|Checking diabetes development in follow up at 3 month|An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
223708690|NCT05093140|DRUG|Camrelizumab|"Induction therapy:~Camrelizumab 200mg, ivd, D1, Rituximab 375mg/m2, ivd, D1 every 3 weeks up to 2 cycles~Immunochemotherapy:~Rituximab: 375mg/m2, ivd, D1; Cyclophosphamide: 750mg/m2, iv or ivd, D1; Hydroxyldaunorubicin: 50mg/m2, iv or ivd, D1; Vincristine: 1.4 mg/m2 , iv(max：2mg), D1; Prednisone: 60mg/m2, po, d1-5 every 3 weeks up to 6 cycles Maintenance therapy: Camrelizumab 200mg, ivd, D1 every 4 weeks up to 6 cycles"
223708691|NCT00938236|DRUG|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
224276158|NCT04099680|PROCEDURE|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
223708692|NCT01067937|PROCEDURE|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
223708693|NCT01634334|BEHAVIORAL|Real-Time Intervention|Lights and Sound Brief Coaching
223708694|NCT01634334|BEHAVIORAL|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
224276159|NCT04099680|DEVICE|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
224276160|NCT04099680|PROCEDURE|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
224276161|NCT04099680|PROCEDURE|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
223708695|NCT04150055|BEHAVIORAL|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
223708696|NCT04905966|BEHAVIORAL|Nutrition education and Physical activity intervention|Schools randomized to the experimental group received nutrition education sessions and physical activity classes.
223708697|NCT05719662|OTHER|Weight bearing exercises|Weight bearing exercises
223708698|NCT05719662|OTHER|Jaffrey's core stability exercises|Jaffrey's core stability exercises
223708699|NCT05161767|DIAGNOSTIC_TEST|Brain MRI (neuroimaging)|Structural and functional brain scans will be taken.
223708700|NCT00651391|DRUG|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
223708701|NCT00651391|DRUG|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
223708702|NCT00651391|DRUG|Placebo|oral placebo once daily in the evening for 12 weeks
223708703|NCT04773756|DRUG|Sofosbuvir 400 MG/ Daclatasvir 60mg|Giving these two drugs for treatment of COVID patients
223708704|NCT04315883|BEHAVIORAL|Quality of Life Assessment|"Evaluation of change of HRQOL survey responses will be performed:~* at baseline (time of treatment) and~* 1 month post treatment~* 6 months post treatment~* 12 months post treatment~* 5 years post-treatment~The HRQOL will be done by phone, mail or email. Responses will be captured and entered into a REDCAP database"
223708705|NCT04315883|RADIATION|Transarterial Radioembolization|"Deliver catheter directed yttrium-90 directly to liver tumors and assess -Progression Free Survival - Local and Metastatic~* Local Tumor Response by calculating the decreases in tumor size and enhancement after treatment. This will be assessed by modified Response Evaluation Criteria for Solid Tumors (mRECIST).~* Resection Rate following treatment~* Transplant Rate following treatment~* Histologic Response by assessing tumor histopathology in patients who undergo tumor resection or liver transplant~* Biologic Response by monitoring serum tumor markers (e.g. alphafetoprotein-AFP) in AFP secreting tumors~* Review of clinical course post-treatment-rehospitalization rate"
223708706|NCT01810861|OTHER|There is no intervention in this study|This is a non-interventional study.
223708707|NCT00167648|DRUG|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
223708708|NCT00167648|DRUG|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
223708709|NCT01796483|DEVICE|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
223708710|NCT01796483|DEVICE|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
223708711|NCT02656914|DRUG|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
223708712|NCT02656914|DRUG|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
223708713|NCT00124228|DRUG|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
223708714|NCT01518348|BIOLOGICAL|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
223708715|NCT02050841|BIOLOGICAL|octaplas|Octaplas S/D Plasma
223708716|NCT02432495|OTHER|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
223708717|NCT02432495|OTHER|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
223708718|NCT01138774|DIETARY_SUPPLEMENT|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
223708719|NCT04850001|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|All patients received standard medical management, including dual antiplatelet therapy (aspirin and clopidogrel) for three months with aspirin or clopidogrel monotherapy thereafter and high-dose statin, and treatment of hypertension to guideline targets.
223708720|NCT03078244|OTHER|N/A, observational study|
223708721|NCT02698046|DIETARY_SUPPLEMENT|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
223708722|NCT02698046|DIETARY_SUPPLEMENT|Placebo starch|200mg of placebo starch three times a day for 4 months
223708723|NCT03918148|DRUG|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
223708724|NCT03918148|DRUG|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
224276162|NCT04099680|PROCEDURE|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
223708725|NCT00002982|BIOLOGICAL|filgrastim|
223708726|NCT00002982|DRUG|carboplatin|
223708727|NCT00002982|DRUG|carmustine|
223708728|NCT00002982|DRUG|cytarabine|
223708729|NCT00002982|DRUG|etoposide|
223708730|NCT00002982|DRUG|ifosfamide|
223708731|NCT00002982|DRUG|melphalan|
223708732|NCT00002982|PROCEDURE|autologous bone marrow transplantation|
223708733|NCT00002982|PROCEDURE|peripheral blood stem cell transplantation|
223708734|NCT00002982|RADIATION|radiation therapy|
223708735|NCT06274320|OTHER|Group A: holistic approach|2-week Lipikar Urea 30% application (once daily in the evening) + 4-week Tolak® treatment (once daily in the evening)
223708736|NCT06274320|OTHER|Group B: Tolak® Standard of use|4-week Tolak® alone treatment (once daily in the evening)
223708737|NCT04792008|BIOLOGICAL|YQ23|Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated
223708738|NCT04792008|BIOLOGICAL|Matching placebo|Single dose of 0.9% normal saline via intravenous route as matching placebo
224276163|NCT02522780|DRUG|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
224276164|NCT02522780|DRUG|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
224276165|NCT05767762|OTHER|scale Idiopathic Clubfoot|The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
224276166|NCT04016194|DIAGNOSTIC_TEST|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
223526898|NCT01208766|DRUG|1 or 2 cycle(s) HDM (High Dose Melphalan)|"\- Melphalan \_ 100 mg/m² \_ i.v. rapid infusion \_ -3, -2\*~\*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
223526899|NCT01208766|DRUG|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"* Bortezomib \_ 1.3 mg/m2 \_ i.v. rapid infusion \_ days 1,4,8,11~* Lenalidomide \_ 25 mg \_ p.o. \_ days 1-21~* Dexamethasone \_ 20 mg \_ p.o. \_ days 1,2,4,5,8,9,11,12"
223526900|NCT03885700|BEHAVIORAL|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition \&Healthy Eating by Mayo clinic \& CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet \& the 2nd month covered the physical activity as follow:~* 1st \& 5th week: A 60-minutesession in health education.~* 2nd \& 6th week: Group counselling.~* 3rd \& 7th week: Students were divided into 8 groups \& each group was asked to make presentation about a task related to the topic.~* 4th \& 8th week: Discussing the presentation."
223526901|NCT05000710|DRUG|Durvalumab|Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks
223526902|NCT05000710|DRUG|Tremelimumab|Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1
223526903|NCT05000710|RADIATION|Low dose irradiation|21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day
223526904|NCT00186459|BEHAVIORAL|Hypocaloric diet of varying macronutrient composition|
223526905|NCT01838226|BEHAVIORAL|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
223526906|NCT05078437|BEHAVIORAL|Medication therapy management|The proposed deprescribing intervention is using a patient-centered framework by: (1) balancing the risks and benefits, and addressing the specific needs of each individual patient, (2) considering the individual patient and the caregiver's preferences and values, and (3) empowering the patient and the caregiver to take responsibility and fully participate in the decision-making process as equal team players.
223526907|NCT01923038|PROCEDURE|First arm: patients ventilated with zero end expiratory pressure|
223526908|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure|
223526909|NCT01923038|PROCEDURE|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
223526910|NCT02261792|PROCEDURE|24 hours Trendelenburg position|Trendelenburg position
223526911|NCT02261792|PROCEDURE|24 hours bed rest|24 hours bed rest after EBP
223526912|NCT02261792|PROCEDURE|EBP|Autologous Epidural Blood Patch
223526913|NCT00989495|DEVICE|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
223526914|NCT06149182|BEHAVIORAL|Life stress interview according to EAET|This interview has the aim to jointly explore potential emotional factors contributing to patients functional somatic symptoms. While exploring this, it has the aim to not only describe such potential patterns but also emotionally process them.
223526915|NCT06149182|BEHAVIORAL|"Psychiatric interview according to region stockholm - basutredning"|This interview has the aim to gain enough information to diagnose some of the main psychiatric disorders
223526916|NCT01416337|DRUG|GSK1120212|2 mg single dose tablet on Day 1 of study
223526917|NCT01416337|DRUG|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
223526918|NCT05368519|DEVICE|Brijjit®|Brijjit® is a non-invasive device which serves as a force modulating tissues bridges (FMTB) to aid in wound healing. This device used in would closure and serves to modify the mechanical forces on a wound which are implicated in adverse outcomes including scar formation and complications like wound dehiscence. Brijjit® is a flexible device which attaches via adhesive to the tissue on either side of the wound, approximates the tissue and off-loads forces.
223526919|NCT03089294|DEVICE|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
223526920|NCT01767987|DRUG|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
223526921|NCT01767987|DRUG|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
223526922|NCT03232567|BIOLOGICAL|NasoVAX|Single ascending dose study
223526923|NCT04198012|DEVICE|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self-care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
223526924|NCT05837481|BEHAVIORAL|Meditation|Guided meditation utilizing breath awareness, body scan and visualization techniques
223526925|NCT05361616|DEVICE|PBM Ortho|The device will be used by the patients at home for one 8 minutes per day (4 minutes each upper and lower) for 7 days.
223708739|NCT05193370|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
223708740|NCT05193370|DRUG|Vasopressin|Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
223708741|NCT00004857|BIOLOGICAL|alemtuzumab|30 mg subQ injection tiw for 6 weeks
223708742|NCT00004857|DRUG|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
224276167|NCT02058160|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
223708743|NCT05964101|DRUG|Nivolumab Injection [Opdivo]|Neoadjuvant treatment stage: Nivolumab +Carboplatin AUC+ paclitaxel
223708744|NCT06154187|DRUG|PBK_L2201|Abaloparatide-SC 80 μg was to be self-administered daily using a Pen Injector device.
223708745|NCT06154187|DRUG|Placebo|Placebo was formulated similar to abaloparatide-SC.
223708746|NCT04628741|BEHAVIORAL|Dynamic Coaching Model|This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.
223708747|NCT04628741|BEHAVIORAL|Apprenticeship Approach|This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
223708748|NCT02059408|OTHER|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm will recommend using creatinine, cystatin C and albuminuria for screening and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage. Recommendations are sent to the primary care provider via an electronic note.
223708749|NCT02059408|OTHER|Screen-Educate and Intensify Treatment|This arm adds option of a pharmacist. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys \<45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
223708750|NCT01153074|DEVICE|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
223708751|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Day 0, Month 6 and 12, respectively.
223708752|NCT02993757|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, SC injection at Month 1, 7 and 13, respectively.
223708753|NCT02993757|BIOLOGICAL|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, IM injection at Day 0 and Month 6, respectively.
223708754|NCT06171295|DIAGNOSTIC_TEST|Blood draw|The blood draws in specified time points
223708755|NCT03948672|DEVICE|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
223708756|NCT06220565|DEVICE|"sensor and wearable device Graded Exercise"|"The program plans to use rational mechanism to provide safe and targeted exercise interventions to patients at different stages of their lives through three aspects: education, motivation and feedback. Through real-time collection of knee function parameters, real-time feedback on the effect of exercise intervention, and tracking the changes in the functional status of patients' knee joints. On the basis of improving knee function, we further improve patients' compliance with exercise intervention.~Considering the community scenario, we plan to use sensors and wearable devices to realize the function of the knee joint on the basis of the existing technology. wearable devices to realize the digital assessment of knee function to reduce patient's time and cost and improve efficiency. At the same time, this digital assessment will provide a basis for decision-making for patient self-management."
223708757|NCT06220565|OTHER|exercise|exercise
223708758|NCT06220565|OTHER|Educational Manual|Educational Manual
223708759|NCT04571320|BEHAVIORAL|Summer STRIPES|See arm description.
223708760|NCT04571320|OTHER|Enhanced School Services as Usual|see arm description.
223708761|NCT00268359|BIOLOGICAL|bevacizumab|
223708762|NCT00268359|DRUG|irinotecan hydrochloride|
223708763|NCT02586129|DRUG|YH14755|20/1500mg, QD
223708764|NCT02586129|DRUG|Metformin|1500mg, QD
223708765|NCT02586129|DRUG|Rosuvastatin|20mg, QD
223708766|NCT03748784|BIOLOGICAL|ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
223708767|NCT05686889|OTHER|Patient self-report|Simulated patient following structured script
223708768|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 200 mg/m2|i.v. bolus injection
223708769|NCT01681472|DRUG|Levoleucovorin 200 mg/m2|i.v. bolus injection
223708770|NCT01681472|DRUG|6R-MTHF (arfolitixorin) 60 mg/m2|i.v. bolus injection
223708771|NCT01681472|DRUG|Levoleucovorin 60 mg/m2|i.v. bolus injection
223708772|NCT00092612|DRUG|MK0653, ezetimibe|
223708773|NCT00092612|DRUG|Comparator: ezetimibe, placebo|
223708774|NCT02012283|OTHER|Food consumption|Cooked vegetables with spices or without spices
223708775|NCT04311775|DEVICE|larengeal mask insertion with video laryngoscopy|it is a method of inserting a laryngeal mask into the airway with videolaryngoscopy
223708776|NCT04311775|OTHER|laryngeal mask insertion|laryngeal mask is a method of inserting atube into the upper airway
223708777|NCT03260101|OTHER|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
223708778|NCT05600452|OTHER|Heat acclimation|Repeated heat exposures with light exercise sufficient to elevate deep body temperature to \~ 38.5C
223526926|NCT06564857|DRUG|Remifentanil|Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
223526927|NCT06564857|DRUG|Rocuronium|Bolus of 0.6 mg/kg Ideal Body Weight rocuronium at anaesthesia induction
223526928|NCT05112640|DEVICE|INSORB: subcuticular stapling device|Under the skin stapling device that delivers absorbable staples
223526929|NCT05112640|DEVICE|Subcuticular monocryl suture manufactured by Ethicon|Under the skin suture placed by hand
223526930|NCT06412666|DRUG|Aficamten|Oral Tablet
223526931|NCT06412666|DRUG|Placebo|Oral Tablet
223526932|NCT00514189|BIOLOGICAL|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
223526933|NCT02527512|DRUG|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
223526934|NCT02527512|OTHER|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
223526935|NCT00103844|DRUG|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
223526936|NCT00103844|DRUG|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
223526937|NCT03271333|OTHER|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
223526938|NCT02583841|PROCEDURE|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
223526939|NCT00189475|DRUG|Montelukast|
223526940|NCT00189475|DRUG|Placebo|
223526941|NCT02474498|DRUG|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
223526942|NCT02474498|DEVICE|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
223526943|NCT02474498|PROCEDURE|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
223526944|NCT04544280|DRUG|Xeomin Injectable Product|Intramuscular injection
223526945|NCT01469247|RADIATION|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
223526946|NCT00244985|BIOLOGICAL|rituximab|IV
223526947|NCT00244985|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
223526948|NCT04942145|DEVICE|virtual reality in dental patients|"The behavioral anxiety response of dental patients (with and without virtual reality) related to psychological factors is studied.~Participants self-complete the questionnaires"
223526949|NCT02164110|BIOLOGICAL|Euvichol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
223526950|NCT02164110|BIOLOGICAL|Shanchol|"* Number of doses and intervals: two doses/Weeks 0 and 2~* Method of administration: oral administration~* Dose of drug to be administered: 1.5 mL/dose"
223526951|NCT04179344|OTHER|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
223708779|NCT02647242|BEHAVIORAL|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
223526952|NCT05032378|BEHAVIORAL|Kinesthetic Awareness Training|One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device
223526953|NCT05032378|BEHAVIORAL|Provision of KAT-assisted physical or occupational therapy|Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
223526954|NCT01771497|DEVICE|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
223526955|NCT03178682|DIAGNOSTIC_TEST|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
223526956|NCT02600650|DIETARY_SUPPLEMENT|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
223526957|NCT02600650|DIETARY_SUPPLEMENT|Placebo Comparator|Daily administration of Placebo Comparator
223526958|NCT06467409|DRUG|Placebo|patient-controlled analgesia(PCA) administration
223526959|NCT06467409|DRUG|morphine hydrochloride injection|patient-controlled analgesia(PCA) administration
223526960|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
223526961|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
223526962|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
223526963|NCT06467409|DRUG|LPM3480392 Injection|patient-controlled analgesia(PCA) administration
224276168|NCT02058160|DRUG|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
223526964|NCT03038087|DEVICE|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~1. A molded plastic headpiece containing the antenna array, and~2. A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
224276169|NCT02058160|DRUG|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
224276170|NCT03563560|DRUG|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
224276171|NCT03563560|DRUG|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
223526965|NCT00654355|DRUG|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
223526966|NCT02160431|BEHAVIORAL|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
223526967|NCT02725684|OTHER|Observational study, no intervention|Observational study, no intervention
223526968|NCT01202162|DRUG|Desflurane|Administratino of Desflurane
223526969|NCT01202162|DRUG|Administration of Sevoflurane|Administration of Sevoflurane
224276172|NCT03563560|DRUG|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
224276173|NCT03563560|DRUG|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
224276174|NCT03563560|DRUG|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
224276175|NCT04309994|OTHER|Myocardial protection system (MPS)|cardioplegia solution, A separate pumpsystem by which Blood cardioplegia with individually composable additives as cardioplegia solution can be used
224276176|NCT04309994|OTHER|Cardioplexol|cardioplegia solution
224276177|NCT03113357|OTHER|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
224276178|NCT03113357|OTHER|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
223526970|NCT06209866|DEVICE|PTA|Percutaneous Trans lumenal Angioplasty
223526971|NCT06264154|OTHER|E-cigarettes|All participants are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. Participants will receive an e-cigarette device and flavored nicotine pods according to their randomly assigned flavor.
223526972|NCT05022719|DEVICE|PillCam Colon2 procedure with MB-MMX|Subjects will undergo a bowel preparation (single dose, 4L PEG), including 200 mg Methylthioninium chloride, corresponding to eight 25 mg MB-MMX tablets and 1 tab of Resolor (Prucalopride 1mg). An experienced Gastroenterologist will read the CCE procedure and complete a subjective questionnaire, to evaluate mucosal enhancement during a CCE procedure, when using MB-MMX as a contrast-enhancement technique.
223526973|NCT01117246|DEVICE|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
223526974|NCT03324841|DIAGNOSTIC_TEST|Caris MI Profiling|Customized comprehensive biomarker testing
223526975|NCT02501447|BEHAVIORAL|Guided audio-visual relaxation|
223526976|NCT06544720|BIOLOGICAL|SCG142 TCR-T cells|Monotherapy of SCG142
223526977|NCT05006495|PROCEDURE|C3 laminectomy|C3 laminectomy preserving semispinalis cervicis inserted into the axis.
223708780|NCT01972113|DIETARY_SUPPLEMENT|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
224276179|NCT03316040|BEHAVIORAL|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
224276180|NCT03033030|DIAGNOSTIC_TEST|Ultrasound|Ultrasound examination
223526978|NCT05006495|PROCEDURE|C3 laminoplasty|Conventional C3-6 laminoplasty, resulting in injury of semispinalis cervicis.
224276181|NCT03848858|BEHAVIORAL|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
223708781|NCT01972113|DIETARY_SUPPLEMENT|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
223708782|NCT01972113|DIETARY_SUPPLEMENT|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
223708783|NCT05844410|DRUG|Corticosteroid|Adults patients admitted to the hospital after a confirmed COVID-19 infection, irrespective of the stage and severity of the disease, were included in the study. Only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity
223708784|NCT03250221|DEVICE|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
223708785|NCT03250221|DEVICE|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
223708786|NCT04005911|DEVICE|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
223708787|NCT01237743|DEVICE|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
223708788|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
223526979|NCT03137823|DIAGNOSTIC_TEST|throat culture|throat culture - from the tonsills and from the bucal surface
223526980|NCT03161873|DEVICE|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
223526981|NCT04661527|DRUG|Sarilumab|Treatment with Sarilumab 200 mg IV x 2 doses 24 hours apart for first 5 patients. If no severe AE and no significant improvement within 48 hours, the dose will be increased for subsequent patients to 400 mg IV for the first dose and 200 mg or 400 mg IV for the second dose 24 hours later. Te second dose will be decided at the investigators discretion.
223526982|NCT05501899|DRUG|Levocarnitine|Adults, or patients ≥ 50 kg: 990 mg PO (by mouth) bis in die (BID, twice a day) Children, or patients \< 50 kg: 50 mg/kg/day PO divided BID (maximum daily dose of 2,000 mg)
223526983|NCT03510689|DIAGNOSTIC_TEST|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
223708789|NCT00795145|DRUG|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
223708790|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
223708791|NCT00795145|DRUG|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
223708792|NCT00795145|DRUG|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
223708793|NCT00795145|DRUG|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
223526984|NCT03510689|OTHER|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
223526985|NCT03510689|OTHER|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
223526986|NCT02786407|DRUG|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
223526987|NCT02786407|DRUG|Placebo|In these studies,patients received placebo administered to 20 injection sites
223526988|NCT05805150|DEVICE|Control Lens (stenfilcon A)|One week wear
223526989|NCT05805150|DEVICE|Test Lens (senofilcon A)|One week wear
223708794|NCT00795145|DRUG|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
223708795|NCT05797675|PROCEDURE|prf + osseodensification|prf+ osseodensification in close sinus lift
223708796|NCT00981201|DRUG|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
223708797|NCT00981201|DRUG|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
223708798|NCT00981201|DRUG|Placebo|"Months 1-3:~By mouth twice daily."
223708799|NCT00981201|DRUG|Placebo|"Months 4-6:~By mouth twice daily."
223708800|NCT00119834|DEVICE|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
223708801|NCT03651869|DRUG|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
223708802|NCT03651869|DRUG|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
223708803|NCT03651869|DRUG|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
223708804|NCT03651869|DRUG|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
223708805|NCT05195671|OTHER|Review|Reviewing all protocols
223708806|NCT01470937|DRUG|Acarbose|acarbose 100 mg PO once daily
223708807|NCT01470937|DRUG|Placebo|acarbose placebo
224276182|NCT01226524|DRUG|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
224276183|NCT03310619|BIOLOGICAL|JCAR017|Gene modified autologous T cells
224276184|NCT03310619|DRUG|Durvalumab|Anti-PD-L1
224276185|NCT03310619|DRUG|CC-122|Pleiotropic Pathway Modifier
224276186|NCT03310619|DRUG|Ibrutinib|Ibrutinib
224276187|NCT03310619|DRUG|CC-220|CC-220
223526990|NCT05885750|BEHAVIORAL|Unprocessed|Participants will consume unprocessed or minimally processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
223526991|NCT05885750|BEHAVIORAL|Mildly processed|Participants will consume mildly processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
223526992|NCT05885750|BEHAVIORAL|Heavily refined|Participants will consume heavily refined processed commercially available plant-based protein-rich foods as meat replacement in their normal diet for one week.
223526993|NCT00219726|DRUG|Imatinib mesylate|
223526994|NCT06007157|BEHAVIORAL|Hypersodic/Hyposodic diet|Participants will undergo a dietary intervention consisting of a week of high-sodium diet (4800 mg/day), followed by a week of low-sodium diet (1200 mg/day).
223526995|NCT01530958|BEHAVIORAL|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials"
223526996|NCT01530958|BEHAVIORAL|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
223526997|NCT01530958|BEHAVIORAL|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
223526998|NCT02284893|DRUG|Saxagliptin|administered orally once daily
223526999|NCT02284893|DRUG|Dapagliflozin|administered orally once daily
223527000|NCT02284893|DRUG|Sitagliptin|administered orally once daily
223527001|NCT02284893|DRUG|Placebo matching with Saxagliptin|administered orally once daily
223527002|NCT02284893|DRUG|Placebo matching with Dapagliflozin|administered orally once daily
223527003|NCT02284893|DRUG|Placebo matching with Sitagliptin|administered orally once daily
223527004|NCT02114645|DRUG|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
223527005|NCT02114645|DRUG|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
223527006|NCT02114645|DRUG|4 mg oral estradiol valerate|estrofem is given twice a day
223527007|NCT03139721|DEVICE|Mosaic model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
223527008|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
223527009|NCT03235986|DRUG|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
223527010|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
223527011|NCT03235986|OTHER|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
223527012|NCT02659085|DRUG|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
223527013|NCT02659085|PROCEDURE|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
223527014|NCT01666366|PROCEDURE|Coronary artery bypass grafting|
223527015|NCT06222021|GENETIC|Genetic analysis of polymorphism of membrane receptors involved in lactate transport|The DNA extracted from the blood samples (through extractor MagCore) will then undergo gene sequencing by Sanger sequencing and/or Custom NGS (Next Generation Sequencing) panels and will be used to identify nucleotide variants within genes involved in lactate transport (MCT-1/4, GPR81).
223527016|NCT06179537|DRUG|BLU-5937|Single and multiple doses assessment
223527017|NCT04560530|RADIATION|Non-enhanced CT scan of the chest|Non-enhanced CT scan of the chest with multi-slice CT scan machine.
223527018|NCT02124980|BEHAVIORAL|Recovery Line|
223527019|NCT00516308|DEVICE|NightHawk|
223527020|NCT02260232|OTHER|exercise training|
223527021|NCT04116684|DEVICE|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
223527022|NCT01061788|DRUG|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~1. 3-6 subjects, Study drug administered per dose level~2. 3-6 subjects, Study drug administered per dose level~   Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~   Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3. 3-6 subjects, Study drug administered per dose level~4. 3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
223527023|NCT02688439|OTHER|Sciatic Nerve block|
223527024|NCT02688439|OTHER|Leg raised 30°|
223527025|NCT02688439|OTHER|Distal tourniquet placed on the lower part of the leg|
224276188|NCT03310619|DRUG|Relatlimab|Relatlimab
224276189|NCT03310619|DRUG|Nivolumab|Nivolumab
224276190|NCT03310619|DRUG|CC-99282|CC-99282
224276191|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
224276192|NCT01936012|DRUG|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
223708808|NCT03473483|OTHER|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~* Sealed and disposable~* Minimum 350 puffs per tank~* Volume of e-liquid per tank \~ 3ml~E-Liquid Characteristics:~* Tobacco flavored~* Nicotine concentration: 15 mg/ml~* Propylene Glycol:\~ 50% (wt / wt)~* Glycerin: \~ 50% (wt / wt)~* Cotinine: \<1 μg/g~* Nornicotine: 5 μg/g~* Myosmine : 3 μg/g~* Anabasine: \<1 μg/g~* Anatabine: \<1 μg/g~* Beta:nicotyrine: \<1 μg/g~* Diacetyl: \<2 μg/g~* 2,3:Pentanedione: \<1 μg/g~* Arsenic: \<0.1 μg/g~* Cadmium: \<0.1 μg/g~* Chromium: \<0.1 μg/g~* Lead: \<0.1 μg/g~* Nickel: \<0.1 μg/g~* Mercury: \<0.05 μg/g"
223708809|NCT03314194|OTHER|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
223708810|NCT00579137|BIOLOGICAL|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients \>15 kg to 30 kg the dose 5 mg; for patients \> 30 kg the dose is 10 mg"
223708811|NCT00579137|DRUG|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
223708812|NCT00579137|BIOLOGICAL|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
224276193|NCT03885336|OTHER|No Interventions|There are no interventions in this study. Participants are observed.
223527026|NCT02688439|OTHER|Leg in a neutral position|
223527027|NCT00834782|PROCEDURE|IOP measurement|Measuring IOP
223527028|NCT04814914|OTHER|KB109 + Self Supportive Care|KB109 is a novel glycan
223527029|NCT04814914|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
223527030|NCT04576559|OTHER|Modified dental visual aids|Modified Dental visual aids in the form of pictures created by the main investigator
223527031|NCT04576559|OTHER|Regular dental visual aids|Regular dental visual aids
223527032|NCT04769284|OTHER|Mental health student|"An ad-hoc questionnaire was designed that included sociodemographic variables related to the characteristics of the students. The variables sex, age, degree, employment situation, coexistence situation, economic situation, origin environment, country of origin, time of residence in the Spanish State were collected.~Personal variables:~* Gender stereotypes: Short version of the Bem Sex Rol Inventory (BRSI).~* International Physical Activity Questionnaire (IPAQ)~* Abbreviated Goldberg Anxiety Scale EADG~* Modified version of EPP-10 related to COVID-19 (EPP-10-C)"
223527033|NCT05093608|DRUG|Selinexor Pill|Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
223527034|NCT05093608|DRUG|Bevacizumab|Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
223527035|NCT05093608|DRUG|Atezolizumab|Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
223527036|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
223527037|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
223527038|NCT00648414|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
223527039|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
223527040|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
223527041|NCT00648414|DRUG|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
223527042|NCT02444754|OTHER|Medical Chart Review|Obtain medical data
223527043|NCT02444754|OTHER|Questionnaire Administration|Complete demographics questionnaires
223527044|NCT02444754|OTHER|Survey Administration|Complete surveys
223527045|NCT03455686|OTHER|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
223527046|NCT05126303|DRUG|RMC-035|Concentrate for Solution for Infusion
223527047|NCT05126303|DRUG|Placebo|Concentrate for Solution for Infusion
223527048|NCT04502914|PROCEDURE|Open-to-air strategy|In open-to-air management, the wound will be washed with a chlorhexidine solution and leave the wound open, or portion of the wound assigned to OTA, to the environment. An electric heat lamp (model no. 53103, 250W, Brandt Industries LLC, Bronx, NY) will be placed at as close to 1 yard (0.91 m) as possible from the wound after daily wound care for 24 hours (+/- 6 hours) to promote drying. However, to prevent excessive drying an hourly spritz of topical solution, e.g., DuoDERM® Hydroactive® gel (ConvaTec Oklahoma City, OK) will be used at the bedside.
223527049|NCT04502914|PROCEDURE|Traditional closed-wound management|In traditional closed-wound management, once a day the wound will be washed with a chlorhexidine solution and closed with a non-adherent dressing such as ADAPTIC® (Acelity, San Antonio, TX) soaked in topical antimicrobial solutions, ointments, and creams designed to promote wound healing.
223708813|NCT00579137|PROCEDURE|Stem cell infusion|stem cells are infused on day 0
224276194|NCT02427399|OTHER|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
224276195|NCT02427399|OTHER|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
224276196|NCT02427399|OTHER|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
224276197|NCT02427399|OTHER|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
223708814|NCT00952042|OTHER|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
223708815|NCT00952042|OTHER|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
223708816|NCT01234831|DEVICE|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
223708817|NCT01234831|OTHER|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
223708818|NCT01999179|DRUG|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
223708819|NCT00880997|DRUG|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
223708820|NCT00880997|OTHER|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
223708821|NCT01545804|DRUG|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
223708822|NCT00569608|OTHER|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
223708823|NCT01686061|OTHER|No intervention- only one time survey|
223708824|NCT04131426|DRUG|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
223708825|NCT04131426|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
223708826|NCT03742830|DEVICE|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
223708827|NCT03128411|DRUG|Bosutinib|All patients will receive bosutinib at a starting dose of 400 mg QD.
223708828|NCT03118713|DRUG|metformin|oral
223708829|NCT03118713|DRUG|ipragliflozin|oral
223708830|NCT03118713|DRUG|glimepiride|oral
223708831|NCT00388596|DRUG|SB-751689|
223708832|NCT03501290|DIETARY_SUPPLEMENT|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
223708833|NCT00004037|DRUG|docetaxel|
223708834|NCT05176145|DEVICE|VisioCyt®|"* Cytological and endoscopic examination is planned as part of the usual management of patients under surveillance of Non-muscle invasive bladder cancer (NMIBC), according to the CCAFU guidelines.~* Urine collection for conventional cytology and VisioCyt® test"
223708835|NCT00570570|PROCEDURE|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
223708836|NCT00570570|OTHER|conventional physiotherapy|trice a week during 6 weeks
223708837|NCT02508831|PROCEDURE|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
223708838|NCT06967935|OTHER|Cognitive memory task on a computer|"Encoding: (1) Participants will learn 60 associations between pairs of items (cue and target) that are presented sequentially at unique locations on a screen, in a given context. 30 pairs are presented once, and 30 pairs are presented repeatedly (4 times).~(2) After learning, the first recall phase begins after a short delay of 30 minutes: 50% of the pairs are tested in a similar way, this time with an assessment of contextual memory.~(3) The remaining 50% of pairs are tested after a 12-hour delay, involving either a day awake (condition 1) or a night asleep (condition 2)."
223708839|NCT06967935|OTHER|Eye tracking|Eye-tracking will be carried out during the task to ensure that participants are focused on the task (quantification of the number and duration of eye fixations in the area of interest corresponding to the target presentation)
223708840|NCT06967935|OTHER|Questionnaires on task-related fatigue|Questionnaire on task-related fatigue (Likert-scale) will be completed by participants between blocks of items during the task
223708841|NCT06967935|OTHER|Questionnaire on task difficulty|Questionnaires on task difficulty (Likert-scale) will be completed by participants at the end of the task
223708842|NCT06967935|OTHER|Karolinska scale|Participants' state of sleepiness will be assessed at the beginning of each stage (encoding, immediate recall, delayed recall) using the Karolinska sleepiness scale
224276198|NCT05761587|OTHER|Questionnaires|questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.
224276199|NCT01459198|BIOLOGICAL|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10\^5 or 10\^6 plaque-forming units (PFU), depending on study arm.
224276200|NCT01459198|BIOLOGICAL|Placebo vaccine|Given intranasally once at a baseline study visit
224276201|NCT00008398|BIOLOGICAL|sargramostim|
224276202|NCT00008398|PROCEDURE|quality-of-life assessment|
224276203|NCT00008398|RADIATION|radiation therapy|
224276204|NCT01096745|DRUG|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
223708843|NCT05929131|OTHER|discharge instructions with pamphlet|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before the parents in the control group are discharged from the pediatric emergency service, in the second group (intervention group with brochure) in accordance with the guidelines of the American Academy of Pediatrics (2020), the parents will be told with the brochure giving the same information about fever in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
223708844|NCT05929131|OTHER|discharge instructions with video|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Before parents in the control group are discharged from the pediatric emergency service, a short 2-minute video will be shown to the American Academy of Pediatrics (2020) guidelines (intervention group with video) giving the same information about high fever to patients in addition to the verbal instructions. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
223708845|NCT05929131|OTHER|verbal discharge instructions only|Parents who agree to participate in the study will be randomly assigned to the control or intervention groups. Parents in the control group will receive the usual verbal information and advice on high fever management in accordance with the guidelines of the American Academy of Pediatrics (2020) prior to discharge from the pediatric emergency service. Instructions will be given by the same researcher to provide homogeneous and consistent information in all three groups. All patients will also receive a discharge report with instructions on post-treatment treatment.
223708846|NCT00875992|DEVICE|ETN with ASLS|Angle stable locking of ETN using ASLS
223708847|NCT00875992|DEVICE|ETN locked with conventional locking bolts|Conventional surgical procedure
223708848|NCT06404645|DEVICE|Near-infrared spectroscopy detection|Cranial CT confirm intracranial haematoma. Then the near-infrared spectroscopy device to collect date by red sensor probe in the corresponding position on the scalp and blue sensor probe on the opposite side of the hematoma. Collect data for 10 minutes.
223708849|NCT03569618|DEVICE|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
223708850|NCT04116970|PROCEDURE|Bronchoscopy|Undergo bronchoscopy with EBUS-TBNA
223708851|NCT04116970|PROCEDURE|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo bronchoscopy with EBUS-TBNA
223708852|NCT05292547|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS using Magventure TMS system is delivered at the dorsolateral prefrontal cortex of consented subjects according to 3 different stimulation schedules.
223708853|NCT02963649|DEVICE|DCB|Drug Coated Balloon
223708854|NCT02963649|DEVICE|PTA|Percutaneous Transluminal Angioplasty
223708855|NCT05733390|DRUG|JZP541|Oral suspension
223708856|NCT05733390|OTHER|Placebo|Oral suspension
223708857|NCT06116578|DRUG|Pembrolizumab|cf Arm A
223527050|NCT05405270|DRUG|Imiquimod|Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.
223527051|NCT05405270|DIAGNOSTIC_TEST|3x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.
223527052|NCT05405270|OTHER|Expectative management|Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
223527053|NCT05405270|DIAGNOSTIC_TEST|2x vaginal swab for microbiome analysis|A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
223527054|NCT00105066|DRUG|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
223527055|NCT00105066|DRUG|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
223527056|NCT05577741|BEHAVIORAL|Multisensory virtual reality pod (SENSIKS©)|Six sessions of 20 minutes of mindfulness.
223527057|NCT05577741|BEHAVIORAL|Cognitive bike (Vélo-cognitif®)|Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).
223527058|NCT05577741|OTHER|Standard treatment|Standard of care treatment
223527059|NCT02908178|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
223527060|NCT03270995|BEHAVIORAL|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
223527061|NCT03270995|BEHAVIORAL|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
223527062|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
223527063|NCT04028830|OTHER|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support|Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
223708858|NCT06116578|DRUG|Pembrolizumab and Olaparib|cf Arm B
223708859|NCT06116578|DRUG|Pembrolizumab adjuvant|After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year
223708860|NCT06141031|DRUG|TTI-101|TTI-101 is an orally bioavailable, small-molecule inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.
223708861|NCT05134935|DEVICE|Defocus Incorporated Multiple Segment (DIMS) Spectacles|18 months of therapy.
223708862|NCT05134935|DEVICE|Orthokerathology lenses (OKL)|18 months of therapy.
223708863|NCT04533165|BEHAVIORAL|Exercise|12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
223708864|NCT06807216|BEHAVIORAL|YATAC|Age-specific rehabilitation for young adult cancer survivors
223708865|NCT06474221|BEHAVIORAL|Electronic Based Psychosocial Intervention (EBPSI)|Electronic based Psycho-social Intervention (EBPSI) described as video based telepsychiatry sessions targeted on brief intervention and coping skills; with a total of 5 sessions on days 10, 30, 45, 60 and 90 after baseline intervention.
223708866|NCT06659926|OTHER|68Ga-PSMA-PET/CT scan|68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure
223708867|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 5 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
224276205|NCT01096745|DRUG|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
223527066|NCT04417985|DEVICE|18F-FDG PET/CT, MRI|
223527067|NCT02886364|BEHAVIORAL|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
223527068|NCT05036343|DEVICE|InPen®|A smartpen that has been FDA approved for children with diabetes age seven years and older that uses an app on a smartphone to help calculate insulin doses using the amount of carbohydrates that will be consumed at a meal along with what the current blood sugar reading is, to give a correction dose as well. The InPen app also serves as a log book to record insulin doses given, blood sugar at the time of a meal, and amount of carbohydrate eaten.
223527069|NCT00105898|PROCEDURE|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
223527070|NCT00105898|PROCEDURE|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
223527071|NCT00105898|PROCEDURE|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
223527072|NCT01771354|BIOLOGICAL|Engerix B Vaccine|
223527073|NCT01771354|BIOLOGICAL|Placebo|
223527074|NCT02733757|DRUG|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
223527075|NCT00031733|BIOLOGICAL|MART-1 antigen|
223527076|NCT00031733|BIOLOGICAL|gp100 antigen|
223527077|NCT00031733|BIOLOGICAL|incomplete Freund's adjuvant|
223527078|NCT00031733|BIOLOGICAL|recombinant interleukin-12|
223527079|NCT00031733|BIOLOGICAL|sargramostim|
223527080|NCT00031733|BIOLOGICAL|tyrosinase peptide|
223527081|NCT00031733|DRUG|alum adjuvant|
223527082|NCT00031733|PROCEDURE|adjuvant therapy|
223527083|NCT01416350|DRUG|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
223527084|NCT01416350|DRUG|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
223527085|NCT01416350|DRUG|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
223527086|NCT03473587|BEHAVIORAL|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
223527087|NCT03473587|BEHAVIORAL|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
223527088|NCT05990686|DRUG|Tramadol Hydrochloride|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)"
223527089|NCT05990686|DRUG|Fentanyl injection|"After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started...Intravenous injection of 1microgram/kg fentanyl will be given to the patient followed by induction agents ( propofol 2mg/kg).~."
223527090|NCT03815344|DRUG|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
223527091|NCT03815344|DRUG|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
223527092|NCT03577457|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
223527093|NCT03577457|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
223527094|NCT03577457|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
223527095|NCT03577457|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
223527096|NCT05233839|OTHER|Telerehabilitation|Application based video home exercise for the degenerative meniscus injury
223527097|NCT05233839|OTHER|Paper Based Rehabilitation|Paper instruction based home exercise for the degenerative meniscus injury
223527098|NCT03145220|DRUG|EA-230|Active intervention
223527099|NCT03145220|OTHER|Placebo (NaCl)|Placebo intervention
223527100|NCT03346837|DRUG|BMS-986205|BMS-986205
223527101|NCT03346837|DRUG|Itraconazole|Oral solution
223527102|NCT03346837|DRUG|Rifampin|Tablet
223527103|NCT01912573|DRUG|Intranasal (IN) naloxone|
223527104|NCT01912573|DRUG|Intravenous (IV) naloxone|
223527105|NCT01912573|DRUG|Intramuscular (IM) naloxone|
223527106|NCT01912573|DRUG|Intraosseus (IO) naloxone|
223527107|NCT05356715|PROCEDURE|Ultrasound guided bilateral ESBP|Patients in group A will be positioned in the lateral position , ESPB will be done under complete aseptic conditions , using , linear ultrasound probe(Philips HD11XE Ultrasound System) , to locate the ESP at the level of the fifth dorsal vertebrae , 22 G spinal needle will be used to inject 20 ml of 0.25% of bupivacaine in the ESP bilaterally, block will done by an expert anesthesiologist , who will not be included in the data collection
223527108|NCT00895804|DRUG|MDMA|capsule, 1.6 mg/kg body weight, single dose
223527109|NCT00895804|DRUG|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
223527110|NCT02395276|DEVICE|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
223527111|NCT05766605|DRUG|Oxaliplatin|130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
223527112|NCT05766605|DRUG|Doxorubicin|20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
223527113|NCT05766605|DRUG|Lobaplatin|50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
223527114|NCT05766605|DRUG|Cisplatin|50 mg per square body surface area was used for monthly transhepatic arterial infusions.
223527115|NCT05766605|DRUG|Oxaliplatin, Leucovorin, fluorouracil|"Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions"
223527116|NCT05766605|DRUG|Lobaplatin, Raltitrexed|Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
223527117|NCT06513247|DIAGNOSTIC_TEST|screening for Islet autoantibody|IAA, GADA, IA-2A, Zn-transporter 8 autoantibodies
223527118|NCT06513247|DIAGNOSTIC_TEST|HLA phenotype and genetic risk score|using DBS filter paper
223527119|NCT01219257|BIOLOGICAL|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
223527120|NCT03549962|PROCEDURE|TKA|Total Knee Arthroplasty
223527121|NCT03701243|PROCEDURE|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
223527122|NCT03701243|PROCEDURE|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
223527123|NCT01413438|PROCEDURE|Craniotomy|
223527124|NCT05977998|DRUG|Paclitaxel|Given by IP (Intraperitoneal injection)
223527125|NCT05977998|DRUG|Dexamethasone|Given by IV (vein)
223527126|NCT05977998|DRUG|Diphenhydramine|Given by IV (vein)
223527127|NCT05977998|DRUG|Famotidine|Given by IV (vein)
223527128|NCT06377319|DIAGNOSTIC_TEST|Cardiac Output Response to Stress (CORS) test|Cardiac Output Response to Stress (CORS) is a novel, non-invasive, easy-to-use test developed by the Newcastle and Coventry Universities. CORS test measures heart function (cardiac output) at rest and in response to short step-exercise using validated electrical signal processing bioreactance technology, similar to an ECG.
223527129|NCT04881084|OTHER|Digital storytelling group|Participants (intervention- group 1) will watch digital stories, short videos describing the experience of recovering from mental illness created as part of this project. Participants in the control group (group 2) will watch social marketing and/or fundraising campaigns on similar topics and complete a few questionnaires. The following standardized scales will be used: The Level of Familiarity Scale (LOF) (which will be used only before exposure to movies); Toronto Empathy Questionnaire (16 items; internal consistency coefficient .79; test-retest reliability coefficient .73), Compassionate Love Scale (21 items; Cronbach's alpha: .95; item-to-total correlations ranging from .46 to .81), Dispositional Positive Emotions Scale (DPES) (5 items; Cronbach's alpha for the compassion subscale: .80; inter-scale correlations: .44), Self-Stigma of Mental Illness Scale-Short Form (SSMIS-SF) (20 items; Cronbach's alpha: 0.91); Difference and Disdain Scales for Public Stigma (DDSPS) (9 items).
223527130|NCT04881084|OTHER|Social marketing/fundraising group|Participants will be randomly assigned to the social marketing/fundraising group (n = 40 participants; 20 Anglophone and 20 Francophone; ages 18-35). Participants will be asked to watch twenty-six social marketing/fundraising videos which will be assessed using a between-subjects design.
223527131|NCT03157895|BEHAVIORAL|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
223527132|NCT02895555|PROCEDURE|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested allograft.
223527133|NCT02895555|PROCEDURE|Allograft|Approx 50 g of allograft bone in the fused site
223527134|NCT03610698|BEHAVIORAL|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
223527135|NCT03610698|OTHER|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
223527136|NCT04205786|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, orally, 2500 mcg, daily, for 90 days
223527137|NCT04205786|OTHER|Blood collection|"Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA"
223527138|NCT04205786|OTHER|Brief Pain Inventory - Short Form survey|Brief Pain Inventory - Short Form survey
223527139|NCT04205786|OTHER|FACT-ES Trial Outcome Index (Version 4)|FACT-ES Trial Outcome Index (Version 4)
223527140|NCT04205786|OTHER|Questionnaire to Assess Adherence to Aromatase Inhibitors|Questionnaire to Assess Adherence to Aromatase Inhibitors
223527141|NCT04205786|OTHER|Demographics Questionnaire|Demographics Questionnaire
223527142|NCT05642338|DIAGNOSTIC_TEST|WATS3D|the WATS3D brush samples the esophagus by abresing the tissue. the brush is directed through the workingchanel of endoscope into the oesophagus
223527143|NCT01272258|DRUG|PRO 140|SC injection
223527144|NCT01272258|DRUG|Placebo|SC injection
224276206|NCT05129189|DRUG|ASC22 group|The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
223527145|NCT02928835|DEVICE|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
223527146|NCT05292703|OTHER|Participatory activity based on art and olfactory stimulation|practicing art in a group under supervision, involving the participants directly in the creative process, allowing them to become co-authors. Participants will meet once a week for 4 weeks for a 2-hour workshop at the Institut Claude Pompidou in Nice in a dedicated space, A different theme will be offered each week. Each workshop will be led by the same artist who will propose creative activities to be carried out by the participants and each session will result in a creation that the participant will take away, bringing into play artistic skills and olfactory identification capacities.
223527147|NCT05292703|OTHER|practicing art virtually in conjunction with olfactory identification|"For the remote group, , they will receive the connection link to the internet application and an individual connection code.~The intervention is a participative activity based on art and olfactory stimulation which consists of practicing art virtually in conjunction with olfactory identification by following a dedicated program developed in partnership with the same artist involved in the workshops in presence, so that the virtual activities are very similar to those of the face-to-face workshop.~The artistic workshops will take place according to 4 themes with a different theme per week. Each workshop end with an original artistic creation received by email, bringing into play artistic skills and olfactory identification capacities. Each participant will connect once a week at their convenience during 4 weeks."
223527148|NCT02205320|BIOLOGICAL|DRL_PG|
223527149|NCT02205320|BIOLOGICAL|Pegfilgrastim Form A|
223527150|NCT02205320|BIOLOGICAL|Pegfilgrastim Form B|
223527151|NCT03464266|COMBINATION_PRODUCT|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
223527152|NCT03464266|DRUG|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
223527153|NCT03464266|DRUG|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
223527154|NCT03464266|OTHER|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
223527155|NCT06494046|OTHER|Non-Interventional Study|Non-Interventional Study
223527156|NCT00037882|DRUG|PEG-Intron|Once weekly injection.
223527157|NCT03014258|BIOLOGICAL|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
223527158|NCT04943679|DRUG|Anti-PD-1/PD-L1|Intravenous injection for up to 2 years
223527159|NCT04943679|DRUG|PEG-Interferon Alfa|3 µg/kg every week by subcutaneous injection for up to 2 years
223527160|NCT01280331|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
223527161|NCT01280331|DRUG|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
223527162|NCT01280331|DRUG|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
223527163|NCT00005830|DRUG|Doxorubicin Hydrochloride|Given IV
223527164|NCT00005830|DRUG|Cisplatin|Given IV
223527165|NCT00005830|RADIATION|Radiation Therapy|Undergo radiation therapy
223527166|NCT04778566|DIAGNOSTIC_TEST|Cologuard test|Cologuard is a stool-DNA screening test for detecting colon cancer
223527167|NCT06099002|OTHER|Changed Medical research Council,Mini Mental Test, Quadriceps Femoris muscle strength measurement,2 min walking test, fall effectiveness scale,Fall risk self-assessment scale|"All individuals were given a respiratory function test to evaluate respiratory functions before and after training Modified Medical research Council to evaluate dyspnea, Mini Mental Test to evaluate cognitive status~, Berg Balance Test to evaluate balance, 2-minute walk test to evaluate walking speed. A hand dynamometer will be used to measure QuadricepsFemoris muscle strength, Fall efficiency scale Fall risk self-assessment scale will be used to evaluate falls."
223708868|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 10 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
224276207|NCT01422486|DRUG|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
224276208|NCT05713227|DIETARY_SUPPLEMENT|White rice|185 g Jasmine (white) rice boiled in 356 g water
224276209|NCT05713227|DIETARY_SUPPLEMENT|Gellan gum|Food grade hydrocolloid polysaccharide 5.5g dissolved in 356g cooking water containing 185g rice
224276210|NCT04461340|DRUG|Sirolimus|oral dose of 6 mg on day1 followed by 2 mg daily for 9 days
224276211|NCT05998291|OTHER|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention|Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
224276212|NCT04536792|DRUG|AG-946|AG-946, oral encapsulated coated-granules or tablets.
224276213|NCT04536792|DRUG|AG-946 Matched Placebo|AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.
224276214|NCT02289820|BIOLOGICAL|MEDI7510|RSV sF antigen plus adjuvant
224276215|NCT02289820|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
223708869|NCT06859333|DRUG|Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg|Capsules, containing 90 mg of imidazolylethylamide of pentanedioic acid and 20 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid
223708870|NCT06619197|OTHER|Global reflexology|The EMC method is a global reflexology technique inspired by the work of the American naturopath Stanley Burrough (Vitaflex, 1976). It is a method of reflexology on the whole body, of acupressure massages (rhythmic and targeted movements) on so-called \&#34;reflex\&#34; zones which is practiced on different areas of the body (feet, hands, arms, legs, collarbone, ear) and allows the stimulation of all systems.
223708871|NCT02439190|DRUG|BMS-986120|
223708872|NCT02439190|DRUG|Aspirin|
223708873|NCT02439190|DRUG|Clopidogrel|
223708874|NCT02900976|BIOLOGICAL|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
223708875|NCT02900976|BIOLOGICAL|Rituximab|Given IV
223708876|NCT06673147|OTHER|Prenatal Nordic Walking|Traditional Nordic walking poles will be modified according to International Nordic Walking Federation guidelines, which meant that the elbows were bent at a 90°angle when holding the poles in a vertical position. Nordic Walking will be conducted in two phases consisting of a 4-week learning phase followed by an 8-week main phase of intervention.
223708877|NCT05701033|OTHER|Access to heritage|Unmediated access to heritage sites for wellbeing
223708878|NCT06866080|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
223708879|NCT07008235|DRUG|Tablet Amitriptyline 10 milligrams|Tablet Amitriptyline 10 milligrams at night will be given to patients along with standard first line treatment of functional dyspepsia
223708880|NCT07008235|DRUG|Tablet Trifluoperazine 1 milligrams twice daily|Tablet Trifluoperazine 1 milligrams twice daily will be given to patients along with standard first line treatment of functional dyspepsia
223708881|NCT04055948|BEHAVIORAL|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments. (note - intervention sessions 2 \& 3 delivered by phone during COVID-19)
223708882|NCT04055948|BEHAVIORAL|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
223708883|NCT06708104|DEVICE|Outdoor horse-assisted perturbation training|This is balance training in which a special carriage, i.e. a dynamic standing platform, is pulled by a horse on the outside surface, providing the trainee with multi-directional 3D balance perturbations that depend on the topography of the training area (various slopes and surface types), the horse walking speed, and its ability to stop, accelerate, and turns.
223708884|NCT06709183|OTHER|Intervention-Control|Nurses in this group will start the first oral care practice by using the oral care retractor on the model. Before starting the procedure, the nurses will fill in the 'Beck Mouth Assessment Guide' and after the procedure, they will fill in the 'Oral Care Practices Evaluation Form'. A rest period of at least 10 minutes will be provided before the second oral care application. Standard oral care will be applied during the second application. Similarly, nurses will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Assessment Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to collect nurses' experiences and opinions about the oral care procedure. During the interview, audio recordings will be made with the knowledge of the nurses.
223708885|NCT06709183|OTHER|Control - intervention|In the first oral care procedure, nurses in this group will perform standard oral care on the model without using the oral care retractor. They will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. There will be a rest period of at least 10 minutes before the second oral care procedure. During this procedure, the second group of nurses who initially perform standard oral care will perform oral care using an oral care retractor. Similarly, they will complete the 'Beck Oral Assessment Guide' before the procedure and the 'Oral Care Practices Evaluation Form' after the procedure. At the end of both procedures, nurses will complete the 'Quebec Assistive Technology User Satisfaction Assessment Questionnaire (Q-ATUSA)' and the 'Interview Form'. The 'Interview Form' will be used to obtain nurses' experiences and opinions regarding oral care practices..
223708886|NCT07049523|DEVICE|Robotic-assisted gait training|"The intervention group will receive robotic-assisted gait training using the RoboCT Pediatric Lower Limb Rehabilitation Robot (RoboCT Limited Co., Hangzhou, China), a pediatric exoskeleton system designed for overground locomotor training. This device integrates real-time motion sensing, adaptive control algorithms, and customizable joint actuation to deliver precise and individualized gait training for children with minimal voluntary motor control. The system allows for the modulation of key gait parameters including joint angles, step length, and walking speed, and incorporates both postural correction and dynamic support harnessing to maintain safety and alignment throughout the session.~Robotic sessions will be conducted three times per week over a period of 24 weeks, with each session lasting approximately 45 minutes. All sessions will be conducted at a designat"
223708887|NCT07048002|OTHER|Managements for NeuroFirst target bundle|"In the intervention group, patient management aims to achieve the NeuroFirst target bundle, including 1) mean arterial pressure (MAP) 65-90 mmHg or within 10% preoperative baseline values, 2) bispectral index (BIS) 40-60, 3) regional cerebral oxygen saturation (rSO2)≥ 60% or within 10% preoperative baseline values, and 4) arterial inflow temperature \<37 ℃ and rewarming rate \< 0.5 ℃/min after exceeding 30℃ during CPB.~To achieve this target bundle, pharmacologic agents, fluid resuscitation, blood transfusion, and other therapeutic modalities will be utilized. These interventions are guided by comprehensive intraoperative monitoring, including conventional hemodynamic monitoring, invasive or non-invasive cardiac output and vascular resistance assessments."
223708888|NCT07048002|OTHER|Managements for institutional routine|MAP, BIS, cerebral rSO2 and arterial inflow temperature during CPB rewarming, will be managed according to institutional routine in accordance with published guidelines.
223708889|NCT07048158|DIETARY_SUPPLEMENT|Perfect Heartio Drink|Perfect Heartio (PH) drink is a nutritional drink composed of diluted herbal extracts of TCM, including ginger, Glycyrrhiza uralensis, Alternanthera sessilis, Panax notoginseng, Red date, Codonopsis pilosula, Ligusticum chuanxiong, Astragalus membranaceus.
224276216|NCT04318431|DIAGNOSTIC_TEST|Data collection and rhinopharyngeal swab|Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
223708890|NCT07053592|BEHAVIORAL|Geriatric Ｂeauty and Ｈealth Care Learning Program|An educational course on geriatric care designed to enhance students' attitudes toward older adults and learning outcomes. The intervention includes lectures, group discussions, and interactive learning activities. Effectiveness is measured using pre- and post-course surveys and focus group interviews.
223708891|NCT07055204|OTHER|"Diapason & Metronome musical learning"|Participants will make music with the two instruments we all have in common: the voice and the body. The method is three-dimensional built on: rhythm, simple sound and harmony. The music sessions will take place in the same place and on the same day of the week, at a fixed time to establish a regularity that is suitable to this population. The courses will be taught in a cultural location, both to give meaning to the approach on a contextual level and to allow patients to be in the city and not in the hospital. A training of the music teachers will be planned before the beginning of the study. This training combined with regular debriefings during the music sessions, should ensure that the teachers' practices are consistent across the different groups.
223708892|NCT06902129|DEVICE|EDDIS Platform - Portable Inhalation Delivery Systems (VMT, Atomizer, Ultrasonic)|A set of three single-use, disposable, closely matched and uniform in size, breath-actuated, digitally monitored portable inhalation devices designed for precision aerosol delivery. Devices include a vibrating mesh (VMT), an atomizer-based unit (ATM), and an ultrasonic micro-vibration unit (ULT). Each system records inhalation parameters and connects via Bluetooth to a mobile application for real-time feedback and logging. Used to assess technical performance, gas dynamics, and digital control functions using a non-active NaCl-based aerosol with chitosan nanoparticles.
223708893|NCT04006613|OTHER|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
223708894|NCT04006613|OTHER|Usual Care|Exercises aimed at improving mobility and balance
223708895|NCT03800914|OTHER|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
223708896|NCT03800914|OTHER|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
223708897|NCT06913764|DEVICE|class I compression stockings of the RAL-GZ 387 standard: 1 month using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) above-knee graduated compression stockings
223708898|NCT06913764|DEVICE|class II compression stockings of the RAL-GZ 387 standard: 1 month using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
223708899|NCT06933017|DEVICE|Portable mask for respiratory gas analysis|This is a portable mask, which is connected to the SplendoHealth app. The Polar sens 10 heartrate monitor and TrainRed NIRS device are also connected to this app. The three devices (mask, heartrate monitor and NIRS) are measuring respiratory gases, heart rate and muscle tissue oxygenation simultanuously and at the end of the 6 min step test, you get an individual cardiorespiratory fitness report.
223708900|NCT06933017|DEVICE|Cardio-pulmonary exercise test|Golden standard for measuring PEM: the double cardio-pulmonary exercise test on a bike.
223708901|NCT06772532|DRUG|BI 456906 - Formulation A|Formulation A
223708902|NCT06772532|DRUG|BI 456906 - Formulation B|Formulation B
223708903|NCT06772532|DRUG|BI 456906 - Formulation C|Formulation C
223708904|NCT02346552|DEVICE|AutoLap|
223708905|NCT00219739|DRUG|Imatinib mesylate 400 mg|
223708906|NCT00219739|DRUG|Imatinib mesylate 600 mg|
223708907|NCT00219739|DRUG|Imatinib 400 mg + Peg-Interferon|
223708908|NCT00219739|DRUG|Imatinib mesylate 400 mg + Cytarabine|
223708909|NCT03740633|BEHAVIORAL|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
223708910|NCT03740633|BEHAVIORAL|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
223708911|NCT03740633|COMBINATION_PRODUCT|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
223708912|NCT06384690|DIETARY_SUPPLEMENT|Micro-vegetable blend|The intervention in this study is 6 weeks with a daily proprietary blend micro-vegetables that has been freeze-dried
223708913|NCT06384690|DIETARY_SUPPLEMENT|Placebo|The intervention in this study is 6 weeks with a placebo supplement
223708914|NCT06680193|BEHAVIORAL|Processing of Positive Memories Technique|"PPMT was administered weekly as a 4-session protocol. In session 1, participants receive psychoeducation on PTSD symptoms, an overview of PPMT, and are assessed for psychological symptoms. Sessions 1-4 involve the detailed processing of a salient positive autobiographical memory to elicit values, affect, strengths, and thoughts related to that positive memory. Homework assignments include listening to an audio recording of that memory, completing a values, affect, strengths, and thoughts log, and engaging in a behavioral activity. In session 4, the therapist also reviews psychological symptoms and addresses termination."
223708915|NCT06709573|DRUG|vasopressin - early initiation|BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 10-20 mcg/min
223708916|NCT06709573|DRUG|vasopressin - standard initiation|BPA fires to provider prompting vasopressin initiation when the norepinephrine dose is between 20-35 mcg/min
223708917|NCT06951191|DRUG|Benzocaine 20%|Benzocaine 20% topical spray
223708918|NCT06951191|DRUG|Lidocaine 2%|Lidocaine 2% injectable solution
223708919|NCT06951191|OTHER|Sham injection|Sham injection to mimic Lidocaine paracervical block. Will use an injection needle and sham inject (no actual injection of fluid)
223708920|NCT06951191|DRUG|Saline 0.9%|Saline spray to mimic use of benzocaine spray
223708921|NCT03128047|DEVICE|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab.
223708922|NCT06775327|DRUG|INCB000631|Oral; Tablet
223708923|NCT06775327|DRUG|Placebo|Oral; Tablet
223708924|NCT01995825|DRUG|Brand lamotrigine|Brand lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
223708925|NCT01995825|DRUG|Generic lamotrigine|Generic lamotrigine tablet 100mg tablets (1-3 either once or twice a day) for two weeks
223708926|NCT00605111|DRUG|biphasic insulin aspart|
223708927|NCT01866774|OTHER|Fecal calprotectin level|
223708928|NCT00002210|DRUG|Delavirdine mesylate|
223708929|NCT03959358|DRUG|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
223708930|NCT03959358|DRUG|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
223708931|NCT01130142|DRUG|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
223708932|NCT01130142|DRUG|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
223708933|NCT06050278|OTHER|Tapestry technology|The study involves the immediate freezing and preservation in liquid nitrogen of a tumor histological sample from surgical resection, obtained from the operating room, within one hour of removal. Surgery is part of the normal clinical practice of patients with lung cancer.
223708934|NCT03809143|DRUG|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
223708935|NCT04127864|PROCEDURE|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
223708936|NCT01539694|DEVICE|LD118033 contact lens|Multifocal contact lens worn on a daily wear basis for 1 week
223708937|NCT01539694|DEVICE|PureVision multifocal contact lens|PureVision multifocal contact lens worn on a daily wear basis for 1 week.
223708938|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
223893753|NCT06786247|BEHAVIORAL|Behavioral Activation|Behavioral activation therapy involves individual weekly sessions with a trained therapist for 12 weeks. The sessions are completed either in-person or via telehealth. The treatment focuses on behavioral manifestations of depression such as isolating, and how these behaviors are interconnected with low mood and depressive emotions. BA helps patients find ways to engage in behaviors that are meaningful to them based on their values, priorities, and goals, with the aim of creating positive loops between doing meaningful activities and improved mood. The therapist provides structure and problem-solving for activating these behaviors and keeping track of changes over time.
223708939|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
223708940|NCT00403234|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
223708941|NCT00403234|DRUG|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
223708942|NCT04944069|DRUG|Almonertinib|110 mg oral once daily
223708943|NCT04944069|DRUG|Bevacizumab|15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
223708944|NCT02139111|DRUG|Placebo|Oral placebo capsule
223708945|NCT02139111|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
223708946|NCT02139111|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
223708947|NCT02139111|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
223708948|NCT02139111|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
223708949|NCT02606448|DRUG|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
223708950|NCT02606448|PROCEDURE|Femoral nerve block|Pre-operative femoral nerve block
223708951|NCT02606448|DRUG|Ropivacaine|Ropivicaine was used in all femoral nerve blocks
223708952|NCT04694781|DRUG|LVGN6051|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
223708953|NCT04694781|DRUG|Pembrolizumab|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks (Q3W). one cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
223708954|NCT01880502|DRUG|Belviq 10mg|Belviq 10mg single dose administration
223708955|NCT01880502|DRUG|Belviq 20mg|Belviq 20mg single dose administration
224276217|NCT01812473|OTHER|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
223708956|NCT01880502|DRUG|Placebo|Placebo single dose administration
223708957|NCT01581788|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
223708958|NCT04407364|DEVICE|CoMatryx Surgical Bovine Collagen|The CoMatryx surgical collagen powder is a soft tissue repair product made of 100% type I bovine collagen
223708959|NCT01810874|PROCEDURE|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
223708960|NCT01810874|PROCEDURE|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
223708961|NCT01542125|DRUG|Liposomal Lidocaine|4% Liposomal Lidocaine
223708962|NCT01542125|DRUG|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
223708963|NCT00957970|DEVICE|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
223708964|NCT00957970|DEVICE|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
223708965|NCT00261144|DRUG|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
223708966|NCT00261144|BIOLOGICAL|Biological|Collagenase injection
223708967|NCT00304291|DRUG|Mitoxantrone|
223708968|NCT05846074|DIAGNOSTIC_TEST|sweat samples and used face mask will be collected|Collection of sweat samples and used face mask will take approximately 15 minutes before or after collection for the SARS-Cov PCR test
223708969|NCT04967144|DIAGNOSTIC_TEST|Nerve conduction study|"Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study."
223708970|NCT04967144|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Test|Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
223708971|NCT00488462|DEVICE|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
223708972|NCT04966624|PROCEDURE|"LUVS ventilatory strategy composed of a bundle of measures"|Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
223708973|NCT04966624|PROCEDURE|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)|Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
223708974|NCT01148472|DRUG|Escitalopram|20mg once daily; orally
223708975|NCT01148472|DRUG|Duloxetine|60mg once daily; orally
223708976|NCT03967652|DIAGNOSTIC_TEST|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
223708977|NCT00027261|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
223708978|NCT00763568|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
223708979|NCT00763568|BIOLOGICAL|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
223708980|NCT01925105|OTHER|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
223708981|NCT04779060|DRUG|intrathecal fentanyle|25 mic fentanyle added to heavy bupivacaine for spinal anesthesia
223708982|NCT04779060|DRUG|dexamethasone|8 mg dexamethasone give intrathecally for spinal anaesthesia
223708983|NCT04779060|DRUG|saline|normal saline will be mixed with bupivacaine intrathecally
223708984|NCT01419678|OTHER|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
223708985|NCT05907876|OTHER|Functional Test|UULEX uses a table of horizontal parallel lines with 8 levels. Each level is 84 cm wide and 8 cm high. The distance between the levels is 15 cm. The subject is seated on a straight chair with his/her feet on the floor facing the wall with the UULEX table. He/she holds a bar weighing 0.2 kg and lifts the bar at hip level. Keeping his/her arms shoulder-width apart, he/she raises the bar to different levels of the chart. As a warm-up, he/she is instructed to raise the bar to the first level and hold this position for 2 minutes. Then the bar is moved to each level and the levels are increased for 1 minute. The starting and ending point of each level is the hip joint. As the exercise progresses each minute, the weight of the bar is increased by 0.5 kg up to a maximum of 2 kg. During the test, a subject can move up to a maximum of a 2kg bar in a maximum of 12 minutes. The subject is instructed to continue the test until limited by the occurrence of symptoms.
223708986|NCT02155062|OTHER|Whole grain rye|
223708987|NCT02155062|OTHER|Whole grain wheat|
223708988|NCT02155062|OTHER|Refined cereal|
223708989|NCT00739674|DRUG|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~* Losartan 50 mg~* Losartan 100 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~* Losartan 50 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 12.5 mg~* Losartan 100 mg/HCTZ 25 mg~* Losartan 100 mg/HCTZ 25 mg + CCB~* Losartan 100 mg/HCTZ 25 mg + increasing CCB"
223708990|NCT00739674|BEHAVIORAL|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension \[DASH\]) including:~* Healthy diet~* Reduction in sodium intake to less than 2300 mmol/day~* Low alcohol consumption (less than 2 standard drinks/day)"
223708991|NCT01594281|DRUG|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
223708992|NCT01594281|PROCEDURE|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
223708993|NCT05392296|OTHER|Power ball|experimental group getting the power ball training with conventional treatment.
223708994|NCT05392296|OTHER|isometric hand grip strengthening exercises|conventional treatment (isometric hand grip training exercises)
224276218|NCT00926367|DRUG|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
224276219|NCT00926367|DRUG|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
224276220|NCT00684944|DRUG|TRx0014|Gelatin capsule, tid
223708995|NCT02373852|DEVICE|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
223708996|NCT04805541|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
223708997|NCT04805541|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
223708998|NCT04805541|DEVICE|EyeCheckup - AI Based DR Screening|"Screening for existence of More than mild or Vision-threatening Diabetic Retinopathy, and/or Diabetic Macular Edema."
223708999|NCT02971397|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223709000|NCT02971397|DRUG|Cytarabine|Given IV
223709001|NCT02971397|DRUG|Daunorubicin Hydrochloride|Given IV
223709002|NCT02971397|OTHER|Laboratory Biomarker Analysis|Correlative studies
223709003|NCT02449655|DRUG|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
223709004|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
223709005|NCT02449655|DRUG|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
223709006|NCT02449655|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
223709007|NCT02033616|BIOLOGICAL|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
223709008|NCT02033616|BIOLOGICAL|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
223709009|NCT03695250|DRUG|IDO1 Inhibitor BMS-986205|Given PO
223709010|NCT03695250|BIOLOGICAL|Nivolumab|Given IV
223709011|NCT06805253|OTHER|Not applicable - observational study|observation only
223709012|NCT02074644|PROCEDURE|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
223709013|NCT02074644|PROCEDURE|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
223709014|NCT03243071|BEHAVIORAL|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
223709015|NCT03243071|BEHAVIORAL|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
223709016|NCT05191524|OTHER|Constrained induced movement|Practice in two sessions per day (supervised) for 3 days per week, for six consecutive weeks. The unaffected limb will be constraint using a knee immobilizer only during practice sessions. We will perform the interventions under the supervision of a trained physiotherapist.
223709017|NCT05191524|OTHER|Proprioceptive Neuromuscular facilitation|Group B will receive PNF intervention given for 30 minutes to the lower limb 3 times a week for 6 weeks
223709018|NCT03268902|DRUG|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
223709019|NCT03268902|DRUG|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
223709020|NCT03268902|DIETARY_SUPPLEMENT|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
223709021|NCT03268902|DRUG|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
223709022|NCT04034485|DRUG|lerodalcibep|PCSK9 inhibitor
223709023|NCT04034485|DRUG|evolocumab|PCSK9 inhibitor
223709024|NCT05055362|OTHER|Honey Spice Group|Consume baked good daily for 10 days and provide samples of saliva, urine and dietary habits and spice intake.
223709025|NCT05144360|DRUG|Atenas|ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
223709026|NCT05144360|DRUG|Atenas placebo|Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
223709027|NCT00283400|DRUG|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
223709028|NCT02339272|OTHER|non interventional|
223709029|NCT05693558|BIOLOGICAL|NVD-003, an autologous 3D scaffold free osteogenic graft|Bone correction and grafting surgery
223709030|NCT04010149|DEVICE|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
223709031|NCT04010149|DEVICE|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
223709032|NCT04171778|OTHER|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
223709033|NCT05614505|DIETARY_SUPPLEMENT|Ready to use therapeutic foods|locally produced therapeutic foods
223709034|NCT02443766|OTHER|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
223709035|NCT02349087|DEVICE|Acute EEG with fast applicable EEG electrode|
223709036|NCT04177797|DRUG|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
223709037|NCT01818232|DRUG|[14C]-LX4211|
223709038|NCT01182987|BEHAVIORAL|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
223709039|NCT00081068|BIOLOGICAL|alemtuzumab|
223709040|NCT00294437|DRUG|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
223709041|NCT03478202|DIETARY_SUPPLEMENT|GOLO RELEASE|GOLO RELEASE plus Diet
223709042|NCT03801291|PROCEDURE|Transvaginal repair|Vaginal incision through which plication of the rectovaginal septum is done
223709043|NCT03801291|PROCEDURE|Transperineal repair|Perineal incision through which plication of the rectovaginal septum is done
223709044|NCT01709513|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets.
223709045|NCT01709513|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet.
223709046|NCT01709513|DRUG|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
223709047|NCT01709513|DRUG|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
223709048|NCT01560403|DRUG|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
223709049|NCT06256965|DIAGNOSTIC_TEST|Detection of peri-operative atrial fibrillation|atrial tissue and plasma from patients with atrial fibrillation detection were analyzed for determine lipid and protein oxidation, and detect markers of myocardial injury.
223709050|NCT03166735|DRUG|BI 1467335|once daily
223709051|NCT03166735|DRUG|Placebo|once daily
223709052|NCT01543958|DRUG|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
223893754|NCT03774082|DRUG|INC424|"Ruxolitinib was taken orally based on age groups as follows:~Group 1 (\>=12y to \<18y): 10mg bid as tablet Group 2 (\>=6y to \<12y): 5mg bid as tablet or liquid Group 3 (\>=2y to \<6y): 4mg/m2 bid as liquid"
223709053|NCT01543958|DEVICE|Sevelamer carbonate|
223709054|NCT04019288|DRUG|Batiraxcept|Given IV
223709055|NCT04019288|BIOLOGICAL|Durvalumab|Given IV
223709056|NCT04401423|DRUG|TXA127|0.5 mg/kg per day
223709057|NCT04401423|DRUG|Placebo|0.5 mg/kg per day
223709058|NCT04781023|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
223709059|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
223709060|NCT00639912|DRUG|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
223709061|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
223709062|NCT00639912|DRUG|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
223709063|NCT00691314|DEVICE|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
223709064|NCT00691314|DRUG|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
223709065|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
223709066|NCT02996578|DIETARY_SUPPLEMENT|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
223709067|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
223709068|NCT02996578|DIETARY_SUPPLEMENT|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
223709069|NCT00049192|BIOLOGICAL|oblimersen sodium|Given IV
223709070|NCT00049192|DRUG|imatinib mesylate|Given PO
223709071|NCT00049192|OTHER|laboratory biomarker analysis|Correlative studies
223709072|NCT01728909|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
223709073|NCT01728909|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
223893755|NCT05093829|BIOLOGICAL|NmCV-5|NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).
223893756|NCT05093829|BIOLOGICAL|MenACWY-TT|MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.
223709074|NCT01099137|DRUG|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
223709075|NCT01099137|DRUG|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
223709076|NCT01112358|DRUG|r-FSH|r-FSH will be administered as specified in the arm description.
223709077|NCT01112358|DRUG|r-hLH|r-hLH will be administered as specified in the arm description.
223709078|NCT01112358|DRUG|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
223709079|NCT01112358|DRUG|r-hCG|r-hCG will be administered as specified in the arm description.
223709080|NCT01112358|DRUG|Progesterone|Progesterone will be administered as specified in the arm description.
223709081|NCT02513342|BIOLOGICAL|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
223709082|NCT02513342|DRUG|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
223709083|NCT02513342|DRUG|Cisplatin|d4，cisplatin，75（mg/m2），iv；
223709084|NCT04389853|PROCEDURE|Flexible ureteroscopy|Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
223709085|NCT04389853|PROCEDURE|Mini-percutaneous nephrolithotomy|PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
223893757|NCT05212610|BIOLOGICAL|Pfizer-BioNTech mRNA COVID-19 vaccine|Participants will receive an initial or additional dose of a highly protective COVID-19 mRNA vaccine for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in an environment where the investigators and staff are experienced in the care of patients with allergic reactions.
224276221|NCT04511572|PROCEDURE|embolization of the middle meningeal artery|The embolization procedure will be as follows: first femoral artery access will be obtained by using a 5 French micropuncture kit and common carotid and external carotid angiography is performed using a standard 5 French diagnostic catheter. A microcatheter is then advanced selectively under roadmap guidance into the middle meningeal artery (MMA), and MMA angiography is performed to evaluate for potential dangerous anastomoses such as the orbital branch to the ophthalmic artery. Embolization is performed using polyvinyl alcohol particles (100 microns in diameter) under blank fluoroscopic roadmap while carefully avoiding reflux. Particles are infused until lack of anterograde flow into the MMA branches is demonstrated on angiography, and the catheters are removed \[31\]. The procedure is performed under local anesthesia.
224276222|NCT06163417|PROCEDURE|laparoscopic|laparoscopic
224276223|NCT03493035|DIAGNOSTIC_TEST|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
223709086|NCT06089499|BEHAVIORAL|Get Palliative Care: four educational learning module videos|Organizational Sponsored public domain educational videos
223709087|NCT03989700|DRUG|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
223709088|NCT00667407|DRUG|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
223709089|NCT00667407|DRUG|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
223709090|NCT00347568|DEVICE|TX-plore|PI has terminated at institution and there is no one available to report.
223709091|NCT01933061|DRUG|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
223709092|NCT01933061|DRUG|Abraxane|Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
223709093|NCT04669132|DRUG|Olanzapine|\- Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
223709094|NCT04669132|DRUG|Netupitant|\- Netupitanto 300 mg, once daily, on chemotherapy day;
223709095|NCT04669132|DRUG|Palonesetron|\- Palonosetron 0.56 mg, once daily, on chemotherapy day;
223709096|NCT01519271|DRUG|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
223709097|NCT01519271|DRUG|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
223709098|NCT01664546|PROCEDURE|Trophectoderm biopsy|
223709099|NCT00791960|DRUG|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
223709100|NCT00791960|OTHER|Placebo|single dose, 10 mL normal saline, IV
223709101|NCT04713215|OTHER|Questionnaire|A short (approximately 20-minute) questionnaire will be administered to patients and carers who meet the inclusion criteria and who have expressed and interested, and consented to completing the questionnaire.
223709102|NCT01140893|DRUG|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
223709103|NCT01140893|DRUG|Placebo|Placebo
223893758|NCT06797765|DEVICE|OCTA|Optical Coherence Tomography Angiography
223527168|NCT03483701|BEHAVIORAL|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
223527169|NCT00572819|DRUG|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
223527170|NCT00572819|DRUG|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
223527171|NCT05007132|BIOLOGICAL|Panitumumab 20 milligram/ML|Participants receive Panitumumab at 6mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
223527172|NCT05007132|BIOLOGICAL|Bevacizumab|Participants receive bevacizumab at 5 mg/ kg intravenously (IV) on Day 1 and 15 of each 28-day cycle. Treatment is continued until occurrence of progression according to RECIST 1.1 criteria as evaluated by the investigator or unacceptable toxicity.
223527173|NCT05007132|DRUG|Trifluridine/Tipiracil Hydrochloride|Participants receive Trifluridine/tipiracil at 35 mg/m² BSA, twice daily, orally on days 1-5 and 8-12
223527174|NCT01506726|DRUG|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
223527175|NCT01506726|DRUG|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
223527176|NCT01957384|DEVICE|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
223527177|NCT01957384|DEVICE|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
223527178|NCT01957384|DEVICE|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~* Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~* Dansac: Nova 1 \& Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~* Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~* ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~* B. Braun: Flexima Active \& Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
223527179|NCT01825863|DRUG|Ropivacaine|
223527180|NCT01825863|DRUG|Saline 9%|
223527181|NCT02006511|DEVICE|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
223527182|NCT02006511|OTHER|Standard of Care wound therapy|Gauze type dressing.
223527183|NCT01283672|OTHER|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
223527184|NCT01413815|DIETARY_SUPPLEMENT|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
223527185|NCT01413815|OTHER|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
223527186|NCT05743309|BEHAVIORAL|Video call sessions|Investigators made video call sessions with the participants.
223527187|NCT04017208|DRUG|ASP2713|Administered intravenously
223527188|NCT04017208|DRUG|placebo|Administered intravenously
223527189|NCT00099814|PROCEDURE|Two different loop designs which deliver distinctive forces|
223527190|NCT05443321|OTHER|Health Information Exchange (HIE) platform|An improved health information exchange (HIE) platform will be developed at the start of the study with key stakeholder input. This platform will be implemented for use after baseline data collection, and will allow for improved data exchange between transferring and accepting hospital. We will allow for a 6-month wash-in period prior to intervention data collection.
223527191|NCT05492045|DRUG|D-1553|D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
223527192|NCT05492045|DRUG|Other|Standard treatment of NSCLC.
223527193|NCT04748237|DIAGNOSTIC_TEST|Coronary computed tomopraphic angiography|CCTA as soon as possible, preferably within 24 hours, but not later than within 21 days.
223527194|NCT02259231|DRUG|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
223527195|NCT02259231|DRUG|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
223527196|NCT02259231|DRUG|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
223527197|NCT02259231|DRUG|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
223527198|NCT02259231|DRUG|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
223527199|NCT06293898|DRUG|BL-M07D1|"Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 by intravenous infusion every 3 weeks.~Other Names:~BL-M07D1"
224276224|NCT03493035|DIAGNOSTIC_TEST|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
224276225|NCT06480825|OTHER|Performance of ultrasonographic scan|Ultra-high frequency ultrasonographic scan of gingival tissues
224276226|NCT06454214|DEVICE|Multi-photon microscopy|To conduct 3D structural imaging on human breast tissues
223709104|NCT03208205|PROCEDURE|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
223709105|NCT01313793|DRUG|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
223709106|NCT01313793|DRUG|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
223709107|NCT06241833|DRUG|PPI|use of PPI concomitant with DAPT
223709108|NCT01101503|DRUG|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~1. For blood glucose control, target HbA1c \>=5.5%and \<=6.0%,fasting blood glucose \>=5.0 mmol/L and \<=6.0 mmol/L, postprandial 2 hour glucose \>= 6.0 mmol/L and \<= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \< =1.9 mmol/L, triglyceride \< =1.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>=120/70 mmHg and \<= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
223709109|NCT01101503|DRUG|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~1. For blood glucose control, target HbA1c \>6.5%and \<=7.0%,fasting blood glucose \>6.0 mmol/L and \<=7.0 mmol/L, postprandial 2 hour glucose \> 7.8 mmol/L and \<= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~2. For blood lipids control, target LDL-C \> 1.9 mmol/L and \< =2.5 mmol/L, triglyceride \> 1.5 mmol/L and \< = 2.5 mmol/L. The drugs include statin and fibrate.~3. For blood pressure control, target \>130/80 mmHg and \<= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~4. Others, such as aspirin."
223709110|NCT01497158|OTHER|Self-help brochure|Self help brochure given at baseline visit.
223709111|NCT01497158|OTHER|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
223709112|NCT02456441|OTHER|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
223709113|NCT02456441|OTHER|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
223709114|NCT06477081|PROCEDURE|FS-LASIK procedure|For the FS-LASIK technique, the following steps will be followed: application of topical anesthesia to mitigate discomfort and pain throughout the procedure, and the patient will be covered with a sterile drape. Subsequently, the patient will be aligned to artificially flatten the entire corneal surface, ensuring head stability with a slight tilt to optimize surgical access and avoid nasal interference. The femtosecond laser system use will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which is responsible for creating a corneal incision to create the flap, with controlled precision to ensure proper separation of corneal layers. The excimer laser will be the Amaris (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), responsible for performing refractive correction on the cornea through selective photoablation. Following photoablation, the flap will be carefully repositioned, and upon completion o
223709115|NCT06477081|PROCEDURE|KLEx|For the KLEx technique, the following steps will be followed: after topical anesthesia, a sterile drape is placed over the patient, and a speculum is inserted into the eye, centered, and aligned with a curved interface cone before applying suction. The laser used will be the ATOS operating system (Schwind eye-tech-solutions, Mainparkstraße 6-10, 63801 Kleinostheim, Germany), which performs photo-dissection starting from the posterior surface of the refractive lenticule, followed by the creation of the lenticule edge. The anterior surface of the refractive lenticule is formed by extending beyond the posterior diameter of the lenticule by 0.5 mm to form the anterior flap, followed by a peripheral cut. Specific FS laser parameters are employed for each patient. Subsequently, the suction is released, and a Siebel spatula is used to separate and reflect the flap. Finally, the refractive lenticule is extracted using toothless forceps through the small incision. Once the procedure is complete
223709116|NCT01489800|BEHAVIORAL|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
223709117|NCT03475368|OTHER|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
223709118|NCT03475368|OTHER|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
223709119|NCT03475368|OTHER|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
223709120|NCT02671305|PROCEDURE|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
223709121|NCT02671305|PROCEDURE|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
224276227|NCT01022255|BIOLOGICAL|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
224276228|NCT03294317|DEVICE|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
223709122|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
223709123|NCT02349321|BEHAVIORAL|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
223709124|NCT02040493|RADIATION|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
223709125|NCT06455644|OTHER|CT group|After completing the AF ablation, select the appropriate LAA occluder based on preoperative CT measurements for implantation.
223709126|NCT06455644|OTHER|DSA group|After completing the AF ablation, select the appropriate LAA occluder based on intraoperative DSA measurements for implantation.
223709127|NCT05317182|OTHER|Occlusal Splints Analogic-Analogic|Take a conventional impression to the patient and conventional fabrication of the splint.
223709128|NCT05317182|OTHER|Occlusal Splints Analogic-Digital|Take a conventional impression to the patient and digital fabrication of the splint.
223709129|NCT05317182|OTHER|Occlusal Splints Digital-Digital|Take a digital impression to the patient and digital fabrication of the splint.
223709130|NCT02200432|OTHER|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
223709131|NCT03198572|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
223709132|NCT03198572|DRUG|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
223709133|NCT03198572|DRUG|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
223709134|NCT00040365|DRUG|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
223709135|NCT00040365|RADIATION|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
223709136|NCT00541931|DRUG|Dietary Supplement: LifePak Nano|Daily use
223709137|NCT01460888|DRUG|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
223709138|NCT01460888|RADIATION|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
223709139|NCT04194398|DEVICE|OCS Lung System|Patients previously transplanted with lungs preserved on the OCS Lung System in the Expand Lung study.
223709140|NCT05292443|OTHER|Observation|observe the association of ctDNA with efficacy of treatment
223709141|NCT02555683|DRUG|QAW039|QAW039 150 mg once daily
223709142|NCT02555683|DRUG|QAW039|QAW039 450 mg once daily
223893759|NCT06832163|DEVICE|Nitric Oxide Generation and Delivery System|"The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.~iNO devices with intelligent closed-loop offline function are required to meet the import and discharge standards. The initial concentration of NO withdrawal is 20ppm. In accordance with the withdrawal criteria outlined in the Chinese Guidelines, it is essential to conduct a comprehensive efficacy evaluation prior to initiating withdrawal. Furthermore, the process of inhaled nitric oxide (iNO) evacuation should commence only if specific conditions are satisfied."
223709143|NCT02555683|DRUG|Placebo|Placebo once daily
223709144|NCT00402415|DRUG|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
223709145|NCT00402415|DRUG|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
223709146|NCT01785693|DRUG|levobupivacaine, clonidine|
223709147|NCT05801276|DIAGNOSTIC_TEST|Methylation assay|Methylation assay of CDO1 and HOXA9 genes in plasma circulating tumor DNA
224276229|NCT02310503|PROCEDURE|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
223709148|NCT05911516|DIETARY_SUPPLEMENT|Pennisetum purpureum|300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
223709149|NCT05911516|DIETARY_SUPPLEMENT|Placebo|Placebo
223709150|NCT05297396|OTHER|Slow Tapering of Chronic Opioid Therapy|Clinically prescribed daily opioids reduced by no more than 10 morphine milligram equivalent per day (MMED) each month for 12 months
223709151|NCT06149546|DIETARY_SUPPLEMENT|Control|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Four scheduled appointments with a dietitian"
223709152|NCT06149546|DIETARY_SUPPLEMENT|Intervention|"* High protein, high energy diet~* Fish oil supplement (ProSure®)~* Pancreatic Enzymes (Creon®)~* A daily individualised step target (10% above your own baseline)~* Seven scheduled appointments with a dietitian~* Six scheduled appointments with a physiotherapist"
223709153|NCT05396612|OTHER|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.|Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
223709154|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein prior to and immediately after resistance training|This arm involved protein ingestion immediately prior to and immediately after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
223709155|NCT05544955|DIETARY_SUPPLEMENT|isolate whey protein 3 hours prior to and 3 hours after resistance training|This arm involved protein ingestion 3 hours prior to and 3 hours after resistance training for 12 weeks. Participants will consume 40 g of isolate whey protein at their recommended timing.
223709156|NCT00526513|DRUG|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
223709157|NCT01562418|BEHAVIORAL|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
223709158|NCT01562418|BEHAVIORAL|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
223709159|NCT01562418|BEHAVIORAL|control group|general instructions no intervention
223709160|NCT06372964|DRUG|Lumateperone|Lumateperone administered orally, once daily.
223709161|NCT06372964|DRUG|Placebo|Matching placebo administered orally, once daily.
223709162|NCT05595096|PROCEDURE|General anesthesia with preservation of spontaneous breathing|non-intubation group, thoracic paravertebral nerve block was performed before anesthesia induction,when the BIS value drops to between 40 and 60, laryngeal mask airway(LMA) is placed,and observation of breathing
223709163|NCT03191422|BEHAVIORAL|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
223709164|NCT02004483|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
223709165|NCT05238402|DRUG|Statin|Statin on COVID 19 patienst
223709166|NCT02061774|DRUG|Acetaminophen|1 gram of intravenous Acetaminophen
223709167|NCT02061774|DRUG|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
223709168|NCT04396678|BEHAVIORAL|PrEP standard of care+behavioral intervention|The intervention includes three main components: 1) group PrEP engagement sessions, which include four educational sessions that situate PrEP in a broader framework of access and barriers to care, provider/patient communication, sexual health, HIV/STI education, harm reduction around drug use, stigma, risk compensation and safe sex, and health/science literacy; 2) peer navigation, which aims to help women navigate healthcare engagement with the SPARC nurse practitioner and other providers; and 3) an mHealth component, consisting of a two-way text messaging system through which women will receive automated daily messages and weekly messages requesting adherence reports.
223709169|NCT01724918|DRUG|Lacosamide|
223709170|NCT06312345|DRUG|Drug: ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
223709171|NCT06190990|OTHER|Otago Exercise + Exer gaming|In this group the participant will receive otago exercises and exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 week
223709172|NCT06190990|OTHER|exer gaming based programme|In this group the participant will receive exer-gaming based exercises. The duration of each session this group will receive is of 60 minutes A total of 12 sessions will be held, 3 times a week for 4 weeks. Reading will be taken on baseline, after 2 weeks and then after 4 weeks.
223709173|NCT03890081|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
223709174|NCT01511198|DRUG|liraglutide|Injected subcutaneously once daily
223709175|NCT01511198|DRUG|metformin|1000 mg twice daily, administered orally
223709176|NCT06345105|DEVICE|Endoscreener QC|Artificial intelligence monitoring of effective withdrawal time
223709177|NCT06210503|PROCEDURE|Pericapcelar group nerve block|In the supine position, a high-frequency linear sensor is placed in the anterior superior iliac spine and then aligned with the ramus of the pubis by rotating the probe counterclockwise approximately 45 degrees. The iliopsoas muscle and tendon, femoral artery, and pectineus muscle were observed in this view.The iliopsoas muscle and its tendon are visualized, as well as the vascular and nerve bundle: femoral artery, vein, and nerve. The needle is inserted laterally to medially in a planar approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the ramus pubis posteriorly. After negative aspiration, local anesthetic will be gradually injected aspirating every 3 mL.
224276230|NCT00249990|DRUG|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
223709178|NCT06210503|PROCEDURE|Fascia iliaca compartment block|In the supine position, a high-frequency linear sensor is placed in the inguinal fold. Scan starting lateral to the femoral artery and the nerve in the inguinal crease to identify the sartorius muscle, tracing the muscle to its origin to the anterior superior iliac spine. A shadow of the iliac crest bone and iliacus muscle will be visible, with the end point of injection being deep in the fascia iliaca and above the iliacus muscle at the lateral aspect of the iliacus muscle. After negative aspiration, local anesthetic will be gradually injected under the fascial plane, aspirating every 3 mL.
223709179|NCT06025097|DRUG|Combination Solution|Methyl Prednisone (Trade name: SOLU-MEDROL) + Platelet rich Plasma (Autologous Biological product) via intra-tympanic rout about 1-1.5 ml.
223709180|NCT02813824|DRUG|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
224276231|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
224276232|NCT01007409|DRUG|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
224276233|NCT06176885|DRUG|Camrelizumab|Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
224276234|NCT04988737|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
224276235|NCT02105909|OTHER|GWAS|
223709181|NCT02813824|DRUG|Placebo (for Aspirin 300)|Daily dose during 4 years
223709182|NCT02813824|DRUG|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
223893760|NCT06790329|PROCEDURE|Endoscopic sleeve gastroplasty with fundal mucosal ablation|Mucosal ablation around the gastric fundus is initially performed using a hybrid argon plasma coagulation (H-APC) probe, following a submucosal saline injection, until ablation coagulum is visible. Subsequently, endoscopic sleeve gastroplasty (ESG) is performed using a full-thickness endoscopic suturing device (Overstitch, Apollo). This is done in a standard manner, employing 6-8 permanent full-thickness sutures along the greater curvature of the stomach in a running plication, starting from the angular incisura and extending proximally while sparing the fundus. Hemostasis is carefully checked and confirmed before the procedure is completed.
224276236|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 1|One dose of Reinovax PCV24 formulation 1（0.5mL）
223709183|NCT02813824|DRUG|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
223709184|NCT04868162|DRUG|MRG003|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or 2.3 mg/kg.
223709185|NCT04868162|DRUG|MRG003+HX008|On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg or the recommended dose by SMC; and HX008 will be administered via intravenous infusion at 3.0 mg/kg
223709186|NCT05887713|DEVICE|Experimental: Alpha-Stim 100|Subjects in CES intervention group will run CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to CES treatment, gather CES usage data for the week and to answer any questions.
223709187|NCT05887713|DEVICE|Sham Comparator|Subjects in CES sham group will run sham CES at home daily for 6 weeks. Study staff will call weekly to ensure adherence to sham CES treatment, gather sham CES usage data for the week and to answer any questions.
223709188|NCT05929885|DRUG|Low Dose OXIRI (LD-OXIRI)|"The LD-OXIRI regimen will be administered in the following sequence:~* metronomic capecitabine (Xeloda; X) 650mg/m2 will administered twice a day on a daily a continuous basis;~* intravenous metronomic oxaliplatin (O) 50 mg/m2 will be infused over 120 minutes on days 1 and 8 of a 21 day-cycle; followed by~* intravenous irinotecan (I) will be infused over 90 minutes on days 1 and 8 of a 21 day-cycle. The dose of irinotecan will be based on the particular patient's UGT1A1\*6 and UGT1A1\*28 genotype status."
223709189|NCT04607746|DEVICE|Capsule Endoscope|Capsule endoscope used to view colonic mucosa
223709190|NCT06395714|OTHER|Personnalized physiotherapy|"Following completion of the ankle go test, patients in experimental group will receive specific instructions for continuing their rehabilitation, which will be passed on to the physiotherapist responsible for the rehabilitation."
223709191|NCT06395714|OTHER|Usual physiotherapy|"Following completion of the ankle go test, patients in active comparator group will receive usual physiotherapy"
223709192|NCT06083142|BIOLOGICAL|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules
223709193|NCT06833268|OTHER|No drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol.
223709194|NCT06466109|BEHAVIORAL|social robot intervention|"In the first and second courses, the patients and their parents freely interact with the social robot PARO for 30 minutes.~In the third course, patients and their parents interact with PARO for 30 minutes using a worksheet that includes naming and recording characteristics of PARO.~In the last course, patients and their parents interact with PARO for 30 minutes using a worksheet that freely recorded their observations about PARO and say goodbye to it."
223709195|NCT06112808|DRUG|BCD-263|BCD-263 at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
223709196|NCT06112808|DRUG|Opdivo|Opdivo at a dose 480 mg administered intravenously every 4 weeks up to 6 cycles
223709197|NCT04781998|DRUG|liraglutide 3 mg (Saxenda®) once-daily|Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
223709198|NCT04572633|DEVICE|HistoSonics System|The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
223709199|NCT02924571|DEVICE|Bone Marrow Aspirate Concentrate (BMAC) + Allograft|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest. Harvest BMAC System delivers high stem cell concentration to the graft site.
223709200|NCT02924571|DEVICE|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft used according to its approved FDA labels, both from an anterior approach using titanium cages as well as from a posterior interbody approach using polyetheretherketone (PEEK) cages.
223709201|NCT02924571|PROCEDURE|Autograft|Autograft with bone marrow aspirate.
223709202|NCT03783949|DRUG|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
223709203|NCT03783949|DRUG|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
223709204|NCT03783949|DRUG|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
223709205|NCT03783949|DRUG|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
223709206|NCT03783949|DRUG|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)
223709207|NCT01428271|OTHER|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
223709208|NCT06260124|OTHER|Slow tempo|A single Greek traditional dance of slow tempo lasting 3-4 minutes.
223709209|NCT06260124|OTHER|Moderate tempo|A single Greek traditional dance of moderate tempo lasting 3-4 minutes.
224276237|NCT06678607|BIOLOGICAL|Reinovax PCV24 formulation 2|One dose of Reinovax PCV24 formulation 1（0.5mL）
223709210|NCT06260124|OTHER|Fast tempo|A single Greek traditional dance of fast tempo lasting 3-4 minutes.
224276238|NCT06678607|BIOLOGICAL|PPSV23|One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
224276239|NCT06678607|BIOLOGICAL|Placebo|One dose of 0.5 mL placebo is aluminum phosphate adjuvant (aluminum content 0.25mg/dose), sodium chloride, succinic acid, polysorbate 80, and water for injection except for antigen components in 24-valent pneumococcal polysaccharide conjugate vaccine
223709211|NCT00434954|DRUG|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
223709212|NCT00434954|DRUG|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
223709213|NCT00997880|DRUG|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
223709214|NCT00997880|DRUG|Rosuvastatin calcium10mg|Rosuvastatin 10mg
223709215|NCT06556511|DRUG|Zinc Sulfate|Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
223709216|NCT06556511|DRUG|Placebo|Placebo is administered with standard therapy in the placebo group for a period of 10 days.
223709217|NCT00836030|OTHER|No treatment given|No treatment given
223709218|NCT02927886|PROCEDURE|Per-oral endoscopy pyloromyotomy|
223709219|NCT02927886|PROCEDURE|Intrapyloric injection of Botulinum toxin|
223709220|NCT00478946|DRUG|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
223709221|NCT00478946|DRUG|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
223709222|NCT00478946|DRUG|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
223709223|NCT06324383|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
223709224|NCT00991120|DEVICE|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
223709225|NCT03403088|DEVICE|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
223709226|NCT03403088|DEVICE|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
223709227|NCT03403088|OTHER|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
223709228|NCT03403088|OTHER|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson \& Johnson®).
223709229|NCT03403088|OTHER|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
223709230|NCT03403088|OTHER|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
223709231|NCT01210131|DRUG|[18F]HX4|Intravenous injection
223709232|NCT06357858|DRUG|INQOVI (decitabine and cedazuridine)|Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
223709233|NCT06357858|DRUG|Nivolumab|Nivolumab will be administered on D8 with every 4 week cycle.
223709234|NCT04790773|OTHER|Amazon Alexa based voice recording patient education|Amazon Alexa based voice recording of medication education material
224276240|NCT05740215|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
223709235|NCT06366100|BEHAVIORAL|Dialectical Behavior Therapy for Substance Use Disorder (DBT-SUD)|"In phase 1, DBT online training will consist of the following contents:~Block 1~1.1. Introduction to the key concepts 1.2. DBT-SUD program 1.3. Why DBT for alcohol addiction? 1.4. Proposed content for the group intervention.~Block 2~2.1. DBT skills training modules~In phase 2, DBT-SUD intervention will consist of about the following sessions:~GOALS OF SKILLS TRAINING AND MINDFULNESS:~S1: Goals of skills training; Observing, Describing and Participating~S2: Non-judgmentally, One-mindfulness, Effectively~DISTRESS TOLERANCE:~S3: Crisis Survival skills~S4: Crisis Survival and Radical Acceptance~ADDICTION SKILLS:~S5: Dialectical Abstinence.~S6: Clear Mind~S7: Burning Bridges-Building New Bridges~S8: Community Reinforcement~EMOTIONAL REGULATION:~S9: Identifying emotions and model of emotion~S10: Check the facts. Opposing Action~S11: Problem Solving. Reducing vulnerability~S12: Self-management and rehabilitation"
223709236|NCT06366100|BEHAVIORAL|Unified Protocol (UP)|"In phase 1, the UP training will have following contents:~Block 1~1.1. Introduction to key concepts 1.2. Why UP for alcohol addiction? 1.3. Dimensional assessment and case formulation. 1.4. Main characteristics of UP~Block 2~2.1. Modules of UP~In phase 2, UP intervention will consist of:~MOTIVATION:~S1: Motivation enhancement for treatment~UNDERSTANDING EMOTIONS:~S2: Understanding and model of emotions S3: Tracking emotional responses~MINDFULNESS:~S4: Emotion awareness~COGNITIVE FLEXIBILITY:~S5: Cognitive reappraisal to increase thinking flexibility~EMOTION DRIVEN BEHAVIORS:~S6: Emotional avoidance S7: Emotion-driven behaviors and alternative action~AWARENESS AND TOLERANCE:~S8: Tolerance of physical sensations~EMOTIONAL EXPOSURE:~S9: Interoceptive and situational emotion exposure S10: Exposure practice~RELAPSE PREVENTION:~S11: Relapse prevention S12: Review of progress"
223709237|NCT05310838|BEHAVIORAL|Behavioral Activation for First Episode Psychosis|Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
223709238|NCT05310838|BEHAVIORAL|Treatment As Usual|Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
223709239|NCT02194855|DRUG|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
223709240|NCT02194855|DRUG|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
223709241|NCT03057678|OTHER|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
223709242|NCT00687895|PROCEDURE|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~1. description of signs and symptoms of malaria disease~2. history taking relevant to malaria and physical examination~3. identification of danger signs and severe illness for referral~4. appropriate treatment~5. counseling patients on the use of drugs.~Malaria microscopy. contents~1. make thick blood smears from patients with fever and stain with Giemsa~2. identify and count malaria parasites~3. maintain the microscope and store blood slides."
223709243|NCT00454623|BEHAVIORAL|drawing serum adiponectin level|
223527200|NCT06821841|BEHAVIORAL|Online Physical Activity Group|The online physical activity group will consist of four 45-60-minute sessions, which participants allocated to this group will be asked to commit to. These sessions will be delivered online and occur for 4 weeks. Discussions within the sessions will incorporate motivational interviewing, focussing on the benefits of physical activity, current physical activity levels, barriers to physical activity and overcoming these, motivation to complete physical activity, and goal setting. Participants allocated to this group will receive weekly reminders to promote attendance. Participants will also be asked to complete a weekly physical activity log that includes detail about the type of physical activity they completed, the duration, intensity, context and comments.
223527201|NCT06821841|BEHAVIORAL|Information Leaflet|Participants will receive an information leaflet that includes information about menopause (e.g. definition, symptoms), the benefits of physical activity for menopause, recommended weekly physical activity levels (based on CMO guidelines), examples of physical activity, and signposting to online resources. Participants will be able to use the information leaflet as they wish, and complete a weekly physical activity log that includes detail about the type of physical activity completed, the duration, intensity, context and comments.
223527202|NCT05079334|BEHAVIORAL|MeTree Questionnaire|"MeTree is a patient driven risk assessment program with Clinical Decision Support (CDS) that enables collection of a three plus generation family health history (FHH) on 128 conditions. CDS is provided in a report with a pedigree and tailored evidence-based guidelines. While patient drive, MeTree also includes a provider-facing report with additional references. These reports promote engagement by both patients and providers and enhance shared decision-making.~MeTree first generates information imported from the participant's EHR record. These data include basic demographic information, any recent lab results, and any listed diseases or conditions from the EHR. Next, MeTree gives the participant an opportunity to fill out a family history tree. The more information the participant provides on their own health and their family member's health, the better MeTree can provide recommendations from current literature."
223527203|NCT00496119|RADIATION|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
223527204|NCT00496119|RADIATION|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
223527205|NCT05164653|DRUG|Sacubitril Valsartan Sodium Hydrate|"Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation."
223527206|NCT05164653|DRUG|Standard treatment|Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
223527207|NCT03815552|DEVICE|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
223527208|NCT03979001|OTHER|complete ophthalmological examination|"collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography"
223527209|NCT05826665|OTHER|Persistent AF ablation assisted with the STAR Apollo Mapping System|This exploratory hypothesis generating data set will be collected during standard AF ablation procedures using FDA cleared technologies as described in their Instructions for Use (IFU). No randomization or experimental protocols will be used during this study, and all follow up will be performed as per the center's standard of care(SOC).
223527210|NCT06638736|OTHER|Wound Closure with sutures vs staples|Closure of the wound with either sutures or staples depending upon the study arm
223527211|NCT06639334|OTHER|Fasttrack pathway for THA/HE prosthesis reduction|"The purpose of this study is to design a fast-track pathway for patients referred to the University Hospital of Southern Denmark, Esbjerg, with high probability of having a dislocated hip prosthesis with the primary aim to reduce the time from arrival to reduction and the total hospitalization time.~The intervention is changed logistic and work pathways at the hospital that should reduce time to reduction significantly. For detailed description we refer to the uploaded protocol."
223709244|NCT00894166|DRUG|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
224276241|NCT05740215|DRUG|Lenvatinib|Lenvatinib capsules
223709245|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
223709246|NCT00894166|DRUG|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
223709247|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
224276242|NCT00846898|DIETARY_SUPPLEMENT|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
223527212|NCT06639334|OTHER|Standard pathway for THA/HE prosthesis reduction|Standard treatment for a dislocated THA/HA at our institution is education in general anesthesia at the operating theater. For detailed description we refer to the uploaded protocol.
223527213|NCT06637150|DRUG|Dalpicilib|Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
223527214|NCT06637150|DRUG|endocrine therapy|standard endocrine therapy
223527215|NCT06210893|OTHER|The cricoid cartilage is located.|The cricoid cartilage is located.
223527216|NCT05371379|BIOLOGICAL|CM338 Injection|A humanized monoclonal antibody.
223527217|NCT06643572|DEVICE|Virtual reality simulator|This virtual reality simulator allows for the simulation of a lumbar transforaminal epidural steroid injection using the patient's 3D lumbar images.
223527218|NCT03126630|BIOLOGICAL|Anetumab Ravtansine|Given IV
223527219|NCT03126630|OTHER|Laboratory Biomarker Analysis|Correlative studies
223527220|NCT03126630|BIOLOGICAL|Pembrolizumab|Given IV
223527221|NCT03126630|OTHER|Pharmacological Study|Correlative studies
223527222|NCT00847730|DEVICE|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
223527223|NCT05908500|BEHAVIORAL|CPR Training|Various durations and frequencies of CPR training
223527224|NCT05908500|DEVICE|CPR Manikin Type|Various types of CPR manikins are compared
223527225|NCT06171802|DRUG|Empagliflozin|10 mg empagliflozin daily for six months
223527226|NCT06171802|DRUG|Placebo|Placebo capsule once daily for six months
223527227|NCT06852898|OTHER|Chiropractic Care|Chiropractic Care is the active comparator arm / intervention. All subjects will receive chiropractic care.
223527228|NCT06852898|OTHER|Radial Extracorporeal Shockwave Therapy (ESWT) - Radial Pulse Therapy|This intervention is answering the question: Does on radial ESWT have additive therapeutic effects on the recovery of acute lower back pain symptoms - better or earlier reduction in pain intensity or improvement in physical function - than chiropractic care / manual therapy alone? Subjects will be randomly assigned to receive chiropractic care and ESWT or only chiropractic care.
223527229|NCT03607500|BEHAVIORAL|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
223527230|NCT03381326|PROCEDURE|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
223527231|NCT05974540|DIAGNOSTIC_TEST|Determination of cricothyroid membrane|"After the patient's head is extended, the pediatric surgeon will be asked to mark the cricothyroid membrane with a pencil using traditional inspection and palpation methods. Then, the cricothyroid membrane will be determined by the Anesthesiology and Reanimation specialist by USG method and the difference will be determined. Demographic and morphometric characteristics of the patients will be recorded. In addition, the length of the cricothyroid membrane, the distance between the cricoid cartilage and the skin, the distance between the cricoid cartilage and the 2nd tracheal ring will be measured by USG.~Mallampati classes of patients with intubation, Cormack-Lehane (CL) glottic appearance grades, Likert scale with intubation difficulties (1: very easy, 2: easy, 3: medium, 4: difficult) will also be recorded."
223527232|NCT05947838|PROCEDURE|Circulating tumoral DNA directed neoadjuvant therapy arm|Given by IV (vein)
223527233|NCT05878795|BEHAVIORAL|WET-SP|WET-SP will consist of 5 treatment sessions; the first session lasting about one hour and each subsequent session lasting approximately 40 minutes. Each session will include a 30-minute written exposure exercise. The participant will be given general instructions for completing the narrative writings and specific instructions for completing the first session. Participants will be instructed to write about the same suicidal crisis during each session. The therapist will emphasize the importance of delving into their deepest emotions surrounding the suicidal crisis as well as the importance of writing detailed information about the crisis. Following writing, the therapist and the participant will process the writing experience. Subsequent sessions involve the therapist iteratively providing feedback to the patient regarding their writing from the previous session.
223527234|NCT05878795|BEHAVIORAL|TAU|TAU includes initial psychiatric stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily throughout the duration of hospitalization and have structured times for psychoeducation groups, case management, medication management, hygiene, and meals.
223527235|NCT05720104|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
224276243|NCT02176278|OTHER|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
223527236|NCT05720104|OTHER|Standard oral hygiene instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
223527237|NCT05136495|OTHER|caffeinated coffee - decaffeinated coffee|Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
223527238|NCT06419361|DRUG|[68Ga]Ga-Sa-DABI-4|Each subject receives a single intravenous injection of \[68Ga\]Ga-Sa-DABI-4.
223527239|NCT01427478|DRUG|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
223527240|NCT01427478|DRUG|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
223527241|NCT05216380|BEHAVIORAL|ActivityLink|"ActivityLink is an implementation program using:~1. Didactic and experiential training sessions for clinic staff to conduct referrals~2. Secure electronic referral webform to refer patients using their email address and phone number~3. Messaging sent to the patient and provider that they have been referred to a program~4. Clinic visual cues (flyers and paper prescription pad) to reinforce referrals~5. Motivational messaging and booster sessions from study staff to encourage referrals and troubleshoot"
223527242|NCT02628535|BIOLOGICAL|MGD009|B7-H3 x CD3 DART protein
223527243|NCT00201279|DRUG|13-cis Retino Acid|
223527244|NCT05185622|DRUG|Vamorolone|Oral administration of vamorolone for 12 weeks.
223527245|NCT03888027|BEHAVIORAL|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
223527246|NCT06413212|DIAGNOSTIC_TEST|Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing.|Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
223527247|NCT05008614|PROCEDURE|Erector spinae plane block group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under ultrasound guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 18G 85 mm perineural catheter (Silverstim, Vygon, Ecouen, France) (basal infusion: 10ml/hr, bolus 5ml, lockout time: 20min)"
223527248|NCT05008614|PROCEDURE|Thoracic epidural analgesia group|"Before surgery, an anesthesiologist will perform unilateral ESP block with catheterization under fluoroscopy guidance in the procedure room.~Drug: Ropivacaine 0.75% Injectable Solution 0.2% ropivacaine is continuously infused to the erector spinae plane at T5 level via 17-gauge catheter (FlexTip Plus®, Teleflex Medical, USA) (Silverstim, Vygon, Ecouen, France) (basal infusion: 3ml/hr, bolus 1ml, lockout time: 20min)"
223527249|NCT04219020|OTHER|Co-created intervention|
223527252|NCT02475993|OTHER|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
223527253|NCT04116489|OTHER|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
223527254|NCT04116489|OTHER|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
223527255|NCT04116489|OTHER|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
223527256|NCT04116489|OTHER|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
223527257|NCT02056769|RADIATION|CT Perfusion|Quantitative CT Perfusion imaging
223527258|NCT06560307|DEVICE|Enterra Therapy System|The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
223527259|NCT02927964|DRUG|Ibrutinib|Given PO
223527260|NCT02927964|RADIATION|Radiation Therapy|Undergo radiation therapy
223527261|NCT02927964|DRUG|TLR9 Agonist SD-101|Given IT
223527262|NCT01150370|DEVICE|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
223709248|NCT00894166|DRUG|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
223709249|NCT00894166|DRUG|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
223709250|NCT00894166|DRUG|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
223709251|NCT03892187|BEHAVIORAL|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
223709252|NCT00944671|DRUG|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
223709253|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
223709254|NCT00944671|DRUG|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
223709255|NCT02324257|DRUG|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
223709256|NCT02324257|DRUG|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
223709257|NCT02324257|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
223709258|NCT05086926|COMBINATION_PRODUCT|Exercises and CSI|"Corticosteroid injection:~The project manager will give the participants one injection with cortisone and lidocaine in the lateral hip at baseline. The procedure will be performed aseptically.~Home exercise program:~The exercise programis based on previous literature and expert opinions that has been synthesized in a Delphi study conducted by our research group. The exercise program consists of three body weighted strength exercises, that are to be performed every second day for a period of 8 weeks. Exercise instructions will be available as a handout and online with video instructions. The corticosteroid injection usually causes a flare-up in pain with a duration of up to 48 hours. Participants will be instructed to begin the exercises as soon as possible after this flare-up has settled."
223709259|NCT00261469|DRUG|topiramate|
223709260|NCT03750955|DEVICE|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
223709261|NCT03750955|DEVICE|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
223709262|NCT05568823|OTHER|Blood sampling|Measurement of markers of disease evolution
223709263|NCT04267822|DRUG|RV521 oral tablet|Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
223709264|NCT04267822|DRUG|Placebo oral tablet|Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
223709265|NCT04286750|DRUG|ACT-1004-1239|ACT-1004-1239 administered as hard capsules for oral use.
223527263|NCT02255656|DRUG|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
223709266|NCT04286750|DRUG|Placebo|Matching placebo administered as hard capsules for oral use.
223527264|NCT04231019|OTHER|self-administered questionnaire|"Self-administered questionnaires with plain language statements and brief description of the clinical features and photographs of MIH were used to determine the knowledge, awareness and perception regarding the prevalence, severity, etiology and treatment modalities of molar-incisor hypomineralization (MIH) among Egyptian fifth year dental students, general dental practitioners and dental specialists.~There were two routes for delivering the questionnaire either as online questionnaire sent to the participants by email or as a hard copy that is hand delivered."
223527265|NCT02370147|BEHAVIORAL|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
223527266|NCT02370147|BEHAVIORAL|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
223527267|NCT06461507|OTHER|Janda's Approach|For Tightened Structures Stretching applied toIliopsoas and Erector spinal muscles (5 repetitions of stretching with 30-s hold for each muscle). For Strengthening of Weakened Structures; Glute bridge and Abdominal crunch(10 repetitions of each).
223527268|NCT05100095|DRUG|Radiation therapy|Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
223527269|NCT04269863|DRUG|Aspirin|control - 81mg. treatment - 81-325mg.
223709267|NCT04403360|PROCEDURE|ESPB|Ultrasound guided performance of ESPB at T12 level after the induction of anesthesia but before the start of the surgery
223709268|NCT04403360|PROCEDURE|Local infiltration by the surgeon|Local infiltration of anesthetics at surgical site after skin incision
223709269|NCT03967301|DIETARY_SUPPLEMENT|Probiotic|Intervention: defined as probiotic consumption
223709270|NCT03967301|DIETARY_SUPPLEMENT|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
223709271|NCT03681665|OTHER|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80\~90% reduced radiation dose compared to standard dose CT.
223709272|NCT00815698|PROCEDURE|suture|suture for mesh fixation
223709273|NCT00815698|PROCEDURE|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
223709274|NCT02027961|BIOLOGICAL|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
223709275|NCT02027961|DRUG|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
223709276|NCT02027961|DRUG|Trametinib|Oral dose of 2 mg trametinib tablet.
223709277|NCT00395681|DRUG|Diprivan|Propofol 200 mg versus 350 mg
223709278|NCT00440414|DRUG|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
223709279|NCT00440414|DRUG|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
223709280|NCT06557044|DRUG|Ropivacaine|PENG block with ropivacaine
223709281|NCT06557044|OTHER|Physiological saline|Placebo control
223709282|NCT03265639|DIETARY_SUPPLEMENT|P-inulin|
223709283|NCT05764421|BEHAVIORAL|motor-cognitive intervention|The intervention included physical activity and integrated cognitive training. The training was conducted in three sessions. The first session was a warm-up and wake-up preparation, in which participants massaged facial acupoints in a seated position to light music. In the middle phase of aerobic exercise, participants raised their legs in a standing position and performed mental exercises to fast-paced music. Session 1: tapping the five fingers of each hand in turn; Section 2: The thumb of both hands in turn to tap the rest of the fingers; Third section: hands five fingers cross fist; Section 4: The five fingers of both hands are stretched out in turn, and then retracted in turn. The final session was a relaxation session in which participants performed inspiratory and expiratory exercises to light music. The integrated cognitive training consisted of 15 minutes of attention training, 15 minutes of memory training, and 15 minutes of executive function training.
223709284|NCT04815681|BEHAVIORAL|Common Elements Toolbox|COMET is an online unguided self-help intervention that lasts approximately 40-50 minutes.
223709285|NCT04815681|BEHAVIORAL|Active Control|The active control condition includes an online self-awareness program that lasts approximately 40-50 minutes. Participants in the control condition will receive access to the intervention after data collection for the study has been completed.
223709286|NCT01180985|DEVICE|galyfilcon A prototype lens|silicone hydrogel contact lens
223709287|NCT01180985|DEVICE|comfilcon A|silicone hydrogel contact lens
223709288|NCT00767962|OTHER|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
223709289|NCT00767962|OTHER|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
223709290|NCT03556735|DEVICE|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
223709291|NCT01315665|DIETARY_SUPPLEMENT|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
223709292|NCT03214146|BIOLOGICAL|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10\^6 cells/kg according to the protocol design.
223709293|NCT01431989|DRUG|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
223709294|NCT01431989|DRUG|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
223709295|NCT04423276|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
223709296|NCT04423276|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
223709297|NCT05781620|DIETARY_SUPPLEMENT|Vitamin D|Participants received 5,000 IU of vitamin D orally twice daily for 4 weeks. If the serum 25(OH)D concentration exceeds 48 ng/mL, the intervention remains the same. However, if the serum 25(OH)D concentration is under 48 ng/mL, the dosage would increase by 2,500 IU. The principle remains the same at week 6.
223709298|NCT05781620|DIETARY_SUPPLEMENT|Medium-chain triglycerides|Participants received the same amount of placebo matching vitamin D orally twice daily.
223709299|NCT00316472|DRUG|Niacinamide|
223709300|NCT05490810|OTHER|Trunk stabilization|"Trunk stabilization exercises with~* Static back: A roll of towel was pressed against the back and the position was held for 10 secs and then released~* Static gluteus: The gluts were pressed inside and hold for 10 secs and then released.~* Abdominal bracing: Brace your abdomen by contracting your entire abdomen. From here Perform different exercises such as raising your arms and then raising your legs.~* Pelvic bridging: In crook lying, engage your gluts and trunk lift your hips towards the ceiling. Hold the position for 10 secs and then release.~* SLR with-hold at 30 and 45 degrees: Ask the supine patient to raise the leg up-to 45 degrees and hold for 10 secs. Then raise the leg up-to 30 degrees then hold for 10 secs."
223709301|NCT05490810|OTHER|Activation exercises|"Activation exercises with~* Upper rectus abdominis (URA) and lower rectus abdominis (LRA): body supine with hips and knees flexed 90°, with feet locked. Participants flexed the trunk (i.e. crunch execution) against resistance at the level of the shoulders..~* External oblique (EO) and internal oblique (IO): side-lying with the hip at the edge of the bench and feet locked by a second operator. Participants performed side-bend exercise against resistance at the level of the shoulder.~* Lower erector spinae (LES) and upper erector spinae (UES): prone position with ASIS at the edge of the bench and feet locked by a second operator. Participants performed a back extension against resistance at the level of the shoulders."
223709302|NCT00129272|DRUG|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
223709303|NCT00129272|OTHER|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
223709304|NCT06145672|PROCEDURE|follicular unit extraction and implantaion|extract hair follicles as grafts from donor area and implant them in recipient area
223709305|NCT02542904|PROCEDURE|mesenteric excision|
223709306|NCT04858633|DRUG|Hydroxychloroquine (HCQ)|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total 5 tablets, cumulative dose of 2000 mg )
223709307|NCT04858633|OTHER|Standard care|Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene
223709308|NCT04858633|OTHER|Placebo|Tablet placebo one tablet 12 hourly on day one followed by one tablet once weekly for 3 weeks (total 5 tablets)
223709309|NCT00319995|DRUG|loratadine; montelukast|
223709310|NCT06557590|DIAGNOSTIC_TEST|18F-FAPI-04|18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
223709311|NCT03525171|DIAGNOSTIC_TEST|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
223709312|NCT03172169|OTHER|no Intervention|no Intervention
223709313|NCT00092638|DRUG|MK0653, ezetimibe|
223709314|NCT00092638|DRUG|Comparator: ezetimibe, placebo|
223709315|NCT00578708|DEVICE|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
223709316|NCT06444971|PROCEDURE|Post isometric Relaxation|"Post isometric relaxation technique: It is defined as a manual procedure which involves the precisely controlled and specifically directed active contraction of a muscle at varying levels of intensity against a counterforce applied by the therapist.~PIR will be applied to following muscles~1. scalene (anterior, middle and posterior)~2. sternocleidomastoid"
223709317|NCT03345914|DRUG|Dupilumab|"Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)"
223709318|NCT03345914|DRUG|Matching Placebo|"Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)"
223709319|NCT03345914|OTHER|Background Treatment: Topical Corticosteroids|All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
223709320|NCT03345914|OTHER|Background Treatment: Moisturizers|All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
223709321|NCT05679219|PROCEDURE|Structured Pes Planus Exercises|Structured pes planus exercise group; short foot exercise, towel picking exercise, toe walking, heel walking, tandem walking, eccentric gastrosoleus stretching at the edge of the stairs, picking objects from the ground with the toes, balance exercises on one foot. the purpose of all these exercises; The aim is to increase the medial longitudinal arch by contracting the intrinsic muscles of the foot, and to improve the balance at the same time. Walking exercises will be performed in the form of 10 meters and 10 rounds, other exercises will be performed with 30 repetitions for both feet and the whole session will be 40 minutes in total.
223709322|NCT05679219|PROCEDURE|Wii Based Exergame|Wii-based exergame group, Nintendo wii game console balance games; In the literature, frequently used ones in different disease groups will be selected and played. In this context, Penguin Slide, Tightrople Tension, Tilt Table, Soccer Heading and Balance Bubble games will be played in each session under the supervision of an expert physiotherapist (executive), each game will be 8 minutes and the session will be 40 minutes in total. The motion sensor will be placed directly opposite the Balance Board. All games are played in a standing upright position on a double-footed Balance Board.
223709323|NCT05679219|PROCEDURE|Wii Based Serious Game|The lower extremity strengthening and balance exercises within the Becure Balance System, developed in cooperation with the Physiotherapist, Academician and Engineer, will be performed by the Wii-based serious game group through the Wii Balance Board. Three games, Balance Surf, Balance Adventure and Balance Maze, which are among the balance games within the Becure Balance System application, will be played for 40 minutes in each session under the supervision of an expert physiotherapist (executive). The Wii Balance Board will be connected via Bluetooth from the menu in the Becure application. Then the Person will stand on the Balance Board and transfer weight in four directions in line with the instructions of the game on the screen.
223709324|NCT04798963|PROCEDURE|On-clamp partial nephrectomy|Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)
223709325|NCT04798963|PROCEDURE|Off-clamp partial nephrectomy|Partial nephrectomy will performed without renal artery clamping
223709326|NCT01358851|PROCEDURE|Cryotherapy|1-2 times during the treatment time
223709327|NCT01358851|DRUG|LAS41005|once daily
223709328|NCT03754569|PROCEDURE|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
223709329|NCT03473171|DEVICE|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
223709330|NCT01347229|DEVICE|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
223709331|NCT03992014|DRUG|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
223709332|NCT03992014|DRUG|[14C]-linerixibat intravenous infusion|\[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
223709333|NCT03992014|DRUG|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
223709334|NCT04396301|DRUG|Fydrane®: (Manufacturer DELPHARM TOURS, FRANCE).|Fydrane®. The active substances in Fydrane are: tropicamide 0.04 mg (anticholinergic), phenylephrine hydrochloride 0.62 mg (alpha sympathomimetic) and Lidocaine hydrochloride 2 mg (amide type local anaesthetics) for each 0.2 ml dose, equivalent to 0.2 mg of tropicamide, 3.1 mg of phenylephrine hydrochloride and 10 mg of lidocaine hydrochloride for 1 ml.
223709335|NCT04224480|DRUG|Pembrolizumab|200mg of intravenous infusion every 3 weeks
223709336|NCT05520112|BIOLOGICAL|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction|Mesenchymal stem cells capable of differentiation in the endometrial-decidual direction
223709337|NCT05520112|OTHER|Standard treatment according to the clinical protocols|Standard treatment of Recurrent Pregnancy Loss according to the clinical protocols
223709338|NCT02403856|DRUG|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
223709339|NCT02403856|DRUG|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
223709340|NCT02403856|PROCEDURE|Ultrasound-guided Needling and Lavage|
223709341|NCT03217656|OTHER|No intervention|
223709342|NCT03584178|DEVICE|Budesonide via MAD device|Delivery through Mucosal Atomization Device
223709343|NCT03584178|DEVICE|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
223709344|NCT02569658|DRUG|Tranexamic Acid|
223709345|NCT02569658|DRUG|Placebo|
223709346|NCT06262880|DIETARY_SUPPLEMENT|plant derived phenolics|Dietary supplement containing plant derived phenolics
223709347|NCT06262880|OTHER|Microcrystaline cellulose (MCC)|Placebo treatment: Microcrystaline cellulose
223709348|NCT01655771|DRUG|TD-1211 Dose 1|
223709349|NCT01655771|DRUG|TD-1211 Dose 2|
223709350|NCT05163977|PROCEDURE|Blumgart Anastomosis|The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
223709351|NCT05163977|PROCEDURE|Cattell Warren Anastomosis|It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
223709352|NCT03326544|OTHER|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
223709353|NCT03326544|OTHER|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
223709354|NCT03365492|DEVICE|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
223709355|NCT00560781|DRUG|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
223709356|NCT04564261|BEHAVIORAL|Personalized Healthy Relationship and Safety Planning Tool|"The app delivers evidence-based information and resources in three sections:~My Relationship: contains a series of activities (e.g., quizzes) to raise awareness of common myths about unhealthy relationships, determine characteristics of healthy relationships, examine the red flags in an unhealthy relationship, and assess risk factors for more severe abuse. Participants are provided with personalized messages about their relationship health and safety based on the answers they endorse.~My Strategies: personalized strategies to increase participants' safety and well-being based on responses in the previous section.~My Resources: direct links to the National Dating Abuse hotline, textline, and chatline, as well as personalized health and safety resources."
223709357|NCT04564261|BEHAVIORAL|Usual Care Teen Relationship and Health Website|The control group website will provide participants with tools to learn about health topics including examining healthy relationships. The resources will be targeted to adolescents. The control group website is not personalized to the participant or their relationship.
223709358|NCT04147702|OTHER|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
223709359|NCT01459471|PROCEDURE|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
223709360|NCT02673138|DRUG|canagliflozin|basal interruption with canagliflozin
223709361|NCT02673138|OTHER|basal interruption without canagliflozin|basal interruption
223709362|NCT01502930|BEHAVIORAL|IRT|Internet-based IRT with therapist support during 6 weeks
223709363|NCT01502930|BEHAVIORAL|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
223709364|NCT00885846|OTHER|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
223709365|NCT00885846|OTHER|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
223709366|NCT04609371|BEHAVIORAL|self-care tools|self-care tools only
223709367|NCT04609371|BEHAVIORAL|lay telephone coaching|coaching
223709368|NCT01953107|OTHER|Oral Ferrous Fumarate|
223709369|NCT01953107|OTHER|Placebo|
223709370|NCT00695409|BIOLOGICAL|rituximab|Given IV
223709371|NCT00695409|DRUG|carmustine|Given IV
223709372|NCT00695409|DRUG|cytarabine|Given IV
223709373|NCT00695409|DRUG|etoposide|Given IV
223709374|NCT00695409|DRUG|melphalan|Given IV
223709375|NCT00695409|PROCEDURE|ASCT|Undergo autologous peripheral blood stem cell transplant
223709376|NCT00695409|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223709377|NCT05253638|DIAGNOSTIC_TEST|Macrophage migration inhibitory factor|Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
223709378|NCT00523562|OTHER|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
223709379|NCT05111873|OTHER|multimodal treatment|combination of medical consultations, psychological therapy, physiotherapy, occupational therapy, disease specific education und progressive muscle relaxation
223709380|NCT00168870|DRUG|Gemcitabine|
223709381|NCT00168870|DRUG|Treosulfan|
223709382|NCT00137579|PROCEDURE|Influenza vaccine intramuscular administration route|
223709383|NCT01983813|OTHER|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
223709384|NCT01983813|OTHER|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
223709385|NCT02085083|BEHAVIORAL|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
223709386|NCT02085083|BEHAVIORAL|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
223709387|NCT01786668|DRUG|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
223709388|NCT01786668|DRUG|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
223709389|NCT01786668|DRUG|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
223709390|NCT01786668|DRUG|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
223709391|NCT05705388|DEVICE|POSE2.0 Endoscopic Gastric Remodeling|The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
223709392|NCT05705388|DRUG|Liraglutide injection|Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
223709393|NCT02129998|OTHER|IVF/ICSI treatment|
223709394|NCT01471470|DRUG|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
223709395|NCT01376284|DRUG|Dutasteride|Collection of safety data
223709396|NCT01530360|DEVICE|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
223709397|NCT04103658|RADIATION|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
223709398|NCT03213522|PROCEDURE|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
223709399|NCT03213522|PROCEDURE|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
223709400|NCT06383078|DRUG|HR070803|HR070803 60 mg/\^2 D1 over 90 minutes.
223709401|NCT06383078|DRUG|Oxaliplatin|Oxaliplatin 85 mg/\^2 D1 over 2 hours.
223709402|NCT06383078|DRUG|Tegafur|initial dose of S-1 is determined according to the body surface area，orally, D1-7.
223709403|NCT06383078|DRUG|Folinic acid|Folinic acid 400 mg/\^2 D1
223709404|NCT06383078|DRUG|5-Fluorouracil|5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
223709405|NCT01786083|BEHAVIORAL|Application of Problem Solving Technique|
223709406|NCT04465474|OTHER|Non Intervention|It's an observational study, no intervention involves.
223709407|NCT02762357|DEVICE|Novosyn® Quick|Episiotomy closure
223709408|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
223709409|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
223709410|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
223709411|NCT02082860|GENETIC|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
223709412|NCT03274024|DEVICE|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
223709413|NCT03274024|PROCEDURE|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
223709414|NCT00939497|DRUG|Risperidone|
223709415|NCT05961332|DEVICE|Spectralis FAF imaging|Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
223709416|NCT05961332|DEVICE|Optos imaging|Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
223709417|NCT05961332|DEVICE|Zeiss Clarus 700 imaging|Zeiss Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
223709418|NCT04550208|OTHER|3D analysis of different landing tasks|General as well as more sport-specific landing tasks are investigated with 3D analysis by using an opto-electronic system
223709419|NCT01251237|DRUG|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
223709420|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
223709421|NCT01412320|OTHER|Cocoa|dissolved in water twice daily
223709422|NCT02579187|PROCEDURE|tooth extraction|The study tooth will be removed
223709423|NCT02579187|RADIATION|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
223709424|NCT02579187|DRUG|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
223709425|NCT02579187|OTHER|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
223709426|NCT02579187|DRUG|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
223709427|NCT02579187|DRUG|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
223709428|NCT02579187|PROCEDURE|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
223709429|NCT02579187|DRUG|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
223709430|NCT02579187|DRUG|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
223709431|NCT02579187|PROCEDURE|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
223709432|NCT02579187|OTHER|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
224276244|NCT02176278|OTHER|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c\<7%, BP\<130/80 mmHg, LDL-C\<1.8 mmol/l, triglyceride\<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
224276245|NCT02176278|OTHER|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
223709433|NCT02579187|PROCEDURE|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 \& 4 weeks post extraction
223709434|NCT02579187|PROCEDURE|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
223709435|NCT02579187|RADIATION|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
223709436|NCT02579187|OTHER|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
223709437|NCT01970046|DRUG|Placebo/Metformin|"* Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~* Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~* Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
223527270|NCT06316570|DRUG|Early Dual Antiplatelet Therapy|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
223527271|NCT06316570|DRUG|Placebo|"Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day)."
223527272|NCT03734536|DEVICE|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
223527273|NCT03734536|DEVICE|Arthroscopic repair of the high-grade (>50%) partial-thickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
223527274|NCT05565118|PROCEDURE|Standard Surgical Treatment|During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
223527275|NCT05565118|PROCEDURE|Intraoperative Electrocorticography|Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology.
223527276|NCT05064618|DRUG|Am80|medicine taken internally
223527277|NCT05064618|DRUG|Gemcitabine|Administered intravenously at a dose of 1000mg/m2
223527278|NCT05064618|DRUG|nab-Paclitaxel|Administered intravenously at a dose of 125mg/m2
223527279|NCT01877278|DEVICE|Wearable pulsed electromagnetic fields|
223527280|NCT06381960|DRUG|Fuzheng Quxie Recipe|Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
223527281|NCT06381960|DRUG|Fuzhengquye Fang Recipe simulant|Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
223527282|NCT01480830|DEVICE|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
223527283|NCT04619628|BIOLOGICAL|COVI-VAC|intranasal, live attenuated vaccine against SARS-CoV-2
223527284|NCT04619628|OTHER|Placebo|normal saline
223527285|NCT06973876|BEHAVIORAL|Pain-Sensitive Teleyoga Primer|The 5-session Pain-Sensitive Teleyoga Primer will be delivered synchronously to participants who will practice from their home. The purpose of the 5-session primer is two-fold: (1) it allows trained yoga instructors to determine physical abilities and limitations of patient participants so that pose modifications may be taught and (2) it provides education to participants on pain neuroscience, breathwork, relaxation, mindfulness, and interoception so that they may apply this knowledge to maximize the benefits of whichever yoga condition they are randomized to. Each session will last approximately 75 minutes. Participants will be provided with a supplementary handout to reinforce content from the sessions.
223527286|NCT06973876|BEHAVIORAL|Synchronous Teleyoga|Participants randomized to receive synchronous teleyoga will be provided information so that they can attend VAPORHCS virtual yoga offerings. They will be encouraged to attend one class per week during the 12 weeks between randomization and follow-up assessment. Attendance will be tracked via a signed note in the medical record. Each session will last approximately 30-60 minutes.
223527287|NCT06973876|BEHAVIORAL|Asynchronous Teleyoga|Participants randomized to receive asynchronous teleyoga will be provided information so that they can access to the digital library of yoga videos on Ompractice, an existing partner with VA Medical Centers. Ompractice contains a suite of yoga video content, and participants will be encouraged to complete one class per week during the 12 weeks between randomization and follow-up assessment. Attendance will be tracked by Ompractice and shared with VAPORHCS.
223527288|NCT03014505|BIOLOGICAL|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
223527289|NCT03014505|OTHER|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
223527290|NCT01757496|DEVICE|Cough Assist|
223527291|NCT05535569|DRUG|Nivolumab, Paclitaxel|Increasing dose levels of paclitaxel (70 mg/m2 or 80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle) in combination with a fixed dose of nivolumab (3 mg/kg on Days 1 and 15 of a 28-day treatment cycle) will be explored using a 3+3 design to evaluate the safety and tolerability and to determine a MTD.
223527292|NCT06269315|OTHER|Cleaning product exposure|Exposure of a small amount of a different household cleaner, hand disinfectant, their ingredients, and control with proper dilution on forearm of donors
223527293|NCT04731597|DRUG|drug interaction|when two drugs are taken together
223527294|NCT06575894|BEHAVIORAL|Adapted Facilitation|Home visiting supervisor trained in adapted facilitation will employ interactive problem-solving focused on supporting the home visitors to implement Mothers and Babies - working with pregnant people, challenges with resources, additional training needs, etc. - based on understanding the individual communities, contexts, and recipients' and home visitors' needs over the course of the project.
223527295|NCT06575894|BEHAVIORAL|Standard Implementation|Standard Mothers and Babies training includes ongoing implementation support from the Mothers and Babies training team
223527296|NCT06460532|OTHER|Baseline treatment|Transcutaneous Electric Nerve Stimulation (TENS) of Care Vision company will be applied, with a pulse duration of 250 microseconds at a frequency of 80 Hz for 15 min in the suboccipital region and the trapezius bilaterally.
223527297|NCT04317742|DEVICE|Sleep Healthy Using the Internet (SHUTi) Intervention Group|"SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time."
223527298|NCT04317742|DEVICE|Online Patient Education (PE) Control Group|The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
223709438|NCT01970046|DRUG|SP2086 50 mg b.i.d/Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~* Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
223527299|NCT06428188|BIOLOGICAL|BCMA/CD19 CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/CD19 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/CD19 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/CD19 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
223527300|NCT06640699|OTHER|exercise|exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.
223527301|NCT06642116|DEVICE|OCEAN|Biodegradable nasal dressing
223527302|NCT06637059|OTHER|observational study|observation alone
223527303|NCT06637813|OTHER|Blood sampling for evaluation of biomarkers|Non-routine diagnostic test evaluations
223527304|NCT06645275|GENETIC|POCT test|Patients undergo POCT testing on the day of warfarin administration, and based on the POCT results, the initial and maintenance doses of warfarin are determined according to the IWPC algorithm.
223527305|NCT06641518|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
223527306|NCT06187714|PROCEDURE|caudal block rate|optic nerve sheath diameter measurement according to caudal block rate
223527307|NCT01716702|BEHAVIORAL|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
223527308|NCT03716973|DEVICE|High Density Programming|Patients implanted with Medtronic spinal cord stimulator will have high density programming.
223527309|NCT06358508|DEVICE|Sapphire 3 Coronary Dilatation Catheter|To pre-dilate Chronic Total Occlusion (CTO) lesions in coronary arteries during the subject's index procedure with Sapphire 3 0.85mm, 1.0mm, and 1.25mm diameter Coronary Dilatation Catheters.
223527310|NCT05289544|BEHAVIORAL|Phone-Based Walk With Ease|6 week phone-delivered Walk With Ease Program
223527311|NCT00883311|DEVICE|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
223527312|NCT02314195|DRUG|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
223527313|NCT02314195|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
223527314|NCT02314195|OTHER|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
223527315|NCT05024162|DIAGNOSTIC_TEST|MRT Accuracy|Predicted Grade Group (GG) by the MRI-based Radiomics Tool (MRT) at each Magnetic Resonance Imaging of the Prostate (MRI-P)
223527316|NCT05024162|DIAGNOSTIC_TEST|MRT Stability|MRT's predicted GG at second MRI-P.
223527317|NCT01527955|OTHER|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
223527318|NCT00552136|PROCEDURE|Ankle Arthroplasty|
223527319|NCT00552136|PROCEDURE|Ankle Arthrodesis|Ankle fusion surgery
223527320|NCT04416711|BEHAVIORAL|Personalized Feedback|The personalized feedback consists of four components: normative feedback, risk/protective feedback, decisional balance/goal setting, and protective strategy review. Personalized feedback targets include readiness to change, perceptions of risk, and misperceptions of peer attitudes/behaviors.
223709439|NCT01970046|DRUG|SP2086 50 mg q.d./Metformin|"* Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~* Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~* Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
223709440|NCT02834260|DRUG|Dexamethasone implant OZURDEX|
223709441|NCT03570697|DRUG|Evolocumab|Participants will receive evolocumab (AMG 145) subcutaneous monthly.
223709442|NCT03570697|DRUG|Placebo|Participants will receive matching placebo subcutaneous monthly.
223709443|NCT03570697|DRUG|Statin therapy|"high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy~Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization."
223709444|NCT04851457|DRUG|Intravenous tirofiban combination therapy|Patients will enter the tirofiban treatment protocol immediately within half an hour after randomization and prior to the femoral artery puncture. Tirofiban is administered as an intravenous bolus dose of 10 μg/kg injection within 3 min and then by an intravenous infusion at a rate of 0.1 μg/(kg·min) for 24 hours.
223709445|NCT00816920|OTHER|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
223709446|NCT01044628|DEVICE|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be \>90%
223709447|NCT01044628|DEVICE|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
223709448|NCT06006741|BIOLOGICAL|MM-specific universal CAR T cells|Infusion of MM-specific universal CAR T cells
223709449|NCT01776840|DRUG|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
223709450|NCT01776840|DRUG|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
223709451|NCT01776840|DRUG|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
223709452|NCT01776840|DRUG|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
223709453|NCT04961931|DRUG|Empagliflozin 10 MG|After qualifying for the study all subjects received oral empagliflozin 10 mg once daily for 7 days.
223709454|NCT01152697|DRUG|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
223709455|NCT01152697|DRUG|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
223709456|NCT01152697|BEHAVIORAL|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
223709457|NCT02974478|DIETARY_SUPPLEMENT|Orange juice with meals|orange juice (20% of energy requirement/day)
223709458|NCT02974478|DIETARY_SUPPLEMENT|Orange juice between meals|orange juice (20% of energy requirement/day)
223709459|NCT02974478|DIETARY_SUPPLEMENT|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
223709460|NCT00214110|DRUG|Tamoxifen|
223709461|NCT05012033|OTHER|No intervention - prednisolone is taken as part if routine clinical care.|Prednisolone given orally prior to taking timed samples for levels
223709462|NCT01390129|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
223709463|NCT01390129|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
223709464|NCT02000583|OTHER|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
223709465|NCT02000583|OTHER|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
223709466|NCT05799170|OTHER|regional trauma care|Study intervention is the establishment of in-hospital trauma treatment centers and the formation of regional trauma care system. Regional trauma care system refers to both the establishment of unified and standardized pre-hospital and in-hospital trauma triage and injury classification warning mechanism and the development of unified trauma treatment process and standard in a main government district (population within 1 million), with secondary general hospitals and above that have strong treatment capability as the trauma treatment centers. Regional trauma care system will strengthen both pre-hospital emergency care and in-hospital emergency treatment while reinforcing the information exchange between in-hospital emergency treatment and specialized treatment. Taking 5 to 6 hospitals with certain trauma treatment capacity as the trauma treatment point, the trauma treatment network is formed relying on the treatment point hospitals within the range of one trauma treatment center.
223709467|NCT03068455|BIOLOGICAL|nivolumab|Specified Dose on Specified Days
223709468|NCT03068455|BIOLOGICAL|ipilimumab|Specified Dose on Specified Days
223709469|NCT00493025|DRUG|cisplatin|Cisplatin IV
223709470|NCT00493025|DRUG|gefitinib|Gefitinib IV
223709471|NCT00493025|DRUG|paclitaxel|Paclitaxel IV
223709472|NCT00493025|PROCEDURE|adjuvant therapy|Postoperative ZD1839
223709473|NCT00493025|RADIATION|radiation therapy|Radiotherapy
223709474|NCT03204578|DRUG|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
223709475|NCT03204578|DRUG|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
223709476|NCT04033575|DRUG|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
223709477|NCT04033575|DRUG|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
223527321|NCT04416711|BEHAVIORAL|Cognitive Skills Training|We will address three cognitive targets: focus on affective cues, focus on non-affective cues, and over-perception of sexual interest. The first module targets enhanced focus on women's affective cues and reduced over-perception of sexual interest. We will introduce the role of men's sexual-perception skills in satisfying social and sexual interactions with women, as well as problematic sexual behavior including RSB and SAB. Next, we will instruct participants that affective information is the best-available nonverbal information about how a woman is feeling about a specific man. This instruction will focus on distinguishing four primary dating relevant cues: sexual-interest, friendliness, sadness, and rejection. More detailed focus on each cue will emphasize the increased difficulty of reading these cues with a new partner and under the influence of alcohol and sexual arousal, as well as the importance of checking verbally on assumptions about a woman's current sexual interest.
223527322|NCT04416711|OTHER|Services As Usual|These participants will receive services as usual
223527323|NCT05972785|DRUG|Calcium channel blocker|Drugs with ATC code C08 will be categorised as calcium channel blockers.
223527324|NCT05972785|DRUG|Beta blocker|Drugs with ATC code C07 will be categorised as beta-blockers.
223527325|NCT05972785|DRUG|Diuretic|Drugs with ATC code C03 will be categorised as diuretics.
223527326|NCT05972785|DRUG|RAS|Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
223527327|NCT05972785|DRUG|Other AHT|Drugs with ATC code C02 will be categorised as other antihypertensives.
223527328|NCT05972785|DRUG|None AHT|None AHT
223527329|NCT01558167|DRUG|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~* Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~* Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~* Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~* Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~* Dose level 5: maximal tolerated dose"
223527330|NCT00291837|DRUG|CT-2106|
223527331|NCT04603560|BEHAVIORAL|Audit and Feedback|A report of the provider's hypertension control rates compared to benchmark will be displayed using principles of social norming. We will present that provider's hypertension control rates compared to the 90th percentile of their peers.
223527332|NCT04603560|BEHAVIORAL|Pharmacist E-Detailing|A pharmacist will review the chart in advance and provide a personalized recommendation for how to intensify the specific patient's antihypertensive regimen based on current guidelines. For example, they might recommend adding an additional medication based on the patient's comorbid conditions and could suggest a starting dose and timeframe for dose escalation.
223527333|NCT04953026|DIAGNOSTIC_TEST|Diagnositic test|The results of shoulder arthroscopy were taken as the gold standard, and MRI examination was taken as the research object.
223527334|NCT00287560|DRUG|propofol (drug)|
223527335|NCT00060125|DRUG|tipifarnib|Given orally
223527336|NCT00060125|OTHER|laboratory biomarker analysis|Correlative studies
223527337|NCT05386966|OTHER|questionnaire|Patient demographic data ( age, gender, residence , work ,Level of education) .Detailed history about the trauma (type, site , manner , mechanism of injury , actual cause of assault , post traumatic period till arrival to hospital ) .Clinical assessment ( Rapid neurological assessment , assesment of Scalp injury ,Presence of other body trauma ,Degree of severity of head injury according to GCS , Radiological finding. Treatment (Conservative or operative intervention ) .Follow up and outcome at the time of discharge by using the GOS .Expected time for healing (\<20 day or \>20 day ).Expectance for permanent infirmity
223527338|NCT02946697|BEHAVIORAL|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
223527339|NCT05185453|BEHAVIORAL|Strengthening Connections for Change|Strengthening Connections for Change is a 12-session curriculum designed to strengthen adolescent-adult support networks, build leadership skills, foster community engagement, and challenge attitudes and behaviors that foster violence involvement. During the program, youth ages 13-17 years invite their self-identified key adult supports to jointly participate in programming including youth-focused, adult-focused and jointly focused activities. Towards the end of programming participants design and carry out a community project to strengthen intergenerational connections and promote community engagement.
223527340|NCT05185453|BEHAVIORAL|Job Readiness Training|Job Readiness Training uses a group discussion format to learn specific skills to prepare for employment including developing goals, seeking jobs, preparing for interviews, and so forth.
223527341|NCT04573504|DRUG|Augmentin/Flagyl or Augmentin/Clindamycin|Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
223527342|NCT04573504|DRUG|Placebo|Placebo
223527343|NCT06983665|DRUG|Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)|Single intravenous administration of 2.0 mg/kg in each period.
223527344|NCT06983665|DRUG|Reference product (AmBisome®, Astellas Pharma US Inc.)|Single intravenous administration of 2.0 mg/kg in each period.
223527345|NCT03777605|DRUG|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
223709478|NCT00214344|BEHAVIORAL|family preparation for withdrawing life support|
223709479|NCT02989545|DEVICE|Anal Tape|
223709480|NCT04149379|DRUG|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
223709481|NCT03173313|DEVICE|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
223709482|NCT01876420|DEVICE|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
223709483|NCT00067405|DRUG|Intravenous micronutrient therapy|
223709484|NCT04352712|OTHER|blood sampling|blood sampling
223709485|NCT02891694|OTHER|in vitro immuno-histo-chemical analysis of corneal epithelium|
223709486|NCT00575991|DIETARY_SUPPLEMENT|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
223709487|NCT02498132|OTHER|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, \& Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
223709488|NCT02498132|OTHER|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
223709489|NCT02498132|OTHER|Treatment as Usual|Individuals will be provided with one on one therapy sessions
223709490|NCT04515394|DRUG|Tepotinib|Participants received Tepotinib film-coated tablets at a dose of 500 milligrams (mg) orally, once daily (QD) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
223709491|NCT04515394|BIOLOGICAL|Cetuximab|Participants received weekly intravenous infusions of Cetuximab at a dose of 250 milligrams per square meter (mg/m\^2) until disease progression (according to Response Evaluation Criteria in Solid Tumors Version 1.1 \[RECIST v1.1\]), death, Adverse event (AE) leading to discontinuation, study withdrawal, or withdrawal of consent, whichever occurs first.
223709492|NCT02300246|PROCEDURE|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
223709493|NCT03766568|DEVICE|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
223709494|NCT05133752|DRUG|Nemonoxacin|500 mg, oral administration, once daily for 7-10 days.
223709495|NCT05901428|DRUG|Docetaxel|Docetaxel is a taxoid antineoplastic agent used in the treatment of breast cancer
223709496|NCT05901428|DRUG|Carboplatin|Carboplatin is a deoxyribonucleic acid (DNA) synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
223709497|NCT05901428|DRUG|Epirubicin|Epirubicin is an antineoplastic agent derived from doxorubicin.Epirubicin, like doxorubicin, exerts its antitumor effects by interference with the synthesis and function of DNA and is most active during the S phase of the cell cycle.
224276246|NCT03385954|OTHER|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
224276247|NCT03385954|OTHER|Control|will receive a lecture of 30 minutes.
224276248|NCT00333853|DEVICE|OneTouch(r) UltraSmart(r)|
223709498|NCT05901428|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
223709499|NCT02167087|PROCEDURE|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
223709500|NCT00318123|DRUG|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
223709501|NCT03223142|DEVICE|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
223709502|NCT01377883|OTHER|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
223709503|NCT01377883|BEHAVIORAL|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
224276249|NCT02725411|DRUG|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
224276250|NCT02725411|BIOLOGICAL|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
224276251|NCT02725411|BIOLOGICAL|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
224276252|NCT02725411|DRUG|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
224276253|NCT02725411|BIOLOGICAL|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
224276254|NCT02054754|DRUG|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
223709504|NCT02389062|OTHER|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
223709505|NCT04314726|DRUG|Amelogenin|amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
223709506|NCT04314726|DRUG|Placebos|placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
223709507|NCT03301701|PROCEDURE|Radical prostatectomy|Radical prostatectomy
223709508|NCT03301701|RADIATION|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
223709509|NCT05975307|DRUG|Toripalimab|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Toripalimab: 240 mg on Day 1, every 3 weeks, totally 3 and 2 cycles in the induction and concurrent phases, respectively."
223709510|NCT05975307|DRUG|Gemcitabine|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Gemcitabine: 1 g/m2 on Days 1 and 8, repeated every 3 weeks, totally 3 cycles."
223709511|NCT05975307|DRUG|Cisplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate ≥ 40 ml/min, 37.5 mg/m2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
223709512|NCT05975307|DRUG|Carboplatin|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Cisplatin: Used when creatinine clearance rate \< 40 ml/min, area under curve = 2 on Days 1 and 2, repeated every 3 weeks, totally 3 cycles."
223709513|NCT05975307|RADIATION|Intensity-modulated radiation therapy|"The patients in this arm will receive 3 cycles of induction treatment containing chemotherapy with gemcitabine and cisplatin/carboplatin, plus toripalimab. Then the ones without progressive disease will receive radical radiotherapy, plus 2 cycles of concurrent toripalimab.~Radiotherapy: performed by using the technique of intensity-modulated radiation therapy, with a total dose of 65 and 45 Gy for the gross tumor and lymphatic drainage regions."
223709514|NCT00647361|DEVICE|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
223709515|NCT04239859|BIOLOGICAL|secukinumab|Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.
223709516|NCT04239859|DRUG|Methotrexate|Oral tablet up to 15mg per week
223709517|NCT04239859|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
223709518|NCT04239859|DRUG|Acitretin|Oral capsule up to 25mg per day
223709519|NCT06030050|BEHAVIORAL|Animal-assisted intervention|The AAI is designed to promote patient comfort, uplift mood, and provide an opportunity for socialization. The nature of the dog interaction involves several different components, including but not limited to: petting the dog, talking to the dog, watching the dog do tricks, conversing with the dog handler, and being prompted to discuss any fond memories/stories of their own personal experiences with human-animal interactions. Therapy dogs are trained and certified animals who are leashed at all times and under direct care of their dog handler, NOT companion animals, personal pets, nor emotional support animals.
223709520|NCT04764773|OTHER|No intervention|No intervention
223709521|NCT06126926|BEHAVIORAL|group therapy|32 weeks of group therapy
224276255|NCT02054754|DRUG|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
224276256|NCT02054754|DRUG|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
224276257|NCT02054754|DRUG|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
224276258|NCT02054754|DRUG|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
224276259|NCT02054754|DRUG|Placebo|
224276260|NCT06325124|OTHER|Muscle energy technique|"They would be receiving treatment as follow:~Muscle energy technique of hamstring and gastro-soleus. Frequency: 10 reps 3 times/week for 4 consecutive weeks Intensity starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
224276261|NCT06325124|OTHER|Conventional PT|"They would be receiving treatment as follow:~Conventional PT including 1-cervical isometric exercises 2-Transcutaneous Electrical Nerve Stimulation (TENS) for 1o minutes 3-hot pack for 10 minutes 4-Stretching exercise for suboccipitals, sternocleidomastoid 5-gentle stretching of calf and hamstrings."
224276262|NCT00678327|BIOLOGICAL|bleomycin sulfate|Given IV
224276263|NCT00678327|BIOLOGICAL|filgrastim|Given subcutaneously
224276264|NCT00678327|BIOLOGICAL|pegfilgrastim|Given subcutaneously
224276265|NCT00678327|DRUG|cyclophosphamide|Given IV
224276266|NCT00678327|DRUG|dacarbazine|Given IV
224276267|NCT00678327|DRUG|doxorubicin hydrochloride|Given IV
224276268|NCT00678327|DRUG|etoposide|Given IV
224276269|NCT00678327|DRUG|prednisolone|Given orally
224276270|NCT00678327|DRUG|procarbazine hydrochloride|Given orally
224276271|NCT00678327|DRUG|vinblastine sulfate|Given IV
224276272|NCT00678327|DRUG|vincristine sulfate|Given IV
224276273|NCT01269476|DRUG|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
224276274|NCT01269476|DRUG|Placebo|Same volumes and frequency as active.
224276275|NCT04937647|OTHER|collection of endoscopic images and videos|collection of endoscopic images and videos
223709522|NCT06126926|OTHER|Treatment as usual|Control participants remain in their current placement and may be eligible for a number of services offered to inmates to facilitate rehabilitation and planning for release to the community, including sexual offender treatment. MnDOC's sexual offender treatment is a two to three year program, thus most of our control subjects will not have enough time remaining on their sentences to complete such treatment. However, a number of them may participate in MnDOC's current program.
223709523|NCT04509869|PROCEDURE|varicocelectomy|operation for varix ligation
223709524|NCT06069505|DIAGNOSTIC_TEST|Aspergillus PCR|Aspergillus PCR will be performed on different volumes of serum and plasma of patients with hematological malignancies with suspicion for invasive fungal infection.
223709525|NCT00891592|BIOLOGICAL|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg"
223709526|NCT00891592|OTHER|Observation Arm|Single infusion of Cord Blood Cells
223709527|NCT01642979|DRUG|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
223709528|NCT01642979|DRUG|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
223709529|NCT01642979|DRUG|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
223709530|NCT05235451|OTHER|Human-Animal Interactions|Human-animal interactions (HAI) is a powerful and cost-effective strategy to improve reading fluencies and comprehension of children with learning differences. Emerging data suggest that HAI help promote classroom behaviors and learning, including effects on cognition, emotional functioning, and motor skills for children with and without learning differences. The HAI reading group will receive reading instruction as usual plus visits from a registered therapy dog team (dog + animal handler) twice a week over 12 weeks.
223709531|NCT01042678|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye
223709532|NCT01235624|GENETIC|genetic analysis|
223709533|NCT02653872|DRUG|AZD7986|Oral solution, single dose, dilution from concentrate
223709534|NCT02653872|DRUG|Verapamil|Extended release tablet for oral use
223709535|NCT02653872|DRUG|Itraconazole|Oral solution
223709536|NCT02653872|DRUG|Diltiazem|Extended release capsule
223709537|NCT04846296|OTHER|Questionnaire|The QLPSD, developed in Spain, was the first questionnaire designed to evaluate HRQoL in adolescents with spinal deformities. It has shown good validity and reliability. English, French and Persian versions of the QLPSD have been developed and validated. Good reliability and ease of use are mentioned in these versions. The QLPSD was designed to examine adolescents with spinal deformities and measure the effect of orthotic and surgical treatments on QoL.
223709538|NCT03617185|OTHER|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
223709539|NCT03617185|OTHER|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
223709540|NCT03617185|PROCEDURE|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
223709541|NCT01611610|OTHER|Functional tests|"The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module"
223709542|NCT01611610|OTHER|Functional tests|"The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module"
223709543|NCT04076475|DEVICE|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
223709544|NCT06458192|BEHAVIORAL|Adaptive Messaging Intervention|The intervention delivers 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. The intervention will apply reinforcement learning to select daily messaging styles to maximize user engagement.
223709545|NCT06458192|BEHAVIORAL|Non-Adaptive Messaging Intervention|The intervention involves 8 weeks of daily text messaging. Messages will arrive throughout the day via SMS to prompt learning and applying cognitive and behavioral self-management strategies, representing a variety of self-management strategies and message tones. Daily messaging styles will be randomly selected.
223709546|NCT06458192|BEHAVIORAL|Psychoeducation-Only Control|An active control which will deliver psychoeducational content via clickable URLs over 8 weeks.
223709547|NCT04136340|OTHER|In-person in clinic follow-up visit|Patient will be seen in-person (i.e. an IR/NV or AFX visit) in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks. Any patients randomized to the in-person group who experience an extraordinary burden and/or are physically unable to attend their in-person visits will be able to be seen by their Supportive Care Service clinician via a home telemedicine visit (patients will return to their original group assignment if possible).
223709548|NCT04136340|OTHER|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
223709549|NCT02506465|DEVICE|iTIND|Temporary Implantable Nitinol Device (iTIND)
223709550|NCT02506465|PROCEDURE|Sham Arm|Foley catheter will be placed and immediately removed.
223709551|NCT04102787|OTHER|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
223709552|NCT01820065|PROCEDURE|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
223709553|NCT02432482|BEHAVIORAL|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
223709554|NCT02432482|BEHAVIORAL|Standard care|Brief advice to quit (\<5 minutes) Self-help brochure Offer of nicotine patches
223709555|NCT01723657|DRUG|Ara-C|"* Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
223709556|NCT01723657|OTHER|Autologous peripheral blood stem cell transplantation.|"* In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
223709557|NCT01723657|OTHER|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
223709558|NCT01723657|DRUG|G-CSF|"* Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
223709559|NCT01723657|OTHER|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
223709560|NCT01723657|OTHER|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
223709561|NCT00032955|DRUG|Buprenorphine/naloxone|
223709562|NCT04795011|OTHER|exercise and manual lymphatic drainage|MLD will be launched with simple neck application. Hemodynamics of blood and lower extremity motoring will be increased by combining active bilateral shoulder-twisting with breathing after effleurage. Cervical lymph nodes will be stimulated. Back-up treatment will be applied for the abdominal area. Suction power in the ductus thoracicus will be increased with breathing exercises. Ventral drainage will be applied to the lower extremity in accordance with the surgery of the patient.
223709563|NCT04795011|OTHER|exercise|range of motion and walking exercise
223709564|NCT02035930|DRUG|dexmedetomidine|
223709565|NCT05923983|OTHER|Clinical decision support|In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team
223709566|NCT05923983|OTHER|Will not receive Clinical Decision Support|In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation
223709567|NCT06107400|GENETIC|RM-004|Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
223709568|NCT04767594|DRUG|Palbociclib + endocrine therapy|Palbociclib + letrozole, or Palbociclib + anastrozole, or Palbociclib + exemestane, or Palbociclib + fulvestrant after prior endocrine therapy In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
223709569|NCT04971707|OTHER|Standardized exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the standard cardiovascular rehabilitation program combining both continuous moderate exercise sessions (MICT) and high intensity interval exercise sessions (HIIT). MICT sessions will be performed 2 times per week and HIIT sessions will be performed once a week.
223709570|NCT04971707|OTHER|HRV-guided exercise training|HRV index will be measured every morning during 5 min. This group will benefit from the individualized cardiovascular rehabilitation program. Daily exercise (MICT, HIIT, or active recovery) will be prescribed according to the HRV-index measured on the morning of the session.
223709571|NCT04134052|DRUG|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
223709572|NCT02846571|BIOLOGICAL|Human Pancreatic Islet Transplantation|Human pancreatic islet transplantation in the eye anterior chamber of legally blind patients with insulin-dependent type 1 or type 2 diabetes
223709573|NCT03020173|OTHER|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
223709574|NCT04197531|OTHER|Irrigation Method|Irrigation Method
223709575|NCT02758704|OTHER|High stress|Generation of a stressful environment during a neonatal intubation procedure.
223709576|NCT02758704|OTHER|Low stress|Absence of stressful stimuli during neonatal intubation procedure
223709577|NCT02758704|OTHER|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
223709578|NCT04736082|OTHER|Intervention Group: Infant Formula with hydrolyzed protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (intervention formula manufactured from extensively hydrolysed whey protein).
223893761|NCT06923735|OTHER|Utilization of the Finnish Nutrition Navigator and the Finnish Nutrition Path|Participant fills in the food intake questionnaire of the Finnish Nutrition Navigator and receives an automated feedback on the diet before the visit to the occupational healthcare. At the visit, the information about the quality of diet can be utilized with the occupational healthcare professional. The client can utilize the self-care path (the Finnish Nutrition Path) for possible dietary changes independently or with the professional.
223709579|NCT04736082|OTHER|Control Group: Infant Formula with intact protein|Infants will receive infant formula during the first 120 days of life with optional follow up until 180 days of life (control formula manufactured from intact cow's milk protein).
223709580|NCT02218749|OTHER|Initially triaged to physiotherapist|
223709581|NCT02218749|OTHER|Initially triaged to physician|
223709582|NCT04328766|DRUG|DWC202005, alone|DWC202005, as a single dose
223709583|NCT04328766|DRUG|DWP14012 + DWC202005|DWP14012 and DWC202005, as a single dose
223709584|NCT04328766|DRUG|DWP14012 + DWC202005, after multiple doses of DWP14012|DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
223709585|NCT02434978|DEVICE|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
223709586|NCT02434978|DRUG|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
223709587|NCT02434978|OTHER|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
223709588|NCT06557915|PROCEDURE|screening|screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
223709589|NCT06557993|OTHER|Serratus Posterior Superior Intercostal Plane Block|The serratus posterior superior muscle is located deep to the rhomboid major and minor. Ligamentum nuchae starts from the processus spinosus of C7-T3 vertebrae and extends to the 2nd-5th. In the ribs, the angulus ends at the upper edge of the rib. Serratus posterior superior -intercostal plane block (SPSİPB) is a newly defined block, and C7-T7 spread has been shown in cadaver studies
223709590|NCT04925908|DIAGNOSTIC_TEST|RT-PCR for SARS-Cov-2|Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
223709591|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 3% NaOCl in partial pulpotomy
223709592|NCT06240130|PROCEDURE|Partial pulpotomy|after caries removal and pulp exposure pulp tissue is amputated and wound lavage done with 2% Chlorhexidine in partial pulpotomy
223709593|NCT04089475|DEVICE|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
223709594|NCT03396705|PROCEDURE|Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy
223709595|NCT02364622|DEVICE|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
223709596|NCT02364622|DEVICE|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
223709597|NCT02364622|DEVICE|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
223709598|NCT05583565|OTHER|sensory integration approach|Sensory integration refers to how the nervous system receives messages from multimodal sensory information systems to maintain balance, posture, and balance by monitoring head movement and stabilizing the eyes about the environment
223709599|NCT05583565|OTHER|traditional physical therapy program|"conventional physiotherapy training programs such as the following: 1)Hand function training by locating the Grading of the hand and training this level until it is well developed to transfer to the next level according to 8 parameters (partner's height-shape-weight-texture -reaction time-speed-accuracy-number of trials).~2\) equilibrium training by promoting posture reaction. 3)ADL activity training (nutrition training-dressing training-toilet training). 4) Functional skill training through walking (walking on sand, weight on legs, and Climbing stairs )."
223709600|NCT00383461|BEHAVIORAL|smoking cessation intervention|
223709601|NCT00383461|OTHER|counseling intervention|
223709602|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
223709603|NCT02326051|DRUG|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
223709604|NCT00003962|BIOLOGICAL|aldesleukin|
223709605|NCT01252147|OTHER|No treatment|No treatment (intervention) will be provided in this study
223709606|NCT02800343|PROCEDURE|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
223709607|NCT00940160|DRUG|QAX576|
223709608|NCT00940160|DRUG|QAX576|
223709609|NCT00940160|DRUG|QAX576|
223709610|NCT00940160|DRUG|Placebo|
223709611|NCT01254331|DRUG|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
223709612|NCT05642767|DIAGNOSTIC_TEST|culture on cetrimide agar|Samples will be inoculated on cetrimide agar using the plating out technique.
223709613|NCT05642767|DIAGNOSTIC_TEST|Staining with Gram stain|colonies on cetrimide agar will be spread on glass slide and stained by gram stain
223709614|NCT05642767|DIAGNOSTIC_TEST|Antibiotic sensitivity testing|Antibiotic sensitivity testing will be done by disc diffusion method according to CLSI
223709615|NCT05642767|DIAGNOSTIC_TEST|Molecular detection to efflux genes and some virulence genes|Molecular detection to efflux genes and some virulence genes by conventional PCR
223709616|NCT02910115|OTHER|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
223709617|NCT02910115|DRUG|Pitocin|Pitocin is administered intravenously according to the usual protocol.
223709618|NCT00892047|DRUG|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
223709619|NCT00892047|DRUG|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
223709620|NCT00406965|DRUG|HAE1 (PRO98498)|
223709621|NCT03354078|PROCEDURE|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
223709622|NCT03354078|PROCEDURE|continous sutures|The way of closure of subcutanous tissue is by continous sutures
223709623|NCT04392752|OTHER|Dieting intervention|This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
223709624|NCT02135770|DRUG|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
223709625|NCT01864655|DRUG|saracatinib|oral drug given to experimental group
223709626|NCT01864655|DRUG|Placebo|Placebo given to placebo group
223709627|NCT02211222|DRUG|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
223709628|NCT03890406|DRUG|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
223709629|NCT03890406|DRUG|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
223709630|NCT01783431|DRUG|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
223709631|NCT01783431|PROCEDURE|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
223709632|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
223709633|NCT05952596|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)
223709634|NCT04710602|PROCEDURE|Minimally invasive surgical fixation of unstable rib cage|Minimally invasive and muscle sparing surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes).
223709635|NCT04710602|PROCEDURE|Large incision surgical fixation of unstable rib cage.|Surgical fixation of ribs and/or sternum in an unstable segment of the chest wall (flail chest) with titan plates or medullary nails (MatrixRib Fixation System, DepuySynthes). Large non muscle sparing incision with simultaneous thoracotomy.
223709636|NCT06322069|OTHER|Self-compassion intervention group|Participants would be provided a 14-days online course, and they need to finish the courses within 21 days.
223709637|NCT00487175|DRUG|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
223709638|NCT00076206|DRUG|CCI-779|
223709639|NCT00076206|DRUG|Placebo|
223709640|NCT03254979|BEHAVIORAL|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~1. A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~2. With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~3. A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
223709641|NCT01993706|DRUG|VRC-HIVMAB060-00-AB|
223709642|NCT02683720|DIETARY_SUPPLEMENT|ONS|randomized clinical trial involving different ONS strategies
223709643|NCT05026411|DIAGNOSTIC_TEST|T 0 Diffusion Tensor MR|Magnetic resonance images has been taken from 20 individuals with eating disorders before fixed orthodontic treatment
223709644|NCT05026411|DIAGNOSTIC_TEST|T 1 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders after 12 months of orthodontic treatment.
223709645|NCT05026411|DIAGNOSTIC_TEST|T 2 Diffusion Tensor MR|Magnetic resonance images will be taken from 20 individuals with eating disorders 6 months after orthodontic treatment finished
223709646|NCT00578383|DEVICE|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
223709647|NCT01672008|DRUG|NOX-100|
223527346|NCT06305429|BEHAVIORAL|HabitE (effective parenting habit) program (in Brazilian Portuguese)|Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
223527347|NCT05576337|OTHER|16 weeks of strength training protocol|16 weeks of strength training protocol
223527348|NCT06602011|COMBINATION_PRODUCT|TACE, Lenvatinib, combined with Tislelizumab group|TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
223527349|NCT02457793|DRUG|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
223527350|NCT02457793|DRUG|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
223527351|NCT04316143|DRUG|Oral zamicastat|Tablets for oral administration under fed conditions containing 100 mg of zamicastat
223527352|NCT00281385|BEHAVIORAL|traditional vs. lifestyle exercise|
223527353|NCT02757768|DRUG|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
223527354|NCT02757768|DRUG|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
223527355|NCT02757768|DRUG|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
223527356|NCT06659900|OTHER|CORE Plus (+)|CORE PLUS intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials, a voucher for a medication starter kit PLUS support from a Community Health Advisor who will serve as a connector to primary care for HTN management and send reminder text messages.
223527357|NCT06659900|OTHER|CORE|CORE intervention will use mHealth technologies to create data linkages with primary care facilities/providers, educational materials and a voucher for a medication starter kit
223527358|NCT06078189|DEVICE|HORUS|"The trapezium-metacarpal arthroplasty consists of the installation of a bipolar prosthesis composed of a metacarpal implant and a trapezial implant articulated through a metacarpal head."
223527359|NCT05929326|DIAGNOSTIC_TEST|complete blood count, PT, aPTT, fibrinogen tests|Pregnant women who are eligible for the study will have their blood collected to run complete blood count, PT, aPTT, fibrinogen tests
223527360|NCT06996314|DEVICE|TVNS + Slow-Paced Breathing (TVNS+SDB)|Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
223527361|NCT06996314|DEVICE|TVNS without Breathing Training (TVNS+NB)|Participants receive active transcutaneous auricular vagus nerve stimulation (taVNS) using electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
223527362|NCT06996314|DEVICE|Sham TVNS + SDB|Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with guided slow-paced diaphragmatic breathing (0.1 Hz). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
223527363|NCT06996314|DEVICE|Sham TVNS + NB|Participants receive transcutaneous auricular vagus nerve stimulation using a sham protocol via electrodes placed at the cymba conchae, combined with spontaneous breathing (no guided breathing exercises). The intervention is performed daily at home for 12 weeks, with each session lasting 60 minutes.
223527364|NCT04890509|DRUG|Bemcentinib|Bemcentinib capsules will be administered orally.
223527365|NCT04890509|OTHER|SoC|The SoC will be administered based on local guidelines.
223527366|NCT06671119|DEVICE|Gastric Mucosal Ablation (GMA)|Endoscopic Gastric Mucosal Ablation (GMA) after sleeve gastrectomy
223527367|NCT05766280|BEHAVIORAL|iCareer Soft Skills Training for Employment|The telehealth iCareer intervention will be delivered during regular educational or vocational services (i.e., services from the Office of Disability Services (ODS) and/or from the school or college counseling center). Six modules of Soft Skills Training (SST), four group sessions for each module with 60 to 90 min for each session (depending on group size) will be delivered by trained project staff (graduate counseling student assistant or graduate counseling intern) via HIPAA-compliant Zoom videoconferencing. If participants are unable to join by Zoom videoconferencing, telephone (a format widely used in Cognitive Behavior Therapy (CBT) for Post Traumatic Stress Disorder (PTSD) treatment delivery and in CBT for depression) will be utilized. Ethical guidelines for providing telehealth over videoconferencing or phone will be followed.
223527368|NCT06516198|OTHER|Auricular Acupressure|Seeds will be placed during the clinic visit by the acupuncturist or the research associate according to the group the patient was assigned to. The care partner will observe the placement. A photograph of the seed placement will be taken and given to the care partner and to the patient after the relevant points are labeled by number or letter. The method of pressing is demonstrated for 1 one of the seeds, the care partner practices pressing on 2 other seeds, and the patient practices pressing on the remaining 2 seeds. Pressing consists of applying pressure, gradually increasing the pressure until the patient expresses discomfort, and maintaining that pressure until 2 minutes have passed. After pressing has been performed for each seed, the seeds are removed in clinic prior to clinic discharge.
223527369|NCT04093453|OTHER|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
223527370|NCT04093453|OTHER|Exercise|1 hour exercise
223527371|NCT04093453|DIETARY_SUPPLEMENT|Sodium Propionate|Participant receive Sodium Propionate
223527372|NCT06668220|DRUG|Dexmedetomidine|Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
223527373|NCT06668220|DRUG|Bupivacain|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
223709648|NCT04961294|DEVICE|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
223709649|NCT03402113|DRUG|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
223709650|NCT03402113|DRUG|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
223709651|NCT04767763|DIAGNOSTIC_TEST|Assessment of TSH, fT3, fT4,TRH, TT3, TT4, rT3 in patients with CVVHDF|blood samples were collected before initiation of CRRT and at 1,2,3,6,9-day following. Last samples were collected 3 days after the end of CRRT.
223709652|NCT00776724|DRUG|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
223709653|NCT00776724|DRUG|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
223709654|NCT04846842|DRUG|Gimatecan|Patients will receive gimatecan orally at the fixed dose level on day 1-5 every 4 weeks.
223709655|NCT03528707|DIETARY_SUPPLEMENT|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
223709656|NCT03528707|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
223709657|NCT06136078|OTHER|rate of appropriate and inappropriate transfers from Methodist interfacility transfers|Evaluating rate for patients experiencing traumatic intracranial subarachnoid hemorrhage or spontaneous bleeds
223709658|NCT01612858|DRUG|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
223709659|NCT01612858|DRUG|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
223709660|NCT03181035|RADIATION|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
223709661|NCT03181035|DRUG|Pimonidazole|oral pimonidazole hypoxia labeling
223709662|NCT01706978|PROCEDURE|Bone Trephination|
223709663|NCT01706978|PROCEDURE|Soft Tissue Trephination|
223709664|NCT01626430|DIETARY_SUPPLEMENT|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
223709665|NCT01626430|DIETARY_SUPPLEMENT|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
223709666|NCT02233114|OTHER|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
223709667|NCT02233114|OTHER|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
223709668|NCT02206074|DIETARY_SUPPLEMENT|Beetroot|
223709669|NCT05431660|OTHER|education and exercise protocol about diabetic foot|In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
223709670|NCT05431660|OTHER|control group|diabetic foot school information booklet and weekly video conference meeting
223709671|NCT03631875|DRUG|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
223709672|NCT02204956|BEHAVIORAL|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
223709673|NCT02204956|BEHAVIORAL|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
223709674|NCT00154635|DRUG|DCB-AD1|
223709675|NCT03757156|OTHER|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
223709676|NCT02364726|PROCEDURE|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
223893762|NCT06728696|PROCEDURE|Immediate implant with with dual zone technique using concentrated growth factor graft.|In the test group, pouch technique + CGFG will be used. The CGFG will be packed in the split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket. A convenient blood sample will be withdrawn from a peripheral venous blood from the patient using a specialized vacutaine. A standard, disposable, 10-ml non- anticoagulant tube and a matching centrifuge device was used. To prepare the CGFG, the centrifuge is accelerated for 30 seconds, then centrifuged at 2700 rpm for 2 minutes, 2400 rpm for 4 minutes, 2700 rpm for 4 minutes, and 3000 rpm for 3 minutes before being decelerated for 36 seconds to stop.
223709677|NCT02364726|BEHAVIORAL|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
223709678|NCT02364726|BEHAVIORAL|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
223709679|NCT04741711|PROCEDURE|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava.|An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines.
223709680|NCT04741711|PROCEDURE|Usual care without ultrasound guidance|Usual care (i.e. without ultrasound guidance)
223709681|NCT06071208|DRUG|Gliflozin|to study whether the use of gliflozin prevented diabetic complications
223709682|NCT05401357|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 1 hour for 42 days.
223709683|NCT05401357|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the other arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm for 42 days.
223709684|NCT00547495|DRUG|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
223709685|NCT00547495|DRUG|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
223709686|NCT00547495|DRUG|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
223709687|NCT00547495|DRUG|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
223709688|NCT02173808|BIOLOGICAL|levonorgestrel butanoate|
223709689|NCT02898129|OTHER|Questionnaire|
223709690|NCT02898129|DEVICE|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
223709691|NCT06558292|OTHER|Virtual Reality Group|Students will experience the operating room environment with virtual reality glasses before clinical practice.
223709692|NCT03254875|BEHAVIORAL|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
223709693|NCT00956969|BEHAVIORAL|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
223709694|NCT00956969|BEHAVIORAL|Relaxation Training|Teaches patients relaxation training
223527374|NCT06681012|DEVICE|Gelsectan®|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
223709695|NCT02043080|OTHER|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
223709696|NCT05274880|DRUG|CKD-393|PO, QD
223709697|NCT00807170|DRUG|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
223709698|NCT00807170|RADIATION|Whole Brain Radiotherapy (WBRT)|
223709699|NCT00807170|DRUG|ZD6474|200 mg as a once daily oral dose, 21 days
223709700|NCT00807170|DRUG|ZD6474|300 mg as a once daily oral dose, 21 days
223709701|NCT02077478|DEVICE|Remifentanil and propofol administration using TCI|
223709702|NCT02077478|DEVICE|Remifentanil and propofol administration using MCI|
223709703|NCT03799731|DRUG|GM102|GM102 7 mg/kg weekly
223527375|NCT06681012|DRUG|Placebo|Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
223709704|NCT03799731|DRUG|Trifluridine/Tipiracil|Lonsurf 35 mg/m² twice daily during 10 days per cycle
223709705|NCT03799731|DRUG|GM102 expansion|GM102 7 mg/kg weekly after a loading dose of 10 mg/kg q1w during 28-day cycle 1
223709706|NCT02014571|DRUG|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
223709707|NCT02014571|DRUG|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
223709708|NCT03890601|BIOLOGICAL|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~* 10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~* 5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
223709709|NCT05950256|DEVICE|N95 mask and surgical mask|Twenty participants were randomly assigned to the N95 mask group (n=10 ) and the Surgical mask group (n=10 ). The N95 mask group and the Surgical mask group were used in two stages alternately. When the first round of the test was completed and after a 24-hour washing out period, the participants of the Surgical mask group and the N95 respirator group were exchanged for the second round of the test.
223709710|NCT01750983|DRUG|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
223709711|NCT01750983|DRUG|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
223527376|NCT06680648|PROCEDURE|addition of oxygeninsufflation via working channel of flexible scope|addition of oxygeninsufflation via working channel of flexible scope in order to improve visibility when advancing the flexible scope
223527377|NCT06680648|PROCEDURE|no-oxygen insufflation|no-oxygen insufflation added to the flexible scope while advancing it
223527378|NCT07010653|DEVICE|Higroscopic Cervical ripening|Participants assigned to the Dilapan-S group will have 3 to 5 rods inserted under aseptic conditions. Placement will follow manufacturer instructions, and rods will remain in place for up to 12 hours unless spontaneous labor or device expulsion occurs earlier. Upon removal, cervical status will be assessed, and induction will continue with prostaglandins or oxytocin based on standard care.
223527379|NCT07010653|DEVICE|Cervical ripening via CRB|Double Balloon Catheter (CRB) Participants randomized to CRB will undergo insertion of a double balloon catheter with inflation of each balloon (approximately 80 mL saline each) according to established protocols. The catheter will remain for up to 12 hours or until spontaneous labor or expulsion. Post-removal management will mirror that of the Dilapan-S group.
223527380|NCT06624995|OTHER|chatbot education|elderly patients interacted with Chatbot to discuss general postoperative complication related inquiries
223527381|NCT07011407|OTHER|Maximal Exercise Test|"Healthy participants will be situated on a cycle ergometer fitted with a 12-lead ECG or chest-strap heart rate monitor. Data from the questionnaire will be stored in a study site file in a locked cabinet in an office. Baseline readings will be obtained whilst on the bike for 3 minutes before the subject embarks on a 3-minute warm-up at 50 Watts (W). The workload (watts) on the bike is then increased to a workload that corresponds to a heart rate of 120 bpm (gentle exercise). The workload will then be increased by 25-50W every three minutes until volitional exhaustion. Between each stage, there will be a 30s rest period where the participant will be cycling with minimal resistance (freewheeling) but will be otherwise stationary on the cycle ergometer. Still images of the face and facial video recordings will be taken during a 30s rest period between increases in exercise intensity. A finger-prick blood sample (glucose \& lactate) will be taken at the beginning and every 3 minutes."
223527382|NCT07010068|DIETARY_SUPPLEMENT|TGF-β2-enriched food for special medical purposes|"The experimental treatment is Modulen-IBD®, a food for special medical purpose, polymeric, enriched with TGF-beta. If the patient refuses the experimental supplementation, NGT will be proposed to ensure the correct intake of Modulen-IBD® supplementation.~If the patient refuses, not tolerates, or there are contraindications to NGT placement, best supportive therapy will be warranted as reported below (BST)."
223527383|NCT07010068|DIETARY_SUPPLEMENT|BST|Best Nutritional Supportive Treatment as per center's policy according to EBMT Handbook 2024
223527384|NCT07010614|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive electrical brain stimulation.
223527385|NCT07010614|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation
223527386|NCT07010614|DEVICE|TMS sham|Sham TMS will be used as a comparator for noninvasive brain stimulation
223527387|NCT07011433|DIAGNOSTIC_TEST|Inflammatory Biomarker Evaluation|Venous blood samples are collected from subjects and analyzed for inflammatory biomarkers, including CD64, presepsin, IL-6, and IL-8, using a Luminex multiplex assay. Results are used for research purposes only and do not affect clinical management.
223527388|NCT06683677|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to extremely preterm infants immediately after birth.
223527389|NCT07011108|OTHER|No intervention (observational study)|no intervention
223527390|NCT06687733|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
223527391|NCT07010393|DRUG|Dabrafenib|150 mg orally twice daily; ≤4 × 28-day cycles
223527392|NCT07010393|DRUG|Trametinib|2 mg orally once daily; same duration
223527393|NCT07010393|DRUG|Selpercatinib|160 mg orally twice daily; ≤4 cycles
223527394|NCT07010393|DRUG|Pralsetinib|retrospective, 400 mg orally once daily; ≤4 cycles
223527395|NCT07010393|DRUG|Lenvatinib|24 mg orally once daily; ≤4 cycles
223527396|NCT07010393|DRUG|Larotrectinib|Larotrectinib 100 mg orally twice daily, continuous 28-day cycles.
223527397|NCT07010393|DRUG|Anlotinib|12 mg orally once daily; 2 weeks on / 1 week off, ≤4 cycles (alternative)
223527398|NCT07010393|DRUG|Pembrolizumab|200 mg IV infusion every 3 weeks; ≤4 cycles
223527399|NCT07010393|DRUG|Sintilimab|200 mg IV infusion every 3 weeks; ≤4 cycles
223527400|NCT07010393|DRUG|Cabozantinib|Cabozantinib 60 mg orally once daily, continuous 28-day cycles.
223527401|NCT07010393|DRUG|Bemosuzumab|China PD-L1 antibody bemosuzumab 900 mg IV every 2 weeks (14-day cycle).
223527402|NCT07010393|PROCEDURE|Conversion Surgery|Conversion Surgery if resectable
223527403|NCT06625710|DRUG|GV1001|Lyophilized peptide from hTERT
223527404|NCT06625710|DRUG|Placebo|0.9 % Normal Saline
223527405|NCT02371187|DRUG|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
223527406|NCT02371187|DRUG|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
223527407|NCT00420706|DRUG|SCA-136|
223527408|NCT00217802|BEHAVIORAL|six-session telephone counseling program|
223527409|NCT03462121|DRUG|RPh201|RPh201 is a well-defined extract from a botanical source
223527410|NCT03462121|OTHER|Placebo|Inactive placebo consisting of the therapeutic vehicle
223527411|NCT02117076|DRUG|Gabapentin immediate release|up to 1200 mg per day
223527412|NCT02117076|DRUG|Gabapentin enacarbil extended release|up to 1200 mg per day
223527413|NCT06022887|BEHAVIORAL|TRE|daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;
223527414|NCT06022887|BEHAVIORAL|MBSR|Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks
223527415|NCT05918146|DRUG|Dextrose|Dextrose injection plus physical therapy
223527416|NCT05918146|DRUG|Normal saline|Normal saline injection plus physical therapy
223527417|NCT04701710|DRUG|Ivermectin / Iota-Carrageenan|The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
223527418|NCT03057340|BIOLOGICAL|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
223709712|NCT06111820|BEHAVIORAL|Improving Access to Community Therapies (iACT)|The Low-intensity Acceptance and Commitment Therapy (LIACT) protocol is based on the empirically supported Acceptance and Commitment Therapy (ACT), and is designed by registered clinical psychologists with consultation from local ACT experts from the Association of Contextual and Behavioural Science (Hong Kong Chapter). The LIACT protocol is also piloted and revised by clinical psychologists to ensure its adaptability to local situations. For individual guided self-help LIACT service, an intake assessment will be conducted to assess the presenting problem of the participants at pre-treatment to ensure the suitability to receive LIACT service. Participants will be given the LIACT self-help workbook collaboratively with a Psychological Wellbeing Practitioner (PWP). Between each session, clients will read through the workbook and complete the exercises suggested in the workbook. In subsequent sessions, PWP will guide clients to overcome the difficulties in performing the LIACT exercises.
223709713|NCT06450262|DRUG|Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
223709714|NCT06450262|DRUG|Synjardy® 12.5mg/1000mg film-coated tablets|1 tablet of Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets
223709715|NCT04370223|BIOLOGICAL|Ozone auto-hemotherapy|ozone auto-hemotherapy
223709716|NCT00660699|DRUG|Gemcitabine|
223709717|NCT00660699|DRUG|Docetaxel|
223709718|NCT00660699|RADIATION|Radiation|
223709719|NCT06646536|OTHER|Anti-gravity treadmill training|Patients will participate to anti-gravity treadmill (Alter G) walking program in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
223709720|NCT06646536|OTHER|Conventional treadmill training|Patients will participate to walking program on a standard treadmill in addition to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
223709721|NCT06646536|OTHER|Standard physiotherapy and rehabilitation program|Patients will participate to physiotherapy and rehabilitation program for 6 weeks, 2 days a week.
223709722|NCT05439447|DIAGNOSTIC_TEST|Patients scheduled for VFSS testing group|Patients scheduled for VFSS testing, patient with voice.
223709723|NCT04203329|DEVICE|Femoral Venous Vascular Closure|Femoral venous vascular closure following catheter-based cardiac ablation a-fib cases utilizing 6-12 French inner diameter procedural sheaths at time of closure.
223709724|NCT06681610|DEVICE|Transcranial Pulse Stimulation|low intensity shock-waves stimulation of the motor cortex, bilateral
223709725|NCT06685809|DRUG|FZ008-145 solution|Dose formulation- Oral solution
223709726|NCT06685809|DRUG|FZ008-145 Tablet|Dose formulation- Oral tablet
223709727|NCT06685809|DRUG|Placebo|Dose formulation- Matching doses
223709728|NCT06685809|DRUG|FZ008-145 Tablet and Placebo|Dose formulation- Oral tablet
223709729|NCT06685809|DRUG|FZ008-145 Tablet and Placebo|Dose formulation- Oral tablet
224276276|NCT06024343|PROCEDURE|MPD Exposure, Repair or Reconstruction|During laparoscopic or robotic pancreatic tumor enucleation, if the main pancreatic duct (MPD) is injured due to its proximity or encasement by the tumor, MPD manipulation is performed. MPD manipulation is categorized into three scenarios: exposed but not injured; simple suture repair (using 5-0/6-0 PROLENE polypropylene suture); and suture repair/reconstruction following stent insertion. Using the F6 ventricular drainage catheter with 1-2 side holes trimmed as the stent, typically requiring 10 cm for passage through the duodenal papilla and 3-4 cm if not passing through. Following stent placement, intermittent suturing reconstructs the MPD, with one stitch securing the stent by passing through both the stent side wall and the MPD.
224276277|NCT00076531|DRUG|Leuprolide Acetate for Injectable Suspension 22.5 mg|
224276278|NCT03819920|BEHAVIORAL|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
223709730|NCT07033832|BEHAVIORAL|ACT-based intervention|"Parents in this group will receive two-hour weekly session with the question-and-answer session at the end. The contents of each session are as follows: (1) the first session consist of introductions of ACT, discussion on stress and struggles, and setting homework, (2) the second section includes role play, and the meaning of value, (3) the third session involves introducing mindfulness of the breath exercise, debrief and homework on practicing mindfulness and (4) the last session includes introduction of thoughts, and putting values into feasible actions."
223709731|NCT06321523|DRUG|Tafamidis 61 milligrams|Tafamidis 61mg as provided in real-world practice
223709732|NCT01752985|DRUG|BMS-813160|
223709733|NCT01752985|DRUG|Placebo matching with BMS-813160|
223709734|NCT06906276|OTHER|Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.|Dual-task walking with the auditory stroop task. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right Navigational and dual-task walking (condition 1 and 2 together)
223709735|NCT06724328|BEHAVIORAL|Gentle Human Touch|the trained NICU nurse will place one hand's fingertips on the baby's forehead along the brow line, while the other hand will be placed around the baby's lower abdomen
223709736|NCT06724328|BEHAVIORAL|Maternal Heartbeat and Gentle Human Touch|maternal heartbeat will be played and GHT steps will be applied simultaneously at the designated times
223709737|NCT06724328|BEHAVIORAL|Maternal Heartbeat|The recording of the mother's heartbeat will be done when the mother's mood is stable and the environment is quiet. A Doppler fetal heart monitor will be used to detect the mother's heartbeat. After ensuring a regular and stable heart rate, the mother's heartbeat will be recorded for 15 minutes using a recording device
223709738|NCT01050868|DEVICE|Accu-Chek Combo Kit mg DE/de|
223709739|NCT01488929|DRUG|TC-5619|
223709740|NCT01488929|DRUG|Placebo|
224276279|NCT03819920|BEHAVIORAL|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
224276280|NCT03847974|DRUG|LIB003|300 mg SC Q4W
224276281|NCT06679673|DRUG|SHR-1701|SHR-1701
224276282|NCT06679673|DRUG|BP102|BP102
224276283|NCT06679673|DRUG|SHR2554|SHR2554
223709741|NCT04099628|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
223709742|NCT03510754|PROCEDURE|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
223709743|NCT03342534|DEVICE|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
223709744|NCT06131697|OTHER|McKenzie Exercises without Mulligan Mobilization|McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.
223709745|NCT06131697|OTHER|McKenzie Exercises with Mulligan Mobilization|"McKenzie Exercises will be comprised of four exercise programs. Retraction with neck flexion, extension, lateral flexion and rotation exercises. Each exercise will be performed with two sets of 10 reps with 10 secs hold twice a week for the time period of four weeks.~Along McKenzie exercises Sustained Natural Apophyseal Glide will be given with the tip of thumb placed at an angle of 45° along the eyeball direction reinforced by another thumb. This exercise will be performed for three sets of six repetitions twice a week for the time period of four weeks."
223709746|NCT01603004|OTHER|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
223709747|NCT03623815|OTHER|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
223709748|NCT01853761|DEVICE|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
223709749|NCT01853761|DEVICE|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
223709750|NCT01853761|DEVICE|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
223709751|NCT01853761|DEVICE|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
223709752|NCT01853761|DEVICE|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
223709753|NCT01853761|DEVICE|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
223709754|NCT02847156|OTHER|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
223709755|NCT03940612|DIETARY_SUPPLEMENT|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
223709756|NCT03940612|DIETARY_SUPPLEMENT|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
223709757|NCT03608098|DEVICE|Short Pulse Duration|The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
223709758|NCT03608098|DEVICE|Long Pulse Duration|The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
223709759|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
223527419|NCT05406531|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
223527420|NCT05406531|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
224276284|NCT06464874|PROCEDURE|Conventional ESD|Conventional ESD is the most suitable method for total resection, especially for large lesions. This method can complete the resection of early gastrointestinal cancer and precancerous lesions, while maintaining the integrity of digestive tract anatomy and physiological function.The operation difficulty of this technique is high, the equipment requirements are high, the operation time is long, and the complication rate is closely related to the technical level of the operator.
223709760|NCT01354678|PROCEDURE|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
223709761|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
223709762|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
223709763|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
223709764|NCT01385566|BIOLOGICAL|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
223709765|NCT01385566|BIOLOGICAL|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
223709766|NCT01385566|BIOLOGICAL|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
223709767|NCT02974166|OTHER|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
223709768|NCT02974166|OTHER|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
223709769|NCT02974166|DRUG|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
223709770|NCT02974166|DRUG|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
223709771|NCT02362217|BIOLOGICAL|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
223709772|NCT02362217|BIOLOGICAL|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
223709773|NCT02362217|BIOLOGICAL|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
223709774|NCT02362217|BIOLOGICAL|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
223709775|NCT00691860|DEVICE|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
223709776|NCT00691860|PROCEDURE|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
223709777|NCT00702039|OTHER|No Music|No music will be played in patients in arm 2 of the study.
223709778|NCT00702039|OTHER|Music Therapy|Classical music being played during intravitreal injection.
223709779|NCT01958333|PROCEDURE|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
223709780|NCT01958333|PROCEDURE|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
223709781|NCT01958333|PROCEDURE|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
223709782|NCT04092582|DRUG|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
223709783|NCT04092582|DRUG|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
223709784|NCT04087265|DIAGNOSTIC_TEST|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
223709785|NCT03210246|DRUG|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
223709786|NCT03210246|DRUG|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
223709787|NCT03210246|DRUG|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
223709788|NCT03210246|DRUG|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
223709789|NCT05865262|DIAGNOSTIC_TEST|ECG|"A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula."
223709790|NCT05865262|DIAGNOSTIC_TEST|blood test (assessing ionic and hormonal circulating levels)|Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
224276285|NCT06464874|PROCEDURE|Hybrid ESD|Hybrid ESD is a better choice, but only can remove the lesion in one piece, but also has a lower technical difficulty than conventional ESD
224276286|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
223709791|NCT03133169|DIAGNOSTIC_TEST|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
223709792|NCT03133169|DIAGNOSTIC_TEST|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
223709793|NCT00690274|DRUG|BF2.649|up to 20mg per day
223709794|NCT00690274|DRUG|Placebo|up to 20mg per day
223709795|NCT05638178|OTHER|No intervention|No intervention, cohort study.
223709796|NCT05214495|DRUG|topical oral Omega-3 hydrogel|Topical oral Omega-3 hydrogel prepared from fish oil
223709797|NCT05214495|DRUG|conventional preventive treatment|"topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)"
223709798|NCT00896246|DRUG|Klean-Prep®|Four litres of solution administered orally as a divided dose.
223709799|NCT00896246|DRUG|Moviprep®|Two litres of solution administered orally as a divided dose
223709800|NCT05236049|BIOLOGICAL|SclerFIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
223709801|NCT01696084|DRUG|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
223709802|NCT01696084|DRUG|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
223709803|NCT02959320|PROCEDURE|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
223709804|NCT01881347|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
223709805|NCT01881347|DIETARY_SUPPLEMENT|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
223709806|NCT01244269|DRUG|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
224276287|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
223709807|NCT01244269|DRUG|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
223709808|NCT01244269|DRUG|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
223709809|NCT01244269|DRUG|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
223709810|NCT03811028|DRUG|SOBI003|weekly i.v. infusion
223709811|NCT00560105|DEVICE|Lung Flute|8 weeks home use, twice daily
223709812|NCT00560105|DEVICE|Acapella|8 weeks home use, twice daily
223709813|NCT02927665|DEVICE|Reshape Integrated Dual Balloon|
223709814|NCT05860478|DEVICE|Wearable device|The wearable device includes a motion sensor, and is worn around the wrist, and the device records a participant's physical activity .
223709815|NCT00071097|DRUG|TMC114/rtv|800mg TMC114/100mg rtv once daily
223709816|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
223709817|NCT00071097|DRUG|TMC114/rtv|400mg TMC114/100mg rtv once daily
223709818|NCT00071097|DRUG|TMC114/rtv|600mg TMC114/100mg rtv twice daily
224276288|NCT03998592|BIOLOGICAL|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
223709819|NCT04511546|DEVICE|BPET Prototype Scan|Scan on the BPET Prototype PET system and qualitative comparison with a PET image acquired on a conventional clinical PET system.
223709820|NCT04250220|DIAGNOSTIC_TEST|e-Health based strategy: PPG-based screening using a smartphone and ECG patch|PPG-analysis via Smartphone-App (Preventicus Heart Beats) and ECG patch
223709821|NCT01012271|OTHER|MRI|MR arthrography is used to evaluate wrist abnormalities
223709822|NCT03090802|BEHAVIORAL|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
223709823|NCT03980041|DRUG|IPI-549 (eganelisib)|IPI-549 (40mg QD) administered orally in 28-day cycles
223709824|NCT03980041|DRUG|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
223709825|NCT03980041|DRUG|Placebos|Placebo administered orally in 28-day cycles
223709826|NCT05338593|OTHER|Outcome|Mortality rate of prolonged therapy.
223709827|NCT01661621|DRUG|Detrusitol 4 mg QD|Group 1
223709828|NCT01661621|DRUG|Doxazosin 4 mg QD|Group 2
223709829|NCT00948701|BEHAVIORAL|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
223709830|NCT01152710|DRUG|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
223709831|NCT03663816|DEVICE|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
223709832|NCT01155232|DRUG|Teriparatide|Forteo (teriparatide)pen daily for 24 months
223709833|NCT05504564|GENETIC|The experiment does not required any intervention|The experiment does not required any intervention
224276289|NCT03998592|OTHER|Placebo|Placebo without active component
224276290|NCT03911180|DEVICE|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
224276291|NCT03275857|DRUG|Cisplatin|Weekly IV
223709834|NCT04157439|OTHER|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
223709835|NCT04157439|OTHER|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique \[sustain pressure, Post Isometric Relaxation (PIR) and SCS\]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
223709836|NCT04481867|PROCEDURE|densah bur|osseodensification densah bur
223709837|NCT04962204|BEHAVIORAL|Virtual meeting between patients/physicians and caregiver|Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day
223709838|NCT04401085|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
223709839|NCT04401085|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
223709840|NCT03368794|BEHAVIORAL|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
223709841|NCT03368794|BEHAVIORAL|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
223709842|NCT00300391|DRUG|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
223709843|NCT00300391|OTHER|Saline placebo|control arem
223709844|NCT06495827|OTHER|No different intenvention|No different intenvention
223709845|NCT04730284|OTHER|Health supplements|tailor-made Synbiotics, 4g per day for 28 days
223709846|NCT02025621|DRUG|Levosimendan|
223709847|NCT02025621|DRUG|Placebo|matching placebo
223709848|NCT03673033|PROCEDURE|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
223709849|NCT05349175|DEVICE|Augmented Infant Resuscitator (AIR)|Real-time visual feedback from the AIR device regarding quality of bag-mask ventilation
223709850|NCT04012983|DIAGNOSTIC_TEST|gingival crevicular fluid level|gingival crevicular fluid collection
223709851|NCT04362982|OTHER|ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.|Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
223709852|NCT06964061|COMBINATION_PRODUCT|PA5436 Ocular Implant, 115mcg|The PA5346 Ocular Implant is supplied preloaded into the needle of a single use Administration Device ready for use.
223709853|NCT02637284|DRUG|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
223709854|NCT02637284|DRUG|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
223709855|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
223709856|NCT00254904|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
223709857|NCT00254904|DRUG|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
223709858|NCT00254904|DRUG|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
223709859|NCT00254904|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
223709860|NCT04032860|DRUG|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
223709861|NCT04032860|DRUG|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
223709862|NCT05115903|DRUG|Tapered doses of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing dose intervals as specified
223709863|NCT05115903|DRUG|Standard dose of TNFi|To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab)
223709864|NCT04664062|BEHAVIORAL|Medication Assisted Treatment|All subjects will undergo MAT induction with buprenorphine. Participants will be randomized to the behavioral aspects of induction, specifically comparing office induction vs home vs synchronous telehealth induction.
223709865|NCT03097094|DIAGNOSTIC_TEST|Male dog|Male dog extract
223709866|NCT03097094|DIAGNOSTIC_TEST|Female dog|Female dog extract
223709867|NCT01871532|DRUG|Gonal-f®|
223709868|NCT00289471|OTHER|No intervention delivered.|No intervention delivered.
223709869|NCT05777590|DRUG|Indocyanine Green Angiogram|Angiogram using ICG dye the occurs directly after conventional angiogram in assessment of frostbite patients undergoing thrombolysis
223709870|NCT06063824|OTHER|Single-Session Method of Levels Intervention|This is a single session of method of levels psychotherapy delivered to patients of GP surgeries in primary care.
223709871|NCT01338766|PROCEDURE|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
223709872|NCT03558776|DIETARY_SUPPLEMENT|linseed oil|linseed oil and defined background diet
223709873|NCT02338141|DEVICE|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
223709874|NCT02338141|DEVICE|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
223709875|NCT02256852|BIOLOGICAL|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
223709876|NCT06103123|DIAGNOSTIC_TEST|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire|Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives
223709877|NCT06103123|OTHER|Baseline Quality of Life questionnaire|Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study
223709878|NCT04945954|OTHER|Drug: Cyclophosphamide|"Administer 14.5mg/kg of Cyclophosphamide once a day for 4days. (intravenously)~Blood sampling of pharmacokinetics(PK) of cyclophosphamide will be performed in all patients who have taken the investigational drug for at least 4 days (For 2 days, It will be administered for pretreatment of transplant, for the other 2 days, It will be administered for Post-transplant treatment for the prevention of GVHD)"
223709879|NCT03069807|OTHER|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
223709880|NCT03069807|OTHER|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
223709881|NCT04066049|BEHAVIORAL|EMT en Español|EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser \& Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
223709882|NCT04706676|BEHAVIORAL|Integrative neuromuscular training (INT)|"Integrative neuromuscular training (INT), contains a multifaceted range of developmentally appropriate activities that incorporate general and specific strength and conditioning elements such as strength, power, motor skill training, dynamic stability, core-focused strength, plyometric and agility. INT can be camouflaged as games and play or performed as structured strength and conditioning program, depending on the participant's age, motor skill level and diagnosis. The intervention is designed to enhance health- and skill-related components of physical fitness.~Parents or guardians will receive education in conducting INT at home, alongside an exercise-kit consisting of training equipment corresponding to the child's age and fitness level (fitness ropes, medicine ball, dumbbells).~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
223709883|NCT04706676|BEHAVIORAL|Active control group: home-based training program|"The active control group is offered a home-based training program consisting of combined aerobic, strength and stretching exercises. Further, they will receive monthly motivational consultations, as described below, concerning the training program. The use of the home-based training program will be monitored through exercise journals.~The INT group will receive usual standardized hospital care, including physiotherapy if needed."
223709884|NCT04706676|BEHAVIORAL|motivational counseling session|"Each child and their parents will participate in a monthly 30-minute motivational counseling session to adjust the intervention and training program according to the child's physical capacity and preferences. Further, the session will determine potential barriers towards performing physical exercise using the Self-efficacy for Exercise Scale.~The sessions are based on the principles in Self-Determination Theory that includes a spectrum of external and internal motivation factors for engaging in exercise. Each session will provide guidelines to increase the general activity levels and adjust the intervention according to the child's preferences and presence of symptoms."
223709885|NCT05834374|OTHER|Contextual variation|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
223709886|NCT05834374|OTHER|Maximum affordances|The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
224276292|NCT02879773|RADIATION|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
224276293|NCT02870439|OTHER|Blood drawn|
224276294|NCT01616316|PROCEDURE|subfascial flap|subfacial dissection to thyroid
223527421|NCT05406531|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
223527422|NCT00005819|DRUG|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
223527423|NCT00005819|DRUG|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
223527424|NCT00005819|DRUG|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
223527425|NCT03864705|DIAGNOSTIC_TEST|Measurement of plasma metformin levels|Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
223527426|NCT00657683|BIOLOGICAL|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
223527427|NCT00657683|BIOLOGICAL|Placebo|1 dose of placebo
223527428|NCT00414557|PROCEDURE|Quadriceps strengthening|
223527429|NCT03420820|BIOLOGICAL|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
223527430|NCT04847037|PROCEDURE|Connected tools|Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
223527431|NCT04528186|DIAGNOSTIC_TEST|Maternal thyroid volume|Maternal thyroid volume measurement
223527432|NCT03224845|BEHAVIORAL|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
223527433|NCT03048370|PROCEDURE|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
223527434|NCT03048370|PROCEDURE|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
223527435|NCT03048370|PROCEDURE|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
223527436|NCT03048370|PROCEDURE|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
223527437|NCT03048370|PROCEDURE|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
223527438|NCT03048370|PROCEDURE|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
223527439|NCT05589909|DIAGNOSTIC_TEST|IL27, PCT, CRP, Blood culture|magnetic bead multiplex platform
223527440|NCT06956391|DRUG|18F-FDG|Participants will be injected with 18F-FDG and imaged for up to 3 hours on a PET scanner
223527441|NCT05973903|DRUG|Lenvatinib|Oral Lenvatinib 20 mg once daily
223527442|NCT05973903|DRUG|Pembrolizumab|intravenous pembrolizumab 200 mg every three weeks
223527443|NCT05973903|DEVICE|Tumor Treating Fields (TTFields)|TTF extra-dermal scalp electrodes
223527444|NCT06788132|COMBINATION_PRODUCT|Cranberry products|One capsule of cranberry extract 100mg equivalent 36 mg, hibiscus extract 20 mg, vitamin C 500 mg with lactobacillus 200 MU per day for 10 days
223527445|NCT06788132|OTHER|Placebo|Starch one capsule per day for 10 days
223527446|NCT01926860|BIOLOGICAL|Prevenar13|
223527447|NCT01926860|BIOLOGICAL|Hepatitis A vaccine|
223527448|NCT03495414|OTHER|Brain Imaging|"* Structural MRI (T1 weighted)~* Diffusion Tensor Imaging (DTI)~* resting state functional MRI (rs-fMRI)~* functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
223527449|NCT03495414|OTHER|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~* intelligence (Ravens Matrices)~* impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~* inhibitory control (Stop Signal Task)."
223527450|NCT03495414|OTHER|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
223709887|NCT04345042|OTHER|Classic Massage (Swedish Technique)|Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
223709888|NCT00379093|BEHAVIORAL|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~* A personalized risk report;~* An educational booklet titled Healthy Drinking as You Age;~* A drinking diary;~* Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
223709889|NCT04503785|DIAGNOSTIC_TEST|Manometry|Transnasal Esophageal manometry and Endoflip Balloon distensibility
223709890|NCT02195583|DRUG|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
223709891|NCT02195583|DRUG|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
223527451|NCT03495414|OTHER|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
223527452|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
223527453|NCT02458729|DRUG|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
223527454|NCT02458729|DRUG|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
223527455|NCT02458729|DRUG|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
223527456|NCT02458729|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
223709892|NCT02195583|DRUG|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
223527457|NCT03731429|DRUG|Lidocaine|prior to extubation
223527458|NCT03731429|DRUG|Saline Solution|Prior to extubation
223527459|NCT02278003|OTHER|memory test|
223527460|NCT02278003|DRUG|Propofol|
223527461|NCT06263803|OTHER|Music listening, classic physical therapy|Participants will listen to the music pieces Pachabel Canon in D major (20 minutes) and Mozart - Sonata for Two Pianos in D, K. 448 (25 minutes), free from external sounds (max 70 dB through headphones).
223527462|NCT04692506|OTHER|Probiotic|The study product is probiotic
223527463|NCT00152126|PROCEDURE|Stem Cell Transplantation|Autologous stem cell transplantation
223709893|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
223709894|NCT02195583|DRUG|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
223709895|NCT02195583|DRUG|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
223709896|NCT02502578|DRUG|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
223709897|NCT04218695|DRUG|Ceftriaxone|Antibiotic
223709898|NCT04218695|DRUG|Normal saline|50cc intravenous once daily
223709899|NCT00752180|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
223709900|NCT00752180|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
223527464|NCT00152126|DRUG|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
223527465|NCT04242680|DEVICE|Brainstim DLPFC|"The active tRNS will be delivered to bilateral DLPFC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right DLPFC, F3 and F4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75 milliampere (mA) (100-500 Hz), the duration of stimulation will be 20 min."
223527466|NCT04242680|DEVICE|Brainstim PPC|"The active tRNS will be delivered to bilateral PPC for five consecutive days for two weeks for a total of ten days.~tRNS will be delivered by a battery driven, random-noise current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The electrodes will be placed on the left and right PPC, P3 and P4 position according to the 10-20 international EEG system for electrode placement, while participants will receive a usual treatment (cognitive training).~Stimulation intensity will be set at 0.75mA (100-500 Hz), the duration of stimulation will be 20 min."
223527467|NCT04242680|DEVICE|Brainstim Sham|The same electrode placement will be used as in the stimulation conditions (Brainstim DLPFC or Brainstim PPC), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held five consecutive days for two weeks for a total of ten days.
223527468|NCT04242680|BEHAVIORAL|Cognitive Training|"A cognitive training (Vektor; Nemmi et al., 2016) will be adiministered concomitantly to Brainstim DLPFC, Brainstim PPC, Brainstim Sham for 20 min.~The training consisted of math exercises (number line, calculations) and math-related exercises (visuo-spatial working memory, mental rotation)."
223527469|NCT06062693|DEVICE|smart sensor egg training|The portable hand trainer has three principal functionalities: (I) Grasping, (II) Pronosupination, and (III) wrist and finger extension. Different exercises can be done.
223527470|NCT06268470|DRUG|Desloratadine plus cilostazol and dipyridamole|Desloratadine 20 mg/day plus cilostazol 150 mg/day and dipyridamole 50 mg/day
223527471|NCT06268470|DRUG|Desloratadine|Desloratadine 20 mg/day
223709901|NCT00983437|DRUG|Armodafinil|
223709902|NCT04538430|DEVICE|SPRINT percutaneous peripheral nerve stimulator placed|Placement of a SPRINT percutaneous peripheral nerve stimulator targeting the bilateral medial branches at the suspected level of pain generation. This procedure is done as standard of care.
223709903|NCT01945281|DRUG|Caspofungin|
223709904|NCT01945281|DRUG|Amphotericin B Deoxycholate|
223527472|NCT03369158|PROCEDURE|patient specific pedicle screw positioning guide|
223709905|NCT04639167|BEHAVIORAL|Paths to everyday life (PEER)|The intervention consists of a 10-week group course and the opportunity of individual companionship to e.g. local activities in civil society, municipal social services, education, health and employment. The 10-week group sessions are delivered by two volunteer peers with their own experiential knowledge of mental vulnerability and mental health difficulties. The aim is to form a constructive community through group sessions where exchanges of lived experiences, mutuality and opportunities for social network development can develop.
223709906|NCT05887622|DIETARY_SUPPLEMENT|Potassium chloride supplement|Subjects will receive 64 mmol of KCl on the high potassium/high sodium condition.
223709907|NCT05887622|DIETARY_SUPPLEMENT|Placebo|Subjects will receive a placebo capsule on the moderate potassium/low sodium diet and the moderate potassium/high sodium diet
223709908|NCT06267105|PROCEDURE|Longitudinal incision|Incision performed longitudinally
223709909|NCT06267105|PROCEDURE|Transverse incision|Incision performed transversally
223709910|NCT06273085|BEHAVIORAL|Patient education|3 sessions of education over phone at 1, 3 and 5 months after discharge, each session includes an overview of benefits and side effects of GDMT, inquiries about reasons of not using optimal doses of GDMT medications, and encouraging adherence to visits with providers.
223709911|NCT04105582|BIOLOGICAL|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
223709912|NCT02023281|BEHAVIORAL|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
224276295|NCT01616316|PROCEDURE|subplatysmal flap|subplatysmal approach to thyroid
223527473|NCT03369158|PROCEDURE|Free hand technique pedicle screw positioning|
223527474|NCT03369158|DEVICE|MUST pedicle screw|
223527475|NCT04924348|PROCEDURE|Experimental: WALANT procedure|"The WALANT technique, performed under ultrasound, includes two punctures.~* The first is a puncture through a medial approach above the wrist and includes two injections. A first subcutaneous injection reproducing a bar above the wrist flexion line, and a second injection above the median nerve. The volumes injected vary from 8 to 10 milliliters (ml).~* The second puncture is performed at the base of the palmar surface of the hand and consists of a 10 ml subcutaneous injection of the local anesthetic in order to take advantage of the vasoconstrictive effects of adrenaline, thus allowing the surgical procedure to be performed without a pneumatic tourniquet."
223527476|NCT04924348|PROCEDURE|Active Comparator: Axial ALR|The anesthetic protocol in the axillary block consists of performing a puncture, using a needle (50 mm 22G with a short bevel), under the armpit at the level of the axillary hollow after skin disinfection. This puncture, performed under ultrasound, allows the injection of the local anesthetic around the median, radial, ulnar and musculocutaneous nerves. The volume injected per nerve can vary from 5 to 8 ml depending on the visual appreciation during the injection.
223527477|NCT04924348|PROCEDURE|Active Comparator: Truncal ALR|The anesthetic protocol in truncal block consists in injecting the local anesthetic around the median and ulnar nerves by a puncture performed at the elbow or forearm (depending on the practitioner's experience). The volumes injected remain the same and the puncture is also performed under ultrasound guidance. Additional local anesthesia is administered by injecting an additional 5 ml above the wrist flexion line to block the sensory territory of the musculocutaneous nerve.
223527478|NCT01689948|BEHAVIORAL|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
223527479|NCT03764969|BEHAVIORAL|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer 2004), and will be carried out by a qualified therapist.
223527480|NCT03764969|BEHAVIORAL|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
224276296|NCT06650124|DRUG|Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.|Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
223709913|NCT00362310|DRUG|indinavir|
223709914|NCT04017078|OTHER|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
223709915|NCT04944251|BEHAVIORAL|Regular Exercise|the third month, for 30 minutes or 1 hour, 3 days a week
223709916|NCT04457635|BEHAVIORAL|Psychotherapy|
224276297|NCT06650124|DRUG|Azathioprine + Prednisolone|In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
223709917|NCT03166007|BEHAVIORAL|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
223709918|NCT03166007|BEHAVIORAL|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
223709919|NCT03226483|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
223709920|NCT03732157|PROCEDURE|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
223709921|NCT03732157|PROCEDURE|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
223709922|NCT01439633|DEVICE|MGH OFDI marking|Imaging of esophagus with OFDI system
223709923|NCT06338371|BEHAVIORAL|Pelvic Floor exercise training|The level of sexual function was determined by implementing FSFI for all individuals included in the sample. The participants were divided into two groups, control and training groups, using the randomization program on the computer. Pelvic floor exercise training was given to one group. Trainings were conducted online on different days. Each training lasted 120 minutes. After training was completed, women in the training group were instructed to perform three sets of 8-12 repetitive pelvic floor muscle contractions per day and to use an exercise diary to record their practice. Women in the training group were also given a booklet and the recording of the training video was shared. the training, a brochure explaining how to perform the pelvic floor muscle exercises, which was included in the training content, was prepared and delivered to the training group on the first day of each week. After the training, FSFI was applied to both groups 3 times, in the 1st, 2nd, and 3rd months.
223709924|NCT05091047|DEVICE|Erchonia EVRL|42 procedure administrations with the Erchonia® EVRL™ administered by the subject at home: Twice daily procedure administrations for 3 weeks.
223709925|NCT00727636|BIOLOGICAL|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
223709926|NCT04152473|DRUG|Proglumide|oral CCK receptor antagonist
223709927|NCT05866900|DEVICE|MiniMed 780G with SmartGuard activated|The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.
223709928|NCT04158492|DIAGNOSTIC_TEST|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
223709929|NCT04158492|DIAGNOSTIC_TEST|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
223709930|NCT05662150|DIAGNOSTIC_TEST|Low frequency repetitive stimulation|Neuromuscular transmission was tested by using short-lasting low frequency RNS (10 stimuli at 3 Hz). The test was applied on the abductor digiti minimi (ADM), anterior tibial, orbiculis oculi, trapezius, anconeus and EDB muscles of one side, in this particular order, by supramaximal stimulation of the corresponding nerve.
223709931|NCT02747875|DRUG|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
223939918|NCT07157982|BEHAVIORAL|COORDINATE Program|"The COORDINATE Program is a nurse-led, multicomponent intervention designed to support older adults with multiple chronic conditions during their transition from hospital to home. The intervention is delivered over a 6-week period and includes the following components:~1. Discharge Planning Visit: Conducted in person or via video, this session includes a needs assessment and shared decision-making conversation to identify participants' values and preferences.~2. Question Prompt List: A tailored list of questions is provided to help participants engage more effectively with their care team.~3. Goal Setting: Participants work with a nurse to identify short-term goals and action steps related to their health and care needs.~4. Symptom Monitoring: Participants track symptoms weekly using a symptom checklist to support ongoing management and communication with providers."
224276298|NCT05690035|DRUG|Tislelizumab & Fruquintinib|combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent
224276299|NCT01041235|DRUG|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
224276300|NCT00054834|DRUG|hLL2 (epratuzumab)|
224276301|NCT01288924|DRUG|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
224276302|NCT01288924|OTHER|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
224276303|NCT00004241|DRUG|tanespimycin|Given IV
223709932|NCT02747875|DRUG|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
223709933|NCT03339908|DEVICE|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
223709934|NCT03069300|DRUG|N-acetyl cysteine (NAC)|
223709935|NCT00884169|DRUG|M518101|Proper quantity twice a day
223709936|NCT00884169|DRUG|placebo|Proper quantity twice a day
223709937|NCT02008760|DIETARY_SUPPLEMENT|Omega Krill with D3|
223709938|NCT03758001|DRUG|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
223709939|NCT03758001|DRUG|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
223709940|NCT03758001|DRUG|Sintilimab|200mg iv infusion day 1 of every 21 days
223709941|NCT03478657|DRUG|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
223709942|NCT03478657|DEVICE|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
223709943|NCT03478657|OTHER|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
223709944|NCT02365831|OTHER|Observation of treatment management|Group/cohort
223709945|NCT01218373|DEVICE|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
223709946|NCT01218373|DEVICE|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
223709947|NCT02226146|BIOLOGICAL|Bertilimumab|
223709948|NCT00386659|DRUG|tenofovir + abacavir + lopinavir/ritonavir|
223709949|NCT00386659|DRUG|tenofovir + abacavir + efavirenz|
223709950|NCT05523752|DEVICE|Proseal Laryngeal Mask|insertion of Proseal Laryngeal Mask
223709951|NCT05523752|DEVICE|Classic Laryngeal Mask|insertion of Classic Laryngeal Mask
223709952|NCT05523752|DEVICE|I-gel|insertion of I-gel
223709953|NCT05523752|DEVICE|Suprema Laryngeal Mask|insertion of Suprema Laryngeal Mask
223709954|NCT04530916|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day wild blueberry powder
223709955|NCT04530916|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder
223709956|NCT00459225|DRUG|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
223709957|NCT01120002|DRUG|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
223709958|NCT01120002|DRUG|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
223709959|NCT02292797|OTHER|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
223709960|NCT00483639|OTHER|Medical chart review|medical chart review
223709961|NCT00483639|OTHER|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
223709962|NCT00483639|PROCEDURE|management of therapy complications|management of therapy complications
223709963|NCT00483639|PROCEDURE|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
223709964|NCT00483639|OTHER|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
223709965|NCT02012101|DEVICE|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
223709966|NCT02012101|DEVICE|oxygen therapy|
223709967|NCT00544518|DRUG|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
223709968|NCT00544518|DRUG|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
223709969|NCT02983825|DEVICE|Continuous positive airway pressure (CPAP); level changes|as per arm description
223709970|NCT04561466|DRUG|Béfizal|600 mf befizal a day for one year
223709971|NCT03573739|PROCEDURE|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
223709972|NCT03573739|PROCEDURE|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
223709973|NCT01702805|PROCEDURE|Liberal Cell Transfusion|
223709974|NCT01702805|PROCEDURE|Restricted red cell transfusion|
223709975|NCT03813069|OTHER|IR3535|The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only
224276304|NCT00004241|OTHER|pharmacological study|Correlative studies
223709976|NCT03813069|OTHER|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
223709977|NCT03813069|OTHER|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
223709978|NCT03964623|DIAGNOSTIC_TEST|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
223709979|NCT04329403|DRUG|Adapalene 0.1% Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
223709980|NCT04329403|DRUG|Differin 0.1% Topical Gel|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
223709981|NCT04329403|OTHER|Placebo|A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
223709982|NCT00197639|DRUG|Ritonavir-boosted indinavir|
223709983|NCT05113758|DIAGNOSTIC_TEST|muscle ultrasound|All participants will undergo a muscle ultrasound on admission and at discharge
223709984|NCT03131778|PROCEDURE|Liver resection|liver resections for colorectal liver metastases
223709985|NCT00900965|DEVICE|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
223709986|NCT00900965|DEVICE|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
223709987|NCT00198939|BEHAVIORAL|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
223709988|NCT00198939|OTHER|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
223709989|NCT01117948|DRUG|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
223709990|NCT01117948|DRUG|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
223709991|NCT02984111|DRUG|normal saline|
223709992|NCT02984111|DRUG|erythropoietin|
223709993|NCT00381550|DRUG|fludarabine phosphate|Given IV
223709994|NCT00381550|DRUG|triapine|Given IV
223709995|NCT00381550|PROCEDURE|laboratory biomarker analysis|Correlative study
223709996|NCT03118648|DIAGNOSTIC_TEST|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
223709997|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
223709998|NCT04875169|DRUG|Core Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
223709999|NCT04875169|DRUG|Core Treatment Placebo Comparator: Placebo|Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
223710000|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#1|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
223710001|NCT04875169|DRUG|Extension Treatment Active Experimental: SHR0302 Dose#2|Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
223710002|NCT00809393|DRUG|tranexamic acid|10 mg/kg
223710003|NCT00809393|DRUG|tranexamic acid|30 mg/kg
223710004|NCT01204437|DRUG|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
223710005|NCT01204437|DRUG|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
223710006|NCT01204437|DRUG|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
223710007|NCT00181155|DRUG|Allopurinol|intravenous infusion of allopurinol (300mg)
223710008|NCT00181155|DRUG|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
223710009|NCT01788228|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
223710010|NCT05000281|DRUG|Ibuprofen|600 mg Ibuprofen 3 times a day for up to six weeks.
223710011|NCT00003257|BIOLOGICAL|Ad5CMV-p53 gene|
223710012|NCT05158465|BEHAVIORAL|Motivational Interviewing|Intervention will include 3 one-on-one motivational interviewing sessions and 3 follow-up calls with a trained MI health educator. These sessions aim to promote better oral hygiene and oral health.
223710013|NCT01204554|DRUG|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
223710014|NCT01323959|BIOLOGICAL|BoostrixTM Polio|Single dose, intramuscular administration.
223710015|NCT01548287|DRUG|AZD5213|AZD5213 doseA daily
223710016|NCT01548287|DRUG|AZD5213|AZD5213 doseB daily
223710017|NCT01548287|DRUG|AZD5213|AZD5213 doseC daily
223710018|NCT01548287|OTHER|Placebo|Placebo tablet daily
223710019|NCT02500160|DEVICE|Patient specific instrumentation (MRI)|
223710020|NCT02500160|DEVICE|Patient specific instrumentation (CT)|
223710021|NCT04067700|PROCEDURE|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
224276305|NCT04615312|DRUG|a CDK4 / 6 inhibitor and a MEK inhibitor|Participant will receive a CDK4 / 6 inhibitor and a MEK inhibitor treatment to determine the maximum tolerated dose
223710022|NCT05708170|DRUG|Ferinject|"Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject)."
223710023|NCT05708170|DRUG|Ferrous Sulfate 200 MG|Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
223710024|NCT00746083|BEHAVIORAL|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
223710025|NCT02762578|DRUG|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
223710026|NCT02762578|DRUG|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
223710027|NCT02886832|DIETARY_SUPPLEMENT|Prostate Health formulation|
223710028|NCT00249860|DRUG|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
223710029|NCT00249860|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
223527481|NCT03764969|BEHAVIORAL|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
223527482|NCT01872884|DRUG|Sevorane Remifentanil|Sevorane Remifentanil
223527483|NCT01872884|DRUG|Remifentanil|Remifentanil
223527484|NCT02141321|DRUG|Misoprostol|
223527485|NCT02141321|DRUG|Placebo|
223527486|NCT04893863|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
223527487|NCT04893863|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
223527488|NCT03980639|DRUG|patient treated with DMARD|Case report of cancer overall
223527489|NCT00148356|DEVICE|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223527490|NCT00148356|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223527491|NCT01595477|BEHAVIORAL|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
223527492|NCT01312480|OTHER|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~1. Ask if the patient smokes.~2. Advise every patient to quit.~3. Assess readiness to quit.~4. Assist in quitting and finding services.~5. Arrange for cessation services and follow-up."
223527493|NCT01312480|OTHER|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
223527494|NCT06285799|DRUG|Low Dose IHAT|Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)
223527495|NCT06285799|DRUG|High Dose IHAT|Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)
223527496|NCT06285799|DRUG|Carob Flour|Twice daily dose of 1 placebo capsule (carob flour)
223527497|NCT04123704|DRUG|Sitravatinib|sitravatinib capsule
223527498|NCT01497730|DEVICE|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
223527499|NCT02985138|PROCEDURE|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
223527500|NCT02985138|PROCEDURE|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
223527501|NCT02985138|DEVICE|Pedicle screw and cage|Pedicle screw and cage
223527502|NCT05773040|DRUG|JV-213|Given by (IV) vein
223527503|NCT05773040|PROCEDURE|Leukapheresis|Given by IV (vein)
223527504|NCT04682847|DRUG|Ferumoxytol injection|This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
223527505|NCT06571942|DRUG|Vilanterol / Umeclidinium (25/62.5 mcg)|One inhalation daily from Ellipta device for three months
223527506|NCT06571942|DRUG|Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)|One inhalation daily from Ellipta device for three months
223527507|NCT06571942|DRUG|Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg|Two inhalations twice daily form pMDI device for three months
223527508|NCT06571942|DRUG|Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg|Two inhalations twice daily form pMDI device for three months
223710030|NCT00249860|DRUG|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
223527509|NCT04389463|OTHER|No intervention|No description
223527510|NCT00939185|DRUG|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
223527511|NCT05870631|BIOLOGICAL|vaccinate with DTaP|vaccinate with DTaP
223527512|NCT05870631|BIOLOGICAL|vaccinate with DT|vaccinate with DT
223527513|NCT02104193|DRUG|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
223527514|NCT02104193|RADIATION|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
223527515|NCT01160185|DRUG|paclitaxel|paclitacel
223527516|NCT01160185|DRUG|cisplatin|cisplatin monotherapy
223527517|NCT01160185|DRUG|topotecan|topotecan
223527518|NCT00004419|DRUG|insulin-like growth factor I|
223527519|NCT00789711|DRUG|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
223527520|NCT00789711|DRUG|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
223527521|NCT06168773|DRUG|Haloperidol Injection|to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
223527522|NCT02695836|OTHER|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
223527523|NCT02695836|OTHER|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
223527524|NCT02695836|OTHER|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
223527525|NCT02695836|OTHER|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
223527526|NCT02695836|OTHER|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
223527527|NCT01596920|OTHER|Tissue|Allograft Tissue Cellular Repair Matrix
223527528|NCT01596920|OTHER|Control|Non-adherent Dressing
223527529|NCT00363298|DRUG|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
223527530|NCT00363298|DRUG|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
223527531|NCT00190957|DRUG|Atomoxetine|
223527532|NCT00190957|DRUG|placebo|
223527533|NCT06213480|DIETARY_SUPPLEMENT|Synbiotic Group|"WBF-038: Noninfectious and nonhazardous lyophilized commensal bacteria (probiotics). Contains no genetically modified organisms (GMOs) and contains no animal ingredients or by-products, and were originally isolated from human sources. The (probiotic) strains are grown in a FDA registered food facility, adhering to Good Manufacturing Practice (GMP) conditions.~Probiotic Ingredients:~Clostridium butyricum WBSTR-0006, Clostridium beijerinckii WB-STR-0005, Anaerobutyricum hallii WB-STR-0008, Akkermansia muciniphila WBSTR-0001, and Bifidobacterium infantis~The product also contains: Chicory inulin and oligofructose (prebiotic fiber), hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation)"
223527534|NCT06213480|OTHER|Placebo Group|Ingredients: Chicory inulin and oligofructose (prebiotic fiber, hypromellose (vegetarian capsule), fruit \& vegetable juice (coloring agent), magnesium stearate and silica (flow agent for encapsulation).
223527535|NCT05713487|OTHER|preventive treatment group|each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
223710031|NCT00259610|DRUG|methotrexate|varies
223710032|NCT00259610|DRUG|sulfasalazine|varies
223710033|NCT00259610|DRUG|hydroxychloroquine|varies
223710034|NCT00259610|DRUG|etanercept|varies
223710035|NCT03726944|BEHAVIORAL|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
223710036|NCT03726944|BEHAVIORAL|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
223710037|NCT03726944|OTHER|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
223710038|NCT02028754|DRUG|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
223710039|NCT02028754|DRUG|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
223710040|NCT02028754|DRUG|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
223710041|NCT04456257|DEVICE|fractional picosecond 1,064 nm laser|The parameter of laser was 8-mm spot size, 0.6 mJ/cm2, 750 ps, 10 Hz, 2 passes. The treatment was done in every 4 weeks for 4 sessions.
223710042|NCT02236403|DRUG|Ivermectin 0.1% Metronidazole 1%|
223710043|NCT02236403|OTHER|None intervention|Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
223710044|NCT04841538|DRUG|ES101|The active ingredient of ES101 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
223710045|NCT01766596|PROCEDURE|Optical Coherence Tomography|
223710046|NCT02399722|DEVICE|WICVAC|combined wound therapy
223710047|NCT02399722|DEVICE|VAC mono therapy|mono therapy
223710048|NCT00002711|DRUG|chemotherapy|
223710049|NCT00002711|DRUG|cisplatin|
223527536|NCT05627921|DEVICE|Extracorporeal Shock Wave Therapy|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex. 1 week after the injection, patients will receive 3 sessions of radial ESWT treatment, 1 session/week. rESWT application will be applied with the 'MODUS ESWT' device and a 35 mm radial soft applicator will be used. rESWT will be applied with a soft applicator. The soft applicator is designed for application to sensitive and painful areas and applications will be painless.Shock waves will be applied at 1500/beat, 8 Hz, 0.030 Mj/mm2, 2 bar per muscle.
223527537|NCT05627921|DRUG|Botilinum Toxin injection|Spastic muscles will be determined by examination. Botulinum toxin-A will be injected into the spastic muscles with Stumplex.
223527538|NCT05755984|DIAGNOSTIC_TEST|3D printed model|scan
223527539|NCT00410683|OTHER|clinical observation|
223527540|NCT00410683|PROCEDURE|adjuvant therapy|
223527541|NCT00410683|RADIATION|3-dimensional conformal radiation therapy|
223527542|NCT02647502|OTHER|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
223527543|NCT02852915|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
223527544|NCT02845414|DRUG|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
223527545|NCT03552029|DRUG|Quizartinib|20 or 30 mg tablets for oral administration
223527546|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
223527547|NCT03552029|DRUG|Milademetan|5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
223527548|NCT03134209|DEVICE|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
223527549|NCT03134209|OTHER|Monocryl + Dermabond|conventional sutures and skin adhesive glue
223527550|NCT03134209|OTHER|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
223527551|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
223527552|NCT01462331|OTHER|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
223527553|NCT01462331|OTHER|Sucrose|12g/dose, three times a day
223527554|NCT01198691|DEVICE|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
223527555|NCT01198691|DEVICE|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
223527556|NCT03537794|DIAGNOSTIC_TEST|PET scans|PET scans and PHNO scans
223527557|NCT04367389|BEHAVIORAL|Physical activity promotion|Physical activity promotion activities consist of two phone or video calls with a therapists, two group video calls with a therapist, a complementary e-learning course and a fitness tracker that was provided.
223527558|NCT04367389|BEHAVIORAL|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for persons with MS. However, they can be adjusted according to participants prior physical activity level and their time for exercise during the week.
223527559|NCT02299245|DRUG|rosuvastatin|different dose of rosuvastatin treatment
223527560|NCT04918082|OTHER|Quality of life questionnaires|Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.
223527561|NCT03336229|BEHAVIORAL|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
223527562|NCT06535854|DEVICE|Prevail DCB|The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.
223527563|NCT06535854|DEVICE|Agent DCB|The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).
223710050|NCT00002711|DRUG|paclitaxel|
223710051|NCT00002711|RADIATION|low-LET electron therapy|
223710052|NCT00002711|RADIATION|low-LET photon therapy|
223710053|NCT04520412|DRUG|GV-971|Administered PO
223710054|NCT04520412|DRUG|Placebo|Administered PO
223710055|NCT04716907|GENETIC|Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region|DNA extraction from blood samples, PCR and Sequencing
223710056|NCT04716907|BIOLOGICAL|Blood sample|Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
223710057|NCT04716907|DIAGNOSTIC_TEST|CT Scan|Thymus and lung imaging
223710058|NCT04716907|BIOLOGICAL|Bronchial fibroscopy|Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
223710059|NCT05586893|DEVICE|Acupuncture therapy and Electroacupuncture|"We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher."
223710060|NCT01802801|OTHER|embryo development|intra- and inter-observator analysis
223710061|NCT04861909|DEVICE|AT LISA tri 839MP|Non interventional study
223710062|NCT01611155|DRUG|venlafaxine|Given PO
223710063|NCT01611155|DRUG|placebo|Given PO
223710064|NCT01611155|OTHER|questionnaire administration|Ancillary studies
223710065|NCT01611155|OTHER|quality-of-life assessment|Ancillary studies
223710066|NCT03219138|DEVICE|Acceleromyography|Use of an uncalibrated acceleromyography
223710067|NCT03325127|DRUG|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
223710068|NCT03325127|DRUG|Zytiga|Abiraterone 1000 mg per day orally
223710069|NCT03325127|DRUG|Xtandi|Enzalutamide 160 mg per day orally
223710070|NCT02617381|OTHER|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
223710071|NCT05849701|DEVICE|Shock wave therapy|using gymna Shock Master 500 with an input voltage of alternating current (AC) 220 Volte, 100 pulses at 0.13 m joule/mm at 3 Hz per session for 6 weeks.
223710072|NCT05849701|DEVICE|Vacuum-assisted closure|Using KCI's Vacuum Assisted Closure Device for six weeks, the pump delivered an intermittent negative pressure of -125 mmHg. The cycle was of seven minutes during which the pump was on for five minutes and off for two minutes, the dressings were changed on the fourth day.
223939919|NCT07157982|BEHAVIORAL|Enhanced Usual Care|Participants in this arm will receive enhanced usual care, which includes standard discharge instructions, scheduled check-ins, and a resource toolkit with educational materials. The content includes guidance on symptom management, advance care planning, and available community resources. Participants will receive follow-up reminders and wellness checks but will not receive the structured, nurse-led intervention provided in the COORDINATE Program.
223710073|NCT03963596|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
223710074|NCT00145522|DRUG|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
223710075|NCT00145522|DRUG|Tibolone|2,5 mg/day for 12 cycles of 28 days
223710076|NCT01358045|DRUG|Diclofenac|Application on the lesion 2 times a day 8 weeks.
223710077|NCT01358045|DRUG|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
223710078|NCT01358045|DRUG|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
223710079|NCT05345977|DEVICE|eMotiph|Mobile application for patients with schizophrenia.
223710080|NCT03555916|DRUG|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
223710081|NCT03555916|DRUG|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
223710082|NCT04276571|DEVICE|exergames with GRAIL virtual immersive reality environment|The participants will perform exergames on GRAIL immersive virtual reality to improve balance (e.g. load shifts, exercises with adaptations to motor perturbations). GRAIL can provide proprioceptive and visual feedback to participants.
223710083|NCT05615168|DIAGNOSTIC_TEST|"Acumen IQ guided hemodynamic optimization"|"Hypotension prediction index (HPI) available with the Edwards Acumen IQ sensor will be used as an early warning system and a diagnostic screen will be used to guide therapeutic interventions."
223710084|NCT05615168|DIAGNOSTIC_TEST|"Flotrac guided hemodynamic optimization"|"Therapeutic interventions guided by real time monitored hemodynamic parameters as measured by Edwards Flotrac sensor."
223710085|NCT01010373|DRUG|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
223710086|NCT06161870|DRUG|individualized vancomycin dosing based on the population pharmacokinetics (PK) model|The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
223710087|NCT06161870|DRUG|empirical vancomycin dosing|The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
223710088|NCT02566486|DEVICE|Reciprocating system|Different root canal instrumentation systems
223710089|NCT02566486|DEVICE|Rotational system|Different root canal instrumentation systems
223710090|NCT05009654|DIETARY_SUPPLEMENT|L-carnitine|
223710091|NCT05009654|DIETARY_SUPPLEMENT|L-leucine|
223710092|NCT05116878|DIETARY_SUPPLEMENT|Omega-3|One capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
223939920|NCT05723107|DRUG|Chemotherapy|Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
223710093|NCT05116878|DIETARY_SUPPLEMENT|Placebo|One cellulose capsule orally twice daily beginning 3 days prior to clinical care surgical intervention and continuing 6 weeks post-operative
223710094|NCT00330070|DRUG|IPL512,602 20 mg once daily|
223710095|NCT00330070|DRUG|IPL512,602 Matching Placebo once daily|
223710096|NCT05552521|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in 4 timepoints: 1st 24h + 7th-10th day; 28th-30th day; 6 months Whole exome sequencing at admission
223710097|NCT02699593|DEVICE|Test Contact Lens|
223710098|NCT02699593|DEVICE|Control Contact Lens|
223710099|NCT00868608|DRUG|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
223710100|NCT03363997|DRUG|Estriol 0.125 mg/day|Application of one vaginal ring
223710101|NCT03363997|DRUG|Estriol 0.250 mg/day|Application of one vaginal ring
223710102|NCT03363997|DRUG|Estriol 0.500 mg/day|Application of one vaginal ring
223710103|NCT06308367|DRUG|Betaine|50mg/kg for 12 weeks
223710104|NCT06308367|DRUG|Placebo|Placebo
223710105|NCT03344796|BEHAVIORAL|Goal attainment|After reviewing daily UV exposure in the prior 10 days, participants will be randomized to structured (select strategies from a list of 7 items) or unstructured (submit a free text description of a strategy) goal attainment.
223710106|NCT05481892|DEVICE|Cellular Home blood pressure (BP) monitoring|Patients receiving intervention will receive cellular home blood pressure (BP) monitoring devices. Some patients will also receive pharmacist support for treatment intervention.
223710107|NCT05108285|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)|OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN
223710108|NCT04916431|DRUG|mRNA-6231|Sterile frozen liquid dispersion for injection
223710109|NCT02706184|DRUG|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
223710110|NCT02706184|DRUG|Placebo|Placebo
223710111|NCT02423759|DRUG|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
223710112|NCT02423759|DRUG|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
223710113|NCT02423759|DRUG|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
223710114|NCT01007539|DIETARY_SUPPLEMENT|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
223710115|NCT01007539|DIETARY_SUPPLEMENT|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
223710116|NCT00180622|PROCEDURE|Spirometry|
223710117|NCT00180622|PROCEDURE|Exhaled Nitric Oxide and Carbon Monoxide|
223710118|NCT00180622|PROCEDURE|Exhaled Breath Condensate|
223710119|NCT00180622|PROCEDURE|Induced Sputum|
223710120|NCT00180622|PROCEDURE|CT Scan|
223710121|NCT00180622|PROCEDURE|Blood test|
223710122|NCT00180622|PROCEDURE|St Georges Questionnaire|
223710123|NCT00180622|PROCEDURE|Bodypletysmography|
223710124|NCT04204343|DRUG|Bupivacaine 0.7 ml/kg|Bupivacaine 0.25% 0.7 ml/kg
223710125|NCT04204343|DRUG|Bupivacaine 0.5 ml/kg|Bupivacaine 0.25% 0.5 ml/kg
223710126|NCT05693948|OTHER|Other: Serum X|Serum X contain arbutin and glutathione
223710127|NCT01725711|DEVICE|OPRA Implant System|
223710128|NCT01810731|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (QIV)|
223710129|NCT01810731|BIOLOGICAL|Inactivated Polio Vaccine|
223710130|NCT01810731|BIOLOGICAL|Double Dose QIV|
223710131|NCT00491816|DRUG|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
223710132|NCT06556381|PROCEDURE|TAP block|Women will receive TAP block.
223710133|NCT04510584|DRUG|Atezolizumab|Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
223710134|NCT04510584|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
223710135|NCT01199965|DRUG|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
223710136|NCT01199965|DRUG|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
223710137|NCT03805269|DRUG|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
223710138|NCT03805269|DRUG|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
223710139|NCT04749706|BEHAVIORAL|Physical training alone|The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.
223710140|NCT04749706|BEHAVIORAL|physical training + protein intake|"The physical activity intervention will consist in 12 weeks of training composed of 3 sessions per week. The three sessions will be mainly composed of resistance training aiming at increasing body weight through increased fat free mass. The main muscle groups (lower limbs, upper limbs and trunk) will be trained. The intervention will be performed under the supervision of a specialized coach.~15 women with constitutional leanness will, on top of the physical training, received a daily protein supplementation corresponding to 20 grams of proteins + 10 grams of Maltodextrine"
223710141|NCT00626223|DRUG|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
223710142|NCT00626223|DRUG|folic acid|5 mg per day of oral folic acid
223710143|NCT04275531|DRUG|Anesthesia Agent|various anesthetic agents used in both general and regional anesthesia
223710144|NCT02179489|PROCEDURE|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
223710145|NCT03756077|DIAGNOSTIC_TEST|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
223710146|NCT04035798|DRUG|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
223710147|NCT01920321|PROCEDURE|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
223710148|NCT04594343|DRUG|Disulfiram|The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
223710149|NCT04594343|DRUG|Placebo|The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
223710150|NCT03593603|DEVICE|Nellcor™ Bedside Respiratory Monitoring System|Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
223893763|NCT06728696|PROCEDURE|Immediate implant with dual zone technique using connective tissue graft.|Patients assigned to the control group will receive pouch technique + CTG. Following implant placement, a split-thickness labial pouch between the labial bone plate and the overlying gingiva of the extraction socket will be performed using 15c mini blade to allow for the placement of a CTG. The pouch preparation will be extended apical beyond the muco-gingival junction and to the neighboring teeth mesiodistally. The CTG will be harvested from the palate with a thickness of 1.5 mm using single-incision technique, which was done approximately 2-3 mm apical to the gingival margin of the maxillary teeth and parallel to the palatal long axis. A resorbable suture will be used to first pierce the labial mucosa along with the periosteum at an apical part, which then exits from the sulcus. Afterward, the CTG will be tucked in the pouch, labial to the suture, and held at a coronal area by using the needle to pierce it from its inner surface toward the labial soft tissue. The knot will then be se
223893764|NCT06837116|BIOLOGICAL|Vaccine|Subcutaneous route vs Intradermal route
223893765|NCT06831396|BEHAVIORAL|Dose comparison (same intervention)|The intervention under investigation is a motor-phonetic approach to articulation therapy, enhanced with ultrasound visual biofeedback (UVBF). The treatment group will receive the intervention immediately, while the waitlist control group will receive treatment after the initial group completes the study. This design allows for comparative outcome assessments between both groups, ensuring that all participants ultimately receive treatment.
223893766|NCT04889755|BEHAVIORAL|SibACCESS|The primary goal of the SibACCESS program is to increase siblings' exposure to and opportunity to process cancer-related cues to decrease onset or intensification of posttraumatic stress. The program is focused on siblings, with a brief parent education component. Parents will receive psychoeducation and brief skills training to support siblings enrolled in the program. Siblings will participate in 7 group sessions and one individual session in which they will learn skills and strategies to confront information about cancer and tolerate uncomfortable thoughts and feelings related to cancer, and thereby reduce avoidance of cancer-related emotions.
223893767|NCT06845475|OTHER|Designed physical therapy program|Both groups will receive a designed physical therapy program, in the form of myofascial trigger points pressure release, stretching of the upper trapezius muscle, strengthening exercises, and infrared radiation for 4 weeks.
223893768|NCT06845475|OTHER|Extracorporeal shock wave therapy (ESWT)|Adolescents of the experimental group will receive Extracorporeal shock wave therapy with the following parameters; low-level energy radial extracorporeal shock wave by (STORZ MEDICAL Master Pulse MP200), each subject received 3 sessions per week for 4 weeks with 700 impulse/session 400 impulse was applied to tight band and 300 impulses will be applied surrounding the tight band, with frequency \[10HZ\], resulting in positive energy flux density \[EFD\] 0.056mJ/mm.
223893769|NCT06911892|OTHER|Group Serratus Anterior Plane Block|Patients will receive a serratus anterior plane block preoperatively under ultrasound guidance. Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis.
223893770|NCT06911892|OTHER|Group Parasternal Block|Patients will receive a parasternal block preoperatively under ultrasound guidance. Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis.
223710151|NCT00662246|RADIATION|respiratory gated proton beam radiotherapy|\- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
223710152|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly|lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
223710153|NCT05656495|DRUG|Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled|lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
223710154|NCT05656495|DRUG|Standard of care|The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
223710155|NCT03914482|DEVICE|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
223710156|NCT01443871|OTHER|Aromatherapy|Subject will assigned inhale aromatherapy
223710157|NCT01443871|OTHER|Pure water|Subject will assigned inhale Pure water
223710158|NCT02124525|DRUG|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
223710159|NCT01400763|DIETARY_SUPPLEMENT|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
223710160|NCT01400763|DIETARY_SUPPLEMENT|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
223710161|NCT01400763|DIETARY_SUPPLEMENT|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
223710162|NCT01400763|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
223710163|NCT00032123|DRUG|erlotinib hydrochloride|
223710164|NCT01710969|BEHAVIORAL|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
223710165|NCT01710969|BEHAVIORAL|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
223527564|NCT06548711|OTHER|Transcutaneous Acupoint Electrical Stimulation (TAES)|Transcutaneous acupoint electrical stimulation (TAES) is a non-invasive treatment method that delivers gentle electrical pulses through the skin to specific acupuncture points on the body. This technique aims to mimic the effects of traditional acupuncture, providing a convenient and painless method of treatment.
223527565|NCT03325322|DIETARY_SUPPLEMENT|Fisetin|Flavonoid family
223527566|NCT03325322|DRUG|Placebo oral capsule|Placebo
223527567|NCT02499926|DIETARY_SUPPLEMENT|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
223527568|NCT04218981|DRUG|Antipsychotic drugs|Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
223527569|NCT04218981|DRUG|Mood stabilizer|Choose lithium or valproate for bipolar disorder group
223527570|NCT04218981|DRUG|Paroxetine|Patients with major depressive disorder are treated with paroxetine
223527571|NCT03148002|DRUG|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
223527572|NCT03148002|DRUG|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
223710166|NCT00417508|DIETARY_SUPPLEMENT|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
223710167|NCT00417508|DIETARY_SUPPLEMENT|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
223710168|NCT05020782|DRUG|Belimumab|INTERVENTION DRUG: BELIMUMAB 10 MG/KG
223710169|NCT05531383|DRUG|Memantine Hydrochloride|study the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) \& serum NSE levels in patients with moderate to severe TBI as well as their outcome.
223527573|NCT05482451|DRUG|Nivolumab|Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.
223527574|NCT05482451|DRUG|all trans retinoic acid|Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
223527575|NCT01282398|DRUG|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
223527576|NCT01282398|DRUG|placebo|the control group wiil take placebo pills for at least two years.
223527577|NCT05234216|OTHER|Informed consent|the investigator will verify the inclusion criteria, the patient's understanding of the protocol and will obtain oral informed consent
223527578|NCT05234216|PROCEDURE|Surgery|The patient will undergo surgery in accordance with standard care
223527579|NCT05234216|BEHAVIORAL|Comfort scale|The patient will be evaluated, in the post-operative care unit, with a comfort scale
223527580|NCT05234216|BEHAVIORAL|Pain|The patient will be evaluated, in the post-operative care unit, with a pain scale
223527581|NCT05234216|OTHER|Questionnaires|Evaluation of the Experience of Local/General Anesthesia
223710170|NCT00635674|DEVICE|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
223710171|NCT03011710|DEVICE|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
223710172|NCT03011710|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
223710173|NCT03011710|DEVICE|Cigarette tip|Placebo device
223710174|NCT01981980|OTHER|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
223710175|NCT01981980|OTHER|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
223710176|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
223710177|NCT01890369|DIETARY_SUPPLEMENT|3g Leucine|Dissolved in 250ml water.
223710178|NCT01890369|DIETARY_SUPPLEMENT|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
223893771|NCT06911892|OTHER|Group Interpectoral+Pectoserratus Plane Block|"Patients will receive an interpectoral + pectoserratus plane block preoperatively under ultrasound guidance.~Thirty minutes after the block, the cutaneous sensory area will be assessed using a pinprick test and outlined on the skin using a UV marker. Subsequently, the incision line for the modified radical mastectomy (MRM) will be marked by the operating surgeon. The resulting drawings will be documented and transferred to a digital template for analysis."
223893772|NCT06913088|PROCEDURE|ultrasonication-mediated microbubbles dressing|The microbubble suspension is diluted with normal saline to a concentration of 2x10\^7 bubbles/mL, applied to a gauze cloth, and covered on the joint skin surface. The joint is ultrasonicated for 3 minutes using an ultrasonic implanter (KUM-2000, NEO-TEC, Taipei, Taiwan), and then piroxicam gel is applied. The parameter values for ultrasonication are duty cycle 0.5, Tempo 10, intensity 70%, and time 3 min. This treatment is performed on day 1, 3, and 5.
223893773|NCT06913088|PROCEDURE|ultrasonication using pure gel|The joint is ultrasonicated for 3 minutes using an ultrasonic implanter (KUM-2000, NEO-TEC, Taipei, Taiwan) with pure gel, and then piroxicam gel is applied. The parameter values for ultrasonication are duty cycle 0.5, Tempo 10, intensity 70%, and time 3 min. This treatment is performed on day 1, 3, and 5.
223710179|NCT05164185|PROCEDURE|Remote ischemic conditioning|Brief cycles of ischemia to a limb. A blood pressure cuff was placed around the right thigh and inflated to 200 mmHg for 4 cycles of 5 minutes.
223710180|NCT01778972|OTHER|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
223527582|NCT02943161|DIETARY_SUPPLEMENT|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
223527583|NCT02534922|BIOLOGICAL|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
223527584|NCT03468998|DEVICE|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
223527585|NCT03468998|DEVICE|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
223527586|NCT03468998|DEVICE|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
223527587|NCT03468998|DEVICE|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
223527588|NCT06305403|DIAGNOSTIC_TEST|serum creatinin level|Serum creatinine and urine amounts will be checked for five days.
223527589|NCT00864279|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
223527590|NCT00864279|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
223527591|NCT01765400|DRUG|Prasugrel 10 mg daily x 2 weeks|
223527592|NCT01765400|DRUG|Clopidogrel 75 mg daily x 2 weeks|
223527593|NCT04236076|DEVICE|PulseHaler|PulseHaler™ is a pulsating positive expiratory pressure ventilation device for treatment of COPD. PulseHaler™ is pre-programmed to deliver airflow at pre-defined frequencies, ranging from 3.5 Hertz (Hz) to 55Hz, and for pre-defined lengths of time.
223527594|NCT04236076|DEVICE|Sham - control|Sham device has the same look as PulseHaler and is set to deliver nominal pressure but it does not contain the active pulsating components.
223527595|NCT00091156|DRUG|gefitinib|
223527596|NCT00091156|PROCEDURE|adjuvant therapy|
223527597|NCT02116023|OTHER|Orange flavored beverage|
223527598|NCT02798757|DRUG|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
223527599|NCT01657188|DEVICE|Cheyne-Stokes respiration by adaptive servoventilation|
223527600|NCT02085863|DRUG|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
223527601|NCT02085863|DRUG|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
223527602|NCT00836706|DRUG|clarithromycin|500 mg Tablet
223527603|NCT00836706|DRUG|BIAXIN®|500 mg Tablet
223527604|NCT03275987|BEHAVIORAL|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
223527605|NCT03275987|BEHAVIORAL|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
223527606|NCT03275987|BEHAVIORAL|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
223527607|NCT02989857|DRUG|AG-120|Tablet administered orally
223527608|NCT02989857|DRUG|Placebo|Tablet administered orally
223527609|NCT01055340|DRUG|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
223527610|NCT01055340|DRUG|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
223527611|NCT01055340|DRUG|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
223527612|NCT01467557|DEVICE|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
223527613|NCT01467557|DEVICE|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
223527614|NCT05271357|PROCEDURE|Bilateral TMS|Stimulation begins with continuous TBS to the right dorsolateral prefrontal cortex (DLPFC) (120 seconds of uninterrupted bursts; 600 pulses per session) followed by intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds per hemisphere.
223710181|NCT01778972|OTHER|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
223710182|NCT01176383|GENETIC|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
223710183|NCT02530684|OTHER|insole|Insoles available on the market without prescription
223710184|NCT00958100|DRUG|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
223893774|NCT06836583|OTHER|trans-nasal pterygopalatine Fossa block|Patients will be placed in 15-degree reverse Trendelenburg position, between the middle and inferior turbinates. This passage will be sterilized by an cotton-tipped applicator soaked with iodine solution. A 20-gauge/5-inch spinal needle will be used after bending 2-3 mm of its tip along the port side with a sterile needle holder to form a 45 angle. The needle will be lubricated with 5% lidocaine jelly, inserted into the nasal meatus and advanced with the bevel pointer facing laterally. Under endoscopic control (0\_ optics, 4 mm diameter), the needle will be inserted between middle and inferior turbinate. A total of 4 ml 0.25% bupivacaine will be injected after negative aspiration just behind and over middle turbinate tail, where the pterygopalatine fossa is deeply located.
223893775|NCT06836583|OTHER|US-guided infrazygomatic percutaneous pterygopalatine Fossa block|"US- guided percutaneous PPFB:~Patients will be placed in the lateral head position; the patient's mouth is slightly opened. Following standard sterile preparations, US linear probe covered with sterile sheath is positioned horizontally on the side of the face just below the zygomatic bone superior to the mandibular notch and anterior to the mandibular condyle to visualize the coronoid process, the lateral pterygoid muscle, the lateral pterygoid plate, and the maxillary bone, and the maxillary artery. Needle will be inserted in-plane parallel to the transducer probe and advanced from medial to lateral toward the pterygopalatine fossa. Following negative aspiration, the injectate is deposited deep to the lateral pterygoid muscle and plate. A total of 4 ml 0.25% bupivacaine will be injected."
223893776|NCT06132867|DRUG|Brigatinib|Brigatinib oral solution
223893777|NCT06132867|DRUG|Brigatinib|Brigatinib tablet
223893778|NCT06462014|DRUG|Relugolix|relugolix
223893780|NCT06931834|DRUG|Probucol|Probucol 250 mg tablets orally up to a daily dose of 1,000 mg
223893781|NCT06932419|OTHER|Ozone exposure|Participants' forearms were exposed to 200 ppb ozone for 2 h at a temperature and relative humidity of 27±2°C and 45%±5%, respectively.
223893782|NCT06932419|OTHER|Clean air exposure|Participants' forearms were exposed to clean air for 2 h at a temperature and relative humidity of 27±2°C and 45%±5%, respectively.
223893783|NCT06931821|DEVICE|Isochronal Late Activation Mapping (ILAM)|an isochronal late activation mapping (ILAM) display with automated last deflection annotation (EnSite X™) will be used to identify regions of isochronal crowding around a line of conduction block for targeted ablation therapy using a standard irrigated tip catheter (Flexability SE \& Tactiflex catheters)
223893784|NCT06931821|DEVICE|High Density Voltage Mapping|high-density voltage mapping will serve as the method to display the electroanatomic substrate for extensive and diffuse ablation within the low voltage area (\<1.5 mV).
223527615|NCT05271357|PROCEDURE|Unilateral TMS|Stimulation involves only intermittent TBS to the left DLPFC (2 seconds on and 8 seconds off; 600 pulses per session); total duration of 3 min 9 seconds.
223527616|NCT01329133|PROCEDURE|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
223527617|NCT01599286|DRUG|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients \>15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
223527618|NCT01599286|DRUG|Placebo|Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
223527619|NCT00864357|DRUG|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
223527620|NCT00864357|DRUG|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
223527621|NCT02729415|PROCEDURE|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
223527622|NCT02729415|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
223527623|NCT02729415|OTHER|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
223527624|NCT02429960|DEVICE|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
223527625|NCT02429960|DEVICE|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
223527626|NCT02429960|DEVICE|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
223527627|NCT02429960|DRUG|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
223527628|NCT02853292|BIOLOGICAL|urine collection|
223527629|NCT00149357|OTHER|Thrombophilia Testing|TP testing in Group 1 and 3 only
223893785|NCT06931496|OTHER|PROSTia test|questionnaire with 50 questions
223893786|NCT06932068|DRUG|Iparomlimab and Tuvonralimab (QL1706)|5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.
223893787|NCT06932068|DRUG|Oxallplation|130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.
223893788|NCT06932068|DRUG|Capectitabine Tablets|1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.
223893789|NCT05194514|DEVICE|SherpaPak™ Device|The SherpaPak™ Cardiac Transport System has been developed to provide a safe, consistent method for cold ischemic storage of donor hearts for transplantation. This device is FDA approved.
224276306|NCT03268096|DEVICE|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
223893790|NCT05194514|OTHER|Cold Storage|FDA-approved method for organ procurement
223893791|NCT04793958|DRUG|MRTX849|28 Day Cycle
223893792|NCT04793958|BIOLOGICAL|Cetuximab|28 Day Cycle
223893793|NCT04793958|DRUG|mFOLFOX6 Regimen|"* Fluorouracil~* Oxaliplatin~* Folinic acid"
223893794|NCT04793958|DRUG|FOLFIRI Regimen|"* Fluorouracil~* Irinotecan~* Folinic acid"
223893795|NCT04494412|DRUG|Zanamivir|Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.
223893796|NCT02443857|DEVICE|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
223893797|NCT02443857|DEVICE|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
224276307|NCT02721550|DRUG|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
224276308|NCT01652508|OTHER|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
224276309|NCT01652508|BEHAVIORAL|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
223527630|NCT01291589|BEHAVIORAL|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
223527631|NCT04348474|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
223527632|NCT04348474|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
223527633|NCT02746315|DRUG|HS-20004|
223527634|NCT02746315|DRUG|Placebo|
223527635|NCT00633126|DRUG|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
223527636|NCT04329884|PROCEDURE|Cooled RFA treatment with COOLIEF* device|Patients who are randomized to receive CRFA will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
223527637|NCT04329884|DRUG|intra-articular corticosteroid injection|Patients who are randomized to receive intra-articular corticosteroid injections will be given the treatment by a specialist into the affected hip with OA, and the patient will be followed to determine amount of pain relief and improved hip joint function.
223527638|NCT04942002|DRUG|Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]|Retrobulbar injection performed by care provider
223527639|NCT04942002|DRUG|Placebo Comparator: Standard treatment + placebo|Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
223527640|NCT00664950|DEVICE|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
223527641|NCT00664950|DEVICE|IntertAn IM nail|interTAN IM nail
223527642|NCT02749916|OTHER|Methods of carotid wall imaging|
223527643|NCT03873545|PROCEDURE|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
223527644|NCT01882816|RADIATION|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
223527645|NCT01882816|DEVICE|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
223527646|NCT01882816|DRUG|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
223527647|NCT01882816|OTHER|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
223527648|NCT04991948|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
223527649|NCT04991948|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
223527650|NCT04991948|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
223527651|NCT03314090|DRUG|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
223527652|NCT01680211|DIETARY_SUPPLEMENT|Salacia bark extract|
223527653|NCT01680211|DIETARY_SUPPLEMENT|Salacia leaf extract|
223527654|NCT01680211|DIETARY_SUPPLEMENT|Sesame seed extract|
223710185|NCT00958100|DRUG|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
223710186|NCT00958100|DRUG|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
223710187|NCT03306563|DIAGNOSTIC_TEST|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
223710188|NCT06509139|DRUG|Drug: Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223710189|NCT06509139|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223710190|NCT06509139|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223710191|NCT06509139|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223710192|NCT03006107|PROCEDURE|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
223710193|NCT03006107|PROCEDURE|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
223710194|NCT04795960|DIETARY_SUPPLEMENT|Low serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
223710195|NCT04795960|DIETARY_SUPPLEMENT|High serine diet|Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
223710196|NCT02564796|DRUG|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
223710197|NCT02564796|DRUG|Iron|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
223710198|NCT04456946|DEVICE|Low Level Laser Therapy|Low Level Laser Therapy
223710199|NCT04456946|DEVICE|Occlusal Splint Treatment|Occlusal Splint Treatment
223710200|NCT02378259|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
223710201|NCT02378259|PROCEDURE|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
223710202|NCT01869517|OTHER|intrastromal corneal ring segments (Keraring) implantation|
223710203|NCT01869517|OTHER|Intrastromal corneal continuous ring (Myoring) implantation|
223710204|NCT02257307|PROCEDURE|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
223710205|NCT02620657|OTHER|Non interventional study|Non interventional study
223710206|NCT00453063|DRUG|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
223710207|NCT00453063|DRUG|Placebo|Two sprays in each nostril once daily in the morning
223710208|NCT00043901|DRUG|lamotrigine|
223710209|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
223710210|NCT03949036|OTHER|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
223710211|NCT05840380|DEVICE|instrumental soft tissue mobilization|Individual supine for application will be deposited. The Graston instrument glides over the tissues of the individual. cream will be applied to make it easier, then the physiotherapist will will stand on its side at the level and graston for 5 minutes. superficially on the thoracolumbal fascia between the sacrum and T12. will be applied
223710212|NCT05560360|DRUG|SHR1459 tablet|100 mg/tablet; administered orally
223710213|NCT05560360|DRUG|Efavirenz tablet|600 mg/tablet; administered orally
223710214|NCT06556342|DRUG|FRD001|FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
223710215|NCT00728793|DRUG|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
223710216|NCT03812471|DEVICE|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
223893798|NCT02443857|DEVICE|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
223893799|NCT02443857|DEVICE|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
223893800|NCT02443857|DEVICE|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
223893801|NCT02443857|DEVICE|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
223893802|NCT04353661|DRUG|Azithromycin|Azithromycin will be administered orally.
224276310|NCT06674421|OTHER|Reliability Analyses|For the reliability analysis test-retest method will use. There will be a one-week break between the first test and the retest.
224276311|NCT01924364|DEVICE|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
224276312|NCT01924364|PROCEDURE|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
223710217|NCT03812471|DEVICE|2D standard measurements and 3D volumes acquisitions|"* 1 abdomen circumference measurement~* 1 femur length measurement~* 1 head circumference measurement~* 1 bi-parietal diameter measurement~* 1 abdominal volume~* 1 thigh volume~* 1 head volume"
223710218|NCT00289783|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
223710219|NCT00289783|BIOLOGICAL|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
223710220|NCT00289783|BIOLOGICAL|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
223710221|NCT00289783|BIOLOGICAL|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
223710222|NCT00289783|BIOLOGICAL|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
223710223|NCT00289783|BIOLOGICAL|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
223710224|NCT00289783|BIOLOGICAL|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
223710225|NCT03726411|PROCEDURE|non-surgical periodontal therapy|scaling and root planing
223710226|NCT02403986|DEVICE|Restylane Vital Skinboosters Lidocaine|
223710227|NCT00566995|DRUG|ZACTIMA (Vandetanib) (ZD6474)|
223710228|NCT02732756|BEHAVIORAL|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
223710229|NCT02732756|BEHAVIORAL|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
223710230|NCT04720066|DIAGNOSTIC_TEST|Ultrasound test|point of care ultrasound performed by PEM physicians to limping children presenting to the PED compared to radiologist performed ultrasound test.
223710231|NCT03013738|BEHAVIORAL|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
223710232|NCT03013738|OTHER|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
223710233|NCT05307146|DEVICE|macro/micro electrode recording|intracranial macro/micro-electrode placement at the cerebral cortex or in deeper brain areas with te use of macro/micro electrode recording. Macro/micro electrodes are placed at the cerebral cortex or in deeper brain areas in order to precisely identify the epileptogenic focus
223710234|NCT06356519|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
223710235|NCT05469191|OTHER|Group 5 STS|"For 8 weeks, 3 times per week and 3 sets of 5 repetitions during the first month, then 5 sets of 5 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
223893803|NCT04353661|OTHER|HP xenon (¹²⁹XE)|HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds
223893804|NCT00667251|BIOLOGICAL|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
223893805|NCT00667251|DRUG|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
223893806|NCT00667251|DRUG|lapatinib ditosylate|1250 mg once daily (while given with taxane). 1500mg once daily (when given alone after taxane completion).
223893807|NCT00667251|DRUG|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
223893808|NCT06352567|OTHER|European Organization for Research and Treatment of Cancer-Chemotherapy Induced Peripheral Neuropathy (EORTC-CIPN20) questionnaire|"It consists of a total of 20 items each is scored from 1: not at all to 4: very much in a 4-point Likert scale. Individuals are requested to fill out by considering their last week. Sensory, motor, and autonomic subscales are reported within its constructs. A total of 9, 8, and 3 items are referred to as sensory, motor, and autonomic disturbances, respectively"
224276313|NCT00152906|PROCEDURE|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
223527655|NCT01680211|BEHAVIORAL|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
223527656|NCT01680211|OTHER|Placebo|
223527657|NCT01139515|DRUG|Eletriptan commercial tablet|20 mg tablet, single dose
223527658|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
223527659|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
224276314|NCT00051818|BEHAVIORAL|Treatment interruption/reinitiation schedule|
223527660|NCT01139515|DRUG|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
223527661|NCT05577156|BEHAVIORAL|Self-questionnaires and semi-structured interview|Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions
223527662|NCT03735355|PROCEDURE|Surgery|Surgical resection of fibrostenotic area
223527663|NCT03735355|PROCEDURE|TTS balloon dilation|Dilation of a stricture using TTS balloon
223527664|NCT03361449|OTHER|Flamingo exercise|Flamingo exercise
223527665|NCT03361449|OTHER|training with kinesthetic ability trainer|training with kinesthetic ability trainer
223527666|NCT03134040|BEHAVIORAL|Incentives (Rebate)|
223527667|NCT03134040|BEHAVIORAL|Incentives (Donation)|
223527668|NCT03134040|BEHAVIORAL|Feedback|
223527669|NCT01400711|OTHER|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
223527670|NCT01400711|OTHER|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
223527671|NCT00066040|DRUG|Cervitec chlorhexidine varnish|
223527672|NCT00066040|DRUG|Duraphat fluoride varnish|
223527673|NCT00066040|DRUG|xylitol gum from Fennobon, Finland|
223527674|NCT02541591|OTHER|Neuroprotective goal directed hemodynamic optimization|
223527675|NCT02541591|OTHER|MAP > 65mmHg|MAP \> 65mmHg
223527676|NCT00002325|DRUG|Fluconazole|
223527677|NCT05892900|DEVICE|Transcutaneous vagus nerve stimulation (tVNS)|The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve
223527678|NCT05892900|DEVICE|Sham transcutaneous vagus nerve stimulation (Sham tVNS)|The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
223527679|NCT01480687|DIETARY_SUPPLEMENT|DHA-EPA|1800 mg/day
223527680|NCT01480687|DRUG|Ciprofibrate|100 mg/day
223527681|NCT01511133|PROCEDURE|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
223527682|NCT01511133|PROCEDURE|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
223527683|NCT03890211|DEVICE|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
223527684|NCT01512576|OTHER|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
223527685|NCT01512576|BEHAVIORAL|relaxation|1 treatment session of 30 minutes
223527686|NCT04803565|DEVICE|Custom-made shoe insole|Subjects will receive a custom-made shoe insole designed on the patient's foot and shoes. The subjects should wear the insole for at least 6 hours per day.
223527687|NCT04803565|DEVICE|Sham conventional Insole|Subjects will receive a conventional insole without any specific property (sham insole)
223527688|NCT03747692|PROCEDURE|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
223527689|NCT03747692|PROCEDURE|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
223527690|NCT01676233|DRUG|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
223527691|NCT01676233|DRUG|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
223527692|NCT01966627|OTHER|ogtt|oral glucose tolerance test
223527693|NCT01966627|OTHER|genotyping|genotyping to look for risk alleles
223527694|NCT01966627|OTHER|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
223527695|NCT01966627|OTHER|stool sample|stool sample taken to investigate metabolites
223527696|NCT01966627|OTHER|liver biopsy|liver biopsy to examine for cellular change and steatosis
223527697|NCT06406933|DRUG|Carbomer Gel/Jelly|The drug is for dry eye syndrome by providing temporary relief from discomfort and irritation.
223527698|NCT02700438|DRUG|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
223527699|NCT02700438|PROCEDURE|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
223527700|NCT03904485|RADIATION|cardiac magnetic resonance(CMR) T2 mapping|T2 value before transplant，3 month and 6month after transplant
223527701|NCT06424002|BIOLOGICAL|Mosquirixs|RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.
223527702|NCT06424002|DRUG|artemether-lumefantrine|A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.
223527703|NCT03243721|DIAGNOSTIC_TEST|7T MRI|A high field MRI that will take approximately one hour.
223893809|NCT04555512|OTHER|Progressive High Intensity Interval Training (PRO-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.
223893810|NCT04555512|OTHER|Constant High Intensity Interval Training (CON-HIIT)|Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
223893811|NCT02365623|DRUG|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
224276315|NCT02050035|OTHER|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
223710236|NCT05469191|OTHER|Group 10 STS|"For 8 weeks, 3 times per week and 3 sets of 10 repetitions during the first month, then 5 sets of 10 repetitions during the second month.~Between each repetition, there will be a rest of 30 to 60 seconds approximately."
223710237|NCT01760629|DEVICE|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
223710238|NCT04896541|BIOLOGICAL|AZD7442 300 mg IM(male)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
223710239|NCT04896541|BIOLOGICAL|AZD7442 600 mg IM (male)|Single dose of 600 mg of AZD7442 or saline placebo on Day 1.
223710240|NCT04896541|BIOLOGICAL|AZD7442 300 mg IV (male and female)|Single dose of 300 mg of AZD7442 or saline placebo on Day 1.
223710241|NCT04896541|BIOLOGICAL|AZD7442 1000 mg IV (male)|Single dose 1000 mg of AZD7442 or saline placebo on Day 1.
223710242|NCT01289080|DRUG|OPC-34712|administered orally
223710243|NCT04650711|DIAGNOSTIC_TEST|p16 protein expression|P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
223710244|NCT03935360|OTHER|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
223710245|NCT00636558|DRUG|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
223710246|NCT00094705|BIOLOGICAL|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
223710247|NCT00094705|BIOLOGICAL|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
223710248|NCT05160493|DRUG|S-ketamine and pregabalin|"S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
223710249|NCT05160493|DRUG|Normal saline and placebo capsule|Normal saline and placebo capsule
223710250|NCT04547712|DEVICE|Adaptive DBS|Subjects for whom both aDBS modes are acceptable will receive Dual and Single Threshold aDBS
223710251|NCT04790929|DEVICE|Muse|Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
223710252|NCT04790929|BEHAVIORAL|Meditation Coaching|Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
223710253|NCT05276024|DEVICE|iFuse Bedrock technique|Lumbosacral arthrodesis on 2 or more spinal segments (including at least L4, L5 and S1 vertebrae) associated with a sacroiliac fusion procedure according to the Bedrock technique using the iFuse 3D system and iliac fixation.
223710254|NCT05496400|RADIATION|Echocardiographic and Doppler studies|"Echographic and Doppler studies will be performed using machine: model GE Vivid iq premium,WUXI,China and we will measure:~1. Cardiac output:~2. Cerebral, intestinal and renal blood flow velocities:"
223710255|NCT00993070|DRUG|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
223710256|NCT00993070|DRUG|placebo|vehicle gel, applied 4 times per day for 8 weeks
224276316|NCT01845064|DRUG|DM199|
224276317|NCT01845064|DRUG|Placebo|
224276318|NCT00206245|DRUG|AZD0865|
223710257|NCT01049100|PROCEDURE|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
223710258|NCT01049100|OTHER|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--\> CT controlled biopsy
223710259|NCT04737382|DIAGNOSTIC_TEST|biopsy|The formalin fixed material will be processed for molecular analysis in a clinically validated diagnostic pipeline according to ISO 15189 or other acceptable standard
223710260|NCT04737382|DIAGNOSTIC_TEST|ctDAN analysis|ctDNA analysis will be performed using the AVENIO ctDNA targeted kit according to the guidelines from the manufacturer with respect to isolation, library preparation and bioinformatics analysis.
223710261|NCT04827381|OTHER|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
223710262|NCT04827381|OTHER|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
223710263|NCT00065689|DEVICE|high-intensity light therapy|
223710264|NCT01937416|BIOLOGICAL|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
223710265|NCT03298867|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
223710266|NCT03298867|OTHER|Placebo|Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
223710267|NCT02746796|DRUG|ONO-4538|
223710268|NCT02746796|DRUG|Oxaliplatin|
223710269|NCT02746796|DRUG|Tegafur- Gimeracil-Oteracil potassium|
223710270|NCT02746796|DRUG|Capecitabine|
223710271|NCT02746796|DRUG|Placebo|
223710272|NCT02318251|OTHER|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
223710273|NCT02318251|OTHER|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
223710274|NCT04941560|OTHER|No intervention|No intervention
223710275|NCT01941667|BEHAVIORAL|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
223710276|NCT01941667|OTHER|Usual Care|Usual care as defined by by the Cardiology Department.
223710277|NCT00384501|DEVICE|Intacs|
223710278|NCT01906632|BIOLOGICAL|DC-CIK Immunotherapy|
223710279|NCT00228384|DEVICE|GORE VIABAHN Endoprosthesis|Implantation
223710280|NCT00228384|DEVICE|Bare Nitinol Stent|Implantation
223710281|NCT02836093|BEHAVIORAL|FACIT-Fatigue 52-point questionnaire|
223710282|NCT00002190|DRUG|Saquinavir|
223710283|NCT00002190|DRUG|Lamivudine|
223710284|NCT00002190|DRUG|Zidovudine|
223710285|NCT04498520|DRUG|Abexinostat Tosylate|Given PO
223710286|NCT04498520|DRUG|Fulvestrant|Given IM
223710287|NCT04498520|DRUG|Palbociclib|Given PO
223710288|NCT01161459|DRUG|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
223710289|NCT01161459|DRUG|FK506|capsule
223710290|NCT05746793|PROCEDURE|endometrium biopsy|"The procedure is performed without any anesthesia and takes approximately 5 minutes.~A small plastic pipelle is put through the cervix into the uterine cavity. The endometrial tissue is aspirated into the pipelle."
223710291|NCT05746793|DIAGNOSTIC_TEST|Transabdominal ultrasound|Evaluation of fetal biometry and doppler flow study using ultrasound.
223710292|NCT05746793|DIAGNOSTIC_TEST|Peripheral phlebotomy|single puncture collection of peripheral venous blood.
223710293|NCT05746793|DIAGNOSTIC_TEST|Urine collection|Collection of urine in a plastic cup.
223710294|NCT05746793|OTHER|MOCK frozen embryo transfer preparative cycle.|Start with daily estradiol (progynova, oestrogel) administration at hormonal baseline (day 2 of the cycle or with confirmation using endocrine evaluation). When adequate thickness (≥6.5 mm) of the endometrium is achieved (usually after 10-14 days), progesterone is administered daily. 6 days after progesterone administration, the pipelle biopsy will be performed. When this test cycle has ended and menstruation starts, patients will be asked to collect their menstrual flow, during the first night of heavy/red flow, in a menstrual cup. The next day patients will be asked to bring their collected menstrual blood to our center and they will undergo a blood analysis needed for the start of their ART treatment.
223710295|NCT05746793|DIAGNOSTIC_TEST|Baseline questionnaire|questionnaire the patient has to fill in
223710296|NCT05746793|OTHER|collection of menstrual blood|collection of menstrual blood during the first day of heavy menstrual flow for at least 6 hours
223710297|NCT05746793|DIAGNOSTIC_TEST|nutritional and metabolic work-up|Including body composition analysis by BIA/whole body MRI and analysis of resting energy expenditure (REE).
223710298|NCT05746793|DIAGNOSTIC_TEST|cardiac work-up|Using transthoracic ultrasound.
223710299|NCT05746793|DIAGNOSTIC_TEST|Blood pressure measurement|Blood pressure measurement
223710300|NCT03100500|DRUG|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
223710301|NCT04720469|DEVICE|MRgFUS thalamotomy|Ablation of untreated thalamus using focused ultrasound to abate tremor.
223710302|NCT00227097|BEHAVIORAL|Education Notebook for anticoagulant treatment|
223710303|NCT02420340|BEHAVIORAL|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
223710304|NCT03438929|DEVICE|Diode laser|Diolaze XL blended modes diode laser
223710305|NCT03424408|DRUG|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
223710306|NCT02099175|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
223710307|NCT02099175|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
223710308|NCT02099175|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
223710309|NCT02099175|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
223710310|NCT02099175|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
223710311|NCT02099175|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
223710312|NCT02099175|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
223710313|NCT02099175|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
223710314|NCT02099175|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
223710315|NCT02099175|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost:~   HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
223710316|NCT01785069|DEVICE|Anatomically shaped, silicone-filled breast implants with low projection or extra-full projection|Surgical implant
223710317|NCT03372044|DRUG|PF-06865571 Immediate release suspension|Suspension
223710318|NCT03372044|DRUG|PF-06865571 Slow release MR tablets|Modified release tablets
223710319|NCT03372044|DRUG|PF-06865571 Fast release MR tablets|Modified release tablets
223710320|NCT03372044|DRUG|PF-06865571 Immediate release tablets|Immediate release tablets
223710321|NCT03249883|DEVICE|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
223710322|NCT04378556|BEHAVIORAL|Nutritional coaching|Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
223710323|NCT06039397|BEHAVIORAL|Semifowler 30' Right Lateral Body Position|Semifowler 30' Right Lateral Body Position Is a regulation of body position by placing the patient's body in a semi-fowler and lateral resting position of 30 degrees
223710324|NCT05624281|DRUG|nintedanib|nintedanib, for patients with fibrosing interstitial lung disease (ILD); in this EAP limited to children and adolescents
223710325|NCT05248061|OTHER|Group A|"Wand exercises; It will be applied to increase the normal range of motion of the joint. Exercises will be performed in the directions of shoulder flexion, abduction, external and internal rotation. Objects such as a round stick, walking stick and towel can be used to assist patients during exercise.~\- \*Pendulum (Codman) Exercises: These exercises will be applied in 90° flexion of the waist, with the healthy hand resting on a solid place, and turning the arm back and forth, to the sides, clockwise and counterclockwise with circular movements.~\*Capsule stretching: Auto stretching (by the patient) will be applied to the posterior region of the shoulder (capsule), pectoralis minor and upper trapezius muscles.~\*Isometric shoulder exercises Isometric exercises will be given in the directions of shoulder extension, abduction, external rotation and internal rotation."
223710326|NCT05248061|OTHER|Group B|"The same exercises as in Group 1 will be suitable for the participants.~* PRP will be applied in the first session and 2 weeks later. Exercises will be started 2 days after PRP application.~* Up to 10 cc of blood will be taken from the PRP group patients by the nurse. 25 mL of venous blood will be collected from each patient at a time, using a syringe containing 2.5 mL of the anticoagulant citrate dextrose solution. After the blood taken is transferred to the special PRP kit and centrifuged for 8 minutes at 3000 rpm, in addition to the 5-6 cc platelet-rich plasma remaining in the upper part of the kit, the entire buffy coat is injected into the syringe from the region compatible with the posterior arthroscopy portal (inferior to the acromion posterolateral bone prominence) by the physician. next, from the end point of the posterior fibers of the deltoid muscle, targeting the subacromial space) will be applied. No buffering or activating agents will be used for PRP."
223710327|NCT02510196|BEHAVIORAL|reminder|
223710328|NCT05454098|DRUG|Clifutinib with fed state|40 mg Clifutinib with food
223710329|NCT05454098|DRUG|Clifutinib with fasted state|40 mg Clifutinib without food
223710330|NCT00134238|DRUG|torcetrapib/atorvastatin|
223710331|NCT00134238|DRUG|atorvastatin|
223710332|NCT05504031|PROCEDURE|Hybrid coronary revascularization|Coronary revascularization is conducted as a combined MIDCAB (LIMA-LAD grafting through a minimally invasive anterior left thoracotomy) and PCI (of all non-LAD stenoses)
223710333|NCT05504031|PROCEDURE|Conventional revascularization|Conventional revascularization with CABG of all significant stenoses through a sternotomy
223710334|NCT04361318|COMBINATION_PRODUCT|Hydroxychloroquine plus Nitazoxanide|Both hydroxychloroquine \& nitazoxanide will be administered orally to participating patients
223710335|NCT04361318|OTHER|Standard care|"Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary"
223710336|NCT00394147|DRUG|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
223710337|NCT00394147|DRUG|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
223710338|NCT04435132|DEVICE|PCL under fluoroscopy with the aid of the robotic device|During the surgery, the robot was positioned over the estimated insertion point. It was aligned to be parallel to the fluoroscope imaging plane as much as possible. The needle is to be placed through the holder, and slightly penetrate the surface of the skin. An x-ray image is then taken to ensure that the whole device can be seen on the screen. Image calibration is then performed through the software GUI. After which, the clinician is also to perform needle tip selection. After which, needle alignment will then be performed. Once needle alignment is complete, the clinician will then advance the trocar needle into the patient's body, using the fluoroscopy to judge the penetration depth. Once the target has been reached, the needle style is to be extracted. The indication of leakage of fluid through the outer needle confirms the success of the procedure.
223710339|NCT02547844|DRUG|efavirenz + emtricitabina + tenofovir|
223710340|NCT02547844|DRUG|rilpivirina + emtricitabina + tenofovir|
223710341|NCT02015572|BEHAVIORAL|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
223710342|NCT02015572|OTHER|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
223710343|NCT01029834|BEHAVIORAL|family based lifestyle and behavioral counseling|16 group meetings
223710344|NCT01029834|BEHAVIORAL|counseling focused on the child|16 meetings
223710345|NCT02252783|DRUG|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
223710346|NCT01228474|OTHER|Select the Number of embryos to transfer|Select the Number of embryos to transfer
223710347|NCT00818480|DRUG|YM155|continuous infusion
223710348|NCT05868395|DRUG|Polatuzumab, bendamustin und rituximab|"* Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle~* Bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle~* Rituximab 375 mg/m2 i.v. on day 1 of each cycle~* Each cycle is 21 days long~* Up to 6 cycles per patients planned"
223710349|NCT04875663|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
223710350|NCT01067690|DRUG|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
223710351|NCT00702195|DRUG|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
223710352|NCT00702195|DRUG|Placebo|single dose of placebo (administered under protocol 38805)
223710353|NCT00702195|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
223710354|NCT02041832|OTHER|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
223710355|NCT02041832|DEVICE|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
223710356|NCT05232175|DRUG|ALT-BB4|Recombinant Hyaluronidase
223710357|NCT05232175|DRUG|0.9%NaCl|Normal Saline
223710358|NCT04742998|OTHER|Acoustic-phonetic decoding task (DAP)|Completion of speech-related quality of life autoquestionnaires Routine speech assessment Acoustic-phonetic decoding task (DAP) two lists of 16 pseudo-words
223710359|NCT04614922|BEHAVIORAL|Acceptance and Commitment Therapy|ACT-based rehabilitation is an interdisciplinary group rehabilitation which includes 7 sessions of group-based ACT therapy. Each session lasts 2½ hours and is offered twice a week. The ACT sessions will be based on a detailed intervention manual, developed specifically for group treatment. Each group will include a maximum of eight patients. The patients are asked to do homework between each ACT-group session.
223710360|NCT03105479|DRUG|Cadazolid|Granules for oral suspension to be administered twice daily
223710361|NCT03105479|DRUG|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
223710362|NCT03105479|DRUG|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
223710363|NCT06144177|OTHER|Dark with star projector|When in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on.
223710364|NCT06144177|DRUG|Preoperative midazolam|Midazolam by mouth preoperatively.
223710365|NCT06144177|OTHER|Parental Presence|A parent or guardian will accompany the child into the OR and be present for the start of induction.
223710366|NCT04833257|DRUG|GP combine with Tislelizumab neoadjuvant therapy+CCRT|chemotherapy combine with anti-PD-1 targeted immunotherapy+concurrent chemotherapy
223710367|NCT05928026|BEHAVIORAL|Financial Support|A debit card will be loaded with $500 and can be used like a typical debit card.
223710368|NCT05876871|DIAGNOSTIC_TEST|Pelvic Binder Radiography|One series of radiographic exposures
223893812|NCT02365623|DRUG|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
223893813|NCT06488222|DRUG|Docetaxel|Subjects will receive 40 mg docetaxel intravesically.
223893814|NCT06488222|DRUG|Gemcitabine|Subjects will receive 1 mg gemcitabine intravesically.
223893815|NCT03509116|OTHER|Observations, documents|Consultation observations, documentary analysis
223893816|NCT03509116|OTHER|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
223893817|NCT05552534|OTHER|STIR PROTOCOL|"Screening, STIR protocol (screening, brief intervention, incentive to download the tobacco info service application, delivery of the tobacco-info-service brochure, initiation of a nicotine patch made by the trained emergency nurse or doctor) then three consultations face-to-face or remotely with a member of the team addictionology at 7 days, 1 and 3 months."
223893818|NCT06146907|OTHER|cognitive motor dual task exercises|exercise program that combined motor tasks such as walking and juggling with cognitive task such as naming fruits or colors in the room.
223527704|NCT03243721|DIAGNOSTIC_TEST|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
223527705|NCT03926455|BIOLOGICAL|Typhax (investigational typhoid fever candidate vaccine)|
223527706|NCT03926455|BIOLOGICAL|Placebo|Placebo is administered to the control group on Day 0 and 28
223527707|NCT03926455|BIOLOGICAL|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
223527708|NCT06247137|DIETARY_SUPPLEMENT|Dietary Supplement|"Dietary supplement formulated with components of natural origin: artichoke, bergamot, folic acid, astaxanthin, Chromium picolinate and excipients.~Oral administration: 1 tablet/day at evening meal"
223527709|NCT06247137|OTHER|Placebo|"Placebo (microcrystalline cellulose, calcium carbonate, magnesium stearate, silica dioxide and iron oxides).~Oral administration: 1 tablet/day at evening meal."
223527710|NCT03978598|DRUG|Etonogestrel|Immediate v. Standard insertion.
223527711|NCT03978598|DEVICE|Nexplanon|Implant.
223527712|NCT04451798|DEVICE|Impella CP microaxial pump|ramp test
223527713|NCT03100526|BEHAVIORAL|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~* Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~* Improve Veteran and staff satisfaction~Objectives:~* Maintain the patient in the home setting as much as possible~* Secure appropriate home environment to facilitate health and well-being~* Utilize comprehensive team-based care~* Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
223527714|NCT05795907|DRUG|SAR443820|Capsule / Oral
223527715|NCT05795907|DRUG|Placebo|Matching Capsule / Oral
223527716|NCT00203190|DRUG|Topiramate|
223527717|NCT00371124|DRUG|Atropine Eye drops|
223527718|NCT00853853|DEVICE|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
223527719|NCT00853853|PROCEDURE|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
223527720|NCT01969734|DEVICE|Zephyr endobronchial valve placement|
223527721|NCT02965781|DRUG|SADBE|Topical solution
223527722|NCT02965781|OTHER|Placebo|Topical solution
223527723|NCT06527885|DRUG|Lurasidone|Patients treated with Lurasidone in according to routine clinical practice, in Italy
223527724|NCT02538614|DRUG|Idelalisib|Tablets administered orally twice daily
223527725|NCT02538614|DRUG|BI 836826|Intravenous administration as a rate-controlled infusion
223527726|NCT01605994|DRUG|BMS-933043|
223527727|NCT01605994|DRUG|Placebo matching with BMS-933043|
223527728|NCT01605994|DRUG|Antacid Buffer Predose Solution|
223527729|NCT03835078|DEVICE|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
223527730|NCT03835078|DEVICE|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
223527731|NCT01145950|DRUG|LBEC0101|Etanercept 25mg, single dose
223527732|NCT01145950|DRUG|Enbrel|Etanercept 25mg, single dose
223527733|NCT02383160|DEVICE|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
223527734|NCT02383160|DEVICE|Sham device|Placebo device with no active therapy
223527735|NCT01203007|DIETARY_SUPPLEMENT|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
223527736|NCT01203007|DIETARY_SUPPLEMENT|Low antigen content diet|Low-antigen content diet for one month
223527737|NCT00726908|DIETARY_SUPPLEMENT|Low carbohydrate|43% CHO
223527738|NCT04955548|PROCEDURE|arthroscopic micro-fracture with autologous adipose gel|Fully cut the adipose tissue taken out under the arthroscopy, transfer the cut adipose tissue to a syringe connected with a double pass, push back and forth through the syringe to physically emulsify the adipose, and centrifuge to obtain the autologous adipose gel, and inject it into the lesion
223527739|NCT04955548|PROCEDURE|arthroscopic micro-fracture|Surgeons routinely perform international standard micro-fracture surgery to repair cartilage damage
223527740|NCT03302767|OTHER|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
223527741|NCT01638507|DEVICE|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
223527742|NCT03474276|DRUG|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
223527743|NCT03474276|DIETARY_SUPPLEMENT|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
223527744|NCT03474276|DRUG|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
223893819|NCT06146907|OTHER|exergaming|Nintendo switch games that involve physical activity by participants to complete
223893820|NCT02995434|DEVICE|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe\_Lucem\_\_Seize\_The\_Light\_VR/"
223893821|NCT02995434|OTHER|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk: http://painstudieslab.com/projects/virtual-meditative-walk/ Wildflowers: https://appadvice.com/app/wildflowers-mindfulness/988835763 Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
223893822|NCT05071729|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant on Day 1.
223893823|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle.
223893824|NCT02732275|DRUG|DS-3201b|DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
223893825|NCT06418555|BEHAVIORAL|A home rehabilitation program centered on exercise|Establish a multidisciplinary team, with team members combining clinical experience, summarizing the best evidence as the basis, and using the theory of behavior change wheels as the framework, to preliminarily construct a home-based cardiac rehabilitation plan suitable for TAVR patients in China's national conditions. Conduct expert consultation using the Delphi method to form the final version of the home cardiac rehabilitation plan for TAVR patients.
223893826|NCT00740948|DRUG|Rituximab (mabthera) Injection|2 \* 1g of Rituximab at the 1st day and at the 14th day.
223893827|NCT00740948|DRUG|Placebo: NaCl 0.9% or Glucose 5%|2\* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
223893828|NCT03047928|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
223893829|NCT03047928|BIOLOGICAL|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
223893830|NCT05543369|DRUG|Elafibranor|Oral Tablet
223893831|NCT04843722|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|Vaccine containing both full length wild type SARS-CoV-2 spike gene optimized for better spike protein expression, and full length wild type SARS-CoV-2 nucleocapsid gene modified to also contain an enhanced T cell stimulation domain (ETSD) to enhance cell-mediated immunity.
223893832|NCT06134128|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Addictions Group|8-week manualized group-based behavioral intervention delivered via telehealth
223893833|NCT02182219|DRUG|BIBF 1120|
223893834|NCT04330430|DRUG|T-VEC|The treatment schedule is based on 4 courses of intralesional T-VEC and 3 courses of intraveneous Nivolumab. T-VEC first, in order to achieve the best synergistic effect with influx of CD8+ T-cells prior to the first Nivolumab dose. T-VEC monotherapy with the dose 10\^8 PFU/mL is given every 2 weeks after 3 weeks of the first T-VEC dose (with the first dose of T-VEC 10\^6 PFU/mL to allow for seroconversion), and Nivolumab will be given every 2 weeks.
223893835|NCT05879757|OTHER|No Intervention|As this is an observational study, no intervention will be administered in this study.
223893836|NCT04179500|DRUG|Pretomanid|pretomanid 200 mg (once daily) for 26 weeks (with meal)
223893837|NCT04179500|DRUG|Bedaquiline|bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
223893838|NCT04179500|DRUG|moxifloxacin|moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
223893839|NCT04179500|DRUG|pyrazinamide|pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
223893840|NCT05556174|OTHER|periodic lung recruitment maneuvers|lung recruitment maneuvers repeated every 30 minutes
223893841|NCT06089707|DRUG|Naloxone Nasal Spray|IN naloxone will be administered to participants, after which a single dose of buprenorphine will be given to participants
223893842|NCT04480918|DEVICE|Electroconvulsive Therapy (ECT)|ECT for the treatment of treatment-resistant depression OR Bipolar Disorder in an active major depressive episode
223893843|NCT04480918|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS for the treatment of treatment-resistant depression in an active major depressive episode
223893844|NCT04480918|DRUG|Ketamine|Intravenous ketamine infusion for the treatment of treatment-resistant depression in an active major depressive episode
223893845|NCT04480918|DRUG|Esketamine|Intranasal esketamine insufflation for the treatment of treatment-resistant depression in an active major depressive episode
223893846|NCT04480918|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS)|TMS for the treatment of OCD
223710369|NCT05358444|BEHAVIORAL|National Diabetes Prevention Program Lifestyle Intervention (DPP)|"The National Diabetes Prevention Program lifestyle intervention (DPP) is a 12-month long, group-based lifestyle intervention for adults at high-risk for type 2 diabetes. The DPP will be delivered by certified coaches from the Johns Hopkins Brancati Center. The program uses the CDC's Prevent T2 curriculum, with a total of 32-34 sessions delivered over a 12-month period. In the initial core period (first 6 months), there are at least 16 sessions delivered on a weekly basis. In the post-core period, additional (at least 6) sessions are offered over a 6 month period. Sessions are delivered either in-person or via a virtual synchronous platform (Zoom)."
223893847|NCT06581770|OTHER|Survey using a questionnaire.|It is a validity and reliability study that can evaluate digital health readiness.
223893848|NCT06581770|OTHER|Survey using a questionnaire.|This is a reliability and validity study.
223893849|NCT04854317|PROCEDURE|Endoscopic gastroplasty|Endoscopic Gastroplasty
223893850|NCT05171075|BIOLOGICAL|Abelacimab|Abelacimab 150 mg
223893851|NCT05171075|DRUG|Dalteparin|Dalteparin 200 IU/kg/day followed by 150 IU/kg/day
223893852|NCT02955784|DEVICE|Sinasprite Mobile App|Mobile App
223893853|NCT06566196|PROCEDURE|Cardiac Cath|Patient will undergo standard of care Cardiac Cath and in addition invasive CPET (Cardiopulmonary exercise testing) will be performed during the procedure.
223893854|NCT03317158|DRUG|Durvalumab (Cohort 1-3)|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
223893855|NCT03317158|RADIATION|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
223893856|NCT03317158|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
223893857|NCT03317158|DRUG|Gemcitabine|Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
223893858|NCT03317158|DRUG|Docetaxel|Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
223893859|NCT03317158|BIOLOGICAL|Tremelimumab|Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
223893860|NCT03317158|DRUG|Durvalumab (Cohort 4/5)|Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
223893861|NCT03317158|OTHER|To be determined|Other regimens to be determined
223893862|NCT03907904|DEVICE|CPOM Optical Neuromonitor|Prior to induction of anesthesia, the CPOM monitor will be secured to the temporal region of the participant's forehead to measure and record the cerebral hemodynamic data before, during, and following intubation. Hemodynamic, respiratory, body temperature, and anesthetic data will be continuously digitally records. The CPOM device will be detached after extubation in the operative room.
223893863|NCT05487170|DRUG|RNK05047|RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).
223893864|NCT04492007|BEHAVIORAL|Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)|Participants will receive personalized self-care information and guidance based on their symptoms and signs of complications (e.g., skin infection, fatigue) from the web-based telehealth PRISMS program. They will also have access through this website a peer support online forum that is moderated by a research nurse as well as professional support through videoconferencing/telephone from the research nurse and also their healthcare providers at the hospital(s) if they experience moderate to severe symptoms and/or abnormal sign (e.g., body temperature is greater than 98.6 C
223893865|NCT06453343|PROCEDURE|Surgical approach: cochleostomy or extended round window|Surgical placement of a cochlear implant electrode array
223893866|NCT03463824|BEHAVIORAL|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
223893867|NCT03463824|BEHAVIORAL|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
223893868|NCT03169790|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223710370|NCT05358444|BEHAVIORAL|Family Diabetes Prevention Program (Family DPP)|The Family DPP has been developed as an augmented version of the National Diabetes Prevention Program Lifestyle Intervention (DPP). It includes all elements of the 12-month, group-based DPP lifestyle intervention, led by a CDC certified-coach using a CDC-approved curriculum (involving around 32-34 sessions). The augmentations of the Family DPP supplement the DPP's sessions to additionally address barriers to adults' own lifestyle change efforts related to being a caregiver of children AND to introduce basic concepts regarding healthy child habits related to dietary intake, physical activity and screen time, and sleep. The Family DPP will involve thus additional sessions that will be delivered to the adult DPP participant, and in which children, ages 5 through 12, may also be engaged.
223710371|NCT05300737|OTHER|intensive medical therapy|Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
223710372|NCT02833064|RADIATION|Non-contrast magnetic resonance imaging|
223893869|NCT03169790|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
223893870|NCT03169790|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223893871|NCT03169790|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223893872|NCT03169790|DRUG|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223893873|NCT03169790|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223893874|NCT03169790|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223893875|NCT03169790|DRUG|Lovaza|Omega-3-acid ethyl esters
223893876|NCT03169790|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
223893877|NCT03169790|DRUG|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
223710373|NCT02833064|OTHER|Biological sampling|Blood, urine, stool and breath sampling and analysis
223710374|NCT04452240|DEVICE|thoracic endovascular repair|Repair of thoracic aorta lesions with the application of a dedicatet stent-graft by endovascular way.
223710375|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation|
223710376|NCT01753141|BEHAVIORAL|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
223710377|NCT03802227|DRUG|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
223710378|NCT03802227|DRUG|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
223893878|NCT03169790|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
223893879|NCT03169790|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
223893880|NCT03169790|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
223893881|NCT03169790|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
223893882|NCT04177823|DRUG|Belantamab mafodotin|Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
223939921|NCT05723107|DEVICE|Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)|"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."
223710379|NCT05602870|DIAGNOSTIC_TEST|non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)|A Fibroscan will be performed and the result will be given to the patient. A follow-up will be organized in the event of a diagnosis of severe fibrosis. If the serologies for hepatitis B and C cannont be recovered, patient will be able to benfit from a rapid diagnostic orientation test (TROD) (minimally invasive capillary venous sampling at the fingertip) for these 2 serologies.
223710380|NCT06652984|OTHER|Exercise 1|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
223710381|NCT06652984|OTHER|Exercise 2|Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
223710382|NCT06338176|OTHER|OPTIMUS-SAB clinical care pathway|Activation of SAB clinical care pathway within EMR system.
223710383|NCT06980454|DRUG|HLX05|A single dose of 250 mg/m2 HLX05 will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
223710384|NCT06980454|DRUG|EU-Erbitux®|A single dose of 250 mg/m2 EU-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
223710385|NCT06980454|DRUG|US-Erbitux®|A single dose of 250 mg/m2 US-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
223710386|NCT06980454|DRUG|CN-Erbitux®|A single dose of 250 mg/m2 US-Erbitux® injection will be given by intravenous drip over 2 h (± 10 min). Antihistamines (e.g., diphenhydramine 20 mg or promethazine 25 mg by intramuscular injection within 30 min prior to dosing) and corticosteroids (e.g., dexamethasone 5 mg by intravenous bolus within 30 min prior to dosing) will be given prior to infusion.
223710387|NCT06655142|DEVICE|ONCObind (Onco-Seraph) 100 Filter|The ONCObind Microbind® Affinity Blood Filter ( ONCObind) manufactured by ExThera Medical Corporation in Martinez, CA. The ONCObind filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. Literature search yielded over 60 publications and 500 treated patients with Seraph platform technology for pathogen removals without and significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of ONCObind consistent with the intended use. ExThera Medical concludes that the known and potential benefits of ONCObind, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.
223710388|NCT06655142|OTHER|Matched Controls|Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with 60 site specific controls, 30 PDAC and 30 CRC.
223710389|NCT01840306|OTHER|Biomarker Analysis|
223710390|NCT06607900|DRUG|hUC-MSC-sEV-001 nasal drops|hUC-MSC-sEV-001 nasal drops
223710391|NCT01330680|DIETARY_SUPPLEMENT|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
223710392|NCT01330680|DIETARY_SUPPLEMENT|Decaffeinated coffee|40 mL dose of decaffeinated coffee
223710393|NCT05334914|BEHAVIORAL|Acceptance Commitment Therapy|"ACT: Consists of 15 sessions, twice per week. Each session is approximately 2.5 hours including breaks. Clients cover 3 modules (OPEN, ACTIVE, AWARE). Any participant who requires access to a device for any part of the study will be provided with one for the duration of the study.~CM: Participants will be given progressive compensation for session attendance via gift cards or e-gift cards amounting to $520.~Motivation Building Session: The study clinician will meet with each of the participants to explain the process of the therapy, reinforce expectations, and address any concerns or hesitations, and build motivation and commitment to fully engage in the program.~ChillTime App Participants rate their emotional state and choose a coping strategy (either physical, emotional, cognitive or spiritual). The app's algorithm learns the individual's strategy preferences over time, allowing for more personalized suggestions. Participants are also able to access coping strategies ad hoc."
223710394|NCT01913678|OTHER|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
223710395|NCT01913678|OTHER|Complete diet|The participants will be given all dietary items in their diet with no additional products.
223710396|NCT01913678|OTHER|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
223710397|NCT06517212|DRUG|Tirzepatide|Patients will receive tirzepatide once weekly for up to 2 years.
223710398|NCT06989489|BEHAVIORAL|Multilevel Adherence Intervention|Participants enrolled in this adherence program will have individualized counseling sessions with their clinical pharmacists regarding their oral anticancer agent based on their risk-stratified monitoring category. Participants will be followed longitudinally and will receive tailored support.
223710399|NCT00876421|DRUG|Placebo|Placebo / 12 weeks
223710400|NCT00876421|DRUG|Tolterodine|4mg / 12 weeks
223710401|NCT00876421|DRUG|ONO-8539|low dose / 12 weeks
223710402|NCT00876421|DRUG|ONO-8539|medium dose / 12 weeks
223710403|NCT00876421|DRUG|ONO-8539|higher dose / 12 weeks
223710404|NCT06677567|OTHER|Air-Q Intubating Airway|Patients will be inserted Air-Q Intubating Airway under general anesthesia
223710405|NCT06677567|OTHER|proseal laryngeal mask|Patients will be inserted proseal laryngeal mask under general anesthesia.
223939922|NCT02842749|DRUG|everolimus|Participants were instructed to take everolimus at a starting dose of 10 mg orally once daily. However, dose adjustments were permitted in order to allow the participant to continue the study treatment.
223939923|NCT07173491|OTHER|classical music group|classical music therapy with standard restorative treatment
223939924|NCT07173491|OTHER|turkish music group|Turkish music therapy with standard restorative treatment
223939925|NCT07173491|OTHER|control|no music therapy with standard restorative treatment
223710406|NCT06676670|OTHER|real acupuncture|Real Acupuncture Group Main acupoints: Hegu (bilateral), Taichong (bilateral), Taiyang (unilateral), shuogu (unilateral), Fengchi (unilateral); Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning Operation method: supine position, skin routine disinfection. The special model of acupuncture and moxibustion (0.30mm × 30mm), fix the gasket on the acupoint skin with seam free tape, and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept for 30 minutes. During this period, the technique of small amplitude uniform lifting, inserting and twisting (3 times) will be performed every 10 minutes. A total of four times of needling will be performed.
223710407|NCT06676670|OTHER|sham acupuncture|"Sham acupuncture group Acupoint selection: select eight stimulation points at the neck and shoulder. Stimulation point 1: the midpoint of the line between the shoulder well and the giant bone (both sides); Stimulation point 2: 5 inches (both sides) of the inferior paraspinal process of the seventh thoracic vertebra; Stimulus point 3: the inferior paraspinal process of the eighth thoracic vertebra will be opened 5 inches (bilateral); Stimulus point 4: 5 inches (both sides) of the infraspinous process of the ninth thoracic vertebra.~Positioning: refer to the 2006 national standard of the people's Republic of China (gb/t 12346-2006) acupoint names and positioning to avoid acupoints.~Operation method: supine position, skin routine disinfection. Streitberger acupuncture (0. 300×30mm). Fix the gasket on the acupoint skin with seam free tape,and then acupuncture. After acupuncture, each acupoint will be lifted, inserted and twisted three times in small amplitude; The needle will be kept fo"
223710408|NCT06604065|DRUG|AMS2434 (amino acids)|The proprietary composition includes leucine, valine, isoleucine, lysine, phenylalanine, threonine, tyrosine, histidine, and methionine. Small amounts of non-caloric flavorings are also included.
223710409|NCT06604065|DRUG|Placebo|Matched non-caloric placebo. Study products will be in powder form and packaged in individual serving sizes and will be dissolved in 8 oz water for consumption.
223710410|NCT06680219|DIETARY_SUPPLEMENT|Placebo|Crystal Light Raspberry Lemonade: Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily (8-12 oz of water is approximately 236-354 mL of water).
223710411|NCT06680219|DIETARY_SUPPLEMENT|Active comparator|"ACTIVE - Nu Biome (Formula #: 95001996; Batch #: EV24931): Mix 3 scoops of powder (with scoop provided) with 8-12 oz of water. Enjoy once daily.~(8-12 oz of water is approximately 236-354 mL of water)."
223710412|NCT06681493|DRUG|YZJ-4729 Tartrate injection|Infusion, QD
223710413|NCT06681493|DRUG|YZJ-4729 simulated injection|Infusion, QD
223710414|NCT06680024|PROCEDURE|Intercostal tube|Intercostal tube drainage as a first management of second stage empyema
223710415|NCT06680024|PROCEDURE|Video assisted thoracoscope|Video assisted thoracoscopic surgery as a first management for second stage empyema
223710416|NCT05240599|OTHER|Exercise Training|Exercise training will be applied 3 times a day for 8 weeks.
223710417|NCT06623682|BEHAVIORAL|Transdiagnostic cognitive behavioural therapy|Transdiagnostic cognitive behavioural therapy for both depression and anxiety that including modules from (1) Mindfulness-based intervention, (2) Rumination-focused cognitive behavioural therapy, and also including modules for insomnia and from Mindwork (Internet-based cognitive behavioural therapy).
223710418|NCT06875102|DEVICE|Acupuncture (ACU)|acupoints will be Baihui (GV20); Zhongwan (CV12), Guanyuan (CV4), bilateral Zusanli (ST36) bilateral Taichong (LV3). The needles will remain for 30 min. Subjects will receive acupuncture twice a week during the 12-week intervention.
223710419|NCT06875102|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|"Transcutaneous Vagus Nerve Stimulation (tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. In the groups receiving simulated tVNS, stimulation will be delivered to the ear lobe, which is devoid of vagal innervation.~Stimulation will be delivered at a frequency of 20 Hz and a pulse width of 200 ms, while the stimulation amplitude will be individually titrated to 1 mA below the level that will lead to a mild unpleasant feeling, according to the parameters defined by Stavrakis et al (2017, 2020)."
223710420|NCT06875102|OTHER|APA (adapted physical activity )|The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks
223710421|NCT06875102|DEVICE|Acupuncture (sham_ACU)|Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention.
223710422|NCT06875102|DEVICE|Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS)|"Simulated Transcutaneous Vagus Nerve Stimulation (sim\_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in simulated mode."
223710423|NCT05656118|DEVICE|Genoss® DCB|Paclitaxel coated balloon with a shellac plus vitamin E excipient
223710424|NCT06631755|DEVICE|Xience Skypoint stent over calcified coronary lesions|Patients with Xience Skypoint stent implanted after OCT assesment of calcification
223710425|NCT03424863|OTHER|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
223710426|NCT06706674|DRUG|Lumateperone high dose|Lumateperone administered orally once daily
223710427|NCT06706674|DRUG|Lumateperone low dose|Lumateperone administered orally once daily
223710428|NCT06706674|DRUG|Placebo|Matching Placebo administered orally once daily
223710429|NCT06704373|OTHER|thoracal manipulation|Thoracal manipulation will be applied only one session.
223710430|NCT06704373|OTHER|Exercise|Both groups will perform the same postural exercises, which will be applied twice a week for 4 weeks. The intervention group will receive thoracic manipulation for one session.
223710431|NCT07033936|OTHER|Questionnaire|An online Questionnaire will be shared via social media such as WhatsApp, Facebook or X for Egyptian medical students and intern to fill
223710432|NCT06702930|OTHER|Morning high-intensity interval exercise|High-intensity interval exercise was performed between 8-10 am
223710433|NCT06702930|OTHER|Evening high-intensity interval exercise|High-intensity interval exercise was performed between 5-7 pm
223710434|NCT07044349|DRUG|Utidelone capsule 75mg/m2/d QD|75mg/m2/d, QD, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223939926|NCT05273463|BEHAVIORAL|Video-Based Intervention|15-minute video about what to expect before, during, and after your surgery
223939927|NCT05273463|BEHAVIORAL|Classroom-Based Intervention|Virtual 30-minute course with an Orthopedic nurse about what to expect before, during, and after your surgery
223939928|NCT07180680|PROCEDURE|laparoscopic assisted transanal proximal rectosigmoidectomy|using laparoscopy for such procedure in children is unique for this study
223939929|NCT07182383|DRUG|Bempedoic acid|"180 mg film coated tablet administered individually or as FDC~Component of FDC"
223939930|NCT07182383|DRUG|Ezetimibe|"10 mg tablet administered individually or as FDC~Component of FDC"
223710435|NCT07044349|DRUG|Utidelone capsule 40mg/m2/d BID|40mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223710436|NCT07044349|DRUG|Utidelone capsule 50mg/m2/d BID|50mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223710437|NCT07044349|DRUG|Utidelone capsule 35mg/m2/d BID|35mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223710438|NCT07050784|DEVICE|Hydrogel electrodes|Neurostimulation using standard self-adhesive hydrogel electrodes
223710439|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion A|Neurostimulation with dry polymer-textile electrodes using Skin Lotion A
223710440|NCT07050784|DEVICE|Dry textile electrodes with gel pads attached to the electrode|Neurostimulation with dry textile electrodes with gel pads attached to the electrode
223710441|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion B|Neurostimulation with dry polymer-textile electrodes with Skin Lotion B
223710442|NCT07050784|DEVICE|Dry polymer-textile electrodes with Skin Lotion C|Neurostimulation with dry polymer-textile electrodes using Skin Lotion C
223710443|NCT07049159|BIOLOGICAL|ShigETEC vaccine|The ShigETEC vaccine will be administered orally 4 times at 3-day intervals as a bacterial suspension in a volume of 30 mL per dose (target to contain 5x10\^10 CFU)
223710444|NCT07049159|OTHER|Placebo|Eligible participants will be randomly assigned in a 1:1 ratio to receive either ShigETEC 5x10\^10 colony forming units (CFU) or placebo. Participants will receive their assigned treatment on Days 1, 4, 7, and 10.
223710445|NCT07049159|BIOLOGICAL|Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU|In the challenge stage all participants will receive 1 oral dose of Shigella flexneri 2457T at a dose of 1.5x10\^3 CFU.
223710446|NCT07049315|DEVICE|Mandibular Advancement Device|A custom-made intraoral appliance designed to reposition the mandible forward during sleep. The device increases the upper airway space by maintaining the lower jaw in a protruded position, aiming to reduce airway collapse and decrease nocturnal gastroesophageal reflux. It is fabricated from heat-cured acrylic based on individual dental impressions and bite registrations taken in a protruded mandibular position.
223710447|NCT07049315|DEVICE|Lower Oral Device Without Mandibular Advancement|A lower jaw oral appliance made of heat-cured acrylic, fabricated from standard dental impressions and bite registration in habitual occlusion. This device does not reposition the mandible but provides posterior dental disocclusion. It is also used in patients with obstructive sleep apnea and serves as an active comparator to evaluate the specific impact of mandibular advancement on nocturnal gastroesophageal reflux.
223710448|NCT06705868|OTHER|Diet-Time-restricted eating (TRE)|Ad libitum time-restricted scheme with a further time-restriction on fruit and vegetable consumption in participants with MASLD
223710449|NCT06705868|OTHER|Lifestyle Management|The SoC intervention refers to an adaptation of a healthier lifestyle in elements that have to do with weight management, adopting healthier dietary habits, alcohol intake reduction, increase physical activity levels, in people diagnosed with MASLD.
223710450|NCT07045077|BEHAVIORAL|AI Chatbot-Assisted Case-Based Learning|Participants in this intervention used a conversational AI chatbot integrated into a case-based learning activity focused on Parkinson's disease. The chatbot simulated a virtual client and responded to student questions in natural language. Students used the chatbot to gather occupational history, clarify symptoms, and explore intervention planning options during a structured 90-minute session.
223710451|NCT07045077|BEHAVIORAL|Traditional Case-Based Learning with Standard Materials|Participants in this intervention completed the same Parkinson's disease case analysis using only traditional educational materials, such as lecture notes, textbooks, and class handouts. No digital or AI-based tool was used. The session was instructor-guided and lasted 90 minutes, during which students worked collaboratively to assess the case and develop intervention plans.
223710452|NCT07047794|OTHER|Assessment|Children with thoracic hyperkyphosis between the ages of 7 and 14 who meet the inclusion criteria will be included in this study, which was conducted to examine the scapular position and its relationships with upper extremity joint range of motion, strength and performance in children with thoracic hyperkyphosis.
223710453|NCT07049627|OTHER|Total Neoadjuvant Therapy (TNT)|Patients included in this retrospective cohort received total neoadjuvant therapy (TNT), consisting of systemic chemotherapy and radiotherapy, followed by curative-intent surgery. No experimental interventions were applied. The analysis focused on evaluating clinical, inflammatory, nutritional, and sarcopenia-based predictors of pathological response.
223710454|NCT07052565|DRUG|Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis|A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-6.0 x10\^5 CART cells/kg）
223710455|NCT07054957|OTHER|Handheld fan|Group using hand fans
223710456|NCT07054957|OTHER|Control Group|pre-test, mid-test and post-test will be administered.
223710457|NCT07055126|OTHER|Individualised dietary counselling, coaching and resource provision around healthy eating for young children|Study participants randomised to receive the intervention will receive nutrition education support, through individualised dietary counselling, coaching and resource provision around healthy eating, with a particular focus on incorporating fresh meat and vegetables into a healthy, sustainable and safe diet for young children. Those in the control group will not receive this individualised nutrition education and supports.
223710458|NCT07053748|RADIATION|Trimodality Bladder-preserving Therapy|High-risk NMIBC patients who have a strong desire to preserve their bladder actively choose to receive Trimodality Bladder-preserving Therapy instead of radical resection.
223710459|NCT07055386|DRUG|GZR102|Administered SC
223710460|NCT07055386|DRUG|GZR18|Administered SC
223939931|NCT07182383|DRUG|Rosuvastatin|"20 mg film coated tablet administered individually or as FDC~Component of FDC"
223893883|NCT05598203|BEHAVIORAL|Operative group of nutrition education|The intervention will be carried out with operational nutritional education groups. Four meetings will be held, each meeting lasting one hour, weekly or fortnightly (according to the availability of the patient). The following foods proposed foods: Meeting 1 = education on classification labels and proposed foods proposed foods (education on classification labels and substitution of Brazilian foods), in this guide meeting the proposal is processed or ultra-processed by an in natura food or minimally processed; Meeting 2 = assembly of the healthy dish (food portions, food index and glycemic load, food clothes), the proposal in this meeting is the assembly of the complete dish in the meals eaten throughout the day; and Encounter 3 = hunger and satiety (aiming to increase the perception of hunger and satiety signals), encounter as a task to be accomplished; Encounter 4 = strengthening change, barriers and difficulties in maintaining habits based on the transtheoretical model of change.
223893884|NCT06404931|PROCEDURE|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus matrix reinforcement and sacrospinous fixation with Anchorsure® device
223893885|NCT06404931|PROCEDURE|Vaginal hysterectomy plus anterior colporrhaphy|Vaginal hysterectomy plus anterior colporrhaphy
223893886|NCT06404931|PROCEDURE|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device|Vaginal hysterectomy plus sacrospinous fixation with Anchorsure® device
223893887|NCT03351504|OTHER|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
223893888|NCT04873401|BEHAVIORAL|Chain-referral|"In the chain-referral intervention, a discrete number of seeds will be recruited from the community partners, trained and incentivized to recruit and refer members of their social networks to receive COVID-19 testing. The peer recruiters are paid for each suvcessful and eligible recruit who enrolls to be tested. Those individuals are then themselves trained to recruit peers from their social networks to receive COVID-19 testing. This is repeated over a period of 4-6 months."
223893889|NCT04873401|BEHAVIORAL|Credible Messenger|In the credible messenger intervention, peers noted to be popular and socially influential individuals with lived experience will be trained to engage within community settings and areas to encourage community members to receive COVID-19 testing at the community partnering agencies. Peers will recruit community members over a period of 4-6 months.
223893890|NCT05178316|DRUG|JZP150|Oral administration of JZP150 once daily in the morning
223893891|NCT05178316|DRUG|Placebo|Oral administration of placebo once daily in the morning
223893892|NCT05384119|DRUG|TTI-101|Oral tablet
223893893|NCT05384119|DRUG|Palbociclib|Oral capsule
223893894|NCT05384119|DRUG|Aromatase inhibitor (AI)|Oral tablet
223893895|NCT05384119|DRUG|fulvestrant|Oral tablet
223893896|NCT05384119|DRUG|ribociclib|Oral tablet
223893897|NCT03457142|BIOLOGICAL|Abatacept|Given IV and SC
223893898|NCT03457142|DRUG|Dexamethasone|Given PO
223893899|NCT03457142|DRUG|Ixazomib Citrate|Given PO
223893900|NCT03457142|OTHER|Laboratory Biomarker Analysis|Correlative studies
223893901|NCT05963711|OTHER|chlorhexidine gluconate 4%|"In case BV associated bacteria will be identified (using molecular sequencing) in male samples, decolonization attempt will be conducted, using a daily wash for 5 days with chlorhexidine gluconate 4%. Following decolonization attempt, male participants will undergo re- sampling, to assess for microbiome changes.~In case there is no change in microbial composition, partners will be instructed to repeat decolonization protocol, and apply a 2 cm diameter volume of 2% clindamycin cream topically to the head of the penis and upper shaft (under the foreskin if uncircumcised) twice daily for seven days following repeated decolonization. Re-sampling will follow."
223893902|NCT06183892|DRUG|Tacrolimus Sustained-release Capsules|"Immediate-release tacrolimus for at least 3 months after liver transplantation, and then convert to tacrolimus sustained-release capsules at a ratio of 1:1 to 1:1.2; Take the medicine once a day on an empty stomach in the morning.~(The specific medication plan is decided by the clinician according to the actual situation)"
223893903|NCT06031402|PROCEDURE|Endoscopy|Endoscopy
223893904|NCT05935618|BEHAVIORAL|ACT-ING program ( Activity-based skill- and strength training to improve ingestion)|The intervention is based on a client-centered Occupational therapy task-oriented approach, in which real objects are employed in a realistic context. The intervention uses the effortful swallowing in combination with advancing steps of liquid and food items as resistive forces to challenge the swallow in a safe environment during eating and drinking activities. Progression is realized based on pre-determined progression rules to ensure the right challenges in combination with safety (Hansen et al, 2023).
223893905|NCT06002932|PROCEDURE|Procedure: planed 2-stent strategy|Procedure: planed 2-stent strategy
223893906|NCT06002932|PROCEDURE|Procedure: provisional 1-stent plus DEB strategy|Procedure: provisional 1-stent plus DEB strategy
223893907|NCT04448002|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers. AIM2ACT contains the following components: 1) ecological momentary assessment to identify personalized strengths and weaknesses in asthma self-management behaviors; 2) collaborative identification and tracking of goals that help early adolescents to become increasingly independent in managing their asthma; and 3) a suite of engaging skills training videos to help dyads understand how to use AIM2ACT and work together to set asthma self-management goals, develop and achieve the goals articulated in a behavioral contract, and engage in problem-solving communication.
223893908|NCT04448002|BEHAVIORAL|mHealth Attention Control Condition|Dyads in the mHealth attention control condition will not receive personalized asthma management feedback, will not be guided through collaborative identification and tracking of asthma self-management goals, and will not have access to skills training videos. Instead, dyads will receive static educational information on their smartphones about behavioral management techniques they can use to target improving asthma self-management.
223893909|NCT05487859|DRUG|Acarbose Tablets|Acarbose Tablets PO ranging from 25 mg initially to 100 mg as tolerated
223893911|NCT05556473|DRUG|1-(2-[18F]FLUOROETHYL)-L-Tryptophan|Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.
223893912|NCT06524843|OTHER|Analysis|Analysis and review of imaging and clinical data
223893913|NCT02753777|OTHER|Questionnaires|
223893914|NCT01856049|OTHER|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
223710461|NCT07054762|DIETARY_SUPPLEMENT|omega-3 supplements in female athletes|Participants in the experimental group were given four capsules of omega-3 fatty acids with breakfast every day for 8 weeks. Each capsule contains 150 mg of omega-3 fatty acids and has a ratio of 60% EPA and 40% DHA. At the beginning of the study, 24-hour food consumption records were taken 8 times, once a week and at the end. In addition, anthropometric measurements, simplified food appetite questionnaire, muscle pain assessment and muscle endurance test were performed at the beginning and end of the study.
223710462|NCT07054762|DIETARY_SUPPLEMENT|Placebo Group|Participants in the control group were given a placebo containing maltodextrin with breakfast every day for 8 weeks. Each capsule contains 250 mg maltodextrin. At the beginning of the study, 24-hour food consumption records were taken 8 times, once a week and at the end of the study. Additionally, anthropometric measurements, a simplified food appetite questionnaire, muscle pain assessment and muscle endurance test were performed at the beginning and end of the study.
223710463|NCT07055035|DEVICE|Bachmann Bundle Pacing|Implantation of a permanent pacemaker system. The atrial lead (Medtronic 3830 active electrode) is surgically positioned and fixed in the Bachmann bundle region, located at the angle between the superior vena cava and the atrium in the mid-posterior position of the high atrial septum. Successful placement is confirmed by achieving a P-wave width shortening of at least 30ms compared to the preoperative P-wave. The ventricular lead is positioned in the mid-to-lower portion of the ventricular septum. Pacing parameters are measured and confirmed to be good.
223710464|NCT07055035|DEVICE|Right Atrial Appendage Pacing|Implantation of a permanent pacemaker system using the conventional technique. The atrial active electrode is surgically positioned and fixed in the right atrial appendage. The ventricular lead is placed in the mid-to-lower portion of the ventricular septum. Pacing parameters (sensing \> 2.0mV; impedance between 300 to 1000Ω; threshold \< 1.5mV) are confirmed to be good.
223710465|NCT07054164|OTHER|dual-task aerobic exercise|In addition to aerobic training during treadmill walks, participants were given some cognitive tasks and were asked to continue these tasks throughout the exercise.
223710466|NCT07054164|OTHER|aerobic exercise|Aerobic training with a treadmill at medium-high intensity, 3 days a week, for 8 weeks, accompanied by a physiotherapist
223710467|NCT07054034|DRUG|MG-ZG122 Humanized Monoclonal Antibody Injection|MG-ZG122 Humanized Monoclonal Antibody Injection
223710468|NCT07054034|OTHER|Placebo|MG-ZG122 Humanized Monoclonal Antibody Injection Placebo
223710469|NCT07054424|OTHER|Conventional occupation therapy|Standard occupational therapy focused on improving daily functional skills through task-specific training and adaptive techniques.
223710470|NCT07054424|OTHER|stretching exercise|Techniques involving passive or active stretching of muscles to enhance flexibility, reduce spasticity, and prevent contractures.
223710471|NCT07054424|OTHER|rTMS|Non-invasive brain stimulation method using magnetic pulses to modulate cortical excitability and promote neural plasticity.
223710472|NCT07054424|DEVICE|bimanual therapy|A training approach that involves simultaneous use of both hands to enhance coordination and functional hand movements through guided exercises, including device-assisted and robot-assisted therapy
223710473|NCT07055412|DRUG|Y-3 for injection（40mg）|"The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd."
223710474|NCT07052994|DRUG|Revumenib|Given by IV
223710475|NCT07052994|DRUG|Cytrabine|Given by IV
223710476|NCT07052994|DRUG|Daunorubicin|Given by IV
223710477|NCT07053553|OTHER|Education|It was planned to provide bed bath training to inpatients because 90.5% of the caregivers of the patients in the experimental group wanted to receive bed bath training.
223710478|NCT07054398|DRUG|Isotretinoin|"* Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons.~* Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris."
223710479|NCT07054359|DIAGNOSTIC_TEST|HBsAg RDT Women|HBsAg will be screened using finger-stick capillary blood during the ANC visit, simultaneously with the HIV test
223710480|NCT07054359|DRUG|Treatment by TDF if HBcrAg RDT positive|300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
223710481|NCT07054359|DRUG|Treatment by TDF|300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
223710482|NCT07054359|OTHER|Social sciences component|"The social sciences component only in Cambodia and Ivory Coast. 3 key sub-studies: i) a socio-economic and behavioral study ii) a health economic evaluation study, and iii) a health policy study.~A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers"
223710483|NCT07054359|DIAGNOSTIC_TEST|HBsAg RDT Infants|At 9 months, all infants will be tested for HBsAg; HBsAg-positive infants will undergo HBV DNA testing, and DBS will be collected for biobank storage.
223710484|NCT07054905|DEVICE|HiCardi wearable ECG|A chest-attached, single-lead wearable ECG device used to collect real-time ECG data from hemodialysis patients. The device records ECG waveforms during dialysis sessions and transmits the data to a secure cloud platform. This non-invasive tool is used to analyze T-wave morphology for early detection of hyperkalemia in patients with chronic kidney disease.
223710485|NCT07055009|DIAGNOSTIC_TEST|Targeted long-read HLA sequencing|Genetic study
223710486|NCT07055009|OTHER|RNA extraction|Nanostring technology, Seattle
223710487|NCT07055009|OTHER|Full Skin examination|Skin and mucosa examination
223893915|NCT04060654|DRUG|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
223893916|NCT03572985|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
223893917|NCT03572985|OTHER|Car-following test|Driving with simulator program for DCV measurement
223893918|NCT03572985|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
223893919|NCT03707951|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
223893920|NCT03707951|DRUG|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
223893921|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
223893922|NCT03906695|DRUG|ASTX727|oral decitabine 5mg + cedazuridine
223893923|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
223893924|NCT03906695|DRUG|ASTX727|oral decitabine 20mg + cedazuridine
223893925|NCT03906695|DRUG|ASTX727|oral decitabine 10mg + cedazuridine
223893926|NCT06537323|DRUG|Femoral nerve block with0.25% bupivacaine guided by ultrasound.|Femoral nerve block with0.25% bupivacaine guided by ultrasound.
223893927|NCT06537323|DRUG|PENG block with0.25% bupivacaine guided by ultrasound.|PENG block with0.25% bupivacaine guided by ultrasound.
223893928|NCT06537323|DRUG|Preoperative IV fentanyl 100microgram|Preoperative IV fentanyl 100microgram
223893929|NCT04887129|DIAGNOSTIC_TEST|COVID-19 RT-PCR test|"Participating individuals (students and employees) will be tested for COVID-19 (RT-PCR) using a specimen collected using a mid-turbinate swab.~This asymptomatic testing regime starts on or after (if scheduling testing requires this to begin on a different day) enrollment and is repeated every 5-14 days for up to 16 months . Anyone testing positive is followed up as described below for symptomatic individuals.~Those presenting with symptoms will be also tested for COVID-19 (RT-PCR). Those with negative test results will return to the asymptomatic testing protocol.~Students who test positive are retested then 3 days until two negative tests. Employees who test positive also be tested every 3 days until two negative tests."
223893930|NCT04887129|OTHER|COVID-19 Vaccine Education Campaign|Utilizing information from focus groups, the investigators will develop and deploy an educational campaign aimed at improving vaccine hesitancy and student health
223893931|NCT05057429|DEVICE|Procellera Bioelectric Dressing|Procellera is single layer, broad-spectrum antimicrobial wound dressing. Embedded in the dressing are microcell batteries made of elemental silver and zinc applied in a dot-matrix pattern. The bioelectric dressing will be applied to surgical site wound with a hydrogel.
223893932|NCT05057429|OTHER|Standard Gauze Dressing|Standard of care non-adherent gauze dressing will be applied to surgical site with vaseline.
223893933|NCT06064721|OTHER|Buerger-Allen Exercise|Buerger-Allen exercise will be taught by researcher and perform by patient at home twice a day
223893934|NCT05150197|DEVICE|VisuALL|Virtual Reality Visual Field Device
223893935|NCT05150197|DEVICE|Humphrey Visual Field|Standard of care Visual Field test
223893936|NCT05624944|DRUG|TS-142 5 mg|Single-dose of 5 mg of TS-142
223893937|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous KR|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous KR femoral component"
223893938|NCT06337123|DEVICE|Device: Physica TT TIbial Plate and Physica Porous PS|"Devices: Physica TT Tibial Plate and Physica Porous KR femoral component~Data collection of population that underwent total knee arthroplasty with Physica TT Tibial Plate and Physica Porous PS femoral component"
223893939|NCT04793841|OTHER|self-sampling kits for STI testing in laboratory|participants in both groups will receive self-sampling kits and deliver the collected samples to laboratory for testing
223893940|NCT02038140|DEVICE|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
223893941|NCT05823363|DRUG|Exparel with Bubivacaine|10ml Exparel mixed with10ml bupivicaine in vaginal cuff
223893942|NCT05823363|DRUG|Bupivacaine only|20ml of Bubivacaine in the vaginal cugg
223893943|NCT05710211|BIOLOGICAL|Clonal architecture determination|"Biological:~* Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing~* Secondary outcome: transcriptomic study by RNA-sequencing"
223893944|NCT03481881|DRUG|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
223893945|NCT04911452|DEVICE|Calmer|Once randomized, infants in the Calmer group will receive treatment for a minimum cumulative total of 3 hours/day during periods when the infant may be too ill to be held or when parents do not wish to hold their infant or are not present. Calmer does not replicate a parent's contact and so the minimum exposure has been tripled. No upper limit of Calmer use will be set. Each day, the research and/or bedside nurse will record the heart and respiratory rates for a two-minute period. The one-minute average will be used to program Calmer for each infant that day to better simulate day-to-day changes in infant-parent contact. The Neonatal Intensive Care Unit (NICU) research nurse will also train the parents/caregivers to self-measure their resting heart and breathing rates so that if they are away from the NICU for more than one day, these values can be sent to the research/ bedside nurse by phone.
223893946|NCT06019533|COMBINATION_PRODUCT|LVDS|Levonorgestrel Vaginal Delivery System
223893947|NCT05939453|OTHER|Sham Light|Sham treatment will be provided from a light box at a distance of at least 70cm but no greater than 90cm.
223893948|NCT05939453|OTHER|Bright Light Therapy|Bright Light Therapy will be provided using light box with an artificial full spectrum lamp at a distance of at least 70cm but no greater than 90cm.
223893949|NCT05454137|BEHAVIORAL|Shared medical appointment|Shared medical appointment
223893950|NCT04635098|DRUG|dexmedetomidine|All participants will be randomly assigned to receive either dexmedetomidine or saline
223893951|NCT04635098|DRUG|saline|All participants will be randomly assigned to receive either dexmedetomidine or saline
223893952|NCT01333969|PROCEDURE|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
223893953|NCT04898777|PROCEDURE|Biliary drainage|Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.
223893954|NCT03332940|DRUG|Tc 99M Sulfur Colloid|Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
223893955|NCT03332940|DRUG|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
223893956|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).
223893957|NCT02625857|BIOLOGICAL|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
223893958|NCT06538961|OTHER|Blood samples: Main Study group|the collection of blood samples at specified time points.
223893959|NCT06538961|OTHER|Data Collection|Donor and Recipient's clinical information including clinical history, demographic characteristics labs, and imaging.
223893960|NCT06538961|OTHER|Urine Sample- Main Study group|-Post-transplant monthly urine sample collection for 6 months in 10-18% of subjects
223893961|NCT06538961|OTHER|Urine sample- Sub-study group|\- Post-transplant monthly urine sample collection for 6 months in all subjects
223893962|NCT06538961|OTHER|Blood sample: Sub-study group|Monthly blood sample collection for 6 months
223893963|NCT04986605|DEVICE|Extracorporeal Photopheresis (ECP)|Drug Intervention using a medical device. The ECP device is already licensed in Canada. License No.7703. ECP treatment, using the drug UVADEX, will be given on 2 consecutive days every 4 weeks for a total of 26 treatment days (48 weeks).
223893964|NCT04986605|DRUG|UVADEX|The phase II aspect of the study refers to the drug, methoxsalen. Methoxsalen is being used off label from the currently approved indications in the monograph. The study is proposing to use methoxsalen in combination with with extracorporeal photopheresis for the treatment of diffuse cutaneous systemic sclerosis. Treatment will be given in addition to standard of care medications for SSc.
223893965|NCT06084572|OTHER|Questionnaires|FSSG \& BEDQ
223893966|NCT05294588|DRUG|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
223893967|NCT05294588|DRUG|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
223893968|NCT05294588|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
223893969|NCT05294588|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
223893970|NCT05294588|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive 2 doses of the 4CMenB vaccine, 0.5 mL intramuscularly
223893971|NCT05294588|BIOLOGICAL|Influenza Vaccine|All participants will receive the quadrivalent influenza vaccine, 0.5 mL intramuscularly.
223893972|NCT05294588|BIOLOGICAL|Tetanus-diptheria Vaccine|All participants will receive the Td vaccine, 0.5 mL intramuscularly.
223893973|NCT05179655|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents (ERITA)|The ERITA intervention as add-on to TAU consists of 11 weeks, manualized online therapy based on the methods of Cognitive Behavioral Therapy (CBT), Dialectical Behavior Therapy (DBT), and Acceptance and Commitment Therapy (ACT) adapted for youth. The ERITA content consists of psychoeducation, emotion recognition, awareness training and theory of emotion regulation, including acceptance and validation skills.
223893974|NCT05179655|OTHER|Treatment as usual|Within Mental Health Services in Denmark child and adolescent psychiatrists provide specialized treatment for young psychiatric patients as outpatient services. In this trial the control intervention is treatment as usual (TAU) and consists of clinical assessment and treatment for patient's current primary psychiatric condition. TAU encounters a variety of clinical treatment and assessment offers, however, all within the field of expertise in child and adolescent psychiatry; out-patient care may consist of treatment for OCD, eating disorders, psychoses or affective disorders. TAU may consist of pharmacological treatment, Family-Based Treatment (FBT), Cognitive Behavioral Therapy (CBT), supportive counselling and/or psychoeducation.
223893975|NCT06206811|DRUG|OD-07656|innate immune modulator
223893976|NCT03310905|PROCEDURE|Abdominal Wall Transplant with another solid organ transplant|Transplant of abdominal wall in combination with another solid organ transplant.
223893977|NCT03310905|PROCEDURE|Abdominal Wall Transplant alone|Abdominal Wall Transplant alone
223893978|NCT06273241|OTHER|food intake|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition as the control condition. The two intervention arms will test the effect of different meals on berberine kinetics. A total amount of 12 blood samples at defined time points (baseline; 1; 2; 3; 4; 5; 6; 7; 8; 24 h) will be taken. For glucose and insulin measurements, blood samples will be obtained at 4 h, 5 h and 6 h .
223893979|NCT05387551|DEVICE|CGM|Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
223893980|NCT05514847|DRUG|Aspirin 81Mg Ec Tab|81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
223893981|NCT05514847|DRUG|Aspirin 162Mg Ec Tab|162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
223893982|NCT05800366|DRUG|Glofitamab|human IgG1-bispecific antibody, via IV infusion
223893983|NCT05800366|DRUG|Polatuzumab|an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion
223893984|NCT05800366|DRUG|Rituximab|Per standard care, via IV infusion
223893985|NCT05800366|DRUG|Doxorubicin Hydrochloride|Per standard care, via IV infusion
223893986|NCT05800366|DRUG|Cyclophosphamide|Per standard care, via IV infusion
223893987|NCT05800366|DRUG|Prednisone|Per standard care, orally
223893988|NCT05260255|DRUG|vitamin D2 ( calciferol )|add on vitamin D2( calciferol ) 40,000 IU/wk ( 2 cap) for 12 weeks
223893989|NCT05260255|DRUG|Placebo|add on placebo ( 2 cap ) for 12 weeks
223893990|NCT04781543|DRUG|HZN-825 BID|300 mg oral tablets BID
223893991|NCT04781543|DRUG|Placebo|Placebo BID
223710488|NCT07054788|OTHER|Flexibility Exercise|"Participants will perform calf muscle stretching exercises. The participant will be asked to keep the knee of the stretched leg straight with the heel flat on the ground, slightly bend the front knee, and push the hips toward a wall.~The exercise will be done in 2 sets of 3 repetitions, every repetition for 30 seconds and a ten-second rest, with a one-minute rest between sets"
223710489|NCT07054788|OTHER|Mulligan mobilization with movement|The Mulligan mobilization techniques involve talar glide and fibular glide. Talar glide involves manually stabilizing the patient's talus and leg with anteroposterior direction pressure, while fibular glide involves a pain-free sustained anterior to posterior, slightly superior, and lateral glide of the distal fibula. The patient is then asked to plantar-flex, invert the foot, and perform overpressure. The technique is performed during ankle dorsiflexion in a closed kinetic chain.
223710490|NCT07054788|OTHER|Kinesiology Taping|"The length of tape is calculated using a formula: B = A + (XA ∗ 0.35), where A is the tape's length, X is the pretension, 0.35 is the 35% tension, and B is the muscle's length from origin to insertion. In this study, 50% pretension was used, and A was added to the tails. Fibular taping is applied immediately after the MWM to improve positional alignment, wrapping around the distal tibia and applying Mueller tape in the same direction. Talar taping involves wrapping Mueller tape from the talus downward and posterior to the calcaneus while holding the ankle in slight dorsiflexion."
223893992|NCT04781543|DRUG|HZN-825 QD|300 mg oral tablets QD
223893993|NCT05176951|DRUG|Treprostinil Palmitil|Oral inhalation using a capsule-based dry powder inhaler device.
223893994|NCT05176951|DRUG|Placebo|Oral inhalation using a capsule-based dry powder inhaler device.
223893995|NCT02852694|DRUG|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
223893996|NCT02852694|DRUG|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients \< 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
223893997|NCT02852694|DRUG|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
223893998|NCT06455631|PROCEDURE|Facilitated Tucking, Oral Breast Milk , Kangaroo Care|Before data collection, the researcher will inform families of newborns meeting the sample criteria about the study and obtain written consent from participating parents. Newborn and parent information will be recorded. Procedures will occur between 08:00 and 16:00, with one researcher, two nurses, and a preterm newborn present during tape removal. Tape removal will be done by the same nurse. Physiological and behavioral responses will be recorded before, during, and after tape removal. Breast milk will be orally administered during tape removal, with the amount adjusted based on gestational age. Measurements will be taken at specified time points, including heart rate, respiratory rate, oxygen saturation, and PIPP-R score. These procedures will also apply to the control group. PIPP-R scores will be recorded by two evaluators based on video recordings.
223893999|NCT06836882|PROCEDURE|Selective caries removal|Selective caries removal followed by cavity disinfection with NaOCl \& CHX in each test group \& no cavity disinfection in control group.
223894000|NCT06836882|PROCEDURE|Selective caries removal with NaOCl|elective caries removal followed by cavity disinfection with NaOCl
223894001|NCT06836882|PROCEDURE|Selective caries removal with CHX|elective caries removal followed by cavity disinfection with CHX
223894002|NCT05887609|DRUG|Mirvetuximab Soravtansine|is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridine-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB).
223894003|NCT05887609|DRUG|Olaparib|Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair.
223894004|NCT05920980|DRUG|lidocaine|Patients in the lidocaine groups, lidocaine 1.5mg/kg/h was continuously infused (using ideal body weight) during the whole procedure, postoperative analgesia pump with lidocaine (lidocaine 50mg/kg, sufentanil 2ug/kg, glassetron 12mg), diluted to 200ml with saline until 72h after surgery. Blood samples will be collected from some patients in the lidocaine group for the measurement of lidocaine plasma concentration.
223894005|NCT05920980|DRUG|Placebo|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 mL.
223894006|NCT03148678|BEHAVIORAL|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
223894007|NCT03148678|OTHER|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
223894008|NCT03148678|OTHER|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
223894009|NCT03148678|BEHAVIORAL|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
223894010|NCT06838520|OTHER|Bone health assessment|Assessments of physical function, DXA scan
223894011|NCT06836817|OTHER|1-Laryngyscopic examination 2-Acoustic analysis|"1. History taking.~2. voice sample by recording (in sustained vowel \|a\| )~3. Auditory Perceptual Assessment (APA): (Kotby et al., 1986)~4. Laryngyscopic examination:~   Patients will taken to a room with a tower on which the 8.5 mm 70 rigid laryngoscope (KARL STORZ - endoscope) (Tele pack X LED).~5. Acoustic analysis: The voice sample will be subjected to computerized acoustic analysis using Multidimensional voice program software(MDVP)."
223710491|NCT07054788|OTHER|Placebo tape|"The formula for cutting tape length is B = A + (XA ∗ 0.35), where A represents the tape's length, X is the pretension, 0.35 is the 35% tension, and B is the muscle's length from origin to insertion. In this study, 50% pretension was used, and A was added to the tails' length. The tape application involves two steps: from below the medial calcaneus to the medial aspect of the lower leg, and from below the lateral malleolus to the lateral aspect."
223710492|NCT07053488|BIOLOGICAL|Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver|Donor liver tissue is perfused outside the body with a CRISPR-Cas9 RNP complex targeting HLA-A, HLA-B, and CIITA, to create a hypoimmunogenic graft. After confirming successful gene knockout, the liver is transplanted into the patient following standard surgical techniques. Post-operative care includes routine immunosuppressive therapy with planned adjustments based on the patient's tolerance and evidence of graft immunogenicity.
223710493|NCT07053215|DEVICE|Argon-Helium Cryoablation|Procedure performed within 7 days before the first dose of PD-1 inhibitor. CT-guided insertion of cryoprobes into the target tumor. Two freeze-thaw cycles: rapid freeze to -135°C to -145°C for 15-20 minutes, followed by thawing.
223710494|NCT07053215|DRUG|Camrelizumab|200 mg intravenously every 3 weeks for 4 cycles.
223710495|NCT07053215|DRUG|Platinum-based doublet chemotherapy|"* Non-squamous NSCLC: Pemetrexed (500 mg/m² IV on day 1) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Squamous NSCLC: Gemcitabine (1250 mg/m² IV on days 1 and 8) plus Carboplatin (AUC 5 mg/mL•min IV on day 1) of each 3-week cycle.~* Administered for 4 cycles."
223710496|NCT07053371|OTHER|Peanut birth ball|The 45 x 80 cm peanut birth ball was positioned between the woman's legs during the first stage's active phase, starting at 4 cm cervical dilatation for the intervention group
223710497|NCT07054307|DRUG|MRG003|MRG003 (2.3 mg/kg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.
223710498|NCT07054307|DRUG|HX008|HX008 (200 mg, IV, Q3W). Treatment continues until disease progression, intolerable toxicity, withdrawal, death, or sponsor termination.
223710499|NCT07054541|PROCEDURE|Ultrasound-guided intervention with assistance of specialized instruments|After detailed evaluation, patients randomized in this group will undergo percutaneous ASD closure under pure ultrasound guidance in the entire process with assistance of specialized instruments
223710500|NCT07054541|PROCEDURE|fluoroscopy-guided intervention|After detailed evaluation, patients randomized in this group will undergo percutaneous ASD closure under fluoroscopic guidance in the entire process
223710501|NCT07053241|DEVICE|Game-App-KNEE|"* In the outpatient clinic phase of the study, the purpose of the study will be explained to individuals who meet the inclusion criteria.~* The mobile-compatible web-based gamified application created for individuals included in the intervention group will be downloaded to patients' phones in the outpatient clinic phase and information will be provided on how to use the application, and the training will be repeated if they have questions.~* Individuals in the intervention group will be able to access both the education module in PDF format and the game module containing the gamified education program for three months in the application.~* In-app reminder messages will be sent to individuals to actively use the application. (We missed you today, warrior, where are you, let's finish this job, etc.)~* Whether the application is actively logged in, how long it is in the application, and the level of success in the game will be monitored by the researcher from the administrator panel."
223710502|NCT07053241|OTHER|Control group (standart care)|Description: In the outpatient clinic phase of the study, the purpose of the study will be explained to individuals who meet the inclusion criteria. -An application will be installed on the phones of individuals included in the control group during the outpatient clinic phase. -In the first information phase, individuals will be registered to the system with their username and password by the researcher via their smartphones or tablets and will be allowed to enter the application. Considering that the participant may forget their username and password, a 'forgot my password' button will be added. -Individuals in the control group will only be able to access the training module in PDF format for three months.
223710503|NCT07053761|DRUG|five - flavor sophora flavescens enteric - coated capsules plus glutamine and warm - water sitz baths|Experimental group: If patients have rectal reactions, RTOG radiation - therapy toxicity grades \>2, plus FOB (+) or fecal calprotectin Fc\>150μg/g, they'll take five - flavor sophora flavescens enteric - coated capsules (4 capsules thrice daily for 8 weeks), plus glutamine and warm - water sitz baths.
223710504|NCT07053761|DRUG|glutamine and warm - water sitz baths|If patients have rectal reactions, RTOG radiation - therapy toxicity grades \>2, plus FOB (+) or fecal calprotectin Fc\>150μg/g, they'll use only glutamine and warm - water sitz baths.
223710505|NCT07055061|BEHAVIORAL|ISO Principle Music Intervention|Participants will receive music playlists designed according to the ISO principle, which involves matching the participant's current emotional state and gradually transitioning to music reflecting a desired mood. The intervention aims to reduce stress and support emotional regulation by guiding affective resonance through music progression.
223710506|NCT07055061|BEHAVIORAL|Compensation Principle Music Intervention|Participants will receive music playlists based on the compensation principle, where the music contrasts the participant's current emotional state by directly presenting tracks aligned with the desired emotional outcome (e.g., calm music for stressed mood). This approach seeks to counteract stress and shift affective states through musical contrast.
223710507|NCT07054827|OTHER|Hemodialysis|The participants receive hemodialysis for 4 hours, 3 times per week
223710508|NCT07054827|OTHER|Intradialytic resistive exercise|"The participants will receive intradialytic resistive exercise for 12 weeks (3 sessions/ week).~Duration: 30 minutes during the first 2 hours of each dialysis session in a recumbent position or seated position.~Time of session: The program starts with a warm-up phase which is 3:5 minutes in the form of light aerobic and stretching exercises for big muscles and ends with a cooling down phase which is 3:5 in the form of light aerobic exercise.~The resistance exercises include exercises for the big muscles of only the Lower Limbs (LL) muscles of single and multiple-joint which are:1- Knee extensors, 2- Knee flexors, 3- Hip flexors, 4- Hip abductors and adductors. using sandbags of different weights. Sandbag weights are placed on the distal third of the tibia for LL exercises.~Intensity: On the Borg's Scale of Perceived Exertion, which will be measured every 5 minutes during exercise."
223894012|NCT02791204|DEVICE|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
223894013|NCT02791204|DEVICE|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
223710509|NCT07054827|OTHER|Intradialytic aerobic exercise|"Patients with chronic kidney disease will receive an intradialytic aerobic exercise for 12 weeks (3 sessions/ week).~Duration: 30 minutes during the first 2 hours of each dialysis session using a stationary bicycle ergometer in a supine position or seated position.~Time of session: The warming up and the cooling down phase consists of 5:10 minutes of slow Pedaling. the main exercise phase consisted of 20 minutes of cycling.~Intensity: The use of the Borg's Scale of Perceived Exertion (RPE) scale enables the intensity of the exercise to be adapted According to the tolerance of each patient.~The use of the RPE scale enables the intensity of the exercise to be adapted According to the tolerance of each patient, the aim was to obtain between 11 light And 14 somewhat hard."
223710510|NCT07054476|OTHER|Intermittent Enteral Nutrition|"Intermittent Enteral Nutrition (IE):~The intervention involves intermittent enteral nutrition using a diabetic-specific enteral formula, administered in 5 separate sessions daily with scheduled breaks between feedings. Each feeding session is followed by a break (1-2 hours). Energy needs are calculated based on the ESPEN guideline (25 kcal/kg/day). This protocol is designed to assess the effects of intermittent feeding in critically ill diabetic patients."
223710511|NCT07054476|OTHER|Continuous Enteral Nutrition (CE)|Continuous Enteral Nutrition (CE): The intervention involves continuous enteral nutrition provided via a diabetic-specific enteral formula, administered 24 hours a day with 1-hour breaks between feeding sessions. The feeding rate starts at 40cc per hour and is gradually increased based on tolerance. Energy needs are calculated using the ESPEN guideline (25 kcal/kg/day).
223710512|NCT07054593|DEVICE|CapScan|Gut sampling capsule
223710513|NCT07053995|PROCEDURE|Vaginal cleaning|Before giving incision for C-section surgery, vaginal cleaning was done with 50cc diluted antiseptic solution as a single push.
223710514|NCT07053995|OTHER|Non vaginal cleansing|Routine abdominal scrubbing was carried out before incision. No vaginal cleaning was done before incision.
223710515|NCT07053462|BIOLOGICAL|Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney|The donor kidney is treated outside the body with CRISPR-Cas9 ribonucleoprotein complexes targeting the genes HLA-A, HLA-B, and CIITA. This genetic intervention knocks out HLA-A/B on donor cells and disables expression of HLA-DR, -DQ, -DP by disrupting CIITA (essential for class II antigen presentation). The goal is to create a transplanted organ with greatly reduced immunogenic surface proteins. (This is a one-time genetic manipulation applied to the donor organ prior to transplantation; no direct gene therapy is given to the patient's own cells.)
223710516|NCT07053462|PROCEDURE|Kidney Transplantation with Standard Care|After gene editing, the donor kidney is implanted into the recipient in a surgical transplant procedure. Standard peri-operative care is provided. All patients will receive standard immunosuppressive therapy post-transplant (such as tacrolimus, mycophenolate, and prednisone, per center protocol) to prevent rejection, though the regimen may be tailored based on the edited graft's expected lower immunogenicity. Patients will be hospitalized for transplant and monitored closely during the immediate post-op period, then followed in clinic frequently for transplant aftercare.
223710517|NCT07052890|DIETARY_SUPPLEMENT|Curcumin, vitamin d and green tea extract|"A combination of the following ingrediants per 4 capsules:~CurcuWin® 1000mg - of which 200mg Curcuminoids~Green Tea Extract 400mg - (0.1-0.5% caffeine)~Vitamin D₃ 50 µg 2000IU"
223710518|NCT07052890|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Placebo - identical capsules containing inert color matched power
223710519|NCT06321757|DEVICE|Percutaneous Coronary Intervention with DCB and DAPT|"* Patients with PCI (DCB) + standard DAPT standard dual antiplatelet therapy (DAPT)~* Patients with PCI (DCB) + short DAPT"
223710520|NCT04997304|COMBINATION_PRODUCT|AirDuo Digihaler|"Participants will receive the AirDuo® Digihaler™ at a dose that is equivalent to the participants' current inhaled therapy dose. Most participants will likely require the high dose inhaler: 232/14 device. This medication will be administered twice daily. The study and treatment will last 1 year.~Participants will also use a home spirometry device and smart device application (app) will be used to track medication usage and allow users to self-assess their respiratory symptoms on a daily basis."
223710521|NCT04997304|COMBINATION_PRODUCT|ProAir Digihaler|Participants will receive the ProAir® Digihaler™ 90mcg at a dose that is equivalent to the participants' current inhaled therapy dose. Most participants will likely require the high dose inhaler: 232/14 device. The ProAir® Digihaler™ will be utilized up to six times per day as needed for acute asthma symptoms. The study and treatment will last 1 year.
223710522|NCT07055347|OTHER|Comprehensive Home-based Cardiac Rehabilitation Program for Postoperative Congenital Heart Disease Patients and Their Caregivers|Intervention Description: For children, provide age-appropriate rehab manuals with pictures and texts to encourage participation. Include gentle physical activities, breathing and stretching exercises. For caregivers, offer detailed manuals and checklists. Organize training. Manage drugs with personalized guidance. Provide health education for both via manuals and video consultations. Focus on mental and physical health with support and activities. Regular phone follow-ups ensure nursing continuity. Multidisciplinary team offers professional support through video consultations and referrals.
223710523|NCT07052955|OTHER|The Normal Riddles Book|"The distribution of the participating children to the experimental and control groups will be carried out by simple random sampling method. Children included in the Normal Riddle Book group will be introduced to a book containing general, entertaining riddles that are not related to health during the pre-circumcision period.~The book will be given to the children approximately 1 hour before the circumcision operation and the children will be allowed to read the puzzles, solve them or interact with the researcher/nurse. The application period is planned as approximately 20-30 minutes.~The children's fear, anxiety and pain levels will be measured before and after the application. During the application process, the children's attention level, interest in the book and general behavior will be observed and recorded."
223894014|NCT06838494|BEHAVIORAL|IVR-CST (Immersive Virtual Reality Cognitive Stimulation Therapy)|IVR-CST involves 14 sessions of cognitive stimulation therapy conducted twice a week in a virtual reality environment. Each session lasts approximately 45 minutes and utilizes head-mounted displays (HMDs) to immerse participants in engaging, themed activities. The therapy aims to enhance cognitive function and social interaction through interactive and stimulating virtual experiences tailored for individuals with mild cognitive impairment (MCI).
223939932|NCT07189052|OTHER|Virtual Reality Rehabilitation|A virtual reality-based rehabilitation program including breathing, stretching, cervical range-of-motion, and posture-strengthening tasks delivered in a gamified seaside environment using a head-mounted VR display. Sessions will last 20 minutes, performed twice per week for 8 weeks (16 sessions total) under supervision.
223894015|NCT06838494|BEHAVIORAL|Intervention Name: Conventional CST (Cognitive Stimulation Therapy)|Conventional CST consists of 14 sessions of cognitive stimulation therapy conducted twice a week, each lasting about 45 minutes. In this arm, participants engage in group activities using physical materials, such as photos, pictures, and real objects, rather than virtual reality. The therapy focuses on providing cognitive stimulation through discussions and activities designed to improve cognitive function and social engagement among individuals with mild cognitive impairment (MCI).
223894016|NCT06788080|DRUG|BioRBC|Autologous biotin-labeled RBCs will be transfused to study participants
223894017|NCT05056194|DRUG|Valiloxybate|XW10172 MR Granules for Oral Suspension
223894018|NCT05056194|OTHER|Placebo|Placebo Granules for Oral Suspension
223894019|NCT03875716|RADIATION|Radiation therapy|Radiation therapy
223894020|NCT06838143|BIOLOGICAL|Ilaris|Prospective observational study. There is no treatment allocation.
223894021|NCT04660955|OTHER|No Intervention - Observational study with MRI|90 minute MRI of the knees
223894022|NCT01639859|OTHER|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
223894023|NCT06834555|DIAGNOSTIC_TEST|Mobile phone thermal imaging|"The patient was supine, and the lower limb was naturally relaxed on a 20cm high stent to drain blood from the vein. The leg temperature was lowered with a cold towel at 2-6 ° C for five minutes. A tourniquet was applied to the upper 1/3 of the thigh and the level of the fibula of the lower leg with enough pressure to block the great saphenous vein and the small saphenous vein. The patient is then asked to stand. The smart phone and the supporting thermal imaging system were used to conduct continuous real-time imaging and take photos of the front, bilateral and rear of the thigh and lower leg. The hot spot of rapid rewarming of the lower limb was marked with a marker."
223894024|NCT06837012|DRUG|Duloxetine - low dose|Only patients who underwent single bilateral Total knee arthroplasty and WITHOUT central sensitisation were evaluated
223894025|NCT06837012|DRUG|Placebo|starch capsules identical in appearance and weight to the duloxetine capsules
223894026|NCT06783153|DRUG|Rifaximin 550 MG|Oral Rifaximin 550mg twice daily from the start of pelvic radiotherapy, with or without chemotherapy, as a preventive measure, and continuing every day until the end of the treatment up to 5 to seven weeks.
223894027|NCT06783153|DRUG|Standard Care Chemoradiation|Patients will receive standard chemotherapy and/or radiation
223894028|NCT06782646|DRUG|Berberine|Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.
223894029|NCT06782646|DRUG|Placebo|Participants will take placebo tablets, a look-alike substance that contains no drug, (500 mg orally twice a day) for 12 weeks.
223710524|NCT07052955|OTHER|Health Riddles Group|"The children included in this group will be presented with the Health Riddles Book, which contains health information and is prepared to reduce fear and anxiety before the circumcision.~The book will be given to the children approximately 1 hour before the circumcision procedure and the children will be allowed to read the riddles or interact with the researcher/nurse. The application time is planned to be 20-30 minutes. Before and after the application, the children's fear, anxiety and pain levels will be measured with the Introductory Information Form, Child Fear Scale, Child Anxiety Scale-State and Wong-Baker Face Pain Scale.~The data obtained from the health riddles group will be compared with the data obtained from the normal riddle and control groups and the unique effect of the riddles containing health information on fear, anxiety and pain will be analyzed."
223710525|NCT06615895|BEHAVIORAL|Telehealth home activity|Several course activities with diverse sensory modalities are provided a week. Caregivers or caretakers need to help children participate in the course content and implement relevant suggestions at least 3-5 times a week for six weeks. The research will be conducted on an online platform. Course announcements, reminders and confirmation of work execution, through caregivers\&#39; feedback records, urge caregivers to engage in parent-child games related to sensory integration and integrated into life at home. Such high-frequency, short-term sensory activities will be adapted to the equipment available at home. It will mainly focus on movement planning, bilateral integration/crossing the midline, vestibular system , visual perception, visual-motor integration, eye movements, core strength activities and Activities focused on balance ability.
223894030|NCT06248190|OTHER|ENHANCE intervention (health systems)|The intervention tools include a consolidated clinical decision support tool, health education posters, waiting room talks, medication list for treatment literacy and a patient health diary. Training session are delivered at all intervention sites and include 1 facility team session to introduce the ENHANCE study to the whole team; 3 clinical sessions for nurses and doctors; 2 sessions for community health workers and health promoters; Maintenance sessions to keep the ENHANCE intervention going for at least 12 months
223894031|NCT06651879|DIAGNOSTIC_TEST|techniques of ultrasound examination of the airway|two different techniques of ultrasound. The techniques are the two views and the five views
223894032|NCT05773378|DEVICE|Pessary Intervention|Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 10-week period.
223894033|NCT05773378|DEVICE|Tampon Intervention|Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 10-week period.
223894034|NCT06832254|OTHER|Cryotherapy|The root canals were irrigated with 2 °C saline solution in final irrigation in cryotherapy group.
223894035|NCT06832254|DRUG|Dexamethasone|Each root canal was irrigated with 1 mL dexamethasone solution in final irrigation in dexamethasone group.
223894036|NCT04718675|DRUG|KB-0742|Oral capsules
223894037|NCT06838299|DEVICE|aerobic exercise + inspiratory muscle training|inspiratory muscle training: Inspiratory muscle training at 60% of maximal inspiratory pressure for 30 minutes/ session, 3 days a week, for 3 months Each patient breathes through a separate mouthpiece. The resistance is adjusted at 60% of maximum inspiratory pressure detected from maximum inspiratory pressure meter and is marked on the training device. A single training session consists of five sets, each contains five inspirations with total of twenty five breaths with one minute of recovery between each set. The resistance was adjusted every week to be 60% of the new maximum inspiratory pressure and if it remained the same, the subject continued to train at the level of the previous week Aerobic exercise: by bicycle ergomete 5-minute warm-up before exercise and a 5-minute cool-down following exercise at intensity (40-65%HR max) were carried out each time. In addition, the exercise was performed in the first half of the dialysis session over a 3 months period for 3 sessions a week
223710526|NCT07054736|DRUG|XKH001 Injection|"100 mg quaque 4 weeks dose group: Subjects will receive 1 mL (1 vial) of XKH001 injection (100 mg) and 5 mL (5 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.~300 mg quaque 4 weeks dose group: Subjects will receive 3 mL (3 vials) of XKH001 injection (300 mg) and 3 mL (3 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.~600 mg quaque 4 weeks dose group: Subjects will receive 6 mL (6 vials) of XKH001 injection (600 mg) subcutaneously each time, once every 4 weeks, for a total of 5 times."
223710527|NCT07054736|DRUG|XKH001 Placebo Injection|Subjects will receive 6 mL (6 vials) of placebo injection subcutaneously each time, once every 4 weeks, for a total of 5 times.
223710528|NCT07053033|PROCEDURE|Surgery|Participants will initially undergo craniotomy and surgical resection of lesions or LITT
223710529|NCT07053033|PROCEDURE|LITT|Participants will undergo 4-core stereotactic biopsy and LITT by experienced neurosurgeons with specific expertise.
223710530|NCT07055087|DRUG|Prasinezumab|Prasinezumab 1500 mg monthly infusion
223710531|NCT07055087|DRUG|Sodium Chloride|Saline infusion (0,9 % sodium chloride) monthly infusion
223710532|NCT07053878|PROCEDURE|Non-Surgical Periodontal Therapy (Step 1 & 2)|Comprehensive supra- and sub-gingival instrumentation (scaling, root planing, ultrasonic and manual instruments), following EFP step-1 and step-2 protocols. Includes individualized oral-hygiene instruction and motivation.
223710533|NCT07053878|PROCEDURE|Supragingival Plaque Removal and Polishing|Professional supragingival scaling with ultrasonic tips plus rubber-cup polishing in a single session. Includes the same individualized oral-hygiene instruction and motivation provided to the experimental group.
223710534|NCT07052968|DEVICE|Echocardiography|Echocardiography is the non invasvive interventional assessment and the RHC is the invasive international assessment of the hemodynamics in PH patients with ckd.
223710535|NCT07055178|DEVICE|Virtual reality (VR) guided meditation therapy|Participants will engage in the TRIPP relaxation app on the MetaQuest 3 VR headset.
223710536|NCT07055178|OTHER|Treatment as usual|Participants undergo a standard vasectomy.
223710537|NCT07054671|DIETARY_SUPPLEMENT|Elderberry-Based Functional Beverage|A polyphenol- and anthocyanin-rich beverage derived from Sambucus nigra L., administered once daily for 12 weeks as a dietary supplement.
223710538|NCT07054671|DIETARY_SUPPLEMENT|Placebo Beverage|A placebo beverage that mimics the elderberry drink in color and flavor but contains no polyphenols or bioactive compounds. Consumed once daily for 12 weeks.
223710539|NCT07054437|OTHER|Gross Motor Development Screening Tool|"This intervention is an automated gross motor development screening tool specifically designed for independently walking children aged one to six years old in Taiwan. What sets it apart is its use of artificial intelligence (AI) algorithms to analyze motion data, enabling early identification of potential gross motor developmental delays.~Unlike traditional methods that rely on manual, visual observation and subjective recording by healthcare professionals, this tool aims to significantly reduce assessment time and human resource costs. Furthermore, its automated nature makes it uniquely suited for telemedicine applications, allowing for remote screenings and overcoming geographical barriers to access early intervention services. The tool will be developed and validated against established developmental norms relevant to the Taiwanese population."
223710540|NCT07055022|PROCEDURE|LLLT|Patients in the LLLT group will receive 3 sessions of LLLT treatment with Eye-light device (Espansione Group S.p.A., Bologna, Italy) 7 days before phacoemulsification (D-7), 7 days after phacoemulsification (D+7), and 30 days after phacoemulsification (D+30). Each session will consist of 15 minutes of light treatment using a wavelength of 625±40 nm and maximum power of 10 W (maximal total fluence of 32 J/cm2 ± 20% per session) applied on the periorbital region. The patients will be asked to close their eyes during the session. The chosen parameters are currently used in the clinical practice of the participating surgeons as treatment for DED; moreover, similar values are reported in published studies
223710541|NCT07055022|PROCEDURE|IPL|Patients in the IPL group will receive 3 sessions of IPL treatment with OptiClear device (Alma Lasers GmbH, Nuremberg, Germany) at D-7, D+7, and D+30. Each session will comprise 90 homogenously spaced pulses of light (wavelength of 550-650 nm, pulse time 10,12 or 15 ms, pulse repetition rate 1-2 Hz) using an energy density of 8-12 J/cm2 adjusted to Fitzpatrick skin type according to the manufacturer's recommendations. The treatment will be applied to the lower eyelid region. Ultrasound gel, as well as protective eye patches will be used, and the patients will be asked to close their eyes during the session. The chosen parameters are currently used in the clinical practice of the participating surgeons as treatment for DED; moreover, similar values are reported in published studies
223710542|NCT07053722|RADIATION|NA-TMT|After neoadjuvant therapy, patients choose trimodality therapy (TMT) for bladder preservation over radical cystectomy.
223710543|NCT07055139|BEHAVIORAL|Digital Aftercare|A structured, app-based digital aftercare program designed for patients recovering from distal radius or clavicle fractures. The 12-week program includes weekly video-guided physiotherapy exercises, educational content on fracture healing, pain management guidance, and milestone-based progression. The program replaces in-person physiotherapy and standard clinic follow-up, with patients instructed to follow the app independently. Medical contact is initiated only in case of uncertainty or complications.
223710544|NCT07055139|BEHAVIORAL|Traditional Aftercare|Standard postoperative follow-up care for patients with distal radius or clavicle fractures, consisting of scheduled clinical visits and in-person physiotherapy sessions according to institutional protocols. The treatment includes individual exercise instruction, physiotherapy, and physician-led follow-up at defined intervals during the 12-week rehabilitation period.
223710545|NCT07053735|DRUG|Nimotuzumab and Radiotherapy|"1. nimotuzumab: 200mg, iv, qw, used for 5 weeks.~2. radiotherapy: radiotherapy is performed according to clinical routine;"
223710546|NCT07053839|BEHAVIORAL|Daily Text Reminder|"The intervention, titled AdhasText, involved sending a daily SMS reminder to caregivers, specifically mothers of children with asthma. The message, If you want to stay healthy, you must use your inhaler, was sent at 7:00 p.m. over a 90 days period."
223939933|NCT07189052|OTHER|Conventional Rehabilitation|Standard physiotherapy including diaphragmatic breathing, trapezius stretching, cervical range-of-motion, and posture-strengthening with proprioceptive neuromuscular facilitation. Sessions will last 20 minutes, performed twice per week for 8 weeks (16 sessions total) under supervision.
223939934|NCT03602859|DRUG|Niraparib|Participants will receive oral capsules of niraparib as a unit dosage strength of 100 milligrams (mg)
223527745|NCT03474276|DIETARY_SUPPLEMENT|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
223710547|NCT07054450|COMBINATION_PRODUCT|All patients in the study will be included in rehabilitation program|A total of 110 consecutive participants with previous diagnosed CR lasting more than 3 months will be enrolled in this study. After initial assessment, participants without surgical recommendation, will be included into two groups: Study Group will be received 10 sessions of rehabilitation program and nutraceutical product daily, 3 months, and Control Group will be received 10 sessions of rehabilitation program. The rehabilitation program include physical therapy (electrical muscle stimulation of the neck muscle and upper limb muscles , low-Level Laser Therapy and ultrasound) and kinetic training.
223710548|NCT07054450|DIETARY_SUPPLEMENT|Study Group will receive a nutraceutical product daily, 3 months.|Study Group will receive a nutraceutical product daily, 3 months in addition to the rehabilitation program.
223710549|NCT07055295|BIOLOGICAL|Rabies Vaccine (Serum-free Vero Cell), Freeze-dried|Receiving three doses of rabies vaccine rabies vaccine manufactured by Sinovac using a three-dose PrEP schedule
223710550|NCT07055295|BIOLOGICAL|Verorab®|Receiving three doses of marketed rabies vaccine manufactured by Sanofi using the three-dose PrEP schedule
223710551|NCT07053020|DRUG|Cytarabine|Given by intravenous adminstration
223710552|NCT07053020|DRUG|Oral Cladribine|Given Orally
223710553|NCT07053176|DRUG|0.5% Lidocaine|0.5% lidocaine injection will be administered in the paravertebral intramuscular region with 12 mm, 30 G needle from C2 to C7 bilaterally
223710554|NCT07053176|DRUG|Saline Solution (NaCl 0,9%)|saline solution will be administered bilaterally in the paravertebral intamuscular region from C2 to C7 with 12 mm 30 G needle
223710555|NCT06603623|DRUG|BHV-2100|BHV-2100 75mg
223710556|NCT06603623|DRUG|BHV-2100|BHV-2100 150 mg
223710557|NCT06603623|DRUG|Placebo|matching placebo
223710558|NCT06753214|OTHER|Telemedicine-Based Education|Intervention through telemedicine
223710559|NCT06753214|OTHER|Standard Care (in control arm)|Sham comparator through telemedicine
223710560|NCT06734975|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.
223710561|NCT06734975|DRUG|Superior laryngeal nerve block - Placebo (saline)|Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.
223710562|NCT03196726|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
223710563|NCT03196726|BEHAVIORAL|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
223710564|NCT01453361|BIOLOGICAL|Vigil™ Vaccine|
223710565|NCT06649604|DEVICE|Vibration Anesthesia Device|The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
223710566|NCT06649604|PROCEDURE|Panretinal Photocoagulation|Laser treatment for diabetic retinopathy done in a standard fashion
223710567|NCT06809608|DRUG|RO7795081|A single dose will be administered orally per study period (see arm descriptions).
223710568|NCT06809608|DRUG|Itraconazole|Administered orally (see arm description).
223710569|NCT06809608|DRUG|Gemfibrozil|Administered orally (see arm description).
223710570|NCT06809608|DRUG|Cyclosporine|A single dose will be administered orally per study period (see arm descriptions).
223710571|NCT06897735|DRUG|Afatinib Dimaleat|printed capsule containing 40 mg afatinib dimaleate
223710572|NCT06897735|BIOLOGICAL|inhalation of afatinib dimaleate|inhalation stable form of afatinib dimaleate at an equivalent therapeutic dose in a single-use maintenance-free ultrasonic inhaler with controlled frequency and number of inhalations
223710573|NCT04175483|OTHER|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
223710574|NCT06926608|BEHAVIORAL|Actívatexto|Actívatexto is a mobile intervention that promotes both smoking cessation and physical activity. Actívatexto integrates four components: 1) a text messaging program that promotes both smoking cessation and physical activity, 2) wearable devices to monitor physical activity, 3) smoking cessation pharmacotherapy (i.e., nicotine replacement therapies), and 4) an online dashboard where the research team manages participants' incoming and outgoing data from both the text messaging program and wearable devices.
223710575|NCT06926608|BEHAVIORAL|Decídetexto|Decídetexto is a mobile intervention that solely promotes smoking cessation. Decídetexto integrates three components: 1) a text messaging program that solely promotes smoking cessation, 2) smoking cessation pharmacotherapy (i.e., nicotine replacement therapies), and 3) an online dashboard where the research team manages participants' incoming and outgoing data from the text messaging program.
223710576|NCT06907329|DIETARY_SUPPLEMENT|NMN|NMN SR tablets(1000mg/tablets) , 1 tablet daily before breakfast
223710577|NCT06907329|DIETARY_SUPPLEMENT|Placebo|Matching Placebo (tablets) once daily before breakfast
223710578|NCT01798004|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223710579|NCT01798004|DRUG|Busulfan|Given IV
223710580|NCT01798004|DRUG|Cisplatin|Given IV
223710581|NCT01798004|DRUG|Cyclophosphamide|Given IV
223710582|NCT01798004|DRUG|Doxorubicin Hydrochloride|Given IV
223710583|NCT01798004|DRUG|Etoposide|Given IV
223710584|NCT01798004|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223710585|NCT01798004|BIOLOGICAL|Filgrastim|Given SC or IV
223710586|NCT01798004|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223710587|NCT01798004|DRUG|Melphalan|Given IV
223527746|NCT04256850|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Teaches acceptance, mindfulness, and values-based skills
223710588|NCT01798004|DRUG|Mesna|Given IV
223710589|NCT01798004|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223710590|NCT01798004|OTHER|Pharmacological Study|Correlative studies
223710591|NCT01798004|DRUG|Topotecan Hydrochloride|Given IV
223710592|NCT01798004|DRUG|Vincristine Sulfate|Given IV
223710593|NCT02823431|DRUG|lidocaine gel|
223710594|NCT02823431|OTHER|Plain aqueous gel|
223710595|NCT00544466|DRUG|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
223710596|NCT00544466|DRUG|melphalan|140 mg/m2 day -2 prior to transplant
223710597|NCT00544466|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
223710598|NCT00544466|RADIATION|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
223710599|NCT02323113|DRUG|TAK-659|TAK-659 tablets.
223710600|NCT04412408|DRUG|Sintilimab|"Sintilimab is administered every 21 days until the disease progresses or treatment is terminated due to unacceptable toxicity. For patients with clinical and radiologic benefits, treatment can last up to 2 years.~Dose: 2 mg / kg intravenously for 60 min (± 10 min window)"
223710601|NCT05960799|DEVICE|CON - Contiplex C™ (CC)|This is a catheter used for peripherical nerve block that is inserted at the same time that the needle is being introduced. When the target is achieved, the needle is retired.
223710602|NCT05960799|DEVICE|CTN - Contiplex|This is the traditional catheter used in this centre for peripheric nerve block. In this catheter the needle is introduced first. When the target is achieved the catheter is then introduced throw the needle and after that the needle is retired.
223710603|NCT05061732|DRUG|Rabeprazole|20mg bid
223710604|NCT05061732|DRUG|Bismuth potassium citrate|0.6g bid
223710605|NCT05061732|DRUG|Metronidazole|0.4g qid
223710606|NCT05061732|DRUG|Clarithromycin|0.5g bid
223710607|NCT05061732|DRUG|Levofloxacin|0.5g qd
223710608|NCT05061732|DRUG|Amoxicillin|1g tid
223710609|NCT05061732|DRUG|Metronidazole|0.4g tid
223710610|NCT05061732|DRUG|Doxycycline|0.1g bid
223710611|NCT05061732|DRUG|Tetracycline|0.5g qid
223710612|NCT02541682|OTHER|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
223710613|NCT04091594|DEVICE|Flexible orthotic|Participants will receive the SIAFO to wear
223710614|NCT04091594|DEVICE|Standard orthotic|Participants will received the standard AFO to wear
223710615|NCT03315624|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
223710616|NCT03947320|DRUG|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
223710617|NCT02320383|BIOLOGICAL|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
223710618|NCT02320383|DRUG|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
223710619|NCT01663532|DRUG|Aripiprazole IM Depot|
223710620|NCT01663532|DRUG|Placebo|Matching Placebo
223710621|NCT02387398|PROCEDURE|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
223710622|NCT02421432|PROCEDURE|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
223710623|NCT05731778|DRUG|Stannous Fluoride Toothpaste|0.454% stannous fluoride toothpaste
223527747|NCT04256850|BEHAVIORAL|Self-Regulation (SR)|Teaches monitoring and reinforcement strategies designed to improve motivation and adherence to positive weight loss behavioral prescriptions.
223527748|NCT01190319|OTHER|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
223527749|NCT01190319|OTHER|Placebo|Placebo beverage, 8 weeks
223527750|NCT00629928|DRUG|Esomeprazole|20mg oral capsule daily
223527751|NCT00629928|DRUG|Esomeprazole|40mg oral capsule daily
223527752|NCT00629928|DRUG|Placebo|
223710624|NCT05731778|DRUG|Colgate fluoride toothpaste|0.76 % Sodium MonoFluorophosphate (MFP)
223710625|NCT03848117|OTHER|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
223710626|NCT03848117|OTHER|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
223710627|NCT00025493|DRUG|docetaxel|
223710628|NCT00393393|DRUG|intra-articular injection of Hylan G-F 20|
223710629|NCT02622308|DEVICE|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
223894038|NCT06838299|DEVICE|resistance exercise + inspiratory muscle training|"Resistance exercise:~Dynamic closed- and open-chain resistance exercises performed by the patients quadriceps and hamstrings muscles . Patients started at 50% of their initial one-repetition maximum (1-RM) with 5 repetitions for each exercise and later progressed to three sets of 8 repetitions at 70% of their 1-RM according to the patient Borg scale of exertion; training loads were increased when patients could comfortably complete three sets with good form.~inspiratory muscle training: Inspiratory muscle training at 60% of maximal inspiratory pressure for 30 minutes/ session, 3 days a week, for 3 months Each patient breathes through a separate mouthpiece. The resistance is adjusted at 60% of maximum inspiratory pressure detected from maximum inspiratory pressure meter and is marked on the training device. A single training session consists of five sets, each contains five inspirations with total of twenty five breaths with one minute of recovery between each set."
223894039|NCT06838299|OTHER|control group|there is no exercise , patients do assessment pre and post 3 months and follow up
223894040|NCT05243342|DRUG|XmAb24306|XmAb24306 will be given via intravenous (IV) infusion
223894041|NCT05243342|DRUG|Daratumumab|Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
223527753|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
223527754|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
223527755|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
223527756|NCT01425814|DRUG|LAS100977|Dry powder inhalation,Once daily, single dose
223527757|NCT01425814|DRUG|Reference|Dry powder inhalation (capsule),single dose
223527758|NCT01425814|DRUG|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
223527759|NCT05617261|OTHER|Conscious sedation|Conscious sedation is a combination of medications to help you relax (a sedative, for example nitrous gas) and to block out pain (commonly known as freezing, for example lidocaine).
223527760|NCT01179230|OTHER|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
223527761|NCT01179230|OTHER|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
223527762|NCT03889652|DIAGNOSTIC_TEST|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
223527763|NCT00144326|DRUG|Tiotropium Bromide|
223527764|NCT00144326|DRUG|Placebo|
223527765|NCT05586295|OTHER|Placebo|Microcrystalline α-cellulose, shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, palm wax.
223527766|NCT05586295|OTHER|EX plus|Furanthiamine hydrochloride (vitamin B1), pyridoxine hydrochloride (vitamin B6), cyanocobalamin (vitamin B12), DL-alpha-tocopheryl acetate 50% (DL-alpha-tocopheryl acetate, sucrose, caprylic acid) Sodium alkenyl succinate starch, corn starch, water, sodium aluminosilicate), shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, γ-oryzanol (γ-oryzanol, rice bran powder ), sucrose, silica, inositol, taurine, talc, oxidized starch, gelatin, magnesium stearate, calcium panpolyate, microcrystalline α-cellulose, riboflavin (vitamin B2), palmar wax.
223527767|NCT06204783|OTHER|Pressure volume (PV) loop measurement|Pressure volume (PV) loop measurement using a conductance catheter
223527768|NCT03386162|DRUG|Alpelisib|fulvestrant (500 mg intramuscular \[as two 5 mL injections\] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
223527769|NCT03386162|DRUG|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
223527770|NCT00995787|DRUG|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
223527771|NCT00995787|DRUG|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
223527772|NCT04768153|BIOLOGICAL|Serology|Serological diagnosis of COVID-19 in patients with cancer from a sample of cancer patients, at 3 and 6 months after implementation of confinement in France
223527773|NCT00064857|DRUG|Pycnogenol|
223527774|NCT04445103|DIAGNOSTIC_TEST|Assessment of cardiac function|Echocardiographic examination and assessment of cardiac biomakers
223527775|NCT01999530|DRUG|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
223527776|NCT06164054|DEVICE|Virtual Reality Rehabilitation System|Participants of the experimental group will undergo treatment with Virtual Reality, both IVR and HB. The intervention will consist of 12 sessions lasting about 1 hour each and carried out with a frequency of three days per week within four weeks. Before starting the rehabilitation, arm illusion with the Handbox is inducted to explore the ability of the patients to perceive the virtual arm as their own. During this task, patients sit on a chair with the injured arm inside the Handbox and are invited to perform slow movements with the hand, such as moving the fingers one at a time and moving the wrist up and down. Moreover, they are invited to keep their attention to the virtual arm project on the screen that follows their natural movements. The arm illusion lasts 3 minutes, and the embodiment questionnaire is administered. Then, the treatment starts with IVR and HB sessions, which are counterbalanced to avoid the learning effect
223527777|NCT06164054|BEHAVIORAL|Traditional therapy|Participants randomly assigned to the control group will receive rehabilitation treatment as per usual clinical practice. Specifically, patients will be directed to rehabilitation facilities according to standard clinical rehabilitation pathways. They will be assigned to a physiotherapist who will administer the rehabilitation treatment for the upper limb impairment. Patients in the control group will receive the same amount of rehabilitation for the recovery of upper limb impairment as the treatment group, which means 3 physiotherapy sessions lasting 1 hour 3 times a week for 4 weeks.
223527778|NCT00565747|DEVICE|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
223527779|NCT00565747|DEVICE|Control culture|The same standard culture medium, but without any additions (ready-to-use)
223939935|NCT03602859|DRUG|Dostarlimab (TSR-042)|Participants will receive 500 mg dostarlimab on day 1 every 3 weeks from cycle 2 to 6 followed by 1000mg of dostarlimab on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
223710630|NCT01481727|DEVICE|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (\>18mmHg) for at least six hours, nocturnal ventilation.
223710631|NCT01481727|DEVICE|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
223710632|NCT05239923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
223710633|NCT01633853|DRUG|Vitamin D2|Treatment with Vit D2.
223710634|NCT01633853|DRUG|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
223710635|NCT02785432|DEVICE|Sham low level laser|Sham laser will be administered using the same time and contact exposure as delivered for the active group, but without any energy delivered.
223710636|NCT02785432|DEVICE|Active low level laser|Active treatment will be delivered using the time, contact, and energy exposures described in the arm description.
223710637|NCT05855252|OTHER|No intervention|No intervention
223710638|NCT01002027|BEHAVIORAL|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
223710639|NCT00030121|DRUG|recombinant human atrial natriuretic polypeptide|
223710640|NCT03159767|DEVICE|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
223710641|NCT00656383|OTHER|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
223710642|NCT00656383|OTHER|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
223710643|NCT00897260|DRUG|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~* Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~* Fludarabine dose adjustment:~  70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
223710644|NCT00897260|RADIATION|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
223710645|NCT00897260|PROCEDURE|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
223710646|NCT01101087|DEVICE|Taurolock|
223710647|NCT01101087|OTHER|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
223710648|NCT05578391|BIOLOGICAL|Convalescent plasma|Admistration of one unit of convalescent plasma
223710649|NCT00756756|DRUG|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
223710650|NCT00756756|DRUG|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
223710651|NCT01032005|OTHER|double fortified salt|Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
223710652|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
223710653|NCT02619552|DRUG|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
223710654|NCT02619552|DRUG|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
223710655|NCT03486548|DRUG|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
223710656|NCT03486548|DRUG|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
223710657|NCT03486548|DEVICE|Ultrasound|ultrasound
223710658|NCT00871260|DRUG|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
223939936|NCT03602859|DRUG|Standard of care|Participants will receive SOC that includes paclitaxel 175 milligrams per square meter (mg/m\^2) on day 1 every 21 days + carboplatin area under the curve (AUC) of 5 to 6 milligrams per milliliter per minute (mg/mL/min) on day 1 every 21 days +/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days for a total of 15 months.
223710659|NCT03539081|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
223710660|NCT03539081|OTHER|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
223710661|NCT03539081|OTHER|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
223710662|NCT03539081|OTHER|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
223710663|NCT03539081|OTHER|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
223710664|NCT03539081|OTHER|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
223710665|NCT03539081|OTHER|Anthropometric Measurements|Height and weight will be obtained.
223710666|NCT03539081|BEHAVIORAL|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
223710667|NCT03539081|BEHAVIORAL|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
223710668|NCT04170816|DEVICE|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
223710669|NCT00542555|DRUG|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
223710670|NCT00542555|DRUG|Naproxcinod 375 mg|
223710671|NCT00542555|DRUG|Naproxen|
223710672|NCT00542555|DRUG|Naproxcinod 750 mg|
223710673|NCT02055716|DRUG|Sulforadex|
223710674|NCT02055716|DRUG|alpha-cyclodextrin|
223710675|NCT03579732|DRUG|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. \< 150 mg daily
223710676|NCT03579732|OTHER|No drug|Non-consumers
223710677|NCT06803914|PROCEDURE|Biomechanical analysis|Biomechanical assessment is performed using a set of sensors (Qualisys Sports Marker Set - functional assessment, already in use at the Clinique du Sport) as well as 3D optoelectronic cameras and force and pressure platforms. These sensors are placed at various points on both lower limbs (hip, knee, ankle) and provide data in different planes (sagittal, frontal, transverse), as well as a comparison of both sides.
223710678|NCT00258401|DIETARY_SUPPLEMENT|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
223710679|NCT00258401|PROCEDURE|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
223710680|NCT00258401|PROCEDURE|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
223710681|NCT01776892|DRUG|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
223894042|NCT04977947|BEHAVIORAL|Healthy Eating for My Infant|The intervention targets problem solving to overcome barriers, behavioral rehearsal and practice of healthy behaviors, promoting readiness to change, goal setting, self-monitoring, and behavioral tracking. Two standard treatment modules will be provided to each family by a study interventionist focusing on infant nutritional requirements, responsive feeding, and mealtime behaviors. Two additional treatment modules will be selected to address the unique needs articulated by each family (e.g., food insecurity, eating healthy on a limited income, emotional eating, engaging other caregivers, maternal mental health). Modules will consider the influence of maternal trauma history and mental health on feeding and eating behavior. The intervention also includes two peer counselor-led sessions during which families can discuss implementation of recommendations and barriers to change with a member of their community who can problem solve and support change.
223894043|NCT05207085|DRUG|Valbenazine Oral Capsule|Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
223894044|NCT05207085|OTHER|Placebo Oral capsule|Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
223894045|NCT06778785|BEHAVIORAL|Digital Intervention|game-based digital intervention app
223710682|NCT01776892|PROCEDURE|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
223710683|NCT02474459|DEVICE|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
223710684|NCT02474459|OTHER|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
223710685|NCT00987220|DRUG|Placebo|Oral
223710686|NCT00987220|DRUG|donepezil (Aricept)|5mg oral
223710687|NCT00990236|DRUG|Enoxaparin dose adjusted Lovenox based on TEG|Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R \>/= 1.0 min and \</= 2.0 min - no change; delta-R \> 2.0 min - decrease dose by 10 mg BID.
223710688|NCT00990236|DRUG|Enoxaparin 30 mg BID|Enoxaparin dose of 30 mg twice a day without any adjustments
223710689|NCT01673867|BIOLOGICAL|Nivolumab|
223710690|NCT01673867|DRUG|Docetaxel|
223894046|NCT06778785|BEHAVIORAL|Health Education|traditional health education app
223527780|NCT03580954|DEVICE|Transcranial Magnetic Stimulation|Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
223527781|NCT00800644|PROCEDURE|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
223710691|NCT04918433|PROCEDURE|Regional anaesthesia|Regional anaesthesia for sternotomy incision for congenital cardiac surgery
223710692|NCT03075540|BEHAVIORAL|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
223710693|NCT01410032|PROCEDURE|Plate fixation|Reconstruction plate
223710694|NCT01410032|PROCEDURE|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
223710695|NCT05021991|DRUG|100 mg PRAX-944|Once daily oral treatment with titration
223710696|NCT05021991|DRUG|60 mg PRAX-944|Once daily oral treatment with titration
223710697|NCT05021991|DRUG|Placebo|Once daily oral treatment
223710698|NCT05021991|DRUG|Flexibly dosed 20 mg to 100 mg PRAX-944|Once daily oral treatment
223710699|NCT04043260|DEVICE|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
223710700|NCT00186030|BEHAVIORAL|HIV Skills-based Prevention|
223710701|NCT02048891|DRUG|GnRH agonist trigger|
223710702|NCT02048891|DRUG|hCG trigger|
223710703|NCT02957877|DRUG|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
223710704|NCT02957877|DRUG|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
223710705|NCT01045720|DRUG|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
223710706|NCT01045720|DRUG|Placebo|Placebo (starch)
223710707|NCT02172924|BIOLOGICAL|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
223710708|NCT02172924|BIOLOGICAL|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
223710709|NCT01827605|OTHER|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
223710710|NCT01827605|DRUG|BEAM|"BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc"
223710711|NCT02345681|DRUG|Furosemide|
223710712|NCT05132920|DRUG|Dexamethasone|3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
223710713|NCT05132920|DRUG|Placebo|3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
223710714|NCT05226715|OTHER|chiropractic manual therapy|high velocity low amplitude thrust into a human joint
223710715|NCT01897844|DRUG|ITF2984 (100, 2000, 3000 mcg bid)|
223710716|NCT01897844|DRUG|Placebo|
223710717|NCT00000409|PROCEDURE|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
223710718|NCT00000409|OTHER|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
223710719|NCT00000409|PROCEDURE|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
223710720|NCT00000409|PROCEDURE|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
223710721|NCT02621697|OTHER|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
223710722|NCT02621697|OTHER|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
223710723|NCT01136148|BEHAVIORAL|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
223894047|NCT06778785|OTHER|Personalization Algorithm|a proprietary algorithm that adaptively adjust the treatment module and parameters to personalize the treatment regime
223894048|NCT05547347|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223710724|NCT01337700|DRUG|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
223710725|NCT01337700|DRUG|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
223710726|NCT00799383|DRUG|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
223710727|NCT00799383|OTHER|Placebo|
223710728|NCT05667844|BEHAVIORAL|interoceptive mind-body exercise|A interoceptive mind-body exercise program in a patient with Generalized Anxiety Disorder and Major Depressive Disorder based on a Multidimensional Assessment of Interoceptive Awareness. Each session of the body-mind intervention lasts 80 minutes and is supervised by physical education professionals. The intervention is divided in 4 parts, that are: Preparatory phase (reception) the subjects will be welcomed through subjective analyzes of the researcher; Initial phase (preliminares) Mindfulness, grounding, sensory stimulation and joint warm-up exercises are performed; main phase (exercises) stretching, mobility, posture and balance exercises are performed with full attention and listening after each exercise; Final phase (relaxation) breathing exercises, stretching exercises, body scanning and relaxation are performed.
223710729|NCT01178957|OTHER|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
223710730|NCT03119831|DRUG|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
223710731|NCT03119831|DRUG|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
223710732|NCT03119831|DRUG|C31G|Rinsing with 15ml for one minute twice daily for 14 days
223710733|NCT00000869|DRUG|Nevirapine|
223710734|NCT03598283|DEVICE|Ultrasound/transient elastography|The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
223710735|NCT02767843|DEVICE|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
223894049|NCT05547347|PROCEDURE|Mammogram|Undergo a mammogram
223710736|NCT01270516|DRUG|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
223710737|NCT01270516|DRUG|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
223710738|NCT01270516|DRUG|Saline|Control
223710739|NCT02265068|DRUG|Ticagrelor|Treatment of ACS patients with Ticagrelor
223710740|NCT02840097|DRUG|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
223710741|NCT02840097|DRUG|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
223710742|NCT04360629|DRUG|Tranexamic Acid|Tranexamic Acid will be given through central vein
223710743|NCT04360629|DRUG|normal saline|normal saline will be given through central vein
223710744|NCT01758562|DEVICE|Caphosol|
223710745|NCT04214769|DIAGNOSTIC_TEST|Audiometry and tympanometry, vHIT, VEMP, ENG|Diagnostic tests
223894050|NCT05547347|PROCEDURE|Ultrasound|Undergo a breast ultrasound
223894051|NCT05547347|PROCEDURE|Ultrasound-Guided Biopsy|Undergo a percutaneous ultrasound-guided breast clip placement
223894052|NCT05547347|DEVICE|Twinkle marker|Patients undergo percutaneous ultrasound-guided breast clip placement with a conventional biopsy marker (if not already present) and a twinkling marker on study.
223894053|NCT06564493|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223894054|NCT06564493|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223894055|NCT06564493|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
223710746|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)|This is dose level 0 (de-escalation).
223710747|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg)|This is dose level 1, the starting dose.
223710748|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg)|This is dose level 2.
223710749|NCT05976555|BIOLOGICAL|BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg)|This is dose level 3.
223710750|NCT05976555|BIOLOGICAL|Maximum tolerated dose|The maximum tolerated dose is yet to be determined.
223710751|NCT02665520|PROCEDURE|liposuction for retrieval of own stem cells from fat cells|
223710752|NCT05831020|OTHER|VAC and bolster dressing|"Bolster dressing- Moist bulky cotton gauze dressing and wrapped with cotton bandage.~Vacuum assisted closure (VAC) dressing- A fenestrated tube placed between two sheets of sterilized foam secured to the surrounding skin using adhesive dressing (OPSITE)."
223710753|NCT04091854|DRUG|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
223710754|NCT00764283|DEVICE|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
223710755|NCT00764283|DEVICE|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
223710756|NCT00764283|DEVICE|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
223894056|NCT06830811|RADIATION|EOSedge imaging|Full body or full spine image
223894057|NCT06836271|DRUG|Isopropyl Alcohol|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 70% Isopropyl alcohol every time it came into contact with the rectal mucosa.
223894058|NCT06836271|DRUG|Povidine-iodine|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with povidine-iodine every time it came into contact with the rectal mucosa.
223710757|NCT05751460|OTHER|Straight leg raise|Diagnostic test, tool for \*g\*
223710758|NCT02161081|PROCEDURE|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
223710759|NCT05497154|BEHAVIORAL|Training Arm|The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
223710760|NCT00530244|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
223710761|NCT00530244|DIETARY_SUPPLEMENT|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
223710762|NCT02794038|DEVICE|Soberlink Cellular Device|BAC breath analyzer
223710763|NCT02794038|DEVICE|BACtrack S80 Pro|BAC breath analyzer
223710764|NCT00969917|DRUG|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
223710765|NCT06164977|PROCEDURE|Percutaneous coronary intervention.|Revascularization of chronic total coronary occlusion.
223710766|NCT02165215|DRUG|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
223710767|NCT02165215|DRUG|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
223710768|NCT02576002|DRUG|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
223710769|NCT02314702|DEVICE|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
223710770|NCT00653744|DRUG|Rosuvastatin|
223710771|NCT00653744|DRUG|Atorvastatin|
223710772|NCT06218693|BEHAVIORAL|VIA Family|A family-based, multi-component, individual-tailored intervention based on case-management.
223710773|NCT06218693|BEHAVIORAL|Treatment As Usual (TAU)|care as usual
223710774|NCT00401596|DRUG|Xolair (omalizumab)|
223710775|NCT00855569|DEVICE|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
223710776|NCT03222336|BEHAVIORAL|Family pedigree and data collection|"1. Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~2. Collect and analyze medical history, genetic and biochemical assessment data"
223710777|NCT03772691|PROCEDURE|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
223710778|NCT03772691|PROCEDURE|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
223710779|NCT06312605|PROCEDURE|Injectable applied vitamin C|Surgical gingival depigmentation is done for all participants, after then they receive injectable vitamin C
223710780|NCT06312605|PROCEDURE|Topical applied Vitamin C|Surgical gingival depigmentation is done for all participants, after then they are instructed to apply topical vitamin C
223710781|NCT06312605|PROCEDURE|Surgical depigmentation only|Surgical gingival depigmentation only without any drug
223710782|NCT05256953|PROCEDURE|Erector spina plane block + general anesthesia|"Bilateral-injection ultrasound-guided bilateral erector spinae plane block~Pre-operatively, with the patient in the sitting position, 20ml 0.25% bupivacaine will be administered between the T9 spinous process and the erector spinae muscles with the guidance of an ultrasound probe placed on a parasagittal plane. The same procedure was applied bilaterally.~Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
223710783|NCT05256953|PROCEDURE|Only general anesthesia|"Intraoperative analgesia: After anesthesia induction tenoxicam 20 mg IV and 30 min. before the end of the surgery paracetamol (1gr) iv was applied.~Postoperative analgesia: IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose.~Rescue analgesia was provided with iv tramadol 30 mg boluses whenever the Visual analog scale pain score \>3, (max doses 300 mg/day)."
223710784|NCT05278208|DRUG|LUTATHERA® (Lutetium Lu 177 dotatate)|Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)
223710785|NCT00612040|DRUG|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
223710786|NCT00612040|DRUG|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
223710787|NCT00612040|DRUG|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
223894059|NCT06836271|COMBINATION_PRODUCT|formaldehit|During repeated procedures while transrectal biopsy was being taken, the biopsy needle was disinfected with 10% formaldehit every time it came into contact with the rectal mucosa.
223894060|NCT06836271|PROCEDURE|Standard BP control|No disinfection method is used in routine use in repetitive procedures when taking a transrectal biopsy.
223894061|NCT03436290|BEHAVIORAL|Palliative Care Intervention|These patients will receive the palliative care intervention.
223710788|NCT00612040|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
223710789|NCT06959368|DRUG|Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg|Participants will receive the respective drug regimens twice daily. The Vonoprazan triple therapy arm will administer Vonoprazan 20 mg, Amoxicillin 1 g, and Clarithromycin 500 mg twice daily. The Standard triple therapy arm will administer Esomeprazole 40 mg, Amoxicillin 1 g, and Clarithromycin 500 mg twice daily.
223894062|NCT06833021|OTHER|Transcriptomic Analysis|FFPE tissue blocks from patients diagnosed with CAC, including low- and high-grade dysplasia and adenocarcinoma, obtained from pathological archives will be used. RNA will be extracted and analyzed using RT-PCR to detect and quantify HBx transcripts, with Sanger sequencing employed for further validation of the results.
223894063|NCT06833021|OTHER|Transcriptomic Analysis|RNA will be extracted and analyzed using RT-PCR to detect and quantify HBx transcripts, with Sanger sequencing employed for further validation of the results. FFPE tissue blocks from CRC, diverticulitis, IC and CD without cancer patients will be utilized as controls.
223939937|NCT03602859|DRUG|Dostarlimab-Placebo|Participants will receive 500 mg of dostarlimab-placebo on day 1 every 3 weeks from cycle 2 to 6 followed by 1000 mg of dostarlimab-placebo on day 1 every 6 weeks to continue up to 3 years in the absence of disease progression, unacceptable toxicity, participant withdrawal, or investigator decision
223939938|NCT03602859|DRUG|Niraparib-Placebo|Participants will receive oral capsules of niraparib-placebo as a unit dosage strength of 100 mg.
223710790|NCT04632667|BEHAVIORAL|Comparison School Group|All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.
223710791|NCT04632667|BEHAVIORAL|Intervention School Group|"This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media."
223710792|NCT03449108|BIOLOGICAL|Aldesleukin|Given IV
223710793|NCT03449108|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
223710794|NCT03449108|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes LN-145-S1|Given IV
223710795|NCT03449108|DRUG|Cyclophosphamide|Given IV
223710796|NCT03449108|DRUG|Fludarabine|Given IV
223710797|NCT03449108|BIOLOGICAL|Ipilimumab|Given IV
223710798|NCT03449108|BIOLOGICAL|Nivolumab|Given IV
223710799|NCT03449108|OTHER|Quality-of-Life Assessment|Ancillary studies
223710800|NCT03449108|OTHER|Questionnaire Administration|Ancillary studies
223710801|NCT05705596|OTHER|Sucrose|10% sucrose corresponding to a regular soft drink
223710802|NCT05705596|DRUG|Hesperetin|increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
223710803|NCT04673617|DRUG|AB-101|NK cell therapy
223710804|NCT04673617|DRUG|Rituximab|Anti-CD20 antibody therapy
223710805|NCT04673617|DRUG|Interleukin-2|Immune cytokine
223710806|NCT04673617|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223710807|NCT04673617|DRUG|Fludarabine|Lymphodepleting chemotherapy
223710808|NCT04673617|DRUG|Bendamustine|Chemoimmunotherapy
223710809|NCT01458236|DRUG|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
223710810|NCT01458236|DRUG|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
223710811|NCT05671705|DIAGNOSTIC_TEST|DEXA Scan|Fu of diagnostic tests
223710812|NCT03829839|DRUG|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
223710813|NCT03829839|DRUG|Lorazepam 1 mg|Oral administration of 1mg lorazepam
223710814|NCT03829839|DRUG|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
223710815|NCT03829839|DRUG|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
223710816|NCT05267847|OTHER|Cryotherapy|local anesthetic injection with articaine 4% 1:100,000 epinephrine then an application ice packs
223710817|NCT05267847|OTHER|Traditional local anesthesia|local anesthetic injection with articaine 4% 1:100,000 epinephrine
223710818|NCT00776204|DEVICE|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
223710819|NCT00776204|DEVICE|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
223710820|NCT00776204|DEVICE|Taxus Libertè|Taxus Libertè stent placed in coronary artery
223710821|NCT05116475|DRUG|Darolutamide 300 mg|Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
223710822|NCT05116475|DRUG|Placebo of Darolutamide|Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
223710823|NCT01478880|PROCEDURE|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
223710824|NCT01478880|PROCEDURE|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
223710825|NCT03466567|DRUG|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
223710826|NCT03466567|DRUG|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
223710827|NCT03466567|DRUG|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
223710828|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
223710829|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
223710830|NCT01277991|DRUG|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
223710831|NCT01277991|DRUG|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
223710832|NCT02273778|PROCEDURE|MRI Scan|
223710833|NCT02273778|PROCEDURE|PET-CT Scan|
223710834|NCT02273778|OTHER|No intervention|
223710835|NCT04551755|DRUG|Ivermectin and Doxycycline|"1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes"
223710836|NCT04551755|OTHER|Placebo|Placebo (1) 2 tab stat then again 2 tab after 12 hours Placebo (2) will be given as 1+0+1 for 10 days
223710837|NCT02021331|DEVICE|immediate implant placement without provisionalization|
223710838|NCT02021331|DEVICE|immediate implant placement with immediate provisionalization|
223710839|NCT02222740|DRUG|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
223710840|NCT02222740|DRUG|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
223710841|NCT03804697|DRUG|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
223710842|NCT00005814|BIOLOGICAL|cetuximab|
223710843|NCT00005814|DRUG|cisplatin|
223710844|NCT00005814|RADIATION|radiation therapy|
223710845|NCT00487877|DEVICE|SenseWear Pro3 Armband|
223710846|NCT00487877|DEVICE|i-button DS2191 H|
223710847|NCT04665700|DRUG|BI 764198|BI 764198
223710848|NCT04665700|DRUG|Placebo|Placebo
223710849|NCT00465036|DIETARY_SUPPLEMENT|Whole flaxseeds, flaxseed mucilage, glucomannan|
223710850|NCT04165200|DIAGNOSTIC_TEST|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
223710851|NCT03800329|DEVICE|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
223710852|NCT03800329|OTHER|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
223710853|NCT01628133|PROCEDURE|ultrasound|sonographic evaluation of intestinal blood flow
223710854|NCT00303732|DRUG|RAD001 (everolimus)|
223710855|NCT00303732|DRUG|PTK787 (vatalanib)|
223710856|NCT00999089|PROCEDURE|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
223710857|NCT00999089|PROCEDURE|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
223710858|NCT00999089|PROCEDURE|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
223710859|NCT03256097|DEVICE|XDP sound processing strategy - Period 0|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
223710860|NCT03256097|DEVICE|XDP sound processing strategy - Period 1|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
223710861|NCT03256097|DEVICE|VG sound processing strategy - Period 1|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
223710862|NCT03256097|DEVICE|XDP sound processing strategy - Period 2|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
223710863|NCT03256097|DEVICE|VG sound processing strategy - Period 2|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
223710864|NCT03256097|DEVICE|XDP sound processing strategy - Period 3|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
223710865|NCT03256097|DEVICE|VG sound processing strategy - Period 3|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend
223710866|NCT03256097|DEVICE|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
223710867|NCT02785120|DRUG|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
223710868|NCT00319553|BIOLOGICAL|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
223710869|NCT00319553|BIOLOGICAL|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
223710870|NCT06264375|BEHAVIORAL|Physical exercise|see group description
223894064|NCT06568029|OTHER|Questionnaire|In the study, the validity and responsiveness of EQ-5D-3L will be assessed. The EQ-5D-3L measures HRQoL and consists of two parts. The first part contains five questions about mobility, daily activities, self-care, pain/discomfort, and anxiety/depression (EuroQoL 1990, Brooks 1996). Each question can be answered with no problem (1), some/moderate problem (2) unable to perform certain activities/having extreme problems (3). The answers can be summarized in an index value based on an existing preference-based value set. In this study, the EQ-5D-3L value set by Dolan (Dolan 1997) will be used for the main analyses and a Swedish experience-based value set in a sensitivity analysis (Burström, Sun et al. 2014). For the EQ-5D-3L index, 1 represents full health and 0 represents a value equal to being dead. EQ VAS measures the persons health today on a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health) (EuroQoL 1990, Brooks 1996).
223894065|NCT05488847|DRUG|Celecoxib|preoperative pain medication given to all patients
223894066|NCT05488847|DRUG|Pregabalin|preoperative and discharge pain medication given to all patients
223894067|NCT05488847|DRUG|Tramadol|preoperative pain medication given to all patients
223894068|NCT05488847|DRUG|Dexamethasone|Intraoperative and discharge pain medication given to all patients
223894069|NCT05488847|DRUG|Acetaminophen|Intraoperative and discharge pain medication given to all patients
223894070|NCT05488847|DRUG|Ropivicaine|Intraoperative pain medication given to all patients
223894071|NCT05488847|DRUG|Epinephrine|Intraoperative pain medication given to all patients
223894072|NCT05488847|DRUG|Ketorolac|Intraoperative pain medication given to all patients
223894073|NCT05488847|DRUG|Tizanidine|Discharge pain medication given to all patients
223894074|NCT05488847|DRUG|Magnesium|Discharge pain medication given to all patients
223710871|NCT01896102|GENETIC|Lenti-D Drug Product (eli-cel)|Participants received a single IV infusion of Lenti-D Drug Product.
223710872|NCT00204230|DRUG|mycophenolate mofetil (drug)|
223710873|NCT03795454|BEHAVIORAL|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
223710874|NCT01725503|DIETARY_SUPPLEMENT|Creatine and Amino Acid supplement|
223710875|NCT01409330|DIETARY_SUPPLEMENT|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
223710876|NCT03415568|DIETARY_SUPPLEMENT|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
223710877|NCT03415568|DIETARY_SUPPLEMENT|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
223710878|NCT05841485|DIAGNOSTIC_TEST|Assessment of coronary microvascular dysfunction using intracoronary pressure-temperature wire|The primary assessment method in this study is the measurement of coronary microvascular dysfunction using a pressure-temperature wire to determine coronary flow reserve (CFR) and index of microvascular resistance (IMR).
223710879|NCT00194948|DRUG|escitalopram|
223527782|NCT05547035|BEHAVIORAL|Patient follow-up of depression|"All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists:~* assess the depression severity by using MADRS scale~* assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures~* the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression."
223710880|NCT00194948|BEHAVIORAL|interpersonal psychotherapy|
223710881|NCT04213417|OTHER|Bobath therapy and Matrix Rhythm Therapy|MRT application that was applied to the study group in addition to the BC was applied to the affected side of the body and lower extremity for 60 minutes in each session.The treatment was started from the thoracic region and a treatment direction was toward the lower extremity in the affected side.During the MRT procedure, the patient's active participation was ensured and the treatment was combined with the exercises.The patients were informed about MRT verbally and in writing before the application. Participants were treated 3 days a week for 4 weeks for a total of 12 sessions.
223894075|NCT05488847|DRUG|Ibuprofen|Discharge pain medication given to all patients
223894076|NCT05488847|DRUG|Oxycodone Hydrochloride 5 Mg|Only given to active comparator group
223894077|NCT06497660|DRUG|Deoxyadrenaline|Deoxyadrenaline is a vasoactive drug
223894078|NCT06497660|DRUG|normal saline|Deoxyadrenaline is a vasoactive drug
223894079|NCT04274764|BEHAVIORAL|Personalized eHealth Education & Motivational Interviewing|This intervention uses a web-based application to generate personalized education materials for patients based on their eye health screening results and barriers to follow up care. A glaucoma counselor trained in brief, glaucoma-specific motivational interviewing (MI) uses the individualized content generated from this web-based application to form the basis of her conversation with the patient to coach the patient to engage in follow-up care.
223527783|NCT01697709|DRUG|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
223894080|NCT05671991|DRUG|Empagliflozin 25 mg vs Placebo|Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
223894081|NCT05671991|DRUG|Empagliflozin 10 MG|Chronic Study- Empagliflozin 10 mg for 8 weeks
223894082|NCT05601752|GENETIC|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 cells on Day 1
223894083|NCT05601752|COMBINATION_PRODUCT|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1 followed by nivolumab 480 mg IV at Week 4 and then every four weeks
223894084|NCT02810704|DRUG|Enteric Coated Aspirin|
223894085|NCT02810704|DRUG|Warfarin|
223894086|NCT02810704|DRUG|Rivaroxaban|
223894087|NCT00051532|DRUG|Seocalcitol|
223894088|NCT06636721|BEHAVIORAL|LuCA Behavioral Intervention|The intervention will integrate aspects of Cognitive Behavioral Therapy (identifying and challenging automatic thoughts, engaging in behavioral activation) and Acceptance and Commitment Therapy (integrating one's values, distancing skills). The intervention will include skills such as problem-solving, communicating with close others and the medical team, and breathing techniques to improve shortness of breath related to lung cancer.
223894089|NCT05436522|DRUG|Remimazolam|Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
223527784|NCT01697709|DRUG|Placebo|placebo capsules
223527785|NCT02545439|DRUG|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
223527786|NCT05849558|DRUG|Ursoplus|Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)
223527787|NCT05849558|DRUG|UDCA 250mg|UDCA 250mg alone
223527788|NCT05849558|OTHER|Placebo|Placebo alone
223527789|NCT04077502|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
223527790|NCT05192278|OTHER|erector spinae block|The patients will do the procedure under fluoroscopic guidance. The patients were placed in prone position. After the identification of the T4 transverse process, the targeted injection site was anesthetized with 3-4 ml of 2% lidocaine. A 25-gauge spinal needle was advanced until it contacted the transverse process at the T4 level. Next, a solution of 1mL of methylprednisolone 40mg/mL with 7 mL of 0.25% bupivacaine and 2mL of nonionic contrast in 10 ml saline 0.9% (group A) and in 20 ml saline 0.9% (group B) will injected. Then another photo will be taken with the fluoroscopy to determine the level of spread in each group. After finished, the patients will transfer to the post-operative care unit and will monitored for any complication for one hour.
223527791|NCT05170802|OTHER|NanoKnife procedure|clinical data regarding use of the NanoKnife system intraoperatively (via laparotomy) to ablate the pancreatic tumors per the treating physicians discretion will be collected.
223527792|NCT02940548|DRUG|Nifedipine GITS|Nifedipine GITS 30\~60mg/day for 8 weeks
223527793|NCT02940548|DRUG|Amlodipine besylate|Amlodipine besylate 5\~10mg/day for 8 weeks
223527794|NCT02684461|DRUG|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
223527795|NCT06140693|OTHER|Continuous exercise at an intensity below the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 80% of the intensity at the ventilatory threshold
223527796|NCT06140693|OTHER|Continuous exercise at an intensity at the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 100% of the intensity at the ventilatory threshold
223527797|NCT06140693|OTHER|Continuous exercise at an intensity above the ventilatory threshold|30 minutes of cycling exercise on a stationary bike at an intensity corresponding to 110% of the intensity at the ventilatory threshold
223527798|NCT06140693|OTHER|Sprint interval training|22 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by four 30-s 'all-out' sprints, each with a 4-min recovery intervals at 25 W
223527799|NCT06140693|OTHER|Reduced-exertion high-intensity interval training|10 min of cycling exercise on a stationary bike with a warm-up at a resistance of 25 W, followed by two 20-s 'all-out' sprints, with a 3-min and a 4-min recovery interval at 25 W after the first and second sprint respectively
223527800|NCT04570202|BEHAVIORAL|EMDR|The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
223527801|NCT02390076|DEVICE|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
223527802|NCT02390076|OTHER|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
223527803|NCT02390076|DEVICE|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
223527804|NCT02390076|DEVICE|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
223527805|NCT01418456|DRUG|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
223527806|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (meta-cognitive imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of meta-cognitive imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
223710882|NCT04213417|OTHER|Bobath therapy|Both groups were treated with the BC as a neurodevelopmental therapy. Considering individual requirements and wishes of the patient, an exercise program that supports active participation of the person was established.Each treatment session was performed for 60 minutes.The treatment program that was established appropriately according to the patient contained weight transfer to the affected side in different positions,approximation to increase proprioceptive input, providing sensorial input to the sole of the foot using materials such as sensory ball,foot-ankle mobilization,functional reach activities, forward-side step, gait, and balance activities. Participants in both groups were treated 3 days a week for 4 weeks for a total of 12 sessions.
223710883|NCT04878497|DRUG|Warfarin|Initiation of warfarin, identified using prescription fill in pharmacy claims
223710884|NCT04878497|DRUG|Dabigatran|Initiation of dabigatran, identified using prescription fill in pharmacy claims
223710885|NCT04878497|DRUG|Rivaroxaban|Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
223710886|NCT04878497|DRUG|Apixaban|Initiation of apixaban, identified using prescription fill in pharmacy claims
223710887|NCT04878497|DRUG|Edoxaban|Initiation of edoxaban, identified using prescription fill in pharmacy claims
223710888|NCT03889106|DRUG|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
223710889|NCT03719612|DRUG|DEFINITY®|All subjects will receive a single dose of DEFINITY®
223710890|NCT00985023|PROCEDURE|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
223710891|NCT00985023|PROCEDURE|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
223710892|NCT02231944|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
223710893|NCT00900237|DRUG|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
223710894|NCT00900237|DRUG|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
223710895|NCT01496248|DIETARY_SUPPLEMENT|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
223710896|NCT02639767|DRUG|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m\^2 for pemetrexed in combination with 75 mg/m\^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
223710897|NCT02639767|RADIATION|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
223710898|NCT02639767|DEVICE|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
223710899|NCT01267760|DEVICE|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
223710900|NCT01281865|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223710901|NCT01281865|DRUG|everolimus|Given PO
223710902|NCT01281865|DRUG|imatinib mesylate|Given PO
223710903|NCT01977742|OTHER|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
223710904|NCT01977742|OTHER|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
223710905|NCT05314751|BEHAVIORAL|Questionnaire and interview|An online survey and an in-depth interview.
223710906|NCT03132818|OTHER|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
223710907|NCT02590003|DRUG|Carboplatin|
223710908|NCT02590003|DRUG|Nab-paclitaxel|
223710909|NCT05197556|DRUG|HSG4112|Once-daily oral administration
223710910|NCT05197556|DRUG|Placebo|Once-daily oral administration
223710911|NCT02437266|OTHER|Scapular mobilization|
223710912|NCT00935363|DRUG|glyburide|single oral dose
223710913|NCT00935363|DRUG|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
223710914|NCT00935363|DRUG|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
223710915|NCT00935363|DRUG|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
223710916|NCT04973137|DRUG|Birtamimab|Intravenous administration of 24 mg/kg birtamimab every 28 days
223710917|NCT04973137|OTHER|Placebo|Intravenous 0.9% Saline administration as a placebo every 28 days
223710918|NCT04973137|DRUG|Standard of Care Chemotherapy|Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care
223710919|NCT04803058|BIOLOGICAL|TCD601|Investigational Product
223710920|NCT04646837|DRUG|Durvalumab|Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
223710921|NCT04646837|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
223710922|NCT04646837|DRUG|Carboplatin/Cisplatin|Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
223894090|NCT05436522|DRUG|Propofol|Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
223894091|NCT01926496|DRUG|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
223894092|NCT01926496|DRUG|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
223894093|NCT03362736|DRUG|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to \[\<=\] 55 kilogram \[kg\] will receive 260 milligram \[mg\] ustekinumab; \> 55 kg to \<= 85 kg will receive 390 mg ustekinumab; and \> 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
223894094|NCT03427580|BEHAVIORAL|MERIT|Metacognitive Reflection and Insight Therapy
223894095|NCT06165978|BEHAVIORAL|Self-monitoring|pedometer/activity band provided to each participant
223710923|NCT00427843|BEHAVIORAL|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
223710924|NCT00123396|BEHAVIORAL|BioCASES and BioTESTS|
223710925|NCT06318169|BIOLOGICAL|Pegozafermin|Subcutaneous injection
223710926|NCT06318169|OTHER|Placebo|Subcutaneous injection
223710927|NCT00268788|DRUG|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
223710928|NCT00268788|DRUG|Intravenous immunoglobulin|Individual dose and frequency
223710929|NCT06455176|PROCEDURE|alveolar cleft Grafting from the symphysis|grafting using particulate bone from the symphysis
223710930|NCT06455176|PROCEDURE|alveolar cleft Grafting from the iliac cancellous bone|grafting using iliac cancellous bone
223710931|NCT05857059|DRUG|Misoprostol 25 mcg|Misoprostol 50 mcg every 2 hours
223710932|NCT05857059|DRUG|Misoprostol 50 mcg|Misoprostol 50 mcg every 2 hours
223710933|NCT01849783|DRUG|dexamethasone|Given PO
223710934|NCT01849783|DRUG|cisplatin|Given IV
223710935|NCT01849783|DRUG|doxorubicin|Given IV
223710936|NCT01849783|DRUG|cyclophosphamide|Given IV or PO
223710937|NCT01849783|DRUG|etoposide|Given IV
223710938|NCT01849783|DRUG|bortezomib|Given IV
223710939|NCT01849783|DRUG|thalidomide|Given PO
223710940|NCT01849783|DRUG|melphalan|Given IV
223710941|NCT01849783|PROCEDURE|autologous stem cell transplant|
223710942|NCT06440902|DRUG|Cetuximab|Cetuximab is given In patients with NeoRAS WT
223710943|NCT03948581|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
223710944|NCT02527135|BEHAVIORAL|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
223710945|NCT04635228|DEVICE|Biodesign Otologic Repair Graft|The Biodesign Otologic Repair Graft is intended for use as grafting material for tympanic membrane perforation closure.
223710946|NCT03604484|PROCEDURE|Tricuspid annuloplasty|Tricuspid annuloplasty
223710947|NCT03500354|DIETARY_SUPPLEMENT|Nutrient drink|High calorie drink with therapeutic supplements
223710948|NCT04461210|DIAGNOSTIC_TEST|Thermographic Imaging and Mechanical Pain Assessment|Assessment of pain sensitivity with mechanical stimulus (cotton swab) and thermographic imaging with infrared camera
223710949|NCT05123729|BEHAVIORAL|Crowdsourced campaign package|Disease prevention intervention developed using a crowdsourcing process.
223710950|NCT05123729|BEHAVIORAL|Rapid Response Teams|Pilot a new hybrid training focused on contact tracing and case investigation.
223894096|NCT06165978|BEHAVIORAL|Goal setting and review|Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)
223894097|NCT06165978|BEHAVIORAL|Education|Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)
223894098|NCT06165978|BEHAVIORAL|Feedback|Daily or weekly feedback for patients (emotional/social support)
223894099|NCT06165978|BEHAVIORAL|Contact|Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)
223894100|NCT06165978|BEHAVIORAL|Exercise|Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2\>88%, HRmax\<96%, Borg\<9)
223894101|NCT06165978|BEHAVIORAL|Report|Daily or weekly reporting for therapists (messages)
223894102|NCT06165978|BEHAVIORAL|Social support|Support meetings (in-person), parallel to educational sessions
223894103|NCT06165978|BEHAVIORAL|Group activities|Group activities (e.g., walking on familiar routes - parks, monumental areas, etc.)
223894104|NCT06165978|BEHAVIORAL|World Health Organization recommendations for being physically active|World Health Organization's recommendations to maintain physical activity levels (i.e., 150-300 minutes/week of moderate to vigorous intensity physical activity; a weekly average of 10,000 steps/day or 100-120 minutes walking, which implies maintaining a pace of 100 steps/minute - corresponding to the average cadence across different age and gender groups).
223894105|NCT06044584|OTHER|No intervention|Observational study with no intervention - Monitoring
223894106|NCT06523413|BEHAVIORAL|Game activity|A game determined by the researcher will be played with the patients in the patient room.
223894107|NCT06523413|DEVICE|Stres Ball|Patients will use the stress ball for 15 minutes.
223894108|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
223894109|NCT02677298|DRUG|Placebo|Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area
223894110|NCT02677298|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles
223894111|NCT04741542|DRUG|SP-420|This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
223894112|NCT03210272|DRUG|Placebo|Tablet
223894113|NCT03210272|DRUG|BI 1358894|Tablet
223894114|NCT03210272|DRUG|BI 1358894 (Test)|Fasting state
223894115|NCT03210272|DRUG|BI 1358894 (Reference)|Fed state
223894116|NCT03611621|DRUG|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
223894117|NCT05397223|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
223894118|NCT05397223|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223894119|NCT05397223|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223894120|NCT05397223|BIOLOGICAL|FLUAD®|adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine
223894121|NCT05397223|BIOLOGICAL|mRNA-1647|Sterile lyophilized product
223894122|NCT03039023|DIETARY_SUPPLEMENT|Choline Bitartrate|500mg choline bitartrate tablets
223894123|NCT03039023|OTHER|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
223894124|NCT03039023|OTHER|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
223894125|NCT03039023|DIETARY_SUPPLEMENT|Phosphatidylcholine capsules|420 mg phosphatidylcholine capsules obtained from a commercial source.
223894126|NCT04130438|DRUG|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
223894127|NCT04130438|DRUG|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
223894128|NCT04130438|OTHER|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
223894129|NCT04926766|RADIATION|External Beam radiotherapy using IMRT technique|2600cGy/ 5 fractions / 1 weeks to ipsilateral whole breast and a sequential tumor bed boost of 5.2 Gy in 2 fractions at the discretion of radiation oncologist
223894130|NCT05847517|DRUG|Metoprolol Injection|"A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted."
223894131|NCT05847517|DRUG|saline 0.9%|"A dilution of 0.9% sodium chloride in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure below 110 mmHg or heart rate below 60 bpm, the infusion shall be stopped and the infusion noted."
223894132|NCT03499821|DEVICE|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
223894133|NCT06478719|DRUG|Placebo|Placebo oral capsule
223894134|NCT06478719|DRUG|FB-1603|FB-1603 (165 mg/cap) oral capsule
223894135|NCT06406881|OTHER|physical therapy|"Ocular muscle exercise which is consist of three exercise like palm exercise, blinking exercise, pencil pushup exercise.~3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. each exercise consist of 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
223894136|NCT06406881|OTHER|myofascial release therapy|"Experimental group given MFR along with neck isometric and ocular muscle exercise.~myofascial release technique on sternocleidomastoid muscle and upper trapezius muscles. Patients will be treated 3 seconds to 2 minutes, three days in a week.~Ocular muscle exercise will perform 3 sets of 10 repetition 5 days a week. As well as strengthening exercise the neck isometric exercise. This exercise will performed 3 sets of 5 repetition 5 days a week.~Total of three sessions ."
223894137|NCT04890041|DRUG|TPO-RA|The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
223894138|NCT05737628|DRUG|BYON4228 + Rituximab|"BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses.~Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles."
223894139|NCT05789602|DRUG|BPI-460372|Subjects will receive BPI-460372 until disease progression
223894140|NCT06348160|BEHAVIORAL|iHERO Toolkit Resource|iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
223894141|NCT06529250|DRUG|HAD|"Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
223894142|NCT06529250|DRUG|Daunorubicin+Cytarabine|"Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment."
223710951|NCT06321393|OTHER|7-week Core stabilization exercise with abdominal drawing-in maneuver technique|A 7-week core stabilization exercise with abdominal drawing-in maneuver technique consists of 2 stages, including the first stage (week 1-2) and the second stage (week 3-7) consisting of exercise program for 20-minute sessions with 3 sessions per week for 7 weeks. These exercise program will be provided to the participants via a weekly video call with the main researcher as a telerehabilitation program.
223710952|NCT05870124|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
223710953|NCT05870124|OTHER|Conventional Medical Management|Conventional Medical Management is the best standard of care treatment for the patient
223710954|NCT01965613|BIOLOGICAL|Xilonix|IV
223710955|NCT04464759|DRUG|Nivolumab|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
223710956|NCT04464759|DRUG|Hydroxychloroquine|Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab
223710957|NCT04464759|DRUG|Ipilimumab|Combination of nivolumab, hydroxychloroquine and ipilimumab
223710958|NCT06114667|DEVICE|Ventilatory support via nasal high flow|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
223710959|NCT06114667|DEVICE|Ventilatory support via NIV|Ventilatory support will be applied in 2h sessions and resumed as needed according to international guidelines for NIV treatment.
223710960|NCT03908177|DEVICE|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
223710961|NCT03908177|DEVICE|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
223710962|NCT02230553|DRUG|Lapatinib|
223710963|NCT02230553|DRUG|trametinib|
223710964|NCT04893707|BIOLOGICAL|CM310|"adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC.~teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC."
223710965|NCT04457336|DRUG|Tildacerfont/Placebo|Tablet, administered daily
223710966|NCT02100904|PROCEDURE|Radiofrequency ablation of fibroids|
223710967|NCT02100904|PROCEDURE|Myomectomy of fibroids|
223710968|NCT05023629|OTHER|Intracoronary balloon inflation|Patients with a significant coronary artery lesion in a proximal coronary segment will undergo intracoronary balloon inflation for 90s prior to PCI.
223710969|NCT04633733|DRUG|HL237 tablet|HL237 400mg will be administered orally twice a day.
223710970|NCT04633733|DRUG|tacrolimus capsule|tacrolimus 5mg will be administered orally once a day.
223710971|NCT01554683|DRUG|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
223710972|NCT02424760|DEVICE|Shoulder hemi-arthroplasty|
223710973|NCT01972100|DEVICE|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
223710974|NCT01972100|OTHER|isokinetic exercise|
223710975|NCT01972100|DEVICE|Placebo low-level laser therapy|
223710976|NCT00479193|DRUG|bacitracin/xeroform|single layer, change every 3 days
223710977|NCT00479193|DRUG|Polymem|single layer of Polymen, change every 3 days
223710978|NCT00163839|BEHAVIORAL|Dietary Therapy|
223710979|NCT01517620|DRUG|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
223710980|NCT03330288|DRUG|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
223894143|NCT05276973|PROCEDURE|Biopsy|Undergo biopsy
223894144|NCT05276973|DRUG|Carboplatin|Given IV
223710981|NCT02581787|BIOLOGICAL|Fresolimumab|Given IV
223710982|NCT02581787|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
223710983|NCT04068870|BEHAVIORAL|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
223894145|NCT05276973|DRUG|Ipatasertib|Given PO
223894146|NCT05276973|DRUG|Paclitaxel|Given IV
223894147|NCT05773820|DRUG|WJB001|"Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts."
223894148|NCT05953155|OTHER|Control|Each educational class will last for 1 hour and consists of evidence-based information about low back pain, including, for example, self-management strategies, pain education, reassurance and common misconceptions about back pain.
223894149|NCT05953155|OTHER|Yoga|Participants in the intervention group will receive, in addition to the educational classes, a course of yoga program led by certified yoga instructors. The program consists of a 60-min group session with up to 10 participants, delivered twice a week for 12 weeks.
223894150|NCT03064217|DEVICE|Making impression at surgery|Making impression at surgery
223894151|NCT03270020|DRUG|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
223894152|NCT06848933|OTHER|Test meal|On days 1, 2 and 3 of the study, a pediatric endocrinologist from the research team will evaluate the continuous glucose monitoring system data and optimize the carbohydrate/insulin ratios. On days 4 and 7 of the study, participants with blood sugar levels between 70-140 mg/dl according to the continuous glucose monitoring system, which is a component of the hybrid closed-loop insulin infusion pump system, will consume the test meal consisting of Dr Oetker Ristorante Pizza Mista (340 grams) (92 g carbohydrate, 33 g protein, 41 g fat) at lunch, under the supervision of a dietician from the research team, by switching the pump to manual mode and entering the carbohydrate amount of the meal into the pump. This application will be repeated on days 11 and 14 of the study, with the participant's pump in automatic mode. Participants will not be allowed to consume food or beverages other than water or exercise for 5 hours after the meal. Blood sugar monitoring will be done with the continuous
223894153|NCT06848933|DEVICE|Each participant will consume the test meal when on Medtronic Minimed 780G and will consume test meal on Medtronic Minimed 780G on manual mode|After the intervention, blood glucose values will be documented from continued glucose measurement system for postprandial 5 hours,and compared in manual mode and auto mode
223894154|NCT06848933|DEVICE|Advanced hybrid closed loop system mode|On days 1, 2 and 3 of the study, a pediatric endocrinologist from the research team will evaluate the continuous glucose monitoring system data and optimize the carbohydrate/insulin ratios. On days 4 and 7 of the study, participants with blood sugar levels between 70-140 mg/dl according to the continuous glucose monitoring system, which is a component of the hybrid closed-loop insulin infusion pump system, will consume the test meal consisting of Dr Oetker Ristorante Pizza Mista (340 grams) (92 g carbohydrate, 33 g protein, 41 g fat) at lunch, under the supervision of a dietician from the research team, by switching the pump to manual mode and entering the carbohydrate amount of the meal into the pump. This application will be repeated on days 11 and 14 of the study, with the participant's pump in automatic mode. Participants will not be allowed to consume food or beverages other than water or exercise for 5 hours after the meal. Blood sugar monitoring will be done with the continuous
223894155|NCT05688111|DRUG|Tranexamic acid injection|Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours
223894156|NCT05688111|OTHER|Glucose water 5%|Placebo group 30ml will be received 12 hourly for 48 hours
223894157|NCT06843850|DEVICE|regenerative endodontics|The effect of different irrigation solutions on lesion healing in regenerative endodontics will be compared.
223894158|NCT06847243|DIAGNOSTIC_TEST|Nutrigenetic diet according the genetic test|Subjects within the nutrigenetic intervention group will be provided with a dietary plan according to nutrient intake characteristics by alghoritm genetic afinity.
223894159|NCT06847243|OTHER|Control intervention group|Subjects within the control intervention group will be provided with a dietary plan according to general nutrient recommendation by the AHA (American Hearth association) and national cholesterol education program
223894160|NCT06844266|PROCEDURE|Administration of the ACT + PA-R questionnaires|"The ACT + PA-R questionnaires will be administered to pediatric patients with a previously confirmed diagnosis of asthma, who attend the Pediatric Allergy Day Hospital for a routine check-up with spirometry before and after physical exertion."
223894161|NCT06844266|PROCEDURE|ACT questionnaire|"The ACT questionnaire will be administered to pediatric patients with a previously confirmed diagnosis of asthma, who attend the Pediatric Allergy Day Hospital for a routine check-up with spirometry before and after physical exertion."
223894162|NCT06848166|DEVICE|liquid embolic agent SQUID 12, liquid embolic agent SQUID 18|Total endovascular embolization of the frontal and parietal branches (less often the occipital branch) of the middle meningeal artery (MMA) with its complete devascularization. In the case of unilateral pain localization, ipsilateral MMA embolization will be performed; in the case of bilateral pain localization, total embolization of both MMA branches will be performed.
223894163|NCT06843616|PROCEDURE|Endoscopic surgery|Using a disposable intracerebral aspiration endoscope to remove the intracerebral hematoma
223894164|NCT06846125|OTHER|GROUP A: Combined Mindfulness and Strength Training|"Week Exercises Reps x Sets 1-2 Mindfulness Training: Breathing exercises, body scans, and meditation. Strength Training: Bodyweight squats, glute bridges, calf raises. 10 x 2 3-4 Mindfulness Training: Guided visualization and mindfulness integration during exercises.~Strength Training: Weighted squats, hamstring curls, lunges. 12 x 3 5-6 Mindfulness Training: Focus on movement awareness and posture during high-intensity drills.~Strength Training: Single-leg squats, step-ups, resistance band lateral walks. 15 x 3 7-8 Mindfulness Training: Integration during advanced functional movements. Strength Training: Plyometric box jumps, Bulgarian split squats, deadlifts. 12 x 4"
223894165|NCT06846125|OTHER|GROUP B: Strength Training Only|Week Exercises Reps x Sets 1-2 Bodyweight squats, glute bridges, calf raises. 10 x 2 3-4 Weighted squats, hamstring curls, lunges. 12 x 3 5-6 Single-leg squats, step-ups, resistance band lateral walks. 15 x 3 7-8 Plyometric box jumps, Bulgarian split squats, deadlifts. 12 x 4
223894166|NCT06845670|OTHER|Wurn technique|Wurn technique is a massage technique and PF relaxation exercises are to relax tighten pelvic floor muscles.
223894167|NCT06846151|DEVICE|retinal functional imaging|this is a proof of concept study
223894168|NCT06841211|PROCEDURE|Targeted and perilesional biopsy (TPLBx)|The biopsy procedure is conducted by highly skilled and experienced urologists who specialize in performing prostate biopsies. A single dose of prophylactic antibiotics (usually cephalosporins) is routinely administered following a test dose 30 min before the procedure. Each patient is placed in the lithotomy position. Povidone-iodine is routinely used to clean perineum before the biopsy. The MRI-TRUS biopsy system is iFUSS (image fusion surgical system, Carbon Med), consisting of a 3D reconstruction and planning software (Carbon Med) and a bi-planar TRUS probe (ECL8-4-B, Carbon Med). Color Doppler examination is performed from the base to the apex. For each predefined mpMRI suspicious lesion, two-core TBs are obtained within the ROI, followed by ring-distributed four cores within a 10-15 mm radius around the ROI. The location of these cores depends on the shape and location of the suspicious lesion.
223527807|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (Imagery rescripting)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of imagery rescripting.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
223527808|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (promoting positive imagery de novo)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of promoting positive imagery de novo.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
223527809|NCT05603260|BEHAVIORAL|Imagery intervention for voice hearing (visuospatial working memory tasks)|"The participants receive intervention for a period of 3 weeks, 6 sessions of 60 minutes.~In-depth identification of images (2 sessions): Identifying imagery which is related to the auditory vocal hallucinations, constructing a micro-formulation with the participant along the lines of regular Cognitive Behavioural Therapy. In this micro-formulation, first triggers of problematic imagery are identified, both quality and appraisals of this image are identified. Subsequent maladaptive behaviour and possible links with earlier experiences are described, as well as maintaining factors.~Imagery intervention (2 sessions): The imagery intervention consists of visuospatial working memory tasks.~Consolidation (2 sessions): Relapse prevention strategies are practiced before the end of intervention."
223527810|NCT02350452|PROCEDURE|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
223527811|NCT02350452|PROCEDURE|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
223527812|NCT06004622|OTHER|Calgary Family Intervention Model|under two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasted about 20 minutes and was conducted by a single researcher to maintain consistency. The scheduling of these sessions took into consideration the physiological and emotional stability of the participants. If any issues or difficulties arose during the course of the sessions, they could be paused. The confidentiality and privacy of the discussion content were ensured. The intervention took place in a dedicated room within the intensive care unit, providing sufficient space and privacy.
223527813|NCT04816032|OTHER|Pennebaker's expressive writing intervention|It focuses on the emotional aspect of the written event
223527814|NCT04816032|OTHER|Neutral writing|Description of neutral topics with less emotional involvement
223527815|NCT01527565|DRUG|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
223527816|NCT06235502|OTHER|Home-based cycle-exercise for COPD patients|Patients will cycle in their own home using a pedal exerciser connected to the 4M-video app
223527817|NCT06235502|OTHER|Standard of Care|Exercise at Fitness Center, home based exercise according to a programme
223527818|NCT02749747|DRUG|Sulpiride use|50mg sulpiride once a day use for 60 days
223527819|NCT02749747|DRUG|Placebo|50mg placebo once a day use for 60 days
223527820|NCT02646410|OTHER|FPD+NDOT|
223527821|NCT02646410|OTHER|FPD+DOT|
223527822|NCT02646410|OTHER|DDD+NDOT|Door to door delivery + non directly observed treatment
223527823|NCT02646410|OTHER|DDD+DOT|Door to door delivery + directly observed treatment
223527824|NCT03981874|OTHER|telephonic interview|Telephonic interview
223710984|NCT00714441|BEHAVIORAL|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
223710985|NCT00714441|BEHAVIORAL|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
223527825|NCT01192074|DEVICE|Ultrasound|Preprocedure ultrasound examination of the spine
223527826|NCT03515421|DEVICE|Frazier 3 Verio|In vitro diagnostic device (IVDD)
223894169|NCT06841211|PROCEDURE|Combined targeted and systematic biopsy (CTSBx)|The biopsy procedure is conducted by highly skilled and experienced urologists who specialize in performing prostate biopsies. A single dose of prophylactic antibiotics (usually cephalosporins) is routinely administered following a test dose 30 min before the procedure. Each patient is placed in the lithotomy position. Povidone-iodine is routinely used to clean perineum before the biopsy. The MRI-TRUS biopsy system is iFUSS (image fusion surgical system, Carbon Med), consisting of a 3D reconstruction and planning software (Carbon Med) and a bi-planar TRUS probe (ECL8-4-B, Carbon Med). Color Doppler examination is performed from the base to the apex. Two-core TBs from the lesion were performed within each predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
223894170|NCT06841952|DRUG|ATRA+Venetoclax+Azacitidine|Participants will receive a standard dose of azacitidine (75mg/m²/day)，venetoclax (target dose, 400 mg)，ATRA 45mg/m²/day
223894171|NCT06841952|DRUG|Chemotherapy drug|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).
223894172|NCT04342962|DRUG|tagraxofusp|Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion. Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3). Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5). In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
223894173|NCT06848322|BEHAVIORAL|resistance exercise|Participants will perform resistance exercise for 8 weeks
223894174|NCT06848322|BEHAVIORAL|aerobic exercise|Participants will perform aerobic exercise for 8 weeks
223894175|NCT06848322|OTHER|Control (placebo)|Participants will maintain their usual lifestyle for 8 weeks.
223894176|NCT05516147|BEHAVIORAL|SAFE at Home|SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
223894177|NCT03992339|DRUG|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
223894178|NCT03868592|PROCEDURE|Gastric sleeve/bariatric surgery|weight loss
223894179|NCT03895567|DRUG|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)|"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."
223894180|NCT03895567|DRUG|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg hard-shell gelatin capsule"
223894181|NCT03895567|DRUG|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg rectodispersible mannitol-based tablet"
223894182|NCT04907136|OTHER|Preferred ENDS|Preferred ENDS without HWL on device
223894183|NCT04907136|OTHER|Preferred ENDS with HWL|Preferred ENDS with a HWL on device
223894184|NCT06235749|DRUG|Calcium Gluconate 10%|Administration of Calcium Gluconate 10% IV following umbilical cord clamping
223894185|NCT06235749|DRUG|sodium chloride 0.9%|Administration of sodium chloride 0.9% IV following umbilical cord clamping
223894186|NCT05027503|OTHER|Exercise with hippotherapy simulator|30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
223894187|NCT05027503|OTHER|Respiratory Physiotherapy|Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
223894188|NCT05737953|DIAGNOSTIC_TEST|cfDNA methylation sequencing and proteome analysis|Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples
223894189|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
223894190|NCT04764448|OTHER|Placebo|Comparator: Placebo Cohort 1 Administered sterile normal saline (0.9% NaCl) matching volume of belcesiran by subcutaneous (sc) injection for 24 weeks. Extension offered to participants.
223894191|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
223894192|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 48 weeks. Extension offered to participants.
223894193|NCT04764448|DRUG|Belcesiran|Administered multiple fixed doses of belcesiran by subcutaneous (sc) injection for 96 weeks.
223894194|NCT04764448|OTHER|Placebo|Administered sterile normal saline (0.9% NaCl) matching volumes of belcesiran by subcutaneous (sc) injection for 96 weeks.
223894195|NCT05873244|DRUG|Zabadinostat (CXD101) and Geptanolimab|"* Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks"
223894196|NCT05873244|DRUG|Lenvatinib and Sorafenib|"Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily"
223894197|NCT06188754|BEHAVIORAL|Time restricted eating|Limiting food intake to 10 hours per day
223894198|NCT06188754|BEHAVIORAL|Mediterranean diet|Dietary advice designed to improve consumption of vegetables, fruits, whole grains, and the use of olive oil.
223894199|NCT04947020|DRUG|Metformin|Metformin use before operation due to previously diagnosed diabetes.
223894200|NCT04497220|BEHAVIORAL|Negative Connotation Langauge|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The control script includes language containing the wording Poke and a burn said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
223939939|NCT07190105|OTHER|Sonocea Sonic Augmentation Technology (SAT)|The Sonocea Sonic Augmentation Technology (SAT) is a sound-based approach delivered via headphones through a smartphone application. The approach uses music soundscapes that have been standardized in format, intensity and duration.
223710986|NCT00714441|BEHAVIORAL|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
223710987|NCT02693119|DRUG|elamipretide (MTP-131) 1% topical ophthalmic solution|
223710988|NCT02693119|DRUG|Vehicle topical ophthalmic solution|
223710989|NCT02284516|DRUG|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
223710990|NCT02284516|DRUG|Placebo|Placebo to match active treatment, BID for 84 days
223710991|NCT01719783|BIOLOGICAL|LAIV H5N2|2 doses provided intranasally
223710992|NCT01719783|OTHER|Placebo|2 doses of placebo provided intranasally
223710993|NCT05478369|BEHAVIORAL|storybook|anxiety and fear during operative
223710994|NCT01350492|BEHAVIORAL|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
223710995|NCT04058730|PROCEDURE|Laparoscopic Roux en Y Gastric by pass surgery|
223710996|NCT04058730|PROCEDURE|Laparoscopic Sleeve Surgery|
223710997|NCT04058730|OTHER|Standard Medical Management|
223710998|NCT06309732|DRUG|Pegfilgrastim|6mg at each cycle
223710999|NCT06309732|DRUG|Dactinomycin|1mg/m2
223711000|NCT06309732|DRUG|Methotrexate|Doses are titrated against renal function. Dosage: 30 mins loading plus 12 hour infusion
223711001|NCT06309732|DRUG|Etoposide|90mg/m2 injection for infusion
223711002|NCT06309732|DRUG|Cisplatin|50mg/m2
223711003|NCT06309732|DRUG|Epirubicin|37.5mg/m2
223711004|NCT05174377|DIAGNOSTIC_TEST|CT-scan algorithm|CADx model was developed with a Support Vector Machine (SVM) algorithm and trained using five-fold cross-validation
223711005|NCT02504710|DEVICE|Kinematic Real Time Feedback|
223711006|NCT02504710|OTHER|Traditional systems of manual therapy teaching|
223711007|NCT06396325|OTHER|Tales from the Magic Keep™|Exergame targeting upper limb and trunk movement designed for use on the Microsoft Azure Kinect Dose: At least 3 times a week for 20 minutes over 8 weeks (8 hours total) Continue with regularly accessed physical activities and rehabilitation services
223711008|NCT06396325|OTHER|Usual Care|Continue with regularly accessed physical activities and rehabilitation services
223711009|NCT01979965|DRUG|Ranolazine (Active drug)|Ranolazine therapy for three months
223711010|NCT01979965|DRUG|Placebo|Placebo therapy for three months
223711011|NCT06446596|OTHER|Exercise supported by the digital physiotherapy and telerehabilitation software TRAK|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through the software a digital physiotherapy and telerehabilitation. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of the TRAK software (https://www.trakphysio.com/es/), which allows the exercises to be carried out in front of a camera that, with the help of an artificial intelligence system, offers feedback to the participant and allows you to keep a record of the sessions. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
223711012|NCT06446596|OTHER|Standard home-based exercise|8 week home therapeutic exercise program that includes flexibility and strength exercises scheduled through a dossier and an exercise diary. The program will be carried out with a frequency of 3 weekly sessions, preferably on alternate days. The program will be carried out with the support of an information dossier of the exercises to be performed and a monitoring diary in which everything related to the sessions carried out will be noted.. As an addition to the home sessions, two face-to-face sessions will be held in the first and fifth weeks, respectively. The exercise program includes three levels of difficulty (easy, intermediate and difficult), with patients advancing to subsequent levels once each level is successfully overcome.
223711013|NCT06480773|DRUG|standard of care chemotherapy|intravenous Paclitaxel or the combination of Bleomycin and Vincristine.
223711014|NCT04574973|DEVICE|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
223711015|NCT04574973|BEHAVIORAL|intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
223711016|NCT03539146|OTHER|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
223711017|NCT03539146|OTHER|Control yogurt|Control yogurt
223711018|NCT02654847|DRUG|Norepinephrine|
223711019|NCT02654847|DRUG|Normal Saline|0.9% sodium chloride solution, used as a diluent.
223711020|NCT04569656|DRUG|hydrolyzed guar gum|treatment with Stick pack 30 ml containing PHGG 5 gr e Hyaluronic Acid 200 mg for 6 weeks
223711021|NCT01199172|BEHAVIORAL|voice hygiene|subjects will receive voice hygiene training
223711022|NCT01199172|BEHAVIORAL|VH + VP|subjects will be trained in voice hygiene and voice production training
223711023|NCT04945577|DIAGNOSTIC_TEST|Inflammatory Parameters|Laboratory measurement of patient's inflammatory status in unit of % and mg/dl
223711024|NCT04945577|OTHER|25 OH Vitamin D Level|Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
223711025|NCT06287190|OTHER|Dental interns|Assessing self-assessment
223711026|NCT00238888|PROCEDURE|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
223711027|NCT00238888|PROCEDURE|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
223711028|NCT01706796|DRUG|PF-06273340|Oral solution, single dose, fasted
223894201|NCT04497220|BEHAVIORAL|Positive Connotation Language|"The study intervention consists of two separate scripts read to the patient by the anesthesiologist performing their labor epidural. The experimental script includes language containing the wording this is numbing medication, which will make the rest of the procedure go easier said prior to numbing medication for the epidural procedure. There will be no difference in the epidural placement, medications, or the rest of the script."
223894202|NCT06407830|OTHER|motor relearning programme|Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.
223894203|NCT06407830|OTHER|electrical muscle stimulations with motor relearning programme|"Treatment protocol includes Brief period of warm up and cool down (5 minutes). Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions of task specific training based on the motor relearning programme. Each task specific training consists of 10 minutes.~Individuals of this group will be provided 3 sessions per week; 1 hour per session; 24 sessions for 8 weeks task specific training based on the motor relearning programme and 10 minutes of the EMS of each muscle during the session."
223894204|NCT06561854|DRUG|Dexamethasone|"ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)"
223894205|NCT05392192|DRUG|ADX-629|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
223894206|NCT05392192|DRUG|Placebo|Subjects will be randomized to receive both ADX-629 and placebo in one of two treatment sequences: One group of subjects will receive ADX-629 during the 1st treatment period and matching placebo during the 2nd Treatment while subjects the other sequence/group will receive the matching placebo in the 1st treatment period and ADX-629 in the 2nd treatment period.
223894207|NCT06379360|DRUG|Hypomethylating agent, Azacitidine or Decitabine|All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
223894208|NCT06104800|OTHER|Calorie-restricted diet with red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (including red meat), 50% carbohydrates, and 25-30% fats.
223894209|NCT06104800|OTHER|Calorie-restricted diet without red meat|Calorie-restricted diet with macronutrient distribution: 1.5 g/kg of ideal body weight in protein (excluding red meat), 50% carbohydrates, and 25-30% fats
223894210|NCT05542238|BEHAVIORAL|One bout of moderate-intensity sub-maximal aerobic exercise|The intervention is a 20-min acute exercise using arm ergometer
223894211|NCT05820997|DRUG|Ropivacaine|Paravertebral at the T7-10 levels bilaterally with 5 cc of 0.5% ropivacaine at each level
223894212|NCT06093841|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
223894213|NCT06093841|DRUG|Fludarabine|Administered according to package insert
223894214|NCT06093841|DRUG|Cyclophosphamide|Administered according to package insert
223711029|NCT01706796|DRUG|PF-06273340|Immediate Release Tablet, single dose, fasted
223711030|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
223711031|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
223894215|NCT06248476|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation is non-invasive stimulation technique which modifies cortical excitability through forming magnetic field
223894216|NCT04010968|DRUG|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~* if BM MRD at M9 \< 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~* if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
223894217|NCT04010968|DRUG|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
223894218|NCT05602779|DEVICE|tVNS Program|Participants will use the Neuvana Xen device 30 minutes a day for 30 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
223894219|NCT05602779|OTHER|Phone App Program|Participants will have access to a specially designed phone app (MindTiles) in order to play a game designed for this study. Participants in the active intervention will be able to connect with a fellow participant who is matched as their peer for social support and they will complete a daily puzzle together and respond to a conversational prompt to encourage communication.
223894220|NCT05602779|COMBINATION_PRODUCT|tVNS and Phone App Program|Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
223894221|NCT05602779|OTHER|Sham tNVS and Control App|Participants will have access to our program's phone app so the can complete the daily puzzle on their own. They will also engage in a sham tVNS session for 30min per day for 30 days during which no stimulation is provided.
223527827|NCT03515421|DEVICE|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
223527828|NCT06544460|PROCEDURE|Secondary cytoreduction|Repeated tumor cell reduction surgery for recurrent ovarian cancer patients
223711032|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
223711033|NCT01706796|DRUG|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
223711034|NCT05132634|OTHER|Hand Massage|Like a massage, the superficial kneading technique which is included in the Swedish massage technique will be applied in a way to create a slight pressure on the patient, and it will be terminated again with the effleurage technique. The procedure was concluded in a way that each massage technique was applied and the massage was for a total of 15-20 minutes.
223711035|NCT03944031|DRUG|LY3372689|Administered orally.
223894222|NCT06405971|DRUG|Metformin|Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
223894223|NCT06262139|DRUG|MT218 injection|a targeted magnetic resonance imaging contrast agent
223894224|NCT04711551|COMBINATION_PRODUCT|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices|PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices
223894225|NCT06813807|DRUG|0.5% TM|From D1 to D10, each subject will receive one drop of 0.5% timolol maleate ophthalmic gel forming solution each in the left and right eyes once daily at the same time every day under fasted condition.
223894226|NCT05415124|DEVICE|HemoPill|The HemeoPill acute capsule is a small, single use, swallowable capsule with optical sensor. Blood detection by direct measurement of blood in the sensor gap, even in an unprepared digestive tract. Wireless transmission of measured values to the HemoPill Receiver. The maximum measuring time is 9 hours. The length of the capsule is 26.3 mm and the diameter is 7.0 mm.
223894227|NCT05415124|PROCEDURE|Endoscopy|Endoscopy is performed as scheduled.
223894228|NCT04353804|OTHER|Treatment Arm: Computerized Cognitive Rehabilitation|Treatment Arm: Computerized Cognitive Rehabilitation
223894229|NCT04353804|OTHER|Active Control computer games|Active Control computer games
223894230|NCT04065776|RADIATION|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
223894231|NCT04561232|BEHAVIORAL|Prone and Upright Locomotor Training|"During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve."
223711036|NCT03944031|DIAGNOSTIC_TEST|[18F]LSN3316612|Administered IV.
223711037|NCT02295410|BEHAVIORAL|CPT|
223711038|NCT00222560|BEHAVIORAL|Intensive physical activity counselling by an integrated physical activity counsellor|
223711039|NCT02502318|PROCEDURE|Video-thoracoscopy|
223711040|NCT02502318|PROCEDURE|thoracotomy|
223711041|NCT00645749|BIOLOGICAL|Helminth ova|2500 ova per dose (liquid form)
223711042|NCT06556771|OTHER|Gongs mobilization + conventional physical therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks
223711043|NCT06556771|OTHER|Kaltenborn mobilization along with traction + conventional therapy|3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks.
223711044|NCT04261868|DEVICE|Virtual Reality|New treatment for amblyopia therapy using playing games
223711045|NCT04261868|OTHER|Patching|Patching
223711046|NCT04044495|OTHER|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
223711047|NCT04044495|OTHER|Actimetry|7 days actimetry
223711048|NCT04044495|OTHER|Sleep Diary|7 days Record of sleep and wake cycle
223711049|NCT06412224|DRUG|RRG001|Administered by subretinal injection. Dosage form: injection.
223711050|NCT00795847|DRUG|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
223894232|NCT06797960|DEVICE|Ultra sound guided Injection of PRF intra articularly|Intra articular injection of PRF
223894233|NCT06797960|DRUG|Intra articular injection of HA|Intra articular injection of HA
223894234|NCT06798480|OTHER|Self-administered survey|An anonymous self-administered online questionnaire hosted on LimeSurvey, lasting approximately 20 minutes, will be completed by participants. A panel of participants representative of the general population will be provided by the Selvitys Institute. In parallel, the self-administered questionnaire will also be distributed via posts on social media platforms (Facebook, YouTube, Instagram, TikTok, Snapchat, and X) over a period of three months.
223894235|NCT05353829|DRUG|Methotrexate|When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
223894236|NCT01901770|OTHER|educational intervention|Receive HPV vaccination educational materials
223894237|NCT01901770|OTHER|educational intervention|Receive influenza vaccination educational materials
223894238|NCT05079789|DRUG|Amiloride|Treatment with amiloride, start dose 5 mg
223894239|NCT05079789|DRUG|Furosemide|Treatment with furosemide, start dose 40 mg
223894240|NCT05329493|DEVICE|Cooling digit device application|Cooling digit device will be applied on subject's right hand ( fifth finger).
223894241|NCT03513614|PROCEDURE|Tailored axillary surgery - both Arms|Axillary lymph node dissection - Arm A
223894242|NCT03513614|RADIATION|Radiotherapy - Arm A|Regional nodal irradiation excluding the dissected axilla - Arm A
223894243|NCT03513614|RADIATION|Radiotherapy - Arm B|Regional nodal irradiation including the full axilla - Arm B
223894244|NCT06167343|PROCEDURE|ACL reconstruction|In addition to surgical reconstruction, any structures that may have been injured concomitantly (meniscus, other ligament) will be repaired in the same surgery.
223894245|NCT06227832|DRUG|KP-001|KP-001
223894246|NCT06227832|DRUG|Metformin|oral dose of 850 mg Metformin
223894247|NCT06227832|DRUG|Midazolam|oral dose of 2 mg Midazolam
223894248|NCT06227832|DRUG|Clarithromycin|oral doses of 1000 mg Clarithromycin
223894249|NCT05578612|PROCEDURE|Dorsal Spanning Bridge Plate Fixation|Dorsal spanning bridge fixation will be performed by board-certified orthopedic surgeons per standard technique.
223894250|NCT05578612|PROCEDURE|Dorsal Spanning Bridge Plate Removal|Dorsal spanning bridge removal will be performed by board-certified orthopedic surgeons per standard technique.
223711051|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
223711052|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
223711053|NCT01474083|DRUG|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
223711054|NCT01474083|DRUG|Placebo|Dose-matched placebo. Oral administration.
223711055|NCT06503055|OTHER|Questionnaire|"A questionnaire targeting a convenience sample of medical field professionals including physicians with different specialties, pharmacists, medical students, nursing staff, and the general population in Gharbia governorate (about 1000 subjects).~The questionnaire will be written and digital in both Arabic and English versions. Moreover, an awareness campaign will be designed to educate the participants on appropriate antibiotic use principles."
223711056|NCT05128318|PROCEDURE|Nissen Fundoplication, cholecystectomy|Collection of adipose tissue pieces in the context of programmed abdominal surgery to treat to treat hiatal hernia, gastroesophageal reflux or vesicular lithiasis. During the surgery treatment, adipose tissue of 1-2 cm3 will be collected for the protocol by laparoscopy by the surgeon in charge of the procedures.
223711057|NCT01536470|OTHER|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
223711058|NCT01536470|OTHER|Ephedryne chorydrate|
223711059|NCT02645097|PROCEDURE|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
223894251|NCT05441969|OTHER|No intervention/expousure|No interventions/expousure since this is an observational study.
223527829|NCT06544460|DRUG|Hyperthermic intraperitoneal chemotherapy|Using the BR-TQR-I intraperitoneal hyperthermic perfusion chemotherapy instrument, after the surgical operation is completed, four drainage tubes are placed in the left and right upper abdomen and lower abdomen respectively. Connect all pipelines and preheat the instrument before starting treatment. The treatment temperature is controlled at 43 ℃± 0.1 ℃, the treatment time is 90 minutes, and the circulation pump flow rate is 400-600ml/min. Within 48 hours after the surgery, cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion. Through the comprehensive effects of circulation flushing, hyperthermia, chemotherapy, and thermochemotherapy sensitization, it kills and removes residual cancer cells or small lesions in the abdominal cavity.
223527830|NCT06634498|OTHER|real rTMS on the dlPFC|During real rTM session, participants will perform the regulation of craving (ROC). In the rest phase, participants need to relax and rest. In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
223527831|NCT06634498|OTHER|Sham (No Treatment)|During the sham rTMS session, participants will perform the regulation of craving (ROC). In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
223527832|NCT00895921|DRUG|Olanzapine|Single intramuscular 10-mg dose
223527833|NCT00895921|DRUG|Aripiprazole|Single intramuscular 9.75-mg dose
223527834|NCT00002673|PROCEDURE|infection prophylaxis and management|
223527835|NCT01451021|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
223527836|NCT03401866|DIAGNOSTIC_TEST|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
223527837|NCT04602845|DRUG|Fentanyl|50ug Fentanyl intravenously
223527838|NCT04602845|DRUG|Flurbiprofen|50mg Fentanyl intravenously
223527839|NCT04602845|DRUG|Midazolam|2.5mg midazolam in 2ml normal saline intravenously
223527840|NCT04602845|DRUG|Remimazolam|3mg Remimazolam in 2ml normal saline intravenously
223527841|NCT05835648|DIETARY_SUPPLEMENT|Nutrasumma|On the basis of daily diet, dietary fiber supplement (Nutrasumma) was given once a day, 1 strip each time, before meals, and the intervention lasted for 3 months.
223527842|NCT00757068|BEHAVIORAL|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
223527843|NCT00757068|BEHAVIORAL|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
223527844|NCT02873156|DRUG|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
223527845|NCT02873156|DRUG|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
223527846|NCT00030264|DRUG|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
223527847|NCT00030264|DRUG|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
223527848|NCT00950521|PROCEDURE|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
223527849|NCT00950521|DRUG|convention therapy|antiplatelet
223527850|NCT00240877|BIOLOGICAL|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
223527851|NCT00240877|OTHER|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
223527852|NCT02012517|DRUG|Prolonged antibiotic treatment|
223527853|NCT02012517|DRUG|Short antibiotic course (standard of care)|
223527854|NCT01358734|DRUG|Azacitidine|Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
223527855|NCT01358734|DRUG|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
223527856|NCT01358734|OTHER|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
223527857|NCT04513236|OTHER|Pre-survey incentive|An incentive of is given in the form of airtime to motivate participants to complete the survey. Participants were sent 0.1X before the were sent a mobile phone survey and an additional 1X after completing the survey.
223527858|NCT04513236|OTHER|Post-survey incentive|An incentive in the form of airtime to motivate participants to complete the survey. Participants were given Bangladeshi Taka or Ugandan Shillings worth of certain airtime for completing the survey.
223527859|NCT01202695|DRUG|AVP-21D9|intravenously, single dose
223527860|NCT01202695|DRUG|Placebo|Placebo comparator
223527861|NCT00355043|DRUG|Zinc sulphate 20 mg|
223527862|NCT01421056|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
223527863|NCT01421056|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
223527864|NCT01421056|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
223711060|NCT00939640|BEHAVIORAL|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
223711061|NCT05954702|PROCEDURE|Supercharged TRAM esophagectomy|Esophagectomy, immediately followed by supercharged esophagogastroplasty. Use the transverse rectus abdominis myocutaneous (TRAM) flap transfers to surgically create a new anastomosis in the left gastroepiploic vessels.
223711062|NCT05954702|PROCEDURE|Conventional Esophagectomy|Esophagectomy, immediately followed by an esophagus reconstruction trough esophagogastroplasty.
223711063|NCT05745012|PROCEDURE|endoscopic mucosal resection|The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.
223711064|NCT05745012|PROCEDURE|sham|The procedure consists of performing endoscopic exploration, no mucosal resection
223711065|NCT04205981|OTHER|Aerobic exercise|8-week aerobic exercise (moderate intensity), 5 times per week, 60 min per session. Exercise training under supervision of trained staff.
223711066|NCT00886561|BEHAVIORAL|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
223711067|NCT03882112|DRUG|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
223711068|NCT03395392|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
223894252|NCT05574946|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction with four strand semitendinosus graft
223939940|NCT07190105|OTHER|Truvaga Electrical Vagus Nerve Stimulator|The Truvaga Electrical Vagus Nerve Stimulator is a general wellness product that sends gentle electrical signals through the skin to stimulate the vagus nerve on the neck.
223527865|NCT06489015|DRUG|Recombinant Human Serum Albumin|Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
223527866|NCT03823989|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
223527867|NCT03823989|RADIATION|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
223527868|NCT06211699|PROCEDURE|Omentopexy with Laparoscopic Sleeve Gastrectomy|Patients with omentum sewed to the remnant gastric staple line during laparoscopic sleeve gastrectomy.
223527869|NCT06211699|PROCEDURE|Clips with Laparoscopic Sleeve Gastrectomy|Patients performed clips to the remnant gastric staple line during laparoscopic sleeve gastrectomy
223527870|NCT05299515|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately four weekly core sessions (approximately 30 minutes-1 hour) with two additional sessions to reinforce core content, and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to assist in their retention and persistence in methadone treatment and incorporating value-driven, substance-free, rewarding activities into their daily life."
223711069|NCT03395392|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
223711070|NCT01513096|DRUG|itopride|itopride, 10mg, twice per day, for 1 day
223711071|NCT02433457|DRUG|CC-292|
223711072|NCT02433457|DRUG|Oral Omeprazole (OMP)|
223711073|NCT00736424|DEVICE|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
223711074|NCT00789490|DIETARY_SUPPLEMENT|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
223711075|NCT00789490|DIETARY_SUPPLEMENT|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
223711076|NCT01050283|PROCEDURE|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
223711077|NCT01743183|DEVICE|Threshold|The load adjustment was done weekly by a single examiner.
223711078|NCT00023946|DRUG|ixabepilone|Given IV
223711079|NCT00023946|OTHER|laboratory biomarker analysis|Correlative studies
223711080|NCT03142178|DRUG|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
223711081|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
223711082|NCT03142178|DRUG|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
223711083|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
223711084|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
223711085|NCT03142178|DRUG|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
223711086|NCT00092157|DRUG|MK0733, simvastatin|
223711087|NCT00092157|DRUG|Comparator: simvastatin|
223711088|NCT02386631|DEVICE|Custom Made Orthotic|Provides longitudinal arch support
223711089|NCT03730675|PROCEDURE|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
223711090|NCT03730675|PROCEDURE|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
223711091|NCT03730675|DRUG|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
223711092|NCT05732246|OTHER|First rib mobilization with balloon breathing exercises|Patient was in the supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner would palpate 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depressed the first rib as able during exhalation.
223711093|NCT03023462|DRUG|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
223711094|NCT03023462|DRUG|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
223711095|NCT03023462|DRUG|Ropivacaine|Local anesthetic for the block
223894253|NCT05218447|DEVICE|Robotic Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
223711096|NCT02494674|BEHAVIORAL|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
223711097|NCT00002532|BIOLOGICAL|filgrastim|
223711098|NCT00002532|DRUG|asparaginase|
223711099|NCT00002532|DRUG|cytarabine|
223711100|NCT00002532|DRUG|daunorubicin hydrochloride|
223711101|NCT00002532|DRUG|dexamethasone|
223711102|NCT00002532|DRUG|etoposide|
223711103|NCT00002532|DRUG|idarubicin|
223711104|NCT00002532|DRUG|ifosfamide|
223711105|NCT00002532|DRUG|leucovorin calcium|
223711106|NCT00002532|DRUG|methotrexate|
223711107|NCT00002532|DRUG|prednisolone|
223711108|NCT00002532|DRUG|vindesine|
223711109|NCT06371443|BEHAVIORAL|Sucking and swallowing exercises|Sucking-swallowing exercises were applied to premature infants in the experimental group (n=41) for 14 days, once a day, 12 minutes before feeding.
223711110|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
223711111|NCT02385682|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
223711112|NCT02169479|DRUG|BIA 9-1067|OPC, Opicapone
223711113|NCT02169479|DRUG|Placebo|PLC, Placebo
223711114|NCT02169479|DRUG|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
223711115|NCT04634383|DEVICE|WFMA - wireless floating microelectrode array|Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
223711116|NCT00431769|DRUG|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m\^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m\^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
223711117|NCT06327009|BEHAVIORAL|fasting month of ramadan|100 patients with glomerulonephritis who decided to fast month of ramadan
223711118|NCT02645201|DIETARY_SUPPLEMENT|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
223711119|NCT02645201|OTHER|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
223894254|NCT05218447|OTHER|Usual Care (UC) Gait Training|"Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting.~Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity."
223894255|NCT04474353|DEVICE|Optune|Noninvasive, portable device which generates tumor treating fields (TTFields) manufactured by Novocure
223894256|NCT04474353|DRUG|Gadolinium|Gadolinium contrast medium
223894257|NCT04474353|DRUG|Temozolomide|Chemotherapy agent
223894258|NCT04474353|RADIATION|Stereotactic radiosurgery (SRS)|Standard of Care: SRS (35 Gy in 5 fractions of 7 Gy), 5-day treatment from Day 2
223894259|NCT05345327|DRUG|Dapagliflozin|SGLT2 inhibitor
223894260|NCT05345327|DRUG|Metformin|Metformin
223894261|NCT05908344|DEVICE|Activated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system capable of producing a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a powered device experiences its specific area of effect. The field potentials generated by the pad are hypothesized to have benefit for sleep.
223894262|NCT05908344|DEVICE|Deactivated Sleep Pad system (Frequen-ZZZ)|The investigational device is a sleep pad and bedside controller system that produces a low-level radio-frequency field potential. An individual laying in the correct orientation and with correct contact distance from the pad portion of a non-powered device experiences all functional aspects of the device except the intended magnetic field potential that is hypothesized to have benefit for sleep.
223894263|NCT05305235|DEVICE|RISE Guide|Smartphone-based intervention that uses Cognitive Bias Modification to change perceptions of stress.
223894264|NCT05305235|DEVICE|Relaxation Control|Guides users through relaxation techniques.
223894265|NCT06451809|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
223894266|NCT05697393|DEVICE|Shaker Pressure Band|
223894267|NCT05885360|DRUG|Istradefylline Pill|"Istradefylline targets adenosine A2A receptors in the basal ganglia, by inhibiting the indirect pathway It is an adjunctive treatment to carbidopa-levodopa indicated to improve on time and decrease off time."
223894268|NCT04257097|DEVICE|RPM - Osteogenics Lubbock Texas USA|25 patients will undergo bone regeneration with a reinforced PTFE mesh, manually shaped and modelled by the operator during surgery (traditional technique), covered with collagen membranes of medium-rapid resorption
223894269|NCT04257097|DEVICE|Yxoss CBR - Reoss Filderstadt Germany|25 patients undergo bone regeneration with a custom-made titanium mesh, digitally designed by an operator before the surgery (digital technique), covered by collagen membranes with medium-rapid resorption
223894270|NCT03352258|RADIATION|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
223894271|NCT04256954|BEHAVIORAL|Peer navigation intervention|A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
223894272|NCT06550141|DRUG|Emapalumab|An interferon gamma (IFNγ) blocking antibody
223894273|NCT06550141|DRUG|Cyclophosphamide|Alkylating agent
223894274|NCT06550141|DRUG|Fludarabine Phosphate|Purine antagonist antimetabolite
223894275|NCT06550141|DRUG|Axicabtagene Ciloleucel|Autologous treatment
223894276|NCT03195699|DRUG|TTI-101|Oral capsule
223894277|NCT03195699|DRUG|TTI-101|Oral tablet
223894278|NCT06256003|DEVICE|UC-A|Mobile app digital therapy
223894279|NCT06256003|DEVICE|UC-N|Mobile app digital therapy
223894280|NCT02924272|DRUG|Ixazomib|Ixazomib Capsules
223894281|NCT05546749|DEVICE|RelieVRx|The virtual reality device that will be piloted is called RelieVRx, which incorporates evidence-based principles of cognitive behavioral therapy, mindfulness, and pain neuroscience education into an immersive and enhanced biofeedback experience. RelieVRx includes breathing training and relaxation response exercises that activate the parasympathetic nervous system. RelieVRx was designed for at-home use and comes with a sequence of daily immersive experiences.
223527871|NCT04223271|DIAGNOSTIC_TEST|Indicor|Handheld device with attached PPG sensor that is paired with a tablet to estimate left ventricular end diastolic pressure. Subjects will blow into the device in order to perform a standardized Valsalva maneuver for 10 seconds. The index finger will be resting in the PPG sensor during the test. Each test requires three efforts, with 45 seconds rest between efforts.
223894282|NCT05546749|DEVICE|Sham VR|The sham VR control is a non-immersive set of 56 daily virtual experiences, tuned to the length of the RelieVRx.
223894283|NCT06213194|OTHER|MindZone|The name of the online training will be MindZone. It consists of combined game-based social cognitive and executive functions skills, and it will be presented on the training website. There is no consensus about the length of time for the training in the literature, so the average time for the training process will be used. This means that the training will last 6 weeks, 7.5 hours in total. To satisfy the training requirement, 1.15 hours (75 mins) of play will be expected from participants each week. Before each game, a brief introduction about the game will be presented and participants will get feedback about their progress. Each participant will conduct the tasks in a different random order. After 6 weeks, a post-test will be completed, and follow-up scores will be obtained after a month. All tasks were designed according to the five intervention areas: working memory, cognitive flexibility, inhibition, cognitive empathy and affective empathy based on the literature.
223894284|NCT04496947|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~* Elicitation of the Relaxation Response (RR) through mind-body techniques;~* Discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and~* Coping strategies and adaptive perspective-taking to promote positive well-being."
223527872|NCT05477888|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,the Penn State Electronic Cigarette Dependence Index (PS-ECDI ).
223894285|NCT04952909|DEVICE|ShortCut™|Splitting bioprosthetic aortic valve leaflets
223894286|NCT04701047|DEVICE|vaginal pessary|insertion and follow up of a vaginal pessary
223894287|NCT04701047|PROCEDURE|Vaginal prolapse surgery|surgery and follow up after vaginal prolapse surgery
223894288|NCT05703490|DIAGNOSTIC_TEST|IADLSys system|Subjects will receive IADLSys system which includes interactive tablet and 5 paired pTAGs (bluetooth sensors to attach to objects of interest at home). The pTAGs monitor activities of daily living to assess if they are being completed and communicate with the tablet to keep record of interactions. We anticipate IADLSys enables to distinguish between groups with and without cognitive impairment and determine the severity of cognitive impairment in the cognitive impaired group.
223894289|NCT05610670|OTHER|Questionnaire|The questionnaire will allow us to complete the information and to collect their experiences regarding the desire and/or achievement of a pregnancy, but also their gynecological follow-up in the broad sense, on the other hand.
223894290|NCT05634954|DRUG|GEH121224 (18F) Injection|Single GEH121224 (18F) Injection
223894291|NCT05634954|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT Scan|Group 1: Dynamic whole-body PET/CT scan will start at the time of injection (8 sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 120 minutes and 240 minutes after injection.
223894292|NCT05634954|DIAGNOSTIC_TEST|Static - PET/CT Scan|Group 2: Static whole-body scans
223894293|NCT06538675|OTHER|Psychotherapy|Patients are assigned to a therapist and will receive psychotherapy
223894294|NCT06546293|OTHER|core stabilization exercises|The program consists of lumbo-pelvic/core strength and stability exercises. The program will be implemented individually under the supervision of a physiotherapist twice a week for 12 weeks.
223894295|NCT06546293|OTHER|daily physical activity program|The program consists of a daily physical activity program established and monitored for participation through weekly exercise tracking chart. The program will be implemented through weekly physiotherapist's control of the exercise tracking chart for 12 weeks.
223894296|NCT06537063|OTHER|G4 DNAm test|Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.
223894297|NCT05182827|OTHER|Tactile stimulation|"The experimental task aims to evaluate the hedonic nature of an affective touch by tactile stimulation.~It consists in stimulating two adjacent regions of the left forearm, delimited and marked, of 9 cm x 4 cm each. In order to limit habituation, the stimulation areas will be alternated.~To stimulate these areas, the investigator (previously trained) strokes the participant with a brush at an optimal speed to stimulate the C-fibers (3 cm/s; slow speed) or not (18 cm/s; fast speed).~Touch will consist of 30 seconds blocks of stimulation, performed on one of the two identified areas, from the elbow to the wrist. In total, 6 stimulation blocks will be done (3 slow and 3 fast), the order and location of which will be random in order to limit habituation.~This stimulation is completely painless. After each block, the participant will evaluate the intensity of the stimulation and its pleasantness."
223894298|NCT06439147|PROCEDURE|U shaped capsular incision during capsulorrhaphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base
223894299|NCT06439147|PROCEDURE|T-shaped capsular incision diuring capsulorraphy|Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
223894300|NCT06438705|DIAGNOSTIC_TEST|SPECT-CT imaging|The subjects were intravenously injected with 99mTc labeled FAPI imaging agent, and drank 300-500ml of water after administration. SPECT-CT imaging was performed 60 minutes later
223894301|NCT03991481|BIOLOGICAL|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
223894302|NCT03991481|BIOLOGICAL|Liquid-stored platelets|Liquid-stored platelets as per standard practice
223894303|NCT06415838|BEHAVIORAL|Brief Behavioral Activation|"A five-session brief behavioral activation treatment delivered face-to-face in the participants' home.~Session outline:~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan."
223894304|NCT06415838|OTHER|Care as Usual|Care as Usual provided by primary care and/or municipal care.
223894305|NCT04378439|BEHAVIORAL|Peer Navigation|"First, as health advisors, community health leaders will raise awareness of HIV, STIs, and HCV and local prevention and care services and help social network members access services. Thus, the community health leader will describe to the process for HCV testing, and how providers are required to maintain confidentiality. As opinion leaders, community health leaders will reframe health-compromising and bolster health-promoting norms and expectations about testing and use of other prevention and care services.~Each community health leader will also conduct formal in-person group activities with their social network members. Our partnership decided that each community health leader will also hold at least 4 formal group sessions during the 12 months of intervention"
223894306|NCT04378439|BEHAVIORAL|mHealth|"In addition to in-person individual and group activities, community health leaders will use mHealth platforms preferred by each social network member (i.e., Facebook , Instagram, testing, and/or GPS-based mobile apps) to communicate with them during the intervention. They will use social media to plan activities and to support use of needed prevention and care services. For example, when planning a group activity (described above), the community health leader will use social media to remind social network members about the activity and help them problem solve barriers to attending. A community health leader and social network member may also communicate in-real-time via social media about the process of participating in a syringe services program or accessing PrEP."
223939941|NCT07188506|DIAGNOSTIC_TEST|Clinical and blood parameters|Clinical data and MRI measurements
223939942|NCT07188506|GENETIC|Illumina Infinium Global Screening Array 4.0 (GSA 4.0)|Genomic analyses
223894307|NCT05308004|OTHER|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering
223894308|NCT06507345|OTHER|Opioid Analgesia (OA) [Multimodal analgesia including opioid drugs]|In line with current standard care, discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs given at regularly scheduled intervals) and opioid tablets 'as needed' for breakthrough pain (i.e., pain that erupts while patients are already taking analgesics). Non-pharmacological pain interventions (i.e., icepacks, music, meditation.) may be recommended by some surgeons as part of standard practice. Given the pragmatic nature of the trial, the specific around-the-clock analgesia and rescue opioid regimens and other non-pharmacological interventions will be determined by the patient's surgeon discretion considering the breast procedure undertaken, co-morbidities, and patient preference.
223894309|NCT06507345|OTHER|Opioid-Free Analgesia (OFA) [Multimodal analgesia not including opioid drugs]|Discharge prescriptions for this group will include around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs). In case of breakthrough pain, rescue analgesia may be provided by (1) using evidence-based non-pharmacological pain interventions (i.e., icepacks, music, and meditation), (2) adding non-opioid drugs not included in the initial regimen, or (3) switching drugs targeting individual variances in analgesia response. The specific around-the-clock and rescue OFA regimens will be determined by the patient's surgeon considering the type of procedure, co-morbidities, and patient preference.
223894310|NCT04302727|BEHAVIORAL|Med-South Weight Loss Intervention|Phase I is a 4-month lifestyle program focused on the basics of healthy eating. Phase II (8 months) focuses on weight loss, followed by a year-long (Phase III) focused on weight loss maintenance. In Phase I, the main counseling sessions happen at monthly visits, with added check-in phone calls. In Phase II, the main counseling sessions will occur weekly for 6-8 weeks. There are also check-in phone calls - number based on weight loss progress. During Phase III, there are 2 main visits and follow-up phone calls. Counseling visits will be in-person with a health counselor and by phone. Of the 14 core counseling sessions, the in-person format will be required for only 4 (the 1st session of each Phase and after 2 months of the weight loss program). The program also includes brief phone calls to check on progress towards goals for lifestyle change. The number of phone calls will depend on success in meeting personal weight loss goals in Phase II or keeping the weight off in Phase III.
223894311|NCT04302727|BEHAVIORAL|WW|If participants are randomized to WW™, they will have access to both the workshop and digital components of the WW™ program for 2 years. The workshop component includes the option of attending weekly group meeting at a WW™ studio (local WW™ office). The digital component can be accessed using the WW™ website or the smart phone App. The study research staff will provide basic instructions on how to use the WW™ digital resources.
223894312|NCT06129825|OTHER|Prospective|Single arm, healthy adult volunteers for blood donation.
223894313|NCT03575897|DIAGNOSTIC_TEST|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
223894314|NCT05167968|OTHER|No intervention (Observational cohort)|"For each patient, evaluation and adhesion to diuretics at inclusion are recorded:~* Self-questioning of medication adherence: Girerd questionnaire~* Assessment of the Medication Possession Ratio~* Social and demographic data~* Comorbidities~* PH characteristics"
223894315|NCT04962672|DRUG|Propofol group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive total intravenous anesthesia (propofol group). Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the propofol group will receive continuous infusions of propofol and remifentanil. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
223894316|NCT04962672|DRUG|Sevoflurane group|20 patients scheduled for the elective craniotomy for suspected high-grade gliomas resection will be enrolled and further randomized to receive Volatile (sevoflurane group) agent for the maintenance phase of anesthesia. Standard fasting and monitoring guidelines will be instituted. All patients will be induced and intubated after administration of intravenous boluses of fentanyl, propofol and rocuronium. For the maintenance phase of anesthesia, patients in the volatile inhalational anesthesia group received a volatile inhalational agent (sevoflurane) and remifentanil infusion. No patients will receive nitrous oxide. Anesthesia will be titrated to keep depth of anesthesia between 35- 55. All patients will be maintained on oxygen in air mixture (40%) and titrate the End Tidal Carbon Dioxide (ETCO2) concentration between 25-30 mm Hg.
223894317|NCT03525964|PROCEDURE|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia \[1\]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
223894318|NCT03525964|PROCEDURE|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
223894319|NCT03525964|PROCEDURE|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
223894320|NCT00916201|DRUG|URB597|10 mg / d for 5 days, orally
223894321|NCT00916201|DRUG|intranasal Insulin|160 IU / d for 5 days, intranasal
223894322|NCT00916201|DRUG|Cannabidiol CR|320 mg / d for 5 days, orally
223894323|NCT04859283|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
223894324|NCT04859283|DRUG|Placebo|Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
223894325|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
223894326|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
223894327|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
223894328|NCT03981952|BIOLOGICAL|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
223894329|NCT03981952|OTHER|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
223894330|NCT04267172|BEHAVIORAL|Surgical simulation training in primary Total Hip Arthroplasty|The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.
223894331|NCT04267172|OTHER|No intervention: Surgical Resident Control Group|Control Group
223894332|NCT04267172|OTHER|No Intervention: Consultant and Fellow Comparator Group|Comparator Group
223894333|NCT06014411|OTHER|Time to bathing (delayed)|Delayed bathing-- patients will be told to begin showering after wound exam and suture removal (10-20 day postoperative).
223894334|NCT06014411|OTHER|Time to bathing (early)|Early bathing--Patients will be told to remove dressings and begin showering with body soap on postoperative day 3.
224276319|NCT01557062|OTHER|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
223894335|NCT05827809|BEHAVIORAL|Unified Protocol (UP-C/A) for children and youth with anxiety disorders and /or depression|A transdiagnostic psychological group treatment, Unified Protocol (UP-C/A), one intervention, is tested for children and youth with anxiety disorders and/or depression seeking help in routine care in two primary care locations. Parents are at the same time offered parent training in a group format coupled with the module the children are working on. Feasibility, acceptability and effect of the intervention will be studied, with child self-report, parent-report and therapist assessment.
223894336|NCT05483283|OTHER|Empowerment and Navigation|Empowerment and Navigation
223894337|NCT05483283|OTHER|SOC|SOC
223894338|NCT05618054|BEHAVIORAL|Looming task|Participants will be asked to look at some pictures during an fMRI scan. Participants will press a button as soon as they see the image appear.
223894339|NCT05984511|PROCEDURE|I-125 Seeds Brachytherapy in PVTT|Iodine125 seed implantation into the PVTT was conducted 3-7 days after TACE when the results of the liver function tests were comparable to those obtained before TACE. Pre-procedural planning was conducted using a three-dimensional conformal radiation therapy treatment planning system (TPS) to determine the number of Iodine125 seeds required, the target location for implantation, the best percutaneous puncture site and the access route. The targeted zone for implantation was the tumour thrombosis in the segmental portal vein, left/right portal vein. Implantation was guided by CT, and the Iodine125 seeds were implanted into the PVTT using 18 G needles and the implantation gun that housed the Iodine125 seeds in the cartridge chamber.
223894340|NCT05984511|PROCEDURE|Transcatheter arterial chemoembolization|TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE).
224276320|NCT01557062|OTHER|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
223527873|NCT05242939|OTHER|Video game|The child will be allowed to play the game they want to play throughout the entire procedure, starting 5 minutes before the inhalation therapy. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
223894341|NCT05984511|DRUG|Atezolizumab plus Bevacizumab|Atezolizumab/bevacizumab (1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks) .
223894342|NCT04645550|DRUG|Apixaban|From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
223894343|NCT04645550|DRUG|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
223894344|NCT04645550|DRUG|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
223894345|NCT04645550|DRUG|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
223894346|NCT04645550|DRUG|Low molecular weight heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
223894347|NCT04191460|DRUG|cRGD-ZW800-1.|Injection of cRGD-ZW800-1 within 48 hours before imaging/surgery
223894348|NCT05886816|DRUG|Mitoquinone/mitoquinol mesylate|Mitochondrial antioxidant
223894349|NCT05886816|OTHER|Placebo|Placebo pills
223894350|NCT06315374|OTHER|Use soft mist inhaler|Only use soft mist inhaler
223894351|NCT06315374|DEVICE|Use soft mist inhaler with a 3D assistive device|Use soft mist inhaler with a 3D-printed assist device
223894352|NCT06107738|DRUG|Iberdomide|Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.
223894353|NCT06107738|DRUG|Daratumumab/rHuPH20 Co-formulation|"Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)"
223894354|NCT03206671|DRUG|Rituximab window|Rituximab window (375 mg/m²)
223894355|NCT03206671|DRUG|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
223894356|NCT03206671|DRUG|Cyclophosphamide|see detailed protocol description
223894357|NCT03206671|DRUG|Cytarabine|see detailed protocol description
223711120|NCT05656508|BIOLOGICAL|ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)|2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
223711121|NCT04971421|DIAGNOSTIC_TEST|ctDNA - circulating tumor DNA|lcWGS and WGS of circulating tumor DNA
223711122|NCT04971421|DIAGNOSTIC_TEST|TEP - Tumor Educated Platelets|sequencing miRNA from TEPs
223711123|NCT03985059|OTHER|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
223711124|NCT05943028|DRUG|Subanesthetic dose of esketamine|Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
223711125|NCT00039078|RADIATION|yttrium Y 90 glass microspheres|
223711126|NCT02326792|OTHER|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
223711127|NCT00005044|DRUG|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
223711128|NCT00005044|DRUG|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
223711129|NCT00005044|DRUG|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
223894358|NCT03206671|DRUG|Dexamethasone|see detailed protocol description
223894359|NCT03206671|DRUG|Doxorubicin hydrochloride|see detailed protocol description
223894360|NCT03206671|DRUG|Vindesine Sulfate|see detailed protocol description
223894361|NCT03206671|DRUG|Etoposide|see detailed protocol description
223894362|NCT03206671|DRUG|Ifosfamide|see detailed protocol description
223894363|NCT03206671|DRUG|Methotrexate|see detailed protocol description
223894364|NCT03206671|DRUG|Prednisolone|see detailed protocol description
223894365|NCT03206671|DRUG|Vincristine|see detailed protocol description
223894366|NCT05424237|BEHAVIORAL|App intervention|usual care plus app ussage with the aim of promote healthy behaviors (diet, physical activity and weight)
223894367|NCT05290792|BIOLOGICAL|Administration of FluMist (Live Attenuated Influenza Vaccine)|Participants will received the intranasal FluMist vaccine that will serve as a proxy for a viral respiratory tract infection and trigger a mild immune response.
223894368|NCT04087707|DRUG|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
223894369|NCT04087707|DRUG|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
223894370|NCT04087707|DRUG|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
223894371|NCT01519154|DRUG|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
223894372|NCT01519154|DRUG|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
223894373|NCT06796387|BEHAVIORAL|Enhanced Implementation of SBAT|"For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~* Telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT school-based DOT of preventive asthma medications~* Follow-up telemedicine asthma control assessments~* Centralized case management support~* Care coordination"
223939943|NCT07188506|DEVICE|dTMS treatment|high-intensity deep transcranial magnetic stimulation (dTMS) device recognized for clinical application in mood disorders
223894374|NCT06796387|BEHAVIORAL|Usual Care|During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
223939944|NCT07189936|DRUG|To Measure levels of circulating monocyte/ T cell doublets at Baseline|To determine the levels of circulating monocyte/ T cell doublets on all the LCPOTS subjects
223711130|NCT00005044|RADIATION|radiation therapy|\[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)\] OR \[regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin\]
223711131|NCT00141843|GENETIC|ReFacto AF|
223711132|NCT00141843|GENETIC|B-Domain deleted Recombinant Factor VIII|
223711133|NCT00141843|GENETIC|BDDrFVIII|
223711134|NCT03988088|DRUG|Lasmiditan|Administered orally.
223711135|NCT04431453|DRUG|Remdesivir|Administered as an intravenous infusion
223711136|NCT05847361|DIAGNOSTIC_TEST|BH4 blood level|from admission to END OF PREGNANCY, a blood sample is taken.
223711137|NCT03574831|DEVICE|Stretta|Stretta
223711138|NCT03823456|OTHER|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
223711139|NCT03823456|OTHER|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
223711140|NCT02256657|BEHAVIORAL|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
223711141|NCT01881074|DRUG|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
223711142|NCT01881074|DRUG|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
223711143|NCT04314934|DRUG|ANAVEX2-73|Oral capsules
223711144|NCT05175508|DRUG|Azacitidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle 28 days
223711145|NCT05175508|DRUG|all trans retinoic acid|ATRA 20mg tid by po on days 1-21 of every cycle 28 days
223711146|NCT02962388|DRUG|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
223711147|NCT02962388|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
223711148|NCT02962388|DRUG|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
223711149|NCT03580993|DIAGNOSTIC_TEST|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
223711150|NCT01354457|DRUG|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
223711151|NCT02563171|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of 2-3 clinical visits.~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
223711152|NCT02563171|OTHER|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
223711153|NCT01206348|DRUG|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
223711154|NCT01332370|DRUG|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
223711155|NCT01332370|DRUG|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
223711156|NCT05675176|DRUG|BCG|Intravesical Instillation
223711157|NCT03622073|OTHER|Misoprostol treatment by Midwife|Medical management of incomplete abortion
223894375|NCT04851145|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics of FFPE biopsies and urine samples|"The biopsy and urine samples will be processed by the OncoProt platform (University of Bordeaux) for proteomic analysis by tandem mass spectrometry (label-free quantification) as follows:~* Biopsies: laser microdissection of the renal cortex, fixation reversion, protein extraction and electrophoretic migration, tryptic digestion.~* Urines: samples concentration by centrifugation/filtration and tryptic digestion according to a protocol adapted from the FASP method (Filter-Aided Sample Preparation)"
223894376|NCT06196801|DRUG|Triple-combination therapy|phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin
223894377|NCT05413018|DRUG|CC-486|Specified dose on specified days
223894378|NCT05413018|OTHER|Placebo|Specified dose on specified days
223894379|NCT05608694|OTHER|Prostate MRI|Group placement is determined by GRS score, Family history, and germline testing
223894380|NCT03652688|BEHAVIORAL|Nightlife Safety Plans (NSP)|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
223894381|NCT03652688|BEHAVIORAL|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
223894382|NCT05487248|OTHER|Blood Sample Collection|"For subjects receiving treatments with a 2- or 4-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 2 weeks after treatment start (day 15)~Plasma :~* Before the treatment start (day 1)~* 4 weeks after treatment start (day 29)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1~For subjects receiving treatments with a 3-weekly schedule, samples for ctDNA testing will be collected at the following timepoints:~Blood :~* Before treatment start (day 1)~* 3 weeks after treatment start (day 22)~Plasma :~* Before treatment start (day 1)~* 6 weeks after treatment start (day 43)~* 8 or 12 weeks after treatment start and every 8 or 12 weeks thereafter (i.e. at the same time of each imaging tumour assessment) until evidence of progressive disease by RECIST 1.1"
223894383|NCT05182034|BIOLOGICAL|SMUP-IA-01(low dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
223894384|NCT05182034|BIOLOGICAL|SMUP-IA-01(mid dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
223894385|NCT05182034|DRUG|Active Control Group Sodium chloride|A single knee administration of Sodium chloride
223894386|NCT05935930|DRUG|Propofol 10 MG/ML Injection|Propofol infusion
223894387|NCT05935930|DRUG|Sevoflurane Inhalation Liquid|Sevoflurane inhalation
223894388|NCT02050802|DRUG|Moxifloxacin 400 mg|
223894389|NCT02050802|DRUG|Macitentan 10 mg|
223894390|NCT02050802|DRUG|Macitentan 30 mg|
223894391|NCT02050802|OTHER|Placebo|
223894392|NCT06343896|OTHER|monitorization reliability|evaluation of the use of the integral pulmonary index in the child patient group
223894393|NCT06158412|DRUG|All-trans Retinoic Acid in combination with the KPD Regimen|"Regimen: 1 course of treatment for 28 days until disease progression or intolerable toxicity occurs~1. ATRA mg/m2/day in 2 oral doses for 3 days. The first dose of ATRA will be given in the morning, two days prior to carfilzomib administration.~   The last ATRA dose will be given in the evening on the day of carfilzomib administration.~2. Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);~3. Pomalidomide 4mg orally daily, d1-21;~4. Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle; ≤75 years: 40 mg/day; \>75 years: 20 mg/day."
223894394|NCT02587897|OTHER|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
223894395|NCT02587897|OTHER|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
223894396|NCT03468218|DRUG|Cabozantinib|Given PO
223894397|NCT03468218|BIOLOGICAL|Pembrolizumab|Given IV
223894398|NCT05478434|DEVICE|Cortico-cortical stimulation plus robot-assisted therapy|15 sessions of cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Paired-pulse stimulation (PAS) technique, with 5ms inter-stimulus time between the two areas (PPC to M1), will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To stimulate the M1 area, the coil will be placed tangentially to the scalp at a 45° angle to the midline, to stimulate the PPC area the center of the coil will be positioned over P4 (10-20 EEG system) tangentially to the skull with the handle pointing downward and slightly medial (10°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
223894399|NCT05478434|DEVICE|Sham cortico-cortical stimulation plus robot-assisted therapy|15 sessions of sham cortico-cortical stimulation between the PPC and the M1 of the lesioned hemisphere and robot-assisted therapy. Sham paired-pulse stimulation (PAS) will be done through two high-power Magstim 200 machines (Magstim® Rapid²). To simulate the real stimulation, the coils will placed in the same sites with different inclination respect to the scalp (90°). Robot-assisted therapy will be performed with an Armeo® Power II (Hocoma), an integrative system composed by a robotic exoskeleton device connected to a laptop for the audio-visual biofeedback for the upper limb therapy.
223894400|NCT05991986|OTHER|somatic cell collection|One or more types of somatic cells will be collected from every participant by collecting approximately 100\~500 ml of midstream urine, 20\~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc.
223894401|NCT02008045|DEVICE|Magnetic Resonance Imaging|Brain MRI without Contrast
223894402|NCT02008045|BEHAVIORAL|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
223894403|NCT05674539|DRUG|Fludarabine and Busulfan|Fludarabine with total dose of 150 mg/m\^2 in combination with Busulfan with total dose of 6.4 mg/kg
223894404|NCT05674539|DRUG|Fludarabine and Melphalan|Fludarabine with total dose of 150 mg/m\^2 in combination with Melphalan with total dose of 140 mg/m\^2
223894405|NCT06636708|COMBINATION_PRODUCT|Nanodropper and Proparacaine HCl 0.5%|The Nanodropper is an eyedrop bottle adaptor that creates smaller eyedrops by coupling to an existing eyedrop bottle. This intervention involves the administration of proparacaine HCl 0.5% using the Nanodropper.
223711158|NCT03622073|OTHER|Misoprostol treatment by Doctor|Medical management of incomplete abortion
223711159|NCT00353795|PROCEDURE|MR Imaging of the Coronary Arteries|
223894406|NCT06636708|COMBINATION_PRODUCT|Standard Eye Drop Bottle with Proparacaine HCl 0.5%|This intervention involves administration of proparacaine HCl 0.5% using a standard eye drop bottle.
223894407|NCT06637904|DIAGNOSTIC_TEST|TriVerity Test|Participants in the post-phase of the study will have a 2.5 ml whole blood draw obtained via venipuncture into a PAXgene® Blood RNA tube. Blood samples will be processed using the TriVerity Cartridge on the Myrna Instrument located in the ED.
223894408|NCT03719443|BIOLOGICAL|VIS649|Single IV dose of study product on Day 1 of study
223894409|NCT03719443|BIOLOGICAL|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
223894410|NCT06638229|DEVICE|The StimaWELL 120MTRS system|A standardized current (dynamic deep wave stimulation) was applied to all patients. Additionally, the mat, which reached a temperature of 40°C, provided heat therapy with electrical stimulation
223894411|NCT06315959|PROCEDURE|Bilateral ultrasound guided erector spinae plane block|"Bilateral ultrasound-guided ESP(total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS).~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
223894412|NCT06315959|DRUG|morphine PCA|IV PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
223894413|NCT06315959|OTHER|Control group|"Patients in this group will not be performed plane blocks. Multimodal analgesia : Intraoperatively, all patients will receive 0.05 mg/kg (IBW) iv morphine. Thirty minutes before the end of surgery, 1 gram of intravenous paracetamol will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5mg/ml morphine. In cases where rescue analgesia is required (NRS score ≥4),iv fentanyl 25-50 mcg and/or ibuprofen and/or ketamine 10 mg will be administered. Patients are routinely administered iv dexamethasone 4 mg and IV 8 mg ondansetron 20 minutes before end of surgery for postoperative nausea and vomiting prophylaxis.~Postoperative chronic pain will be assessed using the Brief Pain Inventory(BPI).~Anxiety and depression status will be evaluated using the Hospital Anxiety and Depression Scale (HADS) .~The character of pain will be evaluated using the Douleur Neuropathique 4 (DN4) score."
223894414|NCT06315959|DRUG|morphine PCA|V PCA of 0,5mg/ml morphine (the bolus dose is 20 µg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
223894415|NCT06365125|BEHAVIORAL|eCHECKUP TO GO|Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
223894416|NCT06365125|BEHAVIORAL|Text messaging boosters|Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
223894417|NCT05647369|DIETARY_SUPPLEMENT|Mastic mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
223939945|NCT07189936|DRUG|To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment|Subjects will be randomized 1:1 to 2-HOBA or matching placebo. The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment
223939946|NCT07189936|DRUG|To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment|The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment and compare it to the placebo arms
224276321|NCT01557062|OTHER|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
224276322|NCT02686762|DRUG|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
224276323|NCT02686762|DRUG|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
224276324|NCT02686762|DRUG|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
224276325|NCT00964873|DRUG|STA-9090 (ganetespib)|Chemotherapy agent
223711160|NCT05216783|BEHAVIORAL|Motivational Interviews|The qualitative research studies performed on the traumatic childbirth experiences indicated that the pregnant women's interaction and communication with the midwives were more effective than the medical intervention methods that were applied.
223711161|NCT06132516|OTHER|HIIT|High Intensity Interval Training On semi-recumbent ergocyclometer, after a symptom-limited graded exercise Test
223711162|NCT06132516|OTHER|LIGT|Low Intensity Group Training Group gymnastics, mainly with short static stretching/strengthening tasks.
223711163|NCT00003710|DRUG|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
223894418|NCT05647369|DIETARY_SUPPLEMENT|Placebo mouthwash|All 30 patients will be randomly assigned to either the mastic mouthwash group A (Art of Nature Mastiha Mouthwash, Mastihashop, Greece) (n = 15) or the placebo mouthwash group B (from the same manufacturer) (n = 15) (Table 1). All patients will be asked to use the mouthwash twice a day (10 ml of mouthwash / 2 times a day for 30 sec for 14 days, every morning and every night after brushing) and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the mouthwash by the participant on the day of the assessments.
223894419|NCT05586516|DRUG|IOA-289|IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
223894420|NCT05080842|DRUG|AC682|Participants will receive AC682 by mouth daily in 28-day cycles.
223894421|NCT06643052|OTHER|No intervention|No intervention
223894422|NCT05845476|OTHER|Patient SOGI Self-Report|"EPIC® MyChart electronic health records messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record (EHR).~Intervention Description:~EPIC® MyChart EHR messages will go to OSUCCC patients of pilot clinics who have incomplete SOGI data in their record and are enrolled in OSU MyChart. The message will request that patients complete SOGI data fields, with an explanation about why it is important for their health care, as well as links to document this information in their electronic health record."
223894423|NCT05845476|OTHER|SOGI Resource for Clinical Care Education (SORCE)|SOGI Resource for Clinical Care Education (SORCE) training includes cultural competency and health education. SORCE training has been used on a smaller scale for two years at the OSUCCC-James, receiving excellent scores for presentation quality, knowledge gained, and presenter expertise. For the present study, SORCE training will be tailored based on results from Aim 1. The training curriculum includes didactic content (basics of the LGBTQ+ community, SOGI data collection for patient care and research, and social determinants of health for the LGBT community, 15 minutes), EHR SOGI data documentation demonstration (10 minutes), and open dialogue and role play (20 minutes). Trainees will be given EHR documentation tip sheets and laminated pocket cards with best practices for asking about SOGI, steps for documenting in the EHR, and additional resources.
223894424|NCT05845476|OTHER|Cancer Center Care Environment|At the level of the OSUCCC, to include all inpatient and ambulatory spaces, the investigators will implement important measures aimed at changing culture and practice. This includes modification of policy and the EHR for SOGI documentation per National Academy of Science Engineering and Medicine recommendations, a multi-pronged approach to making the environment of care more visibly welcoming for SGM people, and leveraging existing diversity, equity, and inclusion structures and initiatives to shift culture at the cancer center.
223894425|NCT06638866|DIAGNOSTIC_TEST|PDAC|Participants with algorithm-identified PDAC will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT/MRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.
223894426|NCT06638866|DIAGNOSTIC_TEST|Pancreatic precursor lesions|Participants with algorithm-identified pancreatic precursor lesions will be independently reviewed by two radiologists. Those highly suspected will be recalled for further diagnostic evaluation, including serological tests (e.g., CA19-9, CEA) and imaging (e.g., contrast-enhanced CT/MRI, EUS-FNA). Participants with a confirmed positive diagnosis will undergo multidisciplinary consultation and specialized treatment, while those with a negative diagnosis will be followed clinically for at least one year.
223894427|NCT06642428|DRUG|Neoadjuvant therapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive injections of vitamin D2 at a dosage of 10 mg until the completion of neoadjuvant therapy. They will undergo the standard neoadjuvant regimen, which includes the 10 mg injection of vitamin D2 per cycle during the therapy. The dosage of neoadjuvant drugs may be tailored based on the physician's clinical judgment.
223894428|NCT06642428|DRUG|Neoadjuvant therapy|Participants will receive the standard neoadjuvant regimen during each cycle of neoadjuvant therapy. The dosage of the neoadjuvant drugs may be tailored based on the physician's clinical judgment.
223894429|NCT06638853|BEHAVIORAL|Distress Tolerance Skills Training|"These lessons are adapted from DBT Skills in Schools: Skills Training for Emotional Problem Solving for Adolescents (DBT STEPS-A) by Mazza et al. and include elements of mindfulness training, psychoeducation about emotions, and techniques/skills for managing extreme emotions."
223894430|NCT06637254|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma
223894431|NCT06637254|DRUG|Placebo|the placebo comparator of study
223894432|NCT06641284|DRUG|Spironolactone|All patients will receive Spironolactone as a part of their GDMT for Heart Failure
223894433|NCT06556394|DRUG|RAG-17|RAG-17 is a therapeutic small interfering RNA (siRNA).
223894434|NCT06556394|DRUG|Placebo|Placebo will be administered via intrathecal injection
223894435|NCT06556940|BIOLOGICAL|LMN-401|Orally delivered tablets and capsules
224276326|NCT02874196|PROCEDURE|Standard arthrography|
224276327|NCT02874196|PROCEDURE|Dual energy arthrography|
224276328|NCT02874196|PROCEDURE|Arthro-tomosynthesis|
224276329|NCT02874196|PROCEDURE|Arthro-tomography|
224276330|NCT02874196|PROCEDURE|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
224276331|NCT02911935|DRUG|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
224276332|NCT02911935|DRUG|Placebo|Placebo suspension
223894436|NCT06641635|COMBINATION_PRODUCT|Moderated hypofractionated online adaptive radiotherapy|"Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
223894437|NCT06641635|COMBINATION_PRODUCT|Conventional radiotherapy|"Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
223894438|NCT04924660|DRUG|TXA127|TXA127 0.5 mg/kg/day infused 3 hours daily for 5 days or until hospital discharge whichever comes first.
223894439|NCT04924660|DRUG|TRV027|TRV027 12mg/h as a continuous 24-hour infusion, infused for 5 days or until hospital discharge whichever comes first.
223894440|NCT04924660|DRUG|Placebo|"NaCl 0.9% infused to match the duration of the agent (3 hours for TXA127 and continuous 24-hour infusion for TRV027, over 30 minutes for APN01.~Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses."
223894441|NCT04924660|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
223894442|NCT04769765|OTHER|Definition of the Individualized Care Pathway|Implementation of an individualized care pathway defined in concertation with a multidisciplinary tele-expertise meeting held every 3 months for one year. These multidisciplinary tele-expertise meetings will be held between each of the normal routine consultations which are part of the normal, basic diabetic program which includes a consultation with a dietitian, monitoring by a state-registered nurse and treatment prescribed by the patient's general practitioner (with or without a consultation with the clinical pharmacist).
223894443|NCT05275855|DRUG|EDI048|Oral Liquid
223894444|NCT05275855|OTHER|Placebo|Oral Liquid
223894445|NCT05712564|OTHER|Questionnaire|Questionnaire for fatigue assessment
223894446|NCT05957536|BIOLOGICAL|D3L-001|Intravenous administration
223894447|NCT03707691|BEHAVIORAL|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
223894448|NCT03707691|BEHAVIORAL|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of \~20 minutes performed at home over a period of 15 weeks.
223894449|NCT03707691|BEHAVIORAL|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
223894450|NCT06082739|OTHER|Exercises|Stretching exercises with and without a bolster, ball, or foam roller.
223894451|NCT06643312|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
223894452|NCT06643494|DIETARY_SUPPLEMENT|N-111|A combination of Acetogenins
223894453|NCT06643494|OTHER|Placebo|Placebo
223894454|NCT06643156|DRUG|GP681 10mg/20mg/40mg|0.5/1/2×20mg power for oral suspension taken orally
223894455|NCT05165407|DRUG|Sintilimab|Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
223711164|NCT00003710|DRUG|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
223711165|NCT02416570|DRUG|Clarithromycin|
223894456|NCT05165407|DRUG|IBI310|IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle
223894457|NCT05165407|DRUG|Surufatinib|Surufatinib 250mg will be taken orally once daily continuously
223894458|NCT06557577|OTHER|No intervention group.|There is no intervention group.
223894459|NCT05818332|OTHER|Observational study|No intervention, observational only
223894460|NCT04280926|DIAGNOSTIC_TEST|Cardiac Troponin Testing|Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
223894461|NCT06576765|DRUG|AZD0780|Dose 1
223894462|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris|Manufactured at Viatris
223711166|NCT02416570|DRUG|Placebo|
223711167|NCT01723345|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
223711168|NCT01768286|DRUG|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
223711169|NCT01768286|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223711170|NCT01095211|DRUG|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
223711171|NCT02083965|BIOLOGICAL|rFVIIIFc|Administered as specified in the treatment arm.
223711172|NCT05203432|DEVICE|Red Light Intervention|Repeated Low-Level Red-Light Therapy
223711173|NCT05203432|DRUG|Atropine|0.01% atropine
223894463|NCT06205407|DRUG|Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.|Manufactured at Neolpharma.
223894464|NCT05402202|OTHER|Healing abutment with scan peg (Neoss implant system, Harrogate, England)|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg
223894465|NCT05402202|OTHER|Customized healing abutment|12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
223894466|NCT05052723|DRUG|Cabozantinib|Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization.
223894467|NCT05052723|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
223894468|NCT04572399|DEVICE|UV Light Treatment|UV light therapy administered while patient is mechanically ventilated
223894469|NCT05504057|DRUG|Antihistamine|Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
223894470|NCT05504057|DRUG|Amantadine|Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
223894471|NCT06220071|OTHER|Case series review of clinical and radiographic data|Extraction of clinical and radiographic data related to patients' history from medical records
223894472|NCT04121858|OTHER|Brain Safe App|The Brain Safe app includes the medication list, a personalized risk calculator, multimedia educational content, and a conversation starter/doctor's report.
223894473|NCT04121858|OTHER|Attention Control App|The attention control app, called Med Safe, includes only the medication list feature.
223894474|NCT05363631|DRUG|Selenomethionine (SLM)|Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)
223894475|NCT05363631|DRUG|Axitinib|Axitinib is a small molecule tyrosine kinase inhibitor.
223894476|NCT05363631|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy
223894477|NCT03810287|DRUG|Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
223894478|NCT04676022|DEVICE|WaveWriter|To receive Spinal Cord Stimulation programming
223894479|NCT04676022|OTHER|Conventional Medical Managament|To receive conventional medical management
223894480|NCT02737878|BEHAVIORAL|Aerobic Training|"Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
223894481|NCT02737878|BEHAVIORAL|Resistance Training|"Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
223894482|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
223894483|NCT02737878|BEHAVIORAL|Balance and Tone Training|"Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
223939947|NCT07189936|DIAGNOSTIC_TEST|To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA|We will Measure changes in Splanchnic venous capacitance after 28 days of Treatment with 2HOBA and compare it with baseline during 30 Mins head up tilt . All the LCPOTS subjects will be randomized 1:1 to 2-HOBA or matching placebo
223711174|NCT03137420|DIAGNOSTIC_TEST|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
223711175|NCT02568774|OTHER|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
223711176|NCT02568774|OTHER|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
223711177|NCT02539446|BEHAVIORAL|stable condition|
223711178|NCT02539446|BEHAVIORAL|unstable condition|
223711179|NCT02539446|BEHAVIORAL|attentional focus|
223711180|NCT04516330|GENETIC|miRNA|miRNA's expressed in breast cancer
223711181|NCT00929383|DEVICE|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
223711182|NCT02481908|DEVICE|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
223711183|NCT01870284|DRUG|Ixekizumab|Administered SC
223711184|NCT01870284|DRUG|Placebo|Administered SC
223711185|NCT01870284|DRUG|Adalimumab|Administered SC
223711186|NCT02718157|DEVICE|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
223711187|NCT00651352|DRUG|4 mg nicotine lozenge|marketed formulation
223711188|NCT00651352|DRUG|2 mg nicotine lozenge|marketed formulation
223711189|NCT00651352|DRUG|2 mg nicotine prototype|2 mg
223711190|NCT00651352|DRUG|4 mg nicotine prototype|4 mg
223711191|NCT02956239|PROCEDURE|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
223711192|NCT02956239|PROCEDURE|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
223711193|NCT02956239|PROCEDURE|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
223711194|NCT04502433|DRUG|CUROSURF® (poractant alfa)|"Three administrations with a 24 hours dosing interval.~Each endotracheal (ET) administration 1, 2, and 3 consisted of poractant alfa bolus:~30mg /kg (Lean Body Weight-LBW) = 0.375ml /kg LBW, diluted with normal saline up to 2ml /kg LBW."
223711195|NCT02935842|OTHER|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
223711196|NCT02935842|OTHER|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
223711197|NCT05281679|OTHER|Low-intensity resistance exercise with blood flow restriction group (L-BFR)|The blood flow restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 40% of 1-RM. The SB protocol consists of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min recovery interval between sets and 3-min between exercises. Blood flow to the active muscle during training will be restricted by a blood flow restriction band (tourniquet) placed at the proximal end of the lower limbs. When the subjects performed training with BFR, the proximal portions of their lower limbs will be compressed at the pressure of 120-160 mmHg by electronically controlled air pressure belts. The air pressure belt will be inflated before the exercise and will remain inflated during one-minute intervals between the sets and will be deflated during the three-minute interval between the exercise.
223711198|NCT05281679|OTHER|High-intensity resistance exercise without blood flow restriction group (H-BFR).|The high-intensity restriction training group will perform 3 sets of Sandbag (SB) resistance exercises, targeting the large muscles of the legs, at 80% of 1-RM. The SB protocol consist of 3 sets of 4 SB exercises. Each set consists of 10 repetitions of 1-RM with a 1-min rest interval between sets and 3-min between exercises.
223711199|NCT01072422|BEHAVIORAL|smoking cessation|Use of trying to quit smoking instrument and quit smoking advice
223711200|NCT00911547|DRUG|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
223711201|NCT00911547|DRUG|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
223711202|NCT00911547|DRUG|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
223711203|NCT00911547|DRUG|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
223711204|NCT04544397|PROCEDURE|Catheter Ablation for AF|Pulmonary vein isolation (PVI) is the mainstay goal of atrial fibrillation (AF) ablation procedures, especially in paroxysmal AF (PAF), and is recommended during all AF ablation procedures. PVI can be obtained with different techniques, using 3D-mapping systems guiding point-by-point radiofrequency (RF) ablation procedures or balloon-based ablation systems (cryo- or laser balloon), introduced to simplify catheter ablation for AF. In particular, the 2nd generation of visually guided laser balloon ablation system (LB2) makes use of laser energy to achieve PVI, leading to better PV occlusion and isolation compared to the 1st generation.
223711205|NCT05412303|OTHER|data collection|age, gender, body weight, height, personal medical history, ASA score, EuroSCORE2, type of cardiac surgery, the preoperative left ventricular ejection fraction, the duration of CPB, the duration of aortic clamping, the need for intraoperative blood transfusion, norepinephrine, dobutamine, creatinine value, time to extubation (hours), any occurrence of complications during the stay in the ICU or in the hospital, and the LOS in the ICU and hospital
223711206|NCT04530526|PROCEDURE|Regenerative Peripheral Nerve Interface|The regenerative peripheral nerve interface (RPNI) has emerged as a novel strategy to treat neuromas in peripheral nerves. The RPNI consists of the residual peripheral nerve end implanted in a skeletal muscle graft, following surgical resection of the injured terminal nerve portion (neuroma). The free muscle graft is separated from its native nerve innervation, leaving open neuromuscular junctions for ingrowth and attachment of nerve fibers from the implanted nerve.
223711207|NCT00034541|BIOLOGICAL|cetuximab|400 mg/m2 i.v. over 120 minutes
223711208|NCT00034541|DRUG|paclitaxel|225 mg/m2, infusion
223711209|NCT00034541|DRUG|carboplatin|30-minute AUC = 6, infusion.
223711210|NCT05230420|OTHER|Clamping|Clamping of chest tube
223711211|NCT05230420|OTHER|Urine bag|Attachment of a urine bag to chest tube
223711212|NCT03691181|DEVICE|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
223711213|NCT01374841|DRUG|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
223711214|NCT01374841|OTHER|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
223711215|NCT02615314|PROCEDURE|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
223711216|NCT00324610|DRUG|capecitabine|
223711217|NCT00808990|DIETARY_SUPPLEMENT|BioFemale|BioFemale 6 months.
223711218|NCT00113503|DRUG|Azathioprine weight-based dose|
223711219|NCT00113503|DRUG|Azathioprine individualised dose|
223711220|NCT05489744|DRUG|[14C]Afuresertib|Suspension containing approximately 125 mg of Afuresertib (containing 150 µCi of \[14C\]Afuresertib) is administered orally on an empty stomach, with approximately 240 mL of water for suspending and drug taking.
223711221|NCT00076843|DRUG|Hu MiK-Beta-1|
223711222|NCT00004762|DRUG|cladribine|
223711223|NCT04903444|DEVICE|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
223711224|NCT02116946|BIOLOGICAL|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
223711225|NCT02116946|OTHER|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
223711226|NCT01201785|DRUG|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
223711227|NCT02774954|BEHAVIORAL|Change the Cycle|See previous response
223711228|NCT03531931|DRUG|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
223711229|NCT02902432|DRUG|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
223711230|NCT03947801|OTHER|Greek Yogurt|Female competitive soccer players (11-16y) will consume 0% plain Greek yogurt immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
223711231|NCT03947801|OTHER|Isoenergetic carbohydrate|Female competitive soccer players (11-16y) will consume an isoenergetic carbohydrate supplement immediately following the training session, 1 h prior to bedtime, as well as one serving between breakfast and lunch on the subsequent day.
223711232|NCT04710173|PROCEDURE|ECMO|VV-ECMO
223711233|NCT05228171|BEHAVIORAL|mCC app|Interviewer use of the mCC app during the 24-hour dietary recall interview.
223711234|NCT04545385|DRUG|TEV-48574|subcutaneous infusion
223711235|NCT04545385|DRUG|Placebo|Matching Placebo
223711236|NCT04629807|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|Intra-Operative Anterior Lumbar Interbody Fusion (ALIF)
223711237|NCT00915278|DRUG|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
223711238|NCT05843045|DEVICE|Indoor Air Quality Mitigation|Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
223711239|NCT02151110|BIOLOGICAL|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
223711240|NCT02151110|BIOLOGICAL|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
223711241|NCT02151110|BIOLOGICAL|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
223711242|NCT02151110|BIOLOGICAL|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
223711243|NCT02151110|BIOLOGICAL|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
223711244|NCT02151110|BIOLOGICAL|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
223711245|NCT02151110|BIOLOGICAL|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
223711246|NCT02151110|OTHER|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
223711247|NCT00850590|DRUG|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
223711248|NCT03801486|OTHER|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
223711249|NCT03801486|OTHER|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
223711250|NCT03018600|BEHAVIORAL|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
223711251|NCT01651247|PROCEDURE|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
223711252|NCT04872582|DRUG|PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab|combined
223711253|NCT01375244|DRUG|Lisinopril|Tablets, 10 mg, single dose
223711254|NCT01375244|DRUG|Zestril|Tablets, 10 mg, single dose
223711255|NCT01546805|DRUG|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
223711256|NCT01546805|DRUG|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
223711257|NCT00001381|DRUG|suramin|
223711258|NCT02294955|DEVICE|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
223711259|NCT02294955|DRUG|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
223711260|NCT02294955|DRUG|Sotalol|Dosage orally 80-160 mg twice daily
223711261|NCT02294955|DRUG|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
223711262|NCT02294955|DRUG|Propafenone|Dosage orally 300 mg twice daily
223711263|NCT02294955|DRUG|Disopyramide|Dosage orally 250-375 mg twice Daily
223711264|NCT02294955|DRUG|Dronedarone|Dosage orally 400 mg twice daily
223711265|NCT05498012|COMBINATION_PRODUCT|placebo dental gel, placebo toothpaste|"* Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
223711266|NCT05498012|COMBINATION_PRODUCT|Cannabidiol dental gel, Cannabidiol toothpaste|"* Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~* Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient."
223711267|NCT05498012|COMBINATION_PRODUCT|Placebo toothpaste, Corsodyl dental gel|"* Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~* Placebo toothpaste; without cannabidiol. For daily use by patient."
223711268|NCT04719286|DEVICE|MinSafeStart app|The intervention is the opportunity of using the MinSafeStart app. Women can register their NVP severity in the app by answering a few questions daily. Based on this, they will get tailored advice on NVP, and get alert when they should see a doctor.
223711269|NCT02649595|OTHER|Red Cross Respite care|See detailed description.
223711270|NCT04074031|DEVICE|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
223711271|NCT01995110|OTHER|high-fat meal A|
223711272|NCT01995110|OTHER|high-fat meal B|
223711273|NCT01995110|OTHER|high-fat meal C|
223711274|NCT02449252|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
223711275|NCT02449252|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week."
223711276|NCT02449252|DRUG|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
223711277|NCT02449252|DRUG|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
223711278|NCT02449252|DRUG|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
223711279|NCT02449252|DRUG|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
223711280|NCT02721485|OTHER|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
223711281|NCT02721485|OTHER|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
223711282|NCT02045810|DRUG|Levobupivacaine|
223711283|NCT02045810|DRUG|Saline|
223711284|NCT01468883|PROCEDURE|M|Modified radical mastectomy
223711285|NCT01468883|RADIATION|X|Excisional biopsy plus radiation
223711286|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
223711287|NCT00677729|DRUG|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
223711288|NCT00651560|DRUG|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
223711289|NCT02264561|OTHER|Food|Active group
223711290|NCT02264561|OTHER|Food|Control group
223711291|NCT03136354|PROCEDURE|Endoscopic Submucosal Dissection|
223711292|NCT03136354|PROCEDURE|Laparoscopic assisted Gastrectomy|
223711293|NCT02369016|DRUG|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
223711294|NCT00335361|DEVICE|Intra Vas Device (IVD)|
223711295|NCT06326385|OTHER|no intervention|no intervention
223939948|NCT07189936|DIAGNOSTIC_TEST|To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo|We will Measure changes in splanchnic venous capacitance during 30 mins head up tilt ,after 28 days of Treatment with Placebo, we will compare it to the subjects who received 2 HOBA for 28 days
223939949|NCT07189936|DIAGNOSTIC_TEST|To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA|To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with 2HOBA at 30 minutes of head up Tilt
223711296|NCT03221283|BEHAVIORAL|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
223711297|NCT02552875|OTHER|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
223711298|NCT02552875|OTHER|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
223711299|NCT02229383|DRUG|Exenatide|2 mg weekly suspension injection
223711300|NCT02229383|DRUG|Exenatide matching placebo|Once weekly Placebo injection
223711301|NCT04601415|DIAGNOSTIC_TEST|ECG from handheld device|Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
223711302|NCT00241943|PROCEDURE|Hepatitis C educational video|
223711303|NCT04586907|DRUG|LY3537021|Administered SC.
223711304|NCT04586907|DRUG|Placebo|Administered SC.
223711305|NCT00672932|DRUG|raltegravir|400 mg two times daily for three months
223711306|NCT03127410|OTHER|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
223711307|NCT02168361|DRUG|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
223711308|NCT02168361|DRUG|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
223711309|NCT02168361|DRUG|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
223711310|NCT02168361|DRUG|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
223711311|NCT04431180|BEHAVIORAL|blood donation SMS|The literature shows that the information extraction and processing in emergency is different from the normal situation. To find the most effective emergency recruitment method during an outbreak, we intervened with a well-balanced group of donors by presenting different emergency recruitment text messages.
223711312|NCT02428517|PROCEDURE|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
223711313|NCT02428517|PROCEDURE|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
223711314|NCT02428517|PROCEDURE|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
223711315|NCT02428517|PROCEDURE|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
223711316|NCT05822661|DIETARY_SUPPLEMENT|Black Seed Oil|Dietary supplement
223711317|NCT05822661|DIETARY_SUPPLEMENT|Placebo|placebo capsules same odor, color and size as the drug but without the active ingredient
223711318|NCT01593657|OTHER|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
223711319|NCT01593657|OTHER|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
223711320|NCT01593657|PROCEDURE|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
223711321|NCT01593657|PROCEDURE|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
223711322|NCT03954665|BEHAVIORAL|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
223711323|NCT03954665|BEHAVIORAL|30s Wingate|30s all-out test to measure peak power output
223711324|NCT03954665|DIETARY_SUPPLEMENT|Ketone|Supplement containing exogenous ketone salts
223711325|NCT03954665|BEHAVIORAL|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
223711326|NCT03954665|BEHAVIORAL|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
223711327|NCT05492214|PROCEDURE|Delayed cord clamping (30s)|The same as that stated in arm descriptions.
223711328|NCT05492214|PROCEDURE|Delayed cord clamping (60s)|The same as that stated in arm descriptions.
223711329|NCT05492214|PROCEDURE|Delayed cord clamping (90s)|The same as that stated in arm descriptions.
223711330|NCT05693389|BEHAVIORAL|acceptance and commitment therapy|ACT attempts to encourage psychological flexibility, acceptance of one's own experiences, and dedication to behaviours that are consistent with one's own values. ACT therapies focus on six key processes to improve psychological flexibility: engagement with the present moment, acceptance, defusion, self as context, values clarification, and committed action.
223711331|NCT05693389|OTHER|routine hospital care|the patients with bipolar disorders who receive routine pharmacological treatment
223711332|NCT02543580|OTHER|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
223711333|NCT02543580|OTHER|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
223711334|NCT00048321|DRUG|ISIS 104838|
223711335|NCT02951065|OTHER|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
223894484|NCT04416815|OTHER|Integrating Health promotion with and for Older People - eHealth|The intervention will be delivered for 6 months on top of usual care. It will be provided by HCPs. If needed one home visit to install the digital platform will be conducted. A HCP will introduce how to use the digital platform and create a personal account. The intervention starts with a person-centred phone-call where a health plan is co-created and potential team members to support this are identified and invited. The health plan includes the older persons' goals, internal and external resources, and need of support from health and/or social-services. This plan will be the point of departure for the forthcoming dialogue. A digital platform will open up for extended and safe communication and visualize the health planning between the older person and team-members in different settings. The older person and the HCP and involved team members on the digital platform will regularly evaluate the health plan and commonly agreed goals.
223894485|NCT05746494|DEVICE|tDCS|active anodal tDCS and sham tDCS
223894486|NCT03736720|DRUG|Fluorouracil|Given IV
223894487|NCT03736720|DRUG|Leucovorin|Given IV
223894488|NCT03736720|DRUG|Liposomal Irinotecan|Given IV
223894489|NCT03736720|PROCEDURE|Quality-of-Life Assessment|Correlative studies
223894490|NCT06027554|DRUG|Mitoquinone Mesylate|MitoQ given 20 mg per day for 12 weeks.
223894491|NCT06027554|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule taken every day for 12 weeks.
223894492|NCT05620342|BIOLOGICAL|iC9.GD2.CAR.IL-15 T Infusion|iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
223894493|NCT05899036|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the cerebral vasculature using pulsatile aspiration. The system is comprised of a sterile one-time use 071 catheter, a sterile one-time use tubing set and a multiuse aspiration pump console.
223894494|NCT05724875|DEVICE|FLASH RT|For T1 (small) lesions: 22 Gy single dose FLASH RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose FLASH RT
223894495|NCT05724875|DEVICE|Conventional RT|For T1 (small) lesions: 22 Gy single dose conventional RT; For T2 (large) lesions: 5 x 6 Gy fractionated dose conventional RT
223894496|NCT02914951|BEHAVIORAL|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
223894497|NCT02914951|OTHER|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
223894498|NCT03168854|BIOLOGICAL|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
223894499|NCT03168854|OTHER|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
223894500|NCT06554158|RADIATION|Radiation Therapy|De-escalation of Adjuvant Radiotherapy
223894501|NCT03762291|BIOLOGICAL|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
223894502|NCT05147649|DIAGNOSTIC_TEST|functional magnetic resonance imaging|functional magnetic resonance imaging
223894503|NCT06072105|OTHER|Telemedicine visits|Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
223894504|NCT06072105|OTHER|Multidisciplinary, personalized symptomatic treatment|Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
223894505|NCT06443125|OTHER|Natural psychotherapy|Draw ideas from traditional Chinese culture, learn from the practice of Morita therapy in Japan, and create local practice experience. At the same time, a variety of research methods such as cognitive assessment and brain imaging were used to establish the scientific, professional and objective evaluation indexes of the therapy.
223894506|NCT04526782|DRUG|Encorafenib 75 MG|450 mg (6 × 75 mg capsule) per day
223894507|NCT04526782|DRUG|Binimetinib 15 MG|45 mg (3 × 15 mg tablet) twice daily
223894508|NCT05409183|DRUG|CRD-740|Tablets administered orally.
223894509|NCT05409183|DRUG|Placebo|Tablets administered orally.
223894510|NCT05595239|DEVICE|blood purification(CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode, 24 hours per day, for 3 consecutive days
223894511|NCT05595239|DEVICE|blood purification(TPE+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in TPE mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
223894512|NCT05595239|DEVICE|blood purification(HP+CVVH)|After the sepsis patients were enrolled, they were treated with blood purification in HP mode 2 hours at first and then in CVVH mode 22 hours in the first two days, and then in CVVH mode 24 hours
223894513|NCT05757596|DRUG|VSA001 injection|The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
223894514|NCT05757596|DRUG|Placebo|0.9% Saline, volume matched
223939950|NCT07189936|DIAGNOSTIC_TEST|To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo|To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with Placebo at 30 minutes of head up Tilt and compare it with the subjects who received 28 days of 2HOBA
223894515|NCT06178198|PROCEDURE|Ablative radioembolization using Yttrium-90 resin microspheres|Based on 99mTc-MAA mapping, a partition model (multi-compartment MIRD) is employed to plan for a radiation dose of 400 (± 30%) to the tumor. If delivering this dose to the tumor is challenging due to lung dose limitations, the maximum feasible dose is administered to the tumor while maintaining the estimated lung dose below 15 Gy. While treating the entire tumor with a single high-dose radioembolization session is preferred, if necessary due to considerations like estimated lung dose, the treatment can be divided into two sessions, keeping the cumulative lung dose below 25 Gy. For any methods not covered in this discussion, refer to the SIR-Sphere user manual by Sirtex.
223894516|NCT02692105|RADIATION|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
223894517|NCT02692105|RADIATION|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
223894518|NCT02274662|BIOLOGICAL|Cultured Thymus Tissue|"Subjects receive cultured thymus tissue which is implanted into the quadriceps muscle. Subjects may receive pre and/or post-implantation immunosuppression.~Potential subjects are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted into the subject's quadriceps muscle under general anesthesia in the operating room. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one year post-implantation. At year 2 post-implantation, subjects are contacted for data collection."
223894519|NCT02274662|PROCEDURE|Blood Draw|
223894520|NCT02274662|DRUG|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
223894523|NCT03709758|DRUG|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
223894524|NCT03709758|DRUG|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
223894525|NCT03709758|DRUG|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
223894526|NCT05504265|DRUG|Preemptive flurbiprofen axetil|50mg once，30min before induction anesthesia
223894527|NCT05504265|DRUG|Postoperative flurbiprofen axetil|50mg bid
223894528|NCT05504265|DEVICE|Patient-controlled analgesia pump|Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
223894529|NCT03469362|PROCEDURE|Extracorporeal Urinary Diversion|Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
223894530|NCT03469362|PROCEDURE|Intracorporal Urinary Diversion|Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
223894531|NCT03472807|OTHER|Collection of blood sample or saliva|at Inclusion
223894532|NCT03472807|OTHER|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
223894533|NCT03472807|OTHER|Collection of blood sample if tumor sample is not available|at Inclusion
223894534|NCT05255224|OTHER|Not applicable as observational study|Not applicable as observational study
223894535|NCT06492512|DRUG|daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily
223894536|NCT06492512|DRUG|alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill|ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
223894537|NCT03194217|DRUG|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
223894538|NCT03194217|DRUG|Placebo|Placebo
223894539|NCT06484309|BEHAVIORAL|Reflexology Group|"* In the 3rd stage of labor, local anesthesia (5 ml lidocaine 2%) will be applied and episiotomy repair will begin.~* Reflexology application will be started at the same time,~* Reflexology application will continue for at least 20-30 minutes during the episiotomy repair until the episiotomy repair is completed,~* Pain will be evaluated with VAS to determine the pain level four times in total: just before suturing, during perineal suturing (internal), during skin suturing and immediately after suturing is completed,~* Approximately 15-20 minutes after the end of the episiotomy repair, a face-to-face interview will be held and the McGill Pain Questionnaire will be filled out."
223894540|NCT06800326|DIAGNOSTIC_TEST|Ultrasound|Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
223894541|NCT06800326|DIAGNOSTIC_TEST|MRE Scan|Participants will have either an ultrasound or magnetic resonance imaging, depending on what scan they have had as part of their standard of care.
223894542|NCT02936752|DRUG|Entinostat|Given PO
223894543|NCT02936752|BIOLOGICAL|Pembrolizumab|Given IV
223894544|NCT04197765|DEVICE|accelerated Thetaburst stimulation|"We will administer 20-30 treatment sessions over the course of the study. The study technician will place the coil over the Fp2 electrode of a 10-20 International EEG system hair net, to approximate stimulation of the R-OFC). For the first three treatments, the study psychiatrist will set treatment intensity to 90% MT, and gradually increase intensity to 120% MT over 20 seconds to maximize tolerability. Subsequent treatment sessions (treatment 4 and onward) will begin, and remain, at 120% MT.~Treatment will occur 4-5 times a day, separated by an at least 45-min interval between sessions on consecutive weekdays. We estimate all study-related treatments will be complete in 5-6 weekdays."
223894545|NCT04197765|DEVICE|Sham Comparator|All parameters will be programmed in the same way as active treatment, however, the treatment will be delivered on the side of the coil that has an internal (hidden) metal shield that will prevent magnetic energy from reaching the skull and brain. Neither the technician, treating physician, nor the patient, will know whether the treatment was delivered from the sham or active side of the coil. The same auditory and tactile cues will be present during active and sham treatment as electrodes will be placed on the scalps of each participant (whether receiving active or sham treatment) that deliver some electrical sensation.
223711336|NCT02951065|OTHER|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
223711337|NCT00032409|BEHAVIORAL|Music therapy-based relaxation/stress reduction|
223711338|NCT04803071|DIETARY_SUPPLEMENT|Experimental group of n-pufas improving cognitive formula|Three times a day, one capsule of n-3pufas improvement cognitive formula capsule (once in the morning, in the evening) and routine treatment for depression, lasting for 12 weeks
223711339|NCT04803071|DIETARY_SUPPLEMENT|General fish oil formula product adjuvant treatment control group|The control group: 1 capsule of general fish oil formula (once in the morning, in the evening) three times a day, plus routine treatment for depression, lasting for 12 weeks
223711340|NCT04803071|DIETARY_SUPPLEMENT|Placebo assisted treatment group|Three times a day, one capsule of placebo adjuvant therapy (once in the morning, one in the evening) and conventional treatment of depression for 12 weeks
223711341|NCT01334164|BEHAVIORAL|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
223711342|NCT01334164|OTHER|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
223711343|NCT06217341|OTHER|In the study, bispectral index monitoring and follow-up will be applied to both groups.|Perioperative Bispectral Index Monitoring (BIS) monitor and Bispectral Index suppression Rate (BIS-SR) monitoring will be applied. The duration and magnitude of BIS-SR values will be examined together with BIS values in terms of recovery agitation.
223711344|NCT00965315|DRUG|Rosuvastatin,SFC fenofibrate|"1. Rosuvastatin 10 mg once daily~2. Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
223711345|NCT02849041|DEVICE|medical imaging|Low-dose CT-scanner
223711346|NCT02849041|BIOLOGICAL|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
223711347|NCT02849041|PROCEDURE|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
223711348|NCT06557902|DRUG|Lumateperone 10.5 mg capsule|Lumateperone 10.5 mg capsule, oral administration
223711349|NCT06557902|DRUG|Lumateperone 21 mg capsule|Lumateperone 21 mg capsule, oral administration
223711350|NCT06557902|DRUG|Lumateperone 5 mg ODT|Lumateperone 5 mg ODT, oral administration
223711351|NCT06557902|DRUG|Lumateperone 10.5 mg ODT|Lumateperone 10.5 mg ODT, oral administration
223711352|NCT06557902|DRUG|Lumateperone 15.5 mg ODT|Lumateperone 5 mg ODT + 10.5 mg ODT, oral administration
223711353|NCT06557902|DRUG|Lumateperone 21 mg ODT|Lumateperone 21 mg ODT, oral administration
223711354|NCT00307645|DRUG|Cyclophosphamide|
223711355|NCT00307645|DRUG|Mycophenolate mofetil|
223711356|NCT00307645|DRUG|Azathioprine|
223711357|NCT00307645|DRUG|Prednisone (and methylprednisolone)|
223711358|NCT03207477|DIAGNOSTIC_TEST|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
223711359|NCT06188533|OTHER|Urinary activin A in AKI|Urinary activin A in AKI patient
223711360|NCT02188108|OTHER|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
223711361|NCT06239766|DIAGNOSTIC_TEST|Breast Cancer Risk Assessment|Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
223894546|NCT06801769|DIAGNOSTIC_TEST|C-peptide|Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT).
223711362|NCT03093883|DRUG|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
223711363|NCT03093883|DRUG|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
223711364|NCT01201850|DRUG|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
223711365|NCT03844880|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
223711366|NCT03844880|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
223711367|NCT00925041|DEVICE|Vedera KXS|one treatment with the Vedera KXS
223894547|NCT04605549|DRUG|CIN-107 2 mg dosing|One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
223894548|NCT04605549|DRUG|CIN-107 4 mg dosing|Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
223894549|NCT04605549|DRUG|CIN-107 8 mg dosing|Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
223894550|NCT06570655|DRUG|Huperzine A injection|intramuscular
223894551|NCT06570655|DRUG|Huperzine A injection|intravenous bolus
223894552|NCT06800690|DIAGNOSTIC_TEST|Urinary Estrogen Level|Women had urinary estrogen metabolite levels measured daily to identify both the nadir (menstruation) and the peak (peri-ovulation) of the cycle. Men were also tested at the same time intervals, approximately two-weeks apart.
223894553|NCT06800495|BEHAVIORAL|THALEA (Thalassemia Education and Awareness) Kit|"By using the opinions obtained by the experts, THALEA's content will then be designed using the Theory of Planned Behaviour (TPB) by Ajzen and Fishbein.~Development of THALEA:~• Language: Malay and English.~• Contents of the THALEA kit: i. PowerPoint or Canva presentations with discussion prompts (softcopy form) ii. Links/joining codes to free educational game platforms such as Kahoot or Quizziz iii. Videos - convey messages on thalassemia awareness and screening importance.~iv. Illustrated guides/brochures - to provide step-by-step tutorials on how to get thalassemia screening in both the public and private healthcare.~• Developer would be the main researcher with aid from: i. Illustrator ii. Video graphic designer iii. Influencers~• Delivery of THALEA to students by: i. Medical personnel"
223894554|NCT06800495|BEHAVIORAL|Basic thalassemia and family health education|They are basic family health education in which it is the usual family health education given by the MOH, usually delivered by a medical officer, to fourth form students at government schools prior to the thalassemia screening programme. It will consist of a delivery of a PowerPoint presentation and videos, that will be obtained from government public health clinics in Klang Valley.
223894555|NCT06800950|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
223894556|NCT06800950|BIOLOGICAL|QIV Control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
223894557|NCT04489771|DRUG|Belzutifan|Oral administration
223894558|NCT03659734|BEHAVIORAL|Motivational Interviewing and Guided Opioid Tapering Support|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
223894559|NCT03659734|BEHAVIORAL|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
223894560|NCT06800924|OTHER|Postural and mobility analysis|Postural and mobility parameters were obtained with the use of the Idiag M360 scan tool (Idiag, Fehraltorf, Switzerland)
223894561|NCT06801613|OTHER|Intervention Group|Group/Cohort Description: Participants with Upper Cross Syndrome (UCS) who undergo the prescribed exercise or treatment protocol.
223894562|NCT06429436|BEHAVIORAL|VENDY|At least 1 machine (vending machine like a snack machine or a machine like a newspaper kiosk) will be placed in the respective community served by the participating organizations. Any person in the community can get naloxone from the machine. The vending machine will require a code that will be placed on the machine for anyone to use. The kiosks are a box that you simply pull open and naloxone can be obtained. Naloxone kits will be provided for free as part of the current naloxone distribution program within each respective organization.
223894563|NCT06801652|OTHER|Sperm morphology indexes|We analyzed all sperm morphology indexes in all groups.
223894564|NCT06147622|DRUG|Prazosin + cyproheptadine|Subjects will receive prazosin + cyproheptadine on day 1 of period 1 or on day 1 of period 2 depending on randomization.
223894565|NCT06147622|DRUG|KT110|Subjects will receive KT110 on day 1 of period 1 or on day 1 of period 2 depending on randomization.
223894566|NCT03603535|DEVICE|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
223894567|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
223894568|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
223894569|NCT06297434|DRUG|J2H-1702|Orally, once daily before meals
223894570|NCT06297434|DRUG|Placebo|Orally, once daily before meals
223894571|NCT05899452|BEHAVIORAL|Bubble blowing (active)|Bubble blowing as a method of active distraction during painful procedure (insertion of an IV cannula)
223894572|NCT05899452|BEHAVIORAL|Video distraction (passive)|Video on a tablet computer as a method of passive distraction during painful procedure (insertion of an IV cannula)
223894573|NCT03241459|DEVICE|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
223894574|NCT03241459|DEVICE|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
223894575|NCT05971563|DIETARY_SUPPLEMENT|Casein|Natural protein
223894576|NCT05971563|DIETARY_SUPPLEMENT|L-amino acids|Synthetic amino acids based protein substitute for Phenylketonuria
223527874|NCT05242939|OTHER|Watching cartoons|The cartoon is 5 min from the application. It will be started to be watched first and will continue until the application is finished. Vital signs (pulse, respiration and SPo2), Child Fear Scale and Child Anxiety Scale-State Statement Scale (CAS-D) will be evaluated by the researcher and the child before, immediately and 5 minutes after the application and recorded in the intervention follow-up form by the researcher.
223894577|NCT05971563|DIETARY_SUPPLEMENT|CGMP-AA|Glycomacropeptide based protein substitute for Phenylketonuria
223894578|NCT06789237|OTHER|weighted blanket|Participants will be covered with a weighted blanket for 30 minutes
223527875|NCT00108381|BEHAVIORAL|tailored cognitive behavior therapy|tailored psychological treatment
223894579|NCT06789237|OTHER|non-weighted blanket|Participants will be covered with a sham non-weighted blanket for 30 minute
223894580|NCT06795633|OTHER|Holistic Care Program for High-Risk Pregnancies|High-risk pregnant women admitted to the perinatology clinic participated in the Holistic Care Program for High-Risk Pregnancies in addition to the midwifery care provided in the clinic.
223894581|NCT03476746|DRUG|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
223894582|NCT03476746|DRUG|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
223894583|NCT06800573|OTHER|Conventional physical therapy|including strengthening exercises for deep neck flexors, rhomboids, lower trapezius and serratus anterior, (2 sets of 10 repetitions per day) and stretching exercises for pectoralis muscles (20seconds hold, 5 repetition.
223894584|NCT06800573|OTHER|lying posture with progression|"Exercise 1, the lying posture with leg extension progression, was aimed to stretch the anterior muscle chain (diaphragm, pectoralis minor, scalene, sternocleidomastoid, intercostalis, iliopsoas, arm, forearm, and hand flexors)(Bonetti et al., 2010).~Exercise 2, the lying posture with flexion of the thighs, was intended to stretch the posterior chain (upper trapezius, levator scapulae, suboccipital, erector spinae, gluteus maximus, ischiotibial, triceps surae, and foot intrinsic muscles)."
223894585|NCT06800573|OTHER|smartphone app exercises|about 50 min a day, 4 days a week for an 8-week period also, performed exercises which were reminded by a smartphone app at predetermined times.
223894586|NCT06546384|DRUG|Semaglutide|"Treatment with semaglutide, following standard clinical practice as per below schedule:~Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d."
223894587|NCT06546384|BEHAVIORAL|Weight reduction recommendations (nutritional and exercise)|Participants will receive nutritional and exercise recommendations and 2 telephone consultations
223894588|NCT06543732|OTHER|Return to work program|The eHealth modules focus on psychoeducation, perceptions of return to work based on a personal plan including problem-solving exercises, relapse prevention, and continuous monitoring. If needed, followed by the participatory approach, a stepwise, collaborative approach to analyse and solve bottlenecks to develop a consensus-based plan for return to work.
223894589|NCT06068686|DRUG|Vildagliptin 50 MG|vildagliptin plus their metformin.
223894590|NCT06068686|DRUG|Glimepiride 3 Mg Oral Tablet|glimepiride plus their metformin
223894591|NCT05480124|DEVICE|tACS brain stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
223894592|NCT05480124|DEVICE|Sham stimulation treatment|Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
223894593|NCT05192863|OTHER|No Intervention|This is a non-interventional study.
223894594|NCT06169254|DEVICE|Transcranial current stimulation (tCS)|Transcranial current stimulation (tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
223894595|NCT06482528|OTHER|Motor Imagery|"After the measurement devices are connected to the individuals, they will be seated in a comfortable chair.~After the calibration of the devices, individuals will undergo a 2-minute relaxation session. During the relaxation session, individuals will be asked to focus on their breathing and relax as much as possible.~Then, heart rate variability, electrodermal activities and respiratory frequencies of the individuals will be measured in a sitting position for 5 minutes. In case of rest, after taking the variables, individuals will be kept to rest for 10 minutes.~After 10 minutes, the devices will be placed on the individuals again and a 2-minute relaxation session will be held.~Then, individuals will be asked to imagine running through kinesthetic imagery for 5 minutes.~Feedback will be given to individuals throughout the entire session. These feedbacks will be given verbally with an audio recording prepared by the physiotherapist."
223894596|NCT05925855|OTHER|US with fastum|apply fastum on trigger point with US
223894597|NCT05925855|OTHER|US with reparil|apply reparil on trigger point with US
223894598|NCT05925855|OTHER|US with plain gel|apply gel on trigger point with US
223894599|NCT03885518|OTHER|Playground Stencils|The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
223894600|NCT03866109|DRUG|Temferon|Genetically modified HSPCs
223894601|NCT06419712|DRUG|vitamin D (cholecalciferol) supplementation|This clinical pilot study administered and compared daily and bolus dosing regi-mens of vitamin D to achieve and maintain optimal serum levels of 25(OH)D in post-COVID patients. The daily dose group received constant and gradual supplementation of cholecalciferol, intended to achieve more stable 25(OH)D levels without peaks. Conversely, the bolus group received a weekly dose that could lead to rapid increases followed by gradual declines in 25(OH)D levels. The Daily dose of cholecalciferol was calculated using the following formula: Daily dose of cholecalciferol = \[Weight (kg) × desired increase in 25(OH)D (ng/ml) × 2.5\] - 10 .
223894602|NCT05225584|DRUG|KT-333|KT-333 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined frequency and dose level.
223894603|NCT02761057|PROCEDURE|Biospecimen Collection|Undergo collection of plasma and serum samples
223894604|NCT02761057|PROCEDURE|Bone Scan|Undergo bone scan
223894605|NCT02761057|DRUG|Cabozantinib S-malate|Given PO
223894606|NCT02761057|PROCEDURE|Computed Tomography|Undergo CT
223894607|NCT02761057|DRUG|Crizotinib|Given PO
223894608|NCT02761057|DRUG|Savolitinib|Given PO
223894609|NCT02761057|DRUG|Sunitinib Malate|Given PO
223894610|NCT05668780|BEHAVIORAL|NIATx Coaching|"The intervention will consist of:~1. a Nominal Group Technique session to identify priorities in integrating HIV/HCV/MOUD~2. rapid cycle improvement coaching sessions from a NIATx coach, using data dashboards and screening alerts to improve identification and treatment for HIV/HCV/OUD~3. training for primary care providers"
223894611|NCT05302089|OTHER|Pain management and shoulder bandage|All Patients receive standard pain management according to the local guidelines and a sling and swathe on the day of injury. After 10 to 14 days, all patients will receive a sling for optional use for one to two weeks and be randomized after oral and written informed consent.
223894612|NCT05302089|OTHER|One-time physiotherapy instruction|Patients are offered a one-time physiotherapy instruction about the course of pain and suggestions for quick and safe return to activities of daily living within the first three months post-injury.
223894613|NCT05302089|OTHER|Usual rehabilitation care|At the visit 10-14 days after the injury, the orthopaedic consultant (senior author SB) will refer the patient to usual rehabilitation care with a physiotherapist in a municipality close to the patient´s home. The physiotherapist then schedules the start date, typically three weeks after the injury. The rehabilitation content and duration is planned according to the choice of the local treating physiotherapist in consultation with the patient.
223894614|NCT05757310|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223894615|NCT05757310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223894616|NCT05757310|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
223894617|NCT05757310|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223894618|NCT05757310|DRUG|Cyclophosphamide|Given PO and IV
223894619|NCT05757310|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo CD4+ T-cell depleted haploHCT
223894620|NCT05757310|DRUG|Pentostatin|Given IV
223894621|NCT05757310|OTHER|Questionnaire Administration|Ancillary studies
223894622|NCT05930353|OTHER|COHORT|this evaluation includes a brief interview with perma profiler scale
223894623|NCT06492239|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
223894624|NCT06492239|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (symptoms onset ≤4.5 h) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
223894625|NCT05030506|DRUG|Belzutifan|40 mg tablet administered orally at a dose of 120 mg
223894626|NCT05030506|BIOLOGICAL|Pembrolizumab|25 mg/mL solution for Infusion in a single-dose vial administered intravenously at a dose of 400 mg
223894627|NCT05030506|DRUG|Lenvatinib|10 mg capsule administered orally at a dose of 20 mg
223894628|NCT04420676|DIETARY_SUPPLEMENT|Omnibiotic AAD|Bacterial strains in Omni-Biotic® 10 AAD are Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 which are embedded in a matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate
223894629|NCT04420676|DIETARY_SUPPLEMENT|Placebo|matrix containing maize starch, maltodextrin, inulin, potassium chloride, hydrolysed rice protein, magnesium sulphate, fructooligosaccharide (FOS), enzymes (amylases), vanilla flavour and manganese sulphate.
223894630|NCT03209154|DIAGNOSTIC_TEST|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
223894631|NCT03209154|DEVICE|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
223894632|NCT02534272|OTHER|Stool sampling and sequencing of gut microbiota.|
223894633|NCT06143306|DRUG|bupivacaine.|an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine
223894634|NCT06143306|DRUG|Saline|an ultrasound guided pectoserratus block with 25 mL of saline
223894635|NCT06267014|BEHAVIORAL|Virtual Reality sessions|One session during 10-15 minutes per week for 6 weeks.
223894636|NCT04948697|DRUG|Ociperlimab|900 mg intravenously once every 3 weeks (dosed in 21-day cycles)
223894637|NCT04948697|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks (dosed in 21-day cycles)
223894638|NCT04948697|DRUG|BAT1706|15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)
223894639|NCT06173206|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
223894640|NCT06173206|DRUG|SPAQ (Guilin Pharmaceuticals)|Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.
223894641|NCT06173206|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
223894642|NCT04338061|DRUG|Teriflunomide|Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.
223894643|NCT04338061|DRUG|Evobrutinib|Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.
223894644|NCT06205368|BEHAVIORAL|Combine mobile app|"* HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing~* Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator.~* Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors~* Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication~* Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits."
223711368|NCT05076292|DRUG|GlucaGen|150 ug or 75\*2 ug glucagon will be administered subcutaneously to the participants before and after exercise.
223711369|NCT05076292|DRUG|Saline|Saline will be used as placebo before and after exercise.
223711370|NCT02178371|PROCEDURE|mCIMT|affected upper limb use with constraint of the healthy hand
223711371|NCT02178371|PROCEDURE|Unimanual therapy without constraint UTWC|affected upper limb use without constraint of healthy hand
223711372|NCT00758836|DRUG|placebo|
223711373|NCT00758836|DRUG|ibuprofen|
223711374|NCT00758836|DRUG|acetominophen|
223711375|NCT00758836|DRUG|telcagepant|
223711376|NCT01817530|OTHER|Elagolix placebo|oral coated tablet
223711377|NCT01817530|DRUG|Elagolix|oral coated tablet
223711378|NCT01817530|DRUG|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
223711379|NCT01817530|DRUG|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
223711380|NCT01817530|DRUG|E2/NETA placebo|oral hard capsule
223711381|NCT00981370|DRUG|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
223711382|NCT00002989|DRUG|busulfan|
223711383|NCT00002989|DRUG|cyclophosphamide|
223711384|NCT00002989|DRUG|idarubicin|
223711385|NCT00002989|DRUG|melphalan|
223711386|NCT00002989|RADIATION|radiation therapy|
223711387|NCT00259337|BIOLOGICAL|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
223711388|NCT00404235|DRUG|carboplatin|
223711389|NCT00404235|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223711390|NCT05134675|DIETARY_SUPPLEMENT|Homemade beer|The data of patients who consume and do not consume homemade beer will be cross-sectionally evaluated and compared.
223711391|NCT02937675|DRUG|Tomivosertib (eFT-508)|eFT508
223711392|NCT00608660|OTHER|acupuncture|staging acupuncture
223711393|NCT00608660|OTHER|acupuncture and moxibustion|staging acupuncture and moxibustion
223711394|NCT00608660|OTHER|electroacupuncture|staging electroacupuncture
223711395|NCT00608660|OTHER|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
223711396|NCT00608660|OTHER|acupuncture|non-staging acupuncture
223711397|NCT00273546|DRUG|XRP6976 (Docetaxel/Taxotere)|
223711398|NCT01841788|DEVICE|Thermal Adhesion Patch|
223711399|NCT01841788|DEVICE|Marketed Thermal Adhesion Patch|
223711400|NCT01841788|DEVICE|Placebo Patch|
223711401|NCT01040975|BEHAVIORAL|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
223711402|NCT03456050|BEHAVIORAL|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
223711403|NCT03456050|BEHAVIORAL|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
223711404|NCT02308605|DEVICE|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
223711405|NCT02123888|RADIATION|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
223711406|NCT03824314|DRUG|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
223711407|NCT03824314|DRUG|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
223711408|NCT03838952|DRUG|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
223711409|NCT05147025|OTHER|Revascularization|Regain pulp vascularity for young permenant teeth
223711410|NCT00594659|BEHAVIORAL|Psychotherapy|Nine session treatment
223711411|NCT00594659|BEHAVIORAL|Computerized Psychotherapy|Nine session computer delivered treatment
223711412|NCT00594659|BEHAVIORAL|Motivational enhancement therapy|Two session treatment
223711413|NCT02798874|DRUG|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
223711414|NCT02798874|DRUG|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
223711415|NCT02352974|DRUG|GAD-Alum|
223711416|NCT02352974|DRUG|Vitamin D|
223711417|NCT01020175|PROCEDURE|Bone marrow transplantation|Patients received bone marrow transplantation
223711418|NCT01020175|PROCEDURE|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
223894645|NCT06205368|BEHAVIORAL|Motivational interview|The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)
223894646|NCT06205368|BEHAVIORAL|HIV/STI testing|Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.
223894647|NCT05895149|OTHER|Flying buttress technique|With the volunteer in a supine position, the researcher who applied the technique positioned himself standing at the head of the massage table, supporting the patient's head. He contacted the occipital region, near the occipital-mastoid suture, with the thenar and hypothenar region of his right hand. He contacted the mastoid process of the contralateral temporal bone with the thenar and hypothenar region of his left hand. The forearms were positioned in a straight line. After a slight initial compression, the researcher applied a rhythmic pumping motion with both upper limbs in a convergent direction. The pressure applied was due to the rhythmic movement of the researcher's body. The technique was performed bilaterally and each one lasted for 2 minutes
223894648|NCT05895149|OTHER|Placebo technique|With the volunteer in a supine position, the researcher placed the palms of their hands on the patient's shoulders. The palm of the hand rested on the acromioclavicular joint with the rest of the hand relaxed. The placebo technique was performed for 4 minutes.
223894649|NCT06543953|DEVICE|HearCare MED-EL App|The main task of the HearCare MED-EL App is to perform technical checks on both implants and audio processors and create backups of audio processor configurations so that these configurations can be written on to an empty audio processor of the same type.
223894650|NCT05485376|DEVICE|Pulmonary Artery Catheter|The pulmonary artery catheter (PAC) is a diagnostic instrument that enables continuous hemodynamic monitoring of cardiac filling pressures, cardiac output, and pulmonary pressures.
223894651|NCT05158101|BIOLOGICAL|AlloEx|cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes
223894652|NCT04703166|DEVICE|Samsung Galaxy Watch Active2|The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
223894653|NCT05202990|DRUG|Fecal Microbiota Transplantation by Stool capsules|"After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces)."
223894654|NCT05202990|DRUG|Fecal Microbiota Transplantation by Intra-rectal enemas|"After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia.~The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas."
223894655|NCT06450782|OTHER|Post-isometric Relaxation Technique|"Sternocleidomastoid muscle Participants are asked to stretch their necks in a spuni position and then turn their heads as far to the side of the target muscle (right side) as possible until a sensation occurs that causes discomfort in the targeted SCM. In this case, the participants are asked to moderately isometrically contract the SKM muscle for 5 seconds and then relax for 3 seconds and the cervical spine is moved to the new barrier.~Masseter muscle Participants are positioned in a sitting position. The jaw is opened as wide as possible. The index and middle fingers of one hand are placed over the lower teeth. The weight of the hand is allowed to provide flexion and traction is applied directly to the midline. In this case, the participants are asked to moderately isometrically contract the bilateral masseter muscles for 5 seconds, then relax for 3 seconds and the participant moves his chin to the new barrier."
223894656|NCT06450782|OTHER|Myofascial Release Technique|"Sternocleidomastoid muscle The head is slightly elevated with the help of a folded towel to prevent discomfort that may develop depending on the position. The researcher sits in a chair next to the participant's head. The chair is placed at approximately 45° to the participant's neck. The participant's head is rotated 30° towards the opposite side of the treated side. The Graston instrument contacts the upper part of the SCM approximately 2 cm below the mastoid process.~Masseter muscle It works both ways. The Graston instrument is placed on the zygomatic process of the temporal bone, approximately 1 cm in front of the ear. The soft tissue is pressed until the bone is contacted. This connection with the periosteum is maintained and a lower tension line is created towards the mandible angle. This line of tension is continued up to the mandible, where the periosteum also comes into play. It is repeated several times."
223711419|NCT02151383|DRUG|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
223711420|NCT01421914|OTHER|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
223711421|NCT01220050|DRUG|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
223711422|NCT01220050|DRUG|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
223894657|NCT06450782|OTHER|Control|Participants will rest for thirty minutes.
223894658|NCT03486067|DRUG|CC-93269|Specified dose on specified days
223894659|NCT06884761|BEHAVIORAL|Maximal Rest|Participants in this group are instructed to follow maximal rest protocols. They are advised to avoid strenuous activities, including prolonged standing, lifting heavy objects, or engaging in physically demanding tasks. This group represents the traditional bed rest approach to managing pregnancies with a short cervix.
223527876|NCT00108381|BEHAVIORAL|standard care|standard psychological treatment
223527877|NCT01818778|OTHER|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
223527878|NCT01818778|OTHER|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
223711423|NCT06567340|DEVICE|StratCare|The StratCare app is a technology that collects data, processes inputs using a machine learning algorithm, and outputs a personalised treatment recommendation using automated decision rules. The inputs for the algorithm include patient-reported measures of depression, anxiety, functional impairment, personality traits, employment status and ethnic background. The algorithm calculates an expected prognosis (i.e., a probability of full remission of depression and anxiety symptoms after treatment), based on which patients are classified as standard (better expected prognosis) or complex cases. Standard cases are matched to low-intensity treatments and later have the option to move to high-intensity, whereas complex cases are matched directly to high-intensity treatments. In addition, the StratCare app is programmed to implement decision rules that ensure compliance with national clinical guidelines for the treatment allocation of patients with specific disorders.
223711424|NCT05686031|OTHER|No interventions were done between groups|No interventions were done between groups
223711425|NCT03432897|DRUG|Olaparib Pill|300 mg BID
223711426|NCT03432897|PROCEDURE|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
223711427|NCT06729242|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
223711428|NCT06729242|OTHER|HIIT session|The HIIT exercise will consist of strength exercises with elastic bands.
223711429|NCT06733129|DRUG|direct IV injection|direct IV injection at dosage of 2 mg/kg (adjusted body weight if BMI \> 30) after completing pre-oxygenation
223711430|NCT06733129|DRUG|combination of Ketamine and Propofol|combination of Ketamine and Propofol described above: consecutive direct IV injection of Ketamine 1 mg/kg and Propofol 1 mg/kg (adjusted body weight if BMI \> 30). Dilution are not necessary.
223711431|NCT04560998|DRUG|Semaglutide|Semaglutide is administered subcutaneously (s.c.; under the skin) once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
223711432|NCT04560998|DRUG|Placebo (semaglutide)|Placebo (semaglutide) is administered s.c. once-weekly for 52 weeks in a dose escalating manner: 0.25 mg from week 1 to week 4, 0.5 mg from week 5 to week 8 and 1.0 mg from week 9 to week 52.
223711433|NCT05794230|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Liquid solution - intramuscular
223711434|NCT05794230|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|Liquid solution - intramuscular
223711435|NCT05794230|BIOLOGICAL|Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)|Oral suspension - oral
223711436|NCT05794230|BIOLOGICAL|Pneumoccocal Vaccine|Suspension for injection - intramuscular
223711437|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR)|Lyophilized powder for injection - subcutaneous
223711438|NCT05794230|BIOLOGICAL|DTwP-HepB-Hib-IPV vaccine|Suspension - intramuscular
223711439|NCT05794230|BIOLOGICAL|DTaP-IPV-Hib-HepB vaccine|Liquid solution - intramuscular
223711440|NCT05794230|BIOLOGICAL|Hepatitis A vaccine|Lyophilized powder for injection - subcutaneous
223711441|NCT05794230|BIOLOGICAL|Rotavirus vaccine|Oral solution - oral
223711442|NCT05794230|BIOLOGICAL|Typhoid conjugate vaccine (TCV)|Suspension for injection - intramuscular
223711443|NCT05794230|BIOLOGICAL|Measles vaccine|Freeze-dried powder for reconstitution and injection - subcutaneous
223711444|NCT05794230|BIOLOGICAL|Varicella vaccine live|Sterile powder and diluent for injection - subcutaneous
223894660|NCT05081037|DEVICE|Wearable Care Group|"Continous glucose monitoring sensor: Study participants wear the sensor on the back of either right or left upper arm for up to 14 days. Glucose levels will be recorded from the interstitial fluid every 15 minutes using intermittent/ flash glucose scanning.~Exercise tracker: A FitBit watch will be given to the participants for use to track physical activity levels."
223527879|NCT01142180|PROCEDURE|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
223527880|NCT01142180|PROCEDURE|No TAE|No TAE procedure will be performed after endoscopic treatment
223527881|NCT02663362|OTHER|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
223527882|NCT00687076|DRUG|Ezetimibe|Daily dose of 10 mg of Ezetimibe
223711445|NCT05794230|BIOLOGICAL|Varicella vaccine live|Lyophilized powder for injection - subcutaneous
223711446|NCT05794230|BIOLOGICAL|Measles, Mumps, and Rubella Vaccine live (MMR)|Lyophilized powder for injection - subcutaneous
223711447|NCT05794230|BIOLOGICAL|Hepatitis A vaccine|Suspension for injection - intramuscular
223711448|NCT04659928|DEVICE|High volume evacuation (HVE)|Intra oral suction will be done and during the procedure,bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab. Patient will be given a mouth rinse.
223711449|NCT04659928|DEVICE|Extraoral vacuum aspirator (EVA)|Extraoral suction connected to dental suction will be used and bacterial colony forming units (cfus) will be captured during dental care by placing large format petri dishes containing bacterial culture media in the dental operatory with open lids. Once aerosol capture is complete, petri dishes will be incubated and quantified under BSL-2 safety conditions in the lab. Patient will be given mouth rinse.
223711450|NCT04659928|DRUG|Hydrogen Peroxide|Subjects will be given 1.5 % Oral Solution of hydrogen peroxide mouth rinse
223711451|NCT04659928|DRUG|Placebo|Subjects will be given a placebo (plain water) mouth rinse
223711452|NCT06065228|OTHER|AlgometRx Nociometer|Physiologic characterization of disease activity
223711453|NCT06911866|DRUG|RC1416|there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
223894661|NCT06128863|DRUG|Pembrolizumab, Eftilagimod alpha|Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
223894662|NCT05359848|OTHER|Diet|Using dietary interventions as an adjuvant tool may represent an effective step toward advancing the treatment options of cancer. Dietary modifications can impact the growth and proliferation of tumors via multiple mechanisms
223894663|NCT03135730|GENETIC|ROHHAD|Suspected and Confirmed ROHHAD cases
223894664|NCT03365882|BIOLOGICAL|Cetuximab|Given IV
223894665|NCT03365882|DRUG|Irinotecan Hydrochloride|Given IV
223894666|NCT03365882|OTHER|Laboratory Biomarker Analysis|Correlative studies
223894667|NCT03365882|BIOLOGICAL|Pertuzumab|Given IV
223894668|NCT03365882|BIOLOGICAL|Trastuzumab|Given IV
223894669|NCT03365882|DEVICE|HER-2 testing|Central testing of HER-2 for eligibility
223894670|NCT05000749|BEHAVIORAL|DBT-SG|Dialectical Behavior Therapy Skills Group (DBT-SG) in addition to VHA treatment as usual. Group is 24 weekly sessions teaching skills in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness.
223894671|NCT05000749|BEHAVIORAL|VHA treatment as usual|VHA treatment as usual for Veterans at risk for suicide attempt
223894672|NCT06377631|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
223894673|NCT06377631|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
223894674|NCT06825273|OTHER|space maintainer|3-D printed partial denture space maintainer will designed for each child patient who has premature loss of primary teeth after doing intraoral scanning
223894675|NCT06825273|OTHER|space maintainer|a conventional impression will be done for a child patient with premature loss of his primary teeth, then a plaster model will gained. A conventional acrylic partial denture will be designed and delivered to the patient.
223527883|NCT00687076|DRUG|Niaspan|Daily dose of 1500 mg of Niaspan
223527884|NCT00687076|DRUG|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
223527885|NCT00687076|BEHAVIORAL|Standard care|Standard of medical care for PAD
223527886|NCT00687076|DRUG|Aspirin|Daily dose of 325 mg of aspirin
223894676|NCT06917768|PROCEDURE|Adenotonsillectomy|Children undergoing adenoidectomy and intracapsular tonsillectomy using Coblation™, by the same surgeon at HDF.
223894677|NCT06917768|DRUG|Prednisolone|The second Group includes children whose parents have refused surgery despite informed understanding of the therapeutic algorithm of OSA. They received medical treatment consisting of a 1-month treatment with intranasal corticosteroids, coupled with a 5-day course of oral corticosteroids (prednisolone) at a safe dose of 1mg/kg.
223527887|NCT00687076|DRUG|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
223527888|NCT00687076|DRUG|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
223894678|NCT06916819|DIAGNOSTIC_TEST|Home-Based Food Challenge|Participants randomised to the intervention arm will undertake a structured home-based oral food challenge over five consecutive days. This begins with an initial supervised dose administered in clinic under medical observation (60-minute monitoring period). Participants will then self-administer increasing doses of the implicated food at home each subsequent day using a standardised protocol adapted from PRACTALL and ASCIA guidelines. Dose intervals are 24 hours to reduce risk of cumulative reactions. Participants are provided with written instructions, emergency action plans, and have daily phone follow-up with allergy nursing staff during the challenge. The challenge food is selected by the participant from their eligible food allergy labels.
223894679|NCT06916819|DIAGNOSTIC_TEST|In-Clinic Food Challenge|Standard of care - Participants randomised to the control arm will undergo a standard in-clinic oral food challenge conducted under direct medical supervision. The protocol used is derived from the PRACTALL consensus and ASCIA position statements and involves administration of increasing doses of the implicated food at 20-30 minute intervals over a 2-3 hour period. Observation continues for 1-2 hours post final dose. The challenge is performed in a hospital outpatient clinic equipped for anaphylaxis management. The food challenged is selected by the participant from their eligible food allergy labels.
223894680|NCT04904796|OTHER|CIMT|CIMT : Constraint-Induced Movement Therapy (CIMT) is a deviation from traditional treatments, used to treat hemiplegia. Its aim is to stimulate the functional use of the affected limb and reverse the process developmental is disregard. In this method, the unaffected or less affected limb is restrained, so the person has to use the affected limb.
223894681|NCT04904796|OTHER|H-HABIT|H-HABIT : Hand-Arm Bimanual Intensive Therapy (HABIT) in children with hemiplegia is a new intervention developed at Columbia University. HABIT aims to improve the use and coordination of both arms in daily function. Unlike CIMT, HABIT focuses on improving the ability to perform bimanual activities. Participants will be monitored via webcam-based software (i.e. ZOOM) while they performed the activities in their own home.
223894682|NCT06786455|DRUG|SHR-1905 Injection|SHR-1905 Injection,medium dose, administered by subcutaneous injection;
223527889|NCT00687076|DRUG|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
223527890|NCT00687076|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
223527891|NCT00575224|DRUG|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
223894683|NCT00587314|OTHER|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
223894684|NCT06848946|COMBINATION_PRODUCT|iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery|iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
223894685|NCT06848946|PROCEDURE|Sham procedure in conjunction with cataract surgery|Sham procedure in conjunction with cataract surgery
223894686|NCT04323137|BEHAVIORAL|Risk reduction|Mailed letter, SMS, and/or patient portal message
223527892|NCT05375422|OTHER|SARAH|Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
223527893|NCT05375422|OTHER|Educational intervention|Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
223527894|NCT00378092|DRUG|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
223527895|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
223527896|NCT00378092|DRUG|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
223527897|NCT05821946|OTHER|Web-Based Multi-Source Training on the Prevention of Urinary Tract İnfections|Before discharge, individuals will be given a user name and password to enter the website by the researcher. The first access to the website will be made via the researcher's computer, and the website will be introduced. Individuals will be shown how to access the compatible website on Android and IOS phones and tablets by the researcher. Web-based multi-source training for individuals to prevent urinary tract infections will begin. The researcher will check the use of educational materials by individuals from the administrator's menu. To increase the effectiveness of the training, reminder, motivating, and supportive messages will be sent to the patients twice a week.
223527898|NCT01203345|DRUG|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
223527899|NCT01203345|DRUG|Placebo|An equal volume of 5 percent albumin solution
223527900|NCT05313581|BEHAVIORAL|START NOW WebApp|"The WebApp is based on the existing manualized START NOW skills training. START NOW aims to improve emotion- and stress regulation, social competence, effective management of encountered problems/crises, subjective well-being and resilience through improving an individual's level of psychological flexibility. It primarily employs a cognitive behaviourally oriented group skills training with integrated components from Dialectical Behavioural Therapy (DBT), Acceptance and Commitment Therapy (ACT), trauma-informed care and Motivational Interview (MI) techniques.~During the training, participants will encounter different exercises to help them train their skills. There are several mindfulness exercises in the form of audio tracks, containing, e.g., instructions on a breathing exercise. The skills training phase takes place over a period of 9 weeks (sessions 1+2, 9+10 and 11+12 are double session)."
223527901|NCT00647647|DRUG|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
223527902|NCT00647647|DRUG|Lamisil® Tablets 250 mg|250mg, single dose fasting
223527903|NCT02243358|DRUG|Folfox6|
223527904|NCT02243358|DRUG|Gemcitabine|
223527905|NCT02243358|RADIATION|Radiation Therapy|
223527906|NCT02243358|PROCEDURE|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
223527907|NCT05665283|DRUG|Ensartinib Hydrochloride|oral ALK inhibitor
223527908|NCT03808935|DRUG|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
223527909|NCT03808935|DRUG|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
223527910|NCT00968409|RADIATION|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
223527911|NCT00968409|OTHER|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
223527912|NCT00968409|OTHER|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
223527913|NCT00968409|DRUG|F18-FFNP|injection of F18-FFNP
223527914|NCT06156150|BIOLOGICAL|tumor vaccine|DC vaccine produced by the Team
223527915|NCT01323608|DRUG|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
223527916|NCT01323608|DRUG|Placebo|Placebo
223527917|NCT00710099|DRUG|sildenafil|systemic absorption of sildenafil
223527918|NCT00710099|DRUG|nitroprussiate iontophoresis|nitroprussiate iontophoresis
223527919|NCT03278561|PROCEDURE|Sputum induction|Sputum induction according to the ERS protocol
223527920|NCT03278561|PROCEDURE|Blood sample|A blood sample of 100ml will be taken.
223527921|NCT04989361|PROCEDURE|Soluble Hyaluronic Acid Microneedle|The soluble hyaluronic acid microneedle eye mask is a nanometer-sized microneedle made of water-soluble hyaluronic acid, which can directly inject the active ingredients into the dermis, and after being absorbed and dissolved by the skin, it can achieve the purpose of improving the water content and elasticity of the skin.
223527922|NCT04989361|PROCEDURE|Non-fractional laser|he non-ablative fractional laser use 1565nm fiber laser, which acts on the target base in the dermis-water. The beam penetrates the epidermis and acts on the dermis. Using the principle of focal light and heat, the tissue cells are heated to initiate the repair process, which promotes increased collagen synthesis, thereby Achieve the effect of firming the skin and improving wrinkles.
223527923|NCT04154722|DRUG|Meropenem Injection|inj meropenum for 10 days
223527924|NCT04154722|DRUG|Azithromycin Powder|syp azithromycin for10days
223527925|NCT03243084|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
223711454|NCT06911866|DRUG|RC1416 Placebo|Each subjects will receive the placebo once by subcutaneous injection.
223711455|NCT04589728|DRUG|Venetoclax plus HMA|patients with AML, ineligible for intensive chemotherapy, treated with the combination of HMA plus venetoclax under the Italian Law N. 648/96.
223711456|NCT06937827|BEHAVIORAL|HF Kit and Follow-ups|"These patients will receive TOCC intervention, which includes: pre-discharge introduction to the program; watching educational videos about heart failure via Mytonomy; receiving the American Heart Association's Get With The Guidelines (GWTG) booklet and a heart failure (HF) kit. These patients will receive a follow-up phone call days 1 to 3 days post discharge from the pharmacist and nurse practitioner to review discharge instructions, provide medication education, and assess clinical status; a second follow-up call will be conducted days 21 to 24 post discharge. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate"
223711457|NCT06951100|DIAGNOSTIC_TEST|CT coronary angiography|To assess the presence of obstructive coronary artery disease, participants will either have coronary angiography as part of their routine care or they will return for a research CT scan of their heart (CT Coronary Angiogram)
223711458|NCT05865028|DRUG|APG-157|Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
223711459|NCT00666029|DRUG|atorvastatin|40 m.g. o.d. tablets for 6 months
223711460|NCT00666029|DRUG|placebo|Placebo
223711461|NCT01534871|BEHAVIORAL|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
223711462|NCT03281577|DRUG|TAK-954|TAK-954 IV infusion.
223711463|NCT03281577|DRUG|Placebo|TAK-954 placebo-matching IV infusion.
223711464|NCT06366932|DRUG|Second-line systemic treatment|Patients with moderate to severe atopic dermatitis refractory to topical medication, who also have previous experience with cyclosporine and an unsatisfactory response, or in whom the use of cyclosporine is considered inappropriate due to contraindication or intolerance, are candidates for treatment with other alternatives (Dupilumab, Tralokinumab, Upadacitinib, Baricitinib, Abrocitinib).
223711465|NCT06366932|OTHER|Folllow-up of second-line systemic treatment already started|If the patient is receiving second-line therapy at the moment of the inclusion, data will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.
223711466|NCT01324843|DRUG|EMLA Cream|
223711467|NCT01324843|DRUG|Aveeno Daily Moist|
223711468|NCT01324843|DEVICE|Derma Vax|
223711469|NCT01324843|PROCEDURE|Intradermal Electroporation|
223711470|NCT01324843|PROCEDURE|Visual Analogue Scale|
223711471|NCT01324843|PROCEDURE|Present Pain Intensity|
223711472|NCT01324843|PROCEDURE|McGill Pain Questionnaire|
223711473|NCT01324843|PROCEDURE|Skin Assessment|
223711474|NCT02079220|DRUG|Arm A|"* Capecitabine~* Oxaliplatin~* Ziv-aflibercept"
223711475|NCT02079220|DRUG|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
223711476|NCT00443261|DRUG|Azacitidine|SC azacitidine
223711477|NCT00443261|DRUG|Cisplatin|cisplatin 75 mg/m\^2 day 8 every 28 days
223711478|NCT02968901|DRUG|macitentan|used in open label
223711479|NCT02968901|DRUG|tadalafil|used in open label
223711480|NCT00117481|DRUG|DR-2001a|DR-2001a administered vaginally each month
223711481|NCT00117481|DRUG|DR-2001b|DR-2001b administered vaginally each month
223711482|NCT00117481|OTHER|Placebo|Placebo administered vaginally each month
223711483|NCT05968391|RADIATION|PET scan metabolic day|11C-Acetate and 11C-Acetoacetate PET scans
223711484|NCT00517816|DRUG|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
223711485|NCT00583609|DRUG|PEG3350|PEG3350
223711486|NCT05677659|DRUG|VGL101|Solution administered via Intravenous Infusion (IV)
223711487|NCT03570073|OTHER|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
223711488|NCT03570073|OTHER|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
223711489|NCT01955096|PROCEDURE|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
223711490|NCT01955096|PROCEDURE|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
223711491|NCT01433991|DRUG|Golvatinib|Participants will receive E7050 50 mg and/or 100 mg tablets. E7050 will be administered orally once daily, in 28-day cycles.
223711492|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 1 mg and/or 4 mg and/or 10 mg capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
223711493|NCT01433991|DRUG|Lenvatinib|Participants will receive lenvatinib 24 mg (1\*4 mg capsule + 2\*10 mg capsule) capsules. Lenvatinib will be administered orally once daily, in 28-day cycles.
223711494|NCT04915144|DRUG|177Lu-DOTATOC|Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
223711495|NCT00769470|BIOLOGICAL|trastuzumab|Given IV
223711496|NCT00769470|DRUG|carboplatin|Given IV
223711497|NCT00769470|DRUG|docetaxel|Given IV
223711498|NCT00769470|DRUG|lapatinib ditosylate|Given orally
223894687|NCT04323137|BEHAVIORAL|Medical records-based recommendation|Mailed letter, SMS, and/or patient portal message
223894688|NCT04323137|BEHAVIORAL|Algorithm-based recommendation|Mailed letter, SMS, and/or patient portal message
223894689|NCT05361317|DEVICE|Nexis® PECA Bunion device|Hallux valgus correction with percutaneous chevron and Akin osteotomy.
223894690|NCT06212752|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa SC will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
223894691|NCT06212752|DRUG|Pemetrexed|Pemetrexed 500 mg/m² by IV Infusion will be administered for nonsquamous NSCLC as per the schedule specified in arm.
223894692|NCT06212752|DRUG|Cisplatin|Cisplatin 75 mg/m² by IV Infusion will be administered for nonsquamous and squamous NSCLC as per the schedule specified in arm.
223894693|NCT06212752|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/min in nonsquamous and AUC 6 mg/mL/min in squamous NSCLC will be administered as per the schedule specified in arm.
223894694|NCT06212752|DRUG|Paclitaxel|Paclitaxel 200 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
223894695|NCT06212752|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m² by IV Infusion will be administered for squamous NSCLC as per the schedule specified in arm.
223894696|NCT06212752|BIOLOGICAL|Pembrolizumab|Pembrolizumab by IV Infusion will be administered for squamous and nonsquamous NSCLC as per the schedule specified in arm; participants may be eligible for second course.
223894697|NCT06212752|DRUG|Filgrastim|Filgrastim will be administered as per the schedule specified for the arm.
223894698|NCT06212752|DRUG|Pegylated filgrastim|Pegylated filgrastim will be administered as per the schedule specified for the arm.
223711499|NCT03275012|DRUG|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and \>15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
223711500|NCT03275012|DRUG|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM\>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
223711501|NCT06256016|OTHER|Neck pain massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
223711502|NCT06256016|OTHER|Neck and thoracic massage|"Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain."
223711503|NCT03542474|BEHAVIORAL|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
223711504|NCT02259868|DRUG|BILR 355 BS /1B, current low dose formulation|
223894699|NCT04229992|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
223711505|NCT02259868|DRUG|BILR 355 BS /1B, current high dose formulation|
223894700|NCT04229992|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
223894701|NCT03770273|BIOLOGICAL|sarilumab|Sarilumab is a fully human anti-IL-6Rα monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling.
223894702|NCT03770273|OTHER|Placebo|Placebo
223894703|NCT00418886|DRUG|Vandetanib|oral once daily tablet
223894704|NCT00418886|DRUG|Pemetrexed|intravenous infusion
223894705|NCT06816992|DRUG|ORIC-114 Dose 1 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
223894706|NCT06816992|DRUG|ORIC-114 Dose 2 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
223894707|NCT06816992|DRUG|ORIC-114 Dose 3 + amivantamab|ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
223894708|NCT06322407|PROCEDURE|Stellate Ganglion Block (SGB)|All SGB procedures will be performed by the same experienced physicians. Patients will be positioned in a supine position with the neck slightly hyperextended and receive a SGB procedure using the B-ultrasound visualization technique (Aurora A5 Ultrasound, Risco Tech Co., Ltd.). 1% lidocaine 5mL (Shanxi Jinxin Shuanghe Pharm Co., Ltd.) will be injected below the prevertebral fascia on the surface of longus colli muscle
223894709|NCT06322407|DRUG|standardized drug treatment|Topiramate(Topiramate, Xi'an Yangsen Pharmaceutical Co., Ltd) will be started at a low dose and then increased gradually until optimally effective, side effects become intolerable, or the maximum recommended dose is reached. During the 4-week up-titration phase, the intention will increase dose weekly in 25 mg increments with the aim of reaching 50-100 mg/day. Ibuprofen((Fenbid, Tianjin Shike Pharmaceutical Co., Ltd)will be chosen as acute treatment, but no more than 10 times per month to avoid medication overuse headache.
223894710|NCT06202118|DEVICE|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
223894711|NCT06152003|BEHAVIORAL|Cognitive Behavioral Therapy for Syndemics and Adherence (CBT-SA)|We anticipate the intervention will contain the following: CBT for depression and trauma, Life-Steps for ART adherence, nutritional counseling, supplementary food parcels, case management, linkage to care. Specific intervention components will be informed by prior aims.
223894712|NCT06562946|DRUG|Pimicotinib|Pimicotinib is supplied as capsules for oral use with a strength of 25 mg/capsule.
223894713|NCT05177848|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
223894714|NCT05177848|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223894715|NCT05177848|OTHER|Nicotine vaping products at 2x market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223894716|NCT05177848|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223894717|NCT05177848|OTHER|Heated tobacco products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223894718|NCT05177848|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223894719|NCT05177848|OTHER|Nicotine pouch products at 2x market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 2x market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223894720|NCT06848738|PROCEDURE|FNB|Endoscopic ultrasound for suspected lung cancer or lymphoma is performed to obtain tissue samples from suspected lesions with the 3rd generation FNB needle
223894721|NCT06848738|PROCEDURE|FNA|Endoscopic ultrasound for suspected lung cancer or lymphoma is performed to obtain tissue samples from suspected lesions with the standard FNA needle
223894722|NCT06849908|DRUG|Baricitinib|Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with Baricitinib 4 mg/day for 6 months.
223894723|NCT06849908|DRUG|Adalimumab|Participants randomized to this arm will maintain their original steroids and/or immunomodulators, combined with ADA (initially ADA 160 mg subcutaneous injection, followed by 80 mg ADA after 2 weeks, then 40 mg ADA every 2 weeks thereafter) for 6 months.
223894724|NCT06626568|DRUG|Compound betamethasone Injection(Gluteal muscle injection)|gluteal injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4
223894725|NCT06626568|DRUG|Compound betamethasone Injection(Subacromial Ultrasound Guided injection)|ultrasound-guided subacromial injection of 1 ml of Compound betamethasone and 4 ml of normal saline at week 0,2,4.
223711506|NCT02259868|DRUG|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
223711507|NCT02259868|DRUG|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
223894726|NCT06626568|OTHER|Normal Saline as Placebo (ultrasound-guided subacromial injection)|ultrasound-guided subacromial injection of 5 ml of normal saline at week 0,2,4.
223894727|NCT06626568|OTHER|Normal Saline as Placebo (gluteal muscle inection)|gluteal injection of 5 ml normal saline at week 0,2,4.
223894728|NCT06626568|BEHAVIORAL|home exercise|The participants were instructed to perform home rehabilitation exercise for 12 weeks. 30 minutes of home-based self-rehabilitation exercises in the morning, afternoon, and evening, with a total of 90 minutes per day. Standard instructional videos and demonstrations by outpatient rehabilitation therapists are provided to participants. Each exercise, including wall-climbing, table-climbing, and back-climbing, should be performed for 10 minutes, with a total of 30 minutes per session.
223894729|NCT06849375|PROCEDURE|phakic IOL implantation|specular microscopy examination to assess endothelial cells before and after phakic IOL implantation
223894730|NCT06850675|OTHER|Clinical performance|Supraglottic airway devices were evaluated for ease of insertion, time of insertion, success rate at first attempt, number of attempts, ease of gastric tube insertion, oropharyngeal leak pressure, and intraoperative and postoperative complications
223527926|NCT03243084|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
223527927|NCT03448211|DRUG|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
223527928|NCT00970398|OTHER|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
223894731|NCT06846307|DRUG|Mannitol|mannitol administration across all three dosages (3x125 cc, 2x250 cc, 3x250 cc) given as an IV drip for 15-20 minutes
223894732|NCT06849856|DEVICE|non-surgical peri-implantitis therapy with airflow device|Airflow device with erythritol powder will be used in the treatment of non-surgical peri-implantitis
223894733|NCT06849856|PROCEDURE|non-surgical peri-implantitis therapy with titanium curette|Titanium curette will be used for non-surgical treatment of peri-implantitis
223894734|NCT05041647|DRUG|25:1 CBD/THC|"* 1 dose (1 mL) of HIGH CBD~* 50 mg/ml CBD and 2 mg/ ml THC"
223894735|NCT05041647|DRUG|5:1 CBD/THC|"* 1 dose (1 mL) of LOW CBD~* 10 mg/ml CBD and 2 mg/ ml THC"
223894736|NCT05041647|OTHER|Placebo|"* 1 dose (1 mL) of PLACEBO~* No active ingredients"
223711508|NCT02259868|DRUG|BILR 355 BS - Suspension low dose|
223711509|NCT02259868|DRUG|BILR 355 BS - Suspension high dose|
223711510|NCT02259868|DRUG|Ritonavir|
223711511|NCT03552315|DIETARY_SUPPLEMENT|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
223711512|NCT03552315|DIETARY_SUPPLEMENT|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
223711513|NCT03340701|DRUG|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
223711514|NCT00479609|DRUG|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
223711515|NCT00479609|DRUG|Placebo|Placebo gel
223894737|NCT05634109|BIOLOGICAL|Transfusion of blood products|The intervention will be either a) administration of 6 units of whole blood or b) administration of blood component therapy in the proportion of 6:6:6 units of red blood cells, plasma, and platelets.
223894738|NCT04581590|OTHER|Cognitive training|Both groups will undergo the motor training where only the type of received electric current is varied (active or simulated sham type) associated cognitive training. The twelve sessions will be performed in three sessions per week for 30 minutes.
223894739|NCT02035787|DRUG|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
223894740|NCT06414213|BEHAVIORAL|Motor Imagery (MI)|Participants watched a standardized video sequence that consisted of an individual completing twenty walking trials (twenty video clips-each clip represents one trial). Participants were instructed to place their focus intently on the person performing the obstacle course and try to imagine themselves doing the skill. Periodically, a reminder would appear to help focus and redirect participant's attention to different aspects of the video or different versions of imagery (visual or kinesthetic). Participants will watch the video first at normal play speed and then in slow motion after a short break (30 secs to 1 min). Total training time will be approximately 20 mins which is consistent with the duration of the locomotor intervention and duration of stimulation.
223894741|NCT06414213|DEVICE|Active tDCS|"The participants received a 20-minute active session of tDCS at a 2-milliamp current."
223894742|NCT06414213|DEVICE|Sham tDCS|"The participants received a 20-minute session of sham tDCS."
223894743|NCT02978456|DEVICE|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus \~10% of distal reference vessel diameter).
223894744|NCT02978456|DEVICE|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
223894745|NCT04612309|DRUG|Immunotherapy|patient treated with at least 1 immunotherapy administration
223894746|NCT03338933|BEHAVIORAL|magnetic resonance imaging (MRI)|All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
223894747|NCT01728857|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223894748|NCT06174272|BEHAVIORAL|Transitional Care Program|Intensive monitoring post discharge for cirrhosis and fluid overload
223894749|NCT06295796|DRUG|MK-8527|Oral Capsule
223894750|NCT04771195|BEHAVIORAL|Examination of students' naturally occurring social ties|In this observational study, features of students' social lives, such as the number of quality of relationships they form, and their subjective loneliness, will be used to predict their mental health and well being at later time points.
223894751|NCT02777879|PROCEDURE|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
223894752|NCT03784014|DRUG|Nilotinib|Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223894753|NCT03784014|DRUG|Ceritinib|Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223894754|NCT03784014|DRUG|Capmatinib|Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223894755|NCT03784014|DRUG|Lapatinib|Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223711516|NCT05169749|PROCEDURE|Control-Service Nurse Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
223894756|NCT03784014|DRUG|Trametinib|Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223711517|NCT05169749|PROCEDURE|Nursing Visiting Group|"Processing Steps~* The State-Trait Anxiety Inventory was applied before the patient education~* The State Anxiety Inventory was applied after the education.~* The pain was monitored in accordance with the surgical patient follow-up protocol for 24 hours postoperatively~* The State Anxiety Inventory was applied again 24 hours after surgery."
223711518|NCT02550106|DRUG|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
223711519|NCT01084746|BEHAVIORAL|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
223711520|NCT01084746|BEHAVIORAL|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
223894757|NCT03784014|COMBINATION_PRODUCT|Trametinib and Dabrafenib|"Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
223527929|NCT00970398|OTHER|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
223527930|NCT00104702|PROCEDURE|adjuvant therapy|
223527931|NCT00104702|PROCEDURE|conventional surgery|
223527932|NCT00104702|RADIATION|radiation therapy|
223711521|NCT04261348|OTHER|No intervention|There is no intervention
223711522|NCT06143813|DIAGNOSTIC_TEST|Selective nerve root block (SNRB)|CT/Fluoroscopy guided nerve root block
223711523|NCT01405248|DRUG|Butylphthalide|20 mg/time per os three times a day. 180days
223711524|NCT01405248|DRUG|Placebo|20 mg/time per os three times a day. 180days
223711525|NCT02628652|DIETARY_SUPPLEMENT|GOS|
223711526|NCT02628652|DIETARY_SUPPLEMENT|GLOS|
223711527|NCT02628652|DIETARY_SUPPLEMENT|FOS|
223711528|NCT04870593|BEHAVIORAL|Information|Elder informed about vaccination.
223711529|NCT04870593|BEHAVIORAL|Buddy|"Elder encouraged to get vaccinated using buddy system, whereby he/she is accompanied to the vaccination site by another adult who could also get the vaccine. A potential buddy also given vaccination information and encouraged to help the elder get to the vaccination site so they could both be vaccinated."
223711530|NCT04870593|BEHAVIORAL|Gossip intervention|"Members of elder's community asked who in the community is good at spreading information. These gossips then asked to spread information about vaccination of elders. If buddy intervention assigned in community, gossips also asked to encourage their communities to use the buddy system to get elders vaccinated."
223711531|NCT04870593|BEHAVIORAL|Information assigned in community|Information intervention assigned for other elders in community.
223711532|NCT04870593|BEHAVIORAL|Buddy assigned in community|Buddy intervention assigned for other elders in community.
223711533|NCT05657912|DEVICE|ECG monitoring|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
223711534|NCT00957554|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
223711535|NCT00957554|DRUG|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
223711536|NCT03807518|BEHAVIORAL|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
223711537|NCT00354744|BIOLOGICAL|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), \< 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
223711538|NCT00354744|DRUG|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
223711539|NCT00354744|DRUG|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
223711540|NCT00354744|DRUG|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
223711541|NCT00354744|DRUG|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
223711542|NCT00354744|DRUG|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
223711543|NCT00354744|DRUG|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
223711544|NCT00354744|PROCEDURE|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
223711545|NCT00354744|RADIATION|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
223711546|NCT00354744|BIOLOGICAL|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
223711547|NCT00109122|BIOLOGICAL|zoster vaccine live (Oka/Merck)|
223711548|NCT00109122|BIOLOGICAL|Comparator: placebo (unspecified)|
223711549|NCT01193530|OTHER|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
223711550|NCT01193530|OTHER|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
223711551|NCT01193530|BEHAVIORAL|Questionnaires|Weekly
223711552|NCT01193530|BEHAVIORAL|Study Diaries|Daily logs
223711553|NCT01193530|DEVICE|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
223527933|NCT04076033|OTHER|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
223527934|NCT03364504|OTHER|urine collection|3 urine collections during 24 hours
223711554|NCT01193530|DEVICE|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
223711555|NCT03539328|DRUG|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
223711556|NCT03539328|DRUG|Gemcitabine|Chemotherapy medication
223711557|NCT03539328|DRUG|Paclitaxel|Chemotherapy medication
223894758|NCT03784014|COMBINATION_PRODUCT|Olaparib and Durvalumab|Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223527935|NCT02095106|DEVICE|Waterproof Cast|
223894759|NCT03784014|DRUG|Palbociclib|"Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
223527936|NCT02095106|DEVICE|Traditional cast|
223527937|NCT03373435|DRUG|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
223527938|NCT03373435|OTHER|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
223527939|NCT00553254|DRUG|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
223527940|NCT04958603|PROCEDURE|"L type release surgery"|Lateral release of the lateral support belt
223527941|NCT00189137|DRUG|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
223527942|NCT00140686|BIOLOGICAL|Rotavirus (vaccine)|
223527943|NCT01018602|DRUG|vildagliptin|100 mg per day over 24 months
223527944|NCT01018602|DRUG|inactive pill|1 pill per day over 24 months
223527945|NCT05263804|OTHER|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection|No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
223527946|NCT05263804|OTHER|Cardiac MRI with gadolinium injection - Ancillary Study|Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
223527947|NCT04722666|DRUG|MIJ821 Intravenous Injection|MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
223527948|NCT04722666|DRUG|Placebo Intravenous Injection|40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
223527949|NCT06456840|DIAGNOSTIC_TEST|ULTRASOUND|Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.
223527950|NCT02008617|DRUG|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
223527951|NCT02008617|DRUG|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
223527952|NCT01741129|DEVICE|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
223527953|NCT01741129|DEVICE|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
223527954|NCT01807884|PROCEDURE|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
223527955|NCT01807884|OTHER|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
223527956|NCT01006733|GENETIC|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
223527957|NCT01006733|DRUG|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
223527958|NCT00751478|DRUG|ALO-01|ALO-01 capsules
223527959|NCT00751478|DRUG|MSIR|immediate release morphine sulfate
223527960|NCT00751478|DRUG|Placebo|Placebo
223527961|NCT02134184|BIOLOGICAL|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
223527962|NCT06637943|DIAGNOSTIC_TEST|POC viscoelastic test|applying viscoelastic test (Rotem or TEG tests) to 1 ml arterial blood sample
223527963|NCT06637943|DIAGNOSTIC_TEST|standard central laboratory test|applying central laboratory test to arterial blood sample
223711558|NCT03539328|DRUG|Liposomal Doxorubicin|Chemotherapy medication
223711559|NCT05998044|OTHER|Pilates Based Exercises|"The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively. Participants will be asked to open the video recording each time they exercise and follow them to do the exercises.~Exercise Program:~* Arm Circles~* Toe Touch~* bridge~* Shoulder Bridge~* Chest Lift~* Hundred~* Roll Up~* Leg Circles~* Chris Cross~* Side Kick~* Side Leg Circles~* one leg kick~* double leg kick~* Swan~* Single leg Stretch~* Double leg Stretch~* saw~* Spine Stretch"
223894760|NCT03784014|DRUG|Glasdegib|Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
223894761|NCT03784014|DRUG|TAS-120|Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
223894762|NCT03784014|OTHER|Next Generation sequencing exome|Both frozentumor material (archived or newly obtained) and blood sample collection will be used for genetic profiling
223894763|NCT06158529|DEVICE|spinal cord stimulator|A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain.
223894764|NCT06158529|DEVICE|high frequency spinal cord stimulation|A spinal cord stimulator is an implanted device that sends low levels and high frequency of electricity directly into the spinal cord to relieve pain.
223894765|NCT01084876|DRUG|CT-P6|Administered every 3 weeks
223894766|NCT01084876|DRUG|Herceptin|Administered every 3 weeks
223894767|NCT01084876|DRUG|Paclitaxel|Administered every 3 weeks
223894768|NCT04927741|OTHER|Sweet Marjoram Essential Oil|"Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
223894769|NCT04927741|OTHER|Grapeseed Oil|"Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping."
223894770|NCT03981705|RADIATION|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
223894771|NCT06338826|DRUG|TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI|"The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from~* NNRTI = efavirenz, rilpivirine, etravirine, doravirine~* PI/r = atazanavir/r ou darunavir/r~* INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir"
223894772|NCT06338826|DRUG|Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)|dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR
223894773|NCT02020720|PROCEDURE|Biopsy|Undergo image-guided biopsy
223894774|NCT02020720|PROCEDURE|Computed Tomography|Undergo 18F-DOPA-PET/CT
223894775|NCT02020720|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
223894776|NCT02020720|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
223894777|NCT02020720|OTHER|Laboratory Biomarker Analysis|Correlative studies
223894778|NCT02020720|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
223894779|NCT02020720|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
224276333|NCT00645827|OTHER|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
223894780|NCT02020720|PROCEDURE|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
223894781|NCT04383119|DRUG|Trabectedin|Trabectedin in monotherapy
223894782|NCT04383119|DRUG|Gemcitabine|Gemcitabine, control arm
223894783|NCT04383119|DRUG|No Intervention: Observational Cohort|Treatment according clinical practice
223711560|NCT05998044|OTHER|control|They will be asked not to participate in any regular exercise for 8 weeks.
223711561|NCT01544283|DRUG|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
223711562|NCT01544283|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
223711563|NCT03489148|BEHAVIORAL|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
223711564|NCT03489148|BEHAVIORAL|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
223527964|NCT05148338|OTHER|Comprehensive risk factor treatment|"1. Apnea screening with Home Sleep Apnea Test. Referral to sleep physician if apnea-hypopnea index (AHI) is greater than 5~2. Weight management counseling by dietician if body mass index (BMI) is above 27 kg/m2~3. Physical activity program under supervision of physiotherapist at a specialized cardiac rehabilitation centre if BMI is over 27 or if there are complaints during exercise~4. Smoking cessation at specialized outpatient clinic~5. Blood pressure control, lipid management, glycaemic control, alcohol intake reduction by specialized AF nurse~6. Motivation and education through a digital health platform"
223527965|NCT05148338|OTHER|Standard of care|Standard usual care: Treatment by cardiologist conform existing guidelines
223527966|NCT06564129|DEVICE|electroencephalography|Fifty-nine EEG electrodes conforming to international standard points were placed using a saline electrode EEG cap (Gelfree, Prysmian, China), and an accompanying portable multimodal EEG acquisition system (Neurohub, Prysmian, China) was used. EEG data were collected using collect software (Brycon, China).
223527967|NCT06642012|OTHER|Cash only|Households received 1 mobile cash transfer per month for 6 months.
223527968|NCT06642012|OTHER|Cash + Social Behavior Change Communication|Households received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.
223527969|NCT06642012|OTHER|Cash + top-up cash|Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
223527970|NCT00737789|DRUG|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
223527971|NCT00737789|DRUG|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
223527972|NCT05072379|DEVICE|colostomy self-care app|The study will use mixed methods as the study design in which content analysis will be used to identify the content suited for the App based on interviews with participants. A systematic research and development process will be utilized to design the text, videos, and images in the App's simulations to provide accurate, consistent, and complete knowledge of the skills needed for colostomy self-care and contending with any potential emergency.
223527973|NCT03060889|DRUG|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
223527974|NCT01707537|BIOLOGICAL|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
223527975|NCT06387381|DRUG|68Ga-PSFA|Each subject receives a single intravenous injection of 68Ga-PSFA.
223527976|NCT00982384|OTHER|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
223527977|NCT00982384|OTHER|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
223527978|NCT00182143|DRUG|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
223527979|NCT00182143|DRUG|Unfractionated Heparin|5000 IU BID
223527980|NCT03758807|OTHER|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
223527981|NCT03758807|OTHER|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
223527982|NCT02300233|DRUG|Volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
223527983|NCT02300233|DRUG|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
223527984|NCT00833690|DRUG|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
223527985|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
223527986|NCT00833690|DRUG|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
223527987|NCT01220661|DRUG|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
223527988|NCT06250829|OTHER|Observational|Observational study of body composition, cytokine profile, immune status, ctDNA, serial radiology.
223527989|NCT03567694|DRUG|HA115|Test Drug
223527990|NCT03567694|DRUG|Placebo|Placebo
223527991|NCT06275867|OTHER|Free high-quality care|Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.
223527992|NCT06275867|OTHER|Close distance|The network of contracted providers is located close to where participants live.
223527993|NCT06275867|OTHER|Far distance|The network of contracted providers is located far to where participants live.
223527994|NCT03896646|PROCEDURE|Computed Tomography|Undergo SPECT/CT HIDA scan
223527995|NCT03896646|OTHER|Hepatobiliary Iminodiacetic Acid Scan|Undergo SPECT/CT HIDA scan
223527996|NCT03896646|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT HIDA scan
223527997|NCT03896646|RADIATION|Yttrium Y 90 Glass Microspheres|Undergo radioembolization with yttrium Y 90 glass microspheres
223527998|NCT03896646|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere radioembolization
223527999|NCT02236910|OTHER|Lu-DOTA-TATE|
223528000|NCT04340570|BEHAVIORAL|Medication management via televisit to home|Pharmacist led home based televisit for medication management
223528001|NCT05763771|BEHAVIORAL|Smart Phone App|Collection of data
223528002|NCT05763771|OTHER|NIcotine Patches|Place on the skin
223528003|NCT06848413|OTHER|Arabic education video intervention based on the Positive Education about Aging and Contact Experiences (PEACE)|This video is designed based on the Positive Education about Aging and Contact Experiences (PEACE), which is suitable for professional medical that is Arabic speaker only.
223894784|NCT05360680|DRUG|CUE-102|CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
223894785|NCT06199869|OTHER|Evaluation of risk factors by direct interview with subjects who have atherosclerotic cardiovascular patients|Individuals identified with a diagnosis of ASCVD will fill a one page form of the associated risk factors they have
223894786|NCT05530070|OTHER|Dietary intervention|Patients will participate in a structured, group-based dietary counseling. Consultations will be organized online (Zoom meeting) lasting approximately 60 min/occasion. The intervention will include 6 sessions for 1 year (monthly for 5 months and finally at month 9). The aim of the counseling is to maintain a GFD and to develop a healthy lifestyle, in line with the Mediterranean diet.
223894787|NCT05530070|OTHER|Standard of care|Patients will receive standard of care and baseline dietary education.
223894788|NCT05530070|DIAGNOSTIC_TEST|Cardiovascular risk-related parameters|Anthropometric measurements (body height, body composition assessment-InBody 770), questionnaires (symptoms, quality of life, dietary adherence, diet quality, cardiovascular risk), assessment of sarcopenia (handgrip dynamometer), urine collection (dietary adherence - urine gluten immunogenic peptide detection), blood collection (immunological tests, hormone levels complemented with routine laboratory panel), transabdominal US examination to assess the extent of fatty liver disease.
223894789|NCT05628870|DRUG|HRS-1358|HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.
223894790|NCT06257576|DRUG|Tamsulosin|"Tamsulosin is a selective antagonist at alpha-1A and alpha-1B-adrenoreceptors in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockage of the alpha-1A receptors causes relaxation of smooth muscles in the bladder neck and prostate, thus decreasing urinary outflow resistance in men.~Tamsulosin will be administered twice a day for two (2) days as an oral tablet containing 0.4 mg of the drug. It is usually administered 30 minutes after a meal to minimize plasma level variations. The 0.4 mg dose of tamsulosin that will be used in this trial has shown adequate safety and tolerability in multiple previously published studies as well as efficacy in treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men.~A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1."
223894791|NCT06257576|OTHER|Control Group|A Foley catheter, which will be placed for the participant's surgical procedure regardless of enrollment in the study, will be removed at midnight on postoperative day 1.
223894792|NCT06069778|DRUG|BNT321 Dose Level 1|Intravenous infusion
223894793|NCT06069778|DRUG|BNT321 Dose Level 2|Intravenous infusion
223894794|NCT06069778|DRUG|mFOLFIRINOX|Intravenous infusion
223894795|NCT06069778|DRUG|BNT321 RP2D|Intravenous infusion
223894796|NCT05700474|BEHAVIORAL|Comprehensive outpatient behavioral health care|Participation will include clinical assessment and outpatient behavioral health services, case management, individual and group counseling, peer support, case management, and education regarding behavioral health and medical care
223894797|NCT06442592|OTHER|Blood sampling|An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.
223894798|NCT06442592|DIAGNOSTIC_TEST|Assessment of neurodevelopment (CA)|The children will be seen by a neuropsychologist, who will then determine whether or not they have neurodevelopmental disorders.
223894799|NCT06442592|DIAGNOSTIC_TEST|Assessment of neurodevelopment (Nantes)|The children will be seen by a multidisciplinary team (including a neuropsychologist), who will then determine whether or not they have neurodevelopmental disorders.
223894800|NCT06442592|OTHER|Assessment of the parental stress|Parents' parental stress will be assessed using the Parental Stress Index (PSI) questionnaire.
224083269|NCT04619394|OTHER|Aquatic exercise - own monitors program|"Supervision of own exercises by the Monitor with its own program. Two weekly sessions, both aquatic in small glass and large. The activity carried out will be aerobic; They will work with their own body weight and the lightweight floating material they offer in these pools. Exercises will be carried out that favor flexibility, elasticity, resistance and the strengthening of the muscular ligaments. The intensity of the exercises will be moderate and adapted in each month of gestation. We will eliminate positions and exercises that overload the pregnant woman, avoiding possible injuries and obstetric alterations.~The start of the program will be established in week 10-12 of the pregnancy and the end in week 37-41.~The total number of sessions of the program will be from 25 to 31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes and adherence to both experimental groups of ≥28 classes."
223894801|NCT06209801|BEHAVIORAL|Mirror therapy|60 seconds of intervention
223894802|NCT06209801|DEVICE|Neuromuscular electrical stimulation|60 seconds of intervention
223894803|NCT06209801|BEHAVIORAL|Motor imagery|60 seconds of intervention
223894804|NCT05386758|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
223894805|NCT05166343|DRUG|Epinephrine Injection|Epinephrine administered via sterile epinephrine injection USP, by 0.3mg or 0.5mg epinephrine auto-injector(s) and/or pre-filled syringe (exact dose).
223894806|NCT04423029|DRUG|DF6002|Specified dose on specified days
223894807|NCT04423029|DRUG|Nivolumab|Specified dose on specified days
223894808|NCT04626583|BIOLOGICAL|Allogeneic MSC|Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cells
223894809|NCT05602571|OTHER|ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught a home exercise program including stretching and eccentric strengthening exercises by an experienced physiotherapist. The eccentric exercises consisted of the following: three sets of 10 repetitions for wrist and elbow ﬂexion; two sets of 10 repetitions for wrist extension strengthening, starting with 50% of maximum strength and density and increasing the resistance each week; and ﬁnally, two sets of 10 repetitions for the wrist ﬂexor and extensor muscle groups comprising 20s of stretching and 10s of relaxing using the unaﬀected hand. Exercise program will be done twice a day for 3 months."
223528004|NCT05448950|DEVICE|VIG Continued Access Study|Small skin incisions will be made for tunneling the graft under the skin in a standard manner. The VIG device is provided pre-loaded within a customized catheter-based delivery system for over-the-wire delivery. The VIG is inserted through an introducer sheath placed in the target vein so that the 'vessel end' of the VIG is deployed within the vein, and the 'graft end' extends out of the vein for connection to the graft. Delivery and deployment will be performed under fluoroscopic guidance. The VIG will be deployed first, connected to the AVG, then the graft and VIG will be flushed and clamped. The arterial anastomosis will then be created using a standard suturing method.
224276334|NCT00645827|OTHER|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + \[3 x scheduled aspart dose\]). For BG \< 70 mg/dL, ½ ampule D50W IV x1 was given.
224276335|NCT04113616|DRUG|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
224276336|NCT04113616|DRUG|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
224276337|NCT04113616|DRUG|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
223528005|NCT04533750|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223528006|NCT04533750|OTHER|Fludeoxyglucose F-18|Given IV
223528007|NCT04533750|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223528008|NCT04533750|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223528009|NCT04533750|DRUG|Peposertib|Given PO
223528010|NCT04533750|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223528011|NCT05327257|DEVICE|iTBS rTMS|Repetitive transcranial magnetic stimulation (rTMS) intermittent Theta Burst Stimulation (iTBS)
223528012|NCT04752566|BIOLOGICAL|Eculizumab|Eculizumab will be administered via IV infusion once a week for 4 weeks.
223528013|NCT04752566|DRUG|Placebo|Placebo will be administered via IV infusion once a week for 4 weeks.
223528014|NCT00750399|DRUG|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
223528015|NCT00750399|DRUG|ranibizumab|intravitreal ranibizumab 0.5 mg
223528016|NCT01786122|OTHER|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
223528017|NCT01786122|BEHAVIORAL|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
223711565|NCT00936156|DRUG|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
223711566|NCT05545709|PROCEDURE|remote robot-assisted spine surgery|Based on the 5G network, the orthopedic robotic remote surgery platform is built at Beijing Jishuitan Hospital, providing primary hospitals with a platform for preoperative consultation, intraoperative communication and surgical robot teleoperation, and postoperative follow-up. With the support of the 5G network, equipment and surgical robots are integrated into the remote surgery service platform, building a high-speed transmission channel between Beijing Jishuitan Hospital and other hospitals.
223711567|NCT04284358|OTHER|Technology integrated instruction neuromuscular training warm-up workshop|Participants will learn of the exercises with a traditional instructor demonstration and verbal explanation. Participants will then attempt the exercise and assess their execution via a video on a peer learning tablet application. This occurs for every exercise and occurs in pairs in which participants can discuss and evaluate an exercise by an exercise's key execution components.
223711568|NCT00002734|BIOLOGICAL|recombinant interferon alfa|
223528018|NCT02588014|OTHER|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
223528019|NCT03465774|DRUG|Doxycycline|Receive via IPC
223528020|NCT03465774|DEVICE|Indwelling Catheter|Receive IPC
223528021|NCT03465774|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223528022|NCT03465774|OTHER|Questionnaire Administration|Ancillary studies
223528023|NCT03465774|OTHER|Survey Administration|Ancillary studies
223528024|NCT05743842|DEVICE|TriSalus™ TriNav™Infusion System|Given by Infusion
223711569|NCT00002734|DRUG|chemotherapy|
223711570|NCT00002734|DRUG|paclitaxel|
223711571|NCT00002734|DRUG|topotecan hydrochloride|
223711572|NCT00002734|RADIATION|lutetium Lu 177 monoclonal antibody CC49|
224276338|NCT01685216|BIOLOGICAL|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
223528025|NCT05743842|DIAGNOSTIC_TEST|Angiogram|X-ray photograph
223528026|NCT05743842|PROCEDURE|Y90-radioembolization procedure|procedure
223528027|NCT05867251|DRUG|AVZO-021|AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
223711573|NCT00002734|RADIATION|yttrium Y 90 monoclonal antibody CC49|
223711574|NCT00455078|PROCEDURE|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
223711575|NCT00455078|OTHER|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
223711576|NCT00455078|PROCEDURE|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
223711577|NCT00455078|PROCEDURE|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
223711578|NCT00455078|PROCEDURE|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
223711579|NCT04714957|OTHER|construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
223711580|NCT05219305|DEVICE|Dental Implant Placement|Placement in an edentulous site that was previously bone grafted in the prior study.
223711581|NCT05882942|DIETARY_SUPPLEMENT|Matcha green tea|This is the condition with the Matcha green tea
223711582|NCT05882942|DIETARY_SUPPLEMENT|Placebo|This is the condition with the placebo
223711583|NCT02282579|DRUG|Pazopanib|Non interventional study
223711584|NCT00312559|BEHAVIORAL|Yoga Training|
223711585|NCT03963037|OTHER|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
223711586|NCT00917566|DEVICE|Airtraq|intubation with airtraq
223711587|NCT00917566|DEVICE|Macintoch|use Macintoch laryngoscope for intubation
223711588|NCT06557564|GENETIC|TruGraf liver gene expression|Blood from the patients undergoing graft liver biopsy will be collected on the day of the liver biopsy, preferable prior to tissue collection or within 48 hours following the biopsy. Two specialized PaxGene tubes containing 2.5mL of blood each will be filled and will be sent to TGI laboratory in USA for processing, storage, and analysis using TGI's proprietary bioinformatics TruGraf will provide UHN with a Liver binary result: ACR or non-ACR. The results data will be batched and sent to UHN at agreed upon timepoints.
223711589|NCT02782728|BEHAVIORAL|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
223711590|NCT02782728|BEHAVIORAL|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
223711591|NCT04263077|OTHER|PLACEBO|The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
223711592|NCT04263077|OTHER|50% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
223711593|NCT04263077|OTHER|75% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
223711594|NCT04263077|OTHER|100% TENSION GROUP|Kinesiotape will be applied to the lateral epicondyle region with 100% tension.
223711595|NCT00266734|DEVICE|RPS Adeno Detector|
223711596|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
223711597|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
223711598|NCT02109783|DIETARY_SUPPLEMENT|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
223711599|NCT00787384|DRUG|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
223711600|NCT06127680|BEHAVIORAL|Brief Health Promotion Advice|Brief Health Promotion advice on exercise and nutrition (protein intake) delivered by a health care professional during routine consultations
223711601|NCT00926328|DRUG|Triclosan, fluoride|Six Month study, brush twice daily
223711602|NCT00926328|DRUG|Fluoride|twice daily usage
223711603|NCT00993200|GENETIC|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
223711604|NCT00993200|DRUG|Warfarin|Usual care warfarin dosing
223711605|NCT00289133|DEVICE|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
223711606|NCT00289133|DEVICE|total knee arthroplasty|cross-linked polyethylene tibial insert
223711607|NCT00726986|DRUG|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
223711608|NCT00726986|DRUG|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
223711609|NCT00726986|DRUG|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
223528028|NCT05867251|DRUG|Palbociclib|Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
223528029|NCT05867251|DRUG|Fulvestrant|Antineoplastic agent, estrogen receptor antagonist
223528030|NCT05867251|DRUG|Letrozole|Antineoplastic agent, aromatase inhibitor
223528031|NCT05867251|DRUG|Ribociclib|Antineoplastic CDK4/6 inhibitor
223528032|NCT05867251|DRUG|Abemaciclib|Antineoplastic CDK4/6 inhibitor
223528033|NCT05867251|DRUG|Carboplatin|Alkylating agent
223528034|NCT05867251|DRUG|Sacituzumab Govitecan-hziy|Trop-2 antibody and topoisomerase inhibitor
223528035|NCT06498050|DRUG|intravitreal injection of Brolucizumab 6 mg in study eye|After disinfecting the conjunctival sac and administering a topical anesthetic, an intravitreal injection of Brolucizumab at a dose of 6 mg is given.
223528036|NCT04474873|PROCEDURE|erector spinae block|we administer 15 cc of 0.5% bupivacaine between the erector spine muscle and the transverse process. The distribution of bupivacain was observed on ultrasound.
223528037|NCT05054101|OTHER|Real-time assessment using the VieCovid2020 smartphone application|a real-time assessment using the VieCovid2020 smartphone application during the first 3 months in add-on to usual psychiatric intervention
223528038|NCT03209258|OTHER|Care bundle of active management|"1. Intensive BP lowering to systolic target of \<140mmHg;~2. Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~3. Treatment of pyrexia to a target body temperature ≤37.5 ℃;~4. Reversal of anticoagulation to target INR \<1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
223528039|NCT03209258|OTHER|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
223528040|NCT01417767|DRUG|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
223528041|NCT01417767|DRUG|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
223528042|NCT06206590|OTHER|Whole-proteomic assay|Whole-proteomic analysis was performed on all the blood samples
223528043|NCT04115306|DRUG|PMD-026|Investigational Drug
223528044|NCT04115306|DRUG|fulvestrant|SERDs
223528045|NCT06186310|OTHER|Aquatic Therapy Group|After the initial evaluations, patients will be given aquatic exercises including personalized strengthening, balance and breathing exercises accompanied by a physiotherapist 3 days a week for total 5 weeks. At the same time, the exercises taught as a home program will be asked to be repeated every day for 5 weeks.
223528046|NCT06186310|OTHER|Conventional Physical Therapy Group|After the initial evaluations, patients in the control group will be taught passive, active, actively assisted or resistant upper and lower extremity exercises as a home program, appropriate to each patient's functional level and muscle strength. Subjects will be asked to perform the exercises every day for 5 weeks, not exceeding an average of 45 minutes, 5 to 10 repetitions of each exercise, depending on fatigue.
223528047|NCT02578251|DRUG|Paracetamol|
223528048|NCT02578251|DRUG|Pethidine|
223528049|NCT03773484|BEHAVIORAL|Opioid naive|Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days
223528050|NCT03773484|BEHAVIORAL|At-risk for long term use|Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days
223528051|NCT03773484|BEHAVIORAL|Long-term opioid recipient|Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days
223528052|NCT05229016|BEHAVIORAL|Reflection on health-related experiences|This is a questionnaire that was designed to make the patient reflect on positive or negative health-related experiences.
223528053|NCT05460286|OTHER|Chiropractic Manipulation|20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
223528054|NCT05460286|OTHER|Spinal Decompression Device Treatment|20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
223528055|NCT01889251|DRUG|Ocriplasmin|
223528056|NCT01889251|DRUG|Sham injection|
223528057|NCT01533623|DEVICE|Mandibular Advancement Device|Nightly wearing time
223528058|NCT01006148|BIOLOGICAL|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
223528059|NCT02740985|DRUG|AZD4635|AZD4635 will be administered orally as a nanosuspension or capsule on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, L, AA, and EA. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 75 mg or 50 mg capsules. Additionally, in Arm CA, AZD4635 will also be administered at 150 mg and 200 mg, or a lower dose of 125 mg or 100 mg may be given.
223528060|NCT02740985|DRUG|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
223528061|NCT02740985|DRUG|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
223528062|NCT02740985|DRUG|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
223528063|NCT02740985|DRUG|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
223528064|NCT02740985|DRUG|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
223528065|NCT01530516|DEVICE|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
223528066|NCT01530516|DEVICE|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
223528067|NCT06379100|DEVICE|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
223528068|NCT00085839|DRUG|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
223528069|NCT00085839|DRUG|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
223528070|NCT03682484|DRUG|MA-0211|oral
223528071|NCT03682484|DRUG|Placebo|oral
223528072|NCT03755427|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
223528073|NCT03755427|BIOLOGICAL|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
223528074|NCT03342222|DEVICE|Interference Screws|tibial fixation for ACL reconstruction
223528075|NCT04653376|PROCEDURE|Tonsillectomy surgery|The tonsillectomy procedure was performed under general anesthesia using the classical dissection method. Extracted tonsil tissue samples were sent to the medical genetics department in tubes to investigate the ER stress and apoptosis.
223528076|NCT00409656|DRUG|Basiliximab|
223528077|NCT01342315|DRUG|33525|Daily dosing
223528078|NCT01342315|DRUG|Placebo|Daily dosing
223711610|NCT00795860|BEHAVIORAL|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
223711611|NCT00795860|BEHAVIORAL|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
223711612|NCT02644642|OTHER|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
223711613|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
223711614|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
223711615|NCT00936559|BIOLOGICAL|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
223894810|NCT05602571|PROCEDURE|PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~10 ml of venous blood taken from the patients will be put into the T-LAB® PRP kit (T-Biotechnology Laboratory, İstanbul, Turkey) and will then be centrifuged. Approximately 3 cc of the PRP obtained will be applied to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
223894811|NCT05602571|PROCEDURE|Sham PRP+ESWT+Exercise|"Radial ESWT treatment will be applied to patients for 3 weeks, once a week for a total of 3 sessions. Radial shock waves will be applied in circular motions by applying gel on the epicondylar area where the most pain and sensitivity is. In each session, 8 Hz, 2.0 bar, 2000 beats will be applied.~Therapeutic Exercise:~All patients will be taught aforementioned home exercise program. Exercise program will be done twice a day for 3 months.~Procedure:~In Sham-PRP group,10 ml of venous blood will be taken and after the same waiting time 3 cc of 0.9% saline will be injected to the tendinosis area under USG guidance. All injections will be performed with long axis in-plane technique, using the ultrasound device (Esaote My Lab 70 XVision 6-18 Mhz linear probe)."
223894812|NCT06519513|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
223894813|NCT05615558|OTHER|Dietary Intervention|Controlled dietary intervention; all food is provided to participants after being allocated to animal or non-animal dietary protein, for a duration of 5 weeks.
223894814|NCT06127225|DRUG|Proliverenol|1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
223894815|NCT06127225|DRUG|Placebo caplets of Proliverenol|2 caplets of Proliverenol Placebo daily
223894816|NCT04259632|BEHAVIORAL|Time Restricted Eating (TRE)|daily eating window restricted to 8 hours
223894817|NCT04259632|BEHAVIORAL|Caloric Restriction (CR)|15% daily caloric deficient
223894818|NCT06581575|BIOLOGICAL|JCXH-105|IM injection
223894819|NCT06581575|BIOLOGICAL|Shingrix|IM injection
223894820|NCT05868213|DRUG|Cannabis (smoked flower)|Self-Directed Use (ad-libitum)
223894821|NCT06409169|OTHER|DBS TaT|Dried Blood Spot (DBS) testing for HCV DCHEQ and Baseline Surveys If at high risk for liver fibrosis, blood draw prior to treatment initiation If low risk for liver fibrosis, Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
223894822|NCT06409169|OTHER|Usual Care|Point-of-care or DBS testing for HCV Blood draw to test liver fibrosis DCHEQ and Baseline Surveys Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
223894823|NCT05482711|OTHER|Time Restricted Eating Intervention|All participants will be asked to adhere to suggested fasting and feeding periods throughout the 8 week study period. These participants will self-monitor eating and sleeping habits as well to present to study staff at checkpoints. Self-reported information will be used during group-mediated intervention sessions throughout the duration of the study, as well.
223711616|NCT06505304|PROCEDURE|Colonoscopy|"The colonoscopy will be performed at 3 or 6 months after surgery according to FC:~* In patients with FCP \>=150µg/g at around 3 months after surgery, a colonoscopy will be immediately performed~* In patients with FCP \<150µg/g at around 3 months after surgery, the colonoscopy will be organized at 6 months after surgery~Colonoscopy will be performed using high definition white-light endoscopy (HD-WLE) followed by virtual chromoendoscopy (VCE). The neoterminal ileum, ileocolic anastomosis and right colon will be assessed.~A follow-up colonoscopy will be performed within 18 months after index colonoscopy, as standard of care."
223894824|NCT06549803|DEVICE|skin bond|"In the skin bond group, fascia closure is performed for incision sites of 10 mm or more, and skin bond is sufficiently applied after subcuticular suture.~For incision sites less than 10 mm, subcuticular closure is performed without closing the fascia, and then skin bond is applied."
223894825|NCT06549803|DEVICE|skin stapler|"In the skin stapler group, fascia closure is performed on incision sites larger than 10 mm, and the skin is closed at 2-3 mm intervals using a stapler.~For incision sites less than 10 mm, skin closure is performed using a skin stapler without closing the fascia."
223894826|NCT06032416|RADIATION|Preoperative CT Scan|Preoperative CT Scan including a bone density calibration phantom. This data will be compared with surgeon intra-operative CRF responses.
223894827|NCT02487056|BEHAVIORAL|Demographic and clinical characteristics, clinical history, symptoms and signs, initial emergency department evaluation, and subsequent inpatient management of HF patients|Demographic and clinical characteristics, clinical history, symptoms and signs, initial emergency department evaluation, and subsequent inpatient management of patients were recorded.
223894828|NCT00885716|BEHAVIORAL|patient training in shared decision making|
223894829|NCT00885716|BEHAVIORAL|cognitive training|
223894830|NCT05363852|DIAGNOSTIC_TEST|Standard set of visual word and picture stimuli|Set ot 145 stimuli: 115 words (three sets of 35 words with positive, neutral, and negative content) and 30 pictures (two sets of 15 photos with positive and negative content).
223894831|NCT06300320|DRUG|TQ05105 tablets|Rovadicitinib (TQ05105) is a novel, oral dual JAK 1/2 and Rho-associated kinases (ROCK) 1/2 inhibitor targeting inflammatory and fibrotic components of cGVHD.
223894832|NCT04904601|DIETARY_SUPPLEMENT|Kale supplement|Kale (blanched freeze-dried Kale) group1
223894833|NCT04904601|DIETARY_SUPPLEMENT|Peas supplement|placebo (Blanched Freeze-dried Peas) group2
223528079|NCT05136027|OTHER|Combined training|Low-intensity interval training and resistance exercise
223528080|NCT06291779|DEVICE|Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio|"* Collect urine from the patient to measure urinary hypoxia, xanthine concentration.~* Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC).~* After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents.~* Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample."
223528081|NCT01172782|DRUG|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
223528082|NCT06107699|OTHER|Patient Navigation|Assigned a Patient Navigator to provide information on transitional care and community resources.
223528083|NCT05880355|DRUG|Dapansutrile|Oral inhibitor of NLRP3
223528084|NCT05880355|OTHER|Placebo|Non-active placebo
223528085|NCT06098573|BEHAVIORAL|High Alert|Participants assigned to the 'High Alert' condition will complete four interactive modules using their smartphones. These modules are hosted online via the Computerized Intervention Authoring Software, version 3.0 (https://www.cias.app \[CIAS\]). CIAS is a non- commercial, easily modifiable, web-based intervention platform used widely in the digital substance use literature. No identifiable information is requested or stored in CIAS. This program is only intended to deliver the content interactively. None of the questions asked in CIAS will be treated as research data. We will only report on the proportion of questions answered by participants (as a measure of adherence). Individual responses to questions will not be analyzed nor reported on. The purpose of the questions is for participants to engage with the content interactively
223528086|NCT06098573|BEHAVIORAL|Information condition|Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
223528087|NCT06098573|BEHAVIORAL|No contact|Participants in the passive control will receive no contact until the three and six-month follow-ups.
223528088|NCT06529237|DIAGNOSTIC_TEST|LDH-based malaria rapid diagnostic test|Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities
223528089|NCT06529237|DIAGNOSTIC_TEST|Malaria rapid diagnostic test|Routine malaria rapid diagnostic tests
223528090|NCT04312022|DIETARY_SUPPLEMENT|Berry extract|Berry extract supplement (hawthorn berry extract, tart cherry extract, bromelain)
223528091|NCT04312022|OTHER|Placebo|Placebo (flour capsule)
223528092|NCT01344226|DRUG|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
223528093|NCT02914938|DRUG|ME-401|60 mg
223528094|NCT02914938|DRUG|Rituximab|IV infusion 375 mg/m2
223528095|NCT02914938|DRUG|Zanubrutinib|80 and 160 mg bid
223528096|NCT04118764|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
223528097|NCT04118764|DRUG|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
223528098|NCT04118764|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
223528099|NCT04118764|OTHER|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
223528100|NCT04118764|OTHER|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
223528101|NCT04716725|DRUG|68Ga-PSMA-11|Given IV
223528102|NCT04716725|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET
223528103|NCT02302222|DEVICE|Customizable Dressing with ActiV.A.C. Therapy Unit|
223528104|NCT02302222|DEVICE|Standard of Care Dressing|
223528105|NCT05974800|BEHAVIORAL|Emergency department caregivers interview|The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an emergency department visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
223528106|NCT01950520|DRUG|Propranolol|Propanolol 160mg, oral, by mouth (Cohort 1 only)
223528107|NCT01950520|DRUG|Pindolol|Pindolol 20mg, oral, by mouth (Cohort 1 only)
223528108|NCT01950520|DRUG|Dantrolene|Dantrolene 100mg, oral, by mouth (Cohort 1 only)
223528109|NCT01950520|DRUG|Magnesium Sulfate|Magnesium Sulfate, infusion, 50 mg/kg bolus followed by maintenance infusion at 2g/h (Cohort 1 only)
223528110|NCT01950520|DRUG|Caffeine|Caffeine 200mg, oral, by mouth (Cohort 2 only)
223528111|NCT01950520|DRUG|Qsymia|Qsymia (topiramate 92mg CR, phentermine 15mg PO), oral, by mouth (Cohort 2 only)
223528112|NCT01950520|DRUG|Topiramate|Topiramate 200mg, oral, by mouth (Cohort 2 only)
223528113|NCT01950520|BEHAVIORAL|Phentermine|Phentermine 37.5mg, oral, by mouth (Cohort 2 only)
223528114|NCT01950520|DRUG|Naltrexone|Naltrexone 100mg, oral, by mouth (Cohort 2 only)
223528115|NCT01950520|DRUG|Mirabegron 50mg|Mirabegron 50mg, oral, by mouth (Cohort 3 only)
223528116|NCT01950520|DRUG|Mirabegron 200mg|Mirabegron 200mg, oral, by mouth (Cohort 3 only)
223528117|NCT01950520|DRUG|Placebo Cohort 1|Placebo, oral, by mouth (Cohort 1 only)
223528118|NCT01950520|DRUG|Placebo Cohort 2|Placebo, oral, by mouth (Cohort 2 only)
223528119|NCT01950520|DRUG|Placebo for Mirabegron|Placebo for Mirabegron, oral, by mouth (Cohort 3 only)
223894834|NCT03444064|BIOLOGICAL|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
223894835|NCT05455281|DEVICE|CHLOE|CHLOE is designed to automatically analyze events related to embryo development from Time Lapse Incubator (TLI) images and provide prediction on the likelihood of embryos developing to the blastocyst. This information can assist embryologists and IVF professionals in the selection of the most viable embryo for transfer or freezing, when there are multiple embryos deemed suitable.
223894836|NCT06488313|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).
223894837|NCT06522516|BEHAVIORAL|Evidence-based caregiving training|This is designed based on evidence of daily living activity ability caregiving, including① Dietary training: guiding caregivers to choose appropriate tableware according to the functional status of disabled elderly people, and training them in eating posture such as changing positions and using tableware; ② Dressing training: guide caregivers to train disabled elderly people on how to put on and take off clothes, shoes, socks, etc.; ③ Personal hygiene training: including washing face, hands, brushing teeth, etc.; ④ Excretion function training: including urination function training and defecation function training; ⑤ Mobile training: including support walking training, cane walking training, etc.; ⑥ Wheelchair training: Guide caregivers to use wheelchairs according to the specific situation of disabled elderly people.
223894838|NCT06522516|BEHAVIORAL|family resilience intervention|The intervention will be developed based on the Maccubbin Family Resilience Theory, and Delphi methods. The content will contain 8 topics and be incorporated into caregiving training manual.
223894839|NCT06522516|BEHAVIORAL|usual service|This means the usual service provided by the local community health center from nurses during bi-weekly home visit.
223894840|NCT06270173|DEVICE|Tripod-Fix Vertebral Body Augmentation System (Tripod-Fix)|The Tripod-Fix is a permanent implant used for vertebral augmentation in patients with osteoporotic vertebral compression fractures.
223894841|NCT05621811|DRUG|Naronapride|Naronapride is a 5HT-4 agonist
223894842|NCT05621811|DRUG|Placebo|Placebo
223894843|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
223894844|NCT04069624|BEHAVIORAL|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
223894845|NCT04069624|OTHER|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
223894846|NCT03729999|DEVICE|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
223894847|NCT06071871|DRUG|Glofitamab|"Glofitamab is given intravenously at a dose of 2.5mg over 4 hours on Cycle 1 Day 8. Patients need to stay in hospital for 24 hours.~Glofitamab is given intravenously at a dose of 10mg over 2 hours on Cycle 1 Day 15. (Patients may need to stay in hospital for 24 hours.) Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1 of Cycles 2-12 (as relevant)."
223894848|NCT06071871|DRUG|Polatuzumab vedotin|Polatuzumab is given intravenously at a dose of 1.8mg/kg on Cycle 1 Day 2, and then Day 1 of Cycle 2-Cycle 6.
223894849|NCT06071871|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
223894850|NCT03903120|BEHAVIORAL|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
223894851|NCT05231993|PROCEDURE|Conization|A cone biopsy to remove abnormal tissue.
223894852|NCT05231993|PROCEDURE|Colposcopy|"1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal"
223894853|NCT03933735|DRUG|TNB-383B|Intravenous (IV) Injection
223894854|NCT03002207|DEVICE|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
223894855|NCT03002207|PROCEDURE|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
223894856|NCT05087693|DRUG|Salbutamol|Inhaling 200ug of salbutamol
223894857|NCT05087693|DRUG|Placebo medication|Inhaling placebo medication
223894858|NCT05087693|OTHER|Ozone|Breathing 170ppb ozone
223894859|NCT05087693|OTHER|Filtered Air|Breathing filtered air
223894860|NCT05087693|OTHER|Exercise|Cycling at 60% of VO2max on a cycle ergometer
223894861|NCT04799704|DIAGNOSTIC_TEST|swabbing of conjunctiva|Each eye will be sampled with a single, sterile, nylon, flocked swab
223894862|NCT06476275|BIOLOGICAL|Influenza A/Texas/71/2017 (H3N2)|Virus will be administered intranasally
223894863|NCT06476275|BIOLOGICAL|Sham placebo|Placebo will be administered intranasally
223894864|NCT06771570|BIOLOGICAL|Silver Nanoparticles Irrigation|to evaluate the postoperative pain, antimicrobial efficiency, and periapical tissue healing following the use of silver nano particles solution as a final irrigation, using either conventional needle irrigation or XP-Endo Finisher activation, in necrotic mandibular molar teeth.
223894865|NCT01504815|DRUG|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
223894866|NCT01504815|RADIATION|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
223894867|NCT01504815|RADIATION|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
223894868|NCT05434078|DEVICE|Orthofeet Shoes|Participants will wear a pair of Orthofeet shoes to wear for 6 weeks
223894869|NCT05846594|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx Assay|Participants will undergo liquid biopsy (FoundationOne® Liquid CDx) on blood samples collected once they have a clinical diagnosis of advanced cancer (as per label). Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. Results of the FoundationOne® Liquid CDx assay will be provided to the investigator to be used in accordance with professional guidelines in oncology for patients with malignant neoplasms.
223711617|NCT06505304|PROCEDURE|Intestinal biopsies|During index colonoscopy, at least 2 biopsies from each of the segments will be taken as standard of practice to assess inflammation in post-operative CD. Only in Irish sites, twelve biopsies - four in the area of ileocolonic anastomosis, four in the neo-terminal ileum and four in the colon just distal to the anastomosis- will be taken for research purposes, in addition to standard-of-care biopsies.
223711618|NCT06505304|PROCEDURE|Confocal laser endomicroscopy|pCLE with fluorescein injection will be performed during index colonoscopy, in centres where is available, to assess early alteration of the barrier function.
223711619|NCT06505304|PROCEDURE|Intestinal ultrasound|All patients will undergo a cross-sectional imaging test as part of their standard of care at 3 and 6 months after surgery. A follow-up IUS will be performed within 18 months after index colonoscopy, as standard of care.
223711620|NCT06505304|DIAGNOSTIC_TEST|Stool|Stool samples will be collected at 3 and 6 months after surgery and used for faecal calprotectin analysis. Research stool will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for metagenomics (only in Irish sites).
223711621|NCT06505304|DIAGNOSTIC_TEST|Blood|Blood will be collected at 3 and 6 months after surgery and used as standard of care. Research blood will be collected during the visit of index colonoscopy and at 12 months after index colonoscopy for research - i.e. proteomic, genomic, cell experiments (only in Irish sites).
223711622|NCT06505304|DIAGNOSTIC_TEST|Saliva|Saliva will be collected during the visit of index colonoscopy and at 12 months after surgery for research - i.e. optical spectroscopy (only in Irish site)
223711623|NCT06505304|OTHER|Clinical follow-up|Patients will be followed-up at 6, 12 and 24 months after index endoscopy. Patients will be evaluated in clinic or by telephone call and the disease will be reassessed. The following scores will be repeated: Harvey Bradshaw Index (HBI) and CD Activity Index score (CDAI). Participants will give an update on their medication use.
223711624|NCT00768157|DRUG|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
223711625|NCT00768157|PROCEDURE|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
223711626|NCT02119364|OTHER|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
223711627|NCT01227434|DRUG|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
223711628|NCT01227434|DRUG|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
223711629|NCT01227434|PROCEDURE|Resection as clinical care|Indicated, intended, surgical resection as clinical care
223711630|NCT05051371|DEVICE|Train of four monitoring|Train of four monitoring in postoperative care unit
223711631|NCT02803255|DEVICE|MAHI Exo-II|
223711632|NCT01783262|DEVICE|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
223711633|NCT01783262|DEVICE|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
223711634|NCT04029831|DRUG|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
223711635|NCT03454711|DEVICE|fMRI|Brain MRI
223711636|NCT03454711|DEVICE|Indirect calorimetry|Resting energy expenditure
223711637|NCT03454711|DEVICE|Bioimpedance|Measurement of body composition
223711638|NCT03454711|BIOLOGICAL|Lipid profile, glucose, HBA1c, metabolomic analysis|Blood sample
223528120|NCT04908046|DRUG|HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .|"Patient starts the initial dose treatment with 5mg QD of HMPL-295S1, during dose escalation, single-dose PK evaluation will be carried out firstly in each dose group.~At the first therapeutic dose level, the single-dose treatment period is 5 days; from the 2nd dose level, the sponsor can determine the adjustment of single-dose treatment period to 3-5 days based on the available PK profile.~Subsequently, the patients will receive oral HMPL-295S1 QD continuously in a therapeutic cycle of 28 days (Day 1 - 28 of each cycle), until reaching the criteria on the end of treatment. The patients in RP2D extended cohort will enter the consecutive treatment period directly."
223528121|NCT04212442|BEHAVIORAL|Independent Living Program for Affordable Housing.|"Two-month program intended to increase physical activity and function, including the following 4 steps:~1. Environmental and Policy Assessments: Nurse facilitator works with the affordable housing staff to identify and recommend feasible interventions to alter the environment, policy, and procedures to optimize resident function and physical activity.~2. Education: Nurse educates residents and study partners in the principles of the Independent Living Program, using established materials and adult learning techniques.~3. Establishing Resident Goals: The nurse completes Capability Assessment Forms and helps resident set goals to increase function and physical activity.~4. The nurse helps to motivate and mentor residents and study partners to achieve and maintain their goals, using evidence-based approaches."
223528122|NCT03858777|DIAGNOSTIC_TEST|cell free DNA|All groups will have blood draws and cfDNA measured
223711639|NCT03454711|BEHAVIORAL|YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)|Questionnaires to characterize eating habits and depression
223711640|NCT03546660|DEVICE|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
223711641|NCT04365296|OTHER|Experimental|The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
223711642|NCT01513343|BEHAVIORAL|Parent and child groups focused on self-regulation of eating|
223711643|NCT05475132|OTHER|Exergaming|exercise games will be done for a total of 8 weeks ,100min of exergaming/week (5 days × 20 min).
223528123|NCT04623593|PROCEDURE|ACDF|Standard operative treatment for anterior cervical discectomy. Through a right or left-sided approach the disc space contents are resected. The endplates are prepared with curettes and the disc space contents are removed. The posterior longitudinal ligament is opened. The dura is visualized to ensure adequate decompression. A cage is implanted in the disc space. The disc removal and cage implantation can be performed at a single level or at multiple levels. The wound is closed in layers, after a prevertebral wound drain is placed.
223711644|NCT05475132|OTHER|Conventional Dexterity Exercises|Exercises traditionally used for dexterity will be done for 8 weeks, 100min of exercises/week (5days × 20 min)
223711645|NCT02034669|DEVICE|Laminectomy|surgical laminectomy with glial scar resection
223711646|NCT02034669|DEVICE|Intradural space|ADSCs injection into Intradural space at damage site
223711647|NCT02034669|DEVICE|Intrathecal|ADSCs Intrathecal into lumbar puncture
223711648|NCT02034669|DEVICE|Intravenous|ADSCs intravenous
223711649|NCT02632981|OTHER|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
223711650|NCT02632981|OTHER|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
223711651|NCT03438669|OTHER|no intervention|no intervention
223711652|NCT00920283|DEVICE|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
223711653|NCT00920283|DEVICE|Driver Cobalt Alloy Coronary Stent|
223711654|NCT04736407|OTHER|Observational sampling of CSF timed around routine clinical repositioning, or not|no true intervention
223711655|NCT00522197|DIETARY_SUPPLEMENT|multi-herbal agent ACAPHA|
223711656|NCT00522197|DIETARY_SUPPLEMENT|Sugar Pill|
223711657|NCT01631981|DRUG|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
223711658|NCT01631981|DRUG|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
223711659|NCT00036452|DRUG|lopinavir/ritonavir|
223711660|NCT00036452|DRUG|emtricitabine|
223711661|NCT00036452|DRUG|stavudine|
223711662|NCT00036452|DRUG|tenofovir DF|
223711663|NCT04645875|OTHER|Sit regimen|See Sit regimen arm description
223711664|NCT04645875|OTHER|SitLess regimen|See SitLess regimen arm description
223711665|NCT05092724|PROCEDURE|fetal blood transfusion|transfusion of fetal blood
223711666|NCT03393637|BEHAVIORAL|Mentors Offering Maternal Support (M-O-M-S)|10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
223711667|NCT01560364|OTHER|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
223711668|NCT03399721|DEVICE|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
223711669|NCT03399721|DEVICE|Chordate S101 Placebo|Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
223711670|NCT05453604|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
223711671|NCT06504095|OTHER|intervention group (Flipped Teaching Method Group)|"Patient safety training will be provided to students using the flipped classroom teaching method, consisting of both out-of-class and in-class activities.~Out-of-Class Activity: For the Flipped Teaching method, a Learning Management System-Web-Based Distance Education System will be established. Lecture videos for each lesson will be uploaded to the system 7 days before the class day. Students will have the flexibility to watch the instructional videos as many times as they wish until the class day.~In-Class Activity: The researcher will come prepared for in-class activities such as question-answer sessions, discussions, brainstorming. No lecturing will be done by the researcher. The researcher will solely guide the students."
223711672|NCT00064337|BIOLOGICAL|filgrastim|
223528124|NCT04623593|PROCEDURE|ACDA|The start of the procedure is the same as in the ACDF group. After the discectomy, a cervical disc prosthesis is placed in the disc space instead of a cage, in accordance with the manufacturer's protocol for implantation and endplate preparation. The disc removal and arthrodesis implantation can be performed at a single level or at multiple levels. Wound closure is similar to the ACDF procedure.
223528125|NCT03592017|DEVICE|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
223528126|NCT06645171|DIETARY_SUPPLEMENT|Fibre drink|One drink will be tested
223528127|NCT04429919|DRUG|AP-325|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
223711673|NCT00064337|DRUG|cyclophosphamide|
223711674|NCT00064337|DRUG|dexamethasone|
223711675|NCT00064337|DRUG|melphalan|
223711676|NCT00064337|DRUG|thalidomide|
223711677|NCT00064337|PROCEDURE|peripheral blood stem cell transplantation|
223711678|NCT01784978|DRUG|Sunitinib|50 mg pd
223711679|NCT01784978|DRUG|Everolimus|10 mg pd
223894870|NCT05846594|DIAGNOSTIC_TEST|Standard of Care Diagnostic Pathway|Participants will undergo the local standard of care diagnostic pathway including tissue biopsy/standard of care (if tissue not available), pathology workup, and molecular workup, according to ESMO guidelines or national guidelines for each tumor type included in this study.
223894871|NCT06161818|DRUG|FLOT-CROSS or CROSS-FLOT|Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT
223894872|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit|Parents will complete the Family Nutrition and Physical Activity risk assessment (Patient Reported Outcome) prior to scheduled well child visit. Parent reported data is integrated into the child's electronic health record to inform the child's primary care provider and the provision of preventive counseling. The primary care provider documents preventive care provided.
223894873|NCT04406441|BEHAVIORAL|Patient Reported Outcome Well Child Visit + Food Care|Adapted Parent Training Program will be delivered via telehealth (video or telephone) to parents by trained Wellness Coaches as 6 individual sessions, distributed throughout a 26-week intervention period. Cooking Matters grocery store tours will be delivered (in-person or virtual) to parents by trained grocery store nutritionists during the 26-week intervention period.
223894874|NCT04719273|DRUG|Extended-release Onapristone|Given PO
223894875|NCT04719273|DRUG|Anastrozole|Given PO
223894876|NCT04719273|OTHER|Quality-of-Life Assessment|Ancillary studies
223894877|NCT04719273|OTHER|Questionnaire Administration|Ancillary studies
223894878|NCT04719273|DIAGNOSTIC_TEST|Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive)|Immunohistochemistry (IHC):Integral : Tissue
223894879|NCT04719273|DIAGNOSTIC_TEST|Progesterone Receptor Positive ( PGR Positive; PR Positive)|Immunohistochemistry (IHC)
223894880|NCT03960476|BEHAVIORAL|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
223894881|NCT03748524|DRUG|Influenza Vaccine|Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
223894882|NCT04060888|DRUG|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
223894883|NCT04060888|DRUG|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
223894884|NCT04060888|DRUG|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
223894885|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
223894886|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (sham device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.
223894887|NCT04978571|DEVICE|percutaneous electrical nerve-field stimulation, PENFS (COVID active device)|A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear
223894888|NCT01814501|BIOLOGICAL|panitumumab|Each vial of panitumumab will contain 20 mL of a sterile protein solution containing a 20-mg/mL solution of panitumumab. The vial will contain approximately 400mg of panitumumab and is for single dose use only.
223894889|NCT01814501|DRUG|irinotecan hydrochloride|Diluted with 5% dextrose (D5W) to a total volume of 500 mL and infused intravenously over 90 minutes. Nothing else should be added to the bag. Patients will be given a dose of 180 mg/M2 by intravenous infusion.
223894890|NCT01814501|DRUG|fluorouracil|Administered intravenously. A bolus of 400 mg/m2 to be followed by a continuous infusion over 46 hrs at a dose of 2400mg/m2.
223894891|NCT01814501|DRUG|leucovorin calcium|Leucovorin will be administered at a dose of 200 mg/m2 over 120 minutes prior to the 5-FU bolus. Leucovorin may be run simultaneously with irinotecan infusion via y-site connection.
223894892|NCT03075254|DEVICE|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
223894893|NCT03075254|DEVICE|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
223894894|NCT03075254|DEVICE|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
223894895|NCT05404958|OTHER|Systems Analysis and Improvement Approach (SAIA)|"What is SAIA? It is a 5-step cycle that is repeated every 4-6 weeks for continuous quality improvement, implemented by Kenyan public health workforce and FP clinic staff, and monitored by Mombasa DOH.~Step 1: Understanding the cascade from FP clinic enrollment to HIV testing to linkage to treatment and prevention services.~Step 2: Use process mapping to identify modifiable bottlenecks. Step 3: Define and implement workflow adaptations to eliminate modifiable bottlenecks.~Step 4: Monitor change in performance. Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
223894896|NCT05936281|DRUG|Genakumab for injection|150 mg/1ml/ vial
223894897|NCT05936281|DRUG|Colchicine|0.5 mg/table
223894898|NCT05851378|DRUG|Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)|Given intravenously at time of imaging
223894899|NCT05851378|PROCEDURE|Magnetic Resonance Image (MRI)|Magnetic resonance imaging is a medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
223894900|NCT05400785|OTHER|Circadian Rhythms for Mood (CRM) application - Active|The study subjects participating in this clinical trial wear wearable activity tracker 24 hours a day for a continuous period of time and run the CRM app once a day to check their conditions (feelings, vitality, sleep, etc.) in the Daily Symptom Assessment (eMoodChart). The active intervention group are provided with mood prediction results and instructions as feedback through the 'life report' and push notification in the application.
223528128|NCT04429919|DRUG|Placebo|During the 10-day double-blind treatment period (Days 1 to 10), subjects will take 4 capsules of the IMP orally once daily in the morning before breakfast.
223894901|NCT05400785|OTHER|Circadian Rhythms for Mood (CRM) application - Sham|The study subjects assigned to the sham intervention group are provided with feedbacks operated by dummy algorithm. The application is visually indistinguishable from active CRM, and it is designed to minimize behavioral change.
223894902|NCT04605809|DEVICE|combined motor and cognitive training|The combined motor and cognitive training group will receive physical fitness training under sitting and standing, walking training while sequentially or simultaneously perform cognitive training for 45 minutes per session, 3 times a week for 4 weeks.
223894903|NCT04605809|DEVICE|motor training alone|The motor training alone group will receive the same set of physical fitness training while sitting, standing, and walking as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
223894904|NCT04605809|DEVICE|cognitive training alone|The cognitive training alone group will receive the same set of cognitive training while sitting as the combined motor and cognitive training group for 45 minutes per session, 3 times a week for 4 weeks.
223894905|NCT06274307|PROCEDURE|Transversus abdominis plane block|A transversus abdominis plane block (TAP) block using a long-acting local anesthetic is used to manage pain during the intermediate (12-24hr) post-operative period following laparoscopic abdominal surgeries. Drug: The local anesthetic to be used in this specific intervention will be 30 to 40ml of Ropivacaine 0.375%, not to exceed a max dose of 3mg/kg of 0.375% and divided equally bilaterally.
223894906|NCT04641897|PROCEDURE|Respiratory rate modification|"During the Low RR and High RR periods, respiratory rate will be set depending on baseline ABG and according a nomogram so as to have an approximate difference of 10 points between groups, while maintining PaCO2 and pH values within safety limits (pH 7.20 to 7.45, and PaCO2 35 to 60 mmHg).~Once defined the target respiratory rate, this will be decreased or increased in 4 points each 30 to 45 min, and ABG repeated at 2 hours. At this time, changes will be made to keep PaCO2 and pH values within safety limits, and ABG repeated at 6 and finally 12 hours.~During the whole period, inspiratory to expiratory ratio will be maintained constant, and only changed to keep inspiratory time above 0.6 seconds (usually at high resp rate)."
223894907|NCT06180135|OTHER|TURKISH COFFEE DRINK|TURKISH COFFEE DRINK
223894908|NCT06180135|OTHER|FENNEL TEA DRINK|FENNEL TEA DRINK
223894909|NCT03682991|OTHER|Aggressive Risk Factor Control|"1. Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2. Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (\>5 drinks at one setting).~3. Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4. Blood Pressure management to achieve a target systolic blood pressure (SBP) of \<120/80 mm/Hg~5. Smoking cessation facilitated through local resources already established at each site"
223894910|NCT03682991|OTHER|Standard of Care|Recommendations based on current guidelines
223894911|NCT03829410|DRUG|Onvansertib|Onvansertib orally.
223894912|NCT03829410|BIOLOGICAL|Bevacizumab|Bevacizumab intravenously.
223894913|NCT03829410|DRUG|FOLFIRI|FOLFIRI intravenously.
223894914|NCT04537312|PROCEDURE|Robot-assisted Nipple Sparing Mastectomy|Under RNSM
223894915|NCT04537312|OTHER|Survey Administration|ancillary correlative
223894916|NCT04537312|DEVICE|RNSM|Robot-assisted Nipple Sparing Mastectomy
223894917|NCT04660929|BIOLOGICAL|CT-0508|anti-HER2 CAR macrophages
223894918|NCT04660929|BIOLOGICAL|Pembrolizumab|anti-PD antibody
223894919|NCT03668977|DIETARY_SUPPLEMENT|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
223894920|NCT04290221|OTHER|Ultrasound-guided percutaneous electrolysis in the lumbar nerve root|This group will be treated with intratissue percutaneous electrolysis using a needle G32 with galvanic current as a cathodic flow electrode in the posterior nerve root of L3 (one times per week / 6 weeks). The intervention will be guided by ultrasound equipment medically certified (Directive 93/42 / EEC) device (EPI Advanced Medicine, Barcelona, Spain).
223894921|NCT04290221|OTHER|Electrical Dry Needling in trigger points|It consists in apply the ultrasound-guided percutaneous electrolysis on active and/or latent TPs in the gluteus medius, quadratus lumborum, and erector spinae muscles of the subjects L3 (one times per week / 6 weeks).
223894927|NCT06324968|DIAGNOSTIC_TEST|Positive serology for anti-SSA|Blood sample which detect serology for anti-SSA.
223939951|NCT07190443|DRUG|Endocrine therapy + Abemaciclib|"This intervention consists of adjuvant endocrine therapy in combination with abemaciclib, a CDK4/6 inhibitor, administered to patients with HR-positive, HER2-negative breast cancer who have undergone curative-intent local treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence.~Abemaciclib is given orally at a dose of 150 mg twice daily for a maximum of 2 years, in accordance with the approved dosing regimen in the adjuvant setting. The choice of endocrine therapy-aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression-is determined based on menopausal status and prior treatment history."
224276339|NCT06270095|DIAGNOSTIC_TEST|Neurocognitive, neuromuscular and neurosensitive tests.|"At T0, the subject realizes a neurocognive test and an self-assessment of health symptoms autonomously on its professional digital tablet. They also realizes two self questionnaires on their state of fatigue (Samn-Perelli Fatigue Scale) and anxiety (Hospital Anxiety and Depression scale).~At T0 + 3 months, the subject follows a standardized medical examination carried out by a physician, assessing neuromuscular score using the Medical Research Council questionnaire and assessing neurosensitivity score using the Incat Sensory Sum Score. If necessary, the DN4 questionnaire for neuropathic pain is used. The same neurocognitive tests than T0, and Samn-Perelli Fatigue Scale and Hospital Anxiety and Depression scale are also repeated."
223711680|NCT04700709|DRUG|Sirolimus Tab.|Orally, once-daily in the morning - The first dose is administered within maximum 6mg/day according to the investigator's judgement, check the blood concentration of Sirolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/ml.
223711681|NCT04700709|DRUG|Mycophenolate Mofetil Cap./Tab.|Up to 1g BID(total 2g daily), PO
223711682|NCT05060302|OTHER|transthoracic echocardiography (TTE)|the included patients have a TTE preoperatively in order to evaluate the RV systolic function. TTE will also be done at day 2 and day-15 during the follow-up surgical consultation.
223711683|NCT04112056|DIETARY_SUPPLEMENT|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
223711684|NCT00385983|DEVICE|Harmonic Scalpel|
223711685|NCT05529303|BEHAVIORAL|Such as art therapy, play therapy, breathing techniques|The Cognitive Behavioral Therapy (CBT) model suggests that the individual's dysfunctional thoughts about self, the world, and/or others are based on irrational or illogical assumptions. An individual's self and his/her view of the world are central to the determination of his/her feelings and behaviors and thus can be changed through changing the individual's thoughts, feelings, and behaviors. CBT techniques are in line with the use of expressive art techniques. The common goal in both CBT and expressive arts is to achieve behavior change in the individual. An intervention program has been prepared by the researcher in line with this literature information.
223711686|NCT05733780|DRUG|Prolectin-M|"Prolectin-M~Precise chemistry based molecule that binds to galectin like receptors on the N terminal of S1 subunit of the Sars-CoV2 virus"
223711687|NCT06959030|OTHER|No Intervention: Observational Cohort|Observation study
223711688|NCT06512870|DIAGNOSTIC_TEST|Near infrared spectroscopy (NIRS)|A technique that relies on differential absorption of infrared light to provide relative estimation of tissue oxygenation, has been successfully used to monitor perfusion of various tissues, including muscle tissue of the lower extremity.
223711689|NCT05268250|BEHAVIORAL|R2D2 mHealth intervention|R2D2 mHealth treatment will use cognitive behavioral therapy, mindfulness, and behavioral activation strategies
223711690|NCT04765488|PROCEDURE|WashIn /WashOut|"According Wash In / WashOut procedure in study group we stop the supply of sevoflurane to the first signs of awakening and record the level of sevoflurane , then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and stop the supply of sevoflurane to the first signs of awakening again, then we resume the supply of sevoflurane to the end-tidal concentration of 1 MAC maintain the anesthesia for 5 min and finally ( the third time) stop supplying sevoflurane and extubate patient after recovery of muscle tone, spontaneous breathing and consciousness."
223711691|NCT01342302|BEHAVIORAL|Psychosocial Intervention for Couples|Intervention delivered on line
223711692|NCT04178564|BEHAVIORAL|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
223711693|NCT04525378|OTHER|Mesenchymal stromal cell-based therapy|Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
223711694|NCT00639431|BEHAVIORAL|direct observation|direct observation of another person's foot moving
223711695|NCT00639431|BEHAVIORAL|mental visualization|mentally imagining moving one's phantom foot/feet
223711696|NCT00000308|DRUG|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
223711697|NCT00000308|DRUG|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
223711698|NCT00000308|DRUG|placebo|placebo
223711699|NCT05937646|DEVICE|AWARE|AWARE is a platform with a visualization dashboard that sits on top of pre-existing, comprehensive EHR systems. AWARE provides clinical decision support tools for the ICU, Emergency Departments and other critical care areas right at the patient's bedside.
223711700|NCT05937646|DEVICE|Electronic Health Record (EHR)|An Electronic Health Record (EHR) is an electronic version of a patients medical history, that is maintained by the provider over time, and may include all of the key administrative clinical data relevant to that persons care under a particular provider, including demographics, progress notes, problems, medications, vital signs, past medical history, immunizations, laboratory data and radiology reports.
223711701|NCT05048290|OTHER|Communication Skills Training|Participate in communication workshops
223711702|NCT05048290|OTHER|Communication Skills Training|Participate in generic communication skills workshops
223711703|NCT05048290|OTHER|Educational Intervention|Develop a video
223711704|NCT05048290|OTHER|Survey Administration|Complete surveys
223711705|NCT06536751|RADIATION|Photobiomodulation|LED photobiomodulation therapy, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). PBM will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght.
224276340|NCT06110286|OTHER|Photorefractive keratectomy|Laser keratectomy by EX500 excimer laser after removal of corneal epithelium either mannually or by laser ablation
224276341|NCT01583634|DEVICE|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
224276342|NCT01583634|DEVICE|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
223528129|NCT03781570|BEHAVIORAL|Placebo Cream|"In the Placebo intervention, participants are given an inert cream with instructions that it is Prodicaine, an effective pain-relieving drug. The cream is applied to two fingers on the left hand."
223528130|NCT03781570|BEHAVIORAL|Control Cream|"In the Control intervention, participants are given an inert cream with instructions that it is a control cream with no effects . The cream is applied to two fingers on the left hand."
223528131|NCT01107496|DRUG|IR Viloxazine|"One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1.~Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6."
223528132|NCT01107496|DRUG|Placebo|Placebo capsules administered orally 3 times a day
223528133|NCT06063551|PROCEDURE|Testicular Biopsy|Testicular biopsy for clinical storage and laboratory research.
223711706|NCT06536751|OTHER|Institution's Standard Physiotherapy|Physiotherapy treatment on the University, occur 2 therapeutic days per week, for 08 consecutive weeks (one of them in the same day of the PBM session). It consists of the use of motor physiotherapy, posture guidelines, stretching, positioning, joint range gain, ergonomics, sensory stimulation and proprioception, motor strengthening, tonus adjustment, functional training of upper and lower limbs, guidelines for the use of orthoses, stands, parapodium, parallel bars or wheelchair when needed. These are 45-minute sessions conducted by a physiotherapist.
223711707|NCT06536751|RADIATION|Photobiomodulation Placebo|The same procedures of PBM group but device will be turned off
223711708|NCT01397890|DRUG|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
223711709|NCT01397890|DRUG|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
223711710|NCT00156052|RADIATION|Conventional whole breast radiation schedule|
223711711|NCT00156052|RADIATION|Hypofractionated whole breast radiation schedule|
223711712|NCT00462618|DRUG|Quetiapine|
223711713|NCT00462618|BEHAVIORAL|Cogntive behavioral therapy|
223711714|NCT06231732|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA
223711715|NCT06231732|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
223711716|NCT00002651|DRUG|bicalutamide|Given orally
223711717|NCT00002651|DRUG|goserelin acetate|Given subcutaneously
223711718|NCT00002651|OTHER|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
223711719|NCT00659048|DRUG|Ciclesonide|Ciclesonide 200µg versus Placebo
223711720|NCT00659048|DRUG|Placebo|placebo
223711721|NCT05666076|PROCEDURE|Pericapsular nerve block|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
223711722|NCT05666076|PROCEDURE|Suprascapular nerve block|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia in shoulder arthroscopy.
223711723|NCT05666076|DRUG|Bupivacaine Hydrochloride|The investigators will perform a pericapsular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride
223711724|NCT05666076|DRUG|Bupivacaine Hydrochloride|The investigators will perform a suprascapular nerve block on that patient group for postoperative analgesia with bupivacaine hydrochloride
223711725|NCT00187200|DEVICE|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
223711726|NCT00187200|DEVICE|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
223711727|NCT00841919|DRUG|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
223711728|NCT00841919|DRUG|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
223711729|NCT00841919|DRUG|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
223711730|NCT00006426|PROCEDURE|Achilles tendon-lengthening surgery|
223711731|NCT00487708|DRUG|canakinumab|
223711732|NCT03493620|PROCEDURE|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
223711733|NCT03493620|PROCEDURE|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
223711734|NCT00638482|DRUG|Hydrochlorothiazide|Hydrochlorothiazide
223528134|NCT03732794|DEVICE|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
223711735|NCT00182884|DRUG|Donepezil|
223711736|NCT05954975|COMBINATION_PRODUCT|BabyCheck and pulse oximetry|"The BabyCheck is a validated scoring system to grade the severity of acute systemic illness in infants up to six months of age. Severity of illness is graded by using a weighted score of a combination of nineteen signs and symptoms. The higher the score, the higher the chance of severe illness.~Nellcor PM10N is a pulse oximeter which is cleared for use in young infants. A sensor for infants will be used, so reliable oxygen saturation and heart rate can be obtained."
223711737|NCT03928119|BEHAVIORAL|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
223711738|NCT03757325|DRUG|DNL747|DNL747
223711739|NCT03757325|DRUG|Placebo|Placebo
223711740|NCT04811885|OTHER|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder|The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
223711741|NCT05231057|OTHER|Pilates exercises|Mat, Pilates band or elastic bands, and Pilate's ball
223711742|NCT05231057|OTHER|Conventional physical therapy program|pain relief, increasing flexibility, and mobility, improving muscle strength
223711743|NCT02717520|DEVICE|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
223711744|NCT05737589|RADIATION|Whole-brain radiotherapy|Radiotherapy is administered to the patient's brain lesions, and the subject's specific treatment plan is developed by two specialized physicians.
223711745|NCT03741062|DEVICE|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
223711746|NCT03741062|DEVICE|Control|Sham treatment with laser unit turned off
223711747|NCT00304746|DRUG|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
223711748|NCT00304746|DRUG|Placebo|Placebo
223711749|NCT05070195|DRUG|SKLB1028|SKLB1028, capsule, oral
223711750|NCT05070195|DRUG|Midazolam|Midazolam Maleate, tablet, oral
223711751|NCT06535386|DRUG|Dexmedetomidine 0.004 MG/ML|Incidence of polyuria during the intraoperative period, associated with dexmedetomidine .
223711752|NCT01198678|DIETARY_SUPPLEMENT|Boost Nutritional Supplement|Boost- Nutritional Supplement
223711753|NCT06469593|DEVICE|Automated insuling delivery system|Closed-loop insulin pumps including MiniMed 780G, Tandom T2-slim x2 and YpsoCamAPS
223711754|NCT00460096|DRUG|Kamada-API|
223711755|NCT00531271|DRUG|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
223711756|NCT03417219|BEHAVIORAL|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
223711757|NCT03417219|BEHAVIORAL|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
223711758|NCT00145782|BEHAVIORAL|Life style|
223711759|NCT03702985|RADIATION|Radiation|Pelvic Radiation: 50Gy/25Fx
223711760|NCT03702985|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
223711761|NCT03702985|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
223711762|NCT03702985|DRUG|Amifostine|400mg/m2 per week
223711763|NCT05831631|DIAGNOSTIC_TEST|Circulating leukocytes immunophenotype|Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
223711764|NCT05831631|DIAGNOSTIC_TEST|Tumor sampling|Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
223711765|NCT00747331|DRUG|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
223711766|NCT00747331|DRUG|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
223711767|NCT00261807|DRUG|Daptomycin 6mg/kg/day|
223711768|NCT01602159|PROCEDURE|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
223711769|NCT01602159|PROCEDURE|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
223711770|NCT01550731|BEHAVIORAL|PREPARE website|Advance care planning website and materials plus an advance directive.
223711771|NCT01550731|BEHAVIORAL|Advance directive|The control group will only receive an advance directive.
223711772|NCT00092989|DRUG|montelukast sodium|Duration of Treatment: 1 dose
223711773|NCT00092989|DRUG|placebo|Duration of Treatment: 1 dose
223711774|NCT00000315|DRUG|Cocaine|
223711775|NCT01036893|DRUG|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
223711776|NCT03747588|PROCEDURE|Minimally-invasive pancreaticoduodenectomy|Minimally-invasive pancreaticoduodenectomy for resection of pancreatic tumor
223711777|NCT03747588|OTHER|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy for resection of pancreatic tumor
223894928|NCT05364879|BEHAVIORAL|Prehabilitation Exercise Intervention|The exercise intervention will consist of light-to-moderate intensity aerobic, resistance, and mobility exercises. These exercises will be performed in a circuit type manner. Participants will perform similar exercises that are modified to meet their individual abilities. Exercise intensity, modifications and substitutions will be determined for each participant based on their medical history, 6 minute walk test results, and baseline frailty scores. Exercise sessions will be performed 3x/wk beginning at 30 min and progressing to 60-min as tolerated for a minimum of four weeks but will continue up until the time of the participants surgery. A hybrid approach will be used for the exercise sessions whereby the participant must attend the first exercise session in person and subsequent sessions will be delivered virtually. Sessions will be overseen by the study Clinical Exercise Physiologist.
223894929|NCT04119544|OTHER|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
223894930|NCT04119544|DEVICE|Intensive Visual Simulation|"* First week: observation, mentalization and then attempt to perform the movements on the screen.~* Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~* From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
223894931|NCT05435677|DRUG|IcoSema|One single dose of IcoSema administered subcutaneously, S.c. into the left thigh
223894932|NCT05435677|DRUG|insulin icodec|One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh
223894933|NCT05435677|DRUG|semaglutide|One single dose of semaglutide administered subcutaneously, S.c. into the left thigh
223894934|NCT06640101|OTHER|sham IMT|with 10% maximum inspiratory pressure (MIP) as the training intensity, IMT will be conducted on a stable surface
223894935|NCT06640101|OTHER|IMT-stable group (sitting on a stable surface)|50% MIP as the training intensity, IMT will be conducted while sitting on a stable surface
223894936|NCT06640101|OTHER|IMT-unstable group (sitting on an unstable surface)|50% MIP as the training intensity, IMT will be conducted while sitting on an unstable surface
223894937|NCT06640101|OTHER|Conventional treatment|Participants in all groups will receive a standardised conventional rehabilitation protocol. It includes limb range of motion, muscle tone reduction, strengthening and endurance of limb muscles, transfer skills, task-directed movements, general gait training, and activities of daily living training.
223894938|NCT03267303|DRUG|TS-091 5mg|Orally taken once daily for 3 weeks
223894939|NCT03267303|DRUG|TS-091 10mg|Orally taken once daily for 3 weeks
223894940|NCT03267303|DRUG|Placebo|Orally taken once daily for 3 weeks
223894941|NCT03321656|DRUG|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
223894942|NCT03321656|DRUG|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
223894943|NCT06642792|DRUG|AK129|Subjects receive AK129 intravenously.
223894944|NCT06642792|DRUG|AK117|Subjects receive AK117 intravenously.
223894945|NCT06547450|BEHAVIORAL|5-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 5-session
223894946|NCT06547450|BEHAVIORAL|8-session UP condition|Unified Protocol (UP) for transdiagnostic treatment of EDs in 8-session
223894947|NCT04234685|DEVICE|High Intensity Physio Light Therapy (HIPL Therapy™)|HIPL Therapy™ is an advanced phototherapy method that utilizes an emission wavelength spectrum that has been optimized for treatment of musculoskeletal disorders (MSD) such as OA.
223894948|NCT04234685|BEHAVIORAL|Education|Participants will take part in education on osteoarthritis, pain neurophysiology, and self-management strategies with the treating physiotherapist. The education will take place during the lab visits and will be brief (5-10 minutes at each session).
223894949|NCT04234685|BEHAVIORAL|Aerobic Exercise|Participants will develop an individualized walking program. The goal will be to walk 30 minutes 5 times/week if able. For all participants who are unable to achieve this walking, they will be provided with a progressive walking program that starts at their baseline (the distance they can walk without being sore an hour later; and without feeling like they will be unable to perform their usual activities of daily living because of the walk). They will be encouraged to then progress by 10-20% each week. Participants will be asked to use a provided walking log to keep track of their progress.
223894950|NCT04234685|BEHAVIORAL|Resistance Exercise|Participants will also be instructed how to perform a series of six exercises: squat, step-up, lunge, single leg stance, knee flexion/extension, and resisted hamstring curl. The exercise technique and dosage will be tailored to the individual's current abilities. For example, if someone is unable to squat down to the level of a chair and return to standing, the chair height will be raised until the participant is able to perform the activity. The participants will begin by being asked to complete one set of 8-12 repetitions of each exercise, once daily, then progress to two or three sets daily as able. They will perform the exercises twice/week in the lab where they will receive support for problem solving and progression. Participants will be asked to use a provided exercise log to keep track of their progress.
223894951|NCT04234685|DEVICE|Placebo Physio Light Therapy (HIPL Therapy™)|Phototherapy delivered at an intensity of 5 mW/cm2, a dosage at which there is no therapeutic benefit expected, but the light will still be visible to the participant.
223894952|NCT05596630|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiotherapy for small intrahepatic recurrent HCC. Radiation dose: Greater than or equal to 40Gy/4-5F, complete treatment within 1 week.
223894953|NCT05866211|OTHER|Previous exposure to SARS-CoV-2|This is an observational study in which no intervention will be applied.
224276343|NCT05188924|DRUG|DKF-306|Active ingredients
224276344|NCT05188924|DRUG|Placebo|Placebo
223711778|NCT04753879|DRUG|Nab-paclitaxel|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
223711779|NCT04753879|DRUG|Gemcitabine|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
223711780|NCT04753879|DRUG|Cisplatin|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
223711781|NCT04753879|DRUG|Irinotecan|"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
223711782|NCT04753879|DRUG|Capecitabine|"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
223711783|NCT04753879|DRUG|Pembrolizumab|"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
223711784|NCT04753879|DRUG|Olaparib|"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
223711785|NCT01317654|OTHER|Observation|Collection of mortality data at 5 years post trial
223711786|NCT05970185|DRUG|PEG-rhG-CSF|Subcutaneous injection of polyethylene glycolized recombinant human granulocyte-stimulating factor injection 6mg bid in the experimental group the day after the end of chemotherapy
223711787|NCT05970185|DRUG|G-CSF|G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
223711788|NCT03597880|OTHER|obese patients|underwent bariatric surgery
223711789|NCT02654834|OTHER|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
223711790|NCT05124314|DRUG|Mifepristone, Oral, 200 Mg|Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
223711791|NCT05124314|DRUG|Misoprostol Pill|Regular treatment with vaginal Misoprostol 800 mcg
223711792|NCT02500420|OTHER|Diagnosis examens|"* Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~* Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
223711793|NCT02527161|DEVICE|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
223711794|NCT05209360|DEVICE|Medial or Lateral Wedge|A foam wedge that is placed inside the shoe under the CDO, that runs along the length of the foot. The tall side of the wedge will be placed on the medial (Medial Wedge) or lateral (Lateral Wedge) aspect of the shoe to preferentially load the medial or lateral side of the foot.
223711795|NCT05209360|DEVICE|Carbon Fiber Custom Dynamic Orthosis|A device that consists of a proximal cuff that wraps around the leg just below the knee, a posterior strut that runs the length of the leg, and a semi-rigid footplate that goes under the length of the foot.
223711796|NCT03155971|DEVICE|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
223711797|NCT02100514|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
223711798|NCT02100514|OTHER|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
223711799|NCT02050516|OTHER|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
223711800|NCT03021941|DRUG|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
223711801|NCT02329912|DEVICE|SmartPill|Application of the SmartPill at the end of surgery
223711802|NCT02459301|DRUG|IPH2201|
223711803|NCT01669226|DRUG|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
223711804|NCT01669226|DRUG|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
223711805|NCT04456608|DRUG|Aspirin|Low and high n-3 PUFA participants will receive 81-mg aspirin once a day, for 6 days.
223711806|NCT06300931|OTHER|educational lecture|An Educational lecture about SDF
223711807|NCT01951274|DRUG|VPD-737|NK1 Receptor Antagonist
223711808|NCT01951274|DRUG|Placebo|
223711809|NCT06201364|PROCEDURE|The external oblique intercostal block|chest wall will be systematically scanned. Initially the probe will be placed in a cephalad to caudad paramedian direction at the anterior axillary line, and the external oblique muscle will be identified at the level ribs 6 and 7 in line with the xiphoid process to confirm correct identification of the external oblique muscle, the probe will be moved in the caudad direction following the external oblique muscle. At the subcostal level, the ultrasound probe will be rotated 90° to see the convergence with the internal oblique and transversus abdominus muscles. The probe will be then moved back to the initial identification point for the external oblique muscle. The EOI plane will be identified deep to the external oblique muscle and superficial to the sixth and seventh ribs and their associated intercostal muscles. Local anesthetic agent will be 20 ml volume (10 ml bupivacaine, 10 ml saline) will be injected under ultrasound guidance and this will be done bilaterally.
223894954|NCT05103670|PROCEDURE|Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA|32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
223894955|NCT04173559|BEHAVIORAL|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. They will also receive feedback regarding sleep if they are not averaging at least 6 hours per night or if they are waking more than twice per night. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
223894956|NCT02577835|DEVICE|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
223894957|NCT02206984|DRUG|Tamoxifen|
223894958|NCT02206984|DRUG|Anastrozole|
223894959|NCT02206984|DRUG|Fulvestrant|
223894960|NCT05519878|OTHER|Best Practice|Undergo routine treatment and usual follow up care
223894961|NCT05519878|DEVICE|Bright White Light Therapy|Undergo bright white therapy
223894962|NCT05519878|BEHAVIORAL|Occupational Therapy|Undergo occupational therapy
223894963|NCT05519878|OTHER|Questionnaire Administration|Complete questionnaires
223894964|NCT03292861|DRUG|Thymoglobulin|Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
223894965|NCT03292861|DRUG|Mycophenolate Mofetil|3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
223894966|NCT03292861|DRUG|Tacrolimus|Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
223894967|NCT03292861|DRUG|Sirolimus|Maintenance doses of sirolimus at 12 months post-transplantation
223894968|NCT03292861|DRUG|Corticosteroids|125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
223894969|NCT06271291|OTHER|Non-Interventional Study|Non-interventional study
223894970|NCT03051997|BEHAVIORAL|Caregiver Contingency Management + Usual Drug Court Treatment|In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
223894971|NCT03051997|BEHAVIORAL|Usual Drug Court Treatment|Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
223894972|NCT04049331|DRUG|Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]|first two doses four weeks apart; following three more doses every ten weeks.
223894973|NCT04049331|OTHER|placebo|first two doses four weeks apart; following three more doses every ten weeks.
223894974|NCT06045936|DRUG|Lidocaine|2 teaspoons of 2% lidocaine injection
223894975|NCT06045936|DRUG|Placebo|Saline injection
223894976|NCT06701968|OTHER|Healthy Nordic Diet|Participants will be adviced a healthy Nordic diet and will also receive certain Nordic foods high in wholegrains and polyunsaturated fat from vegetable sources
223894977|NCT06701968|BEHAVIORAL|Usual Care|Usual care lifestyle advice and national and general recommendations on diet
223894978|NCT05991115|BEHAVIORAL|Hospital to Home Transition (H2H)|The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
223894979|NCT06801938|PROCEDURE|Perioperative Cystoscopy and Methylene Blue Test|The ability of perioperative methylene blue and cystoscopy versus postoperative cystoscopy to detect complications will be compared in patients.
223894980|NCT06801795|DEVICE|AviClear|"Participants will receive as many as 4 treatments, each treatment lasts approximately 10 minutes, with intervals of up to 5 weeks apart. The treatments will be conducted in person. Participants will be followed at approximately week 5 post-treatment completion (via phone) at 12 weeks and 24 weeks post treatment completion onsite.~This is a 1726 nanometer laser treatment"
223894981|NCT04776330|BIOLOGICAL|BCMA targeted prime CAR-T cells|BCMA targeted prime CAR-T cell therapy
223894982|NCT06797622|DRUG|Trastuzumab deruxtecan (T-DXd)|Trastuzumab deruxtecan (T-DXd)
223894983|NCT06795841|RADIATION|Photobiomodulation|It was applied for upper respiratory tract over tonsils, trachea, and main bronchi (bilaterally parasternal at the level of angle of Lewis)
223894984|NCT06795841|PROCEDURE|Myofascial release therapy|technique was applied from supine position, with both hands cupping both diaphragmatic domes
223711810|NCT06201364|PROCEDURE|Paravertebral block|involve injection of local anaesthetic in a space immediately lateral to where the spinal nerves emerge from the intervertebral foramina. This technique is being used increasingly for not only intra-operative and post-operative analgesia but also as a sole anaesthetic technique for carrying out various procedures.
223711811|NCT06008821|PROCEDURE|Bilateral paravertebral block with 0.25% ropivicaine with 1:400,000 epinephrine|60mL of 0.25% ropivacaine will be injected into the PVB at thoracic vertebrae T3/4 level bilaterally (30mL at each site for a total of 2 injections)
223711812|NCT06008821|PROCEDURE|Bilateral sham block with normal saline|10 mL of normal saline will be injected into subcutaneous space at the T3/4 level bilaterally (5 mL at each site for a total of 2 injections)
223711813|NCT03391037|DIAGNOSTIC_TEST|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
223711814|NCT05198999|OTHER|Aquatic-based Plyometric Exercises|The Aqua-PLYO group received the aquatic plyometric exercise training for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association
223711815|NCT05198999|OTHER|Standard Physical Therapy|The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
223711816|NCT00724932|DRUG|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
223711817|NCT00724932|DRUG|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
223711818|NCT00724932|DRUG|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
223711819|NCT00724932|DRUG|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
223711820|NCT04922970|OTHER|Strength training|The interventon consist of 3 weekly, supervised group sessions for 4 months (16 weeks). The sessions consist of progressive full body strength training with a primary focus on lower extremity muscle strength. The leg exercises are leg press, knee extension and leg curl. In addition, participants will perform two upper body exercises. Physical assessment will take place immediately and monthly until 4 months.
223711821|NCT03885258|DRUG|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
223711822|NCT03981770|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
223711823|NCT06022744|DRUG|LX109|LX109 gene injection Specification: 0.2ml/bottle, 1.4×1012VG/ml Administration route: intravitreal injection, injection volume 0.05ml/eye
223711824|NCT01322269|DRUG|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
223711825|NCT03385460|OTHER|ESWL BOTOX|ESWL after intrravesical BOTOX
223711826|NCT06260852|DIAGNOSTIC_TEST|Diagnostic Test: Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
223711827|NCT00870883|DRUG|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
223711828|NCT00762229|DRUG|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
223711829|NCT00762229|DRUG|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
223711830|NCT04391647|OTHER|First-void urine collection|"* One time collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.~* IF HPV positive and the woman gave consent to be contacted again: Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) each day during 14 days (n = 14)"
223711831|NCT04391647|OTHER|Blood draw|\- One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
223711832|NCT06457880|PROCEDURE|PENG BLOCK|Preoperative ultrasound guided PENG block (ropivacaine 0.5 % 20 mL)
223711833|NCT06457880|PROCEDURE|Femoral Nerve Block|Preoperative ultrasound guided femoral nerve block (ropivacaine 0.5 % 15 mL)
223711834|NCT06457880|PROCEDURE|Obturator Nerve Block|Preoperative ultrasound guided obturator nerve block (ropivacaine 0.5 % 5 mL)
223711835|NCT05648383|BEHAVIORAL|mHealth intervention|Participants will receive mHealth intervention (mobile apps) and counseling sessions along with standard care
223711836|NCT05648383|BEHAVIORAL|Standard care|Participants will receive standard care, including lifestyle recommendations.
223711837|NCT02218320|DRUG|Raltegravir|
223711838|NCT02218320|DRUG|Dolutegravir|
223711839|NCT02218320|PROCEDURE|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
223711840|NCT06304129|DIAGNOSTIC_TEST|Blood ponction|Blood ponction
223711841|NCT02459210|BEHAVIORAL|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
223711842|NCT02459210|BEHAVIORAL|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
223711843|NCT03681431|DRUG|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
223711844|NCT03681431|DRUG|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
223711845|NCT03122769|RADIATION|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
223711846|NCT03084770|DIAGNOSTIC_TEST|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.
223711847|NCT03084770|OTHER|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
223711848|NCT06505174|OTHER|Hydroxypropyl Guar-based artificial tears four times per day|Use of hydroxypropyl Guar-based artificial tears four times per day
223711849|NCT02702154|DEVICE|High-frequency rTMS|20 Hz active stimulation, twice daily
223711850|NCT02702154|DEVICE|Low-frequency rTMS|1 Hz active stimulation, twice daily
223711851|NCT02702154|DEVICE|Sham rTMS|Sham stimulation, twice daily
223711852|NCT03342365|DIAGNOSTIC_TEST|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
223711853|NCT00253227|DRUG|galantamine hydrobromide|
223711854|NCT02661659|BIOLOGICAL|Multipeptide vaccine S-588210|
223711855|NCT00004132|BIOLOGICAL|filgrastim|
223711856|NCT00004132|BIOLOGICAL|palifermin|
223894985|NCT06795841|DEVICE|traditional chest physiotherapy|included traditional chest physiotherapy (postural drainage, percussion and shaking), stretching exercise
223894986|NCT06801873|OTHER|Endotoxin (E. coli O:113, Reference Endotoxin)|Intravenous administration of 1 ng/kg (total body weight) endotoxin (Lot no. 94332B1; List Biological Laboratories, Campbell, USA). This is a non-investigational product. Endotoxin is used as challenge agent to achieve a controlled inflammatory state.
223894987|NCT06800391|COMBINATION_PRODUCT|Capecitabine 1250 mg/m2 /day - Cyclophosphamide 50Mg/day|Capecitabine (1250 mg/m2 /day) and Cyclophosphamide (50 mg/day) continuous daily dosing. Cycles are to be repeated every 28 days for a total of 6 cycles.
223894988|NCT05672849|DEVICE|Modified Surgical Instruments/Devices (Sheaths and Irrigator)|Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
223894989|NCT06801366|DIAGNOSTIC_TEST|Parent-recorded smartphone video clips|Parents will record smartphone video clips of their child asleep, which will be scored by pediatric sleep physicians for presence of moderate-severe OSA. Children will then undergo clinically indicated polysomnography (PSG). Video clips will be evaluated for diagnostic accuracy, with PSG as the gold standard.
223894990|NCT05100251|DRUG|WBC100 QOD|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 7 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QOD. The second dose group is 1mg QOD. The third dose group is 1.5 mg QOD. The fourth dose group is 2.0 mg QOD. The fifth dose group is 2.5 mg QOD. The sixth dose group is 3.0 mg QOD. The seven dose group is 3.5 mg QOD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
223894991|NCT05100251|DRUG|WBC100 QD|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
224276345|NCT02932917|DEVICE|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
223711857|NCT00004132|DRUG|cyclophosphamide|
223711858|NCT00004132|DRUG|etoposide|
223711859|NCT00004132|DRUG|ifosfamide|
223711860|NCT00004132|PROCEDURE|quality-of-life assessment|
223711861|NCT00004132|RADIATION|radiation therapy|
223711862|NCT04289662|DRUG|K-924 LD|Pitavastatin 2 mg / Ezetimibe 10 mg tables
223711863|NCT04289662|DRUG|K-924 HD|Pitavastatin 4 mg / Ezetimibe 10 mg tables
223711864|NCT00560456|OTHER|Chronic sleep restriction and driving simulator|"* One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator"
223711865|NCT00210405|DIETARY_SUPPLEMENT|"Sprinkles containing mulitple micronutrients"|
223711866|NCT00210405|BEHAVIORAL|Education/communication on use of micronutrient sprinkles|
223711867|NCT00210405|DIETARY_SUPPLEMENT|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
223711868|NCT05911529|BEHAVIORAL|Motivational Interviewing|In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
223711869|NCT05911529|BEHAVIORAL|Supportive conversations|"In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995)."
223711870|NCT04978961|BEHAVIORAL|Focused Acceptance & Commitment Therapy (FACT)|FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.
223711871|NCT04978961|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
223711872|NCT05306275|DRUG|CSL312|Factor XIIa antagonist monoclonal antibody for subcutaneous use
223711873|NCT02425371|OTHER|Screening and treatment of comorbidities|Screening and treatment of comorbidities
223711874|NCT02425371|OTHER|Placebo Comparator|No screening of comorbidities
223711875|NCT06341075|DEVICE|Magnetic Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
223711876|NCT04253444|BEHAVIORAL|slow deep breathing|Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
223711877|NCT04253444|BEHAVIORAL|sham breathing|Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
223711878|NCT02940912|DRUG|Apomorphine|cross-over with start with Apokinon in the 1st phase- in the 2nd phase of continuous treatment with Physiologic Serum.
223711879|NCT02940912|DRUG|Placebo|cross-over with start with.Physiologic Serum in the 1st phase- in the 2nd phase of continuous treatment with Apokinon.
223711880|NCT05310695|OTHER|NSAC - rapid|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment within 4 weeks of referral.
223711881|NCT05310695|OTHER|NSAC - ordinary|NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in muskuloskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with a multi-diciplinary clarification or treatment of problems with the intent of improved function and return to work. Clinicians are provided survey information on the patients potential health problems, motivation for work, barriers for return to work and work environment prior to consultation. In this intervention arm, patients are offered treatment at 10-14 weeks after referral.
223711882|NCT05310695|OTHER|NSAC - active control|The active control intervention is provided by the NSAC personnel, but patients are offered a single monodisciplinary examination close to the end of the diagnosis-specific deadline suggested in guidelines, which will vary between 8-26 weeks. Employment counsellors may not be involved in consultations, other cross-disciplinary consultations are restricted, and work-related factors are not to be focused on during examination. Clinicians are provided survey information only on the patient's potential health problems prior to consultation. Patients are provided a health-focused examination, with the aim of symptom-relief.
223711883|NCT05286437|DRUG|Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole|Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
223711884|NCT00753571|DRUG|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2"
223711885|NCT05185193|DEVICE|radiofrequency|Radiofrequency of 9.50v, 218.5mA and 2.076W is applied once a day for 30 minutes, a total of 3 times
223711886|NCT05185193|DEVICE|sham stimulation|The appearance is the same as the medical device for clinical trials, and when applied, the sound and the amount of light visible from the outside are designed to be the same as the medical device for clinical trials. The external light was the same, and only the high frequency that stimulates the dermis was blocked. The sham device was applied once a day for 30 minutes, a total of 3 times.
223711887|NCT06175455|DEVICE|dynamic chest radiography|A recent technological advancement in this field is dynamic chest radiography (DCR), which is a low-dose imaging system capable of producing continuous moving images
223711888|NCT04255108|DEVICE|Cova Patch|CoVa Patch will measure quasi-continuously, approximately every 5 minutes for a period between 6 to 48 hours
223711889|NCT02981420|BEHAVIORAL|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
223711890|NCT03959553|DRUG|GV1001|Lyophilized peptide from hTERT
223528135|NCT03709472|BEHAVIORAL|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
223528136|NCT03709472|BEHAVIORAL|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
223528137|NCT05644301|DRUG|Celecoxib|Oral capsule, 200 mg, twice daily, for 12 weeks
223528138|NCT05644301|DRUG|Minocyclin|Oral capsule, 100 mg, twice daily, for 12 weeks
223528139|NCT05644301|DRUG|Placebo|Oral capsule, no active substance, twice daily, for 12 weeks
223528140|NCT03030755|OTHER|Optical coherence tomography|
223528141|NCT03559556|OTHER|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
223528142|NCT05826054|DIETARY_SUPPLEMENT|Montbretin A|The investigational product is 95% pure montbretin A (MbA), a glycosylated acyl-flavonol isolated from the corms (bulbs) of the Crocosmia plant through hot water extraction. It is a potent and specific inhibitor of human pancreatic amylase (HPA).
223528143|NCT06479707|BEHAVIORAL|Digital Literacy Intervention|This intervention consists of 4-6 home visits with 3-4 interim phone calls based on the participant's individual digital literacy needs and goals. Each participant will receive internet connectivity (if not already available), a tablet (if not already available) and tailored action plans co-developed by the participant and the interventionist.
223528144|NCT06621589|BEHAVIORAL|Nutritional Counseling|The intervention involves nutritional counseling aimed at improving dietary habits and overall health to participants. During the 2-month period, participants will receive guidance on nutrition, diet planning, and lifestyle changes tailored to their needs. Assessments of knowledge, attitudes, and health metrics will be conducted before and after the counseling sessions to measure the effectiveness of the intervention
223528145|NCT05498090|DRUG|Fenofibrate 145 mg|Fenofibrate 145 mg PO daily for 4 weeks
223528146|NCT06464640|DEVICE|"Online Interactive Podcast Program Living with Type 1 Diabetes to Grown-Up"|The podcast content was designed based on the results of previous research.Subjects will be randomly assigned to either the experimental group (N=44) or the comparison group (N=44). Comparative analyses will focus on variations in disease control, emotional disturbance,confidence in self-management, self-care behaviors, diabetes knowledge,interpersonal disturbance, and family conflict at baseline, and post-interventions of immediate, 3-month, and 6-month periods.
223528147|NCT06464640|DEVICE|E-book|Participants in the active control group will use Ebook.According to the research results from the project leader\&#39;s app effectiveness evaluation (Chiang, 2020-2022), the e-book did not show significant effects on blood sugar control, disease management confidence, self-care behaviors, disease-related knowledge, or interpersonal distress. Therefore, the active control group received a sham treatment in the form of an e-book. The research team extracted content from the CEO APP e-book, with an expert validity of 0.91, and reorganized it into an electronic health education manual titled \&#34;Transitioning from Adolescence to Early Adulthood: The Ins and Outs of Type 1 Diabetes.\&#34;
223528148|NCT03141970|DRUG|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
223528149|NCT03366259|DRUG|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
223528150|NCT03366259|PROCEDURE|elective cesarean section|elective cesarean section for full term patients
223528151|NCT04464538|BEHAVIORAL|WALC-R|Initial group education session and individualized coaching (remote)
223528152|NCT04464538|OTHER|Information leaflet|Participants in the control group will complete baseline measures, and then they will receive written information on the benefits of increasing activity levels. This advice will be given in accordance with NHS guide on physical health.
223528153|NCT03659721|BEHAVIORAL|FACAM|Support person
223528154|NCT03659721|BEHAVIORAL|Care as Usual|Usual care
223528155|NCT03659721|BEHAVIORAL|COS-P|Attachment based therapy
223528156|NCT03506360|DRUG|Dexamethasone|Given PO
223528157|NCT03506360|DRUG|Ixazomib Citrate|Given PO
223528158|NCT03506360|OTHER|Laboratory Biomarker Analysis|Correlative studies
223528159|NCT03506360|BIOLOGICAL|Pembrolizumab|Given IV
223528160|NCT02025218|DRUG|Gefitinib standard dose|
223528161|NCT06499961|BEHAVIORAL|Digital version of Holistic Healthy Life Education|Participants need to attend a two-day workshop related to (1) health risk appraisal and self-care; (2) exercise, fitness and self-acupressure; (3) emotion and stress management; (4) the whole food plant-based (WFPB) diet; and (5) meditation and mindfulness practices, led by a multi-disciplinary team. Before the intervention commences, they will take pre-blood test and further receive the e2HLE with Hera Leto for three months. During the intervention, participants will attend (1) nine weekly workshops pertaining to WFPB diet, exercise, fitness and self-acupressure, and meditation and mindfulness and followed by weekly tele-counselling sessions; (2) three process evaluation practice sharing sessions in the format of focus group, making up a total of twelve sessions. The process evaluation practice sharing sessions will be audio-recorded; (3) mutual support networking platform will be held between case managers and participants within Hera Leto system.
223528162|NCT06499961|OTHER|Waitlist control|usual care first, then switch to receive the intervention
223528163|NCT02496000|DRUG|ORMD-0801|Oral Insulin
223528164|NCT02496000|DRUG|Placebo Comparator|Placebo
223528165|NCT05040932|DRUG|YH004|IV infusion once every 3 weeks (Q3W).
223528166|NCT02898038|DIETARY_SUPPLEMENT|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
223528167|NCT05806528|OTHER|Ultrasound|Use ultrasound to make placental invasion index
223528168|NCT03852420|DEVICE|LUMINIZE RF Balloon Catheter|Ablation Therapy with the LUMINIZE RF Balloon Catheter
223711891|NCT03959553|DRUG|Normal saline|0.9% normal saline
223711892|NCT03661671|DIAGNOSTIC_TEST|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
223711893|NCT00005639|DRUG|Azacitidine Injection|subcutaneous injection (SC)
223711894|NCT00005639|DRUG|sodium phenylbutyrate|continuous intravenous (CIV)
223711895|NCT01343420|BIOLOGICAL|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
223711896|NCT03266536|BEHAVIORAL|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
223711897|NCT06162936|DIAGNOSTIC_TEST|Phagoburst|The main objective is to perform oxidative burst activity in pediatric patients with a definitive diagnosis of IBD and compare them with healthy controls.
223711898|NCT06162936|DIAGNOSTIC_TEST|Lymphocytes subsets|To determine lymphocytes subsets in patients with suspicion of IEI
223711899|NCT06162936|DIAGNOSTIC_TEST|Genetic testing|Perform targeted genetic testing in those with reduced to absent oxidative activity in search of PIDs and susceptibility variants
223711900|NCT03795623|OTHER|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
223711901|NCT03795623|OTHER|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
223711902|NCT02800681|OTHER|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
223711903|NCT02800681|OTHER|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
223711904|NCT02800681|OTHER|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
223711905|NCT02800681|OTHER|Other general interviewer ratings|1\. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
223711906|NCT05902520|BIOLOGICAL|DP CD8 TIL|intravenous infusion of T cell suspension
223711907|NCT05902520|BIOLOGICAL|DP CD8 TIL KD|intravenous infusion of T cell suspension
223711908|NCT05902520|BIOLOGICAL|Low dose IL-2|Low dose IL-2 delivered subcutaneously for 1, 2 or 3 weeks
223711909|NCT04203498|DRUG|Nabiximols|Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
223711910|NCT04203498|DRUG|Placebo|Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
223711911|NCT05243355|DRUG|"Envafolimab and Chemotherapy and Recombinant Human Endostatin"|"Envafolimab: 300 mg，D1，Q3W,until PD or intolerable toxicity Chemotherapy: Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w; Cisplatin: 75mg / m2, 1-3 days, or carboplatin: AUC 5, D1, Q3w, 4-6 cycles in total.~Recombinant Human Endostatin：210mg，CIV 72h，d1-3，Q3W，4-6 cycles in total."
223711912|NCT05089279|DRUG|D113|QD, PO
223711913|NCT05089279|DRUG|CKD-349|QD, PO
223711914|NCT06150625|OTHER|Orthopedic Manaual Therapy|Can include either spinal mobilizations or spinal manipulation therapy targeting the stiff or symptomatic level of the lumbar spine. Various types of mobilization or manipulation may be used based on the therapists clinical reasoning. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data. Common mobilizations techniques involve gently and repeatedly applying pressure over different parts of the patient's spine that is associated with their symptoms. For a manipulation, the patient will be positioned in side-lying position. The therapist will then position the patient further to target the symptomatic level. The patient is asked to take a deep breathe in and out. The therapist will slowly add pressure through the trunk and apply a fast but small thrust motion toward the table.
223711915|NCT06150625|OTHER|Dry Needling|dry needling both sides of the symptomatic level(s) of the lumbar spine as well as needling other areas in the lower extremity and pelvis based on the results of their clinical evaluation and/or the subjects presenting symptoms. Dry needling involves the insertion of a monofilament needle (nothing is injected) into symptomatic soft tissue. The therapist will determine which technique and dosage parameters for each subject based on individual patient clinical data.
223711916|NCT06150625|OTHER|Home exercise program|5 exercises will be selected from 10 options intended to reinforce the improvements made from treatment.
223711917|NCT06150625|OTHER|Patient education|Patient education on the low back condition, advice to stay active, and home exercise performance.
223894992|NCT05100251|DRUG|WBC100 BID|"The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type"
223894993|NCT06801730|DRUG|Irinotecan liposome combined with bevacizumab|Irinotecan liposomes, 50mg/m2, d1, 90 min intravenously, Q2W; Bevacizumab 10mg/kg, d1, Q2W;
223894994|NCT05558501|OTHER|Mild Intermittent Hypoxia|The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
223894995|NCT05558501|OTHER|Sham MIH|"During sham MIH the participants will be exposed to compressed air (the equivalent of room air)."
223894996|NCT03793972|OTHER|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
223894997|NCT03793972|OTHER|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
223894998|NCT06560112|DRUG|AK104|ivgtt
223894999|NCT06560112|DRUG|AK112|ivgtt
223895000|NCT06560112|DRUG|Chemotherapy|ivgtt
223895001|NCT04509674|DRUG|Empagliflozin|Empagliflozin
223711918|NCT05763095|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
223895002|NCT04509674|DRUG|Placebo|Placebo
223895003|NCT02979522|DRUG|Brentuximab vedotin|Brentuximab vedotin infusion
223895004|NCT02979522|DRUG|Doxorubicin|Doxorubicin infusion
223895005|NCT02979522|DRUG|Vinblastine|Vinblastine infusion
223895006|NCT02979522|DRUG|Dacarbazine|Dacarbazine infusion
223895007|NCT04636229|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
223895008|NCT04636229|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
224083270|NCT04619394|OTHER|Aquatic exercise - AIPAP program|"Supervised by a midwife with AIPAP method. AIPAP method is divided into 10 sessions of 50 minutes that are repeated cyclically with a total of 120 exercises. The sessions are divided into 5 groups with different objectives: 2 sessions of aerobic capacity improvement, 2 sessions of strength improvement, 2 sessions of pelvic elasticity, 2 coordination sessions and the last 4 sessions of the previous ones.~The beginning of the program will be established in week 10-12 of pregnancy and the end in week 37-41.~The total number of sessions of the program will be 25-31 (28 sessions of minimum compliance), with a frequency of 2 sessions per week. The duration of these will be 50 minutes in both experimental groups. It will be necessary to obtain an adherence to both experimental groups of ≥28 classes."
223711919|NCT06372301|DIAGNOSTIC_TEST|Dobutamine stress echocardiography|Patients will be investigated with dobutamine stress echocardiography (increasing doses of dobutamine infusion and simulatneous echocardiogarphic evaluation) to assess aortic valve area and projected aortic valve area.
223711920|NCT05992181|OTHER|NEORTHO|early orofacial stimulation
223711921|NCT00344708|PROCEDURE|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
223711922|NCT02258425|BEHAVIORAL|FEM-CARE|
224083271|NCT01262976|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular, 2 doses
224083272|NCT01262976|BIOLOGICAL|Physiological saline|Intramuscular, 2 doses
224083273|NCT03686566|DRUG|13C-glucose|Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes
223711923|NCT02258425|BEHAVIORAL|Health Promotion|
223711924|NCT01210469|OTHER|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
223711925|NCT01210469|OTHER|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
223711926|NCT01686308|PROCEDURE|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
223711927|NCT01686308|PROCEDURE|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
224083274|NCT03686566|OTHER|No glucose infusion|Only includes standard pre-operation nursing care
224083275|NCT05574179|DRUG|Dexmedetomidine injection|Inj precedex 200mcg in 1ml given in stat doses
224083276|NCT05574179|DRUG|Midazolam|Inj.midazolam 5mg/5ml given in stat doses
223895009|NCT06800612|DRUG|Oncologic drugs administered for treatment of breast cancer|Data on oncologic drugs administered for treatment of breast cancer will be recorded
223895010|NCT06800612|DRUG|Oncologic drug administered for treatment of gynecologic cancer|Data on oncologic drugs administered for treatment of gynecologic cancer will be recorded
223895011|NCT05480384|DRUG|Nivolumab|Nivolumab, 360 mg IV every 3 weeks for 17 doses (12 months)
223895012|NCT05480384|DRUG|Trastuzumab deruxtecan|Given in combination with Nivolumab.
223895013|NCT04943497|OTHER|ribociclib|There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.
223895014|NCT04943497|OTHER|aplelicib|There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.
223895015|NCT04943497|OTHER|mono endocrine therapy|There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
223895016|NCT04943497|OTHER|chemotherapy|There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.
223895017|NCT06196099|DEVICE|Blood Flow Restriction|The study participants were instructed to rest quietly in a seated position for 10 minutes. During the last 3 minutes of the resting period, upper arm blood pressure was measured twice using an automatic blood pressure monitor (BP170, InBody, Korea). The blood flow restriction cuffs (BFR Therapy Cuff, BFR Therapy Co., USA) - measuring 5cm in width and 60cm in length - were applied to the upper third of the thigh on both legs. To maintain consistency in measurements, the distance from the proximal part of the kneecap to the distal edge of the cuff was measured. A Capillary Reaction Time (CRT) test was used to assess the appropriateness of the cuff pressure; this involved applying thumb pressure to the quadriceps muscle after cuff application and timing how long it took for the skin color to return to normal.
223895018|NCT06196099|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation (NMES) was applied five times a week for one week using a four-channel stimulator (Compex Physio, Chattanooga, Switzerland). The stimulation protocol was set to a frequency of 35Hz, with electrodes attached to the vastus lateralis and vastus medialis muscles. The therapist adjusted the intensity and alternating output of the electrodes selectively to facilitate the squat exercises required during the intervention. During the stimulation period, participants were engaged in a squat exercise program, with the total duration of stimulation being 10 minutes.
223895019|NCT06196099|BEHAVIORAL|Squat exercise|In this study, the squat exercise was performed in four sets. Participants were instructed to position their feet shoulder-width apart and educated to squat in such a way that their knees did not extend beyond their toes. To ensure consistency in performing the squat at the same angle, a mark was made on the wall at the pelvic height during a 90° squat. This allowed participants to perform squats at the same height. The exercise was conducted under the guidance of a physical therapist with five years of clinical experience.
223895020|NCT06801990|PROCEDURE|S1 transforaminal epidural steroid(dexamethasone) injection|"The designed study will examine the effect of oblique entry angles on contrast distribution patterns and treatment outcomes. Therefore, it aims to compare the smallest and largest angles that can be achieved under co-axial imaging at the S1 foramen. For this purpose, patients will be divided into two groups through randomization using a computer program. In the first group, after angling cranially and visualizing the foramen, the needle entry point will be determined. In the second group, after achieving optimal imaging by cranially angling the C-arm fluoroscope, an additional ipsilateral oblique angle will be applied to the fluoroscope.~In this context, Plastaras et al. reported that an angle of 5° ± 5° is the most suitable range for the S1 foramen. Additionally, another study examining dorsal and ventral S1 foramen via tomography images found that the average angle providing the widest view of the dorsal foramen was 26.6° ± 3°. In the current study, no oblique angle will be applied"
223895021|NCT02972801|PROCEDURE|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
223895022|NCT06801132|BEHAVIORAL|Online self-delivered death anxiety intervention|"The online self-guided death anxiety intervention developed in this study is based on the Death Education and CBT framework. It took approximately two hours to complete the full intervention. The main content includes:~1. Emotional reactions and behavioral manifestations about death, fear management theories, and Chinese cultural attitudes toward death;~2. Imagine what you would like to say to yourself at the end of your life, and learn about various attitudes towards death through numerous examples;~3. Expressive writing, with moderate emotional exposure to stimulate reflection, accompanied by breathing exercises and positive thinking about death, to improve tolerance and control of death anxiety, and finally to correct biased perceptions by examining bad beliefs about death;~4. Prioritize the importance of things and make a practical action plan to enrich your life."
223895023|NCT06801132|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked not to use our death anxiety intervention or seek additional help related to death anxiety during the 1-week intervention period. After the one-month follow-up of the experimental group, the WL group will receive the same intervention for death anxiety. WL participants will also be given contact information to use in case of increasing distress.
223895024|NCT06800911|OTHER|Questionnaires|Metacognition Questionnaire Penn State Worry Questionnaire Ruminative Response Scale Anger Rumination scale Difficulties in Emotion Regulation Scale Emotional Eating subscale of the Dutch Eating Behavior Questionnaire
223895025|NCT06801028|BIOLOGICAL|injection Sekucinumab|All patients with erythrodermic psoriasis (EP), who will receive subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every 4 week. At weeks 0, 4, 8, 12, 16 and 20 the psoriasis area and severity index (PASI) will be recorded and adverse drug reactions, patient's satisfaction and recurrence will be observed.
223895026|NCT06800677|PROCEDURE|Hysterectomy|Elective hysterectomy
223895027|NCT06800898|OTHER|Blood samples and Questionnaires|"Blood samples for methylation of the promoter of the OX-A and OX-B genes and questionnaires:~Eating Disorder Examination Q Eating Disorder Inventory 3 Major Depression Inventory Symptom Checklist-revised ESS - Epworth Sleepiness Scale Pittsburgh Sleep Quality Index Horne \& Ostberg questionnaire"
223895028|NCT05597345|DRUG|Selinexor|Low-dose Selinexor for the Treatment of Intermediate to High-Risk Smoldering Multiple Myeloma
223711928|NCT04010695|DIAGNOSTIC_TEST|SD Biosensor G6PD Analyzer|The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
223895029|NCT06457945|BEHAVIORAL|ASRT|The task involves the presentation of a visual stimulus in one of four horizontal locations on the screen, and participants are instructed to indicate the location of the target stimulus by pressing the corresponding key on the keyboard. In case of correct response, the target stimulus disappears, and after a 120 ms interstimulus interval, the next stimulus appears. In case of an incorrect response, the target stimulus remains in place until the first correct response. The stimuli follow a probabilistic eight-element sequence, with pattern and random elements alternating with each other. Each participant will be assigned to one of 24 possible sequences throughout the task. The ASRT task will be composed of 25 blocks, with each block containing ten repetitions of the eight-element sequence. After each block, participants will have to take a short break and answer the thought probes before continuing. All patients will perform the task one time.
223711929|NCT04010695|DIAGNOSTIC_TEST|Pointe Scientific Test Kit|The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
223711930|NCT04010695|DIAGNOSTIC_TEST|HemoCue System|The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
223711931|NCT01076920|GENETIC|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
223711932|NCT06284031|PROCEDURE|3 fractions HDR brachytherapy|"The 3 fractions of HDR brachytherapy may be delivered in the following ways:~Option 1: 3 insertions over 2 non-consecutive days:~Option 2: 3 insertions over 3 non-consecutive days"
223711933|NCT01235689|BIOLOGICAL|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
223711934|NCT01235689|DRUG|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
223895030|NCT06457945|BEHAVIORAL|Questionnaires|"All patients will have to fill questionnaire at the beginning of the study~* Spontaneous and Deliberate Mind Wandering Scales (SDMWS)~* Epworth Sleepiness Scale~* Narcolepsy Severity Index~* Idiopathic Hypersomnia Severity Scale~* Hospital Anxiety and Depression scale~* Horne \& Ostberg questionnaire~* Attention Deficit Hyperactivity Disorder (ADHD) auto-evaluation~* Pittsburgh Sleep Quality Index~* Insomnia Severity Index~* Psychotic-like experiences scale"
223895031|NCT06457945|DEVICE|Electrophysiological recordings|A subset of patients in each arm will undergo polysomnography recording (EEG, EOG, EMG, ECG) during the ASRT
223895032|NCT04336228|DRUG|Escitalopram|20mg daily for 3-4 weeks.
223895033|NCT04336228|DRUG|Placebo oral tablet|20mg placebo tablet daily for 3-4 weeks.
223895034|NCT03197662|DRUG|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
223895035|NCT03197662|DRUG|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
223895036|NCT06453551|DRUG|TRN501 - Dose 1|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895037|NCT06453551|DRUG|TRN501 - Dose 2|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895038|NCT06453551|DRUG|TRN501 - Dose 3|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223711935|NCT01235689|DRUG|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
223711936|NCT00678093|OTHER|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
223895039|NCT06453551|DRUG|TRN501 - Dose 4|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895040|NCT06453551|DRUG|TRN501 - Dose 5|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895041|NCT06453551|DRUG|TRN501 - Dose 6|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895042|NCT06453551|DRUG|TRN501 - Dose 7|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895043|NCT06453551|DRUG|TRN501 - Dose 8|Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
223895044|NCT04757519|BEHAVIORAL|DPP-GLB Standard|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.
223895045|NCT04757519|BEHAVIORAL|DPP-GLB Enhanced|The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
223895046|NCT05620771|DRUG|Atezolizumab and Bevacizumab|Patients will receive atezolizumab + Bevacizumab for 21 days after standard of care therapy is complete.
223895047|NCT05620771|DRUG|Y90 + TKI|Patients will receive TKI for 21 days after standard of care therapy is complete.
223895048|NCT02474862|BEHAVIORAL|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
223895049|NCT02474862|BEHAVIORAL|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
223895050|NCT03318406|DEVICE|Bronchoscopic Thermal Vapor Ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
223895051|NCT01214616|DRUG|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
223895052|NCT01214616|DRUG|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
223895053|NCT01214616|DRUG|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
223895054|NCT03721952|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person or by telephone with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
223895055|NCT05565534|BEHAVIORAL|Nurse-practitioner led intervention|"* Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~* Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy."
223895056|NCT03367533|DRUG|Ketamine|Intravenous ketamine
223895057|NCT03367533|DRUG|Perampanel|Oral perampanel (6 mg)
223895058|NCT03367533|DRUG|Placebo|Oral placebo
223895059|NCT04461405|BEHAVIORAL|INTEGRATE-D|INTEGRATE-D provides primary care practices with evidence-based training and support which includes: (1) Electronic health record (EHR)-based support-to help align EHR use with ADA recommendations and enable screening for depression, anxiety, DM distress, cognitive impairment, and self-management, and support identifying and tracking progress on patient treatments and goals; (2) Audit and feedback which involves assisting practices in accessing clinically relevant, actionable data reports to inform measurement and identification of care gaps in DMII and behavioral health care; (3) Skill-building resources including training on ADA-recommended care; and (4) Facilitation-to help implement the above strategies and the practice changes needed to align care with ADA recommendations.
223895060|NCT05699928|DIAGNOSTIC_TEST|General pediatrician autism diagnostic assessment|General pediatricians will assess children for possible autism spectrum disorder diagnosis as they usually would (i.e. no specific tests will be required).
223895061|NCT05699928|DIAGNOSTIC_TEST|Multidisciplinary team diagnostic assessment|The multidisciplinary team will assess children for possible autism spectrum disorder diagnosis. The team consists of a developmental pediatrician, a psychologist, and a psychometrist. Administered tests include the Autism Diagnostic Interview - Revised (ADI-R; a developmental history will be substituted for children with a developmental age of \<18 months), the Autism Diagnostic Observation Schedule (ADOS), and the Mullen Scales of Early Learning. When needed and available, the team will call a preschool or school teacher to gather more information about the child.
224083277|NCT05360667|OTHER|Standard care plus plus Exergame-based multicomponent training program|"The program contains PRT and functional movement of the four extremities but mainly upper limbs. We will use the commercialized exergame Ringfit Adventure (RFA) to deliver the program.~RFA is a ﬁtness action role-playing game. The player advances the story while exercising as the movement of the player is linked to the main character on the screen. The movements of the player and battle actions are based on performing certain physical activities using the Ring-Con and Leg Strap. RFA itself could estimate the optimal exercise intensity for each player and performs ﬁne-tuned up-and downregulation based on these physiological feedbacks. Therefore, it has become possible to provide an appropriate amount of exercise for all generations from children to the elderly.~The standard care is applied as usual in our LTCF. (descriped as the below in the control group)"
223528169|NCT02229682|RADIATION|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
224083278|NCT05360667|OTHER|Standard care|The standard care in the control group is applied as usual in our LTCF, in the way of group activity, including calisthenics (that could be done in sitting position), horticultural therapy, and group activity of peace (like tabletop games). The programs are performed twice per week, about 30 to 60 minutes (depends on different activity), leading by a therapist.
224083279|NCT03129074|DRUG|Varlitinib|everyday
224083280|NCT03129074|DRUG|Capecitabine|from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
224083281|NCT01552681|BIOLOGICAL|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
223711937|NCT01443182|BEHAVIORAL|STAIR|Skills Training in Affective and Interpersonal Regulation
223711938|NCT01443182|BEHAVIORAL|MPE|Modified prolonged exposure (MPE)
223711939|NCT01443182|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing
223711940|NCT01443078|DRUG|pemetrexed|
223711941|NCT01443078|DRUG|cisplatin|
223711942|NCT01443078|DRUG|Carboplatin|
223711943|NCT01443078|DRUG|Gemcitabine Hydrochloride|
223711944|NCT01443078|DRUG|Vinorelbine Tartrate|
223711945|NCT01443078|DRUG|Docetaxel|
223711946|NCT05113290|DRUG|Recombinant Human Adenovirus Type 5 injection|Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was \> 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
223711947|NCT05113290|DRUG|Sorafenib|Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
223711948|NCT03700593|DEVICE|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
223711949|NCT04257734|OTHER|observation|different serum antibodies status
223711950|NCT00163878|PROCEDURE|Sensory Stimulation|
223711951|NCT00163878|DEVICE|Sesnory Modality Assessment and Rehabilitation Technique|
223711952|NCT05760560|DRUG|Sugammadex|At the end of surgery, neuromucular blockade will be reversed with 2mg/kg or 4mg/kg sugammadex depending on the depth of neuromuscular blockade.
223711953|NCT05915221|PROCEDURE|SMS|Receive SMS
223711954|NCT05269433|BEHAVIORAL|OCAT-sham|Placebo version of the online contingent attention training preceded by a psycho-education movieclip.
223711955|NCT05269433|BEHAVIORAL|OCAT|Online contingent attention training preceded by a psycho-education movieclip.
223711956|NCT05269433|OTHER|Psycho-education video|All groups watch a psycho-education video before the start of the 10-day attention training.
223711957|NCT05269433|OTHER|Motivational video|Participants in the OCAT+ condition watch a short motivational video before each training session.
223711958|NCT01809106|DRUG|Morphine|60 mg /24 ore
223711959|NCT01809106|DRUG|Fentanyl|25 microg/h
223711960|NCT01809106|DRUG|Buprenorphine|35 microg/h
223711961|NCT01809106|DRUG|Oxycodone|40 mg /24 ore
223711962|NCT05616975|OTHER|test-retest reliability|Assessing the test-retest reliability of SWAY Balance, Functional, and Cognitive tests.
223711963|NCT05616975|OTHER|construct validity|Investigating the construct validity of SWAY Balance, Functional, and Cognitive tests.
223711964|NCT05616975|OTHER|normative data|Collection of normative SWAY Balance, Functional, and Cognitive data.
223711965|NCT01182142|DRUG|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
223711966|NCT00389597|DEVICE|Cervical Artificial Disc|Cervical artificial disc mechanical device
223711967|NCT02399371|BIOLOGICAL|Pembrolizumab|Given IV
223711968|NCT02399371|OTHER|Laboratory Biomarker Analysis|Correlative studies
223711969|NCT02399371|OTHER|Pharmacogenomic Study|Correlative studies
223711970|NCT05123170|DRUG|Dexmedetomidine Injectable Solution [Dexdomitor]|two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
223711971|NCT05123170|DRUG|Lidocaine IV|Intravenous regional anaesthesia
223711972|NCT00508365|DRUG|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
223711973|NCT00508365|DRUG|Placebo|Placebo capsules to match each dose level will be provided.
223711974|NCT00508365|DRUG|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
223711975|NCT02106975|DRUG|Ascorbic Acid|Intervention
223711976|NCT02106975|DRUG|Placebo: 5% Dextrose in water|Placebo
223711977|NCT02467075|DRUG|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
223711978|NCT02467075|DRUG|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
223711979|NCT01272973|DRUG|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
223711980|NCT01272973|DRUG|placebo|Placebo (oral) administered once daily for 10 weeks.
223711981|NCT01272973|DRUG|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
223711982|NCT02168127|DRUG|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
223711983|NCT02168127|DRUG|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
223711984|NCT00834223|DEVICE|Aquashunt|A shunt which is implanted into the suprachoroidal space.
223711985|NCT05594056|PROCEDURE|Transorbital ultrasound of the optic nerve sheet|Measurement of the optic nerve sheet with a linear transducer (7,5 MHz).
223711986|NCT03951155|BEHAVIORAL|Muscle Relaxation|"* Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~* Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~* Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~* Finally, ask him/her to notice how his/her muscles feel after the exercise."
223711987|NCT01469312|OTHER|modified pasta|50 grams carbohydrate as a single breakfast meal
223895062|NCT05699928|DIAGNOSTIC_TEST|Autism Assessment for Preschoolers with Language Element Sequence|The AAPLES was developed at the Glenrose/Holland Bloorview and is designed for children who have flexible phrase speech. The assessment will be conducted virtually over Zoom Health by a trained clinician. This tool involves coaching the caregiver to interact with the child in specific ways to allow a trained professional to observe for features of ASD while watching remotely. It should take about 30-45 minutes. The individual who conducts the assessment will be blinded to the results of the other assessments. This virtual assessment will occur after the other assessments have been completed so as to not delay the child receiving a potential diagnosis.
223895063|NCT05918328|DRUG|Albumin paclitaxel+trastuzumab+pyrrolitinib|albumin paclitaxel （260mg/㎡ every 3 weeks or 125mg/㎡ weekly）+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg, once every 3 weeks)+pyrrolitinib (320mg, QD), 3 weeks as one cycle.
223895064|NCT05918328|DRUG|Docetaxel+Carboplatin+trastuzumab+Parstuzumab|Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
223895065|NCT06801470|DRUG|CD-001|CD-001 administered as an intravenous (IV) infusion.
223895066|NCT02893267|DEVICE|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
223895067|NCT02893267|OTHER|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
223895068|NCT02893267|OTHER|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
223895069|NCT02893267|DEVICE|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
223895070|NCT04064424|OTHER|Prevention video advertisement|Skin Cancer Prevention videos
223895071|NCT04064424|OTHER|Prevention images for advertisement|Skin Cancer Prevention images
223895072|NCT04064424|OTHER|No Advertisement|No skin cancer prevention videos or images were advertised.
223895073|NCT05505916|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
223895074|NCT05505916|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg
223895075|NCT06129344|OTHER|Manual Lymphatic Drainage Group|Manual Lymphatic Drainage Group:Performed by physiotherapists trained by Dr. Vodder School and licensed in Lymphatic Consolidation Detoxification Therapy (CDT). The patient's treatment posture is to lie down. First, start with the neck lymphatic drainage technique. After performing bilateral axillary lymph node activation and lymphatic valve contraction, the bilateral breast lymph fluid is drained to the bilateral lymph nodes. The time is about 20 minutes. Assist in removing milk from both breasts for 15 minutes each. Once a day for three consecutive days of treatment.
223895076|NCT06129344|OTHER|Ultrasound therapy group|Ultrasound therapy group: performed by a physical therapist. This study uses an ultrasonic therapy device (model: UTO US-750 Therapeutic Ultrasound), frequency: 1MHz, intensity set to 1.0 Watt/cm2, pulsed mode, duty cycle 100%, treatment time 2 5 minutes on each side, and then assist in removing the breast milk from both breasts for 15 minutes on each side. Once a day for three consecutive days of treatment.
223895077|NCT06033898|BEHAVIORAL|12 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1000 steps. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
223895078|NCT06033898|BEHAVIORAL|24 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 24 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
223895079|NCT06033898|BEHAVIORAL|36 hours of physical inactivity|A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 10,000 steps per 24 hours for 48 hours, and then limit their steps below 1,000 - 1,500 steps per 12 hours for 36 hours. A diet record form, a sleep record, and a step record form will be given to participants to log in their diet, sleep time and steps taken through out the whole trial. Participant will be asks to mimic the diet between trials.
223895080|NCT05292365|BEHAVIORAL|RE-PACT Intervention|"* Create respiratory illness action plan~* Weekly mHealth text messages~* Monthly study assessments~* Action planning and JIT coaching"
223895081|NCT06514677|PROCEDURE|Ultrasonic Carbon Tip|Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment
224083282|NCT01552681|OTHER|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
224083283|NCT03624322|DRUG|Zyprexa IM|5mg
223528170|NCT03543423|OTHER|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
223895082|NCT06514677|PROCEDURE|Titanium Curette|Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
223895083|NCT05299931|DRUG|Ustekinumab|dose escalation from every 8 weeks to every 4 weeks only in arm 2
223895084|NCT06398886|BEHAVIORAL|Ericksonian Hypnosis|The Ericksonian hypnosis intervention was designed to create a nurturing and therapeutic setting, specifically tailored to the unique challenges of prolonged grief faced by university students. This approach focused on accessing the subconscious, using symbolic and imaginative techniques to facilitate change. The goal was to alleviate the emotional pain associated with prolonged grief and to empower students to adapt more effectively to their loss. This intervention highlighted the transformative potential of Ericksonian methods in addressing deep-seated emotional issues through gentle and indirect therapeutic modalities.
223895085|NCT06398886|BEHAVIORAL|Cognitive Behavioral Therapy|The CBT intervention aimed to provide a supportive and healing environment, addressing the specific challenges of prolonged grief within a university student population. The focus was on developing concrete skills to manage the cognitive and behavioral aspects of grief. This approach sought to mitigate the pain of prolonged grief and empower students to adapt more healthily to their loss, emphasizing practical strategies for change and coping. Participants were encouraged to actively engage in exercises that challenged their thought patterns and promoted behavioral adjustments tailored to their individual needs.
223895086|NCT05315999|DRUG|Palonosetron Hydrochloride|Palonosetron (500µg): single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
223895087|NCT05315999|DRUG|Placebo|Placebo: single dose per os 1-2 hours before the start of opioid-therapy (WHO II \& III)
223895088|NCT04818060|OTHER|Clinical Assessments|A neurological evaluation will be administered to all participants at baseline, 1 year and 2 year follow-up visits. Motor exams and premorbid IQ assessments will be video-recorded for rater reliability assessments conducted randomly throughout the research project.
223895089|NCT04818060|DIAGNOSTIC_TEST|MRI Scan|At baseline and 2 year follow-up all participants will undergo a 60-minute 3T MRI scanning session which will consist of measures of the volume of brain tissue and cerebral spinal fluid, as well as connections in the brain measuring water pathways and pictures of the brain active and at rest.
223895090|NCT04818060|DIAGNOSTIC_TEST|Lumber Puncture (LP)|Participants will be asked to complete a LP at both onsite study visits (baseline and 2 year follow-up). Blood collection following the procedure will consist of about 80mL and will be stored at a repository for biomarker analysis.
223895091|NCT06208215|DRUG|RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
223895092|NCT06208215|DRUG|RZ358 (10 mg/kg) or Placebo + SOC|Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
223895093|NCT06208215|DRUG|RZ358 (5-10 mg/kg) + SOC|Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
223895094|NCT05077618|OTHER|sampling of dental plaque and blood sample during the treatment|sampling of dental plaque and blood sample analysed on day 1
223895095|NCT04932434|DRUG|Psilocybin therapy|"* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring"
223895096|NCT05964465|DRUG|Dupilumab|Monoclonal antibody blocking interleukin 4 and interleukin 13
223895097|NCT06481475|BIOLOGICAL|YY003|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
223895098|NCT06481475|BIOLOGICAL|Vehicle Control|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.25 ml, 0.05 ml per site.
223895099|NCT02496754|DRUG|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
223895100|NCT02496754|DRUG|GnRH-anta|In control group, patients use GnRH-antagonist. Patients' serum or follicle fluid will be collected if needed.
223895101|NCT05973981|BEHAVIORAL|Package standardization|Conditions vary in terms of amount of cigarette packages that are subject to standardization
223895102|NCT05381597|DRUG|Combination cream of 5-fluorouracil and calcipotriene|Apply the cream to the size of the lesion extending to the 0.5 cm area of skin surrounding the lesion.twice a day for 7 days and the treatment can be extended to 14 days based on evaluation at 7 days.
223895103|NCT05381597|DRUG|5-fluorouracil cream|Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
223895104|NCT04702581|DRUG|PCV chemotherapy|"1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given."
223895105|NCT04702581|DRUG|Radiotherapy and PCV chemotherapy|"Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally"
223895106|NCT04920812|GENETIC|diagnosis of mitochondrial myopathy|• Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
223895107|NCT05792280|DEVICE|AI system|Patients will undergo EUS examination with the assistance of AI system.
223895108|NCT05730231|OTHER|Effects of calorie restriction and time-restricted eating on human health|Calorie restriction plan will be prepared for each participant. After nutritional data collection at baseline, all participant will attend educational sessions about healthy diet and beneficial effects of time-restricted eating. To estimate total energy needs, individuals' RMR will be measured from indirect calorimeter and multiplied by the appropriate factor of physical activity (from 1.3 to 1.6), and then a reduction of 200-500 kcal will be made. Macronutrient composition of the diet will be approximately 45-55% of carbohydrate, 30-35% of fat, and 15-20% of protein. 30% of daily energy intake will be consumed by breakfast, 40% by lunch and 30% by dinner. During posting participants will be allowed to consume only water and herbal infusions without added sugars or sweeteners. Dietary intake of participants will be followed during the study using a 24-h recall. Dietary data will be analysed using the Open Platform for Clinical Nutrition accessible through the website http://opkp.si/.
223895109|NCT01463423|RADIATION|iSABR, 25 Gray in 1 fraction for small peripheral tumors|Radiotherapy procedure for participants with small peripheral tumors ≤ 10 cc.
224083284|NCT03624322|DRUG|Zydis|10mg orally disintegrating wafer
224276346|NCT00756717|DRUG|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
223528171|NCT03543423|OTHER|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
223528172|NCT01555580|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
223528173|NCT02422108|DRUG|Denosumab|
223528174|NCT05446207|OTHER|Routine Physiotherapy and Task-oriented Training|The routine physiotherapy treatment will include TENS and Hot pack. The task oriented training for lower extremity will include walking training on the ground, equal weight bearing sit-to-stand exercises, resistance exercises e.g. leg press, leg extension, and leg curl and reaching tasks for improving balance. There will be a rest period of 5 minutes between each set of training.
223528175|NCT05446207|OTHER|Music Therapy and Task oriented Training with Routine Physiotherapy|Relaxing Music will be provided through headphones having voice cancellation property for 15 minutes.
223528176|NCT04736355|DRUG|DAOIB|oral, for 24 weeks
223528177|NCT04736355|DRUG|Placebo|oral, for 24 weeks
223528178|NCT06638918|DEVICE|Virtual Reality|The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
223528179|NCT06644326|DRUG|100mg IkT-148009 Wet|100mg wet tablet formulation
223528180|NCT06644326|DRUG|200 mg Itraconazole|2 100mg capsules
223528181|NCT06644326|DRUG|100mg IkT-148009 Dry|100mg dry tablet formulation
223528182|NCT06644326|DRUG|50mg IkT-148009 Wet|50mg wet tablet formulation
223528183|NCT00301860|BIOLOGICAL|anti-thymocyte globulin|
223528184|NCT00301860|BIOLOGICAL|filgrastim|
223528185|NCT00301860|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223528186|NCT00301860|DRUG|cyclosporine|
223528187|NCT00301860|DRUG|fludarabine phosphate|
223528188|NCT00301860|DRUG|melphalan|
223528189|NCT00301860|DRUG|methotrexate|
223528190|NCT00301860|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223711988|NCT05728021|BEHAVIORAL|Recovery Record Aftercare|"Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16."
223711989|NCT05728021|BEHAVIORAL|Treatment as usual (TAU)|Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
223711990|NCT02583126|BEHAVIORAL|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
224276347|NCT00685750|PROCEDURE|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
224276348|NCT04066413|OTHER|Standard infant formula|Standard infant formula
224276349|NCT04066413|OTHER|Infant formula supplemented with HMO|Infant formula supplemented with HMO
223528191|NCT00301860|PROCEDURE|peripheral blood stem cell transplantation|
223528192|NCT03643237|BEHAVIORAL|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
223528193|NCT03643237|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
223528194|NCT06599320|OTHER|Oral rehabilitation with dental implants|Patients rehabilitated with implant-supported fixed partial dental prostheses
223528195|NCT06985927|BEHAVIORAL|psychotherapeutic sessions|Analysis of effect of psychotherapeutic sessions based on self-concept and autobiographical memory on alcohol addiction
223528196|NCT06660420|DRUG|Cyclophosphamide|Given by IV
223528197|NCT06660420|DRUG|Fludarabine|Given by IV
223528198|NCT04327817|DEVICE|Multifidus stimulator|"Patient eligible for the study and have provided consent will have a baseline PET scan. Multifidus ReActiv8 Stimulator will be inserted using standard treatment for lumbar pain at Barts Health NHS Hospitals.~All patients who receive the Reactiv8 system will continue to receive multifidus stimulation 20Hz for the next 6 months as per standard of care of multifidus stimulation; at the end of this period, the patients will undergo PET scanning and questionnaires. Thereafter, stimulation will continue and 3rd PET scan will be performed at 1year post implant."
223895110|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium peripheral tumors|Radiotherapy procedure for participants with medium peripheral tumors \> 10 cc and ≤ 30 cc.
223895111|NCT01463423|RADIATION|iSABR, 54 Gray in 3 fractions for large peripheral tumors|Radiotherapy procedure for participants with large peripheral tumors \> 30 cc.
223711991|NCT03241875|DRUG|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
223711992|NCT03241875|DRUG|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
223895112|NCT01463423|RADIATION|iSABR, 40 Gray in 4 fractions for small central tumors|Radiotherapy procedure for participants with small central tumors ≤ 10 cc.
223895113|NCT01463423|RADIATION|iSABR, 50 Gray in 4 fractions for medium central tumors|Radiotherapy procedure for participants with medium central tumors \> 10 cc and ≤ 30 cc.
223895114|NCT01463423|RADIATION|iSABR, 60 Gray in 8 fractions for large central tumors|Radiotherapy procedure for participants with large central tumors \> 30 cc.
223895115|NCT06107634|PROCEDURE|Gastropexy|"In the intervention group, a three-point gastropexy is added to the repair. First, the right fundus flap is adapted posteriorly to the crural portion of the diaphragm with a 2-3 cm long running non-absorbable suture (posterior gastropexy). Second, the left fundus flap is adapted to the diaphragm anterolateral to the hiatus with a 2-3 cm long running non-absorbable suture (left anterolateral gastropexy). Finally, the minor curvature of the anterior stomach wall is adapted during reduced intraabdominal pressure to the anterior abdominal wall with a 2-3 cm long running non-absorbable suture (anterior gastropexy)."
223895116|NCT06107634|PROCEDURE|Paraesophageal hernia repair|Ultrasonic shears are used for dissection. The herniated viscera are completely reduced into the abdomen and the hernia sac in fully dissected and resected. The esophagus is mobilized intraabdominally until at least 3 cm rests below the hiatus without tension. The anterior and posterior vagal nerves are identified and preserved. A posterior crural closure with running non-absorbable sutures is performed. An additional anterior crural closure may be performed at the surgeon's discretion. The fundus is mobilized to allow a floppy fundoplication. A total fundoplication is created by three interrupted non-absorbable sutures. No bougies are used routinely for calibration of the fundoplication.
223895117|NCT05858515|DRUG|Baricitinib 4 MG|Nonproprietary name: Baricitinib
223895118|NCT05858515|DRUG|Placebo|Placebo
223895119|NCT06021197|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of CIAS
223895120|NCT06021197|DRUG|Placebo Cap|Use of placebo as a comparator
223895121|NCT05033314|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg PO daily as thromboprophylaxis
223895122|NCT05033314|DRUG|Placebo|matching placebo daily
223895123|NCT04541147|DRUG|Dexamethasone|dexamethasone solution or tablet (depending on age of patient) at 0.5mg/kg/day max of 8mg/day, administered on post-operative days 1,3,5,7.
223895124|NCT04541147|DRUG|Analgesics|"standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)"
223895125|NCT05596539|OTHER|Data collection|Collection data from diagnostic Data collected following to medical exam as part of care
223895126|NCT05998226|OTHER|Virtual Antimicrobial stewardship Team (VAT)|The VAT consists of at least a clinical microbiologist and a clinician from the NH. Ideally, a pharmacist will also attend. They conduct a weekly (digital) meeting for nine months to evaluate the antibiotic prescriptions of the clinician attending the VAT meeting, based on a standardized protocol according to the current national infection treatment guidelines.
223895127|NCT01030328|DRUG|Placebo|2 sugar pills by mouth once a day.
223895128|NCT01030328|DRUG|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
223895129|NCT06330116|DEVICE|IQoro|Please refer to arm/group description for information
223895130|NCT06330116|DEVICE|eXciteosa|Please refer to arm/group description for information
223895131|NCT06330116|BEHAVIORAL|Grouptraining|Please refer to arm/group description for information
223895132|NCT05374525|DRUG|APRETUDE|Available as intramuscular injection.
223895133|NCT05374525|DRUG|Cabotegravir OLI|Available as marketed orally administered tablets.
223711993|NCT03241875|DRUG|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
223711994|NCT03546062|OTHER|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
223711995|NCT05840783|DEVICE|Open ended needle irrigation|irrigation during root canal shaping and cleaning using an open-ended needle
223711996|NCT05840783|DEVICE|side vented needle irrigation|irrigation during root canal shaping and cleaning using a 30-guage side-vented needle
223711997|NCT05840783|DEVICE|Sonic activation|Agitation of root canal irrigation solution with a sonic activation device (Endoactivator).
223895134|NCT05845216|DEVICE|ACTIVE Transcranial photobiomodulation (tPBM)|fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)
223895135|NCT05845216|DEVICE|SHAM Transcranial photobiomodulation (tPBM)|fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
223895136|NCT04619069|RADIATION|SBRT|SBRT to all sites of metastatic disease as seen on PSMA PET scan
223895137|NCT04619069|DRUG|Hormone therapy|Intermittent Hormone Therapy per physician discretion (Min. 8 months)
223895138|NCT06286397|DRUG|1% Clascoterone|Application of 1% clascoterone cream twice daily to affected area for 12 weeks.
223895139|NCT06286397|DRUG|Vehicle Cream|Application of a vehicle cream to the natal cleft twice daily for 12 weeks
223895140|NCT04495894|DRUG|Preoperative Ketorolac|30 mg ketorolac will be administered intravenously 30 minutes prior to incision.
223895141|NCT06799637|DRUG|XNW28012|Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, progression of disease with no clinical benefit, or withdrawal of informed consent.
224083285|NCT03624322|DRUG|INP105|Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
224083286|NCT03624322|DEVICE|I231 POD® Device|Precision Olfactory Delivery (POD) device
224083287|NCT02690194|DEVICE|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
223895142|NCT06243913|PROCEDURE|IUI with vitrified sperm from donor:|"After signing the informed consent, the clinic's Matching team will assign a donor semen straw based on phenotypic characteristics, blood group, and genetic compatibility (if applicable), with the female partner.~On the day of the Intrauterine Insemination (IUI), the laboratory team will thaw the assigned donor semen straw and post-thaw sperm parameters will be analyzed, including the total number of sperm with progressive motility. Subsequently, the IUI will be performed following the standard protocol."
223895143|NCT05661669|DRUG|Ketamine|The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes.
223895144|NCT05661669|DRUG|Saline|The placebo will be a 0.9% saline solution administered over 40 minutes.
223711998|NCT01703325|DRUG|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~* Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~* Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~* Group C: Controlled group"
223711999|NCT03410329|OTHER|Resistance training|Physical activity
223712000|NCT05719376|DRUG|Monofer (experimental)|Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
223712001|NCT05719376|DRUG|control group|Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
223712002|NCT00099541|DRUG|zoledronic acid|
223712003|NCT06081712|DRUG|TNP-2198|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
223712004|NCT06081712|DRUG|TNP-2198 Placebo|TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
223712005|NCT00285233|BIOLOGICAL|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
223712006|NCT00028782|DRUG|etanidazole|Given IV
223712007|NCT00028782|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223712008|NCT00028782|OTHER|laboratory biomarker analysis|Correlative studies
223895145|NCT05682937|DEVICE|HFOV-sigh|HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5.
223895146|NCT05650775|DRUG|Concerta|3-week trial of oral methylphenidate extended release
223895147|NCT05650775|DRUG|Adderall-XR|3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
223895148|NCT06279221|DRUG|LITFULO|as provided in real world practice
223895149|NCT05865561|OTHER|VOC sampling|"* Systematic sampling during the day: Samples every 3 hours (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period.~* Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time.~The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it."
223895150|NCT06058949|BEHAVIORAL|Health Protection and Promotion|An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
223895151|NCT06058949|BEHAVIORAL|General Health Program|Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
223895152|NCT06204094|RADIATION|node-sparing short-course radiotherapy|5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes
223528199|NCT03657485|DIETARY_SUPPLEMENT|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
223895153|NCT06204094|DRUG|Sintilimab|200mg intravenous infusion d1 of each cycle\*8cycles
223895154|NCT06204094|DRUG|Capecitabine|1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles
223528205|NCT06268249|DRUG|Ulinastatin|Ulinastatin was pumped continuously during the operation
223528206|NCT06615219|OTHER|Intergroup contact training|The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.
223528207|NCT06615219|OTHER|Regular course training only|The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
223528208|NCT06670417|DEVICE|Low level laser therapy watch: The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light|"Low level laser therapy watch:~The laser watch device was a semiconductor LLL therapeutic apparatus, (model:SL-03 GaALAs semiconductor) Domer Laser Therapy Watch class 3B 650nm low-level laser light. It provides 18 individual laser beams used for extravascular blood irradiation (transcutaneous) through radial and ulnar vessels at the wrist site."
223895155|NCT06204094|DRUG|Oxaliplatin|130mg/m2, intravenous infusion,d1 of each cycle\*8cycles
223895156|NCT06204094|PROCEDURE|TME surgery|laparoscopic or robotic TME surgery for non-cCR patients
223895157|NCT06204094|PROCEDURE|watch and wait|WW for cCR patients
223895158|NCT04535271|DRUG|Trabectedin|This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
223895159|NCT06242405|BIOLOGICAL|umbilical cord-mesenchymal stem cells|Umbilical cord mesenchymal stem cells injected through peripheral veins
223895160|NCT06083324|OTHER|Dose escalated resistance training|All individuals will be engaging in resistance training during and/or after their cancer treatment
223895161|NCT05579899|DRUG|EVO101|Topical Cream
223895162|NCT03937128|BEHAVIORAL|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
223895163|NCT03937128|BEHAVIORAL|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
223895164|NCT06224790|DRUG|Pirfenidone|Capsule Pirfenidone 1200mg/ day in divided doses for 3 months
224083288|NCT02690194|DEVICE|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
224083289|NCT03671057|DEVICE|HospiAvontuur|To be included in the study children should play the game at least one time together with one parent
223712009|NCT05241743|OTHER|radiological examination, pain, nomophobia, phone addiction|120 patients who applied to the clinic with the complaint of neck pain and were diagnosed with cervical hypolordosis by radiological examination will be included in the study. After giving the necessary verbal and written information about the study, a link will be sent to the phones of the patients whose informed consent was obtained. Patients will access evaluation questions and survey questions via this link. Personal information with the Sociodemographic Data Form prepared by us; pain severity by Visual Analogue Scale (VAS); phone addiction level with the Smartphone Addiction Questionnaire (Young Population); nomophobia levels will be evaluated with the Nomophobia Scale.
223712010|NCT01041833|DRUG|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
223712011|NCT01041833|DRUG|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
223712012|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
223712013|NCT00087607|DRUG|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
223712014|NCT00087607|DRUG|Ribavirin|1000/1200mg/day po
223712015|NCT00087607|DRUG|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
223712016|NCT02836730|PROCEDURE|Low back pain surgery|
223712017|NCT02015754|DRUG|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
223712018|NCT02015754|DEVICE|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
223712019|NCT02015754|PROCEDURE|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
223712020|NCT03824730|DEVICE|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
223712021|NCT05987228|DIETARY_SUPPLEMENT|Thymus vulgaris|500 mg of Thymus vulgaris (capsules) was given orally twice daily
223712022|NCT02694965|OTHER|observational|
223712023|NCT03277664|BEHAVIORAL|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
223712024|NCT02041884|BEHAVIORAL|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
223712025|NCT02041884|BEHAVIORAL|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
223895165|NCT06224790|OTHER|Placebo|2 Capsules 3 times a day for 3 months
223895166|NCT05750680|DRUG|DOACs|outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
223895167|NCT06506084|DRUG|Ropeginterferon alfa-2b|"Data will be collected at each visit during the observational study (total duration: 24 months). In accordance with routine clinical practice in this patient population, visits are expected to take place every 6 months.~Patients who discontinue ropeginterferon alfa-2b treatment at any time will no longer be followed up."
223895168|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Liquid Formulation) is an investigational vaccine that is a preformulated, sterile, milky-white suspension for IM injection. It consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and CPG 7909 adjuvant
223895169|NCT04660201|BIOLOGICAL|AV7909|AV7909 (Lyophilized Formulation) is a thermostable, lyophilized version of the liquid AV7909 formulation. Sterile, milky-white suspension for intramuscular injection. It consists of polysorbate 80, CPG7909 adjuvant and AVA bulk drug substance
224083290|NCT03671057|DRUG|Midazolam|current practice in Jessa
223895170|NCT06537622|OTHER|Implementation group|Implementation strategies to increase uptake of the clinical practice guidelines for earlier diagnosis of cerebral palsy
223895171|NCT06537622|OTHER|Standard of care|No active implementation strategies
223895172|NCT04064164|BEHAVIORAL|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
223895173|NCT06332430|DRUG|CAN2109|CAN2109 IT injection (once every 3 weeks)
223895174|NCT05604391|PROCEDURE|Free gingival graft placed apically|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing it in the apical region of the gingival recession according to the randomly selected positioning technique.
223895175|NCT05604391|PROCEDURE|Free gingival graft placed coronally|For free gingival graft operation, the recipient area will be prepared with a half-thickness flap. A graft with a thickness of approximately 1.5 mm and a width and height of the recipient bed will be obtained from the palatal region in accordance with the recipient bed, and it will be sutured by placing the coronal region of the gingival recession according to the randomly selected positioning technique.
223895176|NCT04172038|BEHAVIORAL|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
223895177|NCT04172038|BEHAVIORAL|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
223895178|NCT04172038|BEHAVIORAL|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences"
223895179|NCT03224858|OTHER|SUMMIT intervention|See description in experimental arm.
223895180|NCT03224858|OTHER|Enhanced usual care|See description in active comparator arm.
223895181|NCT06176664|DEVICE|Low flow oxygen|Standard nasal cannula oxygen up to 2 liters/minute
223895182|NCT06176664|DEVICE|High-flow nasal cannula oxygen|High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
223895183|NCT02951845|DRUG|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
223895184|NCT02951845|DRUG|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
223895185|NCT02951845|DRUG|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 2.
223895186|NCT05373862|DEVICE|Globe-Shaped, High-Density, Multi-Electrode Mapping Catheter|Participants scheduled to have a clinically-indicated catheter mapping and ablation procedure using globe-shaped, high-density, multi-electrode mapping catheter for management of atrial procedure (scar-related atrial tachycardia, persistent atrial fibrillation, paroxysmal atrial fibrillation) and Ventricular procedures (ventricular tachycardia, premature ventricular complex).
223895187|NCT04724447|DRUG|Valganciclovir|2 x 450mg VGCV tablets
223895188|NCT04724447|DRUG|Placebo|Placebo equivalent of 900mg/day VGCV
223895189|NCT06179407|DRUG|MK-6552|Oral capsule administered according to allocation (Part 1)/randomization (Part 2).
223895190|NCT06179407|DRUG|Placebo|In Part 2, participants will receive multiple days of placebo dosing (7 consecutive days).
223895191|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
223895192|NCT06160908|DEVICE|sham NirsCure|Non near-infrared light irradiation；only the equipment appearance is consistent with the test device；Once a day, once for 30 minutes, 6 times a week
223895193|NCT06160908|DEVICE|NirsCure|True near-infrared light； Once a day, once for 30 minutes, 6 times a week
223895194|NCT05179187|BEHAVIORAL|Movement task|Computer task with experimental conditions manipulating sensory and motivation cues for movement.
223895195|NCT05736133|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management or presented with group exercise options. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations such as comorbidity or frailty. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral. All individuals may have their medications reviewed by a physician if deemed appropriate by the PT or requested by the participant."
224083291|NCT02769728|DEVICE|EndoBarrier|implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
224083292|NCT01822808|DRUG|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
224083293|NCT01822808|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
223895196|NCT05736133|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
223895197|NCT06072768|DRUG|15-day taper prednisone|The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.
223895198|NCT06072768|DRUG|150-day taper prednisone|The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
223895199|NCT06561698|DRUG|Vonoprazan|Potassium competitive acid blocker
223895200|NCT06561698|DRUG|Amoxicillin|Antibiotics for H. pylori eradication
223895201|NCT06561698|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223895202|NCT06561698|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
223895203|NCT05183204|DRUG|Paxalisib|Patients will receive paxalisib starting at a dose of 45 mg/day. If well tolerated after 28 days, the dose of paxalisib will be increased to 60 mg/day.
223895204|NCT05183204|DRUG|Metformin|Patients will receive metformin on Cycle 1, Day 1 at a starting dose of 850 mg QD, and if tolerated, will be increased to 850 mg BID on Cycle 2, Day 1 (1700 mg/day). If that dose is tolerated, metformin will be increased to 850 mg TID (2550 mg/day) beginning on Cycle 3, Day 1.
223895205|NCT05183204|OTHER|Ketogenic Diet|The ketogenic diet is high-fat, low carbohydrate diet. Ketogenic diet will be maintained on a continuous basis starting on Cycle 1, Day 1 and continuing throughout the trial.
223895206|NCT05096234|DRUG|[ 18F]F-AraG PET|Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
223895207|NCT04059484|DRUG|Amcenestrant|"Pharmaceutical form: Capsule~Route of administration: Oral"
223895208|NCT04059484|DRUG|Fulvestrant|"Pharmaceutical form: Solution for injection~Route of administration: Intramuscular"
223895209|NCT04059484|DRUG|Anastrozole|"Pharmaceutical form:Tablets or capsules~Route of administration: Oral"
223895210|NCT04059484|DRUG|Letrozole|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
223895211|NCT04059484|DRUG|Exemestane|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
224276350|NCT04979858|DEVICE|Focal Mask|The treatment group will receive and use the focal mask.
223895212|NCT04059484|DRUG|Tamoxifen|"Pharmaceutical form: Tablets or capsules~Route of administration: Oral"
224276351|NCT05815849|DIETARY_SUPPLEMENT|Olive oil|0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
224276352|NCT04547933|DIAGNOSTIC_TEST|Bladder diary|A 3-day bladder diary recording daily drinking fluid amount, daily urine amount, urgency and urinary incontinence episodes.
224276353|NCT05352438|OTHER|Manual Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Manual Therapy group received a manual therapy program applied as 2 sessions of 45 mins each week for 4 weeks (total 8 sessions) by an investigator. Soft tissue and joint mobilizations were applied to the TMJ and surrounding structures and to cervical segments, trigger point treatment was applied to trigger points, and myofascial loosening was performed. Patients were instructed to perform the exercises learned in the home exercise program in 3 sets of 10 repetitions every day."
223895213|NCT06371300|DEVICE|Red LLLT|Mask with LEDs emitting at wavelengths of 633nm to facial and eyelids region with their eyes closed
223895214|NCT06371300|DEVICE|Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm to facial and eyelid regions with their eyes closed
223895215|NCT06371300|DEVICE|Sham Red LLLT|Mask with LEDs emitting at wavelengths of 633nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
223895216|NCT06371300|DEVICE|Sham Blue LLLT|Mask with LEDs emitting at wavelengths of 428nm, but with \<10% fluence power output, to facial and eyelids region with their eyes closed
223895217|NCT06254313|OTHER|Additional tubes and LBA|4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA)
223895218|NCT04897256|BEHAVIORAL|TURN-IT exercise program|Based on the exercise motor learning principles, participants spend 10-15 minutes at each Exercise Station that focuses on particular constraints of turning ability. The stations will focus on important underlying aspects of turning, such as weight-shifting and increasing axial rotation during functional turning tasks. Each station will be progressed across levels to make more challenging (such as adding a dual task). Initially participants will be supported in an overhead body-weight support system (ZeroG) to allow them to practice challenging exercises without the risk of falling.
223895219|NCT02949362|DRUG|Teduglutide|0.05mg/kg
223895220|NCT02949362|OTHER|SOC|Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
223895221|NCT01000961|DRUG|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
223895222|NCT01000961|DRUG|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
223895223|NCT06092671|OTHER|Family-centred perioperative care for anaesthesia|The patient in intervention group and parent will receive the Family-centred perioperative care for anaesthesia, including video education, anaesthesia mask practice, electronic pamphlet, distraction strategies and parental presence. The patient will not receive sedatives before surgery. During the anesthesia induction period, it is recommended that the parent be instructed by the anesthesiologist to complete the induction of inhalation of the anesthesia mask, and the patient will be accompanied by the parent during the awakening period.
223895224|NCT01701817|OTHER|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
223895225|NCT05156983|DRUG|TAK-330|Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.
223895226|NCT05156983|DRUG|SOC 4F-PCC|Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
223895227|NCT03986697|DRUG|Biktarvy|Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
223895228|NCT06177457|DRUG|PF-07293893|PF-07293893 will be administered as tablets every day (QD) over 14 days
223895229|NCT06177457|DRUG|Placebo|Placebo will be administered as tablets; QD over 14 days
223895230|NCT06177457|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
223895231|NCT05780372|RADIATION|Intensity Modulated Radiation Therapy|All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
223895232|NCT05780372|DRUG|Chemotherapy|Chemotherapy will be arranged by the physician-in-charge according to the NCCN guideline, patient's stage and physical condition.
223895233|NCT06165146|DRUG|Repaglinide|Administered orally.
223895234|NCT06165146|DRUG|Pirtobrutinib|Administered orally.
223895235|NCT03390322|DEVICE|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
223895236|NCT06784076|DRUG|Anifrolumab|Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC
223895237|NCT02222155|DRUG|CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
223895238|NCT02222155|DRUG|CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids|
223895239|NCT02222155|OTHER|Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids|
223895240|NCT05879055|DRUG|PM8002|IV infusion
224083294|NCT00570102|DIETARY_SUPPLEMENT|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
224083295|NCT00570102|DIETARY_SUPPLEMENT|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
224083296|NCT05906277|DIAGNOSTIC_TEST|Biopsy|Liquid biopsy, re-biopsy, tissue biopsy
224083297|NCT01245088|DRUG|chondroitin sulfate|400 mg orally three times daily for 8 weeks
224083298|NCT01150084|OTHER|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
223895241|NCT05879055|DRUG|FOLFIRI|IV infusion
223895242|NCT02976480|PROCEDURE|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
223895243|NCT02976480|PROCEDURE|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
223895244|NCT05817357|DEVICE|Rensair Compact air purifier unit|Installation of Rensair Compact air purifier (Rensair Ltd.) in the homes of children/young people participating in this study
223895245|NCT04713774|DEVICE|High-resolution peripheral quantitative CT scanner (HRpQCT)|HR-pQCT images of the distal radius and distal tibia (non-dominant, non-fractured limb) will be obtained using the XtremeCT device with standard protocols. HR-pQCT images wil be analysed with standard software and extended cortical measures software. This software identifies the periosteal and endosteal boundaries, enabling assessment of cortical micro- structural bone properties, including apparent cortical thickness (Ct.Th, mm), cortical tissue mineral density (TMD, mgHA/cm3) and cortical porosity (Ct.Po, %).
223895246|NCT04633122|DRUG|Ripretinib|Oral kinase inhibitor
223895247|NCT04633122|DRUG|Sunitinib|second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib
223895248|NCT05260957|DRUG|Mosunetuzumab|"Induction Phase (Days -42 through -7):~* 1 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -42.~* 2 mg of Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -35.~* 60 mg of Mosunetuzumab administered via intravenous (IV) infusion on (given as per treatment guidelines) on Days -28 and -7.~Consolidation Phase (Day +1 through Day +90): 30 mg IV Mosunetuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +14, +35, +56 and +77."
224083299|NCT01150084|OTHER|delayed treatment|to start at week 10
223712026|NCT02041884|OTHER|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
223712027|NCT02516046|DRUG|Flortaucipir F18|370 megabecquerel (MBq) IV single-dose
223712028|NCT02516046|PROCEDURE|PET Scan|positron emission tomography (PET) scan
223712029|NCT04589806|PROCEDURE|2-stage ridge splitting|two-stage alveolar ridge splitting technique using piezoelectric device with simultaneous implant placement in order to treat narrow posterior mandibular ridges avoiding the risks of malfracture and necrosis of the split part
223712030|NCT05960552|DIAGNOSTIC_TEST|The PReTEE group|Prior to clinical application of PReTEE, all participants designated must receive professional training. They need to receive lectures focusing on the clinical thinking flowchart of rescue transesophageal echocardiography, in conjuntion with the simulator-based training. The discriminating ability of PReTEE will be further assessed in real clinical scenario, that is, within the specified 120 seconds participants in the PreTEE group need to provide the leading causes with regard to difficult separation from cardiopulmonary bypass in high-risk cardiac surgical procedures. All examinations will be supervised by a TEE expert owning to safety considerations but without help in views acquirement or interpretation. After completion of study assessments, the TEE expert will perform a standard comprehensive TEE, the results of which was reported to the attending cardiac anesthesiologist in charge of the patient and the recorders.
223712031|NCT05960552|DIAGNOSTIC_TEST|The conventional TEE group|Before cardiopulmonary bypass separation, conventional TEE examinations will be performed within the specified 120 seconds. Then, the expert will also perform a standard comprehensive TEE; the leading cause should also be presented to the attending anesthesiologists and recorders.
223712032|NCT02834039|PROCEDURE|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
223712033|NCT02834039|PROCEDURE|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
223712034|NCT06474702|DEVICE|'Fitbit charge 4' 'smart-watch'-|smartwatch device that collects physiological measures
223712035|NCT04594811|DRUG|NT-I7|Administered by intramuscular (IM) injection.
223712036|NCT04594811|DRUG|Nivolumab|Administered by intravenous (IV) injection.
223712037|NCT02653183|DEVICE|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
223712038|NCT02653183|DEVICE|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
223712039|NCT00108173|DRUG|Zyban|
223712040|NCT00919425|OTHER|biologic sample preservation procedure|
223712041|NCT01404858|BEHAVIORAL|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
223712042|NCT01646723|BEHAVIORAL|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
223712043|NCT00317005|DRUG|folate treatment|
223712044|NCT01170858|DRUG|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
223712045|NCT01170858|DRUG|glucose solutions|
223712046|NCT00399750|DRUG|oxaliplatin|
223712047|NCT00399750|DRUG|fluoropyrimidine|
223712048|NCT00399750|DRUG|bevacizumab|
223712049|NCT00939770|DRUG|Crizotinib|Given PO
223712050|NCT00939770|OTHER|Laboratory Biomarker Analysis|Correlative studies
223895249|NCT05260957|DRUG|Polatuzumab|"Induction Phase (Days -42 through -7): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Day -28.~Consolidation Phase (Days +1 through +90): 1.8mg/kg of Polatuzumab administered via intravenous (IV) infusion (given as per treatment guidelines) on Days +35, +56 and +77."
223712051|NCT00939770|OTHER|Pharmacological Study|Correlative studies
223712052|NCT00939770|OTHER|Questionnaire Administration|Ancillary studies
223712053|NCT03816384|DEVICE|Standard of Care|Standard of care urinary drainage system.
223712054|NCT03816384|DEVICE|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
223712055|NCT03816384|DEVICE|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
223712056|NCT03931161|DRUG|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
223712057|NCT03931161|DRUG|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
223712058|NCT03659500|DIAGNOSTIC_TEST|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
223712059|NCT03659500|DIAGNOSTIC_TEST|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
223712060|NCT00489138|DRUG|Ertapenem|1g a day by drip of 30 min
223712061|NCT03137537|DRUG|Ivabradine|lower heart rate in heart failure patients.
223712062|NCT03137537|DRUG|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
223712063|NCT00831025|BIOLOGICAL|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
223712064|NCT00831025|BIOLOGICAL|Placebo|Placebo for subcutaneous monthly administration
223712065|NCT05856071|DEVICE|goniometer|to measure the range of motion
223712066|NCT05856071|OTHER|clamshells exercises|clamshells exercises
223712067|NCT05856071|OTHER|traditional physical therapy|traditional physical therapy
224083300|NCT05689619|DIETARY_SUPPLEMENT|Silibinin|Silibinin 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
223895250|NCT05260957|BIOLOGICAL|CAR-T Cell Therapy|Participants will receive CAR-T Cell therapy via infusion on Day 0 (given as per treatment guidelines). Prior to CAR-T Cell Therapy, participants will begin receiving lymphodepleting chemotherapy on Days -5 through -3 (given as per treatment guidelines).
223895251|NCT04380558|OTHER|Pulmonary rehabilitation|"Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2)."
223895252|NCT03307343|BEHAVIORAL|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
223895253|NCT05564273|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may receive supplements, diet recommendations, and app coaching.
223895254|NCT05564273|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may receive supplements, diet recommendations, and app coaching.
223895255|NCT05088876|DRUG|Placebo|Blinded withdrawal of regular co-medication with paracetamol
223895256|NCT05088876|DRUG|Paracetamol|Paracetamol in the dose already used
223895257|NCT05385367|OTHER|Regional anesthetic|Patient having just the nerve block for surgery
223895258|NCT05385367|OTHER|General anesthetic|Patient having just general anesthetic ie. 'go completely under' for surgery
223895259|NCT05385367|OTHER|Combined general anesthetic and regional anesthetic|Patient having a combination of a nerve block and general anesthetic for surgery
223895260|NCT06636123|DRUG|Investigational Agent Administration|GZ17-6.02 will be taken orally with a high-fat meal at a fixed dose of 375 mg twice daily each day of a 28-day cycle, continuing until progression or intolerable toxicity
223895261|NCT05831566|DRUG|Budesonide/Formoterol fumarate dihydrate|"The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders."
223895262|NCT06636006|BEHAVIORAL|Aerobic Exercise|50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)
223895263|NCT06636006|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
223895264|NCT06261437|OTHER|CCAR|The CCAR will be consumed as the sole source of nutrition during a 7-day military training exercise.
224083301|NCT05689619|OTHER|Placebo|Placebo 1 g/day taken orally plus standard systemic therapy for NSCLC or BC
224083302|NCT05305807|OTHER|Postural exercises|Postural correction exercises are effective in improving forward head posture and it effectively decrease neck pain and increase ROM Exercise training and ergonomic guidelines concerning the use of touchscreen smartphones will reduce the risk of developing upper extremity musculoskeletal disorders
224083303|NCT04613726|DRUG|ondansetron|group consisted of receiving IV 8 mg ondansetron diluted in 10 ml of normal saline
224083304|NCT04613726|DRUG|Granisetron|Another comparator group consisted of receivingIV 3 mg granisetron diluted in 10 ml of normal saline
224083305|NCT04613726|DRUG|Saline|Control group consisted of patients receiving IV 10 ml normal saline
224083306|NCT02373761|DEVICE|Stryker Triathlon Tritanium primary knee|
224083307|NCT04853628|BEHAVIORAL|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).
223895265|NCT06261437|OTHER|FSR|The FSR will be consumed as the sole source of nutrition during a 7-day military training exercise.
223895266|NCT04630899|OTHER|Active joint mobilization|The participants bend his knees in a prone position. The physical therapist holds the medial malleolus with one hand and the lateral malleolus with the other. At the same time, the physical therapist touches the participant's soles to the sternum area and presses them in the dorsal direction. At this time, medial malleolus glides anterior and lateral malleolus glides posterior. The first procedure is to passively recognize movement. The second procedure is accompanied by active movement of the participant.
223895267|NCT04630899|OTHER|Passive joint mobilization|PJM uses Maitland's Mobilization method, grade III (high amplitude in the end range of the joint and 1 second vibration in the middle range through linear motion in which tissue resistance is felt). The participant is in a supine position, and the physical therapist holds the talus with one hand and the tibia with the other hand, and performs joint mobilization in the posterior direction with the hand holding the talus.
223895268|NCT05991882|BEHAVIORAL|Condition 1: Craving daily+PBS daily|Participants in this condition will complete ecological momentary assessment (EMA) for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
224083308|NCT04853628|BEHAVIORAL|Alerta Alcohol 2.0|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
223712068|NCT01211470|DRUG|Daptomycin|Active Comparator: Daptomycin.
223712069|NCT01211470|DRUG|PMX-30063-investigational drug|Experimental: PMX-30063
223712070|NCT03338010|DRUG|LY2963016|Administered SC
223712071|NCT03338010|DRUG|Lantus®|Administered SC
223712072|NCT01211730|DRUG|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
223712073|NCT01752361|DEVICE|Motilis-3D transit|
223712074|NCT01146665|BEHAVIORAL|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
223712075|NCT01146665|BEHAVIORAL|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
223712076|NCT01601730|DRUG|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
223712077|NCT01601730|DRUG|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
223712078|NCT01601730|DRUG|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
223712079|NCT01601730|DRUG|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
223712080|NCT03801343|DIETARY_SUPPLEMENT|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
223712081|NCT04211883|BEHAVIORAL|ACTIVE intervention|The Project ACTIVE intervention was adapted to suit workflow demands of our busy inner-city clinic: (1) identify patients who could most benefit from improvements in adherence to evidence-based preventive care, (2) use a validated mathematical model to quantify and rank the estimated amount of health benefit that would arise from improved adherence to each USPSTF preventive care guideline, (3) communicate this information in a manner informed by risk communication studies relevant to patients from disparate cultural groups and with low literacy and numeracy, (4) engage the patient in a shared decision making process in which the patient identified which preventive health goals aimed to achieve, and (5) set particular action steps for the next visit that were congruent with these goals .
223712082|NCT06062134|PROCEDURE|Pericapsular nerve group block|Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.
223712083|NCT06062134|DRUG|18 mL ropivacaine 0.5% + 2 mL radiopaque contrast|20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)
223712084|NCT01848730|DRUG|CNV2197944|
223712085|NCT01848730|DRUG|Placebo|
223712086|NCT05091359|DEVICE|Study group with absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate paste|Application of absorbable graft of tricalcium ß phosphate / calcium sulfate hemihydrate in paste for prevent loosening of Dynamic Hip Screw implant
223712087|NCT00816595|BIOLOGICAL|bevacizumab|Given IV
223712088|NCT00816595|BIOLOGICAL|pegfilgrastim|Given subcutaneously
223712089|NCT00816595|BIOLOGICAL|rituximab|Given IV
223712090|NCT00816595|DRUG|cyclophosphamide|Given IV
223712091|NCT00816595|DRUG|pentostatin|Given IV
223712092|NCT01631344|OTHER|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
223712093|NCT00293033|DRUG|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
223712094|NCT00293033|DRUG|Placebo|
223712095|NCT00036517|DRUG|PHY906|
223712096|NCT05494931|PROCEDURE|corneal neurotomy|Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
223712097|NCT06557655|DIETARY_SUPPLEMENT|caffeinate chewing gum|participants either chewed caffeinated gum (CAF) containing 3 mg/kg caffeine or a caffeine-free placebo gum (PLA) for 10 minutes prior to undertaking a series of tests on-ice and off-ice.
223712098|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations containing MLYAAT-1002®.|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the active comparator on the randomly assigned side of the split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 56 days.
223712099|NCT06188338|COMBINATION_PRODUCT|Fractional picosecond laser treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the fractional picosecond laser, followed by the first application of the placebo comparator on the randomly assigned side of the split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 56 days.
223712100|NCT04449601|OTHER|clinical assesment|Comparison of Hypertensive group and normotensive group
223895269|NCT05991882|BEHAVIORAL|Condition 2: Craving daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
223895270|NCT05991882|BEHAVIORAL|Condition 3: Craving trigger+PBS daily|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
223895271|NCT05991882|BEHAVIORAL|Condition 4: Craving trigger+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
223895272|NCT05991882|BEHAVIORAL|Condition 5: PBS daily+ PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
223895273|NCT05991882|BEHAVIORAL|Condition 6: Craving daily+Craving trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
223895274|NCT05991882|BEHAVIORAL|Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
223895275|NCT05991882|BEHAVIORAL|Condition 8: No daily or trigger craving or PBS|Participants in this condition will complete EMA for six weeks. Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting. Participants will not receive any further intervention strategies.
223895276|NCT05601596|DIAGNOSTIC_TEST|Analysis of menstrual blood to predict endometriosis|Menstrual blood from controls and symptomatic cases will be analyzed using single cell RNA-sequencing to develop a panel of biomarkers that can be developed into a screening test or diagnostic test for endometriosis.
223895277|NCT06365437|BIOLOGICAL|TCD601|Investigational Product
223895278|NCT06365437|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
223895279|NCT06365437|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
223895280|NCT06365437|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
223895281|NCT06365437|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
223895282|NCT06631391|BIOLOGICAL|umbilical cord blood NK cells|This is a phase I prospective clinical trial, including phase Ia and phase Ib. Phase Ia include 3 dose levels, utilizing a 3+3 design principle, and each dose level will enroll at least 3 subjects. The recommended dose for phase Ia was used in phase Ib. Each patient receives two courses of umbilical cord blood NK cell therapy (a total of 8 infusions of umbilical cord blood NK cells) and other therapy.
223895283|NCT06262932|DRUG|Amiodarone|Assess the effectiveness of repeated bolus dosing strategies of amiodarone.
223895284|NCT06609889|GENETIC|ION283|Anti-sense Oligonucleotide therapy that includes intrathecal (IT) injections by lumbar puncture (LP) with dose level of 15 mg.
223895285|NCT04979130|DRUG|Semaglutide|Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
223895286|NCT04979130|DRUG|Placebo|Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
223895287|NCT00144261|DRUG|nevirapine|
223895288|NCT04881032|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|Four intravenous injections of AGuIX will be delivered. Phase I : Three dose levels may be explored 50 mg/kg, 75 mg/kg and 100 mg/ kg. Phase II : recommended dose
223895289|NCT04881032|RADIATION|radiotherapy|60 Gy in 6 weeks
223895290|NCT04881032|DRUG|Temozolomide|"Concomitant chemotherapy consists of temozolomide (TMZ) at a dose of 75 mg per square meter per day, given 7 days per week from the first day of radiotherapy until the last day of radiotherapy.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
223895291|NCT04056520|DEVICE|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~* Traumatic spinal fractures and/or traumatic dislocations.~* Instability or deformity.~* Failed previous fusions (e.g. pseudarthrosis).~* Tumors involving the cervical spine.~* Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
223895292|NCT04893629|BIOLOGICAL|mono nuclear cells injection|trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group
223895293|NCT04893629|DRUG|Digoxin+furosemide+captopril|classical heart failure medical treatment
223895294|NCT05738148|DRUG|Vasopressin|"Vasopressin group Vasopressin will be via umbilical vein catheter (0.4 IU/kg per dose - first line) or alternatively via an endotracheal tube (8 IU/kg) every three to five minutes as needed with a maximum of two doses if there is no ROSC \[2,3\] After that, the clinical team must convert to give epinephrine (0.02 mg/kg per dose) as long as CPR is ongoing."
223895295|NCT05738148|DRUG|Epinephrine|"Epinephrine group Epinephrine will be administered according to current resuscitation guidelines either via umbilical vein catheter (0.02 mg/kg per dose) or via endotracheal tube (0.1 mg/kg) every three to five minutes as needed\[2,3\]. Chest compressions and epinephrine will be continued until ROSC."
223895296|NCT03847636|DEVICE|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
223895297|NCT04185298|BEHAVIORAL|mSIM intervention plus activity monitoring|Participants will receive the full mSIM intervention and be monitored (via Fitbit)
223895298|NCT04185298|BEHAVIORAL|Activity monitoring|Participants will have activity monitored (via Fitbit)
223895299|NCT01798498|DEVICE|Princess® VOLUME|
223895300|NCT03896789|OTHER|PEGASUS Program for Care|This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
223895301|NCT06360237|DRUG|Olezarsen|Olezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
223895302|NCT05495490|PROCEDURE|Osseodensification Internal Sinus Lift|"The osteotomy for the Osseodensification internal sinus lift begins with the advancement of a twist drill at 800 rpm and saline irrigation to within 1-2 mm of the sinus floor. The osteotomy is then widened by employing a series of osteotomy drills rotating at 800 rpm. Infracture of the sinus has occurred when the final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation (haptic feedback) occurs. After infracture, the graft material will be injected into the osteotomy site. Using the final osteotomy drill, the graft is guided apically. This procedure is repeated incrementally to raise the membrane. Once sufficient space has been created beneath the antral membrane, the implant will be inserted followed by suturing."
223895303|NCT05495490|PROCEDURE|Osteotome Internal Sinus Lift|"The osteotomy for the Osteotome internal sinus lift will begin with standard drills and saline irrigation to prepare the implant socket with a working length that is 1-2 mm shorter than the residual bone height as determined by radiographic examination. After preparation, a series of osteotomes of varying diameters will be sequentially utilized to widen the osteotomy and elevate the Schneiderian membrane by vertical tapping to create a greenstick fracture. The Valsalva maneuver (nasal blowing test) will be performed to determine the integrity of the Schneiderian membrane. During the osteotomy, the graft material will be injected and slowly placed into the elevated space using osteotomes until the desired depth is reached. Implant placement and suturing will conclude the procedure."
223895304|NCT03447470|DRUG|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.
223895305|NCT03447470|DRUG|Nivolumab|"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"
223895306|NCT06798870|DEVICE|removable appliances|removable appliances; clear aligner and removable inclined plane, for correcting anterior crossbite vin mixed dentition patient
223895307|NCT03993171|DRUG|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
223895308|NCT05389202|OTHER|Perfusion CT scanning|Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
223895309|NCT06283238|DRUG|Immune checkpoint inhibitor (ICI) or chemotherapy alone|Immune checkpoint inhibitor (i.e. pembrolizumab, nivolumab, or another checkpoint inhibitor) or chemotherapy alone
223895310|NCT05976672|OTHER|PRSS (Peer Recovery Support Specialist)|Upon receiving an alert through a study dashboard, the PRSS (who is blinded in not knowing whether the alert was caused by data anomaly or a random generation), the PRSS will be able to access identifiable contact details and contact the participant by phone and provide the necessary support assistance (e.g., locations of AA/NA meetings, sleep and/or relaxation techniques, etc).
223895311|NCT06147726|OTHER|Upper extremity position matching exercises in virtual reality|In addition to conventional treatment approaches for 20 minutes 2 days a week for 8 weeks, joint positioning exercises (4 different game sequences of 4 minutes, 1 minute rest between each sequence, total 20 minutes) designed specifically for the individual's existing range of motion will be applied to the VR group.
223895312|NCT06147726|OTHER|Conventional physiotherapy|proprioceptive neuromuscular facilitation techniques, parkinson-specific upper extremity and balance and gait exercises
223895313|NCT06806462|GENETIC|Biomolecular profile of bone metastases|Describe the biomolecular profile of bone metastases
223895314|NCT05901246|DIETARY_SUPPLEMENT|PS-containing dietary supplement|Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day)
223895315|NCT05901246|OTHER|Placebo|Sachet containing the excipients of the ingredient (2,25 g placebo/day)
223895316|NCT06806605|OTHER|3d analisys|To analyze the orthodontic-surgical set-up carried out as part of the normal care pathway of patients operated since January 2015 and who completed treatment on May 30, 2020 in the Orthodontic First patient.
223895317|NCT06528145|OTHER|Evalation|Post Covid Functional Scale (PCFS) was used to assess the functional status of the participants; Short Form- 36 (SF-36) questionnaire was used to assess quality of life; 30 s sit-to-stand test (30s-STS) and 6 min walk test (6 MWT) were used to assess functional capacity.
223895318|NCT02405858|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
223895319|NCT02405858|DRUG|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
223895320|NCT06821334|BIOLOGICAL|MK-6194|Subcutaneous Administration
223895321|NCT06821334|BIOLOGICAL|Placebo|Subcutaneous administration
224276354|NCT05352438|OTHER|Splint Therapy Group|"Patient education directed at parafunctional behaviors was given, and an exercise program was taught, with all the patients instructed to perform these exercises at home. The home exercise program included diaphragmatic breathing exercises, chin-tuck exercises, mandibular resistance exercises, and neck muscle stretching exercises. The patients were instructed to perform the exercises as 3 sets of 10 repetitions per day.~In addition to the patient education and home exercises, the Splint Therapy group was given a static occlusal splint, and adjustments were made as necessary. All the patients in this group were instructed to use the splint when sleeping for a period of one month."
223895322|NCT05000684|DRUG|JS004 in combination with toripalimab|Usage and dosage: 200mg of JS004 combined with 240mg of JS001 is given every 3 weeks
223895323|NCT06137963|OTHER|Transform10 Diabetes Prevention Program|"The Transform10 app includes a Centers for Disease Control (CDC)-approved diabetes prevention program.~The self-paced curriculum and optional video content covers:~* Strategies to overcome emotional eating using cognitive behavioral therapy principles.~* Improving cardiovascular function with capacity-matched training programs using participants' estimated cardio scores.~* An introductory-level course for increasing muscle and bone density foundation via strength training.~* Education regarding physical therapy and expectations for patients.~The Transform10 app also provides access to lifestyle coaches who discuss evidence-based information regarding hunger and insulin, macronutrient strategies, time-restricted intermittent fasting, and inflammation."
223895324|NCT06807567|OTHER|Receipt of healthcare for long-term conditions|The patient participants are people who are already receiving healthcare for CKD and/or hypertension, diabetes, HIV, heart failure and/or stroke at one of the named study sites, for at least 6 months prior to recruitment into this qualitative study. The caregiver participants are caregivers for patients meeting these criteria.
223895325|NCT06807567|OTHER|Provision of healthcare|The healthcare worker participants are all providing care to patients with long-tem conditions, at one of the names study sites
223895326|NCT06807567|OTHER|Policy making|The policy makers recruited to this study will be individuals involved in policy making for long-term conditions in Malawi
223895327|NCT03382652|DEVICE|Metal-on-Metal Articulation|\<Metal-on-Metal Articulation\>: Metasul® Taper Liner and Metasul Femoral Head, \<Acetabular Component\>:Continuum Acetabular Shell, \<Femoral Component\>: Zimmer® M/L Taper Hip Stem
223895328|NCT06141187|PROCEDURE|Vertebroplasty|PVP
223895329|NCT06141187|PROCEDURE|Sham Vertebroplasty|Sham PVP
223895330|NCT04810650|OTHER|Mobility Dynamic Treatment Intervention|"1\) Access to a mobility coordinator who will assist with transfers, rescheduling, and out-of-facility refills; 2) Provision of a travel pack with alternative ART packaging options (e.g. ziplock bags, envelopes, pill boxes), a packing list and mobility coordinator phone contact for unplanned travel; 3) Screening at every clinic visit for planned mobility; 4) Mobile number and mobile minutes for unexpected travel; 5) Provision of longer refills (up to 6-months) for planned travel"
223895331|NCT04810650|OTHER|Health Living Intervention for Heavy Alcohol Users|1\) Two in-person alcohol counseling sessions with support from a clinical psychologist; 2) Monthly booster phone calls
223895332|NCT04810650|OTHER|Hypertension Linkage|1\) Travel voucher (financial incentive) conditional on linkage to hypertensive care; 2) Phone call reminders for missed visits
223895333|NCT04810650|OTHER|PrEP/PEP at Outpatient Clinics|Intervention delivered at Outpatient Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
223895334|NCT04810650|OTHER|PrEP/PEP at Antenatal Clinics|Intervention delivered at Antenatal Clinics: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
223895335|NCT04810650|OTHER|PrEP/PEP at Community Households|Intervention delivered in community by village health team: Counseling and education on and choice between prevention modalities (e.g. PrEP, PEP, condoms), choice of service location, provision of a clinical officer's or nurse's mobile telephone number for immediate PEP starts any day of the week, routine assessment of barriers to initiation or adherence to PrEP/PEP, including the offer of personalized potential solutions such as choice of in-clinic or offsite service delivery, psychologic supports for traumatic experiences, and offer of concurrent, additional health or prevention related services
223895336|NCT04810650|OTHER|Standard of Care|Local country standard of care protocols
223895337|NCT04810650|OTHER|Hypertension Community|Hypertension care delivered at home with clinician telehealth, facilitated by lay health worker to measure blood pressure and deliver medications
223895338|NCT06357013|PROCEDURE|Bilateral Suprainguinal fascia iliaca compartment block|Suprainguinal fascia iliaca compartment block (S-FICB) is one of the commonly used regional analgesia techniques for postoperative analgesia in lower extremity surgeries.
223895339|NCT06357013|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia is applied to the posterior part of the knee, including the periosteum, ligaments, muscle and/or skin area before closing the surgical field.
223895340|NCT05794243|DRUG|LY3493269|Administered orally.
223895341|NCT05794243|DRUG|Sodium Caprate (C10)|Administered orally.
223895342|NCT05794243|DRUG|Salcaprozate Sodium (SNAC)|Administered orally.
223895343|NCT06688448|DEVICE|Dafodil prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
224276355|NCT02262559|DRUG|BIBR 277 tablet|
224276356|NCT02262559|DRUG|BIBR 277 capsule|
223712101|NCT05378178|DRUG|HS-10381|Each subject will receive a single dose(C0) of HS-10381 and then repeat doses(C1, C2…) for 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
223712102|NCT03158025|DRUG|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
223712103|NCT03158025|DRUG|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
223712104|NCT03158025|DRUG|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
223712105|NCT03158025|DRUG|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
223712106|NCT03158025|DRUG|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
223712107|NCT03158025|DRUG|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
223712108|NCT01586065|DEVICE|Continuous Glucose Monitor (CGM)|CGM during 24-hr CRC stay.
223712109|NCT06426810|DEVICE|Electrosurgical bipolar system (LigaSure)|Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
223712110|NCT03503175|DEVICE|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
223712111|NCT03503175|DEVICE|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
223712112|NCT01122771|DRUG|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
223712113|NCT01122771|DRUG|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
223712114|NCT01122771|DRUG|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
223712115|NCT01122771|DRUG|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
223712116|NCT06270810|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on the treadmill at 40-60% of the participants' heart rate reserves. Each aerobic exercise session will last for 40 minutes. All participants will be monitored with a heart rate monitor throughout the exercise sessions. During the first three-week, participants will exercise on the treadmill at intensities between 40-50%, and between fourth and eighth weeks, 50-60% of their heart rate reserves. Participants will wear an accelerometer on their non-dominant wrist during the intervention to monitor the physical activity and sedentary behavior data. At the same time, these participants will be asked not to change their routine diet during the intervention period.
223712117|NCT06270810|BEHAVIORAL|Increasing non-Exercise Physical Activity|Participants who will carry out this intervention will increase their non-exercise physical activities. Before intervention period, participants will receive face-to-face training to increase their non-exercise physical activities. This training will generally consist of recommendations based on the study which effectively reduced sedentary behavior (SB) with non-exercise physical activities (Sarah Kozey-Keadle et al. 2012). A one-on-one interview will be held with each participant every week to learn about strategies by which the volunteers successfully increased their non-exercise physical activities in the previous week, and the difficulties or barriers they encountered. New strategies to overcome these difficulties and barriers will be discussed and suggestions will be made. Participants will wear an accelerometer on their non-dominant wrist to monitor the physical activity and SB data, and will be asked not to change their routine diet during the intervention period.
223712118|NCT05250882|OTHER|Enhanced perioperative care protocol|See arm/group description
223712119|NCT01577108|DIETARY_SUPPLEMENT|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
223712120|NCT01577108|DIETARY_SUPPLEMENT|Placebo|oral taking 2 capsules before sleeping per day for 14 days
223712121|NCT00365508|DRUG|nicotine lozenge|nicotine lozenge
223712122|NCT00365508|DRUG|nicotine patch|transdermal nicotine patch
223712123|NCT02753114|DRUG|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
223712124|NCT02753114|DRUG|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
223712125|NCT00783237|DRUG|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
223712126|NCT00783237|DRUG|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
223712127|NCT04301037|PROCEDURE|Tension band wires|medial malleolus fracture fixed with tension band wiring): 2 k.wires (1.6 mm) are inserted perpendicular to the fracture site. Again the position is checked under image intensification for the correct direction and length. We drilled a 2.5mm hole with a protection sleeve, 2-3cm above the level of the horizontal joint line, aiming the drill bit slightly inferiorly to avoid screw pullout. We inserted a 3.5mm unicortical screw about 30 mm in length (with or without washer), 2-3mm is left for the wire between the bone and screw head before full tightening. A steel wire is constructed into a figure of eight between the screw the reduction k. wires, then twisted to achieve interfragmentary compression
223712128|NCT04301037|PROCEDURE|Cannulated screws|In group 2 (15 patients with medial malleolus fixed by 2 cannulated screws): Two guide wires (1.6mm) are inserted perpendicular to the fracture site, the appropriate length, proper insertion site including the distance from the articular surface is checked fluoroscopically .the length is measured .drilling of the bone through the threaded guide wire with a cannulated drill bit (3.2mm). A two 4.5mm partially threaded cannulated screws (with or two washers) are inserted through the guide to achieve Compression, the guide wires are then removed
223712129|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
223712130|NCT00751933|BIOLOGICAL|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
224276357|NCT05794087|OTHER|Clean Air|Subjects will be exposed to clean air for 3 hours.
224276358|NCT05794087|OTHER|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
224276359|NCT02150356|OTHER|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
224276360|NCT02150356|OTHER|Control|Diet based on refined cereal products for a period of 8 weeks.
224276361|NCT03860337|DIETARY_SUPPLEMENT|Alginate Sausage|Alginate sausage
224276362|NCT03860337|OTHER|Control Sausage|Control Sausage
224276363|NCT02654015|DEVICE|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
223712131|NCT00751933|DIETARY_SUPPLEMENT|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
223712132|NCT00751933|OTHER|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
223712133|NCT04600557|BEHAVIORAL|Describing a shameful experience using a self-compassionate prompt|Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
223712134|NCT04600557|BEHAVIORAL|Receiving compassionate responses from confederates|Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
223712135|NCT04600557|BEHAVIORAL|Describing a shameful experience using a neutral prompt|Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
223712136|NCT04600557|BEHAVIORAL|Receiving no response from confederates|Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
223712137|NCT04939116|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule
223712138|NCT04939116|DRUG|Placebo|Orally administered placebo capsule
223712139|NCT02450591|DRUG|Erlotinib|
223712140|NCT02450591|OTHER|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
223712141|NCT01044875|PROCEDURE|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
223712142|NCT02623023|DRUG|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
223712143|NCT02623023|OTHER|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
223712144|NCT04782661|DRUG|JNJ-70075200|JNJ-70075200 solution or solid formulations will be administered orally.
223712145|NCT04782661|DRUG|Placebo|Placebo solution will be administered orally.
223712146|NCT04219007|DRUG|Vosoritide|After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
223712147|NCT05658120|DRUG|noradrenaline/adrenaline|norepinephrine adrenaline in patients with Swan-Ganz catheter monitoring during liver transplantation
223712148|NCT05884996|OTHER|PNF training|Resistance training with elastic bands in diagonals of PNF
223712149|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
223712150|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
223712151|NCT05510375|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
223712152|NCT05510375|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
223712153|NCT02211079|DRUG|JNJ-54861911|JNJ-54861911, 50 mg (2\*25 mg tablets) orally once daily from Day 2 to Day 9.
223712154|NCT02211079|DRUG|Caffeine|Single oral dose of caffeine 100 mg (2\*50 mg tablets), on Day 1, 2, and 9.
223712155|NCT02211079|DRUG|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
223712156|NCT02211079|DRUG|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
223712157|NCT05248867|DRUG|Placebo|Placebo solution for injection
223712158|NCT05248867|DRUG|AGN-151586|AGN-151586 solution for injection
223712159|NCT02562534|DEVICE|MRI compatible ElectroCardioGraph|MRI with ECG control for people with healthy heart or heart diseases
223712160|NCT01482845|DRUG|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
223712161|NCT01482845|DRUG|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
223712162|NCT03245515|DRUG|BMS-986195|specified dose on specified days
223712163|NCT04753983|DIAGNOSTIC_TEST|Functional magnetic resonance imaging (fMRI)|Diagnostic imaging measuring the metabolic changes that occur within the brain used for measuring and mapping brain activity
223712164|NCT05309408|DIAGNOSTIC_TEST|Venipuncture|Venipuncture
223712165|NCT05309408|DIAGNOSTIC_TEST|Lumbar Puncture|Lumbar Puncture
223712166|NCT02369432|DRUG|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
223712167|NCT00002554|DRUG|busulfan|
223712168|NCT00002554|DRUG|cyclophosphamide|
223712169|NCT00002554|DRUG|methotrexate|
223712170|NCT00002554|PROCEDURE|allogeneic bone marrow transplantation|
223712171|NCT00002554|RADIATION|radioimmunotherapy|
223719019|NCT00901316|PROCEDURE|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
223895344|NCT06688448|DEVICE|Aortic Valve Replacement - Inspires Resilia prosthesis|Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
223712172|NCT01960400|DEVICE|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
223712173|NCT01960400|DEVICE|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
223712174|NCT03928353|DRUG|PB2452 Infusion|30 minute - 24 hour infusion
223712175|NCT03928353|DRUG|Placebo - Sodium Chloride|30 minute - 24 hour infusion
223712176|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
223712177|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
223712178|NCT03928353|DRUG|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
223712179|NCT03928353|DRUG|PB2452 Infusion|30 minute - 16 hour infusion
223712180|NCT03928353|DRUG|Placebo - Sodium Chloride|Placebo - Sodium Chloride
223712181|NCT02695225|BEHAVIORAL|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
223712182|NCT02695225|BEHAVIORAL|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
223712183|NCT05866406|BEHAVIORAL|Time restricted eating|Participants assigned to the TRE group will have to consume all their daily meals and snacks during a 9-hour window for 12 weeks.
223712184|NCT05866406|BEHAVIORAL|Extended eating window|Participants assigned to the control group will have to consume all their daily meals and snacks during a 14-hour window for 12 weeks.
223712185|NCT05866406|BEHAVIORAL|Healthy diet|Participants will be provided nutrition education and counselling to follow a diet consistent with the existing guidelines for chronic disease prevention.
223712186|NCT05262608|DRUG|Olaparib|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily
223712187|NCT02236975|DEVICE|BuMA Supreme Biodegradable drug coating coronary stent system|
223712188|NCT02236975|DEVICE|Resolute Integrity durable polymer stent system|
223712189|NCT02106260|DRUG|CLS003|
223712190|NCT03321266|DEVICE|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
223712191|NCT00743483|DRUG|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
223712192|NCT04375371|PROCEDURE|Bariatric surgery|Obese patients who haveundergone bariatric surgery as part of routine clinical management within the indication of this intervention.
223712193|NCT01881360|OTHER|Gluten-free diet|A diet that is free of the gluten component
223712194|NCT01881360|OTHER|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
223712195|NCT05875363|OTHER|collect data|"The Juvenile Affairs Division provided the records without person-identifiable data (i.e., name, ID) to the researchers. The researchers coded the above data (i.e., the offenders' sociodemographic data, medical history, and criminal history).~Demographic characteristics were collected, which are the offenders' age, gender, occupation, education level, and residence (district). We recorded the offenders' household members (without the name or age), main caregivers (e.g., father, or mother), and the parents' socioeconomic and marital status. We also tracked whether the offenders live with family members with mental illness, whether they are from at-risk families, and whether had been victims of domestic violence. The medical history and deviant (or criminal) behaviors will be collected in the attached measure."
223712196|NCT02914119|DRUG|Rocuronium|
223712197|NCT02914119|DRUG|Succinylcholine|
223712198|NCT02914119|DRUG|Cisatracurium|
223712199|NCT02914119|DRUG|Mivacurium|
223712200|NCT02914119|DEVICE|Objective neuromuscular monitoring (acceleromyography)|
223712201|NCT02914119|DRUG|Sugammadex|
223712202|NCT02914119|DRUG|Neostigmine|
223712203|NCT04573712|OTHER|Follow up and Assessment|each patient should wear an actigraph during a week and will be do some tests during 2hours (6min walk, apathy inventory, fatigue severity scale etc...)
223895345|NCT03099499|DRUG|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
223895346|NCT03942419|DRUG|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered with a microdose dispenser
223895347|NCT03942419|DRUG|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered with a microdose dispenser
223895348|NCT03942419|DRUG|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered with a microdose dispenser
223895349|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
223895350|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 100mcg
223895351|NCT04985760|BIOLOGICAL|Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Investigational vaccine composed of Trimer 4571 500mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent
223895352|NCT04985760|BIOLOGICAL|Placebo control for Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant|Volume matched control for Trimer 4571 vaccine 500mcg
223895353|NCT04600960|DRUG|Eltrombopag|The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.
223895354|NCT05328687|DIAGNOSTIC_TEST|Shear wave elastography|or measuring the muscle stiffness, we use a linear 9 MHz ultrasound probe (9L) and the Logic E9 scanner, both from GE Healthcare (Chalfont St Giles, UK). All measurements are performed with the probe parallel to the muscle fibers. We will measure the stiffness of the trapezius muscle in the middle botulinum toxin A injection side (G1) according to the PREEMPT protocol. All data are saved as images by the observer and subsequently analyzed by a blinded observer.
223895355|NCT05729945|BEHAVIORAL|home visiting|The intervention is a three year program that serves families and their first born children through home visiting using paraprofessionals to deliver a hybrid curriculum using the Partners for a Healthy Baby curriculum developed by Florida State University in January 2015.
223895356|NCT01093547|PROCEDURE|Blood samples|Samples taken monthly
223895357|NCT01093547|PROCEDURE|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
223895358|NCT02369770|DEVICE|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
223895359|NCT05965440|DRUG|impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients|Analysis of microbiota
223895360|NCT04987723|OTHER|Holter monitoring|Assessment of HRV shall be performed in all enrolled patients. Ventricular HRV will be derived from a continuous 24-hour period of a 48-hour ambulatory Holter recording during AF. Participants will be requested to avoid alcohol and caffeine from 24-hours prior to fitting and any activity more strenuous than walking for the recording duration. After initial fitting, a 20-minute high-resolution ECG recording will be performed lying supine at rest.
223895361|NCT04987723|OTHER|stress echocardiography|Echocardiography will be performed using a GE Vivid 9 echocardiography machine (Vingmed-General Electric, Horten, Norway) equipped with a phased-array 3.5 MHz transducer. All measurements will be made according to the guidelines set by the British Society of Echocardiography.
223895362|NCT04987723|OTHER|Cardiac MRI|Contraindications to MRI will be excluded using the appropriate departmental screening forms. A trained scanner operator or radiographer will co-ordinate and supervise the scan. Cardiac MRI will be performed at 1.5T (Aera, Siemens Healthineers, Erlangen, Germany) with a protocol consisting of cine imaging, stress and rest perfusion, and late gadolinium enhancement (LGE).
223895363|NCT04987723|OTHER|Patient questionnaires|Two validated Health Related Quality of Life (HRQoL) surveys designed for patients with AF will be used; the AF Effect on Quality of Life (AFEQT) and Barts AF Patient reported objective measure (PROM).
223895364|NCT06803199|DRUG|FSH and LH|In the study group, participants receive FSH and LH in IVF cycle
223895365|NCT06803199|DRUG|FSH|In the control group, participants receive FSH alone in IVF cycle
223895366|NCT06800443|OTHER|Silica-based fluoride toothpaste containing clay, charcoal, blue covarine and green covarine|Silica-based toothpaste containing charcoal, clay, blue covarine, green covarine and fluoride as sodium fluoride
223895367|NCT06800443|OTHER|Silica-based fluoride toothpaste with blue covarine|Silica-based toothpaste containing lower level of blue covarine and fluoride as sodium monofluorophosphate
223895368|NCT06800443|OTHER|Silica-based fluoride toothpaste with blue covarine|Silica-based toothpaste containing higher level blue covarine and fluoride as sodium monofluorophosphate
223895369|NCT06800443|OTHER|Control silica-based fluoride toothpaste|Control silica-based toothpaste containing fluoride as sodium fluoride
224083309|NCT00687791|DEVICE|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
224276364|NCT02654015|OTHER|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
224276365|NCT03077009|DRUG|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
224276366|NCT02846233|DRUG|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
224276367|NCT02846233|DRUG|basal insulin|The participant will continue with the basal insulin.
224276368|NCT02846233|DRUG|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
223719020|NCT02805010|DRUG|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
223719021|NCT02805010|OTHER|Placebo|On Day 1, subjects will receive a single SC dose of placebo
223719022|NCT00052481|PROCEDURE|quality-of-life assessment|
223719023|NCT05820178|DEVICE|tDCS|On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
223719024|NCT05820178|DEVICE|rTMS|On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
223719025|NCT02197130|DRUG|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
223719026|NCT02197130|DRUG|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
223719027|NCT02197130|OTHER|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
223719028|NCT06055010|OTHER|No interventions|Considering the retrospective nature of this project and use of existing clinical and technical data, this project contains no interventions or prospective inclusion of healthy subjects / patients for the execution of experiments.
223719029|NCT04812145|RADIATION|Chemoradiation|Hypofractionated radiotherapy with concurrent Gemcitabine
223719030|NCT01072331|DRUG|MP-513|MP-513 10 mg, once a day, for 4 weeks
223719031|NCT01072331|DRUG|MP-513|MP-513 20 mg, once a day, for 4 weeks
223719032|NCT01072331|DRUG|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
223719033|NCT02320669|DRUG|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
223719034|NCT02320669|DRUG|Placebo|Bolus of Placebo followed by infusion for 48 hours
223719035|NCT04257981|DEVICE|Brain stimulator v3.0|Brain stimulator v3.0 will be used to deliver 1.5 mA current over the scalp corresponding to the primary motor cortex. The current will be delivered via two surface electrodes 5 × 5 cm placed on the scalp, validated by the previous research
223719036|NCT04257981|OTHER|Sham Comparator: Control group|The sham set-up will follow a similar protocol as the experimental group but the intensity of the current will be ceased after 30 seconds of stimulation. Participants in the Sham group will feel the identical sensation as the experimental group and will be unable to differentiate between actual and sham tDCS such procedure is validated in earlier studies
223719037|NCT00607009|BEHAVIORAL|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
223719038|NCT04948710|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
223719039|NCT02937883|OTHER|Empowerment intervention|Empowerment intervention for persons with young onset dementia
223719040|NCT00637338|BIOLOGICAL|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
223719041|NCT00637338|BIOLOGICAL|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
223719042|NCT05466656|OTHER|Continuous quality improvement cycle model|The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
223719043|NCT04584151|PROCEDURE|regional analgesia|Insertion of bilateral ESP catheters
223719044|NCT03153969|DEVICE|SHOFU Beautifil II LS|Placed under manufacturer's instructions
223719045|NCT03153969|DEVICE|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
223719046|NCT01737697|DRUG|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
223719047|NCT01737697|DRUG|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
223719048|NCT01737697|DRUG|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
223719049|NCT01737697|DRUG|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
223719050|NCT05038436|DEVICE|Polyglucosamine L112|Two tablets once daily per os
223719051|NCT04367428|BIOLOGICAL|Administration of probiotics|Patients will receive the previously mentioned combination of probiotics before and after surgery
223719052|NCT03338998|DRUG|BAF312 solution|Solution for intravenous (IV) infusion - 4.5mg/4.5mL
223719053|NCT03338998|DRUG|Matching Placebo for BAF312 solution|Solution for intravenous (IV) infusion - 0mg/4.5mL matching placebo
223719054|NCT03338998|DRUG|BAF312 tablet|2 mg film-coated tablet
223719055|NCT03338998|DRUG|Matching Placebo for BAF312 tablet|0 mg film-coated tablet matching placebo
223719056|NCT01372462|DEVICE|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
223719057|NCT01372462|DEVICE|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
223719058|NCT01372462|DEVICE|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
223719059|NCT00653120|DRUG|Propranolol|ER capsules, 160 mg, single-dose
223719060|NCT00653120|DRUG|Inderal-LA|ER capsules, 160 mg, single-dose
223719061|NCT03288129|DRUG|Perampanel|film-coated tablets
223719062|NCT00386438|PROCEDURE|Honan balloon application|
223895370|NCT06801327|DEVICE|Simeox|The Investigators chose to evaluate this device for respiratory physiotherapy in our patients because it is the only one that offers innovative technology, as, unlike other commercially available devices, it does not require the patient to perform forced breathing. Instead, the patient can exhale calmly at tidal volume. This is expected to reduce the patient's effort and improve compliance with treatment. Furthermore, the vibratory signal with small, rapid, and sequential depressions within the airways could be more effective in mobilizing mucus from the airways, preventing collapse.
223895371|NCT06802120|OTHER|osteopathy real|treatment with real osteopathy 2 times a week for 8 weeks
223895372|NCT06802120|OTHER|sham osteopathy|treatment with sham osteopathy 2 times a week for 8 weeks
223895373|NCT05390918|BEHAVIORAL|TAILOR|"The first TAILOR session will assess existing sleep problems from both the adolescent's and parent/legal guardian's perspectives, concluding with offering a CBT strategy to try. Session 2 will involve getting feedback from the family on that specific strategy and then offering additional CBT strategies. The remaining sessions will be devoted to refining the use of CBT strategies. MI will be integrated as the communication style throughout, including reflective listening, rolling with resistance, and showing deference to the family's ultimate decisions. The interventionist will also use the elicit-provide-elicit approach from MI. The interventionist will elicit the family's own ideas for improving the adolescent's sleep, ask for permission to provide his/her own suggestions, and then gauge the family's reactions to those suggestions, versus simply recommending a CBT strategy and problem-solving barriers to implementation."
223895374|NCT05390918|OTHER|Enhanced Usual Care|The study clinician will conduct suicide risk screening and further assessment and safety planning where deemed necessary.
223895375|NCT06803459|OTHER|Baduanjin|36 times.
223895376|NCT06803459|OTHER|PNF|36 times.
223895377|NCT06803875|BIOLOGICAL|Autologous hALK.CAR T cells|Autologous chimeric antigen receptor T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor
223895378|NCT06802796|DIAGNOSTIC_TEST|Plasma NGAL test|Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.
223895379|NCT06208527|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of 2000 mg NR is administered daily for 1 year.
223895380|NCT06208527|OTHER|Placebo|Placebo tablet identical in taste, shape and appearance to NR tablets.
223895381|NCT06082804|OTHER|APN and medical management|Patients are followed by the advanced practice nurse and the hematologist.
223895382|NCT06082804|OTHER|Medical management|Patients are followed by the hematologist only (standard of care).
223895383|NCT06082804|BEHAVIORAL|Quality of life assessment|EORTC-QLQ-C30 questionnaire
223895384|NCT06082804|BEHAVIORAL|Treatment compliance assessment|GIRERD questionnaire
223895385|NCT05261282|BEHAVIORAL|Mindful Hand Hygiene|Physicians and nurses randomized to the intervention arm will receive mindfulness education and tools to prompt mindfulness during hand hygiene.
223895386|NCT05828680|OTHER|Observation|No intervention
223895387|NCT00216840|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
223895388|NCT06306612|DRUG|Systemic Chemohormonal Therapy|Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
223895389|NCT06306612|DRUG|Systemic Hormonal Therapy|Under continuous ADT, oral darolutamide 600mg twice per day
223895390|NCT06306612|PROCEDURE|Cytoreductive Prostatectomy|Cytoreductive prostatectomy was performed after six cycles of neoadjuvant systemic chemohormonal therapy.
223895391|NCT06306612|PROCEDURE|Postoperative Adjuvant Radiotherapy|Postoperative adjuvant radiotherapy of prostate bed is performed, if margin positive, with conventional segmentation and the dose of 64-72Gy.
223895392|NCT04788511|DRUG|Semaglutide|"Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~Dose gradually escalated from 0.25 mg until target dose. The study will last for approximately 59 weeks."
224276369|NCT02846233|DRUG|Metformin|The participant will continue with metformin.
224276370|NCT01776528|BIOLOGICAL|NGM282|
223895393|NCT04788511|DRUG|Placebo (semaglutide)|"Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks."
223895394|NCT04529577|DEVICE|His-bundle pacing|"A standard pacing electrode (Medtronic 4076) will be placed in RV apex (or RV septum as a secondary option) and in the right atrial appendage (if indicated).~A dedicated His-bundle pacemaker electrode (Medtronic 3830) will be placed in the region of His bundle, using a dedicated introducer sheath (Medtronic C304 or Medtronic C315). His-bundle potentials will be identified and His-bundle capture (non-selective or selective) will be ascertained using an electrophysiology recording system. Device programming will focus on providing physiological atrioventricular delay and safety RV pacing as backup."
223895395|NCT05918263|BEHAVIORAL|High-Intensity Interval Training Exercise Program|Home-based, virtually supervised, aerobic exercise program of 48 sessions accessible via internet-enabled tablet (provided to participant if needed). Participants will be supplied with stationary bike, heart rate monitor, and blood pressure monitor.
223895396|NCT03737734|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223895397|NCT05828459|DRUG|OT-A201|OT-A201 IV infusion qw or q2w
224276371|NCT01776528|BIOLOGICAL|Placebo|
224276372|NCT04055545|OTHER|HIIT|"* 5 min. warm up~* 10 × 60 seconds burst~* 60 seconds recovery after each burst~* Burst phase: HRR \>90%~* Recovery phase: HRR btw. 30-39%~* 5 min. cool down"
224276373|NCT04055545|OTHER|MICT|"* 5 min. warm up~* 20 min. continuous cycling: HRR btw. 40% - 59%~* 5 min. cool down"
224276374|NCT00047047|DRUG|gemcitabine hydrochloride|Given IV
224276375|NCT00047047|DRUG|tanespimycin|Given IV
224276376|NCT00047047|DRUG|cisplatin|Given IV
224276377|NCT00047047|OTHER|laboratory biomarker analysis|Correlative studies
224276378|NCT03082651|OTHER|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
223712204|NCT00873912|BIOLOGICAL|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10\^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
223712205|NCT00873912|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
223712206|NCT02085122|OTHER|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
223712207|NCT04649320|OTHER|questionnaire|"1. 13-item questionnaire about cancer patient's distress and everyday life,~2. EORTC-QLQ-C30"
223712208|NCT02276001|DRUG|K-877|
223712209|NCT02276001|DRUG|Cyclosporine|
223712210|NCT01466153|DRUG|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
223712211|NCT01466153|DRUG|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
223712212|NCT01466153|DRUG|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
223712213|NCT00713856|PROCEDURE|Custom PRK with iris registration|PRK
223712214|NCT00713856|PROCEDURE|Conventional PRK|PRK
223712215|NCT03105791|OTHER|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
223712216|NCT05827380|BEHAVIORAL|Gait adaptability training|During a period of approximately 5 weeks participants will receive 10 one hour training sessions aimed at improving gait adaptability, using the C-mill (an instrumented treadmill with augmented reality). Several aspects of gait adaptability, such as obstacle avoidance, accelerating/decelerating and precision stepping, will be offered.
223712217|NCT03708016|DEVICE|Robot gait training|Lokomat robot training was applied to stroke patients.
223712218|NCT03708016|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
223712219|NCT03144960|PROCEDURE|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
223712220|NCT05250778|BEHAVIORAL|Nudge|Room intervention
223712221|NCT01213329|DRUG|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
223712222|NCT06504680|PROCEDURE|Repair of flexor tendon injury zone ll using 8- strand|Repair cut flexor zone ll using 8-strand with and without splinting the wrist
223712223|NCT01684956|PROCEDURE|Intradermal injection|
223712224|NCT01684956|PROCEDURE|Subcutaneous injection|
223712225|NCT00150748|DRUG|Levetiracetam 166 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use"
224276379|NCT03082651|OTHER|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
224276380|NCT03082651|OTHER|Constant training|Runners will be assigned identical training sessions over a 7-day period.
223712226|NCT00150748|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use"
223712227|NCT00150748|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use"
223712228|NCT04138238|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
223712229|NCT03483740|BEHAVIORAL|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
223712230|NCT03483740|BEHAVIORAL|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
223712231|NCT05774678|RADIATION|Group 1 (preoperative radiation hypofractionated)|radiation schedules/regimens before your scheduled breast surgery
223712232|NCT05774678|OTHER|Group 2 (preoperative radiation conventionally fractionated)|radiation schedules/regimens before your scheduled breast surgery
223712233|NCT05497609|OTHER|no intervention. Care as ususal|No intervention
223712234|NCT04859361|DRUG|Aldara 5% Topical Cream|5% Imiquimod cream (1 sachet) will be administered via menstrual cup, before going to sleep, 3 times per week for 16 weeks. Menstrual cup will be inserted in the vagina for a duration of 6-8 hours. In case of severe side effects applications can be reduced to twice per week and if side effects are persistent, to once per week. For maximum control of cervical disease, control colposcopy with a PAP smear and a punch biopsy will be scheduled at 10 weeks to rule out progression, and at 20 weeks after treatment initiation to evaluate treatment success. At 20 weeks, biopsies will be performed at the locations where lesions were previously present, and if there are any new lesions present, additional biopsies will be performed. In case of disease progression or persistence, treatment with LLETZ will be offered.
223719063|NCT03129178|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
224083310|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
223895398|NCT05828459|DRUG|IMids|Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
223895399|NCT05828459|DRUG|Bevacizumab|Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
223895400|NCT05828459|DRUG|Paclitaxel|Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
223895401|NCT05828459|DRUG|TBD Compound|Combination regimen for hematological malignancy
223895402|NCT04250116|DRUG|NOAC monotherapy|Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
223895403|NCT04250116|DRUG|Dual antithrombotic therapy with NOAC and clopidogrel|Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
223895404|NCT06645483|OTHER|ChatGPT-assisted instruction|"ChatGPT will interactively support students by answering questions, initiating discussions, and providing customized learning materials in line with the course objectives. It will be supervised by the instructor to ensure guidance and prevent misinformation.~Duration: ChatGPT-assisted learning for the first two weeks, followed by traditional teaching for the next two weeks."
223895405|NCT06645483|OTHER|Traditional lecture-based instruction|"Students will learn through a traditional teaching format, where the instructor delivers the course content through lectures and presentations.~Duration: Traditional teaching for the first two weeks, followed by ChatGPT-assisted learning for the next two weeks."
223895406|NCT05185947|DRUG|Paclitaxel|Paclitaxel: Intraperitoneal (IP) paclitaxel will be dosed at 60 mg/m2 to be infused over 1 hour on Day 1 of each 3-week cycle; participants with unresectable, but stable or responding disease after C1 through C3 will dose increase IP paclitaxel to 80 mg/m2 for Cycles 4-6. Intravenous (IV) paclitaxel will be infused over 1 hour on Day 2 of the first week of Cycle 1, followed by Day 1 of the subsequent treatment weeks; IV paclitaxel will be dosed at 60 mg/m2 for Week 1 of Cycle 1 and, if tolerated, at 80 mg/m2 for subsequent treatments.
223895407|NCT05185947|DRUG|Nilotinib|Oral nilotinib will be dosed at 300 mg twice daily. Nilotinib will be administered continually from the loading dose (Day -4) leading up to laparoscopy #2 onward.
223895408|NCT06153810|DEVICE|Biofeedback stimulation|Delivery of the vibratory biofeedback stimulus
223895409|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
223895410|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
223895411|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
223895412|NCT06510062|DEVICE|Sustained Acoustic Medicine|The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity delivering 18,720 Joules of ultrasound per 4 hour treatment.
223895413|NCT06510062|DRUG|2.5% Diclofenac Patches|Topical pain relief gel worn via SAM patch.
224276381|NCT03082651|OTHER|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
224276382|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
223895414|NCT04837248|OTHER|Active Comparator: Group 1. Conventional treatment|"Patients will be treated using a physiotherapy programme without digital support. A written document with exercises and recommendations will be given to them on the first day. This booklet will detail the exercises they can do depending on their surgery and the weeks elapsed, as well as the recommendations adapted according to the needs identified in the motivational interview (MI). This is the treatment that is currently being applied in the hospital.~The patient will carry out the treatment at home and will come back after 20 sessions for the corresponding assessment."
224276383|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
223895415|NCT04837248|OTHER|Experimental: Group 2. Experimental treatment.|"A digitally supported physiotherapy programme including:~* Group session: expectations, interests, experiences with regard to their health problem and the consequences on their life, joint exercise and discussion with subsequent debate will be held.~* Exercise session: each week, patients will find different exercise videos on the platform according to the phase of recovery in which each one of them is, having been previously evaluated in the group session.~* Relaxation session: this will be carried out by means of audio that will be posted on the platform and that the patient will be able to perform simultaneously.~* Empowerment session: audio sessions that will deal with those needs that frequently arise after breast surgery in their daily lives, focusing on limiting beliefs (e.g. fear of moving), positive thoughts and information extracted from the motivational interview that should be developed."
223895416|NCT05682157|OTHER|Paula Method of muscle exercises|12 weekly sessions of Paula Method of exercise
224276384|NCT03655977|DRUG|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
223895417|NCT03637660|DRUG|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
224083311|NCT03625440|DIAGNOSTIC_TEST|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
224276385|NCT03655977|DEVICE|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
224276386|NCT04330547|DRUG|Analgesic administration|"* Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)"
223895418|NCT05733910|RADIATION|simultaneous integrated boost of carbon ions radiation therapy|"CIRT Treatment will be delivered in 16 fractions, 4 fractions per week. Treatment plans will be calculated with a Simultaneous Integrated Boost Approach (SIB).~The HR-CTV will receive a total dose of 65.6 GyRBE (4.1 GyRBE/fraction). The LR-CTV will simultaneously receive a total dose of 54.4 GyRBE (3.4 GyRBE/fraction) or 48 GyRBE (3 GyRBE/fraction) at discretion of Radiation Oncologist depending on the prognostic factors (54.4 GyRBE in case of macroscopical perineural invasion or positive margin along the nerve, 48.0 Gy(RBE) in case of elective perineural irradiation or microscopic focal intratumor perineural invasion)."
223895419|NCT05304481|BIOLOGICAL|ATL administration|Subjects have ATL administration using intravenous infusion
223895420|NCT06333041|DRUG|Epidiolex|Epidiolex (cannabidiol) oral solution is a clear, colorless to yellow liquid containing cannabidiol at a concentration of 100 mg/mL. Inactive ingredients include dehydrated alcohol (7.9% w/v), sesame seed oil, strawberry flavor, and sucralose.
223895421|NCT06333041|DRUG|Placebo|Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
223895422|NCT04929951|BIOLOGICAL|Micro Fragmented Adipose Tissue|Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
223895423|NCT04929951|BIOLOGICAL|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
223895424|NCT05846867|DRUG|AK119|AK119 IV every 2 weeks.intravenous infusion
223895425|NCT05846867|DRUG|AK112|AK112 IV every 2 weeks.intravenous infusion
223895426|NCT05846867|DRUG|Oxaliplatin|Oxaliplatin: 85mg/m2, intravenous infusion
223895427|NCT05846867|DRUG|Irinotecan|Irinotecan 180mg/m2, intravenous infusion
223895428|NCT05846867|DRUG|Calcium folinate|Calcium folinate: 400mg/m2, intravenous infusion
223895429|NCT05846867|DRUG|Fluorouracil|Fluorouracil 400mg/m2, intravenous injection
223895430|NCT05948306|OTHER|Critical Patient-Centered Skin Care Protocol|"A patient-centered skin care protocol prepared by the researchers in accordance with the Stetler Model will be applied to the experimental group.~Sub-titles of this protocol; evaluation of risk factors, examination of the skin from head to toe, skin hygiene, examining the effects of critical illness on the skin, mobilization and re-positioning, incontinence management, maintaining nutrition, and using a support surface. For each sub-heading, application items regarding patient demands and suggestions will be added."
223895431|NCT04652700|DRUG|ISL|ISL 60 mg tablet, QM, orally for up to 24 months
224276387|NCT04330547|DRUG|Placebo administration|Folavit (folic acid, 0.4 mg)
224276388|NCT00358631|DRUG|SSR149415|
224276389|NCT01817686|OTHER|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
223528209|NCT06670417|OTHER|Buerger Allen exercise|Procedure-Keep the Buerger Allen exercise board on the cot. Elevate the lower extremities to an angle of 45 to 90 degree with the help of exercise board. Provided support to the lower extremities to maintain the position. Make the subject to maintain the same position in the same manner until the skin blanches (appears dead white). Lower the feet and the legs below the level of the rest of the body until redness appears (care should be taken that there is no pressure against the back of the knees). Place the legs flat on the bed for a few minutes. Ask the subjects to sit in a relaxed position while each foot is flexed and extended then inverted and everted for 3 minutes till the feet turns entirely pink. Ask the subject to rotate the feet in all the direction. Make the subject to lie quietly for 5 minutes, keeping legs warm with a blanket
223895432|NCT04652700|DRUG|FTC/TDF|Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
223895433|NCT04652700|DRUG|FTC/TAF|Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
223895434|NCT04652700|DRUG|Placebo to ISL|Placebo ISL 0 mg tablets QM, orally for up to 24 months.
223895435|NCT04652700|DRUG|Placebo to FTC/TDF|Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
223895436|NCT04652700|DRUG|Placebo to FTC/TAF|Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
223895437|NCT04507568|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be administered to both arms at baseline, and at the first and last day of treatment.
223895438|NCT05955066|DRUG|Baricitinib 4 MG|1 capsule (4mg) daily for 24 weeks
223895439|NCT05955066|DRUG|Placebo|1 capsule daily
223895440|NCT04187833|DRUG|Nivolumab|480mg intravenously every 4 weeks (28 days)
223895441|NCT04187833|DRUG|Talazoparib|1mg orally daily
223895442|NCT06067139|OTHER|SHUTi|"Each core includes a variety of interactive features, such as animations, vignettes, myth and reality buttons that reveal common misperceptions and facts about sleep, learn more buttons that provide in-depth information about a topic, and quizzes. All cores follow a similar structure with objectives, main content, homework, and review. Participants are free to revisit cores as many times as they like."
224083312|NCT01987908|DRUG|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
224276390|NCT01817686|OTHER|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
223528210|NCT06670417|OTHER|Regular wound care|Regular wound care and dressing to the wound and ulcer
223528211|NCT06221449|PROCEDURE|Positive end expiratory pressure|"The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O."
223528212|NCT06541197|OTHER|Robotic rehabilitation combined with Functional Electrical Stimulation (FES) bicycle ergometry group|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks. For FES bicycle ergometry, a current-controlled six-channel stimulator (RT 300-SLSA; Restorative Therapies, Baltimore, MD, USA) will be used. The quadriceps, hamstring and tibialis anterior muscles will be stimulated bilaterally with six channels through 3 × 4 cm2 adhesive surface electrodes. Stimulation intensity will be adjusted according to palpable muscle contraction and sensory discomfort felt by patients with incomplete SCI. The pedaling cadence range will be set to 40-50 rotations per minute. FES bicycle ergometry will be performed in 30-minute sessions for 4 weeks for a total of 20 sessions before robotic rehabilitation.
223528213|NCT06541197|OTHER|Robotic rehabilitation|Robotic rehabilitation will be applied in 30-minute sessions with Lokomat v5 (Hocoma, Volketswil, Switzerland) device for lower extremity rehabilitation. Robotic assisted walking exercise will be performed in the walking exercise robot for a total of 20 sessions for 4 weeks.
223528214|NCT06672341|DIAGNOSTIC_TEST|Endometrial Cytology Testing|Endometrial Cytology Examination Liquid-based endometrial cytology is an emerging minimally invasive screening technique. This method involves collecting endometrial cells and tissues from the uterus and its downstream anatomical structures. The samples are preserved and analyzed using either liquid-based cytology techniques or tissue smear methods to reach a pathological diagnosis. Compared to invasive procedures such as fractional curettage, liquid-based cytology offers advantages in the screening of endometrial cancer, including being minimally invasive, convenient, and low-risk.
223528215|NCT06672341|DIAGNOSTIC_TEST|Cervical Methylation Testing|Cervical Cell Methylation Testing Cervical cell methylation testing is another promising method for methylation-based screening of endometrial cancer. This approach targets specific genes that undergo methylation in the early stages of endometrial cancer. The combined methylation analysis of four genes (CD01, BHLHE22, ACTB, and SEPTIN9) uses menstrual blood or vaginal secretions as samples, offering advantages such as safety, non-invasiveness, and self-collection. This method has shown high sensitivity and specificity for the early detection of endometrial cancer. Ongoing research suggests that the sensitivity and specificity of cervical cell methylation testing can reach 93.2% and 96%, respectively, although this data is yet to be published.
223528216|NCT06674746|BEHAVIORAL|SOLUTION FOCUSED APPROACH|The interviews with the control group were planned as eight sessions. There will be defined time intervals between sessions. It is estimated to take 6 months.
223528217|NCT06673875|PROCEDURE|conservative treatment of stress urinary incontinence - pelvic floor muscle training|evaluation of pelvic floor muscle rehabilitation to change the clinical severity of urinary incontinence
223528218|NCT06673875|DEVICE|vaginal device Aniball INCO|"the firt group - the pelvic floor muscle training with vaginal device Aniball INCO according manual after education by the urogynecologist, who is educated in pelvic floor dysfunction.~the second group - the pelvic floor muscle training without vaginal device, the education was performed by certified physiotherapist trained in pelvic floor disorder."
223528219|NCT06997926|PROCEDURE|blood sampling|Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected
223528220|NCT06999278|DRUG|Levothyroxin|Levothyroxin 50ug/d from randomization until delivery
223528221|NCT06999278|DRUG|Placebo|Placebo to levothyroxin
223528222|NCT07004439|DEVICE|RefluxStop™ implantation|Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
223528223|NCT07004335|DRUG|Iparomlimab and Tuvonralimab Injection plus Bevacizumab|The experimental group will receive intravenous infusion of anti PD-1/CTLA-4 (Iparomlimab/Tuvonralimab) Injection (5 mg/kg) and Bevacizumab (dose 7.5mg/kg) once every 3 weeks up to 35 cycles (105 weeks).
223528224|NCT07004153|DEVICE|Smart Coaching Insulin Pen|Subjects randomized to the intervention group will use the DIA:CONN P8 smart insulin pen with full functionality, including Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. During the 12-week application period, including the baseline visit, participants will visit the hospital up to 5 times. At the start of the period, initial basal and bolus doses will be determined using the Setup Wizard and reviewed by investigators. Throughout the study, subjects will receive real-time insulin dose recommendations and coaching via the DIA:CONN app based on CGM data, carbohydrate input, and insulin dosing history.
223528225|NCT06998277|OTHER|Dietary therapy|"Participants with quiescent UC will undergo a 10-day observational period followed by 15-days of the UC-TREAT dietary intervention. Disease activity, quality of life, and gastrointestinal symptoms will be assessed throughout"
223528226|NCT06998277|OTHER|Dietary therapy|"Healthy participants will undergo a 10-day observational period, followed by 15-days of the UC-TREAT dietary intervention. Gastrointestinal symptoms will be assessed throughout."
223895443|NCT06067139|OTHER|Patient Education|The PE website will present content in a simple, static form, without interactive components; and all content on the website will be provided at once, rather than in modules that unlock over time. The PE website will also not provide personalized or individually tailored treatment recommendations.
223895444|NCT06579599|OTHER|an integrated working group nursing|(1) Establishment of an integrated team in the operating room; (2) Development of a nursing plan; (3) Nursing safety training and reflection in the operating room; (4) Designate a person to manage instruments and equipment in the operating room and establish protocols (5) Nurses should also participate in the development of the patient's individualized surgical plan communicate with the surgeon about the preparation of items needed for surgery to ensure seamless coordination. Assist anesthesiologists and surgeons and oversee the implementation of aseptic procedures.
223895445|NCT05603143|DRUG|Obeldesivir|Tablets administered orally without regard to food.
223895446|NCT05603143|DRUG|Obeldesivir Placebo|Placebo tablets administered orally without regard to food.
223895447|NCT04209465|DRUG|BDTX-189|Participants received a daily, oral dose of BDTX-189 as part of a 3 week cycle.
223895448|NCT03097549|DEVICE|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
223895449|NCT03097549|DEVICE|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
223895450|NCT05783102|BEHAVIORAL|Knowledge and Interpersonal Skills to Develop Exemplary Relationships|During this 9-week psychoeducational intervention, participants will complete eight weekly, self-paced lessons that include a short video vignette, written text, a reading quiz, and a reflection exercise. Topics include understanding a dementia diagnosis, communicating with a person you care for about challenging topics, finding a balance between safety concerns and independence, and more. Each lesson takes an estimated 1 hour to complete. Independent KINDER lessons can be completed using a printed or digital copy of the KINDER Workbook. In addition, participants will be asked to participate in three, 1.5-hour group discussion sessions with other caregivers and a facilitator. These sessions will take place over Zoom video conference.
223895451|NCT04759794|DIAGNOSTIC_TEST|Cytology staining|"Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~1. conventional cytology staining method~2. new cytology staining method using the antibody of aminoacyl-tRNA synthetases"
223895452|NCT04148560|OTHER|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
223895453|NCT03041805|PROCEDURE|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
223895454|NCT03041805|PROCEDURE|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
223895455|NCT03041805|PROCEDURE|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
223895456|NCT03041805|PROCEDURE|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
223895457|NCT03041805|PROCEDURE|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
224276391|NCT01817686|OTHER|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
223895458|NCT03041805|PROCEDURE|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
223895459|NCT03041805|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
223895460|NCT03041805|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
223895461|NCT06381700|OTHER|MySmile app|"The MySmile app contains several features:~A) Knowledge Hub~1. Do You Know section: This section consists of seven (7) topics where users can learn about oral health knowledge.~2. Quiz time section: In this section, school children can play games and challenge themselves.~B) Track yourself Brushing diary Diet diary~C) Get help~1. Ask an expert~2. Find your dentist~3. Friendly reminders"
223895462|NCT06381700|OTHER|Control|"This will receive the usual School Dental Service.~School Dental Service provide students who need dental treatment and will be called to be given treatment. Among the treatments given include:~* Dental filling~* Full mouth scaling~* Dental extraction~* Preventive treatment, such as topical fluoride application~All treatment is free of charge except for dentures, crown/bridge work and orthodontics. Treatment for school children is based on normative needs assessment as determined by the dentist. A child is defined as orally fit when all required treatment in the SDS has been completed and appropriate oral hygiene status is maintained."
223895463|NCT05492318|DRUG|Givinostat 10 mg/mL|10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.
224083313|NCT01987908|OTHER|Placebo|
223895464|NCT05492318|DRUG|Midazolam 1mg/ml IV|Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
224276392|NCT03853369|DRUG|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
224276393|NCT06073847|DRUG|Fedratinib|According to the approved label
223712235|NCT04859361|PROCEDURE|LLETZ|LLETZ will be performed in an outpatient setting with local anesthesia, using KLS Martin Maxium with loop devices ranging from 10 mm to 20 mm in size. The excision will be performed using monopolar current with a cut frequency set to 100-150 W. Treatment success will be evaluated in accordance with our national guidelines 24 weeks after the procedure using a PAP smear with or without a punch biopsy.
223712236|NCT05433493|BEHAVIORAL|Cognitive stimulation|"The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant."
223712237|NCT03145974|DEVICE|mechanical ventilation|ventilatory support
223712238|NCT06180772|BEHAVIORAL|FIT FIRST|High intensity sports drills and games
223712239|NCT01088997|DRUG|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
223712240|NCT02383498|OTHER|Placebo|Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
223712241|NCT02383498|BIOLOGICAL|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
223712242|NCT02383498|RADIATION|Radiotherapy|Standard of care
223712243|NCT02383498|DEVICE|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
223712244|NCT04676074|DEVICE|Electronic Upper limb( body) ergometer|Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
223712245|NCT03859505|DEVICE|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
223712246|NCT03859505|DEVICE|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
223712247|NCT03225885|OTHER|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
223712248|NCT03225885|OTHER|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
223712249|NCT05871645|PROCEDURE|Jakarta Surgical Uterine Conservation (JSICA) Technique|a. Identifying the placenta accrete site; b. Meticulous dissection to create a bladder flap; c. Incision 1 cm above the placenta accrete; d. Fetal delivery; e. Bottom incision to resect the placenta; f. Placental delivery; g. Uterus without placenta; h. The resection area is approximated using interrupted horizontal mattress suture; i. The continuous suture used to close all incision areas; j. Evaluation of uterine contraction
223712250|NCT05871645|PROCEDURE|Standard Hysterectomy|The main types of hysterectomy are abdominal, vaginal, and laparoscopic hysterectomy
223712251|NCT04137705|OTHER|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen, heart, lungs and aorta
223712252|NCT03913312|BIOLOGICAL|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6
223712253|NCT06337877|PROCEDURE|Depth of sedation monitoring|In the study, group rates of patient state index (PSI) \[(below 25); (25-50); (51-75); (above 75)\] will be determined within a 24-hour timeframe in patients undergoing therapeutic paralysis. The concordance between PSI rates\* determined at baseline (time zero) and Richmond Agitation-Sedation Scale (RASS) \[(between -4 and -5); (between -3 and -2); (equal to or greater than -1)\] rates will be assessed. Suppression rate (SR) and electromyography (EMG) values will be obtained from patients, and significant differences among PSI groups \[(below 25); (25-50); (51-75); (above 75)\] in terms of these data will be examined. Additionally, changes in Propofol (mg/hour), Midazolam (mg/hour), Fentanyl (mg/hour), and Rocuronium (mg/hour) values will be analyzed for each time interval.
224276394|NCT01489605|DEVICE|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
224276395|NCT01489605|DEVICE|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
224276396|NCT05317195|OTHER|NP-1|NP-1; 8.4 mg nicotine; pH 8.0; moisture 30
224276397|NCT05317195|OTHER|NP-2|NP-2; 8.4 mg nicotine; pH 9.0; moisture 30
223712254|NCT04280133|BEHAVIORAL|Educational Video Tool|The video educational tool was written by the investigators in collaboration with a panel of experts on CAR T-cell therapy, medical ethicists, palliative care clinicians, and oncologists.
223712255|NCT03261973|DEVICE|DV8|DV8 esophageal deviation tool
223712256|NCT01006174|OTHER|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
223712257|NCT01006174|OTHER|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
223712258|NCT01006174|OTHER|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
224276398|NCT05317195|OTHER|NP-3|NP-3; 3.6 mg nicotine; pH 8.0; moisture 15
224276399|NCT05317195|OTHER|NP-4|NP-4; 3.6 mg nicotine; pH 8.0; moisture 30
224276400|NCT05317195|OTHER|Velo-NP|Velo-NP; 10 mg nicotine;
224276401|NCT05317195|OTHER|Zyn-NP|Zyn-NP; 3 mg nicotine;
224276402|NCT05327712|BEHAVIORAL|Control group|No outreach during the intervention period beyond an initial eligibility notice.
224276403|NCT05327712|BEHAVIORAL|Email only|Email reminders in addition to an initial eligibility notice.
224276404|NCT05327712|BEHAVIORAL|Phone only|Phone call offering enrollment assistance in addition to an initial eligibility notice.
224276405|NCT05327712|BEHAVIORAL|Phone and email|Phone call and email reminders in addition to an initial eligibility notice.
224276406|NCT00166452|DRUG|Lenalidamide|
223528227|NCT07005375|BEHAVIORAL|thermal mineral water bath|One group will bathe in a pool filled with 36°C thermal mineral water of the Palatinus Spa for 3 weeks, 5 days a week, for a total of 15 sessions, 20 minutes per session. Bathing in the thermal mineral water takes place in the medicinal water pool. The control group does not receive balneotherapy. Both groups can continue their usual training plan.
223528228|NCT06673784|DIAGNOSTIC_TEST|ophthalmic saline eye drops|for optical examination
223528229|NCT06673784|DRUG|Saline|Most one natural and not effects on study
223528230|NCT06675734|DRUG|diclofenac sodium solution|The experimental group consisted of patients in whom diclofenac sodium was administered IM and the control group consisted of patients in whom diclofenac sodium was administered orally only.
223528231|NCT07002905|DRUG|ASC30 tablets or ASC30 tablets A1 or placebo|Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily
223528232|NCT05317858|DEVICE|Blood Brain Barrier Opening - Oncology|BBB opening via Exablate Type 2 system with microbubble resonators on the day of ICI infusion to treat brain metastases.
223528233|NCT05317858|DRUG|Pembrolizumab|Pembrolizumab infusion
223528234|NCT05317858|DRUG|Atezolizumab|Atezolizumab infusion
223528235|NCT05317858|DRUG|Cemiplimab|Cemiplimab infusion
223528236|NCT05317858|DRUG|Nivolumab|Nivolumab infusion
223528237|NCT05317858|DRUG|Iptilimumab|Iptilimumab infusion
223528238|NCT04255563|DEVICE|DCB treatment|DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
223528239|NCT03274466|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
223528240|NCT03274466|DEVICE|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
223528241|NCT04070846|DRUG|[14C] LC350189|Carbon-14 labelded LC350189
223528242|NCT00174629|DRUG|Docetaxel/DDP|
223528243|NCT00174629|DRUG|docetaxel/gemcitabine|
223528244|NCT01564329|DRUG|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
223528245|NCT00618787|DEVICE|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
223528246|NCT00618787|DEVICE|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
223528247|NCT03334955|PROCEDURE|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
223528248|NCT02337556|OTHER|Peptamen Bariatric|Commercially available enteral diet
223712259|NCT05695209|BEHAVIORAL|Coaching and Decision Aid|Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents
223712260|NCT06976853|DRUG|Tirzepatide|Addition of tirzepatide to current biological therapy
223712261|NCT06976853|DRUG|Standard of care treatment|Intervention will be to change patient's current therapy to a 3rd or later advanced biologic patient have never been exposed to
223712262|NCT06387459|DEVICE|Fabric-Type Knee Extensor Muscle-Mimicking Orthosis|The intervention device is a fabric-based orthosis incorporating shape-memory alloy springs designed to mimic the action of knee extensor muscles. The primary function of this orthosis is to provide supplementary support to the knee joint during walking, aiming to stabilize the gait of elderly individuals affected by muscle weakness or degenerative joint conditions. Material: The orthosis is made from a lightweight, flexible fabric that allows for breathability and comfort during extended wear. Mechanism: Embedded within the fabric are shape- memory alloy springs that function similarly to biological muscles.
223712263|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single dose orally
223712264|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
224276407|NCT02343965|OTHER|Touch-massage|
224276408|NCT00096239|DRUG|CP-547,632|
224276409|NCT03858127|OTHER|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
224276410|NCT03858127|OTHER|Examination of genitalia|Examination of genitalia
224276411|NCT03858127|OTHER|Video messaging|Short video of infant recorded at home by the parents
223895465|NCT05492318|DRUG|Midazolam 2.5 mg oromucosal solution|"Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration.~Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose.~Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose."
223895466|NCT05492318|DRUG|Dabigatran etexilate 75 mg oral hard capsules|"Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration.~Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose."
223895467|NCT01892137|DRUG|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
223895468|NCT05008835|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
223895469|NCT05008835|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
223895470|NCT05008835|DRUG|Placebo|Placebo
223895471|NCT04171999|OTHER|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
223895472|NCT05048056|DRUG|Placebo|Placebo subcutaneous injection every 2 weeks for 16 weeks then Crossover to AK120 Regimen 1
223895473|NCT05048056|DRUG|AK120|AK120 Regimen 1- subcutaneous injection every 2 weeks.
223895474|NCT05048056|DRUG|AK120|AK120 Regimen 2- subcutaneous injection every 2 weeks
223895475|NCT03973853|BEHAVIORAL|Virtual reality driving stimulation program|This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
223895476|NCT03973853|BEHAVIORAL|TAU|This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
223895477|NCT06269978|PROCEDURE|Biopsy|Undergo biopsy
223895478|NCT06269978|PROCEDURE|Biospecimen Collection|Undergo collection of blood and IP fluid samples
223895479|NCT06269978|PROCEDURE|Computed Tomography|Undergo CT
223895480|NCT06269978|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
223895481|NCT06269978|DRUG|Fluorouracil|Given via IP infusion
223895482|NCT06269978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223895483|NCT06269978|DRUG|Oxaliplatin|Given via IP infusion
223895484|NCT06269978|PROCEDURE|Surgical Procedure|Undergo placement of indwelling IP port
223895485|NCT04079686|DRUG|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
223895486|NCT04079686|OTHER|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
223895487|NCT04505904|DRUG|Syntocinon|Synthetic oxytocin spray, 24 IU per spray.
223895488|NCT04505904|DRUG|Placebo|Placebo spray with no active ingredient.
223895489|NCT03629990|BEHAVIORAL|Approach Bias Modification (ABM)|Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
223895490|NCT03629990|BEHAVIORAL|Sham ABM|"Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention."
223895491|NCT03629990|BEHAVIORAL|Psychosocial therapy for cannabis use disorder.|All participants will receive psychosocial therapy for cannabis use disorder.
223528249|NCT02337556|OTHER|Replete|Commercially available enteral diet
223528250|NCT01096251|BEHAVIORAL|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
223528251|NCT06301113|DIETARY_SUPPLEMENT|CBD infused candy|300 Nano mg CBD Candy cherry flavor
223895492|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
224276412|NCT06616727|DRUG|SNC109|SNC-109 CAR-T Cells, first dose from 5×104 CAR+ T Cells, treatment follows the operation and the next dose would be deiced by SRC
224276413|NCT01676129|PROCEDURE|Nocipoint Therapy|
224276414|NCT01676129|PROCEDURE|Physical Therapy|
224276415|NCT05038891|DIAGNOSTIC_TEST|Digital Cervical Exam|Standard Digital Cervical Exam by an experienced OB provider
223712265|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
223712266|NCT05263895|DRUG|PF-07321332/ritonavir|PF-07321332 ritonavir will be administered as single oral dose orally.
223712267|NCT05263895|DRUG|PF-07321332|PF-07321332 will be administered as single oral dose orally.
223712268|NCT07001826|PROCEDURE|Virtual Surgical Planning (VSP) with Patient-Specific Plates (PSPs)|Patients will undergo orthognathic surgery using Virtual Surgical Planning (VSP) combined with custom-fabricated Patient-Specific Plates (PSPs). High-resolution CT scans will be used to create 3D models of each patient's craniofacial structure. Surgical plans will be developed using specialized CAD software, and PSPs will be designed and manufactured using 3D printing and milling techniques. During surgery, these custom plates and accompanying cutting guides will be used to accurately reposition the maxilla, ensuring precise correction of maxillary cant. This approach aims to improve surgical accuracy, reduce operating time, and enhance postoperative outcomes.
223712269|NCT06677021|BEHAVIORAL|Exercise|Physical activity promotion and engagement
223895493|NCT04419779|DEVICE|Duodenal Mucosal Resurfacing (Sham)|The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
223895494|NCT04277442|DRUG|Decitabine|Given IV
223895495|NCT04277442|BIOLOGICAL|Nivolumab|Given IV
223895496|NCT04277442|DRUG|Venetoclax|Given PO
223895497|NCT04118660|OTHER|Tissue Banking|Blood, tissue, and fluid collection
223895498|NCT03544281|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as an infusion.
223895499|NCT03544281|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg,orally, with belantamab mafodotin and dexamethasone.
223895500|NCT03544281|DRUG|Dexamethasone|Dexamethasone will be administered as 20 or 40 mg, orally with belantamab mafodotin.
224276416|NCT05038891|DIAGNOSTIC_TEST|Transperineal Ultrasound|Self-administered transperineal ultrasound after instruction by a health care professional
223528252|NCT06301113|DIETARY_SUPPLEMENT|Sugar free Candy|Raspberry flavored sugar free candy
223528253|NCT04514835|DRUG|Cisplatin+Capecitabine+Sintilimab|"The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months."
223528254|NCT01107886|DRUG|Saxagliptin|5 mg or 2.5 mg once daily
223528255|NCT01107886|DRUG|Placebo|
223528256|NCT05512338|OTHER|Treatment|ACT-informed interventions combined with standard physiotherapy methods.
223528257|NCT05512338|OTHER|Active control group|Standard physiotherapy methods.
223528258|NCT03761550|COMBINATION_PRODUCT|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
223528259|NCT04392076|PROCEDURE|Image Guided Ablation|Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer
223528260|NCT02007460|BEHAVIORAL|Exercise|multidirectional unilateral hopping exercise
223528261|NCT03027596|PROCEDURE|Remote ischemic conditioning|
223528262|NCT03772925|DRUG|Belinostat|Given IV
223528263|NCT03772925|DRUG|Pevonedistat|Given IV
223712270|NCT07004777|OTHER|Isocaloric diet including chia and pumpkin seeds|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates the intake of pumpkin and chia seeds."
223895501|NCT03544281|DRUG|Bortezomib|Bortezomib will be administered as 1.3 mg/m\^2, as SC or IV, with belantamab mafodotin and dexamethasone.
223895502|NCT04008355|DRUG|AZP2006 oral solution|Once daily intake in the morning
223895503|NCT04008355|DRUG|Placebo oral solution|Once daily intake in the morning
224276417|NCT05038891|DIAGNOSTIC_TEST|Transvaginal Ultrasound|Self-administered transvaginal ultrasound after instruction by a health care professional
224276418|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
224276419|NCT03259789|DRUG|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
224276420|NCT03259789|DRUG|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
224276421|NCT02546050|DRUG|Metformin|
224276422|NCT01879631|PROCEDURE|radial keratotomy|
224276423|NCT01071031|BIOLOGICAL|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
223528264|NCT06896903|DIAGNOSTIC_TEST|Coronary reactivity testing with and without nitrates|CRT will be performed in the left and right coronary arteries. Measurements will be obtained in each of the coronaries first without intracoronary nitrates followed by a dose of 200-500 mcg of intracoronary nitrates and repeat measurements.
223528265|NCT06835959|BEHAVIORAL|Moms@Home|Participants will use a storytelling mobile health app for daily home-based blood pressure monitoring and symptom/medication adherence tracking.
223528266|NCT06835959|BEHAVIORAL|Enhanced Standard of Care|Participants will use a paper journal daily to track home-based blood pressure values
223712271|NCT07004777|DIETARY_SUPPLEMENT|Isocaloric diet plus fish oil|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates EPA + DHA supplement (fish oil) to the diet."
223712272|NCT07004777|OTHER|Isocaloric diet including salmon|"Diet based on participant-specific energy expenditure. With the following macronutrient distribution: 50% carbohydrates, protein 20% and 30% fats.~This dietary intervention consists of a four-week follow-up period and incorporates the intake of salmon."
224276424|NCT01071031|BIOLOGICAL|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
224276425|NCT01071031|BIOLOGICAL|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
224276426|NCT04972331|PROCEDURE|Arthroscopic Partial Meniscectomy|"Arthroscopic partial meniscectomy was performed by three senior surgeons using two standard portals, no outflow cannula, a 5.5-mm 30° arthroscope, and a pressure-controlled irrigation system.~A standard surgical protocol was used to document possible findings in the cartilage, ligaments, synovium, and medial and lateral meniscus. In each case, surgery was limited to resection with limited debridement of the articular surface lesion, preserving as much of the meniscus as possible. Patients who underwent additional procedures, such as removal of loose bodies or subchondral drilling for any articular lesions, were excluded from this study (Figure 1). No patients underwent total meniscectomy or meniscal repair."
223895504|NCT05922176|OTHER|Evaluation of clinical indicators, Sample collection before& after immunotherapy|"A. Evaluation of clinical indicators before immunotherapy~1. Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~2. American house dust mite-specific immunogloblin G4 (sIgG4)~3. American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'"
223528267|NCT03272932|OTHER|No intervention|No intervention
223528268|NCT05301764|COMBINATION_PRODUCT|LVGN6051 and Anlotinib|"LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week."
223528269|NCT06089317|DRUG|TCM ultrasonic atomization treatment with herbal Compound Decoction (CD)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the CD group is TCM compound decoction.~The prescription of atomization solution in the CD group contains Honeysuckle flower (金銀花) 5g, Chrysanthemum flower (菊花) 5g, Pale betterflybush flower (密蒙花) 5g, Mild mint herb (薄荷) 5g, Barbary wolfberry fruit (枸杞子) 10g, and Ophiopogon japonicus (麥冬) 5g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
223528270|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Dendrobii Caulis (DC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the DC group is Dendrobii Caulis extracts.~The prescription of the DC group contains Dendrobium (石斛) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
223528271|NCT06089317|DRUG|TCM ultrasonic atomization treatment with Houttuynia Cordata (HC)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the HC group is Heartleaf Houttuynia Herb extracts.~The prescription of the HC group contains Heartleaf Houttuynia Herb(魚腥草) 35g.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
223528272|NCT06089317|DRUG|Placebo TCM ultrasonic atomization treatment (PA)|"The subjects will receive TCM ultrasonic atomization treatment with the ultrasonic nebulizer (WH-2000, YueHua, China) 6 days a week, once daily, 10 minutes per session, for 4 weeks. The solution for atomization of the PA group is low-concentration compound decoction (5%) same with the CD group.~Subjects will be treated with hypromellose 0.3% w/v eye drops four times per day too."
223528273|NCT06089317|DRUG|Artificial Tears (AT)|The subjects will receive lubricant eye drop (Hypromellose 0.3% w/v Eye Drops) four times per day only.
223528274|NCT06510621|PROCEDURE|Socket-Shield Technique|A high-speed turbine was used to cut the tooth crown 1.5-2 mm from the buccal gingival margin. The tooth was then divided along the long axis, approximately 2 mm from the buccal side(Figure 1c, 1d). The palatal roots were removed using minimally invasive elevation and extraction forceps. Next, the buccal socket-shield was trimmed to approximately 4-6 mm in height (1 mm from the buccal gingival margin)\[18\], 3-4 mm in width, and 1-1.5 mm in thickness\[19,20\]. The trimming process required with clear visualization of the shield and calibration by periodontal probe. Finally, the socket-shield was removed by minimally invasive forceps when the adjacent tooth moved proximate to the shield during the process of closing orthodontic gap.
223528275|NCT02445911|DRUG|KQ-791|Capsules administered orally
223528276|NCT02445911|DRUG|Placebo|Capsules administered orally
223528277|NCT06919887|OTHER|EMMII|The tool/app, consists of educational components designed to enable women to more effectively identify menopause symptoms and feel confident in seeking treatment to address their symptoms. The tool/app also produces a tailored menopause discussion guide for patients to bring to their primary care appointment.
223528278|NCT06919887|OTHER|Comparison Group|Receive educational menopause pamphlet describing menopause symptoms and evidence-based treatment options.
223528279|NCT04309682|PROCEDURE|crestal sinus approach technique|a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
224276427|NCT04972331|PROCEDURE|Platet- Rich-Plasma|Peripheral venous blood was collected from all patients, which was then centrifuged to isolate red blood cells from the upper plasma layer. We used the Arthrex® kit APC®. The upper plasma layer was carefully collected with a serological pipette and placed in a new centrifuge tube or set aside for injection. The 5 mL remaining upper plasma layer was centrifuged again to separate platelet-poor plasma from PRP for 7 min. We activated the PRP sample by adding calcium chloride through ultraviolet irradiation, and then a 4- to 8-mL sample was used for two injections. One injection was performed intra-articularly with a supero-lateral approach. One ultrasound-guided injection was performed at the meniscal wall. Our protocol allowed us to have \< 1% blood cells and \<1% white cells in the injection.
223712273|NCT06679699|DEVICE|Trunk control exercises combined with patient education program|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces. In addition, the experimental group provided a patient education program which focuses on the importance of trunk control and benefits of trunk control exercises during the rehabilitation process. Further, caregivers and family members were also explained about the patient education program and adherence with treatment protocol during and after the interventions.
223712274|NCT06679699|DEVICE|Trunk control exercises|Patients in this group received about 45-60 minutes of trunk control exercises in lying and sitting, 5 days a week for 4 consecutive weeks. Each exercise was performed with 10-20 repetitions per session depending on the patient's ability. Trunk exercises or other activities targeting the trunk while sitting and lying, to minimize the influence of lower extremity function performed either on a stable or unstable surfaces.
223712275|NCT06865989|DEVICE|Omnipod 5 SmartAdjust 2.0 System|Omnipod 5 System with changes
223712276|NCT06865989|DEVICE|Omnipod 5 System|Cleared device as comparator
223712277|NCT06868381|DRUG|Baricitinib (LY3009104) 4 mg|baricitinib 4 mg tablet taken orally once daily
223712278|NCT06614868|BEHAVIORAL|Acceptance and Commitment Therapy|Up to 16 session of unstructured counseling therapy informed by Acceptance and Commitment Therapy tradition.
223712279|NCT06614868|BEHAVIORAL|Treatment as Usual (TAU)|Unstructured counseling
223712280|NCT07007936|DRUG|SSS17 Capsule (6 Dose Levels)|Arm1 ： This dose-ranging study evaluates 6 dose levels of oral SSS17 capsules under two regimens: Once weekly、 Twice weekly
223712281|NCT07007936|DRUG|Placebo Drug|Arm2：placebo The placebo intervention was matched with the six dose levels of SSS17, with each dose level assigning participants in a ratio of 4:1 (SSS17 to placebo).
223712282|NCT06681779|DEVICE|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
223712283|NCT06681779|OTHER|Standard of Care (SOC)|Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
223712284|NCT06680544|DRUG|Voriconazole high dose|Oral voriconazole 200mg once a day for a maximum of 28 days
223712285|NCT06680544|DRUG|Voriconazole low dose|Oral voriconazole 200mg twice a day for a maximum of 28 days
223712286|NCT07055321|DRUG|ETH47|Dose level 1; single intranasal administration
223712287|NCT07055321|DRUG|ETH47|Dose level 2; single intranasal administration
223712288|NCT07055321|DRUG|ETH47|Dose level 3; single intranasal administration
223712289|NCT07055321|DRUG|ETH47|Dose level 4; single intranasal administration
223712290|NCT07055321|DRUG|ETH47|Dose level 5; single intranasal administration
223712291|NCT07055321|DRUG|ETH47|Dose level 1; single inhaled administration
223712292|NCT07055321|DRUG|ETH47|Dose level 2; single inhaled administration
223712293|NCT07055321|DRUG|ETH47|Dose level 3; single inhaled administration
223712294|NCT07055321|DRUG|ETH47|Dose level 4; single inhaled administration
223712295|NCT07053904|DRUG|Sequential use of P1101 and P1801|Sequential use of ropeginterferon alfa-2b and P1801 (anti PD-1 antibody drug)
223712296|NCT07053280|DEVICE|Teleaudiological tests|Initially, the FPT, DPT, RGDT, and SSWT were administered face-to-face; one month later, the same tests were repeated via teleaudiology, with the audiologist and participant in separate rooms using identical laptops and headphones, without visual or auditory contact.
223712297|NCT07055191|PROCEDURE|Transoral Endoscopic Thyroidectomy by Vestibular Approach|Transoral Endoscopic Thyroidectomy by Vestibular Approach
223712298|NCT07055191|PROCEDURE|Anterior Cervical thyroidectomy|Anterior Cervical thyroidectomy
223712299|NCT07053189|DEVICE|Clear Aligner treatment|Interproximal enamel reduction and attachment impact
223712300|NCT07053475|DRUG|Ferric Carboxymaltose|Intravenous infusion of 1 gram FCM during index hospital stay, followed by a second dose at Week 6 (1,000 mg if \> 70 kg or 500 mg if ≤ 70 kg).
223712301|NCT07053475|DRUG|Ferrous Sulfate|Oral administration of one 150 mg capsule every 48 hours for 12 weeks.
223712302|NCT07053319|DRUG|Empagliflozin 25 MG plus Pioglitazone placebo|A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
223712303|NCT07053319|DRUG|Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo|Placebo-Inert tablet
223712304|NCT07053319|DRUG|Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)|Pioglitazone, a medication used in the management and treatment of type 2 diabetes mellitus. It is in the thiazolidinedione class of medications
223712305|NCT07053319|DRUG|Pioglitazone placebo + Empagliflozin placebo|Placebo-Inert tablet
223712306|NCT07055217|BEHAVIORAL|Mindfulness Training|"A single 45-minute mindfulness training will be provided to all at-risk participants at visit 2. Clinically trained study staff will conduct the training with the aim of teaching mental noting, a core mindfulness technique to be practiced and employed during neurofeedback. Mental noting is a major component of Vipassana (insight mindfulness meditation); its key principles include: concentration, observing sensory experience,'' not 'efforting', and contentment.Specifically, participants will be taught to mentally label/note whatever sensation is most prominent in their sensory experience from moment to moment (e.g., seeing, hearing, feeling, thinking). Training will be personalized to identify scenarios in which mental noting can be applied in the context of each person's daily life, explaining the goal of using these strategies to manage distress in daily life."
223895505|NCT05922176|OTHER|Sample collection before& after immunotherapy|"B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)"
223895506|NCT06333808|DRUG|Bictegravir|Tablets administered orally without regard to food
223895507|NCT06333808|DRUG|Lenacapavir|Tablets administered orally without regard to food
223895508|NCT06333808|DRUG|B/F/TAF|Tablets administered orally without regard to food
223895509|NCT06333808|DRUG|Placebo to match B/F/TAF|Tablets administered orally without regard to food
223895510|NCT06333808|DRUG|Placebo to match BIC/LEN|Tablets administered orally without regard to food
223712307|NCT07055217|BEHAVIORAL|Mindfulness-based Neurofeedback (Real mbNF)|Before the MRI scan, participants will practice mental noting by verbalizing their mental label, with the study clinician providing feedback. Participants will then complete a silent practice of mental noting while viewing simulated neurofeedback. All participants will be trained until they feel competent to use mental noting in the scanner. Study clinicians will show 85% fidelity on the mindfulness training assessment before working with participants and sessions will be recorded and 10% of sessions will be assessed quarterly for fidelity. During active mbNF (6 runs, 2.5 mins each), participants will use mental noting with the aim of controlling the visual feedback; specifically, they will attempt to move the position of the white dot toward the (upper) red circle and away from the (lower) blue circle.
223712308|NCT07055217|BEHAVIORAL|Sham mindfulness-based neurofeedback (Sham mbNF)|During sham mbNF condition, participants will undergo similar MRI scan procedures. The primary difference in scan procedures is that rather than receiving mbNF, participants will view a visual display (i.e., white dot, red and blue circles) extracted from a previously acquired mbNF session. Thus, the visual display will be independent from brain activity in the sham condition and will simply mirror the stimuli observed by those in the mbNF group. This ensures that participants across groups are viewing equivalent stimuli for the same amount of overall time.
223712309|NCT07054775|DRUG|Morphine Sulfate|intrathecal administered morphine
223712310|NCT07054970|BIOLOGICAL|CT-P55|150 mg in 1.0 mL, administered as a single SC injection via PFS
223712311|NCT07054970|BIOLOGICAL|US-licensed Cosentyx|150 mg in 1.0 mL, administered as a single SC injection via PFS
223712312|NCT07054970|BIOLOGICAL|EU-approved Cosentyx|150 mg in 1.0 mL, administered as a single SC injection via PFS
223712313|NCT07053631|DEVICE|venous occlusion pressure Measurement|non-invasive venous occlusion pressure of a targeted periorbital vein is measured in parallel to clinical standard CSF dyanmic testing including standard CSF infusiontest
223712314|NCT07053527|BEHAVIORAL|PrEP Awareness and Uptake Educational Program|This intervention targets African American college students aged 18-26 using a tailored, community participatory approach. It is delivered by trained peer educators and focuses on increasing PrEP awareness, access, and uptake through interactive, behaviorally focused sessions. Developed with input from focus groups to ensure relevance, the program includes a 6-month follow-up to assess sustained impact, distinguishing it from general PrEP education efforts.
223712315|NCT07053982|PROCEDURE|Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery|This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.
223712316|NCT06897527|DRUG|Dostarlimab|Dostarlimab will be administered.
223712317|NCT06903195|DRUG|Black chokeberry extract in capsules with 18% standardization of the anthocyanins content|"Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan."
223712318|NCT06903195|DRUG|Chokeberry fiber in capsules|"Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan."
223712319|NCT04783857|DRUG|Progesterone 200 MG Oral Capsule|Progesterone, 200mg, once daily, oral tablet/capsule
223712320|NCT06939504|DRUG|HRS-9813 Capsule|HRS-9813 capsule.
223712321|NCT06939504|DRUG|HRS-9813 Tablet|HRS-9813 tablet.
223712322|NCT06004128|DRUG|VYD222|Monoclonal antibody
223895511|NCT06227221|DRUG|Sorafenib|Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.
223895512|NCT06227221|DRUG|Placebo|Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
223895513|NCT05970367|OTHER|Intensive rehabilitation programme|"Intensive rehabilitation using advanced technology, based on the patient's goals.~Including cardiovascular fitness training, goal-oriented training, physiotherapy with and without advanced technology and self-management."
224083314|NCT04058587|DRUG|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
223712323|NCT05628883|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
223712324|NCT05628883|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL over approximately 1 hour per day for 2 days.
223712325|NCT05628883|DRUG|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 15 to 30 minutes for 5 days, prior to T-Cell infusion
223895514|NCT06240325|BEHAVIORAL|SPP|SPP prioritizes increasing sleep duration and regularizing sleep-wake timing. The provider and youth review the youth's sleep pattern, based on sleep diary data collected before and during the program and actigraphy data collected at baseline. They discuss benefits to the current sleep pattern, reasons for changing sleep, and they create an action plan. Psychoeducation about healthy sleep is offered via a handout developed by our group. Youth and provider jointly select SPP strategies relevant to the contributors to poor sleep for each youth (e.g., time management, limiting weekend oversleep). In the second session they review progress and adjust the plan. Parents participate for part of each session to learn about their child's sleep and to discuss ways they can support their child to make the planned changes.
223895515|NCT06240325|BEHAVIORAL|Sleep Psychoeducation|Using the pamphlet also used in SPP, SPE will present sleep hygiene practices commonly included in sleep education programs and endorsed by national health organizations.
223895516|NCT06456671|OTHER|All nicotine/ tobacco products at market price|Nicotine/tobacco products available in the Experimental Tobacco Marketplace at market price. Note that all participants will complete all the specified conditions.
223895517|NCT06456671|OTHER|Nicotine vaping products at 1/2 market price|Availability of nicotine vaping products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223895518|NCT06456671|OTHER|Heated tobacco products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223895519|NCT06456671|OTHER|Nicotine pouch products at 1/2 market price.|Availability of heated tobacco products in the Experimental Tobacco Marketplace at 1/2 market price. Other nicotine/tobacco products at market price. Note that all participants will complete all the specified conditions.
223895520|NCT03758521|DEVICE|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
223895521|NCT03758521|DEVICE|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
223895522|NCT03758521|DEVICE|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
223895523|NCT03758521|PROCEDURE|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
223895524|NCT04113642|OTHER|ultrasonographic measurement of abdominal muscle thickness at four positions|Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
223895525|NCT01693263|OTHER|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
223895526|NCT02650414|BIOLOGICAL|Cohort 1|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22 cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22 cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22 cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22 cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22 cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22 cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22 cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22 cells/kg"
223895527|NCT02650414|BIOLOGICAL|Cohorts 2|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells/kg as a split dose over three days as follows:~Day 1, 10% fraction: 0.2-1x10\^6 CART22-65s cells/kg Day 2, 30% fraction: 0.6-3x10\^6 CART22-65s cells/kg Day 3, 60% fraction: 1.2-6x10\^6 CART22-65s cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over three days as follows:~Day 1, 10% fraction: 1-5x10\^7 CART22-65s cells/kg Day 2, 30% fraction: 0.3-1.5x10\^8 CART22-65s cells/kg Day 3, 60% fraction: 0.6-3x10\^8 CART22-65s cells/kg"
223895528|NCT02650414|BIOLOGICAL|Cohort 3|"Subjects \<50kg will receive 0.2-1 x 10\^7 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.5-2.5x10\^6 CAR T cells/kg Day 2, 75% fraction: 1.5-7.5x10\^6 CAR T cells/kg~Subjects ≥50kg will receive 1-5x10\^8 CART22-65s cells as a split dose over two days as follows:~Day 1, 25% fraction: 0.25-1.25x10\^8 CART22-65s cells Day 2, 75% fraction: 0.75-3.75x10\^8 CART22-65s cells"
223895529|NCT04517149|BIOLOGICAL|4D-125 IVT Injection|4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
223895530|NCT04517149|OTHER|Observational|Natural History
223895531|NCT06000059|BEHAVIORAL|Radio Drama|An hour long radio drama adapted from from a previous community-led theater intervention
223895532|NCT03160612|BEHAVIORAL|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
223895533|NCT04747613|DRUG|Iptacopan|Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral
223895534|NCT02547987|DRUG|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
224276428|NCT04972331|OTHER|Post-intervention|All patients were discharged the day after surgery with no limitation of mobility but with restrictions on sports for four weeks. Interruption of work was given for 10-45 days. The same analgesics and NSAIDs were administered in both groups for two weeks. All patients then received a rehabilitation program conducted by a physiotherapist, using the same protocol as in the PRP group for four weeks.
224276429|NCT01279382|BEHAVIORAL|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
224276430|NCT01279382|BEHAVIORAL|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
224276431|NCT01279382|OTHER|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
224276432|NCT01143831|DIETARY_SUPPLEMENT|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
224276433|NCT03901157|DIETARY_SUPPLEMENT|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
224276434|NCT03901157|DIETARY_SUPPLEMENT|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
223712326|NCT05628883|DRUG|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously every 8 to 12 hours beginning within 24 hours after T-cell infusion.
223712327|NCT03749447|DRUG|Bardoxolone methyl|Bardoxolone methyl capsules
223712328|NCT00995826|DRUG|CS-8958|Inhaled CS-8958
223712329|NCT00995826|OTHER|Placebo|Inhaled placebo
223712330|NCT05316688|PROCEDURE|Near Infrared Imaging|Undergo NIR imaging
223712331|NCT05316688|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223712332|NCT05316688|DRUG|Tozuleristide|Given IV
223712333|NCT04613063|OTHER|Diagnostic laparoscopy|A diagnostic laparoscopy was performed where a dilated jejunum was encountered with impaction of fecal content. Surgery was converted to open surgery, where a longitudinal enterotomy of 5 cm after the transition zone was created, evacuating manually the fecal material with mucous secretion.
223712334|NCT04608929|BEHAVIORAL|Kegel exercise-focused interventions|After the patients in the intervention group were interviewed on the telephone, the second home visit. During this visit, the patients were trained on Kegel exercises and they were administered the ICIQ-SF. Six weeks after the second visit, the third home visit was paid to determine whether the patients did the Kegel exercises and whether they did them accurately, to assess the perceived impact and to re-administer the ICIQ-SF. After the 2nd and 3rd visit, the patients were called once a week for 6 weeks to monitor if they kept up with doing the Kegel exercises as they were taught. Six weeks later, the 4th home visit were paid to the patients. During this visit, whether the patients did the Kegel exercises and whether they did them accurately was determined, the perceived impact was assessed and the ICIQ-SF was re-administered.
223712335|NCT04608929|OTHER|Home visit and scale evaluations|After the 1st visit, the patients included in the control group were called by phone and the 2nd home visit was planned. During the second home visit, the ICIQ-SF was administered to them. At the 3rd home visit paid 6 weeks after the 2nd visit, the ICIQ-SF was re-administered to the patients and the perceived impact assessment was performed. During the 4th home visit paid 6 weeks after the 3rd home visit, the ICIQ-SF was re-administered to the patients, assessment of the perceived impact was performed, and finally they were given training on Kegel exercises.
223712336|NCT03435861|DRUG|VX-745|active drug capsules
223712337|NCT03435861|DRUG|placebo|placebo capsules
223712338|NCT05407402|BEHAVIORAL|laughter yoga practice|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
223712339|NCT05407402|BEHAVIORAL|watching funny videos|To reduce the pain and increase the comfort of individuals diagnosed with migraine with these planned interventions.
223712340|NCT01309594|PROCEDURE|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
223712341|NCT00842608|BEHAVIORAL|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can \& cannot receive Haldol"
223712342|NCT00842608|PROCEDURE|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
223712343|NCT00842608|DRUG|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
223712344|NCT00842608|PROCEDURE|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
223712345|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
223712346|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
223712347|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
223712348|NCT01691339|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
223712349|NCT04002713|OTHER|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
223712350|NCT04002713|OTHER|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
223712351|NCT02792881|PROCEDURE|Laparoscopic completion total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic completion total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent. For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and the anastomotic procedure will be performed extracorporeally through an auxiliary incision.
223712352|NCT02126020|DRUG|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
223712353|NCT03486223|DRUG|GSK2256294|Drug will be taken daily by mouth for 7 days.
223712354|NCT03486223|DRUG|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
223712355|NCT05902455|PROCEDURE|Punch biopsy|Punch biopsy of oral squamous cell carcinoma tumor and a control biopsy of healthy oral mucosa are collected during primary tumor excision surgery from each recruited patient.
223712356|NCT01819831|RADIATION|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
223895535|NCT02547987|DRUG|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
223895536|NCT04282148|DEVICE|ABT NG DES 48 EECSS|Each participant will receive ABT NG DES 48 EECSS with appropriate diameter
223895537|NCT02146378|DRUG|Vyndaqel|20mg/day
223895538|NCT06547866|DRUG|zanubrutinib + BGB-11417|"The investigational medicinal products (IMP) are Zanubrutinib (BGB- 3111) and BGB-11417.Treatment will be administered for a total of twenty 28 day cycles:~Cycle 1 with zanubrutinib only~Cycle 2 with zanubrutinib plus BGB-11417 ramp-up cycle 2, day 1 : 10mg cycle 2, day 2 : 20 mg cycle 2, day 3 : 40mg cycle 2, day 4-7 : 80md daily cycle 2, day 8 and beyond : 160 mg daily~Cycles 3-20 with zanubrutinib plus BGB-11417 full dose"
223895539|NCT05589194|BEHAVIORAL|Nursing Practices Based on Kolcaba's Comfort Theory|Nursing interventions planned to be carried out within the scope of the research will be based on Comfort Theory. Nursing interventions will be planned according to the needs in the physical comfort (diet practice, providing effective and correct pelvic floor muscle contraction, repetitive and regular yoga practice training), psychospiritual comfort (appreciation and encouragement, self-confidence, expressing the feeling of embarrassment, expressing fear, confidence, repetitive and regular practice of yoga practice, meditation), sociocultural comfort (to be informed, to develop effective interpersonal communication, to interact with other women with SUI) and environmental comfort (Informing about making the necessary arrangements to prevent possible situations such as sleep disruption and falling, bad smell, etc. and performing nursing practices by respecting privacy). The yoga practice will carry out with the participation of 60-minute group yoga classes twice a week for 6 weeks.
223895540|NCT04925986|DRUG|Sitravatinib|Groups 1A and 2A receive Sitravatinib 100mg orally (PO) daily starting on cycle 1 day 1 (C1D1). Groups 1B and 2B) receive Sitravatinib 100mg orally (PO) daily starting on Cycle 2 Day 1 (C2D1).
223895541|NCT04925986|DRUG|Pembrolizumab|All groups (1A, 1B, 2A, 2B) receive Pembrolizumab 200mg intravenous every three weeks (IV Q3w) on cycle 1 day 1 (C1D1).
223895542|NCT04861571|DIETARY_SUPPLEMENT|Dietary intervention with very low calorie diet (VLCD)|The VLCD program will last 8 weeks. The only sources of nutrition during this phase are the Optifast® products providing up to 800 kcal per day. Two liters (67.63 fl oz) of water should also be consumed each day. Participants will be instructed to use 5 replacement meals per day (800 kcal total) with 40% of calories as protein, 40% as carbohydrate, and 20% as fat.
223895543|NCT04861571|OTHER|Control Arm|The control group will consume a lower calorie diet and will be instructed to reduce their usual intake of normally consumed foods by up to 500 kcal per day but no less than 1200 kcal per day.
223895544|NCT06181760|DRUG|Fenretinide|Ascending single doses of oral fenretinide
223895545|NCT06181760|DRUG|Placebo|Single oral dose of matching placebo capsules
223895546|NCT06647160|DEVICE|Blue star MAX-5 spectacle lens|The children in the experimental group will wear Blue star MAX-5 spectacle lens and receive follow-up examinations every half year.
223895547|NCT06647160|DEVICE|Single-vision spectacle lens|The children in the single-vision lenses group will wear single-vision spectacle lens and receive follow-up examinations every half year.
223895548|NCT03524612|DRUG|eltrombopag|12.5, 25, 50 and 75 mg tablets for oral use once daily
223895549|NCT06083948|DRUG|Noradrenalin|Infusion of noradrenaline during anesthesia and surgery
223895550|NCT06083948|DRUG|Phenylephrine|Infusion of phenylephrine during anesthesia and surgery
223895551|NCT04612699|DRUG|Jaktinib|Administered orally
223895552|NCT04612699|DRUG|Placebo|Administered orally
223895553|NCT06450522|OTHER|Pharmacist co-management of HF medication optimization|"In addition to usual care, participants with an initial Post-Discharge Medicine Clinic visit randomized to the intervention arm will receive pharmacist co-management of their medications, with the intent of to achieve rapid, maximum-tolerated pharmacotherapy for HFrEF as outlined by the 2021 CCS HF guidelines, and for HFmrEF/HFpEF as outlined by the 2022 ACC/AHA HF guidelines. This intervention will be delivered by a staff pharmacist at the St. Paul's Hospital, using the standard procedures outlined below:~For HFrEF: Where possible, a patient will be prescribed the combination of an ARNI, evidence-based beta-blocker, MRA, and SGLT2i at target HFrEF doses, along with personalized therapies as outlined in the 2021 CCS HF guidelines.~For HFmrEF: We will target ACEI/ARB/ARNI+BB+MRA+SGLT2i. For HFpEF: We will target SGLT2i+MRA +/- ACEI/ARB/ARNI. The intervention will incorporate key components identified in a systematic review of observational studies of pharmacist-led optimization of HF."
223895554|NCT06450522|OTHER|Usual care|Usual care
223895555|NCT04470453|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
224276435|NCT02898701|BEHAVIORAL|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
224276436|NCT05550792|DEVICE|optimizer smart|The CCM implantation procedure was performed in the right precordial region of the chest (the right subclavian area). Two active fixation Ingevity leads (Boston Scientific) were advanced via the right subclavian vein into the right ventricle (RV) and actively fixed to the right ventricular septum for ventricular sensing and delivery of CCM signals.
223895556|NCT04470453|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
223895557|NCT04404088|DRUG|Acalabrutinib|Given PO
223895558|NCT04404088|DRUG|Lenalidomide|Given PO
223895559|NCT04404088|BIOLOGICAL|Rituximab|Given IV
223895560|NCT04770532|DRUG|Insulin degludec|Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks
223895561|NCT04770532|DRUG|Insulin Icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
223895562|NCT01414400|OTHER|Blood draw for culture|Blood will be drawn and sent for culture.
223895563|NCT05457647|DEVICE|Riboflavin/UV-A corneal cross-linking|Corneal cross-linking procedure is performed using the C4V CHROMO4VIS™ medical device equipped with theranostic software module in all participants. Participants will receive a single dose of the 0.22% riboflavin ophthalmic solution, RitSight™. Application of the riboflavin eye drop is done for 15 minutes for the epi-off CXL treatment and 20 minutes for the epi-on CXL treatment. Estimates of riboflavin concentration into the cornea are monitored by the C4V CHROMO4VIS™ system during the dosing phase of treatment. Once the pre-set dosing phase is completed, the C4V CHROMO4VIS™ system provides the Operator the access to the UV-A light irradiation of the cornea with 5.4 J/cm2 total energy dose (10 mW/cm2 for 9 min.) and 7.00 mm light beam diameter in all participants. Estimates of treatment efficacy by calculation of theranostic score are performed by the C4V CHROMO4VIS™ system during UV-A light irradiation.
223895564|NCT06340282|DEVICE|Virtual reality|Immersive virtual reality
224276437|NCT03710044|DRUG|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
224276438|NCT00005858|BIOLOGICAL|LMB-9 immunotoxin|
223895565|NCT06340282|BEHAVIORAL|multicomponent exercise|individualized exercise
223895566|NCT04938492|BEHAVIORAL|Cognitive Behavioral Therapy for loneliness (CBT-L)|6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use.
223895567|NCT04938492|BEHAVIORAL|Physical Health Education Training (PHET)|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
223895568|NCT04982237|BIOLOGICAL|AK104|IV infusion
223895569|NCT04982237|DRUG|paclitaxel|IV infusion
223895570|NCT04982237|DRUG|carboplatin|iv infusion
223895571|NCT04982237|DRUG|cisplatin|iv infusion
223895572|NCT04982237|DRUG|bevacizumab|iv infusion
223895573|NCT04982237|DRUG|Placebo|iv infusion
223895574|NCT04841148|DRUG|HCQ|600 mg tablets twice daily D1-28 of each 28-day cycle
223895575|NCT04841148|DRUG|Avelumab|10 mg/kg, IV, D1 and D15 of each 28-day cycle
224276439|NCT02104869|BIOLOGICAL|Trivalent influenza vaccine (inactivated and fragmented).|
224276440|NCT02063217|DRUG|Sodium Oxybate|Sodium oxybate h.s.
224276441|NCT02063217|BEHAVIORAL|Sleep deprivation|36hr sleep deprivation
224276442|NCT00233155|DRUG|Capsaicin Dermal Patch|
224276443|NCT00889252|DEVICE|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
224276444|NCT00889252|DEVICE|contact lens|Placebo contact lens
223895576|NCT04841148|DRUG|Palbociclib|125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
223895577|NCT05866562|DRUG|Dupilumab|Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;
223895578|NCT05866562|DRUG|Placebo|Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
223895579|NCT04899141|DEVICE|Percutaneous Coronary Intervention|stenting with the ihtDEStiny® sirolimus eluting stent
223895580|NCT05646589|BEHAVIORAL|Person-centred care transition support|Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
223895581|NCT05646589|BEHAVIORAL|Regular care transition|Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
223895582|NCT06041568|DRUG|Imvotamab|Administered intravenously
223895583|NCT05739279|DIAGNOSTIC_TEST|STAR-Sonographic Thigh Adjustment Ratio|With ultrasonography, anterior thigh muscle thickness on the dominant extremity side will be measured at a 50% level between the anterior superior iliac spine and the upper pole of the patella in the supine position. The STAR-sonographic thigh adjustment ratio will be calculated by dividing the anterior thigh muscle thickness (mm) by the body mass index.
223895584|NCT05739279|DIAGNOSTIC_TEST|Hand Grip Strength|Hand grip strength will be measured with a Jamar dynamometer used in the second grip position, in a sitting position with shoulders adducted and neutrally rotated, elbows flexed to 90°, and forearms/wrists in the neutral position. Three repetitive measurements will be made from the dominant side and the maximum value obtained for analysis will be taken.
223895585|NCT05739279|DIAGNOSTIC_TEST|Chair Stand Test|For the 5-repeat stand-up test, patients will be asked to get up from a chair without an armrest and sit (at the start) five times as fast as possible with their arms crossed over their chest.
224276445|NCT06435832|DRUG|Absorbable Gelatin|After tooth extraction, only saline irrigation was applied and a absorbable gelatin sponge was placed in the socket.
224276446|NCT06435832|DRUG|Chlorhexidine|After tooth extraction, after irrigation with saline, 2% chlorhexidine gel was absorbed into gelatin sponges and placed into the socket.
223895586|NCT05739279|DIAGNOSTIC_TEST|6 Meter Gait Speed|For walking speed measurements, patients will be asked to stand with both feet touching the starting line and walk at their normal speed on a 6-meter track after the command. The time between the start and end will be measured with a stopwatch and converted to meters/second. Three consecutive measurements will be made for both and average values will be taken for the analyses.
224276447|NCT06435832|DRUG|Tranexamic acid|Tranexamic acid 50mg/ml for injection after saline irrigation after tooth extraction solution into gelatin sponges was applied to the socket after it was cured.
224276448|NCT01004445|DRUG|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
224276449|NCT01004445|DRUG|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
224276450|NCT01004445|DRUG|Placebo|Two aerosol treatments per day (one treatment every 12hr)
224276451|NCT06315387|DRUG|4-MUST, 1 tablet|4-methylumbelliferyl trimebutine sulfate, 128 mg
224276452|NCT06315387|DRUG|4-MUST, 2 tablets|4-methylumbelliferyl trimebutine sulfate, 256 mg
224276453|NCT06315387|DRUG|4-MUST, 3 tablets|4-methylumbelliferyl trimebutine sulfate, 384 mg
223895587|NCT02683447|OTHER|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
223895588|NCT05436600|OTHER|Exercise Intervention|The exercise intervention group will undergo 12 weeks of AeroBal exercise training (approximately 3 times/week). Each exercise session will consist of a 5-minute warm-up walk, approximately 30 minutes of aerobic exercise at a goal of 60-75% HRmax, 15 minutes of balance exercises, and a 5-minute cool-down walk.
223895589|NCT05555199|RADIATION|99mTc-nanocolloid|Injection of 99mTc-nanocolloid when lung cancer is diagnosed during a navigation bronchoscopy, followed by one or two SPECT/CT-scans.
223895590|NCT05555199|DRUG|ICG|If patient undergoes surgery to treat the lung cancer, ICG will be injected and retrieved fluorescent lymph nodes will undergo additional pathological assessment.
223895591|NCT03448107|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
223895592|NCT03448107|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
223895593|NCT03448107|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
223895594|NCT04025554|DRUG|Anakinra|100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
223895595|NCT06351306|DRUG|Thioguanine (Tabloid ®)|60-80mg/m\^2 oral tablet
223895596|NCT06351306|DRUG|DecitabineCedazuridine (Inqovi ®)|35 mg decitabine and 100 mg cedazuridine oral tablet
223895597|NCT05972655|RADIATION|Modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
223895598|NCT05972655|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
223895599|NCT05972655|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
223895600|NCT05972655|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223895601|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, iron and B12 in Whey Protein|Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
223895602|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Rice Protein|Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)
223895603|NCT06232642|DIETARY_SUPPLEMENT|Lactoferrin, Iron and B12 in Maltrodextrin|Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
223895604|NCT02377999|DRUG|Picato|
223895605|NCT05639478|OTHER|Foot-related exercises|Face to face foot-related exercises, supervised by physiotherapist and based in the specific software (Sistema de Orientação do Pé diabético, SOPED) and or booklet, in addition to self-care recommendations and foot care by international consensus. The maximum duration of a session is 40 min and should be be performed 1-2 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the physiotherapist. The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression.
224276454|NCT02111122|DRUG|Sodium Oxybate|
224276455|NCT02111122|DRUG|Placebo|
224276456|NCT02095340|OTHER|Positive Interpretation Bias Training|
223895606|NCT06837324|DEVICE|home-based Neofect Smart Glove|a total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart Glove, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeks.
223895607|NCT06837324|OTHER|home-based occupational therapy|a total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
223895608|NCT05030233|BEHAVIORAL|Nurse-Administered Touch Intervention|The nurse-administered touch intervention is a bare-handed, comforting touch intervention administered during an episode of essential nursing care. The bedside nurse will cradle the infant's head with one hand, using the other hand to gently support the infant's lower body and legs in a flexed position. The touches will be administered for 1 minute at the start of the essential care episode, 30 seconds after the diaper change, and 1 minute at the conclusion of the care episode.
223895609|NCT05771545|OTHER|Telepsychiatry|Instead of coming to the hospital physically, the attending psychiatrist will evaluate the patient via a video-link.
223895610|NCT06830018|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.
223895611|NCT06830018|COMBINATION_PRODUCT|Standard Treatment|Standard Treatment，First-line treatment (chemotherapy + immunotherapy/targeted therapy)
223895612|NCT06793839|DEVICE|Transcranial Enhanced Ultrasonography localizing microscopy|3 bilateral transcranial enhanced (with Sonovue) ultrasonography per patient to visualize cranial arteries of the anterior circulation of the brain
223895613|NCT03920267|DRUG|BMS-986165|Specified dose on specified days
223895614|NCT04437615|PROCEDURE|Colonoscopy|Standard of care colonoscopy, with added use of CDSD as an adjunctive tool
223895615|NCT04437615|DEVICE|Clinical Decision Support Device|The investigational device consists of software residing on a dedicated computer enabling display of predicted diminutive polyp histology during colonoscopy.
223895616|NCT06915363|DEVICE|BioPoly|partial resurfacing knee replacement
223895617|NCT06915363|PROCEDURE|surgical standard of care (SSOC)|either microfracture or debridement
223895618|NCT05214911|DRUG|Desloratadine , Prednisolone|FDC desloratadine 0.5 mg/mL/prednisolone 4 mg/mL from Eurofarma Laboratórios SA
223895619|NCT05214911|DRUG|Desloratadine|Desloratadine 0.5 mg/mL (Desalex® - Eurofarma Laboratórios SA)
223895620|NCT06932523|BIOLOGICAL|Recombinant herpes zoster vaccine with low-dose adjuvant|Candidate 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
223895621|NCT06932523|BIOLOGICAL|Recombinant herpes zoster vaccine with high-dose adjuvant|Candidate 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
224276457|NCT02095340|OTHER|Neutral Interpretation Bias Training|
224276458|NCT04227041|DRUG|Pyrotinib in combination with capecitabine|Pyrotinib in combination with capecitabine
223895622|NCT06932523|BIOLOGICAL|Low-dose adjuvant|Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule
223895623|NCT06932523|BIOLOGICAL|High-dose adjuvant|Adjuvant control 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule
223895624|NCT06932523|BIOLOGICAL|Shingrix (GSK)|Positive control, Intramuscular injection, 0, 2 months schedule
223895625|NCT06932523|BIOLOGICAL|Normal Saline|Placebo control, Intramuscular injection, 0, 2 months schedule
223895626|NCT05772845|BEHAVIORAL|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
223895627|NCT05772845|BEHAVIORAL|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
223895628|NCT04410341|DRUG|Vildagliptin 50 MG|Vildagliptin, an antidiabetic drug that inhibits the dipeptidyl peptidase- 4 (DPP-4), increases glucagon-like peptide-1 (GLP-1) and regulates blood glucose levels, favoring weight loss and lowering cardiovascular risk.
223895629|NCT04410341|DRUG|Escitalopram 20 mg|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
223895630|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
223895631|NCT03982524|BEHAVIORAL|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
223895632|NCT06801808|DIETARY_SUPPLEMENT|Myosave|Nutritional supplementation with Myosave
223895633|NCT06477406|DRUG|Cannabidiol|Custom formulation of a hemp-derived sublingual solution that is high in CBD and includes other cannabinoids and terpenes.
223895634|NCT06477406|DRUG|Placebo|An active placebo containing supplemental terpenes matched to the high-CBD product.
223895635|NCT06954662|DRUG|Amino acid supplement|a targeted amino acid supplement designed to provide dietary nutrients that are commonly deficient in people with PD while minimizing interference with L-Dopa medication
223895636|NCT06954662|DIETARY_SUPPLEMENT|Whey Protein Supplement|Whey protein is one of the primary proteins found in all dairy products. It is a complete protein as it contains all the essential amino acids. We will use a 20 gram dose.
223895637|NCT06954662|DIETARY_SUPPLEMENT|Isonitrogenous Placebo Supplement|The control supplement used in this study is an isonitrogenous placebo beverage. This supplement will consist of an inert amino acid (alanine) with the same amino acid load as the whey protein and the targeted amino acid supplement (16.2 grams).
223895638|NCT06228846|DRUG|YY001|Oral
223895639|NCT01105234|DRUG|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
223895640|NCT02710734|DRUG|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
224276459|NCT05435534|OTHER|ActiveFLS intervention|"* A comprehensive geriatric assessment with a multicomponent physical exercise program guideline based on ActiveHip+ for 3 months. In the subsequent revisions, exercise guidelines from the Vivifrail program will be given~* A protocolized nutritional intervention will be carried out. In case of oral nutritional supplementation, supplements enriched in β-hydroxy-β-methylbutyrate (HMB) will be selected~* Osteoporosis treatments according to national guideline~* A review and adaptation of the treatment will be carried out according to the STOPP (Screening Tool of Older Persons' Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria~* An approach will be made to the patient's mood and fear of falling. In case of depression, both pharmacological and non-pharmacological approaches will be assessed~* Screening for cognitive impairment will be performed. In the event of evidence of memory problems, a recommendations for cognitive stimulation will be delivered"
223895641|NCT02710734|DRUG|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
223895642|NCT02710734|DRUG|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
223895643|NCT02710734|DRUG|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
223895644|NCT02710734|RADIATION|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
223895645|NCT02710734|PROCEDURE|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
223895646|NCT02710734|DRUG|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
223895647|NCT02710734|DRUG|Mitomycin C|Intravenous on day 1 with radiation treatment
223895648|NCT04420975|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
224276460|NCT05435534|OTHER|Usual care group|Participants randomly assigned to the usual care group will receive normal outpatient care, including physical rehabilitation when needed.
224276461|NCT00044876|DRUG|CDB-2914|
224276462|NCT01160640|DRUG|Ceftriaxone|ceftrixone 250mg IM single dose
224276463|NCT01160640|DRUG|Doxycycline|Doxycycline 100 mg PO bid x 14 days
223895649|NCT04420975|BIOLOGICAL|Nanoplexed Poly I:C BO-112|Given intratumorally
223895650|NCT04420975|BIOLOGICAL|Nivolumab|Given IV
223895651|NCT04420975|RADIATION|Radiation Therapy|Undergo radiation therapy
223895652|NCT06016712|DEVICE|SENSIMED Triggerfish Eye Lenses|Contact lenses used for measuring intraocular pressure.
223895653|NCT05417009|DEVICE|trans-cutaneous auricular sensory stimulation|Transcutaneous auricular sensory stimulation
223895654|NCT04997369|DEVICE|Rezum|The Rezum system is an ablative procedure for patients with benign prostatic hyperplasia (BPH).
223895655|NCT05439759|BEHAVIORAL|Condition 1: Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
224276464|NCT01160640|DRUG|Metronidazole|metronidazole 500 mg PO bid x 14 days
223895656|NCT05439759|BEHAVIORAL|Condition 2: Training spatial integration|Spatial integration involves what the investigators refer to as mid-level vision. Spatial integration is a concern in developing a PRL since an area of the visual periphery that is best suited to discriminate a simple visual feature may not be appropriate to integrate information across objects, such as in reading or recognizing facial identity or expression. The investigators address this issue with a targeted spatial integration training approach developed by MPI Seitz and based on contour integration tasks used in previous PL studies to train mid-level visual processes. Target stimuli consist of contours formed by spaced Gabors. The difficulty is manipulated by varying orientation jitter of Gabors. Several optotypes will be included to promote generalization, including shapes and facial expressions.
223895657|NCT05439759|BEHAVIORAL|Condition 3: Training spatial attention|The investigators will implement a task structure that requires participants to alternate between holding and switching attention and making targeted eye movements. The basic task is to press a key whenever a red-circle appears in a series of other colored-circles, with a target presented every 2 to 4s. Participants must maintain vigilance for relatively long periods, detect objects in the near periphery, switch attention based upon exogenous and endogenous cues, and make eye- movements to move areas of spared vision to those locations. These are aspects of attention and eye movements not incorporated in Conditions 1 and 2.
223895658|NCT05439759|BEHAVIORAL|Condition 4: Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision,Condition 4 combines the elements of Conditions 1-3.
223895659|NCT06158399|DRUG|Azacitidine in combination with R-CHOP|"Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5"
223895660|NCT06567821|DEVICE|RELIEVA SPINPLUS® NAV Balloon Sinusplasty System|The non-navigated device being used is the RELIEVA SPINPLUS® Balloon Sinusplasty System and the navigated device being used is the RELIEVA SPINPLUS® NAV Balloon Sinusplasty System. Both devices being used are standard devices that are currently FDA approved and used in practice for sinus dilation at Cedars-Sinai Medical Center.
223895661|NCT06074419|DEVICE|Occulus quest 2 virtual reality glasses|Patients will be shown nature videos via the specified virtual reality connection.
223895662|NCT06656013|BEHAVIORAL|Motivational Interview|After the preparation session, 4 sessions of motivational interviewing will be applied. Motivational interviewing techniques will be used in the interviews to target behavioral change.
223895663|NCT03725878|PROCEDURE|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
223895664|NCT03725878|PROCEDURE|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration \>400 ng/ml before pregnancy is recommended.
223895665|NCT03725878|PROCEDURE|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
223895666|NCT06410391|RADIATION|Ultrasound|"Gestational age, biparietal diameter and head circumference are measured. then 2 techniques are used according to the 2007 International Society of Ultrasound in Obstetrics and Gynecology guidelines for a US evaluation of the fetal central nervous system (CNS) (10) : 1- the axial transventricular technique including the posterior portions of the lateral ventricles, falx, CSP, and Frontal horn 2- the trans-cerebellar technique, including the cerebellum, cisternal magna, cerebellar peduncles, CSP, and FHs. CSP visualization and width, FH width, anterior horn width (AHW), center from the horn distance (CFHD), upside and downside measurement.~The corpus callosum is identified in the midsagittal plane. The image selected for CC measurement in addition to cerebellar vermis and cisterna magna"
223895667|NCT02203552|DRUG|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
223895668|NCT02203552|OTHER|placebo|Placebo given by mouth for 9 weeks
223895669|NCT02203552|OTHER|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
223895670|NCT02203552|OTHER|Questionnaire administration|The CES-D and STAI will be administrated weekly.
223895671|NCT03208062|OTHER|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
224276465|NCT01160640|DRUG|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
224276466|NCT01105182|PROCEDURE|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
223712357|NCT01819831|PROCEDURE|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
223712358|NCT04602988|DEVICE|EEG|EEG monitoring of brain rhythms
223712359|NCT01912365|PROCEDURE|Above Elbow Cast|
223712360|NCT01912365|PROCEDURE|Long Arm Splint|
223712361|NCT00289445|DRUG|Mitomycin C|
223712362|NCT00289445|DRUG|5-FU|
223712363|NCT00289445|DRUG|Folinic acid|
223712364|NCT01224860|DRUG|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
223712365|NCT01224860|DRUG|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
223712366|NCT01816282|DRUG|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
223712367|NCT01506713|DRUG|Clopidogrel|Clopidogrel Tablets 75 mg
223712368|NCT01165437|DEVICE|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
223712369|NCT04773860|OTHER|Muscle Energy Techniques|A 4 week intervention will be carried out consisting of Muscle Energy Techniques on the accessory muscle of respiration. That is, Pectoralis Minor, Sternocleidomastoid, Upper trapezius, Scalene muscles and Latissimus Dorsi
223712370|NCT02279420|DEVICE|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
223712371|NCT00325728|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
223712372|NCT00325728|DRUG|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
223712373|NCT03423381|OTHER|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
223712374|NCT03423381|OTHER|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
223712375|NCT03423381|OTHER|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
223712376|NCT03423381|OTHER|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
223712377|NCT03423381|OTHER|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
223712378|NCT03423381|OTHER|Control product|A cereal based product with low concentrations of df
223712379|NCT02066805|DRUG|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
223712380|NCT01948947|DEVICE|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
223712381|NCT01948947|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
223712382|NCT01153347|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
223712383|NCT01153347|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
223712384|NCT03169556|DEVICE|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
223712385|NCT03169556|DEVICE|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
223712386|NCT01874613|DEVICE|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
223712387|NCT01874613|DEVICE|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
223712388|NCT00297830|DRUG|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
223712389|NCT00297830|DRUG|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
223712390|NCT00297830|OTHER|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
223712391|NCT00297830|OTHER|Placebo Alendronate|Placebo alendronate 70 mg once weekly
223712392|NCT06959641|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223712393|NCT06959641|PROCEDURE|Computed Tomography|Undergo CT scan
223712394|NCT06959641|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223712395|NCT06959641|OTHER|Survey Administration|Ancillary studies
223712396|NCT06959641|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223712397|NCT06959641|DRUG|Zanzalintinib|Given PO
223712398|NCT00565786|DEVICE|ArCom® Polyethylene|Argon packaged compression molded polyethylene
223712399|NCT00565786|DEVICE|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
223712400|NCT06064422|BEHAVIORAL|BeatIt-MV|BeatIt-MV, designed to be implemented with minimally verbal autistic individuals, is an adaptation of BeatIt-2. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
223712401|NCT01651377|DRUG|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
223895673|NCT06829082|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Antiretroviral therapy (ART) has advanced with the introduction of integrase strand transfer inhibitors (INSTIs), such as the fixed-dose combination of tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC), known as Biktarvy®. This regimen is preferred for its high genetic barrier to resistance, minimal drug interactions, and once-daily, single-tablet formulation, which enhances adherence and long-term treatment outcomes. While clinical trials have demonstrated its efficacy, real-world data specific to Colombia are lacking.
223712402|NCT01651377|DRUG|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
223712403|NCT01548651|DRUG|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
223712404|NCT01548651|DRUG|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
223712405|NCT01619696|PROCEDURE|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
223712406|NCT02069717|OTHER|Not applicable-observational study|
223712407|NCT05096221|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec.
223712408|NCT05096221|GENETIC|placebo|Single IV infusion of matching placebo.
223712409|NCT03632200|OTHER|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
223712410|NCT00236587|DRUG|risperidone|
223712411|NCT04096729|OTHER|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
223712412|NCT00002946|DRUG|penclomedine|
223712413|NCT00779701|DRUG|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
223712414|NCT04655378|OTHER|Mass Sepctrometry|Mass spectrometry (LC/MS) of purified immunoglobulins
223712415|NCT02733432|DRUG|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
223712416|NCT02733432|DRUG|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
223712417|NCT02733432|DRUG|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
223712418|NCT02733432|DRUG|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
223712419|NCT02733432|DRUG|Fluconazole|oral fluconazole (150mg) on Day 1
223712420|NCT01748669|DIETARY_SUPPLEMENT|Garlic oil|Oral administration
223712421|NCT04678661|DEVICE|Smartphone application and web portal|"My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. MDC is intended as an aid to the patient to provide dose suggestions based upon the HCP's independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient Instructions. The application uses the dose plan instructions provided by the patient's HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient's Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.~MDC includes a Maintenance Module designed to support patients in maintaining proper insulin dosingby enabling logging of administered doses of prescribed diabetes medications and BGM and providing dosing and measurement reminders."
223712422|NCT04678661|BEHAVIORAL|Standard Insulin Therapy Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
223712423|NCT04433403|OTHER|pathogenic microorganism|Detection of pathogenic microorganisms in adult severe pneumonia by second generation sequencing
223895674|NCT02921230|DEVICE|Peripheral stenting|stent implantation during the index procedure
223895675|NCT04691297|OTHER|Escape|The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
223895676|NCT04691297|OTHER|Standard Care|Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
223895677|NCT06089980|BEHAVIORAL|Effects from acute kratom exposure|Participants who regularly use commercial Kratom products will orally consume a known quantity of kratom under direct observation on first study day; following this, participants will stop kratom use for approximately 2 nights and 2.5 days for the duration of the study.
223895678|NCT06232902|DRUG|QL1101|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
223895679|NCT06232902|DRUG|Avastin®|3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
223895680|NCT02808182|DRUG|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
223895681|NCT02808182|OTHER|[7,7,8,8-2H]-palmitate|using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min
223895682|NCT02808182|OTHER|[U-13C]-palmitate|oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
223895683|NCT02808182|PROCEDURE|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
223895684|NCT02808182|OTHER|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
223895685|NCT04266275|DRUG|Curcumin C3 Complex|"Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
223895686|NCT04266275|DRUG|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes."
223895687|NCT05044793|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
223895688|NCT06849193|DRUG|Systemic chemotherapy combined with immunotherapy|The electronic medical record system was used to collect patients' basic information and treatment plan information, including treatment plan, administration cycle, administration date, administration dose, frequency, number of cycles, efficacy, adverse reactions, etc.
223895689|NCT06510257|DRUG|Reconyl|1 tablet of Reconyl, 3 times daily
223895690|NCT06510257|DRUG|Placebo tablet of Reconyl|1 tablet of placebo Reconyl, 3 times daily
223895691|NCT06846918|BEHAVIORAL|High-Intensity Interval Training|"The high-intensity interval training (HIIT) protocol will run for 12 weeks, with two weekly sessions, totaling 24 sessions. Each 20-minute session will follow a group-based circuit format with functional exercises (e.g., jogging, jumping jacks, step-ups). High-intensity phases will be performed at maximum effort, while moderate-intensity phases will be maintained at a Borg scale rating of 4-6.~Training will amount to 40 minutes per week. The intensity ratio will progress over time:~* Weeks 1-4: 15 sec high / 60 sec moderate (1:4)~* Weeks 5-8: 15 sec high / 45 sec moderate (1:3)~* Weeks 9-12: 15 sec high / 30 sec moderate (1:2)~* Weeks 13-16: 15 sec high / 15 sec moderate (1:1)~This progressive structure ensures gradual adaptation while maximizing effectiveness."
223895692|NCT06846918|BEHAVIORAL|Exercise Snacks Protocol|The exercise snack protocol will last for 12 weeks, with sessions held twice a week, totaling 24 sessions. The exercise snacks will amount to 40 minutes per week, divided across the five weekdays. Participants will be required to perform 4 minutes of functional exercises (e.g., jogging in place, jumping jacks in place, modified burpees in place, etc.) in both the morning (AM) and evening (PM), completing a total of 8 minutes per day. The exercises must be performed at high intensity, with a score of \>8 on a modified Borg scale.
223895693|NCT06848764|DRUG|Lidocaine|Patients will receive lidocaine (1.5 mg/kg loading then 1mg/kg/h infusion) just after induction of anesthesia induction and continued until the end of the operation.
223895694|NCT06848764|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg/kg/h just after induction of anesthesia induction and continued until the end of the operation.
224276467|NCT04993417|OTHER|Motor imagery technique along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. The patients were mentioned to play out the emotional facial appearances for non-verbal correspondence i-e pleasure, misery, interest, appall, dread, irritation and shock. Patients were then requestedto envision himself winking, for instance, envisioning himself in a wonderful and natural social setting, at that point the patient cognitively addresses, with his eyes shut, the movement of decaying the recognized central issues, without creating any specific movement.
223895695|NCT06843707|OTHER|Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.|This study focuses on monitoring serum metabolites in lung cancer patients by utilizing tissue and peripheral blood samples. By analyzing the metabolic profiles of serum, the research aims to identify significant metabolic alterations associated with lung cancer progression, treatment response, and overall prognosis. The study seeks to provide a comprehensive understanding of how metabolic changes in serum reflect disease dynamics and therapeutic outcomes, ultimately contributing to the development of more accurate diagnostic and prognostic biomarkers for lung cancer management.
223895696|NCT06848556|DRUG|tirapazamine|Intra-arterial injection into the tumor feeding artery
223895697|NCT06848556|PROCEDURE|Transarterial Embolization|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
223895698|NCT06848556|PROCEDURE|TACE|Patients received standard Transarterial Chemoembolization (TACE) with intra-arterial injection of a mixture of epirubicin and iodized oil at a personalized dose, followed by embolization completed by injecting a suspension of gelatin sponge and contrast agent.
223895699|NCT06178900|DIAGNOSTIC_TEST|Assisted by the AI-Gatekeeper software group|The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.
223895700|NCT06849947|DRUG|Ribociclib with fulvestrant|"▪ Ribociclib group~\- Ribociclib (600 mg orally once daily on days 1 to 21 in a 28 day cycle) + Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day 15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)"
223895701|NCT06849947|DRUG|Physician's choice treatments group|"▪Fulvestrant or exemestane group~1. Fulvestrant (500mg intramuscular injection on day 1 in a 28 day cycle and day15 of Cycle 1) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or periomenopausal women) OR,~2. Exemestane (25 mg orally once daily on day 1 to 28 in a 28 day cycle) + Everolimus (10 mg orally once daily on day 1 to 28 in a 28 day cycle) ± Leuprorelin (3.75 mg subcutaneously every 28 days in premenopausal or perimenopausal women)"
223895702|NCT05623202|BEHAVIORAL|Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults|The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
223895703|NCT04469842|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Immunosuppression regimen with Tacrolimus Extended Release as the backbone.
223895704|NCT04469842|DRUG|Tacrolimus|Standard Immunosuppression regimen with Intermediate-Release Tacrolimus.
224276468|NCT04993417|OTHER|Mime Therapy along with EMS|All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
223712424|NCT04394117|DRUG|Angiotensin Receptor Blockers|Angiotensin Receptor Blockers (ARBs) have been in clinical use for more than 30 years for their cardiac and renal protective effects. ARBs mechanism of action is through selective inhibition of angiotensin-II (Ang-II) by competitive antagonism of the angiotensin receptor. ARBs displace ang-II from the angiotensin I receptor and produce their protective effects by reducing the downstream effects of ang-II induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic response The virus causing COVID-19, SARS-CoV-2, binds to the extracellular portion of Angiotensin-Converting-Enzyme-2 (ACE2) expressed on type II alveolar cells in the lungs which is followed by internalization of ACE2 before downregulating membrane ACE2 expression. Both these components appear to require angiotensin receptor Type 1 (AT1R), and ARBs, which block the actions of AT1R, would reduce the severity of COVID-19 and reduce the duration of symptoms
223712425|NCT04394117|OTHER|Placebo|Placebo
223895705|NCT04469842|DRUG|Mycophenolate Mofetil Hydrochloride|Standard immunosuppression of the anti-proliferative class.
223895706|NCT04469842|DRUG|Prednisone|Standard immunosuppression (corticosteroid class).
223895707|NCT04469842|DRUG|Azathioprine|Standard immunosuppression of the anti-proliferative class.
223895708|NCT05691270|BEHAVIORAL|IN-Control (Birth Control Navigator Program)|Pilot Study of IN-Control Program within the state of Indiana
223895709|NCT05281237|DEVICE|AveCure 16 Gauge Flexible Microwave Ablation Probe|Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
223895710|NCT05549713|PROCEDURE|Upper blepharoplasty|Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
223895711|NCT04843683|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy (SBRT) is a type of radiation treatment that delivers precise, high dose radiation to targeted areas. In this study, a single treatment of SBRT will be delivered to the abnormal area of a participant's heart that is causing dangerous heart rate and rhythm changes (arrhythmia).
224276469|NCT00996697|DRUG|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
224276470|NCT00996697|DRUG|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
224276471|NCT03433404|PROCEDURE|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
223712426|NCT02430012|BEHAVIORAL|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
223712427|NCT05777850|PROCEDURE|Conventional cavotricuspid isthmus ablation|Point-by-point 25-40 W applications at the CTI of unlimited duration until achieving the pre-established Ablation Index.
223895712|NCT05681572|DRUG|Midazolam|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Midazolam , by a blinded nurse.
223895713|NCT05681572|DRUG|Dexmedetomidine|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Dexmedetomidine , by a blinded nurse.
223895714|NCT05681572|DRUG|Placebo|45 minutes before entering the operating room, patient receives the oral treatment according to their randomization arm, here Grenadine Syrup, by a blinded nurse.
223895715|NCT03985839|DEVICE|MICRORAPTOR™ REGENESORB™ Suture Anchor|Smith \& Nephew MICRORAPTOR™ REGENESORB™ Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone.
223895716|NCT03985839|DEVICE|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor|MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor is fixation device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (REGENESORB™), and a non-absorbable PEEK (Polyether ether ketone) distal anchor tip.
223895717|NCT03985839|DEVICE|MICRORAPTOR™ Knotless PEEK Suture Anchor|The MICRORAPTOR™ Knotless PEEK Suture Anchor is a class IIb device, which consists of an anchor on an inserter, and a suture threader. The anchor consists of the following components: a proximal anchor body (PEEK), and a non-absorbable PEEK distal anchor tip.
223895718|NCT06177990|OTHER|Caregiver as Navigator: Develop Skills Online (CAN-DO) program|"Online, asynchronous psychoeducation program for dementia family caregivers. The program is meant to enhance caregivers' knowledge and skills for navigating healthcare, financial, legal, and family systems.~The program has three main sections.~* The first section provides information and how to prepare for using the healthcare system and community-based services in dementia care and support.~* The second provides information about how to be more effective when using the financial and legal system either for yourself or your person.~* The third section of the course provides information about ways to manage and navigate family dynamics present in various caregiving scenarios more effectively."
223895719|NCT06177990|OTHER|Healthy Living online course|"Online program for dementia family caregivers about Healthy Living for the first 4 months post-randomization."
223895720|NCT01396278|DRUG|Placebo|Placebo matching fluticasone propionate HFA MDI
223895721|NCT01396278|DRUG|Fluticasone propionate|Fluticasone propionate HFA MDI
223895722|NCT01396278|DRUG|BI 54903|BI 54903 via Respimat inhaler
224276472|NCT03433404|PROCEDURE|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
223712428|NCT05777850|PROCEDURE|High-power short-duration ablation|Point-by-point 90W applications at the CTI ablation during 4 seconds.
223712429|NCT00019097|DRUG|autologous tumor cell vaccine|
223712430|NCT00019097|DRUG|keyhole limpet hemocyanin|
223712431|NCT00019097|DRUG|melphalan|
223895723|NCT01088542|BEHAVIORAL|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
223895724|NCT06151015|OTHER|Nitrate-rich beetroot juice plus calorie-restricted diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a calorie-restricted diet (1,000kcal deficit).
223895725|NCT06151015|OTHER|Nitrate-rich beetroot juice plus weight-maintenance diet|One daily bottle (70ml) of nitrate-rich beetroot juice with a weight-maintenance diet (energy will be met).
223895726|NCT04786106|DRUG|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)|Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.
224276473|NCT00268762|DRUG|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
223712432|NCT00019097|DRUG|sargramostim|
223712433|NCT03391180|DRUG|ICON Remineralization|A material used for the Remineralization of white spot lesions.
223712434|NCT03391180|DRUG|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
223712435|NCT05393804|BIOLOGICAL|Ide-cel (bb2121)|Eligible patients will undergo leukapheresis, receive lymphodepleting (LD) chemotherapy followed by infusion of Ide-Cel or Cilta-Cel, and be monitored daily for 14 days, three times a week until day + 30 after CAR T infusion and monthly until 12 months post CAR T infusion.
223712436|NCT06281223|OTHER|intraoperative neuroelectrophysiological monitoring|"The procedure involves intraoperative neuroelectrophysiological monitoring. The aim is to record the electrical activity of the central and peripheral nervous system at several levels during a neurosurgical procedure.~The equipment used comes from INOMED and consists of :~* a recording station (ISIS)~* scalp corkscrew electrodes (2 to 4 electrodes)~* a 4-pin FSR spinal cord electrode (Ad-Tech)~* hook electrodes for roots/radicles (X2)~* needle electrodes for muscles (X18)~Electrode placement and recording take place in the operating room while the patient is under general anaesthetic (intubated and sedated)."
223712437|NCT04200950|DEVICE|Previse|Machine learning algorithm for early acute kidney injury (AKI) prediction.
223712438|NCT03821883|DRUG|Aspirin Tablet|Aspirin 100mg qd
223712439|NCT03821883|DRUG|Placebo|Placebo qd
223712440|NCT04483141|DIAGNOSTIC_TEST|Abbey Pain Scale|Hetero-assessment of pain
223712441|NCT04146233|OTHER|Point of care gastric ultrasound|Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
223712442|NCT03094169|DRUG|AVID100 IV|AVID100 is administered once every 3 weeks
223895727|NCT04786106|PROCEDURE|Penile Plication Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
223895728|NCT04786106|PROCEDURE|Incision and Grafting (I&G) Surgery|Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures \<70 degrees; I\&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I\&G) will ultimately be decided based on the primary investigator's clinical judgment.
223712443|NCT04645953|COMBINATION_PRODUCT|3mg AZ-010|Subjects who received a single inhaled dose (3mg)
223712444|NCT04645953|COMBINATION_PRODUCT|1mg AZ010|Subjects who received a single inhaled dose (1mg)
223712445|NCT04645953|COMBINATION_PRODUCT|Staccato Placebo|Subject who received a single inhaled dose (Staccato Placebo)
223895729|NCT04786106|DEVICE|RestoreX Penile Traction Device|RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.
223895730|NCT02143726|DRUG|sorafenib|Given PO
223895731|NCT02143726|DRUG|everolimus|Given PO
223895732|NCT04175119|DEVICE|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
223895733|NCT02322060|PROCEDURE|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
223895734|NCT02322060|PROCEDURE|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
223895735|NCT02322060|PROCEDURE|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
223895736|NCT02322060|PROCEDURE|Ovarian superficial cut|Superficial cut of the ovarian cortex by laparoscopy or laparotomy
223895737|NCT05141487|DEVICE|UroMonitor|The UroMonitor is small wireless sensor that is temporarily inserted into the bladder. While in the bladder it transmits bladder pressure measurements to an external radio. After a short period of use it is removed using an extraction string and discarded.
223895738|NCT05141487|DEVICE|ASCU|The ASCU is a wearable nerve stimulator containing a radio and computer processor. It receives pressure information from the bladder and determines when to turn on sacral nerve stimulation. It is only used temporarily during research visits.
223895739|NCT03899103|DRUG|Rituximab|First course Course Rituximab at Randomization.
223895740|NCT03899103|DRUG|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
223895741|NCT05050591|DEVICE|Patient-Specific Silicone Airway Stent|The Patient-Specific Airway Stent is a silicone stent indicated for use in adults that have stenosis of the airway. Current silicone stents have stock dimensions that do not conform to the patient's airway anatomy. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally design the stent to his/her desired dimensions. Finally, according to the physician's design, a patient-specific stent can be manufactured using additive manufacturing technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
223939952|NCT07190443|DRUG|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|"This intervention consists of adjuvant endocrine therapy alone in patients with HR-positive, HER2-negative breast cancer who have undergone curative treatment for their first LRR, including ipsilateral breast tumor recurrence, chest wall recurrence, or regional lymph node recurrence.~The choice of endocrine therapy (aromatase inhibitor, tamoxifen, or tamoxifen plus ovarian function suppression) is determined based on the patient's menopausal status and prior treatment history, as specified in the protocol. Treatment is continued for five years or until disease recurrence, unacceptable toxicity, or withdrawal of consent.~This intervention does not include CDK4/6 inhibitors."
223712446|NCT04613375|DIAGNOSTIC_TEST|Urine sample collection|Serotype specific UAD (urinary antigen detection) test
223712447|NCT04613375|DIAGNOSTIC_TEST|Saliva collection|Streptococcus pneumonia identification in saliva samples by culture or PCR / RSV identification in saliva samples by PCR
223712448|NCT03800134|DRUG|Durvalumab|1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
223712449|NCT03800134|OTHER|Placebo|Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period
223712450|NCT03800134|DRUG|Carboplatin|Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles
223712451|NCT03800134|DRUG|Cisplatin|75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles
223712452|NCT03800134|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
223712453|NCT03800134|DRUG|Paclitaxel|200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.
223712454|NCT03800134|DRUG|Gemcitabine|1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.
223712455|NCT03800134|PROCEDURE|Surgery|Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
223895742|NCT05787379|BEHAVIORAL|Concordant Care Training|Concordant Care training has four components. 1. Clinicians will complete \~3 hours of online, asynchronous training that will teach them practices including validate Veterans' experiences with Long-COVID, develop shared understanding with patients about Long-COVID, and develop patient-centered action plans. Clinicians will be provided with handouts, case examples, video demonstrations, and practice exercises to help them integrate these practices into care. 2. Tele-mentoring groups will be offered \~bi-weekly and be open to all clinician participant in the Concordant Training arm. Content will include review of specific cases, didactics on specific Concordant Care practices, role-play exercises, and review of session recordings. At least two sessions are required. 3. Clinician Pocket Card that serves as a reminder of the Concordant Care process. 4. An electronic prompt will be sent to enrolled Veterans encouraging them to speak with their clinician about their Long-COVID concerns.
223895743|NCT05787379|BEHAVIORAL|Education Packet Training|Clinicians randomized to the control arm will receive a comprehensive information packet with the latest understanding of Long-COVID. Clinicians will also be provided a packet directing them to relevant VA trainings for Long-COVID. Whole Health trainings which focus on wholistic integrated approaches to care will be highlighted. Whole Health is important for all Veterans, and it is thought to be particularly relevant for poorly understood conditions that don't easily fit in traditional medical model.
223895744|NCT05256394|BEHAVIORAL|Pain Manager + tailored implementation support|Individualized training, technical assistance, and workflow assessments.
223895745|NCT04774965|DEVICE|Slumber Curve sleep aid|Patients who undergo rotator cuff repair and have been consented and randomized to the experimental group will be given a Slumber Curve sleep aid to be used during sleep. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Slumber Curve, patients will be given instructions on how to use the sleep aid while sleeping, and will be asked to use Slumber Curve nightly.
223895746|NCT06239402|OTHER|Observation|Observation of mortality, haemorrhagic and ischemic events in the studied population
224276474|NCT03972696|RADIATION|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
224276475|NCT02827682|DEVICE|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
224276476|NCT02827682|DEVICE|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
223712456|NCT06285279|DRUG|FKC288|"The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.~Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion."
223712457|NCT04993521|PROCEDURE|Block type|Regular block type
223712458|NCT02737098|OTHER|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
223712459|NCT02737098|OTHER|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
223712460|NCT01603498|DRUG|Dexamethasone|Dexamethasone 8mg
223712461|NCT01603498|DRUG|Methylprednisolone|Methylprednisolone 40mg
223712462|NCT04718298|DEVICE|ProFlor laparoscopic technique|Inguinal hernia repair laparoscopic
223712463|NCT00899054|DRUG|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
223712464|NCT00899054|RADIATION|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
223712465|NCT03311633|PROCEDURE|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
223712466|NCT06568614|DRUG|BG-89894|Administered orally
223712467|NCT06414889|DRUG|G-CSF (filgrastim or biosimilar)|Given by IV or SC
223712468|NCT06414889|PROCEDURE|Apheresis|Given by procedure
223712469|NCT06414889|DRUG|Plerixafor|Given by IV
223712470|NCT05845450|DRUG|Trastuzumab deruxtecan|trastuzumab deruxtecan 5.4 mg/kg IV on day 1
223712471|NCT05845450|DRUG|Durvalumab|durvalumab 1500 mg IV on day 1
223712472|NCT05845450|DRUG|Panitumumab|panitumumab 6 mg/kg IV on days 1 and 15
223712473|NCT05845450|DRUG|Botensilimab|botensilimab 1 mg/kg on day 1
223712474|NCT05845450|DRUG|Balstilimab|balstilimab 3 mg/Kg on days 1 and 15
223712475|NCT05845450|DRUG|Sotorasib|sotorasib 960 mg orally once daily from day 1 to 28
223712476|NCT05845450|DRUG|Vorbipiprant|vorbipiprant 90 mg orally bid from day 1 to 28
223712477|NCT05845450|DRUG|Nivolumab|240 mg IV on days 1 and 15
223712478|NCT01964859|BIOLOGICAL|autologous skin fibroblasts|
223712479|NCT05219721|DRUG|CAR-T (CAR-GPRC5D)|CAR-GPRC5D (RD118) is an individualized, gene-modified autologous T-cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. The CAR structure comprises a fully human single-domain antibody fragment (VHH) targeting GPRC5D, fused with intracellular co-stimulatory (4-1BB) and activation (CD3ζ) signaling domains.
223895747|NCT03900793|DRUG|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily, dose level 2 dosing will not exceed 100 mg daily, and dose level 3 dosing will not exceed 150 mg total daily (75 mg twice daily). Doses should be taken at approximately the same time daily and patients should fast for at least 4 hours prior to dosing
223712480|NCT03346018|DIAGNOSTIC_TEST|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~1. Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~2. Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~3. Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~4. Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
223712481|NCT06960564|DEVICE|Hyaluronic Acid injections|Intra-articular hyaluronic acid will be administered to 30 selected patients. Blood and synovial fluid samples will be collected before HA injection and 1 week after 3 sessions of HA injection with one week interval. Home exercise programme will be given.
223712482|NCT06960564|OTHER|Saline -- placebo comparator|Intra-articular saline (SF) will be administered to 20 selected patients. Blood and synovial fluid samples will be collected before and 1 week after 3 session of salin injection with one week interval. Home exercise programme will be given.
223712483|NCT05307055|DEVICE|STN DBS - Theta Burst|200 Hz intraburst stimulation for 0.1 second repeated at intervals of 5hz with an existing device
223712484|NCT05307055|DEVICE|STN DBS - Gamma|Standard of care gamma stimulation with an existing device
223712485|NCT06360536|BEHAVIORAL|Resistance Training|A home-based resistance training condition that is delivered through a web-based platform.
223712486|NCT03296098|DRUG|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
223712487|NCT04797078|PROCEDURE|Transperineal biopsy|Transperineal free hand MRI-US fusion prostate biopsy
223712488|NCT04797078|PROCEDURE|Transrectal biopsy|Transrectal MRI-US fusion prostate biopsy
223712489|NCT06558396|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (20 minutes), nutrition education lesson/cooking lab (65 minutes, odd weeks) OR professional development session (65 minutes, even weeks). On any day during the 2-week cooking period, the students will make a dish using groceries they received with their parent/guardian (1 hour).
223712490|NCT05799586|BEHAVIORAL|Traditional Chinese Medicine health preservation group|The traditional Chinese medicine health preservation intervention for depression was developed based on a previous systematic review and meta-analysis of Traditional Chinese medicine based integrated health interventions for depression, traditional Chinese medicine health preservation textbooks, clinical practice guidelines related to traditional Chinese medicine health preservation and traditional Chinese medicine treatment for depression. The content and structure of traditional Chinese medicine health preservation for depression was achieved among Hong Kong traditional Chinese medicine experts via a Delphi study.
223712491|NCT05799586|BEHAVIORAL|Waitlist control group|Usual care
223712492|NCT03191188|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
223712493|NCT03191188|DRUG|Placebo Oral Tablet|Placebo
223712494|NCT04736693|DRUG|Raloxifene|Raloxifene dispensing claim is used as the reference group.
223712495|NCT04736693|DRUG|Zoledronic Acid|Zoledronic Acid dispensing claim is used as the exposure group.
223712496|NCT03260309|PROCEDURE|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
223712497|NCT03260309|PROCEDURE|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
223712498|NCT03070028|PROCEDURE|crystallised phenol|crystallised phenol will be applied to sinus cavity
223712499|NCT03070028|PROCEDURE|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
223712500|NCT04203654|BEHAVIORAL|cognitive-behavior group therapy|cognitive-behavior group therapy Frequency: thrice a week Treatment duration: 16 week
223712501|NCT04203654|BEHAVIORAL|Individual supportive psychotherapy|Individual supportive psychotherapy 3 sessions during the 16-week treatment period
223712502|NCT06013397|DIETARY_SUPPLEMENT|Ketogenic diet|"Ketogenic diet (KD) is a high-fat, low-carbohydrate and moderate protein diet pattern, suitable for refractory epilepsy, glucose carrier protein 1 deficiency, pyruvate dehydrogenase deficiency, tumors and some genetic metabolic diseases. The ketogenic diet has been used to treat epilepsy for nearly 100 years, and its safety has been recognized by the medical community. In 2015, the ketogenic diet was included in the Clinical Diagnosis and Treatment Guidelines - Epilepsy Volume and became a commonly used treatment for refractory epilepsy."
223712503|NCT05944887|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
223712504|NCT05944887|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
223712505|NCT05944887|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol
223712506|NCT05944887|PROCEDURE|gastroscopy|esogastroduodenoscopy
223712507|NCT01921387|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
223712508|NCT01921387|DRUG|Carmustine|Given IV
223712509|NCT01921387|DRUG|Cytarabine|Given IV
223712510|NCT01921387|DRUG|Etoposide|Given IV
223712511|NCT01921387|OTHER|Laboratory Biomarker Analysis|Correlative studies
223712512|NCT01921387|DRUG|Melphalan|Given IV
223712513|NCT01921387|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
223712514|NCT01921387|RADIATION|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
223712515|NCT00030290|PROCEDURE|high-intensity focused ultrasound ablation|
223895748|NCT03900793|DRUG|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2. Sunitinib is given as capsules or liquid formulation. Doses should be taken at approximately the same time daily.
223712516|NCT05046093|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|"When the lung nodule is visualized by thin bronchoscope (4mm) with R-EBUS, cryobiopsy is performed. If not visualized, ultrathin (3mm) bronchoscope is used.~Cryobiopsy is performed with 1.1mm cryo-probe."
223712517|NCT04946747|DEVICE|Modern microelectrical mechanical systems (MEMS) head-impact sensors|Both groups will wear our smart head-impact sensor system (MEMS head-impact sensors) to measure their response to training.
223712518|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with consistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Trained group will have the conditioned stimulus (CS, images of opposing players approaching) and the unconditioned stimulus (US, a voice cue to stiffen the neck by the coach) always being delivered with a consistent timing relationship (e.g. a 250 msec delay between the CS and the US), causing the conditioned response (neck stiffening) to emerge.
223712519|NCT04946747|OTHER|Virtual Reality (VR) Goggle Use with inconsistent timing of Conditioned Stimulus and Unconditioned Stimulus|The Control group will also receive the same CS and the same US as trained group, but the CS and the US will bear no consistent timing relationship, therefore never causing any CR to emerge.
223712520|NCT00318448|DRUG|Zolpidem (SL800750)|
223712521|NCT06556368|DRUG|Tarcocimab tedromer|Intravitreal injection
223712522|NCT06556368|DRUG|Tabirafusp tedromer|Intravitreal injection
223712523|NCT06556368|DRUG|Aflibercept|Intravitreal injection
223712524|NCT02537119|PROCEDURE|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
223712525|NCT02537119|PROCEDURE|Massage therapy|Rubbing on hamstrings
223712526|NCT03593096|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
223712527|NCT03593096|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
223712528|NCT05010057|DIETARY_SUPPLEMENT|New Zealand blackcurrants (NZBC)|NZBC capsules containing anthocyanin-rich blackcurrant extract
223712529|NCT05010057|DIETARY_SUPPLEMENT|Placebo (PLA)|Placebo capsules containing microcrystalline cellulose
223712530|NCT01998776|DRUG|Misoprostol|Misoprostol 200ug four times daily
223712531|NCT01998776|DRUG|Placebo|Placebo Starch four times daily
223712532|NCT02261896|DRUG|Placebo|Evaluate usefullness of antibiotic prophylaxis
223895749|NCT05286970|DRUG|AK115|Abdominal subcutaneous injection
223712533|NCT02261896|DRUG|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
223712534|NCT06095583|DRUG|Tifcemalimab injection|200mg once every 3weeks
223712535|NCT06095583|DRUG|toripalimab injection|240mg once every 3 weeks
223712536|NCT06095583|DRUG|Placebo for Tifcemalimab|every 3weeks
223712537|NCT06095583|DRUG|Placebo for toripalimab|every 3weeks
223712538|NCT00541593|PROCEDURE|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
223712539|NCT05434000|DRUG|Hydroxyurea|Children at risk of developing stroke (TCD values\>200cm/s) will be given 20mg/kg of Hydroxyurea
223712540|NCT01497431|DIETARY_SUPPLEMENT|Selenium|Given PO
223712541|NCT01497431|OTHER|Placebo|Given PO
223712542|NCT01497431|OTHER|Laboratory Biomarker Analysis|Correlative studies
223712543|NCT01497431|OTHER|Pharmacological Study|Correlative studies
223712544|NCT01497431|DRUG|Methylselenocysteine|Given PO
223712545|NCT06066164|DEVICE|Transcranial magnetic stimulation (TMS)|Trans-cranial magnetic stimulation (TMS) is a safe and painless technique for evoking activity in neurons in the human brain through the intact scalp and skull To measure cortical excitability
223712546|NCT03605589|DRUG|Blinatumomab|Continuous IV infusion
223712547|NCT03605589|DRUG|Pembrolizumab|IV infusion
223712548|NCT00135096|DRUG|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
223712549|NCT00135096|DRUG|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
223712550|NCT02241629|DRUG|placebo|placebo of levo phencynonate hydrochloride
223712551|NCT02241629|DRUG|levo phencynonate hydrochloride|levo phencynonate hydrochloride
223712552|NCT00327275|BEHAVIORAL|strength training|
223712553|NCT06264414|DRUG|DTT106|oral route
223712554|NCT06264414|DRUG|Dutasteride-Tamsulosin|oral route
223712555|NCT01004965|OTHER|laboratory biomarker analysis|
223712556|NCT06142071|BEHAVIORAL|Telephone questionnaire|Telephone questionnaire, which includes questions on participant's demographics, anxiety/depression scores, what support they find helpful and what additional support they feel would be beneficial
223712557|NCT03828175|PROCEDURE|spinal anesthesia monitoring|"After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative"
223712558|NCT02051504|BEHAVIORAL|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
224276477|NCT04046380|DIAGNOSTIC_TEST|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
224276478|NCT05179122|PROCEDURE|Surgical drain|In this arm a surgical drain will be inserted prior to surgical wound closure
223712559|NCT02051504|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
223712560|NCT02051504|PROCEDURE|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
223712561|NCT02051504|PROCEDURE|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
223712562|NCT02051504|PROCEDURE|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
223712563|NCT02051504|PROCEDURE|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
223712564|NCT02051504|OTHER|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
223712565|NCT03582878|DRUG|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
223712566|NCT03582878|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
223712567|NCT00510497|BIOLOGICAL|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
223712568|NCT03206775|BEHAVIORAL|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~* Visual Sweeps~* Sustained Visual Attention~* Associative Learning--Visual~* Associative Learning--Auditory~* Emotion Motion~* Voice Choice"
223712569|NCT03206775|BEHAVIORAL|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~* On trails: Learning~* Line Length Discrimination~* Tap the Emotion~* Sound Sweeps~* BIS/BAS~* TEPS~* Feasibility survey"
223712570|NCT03206775|BEHAVIORAL|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~* Visual Time Order Judgment~* Target Tracker~* Emotional Face~* Auditory Sound Discrimination~* BIS/BAS~* TEPS~* Feasiblity assessment"
223712571|NCT03206775|BEHAVIORAL|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~* Stroop 2AFC~* Visual Task Switcher~* Beep Seeker~* Voice Choice~* BIS/BAS~* TEPS~* Feasibility Survey"
223712572|NCT04568044|PROCEDURE|Blood sample|Peripheral blood sample will be obtained.
223712573|NCT01706146|DRUG|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
223712574|NCT03831399|DIETARY_SUPPLEMENT|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
223712575|NCT03831399|DIETARY_SUPPLEMENT|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
223712576|NCT02128971|DIETARY_SUPPLEMENT|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
223712577|NCT02128971|DIETARY_SUPPLEMENT|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
223712578|NCT02128971|DIETARY_SUPPLEMENT|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
223712579|NCT02128971|DIETARY_SUPPLEMENT|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
223712580|NCT02128971|DIETARY_SUPPLEMENT|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
223712581|NCT02128971|DIETARY_SUPPLEMENT|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
223712582|NCT04459728|BEHAVIORAL|Wellness Element 1: Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
223712583|NCT04459728|BEHAVIORAL|Wellness Element 2: Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
223712584|NCT04459728|BEHAVIORAL|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
223712585|NCT04459728|BEHAVIORAL|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on social connectedness; adherence documented online daily
223712586|NCT04459728|BEHAVIORAL|Wellness Element 5 - Nutrition|Daily wellness element focusing on nutrition; adherence documented online daily
223712587|NCT04459728|BEHAVIORAL|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
223712588|NCT04459728|BEHAVIORAL|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
223712589|NCT00932100|DRUG|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
223712590|NCT00932100|DRUG|Heparin|IV dose per standard of care at the local institution
223712591|NCT01597531|DRUG|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
223712592|NCT01597531|DRUG|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
223895750|NCT05286970|DRUG|Placebo|Abdominal subcutaneous injection
223895751|NCT06492031|DRUG|Icodextrin Peritoneal Dialysis Solution|The treatment modality, treatment frequency, treatment dose, duration of dwell, and length of treatment, as determined and supervised by a prescribing physician experienced in treating ESRD with PD.
223895752|NCT06492031|DRUG|Glucose Peritoneal Dialysis Solution|The treatment modality, number of daily dialysate exchanges, dialysate concentration, exchange dosage of dialysate, duration of dwell, and length of treatment for PD patients as determined by the clinician.
223895753|NCT04515576|DRUG|LY3493269|Administered SC
223895754|NCT04515576|DRUG|Dulaglutide|Administered SC
223895755|NCT04515576|DRUG|Placebo|Administered SC
223895756|NCT06166654|DRUG|Acetazolamide|1\. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.
223895757|NCT06166654|DRUG|Metolazone 2.5 MG|2\. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.
224276479|NCT03578822|DRUG|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
223712593|NCT01597531|DRUG|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
223712594|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.|Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
223712595|NCT04590131|PROCEDURE|recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.|Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
223712596|NCT03499977|BEHAVIORAL|Sitting|10 min bouts
223712597|NCT03499977|BEHAVIORAL|Light-Intensity Cycling|10min bout
223712598|NCT03499977|BEHAVIORAL|Moderate-Intensity Cycling|10 min bout
223712599|NCT03499977|BEHAVIORAL|High-Intensity Cycling|10 min bout
223712600|NCT00675948|DRUG|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
223712601|NCT00675948|DRUG|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
223712602|NCT03857893|DEVICE|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
223712603|NCT03857893|DRUG|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
223895758|NCT06166654|OTHER|Double-placebo|This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
223895759|NCT05777889|OTHER|Forward Looking InfraRed Camera|"Forward Looking InfraRed Camera:~1. We will use a FLIR T420 or T62101 camera with a resolution of 320\*240.~2. Each image will be captured perpendicularly with a 1-inch gap on all four sides.~3. A Myler blanket placed in the background will separate the feet from the background.~4. The camera will be normalized to a temperature range of 15°C to 40°C.~5. The images will be saved in radiometric JPEG format.~6. Once the images have been transferred to a computer, we will remove the background.~7. Next, we'll make a temperature histogram with 0.1°C temperature bin resolution.~8. The before and after histograms (IB, IA) will be compared to see which one indicates more extreme temperature distributions.~9. Those who improve by 30% or more are considered to have had a successful spinal cord stimulation."
224276480|NCT03578822|DRUG|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
224276481|NCT03578822|DRUG|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
224276482|NCT03578822|DRUG|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
224276483|NCT05820828|DIAGNOSTIC_TEST|Volume control|Volume control in venous reservoir during extracorporeal circulation.
224276484|NCT05289557|DRUG|Bonjesta|Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
223712604|NCT05146310|DEVICE|I.SPACE®|"I.SPACE® is a viscoelastic sodium hyaluronate gel use as a surgical aid in ophthalmic anterior segment surgery by maintaining the intraocular space and protecting the corneal endothelium.~The baseline injection is performed at V1. The volume of product to use will be at the Investigator discretion, and will be completely removed after surgery."
223712605|NCT02582983|DRUG|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
223712606|NCT00742430|PROCEDURE|PCI|percutaneous coronary intervention in stable coronary artery disease
223712607|NCT01528475|BEHAVIORAL|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
223712608|NCT05428046|BEHAVIORAL|MHL intervention|The current MHL intervention is a brief online intervention and comprises two modules. The first module is a short video introducing a teenage girl with bulimia nervosa. The second module is an online lecture comprising information about eating disorders including the prevalence, symptoms, type, cause, treatment, a related symptom checker, and sources of help. The above two modules are implemented in a single session lasting approximately 2 hours.
223712609|NCT05428046|BEHAVIORAL|Waiting list|Participants assigned to the waiting list group will not receive any intervention until the end of the 12 weeks follow-up. They received the same intervention as the MHL intervention group after the 12 weeks follow-up test.
223712610|NCT03461913|PROCEDURE|Cesarean section|Lower segment elective Cesarean section
223712611|NCT03026660|DIETARY_SUPPLEMENT|Moringa Oleifera|
223712612|NCT03026660|DIETARY_SUPPLEMENT|Cabbage Placebo|
223712613|NCT00528463|PROCEDURE|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
223712614|NCT05178771|OTHER|Platelet rich fibrin|"1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted."
223712615|NCT03280901|OTHER|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
223712616|NCT02275858|DEVICE|Stiffening wire|Stiffening wire
223712617|NCT02275858|DEVICE|Placebo wire|Placebo wire
223712618|NCT04044378|DRUG|Famitinib|famitinib with RP2D orally daily
223712619|NCT04044378|DRUG|Ifosfamide|ifosfamide 1.8g/m2/d d1-3, 15-17 Q4W infusion
223712620|NCT04044378|DRUG|Camrelizumab|camrelizumab 200mg infusion once Q2W
223712621|NCT01476956|OTHER|Observational study|RA patients on standard DMARD therapy
223712622|NCT04449081|BEHAVIORAL|Knowledge, Attitude, Practice, Awareness, Preference|KAP, Awareness level and Preference were assessed using questionnaires
223712623|NCT04843137|DEVICE|Cervical Transcutaneous Electrical Spinal Cord Stimulation|Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
223712624|NCT04302896|DRUG|dolutegravir oral tablet 50mg|"Tivicay® (dolutegravir, DTG), a HIV-1 integrase strand transfer inhibitor (INSTI), is FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 30kg. Tivicay® 50mg tablets \[GlaxoSmithKline\] are yellow, round, film-coated, biconvex tablets debossed with SV 572 on one side and 50 on the other side. The inactive ingredients in each tablet are D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients iron oxide yellow macrogol/PEG, polyvinyl alcohol-part hydrolyzed, talc, and titanium dioxide."
223712625|NCT04302896|DRUG|emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg|"Descovy® (emtricitabine/tenofovir alafenamide, FTC/TAF) is a combination of two HIV nucleoside analog reverse transcriptase inhibitors (NRTIs) FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg. Descovy® 200 mg/25 mg tablets \[Gilead\] are blue, rectangular-shaped, and film-coated with GSI debossed on one side and 225 on the other side. The inactive ingredients are croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablets are film-coated with a coating material containing indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide."
223712626|NCT04302896|DRUG|tenofovir disoproxil fumarate oral tablet 300mg|"Viread® (tenofovir DF, TDF) is a nucleotide analog HIV-1 reverse transcriptase inhibitor and a hepatitis B reverse transcriptase inhibitor FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents and for the treatment of chronic hepatitis B in adults and pediatric patients 2 years of age and older weighing at least 10kg. Viread® 300mg tablets \[Gilead\] are almond-shaped, light blue, film-coated tablets containing 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with GILEAD and 4331 on one side and with 300 on the other side. The inactive ingredients in each tablet are croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. Viread® 300mg tablets are coated with Opadry II Y-30-10671-A, which contains FD\&C blue #2 aluminum lake, hypromellose 2910, lactose monohydrate, titanium dioxide, and triacetin."
223895760|NCT05834257|PROCEDURE|Normal Saline for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Normal Saline infusion (as clinically prescribed).
223712627|NCT04302896|DRUG|lamivudine oral tablet 300mg|"Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide."
223712628|NCT03699605|OTHER|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
223712629|NCT03699605|OTHER|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
223712630|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
223712631|NCT03236285|BEHAVIORAL|Continous exercise training in the fed state|Continous exercise training in the fed state
223712632|NCT03236285|BEHAVIORAL|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
223712633|NCT03236285|BEHAVIORAL|Continous exercise training in the fasting state|Continous exercise training in the fasting state
223712634|NCT06091631|PROCEDURE|Magnesium sulfate vaporization|pre-opeative magnesium sulfate vaporization
223712635|NCT05253729|DEVICE|Focused ESWT|F-ESWT (dose 0.01-0.15 mJ/mm2, frequency 4-5 Hz, 1500 shocks) was applied perpendicular to the palmar side of the wrist which was done once a week for a total of three sessions plus conservative treatment.
223712636|NCT05253729|BEHAVIORAL|Control|Participants in the control group received only conservative treatment including disease education, advice about proper posture and activity, night wrist splint and nerve gliding exercise.
223712637|NCT04946383|DRUG|Dasatinib plus Quercetin|Dasatinib plus Quercetin
223712638|NCT02477150|BIOLOGICAL|Zostavax|Vaccination of a zoster vaccine (Zostavax)
223712639|NCT02477150|BIOLOGICAL|placebo|placebo administration
223712640|NCT05251987|BIOLOGICAL|PD1+ T Cell Expression|The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
223712641|NCT02259881|DRUG|Low dose of BIBT 986 CL, per i.v. infusion|
223712642|NCT02259881|DRUG|Medium dose of BIBT 986 CL, per i.v. infusion|
223712643|NCT02259881|DRUG|High dose of BIBT 986 CL, per i.v. infusion|
223712644|NCT02259881|DRUG|Placebo|
223712645|NCT02259881|DRUG|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
223712646|NCT00078182|DRUG|Tenofovir DF|
223712647|NCT05604352|DEVICE|DiaSole|Diabetic ulcer offloading insole
223712648|NCT04655638|DEVICE|High Flow Nasal Therapy|High flow nasal therapy will be delivered by any device (standalone machine or ventilators able to deliver it). The initial flow rate will be set at 40 L/min and potentially increased up to 60 L/min, according to patient tolerance. Large-bore nasal prongs will be selected according to the size of patients' nostrils (i.e. 2/3 of the diameter of the patient's nostril). A surgical mask will be placed on top of the HFNT interface. The temperature will be set at 37°C or 34 °C according to the patient's comfort. The FiO2 will be adjusted to maintain SpO2 between 92-96%.
223712649|NCT04655638|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen therapy will be delivered by any device or combination of devices used for delivering oxygen such as nasal cannula, Venturi Mask or Mask with or without a reservoir bag as per usual local practice. Oxygen flow will be titrated to achieve SpO2 between 92-96%.
223712650|NCT05310890|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
223712651|NCT05310890|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
223712652|NCT02114216|PROCEDURE|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
223712653|NCT05617469|OTHER|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images|develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis
223712654|NCT06072846|BEHAVIORAL|Reiki Energy Therapy|Reiki Therapy will be applied to the intervention group
223712655|NCT00469274|DRUG|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
223712656|NCT00469274|DRUG|Antibiotic PEP|TMP-SMX DS po BID for 14 days
223712657|NCT01059591|DRUG|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
223712658|NCT01059591|DRUG|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
223712659|NCT01059591|RADIATION|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
223712660|NCT01081678|DRUG|Placebo|Administered by subcutaneous (under the skin) injection
223712661|NCT01081678|DRUG|Romosozumab|Administered by subcutaneous injection
223895761|NCT05834257|PROCEDURE|PlasmaLyte for fluid resuscitation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).
223895762|NCT05834257|PROCEDURE|Ringer's Lacatate for fluid resusciation|Fluid resuscitation is a critical and essential part in cardiac surgery procedures. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
223895763|NCT01085253|OTHER|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
223895764|NCT04637620|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of MDD
223895765|NCT04637620|DRUG|Sertraline|Use of SSRI as an active comparator
223895766|NCT04637620|DRUG|Placebo Cap|Use of placebo as a comparator
223712662|NCT03728920|OTHER|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
223712663|NCT04824352|DRUG|apatinib|Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
223712664|NCT00158574|DRUG|sulphadoxine-pyrimethamine|
223712665|NCT00158574|DRUG|mefloquine|
223712666|NCT00158574|DRUG|Chlorproguanil-dapsone|
223712667|NCT00158574|DRUG|Placebo|Placebo
223712668|NCT00158574|DRUG|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
223712669|NCT00158574|DRUG|IPTi mefloquine|IPTi doses 1 \& 2 at ages 2 \& 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
223712670|NCT00158574|DRUG|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
223712671|NCT02326532|OTHER|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
223712672|NCT02326532|OTHER|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
223712673|NCT01507012|DIETARY_SUPPLEMENT|Berry Polyphenols|
223712674|NCT01507012|DIETARY_SUPPLEMENT|Placebo|Placebo control containing sugar and artificial flavouring.
223712675|NCT02624609|OTHER|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
223712676|NCT02624609|OTHER|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
223712677|NCT02249585|DEVICE|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
223895767|NCT04648878|OTHER|Hybrid combination of physical therapy and powered exoskeleton|18 alternating visits of conventional physical therapy and powered exoskeleton gait training with a wearable robotic powered exoskeleton , three times a week for approximately 6 weeks
223895768|NCT04648878|OTHER|Powered Exoskeleton Only|18 visits of powered exoskelton only, three times a week for approximately 6 weeks
223712678|NCT02249585|DEVICE|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
223712679|NCT02249585|DRUG|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
223712680|NCT02249585|DRUG|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
223712681|NCT04130620|DIAGNOSTIC_TEST|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
223712682|NCT02062021|OTHER|No intervention|
223712683|NCT04574011|DIAGNOSTIC_TEST|Passive leg raising|Raise the patient's lower limb at a 45 degree angle while lying down
223712684|NCT02118883|OTHER|Essentia Water|
223712685|NCT02118883|OTHER|Bottled water|
223712686|NCT01934023|DRUG|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
223712687|NCT01934023|DRUG|Placebo|
223712688|NCT03998930|OTHER|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
223712689|NCT01610570|DRUG|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
223712690|NCT02900339|DEVICE|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
223712691|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
223895769|NCT04648878|OTHER|Physical Therapy only|18 visits of physical therapy only, three times a week for approximately 6 weeks
223895770|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
223895771|NCT01461655|DRUG|marketed topical NSAID|once daily application, 4 weeks
223712692|NCT00444912|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5\*10\^6 CD34+ cells/kg were collected.
223712693|NCT00444912|BIOLOGICAL|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
223712694|NCT02508181|DEVICE|I-gel|supraglottic airway device without cuff
223712695|NCT02508181|DEVICE|LMA Supreme|supraglottic airway device with cuff
223712696|NCT00149162|DRUG|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
223712697|NCT02295384|OTHER|Retrospective Audit|Retrospective Audit
223712698|NCT01698372|DEVICE|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
223712699|NCT04326556|OTHER|Prospective cohort for etiological and prognostic purposes|Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
223712700|NCT00310167|RADIATION|radiation therapy|
223712701|NCT01517711|DRUG|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
223712702|NCT01517711|DRUG|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
223712703|NCT01466335|DRUG|Ronacaleret (100mg tablet)|100mg tablet
223712704|NCT01466335|DRUG|Placebo|matching placebo tablet
223712705|NCT03800797|DRUG|Loxoprofen sodium hydrogel patch|100 mg per day
223712706|NCT03800797|DRUG|Loxoprofen sodium tablet|60 mg t.i.d.
223712707|NCT02376231|DEVICE|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
223712708|NCT02560597|PROCEDURE|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
223712709|NCT04157491|DRUG|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
223712710|NCT00318422|DRUG|liraglutide|
223712711|NCT00318422|DRUG|rosiglitazone|
223712712|NCT00318422|DRUG|glimepiride|
223712713|NCT04218630|OTHER|Reformer pilates exercises|The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.
223712714|NCT04218630|OTHER|Home mat pilates exercises|The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
223712715|NCT03415334|BEHAVIORAL|behavioral development for change|"1. Social Marketing Principles (4 Ps) Product, price, place and promotion~2. Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
223712716|NCT01906398|OTHER|ketogenic diet|KD will consist of 3:1 \[fat\]: \[protein + carbohydrate\] weight ratio, with 1600 kcal restriction
223712717|NCT01007812|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
223712718|NCT01007812|DEVICE|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
223712719|NCT01091974|DRUG|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
223712720|NCT01091974|DRUG|Placebo Comparator|Placebo for 47 days
223712721|NCT01091974|BEHAVIORAL|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
223712722|NCT04556513|OTHER|Paraclinical examination|Respiratory functional tests
223712723|NCT04556513|OTHER|Clinical Examination|Clinical Examination
223712724|NCT04556513|OTHER|Semi-directive interview|By phone
223712725|NCT04556513|OTHER|quality of life questionnaires|SF36, VSRQ, IESR, HADS
223712726|NCT04524910|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
223712727|NCT04511169|BEHAVIORAL|digital self-help|The digital self-help program is targeting every-day ADHD symptoms in adults with a diagnosed ADHD
223712728|NCT02325960|DRUG|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
223712729|NCT02325960|DRUG|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG \<6.1 mmol/L. Titration is only allowed in first 4 weeks.
223895772|NCT01461655|DRUG|vehicle gel|once daily application, 4 weeks
223895773|NCT01461655|DRUG|marketed topical retinoid|once daily application, 4 weeks
223895774|NCT05740904|OTHER|New defocus spectacle lenses|The children in the new defocus spectacle lens group will wear new defocus spectacle and receive follow-up examinations every half year.
223895775|NCT05740904|OTHER|Convenional aspheric single-vision spectacle lenses|The children in the convenional aspheric spectacle lenses group will wear conventional aspheric single-vision spectacle and receive follow-up examinations every half year.
223895776|NCT06470191|DRUG|B007|B007： Subcutaneous injection was administered on days 1 and 15
223895777|NCT06470191|DRUG|Cyclosporin Capsules|Cyclosporin Capsules： Orally, 3.5 mg/kg/d；
223712730|NCT02499783|BIOLOGICAL|adalimumab|subcutaneous injections of adalimumab
223712731|NCT02499783|OTHER|placebo|subcutaneous injections of placebo
223712732|NCT03873844|BEHAVIORAL|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
223712733|NCT03873844|BEHAVIORAL|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
223712734|NCT05090059|DEVICE|Lower limb myofascial trigger points f-ESWT|3 weekly sessions of focused Extracorporeal Shockwave treatment with a frequency of 5 Hz, an energy flux density of 0.05-0.167 mJ(millijoule)/mm2, administered on 3-4 myofascial lower limb trigger points (identified according to the approach of Fascial Manipulation), 1500 shocks per point.
223712735|NCT04387032|OTHER|HVLA Manipulations|The procedure of experimental manipulation: the patient lay on the healthy side with the straight lower limb, and the torso turned towards the dysfunctional side, whose lower limb was bent in the hip and knee joint, and the hands rest on the lower ribs on the same side. The therapist allowed the initial loosening of the tissues and chose the movement barrier with his stabilizing hand. Then, with the treatment hand, he introduced the HVLA thrust through the iliac bone towards the bottom, while giving the iliac bone a posterior or anterior rotation - meaning, the opposite to the occurring dysfunction. If during the manipulation, no cavitation sound was heard, the HVLA thrust was repeated once.
223712736|NCT04387032|OTHER|Sham Manipulation|The sham procedure was the same, but no external force was introduced in the form of a therapeutic impulse.
223712737|NCT00597181|PROCEDURE|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
223712738|NCT00597181|PROCEDURE|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
223712739|NCT02018185|DEVICE|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
223712740|NCT02018185|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
223712741|NCT01866293|DRUG|Cabozantinib (XL184)|
223712742|NCT00002378|DRUG|Ritonavir|
223712743|NCT00002378|DRUG|Nelfinavir mesylate|
223712744|NCT00002378|DRUG|Saquinavir|
223712745|NCT00002378|DRUG|Delavirdine mesylate|
223712746|NCT00002378|DRUG|Lamivudine|
223712747|NCT00002378|DRUG|Stavudine|
223712748|NCT00002378|DRUG|Zidovudine|
223712749|NCT02652754|DRUG|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
223712750|NCT03050554|DRUG|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
223712751|NCT03050554|RADIATION|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
223712752|NCT06263205|PROCEDURE|Non-Dressing of Surgical Wound|In this intervention, participants undergoing gastrointestinal tumor surgery will receive standard wound disinfection and initial postoperative care, which includes the application of dressings immediately after surgery. However, unlike traditional methods, the dressings will be removed 48 hours post-surgery, and the surgical wounds will then be left exposed without any further dressing. This method is intended to evaluate the effects of an exposed surgical wound on healing, pain, and healthcare costs, compared to traditional dressing methods.
223895778|NCT04053283|BIOLOGICAL|NG-641|NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.
223895779|NCT03609593|DRUG|Bendamustine|Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
223895780|NCT03609593|DRUG|Venetoclax|"Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration."
223895781|NCT03609593|DRUG|Rituximab|For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
223895782|NCT04791371|BEHAVIORAL|Cardiovascular exercise|15 weeks of cardiovascular exercise 3x/week for 50 minutes/session
223895783|NCT05116527|DRUG|Marijuana, Hash, THC, or Grass|Marijuana flower with a high THC content
223895784|NCT05116527|DRUG|Placebo|Placebo THC - marijuana flower with no THC content
223895785|NCT05670067|PROCEDURE|maxillary tuberosity bone graft (autogenous graft)|the usage of maxillary tuberosity as source of autogenous graft supplying the needed cells for bone regeneration
223895786|NCT05670067|PROCEDURE|Bone graft (xenograft)|xenograft is bone graft material that is obtained from porcine, bovine or equine source
223895787|NCT06254846|OTHER|Urine sample, 1st stream|Use of the Colli-Pee® device for collecting the first urine stream
223895788|NCT06254846|OTHER|Cervico-vaginal swab|"Use of a gold standard reference method = HPV PCR using the Anyplex® II HPV HR kit (Seegene) carried out on a cervico-vaginal swab in ThinPrep® medium (liquid medium medium into which the cervico-vaginal swab is discharged)."
223895789|NCT05398484|DRUG|Psilocybin 25 mgs|One capsule containing 25mg of psilocybin will be administered with water orally. The appearance of psilocybin is Size 2 HPMC opaque.
223895790|NCT05398484|DRUG|Niacin 100mg|One capsule contains 100mg of niacin will be administered with water orally. The appearance of the active placebo is Size 2 HPMC opaque.
223895791|NCT05398484|BEHAVIORAL|Psychotherapy|The manualized psychotherapy platform will consist of 6 hours of preparatory psychotherapy (prior to the single medication session) and 8 hours of integration psychotherapy following the dosing session.
223895792|NCT06329141|DRUG|Vutiglabridin|Once-daily oral administration
223895793|NCT06329141|DRUG|Placebo|Once-daily oral administration
223895794|NCT06445985|OTHER|Hydrotherapy|Physiotherapy led pool session
223895795|NCT05191901|OTHER|Stress Ball|Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
223895796|NCT06073119|DRUG|SAR441566|Tablet
223895797|NCT06073119|DRUG|Placebo|Tablet
223895798|NCT05238285|BEHAVIORAL|Production of vocal sounds|"Participants will be asked to produce vocal sounds of different nature according to the non-verbal parameters of interest for the given study.~For example, they can read a script containing vowels ('a', 'e', 'i', 'o', 'u'), short sentences ('hello, how are you'), longer passages of standardised reading texts, and can also be asked to speak freely about any topic ('freedom of speech'). They can be asked to play a role or to imitate a particular emotional state. For example, imagine that you have just been told that you have won a million euros in the lottery. Produce a vocalisation to express your excitement or talk to your dog your dog by imagining that he has done a negative action and then do the same thing by imagining that this time imagining that the action was positive."
223895799|NCT03820687|OTHER|Clinical Trial Educational Video|Bilingual, culturally tailored educational video, low literacy booklet, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trial participation.
223895800|NCT03820687|OTHER|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
223895801|NCT03820687|OTHER|Low literacy booklet|A bilingual low-literacy booklet with educational content about clinical trials.
223895802|NCT03820687|OTHER|Navigator|Support will be provided by a patient navigator to empower cancer patients to make an informed decision about cancer clinical trial participation by increasing awareness of clinical trials and MCC services, positive attitudes, and intentions to consider clinical trials as an appropriate treatment option for cancer.
223895803|NCT01972347|DRUG|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
223895804|NCT01972347|DRUG|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
223895805|NCT05447741|DIAGNOSTIC_TEST|Quantitative Ultrasound|Shear Wave Elastography acquisition. RF data acquisition (for HDK parameters calculation).
223895806|NCT05945069|DEVICE|TriLift device|Dynamic Muscle Stimulation combined with tripolar Radiofrequency, administered on the skin of the inferior orbital rim and below the lower eyelids
223895807|NCT03160794|DIAGNOSTIC_TEST|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, \[18F\]DCFPyL
223895808|NCT03160794|RADIATION|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using \[18F\]DCFPyL PET/MRI
223895809|NCT05187351|PROCEDURE|Percutaneous coronary intervention of the native coronary artery with Synergy|This is a registry study that will enroll patients with a 50-100% de novo SVG lesion and treated with percutaneous coronary intervention of the corresponding native coronary artery using a SYNERGY stent.
223895810|NCT04971395|DRUG|Placebo|Single dose of 2 or 4 mg/kg
223895811|NCT04971395|DRUG|XTMAB-16 2 mg/kg|Single dose of 2 mg/kg
223895812|NCT04971395|DRUG|XTMAB-16 4mg/kg|Single dose of 4 mg/kg
223895813|NCT06581237|OTHER|Eat2Win App|Voluntary use of the app will occur throughout the sport season.
223895814|NCT04968210|DRUG|Hyperpolarized 13C-pyruvate|Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
223712753|NCT06263205|PROCEDURE|Regular Dressing Change of Surgical Wound|This intervention involves the standard postoperative wound care for participants with gastrointestinal tumors. After surgery, the surgical wounds will be disinfected and covered with dressings. These dressings will be changed every 48-72 hours, following traditional wound management practices. The purpose of this intervention is to serve as a comparator for assessing the effectiveness of the non-dressing approach, focusing on wound healing, pain management, and healthcare costs.
223712754|NCT00415805|DRUG|Multihance|0.5 Molar, single injection at 0.2 mL/kg
223712755|NCT00415805|DRUG|vasovist|0.25 molar single injection 0.03 ml/kg
223712756|NCT00555971|DRUG|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
223712757|NCT00555971|DRUG|placebo|Subjects randomized to Placebo prior to aspirin desensitization
223712758|NCT04985864|DEVICE|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
223712759|NCT04985864|DEVICE|Treadmill gait training|Lokomat robot training was applied to stroke patients.
223712760|NCT03183076|OTHER|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
223712761|NCT03183076|DRUG|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
223712762|NCT06440096|DIAGNOSTIC_TEST|hemogram|hemogram
223712763|NCT01525810|DRUG|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention \[subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)\]
223712764|NCT01815216|PROCEDURE|Bariatric surgery|Gastric bypass surgery
223712765|NCT01815216|BEHAVIORAL|Brain activity in resting state|Measure of activity in brain networks during resting state
223712766|NCT01815216|BEHAVIORAL|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
223712767|NCT03916120|GENETIC|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
223712768|NCT06238583|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
223712769|NCT03497208|PROCEDURE|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
223712770|NCT03497208|PROCEDURE|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
223712771|NCT03497208|RADIATION|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
223712772|NCT06096753|DEVICE|Bruxoff gnathological function analysis|The recordings will be carried out for 3 randomly selected nights within 3 weeks, with at least 4 hours of sleep per night.
223712773|NCT03528772|DRUG|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
223712774|NCT03528772|DRUG|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
223712775|NCT06131801|OTHER|1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.|Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.
223712776|NCT05051072|PROCEDURE|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"|"Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia"
223712777|NCT02335866|PROCEDURE|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
223712778|NCT02335866|PROCEDURE|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
223712779|NCT05539794|BEHAVIORAL|lifestyle and physical exercise|"the intervention group will follow a physical exercise and health counselling intervention--see below.~The exercise program will be performed in the hospital gymnasium (3 supervised sessions/week of aerobic and muscle strength exercises) or in the patients' room (during phases of treatment-induced immunodepression, where isolation is needed to prevent infections). It will also include specific training of the respiratory ('inspiratory') muscles (e.g., diaphragm) on 5 days/week. The counselling program will include psychological (once weekly), nutritional (twice monthly), support (with survivors of adolescent cancer, twice/month) and educational (for relatives/caregivers, once monthly) sessions."
223712780|NCT05081609|DRUG|TransCon IL-2 β/γ|TransCon IL-2 β/γ will be administered as an intravenous (IV) infusion
223712781|NCT05081609|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion
223712782|NCT05081609|DRUG|Chemotherapy drug|SOC chemotherapy will be administered as an intravenous (IV) infusion
223712783|NCT05081609|DRUG|TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist will be administered as an IT (Intratumoral) injection
223712784|NCT05081609|PROCEDURE|Surgery|Surgery will take place 4-6 weeks after last dose of study treatment.
223712785|NCT05081609|DRUG|Trastuzumab|Trastuzumab will be administered as an intravenous (IV) infusion
223712786|NCT05081609|DRUG|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine (T-DM1) will be administered as an intravenous (IV) infusion
223712787|NCT03972306|DRUG|Ocrelizumab|Administered by subcutaneous Injection
223712788|NCT03972306|DRUG|Ocrelizumab|Administered by Intravenous (IV) Injection
223712789|NCT03972306|DRUG|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
223895815|NCT03298542|DRUG|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
223895816|NCT03298542|DRUG|Placebo|Matching placebo to golimumab.
223895817|NCT05858944|DRUG|Intensive Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
223895818|NCT05858944|DRUG|Standard Home BP control|If the target home BP level is not achieved during the follow-up periods, type and dosage of antihypertensive drugs will be adjusted according to current guidelines and physician's clinical experience.
223895819|NCT02924818|OTHER|Clinical assessment|
223895820|NCT02924818|BEHAVIORAL|questionnaires|
223712790|NCT00868985|DRUG|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
223712791|NCT00868985|DRUG|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
223712792|NCT06492967|BEHAVIORAL|Systematic Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
223712793|NCT06492967|BEHAVIORAL|Flexible Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
223712794|NCT03963375|DRUG|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
223895821|NCT02924818|OTHER|pulmonary function test|
223895822|NCT02924818|BIOLOGICAL|blood test|
223895823|NCT02924818|BIOLOGICAL|microbiology|
223895824|NCT02924818|BIOLOGICAL|histology|
223895825|NCT02924818|OTHER|imaging|
223895826|NCT06063499|BEHAVIORAL|Healthy Minds Program for Addictions|The Healthy Minds Program for Addictions is a 6-week, hybrid version of the original Healthy Minds Program (HMP), in which all lessons are adapted from the original lessons available in the app and delivered exclusively in person over weekly group sessions. The HMP has \>100 guided audio practices that address 4 constituents of wellbeing: awareness, connection, insight, and purpose. Study participants will have access to specific practices from the HMP that are particularly relevant to the needs of populations with substance use disorders and trauma.
223712795|NCT01274078|BIOLOGICAL|Blueberries|150 grams of frozen blueberries on the same day as exercise
223712796|NCT05410483|DRUG|Docetaxel|Hyperthermic Intraperitoneal Docetaxel
223712797|NCT00518284|DRUG|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.
223712798|NCT04619927|GENETIC|Direct CYP2C19 genotyping|CYP2C19 genotype will be determined by the Spartan RX CYP2C19 point-of-care system.
223712799|NCT04619927|GENETIC|CYP2C19 genotyping at the end of the study|Blood-based CYP2C19 genotyping will be performed at the end of the study
223712800|NCT04619927|DRUG|Poor metabolisers|Acetylsalicylic acid 100mg once daily plus rivaroxaban 2.5mg twice daily
223712801|NCT04619927|DRUG|Intermediate metabolisers|Clopidogrel 75mg twice daily
223712802|NCT04619927|DRUG|Normal metabolisers and unknown metaboliser state|Clopidogrel 75mg once daily
223712803|NCT00307177|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
223712804|NCT00307177|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
223712805|NCT05752292|BEHAVIORAL|Standard Health Information|Standard health information about postpartum screening and lifestyle programs for diabetes prevention
223712806|NCT05752292|BEHAVIORAL|Values Affirmation (VA)|Interactive prompts to reflect on core personal values
223895827|NCT04333888|BEHAVIORAL|Neurofeedback|fMRI neurofeedback training of amygdala downregulation
223895829|NCT03953508|OTHER|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
223895830|NCT05547750|DRUG|Vitamin K2|Vitamin K2 is a fat-soluble and one of the body's indispensable vitamins. It is mainly synthesized by gut bacteria in the body and plays a role in the mitochondrial electron transport chain. It boosts calcium metabolism, acts on osteoblasts, and promotes bone tissue calcification. It also inhibits osteoclasts from causing bone resorption, thus increasing bone density, and preventing osteoporosis. Furthermore, it regulates the use of calcium and promotes the inhibition of vascular calcification by matrix Gla protein (MGP) activity. Vitamin K2 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' activity. It does not enhance the carboxylation of prothrombin in healthy individuals. Vitamin K2 administration does not alter the hemostatic balance in healthy populations without anticoagulation treatment. Thus, vitamin K2 is deemed to have a good safety profile.
223895831|NCT05547750|DRUG|Placebo|Similar-looking placebo tablets
223895832|NCT05480761|BIOLOGICAL|Sucraid (sacrosidase) Oral Solution 8500 IU/mL|Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.
223895833|NCT03771417|BEHAVIORAL|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
223895834|NCT04147832|OTHER|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
223895835|NCT06552507|PROCEDURE|Duroplasty|The investigators open the dura from midline and repaired with fish mouth for dura augmentation
223895836|NCT03249181|DRUG|Dolutegravir|Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
223712807|NCT05752292|BEHAVIORAL|Tailored Risk Information (TRI)|Interactive prompts to provide tailored information on risk factors for type 2 diabetes
223895837|NCT03249181|DRUG|Standard of Care (EFV + 2 NRTI backbone)|Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
223895838|NCT03368963|DRUG|Nanoliposomal Irinotecan|Given IV
223895839|NCT03368963|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223895840|NCT05937256|PROCEDURE|Quadratus lumborum block type III|Patients will be placed in lateral decubitus position with the side of the target stone facing up. After sterilization and draping of the skin, using US probe the block will be applied targeting the fascial plane between the quadratus lumborum and psoas major muscles (anterior aspect of the quadratus lumborum). After 20 min, sensory blockade will be evaluated with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients will be transferred to ESWL Room.
223895841|NCT05937256|PROCEDURE|Erector spinae plane block|Patients will be placed in the lateral decubitus position according to the selected site. After sterilization and draping of the skin, using US probe, the block will be applied in the plane deep to the erector spinae muscles and superficial to the transverse process. After 20 min, sensory blockade will be assessed with pinprick test, if loss of sensation is achieved at the T7-L1 dermatome site, the block is considered successful and patients is transferred to ESWL Room.
223895842|NCT06392373|DIETARY_SUPPLEMENT|CHO+PRO|0.9 g CHO/kg/hr + 0.3 g PRO/kg/hr
223895843|NCT06392373|DIETARY_SUPPLEMENT|CHO|1.2 g CHO/kg/hr
223895844|NCT04998682|PROCEDURE|Axillary Dissection|A surgical procedure that opens the armpit (axilla) to identify, examine, or remove lymph nodes. Axillary dissection will be performed during SoC breast cancer surgery.
223895845|NCT04975399|DRUG|CC-92328|CC-92328
223895846|NCT06508697|DIAGNOSTIC_TEST|invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement|A consecutive series of patients who underwent Coronary computed tomography angiography (CTA) within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement were candidates for this study at Fujita Health University Hospital, Bantane Hospital, and Nagoya First Red Cross Hospital
223895847|NCT05506319|OTHER|Norepinephrine|The patients will be randomized for the initial suspension of norepinephrine (norepinephrine group).
223895848|NCT05506319|OTHER|Vasopressin|The patients will be randomized for the initial suspension of vasopressin (vasopressin group).
223895849|NCT02100813|DRUG|LEO 43204|
223895850|NCT02100813|DRUG|Placebo|
223895851|NCT06484686|BIOLOGICAL|Live Attenuated Varicella Vaccine|lyophilized powder, subcutaneous injection
223895852|NCT04552223|DRUG|Nivolumab|Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
223895853|NCT04552223|DRUG|Relatlimab|Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
223895854|NCT05087667|DEVICE|Implantation of Ortholoop cerclage|implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention
223895855|NCT05087667|DEVICE|Implantation of Cerclage used in current practice|implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention
223895856|NCT05239299|OTHER|No intervention, observational study|Focus Group
223895857|NCT04856163|BEHAVIORAL|Telelactation support|Participants will get unlimited access (through 24 weeks postpartum) to video calls with lactation consultants who are available 24/7. Participants can use the service as demanded.
223895858|NCT06108596|DRUG|Sintilimab with Interleukin-2+CAPOX|Sintilimab with Interleukin-2+CAPOX
223895859|NCT03762915|DRUG|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
223895860|NCT02853851|OTHER|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
223895861|NCT05516836|OTHER|Multicomponent exercise program|"Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed."
223895862|NCT05516836|OTHER|Tele-health primary care rehabilitation program|A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
223895863|NCT06557434|DEVICE|MIRIA|The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.
223895864|NCT04784832|DEVICE|Transcranial magnetic stimulation|Magnetic stimulation of the cortex
223895865|NCT04784832|DEVICE|Peripheral Nerve Stimulation|Electric stimulation of the nerves
223895866|NCT04784832|DEVICE|Transcranial direct current stimulation|Electric stimulation of the cortex
223895867|NCT04784832|DEVICE|Paired Associative Stimulation|Combined magnetic and electric stimulation of cortex and nerve, respectively
223895868|NCT04784832|DEVICE|Wrist|Short-term immobilization of the arm
223895869|NCT04784832|DEVICE|Robotic arm|External perturbation of force field induced by robotic arm
223895870|NCT04784832|DEVICE|Cervicomedullar stimulation|Electric stimulation of the muscle
223895871|NCT04784832|OTHER|Physical training|Training to perform the task by actually doing the task
223895872|NCT04784832|OTHER|Mental training|Training to perform the task by imaging doing the task
224083315|NCT05675007|DIETARY_SUPPLEMENT|Colon-delivered multivitamin supplement|Colon-delivered multivitamin supplement containing the following dose of the indicated vitamin: vitamin B2 (10 mg), vitamin B3 (4.0 mg), vitamin B6 (1.4 mg), vitamin B9 (400 μg), vitamin C (200 mg) and vitamin D3 (15ug). Vitamin capsules are filled with microcrystalline cellulose and magnesium stearate up to 200 mg. Control of release in the colon is achieved by the Eudragit S 100 coating layer technology that surrounds the vitamins contained in the core capsules.
223712808|NCT05752292|BEHAVIORAL|Motivational Interviewing-based (MI)|Interactive prompts based on principles of motivational interviewing
223712809|NCT05752292|BEHAVIORAL|Action planning (AP)|Interactive prompts to problem solve challenges
223712810|NCT03294759|OTHER|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
223712811|NCT03294759|OTHER|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
223712812|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
223712813|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
223712814|NCT04990557|DRUG|PD-1 and ACE2 Knockout T Cells|Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
223712815|NCT01299740|BEHAVIORAL|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
223712816|NCT01299740|OTHER|Control Group|Treatment as usual
223712817|NCT00801632|PROCEDURE|Kidney Transplantation|Surgical transplantation of donor kidney
223712818|NCT00801632|PROCEDURE|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
223712819|NCT00801632|BIOLOGICAL|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
223712820|NCT00801632|DRUG|cyclophosphamide|60 mg/kg infusion on days -5, -4
223712821|NCT00801632|BIOLOGICAL|rituximab|375 mg/m\^2 infusion on days -7, -2, 5, and 12
223712822|NCT00801632|DRUG|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
223712823|NCT00801632|DRUG|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
223712824|NCT00801632|RADIATION|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
223712825|NCT01028144|BEHAVIORAL|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
223712826|NCT01028144|BEHAVIORAL|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
223712827|NCT06263361|DIAGNOSTIC_TEST|MRI imaging|To characterize the peritumoral area in PCNLs through the use of advanced MRI sequences.
223712828|NCT06263361|DIAGNOSTIC_TEST|Cerebral biopsy|To evaluate the predictive value of sodium fluorescence to confirm ex-vivo the diagnostic tumor tissue prior to histopathological examination.
223712829|NCT00626964|PROCEDURE|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
223712830|NCT00626964|BEHAVIORAL|Conservative Treatment:|Intensive Lifestyle Intervention Program
223712831|NCT06448286|PROCEDURE|Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|Undergo CEST MRI
223712832|NCT06448286|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
223712833|NCT06448286|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223712834|NCT06448286|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
223712835|NCT06448286|PROCEDURE|Surgical Procedure|Undergo surgical resection
223712836|NCT06448286|DRUG|Temozolomide|Given PO
223712837|NCT04282785|DIAGNOSTIC_TEST|Concentration monitoring of antibiotics in plasma|Plasma antibiotic concentration will be measured using a bedside method with UV-VIS spectroscopy. These measurements will be validated with golden standard that is HPLC-MS.
223712838|NCT05500222|DRUG|Resmetirom|Randomized 80 mg
223712839|NCT05500222|DRUG|Placebo|randomized matching placebo
223712840|NCT04339686|DIAGNOSTIC_TEST|Thoracic CT Scan|Retrospective analysis of the thoracic CT scan results compared to final discharge summary
223712841|NCT04868175|DRUG|Timolol|Topical eye drops for lowering intraocular pressure Beta blocker to reduce aqueous production
223712842|NCT04868175|DRUG|Travatan|Topical eye drops for lowering intraocular pressure Prostaglandin analogue to increase aqueous outflow
223712843|NCT04868175|DRUG|Hypromellose|Placebo eye drop, lubricant
223712844|NCT04167579|DEVICE|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
223712845|NCT00798980|DRUG|Mirena (BAY86-5028)|Nulliparous Women
223712846|NCT04208633|PROCEDURE|Horizontal placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
224083316|NCT05675007|DIETARY_SUPPLEMENT|Placebo capsule|Placebo capsule containing microcrystalline cellulose and magnesium stearate up to 200 mg. Placebo capsules are coated with the Eudragit S 100 coating layer.
224083317|NCT02946801|DRUG|Essential oils|
224083318|NCT02946801|DRUG|Essential oils without alcohol|
224083319|NCT02946801|DRUG|Sterile water|
223712847|NCT04208633|PROCEDURE|Vertical placement of the intraocular lens in the capsular bag|The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
223712848|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
223712849|NCT00779740|DRUG|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
223712850|NCT06557837|DIAGNOSTIC_TEST|Questionnaires and pain assessment|Participants complete two questionnaires: the Oswestry Disability Index (ODI) and the EQ-5D-5L. They also rate their low back pain using the Visual Analogue Score (VAS) scale and respond to two additional questions about their posture and gait.
223712851|NCT06557837|DIAGNOSTIC_TEST|Standing sagittal whole spine X-ray|Participants undergo standard preoperative X-ray imaging of the entire spine to capture the upright posture. This imaging is conducted before and after 6-minute of continuous walking to compare changes in spino-pelvic and sagittal balance parameters.
223712852|NCT06557837|DIAGNOSTIC_TEST|Dynamic test|With the dynamic test, we analyze body movements of participants during gait using 49 reflective markers placed on their bodies according to the Qualisys PAF package: Instituti Ortopedici Rizzoli (IOR) and 10 EMG electrodes on specific leg and back muscles. Participants walk for 6 minutes between two cones set 7 meters apart, while a 12-camera Qualisys Motion Capture System tracks marker movements for comprehensive kinematic analysis. Data are recorded at five key moments: standing before and after the test, and during three phases of gait (at the beginning, middle, and end). Participants are barefoot and dressed in underwear for accurate measurement. Static recordings before and after walking involve stepping on a tensiometric force plate to measure the center of gravity. Before the test, participants perform stretching exercises to ensure consistent preparation.
223712853|NCT06557837|DIAGNOSTIC_TEST|Muscle strength and body composition measurement|Participants have their body composition analyzed and the maximum isometric strength of their paraspinal and abdominal muscles measured using the Dr. Wolff BackCheck device.
223712854|NCT04672993|DEVICE|Urine collection device for men|Use of urine collection device for men
223712855|NCT01387932|DEVICE|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
223712856|NCT01387932|PROCEDURE|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
223712857|NCT00740389|DRUG|TMC125|
223712858|NCT01352104|BEHAVIORAL|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
223712859|NCT00205881|DEVICE|HiRes 90K Bionic Ear System|Cochlear implant system
223712860|NCT05913492|BEHAVIORAL|Simulation training|"Each volunteer went through two simulation scenarios of difficult airway management: 1) cannot intubate, can ventilate (CI), 2) cannot intubate, cannot ventilate (CICV) with the assistance of the training centre operator. Following the first simulation round, volunteers were trained on the same day in difficult airway management according to DAS guidelines, using the same equipment as during the simulation. The participants repeated the simulation scenarios immediately after the training and six months later."
223712861|NCT03867188|DRUG|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
223712862|NCT01015599|BEHAVIORAL|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
223712863|NCT01781754|PROCEDURE|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
223712864|NCT04946968|DRUG|Oral Dacomitinib|All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
223712865|NCT01423578|BEHAVIORAL|Hatha Yoga (HY)|3 Sessions of yoga instruction
223712866|NCT01423578|BEHAVIORAL|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
223712867|NCT01423578|BEHAVIORAL|Smoking Cessation Counseling|4 smoking cessation counseling visits.
223712868|NCT03463512|DRUG|Racecadotril plus ORS|Racecadotril plus ORS
223712869|NCT03463512|DRUG|ORS|ORS
223895873|NCT05534802|DRUG|Ulinastatin|On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
223895874|NCT05534802|OTHER|saline|On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
223895875|NCT06453902|DRUG|TGRX-678|All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
223895876|NCT04966247|OTHER|Microdialysis|Monitoring real-time cerebral biomarkers using microdialysis method
224083320|NCT03817372|DEVICE|Anterior-posterior electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
223712870|NCT04442412|DRUG|Vitamin D3 (Cholecalciferol)|patients in the Experimental arm (Arm B) will receive also a prephase therapy with VitD and a supplementation of VitD during the intere period of immunochemotherapy according to a prefixed schedule. Choice of type of immunochemotherapy will not rely on Comprehensive Geriatric Assessment (CGA) result, but treatment at reduced doses with R-miniCHOP is highly recommended option for UNFIT and FRAIL patients.
223712871|NCT04442412|DRUG|RCHOP o R-miniCHOP at standard doses|"Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP~o R-miniCHOP at standard doses"
223712872|NCT01627483|OTHER|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
223712873|NCT06212154|BIOLOGICAL|ThisCART19A|Participants will receive ThisCART19A cell infusion after preconditioning, and they need to be closely monitored for 28 days following CAR-T cell infusion.
223712874|NCT01293773|DEVICE|Taxus Element stent|paclitaxel-eluting stent
223712875|NCT01293773|DEVICE|Integrity Resolute stent|ABT 578-eluting stent
223712876|NCT01293773|DEVICE|Xience Prime stent|Everolimus-eluting stent
223712877|NCT05934578|OTHER|Exercise training|Aerobic and light muscle resistance exercise by online cardiovascular rehabilitation
223712878|NCT04641858|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
223712879|NCT04641858|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the right deltoid region.
223712880|NCT01022749|DRUG|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
223712881|NCT01022749|BIOLOGICAL|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
223712882|NCT05642988|DEVICE|LifeSignals 1AX Biosensor|Biosensor worn by patients for 30-days after intra-abdominal or pelvic surgery on discharge from hospital
223712883|NCT04789499|DRUG|Theophylline Powder|Twice daily nasal irrigation with 400 mg theophylline capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
223712884|NCT04789499|DRUG|Placebo Comparator|Twice daily nasal irrigation with 500 mg lactose powder capsules and USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets dissolved in 240 ml of distilled water.
223712885|NCT00519454|OTHER|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
223712886|NCT04805762|OTHER|Your COACH Next Door|Children in the study are attending the lifestyle intervention Your COACH Next Door. A coach is supporting the child and it's family to reach their goals regarding lifestyle.
223712887|NCT00005118|DRUG|Indinavir sulfate|
223712888|NCT00005118|DRUG|Ritonavir|
223712889|NCT04326829|DRUG|QL1604|QL1604, IV infusion
223712890|NCT04016233|DRUG|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
223712891|NCT00644657|DRUG|Clopidogrel|All subjects will receive a 300 mg loading dose
223712892|NCT05626062|DEVICE|Toilet alarm|A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
223712893|NCT00513656|DRUG|Oxycodone|
223712894|NCT00513656|DRUG|Oxycodone/Naloxone|
223712895|NCT02225561|PROCEDURE|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~* Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~* The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~* Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
223712896|NCT02225561|PROCEDURE|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
223712897|NCT01407822|DRUG|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
223712898|NCT01407822|DRUG|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
223712899|NCT04121975|RADIATION|Radiotherapy|Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
223712900|NCT04121975|DRUG|Endostar|30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
223712901|NCT04121975|DRUG|Cisplatin|30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
223712902|NCT00785265|BEHAVIORAL|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
223712903|NCT00785265|BEHAVIORAL|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
223712904|NCT01581775|DRUG|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
223712905|NCT03531359|DEVICE|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
223712906|NCT03531359|DRUG|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
223712907|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
223712908|NCT02688049|BIOLOGICAL|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
223712909|NCT02941991|BIOLOGICAL|hESC-RPE|sub-retinal injection
223712910|NCT02998983|DRUG|Racotumomab|
223712911|NCT02027519|OTHER|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~* Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~  * Self-administer HIV rapid test and read test results~ * Provide study staff with self-testing result~ * Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
223712912|NCT02362581|OTHER|prophylaxis treatment, on demand treatment|
223712913|NCT02217878|DRUG|Morphine|IV bolus injection
223712914|NCT02217878|DRUG|Placebo|IV bolus injection
223712915|NCT02217878|DRUG|Ticagrelor|180 mg loading dose
223712916|NCT04965727|PROCEDURE|Device implantation|The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
223712917|NCT02771431|OTHER|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
223712918|NCT04394975|COMBINATION_PRODUCT|Biological : Toripalimab Drug: Axitinib|Biological: Toripalimab, Intravenous infusion Drug: Axitinib, oral tablet
223712919|NCT04394975|DRUG|sunitinib|Drug: Sunitinib, oral capsule
223712920|NCT01663025|BEHAVIORAL|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
223712921|NCT05371431|OTHER|Traditional rehabilitation training|The non-BFR group undertook traditional rehabilitation training only. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
223712922|NCT05371431|OTHER|Blood flow restriction combined with traditional rehabilitation training|BFR group completed the traditional rehabilitation training with a medical grade tourniquet applied on the upper arm. Patients participated in 2 training sessions per week with at least 48 hours rest in between for continuous 6 weeks. Clinical assessment of grip strength, pinch strength (tip pinch strength, key pinch strength and tripod pinch strength), ROM of wrist, PRWE score, muscle stiffness and radiographic outcomes, was conducted at the 6th and 12th week from the date of initial DRF.
223712923|NCT04874584|BEHAVIORAL|CTNSM|The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .
223712924|NCT04874584|BEHAVIORAL|Standard of Care Chemotherapy Education|Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.
223712925|NCT00334958|DRUG|Placebo|For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 placebo tablets twice daily.
223712926|NCT00334958|DRUG|Rufinamide|For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
223712927|NCT02809612|BEHAVIORAL|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
223712928|NCT03802760|DEVICE|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
223712929|NCT01332643|GENETIC|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
223712930|NCT00105417|DRUG|IL-7|
223712931|NCT00352339|DRUG|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
223712932|NCT00352339|DRUG|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
223712933|NCT00352339|DRUG|Abilify|Start with abilify and keep it through the end of study
223712934|NCT03363958|PROCEDURE|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
223712935|NCT03363958|PROCEDURE|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
223712936|NCT03773263|DRUG|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
223712937|NCT03773263|PROCEDURE|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
223712938|NCT03773263|PROCEDURE|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
223712939|NCT03773263|DRUG|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
223712940|NCT04937231|OTHER|Aerobic exercises|"For Week 1 and 2 : Treadmill 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 10-20 minutes For Week 3 and 4; Cycle ergometer 3-5days/weeks~Intensity:~50-70 vo2 peak Or HRR 60-80% Duration of 30-40 minutes"
223712941|NCT04937231|OTHER|Resistance exercises|"For Week 1 and 2; 2 x 10 rep (unilateral leg press) 4x 12 reps (Bilateral leg press~1 x 8 rep ( unilateral arm curls For Week 3 and 4; 1 x 10 reps Shoulder press~1 x15 rep Bilateral knee extension~1 x 10 reps Bilateral arm curls"
223712942|NCT04937231|OTHER|Combined training|For Week 1 and 2; Aerobic exercise on Treadmill along with dumbbell to perform upper limb exercises (biceps curls, side curls extensions, upright row, back fly) and used Thera band to perform lower limb exercises for 10-20 minutes For Week 3 and 4; Aerobic exercise on Treadmill along with dumbbell and Thera band to perform upper limb and lower limb exercises for 30-40 minutes
223712943|NCT05116618|DIAGNOSTIC_TEST|InVisionFirst-Lung ctDNA assay|An enhanced tagged/targeted-amplicon sequencing technology for detection of genomic alterations in 36 commonly mutated genes in plasma ctDNA with a sensitivity of 73.9% and specificity of 99.8%.
223712944|NCT00622401|BIOLOGICAL|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
223712945|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 30ng/kg
223712946|NCT00622401|DRUG|Interleukin-12|Given subcutaneously at dose of 100ng/kg
223712947|NCT01514071|BEHAVIORAL|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
223712948|NCT01338103|DRUG|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
223712949|NCT03513458|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
223712950|NCT03513458|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
223712951|NCT03513458|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
223712952|NCT00844675|DRUG|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
223712953|NCT00844675|DRUG|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
223712954|NCT01194466|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
223712955|NCT02938312|BEHAVIORAL|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
223712956|NCT02938312|BEHAVIORAL|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
223712957|NCT06424574|BEHAVIORAL|motivational interview|"The sample of the second phase of the study consisted of 74 parents with Type 1 diabetes children, 37 of which were in the study group and 37 in the control group. İn the collection of data process, Descriptive Information Form, University of Virginia Parent Low Blood Sugar Scale, BAKAS Care-Giving Impact Scale, Fatigue Severity Scale, Parental Version Of The Diabetes-Specific Self-Compassion Scale SCS-(Dp) was used. The scales were applied at the beginning of the study and 10 weeks after the first data. After the first test data were obtained from each parent in our research group, four face-to-face motivational interviews were conducted at two-week intervals. In the xvii interviews, attempts were made to change and improve the behaviors and skills that parents felt inadequate within the scope of fear of hypoglycemia, caregiving, fatigue and self-compassion."
223712958|NCT06361433|DRUG|HUFF-01|autologous MSC combined with scaffold
223712959|NCT04525846|OTHER|PFMT|"* program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)"
223712960|NCT04525846|OTHER|non PFMT|Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
223712961|NCT01263977|DEVICE|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
223712962|NCT00781274|DRUG|MP-424|750 mg every 8 hours for 12 weeks
223712963|NCT00781274|DRUG|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
223712964|NCT00781274|DRUG|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
223712965|NCT05400109|BIOLOGICAL|UF-KURE19 CAR-T cells|UF-KURE19 cells are initially generated from a starting autologous apheresis sample. T cells are activated and transduced with Kure19 lentiviral vector that consists of a 3rd generation vector with an scFV (FMC63) that targets CD19. The product is harvested at 17-20hr after culture and cryopreserved
223712966|NCT05400109|DRUG|Fludarabine|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
223712967|NCT05400109|DRUG|Cyclophosphamide|The mechanism of action is thought to involve cross-linking of tumor cell DNA
223712968|NCT01957930|DRUG|Intensified insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
223712969|NCT01957930|DRUG|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
223712970|NCT05626985|DIAGNOSTIC_TEST|GAMAD|Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
223712971|NCT04953754|DIETARY_SUPPLEMENT|Melatonin|The melatonin group will receive 5mg melatonin nightly
223528280|NCT04309682|PROCEDURE|Lateral sinus approach|a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
223528281|NCT06054542|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the DESQ
223528282|NCT07145905|DEVICE|TCRM|N=128
223528283|NCT00583583|DEVICE|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
223528284|NCT01649869|OTHER|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
223528285|NCT01649869|DRUG|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
223528286|NCT07161323|OTHER|Sustained Natural Apophyseal Glide (SNAG)|In this intervention, participants will initially receive the SNAG technique targeting the L5-S1 lumbar segment. Participants will be seated on a treatment table with feet flat and knees at 90°. The therapist will position a specialized Mulligan belt around the L5-S1 segment and anchor it around their pelvis to generate a gentle traction force via controlled hip movement. While this force is applied, participants will perform active trunk flexion, holding the end-range position for 30 seconds. This movement will be repeated six times, constituting a 3-minute set. A total of 4 sets will be administered, with 2-minute rest periods between sets.
223528287|NCT07161323|OTHER|Sciatic Nerve Mobilization Exercises (SNME)|Participants will sit with hips and knees at 90° flexion, feet flat on the floor. The involved leg will be fully extended at the knee. In this position, the participant will be asked to perform ankle dorsiflexion and neck extension simultaneously (applying tension to the distal part of the sciatic nerve while relaxing the proximal part) and hold for 3 seconds. Next, the participant will plantarflex the ankle and flex the neck (tensioning the proximal end while relaxing the distal), again holding for 3 seconds. This 6-second sequence will be repeated 10 times per set. The exercise will be performed in 3 sets per leg, with 3-minute rests between sets.
223528288|NCT07159737|PROCEDURE|Two-stent strategy|DES from LMCA to LAD and DES to LCx using a recognised bifurcation technique such as double kissing crush (DK crush), Culotte, T-stenting or T and small protrusion (TAP).
223528289|NCT07159737|PROCEDURE|Hybrid Strategy|DES from LMCA to LAD and DCB to LCx. No LCx DES unless bail-out needed.
223528290|NCT07161193|BIOLOGICAL|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
223528291|NCT06146062|DRUG|Mesenchymal Stromal Cells (MSC)|3 injections one week apart
223528292|NCT06146062|DRUG|placebo|3 injections one week apart
223712972|NCT04953754|DEVICE|Phillips Actiwatch Spectrum Plus|Both groups will be monitored by the FDA-cleared Actigraph
223712973|NCT03406767|OTHER|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
223712974|NCT03406767|OTHER|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
223712975|NCT06098092|OTHER|Long-term non-invasive Blood pressure monitoring|All measurements during the experiment include only non-invasive Blood pressure and Heart rate measurements. Measurements will be taken using a smartwatch attached to the wrist and a digital tonometer with a cuff placed on the other arm. Paired readings will be compared.
223712976|NCT00129428|PROCEDURE|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
223712977|NCT04794842|DRUG|Tetracaine 5% drops|same as information in the arm/group description
223712978|NCT04794842|DRUG|Phenol 90% concentration|same as information in the arm/group description
223712979|NCT03892096|DIAGNOSTIC_TEST|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
223712980|NCT01147523|DRUG|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
223712981|NCT02532088|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
223712982|NCT02532088|DIETARY_SUPPLEMENT|Placebo|Placebo
223712983|NCT02021773|DRUG|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
223712984|NCT02021773|DRUG|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
223712985|NCT02021773|DRUG|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
223712986|NCT01950975|BIOLOGICAL|Peripheral blood samples in EDTA tubes|
223712987|NCT01950975|PROCEDURE|Skin biopsies|
223712988|NCT03691259|OTHER|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
223712989|NCT03993795|OTHER|A19010-W|A snus product
223712990|NCT03993795|OTHER|B19010-F|A snus product
223712991|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fasting conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
223712992|NCT00768183|DRUG|KADIAN Capsule + water (under fasting conditions)|Capsules 100mg + 240 mL in 4 shots of 60 mL
223712993|NCT00768183|DRUG|morphine sulfate IR oral solution + water|Morphine sulfate IR oral solution + water (under fasting conditions)
223712994|NCT00768183|DRUG|KADIAN Capsule + alcohol (under fed conditions)|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
223712995|NCT04456530|DRUG|Aveed 750 MG in 3 ML IM Injection|Participants in the Testosterone Group will receive two IM Aveed injections 1 month apart.
223712996|NCT04456530|OTHER|Normal Saline 3 ML IM Injection|Participants in the Control Group will receive two IM normal saline injections 1 month apart.
223712997|NCT01388738|DRUG|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os
223712998|NCT01388738|DRUG|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
223712999|NCT01388738|DRUG|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
223713000|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
223713001|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
223713002|NCT01534962|DRUG|Ranolazine|Oral administration, BID; for a maximum of 112 days.
223713003|NCT01534962|DRUG|Placebo|Oral administration, BID; for a maximum of 112 days.
223713004|NCT06097286|PROCEDURE|external oblique intercostal plane block|o EOIP Group (ŋ=25): Patients will receive ultrasound guided External oblique intercostal plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
223895877|NCT05369533|DEVICE|Telerehabilitation|The telerehabilitation system will deliver rehabilitation treatment sessions via a secured internet-connected computer. TR sessions will be a combination of games, exercises, stroke education, assessments, in addition to videoconferencing with therapists to discuss progress, issues, goals, and changes to the treatment plan.
223713005|NCT06097286|PROCEDURE|erector spinae plane block|o ESP Group (ŋ=25): Patients will receive ultrasound guided Erector spinae plane block with 20 ml of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a total volume of 20 ml.) at the end of procedure, unilaterally or bilaterally according to the surgery.
223713006|NCT01760460|DRUG|Anacetrapib|
223713007|NCT01760460|DRUG|Placebo for anacetrapib|
223713008|NCT06385600|DRUG|Labetalol|Group L will recieve labetalol intravenous infusion (Trandate, Gsk) in a concentration of 10 mg/ ml, thus 50 mg/ml equals to 5 ml/hr. The starting infusion rate of the antihypertensive medication is 5 ml/hr for an 80 Kg patient.
223713009|NCT06385600|DRUG|Phentolamine|Group P will receive phentolamine intravenous infusion (Rogitamine) in a concentration of 10 mg/ml, thus 1 µg/Kg/min equals to 4.8 ml/hr for an 80 Kg patient.
223713010|NCT00190671|DRUG|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
223713011|NCT00190671|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
223713012|NCT00190671|DRUG|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
223713013|NCT02911714|DRUG|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
223713014|NCT04903275|PROCEDURE|Topical fluoride application and Laser irradiation|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS\_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.
223713015|NCT04903275|PROCEDURE|Topical fluoride application|Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
223713016|NCT05846971|OTHER|Educational materials on validated methylation assay|Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.
223713017|NCT01460004|DEVICE|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
223713018|NCT03697473|OTHER|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
223713019|NCT03697473|OTHER|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
223713020|NCT00191269|DRUG|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
223713021|NCT00191269|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
223713022|NCT01583491|PROCEDURE|autologous platlet rich fibrin|one dose immediate after surgery
223713023|NCT01583491|PROCEDURE|one side in control group|control group insert any things after surgery
223713024|NCT04749277|OTHER|CAD EYE® (Fujifilm, Europe, Gesellschaft mit beschränkter Haftung, Dusseldorf, Germany)|"Methods plan~Phase 1. Brief virtual chromoendoscopy training on the characterization of colorectal polyps (WLI, LCI and BLI)~Phase 2. CAD EYE® system applied during colonoscopy retrieval:~2.1. CAD EYE® system OFF: Virtual chromoendoscopy (BLI) - independently characterization of a suspected polyp in WLI and BLI by the first endoscopist and by the second endoscopist (iconographic record) 2.2. CAD EYE® system ON: Characterization mode (BLI): Characterization of a suspected polyp by CAD EYE® and respectively level of characterization (1 to 3) (iconographic record) Phase 3. Histopathological evaluation (pathologist with gastrointestinal expertise): Resection and recovery of a suspected polyp for anatomopathological characterization"
223713025|NCT01807975|OTHER|Forced oscillation|
223713026|NCT01738542|DRUG|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
223713027|NCT01738542|DRUG|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
223713028|NCT01738542|DRUG|Statins|
223713029|NCT01738542|DRUG|Antihypertensive therapy|
223713030|NCT01742702|DRUG|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
223713031|NCT01742702|DRUG|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
223713032|NCT01742702|DRUG|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
223713033|NCT01742702|DIETARY_SUPPLEMENT|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
223713034|NCT01742702|DIETARY_SUPPLEMENT|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
223713035|NCT01742702|DRUG|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
223713036|NCT01745133|DRUG|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
223713037|NCT01745133|DRUG|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
223713038|NCT01745133|DRUG|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
223713039|NCT01551992|PROCEDURE|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
223713040|NCT03108677|OTHER|Blood samples|15 ml peripheral blood
223713041|NCT01741974|DIETARY_SUPPLEMENT|Karinat|
223713042|NCT01741974|DRUG|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
223713043|NCT05624593|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
223713044|NCT05624593|DEVICE|Predicate|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
223713045|NCT03031197|COMBINATION_PRODUCT|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
223713046|NCT03021070|OTHER|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
223713047|NCT05516394|PROCEDURE|Laparoscopic liver resection|Liver tumors are resected with minimally invasive approach, laparoscopically.
223713048|NCT02412995|OTHER|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
223895878|NCT05369533|DRUG|Sinemet Pill|Sinemet 25/100 will be taken 1 hour prior to TR, for the first 18 sessions.
223895879|NCT05369533|DRUG|Placebo|Placebo will be taken 1 hour prior to TR, for the first 18 sessions.
223895880|NCT05931614|BEHAVIORAL|Free fluid intake|Patients are recommended a free fluid intake
223895881|NCT03455582|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
223895882|NCT03455582|OTHER|Ecological evaluation|Virtual reality task and Actual reality
223895883|NCT03455582|OTHER|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
223895884|NCT03455582|OTHER|Psychological evaluation|questionnaires for depression, anxiety and fatigue
223895885|NCT03455582|DEVICE|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
223895886|NCT04409600|BEHAVIORAL|Supervised Gait Retraining|The participants allocated to this group will attend 8 sessions during the course of 6 weeks in the clinic with a trained medical professional to complete a supervised gait retraining program.
223895887|NCT04409600|BEHAVIORAL|Home Based Gait Retraining|The participants allocated to this group will have 1 session in the clinic with a trained medical professional and be given a gait retraining program to complete at home.
223895888|NCT04409600|DRUG|Saline Injection|The participant will receive a saline injection to their painful lower leg compartment(s).
223895889|NCT04409600|DRUG|Botulinum Toxin Injection|The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
223895890|NCT00881621|DRUG|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
223895891|NCT05921747|OTHER|Standard core stability exercise program|The core stability exercises included Bridging, Pelvic rotation, Abdominal Tuck in, Knee to chest and Squatting. Pre and post measurement will be taken before and after the session.
223895892|NCT05921747|DEVICE|Off-the-shelf virtual reality system|HTC Vive (HTC Corporation, Bellevue, WA) VR Head-Mounted Display (110º field of view, 1080 × 1200 pixels/eye, 90 Hz refresh) along with the Vive hand controllers and trackers to provide an immersive VR experience. The Vive Tracker can be used to track limb and trunk position and motion while in a VR experience. This setup will be paired with a gaming computer with the power to run a VR experience at a high frame rate to mitigate the risk of motion sickness. KVET™( Karuna Virtual Embodiment Training) consists of 10-30 minute sessions of exercises in an embodied VR experience.
223895893|NCT03158714|BEHAVIORAL|Couples Connecting Mindfully|
223895894|NCT03158714|BEHAVIORAL|ELEVATE|
223895895|NCT02118272|DEVICE|Physica KR|
223895896|NCT04574024|DRUG|NBT-NM108|MS Patients received NBT-NM108 at 60 g/day.
223895897|NCT03936322|DEVICE|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
223895898|NCT06800131|DEVICE|Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)|A total of 40 subjects will be enrolled, 30 subjects administered trans-dermally via Microneedle Array Patch (MAP).
223895899|NCT06800131|BIOLOGICAL|Active comparator vaccine via intramuscular injection|10 subjects administered with active comparator vaccine via intramuscular injection.
223895900|NCT05474404|DIAGNOSTIC_TEST|Cervical smear test|collection of cervical cells using spatula
223895901|NCT05760885|BEHAVIORAL|Balance training with sensory augmentation|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, sensory augmentation will be delivered with an intensity controlled in real-time by their center of pressure motion. The difficulty of the balance training task will progressively increase over successive training sessions.
223895902|NCT05760885|BEHAVIORAL|Balance training|Participants will complete 20 balance training sessions, in which they are required to keep their balance while standing on a platform that translates under their feet. During training, no sensory stimulation will be delivered. The difficulty of the balance training task will progressively increase over successive training sessions.
223895903|NCT06439004|OTHER|Quantitative Sensory Testing|Performing QST on the dominant hand, right forearm, right flank and lower back.
223895904|NCT02672917|DRUG|MVT-5873|intravenous infusion (IV)
223895905|NCT02672917|DRUG|modified FOLFIRINOX (mFOLFIRINOX)|IV
223895906|NCT02672917|DRUG|gemcitabine + nab-paclitaxel|IV
223895907|NCT04979104|PROCEDURE|Hip arthroplasty with SL Cementless|Total or partial hip arthroplasty with implant of SL cementless femoral stem.
223895908|NCT06799611|DRUG|CM336 Injection|subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol
223895909|NCT06293079|OTHER|Exercise Program|Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
223895910|NCT04447911|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg per os once daily for 30 days
223895911|NCT04447911|DRUG|Placebo|Placebo per os once daily for 30 days
223895912|NCT05275231|BEHAVIORAL|Intensive lifestyle interventions (ILIs)|Intensive lifestyle interventions (ILIs) is a group-based programs designed to promote weight loss through a combination of diet, activity, and behavior change, decrease Type 2 Diabetes (T2D) incidence in people with prediabetes and reduced complications among people with T2D.
223895913|NCT05994157|DRUG|CD38-SADA:177Lu-DOTA Complex|The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
223895914|NCT05603481|DEVICE|Continuous Glucose Monitor|Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
223895915|NCT05856786|DIAGNOSTIC_TEST|Optical coherence tomography|Posterior segment OCT (a non-contact procedure performed over one minute) is additionally performed for patients participating in this study. Proportion of change in measurements in microns will be analyzed.
223895916|NCT01160211|DRUG|Lapatinib|1000 mg by mouth once a day
223895917|NCT01160211|DRUG|Trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks (q3weeks)
223528293|NCT05894655|BEHAVIORAL|COVID-19 walk-up, on-site testing strategy|This strategy is a no-appointment, walk-up point-of-care PCR and rapid testing strategy for clinic patients and community members. It will be offered 5 days/week for 7 hours during the first 3 months of the trial at Clinic 1. The intensity will decrease over the trial ending with 1 SYH Medical Assistant overseeing the testing protocol. Bilingual research staff will be trained to oversee onsite testing.
223528294|NCT05894655|BEHAVIORAL|Community Health Worker (CHW) leading testing navigation and general preventive care reminders|This strategy provides health counseling about when COVID-19 testing is recommended, which test to use, testing instructions, and how to interpret results. Community Health Workers (CHW) will also offer general preventive health care reminders such as flu shots, blood pressure checks, and A1c screenings. This strategy will be available full-time during the first 3 months of roll-out at each clinic and after 3 months, the CHW will be available as needed. Trained bilingual CHW will be supervised by a SYH employee.
223528295|NCT05894655|BEHAVIORAL|No-cost self-testing kit vending machines|This strategy includes vending machines that will provide interactive instructions for accessing free self-testing COVID-19 kits located outside of clinics for patients and community members to use anytime. The vending machines will be available 24 hours/day, 7 days a week.
223528296|NCT05459753|RADIATION|(18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET|Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
223528297|NCT05459753|RADIATION|Dihydrotetrabenazine (DTBZ) PET|Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
223528298|NCT06439771|DRUG|YL202 should be intravenously infused|For each patient, YL202 should be intravenously infused over 60±10 min.
223528299|NCT02333799|DRUG|Bedaquiline|100mg tablets
223895918|NCT01160211|DRUG|Aromatase Inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
223528300|NCT02333799|DRUG|PA-824|200mg tablets
223528301|NCT02333799|DRUG|Linezolid|Scored 600mg tablets
223528302|NCT06834321|DRUG|Homoharringtonine combined with androgen deprivation therapy|Homoharringtonine 1mg intravenous infusion +5% glucose injection 250ml intravenous infusion, once a day for two consecutive days, repeated administration after three weeks of intermittent treatment, lasting two cycles + continuous androgen deprivation therapy.
223528303|NCT06834321|DRUG|Placebo combined with androgen deprivation treatment group|Placebo 1mg intravenous infusion +5% glucose injection 250ml intravenous infusion, once a day for two consecutive days, and repeated administration after a break of three weeks for two cycles + continuous androgen deprivation therapy,placebo is 5% glucose injection.
223528304|NCT06834321|PROCEDURE|radical prostatectomy|Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle.
223528305|NCT05411718|DRUG|Naproxen|Given by PO
223528306|NCT05411718|DRUG|Aspirin|Given by PO
223528307|NCT04565509|BEHAVIORAL|General Communication Message|A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.
223528308|NCT04565509|BEHAVIORAL|Focused/Targeted Message|A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.
223528309|NCT04565509|BEHAVIORAL|Best Message Alone|The best message will be either the general or focused/targeted message described above.
223528310|NCT04565509|BEHAVIORAL|Best Message + Augmented Message or Implementation Strategy|The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
223528311|NCT00710944|DEVICE|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
223528312|NCT06471712|DRUG|18F-LNC1007 Injection|Healthy volunteers will receive 1 MBq/kg and cancer patients will receive 3.7 MBq/kg. The injection will be carried out on the scan bed via an IV indwelling catheter. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
223528313|NCT02229357|BIOLOGICAL|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
223528314|NCT05612230|OTHER|Data analysis|Data analysis is based on a single database from the National Health Medical Data (North Center).
223528315|NCT05613556|DEVICE|Orpyx SI® Sensory Insole System|Orpyx SI Sensory Insole System consists of Orpyx Custom Insoles and Orpyx Sensory Technology. The Orpyx Custom Insoles are precisely fabricated for an individual's feet. The Orpyx Sensory Technology, a powered limb overload warning technology, is compatible with the Orpyx Custom Insoles. It is intended for monitoring physiological parameters, such as plantar pressure, motion and temperature, and providing real-time cues for pressure offloading as the patient goes about their daily activities
223528316|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 4 weeks
223528317|NCT02443935|DRUG|MGN1703|60 mg s.c. twice weekly for 24 weeks
223528318|NCT00314613|DRUG|Antipsychotic/Risperidone Consta|
223528319|NCT06218459|OTHER|Oldpain2go®|OldPain2Go® is a non-medical intervention for the treatment of chronic pain conditions including, but not limited to Chronic Low Back Pain. The underlying premise is rooted in the biopsychosocial model of pain, where the cause of ongoing pain and the development of chronicity, is believed to lie beyond simple tissue damage, injury or malfunction. The intervention draws upon subconscious communication as a means to help patients to re-frame their pain as less threatening and remove old, out of date, pain messages that no longer serve a purpose.
223528320|NCT06218459|OTHER|Jacobson's progressive relaxation|Jacobson's progressive relaxation is a technique commonly used for eliciting the relaxation response and relieving muscular tension. It involves sequentially relaxing various muscle groups, often starting at the head and moving down the body to the feet.
223528321|NCT00674921|DRUG|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
223528322|NCT00674921|DRUG|Placebo|starch, magnesium stearate, sodium lauryl sulphate
223528323|NCT02840630|OTHER|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
223895919|NCT01160211|DRUG|Lapatinib|1500 mg by mouth once daily
223895920|NCT05417100|DRUG|Methadone|methadone 0.2 mg/kg IV.
223528324|NCT01657370|DRUG|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
223895921|NCT05167409|DRUG|Evorpacept (ALX148)|IV QW
223895922|NCT05167409|DRUG|Cetuximab|IV QW
223895923|NCT05167409|DRUG|Pembrolizumab|IV Q3W
223895924|NCT02734290|DRUG|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
223895925|NCT02734290|DRUG|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
223895926|NCT02734290|DRUG|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
223895927|NCT03158129|DRUG|Carboplatin|Given IV
223895928|NCT03158129|DRUG|Cisplatin|Given IV
223895929|NCT03158129|DRUG|Docetaxel|Given IV
223528325|NCT01657370|DRUG|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
223713049|NCT02412995|OTHER|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
223713050|NCT02412995|OTHER|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
223713051|NCT02412995|OTHER|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
223713052|NCT02412995|OTHER|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
223713053|NCT02412995|OTHER|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
223713054|NCT03290872|DEVICE|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
223713055|NCT03290872|DEVICE|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
223895930|NCT03158129|BIOLOGICAL|Ipilimumab|Given IV
223895931|NCT03158129|BIOLOGICAL|Nivolumab|Given IV
223895932|NCT03158129|DRUG|Pemetrexed|Given IV
223895933|NCT05862454|DRUG|Magnesium|Magnesium injection therapy
223895934|NCT06257641|OTHER|High-intensity Mediterranean diet intervention|Dietary education for the adoption of the Mediterranean diet, with monthly monitoring - mostly online - by nutritionists with experience in the field. Patients will be given 500 ml of extra virgin olive oil per week and informative material about the Mediterranean diet, as well as recipes and weekly menus.
223895935|NCT06643195|OTHER|ImmediateAllogeneic Hematopoietic Stem Cell Transplantation|patients proceeded to allogeneic HSCT as soon as possible. Patients were allowed to receive low-dose chemotherapy that is not intended for the purpose of achieving a second remission.
223895936|NCT06643195|OTHER|Retreatment|Receive a second course of anti-leukemic treatment prior to allogeneic HSCT. The anti-leukemic treatment regimen will be determined based on the genetic mutation status. Patients without targetable mutations will receive a combination of BCL-2 inhibitors and demethylating agents as salvage chemotherapy. Patients with targetable mutations will receive appropriate targeted therapy (e.g., FLT3 inhibitors, IDH inhibitors).
223895937|NCT06521671|DEVICE|Dynaloc implant|Internal fixation with Dynaloc implant
223895938|NCT06521671|DEVICE|Cannulated cancellous screws|Internal fixation with two or three cannulated cancellous screws
223895939|NCT06801457|OTHER|NBO|NBO will be conducted with inhalation of 100% oxygen.
223895940|NCT06801457|OTHER|Control|Best medical care
223895941|NCT06800378|DRUG|Zolpidem 10 mg|Zolpidem tartrate 10 mg tablet (taken before bedtime)
223895942|NCT06800378|OTHER|Placebo|Starch 10 mg tablet (taken before bedtime)
223895943|NCT06801483|OTHER|Strengthening|All subjects will recieve an ankle muscle strenghening training program twice a week for six weeks.
223895944|NCT05721560|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
223895945|NCT05537467|OTHER|Music|Patients randomized to the music group will listen to upbeat music using headphones.
223895946|NCT06266806|BEHAVIORAL|Nurse Consultancy Program to Develop Breastfeeding Self-Efficacy Resources|Breastfeeding Self-Efficacy Resources Developing Nurse Consultancy Program (EMÖZGEDAP) was developed based on Denis's Breastfeeding Self-Efficacy theory along with the hypnobreastfeeding philosophy. In the individual counseling program focusing on the philosophy of hypnobreastfeeding, it will be emphasized that breastfeeding is an intuitive, natural, and unique process. Techniques such as affirmations, breathing exercises, relaxation, endorphin, serotonin, and oxytocin-enhancing practices will be used. Concepts from Dennis' breastfeeding self-efficacy theory will be integrated into the training program. The individual counseling program will be carried out by adult education criteria, methods such as slide presentation, three-dimensional models, video, role-play, peer opinions with positive breastfeeding experiences, case discussion, and question and answer will be used.
223895947|NCT05092126|BEHAVIORAL|Exercise|Calculate oxygen consumption
223895948|NCT06778811|DRUG|Intraoperative infusion of dexmedetomidine|Intraoperative infusion of 0.3ug/kg/h dexmedetomidine
223895949|NCT06778811|DRUG|Intraoperative infusion of esketamine|Intraoperative infusion of 0.3mg/kg/h esketamine
223895950|NCT06778811|DRUG|Saline control|Intraoperative infusion of equal volumes of saline
223895951|NCT04855786|PROCEDURE|Thoracic duct drainage|drain placement into the thoracic duct
223895952|NCT05879211|BEHAVIORAL|Feedback|Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
223895953|NCT04934865|DEVICE|Patients treated for their lung cancer.|"In addition to the weekly Moovcare® Lung follow-up, patients will benefit from standard oncological follow-up at the discretion of their oncologist according to standard recommendations for 2 years. Questionnaires will be completed at different times as mentioned below on the global study scheme and Flowchart.~In an active treatment situation, the pace of consultations will be adapted to the pace of treatment administration, according to standard recommendations. It may be lengthened in the absence of a clinical application or biological alert at the discretion of the investigator."
223895954|NCT02359825|DRUG|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
223895955|NCT05538338|OTHER|Platelet Rich Plasma Intrauterine infusion|an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group of participants
223895956|NCT05538338|OTHER|Normal saline Intrauterine infusion|an intrauterine infusion of normal saline will be administered to this group of participants
223895957|NCT03676764|DRUG|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
223895958|NCT03676764|DRUG|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
223895959|NCT02561585|DRUG|LEO 124249|
223895960|NCT02561585|OTHER|Vehicle|
223895961|NCT05831345|DRUG|Methadone Hydrochloride|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
223895962|NCT05831345|DRUG|Sufentanil Citrate|Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
223895963|NCT05393193|DIAGNOSTIC_TEST|Point-of-Care Cepheid Xpert HIV-1|Post-partum HIV-positive women with pre-determined risk factors for vertical HIV transmission will be offered point-of-care HIV testing for their newborns for early infant HIV diagnosis.
223895964|NCT05393193|DRUG|DTG/ABC/3TC|Infants will be started on a combination of NVP/ZDV/3TC. A switch to DTG/ABC/3TC will occur for all infants at or after 4 weeks (28 days) post-delivery for those weighing ≥3kg. Dosing of all ART will be weight-based by the Botswana treatment guidelines.
223895965|NCT05574075|DIAGNOSTIC_TEST|Diffusion tensor imaging|white matter imaging markers
223895966|NCT03622749|DEVICE|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
223895967|NCT04947449|DEVICE|fractional CO2 laser|Standard of care laser treatment of burn-related injuries will be performed. This protocol assesses the effects of those treatments on skin blood flow and sweating responses.
223895968|NCT06524310|DEVICE|Stimulation with low frequency rTMS at 1 Hz|Stimulation with low-frequency rTMS at 1 Hz with 90% MT will be applied with a total of 180 pulses each time, which contained 18 trains with ten pulses and an interval of 20 s between any two adjacent trains. The TMS treatment course will be administered twice per week for 9 weeks; the first six treatments will be over the left DLPFC, the second six sessions will be over the right DLPFC, and the remaining six times will be placed on the bilateral DLPFC stimulation (64).
223895969|NCT04090086|DRUG|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
223895970|NCT04090086|DRUG|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
223895971|NCT06109181|GENETIC|LX2020|LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2)
224083321|NCT03817372|DEVICE|Anterior-lateral electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
223895972|NCT06559124|OTHER|Traditional Physiotherapy + Sham Kinesiotape|"As exercise training, joint range of motion, flexion and abduction external cycle will be practiced with the gymnasts.~Circumference measurements will be taken for shoulder bone swelling and for atrophy.~Shoulder joint mobilizations will be applied (posterior cutting for flexion limitation, downward shifting and scapular mobilizations for abduction limitation).~Flexion and abduction will be stretched externally. Friction massage will be applied. Strengthening exercises for flexion, abduction and external rotation in the lower and upper segments of the shoulder with dumbbells and theraband, shoulder wheel and finger ladder will be practiced.~Codman exercises and staff exercises will be practiced."
223895973|NCT06559124|OTHER|Kinesiotape with Facilitation Method + Traditional Physiotherapy|Kinesio tape will be applied with 0 tension at the starting point when the arm is in a relaxed position and will be slightly heated. Since the deltoid muscle is a three-headed muscle, it will be applied with 0 tension in the flexed position at the elbow, for the front part, the arm with the elbow in full extension, and for the middle part of the deltoid, the I tape will be applied along the muscle without applying tension.
223895974|NCT06559124|OTHER|Kinesiotape with Inhibition Method + Traditional Physiotherapy|The Y-shaped kinesio tape will be placed on the deltoid muscle with inhibition and mechanical correction technique, and the Y-shaped kinesio tape will be placed on the supraspinatus muscle with inhibition technique, 3 cm below the humerus tuberculum deltoidea without tension. The Y tape will be applied along the outer edge of the anterior deltoid of the forearm with 15-25% light tension, and the posterior arm will be applied along the outer edge of the posterior deltoid with 15-25% light tension up to the lateral acromion. The last 3-5 cm of the tails will be applied to their permanent locations without tension. The shoulder will be held in maximum transverse extension and external rotation for the forearm of the Y support, and in 45 degrees transverse flexion and horizontal adduction for the posterior arm of the Y support. In addition, ultrasound, electrotherapy and cold application will be applied to the participants depending on their tolerance.
223895975|NCT01076062|PROCEDURE|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
223895976|NCT03134196|DRUG|Masked Placebo|Oral Placebo
223895977|NCT03134196|DRUG|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
223895978|NCT05976139|DEVICE|subthreshold treatment with micropulsed laser|"The laser instrument used is the Q 577® Laser System, Iridex, wavelength 577 yellow. The standard pattern used is:~* Power: 5% Duty Cycle~* Power 250 mw~* Pulse duration 200 ms~* Spot size 100 micron~* Pattern spacing 0.0 confluente, griglie 7x7"
223895979|NCT06427005|DRUG|Fruquintinib|Fruquintinib 5 mg daily for 14 days followed by a 7-day break
223895980|NCT06427005|DRUG|S-1|S-1 80-120 mg daily for 14 days, followed by a 7-day break
223895981|NCT06427005|DRUG|raltitrexed|raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
223895982|NCT06531421|OTHER|Equity Report Cards|At month 2 the investigators will distribute EMS Agency-level 'Equity Report Cards' to both agency leadership and all frontline EMS providers. This 'Equity Report Card' will contain monthly pooled, agency-level information summarizing clinical data for injured children stratified by race/ethnicity. At month 7 the investigators will also distribute Battalion-level 'Equity Report Cards' to agency leadership and all frontline EMS providers.
223895983|NCT06416111|DEVICE|NIRS|Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).
223895984|NCT06416111|OTHER|Pinprick Test|"With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling"
223895985|NCT06416111|OTHER|Modified Bromage Scale|"Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers."
223895986|NCT06416111|DRUG|Bupivacaine|Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
223895987|NCT06416111|DRUG|Prilocaine|Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
223719064|NCT05776615|OTHER|mobile application|"In the collection of Mobile Application group data, they will be asked to fill out the forms.The mobile application will be introduced, the application will be downloaded from the virtual market (Google Play Store or App Store) to the phone, login will be provided by giving a user name and password, and how to use the application will be explained. Participants will be asked to provide nursing care using this application once a week for 3 months.Nursing Diagnosis Perception Scale with nurses at the end of the 1st month and at the end of the 3rd month;  MıssCare Questionnaire in the Neonatal Intensive Care Unit(NICU); System Availability Scale will be applied."
223895988|NCT06189209|DRUG|Tenalisib|Tenalisib will be administered 800mg/ 400mg BID, orally
223719065|NCT02579239|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
223719066|NCT02579239|BIOLOGICAL|Placebo|Concentrate for solution for infusion
223713056|NCT06011044|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block test is a medical intervention that involves the administration of a local anesthetic to the intercostal nerves, which are located between the ribs. The intervention involves injecting a small amount of anesthetic solution near the targeted intercostal nerves, which temporarily numbs the area and provides potential pain relief. The intercostal nerve block test is considered a diagnostic tool to help guide further treatment decisions for conditions such as intercostal neuralgia, rib fractures, or postoperative pain. It is generally a safe and well-tolerated procedure, often performed under local anesthesia or with the assistance of image guidance to ensure accurate needle placement. Following the test, the patient's response is evaluated, and if pain relief is achieved, it may indicate that intercostal nerve block injections could be an appropriate treatment option.
223713057|NCT00785694|DRUG|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
223713058|NCT06236672|DRUG|GLP-1 receptor agonist|GLP-1 RA initiated between January 2019 and December 2022
223713059|NCT06236672|DRUG|basal insulin|basal insulin initiated between January 2019 and December 2022
223713060|NCT03652597|DEVICE|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
223713061|NCT03482544|DRUG|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
223713062|NCT03482544|OTHER|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
223713063|NCT04600141|DRUG|Tocilizumab|Tocilizumab infusion 8mg/kg/dose - Intravenous single dose.
223713064|NCT04600141|DRUG|Heparin - Therapeutic dosage|Intravenous Non-Fractional Heparine (HNF) starting at 18UI/kg/h adjusted according to a nomogram to achieve an Activated Partial Thromboplastin Time (ATTP) from 1.5 To 2.0 times the reference Value; or Low Molecular Weight Heparin (LMWH) subcutaneous dosage of 1mg/kg per dose every 12 hours
223713065|NCT04600141|DRUG|Heparin - Prophylactic dosage|Subcutaneous Non-Fractional Heparine 5000U every 8 hours OR Subcutaneous Low Molecular Weight (LMWH) 40mg/day.
223713066|NCT00003165|DRUG|doxorubicin-HPMA conjugate|
223713067|NCT01804465|DRUG|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
223713068|NCT01804465|DRUG|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
223713069|NCT06376292|DRUG|Intrathecal Injection of Thiotepa+Radiation+Systemic Treatment of Primary Diseases|Participants will receive a comprehensive treatment plan consisting mainly of whole brain 30Gy/10F radiotherapy combined with intrathecal injection of Thiotepa. The injection was administered by qualified individuals (certified personnel in the radiotherapy department of our hospital) twice a week for a total of 4 weeks. Thiotepa was injected 10mg each time, mixed with cerebrospinal fluid, and then injected slowly for 5-10 minutes.
223713070|NCT00004771|DRUG|leuprolide|
223713071|NCT00004771|DRUG|testosterone|
223713072|NCT05739188|BIOLOGICAL|Anti-GPRC5D CAR-T cells infusion|"This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%."
223713073|NCT00668707|DIETARY_SUPPLEMENT|melatonin|20 mgs ingested nightly
223713074|NCT00668707|DIETARY_SUPPLEMENT|placebo|similar to experimental in all ways except for lack of active ingredient
223713075|NCT00057278|DRUG|gabapentin|
223713076|NCT03274128|RADIATION|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
223713077|NCT03274128|PROCEDURE|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
223713078|NCT03857048|OTHER|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
223713079|NCT03857048|OTHER|Exercise training|16-wk supervised endurance exercise training program
223713080|NCT03857048|OTHER|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
223713081|NCT00084383|BIOLOGICAL|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
223713082|NCT01045525|PROCEDURE|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
223713083|NCT01045525|BEHAVIORAL|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
223713084|NCT03893370|DEVICE|RejuvenAir System|RejuvenAir Metered CryoSpray
223713085|NCT03893370|DEVICE|Sham Control Procedure|Sham Control Procedure
223719067|NCT02194244|DRUG|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
223719068|NCT02194244|DRUG|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
223895989|NCT00875277|DRUG|LEO 29102 cream|
223895990|NCT00875277|DRUG|LEO 29102 Cream Vehicle|
223895991|NCT00875277|DRUG|Betamethasone Dipropionate Cream|
223895992|NCT00875277|DRUG|LEO 29102 Plus Calcipotriol Cream|
223895993|NCT00875277|DRUG|LEO 29102 Plus Betamethasone Dipropionate|
223895994|NCT00875277|DRUG|Daivobet® Ointment|
223895995|NCT03800108|PROCEDURE|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
223895996|NCT03696784|BIOLOGICAL|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
223895997|NCT03696784|DRUG|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
223713086|NCT04368676|OTHER|Sudarshan Kriya Yoga (SKY)|The SKY program is a standardized, easy to learn sequential breathing yoga consisting of regulated breathing techniques followed by a timed rhythmic breathing practice. Participants will learn various exercises including rhythmic breathing, gentle yoga, and guided meditation.
223713087|NCT04368676|OTHER|Health Enhancement Program|HEP is a structured group program designed to help participants with information and instruction how to lead a healthier life. Participants will be provided psychoeducation and support regarding healthy active living using techniques like music therapy, diet control, exercise, and monitoring these via journaling.
223713088|NCT00191139|DRUG|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
223713089|NCT00191139|DRUG|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
223713090|NCT00191139|DRUG|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
223713091|NCT00191139|DRUG|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
223713092|NCT00191139|RADIATION|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
223713093|NCT05534737|OTHER|MAICP + usual care of social services|The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
223713094|NCT05534737|OTHER|Control|usual care of social services
223713095|NCT04667871|PROCEDURE|cataract surgery|Eyes for cataract surgery
223713096|NCT02465515|BIOLOGICAL|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
223895998|NCT03696784|DRUG|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
223895999|NCT03696784|DRUG|AP1903|"0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS."
223896000|NCT03696784|DRUG|Cyclophosphamide|500 mg/m2/day administered by IV over 3 consecutive days
223896001|NCT01293526|DEVICE|Control|Patients who respond will have leads will be placed using standard procedures.
223713097|NCT02465515|BIOLOGICAL|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
223713098|NCT02465515|BIOLOGICAL|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
223713099|NCT02696460|PROCEDURE|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
223896002|NCT01293526|DEVICE|Experimental|Patients who respond will have their leads placed based on study measurements.
223713100|NCT02696460|PROCEDURE|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
223713101|NCT06555536|OTHER|Tele OI|A data collection and Telemedicine tool translated into an APP.
223713102|NCT04216238|BEHAVIORAL|quasi-experimental Pre-test/Post-test design|surveys to document progress
223896003|NCT01293526|DEVICE|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
223896004|NCT03443388|DEVICE|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
223896005|NCT05916664|BEHAVIORAL|Kinto Care Coaching|Describe the basics of the intervention
223896006|NCT04118192|PROCEDURE|Tumour bed core biopsy|Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment
223896007|NCT05885464|BIOLOGICAL|BEAM-201|A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens
223713103|NCT04395404|DIAGNOSTIC_TEST|MRI|Patients with unilateral ASS, with and without the prosthesis in situ, are analysed by 3D- magnetic resonance imaging (MRI) with 64 channel head coil using T1 and T2 weighted, DIXON/ IDEAL, and T2 inversion recovery sequences.
223713104|NCT02419105|DRUG|Testosterone|transdermal gel, 75 mg daily
223713105|NCT02419105|DRUG|Colecalciferol|drink solution, 24000 IU once per month
223713106|NCT02419105|DRUG|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
223713107|NCT02419105|DRUG|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
223713108|NCT03846804|DIAGNOSTIC_TEST|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
223713109|NCT00072566|BIOLOGICAL|Bevacizumab|Given IV
223713110|NCT00072566|DRUG|Cyclophosphamide|Given PO
223713111|NCT00072566|OTHER|Laboratory Biomarker Analysis|Correlative studies
223713112|NCT04184713|DIETARY_SUPPLEMENT|Experimental Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.
223713113|NCT04184713|DIETARY_SUPPLEMENT|Control Group|Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.
223713114|NCT02325037|DRUG|GLPG1837 single ascending doses|Single dose, oral suspension
223713115|NCT02325037|DRUG|Placebo single dose|Single dose, oral suspension matching placebo
223713116|NCT02325037|DRUG|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
223713117|NCT02325037|DRUG|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
223713118|NCT05096793|DIETARY_SUPPLEMENT|beta alanine|On day 1, all participants completed the 6-MRT corresponding to baseline. Then, on days 2 and 3, each participant performed the 6-MRT with 30 mg·kg-1 and 45 mg·kg-1 of BA (low and high-dose trials, respectively). BA was purchased in powder format from a factory specializing in sports supplements. BA was colorless when diluted in water and had a characteristic taste. This format of BA (powder) allowed personalized dosing for each participant. The research team performed the personalized dosing before the application of the treatment. Between the evaluation days, there was 72 hours difference. The 30 mg·kg-1 or 45 mg·kg-1 BA administration was done with a double-blind method. Thus, on day 2, 50% of the sample performed the 6-MRT supplemented with 30 mg·kg-1 BA, while the other 50% performed the 6-MRT with 45 mg·kg-1 BA. On day 3, those participants who completed the 6-MRT with 30 mg·kg-1 BA now performed with 45 mg·kg-1 BA and vice versa.
223713119|NCT05610683|DEVICE|Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer|Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
223713120|NCT04638257|BIOLOGICAL|Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14|Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy
223713121|NCT04638257|OTHER|Placebo|Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
223713122|NCT05442814|PROCEDURE|Posterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by posterior approach
223713123|NCT05442814|PROCEDURE|Anterior suprascapular block|Diaphragmatic thickness fraction will be evaluated in the participant underwent suprascapular block performed by anterior approach
223713124|NCT03704467|DRUG|M6620|Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
223713125|NCT03704467|DRUG|Avelumab|Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
223713126|NCT03704467|DRUG|Carboplatin|Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
223713127|NCT00345839|DRUG|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
223713128|NCT00345839|DRUG|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
223713129|NCT05544734|DRUG|Hydrocodone 5Mg/Acetaminophen 325Mg Tab|5 mg/325 mg tablet
223713130|NCT05544734|DRUG|Acetaminophen 1000mg|1000 mg tablet
223713131|NCT05544734|DRUG|Ibuprofen 400 mg|400 mg tablet
223713132|NCT04119921|DRUG|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
223713133|NCT04119921|DRUG|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
223713134|NCT04119921|DRUG|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
223713135|NCT04119921|DRUG|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
223719069|NCT01125267|BEHAVIORAL|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
223719070|NCT01125267|BEHAVIORAL|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
223896008|NCT03059030|DEVICE|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
223896009|NCT06343649|OTHER|Visual|Delivery of images to conduct several exercises of Explicit Motor Imagery
223713136|NCT01109797|BEHAVIORAL|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
223713137|NCT01109797|BEHAVIORAL|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
223713138|NCT01084083|BIOLOGICAL|cetuximab|Given IV
223713139|NCT01084083|RADIATION|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
223713140|NCT01084083|DRUG|Paclitaxel|Given IV, 90 mg/m\^2 on days 1, 8 and 15
223713141|NCT01084083|DRUG|Cisplatin|Given IV, 75 mg/m\^2 on day 1
223713142|NCT01410201|DRUG|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
223713143|NCT04670198|BEHAVIORAL|Youth Empowerment Skills|The Youth Empowerment Skills (YES) programme is a novel psychoeducational intervention with simulation-based experiential learning tailored to the needs of young people. It is based on a social-cognitive learning model, and comprises attendance at 3 all-day YES sessions in non-healthcare settings (groups of 10); and then post-programme networking through social media and follow-up events facilitated by the youth worker. Sessions are led by a peer-educator and a health professional
223713144|NCT04670198|BEHAVIORAL|Waiting-list control|Usual care for 6 months, followed by the YES programme.
223713145|NCT04838483|DEVICE|Indirect adhesive restoration of posterior teeth|Indirect restoration of significant loss of dental hard tissue
223713146|NCT06400862|COMBINATION_PRODUCT|eOCT implantation|eOCT is regarded as an Advanced Therapy Product (ATP).
223713147|NCT06149832|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|The patient's mouth (including buccal mucosa, tongue and lip) was applied with MSCs: MSCs (1×10\^6/ml) dressing was applied 4 times/day for 2 weeks.
223713148|NCT01797744|OTHER|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
223713149|NCT00004211|BIOLOGICAL|PSA RNA-pulsed dendritic cell vaccine|
223713150|NCT02022852|DRUG|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
223713151|NCT02022852|DRUG|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
223713152|NCT01675791|BIOLOGICAL|ALK tree AIT 0.5 DU|
223713153|NCT01675791|BIOLOGICAL|ALK tree AIT 1 DU|
223713154|NCT01675791|BIOLOGICAL|ALK tree AIT 2 DU|
223713155|NCT01675791|BIOLOGICAL|ALK tree AIT 4 DU|
223713156|NCT01675791|BIOLOGICAL|ALK tree AIT 7 DU|
223713157|NCT01675791|BIOLOGICAL|ALK tree AIT 12 DU|
223713158|NCT01675791|BIOLOGICAL|ALK tree AIT Placebo|
223713159|NCT04096664|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
223713160|NCT03305341|BIOLOGICAL|COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use|"* By the percutaneous route with the multiple puncture device~* NOVAVAX COVID-19 VACCINE 1.0 mL plus BCG Organism 50 MG Mix"
223713161|NCT04543838|DIAGNOSTIC_TEST|Intervention|Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP) intraoperative monitoring
223713162|NCT04543838|OTHER|Standard of Care BP management|If blood pressure (BP) control is determined to be necessary, standard of care practices to manage it will be implemented
223713163|NCT04518072|OTHER|Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)|assessed biomarker in clinical samples
223713164|NCT05343052|OTHER|Patient Reported Outcomes Surveys|"* Oslo Sports Trauma Research Center Hamstring Injury Screening Questionnaire (HaOS) at baseline~* Functional Assessment Scale for Acute Hamstring Injuries (FASH) within 7 days of injury and within 7 days of return to sport (RTS)"
223713165|NCT05343052|OTHER|Clinical Assessments|"* Injury History at baseline, within 7 days of injury, within 7 days of RTS~* Pain and Function Assessments within 7 days of injury, within 7 days of RTS"
223713166|NCT05343052|OTHER|Biomechanical and Neuromuscular Assessments|"* Eccentric Strength measure at baseline and within 7 days of RTS~* Sprinting Biomechanics at baseline and within 7 days of RTS"
223896010|NCT06343649|OTHER|Auditory|Delivery of audio recordings to conduct several exercises of Explicit Motor Imagery
223896011|NCT06516705|BEHAVIORAL|Hypoglycemia education|Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
223713167|NCT05343052|DEVICE|Conventional MRI|at baseline, within 7 days of injury, and within 7 days of RTS
223713168|NCT07000383|DEVICE|Gelsectan|Gelsectan is a medical device containing xyloglucan, pea protein, and tannins, administered orally. Dosage: 2 capsules BID during Month 1, followed by 1 capsule BID during Month 2.
224276485|NCT05289557|DRUG|Placebo|Sugar pills with no active ingredients. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
224276486|NCT02225457|OTHER|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
223713169|NCT07000383|DRUG|Antispasmodic Agent|An oral antispasmodic medication, prescribed according to standard clinical practice for IBS-D.
223713170|NCT06680804|OTHER|chance for vaginal delivery.|chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy
223713171|NCT07053930|DRUG|Intraumbilical oxytocin|Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.
223713172|NCT07053930|DRUG|Intravenous oxytocin|Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.
224276487|NCT02225457|DIETARY_SUPPLEMENT|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
224276488|NCT02225457|DIETARY_SUPPLEMENT|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
224276489|NCT03108820|BEHAVIORAL|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
223528326|NCT01657370|DRUG|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
223528327|NCT02648581|DRUG|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
223528328|NCT00003486|DRUG|antineoplaston A10|
223528329|NCT00003486|DRUG|antineoplaston AS2-1|
223528330|NCT00003486|PROCEDURE|alternative product therapy|
223528331|NCT00003486|PROCEDURE|biological therapy|
223528332|NCT00003486|PROCEDURE|biologically based therapies|
223528333|NCT00003486|PROCEDURE|cancer prevention intervention|
223528334|NCT00003486|PROCEDURE|complementary and alternative therapy|
223528335|NCT00003486|PROCEDURE|differentiation therapy|
223528336|NCT04630483|OTHER|INHA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
223528337|NCT04630483|OTHER|TIVA|NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values
223528338|NCT04670796|DRUG|HLX02|subject receive one dose of HLX02
223528339|NCT04670796|DRUG|EU-sourced Trastuzumab (Herceptin®)|subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
223528340|NCT04670796|DRUG|US-licensed Trastuzumab (Herceptin®)|subject receive one dose of US-licensed Trastuzumab (Herceptin®)
223528341|NCT01296308|OTHER|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
223528342|NCT03744637|DRUG|Frespaciguat|Single inhaled dose of frespaciguat 120, 165, 240, 300, 360, or 480 ug depending upon randomization
223528343|NCT03744637|DRUG|Placebo|Single inhaled dose of placebo to match frespaciguat
223528344|NCT03440385|DRUG|Ozanimod|Specified dose on specified days
223528345|NCT03440385|OTHER|Placebo|Specified dose on specified days
223528346|NCT04103242|OTHER|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
223528347|NCT05915377|OTHER|READI-SET GO UB-CAM delirium screening into EHR|UB-CAM Delirium screening tool integrated into EHR with education on best practices for delirium management
223528348|NCT06288568|OTHER|No intervention|No intervention
223528349|NCT02238301|OTHER|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
223528350|NCT02238301|OTHER|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
223528351|NCT02354573|DRUG|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
223528352|NCT00663078|BEHAVIORAL|Brief CBT Group therapy|CBT based therapy also expert patient programme
223528353|NCT00692328|BEHAVIORAL|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
223719071|NCT04460404|BEHAVIORAL|Lifestyle consultation|"Collect relevant data of patients included in the study through outpatient consultation, telephone follow-up, questionnaire follow-up, etc., including:~1. Basic information~2. Digestive tract symptoms:~   A constipation-related symptoms B abnormal symptoms~3. Fecal traits~4. Lifestyle habits~5. Others"
224276490|NCT03108820|OTHER|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
224276491|NCT00178711|DEVICE|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
224276492|NCT00089973|DRUG|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
224276493|NCT02159820|DRUG|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
223896012|NCT03463785|OTHER|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol. The OSA patients will be treated with mandibular advancement device.
223719072|NCT01682109|DRUG|Valacyclovir|
223719073|NCT04176666|DEVICE|NettOpp|NettOpp is a mobile application for adolescents aged 11-16 years who have been exposed to cyberbullying or cyberaggression.
223719074|NCT00601211|DRUG|Pilocarpine|
223719075|NCT04648553|BEHAVIORAL|Task-Based Grounding|Three 50 minutes sessions with an interventionist that includes 6 non-punitive components of treatment common in Behavioral Parent Trainings: Education on behavior change, positive one-on-one time between parents and their children, differential attending to positive and negative behaviors, effective praise, giving effective instructions, and using a point and reward system to encourage prosocial behaviors. These components are distilled into 5 skill modules and paired with Task-Based Grounding, which involves a brief restriction of privileges and provides children with the opportunity to end the restriction by completing a prosocial task.
223719076|NCT04648553|BEHAVIORAL|Connected Care (Enhanced Treatment as usual)|Two sessions with a facilitator. The facilitator does NOT provide any guidance to the parent on managing their child's behavior, but provides empathy and problem solving to help them find a resource that best fits their needs. It is particularly geared towards helping parents connect with Behavioral Parent Trainings to address the needs of children with oppositional, defiant, or aggressive behaviors.
223719077|NCT00558558|DRUG|Haelan|4 oz orally twice daily for 8 Weeks
223719078|NCT02014025|PROCEDURE|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
223719079|NCT02014025|PROCEDURE|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
223719080|NCT05190159|DEVICE|Monster Screw System|Subjects who have undergone a foot and/or ankle procedure involving the index device
223719081|NCT05222737|DEVICE|medency diode laser|intra pocket application of diode laser
223719082|NCT05222737|DRUG|spirazole forte|adminstration of spirazole forte with a dose 17 mg per kg
223719083|NCT02460627|DRUG|Lidocaine adhesive tape|700 mg for 12 hours
223719084|NCT02460627|OTHER|Adhesive tape|For 12 hours
223719085|NCT02217267|DRUG|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
223719086|NCT02217267|DRUG|Placebo|
223719087|NCT01371175|BIOLOGICAL|DNA.HIVA|0.5mg DNA.HIVA or placebo
223719088|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^6 pfu MVA or placebo
223719089|NCT01371175|BIOLOGICAL|MVA.HIVA|5x10\^7 pfu MVA or placebo
223719090|NCT01371175|BIOLOGICAL|MVA.HIVA|2.5x10\^8 pfu MVA or placebo
223719091|NCT05858762|DIAGNOSTIC_TEST|Breast digital tomosynthesis|Introduction of an almost three-dimensional imaging technique called breast digital tomosynthesis
223719092|NCT04771039|OTHER|reason for consultation|search in medical files for reasons for ophthalmology consultation, functional signs, clinical signs, treatment, characteristics of IBD
223719093|NCT01265368|BIOLOGICAL|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
223719094|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
223719095|NCT01407315|DEVICE|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
223719096|NCT03641274|OTHER|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
223719097|NCT01433614|DRUG|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
223719098|NCT01433614|DRUG|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
223719099|NCT01433614|DRUG|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
223719100|NCT01411202|DRUG|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
223719101|NCT01411202|OTHER|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
223719102|NCT04805424|PROCEDURE|Lipo-abdominoplasty|Abdominoplasty plus liposuction
223719103|NCT04805424|PROCEDURE|Abdominoplasty|Abdominoplasty
223896013|NCT03651349|DRUG|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
224276494|NCT02159820|DRUG|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
224276495|NCT03545880|OTHER|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
223896014|NCT03651349|DRUG|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
223896015|NCT05400252|BEHAVIORAL|Omnis Salutis|Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports
223896016|NCT05400252|BEHAVIORAL|Health and Wellness|Health \& Wellness is an educational wellness intervention
223896017|NCT04507178|DRUG|Nadroparin Injectable Product|high dose LMWH compared to prophylactic dose LMWH
223896018|NCT06519305|OTHER|Survey completion|Participants will be asked to fill out the survey via email.
223896019|NCT05642923|DRUG|Synthetic Vitamin B1|Synthetic Vitamin B1 400 mg per day
223896020|NCT05936658|DRUG|[F-18]Florastamin|A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
223896021|NCT05332756|OTHER|Conservative management|Patients and their first-degree relatives will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
223896022|NCT05470088|OTHER|Neuroimaging (MRI)|Multimodal magnetic resonance imaging
223896023|NCT05227248|DIETARY_SUPPLEMENT|Dark chocolate|Patients were administered 20 grams of dark chocolate
223896024|NCT05227248|DIETARY_SUPPLEMENT|Milk Chocolate|Patients were administered 7.5 grams of milk chocolate
223896025|NCT05776134|BIOLOGICAL|Brexucabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
223896026|NCT06544707|DRUG|0.003% AR-15512|Ophthalmic solution administered via topical ocular instillation
223896027|NCT05332366|DRUG|Delgocitinib cream|Cream for topical application
223896028|NCT05332366|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
223896029|NCT04292223|DRUG|Pimavanserin|Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
223896030|NCT06615518|PROCEDURE|transforaminal endoscopic lumbar discectomy|"FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge."
223896031|NCT06615518|PROCEDURE|Interlaminar endoscopic lumbar discectomy|"FELD is a minimally invasive spine surgery technique performed through small incisions using an endoscope. The procedure involves accessing the herniated disc through either the transforaminal (TELD) or interlaminar (IELD) approach, depending on the location of the disc herniation. The endoscopic approach allows for direct visualization of the affected area using a camera, and specialized instruments are used to remove the herniated portion of the disc.~What distinguishes this intervention:~* Small incisions (typically \&amp;lt;1 cm) result in less soft tissue damage compared to traditional open surgery.~* Real-time endoscopic visualization allows for precise disc removal and reduced trauma to surrounding structures such as muscles and ligaments.~* Minimized postoperative pain and faster recovery times due to the less invasive nature of the procedure.~* Outpatient or short hospital stay is often possible, contributing to faster patient discharge."
223896032|NCT06615518|PROCEDURE|Microdiscectomy|"Microdiscectomy is a conventional surgical technique for treating lumbar disc herniation, involving a small open incision. In this procedure, the surgeon makes an incision typically between 2-3 cm in length, then uses an operating microscope to gain magnified visualization of the herniated disc. The surgeon removes part of the lamina (laminotomy) to access the disc and nerves. Special instruments are used to remove the herniated portion of the disc that is compressing the spinal nerves, relieving symptoms such as pain, numbness, and weakness.~What distinguishes this intervention:~* Larger incision (2-3 cm) compared to FELD, but still smaller than traditional open discectomy, allowing better visualization.~* Microscopic magnification allows precise removal of disc material while minimizing trauma to surrounding neural structures.~* Direct access to the affected area via the removal of part of the lamina (laminotomy), offering a well-established and highly effective approach to reli"
223896033|NCT00753545|DRUG|AZD2281|Tablets Oral BID
223896034|NCT00753545|DRUG|matching placebo|matching placebo bid
223896035|NCT02531607|OTHER|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
224083322|NCT01629407|OTHER|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
224083323|NCT00797693|DRUG|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
224276496|NCT03545880|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
223896036|NCT06799442|PROCEDURE|Erector Spinae Plane Block|Patients will be placed in lateral position with the surgical site upward. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. An echogenic needle needle will be inserted using an in-plane approach and craniocaudally direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging.
223896037|NCT06799442|DRUG|Dexmedetomidine|50 mic dexmedetomidine which is diluted to 2ml.
223896038|NCT06799442|DRUG|fentanyl|100 mic fentanylwhich is also diluted to 2 ml.
223896039|NCT06791252|BEHAVIORAL|genital hygiene education|"The pregnant women in the experimental group were given genital hygiene training individually and in their own homes by the researcher. During the training, the privacy of the client was observed and the researcher and the pregnant women were left alone in the room where the training would be given. Care was taken to ensure that the environment was quiet and calm while the training was given. It was preferred that the pregnant women be in the most comfortable position during the training.~The training was completed by explaining each topic in the training booklet in an average of 20-25 minutes.~Genital hygiene training content:~Session 1 (Day 1): After the introduction phase, information was given about the method to be followed in the study to the pregnant women who agreed to participate in the study. Then, the Minimum Informed Consent Form was given to these women, and the pregnant women who approved the form after reading it were included in the study. Pre-test data were collecte"
223896040|NCT06793137|DRUG|Metronidazole|This intervention involves administering the oral antibiotic metronidazole during the first seven days of radiotherapy for patients with locally advanced rectal adenocarcinoma who are undergoing total neoadjuvant treatment. Metronidazole is considered a safe medication, with a very low risk of adverse effects. It is commonly used to treat infections caused by anaerobic bacteria that are part of the intestinal microbiota. Additionally, it is well established that certain genera of anaerobic bacteria are linked to a poorer response to treatment.
223896041|NCT05754073|DRUG|1. Intranasal oxytocin spray|30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
223896042|NCT05754073|DRUG|2. Intranasal placebo spray|30 IU, twice daily for 12 months in the placebo comparator arm in double-blinded phase
223896043|NCT05754073|DRUG|3. Intranasal Oxytocin spray|30 IU, twice daily for 6 months in both experimental and placebo comparator arm in open-label phase
223896044|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.015%)|QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
223896045|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.03%)|QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
223896046|NCT06016972|DRUG|Experimental: QLS-111 ophthalmic solution, (0.075%)|QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
223896047|NCT06016972|OTHER|QLS-111 ophthalmic vehicle solution|Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.
223896048|NCT04840797|DEVICE|HeartStart HS1|Automated External Defibrillator
223896049|NCT05144763|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
223896050|NCT06541145|DRUG|Mupirocin|Participants will place a pea-sized amount (or approximately 1cm ribbon) of 2% mupirocin ointment (Duke formulary) on a cotton swab and gently massage it into the anterior nares twice daily for 5 days.
223896051|NCT06541145|DRUG|Chlorhexidine baths|Participants will be instructed to use pre-packaged chlorhexidine cloths. Each cloth will be used to wipe designated body areas (i.e., arms, legs, chest and neck, back and perineum) once a day for 5 days. These are inexpensive cloths that are easy to use and have been shown to be effective at eradicating Staph aureus carriage. Ideally, participants will be instructed not to rinse off immediately after using the cloths. Baths should be performed on the same 5 days as they apply the intranasal mupirocin.
223896052|NCT05364515|DRUG|PRGF|"Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)"
223896053|NCT05364515|DRUG|Clobetasol Propionate|0.05 propionate clobetasol: daily (first month), alternate (second moth), twice per week (from third month)
223896054|NCT04848740|DEVICE|ReLex-smile|Using VisuMax femtosecond laser we created the stromal pocket with diameter of 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness set to 130 μm from corneal surface and 4 mm superior incision. Hinge position flap was set at 90° angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values We noticed during intervention that implantation of fresh lenticule depends from corneal thickness, for example if c.th.is 300-400 μm we implanted 1/2 stroma, if c.th.is 400 μm or more we implanted 1/3 stroma Example: if corneal thickness is 300 μm we implanted 150 μm (becoming 450 μm) we added more stroma due to more live keratocytes and stromal steam cells, aiming to overcome dead and non-functional keratocytes
223896055|NCT03686345|DRUG|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
224276497|NCT05993390|DRUG|Sugammadex|Intravenous administration of sugammadex 2mg/kg.
223896056|NCT05182398|OTHER|Assesment|Modified Four Square Step Test, Berg Balance Scale, Dynamic Gait Index ,Activity-Specific Balance Confidence Scale
223896057|NCT02432404|DRUG|NuvaRing|
224276498|NCT05993390|DRUG|Neostigmine|Intravenous administration of neostigmine 0.05mg/kg with glycopyrrolate 0.01mg/kg
224276499|NCT06223724|DEVICE|STOP|Software to measure impedance telemetry data
224276500|NCT06223724|DEVICE|MAESTRO|Software to measure impedance telemetry data
223896058|NCT06100900|DRUG|BCX10013|Multiple dose levels may be tested in this study.
223896059|NCT04701645|COMBINATION_PRODUCT|Microdevice|"Placement of 1 to 6 implantable microdevices with multiple miniature drug reservoirs into a tumor mass 24 +/- 8 hours prior to surgery. Drugs will be released over 24 (+/- 8) hours while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice will harbor up to 20 drugs and drug combinations relevant to the treatment of ovarian cancer.~* Each drug or drug combination will be released from a single, separate reservoir. At least two reservoirs will harbor a drug vehicle only.~* Drugs will include all or a subset of the following: Cisplatin, Carboplatin, Paclitaxel, Doxorubicin or pegylated liposomal doxorubicin (PLD), Cyclophosphamide, Etoposide, Gemcitabine, Ifosfamide, Pemetrexed, Topotecan, Vinorelbine, Olaparib, Niraparib, Rucaparib, Carboplatin + paclitaxel (combination), Carboplatin + doxorubicin (combination),Carboplatin + gemcitabine (combination)"
223896060|NCT04101851|PROCEDURE|omission of SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
223896061|NCT05761366|DRUG|Al18F-PSMA-BCH PET/CT|Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.
223896062|NCT04963270|DRUG|Satralizumab|Satralizumab will be administered as a subcutaneous injection
223896063|NCT04963270|OTHER|Placebo|Satralizumab placebo will be administered as a subcutaneous injection
223896064|NCT05136417|DEVICE|intra-procedural intracardiac echocardiography (ICE) probe|placing the WATCHMAN FLX device using the intra-procedural intracardiac echocardiography (ICE) probe.
223896065|NCT04026555|OTHER|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
223896066|NCT04026555|OTHER|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
223896067|NCT04859530|DIAGNOSTIC_TEST|AVC test|The AVC test will be performed during VIA by local midwives: 120 second videos focused on the cervix will be taken right after the application of acetic acid on the cervix. The recording smartphone will be fixed on a tripod situated 15cm away from the cervix.
223896068|NCT06800222|OTHER|modern agents rehab|rehabilitation interventions containing modern physical agents together with classical interventions
223896069|NCT06800222|OTHER|classical rehab|classical rehabilitation interventions
223896070|NCT06213298|DRUG|Kava|75 mg kavalactones
223896071|NCT06213298|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
223896072|NCT06475521|OTHER|Infant Formula|Test group
223896073|NCT05218226|DRUG|Avatrombopag|The subjects will initiate treatment with 60 mg/d Avatrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 60 mg daily. Subjects whose platelet count ≤100×109/L，the Avatrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Avatrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Avatrombopag to 20mg once every other day or lower frequency during the treatment period, Avatrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Avatrombopag if the platelet is greater than 50×109/L.
223896074|NCT05948618|BEHAVIORAL|Embodied Conversational Agent|The ECA- PRO measures will included PROMIS Profile measures, which include depression, anxiety, fatigue, pain intensity, and interference, fatigue, sleep disturbance, physical function, and satisfaction with social roles. In order to reduce boredom and confusion, equivalent forms of different items will be selected from the items pools. In this way, participants are not answering the same questions twice within one session.
223896075|NCT05948618|BEHAVIORAL|REDCap Survey|An internet-based measure will use PROMIS Profile measures which will include depression, anxiety, fatigue, pain intensity and interference, sleep disturbance, physical function and satisfaction with social role
223896076|NCT06797986|BIOLOGICAL|BVAC-E6E7 (low level)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
223896077|NCT06797986|BIOLOGICAL|BVAC-E6E7 (high level)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
223896078|NCT06797986|BIOLOGICAL|BVAC-E6E7 (RP2D)|BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
223896079|NCT05367414|OTHER|aromatherapy massage (diluted tea tree oil)|massage with diluted tea tree oil was applied
223896080|NCT05367414|OTHER|aromatherapy massage (sweet almond oil)|massage with sweet almond oil was applied
223896081|NCT05206422|DEVICE|Doraya Catheter|The Doraya Catheter is a temporary intravenous flow regulator, positioned in the inferior vena cava below the level of the renal veins
223896082|NCT06798090|DEVICE|Band and Loop Space Maintainer Produced with Three-Dimensional Printer|Band and loop space maintainer produced with three-dimensional printer using micro laser sinterisation method
223896083|NCT06798090|DEVICE|Band and Loop Space Maintainer Produced with Conventional Technique|Band and loop space maintainer produced with conventional methods
223896084|NCT04227769|DRUG|Anakinra Prefilled Syringe|Subcutaneous injection of 100 mg/ 0.67 ml of Kineret or placebo
223896085|NCT03737643|DRUG|Bevacizumab|Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
223896086|NCT03737643|DRUG|Durvalumab|Durvalumab by intravenous infusion
223896087|NCT03737643|DRUG|Olaparib|Olaparib tablets
224276501|NCT03911115|OTHER|Food preference questionnaire|This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
224276502|NCT05691153|DRUG|ThisCART19A with Dose Level 1|ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
223896088|NCT03737643|DRUG|Placebo olaparib|Placebo tablets to match olaparib
223896089|NCT03737643|DRUG|Durvalumab placebo|Matching placebo for intravenous infusion
223896090|NCT03737643|DRUG|Carboplatin+Paclitaxel|Standard of care chemotherapy
223896091|NCT04150900|DRUG|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
223896092|NCT04150900|DRUG|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223896093|NCT06771401|DIAGNOSTIC_TEST|cervical mucus sampling|Monitoring of menstrual cycle will be conducted in the follicular, ovulatory and luteal phases during which cervical mucus, serum and urine samples will be collected and pelvic ultrasound scans performed (3-5 ultrasound scans/samples within the cycle).
223896095|NCT06547268|DEVICE|Wireless sensor and platform|Skin-mounted sensor that pairs with tablet platform
223896096|NCT06414018|DRUG|Alfentanil|alfentanil 10ug/kg is used for anesthesia induction
223896097|NCT03547323|DEVICE|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
223896098|NCT03547323|DEVICE|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
223896099|NCT06798376|DRUG|≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy|Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no more than 4 cycles
223896100|NCT06798376|DRUG|≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy|Any PD-1 inhibitors combined with any chemotherapy regimen given before surgery for no less than 5 cycles
223896101|NCT06798376|PROCEDURE|Gastrectomy|Any type of surgical procedure for gastric adenocarcinoma patients in which part or all of the stomach is removed
223896102|NCT06433245|PROCEDURE|effect of 3% and 5% sodium hypochlorite on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and hemostasis is achieved with 3% sodium hypochlorite in control group and 5% sodium hypochlorite in experimental group followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
223896103|NCT05478564|OTHER|Intraoperative fluids and vasoactive drugs management protocol|Limitation of hypotensive events during open surgery for abdominal aorta repair
223896104|NCT04856982|DRUG|Tofersen|Administered as specified in the treatment arm
223896105|NCT04856982|DRUG|Placebo|Administered as specified in the treatment arm
223896106|NCT03483610|BEHAVIORAL|Provider Referral|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
223896107|NCT03483610|BEHAVIORAL|Text Messaging|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
224276503|NCT05691153|DRUG|ThisCART19A with Dose Level 2|ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
223896108|NCT04221945|BIOLOGICAL|Pembrolizumab|IV infusion
223896109|NCT04221945|DRUG|Placebo for pembrolizumab|IV infusion
223896110|NCT04221945|DRUG|Cisplatin|IV infusion
223896111|NCT04221945|RADIATION|External Beam Radiotherapy (EBRT)|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
223896112|NCT04221945|RADIATION|Brachytherapy|Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed
223896113|NCT06461845|OTHER|Whole Body Vibration group|This group will be given WBV training session, by using a WBV platform was conducted to the study group. The wBV program comprises various positions such as the child stands in an erect position, sitting, and in kneeling position on vibrating platform. This platform vibrates horizontally at a frequency ranged from 10 to 25 Hz. The participants had to carry out each position for 2 min in the first month, and then it was increased to 3 min in the second month. The rest period between each position was 1 min in the first month, then it became half a minute in the second month. The duration of the vibration exposure was 10 min.
223896114|NCT06461845|OTHER|conventional therapy|This group will be provided with the conventional physical therapy. To this, stretching activities to keep up muscle elasticity particularly Achilles tendon, hamstring muscles, hip flexors and adductors; strength training to hip flexor, knee extensor, and ankle dorsiflexor;
223896115|NCT02994160|OTHER|Fast electrode|Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
223896116|NCT06158139|BIOLOGICAL|iC9-CAR.B7-H3 T cell infusion|iC9-CAR.B7-H3 T cell product will be administered via intravenous injection over 5 - 10 minutes.
223896117|NCT04624633|DRUG|Acalabrutinib|Oral, twice a day, predetermined dosage
223896118|NCT04624633|DRUG|Umbralisib|Oral, once a day, predetermined dosage, each 28 day cycle up to 24 cycles
223896119|NCT04624633|DRUG|Ublituximab|28 day cycle, starting cycle 7 via iv, on at predetermined dosage and timepoints in each cycle
223939953|NCT07189104|BEHAVIORAL|SAGA for Toddlers|SAGA for Toddlers includes training sessions and workshops for the ECEC personnel on the mentalization-based shared reading intervention following the SAGA model. During the intervention shared reading sessions (5-10-minutes each) are held for groups of 2 to 3 children for 10 weeks (at least 3 sessions per week) at the ECEC by the personnel. Caregivers are involved in the intervention via caregiver meetings held at the ECEC by the investigators.
224276504|NCT03235141|DRUG|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
223896120|NCT01667952|GENETIC|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
223896121|NCT01667952|GENETIC|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
223896122|NCT01667952|OTHER|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
223896123|NCT05552014|BEHAVIORAL|Natural Psychotherapy|"Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics."
223896124|NCT05552014|BEHAVIORAL|Mental Health Education|Mental Health Education Seminar
223896125|NCT06529770|OTHER|NMP-e|"The US-PNM intervention uses a square-wave biphasic current (10 Hz, 250 ms pulse width) at maximum tolerable intensity for 1.5 minutes (10 seconds 10 times), per Fermín Valera and Fran Minaya's protocol. Participants will lie on their side, with the area cleaned and an ultrasound probe cover used.~Needles (Agu Punt, Spain) will be inserted perpendicularly to target the nerve perineurium. For the axillary nerve (C5-C6), a 0.40/0.50×25 mm needle will be used in a short axis at 80°. For the suprascapular nerve (C5-C6), a 0.30/0.40×25 mm needle will be used.~Each session involves two needle insertions, with the needle stationary and monitored by a physiotherapist with two years of experience."
223896126|NCT04802954|OTHER|Video acquisition|One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
223896127|NCT04316871|DRUG|1.5 mg of Morphine Sulfate|1.5 mg of Morphine Sulphate will be given epidurally.
223896128|NCT04316871|DRUG|Normal saline|Normal saline will be given epidurally.
223896129|NCT04316871|DRUG|3 mg of Morphine Sulfate|3 mg of Morphine Sulphate will be given epidurally.
223896130|NCT04316871|DRUG|4.5 mg of Morphine Sulfate|4.5 mg of Morphine Sulphate will be given epidurally.
223896131|NCT05307133|OTHER|Sleeve Gastreextomy|The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
223896132|NCT05366075|OTHER|Intervention 1 (simple exercise program)|Up to four sessions per day (total duration 20-30 minutes/day). Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week). At discharge, the participants will be encouraged to continue with the exercise program at home.
223896133|NCT05366075|OTHER|Intervention 2 (comprehensive exercise program)|Two daily sessions (morning and afternoon) of 20 minutes' duration each. Performed at the hospital on all weekdays from baseline until hospital discharge (around 1 week).
223896134|NCT05087992|DRUG|BI 905711|BI 905711
223896135|NCT05087992|DRUG|FOLFIRI|FOLFIRI
223896136|NCT05087992|DRUG|Bevacizumab|Bevacizumab
223896137|NCT05758922|DRUG|AZ-3102 (Dose 1)|"Pharmaceutical form: capsule~Route of administration: oral"
223896138|NCT05758922|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
223896139|NCT05758922|DRUG|AZ-3102 (Dose 2)|"Pharmaceutical form: capsule~Route of administration: oral"
223896140|NCT04900818|DRUG|TJ033721 (givastomig)|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
223896141|NCT04900818|DRUG|TJ033721 (givastomig) , nivolumab, chemotherapy|Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy
223896142|NCT01842542|DEVICE|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
223896143|NCT06381284|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
224083324|NCT01262625|DEVICE|CCTA|Complete diagnostic CCTA per protocol specifications.
224083325|NCT01262625|DEVICE|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
224083326|NCT00827190|DRUG|ILS-920|
224083327|NCT00110942|DRUG|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
224083328|NCT00110942|OTHER|Placebo|SC placebo injection Q4W for 3 doses
224083329|NCT03153839|BEHAVIORAL|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
224083330|NCT05704478|DRUG|Vericiguat|soluble guanylate cyclase stimulator
224083331|NCT02789657|DRUG|paclitaxel|80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
224083332|NCT02789657|DRUG|Trastuzumab|Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
224083333|NCT02789657|DRUG|Pertuzumab|every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
224083334|NCT02789657|DRUG|carboplatin|AUC 2 administered weekly with no planned treatment breaks
224083335|NCT02789657|PROCEDURE|Breast surgery|breast conserving or mastectomy
224276505|NCT03235141|DRUG|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
223713173|NCT07053696|DRUG|Technetium-99m Diethylenetriaminepentaacetic Acid|Technetium-99m Diethylenetriaminepentaacetic Acid A single inhaled dose of 99mTc-DTPA in 0.9% sodium chloride solution, total volume 2 ml, with radioactivity of 500-800 µCi. The solution is radiolabeled only in the aqueous phase to allow gamma scintigraphic imaging of pulmonary deposition. Delivered via breath-actuated EDDIS system. The formulation includes a non-labeled microdose of perfluorocarbon emulsion to simulate clinical aerodynamic behavior.
223713174|NCT07053696|DEVICE|EDDIS-IDDS (Enhanced Digital Dose Inhalation Delivery System)|Portable, maintenance-free breath-actuated inhalation delivery system with integrated digital sensors. Records real-time data including inspiratory volume, flow rate, duration, and breath-hold time. Provides controlled aerosol delivery and secure transmission of inhalation parameters to the clinical monitoring platform.
223713175|NCT07055373|DEVICE|Transauricular Vagal Nerve Stimulation|Transauricular VNS will be administered using the Parasym aVNT (auricular vagal neuromodulation therapy) Device (Nurosym, London, UK). The Parasym aVNT Device delivers non-invasive neuromodulation targeting the auricular branch of the vagus nerve via the tragus of the outer ear. All participants will receive four weeks of twice daily (morning and evening) 45-minute sessions of taVNS (frequency ≥ 25Hz; pulse width =250µs (Fig). The safety and tolerability of taVNS has been demonstrated in seven studies with a total of 205 (116 active, 121 sham) cardiovascular patients. Stimulation protocols ranged from 43 min to 8 hrs daily, for 1 day to 6 months. There were no device-related serious adverse events. Three patients (1.5%) experienced minor adverse events, i.e., dermal paresthesias (light tingling at the ear). No differences in tolerability were observed between active and sham taVNS \[21\].
223713176|NCT07054645|DIETARY_SUPPLEMENT|Elderberry Anthocyanin Chewing Gum|Participants receive a functional chewing gum containing encapsulated elderberry (Sambucus nigra L.) anthocyanins standardized for cyanidin-3-glucoside and cyanidin-3-sambubioside. The gum is formulated to be geriatric-friendly (soft, low-elasticity) and is administered twice daily for 6 weeks. It enables transmucosal polyphenol delivery through buccal absorption.
223713177|NCT07054645|DIETARY_SUPPLEMENT|Placebo Chewing Gum|Participants receive a placebo chewing gum identical in appearance, taste, and texture to the active gum but containing no elderberry anthocyanins or bioactive compounds. The gum is administered twice daily for 6 weeks to match the intervention group.
223713178|NCT07053332|DRUG|PD-1/CTLA-4 combination antibody with low-dose radiotherapy|"* PD-1/CTLA-4 combination antibody: Iparomlimab and Tuvonralimab， 5mg/kg on day 1, day 22, and day 43, administered via intravenous infusion, for a total of three cycles before surgery and maintained for up to 1 year after surgery.~* Radiotherapy: To be conducted within one week of the start of immunotherapy, with a total dose of DT: 30Gy, 2.5Gy × 12 fractions, once daily, five times per week. The preoperative radiotherapy target area will be delineated by the radiation oncologist in accordance with the NCCN Guidelines for Gastric/Esophagogastric Junction Cancers 2022 and in consultation with the opinions of the general surgeon.~* Surgery: Surgical treatment will be completed within 3-5 weeks after the completion of neoadjuvant therapy.~* Adjuvant therapy: Postoperative immunotherapy will be maintained for up to 1 year."
223713179|NCT05166083|OTHER|Testosterone Hormon Therapy|Testosterone isocaproate, ... ml, 8 doses, once per 21 days
223713180|NCT06756451|DRUG|RJK-RT2831 dose-escalation phase Ia|there are seven doses(1mg-160mg) in this part. The subjects will receive RJK-RT2831 injection twice a week by intravenous push or intravenous infusion for 4 weeks until the end of one dosing cycle (28 days). After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
223713181|NCT06756451|DRUG|RJK-RT2831 Dose Expansion Phase Ib|there are four doses in this part. The subjects will be randomized in a 1:1 ratio to receive one dose level of RJK-RT2831 intravenous infusion twice a week for 4 weeks until the end of one dosing cycle (28 days).After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
223713182|NCT06843044|DRUG|Ranquilon|1 mg tablets
223713183|NCT06843044|DRUG|Afobazole|10 mg tablets
223713184|NCT06540638|BEHAVIORAL|Web based education program|In a pre-operative assessment, 1-30 days prior to their scheduled surgery, patients will be asked to participate in our web-based educational program. The content of our e-module included: introduction to brain health, surgery, and delirium, causes and risk factors, modifiable risk factors, and delirium prevention. The program will be delivered on a research laptop/iPad at the clinic. The entire program, including pre- and post-education questionnaires and satisfaction survey should take about 20 minutes to complete.
223713185|NCT06541548|DEVICE|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
223713186|NCT06541548|DEVICE|pQCT|Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
223713187|NCT06541548|DEVICE|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck.
223713188|NCT05347238|DRUG|Dopamine|Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.
224276506|NCT03685409|DRUG|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
224276507|NCT03685409|DRUG|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
223713189|NCT05347238|DRUG|Norepinephrine|Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
223713190|NCT04914923|DEVICE|Muse|Muse is an EEG headset device created by Interaxxon to track brain waves during mindfulness sessions.
223713191|NCT04914923|BEHAVIORAL|Cognitive Behaviour Therapy (CBT)|Cognitive behavioural therapy (CBT), incorporating exposure/response prevention (ERP) and cognitive therapy, is considered the gold-standard treatment for OCD. The efficacy of CBT has been well established, with numerous studies demonstrating that it leads to significant and lasting reduction in OCD symptoms for the majority of completers.
223713192|NCT04914923|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-based interventions (MBIs) including MBCT, are interventions that incorporate formal and informal mindfulness practice in order to treat mental health concerns.
223713193|NCT06618027|BEHAVIORAL|BREATHE-T1D|BREATHE-T1D was adapted from Learning to BREATHE, a group mindfulness-based intervention for teens. It teaches mindfulness strategies adapted to be specific and relatable to, teens with T1D to improves symptoms of depression and anxiety as well as diabetes self-management.
223713194|NCT06618027|BEHAVIORAL|HealthEd-T1D|HealthEd-T1D is a 6 week, virtual, group based diabetes education group.
223713195|NCT00892853|PROCEDURE|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
223713196|NCT01533389|DRUG|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
223713197|NCT01533389|DRUG|Placebo|dosage form : capsule dosage : placebo 4mg\*2 (8mg) frequency and duration : QD, 4weeks
223713198|NCT01218113|BIOLOGICAL|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
223713199|NCT01218113|DRUG|Placebo|1 or 3 doses according to protocol schedule
223713200|NCT04840615|BIOLOGICAL|LMB-100|LMB-100 administered into lesion on days 1 and 4 during cycle 1.
223713201|NCT04840615|DRUG|ipilimumab|Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
223713202|NCT04840615|DRUG|Diphenhydramine|Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
223713203|NCT04840615|DRUG|Famotidine|Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
223713204|NCT04840615|DRUG|Acetaminophen|Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
223713205|NCT04840615|DRUG|Dexamethasone|Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
223713206|NCT04840615|PROCEDURE|Biopsy|As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
223713207|NCT04840615|DIAGNOSTIC_TEST|FDG-PET|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
223713208|NCT04840615|DIAGNOSTIC_TEST|CT CAP|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
223713209|NCT04840615|DIAGNOSTIC_TEST|MRI|At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
223713210|NCT04840615|DIAGNOSTIC_TEST|ECG|At screening, Cycle 1 Day 1, Cycles 2, 3, \& 4 Day 1 and Follow-Up Visit (4-6 weeks after end of treatment).
223713211|NCT04840615|DIAGNOSTIC_TEST|Echocardiogram|At screening.
223713212|NCT04353518|DRUG|Suspension of heat killed (autoclaved) Mycobacterium w|Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.
223713213|NCT04353518|OTHER|Placebo|Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
223713214|NCT00075010|DRUG|Decitabine|15 mg/m\^2 by vein over 1 hour times 10 days
224083336|NCT02789657|DRUG|AC|"doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles"
224083337|NCT00046787|DRUG|OSI-211 (Liposomal Lurtotecan)|
223713215|NCT00075010|DRUG|Valproic acid|20 mg/kg given orally daily for 10 days
223713216|NCT00967668|BEHAVIORAL|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
223713217|NCT00967668|BEHAVIORAL|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
223896144|NCT06381284|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
224083338|NCT04681404|PROCEDURE|Knee Arthroplasty|Comparison of TKA, UKA and healthy controls in relation to balance, function and QOL
224083339|NCT05647330|DRUG|Hydroxychloroquine Combined With Gemcitabine|Hydroxychloroquine combined with chemotherapy
224083340|NCT00424970|DRUG|acetazolamide|
223713218|NCT06109441|BIOLOGICAL|ALTB-268|ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.
223713219|NCT01793649|DRUG|GS-5737|A single dose of GS-5737 in 2.8% saline
223713220|NCT00115739|DRUG|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
223713221|NCT04108793|OTHER|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
223713222|NCT04234750|BIOLOGICAL|mesenchymal stem cell conditioned medium-derived pleiotropic factor|After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
223713223|NCT03982407|DRUG|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
223713224|NCT00951223|DRUG|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
223713225|NCT00313157|DRUG|Metoprolol|
223713226|NCT00313157|DRUG|Diltiazem|
223713227|NCT00313157|DRUG|Verapamil|
223713228|NCT00313157|DRUG|Carvedilol|
223713229|NCT01472302|DEVICE|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
223713230|NCT01472302|DEVICE|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
223713231|NCT01685281|DRUG|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
223713232|NCT01685281|DRUG|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
223713233|NCT02519036|DRUG|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
223713234|NCT02519036|DRUG|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
223713235|NCT02519036|DRUG|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
223713236|NCT02519036|DRUG|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
223713237|NCT02519036|DRUG|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
223713238|NCT02519036|OTHER|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
223713239|NCT03636932|DRUG|N-acetylcysteine (NAC)|Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
223713240|NCT03636932|DRUG|Placebo|Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
223713241|NCT03636932|BIOLOGICAL|Blood sample|Circulating tissue factor assay
223713242|NCT03636932|BIOLOGICAL|Blood sample|The test of pro-coagulant activity of the tissue factor
223713243|NCT04084665|DRUG|Guselkumab|Guselkumab
223713244|NCT05466162|OTHER|Soft tissue mobilization|"Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs"
223713245|NCT05466162|OTHER|Joint and nerve mobilization|"Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs."
223713246|NCT02073760|OTHER|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
223713247|NCT01539850|DEVICE|OMS102|Subjects will receive implanted OMS102 System.
223713248|NCT04177160|BEHAVIORAL|Music|Subjects sit still and listen to preferred music for 5 minutes.
223713249|NCT04177160|BEHAVIORAL|White noise|Subjects sit still and listen to white noise for 5 minutes.
223713250|NCT00787891|DRUG|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
223713251|NCT00787891|DRUG|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
223713252|NCT03210168|OTHER|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
223896145|NCT06381284|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
223713253|NCT06049940|BIOLOGICAL|Investigational tetanus vaccine, adsorbed|The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.
223713254|NCT06049940|BIOLOGICAL|Control tetanus vaccine, adsorbed|The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
223896146|NCT04002518|DEVICE|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
223896147|NCT05119491|DEVICE|uitrasonography and spirometry|chest uitrasonography and spirometry
223528354|NCT05215145|BEHAVIORAL|Baby Navigator Bundle|The Baby Navigator Bundle includes 1) Baby Navigator, an online collection of resources: videos, growth charts, milestones, short articles, checklists, tools, and tips to help families promote early learning. Tools are customized to the child's age (in months). Baby Navigator can be found at https://babynavigator.com. 2) Social Communication (SoCo) Growth Charts is a self-guided app for parents of babies from birth to 24 months. Parents can watch video clips of early milestones and chart their child's social communication development. 3) Baby Navigator Webinars are held twice a month. Parents can learn how to support their child's growth from birth to 24 months. Content and videos focus on social communication milestones. Expert-led sessions cover a range of topics: gestures and sounds babies need to learn to talk, everyday activities that encourage learning, getting ahead of the Terrible Twos, and how Baby Navigator can help families.
223528355|NCT05215145|BEHAVIORAL|Baby Navigator Bundle + Individual-ESI|Continued Baby Navigator Bundle. Addition of ESI mobile coaching. ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that session's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are also invited to and guided through the Autism Navigator How-To Guide for Families online course.
223528356|NCT05465304|DRUG|Azithromycin|The assessment of efficacy of azithromycin in preventing premature labour.The duration between administrating azithromycin as monotherapy and polytherapy and labour is calculated
223528357|NCT00925275|DRUG|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
223528358|NCT01893086|PROCEDURE|LH alone|LH, laparoscopic hysterectomy
223528359|NCT01893086|PROCEDURE|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
223528360|NCT04423432|OTHER|Lower Extremity Resistance Exercise Training|3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
223528361|NCT04423432|OTHER|Home Exercise Plan|"2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)"
223528362|NCT04423432|DEVICE|Electrotherapy + Heating|Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes
223528363|NCT04423432|PROCEDURE|Joint Mobilization|"1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization"
223528364|NCT04423432|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
223528365|NCT04423432|DIETARY_SUPPLEMENT|Glucoseamine/ Chondritin Sulfate Supplementation|Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
223528366|NCT01163942|DRUG|G-CSF|Yes/no addition of G-CSF
223528367|NCT01163942|DRUG|Early retreatment with ATG|Yes/no early retreatment with ATG
223528368|NCT00043602|BEHAVIORAL|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
223528369|NCT00043602|BEHAVIORAL|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
223528370|NCT01880463|DRUG|Omega-3 fatty acids (fish oil)|
223528371|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3|
223528372|NCT01880463|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
223528373|NCT01880463|DRUG|Fish oil placebo|
223528374|NCT02682056|DEVICE|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
223528375|NCT02682056|DEVICE|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
223528376|NCT02682056|DEVICE|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
223528377|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
223528378|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
223896148|NCT06577090|BIOLOGICAL|Nimacimab injection|Nimacimab injection 200 mg
223896149|NCT06577090|BIOLOGICAL|Nimacimab placebo injection|matching nimacimab placebo injection
223896150|NCT06577090|COMBINATION_PRODUCT|semaglutide injection|semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg
223896151|NCT05759156|DRUG|Tranexamic acid injection|The intervention consists of administration of 1gm of Tranexamic acid (TXA) intravenously or 10-mls of placebo (normal saline) intravenously, slowly over 30-60 sec, within 3 mins of the delivery of baby.
223896152|NCT06321809|BEHAVIORAL|intensive lifestyle|INTENSIVE LIFESTYLE INTERVENTIONS
223896153|NCT06529796|DRUG|IXP|Tablet for oral administration.
223896154|NCT02436096|DRUG|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
223528379|NCT00793520|DRUG|Placebo|Twice daily oral administration of placebo for 5 weeks.
223528380|NCT00793520|DRUG|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
223528381|NCT04548908|DIAGNOSTIC_TEST|Serelogy testing, RT PCR|Serology testing for all the participants and RT PCR for participants with symptoms
223528382|NCT06253650|DRUG|Experimental|6 cycles of: T-DXd at the dose of 6.4 mg/kg intravenous every 3 weeks plus capecitabine 1000 mg/sqm BID orally on days 1-14 every 3 weeks or 5-fluorouracil 600 mg/m2/day continuous intravenous infusion on days 1-5 every 3 weeks as per Investigator's choice
223528383|NCT06253650|DRUG|Control|4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
223528384|NCT01212900|DRUG|Statins, HMG CoA|Statin therapy
223896155|NCT02436096|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks.
223528385|NCT01090596|DRUG|Naproxen|500mg naproxen, twice daily for 7 days
223528386|NCT01090596|DRUG|Placebo|1 tab,twice a day for a seven days
223528387|NCT02260037|DRUG|Epinastine nasal|
223528388|NCT02260037|DRUG|Placebo|
223528389|NCT04120467|OTHER|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
223528390|NCT04120467|OTHER|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
223528391|NCT01168596|DRUG|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
223528392|NCT01168596|DRUG|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
223528393|NCT00649584|DRUG|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
223528394|NCT00649584|DRUG|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
223528395|NCT06529432|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
223528396|NCT06529432|DRUG|Bupivacaine Hydrochloride Injection|Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
223528397|NCT05157360|DRUG|HAT|hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
223528398|NCT05157360|DRUG|Placebo|normal saline solution
223528399|NCT00794430|DRUG|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
223528400|NCT00794430|DRUG|Placebo|Capsule, bid, for 13 weeks
223528401|NCT00004200|DRUG|prinomastat|
223528402|NCT00004200|DRUG|temozolomide|
223528403|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
223528404|NCT00876447|BIOLOGICAL|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.
223528405|NCT00123630|DRUG|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
223528406|NCT00123630|DRUG|Placebo|Placebo given IV once every 2-4 weeks based on weight
223528407|NCT00318682|DEVICE|FIBROSCAN|diagnostic examination of the hepato fibrosis
223528408|NCT01900366|PROCEDURE|Fat Biopsy|Fat biopsy
223528409|NCT01175122|BIOLOGICAL|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
223528410|NCT01098747|DRUG|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
223528411|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
223528412|NCT01098747|DRUG|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
223528413|NCT01098747|DRUG|Placebo|Single-dose of placebo
223528414|NCT06469983|DEVICE|ErigoBasic or ErigoPro®|Static bed with integrated robotic stepper (ErigoBasic) and optionally integrated with Functional Electrical Stimulation (FES ErigoPro®). The Erigo is a robot designed to be used for early functional mobilisation of patients with neurological manifestations or who are bedridden, even in intensive care. It is a tilt table equipped with an integrated passive stepper controlled by microprocessors that generate physiological leg movements: the patient's thighs are secured by straps to the movement mechanisms and the feet are secured to plates equipped with shock absorbers, while the upper body is held in place by a sling integrated into the table. Erigo provides active functions: gradual elevation in orthostatism up to 90°, controlled and independent mobilisation of the lower limbs, and functional stimulation.
223528415|NCT06469983|BEHAVIORAL|Traditional Verticalization|gradual verticalization (from supine position up to maximum 90°, in 3 steps), depending on the patient's vital signs compliance, using a traditional standing device (i.e., non-robotic traditional tilt table)
223528416|NCT01876498|PROCEDURE|Xiaflex surgery|Xiaflex surgery
223528417|NCT02684968|PROCEDURE|Colorectal surgery|
223528418|NCT00158678|PROCEDURE|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
223528419|NCT00158678|PROCEDURE|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
223528420|NCT00158678|DRUG|concomitant cisplatin|100 mg/m2 D1, D22, D43
223528421|NCT02692196|DEVICE|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
223528422|NCT05775445|PROCEDURE|Blood draw|2 6ml blood tubes will be collected from patient
223528423|NCT02665910|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
223528424|NCT02665910|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
223528425|NCT02408744|DRUG|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
223528426|NCT04868292|DRUG|SPR206|Three 100 mg SPR206 intravenous doses administered every 8 hours
223528427|NCT04983784|BEHAVIORAL|walking|walking for 12 weeks at home
223528428|NCT04983784|OTHER|Routine care|Routine care
223528429|NCT00189423|DEVICE|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
223528430|NCT00189423|PROCEDURE|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
223528431|NCT05685784|DEVICE|Bytelfies kit - sensor dot|"Participants will be asked to undergo a standard of care gait analysis and PSG whilst simultaneously wearing sensor dots.~GAIT: sensor dots will be placed in the neck, on the chest and one on both ankles.~PSG: sensor dots will be placed on the forehead, chin, chest, abdomen, both legs(tibialis anterior) and an SpO2 device will be placed on the finger middle finger of the non-dominant hand"
223528432|NCT02004158|BEHAVIORAL|Positive psychology intervention|
223528433|NCT04622592|BIOLOGICAL|Instramuscular vaccine|On Day 0, a single injection of the assigned dose of the vaccine into the deltoid region of the arm
223528434|NCT01502384|OTHER|neurological examination|motor and cognitive functions
223528435|NCT02996396|DEVICE|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
223528436|NCT03388372|BIOLOGICAL|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
223528437|NCT03388372|DRUG|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
223528438|NCT03388372|RADIATION|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
223528439|NCT05026164|DIETARY_SUPPLEMENT|CHI-202|Blend of cannabinoids \& other ingredients
223528440|NCT05026164|DIETARY_SUPPLEMENT|CHI-101|Placebo
223528441|NCT00641693|DRUG|Budesonide|16mg Nasal Spray
223528442|NCT00641693|DRUG|Budesonide|32mg Nasal Spray
223528443|NCT00641693|DRUG|Budesonide|64mg Nasal Spray
223528444|NCT00641693|DRUG|Placebo|
223528445|NCT03901430|BEHAVIORAL|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
223528446|NCT05125003|BEHAVIORAL|FITBI|parents learn to identify high probability cues in the environment that can elicit RRBI symptoms and teach their child to inhibit repetitive behaviors and instead replace them with alternative and flexible play behaviors; and (b) teach parents how to embed this FITBI approach into their child's everyday routines
223528447|NCT05125003|BEHAVIORAL|Parental Education|Sessions will cover relevant information on young children with ASD, including understanding the ASD diagnosis, developmental changes in ASD, educational planning, advocacy, and treatment options.
223528448|NCT05542888|PROCEDURE|Sacroiliac joint mobilization|Sacroiliac joint mobilization will be performed with the patient in side lying position in which grade I,II pain relief mobilization will be given in PA direction.It will be given as 1 set of 30 oscillations per session, 3 times per week for 4 weeks.
223528449|NCT05542888|PROCEDURE|Standard therapy|Postural education, Hot pack, Antenatal exercises
223528450|NCT02798887|PROCEDURE|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
223528451|NCT05178186|PROCEDURE|Thyroidectomy|Surgery for thyroid carcinoma
223528452|NCT06173089|DEVICE|Remote monitoring|Remote monitoring for patients with an ICD/CRT device
223528453|NCT00003249|DRUG|carboxyamidotriazole|
223528454|NCT00003249|DRUG|chemotherapy|
223528455|NCT00003249|DRUG|ketoconazole|
223528456|NCT01518413|DRUG|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
223528457|NCT01518413|DRUG|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
223528458|NCT05552404|OTHER|conservative therapy|bed rest, fluids, abdominal binder, oral paracetamol, and caffeine
223528459|NCT05552404|DRUG|Aminophylline|conservative therapy plus Aminophylline (250mg of Aminophylline dissolved in 100ml normal saline for intravenous infusion over 30 minutes)
223528460|NCT05552404|PROCEDURE|trans nasal sphenopalatine ganglion block|conservative therapy plus sphenopalatine ganglion block SPGB using hollow cotton swab and lidocaine 2%
223896156|NCT06185101|BEHAVIORAL|STEP-UP|The STEP-UP chronic pain self-management intervention (Support, Training, and Education for Pain Self-Management - Using Podcasts) will feature an educational podcast series teaching core pain self-management skills. Podcasts will be supplemented by sessions with a Community Health Worker taking place at designated times over a 7-week period. The Community Health Worker will guide participants in a modified Patient Priorities of Care (PPC) approach to help them identify their values and priorities and develop goals that reflect these.
223896157|NCT05211635|DIETARY_SUPPLEMENT|Vitamin D|One capsule daily for 84 days
223896158|NCT05211635|OTHER|Placebo|One capsule daily for 84 days
223896159|NCT05339451|DIAGNOSTIC_TEST|Blood biomarkers|Blood biomarkers in plasma and serum.
223896160|NCT06311565|BEHAVIORAL|Education|Individuals in this group will be trained on acquiring healthy lifestyle behaviors to protect against colorectal cancer. Training will be individual, face-to-face and in the form of question and answer. At the end of the training, training brochures prepared by the researchers after taking expert opinions will be distributed to the participants. The training will take approximately 25-30 minutes. The training will take place in the training hall at the family health center.
223896161|NCT06224530|DRUG|Levetiracetam|Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
223896162|NCT06224530|DRUG|Placebo|Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
223896163|NCT05145309|DRUG|KMgCit|Supplement that provide K, Mg, and citrate
223896164|NCT05145309|DRUG|Placebo|Power with identical appearance to KMgCit
223896165|NCT01824394|DEVICE|nMARQ Navigation Catheters|
223896166|NCT01824394|DEVICE|NaviStar ThermoCool Catheters|
223896167|NCT06639503|DRUG|Bupivacain|5mL 0.25% bupivacain
223896168|NCT04722848|DRUG|Ponatinib + Blinatumomab|"Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation"
224276508|NCT02378909|DEVICE|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
224276509|NCT02926755|PROCEDURE|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
223528461|NCT01871376|DRUG|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
223528462|NCT03028701|DRUG|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
223528463|NCT01681147|BEHAVIORAL|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
223896169|NCT04722848|DRUG|Chemotherapy + Imatinib|patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
223896170|NCT03787693|BEHAVIORAL|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
223896171|NCT00179829|PROCEDURE|WT 1 Testing|
223896172|NCT06807788|DRUG|Clopidogrel|Clopidogrel 75 mg once a day for 14 days.
223896173|NCT05378893|DRUG|DR10624 for injection|administered via subcutaneous injection
223896174|NCT05378893|DRUG|Placebo|administered via subcutaneous injection
223896175|NCT06014593|DEVICE|expirogram|Recovery of heart failure data (left ventricular ejection fraction LVEF on cardiac echography (in mL), VO²max during, maximal cardio-pulmonary exercise test, plethysmographic spirometry, carbon monoxide transfer, NT-ProBNP assay,), clinical examination and finally expirogram with the device measuring the 4 exhaled biomarkers (CO/NO/Acetone/Isoprene).
223896176|NCT06300528|DRUG|Pemigatinib|Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
223896177|NCT04750200|PROCEDURE|Embolization of the Middle Meningeal Artery|EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
223896178|NCT05757778|PROCEDURE|Sensory Nerve Coaptation|Nerve reconstruction will employ an off-the-shelf nerve graft coapted to the donor anterior intercostal nerve branch laterally and medially at the underside of the nipple. The anterior intercostal nerve branch and nerve graft coaptation will be performed in a standard fashion with a 1 mm gap between the ends of the graft and the donor nerve. Medially, the nerve graft will be inset into the underside of the preserved nipple-areola complex using 8-0 or 9-0 epineural stitches from the nerve allograft. All nerve coaptations will be performed under loupe magnification as is standardly performed.
224083341|NCT03228563|OTHER|Probioics|CKD Patients were supplemented with two capsules of probiotics containing 2.5\*10\^9 CFU Lactobacillus acidophilus (TYCA06), Bifidobacterium longum (BLI-02) and Bifidobacterium bifidum (VDD088) twice daily for 12 months.
223713255|NCT01258582|PROCEDURE|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
223713256|NCT01258582|PROCEDURE|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
223713257|NCT03216889|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
223713258|NCT03216889|BEHAVIORAL|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
223713259|NCT03468153|BIOLOGICAL|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
223713260|NCT02076698|PROCEDURE|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
223713261|NCT02076698|DRUG|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
223713262|NCT00911118|RADIATION|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
223713263|NCT03303924|DRUG|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
223713264|NCT06327347|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
223713265|NCT04635943|DRUG|Ivermectin|One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).
223713266|NCT04635943|DRUG|Placebo|The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
223713267|NCT03630627|DRUG|SB26|SB26 administered intravenously
223713268|NCT03630627|DRUG|Placebo|Placebo administered intravenously
223713269|NCT05163444|DEVICE|Gait analysis with rolling cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
223713270|NCT05163444|DEVICE|Gait analysis with quadripod cane|6 minutes walking test 10 meters walking test Before this experimentation, we will fix wearables sensors on the shoes.
223713271|NCT01523860|DRUG|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
223713272|NCT04044612|OTHER|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
223713273|NCT05149196|OTHER|Targeted hemodynamic management|"During anesthesia, hemodynamic managements include active hydration (\>10 ml/kg/h), use of inotropes (dobutamine), and forced diuresis; the targets are to maintain pulse pressure variation \<9%, mean arterial pressure ≥85 mmHg, and urine output \>200 ml/h (3ml/kg/h).~During the first 48 hours after surgery, systolic blood pressure is maintained ≥110 mmHg or within 20% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or vasoactive infusion."
223713274|NCT05149196|OTHER|Routine care|"During anesthesia, hemodynamic managements are conducted according to routine practice and usually include fluid infusion at a rate of 6-8 ml/kg/h without inotropics; the targets are to maintain mean arterial pressure ≥60 mmHg and urine output \>0.5 ml/kg/h.~During the first 48 hours after surgery, hemodynamic management is performed according to routine practice."
223713275|NCT01821521|DRUG|AGSPT_L20|
223713276|NCT01821521|DRUG|Pantoloc 40mg|
223713277|NCT00000883|DRUG|Azithromycin|
223713278|NCT01793896|BEHAVIORAL|Control period|Analysis at recruitment and after a month without any intervention
223713279|NCT01793896|BEHAVIORAL|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
223713280|NCT01793896|BEHAVIORAL|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
223713281|NCT01793896|BEHAVIORAL|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
223713282|NCT02498184|OTHER|acupuncture|
223713283|NCT02957305|DRUG|Misoprostol 400mcg Tab|400µg of misoprostol (2 tablets)
223713284|NCT02957305|DRUG|Misoprostol 200mcg Tab|200µg of misoprostol (1 tablet)
223713285|NCT05157984|PROCEDURE|ZPOEM|Zenker's diverticulum management by Per oral endoscopic myotomy (POEM)
223713286|NCT05120128|DEVICE|Acuvue® Oasys 1-Day|TEST Lens
223713287|NCT00870441|DRUG|ASP2151|Oral
223713288|NCT00870441|DRUG|Valacyclovir|Oral
223713289|NCT00870441|DRUG|Placebo|Oral
223713290|NCT00684099|DRUG|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
223713291|NCT00684099|DRUG|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
224083342|NCT05152940|DRUG|Ertugliflozin|Treatment with Ertugliflozin 5 mg oral once per day for one month
223713292|NCT00395304|DRUG|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
223713293|NCT00395304|DRUG|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
223713294|NCT00395304|DRUG|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
223713295|NCT01723488|RADIATION|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
223713296|NCT02938104|DIETARY_SUPPLEMENT|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
223713297|NCT02938104|BEHAVIORAL|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
223713298|NCT02938104|BEHAVIORAL|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
223713299|NCT06011057|DIAGNOSTIC_TEST|Serum C reactive protein (CRP) level|An immunoturbidimetric method using a Modular P Analyzer will be used to carry out HSCRP assay, with a quantitation limit of 0.5 mg/L.
223713300|NCT06011057|DIAGNOSTIC_TEST|Ultrasound|All examinations will be carried out by an experience operator with a transvaginal probe on high-resolution ultrasound machines. Pregnancies will be dated from the LMP. Other measurements will be obtained during the scan as the mean gestation sac diameter, volume of the gestation sac and the embryonic heart rate (FHR).
223713301|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
223713302|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
223713303|NCT01234285|DRUG|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
223713304|NCT01234285|DRUG|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
223713305|NCT01970397|DEVICE|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
223713306|NCT01970397|DEVICE|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
223713307|NCT05542160|DIETARY_SUPPLEMENT|Pumpkin seed extract (IRK-19)|Placebo: Dietary fiber powder, two capsules/day (600 mg/day), continued use for 3 months Treatment: Pumpkin seed extract powder, two capsules/day (600 mg/day), continued use for 3 months
223713308|NCT00952978|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
223713309|NCT00952978|DRUG|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
223713310|NCT02695901|DRUG|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
223713311|NCT02695901|DRUG|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
223713312|NCT00681083|DEVICE|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
223713313|NCT00681083|DEVICE|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
223713314|NCT01524471|PROCEDURE|Per Oral Endoscopic Myotomy|
223713315|NCT03414060|DEVICE|Menstrual Cup|
223713316|NCT04433377|PROCEDURE|Suprascapular nerve block|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg / mL + 2.63 mg / mL; 1 mL), 0.5 % bupivacaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 22 gauge 90-mm injector
223713317|NCT04433377|PROCEDURE|Subacromial injection|A betamethasone dipropionate plus betamethasone sodium phosphate solution (6.43 mg/mL + 2.63 mg/mL; 1 mL), 2% lidocaine (2 mL) and physiological serum (2 mL) are injected with an in-plane technique using a 21 gauge 38-mm injector.
223713318|NCT03305575|DRUG|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
223896179|NCT05003180|PROCEDURE|Surgical stabilization|The surgical stabilization can be either open or minimally invasive. The recommended procedure is posterior fixation with pedicle screws and rods. Both short and long segment fixation are allowed in the study. It is up to the treating surgeon to decide on fusion or decompression. If feasible, pedicle screws are inserted in the fractured vertebra.
224083343|NCT05152940|DRUG|Placebo|Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
223713319|NCT03305575|DRUG|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
223713320|NCT00903396|DRUG|palonosetron hydrochloride|Given IV
223713321|NCT00903396|OTHER|placebo|Given IV
223713322|NCT02034201|DRUG|Lisdexamfetamine|
223713323|NCT02034201|DRUG|Placebo|
223713324|NCT05956496|OTHER|Allograft Material ADM-S|A piece of the allograft material (ADM-D) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
223713325|NCT05956496|OTHER|Allograft Material ADM-D|A piece of the allograft material (ADM-S) will be hydrated per the manufacturers guidelines and adapted to the recipient area after reflection of a partial thickness flap. The flap will be coronally advanced to completely cover the graft material per standard care for this procedure.
223713326|NCT00315172|PROCEDURE|Non-Exercise Activity Thermogenesis (NEAT)|
223713327|NCT02705469|DRUG|ZEN003694|
223713328|NCT02577978|DEVICE|Medacta GMK posterior stabilized prosthesis|
223713329|NCT02577978|DEVICE|Medacta GMK Sphere prosthesis|
223713330|NCT03794297|DRUG|Dabrafenib Mesylate|Given PO
223713331|NCT03794297|OTHER|Quality-of-Life Assessment|Ancillary studies
223713332|NCT03794297|OTHER|Questionnaire Administration|Ancillary studies
223713333|NCT03794297|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223713334|NCT00441714|PROCEDURE|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
223713335|NCT01335191|BIOLOGICAL|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
223713336|NCT01335191|OTHER|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
223713337|NCT03340688|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
223713338|NCT04660877|DIETARY_SUPPLEMENT|Cheddar Cheese|20g of protein from cheddar cheese
223713339|NCT04660877|DIETARY_SUPPLEMENT|Milk|20g of protein from milk
223713340|NCT06506656|DEVICE|Hyadrol®|Sterile single-use Medical Device for intra-articular injections
223713341|NCT04269447|DIAGNOSTIC_TEST|Structured imaging follow-up|Structured imaging follow-up protocol with ultrasound (US) and computed tomography (CT) examinations as compared to current standard surveillance protocol for individualized estimations of AAA growth.
223713342|NCT01023620|DRUG|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
223713343|NCT01023620|OTHER|Observation|Participants will be observed for 16 weeks but will not receive drug
223713344|NCT05812196|DIAGNOSTIC_TEST|Lung function test|Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.
223713345|NCT05812196|BIOLOGICAL|COVID infection|Verified COVID-19 infection.
223713346|NCT01572558|PROCEDURE|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
223713347|NCT01572558|DRUG|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
223713348|NCT04188847|DRUG|Chemotherapy plus apatinib|"A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6."
223713349|NCT06364098|DRUG|Misoprostol|400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
223713350|NCT00232609|DEVICE|GameCycle Exercise System|
223713351|NCT05279183|DIETARY_SUPPLEMENT|Erythritol|Subject specific dose of erythritol dissolved in 300 mL tap water.
223713352|NCT05279183|DIETARY_SUPPLEMENT|Sucrose|30 g sucrose dissolved in 300 mL tap water.
223713353|NCT05279183|DIETARY_SUPPLEMENT|Sucralose|Subject specific dose of sucralose dissolved in 300 mL tap water.
223713354|NCT00933972|DRUG|RO4998452|20mg po single dose
223713355|NCT00838396|DRUG|XP19986 CR|
223713356|NCT00838396|DRUG|Placebo for XP19986 CR|
223713357|NCT01434667|BEHAVIORAL|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
223713358|NCT01434667|BEHAVIORAL|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
223713359|NCT06374901|DRUG|Tislelizumab|Preoperative treatment with Tislelizumab
223713360|NCT06374901|DRUG|SOX/XELOX|Preoperative treatment with SOX/XELOX
223713361|NCT02417831|DRUG|tamsulosin capsules|
223713362|NCT02417831|DRUG|tamsulosin HCl|
223713363|NCT02647203|DRUG|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
223713364|NCT04922775|PROCEDURE|conventional taping|Participants will accept conventional taping before muscle fatigue exercise.
223713365|NCT04922775|PROCEDURE|Chinese medicine technique taping|Participants will accept Chinese medicine technique taping before muscle fatigue exercise.
223713366|NCT05166824|DEVICE|TempSure|Radiofrequency platform
223713367|NCT05166824|DEVICE|Scalpel|Cold knife
223713368|NCT05166824|DEVICE|Bovie|Electrosurgery and electrocautery platform
223713369|NCT05166824|DEVICE|Pelleve|Radiofrequency platform
223713370|NCT02034110|DRUG|Dabrafenib|A 150 mg twice daily capsule administered orally on a continuous basis.
223896180|NCT06766487|BEHAVIORAL|Tongue resistance exercises|"The TRE program consisted of the following exercises:~Exercise 1: Tongue Protrusion and Retraction Against Resistance, Exercise 2: Anterior Tongue Protrusion and Retraction Against Resistance, Exercise 3: Middle Tongue Protrusion and Retraction Against Resistance, Exercise 4: Middle Tongue Elevation with Pharyngeal Sound Production, Exercise 5: Tongue Elevation and Posterior Sweeping, and Exercise 6: Saliva Swallowing with Lip Closure."
223896181|NCT06766487|BEHAVIORAL|cheek bulging exercises|Cheek bulging exercises involved a series of movements: Lip Closure: Participants began by closing their lips. Unilateral Cheek Bulging: They then bulged their right cheek, followed by relaxation and return to the initial position. This was repeated on the left side. Bilateral Cheek Bulging: Finally, participants bulged both cheeks simultaneously.
223896182|NCT05780437|BIOLOGICAL|AZD7442|AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
223896183|NCT05780437|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
223896184|NCT05780437|BIOLOGICAL|Remdesivir|Antiviral agent
223896185|NCT06584812|DRUG|Tiprogrel|Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
223896186|NCT06584812|DRUG|Tiprogrel|Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.
223896187|NCT06584812|DRUG|Clopidogrel|Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.
223896188|NCT06584812|DRUG|Ticagrelor|Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.
223896189|NCT03198702|DRUG|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
223896190|NCT03198702|OTHER|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
223896191|NCT03452579|DRUG|Nivolumab|240mg
223896192|NCT03452579|DRUG|Standard Dose Bevacizumab|10mg/kg
223896193|NCT03452579|DRUG|Low Dose Bevacizumab|3mg/kg
223896194|NCT04891224|OTHER|Pathway Platform mobile app|The pathway platform intervention involves 3 components: 1. The patient facing app which will: a) Gather health information related to depression management and patient-Provider engagement. b) Clinical data collection; PHQ-9, WHO-5, PDQ-D-5, medication adherence and side effects, goal setting and goal tracking. c) Research data; Patient Activation Measure -13\[PAM-13\], CollaboRATE, and Work and Social Adjustment Scale \[WSAS\]. 2. Electronic Medical Record Integration - a) Data collected in the app is accessible to care team in real time. b) Provide a longitudinal summary to assist in decision making and depression management. 3. Educational Scaffolding - a) Training program describing how the Pathway Platform can support care team members in clinical processes related to measurement-based care and shared-decision making. b) Includes ongoing feedback with up to three audit cycles.
223896195|NCT04832282|DEVICE|Napoleon|The Micro-Tech Endoscopic Measurement Device named Napoleon is a small catheter with a 30mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA. The device was originally intended to measure polyps. However, it is used off-label in this study and is considered investigational.
223896196|NCT04832282|OTHER|Visual estimation|For each case, endoscopists will first visually estimate the diameter of the GJA by comparing its size to the upper endoscope.
223896197|NCT02658565|PROCEDURE|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
223896198|NCT06772480|DRUG|Thalidomide|Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months
223896199|NCT06772480|PROCEDURE|Argon Plasma Coagulation|Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.
223896200|NCT05870527|DEVICE|Electrical stimulator|Electrical stimulation will be used to stimulate the Arnold's nerve and measure pupil dilation. The electrical stimulator is part of the standard facial nerve monitoring unit that we utilize in cochlear implantation and will be setup prior to surgery in standard fashion. The device allows for constant current stimulation, with stimulus range between 0-30 mA.
223896201|NCT06360757|DIAGNOSTIC_TEST|NeuMoDx SARS-CoV-2 Assay|The NeuMoDx™ SARS-CoV-2 Assay is an automated, in vitro nucleic acid amplification test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal (NP) swabs in transport medium obtained from symptomatic individuals suspected of COVID-19 infection. The NeuMoDx SARS-CoV-2 Assay as performed on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System incorporates automated RNA extraction to isolate target nucleic acids from the specimen and real-time reverse transcription PCR targeting two conserved regions of the SARS-CoV-2 genome.
223896202|NCT04542161|DRUG|NAC 900mg/day|self administer NAC 900mg/day caplets for a four week period
223896203|NCT04542161|DRUG|NAC 3600mg/day|self administer NAC 3600mg/day caplets for a four week period
223896204|NCT04542161|DRUG|NAC 0mg/day (Placebo)|self administer NAC 0mg/day (placebo) caplets for a four week period
223896205|NCT05868902|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
223939954|NCT07186647|PROCEDURE|laparoscopic-assisted Swenson-like (LASwL)|Following port placement, laparoscopic exploration was performed to evaluate the spastic colonic segment and transitional zone. An aperture was created in the sigmoid mesentery, and the sigmoid colon was mobilized. The proximal ganglionic bowel was mobilized while preserving the marginal arcades. The peritoneal reflection was sharply incised to facilitate dissection and mobilization of the aganglionic rectum. The procedure diverged between the two groups at this juncture: LASwl group: The rectum below the peritoneal reflection was dissected circumferentially up to a level 2 cm above the anal verge . LASo group: The rectum below the peritoneal reflection was minimally mobilized (within 1 cm of the peritoneal reflection). Following laparoscopic dissection, the ports were left in situ, and the position was adjusted for transanal dissection of the remaining rectum.
223896206|NCT06697717|OTHER|Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients, utilizes real-time transpulmonary pressure measurements (alveolar pressure minus pleural pressure, estimated via esophageal manometry) to individualize PEEP settings. This approach accounts for the impact of intra-abdominal hypertension (IAH) on pleural pressure and lung compliance, ensuring precise alveolar recruitment while minimizing overdistension and ventilation-induced lung injury (VILI). PEEP is titrated to maintain a positive end-expiratory transpulmonary pressure (e.g., \>0 cmH₂O) and optimal driving pressures, dynamically adjusted based on intra-abdominal pressure and lung mechanics. This method integrates advanced esophageal pressure monitoring with traditional parameters such as plateau pressure, compliance, and PaO₂/FiO₂ to guide clinical decisions. By addressing the pathophysiological interplay between thoracic and abdominal compartments, the intervention aims to enhance oxygen."
223896207|NCT06697717|OTHER|EIT-Guided PEEP Titration in IAH and ARDS Patients|"The intervention, EIT-Guided PEEP Titration in IAH and ARDS Patients, utilizes electrical impedance tomography (EIT) to optimize PEEP settings based on real-time, regional lung ventilation and perfusion distribution. This approach differs from conventional methods that rely on global oxygenation or compliance indices by providing dynamic, bedside imaging of lung mechanics and aeration patterns. In patients with intra-abdominal hypertension (IAH) and ARDS, EIT identifies areas of alveolar overdistension and collapse, allowing precise PEEP titration to achieve optimal lung recruitment while minimizing ventilation-induced lung injury (VILI). The intervention dynamically adjusts PEEP levels to balance regional ventilation, enhance oxygenation, and mitigate the effects of IAH on thoracic mechanics. By integrating advanced imaging technology with traditional ventilatory parameters, this method offers a personalized strategy to improve respiratory mechanics and clinical outcomes."
224276510|NCT03794245|BEHAVIORAL|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
224276511|NCT03794245|BEHAVIORAL|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
223713371|NCT02034110|DRUG|Trametinib|A 2 mg once daily tablet administered orally on a continuous basis.
223713372|NCT04077827|DRUG|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
223713373|NCT01842074|DRUG|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
223713374|NCT04758169|OTHER|Enhanced Homestead Food Production|Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.
223713375|NCT04758169|OTHER|Control|Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
223713376|NCT05382624|PROCEDURE|Abdominal circumference was measured at the umbilical level in the standing position at the end of a normal expiration.|The operation time (the time from the beginning of the surgical incision until the end of surgery), anesthetic complications, such as nausea or vomiting, the number of patients requiring ephedrine and atropine, the total amount of intravenous fluid used, and the total amount of ephedrine used during surgery were recorded.
223713377|NCT00813306|DRUG|AZD2066|13 mg oral solution, 1 single dose
223713378|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
223713379|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
223713380|NCT00813306|DRUG|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
223713381|NCT00813306|DRUG|Placebo|Oral solution, 1 single dose
223713382|NCT04036344|BEHAVIORAL|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
223713383|NCT00523016|PROCEDURE|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
223713384|NCT00523016|PROCEDURE|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
223713385|NCT01367210|DRUG|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
223713386|NCT01367210|DRUG|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
223713387|NCT00030810|RADIATION|Hyperfractionated|Hyperfractionated radiotherapy
223713388|NCT00030810|DRUG|Taxotere/Cisplatin|Taxotere/Cisplatin
223713389|NCT00030810|PROCEDURE|conventional surgery|conventional surgery
223713390|NCT03729089|OTHER|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
223713391|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|Patients will be injected, intrathecally, with 2 mCi 131I-Omburtamab during week 1 of a 5 week cycle.
223713392|NCT00089245|DRUG|Iodine I 131 MOAB 8H9|The dose used in this study is 50 mCi 131IOmburtamab, (averaging 5 mCi/mg Omburtamab at 50 mCi dose) which will be administered to each patient during week 2 of a 5 week cycle.
224276512|NCT03794245|BEHAVIORAL|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
224276513|NCT03794245|BEHAVIORAL|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
223896208|NCT05221671|OTHER|information leaflet|Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
223713393|NCT03180723|DRUG|Rituximab|Intravenous injection
223713394|NCT03180723|DRUG|Cyclosporin|Oral tablets
223713395|NCT03780855|DEVICE|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
223713396|NCT01803204|OTHER|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
223713397|NCT03779802|OTHER|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
223713398|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils|4 months consumption
223713399|NCT01611649|DIETARY_SUPPLEMENT|Formula containing plant oils|4 months consumption
223713400|NCT01611649|DIETARY_SUPPLEMENT|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
223713401|NCT02131194|DIETARY_SUPPLEMENT|Lenstatin|Dietary Supplement Lenstatin
223713402|NCT02131194|DRUG|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
223713403|NCT04314336|DRUG|Public procurement|Cost minimisation study through public procurement
223713404|NCT04314336|DRUG|Drug and Therapeutics Committee|Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
223713405|NCT02835820|DIETARY_SUPPLEMENT|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
223713406|NCT02272491|DEVICE|ZrO2 (Straumann CARES)|"1. Straumann CARES Variobase Abutment RN~2. Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
223713407|NCT02272491|DEVICE|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
223713408|NCT03554746|OTHER|GC group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation"
223713409|NCT03554746|OTHER|CG group|"1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps"
223713410|NCT02102906|PROCEDURE|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
223713411|NCT05066113|DEVICE|Radiofrequency-Based treatment|"RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits."
223713412|NCT04957901|DRUG|Pediatric lymphoma protocol|The tumor tissue (FFPE) and plasma samples (bone marrow or cerebrospinal fluid samples if necessary) from the newly diagnosed patients were collected and sequenced by 475 genes panel before, during and post treatment.
223713413|NCT04079101|DRUG|BIIB104|Administered as specified in the treatment arm.
223713414|NCT04079101|DRUG|Placebo|Administered as specified in the treatment arm.
223713415|NCT06502496|BEHAVIORAL|art-therapy|Over the 6 sessions, different artistic techniques will be explored, depending on the artist leading the workshop: stencil, graffiti, spray paint, collage, oil pastel, calligraphy and acrylic doodling. A collective work may also be proposed.
223713416|NCT06502496|BEHAVIORAL|relaxation|relaxation sessions with the referent psychologist
223713417|NCT02478996|OTHER|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
223713418|NCT04261777|DRUG|Ferrotran® (Ferumoxtran-10)|"Ferrotran® in a dose of 0.13 mL/kg body weight of the reconstituted freeze-dried preparation (i.e. 2.6 mgFe/kg body weight). The recommended dose should be diluted in 100 mL of NaCl 9 mg/mL (0.9%) solution for injection/infusion prior to administration via the infusion filter as a slow intravenous infusion over 30 minutes (at a maximum rate of 4 mL/min).~Ferrotran® will be administered once to each patient. Histologically confirmed diagnosis and pre-operative staging are performed prior to the study as part of standard care. Surgery (RP with ePLND) and sampling of tissue specimens is performed after the Ferrotran®-enhanced MRI as part of standard care."
223713419|NCT02367183|DRUG|GED-0301|
223713420|NCT02367183|DRUG|Placebo|
223528464|NCT01681147|BEHAVIORAL|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
223528465|NCT00183248|DRUG|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
223713421|NCT06145061|DEVICE|all patients and healthy people will receive at least 3 infrared thermal imaging examinations of acupoints and pain threshold examinations of acupoints.|Infrared thermal imaging detection scheme of acupoints:Detection equipment NEC R550 infrared thermal imager.Records the corresponding acupoints coordinates,and starts to collect the infrared thermal image.and 6 images will be taken continuously for each detected part.The infrared thermograms were stored and extract the temperature values of the corresponding coordinates of the acupoints.The average temperature values of the acupoints in the six infrared thermograms were calculated as their temperatures.Pain threshold detection scheme of acupoints:The instrument and equipment use the FDX25 hand-held pain threshold test instrument to explore the acupoints.Place the probe of the pain measuring instrument vertically on the pain measuring acupoint, slowly and steadily press downward at a constant speed, and stop pressing immediately when the subject begins to feel pain. At this point, the reading on the display is the subject's pain threshold. All acupoints shall be measured once in total.
223713422|NCT00286403|DRUG|Fenoldopam Mesylate and/or MESNA|
223713423|NCT00332007|DRUG|Tonabersat|two tablets once daily
223713424|NCT00332007|DRUG|Placebo|two tablets once daily
223713425|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
223713426|NCT01620671|PROCEDURE|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
223713427|NCT04568070|DIAGNOSTIC_TEST|mini-BESTest (Mini-Balance Evaluation Systems Test)|Balance evaluation test that has 14 tasks leading to a total possible score of 28 points requires only 10 to 15 minutes to conduct.
223713428|NCT04568070|DIAGNOSTIC_TEST|Berg Balance Scale|The scale is a 14-item objective measure designed to assess static balance and fall risk in adult populations.
223713429|NCT04568070|DIAGNOSTIC_TEST|Timed Up and Go Test|It is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
223713430|NCT04568070|DIAGNOSTIC_TEST|Functional Reach Test|The Functional Reach Test is a single item test developed as a quick screen for balance problems in older adults. A score of 6 or less indicates a significant increased risk for falls. A score between 6-10 inches indicates a moderate risk for falls.
223713431|NCT01876797|DRUG|ticagrelor/prasugrel|
223713432|NCT02268344|DEVICE|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
223713433|NCT04979468|DRUG|DOVATO|Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
223713434|NCT01867424|DRUG|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
223713435|NCT01056653|BEHAVIORAL|Standard Dose|Two intevention home visits
223713436|NCT01056653|BEHAVIORAL|High Dose|Four intervention home visits
223713437|NCT01056653|BEHAVIORAL|Comparison Group|One home visit, information only
223713438|NCT05205330|DRUG|CR6086|oral CR6086, twice a day for 14 days
223713439|NCT05205330|BIOLOGICAL|AGEN2034|AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
223713440|NCT06081205|OTHER|Admission in the Cardiac Intensive Care Unit (CICU)|all patients admitted in the CICU will be enrolled in the study provided they give their informed consent.
223528466|NCT00183248|DRUG|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
223528467|NCT00183248|DRUG|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
223528468|NCT00183248|DRUG|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
223528469|NCT00183248|PROCEDURE|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
223713441|NCT05119517|OTHER|Osteopathic manipulative medicine pedal pump|In this 7 minute intervention, the patient receives 2 minutes of myofascial release of the thoracic inlet and then 5 minutes of the pedal pump technique
223713442|NCT03443375|OTHER|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
223713443|NCT02179242|OTHER|Cardiac rehab|
223713444|NCT02057679|DRUG|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
223713445|NCT02057679|DRUG|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
223713446|NCT00349531|DRUG|Pramipexole|
223528470|NCT00183248|PROCEDURE|Kidney transplant|Occurs at study entry
223528471|NCT01144650|DRUG|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
223528472|NCT01144650|DRUG|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
223528473|NCT02482311|DRUG|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
223713447|NCT05561049|DRUG|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens|Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
223896209|NCT04487054|OTHER|Pro-active palliative care|Patient with high risk of mortality in ICU will be identified using our previously validated prognostic model. Intervention phase will employ pro-active palliative care on eligible patients after they survive 48 hours in ICU.
223896210|NCT04474613|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy done on a blood draw, taking approximately 7 days
223896211|NCT04345250|OTHER|Energy restriction|A 25% reduction in total caloric intake, as calculated through the app. Therefore, during the control period, participants will input what they consume into the Eat This Much app, then the app will calculate the 25% reduction in calories to present participants with how much to consume of the same foods. By doing this their diet will not be altered in terms of macronutrients or micronutrients, but solely on calories.
223896212|NCT06798987|OTHER|Meteorological conditions and air pollution|Climate change e.g. global surface temperature rise; extreme weather events e.g. heat waves, floods
223896213|NCT05377242|DIETARY_SUPPLEMENT|Curcumin|"Curcumin (chemical C21H20O6) is derived from turmeric (Curcuma longa) root extract, standardized to contain 95% curcuminoids. The greatest obstacle with curcumin is its poor natural bioavailability. To help circumvent that issue, a piperazine is included as black pepper 5.3mg (Piper nigrum) fruit extract standardized to 95% piperine. The botanical we are using is provided by Pure Encapsulations. Curcumin being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive curcumin. Participants will receive placebo, low-dose (500 mg/day), medium-dose (1000 mg/day), and/or high dose (2000 mg/day) curcumin in a randomized order."
223896214|NCT05377242|DIETARY_SUPPLEMENT|Resveratrol|"Resveratrol (chemical C14H12O3) is provided as 99% Pure Trans-Resveratrol (MegaResveratrol) from polygonum cuspidatum root). Resveratrol being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive resveratrol. Participants will receive placebo, low-dose (250 mg/day), medium-dose (500mg/day), and/or high dose (1000mg/day) resveratrol in a randomized order."
223896215|NCT05377242|DIETARY_SUPPLEMENT|Stinging Nettle|"Stinging nettle is derived from nettle (Urtica spp) leaf. The botanical we are using is provided by Pure Encapsulations. Stinging Nettle being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive stinging nettle. Participants will receive placebo, low-dose (435mg/day), medium-dose (870mg/day), and/or high dose (2610mg/day) stinging nettle in a randomized order."
223896216|NCT05352074|PROCEDURE|Total colectomy with ileorectal anastomosis|Following complete colonic mobilization without preservation of the ileocolic vascular pedicle, the surgical specimen was extracted by extending the right lower quadrant trocar incision to approximately 4-5 cm. A resection of ileum, 2-3 cm proximal to the ileocecal junction, will be conducted by stapler. The anvil of a 29-mm circular stapler was inserted into the proximal ileal lumen and repositioned intra-abdominally. Ileorectal anastomosis was performed by transanal insertion of the circular stapler, aiming to achieve a tension-free, contamination-minimized reconstruction. Finally, a closed suction drain was placed in the rectouterine pouch (Douglas pouch), and all abdominal incisions were closed in layers.
223896217|NCT05352074|PROCEDURE|Subtotal colectomy with cecal-rectal anastomosis|Following complete colonic mobilization with preservation of the ileocolic vascular pedicle and its branches, the surgical specimen was extracted by extending the right lower quadrant trocar incision to 4-5 cm. After insertion of the anvil from a 29-mm circular stapler through the ascending colon resection margin, a resection about 3 cm distal to the ileocecal junction will be conducted. The cecum was then positioned in the pelvis without rotational torsion, and an antiperistaltic cecorectal anastomosis was created between cecal fundus (after appendectomy) and the rectal stump. The anastomosis was performed via transanal insertion of the circular stapler to ensure tension-free, contamination-controlled reconstruction. Finally, a closed suction drain was placed in the rectouterine pouch (Douglas pouch), and all abdominal incisions were closed in a layered fashion.
224083344|NCT03628027|DEVICE|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
224083345|NCT00778973|DRUG|sertraline 100 mg tablets|
224083346|NCT01785355|OTHER|Dental treatment|"1. The preliminary stage deals with:~   * assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~  * education of the patient regarding correct oral hygiene habits;~2. Phase I Therapy:~   * plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~  * evaluation of response to the treatment~3. Phase II Therapy - surgical phase:~   * extraction of hopeless teeth~  * evaluation of the surgical results.~4. Maintenance phase:~   * periodic reevaluation of plaque and calculus and of periodontal conditions."
224276514|NCT01394133|DRUG|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
223528474|NCT02589821|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
223528475|NCT02589821|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
223528476|NCT03309202|DRUG|PF-05221304|25 mg dose
223528477|NCT05294887|DRUG|Bisoprolol|beta-adrenergic receptor blocker
223528478|NCT05294887|DRUG|Diltiazem|calcium channel blocker
223528479|NCT05294887|DRUG|Placebo|Placebo
223713448|NCT05690373|DIETARY_SUPPLEMENT|Probiotic effect on influenza vaccine response|Seroconversion rate: the percentage of subjects achieving at least a 4-fold increase or an increase from \>10 to 40 in Ab titre for seronegative subjects.
223713449|NCT02892578|OTHER|electrocardiogram|
223713450|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
223713451|NCT01751178|DRUG|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
223713452|NCT02933723|PROCEDURE|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
224276515|NCT04428645|DEVICE|DailyDose Decision Support|DailyDose provides on-demand, real-time dosing recommendations for insulin meal boluses and basal insulin doses as well as the option to receive recommendations for meals and exercise. DailyDose is an information system comprised of (1) a smart phone app that both collects continuous glucose measurement (CGM) data, insulin data, and fitness data and presents suggestions back to the user, (2) a cloud based information system that stores the raw data and relays suggestions to the user, (3) a glucoregulatory model, automatically personalized for each user, that resides on a cloud server and is fit with the user's individual glucose data, and (4) an adaptive agent that provides insulin dosing options and suggestions as well as meal and exercise recommendations to the user based on the subject's own outcomes and simulations done on the glucoregulatory model.
224276516|NCT06273709|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|(Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
224276517|NCT01344031|DRUG|Akt Inhibitor MK2206|Given PO
223713453|NCT06028139|BEHAVIORAL|Continuous glucose monitoring and health coaching|"Each CGM device will work for 14 days. The participants will use the CGM devices for the first two-week period in the first three months of the trial, and the first two-week period of the second three months of the trial.~Participants will interact with health coach throughout the study duration."
223713454|NCT06028139|BEHAVIORAL|EMPOWER mobile app|Nudges will be delivered through the EMPOWER mobile app. Participants will log lifestyle information such as diet and physical activity, and clinical information such as medication and HbA1c levels through the EMPOWER mobile app.
223713455|NCT04406376|DRUG|Prednisone tablet|Treatment of Bell's Palsy with prednisone, with or without tapering down.
223713456|NCT02616406|DEVICE|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
223713457|NCT01483755|PROCEDURE|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
223713458|NCT01483755|PROCEDURE|Percutaneaous intervention|Conventional primary percutaneaous intervention
223713459|NCT00288054|BIOLOGICAL|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
223713460|NCT00288054|DRUG|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
223713461|NCT00288054|RADIATION|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
223713462|NCT06278701|OTHER|late-evening snacks|have an additional meal 1h before bedtime (total calories 200-275kcal, protein 11.5g-18g, complex carbohydrates 25-55g).
223713463|NCT02040571|DEVICE|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
223713464|NCT02040571|DEVICE|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
223713465|NCT04565470|OTHER|online questionnaire|Web-based questionnaire about use of self-management strategies
223713466|NCT04882618|DRUG|Indocyanine green|indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
223713467|NCT04444102|PROCEDURE|Yoga-based stretching|"Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators."
223713468|NCT01850628|DRUG|Paclitaxel|
223713469|NCT01850628|BIOLOGICAL|trastuzumab|
223713470|NCT01850628|BIOLOGICAL|pertuzumab|
223713471|NCT03203616|DRUG|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
223713472|NCT04957004|DEVICE|CPAP|CPAP ventilator was worn at nigh
223713473|NCT04420442|PROCEDURE|Scar Transformation Group|Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
223713474|NCT00261222|DRUG|Amodiaquine|
223713475|NCT02084693|DEVICE|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
223713476|NCT01158157|BIOLOGICAL|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
223713477|NCT01155271|OTHER|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
224276518|NCT01344031|DRUG|Anastrozole|Given PO
224276519|NCT01344031|DRUG|Fulvestrant|Given IM
224276520|NCT01344031|OTHER|Laboratory Biomarker Analysis|Correlative studies
224276521|NCT04341337|OTHER|interview|questionnaire about ethics in surgery
223896218|NCT06802510|PROCEDURE|Microwave Ablation|The MWA group followed a similar resection procedure as the control group. The area of ablation was evaluated strictly by radiologists and surgeons according to the following criteria: 1) Areas of tumor response, progression, or suspicious invasion (intermediate-high signal and edema range in T2) were assessed. Wide margins of at least 2-3 cm or more were obtained over the normal tissue around the tumor. Ablation margins were covered using a microwave ablation array with antennas (Microwave Ablation System BD-GT, Baird Medical LLC), aimed at completely inactivating the tumor in situ. Ablation needles were strategically arranged to form a matrix covering the target zone. The ablation time and power were determined based on the extent of the lesion, ensuring the temperature of the ablation area remained between 70-80°C. A 50 ml syringe was used to continuously drip and spray ice-cold saline to keep surrounding tissue temperatures below 40-43°C.
223896219|NCT05227664|DRUG|AK117|Intravenous (IV) infusion
223896220|NCT05227664|DRUG|AK112|Intravenous (IV) infusion
223896221|NCT05227664|DRUG|Nab paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
223896222|NCT05227664|DRUG|paclitaxel|Paclitaxel at a starting dose of 90 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
223896223|NCT05452889|DIAGNOSTIC_TEST|18F-FGLN PET Imaging|PET/CT Imaging: The study visit will take around 3-4 hours, the duration of PET will be around 90 minutes. Women should have negative pregnancy test prior to the study. An intravenous catheter will be placed in the subject's opposite arm, which will be used for radiotracer administration. A low-dose helical CT scan will be performed during a \~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses. Participants will be retained in the PET facility following the PET scan to promote urination to increase elimination of the radiotracer.
223896224|NCT05452889|DRUG|(18F)FPGLU|\[F-18\]FGln is a natural glutamine derivative was synthesized to explore its potential application of imaging glutamine uptake for cancer diagnosis. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
223896225|NCT05476913|DEVICE|geko™ device|Neuromuscular electrical stimulation of the peroneal nerve
223896226|NCT05235750|BEHAVIORAL|Self-affirmation writing|Writing with a focus on self-affirmation at the time following a diagnosis of an advanced cancer
223896227|NCT04809311|DRUG|Oral antidiabetetic drugs|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
223896228|NCT04809311|DRUG|Basal insulin|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
223896229|NCT04809311|DRUG|Glucagon-like peptide-1 (GLP-1)|"During the study, no medical drugs will be supplied to the patients. Patients will continue their antidiabetic treatment independently of this study and at the treating physician's discretion as part of usual clinical practice.~Approximately 12-week study duration"
223896230|NCT06105684|DRUG|Capecitabine Pill|Will be given once per day by mouth
223896231|NCT03092518|PROCEDURE|Surgery|Heated Intraperitoneal Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate
223896232|NCT03092518|DRUG|Cisplatin|Cisplatin (90 mg/m\^2) will be administered via circuit to the peritoneal cavity
223896233|NCT03092518|DRUG|Mitomycin C|Mitomycin C 10 mg/m\^2 will be administered via circuit to the peritoneal cavity
223896234|NCT03092518|DRUG|Sodium Thiosulfate|Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
223896235|NCT03092518|PROCEDURE|Tumor Biopsy|At screening, baseline (if not done at screening) and operation (as clinically indicated).
223896236|NCT03092518|DIAGNOSTIC_TEST|CT C/A/P|At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.
223896237|NCT03092518|DIAGNOSTIC_TEST|PET-CT|At screening, baseline (if not done at screening), post op care, post-discharge visits/follow-up, semi-annual follow-up and annual follow-up.
223896238|NCT03092518|DIAGNOSTIC_TEST|MRI|If computed tomography (CT) contraindicated.
223896239|NCT03092518|DIAGNOSTIC_TEST|EKG|At screening and baseline (if not done at screening).
223896240|NCT02301910|DRUG|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
223896241|NCT02301910|DRUG|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~* 55 to \<60 30 mg 6 ml~* 60 to \<70 35 mg 7 ml~* 70 to \<80 40 mg 8 ml"
223896242|NCT02845882|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
223896243|NCT02845882|DRUG|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
223896244|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
223896245|NCT02845882|DRUG|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
224276522|NCT05554887|OTHER|Thrust manipulation|Participants will be positioned prone and the clinician will perform a high-speed, low-amplitude thrust into the most symptomatic segment of the thoracic spine. TM type, thrust direction, and number of thrusts will be at the clinician's discretion and will be based on the individualized assessment of the patient.
223713478|NCT03903068|DEVICE|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
223713479|NCT03903068|DEVICE|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
223713480|NCT01815801|OTHER|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
223713481|NCT01815801|OTHER|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
223713482|NCT01060813|DIETARY_SUPPLEMENT|Leucine supplements|leucine supplements
223713483|NCT00000789|DRUG|Stavudine|
223713484|NCT00000789|DRUG|Zidovudine|
223713485|NCT01826188|DRUG|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
223713486|NCT01826188|DRUG|Placebo|olive oil without cannabis
223713487|NCT00332163|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
223713488|NCT00332163|DRUG|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
223713489|NCT00332163|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
223713490|NCT00332163|DRUG|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
223713491|NCT00332163|DRUG|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
223713492|NCT02519257|PROCEDURE|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
223713493|NCT02519257|PROCEDURE|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
223713494|NCT01292811|DEVICE|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
223713495|NCT01292811|OTHER|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function \[15\].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
223713496|NCT02895230|OTHER|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
223713497|NCT00001190|DRUG|Deslorelin|
223713498|NCT02621060|DRUG|Placebo|Placebo: 1200 mg per day for three months
223713499|NCT02621060|DRUG|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
223713500|NCT00573612|BEHAVIORAL|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
223713501|NCT00573612|BEHAVIORAL|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
223713502|NCT03495219|PROCEDURE|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
223713503|NCT03733470|DRUG|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
223713504|NCT05830968|DEVICE|Morpheus8 Applicator Radiofrequency device|Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \~6 months, depending on subject recruitment rate.
223713505|NCT03787732|DRUG|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
223896246|NCT02845882|DRUG|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
223896247|NCT02845882|DRUG|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
223896248|NCT02845882|DRUG|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
223896249|NCT03490201|DEVICE|Market Approved RF Ablation System|Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.
223896250|NCT03490201|DEVICE|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment using an ablation system that is not FDA approved.
223896251|NCT04838288|DRUG|Change from Prograf to Envarsus XR|Change from Tacrolimus taken twice a day to Envarsus XR taken once a day
223896252|NCT05965765|DIAGNOSTIC_TEST|Total knee arthroplasty|who got total knee arthroplasty because of osteoarthritis
223896253|NCT05965765|DIAGNOSTIC_TEST|osteoarthritis without surgery|who has osteoarthritis and didn't get any surgery
223896254|NCT05965765|DIAGNOSTIC_TEST|control group|healthy people
223896255|NCT06047353|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
223896256|NCT06047353|DEVICE|Positive Airway Pressure (PAP) therapy|Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
223896257|NCT06381258|PROCEDURE|Ultrasound|Fetal echocardiography using ultrasound device
223896258|NCT04529044|PROCEDURE|Biopsy|Undergo biopsy
223896259|NCT04529044|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223896260|NCT04529044|PROCEDURE|Computed Tomography|Undergo PET/CT
223896261|NCT04529044|RADIATION|Gallium Ga 68-DOTATATE|Receive 68Ga
223896262|NCT04529044|DRUG|Lutetium Lu 177 Dotatate|Given IV
223896263|NCT04529044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223896264|NCT05897710|OTHER|Virtual World-Based Cardiac Rehabilitation (VWCR)|12-week virtual world technology-based program via Second Life platform. Weekly virtual visits with nurse coach and exercise physiologist, weekly education sessions, and social support group discussions within the virtual world environment.
223896265|NCT05897710|OTHER|Center-Based Cardiac Rehabilitation (CBCR)|Traditional 12-week in-person cardiac rehabilitation program; standard of care at participant's cardiac rehabilitation facility
223896266|NCT05265546|DRUG|Psilocybin|The effects of different doses of psilocybin (0 - 14 mg) will be compared.
223896267|NCT06313892|BEHAVIORAL|Home based Exercise|The participants in the study group will be given an online personalized exercise program at home in non dialysis days. Synchronous tele-exercise will be delivered using the free teleconference application (app) (Google Meets software). The groups of tele-exercises will be private and the professional will send the link for each training session and will control the access of the participants. Each session will be 40 to 45 min in duration for 3 days per week over 12 weeks, 36 sessions in total.
223896268|NCT04883463|DEVICE|Epidural stimulation|Epidural electrical stimulation implant weekly sessions for 21 months.
223896269|NCT04851340|OTHER|Cow's Milk|Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
223896270|NCT04851340|OTHER|Soy Milk|Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
223896271|NCT06296498|PROCEDURE|Leukocyte Platelet-rich fibrin|Leukocyte-PRF (L-PRF) contains neutrophils and macrophages that facilitate bacteria and necrotic tissue elimination via phagocytosis
223896272|NCT06296498|OTHER|Standard of care OFD|Open flap debridement (OFD) is one periodontal surgical procedure that is used to improve periodontal health by providing access to the tooth roots and alveolar bone.
223896273|NCT06005987|BEHAVIORAL|OneTouch Reveal application|Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
223896274|NCT06459726|OTHER|shi style mobilization|Step 1 soothing tendon stepTherapist will aerate patient's neck 3 to 6 times.Step 2 moblization step Therapist will apply low velocity small amplitude oscillatory movement without thrust. Head will be in 45 degrees of flexion or extension. Repeat this for 3 to 6 times. Then distraction force is applied to the cervical. Step 3 dredging collateral step Therapist holds thenar and hypothenar muscles of patient's hand on affected side and gently shook the upper limb ebb and flow with small shaking and high frequency. Repeat the procedure 3 times 6 sesions over 2 weeks for 20minutes
223896275|NCT06459726|OTHER|SNAGS|Patient will receive sustained natural apophyseal glides as described by brian mulligan. Patient position will be upright sitting when therapist will apply a sustained passive assesory glide while patient moves actively through available physiological range of motion in the direction in which symptoms are produced. the headache SNAG technique will be performed with the patient sitting on a chair in the erect posture. The therapist will handle C2 spinous process with the middle phalanx of one hand. With the other hand, he will perform ventral gliding on C2 for 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Patient will be asked to report dizziness or any other symptom after procedure. If patient reports symptom then angle of application is changed to ensure symptom free treatment in all patientsNumber of repetitions are increased gradually from 6 to 10 and end physiological movement is maintained for 10second
223896276|NCT03115476|DRUG|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
223896277|NCT03115476|DRUG|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
223896278|NCT03115476|OTHER|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
224276523|NCT05554887|OTHER|Sham thrust manipulation|The same protocol will be applied as the push thoracic manipulation application, but no push will be applied.
224276524|NCT05089890|DEVICE|Sorbact® Compress|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
224276525|NCT05089890|DEVICE|Sorbact® Gel Dressing|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
223713506|NCT03787732|OTHER|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
223713507|NCT05722782|DRUG|Piroxicam|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
223713508|NCT05722782|DRUG|Acetaminophen|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with 1000 mg Acetaminophen per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
223713509|NCT05722782|DRUG|Placebo|Patients allocated to this arm received , as a second line treatment of renal colics , a five days treatment with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacy and the side effects of the treatment
223713510|NCT03396185|DRUG|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
223713511|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
223713512|NCT02529189|DIETARY_SUPPLEMENT|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
223713513|NCT02711397|OTHER|Observational study|Comparison excretion levels of gluten immunogenic peptides
223713514|NCT04329897|BEHAVIORAL|Software Messaging|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
223713515|NCT00695877|BIOLOGICAL|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
223713516|NCT04379024|DRUG|DUAVEE 0.45Mg-20Mg Tablet|One capsule daily for 6 months (+/- 1 month)
223713517|NCT06143644|OTHER|Serial ctDNA monitoring|Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
223713518|NCT00249756|BEHAVIORAL|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
223713519|NCT00249756|BEHAVIORAL|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
223713520|NCT05731895|DRUG|BI 425809 (iclepertin)|BI 425809 (iclepertin)
223713521|NCT01010061|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
223713522|NCT01010061|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
223713523|NCT01010061|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
223713524|NCT01247909|DRUG|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
223713525|NCT03379805|DIAGNOSTIC_TEST|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
223713526|NCT03379805|DIAGNOSTIC_TEST|Non-contrast MRI|The anatomy is described using non-contrast MRI.
223713527|NCT03379805|DIAGNOSTIC_TEST|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
223713528|NCT01885403|DEVICE|non-invasive respiratory parameter measurements|
223713529|NCT03012438|DEVICE|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
223713530|NCT06177743|DEVICE|Coroflex ISAR NEO stent|Percutaneous coronary intervention with Coroflex ISAR NEO stent
224276526|NCT05089890|DEVICE|Sorbact® Ribbon Gauze|"Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds.~The purpose of the study is not to compare between the devices, but to study each device on its own."
224276527|NCT01090245|BEHAVIORAL|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
223713531|NCT03470441|DRUG|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
223713532|NCT03470441|OTHER|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
223713533|NCT05109156|OTHER|This is an observational study|This is an observational study
223713534|NCT06533501|OTHER|Dietary Leucine Intakes|Participants consume 8 hourly meals that contain the assigned test leucine intake. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g.kg.d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
223713535|NCT04029948|PROCEDURE|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
223713536|NCT04029948|PROCEDURE|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
223713537|NCT03559660|DRUG|Certolizumab Pegol|
223713538|NCT02433405|BIOLOGICAL|Fetuin-A|Acute phase protein
223713539|NCT02433405|BIOLOGICAL|Serum Amyloid A|Acute phase protein
223713540|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
223713541|NCT01520012|DRUG|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
223713542|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
223713543|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
223713544|NCT01520012|DRUG|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
223713545|NCT06317727|DEVICE|Irreversible Electroporation using EndoVE(Endoscopic Vacuum Electrode) and electrical pulses generated using ePORE(electroporation device)|The use of pulsed field ablation via irreversible electroporation delivered during flexible lower gastrointestinal endoscopy
223713546|NCT05749965|PROCEDURE|Unicompartmental knee arthroplasty|medial unicompartmental knee arthroplasty
223713547|NCT00169546|DRUG|Salmeterol/fluticasone propionate|
223713548|NCT00169546|DRUG|Fluticasone propionate|
223713549|NCT06546007|DIAGNOSTIC_TEST|CTC-DNA|ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
223713550|NCT03768414|DRUG|Cisplatin|Given IV
223713551|NCT03768414|DRUG|Gemcitabine Hydrochloride|Given IV
223713552|NCT03768414|DRUG|Nab-paclitaxel|Given IV
223713553|NCT06181331|BEHAVIORAL|eConquerFear|The key goals of this e-intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
223713554|NCT06181331|BEHAVIORAL|eHealthMaintenance|eHealthMaintenance is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
223713555|NCT06181331|BEHAVIORAL|ConquerFear|ConquerFear is an intensive version of eConquerFear, which consists of 6 face-to-face therapist-led sessions.
223713556|NCT06181331|BEHAVIORAL|eConquerFear+eHealthMaintenance|The combination of eConquerFear and eHealthMaintenance interventions, that consists of 10 weekly online modules.
223713557|NCT03128879|DRUG|Ibrutinib|Given PO
223713558|NCT03128879|DRUG|Venetoclax|Given PO
223713559|NCT03128879|DRUG|Acalabrutinib|Given BID
223713560|NCT06249165|DRUG|Inclisiran|Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
223713561|NCT02571777|DRUG|QVM149 150/50/160|
223713562|NCT02571777|DRUG|QVM149 150/50/80|
223713563|NCT02571777|DRUG|QMF149 150/320|
223713564|NCT02571777|DRUG|QMF149 150/160|
223713565|NCT02571777|DRUG|salmeterol/fluticasone|
223713566|NCT02192138|PROCEDURE|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
223713567|NCT02192138|DEVICE|Pleural catheter|
223713568|NCT02192138|DEVICE|Pleural manometer|
223713569|NCT03566888|DEVICE|Blood pressure assessment|Validation of an automated blood pressure device
223713570|NCT03633656|DEVICE|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
223713571|NCT03633656|DEVICE|Model Predictive Control of Iron Dosing|Model Predictive Control of Iron Dosing
223896279|NCT01052467|DRUG|Xamiol® Gel|Once daily application for about 4 weeks
223939955|NCT07186647|PROCEDURE|laparoscopic-assisted Soave (LASo)|Transanal endorectal procedure was conducted according to the standard technique described by De la Torre-Mondragon and Ortega-Salgado \[12\]. A circular incision was made in the mucosa, and mucosectomy was performed. The muscle sleeve was cut, connecting the two dissection planes circularly . After keeping the muscular cuff as short as possible, a longitudinal incision was made posteriorly. Then, the bowel was extracted, and the anastomosis was performed as described above.
223896280|NCT06279780|DIETARY_SUPPLEMENT|very low-calorie diet|Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
223896281|NCT03333616|DRUG|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
223896282|NCT03333616|DRUG|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
223719104|NCT01725178|BEHAVIORAL|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
223896283|NCT05559931|DRUG|N,N-Dimethyltryptamine|IV infusion over 6 hours
223896284|NCT05559931|DRUG|Placebo|Placebo infusion over 6 hours
223896285|NCT05266495|OTHER|Brolucizumab|There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.
223896286|NCT04980248|BIOLOGICAL|ALXN1850|ALXN1850 will be administered as an IV infusion and via the SC route.
223896287|NCT04828681|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Cardiac magnetic resonance imaging was performed 5.0 ± 5.8 days after the primary PCI. MVO, infarct size, and myocardial salvage index were quantitatively assessed in CMR.
223896288|NCT06178887|DIAGNOSTIC_TEST|imaging|cardiac angioMR
223896289|NCT05257486|DEVICE|Xoft eBx|The Xoft Axxent Electronic Brachytherapy (eBx) System allows for the administration of high dose rate brachytherapy treatments using an electronic source
223896290|NCT02933736|DRUG|Ribociclib|
223896291|NCT05545150|PROCEDURE|Intraoperative Imaging|Clarix Imaging Volumetric Specimen Imager
223896292|NCT05545150|DEVICE|Lumpectomy|Per standard of care (SOC)
223896293|NCT06298318|OTHER|Vodka|BMI: if 18.5 ≤ BMI \< 24.0, individuals received 1.0 g/kg body weight of vodka; if 24.0 ≤ BMI ≤ 28.0, individuals received 0.8 g/kg body weight of vodka.
223896294|NCT06298318|OTHER|water|equal amount of non-alcoholic beverages with the same taste and colour but without alcohol
223896295|NCT03976362|BIOLOGICAL|Pembrolizumab|IV infusion
223896296|NCT03976362|DRUG|Carboplatin|IV infusion
223896297|NCT03976362|DRUG|Paclitaxel|IV infusion
223896298|NCT03976362|DRUG|Nab-paclitaxel|IV infusion
223896299|NCT03976362|DRUG|Olaparib|Tablets
223896300|NCT03976362|DRUG|Placebo|Placebo to olaparib, tablets
223896301|NCT04852783|DEVICE|Contour Neurovascular System|Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
223896302|NCT00613106|DRUG|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
223896303|NCT00613106|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
223896304|NCT05574387|DRUG|Metformin|Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)
223896305|NCT03142568|DRUG|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
223896306|NCT03142568|OTHER|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
223896307|NCT03906331|DRUG|Selpercatinib|Open-label expanded access
223896308|NCT03593018|DRUG|Oral azacitidine|Azacitidine tablets
224083347|NCT00217919|BEHAVIORAL|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
224083348|NCT03932552|OTHER|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
224083349|NCT03932552|OTHER|nutritional therapy|individualised nutritional intervention
223896309|NCT03593018|DRUG|Romidepsin|Romidepsin injection
223896310|NCT03593018|DRUG|Bendamustine|Bendamustine injection
223896311|NCT03593018|DRUG|Gemcitabine|Gemcitabine injection
223896312|NCT06283498|DEVICE|Device Morpheus8V|Assigned to be treated using the modified Morpheus8V
223896313|NCT04028947|PROCEDURE|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
223896314|NCT02396134|BIOLOGICAL|CMVpp65-A*0201 peptide vaccine|Given SC
223896315|NCT02396134|OTHER|Placebo|Given SC
223896316|NCT02396134|OTHER|Laboratory Biomarker Analysis|Correlative studies
223896317|NCT01565109|DRUG|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
224083350|NCT00236080|DRUG|PROVIGIL 200 mg|PROVIGIL 200 mg/day
223896318|NCT01565109|RADIATION|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
223896319|NCT06129019|BEHAVIORAL|Reiki|Reiki application will be done
223896320|NCT06122142|DEVICE|Transfluthrin - delivery by paid study personnel|Passive emanator with formulated transfluthrin, SR product will be delivered by paid study personnel
223896321|NCT06122142|DEVICE|Transfluthrin - delivery by voucher system|Passive emanator with formulated transfluthrin, voucher which will be used to redeem for SR product(s) on a monthly basis for each head of household.
223896322|NCT06122142|DEVICE|Transfluthrin - delivery by village health teams|Passive emanator with formulated transfluthrin, village health teams will distribute SR products.
223896323|NCT05938478|DRUG|Tralokinumab|This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
223896324|NCT05703074|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|4 capsules (a total of 1000 mg) 2 times daily for 84 days
223896325|NCT05703074|BEHAVIORAL|Mind-body reprocessing therapy (MBRT)|4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.
223896326|NCT05703074|BEHAVIORAL|Care as usual|A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner
223896327|NCT05703074|DIETARY_SUPPLEMENT|Placebo|4 capsules (empty) 2 times daily for 84 days.
223896328|NCT00742482|DRUG|HL 10|Freeze dried HL 10
223896329|NCT03596788|DIETARY_SUPPLEMENT|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
223896330|NCT03596788|DIETARY_SUPPLEMENT|Placebo Beverage|The placebo beverage will contain aspartame.
223896331|NCT06408688|DRUG|Immune checkpoint inhibitors plus Iscador® Qu.|Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.
223896332|NCT06408688|DRUG|Immune Checkpoint Inhibitors|Standard cancer treatment.
223896333|NCT06424223|PROCEDURE|Horizontal Ridge augmentation|"A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures."
223896334|NCT01424150|OTHER|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
223896335|NCT01424150|OTHER|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
223896336|NCT05732805|BIOLOGICAL|BCD-217|Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
223896337|NCT05732805|BIOLOGICAL|BCD-100|Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).
223896338|NCT05732805|BIOLOGICAL|Placebo|Placebo
223896339|NCT06330233|OTHER|Moxibustion|The recruited patients all received diabetes mellitus education. Patients with combined hypertension and hyperlipidemia received daily treatment to lower their blood pressure and blood lipids. The medication was based on their current self-medication, to keep their conditions under normal control. The drug treatment group received mecobalamin tablets and epalrestat orally for four weeks along with their daily treatment. Moxibustion 15-minute group: The selected acupoints of moxibustion are Zusanli(ST 36), Sanyinjiao(SP 6), Quchi(LI 11), and Kunlun(BL 60), moxa cones were pasted on the acupoints and moxibustion was applied by ignition, each time for 15 minutes at each acupoint, once every three days, twice a week, four consecutive weeks of treatment. The moxibustion 30-minute group except for the operating time will use the same intervention as above.
223896340|NCT06517264|DRUG|Antibiotic|antibiotic treatment, analgesics and hygienic-dietetic measures
223896341|NCT06517264|OTHER|Non antibiotic|Analgesics and hygienic-dietetic measures
223896342|NCT04158804|DIAGNOSTIC_TEST|procalcitonin|accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
223896343|NCT02423603|DRUG|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
223896344|NCT02423603|DRUG|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
223896345|NCT02423603|DRUG|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
223896346|NCT06020677|OTHER|L-WebTIPS|This mobile health application includes cultural adaption and grounding of a previously developed and tested tailored mHealth intervention, WebTIPS. LWebTIPS is a culturally adapted mHealth intervention that is aimed at the child and parent and strives to improve clinical outcomes and patient experience of Latinx children. Tailoring variables include: Simpatia, Religiosity and Familism.
223896347|NCT06139458|BEHAVIORAL|Cryotherapy|Participants will receive cryotherapy on both hands and feet
223896348|NCT06139458|BEHAVIORAL|Compression|Participants will receive compression on both hands and feet
223896349|NCT02774746|OTHER|35-week delivery|Induction at 35 weeks gestational age
223896350|NCT02774746|OTHER|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
223896351|NCT05084508|BIOLOGICAL|Investigational varicella vaccine low potency|1 dose of a low-potency investigational varicella vaccine administered subcutaneously.
223896352|NCT05084508|BIOLOGICAL|Investigational varicella vaccine medium potency|1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.
223896353|NCT05084508|BIOLOGICAL|Investigational varicella vaccine high potency|1 dose of a high-potency investigational varicella vaccine administered subcutaneously.
223896354|NCT05084508|BIOLOGICAL|Licensed varicella vaccine Lot 1|1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.
224083351|NCT00236080|DRUG|Armodafinil 250 mg|Armodafinil 250 mg/day
223896355|NCT05084508|BIOLOGICAL|Licensed varicella vaccine Lot 2|1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.
223896356|NCT05084508|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.
223896357|NCT05084508|BIOLOGICAL|Hepatitis A vaccine|1 dose of a hepatitis A vaccine administered intramuscularly.
223896358|NCT05084508|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.
223896359|NCT05296525|DRUG|GDA-201|NAM-expanded allogeneic NK cells
223896360|NCT06300047|OTHER|Non-Medical Transition Coordinator|Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
223896361|NCT05606887|OTHER|Wearable Device and Ecological Momentary Assessments|"The intervention will consist of three components:~1. Completion of brief text-message based surveys 2-3 times per week~2. Wearing a wrist-based wearable device to generate individual data insights on physiological data related to stress and well-being, including heart rate variability, stress scores, and sleep quality~3. Individual biweekly reports of survey response trends and curated resources intended to support participant well-being"
223896362|NCT02213731|OTHER|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
223896363|NCT06264986|DIETARY_SUPPLEMENT|Ashwagandha|The intervention will be 600mg of KSM-66, a branded supplement derived from the root extract of the herb ashwagandha, with a consistent rate of 5% withanolides for 28 days. It is the most clinically studied extract of the herb and is the only type of ashwagandha to receive third party testing certification (Informed Sport, Informed Ingredient, Banned Substances Control Group, Clean Label Project). The laboratory where the product is made, Ixoreal Biomed, has received Current Good Laboratory Practices (cGLP), quality controlled and tested against heavy metals and pesticides.
223896364|NCT06264986|OTHER|Placebo|600mg chickpea flour in a hydroxypropyl methylcellulose capsule, once a day for 28 days
223896365|NCT04536857|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
223896366|NCT06815835|BIOLOGICAL|Measles-Rubella vaccine (Live) I.P. (Freeze Dried) of M/s. Zydus Lifesciences Ltd|Live attenuated vaccine
223896367|NCT06815835|BIOLOGICAL|Yellow fever Vaccine (WHO prequalified)|Live attenuated vaccine
223896368|NCT06072807|DIAGNOSTIC_TEST|Brain Imaging with 18F-FES|Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
224276528|NCT01090245|BEHAVIORAL|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
223528480|NCT05971095|DEVICE|Percutaneous neuromodulation using the EPTE® Bipolar System device|"The two stimulation protocols will be applied consecutively. Firstly, the high-frequency protocol (HFS) will be applied in order to produce potentiation of the non-nociceptive pathway, using the pulsed square waveform and 5 bursts of stimulation lasting 5 seconds at a frequency of 100 Hz separated by 55 s interval between bursts. Adjustments to amplitude and pulse width are made until the patient experiences paresthesias at a perceptible but not painful intensity, and the intensity will be set 200 μA above the detection threshold for each subject.~In order to depress the nociceptive pathway, the low-frequency protocol (LFS) with stimulation at 2 Hz for 16 min with an intensity of 1000μA will subsequently be switched to. To ensure the recruitment of higher threshold type C nociceptive fibers, the intensity level will be programmed at the pain threshold for each subject."
223896369|NCT02918890|OTHER|Constraint-induced Movement Therapy|
223896370|NCT02918890|OTHER|Hand-arm Bimanual Intensive Therapy|
223896371|NCT04898413|BEHAVIORAL|Group-based acceptance and commitment therapy (ACT)|Group-based ACT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and experiential avoidance in caregiving, (b)mindfulness and acceptance of aversive emotions, sensations, and thoughts, (c) behavior management for care recipients' BPSD, and (d) clarifying and choosing one's value, and taking actions toward the chosen values. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based ACT intervention.
223896372|NCT04898413|BEHAVIORAL|Group-based cognitive behavioral therapy (CBT)|Group-based CBT intervention by professional psychotherapist consists of four modules: (a) psychoeducation about dementia and distress in caregiving, (b) cognitive restructuring and relaxation, (c) behavior management for care recipients' BPSD, and (d) increasing pleasant activities. Each session lasts about 90 minutes and will be held every two weeks. Group-based reminiscence therapy for care recipients will be conducted by a professional psychotherapist other than the one conducting group-based CBT intervention.
223528481|NCT03970031|DRUG|MSDC-0602K|MSDC-0602K tablet
223528482|NCT03970031|DRUG|Placebo|Matching tablet
223528483|NCT05228418|DRUG|Naltrexone Pill|Naltrexone oral bridge to IM naltrexone maintenance therapy
223896373|NCT05758688|RADIATION|Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)|The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
223896374|NCT03138863|DEVICE|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio-opaque inclusion
223896375|NCT03138863|DEVICE|Catheter System|100 cm tapered micro-catheter
223896376|NCT05479578|DRUG|Cyclophosphamide|Given PO
223896377|NCT05479578|DRUG|Dexamethasone|Given PO
224276529|NCT06105450|DIAGNOSTIC_TEST|Comprehensive assessment of respiratory muscle function.|Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
224276530|NCT06139133|DRUG|Placebo supplementation|Placebo
224276531|NCT06139133|DRUG|Vitamin D supplementation|Vitamin D3 supplementation (2 00,000 IU/Week)
224276532|NCT00677872|DRUG|PRX-08066|
224276533|NCT02367872|DRUG|TAK-272|TAK-272 tablet
223896378|NCT06207227|DEVICE|VITA AV Clinical System|The VITA AV Clinical System that works on the principle of negative pressure suction to the vaginal wall to treat VA, based on the idea of the clinical application in wound healing which is intended to elicit improvements in the rate of angiogenesis, moisture and HA production post-treatment. It is believed that the VITA AV Clinical System will provide a more effective treatment by improving the underlying cellular deficiencies associated with VA.
223896379|NCT04065841|DRUG|Tropifexor|100mcg+30mcg+10mcg capsules of tropifexor taken orally every day until the 140 mcg capsule of tropifexor taken orally every day is produced, then patients will switch to the single 140mcg capsule taken orally every day
223896380|NCT04065841|DRUG|Licogliflozin|30mg tablet of licoglifozin taken orally every day
223896381|NCT04065841|OTHER|Placebo|licogliflozin placebo + tropifexor placebo
223896382|NCT03651414|OTHER|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
223896383|NCT05601687|PROCEDURE|Direct Endoscopic Necrosectomy|Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures
223896384|NCT05601687|PROCEDURE|Step-up Approach|"Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON."
223896385|NCT04222972|DRUG|Pralsetinib|Administered orally
223896386|NCT04222972|DRUG|Carboplatin|Administered IV
223896387|NCT04222972|DRUG|Cisplatin|Administered IV
223896388|NCT04222972|DRUG|Pemetrexed|Administered IV
223896389|NCT04222972|DRUG|Pembrolizumab|Administered IV
223896390|NCT04222972|DRUG|Gemcitabine|Administered IV
223896391|NCT04222972|DRUG|Paclitaxel|Administered IV
223896392|NCT04222972|DRUG|Nab-Paclitaxel|Administered IV
223896393|NCT01420237|DEVICE|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
223896394|NCT06065176|BIOLOGICAL|Novavax COVID-19 vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Novavax vaccine.
223896395|NCT06065176|BIOLOGICAL|Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)|Participants will receive a single dose of the Pfizer vaccine.
223896396|NCT06199453|DRUG|Lutetium (177Lu) vipivotide tetraxetan|6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
223896397|NCT05981833|DEVICE|Repair with DAA (dermal allograft augmentation)|Patients undergo rotator cuff repair with dermal allograft augmentation.
223896398|NCT06243016|BEHAVIORAL|High-Intensity Interval Training (HIIT) Breaks to Sitting|HIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min HIIT Breaks. During sitting participants will engage in standardized sedentary activities. Each 6-min HIIT break comprises a one-minute warm-up, followed by a 2-minute high-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2 minutes at high intensity.
223896399|NCT06243016|BEHAVIORAL|Light-Intensity Interval Training (LIIT) Breaks to Sitting|LIIT Breaks: a 3.5-hour sitting will be interrupted every 30 min with 6-min LIIT Breaks. Each 6-min LIIT break comprises a one-minute warm-up, followed by a 2-minute light-intensity interval, one minute rest (sitting on a cycle ergometer) followed by another 2-minute light-intensity interval.
223896400|NCT04492722|DRUG|AZD5718|Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.
223896401|NCT04492722|DRUG|Dapagliflozin 10 mg|Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
223896402|NCT04492722|DRUG|Placebo|Participants will receive once daily oral dose of placebo matched to AZD5718, and will continue until Week 20.
223896403|NCT02923570|RADIATION|Photon intensity modulated radiation therapy (IMRT)|Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
223896404|NCT02923570|RADIATION|Proton beam radiotherapy (PBRT)|Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
223528484|NCT03790189|BIOLOGICAL|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
223528485|NCT01511302|DRUG|RNS60|RNS60, 2ml, nebulized twice daily.
223896405|NCT04801485|DIETARY_SUPPLEMENT|D-chiro inositol|Active group receives inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.
223896406|NCT04801485|DIETARY_SUPPLEMENT|Placebo|Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.
223896407|NCT03286699|BEHAVIORAL|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
223528486|NCT01511302|DRUG|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
223896408|NCT03286699|BEHAVIORAL|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
223896409|NCT06275945|DEVICE|Voro Urologic Scaffold|radical prostatectomy
223896410|NCT04946253|BEHAVIORAL|DOCC: Evidence-based treatment for disruptive behavior and ADHD|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. The content covers key topics related to the treatment of behavior problems (e.g., self-management, positive parenting) and ADHD (e.g., psychoeducation, medication).
223896411|NCT04946253|BEHAVIORAL|TEAM: Implementation support strategies at the care team level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Coaching and consultation will be provided to the provider care team to support the use of collaborative care for behavior problems and ADHD. The TEAM intervention includes regular virtual meetings or calls with the providers (about once/month, on average) that cover core chronic care model functions, including registry use, case-finding, collaborative care team roles, and workflows outlining how DOCC is delivered in the practice.
223896412|NCT04946253|BEHAVIORAL|Implementation support strategies at the leadership level following standard implementation of DOCC|Practices will learn and then deliver DOCC in treatment sessions with caregivers and/or children. Practice facilitation will be provided to practice leaders to help them support the care team's use of collaborative care for behavior problems and ADHD. The LEAD intervention includes regular virtual meetings or calls with practice leaders (about once/month, on average) that cover the assessment of practice capacity/barriers, ways to overcome organizational barriers and support staff use of DOCC, promoting innovation, and leveraging practice resources to support DOCC delivery and maintenance in the practice.
223896413|NCT06252233|BEHAVIORAL|patient- and physician-centered QoL monitoring|Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.
223896414|NCT06252233|OTHER|Placebo|Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.
223896415|NCT03752203|DRUG|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
223896416|NCT03752203|DEVICE|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
223896417|NCT03631784|DRUG|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
223896418|NCT03631784|DRUG|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m\^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
223896419|NCT03631784|DRUG|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
223896420|NCT03631784|DRUG|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
223896421|NCT03631784|DRUG|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
223896422|NCT03631784|RADIATION|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
223896423|NCT03631784|DRUG|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m\^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
223896424|NCT03631784|DRUG|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
223896425|NCT03373695|DEVICE|Dissolve™|Dissolve™ are to be used in the trial
224276534|NCT01164657|DEVICE|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
224276535|NCT04791007|DRUG|OB-002|vaginal or rectal administration
224276536|NCT04791007|DRUG|Placebo|vaginal or rectal administration
224276537|NCT02625298|DEVICE|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
224276538|NCT02625298|DEVICE|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
224276539|NCT06529874|OTHER|Pressure pain tolerance measurement using Digital Pressure Algometer|Pressure pain tolerance will be measured using pressure algometer for all participants in both groups. Pressure pain tolerance will be measured in a relaxed sitting position to evaluate on quadriceps muscle. Initially, a teddy bear will be used for demonstration.
224276540|NCT06529874|OTHER|Balance assessment using HUMAC balance system|"HUMAC balance system will be calibrated, then will conduct~1. center of pressure: will instructed child to stand on platform, and maintain own body stability, and focus on the red dot in the center of screen that will move in response to body sway. after a rest, second trial will be done.~2. Eye open/ closed firm surface tests: First for Eye open firm surface test; the child will be asked to look at a target on the wall that was set at his/ her eye level, and to stare at this target for 30 seconds while standing on firm surface. After 5 seconds rest. Eye closed firm surface test; child will be asked to close his/ her eyes for 30 seconds, and conducting the same procedures for balance testing.~The researcher will documented the values resented on the screen ."
223896426|NCT03373695|DEVICE|SeQuent®Please|SeQuent®Please are to be used in the trial
223896427|NCT05494411|DRUG|Mitomycin for pyelocalyceal solution|
223939956|NCT07190469|DRUG|PQ203|PQ203 is a peptide drug-conjugate given once weekly by intravenous infusion intended for the treatment of advanced solid tumor cancers including triple negative breast cancer.
223896428|NCT06423482|OTHER|PEEK bar|The framework will be constructed from Poly-Ether-Ether-Ketone (PEEK). The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
223896429|NCT06423482|OTHER|Titanium bar|The framework will be constructed from titanium. The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
223896430|NCT03848689|OTHER|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
223896431|NCT03848689|OTHER|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
223896432|NCT03650894|DRUG|Nivolumab|Nivolumab 240 mg IV every 2 weeks
223896433|NCT03650894|DRUG|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
223896434|NCT03650894|DRUG|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
223896435|NCT04589026|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
223896436|NCT04589026|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
223896437|NCT04484012|DRUG|Acalabrutinib|Given PO
223896438|NCT04484012|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
223896439|NCT00597805|BEHAVIORAL|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
223896440|NCT02876588|OTHER|Unrestricted|Users may open up to 4 patient records at a time.
223896441|NCT02876588|OTHER|Restricted|Users are restricted to open 1 patient record at a time.
223896442|NCT01956084|DRUG|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
223896443|NCT01956084|DRUG|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
223896444|NCT04722575|DRUG|Cobimetinib 20 MG Oral Tablet|Cobimetinib 60 mg qd p.o. from week 1 to week 3 and week 5 to week 6. Week 4 off.
223896445|NCT04722575|DRUG|Vemurafenib 240 Mg Oral Capsule|960 (arm A) /720 (arm B) mg bid p.o. from week 1 to week 6.
223896446|NCT04722575|DRUG|Atezolizumab 1200 MG in 20 ML Injection|840 mg IV for 2 cycles for Arm B and C. After surgery in all arms 1200 mg IV for 52 weeks
223528487|NCT01511302|DRUG|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
223896447|NCT04788004|OTHER|Online survey|There are no interventions planned for this study. This is an observational study only.
223896448|NCT06822803|BEHAVIORAL|Gardening Nutrition Education Program|This intervention was a 6-week Social Cognitive Theory based, urban gardening, cooking and nutrition education program designed to change health behavior mediators, fruit and vegetable intake, stress, and life satisfaction in food insecure college students.
223896449|NCT06110975|OTHER|deprescribing-intervention|"The clinical guideline on Deprescribing drugs for OAB in The North Denmark Region serves as the basis for the intervention. The guideline provides recommended procedures for the deprescribing process. The guideline offers procedures for the deprescribing process and includes a deprescribing algorithm and a symptom questionnaire designed to evaluate the impact of medications utilized in the treatment of OAB."
223896450|NCT06017544|PROCEDURE|PCI|The T2DM affected by AMI will be referred for receiving PCI.
223528488|NCT04734210|DRUG|0.02% Betamethasone Sodium Phosphate|topical corticosteroid solution
223528489|NCT04734210|DRUG|0.04% Betamethasone Sodium Phosphate|topical corticosteroid solution
223528490|NCT04734210|DRUG|Placebo|topical vehicle solution
223528491|NCT00331721|DRUG|Enecadin|Dose escalating
223528492|NCT00331721|DRUG|Placebo|Placebo comparator
223528493|NCT03699202|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
223528494|NCT03699202|DRUG|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
223896451|NCT03506867|BEHAVIORAL|Life skills, training, education and work/volunteer opportunities|Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).
223896452|NCT03506867|BEHAVIORAL|Standard Care|Usual care will receive information on locally available services.
223896453|NCT02733328|PROCEDURE|CPB Surgery|
223896454|NCT06054776|DRUG|Acalabrutinib|Given PO
223896455|NCT06054776|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223896456|NCT06054776|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsies
223896457|NCT06054776|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
223896458|NCT06054776|PROCEDURE|Echocardiography|Undergo ECHO
223896459|NCT06054776|BIOLOGICAL|Glofitamab|Given IV
223896460|NCT06054776|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223896461|NCT06054776|BIOLOGICAL|Obinutuzumab|Given IV
223896462|NCT06054776|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223896463|NCT04616469|PROCEDURE|Root canal treatment using TruNaomy rotary files|Trunatomy rotary files will be used for the process of cleaning and shaping of the root canal system
224083352|NCT00236080|DRUG|Armodafinil 200 mg|Armodafinil 200 mg/day
224083353|NCT00236080|DRUG|Armodafinil 150 mg|Armodafinil 150 mg/day
223896464|NCT04616469|PROCEDURE|Root canal treatment using race rotary instruments|Race rotary files will be used for the process of cleaning and shaping of the root canal system
223896465|NCT06253130|DRUG|IMP1734|PARP1 selective inhibitor
223896466|NCT06183216|BIOLOGICAL|Sinovac PCV13|0.5 mL dose of Sinovac PCV13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
223896467|NCT06183216|BIOLOGICAL|PREVNAR 13|0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
223896468|NCT04624906|DRUG|Acalabrutinib|100 mg oral capsules twice daily for 1 year
223896469|NCT04624906|DRUG|Bendamustine|90 mg/m2 on days 1 and 2 of each cycle.
223896470|NCT04624906|DRUG|Rituximab|day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
223896471|NCT05147701|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223896472|NCT04921917|OTHER|neoadjuvant exercise therapy|brief exercise regimen completed immediately prior to neoadjuvant radiation therapy. Rubber bands will be used for the exercise training of patients with lower extremity tumors while an electronic hand-held dynamometer will be used for the exercise training for patients with upper extremity tumors.
223896473|NCT05123118|BEHAVIORAL|Integrated intervention of smoking cessation and breastfeeding|The intervention group will receive an integrated intervention of smoking cessation and breastfeeding: education and counseling, monitoring and feedback, and contingent financial incentives.
223896474|NCT05123118|BEHAVIORAL|Attention placebo control|Participants in the control group will receive usual prenatal care from physicians, nurses, or social workers. They will receive best standard care on smoking cessation and breastfeeding, including referral to the New York State Smokers' Quitline and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).
223896475|NCT03301506|DRUG|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group if tolerability issues noted in the previous study.
223896476|NCT03301506|DRUG|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group unless there are tolerability issues.
223896477|NCT06597305|BEHAVIORAL|Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)|Twenty session cognitive behavioral therapy for Anorexia Nervosa (CBT-20-AN) is an treatment for Anorexia Nervosa delivered by a mental health clinician. This treatment (CBT-20-AN) lasts just 20 sessions and has been designed to allow individuals with AN to reap the benefits of CBT for eating disorders (up to 40 sessions) in less time, increasing access to care and shortening time to symptom reduction.
223896478|NCT06918925|DRUG|JUV-161, Placebo|Single-Ascending, Placebo-Controlled
223896479|NCT05144529|DRUG|Nivolumab|Nivolumab IV 240 mg
223896480|NCT05144529|DRUG|Ipilimumab|Ipilimumab IV 1 mg/kg
223896481|NCT05144529|DRUG|Evolocumab|Evolocumab 14 mg subcutaneous injection
223896482|NCT02251548|DRUG|Ibrutinib|Oral BTK inhibitor
223896483|NCT02251548|DRUG|Fludarabine|IV purine analogue chemotherapy agent
223896484|NCT02251548|DRUG|Cyclophosphamide|IV alkylator chemotherapy agent
223896485|NCT02251548|DRUG|Rituximab|IV anti-CD20 monoclonal antibody
223896486|NCT04598230|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants randomized to this arm will receive up to 20 sessions of evidence based cognitive behavioral therapy (CBT) of extended duration, with more exposure tasks and greater family involvement than has been studied in the past.
224276541|NCT06529874|OTHER|Lower limb muscular strength using Lafayette hand held dynamometer|Lower limb muscular ' Isometric quadriceps strength' will be measured for all participants in both groups. each participating child will be instructed to sit to assess the strength of knee extension, which minimize positional changes, and enhance feasibility of this clinical test. then The researcher will apply resistance to child's quadriceps to gain maximal voluntary isometric contraction with pressing the activated Lafayette hand held dynamometer padded stirrup against quadriceps belly, then recorded and documented measured value.
224276542|NCT00851006|DRUG|Creatine Monohydrate|Creapure brand of creatine monohydrate
223896487|NCT04598230|DRUG|Combination therapy (COMB)|Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
223896488|NCT06791265|DEVICE|Guided Eminectomy|The patients will be subjected to computer-guided osteotomy utilizing a virtually preplanned cutting guide
223896489|NCT06791265|PROCEDURE|Free hand Eminectomy|The patients will be subjected to a free-hand Eminectomy utilizing the routine surgical technique
223896490|NCT06930183|DRUG|Awake thoracic epidural anesthesia|Patients will preoperatively receive awake thoracic epidural anesthesia.
223896491|NCT06930183|DRUG|General anesthesia|Patients will receive general anesthesia.
223896492|NCT06845306|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected before anastomosis is created, to quantitatively assess the perfusion status of the bowel.
223896493|NCT06845306|OTHER|Conventional Bowel Anastomosis group|conventional perfusion assessment
223896494|NCT06931184|OTHER|self-sampling|increase screening coverage by self-sampling
223896495|NCT06835777|COMBINATION_PRODUCT|Positive Expectation|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance enhancing neurostimulant,. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance enhancing qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.
223896496|NCT06835777|COMBINATION_PRODUCT|Negative Expectation|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about the deceptive substance, presenting it as a performance inhibiting neuro-depressant. Participants will be given the opportunity to ask questions and will receive a handout of the key points of the presentation. After the presentation, participants will be set up with a high-density EEG and given two inert pills filled with cornstarch. Participants will be reminded of the performance inhibiting qualities of the deceptive substance by implicit adjectives on a screen. Afterwards, experimental performance outcomes will be collected using a dynamometer.
224083354|NCT00236080|DRUG|Placebo|Matching placebo tablets
223896497|NCT06835777|OTHER|Control|The lead researcher will deliver a short presentation (8 minutes) to participants informing them about EEG research and set ups and give general information about isometric strength testing. They will be shown neutral adjectives unrelated to performance instead of implicit adjectives related to performance (experimental groups). EEG set up and strength testing remains the same as the experimental groups.
223896498|NCT06843954|DRUG|Bevacizumab|bevacizumab (7.5mg/kg every 21 days) for minimum of 3 cycles
223896499|NCT04421066|PROCEDURE|Gingival and bone sample collection|Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.
223896500|NCT04421066|PROCEDURE|Healthy individuals|Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
223896501|NCT02674295|DRUG|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
223896502|NCT02674295|DRUG|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
223896503|NCT06202651|DEVICE|Nd:YAG Laser|"Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure."
223896504|NCT05969080|BEHAVIORAL|Treatment for Self-Injurious Behaviors|Treatment for Self-Injurious Behaviors (T-SIB) incorporates evidence-based approaches to replace NSSI with behaviors that improve psychosocial functioning.
223896505|NCT05969080|OTHER|Treatment As Usual|Participants randomized to the TAU condition will be provided with referrals to both Durham VA and local community mental health resources and offered a consult for Durham VA mental health services.
223896506|NCT05688956|DIETARY_SUPPLEMENT|Fortimel Advanced, Nutricia|Per 200 mL serving size: 300 kcal, 21 g whey protein, 3 g leucine \& 10 µg Vitamin D.
223896507|NCT05688956|OTHER|Resistance Exercise programme|Participants will participate in the resistance-based exercise programme twice a week for 12-weeks via Zoom. Each session will last between 45-60 minutes with 2-3 sets and 8-12 reps, twice a week for the 12 weeks.
223896508|NCT05688956|OTHER|Dietary advice|Standard dietary advice to increase intake of protein, leucine and vitamin D using available literature designed for those at risk of malnutrition will be provided to both groups by the research nutritionist. Literature provided will include booklets containing lists of foods high in protein, leucine and vitamin D plus easy-to-prepare meal ideas. The dietary advice provided will be informed by the 24-hour dietary recall information obtained from each participant.
223896509|NCT06295328|DRUG|Terbinafine|terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
224083355|NCT03882424|BIOLOGICAL|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
224083356|NCT03882424|BIOLOGICAL|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
224083357|NCT03882424|BIOLOGICAL|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
224083358|NCT01214044|DRUG|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
224083359|NCT05709808|OTHER|Kinesio-taping|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance
224083360|NCT05709808|OTHER|exercises|A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
224083361|NCT05709808|OTHER|mixed kinesiotape plus exercises|kinesiotape is a method of taping used to improve support and increase proprioceptive awareness of the joint, while the exercise program was designed to improve postural stability and balance. A standard proprioceptive training program will be implemented three times a week. The training includes both static and dynamic balance on Wobble board with the eyes open while the last stage will be repeated with the eyes closed.
223896510|NCT06295328|DRUG|Placebo|Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.
223896511|NCT06295328|DRUG|Tenofovir|Tenofovir 245mg standard of care
223896512|NCT02722525|PROCEDURE|Magnetic Resonance Imaging|Undergo treadmill stress CMR
223896513|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete treadmill exercise
223896514|NCT02722525|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
223896515|NCT02722525|BEHAVIORAL|Exercise Intervention|Complete resistive lower extremity exercise
223896516|NCT02722525|PROCEDURE|Spectroscopy|Undergo skeletal muscle PMRS
223896517|NCT02722525|OTHER|Laboratory Biomarker Analysis|Correlative studies
223896518|NCT02908477|RADIATION|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
223896519|NCT02908477|DRUG|Docetaxel|15 mg/m2. Experimental arm only.
223896520|NCT02908477|DRUG|Cisplatin|40 mg/m2. Standard arm only.
223896521|NCT02140554|GENETIC|lovo-cel|lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
223896522|NCT05590403|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose administered intramuscularly at Day 1.
223896523|NCT05590403|DRUG|Placebo|One dose administered intramuscularly at Day 1.
224083362|NCT01056445|PROCEDURE|valsalva maneuver|valsalva maneuver after carotid stenting
224083363|NCT01056445|PROCEDURE|valsalva maneuver|valsalva maneuver after carotid stenting
224276543|NCT00003751|DRUG|penicillamine|
224276544|NCT00003751|RADIATION|radiation therapy|
223896524|NCT04838418|PROCEDURE|Optic nerve sheath diameter measured by transorbital ultrasound|Optic nerve sheath diameter measured 3 mm behind eyeball. For every eyeball 2 measurements in axial and 2 measurements in sagital projections are performed. Summary value for every eyeball is arithmetic mean from these 4 measurements.
223896525|NCT06315855|BEHAVIORAL|Telehealth Intervention (THI)|The THI is a 6-month intervention. On a monthly basis, the survivor will be queried via telehealth (zoom or smart phone) oral and health related symptoms by nurse practitioner or navigator. Based on the initial imaging and the monthly assessments, the patients will be provided with tools and instructions for oral health maintenance which may consist of mucositis management and/or diet and lifestyle counseling. All participants will be provided a Resource directory that is to be used to identify a dentist that is best suited for him/her. Post intervention, follow-up assessments will be conducted at 6-, 9- and 12-months post randomization.
223896526|NCT05659537|DRUG|Dulaglutide|Administered SC
223896527|NCT05720546|OTHER|Baseline Survey|A survey that measures participant satisfaction will be offered to participants during infusion at baseline.
223896528|NCT05720546|OTHER|Semi-structured interviews|Semi-structured interviews will be conducted in the same infusion spaces.
223896529|NCT05720546|OTHER|Follow-up Survey|A survey that measures participant satisfaction will be offered to participants during following infusion.
223896530|NCT05988684|DRUG|Metformin|Patients randomized to metformin group will be instructed to take 500 mg metformin daily for 1 week before titrating up to twice a day
223896531|NCT04503551|DRUG|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
223896532|NCT04503551|DRUG|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
223896533|NCT04871191|DRUG|Rituximab|375 mg/m²/week for four consecutive weeks (Week 0, 1, 2 and 3) Maintenance rituximab at a fixed dose of 500 mg will be administered at week 24 and at week 52.
223896534|NCT04871191|DRUG|Tocilizumab|Subcutaneous injection of 162 mg per week
223896535|NCT04871191|DRUG|Tofacitinib|\- Tofacitinib, administered orally at a dose of 5 mg twice a day. Tofacitinib will start at week 0. Treatment will be continued until week 52
223896536|NCT06221800|DIAGNOSTIC_TEST|Microbiome|Stool and saliva samples will be collected
223896537|NCT03715738|OTHER|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
223896538|NCT06331182|DRUG|Ketamine|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml ketamine (50 mg) after induction of general anesthesia.
223896539|NCT06331182|DRUG|Dexmedetomidine|Patients will receive external oblique intercostal plane block using 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg after induction of general anesthesia.
223896540|NCT06331182|DRUG|Bupivacaine|29 ml bupivacaine 0.25%
223896541|NCT05289414|DEVICE|Radiofrequency on mid cervical medial branches|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency on mid cervical medial branches
223896542|NCT05289414|DEVICE|Radiofrequency|patients with diagnosis of cervicogenic headache will be subjected to radiofrequency on Greater occipital nerve
223896543|NCT06425068|DEVICE|Exposure of the patient to a novel air mattress.|"see information provided in the Arms section (experimental)"
223896544|NCT06425068|DEVICE|Exposure of the patient to a conventional foam mattress.|"see information provided in the Arms section (active comparator)"
223896545|NCT05200104|DRUG|PXL065|PXL065 22.5 mg QD
223896546|NCT06016920|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) starting at Week 1/Day 1 during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 48. A total of up to 10 i.m. administrations will be given.~VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
223896547|NCT06016920|DRUG|Pembrolizumab|"Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes."
223896548|NCT05605587|DRUG|Leflunomide 20 mg|once daily for 6 months
223896549|NCT03984201|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
224083364|NCT04255667|PROCEDURE|Eyelid margin crush|after marking eyelid , hemostat is used for eyelid margin incision crush . Then eyelid surgery is done
224083365|NCT00602355|DRUG|Sertraline|"Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care."
224083366|NCT00602355|DRUG|Placebo|"Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline."
224276545|NCT02320162|BEHAVIORAL|Experiential learning oral health education|
224276546|NCT04238546|DEVICE|sirolimus-coated balloon catheter|angioplasty with sirolimus-coated balloon catheter
224276547|NCT04238546|DEVICE|uncoated balloon catheter|angioplasty with uncoated balloon catheter
223896550|NCT06192316|BEHAVIORAL|3x3 between-subjects experimental exposure|"Participants will be randomly assigned to conditions in a 3 (Nicotine Concentration: None on label, Low, High) x 3 (Nicotine Source Claim: None, Tobacco Free, Synthetic Nicotine) between-subjects design. We will stratify randomization by young adult susceptible non-users and adult tobacco users for balance across the conditions. Participants will view 16 oral nicotine pouch pack images in random order that correspond to the nicotine concentration and source claim condition they are randomized to. Within each condition, pack images will vary by 4 brands and 4 flavors per brand. While viewing the images, we will collect psychophysiological data including heart rate, galvanic skin response, and eye tracking."
223896551|NCT04265625|DEVICE|endoscopic guidance|Percutaneous tracheotomy performed by endoscopic guidance
223896552|NCT05114616|DEVICE|NextSense EEG-enabled earbuds|Each NextSense EEGBud device comes with a universal-fit and/or custom-fit earmold with biometric sensors to detect the EEG, motion (via tri-axial accelerometers), and heart rate. The custom mold is created employing a 3D printer following capture of the geometry unique to each patients' ears with a ring laser scanner to an accuracy of within 0.1 mm. This design process allows for a custom fit and therefore both comfort and complete, consistent contact with the inner surface of the ear canal, providing high quality capture of signals reflecting brain activity, and head, and eye movements. In addition to the custom fit earmold, universal fit earmolds are available as well. The universal fit earmolds were designed also to allow for comfort and consisten contact with the inner surface of the ear canal to provide high quality signal capture of brain activity, and head and eye movements.
223896553|NCT05114616|DEVICE|Ellcie Healthy Glasses|Ellcie Healthy glasses frames are embedded with multi-modal sensors for measuring eye movements, head movement, and ECG.
223896554|NCT02694809|DRUG|Conjugated Estrogens/Bazedoxifene|Given PO
223896555|NCT02694809|OTHER|Laboratory Biomarker Analysis|Correlative studies
223896556|NCT02694809|OTHER|Pharmacological Study|Correlative studies
223896557|NCT02694809|OTHER|Placebo|Given PO
223896558|NCT02694809|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223896559|NCT02694809|OTHER|Questionnaire Administration|Ancillary studies
223896560|NCT03085316|DEVICE|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
223896561|NCT06244810|DEVICE|Lingual retainer from Fiber|lingual retainer manufactured from fiber using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
223896562|NCT06244810|DEVICE|Lingual retainer from metal|lingual retainer manufactured from metal using CAD-CAM technique applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
223896563|NCT06244810|DEVICE|Traditional retianer from braided|lingual retainer manufactured using traditional technique from stainless steel applied to the lingual surfaces of the mandibular incisors and evaluated every month over a period of 6 months.
223896564|NCT06641895|GENETIC|BBM-D101|BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
223896565|NCT06638567|OTHER|Basal bolus insulin regimen|Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
223896566|NCT04205968|DRUG|Fluorouracil|Given IV bolus or IV
223896567|NCT04205968|DRUG|Irinotecan|Given IV
223896568|NCT04205968|DRUG|Irinotecan Hydrochloride|Given IV
223896569|NCT04205968|DRUG|Leucovorin|Given IV
223896570|NCT04205968|DRUG|Leucovorin Calcium|Given IV
223896571|NCT04205968|DRUG|Paclitaxel|Given IV
223896572|NCT04205968|BIOLOGICAL|Ramucirumab|Given IV
223896573|NCT06488365|DEVICE|Cytophone|"The Cytophone clinical prototype incorporates two pulse lasers, optical system for delivery of laser light to the skin, ultrasound transducer array and detection electronics for acquisition of acoustic waves from CTCs.~Parameters of lasers:~C-Wedge 1064 (Bright Solutions, Cura Carpignano (PV), Italy): Wavelength,1064 nm; pulse width, 0.6 ns; pulse rate: 1 kHz; pulse energy, 240 μJ.~C-Wedge 18901 (Bright Solutions, Cura Carpignano (PV), Italy):~Wavelength, 770 nm; pulse width 3 ns; pulse rate, 1 kHz; pulse energy, 240 μJ. Detection of acoustic waves from CTCs is performing by a focused ultrasound transducer array placed in an acoustic contact with the skin of the subject with ultrasound gel. The signals from the transducers are amplified with a 16 channel amplifier, then digitized by a 12-bit, 500 MSPS high speed board digitizer (ATS9350, AlazarTech, Canada). This information is then transferred to a data recording system using a secure computer."
223896574|NCT06308497|OTHER|Probiotic Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day Probiotic supplementation with daily assumption of Limosilactobacillus Reuteri Prodentis® tablet (PerioBalance, Gum®)
223896575|NCT06308497|OTHER|Standard Treatment|Professional in-office debridement every 3 months Use of soft-picks® advanced interdental cleaners (Gum®) followed by toothbrushing with ActiVital toothpaste (Gum®) with coenzyme Q10 and sonic daily electric toothbrush (Gum®) twice a day
223896576|NCT05937152|DRUG|Eptinezumab|Intravenous (IV) infusion of 300 mg
223896577|NCT05937152|DRUG|Placebo|Intravenous (IV) infusion of placebo (looks exactly like the study drug, but it contains no active ingredients)
223896578|NCT06181006|DRUG|Pirtobrutinib|Administered orally.
223896579|NCT06640049|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223896580|NCT06257485|DIAGNOSTIC_TEST|99mTc-pyrophosphate Single Photon Emission Computed Tomography|All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
223896581|NCT03701399|DRUG|troriluzole|Administered orally
223896582|NCT03701399|DRUG|Placebo|Administered orally
223896583|NCT06644157|DEVICE|Laser Néo Élite|One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
223896584|NCT05384496|DRUG|Nivolumab and/or Ipilimumab|Combination of nivolumab 3mg/kg IV every 3 weeks with ipilimumab 1mg/kg or nivolumab 480mg IV every 4 weeks as monotherapy is considered standard of care for patients with unresectable locally advanced or metastatic mucosal melanoma.
223896585|NCT05384496|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT upon local or oligometastatic progression. The prescribed dose of SBRT will be 30 Gy in 5 fractions.
223896586|NCT05384496|DRUG|axitinib|5mg twice daily
223896587|NCT05494723|DRUG|YB-1113|Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)
223896588|NCT06645145|BEHAVIORAL|Orthographic facilitation|Half of participants will receive orthographic support (text support) while learning new verbs. The investigators will compare learning with and without text support to determine if this aids verb learning.
223896589|NCT05586997|DEVICE|Bonded-Hyrax|The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars
223896590|NCT05586997|COMBINATION_PRODUCT|Bonded Rapid Maxillary Expansion and low-Level Laser therapy|Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
223896591|NCT06224764|OTHER|Mother and Father questionnaires|Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
223896592|NCT03866525|BIOLOGICAL|OH2 injection, with or without irinotecan or HX008|OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody
223896593|NCT03905005|PROCEDURE|Mandibular reconstruction with free tissue transfer.|Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).
223896594|NCT05347693|DRUG|Sodium Zirconium Cyclosilicate (SZC)|"White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language."
223896595|NCT05347693|DRUG|Local standard of care|Local SoC in the country to be used as per local label
223896596|NCT04895631|DRUG|18F-Fluorocholine|One-time injection of 4-7 millicurie (mCi)
223896597|NCT04895631|PROCEDURE|Positron emission tomography (PET)|Imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities
223896598|NCT06150326|DEVICE|medical honey Activon® 25g Tube|no blinding procedures will be set up for the adminisration of the treatement
223896599|NCT06150326|DEVICE|standard of care|no blinding procedures will be set up for the adminisration of the treatement
223896600|NCT05511909|DRUG|Buspirone|Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
223896601|NCT05511909|DRUG|Lofexidine|Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
223896602|NCT05511909|DRUG|Placebo|Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
223896603|NCT06532994|OTHER|Early rehabilitation intervention|"Based on the indications for early rehabilitation intervention outlined in the Chinese Expert Consensus on Neurological Critical Care Rehabilitation, early rehabilitation interventions are categorized into three stages according to the patient's consciousness level (GCS score), degree of cooperation (S5Q score), and sedation status (RASS score)"
223896604|NCT04342494|BEHAVIORAL|Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback."
223896605|NCT04342494|DEVICE|Headspace app + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Headspace is an app designed to train the user in mindfulness practices."
223896606|NCT04342494|DEVICE|Headspace app + Enhanced Feedback + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Headspace is an app designed to train the user in mindfulness practices."
223896607|NCT04342494|DEVICE|SilverCloud + Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
223896608|NCT04342494|DEVICE|SilverCloud app +Enhanced Feedback +Standard Feedback|"Standard Feedback (SF) All participants will receive the standard feedback that is standard feedback from the activity trackers. Feedback includes activity level, heart rate, and progress toward daily activity goals on the device itself.~Enhanced Feedback (EF) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Feedback will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual feedback.~Silvercloud is an app designed to deliver cognitive behavioral therapy."
223896609|NCT04700878|BEHAVIORAL|Internet-based compassion course for stress managemant|A five week long, structured self-help program with weekly reports to, and feedback from a compassion-focused (CFT) therapist over the Internet. Includes traditional CFT-methods for stress-related problems.
223896610|NCT04700878|BEHAVIORAL|General Internet-based cognitive behavioural course for stress management|A five week long, structured self-help program with weekly reports to, and feedback from a cognitive-behavioral (CBT) therapist over the Internet. Includes traditional CBT-methods for stress-related problems.
223896611|NCT05119023|BEHAVIORAL|SRT Observational Learning|All participants completed a computer-based serial response time (SRT) task intended to measure observational (implicit) learning ability. The SRT Observational learning task is a classic paradigm, which has been integral to the understanding of implicit learning (see Schwarb \& Schumacher, 2012). The current task is a replication of classic SRT tasks first described by Nissen and Bullemer (1987), adapted for eye-tracking by Kinder et al. (2008). In this task, participants look at a dot move from one of 4 positions on a computer screen. Unbeknownst to participants, dot movement followed a 12-movement pattern for most experimental blocks. Eye-tracking data is collected and eye fixations within regions of interest trigger trial advancement. Learning ability is evaluated as a comparison of saccadic response times during sequenced trials relative to pseudorandomized trials.
223896612|NCT05119023|BEHAVIORAL|AGL Observational Learning|All participants completed a computer-based observational artificial grammar learning (AGL) task. The AGL Observational learning task is another classic test of implicit learning involving learning of ordered items through exposure (Schuchard \& Thompson, 2017). Artificial grammars contain hierarchal dependencies, similar to the rules that govern word-order and syntax in natural language. In this task, participants look at sequences of geometric shapes on a computer screen. Participants judged if two sequences matched or did not match. After training, participants are shown sequences and must judge if sequences adhere to the pattern or not.
223896613|NCT05119023|BEHAVIORAL|AGL Rule-based Learning|All participants completed a computer-based rule-based learning task intended to measure rule-based (explicit) learning ability of an artificial grammar expressed in nonlinguistic form (sequences of shapes). In this task, participants look at sequences of geometric shapes on a computer screen. Through visuals and verbal instruction, they are taught 5 rules that govern sequences. After learning rules, participants are asked to judge via button press whether novel sequences adhere to rules or not.
223896614|NCT05119023|BEHAVIORAL|Standardized cognitive-linguistic assessment|Participants completed standardized cognitive-linguistic assessments that evaluate their ability to produce and understand language and evaluate cognitive skills of attention, executive function and working memory important for learning. Tests involve paper and pencil, looking at pictures, listening to words, indicating responses on a keyboard and talking.
223896615|NCT05119023|OTHER|Brain imaging|Enrolled participants who were safe to scan via magnetic resonance imaging (MRI) completed a structural MRI scan between one-month and five months from behavioral testing of learning.
223896616|NCT05944289|BEHAVIORAL|Acceptance and Commitment Therapy|a four-week workshop based on the principles and procedures of Acceptance and Commitment Therapy
223896617|NCT05944289|BEHAVIORAL|Caregiver Support Group|Caregiver support group to run parallel to the ACT intervention group.
223896618|NCT04816851|PROCEDURE|OZAKI technique|an alternative way of repairing aortic valve, involving the use of autologous pericardium for the aortic leaflet reconstruction. Diseased leaflets are removed carefully. The distance between each commissure is measured with invented sizing apparatus. The new leaflet of the size corresponding to the measured value is trimmed with an original template from glutaraldehyde-treated autologous pericardium. Finally, the annular margin of the pericardial leaflet was running sutured with each annulus. Commissural coaptation was secured with additional sutures. The coaptation of three new leaflets were always insured with direct vision.
223896619|NCT06156163|OTHER|Perturbation training|The exercise program will be applied 2 days/week for 8 weeks, with the addition of progressive perturbation conditions.
223896620|NCT06156163|OTHER|Exercise|The exercise program will be applied 2 days/week for 8 weeks.
223896621|NCT03153410|DRUG|Cyclophosphamide|"200 mg/m\^2, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
223896622|NCT03153410|DRUG|GVAX Pancreas Vaccine (GVAX)|"5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
224083367|NCT00602355|BEHAVIORAL|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
224083368|NCT00602355|BEHAVIORAL|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
224083369|NCT00602355|BEHAVIORAL|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
224083370|NCT02471157|OTHER|Observation|
224083371|NCT02772757|BEHAVIORAL|standard hearing aid fitting|standard hearing aid, face-to-face fitting
224083372|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using average RECDs
224083373|NCT02772757|BEHAVIORAL|coupler-based fitting|coupler-based fitting using measured RECDs
223896623|NCT03153410|DRUG|Pembrolizumab|"200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
223896624|NCT03153410|DRUG|IMC-CS4|"75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle."
223896625|NCT04976660|DRUG|TT-4|TT-4 orally administered QD starting at 200 mg and will be increased to 800 mg (dosing may be increased to BID, if appropriate based on emerging safety, PK or PD data).
223896626|NCT04817735|PROCEDURE|TAVI|TAVI sizing with dedicated algorithm
223896627|NCT03408340|PROCEDURE|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
223896628|NCT03408340|DRUG|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
223896629|NCT05915988|DEVICE|UNEEG EpiSight solution|Implantation subcutis under local anesthetics
223896630|NCT05415501|BEHAVIORAL|Sentence training|Participants will be trained to read, make, and recall sentences during each session.
223896631|NCT06798727|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
223896632|NCT06798727|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
223896633|NCT06798727|DRUG|High Hyal Plus|A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)
223896634|NCT06051695|BIOLOGICAL|A2B694|Autologous logic-gated Tmod CAR T cells
223896635|NCT06051695|DIAGNOSTIC_TEST|xT CDx with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
223896636|NCT06800365|DEVICE|Sensor|The FreeStyle Libre Pro sensor is a device whereby a sensor is inserted into subcutaneous tissue (upper arm) and measures the interstitial blood glucose which is then available for later download. It comes pre-calibrated meaning that no fingerstick glucose monitoring is required to improve accuracy of the sensor.
223896637|NCT00131703|DRUG|Amodiaquine|
223896638|NCT00131703|DRUG|Sulphadoxine-pyrimethamine|
223896639|NCT00131703|DRUG|Chloroquine|
223896640|NCT02838381|OTHER|Additional biological samples|blood and tissue samples
223896641|NCT04806451|DRUG|Crinecerfont|CRF type 1 receptor antagonist
223896642|NCT04806451|DRUG|Placebo|Non-active dosage form
223896643|NCT06801392|PROCEDURE|pulsed-field ablation|PVI + PW ablation
223896644|NCT04893278|OTHER|Virtual reality|Use of Virtual reality goggles during procedure
223896645|NCT06699433|BEHAVIORAL|Virtual standardized patients (VSPs)|Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases
223896646|NCT06699433|BEHAVIORAL|Case teaching manuals|Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases
223896647|NCT06699433|BEHAVIORAL|Case teaching videos|Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
223896648|NCT06517680|OTHER|tight control management|Patients will be seen every month for the first 3 months of follow-up During these consultations, shoulder pain and function will be assessed. Treatment adjustments (steroid injections, drugs and physiotherapy) will be proposed in line with predefined objectives.
223896649|NCT06517680|OTHER|standard follow-up|Patients are monitored according to standard practice
223896650|NCT06801301|DEVICE|whole body vibration|Standing in different static positions or exercising on a vibrating platform.The mechanical stimuli of vibration transmitted to the body and stimulate muscle spindles which activate the alpha motor neurons and initiates muscle contractions comparable to the ''tonic vibration reflex. The effect of WBV on the neuromuscular properties of skeletal muscles and spinal mechanisms is demonstrated by a decreased electromechanical delay.
223896651|NCT06801301|OTHER|Resistance Exercise|Resistance training as a mode of exercise to promote several health benefits, including improvements in the muscle mass and strength of healthy adults.Resistance training, where muscles are required to contract against an opposing load, has been shown to be a beneficial form of rehabilitation in clinical populations prone to muscle wasting, providing stimuli to increase protein synthesis and muscle mass.
223896652|NCT04705623|BEHAVIORAL|Iyengar Yoga|Weekly 90 minute Iyengar Yoga classes taught y a professional instructor. Twice weekly 45 minute self practice of Iyengar Yoga at home by the participants
223896653|NCT03530774|DIETARY_SUPPLEMENT|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
223896654|NCT03530774|DIETARY_SUPPLEMENT|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
223896655|NCT05796739|DIAGNOSTIC_TEST|Non-invasive stress test|Nuclear imaging, stress echocardiography, exercise electrocardiography, stress cardiac magnetic resonance imaging
223896656|NCT05796739|DIAGNOSTIC_TEST|Medical treatment without further testing|Optimal medical treatment for primary prevention.
223896657|NCT05835336|DEVICE|VIZO Glasses|Eyeglasses with personalized peripheral retinal stimuli
223896658|NCT05303090|DRUG|H101|H101 intratumorally injection starts at day 0.
223896659|NCT05303090|DRUG|Tislelizumab|Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223896660|NCT05303090|DRUG|lenvatinib|lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223896661|NCT06801925|PROCEDURE|GPT-4o and RAG Voice Chatbot for PHQ-9 Screening|"This study involves the use of a voice-based chatbot powered by GPT-4o and Retrieval-Augmented Generation (RAG) to conduct depression screening using the Patient Health Questionnaire-9 (PHQ-9).~The chatbot aims to evaluate the feasibility and acceptability of using AI-powered conversational tools for mental health screening.~Participants interact with the chatbot in a single session, answering PHQ-9 questions and receiving responses generated using GPT-4o and RAG technologies."
223896662|NCT02719314|DRUG|Glucocorticoid treatment|Glucocorticoid treatment
223896663|NCT06224725|OTHER|dietary acrylamide exposure measured via biomarkers in blood (hemoglobin adducts of acrylamide and glycidamide)|Each of two acrylamide biomarkers will be modeled as continuous (per 10 pmol/g increment) and in categories (tertiles or quartiles) to assess potential nonlinear dose-response.
223896664|NCT06800417|DEVICE|Percutaneous fixation by internal cemented screw (InnoFix®)|Percutaneous fixation by internal cemented screw
223896665|NCT06453616|BEHAVIORAL|Hello bundle|"Hello Bundle comprises : posters, email reminders, morning huddles, hello jar, hello board and a led example.~Participants will have to fill out a questionnaire before and after the intervention.~The main components of the questionnaire include respondent's characteristics, visitation policies, team-family interactions, family-centeredness (VAS), and practices at the end of life. ICU-conflicts (VAS), symptoms of burnout, and a VAS to rank the ethical climate, satisfaction with work, and intent to leave the job. Symptoms of burnout will be measured using the validated version of the 22-item Maslach Burnout Inventory (MBI, Human Services version)"
223896666|NCT04289870|DEVICE|Trillium™|Trillium™ Stent Graft for Functional Tricuspid Valve Replacement
223896667|NCT05076279|PROCEDURE|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
223896668|NCT03197571|BIOLOGICAL|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223896669|NCT03197571|BIOLOGICAL|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
223896670|NCT03197571|DRUG|capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223896671|NCT03197571|DRUG|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223896672|NCT03197571|DRUG|cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223896673|NCT03197571|DRUG|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223896674|NCT03197571|DRUG|fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
223896675|NCT03197571|DRUG|leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223896676|NCT03197571|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223896677|NCT03197571|DRUG|Lovaza|Omega-3-acid ethyl esters
223896678|NCT03197571|RADIATION|Stereotactic Body Radiation Therapy|(SBRT)
223896679|NCT03197571|BIOLOGICAL|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
223896680|NCT03197571|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
223896681|NCT03197571|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine
223896682|NCT03197571|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223896683|NCT03197571|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
223896684|NCT03197571|BIOLOGICAL|GI-4000|RAS yeast vaccine
223896685|NCT03197571|BIOLOGICAL|GI-6207|CEA yeast vaccine
223896686|NCT03197571|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223896687|NCT03197571|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
223896688|NCT06800703|BEHAVIORAL|follow up interviews for 12 months to determine opioid use|Follow-up
223896689|NCT06801184|BIOLOGICAL|Plasma Sample|A peripheral venous blood sample will be collected on the day of the inclusion consultation and during the follow-up consultation at V2. These samples will be collected in a single2 tubes (4 mL and 5 mL)l tube and will be taken simultaneously with routine blood samples, which require 2 tubes (10 3 mL and 4 mLl).
224276548|NCT05626387|DRUG|Mycophenolate Mofetil plus prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms. Mycophenolate mofetil (MMF) is an immunosuppressive drug that acts by inhibiting the proliferation of T-lymphocytes and suppressing the recruitment of lymphocytes and monocytes into the sites of inflammation.
223896690|NCT06801184|BIOLOGICAL|Stool Sample|Approximately 1 gram of stool will be collected by the patient at home within 72 hours following the inclusion consultation and the follow-up consultation at V2, using the kits provided along with the instructions. The stools will be immediately collected into two tubes: one tube with nucleic acid preservative and one tube conservative to ensure for future metabolomic analyses. The patient will then send the sample using the pre-paid envelope included in the kit to the HCL microbiota biobank (CRB GHN) for aliquoting and storage at -80°C.
223896691|NCT06226662|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
223896692|NCT06226662|DRUG|Placebo|Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
223896693|NCT06245369|BEHAVIORAL|learning modules (within app)|"Behavioral:~Participants will have access to a weekly learning module created as Kahoot courses. Each module will include some or all (as applicable) of the following:~* A brief educational video discussing the week's topic~* A brief video sharing ideas for applying the educational content into daily life~* PDF of meal swap examples~* A weekly goal or challenge~* Recipes"
223896694|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Experimental|"Behavioral:~Diet (track by in app database). App homepage displays dietary intake graph -circles -. Participants will see an empty circles for the goal nutrients at the start of each day, which will fill up as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely full."
223896695|NCT06245369|BEHAVIORAL|SWITCH app (self-regulation features) - Comparator|"Diet (track by in app database). App homepage displays dietary intake graph -circles -.~Participants allocated to the control group, tracking intake of nutrients to lower, will see a full circle at the start of each day which depletes, or empties, as the participant tracks his/her food intake. If the participant consumes an excess beyond the nutrient intake goal, the circle will remain entirely empty and the reported totals below the intake circles will display the current intake totals."
223896696|NCT06802042|OTHER|Intervention with probiotic bacteria|The intervention group (n=20) received free intervention with probiotic bacteria (Lactobacillus reuteri DSM 8 +) for 4 weeks (1 bag bid)
223896697|NCT06802042|DRUG|Lactulose oral solution treatment|The control group (n=20) received lactulose oral solution free of charge for 4 weeks (1-2 bags qd for the first three days, and then increased or reduced according to constipation)
223896698|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns with retention grooves|Zirconia-based primary anterior crowns with retention grooves
223896699|NCT06354647|PROCEDURE|Zirconia-based primary anterior crowns without retention grooves|Zirconia-based primary anterior crowns without retention grooves
223896700|NCT06801353|BIOLOGICAL|Stapokibart|Stapokibart subcutaneously every two weeks
223896701|NCT06801353|DRUG|Mometasone Furoate Nasal Spray (MFNS)|mometasone furoate nasal spray 200 μg once daily
223896702|NCT05191472|BIOLOGICAL|Pembrolizumab|Given IV
223896703|NCT06039176|DEVICE|HeartMate 3 (R) left ventricular assist device|No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
223896704|NCT05910164|DEVICE|PELGRAZ prefilled syringe or PELGRAZ prefilled pen|PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz
223896705|NCT02648997|DRUG|Nivolumab - 240 mg|240 mg every 2 weeks
223896706|NCT02648997|DRUG|Ipilimumab - 1 mg/kg|1 mg/kg every 3 weeks
223896707|NCT02648997|DRUG|Nivolumab - 480 mg|480 mg once every 4 weeks
223896708|NCT02648997|DRUG|Nivolumab - 3 mg/kg|3 mg/kg every 3 weeks
223896709|NCT02648997|RADIATION|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
223896710|NCT05513716|OTHER|Retrospective tissue sample analysis|Archival formalin-fixed, paraffin-embedded (FFPE) tumour tissue from colorectal cancer peritoneal metastasis and paired primary tumours, where available - taken as standard care
223896711|NCT06206291|DRUG|Placebo|Matching placebo twice daily for first 4 weeks
223896712|NCT06206291|DRUG|Cannabidiol (CBD) 200mg|First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
223896713|NCT06206291|DRUG|Cannabidiol (CBD) 400mg|Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
223896714|NCT06799221|BIOLOGICAL|Out-of-specification obecabtagene autoleucel|Out-of-specification (OOS) obecabtagene autoleucel (obe-cel) given as a split-dose infusion based on tumor burden assessment at lymphodepletion according to the United States prescribing information.
223896715|NCT05888870|DRUG|SCT800 and Daratumumab|SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
223896716|NCT05888870|DRUG|SCT800|SCT800 50IU/kg TIW alone
224276549|NCT05626387|DRUG|Prednisolone|Prednisolone is a glucocorticoid that suppresses inflammation by several mechanisms.
224276550|NCT00527917|DEVICE|placebo|bladder instillation
223896717|NCT03003572|OTHER|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
224276551|NCT00527917|DEVICE|Uracyst|20 ml sterile solution for weekly intravesical instillation
223896721|NCT04719390|BEHAVIORAL|Text Message|"Maternal-Focused Message: When randomized to receive a maternal-focused message, participants will receive a message that is focused on the transition to motherhood and the joys and challenges of caring for a newborn.~Drinking-Focused Message:~When randomized to receive a drinking-focused message, participants will receive a message that is focused on reducing alcohol use.~All messages of both types are designed to map onto behavior change techniques that are empirically supported for alcohol use."
223896722|NCT06300372|PROCEDURE|M-TAPA plane block|As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied bilaterally (60 ml in total).
223896723|NCT06300372|PROCEDURE|Postoperative pain management|For preemptive analgesia, morphine (Morfin ®) 0.05mg/kg and Ibuprofen 400mg IV (Ibuprofen®) will be administered to all patients before the surgical incision. An additional dose of ibuprofen 400mg IV, meperidine (Aldolan ®), and tramadol (Contramal®) 1mg/kg IV will be administered to all patients 30 minutes before wound closure.10 mcg/ml fentanyl containing PCA will be connected to all patients without infusion and boluses 0,35 mcg/kg,15-minute lockout period, maximum 100 mcg per hour. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®)will be administered as a rescue analgesic.
223896724|NCT06410287|OTHER|ArtSpective|ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
223896725|NCT04244214|OTHER|More Stamina|More Stamina is a gamified task organization tool designed to help persons with MS manage their energy, to minimize the impact of fatigue in their day to day life.
223896726|NCT06382155|DRUG|Vosoritide Injection|Experimental Drug Lyophilized powder for reconstitution
223896727|NCT06382155|DRUG|Human Growth Hormone|Commercial product containing somatotropin
223896728|NCT06382155|DRUG|Placebo|Lyophilized powder for reconstitution
223896729|NCT05746455|BEHAVIORAL|Motivation Skills Training (MST)|MST is a weekly group-based skills training intervention that aims to improve knowledge about one's level and sources of motivation, the ability to monitor and regulate (understand and manage) motivation, so that one can better initiate and sustain goal-directed behavior.
223896730|NCT05822414|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be injected at the second thoracic vertebral level for patient undergoing rotator cuff repair surgery
223896731|NCT06475846|DRUG|HRS5580|HRS5580; low dose
223896732|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
223896733|NCT06475846|DRUG|HRS5580|HRS5580; middle dose
223896734|NCT06475846|DRUG|Ondansetron|Ondansetron
223896735|NCT06475846|DRUG|blank preparation|blank preparation.
223896736|NCT05453773|OTHER|Questionnaire Administration|Ancillary studies
223896737|NCT05453773|BEHAVIORAL|Tobacco Smoking|Smoke waterpipe tobacco
223896738|NCT01186224|DRUG|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
223896739|NCT06242821|OTHER|Standard of Care (SOC)|Patients will continue with their current standard of care treatment.
223896740|NCT06242821|OTHER|Yoga|Patients will be randomized to participate in the Yoga intervention. This will consist of online 20 min yoga classes, 2 times per week. The class will be a set protocol, and patients will be given the protocol to do at home if desired.
223896741|NCT03195777|DEVICE|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, \[FDG\] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
223896742|NCT05231187|DIAGNOSTIC_TEST|T2Resistance Panel|"The T2Resistance Panel is an in vitro diagnostic medical device that runs on the T2Dx instrument and detects bacterial markers that are commonly associated with antibiotic resistance. T2Resistance Panel detects thirteen (13) markers of resistance in seven detection channels:~1. blaKPC~2. blaCTX-M~3. blaNDM / blaVIM / blaIMP~4. blaOXA-48 Group~5. vanA / vanB~6. mecA / mecC~7. AmpC (blaCMY / blaDHA)"
223528495|NCT02138825|DRUG|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
223896743|NCT04869449|DRUG|Ketoconazole|400 mg (two 200 mg tablets) orally
223896744|NCT05130762|DEVICE|BD PureHub™ Disinfecting Cap Placements: Attachments/removals|Attachment/Removals of BD PureHub™ Disinfecting Cap
223896745|NCT04988074|DRUG|Cemiplimab|Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
223896746|NCT05594693|OTHER|Questionnaire|Electronic self-report questionnaires before and after integrative interventions, and monthly.
223896747|NCT05594693|OTHER|Physical Exam|Physical measures before and after integrative interventions, and monthly. Thoracic kyphosis will be measured with a non-invasive gravity dependent inclinometer (Isomed Inc.).
223896748|NCT05640115|DEVICE|Ureteral Stent|A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
223896749|NCT05640115|DEVICE|Percutaneous Nephrostomy Tube Placement|A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
223896750|NCT00391365|PROCEDURE|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
223896751|NCT04184375|BEHAVIORAL|cognitive stimulation|"Patients participate in one session per week according to the following schedule:~* 2 sensory stimulation sessions: identify sensations, emotions, how to manage them.~* 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness.~* 2 voluntary attention sessions: improve daily attention.~* 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities.~* 2 sessions of structuring through language: impact on social life.~* 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips."
223896752|NCT03017755|OTHER|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
223896753|NCT04840355|DRUG|Sintilimab Injection|The recommended dose for intravenous infusion is 200 mg on day 1.Courses repeat every 21 days for up to 6 months in the absence of disease progression or unacceptable toxicity.
223896754|NCT02023866|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
223896755|NCT02648542|OTHER|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
223896756|NCT02648542|DEVICE|transcranial direct current stimulation|Low-current electrical brain stimulation
223896757|NCT02648542|OTHER|Combined CAS and tDCS|Combined auditory and electrical stimulation
224083374|NCT04911010|BEHAVIORAL|Prolonged Exposure|In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
223528496|NCT02138825|DRUG|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
223896758|NCT02648542|OTHER|Sham stimulation|Sham stimulation
223896759|NCT06397456|BEHAVIORAL|In-Person Patient Education|In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.
223896760|NCT06397456|BEHAVIORAL|Commitment to Change|Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.
223896761|NCT06397456|BEHAVIORAL|Blood pressure monitoring|Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.
223896762|NCT06397456|BEHAVIORAL|Written Patient Education|Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.
223896763|NCT06397456|BEHAVIORAL|Text-based reinforcement for CKD self-management|Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection
223896764|NCT06397456|BEHAVIORAL|Community-based education session, reinforcement for self-management|"Patient educator will use provide a booster session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection"
223896765|NCT06397456|BEHAVIORAL|Text-based reinforcement for general health self-management|Patient educator will use text messages to send general health management messages
223896766|NCT06170034|BEHAVIORAL|Satisfaction questionnaire|Satisfaction questionnaire to assess how TIA patients feels about their medical care.
223896767|NCT06170034|OTHER|Medical care questionnaire|Recording appointments and results of examinations and consultations in TIA management
223896768|NCT06041867|BIOLOGICAL|Influenza vaccine|Single dose of the Influenza vaccine Participants have to wait until they are invited to receive the vaccine by the general practitioner; this study does not interfere with national planning of the vaccine
223896769|NCT06041867|DIETARY_SUPPLEMENT|Agaricus bisporus capsules|Participants have to consume 10 capsules per day containing 500 mg Agaricus bisporus powder each, corresponding to a total Agariicus bisporus powder intake of 5 g daily
223896770|NCT06041867|DIETARY_SUPPLEMENT|Control capsules|Participants have to consume 10 capsules per day containing 500 mg maltodextrin each, corresponding to a total maltodextrin intake of 5 g daily
223528497|NCT03914690|DRUG|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
223528498|NCT03914690|DRUG|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
223528499|NCT00693758|DRUG|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
223528500|NCT00693758|OTHER|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
224083375|NCT01450176|DRUG|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
223896771|NCT04538274|BEHAVIORAL|peer-driven intervention|Trained patient researchers will conduct 3 motivational sessions, according to the principle of motivational enhancement and cognitive-behavioral therapies, by videoconference meetings of 45 to 60 minutes duration with 5 to 8 patients within 6 months after each patient's inclusion.
223713572|NCT04454294|OTHER|Control|"Common Process Steps:~1. Informed consent forms will be signed by those who wish to take part in the research.~2. The form in which individual characteristics are questioned will be filled.~3. Hands will be washed, gloves will be worn.~4. Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~5. Drains will be kept parallel to the ground and upright.~6. Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~7. It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~8. Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~9. To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery"
223713573|NCT04454294|OTHER|Experimental Group (Absorption Group)|"1. Common process steps~2. Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~   * The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~  * From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~3. Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~4. Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~5. The application will continue without interruption until the patient's drain need and the doctor's request is ended.~6. During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
223713574|NCT04454294|OTHER|Experimental Group (Milking Group)|"1. Common process steps will be applied~2. Operation will start from the area near the drain entrance point~3. Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~4. The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~5. This process will be repeated in the distal part.~6. After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method."
223713575|NCT03628820|BEHAVIORAL|Dog Therapy|5 minutes spent with therapy dog during shift
223713576|NCT03628820|BEHAVIORAL|Coloring|5 minutes spend coloring mandalas during shift
223713577|NCT03678298|OTHER|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
223713578|NCT06770842|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa 2b is administered subcutaneously once every 2 weeks. The dosing will be 250mcg at Week 0, 350mcg at Week 2, 500mcg at Week 4, and 500mcg every 2 weeks thereafter
223713579|NCT05012982|DEVICE|AirBand|The AirBands will be placed at each of the two training sessions and inflated while an ultrasound probe is placed over the femoral artery. The cuff will be inflated until the artery reaches 60% occlusion. The force will be applied using a wireless Bluetooth signal; participants will not be asked to adjust the device. Participants will be observed by a certified Personal Therapist throughout the training session in order to determine compliance and ensure safety as is standard protocol for a physical therapy session.
223713580|NCT05012982|DEVICE|uninflated AirBand|Uninflated AirBand will be used as the control intervention during the session in which BFR is not performed
223713581|NCT05076500|PROCEDURE|Biopsy and blood sample collection|"A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected."
223713582|NCT03961568|DRUG|Cenobamate|active drug
223713583|NCT04480008|BEHAVIORAL|Resilient Living Program|Participants will be given the journal Resilient Living with Dr. Sood: Building Strength for Difficult Days to use throughout the study. The initial session with one of the investigators will be an introduction and a review of Module 1: Gratitude, and will last 30-60min. Three follow-up sessions will occur approximately every two weeks and the participants should view the videos before those virtual meetings (Session 2 will review Module II: Mindful Presence; Session 3 will review Module III: Kindness; Session 4 will review Module IV: Resilient Mindset). The videos will take approximately 30 minutes each to review and virtual sessions will each take 30-60 minutes.
223713584|NCT04249531|DRUG|Amikacin Inhalation Dry Powder|Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
223713585|NCT04249531|DRUG|Amikacin Injectable Product|patient wil receive one dose of 400 mg amikacine intravenously in week 1
223713586|NCT05647460|PROCEDURE|computer guided screw holes locating guide and custom-made plates|"Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa."
223713587|NCT05647460|PROCEDURE|conventional plates|mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
223896772|NCT05743868|BEHAVIORAL|Standardized Dinner|De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
223896773|NCT05743868|BEHAVIORAL|Premeal exercise|DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
224083376|NCT01450176|DRUG|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
224083377|NCT03839108|OTHER|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
223528501|NCT00693758|OTHER|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
224276552|NCT00968019|DEVICE|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
224276553|NCT02569541|DRUG|sodium fusidate|
224276554|NCT01109576|BEHAVIORAL|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
223528502|NCT00693758|DEVICE|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
223528503|NCT00693758|DEVICE|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
223528504|NCT05640427|DRUG|Dexmedetomidine|Groups D1 received general anesthesia with intravenous pump of 0. 2μg/kg/h dexmedetomidine to 30min before the end of the operation.Groups D2 received general anesthesia with intravenous pump of 0. 5μg/kg/h dexmedetomidine to 30min before the end of the operation.
223528505|NCT05640427|DRUG|normal saline|The same capacity of 0.9% normal saline was used in group C
223528506|NCT05539547|DEVICE|Neuromuscular Electrical Nerve Stimulation|"Application of NMES on quadriceps muscle groups bilaterally~Frequency: \>50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days"
223528507|NCT05539547|OTHER|Usual Physiotherapy treatment (Chest Physiotherapy and mobility)|Daily chest physiotherapy and mobility
223528508|NCT01229566|DRUG|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
223528509|NCT03714516|BEHAVIORAL|Psychological internet intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
223528510|NCT04028258|DIETARY_SUPPLEMENT|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
223528511|NCT04028258|DIETARY_SUPPLEMENT|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
223528512|NCT00004128|BIOLOGICAL|aldesleukin|
223528513|NCT00004128|BIOLOGICAL|filgrastim|
223528514|NCT00004128|DRUG|busulfan|
223528515|NCT00004128|DRUG|cyclophosphamide|
223528516|NCT00004128|DRUG|cytarabine|
223528517|NCT00004128|DRUG|daunorubicin hydrochloride|
223528518|NCT00004128|DRUG|etoposide|
223528519|NCT00004128|PROCEDURE|autologous bone marrow transplantation|
223528520|NCT00004128|PROCEDURE|peripheral blood stem cell transplantation|
223528521|NCT00004128|RADIATION|radiation therapy|
223528522|NCT03367104|DEVICE|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
223528523|NCT00909701|DIETARY_SUPPLEMENT|PreOP Booster|1 serving of 400 ml per study arm
223528524|NCT00909701|DIETARY_SUPPLEMENT|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
223528525|NCT00151021|BEHAVIORAL|Tailored web-based walking program|
223528526|NCT02769793|DRUG|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
223528527|NCT02769793|DRUG|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
223528528|NCT03060837|DIAGNOSTIC_TEST|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
223528529|NCT03060837|OTHER|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
223528530|NCT03060837|OTHER|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
223528531|NCT03060837|OTHER|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
223528532|NCT03060837|PROCEDURE|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
223528533|NCT03060837|PROCEDURE|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
223528534|NCT02755961|BEHAVIORAL|Dietary education|
223528535|NCT02755961|BEHAVIORAL|Education on phosphate binder use|
223528536|NCT00577369|OTHER|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
223528537|NCT00781547|DRUG|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
223528538|NCT03493958|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face cognitive behavioral therapy for insomnia (CBT-I) components including sleep restriction, stimulus control, sleep hygiene, cognition
223528539|NCT02229617|DRUG|Subcutaneous testosterone|
223528540|NCT03319641|DIAGNOSTIC_TEST|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
223528541|NCT05656157|DEVICE|Medical device|Clinical decision support system
223528542|NCT02969070|DIETARY_SUPPLEMENT|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
223896774|NCT06205420|DRUG|Injectable composite resin restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and highly filled flowable composite will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
223896775|NCT06205420|DRUG|Injectable giomer restoration|"The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel."
223896776|NCT00454467|PROCEDURE|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
223896777|NCT00454467|PROCEDURE|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
223896778|NCT00454467|PROCEDURE|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
223896779|NCT00454467|PROCEDURE|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
223896780|NCT00454467|PROCEDURE|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
223896781|NCT00454467|PROCEDURE|Cost Data|Cost Data will be collected via hospital billing databases.
223896782|NCT00454467|PROCEDURE|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
223896783|NCT04585594|BEHAVIORAL|Mi Propio Camino (MPC)|The Mi Propio Camino (MPC) intervention will be comprised of four sessions. Session 1 will encompass: the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, introduce MPC personal experience monitoring, and usage the mHealth kit. Subsequently, sessions 2-4 will emphasize the benefits of personal experience monitoring through 1) personal insight (finding what works for them) and 2) empowerment to work with their providers. Session 2 will reinforce this by introducing: synergy between medication and lifestyle, principles of heart-healthy eating and physical activity. Session 3 will incorporate discussion of negative beliefs about medication and patient directed lifestyle learning-rotating stations. Lastly, session 4 will introduce the continuation of personal experience monitoring on their own through the use of behavioral strategies for adherence and provider communication strategies.
223896784|NCT04585594|BEHAVIORAL|Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)|The HCP intervention will be comprised of four sessions and introduce seven lifestyle strategies (LS) subdivided per these sessions. Session 1 will encompass the facts about high blood pressure (BP), understanding blood pressure readings, provide an overview of changes one can make to manage their BP, present specific health threats from high BP, and incorporate LS1: taking control of your medication. Subsequently, sessions 2-4 will reinforce the benefits of taking medications through presenting 1) reduced risk for complications and 2) strategies to remember to take medications. Session 2 will present LS2: eating a well-balanced, low-salt diet and LS3: enjoying regular physical activity. Session 3 will follow with introducing LS4: maintaining a healthy weight and LS5: shaking the salt habit while eating out. Session 4 will present LS6: managing stress and LS7: working together with their doctor followed by a review of strategies they can continue on their own.
223896785|NCT02807129|BIOLOGICAL|blood withdrawn|
223896786|NCT02807129|BIOLOGICAL|urine collection|
224083378|NCT03839108|DRUG|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
224276555|NCT03864185|BIOLOGICAL|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
224276556|NCT03864185|OTHER|Placebo|Administer placebo IV infusion once weekly for 4 doses.
224276557|NCT04251858|PROCEDURE|Dental Scaling|The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.
224276558|NCT04251858|OTHER|Oral hygiene instruction|Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
224276559|NCT00692315|DRUG|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
224276560|NCT04028856|DRUG|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
224276561|NCT05387070|DRUG|TransCon PTH|TransCon PTH is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for SC injection.
224276562|NCT05387070|DRUG|placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
223896787|NCT06259227|OTHER|Cardiorespiratory fitness (CRF) training|The CRF training will take place on an arm cycle ergometer, or on an recumbent cross trainer. The duration and intensity of these 2 CRF gait training sessions will be determined by scientific exercise guidelines. A practical way of increasing vigorous-intensity exercise is high-intensity interval training (HIIT). The HIIT intervention consist of 2-3 trainings per week, with each exercise session including a 5-minute warm-up, 30-second interval periods (with a power output up to 90% of the peak power output (PPO)), and 30-second recovery periods. There are 5 minutes of 50% of PPO between interval periods. The number of interval periods increases during the intervention period, resulting in a maximum total training time of 35 minutes.
223896788|NCT06636344|OTHER|Pseudoxanthoma Elasticum|Answer to the PSQ-18, patient care confidence score (likert scale) and SF-12 questionaries at each visit, for an estimated duration of 15 minutes.
223896789|NCT04955470|DRUG|Ketamine Injectable Solution|A 10 mg/mL solution of ketamine will be infused over a 40 minute period at a dose of 0.05mg/kg.
223896790|NCT04955470|DRUG|Midazolam Injectable Solution|A 5 mg/mL solution of midazolam will be infused over a 40 minute period at a dose of 0.02 mg/kg.
223896791|NCT04955470|DRUG|Normal Saline 0.9% Injectable Solution|A 0.9% normal saline solution will be infused over a 40 minute period.
223896792|NCT06635226|DRUG|ID110521156|ID110521156 capsules taken orally once daily
223896793|NCT06635226|DRUG|Placebo of 110521156|ID110521156 placebo capsules taken orally once daily
223896794|NCT04704648|PROCEDURE|Surgical|"The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).~As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency."
223896795|NCT06635720|DRUG|Prednisone|This study will compare two steroid dosing protocols for the treatment of childhood nephrotic syndrome relapses. The medications used for both intervention and control arms are oral prednisone 5mg tablets (DIN: 00312770) for children able to swallow or use crushed tablets, or oral prednisolone sodium phosphate 5mg base/5mL liquid (DIN: 02245532). Participants hospitalized after study enrollment will be permitted to switch to intravenous methylprednisolone sodium succinate (DIN: 02367955) at the same dose without being considered to have violated their treatment assignment.
223896796|NCT05335850|BEHAVIORAL|Isha Kriya|Isha Kriya is a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily.
223896797|NCT05335850|BEHAVIORAL|Nadi Shuddhi|Nadi Shuddhi is a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.
223896798|NCT05335850|BEHAVIORAL|Nada Yoga|Nada Yoga is a 6-minute meditation that uses sound to create balance and stability in the body and mind.
223896799|NCT05335850|OTHER|Routine Daily Activity|"Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.~Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm."
223896800|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 0.33 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
223896801|NCT06451159|BIOLOGICAL|KYV-101 (Biological) - 1 ×10^8 cells|KYV-101 is a type of treatment called CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cells that cause inflammation. T-cells are a type of white blood cell.
223896802|NCT06451159|DRUG|Chemotherapy: cyclophosphamide (CYC)|Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
223896803|NCT06451159|DRUG|Chemotherapy: fludarabine (FLU)|Participants will receive one 3-day cycle of lymphodepletion with FLU 30 mg/m2 prior to administration of KYV-101.
223896804|NCT06798116|PROCEDURE|Experimental: open flap debridement and demineralized freeze-dried bone allograft and mixed with liquid (PRF|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement and DFDBA and mixed with liquid (PRF)"
224083379|NCT05316714|PROCEDURE|Nanofat grafing|NANOFAT REGENERATIVE SURGICAL GRAFTING IN PRNILE ALBUGIANEA OF PATIENTS AFFECTED BY PEYRONIES' DISEASE
224083380|NCT03235687|DIAGNOSTIC_TEST|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
224083381|NCT04698525|DRUG|Valproate Sodium|Comparison between two actives
224083382|NCT04698525|DRUG|Memantine|Memantine
224083383|NCT05384041|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)|The indicated use in adults (ages 21-65 years) is for 20 minutes twice daily, upon waking for the day and at bedtime. The treatment period of the intervention will have a duration of four weeks.
224083384|NCT05384041|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)|The placebo device is designed to provide exactly the same patient experience as the active device; however, the placebo device will not deliver the same frequencies as the active device. The placebo device will provide no therapeutic benefit.
224276563|NCT00435305|DRUG|Meropenem|
224276564|NCT00435305|DRUG|Vancomycin|
224276565|NCT00435305|DRUG|Linezolid|
223896805|NCT06798116|PROCEDURE|defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, defects will be treated with open flap debridement and liquid (PRF) mixed with denatured albumin gel (ALB-PRF) will be injected in periodontal intrabony defects."
223896806|NCT06798116|PROCEDURE|defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and collagen membrane"
223896807|NCT06798116|PROCEDURE|open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane.|"Drawing 9 ml of blood into plastic test tubes without anticoagulants and other additives. This is followed by a centrifugation process according to the protocol for liquid PRF by using centrifuge under 2700rpm for 8 min.~The yellow top layer, formed upon centrifugation, consists of platelet-poor plasma that will be collect by a syringe in a volume of 2 ml, liquid PRF and buffy coat that will also be collected by a syringe in a volume of 4 ml. The Platelet-Poor plasma in the syringe will be transferred to a special machine that increases its temperature to 75°C for 10 minutes. ALB-PRF will be prepared by mixing the albumin gel with liquid concentrated growth factor including the buffy coat in a separate syringe by utilizing a female luer lock connector to obtain the injectable ALB-PRF in final ready form. in this group;, the defects will be treated with open flap debridement , DFDBA mixed with liquid (PRF) and ALB-PRF membrane."
223896808|NCT06417255|OTHER|kinesiotape application|The strips used for kinesiological taping can be applied by giving different shapes. These shapes are I, Y, X, ring (donut), rake and net
223896809|NCT06417255|OTHER|foam roller application|"In the foam roller group, Actifoam brand non-serrated foam rollers with a size of 15x90 cm were used."
223896810|NCT06634654|PROCEDURE|Total Knee Arthroplasty|Total Knee Arthroplasty is performed using conventional surgical techniques.
223896811|NCT06634654|DIAGNOSTIC_TEST|Multifaceted diagnostic assessments|Multifaceted diagnostic assessments involving genetic analysis, biomechanical data collection, radiographic imaging, and psychological evaluations.
223896812|NCT06634654|BEHAVIORAL|Follow-ups|Postoperative follow-up includes behavioral interventions, such as lifestyle counseling and rehabilitation programs, tailored based on AI-driven insights into individual patient recovery profiles.
223896813|NCT06634654|GENETIC|Genetic screening|Genetic screening and analysis, including whole exome sequencing, are conducted to identify genetic markers that might influence the outcomes of knee arthroplasty. This data is utilized within AI models to predict patient-specific surgical outcomes and recovery processes.
223896814|NCT03367299|DRUG|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
223896815|NCT06502717|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
223896816|NCT03023410|PROCEDURE|VERASENSE|Sensor-Assisted Revision TKA
223896817|NCT03956407|DEVICE|Suprathreshold repetitive peripheral sensory stimulation|Suprathreshold repetitive peripheral sensory stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For suprathreshold stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
223896818|NCT03956407|DEVICE|Subthreshold repetitive sensory stimulation|Subthreshold repetitive sensory stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For subthreshold stimulation, intensities will be set at 10mv - 15mv lower than de lowest intensity able to induce sensory paraesthesias, and adjusted if required.
223896819|NCT05141695|DEVICE|therapeutic repetitive peripheral magnetic stimulation|Patients in the treatment group will receive peripheral magnetic stimulation therapy for the upper extremity arm/forearm spastic muscles on the hemiplegic side for a total of ten sessions once a day, five sessions a week, for two weeks, each session lasting ten minutes. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
224083385|NCT01360645|DRUG|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
224083386|NCT01360645|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
224083387|NCT01360645|DRUG|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
224083388|NCT00562380|BIOLOGICAL|ganitumab|
224083389|NCT00562380|OTHER|laboratory biomarker analysis|
224083390|NCT00562380|OTHER|pharmacological study|
224083391|NCT00562380|PROCEDURE|biopsy|
224276566|NCT00435305|DRUG|Piperacillin/Tazobactam|
224276567|NCT00435305|DRUG|Cefepim|
224276568|NCT00435305|DRUG|Ceftazidim|
224276569|NCT01550367|DRUG|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
224083392|NCT03981432|BEHAVIORAL|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
223713588|NCT05315544|DEVICE|CSI pVAD system|The CSI percutaneous ventricular assist device (pVAD) is being investigated as a temporary left ventricular system intended to support and/or provide hemodynamic stability during high-risk percutaneous coronary interventions.
223713589|NCT03155282|PROCEDURE|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
223713590|NCT05279339|OTHER|Exercise|Upper limb exercises using an elastic band.
223713591|NCT02358174|PROCEDURE|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
223713592|NCT02358174|OTHER|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
223713593|NCT02358174|OTHER|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
223713594|NCT02330237|DRUG|natural gels|whole fruits and vegetables
223713595|NCT02330237|DRUG|Placebo|
223713596|NCT02541019|DRUG|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
223713597|NCT02541019|DRUG|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
223713598|NCT00828997|BIOLOGICAL|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
223713599|NCT05894408|OTHER|this is no intervention|this is no intervention
223713600|NCT04806997|DIAGNOSTIC_TEST|Vascular occlusion test|The VOT procedure was conducted twice in each patient, before and 15 min after intrathecal injection. An NIRS sensor (INVOSTM 5100C Cerebral/Somatic Oximeter; Medtronic, Minneapolis, MN, USA) was attached to the patient's gastrocnemius muscle. A tourniquet (A.T.S ® 3000 Automatic Tourniquet System; Zimmer Inc., Warsaw, IL, USA) was applied to the thigh and inflated to a pressure value 50 mmHg over the patient's baseline systolic blood pressure in the leg and maintained for 5 min. After a 5-min ischemic period, the tourniquet was rapidly deflated to 0 mmHg. The StO2 data was continuously recorded during the VOT procedure. After confirmation of spinal anesthesia using cold sensitivity, the VOT procedure was repeated in the same manner as mentioned above. The occlusion slope and recovery slope were calculated based on the measured StO2 data.
223713601|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation|"Position the patient on a chair with a backrest and stand behind the patient. Support the patient's arm under the crook of the elbow with the shoulder joint abducted to 90° and medially rotated. The forearm will automatically fall into pronation. Place the thumb of your other hand in the web space between the patient's thumb and index finger and fully flex the patient's wrist and pronate the forearm. Move the hand supporting the crook of the elbow on to the posterior surface of the elbow joint and, while maintaining full Wrist flexion and pronation, extend the patient's elbow until you feel that all the slack Has been taken up in the tendon. Step sideways to stand behind the patient's head, Taking Care to prevent the patient from leaning away either forwards or sideways, which would reduce the tension on the tendon.~Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
223713602|NCT06087081|OTHER|Baseline Treatment along with Mill's manipulation and Mulligan's pain relief phenomena|"In addition to Group A mentioned protocols Pain release phenomenon (PRP) was delivered as well. The Pain Release Phenomenon Technique (PRPS) is a technique pioneered by Brian Mulligan for management of Pain. There are different types of Pain release Phenomenon as follows:~1. Stretch PRP: affected muscle is eccentrically contracted.~2. Contraction PRP: affected muscle is concentrically contracted.~3. Compression PRP: affected joint surfaces are compressed together.~4. Distraction PRP: affected joint surfaces are distracted away from each other. The types of PRP are performed along with pertained duration of hold time by the therapist. And always painful PRP technique is chosen for the treatment. In the present study stretch PRP technique was used which provoked pain stimuli and was maintained for 15-20 seconds. Each exercise will be done 10 times for 5 sets each with a rest interval of 10 seconds in between each set for a period of 4 weeks"
223713603|NCT05003986|DRUG|Sparsentan|Population 1: 800 mg Sparsentan (oral suspension)
223713604|NCT05003986|DRUG|Sparsentan|Population 2: 400 mg Sparsentan (oral suspension)
223713605|NCT05003986|DRUG|Sparsentan|Population 3: 400 mg Sparsentan (tablets)
223713606|NCT00244010|DEVICE|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
223713607|NCT04850937|DRUG|Esketamine|The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
223713608|NCT04850937|DRUG|normal saline|The experimental group will be given 0.5ml/kg normal saline intravenously after anesthesia induction
224083393|NCT03981432|BEHAVIORAL|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224083394|NCT03981432|BEHAVIORAL|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
224083395|NCT01390792|DRUG|Zanamivir hydrate|
224083396|NCT02557425|OTHER|No intervention in PROTECT|
223896820|NCT05141695|DEVICE|sham repetitive peripheral magnetic stimulation|rPMS will not be given to the sham group, the device will not be operated, the probe of the device will be positioned in the same way as the patients in the treatment group for ten minutes, and the sounds recorded during the operation of the device will be heard by the patients. Patients and evaluators will not know which group the patients are in. Ten sessions of stretching exercises will be applied to all patients once a day, five sessions a week, with each session lasting 20 minutes.
223896821|NCT06324721|OTHER|Measurements for breast cancer related lymphedema (volumetric measurements, bioimpedance spectroscopy, bioimpedance analysis, tissue dielectric constant measurements, ultrasonography)|"Assessments related to different types of breast cancer related lymphedema at arm (1. self-reported swelling at arm, 2. subjective arm lymphedema, 3. objective arm lymphedema) using the Norman questionnaire, volume measurements (volumetry and perimetry), bioimpedance spectroscopy, and bioimpedance analysis~Assessments related to different types of breast cancer related lymphedema at trunk/ breast (1. self-reported swelling at trunk/ breast, 2. subjective trunk/ breast lymphedema, 3. objective trunk/ breast lymphedema) using the Norman questionnaire, tissue dielectric measurements, and ultrasonography"
223896822|NCT06324721|OTHER|Measurements for lymphatic problems (volumetric measurements, tissue dielectric measurement, lymphofluoroscopy)|Clinical assessments related to lymphatic problems (1. amount of swelling at arm by relative arm volume difference, 2. amount of swelling at trunk by percentage water ratio, 3. severity of dermal rerouting at upper limb and trunk by lymphofluoroscopy (i.e., near-infrared fluorescence imaging device)
223896823|NCT06324721|OTHER|Measurements for sensory processing problems by monofilaments, algometer, goniometer, and neurosensory analyzer|Clinical measurements related to nociceptive, neuropathic and central sensory problems based on the Quantitative Sensory Testing principles using different devices algometer, goniometer, standardized set of monofilaments, and neurosensory analyzer
223896824|NCT06542484|DRUG|Gefapixant Citrate|An additional treatment of gefapixiant will be performed for 12 weeks.
223896825|NCT05243108|DIETARY_SUPPLEMENT|dietary nucleotides|1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;
223896826|NCT05243108|DIETARY_SUPPLEMENT|placebo|placebo
223896827|NCT03437057|OTHER|acetylsalicylic acid (below or equal to) 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
223896828|NCT04799899|BEHAVIORAL|Adapted MBCT|The adapted MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health.
223896829|NCT04799899|BEHAVIORAL|Cardiac Health Enhancement|The cardiac health enhancement control group will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will learn about depression and cardiac health.
223896830|NCT04718805|DRUG|Darunavir|Participants will receive a single dose of Darunavir tablets orally as per assigned treatment sequence.
223896831|NCT04718805|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablets orally as per assigned treatment sequence.
223896832|NCT04718805|DRUG|Darunavir/Cobicistat FDC|Participants will receive a single dose of darunavir and cobicistat FDC tablets orally as per assigned treatment sequence.
223896833|NCT00470704|DRUG|Lapatinib|
223896834|NCT00470704|DRUG|Herceptin|
223896835|NCT03838549|PROCEDURE|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
223896836|NCT05051761|DRUG|Jaktinib|Administered orally.
223896837|NCT05051761|DRUG|placebo|Administered orally.
223896838|NCT06631508|OTHER|Preoperative Period, Postoperative Period, 2th week after discharge, 6th week after discharge, 10th week after discharge, 14th week after discharge|Showing training videos to patients before and after pelvic organ prolapse surgery and following up after discharge
223896839|NCT04634513|BIOLOGICAL|strain CVD 1208S-122|Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli
223896840|NCT04634513|OTHER|Placebo|Sodium bicarbonate buffer
223896841|NCT04153032|DRUG|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
224276570|NCT01550367|DRUG|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
223896842|NCT04153032|DRUG|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
223896843|NCT03618771|DEVICE|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
223896844|NCT06629168|DIAGNOSTIC_TEST|lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and 10-meter-walking test prior and 4 hours after lumbar puncture. Mini-mental state examination is done.
223896845|NCT06629168|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of cerebrospinal fluid. It is test of responsivity to ventriculo-peritoneal shunt placement
223896846|NCT06629168|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally). Telemetric prechamber placement according the randomization (www.randomization.com) and the envelope method of choosing of patients.
223896847|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #1|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 3 month after surgery. Brain CT control.
223896848|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #2|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 6 month after surgery. Brain CT control.
223896849|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #3|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score 9 months after surgery. Brain CT control.
224276571|NCT01531504|DEVICE|ViKY UP|laparoscopic-assisted hysterectomy procedure
223528543|NCT02969070|DIETARY_SUPPLEMENT|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
223896850|NCT06629168|DIAGNOSTIC_TEST|Follow-up control #4|Patients after VP shunt placement are assesed in gait, general condition and mini-mental state examination score a month after surgery. Brain CT control, 10-meter-walking test, MMSE, self-assessment.
223896851|NCT06629168|DIAGNOSTIC_TEST|Telemetric prechamber reading|Non-invasive reading of telemetric prechamber made during each follow-up control.
223896852|NCT06629168|OTHER|Valve setting change|Changing of valve setting according patient's actual condition. Decission based on clinical state, radiological finding on CT and values readed from telemetric prechamber. Timing - each follow-up control.
223896853|NCT06202352|BEHAVIORAL|Meditation and Yoga|The yoga and meditation intervention will use a 60-minute vinyasa yoga class once a week, followed by a guided yoga instruction booklet that takes an average of 30 minutes to read. The intervention will be carried out in the last eight weeks of the spring semester, when hospital practices are most intense and before the final exams. Posttest forms will be filled out the week of final exams. The time devoted to meditation will be increased every week for the last two weeks, starting with 5 minutes and gradually increasing to 20 minutes in the eighth week.
223896854|NCT04019873|DRUG|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
223896855|NCT04019873|DRUG|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
223896856|NCT04019873|DRUG|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
223896857|NCT04118608|OTHER|No intervention|No intervention
223896858|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
223896859|NCT05515406|DRUG|ONO-7018|ONO-7018 tablet(s) are administered orally
223896860|NCT02305277|DRUG|BIA 9-1067 (clinical micronized, CM)|
223896861|NCT02305277|DRUG|BIA 9-1067 (to-be-marketed, TBM)|
223896862|NCT06798688|DEVICE|A non-invasive cardio-respiratory sensor will be applied on the subjects to measure parameters to identify exacerbations|"This Study aims to pilot software algorithms based on respiratory features and hemodynamics for predicting exacerbations on a total of 20 participants with COPD. The end-points of this Study includes the following:~1. To validate respiratory-based biomarkers in models to predict exacerbations - benchmarking to be done versus physician assess exacerbations, emergency department visits, hospitalizations and any other visit.~2. To validate level of compliance, drop-out rate and if additional measures are required to get participants to follow-on"
223896863|NCT06629597|DRUG|YL201|YL201 will be administered intravenously on Day 1 of each 3-week cycle at RP3D dose level.
223896864|NCT06629597|DRUG|Docetaxel|Docetaxel will be administered intravenously at 75 mg/m2 on Day 1 of each 3-week cycle.
223896865|NCT06629597|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
223896866|NCT06629597|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Day 1 and 8 of each 3-week cycle
223896867|NCT06151834|PROCEDURE|KeriFuse implant implantation|The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
223896868|NCT04815720|DRUG|pepinemab + pembrolizumab|The Safety Run-in phase will begin at 20 mg/kg pepinemab with a fixed dose of 200 mg pembrolizumab. The dose of pepinemab may be reduced to 15 mg/kg or 10 mg/kg with a fixed dose of 200 mg pembrolizumab if the initial pepinemab dose of 20 mg/kg is found to not be well tolerated. Once a recommended phase II dose of pepinemab is determined it will be utilized in the Dose Expansion phase in combination with 200 mg pembrolizumab.
223896869|NCT05425498|OTHER|Physical activity program|12-weeks physical activity program will be applied by giving pedometer. 12 telephone sessions will be held once a week according to motivational interview techniques based on the Transtheoretical Model.
223896870|NCT06254807|DRUG|CT-0525|Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor
223896871|NCT05540860|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
223896872|NCT05540860|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
223896873|NCT05540860|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
223896874|NCT05540860|DRUG|Sevasemten Dose 4|Sevasemten is administered orally once per day
223896875|NCT05540860|DRUG|Sevasemten Dose 5|Sevasemten is administered orally once per day
223896876|NCT05540860|DRUG|Placebo|Placebo is administered orally once per day
223896877|NCT05806346|DRUG|TXA administration|Tranexamic acid intravenous administration
223896878|NCT05806346|DRUG|Placebo administration|Placebo (normal saline) intravenous administration
223896879|NCT06789705|DRUG|MDMA|MDMA will be administered in a single dose of 50 mg (2 capsules of 25 mg MDMA) or 25mg (1 capsule of 25 mg MDMA, 1 capsule containing only mannitol filler) and given at treatment visit.
223896880|NCT06789705|OTHER|Placebo|Placebo will be prepared as identical gelatin capsules containing only mannitol filler and given at treatment visit.
223896881|NCT04683744|OTHER|Semi-structured interviews-Patients|The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
223896882|NCT04683744|OTHER|Semi-structured interviews-Health system|The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
223896883|NCT06086418|DRUG|0.9 % Sodium Chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
223896884|NCT06086418|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
224083397|NCT06370416|DRUG|Trilaciclib|After pathological diagnosis of NSCLC, 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
224083398|NCT01912625|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
223896885|NCT06086418|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
223896886|NCT03560583|DRUG|Metoclopramide|Metoclopramide 10 mg BID
223896887|NCT03560583|DRUG|Placebo Oral Tablet|Placebo 10 mg BID
223896888|NCT04309188|DEVICE|Senaptec Strobe Glasses|The glasses use liquid crystal technology that causes a flicker from clear to opaque to enhance vision.
223896889|NCT04309188|OTHER|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
223896890|NCT04472598|DRUG|Navitoclax|Tablet; Oral
223896891|NCT04472598|DRUG|Ruxolitinib|Tablet; Oral
223896892|NCT04472598|DRUG|Placebo for Navitoclax|Tablet; Oral
223896893|NCT04021498|DRUG|Simvastatin 40mg|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
223896894|NCT04021498|OTHER|Placebo|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
223896895|NCT06628258|OTHER|Moiz Cleansing Lotion|"Mode of Usage: Apply 5-10 ml of Moiz Cleansing Lotion to wet skin. Massage gently for 1-2 minutes, then rinse and pat dry.~Frequency: Twice a Day Route of Administration: Topical."
223896896|NCT03903107|PROCEDURE|Conventional fluoroscopy guided Conduction System Pacing(CSP)|conventional standard approach Conduction System Pacing(CSP) using fluoroscopy
223896897|NCT03903107|PROCEDURE|Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)|Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy
223896898|NCT05156710|DRUG|BIVV020 (SAR445088)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
223896899|NCT05156710|DRUG|Intravenous immunoglobulin (IVIg)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
223896900|NCT05156710|DRUG|Rituximab or biosimilar|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
223896901|NCT05156710|DRUG|Antithymocyte globulin (ATG)|Pharmaceutical Form: Solution for injection Route of Administration: Intravenous
223896902|NCT05156710|DRUG|Tacrolimus|Pharmaceutical Form: Tablet Route of Administration: Oral
223896903|NCT05156710|DRUG|Mycophenolate|Pharmaceutical Form: Tablet Route of Administration: Oral
223896904|NCT05156710|DRUG|Corticosteroids|Pharmaceutical Form: Vary Route of Administration: Vary
223896905|NCT05843448|BIOLOGICAL|PD-L1/IDO Peptide Vaccine|Given SC
223896906|NCT05843448|BIOLOGICAL|Pembrolizumab|Given IV
223896907|NCT05449132|DRUG|RTX-GRT7039|RTX-GRT7039 intra-articular injection.
223896908|NCT05449132|DRUG|Placebo|Placebo matching RTX-GRT7039 intra-articular injection.
223896909|NCT04048993|OTHER|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
223896910|NCT04902352|PROCEDURE|No Periadventitial dissection of the SMA|lymphoneural tissue around SMA left intact
224083399|NCT01912625|DRUG|Carboplatin|Given IV
223528544|NCT05242289|DEVICE|CytoSorb|Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
223528545|NCT05168761|PROCEDURE|partial nephrectomy|
223896911|NCT04902352|PROCEDURE|Periadventitial dissection of the SMA|"For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from angle of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well."
223896912|NCT05720949|DRUG|Genicular Nerve Block with bupivacaine and preservative free dexamethasone|"A genicular nerve block is a peripheral nerve block that temporarily anesthetizes the sensory terminal branches innervating the knee joint by injecting local anesthesia. This results in anesthesia of the anterior compartment of the knee.~The genicular nerve block consists of 20cc of 0.25% bupivacaine with 2mg of preservative free dexamethasone and will be applied to the superomedial genicular nerve, superolateral genicular nerve, inferomedial genicular nerve, and nerve to vastus intermedius.~Bupivacaine - Drug class: Sodium channel blocker~Dexamethasone - Drug class: Glucocorticoid"
223896913|NCT05068791|DRUG|Psilocybin|0.36 mg/kg will be administered orally to participants
223896914|NCT05068791|DRUG|Dextromethorphan|2.6 mg/kg of active placebo will be administered orally to participants
223896915|NCT05464160|DEVICE|Focal Muscular Vibration using the EVM EVO medical device (Endomedica, Italy)|"FMV will be applied 7 times per week for 3 weeks (21 total applications), using the EVM EVO medical device (Endomedica, Italy), applying an intensity of 100 Hz for a total of 23 minutes."
223896916|NCT05464160|OTHER|Conventional Rehabilitation|Conventional treatment will focus on joint mobilization, muscle stretching, and neuromuscular facilitation activities, using the main rehabilitation methods (e.g., neurocognitive theory, Bobath Concept, Progressive Neuromuscular Facilitation, etc...)
223896917|NCT05987735|BEHAVIORAL|BLAME-LESS|The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
223896918|NCT05934994|OTHER|Bone scan|the bone scintigraphy will include 3 stages: study of perfusion then early tissue uptake and finally late bone fixation
223896919|NCT05467345|DEVICE|Contour Next and Contour Plus Elite BGMS testing of neonatal blood|The purpose of this study is to extend the intended use of two BGMSs to include testing of neonatal blood by Health Care Professionals in a clinical setting for the quantitative measurement of glucose levels in neonates.
224083400|NCT01912625|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
224083401|NCT01912625|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223896920|NCT03830762|DRUG|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
223896921|NCT03830762|DRUG|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
223896922|NCT03344250|DRUG|EGFR BATs with TMZ following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
223896923|NCT03344250|DRUG|Weekly EGFR BATs following SOC RT/TMZ|Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
223896924|NCT05210608|BEHAVIORAL|Working Memory Training + Behavioral Intervention|Participants will be randomized to complete 10 sessions of a Working Memory Training. All participants will receive behavioral activation (a behavioral intervention for smoking cessation) and nicotine patches.
223896925|NCT06003543|BEHAVIORAL|Virtual Reality|Virtual Reality
223896926|NCT02813135|DRUG|Ribociclib|
223896927|NCT02813135|DRUG|Topotecan|
223896928|NCT02813135|DRUG|Temozolomide|
223896929|NCT02813135|DRUG|Everolimus|
223896930|NCT02813135|DRUG|Adavosertib|
223896931|NCT02813135|DRUG|Carboplatin|
223896932|NCT02813135|DRUG|Olaparib|
223896933|NCT02813135|DRUG|Irinotecan|
223896934|NCT02813135|DRUG|Vistusertib|
223896935|NCT02813135|DRUG|Nivolumab|
223896936|NCT02813135|DRUG|Cyclophosphamide|
223896937|NCT02813135|DRUG|Selumetinib|
223896938|NCT02813135|DRUG|Enasidenib|
223896939|NCT02813135|DRUG|Lirilumab|
223896940|NCT02813135|DRUG|Fadraciclib|
223896941|NCT02813135|DRUG|Cytarabine|
223896942|NCT02813135|DRUG|Dexamethasone|
223896943|NCT02813135|DRUG|Ceralasertib|
223896944|NCT02813135|DRUG|Futibatinib|
224276572|NCT02734524|BIOLOGICAL|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell \>1×10\^9，q28d\*4
223896945|NCT02813135|DRUG|Capmatinib|
223896946|NCT02813135|DRUG|Avelumab|
223896947|NCT02813135|DRUG|Peposertib|
223896948|NCT03315806|OTHER|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
223896949|NCT03315806|OTHER|Placebo|140 mL of beetroot juice isent of nitrate
223896950|NCT06289647|DRUG|Azithromycin|In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
223896951|NCT05547633|OTHER|sinusitis screening consultation|"Questioning to look for suspicious anamnestic elements such as rhinorrhea, nasal obstruction, smell disorders, facial pain and clinical examination including nasofibroscopy.~Patients with signs of sinusitis will be managed according to current recommendations (diagnostic imaging tests, medical treatment or even surgery if necessary)."
223896952|NCT05413265|BEHAVIORAL|Phases 1 and 2|Phase 1 participants will help inform the cultural adaptation of the study design and materials. Phase 2 will enroll 10 dyads (20 individuals) of AN/AI people who smoke and a family member. Dyad participants will help beta-test the feasibility and acceptability of the financial incentives intervention.
223896953|NCT01120223|DRUG|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
223528546|NCT04968483|OTHER|Data collection|The general data, data of postoperative complications, data of nutritional assessment and nutritional support will be collected.
223528547|NCT01854684|DRUG|Temoporfin|Given IV
223528548|NCT01854684|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223896954|NCT04070066|OTHER|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
223896955|NCT04070066|OTHER|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
223896956|NCT06415942|OTHER|Maternal Outcome Monitoring and Support system|The Maternal Outcome Monitoring and Support system is a mobile health application that allows participants to choose symptoms they may be having that are warning signs of pregnancy related death. They then receive decision support about when they should seek medical care (call their provider or go to an emergency room).
223896957|NCT05438823|OTHER|Educational Programe|IBK-EBP will be administered to parents in six sessions in six days. After six days of training, the mobile application will be used by parents for 8 weeks. The frequency of use of the mobile application will be left entirely to the needs of the parents and reminders will be made through the mobile application. In addition, the video used during the face-to-face training, progressive relaxation exercise videos and motivational sentences will also be included in the mobile application.
223896958|NCT05842265|OTHER|Self acupressure|patients will do self acupressure
223896959|NCT06245187|OTHER|GWTG Atrial Fibrillation program|Evidence based recommended therapies and counseling prior to hospital discharge.
223896960|NCT05375643|BEHAVIORAL|SURGE|Video with or without person to person guidance to support decision making around genetic testing
224276573|NCT02734524|DRUG|Taxol|135-175mg/m2,q28d\*4
224276574|NCT02734524|DRUG|Carboplatin|AUC=5,q28d\*4
223896961|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in EFT
223896962|NCT05012176|BEHAVIORAL|Behavioral Intervention|Participate in ERT
223896963|NCT05012176|OTHER|Quality-of-Life Assessment|Ancillary studies
223896964|NCT05012176|OTHER|Questionnaire Administration|Ancillary studies
223896965|NCT06543537|BEHAVIORAL|Collaborative Agenda-Setting Intervention|A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.
223896966|NCT06494943|DRUG|Sintilimab|PD-1 inhibitor
223896967|NCT06494943|DRUG|IBI110|LAG-3 inhibitor
223896968|NCT06494943|DRUG|Paclitaxel|Chemotherapy
223896969|NCT06494943|DRUG|Cis Platinum|Chemotherapy
223896970|NCT06494943|PROCEDURE|Surgery|Definitive surgery
223896971|NCT06494943|RADIATION|Adjuvant radiation|Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.
223896972|NCT02912897|BIOLOGICAL|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
223896973|NCT05689684|DIETARY_SUPPLEMENT|AG+XOS+AXOS|4-month parallel randomized controlled study
223896974|NCT05689684|DIETARY_SUPPLEMENT|Placebo Maltodextrin|4-month parallel randomized controlled study
223896975|NCT05871905|DRUG|TY-9591|C14 TY-9591
223896976|NCT05653661|PROCEDURE|Biopsy|Undergo tissue biopsies
223896977|NCT05653661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224276575|NCT06199960|OTHER|Doustim protocol|In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
223896978|NCT05653661|PROCEDURE|Computed Tomography|Undergo CT scans
223896979|NCT05653661|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
223896980|NCT05653661|DRUG|Nab-paclitaxel/Danburstotug Complex AP160|Given IV
224083402|NCT01912625|OTHER|Laboratory Biomarker Analysis|Correlative studies
224276576|NCT02991560|OTHER|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
224276577|NCT02991560|OTHER|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
224083403|NCT01912625|DRUG|Paclitaxel|Given IV
224083404|NCT01912625|OTHER|Pharmacological Study|Correlative studies
223896981|NCT04613947|BEHAVIORAL|Informed consent|The style of informing patients about the procedure they will undergo
223896982|NCT04613947|PROCEDURE|Third molar surgery|Surgical extraction of the third molar tooth
223896983|NCT01521039|PROCEDURE|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
223896984|NCT05462353|DRUG|2mg of ASC41|ASC41 tablet administered orally once daily.
223896985|NCT05462353|DRUG|4mg of ASC41 (2 tablets of 2 mg ASC41)|ASC41 tablets administered orally once daily.
223896986|NCT05462353|DRUG|Placebo|Placebo tablets administered orally once daily.
223896987|NCT05851573|BEHAVIORAL|Psychosocial intervention|an SLP-administered 5-week treatment focused on psychological well-being
223896988|NCT00832325|BEHAVIORAL|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
223896989|NCT00832325|BEHAVIORAL|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
223896990|NCT00832325|BEHAVIORAL|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
223896991|NCT04114877|BEHAVIORAL|Attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. AR is the most commonly used CBM intervention in the study of addiction-related attentional bias. The idea behind AR is to reduce attentional bias and therefore minimize exposure to drug cues, because attention to such stimuli may provoke craving and undermine cessation attempts.
224083405|NCT01912625|DRUG|Trametinib|Given PO
224083406|NCT00682058|OTHER|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
224276578|NCT02991560|DEVICE|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
224083407|NCT04750460|DRUG|Teriparatide|Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day.
224083408|NCT00000815|BIOLOGICAL|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
224276579|NCT02991560|DEVICE|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
224276580|NCT02992613|PROCEDURE|total knee arthroplasty with ultra-congruent (UC) insert|
224276581|NCT02992613|PROCEDURE|total knee arthroplasty with posterior-stabilized (PS) insert|
223528549|NCT01854684|DRUG|Photodynamic Therapy|Undergo intraoperative PDT
223528550|NCT01854684|OTHER|Laboratory Biomarker Analysis|Correlative studies
223528551|NCT01854684|OTHER|Pharmacological Study|Correlative studies
223528552|NCT00845702|DRUG|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
223528553|NCT00845702|OTHER|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
223528554|NCT00548886|DRUG|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
223528555|NCT04442009|OTHER|Group SCPB|In group SCBP, SCBP block will be performed. Patients will be administered dexketoprofen 50 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
223528556|NCT05383261|OTHER|exercise|aerobic and resisted ex
223528557|NCT04541615|PROCEDURE|Online course with proficiency test|Participants will receive an online e-course with a proficiency test at the end. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
223528558|NCT04541615|PROCEDURE|Online course|Participants will receive an online e-course but are not required to pass the proficiency test. Afterwards, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
223528559|NCT04541615|PROCEDURE|Standard training group|After receiving a traditional lecture, participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end.
223528560|NCT04541615|PROCEDURE|Apprenticeship group|Participants will have to perform a hermetic circular anastomosis that allows connecting two anatomical tubular structures using an outside-inside direction in the stomach and inside-outside in the cloaca. Two hemi-continuous sutures must be performed, knotting the two treads at the end. Participants will only receive papers on how the task will be performed and clinicians will help them with completion of the task.
223528561|NCT04703140|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|2 nasopharyngeal swabs taken for PCR and COVIDISC
223528562|NCT01239940|DEVICE|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
223528563|NCT01239940|DEVICE|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
223528564|NCT03425916|OTHER|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
223528565|NCT06489002|OTHER|Implementation Support|Health centers receiving the intervention will have access to implementation support strategies designed to support adoption of social needs screenings and referrals to community organizations for patients with unmet social needs receiving care management. Implementation support will be provided by an OCHIN trainer, practice facilitators, workflow engineer, and analysts.
223528566|NCT03839914|DRUG|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
223528567|NCT00735150|BEHAVIORAL|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
223528568|NCT06227949|DRUG|Luveris|Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
223528569|NCT05420571|PROCEDURE|digital impression|3D printed models after digital impressions
223528570|NCT05420571|PROCEDURE|alginate impression|Alginate impressions after plaster model infusion to make models
223528571|NCT06157034|OTHER|Placebo|Inert Material
223528572|NCT06157034|DIETARY_SUPPLEMENT|Zingier officinale powder|The raw form of Zingiber officinale will be grounded in powder by manual grinding and will be encapsulated.
223528573|NCT06157034|DIETARY_SUPPLEMENT|Carum carvi, L powder|The raw form of Carum carvi, L will be grounded in powder by manual grinding and will be encapsulated.
223896992|NCT04114877|BEHAVIORAL|Visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues. In the typical VP task, a pair of pictures or words (e.g. one smoking-related and one neutral) is briefly presented simultaneously side by side on a computer screen. After the pictures disappear, a probe stimulus (e.g. a small dot) is presented in the location that had been occupied by one of the pictures (or words), and participants are required to press a key as quickly as possible in response to the probe. Attentional bias for drug-related cues is detected by a faster response to a probe that replaces a drug-related stimulus (vs. a neutral stimulus), since attention will have been preferentially allocated to that area of visual display. The traditional VP task only assesses attentional bias, and does not modify it in any way.
223896993|NCT05950841|DRUG|Low dose IHAT|Once daily dose of 1 capsule (100mg per capsule IHAT) and Once daily dose of 1 capsule (carob flour)
223896994|NCT05950841|DRUG|High Dose IHAT|Twice daily dose of 1 capsule (100mg per capsule IHAT)
223896995|NCT05950841|DRUG|Carob flour|Twice daily dose of 1 capsule (carob flour)
223896996|NCT05255965|DIAGNOSTIC_TEST|level of IL-8+ initial T cells|5ml peripheral venous blood was taken before surgery or biopsy, and the levels of initial T cell with IL-8+, PLXND1+, PTK7+ or CR2+ were detected and recorded within 6 hours, respectively.
223896997|NCT04284865|OTHER|Web Platform|The intervention involves the use of the web platform for 12 months combined with a monthly phone follow-up.
223896998|NCT05569122|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|"Testing with an exercise bicycle that is considered standard of care for determination of exercise capacity. Participants will complete about 20 minutes of pedaling in a stationary exercise bike"
223896999|NCT05569122|DEVICE|pGz Bed|Participants will lay down on a passive exercise (pGz) bed for 45 minutes during which the bed will administer passive exercise through periodic acceleration
223897000|NCT05569122|DEVICE|Gentle Jogger|Participants will have passive exercise delivered through the gentle jogger device for 45 minutes. This may be sitting down (aim 1 participants) or laying down (aim 2 participants)
223897001|NCT05569122|DEVICE|Exercise Pedal|Participants will exercise while laying down for 20 minutes with an exercise pedal that attaches to the bed
223897002|NCT05569122|DRUG|Lumason® contrast agent|Contrast agent used during a vascular ultrasound of the upper leg. Will occur at each study visit twice before and after pGz bed, gentle jogger, exercise pedal or CPET. Drug Administration will be through an IV line and take about 5 - 10 minutes.
223897003|NCT06298227|OTHER|Postoperative analgesia management with Paracerol® and IV PCA with Talinat®|In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.
223897004|NCT06298227|OTHER|Erector spinae plane block|The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
223897005|NCT06298227|OTHER|Quadratus lumborum plane block|QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
223897006|NCT06386094|DIAGNOSTIC_TEST|Echocardiographic assessment|M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
224083409|NCT00000815|BIOLOGICAL|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
224083410|NCT04669990|DRUG|Remdesivir|The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
224276582|NCT03540849|DRUG|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
224276583|NCT03620617|DIETARY_SUPPLEMENT|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
224276584|NCT05054049|DEVICE|Interventional Diagnostic Device Arm|Point of care testing venous blood diagnostic device.
224276585|NCT05054049|OTHER|Usual care|Usual care provided to patient without use of point of care testing device
224276586|NCT05290337|DRUG|zanubrutinib|BTK inhibitor
224276587|NCT04225260|BIOLOGICAL|botulinum toxin neuromodulator|A dose of QM1114-DP will be injected in the GL area and in the LCL area.
224276588|NCT01785394|DRUG|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
224083411|NCT01670266|DRUG|ONO-9054|
224276589|NCT03651908|PROCEDURE|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
223528574|NCT06157034|DIETARY_SUPPLEMENT|Mentha spicata oil|Mentha spicata L will be extracted in the form of oil and will be encapsulated.
223528575|NCT03181191|OTHER|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
223528576|NCT01603654|DRUG|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
223528577|NCT01603654|DRUG|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
223528578|NCT02862093|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
223528579|NCT05109741|BEHAVIORAL|Internet-based Psychodynamic Therapy|Internet-based Psychodynamic Therapy based on the SUBGAP model developed by Farrell Silverberg
223528580|NCT05109741|BEHAVIORAL|Internet-based Behavioral Activation|Internet-based Behavioral Activation based on the BATD-R model developed by Carl Lejuez and others.
223528581|NCT04009980|OTHER|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
223528582|NCT04009980|OTHER|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
223528583|NCT04037215|OTHER|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
223528584|NCT04422496|DRUG|HEC96719|"single-Dose Study: Each dose of HEC96719 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and multiple-dose study."
223713609|NCT03937297|BEHAVIORAL|Six Arts|"The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts."
223713610|NCT03937297|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)
223713611|NCT03937297|BEHAVIORAL|Usual Care|usual dementia care provided by participating center
223713612|NCT01004705|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
223713613|NCT01004705|DRUG|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
223713614|NCT00717691|DEVICE|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
223713615|NCT00717691|OTHER|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
223713616|NCT06506708|OTHER|Hydrotherapy + massage|The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
223713617|NCT04374721|DIAGNOSTIC_TEST|circadian gene expression evaluation|patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
223713618|NCT06499311|OTHER|Foot Reflexology|Foot Reflexology is an alternative medical practice involving the application of pressure to specific points on the feet. It has been reported as a non-invasive complementary therapy that was addressed as an effective technique that is reported to reduce premenstrual symptoms.
223713619|NCT06499311|OTHER|Acupressure|Acupressure is a sort of massage therapy, was addressed as an effective technique that is reported to reduce premenstrual symptoms. Acupressure is a well-known form of Traditional Chinese Medicine that is a component of alternative treatments.
223713620|NCT01755078|DRUG|Sevelamer HCl|Non-metal phosphate binder
223713621|NCT01755078|DRUG|Calcium-based phosphate binder|
223713622|NCT03220178|DRUG|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
223713623|NCT03220178|DRUG|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
224083412|NCT01670266|DRUG|Placebo|
223713624|NCT03220178|DRUG|Anastrozole|1mg per day
223713625|NCT03220178|DRUG|Letrozole|2,5mg/day
223713626|NCT03220178|DRUG|Exemestane|25mg/day
223713627|NCT05249374|DRUG|Recombinant Human Serum Albumin|10 g/bottle (20%, 50 mL)
223713628|NCT05249374|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
223713629|NCT06340373|DEVICE|DCB Angioplasty|Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function
223713630|NCT02016573|DEVICE|Renal Denervation|Renal Denervation Catheter
223713631|NCT03830632|OTHER|Plyometric Training|
223713632|NCT03830632|OTHER|Traditional Training|
223713633|NCT04600375|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
223713634|NCT04600375|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
223713635|NCT03095612|DRUG|Selinexor|Selinexor once weekly oral or twice weekly oral
223713636|NCT03095612|DRUG|Docetaxel|Docetaxel once every 3 weeks (75 mg/m2 IV)
223713637|NCT04425512|DIAGNOSTIC_TEST|Complete Blood Count|Complete Blood Count samples
223713638|NCT04273204|DIAGNOSTIC_TEST|one leg standing test, gross motor function measurement, pedobarographic measurement|OLST:During the OLST,the participants were asked to shoes off,place both hands on their hips and look at a point on the wall at eye level.A recording stopwatch was used to assess their standing duration on one leg while keeping the other leg in 90 degrees of knee flexion.The test was stopped when the contralateral foot touched the ground or when the participant broke 90 degrees of knee flexion.The OLST was repeated three times for each leg.GMFM:To assess standing and walking,running and jumping functions of the UCP group,the D and E dimensions of GMFM were utilized by a certificated physiotherapist.Each item was tested by three trials and the best trial was used.Pedobarography:The participants' plantar pressure was analyzed using pedobarography.For each participant, the pedobarography was calibrated before the assessment.During the pedobarographic analysis, the participants walked barefoot in 90 BPM cadence. Three steps were analyzed for each side.
223713639|NCT06139107|DRUG|Abemaciclib|150mg twice a day for 3 cycles prior to radiation.
223713640|NCT06139107|DRUG|Letrozole|Letrozole 2.5mg daily
223713641|NCT05518019|DIETARY_SUPPLEMENT|The Daily Supplement|"Each serving of the dietary supplement (defined as 1 softgel) contains the following formulation:~Organic Broad Spectrum Hemp Extract 35mg Bio-Terpene Complex 52mg Palm Monoglycerides Organic Hemp Seed Oil, Clove Bud Oil, Black Pepper Berry Essential Oil Curcumin (Turmeric Root) Essential Oil~Inactive ingredients: Organic Flaxseed Oil, Gel Shell (Modified Tapioca Starch, Glycerin, Purified Water, Maltitol"
223713642|NCT04076397|PROCEDURE|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
223713643|NCT04076397|OTHER|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
223713644|NCT01238510|PROCEDURE|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
223713645|NCT01238510|PROCEDURE|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (\>50% in visual) or TIMI flow grade (\<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
223713646|NCT05679323|OTHER|KATZ index of independence in activities of daily living|KATZ index measures self-care tasks using a dichotomous rating (dependent-0/independent-1) including; bathing, dressing, toileting, transferring to and from a chair, maintaining continence, and feeding. Six points are considered independent and 0 points are considered fully dependent. Assessment of each patient is made through a phone call at day 1, 3 and 5 after discharge
223713647|NCT04447794|BEHAVIORAL|Step Away Chatbot|"The Step Away chatbot utilizes AI technology to provide mobile, web-based, person-centered, behavioral-based interventions and timely support for individuals seeking to reduce their alcohol use. Participants interact with the chatbot through interactive text.~The Step Away chatbot is informed by the following theoretical constructs: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. It uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. It proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
223713648|NCT04447794|BEHAVIORAL|Step Away App|"The Step Away app is a smartphone-based mobile intervention system.~It is informed by three theoretical constructs that are considered the most important active ingredients for person-centered, behavioral-based intervention and treatment in addictions: (1) motivational enhancement; (2) relapse prevention; and (3) community reinforcement. Step Away uses the Relapse Prevention (RP) model, which is informed by cognitive behavioral theory and has evolved to reflect the dynamic, non-linear relationships between contextual triggers and coping, as mediated by motivation, mood, and self-efficacy. Step Away proactively encourages the user to identify and include supportive others in treatment; to identify and plan non-drinking, recreational activities; and to develop other non-drinking lifestyle skills and strategies."
223713649|NCT03771820|DRUG|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
223713650|NCT03771820|DRUG|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
223713651|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.25% Injection Solution_#2|40cc
223713652|NCT05062356|DRUG|EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge|10cc
223713653|NCT05062356|DRUG|Bupivacaine Hydrochloride 0.5% Injection Solution_#2|20cc
223713654|NCT05062356|DRUG|Ketorolac|15mg
223713655|NCT03990454|DRUG|SLC-391|SLC-391 is an AXL inhibitor
223713656|NCT00762060|DEVICE|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
223713657|NCT00762060|DRUG|Patient controlled analgesia|IV opioids delivered via PCA
223713658|NCT05142163|OTHER|Intraoperative SVV Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain SVV \<11%, for values \>11%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
223713659|NCT05142163|OTHER|Intraoperative PVI Guided Fluid Therapy|Patients will receive intraoperative maintenance Fluids as crystalloids to maintain PVI \<10%, for values \>10%colloid bolus 6%hydroxyethyl starch will be given and fluid responsiveness noted.
223713660|NCT06475586|DRUG|Semaglutide|0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks
223713661|NCT00000371|DRUG|D-cycloserine|50 mg/daily by mouth
223713662|NCT00000371|DRUG|Placebo|50 mg/day of placebo by mouth
223713663|NCT02571075|OTHER|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
223713664|NCT04070885|PROCEDURE|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
223713665|NCT04070885|PROCEDURE|Urine sample|The urine will be taken from three 15 ml tubes.
223713666|NCT05871775|BEHAVIORAL|Personalized exercise|After selective functional movement evaluation, customized interventions for each patient
223713667|NCT05871775|BEHAVIORAL|Stabilization exercise|Neck stabilization exercise and sensorimotor program
223713668|NCT05871775|BEHAVIORAL|General exercise|General mobility exercise and strength exercise program
223713669|NCT03916991|OTHER|Exercise|Hip focused Neuromuscular Activation Exercise
223713670|NCT04092439|DIETARY_SUPPLEMENT|Watermelon Juice|100% Watermelon Juice
223713671|NCT02237131|DRUG|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
223713672|NCT02237131|DRUG|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
223713673|NCT00963937|DRUG|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
223713674|NCT00963937|DRUG|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
223713675|NCT00963937|DRUG|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
223713676|NCT02433730|DRUG|Testosterone|intramuscular injection
223713677|NCT02433730|DRUG|placebo|intramuscular injection
223713678|NCT00864383|DRUG|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
223713679|NCT02197520|DRUG|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
223713680|NCT02197520|DRUG|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
223713681|NCT02197520|DRUG|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
223713682|NCT01306903|DEVICE|MECC|Minimized extracorporeal circulation
223713683|NCT01306903|DEVICE|MOPS|Modified and optimized perfusion system Frankfurt
223713684|NCT01306903|DEVICE|Super MOPS|Super modified and optimized perfusion system Frankfurt
223713685|NCT03756844|BEHAVIORAL|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
223713686|NCT03147261|OTHER|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
223713687|NCT00158158|DRUG|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
223713688|NCT00158158|OTHER|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
223713689|NCT02740881|OTHER|Counselor Training Methods|
223713690|NCT03912168|OTHER|Question Prompt List|Question prompt list for common orthopaedic conditions
223713691|NCT03912168|OTHER|3 questions list|3 questions from the AskShareKnow model
223713692|NCT03253276|DRUG|Obeticholic acid|Placebo-controlled
223713693|NCT03253276|DRUG|Placebos|
223713694|NCT05641324|DRUG|ANV419|ANV419 administered by intravenous (IV) infusion
223713695|NCT05641324|DRUG|Lenalidomide with low-dose dexamethasone|Lenalidomide and dexamethasone administered orally
223713696|NCT05641324|DRUG|Daratumumab|Daratumumab administered by subcutaneous injection
223713697|NCT05827510|DEVICE|BTL-585F|BTL-585F device with BTL-585-4 applicator
223713698|NCT02880059|DEVICE|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
223713699|NCT01271062|PROCEDURE|gastric bypass surgery|
223713700|NCT01271062|PROCEDURE|abdominal surgery|
223713701|NCT01271062|BEHAVIORAL|very low caloric diet|
223713702|NCT02574468|DRUG|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
223713703|NCT02574468|PROCEDURE|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
224083413|NCT00055952|DRUG|exatecan mesylate|
224276590|NCT01204125|DRUG|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
223713704|NCT01634724|DRUG|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
223713705|NCT03240302|DEVICE|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
223713706|NCT03240302|DEVICE|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
223713707|NCT04960501|PROCEDURE|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella|New type of tension band or patellar tension reduction band for treatment of lower pole fracture of patella
223713708|NCT05963594|DIETARY_SUPPLEMENT|Oligomalt|The investigational product (Oligomalt) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
223713709|NCT05963594|DIETARY_SUPPLEMENT|maltodextrin|The investigational product (maltodextrin) dissolved in 300 ml water will be consumed over approximately 10 minutes in the morning of the study visit after a fasting period of at least 10 hours.
223713710|NCT01889004|DRUG|Dexmedetomidine|Escalating concentrations until loss of responsiveness
223713711|NCT01889004|DRUG|Propofol|Escalating concentrations until loss of responsiveness
223713712|NCT04173988|GENETIC|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~* For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10\^6 CAR+ cells/kg~* For children with body weight \> 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10\^8 CAR+ cells."
223713713|NCT04173988|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223713714|NCT04173988|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223713715|NCT06273410|OTHER|Cention N|Cention N will be manipulated using the standard powder: liquid ratio which is, one scoop of powder with one drop of liquid. Powder and liquid will be dispensed on the mixing pad and mixed using a plastic spatula according to the manufacturer's instruction for 45-60 seconds
223713716|NCT06273410|OTHER|Cention N + Adhesive|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds
223713717|NCT06273410|OTHER|Bulk Fill Composite|Cavity will be rinsed with water to remove all residue. Etchant will be applied onto the prepared cavity for 15 seconds and thoroughly rinsed with water spray and gently dried with air jet. A layer of Tetric N Bond universal will be applied on the enamel \& dentin surface using a disposable applicator, the material will be gently brushed into dentin for at least 10 seconds.
223713718|NCT00714649|DRUG|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
223713719|NCT05192967|BEHAVIORAL|Pandemic preparedness via video|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
223713720|NCT05192967|BEHAVIORAL|Pandemic preparedness via classical method|A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
223713721|NCT01422018|DRUG|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
223713722|NCT03403075|BEHAVIORAL|ETAF|Therapeutic education and Physical activity
223713723|NCT03403075|BEHAVIORAL|Usual care|Usual care
223713724|NCT04411654|GENETIC|LY3884961|Participants will receive a single dose of LY3884961 administered intracisternally.
223713725|NCT04411654|DRUG|Methylprednisolone|Single IV pulse administered as concomitant medication.
223713726|NCT04411654|DRUG|Sirolimus|Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
223713727|NCT04411654|DRUG|Prednisone|Administered orally as concomitant medication, followed by dose tapering.
223713728|NCT03530358|DEVICE|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
223713729|NCT03530358|BEHAVIORAL|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
223713730|NCT01310153|PROCEDURE|prone positioning|newborn babies in prone positioning
223713731|NCT01310153|PROCEDURE|Supine|newborn babies in supine positioning
223713732|NCT06429137|DRUG|BI 3731579|BI 3731579
223713733|NCT06429137|DRUG|Matching placebo to BI 3731579|Matching placebo to BI 3731579
223713734|NCT01928069|DRUG|Torrent's Montelukast Sodium Tablets 10 mg|
223713735|NCT02048969|DRUG|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
223713736|NCT02048969|DRUG|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
223713737|NCT01395667|OTHER|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
223897007|NCT06799468|PROCEDURE|liver transplantation|Liver transplantation or hepatic transplantation is the replacement of a diseased liver with the healthy liver from another person (allograft). Liver transplantation is a treatment option for end-stage liver disease and acute liver failure, although availability of donor organs is a major limitation. Liver transplantation is highly regulated, and only performed at designated transplant medical centers by highly trained transplant physicians. Favorable outcomes require careful screening for eligible recipients, as well as a well-calibrated live or deceased donor match.
223897008|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
223897009|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 1.1|Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.
223897010|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
223897011|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 2.1|Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.
223897012|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
223897013|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 3.1|Participants will use their Radicle Relaxation Active Study Product 3.1 as directed for a period of 6 weeks.
223897014|NCT06378801|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
223897015|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.1|Participants will use their Radicle Relaxation Active Study Product 4.1 as directed for a period of 6 weeks.
223897016|NCT06378801|DIETARY_SUPPLEMENT|Relaxation Active Study Product 4.2|Participants will use their Radicle Relaxation Active Study Product 4.2 as directed for a period of 6 weeks.
223897017|NCT03804944|RADIATION|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
223897018|NCT03804944|DRUG|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
223897019|NCT03804944|BIOLOGICAL|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
223897020|NCT05344469|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.
223897021|NCT05344469|OTHER|glatiramer acetate|There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.
223897022|NCT05344469|OTHER|interferon β1|There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.
223897023|NCT06040320|DRUG|Polatuzumab vedotin|Given at 1.8 mg/kg
223897024|NCT06040320|DRUG|Rituximab|Given at 375 mg/m\^2
223897025|NCT06040320|DRUG|CHP|Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
223897026|NCT04295798|DEVICE|Conventional tDCS|The anode will be placed over F3 and the cathode over the contralateral supraorbital margin. At the beginning of stimulation, the current will be increased from 0.1 mA, in 0.1 mA increments over 60 seconds, up to a maximum of 1.8 mA. At the end of each session, current will be automatically ramped down to 0.0 mA over a 60 second period.
223897027|NCT04295798|DEVICE|Optimized tDCS|This intervention will utilize eight gel electrodes with placement and current parameters optimized to the cohort, with the goal of generating an average nE over the left dlPFC of the same size as the one delivered by a conventional montage using sponges. The direct current delivered by any one electrode will however never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20- minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
223897028|NCT04295798|DEVICE|Conventional Sham|Conventional sham will be used to maximize blinding of conventional sponge-based stimulation. The same sponge placement, ramp-up procedure, and session duration described above will be used; however, current will be automatically ramped down 60 seconds after ramp-up.
224276591|NCT01204125|DRUG|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
223897029|NCT04295798|DEVICE|Optimized Sham|An active sham will be used in which very low-level currents (0.5 mA max) are transferred between the same electrodes used in the active condition throughout the entire 20-minute session. This intervention will be optimized to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS. We have shown that this active sham effectively blinds participants and operators to stimulation condition and does not affect functional outcomes.
223897030|NCT06772831|BEHAVIORAL|Cognitive Reappraisal by Distancing|Reappraisal-by-distancing treatment. Patients meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique.
223897031|NCT06772831|BEHAVIORAL|Downregulate condition|Patients either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
223897032|NCT06429319|DEVICE|"Hydrous biopolymer with silver ions Argiform (HBISA) endoprosthesis of synovial fluid NOLTREX™"|If clinically indicated patients received a repeat course of NOLTREX™ (one or two weekly intra-articular injections of 4.0 NOLTREX™ at the investigator's discretion depending on the stage of OA and clinical response to treatment).
224083414|NCT00617877|DRUG|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
224276592|NCT01074008|DRUG|ABT-450|50 mg capsules co-administered with ritonavir
224276593|NCT01074008|DRUG|ABT-072|50 mg tablet
224276594|NCT01074008|DRUG|ABT-333|400 mg tablet
224276595|NCT01074008|DRUG|Ritonavir|100 mg capsules co-administered with ABT-450
224276596|NCT01074008|DRUG|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
224276597|NCT01074008|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
223897033|NCT04611022|BEHAVIORAL|HPV Educational Intervention|The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p \< .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
223897034|NCT04063501|OTHER|Bronchoscopy|The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
223897035|NCT04063501|OTHER|Research Procedures|electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
223897036|NCT04872413|PROCEDURE|Biospecimen Collection|Undergo blood, saliva or tissue sample collection
223897037|NCT04872413|OTHER|Follow-Up|Undergo follow-up
223897038|NCT04045184|OTHER|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
223897039|NCT06771167|BEHAVIORAL|Building Community Resilience Program (BCR)|To improve CHW resilience and wellbeing, during each BCR cycle, the 6 participating CBOs will send groups of four to six CHWs to six virtual, hour-long, evidence-based interactive workshops (48-72 CHWs over the 2 cycles).
223897040|NCT05693740|PROCEDURE|Accelerated crosslinking (ACXL)|Epithelium-off accelerated corneal crosslinking is a procedure in which the cornea is soaked with riboflavin followed by exposure to ultraviolet irradiation in either pulsed-light or continuous-light modes to strengthen the corneal stroma and halt keratoconus progression.
223897041|NCT05601440|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
223897042|NCT05601440|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
223897043|NCT05601440|OTHER|Observation|Monitoring arm
223897044|NCT05601440|DRUG|Niraparib|Dose and schedule will be assigned at enrolment
223897045|NCT05601440|DRUG|Fulvestrant|Dose and schedule will be assigned at enrolment
223897046|NCT05601440|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
223897047|NCT06293339|BIOLOGICAL|CHMI with 3D7 malaria|Controlled human malaria infection with 3D7 malaria through mosquito bites
223897048|NCT03495986|DEVICE|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
223897049|NCT03495986|BEHAVIORAL|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
223897050|NCT06020755|DRUG|Toripalimab|200mg q2w intravenous
223897051|NCT06020755|DRUG|Actinomycin-D|1.25mg/m2，2mg max dose, q2w, intravenous
223897052|NCT05378035|DIAGNOSTIC_TEST|Blood Tests|Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.
223897053|NCT05792176|BEHAVIORAL|Music Training Intervention|The Music Training Intervention (MTI) entails 12-weeks of online instruction to learn to play the ukulele. Participants will be taught the basic information on how to handle and hold the ukulele, musical chords, and popular songs. They will be instructed to play at least 30-minutes a day, five days a week.
224276598|NCT01074008|OTHER|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
224276599|NCT00578968|DRUG|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
223897054|NCT05792176|BEHAVIORAL|Music Listening|Participants randomized to this arm will be asked to listen to their preferred music for at least 30 minutes, 5 days a week. A member of our research team will call them every week to answer any questions they have about the ML protocol. They will be asked to record their experience in a practice log.
223897055|NCT06800235|OTHER|Computer-Assisted Simulation|Nursing students in the experimental group were informed about computer-based simulation. They were also informed about the aspiration skill form and general competency scale.
223897056|NCT06800235|OTHER|Control grup|Nursing students in the control group were informed about the standard procedure/traditional method. They were also informed about the aspiration skill form and general competency scale.
223897057|NCT05968586|OTHER|Body positioning|Body positioning of infants prone vs supine.
223897058|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (before physical activity)|Simultaneous blood pressure and heart rate measurements at minutes 2 and 5.5 of the experiment.
223897059|NCT05302193|OTHER|Physical activity|Five minutes of physical activity, between times 7.5 min and 12.5 min of the experimental part. Riding on a spinning ergometer with a standardized load of 1 W/kg.
224083415|NCT00617877|DRUG|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
224276600|NCT00578968|DRUG|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
224276601|NCT02166853|DRUG|sevoflurane|Sedation with inhaled sevoflurane
224276602|NCT02166853|DRUG|midazolam|Sedation with intravenous midazolam
224276603|NCT00320853|DRUG|Vitamin D|
224276604|NCT00603564|PROCEDURE|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
224276605|NCT05080608|OTHER|Surgery|Treatment according to clinical practise
223713738|NCT05051618|BEHAVIORAL|POWER-MS|"The POWER-MS intervention includes both aerobic exercise and resistance exercise:~Aerobic Exercise:~The goal of the aerobic exercise training is for participants to achieve three moderate-intensity walking sessions of 30+ minutes per session by the end of the 16-week intervention.~Resistance Exercise:~Participants will complete resistance exercise training that consists of 1-2 sets (10-15 repetitions) of 5-10 exercises targeting the lower body, upper body, and core muscle groups performed three days per week, with the sets, repetitions and number of exercises increasing based on an individualized difficulty level."
223713739|NCT05051618|BEHAVIORAL|FLEX-MS|The FLEX-MS intervention is specifically a stretching exercise prescription. All exercise movements are consistent throughout the program. At the beginning of the program, the stretching exercise sessions will take five minutes (1 set) three days per week (15 minutes per week). By the end of the 16-week program, the sessions will take about 30 minutes (2 sets) to be performed three days per week (1.5 hours per week).
223713740|NCT00369824|BIOLOGICAL|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
223713741|NCT00369824|BIOLOGICAL|Menactra TM|One dose of vaccine administered intramuscularly
223713742|NCT00369824|BIOLOGICAL|Boostrix TM|One dose of vaccine administered intramuscularly
223713743|NCT01831648|OTHER|Blood sample|
223713744|NCT00229593|DRUG|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
223713745|NCT00229593|DRUG|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
223713746|NCT04873115|OTHER|Placebo|Sialanar placebo
223713747|NCT04873115|DRUG|Sialanar|Sialanar - a licensed glycopyrronium bromide product
223713748|NCT04873115|OTHER|Oral Rehabilitation|Standard oral rehabilitation for provided drooling
223713749|NCT04397601|DRUG|Folfiri/Bevacizumab|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.
223713750|NCT04397601|DRUG|Folfiri/Aflibercept|Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
223713751|NCT04493073|PROCEDURE|Trabectulectomy|decrease IOP
223713752|NCT04493073|DRUG|Mitomycin|Decrease bleb failure
223713753|NCT04493073|DEVICE|Ologen Collagen Implant|Ologen Collagen Implant (Aeon Astron Europe, Netherlands)
223713754|NCT04493073|DEVICE|Mitomycin-C Kyowa®|Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
223713755|NCT06385951|DIAGNOSTIC_TEST|Procedure for patients|We will screen patients who undergo an MRI and neuropsychological examination as part of their diagnostic workup. If inclusion and exclusion criteria are met, patients will be asked to undergo additional investigations (FDG-PET, lumbar puncture, tau and amyloid PET and the ALLO iVR task).
223713756|NCT06385951|DIAGNOSTIC_TEST|Procedure for healthy controls|Healthy controls will be asked to undergo a neuropsychological examination, the ALLO iVR task, an MRI, FDG-PET and tau-PET.
223713757|NCT00375648|DRUG|Zoledronic acid|
223713758|NCT00210483|DRUG|almotriptan malate|
223713759|NCT01959074|DRUG|Naftopidil|Naftopidil 75mg 1T qd hs
223713760|NCT01959074|DRUG|Placebo for Naftopidil|Placebo 1T qd hs
223713761|NCT01959074|DRUG|Standard treatment|aceclofenac 100mg on demand
223713762|NCT01086761|BIOLOGICAL|MP0112|Single intravitreal injection of MP0112 in the study eye.
223713763|NCT04528732|BEHAVIORAL|Group Cognitive Behavioral Therapy (G-CBT)|G-CBT consists of 10-session for HIV/AIDS-associated stigma, utilizing core components of CBT, including psychoeducation, cognitive restructuring, and skill-building to increase adaptive coping mechanisms.
223713764|NCT04528732|BEHAVIORAL|Multiple Family Group (MFG)|MFG consists of 10-sessions that strengthen family relationships intended to address HIV/AIDS-associated stigma at the individual level and within families. The core components of MFG are known as 4Rs and 2S's: rules, responsibility, relationships, respectful communication, stress and social support.
223713765|NCT05495620|DRUG|Carfilzomib|"Intravenous~carfilzomib, lenalidomide, dexamethasone"
223713766|NCT05495620|DRUG|Lenalidomide|Oral
223713767|NCT05495620|DRUG|Dexamethasone|Oral or intravenous
223713768|NCT02244112|DRUG|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
223713769|NCT02244112|DRUG|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
223713770|NCT04905758|PROCEDURE|platform switching|reduced implant abutment interface
223713771|NCT04905758|PROCEDURE|platform amtching|matched implant abutment interface
223713772|NCT03375606|BIOLOGICAL|CSL730|Solution for IV infusion
223713773|NCT03375606|OTHER|Placebo|Saline solution for IV infusion
223713774|NCT01262911|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
223713775|NCT01262911|DRUG|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
223713776|NCT02888301|PROCEDURE|Computed Tomography|Undergo 18F-clofarabine PET/CT
223713777|NCT02888301|RADIATION|Fluorine F 18 Clofarabine|Given IV
223713778|NCT02888301|PROCEDURE|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
223713779|NCT00740571|DRUG|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
223713780|NCT00740571|DRUG|pregabalin|Strategy in which patient starts with pregabalin
223713781|NCT02094677|DEVICE|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
223713782|NCT02094677|DEVICE|etafilcon A|Participants were randomized to wear etafilcon A control lens.
223713783|NCT02094677|DEVICE|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
223713784|NCT00654017|DRUG|placebo|Placebo comparator to be given per protocol.
223713785|NCT00654017|DRUG|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
223713786|NCT05399641|DRUG|Ibrexafungerp|Each day dosing will consist of two 150mg tablets taken BID.
223897060|NCT05302193|OTHER|Calm measurement of blood pressure and heart rate (after physical activity)|Simultaneous blood pressure and heart rate measurements at times 15.5, 17, 20.5 and 22 minutes of the experimental part.
223897061|NCT03509012|DRUG|Durvalumab|IV (intravenous)
223897062|NCT03509012|DRUG|Tremelimumab|IV
223897063|NCT03509012|DRUG|Cisplatin (dose level 4)|IV
223897064|NCT03509012|DRUG|Cisplatin (dose level 3)|IV
223897065|NCT03509012|DRUG|Carboplatin (dose level 1)|IV
223897066|NCT03509012|DRUG|Carboplatin (dose level 2)|IV
223897067|NCT03509012|DRUG|Etoposide (dose level 1)|IV
223897068|NCT03509012|DRUG|Etoposide (dose level 2)|IV
223897069|NCT03509012|DRUG|Paclitaxel|IV
223897070|NCT03509012|DRUG|Pemetrexed|IV
223897071|NCT03509012|RADIATION|External beam radiation (dose level 1)|radiation therapy
223897072|NCT03509012|RADIATION|External beam radiation (dose level 2)|radiation therapy
223897073|NCT03509012|RADIATION|External beam radiation (hyperfractionated)|radiation therapy
223897074|NCT03509012|DRUG|Cisplatin (dose level 1)|IV
223897075|NCT03509012|DRUG|Cisplatin (dose level 2)|IV
223897076|NCT03509012|RADIATION|External beam radiation (standard)|radiation therapy
223897077|NCT05376579|OTHER|siponimod|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study after the independent decision by physician and patient to start siponimod treatment as routine clinical care.
223897078|NCT01724580|DRUG|Baricitinib|Administered orally
223897079|NCT06798246|DRUG|Chemotherapy|Gemicitabin and cisplatin
223897080|NCT06798246|DRUG|Immunotherapy|PD-1/PD-L1
223897081|NCT06798246|DRUG|ADC|ADC drug like RC48
223897082|NCT06798246|DRUG|Chemotherapy combined with immunotherapy|Chemotherapy combined with immunotherapy
223897083|NCT06381713|BEHAVIORAL|High intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks."
223897084|NCT06381713|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|"Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks."
223897085|NCT06772818|DRUG|Nemtabrutinib|Oral Tablet
223897086|NCT06581003|DRUG|Oxygen 99.7 %|The experimental group will undergo HBOT in a specialized chamber at a pressure of 2.0 ATA. Oxygen will be delivered at 100% for 60 minutes.
223897087|NCT06581003|DRUG|Oxygen 21 %|The control group will be placed in the same specialized chamber, but pressure will be 1.0 ATA (normobaric), and oxygen will be delivered at 21% (normal oxygen concentration in room air) for 60 minutes.
223897088|NCT04927364|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H7 coil|The study will utilize the H7 coil to administer Deep Transcranial Magnetic Stimulation (dTMS) to the dorsal anterior cingulate cortex (dACC), a core salience network node.
223897089|NCT04380545|DRUG|Fluorouracil|Given IV
223897090|NCT04380545|BIOLOGICAL|Nivolumab|Given IV
223897091|NCT04380545|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Given SC
223897092|NCT04872738|OTHER|Survey|Patients in all groups will complete surveys about their decision to receive or not to receive the COVID-19 vaccine. For those who did receive the vaccine, they will indicate their experience with the vaccination and any side effects they may have experienced.
223897093|NCT05578300|DIAGNOSTIC_TEST|Thrombus analyses|Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
223897094|NCT05578300|DIAGNOSTIC_TEST|Imaging assessment|All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
223897095|NCT05255159|DIAGNOSTIC_TEST|18F-DOPA with furosemide|Diagnostic 18F-DOPA PET/CT scan
223897096|NCT03122847|DRUG|Methylprednisolone|Intravenous methylprednisolone
223897097|NCT04583293|OTHER|No intervention|This study does not involve any intervention or new treatment.
223897098|NCT04971889|BEHAVIORAL|Diabetes MNT|Group-based MNT sessions that provide evidence-based dietary self-care information, behavioral skills, and goal setting related to managing carbohydrate and fat intake
223897099|NCT04971889|BEHAVIORAL|Motivational Interviewing|Group-based support for dietary self-care motivation using culturally-adapted motivational interviewing exercise
223897100|NCT06063083|BEHAVIORAL|"Tell Me More (Dime Mas)"|Participants will receive an initial approximately 1 hour outreach session followed by up to 3 approximately monthly check-in outreach attempts (approximately 15 minutes each). All study visits can be done in person or remotely. Each contact will involve helping participants get connected to PrEP, HIV testing, and behavioral health treatment.
223897101|NCT06063083|BEHAVIORAL|"Peer Ambassador Stories [Listen Miami (Oye Miami)]"|Participants will receive a link to a website featuring stories of local Latino MSM using PrEP, HIV testing, and behavioral health treatments. Participants will receive intermittent (based on personal choice) reminders to view the website. The website will also show referrals to services and provide the option to submit a story via written, video, or audio recording. Participants can access the website using a personal electronic device at any time during within the study period.
223897102|NCT06063083|BEHAVIORAL|Standard Community Outreach|Participants will receive the standard community outreach, which will be a list of referrals for HIV testing, PrEP, and behavioral health treatments.
223897103|NCT03624608|DEVICE|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
223897104|NCT03916510|BIOLOGICAL|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
223897105|NCT03916510|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
223897106|NCT03916510|RADIATION|Radiotherapy|50 Gy/25#
223897107|NCT04219280|DRUG|Quillivant XR|Long-lasting liquid solution of Quillivant XR.
223897108|NCT04219280|DRUG|Placebo|Liquid solution to mimic the color and taste of Quillivant XR.
223897109|NCT06486584|BEHAVIORAL|Contingency Management|Contingency management payment for no disruptive behaviors each week.
223897110|NCT05219123|OTHER|ERCP with no PD cannulation|ERCP with no PD cannulation
223897111|NCT05219123|OTHER|ERCP with single PD cannulation|ERCP with single PD cannulation
223897112|NCT03523975|DRUG|Venetoclax|PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
223897113|NCT03523975|DRUG|Lenalidomide|10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
223897114|NCT03523975|DRUG|Rituximab|375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
223897115|NCT00300859|BEHAVIORAL|brief motivational intervention|
223897116|NCT04899310|BIOLOGICAL|mRNA-3705|A sterile liquid for injection
223897117|NCT00858312|OTHER|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
223897118|NCT00858312|OTHER|Low Dairy|less than 1 serving of dairy foods per day.
223897119|NCT00621894|DRUG|LGD-4665|LGD-4665 Thrombopoietin mimetic
223897120|NCT00621894|DRUG|Placebo|Placebo
223897121|NCT04650269|DRUG|Biktarvy 50Mg-200Mg-25Mg Tablet|Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
223897122|NCT04650269|OTHER|HIV care|HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.
223897123|NCT06236620|DIETARY_SUPPLEMENT|Processing of wheat|Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
223897124|NCT05398679|DRUG|Cefaclor|cefaclor intravenous 2 gr/day
223897125|NCT05398679|DRUG|Ciprofloxacin Tablets|500-750 mg/12 hrs (maximum 3g x day)
223897126|NCT05398679|DRUG|Ciprofloxacin Injection|1200 mg/day maximum dose IV
223897127|NCT05398679|DRUG|Clindamycin Oral Capsule|600 mg/8 hours (maximum 1.800 mg x day)
223897128|NCT05398679|DRUG|Clindamycin Injection|600 mg/8 hours (maximum 1.800 mg x day) IV
223897129|NCT05398679|DRUG|Dicloxacillin Oral Capsule|1g/8 hours (maximum 4 gr day)
223897130|NCT05398679|DRUG|Dicloxacillin|1g/8 hours (maximum 4 g x day) IV
223897131|NCT05398679|DRUG|Fusidic Acid Only Product in Oral Dose Form|0,750g/12 hours (maximum 1,5 g x day)
223897132|NCT05398679|DRUG|Fusidic Acid Only Product in Parenteral Dose Form|0,75 g/12 hours (maximum 1,5 g x day)
223897133|NCT05398679|DRUG|Levofloxacin Oral Tablet|0.5g/12-24hours (maximum 1 g x day)
223897134|NCT05398679|DRUG|Levofloxacin Injection|0.5g/12-24hours (maximum 1 g x day)
223897135|NCT05398679|DRUG|Linezolid Oral Tablet|0,6 g/12 hours (maximum 1200 mg x day)
223897136|NCT05398679|DRUG|Linezolid Injectable Product|0,6 g/12 hours (maximum 1200 mg x day)
223897137|NCT05398679|DRUG|Moxifloxacin tablet|0,4 g/day (maximum 400 mg x day)
223897138|NCT05398679|DRUG|Moxifloxacin Injectable Product|0,4 g/day (maximum 400 mg x day)
223897139|NCT05398679|DRUG|Rifampicin Only Product in Oral Dose Form|0,3-0,5 g/12 hours (maximum 1200 mg x day)
223897140|NCT05398679|DRUG|Rifampicin Only Product in Parenteral Dose Form|0,3-0,6 g/12 hours (maximum 1200 mg x day)
223897141|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
223897142|NCT05398679|DRUG|Sulfamethoxazole / Trimethoprim Injectable Product|sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
223897143|NCT05398679|DRUG|Tedizolid Oral Tablet|200 mg tedizolid (maximum x day)
223897144|NCT05398679|DRUG|Tedizolid Injection|200 mg (maximum x day)
223897145|NCT05398679|DRUG|Amoxicillin Capsules|1 gr/6 hours (4 g x day)
223897146|NCT05398679|DRUG|Amoxicillin|1 gr/6 hours (4 g x day) Intravenous
223897147|NCT05398679|DRUG|Cefaclor Capsules|2 gr/day
223897148|NCT01437709|BIOLOGICAL|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
223897149|NCT01437709|OTHER|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 \& 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
223897150|NCT06408181|DRUG|Aspirin 162 mg|Aspirin is a nonsteroidal anti-inflammatory drug.
223897151|NCT06408181|DRUG|Aspirin 81mg|Aspirin is a nonsteroidal anti-inflammatory drug.
223897152|NCT06542588|COMBINATION_PRODUCT|HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)|Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy
223897153|NCT05858424|OTHER|Multidisciplinary day hospitalization|"This multidisciplinary day hospitalization will consist at least of a psychological interview, an interview with a social worker and a medical interview. The objectives of this medical interview, conducted by a clinician researcher, are to summarize the pathology, the treatment(s) received, and to develop a personalized after-cancer plan.~The psychological interview will assess the needs for further care, and will refer the former patient if necessary.~The social interview will take stock of the former patient's return to school and/or professional life, and direct him/her to possible applications for social assistance if needed.~If needs of supportive care emerge from the history of treatment period, some consultations can be added during the day hospitalization, like an interview with a dietician or an adapted physical activity assessment."
223897154|NCT04118088|BIOLOGICAL|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
223897155|NCT06353191|OTHER|Non-Interventional Study|Non-interventional study
223897156|NCT04266730|BIOLOGICAL|PANDA-VAC|The primary therapeutic neoantigen vaccine product, Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine (PANDA-VAC), will be comprised of 6 peptides at a dose of 300 micrograms (µg) per peptide admixed with local adjuvant Stabilized polyriboinosinic/polyribocytidylic acid (Poly-ICLC).
223713787|NCT03408483|DRUG|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
223713788|NCT03408483|DRUG|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
223713789|NCT00037141|DRUG|dehydrated alcohol|
223713790|NCT01300650|DRUG|Anakinra|Anakinra 100 mg subcutaneous injection daily
223713791|NCT03566160|DEVICE|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
223713792|NCT04633018|DEVICE|AsthmaMD mobile application|asthma management app with Spanish-language user interface
223713793|NCT04633018|OTHER|Usual care|Asthma management without the app
223713794|NCT04054505|DIETARY_SUPPLEMENT|EZPAK|One packet with breakfast for three months
223713795|NCT04054505|DIETARY_SUPPLEMENT|Placebo|One packet with breakfast for three months
223713796|NCT03805399|DRUG|Pyrotinib with Capecitabine|If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
223713797|NCT03805399|DRUG|AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4)|B1: if patients were LAR subtype without HER2 gene activated mutation, but had PI3KCA mutation, she would receive everolimus 10mg qd combined with AR inhibitor SHR3680 240mg qd continuously ; B2: if patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150mg qd (three week on one week off); B4: If patients were LAR subtype without HER2 gene activated mutation or PI3KCA mutation, she would receive AR inhibitor SHR3680 240mg qd combined with EZH2 inhibitor SHR2554 300mg bid continuously
223713798|NCT03805399|DRUG|anti PD-1 with nab-paclitaxel|If patients were IM subtype, she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw (three week on one week off).
223713799|NCT03805399|DRUG|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
223713800|NCT03805399|DRUG|BLIS with anti-VEGFR included therapy|"If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w"
223713801|NCT03805399|DRUG|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
223713802|NCT03805399|DRUG|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
223713803|NCT05890508|DEVICE|Acupuncture|Disposable acupuncture needles (0.20 mm in diameter) are are used in the study. The acupoints are GV20(Baihui), EX-HN1(Sishencong), EX-HN3(Yintang), SP6(Sanyinjiao), ST36(Zusanli), ST40(Fenglong), and LR3(Taichong). Electrical stimulation will be delivered with waves at 2-5 Hz from an electroacupuncture device. The needles will be retained in position for 30 minutes.
223713804|NCT05890508|DEVICE|Sham-acupuncture|"Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2/ 0.30 x 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality and then connecting the needle to the incorrect output socket of the electrical acupuncture stimulation instrument. The sham points are pseudo stimulation."
223713805|NCT01702961|DRUG|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
223713806|NCT01702961|DRUG|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
223713807|NCT01702961|DRUG|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
223713808|NCT01702961|DRUG|BCNU|BCNU 300 mg/m2 IV given on Day -6
223897157|NCT04266730|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
223897158|NCT05148507|DEVICE|PROKERA|Amniotic membrane is the sac that encloses the baby during pregnancy. Amniotic membrane has been used to treat many ocular (eye) diseases and repair ocular surface damage. PROKERA contains amniotic membrane fastened between a ring system and can be worn in the eye like a contact lens. PROKERA is a medical device that was cleared by the United States food and drug administration (FDA) in 2003.
223897159|NCT03539822|DRUG|Cabozantinib|by mouth
223897160|NCT03539822|DRUG|Durvalumab|infusion
223897161|NCT03539822|DRUG|Tremelimumab|infusion
223897162|NCT04169906|DRUG|Placebo|Participants will receive placebo once daily for 7 consective days
223897163|NCT04169906|DRUG|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
223897164|NCT04169906|DRUG|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
223897165|NCT04169906|DRUG|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
223713809|NCT01702961|DRUG|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
223713810|NCT01702961|DRUG|Stem Cells|Stem cells given on Day 0
223713811|NCT01209611|PROCEDURE|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
223713812|NCT01209611|PROCEDURE|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
223713813|NCT01374997|OTHER|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
223713814|NCT05622175|DRUG|F8IL10|"The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10"
223713815|NCT02185092|DIETARY_SUPPLEMENT|Lactobacillus GG|probiotic supplement
223713816|NCT02185092|OTHER|Sugar pill|placebo
223713817|NCT04489628|DRUG|Vitamin D3 or Placebo|): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.
223713818|NCT04489628|DEVICE|Doctella telehealth monitoring|Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
223713819|NCT00255125|DRUG|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
223713820|NCT00255125|DRUG|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
223713821|NCT01939808|OTHER|Splint Neutral|
223713822|NCT01939808|OTHER|Splint Extended|
223713823|NCT03180073|DIAGNOSTIC_TEST|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
223713824|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
223713825|NCT03180073|DIAGNOSTIC_TEST|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
223713826|NCT05364190|DRUG|Canagliflozin|Canagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
223713827|NCT05364190|DRUG|Empagliflozin|Empagliflozin will be used in hospitalized heart failure patients regardless of their diabetic state.
223713828|NCT05142111|BEHAVIORAL|Therapy|Discussion with therapist
223713829|NCT03488732|DEVICE|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
223713830|NCT05235048|PROCEDURE|Tooth extraction|Atraumatic tooth extraction without flap elevation
223713831|NCT05235048|PROCEDURE|Tooth extraction and socket seal with connective tissue graft|Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
223713832|NCT05235048|PROCEDURE|Tooth extraction and socket seal with BRG and connective tissue graft and|Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
223713833|NCT05235048|PROCEDURE|Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft|Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
223713834|NCT05890885|PROCEDURE|Real left prefrontal tDCS - sham|Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
223713835|NCT05890885|PROCEDURE|Sham - Real left prefrontal tDCS|Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period
224276606|NCT02106533|OTHER|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
223713836|NCT00674362|BIOLOGICAL|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
223713837|NCT00674362|BIOLOGICAL|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
223713838|NCT01908283|BIOLOGICAL|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
223713839|NCT00923156|DRUG|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
223713840|NCT00923156|DRUG|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
223713841|NCT00923156|DRUG|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
223713842|NCT00923156|DRUG|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
223713843|NCT01899261|RADIATION|Stereotactic Radiosurgery|Undergo SBRT
223713844|NCT03656432|DRUG|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
223713845|NCT06040931|PROCEDURE|Bronchoscopy|Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
223713846|NCT04066023|DRUG|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.
223713847|NCT04066023|DRUG|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
223713848|NCT01552993|DRUG|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
223713849|NCT01552993|DRUG|sucrose|pacifier and sucrose
223713850|NCT02212795|DRUG|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
223713851|NCT02212795|DRUG|Levofloxacin 250mg|Levofloxacin 250mg single dose
223713852|NCT02212795|DRUG|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
223713853|NCT05468060|DRUG|PA1010|Placebo as control
223713854|NCT05058820|OTHER|Post Facilitation stretch|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Post facilitation stretch 15 secs isometric hold/ 15 secs stretch/ 30 secs relax/ 5 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
223713855|NCT05058820|OTHER|Active Isolated Stretching|Hot pack 10 mins/ 1set/ (3 days/ week), TENS 10 mins/ 1 set/ (3 days/ week), Active Isolated Stretching 2 secs hold/ 10 reps/ 1 set/ (3 days/ week), Deep friction massage 5 minutes/ (3 days/ week). A total of 6 weeks (18 sessions, 3 days/ week) were given each consisting of 30 mins.
223713856|NCT05476471|BEHAVIORAL|multicomponent exercise training program|One supervised 60 minutes training sessions per week were organized combining warm-up, speed-walking, resistance exercise, static and dynamic balance. Supervised walking sessions were for 10-20 minutes at a target intensity of 13-15 on the Borg scale. Thereafter, 10 resistance exercises targeting lower body, trunk and upper body muscles were performed with elastic band. In addition, participants were instructed to accumulate 150 minutes per week of moderate intensity aerobic activity in bouts of at least 10 minutes, and at least 2-3 days all major muscle groups training.
223713857|NCT03214939|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
223713858|NCT04524546|DIAGNOSTIC_TEST|Sterno-mental displacement test|While the patient is in sitting position, (SMD neutral) will be is measured using tape as the distance between upper borders of the manubrium sterni to the mentum with the head in a neutral position. The (SMD extension) will be then measured in the same way with the head extended on the neck. The difference between SMD extension and SMD neutral will be then calculated as sternomental displacement (SMDD).
223713859|NCT00807729|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
223719105|NCT06464848|OTHER|Narrative identity task|All participants will be asked to develop five personal narratives in response to different types of questions: trauma, transgression, negative memory, self-definition, and turning point. For each story, participants will be asked to provide details of where they were, who they were with, what happened and how they and others reacted, what happened, how they reacted and how others reacted (if at all).
223719106|NCT05621369|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
224276607|NCT03027908|OTHER|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
224276608|NCT03027908|OTHER|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
224276609|NCT01004315|DRUG|KUC-7483|
224276610|NCT01004315|DRUG|Placebo|
224276611|NCT01004315|DRUG|Tolterodine|
224276612|NCT05386056|DRUG|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
224276613|NCT05386056|DRUG|Sinoporphyrin Sodium|0.2mg/kg, intravenously on day -2 of cycle 1.
224083416|NCT03633188|BIOLOGICAL|Patients treated by antibiotherapy|"Biological samples (stool, blood, swabs) will be collected :~* Blood sampling (12 ml) at baseline (week 0) at the end of treatment (W6/W24),and 15 days after antibiotherapy stop (optional) (W8/W26),~* Feces collection at baseline (week 0) during antibiotic treatment (W2), at the end of treatment (W6/W24),15 days after antibiotherapy stop (W8/W26), and W26 after baseline~* Swab samples (nasal and rectal) at baseline at week 0 and at the end of treatment (W6/W24),"
224276614|NCT05386056|PROCEDURE|Photodynamic therapy|PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
224276615|NCT04253015|OTHER|Data-collection|Data will be collected on dose, total cumulative amount of dinutuximab beta per course, dose interruptions, dose discontinuations, prophylactic treatment, use of all concomitant analgesia, assessments of pain, and occurrence of neurotoxicity, visual impairment, capillary leak syndrome, cardiovascular events and hypersensitivity reactions and other AEs.
224276616|NCT00108628|BEHAVIORAL|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
223713860|NCT00807729|PROCEDURE|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
223713861|NCT01193699|DRUG|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
223713862|NCT03442205|PROCEDURE|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
223713863|NCT03442205|PROCEDURE|ERCP technique + LC|ERCP technique + LC
223713864|NCT03442205|PROCEDURE|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
223713865|NCT05840367|BEHAVIORAL|Partner present in the operation room|The partner (father, co-mother or other close relative present for the birth) is present in the operation room during the entire category 1 cesarean section. This is standard clinical practice in this particular hospital since June 2021.
223713866|NCT02352129|OTHER|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
223713867|NCT03386448|DRUG|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
223713868|NCT03386448|DRUG|placebo arm|participants will receive placebo medications
223713869|NCT06440720|OTHER|ELDOA ,UPPER THORACIC MOBILIZATION AND MOBILITY EXERCISE|Already mentioned
223713870|NCT00536185|DIETARY_SUPPLEMENT|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
223713871|NCT00536185|DIETARY_SUPPLEMENT|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
223713872|NCT03840798|OTHER|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets"
223713873|NCT02685410|OTHER|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
223713874|NCT03583697|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
223713875|NCT03583697|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
223713876|NCT06557746|OTHER|Coca-Cola|100 ml Coca-Cola every 30 minutes during the operation
223713877|NCT06557746|OTHER|Supplemental oxygen|Continuous supply of oxygen (2 L/min) during the operation
223713878|NCT00114530|BIOLOGICAL|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
223713879|NCT00114530|DRUG|cyclophosphamide|An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
223713880|NCT04889807|OTHER|measure of EtCO2 variation|measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
223713881|NCT04051528|PROCEDURE|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
223713882|NCT04051528|PROCEDURE|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
223897166|NCT04867122|BEHAVIORAL|Problem-Solving Therapy|Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.
223897167|NCT04867122|OTHER|Attention-matched Control|"Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team."
223897168|NCT04867122|OTHER|In-depth interviews|The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.
223897169|NCT03227146|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
223897170|NCT03227146|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
223897171|NCT04807192|RADIATION|stereotactic body radiotherapy|one administration of SBRT 8 Gy at D1
223897172|NCT04807192|DRUG|CMP-001|4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
223897173|NCT06468280|PROCEDURE|Local treatment (Surgical)|Radical gastrectomy with standard D2 lymphadenectomy will be performed, along with radical surgery for resectable metastatic lesions.
223897174|NCT06468280|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
223897175|NCT06468280|DRUG|XELOX Chemotherapy Regimen|"Oxaliplatin: 130 mg/m² administered via a 3-hour intravenous infusion on D1 of each 3-week cycle.~Capecitabine: 1000 mg/m² taken orally twice daily. The first dose is administered on the evening of D1, and the last dose on the morning of D15, consisting of 2 weeks of treatment and a 1-week break in each 3-week cycle."
223897176|NCT06468280|PROCEDURE|Local Treatment (Non-surgical)|"Additional local treatment for unresected metastatic lesions during phase 2 systemic therapy is permitted, including:~* Bone metastasis, distant lymph nodes, adrenal metastasis: Radiation therapy.~* Lung and liver metastasis: Radiofrequency ablation, interventional embolization, or radiation therapy.~* Peritoneal metastasis: Hyperthermic intraperitoneal chemotherapy (HIPEC).~* Other metastatic lesions: Non-surgical treatment options discussed by the multidisciplinary team."
223897177|NCT05634967|OTHER|Kesimpta|Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
223897178|NCT04091750|DRUG|Nivolumab|"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"
223897179|NCT04091750|DRUG|Ipilimumab|Induction: 1mg/kg IV every 3 weeks x 4 cycles
223897180|NCT04091750|DRUG|Cabozantinib|Induction and Maintenance: 40mg PO daily
223897181|NCT03504488|BIOLOGICAL|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
223897182|NCT03504488|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
223897183|NCT02584244|DRUG|LUM015|
223897184|NCT02584244|DEVICE|LUM 2.6 Imaging Device|
223897185|NCT04106466|DEVICE|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
223897186|NCT06773273|PROCEDURE|CapsuLaser-Assisted Capsulorhexis and Flanged Prolene Suture|CapsuLaser-Assisted Capsulorhexis and Flanged 6-0 Prolene Suture for Cionni Ring Scleral Fixation
223897187|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex
223897188|NCT05468853|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the inion
223897189|NCT06114940|DRUG|Toripalimab|"Preoperative: Toripalimab 240mg, IV on day 1 in a 3-week cycle. Preoperative Toripalimab contains 4-5 cycles.~Postoperative: Toripalimab 240mg, IV on day 1 of a 3-week cycle. Postoperative Toripalimab following surgery within 4 weeks for patients mentioned above in cohort 1, 2 and 3."
223897190|NCT06114940|DRUG|Lenvatinib|"Preoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Preoperative Lenvatinib contains 4-5 cycles.~Postoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Postoperative Lenvatinib following surgery within 4 weeks for patients in cohort 3.~Adjustment of dose: For patients with intolerable adverse reactions (CTCAE v5.0 grade 3 or grater), the dose could be reduced to 12mg for those who were suitable to continue taking the drug after systematic evaluation by the investigator. Patients who are assessed as intolerable and not suitable for continued medication will discontinue and undergo nephrectomy within 4 weeks."
223897191|NCT03033446|RADIATION|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
223897192|NCT03033446|DRUG|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
223897193|NCT05700123|PROCEDURE|In-Office Hysteroscopy|In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
223897194|NCT01192464|DRUG|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
223897195|NCT06774209|DIAGNOSTIC_TEST|three kinds of examinations|Following the enrollment of patients, both Gallium-68 labeled Fibroblast Activation Protein Inhibitor-04 Positron Emission Tomography/Computed Tomography (68Ga-FAPI-04 PET/CT) and Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) scans are carried out. Additionally, within a one-week interval before and after the aforementioned examinations, Fluorine-18 labeled Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) is performed on the same cohort of patients.
223897196|NCT04457687|DRUG|Lorcaserin|Lorcaserin 10 milligram (mg) tablets orally.
223897197|NCT06797557|DIAGNOSTIC_TEST|2D Ultrasound|"* Crow- rump length (CRL) measurement using 2D ultrasound. Proper measurement of the CRL was done according to obtaining a true, unflexed, longitudinal section of the embryo or fetus, with the end-points of the crown (the top of the head) and rump (the end of the trunk) clearly defined, and then placing the calipers correctly on these defined end-points.~* Yolk sac diameter (largest outer to outer measure).~* Mean gestational sac diameter (arithmetic mean of 3 diameters).~* Embryonic heart rate. the heart rate was determined from M-mode tracings using electronic calipers .The sweep speed was set at 4 s and the calculation of the heart rate was made by measuring the time interval of two cardiac cycles, using clearly identified points in the M-mode tracing"
223897198|NCT06797557|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound rotational VOCAL method was used. YSV measurement (axial, sagittal and coronal). The sagittal plane was chosen as the reference plane and 'scanned' to obtain the longest axis of the yolk sac. Then a magnification of image was used and the yolk sac moved to the center of the plane. The VOCAL switch was then activated using a 30° rotation angle and the manual setting. Calipers were positioned on the superior and inferior extremities of the structure and after obtaining six sequential planes, the equipment automatically displayed the yolk sac as a 3D image with its volume in cm3
223897199|NCT06774937|DIAGNOSTIC_TEST|All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his|"Thorough clinical examination:~1\. General examination including general look, vital signs and anthropometric measurements.~2\. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) \[36\] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible)."
223897200|NCT06774937|DIAGNOSTIC_TEST|EMG ,rNST,Ach R antibodies & thyroid function|"C) Investigations:~1. Electrophysiological testing:~   EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes.~   NCS: including repetitive nerve stimulation test (r NST)~2. laboratory studies:~   * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS.~  * Thyroid function tests :~3. Imaging:~   • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed.~4. molecular studies (when possible)."
223897201|NCT03560609|DEVICE|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
223897202|NCT03560609|DEVICE|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
223897203|NCT03560609|DEVICE|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
223897204|NCT03560609|DEVICE|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
223897205|NCT03560609|DEVICE|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
223897206|NCT04293055|BEHAVIORAL|Maintenance program|1-year weight loss maintenance program, consisting of monthly newsletters
224276617|NCT00108628|BEHAVIORAL|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
224276618|NCT05799196|PROCEDURE|Microfracture|Microfracture was made in the non-weight bearing chondral to provide the release of MSC and growth factor.
224276619|NCT01828645|DIETARY_SUPPLEMENT|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
224276620|NCT04649697|DRUG|Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer.
223897207|NCT04293055|BEHAVIORAL|Phone coaching|Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
223897208|NCT06271278|BEHAVIORAL|Emotional Freedom Technique|Emotional Freedom Technique (EFT) is a powerful and effective practice that enables individuals to release negative emotions and achieve mental and physical relaxation. EFT is a form of counselling based on acupuncture points, which are areas of low electrical and energy flow in the body. Stimulating these points causes the brain to secrete dopamine. EFT involves stimulating specific points on the body where energy flow is low. This is done by gently tapping on these areas with the fingers, which releases dopamine. The process is painless and can be performed by the individual themselves.
223897209|NCT02839161|BIOLOGICAL|Na-GST-1/Alhydrogel|
223897210|NCT02839161|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel|
223897211|NCT02839161|BIOLOGICAL|Hepatitis B Vaccine|
223897212|NCT06439979|BEHAVIORAL|RAYS Intervention|Developmental baseball leagues will be randomly assigned to RAYS vs. control. Outcomes include directly-observed child sun safety behaviors after controlling for environmental ultra-violet radiation (UVR), with parent-reported child sun protection and other related endpoints at 1 year.
223897213|NCT05165524|DEVICE|QS Nd:YAG laser|Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.
223897214|NCT05165524|DRUG|Triple cream|Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
223897215|NCT05507684|OTHER|Nature-based social prescribing group intervention|"Groups of 5-12 persons will formed from one assisted living facility. All of them will undergo an individual interview to assess their wishes for the nature-based activities.~Participants meet in a closed group for 9 times once a week for 10 weeks. All 2-4 hour sessions will include nature-based activities and mutual discussions about the experiences of nature and loneliness.~2 professionals will facilitate and observe the group more thoroughly, give feedback to each other, and make use of group dynamics. They write diaries on each session and receive feedback from their trainers. The groups are objective oriented (aiming to alleviate loneliness, to improve participants' self-efficacy), client oriented and aim with favorable group dynamics to mature, self-directing group in which the participants have made friends with each other and want meet with each other without the facilitators after the official group intervention is over."
223897216|NCT06269484|DRUG|Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)|"placebo capsule (matching zibotentan capsule)~placebo tablet (matching dapagliflozin tablet)"
223897217|NCT06269484|DRUG|Zibotentan + placebo (placebo matching dapagliflozin tablet)|"zibotentan capsule~placebo tablet (matching dapagliflozin tablet)"
223897218|NCT06269484|DRUG|Zibotentan + dapagliflozin|"zibotentan capsule~dapagliflozin 10 mg tablet"
223897219|NCT06807814|COMBINATION_PRODUCT|Constraint-Induced Movement Therapy (CIMT))|A well-defined and structured rehabilitation program that restricts the use of the unaffected limb to promote the functional recovery of the affected limb in chronic stroke patients(Franck et al., 2019). Sit-to-stand transitions, Indoor overground walking (forward, backward, and sideways), Weight-bearing movements in different directions: Stepping over obstacles and climbing stairs, Ideally, specific tasks to involve the paretic limb according to the activity of stroke survivors. This task was repeated ten times as part of the therapy sessions. Dynamic strengthening exercises like squats and lunges are integrated, progressively increasing intensity as patients gain confidence and strength. Balance and core stability exercises, including single-leg stances and seated weight shifts on therapy balls, address postural control and stability.(Cabanas-Valdés \& Boix-Sala, 2021)
223897220|NCT06807814|BEHAVIORAL|Mirror Therapy|A specific intervention that uses a mirror to create a visual illusion of the affected limb, with the goal of improving motor function and quality of life in chronic stroke patients. The MT protocol included 10 minutes of warm-up, 1 hour of mirror box training, and 50 minutes of functional task practice. The warm-up activities included stretching and passive range of motion exercises. During the mirror box training, a mirror box that reflected the image of the unaffected arm was placed in the participant's midsagittal plane. Participants were required to symmetrically move both hands as simultaneously as possible while watching the reflection of the unaffected arm in the mirror as if it were the affected one. To ensure that the participants focused on the reflection, the unaffected arm was placed in the mirror box, and vision of the affected arm was occluded by a vertical board placed beside the mirror box. The activities consisted of transitive (eg, gross motor tasks, such as reaching
223897221|NCT02103361|DRUG|Ustekinumab|
223897222|NCT02103361|DRUG|Guselkumab|
223897223|NCT05966961|DEVICE|Novosyn® in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
223897224|NCT05966961|DEVICE|Polyglactin 910 in emergency or elective laparotomy or laparoscopic surgery|Fascia closure (and subcutaneous closure if applicable) after emergency or elective laparotomy or laparoscopic surgery.
224276621|NCT04649697|DRUG|Nanoparticulated Rebamipide|A mucosal protection drug developed in Japan for the treatment of gastritis and gastric ulcer will be used in nanotechnology.
224276622|NCT04649697|DRUG|Clobetasol Propionate|A corticosteroid drug used as a gold standard for treatment of methotrexate induced oral ulceration.
224276623|NCT01350934|DRUG|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
224276624|NCT01350934|DRUG|Calcitriol|0.25 μg once daily orally
224276625|NCT01350934|DIETARY_SUPPLEMENT|Calcium 500 mg|one 500 mg tablet once daily
223897225|NCT06410950|DIAGNOSTIC_TEST|MyotonPRO Assessment of Muscle Biomechanical Properties|"Muscle assessments will be conducted using the MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. Measurement patterns and subject data will be uploaded to the device via computer. Each evaluation will be performed bilaterally.~Subjects' muscle measurement points will be marked prior to assessment. The physiotherapist will position the device perpendicular to the muscle body and apply downward pressure (18N). Pressure should be maintained until the device's probe light changes from red to green. Five measurement pulses will then be applied. Each pulse lasts 15 ms with an 8 ms interval between pulses.~The SENIAM sensor location guide will be used to determine the approximate motor point for MyotonPRO measurements."
223897228|NCT04201457|DRUG|Dabrafenib|Dabrafenib capsule; Dabrafenib Dispersible Tablet
223897229|NCT04201457|DRUG|Trametinib|Tablet; Powder for Oral Solution
223897230|NCT04201457|DRUG|Hydroxychloroquine|Tablet
223897231|NCT03123848|DRUG|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
223897232|NCT01369355|DRUG|Placebo SC|Placebo will be administered subcutaneously.
223897233|NCT01369355|DRUG|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
223897234|NCT01369355|DRUG|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
223897235|NCT01369355|DRUG|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
223897236|NCT01369355|DRUG|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
223897237|NCT06296459|OTHER|3D R100 scanner|A cone beam computed tomography used for planning of implant surgery
223897238|NCT06296459|OTHER|Conventional Radiograph|Imaging used as standard of care to plan for implant surgery
223897239|NCT01902173|PROCEDURE|Biopsy|Undergo a biopsy
223897240|NCT01902173|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223897241|NCT01902173|PROCEDURE|Computed Tomography|Undergo a CT scan
223897242|NCT01902173|DRUG|Dabrafenib Mesylate|Given PO
223897243|NCT01902173|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223897244|NCT01902173|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223897245|NCT01902173|DRUG|Uprosertib|Given PO
223897246|NCT04625270|DRUG|avutometinib (VS-6766)|avutometinib (VS-6766) monotherapy
223897247|NCT04625270|DRUG|avutometinib (VS-6766) and defactinib|avutometinib (VS-6766) and defactinib combination
223897248|NCT02262728|DRUG|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
223897249|NCT02262728|DRUG|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
223897250|NCT02262728|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
223897251|NCT04014088|DEVICE|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
223897252|NCT06495216|DEVICE|Pulsed Field Ablation by a Balloon Catheter with the TRUPULSE Generator|Pulsed field ablation balloon catheter and TRUPULSE generator will be used for PV ablation.
223897253|NCT04207723|OTHER|Transcutaneous posterior tibial nerve stimulation|Three (3) sessions per week per twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual.
223897254|NCT04207723|DRUG|Paroxetine|paroxetine 20 mg / day taken in the morning hours, per 12 weeks.
223897255|NCT06422936|DRUG|BO-112|Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
223897256|NCT05349500|BEHAVIORAL|OA CARE Intervention|"Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals."
223897257|NCT05349500|BEHAVIORAL|Usual Care control group|Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
223897258|NCT05426837|BEHAVIORAL|Combatting Social Isolation|A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.
223897259|NCT05426837|BEHAVIORAL|Health Education Training|Control condition where participants learn about healthy lifestyle behaviors.
223897260|NCT04485104|DRUG|GWP42003-P|Oral Solution
223897261|NCT03715478|DRUG|GSK2857916 with Pomalidomide and Dexamethasone|Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
223897262|NCT06129682|OTHER|Self rehabilitation at home|6 week program of exercise at home of gradual intensity and duration
223897263|NCT05871385|DEVICE|rTMS group|Twenty eight randomly assigned patients with peripheral vestibular disorders will undergo 10 Hz rTMS to the dorsolateral prefrontal cortex of their dominant hemisphere; in addition to designed vestibular rehabilitation exercises
223897264|NCT05871385|DEVICE|placebo rTMS group|Twenty eight randomly assigned patients with peripheral vestibular disorders will undergo placebo rTMS plus designed vestibular rehabilitation exercises.
223897265|NCT05781893|OTHER|Digital intervention (DiLCoS)|The DiLCoS substudy comprises a digital intervention. A smartphone app is used to provide the patient with a 12-week exercise program, including physical elements (in the form of breathing exercises, relief positions and relaxation techniques), psychoeducational elements (e.g., information about fatigue, neurocognitive symptoms, media consumption, healthy diet), self-monitoring elements (activity planning, energy management), and psychological elements (e.g., guided exercises to improve acceptance of current situation, cognitive distancing from negative thoughts, imagination techniques for pain management). It holds promise for significantly improving the management and quality of life of individuals living with PCC.
223897266|NCT05781893|OTHER|Data collection|Data collection on sociodemography, clinical data (retrieved from regular care for PCC in the UHB medical outpatient clinic), biomarkers derived from blood samples, neurocognitive testing, psychometric questionnaires, and measures of physical performance.
223897267|NCT06545214|PROCEDURE|Video-EEG monitoring|Video-EEG monitoring
223897268|NCT06545214|PROCEDURE|Respiratory monitoring and polysomnography|heart rate, pulse oximetry (oxygen levels in the blood), nasal airflow, respiratory effort (thoracic and abdominal) and capnography (carbon dioxide (CO2) levels in exhaled air)
223897269|NCT06545214|PROCEDURE|1 Hypercapnic challenge while participant is awake|The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
223897270|NCT06545214|PROCEDURE|2 Hypercapnic challenges while participant is sleeping|"In the evening, as soon as the doctor detects on the EEG that the patient/subject is in deep sleep, various tests will be carried out to assess reactivity to wakefulness.~Two hypercapnic challenges will be carried out during sleep, using the same procedure as for wakefulness. The test will be stopped when the healthy patient/subject wakes up, or when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in case of intolerance."
223897271|NCT06545214|PROCEDURE|Auditory stimulus|Two auditory stimulus tests will be carried out during the patient's sleep. Using headphones, the investigator will administer auditory stimuli at regular, progressively louder intervals to determine the ability of the patient/ healthy subject to awaken to an auditory stimulus.
223897272|NCT06545214|OTHER|Questionnaires|Questionnaire to assess caffeine consumption habits Quality of life questionnaires QOLIE-31 Anxiety and depression questionnaires HADS
223897273|NCT05869760|OTHER|Carotenoid Intake|Carotenoid intake calculated from food diary records reported by guardians.
223897274|NCT05869760|OTHER|Serum carotenoid concentrations|Serum carotenoid concentrations measured by HPLC.
223897275|NCT04821440|DEVICE|Water displacement volumetry|The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
223897276|NCT04821440|DEVICE|Three dimension volumetry|The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
223897277|NCT05222451|OTHER|DGA Diet|"A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium."
223897278|NCT05222451|OTHER|MCT Diet|A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
223897279|NCT05222451|OTHER|KETO Diet|A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
223897280|NCT06479486|DIAGNOSTIC_TEST|Assigned Interventions|warm up: global range of motion exercises; breathing control. Aerobic training: walking, cycling, stepping Resistance training: free weights(major muscle groups of upper and lower limbs and trunk Cool down; Breathing control and stretching exercises.
223897281|NCT00227344|DEVICE|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
223897282|NCT00227344|DRUG|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
223897283|NCT04057638|PROCEDURE|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
223897284|NCT04152655|DRUG|Idebenone|30mg tablets three times a day
223897285|NCT04152655|DRUG|Placebo oral tablet|placebo tablets three times a day
223897286|NCT01987895|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
223897287|NCT01987895|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
223897288|NCT01987895|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
223897289|NCT01987895|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
223897290|NCT06107010|DEVICE|Use of the Atalante exoskeleton|Six weeks of exoskeleton sessions replacing conventional therapy sessions three times a week
223897291|NCT04696185|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 mg (daily oral dose)
223897292|NCT04325035|DRUG|Istaroxime|Reconstituted istaroxime and lactose lyophilized powder delivered via IV infusion
223897293|NCT04325035|DRUG|Placebo|Reconstituted placebo (lactose lyophilized powder) delivered via IV infusion
223897294|NCT05956756|BEHAVIORAL|Health and resiliency programming|Students will engage in resilience programming as part of their regular coursework including mindfulness training, lifestyle medicine interventions, and creating a coping plan.
223897295|NCT04920175|OTHER|Novel Real-time Neonatal Sleep Stage Detection Algorithm|Comparison of Novel Real-time Neonatal Sleep Stage Detection Algorithm to gold standard concurrent polysomnogram.
223897296|NCT03878472|DRUG|SHR1210|The patients will receive at least two cycles of SHR-1210 (200 mg, invdrip d1) every two weeks and be accessed for operational suitability every two cycles.
223897297|NCT03878472|DRUG|Apatinib|The patients will received apatinib (250mg po qd) until 10 ± 2 days before surgery.
223897298|NCT03878472|DRUG|S1|The patients will received S1 (50 mg/m2, po, bid, d1-d10) every two weeks and be accessed for operational suitability every two cycles.
223897299|NCT03878472|DRUG|Oxaliplatin|The patients will receive at least two cycles of oxaliplatin (85 mg/m2 d1) every two weeks and be accessed for operational suitability every two cycles.
223897300|NCT05081999|OTHER|Medical Assessment|medical hx, events inquiry, adherence to treatment arm periodically over 4 years
223897301|NCT05081999|OTHER|Quality of Life Assessment|online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
223897302|NCT06807398|GENETIC|Data will be used to develop a novel predictive model assessing the risk of LNI.|The epigenetic signature will be tested on DNA extracted from PCa tissue obtained at prostate biopsy. For each patient, 2 positive cores will be analysed. The 2 cores will be selected as follows: (i) one core from the index lesion; the core with the highest Gleason Score will be selected. In case of two or more cores with the same Gleason Score, the one with the highest percentage of cancer involvement will be selected; (ii) one core with the highest Gleason score outside the index lesion. In case of two or more cores with the same Gleason score, the one with the highest percentage of cancer involvement will be selected. The epigenetic signature will be tested on DNA extracted from prostate cancer tissue obtained from the two positive cores. In particular, the epigenetic score will be calculated on the prostatic tissue using the epigenetic signatures previously identified \[8\].In patients diagnosed with PCa who will be treated with RP, ePLND will be performed when the predicted LNI risk
223897303|NCT04682691|DRUG|Erythromycin (400mg)|oral Erythromycin (400mg)
223897304|NCT04682691|DRUG|metoclopramide (10mg)|oral metoclopramide (10mg)
223897305|NCT04682691|DIETARY_SUPPLEMENT|naturally flavored water|naturally flavored water
223897306|NCT06072235|BEHAVIORAL|Verbal communication|Verbal communication; by talking and listening
223897307|NCT05317611|DRUG|Intraperitoneal instillation of ondansetron and bupivacaine|The aim is to detect the effect of intraperitoneal instillation of ondansetron for prevention of postoperative nausea and vomiting
223897308|NCT05317611|DRUG|Intravenous ondansetron and intraperitoneal instillation of bupivacaine|The aim is to detect effect of intravenous ondansetron for prevention of postoperative nausea and vomiting
223897309|NCT05317611|DRUG|Intraperitoneal instillation of bupivacaine|The aim is to detect effect of intraperitoneal instillation of bupivacaine
223897310|NCT05364671|DRUG|Raphamin|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. On the first day, 8 tablets should be administered using the following regimen: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), then additionally one tablet 3 times with regular time intervals. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 5 days.
223897311|NCT05364671|DRUG|Placebo|Tablet for oral use. The drug is administered not during meals. The tablet should be held in mouth until complete dissolution. Placebo is administered according to the Raphamin regimen.
223897312|NCT03511846|DRUG|Oral capsaicin|Subjects will drink a solution with capsaicin
223897313|NCT03511846|DRUG|Topical capsaicin|Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
223897314|NCT03511846|DRUG|Intranasal capsaicin|Capsaicin cream will be applied to the nostril
223897315|NCT03511846|OTHER|Cold Water Irrigation|Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
223897316|NCT03511846|OTHER|Medical Air|Subjects will be exposed to medical air
223897317|NCT03511846|DRUG|Low Flow Oxygen|Subjects will be exposed to oxygen gas between 1-9 L/min
223897318|NCT03511846|DRUG|High Flow Oxygen|Subjects will be exposed to oxygen gas between 10-25 L/min
223897319|NCT06059339|OTHER|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups|Procedure/Surgery: Regional Block Comparison Comparing postoperative pain and opioid consumption in groups
223897320|NCT06413810|OTHER|Calmarell|Food ingredient
223897321|NCT06413810|OTHER|Placebo|Blinded placebo
223897322|NCT02359890|DEVICE|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
223897323|NCT04755517|OTHER|Frequent information of cytological/ HPV DNA screening results|"All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.~All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end."
223897324|NCT05090033|OTHER|ofatumumab|There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
223897325|NCT06772870|DRUG|DT-216P2|DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
223897326|NCT06772870|DRUG|Saline|Normal saline solution will be used as placebo control.
223897327|NCT05968937|DRUG|20 mg baclofen vaginal suppository daily per vagina|20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy
223897328|NCT05968937|DRUG|Placebo|Vaginal suppository composed of Supposibase F daily per vagina
223897329|NCT05256017|DRUG|Acoziborole|Single dose administration of acoziborole (3 tablets of 320 mg) on Day 1
223897330|NCT05256017|DRUG|Placebo|Single dose administration of placebo (3 tablets of 320 mg) on Day 1
223897331|NCT06770530|DRUG|Fluconazole|400 mg inravenous Fluconazole, single dose 200 ml
223897332|NCT06770530|DRUG|Isotonic saline solution|Intravenous saline solution, single dose 200 ml
223897333|NCT05782582|DIAGNOSTIC_TEST|Package investigation|Investigations performed on a single visit, according to arm description
223897334|NCT05782582|DEVICE|Sound registration with Cadscore® and added risk calculation|Recording of cardiac diastolic sounds enabling the calculation of a risk score.
223897335|NCT05782582|DIAGNOSTIC_TEST|Standard investigation|Sequential investigations according to arm description
223897336|NCT05465928|DEVICE|Active rTMS|rTMS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each rTMS treatment, the magnetic field is generated by a coil which is placed on the head near the brain region of interest, and further, an electrical current is induced to modulate brain activity.
223897337|NCT05465928|DEVICE|Sham rTMS|The sham rTMS stimulation is performed based on a sham coil which will mimic scalp sensations and the acoustic artifact of the active stimulation, without delivering any magnetic pulse.
223897338|NCT04018859|DEVICE|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
223897339|NCT04018859|DRUG|Saline|intradermal injections to the eyebrows
223897340|NCT06807658|BEHAVIORAL|Experimental: Cardiac tele-rehabilitation|Patients will connect to their health care provider via a tele-call
223897341|NCT06807658|BEHAVIORAL|Other: Control, in person cardiac rehabilitation|Patients will attend an ambulatory cardiac rehabilitation unit
223897342|NCT05368402|DRUG|Ladarixin|The two daily oral doses of ladarixin (400 mg each dose) were administered at about a 12-hour interval (morning and evening; ideally between 6:30/11:30 and 18:30/23:30). At each administration, 2 capsules were swallowed with a glass of water, at least 2 hours apart from breakfast or dinner
223897343|NCT05368402|OTHER|Placebo|Placebo was administered with the same ladarixin schedule.
223897344|NCT04500613|PROCEDURE|Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.
223897345|NCT04500613|OTHER|No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)|Patients who are randomized to this group will not receive a bilateral erector spinae plane block
223897346|NCT03947190|BIOLOGICAL|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
223897347|NCT03947190|BIOLOGICAL|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
223897348|NCT03947190|BIOLOGICAL|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
223897349|NCT03092635|DRUG|OPC|OPC is a derivative of grape seed extract
223897350|NCT04493645|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to restore ankle joint range of motion, strength, postural control, and functional movement. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
223897351|NCT04493645|BEHAVIORAL|Foot Intensive Rehabilitation (FIRE)|6 weeks of FIRE will be given along with elements of SOC. Each participant will be expected to complete 2 supervised sessions and 3 unsupervised at home sessions per week.
223897352|NCT05564221|DRUG|YH35324|Subcutaneous injection of YH35324
223897353|NCT05564221|DRUG|Placebo|Subcutaneous injection of None of active ingredient
223897354|NCT05564221|DRUG|Omalizumab|Subcutaneous injection of Omalizumab
223897355|NCT03536754|OTHER|Placebo|Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
223897356|NCT03536754|DRUG|CCX140-B|One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
223897357|NCT03536754|DRUG|CCX140-B|Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.
223897358|NCT03536754|DRUG|CCX140-B|Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
223897359|NCT05300464|DEVICE|Clinical investigation medical device class IIa marked CE|Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
223897360|NCT05490459|DEVICE|Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)|Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
223897361|NCT06758752|DIETARY_SUPPLEMENT|ZAX.1400.EC.02|ZAX.1400.EC.02, applied twice daily for 3 weeks after enrolment
223897362|NCT06758752|DRUG|Placebo|Placebo, applied twice daily for 3 weeks after enrolment
223897363|NCT06109194|OTHER|Joint mobilization|Grade III manual joint mobilization as standard-of-care physical therapy intervention
223897364|NCT06451549|DEVICE|Syndi recommender system for mental health apps|Syndi is a mental health app recommendation system. It provides personalised suggestions of apps to help users self-manage their mental health based on a clinical assessment.
223897365|NCT03997903|DRUG|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
223897366|NCT04919057|DEVICE|GelPOINT®|The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
223897367|NCT06780371|OTHER|Emotional Freedom Technique|"Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels.~Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with SUDS again"
223897368|NCT04858321|PROCEDURE|Passive heating|8-12 x1 h water immersion (to the clavicle, @40 °C, rectal temperature \~38.5 °C and \<39 °C) sessions over a period of 14 days.
223897369|NCT05057247|DRUG|Duvelisib|"Duvelisib capsules should be swallowed whole with a glass of water (approximately 8 ounces).~Advise patients not to open, break, or chew the capsules. Duvelisib may be administered without regard to meals; however, subjects should avoid grapefruit and grapefruit juice while on duvelisib.~continue for up to 24 months."
223897370|NCT05057247|DRUG|Docetaxel|Docetaxel chemotherapy once every 21 days (by intravenous infusion) over about 30- 60 minutes at each visit. This will continue for up to 24 months
223897371|NCT06803160|PROCEDURE|Laparoscopic Extravesical Fistula Excision of Uterovesical Fistula|• In extravesical approach, the posterior bladder wall and the anterior uterine wall around the fistula will be dissected. Scar tissue around the orifice of the fistula will be removed and trimmed. After suturing uterine and bladder wall, intervening omentum will be placed in-between.
223897372|NCT06803160|PROCEDURE|Laparoscopic Combined Fistula Excision of Uterovesical Fistula|• In the combined approach, bladder will be opened bivalved till the site of the fistula. Scar tissue around the orifice of the fistula will be removed and trimmed. Careful dissection around the bladder and uterus will be done to suture both walls and place an intervening omentum in-between.
223897373|NCT06803394|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
223897374|NCT06803394|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
223897375|NCT02774421|DRUG|Trastuzumab after SubQ GM-CSF|Administration of trastuzumab following subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Trastuzumab is a monoclonal antibody targeting HER2-positive cancers, commonly used in breast and gastric cancer treatment.
223897376|NCT02774421|DRUG|Trastuzumab in combination with SubQ GM-CSF|Combine trastuzumab, a monoclonal antibody targeting HER2-positive cancers, with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF functions as an immune system modulator, promoting the activation and proliferation of dendritic cells, macrophages, and granulocytes.
223897377|NCT06760403|DRUG|Hypochlorous acid|Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
223897378|NCT06804044|BEHAVIORAL|Intermittent Fasting|A 16:8 intermittent fasting with a daytime eating window model was applied.
223897379|NCT06804044|BEHAVIORAL|Standart Diet Therapy|Meal plan with 3 main meals and 3 snacks was applied.
223897380|NCT05024734|DRUG|Epirubicin|"In PDOs from patients that show highest response to Epirubicin, this drug will be instilled intravesically once weekly for 6 times.~Epirubicin is also the default drug, in case of failure of drug prediction in the in-vitro drug screen in PDO.~Epirubicin will be used as a concentrate for injection/instillation 2 mg/ml in total 50mg per vial. Prior to use, the concentrate for injection is diluted with 25ml of 0.9% saline solution to obtain the final Solution with 1mg/ml of Epirubicin."
223897381|NCT05024734|DRUG|Mitomycin|"In PDOs from patients that show highest response to Mitomycin, this drug will be instilled intravesically once weekly for 6 times.~Mitomycin C will be used as 20mg dry powder. Prior to use, the powder will be dissolved in 50ml of 0.9% saline solution according to the manufacturer instructions"
223897382|NCT05024734|DRUG|Gemcitabine|"In PDOs from patients that show highest response to Gemcitabine, this drug will be instilled intravesically once weekly for 6 times.~Gemcitabine will be used as 2000 mg/50ml. For intravesical application, 1000mg of gemcitabine (corresponding to 25ml) will be diluted in 25ml 0.9% saline solution, to obtain the gemcitabine concentration of 1000mg/50ml used for instillation."
223897383|NCT05024734|DRUG|Docetaxel|"In PDOs from patients that show highest response to Docetaxel, this drug will be instilled intravesically once weekly for 6 times.~Docetaxel will be used as 140mg/7ml solution. For intravesical application, 48.825ml of saline will be added to 1.875ml Docetaxel solution (according 37.5mg of Docetaxel). The concentration of this solution is 0.74mg/ml by a total volume of the instillation solution of 50,7."
223897384|NCT06502327|OTHER|Instructions A|"Instructions A are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
223897385|NCT06502327|OTHER|Instructions B|"Instructions B are printed visual instructions for health students for inserting a laryngeal mask into neonatal mannequins."
223897386|NCT06132503|DRUG|LP-284|LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.
223897387|NCT06461832|PROCEDURE|Group 1|In patients undergoing a hysterectomy, an epidural catheter is placed via the L3-4 or L4-5 spinal space, followed by the application of a standardized general anesthesia protocol.
223897388|NCT06461832|PROCEDURE|Group 2|In patients undergoing hysterectomy, 15-20 mg of heavy bupivacaine is injected into the intrathecal area via the L3-4 or L4-5 spinal space, using a spinal needle. Following the removal of the spinal needle, an epidural catheter is then placed through the same opening.
223897389|NCT06802302|BEHAVIORAL|Planet Nutrition Program|"The intervention in this study will be the same for both intervention groups, both based on the previously designed and tested Planet Nutrition Program (PNP). The program components include: nutrition education lessons (one 1-hour session per week), physical activity classes (two 1-hour sessions per week), and nutrition information for parents. The intervention will be implemented from February to June 2025."
223897390|NCT01597388|DRUG|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
223897391|NCT01597388|DRUG|Fulvestrant|IM monthly after loading dose
223897392|NCT05328362|BEHAVIORAL|CanCope|Messages prompted participants to use mindfulness-based or distraction-based coping strategies, or a thank-you message which served as an attention control. If participants reported elevated craving (4 or greater) prior to a decision point, they received either a coping strategy message or a control message. If participants reported craving levels of less than 4 they received a control message.
223897393|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for severity of sleep disorders|Participants report the severity of their sleep disorders on a self-rating scale form 0-10 (0=no sleep disorders, 10= maximum sleep disorders).
223897394|NCT04879264|DIAGNOSTIC_TEST|self-rating scale for distress caused by sleep disorders|Participants report their distress caused by sleep disorders on a self-rating scale form 0-10 (0=no distress, 10= maximum distress).
223897395|NCT05562297|DRUG|sintilimab|Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
223897396|NCT05562297|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
223897397|NCT05562297|DRUG|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
223897398|NCT06345157|DRUG|Ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate treatment with ofatumumab (Kesimpta®) will be based solely on clinical judgement and according to the SmPC and AIFA reimbursement criteria.
223897399|NCT02907554|DRUG|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
223897400|NCT02907554|DRUG|Placebo|control group receives a placebo
223897401|NCT06141720|BEHAVIORAL|pain education|Pain education
223897402|NCT06141720|BEHAVIORAL|mindfulness of pain introduction and intervention|Brief mindfulness of pain introduction and intervention
223897403|NCT04632992|DRUG|Entrectinib|Entrectinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 600 milligrams (mg) per day once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
223897404|NCT04632992|DRUG|Inavolisib|Inavolisib will be self-administered by participants orally at home (except on clinic days) at the same time each day, on a starting dose of 9 mg/day QD until disease progression, intolerable toxicity, or consent withdrawal.
223897405|NCT04632992|DRUG|Alectinib|Alectinib will be self-administered by participants orally at home (except on clinic days), at the same times each day, on a starting dose of 600 mg twice a day (BID) until disease progression, intolerable toxicity, or consent withdrawal.
223897406|NCT04632992|DRUG|Ipatasertib|Ipatasertib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg QD until disease progression, intolerable toxicity, or consent withdrawal.
223897407|NCT04632992|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg for participants on Day 1 of each 21-day cycle until unacceptable toxicity or progressive disease (or loss of clinical benefit).
223897408|NCT04632992|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at 3.6 mg per kilogram (kg) of body weight by IV infusion every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
223897409|NCT04632992|DRUG|Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab once every 3 weeks.
223897410|NCT04632992|DRUG|Tucatinib|Tucatinib 300 mg will be administered orally BID continuously starting from Cycle 1 Day 1 onwards.
223897411|NCT04632992|DRUG|Investigator's Choice of Chemotherapy|Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
223897412|NCT04632992|DRUG|Paclitaxel|The dose of paclitaxel is 80 mg/m2 administered by IV infusion on Days 1, 8, and 15 of each 28-day cycle. The paclitaxel infusion will be delivered over at least 60 minutes for each dose per institutional guidelines and administered after the oral dose of ipatasertib.
223897413|NCT04632992|DRUG|Tiragolumab|Following the administration of atezolizumab and an observation period, participants will receive 600 mg tiragolumab at a fixed dose administered by IV infusion on Day 1 of each 21-day cycle.
223897414|NCT04632992|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days), at the same time each day, on a starting dose of 400 mg/day (four 100-mg capsules per day) once a day (QD) until disease progression, intolerable toxicity, or consent withdrawal.
223897415|NCT06036849|PROCEDURE|Spinal manipulation|The manipulation will be delivered to the articular pillar of the most painful level of the cervical spine, as determined by the patient history \& physical examination, by a registered and practicing chiropractor. The participant will be positioned supine with the head supported by the clinician's hands. The articular process of the involved vertebra will be contacted by the antero-lateral aspect of the proximal phalanx of the second digit of the clinician's index finger. The head will be taken into flexion, ipsilateral lateral flexion and contralateral rotation to the pre-manipulative position. A rapid, controlled low-amplitude thrust will be applied in a further posterior-anterior line of drive. Ipsilateral in this instance means the same side as the primary contact i.e. for manipulation applied to the right side, the right side of the participant's neck will be contacted.
223897416|NCT06036849|PROCEDURE|Spinal mobilization|The mobilization will consist of one set of posterior-anterior spinal mobilization applied with either a crossed-thumb or pisiform contact centrally over the spinous process of the most painful level of the cervical spine by a registered and practicing health care practitioner (i.e. physiotherapist).
223897417|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 4to6 s|The SpO2 averaging time will be set to 4to6 s for the next 12 hours.
223897418|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 10 s|The SpO2 averaging time will be set to 10 s for the next 12 hours.
223897419|NCT05274386|DEVICE|Fabian ventilator with PRICO system (Acutronic Medical Systems AG, Hirzel, Switzerland); SpO2 averaging time set to 16 s|The SpO2 averaging time will be set to 16 s for the next 12 hours.
223897420|NCT05823116|DRUG|Vancomycin Continuous Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The total daily dose is infused over a period of 24 hours.
223897421|NCT05823116|DRUG|Vancomycin Intermittent Infusion|A precision drug dosing platform will be used to determine the empiric dosing regimen and the dosing parameter targeted will be an area-under-the-curve (AUC) of 500 mg⸱hr/L (range 400-600 mg⸱hr/L). The dose is infused at rates of 1 gram per hour in every 8, -12, or -24 hour intervals.
223897422|NCT04561947|PROCEDURE|Tunnel technique|After local anesthesia, the exposed root surfaces were mechanically treated with curettes. A tunnelling knives were used to prepare a split-thickness flap and create a continuous tunnel in the buccal soft tissues, following the intrasulcular incision with a #69 microblade. Split-thickness flap preparation was performed to beyond the mucogingival junction with supraperiosteal dissection by placing the tunneling knives to the soft tissue. This process was repeated by entering through the sulcus of each tooth. After the elevation of the flap, a papilla elevator placed under the flap was entered through the sulcus to mobilize the papilla, the periosteum at the base of the papilla was cut, and the full-thickness flap was elevated.
223897423|NCT04561947|PROCEDURE|Connective tissue graft|CTG was harvested using the de-epithelialized connective tissue graft technique. The epithelial tissue on the outer surface of the graft was removed with a 15 blade and a 1-mm-thick graft was obtained.
223897424|NCT04561947|OTHER|Concentrated growth factor membrane|Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
223897425|NCT05704322|OTHER|Wim Hof Methode|The intervention groups will follow a 7-weeks intervention, with one practice session per week at the rehabilitation center led by Wim Hof or one of his instructors. Besides these joint weekly sessions, the intervention groups have to practice daily at home with the Wim Hof Method app.
223897426|NCT04923984|PROCEDURE|Embolization of the middle meningeal artery|embolization of the middle meningeal artery with an embolic agent.
223897427|NCT03070106|DIETARY_SUPPLEMENT|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
223897428|NCT04448301|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
223897429|NCT02962557|DEVICE|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
223897430|NCT05956067|DEVICE|Green Light stimulation|A portable battery-operated ganzfeld light display will be used to deliver green light for 2 hours per day for 5 consecutive days.
223897431|NCT05956067|DEVICE|Equal Energy White stimulation|A portable battery-operated ganzfeld light display will be used to deliver white light for 2 hours per day for 5 consecutive days.
223897432|NCT05956067|DEVICE|S-cone modulating white light|A portable battery-operated ganzfeld light display will be used to deliver S-cone modulating light for 2 hours per day for 5 consecutive days.
223897433|NCT04513639|DRUG|Early treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at MRD reapperance
223897434|NCT04513639|DRUG|Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab|Second line treatment will start at progressive disease
223897435|NCT02381353|DRUG|Bupivacaine|Intraoperative orbital injection of local pain medication
223897436|NCT06074536|PROCEDURE|patient-centered approach training|face to face training of general practitioner of interventional arm
223897437|NCT05647304|DEVICE|RGn550 5 Hz-PWM|RGn550 with a 5 Hz-pulsed wave mode light emission
223897438|NCT05647304|DEVICE|RGn550 10 Hz-PWM|RGn550 with a 10 Hz-pulsed wave mode light emission
223719107|NCT05621369|BEHAVIORAL|Psoriasis Draw|Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
223719108|NCT05621369|BEHAVIORAL|Psoriasis Area Photo|Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
223719109|NCT05621369|BEHAVIORAL|Finger and Toe Photos|Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
223719110|NCT05621369|BEHAVIORAL|Digital Jar Open|Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
223719111|NCT05621369|BEHAVIORAL|30 Second Walk|Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
223719112|NCT05621369|OTHER|Psorcast mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
223719113|NCT03410043|DRUG|Osimertinib|Given PO
223719114|NCT03410043|RADIATION|Radiation Therapy|Undergo radiation therapy
223719115|NCT03410043|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223719116|NCT06367959|BEHAVIORAL|Esays|Participants will write about their experiences One (1) time each week for 3 weeks at the beginning of the study and then 1 more time 9 months later. Participants will be asked to write about their experiences with cancer in English or Chinese and to write as much as they can for about 20-30 minutes for each essay.
223719117|NCT06367959|BEHAVIORAL|Questionnaires|"Participants will answer a questionnaire at the beginning of the study and then 3, 6, and 12 months later.~Participants will also answer a questionnaire about their thoughts on writing and on the study after they complete the third essay."
223719118|NCT06978270|BEHAVIORAL|Healthy Eating: Provider and Parent Components|Healthy Eating intervention for child care providers: Peer coaching using brief MI online, tailored materials, coach-led online support groups for FCCP and children's tableware and food toys; 2) Brief training on using and scheduling messages within the Classtag App; 3) Posters for the FCCH. Also for parents, healthy eating encoragement and communication from childcare providers including via the Classtag App, newsletters, videos and tableware/food toys focused on child diet at home.
223719119|NCT06978270|BEHAVIORAL|Healthy Start: Reading Readiness Childcare Proiver and Parent Materials|Reading readiness intervention for child care providers: Peer coaching using brief MI online, tailored materials, coach-led online support groups for FCCP and children's books; 2) Brief training on using and scheduling messages within the Classtag App; 3) Posters for the FCCH. Also for parents, reading readiness encoragement and communication from childcare providers including via the Classtag App, newsletters, books focused for use at home.
223719120|NCT06192004|OTHER|None (Observational Study)|Not applicable since Observational Study
223719121|NCT03782961|DEVICE|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
223719122|NCT07001345|PROCEDURE|Alveolar Ridge Reconstruction|Alveolar ridge preservation with either xenograft of allograft material
223719123|NCT06546267|RADIATION|Image Guided Radiotherapy|Patients treated with IGRT for Prostate cancer will be evaluated
223719124|NCT06546267|RADIATION|Intensity Modulated Radiotherapy|Patients treated with IMRT for Prostate cancer will be evaluated
223719125|NCT06546267|RADIATION|Stereotactic Body Radiotherapy|Patients treated with SBRT for Prostate cancer will be evaluated
223719126|NCT06621472|PROCEDURE|Retrolaminar block group|patients will be placed in a sitting position. The transducer will be positioned vertically 3 cm lateral to the midline at the level of the 7th thoracic transverse process. The muscles of the back, the transverse process, and the pleura between two transverse processes will be visualized. The needle will be introduced in a cranial-caudal direction toward the lamina using the in-plane method until the tip lay in the lamina 1 mL of normal saline will be injected to confirm the correct needle tip position by visualizing the spread. After negative aspiration, 20 mL of 0.25% isobaric bupivacaine. The procedure will be repeated on the opposite side.
223719127|NCT06621472|OTHER|subcostal TAP technique|The transducer will be placed obliquely along the subcostal margin near the xiphisternum in the midline of the abdomen. The rectus abdominis muscle and underlying transversus abdominis muscle will be identified. The position of the transversus abdominis muscle will be confirmed by sliding the transducer laterally until the aponeuroses of the external and internal oblique muscle will be visualized. The transversus abdominis muscle will be then identified, being posterior to the internal oblique muscle and will be followed back medially to confirm its position beneath the rectus muscle. the needle will be introduced through the rectus muscle in a superomedial-to-inferolateral direction towards the transversus abdominis muscle using the in-plane method, and 20 mL of 0.25% isobaric bupivacaine will be injected
223719128|NCT06621472|OTHER|thoracic Epidural|Before induction of general anesthesia the epidural catheter was inserted under sterile condition with a loss of resistance technique by an 18G needle at a mid-thoracic level (Th 7-10) to cover the dermatomes innervating the incision in the upper abdomen. The epidural infusion consisting of bupivacaine 1 mg/mL, and fentanyl 2 μg/mL was activated on the attending anesthesiologist's decision. Following the hospital protocols, the infusion rate was initiated at 5-10 mL/h, increased to maximum 15 mL/h if necessary, bolus dose of 5 mL was allowed every 30 minutes.
223719129|NCT07015645|PROCEDURE|Gamma Knife Radiosurgery|Patients received gamma knife radiosurgery (GKRS) treatment for pituitary adenomas.
223719130|NCT05263206|DRUG|Dupilumab|Injection solution subcutaneous
223719131|NCT05263206|DRUG|Placebo|Injection solution SC
223719132|NCT05263206|DRUG|Fexofenadine (loratadine if not available)|Tablet or capsule Oral
223719133|NCT05048979|OTHER|Exercise|Telehealth-facilitated supervised exercise program. Veterans with PAD will be enrolled in a 12-week, 3 day a week, aerobic training program in a self-selected location.
223719134|NCT05992311|DRUG|Montelukast|This group will receive the montelukast treatment.
223719135|NCT05992311|OTHER|Placebo|This group will receive a placebo pill instead of montelukast
223897439|NCT04605770|DRUG|pemetrexed+cisplatin|"Pemetrexed 500 mg/m2 (Day 1) and cisplatin 75 mg/m2 (Day 1) will be given via intravenous (IV) infusion. Each cycle consists of 21 days, and this combination therapy will be continued until Cycle 6. Starting from Cycle 7, pemetrexed alone will be administered every 3 weeks (Q3W) as IV infusion until disease progression.~Vitamin B12 1000 mcg intramuscular (IM) injection will be given within 14 days prior to the first dose of pemetrexed, every 9 weeks (on the same day as study treatment) thereafter, and then 21 days after the last dose of pemetrexed. Folic acid 1 mg will be administered daily starting from 14 days before the first dose of pemetrexed and continued until 21 days after the last dose of pemetrexed. Study treatment will be continued until PD, unacceptable AE, or decision to discontinue by subject or physician."
223897440|NCT06332326|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation: patients will receive non-invasive vagus nerve stimulation.
223897441|NCT06332326|BEHAVIORAL|vestibular rehabilitation|vestibular rehabilitation: Patients will be given specially structured vestibular rehabilitation exercises.
223897442|NCT05903807|DRUG|68Ga-FAPi-46|Ovarian cancer patients undergo 68Ga-FAPI-46 at primary staging and at restaging
223897443|NCT04906447|BEHAVIORAL|Guided Relaxation|Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
223897444|NCT04906447|OTHER|Acupuncture|Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
223897445|NCT05437055|DEVICE|Mechanical Thrombectomy (Penumbra System with Thunderbolt)|Subject will receive Penumbra System with Thunderbolt
223897446|NCT02638116|DRUG|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
223897447|NCT02638116|DRUG|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
223897448|NCT04594278|BEHAVIORAL|Mindfulness Based Intervention|A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.
223897449|NCT06144086|DRUG|Foscenvivint|Administered by intravenous (IV) infusion over 3-4 hours
223897450|NCT06559332|DIAGNOSTIC_TEST|Risk-based CAD management|Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.
223897451|NCT06559332|DIAGNOSTIC_TEST|Invasive coronary angiography|Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
223897452|NCT03603600|DEVICE|enVista MX60E|enVista MX60E monofocal IOL
223897453|NCT03603600|DEVICE|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
223897454|NCT06488508|BEHAVIORAL|MoveEarly|"The intervention has two levels: the kindergarten level and the child level.~1. Staff will receive approximately 60 hours of professional development, including 6 full-day physical seminars, 2 full-day kindergarten visits, 6 written tasks with follow-up webinars and an online resource. The focus will be how to promote movement, play and exploration among children aged 1-6 years.~2. Staff is supposed to promote children's movement, play and exploration through 7 pedagogical principles: 1. Value, understand and promote movement, 2. Value, understand and promote play, 3. Value, understand and promote exploration, 4. Create rich physical environments, 5. Create opportunities for meaningful participation, 6. Create good balance between challenge and support, and 7. Create good dialogue through action and words."
223897455|NCT05028972|OTHER|Personal Amplifier|The intervention group will receive personal amplifiers (PockeTalkers) while they receive care in the ED
223897456|NCT05028972|OTHER|No Personal Amplifier|The control group will not receive personal amplifiers while they receive care in the ED
223897457|NCT01497184|PROCEDURE|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
223897458|NCT01497184|GENETIC|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10\^6/m\^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
223897459|NCT03807310|DIETARY_SUPPLEMENT|Targeted nutrient supplementation (Long-drink)|Once daily for at least 12 months
223897460|NCT03807310|DIETARY_SUPPLEMENT|Placebo supplement|Once daily for at least 12 months
223897461|NCT03807310|BEHAVIORAL|Counselling|Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
223897462|NCT06647225|DEVICE|Artificial intelligence augmented ultrasound|"The hip ultrasound is performed using a handheld device (Exo Iris) that uses a pocket-sized ultrasound probe and is run through an application on an IoS (Apple mobile) operation system. . A real-time algorithm detects and records the anatomical landmarks. When there are enough images for analysis the operator is notified that the scan is complete. From here, the images are then classified as: the hips as healthy, follow-up recommended, or suboptimal (repeat scan)."
223897463|NCT06528704|DEVICE|Ventilation feedback device|Device showing delivered ventilation frequency and volume.
223897464|NCT06422325|DEVICE|MPC closed-loop system in insulin only mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.
223897465|NCT06422325|DEVICE|MPC closed-loop system in insulin/pramlintide mode|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer both insulin and pramlintide continuously for managing blood sugar. The system will deliver pramlintide in a fixed ratio to insulin at 6 mcg of pramlintide delivered for every 1 unit of insulin.
223897466|NCT05226806|OTHER|Measurement of cardiorespiratory performance in 3 different settings|"The study is divided into three examinations days, which extend over a maximum of 2 weeks:~* Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~* Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~* Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks"
223897467|NCT05226806|OTHER|GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES|General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
223897468|NCT04793737|RADIATION|Precision Radiation (SBRT)|Precision radiation of melanoma metastases
223897469|NCT05804136|DEVICE|Duramesh|Laparotomy closure with Duramesh
223897470|NCT05804136|DEVICE|Polydioxanone suture|Laparotomy closure with standard PDS
223897471|NCT06539104|PROCEDURE|arteficial inteligence evaluation of oocyte and embryo development|apply AI to find out the complex oocyte quality, embryo development, embryo ploidy and pregnancy success probability from the sequence of the data starting from the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse record of early embryo development.
223897472|NCT06500598|DRUG|Evinacumab|
223897473|NCT02361827|PROCEDURE|Embryo transfer|For patients in each group after oocyte retrieval, they will have embryo transferred 3 or 5 days after oocyte retrieval. For FET cycles, they will have ET with an euploid blastocyst.
223897474|NCT06001749|DRUG|Psilocybin|A tryptamine derivative, capsule, taken orally.
223897475|NCT04523493|COMBINATION_PRODUCT|Toripalimab combined with Lenvatinib|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w). combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
223897476|NCT04523493|COMBINATION_PRODUCT|Placebo combined with Lenvatinib|"Control group:~Placebo, one unit, IV infusion, once every 3 weeks, combined with Lenvatinib 12 mg/day (Body Weight≥60 kg) or 8 mg/day (Body Weight\<60 kg) oral administration, once daily. Continuous infusion, in a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
223897477|NCT06956300|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
223897478|NCT06956300|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
223897479|NCT04989686|OTHER|Microsampling|Volumetric absorptive microsampling (VAMS) with Tasso-M20 devices allows for the accurate and precise collection of a fixed small volume of blood from a capillary needle without the need for phlebotomy.
223897480|NCT06405607|DRUG|Psilocybin|30 mg single dose
223897481|NCT06405607|DRUG|Ketamine|0.75 mg/kg weight-based single dose
223897482|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Safe Sleep Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education. This intervention will be testing the effectiveness of a newly developed educational module on safe sleep education.
223897483|NCT06074211|BEHAVIORAL|Safety in Seconds mobile app: Car Seat Safety Education|The Safety in Seconds mobile app is a platform previously developed to deliver targeted injury prevention education, including fire and car seat safety.
223897484|NCT06101745|DRUG|Nizaracianine Triflutate|Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0 or 2.5 mg depending on trial phase.
223897485|NCT06101745|DRUG|Placebo Comparator|In Phase 3A only, \~50 subjects will be randomly allocated to receive sugar placebo
223897486|NCT04511845|DRUG|SPYK04|SPYK04 capsule
223897487|NCT06130501|DEVICE|Sparrow Ascent tAN|The Sparrow Ascent device from Spark Biomedical (Dallas, TX), applies stimulation frequencies of 15 Hz at the cymba concha (vagal innervation) and 100 Hz anterior to the tragus (trigeminal innervation). Both tAN and active sham conditions have square biphasic waveforms with identical pulse widths of 250 µs separated by a 125 µs interval between pulses. Stimulation is applied using a duty cycle of 5-minutes ON and 10 seconds OFF. The stimulation intensities (mA) will be programmed for each individual based on the highest amplitude for each channel that is both comfortable and perceptible. Patients using the device may alter the intensity of stimulation at these sites using the Patient Controller to achieve the desired effect.
223897488|NCT06130501|DEVICE|Sparrow Ascent Active Sham|The Sparrow Ascent Active Sham is a modified version of the Sparrow Ascent tAN System that has been designed to provide sub-therapeutic stimulation to the trigeminal nerve only and no stimulation to the vagus nerve. The trigeminal nerve will receive 1 Hz stimulation at the temporomandibular region at an amplitude that is comfortable and perceptual. The pulse duration will be set to a value that does not exceed 250 μs in a square biphasic waveform. The patient controller device for the active sham will give the appearance that stimulation is being applied at both vagal and trigeminal electrode sites.
223897489|NCT05909137|RADIATION|IMRT+adjuvant immunotherapy|The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table.
223897490|NCT05147844|DRUG|Toripalimab|"Toripalimab: 240mg, iv. Q3W for 1 year or until disease progression/intolerable toxicity~Radiotherapy:~Newly diagnosed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 70 Gy, pGTVnd 99Gy, pCTV1, 60 Gy, pCTV2, 54 Gy, 33 times, completed in 7 weeks.~Relapsed patients: IMRT for nasopharynx lesions and cervical lymph nodes, pGTVnx 60Gy, pGTVnd 60Gy, 20-25 times, completed in 4-5 weeks.~Newly diagnosed and relapsed patients: SBRT for oligometastatic lesions, pGTV 25-40 Gy, 3-5 times, completed in 1-2 weeks."
223897491|NCT06010004|DRUG|Orforglipron|Administered orally
223897492|NCT05056376|BEHAVIORAL|Digital Diabetes Prevention Program (dDPP)|"The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc."
223897493|NCT05056376|BEHAVIORAL|Human Coach-based Diabetes Prevention Program (hDPP)|The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
223897494|NCT05837533|OTHER|Communication model|During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
223897495|NCT05925582|OTHER|vestibular based exercise program|this group's participants will involve in vestibular based exercise program
223897496|NCT05925582|OTHER|calisthenic based exercise program|this group's participants will involve in calisthenic based exercise program
223897497|NCT06086821|DIAGNOSTIC_TEST|Periodontal Re-Evaluation|Recording of the periodontal charting
223897498|NCT06505863|PROCEDURE|Transanal total mesorectal excision|Transanal approach in surgical treatment of rectal cancer along the anatomical and embryological planes, called total mesorectal excision, as described in 1988 by Heald et al.
223897499|NCT06505863|PROCEDURE|Abdominal total mesorectal excision|Patients who underwent laparoscopic, robotic, or open total mesorectal excision with anastomosis for primary rectal cancer UICC stage I to III
223897500|NCT06413537|DRUG|SPG601|synthetic small molecule
223897501|NCT06413537|DRUG|Placebo|Placebo
223897502|NCT06486636|PROCEDURE|Left Posterior Pericardiotomy|The surgeon will perform a left posterior pericardiotomy while the patient is on cardiopulmonary bypass. A soft channel drain will be put into place at an angle directed toward the posterior pericardium. The surgeon will grasp the pericardium and use cautery to make a 4- to 5-cm opening between the left inferior pulmonary vein and the diaphragm. The previously prepared channel drain is cut to the desired length and placed through the pericardiotomy along the diaphragm and into the pleural space.
223897503|NCT06561971|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
223897504|NCT04617496|BEHAVIORAL|Combined speech and exercise intervention|Home-based exercise intervention with interactive automated speech response features
223897505|NCT04617496|BEHAVIORAL|Health education|Provision of general information about a variety of topics
223897506|NCT05452408|DRUG|Antitumor B KAC|ATB-KAC will be administered at a dose of 720 mg three times per day (roughly spaced every eight hours) as has been studied for ATB-KAC in human oral leukoplakia trials and in esophageal cancer prevention trials. ATB-KAC may be taken with or without food.
223897507|NCT06215560|OTHER|PDMP Check CDS|Clinical decision support in the form of a EHR-integrated, provider facing alert suggesting providers consult the patient PDMP in line with State legislation.
223897508|NCT03812679|DEVICE|AMIA APD Solution Generation System|The AMIA APD Solution Generation System consists of the AMIA APD Cycler, Sharesource Platform, AMIA APD Concentrates, a disposable set, a bag tray, a Water Softener, and a Water Device (WD).
223897509|NCT05607381|BEHAVIORAL|Meditation|Participants will complete 8 sessions of meditation training with therapy as a means of coping with chronic pain and opioid-related issues.
223897510|NCT05607381|OTHER|Usual care|Participants will receive usual care for chronic low back pain (e.g., analgesic medication, pain management consultant from a physician, physical therapy, etc.).
223713883|NCT04051528|PROCEDURE|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
223713884|NCT06555497|DRUG|topical 1% methotrexate gel|topical 1% methotrexate gel
223713885|NCT06555497|DRUG|clobetasol propionate 0.05% ointment|clobetasol propionate 0.05% ointment
223713886|NCT05806411|DIAGNOSTIC_TEST|Analysis of calcific aortic valves|Microbiologic analysis of calcofic aortic valves
223713887|NCT00777114|DRUG|bortezomib, tositumomab|"1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
223713888|NCT02656537|DEVICE|EnSite™ HD Grid Catheter mapping system|
223713889|NCT02538029|BEHAVIORAL|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
223713890|NCT02538029|BEHAVIORAL|Single Task Group|Performing motor or cognitive tasks alone.
223713891|NCT00371280|PROCEDURE|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
223713892|NCT00077961|DRUG|CAMPATH (alemtuzumab)|
223713893|NCT00716534|DRUG|ABT-869|12.5 mg ABT-869
223713894|NCT00716534|DRUG|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
223713895|NCT00716534|DRUG|ABT-869|7.5 mg ABT-869
223713896|NCT00716534|DRUG|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
223713897|NCT00716534|DRUG|Paclitaxel|Paclitaxel (200 mg/m2)
223713898|NCT05146895|DRUG|Imiquimod treatment|As an control arm, for patients with flat warts
223713899|NCT05146895|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with flat warts
223713900|NCT02545556|PROCEDURE|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
223713901|NCT01861860|DEVICE|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain \> 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
223713902|NCT06042504|OTHER|Survey|"Subjects will complete a survey. The survey consists of two parts, A and B. During part A subjects will indicate which of the 5 cohorts they identify as. Successively in part B, subject will complete a survey known as the Perceived Stress Scale (PSS)."
223713903|NCT01673217|DRUG|decitabine|Given IV
223713904|NCT01673217|BIOLOGICAL|NY-ESO-1 peptide vaccine|Given SC
223713905|NCT01673217|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223713906|NCT01673217|BIOLOGICAL|sargramostim|Given SC
223713907|NCT01673217|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
223713908|NCT01673217|OTHER|immunohistochemistry staining method|Correlative studies
223713909|NCT01673217|OTHER|liquid chromatography|Correlative studies
223713910|NCT01673217|OTHER|mass spectrometry|Correlative studies
223713911|NCT01673217|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223713912|NCT01673217|OTHER|laboratory biomarker analysis|Correlative studies
223713913|NCT01673217|GENETIC|DNA methylation analysis|Correlative studies
223713914|NCT01673217|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223713915|NCT05995483|OTHER|Early Diagnosis on BSE|the System Which Sends Reminder Notifications Directing Them to the Website Containing BSE Training Along With the Illustrations Created for the Practice Prepared by the Researcher on the Determined Ideal Day.
223713916|NCT03708081|PROCEDURE|ProTaper Next|Root canal instrument
223713917|NCT03708081|PROCEDURE|TF Adaptive|Root canal instrument
223713918|NCT01995474|OTHER|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
223713919|NCT01995474|OTHER|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
223713920|NCT01064310|DRUG|pazopanib|oral anti-angiogenic treatment
223713921|NCT01064310|DRUG|sunitinib|oral anti-angiogenic treatment
223713922|NCT03634657|RADIATION|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
223713923|NCT03634657|RADIATION|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield \& X-ray protective strips
223713924|NCT03634657|RADIATION|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
223713925|NCT02384486|BEHAVIORAL|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
223713926|NCT02384486|OTHER|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
223713927|NCT04427371|OTHER|the levels of pyroptosis|Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
223713928|NCT01826877|BIOLOGICAL|AdGMCAIX-transduced autologous dendritic cells|Given ID
223713929|NCT01826877|BIOLOGICAL|therapeutic autologous dendritic cells|Given ID
223713930|NCT01826877|OTHER|laboratory biomarker analysis|Correlative studies
223897511|NCT04435054|DIAGNOSTIC_TEST|Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.|"Non-invasive blood biological tests - NAFLD Fibrosis Score, FIB-4, Fibrotest, FibrometerNAFLD~Non-invasive imaging:~\- Transient elastography (FibroScan), Shear Wave imaging, Magnetic resonance imaging (MRI-PDFF and MRE) in a subgroup of participants."
223897512|NCT05653427|DRUG|Amivantamab|Amivantamab will be administered intravenously.
223528585|NCT00127439|PROCEDURE|Manually Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
223713931|NCT04851080|DEVICE|Heart Rate Variability|"Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health."
223713932|NCT04851080|DEVICE|Spirometry|Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
223713933|NCT04851080|BEHAVIORAL|Testing of psycho-physiological functions using four questionnaires|Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
223713934|NCT06556732|DRUG|Eplereone|Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
223713935|NCT00679432|PROCEDURE|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
223713936|NCT00679432|DRUG|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
223713937|NCT00679432|DRUG|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
223713938|NCT00679432|DRUG|Placebo|Placebo
223713939|NCT00679432|DRUG|Asacol® 400 mg|2400 mg/day, 400 mg tablets
223713940|NCT00272012|DRUG|Insulin glulisine|
223713941|NCT00192569|DRUG|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
223713942|NCT00192569|DRUG|Ribavirin (HIV conifected patients only)|"* genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
223713943|NCT02011971|DRUG|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
223713944|NCT01699360|DRUG|Cyclosporine A, Tacrolimus, Sirolimus|
223713945|NCT02339584|DRUG|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
223713946|NCT02339584|DRUG|Brinzolamide 10 mg/mL eye drops, suspension|
223713947|NCT02339584|DRUG|Brimonidine 2 mg/mL eye drops, solution|
223713948|NCT02339584|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
223713949|NCT00260481|DRUG|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
223713950|NCT00260481|DRUG|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
223713951|NCT03915821|DEVICE|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
223713952|NCT04742985|DIETARY_SUPPLEMENT|Green tea combined extracts group|Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks
223713953|NCT04742985|DIETARY_SUPPLEMENT|Placebo group|Placebo 320 mg/day during 8 weeks
223713954|NCT05566743|DRUG|Capecitabine|maintenance capecitabine after 4 months of FOLFRINOX
223713955|NCT05566743|OTHER|follow up|follow up after 4 months of FOLFRINOX
223713956|NCT01558232|DEVICE|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
223713957|NCT01408927|OTHER|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
223713958|NCT01408927|OTHER|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
223713959|NCT01408927|OTHER|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
223713960|NCT06204601|OTHER|Education According to Meleis' Transitional Theory to Patients With Pacemaker|Patients in the experimental group will be trained according to Meleis's Transition Theory.
223713961|NCT02100085|BIOLOGICAL|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
223713962|NCT05315401|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
223713963|NCT05315401|DIETARY_SUPPLEMENT|Placebo|This project aims to evaluate the efficacy of oral administration of probiotic at 9 log CFU/day as adjunctive treatment in reducing the severity depression in female patients with major depressive disorder with treatment-as-usual compared to placebo and ACT via use of questionnaires.
223713964|NCT05315401|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Patients will be provided with ACT for 12 weeks with treatment as usual. The ACT intervention will be conducted in a group of 10 for each session. The ACT modules covered over 12 sessions, 1 hour in each session. The sessions will be held every week.
223713965|NCT05425134|DIAGNOSTIC_TEST|PET/CT-based Deep Learning Signature|Deep Learning Signature Based on PET-CT for Predicting Occult Nodal Metastasis of Clinical N0 Non-small Cell Lung Cancer
223713966|NCT06537817|DRUG|HT-4253|HT-4253 Single or Multiple doses administered orally as a tablet
223713967|NCT06537817|DRUG|Placebo|Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet
223713968|NCT01980940|DRUG|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
223713969|NCT01980940|DRUG|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
223713970|NCT01980940|DRUG|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
223713971|NCT01980940|DRUG|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
223713972|NCT01980940|DRUG|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
223713973|NCT01980940|DRUG|Placebo|Placebo gel applied topically.
223713974|NCT01980940|DRUG|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
223713975|NCT01980940|DRUG|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
223713976|NCT04242719|DEVICE|Electromagnetic stimulation|Retinal electromagnetic stimulation A high-frequency repetitive electromagnetic stimulation protocol has been defined in the literature and was applied in groups 1 and group 2 via a novel device developed specifically for ophthalmic usage (Magnovision-TM, Bioretina Biyoteknoloji AŞ, Ankara,Turkey). The patients underwent 10 consecutive sessions of rEMS application. Parameters for the treatment were 42 hertz frequency/min, 30 minutes of duration and mild operating cycle. The power of the electromagnetic field was 2000 milligauss, which is a very low dose and within the safety limits of World Health Organisation. In group 2, sub-tenon aPRP injections were also performed immediately after the first, fifth, and tenth sessions of rEMS application.
223713977|NCT04242719|BIOLOGICAL|Platelet rich plasma|About 20 ml of blood was drawn from the patient's antecubital vein and inserted into two 10-ml vacutainer tubes that contain trisodium citrate (T-LAB PRP Kit, T-Biyoteknoloji, Bursa, TURKEY). These tubes were placed in a refrigerated (+4 °C) centrifuge (Nüve NF 1200R, Nüve Laboratuar Teknolojileri, Ankara, TURKEY) and spun at 2500 rpm (580×g) for 8 min within 30 min of collection. Three different layers formed in the tubes: red blood cells at the bottom, platelet-rich plasma in the middle, and platelet-poor plasma in the top layer. A total of 1.5 ml of the middle layer (which mainly contained platelets) was withdrawn by syringe and immediately injected into the sub-tenon space of each eye after topical anesthesia with proparacaine hydrochloride (Alcaine, Alcon, USA) drops.
223713978|NCT02939430|DRUG|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
223713979|NCT02939430|DRUG|Intravenous neostigmine and atropine|
223713980|NCT00180050|DRUG|Budesonide|
223713981|NCT03033004|DEVICE|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
223713982|NCT03033004|DEVICE|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
223713983|NCT03033004|DEVICE|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
223897513|NCT05028634|BIOLOGICAL|Tetanus, diphtheria, and acellular pertussis vaccine|Tdap
223897514|NCT05028634|BIOLOGICAL|Pneumococcal polysaccharide vaccine|PPSV23
223713984|NCT03000283|DRUG|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
223713985|NCT00496652|RADIATION|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
223713986|NCT00496652|DRUG|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
223713987|NCT05556330|PROCEDURE|computer guided autogenous cortical shell technique|computer guided autogenous cortical shell technique
223713988|NCT02476383|PROCEDURE|spinal manipulative therapy|refer to arm descriptions
223713989|NCT04050579|DEVICE|on-pump intracardiac echocardiography|Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
223713990|NCT04724980|DRUG|PRGN-2012 - Phase I; Dose Level 1|In Phase 1, dose level 1 of the clinical trial, PRGN-2012 is administered at 1 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
223713991|NCT04724980|DRUG|PRGN-2012 - Phase I; Dose Level 2|In Phase 1, dose level 2 of the clinical trial, PRGN-2012 is administered at 5 × 10\^11 particle units as adjuvant therapy prior to standard debulking surgery.
223713992|NCT04724980|DRUG|PRGN-2012 - Phase II; Dose Level 2|The Phase 2 portion is designed as a dose expansion study where patients are treated at the RP2D of 5 x 10\^11 PU.
223713993|NCT04685317|DEVICE|Sentinel® Cerebral Protection System|A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.
223713994|NCT04685317|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
223713995|NCT05192941|DRUG|Inclisiran Sodium|Subcutaneously injected on Day 1, Day 90, and Day 270
223713996|NCT05192941|DRUG|Placebo|Placebo to inclisiran 300 mg subcutaneously
223713997|NCT04177914|PROCEDURE|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
223713998|NCT04177914|DEVICE|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
223713999|NCT05955001|DRUG|Tadalafil 5mg / Placebo|Patients after Holmium laser Enucleation of Prostate (HoLEP) will receive single daily dose of Tadalafil for 3 months and compared to Placebo
223714000|NCT06330051|BEHAVIORAL|improvement acute reperfusion treatment quality for stroke through spatiotemporal computing|"1. Intelligent bracelet automatic positioning device and data feedback system based on spatiotemporal computing technology~2. Continuous in-hospital procedure improvement based on P-D-C-A cycle for AIS"
223714001|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine.
223714002|NCT06681805|DRUG|Mirtazapine + Bupivacaine + Morphine|Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
223714003|NCT06681805|DRUG|Placebo + Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine.
223714004|NCT06681805|DRUG|Placebo+ Bupivacaine + Morphine|Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine.
223714005|NCT07015879|BEHAVIORAL|Continuous Care Counseling Based on the Roy Adaptation Model|Patients in the control group will receive the clinic's routine treatment and nursing care. This care includes preoperative and postoperative information, prevention of leg flexion, monitoring of vital signs, pain management, discharge education, and discharge of patients without complications three days after surgery. In addition, patients' overall comfort and quality of life will be assessed face-to-face five days before surgery and on the second postoperative day, and by telephone at the first and third months after discharge.
223714006|NCT07015021|DRUG|Daratumumab|Daratumumab: 16mg/Kg, IV or 1800mg Sc; C1-2 d1,8,15,22; C3-6 d1,15; C7-12 d1
223714007|NCT07015021|DRUG|Cafizomide|Cafizomide: 20mg/m2; C1-8 d1,2,8,9,15,16； C9-12 d1,2,15,16；After tolerance to 20mg/m2, the dose of C1D1 and C1D2 can be adjusted to 27g/m2.
223714008|NCT07015021|DRUG|Pomalidomide|Pomalidomide: 4mg, PO,d1-21
223714009|NCT07015021|DRUG|Dexamethasone|Dexamethasone: 20mg, po,d1, 2,8,9,15,16,22,23.
223714010|NCT07054125|BEHAVIORAL|Education, lifestyle counseling, and peer support|"This research study is investigating whether a diabetes virtual group visit program using a continuous glucose monitor (CGM) can help improve glucose levels and quality of life in individuals with uncontrolled type 2 diabetes.~People in the study will join group visits virtually to discuss using CGM, understanding CGM, and other information about ways to bring blood sugars to your goal (nutrition, movement, reducing stress, and techniques to start a new habit)."
223897515|NCT05028634|BIOLOGICAL|Seasonal influenza vaccine|Seasonal influenza vaccine
223897516|NCT05006963|OTHER|manual therapy and therapy by exercise|In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
223897517|NCT02637505|PROCEDURE|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
223897518|NCT02637505|PROCEDURE|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
223897519|NCT06085807|OTHER|Survey|Groups will receive a survey to assess attitudes about diagnosis, treatment, and genetic testing in ADPKD.
223897520|NCT05818423|BEHAVIORAL|Brain Health Academy|The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).
223897521|NCT05818423|BEHAVIORAL|Brain Health Together|The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).
223897522|NCT05818423|BEHAVIORAL|Maintain Brain Health Together|The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).
223897523|NCT06470568|BEHAVIORAL|Progressive Resistance exercise training|"The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions)."
223897524|NCT06188949|DIETARY_SUPPLEMENT|Dolichos biflorus (Horsegram) seed extract|1 capsule twice a day (Before breakfast \& dinner)
223897525|NCT06188949|DIETARY_SUPPLEMENT|Carica papaya leaves extract|1 capsule twice a day (Before breakfast \& dinner)
223897526|NCT06188949|DIETARY_SUPPLEMENT|Placebo (MCC)|1 capsule twice a day (Before breakfast \& dinner)
223897527|NCT05789524|DRUG|SerpinPC|Administered as SC injection.
223897528|NCT03461354|OTHER|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
223897529|NCT03461354|OTHER|Sodium Bicarbonate|Sodium bicarbonate oral rinse
223897530|NCT05426265|DEVICE|MEL-T01|A 12 week intervention with MEL-T01.
223897531|NCT05426265|DEVICE|MEL-S01|A 12 week intervention with MEL-S01.
223897532|NCT05257070|DIAGNOSTIC_TEST|fingerprick|In addition to the standard venous samples, dried blood spot samples trough a fingerprick will be collected.
223897533|NCT03079999|DRUG|Aspirin|Twice daily aspirin
223897534|NCT03079999|DRUG|Placebo|Twice daily placebo
223897535|NCT04508543|OTHER|Non-verbal communication score|1\. To compare nonverbal communication score (NCS, range 0 - 4) between minority and Caucasian non-Hispanic patients. The score is a sum of four components, each contribute to a score range 0 - 1. The four components are: percent time spent with open body language, percent time spent interacting with the patient or surrogate, distance from the patient along the long axis of the patient's body (distance from the head), and distance from the patient along the axis perpendicular to the patient's body (distance from the handrail).
223897536|NCT03584945|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment team will offer a course of up to 12 cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Due to Covid, therapy sessions are offered via remote video conference (in clinic sessions made available if clinically indicated). Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
223897537|NCT03584945|OTHER|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
223897538|NCT05290766|PROCEDURE|placement of four dental implants|"placement of four dental implants according to the  All on four concept"
223897539|NCT05290766|PROCEDURE|placement of two dental implants|"placement of two dental implants according to  All on two concepts"
223897540|NCT05290766|DEVICE|mandibular full arch prosthesis|loading of the mandibular fixed full-arch screw-retained metal acrylic prosthesis
223897541|NCT05675969|OTHER|Blood sample|Collection of 2 additional tubes of 4.5mL of citrate blood
223897542|NCT06005454|DIETARY_SUPPLEMENT|Fish oil (Omega)|We will use a dietary supplement source of omega 3 fatty acids from the available syrup ( each 5 ml contain 640 mg of high DHA Fish oil) so we will give it in a dose 2.7 ml twice daily for children between 1 and 3 years and 3.5 ml twice daily for children between 4 and 5 years.
223897543|NCT05122325|DEVICE|Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device|"Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable)."
223897544|NCT05122325|DEVICE|Genital vibration with Ferticare 2.0® vibrator|Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.
223897545|NCT05122325|DEVICE|TENS® EMS NMS60 device_sham intervention|"Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment."
223897546|NCT04671446|DIAGNOSTIC_TEST|Autoantibody ELISA|Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.
223897547|NCT04671446|DIAGNOSTIC_TEST|Granulocyte Immunofluorescence|The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.
223897548|NCT03060421|DEVICE|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
223897549|NCT05486078|DEVICE|MD Tissue Collagen Medical Device|"The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas."
223897550|NCT04119791|OTHER|wild rice|30 grams of wild rice in the form salad, snack bar and soup
223897551|NCT04256941|DRUG|Abemaciclib|Given PO
223897552|NCT04256941|DRUG|Anastrozole|Given PO
223897553|NCT04256941|DRUG|Fulvestrant|Given IM
223897554|NCT04256941|DRUG|Letrozole|Given PO
223897555|NCT04256941|DRUG|Palbociclib|Given PO
223897556|NCT04256941|DRUG|Ribociclib|Given PO
223897557|NCT06257303|OTHER|Frontal Plane Projection Angle|Participants will stand with their feet aligned in the sagittal plane and their arms crossed across their chests. By prior instruction, subjects will be asked to squat up to 60º knee flexion in a controlled manner without losing their balance, before returning to the starting position. Digital recordings of the frontal plane will be made while individuals perform a single-leg squat test at 60º knee flexion 3 times.
223897558|NCT02933970|OTHER|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
223897559|NCT03300648|OTHER|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
223897560|NCT03300648|DRUG|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
223897561|NCT05914363|OTHER|Sealed washable floor plus behaviour change|Replacement of rudimentary floors with a cement stabilised floor in all rooms in the dwelling
223897562|NCT05914363|BEHAVIORAL|Behaviour change intervention|Support for behaviour change through 'floor clubs' and the provision of printed guides
223897563|NCT05914363|DRUG|Routine deworming|Treatment of all household members for STH infections (400 mg albendazole in those aged 24 months and above; 200 mg albendazole in those aged 12-23 months)
223897564|NCT05914363|PROCEDURE|treatment for tungiasis|Treatment of tungiasis in those affected by heavy infections (at 0 and 12 months) according to county Department of Health recommendations
223897565|NCT02664337|OTHER|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
223897566|NCT02664337|OTHER|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
223897567|NCT04728347|BIOLOGICAL|ARCT-021|ARCT-021 single dose
223897568|NCT02289209|RADIATION|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
223897569|NCT02289209|DRUG|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
223897570|NCT05636514|DRUG|Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET|Fixed dose treatment cycles 1 to 6. Cycle 1 is monotherapy, cycles 2 to 6 combination therapy with defactinib.
223897571|NCT05636514|DRUG|Defactinib|"Defactinib treatment will commence with at the starting dose (dose level 1) from cycle 2 to 6.~Dose escalation/de-escalation will proceed based on the MTD determination.~Dose Level 1: 200mg Defactinib twice daily (starting dose level)~Dose Level 2: 400mg defactinib twice daily~Dose Level -1: 200mg Defactinib daily"
223897572|NCT04864080|BEHAVIORAL|Computer game/task|N-back, COGED, PacMan game, Bandit task, Websurf task.
223897573|NCT04864080|BEHAVIORAL|Health surveys online|Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
223897574|NCT06127784|OTHER|Motivational interviewing counselling session|Individually tailored treatment summary and survivorship care plan provided within a 1-hour 1 hour counseling session with a clinical nurse specialist
223897575|NCT01605565|PROCEDURE|A nasal brushing|A nasal brushing in every nostril
223714011|NCT07054086|DRUG|Neoadjuvant Chemotherapy (NACT)|"The planned regimen for neoadjuvant therapy may include one or more of the following agents:~1. Paclitaxel Injection~2. Albumin-bound paclitaxel Injection (Abraxane® equivalent formulation)~3. Cisplatin Injection~4. Carboplatin Injection~5. Nivolumab~6. Pembrolizumab~7. Toripalimab~8. Tirilibumab~9. Camrelizumab The specific agent(s) and their combination will be selected based on the patient's clinical treatment protocol. The final regimen must be approved jointly by the principal investigator and the attending physician according to established clinical guidelines and individualized patient factors."
223714012|NCT07053228|BEHAVIORAL|Nature-based virtual reality|"Participants in this group will receive standard pain management care plus one session of immersive virtual reality (VR) using Oculus Go headsets. The session consists of viewing a nature-themed 360º video (e.g., beach, waterfall, songbirds) for approximately 8 minutes, accompanied by synchronized natural sounds.~The VR experience is designed to promote distraction, relaxation, and emotional engagement with nature to support pain relief and emotional regulation. The equipment is sanitized between uses according to hospital infection control protocols."
223714013|NCT07053228|DRUG|Standard Pain Management|"Participants in this group will receive the institution's standard pharmacological pain management, monitored and adjusted by the Pain Control Team using the hospital's electronic medical record system. This may include opioid and non-opioid analgesics according to clinical evaluation.~No complementary interventions will be provided during the study period."
223714014|NCT07054697|DRUG|Homoeopathic medicines|
223714015|NCT07054697|DRUG|Placebo|
223714016|NCT07054697|BEHAVIORAL|THERAPY|SPEECH THERAPY / OCCUPATIONAL THERAPY
223714017|NCT07054229|DRUG|Contrast enhanced Ultrasound|Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
223714018|NCT07054229|GENETIC|88-gene panel for thyroid cancer|"88-gene panel refers to a testing combination that includes 88 genes, which are typically associated with the onset, progression, and prognosis of thyroid cancer."
223714019|NCT07053150|DRUG|Sintilimab|Dosage Form: Intravenous (IV) infusion Dosage: 200 mg Frequency: Every 3 weeks (Q3W) Duration: Until disease progression, unacceptable toxicity, or up to 2 years
223714020|NCT07053150|DRUG|Pyrotinib|Dosage Form: Oral tablet Dosage: 400 mg once daily (QD) Frequency: Continuous daily dosing Duration: Until disease progression or intolerable toxicity
223714021|NCT07053150|DRUG|Optional Chemotherapy|"1. FOLFOX:~   Oxaliplatin 85 mg/m² IV Day 1, leucovorin 400 mg/m² IV Day 1, 5-FU 400 mg/m² IV bolus + 2400 mg/m² continuous infusion over 46h (Days 2-3)~2. GEMOX:~   Gemcitabine 1000 mg/m² and oxaliplatin 100 mg/m² IV Day 1~3. GC:~   Gemcitabine 1000 mg/m² and cisplatin 25 mg/m² IV on Days 1 and 8~4. XELOX (CapeOX) Oxaliplatin 130 mg/m² IV Day 1, capecitabine 1000 mg/m² PO BID Days 1-14~5. SOX:~   Oxaliplatin 130 mg/m² IV Day 1, S-1 PO BID Days 1-14 (dose based on BSA: \<1.25 m² = 40 mg, 1.25-\<1.5 m² = 50 mg, ≥1.5 m² = 60 mg)~6. TS:~   Paclitaxel 80 mg/m² IV Days 1 and 8, S-1 as above~7. mFOLFOX6: Same as FOLFOX; used primarily in colorectal cancer~8. FOLFIRINOX:~   Leucovorin 400 mg/m², 5-FU (bolus + continuous), irinotecan 180 mg/m², oxaliplatin 85 mg/m² IV Day 1~9. AG:~Nab-paclitaxel 125 mg/m² and gemcitabine 1000 mg/m² IV on Days 1 and 8"
223714022|NCT07053813|BEHAVIORAL|Web resources|Mailed educational resources through portal and USPS mail
223714023|NCT07053813|BEHAVIORAL|Personalized outreach|Phone call to discuss due and overdue screening and other personalized risk management recommendations
223714024|NCT07054268|OTHER|Nurse-Led ABCDEF Bundle Implementation|This intervention is distinguished by its structured, nurse-led delivery of all six components of the ABCDEF bundle, with nurses serving as primary implementers rather than multidisciplinary teams. Unlike other studies that may focus on select elements of the bundle or physician-led application, this study emphasizes standardized nursing protocols and daily documentation to ensure consistent implementation and evaluation across all components specifically targeting delirium prevention and management in ICU patients.
223714025|NCT06018402|OTHER|physical therapy|The physical therapy program is planned as a total of 15 sessions in the lumbar region, each session consisting of TENS (50-100 Hz stimulation frequency, 200 µs pulse duration, intensity is increased as much as the patient could tolerate, 20 minutes in total), hotpack (to be placed on the painful area, 20 minutes), US (1 mHz frequency, 10 minutes, 1.5 watt/cm2 intensity).
223714026|NCT06018402|OTHER|physical therapy + espb|"the same physical therapy program, in addition Ultrasound-guided lumbar ESPB is performed using an in-line cephalic approach, and after contacting the corner of the L3 transverse process, a small dose of saline is injected into the fascial space between the L3 transverse process and the erector spinae muscles to lift off the fascia. After verification, a mixture of 20 mL of 1% lidocaine and 3 mg betamethasone is administered for unilateral injection. The procedure is performed bilaterally."
223714027|NCT06290336|OTHER|Pre-operative exercise therapy and education|Pre-operative supervised exercise therapy consisting of individualized strength, mobility and balance exercises and continuous education through individual discussions of expectations of post-operative recovery, pain and swelling, course of rehabilitation, long term function and activity level etc. Twice a week, approximately one hour/session.
223714028|NCT06290336|OTHER|Standardized pre-operative information session|As part of the standard care procedure, patients in the intervention and control group will participate in a standardized pre-operative information session approximately 2 weeks before surgery. General information regarding preparations before surgery (e.g. preparing the home environment), events during the hospital stay and the rehabilitation process after discharge will be provided.
223714029|NCT06106035|BEHAVIORAL|low-fat vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
223714030|NCT05286788|DRUG|Binimetinib Oral Tablet [Mektovi]|Binimetinib oral continuous dosing 32 mg/m2 PO BID for 4 weeks
223714031|NCT04819646|DIETARY_SUPPLEMENT|Marine Lipid Oil Concentrate Formulation|Marine Lipid Oil Concentrate softgels
223714032|NCT04819646|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement capsules
223714033|NCT02106091|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
223897576|NCT06574425|OTHER|long-term, high blood flow hemoadsorption therapy|Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group
223897577|NCT04061382|PROCEDURE|Venepuncture|"One study visit will be conducted by research study staff and blood sampling will be carried out.~Up to three follow-up visits will be conducted for a percentage of participants, where additional blood samples will be collected. The blood sample will initially focus on looking at population immunity to diphtheria, group C invasive meningococcal disease and SARS-CoV-2."
223897578|NCT04061382|PROCEDURE|Oral fluid swab|Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
223897579|NCT03766009|OTHER|Usual Care|Usual Care
223897580|NCT03766009|OTHER|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
223897581|NCT04790396|DEVICE|Carotid ultrasound under pulsed-wave doppler mode|Carotid ultrasound under pulsed-wave doppler mode to check whether carotid pulse is present
223897582|NCT06142630|OTHER|Alteration of patients' position after erector spinae plane block|After the erector spinae plane block was completed, the patients kept supine, lateral or prone position according to the group allocated for 30 minute to ensure the spread of local anesthetic
223897583|NCT04526704|DRUG|Pexidartinib|200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
223897584|NCT02737436|DRUG|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
223897585|NCT02737436|DRUG|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
223897586|NCT02737436|PROCEDURE|Functional MRI scanning|All study participants underwent two functional MRI scanning visits. On one occasion this was after receiving an intranasal dose of oxytocin; on the other occasions, after receiving intranasal placebo dose.
223897587|NCT05607732|DIAGNOSTIC_TEST|MyCog|MyCog uses well-validated, self-administered, iPad-based measures from the NIH Toolbox for the Assessment of Neurological Behavior and Function Cognition Battery to provide an efficient and sensitive cognitive screen that can be easily implemented in primary care. Preliminary data shows these tests can discriminate between cognitively normal older adults and those with CI (specifically mild cognitive impairment); enabling physicians to assess CI in ways currently not available.
223897588|NCT04573153|DRUG|Hydroxychloroquine + Metabolic cofactor supplementation|Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
223897589|NCT04573153|DRUG|Hydroxychloroquine + Sorbitol|Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
223897590|NCT06795282|DRUG|MTA|MTA is primarily composed of tricalcium silicate, dicalcium silicate, bismuth oxide (for radiopacity), and small amounts of calcium sulfate. MTA is highly biocompatible, making it suitable for use in the root canal system and areas in close contact with tissues.
223897591|NCT04674462|BIOLOGICAL|CpG-adjuvanted HBV Vaccine|Subjects receiving CpG-adjuvanted HBV vaccine will require two doses at 0 and 1 month after initiation. The second dose will be considered the same as the one month time point following the first dose.
223897592|NCT04674462|BIOLOGICAL|Traditional HBV Vaccine|Subjects receiving traditional HBV vaccine series will require three doses at 0, 1, and 6 months after initiation. The second dose will be considered the same as the one month time point following the first dose.
223897593|NCT06022302|DRUG|Diet + laxative|The participants will start by consuming one sacket of Movicol powder (13 g macrogol 3350) on the first day. On day 2, the participants will consume two sackets of Movicol powder (26 g macrogol 3350), one with breakfast in the morning and one before sleep in the evening. The participants will continue consuming two sackets per day (one morning, one evening) until the following study visit, day 8 (seven days in total). If the participants have a very loose stomach (recorded as Bristol stool scale ≥6), they will be instructed to reduce Movicol by one sacket/day. In case the participants have not passed a stool on day 2 or in the morning of day 3, the participants will increase the dose to a maximum of three sackets of Movicol powder (39 g macrogol 3350) per day (morning, noon, and evening) and continue this until the following study visit at day 8. If three sackets cause very loose stomach the participants will decrease the number of sackets consumed.
223897594|NCT06022302|OTHER|Diet only|This is only a control and participants will not receive Movicol.
223897595|NCT03667599|OTHER|home care|This is the interventional arm where patients receive the transplant care in their homes.
223897596|NCT02869074|GENETIC|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
223897597|NCT05682885|PROCEDURE|Lymphatic Bypass Supermicrosurgery|Axillary Lymph Node Dissection with Lymphatic Bypass Supermicrosurgery
224276626|NCT06120634|PROCEDURE|Open surgical method|After separating the preputial skin from glans and removing smegma, two artery clips were applied on the dorsal skin in the center to mark the skin to be divided. Crushing the skin for a couple of minutes, prior to incising, helps to reduce bleeding. The skin was cut about 2-3 mm short of the coronal sulcus. Similarly, 2-3 mm cuff of prepuce was circumferentially cut proximal to the corona. Using bipolar diathermy or catgut 4/0, frenular artery along with dorsal artery and vein of penis were coagulated or ligated respectively to achieve hemostasis. The skin and prepuce were approximated and sutured with catgut 4/0 at four places- ventral, dorsal, and two lateral points. Finally, a dressing with antibiotic ointment was applied to the wound.
223714034|NCT06526078|BEHAVIORAL|Cognitive Training|Sessions of cognitive training exercises (15-20min each) self-administered via a web app
223714035|NCT06526078|BEHAVIORAL|Sham Training|Sessions of sham training exercises (15-20min each) self-administered via a web app
223714036|NCT06257082|OTHER|Online Survey|Participants must self-identify as Latinx adults and complete a brief online survey adapted from validated survey instruments for eye health literacy and trust in healthcare (CADEES and T-HCT scale) both before and after viewing the video-based, patient education intervention to obtain a pre to post-comparison of any differences in their responses.
224276627|NCT06120634|PROCEDURE|Plastibell method|The prepuce was separated all around the glans, up to the coronal sulcus, and smegma was removed. A dorsal slit in the skin was made, after crushing the skin for a couple of minutes, long enough to accommodate the passage of an appropriate-sized plastibell. Once the distal edge of the bell snugly fit at or near the coronal sulcus, a ligature was applied and tightened around the sulcus on the bell. The extra preputial skin was cut with either scissors or a surgical blade, after breaking apart and discarding the handle of the plastibell. The urethral meatus was examined and its visibility was ensured prior to returning the baby boy to his parents. The baby was kept under observation for 30 minutes in the surgical ward and re-examined to ensure there was no hematoma or bleeding.
224276628|NCT01196117|DEVICE|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
223714037|NCT05996718|BEHAVIORAL|Training program pilot|This intervention for informal caregivers consists of training that will introduce participants to improvisational (improv) theatre and teach its core communication skills.
223714038|NCT05035862|DRUG|Albuterol Sulfate|Participants who experience symptoms of cough, dyspnea, chest tightness or wheezing will initiate use of albuterol (2 inhalations, 90 mcg/actuation) by metered dose inhaler (MDI) every 20 minutes for up to 1 hour and then every 4 hours if necessary.
223714039|NCT05035862|DRUG|Interferon gamma-primed mesenchymal stromal cells (MSCs)|IFNγ-primed bone marrow MSCs at a dose level of 2x106 cells/kg and a dose level of 5x106 cells/kg
223714040|NCT05035862|DRUG|Prednisone|Prednisone is recommended if the participant uses more than 12 inhalations of albuterol in 24 hours (excluding preventive use before exercise), or if the patient has ongoing symptoms for 48 hours or longer. The recommended prednisone dose for acute exacerbations is 2 mg/kg/day (maximum 60 mg) as a single dose for two days followed by 1 mg/kg/day (maximum 30 mg) as a single dose for two days. All administered doses will be rounded down to the nearest 10 mg.
223714041|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 1 (nOPV1)|Live attenuated novel poliomyelitis virus type 1 at two different dosages, containing middle-dose (MD) 10\^6.0, or high-dose (HD) 10\^6.5 CCID₅₀/dose
223714042|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 2 (nOPV2)|Live attenuated novel poliomyelitis virus type 2 administered at low-dose (LD) 10\^5.3 and HD 10\^5.6 CCID₅₀/dose.
223714043|NCT06137664|BIOLOGICAL|Novel oral poliomyelitis vaccine type 3 (nOPV3)|Live attenuated novel poliomyelitis virus type 3 at two different dosages, containing MD 10\^6.0, or HD 10\^6.5 CCID₅₀/dose.
223714044|NCT06137664|BIOLOGICAL|Bivalent Oral Poliomyelitis Vaccine (bOPV)|Live attenuated poliomyelitis viruses types 1 and 3 (Sabin strains). Each dose (2 drops = 0.1 mL) contains not less than 10\^6.0 infective units of type 1 and 10\^5.8 of type 3.
223714045|NCT00196755|DRUG|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
223714046|NCT00196755|DRUG|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
223714047|NCT01713686|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223714048|NCT04147130|OTHER|MultiPAP Plus|Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
223714049|NCT04147130|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
223714050|NCT04897308|PROCEDURE|Local injection of shoulder joint|Under ultrasound guidance , local shoulder joint injection will be done
223714051|NCT02945683|DIETARY_SUPPLEMENT|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
223714052|NCT02945683|DIETARY_SUPPLEMENT|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
223714053|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
223714054|NCT01359397|DRUG|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
223714055|NCT01622504|DRUG|MVP005|2 mg single dose administered intranasally
223714056|NCT01622504|DRUG|MVP005|4 mg single dose administered intranasally
223714057|NCT01622504|DRUG|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
223714058|NCT00634894|DRUG|Femara|2.5 mg by mouth daily x 12 weeks
223714059|NCT00634894|DRUG|Placebo|Placebo capsule by mouth daily x 12 weeks
223714060|NCT04441606|RADIATION|68Ga-FAPI-04 PET/CT|"* Patients will undergo two scans: first a routine FDG PET scan and a FAPI PET scan, within 10 days.~* Scans will be interpreted by board certified Nuclear medicine physicians and board certified radiologists.~* Immunohistochemical analysis with specific staining for FAP will be performed in removed malignant tissues, either at surgery or from biopsy, to assess a possible correlation between the intensity of uptake and the level of FAP expression."
223714061|NCT04096963|DEVICE|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
223714062|NCT04057612|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
223714063|NCT04057612|OTHER|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
223714064|NCT03150017|OTHER|SPIRE|Online pain management programme.
223714065|NCT05678933|DRUG|Azacitidine|Azacitidine (75mg/ m2) will be administered at day 1-5 by subcutaneous injection of each 21-day cycle.
223714066|NCT05678933|DRUG|Chidamide|Chidamide (20 mg) will be taken orally twice a week for two weeks of each 21-day cycle.
223714067|NCT05678933|DRUG|Cyclophosphamide|Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
223714068|NCT05678933|DRUG|Epirubicin|Epirubicin (70mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
223714069|NCT05678933|DRUG|Vincristine|Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.
223714070|NCT05678933|DRUG|Prednisone|Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
223897598|NCT06639724|COMBINATION_PRODUCT|Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)|Fostamatinib is a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura but it has not been studied in PDAC. The investigators hypothesize that Syk inhibition reprograms macrophages to an immunostimulatory phenotype in the tumor microenvironment. Thus, Syk inhibition with fostamatinib in combination with chemotherapy could improve outcomes for patients with PDAC while having a favorable safety profile.
223897599|NCT06642649|PROCEDURE|General Anesthesia (control group)|Only General Anestesia
223897600|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined (local anesthetic, morfine and no fentanyl)|General anesthesia + spinal anesthesia with local anesthetic and morfine
223897601|NCT06642649|PROCEDURE|General Anesthesia + Spinal anesthesia combined (local anesthetic, morfine and 20 mcg fentanyl)|General anesthesia + spinal anesthesia with local anesthetic, morfine and fentanyl
223897602|NCT06640959|PROCEDURE|Procedure - blood, urine and stool sample collection|Samples will be collected (blood, urine, stool and optional rectal swab) at baseline (prior to the start of radiotherapy), weekly during radiotherapy for 4 weeks, 6-8 weeks and 12 weeks from start of radiotherapy, and at 6-month and 12-month follow-up appointments
223897603|NCT06642675|DEVICE|Intermittent theta burst stimulation(iTBS)|By using the TMS Navigation System, the iTBS will be targeted at the left Supramarginal Gyrus.iTBS will be performed using Magstim Rapid² stimulator, parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 1800 pulses per session, intensity of 90% resting motor threshold(RMT), total duration of 10 minutes.
223897604|NCT06642675|DEVICE|Sham stimulation|Patients in sham group would receive the same intervention procedure as the active ITBS group, but the coil will be replaced with sham coil, which provides the sensation of TBS without enough magnetic energy to reach the cortex.
223897605|NCT02105766|DRUG|Alemtuzumab|Immunosuppressant
223897606|NCT02105766|DRUG|Sirolimus|Immunosuppressant
223897607|NCT02105766|DRUG|Cyclophosphamide|Immunosuppressant
223897608|NCT02105766|DRUG|Pentostatin|Immunosuppressant
223897609|NCT02105766|PROCEDURE|Radiotherapy|Immunosuppressant and myelosuppressant
223897610|NCT02105766|DRUG|Filgrastim|mobilize peripheral blood stem cells for apheresis collection
223897611|NCT06568367|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
223897612|NCT06568367|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
223897613|NCT06568367|DRUG|Placebo|Placebo tablets, taken once daily
223897614|NCT06264141|DRUG|Nitric Oxide Releasing Solution|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
223897615|NCT06264141|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual-chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
223897616|NCT02427698|PROCEDURE|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
223897617|NCT02427698|PROCEDURE|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
223897618|NCT06644066|PROCEDURE|Partial pressure of Oxygen Control method|During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
223897619|NCT06643676|PROCEDURE|Targeted Endodontic Microsurgery Using 3d Printed surgical guide using the patient's CBCT data|Patients with apical periodontitis with intact cortex in madibular molars receiving Targeted Endodontic surgery or Guided Endodontic Microsurgery with surgical guide fabricated using the cbct data following failure of non surgical root canal treatment
223897620|NCT06643676|PROCEDURE|Conventional Endodontic Microsurgery with a free hand procedure using bur and CBCT analysis|A conventional endodontic microsurgery using arbitrary localisation technique using the cbct data and performing the surgery with a carbide bur.
224276629|NCT01196117|DEVICE|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
223897621|NCT06644378|DRUG|[14C]-LY3866288|Administered orally.
223897622|NCT06644378|DRUG|LY3866288|Administered orally.
223897623|NCT06644378|DRUG|[14C]-LY3866288|Administered IV.
223897624|NCT06547099|DIAGNOSTIC_TEST|Clinical tau PET|Tau PET (flortaucipir)
223897625|NCT06547099|DIAGNOSTIC_TEST|Clinical amyloid test|Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test
223897626|NCT06547099|OTHER|Research blood collection|Research blood assays for amyloid, tau, and neurodegeneration
223897627|NCT06547099|OTHER|Cognitive assessments|Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
223897628|NCT06157749|OTHER|Gait analysis|It will be carried out on a 10-meter flat surface, with the participant walking at normal walking speed.
223897629|NCT03850756|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
223897630|NCT03850756|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
223897631|NCT03850756|DIAGNOSTIC_TEST|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
223897632|NCT06578182|DRUG|Colchicine|Colchicine 0.5mg tablets once a day for 3 to 4.5 years
223897633|NCT06578182|DRUG|Placebo|Placebo tablets once a day for 3 to 4.5 years
223897634|NCT00554788|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
223897635|NCT00554788|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
223897636|NCT00554788|DRUG|Carboplatin|Given IV
223897637|NCT00554788|DRUG|Cisplatin|Given IV
223897638|NCT00554788|DRUG|Cyclophosphamide|Given IV
223897639|NCT00554788|DRUG|Etoposide|Given IV
223897640|NCT00554788|BIOLOGICAL|Filgrastim|Given SC
223897641|NCT00554788|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
223897642|NCT00554788|RADIATION|Radiation Therapy|Undergo radiotherapy
223897643|NCT00554788|DRUG|Thiotepa|Given IV
223897644|NCT00554788|DRUG|Vincristine Sulfate|Given IV
223897645|NCT02702102|DRUG|11C-PBR28|Up to 20 millicuries
223897646|NCT03897465|DEVICE|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
223897647|NCT03897465|DEVICE|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
223897648|NCT03272698|DRUG|Ketamine|IV Ketamine 0.50 mg/kg
223897649|NCT03272698|PROCEDURE|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
223897650|NCT05244486|DEVICE|RestoreX 1-6 months (randomized phase)|Study participants are recommended utilize the device for 30-60 minutes, 5-7 days a week starting at 1 month post-prostatectomy and continuing until 6 months.
223897651|NCT05244486|DEVICE|RestoreX 6-9 months (open label phase)|Both the treatment and control arms will be allowed to use the therapy from 6-9 months post-prostatectomy (open label phase). Only straight traction will be used (no counterbending).
223897652|NCT06446024|DEVICE|Mechanical aspiration thrombectomy|Mechanical thrombectomy is an endovascular technique for removing blood clots from vessels. Penumbra's Indigo system actively extracts thrombus using a continuous vacuum pump, enabling aspiration of thrombus of various sizes and lengths.
223897653|NCT04532047|DRUG|Aldurazyme (laronidase)|Enzyme replacement therapy for lysosomal storage diseases
223897654|NCT05557812|DRUG|non-eugenol based ZOE base material with Ferric Sulfate in primary molar pulpotomies|non-eugenol based ZOE base material placed over ferric sulphate, during vital pulp therapy (pulpotomy) in primary molars
223897655|NCT05557812|DRUG|eugenol based zinc oxide and Ferric Sulfate|eugenol based zinc oxide base material placed over Ferric Sulfate medicament, during vital pulp therapy (pulpotomy) in primary molars
223897656|NCT02985957|BIOLOGICAL|Nivolumab|Specified dose on specified days
223897657|NCT02985957|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223897658|NCT02985957|DRUG|Cabazitaxel|Specified dose on specified days
223897659|NCT02985957|DRUG|Prednisone|Specified dose on specified days
223897660|NCT06308107|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
223897661|NCT05781347|PROCEDURE|Radiofrequency Energy to the LES (Stretta Procedure)|The Stretta procedure is an endoscopic treatment performed under general anesthesia. It utilizes radiofrequency (RF) energy delivered to the lower esophageal sphincter (LES) and the gastric cardia to enhance the antireflux barrier.
223897662|NCT05781347|DEVICE|Stretta|Stretta is a FDA approved device for the management of GERD.
223897663|NCT06345898|DRUG|JWK002|Subretinal administration of gene therapy vector JWK002 to one eye.
223897664|NCT06393998|DEVICE|Breathing with CO2 during daytime and night at high altitude|Subjects wear the mask connecting to low dose CO2 supplied by a novel device during daytime and sleep dependent on the randomization once arriving high altitude.
223897665|NCT06393998|DEVICE|Sleep and doing exercise test under inhalation of air|Subjects wear the mask connecting to air supplied by the novel device during daytime and sleep dependent on the randomization once arriving high altitude.
223897666|NCT03266302|DEVICE|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
223897667|NCT05829265|BEHAVIORAL|A digital social intervention by primary care clinicians.|"The intervention in this study will involve a structured consultation with a primary care clinician (e.g. a general practitioner (GP) or practice nurse) to promote online peer support, followed by engagement with the OHC of the Asthma + Lung UK (ALUK) charity. The intervention will either be delivered in person (in the general practices) or virtually. The aim is for the intervention to involve a face-to-face, one-off consultation, lasting approximately 30 minutes, during which a primary care clinician will:~* Signpost and sign patients up to the ALUK OHC, by thoroughly explaining terms of conditions of use and providing log in details.~* Introduce norms and values for passive (just reading) and active (writing OHC posts) participation.~* Encourage seeking and offering self-management information and support, by emphasising that the OHC could be used ad hoc (e.g. when feeling unwell, or when there are information or emotional needs)."
223897668|NCT06062082|PROCEDURE|adrenalectomy|laparoscopic exeresis of the adrenal gland
223897669|NCT05852184|OTHER|Hb Scope APP|"The study intervention is the Hb Scope APP, a camera-based real-time Hb estimation tool using a data collection function and a machine learning-based algorithm to analyze the image of HD tubing and output the estimated Hb value.~Our proposed Hb Scope APP can provide a non-invasive and real-time estimation of Hb level for detecting the alarming Hb status (i.e., \<=10 g/dL) during every HD session. The software is for information management purposes only and is not intended for diagnostic use."
223897670|NCT04818255|BEHAVIORAL|PET Biomarker Disclosure|Participants receive information about whether they currently have elevated or not-elevated amyloid and/or tau based on recent PET imaging conducted as part of an affiliated research study (no additional imaging is required for this project). Participants meet with a licensed clinical neuropsychologist to discuss their biomarker status, the meaning of this information, and potential next steps to consider based of their status. Participants receive written summaries of this information, as well as resources as deemed necessary or as requested.
223897671|NCT06785961|PROCEDURE|Regeneration of traumatic tooth|Revascularization is a new treatment method for immature necrotic , pulp revascularization allows also the stimulation of the apical development and the root maturation of immature teeth ( growth and thickening of dentinal walls ).
223897672|NCT05850546|DRUG|Rituximab|Rituximab 375 mg/m2 added to guideline-recommended corticosteroid therapy
223897673|NCT05850546|DRUG|Corticosteroid|guideline-recommended corticosteroid therapy
223897674|NCT02284919|DRUG|[18F]ISO-1|\[18F\]ISO-1 PET/CT scan
223897675|NCT04447651|OTHER|Recommendation for treatment with immunotherapy|Patients with a SF3B1, U2AF1 or SRSF2 mutation will be reviewed by the molecular tumor board and treatment recommendations will be given to the patient's treating oncologist.
223897676|NCT04246437|DRUG|[18F]FDOPA|Patients will receive a 3-D emission scan following a 6-8 mCi slow bolus injection of \[18F\]FDOPA over a 30 second period. Serial scans are started simultaneously with the bolus injection of radiotracer and are obtained for approximately 95 minutes.
223897677|NCT04246437|DRUG|Carbidopa 200mg oral dose|30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
223897678|NCT04246437|DRUG|Entacapone 400mg oral dose|30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
223897679|NCT05463432|DRUG|HR19024|Intravenous infusion
223897680|NCT04728932|DRUG|Levosimendan|A continuous infusion of Levosimendan over 24h
223897681|NCT04728932|DRUG|Placebo of Levosimendan|A continuous infusion of Placebo of Levosimendan over 24h
223897682|NCT06328647|DEVICE|POC Quantra QPlus System|The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.
223897683|NCT06328647|OTHER|Routine care|Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
223897684|NCT06801509|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
223897685|NCT06801509|BIOLOGICAL|Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
223897686|NCT06801509|BIOLOGICAL|Placebo control: Saline|The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;
223897687|NCT06801509|BIOLOGICAL|Shingrix®|Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart
223897688|NCT06801509|BIOLOGICAL|Ganwei®|Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60；
223897689|NCT06565819|DIAGNOSTIC_TEST|The second near-infrared region (NIR-II) imaging for lower extremity peripheral artery disease (PAD)|DUS was used as reference criteria to screen out patients newly diagnosed with PAD during follow-up. In this study, NIR-II imaging results of patients at follow-up and initial examination were collected to obtain a threshold for early diagnosis.
223897690|NCT03884946|OTHER|Getting Off App|"A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included."
223897691|NCT06801106|DEVICE|Acapella|is an airway clearance device that combines the resistive features of a positive expiratory pressure device with oscillations, which diminishes the mucus adhesiveness and decrease the collapsibility of airways
223897692|NCT06801106|DEVICE|Lung flute|is a new oscillatory positive expiratory pressure (OPEP) device that produces a low frequency acoustic wave with vigorous exhalation that increases mucociliary clearance
223897693|NCT06794333|PROCEDURE|Transperineal laser Ablation|Treatments are performed with the combined EchoLaser EVO system (Elesta SpA - Calenzano, FI). The EchoLaser EVO consists of the Echolaser X4, a multi-source laser system with a wavelength of 1064 nm, and the Echolaser Smart Interface (ESI). The procedure are performed with the patient in the lithotomy position. Local anesthesia of the perineal region and periprostatic block with lidocaine is administered under ultrasound guidance. A catheter is placed during the irradiation to allow continuous irrigation of the urethra with saline solution, protecting the urethra from temperature rise. The Echolaser Smart Interface, defines: the number and positioning of fibers, the optimal dose, and the need for multiple pullbacks. 2 to 4 21G needles are inserted simultaneously (1 or 2 per lobe) in the peri-urethral area via transperineal ultrasound guidance. A 300-micron optical fiber will be placed in each needle. Each treatment delivers a maximum energy of 1800 J per fiber with a power of 3-5 W.
223897694|NCT06794333|PROCEDURE|Rezum Vapor Therapy|The treatment involves the insertion of a radiofrequency needle into the prostate tissue and the emission of water vapor. Treatment under local anesthesia/sedation. Treatment planning using the REZUM device, with the number of injections proportional to the recommended therapeutic scheme based on prostate volume (1 injection every centimeter starting 1 cm below the bladder neck and 1 cm in front of the verumontanum). Water vapor emission for 9-second intervals with a maximum of 9 applications per patient. Three-way bladder catheter to decrease local temperature. The bladder catheter will be removed 15 days after patient discharge. Regarding the REZUM, it is a system that uses sterile single-use handpieces available within the company, where a special optics is inserted for direct visualization. The handpiece features a device that allows the manual insertion of a needle into the prostate, from which water vapor is emitted for the described treatment.
223714071|NCT05965492|DRUG|Acetaminophen|"Day 1 and Day 2: 1000 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 3000 mg.~Day 3 and Day 4: 825 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 2475 mg.~Day 5: 500 mg two times a day and 325 mg once a day administered via tablet by mouth for a total cumulative daily dose of 1325 mg.~Day 6: 500 mg once a day and 325mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1150 mg.~Day 7: 500 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 1000 mg."
223714072|NCT05965492|DRUG|Celebrex|"Day 1: 200 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 400 mg.~Day 2 and Day 3: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 4: 100 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 5: 50 mg twice a day administered via tablet by mouth for a total cumulative daily dose of 100 mg.~Not prescribed on Days 6 and 7."
223714073|NCT05965492|DRUG|Gabapentin|"Day 1 and Day 2: 300 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 900 mg.~Day 3: 200 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 600 mg.~Day 4: 200 mg two times a day and 100mg once a day administered via tablet by mouth for a total cumulative daily dose of 500 mg.~Day 5: 100 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 300 mg.~Day 6: 100 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 200 mg.~Day 7: 100 mg once a day administered via tablet by mouth for a total cumulative daily dose of 100 mg."
223714074|NCT05965492|DRUG|Famotidine|Day 1- Day 7: 20 mg once a day administered via tablet by mouth for a total cumulative daily dose of 20 mg.
223714075|NCT05965492|DRUG|Decadron|"Day 1: 4 mg three times a day administered via tablet by mouth for a total cumulative daily dose of 12 mg.~Day 2: 4 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 8 mg.~Day 3: 2 mg two times a day administered via tablet by mouth for a total cumulative daily dose of 4 mg.~Not prescribed on Days 4 through 7."
223714076|NCT05965492|DRUG|Oxycodone|A prescription of oxycodone as per standard of care will be provided to participants in case of breakthrough pain.
223714077|NCT01637935|DRUG|Pioglitazone|Pioglitazone tablets.
223714078|NCT03164135|GENETIC|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
223714079|NCT01361152|DEVICE|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
223714080|NCT01361152|DEVICE|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
223714081|NCT03037775|OTHER|Baseline|measurement of baseline hemodynamic parameters
223714082|NCT03037775|DEVICE|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
223714083|NCT03037775|DEVICE|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
223714084|NCT03037775|DEVICE|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
223714085|NCT04027062|BEHAVIORAL|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
223714086|NCT03308201|DRUG|Hemay022+exemestane|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets combination with exemestane."
223714087|NCT03308201|DRUG|Hemay022+letrozole|Part two: Hemay022 combination with letrozole.
223714088|NCT03308201|DRUG|Hemay022+ fulvestrant|Part two: Hemay022 combination with fulvestrant.
223714089|NCT03240484|DIAGNOSTIC_TEST|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
223714090|NCT03240484|OTHER|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
223714091|NCT03543475|DEVICE|arabin pessary|arabin pessary: silicon device
223714092|NCT03543475|DEVICE|no pessary|control group
223714093|NCT04565106|DEVICE|Closed-loop control of oxygen supplementation by O2matic|Closed-loop control of oxygen supplementation to achieve a target SpO2 of 92 - 96 %
223714094|NCT03725930|DRUG|Clonidine|clonidine intranasal premedication in preschool infants
223714095|NCT03725930|OTHER|Placebo|Placebo intranasal premedication
223714096|NCT04847011|OTHER|Fasting|Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
223714097|NCT00417469|DEVICE|NADGL|
223714098|NCT03118115|DEVICE|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
223897695|NCT06796296|PROCEDURE|Transanal Irrigation (TAI)|The combination of transanal irrigation (TAI) and Loperamide involves administering Loperamide orally, with a daily dosage of 2mg. This is complemented by the use of TAI, a method in which patients self-administer water into the rectum through an enema, aiming to enhance bowel management and potentially alleviate sysmptoms associated with LARS
223897696|NCT04824235|OTHER|Amniotic Chorion Membrane and Bio-Oss xenograft|Bioxclude Amniotic Chorion Membrane with xenograft (Bio-Oss) for ridge preservation
223897697|NCT04824235|OTHER|Amniotic Chorion Membrane only|Bioxclude Amniotic Chorion Membrane only
223897698|NCT02645149|DRUG|Standard therapy or clinical trial|Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
223897699|NCT02645149|DRUG|Matched targeted therapy|Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.
223897700|NCT02645149|DRUG|Trametinib and / or supportive care|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
223897701|NCT02645149|DRUG|CDK4/6 and MEK inhibitor|"Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib."
223897702|NCT02645149|DRUG|Compassionate Access Targeted Therapy|Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
223897703|NCT06554093|DEVICE|Medical Device - PKS|The PKS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw instrumentation in patients undergoing posterior fusion in single or multiple levels.
223897704|NCT06242028|DRUG|Group P|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine and 4 mg dexamethasone.
223897705|NCT06242028|DRUG|Group S|In this group, US guided PENG block will be performed with 20 cc 0.25% bupivacaine. In addition, 4 mg dexamethasone will be administered intravenously.
223897706|NCT05805865|DRUG|Toothpaste Tablet|Colgate Anywhere Toothpaste Tablets
223897707|NCT05805865|DRUG|Conventional Toothpaste|Colgate Cavity Protection
223897708|NCT05393882|RADIATION|Computed tomography coronary angiogram|"Preparation~* Rate control with oral beta-blockers or calcium channel blockers to achieve the target heart rate of 60 to 70 beats per minute~* Sublingual Nitroglycerin to be given on table if not contraindicated, 5 minutes prior to scanning~* 18G angiocath at a large antecubital vein for intravenous contrast injection~Scanning procedure Contrast CT angiogram (Retrospective gating)~* Contrast medium and injection protocol: 75ml Omnipaque 350 with 50ml saline chaser~* Automatic triggering started at the aorta of the level of left main coronary artery when the relative reached 100~* Scanning coverage: From the thoracic inlet to diaphragm"
223897709|NCT04742205|DRUG|Tranexamic Acid 500 MG|Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
223897710|NCT05978180|DEVICE|Medical Device : HO-1|The injection will be performed at Day 1.
223897711|NCT05978180|DEVICE|Medical Device : HS-3|The three injections will be performed at Days 1, 8 and 15.
223897712|NCT05978180|DEVICE|Medical Device : SINOVIAL® ONE|The injection will be performed at Day 1.
223897713|NCT06346691|DRUG|Doxofylline|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
223897714|NCT06346691|DRUG|Procaterol|Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period, and then 4 weeks of treatment with the other drug.
223897715|NCT03274310|BEHAVIORAL|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
223897716|NCT05664477|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).
223897717|NCT05664477|DRUG|Placebo|Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
223897718|NCT00817219|DRUG|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
223897719|NCT06801249|DRUG|Metarapone|Metirapone is an inhibitor of the enzyme 11-β-adrenal hydroxylase, which is deputed to catalyze the conversion of 11-desoxycortisol (11-S) to cortisol and 11-deoxycorticosterone (DOC) to corticosterone.
223897720|NCT06801249|DRUG|Standardized antihypertensive therapy|Standardized antihypertensive therapy, as provided in the normal course of care and in accordance with current European guidelines.
223897721|NCT06801951|OTHER|acute resistance exercise with oral nutrition supplementation|acute bout of resistance exercise on an isokinetic exercise machine of each limb (i.e., right and left arm and right and left leg) allowing control of velocity and force. Immediately upon completion, 1 serving of liquid nutrition supplement will be consumed. An additional serving of the liquid nutrition supplement will be sent home for consumption in the evening.
223897722|NCT06801951|OTHER|stable tracer infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
223897723|NCT06567353|DEVICE|Multi-mode tumor treatment system|All subjects are treated using the multi-mode tumor treatment system (Shanghai MAaGI Medical Technology Co., Ltd), with the treatment procedure conducted according to the temperature control mode for tumor ablation. The treatment procedure includes: rapid freezing of the tumor tissue to form an ice ball extending 5mm beyond the lesion, maintaining this state for 5 minutes, followed by thawing and rewarming; subsequently, RFA is performed to ensure complete ablation, with the ablation zone including a safety margin of 5-10mm around the tumor.
223897724|NCT06567353|DEVICE|Radiofrequency ablation therapeutic apparatus|All subjects are treated using the radiofrequency ablation therapeutic apparatus (MedSphere International (Shanghai) Co., Ltd.), with the treatment procedure conducted according to the preset power and time parameters to ensure a safety margin of 5-10mm.
223897725|NCT03496402|OTHER|Sampling on blood, bone marrow and cerebrospinal fluid|biological sampling during treatment and follow-up
223897726|NCT02132936|DRUG|LEO 90100 aerosol foam|
223897727|NCT02132936|DRUG|Aerosol foam vehicle|
223897728|NCT02132936|DRUG|Calcipotriol BDP gel|
223897729|NCT02132936|DRUG|Gel vehicle|
223897730|NCT06523595|DRUG|VX-993|Suspension for Oral Administration.
223897731|NCT06523595|DRUG|Metformin|Tablets for Oral Administration.
223897732|NCT06009458|DEVICE|Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear|Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
223897733|NCT04426968|DRUG|Hepalatide 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
223897734|NCT04426968|DRUG|Hepalatide 4.2mg|4.2mg/day subcutaneously (s.c.) for 24 week
223897735|NCT04426968|DRUG|Hepalatide 6.3mg|6.3mg/day subcutaneously (s.c.) for 24 week
223897736|NCT04426968|DRUG|placebo 2.1mg|2.1 mg/day subcutaneously (s.c.) for 24 week
223897737|NCT04426968|DRUG|placebo 4.2mg|4.2 mg/day subcutaneously (s.c.) for 24 week
223897738|NCT04426968|DRUG|placebo 6.3mg|6.3 mg/day subcutaneously (s.c.) for 24 week
223897739|NCT04426968|DRUG|Pegylated Interferon|180 ug/week subcutaneously (s.c.) for 28 week
223897740|NCT05564611|DRUG|Omalizumab 150mg|A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
223897741|NCT05456360|DEVICE|ViSi Mobile device|Participants will wear the device on your wrist like a watch, and it will continuously (non-stop) monitor your pulse, blood pressure, temperature, breathing rate, heart rate, and pulse rate
223897742|NCT05456360|DRUG|Sleep enhancement intervention|Participants will receive a medication administration will be limited to before bedtime.
223897743|NCT00819546|DRUG|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
223897744|NCT00819546|DRUG|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
223897745|NCT05857384|DRUG|IHL42X|IHL-42X consists of acetazolamide and dronabinol.
223897746|NCT05857384|DRUG|Acetazolamide 250 MG|A solid tablet containing 250 mg acetazolamide
223897747|NCT05857384|DRUG|Dronabinol 2.5 MG|A soft gelatin capsules containing 2.5mg dronabinol
223897748|NCT05064124|DEVICE|CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
223897749|NCT05660798|BEHAVIORAL|heated tobacco - lifestyle intervention|Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
223897750|NCT03992755|DRUG|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
223897751|NCT06799299|OTHER|No Intervention|No intervention
223897752|NCT06190691|DRUG|Pirtobrutinib|Administered orally
223897753|NCT04290546|DRUG|Interleukin-15 Superagonist (N-803)|"\-- Starting the day after (Cycle 1, Day +1) CIML NK-enriched cell infusion, at least 12 hours after CIML NK cell infusion is completed and up to 48 hours after CIML NK cell infusion, each participant will receive N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles).~N-803 dosed at 15 mcg/kg subcutaneously every 21 days for 4 total doses (a cycle being every 21-days, so 4 cycles) for cohorts 1 and 2, and 6 total doses in cohort 3. The dose should be calculated based on body weight at study entry, and recalculated only if greater than 10% change in weight."
223897754|NCT04290546|BIOLOGICAL|CIML NK cell Infusion|(Dose 0 or -1) infused on Day 0
223897755|NCT04290546|DRUG|Ipilimumab|single dose of lead-in ipilimumab via iv per protocol determined dose
223897756|NCT04290546|DRUG|Cetuximab|Starting day +15, every 14 days for 8 total doses via IV per protocol
223897757|NCT05575505|DRUG|Pentoxifylline 400 MG|Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
223897758|NCT05534971|PROCEDURE|Central venous catheter insertion|The clinical team will use the technique to establish central venous access
223897759|NCT02485938|DRUG|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
223897760|NCT05571865|DIETARY_SUPPLEMENT|Probiotic|Oral administration of a probiotic
223897761|NCT05979974|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A high energy of high-PEMF with a rate of 3 pulse per second is applied to the patient.
223897762|NCT05979974|OTHER|physiotherapy|Physiotherapy such as shoulder passive and active-assisted range of motion (ROM) exercises, Pendulum exercises, Codman's exercises and Cross-body reach exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
223897763|NCT05979974|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(high energy, a rate of 3 pulse per second) with the difference that the energy output doesn't export to the patient.
223897764|NCT06799182|PROCEDURE|periodontal treatment|Based on the results of the dental examination and the diagnosis of the periodontal tissue condition according to the new classification of periodontal disease, we performed appropriate non-surgical treatment of periodontal disease, provided oral hygiene instruction, and took a biofilm sample from the deep periodontal pocket. We then collected a sample of the altered mucosa during bowel surgery for colorectal cancer and conducted a microbiological investigation using quantitative culture to compare the presence of Fusobacterium nucleatum and Porphyromonas gingivalis in the pariodontal pocket and altered intestinal mucosa.
223897765|NCT03477968|DIAGNOSTIC_TEST|DDimer test|Measuring the level of DDimer in blood sample
223897766|NCT06635538|DRUG|Corifollitropin alfa (CFA) 150 mcg + Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, a single injection of 150 mcg of CFA (Stimulation Day 1) will be administered.
223897767|NCT06635538|DRUG|Clomiphene Citrate (CC) 100 mg/day from D1|On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
223897768|NCT06635538|DIAGNOSTIC_TEST|Monitoring cycle|Scan controls and blood exams will be performed on stimulation days 1, 6, 8, 10 and, according to clinical needs, until trigger day.
223897769|NCT04961619|DRUG|dabrafenib|There is no treatment allocation. Patients administered dabrafenib by prescription that have started before inclusion of the patient into the study will be enrolled.
223897770|NCT04961619|DRUG|trametinib|There is no treatment allocation. Patients administered trametinib by prescription that have started before inclusion of the patient into the study will be enrolled.
223897771|NCT03513562|DRUG|Ibrutinib|Given PO
223897772|NCT03513562|OTHER|Laboratory Biomarker Analysis|Correlative studies
223897773|NCT03513562|DRUG|Venetoclax|Given PO
223897774|NCT06334965|OTHER|Simultaneous 18F-Choline PET-MRI|before first TARE administration (after work-up procedure) and one month after TARE administration
223897775|NCT06636149|OTHER|Circuit of maternal position changes during labor|"The intervention cohort will undergo the circuit of position changes every 2 hours. The circuit will be repeated up to 3 times or until the second stage of labor is achieved, delivery occurs, or labor arrest diagnosis is made. Participants will be considered as adherent to intervention arm if they undergo one complete circuit of maneuvers. Nurses will keep patients on continuous fetal monitoring during the circuit of position changes. Any persistent non-reassuring fetal status in one position of the circuit will prompt progression to the next position in the circuit. The planned circuit of maneuvers will be:~10-minutes of side-lying release on one side 10-minutes of side-lying release on other side 10-minutes of open-knee chest 10-minutes of shaking apples 20-minutes of flying cowgirl on one side 20-minutes of flying cowgirl on opposite side as position 5 20-minutes of running man on same side as position 5 20-minutes of running man on opposite side as position 5"
223897776|NCT05882292|DRUG|ABN401|ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
223897777|NCT05697302|BEHAVIORAL|Education|Interviews will be held twice a week in the first two weeks of the first month, once a week in the following weeks, and once every two weeks in the second month, 8 times in a total of 2 months. The number of 8 interviews planned in the research may increase specifically for the situation of the mother and the baby. Interviews will be held at the mothers' homes or at the Family Health Center. An individualized message will be sent to mothers, two days a week, in accordance with their mobile communication tool, relactation needs. In addition, if the mothers request, they can call the researcher via mobile communication via video or voice and receive live support regarding their questions and questions.
223897778|NCT05697302|BEHAVIORAL|Follow-up|Among the data collection forms, LATCH-Breastfeeding Diagnostic Scale and IMDAT-The Baby's Breastmilk Scoring System will be applied at each interview, and the Breastfeeding Self-Efficacy Scale and Breastfeeding Motivation Scale will be applied at the first interview, at the end of the 1st month and at the end of the 2nd month. Mother interviews will be held in their homes or at the Family Health Center (whichever they prefer). At each meeting, an appointment schedule will be made for the next meeting and this information will be shared with the mothers in writing.
223897779|NCT05697302|BEHAVIORAL|Referral to Lactation and Relactation Polyclinic|Due to the nature of the research, mothers in the control group will not be given any training, and they will be referred to the Lactation and Relaxation Polyclinic in Erzincan Mengücek Gazi Training and Research Hospital.
224276630|NCT03547635|OTHER|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
223897780|NCT03524183|BEHAVIORAL|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
223897781|NCT03016754|DEVICE|Wearable Cardioverter Defibrillator|LifeVest is the brand of Wearable Cardioverter Defibrillator used in this study.
223897782|NCT06634797|BIOLOGICAL|mRNA-1273.712|Intramuscular (IM) injection.
223897783|NCT06634797|BIOLOGICAL|Placebo|Sodium chloride for IM injection.
223897784|NCT03671629|OTHER|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
223897785|NCT03570632|DRUG|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
223897786|NCT03839940|DRUG|Dexamethasone|Given as mouthwash
223897787|NCT03839940|OTHER|Placebo|Given as mouthwash
223897788|NCT03839940|OTHER|Questionnaire|Ancillary studies
223897789|NCT03839940|OTHER|Quality-of-Life Assessment|Ancillary studies
223897790|NCT03839940|DRUG|Everolimus|Standard of care
223897791|NCT06086886|DRUG|BMS-986454|Specified dose on specified days
223897792|NCT06086886|OTHER|Placebo|Specified dose on specified days
223897793|NCT02103725|DRUG|pimecrolimus 10 mg/g cream|
223897794|NCT02103725|DRUG|Vehicle cream|
223897795|NCT04340596|BIOLOGICAL|N-803 (IL-15 Superagonist)|Administered by subcutaneous (SQ) injection
223897796|NCT04340596|BIOLOGICAL|VRC07-523LS|Administered by intravenous (IV) infusion
223897797|NCT04340596|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
223897798|NCT04599192|OTHER|No study intervention|The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
223897799|NCT03241745|DRUG|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
223897800|NCT03180216|BIOLOGICAL|Virus Specific T cells (VSTs)|"This Phase I dose-escalation trial is designed to evaluate the safety of rapidly generated multivirus-specific T-cell products with antiviral activity against CMV, EBV, adenovirus, HHV6, BK virus, JC virus, and human parainfluenza-3 (HPIV3), derived from eligible HSCT donors.~In this trial, we will utilize a rapid generation protocol for broad spectrum multivirus-specific T cells for infusion to recipients of allogeneic hematopoietic stem cell transplant (HSCT), who are at risk of developing EBV, CMV, adenovirus, HHV6, BKV, JCV and/or HPIV3, or with PCR/culture confirmed active infection(s) of EBV, CMV, adenovirus, HHV6, BKV, JCV, and/or HPIV3 that has failed to resolve with at least 14 days of standard antiviral therapy (if available and tolerated). These cells will be derived from HSCT donors, and the study agent will be assessed at each dose for evidence of dose-limiting toxicities (DLT)."
223897801|NCT04647240|BIOLOGICAL|Dermacyte® Liquid (human amniotic fluid)|Subcutaneous injection into and/or around wound bed weekly
223897802|NCT06469138|DRUG|Bemcentinib|Each 200 mg dose contains approximately 32.8 μCi (1.21 MBq) of 14C-bemcentinib and is administered as a single dose on Day 1 of the study.
223714099|NCT00709761|DRUG|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
223897803|NCT02693223|OTHER|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
223714100|NCT04984330|DRUG|Selinexor|Selinexor will be given orally at a dose of 60mg once weekly on the first day of the week (day 1, 8, 15, and 22) for Cycle 1 and up to Cycle 12.
223714101|NCT04984330|DRUG|Dexamethasone|Dexamethasone will be given orally at a dose of 20mg, if tolerated, or at a reduced dose if required, 30 to 60 minutes prior to selinexor for first 2 days of each week only (days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle).
223714102|NCT03859752|BIOLOGICAL|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
223714103|NCT03234933|OTHER|Mobility Tracker|Tracking Patient's movements and calories
223714104|NCT04335461|PROCEDURE|Cephalomedullary nailing of extracapsular hip fracture|All patients will undergo cephalomedullary nailing of their extracapsular hip fractures. Both short and long nails will be used based on fracture morphology.
223714105|NCT04335461|DEVICE|cephalomedullary nail|Implants to be used will be variable, but include Stryker Gamma, Synthes Trochanteric Fixation Nail, Smith and Nephew Intertan.
223714106|NCT04335461|DRUG|Regional Anesthetics|Marcaine 0.25% will be administered for the two experimental arms, as described in above protocol.
223714107|NCT04487392|DRUG|Estrogen vaginal cream group (group A)|The participants selected for group A will be provided with estriol 0.01% vaginal cream, which should be applied at home: 1 intravaginal applicator at night, daily for 2 weeks, followed by 2 times a week, on alternate days (Monday - Thursday) for another 2 weeks.
223714108|NCT04487392|RADIATION|Photobiomodutation group (group B)|The participants selected for group B will be undergo photobiomodulation with red LED. With the participant in the lithotomy position, the speculum will be introduced into the vaginal canal and a vaginal wash with 0.9% saline will be performed to remove secretions. Afterwards, the speculum will be removed and the device with a red LED inserted up to about 6 cm from the introitus. A non-lubricated condom will be used in the LED device for patient protection. Sessions will take place once a week for 4 weeks.
223714109|NCT03435484|OTHER|Arm A|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
223897804|NCT05084235|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
223897805|NCT05084235|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling
223897806|NCT06046742|BIOLOGICAL|M1-c6v1|Intravenous drip administration
223897807|NCT00085735|DRUG|Cisplatin|Given IV
223897808|NCT00085735|RADIATION|Craniospinal Irradiation|Undergo craniospinal Irradiation
223897809|NCT00085735|DRUG|Cyclophosphamide|Given IV
223897810|NCT00085735|RADIATION|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
223897811|NCT00085735|OTHER|Laboratory Biomarker Analysis|Correlative studies
223897812|NCT00085735|DRUG|Lomustine|Given orally
223897813|NCT00085735|OTHER|Quality-of-Life Assessment|Ancillary studies
223897814|NCT00085735|RADIATION|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
223897815|NCT00085735|DRUG|Vincristine Sulfate|Given IV
223897816|NCT03589339|DRUG|NBTXR3|Single intra Tumoral injection
223897817|NCT03589339|RADIATION|SABR|Radiotherapy given as a definite number of fractions at the dose defined for each radiation field
223897818|NCT03589339|DRUG|Nivolumab|Anti-PD-1 monotherapy
223897819|NCT03589339|DRUG|Pembrolizumab|Anti-PD-1 monotherapy
223897820|NCT05006859|OTHER|Cohorte|Assessment of postural wheelchair disorders, as well as PW pain, and pressure ulcers associated with sitting
223897821|NCT05582668|PROCEDURE|Bariatric surgery|Bariatric surgery
223897822|NCT05921357|OTHER|Questionnaire|Questionnaire and examine
223897823|NCT06242119|DIAGNOSTIC_TEST|J-PET scan|Diagnostic Test: Positron-Emission Tomography Imaging Examination of radiation distribution in the patient body after completing a routine examination on a PET diagnostic device. J-PET prototype tests will be carried out in patients who have undergone a classic PET examination after administration of \[18F\]FDG), \[68Ga\]Ga-PSMA, \[18F\]choline or \[68Ga\]Ga-DOTATATE). The duration of the additional exam will be approximately 20 minutes.
223897824|NCT02657486|DRUG|BGJ398|
223897825|NCT05342064|OTHER|patient-centered TB preventive therapy|The intervention phase includes i) enrolling participants who have had TB disease excluded and allowing participant selection of a preferred TPT regimen, and ii) randomizing participants to one of two participant adherence support modalities.
223897826|NCT05342064|OTHER|TB preventive therapy adherence support|As part of this study, enhanced adherence support will be provided via bi-directional messaging and/or via clinic phone calls. All participants randomized to enhanced adherence support will receive a weekly text reminder beginning seven days after the initiation. Each message will ask participants if they would like to be contacted to discuss any questions and will prompt participants to ask questions by text if more convenient or preferable. All text-based questions from participants will be answered by a trained nurse with back up from a physician.
223897827|NCT04436835|BEHAVIORAL|Psychotherapy|Undergo ART
223897828|NCT04436835|OTHER|Questionnaire Administration|Ancillary studies
223897829|NCT06770231|OTHER|Single drill system|New system for drilling
223897830|NCT05388916|OTHER|Cosentyx|Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
223897831|NCT03844074|BIOLOGICAL|bevacizumab|1.25 mg, intravitreal injection
223897832|NCT03844074|BIOLOGICAL|ranibizumab|0.5mg, intravitreal injection
223897833|NCT02857777|DRUG|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
223897834|NCT03016533|DRUG|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 50 mg tablets.
223897835|NCT03016533|DRUG|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
223897836|NCT03016533|DRUG|ABC/DTG/3TC immediate release tablets|ABC/DTG/3TC immediate release tablets will be provided as biconvex, oval tablets containing 600 mg ABC, 50 mg DTG and 300 mg 3TC.
223897837|NCT03016533|DRUG|ABC/DTG/3TC film-coated dispersible tablets|ABC/DTG/3TC dispersible tablets will be provided as biconvex, oval, film-coated tablets containing 60 mg ABC, 5 mg DTG and 30 mg 3TC.
223897838|NCT04473222|BEHAVIORAL|Sleep Well!|Sleep Well! is a brief, behavioral sleep intervention. The intervention was originally comprised of healthy sleep advice and tested in the context of a sleep health education campaign for impoverished children. Based on preliminary research regarding the need for sleep intervention in primary care, Investigators have expanded the intervention to more comprehensively address poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Intervention components are based on effective pediatric behavioral sleep treatments.
223897839|NCT04473222|BEHAVIORAL|Sleep education|Sleep education for caregivers of toddlers and preschoolers is provided via a Parent Family Education handout available to families and clinicians in the CHOP primary care network. The handout contains evidence-based advice about healthy sleep in early childhood.
223897840|NCT02919306|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
223897841|NCT02919306|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
223897842|NCT02919306|DRUG|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
223897843|NCT04636528|DEVICE|Digital rehabilitation|"Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist."
223897844|NCT04636528|DEVICE|Conventional rehabilitation|"Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, physical therapists will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week)."
223897845|NCT06519487|BEHAVIORAL|Cyberball|"Cyberball™ is a virtual social exclusion game that simulates social interactions and acute discrimination experiences in a controlled laboratory setting. The game involves passing a virtual ball between players represented by images. In this study, only the participant is a real player, while the other players are pre-programmed virtual avatars controlled by the experimenter using Cyberball software. The ethnicity of these virtual players can be manipulated by changing the stock photos used to represent them. Participants in the Race-Based Social Exclusion condition play Cyberball with virtual players who appear to be of a different ethnicity from the participant. In the Non-Race-Based Social Exclusion, the participant plays with virtual players who do not have any obvious ethnic differences from the participant, and social inclusion is a washout condition where the participant receives the ball from the virtual players, regardless of the ethnicity of the avatars."
223897846|NCT06561477|OTHER|Intensive care cirrhosis outcome (ICCO) score|ICCO score will be calculated for the participants to use it as a predictor for mortality and ICU outcome The ICCO score is 0.3707 + (0.0773 x bilirubin (mg/dl)) - (0.00849 x cholesterol (mg/dl)) -(0.0155 x creatinine clearance (ml/min)) + (0.1351 x lactate (mmol/l))
223897847|NCT06192329|BEHAVIORAL|Hot water therapy|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 105°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
223897848|NCT06192329|BEHAVIORAL|Warm water immersion|On days 2-6 and 8-12 of the therapy sessions, the participants will immerse themselves up to the shoulder in 97°F water for \~30 min, followed by immersion to the hip level for \~60 min (total immersion time of 90 min).
223897849|NCT06293950|BIOLOGICAL|WJMSC|\- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
223897850|NCT06186401|BIOLOGICAL|E-SYNC T Cells|Given IV
223897851|NCT06186401|DRUG|Cyclophosphamide (non-investigational)|Given IV
223897852|NCT06186401|DRUG|Fludarabine (non-investigational)|Given IV
223897853|NCT06186401|PROCEDURE|Leukapheresis|Undergo leukapheresis
223897854|NCT06186401|PROCEDURE|Surgical resection|Undergo surgical resection of tumor tissue
223897855|NCT04195698|DRUG|Upadacitinib|Upadacitinib will be administered oral as tablet
223897856|NCT06662890|OTHER|Supersaturated oxygen|"Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy"
223897857|NCT06662890|OTHER|Sham (No Treatment)|Control (sham) procedure involving wrist manipulation in addition to standard care.
223897858|NCT06806566|OTHER|Carvacrol|"1-absorbable gelatine sponge soaked in carvacrol oil placed in the palatal donor site.~Procedure:~The palatal sites will be anaesthetized with 0.3 ml of a solution of 4% Articaine and 0.001% Adrenalin. Graft harvesting will be performed by basic surgical techniques previously described by Miller (1982). A rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection.~The graft will then be used as it on the recipient bed. The graft dimensions will be recorded (width and length). Denuded palatal area will then be protected using a carvacrol loaded absorbable gelatin sponge (test group)"
223897859|NCT06806566|OTHER|Gelatin Sponge Sheet|"Absorbable gelatin sponge placed in the palatal donor site~Procedure:~The palatal sites will be anaesthetized with 0.3 ml of a solution of 4% Articaine and 0.001% Adrenalin. Graft harvesting will be performed by basic surgical techniques previously described by Miller (1982). A rectangular shaped piece of mucosa will be harvested from the area of the hard palate by a split-thickness dissection.~The graft will then be used as it on the recipient bed. The graft dimensions will be recorded (width and length). Denuded palatal area will then be protected using a absorbable gelatin sponge(control group)."
223897860|NCT05459688|DRUG|CIN-107|2 mg of CIN-107, once a day for 52 weeks
223897861|NCT06806358|DEVICE|IUD insertion|"* Perform a bimanual examination~* Insert a warm, moistened speculum.~* Cleanse the cervix with an antiseptic solution.~* Open the sterile insertion instruments without touching~* Remove the tenaculum by its handle and grasp the anterior or posterior lip of the cervix.~* Apply gentle traction with the tenaculum to straighten the canal.~* Remove the sound by its handle and gently insert it to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed~* Open the IUD pack without touching its contents.~* Put on sterile gloves.~* Load the IUD and insert it into the uterine cavity according to the manufacturer instructions.~* Gently remove the tenaculum.~* Trim the strings of the IUD to 3-4 cm in length~* Remove the speculum and assess the woman."
223897862|NCT05740813|DRUG|ABBV-CLS-7262 Dose 1|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
223897863|NCT05740813|DRUG|ABBV-CLS-7262 Dose 2|ABBV-CLS-7262 is administered orally once per day for 24 weeks.
223897864|NCT05740813|DRUG|Matching Placebo|Matching placebo is administered orally once per day for 24 weeks.
223897865|NCT06577584|OTHER|Follow-up in the Diabetes Care Trajectory|Being followed-up in the Diabetes Care Trajectory in Belgium
223897866|NCT06577584|OTHER|Follow-up in the Diabetes Convention|Being followed-up in the Diabetes Convention in Belgium
223897867|NCT04680403|OTHER|Exercise|supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
223897868|NCT04478890|DIAGNOSTIC_TEST|Hemodynamic assessment|Hemodynamic assessment of the right ventricle using pressure-volume loop catheter and pulmonary artery catheter
223897869|NCT06087536|DRUG|OMN6|"Cohort 1: 50 mg x 3/day Cohort 2: 100 mg x 3/day Cohort 3: 150 mg x 3/day~3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days"
223897870|NCT06087536|DRUG|Placebo|3 x 3-hour IV infusions for 1 Day of treatment concomitant with background antimicrobial treatment with meropenem plus colistin for 7 to 14 days
223897871|NCT06313866|DIETARY_SUPPLEMENT|control|Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.
223897872|NCT06313866|OTHER|Electronuchal acupuncture group treatment|Electronuchal acupuncture
223897873|NCT06313866|OTHER|Smell therapy group treatment|nasal suction intervention with volatile oil of Acorus calamus
223897874|NCT06313866|OTHER|Electronuchal acupuncture combined with smell and inhalation therapy group treatment|On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.
223897875|NCT06313866|OTHER|Sham stimulation|In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.
223897876|NCT06806501|BEHAVIORAL|Unilateral Resistance Exercise|Resistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets.
223897877|NCT04908722|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injections of Ad26.COV2.S.
223897878|NCT06807385|OTHER|Reaction Training|"* The exercise list consists of 15 different exercises that aim to both shorten reaction time and improve stability with upper and lower extremity movements in different positions. In addition, the program includes both dual motor tasks and difficulties that require the physiotherapist to give the patient constantly changing motor tasks (tasks related to the color of the light to be touched, giving the command to read lights that are lit in different directions) and a second cognitive task.~* Each station will be worked for 3 minutes, with at least 1 minute of rest between stations. Sessions will be planned by selecting the exercises in the exercise list for 60 minutes.~  * Appropriate modifications will be made to the station so that the difficulty of the exercise in the relevant station will be moderate (12-15 points) according to the Borg scale."
223897879|NCT06807385|OTHER|Conventional Exercises|"The exercises used in reaction training will be applied as in conventional training without reaction training system. The difficulty of the exercise will be increased by changing the support surface and ground properties, taking the difficulty perceived by the individual as the criterion, as in reaction training.~The exercise list consists of 15 different exercises that aim to improve stability with upper and lower extremity movements in different positions. In addition, the program includes both dual motor tasks and difficulties that require the physiotherapist to give the patient constantly changing motor tasks and a second cognitive task. Each station will be worked for 3 minutes, with at least 1 minute of rest between stations. Sessions will be planned by selecting the exercises in the exercise list for 60 minutes. Appropriate modifications will be made to the station so that the difficulty of the exercise in the relevant station will be moderate (12-15 points for Borg Scale)."
223897880|NCT04863222|DEVICE|Biodentine|During a patients procedure, one tooth will receive Biodentine instead of MTA.
223897881|NCT04863222|BIOLOGICAL|mineral trioxide aggregate (MTA)|mineral trioxide aggregate (MTA)
223897882|NCT04931810|BEHAVIORAL|All Nations Breath of Life|Same.
223897883|NCT02319759|DRUG|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
223897884|NCT02319759|DRUG|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
223897885|NCT02319759|DRUG|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
223897886|NCT05827718|BEHAVIORAL|Method of Contact|Behavioral Intervention studied here is the method of contact (text vs. email vs. email+text).
223897887|NCT05827718|BEHAVIORAL|Source of Contact|Behavioral Intervention studied here is source of contact (personal clinic vs. research team)
223897888|NCT05827718|BEHAVIORAL|Framing Method (Appeal to Altruism or Social Proof|"Behavioral Intervention studied here is the framing methods appeal to altruism and social proof"
223897889|NCT05827718|BEHAVIORAL|Incentive Structure|Behavioral Interventions studied here are guaranteed vs. lottery incentives
224276631|NCT03547635|DEVICE|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
224276632|NCT03547635|OTHER|Standard of Care|"* Coban™~* Conforming gauze~* Optifoam® non-adhesive dressing~* Cotton Gauze~* Normal saline (liquid or gel)~* Non-adhering dressings~* Steristrips~* An offloading boot (Pneumatic Short Leg Walker), as appropriate"
224276633|NCT05527158|BEHAVIORAL|Yi Jin Jing exercise|Yi Jin Jing of The General Administration of Sport of China, which consists of twelve operational processes as the standard intervention
223897890|NCT03131154|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
223897891|NCT03131154|DRUG|Vehicle of ADX-102 Ophthalmic Solution|Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
223897892|NCT02187848|DRUG|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
223897893|NCT06424236|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks, at escalating doses; at target, dosing was every 2 weeks
223897894|NCT06550219|DEVICE|Nasal humidified heated high flow cannula (NHHHC)|Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.
223897895|NCT06550219|DEVICE|Nasal intermittent positive pressure ventilation (NIPPV)|Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.
224276634|NCT00078741|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
224276635|NCT00883935|DRUG|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
224276636|NCT00883935|DRUG|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
224276637|NCT00883935|DRUG|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
224276638|NCT00883935|DRUG|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
224276639|NCT06469619|BEHAVIORAL|Music listening|Listening to music of one's choice one hour daily.
224276640|NCT03297619|BEHAVIORAL|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
223714110|NCT03435484|OTHER|Arm B|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
223714111|NCT01565512|DRUG|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
223714112|NCT01565512|DRUG|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
223714113|NCT02781831|PROCEDURE|Standard rehab|Standard hospital based rehabilitation for patients with stroke
223714114|NCT02781831|DEVICE|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
223714115|NCT00043914|DRUG|lamotrigine|
223714116|NCT02550990|BEHAVIORAL|Cognitive training|
223714117|NCT02550990|BEHAVIORAL|Aerobic exercise training|
223714118|NCT02550990|BEHAVIORAL|Sequential combination of aerobic exercise and cognitive training|
223714119|NCT01918774|BEHAVIORAL|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
223714120|NCT01606800|DRUG|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
223714121|NCT01606800|DRUG|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
223714122|NCT02963792|OTHER|Preventing Professionals burnout|
223719136|NCT05231954|OTHER|Passive Digital Marker for screening for ADRD|Patients in the primary care clinics randomized to PDM+QDRS will have Electronic Health Record Data of their patients run through the PDM, a machine learning algorithm which can predict ADRD one year and three years prior to its onset. In addition, patients from these clinics will have their patients complete the QDRS, a validated patient reported outcome (PRO) tool. This combined approach will assess the value of early detection of ADRD and if the annual well visit can overcome the barriers related to early detection of ADRD.
223719137|NCT03053193|DIAGNOSTIC_TEST|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the full genome testing array.
223719140|NCT03355521|OTHER|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
223719141|NCT03355521|OTHER|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
223719142|NCT03985631|OTHER|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
223719143|NCT01114425|DRUG|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
223719144|NCT01114425|DRUG|Truvada®|
223719145|NCT06243991|DEVICE|in vivo Corneal Confocal Microscopy|CCM was performed using the Heidelberg Retinal Tomograph 3 with the Rostock Cornea Module (HRT3-RCM, Heidelberg Engineering GmbH, Germany) under topical anesthesia. A viscous gel (Viscotears, Novartis Pharmaceuticals UK) served as a coupling agent between the cornea and the applanation cap. The subjects were instructed to focus on the fixation light with the unexamined eye to ensure proper positioning. Five high-quality images of the SNP were selected and analyzed using the automated tracing of nerve fibers program (ACCMetrics, M.A. Dabbah, Imaging Science and Biomedical Engineering, Manchester, England).
223719146|NCT06243991|DIAGNOSTIC_TEST|Corneal Sensitivity|Corneal sensitivity was evaluated using a Cochet-Bonnet esthesiometer (Luneau Ophtalmologue, Chartres, France), comprising a nylon filament measuring 60 mm in length and 0.12 mm in diameter. Participants were instructed to maintain a forward gaze while the esthesiometer gently made perpendicular contact. The procedure involved gradually decreasing the filament length in 5 mm increments, starting from 60 mm, until the initial response from the subject was detected.
223719147|NCT06243991|DEVICE|Non invasive tear break up time|Noninvasive tear break-up time (NI-TBUT) was assessed using a Sirius Scheimpflug camera (CSO, Florence, Italy) and the device automatically provided the average NI-TBUT value
223897896|NCT06550219|DEVICE|Nasal continuous positive airway pressure NCPAP|Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.
223897897|NCT06550219|DEVICE|lung ultrasound|Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).
223897898|NCT04501536|BEHAVIORAL|Word Learning Intervention|The word learning intervention uses the 10 commercially available children's books and 6 target vocabulary words from each book that meet common criteria for appropriate vocabulary targets. Children will receive 1-on-1 treatment sessions with a trained, speech-language research assistant. Each week, 2 of 10 storybooks chosen for the study will be read with 3 of 6 targeted vocabulary words targeted from each book. The book and words targeted will be consistent between random assignment conditions. For each book reading, speech-language interns will implement word learning strategies during pre reading, during reading, and post reading. Strategies include providing a definition, a synonym, and a contextual sentence. The number of strategies used will vary on which word is being targeted; all words will be randomly assigned to a particular dose, ranging from 0 (no strategies) to 20 (all of the strategies at each reading).
223897899|NCT05206929|OTHER|Self Managed Care|Self Managed Care
223897900|NCT04213872|BEHAVIORAL|Meditative Movement|The Meditative Movement program is a blend of meditation and exercise based on Tai Chi and Qigong.
223897901|NCT04734626|DIAGNOSTIC_TEST|Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence|CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise
223897902|NCT05292625|BIOLOGICAL|UC-MSC infusion via intravenous route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intravenous (IV) route with a 3-month intervening interval
223897903|NCT05292625|BIOLOGICAL|UC-MSC infusion via intrathecal route|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1.5 million cells/kg patient body weight via the intrathecal route with a 3-month intervening interval
223897904|NCT05292625|OTHER|standard stroke treatment and rehabilitation therapy|Each patient can receive up to 30 days of rehabilitation therapy
223897905|NCT06806826|DRUG|Omalizumab|The patients in the study group were started on omalizumab and intranasal fluticasone propionate. Omalizumab was administered subcutaneously to these patients at a dose of 300 mg once a month. . Twenty-five patients in the control group were started on intranasal fluticasone propionate spray and a tablet containing 5 mg desloratadine+10 mg montelukast sodium at the same dose and in the same manner as the patients in the study group. The patients were asked to use 100 mg of suspension equivalent to 50 micrograms of fluticasone propionate as two sprays into each nostril once daily and to use the tablet once daily. Patients in both groups were asked to fill out the visual analog scale and their total Ig E levels were checked. Patients who were called for a check-up after eight to ten weeks were evaluated again with the visual analog scale.
223897906|NCT03183570|DRUG|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered
223897907|NCT04016142|DRUG|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
223897908|NCT02162563|DRUG|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
223897909|NCT02162563|DRUG|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
223897910|NCT02162563|DRUG|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
223897911|NCT03339713|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp.
223897912|NCT03339713|BIOLOGICAL|Fluarix|Fluarix will be administered as intramuscular injection.
223897913|NCT03339713|BIOLOGICAL|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
223897914|NCT05917171|BEHAVIORAL|painTRAINER|painTRAINER is an 8 week online behavioral pain coping skills training program derived from cognitive behavioral therapy approaches, which includes 45 minute behavioral coping sessions to be completed over 8 weeks. Weekly sessions are guided by an automated coach that teaches skills for coping with pain.
223897915|NCT06425211|BEHAVIORAL|Therapeutic exercises|Recognition of the pelvic area, respiratory management, lumbo-pelvic mobilization, discrimination of abdomino-pelvic contraction and myofascial release techniques.
223897916|NCT06425211|DEVICE|Perineal electromyographic biofeedback|Free muscle work and gross motor coordination:
223897917|NCT06425211|DEVICE|Electrical stimulation|Muscular proprioceptive work: 50 Hz 300 µs
223897918|NCT06213857|DIETARY_SUPPLEMENT|Silymarin|Silymarin (milk thistle), an extract obtained from Silybum marianum seeds containing a complex of flavonolignans with a potent intracellular antioxidant property. The first usage of Milk thistle was for its hepatoprotective and antioxidant activities, but in the recent years it has been used to control of immune based murine colitis by healing of bowel histology and reduction of bowel inflammatory cytokines especially TNF-α, interleukin-1β (IL-1β), and nuclear factor κB (NF-κB). Silymarin has anti-viral, immunomodulation, anti-inflammatory effects as well as antioxidant properties by scavenging free radicals and increasing the glutathione concentrations, protective and wound healing effects. It increases the gene expression of antioxidant enzymes and the number of the most important protection mechanisms against free-radicals damage containing superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase.
223897919|NCT06213857|DRUG|Mesalamine|A 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission.
223897920|NCT06213857|DRUG|Azathioprine|An immunosuppressive medication that is used for the treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis). It works by decreasing the activity of the body's immune system so it will not attack itself.
223897921|NCT06143293|DEVICE|Vagus nerve stimulation device: acute and chronic administration of investigational vagus nerve stimulation parameters|Duty cycle: At Visit 1, while the frequencies are being changed over Period 1, 2, and 3, duty cycle will be held constant at the participant's randomly assigned first duty cycle setting. At Visit 2, duty cycle will be held constant at the participant's randomly assigned second duty cycle setting. At Visit 2 the participant will receive whichever duty cycle they were not randomly assigned at Visit 1. Therefore, by completing the combination of three frequencies at two duty cycles, each participant will have received all six possible VNS parameter combinations over the two study visits. Chronic period: The VNS setting for the Chronic Period in between Visit 1 and Visit 2 will be the same settings as tested during Visit 1 Period 3. Since Visit 1 Period 3 settings were already randomly assigned to each participant, another randomization for the chronic period is not needed.
223897922|NCT05553860|OTHER|Speech positioning technique|Speech positioning technique
223897923|NCT01959425|OTHER|Off OAT Group (Test)|Discontinuation of OAT Therapy
223897924|NCT01959425|OTHER|On OAT Group (Control)|Continuation of OAT Therapy
223897925|NCT02649842|DEVICE|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
223897926|NCT06162728|DRUG|Briquilimab|Subcutaneous Administration
223897927|NCT06162728|OTHER|Placebo|Placebo Comparator
223897928|NCT06216808|DEVICE|HyperQure Renal Denervation System|"The HyperQure RDN System consists of a generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a laparoscopic approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessel is planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN is also performed on the branch or accessory vessel confirmed to be suitable for the procedure by CTA."
223897929|NCT04619745|OTHER|Individualized Home and Play-Based Physical Activity Plans|Play-based, parent led interventions optimized to support age appropriate physical activity, and motor skills among young children with congenital heart defects.
223897930|NCT04079855|OTHER|Diet composition 1|A diet with a specified macronutrient composition different from arms 2 and 3.
223897931|NCT04079855|OTHER|Diet composition 2|A diet with a specified macronutrient composition different from arms 1 and 3.
223897932|NCT04079855|OTHER|Diet composition 3|A diet with a specified macronutrient composition different from arms 1 and 2, based on the current information about the US macronutrient composition.
223897933|NCT06821958|DEVICE|Radiofrequency electromagnetic field treatment|Radiofrequency electromagnetic field treatment using a carrier frequency of 13.56 MHz
223897934|NCT02835222|DRUG|Cytarabine|Given IV
223897935|NCT02835222|DRUG|Daunorubicin Hydrochloride|Given IV
223897936|NCT02835222|DRUG|Selinexor|Given PO
223897937|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
223897938|NCT05540665|DRUG|Daxdilimab|"Daxdilimab will be administered subcutaneously as two injections for each dose.~Other Names: HZN-7734"
223897939|NCT05540665|DRUG|Placebo (Normal Saline)|Placebo will be administered subcutaneously as two injections for each dose.
223897940|NCT06384183|DEVICE|Kerecis Fish Skin Graft|Patients already treated with a Kerecis device
223897941|NCT03881098|PROCEDURE|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
223897942|NCT03881098|PROCEDURE|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
223897943|NCT03881098|PROCEDURE|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
223897944|NCT06807762|DRUG|Cannabis oil|"Healthy subjects will be treated with a solution of Cannabis sativa extract diluted in MCT oil, at doses ranging from 39.62 mg to 791.4 mg. This protocol will be divided into two stages:~Stage 1 - Determination of the Maximum Tolerated Dose (MTD): Participants (n=60) will be dynamically randomized and will receive Cannabis sativa extract (GreenCare, 79.14 mg/mL) as a single dose after breakfast, with doses ranging from 39.62 mg to 791.4 mg.~Stage 2 - Assessment of the MTD: All participants (n=12) will receive the MTD determined in Stage 1, administered in two daily doses for 14 consecutive days."
223897945|NCT02619838|DEVICE|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
223897946|NCT01715285|DRUG|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
223897947|NCT01715285|DRUG|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
223897948|NCT01715285|OTHER|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
223897949|NCT01715285|DRUG|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
223897950|NCT01715285|DRUG|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
223897951|NCT04022850|BEHAVIORAL|A non-reflective decision assistance strategy|A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
223897952|NCT04022850|BEHAVIORAL|A both reflective and non-reflective decision information strategy|"This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients."
223897953|NCT04022850|BEHAVIORAL|A reflective decision structure strategy|The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
223897954|NCT05181540|BIOLOGICAL|AB-205|Allogeneic genetically engineered human umbilical vein endothelial cells
223897955|NCT05181540|OTHER|Placebo|Placebo
223897956|NCT06060782|DRUG|Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen|"All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days"
223897957|NCT05397912|DIAGNOSTIC_TEST|Uterine Elastography|Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
223897958|NCT02876510|DRUG|Fludarabine|Fludarabine infusion
223897959|NCT02876510|DRUG|Cyclophosphamide|Cyclophosphamide infusion
223897960|NCT02876510|BIOLOGICAL|IMA101 product|i.v. infusion of IMA101 product(s).
223897961|NCT02876510|BIOLOGICAL|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
223897962|NCT02876510|DIAGNOSTIC_TEST|IMADetect|IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
223897963|NCT02876510|DRUG|Atezolizumab|Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
223897964|NCT05505292|DRUG|Lifitegrast 5% Ophthalmic Solution|Dosed twice a day for 8 weeks
223897965|NCT05505292|OTHER|Lifitegrast Ophthalmic Solution Vehicle|Dosed twice a day for 8 weeks
223897966|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
223897967|NCT05358535|DRUG|Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)|"The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).~The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab."
223897968|NCT06771466|PROCEDURE|Bilateral Ultrasound-Guided Erector Spinae Plane Block (group E)|The curvilinear ultrasound transducer should be placed in a cephalocaudal orientation over the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level. The transverse process will be more superficial and wider, while the rib will be deeper and thinner. Upon verification of the transverse process, the trapezius muscle, rhomboid major muscle (if performing at T5 level or higher), and erector spinae muscle should be identified superficial to the transverse process. The Tuohy needle should be inserted superior to the ultrasound probe using an in-plane approach in the cephalad to caudal direction.
224276641|NCT03297619|BEHAVIORAL|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
223714123|NCT04189159|BEHAVIORAL|PROMPT|PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
223714124|NCT05955105|DRUG|ILB-2109|ILB-2109 tablets will be administered by mouth every day in 21-day cycles
223714125|NCT05955105|DRUG|Toripalimab|Toripalimab injection will be administered via IV every 21 days.
223714126|NCT06053294|OTHER|CS- Beverage|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose. Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223714127|NCT06053294|OTHER|CS+Fast|(CS+): Flavored beverage solution with 110 calories of sucrose. Participants will consume flavored beverage solutions containing 110 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223714128|NCT06053294|OTHER|CS+Slow|(CS+): Flavored beverage solution with 110 calories of maltodextrin. Participants will consume flavored beverage solutions containing 110 calories of maltodexrin in 6 exposure sessions within 1 week.One exposure session will include pre- and post-consumption blood draws and indirect calorimetry measurement over a 2-hour period. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223714129|NCT01687998|DRUG|Evacetrapib|Administered Orally
223714130|NCT01687998|DRUG|Placebo|Administered Orally
223714131|NCT03613545|PROCEDURE|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
223714132|NCT03613545|PROCEDURE|Infusion of sham|Infusion of sham
223714133|NCT03613545|DRUG|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
223714134|NCT01337739|DRUG|Placebo Comparator|Placebo administration (.9 normal saline sterile)
223714135|NCT01337739|DRUG|Active Comparator|Administration of Dexmedetomidine
223714136|NCT05777577|DIETARY_SUPPLEMENT|probiotic therapy|probiotic including bifidobacterium
223714137|NCT03711812|PROCEDURE|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
223714138|NCT03711812|PROCEDURE|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
223714139|NCT03677531|OTHER|Quality-of-Life Assessment|Ancillary studies
223714140|NCT03677531|OTHER|Questionnaire Administration|Ancillary studies
223714141|NCT03677531|RADIATION|Radiation Therapy|Undergo RT
223714142|NCT03677531|OTHER|Video|Watch video of choice during RT
223714143|NCT01135420|BEHAVIORAL|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
223714144|NCT01135420|OTHER|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
223714145|NCT05135117|OTHER|NeuroRescue Cooling Collar|Between bouts of exercise subjects will be provided cooling on the neck with the NeuroRescue Collar. The custom sized cooling collar has ice water (which is kept around 2 degrees celsius) that is circulated through a neoprene sleeve that is attached to their neck for the cooling period.
223714146|NCT05135117|OTHER|Ice Towel|Between bouts of exercise subjects will be provided cooling on the neck with a towel. The towel will be kept in ice water (which is kept around 2 degrees celsius) and placed around the neck of the individual during the cooling intervention period.
223714147|NCT05500105|OTHER|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
223714148|NCT01182675|DRUG|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
224276642|NCT03028896|PROCEDURE|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
224276643|NCT03798379|OTHER|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
224276644|NCT04083352|DIETARY_SUPPLEMENT|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
224276645|NCT04083352|DIETARY_SUPPLEMENT|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
223897969|NCT06771466|PROCEDURE|Bilateral Ultrasound-guided Quadratus Lumborum, Lateral approach (group Q)|With the patient positioned in the lateral position, scanning is usually started at the mid-axillary line between the iliac crest and subcostal margin, moving the probe posteriorly until tapering of the three abdominal muscle layers and appearance of fascia transversalis and QL muscle are observed. The fascia transversalis usually appears as a hyperechoic layer, which forms a safe landmark to separate the muscle layers from the peri-nephric fat and the abdominal contents
223897970|NCT05959863|DIAGNOSTIC_TEST|Captopril Challenge Test|Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
223897971|NCT05998785|DEVICE|TAPESTRY Biointegrative Implant|Collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues. Preclinical studies of the Tapestry implant showed dense collagenous fibrous connective tissue ingrowth into and around the implant.
223897972|NCT01762462|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223897973|NCT06266403|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
223897974|NCT06266403|BEHAVIORAL|Clear Speech|"PALS and age-matched speakers will read critical words consisting of target segments (e.g., hid, ship, net) in random order four times. These words will be embedded in the carrier phrase Click on the \_\_\_ this time. Participations will be instructed to overenunciate the critical words."
223897975|NCT06266403|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
223897976|NCT06266403|BEHAVIORAL|Clear Speech Structured Communicative Interaction|"Two interlocutors, one with ALS and a typical, unfamiliar interlocutor or an age-matched speaker and a typical interlocutor, will work together. On each trial, one of the interlocutors will be randomly chosen to be the speaker and the other will be the listener. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. The speaker will be instructed to overenunciate the critical words. After the listener has made their selection, both participants will receive feedback on trial success."
223897977|NCT02356653|DEVICE|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
223897978|NCT06252285|BIOLOGICAL|RSVt Vaccine|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
223897979|NCT06252285|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
223897980|NCT03959696|BEHAVIORAL|Notification|Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
223897981|NCT03959696|BEHAVIORAL|Training|The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
223897982|NCT05917067|DIAGNOSTIC_TEST|Fluorescence imaging of the parathyroid glands of children|Patients that participate in this study will always receive standard care. For the purpose of this study, the camera settings (i.e. camera distance to the operating field, switching of OR-lights, and angle of the camera on the operating field) and ICG-protocol (i.e. dose, injection speed) will be standardized among the participating centers in order to generate an homogeneous data set for quantification of the fluorescence signal intensity.
223897983|NCT06802718|DRUG|Interferon|Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.
223897984|NCT06489106|DEVICE|Activity based upper extremity training with and without stimulation|Activity-based upper extremity training (AB-UET) will be administered 5d/week and 1 hour 30 minutes/session. For AB-UET+ stimulation (scTS), UE tasks will be repeated with and without scTS so that scTS is administered intermittently for the duration of \~ 10 minute/bouts.
223897985|NCT03913702|DRUG|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
223897986|NCT03913702|DRUG|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
223897987|NCT06435039|DRUG|APL-1202|APL-1202 IR tablets.
223897988|NCT06435039|DRUG|APL-1501|APL-1501 ER capsules.
223897989|NCT04034706|OTHER|DEXA|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
223897990|NCT04034706|OTHER|Magnetic Resonance (MR) Assessment of the Abdomen|Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
223897991|NCT04034706|OTHER|MR assessment of Whole Body Fat|Volumetric measurement of fat, muscle and bone
223897992|NCT04034706|PROCEDURE|Adipose tissue biopsy|0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
223897993|NCT04034706|OTHER|Oral glucose tolerance test|Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
223897994|NCT06446661|OTHER|High Intensity|Daily texts
223897995|NCT06446661|OTHER|No Text Messagings|Standard Care
223897996|NCT06446661|OTHER|Low Intensity Text Messaging|Weekly Texts
223897997|NCT06403020|PROCEDURE|Block|qadratus lumboroum (QL) block
223897998|NCT06532591|DRUG|cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin|PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w
223897999|NCT03375892|OTHER|Deep Inspiration Breath Hold during Radiation|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
223898000|NCT03375892|OTHER|Free breathing during radiation|The patient will be instructed to breathe freely.
223898001|NCT04169386|DRUG|AK102|AK102 single dose administered subcutaneously
223898002|NCT04169386|DRUG|Placebo|Placebo single dose administered subcutaneously
223898003|NCT05714306|BIOLOGICAL|PEP-DC1|PEP-DC1 vaccine comprises autologous dendritic cells pulsed with personalized peptides detected or predicted a priori (using our current integrated antigen identification methodologies).
223898004|NCT05714306|BIOLOGICAL|OC-DC|OC-DC vaccine is an autologous dendritic cell vaccine loaded with autologous oxidized tumor lysate.
223898005|NCT05714306|BIOLOGICAL|PEP-DC2|PEP-DC2 comprises autologous dendritic cells pulsed with the peptides detected or predicted after vaccination with OC-DC.
223898006|NCT05714306|DRUG|Low dose cyclophosphamide|Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
223898007|NCT05071963|DEVICE|Treatment of Intracranial Aneurysms|Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™
223898008|NCT05396586|BEHAVIORAL|N-back|The training program is a personal device-based adaptive version of a visual N-back task, either devoid of game elements or embedded in a gamified platform game
223898009|NCT05396586|BEHAVIORAL|Span|The training program is a personal device-based adaptive version of a visual working memory span task, either devoid of game elements or embedded in a gamified platform game
223898010|NCT05396586|BEHAVIORAL|Multisensory|The training program is a personal device-based adaptive version of an N-back task that features visual stimuli (Unisensory) or visual stimuli paired with unique sounds (Multisensory) and is devoid of game elements
223898011|NCT06470672|DRUG|SHR-A1921|Anti-TROP-2 ADC
223898012|NCT06470672|DRUG|Adebrelimab|PD-L1 inhibitor
223898013|NCT03940690|DRUG|Anti-VEGF injections of bevacizumab|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
223898014|NCT03940690|DEVICE|Laser|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
223898015|NCT04006717|DEVICE|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
223898016|NCT04006717|PROCEDURE|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
223898017|NCT05758376|BEHAVIORAL|Recovery Bridge|Recovery Bridge is a Peer Specialist facilitated intervention designed to help Veterans being discharged from an inpatient psychiatric hospitalization bridge the gap to outpatient care and community living
223898018|NCT06499896|BIOLOGICAL|MTP-101-C|MTP-101-C is a screened, freeze-dried, encapsulated, full spectrum, healthy donor fecal microbiota product.
223898019|NCT04844073|DRUG|TAK-186|TAK-186 IV infusion.
223898020|NCT06156371|OTHER|lymphatic drainage massage|"Before the application, the patient will be placed in a supine position and the feet will be elevated to 45 degrees by the researcher. After the infraclavicular lymph node, located at the point where the veins in the neck area meet the thymus gland, is stimulated with a pumping action, lower extremity applications will be started in the form of upper legs, lower legs and feet; By stimulating the inguinal lymph node in the upper leg application, the popliteal lymph node in the lower leg application, and the medial malleolus lymph node in the foot application, the mobility of the lymph fluid in the direction of the stimulated lymph node is used using stroking, pumping, circular movements or rolling movements according to the weight characteristic, body type and preference of the patient. will be provided. Finally, passive exercise will be performed 5 times, repeating both legs in flexion and extension positions, and the infraclavicular lymph node will be stimulated."
223898021|NCT06156371|OTHER|classic massage|The application will be done by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration will be used. The application will start with efflorescence and end with the same technique. To the upper leg; Starting from the knee to the groin, to the lower leg; The application will be made in the direction of the muscle fibers, starting from the ankle to the knee. Appropriate techniques will be used depending on the characteristics of the application areas, and each technique will be repeated 5-10 times. In the final stage, passive exercise will be performed by moving to the foot and applying flexion and extension to the ankle 5 times. The application will be completed by applying similar applications to the upper and lower legs on the back of the foot and the outer and lower surface of the foot. Olive oil will be used as essential oil during application.
223898022|NCT06500130|DEVICE|Body Surface Gastric Mapping|All study participants will be in this group and will have a total of three body surface gastric mapping tests conducted, pre, during and post liraglutide.
223898023|NCT05562752|DIETARY_SUPPLEMENT|Probiotic|multistrain probiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 12 weeks.
223898024|NCT05562752|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 12 weeks.
223898025|NCT04844463|DRUG|JNJ-68179280|JNJ-68179280 will be administered as an oral capsule.
223898026|NCT04844463|OTHER|Placebo|Matching placebo will be administered as an oral capsule.
223898027|NCT05311007|OTHER|Evaluation of the incidence and nature of adverse events|Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
223898028|NCT02677805|DRUG|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
223898029|NCT02677805|DRUG|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
223898030|NCT02677805|DRUG|Botulinum Toxin A - Open Label|Open Label Extension Phase with Experimental Drug; Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
223898031|NCT05696132|DRUG|Betadine|Nasal decolonization with betadine gel
223898032|NCT03409614|DRUG|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
223898033|NCT03409614|DRUG|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
223898034|NCT03409614|OTHER|Chemotherapy|Platinum-based doublet chemotherapy Part 1
223898035|NCT03409614|DRUG|Placebo|Matching placebo Part 2
223898036|NCT02291302|OTHER|integrated pest management|integrated pest management and environmental strategy
223898037|NCT02291302|OTHER|air purifier|air purifiers
223898038|NCT02291302|OTHER|No intervention (control)|no integrated pest management and sham air purifier
223898039|NCT06030700|OTHER|Controlled Conditions|Use of FoodImage app to take pictures of food and/or receipts.
223898040|NCT05925985|OTHER|NA-Observational Registry|NA Observational Registry
223898041|NCT05027841|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
223898042|NCT06118905|DRUG|Denosumab 60 MG/ML|Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV
223898043|NCT06118905|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Infusion|Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
223898044|NCT04350463|DRUG|CC-90011|CC-90011
223898045|NCT04350463|DRUG|Nivolumab|Nivolumab
223898046|NCT04111536|DRUG|liothyronine|Each treatment period of liothyronine was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo.
223898047|NCT04111536|OTHER|Placebo|Each treatment period of placebo was approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - LT3.
223898048|NCT06487650|BEHAVIORAL|sleep intervention|At the beginning of the intervention, participants will have an orientation and overview of the program. Then, participants will follow the curriculum of modules, and professional feedback to complete the intervention.
223898049|NCT06487650|BEHAVIORAL|Control group|Participants in control group will follow standardized usual care and a perinatal health booklet
223898050|NCT03689842|PROCEDURE|Uterine transplantation|Uterine transplantation from living donor
223898051|NCT05275439|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
223898052|NCT05275439|DRUG|Azacitidine (AZA)|Chemotherapy drug approved for use in MDS and AML.
223898053|NCT05275439|DRUG|Venetoclax|Drug approved for use in AML.
223898054|NCT04234022|DRUG|Zn-DDC|Zn-DDC added to myeloma samples for culturing
223898055|NCT04234022|DRUG|Lanalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
223898056|NCT04234022|DRUG|Pomalidomide with Zn-DDC|Lanalidomide with Zn-DDC added to myeloma samples for culturing
223898057|NCT06430437|DRUG|SHR-A1811|Drug: SHR-A1811 administered intravenously every 3 weeks (Q3W)
223898058|NCT06430437|DRUG|Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin|"Drug: Camrelizumab administered intravenously every 3 weeks (Q3W)~Drug: Pemetrexed Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Paclitaxel Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Carboplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)~Drug: Cisplatin Based on the investigator's choice was administered intravenously every 3 weeks (Q3W)"
223898059|NCT06519877|DIETARY_SUPPLEMENT|Soluble corn fiber|Soluble corn fiber, also referred to resistant maltodextrin, is a type of dietary fiber made from corn starch. Soluble corn fiber is typically used to thicken processed foods and has been marketed as a prebiotic to improve digestive health.
223898060|NCT05289063|DRUG|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
223898061|NCT05289063|DRUG|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
223898062|NCT05289063|OTHER|Continuous Positive Airway Pressure Therapy|CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP.
223898063|NCT06419075|DRUG|Tranexamic acid|The intervention of 50 cc TXA (2 mg/mL) local infiltration is determined after carefully reviewing the literature. Scarafoni et al. recommends that the local TXA should not exceed at a concentration of 5-10 mg/mL to avoid cytotoxicity that may affect the wound re-epithelialization (22). In a prospective study on facelift bleeding, Kochuba et al. demonstrates that local TXA (1-2 mg/mL) with total 100 mg and 200 mg TXA safely and effectively decreased bleeding, operating room time, and drain output compared with traditional local anesthetic technique (14). Fathimani et all reports the local use of modified tumescent anesthesia solution with low TXA concentration (2 mg/dL) and total average dosage of TXA ranging 120-1000 mg is safe and promising in achieving less ecchymosis, edema, and seroma in common facial cosmetic surgical procedures (31). With a total dosage of 100 mg TXA and a volume of 50 cc injection, the concentration is calculated to be 2 mg/dL.
223898064|NCT06419075|DRUG|Vasopressin|The intervention of 50 cc Vasopressin (0.1U/mL) local infiltration is determined from several systematic reviews. Hafidh et al. shows that injection of diluted Vasopressin (3.6 to 10 units) with various concentration during hysterectomy significantly reduces the intraoperative blood loss when compared to placebo, and without increasing the hazard of cardiovascular toxicities. Cui et al. reports similar results, but including other vaginal surgeries. The common preparation for dilute Vasopressin is 0.1 U/mL or 1.0 U/mL from a 1cc vial of 20 U/mL Vasopressin. The advantage of 0.1 U/mL concentration is to avoid a relatively large bolus of concentrated 1.0 U/mL Vasopressin injected intravascularly by accident. A cumulative total dose of 4 to 6 units of Vasopressin administered in a dilute solution is proposed to be an upper limit. Therefore, the cumulative total dose of 5 units Vasopressin from 50 cc (0.1U/mL) is in the safe therapeutic range.
223898065|NCT06419075|OTHER|NaCl 0.9%|The intervention of 50 cc NaCl 0.9% local infiltration serves a placebo control.
223898066|NCT05339425|OTHER|No additional intervention will be administered.|No additional intervention will be administered.
223898067|NCT05622006|BEHAVIORAL|Sedentary breaks|Interrupting sitting with different frequencies of walking/jogging at moderate intensity.
223898068|NCT05030675|DRUG|Fostamatinib|Given PO
223898069|NCT03810196|DEVICE|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients will receive CD45RA depleted infusion after the TCRab PSCT.
223898070|NCT05710744|BEHAVIORAL|Shared decision making tip sheet|Physicians will view tip sheets containing best practices for shared decision making with diverse families.
223898071|NCT04364256|DEVICE|RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)|Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
223898072|NCT05714761|DEVICE|Dexcom glucose sensor|Use of a Dexcom G6 Pro
223898073|NCT05119842|DEVICE|APrevent® VOIS-Implant|To compare the voice quality assessed by the change in G-Score from GRBAS-Scale between before and after permanent APrevent® VOIS implantation.
223898074|NCT05632107|DEVICE|TOF-Watch®；DELSYS® Wireless surface EMG|TOF-Watch® is the most widely accepted AMG-based neuromuscular monitor; and DELSYS® Wireless surface EMG is a new technology that allows for the simultaneous acquisition of EMG and AMG signals in a wireless manner.
223898075|NCT04605081|DRUG|Naltrexone and Bupropion (NB) medication|NB medication will be taken daily in pill form.
223898076|NCT04605081|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
223898077|NCT05257967|DIAGNOSTIC_TEST|Lumbar puncture and Phlebotomy|Sampling of cerebral spinal fluid and plasma.
223898078|NCT05857761|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|Five sessions of active rTMS therapy will be distributed over 2 weeks (20 Hz, 2000 pulses, 90% resting motor threshold) will be delivered to left dorsolateral pre-frontal cortex (DLPFC) around 6 months post-trauma.
223898079|NCT05857761|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Five sessions of sham rTMS therapy will be distributed over 2 weeks
223898080|NCT03674424|DRUG|Avelumab|Chemotherapy with or without avelumab followed by surgery
223898081|NCT03674424|PROCEDURE|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
223898082|NCT03674424|COMBINATION_PRODUCT|CG|Chemotherapy 4 cycles of 3 weeks
223898083|NCT03674424|COMBINATION_PRODUCT|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
223898084|NCT03674424|COMBINATION_PRODUCT|PG|Chemotherapy 2 cycles of 4 weeks
223898085|NCT06580158|DEVICE|AI-ECG Dashboard|Patients standard of care ECG's will be processed through the AI-ECG Dashboard
223898086|NCT06580158|DIAGNOSTIC_TEST|Point of care ultrasound (POCUS)|Patients will undergo a ultrasound to confirm diagnosis of atrial stenosis or diastolic dysfunction.
223898087|NCT06580899|DEVICE|Intra-articular catheter|Intra-articular catheter pump with existing standard-of-care multimodal pain management protocol in the immediate post-op period
223898088|NCT06580899|OTHER|Routine Standard of Care Treatment|No changes to what would occur outside of the study.
223898089|NCT06580067|BEHAVIORAL|Pray Until Something Happens (PUSH)|Self-monitoring of outcomes + alerts/reminders + use of PUSH
223898090|NCT06580067|BEHAVIORAL|Self-monitoring|Self-monitoring of outcomes + alerts/reminder
223898091|NCT04518280|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
223898092|NCT04518280|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
223898093|NCT04518280|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223898094|NCT04518280|RADIATION|Short-course radiotherapy|Shor-course radiotherapy: 25Gy/5Fx
223898095|NCT05986422|DRUG|Methylprednisolone|The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
223898096|NCT04547920|DEVICE|Wearable Bladder Modulation System|Wearable Closed-Loop, Continuous Sensing Tibial Nerve Stimulation Device
223898097|NCT05535933|DRUG|HMPL-523(300mg PO QD)|HMPL-523(300mg PO QD)
223898098|NCT05535933|DRUG|Placebo|Placebo(300mg PO QD)
223898099|NCT05215353|OTHER|Music Therapy|Participants will receive seven weekly 60-minute treatments of music therapy. All sessions will be delivered virtually through Zoom.
223898100|NCT05215353|OTHER|Cognitive Behavioral Therapy|Participants will receive seven weekly 60-minute treatment of cognitive behavioral therapy. All sessions will be delivered virtually through Zoom.
223898101|NCT05215353|OTHER|assessments|Participants will complete study assessments prior to randomization (week 0) and at weeks 4, 8, 16, and 26. A subgroup of 60 survivors will complete optional semi-structured interviews after treatment to understand their unique experiences with MT or CBT. All participants will be followed for 26 weeks.
223898102|NCT05613153|DIETARY_SUPPLEMENT|Peppermint Oil|Participants weighing more than 40 kg will receive 2 peppermint oil capsules 3 times a day. Smaller children who weigh between 30 kg and 40 kg will receive 1 capsule of peppermint oil 3 times a day. All subjects will receive 8 weeks of treatment.
223898103|NCT05095701|BIOLOGICAL|Investigational Live Attenuated Varicella Vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.
223898104|NCT05095701|BIOLOGICAL|Placebo (Freeze Dired Dilution)|The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.
223898105|NCT05847166|RADIATION|[99mTc]Tc-PSMA-T4|\[99mTc\]Tc-PSMA-T4 for intravenous administration. The investigational medicinal product is to be prepared directly in a clinic by radiolabeling the radiopharmaceutical kit containing PSMA-T4 as a drug substance with sodium pertechnetate (99mTc) injection. The \[99mTc\]Tc-PSMA-T4 radiopharmaceutical should be used for targeted radionuclide SPECT imaging in patients with tumors and metastases of prostate cancer. The investigational medicinal product \[99mTc\]Tc-PSMA-T4 is dedicated for intravenous administration in radioactivity dose (555 - 740 MBq in cohorts A, B, C.
223898106|NCT01451502|BIOLOGICAL|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
223898107|NCT06530355|OTHER|The same evaluation methods were used for both groups. No intervention was applied to individuals in two groups..|No intervention was applied to individuals in this group.
223898108|NCT02547233|DRUG|LEO 43204 gel|
223898109|NCT02547233|DRUG|Vehicle gel|
223898110|NCT03870633|OTHER|Medical Chart Review|Undergo medical chart abstraction
223898111|NCT03870633|OTHER|Interview|Complete telephone interview
223898112|NCT03870633|OTHER|Questionnaire|Ancillary studies
223898113|NCT03870633|OTHER|Quality-of-Life Assessment|Ancillary studies
223898114|NCT05068232|RADIATION|Ablative Radiation|Ablative radiation therapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor or very specific area of the body, while limiting the radiation that affects surrounding organs.
223898115|NCT05068232|DRUG|Durvalumab|Durvalumab is an immunotherapy drug -- a drug used to help boost your immune response to fight cancer.
223898116|NCT05068232|DRUG|Etoposide|Etoposide is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
223898117|NCT05068232|DRUG|Carboplatin|Carboplatin is a chemotherapy drug approved for different kinds of cancer, including small cell lung cancer.
223898118|NCT05797753|DRUG|SAR443820|Tablet by oral administration
223898119|NCT05797753|DRUG|SAR443820|Capsule by oral administration
223898120|NCT05797753|DRUG|Erythromycin ethyl succinate|Tablet by oral administration
223898121|NCT05797753|DRUG|Itraconazole|Capsule by oral administration
223898122|NCT06066346|DRUG|Talquetamab|Talquetamab will be administered SC until disease progression
223898123|NCT05866640|DEVICE|F2 filter and delivery system|Placement of F2 device in aorta to cover great cerebral vessels
223898124|NCT04103879|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+\>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
223898125|NCT06332378|OTHER|Experimental group 1 :Ball training|Ball training Training in sitting position (the participants sat on the ball and did the exercises): holding balance position on the ball, active movements (flexion, extension, abduction, adduction) of one upper extremity, active movement of two upper extremities, trunk movements (bending forward and rotation), raising heel, raising toes, raising heel and toes simultaneously, resistance against perturbation, and weight shifting on ball and 2-Training in standing position: moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand, throwing the ball against the wall with foot
223898126|NCT06332378|OTHER|Experimental group 2 :Frenkel Exercises|"Frenkel Exercises Supine position~1. Flex and extend one leg, heel sliding down a straight line on table.~2. Abduct and adduct leg with knee and hip extended, leg sliding on table. Sitting position~1\. Place foot on therapist's hand, which will change position. 2. Raise leg and put foot on traced footprint on the wall. 3. Rise and sit with knees together. Standing position~1. Place foot forward and backward on a straight line.~2. Walk along a winding strip.~3. Walk between two parallel lines"
223898127|NCT06332378|OTHER|Control Group|By using random allocation, the participants will divided into three groups: an intervention group (N=30) that receive ball training exercise, another intervention group (N=30) that receive Frenkel training exercise and a control group (N=30
223898128|NCT05780723|DRUG|Treatment group: Rectal instillation of QHQYP|QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
223898129|NCT05780723|DRUG|Control group: Mesalazine enema treatment|Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
223898130|NCT03758989|DRUG|Rituximab Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
223898131|NCT03758989|DRUG|Cyclophosphamide|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
223898132|NCT03758989|DRUG|Doxorubicin|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
223898133|NCT03758989|DRUG|Vincristine|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
223898134|NCT03758989|DRUG|Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
223898135|NCT05127187|DIAGNOSTIC_TEST|Rapid diagnosis test against HIV and hepatitis C and B|combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample
223898136|NCT06623253|OTHER|not aplicable|no intervention
223898137|NCT04922229|PROCEDURE|RCT|This is the standard of care for this diagnosis
223898138|NCT04922229|PROCEDURE|Pulpotomy|For cases with normal apical tissues, pulpotomy using tricalcium silicates has been shown to have high clinical success. Either partial or complete pulpotomy will be performed depending on the size of pulp exposure.
223898139|NCT06044025|DRUG|Metformin|Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.
223898140|NCT06044025|DRUG|Turmeric|Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
223898141|NCT05620433|OTHER|Joint Effort|The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and higher) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
223898142|NCT05620433|OTHER|Brief normative feedback and standard information|The brief normative feedback is based on the frequency of cannabis use. Participants will also be offered basic reliable non-personalized information on lower-risk cannabis use in the form of official public websites.
223898143|NCT05444751|DRUG|General anesthetic|"Maintenance of general anesthesia: propofol infusion (50-150 μg.kg.min-1); ketamine infusion (up to 50 mg total); and inhaled anesthetic agent (isoflurane or sevoflurane) up to 0.5 MAC. N20 is not permitted.~Emergence from general anesthesia: N20 may be used during closure of the surgical incision to facilitate rapid emergence."
223898144|NCT05444751|DRUG|SA + ESP|"The choice of local anesthetic for spinal anesthesia will be confirmed after consultation with the attending surgeon to determine duration of surgery. For expected surgical times less than 90 minutes, up to 4 mL 1.5% mepivacaine (60 mg) will be used. Where the anticipated surgical duration is longer than 90 minutes, 2 mL 0.5% bupivacaine (10 mg) may be substituted. After patient (prone) positioning, maintenance of sedation will be achieved with a target RASS score of 0 to -1.~Propofol (25-50 μg.kg.min-1) and ketamine (up to 50 mg total dose) infusions will be titrated to effect. Intermittent boluses of propofol (10-20mg) may be used to achieve the desired sedation, as needed.~Patients will be offered to option of awake surgery, where no sedation will be provided, if preferred. Patients will be informed that at any time before or during the procedure, they may change their mind, and receive sedation."
223898145|NCT01363388|DRUG|Placebo|BID for 84 days
223898146|NCT01363388|DRUG|CCX168|BID for 84 days
223898147|NCT05919290|OTHER|MRI|Non-invasive imaging technique that is used to take pictures of organs within the body.
223898148|NCT02489903|DRUG|RRx-001|
223898149|NCT02489903|DRUG|Cisplatin|
223898150|NCT02489903|DRUG|Etoposide|
223898151|NCT02489903|DRUG|Carboplatin|
223898152|NCT02489903|DRUG|Irinotecan|
223898153|NCT02489903|DRUG|Vinorelbine|
223898154|NCT02489903|DRUG|Doxil|
223898155|NCT02489903|DRUG|Gemcitabine|
223898156|NCT02489903|DRUG|Taxane|
223898157|NCT02489903|DRUG|Paclitaxel|
223898158|NCT02489903|DRUG|Nab-Paclitaxel|
223898159|NCT02489903|DRUG|Pemetrexed|
223898160|NCT05855083|DRUG|Biological: narsoplimab|Treatment with narsoplimab 4 mg/kg will be administered
223898161|NCT02859961|DRUG|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
223898162|NCT02859961|DRUG|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
223898163|NCT02859961|DRUG|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
223898164|NCT05366179|DRUG|CAR.B7-H3T cells infusion|"The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2)."
223898165|NCT04768257|BEHAVIORAL|Physical activity|We will assess physical activity patterns of patients at baseline (at discharge from hospital or at patients' home), at 12 weeks and 6 months, through an objective measurement (triaxial accelerometer).
223898166|NCT05126433|DRUG|Lurbinectedin|Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)
223898167|NCT05521269|DRUG|ANX1502|ANX1502 is a prodrug of ANX1439.
223898168|NCT05521269|DRUG|Placebo|Placebo comparator.
223898169|NCT04137289|DRUG|BI 905711|BI 905711
223898170|NCT03197584|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223898171|NCT03197584|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
223898172|NCT03197584|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223898173|NCT03197584|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223898174|NCT03197584|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223898175|NCT03197584|DRUG|Fulvestrant|7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol
223898176|NCT03197584|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223898177|NCT03197584|DRUG|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223898178|NCT03197584|DRUG|omega-3 acid ethyl esters|omega-3 acid ethyl esters
223898179|NCT03197584|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
223898180|NCT03197584|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
223898181|NCT03197584|BIOLOGICAL|ALT-803|Recombinant human super agonist IL-15 complex
223898182|NCT03197584|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-HER2 vaccine
223898183|NCT03197584|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223898184|NCT03197584|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1 vaccine
223898185|NCT03197584|BIOLOGICAL|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
223898186|NCT03197584|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
223898187|NCT03197584|BIOLOGICAL|haNK®|NK-92 \[CD16.158V, ER IL-2\]
223898188|NCT06324318|BEHAVIORAL|Parenting in 2 Worlds (P2W)|P2W is a culturally-adapted parenting intervention designed specifically for urban American Indian families. It is a 10-week, 10-lesson manualized curriculum with accompanying videos, designed to be facilitated by American Indians from the local communities. The workshop lessons cover topics like the identification of family values, culturally influenced child rearing values and traditions, sources of support for parents, and ways to improve parenting skills to communicate with, monitor, and guide adolescents to avoid substance use, unprotected sex and other risk behaviors
223898189|NCT06324318|BEHAVIORAL|Healthy Families in 2 Worlds (HF2W)|HF2W is a 10-week informational family health program. The workshop lessons cover topics such as oral health, CPR and first aid, dating safety, and teen mental health.
223898190|NCT04623944|BIOLOGICAL|NKX101 - CAR NK cell therapy|NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.
223898191|NCT06554782|DEVICE|manual u-shaped toothbrush|manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
223898192|NCT06528626|DIAGNOSTIC_TEST|rapid HIV and HCV serological tests|In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
223898193|NCT06581952|BEHAVIORAL|Poem writing|"The poem themes will focus on accomplishment moments, joyful moments, and gratitude. Participants will be motivated to write at least one poem in each session. The instructor will lead the participants to improve the poem after the participants complete the first draft. The participants will be encouraged to perform in reading their completed poem, sharing their feelings and expressing the meaning of the poems during the session.~In the second session, participants will be invited to do a poem reading performance using one of their newly written poems."
223898194|NCT05500443|DIETARY_SUPPLEMENT|Vitamin K2 (Menaquinone-7)|Oral supplementation with vitamin K2 (Menaquinone-7 (MK-7)) 720 µg/day and D 25 µg/day
223898195|NCT04580446|RADIATION|Hypofractionated intensity modulated radiotherapy|Hypofractionated intensity modulated radiotherapy with concurrent chemotherapy (weekly cisplatin)
223898196|NCT04430179|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300 mg every other week for 24 weeks
223898197|NCT04430179|OTHER|Placebo|No active drug
223898198|NCT05415904|OTHER|HANTA-NE|Observational cohort study
223898199|NCT05506449|DEVICE|Impella CP®|"Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm."
223898200|NCT05506449|OTHER|Standard of Care|This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
223898201|NCT06180954|DRUG|[14C]-LOXO-305|Administered orally
223898202|NCT06180954|DRUG|LOXO-305|Administered orally
223898203|NCT06180954|DRUG|[14C]-LOXO-305|Administered IV
223898204|NCT06417918|BEHAVIORAL|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
223898205|NCT03208686|BEHAVIORAL|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology - a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
223898206|NCT05329220|BIOLOGICAL|ABNCoV2|ABNCoV2 100μg single dose
223898207|NCT05329220|BIOLOGICAL|Comirnaty|Comirnaty
223898208|NCT04204265|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
223898209|NCT05092386|BIOLOGICAL|Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine|The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.
223898210|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)|The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.
223898211|NCT05092386|BIOLOGICAL|Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)|The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.
223898212|NCT05523999|OTHER|Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA|Prospective study within the EMS 95, to evaluate if the maximum delay of 90 seconds between the call to the EMS and the recognition of the cardiac arrest is reached.
223898213|NCT04325334|BEHAVIORAL|Running volume increase|"Participants will receive a 12-week running program to increase their running volume by approximately 10% per week on average, and in accordance with the 10% rule advocated to minimize injury rates. For the purpose of this study, participants will run using their habitual technique - i.e. no specific instructions on 'how' to run will be provided; rather, they will simply be instructed on 'how much' to run."
223898214|NCT02165007|DRUG|peripheral blood stem cell graft that are CD34+ selected|The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.
224276646|NCT03492970|BIOLOGICAL|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
224276647|NCT06137404|OTHER|Splint|Comparison of splints for trigger finger
223898215|NCT05086497|DIAGNOSTIC_TEST|Whole Brain Spectroscopy Imaging Array Mapping Layout|All study participants will receive whole brain spectroscopy imaging as a part of MRI study time points. Participants assigned to the advanced MR imaging array mapping layout study arm will receive tumor treating fields mapping from Optune that is created from the spectroscopy sequences or advanced MR imaging. Participants assigned to the conventional array mapping layout will still receive advanced imaging sequences or spectroscopy imaging at all time points.
223898216|NCT04908423|DRUG|Xeomin®|To discover whether injection into the upper extremity with Xeomin® triggers improvements in gait-related mobility and quality of life in adults with hemiparesis secondary to stroke.
223898217|NCT06137482|DRUG|REGN13335|Administered intravenous (IV) or subcutaneous (SC), sequential ascending single dose
223898218|NCT06137482|DRUG|Matching Placebo|Administered IV or SC, sequential ascending single dose
223898219|NCT04969094|OTHER|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 3-months
223898220|NCT04969094|OTHER|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 3-months
223898221|NCT04983368|DRUG|Xanamem® 5 mg|"Oral Xanamem® (UE2343) capsules 5 mg, administered orally once daily."
223898222|NCT04983368|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (5 mg, 10 mg Xanamem® QD) except that it contains no active ingredient.
223898223|NCT04983368|DRUG|Xanamem® 10 mg|"Oral Xanamem® (UE2343) capsules 10 mg, administered orally once daily."
223898224|NCT04324164|DRUG|Third-generation EGFR-TKI|Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
223898225|NCT04324164|DRUG|EGFR-TKI|All EGFR-TKI
223898226|NCT04451135|DIAGNOSTIC_TEST|Electroencephalographic (EEG)|EEG on nights after ECT session will be recorded using the DREEM device. Sleep EEG data will also be acquired for a minimum of one night prior to the first ECT session, providing a true baseline measure. The DREEM device allows continuous recording of multichannel EEG
223898227|NCT04451135|DIAGNOSTIC_TEST|Closed loop acoustic stimulation (CLAS)|Closed loop acoustic stimulation will be enabled on the DREEM headband on a subset of study participants. The device delivers stimulation in phase with the upstroke of the EEG slow wave (STIM) to boost slow oscillation activity. The timing of this stimulus augments the expression of subsequent slow waves.
223898228|NCT04451135|DIAGNOSTIC_TEST|Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16)|The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) is a measure of depression symptom severity that has been validated for clinical and research use53. It is a standard self-report measurement completed by patients prior to each ECT session
223898229|NCT04451135|DIAGNOSTIC_TEST|Ictal Electroencephalographic (EEG) Measurements|A high-density 65-electrode EEG scalp electrode net (EGI/Philips) with Elefix conductive gel injected within Ag/AgCl electrode sensors is utilized to monitor brain activity during the ictal period
223898230|NCT04451135|DIAGNOSTIC_TEST|Post-Ictal Electroencephalographic (EEG) Suppression Measurements|A board-certified epileptologist will review all seizures to assess seizure parameters, including duration of seizure and interval of PGES. Preprocessing of the PGES periods will be accomplished with band-pass filtering from 2 to 30 Hz with 1st order Butterworth filters.
223898231|NCT04451135|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Following EEG preprocessing of DREEM sleep recordings, SWA will be quantified using a custom-written MATLAB module as the average of total power spectral estimates within the 0.5-4 Hz frequency band in one minute intervals, during the first cycle of N3 sleep.
223898232|NCT06490276|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
223898233|NCT06490276|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
223898234|NCT05038878|DRUG|Elagolix|Patients will be given Elagolix 200 mg orally twice daily for a total of 6 months
223898235|NCT05714683|DRUG|Semaglutide|All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
223898236|NCT05854550|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
223898237|NCT03327805|DIETARY_SUPPLEMENT|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
223898238|NCT03327805|DIETARY_SUPPLEMENT|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
223898239|NCT04985487|OTHER|brolucizumab|Prospective observational study. There is no treatment allocation. Patients administered brolucizumab, that have started before inclusion of the patient into the study will be enrolled.
223898240|NCT01783288|OTHER|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
223898241|NCT01783288|OTHER|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured \& collected in the supine (lying) and upright position for each participant.
223898242|NCT01783288|PROCEDURE|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
223898243|NCT01783288|OTHER|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
223898244|NCT06454812|DEVICE|Mechanical vibration|The vibration device will be placed on the procedure site (on the vastus lateralis muscle) on the left extremity and fixed through a long gauze. The vibration device will be operated for 30 seconds with reference to previous studies, then the nurse will administer routine intramuscular Hepatitis B vaccine. A gap of approximately 1-2 cm will be left between the device and the injection site. After the vaccination procedure is completed, the vibration will be terminated. The same procedure was repeated for DTaP-IPV-Hib vaccine administered to the the right extremity. The baby will be swaddled and placed in the mother's lap.
223898245|NCT06454812|BEHAVIORAL|Helfer skin tap technique (HSTT)|In this group, HSTT consisting of 4-stage strokes will be applied to the vaccination site. The nurse will make approximately 10 strokes for 5 seconds with the palmar side of the fingers of the dominant hand to the injection site to relax the muscles (Stage 1). The nurse will give a V-shaped position to the thumb and index finger of the non-dominant hand and give 3 strokes to the injection site with the palmar side of the fingers (Stage 2). The skin entry site of the needle will remain inside the V-shape. Simultaneously with the 3rd stroke, the nurse will insert the needle into the muscle at a 90 degree angle. The nurse will inject the vaccine into the muscle while continuing to tap the skin with the palmar side of the fingers of the non-dominant hand (Stage 3). The nurse will make 3 strokes on the skin with the palmar side of the fingers of the non-dominant hand at the injection site, simultaneously with the 3rd stroke, the needle will be removed from the baby's skin (Stage 4).
223898246|NCT04036682|DRUG|CLN-081|CLN-081 tablets
223898247|NCT06251180|DRUG|Rocbrutinib|orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
223898248|NCT06251180|BIOLOGICAL|Rituximab|375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
223898249|NCT06251180|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
223898250|NCT06251180|DRUG|doxorubicin|50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
223898251|NCT06251180|DRUG|Vincristin|1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
223898252|NCT06251180|DRUG|Prednisone|100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.
223898253|NCT02561936|DRUG|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
223898254|NCT02561936|DRUG|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10\*2.5 mg tablets.
223898255|NCT02561936|DRUG|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10\*2.5 mg tablets.
223898256|NCT02561936|DRUG|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
223898257|NCT02561936|DIETARY_SUPPLEMENT|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter \[mL\]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) \[189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins\]).
223898258|NCT05775471|PROCEDURE|Biopsy|Undergo tissue biopsy
223898259|NCT05775471|PROCEDURE|Biospecimen Collection|Undergo blood and urine collection
223898260|NCT05775471|DRUG|Enfortumab Vedotin|Given IV
223898261|NCT05775471|PROCEDURE|MR Urography|Undergo MRU
223898262|NCT05775471|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy
223898263|NCT05775471|BIOLOGICAL|Pembrolizumab|Given IV
223898264|NCT06273293|DIAGNOSTIC_TEST|Fractional Flow Reserve|"Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~1. Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~2. Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~3. Determination of the diastolic dPR index: the average value (2-3 determinations).~4. Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center."
223898265|NCT04835506|DRUG|Infliximab|infliximab
223898266|NCT05687084|DEVICE|Uterine manipulator use|The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.
223898267|NCT02141919|RADIATION|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
223898268|NCT06493227|OTHER|No routine fibrinolysis inhibitors after surgery|Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.
223898269|NCT06493227|OTHER|Routine fibrinolysis inhibitors after surgery|During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.
223898270|NCT03484364|BEHAVIORAL|ENACTS|Peer-facilitated, self-care BP education delivered every other week for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $50 of groceries every other week (4 times) over 8 weeks.
223898271|NCT05166382|BEHAVIORAL|Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their first research visit.
223898272|NCT05166382|BEHAVIORAL|Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)|Providers and patients will be informed of CVD-T2D test results that predict the risk of cardiovascular events over the next 4 years after their second research visit.
223898273|NCT04099394|BEHAVIORAL|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
223898274|NCT04099394|BEHAVIORAL|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
223898275|NCT06426940|OTHER|anesthesia-related critical events|anesthesia-related critical events
223898276|NCT03931174|BEHAVIORAL|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
223898277|NCT03931174|BEHAVIORAL|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
223898278|NCT04813926|DRUG|Riociguat (Adempas, BAY63-2521)|Follow clinical practice.
223898279|NCT06177912|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
223898280|NCT06177912|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
223898281|NCT03322267|DRUG|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
223898282|NCT05513443|PROCEDURE|Irreversible electroporation, IRE|IRE involves the use of high voltage electrical pulses to treat solid tumors by increasing membrane permeability and inducing membrane disruption, leading to cell death. The technique is used in Sweden today in radical ablative therapies in the treatment of tumors in the liver, kidney and pancreas. Prior to treatment a Foley catheter is placed. During the treatment, which takes place under anesthesia, the patient is placed in gynecological position and the tumour lesion is located with BK transrectal fusion ultrasound. Thereafter the needles are placed transperineal around the tumor in the prostate using a brachytherapy grid (17Ga Civco brachytherapy grid), guided by the ultrasound/MRI fusion images. Through the needles electrical pulses are then sent to treat the tumor in the center using the Nanoknife technique. After treatment patients are treated with diuretics to flush the kidneys post treatment.
223898283|NCT05513443|PROCEDURE|Radical prostatectomy|Radical prostatectomy
223898284|NCT05513443|RADIATION|Radiation therapy|Radiation therapy for prostate cancer
223898285|NCT06005168|DRUG|Cefazolin for Injection|2 grams or 3 grams based on standard of care or morphomic-based decision
223898286|NCT06036914|DRUG|Bumetanide|Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.
223898287|NCT06036914|DRUG|Furosemide|"Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID."
223898288|NCT05898529|DIAGNOSTIC_TEST|Rapid antigen test|COVID-19 rapid antigen testing of nasal swab
223898289|NCT03046251|DRUG|Natalizumab|
223898290|NCT05119387|OTHER|Observation|Observation of genetic characteristics
223898291|NCT05251129|DRUG|Atorvastatin 80 Mg Oral Tablet|Higher intensity statin
223898292|NCT05251129|DRUG|Pravastatin 40 Mg Oral Tablet|Lower intensity statin
223898293|NCT05757453|DEVICE|mHealth|Mobile platform
223898294|NCT06742593|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
223898295|NCT05564104|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
223898296|NCT03705416|PROCEDURE|Endoscopy|endoscopic suturing of stomach
223898297|NCT03705416|PROCEDURE|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
223898298|NCT06075615|DRUG|dacomitnib|patients with dacomitnib as first line treatment for advanced NSCLC with brain metastasis
223898299|NCT06127914|BEHAVIORAL|Learning Early Infant Feeding Cues|"The LEIFc intervention includes individualized responsive feeding education and promotion using the SS-OO-PP-RR (or super, Setting the Stage, Observation and Opportunities to Embed, Problem Solving and Planning, Reflection and Review coaching approach as a guide. An interventionists interacts with mother-infant dyads during a feeding session at infant ages of 1, 2, 3, 4, and 5 months and coaches the mother on responsive feeding. In particular infant cues of hunger and fullness and tips to assist the mother in making decisions regarding feeding her infant. This will begin with milk based feedings (either breastmilk from breast or bottle, or formula from a bottle), and continue through the transition to solid (complementary) foods."
223898300|NCT06214312|DIAGNOSTIC_TEST|Lung Ultrasounds|An ultrasound exam of the lungs to identify possible areas of atelectasis.
223898301|NCT06648642|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues
223898302|NCT04870177|DRUG|AK112|AK112 infusion biweekly
223898303|NCT01467427|DRUG|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
223898304|NCT05503927|OTHER|No Intervention|This is a non-interventional study, therefore no intervention is used.
223898305|NCT03492216|BEHAVIORAL|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) \<300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
223898306|NCT03492216|BEHAVIORAL|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
223898307|NCT05680363|DEVICE|HyperSperm|Multi-step sperm preparation
223898308|NCT05680363|DEVICE|Standard Sperm Preparation|Standard sperm preparation
223898309|NCT03847714|DIETARY_SUPPLEMENT|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
223898310|NCT03847714|DIETARY_SUPPLEMENT|placebo|similar looking and tasting powder
223898311|NCT05787821|DEVICE|Total Knee Arthroplasty|Total knee replacement.
223898312|NCT05206500|DRUG|Antibiotic|FDA approved and marketed antibiotic treatment for the patients with UTI symptoms and CC \>0 and \<10,000
223898313|NCT05206500|DEVICE|Next Gen|Next Generation Sequencing (NGS) is available to detect bacteria in urine based on bacterial genomes.
223898314|NCT03717142|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
223898315|NCT05858125|OTHER|Social Media Navigation Aid Kit|"The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to \>65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference."
223898316|NCT06448182|DIETARY_SUPPLEMENT|Postbiotic|1 capsule of postbiotic daily in the morning
223898317|NCT06448182|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo daily in the morning
223898318|NCT04196413|DRUG|GD2 CAR T cells|Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor
223898319|NCT04196413|DRUG|Fludarabine|Fludarabine 25 mg/m2 per day IV for days -4, -3, -2
223898320|NCT04196413|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
223898321|NCT07062770|DEVICE|Continuous positive airway pressure (CPAP)|Subjects will be administered either 0, 5 or 10 cmH2O
223898322|NCT07062770|OTHER|Mask exhaust port flow|Subjects will be administered varying levels of exhaust flow: 35, 23, 18, 13 and 8 L/s
223898323|NCT03869866|BIOLOGICAL|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
223898324|NCT06454136|DEVICE|OTX-207|Experimental Pscyhoeducation and Intervention App
223898325|NCT06454136|DEVICE|Comparator App + Treatment as Usual (TAU)|Digitized content and information included in standard of care (i.e., TAU)
223898326|NCT02566668|OTHER|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
223898327|NCT05473767|BEHAVIORAL|Family Check Up Heart|Family Check-Up Heart consists of the Family Check up with an added heart health component. The Family Check-Up Heart assessment will include evaluations of maternal cardiovascular health; specifically, measurement of maternal blood pressure, body mass index, diet quality, exercise, and smoking, which will be included in the feedback session. After the Feedback Session participants will also receive information about healthy eating and weight loss, stress management, and smoking and to monitor weight and blood pressure.
223898328|NCT05473767|BEHAVIORAL|Family Check-Up|"The Family Check-Up typically takes place over the course of 3-5 sessions, each about an hour long. First, a trained Family Check-Up family coach will conduct an Initial Interview. Second is an assessment of that includes questionnaires and videotaped interaction tasks. Third, during the Feedback Session, the family coach discusses with the participant strengths and challenges for their child and family as a whole. They then set goals for their family to support and maintain strengths, and to address any areas of concern. After the Feedback Session families have the option to continue meeting with their family coach to support the child's development and improve parental well-being."
223898329|NCT05931432|OTHER|Comprehensive Well-Being Intervention|The intervention group will receive an 18-month comprehensive suite of services including: 1) monthly automated text messaging reminders about wellbeing resources focused on a range of topics (e.g. mindfulness, stress management, childcare support, racial trauma, diversity and inclusion) and assignment to a one-hour quarterly peer support group with an expectation of regular attendance. Half of these sessions will be self-directed discussion topics and half will be facilitated discussions. The content of monthly text messaging resources and discussion topics for the peer-support groups will be informed by the Aim 1 qualitative findings.
223898330|NCT04625283|DRUG|Ketamine|Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
223898331|NCT04625283|DRUG|Placebo|Participants in the placebo arm will receive intraoperative and postoperative saline.
223898332|NCT06770179|OTHER|recruitment maneuver|in the group 2, in addition to the fixed PEEP of 5 cm H₂O, a recruitment maneuver is planned at the end of the surgery. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, before extubation.
223898333|NCT06770179|OTHER|positional recruitment maneuver|In the third group, in addition to the fixed PEEP, a recruitment maneuver will be performed at the end of the surgery before extubation. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, with 3 breaths in the right lateral decubitus position and 3 breaths in the left lateral decubitus position
223898334|NCT04502888|DRUG|Drug: SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
223898335|NCT05964868|DRUG|Liposomal Bupivacaine|Patients will receive post-operative liposomal bupivacaine (EXPAREL®) at the surgical site at the completion of their septorhinoplasty.
223898336|NCT05964868|DRUG|0.25% bupivacaine with 1:200,000 epinephrine|Non-liposomal encapsulated bupivacaine at the surgical site at the completion of septorhinoplasty.
223898337|NCT05964868|OTHER|Placebo - Saline solution|This group will receive a one-time 5 mL injection of saline post-operatively at the surgical site.
223898338|NCT05915013|DRUG|Ketamine|Intravenous ketamine
223898339|NCT05915013|DRUG|Perampanel|Oral perampanel (6 mg)
223898340|NCT05915013|DRUG|Placebo|Oral placebo
223898341|NCT06228924|GENETIC|TN-401|TN-401 is a recombinant adeno-associated virus serotype 9 (AAV9) gene therapy containing Plakophilin-2 (PKP2) transgene. It is a single (one-time) intravenous dose.
223898342|NCT03462030|DRUG|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
223898343|NCT03462030|DRUG|Placebo: Tapioca Powder|Placebo control.
223898344|NCT06807931|OTHER|Interactive film|An interactive film, co-produced with young people, that aims to provide young people with a virtual experience of making choices and facing consequences in various life scenarios. At key moments the action is paused and the user decides the outcome. The particular film series that was commissioned and included in the trial was 'Jessica's story', which focused on perinatal mental health, as well as many other public health issues relevant to young people, including mental wellbeing, domestic violence, and help-seeking behaviour.
223898345|NCT01867554|GENETIC|gene analysis|gene analysis
223898346|NCT05020249|DRUG|bimekizumab|Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
223898347|NCT05020249|OTHER|Placebo|Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
223898348|NCT06129188|DRUG|Remimazolam|Remimazolam is an ultra-short acting benzodiazepine medication. Benzodiazepines are a class of drug that directly interact with gamma-aminobutyric acid (GABA) and modifiable chloride channels through polysynaptic pathway inhibition. The anxiolytic properties of benzodiazepines make them useful as sedatives.
223898349|NCT06129188|DRUG|Propofol|Standard of care usage of the intravenous anesthetic agent propofol to achieve adequate sedation conditions for the procedure.
223898350|NCT05465629|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
223898351|NCT05465629|DIETARY_SUPPLEMENT|VIOME-designed condition-based supplements|Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
223898352|NCT05298358|BIOLOGICAL|RIC alloBMT w PTCy in refractory SSc|"The preparative regimen:~* Thymoglobulin 0.5 mg/kg IV day -9~* Thymoglobulin 2 mg/kg IV Days -8, -7~* Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6,-5~* Fludarabine 30 mg/m2 IV Days -6, -5, -4, -3,-2~* Total body irradiation (TBI) 400cGy~* Day 0- infusion of unmanipulated bone marrow~The GVHD prophylaxis regimen:~* Cy 50 mg/kg IV Days 3, 4~* Tacrolimus (FK-506) (IV or oral (po)) beginning Day 5 with dose adjusted to maintain a trough level of 5-15 ng/mL. Sirolimus may be substituted for tacrolimus.~* Mycophenolate mofetil (MMF) 15 mg/kg po TID, maximum dose 1 g po TID Day 5 - Day 35~* Filgrastim (G-CSF) 5 µg/kg SQ daily beginning Day 5 until absolute neutrophil (ANC) is greater than 1000/µl over at least 2 days.~Supportive care:~* Mesna- 10 mg/kg/ IV Day 3, 4~* Patients will receive infection prophylaxis and treatment according to institutional guidelines."
223898353|NCT05775965|DRUG|Rivaroxaban 10mg|Rivaroxaban 10mg daily for 35 days post hip fracture surgery
223898354|NCT05775965|DRUG|acetylsalicylic acid (ASA) 81mg Oral Tablet|acetylsalicylic acid (ASA) 81mg daily for 35 days post hip fracture surgery
223898355|NCT06635889|DRUG|Bupivacaine|The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.
223898356|NCT06635889|OTHER|Normal saline|Placebo of 50 ml of Normal Saline
223898357|NCT05140200|BIOLOGICAL|GSK3511294|GSK3511294 will be administered.
223898358|NCT06125132|PROCEDURE|Restoration with-tooth colored material|Restoration of abrasions with different composite resin materials
223898359|NCT03692494|OTHER|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
223898360|NCT03692494|OTHER|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
223898361|NCT06616454|BEHAVIORAL|Intervention group - Time restricted feeding|Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
223898362|NCT06648811|DEVICE|Pain management after surgery|Kinesio tapes will be applied to the patients in the study group after gynecological laparoscopic operations. The routine pain management will also be provided in these patients in addition to the kinesio tapes. Only postoperative pain management will be provided to the patients in the control group. The patients will be consisted of only the patients who will be operated laparoscopically for gynecological diseases.
223898363|NCT04066244|DRUG|BLZ945|Investigational drug capsules taken orally or via enteral infusion
223898364|NCT05974254|DEVICE|Acupuncture|Electroacupuncture
223898365|NCT06771557|OTHER|656 Online Platform|The 656 Platform provides valuable information regarding three common ailments among the elderly, namely stroke, dementia, and fall-related fractures. Serving as an online platform, the 656 Platform incorporates a Chatbot feature that facilitates connections between local caregivers, social workers, and community members to various services. Serving as an online platform, the 656 Platform incorporates an AI Chatbot and a Live Chat feature that facilitates connections between local caregivers, social workers, and community members to various services. Apart from this, the 656 Platform offers several features that enhance its functionality and user experience, including problem-based elderly resource database, interim care solutions, exchange forum, data analytics and research, and professional knowledge and resources.
223898366|NCT01073566|DEVICE|Finesse|Finesse Insulin Delivery Patch
223898367|NCT01073566|DEVICE|Pen/Syringe (Usual injection device)|Pen/Syringe
223898368|NCT06765993|DRUG|Isosorbide oral solution|30 mL, TID
223898369|NCT06765993|DRUG|Placebo|30 mL, TID
223898370|NCT02936102|DRUG|FAZ053|Anti-PD-L1 Antibody
223898371|NCT02936102|DRUG|PDR001|Anti-PD-1 Antibody
223898372|NCT04131101|BEHAVIORAL|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
223898373|NCT05188092|OTHER|Lung ultrasound guided deresuscitation|"With every new LUS examination, the following scenarios, with distinct recommendations, are possible:~1. LUS observations suggest massive pulmonary fluid overload, with the recommendation to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance of at least -1500 ml in the next 24 hours;~2. LUS suggests some pulmonary edema and/or significant pleural effusion. These LUS observations suggest little pulmonary fluid overload, with the suggestion to minimize fluid infusion and start fluid withdrawal, targeting a negative fluid balance at least -500 ml in the next 24 hours;~3. LUS suggests absence of pulmonary edema and no pleural effusion. These LUS observations suggest no fluid overload, with the suggestion to target a neutral fluid balance in the next 24 hours."
223898374|NCT05057845|DRUG|Tislelizumab|Tislelizumab will be initiated on day 14 after cryoablation. Tislelizumab will be administered at 200 mg i.v. every 3 weeks
223898375|NCT05057845|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223898376|NCT05057845|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
223898377|NCT05082181|BEHAVIORAL|UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)|UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.
223898378|NCT05082181|BEHAVIORAL|BOOST (Bringing Out Our Strength Together)|BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
223898379|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
223898380|NCT02600598|DRUG|LEO 43204 Gel, 0.037%|
223898381|NCT05073666|OTHER|NO INTERVENTION|NO INTERVENTION
223898382|NCT04443907|BIOLOGICAL|OTQ923|Single intravenous infusion of OTQ923 cell suspension
223898383|NCT04443907|BIOLOGICAL|OTQ923|Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis
223898384|NCT04218708|OTHER|Nicotine patch and gum|Nicotine patch and gum will be given to subjects in the Nicotine replacement therapy cohort every visit after providing exhaled CO/Saliva cotinine test.
223898385|NCT04218708|BEHAVIORAL|Minnesota Nicotine Withdrawal Scale (MNWS)|The MNWS assesses symptoms associated with nicotine withdrawal (i.e., craving, irritability, anxiety, difficulty concentrating, restlessness, increased appetite or weight gain, depression, and insomnia).
223898386|NCT04218708|BEHAVIORAL|ASSIST (the Alcohol, Smoking and Substance Involvement Screening)|The ASSIST is the Alcohol, Smoking and Substance Involvement Screening Test. It is a brief screening questionnaire to find out about people's use of psychoactive substances (alcohol, smoking and substance involvement).
223898387|NCT04218708|BEHAVIORAL|Counseling|At each study visit, participants will receive counseling protocol that will be based on effective counseling manuals. The PI will train the research assistant who will assist the PI in tailoring the manual to the target group: counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects known to contribute to smoking among PLWHA (e.g., tips on dealing with depression and feeling stigmatized particularly in relation to HIV).
223898388|NCT04218708|OTHER|NIDA Standardized Research E-cigarettes (SREC)|"NIDA SREC has a case with a liquid tank. The e-liquid is supplied in sealed disposable cartridges that deliver \>300 puffs / cartridge. The SREC uses a battery recharged via a micro USB port. A single charge is designed to outlast the capacity of an e-liquid cartridge. The e-liquid is tobacco flavored and contains nicotine."
223898389|NCT01579409|OTHER|PNNS guidelines|Application of PNNS guidelines
223898390|NCT03168971|BEHAVIORAL|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
223898391|NCT02100891|PROCEDURE|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
223898392|NCT02100891|DRUG|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
223898393|NCT01389856|DRUG|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
223898394|NCT01389856|DRUG|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
223898395|NCT06807671|OTHER|Experimental Group|Patients in the intervention group received HBM based training for a period of 6 months. During the training, one-on-one interviews were provided with each patient. Patients were shown a power point presentation, a brochure, and 3 training videos. Any questions patients had were answered one-on-one.
223898396|NCT04326673|OTHER|Testosterone Measurements in healthy volunteers after fasting|salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
223898397|NCT04326673|OTHER|Testosterone Measurements after glucose loading|salivary tstosterone and blood testosterone measurements
223898398|NCT03903562|BIOLOGICAL|V503|0.5 mL 9vHPV VLP Vaccine
223898399|NCT03309306|OTHER|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
223898400|NCT03309306|BEHAVIORAL|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~1. Feedback on the amount of food waste their household created during the first week,~2. A goal to reduce the next week's food waste by 20% or more, and~3. Tips on how to reduce household food waste adapted from current consumer campaigns"
223898401|NCT06122324|DRUG|Lidocaine Hydrochloride|Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
223898402|NCT03916042|DRUG|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
223898403|NCT03916042|DRUG|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
223898404|NCT05916456|DIAGNOSTIC_TEST|The Hand10 Questionnaire|The Hand10 Questionnaire is a questionnaire consisting of 10 short questions used in the evaluation of upper extremity diseases. These questions are easy to understand and illustrated questions. Unlike other questionnaires, thanks to these features, it can be used in adults as well as in the elderly and children. Tore et al. In their study, the internal consistency of Hand10 was evaluated with Cronbach's alpha value according to statistical results and found it to be 0.919. According to these results, it has been determined that Hand10 is a reliable and valid assessment tool for patients with upper extremity disorders in the Turkish population.
223898405|NCT05916456|DIAGNOSTIC_TEST|DASH Questionnaire|DASH Questionnaire is one of the widely used questionnaires consisting of 30 items. There are five options for each answer. While getting answers ranging from 1 to 5; 1 means no symptoms and 5 means very severe symptoms. The total DASH score ranges from 0 to 100; 0 means no injury and 100 means serious injury. Contrary to the Hand10 questionnaire, DASH was not suitable for assessing upper extremity disorders in patients over 65 years of age.
223898406|NCT05916456|DIAGNOSTIC_TEST|Boston carpal tunnel syndrome questionnaire|Boston carpal tunnel syndrome questionnaire (BKTSA) will be used to evaluate the functionality level and symptom severity of the patients. In this questionnaire, which consists of 2 parts: symptom severity and functional capacity, the average score for each part will be calculated by dividing the total score obtained by the number of questions. An increased score indicates decreased functional capacity and increased symptom severity.
223898407|NCT04855032|BEHAVIORAL|Reactive Perturbations|A novel device will be used to apply controlled mediolateral perturbations to participants' trunk as they walk on a treadmill, requiring reactive responses to avoid a loss of balance. All perturbations will have a duration of 200 ms, and will be applied immediately after onset of the swing phase with either the paretic or non-paretic leg. If in a given training session, a participant does not experience any losses of balance, the perturbation magnitude will be increased in the next training session. Perturbations will begin at 3% body weight (BW), and will progress in increments of 3% BW up to a maximum of 15% BW. The structure of the Reactive perturbation session will be identical to that used for Proactive perturbation training sessions, including overground trials, treadmill trials without perturbations, and Perturbed and Catch trials in which Perturbations are delivered.
223898408|NCT04855032|BEHAVIORAL|Proactive Perturbations|A novel device will be used to perturb the relationship between pelvis motion and step width by applying mediolateral forces to participants' legs. Participants will first perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device. Participants will then perform a 3-minute treadmill walking trial at their self-selected speed, in which they again do not interact with the perturbation device. Participants will then perform a series of alternating 3-minute Perturbed and Catch trials, all at their self-selected speed. For the Perturbed trials, perturbations will be delivered in each step throughout the trial. For the Catch trials, perturbations will cease for the final minute of walking. A total of 5 Perturbed and 5 Catch trials will be performed. Finally, participants will perform a 3-minute overground walking trial at their self-selected speed, in which they do not interact with the perturbation device.
223898409|NCT04893434|DRUG|Gadobutrol|Each patient will undergo 3 Gadavist injections. The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s. Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).
223898410|NCT04893434|DIAGNOSTIC_TEST|MRI|All subjects will be imaged on the same 3T MRI scanner (GE Healthcare, USA) at MSK for all examinations. For SA1, subjects will undergo a single research DCE-MRI exam. Patients in SA2 will undergo a standard of care pelvic MRI at baseline (which includes DCE-standard) in accordance with standard clinical operating procedures at MSK.
223898411|NCT04738708|OTHER|Patients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.|Patients are given a series of questions evaluating cognitive and psychosocial outcomes, either via hardcopy in-person or online internet-facing questionnaire.
223898412|NCT05062187|OTHER|Proprioseption in hemiparetics|Proprioception on balance and gait functions in hemiparetic individuals
223898413|NCT05039151|BIOLOGICAL|interstitial fluid sampling|The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.
223898414|NCT05039151|BIOLOGICAL|blood sampling|A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2
223898415|NCT03167177|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223898416|NCT03167177|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
223898417|NCT03167177|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223898418|NCT03167177|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223898419|NCT03167177|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223898420|NCT03167177|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223898421|NCT03167177|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223898422|NCT03167177|DRUG|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223898423|NCT03167177|BIOLOGICAL|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
223898424|NCT03167177|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
223898425|NCT03167177|RADIATION|Stereotactic Body Radiation Therapy|radiation
223898426|NCT03167177|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223898427|NCT03167177|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223898428|NCT03167177|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
223898429|NCT03167177|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
223898430|NCT03167177|BIOLOGICAL|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
223898431|NCT03167177|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
224276648|NCT05110911|BIOLOGICAL|Influenza vaccination: Fluarix Tetra, Vaxigrip Tetra, Fluquadri, Fluad Quad, Afluia Quad, Flucelvax Quad|Influenza vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
223898432|NCT03167177|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
223898433|NCT06306443|DRUG|extended-release buprenorphine (XR-B)|buprenorphine
223898434|NCT05685615|DRUG|BV100 plus Polymyxin B|Rifabutin for Infusion plus Polymyxin B for Injection
223898435|NCT05685615|DRUG|BAT|The best avaialble antibiotic therapy to treat CRAB
223898436|NCT05604508|OTHER|Many posters with prices|No poster number or price restrictions
223898437|NCT05604508|OTHER|Many posters, no prices|No poster number restrictions, but price restrictions
223898438|NCT05604508|OTHER|Fewer posters, no price restrictions|Poster number restrictions, but no price restrictions
223898439|NCT04922333|DRUG|Risedronate|150mg over-encapsulated risedronate
223898440|NCT04922333|DRUG|Placebo|Capsules containing placebo tablets
223898441|NCT05702138|OTHER|Physical therapy|The study evaluates three physical therapeutic approaches to improve mobility and balance after traumatic brain injury (TBI).
223898442|NCT03420547|BEHAVIORAL|RISE|Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
223898443|NCT06064136|PROCEDURE|Psoas tenotomy under ultrasound|Tenotomy of the ilio-psoas tendon under ultrasound is performed using an ultrasound machine, a 3 mm Acufex hook blade and a specific kit usually used for guided vertebroplasty and which allows the introduction of the Acufex hook blade atraumatically (foam end). The patient, under general anesthesia, is placed in supine position with the hip extending from 15 to 20°.
223898444|NCT06802744|DEVICE|Addition of an artificial air-pocket device during simulated avalanche burial|In contrast to the control group, the subjects in this arm are provided with a functioning device that directs the exhaled air away from the area of the respiratory cavity.
223898445|NCT06802744|DEVICE|Addition of a non-functioning artificial air-pocket device during simulated avalanche burial|In contrast to the intervention arm, the subjects in this arm are provided with a non-functioning artificial air-pocket device which does not redirect the exhaled air away from the breathing-cavity.
223898446|NCT06803381|OTHER|Salivary test|"In order to determine the quantity and quality of patients saliva before food tasting a saliva test will be performed using a Saliva-Check BUFFER kit. A small quantity of saliva will be collected and discarded immediately after the test result obtained.~The test will be done only once for each patient."
223898447|NCT06803381|OTHER|Food tasting|Patients will be invited to taste four different food samples, 2 sweet and 2 salty samples, and to evaluate them using a visual analog scale (0 : I don't like at all to 100 : I like a lot). The intervention will be done once for each patient during one of their standard of care treatment visit.
223898448|NCT06803381|OTHER|Questionnaires|Patients will be invited to answer to some questionnaires : socio-demographics, appreciation of food samples, self-assessment of oral symptoms and sensory perceptions, QLQ-C30 quality of life and food quality of life questionnaire. They will answer to all questionnaires only once during participation to the study.
224276649|NCT05110911|BIOLOGICAL|SARS-CoV-2 vaccination: Comirnaty or Vaxzevria|SARS-CoV-2 vaccine made available to healthcare workers at the participating healthcare sites, as part of their free vaccination campaigns for healthcare workers.
223898449|NCT06803381|OTHER|sensory capacity evaluation|"For the sensory capacity the test 6-n-propylthiouracil (PROP) taste strip will be used. One tasting strip will be placed on the tongue and patients will be asked to assess the intensity of bitterness.~The test will be done only once for each patient."
223898450|NCT03964571|DIAGNOSTIC_TEST|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
223898451|NCT06485609|PROCEDURE|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection|radical right hemicolectomy combined with indocyanine green fluorescence imaging lymphatic tracer dissection
223898452|NCT05972005|OTHER|The Intervention (Stronger at Home Intervention)|The home-based intervention includes 8 visits by a PT and/or PTA. The PT conducts 3 visits for initial assessment, program design, coaching, and discharge assessments. The program targets personal goals and provides pain self-management support. The second PT visit at 6 weeks allows for reassessment and adjustments. The intervention ensures adherence through multiple sessions, tailored exercises, barrier-solving support, and motivational strategies. The PTA conducts solo visits every other week, assisting with exercises and education under PT supervision. This inclusion reduces wait times and improves efficiency. The clinical team consists of at least 2 PTs and 2 PTAs trained for 3 days. The exercise program adheres to evidence-based principles, involving a 30-minute session with warm-up, exercise, and cool-down. Participants are encouraged to exercise 5 times a week, focusing on strengthening, balance, and functionality. Feasible compliance rates were observed in the pilot study.
223898453|NCT05972005|OTHER|Usual care (Control)|The control group will receive usual home care provided by the healthcare system, which could vary between cases. We'll document their received care during follow-ups as it is inconsistent and poorly recorded. Regular check-in calls by the study coordinator will remind them of assessments, reducing attrition.
223898454|NCT05434312|DRUG|TGRX-678|Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
223898455|NCT01422434|DRUG|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
223898456|NCT01422434|DRUG|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
223898457|NCT01422434|DRUG|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
223898458|NCT06802237|OTHER|Other|Assess and Evaluate hair growth and scalp health
223898459|NCT06802432|DRUG|1 g of methylprednisolone (divided into 250 mg every 6h started once the patient arrived the pos-toparative ICU)|1 g of methylprednisolone (divided into 250 mg every 6h started once the patient arrived the pos-toparative ICU)
223898460|NCT05856552|BEHAVIORAL|CBT|Cognitive behavioral therapy delivered by community resource persons via home visits.
223898461|NCT05856552|BEHAVIORAL|Group Activities|Weekly hour-long group activities delivered by community resource persons in community spaces.
223898462|NCT04590664|DRUG|Verteporfin|Given IV
223898463|NCT06803264|OTHER|Activity Oriented therapy (N.A.P.)|"The following six exercises were used, each of which was performed 10 times. Their progression was introduced by changing positions, individually adjusted to the patient's capabilities.~1. Eccentric infrahyoid muscle work during breathing activity and phonation of the lsound.~2. Reciprocal innervation of suboccipital muscles in gaze activity.~3. Stimulation of the diaphragm in the activity of breathing and phonation.~4. Repeated eccentric activity of the sternocleidomastoid (SCM) muscles during body transfer activity.~5. Repeated eccentric activity of scalene muscles in blanket pulling activity.~6. Eccentric work of suboccipital muscles in the activity of biting a snack."
223898464|NCT06803264|OTHER|Traditional therapy|"Traditional therapy included:~1. Isometric work of the neck muscles.~2. Self-assisted active exercises for the shoulder girdle muscles.~3. Active exercises in relief for the muscles of the shoulder girdle performed in the sitting position in the transverse plane.~4. TENS current treatment performed in the cervical spine and shoulder girdle in the forward lying position.~5. The local cryotherapy treatment with carbon dioxide."
223898465|NCT05006872|DEVICE|DIABE-TEXT|Participants will receive 170 text messages in their mobile phones during twelve months.
223898466|NCT03424018|DRUG|BMN 111|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
223898467|NCT06802627|OTHER|Education session|"The information that will be delivery is going to be focused on:~* Lifestyle changes regarding nutrition and daily physical activity.~* Abstinence of the additive behaviors smoking, alcohol, and drug consumption.~* Personal hygiene care and hospital routines.~* Importance of postoperative physiotherapy. A booklet summarizing the information provided at the education session will be delivered for all participants."
223898468|NCT06802627|OTHER|Inspiratory muscle training group|"Education Session (described in the control group) Inspiratory muscle training (IMT) After the education session, patients will start the IMT program that will last two weeks.~The IMT will be 5 days/ week, lasting 20 minutes, using the PowerBreath KH2 device. In the first week, the intensity of the PowerBreath KH2 will be set at 50% of the maximal inspiratory pressure (with 12 breaths per minute), and it will be increasing by 10% in the second week (with 15 breaths per minute). Patients will be continuously monitored by an oximeter and modified Borg scale"
223898469|NCT06802627|OTHER|Expiratory muscle training group|"Education Session (described in the control group) Expiratory muscle training (EMT)~After the education session, patients will start the EMT that will last two weeks, 5 days a week. The sessions will last 20 minutes and will be structured as follows:~4 minutes of total body stretching exercises 8 minutes of abdominal resistance exercises:~1. First week: 2 exercises, 4 sets of 8 repetitions~2. Second week: 2 exercises, 4 sets of 10 repetitions 8 minutes of specific EMT using the Philips Respironics Threshold PEP device (Load: 20 cmH2O; 10 expirations for minute) Patients will be continuously monitored by an oximeter and modified Borg scale."
224276650|NCT06079073|BEHAVIORAL|Orofacial myofunctional therapy with autofeedback|Participants opening a code unlocking the OMTa treatment module of the application will be given a direct communication link to the PhD students, Diana Hansen (Norway) and Andres Koster (Estonia) and two research co-ordinators. Dr. Hansen and Andres Köster has obtained an Academy of Orofacial Myofunctional Therapy (AOMT) certification diploma. One physical start up session will be scheduled at Ahus and at North Estonia Medical Center. This 60 minute session will be used to instruct participants in OMT exercises and use of the app. All participants will receive a disposable toothbrush and standardized balloons. After that, biweekly video sessions (time 20-30 min) will be scheduled.
223898470|NCT06802627|OTHER|Global exercise training group|"The GET-G will be submitted to an education session (equal to the CG) plus 2-weeks of physical exercise, 3 sessions per week, 45-60 minutes.~The structure is:~Warm-up: 5 minutes of whole-body stretching exercises~Main workout:~-Aerobic: Week 1: 20 min of treadmill walking at 70% of the mean speed achieved on the 6-minute walk test and limited by 80% of the max theoretical heart rate. Week 2: 20 min of treadmill walking at 80% of the mean speed achieved on the 6-minute walk test and limited by 80% of the max theoretical heart rate.~-Resistance Week 1: 8 exercises, 2 sets of 8-10 repetitions, using body weight and elastic bands. Week 2: 8 exercises, 2 sets of 10-12 repetitions, using body weight and elastic bands Coll-down: 5 min of whole-body stretching exercises, holding the point of feeling lightness discomfort for 15 seconds.~Patients will be continuously monitored by an oximeter and modified Borg scale."
223898471|NCT06314399|DIAGNOSTIC_TEST|Bile culture and phenotypic antibiogram resistance test|Extraction of 3-5ml of bile from surgical specimen (gallbladder) to be taken for bacterial culture testing and phenotypical antibiogram resistance if positive
223898472|NCT04991324|DRUG|Vitamin D3|24,000 IU cholecalciferol
223898473|NCT05756777|DRUG|Gilteritinib|Dose level (-1) 80mg, (1) 120mg, (2) 120mg
223898474|NCT05756777|DRUG|Ivosidenib|Dose level (-1) 250mg, (1) 250mg, (2) 500mg
223898475|NCT05756777|DRUG|Enasidenib|Dose level (-1) 50mg, (1) 50mg, (2) 100mg
223898476|NCT06542939|BEHAVIORAL|Integrated CHW Intervention|Participants will undergo all 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources. There will be two one-on-one virtual meetings, up to 9 follow-up phone calls to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.
223898477|NCT06542939|BEHAVIORAL|CHW Session 1 Only|Participants will attend only the first group-based health education session on hypertension and diabetes management.
223898478|NCT06007274|OTHER|No intervention|No intervention
223898479|NCT04687631|DRUG|mFOLFOXIRI plus Cetuximab|cetuximab 500mg/m2 + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
223898480|NCT04687631|DRUG|mFOLFOXIRI Plus Bevacizumab|bevacizumab 5mg/kg + oxaliplatin 85 mg/m2 + irinotecan 165 mg/m2 + folinic acid 400 mg/m2 + 5-fluorouracil 2400 mg/m2 46h infusion starting on day 1, every 2 weeks
223898481|NCT06413433|DRUG|Solriamfetol 150 mg|Solriamfetol tablets, taken once daily
223898482|NCT06413433|DRUG|Solriamfetol 300 mg|Solriamfetol tablets, taken once daily
223898483|NCT06413433|DRUG|Placebo|Placebo tablets, taken once daily
223898484|NCT06800105|OTHER|High fat smoothie|Participants will consume a standardized 490 kcal high-fat smoothie, consisting of 57% fat, 23% carbohydrate, and 20% protein.
223898485|NCT03291028|BIOLOGICAL|Immune checkpoint inhibitor targeting PD1|RCC and UC patients treated with immune checkpoint blockade
223898486|NCT06432647|DRUG|ATH-1105|ATH-1105 in oral form. Participants will be administered ATH-1105 once in Part A and once daily for 10 days in Part B.
223898487|NCT06432647|DRUG|Placebo|Placebo in oral form. Participants will be administered Placebo once in Part A and once daily for 10 days in Part B.
223898488|NCT06803277|PROCEDURE|endodontic retreatment|Root canal retreatment is recommended when endodontic disease persists or develops after root canal treatment. Root canal retreatment is believed to be the elimination of the main causes of treatment failure.
223898489|NCT05915065|DEVICE|Coapt Phantom Limb Pain Management System|The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
223898490|NCT06800118|DEVICE|Music intervention|Music will be played for patients undergoing coronary angiography, and vasospasm and pain levels will be evaluated.
223898491|NCT04903899|COMBINATION_PRODUCT|177Lu-DOTATATE|A weight-based activity of 200 MBq kg-1 will be used for the first dose. The activity of the second dose will be calculated based on whole body activity scans as well as SPECT CT scans to determine the absorbed kidney dose. The aim is to administer 177Lu-DOTATATE corresponding to a whole-body dose of 1,2 Gy, with a cumulative whole-body dose of about 2,4 Gy over two courses, and not exceeding a cumulative renal dose of 23 Gy, in order to avoid renal toxicity.
223898492|NCT06800196|DRUG|KNT-0916|• KNT-0916 is an oral inhibitor of FGFR2.
223898493|NCT04309474|DRUG|Elezanumab|Intravenous (IV) infusion
224276651|NCT05695651|DIAGNOSTIC_TEST|triglyceride glucose index and HOMA IR|"TyG index was calculated as formula: ln\[fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2\].~an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance)."
224276652|NCT06045390|OTHER|App|"App features (App will be used during the office visit):~* Pictorial representation of drops (color-coded) and schedule.~* Quiz to assess understanding of the regimen.~* Narrated instructions (language-concordant) on how and when (frequency and eye laterality) to take each drop.~* Graphical print-out of the regimen."
223898494|NCT04309474|DRUG|Placebo|Intravenous (IV) infusion
223898495|NCT06611592|DRUG|Pramipexole 0.088mg/tid|Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).
223898496|NCT06611592|DRUG|Pramipexole 0.18 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt)."
223898497|NCT06611592|DRUG|Pramipexole 0.35 mg/tid|"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt)."
224276653|NCT00676650|DRUG|Prednisone|5 mg BID, oral
224276654|NCT00676650|DRUG|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
223898498|NCT06800469|DIAGNOSTIC_TEST|Microbiota analysis|Upon acquisition of informed consent, fecal, digiunal mucosa, biliary and pancreatic fluid samples will be collected for microbiota analysis
223898499|NCT06801782|BEHAVIORAL|Experimental Cognitive training in Immersive Virtual Reality and Telemedicine approach|The cognitive training involved a 4-week immersive virtual reality program to improve planning, cognitive flexibility, and information updating in patients with mild cognitive impairment related to Parkinson's disease. Over 12 sessions of 30 minutes each, participants trained in a virtual supermarket to strengthen attentional and executive skills. The planning task required creating and following a route to collect items while following rules, with increasing complexity. The cognitive flexibility task involved alternating between selecting items from different categories, with difficulty rising due to more categories and distractors. The updating task, set at a virtual checkout, challenged participants to memorize and recall items on a conveyor belt, with difficulty increasing based on sequence length and item count. Progression to higher levels required three successful trials, with feedback provided to support performance improvement
223898500|NCT06801782|BEHAVIORAL|Active Comparator #1|The active placebo used the same virtual environment, Oculus Go system, and telemedicine setup as the training group, but engaged in tasks with low cognitive demands, mimicking everyday activities. The placebo-planning task involved following a fixed shopping list order in a modified version of the Zoo Map Test. The placebo-shifting task required selecting items from shelves without alternating between categories, while the placebo-updating task involved recalling only the last item from a conveyor belt sequence. The sessions mirrored the training group's structure, with 12 sessions over 4 weeks (3 per week, 30 minutes each), maintaining the same frequency, duration, and levels than Training.
223898501|NCT01753414|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Daily fractions
223898502|NCT01753414|PROCEDURE|Surgery|Radical resection
223898503|NCT06802458|OTHER|Motivational interviewing|A total of 9 sessions were conducted, including 1 preparation session, 6 motivational interviews, 1 initial follow-up interview one week after the intervention, and 2 follow-up interviews 4 weeks after the initial follow-up. Considering the interactive training method, the motivational interviewing sessions were conducted in the training room of the Health Center in groups of 10 at three different days (Monday, Thursday, Friday) once a week, through face-to-face sessions each lasting 50-60 minutes. During the interviews, the women were provided with counseling to activate their own sources of motivation, develop healthy lifestyle behaviors and improve their quality of life specific to menopause
223898504|NCT06803212|OTHER|Conventional Physiotherapy Program|The patients' conventional physiotherapy program included stretching, strengthening, balance, and coordination exercises according to their individual needs
223898505|NCT06803212|OTHER|Dual-Task Interference|This intervention consisted of counting backward, reading words backward, and remembering word exercises.
223898506|NCT06803108|BEHAVIORAL|pyramidal activity program|the participating subjects of this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in one group. In this group, a pyramidal training will be adopted for nearly 60 minutes (nearly two rounds of 21 minutes of running on electronic treadmill will be separated with 10 minutes of rest between the two rounds. Also, warming (4 minutes before start of pyrimidal trianing) and cooling (4 minutes after pyramidal training) will be done through gentle stretching exercises/activities. this form form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned, the this group will follow low clorie diet
223898507|NCT06803108|BEHAVIORAL|aerobic activity program|the participating subjects of the this group of this study will be fatty liver subjects (19 subjects in this group). aerobic training on electronic treadmill will be adopted for 60 minutes in this group with moderate intensity. the form of exercise will be done three times per week. the total study time will be 12 weeks. to be mentioned , this group will follow low clorie diet
223898508|NCT02889159|BIOLOGICAL|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
223898509|NCT02889159|BIOLOGICAL|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
223898510|NCT02889159|BIOLOGICAL|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
223898511|NCT02889159|PROCEDURE|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
223898512|NCT05139121|DRUG|MR-100A-01|Transdermal contraceptive delivery system
223898513|NCT06800521|BEHAVIORAL|Mixed Reality Breastfeeding Education|"Mixed Reality Breastfeeding Education:~This intervention includes an innovative mixed reality-based educational strategy combined with traditional breastfeeding counseling. Participants use mixed reality goggles to experience immersive breastfeeding scenarios, interact with audio-visual materials tailored for breastfeeding education, and engage with realistic breastfeeding simulations. The session is delivered once during the third trimester of pregnancy and lasts approximately 90 minutes. This intervention is designed to improve maternal confidence, satisfaction, and adherence to exclusive breastfeeding through an engaging and practical learning environment."
223898514|NCT06800521|BEHAVIORAL|Traditional Breastfeeding Counseling|This intervention involves standard prenatal breastfeeding education provided by trained healthcare professionals. Participants receive verbal and visual explanations of breastfeeding techniques, benefits, and solutions to common challenges. Delivered in a single session during the third trimester of pregnancy, the session lasts approximately 60 minutes and represents the current standard of care in breastfeeding education.
223898515|NCT06802770|DIAGNOSTIC_TEST|Anxiety, Depression levels|Parents of children with spina bifida will be filled out symptom scores regarding depression and anxiety levels.
223898516|NCT05209997|OTHER|Source document data collection|Data from all adult patients, of both sexes, for whom combination treatment with sibutramine and topiramate, both at any dose/dosage, were prescribed between the year 2011 and the beginning of the study will be colected in the study.
223898517|NCT05176509|DRUG|YH003|YH003 will be administered intravenously over 60 minutes every 21-day cycle.
223898518|NCT05176509|DRUG|YH001|YH001 will be administered intravenously over 60 minutes every 21-day cycle.
223898519|NCT05176509|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
223898520|NCT04925505|PROCEDURE|Interscalene brachial plexus blocks with ultrasound guidance under general anesthesia|Ultrasound-guidance, interscalene brachial plexus blocks, in-plane technique, perineural injection, 0.5% ropivacaine 12.5ml and 0.2% lidocaine 12.5ml
223898521|NCT04341896|OTHER|Caregivers|Individuals who cared for themselves and their transplant recipient before and after kidney donation
223898522|NCT04341896|OTHER|Non-caregivers|Individuals who donated a kidney as a living donor but did not serve as the primary caregiver for their recipient
223898523|NCT03032107|DRUG|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
223898524|NCT03032107|DRUG|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
223898525|NCT05499377|DEVICE|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).
223898526|NCT01972919|RADIATION|Radiation Therapy|Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.
223898527|NCT01972919|DRUG|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
223898528|NCT02728284|PROCEDURE|cardiovascular MRI (CMR)|CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
223898529|NCT02728284|PROCEDURE|Conventional Cardiologic Evaluation|ECG (gating), and respiratory motion effects
223898530|NCT05913297|DIAGNOSTIC_TEST|Magnetic Resonance|Magnetic Resonance
223898531|NCT05913297|DIAGNOSTIC_TEST|Polysomnographic evaluation|Polysomnographic evaluation
223898532|NCT04971681|DEVICE|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Subjects will receive one session of low frequency repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC), within the following stimulation parameters: Continuous 20-minute train of 1 Hz rTMS, at 110% of motor threshold (MT), for a total of 1200 pulses
223898533|NCT04971681|DEVICE|Sham|The active and sham functions share the same acoustic properties and sham mimics cutaneous stimulation, facilitating double-blinding.
223898534|NCT04191655|DEVICE|High Definition Colonoscopy|A colonoscopy that used high definition (HD) camera
223898535|NCT04191655|DEVICE|Dye Spraying Chromocolonoscopy|A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
223898536|NCT00686335|DRUG|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
223898537|NCT00686335|DRUG|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
223898538|NCT04767906|DRUG|Cabozantinib|The medication is taken once a day for 336 days (max.). The start dose is 60mg and can be reduced according to the physicians decision. 40mg and 20mg are also available.
223898539|NCT06274970|OTHER|Enhanced recovery protocols|Aforementioned in the detailed description
223898540|NCT06274970|OTHER|Conventional Protocols|Conventional protocols for non-ERASP group Eg: No preoperative vitamin D and calcium supplementation etc.
223898541|NCT03495973|DRUG|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
223898542|NCT06030141|OTHER|sesame oil application|sesame oil application
223898543|NCT06030141|OTHER|nigella sativa oil application|nigella sativa oil application
223898544|NCT05337163|DIAGNOSTIC_TEST|Diagnostic Test: Sputum DNA methylation analysis|Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
223898545|NCT05337163|PROCEDURE|chest CT or pathological examination|Subjects will undergo chest CT or pathological examination.
223898546|NCT05507099|BIOLOGICAL|Bone Marrow Aspirate, Lipoaspirate Concentrate|Autologous Cell Therapy.
223898547|NCT02598219|DRUG|Pre-operative SN mapping with radionucleide|"1. Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~2. Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~3. Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
223898548|NCT02598219|DRUG|Intra-operative SN mapping with patent V blue dye|"1. Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~2. Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~3. SN are detected by direct visualization of blue colored lymphatics and node"
224276655|NCT00676650|DRUG|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
224276656|NCT00676650|DRUG|Prednisone|5 mg BID, oral
224276657|NCT00774241|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
223898549|NCT02598219|DRUG|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
223898550|NCT02598219|PROCEDURE|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"* Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~* Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~* Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
223898551|NCT02598219|PROCEDURE|Current initial staging protocols|Current French initial staging protocols
223898552|NCT06098833|DRUG|Sildenafil|Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
223898553|NCT06098833|DRUG|Ora-Blend|Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
223898554|NCT06315920|DRUG|Parecoxib|Single dose of 40mg of IV Parecoxib.
223898555|NCT06315920|DRUG|Morphine|Single dose of 5 mg of IV Morphine.
223898556|NCT05022316|OTHER|CDS Tool Access|Clinics receiving the intervention will have access to EHR-based CDS tools designed to support social risk-informed care. Prior to tool activation in participating community health centers (CHCs), clinic staff members will be oriented to the CDS tools by an EHR trainer (either on-site or remotely).
223898557|NCT05369975|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
223898558|NCT05369975|OTHER|Normal Transplantation Routine|Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
223898559|NCT02268253|DRUG|Tagraxofusp Injection|Tagraxofusp was administered as a 15-minute intravenous infusion once daily for the first 3 consecutive days of each dosing cycle.
223898560|NCT02674100|OTHER|Registry|
223898561|NCT05932992|OTHER|Mother education on how to perform MUAC assessment|Mothers will be trained to perform MUAC weekly on their children
223898562|NCT06166381|DRUG|Parenteral Antibacterial Agents|Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
223898563|NCT06166381|DRUG|Parenteral Antibacterial Agents plus Vancomycin pre-soaked graft|in addition to the parenteral ceftriaxone intravenous injections, the ACL graft will be soaked in the vancomycin solution for 20 minutes when prepared outside the body of patient.
223898564|NCT05672069|PROCEDURE|Osteosynthesis|Foot pathologies
223898565|NCT05915286|DRUG|Furosemide|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
223898566|NCT05915286|DRUG|Chlorthalidone|Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
223898567|NCT05655091|DRUG|FLU or CZO as continuous infusion|Continuous infusion FLU or CZO coupled with real-time TDM and subsequent dose adjustment. A loading dose will be administered prior to the first continuous infusion. The loading dose (maximum of 2g as licensed according to the SmPC) and the dose of the continuous infusion will be calculated according to a pharmacokinetic model taking into account patient's characteristics (e.g. age, sex) and the measured drug concentration. The maximum daily dose of FLU and CZO will not exceed 12 grams per day according to the SmPC.
223898568|NCT05655091|DRUG|standard FLU or CZO intermittent bolus administration|Standard FLU or CZO intermittent bolus administration according to the local guidelines adjusted to the renal function without TDM-guided dose adjustment.
223898569|NCT06575751|DRUG|Broad Spectrum Cannabidiol (bsCBD) 400 mg|Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
223898570|NCT06575751|DRUG|Broad Spectrum Cannabidiol (bsCBD) 200 mg|Participants in this Arm will take 200 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
223898571|NCT06575751|DRUG|Placebo|Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
223898572|NCT05318222|DIAGNOSTIC_TEST|Whole genome sequencing (WGS)|WGS will identify copy number variations (CNVs), single nucleotide variants (SNVs), as well as triplet repeat disorders in children with rare diseases
223898573|NCT04752826|DRUG|BI-1808|BI-1808 administered as a flat-dose IV infusion once every 3 weeks
223898574|NCT04752826|DRUG|Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection|Pembrolizumab administered as a flat-dose IV infusion once every 3 weeks.
223898575|NCT06462625|OTHER|High tibial osteotomy|Correction of lower limb malalignement with tibial bone wedge insertion/removal
223898576|NCT04855695|DRUG|Acalabrutinib|"Each study drug is given according to a different schedule:~Acalabrutinib: Oral, dosage per protocol, start cycle 1 and beyond according to schedule outlined in protocol"
224276658|NCT00774241|DRUG|docetaxel|75mg/m2 every 3 weeks for 18 weeks
224276659|NCT02301741|BEHAVIORAL|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
223898577|NCT04855695|DRUG|Venetoclax|Venetoclax: oral. daily, dosage per protocol, start cycle 3 and beyond according to schedule outlined in protocol
223898578|NCT04855695|DRUG|Obinutuzumab|Obinutuzumab: intravenous infusion, dosage per protocol, drug during cycles 2 and beyond according to schedule outlined in protocol
223898579|NCT06350851|BIOLOGICAL|Biological samples collection (blood drawing + feces)|Blood and feces samples will be collected from each volunteer.
223898580|NCT04162938|OTHER|Patient-Centered Electronic App|The coordinator will enter lab information to generate the patient's Fibrosis-4 score for liver fibrosis staging. With the information of liver fibrosis staging and survey responses, the app will generate individualized reports of the participant's comprehensive HCV disease progression, knowledge, and level of interest in receiving HCV care. The app will then deliver a streamlined, tailored, brief education message and include information regarding services and assistance for receiving HCV care.
223898581|NCT06331858|DEVICE|hip device-assisted concentric abductor strengthening (HDACAS)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
223898582|NCT06331858|DEVICE|knee device-assisted concentric flexor-extensor strengthening (KDACFES)|All participants received device-assisted strengthening exercises with increasing doses according to a pre-determined strengthening program for a total of 6 weeks, 4 days a week, and a total of 24 sessions
223898583|NCT05183464|BIOLOGICAL|saliva samples|Collection of salivary a-amylase during the day (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm) with Salivette.
223898584|NCT05183464|BEHAVIORAL|Stanford sleepiness scale|"The Stanford Sleepiness Scale evaluates sleepiness at the time of the evaluation. The subjects have to choose the statement best representing their level of sleepiness on a scale ranging from 1 to 7: the higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
223898585|NCT05183464|BEHAVIORAL|Karolinska Sleepiness Scale|"The Karolinska Sleepiness Scale assesses the perceived level of sleepiness at the time of the evaluation on a 9-points scale. The higher the score, the higher the sleepiness.~This scale will be submitted to the children before each salivary sampling (5 times a day: at 8:00 am, 9:00 am,1:00pm, 4:00pm and 8:00pm)"
223898586|NCT05183464|BEHAVIORAL|Epworth Sleepiness Scale|"The Adapted Epworth Sleepiness Scale for children in which the item falling asleep while in a car stopped in traffic was replaced by falling asleep at school assesses the risk of falling asleep in 8 daily-life situations estimated on a 4-point Likert scale. The total score is the sum of the scores for the 8 items: a higher score represents greater sleepiness and the pathological threshold is higher than 10.~This scale will be submitted to the children one time, at the onset of the hospitalization."
223898587|NCT05183464|BEHAVIORAL|BLAST test|"The BLAST (Bron/Lyon Attention Stability Test) is a computerized attention test evaluating brief lapses of attention with 4 measures: reaction times, errors and two composite measures (Stability and Intensity). The subjects have to detect the presence or the absence of a specific stimulus during approximatively 60 trials for 3 minutes. Normative data are available for both children and adults.~This test is part of the neuropsychological evaluation, conducted the afternoon of the first day of hospitalization. The test is realized at 4:00pm."
223898588|NCT04417530|DRUG|AU-011|AU-011 Via Suprachoroidal Administration
223898589|NCT04417530|DEVICE|Suprachoroidal Microinjector|Suprachoroidal Injection Device
223898590|NCT04417530|DEVICE|PDT Laser|Laser Administration
223898591|NCT06195332|PROCEDURE|open TAR|Participants will undergo open TAR repair according to the assigned treatment arm.
223898592|NCT06195332|PROCEDURE|endoscopic TAR|Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
223898593|NCT05949788|OTHER|No intervention|Retrospect study, no direct intervention
223898594|NCT06565078|DRUG|Immune Globulin Subcutaneous (Human), 20% Solution|CUVITRU 20% Solution
223898595|NCT01834300|BEHAVIORAL|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
223898596|NCT01834300|BEHAVIORAL|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
223898597|NCT04868903|DIETARY_SUPPLEMENT|Vitamin D3|Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
223898598|NCT01824537|BIOLOGICAL|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Avaxim).
223898599|NCT01824537|BIOLOGICAL|Hepatitis A vaccine|Provided by Sanofi Pasteur.
224276660|NCT02059811|OTHER|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
223898600|NCT06618989|OTHER|Blood sampling and follow-up call|An additional 1.5 mL of blood will be collected at the time of the child care in the pediatric emergency department. In addition, a telephone call for patient follow-up (unless still hospitalized) will be done.
223898601|NCT04179448|PROCEDURE|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
224276661|NCT02059811|OTHER|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
224276662|NCT05992987|DIAGNOSTIC_TEST|Adenosine deaminase serum level|Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).
223898602|NCT04179448|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
223898603|NCT03374085|DRUG|CC-92480|CC-92480
223898604|NCT03374085|DRUG|Dexamethasone|Dexamethasone
223898605|NCT05362487|DEVICE|Spiriva® Respimat®|Spiriva® Respimat®
223898606|NCT05362487|DEVICE|Spiriva® HandiHaler®|Spiriva® HandiHaler®
223898607|NCT05362487|DRUG|Tiotropium bromide|Tiotropium bromide
223898608|NCT02725463|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
223898609|NCT06350279|DRUG|HSK39297|50-600mg
223898610|NCT04274127|DIAGNOSTIC_TEST|early detection kit composed of 2 questionnaires (M-CHAT-R + CSBS-ITC)|completion of 2 questionnaires (M-CHAT-R + CSBS-ITC) followed by a confirmation of the detection with a phone call by a neuropsychologist, in children aged 16 to 24 months seen by their usual general practitioner or pediatrician or child care centers or attending nurseries.
223898611|NCT01743807|DRUG|GNKG168|"GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.~Dose Level 0: 0.15 mg/kg Dose Level 1: 0.25 mg/kg Dose Level 2: 0.75 mg/kg Dose Level 3: 1.5 mg/kg~The starting dose level for the trial will be 0.25 mg/kg. If that dose level proves to be intolerable, the dose will be reduced to 0.15 mg/kg (dose level 0). If the 0.15 mg/kg dose level is intolerable due to DLTs, TACL, the Principal Investigator, and Medical Monitor will then decide the best course of action for subsequent administration of GNKG168."
223898612|NCT04658342|DIAGNOSTIC_TEST|Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)|"The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment."
223898613|NCT01935869|DRUG|LEO 90100|
224276663|NCT05992987|DIAGNOSTIC_TEST|IgE antibodies serum level|Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
224276664|NCT00560924|DRUG|estradiol, 25 mcg|
224276665|NCT02297841|DEVICE|Experimental: Novel lubricant Miami Fragrance|
223898614|NCT01935869|DRUG|Vehicle|
223898615|NCT01935869|DRUG|Petrolatum ointment|
223898616|NCT04096040|DEVICE|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
223898617|NCT03333590|BIOLOGICAL|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
223898618|NCT04973254|OTHER|CAB-RPV LA|Monthly administration of injectable HIV medication
223898619|NCT04973254|OTHER|Standard treatment within an HIV clinic|Standard of care for HIV positive patients will be provided in the HIV clinic that may include HIV medication or may include oral medications.
223898620|NCT05373823|OTHER|MySmartSkin enhancement|Focuses on MySmartSkin web application/intervention including enhancements using stakeholder collaboration and input
223898621|NCT05373823|OTHER|Educational webpage on Skin Self-Examination|Longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas
223898622|NCT05373823|OTHER|Assess implementation outcomes|A mixed-methods study with multi-level stakeholders to assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.
223898623|NCT06355622|DIAGNOSTIC_TEST|Characterization of pain|Standardized scales and questionnaires to detect and characterize pain, blood sample for pain biomarkers, neurophysiological tests
224276666|NCT02297841|DEVICE|Experimental: Novel lubricant Miami no Fragrance|
224276667|NCT02297841|DEVICE|KY Liquid lubricant|
224276668|NCT02297841|DEVICE|Astroglide Gel lubricant|
224276669|NCT02332005|DRUG|diepalrestat choline|aldose reductase inhibitor
223898624|NCT06360796|DRUG|[(14)C]ADC189|Each subject take a single oral dose of about 45 mg (about 100 μCi) \[(14)C\]ADC189 on Day 1 of the study, and be observed by 504 hours.
224276670|NCT02332005|DRUG|Placebo|Placebo
224276671|NCT03465150|OTHER|acne|Patient with acne
224276672|NCT01681862|BEHAVIORAL|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
224276673|NCT01099306|OTHER|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
223898625|NCT05920824|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound scan of the heart
223898626|NCT06486103|OTHER|MetSheFlora - Vaginal Health|Take one slow-release capsule twice a day, after meal.
224276674|NCT02656251|DRUG|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
224276675|NCT02656251|DRUG|placebo|Use of placebo every 12 hours for 04 days
224276676|NCT02656251|DRUG|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
223898627|NCT05967364|BEHAVIORAL|Wingman-Connect|Training occurs in three 2-hr blocks over several days in class groups. Targeted Skills focus on protective factors (Four Cores) supportive of mental health, theoretically linked to reduced suicide risk, and essential to an Airmen's job success: (1) Healthy relationships and accountability spanning USAF and family/intimate relationships (Kinship); (2) Meaning and value in work and life (Purpose), (3) Informal and formal help-seeking (Guidance); and (4) Activities that give strength and balance emotions (Balance). Activities progress from individual to group skill-building activities. Kinship modules at operational base (FTAC) expand focus on growing and sustaining relationships with intimate partners, friends, and family; and Guidance more on senior mentors at work. To extend training impact, facilitators implement activities once per quarter that bring concepts into base activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
223898628|NCT05967364|BEHAVIORAL|Stress Management|Stress management training (also done in class groups) reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
223898629|NCT04390308|PROCEDURE|Ovarian puncture|Egg collection
223898630|NCT04390308|OTHER|Hormonal blood Test|AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)
223898631|NCT04390308|DIAGNOSTIC_TEST|Transvaginal ultrasound|Doppler of arteria ovarica. Resistance index
223898632|NCT04835129|DRUG|Isatuximab (for run-in portion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 2 and days 1 and 15 of subsequent cycles.
223898633|NCT04835129|DRUG|Isatuximab (for expansion)|10 mg/kg IV on days 2, 8, 15, 22 of cycle 1 and days 1 and 15 of subsequent cycles.
223898634|NCT04835129|DRUG|Pomalidomide|4 mg PO days 1-21 of each cycle.
223898635|NCT04835129|DRUG|Elotuzumab|10 mg/kg on days 1, 8, 15, 22 of cycles 1 and 2; 20 mg/kg on day 1 of subsequent cycles.
223898636|NCT04835129|DRUG|Dexamethasone|40 mg (20 mg if \>75 years) PO or IV on days 1, 8,15 and 22 of each cycle.
223898637|NCT05170009|DRUG|Baloxavir Marboxil|Weight-adjusted Baloxavir Marboxil (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline, day 4, and day 7.
223898638|NCT05170009|DRUG|Placebo|Placebo at baseline, day 4, and day 7.
223898639|NCT05170009|DRUG|Oseltamivir|Oseltamivir 75 mg twice daily for 10 days.
223898640|NCT03344094|DRUG|ocrelizumab|FDA-approved MS drugs
223898641|NCT03808818|OTHER|Behavioral, Psychological or Informational Intervention|Receive information about tobacco cessation
223898642|NCT03808818|DRUG|Nicotine Replacement|Given NRT patch or lozenge (or both)
223898643|NCT03808818|OTHER|Quality-of-Life Assessment|Ancillary studies
223898644|NCT03808818|OTHER|Survey Administration|Ancillary studies
223898645|NCT03808818|OTHER|Tobacco Cessation Counseling|Receive virtual tobacco cessation counseling
223898646|NCT00243464|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
223898647|NCT05292118|DEVICE|Navitian|Patients in whom treatment with (Navitian) has been attempted
223898648|NCT06016959|OTHER|Dietetic intervention|Dietetic intervention involves individualised and tailored dietary advice to patients struggling with their nutrition. This includes optimising energy and protein intake to improve malnutrition \& also giving dietary advice to support with nutrition impact symptoms e.g. bloating.
224276677|NCT04310254|PROCEDURE|EDTA and CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with Qmix 2in1 solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
223898649|NCT06016959|OTHER|Diet sheet (placebo)|Patients randomised into the group receiving a diet sheet will be sent out Royal Brompton \& Harefield Hospital's Poor Appetite diet booklet which involves general strategies to improve nutritional status (energy and protein)
223898650|NCT05285683|DRUG|Methylphenidate|0.5 mg/kg
223898651|NCT05285683|DRUG|carbidopa-levodopa|25 mg/100 mg
223898652|NCT05285683|DRUG|Placebo|oral pill
223898653|NCT05943509|BEHAVIORAL|Alternative rehabilitation strategies|Counseling intervention.
223898654|NCT05943509|BEHAVIORAL|Usual Care|Usual care audiology pathway.
223898655|NCT05134922|DRUG|Gedatolisib|Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.
223898656|NCT05457465|DRUG|Cannabidiol|Custom formulation of a hemp-derived, high-CBD product that contains no THC.
223898657|NCT04304625|DRUG|Tranexamic Acid / Sodium chloride|After the routine prophylactic IV or IM injection of the uterotonic used in the hospital protocol's -either oxytocin or carbetocin - (as recommended by the 2014 guidelines for prevention and management of postpartum hemorrhage from the CNGOF), the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped
223898658|NCT01836497|DEVICE|SD01 ICD lead|
223898659|NCT03203603|OTHER|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
223898660|NCT05838313|BEHAVIORAL|Elective Induction of Labor Decision Support Tool|Decision support tool for people having their first baby and planning vaginal delivery without a medical indication for induction of labor
223898661|NCT04704986|DEVICE|PVI using the Arctic Front Cryoballoon (Medtronic)|"Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
224276678|NCT04310254|PROCEDURE|EDTA Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with EDTA solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
223898662|NCT04704986|DRUG|PVI using the PolarX Cryoballoon (Boston Scientific)|"Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring."
223898663|NCT05415722|DRUG|TERN-501|Investigational drug
223898664|NCT05415722|DRUG|TERN-101|Investigational drug
223898665|NCT05415722|OTHER|Placebo|Matching placebo
223898666|NCT04410536|DRUG|Symptomatic drugs|indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide
223898667|NCT04410536|DRUG|Bridge therapy|prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day
223898668|NCT04410536|BEHAVIORAL|Mindfulness program|home based withdrawal program
223898669|NCT05028738|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.
223898670|NCT02650505|DRUG|LEO 43204|
223898671|NCT02650505|DRUG|LEO 43204 Vehicle|
223898672|NCT05135390|DRUG|HSK21542|three times per week
223898673|NCT05135390|DRUG|Placebo|three times per week
223898674|NCT06156592|PROCEDURE|Cardiac valve replacement surgery under high spinal anesthesia combined with light general anesthesia|Before induction of general anesthesia, a high spinal anesthesia will be given using 37.5 mg of 0.75% heavy bupivacaine with 20 mcg fentanyl and 250 mcg epimorphine in sitting position at the lumbar intervertebral spaces between the L2-3 or L3-4 vertebrae. Patients will lie supine immediately afterwards, and sensory loss to ice will be performed every 15 seconds. Subsequently, the patient will be placed in 15-degree Trendelenburg (ensured by clinometer). Following general anesthesia will be induced and trachea will be intubated after 5 ml of 4% lignocaine spray on vocal cords and trachea. Hemodynamics will be aimed at MAP between 65-100 mmHg and heart rate between 50-100 beats /min by use of various inotropic, inodilators and vasoactive cardiac drugs based on anesthesiologists' clinical judgement.
223898675|NCT06645574|OTHER|The multidisciplinary preventive approach among young people involved in intensive sports activities. Athlete will see doctor and physiotherapist.|"Athletes will have 2 times per years prevention examination:~* A standard medical examination~* A physiotherapy assessment with strength assessment~* They will complete psychometric evaluation self-questionnaires"
223898676|NCT06398132|OTHER|Usual Care|Usual Care includes among others, over-the-counter or prescribed painkillers, treatment modalities such as physiotherapy and/or psychotherapy, privately accessed or via the National Health Service, exercise, etc.
223898677|NCT05418010|DRUG|Tysabri Injectable Product|Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
223898678|NCT05418010|DRUG|Placebo|Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
223898679|NCT06068985|DRUG|PHESGO|Subcutaneous formulation with pertuzumab and trastuzumab.
224276679|NCT04310254|PROCEDURE|CHX Solution|The teeth in this group were treated according to the guidelines for root canal treatment in single-session. The filling was removed and cavity was opened. After standart irrigation protocol, root canals were irrigated with CHX solution and obturated with gutta percha. Coronal restoration was complete using composite and/or fully crown if necessary.
224276680|NCT03721887|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
224276681|NCT05604651|OTHER|no intervention|no intervention
223898680|NCT05366465|OTHER|SMA adult patients|An online questionnaire aimed at collecting demographic and social data, and data concerning activity limitations, participation and quality of life of SMA patients from validated scales : QOLNMD, Rosenberg.
223898681|NCT06458868|OTHER|salt water or tap water before UVA|Instead of using standard bath PUVA, this study investigates the efficacy of tap water or salt water with UVA in the treatment of palmoplantar psoriasis.
223898682|NCT06238609|DEVICE|Intervention Group|Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
223898683|NCT06238609|DEVICE|Control Group|Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
223898684|NCT05295927|DRUG|EPI-7386|EPI-7386 will be administered orally once daily.
223898685|NCT05295927|DRUG|Abiraterone Acetate|Abiraterone Acetate will be administered orally once daily.
223898686|NCT05295927|DRUG|Prednisone or Prednisolone|Prednisone or Prednisolone will be administered orally twice daily.
224276682|NCT06176560|DRUG|Mesalazine|Oral Formulation
223898687|NCT05295927|DRUG|Apalutamide|Apalutamide will be administered orally once daily.
224276683|NCT04515420|DRUG|noradrenaline|noradrenaline infusion
224276684|NCT00683592|DRUG|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
224276685|NCT00683592|DRUG|placebo|placebo
223898688|NCT06646523|OTHER|High-speed bodyweight resistance training|"The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits."
223898689|NCT06646523|OTHER|Control group (Bodyweight intervention, usual speed)|"The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group."
223898690|NCT06646562|DRUG|Cabotegravir LA + Rilpivirine LA|Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
223898691|NCT06581523|BEHAVIORAL|SKY Breath and Meditation|SKY Breath and Meditation is a unique breath-based technique that uses cyclical, rhythmic patterns of breath to bring the mind and body effortlessly into meditation. It has been empirically validated and holds distinct advantages over other forms of meditation.
223898692|NCT04968808|PROCEDURE|Staged in-hospital complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
223898693|NCT04968808|PROCEDURE|Immediate complete revascularization|Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
223898694|NCT04361331|DRUG|Lenvatinib combined with gemox|Arm2: Lenvatinib + gemox
223898695|NCT04361331|DRUG|Toripalimab combined with lenvatinib|Toripalimab combined with lenvatinib
224276686|NCT05732181|DRUG|The skin lidocaine patch.|The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.
224276687|NCT05732181|DRUG|Placebo|patch without drugs
224276688|NCT03504124|OTHER|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
224276689|NCT04834895|OTHER|mhealth exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the M.ü Neck Exercises application according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
224276690|NCT04834895|OTHER|brochure exercise group|Participants were asked to perform 18 exercises specially prepared for neck pain in the brochure according to the number of repetitions specified in the application.Participants will be asked to do home exercises 3 days a week for 6 weeks
223528586|NCT00127439|OTHER|Robotic Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
223714149|NCT01182675|DRUG|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
223714150|NCT01658462|DRUG|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
223714151|NCT01658462|DRUG|Nintedanib|"200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered"
223714152|NCT01658462|DRUG|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
223898696|NCT04629716|OTHER|Medical Cannabis|Medical marijuana is defined by Florida state statue 381.986 as all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a medical marijuana treatment center for medical use by a qualified patient.
223898697|NCT02939755|BEHAVIORAL|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
223898698|NCT02939755|BEHAVIORAL|Enhanced Usual Care|usual care from health providers
223898699|NCT06349837|DRUG|Tislelizumab|Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.
223898700|NCT06349837|RADIATION|Low Dose Radiotherapy|LDRT (d1-d3): 6Gy/3f with conventional external beam radiation.
223898701|NCT06349837|RADIATION|Stereotactic Ablative Radiotherapy|Partial SBRT at dose escalation levels: 24Gy/3f, 30Gy/3f, 45Gy/3f.
223898702|NCT04182204|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin 1.8 mg/kg for a maximum dose of 240 mg/cycle IV on Day 1 of each 21-day cycle for up to 8 cycles.
223898703|NCT04182204|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle for up to 8 cycles.
223898704|NCT04182204|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycles.
223898705|NCT04182204|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV on Day 2 of each 21-day cycle for up to 8 cycle.
223898706|NCT06077513|PROCEDURE|CAD-CAM designed and preprinted Ti-Mesh frame|CAD-CAM technology which is the process of designing and manufacturing a custom-made dental device, or a patient-specific dental device from an industrialized product, with the aid of a computer.will be used to plan and preprint a 3-D Ti-Mesh frame prior to the surgery.
223528587|NCT02697357|BEHAVIORAL|Psychosocial Instruments|
223714153|NCT06284746|DRUG|Tirolizumab+SOX/XELOX|Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
223714154|NCT06284746|DRUG|SOX/XELOX|Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
223714155|NCT05453656|BEHAVIORAL|exercise|physical activity promotion and engagement following kidney transplantation
223714156|NCT03986502|OTHER|Media Intervention|Watch web-based financial literacy video
223714157|NCT03986502|OTHER|Informational Intervention|Receive information on financial counseling and medical cost assistance
223714158|NCT03986502|OTHER|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
223898707|NCT06077513|PROCEDURE|Conventional chairside fabrication of Ti-Mesh frame|A three-dimensional frame or cage of Ti-Mesh or Ti-reinforced d-polytetrafluoroethylene (PTFE) will be fashioned during the surgery to contain, shape and stabilize the bone graft materials (the internal scaffold). This 3-D frame will be custom fabricated from a perforated Ti Mesh sheet material at the time of surgery which takes considerable time and skill.
223898708|NCT03906708|OTHER|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
223898709|NCT04251117|BIOLOGICAL|GNOS-PV02|GNOS-PV02 delivered by intradermal injection and electroporation
223898710|NCT04251117|BIOLOGICAL|INO-9012|INO-9012 delivered by intradermal injection and electroporation
223898711|NCT04251117|DRUG|Pembrolizumab|Pembrolizumab administered as an intravenous (IV) infusion
223898712|NCT04251117|DEVICE|CELLECTRA®2000 EP Device|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
223898713|NCT05477095|BIOLOGICAL|UB-313|A synthetic peptide-based immunotherapy
223898714|NCT05477095|BIOLOGICAL|Placebo|Normal saline
223898715|NCT04213547|BEHAVIORAL|Loss frame sleep extension intervention|Aim 2 will be an interventional study design utilizing Fitbit and text messaging to perform a loss-framed incentive intervention designed to motivate participants to increase their sleep duration. Glycemic control will be measured via laboratory testing of hemoglobin A1c and Libre continuous glucose monitoring (CGM) for 2 weeks pre- and post-intervention. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.
223898716|NCT04518917|BEHAVIORAL|Mentally Singing|Participants sing their song in their head and match their footfalls to the beat.
223898717|NCT04518917|BEHAVIORAL|Listening to music|Participants listen to their song and match their footfalls to the beat.
223898718|NCT03443128|DRUG|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
223898719|NCT03937609|DRUG|Infliximab|infliximab iv 5mg/kg
223898720|NCT05322031|DRUG|Aripiprazole|Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
223898721|NCT04537715|DRUG|Tazemetostat|A single, oral, 400 mg dose of tazemetostat on Day 1, Day 15, and Day 36; and tazemetostat (oral 400 mg) tablets twice daily on Days 3 - 14 and Days 21 - 35.
223898722|NCT04537715|DRUG|Itraconazole|Oral 200 mg itraconazole once daily on Days 18 - 38
223528588|NCT02697357|BEHAVIORAL|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
223528589|NCT01113684|DEVICE|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
223528590|NCT01508364|DRUG|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
223528591|NCT04992130|BEHAVIORAL|Pre-season supplementary neurologic training program|A two-month standardized, pre-season, supplementary multi-modal training program will be prescribed to 200 athletes (intervention cohort) by a team of experienced sport science and medicine professionals targeting the specific intrinsic risk factors of interest identified in the current concussion and ACL prevention literature.
223714159|NCT03986502|OTHER|Questionnaire Administration|Ancillary studies
223714160|NCT03986502|OTHER|Quality-of-Life Assessment|Ancillary studies
223898723|NCT04537715|DRUG|Tazemetostat|A single, oral, 800 mg dose of tazemetostat on Days 1, 15, and Day 24 ; and tazemetostat (oral 800 mg) twice daily on Days 3 - 14 and on Days 17 - 23.
223898724|NCT04537715|DRUG|Rifampin|Oral 600 mg rifampin once daily on Days 17 - 25.
223898725|NCT04266418|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
223898726|NCT04266418|DIETARY_SUPPLEMENT|Banana flower stamens extract|consume 1 sachet per day for 2 months
223528592|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
223528593|NCT00672997|DRUG|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
223528594|NCT01641575|DRUG|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
223528595|NCT03569189|OTHER|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
223528596|NCT01137890|DRUG|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
223528597|NCT01137890|DRUG|Placebo|capsules administered in split doses at 22:00 and 09:00.
223528598|NCT01137890|DRUG|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
223528599|NCT01137890|BEHAVIORAL|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
223528600|NCT01137890|BEHAVIORAL|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
223528601|NCT00073125|DRUG|ABT-510/Thrombospondin-1 mimetic|
223528602|NCT00583219|DRUG|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
223528603|NCT00583219|DRUG|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
223528604|NCT04046640|DEVICE|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: a NEC InfRec R450 infrared thermal imaging camera~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
223528605|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Exercise and Nutrition|During radiation, participants will attend in-person supervised resistance training sessions once a week for 7 weeks, followed by 2 ZOOM video conference supervised resistance training sessions every week for 5 weeks, after radiation. Sessions will last approximately 30 minutes. During radiation, participants will be provided 15 meals each week for 7 weeks, 105 meals total. Participants will be asked to participate in 1 weekly dietary coaching session (in-person during radiation and video conference following radiation), create weekly SMART goals, follow an alternative Mediterranean diet pattern, and log all meals, snacks, and supplements consumed for the 12-week intervention.
223528606|NCT05798780|BEHAVIORAL|ENHANCE Intervention - Nutrition Only|During chemoradiotherapy, participants will be provided 15 meals each week for 7 weeks (105 meals total) that will accommodate common NIS concerns (ex. dysphagia and difficulty chewing) following an aMED dietary pattern (5 breakfast, 5 lunch, and 5 dinner), will be taught proper portion size, and will be asked to record percentages of each meal consumed in a provided food journal, in addition to any outside meals, snacks, or nutritional supplements. They will be provided with dietary coaching weekly to discuss NIS, aMED diet compliance, and set weekly SMART goals (approximately 30 min). Following completion of chemoradiotherapy (5 weeks), participants will be provided dietary coaching weekly (in-person or via videoconference), discuss NIS, aMED diet compliance at home, and set weekly SMART goals (30 min). Trainers will monitor participants' Fitbit active minutes in real time throughout the intervention period and provide aerobic exercise encouragement accordingly.
223528607|NCT05533463|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
223528608|NCT02090764|DRUG|Ozenoxacin|
223528609|NCT02090764|DRUG|Placebo|
223528610|NCT00754572|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
223528611|NCT00754572|DRUG|methotrexate|10-25mg oral or parenteral weekly.
223528612|NCT01598155|PROCEDURE|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
223714161|NCT00717197|DRUG|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
223898727|NCT04061967|OTHER|Sending of screening summon.|"2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent."
223714162|NCT03464305|DRUG|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
223714163|NCT03464305|DRUG|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
223714164|NCT04276792|BEHAVIORAL|TCU Opioid-Treatment Linkage Model (O-TLM)|The O-TLM is focused on best practices for improving screening, identifying and linking to MOUD providers, reducing stigma, and addressing other important factors that impact justice-involved individuals returning to their communities.
223714165|NCT03326102|DRUG|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
223714166|NCT03326102|DRUG|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
223714167|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
223714168|NCT00982137|BIOLOGICAL|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
223714169|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
223714170|NCT00982137|BIOLOGICAL|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
223714171|NCT00566371|DRUG|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
223714172|NCT00566371|DRUG|placebo|placebo
223714173|NCT04767932|BEHAVIORAL|vibration machine|Experimental: vibration intervention the experimental group will perform 20mins/ section, three times weekly for 8 weeks vibration training
223714174|NCT03387332|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
223714175|NCT00674544|BEHAVIORAL|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
223714176|NCT02575495|DRUG|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
223714177|NCT02575495|DRUG|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
223714178|NCT01648101|DRUG|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
223714179|NCT01648101|DRUG|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
223714180|NCT01648101|OTHER|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
223714181|NCT03003390|DRUG|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
223714182|NCT05044390|PROCEDURE|Lung transplantation (single, lobar or bilateral lung transplantation)|Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis
223714183|NCT02272595|OTHER|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
223714184|NCT02272595|OTHER|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
223714185|NCT03267706|OTHER|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
223714186|NCT00649324|DRUG|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
223714187|NCT00649324|DRUG|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
223714188|NCT00869154|BEHAVIORAL|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
223714189|NCT00869154|BEHAVIORAL|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
223714190|NCT03311724|DRUG|Tirzepatide|Administered SC
223714191|NCT03311724|DRUG|Placebo|Administered SC
223714192|NCT02704117|DEVICE|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
223714193|NCT01393496|OTHER|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
223714194|NCT01393496|OTHER|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
223714195|NCT04616378|OTHER|Phase 2 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
223714196|NCT04616378|OTHER|Phase 2 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
223714197|NCT04616378|OTHER|Phase 3 No Prosthesis|No prosthetic device is attached.
223714198|NCT04616378|OTHER|Phase 3 Robotic Prosthetic Leg|The RPL consists of a passive-dynamic ankle, powered knee, and an on-board inertial measurement sensors with an on-board kinetic and kinematic data collection system for analysis.
223714199|NCT04616378|OTHER|Phase 3 Prescribed Prosthesis|Everyday used prosthesis that was prescribed by their physician.
223714200|NCT05479084|OTHER|Kinesiotaping|Kinesio taping will be applied on the lower part of the trapezius.
223714201|NCT03143439|BEHAVIORAL|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
223714202|NCT04011267|OTHER|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
223714203|NCT02379871|OTHER|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
223714204|NCT02379871|OTHER|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
223714205|NCT06115213|BEHAVIORAL|Patient counselling|Patient counseling, lifestyle modifications, medication evaluation, and adherence
223714206|NCT03870698|PROCEDURE|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
223714207|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
223714208|NCT01648946|BIOLOGICAL|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
223714209|NCT04828252|DEVICE|Low level laser treatment|The intervention protocol includes 2 wavelength as the experimental group, each of the were 808nm, 660nm, and 1 placebo intervention which output total power is only 0.0072W.
223714210|NCT05077722|DEVICE|Garmin|A smartwatch device that measures subjects level of activity, heartrate, respirations and quality of your sleep at night. Artificial intelligence will be applied to analyze all the data over the course of 12 weeks to monitor and attempt to predict the onset of tantrums or disruptive behavior. Subjects are required to wear the watch at least 70% of the day and night each day for 70% of days during 12 weeks of treatment.
223714211|NCT04869644|BEHAVIORAL|Goal setting|Goal setting: set or agree on a goal defined in terms of behavior to be achieved.
223714212|NCT04869644|BEHAVIORAL|Action Planning|Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity.
223714213|NCT04869644|BEHAVIORAL|Self-monitoring of behavior|Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.
223714214|NCT04869644|BEHAVIORAL|Behavioral Practice/Rehearsal|Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.
223714215|NCT04869644|BEHAVIORAL|Habit Formation|Prompt rehearsal \& repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
223714216|NCT02728609|DEVICE|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
223714217|NCT02728609|DEVICE|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
223714218|NCT04374032|DRUG|metenkefalin + tridecactide|ENKORTEN® 5 mg + 1 mg Lyophilisate for Solution for Injection
223714219|NCT04374032|DRUG|The standard of care|The usual therapeutically established protocol, for the treatment of patients with moderate to severe COVID-19 infection prescribed by The Agency for medicinal products and medical devices of Bosnia and Herzegovina
223714220|NCT06499155|DEVICE|Use of periacryl in gingival recession closure procedures|Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.
223714221|NCT06499155|PROCEDURE|Use of sutures in gingival recession closure procedures|Both recipient and donor areas will be closed with traditional suturing techniques.
223714222|NCT00871702|GENETIC|CD34-TK75 transduced donor lymphocytes|
223714223|NCT00871702|RADIATION|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
223714224|NCT04988178|OTHER|Data extraction from medical files|Data extraction from medical files
223714225|NCT04736836|DRUG|Rifaximin|locally absorbed antibiotic
223714226|NCT02415660|PROCEDURE|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
223714227|NCT02415660|PROCEDURE|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
223714228|NCT02415660|BEHAVIORAL|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
223714229|NCT02415660|BEHAVIORAL|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
223714230|NCT02415660|PROCEDURE|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
223714231|NCT02415660|DEVICE|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
223714232|NCT02824874|DRUG|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg\*1T/day for 5days, QD, PO
223714233|NCT02824874|DRUG|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg\*1T/day for 5 dyas, QD, PO
223714234|NCT05209958|DIAGNOSTIC_TEST|Neutrophil Lynphosite ratio|The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
223714235|NCT04388800|OTHER|Confront and Navigate Depression Online (CANDO)|This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
223714236|NCT00653055|DRUG|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
223714237|NCT00653055|DRUG|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
223714238|NCT01455259|BIOLOGICAL|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
223714239|NCT05246683|OTHER|observational|registry
223714240|NCT01272674|OTHER|exercise training|4 weeks supervised physical exercise training
223714241|NCT06069882|BEHAVIORAL|Cognitive Rehabilitation|"Cognitive Rehabilitation is a person-centred, goal-oriented, problem-solving therapy aimed at managing or reducing functional disability, mitigating excess disability, and maximising engagement and social participation (Clare et al., 2019, p. 710). For this multiple-baseline SCED, there will be a baseline phase where participants will be assessed on goal attainment without an intervention. This phase will be either 3, 4, 5 weeks long and be determined for the participants using an electronic randomiser programme. Thereafter, facilitators will help participants devise personal rehabilitation plans to achieve one of these goals using evidence-based rehabilitative methods. These methods may include the use of environmental adaptations and prompts, introduction of compensatory strategies, procedural learning of skills, and methods for learning or relearning relevant information. The personal rehabilitation plan is put into practice for 6 weeks during the intervention phase of the study."
223714242|NCT01090843|PROCEDURE|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
223714243|NCT01090843|DEVICE|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
223714244|NCT01090843|DEVICE|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
223714245|NCT04246450|DEVICE|Implantable Cardioverter Defibrillator (ICD) insertion|Implantation of ICD when arrhythmic risk is deemed high in those with LVEF between 35%-50%, and to all with LVEF\<35%. Aim to determine whether risk stratification accuracy can be improved more than that of the current approach regarding primary prevention of sudden cardiac arrhythmic death in nonischemic dilated cardiomyopathy patients (no ICDs to those with LVEF between 35%-50% and ICDs to all with LVEF \<35%. In patients in the LVEF \<35% groups, ICDs will be used as implantable recorders, to determine whether occurrence of major arrhythmic events (MAEs) can be better predicted by NIRFs/PVS than by LVEF alone.
223714246|NCT02782637|OTHER|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
223714247|NCT03716037|OTHER|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
223714248|NCT01850875|BEHAVIORAL|Eye-Movement-Desensitization-Reprocessing|
223714249|NCT04614597|BIOLOGICAL|Sabin strain inactivated polio vaccine|Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
223714250|NCT06431087|OTHER|Mindfulness course|Online or in presence Information on Mindfulness, healthy diet and exercise.
223714251|NCT01389817|DEVICE|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
223714252|NCT02251184|DRUG|Aggrenox|
223714253|NCT02251184|DRUG|Dipyridamole|
223714254|NCT02251184|DRUG|Aspirin|
223714255|NCT02251184|DRUG|Lansoprazole|
223714256|NCT04800354|BEHAVIORAL|Nurse-led Mindfulness Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time they experience intense pain or take pain medication before and after surgery.
223714257|NCT04800354|BEHAVIORAL|Nurse-led Pain Psychoeducation|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
223714258|NCT01749137|DRUG|Setmelanotide|Daily subcutaneous infusion
223714259|NCT01749137|DRUG|Placebo|Daily subcutaneous infusion
223714260|NCT00388960|DRUG|Amrubicin|"Amrubicin 45mg/m\<2\> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression."
223714261|NCT00388960|DRUG|Cisplatin|"Amrubicin 40mg/m\<2\> IV days 1, 2, 3 plus Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression."
223714262|NCT00388960|DRUG|Etoposide|Cisplatin 75mg/m\<2\> IV day 1 plus etoposide 100mg/m\<2\> IV day 1 and 200mg/m\<2\> orally days 2, 3 or etoposide 100mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until disease progression.
223714263|NCT03627143|OTHER|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~1. Selection of one or more local physician champions from both the ED as well as the cardiology group;~2. Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~3. Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~4. Development of local action plan addressing local barriers to implementation;~5. Provision of the free Smartphone App to be developed for the guidelines;~6. Regular reminders provided by the local research staff;~7. Audit and feedback charts of site compliance"
223714264|NCT01758432|COMBINATION_PRODUCT|PRT064445/Apixaban|
223714265|NCT01758432|COMBINATION_PRODUCT|Placebo/Apixaban|
223714266|NCT01758432|DRUG|Placebo|
223714267|NCT01101984|DRUG|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
223714268|NCT01101984|DRUG|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
223714269|NCT00277147|DRUG|BB IND 6989|
223714270|NCT03439553|BEHAVIORAL|Ads display with target websites|Ads are shown, but users are referred to control websites.
223714271|NCT03439553|BEHAVIORAL|Ads display with control websites|Ads are shown, but users are referred to control websites.
223714272|NCT03918122|OTHER|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
223714273|NCT00959231|DRUG|cyclophosphamide|
223714274|NCT00959231|DRUG|cyclosporine|
223714275|NCT00959231|DRUG|fludarabine phosphate|
223714276|NCT00959231|DRUG|mycophenolate mofetil|
223714277|NCT00959231|OTHER|laboratory biomarker analysis|
223714278|NCT00959231|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223714279|NCT00959231|PROCEDURE|umbilical cord blood transplantation|
223714280|NCT00959231|RADIATION|total-body irradiation|
223714281|NCT02991248|DEVICE|robotic training|robotic training by applying pelvis force perturbation
223714282|NCT02991248|DEVICE|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
223714283|NCT02991248|DEVICE|treadmill|conventional treadmill training only
224276691|NCT02814708|BIOLOGICAL|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow-up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST-1 binding Ab titer of \< 20 to \> 40 or a 4-fold increase in TSST-1 binding Ab titer .
223714284|NCT04946006|DRUG|Oxytocin|Oxytocin will be prepared in a 1L bag of Ringer's lactate, to be infused at a rate of 125 ml/h.
223714285|NCT04072497|BIOLOGICAL|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus \>=4.3 LgPFU per dose)
223714286|NCT04072497|BIOLOGICAL|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus \>=3.3 LgPFU per dose)
223714287|NCT04072497|BIOLOGICAL|one shot of placebo|one shot of placebo with no live virus
223714288|NCT00732017|DEVICE|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
223714289|NCT00732017|DEVICE|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
223714290|NCT00732017|OTHER|standard physical therapy treatment|"* Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
223714291|NCT00621985|DRUG|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
223714292|NCT00621985|DRUG|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
223714293|NCT02720991|DRUG|Mifepristone|200 mg of oral mifepristone
223714294|NCT02720991|DRUG|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
223714295|NCT01251601|OTHER|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
223714296|NCT00669227|OTHER|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
223714297|NCT00669227|OTHER|placebo suspension|intracoronary administration at the same day as cell aspiration
223714298|NCT06177327|OTHER|Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.|Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
223714299|NCT00209469|DRUG|alendronate sodium|
223714300|NCT06119945|DRUG|DWJ1568|One tablet of DWJ1568
223714301|NCT06119945|DRUG|DWC202215|One tablet of DWC202215
223714302|NCT02587234|DEVICE|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
223714303|NCT03856892|OTHER|High Dose Yoga|"Participants engage in an intensive full yoga practice of hatha breath-based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices. The high dose of yoga is an interpretation of the Translational Model of Yoga (TMY) and Yoga Process formula, both developed in this study's cultural research: a systematized psycho-physical yoga method of Hatha Zone (HZ) focus (below-navel, exhale, inner focus), incorporating key components of practice-focus-surrender (PFS) approach and repeat-engage-trust (RET) elements."
223714304|NCT03856892|OTHER|Medium Dose Yoga|"The medium dose of yoga is a regular practice of primarily body-posture training with minimal reference to the breath, but with a longer period of time duration in training prior to intervention commencement. Participants have 5 months of pre-training before initiating the intervention."
223714305|NCT03465306|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
223714306|NCT03465306|DEVICE|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
223714307|NCT05083572|DRUG|Colonic lavage with polyethylene glycol|The subjects will orally consume a split dose of bowel preparation (PEG); 2 litres in the evening (Day -1) and another 2 litres the following morning (Day 1).
223714308|NCT05083572|DIETARY_SUPPLEMENT|Probiotic|The subjects will self-administer orally two capsules of Vivomixx with room temperature water (as heat may inactivate the live bacteria, rendering it less effective) twice daily for 28 days.
223714309|NCT05083572|DRUG|Antibiotic|"The subjects will undergo pre-treatment to cleanse the gut by consuming orally one tablet of antibiotic rifaximin (200mg) daily for 14 days prior to the initiation of Vivomixx course."
223714310|NCT00490360|DRUG|Gemcitabine / Cisplatin|
223714311|NCT01877265|DRUG|LY2605541|
223898728|NCT05477420|OTHER|Decision Aid|Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
223898729|NCT04948749|DEVICE|Drug Eluting Stent implantation|The Maurora ® Sirolimus Eluting Stent System for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
223898730|NCT04948749|DRUG|Aggressive medical treatment|Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 6 months after enrollment).
223898731|NCT04948749|BEHAVIORAL|Risk factor management|Management of risk factors (hypertension, diabetes, lipoprotein metabolism disorder, smoking and exercise)
223898732|NCT04948749|DRUG|Standard medical treatment|Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per day for 3 months after enrollment).
223898733|NCT05467657|DEVICE|repetitive Transcranial Magnetic Stimulation|It will be applyed a magnetic field over the Somatosensory cortex of the patient that pretends to hiperexcite the membrans of the neurons inthis area to enhance motor learning
223898734|NCT02903290|OTHER|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait
223898735|NCT02903290|OTHER|walking track GAITRite,manual dynamometer, and treadmill|walking track GAITRite,manual dynamometer, and treadmill
223898736|NCT03895359|RADIATION|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
223898737|NCT03895359|DRUG|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
223898738|NCT05731609|OTHER|Resistance Intensive Personal Training|Personalized power training program focused on participant goals.
223898739|NCT02191618|DEVICE|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
223898740|NCT04818268|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
223898741|NCT04818268|OTHER|cTBS|continuous theta-burst stimulation
223898742|NCT02316002|DRUG|Pembrolizumab|
223898743|NCT05109494|RADIATION|Conventional Fractionated|50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive \> 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.
223898744|NCT05109494|RADIATION|Hypofractionated|27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive \> 97% of the prescribed dose
223898745|NCT03031470|DRUG|Reparixin|"Reparixin was administered as a continuous intravenous infusion for 7 days (Day 0 to Day 6) (168 hours).~Reparixin was provided as 33 mg/ml concentrated solution to be diluted for i.v. infusion, packaged into 250 mL clear glass vials. To give a final concentration of 11 mg/mL, the content of a vial (250 ml) was diluted with 500 ml of 0.9% sterile saline to a total volume of 750 ml. The dosing solution was placed in a 1000 ml sterile empty Infusion Bag. Dosing solutions were to be used within 72 h from preparation, unless more restrictive rules.~Reparixin infusion started approximately 60-90 minutes before the anticipated time of OLT. Infusion interruption was allowed for no more than 60 min.~All patients received standard immunosuppressive therapy in accordance with the Russian Transplant Society Guidelines for liver transplantation.~Patients and allograft survival were monitored up to 1 year after OLT."
223898746|NCT03031470|OTHER|Control|The patients who were randomized in the control group, did not receive any study therapy. The patients of both groups received the standard immunosuppressive therapy with Tacrolimus only or together with mycophenolates, or a combination of Tacrolimus/Cyclosporine with mycophenolates and/or glucocorticosteroids. The patients with hepatocellular carcinoma and impaired renal function could receive a combination of drugs that includes everolimus. Basiliximab in association with methylprednisolone was used for the induction of immunosuppression.
223898747|NCT06628557|OTHER|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients|The Effect of Mandala Art Therapy on Anxiety and Pain in Patients
223898748|NCT03461276|BIOLOGICAL|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminum hydroxide as adjuvant.
223898749|NCT03461276|BIOLOGICAL|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminum hydroxide) without the conjugate.
223898750|NCT05770284|OTHER|12 weeks exercise|12 weeks exercise
223714312|NCT02161367|DRUG|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
223898751|NCT05770284|OTHER|Standard Medical Treatment|Standard Medical Treatment
223898752|NCT05964998|DEVICE|transcranial direct current stimulation|Current will increase to 1.5 milliamps within 30 seconds and then maintain for 20 minutes
223898753|NCT05964998|DEVICE|Sham transcranial direct current stimulation|Current will increase up to 1.5 milliamps within 30 seconds and then decrease back down over the next 30 seconds to 0 milliamps; subjects will received 0 milliamps for 20 minutes
223898754|NCT06056219|DEVICE|Mirror therapy|30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
223898755|NCT06056219|DEVICE|Virtual reality-based mirror therapy with rhythmic skill training|30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
223898756|NCT06056219|OTHER|Task-oriented training|20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
223898757|NCT05841797|BEHAVIORAL|In-Person Program Management Plus (PM+)|PM+ sessions conducted in-person by mentor mothers
223898758|NCT05841797|BEHAVIORAL|Mobile Program Management Plus (mHealth PM+)|PM+ sessions conducted via phone
223898759|NCT05933135|DRUG|Factor XIII Injection|Patients could have had an Factor XIII Injection in clinical routine
223898760|NCT06304610|BEHAVIORAL|Questionnaire|Questionnaire to probe socio-demographic data and information regarding sexual and reproductive health.
223898761|NCT06304610|PROCEDURE|HPV self-sample|Collection of HPV self-sample. The study nurse will explain step by step how the participant should take the test. The participant will also be given written instructions and the study nurse will always be around if the participant has any questions. The participant will be asked to take the self-sample in a private room with toilet. After collection the sample is handed back to the study nurse, who will then take the samples to the laboratory for analysis.
223898762|NCT06304610|PROCEDURE|Endocervical sample|Endocervical sample taken by the gynaecologist. This procedure can be somewhat uncomfortable but not painful. The participant may always ask questions if she has any doubts or questions. The gynaecologist will perform the standard colposcopy examination after collection (for which the woman sits in the colposcopy waiting room)
223898763|NCT04974099|DEVICE|RoadMAB|The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
223898764|NCT04974099|DRUG|Precision dosing with a dashboard|The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
223898765|NCT02679352|DEVICE|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
223898766|NCT04927299|DRUG|Losartan/Chlorthalidone in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
223898767|NCT04927299|DRUG|Losartan + hydrochlorothiazide in fixed dose|1 tablet, once a day of 50 mg/12.5 or 100 mg/ 25 mg
223898768|NCT06324604|DRUG|Placebo|Placebo
223898769|NCT06324604|DRUG|MTX-101|MTX-101 (bispecific CD8 Treg modulator)
223898770|NCT05825547|PROCEDURE|Cryotherapy treatment|Cryotherapy treatment administered by an interventional radiologist: the cryotherapy needle is placed under local anesthesia, ultrasound monitoring in real time. A complete cryotherapy cycle is performed with: freezing until the entire tumor is frozen as judged by ultrasound, then thawing for the same duration and refreezing according to the same principle.
223898771|NCT05817786|DEVICE|electrical stimulation of the brachial plexus nerve roots|treated by chronic electrical stimulation of the brachial plexus nerve roots
223898772|NCT05817786|OTHER|sham stimulation|treated by sham stimulation
223898773|NCT06190613|BEHAVIORAL|Combination Peer navigation and mHealth intervention|Peer navigation and SMS text message medication reminders (adapted to YMSM and YTW in community outreach-based delivery approach)
223898774|NCT04446481|DEVICE|Neurofeedback|Neurofeedback will be tested in both groups of Vets
223898775|NCT04623671|BIOLOGICAL|CAP-1002|Peripheral infusion of 150 million cardiosphere-derived cells (CDCs)
223898776|NCT04623671|BIOLOGICAL|Placebo|Matching placebo solution
223898777|NCT04745637|DRUG|Ruxolitinib|Patients receive Ruxolitinib
223898778|NCT04742452|PROCEDURE|Superior Capusular Reconstruction|Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.
223898779|NCT04742452|PROCEDURE|Partial Rotator Cuff Repair|Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
223898780|NCT06210477|DRUG|medical treatment for lower urinary tract symptoms|The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
223898781|NCT06455917|DRUG|Combination of TIL Transfer and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment.~* TIL transfer: transfer of the TIL product (i.v., 1 infusion of 5 x109 - 2 x1011 lymphocytes, day 0).~* Interleukin-2 (IL-2) therapy: administration of Aldesleukin (600'000 IU/kg body weight, i.v., every 8 hours for up to 15 doses)."
223898782|NCT05095935|OTHER|N/A observational registry|N/A observational registry
223898783|NCT03954522|OTHER|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
223898784|NCT04542317|BEHAVIORAL|REACH VN|4-6 sessions delivered over the course of 2-3 months.
223714313|NCT02161367|DRUG|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
223898785|NCT04542317|BEHAVIORAL|Enhanced control|A single session providing education about dementia
223898786|NCT05066412|OTHER|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology|CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
223898787|NCT05760274|DIAGNOSTIC_TEST|multichannel intraluminal impedance and pH monitoring (MII/pH)|A pH-MII probe is inserted nasally into the esophagus, and the position verified by chest radiograph. pH-MII data are evaluated using manufacturer's software, and each tracing is manually reviewed and validated.
223898788|NCT05831241|DIETARY_SUPPLEMENT|Ashwagandha|KSM-66 Ashwagandha is the active ingredient in Waithania somifera, a medicinal plant in Indian medicine. Ashwagandha is known as an adaptogen, an herb in capsule form that protects the body from stress.
223898789|NCT05831241|OTHER|Placebo|Placebo means that the capsules will not contain Ashwagandha but some other inactive substance.
223898790|NCT05739643|BIOLOGICAL|FBX-101|A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
223898791|NCT04983043|DRUG|Low dose QiShen YiQi Dripping Pills 3 bags|Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
223898792|NCT04983043|DRUG|High dose QiShen YiQi Dripping Pills 3 bags|High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
223898793|NCT04983043|DRUG|QiShen YiQi Dripping Pills placebo 3 bags|QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
223898794|NCT06397846|OTHER|Biological sample|blood sample will be collected at baseline
223898795|NCT05590962|OTHER|EHR Nudge|Clinicians in Arm 1 (intervention) will receive a EHR notification with option to opt-out for palliative care referral for any eligible high-risk patient, defined by a risk score ≥1 for Stage IV cancer patients and ≥2 for Stage III cancer patients. If the risk score is above 8, they will be scheduled within 2 weeks, and all other patients will be scheduled within 4 weeks. Clinician will have the option to opt-out for any patient by responding to the notification which will be sent to the research coordinator. If the clinician does not respond, the research coordinator will approach patient via telephone, explain the rationale for referral based on a predetermined script, and offer and schedule an outpatient or telemedicine palliative care consultation per patient preference. Follow-up visits will occur at the discretion of the palliative care clinician, usually monthly.
223898796|NCT05575440|PROCEDURE|Computed Tomography|Undergo a PET/CT scan
223898797|NCT05575440|RADIATION|Fluorine F 18 Tetrafluoroborate|Given IV
223898798|NCT05575440|PROCEDURE|Positron Emission Tomography|Undergo a PET/CT scan
223898799|NCT05575440|OTHER|Survey Administration|Ancillary studies
223898800|NCT03848065|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
223898801|NCT03848065|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
223898802|NCT03848065|BIOLOGICAL|Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)|Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
223898803|NCT02659735|DRUG|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
223898804|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
223898805|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
223898806|NCT02659735|DRUG|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
223898807|NCT05721209|DEVICE|C-Mill with AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
224276692|NCT00344214|BEHAVIORAL|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
223898808|NCT05721209|DEVICE|C-Mill without AR/VR Guidance|Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
223898809|NCT05721209|DEVICE|Zeno 3-Layer Walkway|Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
223898810|NCT05721209|DEVICE|Hunova|Used to conduct fall-risk assessment.
223898811|NCT03908099|BEHAVIORAL|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
223898812|NCT03908099|OTHER|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
223898813|NCT00670358|BIOLOGICAL|pegfilgrastim|
223898814|NCT00670358|BIOLOGICAL|rituximab|
223898815|NCT00670358|DRUG|cyclophosphamide|
223898816|NCT00670358|DRUG|doxorubicin hydrochloride|
223898817|NCT00670358|DRUG|lenalidomide|
223898818|NCT00670358|DRUG|prednisone|
223898819|NCT00670358|DRUG|vincristine sulfate|
223898820|NCT00670358|GENETIC|polymorphism analysis|
223898821|NCT00670358|OTHER|laboratory biomarker analysis|
223898822|NCT04118673|BEHAVIORAL|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
223898823|NCT05949645|DEVICE|Apreo Implant Group|One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
223898824|NCT03847480|RADIATION|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
223898825|NCT05029635|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 24 weeks
223898826|NCT05029635|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
223898827|NCT05610644|OTHER|isocaloric, isonitrogenous meals|Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
223898828|NCT04672863|BEHAVIORAL|Dietary Intervention|Modified Mediterranean diet approved by the Nutrition Team at the Transplant Center and it emphasizes consumption of fruits, vegetables, whole grains, beans and nuts, in addition to low salt (2-2.4g/day), moderate amounts of lean protein (primarily fish and poultry) in addition to low to moderate quantities of monounsaturated fats. The modifications to the traditional Mediterranean diet are: no alcohol consumption and fewer added fats. In addition, close scheduled followup on diet and progress with study team.
223898829|NCT06625892|BEHAVIORAL|the multidimensional interventions|The study participants will receive cognitive behavior therapy intervention for six weeks, one session per week, 45 minutes each time, and exercise training for twelve weeks, twice sessions per week, 60 minutes each time.
223898830|NCT06164002|OTHER|change in restoration material and margin design.|comparing two different materials and two different designs. use artificial intelligence in the prediction of follow up results
223898831|NCT00185744|RADIATION|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
223898832|NCT00185744|PROCEDURE|Lumpectomy|
223898833|NCT00185744|RADIATION|Whole Breast Radiotherapy|six and a half week treatment
223898834|NCT00185744|RADIATION|Intracavitary Brachytherapy|5 day treatment
223898835|NCT00185744|RADIATION|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
223898836|NCT00185744|RADIATION|Stereotactic APBI|4 day treatment
223898837|NCT03496168|DRUG|mavacamten|mavacamten capsules
223898838|NCT03865498|BEHAVIORAL|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
223898839|NCT03865498|BEHAVIORAL|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
223898840|NCT02379793|DRUG|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
223898841|NCT02124239|DRUG|Ingenol mebutate|
223898842|NCT04164069|BIOLOGICAL|Bevacizumab|Given IV
223898843|NCT04164069|DRUG|Dasatinib|Given PO
223898844|NCT04164069|DRUG|Fluorouracil|Given IV
223898845|NCT04164069|DRUG|Leucovorin|Given IV
223898846|NCT04164069|DRUG|Leucovorin Calcium|Given IV
223898847|NCT04164069|DRUG|Oxaliplatin|Given IV
223898848|NCT04164069|OTHER|Quality-of-Life Assessment|Ancillary studies
223898849|NCT02619994|DRUG|Linezolid|
223898850|NCT02619994|DRUG|Delamanid|
223898851|NCT02619994|DRUG|Levofloxacin|
223898852|NCT02619994|DRUG|Pyrazinamide|
223898853|NCT02619994|DRUG|Locally-used WHO-approved MDR-TB regimen in Korea|
223898854|NCT06004479|OTHER|Carotenoid Intake|Carotenoid intake assess by 24 hour dietary recalls
223898855|NCT06004479|OTHER|Serum carotenoid concentration|Serum total carotenoid concentration
223898856|NCT05241392|BIOLOGICAL|B7-H3-targeting CAR-T cells|Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.
223898857|NCT04773691|DEVICE|Active rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: 10 Hz, 1000 pulses per session, 110% of SM, cortical target: right DLPFC"
223898858|NCT04773691|DEVICE|Placebo rTMS|"Two rTMS stimulation sessions spaced 15 minutes apart are delivered daily for 5 consecutive days.~A total of 10 sessions. Stimulation parameters: delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation."
223898859|NCT04773691|OTHER|Questionnaires|questionnaires for craving assessment: EVA, OCDS, CGI and ADS and signs of physical withdrawal by CIWA
223898860|NCT04773691|DEVICE|Breathalyzer|estimation of blood alcohol level
223898861|NCT05947357|OTHER|Nutrition Assistance Program|Patients will receive in the intervention group a $40.00 per month voucher for 6 months for use in the produce section of a local grocery store.
223898862|NCT05445167|DRUG|KLH-2109|Oral administration
223898863|NCT05445167|DRUG|Placebo|Oral administration
223898864|NCT05614661|BEHAVIORAL|Mom Power|Experimental participants will receive virtual Mom Power via phone/internet connection. Control participants will receive mail information and confirmation phone calls.
223898865|NCT06543381|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223898866|NCT06543381|DRUG|Olutasidenib|Given PO
223898867|NCT04767282|OTHER|Fruit and Vegetable Prescription|$15 voucher for fruit and vegetables
223898868|NCT04923945|DRUG|Savolitinib|Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest. Or patient will receive Savolitinib \[Savolitinib 300 mg, po, twice per day (BID) continuously in patients with baseline weight ≥50 kg, and Savolitinib 200 mg, po, BID in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
223898869|NCT06068530|DRUG|DHA/piperaquine and a SLD-PQ|Participants in Arms 1 and 2 will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1, and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2 (i.e. the day of vaccination and each day for 2 days after). The drug dose is based on the weight of the participant at the first visit (M0D0). Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. In addition, each participant will receive a single low dose primaquine on the day of vaccination (Day 0; Table 4). One single low dose primaquine of approximately 0.25 mg/kg (Thai Government Pharmaceutical Organisation) will be administered. Children under 10kg do not receive PQ.
223898870|NCT06068530|BIOLOGICAL|Study vaccine R21/Matrix-M™|The mixing prior to administration strategy will involve withdrawal of 0.5 mL antigen from one vial of R21 Malaria vaccine and adding it to Matrix-M1 vial. 0.5 mL of R21 antigen shall be withdrawn from another vial of R21 Malaria vaccine and be added to the same Matrix-M1 vial. The total volume in Matrix-M1 vial will be 1.5 mL. After addition the content will be mixed gently, and 0.75 mL of the mixture will be withdrawn and administered to participants. Each dose of 0.75mL (after mixing of R21 with Matrix-M1) will contain 10 µg of R21 and 50 µg for participants 14 years and older. In children up to 14 years a 5 μg will be used.
223898871|NCT01048281|PROCEDURE|Blood draw|
223898872|NCT01048281|PROCEDURE|Tissue tumor biopsy|
223898873|NCT03194685|DRUG|FF-10101-01|FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.
223898874|NCT05869383|DRUG|Ophiochepalus striatus extract|Ophiochepalus striatus extract 2x5 grams
223898875|NCT05869383|DRUG|Placebo|Placebo 2x5 grams
223898876|NCT04552756|DIAGNOSTIC_TEST|Seizure Diary|"The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline.~To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present."
223898877|NCT04473430|DEVICE|Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM)|"Dexcom G6, a factory-calibrated CGM system, is innovative in many aspects: 1) it does not require finger stick POC BG for calibration, 2) the sensor is small, compact, light-weight, 3) has no interference with several substance and drugs, and 4) protective urgent low soon alarm, with proven prediction of hypoglycemia within 20 minutes in advance.~Dexcom G6 monitors glucose continuously (24 hrs) and displays real-time glucose values, glucose trends/arrows and alarms, including the urgent low soon alarm (predictive of hypoglycemia \< 55 mg/dL within the preceding 20 minutes).~Diagnostic Test: Real-time CGM will be used to collect outcomes variables"
223898878|NCT04473430|DEVICE|POC Glucose Testing|"POC BG (standard of care) uses commercially-available glucose meters for blood glucose monitoring. It is approved to be used in dialysis populations.~Diagnostic Test: Professional CGM will be used to collect outcomes variables (including during the POC BG testing)."
223898879|NCT05703932|OTHER|home-based exercises|Joint range of motion and stretching exercises for cervical, thoracic and lumbar spine, stretching for erector spina, hamstring and shoulder muscles, chest expansion, abdominal and diaphragmatic breathing exercises will be applied. Exercises will be performed at submaximal level, paying attention to blood pressure, arterial (TA) and heart rate.For the patients in the exercise group, it was planned to perform the exercise program 5 days a week in 1 set with 10 repetitions, 40 minutes/day.
223898880|NCT02535338|DRUG|Erlotinib Hydrochloride|Given PO
223898881|NCT02535338|OTHER|Laboratory Biomarker Analysis|Correlative studies
223898882|NCT02535338|DRUG|Onalespib Lactate|Given IV
223898883|NCT02535338|OTHER|Pharmacological Study|Correlative studies
223898884|NCT03761446|BEHAVIORAL|Bed rest|The participant will remain in bed rest for 10 complete days.
223898885|NCT04454788|DRUG|Tenecteplase|Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
223898886|NCT04454788|DRUG|Standard Care (which may include intravenous Alteplase)|Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
223898887|NCT05658874|DRUG|Multimodal Bundle Drugs|multimodal pain therapy
223898888|NCT05658874|PROCEDURE|Operative Cystoscopy|Evaluate bladder and treat Hunner lesions with kenalog or fulguration as appropriate
223898889|NCT05658874|BEHAVIORAL|Behavioral health consultation/therapy|Patient to see behavioral health/psychiatric care
223898890|NCT05658874|OTHER|Pelvic floor physical therapy|Patient to have evaluation and treatment by a trained pelvic floor physical therapist
223898891|NCT05658874|OTHER|Usual Urogynecologic care|Usual care from practicing academic Urogynecologist
223898892|NCT05658874|DRUG|Bladder Instillation|Intravesical lidocaine, heparin, sodium bicarb, Kenalog, gentamicin
223898893|NCT05658874|DRUG|Vaginal estrogen|Topical vaginal estradiol application
223898894|NCT05658874|DRUG|Methenamine|UTI prevention/bladder therapeutic
223714314|NCT06352801|BEHAVIORAL|Self-Compassion Intervention|Children participants are expected to learn the concepts of self-compassion and strategies of applying self-compassion to their daily lives.
223898895|NCT05658874|DRUG|Amitriptyline/Gabapentin|Part of multimodal pain therapy
223898896|NCT06417944|DIAGNOSTIC_TEST|Scoliosis study form|Scoliosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in detail.
223898897|NCT06417944|DIAGNOSTIC_TEST|Scoliosis X-ray (orthorontgenogram)|Patients whose Adam's forward bending test and clinical evaluation results are compatible with scoliosis, scoliosis graphy are requested. (Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 5 degrees in those with BMI (Body Mass Index) above 85%. If it is below 85% and above 7 degrees, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis film will be requested.).Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
223714315|NCT05416502|PROCEDURE|Ultrasound|Enrolled patients underwent ultrasound scan of kidneys, ureters, and the bladder.
223714316|NCT00950105|DRUG|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
223714317|NCT00706823|DEVICE|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
223714318|NCT00706823|DEVICE|Laryngeal Mask Airway-Unique|supra-glottic airway device
223714319|NCT00589251|OTHER|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
223714320|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
223714321|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
223714322|NCT03985449|OTHER|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
223714323|NCT00009698|BIOLOGICAL|aldesleukin|Given SQ and IV
223714324|NCT01415284|DRUG|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
223714325|NCT00121602|DRUG|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
223714326|NCT00709683|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223714327|NCT05258175|OTHER|KT|Kinesio tapping will be applied in three session and it will be changed on every fifth day in total 15 days.
223714328|NCT05258175|OTHER|Standardized physiotherapy protocol|3 sets with five repetitions per day for total of 15 days.
223714329|NCT04949048|DEVICE|Magneto PE Kit|All enrolled patients will be treated with Magneto PE Kit
223714330|NCT04381403|OTHER|Bio-descaling D-Tart toothpaste|Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
223714331|NCT04381403|OTHER|Crest® toothpaste|Patients received Crest toothpaste; Anti-tartar toothpaste
223714332|NCT04325581|DRUG|Liraglutide 6 MG/ML|Liraglutide in incremental dose upto maximum of 1.8 mg per day SC daily
223714333|NCT04325581|DRUG|Placebos|Normal Saline SC daily
223714334|NCT05577260|DRUG|magnesuim sulphate|magnesuim sulphate
223714335|NCT05577260|DRUG|Dexmedetomidine|Dexmedetomidine
223714336|NCT05577260|DRUG|isobaric bupivacaine|20ml isobaric bupivacaine 0.25%
223714337|NCT02926365|BEHAVIORAL|ICBT|
223714338|NCT01228760|DRUG|ASG-5ME|IV
223714339|NCT03068130|DRUG|Bardoxolone methyl|Capsules of Bardoxolone methyl
223714340|NCT01144286|DRUG|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
223714341|NCT01144286|DRUG|placebo|placebo, single dose
223714342|NCT06304376|PROCEDURE|Alveolar ridge grafting|Alveolar ridge grafting was carried out using anterior iliac crest bone graft. Khoury shell technique was the method of ridge reconstruction via a cortical bone shell was fixed away from alveolar ridge using two micro-screws and the gap created was filled by cancellous bone
223714343|NCT03535844|OTHER|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
224276693|NCT00344214|BEHAVIORAL|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
224276694|NCT03523247|BEHAVIORAL|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
223714344|NCT03535844|OTHER|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
223714345|NCT03445715|GENETIC|ART-I02|Single Intra-articular injection in the wrist joint
223714346|NCT01303107|DRUG|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
223714347|NCT05009121|DIAGNOSTIC_TEST|Box and Block Test|"At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions."
223714348|NCT03130257|DIAGNOSTIC_TEST|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure once within the subsequent three weeks.
223714349|NCT03130257|DIAGNOSTIC_TEST|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to two measurements in the morning and two in the evening for at least 5 days over three weeks.
223714350|NCT03130257|DIAGNOSTIC_TEST|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
223714351|NCT03130257|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring (Reference Standard)|Participants will be asked to wear an arm cuff and ambulatory blood pressure monitor for 24 hours, with measurements taken every 30 minutes during the day and every 60 minutes at night.
223714352|NCT02698839|DEVICE|BuMA Supreme|Stent platform: cobalt-chromium alloy
223714353|NCT02698839|DEVICE|BuMA™|Stent platform: stainless steel
223714354|NCT03903848|OTHER|Exercise|Single session of treadmill walking and resistance exercise
223714355|NCT05930912|DIAGNOSTIC_TEST|Psychoanalysis|Case-specific psychoanalysis is performed, including the participant's background during birth.
223714356|NCT05930912|DRUG|sertraline 50mg|After the initial assessment of 50 mg/d, the treatment dosage is determined at 100 mg/d.
223714357|NCT05930912|DRUG|Duloxetine 20 MG|Duloxetine is used with 20 mg/night for subsidiary effects with sertraline.
223714358|NCT05930912|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is tailored to the participant's current activities and life decisions.
223714359|NCT06959602|PROCEDURE|Final Irrigation with 2.5% Sodium Hypochlorite|After supragingival scaling and removal of caries or defective restorations, the tooth will be isolated and disinfected with 3% H202 and 2.5% NaOCl. Access preparation will be done using a sterile high-speed bur under sterile saline irrigation, followed by re-disinfection. NaOCl will be neutralized with 5% sodium thiosulphate, and sterility will be confirmed via paper point sampling. Only teeth with negative sterility samples will proceed. Sample S1 will be collected after saline irrigation and mild instrumentation with a sterile K-file #15, using an apex locator. Paper points will absorb canal fluid and be frozen in Tris-EDTA buffer at -20°C. Complete chemomechanical preparation will follow, with irrigation after each instrument change. Cervical and mid-thirds will be enlarged with Gates-Glidden burs and the apical third with NiTi RaCe files (40/04). Sample S2 will be taken after preparation. Group A will receive final irrigation with 2.5% NaOCl before collection of sample S3.
223714360|NCT06959602|PROCEDURE|Passive Ultrasonic Irrigation (PUI) with Sodium Hypochlorite|Activation of 2.5% sodium hypochlorite solution inside the root canal system using Passive Ultrasonic Irrigation (PUI) after chemomechanical preparation. Group B, sample (S3).
223714361|NCT06959602|PROCEDURE|XP-Endo Finisher Activation with Sodium Hypochlorite|Mechanical activation of 2.5% sodium hypochlorite solution using the XP-Endo Finisher instrument following chemomechanical preparation.Group C, sample (S3).
223714362|NCT02380781|BEHAVIORAL|Information in the form of a video|see intervention description
223714363|NCT05951673|OTHER|Safe Space based life skills training program|This is a Safe Space based life skills training program given to adolescent girls. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change.
223714364|NCT05951673|OTHER|Safe Space based life skills training program + Digital Skills|This is a Safe Space based life skills training program given to adolescent girls complemented with a digital literacy training program. Girls receive a 12 month long training on life skills such as negotiation skills, communication skills, sexual and reproductive health, gender-based violence and climate change. The adolescent girls in this group also receive a digital literacy training program that covers content on word processing. database management and analysis, online marketing, online safety and programming.
223714365|NCT02208557|PROCEDURE|Reinforcement with Absorbable Mesh|
223714366|NCT02208557|RADIATION|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
223714367|NCT02208557|OTHER|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
223714368|NCT00160693|BIOLOGICAL|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
223714369|NCT01966159|DEVICE|SYNERGY Investigational Device|percutaneous coronary intervention
223714370|NCT01966159|DEVICE|PE Plus Investigational Device|percutaneous coronary intervention
223714371|NCT01824641|DEVICE|Eliminate aspiration catheter|Eliminate aspiration catheter
223898898|NCT06417944|DIAGNOSTIC_TEST|Pulmonary function test|Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. We will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
223898899|NCT06417944|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter- cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
223898900|NCT06417944|PROCEDURE|Three-dimensional Exercise (BSPTS Schroth Exercise)|"It only provides outpatient treatment, but it has different practices, intensive or regular, depending on local and external patients. For local patients, it is applied once a week, accompanied by a therapist, and the treatment duration is determined according to the patient's condition. In patients coming from outside; It can be continued as 2 hours a day for 10 days, then as additional treatment for 1-2 weeks for 3-6 months depending on the patient's condition. I In regular treatment; 30 sessions of 90 minutes group treatment, the first 8 sessions are carried out under the supervision of a therapist for a shorter period of time.~We will give 10 sessions of BSPTS Schroth exercises, either outpatient or inpatient. After 10 sessions of the Schroth exercise program, the home program will continue two months after outpatient/inpatient schroth exercise(Home program: 5 days/week, 45-60 minutes for all patients)."
223898901|NCT06417944|PROCEDURE|Home Exercise|In the home exercise program; daily living activities, neutral pelvis exercises, coronal balance exercises, rotational angular breathing exercises and axial elongation exercises were taught by the physiotherapist in one session. A total of 10-week home exercise program was planned, with exercises to be performed twice a week for the first two weeks, once every 15 days for 1 month (twice in one month), and then once a month.
223898902|NCT03625349|DRUG|NG-Monomethyl-L-Arginine|Inhibitor of nitric oxide synthase.
223898903|NCT06494891|DRUG|Intravenous Alcohol|Participants will receive intravenous alcohol (6% ethanol v/v in saline; obtained from the Ronald Reagan UCLA Medical Center Investigational Drug Service) over the course of an alcohol challenge. During the challenge, participants will be administered alcohol designed to reach target BrACs of 20, 40, and 60 mg%, each over 15 min. After reaching the last target BrAC (0.06 g/dl) participants will complete a self-administration (SA) paradigm. Participants will be invited to work (button press) for alcohol according to a log-linear progressive ratio schedule.
223898904|NCT06251609|DRUG|Naloxone 2 MG|The intervention consists of naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via the IV or IO route. The study intervention will be administered immediately (within 5 minutes) following the first dose of epinephrine. When naloxone hydrochloride is administered intravenously, the onset of action is generally apparent within two minutes. The naloxone will be administered following the first dose of epinephrine. The control is saline 2ml will be supplied in pre-filled syringes within numbered trial treatment packs. They will be identical in appearance to the naloxone syringes.
223898905|NCT06251609|DRUG|Saline 2ml|Placebo
223898906|NCT06308861|DRUG|Single administration Amg dose Group|Orally, Amg tablet single administration
223898907|NCT06308861|DRUG|Single administration Bmg dose Group|Orally, Bmg tablet single administration
223898908|NCT06308861|DRUG|Single administration Cmg dose Group|Orally, Cmg tablet single administration
223898909|NCT06308861|DRUG|Single administration Dmg dose Group|Orally, Dmg tablet single administration
223898910|NCT06308861|DRUG|Single administration Emg dose Group|Orally, Emg tablet single administration
223898911|NCT06308861|DRUG|Single administration Amg dose Group-Placebo|Orally, Placebo Amg tablet, single administration
223898912|NCT06308861|DRUG|Single administration Bmg dose Group-Placebo|Orally, Placebo Bmg tablet, single administration
223898913|NCT06308861|DRUG|Single administration Cmg dose Group-Placebo|Orally, Placebo Cmg tablet, single administration
223898914|NCT06308861|DRUG|Single administration Dmg dose Group-Placebo|Orally, Placebo Dmg tablet, single administration
223898915|NCT06308861|DRUG|Single administration Emg dose Group-Placebo|Orally, Placebo Emg tablet, single administration
223898916|NCT06308861|DRUG|Multiple administration Amg dose group|Orally, Amg 1 tablet, once a day for 3 days, multiple administration
223898917|NCT06308861|DRUG|Multiple administration Bmg dose group|Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
223898918|NCT06308861|DRUG|Multiple administration Cmg dose group|Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
223898919|NCT06308861|DRUG|Multiple administration Dmg dose group|Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
223898920|NCT06308861|DRUG|Multiple administration Emg dose group|Orally, Emg 1 tablet, once a day for 3 days, multiple administration
223898921|NCT06308861|DRUG|Multiple administration Amg dose group - Placebo|Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
224276695|NCT01949753|BEHAVIORAL|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
224276696|NCT01949753|BEHAVIORAL|Exposure therapy|Exposure with response prevention without pharmacological facilitation
223714372|NCT01824641|PROCEDURE|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
223714373|NCT03698149|DEVICE|PMT/Blackrock Combination Device|PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
223898922|NCT06308861|DRUG|Multiple administration Bmg dose group - Placebo|Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
223898923|NCT06308861|DRUG|Multiple administration Cmg dose group - Placebo|Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
223898924|NCT06308861|DRUG|Multiple administration Dmg dose group - Placebo|Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
223898925|NCT06308861|DRUG|Multiple administration Emg dose group - Placebo|Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
223898926|NCT03907878|BIOLOGICAL|Ligelizumab|Liquid in vial
223898927|NCT04775381|DRUG|Vitamin D|Patients will receive a cholecalciferol supplementation added to a fruit juice.
223898928|NCT04858230|DEVICE|LymphoPilot|"LymphoPilot is an investigational medical device composed of an implanted part (pump, drainage catheter and output catheter), implanted in the subcutaneous tissue of the arm or of the leg and draining excess fluids to the supraclavicular or abdominal subcutaneous tissue, where fluids are naturally reabsorbed by the healthy lymphatic and venous system. The implanted part is activated and controlled via a wearable device.~The subcutaneous implantation of the device is performed in loco-regional or general anesthesia, in ambulatorial settings, and the patient is dismissed from the hospital on the same day of the procedure.~Patients will wear the external controller continuously throughout the study, except 30 minutes per day, to allow taking a shower/bath. The implanted device will be removed with a surgical procedure in local anesthesia 8 weeks after device implantation."
223898929|NCT04804696|DRUG|Toripalimab|Patients received toripalimab 240 mg I.V. drip on days 1 and 22.
223898930|NCT04804696|DRUG|Paclitaxel|Patients received paclitaxel of 175mg/m2 I.V. drip on days 1 and 22.
223898931|NCT04804696|DRUG|Cisplatin|Patients received cisplatin of 70mg/m2 I.V. drip on days 1 and 22.
223898932|NCT05144009|DRUG|Loncastuximab Tesirine|Intravenous (IV) Infusion
223898933|NCT05144009|DRUG|Rituximab|Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
223898934|NCT04380051|BEHAVIORAL|sensory-tonic stimulation|sensory-tonic stimulation done by the parents to the child, five times a week during 15 minutes at each time
223898935|NCT04380051|BEHAVIORAL|skin-to-skin contact|skin-to-skin contact left free for parents
223898936|NCT04469296|DIETARY_SUPPLEMENT|iso-caloric ketogenic diet|Each patient will be offered a daily diet plan that includes the different groups of low glycemic index foods to bring to each meal and snack, with the notion of quantity. Carbohydrate-free foods can be consumed ad libitum. Dietary advice will be given to increase the consumption of lipid foods (vegetable oils, butter, cheeses, fatty fish, etc.) so that 65% of the total energy intake is provided by lipids. In addition, a list of unauthorized sugars and sweeteners substitutes will be proposed as well as a low glycemic index food composition table centered on carbohydrates for better control of food choice
223898937|NCT04469296|DIETARY_SUPPLEMENT|protein restricted diet|A diet reducing by 20% the amount of protein compared to the usual intake of the patient will be proposed. This new ration will be carried out by calculating the proportion of total energy intake provided by the amount of protein reduced by 20% compared to the usual intake, and by modifying lipid and carbohydrate intakes to obtain an isocaloric ration.
223898938|NCT03966313|DEVICE|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~* After anesthetic induction~* Before starting the device~* 2h, 6h and 48h after starting the device"
223898939|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 15g/d|Supplementation with 15g/day of SPF or Comparator
224276697|NCT05112419|DRUG|Zibotentan|All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
223898940|NCT05025462|DIETARY_SUPPLEMENT|Supplement dose 7.5g/d|Supplementation with 7.5g/d of SPF ou comparator
223898941|NCT04358874|OTHER|Medication reconciliation|Medicines currently being taken will be reviewed and compared to the medicines that were prescribed at discharge.
223898942|NCT04358874|OTHER|Blood Pressure Management|Blood pressure will be checked at follow-up visits and medicines will be adjusted if blood pressure is above target range (\>160/100)
223898943|NCT05759754|DRUG|TCM+ Routine Therapy|"The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued."
224276698|NCT01514994|DEVICE|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
224276699|NCT04688580|DRUG|XW10172|Various formulations
224276700|NCT04983524|DIETARY_SUPPLEMENT|propolis|resinous product of honeybees
223898944|NCT05759754|DRUG|Routine Therapy|Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
223898945|NCT05777460|DEVICE|Thoracic endovascular aortic repair (TEVAR)|The TEVAR procedure involves the placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
223898946|NCT06105918|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223898947|NCT06105918|PROCEDURE|Computed Tomography|Undergo rhPSMA-7.3 PET/CT and SPECT-CT
224276701|NCT04983524|DRUG|Calcium Hydroxide|Gold standard control intracanal medicament
223714374|NCT00080808|DRUG|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
223714375|NCT00080808|DRUG|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
223898948|NCT06105918|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223898949|NCT06105918|OTHER|Flotufolastat F-18|Given IV
223898950|NCT06105918|DRUG|Lutetium Lu 177 PSMA-10.1|Given IV
223898951|NCT06105918|PROCEDURE|Positron Emission Tomography|Undergo rhPSMA-7.3 PET/CT
223898952|NCT06105918|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT-CT scan
224276702|NCT02262741|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
224276703|NCT02262741|BIOLOGICAL|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
224276704|NCT04815109|OTHER|Encephalography measurement|Encephalography measurement and partially aggravated sedation.
224276705|NCT00236145|DRUG|ACTIQ (Oral transmucosal fentanyl citrate)|
224276706|NCT05179161|DEVICE|Prone crawl positioning|Breast cancer patients are placed in a prone position with the ipsilateral arm besides the body rather than extended besides the head on a dedicated couch that provides the required support for maintaining this position.
224276707|NCT01189682|PROCEDURE|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
223714376|NCT00080808|DRUG|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
223714377|NCT00080808|DRUG|Sildenafil citrate|Oral sildenafil as needed
223714378|NCT00080808|PROCEDURE|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
223714379|NCT01925053|OTHER|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
223714380|NCT01925053|OTHER|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
223714381|NCT04985097|PROCEDURE|Implantation of trifocal diffractive intraocular lenses|Postsurgical monocular and binocular assessment of corrected and uncorrected near, intermediate and distance visual acuity and near and distance mesopic contrast sensitivity before and after the assigned vision training
223714382|NCT02353104|DIETARY_SUPPLEMENT|Onion-Pumpkin Extract|
223714383|NCT02285803|DEVICE|transcranial direct current stimulation (tDCS)|
223714384|NCT03039283|DEVICE|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
223714385|NCT01207791|BEHAVIORAL|screening|Brief screening to assess eligibility and collect minimal baseline data
223714386|NCT01207791|BEHAVIORAL|assessment|comprehensive substance use assessment
223714387|NCT01207791|BEHAVIORAL|referral|referral to treatment if indicated or requested
223714388|NCT01207791|BEHAVIORAL|Brief intervention|30-minute brief intervention session in ED
223714389|NCT01207791|BEHAVIORAL|booster sessions|two 15-minute booster counseling sessions conducted by telephone
223714390|NCT00189982|DRUG|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
223714391|NCT05614830|OTHER|Dry needling ,|The intervention group will receive sessions of dry needling to relief myofacial pain on trapezius
223714392|NCT05614830|OTHER|usual physical therapy program|Therapeutic exercise
223714393|NCT05634720|DRUG|HA Chemotherapy|Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).
223714394|NCT04260256|DRUG|[18F]F-AraG|\[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
223714395|NCT03673852|BEHAVIORAL|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
223714396|NCT03673852|BEHAVIORAL|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
223714397|NCT00905411|BEHAVIORAL|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
223714398|NCT05310461|PROCEDURE|Transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement|Early transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
223714399|NCT05310461|PROCEDURE|Deferred treatment, with intervention once AVA is ≤1.0 cm2 or if concomitant mitral regurgitation meets an indication for intervention|Deferred transcatheter or surgical aortic valve replacement with or without transcatheter or surgical mitral valve repair/replacement.
223714400|NCT06485765|OTHER|Diet planning|Healthy eating planning
223714401|NCT04907656|BEHAVIORAL|dCBT|As per arm of the same name
223714402|NCT06383819|DRUG|Longidaza®|dose 3000 IU intramuscularly once every 5 days, 15 injections
223714403|NCT06383819|DRUG|Placebo|intramuscularly once every 5 days, 15 injections
223714404|NCT02980497|OTHER|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
223714405|NCT02980497|OTHER|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
223714406|NCT05386680|GENETIC|OAV101|Intrathecal administration of OAV101 at a dose of 1.2 x 10\^14 vector genomes, one time dose
223714407|NCT05469035|OTHER|Mobile-based video|Nurses in the experimental group participated in mobile-based video learning.
223714408|NCT05469035|OTHER|Face-to-face|Nurses in the experimental group participated in face-to-face learning.
223714409|NCT03197454|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
223714410|NCT03197454|OTHER|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
223714411|NCT03736733|OTHER|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
223714412|NCT03736733|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
223714413|NCT05167929|BEHAVIORAL|Self-determination Enhancement Group|The self-determination enhancement group - Each group has eight participants. There will be 10 sessions per group and each session will last 1.5 hours.
223898953|NCT03270501|DRUG|Golimumab|"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."
223714414|NCT05167929|BEHAVIORAL|Self-determination Enhancement Plus Group|The self-determination enhancement PLUS group - Each group has eight participants and their caregivers. There will be 10 sessions per group and each session will last 1.5 hours. Meanwhile, their caregivers will attend four sessions separately and each session will last 1.5 hours.
223714415|NCT05167929|BEHAVIORAL|Leisure activity group|Leisure activity group - Leisure activity group is the comparison group. Each group will consist of eight adults with mild intellectual disability. There will be 10 sessions for the group and each session will last for 1.5 hours.
223714416|NCT06354309|OTHER|Virtual reality game|Pre and post control study after use virtual reality game
223714417|NCT03944421|OTHER|Red and Processed Meat|Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
223714418|NCT03944421|OTHER|Quorn|Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
223714419|NCT01847274|DRUG|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
223714420|NCT01847274|DRUG|placebo|
223714421|NCT05210335|OTHER|Clinical pharmacist's recommendation to physicians about drug related problems|Clinical pharmacist's recommendation to physicians about drug related problems
223714422|NCT06055101|DRUG|DEXMEDETOMIDINE|"DXM is a nonselective α2 agonist. Alpha2 adrenoreceptors, the overall response to α2 adrenoreceptors agonists is related to the stimulation of α2 adrenoreceptors located in the CNS and spinal cord. These receptors are involved in the sympatholysis, sedation, and antinociception effects of α2 adrenoreceptors.~DEXMEDETOMIDINE (DXM) DXM shows a high ratio of specificity for the α2 receptor (α2/α11600: 1) compared with clonidine (α2/α1 200: 1), making it a complete α2 agonist. (76) DXM belongs to the imidazole subclass of α2 receptor agonists, similar to clonidine. It is freely soluble in water."
223714423|NCT06055101|DRUG|Neostigmine|Neostigmine is an indirect cholinomimetic agent. It produces its primary effects by inhibiting the action of AChe, which hydrolyzes acetylcholine (ACh) to choline and acetic acid. By inhibiting AChe, the indirect-acting drug increases the concentration of spinal endogenous ACh. This drug is, in effect, amplifiers of endogenous ACh and act primarily where ACh is physiologically release. It combines reversibly with AChe by the formation of an ester linkage, which lasts about 30 minutes. The pharmacokinetic of neostigmine administered by bolus injection is linear with respect to bolus injection.
223714424|NCT06055101|DRUG|Bupivacaine|"The onset of sensory blockade following spinal block with bupivacaine is very rapid (within one minute); maximum motor blockade and maximum dermatome level are achieved within 15 minutes in most cases.~The conduction of nerve impulses along nerve fibers is related to changes in the electrical gradient across the nerve membrane and movement of predominantly sodium ions (but also potassium ions) from intracellular to extracellular fluid and vice versa. Bupivacaine work by reversibly blocking specific areas of the nerve cell membrane, known as sodium channels. It contains a mixture of ionized and un-ionized particles which, when injected into body tissues, make more un-ionized particles available, which are lipid soluble and able to penetrate the nerve cell membrane."
223714425|NCT04868214|DEVICE|coagulation measurements|peak and trough coagulation measurements of patients treated with Xarelto, Eliquis, or Lixiana and coagulation measurements of healthy proband blood spiked with eiter Xarelto, Eliquis or Lixiana.
223714426|NCT03398785|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
223714427|NCT00860483|OTHER|observational|PET Scan
223714428|NCT05276531|DRUG|subcutaneous progesterone|clinical pregnancy rates
223714429|NCT05276531|DRUG|vaginal progesterone|clinical pregnancy rates
223714430|NCT03471520|BEHAVIORAL|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
223714431|NCT03727230|OTHER|Blood transfusion|Transfusion with RhD+ blood product rather than rare RhD-negative blood to Asian-type DEL recipients
223714432|NCT01373242|DRUG|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
223714433|NCT02699814|BEHAVIORAL|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
223714434|NCT02393183|DRUG|ASTED|A tablet of ASTED will be taken twice a day
223714435|NCT02393183|DIETARY_SUPPLEMENT|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
223714436|NCT02393183|OTHER|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
223714437|NCT05876975|PROCEDURE|laparoscopic pectopexy|Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
223714438|NCT01186965|BEHAVIORAL|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
223714439|NCT02616081|OTHER|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
223714440|NCT02616081|OTHER|Indwelling Catheter|Indwelling catheterization is a standard of care.
223714441|NCT02616081|OTHER|Surgery|Bladder surgery is a standard of care.
223714442|NCT02616081|OTHER|Voiding|Voiding spontaneously is a standard of care.
223714443|NCT06643286|DEVICE|Digizorg Melanoma app|The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.
223714444|NCT04377620|DRUG|Placebo|Placebo administered BID approximately 12 hours apart
223714445|NCT04377620|DRUG|Ruxolitinib|Ruxolitinb administered BID approximately 12 hours apart
223714446|NCT02966262|DEVICE|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
223719148|NCT06243991|DIAGNOSTIC_TEST|Ocular Surface Disease Index Qestionnaire|The Ocular surface disease index (OSDI) questionnaire consists of a total of 12 questions categorized into three subscales as follows: ocular symptoms, vision-related function, and environmental triggers. Each patient is asked to rate the symptoms on a 5-point scale ranging from never (0 score) to always (4 score) for every question in the questionnaire. The fourth and fifth questions in the first section, concerning blurred vision and reduced vision symptoms, were excluded from the questionnaire as these symptoms may already be present in patients with keratoconus disease. The total OSDI score was calculated according to the formula: OSDI = \[(sum of scores for all questions answered) × 100\] / \[(total number of questions answered) × 4\].
224276708|NCT05338853|OTHER|Gongs mobilization|to deal adhesive capsulitis
224276709|NCT05338853|OTHER|scapular mobilization|scapular mobilization
224276710|NCT01927991|BEHAVIORAL|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
224276711|NCT06678230|DRUG|Anlotinib|Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.
223714447|NCT05199181|PROCEDURE|Full pulpotomy|After applying the rubber dam. Caries, and weak tissues were removed, and the endodontic access was prepared with a carbide bur. Most of the pulp was removed with a sterile high-speed diamond bur under sterile saline solution irrigation and amputated to the canal orifices level. Hemostasis was achieved by irrigation of the cavity with the same solution and an application of small cotton pellets for max.10 min. White Mineral Trioxide Aggregate was mixed according to the manufacturer´s instructions and was placed against the wound after successful hemostasis using an amalgam carrier and packed using an amalgam standard condenser. The material was adapted and a moistened cotton pellet was placed directly over the Mineral Trioxide Aggregate. After 15 minutes, the cotton was removed and the tooth was restored with amalgam. A postoperative radiograph was taken after restoration, general care instructions were given to the patients, and the recommendation of three analgesic intakes.
223714448|NCT00199680|PROCEDURE|PET|
223714449|NCT01236482|DRUG|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
223714450|NCT03452423|PROCEDURE|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
223714451|NCT03692247|OTHER|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
223714452|NCT03738683|DRUG|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
223714453|NCT04571879|DRUG|Nebulized Lidocaine|Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
223714454|NCT04571879|DRUG|Intranasal Midazolam|Intranasal Midazolam for reducing anxiety of Nasogastric Tube insertion
223714455|NCT04571879|OTHER|Placebo|Nebulized normal saline and intranasal normal sline
223714456|NCT03367221|DEVICE|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
223714457|NCT01439269|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
223714458|NCT05069532|RADIATION|MSCT chest|CORAD 4-5 MSCT chest
223714459|NCT05069532|DIAGNOSTIC_TEST|PCR|PCR positive for COVID-19
223714460|NCT03713359|BIOLOGICAL|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
223714461|NCT03713359|BIOLOGICAL|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
223714462|NCT02849678|DRUG|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
223714463|NCT02849678|DRUG|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
223714464|NCT03129165|OTHER|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
223714465|NCT06298591|PROCEDURE|co2 laser|laser
223714466|NCT00424983|DRUG|Zoledronic acid|
223714467|NCT03204903|PROCEDURE|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
223714468|NCT03204903|PROCEDURE|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
223714469|NCT00372762|DRUG|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
223714470|NCT00372762|DRUG|Bumetanide|Equivalent dose to pre-existing furosemide will be used
223714471|NCT00372762|DRUG|furosemide|20mg to 80mg orally once or twice daily
223714472|NCT00372762|DRUG|bumetanide|0.5mg to 2mg orally once or twice daily
223714473|NCT05042154|DEVICE|WatchPAT|The WatchPAT One can detect the presence of OSA based on measurement of peripheral arterial tone (PAT), pulse rate, oxygen saturation, actigraphy, snoring, and body position.
223898954|NCT05355766|DRUG|CN128 Tablets|Iron chelator, oral tablets
224276712|NCT04390230|PROCEDURE|Penile prostheses implantation|Penial implantation with either Coloplast or Boston Scientific - AMS IPPs between 2014 and 2019, by 2 surgeons of the University Hospital of Nice, France
224276713|NCT01459757|OTHER|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
224276714|NCT03656263|DIAGNOSTIC_TEST|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
224276715|NCT02252445|DRUG|Propofol|Propofol will be administered.
223714474|NCT04229420|DEVICE|Ultrasound guided Rectus sheath block vs Erector spinae plane block|Ultrasound guided Rectus sheath block vs Erector spinae plane block
223714475|NCT04784377|OTHER|high intensity laser in addition to traditional physical therapy exercises|"high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
223714476|NCT04784377|OTHER|low level laser in addition to traditional physical therapy exercises|"patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles."
223714477|NCT04784377|OTHER|traditional physical therapy exercises|Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
223714478|NCT06450821|PROCEDURE|PRIOR [Proactive Intensive Oral Review & Treatment]|Intervention Arm: Professional Oral Health Care (POHC) referred to as PRIOR \[Proactive Intensive Oral Review \& Treatment\] prior to chemotherapy.
223714479|NCT00420693|DRUG|sevoflurane|
223714480|NCT03859778|OTHER|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
223714481|NCT05289791|OTHER|ultrasonic activation of bioceramic sealer|activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
223714482|NCT01830478|DRUG|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
223714483|NCT01830478|DRUG|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
223714484|NCT03333447|OTHER|MRI|
223714485|NCT02497339|BEHAVIORAL|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
223714486|NCT02144623|DRUG|Valproate|
223714487|NCT05473390|OTHER|functional electrical stimulation|functional electrical stimulation on back muscles
223714488|NCT05473390|OTHER|kinesotaping|no intervention
223714489|NCT00289991|DRUG|Itraconazole|Prophylaxis
223714490|NCT00289991|DRUG|Vfend - voriconazole|Prophylaxis
223714491|NCT05969145|PROCEDURE|application of thermophor|The experimental group will be given hot and cold application to the bladder
223714492|NCT02607150|OTHER|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
223714493|NCT02814578|OTHER|Optical coherent tomography|comparative method for BVS
223714494|NCT02814578|OTHER|IntraVascular UltraSound|The method of goldstandard for decision stent choice
223714495|NCT05373745|BEHAVIORAL|Active Brains 1|Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
223714496|NCT05373745|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity."
223714497|NCT04159571|DEVICE|Real TBS to the vmPFC|This will be delivered with the Magventure Magpro system; active sham coil (double blinded)
223714498|NCT04159571|DEVICE|Sham cTBS to the vmPFC|The MagVenture MagPro system has an integrated active sham that uses two surface electrodes placed on the skin beneath the coil.
223714499|NCT03118635|BEHAVIORAL|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
223714500|NCT00839891|DRUG|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
223714501|NCT01776112|OTHER|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
224276716|NCT02252445|DRUG|Sevoflurane|Sevoflurane will be administered.
224276717|NCT00329160|DRUG|Rosuvastatin|2.5-20 mg
224276718|NCT00329160|DRUG|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
224276719|NCT04459676|DRUG|Standard of Care (SOC) + ANG-3777|Standard of Care (SOC) + ANG-3777
224276720|NCT04459676|DRUG|Standard Of Care (SOC) + Placebo|Standard Of Care + Placebo
224276721|NCT00458289|DRUG|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
224276722|NCT00485004|DEVICE|Cutting balloon|Cutting balloon
224276723|NCT00485004|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent
224083417|NCT00786045|OTHER|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
224276724|NCT05810857|DIAGNOSTIC_TEST|Motor Relearning Program|patients will receive Motor Relearning Program including static and dynamic sitting and standing balance while static sitting balance
224276725|NCT05810857|DIAGNOSTIC_TEST|Mirror Therapy|"Mirror Therapy protocol. The baseline treatment will be weight bearing in standing which is extension of knee and weight bearing in standing on inclined"
223714502|NCT01776112|OTHER|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
223714503|NCT01606007|DRUG|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
223714504|NCT01606007|DRUG|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
223714505|NCT01606007|DRUG|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
223714506|NCT01606007|DRUG|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
223714507|NCT01606007|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
223714508|NCT02207296|DEVICE|Plethysmographic variability index|
223714509|NCT02324296|DRUG|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
223714510|NCT02667054|DRUG|RX0041 4%|Anesthetic
223714511|NCT02667054|DRUG|Placebo|Placebo Comparator
223714512|NCT02667054|DRUG|RX0041 8%|Anesthetic
223714513|NCT05528354|DRUG|VEN and DEC based conditioning regimen|"Patients with age\<50 years and HCT-CI\<3:~Haploidentical transplantation: AraC 2g/m2 d-10\~d-9, BU 0.8mg/kg q6h d-8\~-6, CTX 1.8g/m2 d-5\~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5\~-2, VEN 400mg/d d-15\~-9, DEC 20mg/m2 d-15\~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7\~-4, CTX 60mg/kg d-3\~d-2, Meccnu 250mg/m2 d-1, VEN d-12\~-8, DEC 20mg/m2 d-12\~-6, and ATG for the unrelated donor type.~Patients with age\>50 years or HCT-CI≥3:~Flu 30mg/m2 d-10\~-5, BU 0.8mg/kg q6h d-7\~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4\~-1, VEN d-15\~-9, DEC 20mg/m2 d-15\~-11.~Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days."
223714514|NCT05528354|DRUG|DEC|"In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed."
223714515|NCT04466735|DIETARY_SUPPLEMENT|Active group|2 x 12 g of EKS/day
223714516|NCT04466735|DIETARY_SUPPLEMENT|Placebo group|Isocaloric placebo supplement with similar salt load but no EKS
223714517|NCT01355757|DEVICE|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
223714518|NCT01355757|DRUG|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
223714519|NCT04289675|DRUG|Interferon-Beta|Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.
223714520|NCT01796561|DIETARY_SUPPLEMENT|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
223714521|NCT03706079|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223714522|NCT03706079|OTHER|Placebo|Placebo subcutaneous injection
223714523|NCT00986557|BIOLOGICAL|adoptive immunotherapy|
223714524|NCT00986557|BIOLOGICAL|alemtuzumab|
223714525|NCT00986557|BIOLOGICAL|in vitro-treated peripheral blood lymphocyte therapy|
223714526|NCT00986557|DRUG|foscarnet sodium|
223714527|NCT00986557|DRUG|ganciclovir|
223714528|NCT00986557|GENETIC|polymerase chain reaction|
223714529|NCT00986557|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223714530|NCT00986557|PROCEDURE|infection prophylaxis and management|
223714531|NCT00986557|PROCEDURE|peripheral blood stem cell transplantation|
223714532|NCT00986557|PROCEDURE|standard follow-up care|
223714533|NCT00986557|RADIATION|radiation therapy|
223714534|NCT01941875|DRUG|Progesterone Effervescent Vaginal Tablets|Experimental
223714535|NCT03839901|OTHER|Home exercise program|Home exercise programme with participants followed up at week 1, 4, 6 and 8.
223714536|NCT04068714|PROCEDURE|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
223714537|NCT00647881|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
223714538|NCT00647881|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fed
223714539|NCT01346228|BEHAVIORAL|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
223714540|NCT05710861|DEVICE|F-HIFU|A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
223714541|NCT05710861|PROCEDURE|Radical Prostatectomy|A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
223714542|NCT05743582|PROCEDURE|Bronchoscopy for sample collection|Participants will undergo a single bronchoscopy and bronchoalveolar lavage to obtain immune cells.
223714543|NCT05743582|PROCEDURE|Blood donation|Participants will donate a single blood sample for isolation of immune cells from peripheral blood.
223714544|NCT05817461|DRUG|AZD0780 tablet|oral, fasted
223898955|NCT03616496|DRUG|Neuraceq PET/CT imaging|PET/CT with Neuraceq injection, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm (if the exams are present in the patient's medical record and are less than 3 months old, they do not need to be repeated
223898956|NCT06513832|BEHAVIORAL|The asthma navigator|The asthma navigator is a Registered Respiratory Therapist and Certified Asthma Educator who will review the care plan at discharge and provide asthma education; assist with follow-up clinic appointment scheduling, medication access, and transportation; and daily as-needed telephone support.
223898957|NCT03340129|DRUG|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
223898958|NCT03340129|DRUG|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks.
223898959|NCT03340129|RADIATION|Stereotactic Radiotherapy|The first dose of immunotherapy Must be given prior to the start of radiotherapy. One fraction at between 16 to 22 Gy or 24 to 30 Gy hypofractionated for larger lesions.
223898960|NCT03340129|OTHER|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
223898961|NCT05988255|DEVICE|Static progressive stretching|A stretching technique applies a mechanical progressive stretch
223898962|NCT05988255|OTHER|Cyclic manual stretching|A stretching technique applies an intermittent manual stretch
223898963|NCT05643846|PROCEDURE|QLB procedure after cesarean section|Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
223898964|NCT05359081|DRUG|SEP-363856|SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks
223898965|NCT04141956|OTHER|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
223898966|NCT04316013|DRUG|Sevoflurane|Inhaled anaesthetic used for maintenance of anaesthesia, dosed as per standard practice
223898967|NCT04316013|DRUG|Propofol|Intravenous anaesthetic used for induction and maintenance of anaesthesia
223898968|NCT04316013|DRUG|Lidocaine IV|1.5mg/kg loading dose over 20 minutes, followed by an infusion of 2mg/kg/hr up to 4 hours and 1.5mg/kg/hour thereafter. Bolus and maintenance dosages of lidocaine will be per actual body weight and capped at a maximum of 100 kg.
223898969|NCT04710498|DRUG|Atezolizumab|Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
223898970|NCT04363606|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
223898971|NCT04363606|BIOLOGICAL|blood test|complete blood count and cytokine concentration, TNF-alpha, LDL oxidized, AOPP, SOD, GPX, catalase, albumin, transthyretin, RBP, transferin, α-1 glycoprotein acide, ferritine, selenium, zinc, magnesium
223898972|NCT04363606|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
223898973|NCT04363606|DEVICE|actigraphy|assessment of sleep quality
223898974|NCT04363606|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging"
223898975|NCT04363606|OTHER|stool analysis|analyze the composition of the intestinal microbiote. concerns only the patients of Saint Etienne
223898976|NCT04363606|OTHER|food diary|3 days of information to determine nutrient intakes. concerns only the patients of Saint Etienne
223898977|NCT06074055|OTHER|FET Protocol|Participants are randomized to either another programmed FET Protocol vs. a modified natural FET protocol
223898978|NCT03287453|OTHER|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
224083418|NCT05274230|DEVICE|Apollo Wearable|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear everyday. They will be asked to continue to wear the device until all study data is collected.
223898979|NCT03287453|OTHER|Survey Administration|Ancillary studies
223898980|NCT02610361|DRUG|BGB-283|"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
223898981|NCT04082689|BEHAVIORAL|Assisted Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The infant is held squatting over a potty or basin, while older children sit on the potty."
223898982|NCT03977662|COMBINATION_PRODUCT|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
223898983|NCT06029062|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
224083419|NCT02295722|DRUG|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
224083420|NCT02295722|DRUG|Melphalan|200 mg/m2
224083421|NCT02295722|OTHER|ASCT|Day 0 - Stem cell infusion
224276726|NCT04501094|DRUG|Bintrafusp alfa (M7824)|1200 mg administered intravenous (IV) every two weeks
224276727|NCT00164372|BEHAVIORAL|Peer Education Intervention|
223898984|NCT06029062|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
223898985|NCT06029062|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
223898986|NCT04039347|DRUG|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
224083422|NCT00805896|DRUG|Songyou|4g/pack
224083423|NCT00805896|DRUG|placebo|4g/pack
223898987|NCT04039347|DRUG|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
223898988|NCT06004388|DEVICE|Click Digital Therapeutic|Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
223898989|NCT05045430|DEVICE|Silver II Non-Woven Dressing|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection."
223898990|NCT05890976|DRUG|Semaglutide|Participants will receive semaglutide tablets orally once daily for 44 weeks.
223898991|NCT05890976|DRUG|Semaglutide Placebo|Participants will receive placebo matched to semaglutide.
223898992|NCT05885880|OTHER|Blue-button screening|Patients will be screened for clinical trial matches using the Blue-button tool
223898993|NCT04531280|OTHER|Home hospital care|Patients receive hospital-level care in their home.
223898994|NCT06402929|BEHAVIORAL|Honest Open Proud - College (HOP-C)|"The program consists of three weekly workshops that are two hours in duration. There is a fourth booster workshop (two hours in duration) one month following program completion. All workshops will be held over an online videoconferencing platform.~HOP-C is a group program led by trained peer facilitators who have lived mental illness experience. Major topics that the program covers are:~1. discussing different types of disclosure;~2. conducting a cost-benefit analysis of disclosing in different situations;~3. strategies to anticipate how certain people will respond to disclosure when deciding on who to disclose to;~4. disclosure via social media; and~5. a guided creation of participants' own disclosure narrative.~During the booster workshop, participants will be encouraged to reflect on their disclosure decisions, and periodically revisit their disclosure cost-benefit analysis in deciding if and when to disclose in the future."
223898995|NCT06426381|BEHAVIORAL|Therapeutic Touch|Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
223898996|NCT06306586|BEHAVIORAL|Digital Treatment for Adolescents With Eating Disorders|"The main aim of the digital treatment is to reduce symptoms of eating disorders and increase life-coping skills. The digital treatment aims to help adolescents with eating disorders to:~* Gain knowledge about the symptoms of eating disorders and the consequences it has on everyday life.~* Be motivated to carry out the treatment.~* Gain knowledge of and skills in regulating food and activity in a more balanced way.~* Gain knowledge of and skills in managing emotions.~* Get tools to develop a better self-esteem.~* Gain awareness of the function of the eating disorder.~* Gain skills in coping with social challenges.~* Get a more realistic image of their bodies and handle information from social media."
223898997|NCT04696042|DRUG|Lanreotide autogel|Lanreotide autogel 90-120 mcg, every 4 weeks
223898998|NCT05329090|DRUG|Rituximab Injection|anti-CD20 monoclonal antibody leading to B-cell depletion, in relapsing and/or refractory IgAV patients
223898999|NCT05329090|DRUG|placebo|placebo experimental treatment
223899000|NCT02815696|DEVICE|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
223899001|NCT03991130|DRUG|IL-2 and Nivolumab|Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
223899002|NCT06344143|DIAGNOSTIC_TEST|Various labs and imaging tests|Dexamethasone Suppression Test, Adrenocorticotropic Hormone (ACTH), Salivary Cortisol Levels, Vasopressin Stimulation test, Fasting Glucose, Fasting Insulin, Complete Metabolic Panel (CMP), Gamma-glutamyl transferase (GGT), Sex Hormone Binding Globulin, Cat scan of abdomen/Pelvis, Whole body dual energy x-ray absorptiometry (DXA) scan, Ultrasound Fibroscan Transient Elastography
223899003|NCT06256432|DRUG|Ambrisentan|Endothelin receptor antagonist
223899004|NCT06256432|DRUG|Terlipressin|Terlipressin
223899005|NCT06411756|BEHAVIORAL|Narrative videos|Culturally targeted narrative videos will be sent via email.
223899006|NCT06411756|BEHAVIORAL|A Fitbit activity tracker|A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.
223899007|NCT06411756|OTHER|Daily text message|A daily adaptive step goal that will be sent via text message with a short positive message.
223899008|NCT06411756|OTHER|Monthly Zoom meeting|Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.
223899009|NCT06411756|OTHER|Website access|Access to Physical Activity Centers Empowerment (PACE) website.
223899010|NCT06411756|OTHER|Printed materials|"Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign."
223899011|NCT06411756|BEHAVIORAL|Printed materials|"Printed materials from the American College of Sports Medicine's Moving through Cancer campaign."
224083424|NCT02251912|DRUG|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
223714545|NCT05817461|DRUG|[14C]AZD0780 Solution for Infusion|intravenous
224083425|NCT02251912|DRUG|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
223714546|NCT05817461|DRUG|[14C]AZD0780 Oral Solution|oral, fasted
223899012|NCT05332522|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
223899013|NCT05319639|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
223899014|NCT05319639|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
223899015|NCT05319639|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
223899016|NCT05319639|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
223899017|NCT05319639|DRUG|Irinotecan|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
223528613|NCT01598155|PROCEDURE|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~* Scaling, planning and polishing of coronary surface;~* Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~* Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
223528614|NCT02384421|DEVICE|Adaptive DBS (Activa PC+S Neurostimulator)|
223899018|NCT05319639|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
223899019|NCT05745246|BEHAVIORAL|e-health training program|"1. Health letters, 44 issues of 90SecondFire Cancer health letters delivered twice a week during six months to firefighters by text or email~2. A problem-solving asynchronous chat room which encourages mutual support and exchange of ideas via a closed asynchronous bulletin board for peer-to-peer support~3. A brief 45-minute pre-recorded online course; it is intended as a summative exercise rather than providing new information."
223899020|NCT06158724|OTHER|Personal Protective Equipment|Simplified PPE for use in COVID-19 departments.
223899021|NCT05246280|DRUG|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
223899022|NCT06412055|DEVICE|NEURO SWING AFO (Fior& Gentz, Lüneburg, Germany)|stiffness-optimized custom-made spring-hinged AFO with the NEURO SWING® system ankle joint build in
223899023|NCT06412055|DEVICE|WalkOn Reaction® (Ottobock, Duderstadt)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (2.8 Nm/degree).
223899024|NCT06412055|DEVICE|Matrix Max2® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (1.4 Nm/degree)
223899025|NCT06412055|DEVICE|Matrix® (TruLife, Dublin, Ireland)|comparator: prefab spring-like AFO without hinge with a predefined stiffness (0.6 Nm/degree)
223899026|NCT06549608|DRUG|Mavacamten|As per product label
223899027|NCT01909245|BIOLOGICAL|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
223899028|NCT01909245|DRUG|Immunosuppressive Agents|Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
223899029|NCT01909245|DRUG|Gastrin 17|Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
223899030|NCT04322279|DIAGNOSTIC_TEST|Serology|SARS-CoV-2 serology
223899031|NCT04322279|GENETIC|Sequencing|Whole exome sequencing
224083426|NCT04333082|OTHER|Data collection|"collection of patient data~Data collection (demographics, prehospital management, duration of ICU and hospital stay, destination at discharge, date(s) of seizure(s), electroencephalographic (EEG) data, seizure history and etiology, number and duration of SE episodes, medication, types of SE according to the current guidelines from the International League of Epilepsy (ILAE), neuroimaging features, comorbidities, laboratory parameters, complications during and after SE , laboratory testing, vital signs, fluid balance) will be performed from the digital medical records, the electroencephalographic and microbiologic database of patients"
224083427|NCT04171739|DRUG|Itraconazole oral solution|200 mg once daily on Days 6 to 15
224083428|NCT04171739|DRUG|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
223528615|NCT02384421|DEVICE|Continuous DBS (Activa PC+S Neurostimulator)|
223528616|NCT02398214|BEHAVIORAL|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to \< 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
223528617|NCT02146157|DIETARY_SUPPLEMENT|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
224083429|NCT04171739|DRUG|Olorofim|Single oral dose on Days 1 and 11
224083430|NCT00501267|DRUG|solabegron and oxybutynin|
223528618|NCT02146157|DIETARY_SUPPLEMENT|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
224083431|NCT01818726|DRUG|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
224083432|NCT01818726|DRUG|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
224083433|NCT01818726|DRUG|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
224083434|NCT00199979|DRUG|Nevirapine|
224083435|NCT03798288|BEHAVIORAL|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
224083436|NCT03798288|OTHER|Usual care|Participants will receive usual care
224083437|NCT04326634|OTHER|controlled exercises|controlled exercises
224276728|NCT04601350|DRUG|remimazolam group was induced with remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia|remimazolam group was remimazolam 0.1 mg/kg followed by a maintenance dose of 0.1 mg·kg-1·h-1 for general anesthesia
224083438|NCT04326634|OTHER|non controlled exercises group|non controlled exercises
223528619|NCT02264314|BEHAVIORAL|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
224083439|NCT03336502|DRUG|Posaconazole|Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
224083440|NCT02249702|DRUG|gemcitabine + docetaxel|
224083441|NCT02249702|DRUG|trabectedin|
224083442|NCT03594968|DIAGNOSTIC_TEST|polycystic ovary syndrome|3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
223528620|NCT02264314|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
223528621|NCT02071615|DRUG|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
223528622|NCT02071615|DRUG|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
223528623|NCT02071615|DRUG|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
223528624|NCT02071615|DRUG|placebo|
223528625|NCT04485702|DRUG|Midazolam injection|2mg IV
223528626|NCT04485702|DRUG|Ketamine Injectable Product|6mg IV
223528627|NCT04485702|DRUG|MELT-100|midazolam 3mg and ketamine 25mg SL tablet
223528628|NCT00998010|DRUG|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
223528629|NCT03274765|DIAGNOSTIC_TEST|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
223528630|NCT04259593|OTHER|exercise training|
223528631|NCT00529048|OTHER|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
223528632|NCT00529048|OTHER|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
223528633|NCT00529048|OTHER|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
223528634|NCT04679454|RADIATION|Phase I|To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
223528635|NCT04679454|RADIATION|Phase II|The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
223528636|NCT01486303|PROCEDURE|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
223528637|NCT04128748|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223528638|NCT04128748|DRUG|Quizartinib|Given PO
223528639|NCT04306926|DRUG|TQB2450|TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
223528640|NCT04306926|RADIATION|SBRT|Give according to the location of the lesion and clinical condition.
223528641|NCT06197243|OTHER|Acupuncture|Patients will receive acupuncture for 12 weeks.
223528642|NCT06197243|OTHER|Yoga|Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.
223528643|NCT06197243|OTHER|Deprescribing|Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.
223528644|NCT06353906|DRUG|Carboplatin/Paclitaxel|Induction: three cycles of intravenous carboplatin AUC5 (max 750 mg) and paclitaxel 175 mg/m2, during cycle 1, 2 and 3 (day 1, 22, 43)
223528645|NCT06353906|DRUG|Pembrolizumab|"Induction: two cycles of intravenous pembrolizumab 400 mg during cycle 1 and 3 (day 1 and 43)~Adjuvant: up to seven cycles of fixed-dose intravenous pembrolizumab 400 mg, on day 1 every 6 weeks within 3-9 weeks after surgery"
223528646|NCT06353906|PROCEDURE|Partial or total penectomy with inguinal and/or pelvic lymph node dissection|Resection of part or all of the penis with complete removal of suspect lymphnodes in the inguinal and/or pelvic area
223528647|NCT05490225|DEVICE|VenaSure|The device will be surgically implanted at the access site in subjects undergoing routine hemodialysis. The device is expected to provide a target to aid in long-term cannulation success.
223528648|NCT05438927|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
223528649|NCT05438927|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, biweekly nutrition counseling from a dietician via telehealth
223528650|NCT05438927|BEHAVIORAL|Fact G Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
223528651|NCT05438927|BEHAVIORAL|General Anxiety Disorder (GAD)-7|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants anxiety with a scale of 0=not at all, 3=Nearly everyday.
223528652|NCT05438927|BEHAVIORAL|Patient Health Questionnaire (PHQ)-9|Participants will take a survey at baseline and weeks 4,8,12 \& 16. The questionnaire measures participants depression with a scale of 0=not at all, 3=Nearly everyday.
223899032|NCT05967195|BEHAVIORAL|Financial Incentive and Text-Messages|"Patient-participants will receive modest financial incentive for attending therapy or medication management appointments combined with text messages to encourage attendance at these appointments. Text messages will be informed by principles of behavioral economics. Maximum incentive = $50/month if all appointments attended. Incentives will be pro-rated by percentage of appointments attended. Pro-rating strategies (e.g., uniform amount per appointment, escalating \[aka, 'back-loaded'\], or decreasing \[aka 'frontloaded'\] will be sequentially changed based on acceptability and other intervention-related data gathered from participants during the trial.~Clinician-participants will not receive any intervention, but will receive surveys and interviews to assess their perceptions about the optimization, acceptability, scalability, and other implementation barriers/facilitators for the intervention."
223899033|NCT06318117|OTHER|Rice infant formula|Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.
223899034|NCT05432427|RADIATION|64Cu-DOTATATE and 18F-FDG|All participants will get a 64Cu-DOTATATE-PET and 18F-FDG-PET/CT.
223899035|NCT06434480|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given.~* For extrahepatic progression: an aim to give ablative dose will be given."
223899036|NCT04599062|DRUG|Talimogene Laherparepvec|Talimogene Laherparepvec
223899037|NCT04599062|RADIATION|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
223899038|NCT04441034|DRUG|Anti-convulsant medications|Anti-convulsants are very commonly used to treat patients with chronic pain.
223899039|NCT04441034|DRUG|Anti-depressant medications|Anti-depressants are very commonly used to treat patients with chronic pain.
223899040|NCT04527315|OTHER|Questionnaires|Various questionnaires will be used to assess short and long-term impacts of depression, anxiety, and other indicators of overall mental health and quality of life
223899041|NCT03374787|DEVICE|Fusion Sound Processor|Sound Processor
223899042|NCT06376734|DEVICE|Transcranial magnetic stimulation|Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
223899043|NCT04074759|BIOLOGICAL|FPT155|A soluble CD80 fusion protein
223899044|NCT04074759|BIOLOGICAL|pembrolizumab|An anti-PD1 antibody
223899045|NCT04230265|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion over 3 days
223899046|NCT04230265|DRUG|Fludarabine (Non-IMP)|Intravenous infusion over 3 days
223899047|NCT04230265|DRUG|TM123 (IMP)|Intravenous Infusion for 20 days
223899048|NCT04230265|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
223899049|NCT06049329|DRUG|NNC0487-0111|Participants will get one tablet to swallow at the same time of the day.
223899050|NCT06049329|DRUG|Placebo (NNC0487-0111)|Participants will get one tablet to swallow at the same time of the day.
223899051|NCT03521830|DRUG|Nivolumab|480mg IV every 4 weeks
223899052|NCT03521830|DRUG|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
223899053|NCT03521830|DRUG|Relatlimab|480 mg IV q4wks
223899054|NCT06036836|BIOLOGICAL|favezelimab/pembrolizumab|IV infusion
223899055|NCT06036836|BIOLOGICAL|pembrolizumab|IV infusion
223899056|NCT06036836|DRUG|lenvatinib|Oral administration of capsule
223899057|NCT03097536|OTHER|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
223899058|NCT03360591|DEVICE|Physiologically-guided strategy|"The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy"
224083443|NCT04673097|OTHER|Icon® resin infiltration|low viscosity resin that can flow through the pores in the enamel surface
224083444|NCT04673097|OTHER|MI paste plus|s a superior form of fluoride ions as it also contains CPP-ACP, enhances mineral release without encouraging the formation of calculus.
223528653|NCT05700643|DIETARY_SUPPLEMENT|Montmorency cherry supplement|Montmorency cherry supplement
223899059|NCT05746299|BEHAVIORAL|Congruent vs. Incongruent|The Congruent vs. Incongruent intervention relates to the feature-based structure of the novel categories (Modular or non-Modular) and whether there is (Congruent) or is not (Incongruent) a match between what was previously learned and the final target category.
223899060|NCT05746299|BEHAVIORAL|Immediate vs. Awake vs. Asleep|Immediate, Awake, and Sleep refer to either no break, 2.5 hours awake, or 2 hours asleep plus a 30-minute post-nap break to account for sleep inertia between learning and target category.
223899061|NCT05746299|BEHAVIORAL|Targeted memory reactivation (TMR)|Targeted memory reactivation (TMR) is the systematic presentation of sounds during sleep that were associated with certain stimuli during learning and will be administered either during slow wave sleep (SWS) or rapid eye movement (REM) sleep.
223899062|NCT05086250|DRUG|Ketamine|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
223899063|NCT05086250|DRUG|Placebo|Weekly oral administration of 0.5mg/kg ketamine for 4 weeks, followed by weekly oral administration of placebo for 4 weeks (separated by a washout period of 2 weeks).
223899064|NCT05086250|DRUG|Placebo|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
223899065|NCT05086250|DRUG|Ketamine|Weekly oral administration of placebo for 4 weeks, followed by weekly oral administration of 0.5mg/kg ketamine for 4 weeks (separated by a washout period of 2 weeks).
224083445|NCT04959357|DIAGNOSTIC_TEST|Two dimensional speckle tracking imaging|lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging
223899066|NCT04786067|DRUG|Belatacept|Patients will have tapering of their multi-drug immunosuppression, until Belatacept is the sole medication in their immunosuppression regimen. Belatacept will be administered as an infusion, as is routinely done clinically.
223899067|NCT04392193|RADIATION|Proton Particle Therapy|Proton therapy will be delivered in a single fraction using the Probeat-V system
223899068|NCT06314724|BIOLOGICAL|Varicella Vaccine|lyophilized powder,subcutaneous injection
223899069|NCT06314724|BIOLOGICAL|Varivax|lyophilized powder,subcutaneous injection
223899070|NCT06332469|BEHAVIORAL|Internet based education and support program for patients awaiting kidney transplantation|"A guided internet based support an education program consisting of 9 modules running over 9 weeks. First, an introductory module is given that involves goal setting, followed by two educational modules with information regarding kidney disease, treatment and self-care in severe renal failure and while waiting for kidney transplantation, and kidney transplant-specific areas. Supportive content consist of three behavioral components spread over five modules/weeks and are based on cognitive behavioural therapy principles. The last module is a summation focusing on consolidating the knowledge learned during the program.~Each module consists of texts, illustrations, short films, reminders to practice physical activity and weekly homework for which the participants receive feedback from a contact person."
223899071|NCT05440630|DIETARY_SUPPLEMENT|Probiotics|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria) for 16 weeks.
223899072|NCT05440630|DIETARY_SUPPLEMENT|Postbiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain postbiotic (Heat treated bacteria) for 16 weeks.
223899073|NCT05440630|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for 16 weeks.
223899074|NCT05017766|OTHER|analysis of antimicrobial resistance|"In samples from patients infected with one of the focus pathogens (E. coli, Klebsiella species, S. aureus, P. aeruginosa) will be:~(i) isolated and pathogenic bacteria characterized; (ii) pathogen in-situ properties at single-cell and bulk average determined; (iii) human metabolites, proteins and cells determined (iv) antibiotic concentration determined (v) bacterial growth monitored~Deducted from the data will be:~1. relevant human components and pathogen properties that are common to most patients with similar indication~2. underlying regulatory networks and triggers in pathogen cells and human tissues.~Clinical outcomes (survival/mortality) and treatment response (response or failure) will be correlated to the in vitro retrieved host and bacterial data."
223899075|NCT03267758|DIETARY_SUPPLEMENT|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.
223899076|NCT03267758|DIETARY_SUPPLEMENT|Placebo first|Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
223899077|NCT03852472|DRUG|Avacopan|Active treatment
223899078|NCT03852472|OTHER|Placebo|Placebo
223899079|NCT06104839|DRUG|NXC736|oral administration
223899080|NCT06104839|DRUG|Placebo|oral administration
223899081|NCT04029337|DEVICE|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
223899082|NCT05627167|OTHER|day time cyclic nutrition|Continuous isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100 mL for 10 hours during the day (e.g. 08:00 to 18:00), via nasal or oro-gastric tube
223899083|NCT05627167|OTHER|continuous nutrition|Isocaloric enteral feeding (1kcal/ml) with 4g of protein per 100ml, continuously 24 hours a day by nasal or oro-gastric tube
223899084|NCT06312436|PROCEDURE|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Temporary aortic occlusion can limit haemorrhage, can help to maintain perfusion to the heart and brain, and may be associated with improved survival.
223899085|NCT05849714|OTHER|Peri-intervention Diabetes Management Algorithm (DIAPI)|Patients and healthcare workers will apply DIAPI's orders.
223899086|NCT05849714|OTHER|Usual Care|Patients and healthcare workers will apply the mainstay management, which is using the treating-physician's recommendations instead of DIAPI's.
223899087|NCT06649552|DIAGNOSTIC_TEST|Psychiatric and psychological diagnostic tests|French validation of the SPI-CY
223899088|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status|In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
223899089|NCT06125860|DIETARY_SUPPLEMENT|Targeted BEP based on baseline nutritional status and monthly GWG monitoring|In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
223899090|NCT06125860|DIETARY_SUPPLEMENT|Universal BEP|In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
224083446|NCT04497519|DRUG|inhaled hydroxychloroquine|ascending dose of iHCQ
224083447|NCT03409874|OTHER|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
224083448|NCT03409874|OTHER|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
224083449|NCT03409874|OTHER|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
223899091|NCT04060082|OTHER|Telephone Interview|Participants will be asked to answer questions about their experiences with FTD.
223899092|NCT05533216|OTHER|Performance of different upper limb functional tests|The participants will have to perform 3 to 5 different upper libm functional tests, depends on the sport they practice.
223899093|NCT05022485|DEVICE|ZNN Bactiguard tibia|Tibia fracture fixation
223899094|NCT06457802|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention.
223899095|NCT06380114|BEHAVIORAL|Communication|Practice personnel (providers and nurses) receive training in communication about HPV vaccination via an online learning module.
224083450|NCT03409874|DRUG|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
223899096|NCT06380114|BEHAVIORAL|Standing Orders|Practice personnel (providers and nurses) receive training in the implementation of standing orders for HPV vaccination via an online learning module and meetings with the study team.
223899097|NCT03497962|PROCEDURE|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
223899098|NCT03497962|PROCEDURE|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
223899099|NCT03161028|DRUG|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
223899100|NCT03161028|DRUG|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
223899101|NCT06269549|OTHER|Non-training Real Dietary Supplement (G1)|One capsule of glucosamine three times daily, and one packet of hydrolyzed collagen.
223899102|NCT06269549|OTHER|Training Placebo Dietary Supplement (G2)|One capsule of placebo glucosamine three times daily, and one packet containing placebo collagen + physical exercise (60 minutes per session twice a week)
223899103|NCT06269549|OTHER|Training Real Dietary Supplement (G3)|One capsule of glucosamine three times daily, and one packet of hydrolyzed collagen + physical exercise (60 minutes per session twice a week)
223899104|NCT05146973|BIOLOGICAL|177Lu-DOTA-TLX591|TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
223899105|NCT03639701|DRUG|Thymidine|Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
223899106|NCT04797897|DEVICE|CORI|unicondylar knee arthroplasty (UKA) treated with CORI
223899107|NCT04797897|DEVICE|Conventional|unicondylar knee arthroplasty (UKA) treated with conventional approach with conventional manual instrumentation
223899108|NCT05700877|OTHER|CAC-based treatment strategy|The intervention is a combination of screening with a heart CT scan and multifactorial intervention based on the screening results. Participants randomized to CAC-based treatment and with screening results showing high risk of CVD, will receive a multifactorial intervention including the combination of two open label investigational medical products: dapagliflozin 10mg/day and semaglutide 0.25 /week or 0.5 /week or 1.0 /week.
223899109|NCT05700877|OTHER|Standard treatment|Participants randomized to standard treatment are recommended to follow updated guidelines for CVD prevention.
223899110|NCT06532487|OTHER|Critical Time Medical-Legal Partnership Intervention|Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
223899111|NCT05966870|OTHER|Unsweetened flavored sparkling water|Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
223899112|NCT06113289|DRUG|ASTX727|Given by PO
223899113|NCT06113289|DRUG|ASTX029-01|Given by PO
223899114|NCT06437574|DRUG|Vytorin|Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.
223899115|NCT06437574|DRUG|Ezetimibe|Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
223899116|NCT06823882|BEHAVIORAL|Floor-Rise Training|Practicing getting up from the floor using the Backward Chaining Method (BCM) for 20 minutes per week for 5 weeks
223899117|NCT06823882|BEHAVIORAL|Video Demonstration|Watching a 20-min video on floor-rise technique and over 5 weeks, with discussions. This video explains how to get up safely from the floor and how to practice.
223899118|NCT04224779|BIOLOGICAL|Biological collection|The biological collection will include samples of blood samples collected at different times but also tumoral biopsy before the surgery.
223899119|NCT06823219|OTHER|endurance training program|Groupe 2: 52 weeks of out-of-hospital physical activity Groupe 3: 8 weeks of in hospital endurance training 3/weeks and 44 weeks of out- of-hospital physical activity
223899120|NCT05093673|DEVICE|Cathodal Cerebellar tDCS|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. The stimulation will be delivered at an intensity of 2 mA for a maximum of 25 minutes.
223899121|NCT05093673|BEHAVIORAL|Semantic Feature Analysis (SFA)|Semantic Feature Analysis (SFA) is a treatment technique designed to improve lexical retrieval by increasing the level of activation within a semantic network. The treatment will proceed according to a series of steps including naming aloud the target picture, generating semantic features, naming aloud the target picture again, and generating a sentence using the target word.
224083451|NCT03409874|OTHER|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
224083452|NCT02431416|DRUG|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
223528654|NCT05700643|DIETARY_SUPPLEMENT|Control|Placebo
223899122|NCT05093673|DEVICE|Sham|2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
223899123|NCT05814666|DRUG|Danvatirsen|Danvatirsen is a STAT3 targeting drug.
223899124|NCT05814666|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2
224083453|NCT02431416|DRUG|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
224276729|NCT04601350|DRUG|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1|control group was induced with midazolam 0.05 mg/kg followed by normal saline maintenance of 0.1 ml·kg-1·h-1
223899125|NCT06821984|PROCEDURE|FGG secured using cyanoacrylate tissue adhesive without sutures.|The intervention involved securing the free gingival graft (FGG) using cyanoacrylate adhesive instead of conventional sutures. After harvesting the graft from the hard palate, hemostasis at the donor site was achieved with gauze compression. The recipient site was prepared with a partial-thickness dissection to ensure a stable graft bed. In the intervention group, cyanoacrylate adhesive was applied along the margins of the graft and underlying periosteal bed, ensuring complete coverage without the use of sutures. The adhesive polymerized within seconds, creating an immediate bond between the graft and recipient site, minimizing micro-movements and reducing the need for additional fixation.
223899126|NCT04438304|DRUG|64Cu-SARTATE|64Cu-SARTATE will be administered at a fixed administration dose, single bolus intravenous injection, peptide mass not exceeding 60µg.
223899127|NCT06823544|DRUG|Alvogyl|this is standard treatment drug
223899128|NCT06823544|DRUG|Eugenol|this not standard drug for the treatment of Alveolar Osteitis but an antiseptic agent
223899129|NCT06823544|DRUG|Nigella Sativa Oil|it not standard medicine for Alveolar Osteitis. it is a herbal medicine
223899130|NCT04990141|PROCEDURE|Peripheral blood collection in cases group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in cases group
223899131|NCT04990141|PROCEDURE|Peripheral blood collection in control group|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data compiled in control group
223899132|NCT06823232|DRUG|[14C]XY0206|On the morning of the day of medication (D1), the subject took \[14C\] XY0206 suspension orally on an empty stomach (containing approximately 37.5 mg/100 µ Ci \[14C\] XY0206).
223899133|NCT06366711|DEVICE|Pregnabit Pro device and PregnaOne platform|Remote CTG device for pregnancy care
223899134|NCT06366711|DRUG|Pulsenmore device|Remote ultrasound device for pregnancy care
223899135|NCT06244511|OTHER|Early Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the first four weeks.
223899136|NCT06244511|OTHER|Late Bipedal Exercise|Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the last four weeks.
223899137|NCT06377371|DIAGNOSTIC_TEST|Brain Imaging with [Cu64]DOTATATE|Patients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.
223899138|NCT06377371|PROCEDURE|Radio-guided Surgery With Neoprobe Utilization|After the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.
223899139|NCT04696289|DIAGNOSTIC_TEST|Standardized catheterization assessment|"There are four components to the pulmonary vein assessment.~1. Angiography: pulmonary artery wedge injection and/or selective pulmonary vein injection.~2. Intravascular ultrasound: manual pullback of IVUS catheter from lobar segment to left atrium.~3. Pressure assessment: pulmonary vein pressure (mmHg) measured before and after (if applicable) intervention.~4. Compliance testing: the compliance of the vein will be measured using a compliant conventional balloon."
223899140|NCT06600022|DRUG|SCTB41|SCTB41 of different doses,IV,every 3 weeks
223899141|NCT03868618|DEVICE|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
223899142|NCT06070870|BEHAVIORAL|Patient Navigation|"Navigation will address the following 4 domains of barriers to screening:~* Individual~* Organizational~* Economic~* Sociocultural At the first visit, navigators will assess the participant's barriers in each of these domains. Any follow-up visits, if necessary, will be used to help the participant overcome these barriers to screening"
223899143|NCT05955729|BEHAVIORAL|On-duty Nap|For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.
223899144|NCT05955729|BEHAVIORAL|Control condition (30-min rest)|For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.
223899145|NCT05955729|DEVICE|EndoPAT|"The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording."
223899146|NCT05955729|DEVICE|Popmeter®|The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.
223899147|NCT05955729|DEVICE|Panasonic EW3109|Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
223899148|NCT05955729|DEVICE|ECG Holter|The Holter takes an ECG during the subject's daily activities at home.
223899149|NCT05955729|BIOLOGICAL|Fasting blood sample|15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).
223899150|NCT05955729|OTHER|Pichot fatigue scale|The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.
223899151|NCT05955729|OTHER|French version of the Recovery Needs Scale (BRD)|BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.
223899152|NCT05955729|OTHER|The Short-Form 36 (SF-36)|The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
223899153|NCT05955729|OTHER|Pittsburgh Sleep Quality Index (PSQI)|24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality
223899154|NCT05955729|OTHER|Epworth questionnaire|8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness
223899155|NCT05955729|OTHER|The Karolinska Sleepiness Scale|The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated.
223899156|NCT05955729|DEVICE|Actimeter|An actimeter will be worn on the non-dominant wrist, uninterrupted day and night, for 7 consecutive days.
223899157|NCT05533918|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
223899158|NCT05533918|BEHAVIORAL|Patient Navigation (PN)|"Patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation, Request PN and No PN. Each person will be randomly assigned between the two types."
223899159|NCT06007352|DRUG|Gentamicin|Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
223899160|NCT06007352|OTHER|Placebo|3 L of NaCl irrigation typically used for ureteroscopy surgery
223899161|NCT06709963|DEVICE|ITBS|"We will use a coil called Cool-6000 A/P to conduct real and sham control. This coil will be placed on the scalp of older adults. The iTBS protocol will begin with a 2-s burst train (totally 30 pulses), repeating every 10 s. Each burst train will consist of 10 triplet pulses with an inter-burst interval of 0.16 s, thus the triplets fire at a rate of 5 Hz. ITBS parameters will include three continuous pulses at 50 Hz repeated at 5 Hz (2s on, 8s off) for a total of 600 pulses.~We will administer two rounds of iTBS per treatment day, with a 15-minute interval between the two sessions. In total, each participant will receive 1,200 stimuli during a single-session iTBS, totaling for 14 days. Each treatment session will last for about 30 minutes. Intermittent θ-burst stimulation intensity will be set at 70% of the resting motor threshold."
223899162|NCT05585814|DRUG|Capecitabine|Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 3 cycles
223899163|NCT05585814|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130mg / m2 on Day 1 every 3 weeks for 3cycles
223899164|NCT05585814|DRUG|Bevacizumab|Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 3 cycles
223899165|NCT05585814|DRUG|Pembrolizumab|Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
223899166|NCT06193577|DIETARY_SUPPLEMENT|Phaseolus Vulgaris L. Dry Extract|Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
223899167|NCT06193577|DIETARY_SUPPLEMENT|Placebo|The placebo control does not contain active ingredients.
223899168|NCT03024437|DRUG|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
223899169|NCT03024437|DRUG|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
223899170|NCT03024437|DRUG|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
223899171|NCT05681923|OTHER|Questionnaires|Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
223899172|NCT05681923|OTHER|Biospecimen collection|urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
223899173|NCT05681923|OTHER|Neurodevelopmental assessment visit|"High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals."
223899174|NCT05681923|OTHER|DNA collection|If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
223899175|NCT06207877|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
223899176|NCT06207877|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
223899177|NCT06207877|DRUG|Placebo|Placebo will be administered subcutaneously.
223899178|NCT06779058|DEVICE|MRE|All imaging studies were performed by using a 1.5T/3.0-T MRI system
223899179|NCT06779058|DEVICE|Liver biopsy|Liver biopsy are performed by well-trained pathologists in accordance with standard operating procedures.
223899180|NCT05969392|DEVICE|Intradiscal Gelified Ethanol (Discogel)|Intradiscal percutaneous injection of an intradiscal Gelified Ethanol
223899181|NCT06778915|PROCEDURE|surgery|surgery
223899182|NCT02601313|BIOLOGICAL|brexucabtagene autoleucel|A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
223899183|NCT02601313|DRUG|Cyclophosphamide|Administered intravenously
223899184|NCT02601313|DRUG|Fludarabine|Administered intravenously
223899185|NCT02601313|DRUG|Axicabtagene Ciloleucel|A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
223899186|NCT03967795|DRUG|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
223714547|NCT05375734|DRUG|Tislelizumab in combination with anlotinib|Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W
223714548|NCT00968513|BEHAVIORAL|Brief Intervention|(N=416) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
223714549|NCT00968513|BEHAVIORAL|Extended Treatment|(N=408) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
223714550|NCT00968513|BEHAVIORAL|Usual Care|(N=132) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
223714551|NCT05546333|DEVICE|Electrical impedance tomography|Non-invasive measure of electrical impedance in the body, with data collected on electrodes on the surface of the body
223714552|NCT06463613|DEVICE|STR Skin Tag Removal device with diary and follow-up|The Investigator will assign an STR version for use, stratifying the number of skin tags in each pool. The investigator will review the subject's skin tags and agree with the subject on the body location and skin tag that will be treated as well as whether the micro or standard size of the study device is appropriate. The Investigator will also verify that the skin tag does not present implications of cancerous tissue. After informed consent and reviewing device labeling, the subject will then have the band(s) placed on the skin tag(s) by the healthcare professional. Once the band has been placed, the Investigator will examine the skin tag, complete study documentation. The subject will then review trial diary instructions, including but not limited to the documentation of all observable characteristics regarding the banded skin tag(s). This diary is electronic (eDiary) and accessed through a secure website and must be fully completed to successfully finish the study.
223714553|NCT06803524|BIOLOGICAL|Pertagen® vaccine|Pertagen® vaccine, manufactured by BioNet-Asia Co., Ltd., Bangkok, Thailand. The vaccine is presented in pre-filled syringe, each containing one human dose (0.5 mL) of aP vaccine.
223714554|NCT06803524|BIOLOGICAL|Adacel® vaccine|Adacel® vaccine, manufactured by Sanofi Pasteur, Ltd, Toronto, Ontario, Canada. The vaccine is presented in a single-dose vial, each containing one human dose (0.5 mL) of Tdap vaccine.
223714555|NCT05774236|DEVICE|Cook´s balloon|Cervical ripening for induction of labor with a mechanical method (Cook´s balloon)
223714556|NCT05774236|DRUG|Vaginal dinoprostone|Cervical ripening for induction of labor with a pharmacological method (vaginal dinoprostone)
223714557|NCT06394310|DEVICE|Dry needling|The dry needling technique will employ in the current proposed study follows the standard technique for needling patients with spasticity
223714558|NCT06394310|DEVICE|Sham dry needling|In the control group, The investigators will use the methods proposed by Cushman et al. to apply sham dry needling (DN) to our participants
223714559|NCT03947450|BIOLOGICAL|Autologous Skin Fibroblasts|The site or whole stump will be injected with autologous fibroblasts
223714560|NCT03947450|BIOLOGICAL|Placebo|The site or whole stump will be injected medium only without autologous skin fibroblasts
223714561|NCT06253572|OTHER|Education|"Educational Skills Program Based on Constructivist Learning Approach~Instructors need to receive training to improve their teaching skills during their graduate education and after their appointment as instructors. In this study, it is aimed to design and implement an Educational Skills Program based on the Constructivist Learning Approach. The design of the training program was based on the Dick, Carey and Carey (DCC) Instructional Design Model, which is widely known among instructional design models and influenced by constructivism theory. It is aimed that the training skills training program will be carried out by taking adult education into consideration and will be learner-centered. In this study, the training plan is based on the Constructivist Learning Approach 5E model, which is proven to be effective in the literature and widely used. The training program will be conducted through distance education to reach instructors living in different cities and to create common time."
223714562|NCT05521191|DRUG|RGLS8429|Solution for subcutaneous injection
223714563|NCT05521191|DRUG|Placebo|Solution for subcutaneous injection
223714564|NCT03044678|BEHAVIORAL|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
223714565|NCT03044678|BEHAVIORAL|Self-Study|Books for youth about anxiety management
223714566|NCT05379231|DEVICE|Hearing aid fitting|A participant will wear a hearing aid with and without a CROS device on the unaidable ear.
223714567|NCT03046758|DRUG|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
223714568|NCT00509444|BEHAVIORAL|Educational materials|
223714569|NCT00509444|BEHAVIORAL|educational materials, plus patient navigation|
223714570|NCT04258865|DRUG|CKD-348 F1|QD, PO
223714571|NCT04258865|DRUG|CKD-348 F2|QD, PO
223714572|NCT04258865|DRUG|CKD-828, D097, D337|QD, PO
223714573|NCT04994600|OTHER|Reduces number of question items|The number of alarm fatigue questions are reduced to about 15 in the CFA\_2nd\_phase group.
223714574|NCT05002452|OTHER|Search of factors predicting therapeutic effects and prognosis|There factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
223714575|NCT06044883|PROCEDURE|Injection of Botulinum neurotoxin (BoNT)|"Botulinum neurotoxin (BoNT) is produced by Clostridium botulinum, an anaerobic ,gram-positive bacterium. Poisoning with BoNT can cause botulism, resulting in generalized paralysis, respiratory failure, and death .There are seven serotypes of BoNT: A, B, C1, D, E, F, and G. BoNT-A is the most commonly used serotype for medical purposes.~Since its first use in 1977 for the treatment of strabismus in children, BoNT-A has since been used in aesthetic medicine and for the treatment of a number of disorders associated with overactive striated muscles, such as strabismus, esotropia, exotropia , focal dystonia, spasticity, and movement disorders.~BoNT-A has also been used in the management of some smooth-muscle disorders, such as achalasia, oesophageal spasm , ptyalism, hyperhidrosis, and intrinsic rhinitis, blepharospasm, muscle spasms and spasticity, axillary hyperhidrosis, and neurogenic detrusor muscle overactivity of the urinary bladder."
223719149|NCT06243991|DEVICE|Corneal tomography|Scheimpflug-tomography device (Pentacam, OCULUS, Wetzlar, Germany) was used for measurement of keratometric values.
223719150|NCT00671697|DRUG|Arsenic Trioxide|
223719151|NCT00671697|DRUG|Decitabine|
224276730|NCT04313010|OTHER|PRF|A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
223528655|NCT06067854|PROCEDURE|the standard procedure - without regional anaesthesia|the standard procedure - without regional anaesthesia
223528656|NCT06067854|PROCEDURE|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon|infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
223528657|NCT05948540|DRUG|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily at least 2 hours after the last meal and within 30 minutes of going to bed.
223719152|NCT02857543|OTHER|Plant-Based Diet|
223719153|NCT02857543|OTHER|American Heart Association Diet|
223719154|NCT02857543|OTHER|Mediterranean Diet|
223719155|NCT05255068|BEHAVIORAL|OPTIMAL|A person-centered mealtime care intervention
223719156|NCT04624568|DEVICE|PAPILOCARE|"Papilocare® is a self-administered vaginal gel. Its single-dose cannula contains hyaluronic acid and pre-biotics (Coriolus Versicolor) that would improve the re-epithelialization of the uterin cervix. By creating a protective film on the cervix, this gel could induce a favorable environment for regression of the cervical intraepithelial lesions 1 and for clearance of Human Papillomavirus.~The specific approach related to our study would be to apply Papilocare® vaginal gel for 6 months for the treated group.~Smear and HPV test will be perform by all patients at 6 and 12 months."
223719157|NCT04121377|OTHER|Resistance training|"Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected."
223719158|NCT04388189|DRUG|Duloxetine|FDA approved antidepressant
223719159|NCT04388189|DRUG|Bupropion|FDA approved antidepressant
223719160|NCT05300620|DEVICE|Custom Foot Orthotics EVA|these are custom foot orthotics made out of Ethyl Vinyl Acetate material
223719161|NCT05300620|DEVICE|Original Liner|these are original shoe liners
223719162|NCT05300620|DEVICE|Custom Foot Orthotics PU|these are custom foot orthotics made out of Expanded Poly Urethane Material
223719163|NCT05300620|DEVICE|Custom Hybrid Foot Orthotics|these are custom foot orthotics made out of a combination of Ethyl Vinyl Acetate and Expanded Poly Urethane Material
223719164|NCT01561365|BEHAVIORAL|Ottawa ankle rules|Ottawa ankle rules implementation
223719165|NCT05815940|BEHAVIORAL|Mobile Application|a mobile application was developed that can be used by children with urinary incontinence and their parents.
223719166|NCT05033860|OTHER|Read leaflets containing knowledge of COVID-19 and vaccination.|Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
223719167|NCT03919214|OTHER|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.
223719168|NCT02313181|OTHER|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
223719169|NCT02313181|OTHER|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
223719170|NCT05439161|DEVICE|surgery|2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study
223719171|NCT01029574|OTHER|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
223719172|NCT04988646|DRUG|Acyclovir 200 MG|Administered with 240 mL of water
223719173|NCT04988646|DRUG|Acyclovir 400 MG|Administered with 240 mL of water
223719174|NCT04988646|DRUG|Zovirax 200 MG Tablet|Administered with 240 mL of water
223719175|NCT04988646|DRUG|Zovirax 400 MG Tablet|Administered with 240 mL of water
223719176|NCT02049281|DRUG|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
223719177|NCT04441021|OTHER|Penicillin Allergy Risk Stratification and Evaluation|This standard of care intervention will provide an antibiotic allergy risk stratification assessment and subsequent amoxicillin oral challenge in patients who stratify as low risk for true allergy
223719178|NCT01191229|DEVICE|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
223719179|NCT01191229|DEVICE|Crystalens AO|25 patients that are previously implanted
223719180|NCT02370134|DEVICE|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
223719181|NCT02370134|DEVICE|sham glove|
223719182|NCT00380952|DEVICE|Dune Device|
223719183|NCT03558854|DRUG|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
223719184|NCT03558854|DRUG|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
223719185|NCT01270412|BIOLOGICAL|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
223719186|NCT01270412|DRUG|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
223719187|NCT03736616|DRUG|Carboplatin|Chemotherapy
223714576|NCT06044883|DIAGNOSTIC_TEST|Penile duplex and shear wave elastosonography (SWE).|Penile duplex study using intracavernosal injection of prostaglandin E1 (PGE1) before and after Botox injection (in the follow-up visit in the 6th week after Botox injection). Penile cavernosal arteries diameters and colored waves will be assessed. Shear wave elastosonography will be conducted comparing the stiffness of penile tissues before and after Botox injection
224083454|NCT00216970|DIETARY_SUPPLEMENT|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
223714577|NCT04178486|BEHAVIORAL|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
223714578|NCT04178486|BEHAVIORAL|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
223714579|NCT04178486|BEHAVIORAL|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
223714580|NCT04178486|BEHAVIORAL|Hypnosis with induction only|Participants received only hypnotic induction.
223714581|NCT05975892|BIOLOGICAL|Transplantation of allogeneic MSCs in periodontal disease|Oral surgery is performed in patients with periodontal disease, under local anesthesia. An incision will be made on the periodontal lesion, A full-thickness flap is elevated on both the buccal and lingual areas and the inner epithelium of the flap removed. Granulation tissue is removed from bone defect area, and a root planning is performed. MSC construct is placed around the bone defect and a collagen membrane is used to cover and close off the bone defect site. The flap will be repositioned and the wound closed by a suture
223714582|NCT04907903|OTHER|internet-based intervention|Intervention consists in 8 weekly online cognitive-behavioral modules (for a total duration of 2 months).
223714583|NCT05022082|OTHER|Chest Physiotherapy- Aspiration- Inhaler drugs group|In the intensive care unit where the study was conducted, the patients who have a respiratory disorder and receive supplemental oxygen therapy with non-invasive mechanical ventilation or an oxygen mask are first administered an inhaler drug therapy placed in the physician's order. It is followed by chest physiotherapy and then oropharyngeal and nasopharyngeal aspiration. However, in practice rendered by the researcher, it is suggested that when chest physiotherapy and aspiration are administered in the first place and then followed by an inhaler drug therapy, it might have a more positive impact on the patient's physiologic parameters.
223714584|NCT03292562|DEVICE|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
223714585|NCT03292562|DEVICE|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
223714586|NCT02485197|OTHER|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
223714587|NCT01369095|DRUG|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)
223714588|NCT01369095|DRUG|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)
223714589|NCT01369095|DRUG|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
223714590|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
223714591|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
223714592|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
223714593|NCT01369095|DRUG|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
223714594|NCT05125757|OTHER|lifestyle modification|for 12 week, the patients of this group will receive their usual immuno-modulating therapy plus life style modification (energy or diet restriction in addition to daily walking, 15000 steps)
223714595|NCT05125757|OTHER|usual lifestyle|the patients will receive the usual immuno-modulating therapy with continued usual diet and activities
223714596|NCT03504657|DEVICE|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
223714597|NCT03504657|DEVICE|stenting angioplasty|Angioplasty with a stenting
223714598|NCT00459628|RADIATION|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
223714599|NCT00459628|RADIATION|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
223714600|NCT00884871|PROCEDURE|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
223714601|NCT00764738|DEVICE|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
223714602|NCT00764738|DRUG|Ranibizumab Ophthalmic|0.5 mg ranibizumab vs 2.0 mg ranibizumab
223714603|NCT02968771|OTHER|Non intervention|
223714604|NCT01203098|DRUG|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
223714605|NCT01203098|DRUG|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
223714606|NCT01203098|DRUG|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
223719188|NCT03736616|DRUG|Ifosfamide|Chemotherapy
223899189|NCT05094908|DRUG|Arnica Tincture|Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.
223899190|NCT02950987|DEVICE|Whole Body MRI|
223899191|NCT03466294|DRUG|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
223899192|NCT04593810|PROCEDURE|INTELLiVENT-ASV|INTELLiVENT-ASV is activated as soon possible. The sensors for ETCO2 and SpO2 are connected and activated. Patient's gender and height are set on the ventilator and patient condition is chosen if applicable.
223899193|NCT04593810|PROCEDURE|CONVENTIONAL VENTILATION|Conventional ventilation consists of VCV or PCV and PSV, depending on patient's activity. None of the semi or fully automated modes of ventilation is allowed at any time.
223899194|NCT07062900|BEHAVIORAL|Low-Intensity Physical Activity|"This includes a structured and progressive 8-week physical activity program involving:~Gentle walking~Portable pedal exerciser~Low-intensity resistance exercises (e.g., resistance bands, seated leg press, hip circles)~Supervised sessions with warm-up and cool-down components"
223899195|NCT07062900|BEHAVIORAL|usual care|Standard Medical Management: Participants continued with their prescribed medications and routine clinical follow-ups for congestive heart failure as directed by their healthcare providers.
223899196|NCT07062978|DRUG|QL1206|QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
223899197|NCT07062978|DRUG|Prolia®|Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
223899198|NCT07062107|PROCEDURE|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery adopts the traditional perfusion system and uses intraoperative optical coherence tomography to assist in observation.
223899199|NCT07062107|PROCEDURE|Phacoemulsification using adaptive fluidics technology|Phacoemulsification surgery adopts the adaptive fluidics system to precisely and dynamically control the pressure and flow rate of the perfusion fluid. During the operation, optical coherence tomography is used to assist in observing the stability of the anterior chamber.
223899200|NCT06773325|BEHAVIORAL|Buzzy application|Buzzy application during heel prick blood collection
223899201|NCT05391230|OTHER|Permethrin-treated lesu|0.5% permethrin soaked baby wraps (lesus)
223899202|NCT05391230|OTHER|Untreated lesu|Water soaked baby wraps (lesus)
223899203|NCT07062172|DIAGNOSTIC_TEST|Low Dose CT Scan|Completed once after screening and eligibility is confirmed.
223899204|NCT06234176|BEHAVIORAL|Personalised psychomotor therapy|"The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment.~The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation.~Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions.~The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted.~During each session, the participant will be required to complete the Duke health profile."
223899205|NCT06234176|OTHER|Usual treatment|Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
223899206|NCT06864234|DRUG|Saline (NaCl)|IV 0.9% NaCl (5 ml)
223899207|NCT06864234|DRUG|Metoprolol Tartrate|Metoprolol Tartrate (5 ml of 1 mg/ml solution for injection)
223899208|NCT06807112|OTHER|Intravenously administered secretin|16 micrograms of liquid secretin will be one-time intravenously administered to patients with PDAC during the first hour of surgery. Four peripheral blood samples will then be collected. Plasmatic levels of ctDNA will be measured. Plasmatic levels of biomarkers such as mRNA, miRNA, siRNA, exoRNA, S100 proteins and amino acids, isolated from the same blood samples, will be measured and analyzed in correlation to tumor volumometry, survival rate etc. in specific intervals during follow-ups.
223899209|NCT04828005|DRUG|Nalmefene hydrochloride|3mg Nasal spray
223899210|NCT04828005|DRUG|Naloxone hydrochloride|4mg Nasal Spray
223899211|NCT05473351|OTHER|Questionnaire|Visual Analogic Scale
223899212|NCT06798064|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stem cells|
223899213|NCT05013957|DIAGNOSTIC_TEST|Methylation analysis|Methylation analysis
223899214|NCT06634823|DRUG|Triamcinolone Acetonide Injectable Suspension|Triamcinolone injection into deltoid muscle (arm)
223899215|NCT06634823|DRUG|Saline injection|Saline injection into deltoid muscle (arm)
223899216|NCT06460948|DRUG|Norethindrone Acetate-Ethinyl Estradiol|Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
223899217|NCT06065631|DEVICE|Eyeglasses|Children with uncorrected/under-corrected refractive error will be provided with either ready made or custom eyeglasses based on their magnitude and types of refractive errors.
223899218|NCT06065631|OTHER|Prescription slip|Children with uncorrected/under-corrected refractive error will be provided with an eyeglasses prescription and letter to parents, but all of them will get eyeglasses at the end of the trial
223899219|NCT00169806|OTHER|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
223899220|NCT06476834|DRUG|Deucravacitinib|Specified dose on specified days
223899221|NCT02975882|DRUG|Irinotecan Hydrochloride|Given PO
223899222|NCT02975882|OTHER|Laboratory Biomarker Analysis|Correlative studies
223899223|NCT02975882|OTHER|Pharmacological Study|Correlative studies
223899224|NCT02975882|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
223899225|NCT02975882|DRUG|Temozolomide|Given PO
223899226|NCT05419479|DRUG|ZIMBERELIMAB|Via IV on two days per cycle, dosage per protocol
223899227|NCT05419479|DRUG|DOMVANALIMAB|Via IV on two days per cycle, dosage per protocol
223899228|NCT05419479|DRUG|APX005M|Via IV on two days per cycle, dosage per protocol
223899229|NCT05419479|DRUG|FOLFIRI|every two weeks through an infusion at a dose determined by physician
223899230|NCT04563507|RADIATION|Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions
223899231|NCT04563507|DRUG|Letrozole 2.5Mg Tab|All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
223899232|NCT04563507|DRUG|Palbociclib 125mg|Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
223899233|NCT06378138|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
223899234|NCT06378138|DRUG|Orelabrutinib|Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
223899235|NCT06275724|OTHER|inclisiran|Prospective observational study. There is no treatment allocation. Patients prescribed with inclisiran are eligible to enroll into this study.
223714607|NCT04188782|DRUG|Sevoflurane|Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
224276731|NCT04313010|OTHER|BC|According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
223899236|NCT05519189|DRUG|Ropivacaine|Peri-anal infiltration of Ropivacaine
223899237|NCT05519189|OTHER|Failure to perform peri-anal ropivacaine infiltration|Failure to perform peri-anal ropivacaine infiltration
223899238|NCT05204667|DRUG|380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily|(2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
223899239|NCT05204667|DRUG|380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily|(2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
224276732|NCT02682550|PROCEDURE|blood drawing|blood drawing
224276733|NCT04491916|DRUG|irone sucrose|drug ingredient: Ferric Hydroxide in complex with sucrose drug dosage form: 270injection/100mg/5ml/Amp
223528658|NCT05948540|DRUG|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
223528659|NCT06640738|DRUG|arm 2|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
223528660|NCT06640738|DRUG|arm 1|"This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun."
223714608|NCT00730405|DRUG|Albaconazole 100mg|Albaconazole for 36 weeks
223714609|NCT00730405|DRUG|Albaconazole 200mg|Albaconazole for 36 weeks
223714610|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 36 weeks
223714611|NCT00730405|DRUG|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
223714612|NCT00730405|DRUG|Placebo 400 mg|Placebo for 36 weeks
223899240|NCT05105958|DRUG|Tideglusib|1000 mg/day per os
223899241|NCT06019949|DEVICE|Transcutaneous spinal cord stimulator|Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.
223899242|NCT06019949|DEVICE|Respiratory Training|Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
223899243|NCT06220019|DRUG|TCM|We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
223899244|NCT03867500|DRUG|Niacin|Intravenous infusion, a titrated dose starting from 0.6 mg/min to a maximum of 2.8 mg/min (likely needed dose = 1.4 mg/min)
223899245|NCT03867500|DRUG|Saline|Intravenous infusion of 0.9% Sodium chloride (NaCl)
223899246|NCT05629858|OTHER|6-h Time restricted eating (TRE)|Ad libitum food intake from 1-7 pm every day Fasting from 7-1 pm every day (18-h fast)
223899247|NCT05629858|OTHER|Calorie restriction (CR)|25% energy restriction every day
223714613|NCT04640285|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
223899248|NCT05629858|OTHER|Control|Usual diet, eating over \>10 h per day
223899249|NCT06460454|DEVICE|PET scan of 18F-FDG|VEREOS PET scanner. Philips VEREOS digital PET-CT scanners are installed in the nuclear medicine department.
223899250|NCT06643754|DRUG|SHR-3276|"Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy."
223899251|NCT06216483|OTHER|PDM Alert|passive digital marker (PDM) for postoperative delirium risk
223899252|NCT04148352|DRUG|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
223899253|NCT04148352|OTHER|Placebo|Placebo injected every 2 weeks for 18 weeks
223899254|NCT04583514|BEHAVIORAL|Control|Weight-stable Control group
223899255|NCT04583514|BEHAVIORAL|Overfeeding|30% Overfeeding group
223899256|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health and NRT|Smart-Treatment Mental Health App and Nicotine Replacement Therapy
223899257|NCT04887558|COMBINATION_PRODUCT|Smart-T Mental Health+ and NRT|Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
223899258|NCT04887558|COMBINATION_PRODUCT|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
223899259|NCT04711447|DEVICE|kinesio-tape|Twenty-two individuals with healthy shoulders completed 10 repetitions of an arm elevation task during three taping conditions (no-tape, experimental KT, sham KT) and 2 loading conditions (no-load and loaded).
223899260|NCT05626153|OTHER|Routine anesthesia care|• Implementing anesthesia management according to current routine practice.
223899261|NCT05626153|OTHER|Improved anesthesia care|"* Encourage regional anesthesia or combined regional-general anesthesia.~* Encourage goal-directed fluid therapy, lung-protective ventilation, and active warming during surgery.~* Encourage extubation in the operating room at the end of surgery.~* Encourage multimodal analgesia after surgery.~* Encourage strict indication for ICU admission after surgery."
223899262|NCT06799624|OTHER|Observation only|Only observation following standard of care (histological diagnosis, molecular classification, progestine therapy)
223899263|NCT05263037|DEVICE|EaseVRx|VR software with interactive content
223899264|NCT05263037|DEVICE|Sham VR|VR with neutral non-interactive content
223899265|NCT06168461|DRUG|Aspirin|162mg aspirin capsule
223899266|NCT06168461|DRUG|Placebo|placebo capsule
223899267|NCT02408354|DRUG|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
223899268|NCT02408354|DRUG|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
223899269|NCT02918253|RADIATION|targeted focal HDR brachytherapy|
223714614|NCT04640285|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of RELX ENDS Menthol flavor product during 8-hour and 5-minute use sessions
223714615|NCT04640285|OTHER|Usual Brand Cigarette|Ad libitum use of subjects usual brand product during 8-hour and single cigarette use sessions
223899270|NCT02918253|RADIATION|Whole-gland HDR Brachytherapy|Control/Standard of Care
223899271|NCT06245421|DEVICE|DM934|1 drop in each eye, 4 to 6 times per day
223899272|NCT06245421|DEVICE|Théalose|1 drop in each eye, 4 to 6 times per day
223899273|NCT06257706|BIOLOGICAL|Vedolizumab|All participants will begin a vedolizumab induction regimen of 300 mg IV at Weeks 0, 2, 6, and 10 followed by vedolizumab 300 mg IV every 8 weeks starting at Week 14. Treatment may be modified at Weeks 22, 30, and/or 38 based on the results of the target assessment at each of these time points.
223899274|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 8 weeks|Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.
223899275|NCT05859100|OTHER|≥ 2 eggs in addition to usual diet for 4 weeks|Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
223899276|NCT04802967|DRUG|Ketoprofen Lysine Salt combined with Gabapentin|KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B
223899277|NCT04802967|DRUG|Ketoprofen Lysine Salt|KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
223899278|NCT04802967|DRUG|Gabapentin|300 mg
223899279|NCT04802967|OTHER|Placebo|2 capsules to maintain the blind
223899280|NCT06057909|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Test that looks at the structure of the brain.
223899281|NCT06057909|DIAGNOSTIC_TEST|Electroencephalography|Non-invasive technique to measure brain waves
223899282|NCT06057909|DIAGNOSTIC_TEST|Electromyography|Technique to evaluate muscle activity
223899283|NCT05957432|DRUG|Black Seed Oil Cap/Tab|possessed anti-H. pylori activity comparable to triple therapy and improved dyspepsia symptoms in infected patients
223899284|NCT05957432|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|H pylori vonoprazan based treatment
223899285|NCT02708810|DEVICE|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
223899286|NCT02708810|RADIATION|80 Gy Radiation|
223714616|NCT04640285|OTHER|Nicorette White Ice Mint nicotine polacrilex gum|Ad libitum use of Nicorette White Ice Mint nicotine polacrilex gum product during 8-hour and 30-minute use sessions
223714617|NCT04821947|OTHER|Rhomboid intercostal plane block or Local anesthetic infiltration of 0.25% Bupivacaine|"for RIB GroupThe following structures will be identified from superficial to deep: trapezius muscle, rhomboid major muscle, intercostal muscles between ribs, pleura, and lung. The tissue plane between the rhomboid major and intercostal muscles will be identified. A 18 gauge Tuohy needle will be advanced in plane from a superomedial-to-inferolateral direction, through the trapezius and rhomboid major muscles. The skin entry point for the first injection will be the T5-T6 level just medial to the scapula.~After the location is confirmed through hydrodissection of 3 ml on the upper intercostal muscles under the rhomboid major muscle, 20ml of bupivacaine (concentration 0.25%) is injected under rhomboid major muscle LA group will receive wound infiltration of VATS incision single-incision with 10mL 0.25% bupivacaine double-incision with 15 mL (10mL+5mL) 0.25% bupivacaine three-port strategy with 17 mL (10mL+5mL+2mL) 0.25% bupivacaine"
223714618|NCT03677362|BEHAVIORAL|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (\~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (\~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
223714619|NCT04743739|DRUG|Rituximab|Rituximab 1000mg, I.V. on Days 1 and 181, and will be retreated or not at Days 15 and 195 according to the CD19+ B cell count.
223714620|NCT04743739|DRUG|cyclosporine|cyclosporine (CsA) will be started at a dose of 3mg/kg/d and adjusted according to the blood levels of the CsA. CsA will be tapered after 6 months and discontinued over a three month period.
223714621|NCT00394732|DEVICE|Total Disc Prosthesis|
223714622|NCT00394732|BEHAVIORAL|Multidisciplinary rehabilitation program|
223714623|NCT02478775|DRUG|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
223714624|NCT02478775|DRUG|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
223714625|NCT02478775|DRUG|Cetrorelix|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
223714626|NCT03851705|DRUG|Inclisiran Sodium for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
223714627|NCT03851705|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for injection)
223714628|NCT03851705|DRUG|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
223714629|NCT03304548|OTHER|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
223714630|NCT06014268|OTHER|electronic clinical decision support system|"eCDSS will alert clinicians if patients with documented atrial fibrillation are admitted to the hospital under their care.~The eCDSS will consist of prompts appearing on patients' electronic health records asking clinicians to clinically assess the risk of stroke (using CHAD2AD2-VASc tool) and the risk of bleeding (using the ORBIT tool) and record the scores on ePJS. Recommendations include reviewing the stroke and bleeding scores in specific cases, referral to an anticoagulation clinic to reduce AF related stroke risk (a referral template and emails/ telephone of the OAC clinics will be provided) and managing modifiable bleeding risk factors."
223714631|NCT03078660|BEHAVIORAL|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
223714632|NCT03078660|BEHAVIORAL|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
223714633|NCT00476697|DEVICE|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
223714634|NCT05277324|OTHER|Protective facial mask|Participants, students of health related professions, who wear protective facial mask daily during their internship/practice in health institutions.
223714635|NCT05188911|DRUG|Abiraterone|Patients would be treated with 1000mg abiraterone qd.
223714636|NCT05188911|DRUG|Prednisone|Patients would be treated with 5mg prednisone bid.
223714637|NCT05188911|DRUG|Androgen deprivation therapy|Patients would get medical or surgical castration.
223714638|NCT00944905|BIOLOGICAL|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
223714639|NCT05369637|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
223719189|NCT03736616|DRUG|Etoposide|Chemotherapy
223719190|NCT03736616|BIOLOGICAL|Rituximab|Anti-CD20 mAb
223719191|NCT03736616|DRUG|Carmustine|Chemotherapy
223719192|NCT03736616|DRUG|Cytarabine|Chemotherapy
223899287|NCT05177146|DRUG|Intravenous Ketamine (IV)|A sterile form of ketamine hydrochloride will be administered over 40-min IV infusion twice per week on non-consecutive days for four weeks. Dosing schedule is determined based on patient's weight, clinical response and tolerability. First treatment session dose will be calculated based on 0.5 mg/kg. Further dose increase will be determined by the study physician. Dose increase will not exceed 0.8 mg/kg. Patients will be closely monitored by available trained personnel with MD being present on site for the full duration of the 2-h supervision period. Specifically, IV induction will be performed under the direct supervision of anesthesiologist or delegate and psychiatrist. Vital signs will be monitored every 30 minutes during the supervision period. Side effects will be managed by the medical team administering the treatment. If required, appropriate rescue medications will be provided depending on the nature of the adverse event.
223899288|NCT05985018|OTHER|Traditional Diet|Provided as an educational leaflet
223899289|NCT05985018|OTHER|Mediterranean Diet|Provided as an educational leaflet
223899290|NCT03853395|DIAGNOSTIC_TEST|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
223899291|NCT05896228|DRUG|Iberdomide|"Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:~* Combination therapy: Cycles 1 to 8: 1 mg per day\*, Days 1 to 21 every 28 days.~* Monotherapy: Cycles 9 to 20: 1 mg per day\*, Days 1 to 21 every 28 days.~(\*) The first 6 patients will begin at 1 mg/day as lead-in with option to increase to 1.3 mg with dose-escalation cohort after two (2) cycles tolerated therapy"
223899292|NCT05896228|DRUG|Carfilzomib|"Participants will receive Carfilzomib (K) therapy intravenously (IV) as follows:~* Cycle 1: 20 mg/m2 per dose on Day 1; 56 mg/m2 per dose on Days 8 and 15~* Cycles 2 to 8: 56 mg/m2 per dose on Days 1, 8, and 15."
223899293|NCT05896228|DRUG|Daratumumab|"Participants will receive Daratumumab (D) therapy subcutaneously (SC) or intravenously (IV) as follows:~* Cycles 1 and 2: 1800 mg SC or 16 mg/kg IV on Days 1, 8, 15, and 22~* Cycles 3 through 6: 1800 mg SC or 16 mg/kg IV on Days 1 and 15~* Cycles 7 and 8: 1800 mg SC or 16 mg/kg IV on Day 1."
223899294|NCT05896228|DRUG|Dexamethasone|"Participants will receive Dexamethasone (d) therapy either orally (PO) or intravenously (IV) as follows:~* Cycles 1 and 2: 40 mg/dose on Days 1, 8, and 15; 20 mg/dose on Day 22~* Cycles 3 and 4: 40 mg/dose on Days 1, 8, and 15~* Cycles 5 through 8: 20 mg/dose on Days 1, 8, and 15."
223899295|NCT05896228|DRUG|Acetaminophen|"Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1."
223899296|NCT05896228|DRUG|Diphenhydramine|"Participants will receive Diphenhydramine either orally (PO) or intravenously (IV) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 25 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 25 mg/dose on Days 1 and 15~* Cycles 7 and 8: 25 mg/dose on Day 1."
223899297|NCT05896228|DRUG|Montelukast|"Participants will receive Montelukast orally (PO) prior to Iber-KDd as follows:~* Cycle 1 only: 10 mg/dose, Days 1, 8, 15, and 22, to be administered prior to the first 4 doses of Daratumumab (D)."
223899298|NCT06799676|DRUG|a combination treatment of Linperlisib and the VRD regimen|Subjects will be administered Linperlisib orally at doses of 40 mg, 60 mg, or 80 mg once daily for 4 consecutive weeks, combined with the VRD regimen at standard doses. Subsequently, during the expansion phase, at least four cycles of Linperlisib at the recommended Phase II dose (RP2D) will be combined with the VRD regimen for induction therapy.
223899299|NCT04434664|DRUG|Amlodipine Besylate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
223899300|NCT04434664|DRUG|Metoprolol Succinate|The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
223899301|NCT05536531|DEVICE|Neuromuscular electrical stimulation (NMES)|Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
223899302|NCT01857245|OTHER|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
223899303|NCT06004973|DEVICE|STAR Particles|A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand) and 100 mg of aloe vera will be applied to the control site on one of the forearms. Two rubbing cycles (20 and 30 cycles at 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated.
223899304|NCT05281809|DRUG|Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)|This protocol describes the use of an automated cell processor and culture system, the CliniMACS Prodigy device sold by Miltenyi Biotec, for the local manufacture of CAR T-cells targeting the CD19 antigen. The manufacturing process will use a lentiviral vector (CAR19) provided by Lentigen, a wholly owned subsidiary of Miltenyi Biotec, to transfect T-cells collected from eligible patients. Live cells will be harvested by the device after culture and infused intravenously to the patient from whom the cells were originally obtained.
224276734|NCT02871050|OTHER|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
224276735|NCT04815434|OTHER|Interview|Interviews will be conducted.
223899305|NCT04321395|DRUG|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
223899306|NCT03524118|DRUG|Clesrovimab|Single ascending doses of clesrovimab will be administered via IM injection.
223899307|NCT03524118|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
224276736|NCT05284084|OTHER|Bed Head elevation, H2 blockers and mouth wash|Elevation of the bed head to 15, 30 and 45 degrees, daily H2 blockers administration and mouth wash BID.
224276737|NCT05284084|OTHER|Data collection for comparison|Data collection for comparison
223714640|NCT05369637|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
223719193|NCT03736616|DRUG|Melphalan|Chemotherapy
223719194|NCT03736616|OTHER|Autologous HSCT|Cellular Therapy
223719195|NCT03736616|DRUG|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
223719196|NCT01095445|DRUG|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
223719197|NCT02638545|DRUG|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
223719198|NCT04658498|OTHER|Procedure: Usual Care (UC)|Intermittent spontaneous breathing periods
223719199|NCT04658498|OTHER|Procedure: UC + HI-IMT|UC + Supervised daily sessions of training including 4 sets of 6-10 full vital capacity breaths against an external load using a tapered flow resistive device (POWERbreathe KH2, HaB International, UK). The maximum tolerable resistance allowing patients to inhale at least 70% of their inspiratory vital capacity will be chosen and progressively increased throughout the training period.
223719200|NCT04658498|OTHER|Procedure: UC + LI-IMT (sham IMT)|UC + superrvised daily sessions of training including 4 sets of 6-10 breaths at the lowest external imposable load with the tapered flow resistive device (POWERbreathe KH2, HaB International, UK) (i.e. 3 cmH2O).
223719201|NCT00301665|BIOLOGICAL|Botulinum toxin type A|
223719202|NCT03619954|BIOLOGICAL|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10\^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10\^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
223719203|NCT04062175|DRUG|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
223719204|NCT04062175|DRUG|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
223719205|NCT00517998|DRUG|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
223719206|NCT03792581|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
223719207|NCT05557981|BEHAVIORAL|Coaching|A novel coaching curriculum based in positive psychology with an emphasis on self-reflection, goal setting and adverse event processing.
223719208|NCT00718835|BEHAVIORAL|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
223719209|NCT00980057|DEVICE|Adaptive CRT (aCRT)|Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function
223719210|NCT00980057|DEVICE|Echo|Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
223719211|NCT05002062|DEVICE|"RehaCom computer-based cognitive training in addition to Conventional physical therapy program"|"Rehacom procedure: It is a computer-based intensive cognitive rehabilitation test used to assess patient's cognitive functions. It includes 32 assessment tasks for attention, memory , logical reasoning\& executive functioning. It composes of regular PC , 1G RAM , DVD drive, 100 GB hard drive with windows XP SP3, 128 MB RAM direct 3D graphic card , Screen at least 19 , regular PC keyboard or Rehacom panel \& printer .The Rehacom software version is (patient enpult (1990-1997) EN/ISO-13485-certified). It is characterized by easy handling, close to reality , motivating for patients."
223719212|NCT05002062|OTHER|Conventional physical therapy program|Conventional physical therapy program for MS patients include aerobic training, resistive training and flexibility program
223719213|NCT00174278|DRUG|Somatropin|
223719214|NCT01722084|BEHAVIORAL|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
223719215|NCT01874132|BEHAVIORAL|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
223719216|NCT00002169|DRUG|Nelfinavir mesylate|
223719217|NCT01286298|PROCEDURE|Laser gingivectomy|Gingivectomy by diode laser
223899308|NCT06095817|BEHAVIORAL|Internet Delivered Brief Intervention (IDBI)|The intervention is an online module that can be accessed through smartphone, tablet, computer or other device. Participants will receive information about alcohol expectancies, alcohol use and norms, identity (service member, veteran, civilian), sleep, stress, and strategies for coping on the job.
223899309|NCT06325332|OTHER|Nirsevimab|Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection
223899310|NCT02716116|DRUG|TAK-788|TAK-788 capsules.
223899311|NCT05935761|DRUG|Pregnenolone|Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
223899312|NCT05935761|DRUG|DHEA|DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
223899313|NCT05935761|DRUG|Placebo|Same as active comparator arms, except placebo dispensed
223899314|NCT01881048|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Given PO
223899315|NCT01881048|DRUG|Celecoxib|Given PO
223899316|NCT04200547|OTHER|Immunomonitoring-based follow-up|"Post-operative follow-up of Crohn's disease patients will be done through the measurement of the residual rate of the drug adalimumab in the serum. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. 3 months after the surgery, serum levels of adalimumab will be measured:~* If the level is below 5ug/mL, adalimumab treatment will be increased to every other week until the end of the study.~* If adalimumab level in the serum is above 5ug/mL, the treatment's frequency will be maintained until the end of the study."
223899317|NCT04200547|OTHER|Standard follow-up|Post-operative follow-up of Crohn's disease patients will be based on clinical and biological parameters. Patients will receive adalimumab treatment every other week, starting 1 month after the surgery. If clinical relapse (CDAI \> 220 together with an increase of 70 points) and biological relapse (CRP \> 10mg/mL and fecal calprotectin \> 100 ug/g) occur, frequency of adalimumab treatment will be increased to once a week.
223899318|NCT06181344|BEHAVIORAL|FCR screening and referral program|Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
223899319|NCT06551246|DRUG|Solifenacin|According to randomization.
223899320|NCT06551246|DRUG|Mirabegron|According to randomization.
223899321|NCT06073665|DRUG|Levothyroxine Sodium|Levothyroxine dose will depend on dose at baseline and randomization group
223899322|NCT00579072|BEHAVIORAL|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
223899323|NCT00579072|BEHAVIORAL|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
223899324|NCT00579072|DEVICE|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
223899325|NCT01824875|DRUG|temozolomide|Given PO
223899326|NCT01824875|DRUG|capecitabine|Given PO
223899327|NCT05273372|OTHER|Placebo|Placebo treatment with the food white rice flour. 1,000 mg BID
223899328|NCT05273372|OTHER|Medical Food - Anhydrous Enol-Oxaloacetate|Active treatment with oxaloacetate. 1,000 mg BID
224276738|NCT02565017|BEHAVIORAL|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
224276739|NCT01230645|DRUG|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
223899329|NCT06021782|OTHER|All subjects-Observation|The sonographer or study team member will scan the lateral vaginal walls (Left and right) directing the probe slightly caudad in direction of the ischial spine (IS). The IS is very echogenic and easily identifiable (bony landmark). Anatomically, the pudendal nerve courses underneath the IS and travels with the vascular bundle of the pudendal artery and pudendal vein. The artery and the vein will be identified using color flow Doppler at the time of the scan. These landmarks, IS, pudendal artery and vein will serve as the basis for the identification of the pudendal nerve.
223899330|NCT06555562|DEVICE|Ultrasound Stimulation|Ultrasound therapy will be administered to the appropriate target.
223899331|NCT06555562|DEVICE|Non-active ultrasound stimulation|Non-active ultrasound therapy will be administered to the appropriate target
223899332|NCT06358274|OTHER|Thru-hiking|planning to embark on the Colorado Trail
223899333|NCT02014649|DRUG|20 mg laninamivir octanoate|
223899334|NCT02014649|DRUG|Placebo|
223899335|NCT02014649|DRUG|40 mg laninamivir octanoate|
223899336|NCT01973179|RADIATION|Radiation therapy|Radiation therapy with protons
223899337|NCT06807229|DEVICE|Transcutaneous electrical nerve stimulation|We will apply high frequency TENS for low back pain relief as it showed effectiveness more than low frequency TENS in pain relief (21). The recommendation is to apply the TENS at the highest tolerable intensity (22). While adjusting the current amplitude in a continuous manner so that its presence will be noticeable throughout the treatment. We applied a TENS device (ENRAF NONIUS Model, four electrodes) with a frequency of 0- 100/HZ and 90-100 pulse /seconds was applied for 20 minutes, to increase circulation and to have pain relief at the first day of menstrual complaints without taking any analgesics. Patients lied in prone position with a thin pillow placed under their abdomen. Two electrodes were placed to the proximal margin of low back area, and two others were placed to the proximal of gluteal region laterally. The intensity of stimulation was increased up to the tolerated level without causing any contraction
223899338|NCT06807229|OTHER|stretching exercises|"The first stretching exercise: The subjects will be asked to stand and bend trunk forward from the hip joint so that the shoulders and back were positioned on a straight line and the upper body was placed parallel to the floor for 5 seconds repetition; 10 times.~The second stretching exercise: The subjects will be requested to stand then raise 1 heel off the floor, then repeat the exercise with the other heel alternatively. The exercise will be performed 20 times.~The third stretching exercise: The subjects will be asked to spread their feet shoulder width, place trunk and hands in forward stretching.~The fourth stretching exercise: The subjects will be asked to spread her feet wider than shoulder width. Then the subject was asked to bend and touch left ankle with her right hand while putting her left hand in a stretched position above her head so that the head was in the middle and her head was turned and looked for her left hand, this exercise was repeated for the opposite foot with"
223899339|NCT06181929|DIAGNOSTIC_TEST|Low dose CT|A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
223899340|NCT06506721|DEVICE|Double ballon device, Cook|"Cook double balloon will be introduced transcervically. The double balloon will be inflated with sterile 0-9% saline solution (maximum 80 ml in each balloon of the double device), then the catheter will be fixed with a tape at the women's thigh without traction. The catheter will remain in place until spontaneously expelled or start of active labour.~If neither happens, the device will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
223899341|NCT06506721|DEVICE|Hygroscopic cervix dilators, Dilapan-S|"A maximum number of 5 hygroscopic cervical dilator rods will be inserted transcervically, after humidification with sterile 0.9% saline solution. They will be fixed in this position by inserting a humidified compress into the vagina. They will remain in place until spontaneously expelled or until start of active labour.~In neither happens, the devices will be removed after 12-24 hours and oxytocin will be administered and amniotomy as soon as feasible. If the cervix remains unfavorable after two cycles of 6 hours of oxytocin infusion, the induction will be classified as unsuccessful and C-section will be performed."
223899342|NCT04255784|DEVICE|Active iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
223899343|NCT04255784|DEVICE|Sham iTBS|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
223899344|NCT05840263|BEHAVIORAL|Qualitative interview|Qualitative interviews will cover four main goals including: (1) key sources of distress in mCRC patients and partners; (2) perceptions of mindfulness, including benefits, definitions, and applications; (3) barriers and facilitators of participation (e.g. home-based and couple-based skills practice, enrollment); and (4) session format preferences, such as session length and frequency.
223714641|NCT05369637|BEHAVIORAL|Behavioral: Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
223899345|NCT05840263|BEHAVIORAL|Cognitive Interviews|The objective of the cognitive interviews (60 minutes, led by the PI) is to ensure the comprehensibility and appropriateness of the drafted participant materials. Published guidelines note a sample size of 12 participants (6 mCRC couples) should be sufficient. Participants will be asked to read, review, and mark up the participant materials in order to identify sections that were difficult to understand. They will also be asked to test playing segments of the audio/video recordings to ensure ease of use. A semi-structured interview format will be used to elicit feedback, including a standard verbal survey assessing ease of reading the material, any difficulties experienced, and suggestions they have for improving the ease of material use. Information generated will be used to update materials as necessary.
223899346|NCT05739149|DIAGNOSTIC_TEST|Microvessel Ultrasound Examination|Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin
223899347|NCT05739149|PROCEDURE|Skin Biopsy|Dermatology will remove a small piece of skin from the affected ulcer area and control skin
223899348|NCT05916170|BEHAVIORAL|Health Warnings|Text-only warnings about one health harm will be displayed in the hookah cafés where data collection is being conducted.
223899349|NCT05916170|BEHAVIORAL|No Warnings|No warnings posted in the hookah café
223899350|NCT02342249|DRUG|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
223899351|NCT02342249|DRUG|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2\*300 mg tablets) will be administered over 5-6 days.
223899352|NCT02342249|DRUG|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
223899353|NCT02342249|DRUG|Placebo|Subjects will receive matching placebo of Oseltamivir
223899354|NCT06068543|DRUG|Epigallocatechin-3-Gallate (EGCG)|800mg Epigallocatechin-3-Gallate (EGCG)
223899355|NCT06068543|DRUG|Microcrystalline cellulose (MCC)|800mg microcrystalline cellulose (MCC)
223899356|NCT06068543|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C)|250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks
223899357|NCT03484078|DEVICE|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
223899358|NCT03484078|DEVICE|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
223899359|NCT01098812|DEVICE|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
223899360|NCT01098812|DEVICE|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
223899361|NCT05180526|DRUG|QLETLI|80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
223899362|NCT05962606|DRUG|AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
223714642|NCT05369637|BEHAVIORAL|Psychoeducation|This component will be based on in-person group sessions (monthly; 60-minute) supervised by a psychologist, aiming to promote the acquisition of important knowledge about secondary prevention and support people understanding, exploring, and self-managing their emotions and impairments.
223899363|NCT05962606|DRUG|Placebo|Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
223899364|NCT01129102|DRUG|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
223899365|NCT01129102|DRUG|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
223899366|NCT01129102|DRUG|Placebo|Placebo for NPC-01
223899367|NCT05360459|RADIATION|Exposure to radiotherapy|Characterization and quantification of intestinal and vaginal microbiota in patients affected by cervical or endometrial cancer who have received pelvic radiotherapy more than 24 months ago.
223899368|NCT06450210|DRUG|psilocybin trihydrate|Microdoses of psilocybin trihydrate will be administered to participants (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg).
223899369|NCT06450210|DRUG|Placebo|Participants will receive a capsule identical in appearance to the active drug that contains an inactive substance.
223899370|NCT06294769|OTHER|essencial oil of lavandula angustifolia|The intervention will consist of the application of aromatherapy with 2% lavender essential oil cutaneously and inhalation via by a nurse, associated with usual care, in the immediate postoperative period
223899371|NCT06294769|OTHER|grape seed vegetable oil|The placebo group will only receive the application of grape seed vegetable oil associated with usual care in the immediate postoperative period.
223899372|NCT05501379|OTHER|No intervention - observational study only|No intervention - observational study only
223899373|NCT06437314|BEHAVIORAL|Aquatic program based on the back school|Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
223899374|NCT04663724|BEHAVIORAL|Computer-Based Treatment|A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
223899375|NCT04971564|OTHER|Blood sampling|Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
223899376|NCT03479671|DRUG|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
223899377|NCT02732834|BEHAVIORAL|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
223899378|NCT02732834|BEHAVIORAL|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
223899379|NCT02732834|BEHAVIORAL|Audio recordings of clinical consultations|
223899380|NCT02732834|BEHAVIORAL|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
223899381|NCT02732834|BEHAVIORAL|2-hour empathic communication skills training|2-hour empathic communication skills training
223899382|NCT02732834|BEHAVIORAL|Standardized Patient Assessments|pre-training SPA, post-training SPA
223899383|NCT02732834|BEHAVIORAL|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
223899384|NCT02732834|BEHAVIORAL|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
223899385|NCT04569435|DRUG|ANX005|IV Infusion
223899386|NCT05681962|DIAGNOSTIC_TEST|Bronchoscopy|Patients will undergo to the bronchial endoscopy procedure required for their clinical condition: toilet bronchoscopy (for secretions, blood, mucus plugs removal), broncho-aspirate (BAS), bronchoalveolar lavage (BAL), brushing for cytology, biopsy, endobronchial ultrasound (EBUS).
223899387|NCT04475679|DEVICE|Adhese Universal DC|Adhese Universal DC, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic DC to bond indirect restorations to the tooth surface
223899388|NCT04475679|DEVICE|Adhese Universal|Adhese Universal, a dental adhesive, will be used in conjunction with the luting cement Variolink Esthetic DC to bond indirect restorations to the tooth
223899389|NCT06086431|DRUG|0.9% sodium chloride|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
223899390|NCT06086431|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
223899391|NCT06086431|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
223899392|NCT03379675|DRUG|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
223899393|NCT03379675|DRUG|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
223899394|NCT03379675|DRUG|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
223899395|NCT05597085|DRUG|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
223899396|NCT04418037|DEVICE|Digital Health Feedback System(DHFS)|We will investigate the feasibility of using the DHFS in hospitalized individuals living with HIV to support ARV adherence.
223899397|NCT02817776|DEVICE|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
223714643|NCT05369637|OTHER|Diagnosis and correction of hearing impairment|This component will be based on a evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and include an otoscopy and an audiogram.
223714644|NCT01496807|DRUG|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
223899398|NCT06788015|DIETARY_SUPPLEMENT|Hydrogen-infused water|Water containing molecular hydrogen
223899399|NCT06788015|DIETARY_SUPPLEMENT|Placebo|Water containing no molecular hydrogen
223899400|NCT06822608|DRUG|dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops|Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
223899401|NCT06822608|DRUG|Placebo|Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
223899402|NCT06441630|DRUG|AD-227A|Per Oral, 1 Tablet, Once a day for 8 weeks
223899403|NCT06441630|DRUG|AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
223899404|NCT06441630|DRUG|AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
223899405|NCT06441630|DRUG|Placebo of AD-227B|Per Oral, 1 Tablet, Once a day for 8 weeks
223899406|NCT06441630|DRUG|Placebo of AD-227C|Per Oral, 1 Tablet, Once a day for 8 weeks
223899407|NCT01134653|OTHER|Jump Stretch|distraction with early mobilization
223899408|NCT06172751|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
223899409|NCT06172751|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
223899410|NCT05472558|BIOLOGICAL|anti-CD19 CAR-NK|lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
223899411|NCT03506308|DEVICE|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
223899412|NCT03543852|BEHAVIORAL|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
223714645|NCT01496807|DRUG|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
223899413|NCT05402293|DIAGNOSTIC_TEST|Blood samples to measure lidocaine levels|Blood sampling is the only intervention Plasma samples will then be analyzed for lidocaine concentration
223899414|NCT06070012|DRUG|Tebentafusp|An anti-cancer medication used to treat uveal melanoma. Tebentafusp is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.
223899415|NCT06128343|OTHER|collection of biological samples|Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas
223899416|NCT05832216|DRUG|Daratumumab|Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
223899417|NCT06316778|BEHAVIORAL|Pelvic floor muscle training|12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.
223714646|NCT00959764|DRUG|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
223714647|NCT00959764|DRUG|Intranasal Calcitonin|Intranasal Calcitonin Spray
223714648|NCT00959764|DRUG|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
223714649|NCT00603616|DRUG|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
223714650|NCT00603616|DRUG|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
223714651|NCT03007160|DRUG|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
223714652|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
223714653|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
223714654|NCT00692341|DRUG|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
223714655|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
223714656|NCT01464099|DRUG|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
223714657|NCT01695265|OTHER|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
223714658|NCT01695265|DEVICE|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
223714659|NCT06287008|PROCEDURE|robot-assisted kidney transplantation|The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
223714660|NCT02893670|PROCEDURE|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
223714661|NCT03031314|DEVICE|barbed suture|
223714662|NCT03031314|DEVICE|standard suture|
223714663|NCT02591290|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
223714664|NCT00836485|DRUG|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
223714665|NCT00836485|DRUG|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
223714666|NCT00836485|DRUG|Olopatadine 0.2%|1 gtt/eye on two separate occasions
223714667|NCT00836485|DRUG|Artificial tears|1 gtt/eye on two separate occasions
223714668|NCT06197971|OTHER|Instrument Assisted Soft Tissue Mobilization|Graston Technique instruments to apply strokes and movements along the length of the muscle fibers. Sweeping strokes, cross-fiber friction, and circular motions patterns will be applied on hamstring muscles.
223714669|NCT06197971|OTHER|Therapeutic Cupping Technique|Stationary cupping technique will be used for a duration of 5-15 minutes with multiple Silicone Cups applied on the Hamstrings.
223714670|NCT03765905|DIAGNOSTIC_TEST|study|Scube-1 scube-2 scube-3
223714671|NCT04193332|DEVICE|NIR optical imaging camera|NIR optical imaging assisted identification of parathyroid glands during thyroid surgery using parathyroid gland autofluorescense
223714672|NCT01306942|DRUG|Dasatinib|
223714673|NCT01306942|DRUG|Trastuzumab|
223714674|NCT01306942|DRUG|Paclitaxel|
223714675|NCT03676010|OTHER|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
223714676|NCT03676010|OTHER|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
223714677|NCT03676010|OTHER|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
223714678|NCT03676010|OTHER|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
223714679|NCT03676010|OTHER|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
223714680|NCT03676010|OTHER|Solid tumours undergoing image-guided tumor ablation|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
223714681|NCT06023459|DRUG|Injectable extended-release buprenorphine|Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
223714682|NCT06023459|DRUG|Sublingual buprenorphine-naloxone|Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial \~2-week period of induction/stabilization.
223714683|NCT03769766|DRUG|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
223714684|NCT03769766|DRUG|Placebo|Take medication one 500mg pill twice daily
223714685|NCT06012669|DIETARY_SUPPLEMENT|High dose Human Lactoferrin|Dietary Supplement and Food Ingredient
223714686|NCT06012669|DIETARY_SUPPLEMENT|Low dose Human Lactoferrin|Dietary Supplement and Food Ingredient
223714687|NCT06012669|DIETARY_SUPPLEMENT|Active Control Bovine Lactoferrin|Dietary Supplement and Food Ingredient
223714688|NCT01390649|BIOLOGICAL|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
223719218|NCT01286298|PROCEDURE|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
223899418|NCT06218303|BIOLOGICAL|MUC1 Peptide Vaccine|MUC1, a therapeutic vaccine, is a transmembrane glycoprotein and a member of the mucin family of molecules.
223899419|NCT06218303|DRUG|Hiltonol®|A synthetic dsRNA viral mimic and host-defense activator, mimics nature by combining the essential elements of human immunity.
223899420|NCT06218303|DRUG|Aromatase Inhibitor|A type of hormone therapy for cancer used to inhibit aromatase to treat a hormone-related breast cancer.
223899421|NCT06771596|DRUG|Nimotuzumab Injection|Nimotuzumab is a highly humanized monoclonal antibody of IgG1 type, with a humanization rate of 95%. It is highly specific, has a long half - life, and shows high selectivity and a high degree of humanization. It can specifically block the epidermal growth factor receptor (EGFR) signaling pathway and mediate immune effects such as antibody - dependent cell - mediated cytotoxicity (ADCC) and complement - dependent cytotoxicity (CDC). It also promotes the endocytosis and degradation of EGFR, thereby inhibiting the proliferation of tumor cells and promoting the apoptosis of tumor cells, reversing the malignant biological behavior of tumor cells at the molecular level.
223899422|NCT05180435|BEHAVIORAL|Family Meals|A family-based multicomponent lifestyle modification intervention with the goal to increase the frequency of family meals and meet physical activity recommendations.
223899423|NCT05180435|BEHAVIORAL|Standard|A family-based multicomponent lifestyle modification intervention with the goal to increase the consumption of fruits and vegetables and and meet physical activity recommendations.
223899424|NCT04638946|BEHAVIORAL|Titration to high intensity exercise (T-HIE)|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Participants will begin at low intensity with the goal of titrating to high intensity by 2 weeks prior to the end of trial (Week 6). If a participant achieves at least 70% of the duration goal at the target heart rate, he/she will be titrated to the next dose level (moderate intensity). This will continue until high intensity exercise is achieved. Prescription is based on heart rate reserve((maximum heart rate \[220-age\] - resting heart rate)\*intensity percent - resting heart rate. Intensity percent lower/upper limits for moderate intensity are 40-59% and for high intensity are 60-84%.
223899425|NCT04638946|BEHAVIORAL|Low intensity exercise prescription|All participants will receive psychoeducation regarding the rationale for using exercise as a strategy to create immediate changes in mood and anxiety. Participants will be instructed in basic motivational principles (e.g., breaking up goals into smaller parts, using rewards) based on information in Exercise for Mood and Anxiety. Prescription is based on heart rate reserve ((maximum heart rate \[220-age\] - resting heart rate)\*30-39% (lower/upper limit of zone) - resting heart rate.
223899426|NCT04780971|DIAGNOSTIC_TEST|post-PCI Pd/Pa|After angiographically successful CTO PCI, intra-coronary physiologic assessment (RFR, FFR, CFR and IMR) and subsequent OCT of the CTO vessel will be performed. OCT may also be performed during a staged procedure when clinically indicated.
223899427|NCT03897374|DIAGNOSTIC_TEST|Genetic Testing|Buccal swab
223899428|NCT06589518|DRUG|Tenofovir Alafenamide Citrate|Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.
223899429|NCT04087759|DRUG|Bedaquiline (Test formulation)|Participants will receive bedaquiline orally.
223899430|NCT04087759|DRUG|Bedaquiline (Reference formulation)|Participants will receive bedaquiline orally.
223899431|NCT02598388|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles).
223899432|NCT02598388|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL IM injection of (1x10\*8 infectious units).
223899433|NCT02598388|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
223899434|NCT05896137|DRUG|CS0159|Oral QD
223899435|NCT05561478|DEVICE|Implantation of Synthesis Plus IOL (control device)|Synthesis Plus IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients.
223899436|NCT05561478|DEVICE|Implantation of Synthesis Plus Toric IOL (investigational device)|Synthesis Plus Toric IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with pre-existing astigmatism.
223899437|NCT06276205|DRUG|Vitamin D|"if Vitamin D level suboptimal, 50,000 IU/week for 8 weeks followed by 2000 IU/d~if optimal Vitamin D level, 2000 IU/d"
223899438|NCT06276205|DRUG|Levothyroxin|commenced at a dose of 1.6mcg/kg/day and will be titrated 8 weekly according to response
223899439|NCT02979327|DRUG|Adderall capsule|25 mg orally one time
223899440|NCT02979327|DRUG|Placebo capsule|Looks exactly like the study drug, but it contains no active ingredient. Taken one time.
223899441|NCT06803719|OTHER|Observations on main concerns and attracting factors when choosing the surgical approach for thyroid disease|Size of incision, cost, operation duration, postoperative recovery, postoperative hospitalization, absence of the anterior incision
223899442|NCT06104384|BEHAVIORAL|Behavioral and supportive therapy|Behavioral and supportive therapy
223899443|NCT04905251|DRUG|Mifepristone-Misoprostol|Non interventional design.
224276740|NCT01230645|DRUG|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
224276741|NCT05850884|DIAGNOSTIC_TEST|stool examination|Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
224276742|NCT00869687|DEVICE|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
224276743|NCT02315261|PROCEDURE|Elective Thoracic and Abdominal Surgery Patients|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection in Elective Thoracic and Abdominal Surgery Patients only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
223714689|NCT00133471|BIOLOGICAL|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
223714690|NCT00133471|DRUG|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
223714691|NCT00133913|PROCEDURE|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
223714692|NCT05574738|OTHER|Observational|
223714693|NCT05136287|DRUG|GLP-1 receptor agonist|Patients are included after GLP1 agonists prescription , at the first dispensation
223714694|NCT02736838|DEVICE|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
223714695|NCT02736838|DEVICE|Laser Doppler|
223714696|NCT00169026|DRUG|Clozapine versus typical (conventional) and atypical antipsychotic medications|
223714697|NCT05046899|DEVICE|BIOpH+ Psoriasis Medical Bath|20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.
223714698|NCT05046899|DEVICE|Cetaphil Moisturizing Lotion|Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.
223714699|NCT03366038|PROCEDURE|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
223714700|NCT05683769|GENETIC|miRNA|Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
223714701|NCT00536562|BEHAVIORAL|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
223714702|NCT06438588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223714703|NCT06438588|OTHER|Dietary Intervention|Given FMD
223714704|NCT06438588|OTHER|Educational Intervention|Receive educational guidelines
223714705|NCT06438588|OTHER|Electronic Health Record Review|Ancillary studies
223714706|NCT06438588|OTHER|Interview|Ancillary studies
223714707|NCT06438588|OTHER|Nutritional Assessment|Receive nutrition counseling
223714708|NCT06438588|OTHER|Questionnaire Administration|Ancillary studies
223714709|NCT01605162|DRUG|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
223714710|NCT01605162|DRUG|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
223714711|NCT00179556|DRUG|Isoflavone supplement|
223714712|NCT04945122|DRUG|Pitavastatin|Pitavastatin 4mg Qn
223714713|NCT04945122|DRUG|Atorvastatin|Atorvastatin 20mg Qn
223714714|NCT00679666|DRUG|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
223714715|NCT00679666|DRUG|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
223714716|NCT00837057|PROCEDURE|crrt|early CRRT (35 ml/kg/h)\& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
223714717|NCT04080375|DRUG|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
223714718|NCT04080375|DRUG|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
223719219|NCT00646009|DRUG|budesonide/formoterol|
223719220|NCT00646009|DRUG|fluticasone/salmeterol|
223719221|NCT00646009|DRUG|albuterol|
223899444|NCT04002830|DRUG|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
223899445|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort A|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
223899446|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 5 µg of OSP:rTTHc
223899447|NCT05559983|OTHER|Placebo Cohort A|Sterile 0.9% sodium chloride
223899448|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort B|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
223899449|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort B|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 10 µg of OSP:rTTHc
223899450|NCT05559983|OTHER|Placebo Cohort B|Sterile 0.9% sodium chloride
223899451|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine Cohort C|OSP:rTTHc Cholera Conjugate Vaccine without Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
223899452|NCT05559983|BIOLOGICAL|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort C|OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate with dose formulation 25 µg of OSP:rTTHc
223899453|NCT05559983|OTHER|Placebo Cohort C|Sterile 0.9% sodium chloride
223899454|NCT02014675|DEVICE|SD01 ICD lead|
223899455|NCT06770296|DRUG|Pyrotinib low dose group|Pyrotinib: 320mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
223899456|NCT06770296|DRUG|Pyrotinib normal dose group|Pyrotinib: 400mg, peros(po),once a day(qd) ,every 3 weeks(q3w) Trastuzumab: 8mg/Kg in the first cycle, 6mg/Kg in the subsequent cycle, intravenous(iv), every 3 weeks(q3w) Docetaxel: 75mg/m2，intravenous(iv), every 3 weeks(q3w)
223899457|NCT04098263|BIOLOGICAL|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
223899458|NCT05030545|DRUG|Eplerenone|After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.
223899459|NCT03069924|BEHAVIORAL|Gain-framed messaging|Gain-framed messaging materials
223899460|NCT03069924|COMBINATION_PRODUCT|Unframed messaging materials|Unframed smoking cessation materials
223899461|NCT05961982|PROCEDURE|Chemical Ablation|Undergo EUS-guided chemoablation
223899462|NCT05961982|PROCEDURE|Computed Tomography|Undergo CT
223899463|NCT05961982|OTHER|Electronic Health Record Review|Ancillary studies
223899464|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Undergo EUS-FNA
223899465|NCT05961982|PROCEDURE|Endoscopic Ultrasound-Guided Radiofrequency Ablation|Undergo EUS-RFA
223899466|NCT05961982|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRI/MRCP
223899467|NCT05961982|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/MRCP
223899468|NCT05420324|DRUG|YH003|YH003 will be administered intravenously over 30 minutes every 21-day cycle.
223899469|NCT05420324|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
223899470|NCT05420324|DRUG|albumin paclitaxel|Albumin paclitaxel will be administered intravenously over 30 minutes every 21-day cycle.
223719222|NCT01408485|DEVICE|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator"
223719223|NCT00465374|PROCEDURE|Change ventilatory parameters with stress index monitoring|
223719224|NCT01738373|DRUG|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
223719225|NCT01235143|DRUG|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
223719226|NCT01235143|DRUG|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
223719227|NCT06281990|BEHAVIORAL|Education|"1. Patients who were planned to undergo sleeve gastrectomy surgery were informed about the perioperative period when they came to the outpatient clinic2-4weeks before surgery and were educated about the exercises to be performed before and after surgery. The content of this education included pain management, breathing exercises,foot rotation, and leg exercises. In addition, the education book prepared by the researchers was given to the patients to make the education and information permanent until the day of surgery.~2. When the patient was hospitalized, anxiety level with the Trait Anxiety scale and pain level with VAS were determined one day before surgery.~3. Postoperatively, the patient's pain level before analgesics every 4-6hours for 2days, the patient's anxiety level with the State Anxiety Scale one day after surgery, the development of complications in the postoperative period, vital signs were evaluated, and the duration of hospitalization was recorded."
223899471|NCT06770218|OTHER|pelvic girdle stability training and therapeutic tapping|pelvic girdle stability training performed along with therapeutic taping in experimental group tapping involves applying strips one and two over the paraspinal region from l4 to t1 in a caudo cephalic directions. strips 3 and 4 along the lower portion of trapezius with a medially directed force from the acromion process to T12 obliquely. total session time 45 minutes to 60 minutes
223899472|NCT06770218|OTHER|pelvic girdle stability training only|participates engaged in pelvic girdle stability training focusing on exercises therapeutics taping was not be administrated during these stability exercises. excercise include pelvic brigde, one leg bridge, calm exercise for gluteus medius, leg lift 4 point kneelig arm lift
223899473|NCT03710902|DIAGNOSTIC_TEST|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
223899474|NCT03710902|OTHER|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
223899475|NCT06480864|DRUG|Adebrelimab Injection|Adebrelimab injection (1200mg) will be administered by intravenous infusion during the induction phase and maintenance phase on day 1 in a 3-week treatment cycle.
223899476|NCT06480864|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate tablets (250 mg) will be administered orally in a 3-week treatment cycle, once a day.
223899477|NCT06480864|DRUG|Carboplatin|Carboplatin (AUC 4-5mg/mL/min) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
223899478|NCT06480864|DRUG|Cisplatin|Cisplatin (75mg/m2) intravenous infusion will be administered during the induction phase on day 1 in a 3-week treatment cycle.
223899479|NCT06480864|DRUG|Etoposide|Etoposide(100mg/m2) intravenous infusion will be administered during the induction phase from day 1 to 3 in a 3-week treatment cycle.
223899480|NCT02872259|DRUG|BGB324+pembrolizumab|Combination
223899481|NCT02872259|DRUG|BGB324+dabrafenib and trametinib|Combination
223899482|NCT02872259|DRUG|pembrolizumab|Monotherapy
223899483|NCT02872259|DRUG|dabrafenib and trametinib|Combination
223899484|NCT03474679|DRUG|Ibrutinib|Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
223899485|NCT06191653|BEHAVIORAL|Mindfulness and Self-Compassion for Caregivers working in Youth Detention Centres|The adapted form of the MSC is a 12-session structured program, delivered on a weekly basis in group. It intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind and courageous way. Each session lasts about 2 hours. Each session has the following structure: Grounding exercise; sharing individual insights about the weekly practice; Reviewing the previous session and link for the session theme; coffee break; soft landing exercise; Formal/Informal practice(s); Session summary and challenges to be applied during the week; Session evaluation and take-off. Each participant receives a manual with the contents shared in each session as well as some space for individual reflections. On the day after each session, a summary email is sent to the participants, resuming the contents and with records of the (in)formal practices delivered. All the sessions will be delivered in a space on each YDC.
223899486|NCT04159675|BIOLOGICAL|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
223714719|NCT00603174|DEVICE|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
223714720|NCT03751696|BEHAVIORAL|Group Coaching|4 sessions of 1-1.5-hour group coaching intervention within 8 weeks
223899487|NCT04684966|DEVICE|Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined quadriceps and triceps surae ESNM using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (EG group).
223899488|NCT04684966|DEVICE|Sham Neuromuscular Electrical Stimulation|Standart pulmonary rehabilitation with combined sham NMES of the quadriceps and triceps surae performed using two identical electrotherapy devices allowing simultaneous stimulation of the quadriceps and triceps (CG group)
223899489|NCT03298386|OTHER|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
223899490|NCT03057964|DEVICE|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
223899491|NCT03057964|DEVICE|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
224276744|NCT05771935|PROCEDURE|ultrasound guided radial versus ulnar artery cannulation|"Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study."
223714721|NCT03751696|BEHAVIORAL|SMS self-help tips|4 mental well-being tips through sms within 8 weeks
223714722|NCT04916821|DIETARY_SUPPLEMENT|propolis|Propolis may be blocked virus entry to cells, and some receptor binding and some cell signal molecules
223714723|NCT00282984|DRUG|placebo|1 mg placebo twice daily by mouth for 12 weeks
223714724|NCT00282984|DRUG|Varenicline|1 mg twice daily by mouth for 12 weeks
223899492|NCT05337306|OTHER|GogyUp Reader|Participants will have unlimited access to the assistive-reading technologies available in the GogyUp Reader app for help understanding post-visit educational documents on type 2 diabetes mellitus disease management.
224276745|NCT06503887|OTHER|Stool sample collection|Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
223714725|NCT03907228|DIETARY_SUPPLEMENT|RHT-3201|PROBIOTIC
223714726|NCT00454896|DRUG|VESIcare®|Oral
223714727|NCT00454896|DRUG|placebo|Oral
223899493|NCT01539083|DRUG|Thalidomide|Thalidomide 100 mg tablet, orally.
223899494|NCT01539083|DRUG|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
223899495|NCT01539083|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 orally.
223714728|NCT05808114|BEHAVIORAL|Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
223714729|NCT05808114|BEHAVIORAL|TAU|Individually tailored and delivered specialized child psychiatric care
223714730|NCT01803061|BEHAVIORAL|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
223714731|NCT03556072|OTHER|Routine ERCP|
223714732|NCT00941005|DEVICE|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
223714733|NCT02087735|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
223714734|NCT02327689|DRUG|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
223714735|NCT02859311|DRUG|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
223714736|NCT03996733|OTHER|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
223714737|NCT03996733|OTHER|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
223714738|NCT03996733|OTHER|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
223714739|NCT03996733|OTHER|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
223714740|NCT02184481|BEHAVIORAL|Working memory training|
223714741|NCT02184481|BEHAVIORAL|Placebo training|
223714742|NCT01919606|DRUG|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
223714743|NCT01128842|DRUG|Neratinib|240 mg once daily by mouth.
223714744|NCT01128842|DRUG|Capecitabine|1500 mg/m\^2 twice daily by mouth.
223714745|NCT04489433|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
223714746|NCT04489433|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
223714747|NCT04489433|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
223714748|NCT06052085|OTHER|Pain Neuroscience Education|Four sessions of Pain Neuroscience Education will be applied. The neurophysiology of pain and the ability of the nervous system to modulate the experience of pain will be explained to the patient.
223714749|NCT06052085|OTHER|Biomedical Pain Education|4 sessions of Biomedical Pain Education will be applied in 6 weeks. Pain will be explained to the patient from a biological point of view.
223714750|NCT06052085|OTHER|Standard Physiotherapy Program|Soft tissue mobilization will be applied to the upper extremity twice a week for 6 weeks. Upper extremity exercises including breathing, warming, stretching and strengthening will be performed twice a week for 6 weeks.
223714751|NCT05394961|PROCEDURE|Treatment in an intensive care unit with a diagnosis of sepsis and/or ARDS and/or covid-19|As above
223714752|NCT02066142|DEVICE|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
223714753|NCT02066142|DEVICE|Ultrasound|
223714754|NCT02464020|DRUG|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
223714755|NCT01478477|DIETARY_SUPPLEMENT|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
223714756|NCT01478477|OTHER|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
223714757|NCT01478477|OTHER|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
223714758|NCT01478477|OTHER|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
223714759|NCT01478477|PROCEDURE|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
223714760|NCT01478477|PROCEDURE|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
223714761|NCT00255112|BEHAVIORAL|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
223714762|NCT02883270|DEVICE|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
223899496|NCT01539083|DRUG|Dexamethasone|Dexamethasone 20 mg orally.
223899497|NCT01539083|DRUG|Prednisolone|Prednisolone 50 mg orally.
223899498|NCT05702073|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
223899499|NCT05702073|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
223899500|NCT05533359|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive a test kit and asking participants if they would like to receive a test kit. Participants who reply yes will receive an additional message with information about how to receive a test kit."
223899501|NCT05533359|BEHAVIORAL|Conversational Agent (CA)|Patients in the CA condition will receive a link to an automated, scripted and interactive conversational agent used to mimic human interaction to: 1) elicit specific hesitancy factors and barriers to testing; 2) provide tailored information to address each individual's hesitancy factors and barriers to testing; and 3) offer access to at-home rapid test kits.
223899502|NCT05533359|BEHAVIORAL|Patient Navigation (PN)|"Participants in the PN condition will receive a call from a Community Health Worker to assist with the process of receiving a COVID test. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to testing such as logistics, as well as fear, skepticism, and hesitancy.~There are two distinct different types of patient navigation. A person can be randomly assigned to either type, or no PN, or a combination of the two types."
223899503|NCT06803706|BEHAVIORAL|6-weeks CBT smoking cessation programme|Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.
223899504|NCT06803706|BEHAVIORAL|Long-term drug therapy within a therapeutic community|The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.
223899505|NCT06293261|DRUG|Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg|Experimental only, not included active and placebo comparator
223899506|NCT06802783|OTHER|Photo consent|The first group was shown photographs of the devices alongside the written consent form, while the second group received only the written consent. The study compared the pain, depression and anxiety scores between the two groups.
223899507|NCT06798519|DRUG|HNC364 Injectable Suspension|Subjects in HNC364 cohort will receive a deep IM injection of HNC364 injectable suspension in the deltoid muscle at a dose of 60 mg every 4 weeks for 4 repeated doses. Subjects will be allowed to leave the clinical site the next day after receiving each dose and return to clinical site on 7 days, 14 days and 28 days (before next administration) after each dose for safety and tolerability assessments. Besides, subjects will return to the clinical site on 4 days after the first dose and the last dose due to PK and PD blood sample collections.
223899508|NCT06798519|DRUG|Rasagiline Tablets|Subjects in rasagiline tablets cohort will receive 1 mg of rasagiline tablets orally once daily for 20 days, followed by 2 mg once daily for 5 days. Subjects will remain domiciled at the clinic stay until Day 26 and have a follow-up visit on Day 29 due to PK and PD blood sample collections
223899509|NCT06800729|DRUG|TIX100, an orally available inhibitor of thioredoxin-interacting protein|TIX100, an orally available inhibitor of thioredoxin-interacting protein
223899510|NCT06800729|DRUG|Placebo|placebo
223899511|NCT06803992|DRUG|Dinoprostone vaginal insert|Described in the arm descriptions
223899512|NCT06803992|COMBINATION_PRODUCT|Dinoprostone gel and Foley catheter balloon|Described in the arm descriptions
223899513|NCT06803550|OTHER|Enhanced recovery after surgery protocol|"ERAS pathway was developed based on the available guidelines and protocols it includes 14 items:~1. Preoperative patient education using an information sheet which includes instructions on postoperative wound care, pain management, and preventing and managing constipation.~2. Single preoperative enema 2 hours prior to surgery.~3. Solid or semisolid food stopped 6 hours before surgery.~4. Clear liquids may be continued up to 2 hours before surgery.~5. Preoperative carbohydrate loading in non-diabetic patients for up to 2 hours prior to surgery in the form of a single 330 ml high-carbohydrate clear drink (apple juice).~6. Saddle anesthesia.~7. Single dose of intravenous 500 mg metronidazole at the time of the anaesthesi induction.~8. Restriction of intraoperative intravenous fluids to less than 500 ml.~9. Balanced chloride-restricted crystalloid solutions should be used for maintenance infusions and fluid boluses.~10. A bundle measures to reduce surgical site infection which includes"
223899514|NCT06803550|OTHER|Routine pathway|This is the routine preoperative preparation at our institute
223899515|NCT06803472|DEVICE|pulsed high intensity laser therapy|The high-intensity laser therapy (HILT), which involves laser radiation with high-intensity, is a kind of novel and powerful . The HILT possesses its own photomechanical, photothermal, and the photo-chemical properties.
223899516|NCT06803472|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy is an acoustic wave that mechanically disrupts tissue by cavitation.Shock waves develop microscopic injuries in scar tissue and break down collagen fibers which lead to scar remodelin .The patient is positioned in a comfortable position. The scar site is prepared with contact gel to conduct the shock waves, 30-50 shocks/cm2 , with an energy flux density of 0.25mJ/mm2 and a frequency of 6Hz. Each treatment region is covered with 2500 to 3000 impulses with an average session time of 10-15min .
224083455|NCT04106622|PROCEDURE|electrophysiological study|"To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF."
223899517|NCT03754699|BEHAVIORAL|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D0 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~* the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~* nature of postoperative pain (inflammatory character, dynamic over time)~* average pain level incurred by the intervention~* the difference between anti-inflammatory and opioid analgesics~* principles of systematic treatment and pain anticipation~* principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
223899518|NCT03754699|BEHAVIORAL|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
223899519|NCT06800664|BEHAVIORAL|Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan|Health providers and management at IG sites will receive ISS (i.e., management support, capacity-building, and social network support) and training on the HOPE implementation plan
223899520|NCT06800664|BEHAVIORAL|Control Group|Providers in the control group will not receive ISS support
223899521|NCT06759805|OTHER|eCardiacRehab|Interdisciplinary supervised home-based digital secondary prevention programme (12-week programme) based on the European Society of Cardiology guidelines for cardiac rehabilitation for patients after percutaneous coronary intervention.
223899522|NCT04105777|DEVICE|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
223899523|NCT04105777|DEVICE|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
223899524|NCT05549349|PROCEDURE|Cholecystectomy|Gallbladder removal
223899525|NCT06803953|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
223899526|NCT06803953|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
223899527|NCT06803953|DIAGNOSTIC_TEST|Nasal Allergen Challenge|nasal allergen challenge with either house dust mite allergens or birch pollen allergens
223899528|NCT06045663|PROCEDURE|laminectomy without lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
223899529|NCT06045663|PROCEDURE|laminectomy with lateral mass fixation|patient will divided into two group the first group will undergo cervical laminectomy without lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation while the second group will undergo cervical laminectomy with lateral mass fixation
223714763|NCT02883270|OTHER|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
223899531|NCT05347667|OTHER|Unilateral Resistance Exercise Leg|One leg will perform unilateral resistance exercise
223899532|NCT05347667|OTHER|Control Leg|One leg will serve as a non-exercise control
223899533|NCT04279236|OTHER|Abbreviated Profile Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
223899534|NCT04279236|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
223899535|NCT04279236|OTHER|Additional follow-up visit|There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
223899536|NCT05944016|DRUG|Dapagliflozin|Dapagliflozin (standard dose 10 mg p.o. once daily)
223899537|NCT05944016|DRUG|Placebo|Placebo (standard dose p.o. once daily)
223899538|NCT02573493|DRUG|nab-Paclitaxel|
223899539|NCT02573493|DRUG|Cisplatin|
223899540|NCT02573493|BIOLOGICAL|Cetuximab|
223899541|NCT02573493|RADIATION|Intensity-Modulated Radiation Therapy|
223714764|NCT03978000|DRUG|IBP-9414|Oral suspension
223714765|NCT03978000|DRUG|Placebo|Sterile water
223714766|NCT00811759|DRUG|sorafenib tosylate|
223714767|NCT00811759|DRUG|temozolomide|
223714768|NCT00811759|GENETIC|gene expression analysis|
223899542|NCT06425133|PROCEDURE|Blood sample|Blood sample for plasma collection, Blood sample for ctDNA (circulating tumoral DNA) collection
223899543|NCT06425133|OTHER|Quality of life questionnaires|EORTC QLQ-C30 questionnaire (Quality of life questionnaire Cancer 30) CR29 questionnaire (Colo-rectal cancer 29) EQ-5D5L questionnaire (EuroQol-5 Dimensions, 5 levels): repeated measures at baseline, M2, M4, M6, M8, M10, M12 and during the end of treatment visit and during the follow-up
223899544|NCT06425133|PROCEDURE|Biopsy|Fresh tumor biopsy at baseline and week 8
223899545|NCT06425133|DRUG|Regorafenib|"For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle."
223714769|NCT00811759|GENETIC|mutation analysis|
223714770|NCT00811759|OTHER|laboratory biomarker analysis|
223714771|NCT00811759|OTHER|pharmacological study|
223714772|NCT00811759|PROCEDURE|biopsy|
223714773|NCT04092400|DEVICE|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
223714774|NCT00511446|DRUG|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
223714775|NCT04688957|PROCEDURE|oseodensification sinus lifting|application of first densah bur with densifying mood (reverse) counterclockwise, 1200 revolution per minute until the sinus is reached then use a wider densah bur with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.
223714776|NCT04688957|PROCEDURE|osteotome sinus lifting|drilling implant site with consecutive drills short of the sinus floor by 1-2mm , using osteotome in appropriate size and application of one tap until sinus floor is elevated, using the final drill for the desired implant diameter
223714777|NCT02599714|DRUG|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
223714778|NCT02599714|DRUG|Palbociclib|cyclin dependent kinase inhibitor
223714779|NCT02599714|DRUG|Fulvestrant|Fulvestrant hormonal therapy as background
223714780|NCT01133873|DRUG|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
223714781|NCT01133873|DRUG|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
223714782|NCT01423318|DRUG|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
223714783|NCT01423318|DRUG|placebo|single dose subcutaneously
223714784|NCT01785264|PROCEDURE|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
223714785|NCT01785264|PROCEDURE|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
223714786|NCT01785264|PROCEDURE|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
223714787|NCT00372671|BEHAVIORAL|Survey|
223714788|NCT00372671|BEHAVIORAL|Survey and videotape|
223714789|NCT06438458|PROCEDURE|Postural change from supine to sitting|Patients go from supine to sitting position in bed (passive)
223714790|NCT06438458|PROCEDURE|Mobilization to a chair|Patients go from the bed to sitting in a chair (active)
223714791|NCT00824720|DRUG|High Dose Device|inserted for 14 days
223714792|NCT00824720|DRUG|Low Dose Device|inserted for 14 days
223714793|NCT00824720|DEVICE|Placebo Device|inserted for 14 days
223714794|NCT06189703|DEVICE|tRNS|transcranial random noise stimulation applied to the right IFG and the left DLPFC
223714795|NCT00895232|DRUG|Cohort I|
223714796|NCT00895232|DRUG|Cohort II|
223714797|NCT00895232|DRUG|Cohort III|
223714798|NCT06067061|COMBINATION_PRODUCT|Atezolizumab + RP1|Patients will be treated in a window period (ie 3 treatment cycles). After evaluation, patients that had no increase in ctDNA after 3 cycles (see Definition of ctDNA status) will continue on the same treatment (intratumoral injections of RP1 in combination with Atezolizumab) for a total of 10 treatment cycles prior to surgery.
223714799|NCT05552001|DRUG|Sacituzumab govitecan|Sacituzumab Govitecan (SG) is given by intervenous route, 10 mg/kg on day 1 and day 8 of 21-day treatment cycles. Patient will receive treatment until disease progression, unacceptable toxicity, or decision to withdraw its participation.
223714800|NCT02044445|PROCEDURE|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
223714801|NCT03120312|PROCEDURE|total hip replacement|primary hip replacement patients during past 5 years．
223714802|NCT06663709|OTHER|BRACE|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 0-3 : Balance: Romberg, tandem standing, single leg stance TUG test Resistance: chair rise, Stair climbing Aerobic exercises: 6mint walk, count reverse from 30, push wall and reverse count from 20 Cognitive: count reverse from 50. Week 4-6: Balance: Sit to stand, functional reach, Tug Test, Perturbation, Kick a ball Resistance: stair climbing Aerobic Exercises: Marching in space, Cycling Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Combination of all Resistance: Combination of all Aerobic Exercises: Cycling , Marching, 6 min Walk Cognitive: Combination of all
223714803|NCT06663709|OTHER|TASK-oriented|Study will be conducted after the approval of Ethical review board. Task oriented training would be perform in 3 times a week for 9 weeks, lasting approximately 40-60 minutes each time. Week 1-3 Warm Up (sit to stand,5 reps)(cycling 3-5 min) , Single leg stand with eye open 15 sec, with eye close 10sec, forward, backward, and side stepping (5 reps) reaching, Transition from sit to stand, Walk then back to sit (3 min),Walk with even steps(3min) Walk with carrying objects. (3min) Week 4-6 Warm up Period, Task oriented training (7 Reps of each task) Week 7-9 Warm up Period, Task oriented training (9Reps of each task)
223714804|NCT01857856|DRUG|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
223719228|NCT05230771|COMBINATION_PRODUCT|Palliative surgery after translational therapy|"A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location."
223719229|NCT05230771|DRUG|Chemotheraoy along|Patients receive only the prescribed chemotherapy.
223899546|NCT06425133|COMBINATION_PRODUCT|Regorafenib + metronomic chemotherapy|"• Regorafenib will be administered 3 weeks out of 4 (1 cycle corresponding to 4 weeks) until progression or unacceptable toxicity.~For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.~* Metronomic chemotherapy will be administrated as following:Cyclophosphamide: 50 mg per os, daily, for 6 months,Capecitabine: 625mg/m²/orally twice daily, for 6 months.~* Low-dose Aspirin: 75 mg orally, daily, until progression."
223899547|NCT05018481|DRUG|Sodium Hyaluronate|Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
223899548|NCT05018481|DRUG|Placebo|A placebo will be given in capsule form to study participants
223899549|NCT06020716|DRUG|Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution|Three times daily
223899550|NCT06020716|DRUG|Placebo|Three times daily
223899551|NCT06493370|DRUG|Intravenous ascorbic acid/vitamin C|A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
223899552|NCT04149704|BEHAVIORAL|ACP video decision aid|10 minute video decision aid describing the goals-of-care options
223899553|NCT04149704|OTHER|Usual Care-|Verbal description of the three types of care
223899554|NCT06494436|DEVICE|All Microvention Class III implantable device CE marked|Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
223899555|NCT03017911|PROCEDURE|Piccline|
223899556|NCT04332926|OTHER|Tobacco product administration and assessment, own brand cigarettes|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
223899557|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
223899558|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
223899559|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
223899560|NCT04332926|OTHER|Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine|4 sample puffs, followed by a 60 minute rest period, hypothetical drug purchase tasks, followed by progressive ratio tasks (single product and two products, with 60 minute rest in between) where participants work to earn puffs of tobacco products; preceded and followed by physiological and subjective assessment
224083456|NCT04760002|DEVICE|NightOwl|The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
224083457|NCT02244242|DRUG|Tamsulosin hydrochloride|
224083458|NCT04055103|OTHER|Monthly feedback, education and linking hospitals|\- Give monthly feedback from LROI-data (revision rate \& patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
224083459|NCT00838591|DRUG|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
224083460|NCT00838591|DRUG|Placebo|
224083461|NCT04753892|OTHER|3SM2-G-CRM197 with squalene adjuvant|Immune challenge agent
223899561|NCT06143917|BEHAVIORAL|parent-child sleep intervention|The intervention plan is as follows: (1) Parent-child sleep education includes two in-person session and four pre-recorded online sessions. Additionally, it provides educational handbooks tailored to the course content, segmented into sections for both parents and newborns. Each session lasts approximately 20 minutes; (2) Heart rate variability measurement and Heart rate variability biofeedback are conducted in classes in person. It guides parents through breathing exercises to activate the parasympathetic nervous system, thereby easing emotions and improving psychological health; (3) Professional counseling and support are provided separately at two weeks, one month, three months, and six months postpartum.
223899562|NCT05832996|DRUG|Refresh Plus Preservative-free Lubricant Eye Drops|Refresh Plus Preservative-free Lubricant Eye Drops at either 4 or 25 degree Celsius
223899563|NCT05641103|OTHER|Patient with splenomegaly or splenectomy|No interventional study
223714805|NCT05983757|DEVICE|Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion|"The AXS Catalyst Distal Access Catheter is indicated for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems, and is also indicated for use as a conduit for retrieval devices.~The AXS Vecta Intermediate Catheter, as part of the AXS Vecta Aspiration System, is indicated in the revascularization of patients with acute ischemic stroke. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment.~The Trevo® Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA)."
223714806|NCT05983757|OTHER|Standard medical management|All subjects should receive the best standard medical therapy based on current AHA guidelines. Subjects randomized to standard medical management (SMM) will receive standard medical therapy only based on the guidelines. All subjects are expected to be admitted to hospital as part of routine best guideline-based care and treated on a stroke unit or neurointensive care unit or equivalent.
223714807|NCT01422174|PROCEDURE|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
223714808|NCT07015827|OTHER|Mango (langra)|Participants will consume mango variety A . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
223714809|NCT07015827|OTHER|mango (chaunsa)|Participants will consume mango variety B . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
223714810|NCT07015827|OTHER|MANGO (SINDHRI)|Participants will consume mango variety C . The test food will provide 50 grams of available carbohydrates, and will be consumed after an overnight fast.
223714811|NCT03835780|OTHER|No intervention|A observation of outcomes in usual practice
223714812|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
223714813|NCT04731363|DIETARY_SUPPLEMENT|erythritol, 30g|Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
223714814|NCT04731363|DIETARY_SUPPLEMENT|xylitol, 5g|Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
223714815|NCT04731363|DIETARY_SUPPLEMENT|glucose, 30g|Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
223714816|NCT07053644|BEHAVIORAL|FRESH-EATS|"1. Six weekly Cooking Matters® for Families sessions. Each session is designed to take 90 minutes including hands-on cooking or other activities.~2. Two 90-minute family workshop sessions will be implemented.~3. Food delivery budget (i.e., the Walmart+ annual membership with free shipping and gift cards to purchase ingredients) will be provided up during the intervention period and local food pantry information will be distributed to families.~4. Community garden at the Cornerstone Family Ministries will be utilized by incorporating garden activities, harvesting, and cooking with the produce from the garden."
223714817|NCT07053644|BEHAVIORAL|Lagged Intervention Control Group|Nutrition education materials that address nutrition in school-age children and families Cooking Matters® for Families will be implemented. Each of six sessions will take about 90 minutes. All lessons will be delivered by qualified nutrition educators along with student assistants at the Cornerstone Family Ministries classrooms. After completing the post-intervention assessment, participants will then receive the other FRESH-EATS intervention components.
223714818|NCT07053436|DRUG|Bispecific Monoclonal Antibody and Triplet Therapy|Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy
223714819|NCT07053436|DRUG|Monoclonal Antibody with Stem Cell Transplant|Isatuximab-KRd with Autologous Stem Cell Transplant
223714820|NCT07054580|BEHAVIORAL|knowledge and awareness|Focus on the level of knowledge and awareness regarding instrument sterilization protocols among healthcare workers in the operation theater.
223714821|NCT07054151|OTHER|No clinical intervention (observational study only)|This is an observational study. No experimental or clinical intervention was applied. Only non-invasive data collection such as capillary refill time and vital sign measurements was performed.
223714822|NCT07054008|PROCEDURE|Microsurgical approach with Digital Microscope|The incision will be sutured with the use of a digital microscope (30 X) (Group 1). The microsurgical approach is a research only procedure that may add time to the total surgical time (\< 6%).
223714823|NCT07054996|OTHER|body awareness therapy|Basic body awareness training will be applied to preschool children in terms of motor development and body perception
223714824|NCT07054996|OTHER|play-based exercise|Play-based exercise training will be implemented for preschool children by designing games that they enjoy playing, in order to support motor development and body perception.
223714825|NCT07053098|OTHER|Implementation Facilitation|Implementation facilitation is a multi-faceted process of enabling and supporting the adoption and integration of best practices into routine clinical care. It involves collaboration to understand a setting's challenges and barriers and working together to identify the best activities to address them. IF will incorporate External Facilitation, a problem-solving implementation strategy that builds supportive interpersonal relationships between an External Facilitator who is outside of the clinic who works with clinics and their identified internal champions to learn their unique barriers to implementation, use strategies to address these barriers, and plan for sustainability by integrating the practice into routine processes and workflows. Other implementation activities that will be used IF include staff training, patient education, audit and feedback, and care coordination.
223714826|NCT07054255|DRUG|Test formulation (Ranolazine extended-release tablets)|A single oral dose of 500 mg, taken with 240mL of water
223714827|NCT07054255|DRUG|Reference formulation (Ranolazine extended-release tablets)|A single oral dose of 500 mg, taken with 240mL of water
223714828|NCT07054047|OTHER|mrTDV|The training of radiologists to implement specialised MRI reporting using the TDV staging system
223899564|NCT05815030|OTHER|video informational/educational intervention|Videos relating to PrEP use, its benefits, side effects, and other information. The educational/round-table video will highlight individuals from diverse backgrounds and identities who will share their experiences using PrEP, including perceived benefits and effectiveness, experienced barriers to PrEP uptake, their reasons for using PrEP, and their own self-efficacy. The control group's (generic / standard video) materials will be focused on PrEP uptake without a kink identity perspective. The treatment group's materials, however, will include videos that feature kink-identified individuals who discuss PrEP uptake through a kink perspective.
223899565|NCT03629678|OTHER|mobile health application|The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
223899566|NCT00528268|DRUG|Sodium phenylbutyrate|Sodium phenylbutyrate is dispensed as a powder, 450-600 mg/kg/day, divided into four doses. For cohort 1, treatment and monitoring continues for 18 months. For cohort 2, treatment and monitoring continues for 24 months.
223899567|NCT06077903|BIOLOGICAL|GT101|Autologous tumor infiltrating lymphocyte injection
223899568|NCT05743049|OTHER|Obtaining blood for analysis of various circulating biomarkers|4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period
223899569|NCT05707975|OTHER|Identifying a relationship between the intensity of eco-anxiety and the severity of suicide risk in adolescents|Relationship between the intensity of eco-anxiety with the 13-item CAS score, and the seriousness of the suicide risk with the C-SSRS score
223899570|NCT05937438|DRUG|Immune Checkpoint Inhibitors|Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year
223899571|NCT02951325|OTHER|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~* Toxicity:~  1. Weekly RT with toxicity scoring.~ 2. RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~ 3. QOL will be assessed at baseline f/b 3-6 monthly.~* Disease evaluation:~  i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
223899572|NCT03556839|DRUG|Atezolizumab|Intravenous Infusion
223899573|NCT03556839|DRUG|Bevacizumab|Intravenous Infusion
223899574|NCT03556839|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
223899575|NCT03556839|DRUG|Paclitaxel|Intravenous Infusion
223899576|NCT06621641|BEHAVIORAL|The new HFNC weaning protocol|Patients will be randomly assigned to two groups: one following the new HFNC weaning protocol and another using the standard care protocol. The new protocol includes stepwise flow reduction based on the patient's clinical stability and uses the Respiratory Assessment Scale (RAS) to monitor weaning progress. The protocol emphasizes a multidisciplinary approach involving pediatricians, nurses, and respiratory therapists, with consistent training and application of weaning criteria
223899577|NCT01251406|DRUG|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
223899578|NCT01251406|DRUG|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
223899579|NCT01251406|DRUG|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
223899580|NCT06192940|BEHAVIORAL|Counseling home caregivers|Advice on the proper use of insulin therapy will be given, if necessary, to caregivers. Patients are reviewed at 1 month of this first visit with a collection of the same data
223899581|NCT02615730|DRUG|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
223899582|NCT02615730|DRUG|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
223899583|NCT04691817|DRUG|Atezolizumab|1200mg infusion
223899584|NCT04691817|DRUG|Tocilizumab|Tocilizumab 6mg/kg or 4mg/kg infusion
223899585|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 5.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
223899586|NCT06052436|BIOLOGICAL|Allogeneic thyTreg 10.000.000|Treg lymphocytic cells, differentiated, allogeneic, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
223939957|NCT07185555|DIETARY_SUPPLEMENT|VLEKT|Participants will follow a Very Low-Energy Ketogenic Therapy (VLEKT) providing 600-800 kcal/day for 4 weeks. The intervention consists of meal replacements (solid or liquid, ready-to-use or reconstituted) with very low carbohydrate content, high-quality proteins (milk, whey, pea, soy), and fiber (inulin, FOS). Gluten-free, lactose-free, and vegan options are available. Meal replacements are provided by Therascience or Penta at discounted prices. Participants will self-monitor capillary ketonemia daily, maintain adequate hydration, and avoid intense physical exercise. The Advanced Hybrid Closed Loop (AHCL) insulin delivery system will be used throughout the study with periodic adjustments based on device downloads. At the end of the 4-week intervention, a structured reintroduction of conventional meals will be initiated.
223899587|NCT05845086|BEHAVIORAL|Preoperative patient education|In this study, preoperative patient education will be given, reinforced with multimedia supported written and verbal teach-back method, created according to the literature. Videos of exercises used to increase postoperative mobilization (deep breathing exercise, coughing exercise, intensive spirometer use, etc.) will be taken by the researcher in a professional studio. The captured videos will be embedded in the PowerPoint presentation and presented to the patient with a tablet computer. The powerpoit presentation should be a maximum of 30 slides and the patient education should take a maximum of 30 minutes. Patients will be evaluated face-to-face on the 1st, 2nd, 3rd days after surgery and by phone on the 15th day. The prepared powerpoint presentation will be left with the patient as a printout. The prepared video will be given to the patient after the training with a program (via WhatsApp, e-mail, bluetooh) on their phones in accordance with the preferences of the patients.
223899588|NCT04402216|BEHAVIORAL|Child Life-led preparation|Support from a certified child life specialist in preparation for MRI
223899589|NCT04402216|BEHAVIORAL|MRI preparation video|A descriptive video about what to expect when undergoing MRI
223899590|NCT04402216|BEHAVIORAL|KindVR Virtual Reality MRI Preparation Experience|A VR experience to prepare pediatric patients for MRI, to be used in addition to support from a certified child life specialist
223899591|NCT05609786|BEHAVIORAL|Personalized safety planning tool|The myPlan Kenya app is a web-based safety planning tool that is secure, private, free and personalized to the user. The app includes multiple, evidence-based modules: Strategies (safety strategies tailored to the user's needs and violence experience); Resources (referrals to local health, safety and justice resources and services); About You (questionnaires that help the user assess their relationship safety and tailor their Strategies, including My Relationship, Red Flags, My Safety, My Priorities); Understanding (knowledge sections that share information on relationships and violence, including Healthy Relationships, Harmful Beliefs About Abuse, About Violence).
223899592|NCT06532162|DRUG|1% Lidocaine Paracervical Block|"A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm)."
223899593|NCT06532162|DRUG|Normal Saline Paracervical Injection|A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
223899594|NCT01453127|DRUG|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
223899595|NCT01453127|DEVICE|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
223899596|NCT06396338|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
223899597|NCT04390009|DIAGNOSTIC_TEST|Entire-body PET-CT scans|Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.
223899598|NCT04390009|DRUG|Amyvid radiopharmaceutical|Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
223899599|NCT04881630|BEHAVIORAL|Automated Mobile Contingency Management (CM)|Financial incentives contingent upon smoking abstinence
223899600|NCT04881630|OTHER|Standard Care (SC)|Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
223899601|NCT06503692|DEVICE|DKutting PTA Scoring Balloon Dilatation Catheter|The device consists of a balloon catheter with scoring elements (triangular cross-section) fixed to the surface of the balloon and distributed radially at every 120°. When the balloon is inflated, the expansion force is focused along the scoring elements, causing it to expand under lower balloon pressure.
223899602|NCT06503692|DEVICE|Peripheral Balloon Catheter|The device is an over-the-wire (OTW) double-lumen balloon catheter. The balloon is inflated to a known diameter at a specified pressure.
223899603|NCT06127550|DEVICE|active taVNS|low level stimulation to the auricular branch of the vagus nerve
223899604|NCT06127550|DEVICE|sham taVNS|device placed with no current administered
223899605|NCT03674567|DRUG|FLX475|tablet
223899606|NCT03674567|DRUG|pembrolizumab (KEYTRUDA®)|IV infusion
223899607|NCT03958838|BEHAVIORAL|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
224083462|NCT04529291|OTHER|Group with walking disorder|During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
223899608|NCT05731791|RADIATION|Radiation Therapy to partial breast|Patients randomized to ARM 1 will receive 3000 cGy in 5 fractions partial breast radiotherapy with CT-based breast radiation treatment (Arm 1) and patients randomized to ARM 2 will receive 3000 cGy in 5 fractions partial breast radiotherapy with MRI-based breast radiation treatment (Arm 2).
223899609|NCT02882425|DRUG|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
223899610|NCT02882425|DRUG|Selexipag for oral use|Tablet containing 200 µg of selexipag
223899611|NCT06488183|PROCEDURE|preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q|preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q
223899612|NCT05723588|DEVICE|active repetitive transcranial magnetic stimulation|Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.
223899613|NCT05723588|DEVICE|sham repetitive transcranial magnetic stimulation|Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.
223899614|NCT05723588|BEHAVIORAL|cognitive behavioral therapy for smoking cessation|All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.
223899615|NCT05723588|DRUG|nicotine replacement therapy|"All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum."
223899616|NCT05296356|DRUG|OSU6162|OSU6162
223899617|NCT04830137|DRUG|NX-2127|Oral NX-2127
223899618|NCT05412381|PROCEDURE|platelet rich plasma (PRP) injection|We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
223899619|NCT05412381|PROCEDURE|placebo saline injection|Patients randomized into the control arm will receive the placebo or saline injection
223899620|NCT04251585|DRUG|Regular Novolin R|Intranasal insulin
223899621|NCT04251585|DRUG|Placebo|Intranasal placebo (0.9% saline)
223899622|NCT04562194|DEVICE|NeVa Stent Retriever|mechanical neurothrombectomy
223899623|NCT05670730|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
223899624|NCT05670730|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion.
223899625|NCT05213390|OTHER|Dora|DORA uses a variety of AI technologies to deliver the patient follow-up call, including: speech transcription, natural language understanding, a machine-learning conversation model to enable contextual conversations, and speech generation. Together, these technologies cover the input, processing and analysis, and output needed to maintain a natural conversation. DORA is configured to deliver calls through a telephone connection as a real-time, stand-alone system: the operator inputs individual patient details to initiate the call and completes a summary in the electronic health record (EHR) afterwards.
223899626|NCT03892265|OTHER|Observational Study|No intervention is included in this observational study.
223899627|NCT06487078|DRUG|Lorlatinib|ALK-positive NSCL treatment
223899628|NCT06407791|DEVICE|LymphaVibe|The LymphaVibe is a newly-developed device that uses a vibratory sequence to gently move stagnant lymphatic fluid from the arm to the nearest group of functioning lymph nodes
223899629|NCT06035237|OTHER|Cold Spray|Cold Spray: Cold sprays, composed of liquefied gases under high pressure, rapidly evaporate from the applied area, causing a sudden drop in skin temperature. This condition leads to the temporary desensitization of pain receptors or the activation of ion channels, resulting in the brief alleviation of pain sensation. Various medical, non-medical, and surgical methods are employed to manage pain. Cold sprays are among non-medical methods, including massage, cold application, and distraction techniques. Therefore, cold sprays cannot be prescribed like medication. They are used for local anesthesia in cases of acute trauma, injections, blood collection, vein puncture, and similar situations.
223899630|NCT05424276|DRUG|IkT-148009|Oral administration gelatin capsule
223899631|NCT05424276|DRUG|Placebo|Oral administration gelatin capsule
223899632|NCT02000050|DRUG|FOLFOX4|FOLFOX4
223899633|NCT02000050|RADIATION|Tomotherapy|Tomotherapy
223899634|NCT02000050|PROCEDURE|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
223899635|NCT03691857|PROCEDURE|Ultrasound algorithm (EMERALD-US)|Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
223899636|NCT06184568|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg. After 4 weeks of continuous administration, continue to increase to IBI362.
223899637|NCT06184568|DRUG|Semaglutide|Once-weekly injections of gradually increased doses of Semaglutide, subcutaneously (SC)，starting dose is semaglutide 0.25mg, after 4 weeks of continuous administration, increase to semaglutide 0.5mg, after 4 weeks of continuous administration, continue Upgrade to semaglutide 1.0 mg for 24 weeks.
223899638|NCT05556655|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive method for stimulating neurons (axons not cell bodies) in the brain.
223714829|NCT07055360|BEHAVIORAL|Resilience-Based Intervention for Stress Reduction and HIV-Related Efficacy (RISE)|RISE is based on Cognitive-Behavior Therapy (CBT) and the Information-Motivation-Behavioral Skills (IMB) Model. RISE will consist of six, weekly sessions, followed by a booster session in week 8, including resilience-building and health-promoting activities of RISE. Sessions will emphasize the participants' strengths, including positive thoughts, beliefs, and behaviors that work for the client and existing assets and supports in the participant's life. Tailored, health-promotion text messages will be sent weekly after each session.
223714830|NCT07055360|BEHAVIORAL|Waitlist control: Text messaging-reminder comparison condition|This control condition will involve reminder text messages for adherence to HIV treatment and engaging in HIV care. As this condition is a waitlist control, participants in this condition will ultimately receive the RISE intervention.
223714831|NCT07055308|DEVICE|SEAPatch|Daily measurement with multisensory patch from day 1 post-surgery maximally up to the day of discharge from hospital.
223714832|NCT06866379|OTHER|Brain imaging|fMRI session with the ALCUE paradigme.
223714833|NCT05613361|DRUG|Colistin|added for infection with multi drug resistant bacteria
223714834|NCT05613361|DRUG|Curcumin|added for the possible nephroprotective effect
223714835|NCT05092022|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cells for screening purposes.
223714836|NCT05888831|DRUG|BMS-986449|Specified dose on specified days
223714837|NCT05888831|DRUG|Nivolumab|Specified dose on specified days
223714838|NCT06912776|OTHER|Participant will view a visual aid picture (appendix A) first|Participant will view a visual aid picture (appendix A) of a post delivery complication first
223714839|NCT06912776|OTHER|Participant will view a visual aid picture (appendix B) first|Participant will view a visual aid picture (appendix B) of a post delivery complication first
223714840|NCT06191575|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7T MRI
223714841|NCT06191575|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223714842|NCT06191575|PROCEDURE|Cognitive Assessment|Undergo cognitive assessment
223714843|NCT06917677|BEHAVIORAL|2000-meter maximal effort test on rowing ergometer|Participants will perform a 2000-meter maximal effort test on a Concept II rowing ergometer, aiming to complete the distance in the shortest possible time. The test simulates a competitive race and serves as a qualification trial. It will be conducted under medical supervision and is intended to induce a high level of physiological and psychological stress representative of elite competition.
223714844|NCT06929871|DEVICE|Mako cementless TKA|Mako robotic-arm assisted total knee arthroplasty using cementless implants
223714845|NCT06929871|DEVICE|Mako cemented TKA|Mako robotic-arm assisted total knee arthroplasty using cemented implants
223714846|NCT05605704|DRUG|Atherolive|The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
223714847|NCT05605704|DRUG|Placebo Atherolive|The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.
223714848|NCT06941077|DRUG|INCB057643|Tablet
223714849|NCT06942377|DRUG|Amlodipine|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine
223714850|NCT06950060|BEHAVIORAL|Moderate-to-high intensity cycling|Participants cycle on a stationary ergometer at an intensity prescribed to reach their lactate threshold, guided by VO2 max results and lactate sampling. The session lasts approximately 20 minutes and is preceded and followed by TMS assessments and a structured motor learning task. This condition is designed to evaluate the effect of exercise-induced metabolic stress on cortical inhibition and motor learning.
223714851|NCT06950060|BEHAVIORAL|Low-intensity cycling|Participants perform 20 minutes of cycling at a light workload below their lactate threshold. Exercise intensity is individualized using heart rate and perceived exertion (Borg RPE scale), avoiding significant metabolic activation. TMS and motor learning are assessed pre- and post-exercise. This condition serves as an active comparator to assess the impact of exercise intensity.
223714852|NCT06950060|BEHAVIORAL|Health education session|Participants receive a 20-minute session of health education content (e.g., wellness, healthy aging). No exercise is performed. Participants undergo TMS and motor learning testing before and after the session. This condition is used to control for attention and cognitive engagement without physical activity.
223714853|NCT06954636|DIAGNOSTIC_TEST|olfactory testing (threshold and identification test)|"In the identification test, 12 sniffin sticks are presented, which the patient has to name using a selection card with four terms each. Both nostrils are tested individually at each visit during the identification test. A correct answer scores one point. A maximum of 12 points is possible.~The threshold test consists of 16 dilution levels. Each level contains one sniffin stick with odor and two blanks. All three sniffin sticks of a dilution level are presented to the patient one after the other with eyes closed. The patient must indicate which of the three sticks contains an odor. Depending on whether the patient gives the correct answer, the three sniffin sticks in the next higher or next lower level are presented next. A maximum of 16 points is possible."
223714854|NCT00688753|DRUG|RAD001|
223714855|NCT05467280|OTHER|Online HIIT Intervention|They will be given HIIT exercise video sessions twice a week for 6 months, through a mobile application where they will also be given nutritional and health advice, webinars and challenges.
223714856|NCT03619486|DEVICE|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
223714857|NCT03619486|DEVICE|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
223714858|NCT03744611|DIETARY_SUPPLEMENT|CE|550mg capsule (Eucommia ulmoides Oliver extract)
223714859|NCT03744611|DIETARY_SUPPLEMENT|Placebo|550mg capsule (Placebo)
223714860|NCT02256904|PROCEDURE|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
223714861|NCT02256904|PROCEDURE|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
223714862|NCT03968484|BIOLOGICAL|platelet transfusion|Transfusion of platelets
223899639|NCT06362668|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
223899640|NCT06362668|DRUG|Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
223899641|NCT05086380|BEHAVIORAL|Mindfulness-based stress reduction therapy|MBSR Therapy is a structured 8-week program that employs mindfulness meditation to alleviate suffering associated with physical, psychosomatic and psychiatric disorders. The program is based upon a systematic procedure to develop enhanced awareness of moment-to-moment experience of perceptible mental processes.
223899642|NCT05086380|DEVICE|Inhibitory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using cTBS stimulation protocol for transcranial magnetic stimulation
223899643|NCT05086380|BEHAVIORAL|Psychoeducation|Participants will learn about the symptoms and how to cope with the symptoms
223899644|NCT05086380|DEVICE|TMS sham|The device will be used to neuromodulate the right TPJ of participants' brain using transcranial magnetic stimulation over the vertex
223899645|NCT05086380|DEVICE|Excitatory TMS|The device will be used to neuromodulate the right TPJ of participants' brain using iTBS stimulation protocol for transcranial magnetic stimulation
223899646|NCT05086380|DEVICE|Virtual Reality|The device will be used to manipulate the perception of symptoms of patients while they are playing a game in virtual/augmented reality.
223714863|NCT05219214|OTHER|Chinese medicine|There are no restrictions on TCM therapy, including Chinese herbal medicine, Chinese patent medicine, external treatment, acupuncture and moxibustion, etc
223714864|NCT03591471|DRUG|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
223714865|NCT03591471|DRUG|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
223714866|NCT03591471|DRUG|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
223714867|NCT03591471|DRUG|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
223714868|NCT03591471|DRUG|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
223714869|NCT03591471|DRUG|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
223899647|NCT05086380|BEHAVIORAL|Neurofeedback|Neurofeedback training will be applied in patients while laying in an MRI scanner. Patients will play a game, which targets the sense of agency, and will receive a real-time feedback about their performance and brain activity. They will learn to self-regulate their performance on the game in order to increase brain activity relevant for the sense of agency.
223899648|NCT02667873|DRUG|SL-801|SL-801 is a small-molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
223899649|NCT04615104|PROCEDURE|Operative|surgical treatment
223899650|NCT04615104|PROCEDURE|Nonoperative|nonsurgical treatment
223899651|NCT06448247|DRUG|SPY001-001|Experimental
223899652|NCT06448247|OTHER|Placebo|Placebo
223899653|NCT06141850|BEHAVIORAL|COVID-19 Test Reporting|Participants will use a simple text-based data reporting tool which they will be asked to use to report any COVID-19 testing during the 12-month long tudy.
223899654|NCT06141850|BEHAVIORAL|Personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages, personalized to participants' diabetes status, race/ethnicity, age group, sex, and/or vaccine/testing history, will be sent in weeks 1-16 of the intervention to encourage adherence to COVID-19 testing and preventive behaviors as well as other behaviors important for diabetes management, prevention, or care.
223899655|NCT06141850|BEHAVIORAL|Non-personalized Nudges via Text Messaging|Weekly behavioral nudges via mobile phone text messages will be sent in weeks 1-16 of the intervention sharing tips lifestyle behaviors important for diabetes management and prevention (e.g., exercise, eating a healthy diet, etc.).
223899656|NCT04052061|BIOLOGICAL|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
223899657|NCT02724449|DEVICE|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
223899658|NCT06180902|DIAGNOSTIC_TEST|Inferior vena cava's diameter ratio|"In mechanical ventilation, the Inferior Vena Cava's maximum diameter (IVCmax) is measured at peak inspiration, and minimum diameter (IVCmin) at expiration's end. The Distensibility Index (IVCDI) is calculated as \[(IVCmax - IVCmin) / IVCmin\] × 100%. In spontaneous breathing, IVCmax is the diameter at expiration's end, and IVCmin at inspiration's end. The Collapse Index (IVCCI) is \[(IVCmax - IVCmin) / IVCmax\] × 100%.~Clinically, an IVCDI/IVCCI ≥ 18% indicates a 'responder'. Values \< 18% denote 'non-responders'."
223899659|NCT06180902|DIAGNOSTIC_TEST|Central venous pressure|"In our protocol, patients lie flat, connected to a saline-filled system for intravenous infusion via a central venous catheter. The system, starting from the subclavian catheter, extends to the 2nd to 3rd intercostal space at the mid-axillary line. The tube's end is raised perpendicular to the bed until saline flow stops, marking the liquid level. The height from the mid-axillary line to this point is measured in millimeters. If the liquid column falls below the mid-axillary line, indicating continuous flow, the CVP is negative, and the catheter is closed to block air entry. CVP readings are taken at exhalation's end.~CVP interpretation:~* CVP ≤ 12 mmHg (16.3 cm H2O) indicates a responder.~* CVP \> 12 mmHg (16.3 cm H2O) indicates a non-responder."
223714870|NCT03591471|DRUG|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
223899660|NCT06180902|DIAGNOSTIC_TEST|Passive leg raising test|"In our protocol, the patient starts flat for initial CVP measurement. Then, the bed is tilted to 45 degrees for the first measurements: Systolic/Diastolic Blood Pressure, Mean Arterial Pressure, and Pulse Pressure (Systolic - Diastolic). Next, the bed is adjusted to elevate the feet, creating a 135-degree angle between torso and legs. After 90 seconds, the second set of measurements, including CVP, is taken. The patient is then returned to the initial position.~Interpreting results:~A responder is indicated by:~* Over 10% Pulse Pressure (PP) increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second measurement CVP ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* Less than 10% PP increase in the second measurement;~* The ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second measurement CVP \> 12 mmHg (16.3 cm H2O)."
223899661|NCT06180902|DIAGNOSTIC_TEST|Fluid challenge|"In our clinical procedure, patients start horizontally for initial measurements: Systolic, Diastolic, Mean Arterial, Pulse Blood Pressures, and Central Venous Pressure (CVP). Then, they receive a balanced crystalloid solution at 4 ml/kg body weight at maximum permissible infusion rate. After infusion, a second measurement set identical to the first is taken.~Interpretation:~A responder is indicated by:~* Pulse Pressure (PP) increase \> 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) \> 1;~* Second CVP measurement ≤ 12 mmHg (16.3 cm H2O).~A non-responder is indicated by the presence at least one of the following:~* PP increase \< 10% in second measurement;~* Ratio of PP change to CVP change (∆PP / ∆CVP) ≤ 1;~* Second CVP measurement \> 12 mmHg (16.3 cm H2O)."
223899662|NCT06180902|PROCEDURE|Fluid infusion|After assessing infusion therapy responsiveness, patients receive balanced crystalloid solutions at 1000 ml, infused at 15 ml/kg/hour, accounting for any prior infusions. Effectiveness evaluation follows, involving cardiac output reassessment (initially measured upon study enrollment). Effectiveness is determined by a ≥10% increase in cardiac output in the second measurement compared to the first. This is quantified as: \[(CO(after) - CO(before)) / CO(before)\] × 100% ≥ 10%, where CO(after) is the post-infusion cardiac output and CO(before) the pre-infusion output.
223899663|NCT06640725|DRUG|Avelumab administration at 10mg/kg|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)"
223899664|NCT06640725|DRUG|Cetuximab (Erbitux)|"Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])"
223899665|NCT03611686|DRUG|Local chemotherapy|Local chemotherapy will be administrated according to local recommendation
223899666|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Application of photobiomodulation;~4. Relative isolation (lip bumper, cotton roll and aspirator);~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Cleaning with cotton and water;~7. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~8. Application of mild compressed air on adhesive for 3 seconds;~9. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~10. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~11. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
223939958|NCT07187648|DIETARY_SUPPLEMENT|Golden Rice Cookies With Piper crocatum|Golden Rice cookies enriched with Piper crocatum were formulated as a functional food containing β-carotene and bioactive compounds (polyphenols, flavonoids, tannins). Participants in the experimental arm consume 20 g twice daily (40 g/day total) for 28 days. The cookies are iso-caloric with control cookies but differ by inclusion of Golden Rice and Piper crocatum.
223714871|NCT03591471|DRUG|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
223714872|NCT05619081|BEHAVIORAL|POWERNAP|POWERNAP of max 30min while participants ly down comfortably
223899667|NCT06538142|PROCEDURE|Restoration with Self-cure Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment);~3. Relative isolation (lip bumper, cotton roll and aspirator);~4. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~5. Cleaning with cotton and water;~6. Application of primer (Stela; SDI, Melbourne, Vic, Australia) on dentin and/or enamel, wait 5 seconds;~7. Application of mild compressed air on adhesive for 3 seconds;~8. Restoration with self-cure composite resin (Stela; SDI, Melbourne, Vic, Australia) extending to adjacent demarcated opacities;~9. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~10. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
223899668|NCT06538142|PROCEDURE|Photobiomodulation + Restoration with Photopolymerizable Bulk-fill Composite Resin|"1. Initial periapical radiograph;~2. Hypersensitivity reading (visual analogue scale for subjective pain of volunteer and SCASS for examiner's assessment;~3. Relative isolation;~4. Application of photobiomodulation;~5. Selective removal of carious tissue with curette (only Code 6 of MIH-SSS criteria);~6. Selective etching of enamel adjacent to demarcated opacities with 35% phosphoric acid for 20s;~7. Active application of universal adhesive (Ambar) on dentin and enamel for 20 seconds (repeat procedure);~8. Application of mild compressed air on adhesive for 5 seconds;~9. Photoactivation for 10s;~10. Restoration with Tetric N Ceram bulk-fill composite resin; with increments up to 4 mm, extending to demarcated opacities;~11. Photoactivation for 10 seconds;~12. Clinical follow up after 48 hours and at four-month intervals for a period of 12 months;~13. Hypersensitivity reading after 48 hours and at four-month intervals for a period of 12 months."
223899669|NCT06539936|DEVICE|Glide|Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.
223899670|NCT06539936|DEVICE|Direct Control|Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
223899671|NCT04770571|DEVICE|observational study|observational
223899672|NCT04390347|DIETARY_SUPPLEMENT|Yakult|A fermented milk product with live microorganisms.
223899673|NCT04390347|DIETARY_SUPPLEMENT|Placebo|A milk product with no live microorganisms.
223899674|NCT06193174|DRUG|C134 Re-Administration|Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
223899675|NCT04550845|BEHAVIORAL|Focus group analyses|Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
223899676|NCT06128382|BIOLOGICAL|OVX033|One single administration intramuscularly on Day 1
223899677|NCT06128382|BIOLOGICAL|Saline solution|One single administration intramuscularly on Day 1
223899678|NCT02852330|DEVICE|SA16 research software|Software for measurement of voltage tomography intraoperatively.
223899679|NCT02852330|DEVICE|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
223899680|NCT03507842|DRUG|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
223899681|NCT03507842|DRUG|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
223899682|NCT03507842|DRUG|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
223899683|NCT05674578|BEHAVIORAL|Patient Navigation|Assigned a patient navigator and receive coaching
223899684|NCT05674578|OTHER|Quality-of-Life Assessment|Ancillary studies
223899685|NCT05674578|OTHER|Questionnaire Administration|Ancillary studies
223899686|NCT06725602|DEVICE|"TQ - Proximal Application (high and tight)"|"Tourniquet application: proximal (high and tight) on arms and thighs."
223899687|NCT06725602|DEVICE|TQ - Controlled application (2-3 inches)|TQ Application: controlled (2-3 inches proximal to the injury) on forearms and legs.
223899688|NCT06515990|DRUG|DM005|An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
223899689|NCT05641402|OTHER|Text messages|Text messages based on behaviour change techniques
223899690|NCT04543357|OTHER|Blood Draw|Blood Samples for NAb and ADA to AAV9
223899691|NCT03364803|OTHER|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
223899692|NCT03364803|OTHER|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
223899693|NCT03364803|OTHER|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
223899694|NCT03364803|OTHER|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
223899695|NCT03364803|OTHER|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
223899696|NCT03364803|OTHER|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
223899697|NCT03364803|OTHER|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
223899698|NCT03364803|OTHER|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
223899699|NCT03364803|OTHER|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
223899700|NCT03364803|OTHER|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
223899701|NCT03364803|OTHER|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
223899702|NCT06352359|DRUG|ONC-841|ONC-841 (anti-SIGLEC10) is a humanized antibody that binds to human sialic acid-binding Ig-like lectin 10 and has a human immunoglobulin G4 (IgG4) Fc domain.
223899703|NCT06566534|BEHAVIORAL|Reminder|Flu shot messages via SMS
223899704|NCT06112275|DRUG|ETX101|ETX101 is composed of a non-replicating, recombinant adeno-associated viral serotype 9 (rAAV9) vector used to deliver a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A).
223899705|NCT04482140|DEVICE|Genta-Foil resorb®|Use of Genta-Foil resorb® to prevent adhesions in patients undergoing hand surgery
223899706|NCT05337189|DIAGNOSTIC_TEST|Urine DNA methylation analysis|Urine specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)
223899707|NCT05337189|PROCEDURE|medical imaging and/or cystoscopy and/or pathological examination|Subjects will undergo medical imaging and/or cystoscopy and/or pathological examination
223899708|NCT04950075|DRUG|INBRX-109|Tetravalent DR5 Agonist Antibody
223899709|NCT04950075|DRUG|Placebo|Placebo
223899710|NCT06349408|DRUG|IBI3001|"The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)"
223899711|NCT03800693|DRUG|Fluorouracil|Given IV
223899712|NCT03800693|DRUG|Leucovorin|Given IV
223899713|NCT03800693|DRUG|Oxaliplatin|Given IV
223899714|NCT04621279|PROCEDURE|Normothermia|Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).
223899715|NCT04621279|PROCEDURE|Whole body therapeutic hypothermia|Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.
223899716|NCT06108336|PROCEDURE|TMS during sequence-demanding task|TMS is administered during the execution of sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
223899717|NCT06108336|PROCEDURE|No TMS during sequence-demanding task|TMS is not administered during the execution of sequence-demanding task.
223899718|NCT06108336|PROCEDURE|TMS during non-sequence-demanding task|TMS is administered during the execution of non-sequence-demanding task. Transcranial magnetic stimulation (TMS) is a safe and non-invasive technique for transiently modulating brain activity
223899719|NCT06108336|PROCEDURE|No TMS during non-sequence-demanding task|TMS is not administered during the execution of non-sequence-demanding task
223899720|NCT06167317|DRUG|GS-0201|Pill administered orally
223899721|NCT06167317|DRUG|Sacituzumab Govitecan|Administered intravenously
223899722|NCT05151926|PROCEDURE|Full weight-bearing|Instruction for full and immediate weight-bearing postoperatively
223899723|NCT05151926|PROCEDURE|Partial weight-bearing|Instruction for partial weight-bearing for 6 weeks postoperatively
223899724|NCT05151926|PROCEDURE|Intramedullary nailing|Intramedullary nailing of the fractured tibial shaft.
223899725|NCT06778577|OTHER|intra-articular corticosteroid injection (IACI) group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
223899726|NCT06778577|PROCEDURE|suprascapular nerve radiofrequency group (SCNRFT)|"SCNRFT is a new choice for treatment of frozen shoulder. The suprascapular nerve is the nerve that is most commonly affected in the condition of a frozen shoulder and it is for this reason that the suprascapular nerve is directly targeted by pulsed radiofrequency treatment. As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to tag the nerve accurately without injury to the nerves or vessels."
223899727|NCT02706704|DRUG|Adalimumab|
223899728|NCT05237648|OTHER|Online Voice quality education module|The novel online module the authors developed consists of a patient education on acoustic-perceptual rating of voice quality (CAPE-V), practice rating sample recordings of others' voices, and the patient's self-rating of their own voice in real time during a standard sentence-reading task. The module also includes the Self-Efficacy Scale for Voice Therapy.
223899729|NCT05237648|OTHER|Vocal hygiene module|The generic online patient education module on vocal hygiene during the waiting period between their initial evaluation and their first therapy session that also includes the Self-Efficacy Scale for Voice Therapy
223899730|NCT04663737|DRUG|Silmitasertib|Capsules
223899731|NCT04663737|DRUG|SOC|Some therapeutics for COVID-19 are available through EUA. SOC treatment availability is expected to change during the course of this trial.
223899732|NCT04855799|DRUG|Aquamin|Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
223899733|NCT06315907|OTHER|Responses to survey questions|All 400 participants will first complete a demographic information survey and the new food noise questionnaire. Of these 400 participants, 250 participants will then complete additional questionnaires to assess construct validity. The remaining 150 participants will be asked to complete the food noise questionnaire again in approximately 1 week to assess test-retest reliability.
223899734|NCT05652699|OTHER|High Flow Nasal Oxygen|Flow 60L/minute. FiO2 according to clinical protocol. Temperature highest tolerated by patient, starting with 37 degrees Celsius.
223899735|NCT05652699|OTHER|Conventional Oxygen Therapy|Nasal Cannula, Venturi Mask or Non-rebreathing mask, according to local clinical protocols
223899736|NCT04215146|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.
223899737|NCT04215146|BIOLOGICAL|Pelareorep|Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.
223899738|NCT04215146|DRUG|Avelumab|Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.
223899739|NCT06585241|BIOLOGICAL|mRNA-1273 Variant-containing Formulation|Sterile liquid for injection
223899740|NCT01943409|DRUG|Intralipid|soybean oil-based lipid emulsion
223899741|NCT01943409|DRUG|ClinOleic|olive oil-based lipid emulsion
223899742|NCT04960735|OTHER|VOICE intervention|"The intervention consists of four stages:~* S1, Value identification and description of current care processes: Needs are detected from two perspectives: feedback from patients and mapping of healthcare processes. ICHOM questionnaires are reviewed. Patient surveys and clinical forms are developed. The methodology for cost analysis is set up.~* S2, Intervention implementation: Patients are recruited according to the eligibility criteria. Their care follows the current healthcare pathway and information is collected at different time points.~* S3, Assessment of outcomes and continued benchmarking: Data and costs are analysed at both local level and Community level (benchmarking). Interviews and focus groups are held (optional). Root cause analysis is performed.~* S4, Best practice sharing: Identifying what lessons could be learned from the best-performing sites, according to the results of the VOICE community benchmarking and following qualitative techniques."
223899743|NCT03480594|DRUG|MRI Tracer|Hyperpolarized \[1-13C\] pyruvate for injection under IND133229 used to enhance MRI/MRS/MRSI using a 3T MRI scanner.
223899744|NCT05353348|DRUG|Iron Sucrose, recombinant human erythropoietin, ascorbic acid|During the 1 week period following admission, 3 consecutive dosing regimens were administered, 200 mg of iron sucrose by intravenous infusion at 8am daily in combination with 150 IU/kg of recombinant human erythropoietin by subcutaneous injection and 2 g of ascorbic acid by intravenous infusion.
223899745|NCT05353348|PROCEDURE|conventional treatment|Treatment in accordance with measures routinely used by the surgeon's team to treat anemia including but not limited to (clinical observation, oral iron supplementation, intravenous iron supplementation, blood transfusion, or other measures) will be documented faithfully by the study team
223899746|NCT06158386|DRUG|Chidamide combined with Linperlisib|Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
223899747|NCT02310646|DRUG|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
223899748|NCT02310646|DRUG|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
223899749|NCT06318143|BEHAVIORAL|TASSH|Strategy for Hemoglobinopathies (TASSH) containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management (Figure 1A describes the components of the intervention).
223899750|NCT04115163|DRUG|Gemcitabine|Given IV
223899751|NCT04115163|DRUG|Nab-paclitaxel|Given IV
223899752|NCT04700163|BIOLOGICAL|C144-LS and C-135-LS|A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein
223899753|NCT05892770|DRUG|Zinc gluconate supplement|Subjects will take a 50 mg zinc gluconate supplement at breakfast for the five days leading up to their next injection appointment. They will also answer questionnaires and provide audio recordings at various time points of the two injection cycles, which is roughly six months.
223899754|NCT05892770|DRUG|Botulinum toxin type A|This is the current standard of care for treatment of spasmodic dysphonia. Botox injection goes into the vocal cord muscle, and will be occur in both the control and experimental arms of the study.
223899755|NCT05256576|OTHER|Implementation of an innovative multi-modal peri-operative care pathway|The innovative multi-modal care pathway includes the implementation of the ERAS pathway, as well as the introduction of a patient-specific tri-modal prehabilitation program. This consists of a physical fitness, nutrition, and patient empowerment intervention.
223899756|NCT05183854|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
223899757|NCT05183854|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
223899758|NCT05183854|OTHER|Questionnaire Administration|Ancillary studies
223899759|NCT06168383|DRUG|HSK31679 80mg|once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.
223899760|NCT06168383|DRUG|HSK31679 160mg|once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.
223899761|NCT06168383|DRUG|Placebo|once daily, oral administration of placebo from Day 1 to Week 52.
223899762|NCT04137367|BEHAVIORAL|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
223899763|NCT04137367|BEHAVIORAL|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
223899764|NCT04499924|DRUG|tucatinib|300 mg given twice daily orally
223899765|NCT04499924|DRUG|trastuzumab|6 mg/kg loading dose will be administered intravenously (IV; into the vein) on Cycle 1 Day 1, followed by 4 mg/kg IV on Cycle 1 Day 15 and then Days 1 and 15 of each cycle thereafter
223899766|NCT04499924|DRUG|ramucirumab|8 mg/kg will be administered IV on Days 1 and 15 of each cycle
223899767|NCT04499924|DRUG|paclitaxel|60 or 80 mg/m\^2 IV on Days 1, 8, and 15 of each cycle
223899768|NCT04499924|OTHER|tucatinib placebo|Given twice daily orally
223899769|NCT04499924|OTHER|trastuzumab placebo|IV on Days 1 and 15 of each cycle
223899770|NCT06042803|OTHER|Human milk collection|Every time the mother would normally feed the child, we ask to collect the total milk volume for the feed from both breasts by an electric pump. For each collection, the volume and time will be noted, the container will be inverted and 5 to 10ml of that volume will be transferred in a polypropylene test tube or other tube type depending on the type of compounds (=sample to determine drug concentration in milk) for analysis (max 10% of the collected volume of each feed). The participant decides how the remainder of the collected milk is used. The milk samples will immediately be stored in the refrigerator (4°C) after being labeled. The samples will be collected by one of the investigators within 24 hours, will be transported on ice and frozen at -80°C until analysis.
223899771|NCT06042803|OTHER|Optionally: maternal blood sample|Blood collection to determine the drug concentration in plasma (6 to 10mL EDTA or other tube type, depending on the type of compound) will be performed at least within 1 hour interval with the first feeding (pumping) after medication intake, and 24 hours after medication intake (with preferable milk collection within 1 hour of blood sampling). The sample label, date and time of sampling will be noted.
223899772|NCT06042803|OTHER|Optionally: child blood sample|Blood collection of the infant to determine systemic exposure of child(1-5% of the total blood volume, according to the FDA guidelines, in an EDTA or other tube type, depending on the type of compound,) will be performed at the same day as the maternal sampling, if parental consent is obtained. The sample label, date and time of sampling will be noted.
223899773|NCT04772937|PROCEDURE|LLETZ|LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed
223899774|NCT04772937|PROCEDURE|LEEP|LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
223899775|NCT06494722|BEHAVIORAL|Diabetes Education|Participants in this arm will receive traditional diabetes education over 5 sessions in the first 3 months of participation and be followed for 6 months.
223899776|NCT06494722|BEHAVIORAL|T1DES|Participants in this arm will receive the T1DES behavioral interventions over 5 sessions in the first 3 months of participation and be followed for 6 months.
223899777|NCT05760144|DRUG|DMPA|The participant will receive the contraceptive injectable, Depo-Provera at the enrollment visit and at 3, 6, 9, and 12 months. Participants will have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
223899778|NCT05760144|DRUG|Etonogestrel implant|The participant will receive the contraceptive implant, Nexplanon at the enrollment visits and have endometrial biopsies at the enrollment visits and at 3, 6, and 12 months.
223899779|NCT04625686|BEHAVIORAL|Mental Health Treatment|Treatment of suicidal ideation
223899780|NCT06138808|OTHER|Stereoelectroencephalography (SEEG)|Participants will under Stereoelectroencephalography (SEEG) as part of standard of care. This is not assigned by the protocol.
223899781|NCT04600466|OTHER|Molecular testing for all participants.|Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
223899782|NCT04600466|OTHER|Germline Testing|Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.
223899783|NCT04600466|OTHER|Survey|Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.
223899784|NCT01648023|DEVICE|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
223899785|NCT01648023|DRUG|Gem-Cis or Gem-Carbo|
223899786|NCT03905148|DRUG|Lifirafenib|RAF Dimer Inhibitor
223899787|NCT03905148|DRUG|mirdametinib|MEK Inhibitor
223899788|NCT05931471|OTHER|Yogurt Intervention|Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
223899789|NCT05827094|OTHER|Mobile app|The main mobile intervention features. Tracking and immediate feedback: Pressing the icon launches a short series of questions with multiple-choice response options focusing on recent meals . The survey items are modeled after the 14-item Mediterranean Adherence Screener using simplified language and intuitive visuals to lower cognitive load. Based on responses to the survey, the app provides an intuitive visualization of the survey results, personalized feedback, and recipes on how to improve the person's diet. On-demand resources: individuals are able to access on-demand resources about the MedD diet, its benefits, and best dietary practices. The recipe page includes a personalized list of simple breakfast, lunch, dinner, and snack recipes based on the survey results with step by step instructions on how to prepare Mediterranean foods. In-app messaging: Individuals are able to receive notifications and send and receive messages.
223899790|NCT05827094|OTHER|Usual Care|Participants randomly allocated to the control group will receive educational materials on healthy eating, as provided on the NIA web page (https://www.nia.nih.gov/health/healthy-eating).
223899791|NCT03735472|DEVICE|Thoraflex™ Hybrid|"The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch."
223899792|NCT05577702|DRUG|Tislelizumab|Administered as an intravenous infusion
223899793|NCT05577702|DRUG|Ociperlimab|Administered as an intravenous infusion
223899794|NCT05577702|DRUG|LBL-007|Administered as an intravenous infusion
223899795|NCT05577702|DRUG|Cisplatin|Administered as an intravenous infusion
223899796|NCT05577702|DRUG|Carboplatin|Administered as an intravenous infusion
223899797|NCT05577702|DRUG|Pemetrexed|Administered as an intravenous infusion
223899798|NCT05577702|DRUG|Paclitaxel|Administered as an intravenous infusion
223899799|NCT04641221|BEHAVIORAL|Weekly Yoga Classes|All participants are invited to attend weekly yoga classes.
223899800|NCT03679078|DIETARY_SUPPLEMENT|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
223899801|NCT05913388|DRUG|GB1211|Administered orally twice daily at 100mg.
223899802|NCT05913388|DRUG|Pembrolizumab|Administered at a fixed dose of 200 mg every 3 weeks intravenously.
223899803|NCT05913388|DRUG|Placebo|Administered orally twice daily at 100mg.
223899804|NCT03957369|DIAGNOSTIC_TEST|HIV-1 plasma RNA Genotyping secuencing by Sanger technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
223899805|NCT03957369|DIAGNOSTIC_TEST|HIV-1 plasma RNA Genotyping secuencing by Ultra-deep sequencing technique|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
223899806|NCT05074303|BIOLOGICAL|Influenza Vaccine|All subjects will receive the influenza vaccine.
223899807|NCT05074303|DIETARY_SUPPLEMENT|Beta-glucan|2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast
223899808|NCT05074303|DIETARY_SUPPLEMENT|Placebo|2 - 250 mg capsules/day of cellulose
223899809|NCT04094298|DRUG|FX006 Injection|One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
223899810|NCT03888950|DIAGNOSTIC_TEST|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
223899811|NCT06522685|DEVICE|transcranial direct current stimulation Soterix REMOTE 1x1 miniCT|Soterix Medical REMOTE Neuromodulation is the only system with device, accessories, and software designed for deployed use. Safe transcranial Electrical Stimulation requires advanced systems designed for consistency and control. REMOTE Neuromodulation is the only system designed from the ground up to allow translation of clinical tES, including tDCS protocols, to diverse deployed environments, while maintaining medical standards.
223899812|NCT03815825|DRUG|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
223899813|NCT03815825|DRUG|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
223939959|NCT07187648|OTHER|Iso-Caloric Control Cookies (Placebo)|Iso-caloric cookies made from standard flour without Golden Rice and without Piper crocatum. Participants in the control arm consume 20 g twice daily (40 g/day total) for 28 days. The cookies are designed to match the intervention cookies in calories and appearance but do not contain the active ingredients.
223939960|NCT07193264|OTHER|Caffeine (200 mg)|Participants receive a single oral dose of 200 mg caffeine under fasting conditions. Blood samples are collected before and three hours after intake to evaluate effects on hematopoietic stem and progenitor cells, including mobilization, function, gene expression, and metabolism.
223939961|NCT07190885|DRUG|YN001|YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).
223899814|NCT04315064|DRUG|Treatment with MTX110|"Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment. If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2 μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions."
224276746|NCT04025294|DEVICE|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
223899815|NCT04690972|PROCEDURE|Blood sample during surgery|During the hepato-bilio-pancreatic surgery, blood is drawn.
223899816|NCT04690972|PROCEDURE|Taking an additional biopsy|As part of the treatment, an additional biopsy is executed and blood is drawn.
223899817|NCT04690972|DIAGNOSTIC_TEST|Blood sample during diagnostic test|Blood sample as part of the care
223899818|NCT05302648|DRUG|Human Derived anti-BCMA CAR-T Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
223899819|NCT04103281|OTHER|Sepsis|Sepsis patients in the ICU with a breathing tube
223899820|NCT06117046|DRUG|Cardiopeptidin|Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
223899821|NCT06117046|DRUG|50 ml of normal saline intravenous infusion|50 ml of normal saline intravenous infusion
223899822|NCT04937179|PROCEDURE|Ischemic Conditioning Low - Sham Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 25mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
223899823|NCT04937179|PROCEDURE|Ischemic Conditioning High - Active Comparator|The use of a Hokanson rapid inflator cuff to restrict blood flow at 225mmHg for 5 minutes followed by a 5 minute reperfusion period, repeated for 5 cycles.
223899824|NCT05443347|BEHAVIORAL|Aerobic exercise|Supervised aerobic exercise
223899825|NCT05443347|BEHAVIORAL|Newsletter|Biweekly newsletter
223899826|NCT06246045|DIAGNOSTIC_TEST|Walking test|"PERT will be activated by AI algorithm. As a result of the discussion, patients will either be determined to be appropriate for immediate invasive strategy versus watchful waiting depending on whether high-risk PE criteria are met.~For those in the intermediate-high risk category, there remains ambiguity on timing and appropriateness of invasive intervention. On day 1 of admission, patients will undergo a walking test evaluating for abnormalities in heart rate, heart rate recovery, and oxygen need. If criteria is met, patients will be randomized in a 2:1 fashion (treatment versus control) to evaluate use of early-invasive strategy."
223899827|NCT06802640|COMBINATION_PRODUCT|Transcutaneous spinal cord electrical stimulation and Kunming Locomotor Training|Patients will undergo Kunming Locomotor Training along with transcutaneous spinal cord stimulation. . The training is at least 1 hour per day, 5 hours per week, for 6 consecutive months.
223899828|NCT06802705|BEHAVIORAL|Psychosocial Stress on Quality of Life|Psychosocial Stress on Quality of Life in Saudi Arabian Patients with Alopecia Areata
223899829|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
223899830|NCT02231164|DRUG|docetaxel|intravenous chemotherapy drug
224276747|NCT04025294|BEHAVIORAL|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
224276748|NCT06239428|BEHAVIORAL|i-TREAT|A 12-session internet-based cognitive behavioral intervention for Danish adolescents and adults with Other Specified Feeding or Eating Disorders.
224276749|NCT06239428|OTHER|Waitlist|A 12-week waitlist with access to online mindfulness material.
223899831|NCT02231164|DRUG|placebo|oral placebo
223899832|NCT02231164|DRUG|nintedanib|oral experimental therapy
223899833|NCT05919810|OTHER|Probiotic|Oral probiotic
223899834|NCT05919810|DIETARY_SUPPLEMENT|Oral herbal powder supplement|oral herbal powder
223899835|NCT05914246|DEVICE|VIOLA proximal seal|VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
223899836|NCT06195319|DRUG|Simufilam|100 mg of \[14C\]-simufilam
223899837|NCT02547363|DRUG|LEO 43204 gel|
223899838|NCT02547363|DRUG|Vehicle gel|
223899839|NCT05634993|OTHER|Assessment|Assessment of disability level and trunk control
223899840|NCT03569631|DRUG|BPN14770|25 mg BPN14770 capsules
223899841|NCT03569631|DRUG|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
223899842|NCT04226313|DIAGNOSTIC_TEST|Self-sampling by Evalyn Brush|Women will perform a cervicovaginal self-sampling at their home using Evalyn Brush.
223899843|NCT04226313|DIAGNOSTIC_TEST|Self sampling by Evalyn Brush home or in GP´s clinic|Women will perform a cervicovaginal self-sampling at their home or the GP´s clinic using Evalyn Brush
223899844|NCT04895761|BIOLOGICAL|DPX-Survivac|"DPX is a novel formulation that when combined with target antigens acts to activate T cells. It is a lipid-based formulation that creates a long lasting depot at the site of injection, forcing an active uptake by antigen presenting cells (APCs). APCs traffic to regional lymph nodes where naïve T cells are activated, inducing strong and sustained immune responses. All arms will receive DPX-Survivac on weeks 2 and 5."
223899845|NCT04895761|DRUG|Letrozole 2.5mg|Aromatase inhibitor all arms will receive
223899846|NCT04895761|DRUG|Cyclophosphamide 50mg|oral chemotherapy used in the neoadjuvant setting for Arm C only
223899847|NCT04895761|RADIATION|XRT 10Gy x2|Directed radiation at week 4 for Arm B only
223899848|NCT05412433|BEHAVIORAL|Patient Level|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations
223899849|NCT05412433|BEHAVIORAL|Multilevel|Electronic data collection with scoring, patient awareness of HIV risk score, patient viewing of PrEP animations, provider electronic health records (EHR) alerts
223899850|NCT05412433|BEHAVIORAL|Control|Standard of care
223899851|NCT05401812|DRUG|Intravenous glucocorticoid therapy|Betamethasone, dexamethasone, or methylprednisolone
223899852|NCT06539520|OTHER|Aerobic training program|Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.
223899853|NCT06539520|OTHER|Selected physical therapy program for post stroke patients|Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
223899854|NCT05281562|DRUG|Lovaza|Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
223899855|NCT05281562|DRUG|L-Arginine Powder|Daily dose of 4.5 grams L-Arginine, powder form.
223899856|NCT05281562|DRUG|Vitamin C|Daily dose of 500 mg Vitamin C, powder form.
223899857|NCT04436276|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
223899858|NCT04436276|BIOLOGICAL|Placebo|Participants will receive Placebo.
223899859|NCT04052971|DRUG|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
223899860|NCT04052971|DRUG|ABN401- Expansion Phase|"Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal."
223899861|NCT05313620|DRUG|Tofacitinib|Tofacitinib 5 MG/day per clinical practice
223899862|NCT05313620|DRUG|Infliximab Adalimumab y Golimumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
223899863|NCT05186025|DRUG|MATA trees or MATA grass|Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids
223899864|NCT06326099|BEHAVIORAL|Brief Online Binge Eating and Drinking Intervention|The intervention is an online mobile phone program developed by our research team. It builds upon efficacious brief alcohol interventions with college students by addressing underlying loss of control, impulsivity, and emotion regulation through the use of videos, interactive activities, and psychoeducation.
223899865|NCT04568759|OTHER|Global postural re-education|GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
223899866|NCT06185491|OTHER|HGI|Data collection from glucose monitoring systems and dosage of glycated hemoglobin and glycated albumin measured 3 times at 6-month intervals (+/- 3 months)
223899867|NCT04380831|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223899868|NCT04380831|DRUG|Cyclophosphamide|Undergo HSCT
223899869|NCT04380831|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TBI using IMRT
223899870|NCT04380831|PROCEDURE|Total-Body Irradiation|Undergo TBI using IMRT
223899871|NCT03709680|DRUG|Palbociclib|Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle
223899872|NCT03709680|DRUG|Temozolomide|Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
223899873|NCT03709680|DRUG|Irinotecan|Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
223899874|NCT03709680|DRUG|Topotecan|Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
223899875|NCT03709680|DRUG|Cyclophosphamide|Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
223899876|NCT06777446|PROCEDURE|Elective Adhesionlysis|See descriptions in study arms
223899877|NCT06777446|DEVICE|Adhesion barrier|At the end of adhesiolysis a barrier will be placed. The adhesion barrier to be used in laparoscopic adhesiolysis is Icodextrin 4% (Adepttm).
223899878|NCT05802056|BIOLOGICAL|Aldesleukin|Given IP
223899879|NCT05802056|PROCEDURE|Biopsy|Undergo biopsy
223899880|NCT05802056|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223899881|NCT05802056|PROCEDURE|Computed Tomography|Undergo PET/CT
223899882|NCT05802056|PROCEDURE|Diagnostic Laparoscopy|Undergo diagnostic laparoscopy
223899883|NCT05802056|DRUG|Fluorouracil|Given IV
223899884|NCT05802056|DRUG|Leucovorin Calcium|Given IV
223899885|NCT05802056|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223899886|NCT05802056|BIOLOGICAL|Nivolumab|Given IV
223899887|NCT05802056|DRUG|Oxaliplatin|Given IV
223899888|NCT05802056|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
223899889|NCT05280548|DRUG|Venglustat (GZ402671)|Tablet; Oral
223899890|NCT05280548|DRUG|Agalsidase alfa|Concentrate for solution for infusion; IV infusion
223899891|NCT05280548|DRUG|Agalsidase beta (GZ419828)|Powder for concentrate for solution for infusion; IV infusion
223899892|NCT05280548|DRUG|Migalastat|Hard capsules; Oral
223899893|NCT01767636|DRUG|Pazopanib Hydrochloride|Given PO
223939962|NCT06389110|DRUG|Alleance®|Atropine sulfate 0.01%, ophthalmic solution.
223939963|NCT06389110|DRUG|Placebo|Ophthalmic solution.
223899894|NCT04881838|DRUG|P regimen|Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1
223899895|NCT04881838|DRUG|Course A1 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
223899896|NCT04881838|DRUG|Course B1 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
223899897|NCT04881838|DRUG|Course A2 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
223899898|NCT04881838|DRUG|Course B2 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
223899899|NCT04881838|DRUG|Course A3 + Vin|vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;
223899900|NCT04881838|DRUG|Course B3 +Vin|vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;
223899901|NCT04881838|DRUG|Maintenance therapy|Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.
223899902|NCT06647810|DRUG|BI 690517 formulation 1|BI 690517 formulation 1
223899903|NCT06647810|DRUG|BI 690517 formulation 2|BI 690517 formulation 2
223899904|NCT06647810|DRUG|Probenecid|Probenecid
223899905|NCT06546592|DEVICE|AI assisted contouring|Initial are generated automatically using software powered by artificial intelligence
223899906|NCT06107231|OTHER|Honey|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)
223899907|NCT06107231|OTHER|Sucrose|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)
223899908|NCT06107231|OTHER|Honey plus almonds|Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
223899909|NCT06107231|OTHER|Sucrose plus almonds|Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
223899910|NCT03547336|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
223899911|NCT03547336|DEVICE|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
223899912|NCT06647888|DRUG|Envlo Tablet|Envlo Tab. 0.3mg
223899913|NCT06647888|DRUG|Envlomet SR Tablet|Envlomet SR Tablet 0.3/ Metformin1,000mg
223899914|NCT06648239|OTHER|Usual Care|In the usual care group, patients will proceed directly to ICA following referral from community cardiology, as is the current standard of care. Research staff will screen participants in this group for significant CAD using the decision support tool; however, the tool's recommendations will not affect their care, as all patients in this group will invariably receive ICA.
223899915|NCT06648239|OTHER|Centralized triage with risk score-based screening for obstructive CAD|Patients randomized to the intervention will have selected features of their medical history, recorded on their referral form, entered into a decision support tool by research personnel to generate a recommendation of whether they should proceed directly to ICA or whether they should receive CCTA. Patients with recommendations for ICA will proceed directly to ICA. Patients with recommendations for CCTA will be referred to CCTA. Based on the results of the CCTA, recommendations for medical management versus referral for ICA will be made.
223899916|NCT04421547|DRUG|Letrozole 2.5mg|This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.
223899917|NCT04421547|DRUG|Standard single agent chemotherapy|Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
223899918|NCT06283251|BEHAVIORAL|PediRISE Resource Program|A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
223899919|NCT06648824|DRUG|Mitapivat|Oral tablets
223899920|NCT06648824|DRUG|Midazolam|Oral syrup
223899921|NCT05200260|PROCEDURE|Primary debulking surgery|Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
224276750|NCT02407067|DEVICE|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
223899922|NCT05200260|PROCEDURE|Neoadjuvant chemotherapy|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
223899923|NCT05200260|DRUG|PARP inhibitor|For patients with BRCA mutated, maintenance therapy of PARP inhibitors following CR/PR after first-line chemotherapy. In this trial, Olaparib 300mg p.o. twice daily is suggested after the front-line therapy.
223899924|NCT05200260|DRUG|Bevacizumab|For patients without BRCA mutated, maintenance therapy of Bevacizumab following CR/PR after first-line chemotherapy. In this trial, Bevacizumab 7.5mg per kilogram intravenous once every 3 weeks is suggested after the front-line therapy.
223899925|NCT06257771|DRUG|Alcohol (Ethanol)|Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.
223899926|NCT02431845|DRUG|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents
223899927|NCT05429476|DRUG|Tissue Plasminogen Activator (Alteplase)|"Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA"
223899928|NCT04413955|DEVICE|Seraph®-100 Microbind® Affinity Blood Filter|Use of an extracorporeal broad-spectrum sorbent hemoperfusion filter to removed SARS-CoV-2 virus and circulating cytokines from the blood
223899929|NCT05977530|BEHAVIORAL|self-rescue training|children will receive training for self-rescue if they are alone in water
223899930|NCT04992767|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention(an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
223899931|NCT04992767|BEHAVIORAL|SunnysideFlex|SunnysideFlex consists of 6 weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. SunnysideFlex has adapted the original Sunnyside intervention with revised, trauma-focused content that covers the impact of PTSD symptoms on the perinatal period and daily functioning, more broadly
223899932|NCT05230043|OTHER|Algometer test|The computerized pressure algometer, AlgoMed (Medoc, Ramat Yishai, Israel), will be used for mechanical pain stimulation to assess information about pain threshold and tolerance. A constant rate of pressure is delivered by the examiner, and the pressure is recorded in Kilopascal (kPa). The stimulation will be applied between the medial and distal joints of the phalanges of the dominant hand.
223899933|NCT05230043|OTHER|functional MRI|"* Two 8s sequences of spin echo field map with phase encoding AP and PA~* A 12:00min bold sequence for resting-state~* A 15:12min bold sequence for gambling task thickness=2mm, Matrix Size = 105×105, FOV=210×210mm2;~* A 6:38min T1w MPR sequence~* A 7:40min T1w MPR sequence~* A 5:57min T2w SPC sequence~* A 8:24min T2w SPC sequence~* A 8:32min FLAIR T2w sequence~* Two 8:26min Multi-echo GRE sequence~* A 8:29min high resolution multi-echo GRE sequence~* Two 6:46min multi-echo GRE sequence with and without magnetic transfer contrast~* Two 6:03min diffusion weighted images with phase encoding AP and PA"
223899934|NCT04203303|OTHER|Observational|Observational
223899935|NCT05633303|OTHER|Substrate guided ablation|Ablation strategy implemented will be dependent on the Arm the patient has been allocated to based on the presence of underlying LVZs.
223899936|NCT04382664|BIOLOGICAL|UV1|UV1 vaccine (300 μg) will be injected intradermally.
223899937|NCT04382664|BIOLOGICAL|Sargramostim|Sargramostim (75 μg) is used as a vaccine adjuvant.
223899938|NCT04382664|BIOLOGICAL|Ipilimumab|Ipilimumab is dosed according to label.
223899939|NCT04382664|BIOLOGICAL|Nivolumab|Nivolumab is dosed according to label.
223899940|NCT04763577|OTHER|Assay of Bradykinin-degradating enzymes.|Aminopeptidase P activity assay; Dipeptidyl peptidase IV activity assay; Angiotensin Converting Enzyme activity assay; MME gene polymorphisme exploration.
223899941|NCT06558253|DRUG|Coenzyme I for Injection|Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
223899942|NCT06122701|DIETARY_SUPPLEMENT|Thiamin p.o.|"A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
223899943|NCT06122701|DIETARY_SUPPLEMENT|Thiamin i.v.|"A single i.v. dose of thiamin 5 mg with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration."
223899944|NCT05891587|DRUG|Semaglutide|Semaglutide pen injector
223899945|NCT05891587|DRUG|Placebo|Saline solution
223899946|NCT04528173|DRUG|Ketorolac|Ketorolac (0.5mg/kg; maximum 15mg intravenously) will be given at end of procedure after evaluation for hemostasis.
223899947|NCT04528173|DRUG|Dexmedetomidine|Dexmedetomidine (1ug/kg with maximum 50ug intravenously) will be given at beginning of procedure.
223899948|NCT04528173|DRUG|Morphine|Morphine (0.05-0.1 mg/kg intravenously) will be given intra-operatively per institutional standard clinical care.
223899949|NCT04528173|DRUG|Fentanyl|Fentanyl (0.5-2 ug/kg intravenously) will be given intra-operatively per institutional standard clinical care.
223899950|NCT05118295|DEVICE|SAVI Scout®|Savi Scout marker is placed within 1 cm of the breast tumor
223899951|NCT04978623|OTHER|high frequency ultrasound|high frequency ultrasound in subgroups of patients with CIDP, anti-MAG, NMMBC and L-S syndrome
223899952|NCT06206876|PROCEDURE|Biopsy|Undergo biopsy
223899953|NCT06206876|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223899954|NCT06206876|PROCEDURE|Computed Tomography|Undergo CT
223899955|NCT06206876|DRUG|DDX5 Degrader FL118|Given PO
223899956|NCT06206876|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223899957|NCT05572957|DRUG|Guideline-Directed Medical Therapy(GDMT)|"Quadruple anti-heart failure drug therapy: BB, ACEI/ARB/ARNI, MRA, and SGLT2i. If the initial dose according to guidelines is tolerated, the protocol would then direct the uptitration of medication dose over time to a specified target dose, unless not well tolerated.~\*Criteria for \<3 months of optimized (complete) GDMT: 1) according to the latest management of HF, any of the new quadruple therapy is not used if the condition allowed; Or 2) the dose of any drug dose not reach the maximum tolerated target; Or 3) under the maximum tolerated dose of BB, ivabradine is not added with a heart rate still ≥70 bpm at rest."
223899958|NCT05572957|COMBINATION_PRODUCT|left bundle branch pacing combined with Guideline-Directed Medical Therapy(LBBP+GDMT)|"GDMT is the same as Drug intervention. LBBP is confirmed when: 1) the LBBB morphology disappeared and the paced RBBB pattern (typical or atypical) is observed in V1; and 2) LVAT is ≤100 ms at low output(≤3 V/0.5 ms); and at least 1 of the following is achieved: a) abrupt shortening of LVAT by \>10 ms during mid/deep septal lead placement with a RBBB pattern in V1 at high output, which then remains short and constant at high and low output with further advancement of the lead to the final position; b) transition from nonselective to selective LBBP (QRS morphology transition from atypical RBBB to typical rsR' pattern in V1 and wide/large S-wave in V6 , with the appearance of an isoelectric segment and no LVAT change at high and low outputs); and c) transition from nonselective LBBP to LV septal pacing (lengthening of LVAT by at least 10 ms with or without obvious QRS morphology transition during threshold testing).~HBP or BiVP is attempted using the standard-of-care technique."
223899959|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation A)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
223899960|NCT05186753|DRUG|Bezuclastinib Tablets (Formulation B)|Bezuclastinib will be administered orally, once daily continuously for 28-day cycles
223899961|NCT05186753|DRUG|Placebo Tablets|Placebo will be administered orally, once daily continuously for 28-day cycles
223899962|NCT06291428|DIAGNOSTIC_TEST|Raman spectroscopy|Raman spectroscopy is proposed as a potential technique for MRD measurement, which is based on the inelastic scattering of light that occurs when it interacts with matter, causing optical scattering, where a portion of the radiation changes its wavelength (by Raman effect). By analyzing the inelastically scattered light, we can obtain a Raman spectrum formed by the intensity of the scattered light as a function of its vibration frequency, thus obtaining information about the biochemical composition of a biological sample.
223899963|NCT05810064|OTHER|Falls-Risk Clinical Decision Support (CDS) Tool|CDS in the Electronic Health Record (EHR) to screen patients at high-risk for future falls enabling referrals to the UW Health Mobility and Falls clinic.
223899964|NCT05698849|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
223899965|NCT00063063|OTHER|No Intervention|
223899966|NCT03888040|OTHER|Exercise|The participant will attend 3 training sessions per week for 8 weeks. Resistance training will be performed by each leg with a load of 30% of maximal strength: one leg with and the other without blood flow restriction.
223899967|NCT06822894|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|UFR is a novel IVUS-derived modality for fast computation of FFR without pressure wires and adenosine
223899968|NCT05943639|OTHER|The Cultural Marginality Theory-Based Education|The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
223899969|NCT01733316|DRUG|RP103|
223899970|NCT01733316|DRUG|Cystagon®|
223899971|NCT05674786|DEVICE|Labyrinth Devices MVI™ Multichannel Vestibular Implant System|Unilateral implantation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System receiver/stimulator including insertion of electrode arrays in the semicircular canal ampullae of the inner ear, followed by motion-modulated prosthetic electrical stimulation.
223899972|NCT05213936|DEVICE|Scalp cooling with hairstyle|Hair will be prepared accordingly for the cooling cap fitting based on which approach the patient prefers: braids/cornrows/twists
223899973|NCT05213936|DEVICE|Scalp cooling with conditioner and water emulsion|Hair will be prepared accordingly for the fitting based on which approach the patient prefers: or conditioner and water emulsion to coat the hair.
223899974|NCT06822088|DRUG|Esketamine|A total of 126 patients undergoing thoracoscopic surgery under elective general anesthesia were randomly divided into three groups: normal saline group (group C), dexmedetomidine group (group D), eschloroacetone group (group E) and dexmedetomidine group (group D), with 42 cases in each group. Group C was continuously injected with the same amount of normal saline, group D was given dextrometin 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery. Group E was given esketamine 0.2 mg/kg 10min before surgery, and maintained at 0.15 mg/kg\*h after intubation until 30min before surgery. Other anesthetic induction and maintenance drugs were consistent among the three groups.
223899975|NCT06822088|DRUG|Dexmedetomidine|group D was given Dexmedetomidine 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery.
223899976|NCT06822088|DRUG|Normal Saline|Group C was continuously injected with the same amount of normal saline,
223899977|NCT03260023|BIOLOGICAL|TG4001|PhIb: Dose escalation PhII: Established RP2D for TG4001
223899978|NCT03260023|DRUG|Avelumab|Anti PD-L1
223899979|NCT06513793|BEHAVIORAL|Roots and Shoots|Four-week intervention involving a self-help guidebook to improve mental wellbeing.
223899980|NCT06513793|BEHAVIORAL|Waiting list|Four-week waiting list period involving treatment as usual.
223899981|NCT06823609|DRUG|QLS1304 tablet|QLS1304 monotherapy dose escalation and expansion
223899982|NCT06413524|DEVICE|Whole-body Vibration Therapy|Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. For the starting position, the patient stands relaxed on the platform, holding the WBV platform handles.
223899983|NCT06413524|DEVICE|Local Vibration Therapy|Each session includes six series, each lasting 2 minutes, with a frequency of 35 Hz and an amplitude of 2 mm, with a 60-second rest interval between series. After the warm-up exercise, the researcher helps the patient wear the localized vibration instrument. During the vibration, participants will hold onto the handle to ensure balance stability.
223899984|NCT05713110|DRUG|tazemetostat|"Dose Escalation Phase (Phase IIa):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days;~Dose Expansion Phase (Phase IIb):~Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days"
223899985|NCT05713110|DRUG|HMPL-689|"Dose Escalation Phase (Phase IIa):~HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days.~Dose Expansion Phase (Phase IIb):~HMPL-689 (RP2D) in a therapeutic cycle of 28 days"
223899986|NCT05535894|PROCEDURE|Ablation of Celiac Ganglion|Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
223899987|NCT06122662|DRUG|AMX0035|Proprietary formulation of sodium phenylbutyrate and taurursodiol
223899988|NCT06122662|OTHER|Placebo|Matching Placebo Comparator
223899989|NCT06555822|DRUG|AZD5004|Participants will receive oral tablets of AZD5004 in Part A and Part B of the study as per arms they are assigned.
223899990|NCT06555822|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
223899991|NCT04716075|DRUG|Acalabrutinib 2x100 MG Oral Capsule + alloSCT|Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
224276751|NCT02407067|DEVICE|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
224276752|NCT04725591|DEVICE|Dexcom G6 Continuous Glucose Monitoring|Collection of glucose data
223899993|NCT06379685|DRUG|PRO-190|Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.
223899994|NCT06379685|DRUG|Systane Ultra®|Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
223899995|NCT05286151|BEHAVIORAL|Rhythm discrimination|Participants will complete a rhythm discrimination task once per year for 3 years.
223899996|NCT05482698|DRUG|MC2-25 cream|Topical application
223899997|NCT05482698|DRUG|MC2-25 vehicle|Topical application
223899998|NCT02639897|OTHER|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
223899999|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
223900000|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
223900001|NCT03879863|DRUG|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
223900002|NCT03879863|DRUG|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
223900003|NCT06330922|OTHER|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be performed two times a week for one hour in small groups (4-5 people). The training will be conducted outdoors at track and field facilities with at least two coaches.
223900004|NCT04214561|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
223900005|NCT04975256|DRUG|MRTX849|KRAS G12C inhibitor
223900006|NCT04975256|DRUG|BI 1701963|SOS1 Inhibitor
223900007|NCT04807972|DRUG|ABBV-927|Intravenous (IV) Infusion
223900008|NCT04807972|DRUG|Budiglimab|Intravenous (IV) Infusion
224276753|NCT04725591|DEVICE|MEDISAFE WITH External Insulin Pump|Insulin delivery
224276754|NCT04725591|DEVICE|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
224276755|NCT04725591|OTHER|Declaration of meals|Patient inputs related to meals
224276756|NCT04725591|OTHER|No declaration of meals|No patient inputs related to meals
224276757|NCT04725591|OTHER|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
223900009|NCT04807972|DRUG|modified FOLFIRINOX|Intravenous (IV) Infusion
223900010|NCT04034862|DRUG|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
224276758|NCT01525576|BEHAVIORAL|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
224276759|NCT05684224|BEHAVIORAL|Dynamic accommodation|Dynamic accommodation will be tracked using the Tobii Glasses
224276760|NCT02083172|DEVICE|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
224276761|NCT02672969|DEVICE|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
224276762|NCT03638596|BEHAVIORAL|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
224276763|NCT03638596|BEHAVIORAL|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
223714873|NCT06834867|BEHAVIORAL|MILAP intervention|The MILAP intervention, developed through participatory research, includes 9 sessions over 9 weeks, totaling 11 hours. It begins with the MilDil component, consisting of two sessions (4 hours) for MIL-DIL dyads, focusing on discussing cultural gender norms, raising awareness about the negative impact of IPV, establishing allyship between MIL and DIL, and empowering DILs while enhancing MILs' support for DILs' freedom of movement. This is followed by two one-hour sessions on Brief Behavioral Activation (BA) to address and prevent depression, involving MILs for necessary family support. Lastly, the husband-wife dyad will engage in four weekly sessions (4 hours) of Behavioral Couples Therapy (BCT), aimed at improving communication, coping strategies, and fostering caring behaviors between partners.
223714874|NCT01535547|DRUG|isavuconazole|oral
223714875|NCT01535547|DRUG|tacrolimus|oral
223714876|NCT04674930|OTHER|Exercise program|Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
223714877|NCT02881437|DRUG|IgHy10|Sub Cutaneous IgHy10 administration
223714878|NCT03187197|DRUG|Pradaxa®|Dabigatran etexilate
223714879|NCT03812094|DEVICE|Enurad 400|Alarm treatment
223714880|NCT03812094|BEHAVIORAL|Basic Bladder advice|Pre-specified Basic bladder advice
223714881|NCT04238598|PROCEDURE|Pulse Radiofrequency|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.
223714882|NCT04238598|PROCEDURE|Standard of Care Intra- Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.
223714883|NCT04238598|PROCEDURE|Placebo Intra-Articular Injection|Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.
223714884|NCT02860013|DEVICE|Telemedicine|
223714885|NCT04943315|PROCEDURE|Monolithic zirconia|posterior crowns
223714886|NCT04943315|PROCEDURE|Metal-ceramic|posterior crowns
223714887|NCT04342156|DRUG|Hydroxychloroquine Sulfate 200 milligram (mg) Tab|Oral tablet of Hydroxychloroquine sulfate
223714888|NCT02975518|BIOLOGICAL|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
223714889|NCT00259649|DRUG|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
223714890|NCT01372267|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
223714891|NCT01372267|BEHAVIORAL|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
223714892|NCT00000445|DRUG|naltrexone (Revia)|
223714893|NCT05713175|DEVICE|EVA plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 45º shore A hardness Ethyl Vinyl Acetate (EVA), which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.
223714894|NCT05713175|DEVICE|Polypropylene plantar orthosis|Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.
223714895|NCT05713175|DEVICE|Fixtoe device|Fixtoe Device, simulating the metatarsophalangeal stabilization tape technique is worn for one month, prior to definitive treatment consisting of a personalized plantar orthosis.
224276764|NCT01374724|BEHAVIORAL|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
224276765|NCT01374724|BEHAVIORAL|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
224276766|NCT01374724|BEHAVIORAL|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
223714896|NCT01113567|DIETARY_SUPPLEMENT|Lactose-free milk|3.5 g of lactose
223714897|NCT01113567|DIETARY_SUPPLEMENT|Whole milk|Whole milk with 24 g lactose
223714898|NCT01220375|DRUG|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
223714899|NCT01220375|DRUG|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
224276767|NCT01374724|BEHAVIORAL|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
223900011|NCT00855036|OTHER|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
223900012|NCT01674140|DRUG|anastrozole|Given orally
223900013|NCT01674140|DRUG|everolimus|Given PO
223900014|NCT01674140|DRUG|exemestane|Given orally
223900015|NCT01674140|DRUG|goserelin acetate|Given subcutaneously or intramuscularly
223900016|NCT01674140|DRUG|letrozole|Given orally
223900017|NCT01674140|DRUG|leuprolide acetate|Given subcutaneously or intramuscularly
223900018|NCT01674140|DRUG|tamoxifen citrate|Given PO
223900019|NCT01674140|OTHER|placebo|Given PO
223900020|NCT06606925|DIAGNOSTIC_TEST|fMRI with virtual reality flight simulator|During this scan, the subject will be wearing the stereogenic goggles called the Visual System HD (NordicNeuroLab) mounted in the scanner via a headcoil that can be adjusted to the subject's comfort using the control arm and completely cover the eyes to prevent light exposure and to clearly visualize eye movement during the flight simulation. The subject will be using a visual response system with customized grips to simulate a stick and throttle in a jet cockpit while visualizing the flight simulation (PICT) in the goggles.
223900021|NCT05694871|DRUG|Palbociclib|Given PO
223900022|NCT05694871|BIOLOGICAL|Cemiplimab|Given IV
223900023|NCT05694871|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
223900024|NCT05694871|PROCEDURE|Computed Tomography|Undergo a CT Scan
223900025|NCT05694871|PROCEDURE|Biospecimen collection|Undergo blood sample collection
223900026|NCT05694871|OTHER|Questionnaire Administration|Ancillary Studies
223900027|NCT06233903|DRUG|18F-mFBG|18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
223900028|NCT04697095|OTHER|Blood samples|: The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
223900029|NCT06066996|DRUG|Transdermal Nicotine Patch|Blinded Nicotine Patch
223900030|NCT06066996|DRUG|Placebo Nicotine Patch|Blinded Patch with No Nicotine
223900031|NCT03536052|DEVICE|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
223900032|NCT06004453|OTHER|Heart Failure medications|There is no treatment allocation. Patients are allocated to the respective cohort based on the treating physician enrolling them in the study. Patients are treated according to the local prescribing information and routine medical practice.
223900033|NCT06273436|OTHER|H.E.A.R. for Mamas|H.E.A.R. for Mamas is a patient and provider informed, multicomponent intervention that uses simple text/phone-based screenings to systematically and frequently monitor women for postpartum complications, chronic conditions and SDoH (Social Determinants of Health) and provides patients with immediate feedback and recommendations based on their screenings.
223900034|NCT05775094|DRUG|Romosozumab|Romosozumab will be administered 210 mg SC as two 105 mg prefilled syringes once every 4 weeks x 12 months. No dose adjustments for romosozumab will be permitted. All efforts will be made to administer romosozumab within the defined study visit windows (+/- 14 days).
223900035|NCT06777888|BEHAVIORAL|Family Healthy Living Program weekly group sessions|Children aged 8-12 and at least one caregiver will meet for 9 weekly virtual group intervention sessions (2 hours per session) with program facilitators and will also have access to a virtual Q and A session and up to 3 virtual cooking classes with a Registered Dietician. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions.
223900036|NCT06777888|BEHAVIORAL|Self-guided Web Portal Resources Only|Children aged 8-12 and at least one caregiver will be offered access to digital educational content and downloadable resources on topics such as physical activity, healthy eating, and positive mental well-being.
223900037|NCT03498612|OTHER|Laboratory Biomarker Analysis|Correlative studies
223900038|NCT03498612|BIOLOGICAL|Pembrolizumab|Given IV
223900039|NCT05239455|DEVICE|Reveos® Automated Blood Processing System|This is a non-interventional study, observing the in vivo performance of LR-RBC units derived from WB processed with the Reveos System.
223900040|NCT06367296|OTHER|Prolonged resistance exercise training|"Training with resistance exercises for upper and lower limbs will be carried out 3 times a week (Monday, Wednesday and Friday) for 12 weeks for all participants. The training will follow the guidelines of the American College of Sports Medicine (American College of Sports Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults, 2009) and will consist of a 5-minute cardiovascular warm-up on a cycle ergometer, followed by weight training. Resistance training will be carried out with exercise machines: 5 sets of leg press, leg extension and leg flexion for lower limbs and 3 sets of chest press and triceps extension for upper limbs. Subsequently, the participants will perform global flexibility exercises for 5 minutes to return to calm."
223900041|NCT06572813|DRUG|Bortezomib Injection|Bortezomib Injection, a kind of chemotherapy drug
223900042|NCT06572813|DRUG|Sintilimab|PD-1 antibody
223900043|NCT06572813|DRUG|mFOLFIRINOX|Combination of oxaliplatin, fluorouracil, irinotecan, leucovorin calcium
223900044|NCT03459729|DRUG|Antitumor B|Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
223939964|NCT07196267|DEVICE|Extracorporeal Shockwave Therapy|Delivered using Shock Master (Master Plus MP200, STORZ Medical AG, Switzerland). Applied at 7 Hz frequency, 2.5-3 bar pressure, for 15 minutes per session, 3 times per week for 8 weeks. Target: supraspinatus tendon region. Applied after Cryoflow therapy in experimental group.
223900045|NCT03134092|OTHER|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
223900046|NCT03134092|OTHER|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of \~ 2-minute length and recorded.
223900047|NCT05844137|BEHAVIORAL|NAFLD Education|NAFLD Education
223900048|NCT05844137|BEHAVIORAL|diet/lifestyle support|diet/lifestyle support
223900049|NCT05844137|DRUG|T2D medication management|T2D medication management
223900050|NCT05844137|DIAGNOSTIC_TEST|clinically-indicated liver testing and care|clinically-indicated liver testing and care
223900051|NCT03666000|BIOLOGICAL|Azer-cel|Infusion of Allogeneic Anti-CD19 CAR T cells
223900052|NCT03666000|DRUG|Fludarabine|Specified dose on specified days
223900053|NCT03666000|DRUG|Cyclophosphamide|Specified dose on specified days
223900054|NCT03666000|DRUG|IL-2|Specified dose on specified days
223900055|NCT03666000|DRUG|Bendamustine|Specified dose on specified days
223900056|NCT05775406|DRUG|KT-253|KT-253 will be administered intravenously per the defined protocol frequency and dose level.
223900057|NCT06126900|OTHER|Smartphone medication intake reminder + educational and motivational text messaging|The intervention includes the use of a smartphone-based medication intake reminder, along with two educational and motivational text messages during the therapy period.
223900058|NCT06153420|DRUG|CIN-103|CIN-103 BID
223900059|NCT06153420|DRUG|Placebo|Placebo for CIN-103 BID
223900060|NCT04200456|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points.
223900061|NCT04200456|OTHER|Placebo|Study participants receive placebo by subcutaneous infusion at pre-specified time points.
223900062|NCT06145386|BEHAVIORAL|Aerobic Exercise and Strength Training|Aerobic Exercise and Strength Training on Physical Activity Level, Quality of Life and Anxiety-Stress Disorder in Young Adults With and Without Covid-19
223900063|NCT03778996|DRUG|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
223900064|NCT06554405|OTHER|Unilateral Intervention|Treatment plan will be applied to the symptomatic side.
223900065|NCT06554405|OTHER|Bilateral Intervention|Treatment plan will be applied to the symptomatic and nonsymptomatic sides.
223900066|NCT05176080|DRUG|Famitinib|Famitinib orally, daily or every other day
223900067|NCT05176080|DRUG|SHR6390|SHR6390 orally, daily for 3 weeks followed by 1 week off
223900068|NCT05176080|DRUG|Fulvestrant|Fulvestrant
223900069|NCT06107387|BEHAVIORAL|Binge Eating Self-help for Teens|Guided self-help intervention
223900070|NCT02098629|DRUG|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
223900071|NCT02098629|DRUG|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
223900072|NCT02098629|DRUG|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
223900073|NCT05085067|OTHER|auto-crossed-linked hyaluronic acid gel|infusing auto-cross linked hyaluronic acid gel into intrauterine cavity after hysteroscopic treatment because of retained products of conception
223900074|NCT07063394|DEVICE|Group 1|Patients in Group 1 will receive standard anesthesia protocol combined with interactive and immersive Virtual Reality (VR) therapy. This includes both engaging in interactive games that require cognitive and motor tasks, such as slicing objects or solving puzzles, and watching immersive 360-degree videos featuring calming environments like natural landscapes. The VR sessions are designed to distract patients from pain perception and reduce anxiety. The intervention will be administered for 3 sessions per day, each lasting 30-45 minutes, over 5 consecutive postoperative days.
223900075|NCT07063394|DEVICE|Group 2|Patients in Group 2 will receive standard anesthesia protocol combined with passive Virtual Reality (VR) therapy. This involves the use of a VR headset to watch immersive 360-degree videos, such as tranquil natural landscapes or underwater scenes, designed to promote relaxation and reduce anxiety. The VR sessions do not require active participation, allowing patients to passively observe calming environments. The intervention will be administered for 3 sessions per day, lasting 30-45 minutes each, over 5 consecutive postoperative days.
223900076|NCT07062744|DEVICE|Swan-Ganz IQ Pulmonary Arterial catheter|"A pulmonary artery catheter (Swan-Ganz catheter) will be inserted via the right internal jugular or subclavian vein using a sterile technique and ultrasound guidance. The catheter is advanced into the pulmonary artery with real-time pressure waveform monitoring to confirm accurate positioning.~Once inserted, the catheter provides continuous invasive hemodynamic monitoring, including measurements of: Right atrial pressure (RAP), Pulmonary artery pressure (PAP), Pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) by thermodilution, Mixed venous oxygen saturation (SvO₂).~These parameters are recorded at predefined intervals and used to guide goal-directed hemodynamic resuscitation. Clinical interventions such as vasopressor/inotrope titration, fluid resuscitation, or ventilatory support will be adjusted accordingly. All procedures will follow institutional protocols and safety standards. Complications (e.g., arrhythmias, infection) will be monitored and managed per protocol."
223900077|NCT07062744|DEVICE|Swan-Ganz IQ catheter|"A pulmonary artery catheter (Swan-Ganz catheter) will be inserted via the right internal jugular or subclavian vein using a sterile technique and ultrasound guidance. The catheter is advanced into the pulmonary artery with real-time pressure waveform monitoring to confirm accurate positioning.~Once inserted, the catheter provides continuous invasive hemodynamic monitoring, including measurements of: Right atrial pressure (RAP), Pulmonary artery pressure (PAP), Pulmonary capillary wedge pressure (PCWP), Cardiac output (CO) by thermodilution, Mixed venous oxygen saturation (SvO₂). These parameters are recorded at predefined intervals and used to guide goal-directed hemodynamic resuscitation. Clinical interventions such as vasopressor/inotrope titration, fluid resuscitation, or ventilatory support will be adjusted accordingly. All procedures will follow institutional protocols and safety standards. Complications (e.g., arrhythmias, infection) will be monitored and managed per protocol."
223900078|NCT07063875|DRUG|Aldesleukin|IL-2 in combination with Tebentafusp
223900079|NCT07062237|OTHER|Ultrashort abstinence|Ultrashort abstinence: producing a sperm sample after 1 hour of abstinence.
223900080|NCT07062237|OTHER|Standard abstinence|Standard abstinence: producing a sperm sample after 2-5 days of abstinence.
223900081|NCT07062913|PROCEDURE|Conventional Rehabilitation|A standard rehabilitation program including positioning, range of motion exercises, stretching, strengthening, and conventional transcutaneous electrical nerve stimulation.
223900082|NCT07062913|DEVICE|Contrast Compression Therapy|Contrast compression therapy using a Game Ready® MED4 ELITE device applied to the affected upper extremity with sequential hot and cold phases and pneumatic compression.
223900083|NCT07062913|PROCEDURE|Conventional Rehabilitation|Same standard rehabilitation program as in the control group.
223900084|NCT07064252|PROCEDURE|Educational Informed Consent Video|Individualized procedure-specific educational video. Videos are developed by a multidisciplinary collaboration of neurosurgeons, medical educators, and patient advocates. Each video is tailored based on location of the pathology, surgical approach, positioning, anticoagulation intake, and intraoperative adjuncts such as electrophysiology. Each video followes a standardized format covering anatomical considerations, preoperative care, the surgical procedure, and postoperative care including potential complications, expected recovery process, and post-surgery instructions.
223900085|NCT07064252|PROCEDURE|Standard informed consent|Standard informed consent, consisting of an in-person verbal consultation with the responsible neurosurgeon supplemented by written documentation and cranial models when applicable
223900086|NCT07063888|RADIATION|Adjuvant Concurrent Chemoradiotherapy with Simultaneous Integrated Boost|Eligibility patients will receive IMRT or VMAT. The prescription dose to high-risk area of tumor bed or positive lymph node was planned at 55-60Gy and the prescription dose to lymphatic drainage regions was planned at 40-45Gy in 20-25 fractions. During radiotherapy, patients will concurrently receive capecitabine (1600 mg/m² on days 1-14, every 21 days for 2 cycles). After radiotherapy, maintenance therapy with capecitabine will continue (2000 mg/m² on days 1-14, every 21 days for 6 cycles). For patients who cannot tolerate capecitabine, S-1 will be used as an alternative.
223900087|NCT07064278|PROCEDURE|Bronchoscopy with Bronchoalveolar Lavage|Flexible bronchoscopy to assess airway patency, remove mucous plugs, and collect bronchoalveolar lavage (BAL) fluid for microbiological and cytological analysis.
223900088|NCT07064278|PROCEDURE|Chest CT with Scoring|Chest CT scans at baseline and day 14 to quantitatively assess lesion range, lesion type, pleural effusion, and lymphadenectasis (Total score: 0-13).
223900089|NCT07064278|DIAGNOSTIC_TEST|Monocyte Subpopulation Analysis|Flow cytometry analysis of peripheral blood to phenotype monocyte subsets (Classical, Intermediate, Non-classical) at baseline and day 14 to guide immunomodulatory therapy.
223900090|NCT07064278|DRUG|Azithromycin, Doxycycline, Prednisone|Sequential azithromycin as baseline therapy. Doxycycline (4 mg/kg/day) was used if BAL results confirmed azithromycin resistance. Oral prednisone (1 mg/kg/day for 5 days) was added if intermediate monocytes were \>15%.
223900091|NCT07064278|OTHER|Supportive Care|Management of cough, wheezing, and fever based on clinical symptoms.
223900092|NCT06801522|DRUG|0.1% xylometazoline nasal drops|Xylometazoline is direct acting, non selective, adrenergic agonist binding with alpha 1\&2 receptors, used for vasoconstriction to decrease nasal bleeding.
223900093|NCT06801522|DRUG|Adrenaline nasal pack|Adrenaline is direct acting, non selective, adrenergic agonist binding with alpha and beta receptors both, used for vasoconstriction to decrease nasal bleeding.
223900094|NCT05335096|BEHAVIORAL|An AI-chatbot-based mHealth intervention|The participants assigned to the intervention group will get access to an AI-chatbot and can interact with the AI-chatbot at any time. In each round of the interactive communication, the chatbot will provide automated personalized messages containing PrEP, mental health, or HIV testing-related information, motivation and skills based on the participants' answers and will continuously update over time.
224276768|NCT00685035|DEVICE|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
223900095|NCT05335096|BEHAVIORAL|An attention-chatbot-based mHealth intervention|The participants assigned to the control group will get access to an attention-chatbot and can interact with the attention-chatbot at any time. In each round of the interaction, the chatbot will provide pre-scripted time-attention health education messages to the participants.
223900096|NCT05335096|BEHAVIORAL|Educational materials|the research assistant will manually sent to the participants' phone a piece of educational material and an online survey link every 30 days (at days 30, 60, 90, 120, 150 and 180).
223900097|NCT05022173|DEVICE|Helmet Non-Invasive Ventilation|The helmet interface is a modality which is used to deliver NIV to patients with respiratory failure. A transparent hood is placed over the entire head of the patient with a seal at the neck using a soft collar.
224276769|NCT00685035|DEVICE|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
223900098|NCT05022173|DEVICE|Facemask Non-Invasive Ventilation|The facemask interface is a modality which is also used to deliver NIV to patients with respiratory failure. A large mask covering the mouth and nose is strapped to the patient's face to create a seal.
223900099|NCT06806943|DEVICE|avatar-based interactions|SUD patients were investigated using the Autobiographical Memory Test in two conditions: face-to-face and avatar-based interactions. Patients had to recall 6 neutral cue words and 6 substance-related cue words for each condition.
223900100|NCT07062497|DRUG|Rectus Sheath Block|Participants in this arm will receive bilateral ultrasound-guided rectus sheath block (RSB) with a solution containing 8 mL of lidocaine 2% + 8 mL of ropivacaine 1%, diluted in 0.9% saline to a total volume of 20 mL, each side, without the addition of clonidine.
223900101|NCT07062497|DRUG|Rectus Sheath Block with Clonidine|Participants in this arm will receive bilateral ultrasound-guided rectus sheath block (RSB) with a solution containing 8 mL of lidocaine 2% + 8 mL of ropivacaine 1% + clonidine 75 mcg, diluted in 0.9% saline to a total volume of 20 mL, each side, without the addition of clonidine.
223900102|NCT06852469|DRUG|Lorazepam 1 mg tablet|Lorazepam is an oral medication which is FDA approved to treat anxiety.
223900103|NCT06852469|DRUG|Placebo tablet|Placebo will match the study drug in mode of administration, color, size, and taste.
223900104|NCT05388149|DRUG|Neratinib|Neratinib administered as 40mg tablets
223900105|NCT02110212|PROCEDURE|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
223900106|NCT02110212|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
223900107|NCT06913855|DRUG|EMLA Cream|EMLA cream is applied once, 3 hours before the tube is removed. EMLA cream will be applied by the researcher in a thin layer to an area of 7-10 cm2, with the chest tube entrance to the skin remaining in the center. It will be covered with a Tegaderm transparent film dressing.
223900108|NCT06913855|PROCEDURE|Cold application|Cold application will be made with an ice cube pack immediately before the chest tube removal procedure. Cold application will be applied to a 7 cm diameter area, with the chest tube entrance to the skin being considered as the center. Skin temperature will be measured with an infrared thermometer and will be ensured to reach 13.0 degrees. Ice pack application is expected to last approximately 9-10 minutes.
223900109|NCT06279351|DRUG|Thalidomide+cetuximab+FOLFOX/FOLFIRI|Thalidomide+cetuximab+FOLFOX/FOLFIRI
223900110|NCT06089278|DRUG|300mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
223900111|NCT06089278|DRUG|600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
223900112|NCT06089278|DRUG|TQH2722 injection matching placebo|Placebo without active substance.
223900113|NCT04520711|BIOLOGICAL|TCR-transduced T cells|TSA-reactive TCR-engineered T cells
223900114|NCT04520711|DRUG|CDX-1140|Recombinant fully human IgG2κ monoclonal antibody
223900115|NCT04520711|DRUG|Pembrolizumab|Humanized immunoglobulin G4 (IgG4) monoclonal antibody
223900116|NCT06325657|BIOLOGICAL|RSVpreF vaccine|RSVpreF vaccine
223900117|NCT06325657|BIOLOGICAL|Placebp|Placebo
223900118|NCT04527185|DRUG|Endotoxin|Endotoxin 0.4ng/kg i.v.
223900119|NCT06783452|OTHER|Exercise|"Clinical Pilates Session:~Each clinical Pilates movement will have three difficulty levels: beginner, intermediate, and advanced. The progression criteria for increasing difficulty will be determined by the prevention of compensatory movements, the ability to activate target muscles, achieving more controlled movements during exercise, and maintaining a more stable posture. This program will include standard hip-focused as well as full-body clinical Pilates movements."
223900120|NCT06783452|OTHER|Exercise|"Conventional Therapeutic Exercise Program:~The Conventional Therapeutic Physiotherapy Exercise Program will consist of strengthening exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors. Additionally, stretching exercises for the hip flexors, extensors, abductors, and adductors, as well as the knee flexors and extensors, will be included. Stretching exercises will be performed at a pain-free point where tension is felt, holding for 10-30 seconds to achieve a total duration of 60 seconds per muscle group. These exercises will represent standard hip-targeted exercises.~During the exercises, patients will be asked to rate their perceived exertion using the BORG scale (0-10). When the difficulty level reaches 5-6 points, progression will first be achieved by increasing the number of sets, followed by the use of resistance bands."
223900121|NCT06416488|BEHAVIORAL|HIIT intervention|Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
223900122|NCT06416488|BEHAVIORAL|General health education|General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
223900123|NCT06533163|DEVICE|Oncomagnetic device|OncoMAGNETX has developed a portable wearable noninvasive magnetic device (Oncomagnetic device) for the treatment of GBM.
223900124|NCT02013583|OTHER|No intervention|This is an observational registry. No interventions are required or provided.
223900125|NCT04682587|DRUG|Axitinib|Inlyta, axitinib
224276770|NCT02041858|OTHER|Altered Alarm Settings|An altered set of alarm parameter settings
223900126|NCT04682587|DRUG|Avelumab|Avelumab, Bavencio
223900127|NCT04682587|DRUG|Pembrolizumab|Pembrolizumab, Keytruda
223900128|NCT06116682|BIOLOGICAL|Amivantamab|Given amivantamab-SC
223900129|NCT06116682|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223900130|NCT06116682|PROCEDURE|Computed Tomography|Undergo CT scan
223900131|NCT06116682|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223939965|NCT07196267|DEVICE|Cryoflow Therapy|Delivered using Cryoflow 1000IR (Model ICE-CT, EC). Applied at 14°C for 15 minutes per session, 3 times per week for 8 weeks. Applied directly over rotator cuff tendon region before ESWT in experimental group.
224276771|NCT00063258|DRUG|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
224276772|NCT00063258|DRUG|Paclitaxel|Planned dose of 200 mg/m\^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
223714900|NCT01220375|DRUG|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
223714901|NCT01220375|DRUG|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
223714902|NCT00779714|DRUG|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
223714903|NCT00779714|DRUG|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
223714904|NCT00779714|DRUG|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
223714905|NCT01301352|OTHER|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
223714906|NCT01260636|DRUG|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
223714907|NCT01260636|DRUG|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
223714908|NCT01055171|DRUG|Propranolol|40 mg; Single Administration.
223714909|NCT01055171|DRUG|Placebo|40 mg; Single Dose.
223714910|NCT02414997|PROCEDURE|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
223714911|NCT02414997|PROCEDURE|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
223714912|NCT02176499|DRUG|Telmisartan, low dose|
223714913|NCT02176499|DRUG|Telmisartan, high dose|
223714914|NCT02176499|DRUG|Placebo|
223714915|NCT02200211|DEVICE|iPad®|Binocular therapy on iPad®
223714916|NCT02200211|OTHER|Patching 2 hours per day, 7 days per week|
223714917|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
223714918|NCT00381485|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
223714919|NCT00381485|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
223714920|NCT04952493|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
223714921|NCT04952493|DRUG|Sodium Iodide I 131|RAI treatment may shrink the tumor
223714922|NCT04952493|DRUG|Penpulimab|Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.
223714923|NCT02584816|BIOLOGICAL|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
223714924|NCT02584816|BIOLOGICAL|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
223714925|NCT02584816|BIOLOGICAL|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
223714926|NCT02584816|BIOLOGICAL|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
223714927|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
223714928|NCT01235351|DRUG|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
223714929|NCT04243967|OTHER|Music therapy|"On the surgery day, the patient is accompanied by music-therapist all the way from her room to the operating theatre in order to monitor and adapt music-therapy intervention.~The patient, prior to the anesthetic, take faces 3 phases of music therapy intervention (1 hour):~* 1° Phase Active Music therapy: the patient takes part in a session of live improvisational music therapy, with the therapist, to elaborate pre-operative stress.~* 2° Phase Relaxation with Receptive Live Music: music therapist play live to relax patients with autogenic training and tunnings breathing.~* 3° Phase playlist listening based on the patient's needs. Patients listen to music with an mp3 player with earphones within the ear canal (H\&H CE mp3/Usb; Headphones on Air in-ear with volume control) with a maximum volume of 60 dB (previously set with a sound level meter)."
223714930|NCT04243967|OTHER|Control|Standard perioperative management including perioperative care (without the use of music / music therapy)
223714931|NCT05979350|DIAGNOSTIC_TEST|Metagenomic next-generation sequencing|Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).
223714932|NCT05979350|DIAGNOSTIC_TEST|Standard work-up for pneumonia|Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
223939966|NCT07196267|BEHAVIORAL|Traditional Physical Therapy Program|tretching of shoulder flexors/adductors/internal rotators Strengthening of shoulder extensors/external rotators Weight-bearing exercises (sitting \& quadruped) Neuromuscular Facilitation (PNF) for upper limb Hand dexterity training using Purdue Pegboard
224276773|NCT00063258|DRUG|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
223714933|NCT06120998|PROCEDURE|Arthroscopic rotator cuff repair|All patients were placed in a semi-sitting position. Initially, a posterior portal was established to explore the inside of the joint, a lateral portal was created for the removal of subacromial bursa, and an additional anterior portal was created for repairing the tendons. Measurements were taken to determine the extent of rotator cuff damage, including its anterior-posterior and medial-lateral dimensions. In cases where complete repair was possible, a single-row or double-row repair technique was used depending on the degree of tendon damage. For situations where complete repair was not feasible, partial repair was performed. If the tendon could be stretched after relaxation, it was repaired to an anatomical position near the bone bed with the assistance of acellular dermal reinforcement. However, if the tendon lacked elasticity and was fully retracted upon relaxation, acellular dermis was used to bridge the tendon back to the anatomical position.
223714934|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
223714935|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
223714936|NCT01567124|DRUG|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
223714937|NCT01567124|DRUG|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
223714938|NCT04717609|PROCEDURE|Saphenous Nerve Block|Preoperative Saphenous Nerve Block for partial Meniscectomy
223714939|NCT04717609|DRUG|Ropivacaine injection|preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
223714940|NCT00378820|BEHAVIORAL|Whey without milk minerals|
223714941|NCT00378820|BEHAVIORAL|Whey with milk minerals|
223714942|NCT00378820|BEHAVIORAL|Casein without milk minerals|
223714943|NCT00378820|BEHAVIORAL|Casein with milk minerals|
223714944|NCT01811654|DEVICE|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
223714945|NCT05478785|DRUG|Cisplatin micelle injection (HA132)|HA132 will be administered intravenously (IV), once per 3 weeks.
223714946|NCT06223178|DEVICE|thumb-tack needle|Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
223714947|NCT06223178|DEVICE|sham thumb-tack needle|Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
223714948|NCT06223178|OTHER|Basic gynecological treatment|Gynecological health care guidance will be provided as patients needed.
223714949|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
223714950|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
223714951|NCT01275885|DIETARY_SUPPLEMENT|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
223714952|NCT00126191|DRUG|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
223714953|NCT00126191|DRUG|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
223714954|NCT00126191|DRUG|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
223714955|NCT00126191|DRUG|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
223714956|NCT00126191|DRUG|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
223714957|NCT00126191|DRUG|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
223714958|NCT00126191|DRUG|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
223714959|NCT00126191|DRUG|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
223714960|NCT00126191|DRUG|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
223714961|NCT00126191|DRUG|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
223714962|NCT01898806|DRUG|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
223900132|NCT06171828|DEVICE|Head-Mounted Display (HMD) to communicate with a supervisor remotely|Participants in the experimental group are oriented on using the education platform and communicating with the supervisor through an HMD for about 5 minutes. They then perform and save their ultrasound imaging. If they require assistance, they request help verbally through the HMD's communication system. The supervisor remotely observes and immediately assists upon request, utilizing the HMD and a 360-degree camera.
223900133|NCT04913012|COMBINATION_PRODUCT|Systematic aerobic training|Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
223900134|NCT04913012|COMBINATION_PRODUCT|Systematic resistance training|Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
223900135|NCT04913012|COMBINATION_PRODUCT|Aerobic training booster sessions|Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).
223900136|NCT04913012|COMBINATION_PRODUCT|Resistance training booster sessions|Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).
223900137|NCT00506519|DRUG|Antithrombin alfa (INN name)|
223900138|NCT00506519|DRUG|Control (Standard treatment)|
223900139|NCT03929952|OTHER|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~* The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~* The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
223900140|NCT03929952|OTHER|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
223900141|NCT01186367|BEHAVIORAL|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
223900142|NCT01186367|BEHAVIORAL|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
223900143|NCT01186367|BEHAVIORAL|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
223900144|NCT01186367|OTHER|Cardiopulmonary exercise test (CPET)|
223900145|NCT01186367|OTHER|Blood draws|Complete blood count
223900146|NCT06114108|OTHER|Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)|The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.
223900147|NCT06114108|OTHER|Surgery|Surgery
223900148|NCT06114108|RADIATION|Radiotherapy|Radiotherapy
223900149|NCT06403111|COMBINATION_PRODUCT|Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy|Participants will receive FMT combined with tislelizumab + pemetrexed + platinum-based treatment (lung adenocarcinoma) / albumin-bound paclitaxel + platinum-based treatment (lung squamous cell carcinoma) for 4-6 cycles. If there is no progression of the disease after 4-6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. Patients will receive tislelizumab maintenance treatment (lung squamous cell carcinoma), or tislelizumab + pemetrexed maintenance treatment (lung adenocarcinoma).
223900150|NCT06075368|DEVICE|GENOSS Sirolimus Eluting Coronary Stent System|The GENOSS SES is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt chromium stent platform and thin strut.
223900151|NCT05264480|PROCEDURE|Bone augmentation with minimally invasive corticotomy (piezotomy)|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Trough the vertical releasing incisions a piezosurgical device is used to perform corticotomy. 1 week after surgery OTM is initiated."
223900152|NCT05264480|PROCEDURE|Bone augmentation without corticotomy|"Double layer tunnel flap preparation. Subperiosteally sticky bone containing platelet rich fibrin (PRF) and xenograft is utilized for bone augmentation, while supraperiosteally PRF membranes are used for soft tissue augmentation. Corticotomy is not performed in this group. 1 week after surgery OTM is initiated."
223900153|NCT05844436|DRUG|Pritelivir|Participants receive a loading dose of 400 mg (4 x 100 mg tablet) pritelivir on first day followed by continuous dose of 100 mg per day.
223900154|NCT06643793|DRUG|Irinotecan liposome (ll) + 5-FU/LV + bevacizumab|"1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w."
223900155|NCT05637320|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems|The intervention arm will consist of a transdiagnostic psychotherapy program: The Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC). MATCH draws from various domains of evidence-based treatment and consists of 33 treatment modules. There are several core module sequences for problem areas such as depression, anxiety, trauma, and disruptive behavior, and a clinician can utilize these sequences based on the primary concern of the presenting child. If an individual reports additional stressors or comorbid conditions, the clinician can modify the sequence of the modules to address these comorbidities. MATCH treatment is flexible and is tailored for each individual client.
223900156|NCT03945292|DRUG|Fazisiran Injection|solution for subcutaneous (sc) injection
223900157|NCT03945292|OTHER|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
223900158|NCT02750826|OTHER|Health Education Program|
223900159|NCT02750826|OTHER|Weight Loss Intervention|
223900160|NCT04374175|BIOLOGICAL|Blood sample|Blood sample will be performed
223900161|NCT06646432|PROCEDURE|Tunnel with connective tissue graft and injectable platelet rich fibrin|Tunnel with connective tissue graft and injectable platelet rich fibrin
223900162|NCT06646432|PROCEDURE|Tunnel with connective tissue graft only|Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
223900163|NCT05789134|OTHER|self-sampling kits for STI testing in the laboratory|Participants will receive the self-sampling kits and their submitted samples would be sent to laboratory for testing
223900164|NCT04472091|DEVICE|Genicular artery embolization (GAE)|Participants will undergo GAE with HydroPearl® Microspheres (polyethylene glycol microspheres, Terumo Medical, Somerset NJ).
223900165|NCT04987320|DRUG|Olpasiran|Subcutaneous injection
223900166|NCT06616857|BEHAVIORAL|NUDGE|Individuals in this condition will receive intervention content to promote physical activity.
223900167|NCT06616857|OTHER|Education|Individuals will receive educational materials about how to increase physical activity
223900168|NCT00310830|DRUG|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
223900169|NCT05403827|DRUG|K-161|K-161 Ophthalmic Solution
223900170|NCT05403827|DRUG|Placebo|Vehicle Solution
223900171|NCT06773286|OTHER|Active Stimulation|Participants will receive activity-based training (ABT) while receiving concomitant, active spinal stimulation (scTS) applied at the cervical and thoracic spinal segments over the dorsal skin with optimized and customized stimulation parameters. Round self-adhesive electrodes will be placed over the skin at the midline of spinous processes as cathodes and a pair of rectangular anodes electrodes will be placed over the anterior iliac crests of the pelvis. The stimulation waveform is rectangular pulse with 1-ms duration filled with a carrier frequency of 5kHz. Target simulation will be sub-threshold for UE muscle activation and verified by the absence of visible muscle contraction. The stimulation parameters will be adjusted as needed throughout the intervention course based on the participant's performance and comfort level. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
223900172|NCT06773286|OTHER|Sham|The sham-control group will go through ABT paired with sham stimulation to control for placebo effects associated with the perception of scTS. Stimulation will be delivered at one cervical location. No stimulation mapping procedure will be performed. During the training session, the stimulation intensity will be briefly ramped up to a level at which the participants report perceiving the stimulation, and then ramped down to 0mA at both the start and the end of session. The stimulator and electrodes will remain attached to the participant while receiving ABT training. The intervention will be administered over 2 consecutive weeks, for 30mins/session and 5 sessions/week, as a part of their daily 3-hour therapy.
223900173|NCT06773286|OTHER|Training only|articipants in ABT group will receive ABT only. ABT will concentrate on activities of gross UE movement, grasping, pinching, gross and fine motor skill. The hand grasp task will focus on grasping objects with different shapes and weights (i.e. weighted container and tennis ball) and placing/removing them from small storage container; the pinch task involves picking up, translating, and releasing small objects with varied sizes (i.e. blocks, dices, marble balls, nuts, etc.). The training therapist selects tasks based on participant's level of impairment and individual goals. The dosage of ABT will be 30 minutes/session, with approximately 15 minutes allocated on each side.
223900174|NCT06807866|DRUG|Duloxetine|Participants will come in person and receive a one time 60 mg dose by mouth.
223900175|NCT06807866|OTHER|Placebo|Participants will come in person and receive a one time 60 mg placebo pill dose by mouth.
223900176|NCT01480440|DEVICE|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
223900177|NCT04072198|DRUG|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
223900178|NCT04072198|DRUG|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
223900179|NCT04072198|DRUG|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
223900180|NCT04072198|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
223900181|NCT04072198|DRUG|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
223900182|NCT04072198|DRUG|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
223900183|NCT04735653|BEHAVIORAL|Personalized Glaucoma Coaching|This is a six-month personalized glaucoma coaching program where a coach trained in motivational interviewing (MI)-based counseling uses a web based tool that generates tailored education to help glaucoma patients identify their barriers to optimal medication adherence and explore potential solutions during three in-person coaching sessions. The coach provides between-session support through four phone calls, with two phone calls between the first and second session and one phone call after each subsequent session. Participants can elect to receive any of the following type of alarm when a dose of medication is due: visual or audible alert or automated text or phone call reminder. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
223900184|NCT04735653|BEHAVIORAL|Enhanced Standard care|Participants will receive non-tailored educational materials about glaucoma from leading sources by mail every 2 months for a total of 3 mailings during the 6-month study period. Glaucoma medication adherence will be monitored electronically for all participants between the baseline visit and the exit visit six months later.
223900185|NCT03810807|DRUG|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
223900186|NCT03810807|DRUG|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
223900187|NCT06353295|OTHER|P4P intervention|The final Peers for PrEP (P4P) intervention components were refined based on stakeholder engagement, key informant interviews, and focus group discussions. Trained peers will deliver the following intervention with remote clinician support and ongoing mentorship: pre-exposure prophylaxis (PrEP) access and refills in community/at hotspots; HIV testing, with option for HIV self-testing (HIVST); Rapid post-exposure prophylaxis (PEP) access for unplanned exposures; Family planning integration; Phone/text messaging hotline for peer support
224276774|NCT04187924|OTHER|Autogenic drainage|Autogenic drainage is an airway clearance technique characterised by breathing control using expiratory airflow to mobilise secretions from smaller to larger airways. The secretions will be collected during the physiotherapy session and during the 24 hours following the session.
224276775|NCT04187924|DEVICE|SIMEOX + Autogenic drainage|SIMEOX is a device generating a succession of gentle depression at the mouth during the expiratory phase associated with autogenic drainage.
224276776|NCT01561924|DRUG|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
224276777|NCT00603395|DEVICE|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
224276778|NCT04619550|OTHER|High tibial osteotomy|Realignment surgery
224276779|NCT05268419|DRUG|Ethanol|Inhalation of 35%-ethanol spray
223714963|NCT01898806|DRUG|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
223714964|NCT01898806|DRUG|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
223714965|NCT01898806|DRUG|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
223714966|NCT03394326|BEHAVIORAL|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
223714967|NCT05924620|DRUG|finerenone|Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
223714968|NCT03178877|OTHER|No intervention|
223714969|NCT00940225|DRUG|Cabozantinib|
223714970|NCT00940225|DRUG|Placebo|
223714971|NCT00500669|DRUG|Betadine|Topically
223714972|NCT04352647|BEHAVIORAL|female athletes|The type of incontinence is assessed, whether there are risk factors and quality of life and psychological performance
223714973|NCT00307294|DRUG|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
223714974|NCT00307294|DRUG|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
223714975|NCT02479178|DRUG|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
223714976|NCT00475358|DRUG|Duloxetine|
223714977|NCT00475358|DRUG|Placebo|
223714978|NCT05364125|OTHER|Olfactory Training|Four aromatic substances will be used (Citrus limon, Eucalyptus radiata, Pelargonium graveolens, Juniperus virginiana)
223714979|NCT05364125|OTHER|Control|Normal Saline will be used
223714980|NCT00612690|BEHAVIORAL|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
223714981|NCT00612690|BEHAVIORAL|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
223714982|NCT02537197|DRUG|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
223714983|NCT04448483|DEVICE|Paretic upper limb functional electric stimulation through RehaStim|"The stimulation will activate upper limb muscles to perform motor rehabilitation exercises for the upper limb with the help of the Gloreha Sinfonia robotic glove that will assist-as-needed hands movements. Motor intention will be detected by a BCI (Brain Computer Interface) from the non-invasive measure of brain activity by using electroencephalography.~The motor rehabilitation exercises include upper limb and hand mobilization and functional tasks, such as hand open/closing, wrist flexion/extension, and reach and grasp a cup, keep and release."
223714984|NCT04448483|DEVICE|Non-invasive transcranial current stimulation through DC-Stimulator|Non-invasive brain stimulation in the form of transcranial direct current stimulation will be provided in addition to the previous intervention.
223714985|NCT02032121|PROCEDURE|Blood specimen|
223714986|NCT02032121|PROCEDURE|Echocardiography|
223714987|NCT00943059|DRUG|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
223714988|NCT00943059|DRUG|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
223714989|NCT03647397|DEVICE|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
223714990|NCT06508424|OTHER|PulseOn|PulseOn - 1 week washout period between interventions 75g crackers
223714991|NCT06508424|OTHER|Wheat flour control|Control -1 week washout period between interventions 75g crackers
223714992|NCT03164902|DEVICE|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
223714993|NCT05450731|OTHER|12-week supervised exercise based cardiac rehabilitation program|12-week exercise-based cardiac rehabilitation intervention on the recurrence of atrial fibrillation (AF) in patients at six- and twelve-months post-ablation procedure.
223714994|NCT02980601|DEVICE|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
224276780|NCT05268419|DRUG|Water Distilled|Inhalation of water distilled spray
224276781|NCT01787110|DRUG|Oxygen|see arm description
224276782|NCT01142141|OTHER|manual therapy, kinesiotherapy|
224276783|NCT02333188|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
224276784|NCT02333188|DRUG|Leucovorin Calcium|Given IV
224276785|NCT02333188|DRUG|Irinotecan Hydrochloride|Given IV
224276786|NCT02333188|DRUG|Fluorouracil|Given IV
224276787|NCT02333188|OTHER|Laboratory Biomarker Analysis|Correlative studies
224276788|NCT03761498|OTHER|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
224276789|NCT03468712|PROCEDURE|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
223714995|NCT02980601|PROCEDURE|STSG|0.012mm STSG
223714996|NCT04569266|OTHER|Specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
223714997|NCT04569266|OTHER|No specific exercise rehabilitation treatment|"Patients meeting the eligibility criteria will be selected consecutively. They will be contacted by telephone after at least 3 months post-resuscitation. The mMRC score is then evaluated. In case of mMRC\>1, the study will then be proposed by the physiotherapist or the referring investigating physician of each participating center during this call. The patient is then offered an appointment on the reference rehabilitation platform of each center. The CDM measurement as well as the quality of life by the SF-12 scale are also carried out.~Randomization will be stratified on the type of management during the resuscitation stay (invasive mechanical ventilation/high-flow nasal oxygen therapy) to ensure a good distribution between the 2 study arms (control or treatment)."
223714998|NCT01575769|DRUG|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
223714999|NCT00844831|DRUG|Lubiprostone|24 mcg bid for 28 days
223715000|NCT01379040|OTHER|Cystic Fibrosis patients|
223715001|NCT05890846|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
223715002|NCT05890846|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 12 weeks.
223715003|NCT05890846|BEHAVIORAL|traditional 1on1 course|Between every two iTBS sessions, the participant will receive a personalized 30-minutes one-on-one behavioral course, 2 courses per day, 5 days per week for 12 weeks.
223715004|NCT01080534|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
223715005|NCT03777878|DRUG|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
223715006|NCT03777878|DRUG|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
223715007|NCT03777878|DRUG|TA|2 ampoules of TA in 100 ml saline by slow infusion
223715008|NCT03777878|DRUG|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
223715009|NCT03777878|DRUG|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
223715010|NCT03777878|DRUG|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
223715011|NCT01779401|DRUG|Clopidogrel 75mg|
223715012|NCT01779401|DRUG|Clopidogrel 150mg|
223715013|NCT01779401|DRUG|Aspirin 100mg|
223715014|NCT01779401|DRUG|Cilostazol 100mg|
223715015|NCT01574131|DRUG|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
223715016|NCT01574131|DRUG|Sugar Pill|pill every day for 6 months
223715017|NCT01619982|DRUG|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.
223715018|NCT01619982|DRUG|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
223715019|NCT05192681|DRUG|Tislelizumab|Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
223715020|NCT04010708|DIAGNOSTIC_TEST|Urinary Iodine Concentration Measurement|UIC
223715021|NCT02747095|DEVICE|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
223715022|NCT02948972|PROCEDURE|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
223715023|NCT02948972|PROCEDURE|In vitro fertilization without surgery|IVF without endometriosis surgery
223715024|NCT04009382|OTHER|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
223715025|NCT04009382|OTHER|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
223715026|NCT05265689|BEHAVIORAL|Bike Club|"Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City."
223715027|NCT05265689|BEHAVIORAL|Bike Club Plus|Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
223715028|NCT03043131|DRUG|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
223715029|NCT03043131|DRUG|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
223715030|NCT03775811|OTHER|AUTOMATED POLYP CLASSIFICATION|COLONIC POLYP HISTOLOGY PREDICTION IN WHITE LIGHT IMAGES COMBINING ARTIFICIAL INTELLIGENCE AND CLINICAL INFORMATION
223715031|NCT02539121|DEVICE|Acupuncture|Acupuncture needles
223715032|NCT02122393|DRUG|Sertraline|
223715033|NCT02122393|BEHAVIORAL|Cognitive Behavioural Therapy|
223715034|NCT00656110|DRUG|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
223715035|NCT00656110|DRUG|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
223715036|NCT00634166|DRUG|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
223715037|NCT00634166|DRUG|Topical Antimicrobial/Antifungal Medications|'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
223715038|NCT01953198|OTHER|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
223715039|NCT01523990|DRUG|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
223715040|NCT01523990|DRUG|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
223715041|NCT01308060|DRUG|Botulinum Toxin Type A|During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.
223715042|NCT01308060|OTHER|Placebo|
223715043|NCT02557620|DRUG|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
223715044|NCT02557620|DRUG|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
223715045|NCT06485882|BEHAVIORAL|Self-Care Training|Animation films are watched children about self-care and social competence
223715046|NCT03748797|OTHER|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
223715047|NCT02292979|DRUG|Doxorubicin|25mg/m2
223715048|NCT02292979|DRUG|Bleomycin|10mg/m2
223715049|NCT02292979|DRUG|Vinblastine|6mg/m2
223715050|NCT02292979|DRUG|Dacarbazine|375mg/m2
223715051|NCT02292979|DRUG|Brentuximab Vedotin|1.2 mg/kg
223715052|NCT06131034|OTHER|Music|Participant in the intervention group will receive music interventions perioperatively.
223715053|NCT06219512|BEHAVIORAL|CPET exercise prescription|Exercise mode: walk Frequency: 5 times/week
223715054|NCT06219512|BEHAVIORAL|6MWT exercise prescription|Exercise mode: walk Frequency: 5 times/week
223715055|NCT06219512|BEHAVIORAL|Regular exercise|Regular exercise
223715056|NCT00111345|DRUG|Anthracyclines|3x12 mg/qm
223715057|NCT00111345|DRUG|liposomal daunorubicin|3x80 mg/qm
223715058|NCT00111345|DRUG|2-CDA|2x6 mg/qm
223715059|NCT00111345|DRUG|AI|AI
223715060|NCT04908878|PROCEDURE|Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block|Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
223715061|NCT04908878|PROCEDURE|Serratus anterior plane (SAP) block|Patients will receive US-guided SAP block after induction of general anesthesia.
223715062|NCT04818398|DRUG|DS-6016a|DS-6016a will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
223715063|NCT04818398|DRUG|Placebo|Placebo will be administered as a single subcutaneous injection into the upper arm, upper part of the thigh, or abdominal wall
223715064|NCT01581931|DRUG|Linagliptin/metformin|FDC
223715065|NCT01581931|DRUG|Metformin|single tablet Metformin
223715066|NCT01581931|DRUG|Linagliptin|single tablet Linagliptin
223715067|NCT02185833|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
223715068|NCT02185833|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
223715069|NCT06374160|BEHAVIORAL|Exercise intervention|Exercise
223715070|NCT06040372|DRUG|LB64640|The investigational product (IP) LB54640 is provided 5 mg, 25 mg and 200 mg strengths.
223715071|NCT06040372|DRUG|Placebo|Placebo is provided as a matching placebo
223719230|NCT01315678|DRUG|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
223715072|NCT04803825|OTHER|Heavy Slow Exercises|"* Load magnitude: A dumbbell as heavy as possible within the given repetitions and sets.~* Number of repetitions: week 1: 15 reps, Week 2-3: 12 reps, Week 4-5: 10 reps, Week 6-8: 8 reps, Week 9-12: 6 reps~* Number of sets: 3~* Rest between sets: 2 - 3 min.~* Number of exercise interventions: 2~* Duration of experimental period: 12 weeks~* Fractional and temporal distribution of the contraction modes per repetition and duration of one repetition: 3s concentric, 2s isometric: while change concentric/eccentric phase, 3s eccentric.~* Rest in-between repetitions: No~* Range of motion: Full range of motion~* Intervention frequency: 3 times a week, with minimum 48 h recovery time in-between."
223715073|NCT04803825|DEVICE|Extracorporeal Shock wave therapy|Two thousand impulses of shock waves are applied to the painful tendon, with a pressure between 1.5 and 3.0 bar (depending on what the patient tolerates). We use a power hand piece that provides energy of 0.01-0.35 mJ/mm2
223715074|NCT04803825|OTHER|Information and advice|Information and advice are based on assessment and will comprise the standardized oral and written information. Participants will be educated regarding pain during and after activities and encouraged to be physically active. With only one session, there is great reliance on self-management. Thus, information and advice are made available through a handout.
223715075|NCT02316808|DIETARY_SUPPLEMENT|Plant stanol ester|Smoothie that contains plant stanol ester
223715076|NCT02316808|DIETARY_SUPPLEMENT|placebo|Smoothie that contains placebo
223715077|NCT04488484|OTHER|Serology test follow-up|"The enrolled participants will be invited to visit ESS. They will then meet the occupational physician, who wil obtain their free, informed and written consent. The information and consent will be recorded in the personal medical follow-up file.The staff will then complete the self-questionnaire and the ESS physician will provide a prescription for the blood samples to be taken.~In case of positive answers to one or more of the questions in this self-questionnaire, the enrolled participant will be contacted in order to schedule another post-COVID-19 consultation with additional examinations if needed (new COVID PCR, scanner, etc.)."
223715078|NCT03156543|DEVICE|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
223715079|NCT03156543|OTHER|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
223715080|NCT00413452|DRUG|Etanercept|50 mg once weekly
223715081|NCT03256565|DIAGNOSTIC_TEST|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
223715082|NCT03583489|DRUG|APD421|10 mg IV
223715083|NCT03583489|DRUG|Placebo|IV
223715084|NCT03583489|DRUG|Ondansetron|4 mg IV
223715085|NCT04214054|OTHER|Moldable self-hardening biphasic calcium phosphate graft|Incision was performed in the canine area then a full thickness mucoperiosteal flap was elevated and exposure of the lateral aspect of the maxillary sinus. Osteotomy of the buccal window was performed using the piezosurgery device followed by meticulous dissection of the sinus membrane. Drilling the site were implants were to be placed, guided by the preformed surgical stent. Implants of appropriate size were torqued to engage the apical aspect of the implant recipient site. The sinus was augmented with moldable self-hardening biphasic calcium phosphate. Repositioning and suturing of the flap using 3-0 black silk suture material.
223715086|NCT04214054|PROCEDURE|No graft material placed - Blood Clot only|A pyramidal full thickness mucoperiosteal flap was performed distal to the canine area with a crestal incision located palatally in the edentulous area and vertical extension of the incision to the buccal vestibule using Bard Parker blade number 15. The flap was reflected exposing the alveolar bone. Lateral window was performed and the sinus membrane was elevated using piezo surgery. Drilling at the sites where implants were to be placed was done using Neobiotech implant drilling Kit. Implants. Implants were placed in a self-tapping fashion using a torque wrench. Flaps were replaced back and sutured using 3-0 black silk suture material.
223715087|NCT05292898|BIOLOGICAL|LCAR-AIO Cells|LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
223715088|NCT05062434|OTHER|Academic detailing and audit and feedback intervention|An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
223715089|NCT00643227|DRUG|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
223715090|NCT00643227|DRUG|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
223715091|NCT00297375|DRUG|tramadol HCl/acetaminophen|
223715092|NCT06769854|DEVICE|Urgent PC|PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.
223715093|NCT05575986|DRUG|Hetrombopag Olamine|Hetrombopag Olamine 7.5mg orally, once a day, for 14 days. This product should be taken on an empty stomach, 2 hours after oral administration before eating, avoid taking it with meals.
223715094|NCT02568800|DRUG|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
223715095|NCT02568800|DRUG|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
223715096|NCT06032442|DIETARY_SUPPLEMENT|ARTNEO|"Dietary Supplement: undenatured collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)~Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals."
223715097|NCT06032442|DRUG|Artra|"Active ingredients:~Glucosamine hydrochloride 500 mg Chondroitin sulfate sodium 500 mg~Excipients:~dibasic calcium phosphate, microcrystalline cellulose, croscarmellose sodium, stearic acid, magnesium stearate.~Orally; adults and children over 15 years of age are prescribed 1 tablet 2 times a day for the first three weeks; 1 tablet 1 time per day for the next weeks and months."
223715098|NCT00674700|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
223715099|NCT00674700|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
223715100|NCT00674700|DRUG|Placebo tablet|One sublingual tablet daily for one year
223715101|NCT02954237|DEVICE|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
223715102|NCT06789861|DRUG|TT5|Direct Intravenous administration of TT5 (5 ascending doses in Single Ascending Dose Part and 3 ascending doses administered during 7 days in Multiple Ascending Dose Part in healthy volunteers) Direct Intravenous administration of TT5 in surgical patients (4 doses administered on the same day) in surgical patients
223715103|NCT06789861|DRUG|Placebo - TT5 vehicle|Intravenous administration of vehicule, according to the same drug regimen than TT5
223715104|NCT06547528|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed.
223715105|NCT06359392|OTHER|No message|Participants will not be exposed to a message in this arm of the intervention.
223715106|NCT06359392|OTHER|Culture-centric message|Participants in this arm of the study will watch a 2-minute video on palliative care developed specifically for these American Indian communities.
223715107|NCT06359392|OTHER|General messge|Participants receiving this intervention will watch a 2-minute video developed by the National Hospice and Palliative Care Organization to teach about palliative care.
223715108|NCT05391698|BEHAVIORAL|Behavioral Parent Training (BPT)|The parent training consists of 8 weekly group sessions where parents are trained on behavior modification techniques, optimal parental practices as well as techniques for the enhancement of their children's cognitive deficits.
223715109|NCT05391698|COMBINATION_PRODUCT|Child Training (iVR + CBT)|The child training program is comprised of 16 individualized weekly sessions. It utilizes the potentials of immersive virtual reality (iVR) technology for the training of focused and sustained attention and combines practices based on cognitive-behavioral approach for children's training on behavioral and emotional self-regulation skills.
223715110|NCT03432702|PROCEDURE|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
223715111|NCT00386048|BEHAVIORAL|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
223715112|NCT02543437|DEVICE|Trident Acetabular X3 Insert|
223715113|NCT03797014|DRUG|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
223715114|NCT02544399|OTHER|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
223715115|NCT01326143|DEVICE|ORM Narval MRD|
223715116|NCT05515081|PROCEDURE|blood sample collection|blood sample colletion at regular intervals
223715117|NCT04925362|OTHER|Biological specimens|"Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)"
223715118|NCT04925362|OTHER|Additional visit|Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
223715119|NCT02687633|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
223715120|NCT04455113|DIAGNOSTIC_TEST|Phosphorus level|infusion
223715121|NCT05448183|DRUG|Toripalimab, Gemcitabine,Oxaliplatin|Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
223715122|NCT05535699|OTHER|exercises|scapular exercise
223715123|NCT02613975|DEVICE|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
223715124|NCT00970567|BEHAVIORAL|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
223715125|NCT03346278|BEHAVIORAL|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
223715126|NCT02298920|DRUG|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
223900188|NCT02675751|DEVICE|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
223900189|NCT06553989|OTHER|osteopatic visceral mobilization|a combination of breathing and visceral mobilizations
223900190|NCT05987410|OTHER|Nordic Walking (NW)|The experimental group will carry out NW sessions three times a week for 12 weeks, supervised by a NW instructor and under the control of a cardiologist. The duration of each NW session will initially be 90 minutes: 10 minutes of warm-up, 60 of NW, and 15 minutes of cool-down. The intensity of the course will be gradually increased each week, starting at 70 to 85% of the heart rate (HR) reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
223900191|NCT05987410|OTHER|Standard Rehabilitation (SR)|The second group will follow a standard rehabilitation program with an initial cardiological prescription and supervised by physiotherapists, carried out 5 days a week with sessions lasting 40 minutes, including 5 minutes of warm-up up), 30 min of aerobic physical activity on a conveyor belt or cycle ergometer and 5 minutes of cooling down (cool down). The intensity of your aerobic activity will gradually increase each week, starting at 70 to 85% of HR reserve. It will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
223900192|NCT05987410|OTHER|Cardiological Counselling (CC)|The third group of participants will receive cardiological counselling with indications of unsupervised aerobic physical activity. The group will also receive indications relating to a balanced diet plan which proposes a moderate (300-400 KCal) daily caloric restriction concerning the usual caloric expenditure, estimated based on initial body composition measurements.
223900193|NCT03371381|BIOLOGICAL|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
223900194|NCT03371381|DRUG|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
223900195|NCT05971147|DIETARY_SUPPLEMENT|Fish oil|Participants in this group will receive 5g fish oil with high EPA and DHA content per day
223900196|NCT06675435|DEVICE|Nitric oxide|20ppm for 15 minutes delivered by INO max(Nitric Oxide) Company : INO therapeutics, Inc.
223900197|NCT06465524|DEVICE|High-intensity laser therapy|High-intensity laser therapy (HILT), also referred to as Class IV laser therapy, involves the administration of collimated and monochromatic electromagnetic radiation within the infrared or red spectrum. It operates at power levels exceeding 500 milliwatts (0.5 W), leveraging both photobiomodulation and thermal effects. This distinguishes HILT from Class III lasers (low-level laser therapy, or LLLT), which lack photothermal effects when operating below 500 mW.
223900198|NCT03647124|DRUG|Lenalidomide|Specified dose on specified days
223900199|NCT04841434|DRUG|Voraxaze Injectable Product|High-dose Methotrexat Infusion: MTX is given at a dose according to the allocated dose level cohort as a 4-hour IV infusion. HD-MTX cycles (up to 6) should be repeated every 14 days, provided that the patient has recovered (i.e., hematopoietic reconstitution) between cycles. A delay of up to 28 days between cycles is permitted in order to allow patients to recover from the preceding dose of MTX. In patients with a decline of the GFR to \<40 mL/min, or in the case of decreased GFR, the decrease is \>50% compared with the pretreatment value, treatment will be terminated. At the start of Cycle 3 the dose of MTX can be escalated to the next level if MTX has been well-tolerated according to the criteria described under dose escalation. Voraxaze: 2000 Units in patients weighing ≤100kg and at least 20 Units per kg body weight in patients weighing \>100kg is given in each HD-MTX cycle as a slow IV injection at 24 hours (+/- 2 hours) after the start of HD-MTX infusion.
223900200|NCT03628924|DRUG|Guselkumab dose 1|Participants will receive guselkumab dose 1 IV.
223900201|NCT03628924|DRUG|Guselkumab dose 2|Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
223900202|NCT03628924|DRUG|Guselkumab dose 3|Participants will receive guselkumab dose 3 SC in Group 3.
223900203|NCT03628924|DRUG|Placebo|Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
223900204|NCT04305548|DRUG|Trabectedin|Treatment with trabectedin: 1.5 mg/m² - 1.3 mg/m² (at investigator's discretion, with a top-dose of 2.6 total mg per cycle), given in 24-hour continuous infusion
223900205|NCT05435014|DRUG|T-ACE Oil|TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
223900206|NCT05435014|DRUG|Lipiodol|TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.
223900207|NCT06401512|BEHAVIORAL|Guided self-determination (GSD) follow-up approach by primary care nurses.|The GSD counseling program consists of four scheduled consultations with a nurse and a digital platform with tools to help people better manage their health. The consultations will be facilitated by using reflection sheets to stimulate written reflection in the context of GSD.
223900208|NCT05907798|PROCEDURE|LIMA Blood flow|30 minutes after induction
223900209|NCT06804083|DRUG|oral combination of colostrum and Serenoa repens extracts (PROSTYM®)|"The composition of PROSTYM® (per capsule) includes bovine colostrum (30 mg), Serenoa extracts (320 mg), glutathione (30 mg), N-acetyl cysteine (20 mg), Ribes nigrum extracts (50 mg), willow extracts (50 mg), zinc (5 mg), selenium (27.5 micrograms), and vitamin E (6 mg).~Drug administration (1 capsule per day) for 6 months."
223900210|NCT05254262|PROCEDURE|Elderly surgical patients|Patients who needs elective or emergency surgery for any reason
223900211|NCT04530799|OTHER|Identification of biomarkers for IAPA via patient sampling|Blood, BAL, microbiome
223939967|NCT07196267|DEVICE|Placebo ESWT and Cryoflow|Identical device setup as active ESWT and Cryoflow, but with energy delivery disabled (no acoustic pulses, no cold air output). Applied for 15 min each, mimicking active treatment to maintain blinding where possible. Used in control group alongside traditional PT.
223900212|NCT05793866|BEHAVIORAL|BUTEYKO RESPIRATORY TECHNIQUE|Buteyko Breathing Technique In recent years, breathing exercises have been used as one of the non-pharmacological, alternative and/or complementary approaches in the management of many chronic diseases and conditions. Buteyko Breathing Technique (BST), Russian Dr. It was developed by Konstantin Buteyko in the 1950s. Dr. Buteyko evaluates the normal respiration over carbon dioxide, the respiratory holding time used in the technique is defined as a control pause, and this value shows the body's oxygenation and carbon dioxide tolerance. BST is a technique performed only through the nose, which includes respiratory control and respiratory hold after inhalation.
223900213|NCT05776563|BEHAVIORAL|Nutrition visits|Participants will receive exercise and dietary counseling from a nutritionist and registered dietician with extensive experience with diabetes and obesity every 2 weeks during the 12 wee
223900214|NCT05776563|OTHER|Intensification of diabetes regimen|Patient will meet every 2 weeks in person or have regular phone calls with an endocrinologist to review glucose control and intensification of the diabetes regimens. Will follow the general strategies outlined in the Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.
223900215|NCT05776563|OTHER|Continuous glucose monitor (CGM)|Individuals with uncontrolled T2DM will be asked use a CGM during the 12 week intervention, to monitor glucose control. Target blood glucose levels will be between 80-130 mg/dl before meals and \< 180 mg/dl at bedtime. Individuals not at goal with glycemic targets will undergo intensification of their regimen. Throughout the study, individuals will be contacted via telephone, email or through additional clinic visits as deemed necessary for maintenance of glycemic control.
223715127|NCT05878145|BEHAVIORAL|Structured rehabilitation exercise program|Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
223715128|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
223715129|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
223715130|NCT03462303|COMBINATION_PRODUCT|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
223715131|NCT03462303|COMBINATION_PRODUCT|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
223715132|NCT02050191|BEHAVIORAL|www.princetonlivingwell.com|
223715133|NCT02871297|DRUG|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
223715134|NCT05389397|BEHAVIORAL|Outreach|Mailed letter, secure message or telephone outreach will be used depending on arm enrolled
223715135|NCT01559597|BIOLOGICAL|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
223715136|NCT00101595|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
223715137|NCT01740193|PROCEDURE|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
223715138|NCT01740193|PROCEDURE|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
223715139|NCT03700775|OTHER|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
223715140|NCT04462445|DRUG|Pazopanib|
223715141|NCT01509950|PROCEDURE|Staples|Staples for closure of cesarean section skin incision
223715142|NCT01509950|PROCEDURE|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
223715143|NCT01509950|PROCEDURE|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
223715144|NCT02183194|DEVICE|Lutonix Paclitaxel Drug Coated Balloon|
223715145|NCT02743169|OTHER|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
223715146|NCT02966028|DRUG|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
223715147|NCT02966028|DRUG|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
223715148|NCT04115839|DRUG|Filgotinib|Tablets will be administered orally once daily with or without food.
223900216|NCT04884724|OTHER|Adaptive Dance Exercise Program|It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
223900217|NCT05285878|DRUG|Fingolimod|0.5 mg daily
223900218|NCT05285878|DRUG|Placebo|0.5 mg daily
223900219|NCT03001713|BEHAVIORAL|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
223900220|NCT03997162|OTHER|Best Practice|Complete standard of care enhanced recovery after surgery protocol
223900221|NCT03997162|OTHER|Quality-of-Life Assessment|Ancillary studies
223900222|NCT03997162|OTHER|Questionnaire Administration|Ancillary studies
223900223|NCT01803477|DRUG|once daily for two consecutive days (Picato)|
223900224|NCT06532734|DEVICE|EsoGuard|device used to collect esophageal cell samples to test for the presence of abnormal cells which may indicate a dx of Barrett's esophagitis.
223900225|NCT06093477|DIETARY_SUPPLEMENT|Fast-Dissolve Melatonin Pill|Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.
223900226|NCT06093477|OTHER|Fast-Dissolve Placebo Pill|Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.
223900227|NCT06453512|DEVICE|Doublebase Once|Emollient
223900228|NCT06155838|OTHER|"Early Adolescent Skills for Emotions (EASE)"|"Weekly Schedule for Teen's and their parents Sessions:~Over the course of 7 sessions, with one session per week lasting 90 minutes, the following core components will be covered:~Week 1: Exploring My Feelings~Week 2: Learning to Calm~Week 3 \& 4: Learning CBT- Restructuring My Thinking, Changing Feelings and My Actions \& Managing My Emotions and Issues~Week 5 \& 6: Fostering Independent Problem-Solving Skills and Seeking Help~Week 7: Relapse Prevention~2.0 For parents/ guardians~Week 3 Psychoeducation (to develop skills to be able to identify, listen, better respond and provide comfort to teens when they are overwhelmed by anxiety and depression).~Week 4 Positive parenting strategies~Week 5 Parents/ guardians Self-care"
223900229|NCT05606731|BEHAVIORAL|Family-Based Childhood Obesity Intervention|The study will focus on the effectiveness of a community- and family-based intervention that will involve multiple family caregivers. The intervention will include in-person and mobile phone components focusing on Latino caregivers of young children, to support evidence-based and age appropriate dietary, media-viewing, and physical activity practices among 2- to 5-year old children.
223900230|NCT05967247|OTHER|The experimental group used App for MBSR intervention|"The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate."
223900231|NCT05967247|OTHER|"the Heart Care Life app"|"Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app."
223900232|NCT05967247|OTHER|APP|APP
223900233|NCT06018233|OTHER|New proposal for regime creation|Interviews and building of proposals in the light of the information obtained and desk based research
223900234|NCT05659654|DRUG|Ursodeoxycholic acid|250 mg/capsule, 2 capsules per day, for 4 weeks
223900235|NCT05657691|DRUG|Xanamem™|Xanamem™ is formulated in green and cream-colored size 3, Coni-Snap-shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains the active pharmaceutical ingredient of UE2343.
223900236|NCT05657691|DRUG|Placebo|Matching placebo which is identical in appearance to the test product (10 mg Xanamem™ QD) except that it contains no active ingredient.
223900237|NCT04016662|DEVICE|Tandem t:slim X2 with HCL or PLGS|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
223900238|NCT05892003|OTHER|Phase 1 Control|Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d). Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
223900239|NCT05892003|OTHER|Phase 2 High Fibre Weight Loss|High Fibre Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) will be fixed at 20g/day for all kcal levels with additional fibre coming from the diet provided. The FOS will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
223900240|NCT05892003|OTHER|Phase 3 High Fibre and Non-Nutritive Sweetener Weight Loss|High Fibre and Non-Nutritive Sweetener Weight Loss diet (30% Fat, 15% Protein, 55% Carbohydrate). Fed to energy deficit (100% RMR). The quantity of fructo-oligosaccharides (FOS) and non-nutritive sweetener (sucralose) will be fixed at 20g/day and 30mg/day respectively for all kcal levels with additional fibre coming from the diet provided. The FOS and sucralose will be split over breakfast, lunch and dinner in drinks/yoghurts which will be compulsory to consume.
223900241|NCT03281798|DEVICE|Fetoscopes|Fetoscopes are telescopes developed for procedures involving fetal interventions and is inserted through the maternal abdomen.
223900242|NCT03281798|PROCEDURE|Fetal Cystoscopy|A fetoscope will be inserted into the fetal bladder via the maternal abdomen and advanced into the fetal bladder outlet. Identified obstruction will be opened using laser.
223900243|NCT04467723|DRUG|Atezolizumab|Atezolizumab is given as an intravenous infusion at 1200 mg every 3 weeks. Pirfenidone is taken by mouth 3 times a day with the dose increasing every 2 week until day 30
223900244|NCT01802788|DEVICE|St Jude Medical Portico replacement aortic valve|
223900245|NCT01802788|PROCEDURE|Transcatheter Aortic Valve Implant|
223900246|NCT05063929|OTHER|Fruit (2 cup eq)|participants will receive 2 cup eq fruits
223900247|NCT05063929|OTHER|Fruit restriction (1/2 cup eq)|participants will receive 1/2 cups eq fruits
223900248|NCT05170386|OTHER|Cognitive training Therapy|"Cognitive training Therapy include: Writing the reminiscences~• Solving a table• Writing a letter making a calendar and writing a note about the daily activities on it Facing patients' fears instead of avoiding them.Using role-playing to prepare for potentially problematic interactions with others.Learning to calm one's mind and relax one's body."
223900249|NCT05170386|OTHER|instructive conventional treatment|instructive conventional treatment breathing relaxation exercise inform of diaphragmatic breathing Practice sleep hygiene such as keeping a regular sleep schedule. Get regular exercise. Minimize noise. Minimize light. Manage the temperature so that you're comfortable.
223900250|NCT06335043|GENETIC|Pharmacogenetics Testing|Genetic test to determine individual genetic compatibility with multiple pharmaceutical drug classes to determine best outcomes for prescription drug treatment.
223900251|NCT06201156|DEVICE|Metered Dose Inhaler With Spacer Device|Bronchodilator Therapy
223900252|NCT05268809|OTHER|Ketogenic diet|The ketogenic diet is a normo-caloric diet composed of high-fat (70%), low-carbohydrate (10%), and adequate protein (20%) that induces fasting-like effects and the production of ketone bodies.
223900253|NCT03021096|OTHER|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
223900254|NCT05082116|DRUG|turoctocog alfa pegol (N8-GP)|N8-GP will be injected into a vein (intravenous injections) every 4 days in at least 28 weeks
223900255|NCT05423444|BEHAVIORAL|TF-CBT|evidence-based psychotherapy for trauma in youth
223900256|NCT05423444|BEHAVIORAL|TAU|treatment as usual
223900257|NCT02043678|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of NIST update) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles
223900258|NCT02043678|DRUG|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
223900259|NCT02043678|DRUG|Abiraterone|1000 mg once daily, oral, with best supportive care
223900260|NCT02043678|DRUG|Prednisone/Prednisolone|5 mg twice daily, oral, with best supportive care
223900261|NCT06499389|PROCEDURE|Systematic and early intensive instrumental respiratory physiotherapy for patients undergoing difficult ventilatory weaning|Patients randomized to this group will receive 3 sessions per day of intensive early respiratory physiotherapy with instrumental techniques from randomization to day 7, before and after any extubation. The strategy will be applied until day 7 of randomization, regardless of the patient's status (intubated or not).
223900262|NCT06499389|PROCEDURE|Protocolized standard-of-care respiratory physiotherapy|Patients in this group will receive standardized and protocolized respiratory physiotherapy to reproduce the usual practices of non-expert centers,1 to 2 sessions of manual respiratory physiotherapy (not assisted by an instrumental technique) per day until the day of successful extubation, or until day 7 if necessary
223900263|NCT03478553|OTHER|Blood draw|Blood draw
223900264|NCT03478553|OTHER|Questionnaire|Pulmonary Fibrosis Questionnaire
223900265|NCT05522075|BEHAVIORAL|Exercise Training|Subjects will be asked to perform exercise training (high-intensity interval training) under supervision, 3 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
223900266|NCT05522075|BEHAVIORAL|Alcohol Abstinence Intervention|Subjects will be asked to abstain from alcohol for 8 weeks. Education materials and bi-weekly consultations will be provided.
223900267|NCT06431997|BEHAVIORAL|Time-limited eating|All participants will be instructed to follow a diet of 1800-2200 kcal/d (45-50% of energy from carbohydrate, 15-20% from protein, 25-30% from fat) based primarily on Dietary Guidelines for Chinese Residents (2022), Dietary guidelines for pregnant women and Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022). Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.
223900268|NCT04855175|DEVICE|Synthetic Bone Allograft (ClearFit)|Patients in this arm will receive ClearFit (synthetic bone allograft)
223900269|NCT04855175|OTHER|Autograft|Patients in this arm will use patient's own bone
223900270|NCT04379596|DRUG|Fluorouracil (5-FU)|5-FU: administered as an IV infusion
223900271|NCT04379596|DRUG|Capecitabine|Capecitabine: administered orally
223900272|NCT04379596|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
223900273|NCT04379596|DRUG|Oxaliplatin|Oxaliplatin: administered as an IV infusion
223900274|NCT04379596|BIOLOGICAL|Trastuzumab|Trastuzumab: administered as an IV infusion
223900275|NCT04379596|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
223900276|NCT04379596|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
223900277|NCT04379596|BIOLOGICAL|Pembrolizumab|Pembrolizumab: administered as an IV infusion
223900278|NCT04379596|BIOLOGICAL|Volrustomig|Volrustomig: administered as an IV infusion
223900279|NCT04379596|BIOLOGICAL|Rilvegostomig|Rilvegostomig: administered as an IV infusion
223900280|NCT06055842|OTHER|over-denture|implant retained overdenture prosthesis.
223900281|NCT05543629|BIOLOGICAL|BMS-986442|Specified dose on specified days
223900282|NCT05543629|BIOLOGICAL|Nivolumab|Specified dose on specified days
223900283|NCT05543629|DRUG|Docetaxel|Specified dose on specified days
223900284|NCT05543629|DRUG|Carboplatin|Specified dose on specified days
223900285|NCT05543629|DRUG|Pemexetred|Specified dose on specified days
223900286|NCT05543629|DRUG|Paclitaxel|Specified dose on specified days
223900287|NCT03216057|DIETARY_SUPPLEMENT|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
223900288|NCT03216057|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
223900289|NCT04568603|DRUG|Islatravir|ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
223900290|NCT05275725|DRUG|Sildenafil|Dose group 1st dose 2nd dose 3rd dose 4-14th doses Treatment Total dose/day frequency dose/day Group 1: #1-14=2 mg/kg q12h (4 mg/kg/day) Group 2: #1 = 2 mg/kg, #2-14 = 2.5 mg/kg q12h (5 mg/kg/day) Group 3: #1 = 2 mg/kg, #2 = 2.5 mg/kg, #3-14 = 3 mg/kg q12h (6 mg/kg/day) Group 4: #1 = 2.5 mg/kg, #2-14 = 3 mg/kg q12h (6 mg/kg/day) Group 5: #1-14 = 3 mg/kg q12h (6 mg/kg/day)
223900291|NCT02007356|BIOLOGICAL|IFN-γ positive selected T-cells|
223900292|NCT03286530|DRUG|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
223900293|NCT03192280|DRUG|Leukotriene B4|Leukotriene B4 (LTB4)
223900294|NCT03192280|DEVICE|FLIR One|Thermal imaging attachment to iPhone
223900295|NCT03192280|DEVICE|SCIO|Handheld near-IR molecular spectroscopy device
223900296|NCT03192280|DEVICE|MS Band 2|"Wearable watch-like device with multiple sensors"
223528661|NCT04914845|DRUG|KPT-9274|KPT-9274 is a first-in-class orally bioavailable, non-competitive, small molecule, dual modulator of p21 protein (Cdc42/Rac)-activated kinase 4 (PAK4) and nicotinamide phosphoribosyltransferase /PBEF/visfatin (NAMPT). NAMPT is the rate-limiting enzyme in the metabolic scavenging pathway that utilizes nicotinamide to replenish nicotinamide adenine dinucleotide (NAD), an essential metabolic cofactor and second messenger. Recent investigations have shown that in in vitro and in vivo models, NAMPT is uniquely essential for relapsed or refractory AML stem cells. Targeting relapsed AML stem cells, through targeting of NAMPT, may allow for a promising therapeutic opportunity for patients with relapsed or refractory AML.
223900297|NCT03192280|DEVICE|AGE reader|Portable bench top device for in-clinic near UV assessment
223900298|NCT03192280|DEVICE|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
223900299|NCT03192280|DEVICE|iPhone 7|Smart phone
223900300|NCT06151119|DIAGNOSTIC_TEST|68Ga FAPI PET/CT|68Ga FAPI PET/CT
223900301|NCT04564742|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets given once daily, per oral use
223900302|NCT04564742|DRUG|Placebo|Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
223900303|NCT05194540|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin-13 (IL-13) and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration
223900304|NCT05382650|BIOLOGICAL|Human rabies immune globulin 300 IU/mL|All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.
223900305|NCT03313076|DRUG|Omega-3 fatty acids (fish oil)|4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks
223528662|NCT02836249|DRUG|TAF|TAF 25 mg tablet administered orally once daily
223528663|NCT02836249|DRUG|TDF|TDF 300 mg tablet administered orally once daily
223528664|NCT02836249|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
223900306|NCT03313076|DRUG|Vitamin D3 (cholecalciferol)|1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.
223900307|NCT03313076|DRUG|Vitamin D3 (cholecalciferol) placebo|1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
223900308|NCT03313076|DRUG|Omega-3 fatty acid placebo|4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
223900309|NCT04573517|PROCEDURE|Amniotomy|Artificial rupture of amniotic membranes
223900310|NCT04573517|DEVICE|Foley balloon|The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
223900311|NCT05512481|DRUG|Camrelizumab|"NEOADJUVANT:~All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；~SURGERY: All participants will have melanoma surgery after 2 cycles of treatment~ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year"
223900312|NCT06073301|DEVICE|Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)|Acellular Fish Skin, used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
223900313|NCT06073301|OTHER|Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)|Acellular Human Cadaver , used to temporize a wound bed prior to autograft. The intention is to prepare the wound bed for optimal autograft take.
223900314|NCT05946070|OTHER|ONKOSIS|ONKOSIS is a mobile phone-based monitoring system in the management of chemotherapy-related symptoms
223900315|NCT05644028|BEHAVIORAL|Emotion Regulation Intervention for ADHD|The intervention will be based on principles from dialectic behavioral therapy. The overall aim of the intervention is to improve emotion regulation skills. The intervention will consist of eight face-to-face group sessions and a digital companion app that the participants can use to practice skills between the sessions. The groups will include mindfulness-based exercises, homework review, introduction to new skills, and peer discussions.
223900316|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy adapted for adolescents (DBT-A)|DBT developed by Marsha Linehan (Linehan 1993a; 1993b) and adapted for adolescents (DBT-A) by Miller, Rathus \& Linehan, 2007 consisting of 20 weeks of weekly individual therapy (60 minutes), multifamily skills training (120 minutes), family therapy sessions as needed and telephone coaching outside therapy sessions.
223900317|NCT04318899|BEHAVIORAL|Dialectical Behaviour Therapy - Standard version (DBT)|DBT developed by Marsha Linehan (Linehan 1993a, 1993 b) consisting of 1 weekly session of individual therapy (60 minutes), 1 weekly session of skills training (120 minutes), and telephone coaching with individual therapists outside therapy sessions as needed.
223900318|NCT03586414|DIETARY_SUPPLEMENT|MITOQUINOL MESYLATE then placebo|MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
223900319|NCT03586414|DIETARY_SUPPLEMENT|Placebo, then MITOQUINOL MESYLATE|'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
223900320|NCT05892991|OTHER|interferential current|this intervention is a type of therapeutic electrical currents of medium frequency used commonly in physical therapy to relieve acute and chronic pain as well as stimulate muscle contraction.
223900321|NCT03655886|PROCEDURE|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
223900322|NCT03655886|RADIATION|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
223900323|NCT05044689|BEHAVIORAL|Questionnaire|Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.
223900324|NCT05044689|DEVICE|Bioimpedance/Body Composition Unit|Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
223900325|NCT04243356|BEHAVIORAL|Nurse Encounter Group|Nurses in this group will meet with former ICU patients in a post ICU clinic visit. This will be a structured meeting for approximately 15 minutes with the nurse and former patient. The encounter will be observed by a member of the research team. Surveys will be completed before and after the visits. Additionally, nurses will be interviewed 4-7 days after meeting with their former patients.
223900326|NCT04243356|OTHER|Nurse control group|This group will complete surveys.
223900327|NCT04821817|DRUG|Normal saline|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
223900328|NCT04821817|DRUG|Rocuronium|peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 0.06 mg/kg of rocuronium in 2 ml normal saline.
223900329|NCT03904147|DEVICE|TriClipTM Device|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
223900330|NCT06074497|DRUG|KGX101- Cohort -1|Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks
223900331|NCT06074497|DRUG|KGX101- Cohort 1|Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
223900332|NCT06074497|DRUG|KGX101- Cohort 2|Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
223900333|NCT06074497|DRUG|KGX101- Cohort 3|Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
223900334|NCT06074497|DRUG|KGX101- Cohort 4|Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
223900335|NCT06074497|DRUG|KGX101- Cohort 5|Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
223900336|NCT06074497|DRUG|KGX101 and Envafolimab|Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
223900337|NCT06126588|DRUG|Everolimus|Patient will be treat during 7 months of Everolimus
223900338|NCT06279949|BEHAVIORAL|Provider training|Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
223900339|NCT06279949|BEHAVIORAL|Clinic protocols|Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
223900340|NCT03583866|DRUG|Candesartan|7 days of Candesartan (16mg/day)
223900341|NCT03583866|DRUG|Placebo|7 days of Placebo
223900342|NCT00769223|OTHER|medical chart review|
223900343|NCT00769223|OTHER|questionnaire administration|
223900344|NCT00769223|PROCEDURE|quality-of-life assessment|
223900345|NCT00769223|RADIATION|brachytherapy|
223900346|NCT00769223|RADIATION|radiation therapy|
223900347|NCT01037881|DRUG|LEO 29102|comparison of different dosages of drug
223900348|NCT01037881|DRUG|Elidel®|comparison
223900349|NCT05775497|BEHAVIORAL|Behavioral weight loss intervention (Online; Rx Weight Loss)|Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.
223900350|NCT05775497|BEHAVIORAL|Minority stress intervention|The Minority Stress Intervention will teach cognitive and behavioral strategies for coping with minority stress with a focus on how minority stress impacts weight loss behaviors. The treatment will primarily address stressors due to sexuality and weight but will also cover how minority stress intersects with other facets of identity. The intervention, while innovative, is adapted from evidence-based treatments using cognitive behavioral therapy (CBT) to address minority stress.Lessons will provide psychoeducation on minority stress related to sexuality, gender, and weight, how it intersects with other aspects of identity, and how it can interfere with weight loss (e.g., unhealthy eating, avoiding exercise and healthcare, reduced motivation, disengaging from the program).The treatment will be delivered in 12 8-10-min lessons/week (a duration comparable to previous treatments) viewed directly after Rx Weight Loss lessons in Wks 1-12.
223900351|NCT05775497|BEHAVIORAL|Social support intervention|The Social Support Intervention will provide sexual minority women with online opportunities to give and receive real-time social support for weight loss efforts. The treatment is based on Social Learning Theory and evidence-based online social support programs used in behavioral weight loss. The intervention will include one video lesson outlining the value of social support for weight loss and well-being, strategies for eliciting support, and an orientation to using the online platform (hosted within Rx Weight Loss). The platform will feature a private forum where participants can post to provide support and discuss their weight loss goals, challenges, and successes. To foster engagement, discussion topics will be automated to post 4 times/week and those who do not participate will be reminded via e-mail to engage (1x/month).
223900352|NCT05775497|BEHAVIORAL|Negative body image intervention|The Negative Body Image Intervention will teach CBT skills for improving negative body image and reducing its impact on weight loss behaviors. The treatment is derived from evidence-based CBT interventions targeting body image for women with obesity during behavioral weight loss and will be adapted to reflect the unique body image ideals and concerns of sexual minority women. Lessons will teach CBT strategies for coping with negative body image and reducing interference with weight loss efforts. The intervention will be delivered in 12 weekly 8-10-minute lessons, a treatment duration comparable to previous treatments and will be viewed immediately following Rx Weight Loss lessons during Weeks 1-12.
223900353|NCT04477460|DIETARY_SUPPLEMENT|Thickened feeds|Thickened feeds directed by medical team
223900354|NCT04477460|DIETARY_SUPPLEMENT|Non-thickened feeds|Non-thickened feeds directed by medical team
223900355|NCT00764751|DRUG|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
223900356|NCT00764751|DRUG|Dovonex® cream|Twice daily application
223900357|NCT00764751|DRUG|Cream vehicle|Twice daily application
223900358|NCT05243680|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.
223900359|NCT04563546|OTHER|Quality Improvement|A quality improvement intervention including reminders, care protocols, and text messages to improve care of myocardial infarction in the KCMC ED
223900360|NCT05214729|DIAGNOSTIC_TEST|Fast ultrafiltration challenge|"The fast ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The fast ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 1000 ml/h, applied for 15 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
223900361|NCT05214729|DIAGNOSTIC_TEST|Slow ultrafiltration challenge|"The slow ultrafiltration challenge will be performed once in all enrolled participants, in the order defined by randomization. The slow ultrafiltration challenge consists of the net removal of 250 ml of ultrafiltrate by setting net ultrafiltration rate to 500 ml/h, applied for 30 minutes. The cardiac output will be measured before and after the UF challenge, by mean of the transpulmonary thermodilution technique, and its relative variation from baseline will be quantified to evaluate the impact of the UF challenge on cardiac preload.~The UF challenge will be preceded and immediately followed by a postural change maneuver to assess the presence or absence of preload dependence. The postural change maneuver is positive in case of a +10% variation in continuous cardiac index over 1 minute, and is considered as the reference diagnostic test to which UF challenge diagnostic performance will be compared."
223900362|NCT05997875|BEHAVIORAL|Educational Materials|"Participants are provided with the Getting Ready: Your Vascular Access Journey video and brochure about hemodialysis vascular access. The video is available for viewing via smartphone or computer. Both the brochure and video were created with input from patients with chronic kidney disease."
223900363|NCT05997875|BEHAVIORAL|Motivational Interviewing|Participants receive coaching with telehealth-based motivational interviewing designed to prepare participants to move forward with vascular access creation. Motivational interviewing will consist of a minimum of 3 and maximum of 8 telehealth sessions with a coach. The coach will use patient-centered communication skills to work though the stages of pre-contemplative, contemplative, preparation, action, and maintenance of an arteriovenous vascular access.
223900364|NCT05997875|BEHAVIORAL|Usual Care|Participants receive the non-standardized vascular access counseling and referral to the chronic kidney disease education class that comprises the standard care provided by their nephrology clinic.
223900365|NCT05997875|OTHER|Patient Lists for Clinicians: System-Level Intervention|Nephrologists and clinic staff receive monthly, provider-specific, lists of patients potentially appropriate for AV access planning based on eGFR thresholds and kidney failure risk. These criteria identify patients at risk for progression to dialysis and are congruent with evidence-based guidelines for optimal timing of AV access evaluation referral.
223900366|NCT01623167|DRUG|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
223900367|NCT01623167|DRUG|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
223900368|NCT01623167|DRUG|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
223900369|NCT01623167|DRUG|Extension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
223900370|NCT05943392|OTHER|EEG recording|EEG recording to assess cortical processing of non-painful tactile, auditory, and/or visual stimuli
223900371|NCT05943392|OTHER|Psychophysics (behavioural experiments)|Behavioural experiments to assess perception of non-painful tactile, auditory, and/or visual stimuli
223900372|NCT02775500|DRUG|apremilast|Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
223900373|NCT05008042|DRUG|Mecobalamin 5 MG|The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
223900374|NCT05008042|OTHER|Placebo Comparator : NaCl 9 mg/ml|Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
223900375|NCT03011333|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
223900376|NCT03011333|DRUG|Bupivacaine HCl without epinephrine|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
223900377|NCT03011333|DRUG|Saline Placebo|Saline placebo via nerve block.
223900378|NCT05320250|OTHER|Single saliva collection|1 ml of saliva will be collected with Salivette swabs.
223900379|NCT05320250|OTHER|Saliva collection, longitudinal|1 ml of saliva will be collected with Salivette swabs. Subjects diagnosed with PD will undergo assessments and saliva sampling before starting rehabilitation treatment (T0), at the end of treatment (T1) and 3 months after the end of treatment (T2).
223900380|NCT04876053|BEHAVIORAL|Healthy Food Delivery Intervention|Each weekly food box will include \~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
223900381|NCT04831580|DEVICE|da Vinci|Minimally invasive robotic-assisted radical or simple hysterectomy
223900382|NCT04831580|OTHER|open surgery|open radical or simple hysterectomy
223900383|NCT04024761|BIOLOGICAL|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
223900384|NCT04024761|DRUG|Fludarabine|Fludarabine is a chemotherapy agent
223900385|NCT04024761|DRUG|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
223900386|NCT04094246|PROCEDURE|Battlefield Acupuncture|Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
223900387|NCT04094246|PROCEDURE|Standard post-surgical rehabilitation|Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
223900388|NCT04844931|PROCEDURE|RIC + PostC + Standard PCI|RIC by arm ischemia initiated on hospital admission plus local PostC by re-inflating the angioplasty balloon after re-opening the infarct-related artery
223900389|NCT04844931|PROCEDURE|Standard PCI|Standard PCI
223900390|NCT04117295|DEVICE|Carmat Total Artificial Heart|Heart replacement therapy
223900391|NCT05554848|DRUG|Dexmedetomidine|dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period
223900392|NCT05554848|DRUG|Magnesium sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
223900393|NCT04520672|OTHER|Blood samples|Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
223900394|NCT04520672|OTHER|Samples from tumor draining vessels|In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
223900395|NCT06382402|RADIATION|CCTA scan|• CCTA will be performed per the standard clinical protocol using a Cannon Aquilion ONE scanner with 16 cm z-axis coverage at 0.5 mm resolution, low contrast, and reduced radiation dose requirements.
223900396|NCT03739853|DRUG|Methotrexate|Used in all three arms of study
223900397|NCT03739853|DRUG|Sulfasalazine|Used in arm 2 of study
223900398|NCT03739853|DRUG|Leflunomide|Used in arm 2 of study
223528665|NCT02836249|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
223715149|NCT04115839|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
223900399|NCT03739853|DRUG|Adalimumab|Used in arm 3 of the study only
223900400|NCT04307355|DEVICE|Transcu O2®|Breasts randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
223900401|NCT04307355|OTHER|Tegaderm|A 10 cm × 12 cm Tegaderm TM Film adhesive (3M Healthcare, Minnesota).
223900402|NCT04307355|OTHER|Silagen|A 10 cm × 12 cm silicon sheet (Silagen, New Medical Technology, Inc, Illinois).
223900403|NCT03051282|DRUG|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
223900404|NCT04100174|RADIATION|focal brachytherapy boost to SBRT|As above
223900405|NCT04817891|DEVICE|HD-tDCS|Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
223900406|NCT05504850|OTHER|Multicultural Health Diet|The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
223900407|NCT03298477|DEVICE|Nellix® System|Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
223900408|NCT04476160|DIETARY_SUPPLEMENT|Cinnamon|children recipe 3 grams by day of cinnamon
223900409|NCT02171650|DRUG|BIBW 2992|
223900410|NCT06412315|DRUG|Citalopram|Participants will receive a single dose (20mg) citalopram. Tablets encapsulated to aid blinding. To take per oral once.
223900411|NCT06412315|DRUG|Placebo|Participants will receive a single dose of placebo (sucrose). Tablets encapsulated to aid blinding. To take per oral once
223900412|NCT05718479|BEHAVIORAL|Trauma Informed Prenatal Intervention (TPI)|TPI is designed to foster behavior change and health coping by enhancing knowledge, beliefs, regulation skills and abilities. In the experimental group, a research staff member will meet with participants and help them to identify a health behavior they want to change, explore the pros and cons of making a change, create a behavior change plan, and learn several mindfulness meditation techniques. The facilitator will check-in with the participants about their behavior change plan in the subsequent sessions regarding progress made, barriers encountered, and changes in the plan and/or goal going forward. Participants will be instructed to implement an at-home mental wellness skills and provided with a tracking log to report the frequency and dose of daily/weekly practice.
223900413|NCT05718479|OTHER|Prenatal Education Topics|In the control group, a research staff member will provide participants with four different weekly prenatal education topics, including information on prenatal care, labor and delivery, postpartum care, and newborn care.
223900414|NCT04210102|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)|"Lung Ultrasound : Ultrasound is a medical imaging technique that relies on the use of ultrasound, inaudible sound waves, which allow to visualize lungs."
223900415|NCT04210102|DIAGNOSTIC_TEST|Chest radiography (CR)|The chest X-ray is a medical imaging examination that provides images of the lungs through the X-ray pulse.
223900416|NCT05440708|DRUG|TTI-101|Oral tablet
223900417|NCT05440708|DRUG|Pembrolizumab|Intravenous (IV) infusion
223900418|NCT05440708|DRUG|Atezolizumab|Intravenous (IV) infusion
223900419|NCT05440708|DRUG|Bevacizumab|Intravenous (IV) infusion
223900420|NCT04198454|OTHER|Compression bandages|Class I (20-30 mmHg) compression bandages or stocking
223900421|NCT04198454|OTHER|Standard wound dressings|Wound dressings alone consisting of gauze and skin tape to cover the wound
223900422|NCT04198454|DEVICE|Fractional ablative carbon dioxide laser|Participant will have laser applied to their wound bed.
223900423|NCT02802618|OTHER|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
223900424|NCT02809443|BIOLOGICAL|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
223900425|NCT00082745|OTHER|Laboratory Biomarker Analysis|Correlative studies
223900426|NCT00082745|OTHER|Questionnaire Administration|Ancillary studies
223900427|NCT05910619|DEVICE|Neurolith Transcranial Pulse Stimulation Active|5hz (200-300 milliseconds) stimulation pulses transcranial pulse stimulation (TPS) will be applied to each of the following five regions twice per session in sequential order with the specified stimulation parameters: left dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses), right dorsolateral prefrontal cortex and inferior frontal cortex extending to Broca's area (2x800 pulses; ROI volume \~136/164 cms), the left lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), the right lateral parietal cortex extending to Wernicke's area (2x400 pulses; ROI volume \~122/147 cms), and the extended precuneus cortex (2x600 pulses; ROI volume 66/92 cms). With a repetition time of 5hz (0.00333 seconds) per pulse at a total of 6,000 pulses per participant, the duration of stimulation is about 20 minutes, not including transition time between ROI localization.
223900428|NCT05910619|DEVICE|Neurolith Transcranial Pulse Stimulation Sham|The intervention procedure described in the Active condition above will also be repeated in participants randomized to the Sham procedure, with the exception of the insertion of a lens over the device by the interventionist to prevent stimulation from reaching the brain.
223900429|NCT02998268|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223900430|NCT02998268|DRUG|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
223900431|NCT02998268|DRUG|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
223528666|NCT03681145|BEHAVIORAL|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
223900432|NCT06008730|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223900433|NCT06008730|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
223900434|NCT06008730|OTHER|Radiology, Treatment Planning|Undergo radiation treatment planning
223900435|NCT05950191|OTHER|long lasting insecticidal nets with chlorfenapyr-pyrethroid (PermaNet Dual)|Next-generation bed net combining insecticides with different modes of action
223900436|NCT05950191|OTHER|long lasting insecticidal nets with PBO-pyrethroid (PermaNet)|Next-generation bed net combining an insecticide with a synergist
223900437|NCT05950191|BEHAVIORAL|Social Behavior Change Communication|The NMCD and other stakeholders will take the lead on Social Behaviour Change Communication (SBCC). SBCC activities will use digital and other platforms, including the following: (1) LLIN launch at the World Malaria Day celebrations; (2) regional in-person advocacy meetings; (3) mass media platforms (for advertisements, mini skits, DJ mentions, radio spots, interactive talks); (4) social media platforms; (5) VHTs; (6) operation hotlines and toll-free call centres; (7) community mobilisation (megaphones); and (8) use of appropriate information, education, and communication materials. Communication will include messages about malaria, and use, care, repair and repurposing of bed nets.
223900438|NCT06458400|DRUG|Tegileridine|single dose+PCA dose
223900439|NCT06458400|DRUG|Oliceridine|single dose+PCA dose
223900440|NCT06458400|DRUG|Morphine|single dose+PCA dose
223900441|NCT06393790|BEHAVIORAL|FMG (Fibromyalgia group)|This intervention will report results of a strength training programme in people with fibromyalgia
223900442|NCT06393790|BEHAVIORAL|HG (Healthy group)|This intervention will report results of a strength training programme in people with no fibromyalgia diagnosis
223900443|NCT06407089|OTHER|Spinertial Group|"Endurance training program of deep cervical flexors and deep cervical extensors with Spinertial device for treatment.~Endurance training program of deep cervical flexors and deep cervical flexors with Spinertial device for treatment."
223900444|NCT04888832|OTHER|Work requirement exemption months|Cross-randomized intervention will test effect of additional exemption months before work requirements in SNAP become binding and extensions of the standard SNAP recertification period.
223900445|NCT04880590|OTHER|Sex intercourse|A heterosexual sexual relationship
223900446|NCT04433351|DEVICE|Enriched rehabilitation|"The enriched rehabilitation is based on the use of sensory-motor integration in addition to conventional speech therapy. The sensory-motor integration method is based on the Ultraspeech-player software. This software allows therapists to display movements of speech articulators (tongue and lips) recorded on a reference speaker during production of vowels or consonants (isolated or combined). Sagittal movements of the tongue are recorded using ultrasound and front views of lip movements are captured through video imaging.~During rehabilitation with the Ultraspeech-player software, patients will be seated in front of a computer screen, observe articulatory movements and listen to phonemes. Then, they will be required to repeat each of them five times and move on to the next phoneme, with the agreement of the experimenter."
223900447|NCT04433351|DEVICE|Simple rehabilitation|The simple rehabilitation is based on conventional speech therapy. The conventional speech therapy will be provided by the speech therapist. Classically, the speech therapist uses word production with repetition and naming exercises. The therapist will show the patient series of pictures associated or not with written words, and the patient is required to name them and/or read aloud the word. In case of impossibility to perform the task, the therapist may can help the patient by using the indexing method or by asking the patient to repeat after him/her. According to patient's competencies and progress, the difficulty of reeducation can increase progressively.
223900448|NCT03026127|BEHAVIORAL|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
223900449|NCT03026127|BEHAVIORAL|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
223900450|NCT04599504|DRUG|Lisdexamfetamine Dimesylate (Medication)|Medication will be taken daily in pill form.
223900451|NCT04599504|OTHER|Placebo|Placebo will be inactive and taken daily in pill form.
223900452|NCT05799105|DRUG|Omeprazole 40 milligrams|Subjects will be randomized to treatment with either open-capsule or intact-capsule omeprazole to assess effect on ulcer healing times. If interim analysis illustrates significantly improved healing in the open-capsule group, the control (intact-capsule) arm will be allowed to cross-over to open-capsule and be followed until confirmed ulcer healing.
223900453|NCT05269667|DRUG|Satralizumab 120 mg|Satralizumab 120 mg will be administered as monotherapy (SC) in the abdominal or femoral region at Weeks 0, 2 (±3 days), 4 (±3 days), and then every 4 weeks (±3 days) till the last administration at Week 92 followed by a clinical evaluation at Week 96. The first dose at Weeks 0 (baseline visit) will be administered at the study site by the designated site staff during the scheduled study visit. The next dose at Week 2 will be self-administered by the patient under the supervision of a designated study staff at the study site. All the subsequent doses will be self-administered by the patient following training from a healthcare provider (for patients who are not able to administer satralizumab SC by themselves, support by a caregiver/nurse is advised).
223900454|NCT05160272|DRUG|AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
223900455|NCT05160272|DRUG|Placebo matching AP-325|Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.
223900456|NCT06285357|DIETARY_SUPPLEMENT|EGCG + folic acid + B12|EGCG + folic acid + B12
223900457|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive high frequency 10 Hz stimulation at 100% of motor threshold over the dorsolateral prefrontal cortex (DLPFC) at 1500 pulses per session with 30 trains of 5 seconds and 0.5 ms stimuli and an inter-train distance of 15 seconds. In 2 daily sessions 4 days a week for 4 weeks."
223900458|NCT05997212|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magstim Rapid 2 stimulator, Airfilled coil (AFC), 8 shape (magnetic field of 0.8 Teslas, 3Kg, pulse 0.5 ms)~Each patient will receive consistent treatment in 2 sessions a day for 20 consecutive business days for 4 weeks. The coil will be placed on the vertex target location."
223900459|NCT05215548|PROCEDURE|therapeutic thoracic surgery|The surgery group would receive therapeutic thoracic surgery with maximal local regional control intent and would prescribe with maintenance afatinib therapy after operation. Patients continue afatinib 1 to 2 weeks after surgery.
223900460|NCT05215548|DRUG|Afatinib|The patient take afatinib treatment for 12 weeks treatment and then receive systemic image study examination before randomization. If exam result showed progression the patient would be excluded from the study. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1).
223900461|NCT06249945|DRUG|Empagliflozin 25 MG|The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.
223900462|NCT06249945|DRUG|Placebo|The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
223900463|NCT06332859|OTHER|Resilience training|The resilience training consists of two sessions of psychological group therapy, each lasting 100 minutes, with a special focus on resilience. Additionally, there are two sessions of relaxation training, known as 'heart yoga', each lasting 25 minutes.
223900464|NCT04794868|DIAGNOSTIC_TEST|CCTA-derived high risk plaque characteristics|Presence of CCTA-derived high risk plaque characteristics
223900465|NCT04794868|DIAGNOSTIC_TEST|CFD-derived hemodynamic parameters|CFD-derived hemodynamic parameters
223900466|NCT06584071|DRUG|PM8002|PM8002 via IV infusion, Q3W
223900467|NCT06584071|DRUG|PM1009|PM8002 via IV infusion, Q3W
223900468|NCT06584071|DRUG|atezolizumab|atezolizumab,1200mg, via IV infusion, Q3W
223900469|NCT06584071|DRUG|bevacizumab|bevacizumab,15mg/kg, via IV infusion, Q3W
223900470|NCT06310018|DEVICE|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis|Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (treated with a total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours for first 10 patients followed by 50 patients treated with total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
223900471|NCT05495269|DRUG|QLS-101 ophthalmic solution, 2.0 %|ophthalmic solution in a single use dropper vial
223900472|NCT05355753|DRUG|CFT8634|Oral dose of CFT8634
223715150|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
223900473|NCT05133973|DEVICE|FiberSense CGM|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
223900474|NCT05681338|OTHER|the medium intensity coughing technique|The medium intensity coughing technique: Immediately before the subcutaneous LMWH injection was given, patients were asked to cough twice at a medium level. After that, they were asked to cough ten seconds later for a second time at the same level, and while they were coughing for the second time, the needle was inserted into the tissue.
223900475|NCT04103593|BEHAVIORAL|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
223900476|NCT04165694|PROCEDURE|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
223900477|NCT06053580|DRUG|Valsartan 40 mg|Valsartan 40mg twice daily for 24 weeks.
223900478|NCT06053580|DRUG|Placebo|Placebo twice daily for 24 weeks.
223900479|NCT04413708|BEHAVIORAL|P3-T PrEP Adherence App|"P3-T provides daily PrEP reminders, a medication tracker and calendar, personalized medication adherence strategies, refill reminders, and tailored adherence support messages; social support via a social wall that includes daily discussion prompts; daily quests to build knowledge and skills; a multimedia knowledge center; interactive narrative collections; personalized adherence counseling provided by an adherence counselor via in-app messaging; in-app rewards; a bank account that rewards daily app use by adding or subtracting a small financial reward based on daily app use; and, a user profile that includes a user-selected avatar."
223900480|NCT00179946|PROCEDURE|HLA typing|
223900481|NCT04989413|DRUG|Placebo oral drops|use of placebo for 12 weeks
223900482|NCT04989413|DRUG|Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg|use of cannabidiol + canabigerol + thc for 12 weeks
223900483|NCT05939830|PROCEDURE|Stained region Lymph Node Biopsy (SrLNB)|Before NST, carbon nanoparticles suspension would be injected into the cortex of positive lymph nodes for staining under ultrasound guidance. Marked lymph nodes will be removed and biopsied after NST.
223900484|NCT05939830|RADIATION|Regional lymph node radiotherapy (RNI) including the axilla|RNI including the axilla covers the supraclavicular region and entire axillary lymphatic drainage area (region I, II and III) ,and is at a dose of 50 Gy/25 times, with additional prophylactic irradiation of the internal breast lymphatic drainage area for eligible patients.
223900485|NCT04824053|DIETARY_SUPPLEMENT|Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
223900486|NCT04824053|DIETARY_SUPPLEMENT|Conventional milk|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 250 mL of milk. The intervention duration will be 3 months"
223900487|NCT04824053|DIETARY_SUPPLEMENT|Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
223900488|NCT04824053|DIETARY_SUPPLEMENT|Conventional yogurt|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of one yogurt. The intervention duration will be 3 months"
223900489|NCT04824053|DIETARY_SUPPLEMENT|Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
223900490|NCT04824053|DIETARY_SUPPLEMENT|Conventional fresh cheese|"The daily intake should reflect habitual consumption habits in real life conditions, without forcing or inducing greater consumption. Therefore, patients will be recommended a daily intake of 50 g of fresh cheese. The intervention duration will be 3 months"
223900491|NCT06328439|DRUG|ANS014004|Specification: 7.5mg; 30mg QD/BID Oral
223900492|NCT05376488|OTHER|One meal|One meal given to assess impact on ammonia levels serially
223900493|NCT06367556|BEHAVIORAL|Emotion and Symptom-Focused Engagement (EASE)|EASE sessions are directed to provide relational support, affect regulation, and problem-solving related to cancer in the child, to changes in spousal, family, and other relationships, and to the burden of multiple individual and family responsibilities.
223900494|NCT02392130|DRUG|Clobetasol propionate 0.05% ointment|
223900495|NCT02392130|DRUG|LEO 130852A gel 1%|
223900496|NCT02392130|DRUG|LEO 130852A placebo gel|
223900497|NCT04349371|DRUG|Chloroquine|Subjects will take two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration.
223900498|NCT04349371|DRUG|Placebo oral tablet|Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
223900499|NCT05022329|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine|This arm receives Pfizer-BioNTech COVID-19 Vaccine
223900500|NCT05022329|BIOLOGICAL|MODERNA SARS-CoV-2 Vaccine|This arm receives MODERNA SARS-CoV-2 Vaccine
223900501|NCT05714891|DRUG|JDQ443|Dose will be assigned at enrollment
223900502|NCT02216240|OTHER|Paramedic|
223900503|NCT02216240|OTHER|Standard care|
223900504|NCT06449196|DRUG|Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing.
223900505|NCT06449196|DRUG|: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)|HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via fractionated dosing
223900506|NCT05615974|DRUG|LM101|Administered intravenously
223900507|NCT05615974|DRUG|Toripalimab|Administered intravenously
223900508|NCT05615974|DRUG|Rituximab|Administered intravenously
223900509|NCT05358717|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
223900510|NCT05358717|DRUG|Placebo|Placebo matching to PTC518 will be administered per schedule specified in the arm.
223900511|NCT05662423|BEHAVIORAL|Expressive Writing about Childbirth|Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.
223900512|NCT05662423|BEHAVIORAL|Neutral Writing|Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
223900513|NCT06550206|BEHAVIORAL|Children's stranger wariness response to strangers|Children will see two strangers, one from a familiar racial background and one from an unfamiliar racial background. Familiar race stranger will be from the same racial background as the child's caregiver and unfamiliar race stranger will not.
223900514|NCT05849090|DRUG|Cephalosporin or clindamycin/vancomycin antibiotics..|Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
223528667|NCT00283166|BEHAVIORAL|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
223528668|NCT05878704|DRUG|GBT021601|Oral
223900515|NCT05849090|DRUG|Vancomycin and Tobramycin antibiotics.|Vancomycin (1 gram) and tobramycin (1.2 grams).
223900516|NCT06010563|DEVICE|Transcatheter pulmonary valve implantation (TPVI)|A valve is implanted through a catheter (a narrow tube) and inserted through the femoral vein into the right atrium, right ventricle and pulmonary artery. After careful positioning, the valve is implanted by inflating a set of a balloons on the delivery catheter or self-expanding. After the catheter has been removed, the incision is closed with stitches, which are removed after the area has healed.
223528669|NCT05291533|OTHER|Virtual Reality (VR) Mindfulness Program|The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
223900517|NCT06010563|DEVICE|VenusP-ValveTM System|"VenusP-ValveTM System consists of two components:~1. Transcatheter Pulmonary Valve (TPV)~2. Delivery System (DS) including Delivery Catheter System (DCS) and Compression Loading System (CLS) The TPV consists of a self-expanding nitinol stent with a single layer tri-leaflet porcine pericardium tissue.~For the Delivery Catheter System (DCS) , the distal (deployment) end of the system features an atraumatic, radiopaque tip. A protective sheath (capsule) covers and maintains the TPV in a crimped position. The handle at the proximal end of the catheter is used to load and deploy the TPV.~The CLS compresses the TPV into the catheter, which including capture tube, valve protection tube, tip support tube, loading mandrels and crimper."
223900518|NCT05331053|DRUG|Atorvastatin|Simvastation acts as a systemic LOX inhibitor.
223900519|NCT04546958|DIETARY_SUPPLEMENT|Whey protein supplements|Nutritional counseling and whey protein supplements for 3 months
223900520|NCT04546958|OTHER|Nutritional counseling|Nutritional counseling by dietitians for 3 months
223900521|NCT05646524|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
223900522|NCT05536752|DRUG|QA102/Placebo|Capsules
223900523|NCT05536752|DRUG|QA102|Capsules
223900524|NCT05536752|DRUG|Placebo|Capsules
223900525|NCT04870515|OTHER|Best Practice|Receive standard lifestyle recommendations
223900526|NCT04870515|OTHER|Dietary Intervention|Receive dietary instructions
223900527|NCT04870515|OTHER|Exercise Intervention|Complete aerobic and strength/resistance exercises
223900528|NCT04870515|OTHER|Quality-of-Life Assessment|Ancillary studies
223900529|NCT04870515|OTHER|Questionnaire Administration|Ancillary studies
223900530|NCT06119464|OTHER|Multimodal Intervention: Education|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
223900531|NCT06119464|OTHER|Multimodal Intervention: Audit and Feedback|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
223900532|NCT06119464|OTHER|Multimodal Intervention: Patient Engagement|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
223900533|NCT06119464|OTHER|Multimodal Intervention: System Changes|The multimodal intervention bundle consists of education, audit and feedback, patient engagement, and system changes.
223900534|NCT06193213|PROCEDURE|measurement of train of four ratio (TOFR) to assess residual neuromuscolar block|Upon arrival of the spontaneously breathing patient in the Post-Anesthesia Care Unit, a researcher will evaluate the TOFR to detect any residual neuromuscular block using the acceleromyographic method at the level of thumb adductor.2 TOFR measurements will be performed 30 seconds apart. If the difference between the two measurements will be ≤ 0.1, the average value will be considered for the purposes of the analysis. In case of a difference \> 0.1, a third measurement will be taken and the average of the two closest results will be considered. If a residual block is detected sugammadex will be administered (2 mg/kg in the case of at least 2 contraction responses to TOF stimulation or 4 mg/kg in the case of no contraction response) to restore normal neuromuscular function , assessed by subsequent TOFR measurement.
223900535|NCT06456762|BEHAVIORAL|iPEACE: Intervention for Parent Education about Care after the ED|Automated texting intervention for parents to increase engagement in their child's outpatient mental health treatment over an 8-week period.
223900536|NCT06456762|BEHAVIORAL|Text Messaging Reminders Only|Weekly automated text reminders to instruct parents to make an appointment with their child's outpatient mental health provider over an 8-week period.
223900537|NCT05179993|OTHER|Microplastics|Detection of microplastics as a yes/no value
223900538|NCT06178549|BEHAVIORAL|HPV Self-Sampling|HPV self-sampling. Participants will be provided with education regarding cervical cancer prevention and Aptima kit and instructions for self-sampling. Patient navigators will assist participants with positive HPV test results to connect with healthcare providers for follow-up screening and care.
223900539|NCT05078970|BEHAVIORAL|Safety Planning Intervention+ (SPI+)|SPI is focused on how the risk of suicidal crisis waxes and wanes over time. At times of heightened risk, a pre-specified and individualized plan targets the internal warning signs that become the cue to use the safety plan. SPI+ strategies focus on patient's narrative of the suicidal crisis and identifying solutions that are antithetical to progressing in a suicidal crisis. The brief structured intervention is conducted in six key steps. Youth in this condition will be offered weekly follow-up, with a minimum of 4 sessions and a maximum of 8 sessions. The goal is to create a crisis response plan to reduce risk when suicidal crises emerge. With adolescents, SPI+ consists of an individual session to elicit crisis narrative and motivation to utilize the safety plan through psychoeducation and follows six steps to achieve the adolescent's goals and return to safety when suicidal urges are high.
223900540|NCT05078970|BEHAVIORAL|Collaborative Assessment and Management of Suicidality (CAMS)|CAMS strategies focus on collaborative deconstruction and treatment of the patient-defined drivers- the problems that make suicide compelling to the patient- and utilizes these problem-focused treatment sessions to treat the drivers as directly related to wish to die. Participants will be assigned to CAMS for a minimum of 4 sessions and maximum of eight sessions. This time frame, based on initial data from our pilot work with adolescents and emerging adults (18-25), suggests that a subset of participants resolve their STB in six to eight sessions. CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients.
223715151|NCT01246700|OTHER|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
223715152|NCT02664844|BEHAVIORAL|Physical activity|
223900541|NCT05078970|BEHAVIORAL|Treatment As Usual|This assigned condition tracks the care received in typical circumstances.
223900542|NCT03264352|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
223900543|NCT03264352|DRUG|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
223900544|NCT03264352|OTHER|Standard treatment by current guideline|No BP-lowering medications are used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
223900545|NCT04187183|OTHER|Fresh Platelet Rich Plasma with leukocyte|autologous Platelet Rich Plasma with leukocyte will be infiltrate in the knee joint
223900546|NCT04187183|OTHER|Fresh Platelet Rich Plasma without leukocyte|autologous Platelet Rich Plasma without leukocyte will be infiltrate in the knee joint
223900547|NCT04895137|DRUG|mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations|mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
223900548|NCT03994653|OTHER|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
223900549|NCT03994653|OTHER|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
223900550|NCT05928572|OTHER|CGM initiation approach|Use of a nutrition-focused approach versus a self-directed approach during CGM initiation
223900551|NCT04509791|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)
223900552|NCT06365216|DRUG|NX210c|3 times a week, for 4 weeks
223900553|NCT06365216|DRUG|Placebo|3 times a week, for 4 weeks
223900554|NCT05831891|DRUG|Fruquintinib combined with Serplulimab|Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
223900555|NCT05501431|DEVICE|Verily Study Watch|The Verily Study Watch is a smartwatch, collecting physiological and/or environmental information. The sensors collect data that include movement and activity, pulse rate, skin impedance, electrocardiogram (ECG), environmental temperature, and ambient light level.
223900556|NCT05456789|DEVICE|combined catheter-thrombectomy and local fibrinolysis|combination of catheter-based thrombectomy with local pulmonary fibrinolysis plus conventional treatment
223900557|NCT05456789|OTHER|conventional treatment|conventional treatment of pulmonary embolism
224083463|NCT04529291|OTHER|Group without walking disorder|"During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team."
223715153|NCT03162991|OTHER|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for \~30-55 minutes per exercise session.
223715154|NCT01244724|DRUG|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
223900558|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (the patient education information about type 2 diabetes, self-management practice tasks (daily, weekly, quarterly), type 2 diabetes patient education program according to DiaPaDeSS algorithms, and measurement questionnaires)
223900559|NCT05902156|BEHAVIORAL|DiaPaDeSS|Web-based mobile health application for patients with type 2 diabetes (only self-management practice tasks (daily, weekly, quarterly), and measurements questionnaires. The diabetes patient education brochure of the Ministry of Health will be sent to the phones of the active control group in pdf format.)
223900560|NCT03172299|DRUG|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
223900561|NCT03172299|DRUG|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
223900562|NCT04554693|DRUG|Metronidazole Oral|250 mg oral three times a day for 14 days
223900563|NCT04554693|DRUG|Placebo|Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
223900564|NCT04982757|DEVICE|MagVenture MagPro System with Brainsight neuronavigation device|10x daily sessions of 1200 pulses of theta-burst stimulation lasting approximately ten minutes.
223900565|NCT05475808|DEVICE|Static wrist splint treatment|Static wrist splint (volar wrist cock-up orthosis): It extends from the proximal of the metacarpophalangeal (MCP) joint to the distal 2/3 of the forearm, supports the wrist from the volar face. It stabilizes the wrist in 20-30 degrees of dorsiflexion and restricts wrist movements. It allows movement of the MCP joints. Patients will be asked to wear this splint continuously at night and for at least 4 hours during the day for 8 weeks.
223900566|NCT05475808|OTHER|Tendon and nerve gliding exercises|"Tendon and nerve gliding exercises will be applied 5 sessions a day for 8 weeks. Each session will hold 10 repetitions and approximately 7 seconds in each exercise position.~These exercises involve a sequence of finger movements (for tendon gliding) and wrist and fingers movements (for median nerve gliding)."
223715155|NCT04763304|OTHER|Gown personal protective equipment (PPE-G) suit|Placement of PPE-G under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
223900567|NCT05475808|DRUG|Wrist local steroid injection|"Wrist local steroid injection:~After proper area cleaning with povidone solution, 1ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml) steroid injection will be applied around the median nerve with a 22 G injector from ulnar side of the wrist proximal crease under ultrasound guidance."
223900568|NCT06254261|DRUG|RAY1225|Administered SC
223900569|NCT06254261|DRUG|Placebo|Placebo
223900570|NCT05787405|OTHER|Artificial Intelligence methods|The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.
223900571|NCT05512793|DIAGNOSTIC_TEST|Standard technique First colonoscopy without PolyDeep|Standard technique First colonoscopy without PolyDeep
223900572|NCT05512793|DIAGNOSTIC_TEST|Combination technique First colonoscopy with PolyDeep|Combination technique First colonoscopy with PolyDeep
223900573|NCT04032704|DRUG|ladiratuzumab vedotin|Intravenous (into the vein; IV) infusion
223900574|NCT04032704|DRUG|pembrolizumab|200mg given by IV on Day 1 of each 21-day cycle
223900575|NCT03286686|BEHAVIORAL|point targets|In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
223900576|NCT03286686|BEHAVIORAL|tactile stimulation|In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
223900577|NCT03286686|BEHAVIORAL|visual images|Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
223900578|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, Family Strengthening, and Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
223900579|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, and Family Strengthening)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
223900580|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Condoms & Contraception, Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
223900581|NCT06223165|BEHAVIORAL|Floreciendo (Foundations, Family Strengthening, and Gender & Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
223900582|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Condoms & Contraception)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Condoms and contraception: Teaches about different forms of condoms and contraception and offers experiential activities on how to use them."
223900583|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Family Strengthening)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Family strengthening: Facilitates learning and practice in how teens and their female caregivers can communicate about sex and addresses family norms and expectations in Latino culture."
223900584|NCT06223165|BEHAVIORAL|Floreciendo (Foundations and Gender & Partner Relationships)|"* Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.~* Gender and relationships: Covers what a healthy relationship looks like and how to recognize intimate partner violence, while discussing how gender and cultural norms in Latino culture influence teens' sexual behavior."
223900585|NCT06223165|BEHAVIORAL|Floreciendo (Foundations)|• Foundations in sexual risk prevention: Covers key topics in sexual and reproductive health and helps participants develop an awareness of sexual behavior risks.
223900586|NCT06148324|BEHAVIORAL|MENTOR Program|"MENTOR is an online wellness program covering 11 wellness modules: Exercise; Nutrition; Mindfulness; Spiritual Practice; Self-Care; Arts \& Leisure; Rest \& Relaxation; Outdoors in Nature; Relationships; Core Values; and Contribution to Others.~The 8-week cycle comprises 40 hours of online group-based instruction and discussion, meeting up to five times per week."
223900587|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (active)|Theta-burst transcranial magnetic stimulation (active) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
223900588|NCT05842473|BEHAVIORAL|Language therapy|Language therapy immediately after each TMS session. Daily sessions for two weeks followed by 1 session per week.
223900589|NCT05842473|DEVICE|Transcranial Magnetic Stimulation (sham)|Theta-burst transcranial magnetic stimulation (sham) delivered over the left dorsolateral prefrontal cortex. Daily sessions for two weeks followed by 1 session per week.
223900590|NCT03767621|OTHER|Indication of revascularization|Device: iFR/FFR
223900591|NCT05195840|BEHAVIORAL|Personalized Treatment for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 includes psychoeducation on the network-informed model of personalized treatment and 14 sessions (sessions 5-19) are focused on the top three targets (4-5 sessions per target). Session 20 is a termination and conclusion session.
223900592|NCT05195840|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|The first three sessions consist of diagnosis and general psychoeducation on EDs and treatment for ED. After mobile-assessment is complete, Session 4 consists of food monitoring, addressing irregular eating, challenging thoughts, making adaptive behavioral changes, and relapse prevention. Session 20 is a termination and conclusion session.
223900593|NCT05781100|BEHAVIORAL|Technology Use during Feeding Conditions|At 1 month and 4 months, mother-infant dyads will be observed during 3 different feeding conditions counterbalanced across 3 days, with a 1-day wash-out period between conditions: TV Use condition: mothers will be asked to watch a 22-minute long TV show on a large tablet while they feed their infants. Mothers will choose from four preselected episodes of popular sitcoms. Mobile Device Use condition: mothers will be asked to use their mobile device in a way they find relaxing and pleasurable. Control condition: mothers will be asked to feed their infant in a room free of all potential technological distractions. During all conditions, mothers will feed their infants their typical milk (breast milk or formula) from their typical mode (breast or bottle).
223900594|NCT06522256|PROCEDURE|High-resolution anoscopy|"The study includes 2 visits:~* a medical consultation for inclusion~* a proctology consultation including the performance of an AHR associated or not with biopsy sampling"
223900595|NCT03647852|DRUG|Methylprednisolone|1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
223900596|NCT03647852|DRUG|IVIG|1\. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
223900597|NCT03647852|DRUG|other basic supportive treatment|"1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d"
223900598|NCT05144776|DIAGNOSTIC_TEST|GeneXpert HBV DNA Viral Load Assay|The Xpert venous blood HBV DNA viral load assay will be adapted to operate using fingerstick capillary blood samples.
223900599|NCT05144776|DIAGNOSTIC_TEST|Dried Blood Spot HBV DNA test|HBV DNA viral load will be measured from a fingerstick capillary dried blood spot sample using a gold standard HBV DNA viral load assay
223900600|NCT05774639|DRUG|Omalizumab Injection|ADL-018 (Omalizumab) solution for injection 150 mg/mL prefilled syringe (PFS)
223900601|NCT05774639|DRUG|Xolair Prefilled Syringe|XOLAIR (omalizumab) injection is supplied as a single dose PFS. Each PFS of XOLAIR contains 150 mg of omalizumab in 1 mL of solution
223900602|NCT05618756|DIETARY_SUPPLEMENT|Acute oral CBD supplementation|1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
223900603|NCT05618756|DIETARY_SUPPLEMENT|Acute oral placebo supplementation|1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.
223900604|NCT00664014|DRUG|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
223900605|NCT00664014|DRUG|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
223900606|NCT05718700|DRUG|Bulevirtide|Administered via subcutaneous (SC) injections
223900607|NCT02861300|DRUG|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
223900608|NCT02861300|DRUG|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
223900609|NCT05187897|BEHAVIORAL|CHV-NEO|CHV-NEO is a two-way SMS platform that supports communication between mothers and community health volunteers between home visits. The platform engages mothers with SMS communication and brings timely information and support - asking critical questions at crucial times in order to assess the needs and health of newborns and assist in care seeking decisions. The CHV-NEO SMS intervention is integrated into the current digital community health toolkit (dCHT) to support CHV workflow.
223900610|NCT04458272|DRUG|DS-1001b|250 mg, twice daily, continuous oral administration
223900611|NCT06007521|OTHER|interview with neurologist|interview with neurologist
223900612|NCT05098613|DRUG|CD19x22 CAR T Cells|Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
223900613|NCT06502639|OTHER|theraplay program|"A play therapy method called thermaplay aids in children's development of stronger bonds and relationships with others. It emphasizes the parts of communication that are nonverbal. When it comes to giving cerebral palsy children with hand therapy that is both effective and motivating, fun approaches have been shown to be both successful and appealing."
223900614|NCT06502639|OTHER|conventional physical therapy|conventional physical therapy program for like stretching and strengthening exercises, sponge ball exercises to the hand, and hand weight bearing exercises
223900615|NCT02465268|BIOLOGICAL|pp65-shLAMP DC with GM-CSF|
223900616|NCT02465268|BIOLOGICAL|unpulsed PBMC and saline|
223900617|NCT02465268|DRUG|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
223900618|NCT02465268|DRUG|Saline|
223900619|NCT02465268|BIOLOGICAL|pp65-flLAMP DC with GM-CSF|
223900620|NCT03424421|PROCEDURE|subscapular sling|semitendinosus subscapular sling procedure
223715156|NCT04763304|OTHER|Coverall personal protective equipment (PPE-C) suit|Placement of PPE-C under direct instructions (audio recording), fluorescent solution full-body spray, removal of PPE under direct instructions (audio recording) and assessment of self-contamination through ultraviolet light scanning. Active (wet wipe cleanse of any fluorescent traces visible under ultraviolet light scanning) and passive (15 minute interval) washout period to prevent a carry over effect on the second allocated intervention.
223715157|NCT02223091|BEHAVIORAL|Consultation by a trained physician|
223715158|NCT02223091|BEHAVIORAL|Consultation by an untrained physician|
223715159|NCT00971594|BEHAVIORAL|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of \~0.2-0.4 kg/wk
223715160|NCT00971594|BEHAVIORAL|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
223715161|NCT00205582|DEVICE|Positron Emission Tomography|
223715162|NCT02577510|DRUG|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament \[7\]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic \[7\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
223715163|NCT02577510|DRUG|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle \[6\]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
223715164|NCT01162512|BEHAVIORAL|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
223715165|NCT00786149|OTHER|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
223715166|NCT00786149|OTHER|Varenicline without counseling|Brief advice, one time during initial session
223715167|NCT02364739|OTHER|Written information|Brochure
223715168|NCT02364739|OTHER|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
223715169|NCT05541770|OTHER|Survey|Healthcare workers/Physicians involved in cancer diagnosis \& management in the Arab countries should respond to a survey
223715170|NCT02887885|DRUG|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
223715171|NCT04271137|COMBINATION_PRODUCT|3D printed PEEK onlay|3d computer-designed Orbital onlay
223715172|NCT04271137|COMBINATION_PRODUCT|Pre-bent orbital mesh|Pre-bent orbital mesh on 3d printed template
223715173|NCT04412369|DIAGNOSTIC_TEST|Non-invasive cardiac imaging|Cardiac MRI ± CT coronary angiography ± Cardiac PET/MRI (68Ga-DOTATATE or 18F-FDG)
223715174|NCT06052605|BEHAVIORAL|Healthy Aging in People with Epilepsy Program|This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
223715175|NCT01628575|PROCEDURE|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
223715176|NCT00003594|DRUG|irinotecan|
223715177|NCT00003594|DRUG|fluorouracil|
223715178|NCT00003594|DRUG|leucovorin calcium|
223715179|NCT00003594|DRUG|oxaliplatin|
223715180|NCT00691015|BIOLOGICAL|rituximab|Given IV
223715181|NCT00691015|DRUG|busulfan|Given IV
223715182|NCT00691015|DRUG|carmustine|Given IV
223715183|NCT00691015|DRUG|cyclophosphamide|Given IV
223715184|NCT00691015|DRUG|cytarabine|Given IV
223715185|NCT00691015|DRUG|etoposide|Given IV
223715186|NCT00691015|DRUG|fludarabine phosphate|Given IV
223715187|NCT00691015|DRUG|melphalan|Given IV
223715188|NCT00691015|RADIATION|total body irradiation (TBI)|Given once or twice daily
223715189|NCT00691015|DRUG|anti-thymocyte globulin IV|Given IV
223715190|NCT03112395|DEVICE|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
223715191|NCT01738321|OTHER|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
223715192|NCT06229340|DRUG|Leflunomide|100 mg daily for 3 days at the loading dose, then 20 mg daily at the standard dose.
223715193|NCT06229340|DRUG|The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab|"Use of one of the possible MEK-inhibitor options:~Trametinib 2 mg once daily orally; Cobimetinib 60 mg on days 1-21, break 7 days, cycle 28 days orally; Binimetinib 45 mg 2 times a day daily orally. + Hydroxychloroquine 600 mg 2 times a day daily orally.~± Bevacizumab 7.5 mg/m² every 3 weeks intravenously."
223715194|NCT01826630|OTHER|CLn BodyWash|Comparing two washes to determine change in bacterial load.
223715195|NCT01826630|OTHER|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
223715196|NCT04160195|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|Dose-escalation trial starting dose: 0.66 x10\^6 CAR+ T cells/kg (weight-based dosing one time) (up to a maximum dose of 10x10\^6 CAR+ T cells/kg based on cohort) infuse on day 0
223715197|NCT04160195|DRUG|Cyclophosphamide|500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
223715198|NCT04160195|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
223900621|NCT05208164|BEHAVIORAL|Mindfunlness Meditation|Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms
223900622|NCT02637479|DEVICE|GammaKnife®|
223900623|NCT02637479|DEVICE|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
223900624|NCT02637479|DEVICE|MRI|
223900625|NCT06491030|DEVICE|Align PJK™ TLSO brace|Patients will get randomized to receiving and wearing a back brace for 6 weeks postoperatively.
223900626|NCT06491030|OTHER|Standard of Care|Patients will receive the standard of care postoperative instructions without a brace
223900627|NCT02867865|DRUG|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
223900628|NCT02867865|DRUG|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
223900629|NCT02867865|RADIATION|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
223900630|NCT02867865|PROCEDURE|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
223900631|NCT02867865|PROCEDURE|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
223900632|NCT03692065|DRUG|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
223900633|NCT05678179|BEHAVIORAL|Telehealth|Patients will participate in standard clinical practice for bariatric surgery preparation with 50% of visits occurring via telehealth.
223900634|NCT05678179|BEHAVIORAL|In Person (Face-2-Face)|Patients will participate in standard clinical practice for bariatric surgery preparation with face-2-face clinic visits.
223900635|NCT06179498|BEHAVIORAL|Partner Navigation Intervention|A two-session, disclosure counselor-led, behavioral intervention to enable the injecting partner to support and navigate the adult PWID to start HCV treatment.
223900636|NCT06138418|PROCEDURE|Neurotomy|Surgical treatment of spastic foot
223900637|NCT04837222|OTHER|No Intervention|This is a non-interventional study.
223900638|NCT06062745|DRUG|18F-fluciclovine|18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body
223900639|NCT06062745|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
223900640|NCT05459857|OTHER|Product A|Heated tobacco (HT) device with Intense HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
223900641|NCT05459857|OTHER|Product B|Heated tobacco (HT) device with Regular HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
223900642|NCT05459857|OTHER|Product C|Heated tobacco (HT) device with Menthol HT sticks, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
223900643|NCT05459857|OTHER|Product D|Subject's own brand combustible cigarette, used under controlled conditions (i.e., completely use a single unit of the product, with puffs taken at 30-second intervals and puffs 3 seconds in duration)
223900644|NCT06394167|DRUG|VX-993|Solution for IV administration.
223900645|NCT06394167|DRUG|Placebo|Solution for IV administration.
223900646|NCT03133546|DRUG|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
223900647|NCT03133546|DRUG|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
223900648|NCT05589389|OTHER|High Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is minimally processed.
223900649|NCT05589389|OTHER|High Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a high Healthy Eating Index along with meat that is further processed.
223900650|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Minimally Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is minimally processed.
223900651|NCT05589389|OTHER|Typical Healthy Eating Index Diet with Further Processed Meat|Participants will consume a diet with a typical Healthy Eating Index along with meat that is further processed.
223900652|NCT04432532|OTHER|No intervention|There are no interventions
223900653|NCT06185790|OTHER|LCHF diet|Low-carb high-fat (LCHF) diet
223900654|NCT06117579|OTHER|Inspiratory muscle training|"Description of a typical session:~Session duration: between 12 and 20 minutes 3 cycles of 30 repetitions with 1 minute of break between each cycle. The patient should inhale as hard as possible against an inspiratory resistance generated by a valve device."
223900655|NCT04732533|OTHER|tES (transcranial electrical stimulation)|"Phase 1: The participant will receive 10, 20-minute sessions of tDCS on Monday-Friday, at approximately the same time of day, over two consecutive weeks.~Phase 2: The participant will receive 22, 20-minute sessions of tES. 10 sessions will take place over the first two weeks on Monday-Friday, at approximately the same time of day. This will be followed by 3 tES sessions per week over four weeks.~Phase 3: The participant will receive up to 260, 20-minute sessions of tES. The participant can complete up to 5 tDCS sessions per week over 52 weeks.~Phase 4: The participant will receive up to 780, 20-minute sessions of tES. The participant can complete up to 5 tDCS sessions per week over 156 weeks."
223900656|NCT06296537|PROCEDURE|Dynamic Neuromuscular Stabilization Training (DNS)|Dynamic neuromuscular stabilization training has been developed, which optimizes the movement system based on the scientific principles of developmental kinesiology. DNS training aims to stimulate the natural movement control system in the brain to activate the body's stabilization system. Supine, prone, oblique sitting, tripod, high kneeling, hanging stance-midstance faze, hanging stance- propulsion, bear, squat exercises will be applied.
223900657|NCT06296537|PROCEDURE|Balance Training|Multi-plane single limb challenges, jumping and landing exercises, proprioceptive exercises, and perturbation exercises
223900658|NCT06296537|PROCEDURE|Conventional Training|Education, electrotherapy, soft tissue fascia massage, stretching, range of motion, strengthening and postural control exercises
223900659|NCT04159259|OTHER|Low fiber diet|Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
223900660|NCT04159259|OTHER|Pea Fiber Bar|Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
223900661|NCT04159259|OTHER|Low fiber diet|Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
223900662|NCT06532877|BEHAVIORAL|Acceptance and Commitment Therapy|Patients and caregivers in the acceptance and commitment therapy arm learn new and more adaptive ways to respond to difficult internal experiences (e.g., fatigue, thoughts, and feelings).
223900663|NCT06532877|BEHAVIORAL|Education/Support|Patients and caregivers in the education/support arm discuss their cancer-related concerns and receive education on services available in their medical center and community.
223900664|NCT05806593|BEHAVIORAL|Get Back pilot|A health-promoting program, targeting physical activity behavior, with a person-centred approach led by a physiotherapist digitally during 12 weeks.
223900665|NCT05448443|DRUG|AD981|Oral administration of AD981 in the morning and before sleep for 14 days
223900666|NCT05448443|OTHER|Placebo|Oral administration of placebo in the morning and before sleep for 14 days
223900667|NCT03468868|BEHAVIORAL|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
223900668|NCT06020391|OTHER|Collaborative drug review|"1. Structured, clinical drug review including medical history, physical examination, and supplementary tests. The work-up will be aimed at evaluating whether current medications are indicated, whether the patient's medical conditions are satisfactorily compensated, whether dosages are appropriate, whether the patient has adverse drug effects, and whether drug-drug or drug-disease interactions are present or likely to occur. The MipAC physicians will receive clinical supervision from a consultant in geriatric medicine.~2. The MipAC physician will offer the patient's FP a telephone meeting with the purpose of combining the assessments of the MipAC physician and the competence of the FP in a common drug review. The two physicians will review the patient's drug list systematically and discuss if any adjustments should be done, as well as the patient's need for further follow-up."
223900669|NCT06164392|DRUG|Indocyanine green|Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
223900670|NCT06075836|OTHER|Cases reading|"The reading will be done remotely via the Report and Image Quality Control site (www.RAIQC.com), an online platform allowing medical imaging viewing and reporting. Participants can work from any location, but the work must be done from a computer with internet access. For avoidance of doubt, the work cannot be performed from a phone or tablet.~The project is divided into two phases and participants are required to complete both phases. The estimated total involvement in the project is up to 20-24 hours.~Phase 1: Time allowed: 2 weeks~\- Review 500 chest X-rays and express a clinical opinion through a structured reporting template (multiple choice, no open text required).~Rest/washout period of 2 weeks.~Phase 2 - Time allowed: 2 weeks~\- Review 500 chest X-rays together with an AI report for each case and express your clinical opinion through the same structured reporting template used in Phase A."
223900671|NCT06075836|OTHER|Ground truthing|Two consultant thoracic radiologists will independently review the images to establish the 'ground truth' findings on the CXRs, where a consensus is reached this will then be used as the reference standard. In the case of disagreement, a third senior thoracic radiologist's opinion (\>20 years experience) will undertake arbitration. A difficulty score will be assigned to each abnormality by the ground truthers using a 4-point Likert scale (1 being easy/obvious to 4 being hard/poorly visualised).
223900672|NCT05356104|DRUG|Exenatide extended release|2mg once weekly via subcutaneous injection
223900673|NCT06166420|OTHER|Experimental|Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
223900674|NCT06166420|OTHER|Active comparator|Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
223900675|NCT05985356|DEVICE|iTBS|iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
223900676|NCT06803758|DIAGNOSTIC_TEST|Teicoplanin Allergy Testing using autologous serum|"In addition to performing teicoplanin allergy skin testing using standard recommended Teicoplanin concentration, we will perform skin testing using autologous serum, the supernatant which is obtained via centrifugation. Skin testing ( skin prick test and intradermal test) will be performed with these additional samples:~1. STpre: Teicoplanin added to blood sample pre-centrigufation.~2. STpost: Teicoplanin added to supernatant post-centrigufation.~3. ST0: Supernatant with no additives ( serum negative control)"
223900677|NCT06027086|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV on Day 1 of each cycle every 28 days.
223900678|NCT06027086|DRUG|DRP-104|"Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration."
223900679|NCT06798896|DRUG|SPN-817|SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
223900680|NCT06798896|DRUG|Placebo|Placebo, bid
223900681|NCT06802419|OTHER|Continuous adductor canal block|Patients will receive continuous adductor canal block.
223900682|NCT06802419|OTHER|Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule|Patients will receive Continuous Adductor Canal Block with additional Infiltration between The Popliteal Artery and Capsule of The Knee
223900683|NCT06803017|BEHAVIORAL|combination of exercise and sport with fast-tempo music|Fast-tempo music selected by the researcher with exercise training and sports training
223900684|NCT06803017|BEHAVIORAL|combination of exercise and sport with slow-temp music|Slow-tempo music selected by the researcher with exercise training and sports training
223900685|NCT06803017|BEHAVIORAL|combination of exercise and sport with no music|Exercise training and sports training without music
223900686|NCT04701671|BEHAVIORAL|Observational (not including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
223900687|NCT04701671|BEHAVIORAL|Observational (including MRI scanning)|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, fMRI imaging, and a semi-structured interview.
223900688|NCT04696965|OTHER|Correct/recheck strategy|One month after recruitment and every 3 months. 1. Check the inhaler step errors of patients by research assistant; 2.Demonstrate the right way by research assistant; 3. give the inhaler check list with marks of the wrong step(s) patients made to patients and 4. confirm the patients do the right way of the previous wrong step(s).
223900689|NCT04696965|OTHER|Usual verbal instruction|One month after recruitment and every 3 months.1. Check the inhaler step errors of patients by research assistant; 2. Verbal instruction with a physical demonstration will be given by educational nurse in usual care.
223900690|NCT06803784|GENETIC|Genetic: whole genome sequencing|Genetic: whole genome sequencing PD Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
223900691|NCT06803784|GENETIC|whole exome sequencing|"Genetic: whole genome sequencing~AD Partecipants will be assessed for disease progression:~* assessment of cognitive disorders (MMSE, MOCA test, clock test);~* assessment of language disorders;~* current drug therapy (and possible start date of treatment);~* date of onset of cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate AD genes"
223900692|NCT06803784|GENETIC|whole exome sequencing|"Genetic: whole genome sequencing~ALS/FTD Partecipants will be assessed for disease progression:~* clinical classification according to El Escorial - revised;~* assessment of cognitive disorders (and classification according to Strong criteria, 2017);~* assessment of language disorders;~* ongoing pharmacological therapy (and possible start date of treatment);~* date of onset of motor and cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate ALS/FTD genes"
223900693|NCT06802679|DRUG|Urokinase|In the higher dose group: 30,000unit (1.5ml) per catheter lumen is instilled per catheter lumen (in both arterial and venous ports respectively). This allows utilization of the entire vial of Urokinase to prevent wastage and to assess if this increase in dose improves catheter patency and survival, thus reducing the need for a TDC exchange in our HD patients. The urokinase lock is dwelled for at least 2 hours, after which aspiration and catheter testing will be done by a trained HD nurse.
223900694|NCT06802679|DRUG|Urokinase|20,000unit (1ml) is instilled per catheter lumen (in both arterial and venous ports respectively); and the remaining 1ml is discarded.
223900695|NCT05399459|DRUG|Rimegepant 25 MG|Single dose of 25 mg orally disintegrating tablet of rimegepant
223900696|NCT05399459|DRUG|Rimegepant 75 MG|Single dose of 75 mg orally disintegrating tablet of rimegepant
223900697|NCT05399459|DRUG|Placebo|Matching placebo tablet
223900698|NCT02596802|DEVICE|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
223900699|NCT04333745|OTHER|Controlled Diet|Participant will consume a controlled low oxalate diet for five days
223900700|NCT04333745|DIETARY_SUPPLEMENT|Carbon-13 Oxalate and Sucralose Ingestion|Subjects will ingest a small amount of carbon-13 oxalate and sucralose, dissolved in water.
223900701|NCT06111027|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation is a non-invasive treatment option. As stimulators, we will apply a pair of light-weight encapsulated cylindrical vibrators to both sides of the larynx (voice box). The vibration frequency for VTS will set be to 100Hz and the participant may feel a mild tingling or vibrating sensation during VTS. The participants will be asked to apply for VTS at home over a period of 8 weeks. The participants will be asked to use this device for 3 days in the first week, 4 days in the second week, 5 days in the third week and 6 days in the fourth week. During the last 4 weeks, the participants will apply VTS on self-selected days as needed, not exceeding 6 times a week, to control and improve symptoms.
223900702|NCT02152046|PROCEDURE|ROP exam with spring loaded retractor|
223900703|NCT02152046|PROCEDURE|ROP exam with screw retractor|
223900704|NCT06802354|DRUG|Ozone|In Ozone group, ozone will be applied at the site of the extraction wound for 30 seconds after the surgical extraction of the third molar, according to the manufacturer's recommendation for wound treatment following tooth extraction.
223900705|NCT06802354|DRUG|Placebo|In the control group, a sham ozone therapy will be applied at the site of the extraction wound for 30 seconds after the surgical extraction of the third molar .
223900706|NCT03221517|OTHER|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
223900707|NCT06501729|OTHER|Kiss|Participants will kiss with their partners for 40 seconds. The kiss will be on the mouth.
223900708|NCT02733003|BEHAVIORAL|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
223715199|NCT00349440|DRUG|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
223715200|NCT00232232|DRUG|Fish oil|
223715201|NCT04167644|DIAGNOSTIC_TEST|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
223715202|NCT04585386|OTHER|Visual analog scale|to measure the lumbar and radicular pain felt by the patient.
223715203|NCT04585386|OTHER|Mac Gill Pain Questionnaire|self-questionnaire that allows a qualitative assessment of chronic pain
223715204|NCT04585386|OTHER|Roland and Morris Disability Questionnaire|functional disability scale for assessing low back pain
223715205|NCT04585386|OTHER|Quebec questionnaire|To access the patient's perception of incapacity
223715206|NCT02332278|PROCEDURE|Early feeding|Fluid diet four hours after cesarean section
223715207|NCT02332278|PROCEDURE|Late feeding|Fluid diet 12 hours after cesarean section
223715208|NCT06033794|DEVICE|Fluorescence laparoscopic system|Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
223715209|NCT02139332|BEHAVIORAL|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
223715210|NCT02139332|BEHAVIORAL|Resource & Referral Group|The Resource \& Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
223715211|NCT00309569|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2
223715212|NCT00309569|DRUG|Methotrexate|Methotrexate 40mg/m2
223715213|NCT00309569|DRUG|Fluorouracil|Fluorouracil 600mg/m2
223715214|NCT00309569|DRUG|Epirubicin|Epirubucin 60mg/m2 (only node-positive patients)
223715215|NCT00309569|OTHER|Surgery|Surgery
223715216|NCT02563223|OTHER|Parabolic flight|
223715217|NCT02563223|DEVICE|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
223715218|NCT01223001|DRUG|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
223715219|NCT01223001|DRUG|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
223715220|NCT03769454|DRUG|PP-001|PP-001 eye drops
223715221|NCT03769454|OTHER|Placebo|Placebo eye drops
223715222|NCT04454268|PROCEDURE|cyst extirpation|complete removal of the cyst without rupture
223715223|NCT00590720|BIOLOGICAL|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
223715224|NCT00590720|OTHER|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
223715225|NCT04023851|DEVICE|Mobile application Brain4U|Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
223715226|NCT01240720|DRUG|131I-F16SIP Radioimmunotherapy (RIT)|"* Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~* Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
223715227|NCT02957422|DIETARY_SUPPLEMENT|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
223715228|NCT02957422|DIETARY_SUPPLEMENT|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
223715229|NCT03355820|PROCEDURE|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (\~5 mL) will be taken from all the subjects, at Day 1.
223715230|NCT04580069|PROCEDURE|Lymphatic drainage|The interventions follow the validated techniques normally used in international rehabilitation
223715231|NCT00707720|DEVICE|TERIS procedure|The implantation of the restrictive implant
223715232|NCT02658903|DEVICE|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
223715233|NCT02658903|DEVICE|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
223900718|NCT05703971|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
223715234|NCT01416064|DRUG|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
223900719|NCT05703971|BIOLOGICAL|atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
223900720|NCT00986856|DRUG|Fucidin® cream|
223900721|NCT03358719|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intracutaneously
223900722|NCT03358719|DRUG|Decitabine|Given IV
223900723|NCT03358719|OTHER|Laboratory Biomarker Analysis|Correlative studies
223900724|NCT03358719|BIOLOGICAL|Nivolumab|Given IV
223900725|NCT03358719|DRUG|Poly ICLC|Given SC
223900726|NCT06331598|DRUG|Atezolizumab|A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
223900727|NCT06331598|DRUG|Tiragolumab|A dose of 840 mg tiragolumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
223900728|NCT05887583|BEHAVIORAL|The Rising New York Road Runners program|The Rising New York Road Runners program provides lesson plans covering fundamental movement skills that are intended to build competence, confidence, and motivation to be physically activity. Family engagement materials (emails, text messages, videos, social media) complement school materials to communicate what children are learning at school related to physical activity and what activities families can do at home together to reinforce these concepts.
223900729|NCT03947814|DRUG|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2\*300 mg tablets.
223900730|NCT03559569|BIOLOGICAL|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
223900731|NCT03020199|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.
223900732|NCT03020199|RADIATION|nb-UVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
223900733|NCT01571700|PROCEDURE|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension \>5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
223900734|NCT05496751|BEHAVIORAL|Low amount, low intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
224276790|NCT06176755|OTHER|Treadmill training with weighted ankle cuffs|"Group A: Treadmill training and Ankle cuff.~Participants in group A will provided with small, motorized, custom-designed treadmills and trained parents to appropriately administer training in their homes. Parents held their infant upright on the treadmill at the front of the belt. The belt of the treadmill, when turned on, moved the infants' legs backward and elicited forward stepping. Whenever infants did not generate steps, parents repositioned the infant to the front of the belt. Infants will receive the protocol about 4 days a week for 1 hour/day for total of 6 weeks at a belt speed of 0.18m/sec. Besides progressively increasing belt speed and daily training duration, we attached to the infants' ankles a small amount of weight that was proportional to their estimated calf mass, and increased the weight over the course of training. Treadmill training terminated when participants walked three steps independently."
224276791|NCT06176755|OTHER|Treadmill training|Treadmill training only
223900735|NCT05496751|BEHAVIORAL|Low amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
223900736|NCT05496751|BEHAVIORAL|High amount, high intensity exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
223900737|NCT05583578|DEVICE|Home-based mobility testing and active tDCS|"A Soterix Clinical Trials tDCS unit will be used for delivery of stimulation for twenty minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm2 sponges placed over the frontal cortices at F3 and F4 (based on the international 10-20 system of standardized brain electrode placement). 2.0mA was"
223900738|NCT05583578|DEVICE|Sham tDCS|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2.0mA of direct current stimulation at the beginning of each rehabilitation session. Since participants habituate to the sensation of tDCS within 30-60 seconds of stimulation, this procedure provides the same sensation of active tDCS.
224276792|NCT04540718|OTHER|Exercise|50 minutes of exercise, consisting of 20 minutes of resistance followed by 30 minutes of aerobic, three times a week for eight weeks.
223715235|NCT04189081|DEVICE|dry mouth rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
223715236|NCT04189081|OTHER|Water Control|negative control
223715237|NCT00910026|PROCEDURE|low tidal volume ventilation|6 ml/kg tidal volume ventilation
223715238|NCT00910026|PROCEDURE|high tidal volume ventilation|12 ml/kg tidal volume ventilation
223715239|NCT03441308|BEHAVIORAL|Educational method of group treatment|
223900739|NCT04165408|DEVICE|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
223900740|NCT05598372|BEHAVIORAL|shotblocker|infant pain during vaccination and mother anxiety
223900741|NCT05598372|BEHAVIORAL|lullaby|infant pain during vaccination and mother anxiety
223900742|NCT02172690|PROCEDURE|Laparoscopic Staging|Laparoscopic Staging
223900743|NCT06529978|DEVICE|CoreMap EP Mapping System Mapping|Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.
223900744|NCT06529978|DEVICE|CoreMap EP Mapping System Map-Guided Ablation|Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.
223900745|NCT06090734|OTHER|My Voice|The web intervention educates patients about their illness and supports them to make their own Advance Care Planning decisions, update these decisions frequently as their clinical condition changes, and to make the ACP process easier and more accessible. The intervention aims to shift implementation of ACP from a provider-led one-time model to a patient-led dynamic model.
223900746|NCT04849572|BEHAVIORAL|Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 1) will watch a 10 to 20 minute sleep hygiene video followed by a post-test questionnaire to confirm participation and understanding.~* Week 5: Arm 1 will again view the educational video at week 5~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 1 will continue re-education~* Week 11: Arm 1 continues education~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
223900747|NCT04849572|BEHAVIORAL|Delayed Sleep Education|"* Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 2) will be controls with no education.~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 2 will join in for video education along with post-test~* Week 11: Arm 2 will undergo reeducation with post-test for 20 mins~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups."
223900748|NCT05201079|BIOLOGICAL|MBK-01|A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.
223900749|NCT05201079|DRUG|Fidaxomicin|Oral administration of 200mg/12 hours of fidaxomicin for 10 days.
223900750|NCT00267137|DEVICE|Pacing Algorithms|
223900751|NCT04752709|DEVICE|ELITONE UUI|External electrical stimulation
223900752|NCT06475638|DEVICE|brachial artery doppler|brachial artery doppler evaluation before and after supraclavicular block
223900753|NCT05299658|DRUG|CNMAu8|CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bi-pyramid, tetrahedron, decahedron, planar spheroids). Those choosing to participate in the OLE period will orally receive 30 mg of CNM-Au8, once daily.
223900754|NCT06132581|DEVICE|Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
223900755|NCT06132581|DEVICE|Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.
223900756|NCT06132581|DEVICE|Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4|Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
223900757|NCT05121545|RADIATION|Pro-GRID|Study participants will receive a single treatment of Pro-GRID therapy. After which, the participants would be able to resume standard therapy (after one week) and receive additional radiotherapy one month after Pro-GRID therapy, if recommended. Participants will be in the study for one year. Follow-up appointments will be scheduled at 1, 3, 6 and 12 months posttreatment, and may include a history and physical exam, labs and/or a CT scan and toxicity assessments.
223900758|NCT01652196|BIOLOGICAL|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
223900759|NCT01652196|DRUG|oxaliplatin|85 mg/m2 IV infused over 2 hours
223900760|NCT01652196|DRUG|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
223900761|NCT01652196|DRUG|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
224276793|NCT04540718|OTHER|Sauna|15 minutes of sauna exposure immediately after exercise intervention, three times a week for eight weeks.
224276794|NCT01530308|DRUG|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
223900762|NCT01652196|OTHER|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
223900763|NCT01652196|PROCEDURE|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
223900764|NCT01652196|RADIATION|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
223900765|NCT01652196|PROCEDURE|PET (positron emission tomography)|Correlative studies
223900766|NCT04000035|OTHER|Health and work environment information and processes|see arm/group description
223900767|NCT06286930|DEVICE|anodal trans cranial direct current stimulation (tDCS)|1 20-minute anodal tDCS stimulation
223900768|NCT06286930|DEVICE|cathodal trans cranial direct current stimulation (tDCS)|1 20-minute cathodal tDCS stimulation
223900769|NCT05252520|DRUG|JNJ-77474462|JNJ-77474462 will be administered subcutaneously.
223900770|NCT02419976|OTHER|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
223900771|NCT02419976|DEVICE|Aeonose|
223900772|NCT03543683|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
223900773|NCT03543683|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
223900774|NCT06148194|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 30 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 30 mL-bottle that is used for probiotic 1 and 2.
223900775|NCT06148194|COMBINATION_PRODUCT|Probiotic 1|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device (Product declaration: No. 210001337/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax product is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 1 billion CFU/mL x 30 mL.
223900776|NCT06148194|COMBINATION_PRODUCT|Probiotic 2|In Vietnam, LiveSpo Navax Kid is manufactured as a Class-A medical device (Product declaration: No. 220002534/PCBA-HN) in accordance with manufacturing standards approved by the Hanoi Health Department, Ministry of Health, Vietnam (Certificate No. YT117-19), and ISO 13485:2016. LiveSpo Navax Kid is prepared in the form of NaCl 0.9% plus B. subtilis and B. clausii at 0.6 billion CFU/mL x 30 mL.
223900777|NCT04594057|BEHAVIORAL|Gaze and Postural Retraining Exercise|"Gaze and Postural Stability The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
223900778|NCT06124079|OTHER|OPY interactive messaging service|2 specific versions of OPY. information. Each version will deliver the same instructions and information about pain management recommendations, and collect the same information about patient pain experience and side effects. The two versions differ in the motivational techniques interspersed throughout the OPY experience.
223900779|NCT06124079|OTHER|Standard care|Standard care currently consists of education materials with the after visit summary (available in MyChart) around opioid use and precautions and disposal information.
223900780|NCT02688140|DRUG|Arsenic trioxide|
223900781|NCT02688140|DRUG|Idarubicin|
223900782|NCT02688140|DRUG|Cytarabine|
223900783|NCT02688140|DRUG|Tretinoin|
223900784|NCT02688140|DRUG|Mitoxantrone|
223900785|NCT02688140|DRUG|Mercaptopurine|
224276795|NCT01530308|DRUG|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
223900786|NCT02688140|DRUG|Methotrexate|
223900787|NCT05219396|DEVICE|Knee arthroplasty|Your knee should be replaced with mobile bearing (MB), medial congruent (MC) and posterior stabilized (PS) design protheses.
223900788|NCT05692960|OTHER|Hypnotic Relaxation Intervention (HRI)|HRI is a combination intervention (Replens™ vaginal moisturizer device and hypnotic relaxation behavioral intervention)
223900789|NCT05692960|DEVICE|Vulvovaginal Atrophy (VVA)|VVA is a standard of care intervention (Replens™ vaginal moisturizer device)
223900790|NCT05386030|COMBINATION_PRODUCT|saypha® VOLUME Lidocaine|Crosslinked hyaluronic acid (HA) 23 mg/mL + 0.3% lidocaine hydrochloride.
223900791|NCT05386030|COMBINATION_PRODUCT|Juvéderm® Voluma™ XC|Crosslinked HA 20 mg/mL + 0.3% lidocaine hydrochloride
223900792|NCT06375343|DRUG|PRO-240|-Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.
223900793|NCT06375343|DRUG|Optive®|\- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.
224083464|NCT05358132|DEVICE|Pneumowave Device placement and data capture|"Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.~Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,"
223900794|NCT04048551|BEHAVIORAL|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
223900795|NCT04048551|BEHAVIORAL|Young Women's Health CoOp (YWHC)|In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
223900796|NCT04208984|DEVICE|Study|After consent and assent the child and parent will be introduced the Lullabreath in pre-op. The purpose of Lullabreath will be explained and the Lullabreath will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the Lullabreath. The anesthesiologist will hook the device up to the anesthesia circuit and start the Lullabreath. The child will then undergo induction of anesthesia while playing the Lullabreath.
223900797|NCT04208984|OTHER|Music Video|After consent and assent the child and parent will be introduced to the game in pre-op. The purpose of the game will be explained and the game will be taught (15 minutes). The parent will complete the PROMIS Proxy Anxiety short form. The children are then taken to the operating room (leave parents) with the game. The anesthesiologist will hook the device up to the anesthesia circuit and start the game. The child will then undergo induction of anesthesia while playing the game. The child can choose to watch one of two music videos (Frozen, Lion King)
223900798|NCT01953588|DRUG|fulvestrant|Fulvestrant 500 mg IM
223900799|NCT01953588|DRUG|anastrozole|Anastrozole 1 mg oral tablet
223900800|NCT05699239|DRUG|TS-172 10mg bid|oral administration of TS-172 10 mg bid
223900801|NCT05699239|DRUG|TS-172 30mg bid|oral administration of TS-172 30 mg bid
223900802|NCT05699239|DRUG|TS-172 60mg bid|oral administration of TS-172 60 mg bid
223900803|NCT05699239|DRUG|TS-172 20mg tid|oral administration of TS-172 20 mg tid
223900804|NCT05699239|DRUG|Placebo|oral administration of placebo
223900805|NCT04524442|DRUG|arginine/lysine|1000 milliliters (mL) administered at a constant rate of 250 mL per hour
223900806|NCT06241872|OTHER|Dry needling group|Dry needling will be performed using a 27-gauge, 5 cm long dental needle, guided by ultrasound, on predetermined trigger points in patients.
223900807|NCT04719832|BIOLOGICAL|GSK3511294 (Depemokimab)|GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
223900808|NCT04719832|DRUG|Placebo|Matching placebo will be administered as a normal saline using a pre-filled syringe.
223900809|NCT04469569|BEHAVIORAL|HPV-PROTECT|HPV-PROTECT is a multicomponent provider-focused intervention specifically tailored for use in pediatric oncology settings, addressing important survivor-specific vaccine issues. The intervention is comprised of three components, i) Provider Communication Training; ii) Assessment and Peer Feedback/ Coaching; and iii) Provider Toolkit. The HPV-PROTECT intervention is designed to increase provider knowledge regarding use of the HPV vaccine in the cancer survivor population, enhance provider skills in delivering brief, compelling HPV vaccine recommendations to parents of young cancer survivors, present ongoing feedback to providers regarding clinic- and provider-level survivor HPV vaccination rates, and decrease barriers to receipt of vaccine by survivors through the provision of Vaccine Action Plans, tailored to local context.
223900810|NCT05819346|BEHAVIORAL|Lifestyle|Participants assigned to the intervention group receive access to a lifestyle mobile application for three months after rehabilitation or treatment has finished. The digital program is target group-specific and includes personalization and interactive elements without face-to-face appointments during the intervention. One virtual appointment at the beginning of the intervention with the study staff ensures that participants familiarize themselves with the mobile application and that they are assigned to a suitable program level. The intervention is mainly based on the following behavior change technique (BCT) clusters: goals and planning, feedback and monitoring, shaping knowledge, and comparison of behavior.
223900811|NCT05024760|DRUG|Chlorhexidine|Chlorhexidine will be inserted into the dental implant internal cavity during dental implant insertion.
223900812|NCT05024760|DRUG|Hydrogen Peroxide|Hydrogen Peroxide will be inserted into the internal cavity of the dental implant during dental implant insertion.
223900813|NCT03355274|DIAGNOSTIC_TEST|Transcutaneous Oximetry|"The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up)."
223900814|NCT03355274|DIAGNOSTIC_TEST|Photopletysmography|Maneuvers are repeted with the photoplestysmography sensors and in front of a Kinect camera.
223900815|NCT03355274|OTHER|Questionnaires of Quality of Life (QoL)|Each subject complete 2 QoL questionnaires : Sf-12 (Short Form 12) and DASH (Disabilities of the Arm, Shoulder and Hand).
223900816|NCT05304364|COMBINATION_PRODUCT|Combination Product: Naltrexone|Naltrexone Implant
223900817|NCT06335095|OTHER|Kinematic sensors|Comparative analysis of kinematic data acquired in supervised and unsupervised environment
223900818|NCT05561595|BEHAVIORAL|Healing HEARTS|Session topics will include: psychoeducation; myths and stereotypes; cognitive distortions and restructuring; coping strategies; interpersonal effectiveness; self-efficacy; mindfulness and self-compassion; acceptance and positive self-image; disclosure and finding support; stigma in health care; and empowerment and advocacy.
224083465|NCT04138160|OTHER|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
223900819|NCT05561595|BEHAVIORAL|Peer Support|Peer support groups will cover general topics such as symptom management, stress, and social support. Stigma will not be a formal topic of discussion, and group leaders will be trained to avoid initiating conversations about stigma; however, to capture realistic discussions in peer support groups, participants will not be prohibited from discussing the topic should they bring it up.
223900820|NCT06380868|PROCEDURE|Intravascular imaging-guided PCI|Intravascular imaging including intravascular ultrasound or optical coherence tomography.
223900821|NCT06380868|PROCEDURE|Angiography-guided PCI group|Deployment of a drug-eluting stent under angiography.
223900822|NCT05456880|BIOLOGICAL|BEAM-101|Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
223900823|NCT03883945|DRUG|AIV001|intradermal injection
223900824|NCT03883945|DRUG|Vehicle|intradermal injection
223900825|NCT04774445|BEHAVIORAL|MyCancerGene|Interactive Health Communication Application
223900826|NCT05228457|DEVICE|Intensive intermittent theta-burst stimulation (iTBS)|Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.
223900827|NCT06130345|BIOLOGICAL|SPIKEVAX|Intramuscular injection
223900828|NCT05109351|BEHAVIORAL|Participating to Boost Meal Participation|The Participating to Boost Meal Participation intervention consists of utilizing marketing and communication strategies to promote school meal participation in elementary school students.
223900829|NCT04826588|DRUG|Methylprednisolone sodium succinate 10 mg/kg intravenously|Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
223900830|NCT04826588|BIOLOGICAL|Human normal immunoglobulin (IVIg)|Human normal immunoglobulin (IVIg) 2g/kg intravenously as a single dose in line with guidance for dosing and administration in Kawasaki disease
223900831|NCT00167674|DRUG|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight \> 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
223900832|NCT00167674|DRUG|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
223900833|NCT05017545|BIOLOGICAL|carfilzomib|"Administered: Intravenously (IV). Carfilzomib is administered intravenously, on two consecutive days, each week for three weeks per cycle. In this study, subjects will receive 2 cycles of carfilzomib. Dosing for each cycle is based on the recommended dosing for carfilzomib monotherapy in the package insert.~Carfilzomib is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma. In this study, carfilzomib will be used in highly sensitized subjects without myeloma who are awaiting a kidney transplant."
223900834|NCT05017545|BIOLOGICAL|belatacept|Administered: Intravenously (IV). Belatacept is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. In this study, belatacept will be used in highly sensitized subjects who are awaiting a kidney transplant.
223900835|NCT05017545|PROCEDURE|Bone marrow aspiration|Subjects will undergo a bone marrow aspiration prior to starting the study regimen and at 16 weeks after starting the study regimen. In subjects who undergo a kidney transplant during the study, another bone marrow aspiration will be done if it has been \>4 weeks since the previous bone marrow aspiration.
223900836|NCT05669599|BIOLOGICAL|Maridebart Cafraglutide|Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.
223900837|NCT05669599|DRUG|Placebo|Participants will receive placebo by SC injection.
223900838|NCT05283915|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablet Route of administration: oral
223900839|NCT06135792|OTHER|Arginine|See arm description
223900840|NCT06135792|OTHER|Placebo|See arm description
223900841|NCT03850600|OTHER|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
224083466|NCT04138160|OTHER|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
223900842|NCT05308108|PROCEDURE|(Adeno)tonsillectomy|registration of PORC in children with OSAS after (adeno)tonsillectomy
223900843|NCT05052125|DRUG|Oxygen|Administering oxygen to achieve the desired peripheral oxygen saturation
223900844|NCT04535349|DIAGNOSTIC_TEST|Whole-body & CZT bone tracer imaging (SPECT)|Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
223900845|NCT02789956|DEVICE|Internal vs. external cad cam co/cr framework|
223900846|NCT04006951|OTHER|Biological collection|"Blood samples are collected at different times :~* Before any treatment~* After pre-operative radiochemotherapy and before surgery (if applicable)"
223900847|NCT03948139|DEVICE|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
223900848|NCT03948139|DEVICE|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
224083467|NCT00358605|DEVICE|The Klearway™ oral appliance|See Detailed Description.
224083468|NCT02952183|DEVICE|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
223715240|NCT01619423|DRUG|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
223715241|NCT01619423|DRUG|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
223715242|NCT01619423|DRUG|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
223715243|NCT01619423|DRUG|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
223715244|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Peach Pod|Participants in this arm will use the air up® drinking system with a peach-flavored pod.
223715245|NCT06290479|DIETARY_SUPPLEMENT|Air Up® Orangeade Pod|Participants in this arm will use the air up® drinking system with an orangeade-flavored pod.
223715246|NCT00961233|DRUG|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
223715247|NCT00961233|DRUG|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
223715248|NCT03172442|DEVICE|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
223715249|NCT03172442|DEVICE|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
223715250|NCT03172442|DEVICE|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
223715251|NCT02687997|OTHER|poligraphy|Sleep study
223715252|NCT04452682|OTHER|COVID 19 impact|The impact of COVID-19 pandemic on Critical limb threatening ischemia and emergency vascular practice
223715253|NCT00972868|DEVICE|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
223715254|NCT05269498|DEVICE|CORTEXPLORER MED|The CORTEXPLORER MED system is a platform that enables surgical navigation using real-time radiological images of patients. The application software formats patient-specific computed tomography or magnetic resonance images taken before surgery. These are displayed on the screen and through mixed reality from different perspectives (axial, sagittal, coronal, diagonal). Before surgery, the surgeon can then create, save and simulate the course along one or more surgical trajectories. As a visualization aid, the surgeon can also create and edit one or more 3D models of the anatomy. During surgery, the system tracks the position of specific surgical instruments in or on the patient's anatomy and continuously updates the position of the instruments on these images.
223715255|NCT04360668|OTHER|Muscle Energy Technique (MET)|The Contract-Relax Agonist-Contract (CRAC) technique will be used, which belongs to the broad MET group. The participant will be in the supine position. The therapist will set the cervical segment in the lateral flexion until a slight soft tissue tension is felt. The technique will consist of two stages. In the first phase (contraction phase), the upper trapezius will be activated against the therapist's resistance (shoulder girdle elevation) - 10 seconds. Then the person undergoing the procedure breathes in and out deeply. Then 10 seconds of antagonist group contraction (shoulder girdle depression) will be performed. Next, the therapist will passively move the participant's shoulder girdle towards the depression. Then the second phase will follow (stretching phase), during which the participant will passively lie in the back position for 30 seconds. Both phases will make up the therapeutic cycle. Each participant will have 5 cycles on each side of the upper trapezius.
223715256|NCT04360668|OTHER|Trigger Point Therapy (TPT)|The technique of Positional Release (PR) will be used, which is one of the broadly understood Trigger Point Therapy. It will consist in compressing the trigger point with a simultaneous shortening of muscle attachments (slight lateral flexion towards the relaxed muscle). The muscle on both sides will be treated. The pressure exerted by the therapist's pincer grip will be acceptable to the patient. The duration of the technique will be 2 minutes for each muscle. While performing this technique, the participant will passively lie on his back.
223715257|NCT04360668|OTHER|Muscle Energy Technique (MET) combined with Trigger Point Therapy (TPT)|For this type of intervention, TPT will first be performed on both sides of the upper trapezius muscle, followed by MET, which will also be performed bilaterally. The detailed method of performing the applied therapeutic techniques for the combined procedure will be identical as in the case of isolated (single) methods.
223715258|NCT04384146|RADIATION|Cyclical Hypofractionated Palliative Radiation (Quad Shot)|3.7 Gy twice daily x 2 days for a total dose of 14.8 Gy per cycle. The next cycle will occur after a 21-28 day break.
223715259|NCT04384146|BEHAVIORAL|EORTC QLQ-C30 questionnaire|at baseline, each cycle of Quad Shot, and at 3 weeks, 3 months and 6 months after last cycle of Quad Shot.
223715260|NCT00585143|DRUG|ABT-335|45 mg once daily for 10 consecutive days
223715261|NCT00585143|DRUG|Rosuvastatin|10 mg once daily for 10 days
223715262|NCT04974840|BEHAVIORAL|Treadmill training combined with/ without thera-band|Treadmill walking training with thera-band Treadmill walking training without thera-band
223715263|NCT04240769|DEVICE|Total or Partial Knee Arthroplasty|Reconstruction of part or all of the native articulation at the knee joint via implant.
223715264|NCT05043506|DRUG|Palbociclib + aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
223715265|NCT05043506|DRUG|Aromatase inhibitor|Aromatase inhibitor monotherapy
223715266|NCT04535648|OTHER|Non-invasive detection method: CRISPR techonology|This study was a laboratory diagnostic study without any intervention.
223900849|NCT05971381|DEVICE|RECELL® Autologous Cell Harvesting Device|The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
223900850|NCT05906095|BEHAVIORAL|LOCK Falls Program|The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
223900851|NCT06685211|DEVICE|Eyetronic rtACS|The repetitive, transorbital alternating current stimulation (rtACS) is a device for non-invasive Interventional Neurophysiology. The electrical charge and current density applied during rtACS safe and able to modulate existing neuronal elements in the eye and brain.
223900852|NCT06685211|DEVICE|Sham rtACS|Participants will wear the Eyetronic system but there will be no active stimulations applied.
223900853|NCT04591275|DRUG|CMAB807 Injection|mAb targeting RANKL, human monoclonal antibody targeting RANKL
223900854|NCT04591275|DRUG|Prolia®|mAb targeting RANKL, human monoclonal antibody targeting RANKL
223900855|NCT03987399|OTHER|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
223900856|NCT04680468|DRUG|Belantamab mafodotin|2.5 mg/kg IV
223900857|NCT06779526|OTHER|Heartfulness Meditation|Receiving an orientation session regarding the study, attending once weekly didactic sessions on Zoom for Heartfulness Meditation, and participating in morning and evening meditation for ten to fifteen minutes daily either by themselves or along with the trainer.
223900858|NCT00070590|DRUG|Bosentan|
223900859|NCT05590351|BEHAVIORAL|First diet: m-health coaching application|Intervention for the study would comprise of a culturally appropriate m-health application called first diet. This application will be developed considering the perceptions, barriers and facilitators identified through formative research. Content of the messages would focus on breastfeeding, its importance and early initiation within one hour of birth, significance of first feed i.e. colostrum, importance of EBF from birth till 6 months, introduction of complementary feeding to 6-8 months old infants and appropriate YCFP. These messages would be drafted in the local preferable language assessed during formative research. The content of the messages would be translated and then back translated to ensure validity. These messages will be short, contextual and tailored according to the women's stage of gestation, delivery and infant's age
223900860|NCT05590351|BEHAVIORAL|Face to Face counselling|Women randomly enrolled in the non-interventional group will receive face-face nutritional counseling instead of mobile application. Once enrolled in the group, Research Assistant (RA) will collect relevant details on the baseline questionnaire like intervention group but on a paper-based questionnaire. Women will be given first face-face counseling on the day of enrollment. The counseling sessions will coincide with the routine vaccination and growth monitoring schedule of the infant after women deliver
223900861|NCT02416258|DRUG|LP0113 aerosol spray|
223900862|NCT02416258|DRUG|Aerosol spray vehicle|
223900863|NCT02416258|DRUG|LEO 90100 aerosol foam|
223900864|NCT02416258|DRUG|Betamethasone dipropionate aerosol spray|
223900865|NCT02416258|DRUG|Calcipotriol aerosol spray|
223900866|NCT02416258|DRUG|Daivobet® gel|
223900867|NCT05631223|BEHAVIORAL|Telemedicine|The intervention will consist of two structured telemedicine visits delivered between two routine office visits and conducted by providers (nurse practitioners and clinical nurse specialists).
223900868|NCT04880863|DRUG|NAP (Naptumomab estafenatox)|Naptumomab estafenatox (NAP; ABR-217620) is a recombinant fusion protein consisting of a chimeric staphylococcal enterotoxin A/E (SEA/SEE) superantigen with several additional substitutions that are linked to a Fab moiety recognizing a tumor-associated glycoprotein, 5T4. NAP is administered at a dose of 10 μg/kg/day by IV bolus on Days 1 - 4 of treatment cycles 1-6. Starting cycle 7, NAP at a higher dose of 15 μg/kg is administered on Day 1.
223900869|NCT04880863|DRUG|Docetaxel|Docetaxel is administered in combination with the study drug, NAP, on Day 5 of the treatment cycles 1-6. Starting cycle 7, Docetaxel is administered in combination with the study drug, NAP, on Day 2.
223900870|NCT04880863|DRUG|Obinutuzumab|Obinutuzumab is administered as pre-medication on Day -13 and -12 of the first treatment cycle.
223900871|NCT04539587|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~EORTC QLQ-C30 EORTC QLQ-BR23 EORTC SHQ-C22"
223900872|NCT04822363|DRUG|Aspirin|Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B
223900873|NCT04822363|DRUG|Clopidogrel|Arms C and E
223900874|NCT03213691|OTHER|Laboratory Biomarker Analysis|Correlative studies
223900875|NCT03213691|DRUG|Selumetinib|Given PO
223900876|NCT03213691|DRUG|Selumetinib Sulfate|Given PO
223900877|NCT01006239|OTHER|No study intervention|The is no study related intervention.
223900878|NCT04757363|DRUG|regorafenib|regorafenib (80 mg on days 1-21 of the 28-day cycle)
223900879|NCT04757363|DRUG|nivolumab|nivolumab (240 mg on days 1 and 15 of the 28-day cycle).
223900880|NCT04757363|DRUG|FOLFOX chemotherapy with oxaliplatin|FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
223900881|NCT04144023|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
223900882|NCT04144023|BIOLOGICAL|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
223900883|NCT04144023|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223900884|NCT04144023|PROCEDURE|Echocardiography|Undergo ECHO
223900885|NCT04144023|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223900886|NCT04144023|PROCEDURE|Biopsy|Undergo biopsy
223900887|NCT04898673|DEVICE|CP1110|Sound Processor
223900888|NCT04898673|DEVICE|CP1000|Sound Processor
223900889|NCT02862210|DRUG|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
223900890|NCT02862210|DRUG|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
223900891|NCT04437264|DIETARY_SUPPLEMENT|Intermittent feed participant|Patients will be assigned to receive intermittent enteral feeding protocol. They will receive four equal volume feeds at 8:00, 12:00, 16:00, and 20:00 hours.
223900892|NCT04437264|DIETARY_SUPPLEMENT|Continuous feeds participant|Patients will be assigned to receive continuous enteral feeding protocol. Typical goal rates are in the range of 60 to 80 mL per hour for 24 hours per day.
223900893|NCT02587403|DEVICE|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
223900894|NCT02587403|DEVICE|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
223900895|NCT01152450|DRUG|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
223900896|NCT01152450|DRUG|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
223900897|NCT01152450|DRUG|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
223900898|NCT06419621|DRUG|PM8002|PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
223900899|NCT06419621|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
223900900|NCT06419621|DRUG|Placebo|Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
223900901|NCT06361056|BEHAVIORAL|Survey|All participants will complete a brief questionnaire.
223900902|NCT06361056|BEHAVIORAL|mHealth app|Eighty Black women with newly diagnosed breast cancer (inclusive of all stages) and who have access to a mobile device or computer will be recruited to the study intervention.
223900903|NCT04866888|PROCEDURE|closure of the uterine wall defect|Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.
223900904|NCT04866888|DIAGNOSTIC_TEST|ultrasound|"Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects.~After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded."
223900905|NCT04866888|DIAGNOSTIC_TEST|outpatient hysteroscopy|Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.
223900906|NCT06407037|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the lateral decubitus position. 30 ml of 0.25% bupivacaine will be used in applications.
223900907|NCT06407037|PROCEDURE|Serratus Posterior Superior Intercostal Plane Block|Serratus Posterior Superior Intercostal Plane Block will be performed unilaterally, under US guidance, before the surgical operation, when the patient is placed in the lateral decubitus position. 30 ml of 0.25% bupivacaine will be used in applications.
223900908|NCT06066125|DRUG|AK111|AK111 regimen 1- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
223900909|NCT06066125|DRUG|AK111|AK111 regimen 2- subcutaneous injection at week 0,1,2, 3,4 and every 4 weeks thereafter until week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
223900910|NCT06066125|DRUG|Placebo|Placebo- subcutaneous injection at week 0,1,2, 3, 4 and week 8. AK111 regimen 2-subcutaneous injection every 4 weeks from week 12 to week 48. The primary endpoint will be evaluated at week 12 and followed up to week 56.
223900911|NCT05648591|DRUG|Iloperidone|oral tablet
223900912|NCT05778695|DIETARY_SUPPLEMENT|Ketone Ester (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate|Ketone ester (KE) dietary supplement (KetoneAid)
223900913|NCT04974138|DRUG|Amlodipine besylate|The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
223900914|NCT04974138|DRUG|Amlodipine besylate and folic acid|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).
223528670|NCT05971407|DEVICE|Remote Ischaemic Preconditioning|RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
223528671|NCT05971407|DEVICE|Sham Remote Ischaemic Preconditioning|Sham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks. Clinic blood pressure is measured at weeks 0, 3 and 6. 24-hour blood pressure is measured at weeks 0 and 6.
223900915|NCT04974138|DRUG|Amlodipine placebos|An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.
223900916|NCT04974138|DRUG|Amlodipine-folic acid placebos|An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
223900917|NCT01544114|DRUG|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
223900918|NCT01544114|DRUG|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
223900919|NCT01544114|DRUG|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
223900920|NCT04649476|DRUG|Camrelizumab|The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.
223900921|NCT04649476|DRUG|Camrelizumanb plus TPF|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
223900922|NCT04517487|BIOLOGICAL|Vaginal Microbiome Transplantation (VMT)|Healthy donors vaginal fluid is introduced into recipients' vagina to replace their indigenous disease-associated microbiome
223900923|NCT04517487|BIOLOGICAL|Placebo|Placebo
223900924|NCT05741372|DRUG|Rosuvastatin|Rosuvastatin
223900925|NCT05741372|DRUG|Digoxin|Digoxin
223900926|NCT05741372|DRUG|Metformin hydrochlorid|Metformin hydrochloride
223900927|NCT05741372|DRUG|Furosemide|Furosemide
223900928|NCT04601987|BEHAVIORAL|Breastfeeding|Counseling about the maternal health benefits of lactation.
223900929|NCT04601987|BEHAVIORAL|Smokefree Homes|Counseling about the importance of smoke-free homes.
223900930|NCT06591026|BEHAVIORAL|Standard Helpline (SH)|One digital helpline session that includes assessment, psychoeducation, and links to resources. Participants are also offered ongoing asynchronous digital support from the helpline.
223900931|NCT06591026|BEHAVIORAL|Motivational Interviewing (MI)|One digital helpline session that includes a structured motivational interviewing brief intervention.
223900932|NCT06591026|BEHAVIORAL|Coping Skills Training (CST)|One digital helpline session that includes a structured cognitive coping skills brief intervention.
223900933|NCT06591026|BEHAVIORAL|Automated Text Messaging (ATM)|Automated text messages are sent daily for 4 weeks.
223900934|NCT06225310|DRUG|Selinexor|Selinexor (KPT-330) is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in t
223528672|NCT04983394|OTHER|Virtual Realty Exercises|motion-controlled video game
223528673|NCT04983394|OTHER|conventional exercises|aerobic, strength, stretching, and neuromuscular exercises
223900935|NCT06225310|DRUG|Ruxolitinib|elective inhibitor of Janus kinase (JAK)
223528674|NCT03270982|DEVICE|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
223900936|NCT06225310|DRUG|Methylprednisolone|Glucocorticoid, steroid
223900937|NCT06823674|OTHER|core endurance test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
223900938|NCT06823674|OTHER|cervical stabilization test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
223900939|NCT06823674|OTHER|cervical proprioception test|The study group was selected from women who did pilates exercises 2 days a week for at least 12 weeks under the supervision of a physiotherapist, while the control group was selected from women who did not participate in any pilates, yoga or exercise program in the last 1 year and were sedentary according to the International Physical Activity Questionnaire. Lateral Bridge Test, Static Trunk Extension Test, Trunk Flexors Endurance Test, Cervical Joint Position Error Test, Cervical Region Deep Flexor Muscle Endurance Tests were applied to the participants and Craniocervical Flexion data of the participants were evaluated with Stabilizer Pressure Biofeedback Device.
223900940|NCT06608394|OTHER|no intervention|no intervention
223900941|NCT06823986|DEVICE|Retraction of anterior teeth by putting miniscrews and power arm|Enmasse retraction of upper anterior teeth after extraction of upper first permanent premolar on miniscrews and power arm
223900942|NCT06823986|DEVICE|Retraction of upper anterior teeth by putting miniscrews and welded hooks in main wire arch|Enmasse retraction of upper anterior teeth after extraction of upper first permanent premolars on miniscrews and welded hooks in main wire arch
223900943|NCT06696924|OTHER|Reciprocal inhibition|First Subjects will start doing baseline warmup exercises which are mentioned then they will perform reciprocal inhibition of the serratus muscle in supine or side-lying. After identifying the antagonist muscles of the serratus anterior, which are typically the rhomboids or the middle and lower trapezius. Athletes will perform a gentle contraction of the antagonist's muscles by retracting or squeezing their shoulder blades together. While the antagonist muscles are contracting, we will ask the athlete to simultaneously relax and lengthen the serratus anterior muscle. The patient can achieve this by protracting or pushing their shoulder blades forward and away from each other.
224083469|NCT00775489|DRUG|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
224083470|NCT00775489|DRUG|Saline|control group will receive normal saline inhaler
223528675|NCT02958865|DRUG|PF-06651600 or Placebo|Delivered orally for 8 weeks.
223528676|NCT02958865|DRUG|PF-06700841 or Placebo|Delivered orally for 8 weeks.
223528677|NCT02958865|DRUG|PF-06700841|Delivered orally for 24 weeks.
223528678|NCT02958865|DRUG|PF-06651600|Delivered orally for 24 weeks.
223900944|NCT06696924|OTHER|Static stretching|"Subjects will perform 2 stretches~1. Standing Wall Stretch: Stand facing a wall with your feet about hip-width apart. Place their palms on the wall at shoulder height, slightly wider than shoulder-width apart. will Lean their body forward, keeping their arms straight, until feel a stretch in their serratus anterior. Hold the stretch for 15 to 30 seconds, then slowly release. Instead of using a wall or object, the athlete will use their opposite hand to hold the stretched arm in position.~2. Seated Cross-Body Stretch: Sit on the edge of a chair or bench. Cross one arm over your chest, placing your hand on the opposite shoulder. The athlete will use the other hand to gently pull the crossed arm closer to your body, feeling a stretch in the serratus anterior. Hold the stretch for 15 to 30 seconds or more, and then switch sides and repeat."
223900945|NCT06238076|DEVICE|Universal surgical device FIBUMAND|This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
223900946|NCT06540911|OTHER|Personalized physical back training program|The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.
223900947|NCT06540911|OTHER|Non-personalized physical back training program|The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
223900948|NCT04223505|DIAGNOSTIC_TEST|Contrast enhanced ECG-gated cardiac CT (CCT)|Contrast enhanced ECG-gated cardiac CT (CCT) is a sensitive, noninvasive alternative method used to exclude of left atrial and LAA thrombus. CCT provides high spatial and good temporal resolution and its ability to detect thrombus has been evaluated. CCT, compared to TEE, for the exclusion of thrombus in the LAA had a sensitivity and specificity of 100% and 99.3%, respectively. A high sensitivity is needed to minimize risk of embolus, and if a thrombus is detected on CT, a confirmatory TEE may be performed or patients may receive anticoagulation. Some argue that the potential benefits of CT and its lower associated procedural risk, the risk:benefit ratio would still favour CT.
223900949|NCT04223505|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|TEE is considered the reference standard to rule-out left atrial (LA) and left atrial appendage (LAA) thrombus prior to cardioversion. Several studies have examined the accuracy of TEE for detecting LAA thrombus. Compared to autopsy and intraoperative findings, TEE has a mean sensitivity of 100% and mean specificity of 99%. Although the gold standard, a TEE-guided therapy is still associated with an embolic rate of 0.8%.
223900950|NCT03096028|OTHER|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
223900951|NCT06370000|DRUG|Oral Azacitidine|Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.
223900952|NCT06778369|PROCEDURE|traingular exclusion technique in mitral valve repair|The prolapsed part of the posterior leaflet is inverted and excluded, not resected toward the left ventricle, and the margins of the prolapsed part are sutured to each other's using proline 5/0, extending from the posterior leaflet edge to the posterior annulus. Then the posterior annulus is reinforced with an annuloplasty band using a treated strip of pericardium. The determination of suitable ring size is subsequently predicated upon the assessment of inter-commissural distance surface area and the anterior leaflet, utilizing sizers that are correlated with typical mitral geometry.
223900953|NCT06536140|OTHER|Home observations and interview|"If persons want to participate, the person will be invited one week before the first observation for a 'warm-up' phone call (W1) as a preparation for the three observations and follow-up interview.~During the observations, SH will be an active participant, offering to help with activities of daily life with the person, so opportunities are created to observe and ask questions (sensory ethnography). The person will be asked to take pictures or make drawings of important things in the house as the observer will be able to better understand how they feel about exercise and PA (visual ethnography). Six weeks after the last observation (W10), formal follow-up interviews (30-60 min) with questions based on the observations that took place, will be held to explore specific issues in-depth."
223900954|NCT06518122|DRUG|HCP1306|Take it once a day per period.
223900955|NCT06518122|DRUG|RLD2302|Take it once a day per period.
223900956|NCT06518122|DRUG|RLD2102|Take it once a day per period
223715267|NCT03323710|DRUG|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
223715268|NCT03323710|DRUG|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
223715269|NCT04590222|OTHER|blood sample|One blood sample of 60 mL (EDTA)
223900957|NCT06779344|OTHER|MxA and CRP tests|A whole blood sample will be collected on the day of randomization for MxA and CRP testing.
223900958|NCT06779344|OTHER|MxA and CRP feedback|MxA and CRP results will be reported to the attending physcian within 4 hours, along with antimicrobial treatment guidelines based on these results.
223900959|NCT06779344|OTHER|Follow up|"Telephone visit will be conducted on Day 14, Day 30, and Day 90 after randomization.~Day 14 and Day 30 follow-up: antimicrobial usage; additional medical visits, hospitalization, death, symptom scores (CAT score and mMRC score).~Day 90 follow-up: Occurrence of another exacerbation of COPD, symptom scores (CAT score and mMRC score), death."
223900960|NCT03058289|DRUG|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations."
223900961|NCT03058289|BIOLOGICAL|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
223900962|NCT03058289|BIOLOGICAL|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
223715270|NCT06428669|DRUG|Nitro-Bid 2 % Topical Ointment|Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
223715271|NCT00913497|DRUG|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
223715272|NCT00913497|DRUG|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
223715273|NCT04284670|OTHER|EXERCISE|The intervention group will perform an 8 week program, 2 sessions a weak for a total of 16 sessions. training will be done on a designated negative gradient treadmill, first two session will be in -5% gradient. sessions 3,4 and 5 will be in -10% gradient, all of the following sessions will be in -15% gradient. exercise intensity will be 70%-80% out of maximal heart-rate. Session length will gradually increase by one minute each training, starting from 10 minutes at the first session, up to 25 minutes on final sessions. each training will start and end with a 2 minutes of warm up and calm down under neutral gradient. Every two minutes of training, Visual Analog Scale and Rating of Perceived Exertion data will be collected from the participants.
223715274|NCT02087397|OTHER|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
223715275|NCT02087397|BIOLOGICAL|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
223715276|NCT03197597|OTHER|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
223715277|NCT00611208|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
223715278|NCT05152914|DRUG|Cerliponase Alfa|Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
223715279|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pilot (two iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screen Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
223715280|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Pre-Injury (one iteration)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
223715281|NCT05111925|OTHER|PREPARE Initial Clinical Assessment - Post-Injury (up to three iterations)|"Participants will complete a comprehensive set of clinical assessments that includes semi-automated field-expedient functional movement quality, joint ranges of motion, and psychosocial assessments. Participants will also report thee most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
223715282|NCT05111925|OTHER|PREPARE Optimized Clinical Assessment|"Participants will complete an optimized set of clinical assessments that may include semi-automated field-expedient functional movement quality, joint ranges of motion, and/or psychosocial assessments. Participants will also report the most recent scores received on the appropriate service-specific physical fitness assessment.~Functional movement quality assessments:~* Two-Minute Walk~* Gait~* Double Leg Squat~* Single Leg Squat~* Jump-Landing~* Single Leg Triple Hop~* Closed Kinetic Chain Upper Extremity Stability Test~* Functional Movement Screening Shoulder Clearing Test~* Prone Plank~* Active Hip Abduction~Joint range of motion assessments:~* Knee Extension~* Hip Abduction~* Hip Internal Rotation~* Hip External Rotation~* Ankle Dorsiflexion~Psychosocial assessments:~* NIH PROMIS Physical Function, Pain Interference, Depression, \& Anxiety~* Tampa Scale of Kinesiophobia"
223715283|NCT01172262|PROCEDURE|MRI|This is an observational study, no intervention will occur.
223715284|NCT06454019|BEHAVIORAL|Phone Outreach|Phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
223715285|NCT06454019|BEHAVIORAL|Standard Notice|Standard notification letter without phone outreach to individuals losing Medicaid and auto-enrolled into Covered California plan to nudge them to act
223715286|NCT02002091|OTHER|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
223715287|NCT00003870|DRUG|cyclophosphamide|
223715288|NCT00003870|DRUG|methotrexate|
223715289|NCT00003870|PROCEDURE|allogeneic bone marrow transplantation|
223715290|NCT00003870|RADIATION|iodine I 131 monoclonal antibody BC8|
223715291|NCT00003870|RADIATION|radiation therapy|
223715292|NCT04862455|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally/intranodally
223715293|NCT04862455|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
224276796|NCT03895619|OTHER|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
223900963|NCT05294042|OTHER|Navigation|The intervention in this study is a model of navigation for families seeking services at the two mental health agencies collaborating on this study. Navigators will implement a model of navigation with caregivers focused on reducing logistical and attitudinal barriers to care.
224276797|NCT00623636|DRUG|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
224276798|NCT00623636|DRUG|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
224276799|NCT00879541|BIOLOGICAL|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
223715294|NCT04862455|BIOLOGICAL|Pembrolizumab|Given IV
223528679|NCT02661815|DRUG|Paclitaxel|Please see arm/group description.
223528680|NCT02661815|DRUG|Ricolinostat|Please see arm/group description.
223528681|NCT02661815|DRUG|Bevacizumab|Please see arm/group description.
223528682|NCT03591159|OTHER|Membran Sweeping|Cervical Membrane Sweeping by digital examination
223528683|NCT00374179|DRUG|CT-322|IV solution, weekly or bi-weekly
223528684|NCT02247921|OTHER|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
223528685|NCT04869397|BIOLOGICAL|Allogeneic Wharton's jelly-MSCs (WJ-MSC)|"The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes."
223528686|NCT04869397|OTHER|Placebo|Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
223528687|NCT03470051|DIAGNOSTIC_TEST|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
223528688|NCT05836909|DIETARY_SUPPLEMENT|Swisse plus cholesterol capsule|Swisse plus cholesterol capsule per day orally for 12 weeks
223528689|NCT05836909|DIETARY_SUPPLEMENT|Placebo|Placebo
223528690|NCT04743232|OTHER|Decision tool for clinicians|Clinical decision aid, using a structured approach to advanced care directives and a comprehensive view of available risk scores.
223528691|NCT05068583|OTHER|Blood Draw|Blood draw at baseline, disease evaluation time point, and pre and post surgery and/or radiation.
223528692|NCT02102945|PROCEDURE|Computed tomography perfusion|Computed tomography perfusion of the head
223528693|NCT02340195|DRUG|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
223528694|NCT05005533|OTHER|Observational|Chronic Obstructive Pulmonary Disease Severity of Individuals by Chronic Obstructive Pulmonary Disease Assessment Test, shortness of breath Modified Medical Research Council scale, cough related quality of life Leicester Cough Questionnaire, respiratory muscle strength with Maximum Inspiratory and Expiratory Pressure, Posture with Spinal Mouse device, pain with Visual Analog Scale, severity of fatigue Fatigue Physical performance of the lower extremities will be evaluated with the Short Physical Performance Test, functional mobility will be evaluated with the Time Up and Go Test, and balance will be evaluated with the Biodex Balance System
223528695|NCT03005002|BIOLOGICAL|Durvalumab|Given IV
223528696|NCT03005002|OTHER|Laboratory Biomarker Analysis|Correlative studies
223528697|NCT03005002|BIOLOGICAL|Tremelimumab|Given IV
223528698|NCT02329587|OTHER|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
223528699|NCT02329587|OTHER|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
223528700|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement with a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink with cooling sensation flavour
223528701|NCT06250426|DIETARY_SUPPLEMENT|Pre-thickened oral nutritional supplement without a cooling sensation flavour|Pre-thickened oral nutritional supplement (ONS) drink without cooling sensation flavour
223528702|NCT05293262|PROCEDURE|Endourological surgery|Includes ureteral stent insertion, ureteroscopies and retrograde intrarenal surgeies
223528703|NCT02010268|OTHER|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
223528704|NCT04078243|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
223528705|NCT01728246|DRUG|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
223900964|NCT06182527|DEVICE|Free Style Libre Pro IQ|Every participant receives a Free Style Libre Pro IQ sensor for 14 days. Glucose levels will be recorded.
223900965|NCT06704204|DRUG|The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks|To date, there have been no studies looking at the use of LAI ART among justice involved PWH, yet a significant opportunity exists to improve HIV treatment outcomes in this high risk population.30
223900966|NCT05436314|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.
223900967|NCT05436314|DRUG|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
223900968|NCT05436314|OTHER|Sham Manual Lymphatic Drainage|Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
223900969|NCT02240862|DEVICE|Carotid Artery Stent|Placement of a stent within the carotid artery
223900970|NCT06667739|BEHAVIORAL|IMPACT-L3|The intervention is a physical activity behaviour change intervention: IMproving Physical Activity through Coaching and Technology following Lower Limb Loss (IMPACT-L3). Two theories provide a framework for IMPACT-L3. One is social cognitive theory and the other is self-determination theory. As mHealth solutions have the potential to increase access and improve health outcomes, IMPACT-L3 will be delivered entirely virtually.
223900971|NCT06344026|BIOLOGICAL|ANPD001|Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
223900972|NCT06344026|DEVICE|Custom Device|A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance
223900973|NCT06261671|DRUG|antioxidants-enriched culture medium (Gx)|Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
223900974|NCT01799265|DEVICE|Somnetics Transcend Auto|
223900975|NCT01799265|DEVICE|Respironics REMstar Auto with C-Flex|
223900976|NCT06389565|BEHAVIORAL|Problem Solving Therapy|Problem solving therapy (PST) is a cognitive-behavioral therapy (CBT)-based intervention that uses seven basic steps to teach problem solving orientation and skills to equip individuals to manage the impact of stressful life events on their mental health.
223900977|NCT06389565|OTHER|Change My Story|Change My Story is a narrative game with a choose-your-own-adventure format in which players navigate emotionally difficult experiences along with the character(s) and interact with the virtual environment to choose a narrative path toward the story's conclusion. It will used to address important obstacles in the mental health treatment gap for Y-PLWH.
223900978|NCT04068246|DRUG|Metformin|1000 mg of Metformin table taken orally daily plus Methotrexate 7.5 mg weekly
223900979|NCT04068246|DRUG|Placebo|Placebo tablet plus plus Methotrexate 7.5 mg weekly
223900980|NCT06492746|DEVICE|HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring|The arterial line with Acumen IQ sensor and Foresight Elite sensor will be connected to the HemoSphere monitor with laptop displaying the CAI parameter.
223528706|NCT01728246|DRUG|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
223528707|NCT00773188|DRUG|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
223528708|NCT00773188|DRUG|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
223528709|NCT00773188|DRUG|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
223900981|NCT06964633|BEHAVIORAL|Kūkākūkā Discussion Sessions|Participants attend a single 2-hour, flip-chart-guided module that integrates a focused health topic (e.g., colorectal cancer screening) with Hawaiian cultural teachings-beginning with an 'ōlelo no'eau (proverb) and guided by trained facilitators-to foster peer discussion, deliver key health information, and assess knowledge via pre- and post-test surveys.
223900982|NCT06067750|DIAGNOSTIC_TEST|Narcotrend compared to Cerebral Function Analysing Monitor (CFAM)|All patients will receive Narcotrend and CFAM monitoring in this observational study
223900983|NCT05251909|BIOLOGICAL|Benralizumab|Benralizumab is a humanized, afucosylated, monoclonal antibody that binds specifically to the IL-5Rα on the target cell and thus directly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab has been widely approved for treatment of asthma.
223900984|NCT05251909|BIOLOGICAL|Placebo|Placebo will be injected as a comparator to injection with Benralizumab to examine effect on both the signs and symptoms of EG/EGE and the underlying eosinophilic inflammation, with dual primary outcome variables
223528710|NCT00502918|DEVICE|CLM - HA Continuous Monitoring System Heart Application|
223528711|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
223528712|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
223528713|NCT03633006|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
223528714|NCT04747041|COMBINATION_PRODUCT|CYSCONTROL/PHYTOCYST Herbal tea|Alternating every month from Day1 to Day15 cyscontrol and phytocyst herbal tea to prevent episode of cystitis
223900985|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
223900986|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
223900987|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
223900988|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 2|Participants will use their Radicle Energy Placebo Control Form 2 as directed for a period of 6 weeks.
223900989|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 2.1 Usage|Participants will use their Radicle Energy Active Study Product 2.1 as directed for a period of 6 weeks.
223900990|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 3|Participants will use their Radicle Energy Placebo Control Form 3 as directed for a period of 6 weeks.
223900991|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 3.1 Usage|Participants will use their Radicle Energy Active Study Product 3.1 as directed for a period of 6 weeks.
223900992|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 4|Participants will use their Radicle Energy Placebo Control Form 4 as directed for a period of 6 weeks.
223900993|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.1 Usage|Participants will use their Radicle Energy Active Study Product 4.1 as directed for a period of 6 weeks.
223900994|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.2 Usage|Participants will use their Radicle Energy Active Study Product 4.2 as directed for a period of 6 weeks.
224083471|NCT05876403|OTHER|Conventional|The participants of controlled group will be given the treatment protocol after baseline measurements controlled breathing techniques (3session per week 10mins for 6 weeks) \& Aerobic exercise(3 session per week for 6 weeks) with 10sec hold into 10reps.outcome measures will be recorded through a digital spirometer \& measurement of 6MWT \& chest expansion.
224276800|NCT00879541|BIOLOGICAL|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
224276801|NCT00879541|BIOLOGICAL|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
224276802|NCT04692584|BEHAVIORAL|The Lullaby Group|"Approximately 15 seconds before the vaccination, each baby's mother began to sing a lullaby. Infant's mother continued to sing lullabies until all the vaccinations, which were given immediately after the BCG vaccination, were completed. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure. All the mothers sang the same lullaby, Sleep and Grow. Mothers were reminded of the words to the lullaby before vaccine administration."
224276803|NCT00784979|DRUG|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
224276804|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching)
224276805|NCT04954690|BEHAVIORAL|Structured Program of exercise for Recipients of Kidney Transplantation (WC + CG)|Structured Program of exercise for Recipients of Kidney Transplantation (weekly coaching + caregiver participation)
224276806|NCT04954690|BEHAVIORAL|Usual Care|Usual Care
223715295|NCT04862455|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223715296|NCT06245031|DEVICE|Sensory Stimulation System (GS120) - Active|Sensory Stimulation System (GS120) - Active settings
223715297|NCT02846714|BEHAVIORAL|FLARE|
223715298|NCT03385564|DRUG|BI 655064|subcutaneous injection
223715299|NCT03385564|DRUG|Placebo|subcutaneous injection
223715300|NCT05210907|BIOLOGICAL|SNUH-CD19-CAR-T|SNUH-CD19-CAR-T is an autologous CAR-T from T cells collected from each patient. Administer a single dose of SNUH-CD19-CAR-T to patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukemia, and evaluate safety and efficacy of SNUH-CD19-CAR-T for 12 months after the infusion.
223715301|NCT00557128|DRUG|COREG CR and lisinopril (FDC)|
223715302|NCT04470323|DIAGNOSTIC_TEST|Flow cytometry|Lymphocyte subsets in peripheral blood were assessed by staining 50 µl of blood sample with 5 µl of Fluoroisothiocyanate (FITC)-conjugated- PD-1, phycoerythrin (PE)-conjugated-CD8, peridinium-chlorophyll-protein (Per-CP)-conjugated-CD4, Peridinium-chlorophyll-protein (Per-CP)-conjugated anti-CD3 and allophycocyanin (APC) conjugated anti-CD28.
223715303|NCT01389388|DRUG|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
223715304|NCT01146834|DRUG|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
223715305|NCT01146834|DRUG|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
223715306|NCT01146834|DRUG|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
223715307|NCT01146834|DRUG|Plerixafor|plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
223715308|NCT03582189|OTHER|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
223715309|NCT01443208|DRUG|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
223715310|NCT01443208|DRUG|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
223715311|NCT01443208|DRUG|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
223715312|NCT01234441|DIETARY_SUPPLEMENT|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
223900995|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 4.3 Usage|Participants will use their Radicle Energy Active Study Product 4.3 as directed for a period of 6 weeks.
223900996|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.1.0|Participants will use their Radicle Energy Placebo Control Form 5.0 as directed for a period of 6 weeks.
223900997|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.1.1 Usage|Participants will use their Radicle Energy Active Study Product 5.1.1 as directed for a period of 6 weeks.
223900998|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.3.0|Participants will use their Radicle Energy Placebo Control Form 5.3 as directed for a period of 6 weeks.
223900999|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.3.1 Usage|Participants will use their Radicle Energy Active Study Product 5.3.1 as directed for a period of 6 weeks.
223901000|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.3.2 Usage|Participants will use their Radicle Energy Active Study Product 5.3.2 as directed for a period of 6 weeks.
223901001|NCT06201689|DIETARY_SUPPLEMENT|Energy Placebo Control Form 5.2.0|Participants will use their Radicle Energy Placebo Control Form 5.2 as directed for a period of 6 weeks.
223901002|NCT06201689|DIETARY_SUPPLEMENT|Energy Active Study Product 5.2.1 Usage|Participants will use their Radicle Energy Active Study Product 5.2.1 as directed for a period of 6 weeks.
223901003|NCT05543915|DEVICE|Active tDCS|The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
223901004|NCT06772220|DIETARY_SUPPLEMENT|Folic Acid 1 MG|Folic Acid 1mg per day
223901005|NCT06772220|DIETARY_SUPPLEMENT|Vitamin B6 25 MG|Vitamin B6, 25mg per day
223901006|NCT06772220|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12, 1,000 ug per day
223901007|NCT03792763|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
223901008|NCT03792763|DRUG|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
224276807|NCT05995379|DIAGNOSTIC_TEST|Donor-derived cell-free DNA|"Cell-free DNA (cfDNA) is fragmented extracellular DNA released in the bloodstream from cells undergoing apoptosis or necrosis. In transplantation, donor-derived cfDNA (dd-cfDNA) is detected in the blood of kidney recipients and has been proposed as a noninvasive biomarker to detect rejection.~One additional blood sample will be collected and dd-cfDNA levels will be centrally analyzed."
223901009|NCT06487182|OTHER|reiki|reiki
223901010|NCT06487182|OTHER|placebo reiki|placebo reiki
223901011|NCT05756985|PROCEDURE|Specimen Collection|Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
223901012|NCT03381196|DRUG|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).
224276808|NCT05484141|OTHER|Rehabilitation with blood blow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
223901013|NCT03381196|DRUG|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
223901014|NCT03381196|OTHER|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
224276809|NCT05484141|OTHER|Rehabilitation without blood flow restriction|The rehabilitation program will be applied 2 days a week, for total of 8 weeks.
224276810|NCT00004441|DRUG|tauroursodeoxycholic acid|
223901015|NCT05058560|DRUG|Tislelizumab|tislelizumab, 200 mg IV Q3W, up to one year.
224276811|NCT00004441|DRUG|ursodiol|
224276812|NCT01198249|DRUG|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
223528715|NCT05708859|DRUG|Tirzepatide|Tirzepatide 15mg Subcutaneous Solution
223528716|NCT05708859|DRUG|Placebo|Volume matched Subcutaneous Solution
223901016|NCT05689515|BEHAVIORAL|Mobile health app|A mobile app provided to participants to assess effectiveness in managing HIV
223901017|NCT06211413|OTHER|no intervention|no intervention
223901018|NCT06801977|GENETIC|Genome-wide genotyping|Whole blood from the participants was used to extract DNA for genotyping.
223901019|NCT05560971|DIETARY_SUPPLEMENT|Palmitoleic acid|Participants will be randomized to either POA or placebo and will be asked to take 2 capsules of the POA or placebo twice a day for 8 weeks.
223901020|NCT05560971|OTHER|Placebo|Medium chain fatty acids in triglyceride form in capsules with the same shape, color, size and odor of POA capsules
223901021|NCT06798168|BIOLOGICAL|Combining bacteriophage therapy with antibiotics for a case with hip PJI|The treatment plan is to treat the patient with weekly intra-articular injections of a personalized phage therapy cocktail (QDP-PSA-011) for 3 consecutive weeks. This will be associated with antibiotics for 6 weeks.
223901022|NCT05260112|OTHER|ERICA|"Over 6 weeks, participants receive evidence-based video learning modules twice a week via a secure and HIPAA-compliant text messaging platform. These modules include: patient education on interstitial cystitis, bladder training, trial of an elimination diet, pelvic floor physical therapy including at-home myofascial trigger point release, guided mindfulness practice, and cognitive behavioral therapy for chronic pain.~At the end of each week, participants receive a check-in message. They also have the opportunity to text questions and concerns, which will be answered using an algorithm-based, clinically validated responses."
223901023|NCT06800560|OTHER|MenoScale|Menopause symptom questionnaire
223901024|NCT06800560|OTHER|Greene Climacteric Scale|Menopause symptom questionnaire
223901025|NCT06800560|OTHER|RAND 36-Item Health Survey 1.0|Quality of life questionnaire
223901026|NCT06800560|OTHER|PREDICT-FFQ-v1|Food frequency questionnaire
223901027|NCT06803420|DEVICE|Portable, ultra-low-field MRI scanner|"This study evaluates a portable, ultra-low-field MRI scanner (the Hyperfine Swoop) combined with artificial intelligence (AI) to detect brain abnormalities.~Patients undergoing a standard brain MRI scan will be invited to have an additional portable MRI scan within 30 days of their clinical scan. The portable MRI scan will take approximately 60 minutes, using multiple imaging sequences, including T2-weighted scans.~The AI system will then analyse the portable MRI images and categorise them as normal or abnormal. The results will be compared with expert neuroradiologist reports from standard MRI scans to validate accuracy.~This intervention aims to assess whether portable MRI with AI can provide a low-cost, accessible alternative to standard MRI, potentially improving triage and reducing waiting times for patients requiring urgent brain imaging."
223901028|NCT06301412|DEVICE|hypothermia|hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
223901029|NCT06798935|PROCEDURE|autologous platelet-rich stroma|Autologous platelet-rich stroma, which is the combined product of stromal vascular fraction and platelet-rich plasma
223901030|NCT06803290|DRUG|VHX-896|Oral tablet
223901031|NCT06802848|DRUG|Xeligekimab injection|This is a real-world study. All treatment regimens are developed and implemented through detailed communication between patients and their treating clinicians. Treatment recommendations are consistent with the medication's prescribing information and treatment guidelines. The recommended dosing for xeligekimab is 200 mg at weeks 0, 2, 4, 6, 8, 10, and 12, followed by every 4 weeks thereafter. Each 200 mg dose is given in 2 separate 100 mg subcutaneous injections. The preferred injection site is the abdomen. Upper arms or thighs are recommended as alternative sites.
223901032|NCT06802926|DRUG|Colchicine|Oral Colchicine 0.5mg qd for 1 year
223901033|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for NON-SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
223901034|NCT06042309|OTHER|SLS|Exposure to SLS on a randomized arm
223901035|NCT06042309|OTHER|Rubber accelerators and control chamber/solution for SLS group|Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.
223901036|NCT06042309|OTHER|Patch test on back|Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
223901037|NCT06802107|BEHAVIORAL|Backward-treadmill Walking|A backward walking program will be applied on the treadmill. To be done 3 times a week / 8 weeks. Before the walking exercises, 5 minutes of warm-up and 5 minutes of cool-down exercises will be performed. While walking on the treadmill, the participant can hold onto the railings. Each participant will start at the speed they choose and gradually increase their perceived exertion rate to 11-13 on the Borg scale, and it is planned to walk for 10 minutes in the first week and gradually for 20-30 minutes in the following weeks.
223901038|NCT06802107|BEHAVIORAL|Forward-treadmill Walking|A forward walking program will be applied on the treadmill. To be done 3 times a week / 8 weeks. Before the walking exercises, 5 minutes of warm-up and 5 minutes of cool-down exercises will be performed. While walking on the treadmill, the participant can hold onto the railings. Each participant will start at the speed they choose and gradually increase their perceived exertion rate to 11-13 on the Borg scale, and it is planned to walk for 10 minutes in the first week and gradually for 20-30 minutes in the following weeks.
223901039|NCT06802107|OTHER|Traditional physiotherapy|"Traditional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.~To be done 3 times a week / 8 weeks. 20 min hotpack + 7 min ultrasound + 20 min TENS and knee osteoarthritis exercises (hip knee flexion extension, knee extension while sitting on a chair, quadriceps isometric exercise in the supine position, straight leg raise exercises) are planned to be applied in the clinic with the physiotherapist. The exercises are planned to be started with 5 repetitions in the first week and the intensity of the exercise is planned to be increased with 10 repetitions, 15 repetitions and 20 repetitions depending on the patient's tolerance."
223901040|NCT02318654|OTHER|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
223901041|NCT02318654|DRUG|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
224083472|NCT05876403|OTHER|PNF|The participants of experimental group will be given the Intervention protocol after baseline measurements. Additionally these 30 participants will also receive PNF technique exercises consisting of Thoracic Vertebral pressure, Anterior Basal stretch, and Intercostal stretch for 20-25 minutes in 3 sessions per week, and outcomes Measures will be recorded through a digital spirometer and measurements of 6 minutes walk test and chest Expansion.
224083473|NCT00480857|DRUG|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
224083474|NCT00611247|DRUG|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
224083475|NCT03851692|OTHER|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
224083476|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
224083477|NCT01948830|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
224083478|NCT04620330|DRUG|avutometinib (VS-6766)|Monotherapy
223715313|NCT01234441|DIETARY_SUPPLEMENT|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
223715314|NCT01234441|BEHAVIORAL|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
223901042|NCT04439019|OTHER|Lifestyle and dietary modification program|"The OA Optimization Program is a lifestyle and dietary modification program. All Patients will be offered this optional program while they await orthopedic consultation. There is an initial group information session for participants followed by medical assessment which includes medical history and physical examination, a previous dietary history, a readiness for change assessment, and screening for contraindications to the program. The patients will then attend group counselling sessions every 3 months for 1 year, or until their surgical date.Patients are encouraged to attend sessions with a family member. Improvement in Quality of Life measures including pain and disability in patients with severe osteoarthritis, as well as improvements in markers of health such as BMI, waist circumference, blood pressure, medication use in diabetic and hypertensive patients, and markers such as serum lipids and markers of inflammation will be shown."
223901043|NCT04140903|DRUG|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
223901044|NCT04140903|DRUG|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
223901045|NCT06464510|DRUG|Early Vasopressin|Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
223901046|NCT06464510|DRUG|Norepinephrine and Vasopressin for Rescue|Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
223901047|NCT05385237|DIAGNOSTIC_TEST|4D-MRI|Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.
223901048|NCT06324071|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
223901049|NCT06324071|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
223901050|NCT06415773|DRUG|HTD1801|HTD1801 1000 mg BID administered orally BID as four capsules
223901051|NCT06415773|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablet administered orally QD
223901052|NCT04972669|DEVICE|Electrical Acupuncture Stimulation|Participants received acupuncture at bilateral Baliao. After skin disinfection, sterile adhesive pads were placed on bilateral Baliao, and acupuncture needles were inserted through the adhesive pads. Following needle insertion, small, equal manipulations of twirling, lifting, and thrusting were performed on all needles to reach de qi. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
223901053|NCT04972669|DEVICE|sham Acupuncture|Participants received sham acupuncture at locations one inch besides bilateral Baliao without needle insertion. Electrodes from the electroacupuncture apparatus were attached transversely to the needle handles. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 2-15 Hz. Participants received 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
223901054|NCT06284213|OTHER|No interventions|This is an observational study with no interventions.
223901055|NCT05258071|DRUG|Pirepemat|Oral use
223901056|NCT05258071|DRUG|Placebo|Oral use
223901057|NCT03388944|BEHAVIORAL|PCT group|In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
223901058|NCT03340519|DEVICE|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
223901059|NCT05868343|OTHER|Center-based Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. Participants will travel to the center twice a week for the duration of the program. Participants receive an individualized exercise program to be completed at the center according to Canadian recommendations. Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
223901060|NCT05868343|OTHER|Hybrid Cardiac Rehabilitation Intervention|The center-based cardiac rehabilitation program is 12 weeks in length. For the first six weeks, participants are required to attend the hospital twice a week. After that, there will be a gradual increase in home sessions for the remaining six weeks. When a patient has a home session, health professionals follow up with a phone call.Twelve pre-recorded educational vignettes on various health topics and two group educational sessions on nutrition are offered to participants in person during the first twelve sessions at the center. In addition, at the beginning of the CR program, participants watch a motivational vignette from one of our patient partners about the importance and benefits of following the CR program. Depending on the needs of each participant, they may be referred to various external clinics within the Vitalité network, such as the Nutrition Service.
223901061|NCT05177692|DEVICE|Vguard|VGuard is a system that has been created to ensure that the patients´ ventricular drainage system and pressure monitor closely follows the patient when the head is adjusted vertically. The system consists of a pressure sensor that is connected to the patients´ head. The pressure sensor is connected to a motorized column that automatically adjusts to keep the zero level at level with the patients´ head at all times.
224083479|NCT04620330|DRUG|avutometinib (VS-6766) and Defactinib|Combination therapy
224083480|NCT05949307|DEVICE|acupuncture|acupuncture
224083481|NCT05949307|DEVICE|laser acupuncture|laser acupuncture
224083482|NCT05949307|DEVICE|Sham-laser acupuncture|Sham-laser acupuncture
223715315|NCT04153669|BEHAVIORAL|Exercise-NMES|Exercise-NMES
223715316|NCT04153669|BEHAVIORAL|Exercise-No NMES|Exercise-No NMES
223901062|NCT04847843|BEHAVIORAL|Mindfulness Orientated Recovery Enhancement|The MORE curriculum has been adapted for this intervention to address food intake behaviors and will provide training in mindfulness techniques to increase awareness of, and self-control over, cravings; reappraisal skills to promote emotion regulation and restructure motivations for highly palatable food intake; and savoring pleasant events and emotions to overcome defects in natural reward processing.
223901063|NCT04847843|BEHAVIORAL|Control Intervention|The curriculum will be based on the Diabetes Prevention Program's Prevent T2 for Life program, which is an evidence-based national healthful lifestyle maintenance intervention. This program includes training in healthful eating, meal planning, and recipe modification; time and stress management; adapting lifestyle habits for continued success during holidays, vacations, and other special situations; and relapse prevention.
223901064|NCT05652179|DRUG|Stellate ganglion block|After the induction of general anesthesia and before the start of the surgery,ultrasound-guided stellate ganglion block is performed, injecting 5 ml of 0.375% ropivacaine.
223901065|NCT05554211|DRUG|Tranexamic acid|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, TxA irrigation will be administered following gentamicin irrigation. TxA irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
223901066|NCT05554211|DRUG|Normal saline|The intervention is a topical application of 50 cc's of 3% tranexamic acid. In the operating room, control normal saline (NS) irrigation will be administered following gentamicin irrigation. NS irrigation solution will be the last irrigation used prior to wound closure in order to assure maximum benefit derived from TxA administration, if any.
223901067|NCT04463576|OTHER|Discharge Prescription|All hospital discharge prescriptions for patients aged 65 or over hospitalized or seen in consultation in the cardiology, internal medicine and neurology divisions of the Bordeaux and Rennes University Hospital and Georges Pompidou European Hospital will be recorded between June 1, 2018 and June 1, 2019.
223901068|NCT05833542|BEHAVIORAL|Health education materials|Participants will receive informational material (designed to be self-guided), including a video and an information sheet about current HIV treatment options (i.e., long-acting injectable and daily oral antiretroviral therapy). These materials will provide a comparison of the risks and benefits of long-acting injectable and oral regimens, set expectations about clinic visits, present information about side effects, and provide additional resources for patients to assist them in preparing to discuss HIV treatment and support options with their medical case manager and clinical provider. Participants receiving this intervention will be offered/pointed to these materials by a medical case manager or patient navigator and will be encouraged to review the materials on their own, but may also go over the materials with staff during a medical case management visit.
223901069|NCT05833542|BEHAVIORAL|Patient-provider decision tool|Participants will receive a shared patient-provider assessment and decision-making tool, utilizing techniques from Motivational Interviewing and based on the Ottawa Patient Decision Aid framework, for weighing each patient's treatment options and their fit to patient interests, needs, assets, and constraints. The tool will facilitate and record patient-provider agreement on an antiretroviral treatment and support-services plan, to be integrated into the broader existing medical case management care plan signed by both patient and provider. The tool will be administered during a medical case management visit and completed by the participant and a patient navigator or medical case manager.
223901070|NCT06258564|BIOLOGICAL|vaccination against human papillomavirus infection (HPV vaccination)|Women with or without HPV vaccination before or after excision
223901071|NCT02175342|DRUG|Tiotropium 0.625 mcg/puff|
223901072|NCT02175342|DRUG|Tiotropium 1.25 mcg/puff|
223901073|NCT02175342|DRUG|Tiotropium 2.5 mcg/puff|
223901074|NCT02175342|DRUG|Tiotropium 5 mcg/puff|
223901075|NCT02175342|DRUG|Placebo solution|
223901076|NCT02175342|DRUG|Tiotropium-18 lactose powder|
223901077|NCT02175342|DRUG|Placebo lactose powder|
223901078|NCT02175342|DRUG|Tiotropium 10 mcg/puff|
223901079|NCT02175342|DEVICE|Respimat|
223528717|NCT06317935|OTHER|ArmeoSenso|ArmeoSenso is an upper extremity virtual reality application with three motion sensors and one hand grip sensor. The device detects the person's body, arm, forearm and hand movements and displays the reflection of the movements on the screen. The application includes studies on upper extremity functions.
223901080|NCT02175342|DEVICE|Handihaler|
223901081|NCT05373719|OTHER|No intervention; observational|No intervention; observational
223901082|NCT06019559|DRUG|K-757 120 mg BID and K-833 100 mg BID|"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8.~Both administered orally."
224083483|NCT01890421|DRUG|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
223528718|NCT06317935|OTHER|Traditional Rehabilitation|It includes traditional occupational therapy and physiotherapy approaches.
223901083|NCT06019559|DRUG|K-757 120 mg BID and matching placebo to K-833|"K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22.~Both administered orally."
223901084|NCT06019559|DRUG|Matching placebo to K-757 and matching placebo to K-833|Both administered orally.
223901085|NCT04094844|OTHER|Wearable activity sensor|Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.
223901086|NCT04094844|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their mobile phones or tablets
223901087|NCT04094844|OTHER|Survey administration|Caregivers and patients will be asked to respond to survey questions at 3 timepoints.
223901088|NCT04094844|BEHAVIORAL|Roadmap 2.0 information system with Positive Activities|Caregivers and patients download the Roadmap 2.0 app on their mobile phones. Caregivers and patients will be instructed on how to operate Roadmap 1.0 on an iPad (inpatient only) and Roadmap 2.0 on a mobile phone (inpatient and outpatient). Caregivers download the Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay.
224276813|NCT05373641|OTHER|Repeated feedback|Repeated feedback monthly based on previous month pain documentation audit results.
224276814|NCT05373641|OTHER|Pain documentation audit|Monthly pain documentation audit
223901089|NCT06166433|BEHAVIORAL|Smoke-free homes intervention|Theory-based intervention involving 3 mailed sets of educational materials and a brief coaching call using motivational interviewing, delivered over a 6-week period.
223901090|NCT06458959|BEHAVIORAL|PEM+|The Young Children's Participation in Environment Measure (YC-PEM), an evidence-based and promising electronic patient-reported outcome (e-PRO) when combined with the Participation and Environment Measure Plus (PEM+) care planning application that yields a summary report and is paired with a program-specific decision-support tool, may support family engaged Early Intervention (EI) service plan development. Intervention group caregivers will complete the YC-PEM e-PRO and PEM+ intervention before their child's annual review of progress. The online summary report will be combined with a program-specific decision-support tool to guide EI service plan development.
223901091|NCT04551040|DRUG|Terazosin|Terazosin 1 mg oral capsule
223901092|NCT03476655|DRUG|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
223901093|NCT04629469|DIAGNOSTIC_TEST|Hyperfine MRI|• Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
223901094|NCT06533566|PROCEDURE|Erector spinae plane block|patients will be placed in the lateral decubitus position. The ESP block is usually performed at the level of fourth transvers process. The ultrasound probe should be placed in a cephalo-caudal orientation over the midline of the back at the desired level.Under aseptic conditions, the block needle will be inserted in plane at an angle of 30-40° in cranial-to-caudal direction until the tip contacted the T4 transverse process at erector spinae plane. After hydro-dissection with 2-3 mL of isotonic saline solution to confirm the correct needle tip position and after negative aspiration to prevent intra vascular injection or position, (20 ml) of plain bupivacaine 0.25% will be injected deep to the erector spinae muscle.
223901095|NCT06533566|PROCEDURE|local wound infiltration|after the surgeon complete the surgery and insert the surgical drains (pectoral and axillary drains) we will inject 20ml of plain bupivacaine 0.25% in each surgical drain, the drains will be clamped for 20 minutes then declamped.
223901096|NCT04711733|OTHER|Interview|The qualitative interview aims to identify the supportive care needs of patients and parents as well as their expectations with regard to a long-term follow-up.
223901097|NCT04711733|OTHER|Self-report questionnaire|"To assess the quality of life, anxiety/depression of former patients and relatives:~For child and adolescent patients (less than 15 years old at inclusion):~* Pediatric Quality of Life Inventory Cancer module~* Screen for Child Anxiety Related Emotional Disorders Revised~* Children's Depression Inventory~For patients over 15 years of age at the time of inclusion and parents:~* 36-Item Short Form Health Survey~* Hospital Anxiety and Depression Scale~To describe and evaluate the offer and use of the network of health professionals who are aware of post-treatment issues: number of consultations, speciality and location of the professionals requested following the long-term follow-up consultation, time between referral and first consultation, evaluation of the geographical accessibility of care around the patient's home."
223901098|NCT04711733|OTHER|Medical consultation|"To assess adherence to long-term follow-up medical consultation:~\- number of patients summoned/ number of consultations carried out ; reason for refusal of long-term follow-up medical consultation To assess medical complications through clinical data collection"
223901099|NCT06505499|OTHER|Gait Profile Score|Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi\_GPS\_calculator spreadsheet developed by Baker (2009).
223901100|NCT06505499|OTHER|Gait Visual Score|Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi\_GPS\_calculator spreadsheet developed by Baker (2009)
223901101|NCT05695924|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
223901102|NCT05695924|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
224276815|NCT02073136|OTHER|Diet with phosphate containing additives|
223901103|NCT05378100|DRUG|Ketamine|Infusion of ketamine 0.5 mg/kg over 40 minutes
223901104|NCT05378100|DRUG|Midazolam|Infusion of midazolam 0.05 mg/kg over 40 minutes
223901105|NCT06460389|DIAGNOSTIC_TEST|Visual Acuity Assessment|Uncorrected visual acuity for nine distances (25, 28, 33, 40, 50, 60, 100, 200, 300 cm) examination via a Democritus Digital Acuity \& Reading Test (DDART).
224276816|NCT02073136|OTHER|Diet without phosphate containing additives|
224276817|NCT04747132|OTHER|Telegeriatric intervention|Individualized, comprehensive and specialized counseling for older adults through the Internet
224276818|NCT05547906|DRUG|ASCA101|IV infusion Twice a Week, 8 times per each Cycle
224276819|NCT03215459|DEVICE|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
224276820|NCT00876356|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
224276821|NCT00876356|DIETARY_SUPPLEMENT|Olive oil|Olive oil 4.5g/day x 12 weeks
224276822|NCT02812771|DRUG|Efinaconazole|Solution
224276823|NCT05240092|BEHAVIORAL|Haptonomy|Haptonomy, as a field dealing with emotional contact through touch, describe the relationship between parents and the unborn baby.
224276824|NCT05443919|DEVICE|TwiFlow-Thrombectomy Catheter System|Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
224276825|NCT01477099|DEVICE|Toothbrushing with a manual brush|Toothbrushing with a manual brush
223901106|NCT05986682|DRUG|Blenrep|Belantamab Mafodotin - blmf (BLENREP) given for the treatment of relapsed and/or refractory multiple myeloma.
223901107|NCT06215521|DRUG|Pirtobrutinib|Administered orally
223901108|NCT06215521|DRUG|Placebo|Administered orally
223901109|NCT06215521|DRUG|Moxifloxacin|Administered orally
223901110|NCT04044768|GENETIC|afamitresgene autoleucel (previously ADP-A2M4)|Single infusion of autologous genetically modified afamitresgene autoleucel (previously ADP-A2M4) Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
223901111|NCT06113068|DEVICE|Fistura® procedure|The Fistura® procedure is performed using a sterile Fistura® catheter (F Care Systems), intended to be connected to an F Care Systems radiofrequency generator (MedRF4000®). The flexible Fistura® catheters used during the procedure allow it to follow the path of the anal fistula, facilitating the closure of the fistula along its entire length. As the catheter can treat fistulas involving the sphincter complex, but without cutting or damaging it, it is expected to be effective in term of continence maintenance.
223901112|NCT04468659|DRUG|Lecanemab|IV infusion.
223901113|NCT04468659|DRUG|Placebo|IV infusion.
223901114|NCT04165330|DRUG|AL3818|"AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle."
223901115|NCT04165330|DRUG|Nivolumab Injection|Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
223901116|NCT06265922|DEVICE|High frequency repetitive transcranial magnetic stimulation|High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.
223901117|NCT06265922|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness
223901118|NCT06052865|BEHAVIORAL|SENSE-plus: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants. Additionally, for very preterm infants with advanced neurological injury, additional 1-2 sessions of weekly motor therapy are added to the SENSE-II program
223901119|NCT06052865|BEHAVIORAL|SENSE: The Supporting and Enhancing NICU Sensory Experiences 2nd Edition (SENSE II) program|The SENSE II program was developed to engage parents in consistently providing positive, developmentally appropriate sensory exposures to their high-risk infants in the NICU every day of hospitalization. The SENSE II program includes specific doses and targeted timing (based on postmenstrual age) of evidence-based interventions of auditory, tactile, vestibular, kinesthetic, olfactory, and visual exposures to be conducted daily through hospitalization for preterm infants.
223901120|NCT06052865|OTHER|Reference/ Standard of care|Infants in the Unexposed group receive the NICU standard of developmental care throughout hospitalization.
223901121|NCT05504317|DRUG|AK111|Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
223901122|NCT05504317|DRUG|Placebo|Subjects will receive corresponding dose of placebo injection subcutaneously.
223901123|NCT01574274|DRUG|SC-PEG|11 doses Intravenously over one hour
223901124|NCT01574274|DRUG|Oncaspar|16 doses Intravenously over one hour
223901125|NCT06225063|OTHER|Pilates|The application of pilates aims to correct real-time deviations observed in the body during movement, to maintain stability, to maintain stability, to gradually form proper sensorimotor ability and improve cervical dysfunction. Pilates is an important part but also a primary point in the stages of rehabilitation, since through it the execution of movement is encouraged earlier thus providing help for the later stages of rehabilitation. Pilates exercises concern movements at all levels of body movement and in various positions.
223901126|NCT06225063|OTHER|Cognitive Functional Therapy|Cognitive component: Educating patients about their perceptions of pain, explaining diagnosis and diagnostic findings, answering questions about their problem and symptoms, progressively challenge their customers in a non-judgmental way, education for multifactorial and biopsychosocial spectrum of pain, encouraging participants to movement and for active participation in daily activities, if receiving a self-management plan participation in activities with a degree of difficulty 2-3/10, tips for more effective sleep Specific functional training: Understanding pain modification through relaxation exercises, awareness and body control, modified body positions for better control of the cervical spine with parallel relaxation of the thoracic spine to participate in fearful or painful activities, engaging in movements of daily activities Lifestyle changes: Gradual increase in physical activity based on patient preferences, stress management and social interaction
223901127|NCT01814813|BIOLOGICAL|HSPPC-96|intradermal infusion
223901128|NCT01814813|DRUG|bevacizumab|intravenous
223901129|NCT05810129|OTHER|concentric-eccentric strength training|Concentric-eccentric cross training in a 6-week immobilization period + 12-week standard kinesic therapy (2 times a week)
223901130|NCT05810129|OTHER|eccentric strength training|Eccentric cross training in immobilization period of 6 weeks + Standard kinesic therapy of 12 weeks (2 times a week)
223901131|NCT05810129|OTHER|standard physical therapy|Men with clavicle fracture immobilized for 6 weeks + standard physical therapy for 12 weeks
223901132|NCT05089019|DRUG|Selpercatinib|Administered orally
223901133|NCT06307951|OTHER|No intervention|No intervention
223901134|NCT06232109|DRUG|Fluvoxamine|Oral
223901135|NCT06232109|DRUG|Itraconazole|Oral
223528719|NCT04440774|BIOLOGICAL|CHIK low dose|A single dose of 5x10\^9 vp ChAdOx1 Chik
223528720|NCT04440774|BIOLOGICAL|CHIK mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Chik
223901136|NCT06232109|DRUG|Paroxetine|Oral
223901137|NCT06232109|DRUG|ASN51|Oral
224083484|NCT00207051|DRUG|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
223901138|NCT06233578|DEVICE|RADPAD|The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
223901139|NCT03821779|BEHAVIORAL|In vivo social exposure|Subjects will be invited to give a 5 minutes oral presentation on the topic of their choice to five examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is prompt to elicit anticipation-type of social anxiety.
223901140|NCT03821779|BEHAVIORAL|Social exposure in a virtual reality setting|Subjects will give a 5 minutes oral presentation on the subject of their choice to a virtual reality panel composed of 5 examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is expected to elicit anticipation-type of social anxiety.
223901141|NCT03821779|OTHER|EEG recording|EEG will be recorded with a standard 16-electrodes cap. Recordings will start before the 5 minutes waiting period and continue throughout oral presentation and recovery. The recovery period will be used as a baseline control
223901142|NCT03821779|DIAGNOSTIC_TEST|Psychometric evaluation|"Subjects will be evaluated prior to inclusion using the following assessment tools~* Anamnestic Association for Methodology and Documentation in Psychiatry (AMDP) questionnaire~* Mini International Neuropsychiatric Interview (MINI 6.0, for psychiatric diagnoses)~* Liebowitz Social Anxiety Scale (LSAS)~* Montgomery Asberg Depression Rating Scale (MADRS)~* Brief Anxiety Scale of Tyrer (BAS)~* State-Trait Anxiety Inventory (STAI A-B)~* Global Assessment of Functioning (GAF)"
223901143|NCT03821779|DIAGNOSTIC_TEST|Visual Analogue Scale of anxiety|"Subjects will be asked to rate their anxiety levels~* immediately before (5 minutes of silent waiting),~* during~* and after the 5-minute oral presentation (recovery)"
223901144|NCT03109210|BEHAVIORAL|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
223901145|NCT03109210|BEHAVIORAL|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
223901146|NCT03858634|DRUG|KPL-716|A loading dose of KPL-716 720 mg (2x maintenance dose) administered via 2 subcutaneous (SC) injections within 30 minutes on Day 1. All subsequent doses of KPL-716 (360 mg maintenance dose) administered via a single SC injection.
223901147|NCT03858634|DRUG|Placebo|Placebo dose administered via 2 SC injections within 30 minutes on Day 1. All subsequent doses of placebo administered via a single SC injection.
223901148|NCT06279416|PROCEDURE|fiberoptic intubation|awake nasal fiberoptic intubation
223901149|NCT06279416|PROCEDURE|laryngeal mask airway-mediated aintree catheter|awake intubation with laryngeal mask airway-mediated aintree catheter
223901150|NCT06279416|PROCEDURE|videolaryngoscopy|awake intubation with videolaryngoscopy
223901151|NCT04676763|DRUG|Substance P|Participants will receive Substance P
223901152|NCT04676763|DRUG|Normal Saline|Participants will receive normal saline as Negative control
223901153|NCT04676763|DRUG|Histamine|Participants will receive histamine as Positive control
223901154|NCT03150173|BEHAVIORAL|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
223901155|NCT03150173|BEHAVIORAL|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
223901156|NCT03150173|DRUG|Buprenorphine|all participants will receive buprenorphine
223901157|NCT06384560|DRUG|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks.
223901158|NCT06384560|DRUG|Folfirinox|FOLFIRINOX is a combination of systemic chemotherapy agents. FOLFIRINOX consists of oxaliplatin at a dose of 85 mg/m2, given as a 2-hour intravenous infusion, immediately followed by leucovorin at a dose of 400 mg/m2 given as a 2-hour intravenous infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute intravenous infusion through a Y-connector. This treatment is followed by a continuous intravenous infusion of 2400 mg/m2 5-FU over a 46-hour period every 2 weeks. (The FOLFIRINOX given in the trial is the modified scheme, whereby the fluorouracil bolus at a dose of 400 mg/m2 is omitted and the irinotecan dose reduced to 150 mg/m2).
223901159|NCT06384560|RADIATION|SABR|SABR will be delivered in an image-guided hypofractionated scheme of 5 fractions of 8 Gy (total 40 Gy), prescribed to 95% of the planning target volume (PTV). Treatment is delivered on five non-consecutive days.
223901160|NCT01593917|DEVICE|Trifecta™ Valve|Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
223901161|NCT04978506|DRUG|BI 1569912|BI 1569912
223901162|NCT04978506|DRUG|Placebo|Placebo
223901163|NCT05553145|DIAGNOSTIC_TEST|Autoimmune Antibody Assays|GAD-65, Islet cell-Ab, IA-2 Ab, anti-insulin Ab, and ZnTn8 Ab
223901164|NCT05713383|BEHAVIORAL|Auditory Feedback|Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
223901165|NCT04043156|RADIATION|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
223901166|NCT04068623|OTHER|Blood sample|Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
223901167|NCT05673772|RADIATION|short-course radiotherapy|25 Gy in 5 fractions for 5 days
223901168|NCT05673772|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours
223901169|NCT05673772|RADIATION|Chemoradiotherapy|45\~50.4 Gy/25fr with concurrent use of either capecitabine or 5-FU+leucovorin(or levoleucovorin or leucosodium)
223901170|NCT05673772|PROCEDURE|TME surgery|TME surgery
223901171|NCT06026605|DRUG|WTX212A|WTX212A infusion once every 21 days
223901172|NCT04070443|DRUG|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
223901173|NCT04070443|DRUG|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
223901174|NCT05921344|DEVICE|Multi-channel Microspatial Offset Raman Scattering Spectroscopy (mμSORS) for Noninvasive Blood Glucose Detection|Blood glucose of participants were measured by venous plasma and multi-channel microspatial offset Raman scattering spectroscopy (mμSORS). The two measurements were collected synchronously and analyzed.
223901175|NCT06283511|OTHER|educational workshops|patient will be proposed to assist to educational workshops + the possibility to assist to a physical rehabilitation programme
223901176|NCT04588064|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
223901177|NCT06116422|BEHAVIORAL|Grocery intervention - unrestricted|Receives financial support in an unrestricted fashion (i.e., can use the money for whatever they need).
223901178|NCT06116422|BEHAVIORAL|Grocery intervention - restricted|Receives financial support restricted to the purchase of items at a grocery store, and with monthly grocery shopping coaching from a trained nutrition expert.
223901179|NCT05099302|OTHER|divert attention|In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
223901180|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
223901181|NCT03509402|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
223901182|NCT04457596|BIOLOGICAL|Trastuzumab Emtansine|Given IV
223901183|NCT04457596|DRUG|Placebo Administration|Given PO
223901184|NCT04457596|DRUG|Tucatinib|Given PO
223901185|NCT04457596|OTHER|Questionnaire Administration|Ancillary studies
223901186|NCT04457596|OTHER|Quality-of-Life Assessment|Ancillary studies
223901187|NCT01192048|OTHER|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
223901188|NCT04322864|OTHER|Therapeutic exercises|Patients will perform strengthening exercises focusing on scapulothoracic muscles and shoulder lateral rotators.
223901189|NCT03538899|DRUG|AProArt-CD34|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
223901190|NCT03538899|DEVICE|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
223901191|NCT03538899|DRUG|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
223901192|NCT05729165|DEVICE|Novafon® Pro|Local vibration therapy. The target muscles were: the orbicularis muscles of the upper and lower lips, the masticatory muscles (masseter, temporalis, pterygoidis) and lingual muscles.
223901193|NCT05729165|OTHER|Conventional Therapy|maneuvers were performed for passive extra-oral and intra-oral thermal stimulation, passive extra-oral and intra-oral tactile stimulation, and elicitation of active movements of the bucco-lingual and pharyngo-laryngeal muscles.
223901194|NCT05988788|OTHER|Epigallocatechin-3-gallate|to be used as a root canal irrigant
223901195|NCT05988788|OTHER|sodium hypochlorite|to be used as a root canal irrigant
223901196|NCT05378113|DRUG|Ondansetron|Ondansetron (Zofran) is a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist commonly used to treat postoperative nausea and vomiting.
223901197|NCT05378113|DRUG|Lidocaine|Lidocaine is a local anesthetic agent used intravenously prior to the propofol injection. Currently the standard of care to help decrease the severity of pain in the injection site, a common side effect of propofol.
223901198|NCT06546891|BEHAVIORAL|Adaptive Rowing|12 supervised and coached sessions of 10-20 minutes of moderate to vigorous exercise using an adaptive rower.
223901199|NCT05304104|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The treatment has three stages. Stage 1 consists of presentation of the CBT model; introduction and discussion of the structure, goals, interventions, and expected outcome of treatment; education regarding binge eating and dieting; and the introduction of self-monitoring techniques for identifying problematic eating practices and triggers. Stage 2 consists of maintaining the normalized eating and self-monitoring procedures but becomes increasingly cognitively oriented. Stage 3 focuses on practicing skills, consolidation of progress and relapse prevention. Treatment will adhere to a manual developed by Dr. Masheb (PI), adapted for Veterans, and written at a seventh-grade reading level.
223901200|NCT03127007|DRUG|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
223901201|NCT03127007|DRUG|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
223901202|NCT05895838|DRUG|Dexamethasone|Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.
223901203|NCT05895838|PROCEDURE|Backrest elevation|Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).
223901204|NCT05895838|PROCEDURE|Early wakeup call|Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.
223901205|NCT05895838|DRUG|Olanzapine|Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.
223901206|NCT06485687|DEVICE|LIFU Neuromodulation|Subjects will undergo a single LIFU of the target brain region
223901207|NCT05530603|BEHAVIORAL|Educational mobile app|7 day educational course to educate American Indian women to receive regular mammogram.
223901208|NCT05335018|DRUG|Glofitamab, Poseltinib, Lenalidomide|"Glofitamab: Increase from 2.5mg for 8days in 1 cycle to 10mg for 15days. 2cycles 1day 30mg, 30 mg on the 1st day of every week thereafter. Poseltinib: 40mg/day bid orally, administered daily from the 1st to the 21st of every week.~Lenalidomide: 20mg/day bid orally, administered daily from the 1st to the 14st of every week."
223901209|NCT05659381|DRUG|Cisplatin|Cisplatin 100mg/m2 IP over 90 minutes at 42 degrees Celcius
223901210|NCT05659381|OTHER|No treatment|No treatment with Cisplatin
223901211|NCT04484727|OTHER|PEEP-step method|By changing PEEP in one or two steps up and down, transpulmonary pressure and the lung P/V curve can be determined using a dedicated software collecting data on tidal-volume changes and pressure changes during the PEEP-changes from the standard monitoring equipment or ventilator.
223901212|NCT06813469|GENETIC|LRS analysis|Long Read Sequencing (LRS) and High-throughput chromosome conformation capture (Hi-C) analysis to explore and functionally characterize the r(14) event and its impact on the three-dimensional (3D) genomic architecture inside the cells of r(14)S patients
223901213|NCT04406623|DRUG|SL-172154|The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
223901214|NCT05126992|BIOLOGICAL|AZD1222|Covid-19 AstraZeneca Vaccine
223901215|NCT04089943|PROCEDURE|Revascularization operation|Participants will be randomized into an endovascular or open bypass procedure.
223901216|NCT04089943|OTHER|Control group|Healthy non-PAD participants will be recruited for the study.
223901217|NCT03965338|DIAGNOSTIC_TEST|fMRI|Screening
223901218|NCT02298504|DRUG|Mineral Trioxide Aggregate|Vital pulp therapy
223901219|NCT02298504|DRUG|Biodentin|Vital pulp therapy
223901220|NCT02298504|DEVICE|Vitrebond|Vital pulp therapy
223901221|NCT04478643|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus Reuteri|Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
223901222|NCT04478643|DIETARY_SUPPLEMENT|Placebo|Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
223901223|NCT06382870|OTHER|education|Providing simulation-based training to nurses on child neglect and abuse in the hospital environment
223901224|NCT05309551|DEVICE|IMT- Intervention group|The resistive load will be readjusted weekly to reach 50% of maximal inspiratory pressure (MIP).
223901225|NCT05309551|DEVICE|IMT- Placebo group|The inspiratory resistive load will be adjusted to the minimum value of the device (9 cm H2O) during all inspiratory muscle training sessions.
223901226|NCT05543655|OTHER|high fidelity simulation|"Each half-day training session will begin with a reminder of the context and general objectives of the training. Nurses will complete the self-assessment and knowledge tests.~The nurses, each in turn, will start the scenario and will immediately assess the workload felt, by the Nasa-TLX grid. During these high-fidelity simulation sessions, an error cart workshop will allow all the other nurses to summon up their knowledge on safety tools upstream of the administration procedure.~The session begins with a briefing and ends with a debriefing."
223901227|NCT05188222|DRUG|Maltodextrin solution|The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
223901228|NCT05188222|DRUG|Placebo solution|Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
223901229|NCT05843799|DRUG|ILB-202|Single i.v. infusion
223901230|NCT05843799|DRUG|Placebo|Single i.v. infusion
223901231|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 1|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 short hairpin (sh)RNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 1 in the dose escalation phase of the study will receive a fixed number of intramuscular (IM) injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 1.2e13 vg/subject."
223901232|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 2|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 2 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 3.6e13 vg/subject."
223901233|NCT06185673|GENETIC|BB-301: Dose escalation phase 1b cohort 3|"BB-301 is composed of an AAV9 capsid, AAV9PL, which delivers the gene of interest, comprised of a recombinant genome encoding a single RNA transcript that produces a codon-optimized, wildtype PABPN1 protein as well as 2 shRNAs directed against the disease-causing mutant PABPN1 gene.~Subjects in cohort 3 in the dose escalation phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, with a total dose of 5.4e13 vg/subject."
223528721|NCT04440774|BIOLOGICAL|CHIK high dose|A single dose of 5x10\^10 vp ChAdOx1 Chik
223901234|NCT06185673|GENETIC|BB-301: Dose expansion phase 2a|Subjects in the dose expansion phase of the study will receive a fixed number of IM injections of BB-301 into the respective pharyngeal constrictor muscles on the day of dosing, at the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D).
223901235|NCT03039751|DRUG|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
223901236|NCT03039751|DRUG|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
223901237|NCT02690558|DRUG|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
223901238|NCT04225273|DEVICE|Sculptra Aesthetic, Lidocaine HCL|No intervention was administered during this extension study.
223901239|NCT05686395|PROCEDURE|Ultrasound-guided Interscalene Block group|ultrasound guided interscalene block versus combined ultrasound guided shoulder anterior capsular block and suprascapular nerve block for arthroscopic shoulder surgery
223901240|NCT05686395|PROCEDURE|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block|Combined Ultrasound guided shoulder anterior capsular block and suprascapular nerve block
223901241|NCT05686395|DRUG|Bupivacaine|bupivacaine 0.25%.
223901242|NCT04016155|DEVICE|Abbott FreeStyle Libre|Flash CGMS
223901243|NCT04016155|DEVICE|Patient Own SMBG|Market SMBG
223901244|NCT05448105|OTHER|My Diabetes Care (MDC)|My Diabetes Care (MDC) is a multi-faceted patient portal intervention that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate diabetes self-care information. In this study, the MDC user-interface was expanded to display additional diabetes health-data, including urine microalbumin and weight/body mass index (BMI) and a Spanish-language version of MDC was available to Spanish-speaking patients with limited English proficiency.
223901245|NCT04893733|DRUG|Vitamin B Complex|"Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo.~Every patients will also received Institution standard of care for AKI"
223901246|NCT04893733|OTHER|STOP AKI protocol|"STOP AKI protocols includes:~S: identify and treat sepsis. Standard measures should be followed to decrease the risk of infection. Close surveillance to identify early signs of infection with appropriate treatment T: avoid nephrotoxins. Avoidance of drugs harmful to the kidneys (e.g. NSAIDs, gentamicin) Care with intravenous iodinated contrast O: optimize blood pressure and optimize volume status. Avoid dehydration e.g. confused patient. Treat hypovolaemia promptly. Consider with-holding patient anti-hypertensives/diuretics until assessed after major surgery or if patient develops sepsis/hypovolemia P: Prevent harm. Identify the cause promptly and manage appropriately to prevent progression. Prevent complications by instituting prompt therapy. Identify drugs excreted through the kidneys and adjust drug doses promptly if AKI develops. Review fluid management plans to prevent inadequate or excessive intravenous fluid administration"
223901247|NCT06224283|PROCEDURE|Cryoablation|Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors
223901248|NCT05341726|BEHAVIORAL|BREATHE Intervention|BREATHE utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
223901249|NCT05341726|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
223901250|NCT06382675|DEVICE|Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2|230 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)
223901251|NCT04174157|OTHER|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
223901252|NCT04174157|DRUG|Zolgensma|Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
223901253|NCT00313222|DRUG|bosentan|
223901254|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 1mA to the scalp.
223901255|NCT05270408|DEVICE|Active Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver 2mA to the scalp.
223901256|NCT05270408|DEVICE|Sham Transcranial direct current stimulation (STARStim 8)|Participants wear a neoprene cap on their head and electrodes filled with gel are attached and will deliver no current to the scalp.
223901257|NCT06030219|DRUG|Omadacycline|10-day course
223901258|NCT06030219|DRUG|Vancomycin Pill|10-day course
223901259|NCT06030219|DRUG|Moxifloxacin|10-day course
223901260|NCT03768505|DRUG|Zandelisib (ME-401)|Zandelisib (ME-401) 60 mg
223901261|NCT05240755|DRUG|Cannabidiol Oil|Subjects will self-administer CBD sublingually.
223901262|NCT05688280|DRUG|1.0% IP-001 for Injection|4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.
223901263|NCT04331639|DIETARY_SUPPLEMENT|vitamin D3|Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
223901264|NCT06269120|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
223901265|NCT05256199|BEHAVIORAL|Multidomain lifestyle intervention|A multidomain lifestyle intervention, including (1) physical activity, (2) cognitive training, (3) cardiovascular risk factor management (Cardiovascular), (4) dietary counselling, (5) Souvenaid, (6) sleep counselling, (7) stress management, and (8) social activities.
223901266|NCT05966727|DRUG|Cholestyramine Powder|Bile salt chelating resin, used as a lipid-lowering treatment.
223901267|NCT02905188|GENETIC|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
223901268|NCT02905188|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
223901269|NCT02905188|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
223901270|NCT02815566|DRUG|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
223901271|NCT02815566|DRUG|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
223901272|NCT05524922|OTHER|Data collection|Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
223901273|NCT06441890|DRUG|Paclitaxel|80mg/m2 IV D1, 8, 15
223901274|NCT06441890|DRUG|Nab-paclitaxel|125mg/m2 IV D1, 8, 15
223901275|NCT06441890|DRUG|Docetaxel|75mg/m2 IV D1
223901276|NCT06441890|DRUG|Trastuzumab|8mg/kg loading, then 6mg/kg IV/SQ D1
223901277|NCT06441890|DRUG|Pertuzumab|840 mg loading, then 420mg IV/SQ D1
223901278|NCT03252847|GENETIC|AAV5-RPGR|Single, subretinal administration of AAV5-RPGR
223901279|NCT02955290|OTHER|Laboratory Biomarker Analysis|Correlative studies
223901280|NCT02955290|BIOLOGICAL|Nivolumab|Given IV
223901281|NCT02955290|BIOLOGICAL|Pembrolizumab|Given IV
223901282|NCT02955290|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
223901283|NCT04014335|DRUG|IONIS-FB-LRx|Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
223901284|NCT05356286|DEVICE|epidural electrical stimulation|Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
223901285|NCT04035434|BIOLOGICAL|CTX110|CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
223901286|NCT05793541|BEHAVIORAL|Phone call|A phone call from a trained study clinician that uses a standardized phone script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the call. This intervention occurs at High Risk only.
223901287|NCT05793541|BEHAVIORAL|Text messaging|A text message conversation initiated by a trained study clinician that uses a standardized text messaging script to (a) conduct a risk assessment and (b) recommend that the participant use their safety plan (any and all included components), which will be reviewed and revised as-needed during the text messaging interaction. This intervention occurs at High Risk only.
224276826|NCT04241133|BEHAVIORAL|The UnProcessed Pantry Project (UP3)|UP3 uses the Social-Ecological Model to target multiple levels, including the food supply in the rural study location (community level), the food environment at the food pantry (environmental level), and participant dietary intake (individual level). It is hypothesized that UP3 will improve access to minimally processed foods and decrease access to ultra-processed foods at the food pantry, which will improve overall dietary quality of individuals as measured by the Healthy Eating Index-2015 compared to baseline and to the control group. Demographic and food security data will characterize the population. Psychosocial factors will be collected to understand changes in knowledge, attitudes, and perceptions about processed foods. Biomarkers of health data (i.e., weight, systolic blood pressure, HbA1c, fasting lipid panel) will be collected to determine the feasibility of measuring potential short-term health effects alongside UP3.
223901288|NCT05793541|BEHAVIORAL|Automated interactive smartphone-based tool|An automated interactive, smartphone-based tool that will (a) (at High Risk only) guide the participant through a risk assessment and (b) (at High and Medium/Low Risk) present recommendation to use and a review of the safety plan.
223901289|NCT05793541|BEHAVIORAL|Non-interactive pop-up messages|Automated non-interactive, static pop-up messages that recommend use of the safety plan or its components (Medium/Low Risk only).
223901290|NCT02378350|DEVICE|Hemodialysis treatment (no specific device is defined)|
223901291|NCT02378350|DRUG|Peritoneal Dialysis treatment (no specific drug is defined)|
223901292|NCT02744677|DEVICE|SAPIEN 3/SAPIEN 3 Ultra RESILIA THV|SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position
223528722|NCT04440774|BIOLOGICAL|ZIKA low dose|A single dose of 5x10\^9 vp ChAdOx1 Zika
223901293|NCT02744677|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
223901294|NCT02744677|DEVICE|SAPIEN 3 Ultra RESILIA THV|SAPIEN 3 Ultra RESILIA THV in the pulmonic position
223901295|NCT04757571|DRUG|Paroxetine|Paroxetine 20 mg tablet plus standard therapy
223901296|NCT04757571|DRUG|Placebo|Placebo tablet plus standard therapy
223901297|NCT05348993|DRUG|G03-52-01|G03-52-01 administered intramuscularly
223901298|NCT05348993|DRUG|Placebo|placebo
223528723|NCT04440774|BIOLOGICAL|ZIKA mid dose|A single dose of 2.5x10\^10 vp ChAdOx1 Zika
223901299|NCT02993159|DRUG|Afimoxifene|Applied to the breast
223901300|NCT02993159|OTHER|Laboratory Biomarker Analysis|Correlative studies
223901301|NCT02993159|OTHER|Placebo|Given PO
223901302|NCT02993159|OTHER|Placebo|Applied to the breast
223901303|NCT02993159|DRUG|Tamoxifen Citrate|Given PO
223901304|NCT02859727|DRUG|CDZ173|140 mg/day
223901305|NCT04855188|DEVICE|YVOIRE Y-Solution 540|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
223901306|NCT04855188|DEVICE|YVOIRE volume plus|Injection into the deep dermis layer and/or subcutaneous layer in the nasolabial folds based on the randomization assignment.
223901307|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 20 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
223901308|NCT06154083|DRUG|Follitropin-delta (Rekovelle) 15 mcg/day from D1|On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
223901309|NCT03482349|PROCEDURE|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
223901310|NCT06253819|OTHER|survey and physical test|6 min. walking test respiratory function test 30 second sit-stand test respiratory muscle test tıme up and go corbin posture analysis Waist/Hip Circumference Ratio Glucose and Cholesterol values Lanss Neuropathic Pain Scale
223901311|NCT05374304|OTHER|Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool|The BC/WC framework guides clinicians to present a choice between two options and uses scenario planning (narrative descriptions of plausible outcomes that acknowledge uncertainty) to describe the best, worst, and most likely case for each option. Scenarios are informed by clinical judgement and knowledge of patient risk factors. These scenarios plus an accompanying graphic aid help patients formulate and express preferences and concerns about treatment burdens and outcomes. The clinician then provides a goal-concordant recommendation.
223901312|NCT05354544|BIOLOGICAL|Autologous adipose derived SVF|A single dose of autologous adipose derived SVF isolated from adipose tissue will be administered to scarred vocal folds.
223901313|NCT06592144|DRUG|Testosterone cypionate (200mg/3ml)|It will be administered intramuscularly every 5 days, totaling 3 doses.
223901314|NCT06592144|OTHER|Sesame oil (3ml)|It will be administered intramuscularly every 5 days, totaling 3 doses.
223901315|NCT05859737|BEHAVIORAL|Disaster Preparedness Education Program|The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.
223901316|NCT05859737|OTHER|Disaster and Emergency Management Presidency Education|Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
223901317|NCT01529593|DRUG|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
223901318|NCT01529593|DRUG|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
223901319|NCT03649633|DRUG|Stress-dose Hydrocortisone plus Vitamin C|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
223901320|NCT03649633|DRUG|isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
223901321|NCT04042233|DRUG|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
223901322|NCT04042233|DRUG|Standard IV administration of vancomycin|IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
223901323|NCT03986931|OTHER|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
223901324|NCT03986931|OTHER|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
223901325|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
223528724|NCT04440774|BIOLOGICAL|ZIKA high dose|A single dose of 5x10\^10 vp ChAdOx1 Zika
223901326|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
223901327|NCT04907851|DRUG|RXC004|RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
223901328|NCT04907851|BIOLOGICAL|Denosumab|Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
223901329|NCT04907851|BIOLOGICAL|pembrolizumab|Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
223901330|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
223901331|NCT04111874|BEHAVIORAL|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
223901332|NCT06071429|DEVICE|MAGNITUDE Sirolimus-eluting Bioresorbable Scaffold|CLTI patients treated with MAGNITUDE BRS
223901333|NCT06071429|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|CLTI patients treated with PTA
223901334|NCT06417021|OTHER|Frontal Ultrasound Machine|Ultrasound machine will be placed in a frontal position
223901335|NCT06417021|OTHER|Lateral Ultrasound Machine|Ultrasound machine will be placed in a lateral position
223901336|NCT06069661|DEVICE|Aortic Stenosis|F2 Filter and Delivery system to cover the 3 great cerebral vessels
224276827|NCT01503333|BEHAVIORAL|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
224276828|NCT03806335|OTHER|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
224276829|NCT03806335|OTHER|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
223901337|NCT04116398|DRUG|Dexamethasone with 2 loading doses followed by PRN regimen.|"* Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~* Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®/Topcon; and/or increase of CSMT \> 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~* Minimal time limit between two IVI : 12 weeks~* Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)"
223901338|NCT05801380|DRUG|AChE inhibitor monotherapy|This is a drug treatment using Donepezil only
223901339|NCT05801380|DRUG|AChE inhibitor and NMDA receptor antagonist combination therapy|This is a drug treatment combining Donepezil and Memantine
223901340|NCT06481280|DIETARY_SUPPLEMENT|Test Formula|Infants will receive an extensively hydrolyzed formula during the double-blind placebo-controlled food challenge (DBPCFC) and will continue on this formula during the open-label feeding phase if they tolerate it.
223901341|NCT06481280|DIETARY_SUPPLEMENT|Placebo Formula|Infants will receive a placebo formula during the DBPCFC to compare against the test formula.
223901342|NCT05472961|BEHAVIORAL|Target and Stimulus|The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
223901343|NCT05711758|PROCEDURE|PSAM Treatment Patients|PSAM is a pylorus-sparing antral myotomy performed under general anesthesia. Endoscopic myotomy is then performed applying the principles of submucosal endoscopy and techniques used during gastric per-oral endoscopic myotomy (G-POEM). A submucosal bleb is created proximal to the pylorus. A longitudinal mucosal incision is made with an endoscopic knife. The endoscope is then introduced into the submucosal space, and the knife is used to dissect the submucosal fibers. Antral myotomy is performed starting proximal to the pyloric ring extending to the mucosal access site. The myotomy entails cutting of the inner circular and oblique muscle bundles or may be full thickness at the discretion of the endoscopist. The mucosal entry is then closed using endoscopic suturing or clips.
223901344|NCT05562401|DEVICE|Coconut Water|Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.
223901345|NCT05562401|DRUG|Oral Electrolytes|Is be considered a drug that not require medical prescrption and containing water, carbohydrates and electrolytes.
223901346|NCT00740454|OTHER|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
223901347|NCT06481436|BEHAVIORAL|Use of ChatGPT|Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
223901348|NCT04638413|BEHAVIORAL|Walking (W)|Participants engage in 30 min of walking daily, for three weeks.
223901349|NCT04638413|BEHAVIORAL|Walking + PolyRules! (W+PolyRules!)|Participants alternate between 30 min of walking on half of the days and 30 min of gamified inhibitory control on the other days.
223901350|NCT04081701|DIAGNOSTIC_TEST|Ga68-DOTATATE-PET/MRI|"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."
223901351|NCT06505980|BEHAVIORAL|Brief Behavioral Parenting Program|The brief behavioral parenting program is a 6 session, group-based behavioral parent training program. The components include support-building, parenting strategy education, and actively practicing parenting strategies. It is delivered through telehealth.
223901352|NCT05452902|BEHAVIORAL|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
223901353|NCT05452902|BEHAVIORAL|Nutrition Education|12 weeks of implementing eating tips and tracking food.
223901354|NCT03849443|DRUG|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
223901355|NCT03849443|DRUG|Vitamin C 250 MG Oral Tablet|Oral method of placebo
223901356|NCT03849443|DRUG|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
223901357|NCT02353819|RADIATION|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
223901358|NCT05810220|DEVICE|Electrode-Neural Interface|Measurements taken from the electrode-neural interface will be used to guide elimination of poorly functioning ABI electrodes and improve speech perception outcomes.
223901359|NCT01529983|PROCEDURE|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
223901360|NCT01529983|DEVICE|High-intensity focused ultrasound|High-intensity focused ultrasound (HIFUS) is an FDA-approved method for periorbital treatment and nonablative tissue tightening. Ultrasound waves induce a vibration in the tissue, generating heat and increasing the tissue temperature within a focal area. The tissue changes depend on amount of heat and exposure duration. These findings are similar to the thermally induced changes within the skin after CO2 laser fractional ablative treatments.
223901361|NCT05486156|OTHER|A Time with e-Nature|"Integrated multisensory experience (aesthetic, emotional and knowledge) in two stages:~1. Observation of nature through the senses (smell, hearing, sight, touch, taste) and the appreciative look.~2. Observation focused on the local avifauna and flora during the trail accompanied by a research biologist from the group."
224276830|NCT03806335|OTHER|General anesthesia|All patients will receive general anesthesia prior to infiltration
223901362|NCT04595630|OTHER|data collection from the hospital records|The clinical data from the patients enrolled in the study, such as the medical history, functional state, and EuroSCORE, and the hematological, basic renal, hepatic, and metabolic chemistry findings (including cTn as defined per the protocol), the operative data (operating time, blood loss, cardiopulmonary and cross-clamp time, number of arterial and venous grafts, the number of distal anastomoses, flow measured at all bypass grafts at the end of the intervention and the need for an assist device) and CCT scan data (at discharge from hospital facility) will be obtained from the hospital records. The data will be entered into a database.
223901363|NCT01210807|DEVICE|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
223901364|NCT01210807|DEVICE|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
223901365|NCT04996017|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
223901366|NCT04996017|DRUG|Placebo|Placebo will be supplied as sterile liquid in 20ml vials. the vial is designed
223901367|NCT06447987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
223901368|NCT06447987|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223901369|NCT06447987|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223901370|NCT06447987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223901371|NCT06447987|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
223901372|NCT06447987|BIOLOGICAL|Cetuximab|Given IV
223901373|NCT06447987|PROCEDURE|Computed Tomography|Undergo CT and PET
223901374|NCT06447987|DRUG|Cyclophosphamide|Given IV
223901375|NCT06447987|PROCEDURE|Echocardiography|Undergo ECHO
223901376|NCT06447987|DRUG|Fludarabine|Given IV
223901377|NCT06447987|PROCEDURE|Leukapheresis|Undergo leukapheresis
223901378|NCT06447987|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223901379|NCT06447987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223901380|NCT06447987|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223901381|NCT06539416|PROCEDURE|MitraClip implantation|The MitraClip is used to catch the leaky parts of the mitral valve, and it is tested to ensure the leak is reduced.
223901382|NCT03566940|BIOLOGICAL|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
223901383|NCT03566940|BIOLOGICAL|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
223901384|NCT05314764|DRUG|Cefiderocol|Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
223901385|NCT00704262|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
223901386|NCT06449287|OTHER|Diet|The diet intervention will start after all baseline testing is complete
223901387|NCT06449287|BIOLOGICAL|Blood Draw|Blood samples will be collected biweekly.
223901388|NCT06449287|BIOLOGICAL|Ketone/Glucose Monitoring|Hand-held glucometer will be used daily to monitor dietary intervention adherence.
223901389|NCT06449287|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
223901390|NCT06449287|BIOLOGICAL|Urine Analysis|24 hour urine collection will be done biweekly.
223901391|NCT06449287|BEHAVIORAL|Neuropsychological Measures - ANAM|The first cognitive assessment will be done via Automated Neuropsychological Assessment Metrics (ANAM). This cognitive battery is a library of computer-based tests of domains including attention, concentration, reaction time, memory, processing speed, decision-making, and executive function.
223901392|NCT03490240|BEHAVIORAL|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
223901393|NCT03490240|BEHAVIORAL|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
223901394|NCT03029884|DEVICE|Open-Loop DBS|Conventional brain stimulation that is tonically providing stimulation, without feedback
223901395|NCT03029884|DEVICE|Sham Stimulation|No Active Stimulation
223901396|NCT03029884|DEVICE|Closed-Loop DBS|Feedback enabled brain stimulation, where stimulation is provided on demand in response to pain biomarkers.
223901397|NCT03189498|DRUG|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
223901398|NCT05358145|BEHAVIORAL|Tinkering Activities|Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.
223901399|NCT05358145|BEHAVIORAL|Control Tinkering Activities|Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.
223901400|NCT05358145|BEHAVIORAL|Board Games Activities|Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
223901401|NCT05405426|OTHER|Red blood cell transfusion|The intervention is a strategy for when red blood cell transfusion will be administered (see description of Arms). However, volume of RBC transfused in the two arms is not specified by this study. Red blood cell transfusion strategy for ECMO weaning and decannulation is not specified by this study. Red blood cell transfusion after ECMO decannulation is not specified by this study.
223901402|NCT04573387|PROCEDURE|Operation|All participants are treated with burr-hole craniotomy and a drainage system as follows. Participants undergo surgical procedure under local anesthesia in the hemisphere with a lateral position, but general anesthesia is performed when participant cannot tolerate the operation. A single 1.5 cm burr hole is drilled over the maximum width of the hematoma cavity. After coagulating with bipolar diathermy, dura mater is opened with a cruciate incision. A soft catheter is placed carefully in all directions of the hematoma cavity for irrigating subdural collections with 1,000 mL warm Ringer's lactate saline until clarification. The drainage catheter is inserted ½ length of the maximum diameter of the hematoma cavity toward the frontal region. After the skin is closed, the catheter was connected to a soft collection bag that is placed under the head for passive drainage. During the drainage period, participants stay in bed until the drain is removed.
223901403|NCT04573387|PROCEDURE|Fixed-time drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. The drainage will be removed after 48 hours.
223901404|NCT04573387|PROCEDURE|Exhaustive drainage|All participants will be treated with a one-burr-hole craniotomy with irrigation and a closed drainage system. If the computed tomography (CT) scan on the first day after surgery indicates that the affected brain region shows sufficient re-expansion, the drainage catheter will be removed when drainage ceases. If subdural collections remain in the hematoma cavity, the participant will be treated with 30,000 U urokinase injection into the hematoma cavity through the catheter. The catheter will be closed and reopened in 1.5-2 hours, and a CT scan will be performed when drainage ceases. If the CT scan shows sufficient re-expansion of the brain, the catheter will be removed. However, if the brain does not show good re-expansion and there is still a residual subdural collection, the above steps will be repeated. If the participant is subjected to urokinase injection for 3 times, the catheter will be removed when drainage ceases.
223901405|NCT04573387|PROCEDURE|Postoperative computed tomography|All participants undergo a CT scan before the drain is removed, and the last CT scan will be performed before the patient is discharged from the hospital.
223901406|NCT05322044|BEHAVIORAL|Financial incentives|Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
223901407|NCT06501859|OTHER|Standard of care physical therapy|Standard rehabilitation protocol for 3 months.
223901408|NCT06501859|DEVICE|Shoulder pacemaker with physical therapy|Standardized rehabilitation protocol with utilization of the shoulder pacemaker device 3 times per week over a 3-month period.
223901409|NCT05477186|BIOLOGICAL|CV0501 (3 μg)|Study vaccine was administered as a single intramuscular injection.
223901410|NCT05477186|BIOLOGICAL|CV0501 (6 μg)|Study vaccine was administered as a single intramuscular injection.
223901411|NCT05477186|BIOLOGICAL|CV0501 (12 μg)|Study vaccine was administered as a single intramuscular injection.
223901412|NCT05477186|BIOLOGICAL|CV0501 (25 μg)|Study vaccine was administered as a single intramuscular injection.
223901413|NCT05477186|BIOLOGICAL|CV0501 (50 μg)|Study vaccine was administered as a single intramuscular injection.
223901414|NCT05477186|BIOLOGICAL|CV0501 (100 μg)|Study vaccine was administered as a single intramuscular injection.
223901415|NCT05477186|BIOLOGICAL|CV0501 (200 μg)|Study vaccine was administered as a single intramuscular injection.
223901416|NCT04164641|DEVICE|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
223901417|NCT05813236|DEVICE|Novosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
223901418|NCT05813236|DEVICE|Monosyn® in resective periodontal surgery|The aim of resective procedures is the re-establishment of a healthy periodontium at a reduced level, accepting as irreversible the destruction that has already occurred. In essence, these procedures are all designed to achieve pocket elimination or reduction by the apical shift of the gingival margin.
223901419|NCT06449638|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223901420|NCT06449638|OTHER|Revita|Participants will receive weekly applications of Revita and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223715317|NCT01822171|OTHER|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
223901421|NCT06449638|OTHER|Relese|Participants will receive weekly applications of Relese and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223901422|NCT06449638|OTHER|Cogenex|Participants will receive weekly applications of Cogenex and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223901423|NCT06449638|OTHER|Enverse|Participants will receive weekly applications of Enverse and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223901424|NCT05643079|PROCEDURE|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with metal/Bio-Tenodesis screws|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by\~10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Metal/Bio-Tenodesis screw(MBS). The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with an MBS in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
223901425|NCT05643079|PROCEDURE|medializing calcaneal osteotomy and/or transfer of the flexor digitorum longus tendon (FDL) with Shark Screws®|"The calcaneus osteotomy is performed dorsal proximal to plantar distal with caution of the peroneal tendons and sural nerve. After mobilization the dorsal fragment is displaced medially by approx.10mm. Thereafter, a guide wire is placed from plantar-lateral into the ventral portion of the calcaneus under fluoroscopic control. After stab incision and length measurement, the osteotomy is fixed with a Shark Screw®. The lateral projection of the edge is straightened. Opening of the tendon sheath of the FDL muscle and dissection distally to Henry's node. Settling of the tendon and arming with a shuttle suture. Tendon diameter measurement. Place a guide wire at os naviculare directed from plantar to dorsal in 20°proximal guidance. Pull through the FDL tendon from plantar to dorsal and fixation with the Shark Screw® in 20°of pointed foot position and inversion with appropriate desired tension. The tendon is then sutured to the stump of the tibialis posterior tendon, retinaculum sutures."
223901426|NCT04137107|DRUG|Oxaliplatin|Given standard of care oxaliplatin
223901427|NCT04137107|DRUG|Duloxetine Hydrochloride|Given PO
223901428|NCT04137107|DRUG|Duloxetine|Given PO
223901429|NCT04137107|OTHER|Quality-of-Life Assessment|Ancillary studies
223901430|NCT04137107|OTHER|Questionnaire Administration|Ancillary studies
223901431|NCT04137107|OTHER|Placebo|Given PO
223901432|NCT01019564|DEVICE|Complete Easy Rub Formula MPS|Multi-purpose solution
223901433|NCT01019564|DEVICE|Aquify MPS|Multi-purpose solution
223901434|NCT05158166|DRUG|DaxibotulinumtoxinA|This is a long-acting alternative to traditional Botox A treatment.
223901435|NCT06078085|OTHER|Postoperative rehabilitation program|The rehabilitation program is created by a physical therapist
223901436|NCT02747303|PROCEDURE|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
223901437|NCT06307600|DRUG|RD06-03 cell injection|The patients in this intervention will use RD06-03 cell injection with 3 dose dose 1: 1×10\^5 CAR+ T Cells/kg dose 2: 3×10\^5 CAR+ T Cells/kg dose 3: 5×10\^5 CAR+ T Cells/kg Dosage form: IV injection Frequency of administration：1 time
223901438|NCT04550182|PROCEDURE|Positioning schedule|"The Braden scale will be collected every morning. Patients' care will be friction and repositioning applied at a frequency defined by the Braden scale:~6 ≥ Braden ≤ 8: alternate positioning every 2 hours 9 ≥Braden ≤ 13: alternate positioning every 4 hours 14 ≥ Braden ≤ 17: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 6 hours.~18 ≥Braden ≤ 23: No alternative of the positioning required, but a friction and an evaluation of the cutaneous state every 12 hours.~Positioning will alternate semi-lateral decubitus at 30, semi-Fowler 30° -30°, half-sitting position 45° with elevation of the lower limbs.~A medical prescription as part of the daily reassessed care will ensure the absence of absolute contraindication to the mobilization or contraindication to certain positions.Friction will be performed during repositioning."
223901439|NCT06295744|RADIATION|Radiation Therapy|WBI with SIB delivered over 5 fractions
223715318|NCT01822171|OTHER|Home medication if needed|Patient will be provided with medication to take home, when needed.
223901440|NCT00324805|BIOLOGICAL|Bevacizumab|Given IV
223901441|NCT00324805|DRUG|Cisplatin|Given IV
223901442|NCT00324805|DRUG|Docetaxel|Given IV
223901443|NCT00324805|DRUG|Gemcitabine Hydrochloride|Given IV
223901444|NCT00324805|OTHER|Laboratory Biomarker Analysis|Correlative studies
223901445|NCT00324805|DRUG|Pemetrexed Disodium|Given IV
223901446|NCT00324805|OTHER|Questionnaire Administration|Ancillary studies
223901447|NCT00324805|DRUG|Vinorelbine Tartrate|Given IV
223901448|NCT04364048|DRUG|Induction Durvalumab|Induction durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 1 cycle,
223901449|NCT04364048|DRUG|Chemotherapy|Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion. The chemotherapy regimen used should be administered per institutional standards following the prescribing guidelines for each drug
223901450|NCT04364048|RADIATION|Radiation|Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons per institutional standards. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa). Therapy will be 1.8-2 Gy per day; 5 days per week, excluding holidays per institutional standard as this is a standard of care regimen for this patient population. 54-66 Gy will be delivered.
223901451|NCT04364048|DRUG|Consolidation durvalumab|Durvalumab at 1500 mg intravenously (IV) will be given on Day 1 of a four week cycle for 12 cycles
223901452|NCT03687814|OTHER|Low FODMAP diet/PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
223901453|NCT03687814|OTHER|sham diet/PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
224276831|NCT00468208|DRUG|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~* 500 mg of abatacept for body weight less than 60 kg~* 750 mg of abatacept for body weight between 60 and 100 kg~* 1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
223901454|NCT06558123|PROCEDURE|block|Single Level and Two Level Deep Parasternal Intercostal Plane (DPIP) Block
223901455|NCT06090305|BEHAVIORAL|levidex|Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).
223901456|NCT06090305|BEHAVIORAL|Control|Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).
223901457|NCT06090305|OTHER|treatment as usual (TAU)|treatment as usual (TAU)
223901458|NCT05792085|BEHAVIORAL|EHR-based GDMT Optimization|Patients will be prescribed appropriate GDMT for HFrEF if they meet clinical criteria by the study team, appropriate lab work and follow up testing will be sent and followed up by the team. All recommendations and plans will be copied to primary care providers who can opt out if disagree, but also to improve telementoring to build clinical comfort.
223901459|NCT06189365|DEVICE|Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder|Subject will receive the Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder.
223901460|NCT05543733|BEHAVIORAL|Home exercise program|Participants will complete a 6-month prescription telemedicine-based structured home exercise program. Baseline information will be used to develop a personalized home exercise program. This program will involve downloading the MyDataHelps application on a mobile device to securely collect wearable device information like step counts, activity minutes, and heart rate. Additionally, participants will have multiple virtual visits as well as the 2 in-person visits.
223901461|NCT06318455|OTHER|Breathing exercise|For 12 weeks they will do kumbaka breathing exercise for 5 minutes twice a day in the morning and evening
223901462|NCT05565417|DRUG|IMT-009|Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
223901463|NCT05565417|COMBINATION_PRODUCT|Fruquintinib|Fruquintinib will be administered according to the FDA-approved United States Prescribing Information (USPI).
223901464|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - More Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for cancer screening status and social needs and provide navigational support to cancer screening and social services.
223901465|NCT05742178|BEHAVIORAL|Educational Materials|Both PN and LI participants will receive tailored educational materials around cancer screening and SDH resources as needed.
223901466|NCT05742178|BEHAVIORAL|Patient Navigation (PN) - Less Intensive|The PN intervention will be administered by trained, bilingual CHWs: they will screen participants for social needs and provide navigational support to social services.
223901467|NCT05096364|BIOLOGICAL|AK111/Placebo|After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
223901468|NCT03206814|OTHER|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
223901469|NCT03206814|OTHER|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
223901470|NCT05743270|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
223901471|NCT05743270|OTHER|CCRT(concurrent chemoradiation therapy)|CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
223901472|NCT05743270|OTHER|carboplatin and paclitaxel|chemotherapeutic agents
223901473|NCT05743270|BIOLOGICAL|nivolumab|anti-PD1 monoclonal antibody
223901474|NCT03173703|DEVICE|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
223901475|NCT03173703|PROCEDURE|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
223901476|NCT03173703|DEVICE|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
224276832|NCT04759079|DEVICE|Acupuncture Needles|Acupuncture Needles placement at the PC6 in association to anti-emetic medication
224276833|NCT04759079|DRUG|Antiemetic Drug|Administration of Anti-emetic medication without acupuncture
224276834|NCT04372784|DEVICE|Cryotherapy|Cryotherapy entails introducing a 9 French catheter via the endoscope's accessory port. The catheter is advanced until it is visualized on the endoscopy monitor. Under 4 psi pressure, liquid nitrogen is sprayed from the catheter for twenty seconds over each four-centimeter segment of stricture
223901477|NCT03550950|DRUG|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
223901478|NCT03550950|DRUG|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
223901479|NCT03550950|DRUG|Placebo|Matching placebo will be administered as IV infusion or SC injection.
223901480|NCT01919554|BIOLOGICAL|500 IR house dust mites allergen extract tablet|One sublingual tablet daily during 10 days
223901481|NCT01919554|BIOLOGICAL|1000 IR house dust mites allergen extract tablet|Two sublingual tablets daily during 10 days
224276835|NCT04372784|PROCEDURE|Esophagogastroduodenoscopy with Balloon Dilatation|This procedure entails deploying a balloon via the accessory port of the esophagogastroduodenoscope under direct visualization and serially inflating the balloon. Balloon dilatation disrupts not only the muscular rings surrounding strictures but also the granulation tissue composing the strictures.
223528725|NCT04440774|BIOLOGICAL|Saline placebo|A single dose of isotonic saline solution (0.9%)
223901482|NCT01919554|BIOLOGICAL|1500 IR house dust mites allergen extract tablet|Three sublingual tablets daily during 10 days
223901483|NCT01919554|BIOLOGICAL|Placebo tablet|One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets
223901484|NCT06020235|DRUG|5% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
223901485|NCT06020235|DRUG|10% Nu-3 gel|The gel is called Nu-3 which is either applied once per day or twice per day to the infected ulcer.
223901486|NCT06020235|DRUG|Placebo|Placebo gel is either applied once per day or twice per day to the infected ulcer.
223901487|NCT05095571|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|For this study EH301 is defined as Investigational Product(s) (IP). The ALS extension study is an open label study with active treatment of all patients thet have passed through the NO-ALS trial.
223901488|NCT06648759|DEVICE|Vagal Nerve Stimulator|The vagal nerve stimulator device is a nonsignificant risk device that provides electrical impulses to the vagus nerve, located in the neck and ear regions. The device (pulse generator) and a wire lead (insulated wire) with electrodes on the end of the wire will send the electrical signals along the vagus nerve to your brainstem to activate various neurochemical coordinates.
223901489|NCT06648759|DEVICE|Placebo Vagal Nerve Stimulator|The sham vagal nerve stimulator device is a nonsignificant risk device that mirrors that of the active stimulator but does not provide electrical impulses to the vagus nerve.
223901490|NCT03906253|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
223901491|NCT05336214|OTHER|Virtual CGM initiation service|Primary care practices will refer patients to an external virtual initiation service staffed by clinical pharmacists, diabetes care and education specialists, and physicians. The initiation service will communicate with eligible patients (referred to the virtual initiation service by their provider) to review device options and provide patient education and support on device use for up to 12 months to help initiate use of the device. The initiation service will communicate with a patient's provider about treatment and follow up, but will not make treatment recommendations directly to patients.
223901492|NCT05336214|OTHER|Online educational module on CGM|Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.
223901493|NCT05336214|OTHER|Practice facilitation|A practice facilitator will support primary care practices in training team members using the American Academy of Family Physicians Transformation in Practice Series on CGM and in implementation of strategies to support CGM use for patients with diabetes in primary care.
223901494|NCT05919602|OTHER|Visualization of an image catalogue|Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
223901495|NCT06151392|DRUG|Probiotic Formula|probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
223901496|NCT06151392|DRUG|Zinc|Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
223901497|NCT06356168|BEHAVIORAL|Social Virtual Reality|Participants interact using virtual reality during dialysis.
223901498|NCT06356168|BEHAVIORAL|Individual Virtual Reality|Participants use virtual reality alone during dialysis.
223901499|NCT06085183|OTHER|Saline Injection 0.9%|Placebo
223901500|NCT06085183|DRUG|Indigotindisulfonate sodium 0.8%|Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice.
223901501|NCT04416984|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
223901502|NCT04416984|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
223901503|NCT04416984|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223901504|NCT04416984|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223901505|NCT04102150|DRUG|Valemetostat Tosylate|Once a day, 200 mg, oral administration
223901506|NCT05151653|DRUG|BI 765250|BI 765250
223901507|NCT05151653|DRUG|Placebo|Placebo
223901508|NCT04399941|DIAGNOSTIC_TEST|Venography|The venography will be performed as part of the patient's standard of care. The dialysis access will be punctured upstream of the arteriovenous anastomosis in AVF or AVG using a 4-F coaxial access set (Micro- puncture; Cook, Inc, Bloomington, Indiana). The contrast will be injected intravenously by a pump with 200 psi and a bolus of 2m/sec for total of 5 ml during upper extremity vein filming and 10 ml of contrast bolus by 3 ml/s during central vein filming while holding the breath in inspiration in anterioposterior plane.
223901509|NCT04399941|DIAGNOSTIC_TEST|Intravascular ultrasound (IVUS)|IVUS will be performed through the same sheath of the coaxial access set using an Eagle Eye Platinum RX digital catheter 7F over a compatible guidewire under fluoroscopic guidance. The lesion will be estimated fluoroscopically from the marker IVUS catheter in the vein and the cranial and caudal margins of stenotic lesion will be directly visualized during pullback of the IVUS catheter.
223901510|NCT04399941|OTHER|Image processing|Image processing will be performed by two radiologists in a blinded manner on the images devoid of personal identifier. An adjudication committee will oversee the process and confirm their findings in case of a discrepancy.
223901511|NCT02307058|RADIATION|LEAD RT|The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
223901512|NCT02307058|RADIATION|HEIGHT RT|The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
223901513|NCT04696263|DEVICE|Da Vinci ® Xi system - MP Robotic Radical Prostatectomy|After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.
223901514|NCT04696263|DEVICE|Da Vinci ® SP system - SP Robotic Radical Prostatectomy|After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
223901515|NCT03387475|DRUG|Deferasirox|iron chelation
223901516|NCT05581017|PROCEDURE|Preoperative biliary drainage|Preoperative biliary drainage before pancreaticoduodenectomy. Might be needed if the biliary tract in obstructed and the surgery cannot be scheduled in near future.
223901517|NCT05056714|OTHER|Questionaries|The patient will answer several questionaries
223901518|NCT03212170|DRUG|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
223901519|NCT05431010|DEVICE|electroacupuncture|Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
223901520|NCT05431010|BEHAVIORAL|Rehabilitation Training|"The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period"
223901521|NCT05115942|DRUG|Hydronidone capsules|After randomization, the experimental group were orally received hydronidone capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d,30 min before meals for 52 weeks.
223901522|NCT05115942|DRUG|The placebo capsules|After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.
223901523|NCT06582355|OTHER|Neurofeedback|The participants will be instructed to use cognitive strategies to upregulate (increase) their brain activity in the selected brain region, with the suggestion that motor imagery may be particularly effective, for example, mental imagery of swimming or playing a musical instrument. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner, and the brain activity of the putamen will be displayed in real-time using a thermometer bar for visualization.
223901524|NCT06582355|OTHER|Kinesthetic imagery|The participants will be instructed to imagine movements during the active blocks. During the rest blocks, the participants will be instructed to relax. The instructions to start and stop the regulation and rest blocks are visualized on a screen in the scanner. No feedback is provided regarding brain activity.
223901525|NCT01197378|DRUG|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
223901526|NCT01205828|DRUG|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
223901527|NCT01205828|DRUG|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
223901528|NCT04458792|OTHER|Paraffin tissue samples|Paraffin tissue samples collected during surgery (neoplasic tissue and normal tissue
223901529|NCT04458792|OTHER|blood sample|MDM2 project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery circulant DNA project : Blood samples collected at different times : Before the surgery, and 1 month after the surgery radiotherapy toxicity : Blood samples collected before the radiotherapy
223901530|NCT03186729|DRUG|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
223901531|NCT06116526|DRUG|Dupilumab - Discontinuation|Drug injections are discontinued.
223901532|NCT06116526|DRUG|Dupilumab - Dose Reduction|The drug is given as a subcutaneous injection.
223901533|NCT06116526|DRUG|Dupilumab - Standard Dose|The drug is given as a subcutaneous injection.
223901534|NCT04455750|DRUG|Enzalutamide|Given PO
223901535|NCT04455750|DRUG|Rucaparib camsylate|Given PO
223901536|NCT04455750|DRUG|Placebo|Given PO
223901537|NCT04455750|DRUG|Leuprolide Acetate|Given IM
223901538|NCT04455750|DRUG|Goserelin Acetate|Given SC
223715319|NCT01822171|OTHER|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
223715320|NCT00183677|DRUG|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
223715321|NCT04563611|OTHER|Turkish Get-up exercise|TG exercise, in 7 different steps (1. Starting position, 2. Supine girya lifting, 3. Elbow supported kettlebell lifting, 4. Hand supported kettlebell lifting, 5. High bridge, 6. Half above knee and lunge position, 7. Standing up) and the return of these different steps.
223901539|NCT04455750|DRUG|Degarelix|Given SC
223901540|NCT04455750|OTHER|Quality-of-Life Assessment|Ancillary studies
223901541|NCT04455750|OTHER|Questionnaire Administration|Ancillary studies
223901542|NCT05546411|DRUG|mFOLFIRINOX|Combination of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin given by intravenous infusion
223901543|NCT05546411|DRUG|5-Fluorouracil (5-FU)|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223901544|NCT05546411|DRUG|Oxaliplatin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223901545|NCT05546411|DRUG|Irinotecan|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223901546|NCT05546411|DRUG|Leucovorin|Part of the FOLFIRINOX drug combination, given by intravenous infusion
223901547|NCT05546411|DRUG|NIS793|Given by intravenous infusion
223901548|NCT05546411|RADIATION|Chemoradiation|Combination of Chemo (Capecitabine) and Radiation Therapy
223901549|NCT05546411|PROCEDURE|Surgery|Surgical removal of tumor
223901550|NCT02606422|DEVICE|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
223901551|NCT02606422|DEVICE|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
223901552|NCT04625465|BEHAVIORAL|CBT Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order, with content equally distributed across the four content areas (i.e., psychoeducation regarding effects of stress, distress tolerance, emotion regulation, alcohol reduction).
223901553|NCT04625465|BEHAVIORAL|Attention Control Text Messaging|Over a 14 day period, participants will receive two text messages per day (one at 8 a.m. and one at 4 p.m.). They will receive hourly reminders for four hours or until the message is read. Participants receive the same messages in the same order. All texts will be supportive messages which express empathy and unconditional positive regard and provide support for dealing with stressors. These messages will be nondirective and will not include any CBT skill suggestions.
223901554|NCT03257462|DRUG|SPR001|SPR001 Capsules
223901555|NCT04221451|DRUG|venglustat GZ402671|"Pharmaceutical form: tablet~Route of administration: oral"
223901556|NCT04221451|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223901557|NCT06777537|DRUG|Talniflumate|Talniflumate was administered
223901558|NCT05881278|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
223901559|NCT06571994|BEHAVIORAL|Low Plastic Intervention|Participants will be provided with food that contain no or low plastic and PAC. This is defined as minimally processed (according to NOVA Classification) fresh produce where the supply chain is either known to be free, or likely to be free of plastic contamination. Foods that are canned, pickled, use plastic storage containers will be either avoided or substituted where possible with glass. Participants will also follow guidance concerning the preparation of their food. Plastic utensils used in the preparation of food will be substituted for non-plastic. Commonly used personal care products, e.g., shampoo and soaps, and cleaning products will be replaced with no/low PAC alternatives. Participants will be supplied with a comprehensive schedule, and instructions for the 4-week intervention.
223901560|NCT04708145|DRUG|Aflibercept Injection|Intravitreal 2mg aflibercept injection
223901561|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10\^7 cells/m\^2~Day 14: 2 x 10\^7 cells/m\^2~The doses are calculated according to the total T cell number."
223901562|NCT02065362|BIOLOGICAL|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10\^7 cells/m\^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10\^8 cells/m\^2 on Day 0, Day 1, or Day 2"
223901563|NCT03629340|DRUG|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
223901564|NCT03629340|DRUG|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
223901565|NCT04818645|DEVICE|ASSERT Insertable Cardiac Monitor|Subjects will be subcutaneously implanted with an Abbott ASSERT ICM with the device implant procedure per standard of care and current labelling. Data related to subjects' arrhythmias, via the Merlin.net Patient CareNetwork will be transmitted on a monthly basis to the treating physician and subsequently to the study coordination and database center (CCRC) at the University of Rochester. Data on the frequency/types of symptomatic (patient triggered) versus ICM detected (asymptomatic) arrhythmic events will be collected and adjudicated. Clinical data on medication, device interventions, cardiovascular events will be collected at follow-up visits.
223901566|NCT04818645|OTHER|Conventional Management and monitoring|Subjects randomized to the conventional management arm of the trial will undergo arrhythmia monitoring based on clinical indications and per standard available modalities including periodic electrocardiograms (ECG), Holter and/or event monitoring.
223901567|NCT03609021|PROCEDURE|Screening Mammography|Provide bilateral mammogram
223901568|NCT03609021|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223901569|NCT06277388|DEVICE|Impedance cardiography|The study conducted a 6-minute walk test (6MWT) in a hospital hallway following ATS guidelines. Patients rested for 10 minutes before the test. Impedance measurements were taken before (2 minutes), during (6 minutes), and after (3 minutes) the walk, recording cardio-dynamic parameters with impedance cardiography (ICG).
224276836|NCT03838341|DEVICE|AtriClip™ LAA Exclusion System|The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
224276837|NCT03838341|DRUG|Oral anticoagulation therapy|Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
224276838|NCT02451306|DRUG|Quetiapine|See information in arm description.
224276839|NCT02451306|DRUG|Placebo|See information in arm description.
223715322|NCT04563611|OTHER|Askling L-Protocol|he protocol consists of 3 different exercises. These are exercise 1 aimed at increasing flexibility, exercise 2 providing strength and trunk / pelvis stabilization, and exercise 3 aiming at specific strengthening. Pain is not allowed to be provoked when performing the exercises.
224276840|NCT00930241|DRUG|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
223715323|NCT04563611|OTHER|Nordic hamstring exercise|To perform this exercise, participants will be asked to stand in an upright position on their knees. Hands and arms will be positioned on the chest and the individuals will be held by the physiotherapist at their heels. The individual will then be asked to lower the upper body forward as slowly as possible. Verbal commands will be given throughout the movement so that the hip and trunk smoothness is not disturbed.
223715324|NCT04563611|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
223715325|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of original formulation.
223715326|NCT05893576|DRUG|HRS9531|Receive a single dose of HRS9531 of new formulation.
223715327|NCT00113022|DRUG|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
223715328|NCT00113022|DRUG|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
223715329|NCT00882063|DRUG|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
223715330|NCT01762878|DRUG|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
223715331|NCT01762878|DRUG|Placebo|Dry powder for oral inhalation once daily using DIKUS device
223715332|NCT00223262|DRUG|Lamotrigine (Drug)|
223715333|NCT03746457|BEHAVIORAL|Behavioral intervention|Individual counseling, group intervention, collective advocacy
223715334|NCT03711461|DEVICE|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
223715335|NCT03711461|DEVICE|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
223715336|NCT03851757|DEVICE|waist-shaped interdental brush|use four times each per interdental space
223715337|NCT03851757|DEVICE|cylindric interdental brush|use four times each per interdental space
223715338|NCT02641808|OTHER|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
223715339|NCT02641808|OTHER|no follicular flushing|
223715340|NCT02159417|OTHER|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~* Knowledge of the disease~* Food~* Physical Activity and care of feet~* The therapeutics"
223715341|NCT02206542|DEVICE|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
223715342|NCT02206542|OTHER|Physical therapy|
223715343|NCT02206542|DEVICE|Electroacupuncture|
223715344|NCT04802317|DIAGNOSTIC_TEST|Identification of the composition of the intestinal microbiota|Identification of the composition of the intestinal microbiota
223715345|NCT00457301|BEHAVIORAL|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
223715346|NCT03217812|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
223715347|NCT03217812|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2 (if serum creatine is \>2 mg/dL at baseline, participants must be administrated 4.5 mg/m\^2 of melphalan, instead of 9 mg/m\^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
223715348|NCT03217812|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
223715349|NCT03217812|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion or daratumumab SC, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
223715350|NCT03208712|DRUG|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
223715351|NCT03208712|DRUG|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
223715352|NCT02107170|DRUG|Sevoflurane|sevoflurane-based general anesthesia
223715353|NCT02107170|DRUG|Propofol|total intravenous anesthesia
223715354|NCT02107170|DRUG|Remifentanil|
223715355|NCT04981548|OTHER|no intervention|no intervention
223715356|NCT00285805|DRUG|Rosiglitazone versus placebo|
223715357|NCT00285805|DRUG|response (sodium excretion) to amiloride infusion|
223715358|NCT00285805|DRUG|response (sodium excretion) to furosemide infusion|
223715359|NCT04817631|OTHER|tuboovarian abscess|Evaluating the surgical and medical management of tuboovarian abscess
223715360|NCT03750617|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
223715361|NCT04942899|DRUG|letrozole|concurrent capecitabine 500 mg three times daily in combination with letrozole 2.5 mg orally once daily.
223715362|NCT05269043|DEVICE|Medimonitor|A digital solution consisting of smartphone/tablet based application gathering data from medical and other devices provided to the patients. These devices are as follows: tablet, smart inhaler, spirometer, blood pressure monitor, pulse oximetry device, particulate matter sensor.
223715363|NCT01887665|BEHAVIORAL|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
223715364|NCT02367443|RADIATION|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
223715365|NCT00478231|DRUG|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
223715366|NCT00436384|PROCEDURE|Monitoring-blood samples drawn for CMV testing|
223715367|NCT04226872|BEHAVIORAL|My Tools for Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions that they face after the person living with dementia has moved to a long-term care setting.
223715368|NCT05021601|PROCEDURE|Bi-atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
223715369|NCT05021601|PROCEDURE|Left atrial ablation|This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
223715370|NCT02957669|BEHAVIORAL|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
223715371|NCT02957669|BEHAVIORAL|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
223715372|NCT05944757|DRUG|PRP plasma rich platelets|Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month
223715373|NCT05944757|DRUG|Autologous serum|Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
223715374|NCT01595607|OTHER|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
223715375|NCT06053996|RADIATION|Hepatopulmonary radio-sterilization|Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
223715376|NCT04338074|DRUG|Tranexamic acid tablets|Oral dosing of 1300 mg p.o. three times per day x 5 days versus identical placebos
223715377|NCT04338074|DRUG|Placebo oral tablet|2 tablets p.o. three times per day x 5 days
223715378|NCT03035409|DRUG|Anamorelin Hydrochloride|Given PO
223715379|NCT03035409|BEHAVIORAL|Exercise Intervention|Undergo physical activity
223715380|NCT03035409|OTHER|Laboratory Biomarker Analysis|Correlative studies
223715381|NCT03035409|OTHER|Nutritional Assessment|Undergo nutritional counseling
223715382|NCT03035409|OTHER|Quality-of-Life Assessment|Ancillary studies
223715383|NCT03035409|OTHER|Questionnaire Administration|Ancillary studies
223715384|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 1|milk supplement with probiotics
223715385|NCT01073033|DIETARY_SUPPLEMENT|milk supplement 2|milk supplement without probiotics
223715386|NCT01607242|OTHER|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
223715387|NCT01607242|OTHER|Voice Handicap Index|Subjective Evaluation of Voice disorders
223715388|NCT01607242|OTHER|Swallowing Assesment|Swallowing function questionnaire
223715389|NCT03954236|DRUG|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
223715390|NCT03954236|OTHER|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
223715391|NCT01202812|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
223715392|NCT01202812|OTHER|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
223715393|NCT02304718|BEHAVIORAL|Stationary bike|
223715394|NCT03734276|OTHER|High intensity activity|Cyclo-ergometer session in high intensity setting
223715395|NCT03734276|OTHER|control arm|Usual care
223715396|NCT05717946|DIETARY_SUPPLEMENT|Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.|We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.
223715397|NCT05717946|OTHER|control group|We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
223715398|NCT01552694|DRUG|Sitagliptin|Oral, 100 mg/day for 2 months
223715399|NCT01552694|DRUG|Placebo|oral, matching placebo daily for 2 months
223715400|NCT03599999|DRUG|Adverse events detection|type of adverse events detected during treatment with Temocillin and imputed to Temocillin
223715401|NCT00672243|DRUG|Erlotinib + sirolimus|Erlotinib \& sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
223715402|NCT02004119|DRUG|KHK4577|
223715403|NCT02004119|DRUG|Placebo|
223715404|NCT01918436|BEHAVIORAL|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
223715405|NCT01918436|OTHER|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
223901570|NCT04735458|OTHER|Procedure/Surgery: Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
223901571|NCT04114669|BEHAVIORAL|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
223901572|NCT04114669|BEHAVIORAL|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
223901573|NCT02820987|DRUG|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
223901574|NCT02820987|DRUG|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
223901575|NCT02820987|DRUG|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
223901576|NCT04269200|DRUG|olaparib|Olaparib tablets
223901577|NCT04269200|BIOLOGICAL|durvalumab|Durvalumab by intravenous infusion
223901578|NCT04269200|DRUG|durvalumab placebo|Matching placebo for intravenous infusion
223901579|NCT04269200|DRUG|olaparib placebo|Placebo tablets to match olaparib
223901580|NCT04269200|DRUG|Carboplatin|Standard of care chemotherapy
223901581|NCT04269200|DRUG|Paclitaxel|Standard of care chemotherapy
223901582|NCT06512805|BEHAVIORAL|Routine transport|"1. Before the transfer of the patient:~   ① The doctor determines the destination of the patient based on the patient's condition and issues transfer orders.~  * The responsible nurse assesses the patient's consciousness, circulation, respiration, etc., and fills out the Transfer Patient Handover Record in the transferring department section.~     * The responsible nurse prepares the equipment, medications, and patient's belongings required for the transfer.~2. During the transfer:~   Monitor the patient's vital signs.~3. Upon arrival at the receiving department:~   * Place the patient with the receiving department nurse. ② Verbally hand over the patient's condition to the receiving department nurse and hand over the patient's belongings and medications.~     * The responsible nurse of the receiving department completes the remaining part of the Transfer Patient Handover Record."
223901583|NCT06512805|BEHAVIORAL|Post-guideline transfer|"In the intervention group, nurses receive implementation strategies developed during the preparation phase. These strategies aim to modify the behavior of healthcare personnel through implementation, thereby conducting evidence-based (based on the guidelines) in-hospital transfer interventions for pediatric patients.The interventions received by pediatric patients are derived from the recommended practices evaluated for evidence availability in the guidelines. These include specific transfer procedures, the Transfer Risk Level Classification Criteria, Personnel Qualifications, Equipment, and Medications Allocation Based on Transfer Risk Level, Transfer Preparation Checklist, and Transfer Handover Checklist 2.0."
223901584|NCT05704543|DRUG|Buprenorphine Extended-Release Injection|Administered as a subcutaneous injection.
223901585|NCT01856478|DRUG|methotrexate|intravenous bolus injection, once weekly
223901586|NCT01856478|DRUG|afatinib|oral intake, once daily
223901587|NCT06827197|DIAGNOSTIC_TEST|Blood test|Blood samples were withdrawn from all the neonates under strict aseptic conditions and stored at -80°C for detecting PGE2 and IL-1β levels. PGE2 and IL-1β concentrations were measured using ELISA.
223901588|NCT03704415|PROCEDURE|Extended endoscopic sinus surgery|ESS of all sinuses
223901589|NCT03704415|PROCEDURE|Limited endoscopic sinus surgery|Partial ethmoidectomy
223901590|NCT05576792|OTHER|Ranibizumab|Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
223901591|NCT02272998|DRUG|ponatinib hydrochloride|Given PO
223901592|NCT02272998|OTHER|laboratory biomarker analysis|Correlative studies
223901593|NCT06248567|DRUG|ZSP1273|Oral
223901594|NCT02310399|DEVICE|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
223901595|NCT06158490|DRUG|JYP0061 15 mg|Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
223901596|NCT06158490|DRUG|JYP0061 30 mg|articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
223901597|NCT06158490|DRUG|Placebo|Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
223901598|NCT05388708|DEVICE|ECMO support|ECMO prescribed by treating physicians for respiratory support in the setting of PARDS.
223901599|NCT05388708|OTHER|PROSpect protocolized therapies|"PROSpect is testing the impact of supine/prone positioning and conventional mechanical ventilation (CMV)/high-frequency oscillatory ventilation (HFOV) on clinical outcomes in 1,000 children with severe PARDS. PROSpect manages severe PARDS subjects using a protocol that reserves ECMO for protocol failure.~The CMV group targets an exhaled tidal volume of 5-7mL/kg of ideal body weight and a peak inspiratory pressure \<28 cm of H2O. The positive end expiratory pressure (PEEP) and FiO2 are titrated by a PEEP-FiO2 titration grid. The HFOV group titrates the mean airway pressure to target a FiO2 \< 0.5 and a goal hemoglobin oxygen saturation of 88-92%. The frequency is titrated between 8-12 Hz and amplitude from 60-90 to achieve a goal pH of 7.15-7.30. Ventilation protocols are implemented until 28 days or extubation. Children randomized to the prone positioning will remain prone for at least 16 consecutive hours per day. Children randomized to supine positioning group remain supine."
223901600|NCT02888327|DRUG|AL-794|
223901601|NCT02888327|DRUG|Oseltamivir|
223901602|NCT02888327|DRUG|Digoxin|
223901603|NCT02888327|DRUG|Midazolam|
223901604|NCT02888327|DRUG|Pitavastatin|
223901605|NCT02888327|DRUG|JNJ-63623872|
223901606|NCT03691935|DRUG|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
223901607|NCT03691935|DRUG|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
223901608|NCT03012971|DRUG|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
223901609|NCT03012971|DRUG|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
223901610|NCT06853080|DRUG|Bortezomib|4 cycles of Bortezomib treatment, with each cycle include 8 doses of Bortezomib at 1.3 mg/m2
223901611|NCT06853262|OTHER|Manual Therapy Protocol|The techniques were divided into three main groups: first, those carried out in transverse planes, then carried out in a specific zone, and finally, those aimed at the course of the vagus nerve. The techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
223901612|NCT06853262|OTHER|Sham Manual Protocol|The Sham techniques were divided into three main groups: first, those carried out in transverse planes, then carried out in a specific zone, and finally, those aimed at the course of the vagus nerve. The Sham techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
223901613|NCT06852404|OTHER|Photovoice|Photovoice is a participant-driven research method that enables individuals to communicate their experiences through visual data. It is especially useful for exploring social issues and the challenges people encounter. In this approach, participants capture images that they find meaningful in relation to the research topic, using these photographs to express their emotions, thoughts, and personal experiences.
223901614|NCT06852924|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
223901615|NCT06852001|DEVICE|X-ray stereotactic radiotherapy for brain metastasis|X-ray stereotactic radiotherapy for brain metastasis
223901616|NCT06842212|DEVICE|Balance Training|balance training exercises performed on the biodex balance system 3 sessions every week for 12 weeks
223901617|NCT06838780|OTHER|No intervention|No intervention for this retrospective study
223901618|NCT02618577|DRUG|Edoxaban|Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF
223901619|NCT02618577|DRUG|ASA|ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.
223901620|NCT02151981|DRUG|Chemotherapy|Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
223901621|NCT02151981|DRUG|Cross-over to Osimertinib|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with Osimertinib 80mg, once daily. These subjects may continue treatment with Osimertinib even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to Osimertinib."
223901622|NCT05536388|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)
223901623|NCT06335823|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
223901624|NCT06335823|DEVICE|Placebo Transcutaneous electrical nerve stimulation (TENS)|All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
223901625|NCT05446168|DRUG|tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
223901626|NCT06426550|PROCEDURE|Periodontal treatment|Conventional periodontal treatment, scaling and root planning, will be performed with ultrasound (Dabi Atlante, Rio de Janeiro, RJ, Brazil) complemented with Gracey curettes (Golgran, São Caetano do Sul, SP, Brazil) on each patient under local anesthesia. The maintenance therapy will include professional plaque control and scaling and root planning in recurrent periodontal pockets, every 30 days, until 3 months, when the periodontal parameters will be reassessed.
224276841|NCT00930241|DRUG|Prograf®|Prograf® (two daily doses of Tacrolimus)
224276842|NCT05425342|DEVICE|Smartwatch ECG|Self-recorded 9-lead smartwatch ECGs
223715406|NCT02303366|RADIATION|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
223715407|NCT02303366|DRUG|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
223901627|NCT05406362|DRUG|VAD044 Part I|capsules to be taken once daily for 12 weeks
223901628|NCT05406362|DRUG|VAD044 Part II|capsules to be taken once daily for 12 months
223901629|NCT05560893|BEHAVIORAL|Relational Savoring Intervention|Relational savoring (RS) involves recalling a time when one supported or comforted another person and doing so brought deep positive emotion (joy, satisfaction, love, or peace); these moments of connection in service of another are common among the CSPs who work for our community agency, but may go unnoticed in the face of the urgent stressors the COVID-19 pandemic has brought about. Prolonging and enhancing attention to these moments has the potential to both help CSPs restore regulation in the face of stress and to motivate CSPs to continue engaging in meaningful work that serves their communities.
223901630|NCT05493072|OTHER|RxConnect|Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
223715408|NCT04925583|RADIATION|Stereotactic body radiotherapy (SBRT)|"* level 0 (de-escalation): 10 x 5.0Gy~* level 1 (start): 10 x 5.5Gy~* level 2: 10 x 6.0Gy~* level 3: 10 x 6.5Gy"
223715409|NCT00004730|DRUG|magnesium sulfate|
223715410|NCT06049238|OTHER|Maitland Mobilization|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
223715411|NCT06049238|OTHER|Post facilitation stretch|"* Hot Pack for 10 mints~* Active and active-assisted exercises (10 reps x 3 sets) for the~* Elbow flexion and extension~* Wrist flexion and extension~* Forearm supination and pronation"
223715412|NCT02349529|BEHAVIORAL|Psychosocial Intervention Group|6 group sessions
223715413|NCT02349529|OTHER|Waiting list control|Treatment as usual
223715414|NCT01007266|BEHAVIORAL|Assignment of a Lay Patient Partner|
223715415|NCT01223430|DRUG|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
223715416|NCT03724032|DEVICE|HD-tDCS*|Non-invasive brain stimulation (active protocol)
223715417|NCT03724032|DEVICE|Sham HD-tDCS*|Non-invasive brain stimulation (sham protocol)
223715418|NCT01323283|DIETARY_SUPPLEMENT|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
223715419|NCT01323283|DIETARY_SUPPLEMENT|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
223715420|NCT05649397|OTHER|cervical manipulation|provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
223715421|NCT05649397|OTHER|conventional therapy|15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
223715422|NCT01102517|PROCEDURE|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
223715423|NCT01102517|PROCEDURE|axillary thoracotomy|axillary thoracotomy lobectomy
223715424|NCT04617171|DRUG|Benralizumab 30 MG/ML [Fasenra]|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
223715425|NCT04617171|DRUG|Placebos|Benralizumab/placebo initiated at an acute severe asthma exacerbation, then continued over a period of 48 weeks
223715426|NCT05509114|DEVICE|Virtual Reality Glasses|The intervention group of patients watched a video with virtual reality glasses during the transrectal biopsy process.
223715427|NCT00001880|DRUG|methotrexate|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
223715428|NCT00001880|DRUG|Cyclosporin|Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
223715429|NCT05593926|DIETARY_SUPPLEMENT|Myota Metabolic Regulator|The functional food, Myota Metabolic Regulator, consisting of 20g of a powdered fibre mix, to be taken daily alongside usual diet for 24 weeks.
223715430|NCT03298165|DEVICE|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
223715431|NCT03752983|DIAGNOSTIC_TEST|blood samples|blood samples
223715432|NCT01070498|DRUG|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
223715433|NCT00873015|DRUG|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
223715434|NCT00873015|DRUG|Saline|14 day continuous infusion of a vehicle control infusion
223715435|NCT03364933|BEHAVIORAL|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~* Weekly check-in with and availability to patient/family~* Attendance at family meetings~* Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~* Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~* The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
223715436|NCT04546815|DRUG|Daptomycin|According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.
223901631|NCT03850418|DRUG|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
223901632|NCT04737941|PROCEDURE|Endothermal Ablation|Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
223901633|NCT04737941|PROCEDURE|Foam Sclerotherapy|Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
223901634|NCT05759637|DIAGNOSTIC_TEST|1mg DST|measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
223901635|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
223901636|NCT00597909|DRUG|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
223901637|NCT00597909|DRUG|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
223901638|NCT06203093|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
223901639|NCT01946789|BIOLOGICAL|ALT-803|N-803 will be administered at the following doses intravenously: 0.3/0.5, 1.0, 3.0, 6.0 ug/kg N-803 will be administered at the following does subcutaneously: 6.0, 10.0, 15.0, 20.0 ug/kg N-803 will be administered intratumorally at a dose of 10.0 ug/kg, followed by N-803 administered subcutaneously at a dose of 15.0 ug/kg. Each treatment cycle consists of 4 weeks on therapy and 2 weeks off. Patients will receive weekly dose of ALT-803 for 4 weeks (Days 1, 8, 15, and 22) used for the identification of the OBD and MTD. After a 2-week rest period (Weeks 5 and 6) and recovery of any dose limiting toxicities to grade 0-1 of Cycle 1, a second 6-week cycle (4 weeks on treatment and 2 weeks off) can begin. After a rest period during Weeks 5 and 6 of Cycle 2, stable or benefitting patients assessed at week 8 +/- 1 may receive up to 2 additional 6-week cycles.
223901640|NCT04935359|DRUG|NIS793|Concentrate for solution infusion (Liquid in Vial)
223901641|NCT04935359|DRUG|Nab-paclitaxel|Per locally approved formulation
223901642|NCT04935359|DRUG|Gemcitabine|Per locally approved formulation
223901643|NCT04935359|DRUG|Placebo|Dextrose 5% in water (D5W) solution for infusion
223901644|NCT05997030|DEVICE|low intensity focused ultrasound (LIFU)|Subjects will undergo undergo a single LIFU of the target brain region
223901645|NCT04703179|OTHER|Genetic test evaluation|Patients with rare and undiagnosed disease and their family members may be evaluated on a case by case basis. The research study may perform multi-omics testing to provide a diagnosis or to provide biomarker discovery.
223901646|NCT04748601|DRUG|Qudexy XR|Extended-Release Capsule
223901647|NCT04748601|DRUG|Placebo|Qudexy XR Matching capsules
223901648|NCT06489405|OTHER|Horticultural practices|The first week of the program was 'Getting to know horticultural practices', the second week was 'Painting pots', the third week was 'Planting vegetable seedlings', the fourth week was 'Preparing compost', the fifth week was 'Making pressed flowers' and the sixth week was 'Harvesting vegetables'.
223901649|NCT05374798|DEVICE|Heart Rate Variability-Biofeedback (HRV-B) via Smartwatch Device Intervention|"Participants will wear activity trackers equipped with continuous ambulatory physiological monitoring and geolocation. Ecological momentary assessment (EMA; 4 times daily plus optional event-triggered reports) of alcohol use, couple conflict including IPV, and affect will be completed via smartphone application for 28 days. During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed. HRV-B will guide participants in an evidence-based paced breathing technique (about 6 breaths per minutes) using visualization on thier mobile device of thier real-time respiratory and cardiac parameters.~During days 21-28, participants will also be prompted to complete a 10 minute self-administered HRV-B session at least once daily. Subjective usability, feasibility, and acceptability of HRV-B will be assessed."
223901650|NCT02816853|DRUG|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
223901651|NCT02816853|DRUG|Placebo|Matching placebo will be administered.
223901652|NCT02816853|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
223901653|NCT06840340|DEVICE|Customised mouthguards|Wore customised mouthguards and measurement athletic performance of baseball and softball performance.
223901654|NCT04861077|DRUG|[18F]FMISO-PET with contrast-enhanced MRI|Triple negative breast cancer patients that are planning to undergo immunotherapy and consent to this study will have 3 imaging visits. Imaging visit 1 will take place before the patients start immunotherapy. Imaging Visit 2 will take place after the patient completes the 1st cycle of immunotherapy and before they start their 2nd cycle. Imaging Visit 3 will take place when the patient completes the 2nd cycle of immunotherapy and before they start the 4th cycle.
223901655|NCT06833944|OTHER|HIIT intervention program|"The HIIT protocol will involve 3 training sessions per week for 18 weeks (a total of 74 sessions lasting 36 minutes). The program will be divided into two phases: phase 1 (adaptation to HIIT training: during the first 4 weeks, the intensity will be progressively increased to ensure the safety and progressive physical conditioning of the patients.~The high-intensity intervals will follow the Norwegian 4 x 4-minute HIIT model: 4 bouts of 4 minutes of high intensity corresponding to a rating of perceived exertion (RPE) 15 to 18 on the Borg 6 to 20 Scale33 and an 85-95%HRmax, interspersed with 3-minute active recovery intervals (RPE of 11 to 13 and 54-69%HRmax). This protocol has been widely applied and is safe in general and in clinical populations. Additionally, this protocol includes the training parameters recently proposed in a recent meta-analysis to maximize the training effects of HIIT on cardiorespiratory fitness (primary outcome)."
223901656|NCT06833944|OTHER|MICT intervention program|"The MICT protocol will involve 3 training sessions per week for 18 weeks (a total of 74 sessions lasting 44 minutes). The workout will be performed at RPE 11 to 13 (54-69%HRmax) to provide an isoenergetic workload (same energy expenditure) as the HIIT group.~Each session will include 3 parts: warm-up (5 min), main MICT workout (34 min), and a cool-down (5 min). Warm-up will include mobility, core, and aerobic exercise involving major muscle groups. The main workout (MICT) will include exercises involving major muscle groups using the same materials and rationale as commented on in the HIIT group. The cool-down phase will include aerobic exercise at a lower intensity, stretching, and relaxation exercises (RPE\<11). The highest and average HR and RPE for each session will be registered."
223715437|NCT02624752|DIETARY_SUPPLEMENT|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
223715438|NCT02033109|DRUG|PC-1005|Intravaginal use
223901657|NCT06840613|OTHER|Myo-Inositol|"Intervention: Patients in this group will receive 2 capsules of Myo-Inositol (2000 mg each) along with 500 mg Glucophage three times a day.~Monitoring: Blood glucose levels will be measured at baseline and after treatment"
223901658|NCT06840613|OTHER|Glucophage|"Intervention: Patients in this group will receive 500 mg Glucophage three times a day.~Monitoring: Blood glucose levels will be measured at baseline and after treatment."
223901659|NCT06833424|PROCEDURE|Dural venous sinus stenting|40 patients with idiopathic intracranial hypertension according to Modified Dandy Criteria will subjected to Dural venous stenting
223901660|NCT06820138|DEVICE|Brainsonix Ultrasound Device|This device delivers low intensity focused ultrasound and delivers either active or sham sonication depending upon the transducer pad used.
223901661|NCT03683277|DRUG|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
223901662|NCT02188264|DRUG|Cyclosporine|Given PO
223901663|NCT02188264|OTHER|Laboratory Biomarker Analysis|Correlative studies
223901664|NCT02188264|OTHER|Pharmacological Study|Correlative studies
223901665|NCT02188264|DRUG|Selumetinib|Given PO
223901666|NCT06837896|DRUG|QLG1080|Oral administration
223901667|NCT06839729|BEHAVIORAL|CEASE+|The intervention will be delivered by the clinician to smoking parents who attend the office visit and to smoking parents not present at the visit via resources sent home with a non-smoking parent. If the smoking parent is present in clinic, the intervention consists of a brief, clinician- delivered motivational intervention that includes messaging around the risks of household smoking, verbal recommendation for establishing home/car smoke-free rules, a printed prescription for nicotine replacement therapy and quitline information, and messaging on the benefits of cessation and a quitline referral. If the smoking parent is not present in clinic, the intervention will include clinician-delivered messaging to the non-smoking parent to share CEASE+ resources with the parent who smokes and an invitation for the parent who smokes to participate in a single call delivered by a culturally-/linguistically-congruent community health worker to connect them to CEASE+ resources.
223901668|NCT06840964|DIETARY_SUPPLEMENT|omega 3 ethyl esters at 90%|2 grams/day of omega 3 capsules will be administered orally, for 12 weeks
223901669|NCT06840964|DIETARY_SUPPLEMENT|Placebo|Mygliol 812
223901670|NCT06840561|DRUG|Local triamcinolone injection combined with fibrin glue spray|TA injection and fibrin glue spray are used in two sessions after ESD immediately (D0) and 7 days later(D7). In the first session, triamcinolone (40mg/1ml/ampul, China) in 100mg total quantity is diluted with 10ml saline to make a 4mg/0.5ml solution and injected in the surface of post-wound symmetrically at 25 points (0.5ml/point) depending on the defective area. But TA injection should avoid muscular injury place. We check the wound to make sure there is no bleeding or perforation after the TA injection, then spray 5-10ml fibrin glue (Porcine fibrin sealant kit, China) on the injection wound. The spray dosage is depending on the wound area. The key point is that the glue could cover all the injection wound. Seven days later, the protocol is carried out again.
223715439|NCT02033109|DRUG|HEC gel|
223715440|NCT02863952|OTHER|Single photon emission computed tomography myocardial perfusion imaging|
223901671|NCT03502590|DEVICE|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
223901672|NCT05887401|BEHAVIORAL|Core|The core intervention will include behavioral lessons, activity tracker, weekly adaptive physical activity goals, weekly tailored feedback summary.
223901673|NCT05887401|BEHAVIORAL|Simplified Nutrition Monitoring (Green)|Simplified diet monitoring using smartphone tracking of green foods using a traffic light approach.
223901674|NCT05887401|BEHAVIORAL|Behavioral: Simplified Nutrition Monitoring (Red)|Simplified diet monitoring using smartphone tracking of red foods using a traffic light approach.
223901675|NCT05887401|BEHAVIORAL|Nutrition Goals (Yes)|Participant will be assigned a personalized weekly nutrition goal related to nutrition monitoring condition.
223901676|NCT05887401|BEHAVIORAL|Nutrition Goals (No)|Participant will not be assigned a personalized weekly nutrition goal.
223901677|NCT05887401|BEHAVIORAL|Supportive Text Messages (Yes)|Participant will receive up to 5 supportive text-messages from the study staff per week.
223901678|NCT05887401|BEHAVIORAL|Supportive Text Messages (No)|Participant will not receive supportive text-messages.
223901679|NCT05887401|BEHAVIORAL|Lesson Delivery (Once)|All behavioral lessons will be made available to participant simultaneously.
223901680|NCT05887401|BEHAVIORAL|Lesson Delivery (Weekly)|A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
223901681|NCT05655195|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
223901682|NCT05655195|DEVICE|GENUS device (sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
223715441|NCT02863952|DEVICE|novel cadmium-zinc-telluride (CZT) SPECT cameras|
223901683|NCT05576155|DRUG|Compound 21|Compound 21 + Ringer's is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M
223901684|NCT05576155|DRUG|Compound 21 + losartan|Compound 21 + losartan (43 µM) is perfused at 10 doses increasing serially for 10 minutes each from 10\^-12 M to 10\^-3 M.
223901685|NCT03756051|OTHER|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have \~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
223901686|NCT03756051|OTHER|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
223901687|NCT05864560|DEVICE|Ankura™ AAA Stent Graft System; Ankura™ Cuff Stent Graft System; Ankura™ AUI Stent Graft System|Patients will be implanted with Ankura™ AAA, Cuff or AUI Stent Graft System in accordance with the Instructions for Use (IFU).
223901688|NCT03478215|BIOLOGICAL|Mesenchymal Stromal Stem Cells (MSCs) Infusion|"Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion."
223901689|NCT03478215|OTHER|Normal Saline (Placebo) Infusion|"Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion."
223901690|NCT02568176|DRUG|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
223901691|NCT02568176|DRUG|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
223901692|NCT02568176|DRUG|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
223901693|NCT01275677|DRUG|Cyclophosphamide|Given IV
223901694|NCT01275677|DRUG|Docetaxel|Given IV
223901695|NCT01275677|DRUG|Doxorubicin|Given IV
223901696|NCT01275677|DRUG|Doxorubicin Hydrochloride|Given IV
223901697|NCT01275677|OTHER|Laboratory Biomarker Analysis|Correlative studies
223901698|NCT01275677|DRUG|Paclitaxel|Given IV
223901699|NCT01275677|OTHER|Quality-of-Life Assessment|Ancillary studies
223901700|NCT01275677|BIOLOGICAL|Trastuzumab|Given IV
223901701|NCT05012683|DEVICE|Point Partial|Patient is fit with Point Partial partial finger prosthetic system
223901702|NCT00335816|DRUG|fluorouracil|Given IV
223901703|NCT00335816|DRUG|leucovorin calcium|Given IV
223901704|NCT00335816|DRUG|oxaliplatin|Given IV
223901705|NCT00335816|PROCEDURE|conventional surgery|Patients undergo surgery
223901706|NCT00335816|RADIATION|radiation therapy|Patients undergo radiotherapy
223901707|NCT00335816|OTHER|laboratory biomarker analysis|Correlative studies
223901708|NCT00335816|GENETIC|DNA analysis|Correlative studies
223901709|NCT00335816|GENETIC|polymerase chain reaction|Correlative studies
223901710|NCT00335816|OTHER|immunohistochemistry staining method|Correlative studies
223901711|NCT05612061|BEHAVIORAL|Indigenous Recovery Planning|"The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future."
223901712|NCT04767841|DRUG|Metformin|Metformin 1000mg tablet plus celecoxib 200 mg capsule
223901713|NCT04767841|DRUG|Placebo|Placebo tablet plus celecoxib 200 mg capsule
223901714|NCT05906017|PROCEDURE|Open Hernia surgery|midline ventral hernia repair - open
223901715|NCT05906017|PROCEDURE|Robotic Hernia surgery|midline ventral hernia repair - robotic
223901716|NCT06518941|DRUG|Donepezil|Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
224276843|NCT03482206|DEVICE|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
224276844|NCT01235715|DRUG|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
223901717|NCT06198426|DRUG|IBI3004|IBI3004 will be administered. The Dose Limiting Toxicity (DLT) will be observed in the first treatment cycle. After completion of the DLT observation period, subjects will continue to receive IBI3004 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
223901718|NCT05002608|BEHAVIORAL|Health Insurance Navigation Tools Program|The program will be delivered via videoconferencing by a navigator over a 3-month period and will consist of 5 sessions. The navigation intervention sessions will be as follows: Session 1- Insurance Plan Basics; Session 2- Your Plan in Relation to Legal Policy; Session 3- Navigating Your Own Plan and Overcoming Obstacles; Session 4- Managing Care Costs; Session 5- Understanding Your Medical Bills.
223901719|NCT05416658|OTHER|The Antipsychotic Medication Decision Aid (APM-DA)|The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.
223901720|NCT06529094|BEHAVIORAL|Provider training|Provider participants will complete TMS training, CAPP-FIT demonstration and simulation in use of the CAPP-FIT with a standardized patient.
224276845|NCT02994394|DRUG|OPC-41061|
223901721|NCT06529094|BEHAVIORAL|CAPP-FIT intervention with RA facilitation|After consent and survey completion, RA to email/text CAPP-FIT link to Veteran the day before established clinic visit. RA to remain available to answer questions to help Veteran participant complete Veteran Survey and submit the responses through eScreening. The Provider Report will appear in CPRS with a Provider notification. RA to meet Veteran participant in the clinic after the clinic visit to complete the Veteran satisfaction survey.
223901722|NCT06529094|BEHAVIORAL|CAPP-FIT implementation during maintenance phase|Providers will attend focus group after Arm 2 to determine sustainability of CAPP-FIT use in clinic workflow. Clinic provider will act on that determination for 10 months during maintenance phase.
223901723|NCT06545188|OTHER|Mortality Attitudes Personality Survey|Two open questions about death and mortality will bei administered to trigger mortality salience
223901724|NCT06545188|OTHER|Dental treatment questions (control condition)|Two open questions about a dental treatment (control condition)
223901725|NCT04164888|DRUG|CIVI 007|hypercholesterolemia agent
223901726|NCT06849219|DRUG|Oxcarbazepine|Oxcarbazepine will be started at a dose of 150 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1800 mg per day.
223901727|NCT06849219|DRUG|Carbamazepine|Carbamazepine will be started at a dose of 100 mg BD, and follow-up will be done every month. Dose will be titrated up if minimal pain relief, to a maximum dose of 1200 mg per day.
223901728|NCT06852352|PROCEDURE|Modified deep cervical Lymphatic-Venous Anastomosis|Deep cervical lymph-vein anastomosis surgery, connecting deep cervical lymph input vein vessels to enhance glymphatic-mediated protein clearance
223901729|NCT06393608|DRUG|Epsom salt|Epsom salt solution in water, 25% concentration
223901730|NCT06393608|OTHER|Water|Water
223901731|NCT06471023|DIETARY_SUPPLEMENT|TP1|Vitamin C formulation 1, 1000 mg
223901732|NCT06471023|DIETARY_SUPPLEMENT|TP2|Vitamin C formulation 2, 1000 mg
223901733|NCT06471023|DIETARY_SUPPLEMENT|TP3|Vitamin C formulation 3, 1000 mg
223901734|NCT06471023|DIETARY_SUPPLEMENT|TP4|regular Vitamin C, 3000 mg
223901735|NCT06471023|DIETARY_SUPPLEMENT|CP|Vitamin C formulation 4, 1000 mg
223901736|NCT06471023|DIETARY_SUPPLEMENT|RP|regular Vitamin C, 1000 mg
223901737|NCT03372317|DRUG|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
223901738|NCT06852417|BEHAVIORAL|Health qigong training|Participants will receive two 60-minute Baduanjin qigong training sessions every week under the instruction and supervision of qualified qigong instructors over 12 weeks (i.e., 24 sessions in total). Baduanjin qigong consists of eight forms of gentle movements, and it takes about 10 to 15 minutes to complete a full cycle. Participants will learn to practice each form gradually over the first 12 sessions. In the remaining 12 sessions, the participants will go through all the movements 2-3 times, with guided practice on rhythmic breathing and mind regulation (attention to body and breathing) to be performed in coordination with the movements. Instructions on each movement, voice-guide audios, and demonstration videos will be provided for participants' daily self-practice. They will be advised to practice Baduanjin for at least 10 minutes every day.
223901739|NCT06850974|DEVICE|Foley Balloon Catheter|18 French Foley Balloon placed trans-cervically and inflated with 30-60ml of Normal Saline.
223901740|NCT06850974|DRUG|Misoprostol|400 mcg of buccal misoprostol sublingual
223901741|NCT06850974|DEVICE|Laminaria|Laminaria will be placed in the cervix according to the following standard formula: Estimated gestational age -10 = number of 5mm laminaria.
223901742|NCT03252834|DIAGNOSTIC_TEST|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
223901743|NCT04818021|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
223901744|NCT04818021|BEHAVIORAL|Facial Skin Stretch|Facial skin stretch
223528726|NCT05703230|OTHER|Structured preoperative multidisciplinary team meeting|"The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?"
223901745|NCT05655702|OTHER|Community based TB intervention|"* 3 bi-annual RDSS (RDSS1, 2 and 3), for TB screening~* A PWID-specific Information and communication (I\&C) TB module to improve PWID awareness about TB,~* Peer group support to facilitate TB treatment initiation and retention,~* Implementation of a peer support contact tracing and screening for active TB in contacts."
223528727|NCT02918448|OTHER|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
223528728|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 25mg|To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
223901746|NCT04532346|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug. hydroxychloroquine has been reported to improve the clinical status of chILD cases wtih genetic causes. The exact mechanism of action of hydroxychloroquine is unknown. In additon to having anti-inflammatory properties, hydroxychloroquine has been shown to affect intracellular processing of surfactant protein.
223901747|NCT04409353|DEVICE|Distraction-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx-Distraction software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
223901748|NCT04409353|DEVICE|Sham VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx-Sham software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
223901749|NCT04409353|DEVICE|Skills-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx+ software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
223901750|NCT04409353|DEVICE|Activity Tracker|Participants among all arms will be provided the option to passively wear a Fitbit Charge 4 throughout their 90-day study enrollment period. The Fitbit collects biometric data such as daily steps, heart rate, hours of sleep, stages of sleep, and sleep efficiency.
223901751|NCT06774820|PROCEDURE|self-blocking tenodesis|the LHB tendon is detached from its origin in the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate later localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
223901752|NCT06774820|PROCEDURE|arthroscopic tenodesis|LHB tendon is detached from its origin, and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-lasso loop tenodesis technique. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
223901753|NCT05341557|DRUG|BPI-371153|Subjects will receive BPI-371153 until disease progression
223901754|NCT06336863|DIAGNOSTIC_TEST|Allosure and TruGraf|Precision medicine will be employed to withdraw immunosuppression in kidney transplant recipients.
223901755|NCT06336863|OTHER|Immunosuppression Taper|An immunosuppression taper will be employed over a 12-month period for those that are deemed immune quiescent.
224276846|NCT04599621|DIAGNOSTIC_TEST|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10),Collection of blood samples to determine the level of uric acid|Collection of blood samples to determine the level of certain cytokines (TNF-α, IL-1β, IL-4 and IL-10) All study participants had blood in the morning on fasting after 8-12 hours of fasting from the cubital vein. Determination of the level of cytokines TNF-α, IL-1β, IL-4 and IL-10 in blood serum by enzyme-linked immunosorbent assay (ELISA). All participants in the study had blood drawn in the morning on fasting after 8-12 hours of fasting from the cubital vein. The level of uric acid was determined on the CYAN Start apparatus using a unified method.
224276847|NCT02203617|BEHAVIORAL|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
223528729|NCT06569524|DRUG|TQA2225/AP025 or TQA2225/AP025 Placebo 50mg|To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)
223528730|NCT06570122|BEHAVIORAL|5A's/5R's advice|5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.
223901756|NCT04081103|DRUG|Nexagon® (lufepirsen) High Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
223901757|NCT04081103|DRUG|Nexagon® (lufepirsen) Low Dose Concentration|Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
223901758|NCT04081103|DRUG|Vehicle|Vehicle is administered topically in the affected eye three (3) times over 28 days.
223901759|NCT04081103|DRUG|Open-label Nexagon® (lufepirsen)|Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
223901760|NCT06169527|DRUG|Dupilumab|Dupilumab cohort
223901761|NCT05701657|OTHER|Diet A|This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, nuts/seeds, and olive oil, and very low amounts of sugar sweetened drinks and desserts. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
223901762|NCT05701657|OTHER|Diet B|This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
223901763|NCT05701657|OTHER|Diet C|This diet has moderate-high amounts of vegetables, meat/poultry/egg, nuts/seeds, dairy and fats/oils, low amounts of fruits, and very low amounts of grains and sugars. Menus are developed for 1600kcal, 2100kcal, 2600kcal, 3200 kcal and 3700 kcal.
223901764|NCT05701657|OTHER|Liquid Mixed Meal Tolerance Test|A liquid mixed meal tolerance test will occur in Module 1 and Module 3. For this test, participants will drink two servings of Ensure® Original, vanilla flavor. The meal will also contain acetaminophen (Tylenol) which will show how the smoothie moves through the participant's gut.
224276848|NCT02203617|BEHAVIORAL|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
223528731|NCT06570122|OTHER|Health warning leaflet|The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
223901765|NCT05701657|OTHER|Diet-Specific Mixed Meal Tolerance Test|The diet-specific mixed meal tolerance test is administered at the end of each dietary intervention period in Modules 2 and 3. The meal test is a breakfast meal similar to the one eaten on the 14-day diets. Thus, three test meals will be used, one for each of the three test diets (Diet A, Diet B, Diet C). The energy (kcal) level of the breakfast meal will be based on each participant's diet prescription. The nutritional composition diet-specific MMTT will be the same test meal for all participants.
223901766|NCT05754203|RADIATION|Super-hyperfractionation Pulse Radiotherapy|Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.
223901767|NCT06609356|PROCEDURE|Study Visit 1|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. The study will randomize participants to first receive a five-hour intravenous insulin infusion to achieve normal plasma insulin concentrations (Eu-Ins) or higher plasma insulin concentrations (Hi-Ins)
223901768|NCT06609356|DRUG|Placebo|"* T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies."
223901769|NCT06609356|PROCEDURE|Study Visit 2|Hyperinsulinemic, euglycemic clamp and flow-mediated dilation (FMD) study. Insulin levels infused during the five-hour insulin infusion will be opposite of the first visit.
223901770|NCT06609356|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).
223901771|NCT04046562|BEHAVIORAL|PAW|Pain and Weight Treatment plus standard of care
223901772|NCT04046562|BEHAVIORAL|Pain Education|Pain Education plus standard of care
223901773|NCT05973890|BEHAVIORAL|WhatsApp|Participants assigned to the WhatsApp arm will receive messages, audios, images and videos in a moderated, closed WhatsApp group over a 14-month duration. The messages aim to motivate blood donation, encourage participants to discuss their blood donation experiences, and allow them to share their motivations for donating blood.
223901774|NCT05973890|BEHAVIORAL|docudrama|Participants randomized to this arm will meet three times (Month 2; Month 5 and Month 10), in a group setting, during the intervention. Each group will have a maximum of 20-40 participants. This is a stand-alone activity, which is not associated with a donation event. During each meeting, participants will be asked to watch, in the group setting, an episode of drama, lasting 15 minutes. The docudrama on blood donation will address participant's concerns regarding blood donation and address common donor fears.
223901775|NCT06469723|OTHER|INFA Program|"Participants will be screened using the INFA Screening tool, comprising of assessments for multiple domains that are part of existing routine admission nursing assessments, including functional decline, delirium, recurrent falls, self-reported hearing and visual impairment questionnaires, malnutrition risk, oral health, and dysphagia screening. Nurse-led protocols will be done to address each identified geriatric syndrome.~Participants with complex cases (defined as delirium and/or high-risk falls) will be referred to the GeriCARE service, with capabilities for performing comprehensive geriatric assessment (CGA) guiding discharge planning. Referrals to geriatricians can be initiated whenever necessary, facilitating access to specialised geriatric medical expertise.~Participants will also receive comprehensive discharge planning and systematic follow-up procedures, done by ward resource nurses."
223901776|NCT05309291|DEVICE|Theranova 400 Dialyzer|Dialysis performed in HD mode.
223901777|NCT05309291|DEVICE|FX 800 Dialyzer|Dialysis performed in HDF mode.
223901778|NCT05332067|DRUG|Omalizumab|"Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe"
223901779|NCT05332067|DRUG|Placebo|Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
223901780|NCT05183828|PROCEDURE|Biospecimen Collection|Undergo collection of saliva samples
223901781|NCT05183828|DRUG|Letrozole|Given PO
223901782|NCT05183828|OTHER|Questionnaire Administration|Ancillary studies
223901783|NCT05944458|DRUG|N acetyl cysteine|Fluimucil 600 mg iv to be taken twice daily as infusion
223901784|NCT05944458|DRUG|Placebo|20 ml normal saline iv every 12 hours
223901785|NCT06856174|DRUG|Transdermal estradiol gel|All participants: Estradiol gel 0.1%, 0.75 grams (corresponding to estradiol 0.75 mg) applied to the skin of the upper thigh once daily for 12 weeks.
223901786|NCT06856174|DRUG|Micronized Progesterone|Participants with intact uterus: Encapsulated micronized progesterone 100 mg orally once daily for 12 weeks.
223901787|NCT06856174|DRUG|Placebo for estradiol gel|All participants: Placebo for estradiol gel 0.1%, 0.75 grams applied to the skin of the upper thigh once daily for 12 weeks.
223901788|NCT06856174|DRUG|Placebo for micronized progesterone|• Participants with intact uterus: Encapsulated placebo for micronized progesterone 100 mg orally once daily for 12 weeks.
223901789|NCT06661824|BEHAVIORAL|Aggression management care bundle|The aggression management care bundle consists of six components. All of these are high-evidence level interventions consisting of behavioral and nursing interventions aimed at managing aggression. These six interventions are: Risk Assessment, Cognitive Remediation Training, Social Skills Training, De-Escalation Techniques, Milieu Therapy, Improving Sleep.
224276849|NCT06616961|DRUG|Semaglutide Pen|"In this study, the intervention involves administering semaglutide (Fitaro) to participants for weight management. The treatment protocol includes the following steps:~Initial Dose: Participants will start with a subcutaneous injection of semaglutide at a dose of 0.25 mg once weekly for the first four weeks to allow for tolerance and adjustment.~Dose Escalation: After the initial period, the dose will be increased at four-week intervals as follows:~Week 5: Increase to 0.5 mg Week 9: Increase to 1 mg Week 13: Increase to 1.7 mg Week 17: Increase to a maximum dose of 2.4 mg, if necessary, based on individual weight loss response and tolerability."
224276850|NCT04982445|DRUG|CABENUVA|CABENUVA will be administered IM at infusion centers/ASAs
224276851|NCT03385135|DRUG|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
223901790|NCT05840172|DEVICE|Test condom A (NRL condom with 5% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
223901791|NCT05840172|DEVICE|Test condom B (NRL condom with 3% benzocaine paste)|In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
223901792|NCT05840172|DEVICE|Control NRL condom|IIn each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
223901793|NCT04581564|BEHAVIORAL|Rhythm-based speech therapy app (i.e., Speech Hero)|Participants will be issued a tablet device pre-installed with a rhythm-based application. They will initially be given a tutorial on how to use the application and encouraged to use application on a daily basis but at the least 5 times a week.
223901794|NCT04581564|BEHAVIORAL|Non-rhythm based (singing) application (conventional speech therapy)|Participants will be issued a tablet device pre-installed with a singing-based application. They will initially be given a tutorial on how to use the application and encouraged to use application on a daily basis but at the least 5 times a week.
223901795|NCT02992704|DRUG|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
223901796|NCT05098704|DRUG|clopidogrel treatment|75 mg daily during 24 months
223901797|NCT05098704|DRUG|Placebo|75 mg daily during 24 months
223901798|NCT05209152|DRUG|AMG 176|Administered as an intravenous (IV) infusion.
223901799|NCT05209152|DRUG|Azacitidine|Administered as an IV infusion or subcutaneous (SC) injection.
223901800|NCT04700072|BIOLOGICAL|Pembrolizumab|Administered via IV infusion at a specified dose on specified days
223901801|NCT04700072|BIOLOGICAL|Pembrolizumab/Quavonlimab|Administered via IV infusion at a specified dose on specified days
223901802|NCT04700072|DRUG|Lenvatinib|Administered via oral capsule at a specified dose on specified days
223901803|NCT06842498|DRUG|FG-3246|FG-3246 will be administered per schedule specified in the arm description.
223901804|NCT04242199|DRUG|INCB099280|INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
223901805|NCT06358261|BEHAVIORAL|Diabetes Prevention Patient Activation Clinical Decision Support Tool|Diabetes Prevention Patient Activation Clinical Decision Support Tool will be used by the doctor during the visit to discuss lifestyle management
223901806|NCT06171698|DEVICE|Research Prototype Monitor|Continuous vital sign is collected via a research prototype monitor
223901807|NCT05673187|DRUG|Adagrasib|Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
223901808|NCT06345755|DRUG|VX-407|Solution or Suspension for oral administration.
223901809|NCT06345755|DRUG|Placebo|Solution or Suspension for oral administration.
223901810|NCT06345755|DRUG|Midazolam|Syrup for oral administration.
223901811|NCT06345755|DRUG|VX-407|Suspension or Tablets for oral administration.
223901812|NCT06867185|DEVICE|Brief Electrical Stimulation Therapy|10-minutes of electrical stimulation to repaired nerve
223901813|NCT06867185|PROCEDURE|Digital Nerve Repair|Standard of care surgical repair of digital nerve injury as determined by health care provider.
223901814|NCT06867835|DRUG|Vyleesi (Bremelanotide Injection)|Single dose of BMT 1.75 mg SC on Day 1
223901815|NCT06872944|DRUG|Melatonin|"Melatonin, or N-acetylmethoxytryptamine, is a hormone secreted by the pineal gland in the brain. Light is the main factor that regulates melatonin production. Melatonin has important biological effects on the body and plays an important role in regulating the sleep wake cycle. Besides circadian rhythm stabilizing, exogenous melatonin has been investigated for other effects such as modulation of blood pressure, body temperature and cortisol control, immune function, and anti-oxidative defense.~Recent studies showed some benefits of perioperative short-acting melatonin in different groups of patients such as quality of recovery after surgery, diminished depressive symptoms and pain score reduction"
223901816|NCT06872944|DRUG|Sugar Coated Tablet|sugar coated tablets will be given to the patients at the night (8 PM) before the procedure and another dose 2 hours before surgery
223901817|NCT02436993|DRUG|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
223901818|NCT02436993|DRUG|Paclitaxel|80 mg/m\^2 IV over 1-3 hours weekly for 12 doses
223901819|NCT02436993|DRUG|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
223901820|NCT02436993|DRUG|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
223528732|NCT06570122|BEHAVIORAL|AI-powered chatbot support|Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
223901821|NCT02436993|DRUG|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
223901822|NCT07040761|OTHER|Two medical questionnaires|Medical questionnaires delivered by hand and completed the same day
224083485|NCT05503381|PROCEDURE|Laparoscopic radical resection of low rectal cancer with transanal specimens|According to the standard laparoscopic anterior rectum resection, the rectum was separated 2-3cm below the tumor, the rectum was severed 1-2cm from the lower edge of the tumor, the rectal stump was connected with the tumor through the anus, and the sigmoid colon was severed 10cm from the upper edge of the tumor. The stapler head was placed in the sigmoid colon stump, and then the sigmoid colon stump was closed with a linear cutting closure device. Then, the sigmoid colon stump is returned to the abdominal cavity through the anus, the distal rectal stump is closed with a suture purse or a linear cutting closure device, and the stapler body is inserted through the anus, and then the anastomosis is completed.
224083486|NCT01133171|BEHAVIORAL|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
223528733|NCT02244515|DRUG|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
223528734|NCT01985789|DRUG|Diphenhydramine|
223901823|NCT07050745|BEHAVIORAL|DADA LINK|"Intervention facilities will receive the DADA-LINK intervention, comprised of:~1. HPV self-sampling: We will provide clinics with HPV self-sampling kits to administer to eligible patients.~2. Care Navigation: One study-supported non-physician care navigator will be assigned to each clinic to support the clinic staff. These trained individuals will be responsible for managing data collection through the mHealth platform to aid the coordination of services and for motivating the clinic staff to adhere to cervical cancer care guidelines.~3. mHealth support for cervical cancer screening and treatment linkage: The WEMA application is a low-cost and highly adaptable open-source application designed for cervical cancer data monitoring and evaluation. Relevant patient information and data on uptake of cervical cancer screening and triage/treatment will be entered in the WEMA platform. The platform will additionally be used to send text messages to patients to facilitate clinic attendance."
223901824|NCT07049497|OTHER|Evaluation of the T cell response in terms of IFN-γ measured by ELISpot|The evaluation of the T cell response will be performed by quantifying the frequencies of SARS-CoV-2-specific T cells producing IFN-γ using an enzyme-linked immunospot assay (ELISpot), with cryopreserved PBMC collected at the designated timepoints (T0, T1, T2, T3, and T4)
223901825|NCT07052006|DRUG|HT-6184|Oral HT-6184
223901826|NCT04168580|OTHER|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
223901827|NCT07056764|OTHER|Standard treatment|Patients will be randomly assigned by drawing lots to determine the initial type of lung vibration treatment they will receive: either standard treatment alone or standard treatment combined with the lung vibration device.
223901828|NCT07056764|DEVICE|Standard treatment + Lung vibration device|Patients will be randomly assigned by drawing lots to determine the initial type of lung vibration treatment they will receive: either standard treatment alone or standard treatment combined with the lung vibration device.
223901829|NCT07058987|BEHAVIORAL|Cardiac Rehabilitation Combined With EECP|This intervention consists of a comprehensive cardiac rehabilitation program that includes individualized aerobic exercise training, health education, psychological support, and lifestyle counseling, combined with enhanced external counterpulsation (EECP) therapy administered according to standard cardiovascular protocols. The combined intervention is designed to improve cardiac function, exercise tolerance, and quality of life in patients with atrial fibrillation.
223901830|NCT07058987|OTHER|Routine Medical Care|Participants in the control group will receive standard medical treatment for atrial fibrillation as prescribed by their attending physicians, without enhanced external counterpulsation or structured cardiac rehabilitation. This may include pharmacological therapy, routine clinical monitoring, and general lifestyle advice.
223901831|NCT07057947|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Injection of local anesthetic between deltoid muscle and subcapsularis tendon
223901832|NCT07057947|PROCEDURE|Interscalene Nerve Block|Injection of local anesthetic between anterior and middle scalene muscles around the roots of brachial plexus
223901833|NCT07057947|DEVICE|Acuson X300 ultrasound,Siemens medical solution INC, Germany|high frequency linear probe
223901834|NCT07059208|PROCEDURE|Atrioventricular nodal ablation|Patients randomised to this arm would undergo physiological pacing followed by atrioventricular nodal ablation
223901835|NCT07059208|PROCEDURE|Pulmonary vein isolation|Patients randomised to this arm would undergo catheter ablation targeted at achieving pulmonary vein isolation
223901836|NCT07062562|OTHER|Sham (No Treatment)|A placebo treatment in which no actual electrical stimulation is delivered, serving as a control for the active NMES.
223901837|NCT07062562|OTHER|NMES|Active neuromuscular electrical stimulation applied to the entire body to induce muscle contractions through small electric currents.
223901838|NCT07062562|DIETARY_SUPPLEMENT|Protein bolus (20g)|A bolus dose of 20 grams of protein provided after the NMES intervention to assess the combined effect of muscle stimulation and protein intake on muscle protein metabolism.
223901839|NCT07062562|OTHER|Standard nutrition|Provision of a normal Western standardized diet.
223901840|NCT07063940|OTHER|Home-based exercise and theory-based motivation support programme|"1. A remotely-monitored personalised home-based exercise programme (HBEP) and~2. An autonomous motivation enhancement programme, known as Empowering Physio, delivered to physiotherapists to support them in delivering the HBEP."
223901841|NCT07063940|OTHER|Patient exercise advice leaflet before and after LT.|Control
223901842|NCT07062029|OTHER|Laughter Yoga|"The laughter yoga intervention consists of four sessions conducted once a week for four weeks. Each session lasts approximately 30 minutes and includes four components:~* Warm-up exercises with clapping and rhythmic movements~* Deep breathing exercises~* Childlike playful activities and laughter exercises~* Laughter meditation and relaxation Sessions are led by a certified laughter yoga leader in a quiet classroom setting that allows participants to move freely and comfortably. The intervention is designed to improve spiritual well-being and perception of spiritual care among nursing students."
223901843|NCT07063004|OTHER|Bruegger's Exercise and Upper Thoracic Mobilization|"Bruegger's Exercise: The position will be held for 10 second at first session and then there will be an increment of 2 seconds during each session.~Upper Thoracic Mobilization: Upper thoracic (T1-T6) mobilization (Maitland mobilization (Grade I, II and III; PA glide) applied in prone lying position from via spinous process. Amount of treatment will be 3-4 mobilizations for a vertebra for 30 seconds approximately."
224083487|NCT01133171|BEHAVIORAL|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
224276852|NCT04077125|DRUG|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
223528735|NCT01985789|DRUG|cetirizine|
223528736|NCT01985789|DRUG|desloratadine|
223901844|NCT07063004|OTHER|Standard Physical Therapy|"Isometric exercises will be done for flexors, extensors, rotators, and lateral flexors of the neck. Isometrically contracting working muscle for 5 seconds against patients own hand, which was placed in compliance with the working muscles, with a total of 10 repetitions.~Passive stretching will apply to Upper trapezius, Levator scapulae, Sternocleidomastoid, Scalene, Pectoralis major and minor muscle for 3-5 repetition 10 with 20-30 second hold. Intensity of exercise will be prescribed according to patient's tolerance level. Duration of stretch will 15 to 30 seconds, 3-5repetition and for 10 minutes.~Postero-anterior Maitland mobilization (Grade I \& II) for C1-C2, Maitland lateral PA glide (Grade-III \& IV) for C3-C6. Time of oscillations will be two or three oscillations in a second for one to two minutes."
223901845|NCT07062601|DRUG|Etomidate and fentanyl group|In the etomidate-fentanyl group (group A), 0.3 mg/kg etomidate and 4 µg/kg fentanyl were given at the induction of anesthesia, followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the surgery, respectively.
223901846|NCT07062601|DRUG|Etomidate and esketamine group|In the etomidate-esketamine group (group B), induction of anesthesia with 0.3 mg/kg etomidate and 0.5 mg/kg esketamine , followed by continuous infusion of propofol at 4-12 mg/kg/h and remifentanil at 3-6 µg/kg/h until the end of the operation
223901847|NCT07063992|OTHER|thoracic facet manipulations|"Group A will receive thoracic facet manipulations of the restricted segments between T3 to T9, in the prone position and cephalic direction. The duration of the intervention will be followed by 4 weeks 3 sessions each week and pre- and post-intervention observations will be recorded.~Bilateral hypothenar Cross bilateral hypothenar manipulationThese flexibility exercises will be targeted for~* Rhomboid and middle trapezius stretching (2-3 times daily; 3 sets for 30 seconds))~* Pectoralis muscle stretch in a corner (2-3 times daily; 3 sets for 30 seconds)~* Prone on the elbow with upper thoracic extension exercise (2-3 times daily; 3 sets for 30 seconds) .~The postural exercises will be the following~* Postural strengthening/ stabilization with back to a wall. The participant will press their arms into the wall while retracting scapulae.~* Trunk rotation stretching in the sitting position"
223901848|NCT07063992|OTHER|thoracic facet and costovertebral manipulations|"Group B will receive thoracic facet and costovertebral manipulations of the restricted segments between T3 to T9 and ribs 3 to 9 (costovertebral joints), in the prone position. The duration of the intervention will be followed by 4 weeks 3 sessions each week and pre and post-intervention observations will be recorded.~Hypothenar Costal Manipulative technique Ilial Hypothenar costal manipulation between T3-T9"
223901849|NCT07062289|PROCEDURE|endoscopic ultrasound-guided portal pressure gradient|This study employs an integrated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG+) protocol uniquely designed for cirrhotic patients with portal vein thrombosis (PVT). Under general anesthesia in the left lateral decubitus position (novel positioning), a linear echoendoscope directs 22G needle puncture of the portal vein and inferior vena cava for direct pressure measurement, with real-time Doppler confirmation to avoid thrombosed vessels. Crucially, this intervention synchronizes diagnostic and therapeutic actions: if high-risk esophageal/gastric varices are identified during EUS, immediate endoscopic therapy (e.g., glue injection) is delivered in the same session. All participants additionally undergo standard hepatic venous pressure gradient (HVPG) measurement via transjugular access within 24 hours, enabling within-patient correlation analysis.
223901850|NCT07064291|OTHER|The Lexical Association Technique (LAT)|"The Lexical Association Technique (LAT) was developed by Niveau, New, and Beaudoin in 2021 (Niveau et al., 2022). It is grounded in principles of memory functioning described in the cognitive psychology literature, particularly the theoretical framework of the Self-Memory System proposed by Conway (2000, 2005).~The technique aims to enhance self-esteem by strengthening associative links between the self and positively valenced concepts stored in memory. To achieve this, it relies on the repeated mental visualization of positive autobiographical episodes paired with positive self-referential linguistic statements.~The effectiveness of this technique in increasing self-esteem has been demonstrated and replicated across three studies, conducted with distinct samples: two involving healthy participants and one involving a clinical sample of individuals with a chronic illness (Niveau et al., 2022, 2023)."
223901851|NCT07064291|OTHER|Placebo of the Lexical Association Technique|"The active control condition is based on the same procedural structure as the Lexical Association Technique (LAT), but without the core therapeutic component - the self-referential content. Participants in the control group are exposed to a series of positive statements, similar in form and valence to those used in the LAT, but referring to others (e.g., generic social roles or entities such as teachers, pharmacists, or animals) rather than the self.~Like in the LAT condition, participants are asked to generate mental imagery based on each statement, visualizing a corresponding positive episodic event. This ensures that the control task involves the same cognitive mechanisms (episodic memory retrieval, positive visualization, and sustained attention), while excluding the specific associative link to the self that constitutes the active ingredient of the intervention.~This control condition was designed to match the LAT in terms of structure, cognitive demand, and duration, and has be"
223901852|NCT07064031|OTHER|Neck Isometrics , TENS and Hot pack|Hot apck and TENS applied for 10min each. Using the same amount of light pressure, gently push your head into your hand as you did before. This time, allow the head to move slowly toward the shoulder against the pressure of the hand. This too can be repeated on the opposite side, forwards, backward, and into left and right rotation
223901853|NCT07062731|BEHAVIORAL|Supervised pelvic floor muscle exercises|4 months of supervised physiotherapy by a women's health physiotherapists (3 sessions in total)
224083488|NCT06439368|DRUG|Dezocine|At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
223528737|NCT01985789|DRUG|placebo|
223528738|NCT01983111|DRUG|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
223528739|NCT01983111|DRUG|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
223528740|NCT01777061|DRUG|[11C]Acetate|intravenous injection of an average of 40 mCi of \[11C\]Acetate
223901854|NCT07061990|DIAGNOSTIC_TEST|Polysomnography (PSG)|Participants underwent overnight polysomnography for a minimum of 7 hours using an E series polysomnography monitor. The monitoring included electroencephalogram (EEG), eye movement, Holter monitoring, airflow, chest and abdominal respiratory movements, and fingertip oxygen saturation. The results were used to diagnose Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) and calculate the Apnea-Hypopnea Index (AHI) for severity classification.
223901855|NCT07061990|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|A whole-brain scan was performed on all participants using a Philips Ingenia 3.0T MRI scanner. The scanning sequences included T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), and Fluid-Attenuated Inversion Recovery (FLAIR). The images were analyzed by two neurologists to identify asymptomatic lacunar infarction and to assess the severity of white matter lesions using the Age-Related White Matter Change (ARWMC) scoring system.
223901856|NCT07061990|DIAGNOSTIC_TEST|Serum Inflammatory Marker Measurement|Fasting venous blood (3mL) was collected from all participants on the day of their brain MRI scan. Serum was separated by centrifugation. Levels of Serum Amyloid A (SAA), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-6 (IL-6) were measured using the Enzyme-Linked Immunosorbent Assay (ELISA) method according to the manufacturer's protocols.
223901857|NCT07063537|DEVICE|Virtual Reality Visual Field (VR-VF)|Both devices administer a standard visual field test. The Humphrey is the gold standard desk top model and the VR-VF is a virtual reality headset designed to deliver visual field testing
223901858|NCT07062432|BEHAVIORAL|Continuous Comprehensive Nursing System|A multi-faceted nursing plan delivered by trained cardiac nurses, extending from the preoperative phase to 3 months post-discharge. In addition to routine inpatient care, the intervention included: preoperative education and psychological support; postoperative individualized rehabilitation guidance; and a continuous post-discharge program. The post-discharge phase involved structured follow-up (monthly phone calls, one 6-week outpatient visit), ongoing psychological support, reinforcement of education on medication adherence, diet, and activity progression, and guidance on a structured home-based exercise program.
223901859|NCT07062432|OTHER|Routine Postoperative Care|Standard institutional postoperative care for patients after Coronary Artery Bypass Graft (CABG) surgery. This care was primarily focused on the inpatient period and included monitoring of vital signs, wound and drainage tube management, respiratory and circulatory support, and progressive diet guidance. The care concluded with standard discharge instructions and did not include the structured, continuous, or extended follow-up provided to the intervention group.
223901860|NCT07062185|DRUG|ENC1018 capsule administration group|ENC1018 capsules were taken orally once a day for 14 days.
223901861|NCT07063407|DRUG|HS-20093 in combination with Adebrelimab|HS-20093 in combination with Adebrelimab will be administered intravenously every 3 weeks until disease progression or other criteria for termination of treatment are met.
223901862|NCT07063641|DEVICE|Percutaneous Electrical Nerve Stimulation (PENS)|Ultrasound-guided percutaneous electrical nerve stimulation applied to the suprascapular nerve using a monophasic or biphasic current at 10 Hz frequency and 250 μs pulse width. Intensity is progressively increased to patient tolerance, aiming to induce visible muscle contractions of the supraspinatus and infraspinatus. Duration of the session is 30 minutes.
223901863|NCT07062952|DIETARY_SUPPLEMENT|Salt substitute|Patient consume salt substitutes daily while strictly adhering to WHO-recommendedsalt intake levels for 1 year.Salt substitutes (potassium-enriched low-sodium salt, primarily NaCl and KCl) reduce sodium content versus regular salt
223901864|NCT07062341|BEHAVIORAL|Self-Help Plus (SH+)|SH+ is a low-intensity, scalable stress management intervention developed by the World Health Organization. It is designed for delivery in humanitarian settings by non-specialist facilitators. The intervention consists of five 2-hour group sessions delivered via pre-recorded audio, supported by an illustrated guidebook adapted to the local cultural and linguistic context (Juba Arabic). Sessions teach mindfulness, acceptance, and value-driven behavior based on principles from Acceptance and Commitment Therapy. In this study, SH+ is delivered to 12 groups of up to 30 South Sudanese refugee mothers in Rhino Camp, Uganda, by trained lay peers from the refugee community. The intervention is paired with Enhanced Usual Care.
223901865|NCT07062341|BEHAVIORAL|Enhanced Usual Care (EUC)|"EUC consists of a one-time, brief psychoeducation session lasting approximately 15 minutes, delivered individually by a trained lay provider under clinical supervision. The session focuses on helping participants understand and manage common symptoms of psychological distress-particularly local expressions such as overthinking-and introduces simple self-management strategies. Participants are also provided with information about available mental health and psychosocial support services within Rhino Camp, including referral pathways to professional care and community-based resources. This intervention serves as a minimal yet contextually relevant comparator that controls for attention and information exposure while remaining distinct from structured therapeutic interventions like SH+."
223901866|NCT07063771|DEVICE|Histotripsy|Histotripsy is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
223901867|NCT07062653|OTHER|Supervised group|A progressive core stability exercise program based on motor control principles will be applied on an online platform through videos under the control of a physiotherapist.
223901868|NCT07062653|OTHER|Non-Supervised group|A core stability exercise program with detailed exercise videos will be implemented at home.
223901869|NCT07062354|DRUG|Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)|Carboplatin + Paclitaxel + Amivantamab hyaluronidase
223901870|NCT07063160|BEHAVIORAL|Pain|Injection was used to determine the level of pain
224083489|NCT02526550|BIOLOGICAL|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
224083490|NCT02526550|BIOLOGICAL|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
223901871|NCT07063160|BEHAVIORAL|Fear of injection|The scale developed determines the fear levels of individuals towards the injection procedure. The scale consists of 14 items. It was developed on a 5-point Likert type, 1-I am not afraid at all, 5- I am very afraid. The scale is calculated based on the item score average. The lowest score that can be obtained from the scale is 1, and the highest score is 5. As the score obtained from the scale increases, the level of fear increases. Stated in their research that the Cronbach Alpha value for the entire scale was 0.92.
223901872|NCT07063160|BEHAVIORAL|Post-injection satisfaction|The scale developed to determine the satisfaction levels of patients regarding the injection process. The scale was developed in a 5-point Likert type, 1-I am not satisfied at all, 5-I am very satisfied. The scale is calculated based on the item score average. The lowest score that can be obtained from the scale is 1, and the highest score is 5. As the score obtained from the scale increases, the level of satisfaction increases. Post-injection satisfaction Scale consists of 9 items. In the study conducted, it was determined that the Cronbach Alpha value of the entire scale was 0.895.
223901873|NCT07064460|DEVICE|Physician Modified Endovascular Graft|The participant's surgeon will modify a commercially available graft tailored to their anatomy for their surgery. All components used to create the final device (PMEG), made specifically for each participant and tailored to their individual anatomy, are FDA-approved, although the final graft itself (the PMEG) is considered investigational.
223901874|NCT07062718|OTHER|Median nerve flossing technique and conventional physical therapy|"Median nerve flossing technique and conventional physical therapy Nerve flossing will be started from root along brachial plexus,median nerve root.~Before starting the procedure ,subjects will be shown the flossing technique as it will be performed actively by the subjects. Each flossing will be performed with 10 repetitions starting from neck,arm,elbow,wrist and whole nerve flossing (12).~It will be a 3 week treatment with 4 session per week (12 sessions)"
223901875|NCT07062718|OTHER|Conventional physical therapy|"The subjects in this group will be treated with TENS and hot pack. All the subjects will be screened according to the inclusion and exclusion criteria .Written informed consent will be taken from all the subjects before the treatment. The subjects will be allowed to withdraw the treatment any time.The subjects will be divided into 2 groups through convenience sampling.All the subjects from both group will be given trancutaneous electric nerve stimulation TENS ,hot pack, isometrics and stretching as a conventional physical therapy followed by respective group techniques~The session will last for 20 -25 minutes , TENS pad will be placed in the suboccipital region and the trapezius unilaterally with hot pack simultaneously for 10 minutes"
223901876|NCT07064590|DEVICE|Transcranial Magnetic Stimulation (TMS)|Patients will receive continuous theta burst stimulation, a five minute treatment protocol with inhibitory effects over the respective brain region 3 times daily. A total of 15 treatments, but will be performed in an accelerated design. Treatment site localization will be based on each patient's individual MRI. Following cortical parcellation using FreeSurfer 7.4.1, the centroid coordinates of the frontal pole will be extracted. For frontopolar stimulation, neuronavigation will be employed to guide coil placement to each patient's frontal pole centroid using Localite Neuronavigator. Stimulation will be performed at 110% resting motor threshold. Pulses will be administered in a burst-firing pattern (3 pulse burst, 50 Hz; 5 Hz \[200-ms\] interburst intervals; 1800 pulses/train with a 60-seconds intertrain interval). To enhance tolerability of frontopolar FP1 TBS, stimulation intensity is gradually escalated from 30% to 110% of resting motor threshold over the first 30 sec of each train.
223901877|NCT07062705|OTHER|Progressive Inhibition of Neuromuscular Structure|The index fingers of both hands were used to palpate two connected locations, referred to as main and endpoints. The locations were located along a neuromuscular structure and were the most and least sensitive sections, respectively. Once an endpoint (region of least sensitivity) was identified, the index finger of one hand was used to provide a moderate ischemia compression; the pressure was kept constant until the course of therapy was finished. After identifying the primary point-the area of greatest sensitivity-a moderate ischemic compression was also applied for 30 seconds using the index finger of the other hand.
223901878|NCT07062705|OTHER|Neural Tissue Mobilization.|The patient sat well back on the end of a plinth with thighs fully supported. The patient was asked to slump. Overpressure was applied to the lumbar and thoracic flexion in attempt to bow the spine rather than the hips. With spinal flexion position maintained, the patient was asked to bend his chin to chest and then overpressure in the same direction was added. The patient was asked to extend his knee actively. The patient was asked to dorsiflex his ankle. The therapist was maintaining the ankle dorsiflexion as a progression for technique. The number of these sequences was repeated several times,through which the amplitude of the technique was increased according to the patient response. The technique was progressed to a point where symptoms reproduced, or it was taken to a point where resistance of the movement was encountered.
223901879|NCT07062848|DIAGNOSTIC_TEST|AI Toolkit for ATTR-CM Diagnosis|An artificial intelligence (AI) toolkit of algorithms that detect ATTR-CM on electrocardiography (ECG), point-of-care ultrasound (POCUS), and transthoracic echocardiography (TTE)
223901880|NCT07063849|BIOLOGICAL|A/Texas|Live Influenza Virus RG-A/Texas/71/2017 H3N2 Dose: 1.0 mL (0.5mL per nostril) of approximately 1x10\^6 TCID50 Administered intranasally by atomizer device Challenge virus will be administered once on Day 1
223901881|NCT06830239|DRUG|Dostarlimab|"Dostarlimab \[Jemperli GlaxoSmithKline (GSK)\] is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.~Dostarlimab is in clinical development for the treatment of subjects with solid tumors, including those with recurrent/advanced dMMR/MSI-H solid tumors who have progressed on standard of care chemotherapy, as monotherapy or in combination with other agents."
223901882|NCT06339710|DRUG|benznidazole 300 mg daily 8 weeks|672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks)
223901883|NCT05619913|DRUG|Eribulin Mesylate|Eribulin mesilate is a first-in-class halichondrin B-based, microtubule dynamics inhibitor7. It inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into non-productive aggregates.
223901884|NCT05619913|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
223901885|NCT07063810|DEVICE|Mixed Reality Rehabilitation|"The mixed reality protocol will be based on 5 perceptual-motor activities (i.e., games specifically developed for the purposes of this study). The activities consist in walking to collect objects, avoid obstacles, or move the upper limbs to catch virtual balls or fit in narrow shapes.~Three games will be performed per session, for a duration of 15 minutes each over 1h sessions with rest times.~The level of the activities will be adapted to the performance of the participants during the course of the protocol, by manipulating game settings: necessary speed, accuracy and movement frequency."
223901886|NCT06441760|OTHER|Video teleconsultation|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while PEM physicians will provide medical direction remotely using video to communicate with EMS personnel via tablet devices.
223901887|NCT06441760|OTHER|Audio support|Each team will participate in 4 video-recorded simulated transports in fully equipped ambulances. Each team will provide resuscitative care in 4 simulated high-risk pediatric transports. EMS personnel will provide care in the ambulance while EM physicians will provide medical direction remotely using audio to communicate with EMS personnel via tablet devices.
223901888|NCT05925972|PROCEDURE|Plane block|Plane block application in laparoscopic hysterectomies
223901889|NCT06934980|DEVICE|Microneedle Device|Microneedle device will be used for collecting dermal interstitial skin fluid samples as defined by the protocol.
223901890|NCT06952387|OTHER|Personalized blood pressure management|"In patients assigned to personalized blood pressure management, clinicians were asked to maintain intraoperative MAP at least at the preoperative mean 24-hour MAP (with a maximum MAP target of 110 mmHg) from anesthesia induction to 2 hors after completion of surgery. If the preoperative mean 24-hour MAP was below 65mmHg, intraoperative MAP was maintained at least at 65mmHg.~The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger fluid challenge (FC) administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration."
223901891|NCT06952387|OTHER|Routine blood pressure management|"In patients assigned to routine blood pressure management, clinicians were blinded to the results of preoperative automated 24-hour blood pressure monitoring, and thus managed blood pressure per institutional routine which generally is to maintain MAP above 60 mmHg.~The mini fluid challenge (mini-FC, 100ml fluid infusion within 1minute) will be used to assess fluid responsiveness. A positive min-FC response (a stroke volume (SV) increase of at least 5%) will trigger FC administration (4ml/kg of balanced crystalloid or colloid within 10 minutes), whereas a negative min-FC response will trigger vasoactive drug administration."
223901892|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no progression, the patient will receive the treatment of 6-10Gy\*3-6F plus Benmelstobart.
223901893|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no progression and the largest lesion measures between 3 cm and 5 cm, the patient will receive the treatment of 3 Gy \* 15 fractions plus Benmelstobart.
223901894|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no disease progression and the largest lesion is larger than 5 cm, the patient will receive treatment with Spatial Fractionated Radiotherapy Technique (SFRT) plus Benmelstobart.
223901895|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, if there is no disease progression, and when the largest lesion is ≤ 3 cm and the patient can maintain the radiotherapy position for 50 minutes, the patient will receive treatment with the hyperfractionated pulsed radiotherapy technique (0.5 Gy \* 16 \* 6 fractions) plus Benmelstobart.
223901896|NCT06953843|DRUG|Benmelstobart combined with chemotherapy|After 4 cycles of treatment with Benmelstobart combined with chemotherapy, Benmelstobart is continued for maintenance treatment.
223901897|NCT06953843|DRUG|Benmelstobart combined with Bevacizumab and chemotherapy|For eligible subjects who have developed resistance to EGFR-TKI, after 4 cycles of treatment with Benmelstobart combined with Bevacizumab and chemotherapy, if there is no disease progression, they will receive the treatment of 6-10Gy \* 3-6 fractions plus Benmelstobart.
223715442|NCT03449797|PROCEDURE|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
223901898|NCT06443775|DRUG|Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)|Eye Drops
223901899|NCT06533761|DRUG|Eganelisib|eganelisib will be administered as monotherapy
223901900|NCT06533761|DRUG|Eganelisib in combination with cytarabine|eganelisib will be administered in combination with cytarabine
223901901|NCT04531709|OTHER|Comprehensive Score for financial toxicity (COST)|Measure indirect and direct health care cost that burden patients and their loved ones.
223901902|NCT04531709|OTHER|Functional Assessment of Cancer Therapy: General (FACT-G)|General quality of life instrument
223901903|NCT04531709|OTHER|EORTC QLQ C-30|Assess quality of life in cancer patients
223901904|NCT04531709|OTHER|EORTC QLQ-TC26.|To measure disease and treatment related quality of life issues relevant to testicular cancer patients that were not explored in the QLQ-C30 questionnaire.
223715443|NCT03449797|PROCEDURE|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
223715444|NCT02095093|DEVICE|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
223715445|NCT02095093|DEVICE|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
223715446|NCT06506149|DEVICE|Microwave ablation(MWA) device|The device for USG-guided MWA treatment would be performed under USG guidance, aiming to ablate the entire thyroid gland, i.e. the right lobe, left lobe, isthmus and pyramidal lobe.
223715447|NCT04026997|DRUG|CIN-102 Dose 1|CIN-102 Dose 1
223715448|NCT04026997|DRUG|CIN-102 Dose 2|CIN-102 Dose 2
223715449|NCT04026997|DRUG|CIN-102 Dose 3|CIN-102 Dose 3
223715450|NCT04026997|DRUG|Placebo|Placebo
223528741|NCT06048029|PROCEDURE|laparscopic Cholecystectomy in children|Evaluate preoperative and operative risk factors for conversion of laparoscopic cholecystectomy to open cholecystectomy
223528742|NCT00855335|DRUG|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
223528743|NCT00855335|DRUG|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
223528744|NCT00855335|DRUG|Etravirine|200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
223528745|NCT00855335|DRUG|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
223528746|NCT00855335|DRUG|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
223528747|NCT03502200|DEVICE|JUUL|Participants randomized to the JUUL group will receive either tobacco or menthol flavored JUUL with 5% nicotine. Will also receive counseling.
223528748|NCT03502200|OTHER|Treatment As Usual|Nicotine Replacement Therapy consisting of nicotine patches and lozenge along with standard quitline counseling.
223528749|NCT04627714|OTHER|Adapted Physical Activity|Intervention consists in 1h30/week of adapted fencing
223528750|NCT05284578|OTHER|Self-compassionate writing intervention|Participants assigned to this intervention were asked to engage in one brief online self-compassionate writing session, where they were asked to write about and experience their feelings from the perspective of an inner compassionate observer.
223528751|NCT05284578|OTHER|Expressive writing intervention|Participants assigned to this intervention were asked to engage in one brief online expressive writing session, where they were asked to explore their deepest thoughts and emotions surrounding an upsetting situation through writing.
223528752|NCT05284578|OTHER|Control writing task|Participants assigned to this condition were asked to engage in a neutral time management writing task.
223528753|NCT05903534|OTHER|Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training|Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling
223528754|NCT05903534|OTHER|Lower Limb Strength Training Group|Lower Limb Strength Training Group
223715451|NCT04352816|DEVICE|Magnetocardiogram|Magnetocardiography (MCG) is a non-invasive, non-contact body-surface method which uses magnetometers to measure and map the magnetic fields generated by the electrical activity within the heart. It offers a better spatial resolution than an ECG recording and opens the possibility of detecting conduction characteristics consistent with arrhythmogenesis.9-15 The application of MCG has been limited by feasibility as devices up to now have been based on superconducting quantum interference devices (SQUID) with supercooled sensors. These machines were often operated in a shielded environment, to decrease magnetic field interference (noise) from electrical devices and other sources of magnetic fields. This was a major limiting factor in deploying these devices in a working environment especially considering, that most hospital wards will have numerous devices that can interfere with the device.
223715452|NCT04094883|BIOLOGICAL|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
223715453|NCT02211937|DRUG|BI 44847 solution, low dose|
223715454|NCT02211937|DRUG|BI 44847 suspension, high dose|
223715455|NCT02211937|DRUG|BI 44847 tablet, low dose|
223715456|NCT02211937|DRUG|BI 44847 tablet, high dose|
223715457|NCT02211937|OTHER|high fat breakfast|
223715458|NCT04747509|OTHER|Blackburn exercises|"Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
223715459|NCT04747509|OTHER|Conventional Physical therapy|"Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set."
223715460|NCT00448981|BEHAVIORAL|Hand hygiene and educational material|
223715461|NCT00448981|DEVICE|Mask, alcohol and hand sanitizer|
223715462|NCT02989714|DRUG|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
223715463|NCT02989714|DRUG|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
223715464|NCT03918785|DIETARY_SUPPLEMENT|Rice germ|25 g twice a day.
223715465|NCT03918785|DIETARY_SUPPLEMENT|Wheat-based supplement|25g twice a day.
223715466|NCT03152071|PROCEDURE|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
223715467|NCT03152071|PROCEDURE|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
223715468|NCT01382212|DRUG|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
223715469|NCT00272740|DRUG|Fulvestrant|
223715470|NCT03440268|DRUG|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
224276853|NCT00897923|PROCEDURE|radionuclide imaging|
223901907|NCT06834100|DRUG|polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y|"Group 1 (n = 40) will receive GNG-DE at a dose of 0.5 mL intramuscularly into the deltoid site.~Group 2 (n = 40) will receive Menactra® at a dose of 0.5 mL intramuscularly into the deltoid site."
223901908|NCT06955923|DRUG|Trigger point injection (lidocaine)|A trigger point injection utilizing lidocaine 1% without epinephrine will be injected into several muscles bellies immediately following surgery to halt a trigger point from forming. One group will receive this type of intervention and the sham group will not receive any type of injection.
223901909|NCT06955923|OTHER|Sham Comparator|This arm of the study will not receive any injection.
223901910|NCT05455034|GENETIC|single-cell sequencing|Treatment is given according to the results of single-cell sequencing.
223901911|NCT04116320|DEVICE|Echopulse|The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.
223901912|NCT04116320|DRUG|Poly ICLC|Poly-ICLC is a TLR3 agonist.
223901913|NCT04116320|DRUG|Standard of Care PD-1 Therapy|PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.
223901914|NCT06956014|DRUG|VER-01|Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product
223901915|NCT06956014|OTHER|Placebo|Comparator without active ingredient
223901916|NCT05678673|DRUG|XL092|Specified doses on specified days
223901917|NCT05678673|DRUG|Nivolumab|Specified doses on specified days
223901918|NCT05678673|DRUG|Sunitinib Malate|Specified doses on specified days
223901919|NCT05211180|BEHAVIORAL|Vida Sana|Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.
223901920|NCT05211180|BEHAVIORAL|Vida Sana y Completa|Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
223901921|NCT06377111|DIETARY_SUPPLEMENT|C-PAN|C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.
223901922|NCT06377111|BIOLOGICAL|Nivolumab|Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.
223901923|NCT06377111|BIOLOGICAL|Ipilimumab|Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
223901924|NCT03491969|DRUG|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
223901925|NCT03491969|DRUG|Placebos|200 mg, po, tid
223901926|NCT03807128|OTHER|Prélèvement sanguin (2*4mL) ou médullaire (2mL)|Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease
223901927|NCT03807128|OTHER|Data collection through questionnaires|Collection of quality of life and occupational exposure data via questionnaires
223901928|NCT05968170|DEVICE|CliniMACS® device|CliniMACS TCR αβ+/CD19+ cell depletion for related or unrelated haploidentical/mismatched/matched hematopoietic stem cell transplant patients and/or high risk GVHD patients.
223901929|NCT02696707|PROCEDURE|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
223901930|NCT02696707|PROCEDURE|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
223901931|NCT00636077|DEVICE|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
223901932|NCT00636077|DEVICE|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
223901933|NCT00636077|DEVICE|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
223901934|NCT00636077|DEVICE|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
223901935|NCT04659616|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223901936|NCT04659616|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
223901937|NCT04659616|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiratie
223901938|NCT04659616|DRUG|Cytarabine|Given IV
223901939|NCT04659616|DRUG|Daunorubicin|Given IV
223901940|NCT04659616|PROCEDURE|Electrocardiography|Undergo ECHO
223901941|NCT04659616|DRUG|Pemigatinib|Given PO
223901942|NCT06181227|DRUG|AVD-104|An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.
223901943|NCT02140021|PROCEDURE|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
223901944|NCT02140021|OTHER|Laboratory Biomarker Analysis|Correlative studies
223901945|NCT05880472|DEVICE|Intratumoral|Comparable to CE-marked QuiremSpheres(R) outside of intended use with minor altered specification.
223901946|NCT06643897|OTHER|Qualitative Interview|40-50 minute-qualitative interview.
223901947|NCT06359223|DIETARY_SUPPLEMENT|coffee consumption|After cesarean section, patients will be allowed to drink coffee.
223901948|NCT06359223|OTHER|control group|Patients will undergo a routine surgical procedure.
223901949|NCT05915806|DIETARY_SUPPLEMENT|High-dose DHA|Direct enteral DHA supplementation at a dose of at least 40 mg/kg/day or DHA supplementation of breast milk or formula aiming for at least 0.4% of total fatty acids.
223901950|NCT05915806|DIETARY_SUPPLEMENT|Control|Control with no or low-dose DHA.
223901951|NCT04867681|BEHAVIORAL|Psycho-education programme|4 individual sessions (S1, S2, S3, S4) of one hour each spread over 2 weeks, i.e. 2 sessions per week. S1 explains the different clinical signs and discusses the prognosis of the disease, S2 deals with the question of drug treatments, their different forms and their mechanisms of action. S3 discusses the evolution of the disease and the organisation of the care pathway. Finally, S4 looks at the aspects of quality of life, lifestyle and the fight against addictive co-morbidities, and concludes with a review of the patient's motivation and involvement in the subjects covered.
223901952|NCT03457402|BEHAVIORAL|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
223901953|NCT00433329|DRUG|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
223901954|NCT00433329|DRUG|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
223901955|NCT05333016|BEHAVIORAL|Multimodal exercise|Multimodal exercise programming including aerobic, resistance, balance, and flexibility exercises
223901956|NCT06807125|PROCEDURE|Resin matrix ceramic block|Milled resin composite block for fabrication of permanent, indirect restorations using a CAD/CAM grinding process. shock absorbing affect due to the dentin- like modulus of elasticity makes BRILLIANT Crios will suited or indirect restoration.
223901957|NCT06803186|DEVICE|High-power laser therapy|"High power laser therapy (HPLT) with a neodymium-yttrium aluminum garnet laser with a pulsating waveform produced by a ( Hilterapia device , ASA, Arcugnano, Vicenza, Italy). It will be set at the following parameters: Nd:YAG laser with pulsed emission (1064 nm), very high peak powers with average power 6 W, high levels of fluency (760 mJ/cm energy density), short pulse duration (250 μs), low frequency (10-40 Hz), and 5-cm probe diameter for 15 minutes.~The scanning will be performed longitudinally \&transversely from the C3 to C7 posterior neck in the paraspinal region, upper back, inter-scapular area, trapezius, sternocleidomastoid muscles, and posterior \& lateral shoulder areas"
223901958|NCT06803186|DEVICE|Placebo (PL) high power laser|laser probe scanning will be applied to the same areas as that applied in the HPLT procedure. PL will be applied while the lights of the device will be on, with no current flowing through the device. Placebo therapy will be applied at the same frequency as HPLT (Three sessions a week for six weeks for a total of 18 sessions; one session will be lasted 15 minutes).
223901959|NCT06803186|OTHER|Conventional physical therapy program|A specific program of 45-min exercise of three sessions a week for six weeks for a total of 18 sessions. Corrective exercises will be performed initially by stretching exercises for(suboccipital, upper trapezeius, scalene, levator scapulae, sternocleidomastoid, pectoralis major/minor muscles) will be given four repetitions with 30 second hold. each with 3 seconds rest between each stretch Then, strengthening exercises will be performed initially in an isometric manner for weak muscles (deep cervical flexors, rhomboidus, and lower trapezeius muscles) will be done initially without weight and afterward by using Theraband and dumbells. All patients will be instructed to achieve three sets of 12 repetitions of the strengthening exercises (isometrics exercises) with 1 to 2 minutes rest in between each set. Contraction will be held for 5 seconds/repetitions. 10-20 repetitions for strengthening exercises and 3 sets of 30 repetitions for endurance exercise
223901960|NCT06806397|DIAGNOSTIC_TEST|Stimulus response task|Participants were tasked with performing a finger extension exercise that required pressing buttons in response to visual stimuli. In cases where physical movement was not possible, participants were instructed to imagine performing the task while focusing on their fingers.
223901961|NCT06530511|DRUG|Polatuzumab vedotin|Polatuzumab: 1.8 mg/kg, IV Drip infusion, D1;
223901962|NCT06530511|DRUG|Rituximab|Rituximab: 375 mg/m2, IV Drip infusion, D1
223901963|NCT06530511|DRUG|Orelabrutinib|Orelabrutinib: 150 mg/time, qd, po, D1-21
223901964|NCT06192771|BEHAVIORAL|ESSI-SURG|Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
223901965|NCT06192771|BEHAVIORAL|Standard-of-Care|Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
223901966|NCT05667857|BEHAVIORAL|Integrative neurocognitive remediation therapy|Integrative Neurocognitive Remediation Therapy is a clinical program of 12 weeks (1 day/week) that combines personalized computerized cognitive training and neurocognitive strategy training, with group sessions of adapted physiotherapy, acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT) and information sessions on cognition, fatigue, nutrition and physical exercise.
223901967|NCT05839080|BEHAVIORAL|Gardens to Bellis|In FoodACT the school garden intervention that will be investigated is the well described and well-developed intervention called Gardens to Bellis. It involves pupils from 4th-5th grade and their teachers. The classes attend 8 school garden sessions distributed across two school years. The sessions start each year in March and ends in November. Pupils are divided into smaller groups, who gets a plot of which they are responsible for preparing, weed and harvest. The purpose is that pupils can cook their own food with the greens, fruits and berries they harvest in the garden and finds in the nature. The pupils and their families will hatch and harvest the school gardens between the session days.
223901968|NCT05839080|BEHAVIORAL|No intervention|Pupils are not receiving any intervention
223901969|NCT06801197|COMBINATION_PRODUCT|MI-Coach: ED Mobile App|The MI-Coach: ED mobile app is a self-guided intervention designed to enhance motivation and readiness for treatment in adults with eating disorders. The app includes seven sequential modules based on motivational interviewing (MI) principles, addressing ambivalence, self-acceptance, compassionate motivation, behavior change goals, sustain and change talk, commitment language, and relapse prevention. Each module incorporates interactive content, including educational videos, articles, and exercises, tailored to support motivation across a range of eating disorder diagnoses. The app is designed to be user-friendly and scalable, providing an accessible, cost-effective solution for individuals on waitlists for formal eating disorder treatment.
223901970|NCT03400826|DRUG|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
223901971|NCT03400826|DRUG|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
223901972|NCT06803433|DEVICE|Aligners|Lower arch in office aligners.
223901973|NCT06803433|DEVICE|Lingual braces|Lingual braces bonded to the lower anterior teeth
223901974|NCT06803433|DEVICE|Active fixed lingual wire|A customized 14 Niti lingual wire customized to the lingual surface of the lower anterior teeth and secured with ligature wires.
223901975|NCT06268535|DRUG|Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023|Disproportionality analysis studying the association between cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023 and heart failure or cardiac dysfunction in the World Health Organization pharmacovigilance database.
223901976|NCT05374681|OTHER|Medical treatment|Medical treatment alone
223901977|NCT05374681|OTHER|Surgical treatment|Surgical treatment alone
223528755|NCT02661750|DRUG|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX\* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
223528756|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
223528757|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
223528758|NCT04161924|DIAGNOSTIC_TEST|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
223528759|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10\^8 cells will be given up to 3x10\^11 anti-MART-1 F5 TCR engineered TIL or PBL."
223528760|NCT00509288|DRUG|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
223528761|NCT00509288|DRUG|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
223528762|NCT00509288|BIOLOGICAL|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e\^11 (with a minimum of 5x10e\^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
223528763|NCT00509288|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
223528764|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
223528765|NCT01259258|PROCEDURE|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
223528766|NCT03127930|BEHAVIORAL|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
223528767|NCT03102086|PROCEDURE|Scaling|Scaling of dental calculus
223528768|NCT01334879|DRUG|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
223528769|NCT03795142|BIOLOGICAL|BGB149|Single Ascending Dose
223528770|NCT03795142|BIOLOGICAL|Placebo|Matching placebo
223715471|NCT03440268|DRUG|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
223715472|NCT04148053|DIAGNOSTIC_TEST|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
223715473|NCT05654337|OTHER|Expert health counseling|Expert advice on dietary education, lifestyle change, and physical exercise schedule
223715474|NCT03830424|PROCEDURE|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
223901978|NCT05374681|OTHER|embolization of the MMA|The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.
223901979|NCT06447480|DRUG|ISOtretinoin 5 MG|"The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d.~After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended."
224276854|NCT00897923|RADIATION|indium In 111-labeled autologous peripheral blood mononuclear cells|
224276855|NCT00897923|RADIATION|indium In 111-labeled autologous polymorphonuclear leukocytes|
223901980|NCT06447480|DRUG|Topical cream|Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
223901981|NCT05295030|OTHER|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
223901982|NCT05295030|OTHER|Kieember Infant formula, Ruibuen®|Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited
223901983|NCT05295030|OTHER|Yashili Infant formula, Ruibuen®|Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China
223901984|NCT04121403|BIOLOGICAL|Rituximab|Biosimilar rituximab concentrate for solution for infusion
223528771|NCT02870426|PROCEDURE|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
223528772|NCT02870426|PROCEDURE|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
223528773|NCT02903862|BEHAVIORAL|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
223528774|NCT02903862|DEVICE|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
223528775|NCT00875446|DRUG|PLACEBO|Placebo
223528776|NCT00875446|DRUG|GSK1223249|I.V Infusion
223528777|NCT04139291|OTHER|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
223528778|NCT00938574|DRUG|Atu027|
223528779|NCT05809089|DEVICE|High flow nasal cannula (HFNC)|"High-flow nasal cannula device was utilized. Humidifier temperature was set at 37°C via large-bore bi-nasal prongs, and inspired oxygen (FiO2) was adjusted to maintain oxygen saturation by pulse oximetry (SpO2) ≥ 90%.The flow was initially set at 10 L/min and titrated upward in 5 L/min steps until patients experienced discomfort.~Patient will be evaluated every 8 hours and discontinued the device for eating, drinking and coughing up secretion and returned back to the device for 72 hours."
223528780|NCT05809089|DEVICE|Noninvasive ventilation (NIV)|Patients initiated NIV; Inspiratory positive airway pressure (IPAP) was initiated at 10-12 cmH2O, and expiratory positive airway pressure (EPAP) started at 4-5 cmH2O. FIO2 was adjusted to maintain SpO2 ≥ 90%. The same protocol as done in HFNC, patient will be evaluated every 8 hours and discontinued the device and returned back to the device for re- evaluation within 72 hours
223528781|NCT01350076|DRUG|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
223528782|NCT01350076|DRUG|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
223528783|NCT01731145|DEVICE|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
223528784|NCT04972279|BEHAVIORAL|Digital message (text + image)|"Messages can be up to 256 characters of text with an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
223901985|NCT04121403|DRUG|Cladribine|Mavenclad oral cladribine tablets
223901986|NCT03850964|DRUG|Pazopanib|gel capsule, with 25mg-similar fills
223901987|NCT03850964|DRUG|Placebo oral capsule|identical gel capsule without active pharmaceutical ingredient
223901988|NCT03132506|OTHER|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
223901989|NCT03397303|OTHER|elastography measurements|elastography measurements
223901990|NCT06771934|BIOLOGICAL|Allergen-specific immunotherapy(AIT)|"Allergen-Specific Immunotherapy(AIT) Protocol: using the house dust mite allergen preparation (Alutard, ALK Company, Denmark). The treatment course was divided into the initial treatment stage and the maintenance treatment stage. The initial treatment stage, also known as the dose accumulation stage, involved injecting the vaccine once a week and usually lasted for 15 weeks. For highly sensitive patients, treatment was carried out according to the dose guidelines for high sensitivity. The maximum dose in the initial treatment stage was the maintenance dose. After reaching the maintenance dose, the first maintenance injection was given 2 weeks later, the second maintenance injection was given 4 weeks later, and thereafter, a vaccine injection was carried out every 4 - 8 weeks."
223901991|NCT06771934|BIOLOGICAL|omalizumab|Omalizumab Treatment Protocol: The dosage and administration frequency (once every 2 weeks or once every 4 weeks) of omalizumab were determined based on the patients' pretreatment serum total IgE (kU/L), age, and body weight (kg). Each dosage ranged from 15 to 600 mg and was administered subcutaneously. If the dosage was ≤ 150 mg, it was injected subcutaneously at 1 site; otherwise, it was injected subcutaneously at 1 to 4 sites respectively. After the first 3 injections, patients were observed in the hospital for at least 2 hours, and after the 4th and subsequent injections, they were observed for at least 30 minutes. During the treatment period, the background medications for asthma control were adjusted according to the patient's condition.
224083491|NCT05740228|DEVICE|Anodal tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
223528785|NCT04380142|DRUG|ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
223528786|NCT04380142|DRUG|Placebo for Levodopa/Carbidopa (LD/CD)|Oral capsule
223528787|NCT04380142|DRUG|Levodopa/Carbidopa (LD/CD)|Oral encapsulated tablet
223528788|NCT04380142|DRUG|Placebo for ABBV-951|Solution for continuous subcutaneous infusion (CSCI)
223528789|NCT04857060|BEHAVIORAL|ACP Educator led, video assisted discussion|For hospitalized patients identified by a defined EHR algorithm, an ACP Educator will meet with the patient in the hospital to provide primary palliative care services such as goals-of-care conversations and clinician communication by leveraging certified video decision aids.
223528790|NCT02184533|DRUG|sodium selenite|Given PO
223528791|NCT02184533|RADIATION|radiation therapy|Undergo radiation therapy
223528792|NCT02184533|OTHER|laboratory biomarker analysis|Correlative studies
223528793|NCT02184533|OTHER|pharmacological study|Correlative studies
223528794|NCT02184533|OTHER|questionnaire administration|Ancillary studies
223528795|NCT04335968|DRUG|Melatonin 4 mg|melatonin 4mg per os every night, starting the evening before surgery (or 2 hours before emergency surgery) and until day 5 after surgery.
223528796|NCT04335968|DRUG|Placebo oral tablet|placebo of this drug with the same schedule, during the same period of time.
223528797|NCT05446064|BEHAVIORAL|Stigma-reduction intervention|The intervention is modularized into four weekly 1-hour group sessions, led by a trained facilitator who provides psychoeducation to promote awareness and understanding of HIV stigma and teach CBT-based coping skills. Each group session will last 45-60 minutes. Participants are introduced to the general CBT model of HIV stigma and encouraged to track thoughts, feelings, and behavioral responses when encountering external stigma or adverse events. The participants further learn to differentiate effective and ineffective coping strategies and practice applying new coping skills to reduce internalized HIV stigma. The interventionist will follow the intervention manual to deliver the intervention and assign homework for group members to practice on their own. In the following sessions, the interventionist will review progress with participants, guide participants through exercises, and identify additional problems to be addressed in subsequent sessions.
223528798|NCT03315377|PROCEDURE|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
223528799|NCT03315377|PROCEDURE|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
223528800|NCT00787150|DRUG|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
223528801|NCT00787150|DRUG|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
223528802|NCT00787150|DRUG|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
223528803|NCT01772654|DEVICE|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
223528804|NCT04537650|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VFSS)|A standardized dynamic radiographic examination of oropharyngeal swallowing
223528805|NCT02268656|DRUG|propofol concentration|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
223528806|NCT01849276|DRUG|metformin hydrochloride|Given orally
223528807|NCT01849276|DRUG|cytarabine|Given IV
223528808|NCT01849276|OTHER|laboratory biomarker analysis|Correlative studies
223528809|NCT04998942|BEHAVIORAL|virtual cardiac wellness program|Participants assigned to this arm will participate in the experimental intervention.
223528810|NCT04998942|BEHAVIORAL|Placebo comparator|Participants assigned to this arm will participate in a placebo intervention.
223528811|NCT04695665|OTHER|Cervical pain|Exercise program for cervical spine according to McGill's approach.
223528812|NCT04695665|OTHER|Thoracic pain|Exercise program for thoracic spine according to McGill's approach.
223528813|NCT04695665|OTHER|Lumbar pain|Exercise program for lumbar spine according to McGill's approach.
223528814|NCT02699307|BEHAVIORAL|Counseling|OT led counseling
223528815|NCT04269954|DRUG|Batroxobin combined with low molecular weight heparin|Standard treatment of Batroxobin combined with low molecular weight heparin
223528816|NCT01262105|DEVICE|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
223528817|NCT03477812|DEVICE|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
223528818|NCT00748605|DRUG|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
224276856|NCT03599921|BEHAVIORAL|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
223715475|NCT03830424|DIETARY_SUPPLEMENT|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
223715476|NCT00506480|PROCEDURE|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
223715477|NCT03565744|BEHAVIORAL|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
223715478|NCT03009981|DRUG|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
223715479|NCT03009981|DRUG|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
223715480|NCT03009981|DRUG|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
223715481|NCT03009981|DRUG|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
223715482|NCT04690998|OTHER|Blood Samples|Genetic, proteomic, neurofilament analysis
223715483|NCT04690998|OTHER|MRI|Spinal and muscular MRI
223715484|NCT04080245|BIOLOGICAL|Treatment Group Live Attenuated Flu Vaccine (LAIV)|We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.
223715485|NCT01009632|BEHAVIORAL|Resonant voice|4-hr of resonant voice exercise
223715486|NCT01009632|BEHAVIORAL|Voice rest|4-hr of complete refrain from any voice use
223715487|NCT01009632|BEHAVIORAL|Spontaneous speech|
223715488|NCT04904328|DEVICE|Lumishade® Active Lens|"Migraine episodes are often triggered or exacerbated by environmental factors, particularly light. Active lens has been designed by blocking particular range of wavelength and hypothetically alleviate symptoms of migraine and thus either treat or prevent migraine headaches from occurring.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
223715489|NCT04904328|DEVICE|Lumishade® Sham Lens|"Lumishade® Sham lens has been designed as inactive and not blocking particular range of wavelength. Thus, it will not alleviate or prevent symptoms of migraine.~(Note, we are reluctant to write any further information around the devices on this public record while the study is active to ensure we maintain the blind of the trial.)"
223715490|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants|As per treatment allocation, PEG 4000 will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
224276857|NCT03599921|BEHAVIORAL|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
223715491|NCT06349031|DRUG|Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants|As per treatment allocation, PEG 3350 + Electrolytes will be administered to participants at a dose of 1.5 gm/kg/day dissolved in water until resolution of fecal impaction or a maximum till 6 days whichever is earlier. Fecal impaction Resolution is defined as : Passage of clear liquid stool and no palpable abdominal fecolith
223715492|NCT00147446|BEHAVIORAL|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
224083492|NCT05740228|DEVICE|Anodal High-Definition (HD) tDCS - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
224276858|NCT03599921|BEHAVIORAL|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
223715493|NCT00147446|OTHER|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
223715494|NCT06394817|OTHER|No intervention|No intervention
223715495|NCT00382577|DRUG|Itopride|
223715496|NCT00382577|DRUG|Placebo|
223715497|NCT03329573|DRUG|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
223715498|NCT03329573|DRUG|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
223715499|NCT01031355|DRUG|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
223715500|NCT01031355|DRUG|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
223715501|NCT01031355|DRUG|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
223715502|NCT05902780|DRUG|Caudal Bupivacaine injection|\- Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
223715503|NCT05902780|DRUG|Caudal Dexmedetomidine Injection|\- Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
223715504|NCT05000463|DRUG|Ozone|The participants will lay flat and the area of injection will be prepared with antiseptic. Maintenance of ultrasonography probe sterility was also guaranteed using a sterile barrier. Under sonographic guidance, superficial peroneal nerve, deep peroneal, sural , asphenous, and tibila nerves will be injected An ozone/oxygen mixture ( 25μg/ml) will be injected in each nerev
223715505|NCT05000463|DRUG|Convtrol group|The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
223715506|NCT01423058|DRUG|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
223715507|NCT03535116|DRUG|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
223715508|NCT03535116|DRUG|Saline|injectable normal saline
223715509|NCT05085652|PROCEDURE|spinal anesthesia induced hypotension in SARS-CoV-2 patients.|SARS-CoV-2 infection prognosis remains unclear during pregnancy. according to ESA, ASRA and WHO regional anesthesia was recommended to use for caesarian section procedures. But at the beginning of the pandemic Chen et al shared their retrospective analyses about regional anesthesia for caesarian section and they showed high spinal anesthesia induced hypotension in 14 patients of the 17 and also again Chen and Zahng et al made another study and this time they found 57,4% hypotension incidence. In our study we aimed to find if the spinal anesthesia safe procedure in the 249 patients and one center hospital.
223715510|NCT00650260|DEVICE|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
223715511|NCT00650260|DEVICE|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
223715512|NCT02777333|BEHAVIORAL|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
223715513|NCT02564549|PROCEDURE|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
223715514|NCT02564549|PROCEDURE|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
223719231|NCT01315678|DRUG|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
223719232|NCT01516697|PROCEDURE|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
223901992|NCT06548022|BEHAVIORAL|Rare Group Problem Management Plus|The World Health Organization's Group Problem Management Plus (Group PM+) intervention has been demonstrated to effectively provide psychological help for adults impaired by distress in communities exposed to adversity. Investigators will test an adapted model for use on-line and with family caregivers of children with rare diseases. Managing Stress. Teaching participants a brief stress management strategy will help them better manage problems related to anxiety and stress. Managing Problems. This is a strategy to apply in situations where a participant is experiencing practical problems (e.g. conflict in the family). Get Going, Keep Doing. This strategy targets depression and inactivity. Strengthening Social Support. Individuals with emotional problems can be isolated from supportive people and organizations. Strengthening social support promotes well-being. Staying Well and Looking Forward. This is a review, ends with a closing ceremony.
223901993|NCT05880966|BEHAVIORAL|Functional Fitness|Six month, thrice weekly functional fitness sessions will include a warm-up (15 minutes), skill or strength work (30 minutes) and a cool down (15 minutes)
223901994|NCT05984433|DEVICE|Auricular acupuncture|Electro auricular acupuncture
223901995|NCT06507735|DIETARY_SUPPLEMENT|Mannose|Mannose is a sugar monomer that is important in the glycosylation of many proteins. The concentration of mannose in mammalian plasma is \~50-100 μM, which is primarily derived from N-glycan processing. Taking dietary mannose supplements can raise the levels of plasma mannose by 3- to 5-fold. There are currently no known adverse effects of mannose supplementation in humans.
223901996|NCT06360328|DEVICE|video laryngoscopy|The residents used video laryngoscopy for endotracheal intubation
223901997|NCT06215430|DRUG|Caffeine Tablet|Administered orally.
223901998|NCT06215430|DRUG|Omeprazole capsule|Administered orally.
223901999|NCT06215430|DRUG|Warfarin tablet|Administered orally.
223902000|NCT06215430|DRUG|Pirtobrutinib|Administered orally.
223902001|NCT05734313|BEHAVIORAL|Unified protocol for cognitive behavioral therapy (UP-CBT)|UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
223902002|NCT05734313|DEVICE|Continuous Glucose Monitoring (CGM)|Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
223902003|NCT04600713|OTHER|PT-X and IMT|The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
223902004|NCT06564948|OTHER|Treatment as usual (TAU)|"TAU patients will be identified using targeted limited chart review methods used in our prior studies, scraping clinical notes in the EHR for criminal justice involvement. Initial Identification terms, police, arrest, court, summons, jail, and crime will be used to identify candidates for police involvement, downloading the sentence in which the keyword appeared and the sentence before and after. Next, an iterative process of editing of the search terms will be conducted to remove patients with negation of the keyword (did not commit a crime), and other sentence characteristics that generate false positives (cardiac arrest). Samples of the resulting dataset will be taken, accuracy assessed by examining the surrounding sentences, leading to further iterations and repetition of the process until a high level of accuracy is achieved."
223902005|NCT06564948|OTHER|Family and Social Justice|Documentation and follow-up by the Cambridge Police Department (CPD) for all mental health-related police calls, including involuntary and voluntary Emergency Department admissions; Established partnerships with city departments, healthcare systems, clergy, courts, businesses, and mental health advocates to ensure timely engagement in mental health treatment and community-based services; Required 40 hours of officer crisis intervention training (CIT), and additional sessions on trauma- informed policing, mental health, procedural justice, race, and crisis negotiation; and Staffing of sworn and civilian staff including specially-trained officers designated to work with individuals living with mental illness, homelessness, and substance abuse.
224083493|NCT05740228|DEVICE|Sham stimulation - Direct Current (DC)-stimulator (Soterix Medical, New York, NY, USA)|"A current of 2 milliamperes (mA) will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.~The motor rehabilitation program include (1) balance exercises , (2) sit-to-stand exercises, (3) step exercises, (4) leg exercises, (5) walking training (6) stair-stepping exercises."
223715515|NCT05165836|PROCEDURE|Erector Spinae Plane block without Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
224083494|NCT03969888|DRUG|ABBV-3067|Tablet taken orally.
224083495|NCT03969888|DRUG|Placebo ABBV-3067|Tablet taken orally.
224083496|NCT03969888|DRUG|ABBV-2222|Capsule taken orally.
224083497|NCT03969888|DRUG|Placebo ABBV-2222|Capsule taken orally.
223902006|NCT06564948|OTHER|Family and Social Justice Service and Navigator (FSJS+Navigator) Intervention|"The FSJS+Navigator intervention adds an Emergency Department (ED)-based Systems Navigator, a community health worker with lived experience (as family member or patient) with criminal justice and mental health systems, to the FSJS. This navigator will enhance communication between Cambridge Police Department (CPD), Cambridge Health Alliance (CHA), and community agencies by being the needed point person within the healthcare system (the FSJS intervention only has a CPD-based social worker) to maintain communication to improve mental health services and prevent deeper justice involvement. The Navigator engages with the FSJS process in step i) of the above sequence, engaging the patient in the CHA ED and obtaining consent. The Navigator then discusses the case with the presenting CPD officer, and relays critical information about the context of the service call to ED staff. Next, the Navigator will administer the baseline CAT-MH/SS and assess additional needs (employment, housing, food)."
223902007|NCT06408220|PROCEDURE|Biopsy|Undergo tissue biopsy
223902008|NCT06408220|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223902009|NCT06408220|PROCEDURE|Breath Test|Undergo H. pylori breath test
223902010|NCT06408220|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
223902011|NCT06408220|OTHER|Questionnaire Administration|Complete questionnaires
223902012|NCT04376502|RADIATION|Radiation Therapy|Radiation therapy for all subjects will consist of treating one tumor of the treating physician's preference (40 Gray (Gy) in 5 fractions), and after a 1-week interval during which ICI is continued alone, radiation therapy will be given to a second and separate tumor (30 Gy in 5 fractions).
223902013|NCT06527339|OTHER|Dry Needling with Vibration|In the PS+V technique, no movements will be performed with the needle once it is correctly inserted. Instead, only vibratory stimulus will be applied for 10 minutes. Since this is a completely novel technique, the optimal duration of application is not yet known; however, it is considered that 10 minutes may be sufficient to demonstrate an effect.
223902014|NCT06527339|OTHER|Conventional Dry Needling|"In the conventional PS technique, the needle will be inserted into the MTrP using the fast-in and fast-out technique described by Hong (1994) at an approximate frequency of 1 insertion per second (1 Hz) without completely withdrawing the needle from the skin. This technique will be maintained for 30 seconds in an attempt to elicit a local twitch response. After the procedure, the treated area will be firmly compressed with a cotton pad for three seconds."
223902015|NCT00912041|DEVICE|Placement of the BrainGate2 sensor(s) into the motor-related cortex|Up to six 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one, two, or three percutaneous pedestals. Neural recordings are made at least weekly for a year or more.
223902016|NCT06689722|OTHER|chiropractic|Chiropractic practice was applied using the diversified technique, which is one of the types of chiropractic techniques.
223902017|NCT06689722|OTHER|sham|The patient was asked if he/she had any pain or other complaints during the trial mobilization. High-velocity, low-amplitude impulses were applied to the inferior and lateral directions for patients who did not describe any complaints.
223902018|NCT06689722|OTHER|ergonomics|"Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa"
223902019|NCT05131425|BEHAVIORAL|Facing Your Fears: ASD/ID|This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.
223902020|NCT05131425|OTHER|Treatment as Usual|The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
223902021|NCT05694624|DRUG|Para Aminohippurate|Measurements of renal plasma flow and glomerular filtration rate
223902022|NCT06521645|OTHER|electroacupuncture|electrical stimulation is given through needles inserted into the skin
223902023|NCT06521645|OTHER|sham needle|needles are inserted shallowly into the skin
223902024|NCT01423656|DRUG|LEO 29102|
223902025|NCT01423656|DRUG|Placebo|Placebo Comparator: LEO 29102 vehicle
223902026|NCT03748953|DRUG|Ixazomib|Ixazomib Capsules
223902027|NCT06026241|OTHER|Collecting data from the medical record|Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
223902028|NCT04746105|DRUG|TS-142|Subjects received single-dose of 10 mg of TS-142 (oral tablet)
223902029|NCT04746105|DRUG|Dose-matched Placebo to TS-142|Subjects received single-dose matched placebo to TS-142 (oral tablet)
223902030|NCT06348992|BEHAVIORAL|Acceptance commitment therapy and yoga|The intervention used a combination of online and offline methods, based on ACT, supplemented by hatha yoga exercise intervention, the intervention group used the combination of offline ACT psychological intervention and online hatha yoga training, and the control group used mental health education, so as to explore and validate the effect of ACT combined with yoga on the improvement of parental parental burnout in children with ASD. The offline ACT psychological intervention was implemented by the researchers and psychologists, and the ACT psychological intervention was carried out once a week in community health centers or hospitals for 8 weeks. Online, a WeChat group was set up for parents with ASD, and Hatha Yoga training content and videos were sent to the group chat, and the researchers and volunteers supervised the training and clocking in and out of the group, three times a week.
223902031|NCT06348992|BEHAVIORAL|Active Comparator: Mental Health Education Group|The control group was provided with 8 weeks of mental health education, including emotional management skills, positive coping styles, and scientific parenting methods.
223902032|NCT05427812|DRUG|ISB 1442 SC injection escalating doses|Participants will receive escalating SC doses of ISB 1442
223902033|NCT05427812|DRUG|ISB 1442 SC injection at RP2D|ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
223902034|NCT05662189|DRUG|68Ga-exendin-4|68Ga-exendin4 PET-CT scan
223902035|NCT05662189|OTHER|mixed meal test|before and after a standardized mixed meal venous blood samples will be collected at time intervals to measure plasma glucose, C-peptide,insulin, glucagon, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) curves
223902036|NCT06377982|BIOLOGICAL|hUCB|hUCB
223902037|NCT06532370|BEHAVIORAL|Contingency Managment|"If the sample be methamphetamine negative, participant will be positively reinforced and offered incentives. Participants immediately draw the reinforcement slip of paper to receive a prize from a selection kept on-site. Approximately, half of the slips offer written praise (e.g. great job!). The other half of slips are then divided between low value (e.g. food gift cards, bus passes), medium value (e.g. prepaid cell phone, clothing gift cards), and a few large value rewards (e.g. iPad, jewelry). Should the sample be positive for methamphetamine, no reinforcement and/or incentive to be provided. Participant will be encouraged to continue to participate in CM program and follow-up on the next CM date."
223902038|NCT04890171|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection by a endoscopist using endoscopic devices
223902039|NCT04890171|PROCEDURE|Surgery|Gastrectomy with lymph node dissection by a surgeon
223902040|NCT05204797|PROCEDURE|Robot-assisted UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.
223902041|NCT05204797|PROCEDURE|Standard technique UKA|Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
223902042|NCT03769155|BIOLOGICAL|Ipilimumab|Given IV
223902043|NCT03769155|BIOLOGICAL|Nivolumab|Given IV
223902044|NCT03769155|BIOLOGICAL|VX15/2503|Given IV
223902045|NCT03769155|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
223902046|NCT06393595|DIAGNOSTIC_TEST|surface enhanced Raman Spectroscopy|"Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried . The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope . The spectra were excited by laser module with a center wavelength of 785 nm. Each of the obtained spectra was a discrete set of 1700 parameters .~For skin Raman spectroscopy an experimental portable RS system was used, including a 785 nm diode laser , a portable commercially available Raman probe to filter the collected scattered radiation, and a portable spectrometer (QE65Pro, Ocean optics, Florida, USA). The scattered radiation was collected from the upper 1 to 2 mm thick skin layer. The Raman spectral range was 780-1000 nm with resolution of 0.2 nm. Each spectrum was recorded at an exposure time of 20 seconds with three-fold accumulation."
223902047|NCT06076187|OTHER|Dual isotope protein digestibility method|Dual isotope method
223902048|NCT05282277|DRUG|Transdermal Estradiol|Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.
223902049|NCT05282277|DRUG|Micronized Progesterone|Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
223902050|NCT05282277|DRUG|Matching Placebo Patch|Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks
223902051|NCT05282277|DRUG|Raclopride C11|All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.
223902052|NCT04174391|BEHAVIORAL|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
223902053|NCT04174391|BEHAVIORAL|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods - equivalent to the extra-virgin olive oil allotment - will be received by participants of this group for free. In addition, advice on physical activity will be provided.
223902054|NCT04873050|DRUG|Semaglutide Pen Injector [Ozempic]|Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
223902055|NCT04873050|DRUG|Placebo semaglutide pen injector|Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
223902056|NCT03626766|BEHAVIORAL|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
223902057|NCT03626766|BEHAVIORAL|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
223902058|NCT03626766|BEHAVIORAL|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
223902059|NCT01269593|DRUG|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
223902060|NCT03833206|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
223902061|NCT04408313|DRUG|XR-B|Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.
223902062|NCT04408313|DRUG|XR-NTX|Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.
223902063|NCT05720416|DIETARY_SUPPLEMENT|protein supplementation|protein supplementation for 16 weeks
223902064|NCT05720416|BEHAVIORAL|muscle strength training|muscle strength training for 16 weeks
223902065|NCT05720416|OTHER|usual care|no intervention
223902066|NCT05968469|DEVICE|Aerobic exercises with cycling ergometry|"A total of 20 sessions of high-intensity interval (HIIT) aerobic exercise program will be applied to the patients using a bicycle ergometer, five days a week and once a day for four weeks. And then, it was planned to perform stretching exercises for the cervical, thoracic and lumbar regions and posture exercises accompanied by a specialist physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
223902067|NCT05968469|OTHER|Stretching exercises|"Stretching exercises for the cervical, thoracic and lumbar regions and posture exercises were planned to be performed with the expert physiotherapist.~The patients will be evaluated by the physician for a total of 3 times at the beginning of the treatment, at the end of the treatment (4th week) and at the 12th week after the start of the treatment. All patients will be evaluated for the parameters in the patient evaluation form, and blood samples taken between 08:00 and 10:00 in the morning and Calprotectin, Visfatin, Leptin, IL-33 serum levels will be measured with the ELISA kit."
223902068|NCT05006157|DEVICE|ViaOne device|ViaOne device is designed to allow percutaneous subxiphoid pericardial access utilizing a proprietary mechanism of entry into the pericardial sac.
223902069|NCT05856344|DEVICE|Spherical tip noncompliant balloon|The main difference of this experimental balloon is the spherical tip, other parameters are consistent with regular noncompliant balloons.
223902070|NCT05856344|DEVICE|Regular noncompliant balloon|The balloon is designed as tapered-tip.
223902071|NCT06194305|OTHER|CBIT|Participants will receive 8 sessions delivered weekly over 10 weeks. All sessions will be video recorded. CBIT components are: 1) Psychoeducation about tics, 2) Functional interventions, 3) Competing response (CR) training, 4) Social support: supportive people (e.g., parent, teacher) , 5) Motivational enhancements, 6) Homework: is assigned each session and typically involves self-monitoring and CR practice. Participants will complete a brief daily homework tracking log in REDCap.
223902072|NCT03533985|BEHAVIORAL|Song of Kin|Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
223902073|NCT03533985|OTHER|Gato box|Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
223902074|NCT03533985|OTHER|Ocean disc|Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
223902075|NCT03533985|OTHER|Contingent singing|Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
223902076|NCT03533985|OTHER|Tonal Vocal holding|Music therapist will provide a vowel, long held tone, sung without vibrato
223902077|NCT03533985|OTHER|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
223902078|NCT06215027|OTHER|Dance|Dance protocol
223902079|NCT06029075|DEVICE|tACS Sham|Sham tACS will applied to the brain through the scalp for 20 minutes.
223902080|NCT06029075|DEVICE|tACS 10Hz|10Hz tACS will applied to the brain through the scalp for 20 minutes.
223902081|NCT06029075|DEVICE|tACS 20Hz|20Hz tACS will applied to the brain through the scalp for 20 minutes.
223902082|NCT06402955|RADIATION|11C-UCB-J|Radiotracer for imaging
223902083|NCT06402955|DRUG|ketamine hydrochloride|There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.
223902084|NCT04974554|BEHAVIORAL|FIT|FIT Families is a home-based intervention that works with youth and caregivers to lose weight and improve their health. The intervention lasts 6 months. Sessions are held twice a week for the first 3 months and then once a week for the second 3 months. These sessions will take place in home with a community health worker. In addition, participants will have the opportunity to earn prizes for completing certain intervention related tasks.
223902085|NCT04974554|BEHAVIORAL|Home-Based Family Support|Home-Based Family Support Group will receive six months of weekly family counseling in the home. The weekly visits have 3 goals: 1) provide basic education in nutrition and physical recommendations for adolescent and adult obesity; 2) assess and monitor weight, physical activity, and diet via logs; and 3) offer opportunities to discuss barriers they identify to adherence to weight loss recommendations. The HBFS CHW will also address non-weight related problems such as peer or family relationship problems during the visits.
223902086|NCT04251429|OTHER|CPH-NEW Healthy Workplace Participatory Program|A participatory program for increasing effectiveness of occupational health and safety committees or peer-led employee teams through root cause analysis, prioritizing health and safety needs for effective problem-solving, identifying feasible interventions, and presenting these to senior leadership. Interventions are selected and implemented by leadership and evaluated by both teams.
223902087|NCT02974998|BEHAVIORAL|Young Women's Health CoOp (YWHC)|Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
223902088|NCT02974998|BEHAVIORAL|Standard HTC|Participants received the standard HTC available in South Africa for this population.
224083498|NCT03875950|BEHAVIORAL|Clinician training intervention|This intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers delivering PrEP to adolescent girls and young women to prevent HIV in Kenya.
224276859|NCT03599921|BEHAVIORAL|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
224276860|NCT00396630|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
223528819|NCT00748605|DRUG|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
223528820|NCT00748605|DRUG|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
223528821|NCT00748605|OTHER|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
223528822|NCT00748605|OTHER|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
223528823|NCT00879398|DRUG|Toviaz treatment|4 mg starting then can be followed by 8 mg
223528824|NCT06501313|DEVICE|Photobiomodulation|Soft laser therapy
223719233|NCT01516697|PROCEDURE|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
223719234|NCT01738360|DRUG|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~* Pre-inclusion between D-35 and D-15~* Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~* A telephone contact between D32 and D34~* A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
223719235|NCT03676257|OTHER|Endocrine therapies|No intervention
223719236|NCT01720121|OTHER|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
223719237|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
223719238|NCT01576263|DRUG|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
223719239|NCT03040102|OTHER|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
223719240|NCT03040102|OTHER|Standard of Care|Standard of Care practice is used
223719241|NCT05182138|OTHER|Unfortified potato plus placebo|Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.
223719242|NCT05182138|OTHER|Zinc Biofortified potato plus placebo|Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.
223719243|NCT05182138|OTHER|Unfortified potato plus zinc supplement|Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
223719244|NCT04953377|BEHAVIORAL|PFMT educational intervention|an educational intervention to learn about the pelvic floor and how to train it
223719245|NCT00331682|DRUG|alvocidib|Given IV
223719246|NCT00331682|DRUG|docetaxel|Given IV
223719247|NCT00790023|DRUG|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
223719248|NCT00790023|DRUG|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
223719249|NCT00790023|DRUG|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
223719250|NCT05136768|DRUG|Sintilimab|Sintilimab: 200mg, administered by intravenous infusion on the first day of each cycle, one cycle every 3 weeks (Q3W), with the maximum cycle of 17. Suspension of Sintilimab administration: patients's request, disease progression, researcher-evaluated SAE
223719251|NCT05136768|RADIATION|SBRT|"At least one metastatic lesion is suitable for SBRT. If applicable, all metastatic lesions were allowed to be irradiated.~Recommended dose: BED ≥ 80Gy. Dose fractionation is determined as per physician's discretion, generally depending on the location of irradiated lesion and the distance to surrounding OARs.~Timing of SBRT: After completing at least 2 platinum-containing chemotherapy plus sintilimab treatments, SBRT can be started after assessing that there is no AE ≥ G2."
223719252|NCT05136768|DRUG|Platinum based chemotherapy|Platinum based single or doublet chemotherapy, one cycle every 3 weeks (Q3W), 4-6 cycles.
223719253|NCT05739097|DIAGNOSTIC_TEST|iron deficiency, coagulation abnormalities|avoid transfusions, where possible
223719254|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
223719255|NCT02468414|BIOLOGICAL|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
223719256|NCT02916108|OTHER|Reading EEG|EEG recording for 5 minutes (not an intervention)
223719257|NCT02503553|BEHAVIORAL|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
223719258|NCT02503553|BEHAVIORAL|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
223719259|NCT01338792|DRUG|oxaliplatin|Given IV
223719260|NCT01338792|DRUG|pemetrexed disodium|Given IV
223719261|NCT01338792|OTHER|questionnaire administration|Ancillary studies
223719262|NCT01338792|OTHER|laboratory biomarker analysis|Correlative studies
223719263|NCT01338792|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223528825|NCT06548724|OTHER|assessment of quality of life before and after anal surgery|"Preoperatively, the state of continence will be assessed using Wexner Incontinence Score (WIS) . Also, the basal state of quality of life (QoL) will be assessed using a validated disease-specific tool known as Quality of Life in patients with Anal Fistula Questionnaire (QoLAFQ) (Ferrer-Márquez et al., , faecal incontinence quality of life (FIQL)~Surgical Techniques:~The selection of surgical technique depends on the type of fistula , patient choice and commitment to guidelines . Follow-up Patients will be followed-up in the outpatient clinic weekly in the first month, then every two weeks in the second month, then at 3, and 6 months postoperatively. The continence state and QoL change will be assessed using QoLAF-Q and GIQLI 3 months and6 months postoperatively."
224276861|NCT00396630|BIOLOGICAL|Placebo|Two-dose oral administration.
223528826|NCT06548048|DIETARY_SUPPLEMENT|Dietary supplement containing plant derived phenolics|Dietary supplement containing plant derived phenolics
223528827|NCT06548048|DIETARY_SUPPLEMENT|Microcrystaline cellulose|Microcrystaline cellulose (MCC)
223719264|NCT01338792|GENETIC|polymorphism analysis|Correlative studies
223719265|NCT00573469|DRUG|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
223719266|NCT00573469|DRUG|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
223719267|NCT00573469|DRUG|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
223719268|NCT02732704|DEVICE|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
223719269|NCT03269383|DRUG|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
223719270|NCT03269383|OTHER|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
223719271|NCT04782427|OTHER|COVID-19 infection|Case of nosocomial infection within the long-term care facility
223719272|NCT01294657|BEHAVIORAL|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
223719273|NCT01294657|BEHAVIORAL|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
223719274|NCT00004978|DRUG|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
223719275|NCT04286321|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
223719276|NCT04286321|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
223719277|NCT04286321|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
223719278|NCT04286321|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
223719279|NCT04286321|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
223719280|NCT04286321|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
223719281|NCT04286321|OTHER|Two egg whites at 0 h|Two egg whites will be consumed on test day along with spinach consumption
223719282|NCT04286321|OTHER|Vegetable oil at 0 h|9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
223719283|NCT04512404|DRUG|HMG-CoA Reductase Inhibitor|
223719284|NCT00336063|DRUG|Azacitidine|Given SC
223719285|NCT00336063|OTHER|Laboratory Biomarker Analysis|Correlative studies
223719286|NCT00336063|OTHER|Pharmacological Study|Correlative studies
223719287|NCT00336063|DRUG|Vorinostat|Given PO
223719288|NCT01044862|DRUG|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
223719289|NCT01044862|DRUG|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
223719290|NCT01044862|DRUG|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
223719291|NCT01652703|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223719292|NCT01652703|OTHER|Placebo|Administered by subcutaneous injection
223719293|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
223719294|NCT02789150|DRUG|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
223719295|NCT05288231|DIAGNOSTIC_TEST|Diagnostic of ECG|All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography
223719296|NCT04078113|OTHER|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
223719297|NCT02790528|DRUG|Atorvastatin|20mg QD
223719298|NCT02790528|DRUG|Placebo|Placebo drug will be administered.
223719299|NCT01384253|OTHER|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
223719300|NCT01384253|BIOLOGICAL|trastuzumab|4 mg/kg.
223719301|NCT05973500|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet for 42 Days
223719302|NCT05769881|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block|After the induction of anesthesia, before the beginning of the operation, the subcostal transversus abdominis region is going to be detected under ultrasound guidance and 25-30 ml of 0.25% bupivacaine will be administered
223719303|NCT05769881|PROCEDURE|Wound site local anesthetic infiltration|After induction of anesthesia, before the beginning of the operation, a total of 20 ml of 0.25% bupivacaine is going to be infiltrated in equal doses to the four regions that will have trocar access
223719304|NCT03167840|BEHAVIORAL|Physical and Cognitive Training|Physical Exercise and Cognitive Training
223719305|NCT03167840|BEHAVIORAL|Physical Training|Physical training alone
224276862|NCT02327325|BEHAVIORAL|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
224276863|NCT02327325|BEHAVIORAL|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
223719306|NCT03167840|BEHAVIORAL|Cognitive training|Cognitive training alone
223719307|NCT05832359|RADIATION|Panoramic rad.|In the study, digital panoramic x-rays of the patients will be evaluated and dental age estimation with Willems method and mandibular bone morphometric measurements will be made.
223719308|NCT00003211|BIOLOGICAL|filgrastim|
223719309|NCT00003211|DRUG|amifostine trihydrate|
223719310|NCT00003211|DRUG|cisplatin|
223719311|NCT00003211|DRUG|cyclophosphamide|
223719312|NCT00003211|DRUG|vincristine sulfate|
223719313|NCT00003211|PROCEDURE|peripheral blood stem cell transplantation|
223719314|NCT00003211|RADIATION|radiation therapy|
223719315|NCT02314897|DEVICE|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
223719316|NCT02314897|DEVICE|RV pacing|Conventional right ventricular pacing.
223719317|NCT06127277|BEHAVIORAL|Next4You|Youth in the intervention arm will have access for four continuous weeks to a mobile intervention that covers topics related to communication, relationships, sexual wellness, contraception, respecting self and partners, and building wealth and wellness.
223719318|NCT04497688|DRUG|PEG-rhG-CSF|Patients received a single dose of PEG-rhG-CSF per cycle. The chemotherapy regimen must meet the interval between two chemotherapy sessions at least 12 days.
223719319|NCT02927522|DRUG|Donepezil|Donepezil a cholinesterase inhibitor, 5mg(1 pill)/ day for 7 days Po, was administrated from the day before surgery.
223719320|NCT02927522|DRUG|Placebo|Placebo, 1 pill/ day for 7 days Po, was administrated from the day before surgery.
223719321|NCT00302250|DRUG|ALT-711 (alagebrium chloride)|
223719322|NCT01604174|OTHER|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
223719323|NCT01604174|OTHER|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
223719324|NCT02155608|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
223719325|NCT02155608|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
223719326|NCT03346785|BEHAVIORAL|Food Photography|Participants will engage in food photography on their smart phones while eating
223719327|NCT03346785|BEHAVIORAL|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
223719328|NCT03346785|BEHAVIORAL|No Phone Use|Participants will not use their smart phones while eating
223719329|NCT03555591|DRUG|Trelagliptin|Trelagliptin tablets
223719330|NCT05002010|DEVICE|Echo|Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
223719331|NCT02376088|DRUG|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
223719332|NCT00253045|BEHAVIORAL|Motivational groups|Motivational interviewing in group format
223719333|NCT01192854|DRUG|Clevudine|Clevudine flexible dosages of 30 mg/day
223719334|NCT01192854|DRUG|Adefovir|Adefovir flexible dosages of 10 mg/day
223719335|NCT01532414|DRUG|Androxal|oral, capsules, taken one time daily, for 3 months
223719336|NCT01532414|DRUG|Placebo|Oral capsule taken one time daily for 3 months
223719337|NCT03633682|BEHAVIORAL|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
223719338|NCT03633682|BEHAVIORAL|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, \& Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
223719339|NCT05013073|OTHER|ASTHMAXcel ED Application|A mobile application designed to assist patients in asthma symptom recognition, treatment best practices, and trigger identification.
223719340|NCT00081484|DRUG|epoetin alfa or beta|iv or sc, as prescribed
223719341|NCT00081484|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
223719342|NCT00187486|DRUG|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
223719343|NCT00187486|DRUG|Temodar|Temodar 200 mg/m\^2/day x 5 days every 28 days
223902089|NCT06149429|BEHAVIORAL|Personalized virtual reality experience|"The intervention that participants will be experiencing is personalized virtual reality experiences. The content of this experience will be determined at the initial visit during which the participant will complete a preference questionnaire which identifies the location they want to go to. These experiences will be filmed on the insta360 One R camera by the research coordinator. Each experience will be approximately 20 minutes. To view the videos participants will wear the Oculus Quest 2 virtual reality headset."
223902090|NCT03532282|BEHAVIORAL|ONLINE ONLY|Access to an online cognitive behavioral therapy for insomnia
223902091|NCT03532282|BEHAVIORAL|STEPPED CARE|A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm (checklist). Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
223902092|NCT05058287|DRUG|Depo-Medrol 40Mg/Ml Suspension for Injection|40mg Depo-Medrol mixed with hemostatic matrix
223902093|NCT05058287|DRUG|Placebo|1 mL of sterile normal saline mixed with hemostatic matrix
223902094|NCT03705715|DRUG|PET with radiotracer [11C]PBR-28 ( or [11C]ER176)|\[11C\]PBR-28 or \[11C\]ER176 will be injected into subjects' veins during PET scanning.
223902095|NCT03705715|OTHER|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
223902096|NCT01427153|PROCEDURE|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
223902097|NCT01427153|PROCEDURE|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
223902098|NCT05259085|DRUG|ALXN2050|ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
223902099|NCT02473536|RADIATION|Stereotactic ablative radiation therapy|SABR
223902100|NCT06492005|DRUG|9MW2821|Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
223902101|NCT06492005|DRUG|PD-1 inhibitior|Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
223528828|NCT04806152|OTHER|High intensity exercise|Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.
223528829|NCT04806152|OTHER|Usual care home exercise|Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week
223528830|NCT00895505|DRUG|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
223902102|NCT06136728|DRUG|Dalfampridine 10 MG [Ampyra]|Dalfampridine (10 mg) every 12 hours for 6 weeks.
223902103|NCT06136728|BEHAVIORAL|Physical therapy|Physical therapy (motor relearning for mobility and balance) one-on-one twice per week for 6 weeks.
223902104|NCT06136728|OTHER|Dalfampridine plus physical therapy|Dalfampridine (10 mg) every 12 hours for 6 weeks while simultaneously receiving physical therapy (motor relearning for mobility and balance) one-on-one twice per week.
223902105|NCT05387954|PROCEDURE|Transcatheter PFO closure|PFO closure followed by dual antiplatelet therapy (aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then by single antiplatelet therapy by aspirin or clopidogrel until the end of the study.
223902106|NCT05387954|DRUG|Oral Anticoagulant, Direct-Acting|Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
223902107|NCT05387954|DRUG|Antiplatelet therapy|Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
223902108|NCT05877261|DEVICE|Cementless Total Knee Replacement|Artificial knee implant inserted by cementless fixation.
223902109|NCT04402255|OTHER|pilates exercise|The key elements of Pilates during supine, prone, side-lying and standing positions will be taught. These key elements are: breathing (diaphragmatic), focusing (neutral position), rib cage placement, shoulder placement, head and neck placement (neutral position). Then, Pilates based 'mat' exercises will be performed by the physiotherapist in the clinic for 8 weeks, 2 days / week, 16 sessions. Each session will be programmed to be 45 minutes. During all exercises, including warm-up and cooling, patients will be asked to provide key elements and protect them during movements. Depending on the condition of the patients, the exercises will be advanced from easy to difficult.
223902110|NCT05190718|DEVICE|Pharyngeal electrostimulation|"Routine treatment:~Pharyngeal stimulation is performed via a nasogastric probe (Phagenyx) for a duration of 10 minutes daily and for at least 3 consecutive days. The number of stimulation repeats until max 2x3 repeats, depends on therapy progress and an interdisciplinary re-evaluation of the patient's rehabilitation potential."
223902111|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then different doses of Remimazolam was injected to two groups of D1 and D2, according to up-and-down method.
223902112|NCT05357430|DRUG|Remimazolam|0.3μg/kg of remifentanil was injected slowly in advance, then the calculated dose from groups of D1 and D2 of remimazolam was injected to group R.
223902113|NCT05357430|DRUG|Propofol|0.3μg/kg of remifentanil was injected slowly in advance, then 1.5-2mg/kg of Propofol was injected to group C
223902114|NCT04240054|DRUG|Bortezomib|Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15
223902115|NCT04240054|DRUG|Isatuximab|Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22
223902116|NCT04240054|DRUG|Cyclophosphamide|Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
223902117|NCT04240054|DRUG|Dexamethasone|Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23
223902118|NCT05773495|OTHER|I-SITE Intervention|I-SITE is a coaching facilitated implementation program that guides clinical personnel through tailored integration of teleophthalmology into primary care workflows.
224083499|NCT01260454|DRUG|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
223528831|NCT00895505|DRUG|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
223528832|NCT02347410|DEVICE|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
223902119|NCT05773495|OTHER|Usual Care Teleophthalmology|All sites will initially receive usual care teleophthalmology, consisting of having an active teleophthalmology program located in the primary care clinic and access to the I-SITE online toolkit. All sites will utilize non-mydriatic retinal cameras (e.g. Topcon NW400) located in their primary care clinic to obtain a single 45-degree photo of the disc and macula with an anterior photo in each eye to provide diabetic eye screening as part of patients' usual care. Images are captured by trained primary care personnel and securely transmitted to eye doctors for evaluation.
223902120|NCT06097910|PROCEDURE|Watchful waiting|Conduct thoracic computed tomography scans every 12 months. The decision regarding surgery is based on the surgeon's evaluation of radiologic follow-up. The reference resection criteria encompass: a) Any lesion that progresses to a tumor diameter larger than 2cm or has CTR greater than 0.25. b) Clinical Tumor, node, metastasis (TNM) stage upstaging.
223902121|NCT05633615|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
223902122|NCT05633615|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223902123|NCT05633615|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
223902124|NCT05633615|DRUG|Cyclophosphamide|Given IV
223902125|NCT05633615|DRUG|Fludarabine|Given IV
223902126|NCT05633615|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
223902127|NCT05633615|BIOLOGICAL|Mosunetuzumab|Given IV
223902128|NCT05633615|OTHER|Patient Observation|Undergo observation
223902129|NCT05633615|DRUG|Polatuzumab Vedotin|Given IV
223902130|NCT05633615|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223902131|NCT05633615|BIOLOGICAL|Tisagenlecleucel|Given IV
223902132|NCT04440982|DRUG|LUM015|LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
223902133|NCT04440982|DEVICE|Lum Imaging System|UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
223902134|NCT03482557|DEVICE|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
223902135|NCT03482557|DEVICE|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
223528833|NCT04862312|BEHAVIORAL|VideoDine|Participants will VideoDine with a dining partner at least six times during an eight week period. VideoDining involves sharing a meal with someone not physically present using video chat technology. Dining partners will be recruited, trained and paired with participants. Participants will be provided Amazon Echo Show devices for video chat.
223528834|NCT06201845|OTHER|Exercise awareness training|Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.
223902136|NCT06799091|DEVICE|Low frequency TENS|Low TENS group participated in twelve sessions of electrical stimulation with low frequency (TENS, 10 Hz/200 μs) was applied with self-adhesive electrodes (size 9 × 5 cm,), in the paravertebral ganglionar region (from T1 to L2). The sessions took place at the same time of the day, lasted 30 min, in an acclimatized room (23 °C) and the intensity of the current was delivered at sensory-level intensity, adjusted every 5 min by the sensory threshold, during the 30 min as tolerated by each subject, but without motor contraction or pain reported by the subject.
223902137|NCT06802822|DRUG|Prevention of Allosensitization|This study evaluates the impact of two different durations of immunosuppressive therapy on kidney transplant patients who return to dialysis after a failed transplant. One group will continue immunosuppressive therapy for two years, while the other will stop the therapy six months after starting dialysis. The goal is to determine if continuing immunosuppression can reduce the risk of allosensitization and improve outcomes, compared to stopping the therapy earlier.
223902138|NCT06798441|OTHER|Brush Only|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. Subjects will record their twice daily product usage on a subject diary.
223902139|NCT06798441|OTHER|Brush / Rinse (Jolly Rancher Prototype)|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
223902140|NCT06798441|OTHER|Brush / Rinse (LISTERINE® Total Care Zero Alcohol)|Subjects will brush twice daily for one timed minute with the toothpaste and toothbrush provided. After brushing for 1 timed minute, subjects will vigorously swish with 10mL (2 teaspoons) of rinse between their teeth for 1 minute and then spit out. Subjects will record their twice daily product usage on a subject diary.
223902141|NCT04662541|OTHER|Mobile Integrated Health (MIH)|MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.
223902142|NCT04662541|OTHER|Transitions of care coordinator (TOCC)|The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
223902143|NCT06800872|OTHER|Multidisciplinary metabolic rehabilitation|Standard in-hospital protocol of multidisciplinary metabolic rehabilitation
223902144|NCT06800872|OTHER|Multidisciplinary metabolic rehabilitation + training with WBVE|Standard in-hospital protocol of multidisciplinary metabolic rehabilitation + 24 sessions (2 sessions per day) of 30 minutes each of training on a vibration platform (WBVE)
223902145|NCT06803589|DRUG|Growth Hormone|"Subjects will receive growth hormone, Sogroya (Somapacitan-beco injections) via weekly injections for 12 weeks.~For males, the fixed dose will be 0.2 mg/day, 1.5 mg per week~For females, the fixed dose will be 0.3 mg/day, 2.1 mg per week"
224083500|NCT06175858|DIAGNOSTIC_TEST|CMR|We will use cmr and bone scintigraphy to detect cardiac amyloidosis due t the high accuracy and reliability
224083501|NCT05776849|OTHER|flipped classroom|Educational presentation, visuals and videos (her own video explaining episiotomy application and repair and other videos shared with the traditional group) prepared for the students on episiotomy were shared one week before the episiotomy application.
224083502|NCT02747030|DRUG|Ocriplasmin intravenously|Retinal vein cannulation with Ocriplasmin infusion
224276864|NCT04212728|BIOLOGICAL|Auotologous AMSCs plus autologous PRP|150 mL subcutaneous abdominal adipose tissue will be harvested via liposuction . AMSCs will be isolated and cultured from adipose tissue. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.Cultured AMSCs will be collected and suspended by 3ml autologous PRP.
223715516|NCT05165836|PROCEDURE|Erector Spinae Plane block with Dexmedetomidine group|Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
223715517|NCT00479726|DRUG|duloxetine hydrochloride|
223715518|NCT00837811|BIOLOGICAL|LY2127399|60 milligrams \[(mg) with potential for dose escalation to 120 mg\] subcutaneously every 4 weeks for 48 weeks
223715519|NCT04490343|DIAGNOSTIC_TEST|Abdominopelvic low dose CT|Patients with urinary stones will undergo multiple computed tomography (CT) examinations
223715520|NCT01063452|DEVICE|Truvalve|Atkinson Product Design urinary slide valve
223715521|NCT01063452|OTHER|Control (catheter drainage bag)|urinary catheter drainage bag
223715522|NCT03477097|OTHER|Nutrition, exercise and social network intervention|
223715523|NCT02914470|DRUG|carbplatin, cyclophophamide, atezolizumab|
223715524|NCT00786734|DRUG|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
223715525|NCT00786734|DRUG|Pitavastatin|4mg daily for 28 days after PCI
223715526|NCT03307967|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
223715527|NCT02578316|DRUG|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
223715528|NCT05637606|DRUG|Ephedrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg). The maximal dose for the ephedrine allowed is 25 mg (10 boluses of 2.5 mg), after this threshold a continuous infusion of norepinephrine will be started
223715529|NCT05637606|DRUG|Norepinephrine|In both the group, the target MAP can be maintained by means of bolus of ephedrine (2.5 mg) or Etilefrine (1 mg). The continuous infusion of norepinephrine, as decided by the attending anesthetist, may be started at any point of the intraoperative period. The starting dose of norepinephrine is the lowest needed to reach the predefined MAP target.
223715530|NCT05637606|DRUG|Etilefrine Hydrochloride bolus|The maximal dose for the etilefrine allowed is 10 mg (10 boluses of 1 mg), after this threshold a continuous infusion of norepinephrine will be started
223715531|NCT05637606|DIAGNOSTIC_TEST|Use of pulse pressure and stroke volume variation (PPV and SVV); use of Mini Fluid Challenge (mini_FC)|PPV, SVV and mini\_FC will guide fluid bolus administration during an episode of intraoperative hypotension, following two predefined algorithms for laparotomic/non laparotomic surgery
223715532|NCT05372419|DRUG|Lebrikizumab|Administered SC
223715533|NCT06046794|OTHER|Analyze of GemCore status|Genomic analyze of GemCore status
223715534|NCT00254761|DRUG|Cannabis|
223715535|NCT02008630|OTHER|Animal-assisted activity|
223715536|NCT02008630|OTHER|Animal-assisted therapy|
223715537|NCT02761252|DRUG|Bilastine 20mg|
223715538|NCT02761252|DRUG|Montelukast 10mg|
223715539|NCT02761252|DRUG|Placebo Bilastine 20mg|
223715540|NCT02761252|DRUG|Placebo Montelukast 10mg|
223715541|NCT00035997|DRUG|Zometa|
223715542|NCT03974191|OTHER|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
223715543|NCT04758104|RADIATION|Yttrium90|Intracystic implantation of 90yttrium colloid
223715544|NCT01423370|DRUG|YHD1023|5g oral once daily
223715545|NCT01423370|DRUG|YHD1023|5g oral twice a day
223715546|NCT01423370|DRUG|YHD1023|10g oral once daily
223715547|NCT01423370|DRUG|Cialis|5mg oral once daily
223715548|NCT01423370|DRUG|Placebo|Oral
223715549|NCT06128044|DRUG|CB-012|CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
223715550|NCT00808626|DRUG|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
223715551|NCT04362072|DRUG|Lorlatinib|25 milligram (mg) tablet
223715552|NCT06816108|DRUG|ONO-7428|Specified dose on specified days
223715553|NCT04443010|DRUG|Onfekafusp alfa|"This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone."
223715554|NCT04443010|DRUG|Temozolomide|Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
224276865|NCT04212728|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
223902146|NCT06799104|OTHER|Pyramidal training|"Pyramidal training prescription:Mode of exercise: aerobic interval training. Intensity: ranging from 20-80% from THR. Duration: 40 minutes per session.Frequency: Three sessions per week for 12 weeks.~The course of the program will be 2 sets of pyramidal training with 10 minutes for rest between them. Each set will be 5 levels of incremental and 5 levels of decremental aerobic exercise and each level 2 minutes on a treadmill.~1. Level one: will be set as a 20% walking of Karvonen formula.~2. Level two: will be set as a 30% running of Karvonen formula.~3. Level three: will be set as a 50%running of Karvonen formula.~4. Level four: will be set as a 70% running of Karvonen formula.~5. Level five: will be set as a 80% running of Karvonen formula."
223902147|NCT06799104|OTHER|Mediterranean diet|"Mediterranean diet:~Meal Composition Main meals consumed daily should be a combination of three elements: cereals, vegetables and fruits, and a small quantity of legumes, beans or other (though not in every meal). Cereals in the form of bread, pasta, rice, couscous or bulgur (cracked wheat) should be consumed as one-two servings per meal. Vegetable consumption should amount to two or more servings per day, in raw form for at least one of the two main meals (lunch and dinner). Fruit should be considered as the primary form of dessert, with one-two servings per meal."
223902148|NCT06803173|OTHER|No intervention|No intervention
223902149|NCT05798845|RADIATION|SBRT+LDRT|primary tumor SBRT, DT: 24Gy/3Fx, d1-3; positive lymph nodes LDRT, DT: 2Gy/2Fx, d1-2, d22-23 (2 cycles)
223528835|NCT06201845|OTHER|physical activity awareness training|In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
223902150|NCT05798845|DRUG|Toripalimab|toripalimab 240mg ivgtt d4, d24 (2 cycles)
223902151|NCT05798845|DRUG|Chemotherapy drug|Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
223902152|NCT05798845|DRUG|Toripalimab|toripalimab 240mg ivgtt d1, d22 (2 cycles)
223902153|NCT06229951|DIETARY_SUPPLEMENT|Collagen|Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day
223902154|NCT06229951|OTHER|Placebo|Control patients will take placebo 2 tabs a day.
223902155|NCT05994937|DEVICE|PAC with HEPA filter intact|A commercially available PAC with a true HEPA filter will be used. Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
223902156|NCT05994937|DEVICE|PAC with HEPA filter removed|Uses the same model as the experimental PAC that is identical in appearance and sound with the HEPA filter removed . Unit will be placed in the bedroom and used continuously (24 hours/day) for a total of 4 weeks.
223902157|NCT05148299|DRUG|Pegcetacoplan|20-cc glass vials-1080 mg
223902158|NCT05445375|OTHER|PAD education video|20-min online multi-media video
223902159|NCT06011174|OTHER|survey application|Participants will only be asked to fill out the questionnaires.
223902160|NCT04631926|BEHAVIORAL|Hip Muscle Exercise|Standardized 12-week hip muscle exercises focusing on the external hip rotators with progressive resistance
223902161|NCT06446960|DRUG|Lidocaine 20mg/ml|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
223902162|NCT06446960|DRUG|Levobupivacaine Hydrochloride 1.25 MG/ML|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
223902163|NCT06446960|DRUG|Sodium Chloride 0.9% Inj|2 bolus administrations at 14 day intervals Route of administration: Peri-Nervous Dosage for administration: 20ml
223902164|NCT03841357|DRUG|Abatacept Injection|Supplied as a weekly injection via a pre-filled syringe
223902165|NCT03841357|OTHER|Usual Care|Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
223902166|NCT04992520|BIOLOGICAL|Shigella sonnei 53G|Shigella sonnei (S. sonnei) strain 53G (Lot 1794); Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
223902167|NCT04992520|BIOLOGICAL|Shigella flexneri 2a 2457T|Shigella flexneri (S. flexneri) strain 2457T (Lot 1617); Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
223902168|NCT05627375|DRUG|Full-dose anticoagulant therapy (AC)|Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE
223902169|NCT05627375|DRUG|Antiplatelet therapy (AP)|Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
223902170|NCT00188539|PROCEDURE|Pre-treatment tumour oxygen measurements (under anesthesia)|
223902171|NCT05942287|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
223902172|NCT05135650|OTHER|Questionnaire Administration|Ancillary studies
223902173|NCT05135650|BIOLOGICAL|Sotrovimab|Given IV
224276866|NCT00357955|BEHAVIORAL|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
223528836|NCT02382146|DRUG|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
223528837|NCT02382146|DRUG|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
223528838|NCT01716000|OTHER|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
223902174|NCT05135650|PROCEDURE|Biospecimen Collection|Undergo blood and nasal swab sample collection
223902175|NCT04326010|DEVICE|Surgery|THA surgery
223902176|NCT03259360|BEHAVIORAL|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
223902177|NCT03259360|BEHAVIORAL|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
223902178|NCT06333561|PROCEDURE|Hepatic arterial infusion chemotherapy|Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
223902179|NCT06333561|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
224276867|NCT00357955|BEHAVIORAL|Interactive Education|interactive lectures with hands-on learning
223902180|NCT06333561|DRUG|Tislelizumab|200mg intravenously every 3 weeks
223902181|NCT06333561|DRUG|Toripalimab|240mg intravenously every 3 weeks
223902182|NCT06333561|DRUG|Sintilimab|200mg intravenously every 3 weeks
223902183|NCT06333561|DRUG|Camrelizumab|200mg intravenously every 3 weeks
223902184|NCT06365970|DRUG|Niraparib|An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
223902185|NCT06365970|DRUG|Dostarlimab|An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
223902186|NCT05245682|DRUG|Tolinapant|Given PO
223902187|NCT05245682|RADIATION|Radiation Therapy|Undergo radiation therapy
223902188|NCT03838263|DRUG|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
223902189|NCT03838263|RADIATION|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
223902190|NCT05724823|OTHER|Virtual Physical Activity Seated Exercises (V-PASE)|The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
223902191|NCT04743167|PROCEDURE|Surgery|Laparoscopic treatment of endometriotic lesions
223902192|NCT04743167|PROCEDURE|IVF|Up to three completed cycles of IVF
223715555|NCT06670794|BEHAVIORAL|Web-based intervention for concerned partners|The web-based intervention will comprise sessions focusing on community reinforcement and family therapy principles including: (1) self-care, (2) positive communication including ways to increase responsiveness to their partner (PPR; i.e., actively listening, showing understanding, expressing interest in what their partner is thinking and feeling, and trying to see where their partner is coming from), (3) understanding their partner's drinking reinforcers, and (4) supporting their partner if they want help and engaging in positive, healthy activities with their partner.
223902193|NCT05712057|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|high frequency rTMS over the right dlPFC
223902194|NCT05712057|DEVICE|electrical scalp stimulation|electrical scalp stimulation over the right dlPFC
223902195|NCT05712057|BEHAVIORAL|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal.
224276868|NCT00357955|BEHAVIORAL|Role modeling|learning from peers with similar disease and problems
224276869|NCT00357955|PROCEDURE|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
224276870|NCT04398979|PROCEDURE|Thoracoscopic Atrial fibrillation Ablation|After blunt dissection of the oblique and transverse sinus, an AtriCure Lumitip Dissector was introduced around the pulmonary veins. Pulmonary vein isolation was achieved with an AtriCure Isolator Synergy ablation clamp around the pulmonary vein antrum at least six times for each side. Ganglionated plexus identification and ablation were performed using an AtriCure Synergy ablation pen. The additional superior and inferior ablation lines connecting the bilateral pulmonary vein isolations were created by applying the AtriCure Synergy ablation pen. Following completion of the ablation on the right side, ablation on the left side was accomplished in a similar manner. The ligament of Marshall was dissected by electrical cautery. Conduction block was confirmed upon completion of the ablation procedure on the left side.
223715556|NCT06670794|BEHAVIORAL|Psychoeducation control|This is a psychoeducation control condition.
223902196|NCT05712057|BEHAVIORAL|Emotional Awareness Training|Emotional awareness training is a behavioral intervention through which participants learn how to identify and evaluate their emotions and the components that make up each emotion.
223902197|NCT04442646|BEHAVIORAL|multidisciplinary lessons|the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization. Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary. Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
223902198|NCT04571255|BEHAVIORAL|Music-Assisted Relaxation|The music therapy sessions are based on MAR (Music-Assisted Relaxation), a music therapy technique that includes listening to live music, combined with deep diaphragmatic breathing and/or guided imagery relaxation. In a first step, the procedure will explained to the patient and he/she will be asked to close his/her eyes or focus on a fixed point on the ceiling or wall. Subsequently, a verbal introduction will be provided for fostering body and respiratory awareness. Then a mental image will be introduced (e.g., sitting on a beach watching the waves of the sea; being on top of a mountain looking at the horizon; imagining a safe and comfortable personalized place) and live music will be provided based on the principles of entrainment. The patient is asked to let himself/herself guide by the music and breath with the music while concentrating on the imagery. Once the music is over, the patient is again asked to become aware and the experience during the session will verbally discussed.
223902199|NCT04880785|DRUG|Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]|change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
223902200|NCT05729438|DIETARY_SUPPLEMENT|BCAA|status of nutrition evaluation after 3 months of BCAA
223902201|NCT05642182|DRUG|SFA002|Study drug formula without excipient
223902202|NCT05642182|DRUG|SFA002|Study Drug SFA002 with excipient (Propionate)
223902203|NCT05574270|DEVICE|IC-8 Intraocular Lens (IOL)|A small aperture extended depth of focus hydrophobic acrylic intraocular lens.
223902204|NCT01642641|PROCEDURE|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
223902205|NCT01642641|PROCEDURE|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
223902206|NCT01642641|PROCEDURE|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
223902207|NCT05465005|BEHAVIORAL|Torque Generation|Relaxed, or flexing about the elbow to 25% or 50% of the maximum elbow torque that one can generate.
223902208|NCT05537064|BEHAVIORAL|Non-visit Based Intervention|At the beginning of the study period, PCPs will be sent an Inbasket message, a secure electronic messaging system included in EPIC, similar to an email. The message will notify them that pended orders for a referral to centralized pharmacy services for statin management will be entered for eligible patients unless the provider opts out. If no opt-out is received from the PCP within 7 days of receiving the message, their eligible patient panels will be referred to a centralized pharmacy team to begin pending referral orders to the PCP for eligible patients. Pharmacists affiliated with the centralized pharmacy service will then enter pended orders for referral to centralized pharmacy services that PCPs can sign either individually or in bulk. After the PCP signs the order for referral to centralized pharmacy services, a pharmacist from the centralized pharmacy team will then reach out to the patient on behalf of their PCP and discuss their indication for statin therapy.
223902209|NCT05537064|BEHAVIORAL|Visit-Based Intervention|"The study team will build an interruptive BestPractice advisory (BPA), a pop-up notification in the EHR that is delivered to the PCP when they open the patient's chart during a non-acute patient visit. The BestPractice Advisory will describe the guideline criteria for which the patient is eligible for statin therapy, and recommend referral to a centralized pharmacy service for statin initiation and management. It will also include a link to a menu for prescribing an appropriate-dose statin, should the PCP want to prescribe a statin without referral to pharmacy services. The option for ordering referral to centralized pharmacy services will be pre-selected, such that if the PCP simply clicks Accept on the BPA, an order for referral to centralized pharmacy services for statin initiation and management will be generated."
223902210|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training|"The Pelvic Floor Dysfunction Prevention Training booklet is cover weight control, perineal hygiene, adequate fluid consumption, not smoking and alcohol use, avoidance of spicy, fizzy and fatty foods and beverages, correct posture and frequency of micturition, prevention of constipation and abdominal pressure."
223902211|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage|"Women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
223902212|NCT05624060|BEHAVIORAL|Pelvic Floor Dysfunction Prevention Training and Perineal Massage and Pelvic Floor Exercise|"Women assigned to this group will apply pelvic floor exercise at least 3 days a week 8-12 times a week, starting from the 34th week of pregnancy until delivery. In addition, women will apply perineal massage for an average of 8-10 minutes at least twice a week, starting from the 34th week of pregnancy until delivery. In addition to perineal massage, the Pelvic Floor Dysfunction Prevention Training booklet will be given to participant."
223902213|NCT06694259|PROCEDURE|Pneumatic retinopexy with transscleral cryopexy|"Pneumatic retinopexy with transscleral cryopexy is a procedure used to treat certain types of rhegmatogenous retinal detachments.~Procedure steps:~Transscleral cryopexy: in this first step, the surgeon uses a cryoprobe applied to the sclera directly over the retinal tear. The cryoprobe emits extreme cold, creating a small, localized freeze that reaches the retina and seals the tear by causing a controlled scar to form. This scar tissue holds the retina in place and prevents further fluid from passing through the tear.~Gas bubble injection: after the cryopexy, a small gas bubble (usually sulfur hexafluoride (SF6) or perfluoropropane (C3F8)) is injected into the vitreous cavity. This bubble applies upward pressure on the retina, gently pressing it against the back wall of the eye, which aids in reattaching the retina.~Head positioning: for several days following the procedure, the patient must keep their head in a specific position so the gas bubble remains aligned with the retinal tear."
223902214|NCT06694259|PROCEDURE|Pneumatic retinopexy with laser photocoagulation|"Pneumatic retinopexy with laser photocoagulation is a minimally invasive procedure used to repair certain types of rhegmatogenous retinal detachments.~Procedure steps:~Gas bubble injection: a small gas bubble, usually sulfur hexafluoride (SF6) or perfluoropropane (C3F8), is injected into the vitreous cavity which rises and applies pressure to the detached retina, pressing it back against the eye wall and helping to reapproximate the retinal layers.~Laser photocoagulation: once the retina is positioned correctly, laser is used to create small burns around the retinal tear. This laser application causes a mild inflammatory response, creating a scar around the tear and effectively welding the retina to the underlying tissue. This seal prevents fluid from reaccumulating beneath the retina.~Head positioning: following the procedure, the patient must keep their head in a specific position for several days. This positioning ensures that the gas bubble stays aligned with the retinal tear."
223902215|NCT05719493|OTHER|multicomponent treatment|The intervention to be evaluated consists of 4 group sessions carried out in two weeks, 6 hours per week divided in 2 days (a total of 12 hours), of active education in nutrition, chronobiology and physical exercise in people diagnosed with Chronic Fatigue Syndrome and Fibromyalgia.
223902216|NCT06103188|DRUG|Placebo|The placebo pill will be given to the patients 1 hour prior to their planned surgery.
223902217|NCT06103188|DRUG|Diazepam|Diazepam will be given to the patients 1 hour prior to their planned surgery.
223902218|NCT06103188|DRUG|Melatonin|Melatonin will be given to the patients 1 hour prior to their planned surgery.
223902219|NCT05411159|PROCEDURE|Opioid-Free Anesthesia (OFA)|"Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
224276871|NCT04719611|DIETARY_SUPPLEMENT|Probiotic|Healthy women receive a probiotic supplement containing 6 x 10\^9 colony-forming units/capsule of Bifidobacterium and Lactobacillus strains.
224276872|NCT03629106|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
224276873|NCT02389842|DRUG|Palbociclib + Taselisib / Pictilisib|
224276874|NCT04492852|PROCEDURE|Polypropylene (PROLENE) sutures|After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
223902220|NCT05411159|PROCEDURE|Standard general anesthesia (OA)|"Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture."
223902221|NCT05813080|DEVICE|"pronia.ai medical device for high risk psychosis prognosis"|In addition to the computer-assisted prognosis of risk for reaching a psychosis, all patients assigned to the active treatment arm will receive additional in-depth clinical diagnostics including neuropsychological testing. Adapted psychological treatment will be offered consisting of 16 to 24 sessions over a period of six months.
223902222|NCT05813080|OTHER|Treatment-as-usual (TAU)|Referral back to the previous care system. Further treatment is left to the referring primary care providers.
223902223|NCT04594447|DEVICE|Physica Kinematic Retaining knee replacement|modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation
223902224|NCT04594447|DEVICE|Physica Cruciate Retaining knee replacement|modular knee prosthesis with posterior cruciate ligament (PCL) preservation
223902225|NCT01541553|PROCEDURE|Cryotherapy|"Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area"
223902226|NCT01541553|DRUG|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
223902227|NCT01541553|DRUG|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
223902228|NCT06158646|DEVICE|kinematic knee prosthesis|Patients with a kinematically aligned total knee prosthesis and having a post-operative follow-up consultation within at least 1 year after their surgery are consecutively pre-selected according to the eligibility criteria.
223902229|NCT06158646|DEVICE|biomechanic knee prosthesis|A group of patients with a mechanically aligned TKA and scheduled for a follow-up consultation 1 year after surgery will be identified to be matched on the aforementioned criteria (sex, age, BMI).
223902230|NCT05445427|DEVICE|vagal nerve stimulator|Non-invasive vagus nerve stimulator
223902231|NCT04486833|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
223902232|NCT04486833|DRUG|osimertinib|Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
223902233|NCT04486833|DRUG|Platinum-Based Chemotherapy|Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
223902234|NCT05582681|DIAGNOSTIC_TEST|Cepheid POC HCV Viremia (RNA) test|The Cepheid Xpert HCV Viral Load (VL) Fingerstick assay is a test designed for the quantitation (amount) of Hepatitis C Virus (HCV) DNA in human whole blood. The HCV RNA result will be compared to standardized laboratory assessment for HCV Viremia. The Cepheid test is for being conducted for research use only and will not be used for HCV diagnosis or treatment decisions.
223902235|NCT05582681|OTHER|HCV education from a health care provider|HCV education provided by health care provider. HCV Education will include HCV disease overview, HCV screening, treatment with G/P, and post treatment assessment and management
223902236|NCT05582681|DRUG|Glecaprevir and Pibrentasvir|G/P will be provided for 8 weeks.
223902237|NCT04632238|BEHAVIORAL|Metrics-driven quality improvement (MDQI)|The intervention broadly consists of training and coaching to clinic staff and leadership on 1) clinical quality measure monitoring; 2) clinical practice process change management; and 3) use of tools for shared decision making and patient treatment progress monitoring.
223902238|NCT05894954|DIETARY_SUPPLEMENT|Precision Medicine Approach|Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics
223902239|NCT05894954|COMBINATION_PRODUCT|Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises|"Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis"
223902240|NCT05894954|BEHAVIORAL|Standard-of-Care|Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen
223902241|NCT05894954|BEHAVIORAL|Lifestyle including diet, exercise, stress management|Combining a tailored diet, exercise and stress management program supported by coaching specialists
223902242|NCT06346678|OTHER|Accuhaler tester|Patients will perform testing with Accuhaler tester, Ellipta tester and Turbutester.
223902243|NCT03623074|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
223902244|NCT03623074|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
224276875|NCT04492852|PROCEDURE|Staple Sutures|After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
223715557|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC\&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
223715558|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
223715559|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
223715560|NCT03185988|DRUG|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
223715561|NCT03506334|DEVICE|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
223715562|NCT03506334|PROCEDURE|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
223715563|NCT01133522|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223715564|NCT01133522|BIOLOGICAL|Placebo|Administered by subcutaneous injection
223715565|NCT06991049|DEVICE|Fully covered self-expandable metal esophageal stent|Esophageal stent placement for patients with benign esophageal strictures not responding to endoscopic dilations.
223902245|NCT06223867|DEVICE|Jaspr App + JAH|With assistance form a research coordinator, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subject will continue to have access to the coping skills and videos via a mobile app after discharge.
223902246|NCT06223867|BEHAVIORAL|ETAU|Usual care for suicidal patients at UMass Memorial ED that may include Behavioral health evaluation by a trained clinician. Environmental safety precautions. Personalized safety upon discharge
223902247|NCT04488497|BEHAVIORAL|Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis|This intervention will help people with RA get tested for hyperlipidemia so that they can later discuss with their physician how to better treat their increased risk for cardiovascular disease.
223902248|NCT04488497|BEHAVIORAL|Standard of care|Participants in this group will not receive peer coaches calls. They will receive additional educational materials about CVD risk and the regular care provided by their doctors.
223902249|NCT04979442|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
223902250|NCT04979442|DRUG|Trabectedin|1.5 mg/m2 body surface area as a 24-hour IV infusion, every 3 weeks
223902251|NCT04722185|DIAGNOSTIC_TEST|Veriton SPECT/CT|The Veriton system represents an FDA approved (510k cleared) new generation of SPECT/CT systems. It consists of 12 small gamma cameras arrayed in a circle around the patient, and is coupled to a 64-slice CT system.
223902252|NCT02149030|OTHER|Cytological screening in A1 and A3|Cytological screening.
223902253|NCT01175356|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
223902254|NCT01175356|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
223902255|NCT01175356|DRUG|Busulfan|Given IV
223902256|NCT01175356|DRUG|Cisplatin|Given IV
223902257|NCT01175356|DRUG|Cyclophosphamide|Given IV
223715566|NCT06995326|DRUG|SGB-3383|SGB-3383 for sc injection, single dose
223715567|NCT06995326|DRUG|SGB-3383-Matching placebo|SC injection, single dose
223715568|NCT06008249|DRUG|Lithium Carbonate 400 MG|Lithium carbonate vs placebo (2:1)
223715569|NCT07005739|BEHAVIORAL|Turkish Folk Dance-Based Exercise Program|Participants in the intervention group received a structured Turkish folk dance-based exercise program in addition to their regular football training. The dance-based intervention consisted of two 45-minute sessions per week for 8 weeks, including traditional Turkish folk dance movements aimed at improving balance, agility, and core stability.
223902258|NCT01175356|DRUG|Doxorubicin Hydrochloride|Given IV
223902259|NCT01175356|DRUG|Etoposide Phosphate|Given IV
223902260|NCT01175356|RADIATION|External Beam Radiation Therapy|Undergo radiotherapy
223902261|NCT01175356|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
223902262|NCT01175356|RADIATION|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
223902263|NCT01175356|RADIATION|Iobenguane I-131|Given IV
223902264|NCT01175356|DRUG|Isotretinoin|Given PO
223902265|NCT01175356|OTHER|Laboratory Biomarker Analysis|Correlative studies
223902266|NCT01175356|DRUG|Melphalan|Given IV
223902267|NCT01175356|OTHER|Pharmacological Study|Correlative studies
223902268|NCT01175356|OTHER|Questionnaire Administration|Ancillary studies
223902269|NCT01175356|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223902270|NCT01175356|DRUG|Topotecan Hydrochloride|Given IV
223902271|NCT01175356|DRUG|Vincristine Sulfate|Given IV
223902272|NCT02268461|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
223902273|NCT02268461|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
223902274|NCT04686175|DRUG|INZ-701|INZ701-101 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
223902275|NCT06407063|PROCEDURE|Micro-decompression alone|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion
223902276|NCT06407063|PROCEDURE|Decompression and instrumented fusion|In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage
224276876|NCT02176668|DRUG|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
223902277|NCT05212090|DIAGNOSTIC_TEST|EOS X-Ray|Repeated Anteroposterior (AP) Pelvis x-ray and Lateral Lumbar EOS x-ray
223902278|NCT05639348|OTHER|Data collection on POD for calculation of the PIPRA score|"Data collection for presence of POD as diagnosed by the 4 A Tests (4AT) or the Intensive Care Delirium Screening Checklist (ICDSC). The collected data will be used to validate the existing PIPRA algorithm and to improve the algorithm and evaluate it in a cross-validation setting. For the model validation the area under the receiver operating characteristics (ROC) curve (AUC) will be computed."
223902279|NCT04565743|BEHAVIORAL|Support on dentification and treatment of patients with high risk of osteoporotic fractures|Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
223902280|NCT06074172|DRUG|Cannabidiol (246mg press pill)|Cannabidiol press pills provided by Steve Goods CBD (Longmont, Colorado). CBD pills were tested by the chemistry lab at CSU Pueblo and by Botanacor in Denver, CO. Both laboratories determined CBD pills to be 99.98% pure with no THC, heavy metals, bacteria, and pesticides detected.
223902281|NCT06074172|DRUG|Placebo (246mg press pill)|Placebo press pills were provided by Steve Goods CBD (Longmont, Colorado). Placebo pills were tested by the chemistry lab at CSU Pueblo and by Botanacar in Denver, CO. Both laboratories determined placebo pills to be pure with no heavy metals, bacteria, and pesticides detected.
223902282|NCT01224184|BEHAVIORAL|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
223715570|NCT06678243|BEHAVIORAL|Smiling instead of Smoking|"Participants randomized to the treatment condition will use the Smiling instead of Smoking (SiS) smartphone app. This app delivers and guides participants through two types of content to help them during their quit attempt: (1) positive psychology content (i.e., happiness habit-building exercises, happiness boost activity, and science-based information on the relevance of positive psychology activities) designed to help nondaily smokers maintain positive affect while they go through the process of smoking cessation; and (2) traditional behavioral smoking cessation content to guide their quit process based on US Clinical Practice Guidelines."
223902283|NCT01224184|BEHAVIORAL|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
223902284|NCT05471154|DEVICE|High Definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is used at 2mA and during 20 minutes and with electrodes positioned on regions F4 (anode), Fp2, Fz, F8 and C4 (cathodes), according to the international 10-20 electroencephalogram system. 5 sessions are given on 5 following days. The material used in this study is the Soterix Medical 1x1 tES mini-CT and HD 4x1 splitter, produced by Soterix Medical Inc., 237 W 35th St, New York, NY 10001, United States of America.
223902285|NCT05372029|BEHAVIORAL|Approach Avoidance Training|"AAT condition, participants use a joystick to respond to the color of the border surrounding the stimulus images presented (i.e., pull for green, push for blue). The stimuli used are alcohol-related images and neutral beverage images. To experimentally manipulate automatic action tendencies, a contingency is set between alcohol stimuli and avoidance behaviors"
223902286|NCT05372029|BEHAVIORAL|Sham Training|In the Sham participants use a joystick to respond to the color of the border surrounding stimulus images presented. There is no contingency between instruction type and pictures (i.e., non-training version of the task)
223902287|NCT05593250|DRUG|SHR-1905|subcutaneous
223902288|NCT05593250|DRUG|placebo|subcutaneous ,placebo
223902289|NCT04005794|BEHAVIORAL|social VR (virtual reality) training|Social skills game that we developed in the R21 phase will be used across 8 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 4-5 weeks.
223902290|NCT04005794|BEHAVIORAL|Cognitive training (control game)|Commercially available cognitive training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
223902291|NCT05216315|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus HDC stimulator (Newronika TM)
223902292|NCT05216315|DEVICE|Sham stimulation|The sham group received direct current only on the ramps to generate a sensation of the effect.10 sessions
223902293|NCT04547309|RADIATION|68Ga/18F-HER2 Affibody PET/CT scan|HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
223902294|NCT06491225|BIOLOGICAL|GTE001 injection|GTE-001 injection to treat Advanced lung adenocarcinoma
223902295|NCT05677113|DRUG|QBECO|QBECO is a site specific immunomodulator (SSI) designed to promote innate immune responses in the gastrointestinal tract and related organs, including the liver. QBECO will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
223902296|NCT05677113|DRUG|Placebo|Placebo will be prepared in the same way as the IP. Placebo will be administered according to the following regimen: 0.1mL self-administered subcutaneous injections every 2 days for 11-120 days preoperatively, and 41 days postoperatively.
223902297|NCT05563038|DEVICE|Scrambler Therapy|"Scrambler Therapy is a non-invasive neuromodulator treatment that focuses on relieving chronic pain through the sending of non-pain signals to the brain through the afferent pain sensory nerves. The signals given off by the scrambler therapy machine are intended to mimic neuronal action potentials through the synthesis of 16 unique waveforms that in combination forms a patient specific cutaneous electrostimulation to reduce pain. These information packets are then carried by the afferent C-fibers, an established system that modulates the sensations received instead of blocking them. The modulated signals are received as nonpainful and endogenous by the central nervous system."
223902298|NCT05563038|DRUG|Standard Medication Management|Medications such as: gabapentin, duloxetine and Lyrica are all FDA approved for treatment of neuropathic pain, particularly that caused by diabetes.
224276877|NCT02176668|DRUG|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
224276878|NCT02176668|DRUG|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
224276879|NCT02176668|DRUG|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
223902299|NCT06041971|DEVICE|AIDANET system|The study will involve testing a new AID system designed to enable full closed loop control and consisting of the following elements: the diabetes assistant (DiAs) prototyping platform (MAF 2019), connected to a Tandem t:AP research insulin pump and a Dexcom G6 CGM, and implementing the University of Virginia (UVA) AIDANET algorithm.
223902300|NCT05180240|DRUG|CardiolRx|Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
223902301|NCT03245489|DRUG|Pembrolizumab|200mg intravenous (IV) over 30 minutes
223902302|NCT03245489|DRUG|Clopidogrel|75mg/day oral
223902303|NCT03245489|DRUG|acetylsalicylic acid|81mg/day oral
223902304|NCT04313972|DRUG|low-dose naltrexone|2mg of low-dose naltrexone nightly for 2 weeks, then 4mg of low-dose naltrexone nightly for 4 weeks
223902305|NCT04313972|DRUG|Placebo oral tablet|1 capsule nighty for 2 weeks, then 2 capsules nightly for 4 weeks
223902306|NCT06580054|PROCEDURE|Computed Tomography|Undergo CT
223902307|NCT06580054|OTHER|Digital Photography|Undergo photographs of tumor
223902308|NCT06580054|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223902309|NCT06580054|BIOLOGICAL|Pembrolizumab|Given IV
223902310|NCT05557838|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
223902311|NCT05557838|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
223902312|NCT04368949|OTHER|Stepping-Up|The intervention group will receive STEPPING-UP, a virtual 12-week, multicomponent intervention that includes tailored task-oriented motor learning exercise and a mobility self-management (SM) program.
223902313|NCT04368949|OTHER|Telephone-Based Coaching Walking Program|The participants assigned to this group will receive a 12-week Telephone-Based Coaching Walking Program (TELE) delivered by a PT who will help participants set short and long term walking goals.
223528839|NCT01716000|BEHAVIORAL|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
223902314|NCT04368949|OTHER|Chair-Based Yoga Program|Participants assigned to this group will receive a virtual 12-week Chair-Based Yoga Program (YOGA), a group-based exercise control where participants will undertake a seated exercise program that includes: warm up, seated and standing yoga poses, cool down.
223902315|NCT06195514|DRUG|TAK-113|Description: TAK-113 5 mg capsules, orally, once daily, in a 3 weeks on/1 week off schedule for each 4-week cycle per treatment guidelines.
223902316|NCT06194773|PROCEDURE|Totalfil|Root canal treatment using TotalFil sealer
223902317|NCT06194773|PROCEDURE|NeoSealer|Root canal treatment using NeoSealer
223902318|NCT06194773|PROCEDURE|AH-Plus sealer|Root canal treatment using AH-Plus sealer
223902319|NCT05642442|DRUG|Placebo|Matching placebo capsule(s) administered every day (QD) orally. Titration may proceed at a rate of 1 matching placebo capsule per day every 7 days as required for optimal efficacy and tolerability up to a maximum number of 3 matching placebo capsules per day.
223902320|NCT05642442|DRUG|Suvecaltamide|Suvecaltamide capsule administered every day (QD) orally. Titration may proceed at a rate of 10 mg suvecaltamide per day every 7 days as required for optimal efficacy and tolerability up to a maximum dose of 30 mg suvecaltamide per day.
223902321|NCT03287336|DRUG|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
223902322|NCT06040866|OTHER|Exercise training|Exercise training will be applied in the non-menstrual period during 2 menstrual cycles as stretching and relaxation exercises. Stretching exercises will include general stretching and specific stretching exercises and will take approximately 20 minutes in total. After the stretching exercises, relaxation exercise will be performed with diaphragmatic breathing for 10 minutes. The exercises will be performed with music accompanied by a physiotherapist once a week, and it will be recommended to do the exercises as a home program for 2 sessions a week.
223902323|NCT06040866|OTHER|Pain neuroscience education|Participants in the first research arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
223902324|NCT06040866|OTHER|Biomedical pain education|Participants in the second research arm will be given biomedical pain education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
223902325|NCT05351801|DRUG|THC (Syndros)|Participants will receive a target dose of 10mg per day of THC (Syndros).
223902326|NCT05351801|DRUG|CBD (Epidolex)|Participants will receive a target dose of 800 mg per day of CBD (Epidolex).
223902327|NCT05351801|DRUG|THC + CBD (Nabiximols)|Participants will receive a target dose of 10.8 mg / 10 mg per day of THC + CBD (Nabiximols).
223902328|NCT05351801|DRUG|Placebo|Placebo
223902329|NCT05289648|DRUG|Niraparib oral capsule|Low dose oral niraparib capsules (2 x 100 mg) once a day for 28 days
223902330|NCT04447469|DRUG|mavrilimumab|anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G \[IgG4\])
223902331|NCT04447469|OTHER|Placebo|matching placebo
223902332|NCT04508088|DIAGNOSTIC_TEST|Coronal T1 weighted spin echo images|Coronal T1 weighted spin echo images will be obtained through the knee with a field of view of 16cm to include distal femoral and proximal tibial metaphyses.
223902333|NCT04508088|DIAGNOSTIC_TEST|Spin-lattice relaxation (T1)|Spin-lattice relaxation (T1) relaxometry acquisition consisting of seven fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
224276880|NCT01722955|OTHER|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
224276881|NCT01722955|OTHER|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
223528840|NCT02824679|DRUG|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
223528841|NCT02824679|DRUG|saline|0.9%normal saline
223528842|NCT02758821|OTHER|No CRP will be measured onsite|No CRP will be measured onsite
223902334|NCT04508088|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at echo times of 20, 30, 40, and 50 ms using 32 signal averages per echo time with a TR of 2.5 s (total scan time = 5.4 minutes). Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
223902335|NCT04508088|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and to perform immune studies. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). We will also evaluate molecular gene signatures from the blood samples that correlate with the previously described bone imaging phenotypes. At that point, the information will be used to develop a CyTOF panel to evaluate differences in immune cellular populations between CD patients with normal versus low BMD, and matched controls.
223902336|NCT04701853|OTHER|Specific abdominal muscle training|Specific abdominal muscle training
223902337|NCT04701853|OTHER|Usual care|Care according to each center.
223902338|NCT05579951|PROCEDURE|Patient specific instrumentation|Total knee replacement with patient specific instrumentation
223902339|NCT05579951|PROCEDURE|Conventional|Total knee replacement with conventional instrumentation
223902340|NCT05579951|DEVICE|Patient specific instrumentation|Medacta GMK Sphere MyKnee Patient specific Instrumentation
223902341|NCT04949100|DEVICE|Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Frequency: Each lead delivers a dual channel microcurrent of 10 and 40 Hz simultaneously.~* Amperage: Adjusted according to BMI: 100 μA for an underweight BMI less 20, 300μA for an overweight BMI greater than 30, and 200μA for normal BMI (20-30). Amperage may be adjusted to 20-300 μA according to comfort.~* Positioning: The patient remains seated for the first 10 minutes with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
223902342|NCT04949100|DEVICE|PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief|"* Duration: 60 minutes.~* Frequency: None~* Electrode placement: There will be one lead placed on the back of the neck and one placed on lower abdomen.~* Amperage: None~* Positioning: The patient remains seated for the first 10 minutes, again, with the investigator watching for any side effects. The patient may stand, sit, lie supine, et cetera for the remainder of treatment."
223902343|NCT02714257|BEHAVIORAL|Enhanced Usual Care plus Exercise Coaching|"For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation."
223902344|NCT06428214|DEVICE|Restylane Shaype|Injection
223902345|NCT06428214|DEVICE|Restylane Defyne|Injection
223902346|NCT06428214|DEVICE|Restylane Lyft lidocaine|Injection
223902347|NCT05312164|DEVICE|HF-OCT Imaging|Subjects undergo HF-OCT imaging of stenosed coronary arteries
223902348|NCT05312164|DEVICE|FFR Pressure Wire|Subjects undergo FFR physiology assessment of stenosed coronary arteries
223902349|NCT05312164|DEVICE|Angiography|Subjects undergo angiography imaging of stenosed coronary arteries
223902350|NCT05846685|OTHER|Patient Phone Interviews|Collecting perceptions about automated falls-risk screening and referral tool
223902351|NCT05846685|OTHER|Patient In Person Interviews|Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
223902352|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)|Dose escalation of BP1001-A intravenously (IV), twice weekly for 4 weeks (28-day cycle) for 6 cycles.
223902353|NCT04196257|DRUG|BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel|Dose expansion of BP1001-A IV twice weekly (Maximum tolerated dose or Maximum admistered dose) plus paclitaxel IV weekly for 4 weeks (28-day cycle) for 6 cycles.
223902354|NCT01696513|PROCEDURE|Suction|
223902355|NCT01696513|PROCEDURE|Subcision|
223902356|NCT05201248|DRUG|Epcoritamab|Subcutaneous Injection (SC)
223902357|NCT05201248|DRUG|Cyclophosphamide|IV Injection
223902358|NCT05201248|DRUG|Rituximab|Intravenous (IV) Infusion
223902359|NCT05201248|DRUG|Doxorubicin|IV Infusion
223902360|NCT05201248|DRUG|Vincristine|IV Infusion
223528843|NCT02758821|OTHER|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 20mg/L.
223902361|NCT05201248|DRUG|Prednisone|Oral; Tablet
223902362|NCT05201248|DRUG|Lenalidomide|Oral; Capsule
223902363|NCT06220006|PROCEDURE|Pulmonary vein isolation|Catheter ablation
223902364|NCT05401578|DRUG|Canakinumab|Canakinumab (Ilaris®, Novartis Switzerland) will be used in the recommended standard dose of 150 mg subcutaneously once. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
223528844|NCT02758821|OTHER|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever \< 40mg/L.
223528845|NCT00249626|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
223528846|NCT01435343|DRUG|fludarabine|30 mg/m2/day intravenously on days 1 to 4
223528847|NCT01435343|DRUG|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
223528848|NCT01435343|DRUG|cytarabine|2 g/m2/day intravenously on days 1 to 4
223902365|NCT05401578|DRUG|Placebo (0.9% NaCl)|1 ml 0.9 % saline solution s.c. Patients will be randomized at visit 2 = Baseline to either placebo (1 ml 0.9 % saline solution s.c.) or treatment with 1 ml 150 mg canakinumab solution s.c. in a 1:1 manner.
223902366|NCT05825755|OTHER|vitalera telemonitoring platform|Patients will be followed-up with measurements from medical devices and health questionnaires delivered through the app
223902367|NCT04103580|BEHAVIORAL|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
223902368|NCT04547049|DRUG|Cytarabine|4 mg/m2/day administered IV day -10 through -9.
223902369|NCT04547049|DRUG|Busulfan|3.2 mg/kg/day administered IV day -8 through -6.
223902370|NCT04547049|DRUG|Cyclophosphamide|1.8 g/m2/day administered IV day -5 through -4.
223902371|NCT04547049|DRUG|Me-CCNU|250mg/m2 once administered orally on day -3.
223902372|NCT04547049|DRUG|Rabbit antithymocyte globulin|Between 6mg/kg total dose administered IV day -5 through -2 AND 7.5mg/kg total dose administered IV day -5 through -2.
223902373|NCT04547049|PROCEDURE|Allogeneic HSCT|Day 0
223902374|NCT04547049|DRUG|Cyclosporin A|2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
223902375|NCT04547049|DRUG|Mycophenolate Mofetil|500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
223902376|NCT04547049|DRUG|MTX|15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
223902377|NCT04145440|DRUG|MOR202|Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
223902378|NCT05131581|OTHER|Changed clinical context|Changed clinical context: from midwifery clinic to youth clinic
223902379|NCT05131581|BEHAVIORAL|Extra time allotted|Extra time allotted for each visit for CST
223902380|NCT05131581|BEHAVIORAL|RLP-information|Midwife-initiated discussion of the Reproductive Life Plan
223902381|NCT00104676|BIOLOGICAL|bleomycin sulfate|At least one course administered
223902382|NCT00104676|DRUG|cisplatin|At least one course administered
223902383|NCT00104676|DRUG|etoposide|At least one course administered
223902384|NCT00104676|DRUG|ifosfamide|Given in a dose-dense sequential fashion
223902385|NCT00104676|DRUG|oxaliplatin|Given in a dose-dense sequential fashion
223902386|NCT00104676|DRUG|paclitaxel|Given in a dose-dense sequential fashion
223902387|NCT05202964|OTHER|Tolerance and adherence to oral antibiotics in patients managed for BJI|"Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery.~The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire).~Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3.~Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse."
223902388|NCT02115724|DIETARY_SUPPLEMENT|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
223902389|NCT02115724|OTHER|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
223902390|NCT02115724|OTHER|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
223902391|NCT02115724|DRUG|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
223902392|NCT05814653|BEHAVIORAL|Family Based Treatment-Primary Care|Novel treatment that borrows key intervention strategies from standard family-based treatment. It uses trained primary care providers (PCPs), in consultation with a mental health provider, to deliver family-based treatment strategies in community-based clinics to increase caregiver self-efficacy to reverse their child's dietary restriction and weight loss.
223902393|NCT05814653|BEHAVIORAL|Family-Based Treatment|Delivered by a mental health provider in a traditional mental health or eating disorder specialty setting. First-line evidence-based treatment for adolescent eating disorders that targets caregiver self-efficacy as a mechanism to facilitate weight restoration and ultimately symptom remission in adolescents.
223902394|NCT04504721|OTHER|light therapy|The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
223902395|NCT04662489|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy
223902396|NCT04662489|PROCEDURE|Radial ablation|Electrical isolation of the pulmonary veins from the left atrium plus radial ablation of rotational activity sites with radiofrequency ablation.
223902397|NCT01837576|DRUG|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
223902398|NCT03838536|DIETARY_SUPPLEMENT|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
223902399|NCT03838536|DIETARY_SUPPLEMENT|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
223902400|NCT06436378|BEHAVIORAL|Music intervention in person|The music intervention consists of listening to two or three pieces of music chosen by each participant that bring them a sense of well-being. One of the two music intervention sessions will be preceded by a moment of relaxation, during which participants will be asked to focus their attention on their breathing, on relaxation, and on the process of self-absorption. This intervention, preceded by a brief moment of relaxation, will take place during the first session for half of the participants and during the second session for the other half.
224276882|NCT03655275|BIOLOGICAL|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
224276883|NCT03655275|BIOLOGICAL|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
224276884|NCT01755975|DRUG|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
224276885|NCT01755975|DRUG|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
223902401|NCT04700176|DRUG|Daratumumab|During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.
223715571|NCT06678243|BEHAVIORAL|QuitGuide|"Participants randomized to the control condition will use the National Cancer Institute (NCI)'s QuitGuide (QG) smartphone app. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
223902402|NCT04700176|DRUG|Pomalidomide|Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21
223715572|NCT07009535|DIAGNOSTIC_TEST|Polysomnography|Assessment of AHI index and pO2 in pediatric patients
223902403|NCT04700176|DRUG|All-trans retinoic acid|ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered
223902404|NCT04700176|DRUG|Dexamethasone|Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
223902405|NCT06081452|BEHAVIORAL|Survey|Members of the public will be asked to complete a survey that collects information on individuals perception of health and disease and their views on breath testing.
223902406|NCT05923216|DIETARY_SUPPLEMENT|High dose OIT|Patients will receive daily a high dose of the sesame paste (1200 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
223902407|NCT05923216|DIETARY_SUPPLEMENT|Low dose OIT|Patients will receive daily a low dose of the sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread.
223902408|NCT05808257|DEVICE|Thulium Fibre Laser|The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
223902409|NCT05808257|DEVICE|Holmium:Yttrium-Aluminum-Garnet|The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
223902410|NCT04568486|OTHER|Diabetes Empowerment Education Program|The Diabetes Empowerment Education Program (DEEP) is an education curriculum designed to help people with pre-diabetes, diabetes, relatives and caregivers gain a better understanding of diabetes self-care. Classes last a total of six weeks, providing participants with eight unique learning modules. Health literacy will be assessed before and after participating in DEEP.
223902411|NCT03726398|DRUG|Opsumit 10 Mg Tablet|Oral tablet taken once daily
223902412|NCT05918380|BEHAVIORAL|PAL2|"Low CVD risk participants (CAC \< 100) will be followed by their primary care provider accompanied by monthly contact with community health workers provided by ACHIEVE Greater who will screen participants for social determinants of health and implement the PAL2.~PAL2 is defined as a community health worked based intervention to mitigate psychosocial and health equity barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education."
223902413|NCT05918380|OTHER|CINEMA|High CVD risk participants (CAC ≥ 100) will be followed by specialists in the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA) at UHCMC. While they too will be assessed, by the CHW for SDOH and a plan developed to address them, this plan will be addressed by the usual resources available in the CINEMA clinic.
223902414|NCT05007067|DEVICE|DELTA Multihole TT|Advance articular destruction generated by primary degenerative or post-traumatic arthrosis or reumatoid arthritis; fracture or avascular necrosis; congenital or acquired deformity.
223902415|NCT06076512|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
223902416|NCT03697096|OTHER|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
223902417|NCT03697096|OTHER|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
223902418|NCT04960384|DRUG|FGF-2|The FGF-2 method of use comprises a pledget of gelatin sponge, with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of fibrin glue used for applications in ear surgery. The concentration of the FGF-2 solution will be 100μg of FGF-2 per 1 mL with an estimated dose of about 20 μg in 0.2ml. Fibrin glue will be applied to secure gelatin sponge after placement according to the size of the membrane perforation. Application of the study treatment will occur at Visit 1 and may be repeated at each follow up visit as needed for a maximum of three treatments in the Randomized Treatment Phase (Visit 1, Visit 2, and Visit 3).
223902419|NCT04960384|DRUG|Placebo|FGF-2 will be replaced with sterile water to saturate a pledget of gelatin sponge. The method will be otherwise identical to the FGF-2 intervention.
223902420|NCT04241250|DEVICE|EAW+SCES (exoskelton and spinal cord epidural stimulation)|Three months of exoskeleton training followed by 6 months of epidural stimulation.
224276886|NCT03081039|DRUG|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
224276887|NCT03081039|DRUG|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
223715573|NCT07008001|DEVICE|Novel spectacle lens design|Use of spectacle lenses may reduce the rate of progression of juvenile myopia
223715574|NCT06681584|DIAGNOSTIC_TEST|CTCA|CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)
223902421|NCT04241250|DEVICE|EAW+TS (exoskelton and transspinal stimulation)|Three months of exoskeleton training followed by 6 months of transspinal stimulation.
223902422|NCT04226547|DEVICE|Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)|Implantation of an Amplatzer Amulet left atrial appendage occluder
223902423|NCT04226547|DRUG|Non-Vitamin K Oral Antagonists|Initiation or continuation of a NOAC drug
223902424|NCT05629039|BEHAVIORAL|Volitional Help Sheets|The volitional help sheet is an intervention which provides an opportunity for people to actively plan their behavioural changes by using a list of situations and solutions. The list of situations are critical situations which provoke unwanted behaviour, and the solutions are the responses to overcome the situations which urge the unexpected behaviour. In the context of smoking behaviour, the list of situations is the situations that will provoke cigarette uptake and the list of solutions is the appropriate responses to reduce or stop the urge to smoke.
223902425|NCT05266365|OTHER|The video-based exercise (VBE) group|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The physiotherapist will create a video record for the patients, including a detailed description of each exercise.~This video recording will be watched at home, and the patients will do video-based exercises by following the instructions in the video."
223902426|NCT05266365|OTHER|The standard exercise group (SE)|"An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~An exercise program will be performed at the clinic."
223902427|NCT01710488|DRUG|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
223902428|NCT01710488|DRUG|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
223902429|NCT05601700|DRUG|Letrozole tablets|ATC: L02BG04
223902430|NCT05601700|DRUG|carboplatin AUC 5 and paclitaxel 175 mg/m2|ATC: L01XA02 and ATC: L01CD01 respectively
223902431|NCT06526117|DRUG|Hydroxyurea|The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.
223902432|NCT06534255|BIOLOGICAL|MegaLT injection|"Three dose groups were set: 1×10\^6/kg, 5×10\^6/kg, and 1×10\^7/kg. The dose escalation was carried out in ascending order using a 3+3 design. To ensure participant safety, enrollment followed a 1+2 rule. Specifically, the first participant in each dose group received the cell infusion and was observed for 14 days. If no dose-limiting toxicity (DLT) was observed, the remaining two participants could then be enrolled and receive cell therapy at the same dose level."
223902433|NCT05626751|DRUG|HZN-825|HZN-825 will be administered BID for 52 weeks
223902434|NCT05035810|BEHAVIORAL|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
223902435|NCT05035810|DRUG|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
223902436|NCT05035810|BEHAVIORAL|No Social Incentive applied|No social incentive will be applied
223902437|NCT05035810|DRUG|Procedure: Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
223902438|NCT06245668|DEVICE|SaCoVLM™ video laryngeal mask|The SaCoVLM™ video laryngeal mask will be placed directly into the hypopharyngeal space until resistance is felt, following the recommended instructions for use.
223902439|NCT06245668|DEVICE|LMA Supreme|The LMA Supreme will be inserted directly by hand and placed into the hypopharyngeal space until resistance is felt, as per the recommended instructions for use.
223902440|NCT05456750|DEVICE|Intravascular laser irradiation of blood|Low intensity intravenous laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.
223902441|NCT06201247|DRUG|JD123 injection|JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
223902442|NCT05983367|DRUG|Ompenaclid|Ompenaclid (RGX-202-01)
223902443|NCT05983367|DRUG|Placebo|Placebo
223902444|NCT05983367|DRUG|Bevacizumab|Bevacizumab
223715575|NCT06681831|DEVICE|DaVinci SP|robotic single-port hysterectomy (R-SPH) with DaVinci SP
223715576|NCT06680518|OTHER|tourniquet|peroperation tourniquet
223902445|NCT05983367|DRUG|FOLFIRI regimen|FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
223902446|NCT05766462|OTHER|Pacemaker lower rate setting|Pacemaker lower rate is set by physician and may be adjusted according to the physician diagnosis.
224276888|NCT03081039|DRUG|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
223715577|NCT06680518|OTHER|No tourniquet|no tourniquet during surgery
223715578|NCT07015450|DRUG|self-manufactured 40% dextrose gel|The self-manufactured 40% dextrose gel was applied in buccal mucosa region
223715579|NCT07015450|DRUG|Standard therapy|standard therapy for asymptomatic transient neonatal hypoglycemia
223902447|NCT04930874|OTHER|NIRS (Near-Infrared Spectroscopy)|NIRS assessment of cerebral autoregulation and cerebral blood flow
223902448|NCT05556291|DRUG|Combinations of Oral Blood Glucose Lowering Drugs|Combination of Ertugliflozin and Sitagliptin
223902449|NCT04275713|DRUG|Metformin|Metformin is an oral antidiabetic drug
223902450|NCT04275713|DRUG|Cisplatin|Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles
223902451|NCT03787264|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
223902452|NCT03787264|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
223902453|NCT03787264|BIOLOGICAL|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
223902454|NCT03787264|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
223902455|NCT04991402|DEVICE|Dolutegravir-based antiretroviral therapy|"This study focuses on the impact of Dolutegravir (DTG)-based antiretroviral therapy (ART) on metabolic health of women and children in pregnancy, delivery and beyond. In order to understand the potential adverse effects of DTG, pregnant women living with HIV- both those initialing DTG-based ART in pregnancy as well as those who were established on DTG-based ART prior to pregnancy, will be less than or equal to 18 weeks' gestation at enrollment to allow for detection of metabolic abnormalities as they begin to develop during the course of pregnancy.~This is considered standard of care."
223902456|NCT06201234|DRUG|Olaparib + Elacestrant|Olaparib 600 mg orally daily and elacestrant 400 mg orally daily
223902457|NCT06201234|DRUG|Olaparib|Olaparib 600 mg orally daily
223902458|NCT03728790|DEVICE|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
223902459|NCT06503471|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
223902460|NCT06503471|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
223902461|NCT03878589|DRUG|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
223902462|NCT03878589|DRUG|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
223902463|NCT03214796|DRUG|Human albumin|Infusion of human albumin
223902464|NCT05909150|DRUG|Sodium chloride solution 3,5%|Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
223902465|NCT05909150|DRUG|Sodium chloride solution 0,9%|Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
223902466|NCT04521712|DIAGNOSTIC_TEST|2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor|All women enrolled in this study will have a 2-hour 75-g oral glucose tolerance test performed immediately postpartum (within 4 days of delivery), at 4-6 weeks postpartum, and at 6 months postpartum. Enrolled women will also wear a continuous glucose monitor for 10 days at each of these time periods. Both women and their infants will have skin fold thickness measured at each of these 3 study visits to estimate body fat composition. Additionally umbilical cord blood and placental biopsies will be collected at delivery and stored for future research.
223902467|NCT00216892|DRUG|Calcipotriol, (calcipotriol + betamethasone)|
223902468|NCT06506591|DRUG|WD-890|Administered P.O.
223902469|NCT06506591|DRUG|WD-890 Tablets Placebo|Administered P.O.
223902470|NCT01476839|BIOLOGICAL|basiliximab|Given IV
223902471|NCT01476839|DRUG|carmustine|Given IV
223902472|NCT01476839|DRUG|etoposide|Given IV
223902473|NCT01476839|DRUG|cytarabine|Given IV
223902474|NCT01476839|DRUG|melphalan|Given IV
223902475|NCT01476839|OTHER|pharmacological study|Correlative studies
223902476|NCT01476839|OTHER|laboratory biomarker analysis|Correlative studies
223902477|NCT01476839|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
223902478|NCT01476839|BIOLOGICAL|yttrium Y 90-labeled basiliximab|Given IV
223902479|NCT03623464|OTHER|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
223902480|NCT03623464|OTHER|Standard of care|Post-operative standard of care information
223902481|NCT05472389|OTHER|Video-electroencephalography|All patients will be monitored 24 hours. Whenever possible, duration of the long-term monitoring will be extended to 48 hours, including a second full night polysomnography. These recordings will also allow us to assess sleep architecture and to capture seizures in some patients video , EEEG, EKG, respiration and other polysomnography data will be centralized at Hospices Civils de Lyon. A copy of the EEG-EKG data required to address the objectives related to cardiac features will then be electronically transferred to Partner 2 (Bonn) Evaluation will be performed blind to other data by the Partner 1 (Lyon) for the respiratory data and by the Partner 2 (Bonn) for the EKG data All primary outcomes and secondary outcomes will be assessed with respect to duration of epilepsy and frequency of convulsive seizures during the baseline period.
223902482|NCT05472389|OTHER|Blood Samples|Blood samples will be collected at V2 in all patients. A total of seven blood samples of 4 ml each will be collected, including five EDTA and two dry. Samples EDTA plasma and serum will then be prepared after centrifugation. In children \< 10 kg, only 5 samples of 4 ml each (22 ml in total), including four EDTA and one dry.
223902483|NCT05260411|BIOLOGICAL|AK102|Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223902484|NCT05260411|BIOLOGICAL|AK102|Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223902485|NCT05260411|DRUG|Placebo|Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223902486|NCT03572374|OTHER|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
223902487|NCT03572374|OTHER|Information Booklet|Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
223902488|NCT05297565|BIOLOGICAL|Nivolumab/rHuPH20|Specified dose on specified days
223902489|NCT05297565|BIOLOGICAL|Nivolumab|Specified dose on specified days
223902490|NCT05895175|OTHER|Questionnaires|Questionnaires
223902491|NCT05228158|DRUG|Tazemetostat|Tazemetostat oral tablets.
223902493|NCT06416800|DRUG|Digoxin|Oral; Tablet
223902494|NCT06416800|DRUG|Rosuvastatin|Oral; Tablet
223902495|NCT06416800|DRUG|Metformin|Oral; Tablet
223902496|NCT06416800|DRUG|Povorcitinib|Oral; Tablet
223902497|NCT06416800|DRUG|Probenecid|Oral; Tablet
223902498|NCT05972187|OTHER|Temperature and Humidity|Temperature and Humidity of room changed
223902499|NCT00223171|DRUG|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
223902500|NCT06288503|OTHER|Hydrolysed Rice Protein Formula|Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
223902501|NCT06288503|OTHER|Cow's Milk Based Extensively Hydrolysed Formula|Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
223902502|NCT05516485|OTHER|Assessment|Undergo grading and recording of tumor consistency/stiffness
223902503|NCT05516485|DEVICE|Magnetic Resonance Elastography|Undergo MRE
223902504|NCT02675777|OTHER|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~1. Identification of a clinical champion and Local Implementation Team.~2. Participatory Design.~3. Training primary care providers and Medical Assistants.~4. EHR clinical decision support tools~5. Weekly facilitated Local Implementation Team meetings.~6. Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~7. Learning sessions for primary care providers during implementation.~8. Social worker use of an EHR registry with weekly supervision.~9. Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
223902505|NCT06114082|PROCEDURE|IDA-TACE|Stable chemoemulsion will be produced by dissolving 10 mg of idarubicin powder (Zavedos; Pfizer, New York, NY, USA) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
223902506|NCT06114082|PROCEDURE|DOX-TACE|Stable chemoemulsion will be produced by dissolving 50 mg of doxorubicin powder (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Republic of Korea) in 2.5 mL of an iodinated contrast agent. This solution will then be mixed with 10 mL of iodized oil (Lipiodol Ultrafluid; Guerbet, Villepinte, France) using a three-way stopcock. This chemoemulsion will be prepared in aliquots (0.8 mL of chemoemulsion in each 1 mL syringe) and injected until the embolization endpoint is achieved.
223902507|NCT05932836|OTHER|No interventions.|No interventions to be administered.
223902508|NCT05664633|DRUG|Sugammadex|Sugammadex or G/N will be given at the end of the procedure once the surgeon communicates with the anesthesiologist. The surgeon will typically do this at the time of putting the closing sutures.
223902509|NCT04979728|OTHER|At Home Self-Collections|Directly observed at home self-collection of blood samples
223528849|NCT01435343|DRUG|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
223528850|NCT01435343|DRUG|plerixafor|intravenously from days 1 to 4
223528851|NCT04772794|OTHER|fraction of inspired oxygen|after induction of general anaesthesia, different fraction of inspired oxygen will be given to patient according to their group allocation
223528852|NCT04940169|PROCEDURE|anterior cruciate ligament recontruction|Firstly graft is harvested with help of arthroscopy femoral and tibial tunnels created then graft placed into tunnels
223528853|NCT06422455|OTHER|Best Practice|Receive provider-based genetic counseling
223528854|NCT06422455|OTHER|Educational Intervention|Receive genetics education
223528855|NCT06422455|OTHER|Electronic Health Record Review|Ancillary studies
223528856|NCT06422455|OTHER|Genetic Counseling|Receive provider-based genetic counseling
223902510|NCT06217393|DRUG|Itopride Hydrochloride 150 mg extended release tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
223902511|NCT06217393|DRUG|Itopride Hydrochloride 50 mg film coated tablets|"The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment)~• Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals"
223902512|NCT03531073|DRUG|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
223902513|NCT04646096|DEVICE|MAKO THA 4.0 System|"Measure how the accuracy and precision of robotic arm-assisted total hip arthroplasty (THA) for placement accuracy of implant position in both the anterior and posterior approach.. The intervention will assess the precision of the MAKO system in placing hip components according to plan. It will compare hip angles executed by the Mako system intraoperatively with the 'gold standard' of 3D computer tomography (CT) scans.~The postoperative CT scan can show the precision of the MAKO system by accurately determining the location of hip replacements in patients after surgery."
223902514|NCT01420783|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223902515|NCT06101056|BEHAVIORAL|Junior Enlisted Component|"Junior Enlisted Airmen (E4 and below) will complete 10 online modules designed to train them on recognizing SH and SA, healthy and unhealthy relationships, and situations that may increase risk for SH and SA. Participants will adopt and practice a lifestyle paradigm of select-detect-protect, in which service members select their personal rule to have only healthy (non-abusive) relationships with their peers and romantic partners, detect signs and situations that might threaten their rules, and protect their rules using communication, management, and avoidance skills. They will be instructed to adopt a zero-tolerance approach to SH and SA and will receive skills training related to communication and conflict resolution for healthy relationships, reduction of SH and SA perpetration, consent communication, reporting incidents of SH and SA, and bystander intervention. Participants who have experienced SH or SA are encouraged to use the Get Help Now feature to access support 24/7."
223902516|NCT06101056|BEHAVIORAL|Leadership Component|"Mid- and advanced-level leaders (E5 and above) will complete 10 online modules designed to train them to recognize forms of SH and SA, how to respond to an incident of SH or SA, and how to create a safe work environment free of SH and SA. Leaders will also adopt and practice the paradigm select-detect-protect. Leaders will select their personal rule to enforce a healthy work environment (free of SH and SA), detect signs and situations that might threaten their rule (e.g., displaying inappropriate pictures on the computer), and protect their rules using communication and management skills. Leaders will also be given background material on SH and SA in the military (e.g., extent of the problem, DoD definitions, and policies) and installation resources for reporting incidents. As with the Junior Enlisted component, Leaders who may have experienced SH or SA are encouraged to use our Get Help Now feature to access support 24/7."
223902517|NCT06101056|BEHAVIORAL|Social Marketing Campaign|"All participating Airmen (including Junior Enlisted Airmen and Leaders) will be exposed to X-CoRe's social marketing campaign, which includes posters, flyers, postcards, and digital content for social media. Messages are designed to increase awareness of consent and foster Wing-wide norms that are supportive of healthy relationships. Resources for Service members to receive support if they have experienced SH or SA will also be provided through the social marketing materials. Social marketing materials, such as posters, will be distributed at hot spots for SA (e.g., dorms)."
223902518|NCT05993442|BEHAVIORAL|Optimised kangaroo care|The intervention of optimised KC implementation consists of two components. Component 1 defines the targeted StSC for optimised KC, while component 2 is the implementation support to put in place a tailored implementation strategy.,
223902519|NCT03206801|PROCEDURE|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
223902520|NCT05597371|OTHER|the use of the platform|the use of the platform
223902521|NCT04525729|DRUG|Rituximab|To evaluate the efficacy and safety of HLX01 combined with RASi in patients with IgAN.
223902522|NCT04525729|DRUG|RAS 2410|To evaluate the efficacy and safety of RASi in patients with IgAN.
223902523|NCT00691002|DRUG|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
223902524|NCT00691002|DRUG|LEO 80190 Vehicle|
223902525|NCT00691002|DRUG|Hydrocortisone|
223902526|NCT00691002|DRUG|Calcipotriol|
223902527|NCT05158374|DRUG|Aspirin tablet|75mg Aspirin once per day
223902528|NCT05158374|DRUG|Metformin|500mg Metformin once per day
223902529|NCT05158374|DRUG|Aspirin and Metformin|75mg Aspirin and 500mg Metformin once per day
224083503|NCT04747925|OTHER|Mulligan two leg rotation core muscle strengthning exercises|Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
223528857|NCT06422455|OTHER|Interview|Ancillary studies
223528858|NCT06422455|OTHER|Survey Administration|Ancillary studies
223528859|NCT00319761|DRUG|Calcitriol|
223528860|NCT02609594|OTHER|Weekly application of Amnioband|Weekly application of Amnioband.
223528861|NCT02609594|OTHER|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
223528862|NCT02609594|OTHER|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
223902530|NCT05605756|DRUG|OnabotulinumtoxinA 145 UNT [Botox]|"Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic."
223902531|NCT05925608|COMBINATION_PRODUCT|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)|CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)
223902532|NCT05925608|DIAGNOSTIC_TEST|Diagnostic Catheterization|Left ventricular catheterization with no active therapy
223902533|NCT06345664|OTHER|Diagnostics and intervention recommendations|All families get the same diagnostics and receive individual treatment recommendations.
223902534|NCT05458518|PROCEDURE|Cesarean wound dressing removal|The cesarean wound dressing is to be removed and the surgical wound exposed
223902535|NCT04324359|DRUG|SURF-201|One drop twice daily (BID) in the study eye for 16 days.
223902536|NCT04324359|DRUG|Placebo|One drop twice daily (BID) in the study eye for 16 days.
223902537|NCT05586334|BIOLOGICAL|Collection of vaginal secretions|In all women included: Vaginal secretion sampling at the time of the obstetrical emergency consultation.
223902538|NCT05586334|BIOLOGICAL|Collection of the placenta and the membranes|In cohort 1, for 30 patients at the Port Royal Maternity Hospital, the placenta and membranes will be collected after delivery
223902539|NCT05586334|OTHER|Administration of EPDS questionnaire|In cohort 3, the EPDS questionnaire will be administered to all participants after the consultation in the emergency department.
223902540|NCT06777797|DEVICE|PU condoms (Test PU Condom A, Test PU Condom B, Test PU Condom C, Test PU Condom D)|Participants will be provided with PU condoms (2 condoms per variant) to use during masturbation.
223902541|NCT06777797|DEVICE|NRL condoms (Test NRL Condom A, Test NRL Condom B, Test NRL Condom C, Test NRL Condom D)|Participants will be provided with NRL condoms (2 condoms per variant) to use during masturbation.
223902542|NCT06319430|OTHER|robots|LEGO robots with adaptation according to child's age and developmental skills.
223902543|NCT06319430|OTHER|conventional|A pack of conventional play tools consists of dolls, teddy bears, miniature wild animals, and small cars. All are available, and the child can choose to play with them.
223902544|NCT06075979|OTHER|Lumbar disc herniation|Patients undergoing surgery for lumbar disc herniation
223902545|NCT06075979|OTHER|Lumbar spinal stenosis|Patients undergoing surgery for lumbar spinal stenosis
223902546|NCT03899259|DRUG|Baricitinib|Administered orally
223902547|NCT03899259|DRUG|Placebo|Administered orally
223902548|NCT02617758|DRUG|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
223902549|NCT02617758|DRUG|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
223902550|NCT05918744|BEHAVIORAL|Sleep Extension|Participants will extend their time in bed by one hour for 2 weeks while being monitored.
223715580|NCT07015112|OTHER|Patient-centered multidisciplinary treatment review|Patient-centered multidisciplinary treatment review is defined as a medication review conducted by a multidisciplinary team (geriatrician, clinical pharmacist, nurse) according to a patient-centered methodology, based on person-centered evaluation of both personal and clinical insights, diagnostic-centered evaluation (based on current guidelines), and drug-centered evaluation (based on adequacy)
223715581|NCT07016113|DRUG|0.005% latanoprost gel|\- Apply 0.005% latanoprost gel to the predetermined skin lesions twice daily (morning and evening) every day for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.
223902551|NCT04888702|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223902552|NCT02947750|DRUG|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
223902553|NCT02947750|OTHER|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
223902554|NCT02947750|DIETARY_SUPPLEMENT|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
223902555|NCT02947750|OTHER|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
223902556|NCT02947750|OTHER|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
223902557|NCT02947750|DIETARY_SUPPLEMENT|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
223902558|NCT02947750|OTHER|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
223902559|NCT04998006|DRUG|Alcohol and Cannabis vs. Alcohol only|Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
223902560|NCT05815953|DEVICE|Polarstem|Stem used in total hip replacement. Manufacturer: Smith \& Nephew Orthopaedics AG, Baar, Switzerland.
223902561|NCT05815953|DEVICE|Corail|Stem used in total hip replacement. Manufacturer: De Puy Int Ltd, Leeds, UK.
223902562|NCT04036695|DEVICE|Reveal LINQ insertable cardiac monitoring system|A small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
223902563|NCT04760652|BEHAVIORAL|Cognitive Behavioral Therapy CBT|CBT: In-person and computer-based components (Good Days Ahead) First 4 weeks of CBT are twice weekly; thereafter weekly CBT
223902564|NCT05795959|BEHAVIORAL|Receive education on precision medicine|Patients who consent to participating in the study and are randomized to the intervention group, will meet 1 on 1 with a trained lay VA volunteer. The trained lay VA volunteer will conduct phone calls with patients until the end of the 1 month enrollment period to deliver education regarding precision medicine.
223902565|NCT06394206|OTHER|Specialized Unit|The participant will be visited every three months for one year
223902566|NCT06394206|OTHER|Usual Follow-Up|The participant will be visited as usual, it means they will be visited at Digestive Consultation
223902567|NCT06067009|BEHAVIORAL|ImPart-Multi - IMproving the decisional PARTnership of Chronic Kidney Disease Dyads with concurrent metabolic disease|ImPart-Multi is a psychoeducational, decision support training program, designed to impact Black chronic kidney disease patients with concurrent metabolic disease and their care partners' ability to 1. contemplate the decision needed, 2. request resources/support, and 3. make an informed patient-centered decision. Participants will participate in either communication training, social support effectiveness training, or a combination of both.
223902568|NCT05296109|DIAGNOSTIC_TEST|Magnetic Resonance Imaging on 3T scanner (Magnetom Prisma, SIemens) with dedicated neurogram sequences (Constructive interference in steady state - CISS; Dual Echo Steady State - DESS)|The MRI examination will consist of both conventional sequences for diagnosis of salivary gland neoplasms (including DWI and DCE-MRI), together with additional neurogram sequences. (please refer to attached protocol for list of sequences)
223902569|NCT05873413|BEHAVIORAL|Motivate-the-Bystander|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for increased bystander behaviors.
223902570|NCT05873413|BEHAVIORAL|Motivate-the-Bystander+Alcohol|A Zoom-based motivational interviewing prevention program that enhances knowledge, motivation, and skills for reduced alcohol use and increased bystander behaviors.
223902571|NCT05873413|BEHAVIORAL|Attention-only Control|A Zoom-based stress reduction program in which progressive muscle relaxation and other techniques are introduced and practiced.
223902572|NCT05139810|DRUG|Donidalorsen|Donidalorsen was administered by SC injection.
223902573|NCT05139810|DRUG|Placebo|Donidalorsen-matching placebo was administered by SC injection.
223902574|NCT05767541|OTHER|Pilates exercises|The Pilates technique consist of hundred, swimming, prone leg lift, single leg stretch, spine stretch forward, arm circles, imprint and release, one leg circles and mini squat.
223902575|NCT05767541|OTHER|Resistance exercises|Resistance training include leg press, shoulder press, bench press, back arm press, seated row, knee extension, leg curl and seated calf raise
223902576|NCT05241860|OTHER|Pharmacotherapy Discontinuation|Stop hormonal medications (Abiraterone, Enzalutamide, Apalutamide, Leuprolide, Goserelin, Degarelix, Relugolix)
223902577|NCT05241860|OTHER|Follow-Up|Undergo follow-up
223902578|NCT05241860|OTHER|Questionnaire Administration|Ancillary studies
223902579|NCT05241860|OTHER|Quality-of-Life Assessment|Ancillary studies
223902580|NCT00798070|DRUG|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
223902581|NCT00798070|DRUG|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
223902582|NCT06177652|OTHER|Paravertebral Block|Ultrasound (US) -guided paravertebral block (PVB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the PVB group.
223902583|NCT06177652|OTHER|Serratus Plane Block|Ultrasound (US) -guided serratus plane block (SPB) with 20 ml 0.5 % bupivacaine will performe preoperatively to all patients in the SPB group.
223902584|NCT03239808|PROCEDURE|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
223902585|NCT03239808|PROCEDURE|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
224276889|NCT04413032|DEVICE|DreaMS|The dreaMS App is a data communication platform collecting data from the patients' mobile devices (smartphone and wearables). We analyze app-based tests, surveys and sensor data.
224276890|NCT03164109|DRUG|GC4419 IV|50mg infused IV over 15 minutes
224276891|NCT03164109|DRUG|Placebo|Infused IV over 15 minutes
224276892|NCT03164109|DRUG|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
223902586|NCT04763174|BEHAVIORAL|mHealth Coping Skills Training for Symptom Management (mCOPE)|mCOPE participants will complete 5 videoconferencing sessions (within 5-9 weeks) with a psychologist, each lasting 45-60 minutes, from a location convenient to the patient (e.g., home, work). Sessions will include cognitive behavioral coping skills designed to target pain, fatigue and psychological distress symptoms unique to colorectal cancer patients. mCOPE will include a mobile app for: 1) coping skills content (e.g., audio, video), 2) daily symptoms assessment and coping skills use tracking transmitting in real-time to study staff, and 4) push notifications for reminders, encouragement, and personalized feedback.
223902587|NCT03191916|DEVICE|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
223902588|NCT03191916|DEVICE|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
223902589|NCT04140734|DEVICE|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
223902590|NCT03828513|DEVICE|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
223902591|NCT03828513|DEVICE|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2\> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
223902592|NCT05986240|DRUG|Danvatirsen|Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
223902593|NCT05986240|COMBINATION_PRODUCT|Danvatirsen + Venetoclax|"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."
223902594|NCT04947397|DIAGNOSTIC_TEST|Pupillometry|Pupillometry prior to extubation
223902595|NCT04547595|OTHER|Hypnosis|given by Expert in this method
223902596|NCT04268199|DRUG|Bortezomib Injection|Subcutaneous injection
223902597|NCT04597541|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.
223902598|NCT05179369|BEHAVIORAL|Standard Care with Well-Mama Intervention|The intervention involves: (1) a Well-Mama checklist on 5 topic areas aligned with leading causes of MM and SMM: (a) mental health/depression; (b) cardiovascular symptoms; (c) safety (e.g., guns at home and intimate partner violence); (d) opioid/substance abuse; and (e) social support, self-agency, and well-being; and (2) Community Doula Navigators (CDNs) who will: (a) conduct biweekly check-ins with pregnant and postpartum women using the Well-Mama List and make appropriate referrals to providers and other resources following check-ins; (b) attend select patient visits; (c) lead virtual pregnancy \& postpartum support groups; and (d) provide labor support.
223902599|NCT05369429|BEHAVIORAL|My Wellbeing Guide|The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
223902600|NCT05985148|RADIATION|Single-fraction stereotactic radiosurgery (SRS)|"Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques."
223902601|NCT05787834|OTHER|Best Practice|Receive usual care
223902602|NCT05787834|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
223902603|NCT05787834|PROCEDURE|Respiratory Muscle Training|Undergo RMT
223902604|NCT05787834|OTHER|Survey Administration|Ancillary studies
223902605|NCT06283589|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
223902606|NCT05566639|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223902607|NCT05566639|BIOLOGICAL|Fluarix Quadrivalent|Sterile suspension for injection.
223902608|NCT03206047|DRUG|Atezolizumab|Given IV
223902609|NCT03206047|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC
223902610|NCT03206047|DRUG|Guadecitabine|Given SC
223902611|NCT03206047|OTHER|Laboratory Biomarker Analysis|Correlative studies
223902612|NCT03206047|DRUG|Poly ICLC|Given SC
223902613|NCT06702722|BEHAVIORAL|Enhanced Friendship Bench|Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.
224276893|NCT01044394|DRUG|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
224276894|NCT03653026|DRUG|Placebo|Tablet for oral administration
223528863|NCT04743648|BEHAVIORAL|Innovative Thinking Development Program (ITDP)|With the implementation of the program, nursing students are expected to develop innovative thinking skills.
223902614|NCT06702722|BEHAVIORAL|Enhanced usual care|Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
223902615|NCT05776810|DIAGNOSTIC_TEST|Diagnostic Test: Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
223902616|NCT05776810|DEVICE|Device: Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
223902617|NCT03819933|BEHAVIORAL|Educational intervention|Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
223902618|NCT04731818|BIOLOGICAL|ZB-06|ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.
223902619|NCT05815810|OTHER|Attuned: A mobile application|Subjects will undergo voice and communication modification therapy via the Attuned application. This consists of an 11 week program consisting of different modules to learn how to modify voice (e.g., pitch, intonation, resonance). At the end of each module, participants will be given exercises to practice what they learned.
223902620|NCT05815810|OTHER|In-Person Voice Modification Therapy|Subjects will undergo standard of care in-person voice modification therapy at Ithaca College.
223902621|NCT03329157|OTHER|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
223902622|NCT04990323|BIOLOGICAL|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+\>1x10\^6/kg)
223902623|NCT01705899|DRUG|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
223902624|NCT03576365|BEHAVIORAL|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~* Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~* Information about perceived control and how improving perceived control can lead to decreased distress~* Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~* Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
223902625|NCT03576365|BEHAVIORAL|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~* Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~* Information on the anatomy of the voice and how the voice works~* Educational materials to help understand voice physiology and function~* Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
223902626|NCT05437172|PROCEDURE|injectable platelet rich fibrin with demineralized dentin graft|after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
224276895|NCT03653026|DRUG|Upadacitinib|Tablet for oral administration
224276896|NCT05560555|DRUG|Tafamidis|61 milligrams (mg) as received in studies B3461028 and B3461045
223715582|NCT07016113|DRUG|0.1% mometasone furoate cream|\- Apply 0.1% mometasone furoate cream to the predetermined skin lesions twice daily (morning and evening) for 12 weeks. - Phototherapy is administered at a dose based on the lesion's location and the response to previous phototherapy sessions. Phototherapy is performed twice a week for 12 weeks.
223715583|NCT07015736|DRUG|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|Standard treatment (50-90 mg/kg/day for 10 days)
223715584|NCT07015736|DIETARY_SUPPLEMENT|Saccharomyces boulardii CNCM I-745|Probiotic sachet, twice daily for 10 or 21 days depending on group assignment
223715585|NCT07016477|DIAGNOSTIC_TEST|Ultra-High Resolution Photon Counting Detector Coronary Computed Tomography Angiography|Clinically indicated Ultra-High Resolution Photon-Counting Detector Coronary Computed Tomography Angiography (UHR PCD-CT CCTA) for the pre-procedural evaluation of patients scheduled to undergo transcatheter aortic valve implantation.
223715586|NCT07014371|DRUG|Ferrous Fumarate Oral Tablet|Ferrous fumarate oral tablet 200 mg is an iron supplement used for the treatment of iron deficiency anemia (IDA). In this study, it is administered as either one tablet daily (OD group) or two tablets on alternate days (AD group), with a treatment duration of 8 weeks. The goal is to compare the efficacy and tolerability of alternate-day dosing versus standard once-daily dosing.
223715587|NCT07014332|DEVICE|Steel ligature|Steel ligatures that are used to ligate wire with bracket
223715588|NCT07014332|DEVICE|Elastomeric ligature|Elastomeric ligature that is used to ligate wire to bracket
223902627|NCT05437172|PROCEDURE|demineralized dentin graft|"after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures."
223902628|NCT06061770|OTHER|Adapted physical activity program|Rehabilitation
223902629|NCT06061770|OTHER|Adapted physical activity self-program|Rehabilitation
223902630|NCT05275543|DEVICE|Paro Robot|Device: PARO therapy seal PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
223902631|NCT04568746|PROCEDURE|emergency vital room|At the arrival of the patient, the qSOFA will be carried out to guide the orientation. Patient with score ≥ 2 will be supported in emergency vital room
223902632|NCT04568746|PROCEDURE|box|patient with score \< 2 will be supported in box
223902633|NCT06160024|BEHAVIORAL|Program to improve data quality of national quality indicators|"Interventions will be developed based on the findings from the first data collection period.~A bundle of interventions (Program to improve data quality of national quality indicators) will be offered to participating long-term care facilities to support changing behavior in data collection procedures via training and supporting material as implementation strategies with the goal to improve the data quality of the national quality indicators. The program will be tested in a separate pilot study. The second data collection period in the current study will be used to evaluate the effect of the implemented program."
223902634|NCT03593317|DRUG|Spironolactone|The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.
223902635|NCT03593317|DRUG|Placebo|Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.
223902636|NCT06338475|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
223902637|NCT06338475|BEHAVIORAL|Individual Supportive Listening (ISL)|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
223902638|NCT04593732|DEVICE|STERN FIX (Sternal Stabilization System)|Sternotomy closure with STERN FIX and supplemented with wires
223902639|NCT04159415|DRUG|Placebo|Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
223902640|NCT04159415|DRUG|Low-Dose REGN4461|IV infusion loading dose or SC injection QW.
223902641|NCT04159415|DRUG|High-dose REGN4461|IV infusion loading dose or SC injection QW.
223902642|NCT03800654|BEHAVIORAL|Mindful Action for Pain|MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.
223902643|NCT03800654|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP is the current gold standard psychosocial intervention for chronic pain and will be compared to MAP in the second arm of the study.
223902644|NCT05571670|DRUG|Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor|Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
223902645|NCT05859204|BEHAVIORAL|OT-led Exercise Group|Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
223902646|NCT05859204|BEHAVIORAL|Treatment as Usual - OT Groups|Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
223902647|NCT06581094|DIETARY_SUPPLEMENT|UCII, glucosamine and curcumin|compound capsules twice daily.
223902648|NCT06581094|DIETARY_SUPPLEMENT|Placebo|Placebo capsules twice daily.
223902649|NCT02710435|DEVICE|Reducer System|An aid in the management of chronic refractory angina pectoris
223902650|NCT04900701|OTHER|Energy status|Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
224276897|NCT06123026|DRUG|Cabergoline|1mg oral cabergoline given to participants once
224276898|NCT06123026|DRUG|Placebo|1 encapsulated placebo tablet given to participants after procedure
223902651|NCT06182033|BEHAVIORAL|Peer-mediated pivotal response training|Teachers support children in the implementation of three strategies directed toward a target child identified as having language impairment and as isolated from the classroom social network.
223902652|NCT03439449|DEVICE|CLEOS software program|Computer-assisted history taking program
223902653|NCT03439449|PROCEDURE|Physician taken history|Conventional history taking by physicians
223902654|NCT06142253|BEHAVIORAL|WATER+CT|This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.
223902655|NCT06142253|BEHAVIORAL|Usual Care|This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
223902656|NCT06176300|BEHAVIORAL|PAR - the SEED Method|The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.
223902657|NCT06176300|BEHAVIORAL|PAR-Youth Voices|Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.
223902658|NCT06176300|BEHAVIORAL|Emerging Leaders hospital-based intervention|Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
223902659|NCT06681909|BEHAVIORAL|UB Campus Veggie Van|The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
223902660|NCT06524492|DEVICE|FlowSense|This study compares the performance of two generations of non-invasive cerebrospinal fluid (CSF) shunt flow assessment devices. Measurements of functional implanted shunts and off-shunt locations will assess the diagnostic non-inferiority of the second-generation device to the first-generation device.
223902661|NCT06270680|DRUG|Vision Edge Pro|Each dose will consist of one supplement capsule containing 10 mg lutein, 2 mg zeaxanthin, 10 mg mesozeaxanthin, 50mg EPA, 250mg DHA. Capsules are to be taken orally, once daily with a meal. Duration of supplementation will last approximately 2 - 5 months, depending on the length of the athletic seasons for the sports recruited.
223902662|NCT06270680|OTHER|Placebo|A sunflower oil placebo containing 380 mg of sunflower oil
223902663|NCT04751071|DRUG|Roflumilast 500Mcg Tab|Roflumilast 500µg tablet once daily for 6 weeks plus the standard therapy
223902664|NCT04751071|DRUG|Placebo|Placebo tablet once daily for 6 weeks plus the standard therapy
223902665|NCT05476328|DEVICE|SPACE|SPACE (Spread Precompensation Advanced Combination Encoder) is a sound coding strategy that is intended to improve spectral resolution, and hence hypothesised to improve cochlear implant (CI) speech understanding in noise. It is an alternative to the ACE sound coding strategy. It has been implemented on the Nucleus 7 CP1000 sound processor for CIC4-based implants.
223902666|NCT05476328|DEVICE|OPAL-SPACE|OPAL-SPACE (combined OPAL and SPACE strategy) aims to preserve as many of the significant features encoded by both OPAL and SPACE strategies individually. Since SPACE codes spectral envelope information, while OPAL codes temporal periodicity information, it is reasonable to suggest that both coding techniques can be combined to improve perception additively.
223902667|NCT05476328|DEVICE|ACE|Advanced Combination Encoder (ACE) is the commercially available, reference sound processing strategy.
223528864|NCT04252079|PROCEDURE|Endovascular Repair of Juxtarenal Aortic Aneurysm|"1. History taking and clinical examination.~2. Preoperative Imaging~   CTA is the cross-sectional imaging modality of choice.~3. Preoperative evaluation~   a-Renal evaluation~   b\_ cardiac evaluation C-Pulmonary evaluation~4. Surgical techniques~   1. Anesthesia The use of general anesthesia due to the duration of the procedures and the necessity to control patient breathing to allow precise imaging and accurate device deployment.~  2. Intra operative imaging A hybrid operating room with high-quality fixed imaging is needed for the performance of FEVAR.~C-Device delivery and deployment all FEVAR procedures begin with access of the femoral arteries by either open or percutaneous technique."
223902668|NCT05476328|DEVICE|Cochlear Device Interface (CDI) Tool|For all strategies, programming will be performed using a research version of Custom Sound and the investigational software: Cochlear Device Interface Tool (CDI Tool). Investigational software will be used to stream stimulation sequences to a commercially available N6 sound processor using the Cochlear NIC4.1 interface.
224276899|NCT01158326|DRUG|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
224276900|NCT01158326|OTHER|Placebo|10 ml of oral placebo every 6 hours for 48 hours
223715589|NCT07014709|DRUG|GLP1 receptor agonist|Patients must be under GLP1-RA treatment for ether diabetes or obesity
223715590|NCT07016464|DRUG|REM0045392|Liquid formulation
223528865|NCT03611712|DRUG|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
223715591|NCT07016464|DRUG|Placebo|Liquid formulation
223715592|NCT07016555|DIETARY_SUPPLEMENT|Oral cooling spray|Use oral spray 3 times per day for 2 weeks
223528866|NCT06032182|BEHAVIORAL|CRESTR Intervention|15 1-hour sessions of CRT + SRT
223902669|NCT06444633|BEHAVIORAL|Community Sensitization + Household visit + Information + Free pre-emptive distribution of ORS+Zinc|The intervention will involve the following: 1) The communities will be sensitized on the importance of ORS and Zinc use for the treatment of child diarrhea, by the Clinton Health Access Initiative (CHAI). 2) Campaigners recruited by CHAI will visit each household in their catchment area that contain at child under 5 years old. 3) During the distribution visits, the campaigners will train caregivers on the dangers of diarrhea and the importance of ORS and zinc use, among other things (including how to prepare, use, and store ORS/zinc, benefits of the treatments, recommended health behaviors such as seeking care, and encouraging basic handwashing and hygiene practices). The caregivers will also receive a flyer describing the same information in their local language, for future reference. 4) Campaigners will then distribute two ORS and zinc co-packs (each co-pack contains two sachets of ORS and 10 tablets of zinc) for free for each child under the age of five in the household.
223902670|NCT05989854|BEHAVIORAL|Exercise|8 week exercise intervention, 3x/wk
223902671|NCT05261204|DEVICE|Transcatheter Aortic Valve Implantation|Patients who are deemed receive TAVI first underwent evaluation of their peripheral arteries before the procedure, in order to separate those eligible for transfemoral placement (TFP) from those who would require transapical placement. Technological advances achieved in the new platforms for the treatment of SHD have allowed the use of reduced size catheters and sheaths in the new armamentarium, favoring the TFP technique. The transcatheter valve (TV) is positioned at the level of the native aortic valve during the final step of valve replacement, when the balloon is inflated within the native valve during a brief period of rapid ventricular pacing. The delivery system i traverses the aorta retrograde over a guidewire from its point of insertion in the femoral artery during the use of TFP. Before balloon inflation, the valve and balloon are collapsed on the catheter and fit within the sheath. After balloon inflation, the calcified native valve is replaced by the expanded TV
223902672|NCT05261204|PROCEDURE|Bioprothesis|The bioprosthesis is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
223902673|NCT05261204|PROCEDURE|Sutureless|The sutureless is implanted using the SAVR procedure during median sternotomy in extracorporeal circulation. Minimally invasive procedures using a thoracotomy approach and peripheral cannulation have found widespread use.
223902674|NCT03352531|BIOLOGICAL|AK-105|Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
223902675|NCT05322408|DRUG|HCW9218|HCW9218 at the assigned dose level is administered as a subcutaneous injection once every 3 weeks for a minimum of 2 treatment cycles unless medically contraindicated.
223902676|NCT04983030|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
223902677|NCT04983030|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
223902678|NCT04983030|BIOLOGICAL|PGT121|PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
223902679|NCT04983030|BIOLOGICAL|PGDM1400|PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
223902680|NCT04983030|BIOLOGICAL|VRC07-523LS|VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
223902681|NCT06237647|DIETARY_SUPPLEMENT|Hyaluronic acid, HA|improve tissue repair
223902682|NCT03710603|DRUG|Daratumumab|Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months \& after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
223902683|NCT03710603|DRUG|Velcade|Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
223902684|NCT03710603|DRUG|Lenalidomide|Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
223902685|NCT03710603|DRUG|dexamethasone|Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
223715593|NCT04774913|PROCEDURE|Chronic total occlusion(CTO) percutaneous coronary intervention (PCI)|CTO PCI completed as a two step procedure with an initial planned CTO modification and a completion procedure after 8-12 weeks
223902686|NCT01456949|DEVICE|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
223902687|NCT04865965|PROCEDURE|Acute Bout of Exercise|Exercising for 60 minutes at 55-60% of VO₂ peak
223902688|NCT05477134|OTHER|Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus|On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
223902689|NCT05314504|DEVICE|YVOIRE Y-Solution 360|Cross-linked sodium hyaluronate gel for injection with lidocaine
223902690|NCT04736823|DRUG|AK112|IV infusion
223902691|NCT04736823|DRUG|Pemetrexed|IV infusion
223528867|NCT06032182|BEHAVIORAL|CRESTR Control|15 1-hour sessions of SRT alone
223715594|NCT04522388|DIETARY_SUPPLEMENT|Ensure Enlive|Ensure Enlive shake twice a day
223902692|NCT04736823|DRUG|Paclitaxel|IV infusion
223902693|NCT04736823|DRUG|Carboplatin|IV infusion
223902694|NCT04736823|DRUG|Docetaxel|IV infusion
223902695|NCT06642636|DEVICE|Intensive Care Unit-specific Virtual Reality|The Intensive Care specific Virtual Reality (ICU-VR) film is designed so that patients received relevant and truthful information regarding their ICU treatment with the aim to reduce stress and anxiety. The final film lasts approximately 12 minutes. Real ICU nurses and ICU physicians re-enacting a typical day/treatment for a mock patient undergoing ICU treatment. The module will be watched via HMD-VR glasses (PICO G2 VR; Pico Technology, Beijing, China) with the SyncVR Relax \& Distract application (SyncVR, Utrecht, the Netherlands).
223902696|NCT05913037|DRUG|Test group (Group A): FCN-159 8 mg, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
223902697|NCT05913037|DRUG|Control group (Group B): Placebo, orally, once daily;|After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
223902698|NCT06207773|OTHER|Educator verbal feedback|the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
223902699|NCT06644261|DRUG|Bupivacaine injection|"Transvaginal: Palpation 1 cm superior and medial to ischial spine to locate pudendal nerve. 22 gauge spinal needle with trumpet will be placed at this location. Upon negative aspiration, 10 mL of 0.25% bupivacaine will be injected bilaterally.~Fluoroscopic: Anesthesia Pain medicine fluoroscopy guided injection of 5 mL 0.25% bupivacaine bilaterally in the area of the pudendal nerve based on surrounding landmarks"
223902700|NCT05857228|PROCEDURE|Endoscopic sinus surgery (ESS)|Endoscopic sinus surgery for removal of nasal polyps and sinus tissue.
223902701|NCT05881005|DIAGNOSTIC_TEST|hepatic MRI|Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
223902702|NCT04884789|DEVICE|COFIS 3D|Patient have to wear the COFIS 3D 20h a day for at least 6 month
223902703|NCT02723591|DRUG|Tacrolimus|Oral Capsule
223902704|NCT02723591|DRUG|Tacrolimus immediate release|Oral Capsule
223902705|NCT04768426|DRUG|Capecitabine|1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
223902706|NCT06789978|OTHER|Extracorporeal cardiopulmonary resuscitation (ECPR)|Prehospital extracorporeal cardiopulmonary resuscitation (ECPR)
223902707|NCT03080987|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
223902708|NCT03080987|DRUG|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
223902709|NCT03080987|DRUG|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
223902710|NCT03080987|OTHER|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
223902711|NCT03080987|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
223902712|NCT06847373|DIETARY_SUPPLEMENT|Cholecalciferol|cholecalciferol 4000 IU daily orally
223902713|NCT06851351|DIAGNOSTIC_TEST|Spirometry and optoelectronic plethysmography|Spirometry for respiratory function and optoelectronic plethysmography for respiratory pattern during wakefulness
223902714|NCT06850272|BEHAVIORAL|Brisk walking|Participants in the brisk walking training group receive an eight-week instructor-led interval brisk walking training (40 minutes/session, three sessions/week).
223528868|NCT05869253|BEHAVIORAL|The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation|: A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
223528869|NCT01207037|PROCEDURE|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
223902715|NCT06850272|BEHAVIORAL|Cognitive-behavioral therapy for insomnia|Participants in the CBT-I group receive standard-of-care group-based eight-session CBT-I (one session/week).
223902716|NCT02424305|DRUG|LEO 43204 gel 0.018%|
223902717|NCT02424305|DRUG|LEO 43204 gel 0.1%|
223902718|NCT02424305|DRUG|LEO 43204 gel 0.037%|
223902719|NCT06851962|DRUG|Metformin|Metformin maximum daily dose 2000 mg
223902720|NCT06851962|DRUG|Dulaglutide|Dulaglutide
223902721|NCT06851962|DRUG|Semaglutide 1.0 mg|Semaglutide
223902722|NCT06851962|DRUG|Empagliflozin (BI 10773)|Empagliflozin
223902723|NCT06851962|DRUG|Canagliflozin|Canagliflozin
223902724|NCT06851962|DRUG|Dapagliflozin|Dapagliflozin
223902725|NCT06851962|DRUG|pioglitazone|Pioglitazone
223528870|NCT02935764|DRUG|Irinotecan|180 mg/m2 iv gtt, d1
223902726|NCT06851962|DRUG|Sitagliptin|Sitagliptin
223902727|NCT06851962|DRUG|Vildagliptin (Galvus)|vildagliptin
223902728|NCT06851962|DRUG|linagliptin|linagliptin
223902729|NCT06852092|DRUG|Carbon-14 labeled HSK39297|Dose A
223902730|NCT05555251|DRUG|BI-1607|administered at different doses in Phase I by intravenous infusions every 3 weeks.
223902731|NCT05555251|DRUG|BI-1607|administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.
223902732|NCT05555251|DRUG|Trastuzumab|administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
223902733|NCT00194285|PROCEDURE|FDG-PET Imaging|
223902734|NCT04535934|OTHER|Adenine 5+ (five stable-labeled nitrogens)|taggant coencapsulated with an excipient
223902735|NCT01471236|DEVICE|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
223902736|NCT01471236|PROCEDURE|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator's final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
223902737|NCT05814055|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.
223902738|NCT05814055|DRUG|AB-free kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.
223902739|NCT06781268|BEHAVIORAL|Life Kinetic Training|Combination of cognitive and physical exercises aimed at improving neuroplasticity, agility, balance, and cognitive functions.
223902740|NCT05936905|OTHER|Acupuncture|Acupuncture 1 time per month
223902741|NCT05936905|OTHER|Chiropractic|Chiropractic 1 time per month
223902742|NCT06383364|BEHAVIORAL|Medication Coordinator|The Medication Coordinator calls the patient app seven days after discharge in the transition of care from hospital to home
223902743|NCT06559553|DRUG|Selinexor+pegaspargase+dexamethasone|Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
223902744|NCT06197178|BIOLOGICAL|LCAR-G08 cells|Prior to infusion of the LCAR-G08, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
223902745|NCT06465381|BEHAVIORAL|Safety Planning Intervention|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
223902746|NCT06465381|BEHAVIORAL|Enhanced Usual Care|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
223902747|NCT06465381|BEHAVIORAL|Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention|All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
223902748|NCT04732065|DRUG|ONC206|Given orally (PO)
223902749|NCT04732065|RADIATION|Standard of Care Radiation Therapy|Undergo RT
223902750|NCT04732065|PROCEDURE|Optional Proton (1H) MR spectroscopy (MRS)|Optional imaging procedure
223902751|NCT03034356|DRUG|Levetiracetam|Anticonvulsant drug
223902752|NCT03034356|DRUG|Placebo|Placebo
223902753|NCT05270213|DRUG|RBS2418|RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1). RBS2418 as monotherapy potentially can have an activating effect on the anti-tumor innate immune response and lead to anti-tumor responses in adult subjects with advanced or metastatic tumors.
223902754|NCT05270213|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
223902755|NCT05270213|DRUG|Other approved anti-cancer therapy|Standard of care (SOC) therapy
223902756|NCT06975436|DIAGNOSTIC_TEST|cobas® BV/CV test|The cobas® BV/CV test is an automated, qualitative in vitro real-time PCR diagnostic test that detects bacteria and yeast associated with bacterial vaginosis (BV) and candida vaginitis (CV), respectively. The test does not distinguish among the pathogens but can give an overall qualitative result indicating the presence or absence of pathogen(s) associated with BV and/or CV.
223902757|NCT06975436|DIAGNOSTIC_TEST|BD Max™ Vaginal Panel|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
223902758|NCT06975436|DIAGNOSTIC_TEST|Cepheid Xpert Xpress MVP|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
223902759|NCT06975436|DIAGNOSTIC_TEST|Hologic Aptima BV Assay|This is an FDA-cleared diagnostic test that will be used as labelled. It will serve as one of three comparators in this study for determining BV patient infection status.
223902760|NCT06429657|DRUG|Ketamine with propofol|Propofol at a rate of 300 mcg/kg/hr (5 mcg/kg/min) with the addition of ketamine at a rate of 1000-5000 mcg/kg/hr (16.67 - 83.33 mcg/kg/min) (using weight at time of admission) with an additional 2 mg/kg (2000 mcg/kg) bolus of ketamine
224276901|NCT00628979|BEHAVIORAL|CBT|cognitive- behavioral treatment for panic disorder.
223528871|NCT02935764|DRUG|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
223528872|NCT02935764|DRUG|Leucovorin|400mg/m2 iv gtt,d1
223528873|NCT02461186|DRUG|Arterolane maleate-piperaquine phosphate (Synriam)|
223528874|NCT02461186|DRUG|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
223528875|NCT04834921|DEVICE|Ultraflux® EMiC®2|Ultraflux® EMiC®2-CVVHD runs in septic shock patients with AKI KDIGO 3 for 24 hours. and patients were randomised to start Ultraflux® EMiC®2-CVVHD in the first day or in the second day from the RRT start; more precisely, crossover randomized to sequence consists in Ultraflux® EMiC®2-CVVHD (first day)+ HFF-CVVHDF(second day) and HFF-CVVHDF (first day) + Ultraflux® EMiC®2-CVVHD (second day) for 48 h total without washout
223528876|NCT06118866|DRUG|placebo-Q2W|placebo, 0mg，SC，Q2W，12 cycles
223528877|NCT06118866|DRUG|HMI-115-120mg-Q4W|HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
223528878|NCT06118866|DRUG|HMI-115-240mg-Q4W|HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)
223528879|NCT06118866|DRUG|HMI-115, 240mg-Q2W|HMI-115, 240mg，SC，Q2W，12 cycles
223902761|NCT06429657|OTHER|Standard of Care propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam|Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the institutional SOC guidelines.
223902762|NCT06128148|DRUG|JYP0322 50 mg qd|JYP0322 is administered orally at a dose of 50 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902763|NCT06128148|DRUG|JYP0322 100 mg qd|JYP0322 is administered orally at a dose of 100 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902764|NCT06128148|DRUG|JYP0322 200 mg qd|JYP0322 is administered orally at a dose of 200 mg qd for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902765|NCT06128148|DRUG|JYP0322 100 mg bid|JYP0322 is administered orally at a dose of 100 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902766|NCT06128148|DRUG|JYP0322 150 mg bid|JYP0322 is administered orally at a dose of 150 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902767|NCT06128148|DRUG|JYP0322 200 mg bid|JYP0322 is administered orally at a dose of 200 mg bid for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902768|NCT06128148|DRUG|JYP0322 150mg tid|JYP0322 is administered orally at a dose of 150 mg tid for a specified duration until unacceptable toxicity, disease progression, or study completion.
223902769|NCT06160388|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
223902770|NCT05528536|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
223902771|NCT05528536|OTHER|Art|To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
223902772|NCT05528536|OTHER|Exercise|An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
223902773|NCT05528536|OTHER|Treatment as usual|treatment as usual within their community centres
223902774|NCT04082117|BEHAVIORAL|Educational video|Educational genetic counseling video
223902775|NCT05111509|DRUG|[203Pb]VMT-α-NET|3 to 5 miliCuries of \[203\]Pb administered intravenously 60 minutes before the start of the scans.
223902776|NCT05111509|DEVICE|SPECT/CT|Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.
223902777|NCT06651099|OTHER|mhealth application|Individuals enrolled in the mhealth intervention will receive tailored content will include exercises focused on mobility, flexibility, core stabilization, and strengthening. Additionally, the mobile application will provide educational material on pain and health, covering topics such as the neurophysiology of pain, the multidimensional nature of low back pain, myths and facts about the condition, the importance of sleep, and stress management, which will include relaxation techniques and mindfulness. All content will be evidence-based, using clinical guidelines, systematic reviews and other high-quality studies to support inclusion in the mobile application. The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
223902778|NCT06651099|OTHER|Conventional exercise therapy|Participants in this intervention will receive a printed booklet containing a description and recommendations for carrying out an exercise program at home, which will be characterized by general exercises (such as strengthening, mobilization). The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
223902779|NCT06978647|DRUG|YTS109 cell|Subjects will receive YTS109 cell (1.5 E6 STAR +T cells/kg) once in this study.
223902780|NCT06408350|BEHAVIORAL|Text Me, Alexis!|Determine the Optimal Intervention for Advancing Transgender Women Living with HIV to Full Viral Suppression
223902781|NCT06655064|OTHER|None- Observational|None- Observational
223902782|NCT03876626|OTHER|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
223902783|NCT03876626|OTHER|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
223902784|NCT05547542|DRUG|CVL-354|Oral solution/capsule
223902785|NCT05547542|DRUG|[11C]-LY2795050|IV injection
223715595|NCT00607815|BEHAVIORAL|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
223902786|NCT05547542|DRUG|[11C]-carfentanil|IV injection
223902787|NCT04754165|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
223902788|NCT04256486|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a faith based organization setting.
223902789|NCT02568566|OTHER|Laboratory Biomarker Analysis|Correlative studies
223902790|NCT02568566|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
223902791|NCT07057232|OTHER|Usual care provided from pain specialist or within a dedicated pain unit|Adult non-cancer chronic pain patients receiving care in outpatient settings from a pain specialist or within a dedicated pain unit
223902792|NCT07059572|DRUG|Group A- 0.15% Guava leaf extract mouthwash group|Participants will be instructed to rinse with 10 ml of 0.15% Guava Leaf Extract Mouthwash twice daily for 30 and 90 days. Each rinse will last for 1 minute, after which the mouthwash is to be expectorated without swallowing.
223902793|NCT07059572|DRUG|Group B- 0.2% Chlorhexidine mouthwash|"Participants will be instructed to rinse with 10 ml of 0.2% Chlorhexidine Mouthwash twice daily for 30 and 90 days. Each rinse will last for 1 minute, after which the mouthwash is to be expectorated without swallowing."
223902794|NCT06765681|OTHER|Diagnosis of both VTE and sepsis|Both diagnoses need to present during ICU stay for case inclusion into this retrospective study
224276902|NCT02718287|BEHAVIORAL|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
223715596|NCT00607815|BEHAVIORAL|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
223715597|NCT06681571|OTHER|TAP Block|TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.
223902795|NCT07062575|DEVICE|ABLE Daily|The participants will receive training sessions with the ABLE Daily at Sint Maartenskliniek. After they pass the skills and knowledge exam, they will receive the ABLE Daily at their disposal at home for twelve weeks
223902796|NCT07064096|OTHER|cawthorne cooksey exercise|Cawthorne Cooksey exercises -Start with low to moderate intensity. Cawthorne Cooksey exercise Training Phase1-In bed exerercises:- Eye movements: 1)Up and down 2)Side to side 3)Moving finger away from face -Phase2-Sitting: Eye movements as above. Head movements at firsts low, then quick later with eyes closed -bending forward and backward -turning from side to side. --Shoulder shrugging and circling -Bending forward and picking up objects from the ground - Phase 3 - Standing: -Eye, Head, Shoulder movements -Throwing ball from hand to hand, hand under knee -Switch to sitting to standing and turning around in between. -Phase 4 - Walk: with eyes closed and open: -Across room -Slope and Stairs
223902797|NCT07064096|OTHER|mental imagery|The mental imagery intervention in this study is a structured, guided cognitive training program designed to enhance the effects of vestibular rehabilitation in young adults with unilateral vestibular hypofunction. Mental imagery (MI) involves the internal visualization and mental rehearsal of physical movements without actual motor output, engaging similar neural pathways as actual execution.
223902798|NCT07063173|DIETARY_SUPPLEMENT|Fruit Bar|Tart Cherry N185
223902799|NCT07063173|DIETARY_SUPPLEMENT|Powdered Drink|Vita Cherry Sport N1244 (FutureCeuticals, Momence, IL)
223902800|NCT07063173|DIETARY_SUPPLEMENT|Commercially available 100% tart cherry juice|100% concentrated Montmorency cherry juice (CherryActive, Sunbury, UK)
223902801|NCT07063173|DIETARY_SUPPLEMENT|Placebo beverage|Placebo beverage
223902802|NCT07064525|DRUG|SPC1001 Low|low-dose combination therapy
223902803|NCT07064525|DRUG|SPC5002|low-dose combination therapy
223902804|NCT07064525|DRUG|SPC5003|low-dose combination therapy
223902805|NCT07064525|DRUG|SPC5004|low-dose combination therapy
223902806|NCT07063368|OTHER|Otago exercises and systematic desensitization with routine physical therapy|Warm-up (5 minutes) Marching in place (assisted), arm swings, side steps Otago Balance Exercises (7 minutes) Knee bends (with support), heel-to-toe stand (with support), side hip abduction (with support) Otago Strength Exercises (8 minutes) Ankle dorsiflexion, seated knee extensions, seated marching Routine Physical Therapy - Strength and Mobility Exercises (15 minutes) Assisted squats or sit-to-stand exercises, standing calf raises (with support), seated bicep curls, seated shoulder press Routine Physical Therapy - Flexibility and Stretching (5 minutes) Hamstring, quadriceps, shoulder, and neck stretches Relaxation Training (7 minutes) Review goals, PMR, deep breathing exercises Gradual Exposure and Visualization (10 minutes) Visualization of safe environments, standing up, walking on flat surfaces, and mildly fear-inducing situations (with assistance) Discussion and Feedback (3 minutes) Share experiences, provide feedback, assign homework
223902807|NCT07063368|OTHER|Otago Exercises and Routine physical Therapy|"Warm-up (10 minutes) Marching in place, arm swings, and side steps. Otago Balance Exercises (10 minutes) Knee bends, heel-to-toe stand, side hip abduction. Otago Strength Exercises (10 minutes) Ankle dorsiflexion, seated knee extensions, seated marching. Routine Physical Therapy - Strength and Mobility Exercises (20 minutes) Assisted squats or sit-to-stand exercises, standing calf raises with support, seated bicep curls, seated shoulder press.~Routine Physical Therapy - Flexibility and Stretching (10 minutes) Hamstring stretch, quadriceps stretch, shoulder and neck stretches, seated torso twist."
223902808|NCT07063368|OTHER|Systematic desensitization and routine physical therapy|"Warm-up (5 minutes) Marching in place, arm swings, and side steps. Routine Physical Therapy - Strength and Mobility Exercises (20 minutes) Assisted squats or sit-to-stand exercises, standing calf raises with support, seated bicep curls, seated shoulder press.~Routine Physical Therapy - Flexibility and Stretching (5 minutes) Hamstring stretch, quadriceps stretch, shoulder and neck stretches. Relaxation Training (10 minutes) Review goals and expectations, PMR, deep breathing exercises. Gradual Exposure and Visualization (15 minutes) Visualization of safe environments, standing up, walking on flat surfaces, and mildly fear-inducing situations (with assistance).~Discussion and Feedback (5 minutes) Share experiences, provide feedback, and assign homework."
223902809|NCT05891600|DEVICE|Smartclic|The SmartClic® autoinjector is a reusable, electromechanical, and single-patient device for the administration of subcutaneously administered biologics.
223902810|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snack with original level of sugar
223902811|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 2|Fruit snack with reduced level of sugar
223902812|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 3|Fruit snack with 0 added sugar - formulation 1
224276903|NCT02718287|BEHAVIORAL|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
224276904|NCT06480500|DRUG|Ketamine hydrochloride|55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
223902813|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 4|Fruit snack with 0 added sugar - formulation 2
223902814|NCT06458946|DIETARY_SUPPLEMENT|Fruit snack 5|Fruit snack from raisins
223902815|NCT06458946|DIETARY_SUPPLEMENT|Confection control|confection
223902816|NCT06185452|DRUG|Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.
223902817|NCT06185452|DRUG|Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration|Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.
223902818|NCT05453916|DRUG|Nitazoxanide 500Mg Oral Tablet|patients receiving treatment with Nitazoxanide 500 mg two times daily for 14 days
223902819|NCT05453916|DRUG|Rifaximin 550Mg Tab|patients receiving treatment rifaximin at a dose of 550 mg three times daily for 14 days
223902820|NCT06041581|BEHAVIORAL|Sleep Healthy Using The Internet (SHUTi)|Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
223902821|NCT06041581|BEHAVIORAL|Telephonic CBT-I|Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
223902822|NCT06041581|BEHAVIORAL|Face-to-Face CBT-I|Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
223902823|NCT06041581|OTHER|Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care|A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
223902824|NCT03951467|OTHER|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Three interviews between the patient and a health advisor trained for the study: two times before discharge from hospital and a telephone reminder within 3 weeks after discharge.~First and second interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: within 3 weeks after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations.~Two interviews by phone with a clinical reseach assistant at 30 days et 90 days after discharge which consist of questionnaire."
223902825|NCT02534168|DEVICE|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
223902826|NCT01370512|DRUG|Droxidopa|100 mg tablets by mouth three times a day
223902827|NCT01370512|DRUG|Pyridostigmine|60 mg tablets by mouth three times a day
223902828|NCT01370512|OTHER|Placebo|Looks exactly like the study drug but contains no active ingredients
224276905|NCT06480500|BEHAVIORAL|i-CBT (Internet-based Cognitive Behavioural Therapy)|Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
224276906|NCT06480500|DRUG|Midazolam Hydrochloride|55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.
224276907|NCT03747653|DRUG|ADVATE|Patients will be administered a single dose of ADVATE.
224276908|NCT03747653|DRUG|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
224276909|NCT05945992|BEHAVIORAL|Emotion regulation|Psycho-education elements concerning the emergence and functions of emotions, progressive muscle relaxation (PMR), analysis of emotional situations and group exercises
224276910|NCT05945992|BEHAVIORAL|Self-acceptance|Exercises and guided self-experience targeting heightened knowledge about oneself and acceptance of all personal strengths and weaknesses, exercises based on the internal family systems by R. Schwartz.
224276911|NCT05945992|BEHAVIORAL|Mindfulness|Guided mindfulness-exercises, different meditation techniques like body scan, breathing meditation. Reflection and exchange within the group
223715598|NCT06681571|OTHER|RSB|Rectus Sheath block will be performed immediately after the induction of anesthesia, under Ultrasond guidence.
223715599|NCT04262570|DEVICE|Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)|Non-invasive transcutaneous imaging of molecular muscle components
223902829|NCT03335670|DRUG|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
223902830|NCT06130410|BIOLOGICAL|COMIRNATY intramuscular injection|Booster injection in the muscle, 1 dose
223902831|NCT06259526|DRUG|Placebo group|(1 pill of 25 mg JS1-1-01 placebo pills +1 pill of 50 mg JS1-1-01 placebo pills+1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
223902832|NCT06259526|DRUG|JS1-1-01 low-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 placebo pills +1 pill of duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
223902833|NCT06259526|DRUG|JS1-1-01 pills; JS1-1-01 placebo pills; Duloxetine hydrochloride placebo capsules|(1 pill of 25 mg JS1-1-01 placebo pills+1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times/day, administered postprandial, for 8 consecutive weeks.
223902834|NCT06259526|DRUG|JS1-1-01 high-dose group|(1 pill of 25 mg JS1-1-01 pills +1 pill of 50 mg JS1-1-01 pills +1 pill of Duloxetine hydrochloride placebo capsule)/time, 2 times per day, administered postprandial, for 8 consecutive weeks.
223902835|NCT06259526|DRUG|Active drug group|(1 Duloxetine hydrochloride enteric coated capsule+1 pill of 25mg JS1-1-01 placebo pills+1 pill of 50mg JS1-1-01 placebo pills)/dose, 2 times per day, administered postprandial, for 8 consecutive weeks.
223902836|NCT06347822|BEHAVIORAL|Therapy Session|Single-session intervention (SSI) based on acceptance and commitment therapy (ACT) and solution-focused brief therapy (SFBT) principles
223902837|NCT05809453|DRUG|Cocaine|Cocaine (cocaine hydrochloride 4% nasal solution) will be administered (3 mg/kg) intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
223902838|NCT05809453|DRUG|Lidocaine|Lidocaine (lidocaine hydrochloride 4% nasal solution) will be administered (3 mg/kg) intranasally prior to entering the warm environmental conditions and performing 60 minutes of exercise.
223902839|NCT05030623|DRUG|Tadalafil 5Mg Tab|Tadalafil 5Mg Tab plus Fluoxetine 20 mg capsule
223902840|NCT05030623|DRUG|Placebo|Placebo Tab plus Fluoxetine 20 mg capsule
223902841|NCT05734833|DIETARY_SUPPLEMENT|Culturelle Probiotic + Fiber|The experimental group will receive the study product which is Culturelle Probiotic + Fiber
223902842|NCT05734833|OTHER|Placebo|The Placebo comparator arm will receive placebo sachets
223902843|NCT06355453|DEVICE|Goldcrest Patch and Three Patch Coupons|Goldcrest patch and three patch coupons will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
223902844|NCT06355453|DEVICE|Goldcrest Patch and Novii Patch|Goldcrest patch and Novii patch will be placed on subject abdomen for 18 hours (+/- 2 hours) of wear. Evaluation of skin integrity and patch performance will be assessed.
223902845|NCT04684940|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
223902846|NCT05159050|DRUG|Paclitaxel-loaded tumor penetrating microparticles|"Paclitaxel-loaded TPM, suspended in 0.5 L of 0.1% (w/v) polysorbate 80 in 0.9% sodium chloride is instilled into the peritoneal cavity over 3 to 5 minutes. Mixing of TPM is achieved by putting patient in 5 different positions for about 80 minutes.~Dose escalation, the starting dose of TPM is 50 mg/m\^2 paclitaxel-equivalents. Dose escalation will follow the Accelerated Titration Design. The dose levels to which patients will be assigned in sequential cohorts are listed below.~Dose escalation schedule of TPM, Dose Level 1\*: 50 mg/m\^2; Dose Level 2: 100 mg/m\^2; Dose Level 3: 135 mg/m\^2; Dose Level 4: 175 mg/m\^2; Dose Level 5: 200 mg/m\^2~\*Starting Dose"
223902847|NCT05867472|DRUG|Isoflurane Inhalant Product|Isoflurane will be administered using an inhalation device
223902848|NCT05867472|DRUG|Sevoflurane inhalant product|Sevoflurane will be administered using an inhalation device
223902849|NCT04891575|BEHAVIORAL|Active Control Intervention educational sessions|The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
224276912|NCT05945992|BEHAVIORAL|Resource activation|Exercises focusing on developing positive emotions and fostering personal strengths, based on the Positive Psychology movement of Martin Seligman, working on individual values, life goals and sense of life.
224276913|NCT05945992|BEHAVIORAL|Control component 1_social behaviors in groups|Control component for emotion regulation
223902850|NCT04891575|BEHAVIORAL|Family Dyad Intervention|The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
223902851|NCT00963417|OTHER|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
223902852|NCT00963417|PROCEDURE|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
223902853|NCT06787703|BEHAVIORAL|Psychological First Aid Intervention|"Psychological first aid is a compassionate and supportive presence designed to mitigate acute distress and asses the need for continued mental health care. The intervention aims to enhance the compassionate presence, assist with needs and promote adaptive functioning. The intervention encompasses seven main themes (RAPID model, emotion stabilization, self-compassion, reframing, instillation of hope and empowerment) that will be covered through a series of five training exercises conducted on 6 sessions. Each session ranged in duration from 30 to 45 minutes.~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition).~The program going along the RAPID PFA model, that represents a simple structure of (R for: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition). The"
223902854|NCT04982796|DRUG|Psilocybin|See description of psilocybin-enhanced psychotherapy arm.
223902855|NCT04982796|BEHAVIORAL|Treatment-as-usual|See description of treatment-as-usual arm.
224276914|NCT05945992|BEHAVIORAL|Control component 2_communication skills|Control component for self-acceptance
223902856|NCT04404881|DRUG|Bevacizumab (Avastin®)|"* Induction Period (first 3 months of bevacizumab treatment):~  \-- Bevacizumab: once every 2 weeks via intravenous infusion for up to 12 weeks.~* Maintenance Period (second 3 months of bevacizumab treatment):~  * Bevacizumab: once every 4 weeks via intravenous infusion for up to 12 weeks."
223902857|NCT05669976|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention integrates a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to mental health and social support resources (e.g., SGM-specific support groups within the community).
223902858|NCT05669976|BEHAVIORAL|Safety Planning Intervention|The Safety Planning Intervention (SPI) is a single-session, empirically supported, suicide prevention intervention. The patient navigator will deliver the SPI.
223902859|NCT04817319|PROCEDURE|Oral care with/without aerosolization|"These treatments involve instruments that produce aerosolization: ultrasonic scaler, rotary instrumentation for caries care, dental extraction, tooth polishing.~These care correspond to examinations of the oral cavity, intraoral X-rays or even periodontal pocket probing."
223902860|NCT03287817|BIOLOGICAL|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells with limited duration of anti-PD1 antibody (pembrolizumab).
223902861|NCT06960941|DIETARY_SUPPLEMENT|TrioBiotix360®|Dietary supplement combining prebiotics and probiotics to promote the balance of intestinal bacterial microflora.
223902862|NCT06960941|OTHER|Booklet with a series of postural hygiene exercises|The booklet will contain a series of postural hygiene exercises to be performed at home
223902863|NCT05365230|OTHER|On-demand personalized follow-up care|On-demand personalized follow-up care (on demand access to a WBCP nurse and an annual follow-up by telephone.
223902864|NCT05365230|OTHER|Guideline-based follow-up care (standard of care)|Follow-up care based on current standard of care guidelines.
223902865|NCT03994367|OTHER|High animal protein isolate|Increased dietary protein content from animal protein isolates
223902866|NCT03994367|OTHER|High animal protein whole food|Increased dietary protein content from animal protein whole food
223902867|NCT03994367|OTHER|High plant protein isolate|Increased dietary protein content from plant protein isolates
223902868|NCT03994367|OTHER|High plant protein whole food|Increased dietary protein content from animal protein whole food
223715600|NCT03676283|OTHER|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
223902869|NCT03854227|DRUG|PF-06939999 dose escalation|PF-06939999 orally at escalating doses on a continuous basis
223902870|NCT03854227|DRUG|PF-06939999 monotherapy|PF-06939999 at the recommended Phase 2 dose orally on a continuous basis
223902871|NCT03854227|DRUG|PF-06939999 in combination with docetaxel|PF-06939999 orally on a continuous basis in combination with docetaxel
223902872|NCT03668236|DRUG|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~* IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~* Fluids used for dehydration: Water or isotonic glucose should be used~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
223902873|NCT04863378|BEHAVIORAL|Walking conversational reminiscence|Triadic walking with prompted conversational reminiscence
223902874|NCT03798093|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
223902875|NCT03798093|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped within 60 seconds of delivery.
223902876|NCT06442527|DEVICE|Virtual Reality|Virtual reality gear and content will be used prior to TMS session as part of the provocation items
223902877|NCT05330351|DIAGNOSTIC_TEST|Gastric Ultrasound|The investigators will compare gastric fluid volume as determined by ultrasound pre-induction vs. gastric volume aspirated via an orogastric tube post-intubation. The results will be stratified into low risk, moderate risk and high risk for aspiration based on ultrasound exam by an investigator off-line.
223902878|NCT03818880|DEVICE|Novel spectacle lens design|Spectacle lens to control progression of myopia
223902879|NCT06134336|OTHER|Interview|No interventional or behavioral intervention will be applied. Only interviews will be conducted through a questionnaire.
223902880|NCT06132282|BEHAVIORAL|Substance Use and Health Risk Intervention (SUHRI)|Technology-based intervention designed as 4 sessions administered on a tablet as a self-directed approach (requiring an onsite proctor) for addressing factors that increase risk for significant health problems. Topics such as SU and risky sex are important but often sensitive or difficult for juvenile justice staff to address in their role as probation officers.
224276915|NCT05945992|BEHAVIORAL|Control component 3_stress management|Control component for mindfulness
224276916|NCT05945992|BEHAVIORAL|Control component 4_constructive conflict resolution|Control component for resource activation
224276917|NCT02457819|DRUG|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
224276918|NCT06217796|COMBINATION_PRODUCT|MydCombi|A single metered spray administered with the MydCombi dispenser
223902881|NCT06557330|DRUG|Bendamustine|Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.
223902882|NCT06557330|DRUG|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
223528880|NCT01193452|DRUG|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
223902883|NCT05138822|DRUG|GSK3882347|GSK3882347 will be administered on each dosing day.
223902884|NCT05138822|DRUG|Nitrofurantoin|Nitrofurantoin will be administered on each dosing day.
223902885|NCT05138822|DRUG|Placebo|Placebo matching study drug (GSK3882347) or Nitrofurantoin will be administered on each dosing day.
223902886|NCT05641441|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery
223902887|NCT04527029|OTHER|No interventions|It is an observational study. No interventions.
223902888|NCT03936959|DRUG|LY3434172|Administered IV
223902889|NCT06027567|DRUG|Semaglutide|Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
223902890|NCT06027567|DIETARY_SUPPLEMENT|Very Low Calorie Diet|Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
223902891|NCT06027567|BEHAVIORAL|Dietician counselling|Counselling by a dietician on weight loss through behavioural changes and life style intervention
223902892|NCT05345015|DEVICE|Radiofrequency Energy Transfer|"Radiofrequency Electrical Currents (TECAR) will be delivered using a winback system (Winback, Villeneuve-Loubet, France) propagating radiofrequency waves of 448 kHz using metallic electrodes via a coupling medium. Radiofrequencies will be used in the capacitive mode , which aims to treat superficial /soft tissues in the area. The active plate will be applied sequentially on the skin in the injured or painful region. The base plate will be located to the other side of the injured body region (for back thigh muscle injuries, for example, the base plate will be located on the frontal thigh area, to close the current circuit. Therapy will be applied for 20 minutes, with a target intensity of 40% and a frequency of 0.5Mhz."
223902893|NCT05345015|DEVICE|Transcutaneous Nerve Stimulation|Transcutaneous nerve stimulation (TENS) will be delivered using a Chattanooga Intellect Advanced Combo system (Chattanooga, Hixson, TN 3 7343, USA). Two electrodes will be placed on the skin at a distance so that they cover the entire painful area. The TENS asymmetric biphasic mode (phase 300 ms, frequency 80Hz, continuous cycle) will be applied. The intensity will be adjusted between 0 and 110A, such that it is tolerable by the participant. The total application time will be 20 minutes or equal to that applied for the TECAR group.
223902894|NCT04944706|DRUG|Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time|Take 3 times a day after meals,24 weeks
223902895|NCT04944706|DRUG|Qishen Yiqi dripping pills 4 bags/time|Take 3 times a day after meals,24 weeks
223902896|NCT04944706|DRUG|Qishen Yiqi dripping pills placebo 4 bags/time|Take 3 times a day after meals,24 weeks
223902897|NCT06338722|OTHER|Making it Work Systemic Sclerosis|One 2 hour virtual meeting per week for 5 weeks, plus an individual meeting with an occupational therapist and a vocational counselor
223902898|NCT05680753|BEHAVIORAL|Physiotherapy|Physiotherapy
223902899|NCT05537259|OTHER|Observation Group|No intervention; this is an observational study.
223902900|NCT06264635|BIOLOGICAL|Platelet-Rich-Plasma|PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.
223902901|NCT06264635|OTHER|Saline|Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
223902902|NCT05580419|BEHAVIORAL|4PCP Course|4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
223902903|NCT04510025|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
223902904|NCT03209102|OTHER|Clinical assessment|"* Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~* and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
223528881|NCT01193452|DRUG|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
223528882|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
223528883|NCT04959331|DRUG|Nitrofurantoin|Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
223528884|NCT04959331|DRUG|Pivmecillinam|Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
223902905|NCT03209102|BEHAVIORAL|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
223902906|NCT03209102|OTHER|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
223902907|NCT03209102|BIOLOGICAL|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
223902908|NCT04119843|DRUG|Mangoral|800 mg manganese chloride \[II\] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
223902909|NCT05172700|DRUG|Pirtobrutinib|Administered orally.
223902910|NCT06360263|COMBINATION_PRODUCT|Densah bur in combination with activated plasma albumin gel|Simultaneous implant placement after transcrestal maxillary sinus lifting using densah burs in combination with activated plasma albumin gel.(APAG). A full mucoperiosteal flap will be elevated, and then reflected with periosteal elevator application of first densah bur (the narrowest) with densifying mood (reverse) counterclockwise, 800-1500 revolutions per minute with copious irrigation until the sinus is reached confirm bur position with a radiograph. Then a wider densah bur (3.0) is used with the same mode and bouncing motion to elevate the sinus floor up to 3 mm in 1mm increments.The sequential densah bur will be used with the same mode and bouncing motion to elevate the the sinus floor 3 mm maximum. After achieving the final planned osteotomy diameter, the osteotomy will be filled with APAG. Then, the desired implant length is inserted.
223902911|NCT05992870|RADIATION|Neoadjuvant radiotherapy|"In case of neoadjuvant chemotherapy, RT will start 3-4 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions or 16 x 2.67Gy 5 fractions per week.~A skin-sparing mastectomy and a immediate implant-based breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment."
223902912|NCT04601857|DRUG|futibatinib and pembrolizumab (KEYTRUDA®))|Patients will receive futibatinib at an oral dose of 20 mg daily and pembrolizumab at an intravenous dose of 200 mg every 3 weeks
223902913|NCT05929430|BEHAVIORAL|Mindfulness program|Six weeks mindfulness program. The program is explained in arm descriptions.
223902914|NCT05929430|BEHAVIORAL|Mindfulness program with Virtual Reality|Six weeks mindfulness program. The program is explained in arm descriptions.
223902915|NCT05043870|DRUG|Infliximab and immunosuppressives|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks, the immunomodulatory agent was azathioprine 1-2mg/kg per day or methotrexate 10-25 mg/m2 week
223902916|NCT05043870|DRUG|Infliximab|the infusion of IFX (5mg/kg) were given at 0, 2, 6 weeks and then every 8 weeks
223902917|NCT04878549|DIAGNOSTIC_TEST|5-gene transcription signature|This is a prospective multisite diagnostic evaluation study to assess a novel approach to the diagnosis of enteric fever. The index test of host gene transcription responses by a 5 gene-signature will be compared to the reference test of blood culture confirmation for a diagnosis of enteric fever in patients with AUFI.
223902918|NCT06165367|DRUG|EmbryoGlue Medium|Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
223902919|NCT06533631|DEVICE|Portable low-field MRI (pMRI)|Participants will receive a pMRI during the study visit.
223528885|NCT04959331|DRUG|Fosfomycin Trometamol Salt|Fosfomycin 3 g one sachet, taken orally, for one day
223528886|NCT05662670|DRUG|WJ13404 tablets|"Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily.~(It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor).~Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D.~Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied."
223528887|NCT06226376|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes."
223528888|NCT03526172|PROCEDURE|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
223528889|NCT03526172|DEVICE|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
223528890|NCT03526172|DEVICE|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
223528891|NCT03526172|OTHER|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
223715601|NCT06711614|OTHER|Intervention Diet|Designed to increase Omega-3 Fatty Acids (Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA)), fruit, and vegetable intake, participants will receive grocery and meal deliveries for approximately 4-weeks via online ordering with dietician counselling.
223715602|NCT06711614|OTHER|Control Diet|Participants will receive weekly food subsidies for their groceries for 4-weeks (\~equivalent to the subsidies to provide groceries in the Intervention arm) but are free to purchase whatever they wish. The participants will continue to have dietician counseling during this time.
223902920|NCT06533631|DEVICE|3T MRI|Gold standard MRI for WMH. Participants will receive a 3T MRI during the study visit.
223902921|NCT05712512|BEHAVIORAL|Neurodevelopmental assessment|individual behavioral and socio-communicative assessment from 6 to 36 months
223902922|NCT05712512|OTHER|Electrophysiological and eyetracking recordings|Investigation of neural and behavioral biomarkers of autism from 6 to 24 months
223902923|NCT02841579|DRUG|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
223902924|NCT05317897|DIAGNOSTIC_TEST|Lung ultrasound examination|45 pediatric patients who will go elective repair of congenital acyanotic heart diseases will be included and will be examined with Lung ultrasound together with arterial blood gases preoperative and postoperative and given a score range from 0-3 according to number of B lines in each region and sensitivity of post-operative lung ultrasound score to extubation within 6 hours was examined.
223902925|NCT04885855|DRUG|Sofosbuvir 400 MG|Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
223902926|NCT04885855|DRUG|Ravidasvir 200mg|Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
223902927|NCT05380752|DRUG|TPOXX IV (Tecovirimat Injection, 10 mg/mL)|IV solution (10 mg/mL) must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to dosing. Once diluted, the drug product should be stored at 2-8°C (36-46°F) and used as soon as possible (i.e., not more than 24 hours after dilution). Given via an IV infusion pump over a 6 hour period, twice daily, and for up to 7 days, or until the physician determines oral TPOXX may be given
223902928|NCT05898711|DEVICE|Fish skin graft|Kerecis Fish Skin Graft - SurgiBind
223902929|NCT05694013|DEVICE|Roche DPM Module|Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support
223902930|NCT05694013|DRUG|Atezolizumab SC|Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)
223902931|NCT05694013|OTHER|Local SOC support|Participants will receive local SOC support
223902932|NCT06055075|DRUG|Forimtamig|Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
223902933|NCT06055075|DRUG|Carfilzomib|Carfilzomib will be administered via IV infusion in combination with forimtamig.
223902934|NCT06055075|DRUG|Daratumumab|Daratumumab will be administered via SC injection in combination with forimtamig.
223902935|NCT04373031|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
223902936|NCT04373031|DRUG|IRX 2|IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
223528892|NCT01380080|DRUG|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
223902937|NCT06530030|DRUG|efanesoctocog alfa|All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
223902938|NCT05113160|BEHAVIORAL|Conversation Treatment for Aphasia|Conversation treatment is a theoretically motivated approach in which a speech language pathologist facilitates discourse about topics of interest to the client using individualized, multi-modal supports. Treatment occurs either in groups of 6-8 people with aphasia or 2 people with aphasia. Individual communication goals are targeted for each group member within the context of naturalistic conversations.
223902939|NCT01551680|RADIATION|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
223902940|NCT06010641|OTHER|head-down position|-20° Trendelenburg as an adjunct to guideline-based treatment,
223902941|NCT05447312|OTHER|Adaptive Music Intervention|Music that has been enhanced by frequencies that are associated with positive feelings as measured by EEG data. Music will be delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning over and above traditional music therapy.
223902942|NCT05447312|OTHER|Traditional Music Intervention|Music that has not been enhanced by frequencies. Music is delivered through the Pi Electronic Inc.'s Venus Speaker that aims to promote psychosocial and cognitive functioning.
223902943|NCT06771908|DIAGNOSTIC_TEST|Conjunctival Swab|CFU/ml by bacterial species before and after prophylaxis.
223902944|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 1)
223902945|NCT05613036|DRUG|[¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2)|\[¹⁴C\]-BI 907828 mixed with BI 907828 (formulation 2)
223902946|NCT05613036|DRUG|BI 907828|BI 907828
223902947|NCT03358810|DEVICE|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
223528893|NCT01380080|DRUG|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
223528894|NCT01380080|DRUG|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
223902948|NCT03965468|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
223902949|NCT03965468|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
223902950|NCT03965468|DRUG|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
223902951|NCT03965468|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
223902952|NCT03965468|PROCEDURE|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
223902953|NCT03965468|RADIATION|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
223902954|NCT03965468|DRUG|Tremelimumab|Tremelimumab is a human mAb of the IgG 2 subclass that is directed against CTLA-4 (CD152), a cell surface receptor that is expressed primarily on activated T-cells and acts to inhibit their activation. Tremelimumab completely blocks the interaction of human CTLA-4 with CD80 and CD86, resulting in increased release of cytokines (interleukin-2 and IFN-γ) from human T-cells, peripheral blood mononuclear cells and whole blood.
223902955|NCT06465641|DRUG|Methylphenidate Hydrochloride|Methylphenidate hydrochloride in capsules
223902956|NCT06465641|DRUG|Placebo|Microcrystalline cellulose in capsules
223902957|NCT06159153|DIAGNOSTIC_TEST|Dynamic Ultrasonography assessment|Ultrasound evaluation that will be compared with an MRI.
223902958|NCT03945552|BEHAVIORAL|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
223902959|NCT04454489|DRUG|Pembrolizumab (immunotherapy)|Pembrolizumab 200 mg will be given every 3 weeks to tumor progression or treatment tolerance.
223902960|NCT04454489|RADIATION|Quad-shot palliative radiotherapy|"* Each cycle of quad-shot radiotherapy will be comprised of 14.8 Gy in 4 fractions (3.7 Gy per fraction) delivered twice daily (at least 6 hours apart) over two consecutive days.~* All patients will receive 1 cycle of quad-shot radiotherapy between ICI cycles 2-3.~* Subsequent cycles may occur between immunotherapy cycles 6-7 and 11-12, if more than 1 cycle can be safely delivered and the patient has experienced less than a partial response at protocol-specified tumor assessments (after C5 and C10). The eligibility for subsequent cycles will be at the discretion of the treating radiation oncologist.~Therefore, the total prescription dose will be:~* 14.8 Gy in 4 fractions for those that complete 1 cycle (all patients will receive 1 cycle)~* 19.6 Gy in 8 fractions for those that complete 2 cycles~* 44.4 Gy in 12 fractions for those that complete 3 cycles"
223902961|NCT05026710|DEVICE|Silicone (Coloplast Imajin Hydro) ureteral stent|During the end of the standard of care ureteroscopy the silicone stent will be placed.
223902962|NCT05026710|DEVICE|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)|During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
223902963|NCT04886726|DRUG|uhCG/EGF|PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
223902964|NCT05419193|DRUG|Propranolol Hydrochloride|"Day of randomization:~propranolol IV vp for 7 days after randomization"
223902965|NCT05419193|OTHER|control group|Patients will receive usual care and drug use in hospital
223902966|NCT05449743|OTHER|Spa therapy|Thermal treatments among the following: pool, Kneipp pool, high pressure shower under immersion in a swimming pool, general jet shower, cataplasm in multiple local application, compress, massage under water or with thermal derivatives, walking corridor
223902967|NCT05802615|BEHAVIORAL|PARITY|The PARITY program reinforces strengths through consistent, community-based Black doula support and protective asset (personal strengths) focused messaging. PARITY promotes wellness-related behaviors (nutrition, physical activity, sleep, and healthcare adherence) and promotes and builds empowered strengths (self-efficacy, social support, motivation, resilience, problem-solving, and self-regulation) through mobile technology and doula support.
223902968|NCT05802615|OTHER|Usual Care|Participants will obtain prenatal care from their usual care provider and a handout on healthy pregnancy.
223719344|NCT00187486|PROCEDURE|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
223902969|NCT04611971|DRUG|Benlysta|Benlysta injection will be administered subcutaneously.
223902970|NCT04611971|DRUG|Candin|Candin will be administered intradermally along with NaCl solution.
223902971|NCT06035224|DRUG|AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally|AK104 (10mg/kg ,Q3W，intravenously) plus lenvatinib(\<60kg，8 mg qd；≥60kg，12mg qd, orally.
223902972|NCT01501955|DEVICE|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
223902973|NCT01501955|DEVICE|Stanmore|Stanmore hip prosthesis
223902974|NCT04075864|BEHAVIORAL|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
223902975|NCT06389084|BEHAVIORAL|Parents Together parenting course|parenting course and coaching calls
223902976|NCT05034328|DEVICE|Healsea® Children|Children will be administered Healsea Children , one puff (1-2 sec) in each nostril twice a day for 10 days on top of conventional therapies, as needed
223902977|NCT05034328|OTHER|Conventional therapies for common cold|Children will receive conventional therapies for common cold, nasal irrigation excluded (antipyretics, mucolytics, decongestants, antitussives, systemic and topical corticosteroids, antibiotics)
223902978|NCT02895464|OTHER|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
223902979|NCT05039788|OTHER|Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements|"Measurement of systolic and diastolic blood pressure, impedancemetry, weight, creatinemia and Pro-BNP measurements At D30 and D90~Measurement of systolic and diastolic blood pressure, impedancemetry, weight, 3 times a week between D30 and D90 post-transplant,"
223902980|NCT05653453|DEVICE|Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel|"Device: Tumor treating fields Subjects will use tumor treating fields until disease progression or for a maximum of 30 months.~Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months."
223902981|NCT05653453|DRUG|Gemcitabine hydrochloride and albumin binding paclitaxel|Drug: Gemcitabine hydrochloride and albumin binding paclitaxel Subjects will receive Gemcitabine hydrochloride and albumin binding paclitaxel until disease progression or for a maximum of 30 months.
223902982|NCT05172999|DEVICE|levonorgestrel-releasing intrauterine system|Enrolled patients will be inserted this device for treating AEH to preserve fertility for 3-6 months or longer till complete response or operation if treatment fails, and the device may be removed if treatment changes.
223902983|NCT05172999|DRUG|Polyethylene Glycol Loxenatide|Initiate injection of Loxenatide will be 0.1mg per week, if the patient can tolerate, the dose will be increased to 0.2mg per week, or else 0.1mg per week will be injected and the injection will last for no more than 28 weeks. If the patient cannot tolerate the least 0.1mg/week, she must be excluded from this trial.
223902984|NCT06460038|DRUG|Tenapanor|Inhibitor of NHE3
223902985|NCT06460038|DRUG|Placebo|Placebo drug
223902986|NCT06802692|BEHAVIORAL|VR glasses and meditation music group|Starting 15 minutes before the ET procedure, participants in the VR glasses and meditation music group will be shown a video of the sea, underwater and forest with VR glasses and will be made to listen to meditation music. At the same time, meditation music will be played. When the ET procedure is completed, the video and meditation music will be stopped. After the procedure, the VR glasses will be disinfected with antiseptic spray before being used on another patient, and disposable ear pads will be placed on the headphones after each patient. Anxiety, pain, vital signs (pulse, diastolic blood pressure, systolic blood pressure, respiration and peripheral oxygen saturation) will be evaluated 15 minutes before and immediately after the ET procedure. 15 minutes after the ET procedure, satisfaction with the ET procedure, the application of VR glasses and listening to meditation music will be evaluated.
223902987|NCT06802692|BEHAVIORAL|Meditation music group|Meditation music group participants will listen to meditation music through headphones starting from 15 minutes before the ET procedure until the procedure is completed. When the ET procedure is completed, the meditation music will be stopped. After the procedure, disposable ear pads will be placed on the headphones for each patient. Anxiety, pain, vital signs (pulse, diastolic blood pressure, systolic blood pressure, respiration and peripheral oxygen saturation) will be assessed 15 minutes before and immediately after the ET procedure. 15 minutes after the ET procedure, satisfaction with the ET procedure and listening to meditation music will be assessed.
223902988|NCT05553301|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5407|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
223902989|NCT05553301|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|"Pharmaceutical Form: Liquid frozen solution in a vial~Route of Administration: Intramuscular Injection"
223902990|NCT05553301|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
223902991|NCT05553301|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|"Pharmaceutical Form: Liquid suspension for injection in pre-filled syringe~Route of Administration: Intramuscular Injection"
223902992|NCT06799663|OTHER|activity questionnaire|Physical activity questionnaire will be applied on children and adolescents to compare the effect of smart phone on physical fitness
223902993|NCT06799663|OTHER|Raven's Progressive Matrices test (RPM)|Raven's Progressive Matrices test will be applied on children and adolescents to compare the effect of smart phone on intelligence
223902994|NCT06799663|OTHER|Postural assessment software|Postural assessment software will be applied on children and adolescents to compare the effect of smart phone on posture
223902995|NCT06536452|OTHER|Non-Interventional Study|Non-interventional study
223902996|NCT05768763|BEHAVIORAL|Community-enhanced reach activities|We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care, working closely with community health workers, integrated in the community health system.
223902997|NCT05768763|BEHAVIORAL|Person-centered care delivery|Structured approach to provide patient-centered biomedical options for HIV prevention (dynamic choice prevention). Tailored services for HIV treatment support using structured life stage evaluation and assessment plan (LEAP) for youth, pregnant women, and persons with or at risk of HIV viral non-suppression, that includes counselling for heavy alcohol users. Structured approach to offer telehealth for severe hypertension follow up.
223902998|NCT05768763|OTHER|Data system enhancement to improve reach and person-centered delivery|Both community-enhanced reach and person-centered delivery will be strengthened through a customized in-country Ministry of Health-compatible community health worker smartphone app and two-way data system linking community health workers and clinical records.
223902999|NCT05768763|BEHAVIORAL|Standard of Care|Standard of Care in Uganda and Kenya
223903000|NCT02474160|OTHER|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
223903001|NCT06801561|PROCEDURE|Laser therapy|This group will be subjected to laser therapy. Er,Cr:YSGG will be used (Waterlase®, Biolase, USA) of a wavelength of 2780 nm at a power of 0.75 W using a frequency of 20 Hz and pulse duration of 140 µs. (33) Irradiation will be performed on the entire occlusal and at the hypomineralized areas. (34) The laser tip will pass in a uniform scanning motion steadily for 20 sec with relative isolation with 11% air and no water-cooling system. During the laser treatment, all safety measures will be followed.
223903002|NCT06801561|PROCEDURE|Glass ionomer sealant|This group will receive glass ionomer sealant. Conditioning of the surface will be done using polyacrylic acid (10%) conditioner for 20 seconds, then rinsed and dried. Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
223903003|NCT06073080|OTHER|Protein Nutrition During Recovery|Dietary Protein Nutrition Distribution
223903004|NCT05651308|BEHAVIORAL|Care coordination delivered based on perceived need|If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
223903005|NCT05651308|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
223903006|NCT02532244|OTHER|sample collection|collection of blood
223903007|NCT05227222|DEVICE|PEP-device|PEP-device
223903008|NCT03625167|OTHER|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
223903009|NCT04465708|BEHAVIORAL|Homework, Organization, and Planning Skills|HOPS is a 16-session, skills training program, provided individually to students in grades 6 through 8 who have OTMP skills deficits that contribute to academic difficulties. HOPS includes two parent consultations and one teacher consultation to promote generalization and maintenance of effects.
223903010|NCT03720197|OTHER|Online questionnaire - Phase 1|Draw an overall picture of the population with type 1 diabetes in Canada in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
223903011|NCT03720197|OTHER|Online questionnaire - Phase 2|Characterize the causes, experience and consequences of hypoglycemia.
223903012|NCT03720197|OTHER|Online questionnaire - Phase 3|Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
223903013|NCT03720197|OTHER|Food questionnaire|24-hour food recall questionnaire
223903014|NCT03720197|OTHER|Pedometer|Participants will wear a podometer for 14 consecutives days
223903015|NCT03720197|OTHER|Waist circumference|Participants will be asked to measure their waist circumference
223903016|NCT03720197|OTHER|Blood and urine tests|Participants will be invited to send us their latests blood and urine test results.
223903017|NCT03720197|OTHER|List of medications|Participants will be invited to send us their list of medications
223903018|NCT03720197|OTHER|Continuous glucose monitor|Participants will be invited to send us the latest report of their continuous glucose monitor
223903019|NCT05825677|DEVICE|tDCS actif|Active brain stimulation
223903020|NCT05825677|DEVICE|tDCS Sham|Sham brain stimulation
223903021|NCT05290363|OTHER|Blood sampling|A 51 mL blood sample will be collected during the study
223903022|NCT05290363|OTHER|synovial aspiration|If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study
223903023|NCT05919979|BEHAVIORAL|34-hour fasting in sedentary conditions|Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
223903024|NCT05919979|BEHAVIORAL|34-hour fasting with high-intensity exercise|Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
223903025|NCT05188287|BEHAVIORAL|HealthyCells|Smoking cessation smartphone app
223903026|NCT05254574|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
223903027|NCT05254574|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
223903028|NCT02608320|DRUG|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
223903029|NCT02608320|DRUG|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
223903030|NCT02608320|DRUG|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
223903031|NCT02608320|DRUG|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
223903032|NCT02608320|DRUG|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
223903033|NCT02608320|DRUG|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
223903034|NCT06102733|BEHAVIORAL|Rehabilitation therapy|Chronic pain rehabilitation therapy
223903035|NCT04602091|OTHER|no intervention|no intervention
223903036|NCT06275360|DRUG|Nivolumab|Carboplatin, paclitaxel, and nivolumab for three cycles (for squamous cell lung cancer) or Carboplatin, pemetrexed, and nivolumab for three cycles (for lung adenocarcinoma) Followed by radiotherapy (60 Gy in 30 fractions) Followed by adjuvant nivolumab (six cycles)
223903037|NCT04990089|DEVICE|VIVO|VIVO is a per-procedural planning tool designed to non-invasively identify the origin of a ventricular arrhythmia.
223903038|NCT02969707|DEVICE|MagPro TMS system (MagVenture, Denmark)|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process. rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark). sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).sham rTMS will be delivered using a MagPro TMS system (MagVenture, Denmark).
223903039|NCT02969707|BEHAVIORAL|Hypnosis|Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnotizability will be measured using the Hypnotic Induction Profile before and after administration of real vs. sham rTMS. Hypnosis will be employed to influence Stroop performance (conflict detection) and for pain management. The hypnotic instructions for this will be pre-recorded and played during fMRI.
223903040|NCT04986995|DRUG|Opicapone|Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
223903041|NCT05203523|DEVICE|transcranial alternative current stimulation (tACS)|A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.
223903042|NCT05203523|OTHER|cognitive exercises|"Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant."
223903043|NCT05572047|DEVICE|Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
223903044|NCT05928091|OTHER|Phone call to an expert team|Patients will be treated as the expert said when the investigator called him
223903045|NCT05283304|DRUG|Buprenorphine injection (BUP-Inj)|Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
223903046|NCT05283304|OTHER|Placebo injection|Sublingual buprenorphine induction, then Placebo injectable (300 mg)
223903047|NCT06074952|OTHER|Aquafina(water), Coca-cola(coke), Tapal(tea), Shan(turmeric), Krikland(honey)|Distilled water will be used as a control medium in the control group. In group B, tea, coke, turmeric, and honey solutions will be used. In group C, tea, coke, turmeric, and honey solutions will be used.
223903048|NCT04314713|DRUG|Scopolamine Hydrobromide Trihydrate|Scopolamine Hydrobromide Trihydrate Intramuscular Injection
223903049|NCT04778046|DRUG|Hyperpolarized 129Xe|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
223903050|NCT06250153|BEHAVIORAL|m-SBIRT (mobile-Screening, Brief Intervention, and Referral to Treatment)|M-SBIRT is a mobile phone-based program designed to enhance delivery of Screening, Brief Intervention, and Referral to Treatment (SBIRT), an evidence-based approach for mental health and substance use screening and treatment. The program utilizes mobile phone text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to substance use disorder treatment services.
223903051|NCT04639232|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
223903052|NCT04639232|DIETARY_SUPPLEMENT|Prob-milk|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
223903053|NCT04639232|DIETARY_SUPPLEMENT|Voluntas-Prob|Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.
223903054|NCT05910229|OTHER|Phone call|In the experimental arm the patient will be called 3 days before the CT scan
223903055|NCT05597358|RADIATION|High Intensity Laser Therapy (HILT)|Nd:Yag 1064 nm pulsed high intensity laser will be applied to the vulvar area.
223903056|NCT05597358|RADIATION|Sham High Intensity Laser Therapy|Nd:Yag 1064 pulsed high intensity laser deactivated probe will be applied to the vulvar area.
223903057|NCT03316573|DRUG|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
223903058|NCT05410496|DRUG|Tenofovir Alafenamide 25 MG|To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
223903059|NCT03222999|OTHER|No intervention planned|No intervention planned
223903060|NCT06362967|COMBINATION_PRODUCT|Immunoadsorption or plasma exchange combined with rituximab, high-dose IVIG|For allogeneic haematopoietic stem cell transplantation patients with high titers of anti-HLA antibodies present in the body, a desensitisation regimen of immunosorbent or plasma exchange combined with rituximab and high-dose IVIG is used prior to transplantation.
223903061|NCT00248287|DRUG|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
223903062|NCT00248287|DRUG|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
223903063|NCT05384431|DIETARY_SUPPLEMENT|Muscle5 and TRIM7|Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
223903064|NCT05384431|OTHER|Mixed exercise|Mixed exercise (aerobic and resistance) three days per week for 12 weeks
223903065|NCT06324942|OTHER|Surgeon-administered Transversus Abdominis Plane Block 0.25% bupivicaine 0.25 mL/kg|Surgeon-administered Transversus Abdominis Plane Block
223903066|NCT03760575|DRUG|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
223903067|NCT03760575|PROCEDURE|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
223903068|NCT03760575|DRUG|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
223903069|NCT03760575|DRUG|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
223903070|NCT06069791|DRUG|Bupivacaine Injection|subcutaneous injection around bilateral greater occipital nerves
223903071|NCT06120972|DRUG|Olaparib tablet|Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
223903072|NCT04282122|RADIATION|Radiotherapy|curative-intent radiotherapy
223903073|NCT05974150|OTHER|Web based survey|online weekly survey
223903074|NCT06256458|DEVICE|NanoBone® Bone Graft|The surgical technique used by the surgeon and the choice of the specific NanoBone product is or was determined solely by the surgeon and is independent of this observational study.
223903075|NCT04186689|OTHER|Routine Dental Examination|Routine dental examination for the pre-school children Questionnaire for their mothers
223903076|NCT05670587|DEVICE|A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection|A wearable cough monitoring device, the Strados Labs Remote Electronic Stethoscope Platform (RESP)ᵀᴹ sensor, with an accompanying mobile application (App) for data collection.
223715603|NCT06722248|BEHAVIORAL|high fidelity simulation-based training|"The intervention is a two-hour high-fidelity simulation training session focusing on newborn assessment, care practices, skin-to-skin contact, and breastfeeding. It uses SimBaby mannequins and breastfeeding models to mimic the hospital environment. Scenarios are tailored to nursing students' learning levels and reviewed by experienced midwives.~The training includes:~Prebriefing: Introduction of learning objectives, scenario background, simulation familiarization, confidentiality discussions, and ground rules.~Intervention: Scenario-based training on baby care and breastfeeding. Debriefing: Plus-delta debriefing model reviewed by simulation educators. The training will be conducted in the nursing simulation laboratory."
223903077|NCT05930418|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac Magnetic Resonance provides more sensitive measure of ventricular volume and ejection fraction as well as novel markers of tissue characterization and edema assessment.
223903078|NCT06784089|OTHER|Geriatric Nutrition Risk Index|GNRI will be calculated from the formula \[1.489 X albumin (g/L)\] + \[41.7 (weight/ideal weight)\]. If the patient's weight is more than their ideal weight, the weight/ideal weight ratio will be accepted as 1. The ideal weight will be calculated for men with the formula \[(Height-100) -(Height-150/4)\], for women with the formula \[(Height-100) -(Height-150/2.5)\]. According to the results, patients will be determined as no risk (GNRI \> 98), low risk (92-98), severe/moderate risk (GNRI \< 92).
223903079|NCT06784089|OTHER|visual analog scale|During the VAS evaluation, the patient will be asked to indicate the location of the pain on a 100 cm long scale where 0: no pain, 100: maximum pain, and the value shown by the patient will be recorded.
223903080|NCT05832437|BEHAVIORAL|BREATHE-Peds Intervention|BREATHE-Peds utilizes Primary Care Providers (PCPs) to deliver a 4-step script that was created by and tailored to Black adults' asthma and inhaled corticosteroid beliefs, as well as their Asthma Control Questionnaire (ACQ) score, measured just prior to the medical visit. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
223903081|NCT05832437|BEHAVIORAL|Control Intervention|The control intervention will be a 9-minute scripted discussion tailored to living a health lifestyle. Step 1: Review of BMI, current diet and exercise (3 minutes). Step 2: Diet/exercise counseling (3 minutes). Step 3: Plan for goal attainment (3 minutes).
223903082|NCT06259981|DRUG|GLY-200|2.0 g GLY-200 (4 x 0.5 g capsules) orally twice daily
223903083|NCT06259981|DRUG|Placebo|4 placebo capsules orally twice daily
223903084|NCT05681624|OTHER|Maternal oxygen supplementation|Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
223903085|NCT05681624|OTHER|Room air|Room air, no mask
223903086|NCT06542263|DEVICE|CPAP|For the non-CPAP group, the intervention includes catheter ablation and conventional treatment for AF combined with OSA; For the CPAP group, the intervention includes catheter ablation and CPAP treatment for AF combined with OSA
223903087|NCT06823817|DIAGNOSTIC_TEST|colpscope|Colposcopic cervical biopsy
223903088|NCT06823245|DRUG|HS-10241|HS-10241 administered orally once at D1
223903089|NCT06714656|OTHER|Food Swap|Personalised food swaps and dietary advice on how to incorporate these swaps into their usual diet
223903090|NCT06582043|OTHER|SCARCr tester 1|Twice daily
223903091|NCT06582043|OTHER|Placebo|Twice daily
223903092|NCT05603910|DRUG|Lenvatinib|Lenvatinib capsules taken daily by mouth
224276919|NCT06353308|BEHAVIORAL|Sexual Violence Prevention|The intervention included a game, five short videos, two posters, and five online quizzes, which were provided with a frequency of two posts per week and a final real-time online workshop. Materials included content on the spectrum of gender and sexual identities and orientations, gender and sexual roles, consent and communication, body positivity and self-acceptance, sexual pleasure and desire, as well as risky sexual behavior associated with dating app use and the legal issues and risks of sexual assault, such as precautionary steps and available resources.
223903093|NCT05603910|DRUG|Pembrolizumab|200 mg Pembrolizumab administered intravenously (IV) once on Days 1, 22 and 43.
223903094|NCT05603910|RADIATION|Hypofractionated External Beam Radiation Therapy|HypoFx whole pelvic EBRT begins on Day 22 and continues for a total of 16 fractions of radiation given at a dose of 2.5 Gy per fraction for a total dose of 40.0 Gy delivered to the pelvis. A pelvic boost HypoFx EBRT consisting of 7 fractions of radiation given at a dose of 2.5 Gy per fraction that will be delivered to site(s) of gross disease of at least 1.0 cm in size. An additional boost total dose of 17.5 Gy administered will be administered over a period of 1.5 to 2.0 weeks.
223903095|NCT06115135|DRUG|Venetoclax|All subjects in Dose Level 0 will receive 1) venetoclax, PO, at 400 mg every day (QD) on Days 1-28 of a 28-day cycle, 2) dexamethasone 40 mg IV, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle; and 3) isatuximab 10mg/kg, IV, on Days 1, 8, 15, and 22 of the first 28-day cycle, and then Days 1 and 15 during subsequent 28-day cycles.
223903096|NCT06777706|DIETARY_SUPPLEMENT|QD (Qing Dai)|Children age 4 years to 17.9 years with mild to moderate UC will receive QD and dosing will be stratified based on body weight at time of enrollment.
223903097|NCT04186117|OTHER|Blood sample|Blood sample before any treatment
223903098|NCT05836155|DIETARY_SUPPLEMENT|Intervention|multispecies probiotic
223903099|NCT04649905|PROCEDURE|Surgical Treatment|Surgical standard-of-care treatment for knee OCD
223903100|NCT04649905|PROCEDURE|Nonoperative Treatment|Nonoperative standard-of-care treatment for knee OCD
223903101|NCT06823726|OTHER|12-week Taekwondo training|"12-week structured Taekwondo training program under the supervision of qualified instructors following a standardized protocol.~Frequency: 3 sessions per week Session Length: 60 minutes per session"
223903102|NCT04476303|DRUG|BEY2153|Capsule
223903103|NCT05531474|PROCEDURE|Bariatric Surgery|Bariatric surgery involves either gastric bypass, sleeve gastrectomy, or duodenal switch, performed at the discretion of the surgeon and according to local practice standards.
223903104|NCT05531474|BEHAVIORAL|Medical Weight Management|The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
223903105|NCT05940194|BIOLOGICAL|COVIVAC vaccine|For prevention Covid-19
223715604|NCT06722248|BEHAVIORAL|conventional training|Conventional training includes lecture, tutorial and basic lab with low-fidelity mannequins.
223903106|NCT06347549|DIAGNOSTIC_TEST|Various intensities of inspiratory muscle training|"Each participant will be instructed to use a pressure threshold inspiratory loading device to perform, in random order, 10 breaths at an inspiratory intensity of 30%, 40%, 50%, 60%, 70%, and 80% of their maximum inspiratory pressure (MIP). A rest period of 15 minutes will be allowed between each inspiratory pressure set of 10 breaths. Simultaneous surface electromyographic (sEMG) recording of the right sternocleidomastoid muscle and ultrasound of right diaphragmatic thickness will be conducted during each breath.~The entire recording procedure will be repeated on a separate day. During the repeat measurements, participants will be provided with specific breathing instruction to focus on the use of the diaphragm and to inhale air to the lower part of the chest."
223903107|NCT02667418|DRUG|Fidaxomicin|200 mg PO twice daily for 10 days
223903108|NCT02667418|DRUG|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
223903109|NCT02667418|DRUG|Vancomycin|125 mg PO for times daily for 10 days
223903110|NCT06175832|DRUG|Elonva®|Single injection
223903111|NCT06175832|DRUG|Puregon®|Multiple injections
223903112|NCT06175832|DRUG|Orgalutran®|Multiple injections
223903113|NCT06175832|DRUG|Gonapeptyl®|Double injection
223903114|NCT06175832|DRUG|Cerazette®|Oral tablet
223903115|NCT01543763|DRUG|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
223903116|NCT03937843|DRUG|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
223903117|NCT03937843|DRUG|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
223903118|NCT03937843|DRUG|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
223903119|NCT03128021|DRUG|Escitalopram Pill|Double-blinded, randomly assigned
223903120|NCT03128021|OTHER|Placebo|Double-blinded, randomly assigned
223903121|NCT03128021|DRUG|Levomilnacipran Pill|Double-blinded, randomly assigned
223903122|NCT03584633|DRUG|Indocyanine Green|The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
223903123|NCT04668560|BEHAVIORAL|Five ways to wellbeing course|A behavioural course over six sessions. Teaching the participants in doing avtivities to promote wellbeing
223715605|NCT06157918|DRUG|SYHA1813 oral solution (2.0g:25mg)|SYHA1813 oral solution, 25mg, oral
223715606|NCT06157918|DRUG|SYHA1813 oral solution (20ml:200mg)|SYHA1813 oral solution, 25mg, oral
223715607|NCT04460482|DEVICE|Near-infrared spectroscopy (NIRS)|NIRS-guided PCI
223903124|NCT06172335|DIETARY_SUPPLEMENT|Cetoleic acid|Very long monounsaturated fatty acid (C22:1n-11)
223903125|NCT06172335|DIETARY_SUPPLEMENT|Control oil|Mix of oils with low cetoleic acid content
223903126|NCT05470036|BEHAVIORAL|Educational intervention.|Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
223903127|NCT05166577|DRUG|Nanatinostat|Phase 1b: Nanatinostat dose escalation starting at 20 mg orally daily, 4 days per week, then Phase 2: Nanatinostat at the confirmed recommended Phase 2 dose
223903128|NCT05166577|DRUG|Valganciclovir|Phase 1b: Valganciclovir starting at 900 mg orally daily, then Phase 2: Valganciclovir at the confirmed recommended Phase 2 dose
223903129|NCT05166577|DRUG|Pembrolizumab|Phase 2: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
223903130|NCT05347446|PROCEDURE|Hybrid ESD|Method of removing colon lesion
223903131|NCT05347446|PROCEDURE|Non-hybrid ESD|Method of removing colon lesion
223903132|NCT05995886|BEHAVIORAL|Wiidookaage'win Facebook Group|An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
223903133|NCT06437080|DRUG|Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg|01 tablet daily for 03 months, This is assigned to Group A.
223903134|NCT06437080|DRUG|Ferric Carboxymaltose|03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
223903135|NCT05433298|BIOLOGICAL|Mesenchymal stem cell|Administration of advanced cell product
223903136|NCT05433298|OTHER|Placebo|Ringer's lactate, albumin and heparin solution
223903137|NCT04054193|DRUG|Fosaprepitant Dimeglumine|Participants received IV fosaprepitant dimeglumine ≤115 mg on Day 1 and ≤80 mg on Days 2 and 3 (dose adjusted for age).
223903138|NCT04054193|DRUG|5-HT3 antagonist|All participants received an oral 5-hydroxytryptamine (serotonin; \[5-HT\]) 3 receptor antagonist on Day 1 and had the option to take on Days 2-3. The dose was as per product label or standard of care.
223903139|NCT04054193|DRUG|Dexamethasone|Participants received optional oral dexamethasone at the investigator's discretion according to product label or standard of care.
223903140|NCT02503423|DRUG|ASTX660|described above
223715608|NCT04460482|DEVICE|Angiography|Angiography guided PCI
224276920|NCT06353308|BEHAVIORAL|Sexual health intervention|This general online sexual health education consisted of online videos, quizzes and game that covered a wide range of diverse topics on love, sex and relationships such as healthy and respectful relationships, body self-esteem, sexual identity and orientation, sexual rights and decision making, in addition to the conventional focus on sexual dysfunction and disease aversion.
224276921|NCT01155102|DRUG|Anastrozole|1 mg tablet
223903141|NCT05816616|DIAGNOSTIC_TEST|Functional imaging of the lungs using MagniXene (hyperpolarized xenon-129) MRI|Patients for this observational study will be selected on a voluntarily basis from the ongoing Airflow-3 interventional clinical trial at Temple University Hospital. For this observational sub-study, patients will have their lung function measured using hyperpolarized xenon-129 MRI prior to TLD treatment, and 90 days post-treatment for a better understanding of treatment effects. This sub-study does not influence in any way the patient treatment or the outcomes for the main Airflow-3 TLD clinical trial.
223903142|NCT02966873|DRUG|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
223903143|NCT02966873|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
223903144|NCT02966873|DRUG|Inactive Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
223903145|NCT02966873|OTHER|Functional magnetic resonance imaging (fMRI)|Participants will be given the option to complete Functional magnetic resonance imaging (fMRI) at two timepoints (pre-treatment and end of treatment).
223903146|NCT02966873|OTHER|Proton magnetic resonance spectroscopy (MRS) Imaging|Participants will be given the option to complete magnetic resonance spectroscopy (MRS) at two timepoints (pre-treatment and end of treatment).
223903147|NCT03080974|DRUG|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
223903148|NCT03080974|PROCEDURE|Irreversible Electroporation|Non-thermal ablation of tumor
223903149|NCT03866408|BEHAVIORAL|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
223903150|NCT03866408|DRUG|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
223903151|NCT03866408|BEHAVIORAL|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
223903152|NCT03866408|DRUG|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
223903153|NCT06611319|DRUG|Prevention of Venous Thromboembolism|Direct oral anticoagulant
223903154|NCT06611319|DRUG|Placebo Oral Tablet|Placebo
223903155|NCT06417554|DRUG|SHR-A2102|SHR-A2102
223903156|NCT06417554|DRUG|SHR-A2102 ; Adebrelimab injection|SHR-A2102 + Adebrelimab injection
223903157|NCT03084536|DRUG|Bupivacaine|-Given after general anesthesia
223903158|NCT03084536|DRUG|Gabapentin|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
223715609|NCT06893315|RADIATION|Photobiomodulation Therapy|Photobiomodulation (PBM) is a non-invasive therapy that uses low-level light, typically from lasers or Light Emission Diodes (LEDs), to stimulate cellular function and promote healing. It works by delivering specific wavelengths of light to target tissues, which enhances mitochondrial activity and increases adenosine triphosphate (ATP) production. PBM is commonly used for pain relief, reducing inflammation, and accelerating tissue repair in conditions like muscle injuries, arthritis, and skin disorders.
223903159|NCT03084536|DRUG|Celecoxib|"* As per routine care~* Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~* Naproxen will be substituted for celecoxib in patients with sulfa allergies."
223903160|NCT03084536|DRUG|Acetaminophen|-As per routine care
223903161|NCT03084536|DRUG|Midazolam|-As per routine care
223903162|NCT03084536|DRUG|Fentanyl|-As per routine care
223903163|NCT01792687|DRUG|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
223903164|NCT01792687|DRUG|Abiraterone acetate|1,000 mg, oral, daily
223903165|NCT01792687|DRUG|Prednisone|5 mg, oral, daily
223903166|NCT04710641|DRUG|MTL-CEBPA|Administered once every 3 weeks on Day 1 of each 3 week cycle.
223903167|NCT04710641|DRUG|Sorafenib|Oral adminstration twice a day
223903168|NCT04504227|DIETARY_SUPPLEMENT|Thin liquid swallows|Thin liquid swallows of formula or breastmilk or other liquid
223903169|NCT04504227|DIETARY_SUPPLEMENT|Slightly thickened liquid swallows|Slightly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
223903170|NCT04504227|DIETARY_SUPPLEMENT|Mildly thickened liquid swallows|Mildly thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
223903171|NCT04504227|DIETARY_SUPPLEMENT|Moderately thickened liquid swallows|Moderately thick liquid swallows of formula thickened with rice cereal or breastmilk or other liquid thickened with Gelmix
223903172|NCT06828783|DIETARY_SUPPLEMENT|ginger extract|Participants will receive a ginger-based capsule
223903173|NCT06828783|OTHER|Placebo|Participants will receive a placebo capsule
223903174|NCT06755983|OTHER|Endorphin massage|For Group 1 (experimental group), patients admitted to the clinic one day before surgery will complete the first two sections of the Patient Diagnosis Form (I. Individual characteristics and II. Health and illness-related data), the Surgical Fear and Anxiety Scale, and the VAS scales after the endorphin massage. The patients will be informed that the endorphin massage will last approximately 20 minutes. According to evidence-based current guidelines, it is stated that the intensity of the patient's pain should be assessed during the preoperative period for pain management planning and goals in the postoperative period. Therefore, patients' pain scores will also be recorded preoperatively using the VAS scale. On the morning of the surgery, before going to the operating room, the endorphin massage will be repeated, and the scales will be applied again. After surgery, patients will have their pain levels measured using the VAS at hours 0, 4, 8, 16, and 24, and the amount of analgesics tak
223903175|NCT05702723|BEHAVIORAL|Smart-3RP|9 sessions of mind-body group treatment program via Zoom platform.
223903176|NCT05702723|BEHAVIORAL|Enhanced Usual Care|14-week group-based, online support group through CancerCare.org.
223903177|NCT05511246|DRUG|Venous ethanol|Cannulation of coronary vein or veins in the VT substrate and balloon injection of ethanol
223903178|NCT05511246|PROCEDURE|Catheter ablation|Endocardial catheter ablation of VT substrate
223903179|NCT01043224|DRUG|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
223903180|NCT05145192|DEVICE|COSMED K5 CPET (Cardiopulmonary Exercise Test)|In this randomized crossover trial of eligible adults, we will compare peak measurements of oxygen consumption (VO2) and carbon dioxide production (VCO2) during three maximal cardiopulmonary stress exercise tests (CPET), each seven to ten days apart. Subjects will be randomized into either the K5 or ParvoMedics (PM) group for their first CPET using a 1:1 randomization scheme and will serve as their own control in the subsequent test seven to ten days after the previous one. After both a K5 and a PM CPETs have been completed, the participants will complete an additional K5 CPET for test-retest reliability. A within-subjects analysis will be performed.
223903181|NCT05145192|DEVICE|ParvoMedics CPET|ParvoMedics CPET
223903182|NCT03946618|DEVICE|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
223903183|NCT04082143|DEVICE|Allograft mucosal enhancement with dental implant|implant placement with allograft mucosal enhancement
223903184|NCT04082143|DEVICE|No allograft mucosal enhancement at time of dental implant placement|implant placement without allograft mucosal enhancement
223903185|NCT06408506|PROCEDURE|Re-Entry Surgery|Re-entry surgery 4 months after the insertion of the implants to reveal implants after osseointegration
223903186|NCT06408506|PROCEDURE|Probing peri-implant bone|Probing peri-implant bone with Dental Probe during surgery
223903187|NCT06408506|PROCEDURE|Scanning peri-implant bone|Scanning peri-implant bone during surgery
223903188|NCT06408506|PROCEDURE|Conventional Impressions|Conventional Impressions during surgery
223903189|NCT06408506|PROCEDURE|Implant Surgery|Placement of 6 implants in the edentulous mandible
223903190|NCT06408506|PROCEDURE|Healing procedure|"All 6 Implants in all patients are let to heal for 4 Months under the same conditions:~The most distal implants are left submerged. The most mesial implants are left transgingival and the Implants in the middle are immediately loaded using gold bar retained dentures"
223903191|NCT04006782|DEVICE|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
223903192|NCT03576885|DRUG|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
223903193|NCT03576885|DRUG|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
223903194|NCT05073458|DRUG|parsaclisinib|parsaclisib will be administered QD orally
223903195|NCT05073458|DRUG|placebo|placebo will be administered QD orally follwed by Parsaclisinib in the open label period
223903196|NCT05971485|DRUG|Melatonin 10 mg|Melatonin 10 mg will be used. 5 mg·kg-1 dissolved in 2 ml of distilled water via enteral route in one single dose 30 minutes before the venous cannula insertion
223903197|NCT05971485|OTHER|Placebo|The placebo group will receive 2 ml of distilled water as a placebo 30 minutes before venous cannula insertion.
223903198|NCT04680221|DRUG|Liposomal bupivacaine|Deposition of liposomal bupivacaine
223903199|NCT04680221|PROCEDURE|TAP block|Transversus abdominis plane block performed to deposit anesthetic
223903200|NCT04680221|DRUG|Deposition of saline|Deposition of saline
223903201|NCT05183048|DRUG|[89Zr]Panitumumab Tracer|All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
223903202|NCT02938377|BEHAVIORAL|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
223903203|NCT02938377|BEHAVIORAL|CBT4CBT|9 computerized modules delivered at the participant's pace
223903204|NCT02938377|DRUG|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
223903205|NCT03337607|DEVICE|rESWT|"rESWT will be performed as follows:~* Four rESWT sessions~* One rESWT session per week~* 4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~* rESWs applied at 15 Hz~* Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~* No application of local anaesthetics"
223903206|NCT03337607|DRUG|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
223903207|NCT03337607|DRUG|Eperisone|3 x 50 mg per day for four weeks
223903208|NCT05577390|OTHER|Intraneural Facilitation Therapy Treatment|Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
223903209|NCT05577390|OTHER|Standard Physical Therapy Treatment|The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
223903210|NCT06438133|OTHER|CIMON|The sensor assess changes in the circumference of the limb and will be applied to the lower limb before compression bandaging is applied.
223903211|NCT06438133|OTHER|Sens Motion|The sensor assess physical activity and the amount of time spent at rest, standing, walking, running and count steps.
223903212|NCT02780219|OTHER|stable amino acid infusion|stable isotopes Such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
223903213|NCT02780219|OTHER|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
223903214|NCT02780219|OTHER|24-hour post exercise amino acid infusion|stable isotopes such as L-\[ring-13C6\]-Phenylalanine, L-\[ring-D4\]Tyrosine, L-\[Methyl-D3\]Tau-Methylhistidine, trans-\[2,5,5-D3\]4-Hydroxy-L-proline, L-\[Guanido-15N2\]-Arginine, L-\[4,4,5,5-D4-5-13C\]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-\[1,2-13C2\]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-\[methyl-D3\]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-\[3,3,4,4-D4\]Homocysteine, L-\[1,2-13C2\]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-\[Dimethyl-13C2\]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-\[3,4-methyl-13C3\]isovaleric acid, 13C3-glycerol is given IV simultaneously
223903215|NCT05683691|DEVICE|Vanquish System|Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.
223903216|NCT03824132|BEHAVIORAL|Improvisational comedy classes|6 consecutive improvisational comedy classes
223903217|NCT03824132|BEHAVIORAL|Waitlist control|After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
223903218|NCT06096311|OTHER|Interviews|Interviews
223903219|NCT01897168|DEVICE|No intervention|
223903220|NCT05785741|DRUG|DB-1310|Administered I.V.
223903221|NCT05785741|DRUG|Trastuzumab|Administered I.V.
223903222|NCT05785741|DRUG|Osimertinib|Oral
223903223|NCT06340763|DEVICE|JETi Hydrodynamic Thrombectomy System|The JETi Hydrodynamic Thrombectomy System is a hydro-mechanical aspiration system intended for the removal of intravascular thrombus. The system is comprised of the JETi Catheter, JETi Pump Set, and JETi Saline Drive Unit (SDU), accessory cart, suction tubing, and non-sterile canister set. The JETi System is designed to simultaneously deliver a stream of high-pressure saline via a displacement pump to the distal tip of the JETi Catheter, while aspirating thrombotic material macerated by the saline stream.
223903224|NCT05716243|DEVICE|The nociception level index monitorization|The nociception level index (NOL) is one of the nociception monitors and stands out from the others with its multi-parameter evaluation. It is generated from five different parameters (heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives).
223903225|NCT05716243|DEVICE|The nociception level index measurement;postoperative|The nociception level index (NOL) will be used postoperatively
223903226|NCT04845191|BIOLOGICAL|hAd5-S-Fusion+N-ETSD vaccine|hAd5-S-Fusion+N-ETSD is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen S fusion protein and N with an enhanced T-cell stimulation domain.
223903227|NCT04704843|DRUG|Guselkumab|Guselkumab will be administered as IV infusion (induction dose) and SC injection.
223903228|NCT04704843|DRUG|Placebo|Matching placebo to guselkumab will be administered as IV infusion (induction dose) and SC injection.
223903229|NCT04053075|OTHER|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
223903230|NCT04053075|OTHER|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
223903231|NCT05686850|PROCEDURE|High-Flow Oxygen|Humidified and heated oxygen with a gas flow at least 50 L/min through nasal cannula
223903232|NCT05686850|PROCEDURE|Non invasive ventilation|NIV will be carried out in pressure-support mode with a minimal pressure-support level of 5 cmH2O targeting a tidal volume around 6 to 8 mL/kg of predicted bodyweight, a positive end-expiratory pressure (PEEP) level at least 8 cm H2O, and FiO2 adjusted to obtain adequate oxygenation
223903233|NCT05873673|DRUG|Coenzyme Q10|cystic jaw defect filled with coenzyme Q10 gel
223903234|NCT05873673|DRUG|control group|cystic jaw defect filled with placebo gel
223903235|NCT06538870|PROCEDURE|Placement of dental implants|Dental implants will be placed in the edentulous area as per standard surgical procedure and as appropriate to bring the patient to standard of care restoratively.
223903236|NCT03235544|DRUG|Parsaclisib|Parsaclisib tablets administered orally with water and without regard to food.
223903237|NCT06025435|OTHER|SAIA-HIV-SSP|The Systems Analysis and Improvement Approach (SAIA) is an evidence-based, multicomponent implementation strategy for improving the delivery of appropriate clinical services for HIV prevention and treatment. It involves five cyclical steps including (1) analyzing service delivery data to identify priority areas for system improvements, (2) mapping processes and building consensus around programmatic modifications to address priority areas, (3) implementing programmatic modifications, (4) assessing effects of programmatic modifications on improving delivery of services across the cascade, and (5) repeating steps 1-4 as needed.
224276922|NCT01729026|OTHER|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
223903238|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
223903239|NCT05698771|DIETARY_SUPPLEMENT|nicotinamide mononucleotide|The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects. A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
223903240|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of n=6 healthy individuals (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
223903241|NCT05698771|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|A total of n=6 individuals with Parkinson's disease (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
223903242|NCT02466737|PROCEDURE|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
223903243|NCT02466737|PROCEDURE|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
223903244|NCT02671890|DRUG|Chemotherapy|
223903245|NCT02671890|DRUG|Disulfiram|Given PO
223903246|NCT02671890|DRUG|Gemcitabine Hydrochloride|Given IV
223903247|NCT02671890|OTHER|Laboratory Biomarker Analysis|Correlative studies
223903248|NCT06323707|BEHAVIORAL|Exercise|Eight sessions of moderate intensity aerobic exercise using recumbent bike within the cancer institution.
223903249|NCT06323707|BEHAVIORAL|Self-management e-module|Eight 15 minute self-management e-modules related to exercise and physical activity for cancer survivors.
223903250|NCT05805280|DEVICE|intravascular ultrasound-guided group|intravascular ultrasound use
223903251|NCT05805280|DEVICE|angiography-guided group|angiography-guided use
223903252|NCT05643638|BIOLOGICAL|CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)|Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
223903253|NCT05643638|BIOLOGICAL|Placebo|The placebo product is identical to CYP-001, except that it contains no active agent
223903254|NCT05643638|DRUG|Corticosteroids|All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
223903255|NCT03653676|OTHER|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
223903256|NCT06339398|BEHAVIORAL|Aerobic exercise|Standardized volume of aerobic exercise, measured as METs-minutes/week
223903257|NCT03696680|RADIATION|FSRT Stereotactic radiation therapy|For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
223903258|NCT06147791|DEVICE|External scrotal drainage|Application of external scrotal drainage during three-component penile prosthesis placement
223903259|NCT06560476|OTHER|Data collection|Subject's data will be collected from patients that are undergoing care using the Optilume drug-coated catheter system.
223903260|NCT06453980|DEVICE|sham tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 1 session.
223903261|NCT06453980|DEVICE|active tDCS|Participants will receive HD-tDCS at 3 milliAmp for 20 minutes, for 1 session.
223903262|NCT05116241|BIOLOGICAL|BPZE1 pertussis vaccine and placebo|Live attenuated pertussis vaccine and placebo
223903263|NCT05116241|BIOLOGICAL|BPZE1 pertussis vaccine and Boostrix|Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine
223903264|NCT05116241|BIOLOGICAL|Placebo and Boostrix|Tetanus, diphtheria, and aP vaccine and placebo
223903265|NCT05009797|PROCEDURE|atrial fibrillation catheter ablation|The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
223903266|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) automatic oxygen flow titration|Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
223903267|NCT03614507|DEVICE|FreeO2 (modèle FO2-220-00) manual oxygen flow titration|Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
223903268|NCT04845503|RADIATION|MR-guided Radiotherapy|Total Dose 37,5 Gy, Single Dose 7,5 Gy, 5 Fractions applied in 1-2 weeks
224276923|NCT03710590|OTHER|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
224276924|NCT03710590|OTHER|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
223903269|NCT06260228|BEHAVIORAL|HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
223903270|NCT06561321|DRUG|Tapinarof|Daily topical Tapinarof use will stop disease advancement and improve the quality of life in patients with palmoplantar keratoderma, through its AhR \& NRF2 agonism properties.
223903271|NCT06134154|OTHER|Endoscopic insufflation gas|Carbon dioxide gas versus air for endoscopic insufflation
223903272|NCT04114084|PROCEDURE|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
223903273|NCT04097730|DRUG|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
223903274|NCT04097730|DRUG|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
223903275|NCT04097730|DRUG|Riboflavin Ophthalmic|All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea.
223903276|NCT04097730|OTHER|Topical Placebo|Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
223903277|NCT04853576|GENETIC|EDIT-301|Administered by IV infusion after myeloablative conditioning with busulfan.
223903278|NCT04830800|BIOLOGICAL|COVIVAC|COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19
223903279|NCT04830800|BIOLOGICAL|Phosphate-buffered saline|Phosphate buffer solution (pH 7.2), manufactured by IVAC
223903280|NCT06559852|BEHAVIORAL|Yoga|Participants will engage in a 12-week virtual yoga course to assess impact on endometriosis-related pain
223903281|NCT04285515|DRUG|Lumateperone|Lumateperone 42mg oral capsule
223903282|NCT04285515|DRUG|Placebos|Placebo oral capsule
223903283|NCT06159075|BEHAVIORAL|Video|A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
223903284|NCT06411028|DIAGNOSTIC_TEST|Polymyography|We will measure muscle activity using surface electromyography and tremor using inertial measurement units while subjects perform rest, posturing and kinetic tasks.
223903285|NCT06411028|DIAGNOSTIC_TEST|Muscle ultrasound|We will obtain B-mode images and videos of upper extremity muscles of the most affected upper extremity.
223903286|NCT06411028|DIAGNOSTIC_TEST|(Functional) magnetic resonance imaging|Subjects will undergo (f)MRI scanning involving concurrent electromyography, accelerometry and functional magnetic resonance imaging.
223903287|NCT06411028|DIAGNOSTIC_TEST|Clinical assessment|We will assess tremor and dystonia severity using clinical scales.
224276925|NCT03710590|OTHER|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
224276926|NCT03710590|OTHER|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
223903288|NCT06411028|DIAGNOSTIC_TEST|Questionnaires|We will collect patient-reported outcomes.
223903289|NCT06411028|DRUG|botulinum toxin injection (BTX A)|Three consequetive botulinum toxin injections of the upper extremities
223903290|NCT05204563|DRUG|Combination of Imipenem/Cilastatin and XNW4107|Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
223903291|NCT05204563|DRUG|Imipenem/Cilastatin/Relebactam|Imipenem/Cilastatin/Relebactam 1.25 g for Injection
223903292|NCT06016608|DIAGNOSTIC_TEST|Magnetic Resonance Angiography, Ocular OCTA, CT Angiography|Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
223903293|NCT03075748|DEVICE|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
224276927|NCT03710590|OTHER|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
223903294|NCT05130476|PROCEDURE|Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography|During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
223903295|NCT04508907|DRUG|Mavyret|Mavyret and Zetia for 8 days to prevent HCV infection in solid organ recipients
223903296|NCT03802682|DRUG|Apalutamide|Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
223903297|NCT04615143|DRUG|Tislelizumab|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.
223903298|NCT04615143|DRUG|Tislelizumab combined with Levatinib|Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
223903299|NCT00293839|DRUG|oxybutynin chloride|
223903300|NCT05946616|OTHER|Transcranial alternating current stimulation (tACS) combined with behavioral intervention|Transcranial alternating current stimulation (tACS) combined with behavioral intervention (memory interference).
223903301|NCT05946616|OTHER|Inactive (sham) stimulation combined with behavioral intervention|Inactive (sham) stimulation combined with behavioral intervention (memory interference)
223903302|NCT05557773|OTHER|Home Based Traditional Scoliosis Exercises|Patients in this group will receive posture exercises, strengthening exercises, diaphragmatic breathing exercises and stretching exercises.
223903303|NCT05557773|OTHER|Core Stability Training|Patients in this group will receive traditional scoliosis exercises. In addition, the training group will receive core stabilization exercises for multifidus, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, iliopsoas, gluteus maximus, and pelvic floor muscles.
223903304|NCT05456490|DRUG|Liposomal Bupivacaine 13.3|Injection into the Intrathecal space
223903305|NCT05456490|DRUG|Bupivacaine|Injection into the Intrathecal space
223903306|NCT05456490|OTHER|Placebo|Injection into the Intrathecal space
223903307|NCT03930498|DRUG|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
223903308|NCT03930498|DRUG|Chemotherapy|Cisplatin and Gemcitabine
223903309|NCT03930498|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
223715610|NCT06893315|OTHER|Hospital Standard Protocol of treatment for pain and healing|Medical team evaluations are conducted daily throughout the hospitalization period, and anti-inflammatory medications (ketoprofen ), analgesics (dipyrone), and, in cases where vulvar edema is observed, ice packs are prescribed. In addition to the standard treatment described, the health care team routinely offers patients the use of laser therapy (photobiomodulation) once a day during hospitalization. Patients who agree to the laser therapy receive both treatments.Patients who do not accept receiving PBM receive exactly only the same standard routine care described. These protocols are standardized at the hospital, and this observational study did not interfere with any care practices.
223903310|NCT06192095|DEVICE|Skin barrier film|Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
223903311|NCT02626533|PROCEDURE|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
223903312|NCT04753697|DRUG|CC-93538|Subcutaneous
223903313|NCT04753697|OTHER|Placebo|Subcutaneous
223903314|NCT06539247|COMBINATION_PRODUCT|Motor Relearning Program with Electrical Muscle Stimulation (MRA + EMS)|This arm received a 30-minute motor relearning program focused on improving foot drop and gait patterns and Electrical Muscle Stimulation (EMS) for Targeted Activation (10 minutes) with 40 mA (default) adaptive, considering both intensity and duration for safe foot lift during walking.
223903315|NCT06539247|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation Technique with Electrical Muscle Stimulation (PNF + EMS)|"This arm received a 30-minute intervention combining Proprioceptive Neuromuscular Facilitation (PNF) techniques and EMS. The program consisted of:~PNF Techniques for Neuromuscular Facilitation (20 minutes) and Electrical Muscle Stimulation (EMS) for Muscle Response Enhancement (10 minutes): Similar to Arm 1, EMS applied to the affected ankle dorsiflexors for 10 minutes with the same parameters."
223903316|NCT03441321|OTHER|Lifestyle and Values Intervention|Participate in Facebook group focusing on avoiding tanning and promoting healthy body image
223903317|NCT03441321|OTHER|Lifestyle Intervention|Participate in Facebook group focusing on other health topics
223903318|NCT03441321|OTHER|Survey Administration|Ancillary studies
223903319|NCT05975359|DEVICE|Interi Manifold Drain System|The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.
223903320|NCT05975359|DEVICE|Jackson Pratt Drain System|The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
223903321|NCT01658930|PROCEDURE|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
223903322|NCT01658930|PROCEDURE|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
223903323|NCT03889093|OTHER|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
223903324|NCT04763330|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) consists of Collaborative Safety Planning, a VA usual care practice. It is a tool that Veterans can use when they are in an acute suicidal crisis. The condition is considered enhanced because Veterans in this condition receive 6 sessions total, Safety Planning which is delivered in 1-2 sessions and 4-5 sessions of check-ins with a brief assessment. Safety Planning involves a worksheet completed by the patient in collaboration with a health provider.
223903325|NCT04763330|BEHAVIORAL|Problem Solving Therapy (PST) plus EUC|"Veterans randomized to this condition received EUC and PST. EUC is delivered in both conditions to ensure the safety of all Veterans enrolled in the study. In addition to EUC, Veterans in this condition receive PST, which teaches patients a structured planful problem solving approach to: 1) identify problems and set goals, 2) generate alternative solutions, 3) select a solution based on cost-benefit analysis, and 4) devise and implement a plan for the solution and assess its effectiveness in solving the problem. This contemporary PST protocol also teaches tool kits to address obstacles highly pertinent to the challenges faced by older Veterans with mental health disorders and active suicidal ideation: emotion dysregulation, hopelessness, and feeling overwhelmed by too much information (brain overload) or stress."
223903326|NCT04850898|BIOLOGICAL|SAB-176|Treatment of influenza
223903327|NCT04850898|OTHER|Placebo|Placebo Control
223903328|NCT06280547|OTHER|Oral health education|Oral Health Education Program performed in the school.
223903329|NCT04328584|PROCEDURE|surgical navigation system|Navigation system providing surgeons with an additional view of the chest wall lesion
223903330|NCT05465031|DRUG|Sacubitril-valsartan|Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
223903331|NCT05465031|DRUG|Placebo|Placebo matching the sacubitril/valsartan (Entresto®) administered in the target dose matching the dosing of 200 mg b.i.d. (97/103 mg) for the period of 24 months. In case of intolerance of target dose of placebo, the physician-in-charge will be able to reduce the dose to placebo matching the dose of 100 mg b.i.d. (49/51mg). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of placebo matching the dose of 200 mg b.i.d.
223903332|NCT06200467|DRUG|BI 456906|Solution for injection
223903333|NCT06200467|DRUG|Placebo to BI 456906|Solution for injection
223903334|NCT06200467|DRUG|Moxifloxacin|Film-coated tablet
223903335|NCT06200467|DRUG|Placebo to moxifloxacin|Film-coated tablet
223903336|NCT03701763|DRUG|Apremilast (CC-10004)|Apremilast (CC-10004)
223903337|NCT03701763|OTHER|Placebo|Placebo
223903338|NCT06640413|DRUG|[177Lu]Lu-OncoFAP-23|3.7, 7.4, or 11.1 GBq to define the RD
223903339|NCT06640413|DRUG|L19IL2|22.5 Mio IU
223903340|NCT03571321|DRUG|Ruxolitinib|"Participants will receive one of 3 doses \[taken by mouth\] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~* Days 1-14 and 29-43~Interim maintenance regimen:~* Days 1-14 and 29-43~Delayed Intensification regimen:~* Days 1-14 and 29-43"
223903341|NCT03571321|DRUG|Cyclophosphamide|"Remission consolidation regimen:~* 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~* 1000 mg/m2 IV on Day 29"
223903342|NCT03571321|DRUG|Cytarabine|"Remission consolidation regimen:~* 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~* 75 mg/m2/day IV or SC on Days 29-32 and 36-39"
223903343|NCT03571321|DRUG|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~* 60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~* 75 mg/m2 on Days 1-84"
223903344|NCT03571321|DRUG|Vincristine|"Remission consolidation regimen:~* 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~* 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
223903345|NCT03571321|DRUG|Pegaspargase|"Remission consolidation regimen:~* 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~* 2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~* 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
223715611|NCT06815237|DIETARY_SUPPLEMENT|Kenetik|Ketone supplement is randomly given once.
223715612|NCT06815237|OTHER|Alcohol beverage|Alcohol beverage is randomly given once. Participants will receive the alcohol beverage that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.050%
223903346|NCT03571321|DRUG|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~* 375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~* 375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~* 375 mg/m2 IV on Days 1 and 8"
223903347|NCT03571321|DRUG|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal \[IT\] administration).~Remission consolidation regimen:~* 15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~* 15 mg on Days 1 and 31~Delayed Intensification regimen:~* 15 mg on Days 1, 29, and 36~Maintenance Therapy:~* 15 mg on Day 1~* 15 mg on Day 29 (First 4 courses only)"
223903348|NCT03571321|DRUG|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~* 100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
223903349|NCT03571321|DRUG|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~* 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~* 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
223903350|NCT03571321|DRUG|Doxorubicin|"Delayed Intensification regimen:~* 25 mg/m2 IV on Days 1, 8, 15"
223903351|NCT03571321|DRUG|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~* 60 mg/m2 on Days 29-42"
223903352|NCT03571321|DRUG|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~* 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~* Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given\]"
223903353|NCT06266338|DRUG|Pembrolizumab|200 mg IV q 3 weeks
223903354|NCT06266338|DRUG|Lenvatinib|20 mg PO daily
223903355|NCT05068310|DEVICE|Cellular resolution full-field optical coherence tomography|Device: ApolloVue® S100 Image System
223903356|NCT05068310|DEVICE|Confocal microscopy|Device: Vivascope® will be used for skin imaging for a subset of skin lesions.
223903357|NCT05068310|DEVICE|Optical coherence tomography imaging|Device: Vivosight® will be used for skin imaging for a subset of skin lesions.
223903358|NCT05068310|DEVICE|Dermoscopy imaging|Device: Dermoscopy imaging will be conducted using but not limited to dermoscope DermLite FotoX®
223903359|NCT05501574|DRUG|Tacrolimus Inhalation Powder|Tacrolimus powder for inhalation to prevent acute allograft rejection
223903360|NCT05501574|DEVICE|Plastiape RS00 Dry Powder inhaler device|dry powder inhaler device
223903361|NCT05966532|BEHAVIORAL|Hot Cognitive Task|"1. Emotion processing:~   * Participants will be shown a series of faces that appear quickly and be asked to identify what emotion is shown.~  * Participants will be shown a face of an emotion and indicate if participant can see the emotion changing.~  * Participant will be shown a series of emotions and asked to respond to only a specific emotion.~2. Motivation reward and processing:~   * Participant will play with a simulated roulette and make a bet to evaluate their decision-making behavior.~  * Participant will be shown colored circles and choose the one more likely to win money.~3. Impulsivity:~   • Participant will be shown a series of stimuli where they will be asked to respond to the correct stimulus.~4. Social cognition:~   * Participant will be shown a series of moral situations in which a character is accidentally or intentionally harmed and be asked to rate the degree of guilt from the perspective of the victim or perpetrator."
223903362|NCT05966532|BEHAVIORAL|Cold cognitive tasks|"* Montreal Cognitive Assessment (MoCA) - This will ask participants questions related to their cognition such as visuospatial skills, naming, memory, attention, language, and recall.~* Measurement of Everyday Cognition (ECog) - This scale will ask participants about their everyday memory, language, visuospatial ability, organization, and divided attention.~* Test of Premorbid Function (TOPF) - This test will evaluate memory performance and abilities of stud participants before onset pre-morbid status.~* California Verbal Learning Test -3rd Edition (CVLT-3) -This test will measure verbal learning and memory of study participants.~* Three tests from the Delis-Kaplan Executive Function System (D-KEFS; Verbal Fluency, Color-Word Interference, and Tower Tests). -These measures assess word finding and problem-solving ability."
223903363|NCT05966532|OTHER|Structural magnetic resonance imaging (sMRI)|This is a non-invasive procedure to assess the structure and function of participant's brain. Structural neuroanatomical data will be acquired using structural magnetic resonance. Imaging (sMRI) with the University of Texas Southwestern (UTSW) 3T (three Tesla field) MRI scanner. Prior to participation, the investigator's team will screen participant's to ensure eligibility to participate in the sMRI scan.
223903364|NCT05966532|OTHER|Magnetoencephalography imaging (MEG)|This is a non-invasive procedure to measure participant's brain activity. Participants will be sitting inside the machine in a chamber, with more space than a traditional MRI machine. A hat will be placed on top of participant's head which records their brain activity. Resting-state and task-based MEG recordings will occur in a three-layer magnetically shielded room (MSR) following our UTSW Advanced Neuroscience Imaging Research (ANSIR) established procedures. Before the scan, five coils will be secured to participant's head and a three-dimensional (3D) digitizer will be used to map the location of the coils, fiducials, and scalp surface. During recording, an electric current with a unique frequency label (i.e., 320 Hz) will be fed to each coil, which will permit real time head location tracking and subsequent offline head motion correction.
223903365|NCT05966532|BEHAVIORAL|four self-report forms per the requirement of the NIH Common Data Elements project|1\) DSM-5 Level 1 Cross Cutting Symptom Measure - Adult Report; a measure of multiple psychiatric symptoms, 2) Generalized Anxiety Disorder-7 (GAD-7; a measure of anxiety symptom severity), 3) Patient Health Questionniare-9 (PHQ-9; a measure of depression symptom severity), and 4) World Health Organization Disability Assessment Scale-2.0 (WHODAS-2.0; a measure of overall general functional status)
223903366|NCT05966532|BEHAVIORAL|Four self-report measures to assess interpersonal functioning|1\) Social Adjustment Scale - Self-report Short Form (SAS-SR: Short), 2) Inventory of Interpersonal Problems (IIP-64), 3) Social Network Index (SNI), 4) Interpersonal Support Evaluation List - 12 Items (ISEL-12).
223903367|NCT05966532|BEHAVIORAL|Clinical assessments|A Demographic and a Medical History Form will be completed. The Mini International Neuropsychiatric Interview (MINI-7.0 for DSM-5) is a structured psychiatric interview that will confirm presence of MDD and any exclusionary neuropsychiatric disorders. To measure depression symptoms/severity, primarily we will use the Clinician Rated Inventory of Depressive Symptomatology (IDS-C), Menstrual history and pregnancy tests for female participants.
224276928|NCT03710590|OTHER|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
224276929|NCT00852917|DRUG|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
224276930|NCT00852917|DRUG|Placebo|One Placebo tablet daily.
224276931|NCT05676983|OTHER|Spiky balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
224276932|NCT05676983|OTHER|Pediatric neurodevelopmental therapy|Bobath therapy
224276933|NCT05676983|OTHER|smooth balance disc|Balance discs consist of smooth and rough surface. Balance training is given to children with cerebral palsy on these two surfaces. Thanks to its balance disc structure, it plays an active role in the development of balance.
224276934|NCT05375019|BEHAVIORAL|Positive discipline program|The intervention group was provided with 8 weekly sessions of a 90 minutes positive discipline program
224276935|NCT05375019|BEHAVIORAL|active control group|free interaction group consisting of topics determined by the families.
224276936|NCT03307564|DEVICE|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
224276937|NCT05962450|BIOLOGICAL|iNKT Cells|the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.
224276938|NCT05962450|DRUG|PD-1|Intravenous infusion, according to the drug instructions.
224276939|NCT05962450|DRUG|Regorafenib|Oral administration, according to the drug instructions.
223715613|NCT06778447|OTHER|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
223715614|NCT06778447|OTHER|Sham|A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.
223903368|NCT05966532|OTHER|ATHF|Psychotropic medication use/ treatment resistance level will be measured/documented with the Antidepressant Treatment History Form-Short-Form (ATHF-SF)
223903369|NCT06396026|DRUG|TLL-018 tablets|Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks
223903370|NCT06396026|DRUG|Placebo tablets|Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.
223903371|NCT06369116|DEVICE|INSTI HCV Self Test|"Each participant will be presented with a packaged self-test and asked to conduct self testing. The Trained Observer will only watch the participant process at a short distance and take notes on the process; at no point will the observer respond to questions or assist with the testing process - only to encourage the participant to try to figure out the process as best they can use the instruction sheet.~The participant will then be permitted to perform the self-test and read their self test result. The observer is also going to observe the test result interpreted by the lay user and also themselves. After this step is complete, the Trained Observer will then perform fingerstick sample collection from lay user and run the sample on INSTI® HCV Self Test. The Trained Observer will then draw a venous whole blood sample from the participant for laboratory testing and final diagnosis will be given to the participant once laboratory results have been received."
223903372|NCT03382106|DRUG|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
223903373|NCT03382106|DRUG|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
223903374|NCT03382106|DIAGNOSTIC_TEST|Pulse wave velocity|Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
223903375|NCT03382106|DIAGNOSTIC_TEST|Carotid artery compliance and stiffness|An echocardiogram is done by using a probe placed on the skin.
223903376|NCT03382106|DIAGNOSTIC_TEST|Pressure wave reflection|Carotid pulse measurement taken using a tonometer probe
223903377|NCT05124704|DRUG|5-8ml 0.375% ropivacaine|5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
223903378|NCT05124704|OTHER|5-8ml normal saline|5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
223903379|NCT06847295|PROCEDURE|Epidural Electrical Stimulation (EES) using an implanted paddle lead and pulse generator combined with a 12-month intensive rehabilitation program.|The intervention consists of surgical implantation of an epidural electrical stimulator using a paddle lead (Medtronic Specify 5-6-5) placed in the lumbar epidural space and a subcutaneously implanted pulse generator (Medtronic Intellis). After a one-month recovery and device calibration period, the stimulator is activated during a 12-month intensive rehabilitation program. Patients receive electrical stimulation during five supervised physiotherapy sessions per week. Stimulation parameters-including pulse width, frequency, and amplitude-are individually optimized based on intraoperative neurophysiological monitoring and ongoing clinical assessments, with the goal of enhancing gait recovery, reducing spasticity, and improving overall motor function and quality of life.
224276940|NCT05567835|DRUG|Fluorouracil|2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
224276941|NCT05567835|DRUG|Leucovorin|200 mg mg/m2 IV over 2 hours Day 1,15
224276942|NCT05567835|DRUG|Oxaliplatin|85 mg/m2 IV over 2 hours Day 1,15
224276943|NCT05567835|DRUG|Docetaxel|60 mg/m2 IV over 60 minutes Day 1,15
224276944|NCT05567835|BIOLOGICAL|GSCF|Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
224276945|NCT02842684|DEVICE|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
223715615|NCT06621719|PROCEDURE|Alveolar Cleft Reconstruction|Alveolar Cleft Reconstruction Using Bone Matrix Prepared from Cancellous Particulates Mixed with Albumin-PRF in study group versus L-PRF in control group
223715616|NCT06826612|GENETIC|SPK-10001|Specified dose on specified days
223715617|NCT06826612|OTHER|Placebo Surgery Control|Placebo Surgery procedure for SPK-10001
224276946|NCT05881642|PROCEDURE|Prostate and seminal-sparing Cystectomy|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
223715618|NCT06669247|DRUG|Linvoseltamab|Administered per protocol
223715619|NCT06669247|DRUG|REGN7945+Linvoseltamab|Administered per protocol
223715620|NCT02513394|DRUG|Palbociclib|
223715621|NCT02513394|DRUG|Standard Adjuvant Endocrine Therapy|
223715622|NCT06822231|DEVICE|High-tech rehabilitative treatment|"Robotic Verticalization System (e.g., Erigo): Assists in regaining upright posture and mobility.~Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises.~Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training.~Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback"
223715623|NCT06822231|OTHER|Rehabilitation|Traditional rehabilitative treatment
223715624|NCT06491654|OTHER|12-week supervised exercise|During the study period (1 week for acute effects, 12 weeks for chronic effects), there will be 8 sessions per month, lasting 40-60 minutes each, with 2 sessions per week on alternate days, totaling 24 sessions. Each session includes: (1) warm-up (mobility exercises); (2) training: 5-min warm-up, followed by 15-min moderate-to-high intensity circuit of 7 functional global exercises with 10 reps each at a perceived exertion effort (RPE) of 5-7 on a scale of 1 to 10; (3) Aerobic exercise: starting at 15 mins, increasing by 5 mins biweekly to 30 mins by week 7; (4) Cool-down (general mobility); (5) Application of cohesive compressive bandage on the affected upper limb, worn for 2 hours post-session, removed at home. Participants may add a cotton bandage and finger bandage if needed.
223903380|NCT06849531|OTHER|Foot Biomechanics and Lower Extremity Muscle Analysis|Focus on Foot Biomechanics
223903381|NCT06849622|DIAGNOSTIC_TEST|Test on blood sample|The blood sample will be drawn by venipuncture during clinical routine. The serum will be tested for coeliac or diabetes 1 auto-antibodies, using Elisa test.
223903382|NCT06849622|DIAGNOSTIC_TEST|Test on dried blood sample|A finger prick will be used to collect Dried blood Spot (DBS) on a special card. The eluted blood spot will be tested, for coeliac and diabetes 1 auto-antibodies, using the same method used for serum, and the same cut-offs for positivity and negativity (Elisa tests)
223903383|NCT03064529|BEHAVIORAL|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
223903384|NCT06849973|DRUG|Drug: Bionetide|NA-921 (Bionetide) solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
223903385|NCT06849973|DRUG|Placebo|NA-921 (Bionetide) placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
223903386|NCT06851182|OTHER|Helfer skin tap technique|In the unit where the study was conducted, IM drug administration is performed through the Vastus Lateralis muscle in children aged 7-12 years and with BMI in the appropriate percentile according to age. No anaesthetic etc. application is performed. In order to create similar conditions in the study, children who are requested to be administered IM (ZOFER® 8mg / 4ml Injectable Solution-Ondansetron hydrochloride dihydrate into the Vastus Lateralis) will be included in the study. IM injection will be performed by the same investigator into the Vastus Lateralis muscle of the patient. A 16mm or 22mm, 22-25gauge sterile disposable sterile disposable needle will be used in all patients for injection administration. the procedure will be performed with helfer skin tap technique. Forms will be applied to the children by the researcher before and after IM injection.
223903387|NCT06851182|OTHER|Shotblocker technique|In the unit where the study was conducted, IM drug administration is performed through the Vastus Lateralis muscle in children aged 7-12 years and with BMI in the appropriate percentile according to age. No anaesthetic etc. application is performed. In order to create similar conditions in the study, children who are requested to be administered IM (ZOFER® 8mg / 4ml Injectable Solution-Ondansetron hydrochloride dihydrate into the Vastus Lateralis) will be included in the study. IM injection will be performed by the same investigator into the Vastus Lateralis muscle of the patient. A 16mm or 22mm, 22-25Gauge sterile disposable sterile disposable needle will be used in all patients. The procedure will be performed using Shotblocker method. Forms will be applied to the children by the investigator before and after IM injection.
223903388|NCT06851026|OTHER|Pilates Exercise|Pilates exercises were applied for 8 weeks
223903389|NCT06851949|DEVICE|Vsling|Implantable ventricular repair device
223903390|NCT04863924|DIAGNOSTIC_TEST|Liquid Biopsy|All patients will have a liquid biopsy with ctDNA molecular profiling
224276947|NCT05881642|PROCEDURE|Conventional Radical Cystoprostatectomy|According to the consensus standard program, remove the accessory tissues including the bladder,prostate and seminal vesicles
224276948|NCT01529307|DRUG|TAS266|TAS266 IV infusions given weekly
224276949|NCT03844724|DEVICE|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
224276950|NCT03844724|DEVICE|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
224276951|NCT00860678|OTHER|Physical activity|
224276952|NCT00860678|OTHER|no Intervention|
224276953|NCT01045707|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
223715625|NCT06772675|BEHAVIORAL|External Facilitation|Designated external facilitators will conduct monthly meetings with local champions at each site. Designated facilitators will follow the developed facilitation guide, that includes content area to cover in each meeting, case scenarios as examples, and tips on how to communicate and support the internal facilitators. The goal is to enable problem-solving and support the local champion in implementing VRP with fidelity
223715626|NCT03677921|DIETARY_SUPPLEMENT|Investigational Product (Bio-Germanium)|"* Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
223715627|NCT03677921|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks"
223715628|NCT04292743|BIOLOGICAL|Eryaspase|intravenous administration of Eryaspase, starting dose 75 units/kg, dose escalation to 100 units/kg, dose reduction 50 units/kg and 25 units/kg
223715629|NCT04292743|DRUG|FOLFIRINOX|intravenous administration of FOLFIRINOX
223715630|NCT03595267|OTHER|Point-of-care screening|"After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations."
223715631|NCT05108090|PROCEDURE|sentinel lymph node biopsy (SLNB)|"Preoperative Lymphoscintigraphy: A standard injection of 2 mCi of 99m-Technetium sulfur colloid. Sequential immediate and delayed images will be obtained using SPECT/CT using a gamma probe. Ten-second counts will be done in areas of high activity to identify location of sentinel lymph node (SLN). After removal of the lymph node, a 10-second count will be done of the lymph node ex-vivo followed by 10-second count of the lymph node resection bed to ensure removal of SLN (less than 10% activity of LN).~Surgical resection: Mohs micrographic surgery followed by SLNB. Intraoperative margins around the tumor will be confirmed through frozen section analysis. Patients with planned free flap reconstruction, will undergo SLNB with intraoperative, frozen section analysis. If lymph node is positive, immediate completion neck dissection will occur."
223715632|NCT06455345|DEVICE|Self-Guided Online ACT Program|Participants will be invited to access the ACT program on the Manage My Pain (MMP) app. Participants will follow the instructions in the app to complete the program in a self-paced manner. The program includes psychoeducational materials, guided mindfulness meditations, and self-reflection activities.
223903391|NCT06851143|DIAGNOSTIC_TEST|18F-DPA-714 PET/MR scan|Saline intravenous solution of 18F-DPA-714 administered at 0.1 mCi/kg by bodyweight
223903392|NCT06852625|BIOLOGICAL|Autologous Tolerogenic Dendritic Cells|• Autologous Tolerogenic Dendritic Cells (D+1 to D+3 post-transplantation), ATDC, 1 million ATDC/Kg over a period of 30 minutes (up to 1 hour) will administer between Day 1 and Day 3 after transplantation.
223903393|NCT06852690|OTHER|exercise with virtual reality goggles|Exercise and smartwatch tracking for type 2 diabetics with virtual reality glasses
223903394|NCT06851403|DRUG|Dupilumab|initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
223903395|NCT06851338|DEVICE|Hypoglossal Nerve Stimulation|Implant of Inspire Upper Airway Stimulation (UAS) system for treatment of obstructive sleep apnea (OSA) in the pediatric down syndrome population
223903396|NCT06851988|OTHER|HIIT & Record of physical activities at home.|After CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times. And record of physical activities at home. According to the record set goal to acheive.
223903397|NCT06851988|OTHER|HIIT only|After CCRT treatment 4-5 week arrange HIIT excise for patient two to three times a week 24-36 times.
223903398|NCT05497440|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.
223903399|NCT05991700|DRUG|Freeze-Dried California Table Grape|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
223903400|NCT05991700|DRUG|Placebo|Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
223903401|NCT04430725|PROCEDURE|Computed Tomography with Contrast|Undergo contrast-enhanced CT
223903402|NCT04430725|PROCEDURE|Microwave Ablation|Undergo microwave ablation
223903403|NCT04430725|OTHER|Questionnaire Administration|Ancillary studies
223903404|NCT04430725|PROCEDURE|Wedge Excision|Undergo wedge resection
223903405|NCT04455308|OTHER|Biological sample collection|10mL blood sample
223903406|NCT06362785|DEVICE|Virtual Reality|The intervention group will engage in immersive virtual reality sessions with interactive activities involving functional movements of the spine and limbs in a virtual environment using Meta Quest 3 goggles. The intervention will last for 6 weeks, comprising a total of 12 sessions, with a maximum duration of 30 minutes of virtual reality and 15 minutes of rest (45 minutes in total per session).
223903407|NCT06362785|BEHAVIORAL|Therapeutic exercise|The control group will receive conventional therapeutic exercise treatment following the recommendations of the Osteoarthritis Research Society International (OARSI), similar to the exercises performed with VR.
224276954|NCT01045707|DRUG|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
224276955|NCT00734942|OTHER|support service|"* professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life"
224276956|NCT03971578|OTHER|No Intervention Provided|No Intervention Provided
223903408|NCT03512327|OTHER|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
223903409|NCT05658471|OTHER|Standardized Research E-Cigarette (SREC)|Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay.
224276957|NCT05208229|DIAGNOSTIC_TEST|WB-MRI|Baseline CT scan (minimum thorax/abdomen/pelvis) and WB-MRI evaluations will be collected: as per clinical practice and Tumor Institute of Romagna (IRST) 185.03 Lu-PSMA protocol, the assessments must not be performed more than 12 weeks prior to study entry and baseline WB-MRI should be performed within 2 weeks from CT scan; CT and WB-MRI will be done at the end of Lutetium 177 PSMA (177Lu-PSMA) therapy and during post-treatment follow-up
224276958|NCT04886063|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
224276959|NCT03834922|OTHER|Prospective data collection|No intervention. It's a prospective data collection.
224276960|NCT05870163|DEVICE|RefluxStop implantation|Standard surgical technique for implantation RefluxStop, as described in the Itructions for Use
223528895|NCT01380080|DRUG|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
223903410|NCT05658471|OTHER|Over the Counter E-Cigarette (EC)|Usual brand e-cigarettes will be provided at the hospital stay.
223903411|NCT05658471|BEHAVIORAL|Biological Samples|Blood, urine, and expired carbon dioxide will be obtained during the course of the study.
223903412|NCT05658471|OTHER|Smoking-related Questionnaires|Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays.
223903413|NCT05076396|DRUG|PM14|PM14 drug product is provided as a sterile lyophilized powder for concentrate for solution for infusion with a strength of 5.0 mg of the active moiety. Patients will receive PM14 as an i.v. infusion in a total volume of 100 mL of 0.9% sodium chloride at the first three dose escalation levels. Thereafter, the volume of infusion can be increased to 250 mL.
223903414|NCT03847311|DRUG|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
223903415|NCT03847311|DRUG|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
223903416|NCT03511664|DRUG|177Lu-PSMA-617|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles. After 4 cycles, patients were assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments were met the patient might received an additional 2 cycles of 177Lu-PSMA-617.
223903417|NCT03511664|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
224276961|NCT05870163|PROCEDURE|Nissen fundoplication|Standard of care Nissen fundoplication surgery
223903418|NCT05215119|PROCEDURE|natural cycle endometrial preparation|Cycles will be monitored from either day-10 or-12, according to patient's menstrual cycle length, with serial analysis of blood serum LH and progesterone levels and assessment of dominant follicle growth. In a spontaneous cycle, ovulation will be determined by a LH surge (\>20 IU/L) and a corresponding rise in progesterone (\>0.8 ng/ml). In a triggered cycle, ovulation will be determined by the administration of an hCG trigger when the dominate follicle reached \>16 mm (and LH was \<20 IU/L).
223903419|NCT05027568|DRUG|IOA-289|Daily oral twice daily dosing of IOA-289
223903420|NCT05027568|DRUG|Nab paclitaxel / gemcitabine|Given in combination with IOA-289
223903421|NCT05424757|DRUG|PEG 3350|"Data and biospecimens will be collected from two groups of children:~* Children who have taken PEG 3350 daily for at least 30 days.~* Children who have NOT taken PEG 3350 for at least 30 days.~No changes to medicines are recommended as part of this study."
223903422|NCT06560554|OTHER|Fermented foods|Participants randomized to the intervention arm will begin to incorporate probiotic fermented foods into their diet during weeks 1-4 of the study (ramp up phase). They will start with one serving of fermented food of their choice a day, increasing to 6+/day as tolerated by the end of week 4. Weeks 5-12 will serve as the intervention maintenance phase, with the target of a daily intake of 6+ servings of fermented foods.
223903423|NCT06560554|OTHER|Control|No information on incorporation of fermented foods will be provided for subjects in the control arm.
223903424|NCT04053322|DRUG|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
223903425|NCT04053322|DRUG|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
223903426|NCT04053322|DRUG|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
223903427|NCT04101344|OTHER|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
223903428|NCT06583187|OTHER|Coloring a mandala picture|In the study, the experimental group was taken to their room on the day they came for circumcision and then had them paint mandalas. The coloring books chosen for mandala painting were determined to be appropriate for the age group of the children. The child was given a book and was given the freedom to paint the figures they wanted. Care was taken to ensure that the environment was quiet so that the child would be comfortable and calm. Care was taken to ensure that the crayons used in mandala painting did not contain carcinogenic substances and were anti-allergic.
223903429|NCT03814759|DRUG|TS-1 + cisplatin|S-1 20mg/m2, bid (D1\~14, D22\~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
223903430|NCT03814759|RADIATION|radiation|radiation 45Gy per 5 weeks
223903431|NCT05824572|OTHER|Clinic visit audio recordings for self-management in older adults|The intervention is audio-recordings of primary care clinic visits that are shared with participating patients. All scheduled visits with study clinicians will be recorded and shared with patients randomized to the intervention group (AUDIO) for 12 months.
223903432|NCT05824572|OTHER|Usual Care|The Usual Care arm participants will receive After Visit Summaries (AVS) per the standard delivery at each institution
223903433|NCT06229860|OTHER|Interview|In-person interview with the study coordinator to complete study questionnaire.
223903434|NCT05516472|DRUG|Microbial Transplant Therapy|Participants will take microbial capsules, 2 capsules daily for 7 days
223903435|NCT05516472|DRUG|Placebo|Participants will take placebo capsules
223903436|NCT06298331|OTHER|Aerobic Exercise|Aerobic exercise training will be given for 8 weeks, 3 days a week on the treadmill in the clinic under the supervision of a physiotherapist, and 8 weeks, the other 2 days a week outside the clinic. The duration of the walking session is 50 minutes (5 minutes warm-up - 40 minutes load - 5 minutes cool down). Walking speed in the clinic will be determined according to the Heart Rate Reserve(HRR) method. In the warm-up and cool-down phases in the clinic, the walking speed will be adjusted in the range of 20-40% of HRR, while in the loading phase it will be adjusted in the range of 40-60% of HRR. Heart rate will be monitored with a monitor that detects heart rate by hand contact on the treadmill. Outside the clinic, walking speed will be determined according to the level of fatigue perceived on the Borg Scale. Outside the clinic, walking speed will be regulated as 10-12 (light) on the Borg scale during warm-up and cool-down phases and 12-14 (slightly difficult) during the loading period.
223903437|NCT06298331|OTHER|Abdominal Massage|Abdominal massage will be performed manually by applying baby oil to the patient's abdomen and while the patient is in the supine position. This application will take approximately 15 minutes. The massage will be performed by the physiotherapist in the clinic 3 days a week for 8 weeks and by the patient outside the clinic 2 days a week for 8 weeks as self-massage.
223903438|NCT06298331|OTHER|Patient Education|Patient education will include information on the definition of constipation, causes of constipation, how constipation occurs, factors affecting constipation, concepts related to constipation, treatment options for constipation, and lifestyle recommendations for constipation, including increasing fluid intake, regulating nutrition, increasing physical activity, and regulating toilet habits.
224083504|NCT04747925|OTHER|mulligan bent leg raise technique, core muscle strengthning exercises|Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
223903439|NCT05783752|BEHAVIORAL|Stair Stepping|1 minute of stair-stepping (30 seconds up, 30 seconds down) at a self-selected pace identified on day 0 starting 15 minutes after each meal
223903440|NCT05783752|BEHAVIORAL|No exercise control|Participants avoid exercise within 1 hour of eating a meal
224083505|NCT01357369|PROCEDURE|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
224083506|NCT02899143|DRUG|Antibiotic|Targeted antimicrobial therapy
223903441|NCT06122441|BEHAVIORAL|Complex lifestyle intervention|The complex lifestyle intervention comprise high-intensity aerobic and strength exercise, behavioral counselling based on Acceptance and Commitment Theory (ACT), and dietary counselling based on Norwegian nutritional guidelines. The different intervention elements are introduced step-wise to reduce initial overload. Participants are progressively transitioned over to the Tromsø municipality and local NGO's, who delivers activities harmonized with the intervention elements. Participants are at this stage also supported by an eTool which digitally reinforces the intervention through web-based information and videos.
223903442|NCT06122441|BEHAVIORAL|Physical activity monitoring and recommendations|Wrist-worn activity trackers that are worn throughout the trial, which monitors steps, activity intensity and energy expenditure. Access to Norwegian physical activity guidelines via the Directorate of Health.
223903443|NCT03930810|PROCEDURE|Surgical biliary diversion|Surgical interruption of enterohepatic circulation
223903444|NCT06555705|OTHER|Placebo|The control group will be given placebo for 3 months
223903445|NCT06555705|DIETARY_SUPPLEMENT|Omega 3|The interventional group will be given omega 3 for 3 months
223903446|NCT06473662|DRUG|Oral insulin|Capsule administered by mouth with a glass of water two times per day, once before breakfast and once before supper
223903447|NCT03551392|DEVICE|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
223903448|NCT03551392|DEVICE|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
223903449|NCT03551392|DEVICE|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
223903450|NCT03551392|DEVICE|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
223903451|NCT05651178|DRUG|Human CD19-CD22 Targeted T Cells Injection|Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
223903452|NCT06011772|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
223903453|NCT06011772|DRUG|Leucovorin|Given IV
223903454|NCT06011772|DRUG|Oxaliplatin|Given IV
223903455|NCT06011772|DRUG|Fluorouracil|Given IV
223903456|NCT06011772|BIOLOGICAL|Bevacizumab|Given IV
223903457|NCT06011772|DRUG|Irinotecan|Given IV
223903458|NCT06011772|BIOLOGICAL|Cetuximab|Given IV
223903459|NCT06011772|PROCEDURE|Metastasectomy|Undergo metastasectomy
223903460|NCT06011772|PROCEDURE|Biospecimen collection|Undergo collection of blood samples
224276962|NCT04523246|BIOLOGICAL|SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)|The Shingrix vaccine is a subunit vaccine that contains the recombinant varicella zoster virus (VZV) glycoprotein E (gE), adjuvanted with the proprietary Adjuvant System (AS01B). The AS01B Adjuvant system consists of two immune-stimulants, the saponin, Quillaja saponaria Molina, fraction 21 (QS21), and the toll-like receptor 4 (TLR4) agonist, MPL (3-O-desacyl-40-MPL) that enhance the release of interferon gamma (IFNϒ), which in turn stimulates activation and recruitment of blood monocyte-derived and resident lymph node dendritic cells to take up and present gE to cluster of differentiation 4 (CD4+) T cells.
224276963|NCT04523246|DRUG|Normal Saline|Sterile normal saline, inactive control.
224276964|NCT03147924|OTHER|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
223903461|NCT06011772|PROCEDURE|Computed Tomography|Undergo CT
223903462|NCT06011772|BIOLOGICAL|Panitumumbab|Given IV
223903463|NCT06839924|BEHAVIORAL|Cognitive Motor Interference|Dual task that uses cognitive in addition to Motor training
223903464|NCT06839924|BEHAVIORAL|traditional physical therapy|physiotherapy program including exercises in addition to physical modalities
223903465|NCT06838819|DEVICE|Continuous glucose monitoring system|Medtronic Simplera™
223903466|NCT06724341|BEHAVIORAL|Distraction|"Control group: inferior alveolar nerve block will be administrated with passive behavior management (displaying animated movies directly on the screen of a mobile device).~Movies group: inferior alveolar nerve block will be administrated with displaying animated movies directly on the screen of a mobile device usage of the augmented reality glasses.~Video games group: Application of active behavior management by usage video games on the screen of a mobile device connected to augmented reality glasses before administration of inferior alveolar nerve block.~Movies and Video games group: An active and passive behavior management will be applied by usage video games before administration of inferior alveolar nerve block and animated movies during administration on the screen of a mobile device connected to augmented reality glasses."
223903467|NCT04345718|DRUG|Extended Release Buprenorphine|XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).
223903468|NCT04345718|DRUG|Treatment as Usual|Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
223903469|NCT05100654|DRUG|Doxycycline|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
223903470|NCT05100654|DRUG|Ciprofloxacin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
223903471|NCT05100654|DRUG|Augmentin|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
223903472|NCT05100654|DRUG|Bactrim|Patients will be given 6 days of oral antibiotics based on local biograms, patient allergies and renal and liver function
223903473|NCT05951725|BIOLOGICAL|Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP)|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
223903474|NCT05951725|BIOLOGICAL|Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
223903475|NCT05951725|BIOLOGICAL|Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib|Three doses of basic immunization were completed at 3, 4 and 5 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
223903476|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
223903477|NCT05951725|BIOLOGICAL|DTaP-IPV-Hib|Three doses of basic immunization were completed at 2, 3 and 4 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
223903478|NCT05951725|BIOLOGICAL|DTcP|Three doses of basic immunization were completed at 2, 4 and 6 months of age, and one dose of booster immunization was completed at 18 to 24 months of age.
223903479|NCT06469216|DRUG|Hyaluronic Acid|Hyaluronic Acid to be used as sodium hyaluronate powder plus inactive ingredient (Carboxy methyl cellulose) and to be dissolved in distilled water
223903480|NCT06469216|OTHER|Placebo|Inactive ingredient (Carboxy methyl cellulose) to be used as powder and to be dissolved in distilled water
223903481|NCT02824315|DRUG|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
223903482|NCT02824315|DRUG|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
223903483|NCT02824315|DRUG|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
223903484|NCT05525286|DRUG|SOT102|SOT102 is an antibody-drug conjugate (ADC) targeting CLDN18.2 with the anthracycline PNU as cytotoxic moiety.
223903485|NCT05690711|DRUG|HRS8179|HRS8179 injection
223903486|NCT05690711|DRUG|Placebo|physiological saline
223903487|NCT03210311|DEVICE|compression|a compression stocking is worn, a garment compression class 2, flat knitted
223903488|NCT04822324|OTHER|Spencer Muscle energy technique with conventional Physiotherapy|"shoulder extension with elbow flexion. shoulder flexion with elbow extension. circumduction with compression circumduction with distraction shoulder abduction and internal rotation with elbow flexion. shoulder adduction and external rotation with elbow flexion stretching tissue and pumping fluids with the arm extended: therapist interlocks his fingertips over the deltoid muscle, patient's hand was placed over the therapist shoulder, and the therapist slowly moved the arm away from the shoulder and released.~During all the movements patient is asked to use their muscle energy against the slight resistance offered by the therapist for 6-8 sec.~conventional therapy Joint mobilization~Exercise therapy:~Self stretching and strengthening exercises"
223903489|NCT04822324|OTHER|Strain counter strain along with conventional Physiotherapy and Spencer Muscle energy technique|"Palpate surrounding and opposing tissues to locate tender point for both shoulder abduction and external rotation.~Use one or two finger pads to monitor fasciculation and TP. Fine-tune position with rotation. Hold the POC (position of comfort) until fasciculation decreases significantly or ceases.~Average positions hold time while pressure is 90 s to 3 min. Transient periods of brief tingling, numbness, and temperature changes might occur. Release tissue or joint slowly and reassess."
223903490|NCT06472115|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions (SPACE) for insistence on sameness (IS)|This study will examine the potential effectiveness of a virtually delivered parent-mediated intervention for insistence on sameness behaviors in autism. This includes a 16 week protocol where caregivers meet weekly for one hour with a study therapist.
223903491|NCT05922722|OTHER|Decision-making tool|The shared decision-making tool is a paper tool or an electronic version which will be available in the clinics for clinic team's use.
223903492|NCT05922722|OTHER|Questionnaire|Questionnaire to assess participant's understanding of the decision-making tool
223903493|NCT04515849|DRUG|Cotadutide 100 micrograms|Cotadutide 100 micrograms administered subcutaneously
223903494|NCT04515849|DRUG|Cotadutide 300 micrograms|Cotadutide 300 micrograms administered subcutaneously
223903495|NCT04515849|DRUG|Cotadutide 600 micrograms|Cotadutide 600 micrograms administered subcutaneously
223903496|NCT04515849|DRUG|Semaglutide|Semaglutide 1.0 miligrams administered subcutaneously
223903497|NCT04515849|DRUG|Placebo|Placebo administered subcutaneously
223903498|NCT06438302|DEVICE|EEG activity measurement|"The nasal ventilation device (placed as part of the research) (AIRVO 2; Fisher and Paykel Healthcare, Auckland, New Zealand) will be positioned via nasal cannulas adapted to the patient's anatomy. The FiO2 will be set at 21% and the flow rate will be fixed at 0 L/min at the inclusion visit. The temperature of the humidified nasal oxygenator will be set at 31°C.~Six 30-minute experimental conditions will be performed successively: 1) 0 L/min flow, FiO2 21%, 2) 30 L/min flow, FiO2 21%, 3) 30 L/min flow, FiO2 100%, 4) 60 L/min flow, FiO2 21%, 5) 60 L/min flow, FiO2 100%, 6) Negative control.~At the end of each condition, a 10-minute thoracic electrical impedance tomography recording, a 10-minute EEG recording, a 10-minute cerebral NIRS recording and an instantaneous temporal Doppler velocity measurement will be performed. A blood gas (1.5 mL) will also be taken at the end of each condition."
223903499|NCT01789099|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
223903500|NCT02978911|PROCEDURE|preoperative cerebral MRI and operative findings|
223903501|NCT05950802|DRUG|Cyclophosphamide|Higher dose than traditional conditioning chemo
223903502|NCT05950802|RADIATION|TLI|radiation given with conditioning chemo
223903503|NCT05706493|OTHER|Non surgical periodontal treatment|Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
223903504|NCT05617599|DEVICE|SUPRAFLEX CRUZ|Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
223903505|NCT03837821|DRUG|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
223903506|NCT04016675|OTHER|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery|After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
224083507|NCT00836433|BEHAVIORAL|CONNECT educational intervention|The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.
223903507|NCT04016675|OTHER|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy|After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
223903508|NCT02975375|PROCEDURE|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
223903509|NCT02975375|PROCEDURE|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
223903510|NCT03995043|BEHAVIORAL|Education|Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
223903511|NCT03995043|BEHAVIORAL|Personal Support|Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
223903512|NCT03995043|BEHAVIORAL|Access to contraception|Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
223903513|NCT01876927|OTHER|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
223903514|NCT01876927|OTHER|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
223903515|NCT04910542|OTHER|Epi-Net Intervention|The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
223903516|NCT06093152|DRUG|Salbutamol|Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.
223903517|NCT05020860|DRUG|Paclitaxel|80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle
223903518|NCT05020860|DRUG|Carboplatin|Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle
223903519|NCT05020860|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle
223903520|NCT05020860|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle
223903521|NCT05020860|DRUG|Doxorubicin|60 mg/m2 IV administered on Day 1 of each 14-day cycle
223903522|NCT05020860|DRUG|Cyclophosphamide|600 mg/m2 IV administered on Day 1 of each 14-day cycle
223903523|NCT05020860|DRUG|Pembrolizumab|"Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen."
223903524|NCT05020860|DRUG|Pertuzumab/Trastuzumab/Hyaluronidase-zzxf|Can be used in place of separate IV formulations of pertuzumab and trastuzumab. 1200 mg pertuzumab/600 mg trastuzumab/30,000 U hyaluronidase administered subcutaneously on Day 1 of the first cycle, followed by a maintenance dose of 600 mg pertuzumab/600 mg trastuzumab/20,000 U hyaluronidase administered subcutaneously every 3 weeks.
223903525|NCT03903796|DRUG|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
223903526|NCT03903796|DRUG|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
223903527|NCT05456516|BEHAVIORAL|Food Rating|Children will rate foods on taste, health, and desire to eat. The order in which they rate the food characteristics is randomly assigned and counter-balanced across participants
223903528|NCT03272217|DRUG|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
223903529|NCT03272217|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
223903530|NCT05890911|DIAGNOSTIC_TEST|Polysomnography|Each of the patients will undergo polysomnography
223903531|NCT05890911|DIAGNOSTIC_TEST|Blood dopamine level measurement|In each of the patients blood dopamine level will be measured
223903532|NCT05890911|DIAGNOSTIC_TEST|Genetical test|Each of the patients will undergo genetical test focusing on selected single nucleotide polymorphisms within genes regulating the concentration of dopamine - the gene responsible for production of the enzyme catechol-O-methyltransferase (COMT) - rs4680 and rs6269 and genes encoding receptors dopamine (DRD1 - rs686, rs5327 and DRD2 - rs1800497).
223903533|NCT04868708|BIOLOGICAL|AK104|Subjects will receive AK104 intravenously.
223903534|NCT04868708|BIOLOGICAL|Bevacizumab|Subjects will receive Bevacizumab intravenously.
223903535|NCT04868708|DRUG|Paclitaxel|Subjects will receive Paclitaxel intravenously.
223903536|NCT04868708|DRUG|Cisplatin or Carboplatin|Subjects will receive Cisplatin or Carboplatin intravenously.
223903537|NCT05095779|BEHAVIORAL|Coaching calls|OTH coaching calls
223903538|NCT05095779|DRUG|Nicotine replacement therapy|8 weeks of nicotine replacement therapy
223903539|NCT05095779|BEHAVIORAL|Financial Incentives|Escalating financial incentives for completing up to 5 coaching calls
223903540|NCT05823376|DRUG|Avatrombopag|Indications for drug reduction and withdrawal: excluding blood transfusion factors, the reduction will be 20mg/d when PLT≥50×10\^9/L; Drug administration will be stopped when PLT≥100×10\^9/L.
223903541|NCT03935295|DRUG|AbobotulinumtoxinA|Paraspinal abobotulinumtoxinA injections (compared to placebo)
223903542|NCT03935295|DRUG|Placebos|Placebo prepared by Ipsen for use as control
223903543|NCT03935295|DEVICE|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
224276965|NCT05393323|OTHER|conventional physical therapy with distraction technique|Distraction will be at suboccipital level and patients will ask to assume a supine position with the head on the plinth. The therapist will use fingertips in both hands from digits 2 through 5, and cups the suboccipital region of the patient and supports the posterior skull. The therapist provides a light distraction to the posterior skull. Distraction will be applied for 10 min with pull for 10 sec and5 sec will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 minute with total intervention period of 4 weeks with 5 sessions per week.
223903544|NCT04024787|BEHAVIORAL|Cognitive-Behavioural therapy for insomnia (CBT-I)|"Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.~One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks."
223903545|NCT04573231|DRUG|18F-DCFPyL|PSMA is highly expressed on prostate cancer and is associated with metastasis and resistance to anti-androgen therapies. Researchers have evaluated the expression of PSMA in the tumor and tumor-associated neovasculature in primary tumors and distant metastases in patients with breast cancer.
223903546|NCT06803667|DEVICE|Radiofrequency ablation alone|Radiofrequency ablation under imaging guidance allows for heating of diseased tissues, and has been used for the treatment of benign and malignant soft tissue masses throughout the body in the United States over the last several decades. Newer radiofrequency ablation devices are smaller and allow for precision temperature regulation; these technologies allow us to safely and precisely deliver heat to diseased tissues while minimizing the heating of nearby healthy tissues. Furthermore, we are able to clearly see these devices under ultrasound, which allows us to move the device in real-time to deliver heat as safely, effectively, and efficiently as possible.
223903547|NCT04976153|BIOLOGICAL|aSMDC|Autologous Muscle Derived Cells for injection into the external anal sphincter
223903548|NCT04976153|OTHER|Placebo|Placebo control is the vehicle solution used for the study product
223715633|NCT06455345|OTHER|Treatment As Usual|Participants will be invited to join a one-session ACT group workshop guided by a psychologist. The session will take place virtually using video call software. The psychologist will guide participants through the workshop agenda, which will include psychoeducational material, guided mindfulness meditations, and partaking in voluntary discussions with other group members.
223903549|NCT06085690|BEHAVIORAL|evidence-based intervention Plan for the Prevention of CRBSI in ICU patients|"On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention."
223903550|NCT04924803|BEHAVIORAL|No video|Weekly text messages
223903551|NCT04924803|BEHAVIORAL|Video Text|Weekly text messages including links to intervention videos
223903552|NCT05000034|PROCEDURE|Weaning protocol|Application of a weaning protocol from the mechanical ventilation
223903553|NCT01271465|PROCEDURE|Kidney Biopsy|biopsy of transplant kidney
223903554|NCT06288477|DRUG|A cotton pellet moistened with full-strength FC|A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
223903555|NCT06288477|DRUG|Neo-Putty|Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
223903556|NCT05033067|BEHAVIORAL|P3BC|The decisional aid will be developed to enhance patients' communication about cystectomy and urinary diversions with the clinicians, patients' decisions and preparation for self-care. Program users will be able to choose from a menu to view and print: a) summaries of their responses to inquiry questionnaire about information needed, b) selected statistics about specific side effects and self-care, and c) streamed video vignettes with patient actors of mixed cancer stages, age, sex, and race talking with a clinician about their treatment outcomes and self-care. An automatically printed 2-page output to facilitate discussion will list: 1) decision role preference; 2) the 4 highest ranked information preference sheets; and 3) a summary of personal factors plus suggested discussion topics to address with the clinician. The 2-pages will be provided to the treating physician by the research coordinator before the patient's next consultation appointment.
223903557|NCT06058533|OTHER|Previsit Imagery Picturebook|This picturebook will include pictures of the dental operatory and materials the patient can expect to see during their dental treatment appointment. The pictures included will be generalized pictures of a dental operatory and dental materials. The picture book will also include some words to describe what is happening during the appointment. It is important to note that pictures of the local anesthetic / needle will not be shown in the picture book but will be used during the appointment. The procedures described are standard protocol at both clinics. The traditional picture book shown will be a hard copy.
223903558|NCT02677961|OTHER|Observation|
223903559|NCT06121258|OTHER|Educational video series|The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
223903560|NCT02323867|DEVICE|Alpha Beta T cell depletion|
224083508|NCT00836433|BEHAVIORAL|FALLS educational intervention|FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions
223903562|NCT06540586|PROCEDURE|anterior Quadratus lumborum block|Patients are placed in the lateral decubitus position. The area where the block will be applied is disinfected with povidine iodine. A convex ultrasound probe is placed on the midaxillary line above the iliac crest. By visualizing the transverse process adjacent to the psoas major and quadratus lumborum muscles, using the in-plane technique, using a 22 gauge 80 mm peripheral block needle after negative aspiration into the anterior layer of the thoracolumbar fascia anterior to the quadratus lumborum muscle muscle, 0.5-1 ml of serum After observing hydrodissection with physiological, 20 ml of 0.25% bupivacaine is injected. The same is done to the opposite side.
223903563|NCT06540586|PROCEDURE|M-TAPA BLOCK|In the M-TAPA block group, with the patient in the supine position, a linear high-frequency linear ultrasound (USG) probe is angled to visualize the inferior surface of the costochondral junction at the level of the 10th costochondral cartilage. Under sterile conditions, using the in-plane technique with a 22G 80 mm peripheral block needle, the needle is advanced posterior to the 10th costal cartilage by taking the lower edge of the cartilage in the sagittal plane as the midline. After hydrodissection with 2-3 ml isotonic saline to confirm the site, 20 ml of 0.25% Bupivacaine is administered under USG guidance. The same procedure is performed on the contralateral side as well.
223903564|NCT06278350|DRUG|D-2570|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
223903565|NCT06278350|DRUG|Placebo|"Randomized in a 1:1:1:1 ratio through the randomization system, and assigned to D-2570 group~1, group 2, group 3 or placebo group."
223903566|NCT06368466|DEVICE|iStatis HBsAg Test|capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples are tested on the iStatis HBsAg Test
223903567|NCT05306028|DRUG|Metformin or insulin treatment|"1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose \> 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose."
223903568|NCT04089137|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
223903569|NCT04383496|BEHAVIORAL|Physical Activity|In-person, virtual conferencing, and telephone sessions, wearable device for daily feedback and motivation
223903570|NCT04633889|DRUG|Deferoxamine|Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
223903571|NCT04633889|DRUG|Normal saline|Normal saline (240mL) intravenous infusion over 12 hours
223903572|NCT04078191|DRUG|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
223903573|NCT06540456|DRUG|Qutenza® 8% Capsaicin Topical System|Treatment of patients with neuropathic LBP and painful lumbosacral radiculopathy using the Qutenza 8% capsaicin topical system.
223903574|NCT06720311|PROCEDURE|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy|Modified Tubeless Super-Mini Percutaneous Nephrolithotomy
223903575|NCT06720311|PROCEDURE|Flexible Ureterorenoscopy|Flexible Ureterorenoscopy
223903576|NCT06720311|PROCEDURE|Shockwave Lithotripsy|Shockwave Lithotripsy
223903577|NCT04032041|DEVICE|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
223903578|NCT04032041|DEVICE|Caliper|Caliper: An OriginCal IP54 digital caliper (Anytime Inc, Granada Hills, CA) was used to take three consecutive physical measurements in millimeters at each identified measurement location. For measurements outside of the caliper's scope a tape measure was used in place of the caliper. Physical measuring devices were reset to zero between each measure.
223903579|NCT06007664|BEHAVIORAL|Tele-Video to Improve Daily Activity|Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
223903580|NCT04965090|DRUG|Amivantamab|Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
223903581|NCT04965090|DRUG|Lazertinib|Lazertinib 240 mg orally once daily and take this continuously, starting C1D1. For patients who weigh \<80 kg, on C1D1, patients will receive amivantamab 350 mg IV, with 700 mg given on C1D2.
223903582|NCT04972552|DIETARY_SUPPLEMENT|coenzyme Q10|Participants will take 800-1200 mg of coenzyme Q10 capsule per day
223903583|NCT04972552|OTHER|Watermelon diet|Participants will be asked to eat watermelon at a minimum of one meal per day 3-5 days a week
223903584|NCT04972552|OTHER|Usual Diet|Participants will be asked to eat a usual diet but not eat any watermelon as part of their usual diet
223903585|NCT04972552|OTHER|Placebo|Participants will be asked to take 800-1200 mg of a placebo capsule per day
223903586|NCT04505865|BEHAVIORAL|Stress Reduction|"The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1\) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being."
223903587|NCT00207636|BEHAVIORAL|Computer Assisted Decision making tool|The intervention consisted of access to a computer tailored decision aid designed to promote informed decision making.
223903588|NCT04174755|DRUG|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
223903589|NCT04174755|BEHAVIORAL|Standard of care|Diet and exercise advice for 40 weeks
223903590|NCT06488456|OTHER|TRSC-C|Data were collected using TRSC-C
223903591|NCT05551728|BEHAVIORAL|ESDM-informed caregiver coaching|The coaching intervention is informed by the Community-Early Start Denver Model (C-ESDM). The intervention has been adapted for the South African context. Training procedures have been adapted for delivery by non-specialist coaches. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) have been developed. Over 12, 1-hour caregiver coaching sessions that are delivered by non-specialists, caregivers are coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors.
223903592|NCT03953196|BIOLOGICAL|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
223903593|NCT03953196|BIOLOGICAL|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
223903594|NCT03953196|BIOLOGICAL|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
223903595|NCT03953196|BIOLOGICAL|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
223903596|NCT03953196|OTHER|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
223903597|NCT03953196|OTHER|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
223903598|NCT00409435|DRUG|pyridostigmine|one 180 mg capsule per day for 3 days
223903599|NCT00409435|DRUG|Placebo|one capsule per day for 3 days
223903600|NCT04636814|DRUG|CHF6001 1600µg|CHF6001 400µg, 2 inhalations bid (total daily dose of 1600µg) and Roflumilast matching placebo, 1 tablet once daily
223903601|NCT04636814|DRUG|CHF6001 3200µg|CHF6001 800µg, 2 inhalations bid (total daily dose of 3200µg) and Roflumilast matching placebo, 1 tablet once daily
223903602|NCT04636814|DRUG|Placebo|CHF6001 matching placebo, 2 inhalations bid and Roflumilast matching placebo, 1 tablet once daily
224276966|NCT05393323|OTHER|conventional physical therapy with traction technique|In cervical traction, patients will ask to lie supine on the treatment table. Head will cradle by physiotherapist from chin and the occiput, and then the physiotherapist will apply traction force in 25 degree neck flexion. Traction will be applied for 10 minutes with pull for 10 sec and 5 sec rest will be applied. Prior to apply this technique all patients will receive 15 minutes of infrared with TENS at cervical spine. The total treatment session will be of 25 min with total intervention period of 4 weeks with 5 sessions per week. All outcome measurements will be assessed before treatment and then reassessed at the end of 4th week.
223903603|NCT04636814|DRUG|Roflumilast|\- 1 tablet of Roflumilast (Daliresp®), 250µg, once daily during the first 4 weeks of treatment then 1 tablet of Roflumilast (Daliresp®), 500µg, once daily for the remaining treatment period and CHF6001 matching placebo, 2 inhalations bid
223903604|NCT04577963|DRUG|Fruquintinib|Oral VEGFR inhibitor
223903605|NCT04577963|DRUG|Tislelizumab|PD-1 inhibitor
223903606|NCT03833154|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
223903607|NCT03833154|OTHER|Placebo|Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
223903608|NCT03833154|DRUG|(Osimertinib cohort, single-arm, open-label separate cohort)|Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
223903609|NCT04675515|BEHAVIORAL|Intensive Tobacco Treatment|Bi-weekly tobacco treatment counseling and regular carbon monoxide monitoring
223903610|NCT06226077|BEHAVIORAL|sleep extension intervention|The sleep intervention aims to increase sleep duration by one-hour (15 minutes/week) over the course of 4-weeks using components from Cognitive Behavioral Therapy for Insomnia. More specifically, the intervention consists of psychoeducation, sleep extension, sleep hygiene, and stimulus control. Participants will meet with Dr. Wu or a trained staff member once a week over the course of 4-weeks via Zoom. The intervention will be adapted based on feedback from the community, knowledge gained during previous interviews.
224276967|NCT02568280|DRUG|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
223903611|NCT06226077|BEHAVIORAL|contact control intervention|The control condition is a contact-control intervention whereby participants will meet with Dr. Wu or a trained staff member once-week over the course of 4-weeks to receive education materials from the Healthy Homes intervention developed by the UT School of Public Health.
223903612|NCT02823145|DRUG|ZX008 (Fenfluramine Hydrochloride)|
223903613|NCT06274034|OTHER|Electronic Health Record Review|Ancillary studies
223903614|NCT06274034|OTHER|Medical Device Usage and Evaluation|Wear MUSE S headband
223903615|NCT06274034|PROCEDURE|Meditation Therapy|Participate in meditation
223903616|NCT06274034|OTHER|Survey Administration|Ancillary studies
223903617|NCT05983809|DEVICE|Technological rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
223903618|NCT06808230|DIETARY_SUPPLEMENT|Cocoa extract|Cocoa extract manufactured as 250 mg capsules
223903619|NCT06808230|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
223903620|NCT06982846|DRUG|Retatrutide|Administered SC
223903621|NCT06982846|DRUG|Placebo|Administered SC
223903622|NCT06595862|BEHAVIORAL|EA-Avatar|The avatar-guided digital intervention includes monitoring of alcohol use and common triggers suicidal thoughts, skills to manage alcohol use and suicidal thoughts, resources on how to access outpatient care and crisis hotlines for suicidal thoughts, and achievements for milestones. In addition, text messages provide reminders to access the avatar platform to learn or practice skills and provide encouragement.
223903623|NCT07000175|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Non-invasive transcutaneous vagus nerve stimulation with special earphones placed in the ear will be applied to the participants for 20 minutes and a single session.
223903624|NCT05292391|BIOLOGICAL|Sm-p80|The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.
223903625|NCT05292391|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
223903626|NCT07019259|DEVICE|Anodyne Therapy System|Survivors will be provided the Anodyne Therapy System Model 120 to use as part of a 6-week at-home light therapy intervention. Participants will be instructed on where apply the device based on location of their symptoms, and will be instructed to use the device for 15 minutes per day, 3 days per week. Proper use of the device will be demonstrated in clinic by a trained physical therapist or study team member.
223903627|NCT06925295|DRUG|Xenon MRI|MRI with Xenon used for contrast
223903628|NCT06925295|DIAGNOSTIC_TEST|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volumes, DLCO and oscillometry
223903629|NCT06925295|OTHER|Quality of Life Questionnaire|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30+QLQ-LC29)
223903630|NCT06925295|OTHER|Medical Research Council Dyspnea score|modified Medical Research Council Dyspnea score (mMRC Dyspnea)
223903631|NCT06925295|OTHER|St. George's Respiratory Questionnaire|St. George's Respiratory Questionnaire (SGRQ)
223903632|NCT06925295|DIAGNOSTIC_TEST|Blood Biomarkers|blood biomarkers of inflammation and injury (e.g. Angiopoetin-2, Interleukin-6, myofibroblast activity, BPD4)
223903633|NCT07050355|DEVICE|rTMS|Subjects will undergo rTMS to the left dorsolateral prefrontal region as a treatment for depression. Treatment will be performed three times per week for 12 weeks (36 sessions) . We will use a standard resting motor threshold (rMT) determination from unaffected abductor pollicis brevis. Treatments will be delivered at the EEG coordinate for F3 (approximating the left DLPFC) and will be found using the Beam-F3 method. A total of 5000 pulses/session will be delivered at 10Hz with an intensity of 120% of rMT.
223903634|NCT07050355|BEHAVIORAL|AEx|The goal of AEx will be 20 minutes of continuous walking at an intensity of \~70% of heart rate reserve (HRR calculated via the Karvonen method). The desired intensity will be achieved by a combination of increasing treadmill speed and incline. Rest breaks will be allowed as needed during training with the goal of progressing to 20 minutes of continuous walking.
223903635|NCT06737029|DIAGNOSTIC_TEST|Enhanced diagnostic workup|"Patients will undergo review by a study physician, including a detailed history and physical examination, as well as review of additional investigations that have been performed thus far.~Based on the precise nature of the complaints, and additional findings, additional diagnostic testing may be requested, including, but not limited to: blood testing, spirometry, computed tomography of the chest, repeat chest X-ray, sputum investigations, or bronchoscopy."
223903636|NCT06891625|OTHER|SMT|In the present study, a short examination of the whole spine and pelvic area will be performed to identify those segments with the highest restricted range of motion compared to other parts. A standard HVLA manipulation of this area is applied, which refers to Maitland grade 5.
223903637|NCT06891625|OTHER|ET|In the present study, the participant will, after short warming up, perform three standard exercises aiming to increase the possibility for a person with back pain to control the full range of spinal, pelvis and hip joints (Exercise 1) to increase the motor control and coordination of the muscles controlling the low back, pelvis and hip joints in flexion and rotation (Exercise 2), and to increase the motor control of muscles controlling the low back, pelvis and hip joints in extension (Exercise 3).
223903638|NCT06891625|OTHER|OLP|"In the present study, the procedure will follow the study of Carvalho, et al. (2016).28 The researcher explains clearly in a positive way to the participants that i) a placebo effect can be powerful, ii) the body can automatically respond to taking placebo pills like Pavlov's dogs that salivated when they heard a clock, iii) that a positive attitude can be helpful, but is not necessary, and iiii) the researcher shows a short video clip (1 minute 25 seconds) of a news report, where participants in an OLP study are interviewed on the positive effects they experienced (https://www.youtube.com/watch?v=Jp14Lhl0T9). Thereafter, the participants are asked to take two pills, containing the inactive substance microcrystalline cellulose from a container clearly labeled with placebo."
223903639|NCT04857723|DEVICE|daily disposable contact lens|Daily disposable contact lens for 3 months
223903640|NCT07057960|OTHER|Group Social Work Intervention Based on Cognitive Behavioral Therapy|"The aim of the intervention is to modify children's bullying-related cognitions and enhance peer relationships through cognitive restructuring, achieved by increasing awareness of cognitions, emotions, and behaviors among children in institutional care.~The content of the intervention was developed using the core principles and techniques of cognitive behavioral therapy."
223903641|NCT07063680|DRUG|Argipressin|Argipressin 0.4 U.ml-1 (i.e. 40IU diluted in 100ml 0.9% NaCl bag)
223903642|NCT07063680|DRUG|Chlorure de sodium|NaCl 0.9%
223903643|NCT07063680|OTHER|Collection of clinical data|At inclusion, D0 to D7, ICU discharge, D30 and D90
223903644|NCT07062692|OTHER|dry needling trigger release therapy|The dry needling intervention involved inserting sterile filiform needles directly into active rhomboid trigger points for 1-2 sessions (1 session/week) to elicit local twitch responses and relieve tension.
223903645|NCT07062692|OTHER|MANUAL TRIGGER POINT RELEASE|The manual trigger point release intervention involved applying sustained pressure to active rhomboid trigger points followed by passive stretching to release muscle tension and improve mobility.
223903646|NCT07063667|OTHER|bulid primary AI model|For the collected patient data, deep learning is used to perform feature screening on the selected or collected images, and malignant risk factors are determined by combining clinical significance. A neural network classifier is trained on the training set data. Variable selection: independent variables (breast MRI images, breast ultrasound images, indicators such as CA199, CA153, CA125, AFP/CEA, etc.), dependent variables (whether suffering from breast cancer and breast cancer subtypes), and the verification accuracy standard is set as the pathological biopsy result.
223903647|NCT07063667|OTHER|verdict model and develop its function|The accuracy of a breast cancer prediction model is typically evaluated using multiple metrics that assess its performance in different aspects
224083509|NCT02061865|DRUG|REGN2176-3|
224083510|NCT02604940|DRUG|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
223903648|NCT07062224|DIETARY_SUPPLEMENT|Probiotic/Prebiotic Supplement|Oral dietary supplement in gel form (10 mL per day) containing 4000 mg of inulin and 1000 mg of tyndallized probiotics. Administered once daily for approximately 98 consecutive days. Produced by Martínez Nieto S.A. (MARNYS®). Intended to modulate gut microbiota and improve glycemic and inflammatory markers.
223903649|NCT07062224|DIETARY_SUPPLEMENT|Placebo Gel|Oral placebo in gel form (10 mL per day), identical in appearance, texture, and taste to the active supplement, but without probiotic or prebiotic components. Administered once daily for 98 days to maintain blinding and control effects.
223903650|NCT07062666|DRUG|SSRIs|take SSRIs for 2 weeks
223903651|NCT07062666|DEVICE|fNIRS|All subjects receive fNIRS examination.
223903652|NCT07062822|OTHER|Resisted exercise|Patients in this group will be applied Kinesio taping 3 times per week over the study period of 6 weeks. Before the kinesio taping, the skin surface will be clean. Patients will positioned lying on their side, hip extended, and knee joint at 60° of flexion. The knee will be tape with an I-shaped kinesio tape starting at the origin of the rectus femoris, and a Y-shaped kinesio tape proximal to the superior patellar border. The taping will be no tension at its base, whereas the portion between the anchor and the superior patella will be stretched ≈40%.
223903653|NCT07062822|OTHER|kinesiology tapping|kinesiology tapping
223903654|NCT07062276|OTHER|Dynamic taping|The dynamic tape is a new type of treatment. The material has high resilience. Its purpose is to help muscles and tissues absorb external forces and reduce tissue energy consumption.
223903655|NCT07062276|OTHER|Kinesio ®|Kinesio ®can effectively improve pain, edema, and assist functional movements. The elasticity of the patch creates wrinkles to relax the extensor pollicis brevis and the abductor longus muscle of the thumb.
223903656|NCT07062510|DEVICE|Dasuit Cusion|The Dasuit cushion is placed on a 40X40X40 wooden box as a chair, and the pressure seating mat is placed on the cushion. Participants were asked to sit on the cushion with hips, knees, and ankles positioned at approximately 90° angles at ease. A tablet was mounted in front of the chair at 30-40 cm from the eyes and at a downward viewing angle of 5-10 degrees. Participants were instructed to watch a 10-minute video to maintain a fixed gaze and minimize head movement. The patient was to sit on the cushion at ease for 1 minute to adjust to the cushion, then under-buttock pressure was recorded for 10 mins.
223903657|NCT07062510|DEVICE|Placebo|The placebo cushion is placed on a 40X40X40 wooden box as a chair, and the pressure seating mat is placed on the cushion. Participants were asked to sit on the cushion with hips, knees, and ankles positioned at approximately 90° angles at ease. A tablet was mounted in front of the chair at 30-40 cm from the eyes and at a downward viewing angle of 5-10 degrees. Participants were instructed to watch a 10-minute video to maintain a fixed gaze and minimize head movement. The patient was to sit on the cushion at ease for 1 minute to adjust to the cushion, then under-buttock pressure was recorded for 10 mins.
223903658|NCT07062510|OTHER|Washout|A 10 min washout period is in between the two interventions. The paitent is asked to walk around at ease.
223903659|NCT07062874|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Participants received supervised exercise training 3 times per week for 6 weeks. Each session included a 10-minute warm-up (walking at 1.5 km/h), a 30-minute aerobic phase at 60-85% heart rate reserve (calculated using the Karvonen formula), and a 10-minute cool-down (walking at 1 km/h). In addition, participants performed resistance training for upper and lower extremities using TheraBands, with 8-10 sets targeting major muscle groups.
223903660|NCT07062874|BEHAVIORAL|Aerobic Exercise Only|Participants followed the same aerobic training protocol as the experimental group-3 sessions per week for 6 weeks, with 10-minute warm-up, 30-minute aerobic exercise (60-85% HRR), and 10-minute cool-down. No resistance training was provided.
223903661|NCT06899087|OTHER|not interventional|This is an observational study
223903662|NCT07063797|DRUG|Denosumab treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients|"1. Antihyperglycemic drug therapy: Follow the Chinese Diabetes Treatment Guidelines and clinical practice standards. Adjust the antihyperglycemic regimen based on blood glucose levels, with a target HbA1c of below 7.5%.~2. Denosumab treatment: Administer 60 mg of denosumab via subcutaneous injection every six months for a total treatment period of one year."
223903663|NCT07063797|DRUG|Eldecalcitol treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients|"1. Antihyperglycemic drug therapy: Follow the Chinese Diabetes Treatment Guidelines and clinical practice standards. Adjust the antihyperglycemic regimen based on blood glucose levels, with a target HbA1c of below 7.5%.~2. Eldecalcitol treatment: Eldecalcitol, 0.75 µg per capsule, taken orally once daily for a total treatment period of one year."
223903664|NCT07063732|DIETARY_SUPPLEMENT|Ketone Monoester (KME)|0.6 g KME per kg body mass; \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate. (Delta G Ketone, TΔS, Oxford).
223903665|NCT07063732|DIETARY_SUPPLEMENT|Placebo|Inert, calorie-free placebo drink that is taste-matched to the ketone monoester supplement
223903666|NCT07064018|DRUG|Spedox-6|Given Intravenously (IV)
223903667|NCT07064018|DRUG|Pegfilgrastim|Given Subcutaneous Injection or IV
223903668|NCT07064018|DRUG|Filgrastim|Given Subcutaneous Injection or IV
223903669|NCT07064122|DRUG|AZD2962|AZD2962 will be administered orally once daily.
224083511|NCT02604940|DRUG|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
224083512|NCT00242476|DRUG|MK0822A|
224083513|NCT05505266|OTHER|observational|observational
224083514|NCT02349178|DRUG|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
224083515|NCT02349178|DRUG|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
224083516|NCT02349178|DRUG|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
223903670|NCT07063225|DRUG|Romiplostim N01|The subjects will receive ropivacaine N01 treatment, with an initial dose of (2-3) µg/kg. When the dose is less than 250 µg, 250 µg (1 vial) can be administered (subcutaneously), once a week. The dose will be increased by (1) µg/kg each week, up to a maximum of 10 µg/kg, until the platelet count reaches ≥ 50 × 10\^9/L. If the platelet count returns to normal, the dose can be reduced according to the platelet level as appropriate.
223903671|NCT07064239|DEVICE|cooling vest|"Cooling vest :~It is one of cooling methods proposed to improve exercise performance in MS by reducing one's core and/or skin temperature before taking on physical work"
223903672|NCT07064239|OTHER|Aerobic exercises|aerobic exercise as any activity that uses large muscle groups, can be maintained continuously and is rhythmic in nature. As the name implies, muscle groups activated by this type of exercise rely on aerobic metabolism to extract energy in the form of adenosine triphosphate (ATP) from amino acids, carbohydrates and fatty acids. Examples of aerobic exercise include cycling, dancing, hiking, jogging/long distance running, swimming and walking
223903673|NCT07061925|DRUG|ALC-2203-1|This group receives ALC-2203-1 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
223903674|NCT07061925|DRUG|ALC-2203-2|This group receives ALC-2203-2 and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
223903675|NCT07061925|DRUG|ALC-2203-AC|This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and ALC-2203-AC, administered three times daily for 7 days.
223903676|NCT07061925|DRUG|Placabo|This group receives a placebo matching ALC-2203-1 or ALC-2203-2, and a placebo matching ALC-2203-AC, administered three times daily for 7 days.
223903677|NCT07064408|DRUG|Esketamine|Intravenous administration of a subanesthetic dose of esketamine (0.25 mg/kg) during induction of general anesthesia. The drug was administered slowly over approximately 30 seconds after midazolam (2 mg) and sufentanil (50 µg), and prior to propofol (2 mg/kg) and rocuronium (0.6 mg/kg). The goal was to evaluate its effect on intraoperative hemodynamic stability and postoperative recovery in elderly patients undergoing thoracic surgery.
223903678|NCT07064408|DRUG|Normal Saline (0.9% Sodium Chloride)|Intravenous administration of an equivalent volume of 0.9% normal saline during anesthesia induction, matching the timing and method of the esketamine group. Used as a placebo comparator.
223903679|NCT07064408|DRUG|Midazolam|Intravenous administration of 2 mg midazolam during anesthesia induction for sedation. Administered prior to study drug.
223903680|NCT07064408|DRUG|Sufentanil|Intravenous administration of 50 µg sufentanil for analgesia during anesthesia induction. Administered prior to study drug.
223903681|NCT07064408|DRUG|propofol|Intravenous administration of 2 mg/kg propofol for loss of consciousness during anesthesia induction. Administered after study drug.
223903682|NCT07064408|DRUG|Rocuronium|Intravenous administration of 0.6 mg/kg rocuronium to facilitate neuromuscular blockade and endotracheal intubation.
223903683|NCT07062055|DRUG|Anti-VEGF|Drug: Bevacizumab (15 mg/kg, IV, every 3 weeks)
223903684|NCT07062055|DRUG|Immunotherapy|QL1706 (7.5 mg/kg, IV, every 3 weeks, administered sequentially after bevacizumab)
223903685|NCT07062055|RADIATION|Local Therapy|Stereotactic Body Radiotherapy (SBRT), total dose of 25-50 Gy in 5 fractions over 1-2 weeks, targeting intrahepatic tumors, portal vein tumor, and/or limited extrahepatic oligometastatic lesions
223903686|NCT04382443|DRUG|Colchicine|At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
223903687|NCT03221426|BIOLOGICAL|Pembrolizumab|IV infusion
223903688|NCT03221426|DRUG|Placebo|IV infusion
223903689|NCT03221426|DRUG|Cisplatin|IV infusion
223903690|NCT03221426|DRUG|Capecitabine|Oral tablets
223903691|NCT03221426|DRUG|5-fluorouracil|IV infusion
223903692|NCT03221426|DRUG|Docetaxel|IV infusion
223903693|NCT03221426|DRUG|Oxaliplatin|IV infusion
223903694|NCT03221426|DRUG|Leucovorin|IV infusion
223903695|NCT05379101|DIAGNOSTIC_TEST|Cardiac magnetic resonance image (CMR)|A magnetic resonance imaging study for assessment of cardiac structure and intracardiac flow
223903696|NCT05379101|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|An imaging test that uses soundwaves that cannot be heard (ultrasound) to take pictures of the heart and vessels.
223903697|NCT05379101|DIAGNOSTIC_TEST|Six-minute Walk Test|A self-paced, test of exercise capacity performed unencouraged intensity that measures the distance that patients can walk on a flat, hard surface in a period of 6 minutes
223903698|NCT04761848|DRUG|Cilostazol 50 MG|Cilostazol 50 MG tablet twice daily
223903699|NCT04761848|DRUG|Placebo|Placebo tablet twice daily
223903700|NCT04375800|DRUG|Doravirine|DOR capsules (3.2 to 100 mg); sachets (3.2 to 100 mg); or tablets (100 mg) taken once or twice daily by mouth.
223903701|NCT04375800|DRUG|2 NRTIs|Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
223903702|NCT06212804|BIOLOGICAL|VIS954|A humanized IgG4 monoclonal antibody.
223903703|NCT06212804|OTHER|Placebo|VIS954 Placebo
223903704|NCT06792812|DRUG|ginger mouthwash|contain Sulfetal Zn® (Zinc Coco Sulphate) has a cleansing and antibacterial action and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
223903705|NCT06792812|DRUG|chlorohexidine mouthwash|Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
224083517|NCT03357393|DRUG|Midazolam|Midazolam is givenas sedation to the Control arm.
224083518|NCT03357393|DRUG|Propofol-Lipuro|Propofol is given as sedation to both intervention arms.
224083519|NCT03357393|DRUG|morphine-scopolamine|Given as premedication for the Control arm and one of the interventions arms.
223903706|NCT06792812|DRUG|Placebo|Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE)and all participants are instructed to decrease stress by a combination of diaphragmatic breathing and muscle relaxation. No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days.
223903707|NCT03856515|DRUG|Nicotine Replacement|Received NRT (Electronic Cigarette - With Nicotine)
223903708|NCT03856515|OTHER|Questionnaire Administration|Ancillary studies
223903709|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette - with Nicotine
223903710|NCT03856515|DEVICE|Electronic Cigarette|Electronic Cigarette -without Nicotine
223903711|NCT06959290|PROCEDURE|Multiple nonpharmacological methods|The preterm babies in this group are swaddled by the nurse with each baby's own blanket 2 minutes before the ROP examination. The nurse will then give the baby 25% dextrose solution orally (0.5ml for those \<32 weeks gestation, 1ml for those \>32 weeks gestation). The nurse then places a pacifier soaked in 25% dextrose solution in the preterm infant's mouth. After these three non-pharmacological methods, the doctor will perform the ROP examination.
223903712|NCT06959290|OTHER|Routine Treatment|The preterm babies in this group are swaddled by the nurse with each baby's own blanket 2 minutes before the ROP examination. After these three non-pharmacological methods, the doctor will perform the ROP examination.
223903713|NCT05378841|PROCEDURE|Surgical Denervation|This is an outpatient procedure performed under local anesthesia (depending on the anesthesiologist's decision), which lasts about 30 minutes.
223903714|NCT06845904|DEVICE|WaveWriter Alpha™ neurostimulation system|Two Boston Scientific WaveWriter Alpha™ Implantable Pulse Generators (IPGs) will be implanted and connected to CoverEdge™ or CoverEdge™ X 32 Surgical Paddle Leads. The leads are positioned to enable targeted stimulation of the spinal cord to optimize control of urinary functions.
223903715|NCT05421065|DRUG|Psilocybin|1 oral dose
223903716|NCT05421065|DRUG|Ketamine|1 oral dose
224276968|NCT02568280|DRUG|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
224276969|NCT04276012|OTHER|Multifactorial intervention|Psychoeducational intervention, recommendations on life style and diet, medication adherence and changes in pharmacological strategy
224276970|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
224276971|NCT01085578|DRUG|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
224276972|NCT01085578|DRUG|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
223903717|NCT05728229|DRUG|Supplement with SiderAl® Med|Nutritional supplementation with special purpose food
223903718|NCT05746546|DRUG|Transdermal Nicotine patch|Participants will wear nicotine transdermal patches daily for 12-15 weeks. Participants will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
223903719|NCT05310773|BEHAVIORAL|Community Stigma Awareness and Education Workshop|Key aspects of the workshop include community stigma awareness of people living with HIV, use of antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP) for prevention of HIV and attitudes towards people who use alcohol and drugs. The workshop adapts a stigma-reduction curriculum based on a stigma-reduction toolkit and community HIV prevention project with community peers with skits to address stigmatizing attitudes and behaviors toward young women and men who use AODs and who may need health services, including HIV treatment and prevention. Selected modules were modified from the existing clinic-based training to fit community stigma awareness and attitudes to focus on aspects of stigma specific to young women and men who engage in syndemic-related behaviors who live in their communities. The stigma awareness and education workshop will be delivered in communities randomized to receive workshops (N=12 communities).
223903720|NCT05310773|BEHAVIORAL|Couples Health CoOp Plus (CHC+)|The Couples Health CoOp Plus (CHC+) was adapted from the initial Couples Health CoOp (CHC)-an empowerment-based intervention developed for South African couples that addresses the syndemic of alcohol and other drug (AOD) use, violence, and HIV risk. It is grounded in Social Cognitive Theory and promotes prevention strategies that address the relational context of equality in which sexual risk takes place. The adapted Couples Health CoOp Plus (CHC+) incorporates antiretroviral therapy (ART)/pre-exposure prophylaxis (PrEP) for a biobehavioral approach with an emphasis on uptake and good adherence (N=12 communities; estimated N=240 couples).
223903721|NCT03971799|BIOLOGICAL|CD33CART autologous|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by autologous CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
223903722|NCT03971799|BIOLOGICAL|CD33CART allogeneic|"The treatment regimen will consist of lymphodepleting (LD) chemotherapy followed by allogeneic CD33CART infusion:~LD option #1 (IV fludarabine 25 mg/m2/dose administered Days -4 to -2 and IV cyclophosphamide 900 mg/m2/dose on Day -2) or LD option #2 (IV fludarabine 30 mg/m2 on days -5, -4, -3, and -2; and IV cyclophosphamide 500 mg/m2 on days -3 and -2).~Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
224083520|NCT03357393|DRUG|Glycopyrrolate|Given as premedication for one of the intervention arms..
223903723|NCT06641973|DEVICE|Robotic balance rehabilitation with hunova® robotic platform|The G-Hun will perform robotic balance treatment with the hunova® robotic platform lasting 30 minutes per session, 2 times a week for 5 weeks, in addition to the services provided in their clinical pathway.
223903724|NCT03257410|DEVICE|Theranova 400 dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
223903725|NCT03257410|DEVICE|Elisio-17H dialyzer|Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
223903726|NCT05407025|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and tissue samples
223903727|NCT05407025|OTHER|Questionnaire Administration|Complete risk factor questionnaire
223903728|NCT05616130|OTHER|Data Collection|Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
223903729|NCT05616130|PROCEDURE|Bone marrow collection and blood collection|At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
223903730|NCT05616130|OTHER|Serial interviews to complete surveys and questionnaires|Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
223903731|NCT05616130|OTHER|Telephone follow up call|The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
223903732|NCT06193642|OTHER|experimental|Subjects diagnosed with OI will undergo a series of assessments using sensor imaging and Gait-Analysis; we will proceed with a careful and detailed collection, analysis and evaluation of functional data typical of Gait-Analysis studies, aimed at identifying that subset of parameters that will prove most interesting and useful for the purposes of the study, thus identifying the sensors and algorithms that can precisely produce the most usable synthetic information for defining the quality of motor function in these patients.
223903733|NCT04943042|DRUG|Avatrombopag|According to prescription
223903734|NCT05022134|BEHAVIORAL|CHOICE-AYA|Adapted contraceptive counseling specific to AYA experiencing homelessness
223903735|NCT05726045|BEHAVIORAL|Standard smoking cessation program (SCP)|Each subject will receive a standard SCP as group treatment once a week (1h) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra \& Buchkremer, 2004), and will be carried out by a qualified therapist.
223903736|NCT05726045|BEHAVIORAL|Cognitive remediation treatment (CRT)|The cognitive remediation treatment (CRT) employs a chess-based battery of tasks (delivered through an app-based online tool), two times per week over six weeks (60min duration per session).
223903737|NCT05726045|BEHAVIORAL|High-intensity interval training (HIIT evening)|"The high-intensity interval training will be delivered through an app environment with several choices of exercise, two times per week over six weeks.~The training will include a 5-minutes warm-up and cool down phase. In between, participants will perform four 4-minutes blocks of exercise at high intensity, interspersed with three 3-minute blocks of low intensity (total of 35 minutes exercise)."
223903738|NCT02179359|DRUG|Reduced Toxicity Ablative Regimen|"* Anti-thymocyte Globulin (ATG)~* Fludarabine~* Busulfan~* Stem Cell Infusion Day 0"
223903739|NCT02179359|DRUG|Reduced Intensity Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Fludarabine~* Total Body Irradiation (TBI)~* Stem Cell Infusion Day 0"
223903740|NCT02179359|DRUG|Myeloablative Preparative Regimen|"* Alemtuzumab~* Cyclophosphamide~* Busulfan~* Stem Cell Infusion Day 0"
223903741|NCT05457959|BIOLOGICAL|Dendritic Cell Tumor Peptide Vaccine|Given ID
223903742|NCT05457959|BIOLOGICAL|Ipilimumab|Given IV
223903743|NCT05457959|PROCEDURE|Leukapheresis|Undergo leukapheresis
223903744|NCT05457959|BIOLOGICAL|Nivolumab|Given IV
223903745|NCT05457959|DRUG|Placebo Administration|Given ID
223903746|NCT05457959|DRUG|Placebo Administration|Given IV
223903747|NCT05457959|DRUG|Poly ICLC|Given IM
223903748|NCT05457959|PROCEDURE|Resection|Undergo standard of care surgical resection
223903749|NCT06329492|BIOLOGICAL|Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)|Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait. This will take approximately 30 minutes. When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint. You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space. If there is excessive fluid in your knee, this may be drained before the injection is performed. The needle will be removed, and a band aid will be placed over the injection site.
223903750|NCT05050747|DRUG|HCG is introduced at day of trigger intra-uterine|hcg is introduced
223903751|NCT05050747|DEVICE|endometrial injury by pipelle|endometrial injury using pipelle on day 8-9 on the same cycle of ovulation
223903752|NCT05486650|DRUG|PD-1 inhibitor|After receiving PD-1 inhibitor treatment in the first three cycles, patients with locally advanced or advanced NSCLC whose curative effect is evaluated as stable disease receive SBRT combined with PD-1 inhibitor treatment
223903753|NCT02276885|RADIATION|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
223903754|NCT02276885|RADIATION|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
223903755|NCT02891824|DRUG|atezolizumab + avastin + platinum-based chemotherapy|"* atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
223903756|NCT02891824|DRUG|placebo + avastin + platinum-based chemotherapy|"* placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~* avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~* platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
223903757|NCT04228731|PROCEDURE|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total knee arthroplasty
223903758|NCT04228731|PROCEDURE|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total knee arthroplasty
223903759|NCT03847207|DRUG|HTL0030310|Solution for Subcutaneous injection
223903760|NCT03847207|DRUG|Pasireotide|Pasireotide 600 μg for subcutaneous injection
223903761|NCT03847207|DRUG|Placebo|Matching placebo Solution
223903762|NCT04808076|PROCEDURE|Shunt surgery|Shunt operation
223903763|NCT05297266|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity
223903764|NCT06101706|BEHAVIORAL|Fatigue assessment|FACIT-F questionnaire and Visual Analog Scale for fatigue
223903765|NCT06101706|BEHAVIORAL|Quality of life assessment|PsAID-12 questionnaire, DLQI questionnaire and SF-36 questionnaire
223903766|NCT06101706|OTHER|Assess severity of psoriatic arthritis|DAPSA score
223903767|NCT06101706|OTHER|Assess severity of cutaneous psoriasis|PASI score
223903768|NCT02714634|DRUG|Methotrexate + targeted therapy administration|"* Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib"
223903769|NCT02714634|DRUG|methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration|
223903770|NCT03693105|DEVICE|Active SAINT Stimulation|"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
223903771|NCT03693105|DEVICE|Sham SAINT Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
223903772|NCT03387592|DRUG|CPT-11|180 mg/m2
223903773|NCT03387592|DRUG|Calcio levofolinate|200 mg/m2
223903774|NCT03387592|DRUG|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
223903775|NCT03387592|DRUG|Capecitabine|1500 mg/m2
223903776|NCT03387592|DRUG|Temozolomide|200 mg/m2
223903777|NCT05168280|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively.
223903778|NCT05168280|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
223903779|NCT02601053|OTHER|Dull movie|A dull movie (duration approximately 90 minutes)
223903780|NCT02601053|OTHER|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
223903781|NCT02601053|OTHER|Heart rate measurement|Heart rate measurement using a actiheart device
223903782|NCT06505928|DRUG|hepalatide|hepalatide of 2.1 mg/d or 4.2mg/d s.c. treatment for 48 weeks
223903783|NCT06407687|DEVICE|Electro Dry Needlig|Electro Dry Needling is a modified form of dry needling which utilises an electro-stimulation unit connected via cables to fine filament needles. The combination of dry needling with electro-stimulation often prolongs the pain relief effect by blocking nerve pathways and preventing pain signals from travelling to the brain.
223903784|NCT06407687|DEVICE|dry needling|Dry needling is a technique that acupuncturists, physical therapists and other trained healthcare providers use to treat musculoskeletal pain and movement issues.
223903785|NCT03743142|PROCEDURE|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
223903786|NCT06142903|OTHER|7 versus 21 medically tailored meals per week|Meals designed to support overall cardiovascular health will be provided to patients in their own home setting.
223903787|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with lower limb cycle ergometer
223903788|NCT06283186|OTHER|Aerobic exercise|Aerobic exercise with upper limb cycle ergometer
223903789|NCT04881903|BEHAVIORAL|Mobile Intervention for Suicidal Thoughts (MIST)|This is an interpretation bias modification intervention that is designed to target cognitive factors that contribute to suicide risk. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
223903790|NCT04881903|BEHAVIORAL|Mobile Intervention for Reducing Anger (MIRA)|This is an interpretation bias modification intervention that is designed to target hostile interpretation bias. Participants will be instructed to complete at least 5 treatment sessions per week for a period of 4 weeks. Each session takes approximately 10 minutes.
223903791|NCT03587272|DRUG|Alemtuzumab, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab daily for 5 days (total dose 1 mg/kg) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
223903792|NCT06645704|DRUG|EP262|Single dose of \[14C\]-EP262 administered orally.
223903793|NCT04157101|BEHAVIORAL|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
223903794|NCT04157101|BEHAVIORAL|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
223903795|NCT06150430|DEVICE|APO|"Subjects will take part in 14 experimental sessions: two baseline sessions (T1-T2), three familiarization sessions (F1-F3), six training sessions (E1-E6), two assessment sessions (one pre-training T3 and one post training T4) and one 2-month follow-up session (T5). Depending on the session, the subject will walk with and/or without the APO. During the assessment sessions (T3-T4), the subject will be evaluated through different standard tests (such as 10MWTs and 2mWTs) and instrumented gait analysis, with and without the APO.~The goal of each training session (E1-E6) will be to achieve a minimum of 30 minutes of overground walking assisted by the APO, leaving up to 15 minutes to rest if needed. Training sessions will occur 2-3 times a week for 2-3 weeks to complete the training protocol."
223903796|NCT05287321|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg with Aspirin 100mg
223903797|NCT05973864|DRUG|Pembrolizumab injection|On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion
223903798|NCT05973864|DRUG|Capecitabine tablets|1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated
223903799|NCT05973864|RADIATION|Local radiotherapy|Local radiotherapy will be performed as per standard practice if indicated.
223903800|NCT06251167|DEVICE|Lateral wedge insoles (LWIs)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. The LWIs will be constructed via 3D printing using a material of uniform density made to the length of the participant's feet, and will incorporate a 6 degree wedge along the lateral edge.
223903801|NCT06251167|DEVICE|Lateral wedge plus custom arch support (LWAS)|Participants will be asked to wear these insoles in their own shoes for at least 5 hours per day for a period of 3 months. These insoles will be designed based on an innovative tablet-based app designed by industry partner Kintec Footlabs, who will be the provider of the insoles for this project. Using the high-fidelity 3D scanning tool available (Apple's True Depth sensor), the Epitek Self-Scanner app captures tens of thousands of 3D data points within a single 1-second capture, and then uploads this foot data to a secure patient record system that is used for insole fabrication. The LWAS insoles will be comprised of variable density material (more dense laterally than medially) and milled directly to produce a full-length shell. The 6 degree wedge will be incorporated along the full lateral length of the insoles.
223903802|NCT03435614|DRUG|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
223903803|NCT04171141|DRUG|PF-07062119|PF-07062119
223903804|NCT04171141|DRUG|Anti-PD1|Anti-PD1 PF-06801591
223903805|NCT04171141|DRUG|Anti-VEGF|Anti-VEGF IV (bevacizumab)
223903806|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
223903807|NCT03526887|DRUG|Pembrolizumab|200 mg, Q3W
223903808|NCT04315701|BIOLOGICAL|Cemiplimab|Given IV
223903809|NCT04315701|PROCEDURE|Resection|Undergo surgical resection
223903810|NCT03457493|DRUG|DPA-714-PET/MRI|DPA-714-PET/MRI
223903811|NCT03457493|DRUG|5-year Follow-up DPA-714-PET/MRI|PET/MRI scan with DPA-714
223903812|NCT03457493|DRUG|DPA-714 Metabolite Analysis|Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
223903813|NCT02599480|DRUG|mirabegron|50 mg daily during 12 months
223903814|NCT02599480|PROCEDURE|Echocardiography|Echocardiography
223903815|NCT02599480|PROCEDURE|Cardiac MRI|Cardiac MRI
223903816|NCT02599480|PROCEDURE|Maximal exercise capacity|Maximal exercise capacity
223903817|NCT02599480|PROCEDURE|Blood sampling|Blood sampling for study assessments and future exploratory studies.
223903818|NCT02599480|PROCEDURE|Endothelial function measurement|EndoPAT assessment
223903819|NCT02599480|RADIATION|18FDG-PET|PET scanning for beige/brown fat activation
223903820|NCT06150261|DIETARY_SUPPLEMENT|AvailOm|5 capsules taken once daily with main meal
223903821|NCT06150261|DIETARY_SUPPLEMENT|Placebo|5 capsules taken once daily with main meal
223903822|NCT06255535|DEVICE|active iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
223903823|NCT06255535|DEVICE|sham iTBS treatment|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
223903824|NCT05647915|DRUG|Berberine plus lifestyle intervention|"berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
223903825|NCT05647915|BEHAVIORAL|Placebo plus lifestyle intervention|"Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc."
223903826|NCT03414489|DRUG|ABC294640|
223903827|NCT05805137|DEVICE|WoundWatch® wound monitoring system|eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
223903828|NCT03314454|DRUG|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
223903829|NCT03314454|DEVICE|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
223903830|NCT05341817|DRUG|Letrozole|Letrozole priming before mTOP is used as an alternative to the use of mifepristone. Women randomly assigned (1:1) to the Letrozole arm will receive 10 mg letrozole daily for 3 days followed by 800 μg misoprostol.
223903831|NCT05341817|DRUG|Mifepristone|Mifepristone priming before mTOP is the current standard of care. Women randomly assigned (1:1) to the Control arm will receive 200 mg mifepristone followed by 800 μg misoprostol 2 days later.
223903832|NCT04855630|DEVICE|DREEM 2 Headband|Participants will wear the DREEM 2 headband for 3 months for a minimum of 4 out of 7 nights per week and will participate in its digital therapeutic Cognitive Behavioral Therapy - Insomnia (CBT-I) intervention (entails brain stimulation to improve slow wave sleep and sleep hygiene counseling tips to improve sleep behaviors).
223903833|NCT04855630|OTHER|Exercise Routine|Participants will partake in a guided exercise routine. Each routine consists of 30-minute mild circuit training session twice per week for 3 months.
223903834|NCT02673996|DRUG|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
223903835|NCT02673996|DRUG|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
223903836|NCT01803542|RADIATION|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
223903837|NCT04612933|OTHER|Intervention group video consultations|"All appointments, scheduled and non-scheduled are by telemedicine using video to commutate with the health care professionals.~Patients will follow their usual treatment."
223903838|NCT06205446|BEHAVIORAL|Healthy subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
223903839|NCT06205446|BEHAVIORAL|Laryngopharyngeal reflux disease subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
223903840|NCT06205446|BEHAVIORAL|Dyspepsia subjects : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
223903841|NCT06205446|BEHAVIORAL|Irritable bowel disorder : abdominal breathing|The guidance content for the second session of self-practice in the first week involves practicing for 5 minutes each day, and recording a week-long diary of diaphragmatic breathing. After the first week, the subjects will undergo a once-off autonomic nervous system test and a questionnaire assessment of physical and mental symptoms. In the second week, the subjects will receive guidance for the second session of daily self-practice, practicing for 5 minutes each time, and recording a week-long diary of diaphragmatic breathing. After the second week, the subjects will undergo another round of autonomic nervous system testing and a questionnaire assessment of physical and mental symptoms.
223903842|NCT04636619|PROCEDURE|Colonic polypectomy|Cold snare resection of colorectal polyps
223903843|NCT04636619|BEHAVIORAL|Online training course|Polypectomy technique online course
223903844|NCT05158738|OTHER|Patients with inherited cardiac condition, onset <16 years old and Parents|Patients with a confirmed diagnosis of an inherited cardiac condition, onset \<16 years old and Parents will have samples that undergo whole genome sequencing and biomarker analysis
223903845|NCT06231342|DEVICE|Direct Laryngoscope (DL)|DL allows visualization of the larynx. It is used during general anesthesia, for surgical procedures of the larynx, and during resuscitation.
223903846|NCT06231342|DEVICE|Video laryngoscope (VL)|VL facilitates intubation while allowing clinicians to share and record real-time high-resolution images and video.
223903847|NCT06231342|PROCEDURE|Endotracheal Tube (ETT) 180|A novel maneuver has been described to decrease the insult from stylet named Endotracheal Tube (ETT) 180; a clockwise rotation of the stylet-loaded Endotracheal Tube (ETT) 180 degrees on its axis right after the tip of Endotracheal Tube (ETT) passes the patient's vocal cords (glottis) before fully inserting the Endotracheal Tube (ETT) and then, pulling the stylet out. This maneuverer allows the stylet to match the posterior angulation of the trachea.
223903848|NCT04280848|DRUG|UCPVax|"The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum."
223903849|NCT04280848|DRUG|Temozolomide|6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
223903850|NCT04929743|DEVICE|BTI Implant|Placement of dental implants of 5.5 vs \>6.5 mm length
223903851|NCT06302816|OTHER|TUPLER exercises|"will be conducting tupler exercises, exercises that are designed to target core muscles in order to improve posture, regain core strength and reducing discomfort.~Each exercise will be repeated 10reps for 3 times on 3 days a week for 8 weeks."
223903852|NCT06302816|OTHER|SCOOP EXERCISES|will be required to complete scoop exercises basically deals with Pilates which is deep core and hip strengthening and stability through breathing patterns with the utilization of transversus abdominis muscle majorly. In each exercise participant will be asked to hold pelvic floor muscles for 8sec, then relax the muscles and count to 10, repeat I for 10 times each day for 3 days a week for 8weeks. Basic commands about the positing, activation and engagement of core along with breathing control were given to the subjects.
223903853|NCT04451226|DRUG|Fezolinetant|Oral
223903854|NCT06241781|BIOLOGICAL|GT101 injection|GT101 injection to treat cervical cancer
223903855|NCT06241781|DRUG|Gemcitabine injection|Gemcitabine injection to treat cervical cancer
223903856|NCT06485206|DEVICE|One level Mobi-C and one level fusion|"Cervical Disc Arthroplasty:~• Mobi-C~Fusion devices:~* One-level cervical plates~  o MaxAn Cervical plate system~* Interbody spacers~  * TrellOss-C - 3D printed Ti interbody~ * Vista-S - PEEK interbody~* Standalone Fixation~  * Ti-Coated ROI-C - PEEK cage w/ Ti coating~ * TrellOss-C SA - 3D printed Ti~* Bone Graft~  * Local Autograft~ * PrimaGen Advanced Allograft"
223903857|NCT04794777|COMBINATION_PRODUCT|Individualised therapy|"Group I - No uptake: treated with conventional SRT against the prostate bed. Group II -Uptake only in the prostate bed: will receive intensity modulated RT (IMRT) including Volumetric Modulated Arc Therapy (VMAT) for prostate bed with simultaneous-integrated boost (SIB) to the PET positive uptake in the prostate bed.~Group III - Uptake in the prostate bed and involvement of regional lymph nodes in the pelvis: will be treated as Group II plus VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes salvage lymph node dissection (SLND).~Group IV - Uptake in regional lymph nodes only: will be treated with VMAT for the pelvic lymph nodes with SIB to the PET positive lymph nodes or pelvic lymph nodes SLND.~Group V - Uptake in extra-pelvic lymph nodes or bone metastasis: systemic treatment instead of surgery or radiation. Local treatment with surgery or radiation is acceptable if curative intention."
223715634|NCT05766423|BEHAVIORAL|The PATTERN Intervention|"The intervention components include:~1. An adherence assessment that requests patients to self-report via MyChart about their medication use. The assessment provides a link between the health center and the patient ahead of a regularly scheduled clinic visit.~2. Care alert notifications directed to a nurse pool and/or member of the clinical care team when a medication adherence related problem is identified by the adherence assessment. The alert will also include the type of problem the patient is experiencing (cognitive, psychological, medical, regiment, social and/or economic). Once they receive these alerts, the care team can then activate appropriate staff and/or resources to respond."
223903858|NCT04794777|RADIATION|Standard salvage therapy|Standard salvage radiotherapy
223903860|NCT05922462|DIETARY_SUPPLEMENT|Greek yogurt|For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
223903861|NCT05922462|DIETARY_SUPPLEMENT|Whey protein|For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
223903862|NCT04620759|DRUG|Psilocybin|The psilocybin used in this study is synthetically manufactured and formulated under current good manufacturing practices (cGMP). The active drug is encapsulated using a size 0 blue gelatin capsule and contains 25 mg of psilocybin.
223903863|NCT04620759|DRUG|Placebo|The placebo used in this study is microcrystalline cellulose, an inert substance, encapsulated using a size 0 blue gelatin capsule.
223715635|NCT06915545|DEVICE|Aortic Arch Single Branch Covered Stent System|to Evaluate the Safety and Efficacy of the Aortic Arch Single Branch Covered Stent System for Aortic Dissection Involving the Aortic Arch
223715636|NCT06937710|DIAGNOSTIC_TEST|Measure of symmetry between the inferior limbs|Hip force moments will be analyzed in the 3 planes (in Nm/Kg) and compared between the two legs.
223715637|NCT01700725|OTHER|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
223903864|NCT06061627|PROCEDURE|LOT-CRT group|"In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads~LBBAP includes LBBP and LVSP.~LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:~1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);~2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:~   1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;~  2. When reducing the output voltage, the LVAT undergoes a sudden change of\>10ms;~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP)."
223715638|NCT01700725|DRUG|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
223903865|NCT06061627|PROCEDURE|BiVP group|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
223903866|NCT04817644|DRUG|Oral semaglutide|Oral semaglutide once daily for a total of 10 days
223903867|NCT06352970|OTHER|TB infection|Outcomes will be compared with regard to result of interferon-gamma release assay test for TB infection
223903868|NCT05728944|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine + Brimonidine combination ophthalmic solution
223903869|NCT05728944|DRUG|Aceclidine|Aceclidine ophthalmic solution
223903870|NCT05728944|DRUG|Vehicle|Proprietary vehicle ophthalmic solution
223903871|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (200 µg/kg) oro-dispersible minitablets
223903872|NCT06404333|DRUG|CHILD-IVITAB|Ivermectin (400 µg/kg) oro-dispersible minitablets
223903873|NCT05608083|BEHAVIORAL|HEARTS classes|HEARTS teaches autistic adults about friendship and healthy dating relationships. HEARTS is 6-sessions long and meets weekly over zoom. Each session is 90 minutes long.
223903874|NCT05608083|BEHAVIORAL|Online discussion group|A 90-minute discussion group will meet online weekly for 6 weeks to discuss friendships and healthy dating relationships for autistic adults.
223903875|NCT06418854|OTHER|Questionnaire|Adapted design questionnaire to estimate the vaccine hesitancy specifically for dengue vaccine
223903876|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.
223903877|NCT04828733|PROCEDURE|laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty|Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.
223903878|NCT04828733|PROCEDURE|Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.|Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
223903879|NCT04096170|DRUG|IV lidocaine|Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
223903880|NCT04096170|DRUG|Placebo|o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
223903881|NCT04233216|DRUG|ISL|ISL 0.75 mg capsule taken by mouth.
223903882|NCT04233216|DRUG|DOR|DOR 100 mg tablet taken by mouth.
223903883|NCT04233216|DRUG|DOR/ISL|100 mg DOR/0.75 mg ISL FDC taken by mouth.
223903884|NCT04233216|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
223903885|NCT04233216|DRUG|Placebo to DOR|Placebo tablet matched to DOR taken by mouth.
223715639|NCT00809276|DRUG|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
223715640|NCT01119612|DIETARY_SUPPLEMENT|Iron|Daily oral dose of 60 mg from enrollment until delivery
223903886|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12% and CITROX|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
223903887|NCT06341439|DEVICE|Mouthwash with chlorhexidine 0,12%|Patients use the undiluted mouthwash 2 times a day for 14 days after performing normal brushing.
223903888|NCT04877717|DRUG|SHR-A1904|SHR-A1904
223903889|NCT05548322|DEVICE|Different surfaces to be touched|The participant will touch various different surfaces and textures, including ones of different temperature and including solids and liquids.
223903890|NCT05548322|BEHAVIORAL|Emotional state change|The emotional state of the participant will be modulated by listening to music.
223903891|NCT05548322|DEVICE|Electrical stimulation|The participant will receive electrical stimulation of single nerve fibers (a few microamps) to artificially excite an individual afferent.
223903892|NCT05461339|DRUG|TAB014 Monoclonal Antibody Injection|intravitreal injection at 1.25mg once every 4 weeks
223903893|NCT05461339|DRUG|Ranibizumab Injection [Lucentis]|intravitreal injection at 0.5mg once every 4 weeks
223903894|NCT03823209|BEHAVIORAL|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
223903895|NCT03823209|BEHAVIORAL|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
223903896|NCT03652389|BEHAVIORAL|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
223903897|NCT04621175|DIETARY_SUPPLEMENT|EAA+W & Carbohydrate|Essential amino acid plus whey beverage with added carbohydrate
223903898|NCT04621175|DIETARY_SUPPLEMENT|EAA+W & EAA|Essential amino acid plus whey beverage with added essential amino acid
223903899|NCT06139016|DEVICE|Virtual reality|Virtual reality gear and content will be used to affect and control the audiovisual perception of patients during a single treatment with ketamine/esketamine
223903900|NCT03484039|BEHAVIORAL|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
223903901|NCT03484039|BEHAVIORAL|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
223903902|NCT03484039|BEHAVIORAL|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
223903903|NCT03484039|BEHAVIORAL|Stress Management|Some subjects will be enrolled in a stress management course.
223903904|NCT05819697|OTHER|FIRE Trial/Track Your Happiness notifications|"All participants will receive notifications to their smart phones 3 times a day for 12 weeks. They will be asked questions related to burning mouth, to exercise as well as non-clinical Track Your Happiness questions, e.g., Are you interacting with anyone right now? How do you feel right now?"
223903905|NCT04050436|DRUG|Cemiplimab|Cemiplimab administered intravenously
223903906|NCT04050436|BIOLOGICAL|RP1|RP1 administered intratumorally
223903907|NCT05503238|BEHAVIORAL|Skin-to-skin contact|Preterm infants will receive maternal-infant skin-to-skin contact at least 1 continuous hour everyday from infant 3 days of life until discharge, and other nursing care will be same as the routine group. During skin-to-skin contact, place naked baby only with diaper on the mother's bare chest in an upright position and tilt the baby's head to one side in a slightly extended position to keeps the airway open, cover the infant with a blanket to keep them warm. A neonatal nurse will be stay with mother and infant to observe and support.
223903908|NCT05503238|OTHER|Routine care|Preterm infants will receive standard nursing care provided by neonatal nurses in accordance with hospital principles during hospitalization.
223903909|NCT02345122|BEHAVIORAL|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
223903910|NCT02345122|OTHER|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
223903911|NCT02057783|OTHER|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
223903912|NCT04481555|DRUG|Azithromycin|Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
223903913|NCT04481555|DRUG|ICS|All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
223903914|NCT03519464|BIOLOGICAL|Gardasil 9|Gardasil 9 administered as a 0.5ml intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
223903915|NCT03855735|BEHAVIORAL|TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
223903916|NCT04044794|BEHAVIORAL|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
223903917|NCT04044794|BEHAVIORAL|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
223903918|NCT06109818|DRUG|ICP-488 Tablets|ICP-488 will be administered as tablet
223903919|NCT06109818|DRUG|ICP-488 Placebo|ICP-488 Placebo will be administered as tablet
223903920|NCT06044090|DRUG|Minocycline|Participants will take 2 pills of 100 mg totaling a 200 mg dose of minocycline per day.
223903921|NCT06044090|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 2 placebo tablets matching the Minocycline tablets daily for 5 days.
223903922|NCT05338801|OTHER|Menthol-flavored e-cigarette|All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.
223903923|NCT05338801|OTHER|Tobacco-flavored e-cigarette|All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.
223903924|NCT05326451|DEVICE|active tDCS|Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
223903925|NCT04910152|DRUG|BRD4 Inhibitor PLX51107|Given PO
223903926|NCT05103384|OTHER|Virtual Reality Environment|Participants complete various tasks in a virtual home and grocery store environment.
223903927|NCT04072458|DRUG|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m\^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
223903928|NCT05563675|DRUG|Long acting muscarinic antagonists (LAMAs) in the evening|LAMAs administered at bedtime (8pm - 2am)
223903929|NCT05058417|DRUG|Empagliflozin 10 MG|participants will receive 10 mg Empagliflozin for 8 consecutive weeks in addition to the standard therapy
223903930|NCT05058417|DRUG|Placebo|participants will receive placebo for 8 consecutive weeks in addition to the standard therapy
223903931|NCT05292157|PROCEDURE|shoulder arthroplasty|range of motion (in degrees) measured in annual postoperative follow-up
223903932|NCT05126082|BEHAVIORAL|PedsBP CDS|The PedsBP CDS is a sophisticated web-based electronic health record (EHR)-linked tool that can be used to address barriers and improve the identification and management of elevated blood pressure (BP) and hypertension (HT) in children and adolescents by providing patient-specific clinical care recommendations in real time and in accordance with national guidelines for BP management in youth.
223903933|NCT03296371|PROCEDURE|Biospecimen Collection|Undergo saliva or buccal mucosa collection
223903934|NCT03296371|OTHER|Laboratory Biomarker Analysis|Correlative studies
223903935|NCT03296371|OTHER|Questionnaire Administration|Ancillary studies
223903936|NCT05718583|DIETARY_SUPPLEMENT|Butyrate|"Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months. The minimum duration necessary for an evaluable participant will be 2 weeks of SCFA supplementation."
223903937|NCT04714476|DEVICE|Made-to-measure compression garment|"Subjects will wear one of two made-to-measure compression garments:~(1) JOBST® Confidence leggins (BT) and (2) JOBST® Confidence Bermuda (ET)"
223903938|NCT04344678|DRUG|Sildenafil Citrate|Esitalopram 20 mg tablet plus Sildenafil Citrate 50 mg tablet once daily
223903939|NCT04344678|DRUG|Placebo oral tablet|Esitalopram 20 mg tablet plus placebo tablet once daily
223715641|NCT01119612|OTHER|Placebo|Daily oral dose from enrollment until delivery
223903940|NCT02591745|PROCEDURE|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
223903941|NCT06014983|DIETARY_SUPPLEMENT|Ferrous fumarate|Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
223903942|NCT06014983|DIETARY_SUPPLEMENT|Ferrous bisglycinate|Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
223903943|NCT03956446|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
223903944|NCT03956446|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
223903945|NCT03956446|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
223903946|NCT05469347|DRUG|Alirocumab|A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
223903947|NCT05469347|DRUG|Placebo|A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
223903948|NCT06442982|DEVICE|insole-type gait analyzer|Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
223903949|NCT06494787|COMBINATION_PRODUCT|Aliya Pulse Electric Field sysem and pembrolizumab|This is a phase 2 study to determine the efficacy of the Aliya Pulse Electric Field system and pembrolizumab in prolonging progression free and overall survival of patients with advanced soft tissue sarcoma
223903950|NCT05222971|DRUG|Durvalumab|"Durvalumab 1,500 mg IV on Day 1~Every 4 weeks"
223903951|NCT05222971|DRUG|Olaparib|"Olaparib 300 mg twice daily~Every 4 weeks"
223903952|NCT05974852|OTHER|Ocrelizumab|Non-interventional
223903953|NCT03553095|PROCEDURE|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
223715642|NCT02385045|DEVICE|i-scan|i-scan function is located on the head of the Pentax endoscopes
223715643|NCT02385045|DEVICE|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
223715644|NCT03478020|DRUG|AQX-1125|Investigational Drug
223715645|NCT03478020|DRUG|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
223903954|NCT02588651|DRUG|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
223903955|NCT03747146|DEVICE|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
223903956|NCT03747146|DEVICE|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
223903957|NCT06208514|BEHAVIORAL|Brief pain exposure therapy (BPET)|"Participants will complete daily logs for 7-days pre-treatment baseline, along with 21 days during the intervention protocol (fibromyalgia participants only will complete the daily logs), and 7 for days post-treatment.~Brief Pain Exposure Therapy will be given for 3 weeks, 1.5 hours per week, telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, mindfulness meditation, and graded exposure techniques for improving tolerance of painful or feared activities. Participants will also be provided handouts and pre-recorded meditation and imagery scripts that participants can use to facilitate between-session practices. In addition, participants will complete surveys through-out the study."
223903958|NCT06801158|DRUG|use of anticancer drugs in monotherapy or in combination therapy|ICSRs involving antineoplastic or immunomodulating agents were included.
223903959|NCT02278744|RADIATION|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 17 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
223903960|NCT02278744|DEVICE|MRI and/or CT|
223903961|NCT04792931|OTHER|description of adult autoimmune myopathies|description of adult autoimmune myopathies
223903962|NCT05429827|OTHER|normal saline|Inject 2 ml normal saline into a myofascial trigger point and evaluate the clinical effects before and after the injection.
223903963|NCT05429827|DRUG|Dextrose 5% in water|Inject 2 ml 5% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
223903964|NCT05429827|DRUG|Dextrose 15% in water|Inject 2 ml 15% dextrose into a myofascial trigger point and evaluate the clinical effects before and after the injection.
223903965|NCT06031623|DEVICE|REBOA|Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.
223903966|NCT06496425|BEHAVIORAL|Music|Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
223903967|NCT04457960|DRUG|JNJ-66525433|Participants will receive JNJ-66525433 oral capsules.
223903968|NCT04457960|DRUG|Placebo|Participants will receive matching placebo oral capsules.
223903969|NCT05348174|BEHAVIORAL|Virtual Reality Assisted Guided Imagery (VRAGI)|The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
223903970|NCT05088915|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP)|"This program is adapted from the B.R.E.A.T.H.E. - Brief Relaxation, Education and Trauma Healing: A Brief Intervention for Persons with PTSD and Co- Occurring Serious Mental Health Conditions. Treatment Program Manual and Patient Handouts (Version 3) by Kim T. Mueser, Rachael Fite, Stanley D. Rosenberg, and Jennifer D. Gottlieb."
223903971|NCT05088915|BEHAVIORAL|Treatment As Usual|Receive standard care treatment and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
223903972|NCT02567669|RADIATION|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
223903973|NCT06348342|OTHER|Pelvic Floor Muscle Exercise|Training for PFME will be given orally and will cover the importance of FME and how to do the exercises, as well as the conditions and frequency of doing the exercises. You will be told that the exercise should be done when the bladder is empty, three times a day (morning, noon and evening) and repeated 10 times in each set. In the first week of exercise, the pelvic floor muscles will be contracted for 3 seconds and relaxed for 3 seconds, and will be increased by 1 second each week. It will be explained that from the 8th week onwards, it will be done by contracting for 10 seconds and relaxing for 10 seconds and will continue. It will be stated that the learning process of pelvic floor muscle exercise may take 6 weeks to 6 months. It will be stated that this exercise should be applied throughout their lives for the sustainability of PFM strength. The training is planned to last approximately 20 minutes. PFME will last for two months. Women in menopause will be given an exercise chart.
223903974|NCT06348342|OTHER|Core Exercise|Activating the contraction of the deep core muscles TrA and mutifidus without disrupting breathing forms the basis of core stabilization exercises. To teach the \&#34;abdominal hallowing\&#34; maneuver, which enables the activation of these muscles, patients will be shown a picture of the TrA muscle and asked to contract their lower abdominal muscles while lying on their back in the hook position. During the maneuver, care will be taken to ensure that no movement occurs in the trunk and pelvis and that diaphragmatic breathing continues. After the abdominal hallowing maneuver is taught, the exercises will be progressed gradually. A home exercise program will be given for this. The 7-level exercise program recommended by Hagins et al. will be used as a home exercise program. The movements in this program load more moments on the muscles that stabilize the lumbar spine as the levels progress. The stages of the exercise program are shared in the brochure to be given to the patients.
223903975|NCT06690411|OTHER|Mulligan Concept|The participants of the Mulligan SNAG group will undergo the Mulligan SNAG technique. Mulligan's SNAG technique is a gentle manual therapy method. This technique is based on the correction of the joint position. There are 3 techniques specified for headache; Headache SNAG, Reverse Headache SNAG, and C1-C2 SNAG.
223903976|NCT06690411|OTHER|Myofascial Release Technique|Myofascial therapy can be described as massage-type manual therapy. The participants of the Myofascial Release Group will undergo the myofascial release technique.
223903977|NCT05606237|DEVICE|Low-level Red Light Therapy Device|The treatment device used in this study is a semi-conductor laser product (Eyerising International Pty Ltd, Melbourne, Australia), emitting low-level red-light with a wavelength of 650 ± 10 nm. Based on calculations done by the manufacturer, the device provides light at a power of 2.00 ± 0.50 mW.
223903978|NCT02216032|OTHER|TMW Curriculum|
223903979|NCT02216032|OTHER|Nutrition Curriculum|
223903980|NCT02749006|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
223903981|NCT02749006|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
223903982|NCT06297863|PROCEDURE|HEAD DOWN TILT -10° to -15°|"Head down tilt -10° to -15° (HDT15) is a positional therapy consisting of tilting the patient with the head -10° to -15° degrees below the rest of the body.~Application of HDT15 will not delay usual care. The standard in-hospital patient pathway, including transfer from neuroimaging room to the angiography suite and the required procedural steps of MT, will allow sufficient time for the application of HDT15. HDT15 duration is expected to be at least 30 minutes (estimated time 30 to 90 minutes), from start to the assessment of the primary efficacy endpoint.~The actual degree of HDT15 will be a range between -10° to -15°, depending on the angiographic system of each clinical site, but it will be maintained at -15° during the Emergency Room phase which is expected to account for \>50% of the total application time."
223903983|NCT05643014|OTHER|Sample collection|This study will involve three sample collections including buccal cells and urine samples
223903984|NCT06590532|PROCEDURE|Endovascular aneurysm repair or aorto iliac endovascular revascularisation with Fusion imaging system Cydar-EV|Cydar-EV image fusion is a CE-marked medical device, which instead of a table-tacked overlay uses computer vision to fuse pre-procedural 3D images with intra-operative 2D fluoroscopy automatically and in real-time.
223903985|NCT06590532|PROCEDURE|Endovascular aneurysm repair or aorto iliac endovascular revascularisation without Fusion imaging system Cydar-EV|patients will be assigned either to an endovascular repair using standard X-ray fluoroscopy imaging alone (the current reference standard)
223903986|NCT03277495|BEHAVIORAL|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
223903987|NCT06467617|DRUG|Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab|"Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle"
223903988|NCT04948398|DRUG|Guselkumab|Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
223903989|NCT05599711|BEHAVIORAL|Transitioning Together (TT) / Juntos en la Transicion (JET)|"1. One individual family joining session when each family dyad meets with group therapists to establish rapport and share their own unique family's background, goals, and supports.~2. A series of four 2.5-hour multi-family group psychoeducation intervention sessions focused on problem-solving education and psychoeducational autism transition-to-adulthood content which can include independence in adulthood, community involvement, guardianship and legal issues, employment and education, health and well-being."
223903990|NCT05599711|BEHAVIORAL|Usual autism transition care|An expedited referral will be made for participants to establish care with a BMC Autism Program Transition/Resource Specialist. Data will be abstracted from the electronic medical record on how many visits each family completes with a BMC Autism Program Transition/Resource Specialist or other BMC Developmental and Behavioral Pediatrics provider throughout the study period.
223903991|NCT05531747|OTHER|Skin biopsy|A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.
223903992|NCT05531747|OTHER|Blood sample|42mL of blood (6 tubes of 7mL) sampled at initiation visit
223903993|NCT04123821|DEVICE|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
223903994|NCT05032040|BIOLOGICAL|vudalimab|Monoclonal bispecific antibody
223903995|NCT00576979|DRUG|cyclophosphamide|Given IV
223903996|NCT00576979|DRUG|etoposide|Given IV
223903997|NCT00576979|PROCEDURE|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
223903998|NCT00576979|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
223903999|NCT00576979|PROCEDURE|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
223904000|NCT00576979|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
223904001|NCT00576979|RADIATION|tomotherapy|Undergo IMRT using helical tomotherapy
224276973|NCT04478526|DRUG|SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)|If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
223904002|NCT05560581|BEHAVIORAL|Digital self-efficacy training|Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.
223904003|NCT05560581|BEHAVIORAL|Ecological Momentary Assessment|Participants will receive questions on mood and social/virtual contacts 3 times per day.
223904004|NCT05729802|DEVICE|HoloSIM Software via Hololens 2|Participants will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
223904005|NCT05729802|OTHER|Training by Mannequin Based Simulation|Participants will train a via traditional mannequin based medical crisis scenario
223904006|NCT03924661|DEVICE|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
223904007|NCT06454331|DEVICE|Transcranial direct current stimulation|The two key landmarks for EEG electrode placement are the nasion and the inion which are used to define the measurement. Measure the distance between the nasion and the inion along the midline of the head. Divide the nasion-inion distance by two to find the midpoint and mark this midpoint on the scalp along the midline. C3 (left hemisphere of the scalp) and C4 (right hemisphere of the scalp), which are placed 20% of the nasion-inion distance from the midline, and M1, which is placed 10% of this distance from the midline, can be determined using these calculations. From the midpoint marked on the scalp, measure to the left and right sides using the calculated 10% and 20% distances. Mark these points as M1 and its mirror position. Clean the scalp at the marked M1 and its mirror position locations to remove any oils or debris.
223904008|NCT06454331|DEVICE|Sham transcranial direct current stimulation|it can apply in sitting or supine lying position but it's important to ensure their comfort and safety while facilitating optimal electrode placement and contact with the scalp. Duration of 20 minutes, with Intensity of 0.5mA, and density of 0.02 mA/cm² for 8 weeks on alternative days
223904009|NCT04861818|BEHAVIORAL|Moderate-intensity aerobic exercise|Eligible participants will come into the lab on day 1 and 3 at the same time of day (either morning at 7-10am or afternoon at 3-5pm). They will be then randomly assigned for a rest or an exercise session prior to the memory test. For the rest condition, they will be required to sit and relax while watching Planet Earth for 30 minutes on a cycle ergometer. During the exercise session, they will complete a moderate-intensity cardiovascular exercise for 20 minutes following a 5-min warm-up and followed by a 5-min cool-down on a cycle ergometer. They will start the memory test immediately after the rest/exercise session.
223904010|NCT06542575|OTHER|DTx-guided HBCR|The Huaxiaoxin WeChat mini program incorporating the core components of guidelines are divided into two main sections. Section 1 comprises interventions such as exercise training, educational programmes and cardiovascular risk factor management. Section 2 provides a secure platform for individualized feedback, just-in-time two-way communication, remote data transmission, and data repository, allowing patients and healthcare providers to access all relevant files anytime and anywhere throughout the 12-month study period.
223904011|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-1|Components of LMN-201
223904012|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-2|Components of LMN-201
223904013|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-3|Components of LMN-201
223904014|NCT04893239|BIOLOGICAL|LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3|Components of LMN-201
223904015|NCT04950712|PROCEDURE|Blood sampling|Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).
223904016|NCT04950712|PROCEDURE|Anogenital lesion swab collection|Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
223904017|NCT06247306|BEHAVIORAL|ScanSTRESS fMRI-paradigm (Streit et al., 2014)|The task is conducted within the MRI scanner and consists of two runs each lasting 11:20 mins., employs a block design and has two different conditions (performance, relaxation), as well as two different task within each condition. Participants undergo the following 2 tasks during the performance condition under time pressure: 1) serial subtraction, 2) a figure matching task. During the performance condition, all participants receive feedback (work faster, mistake, too slow) and are reprimanded concerning their performance. Two investigators in white coats observe the participants with critical facial expression, which is projected to participants through live-video feed during the tasks. The relaxation condition includes easy versions of arithmetic and figure matching task without time constrains or any type feedback on their performance. Performance and relaxation phases are appear in alternating order.
223715646|NCT04588948|DRUG|Intravitreal Aflibercept|Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
223715647|NCT05412745|DEVICE|Kaloidon Plus|topical application; twice daily
223715648|NCT05412745|DEVICE|silicone gel|topical application; twice daily
223715649|NCT05621785|DEVICE|Lung Ultrasonografi|All babies under 32 weeks of gestation will be included in the study. All data of postnatal corticosteroid users will be recorded using lung USG
223904018|NCT06247306|BEHAVIORAL|real-time fMRI neurofeedback|"Two real-time fMRI neurofeedback sessions of 9:30 minutes each are conducted. During these sessions, the participants are instructed to regulate a feedback signal from the ACC. Participants are assigned to either the experimental or Yoke-control group through an automated double-blind procedure. In the neurofeedback sessions, participants in the experimental group receive a feedback signal indicating their current ACC activation. Participants in the control group receive the recorded feedback signal from another participant. The neurofeedback sessions follow a block structure with alternating feedback and rest periods.~Before, between, and after the two sections of the fMRI examination, subjective stress levels and alcohol craving are assessed, and saliva samples are collected for cortisol level determination."
223904019|NCT06301516|BEHAVIORAL|Virtual Reality|VR: The goal of the VR intervention is to provide youth an immersive, engaging, and therapeutic environment to reduce CD and CU traits
223904020|NCT06301516|OTHER|Comparative Control|Complete a one-time PowerPoint presentation that provides an overview of emotion expressions and instructions on how to recognize emotions in others.
223904021|NCT04031820|PROCEDURE|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
223904022|NCT04031820|PROCEDURE|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
223904023|NCT06289517|DRUG|68Ga-Her2-affibody|68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.
223904024|NCT06292325|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard therapy for Obstructive Sleep Apnea. It consists of a machine that delivers a constant and steady air pressure through a mask worn over the nose or both nose and mouth during sleep. This continuous flow of air helps to keep the airway open, preventing episodes of airway collapse and obstruction characteristic of OSA. CPAP therapy is highly effective in reducing symptoms such as snoring, daytime sleepiness, and fatigue, as well as improving overall sleep quality and decreasing the risk of complications associated with untreated OSA, such as cardiovascular issues. It is considered the gold standard treatment for moderate to severe OSA and is often prescribed after a sleep study confirms the diagnosis. CPAP machines come in various designs and features to suit individual needs and preferences, and proper adjustment and compliance are essential for optimal treatment outcomes.
223904025|NCT06355752|OTHER|Dry needling of lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. Ten incisions will be made in the muscle.~The head will rest comfortably on a pillow"
223904026|NCT06355752|OTHER|Sham dry needling lumbar iliocostalis muscle|"Subjects will be treated with dry needling to the quadratus lumborum muscle. To do this, the subject will be lying laterally on the contralateral side and with the hip in an adducted position. The placebo needle will move 10 times imitating the real procedure.~The head will rest comfortably on a pillow"
223904027|NCT05805176|DEVICE|ADHD Therapy|investigational game-play therapy
223904028|NCT05787470|BEHAVIORAL|Quantative sensory testing|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
223904029|NCT05787470|DIAGNOSTIC_TEST|Blood Draw|Sample of blood will be taken.
223904030|NCT05099679|BEHAVIORAL|Cognitive behavioral therapy (supportive counseling)|Patients will complete a psychosocial intake that generally takes up to 2 hours, but the time required for the intake varies per patient. Subsequently they will be offered up to 7 optional counseling sessions with a clinical social worker
223904031|NCT05099679|BEHAVIORAL|Virtual Cardiac Rehabilitation|If eligible, patients will be referred to Movn Health Virtual Cardiac Rehabilitation to provide approximately 3 exercise sessions per week, with approximately eight coaching sessions over a 12 week period
223904032|NCT05772767|OTHER|Biological sample collection|Collection of tumor tissue and blood for stem cell culture and organoids generation.
223904033|NCT05772767|OTHER|Dissecting ciliogenesis players|Assessment of cilium-related transcriptome in glioblastoma stem cells. Modulation of cilium-related genes and administration of cilium-targeted drugs to glioblastoma stem cells in vitro and ex vivo in glioblastoma brain organoids.
223904034|NCT05772767|DIAGNOSTIC_TEST|Validating ciliogenesis players|Cilium-related signature will be studied in tumor tissue to evaluate its prognostic role.
223904035|NCT05698875|OTHER|Breakfast meals|Test meal 1: HGL Test meal 2: HGLP Test meal 3: MGL Control meal: usual breakfast
223904036|NCT06551935|BEHAVIORAL|Habitual sleep habits without intervention|Sleep habits maintenance
223904037|NCT06551935|BEHAVIORAL|Sleep extension and sleep hygiene|Players will extend their time in bed by 25%, based on their baseline sleep, and adopt sleep hygiene behaviors: relatively fixed sleep schedule; do not lie in bed awake for long periods of time; no caffeine and no alcohol prior to bedtime; avoid heavy meals close to bedtime; sleep environment cool, dark and quiet; low exposure to screen lights before bedtime, only with nightshift mode and low luminosity (avoid high cognitive demanded activities, like gaming); low luminosity near to bedtime; ensure adequate exposure to light in the morning.
224083521|NCT02342132|DEVICE|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
223904038|NCT06689098|DIAGNOSTIC_TEST|Magnetocardiography scan|The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.
223904039|NCT05010421|DRUG|Clobetasol 0.05% Emollient Top Cream|Topical corticosteroid treatment of affected vulvar skin areas.
223904040|NCT05010421|DEVICE|Non-ablative CO2 Laser|Superficial non-ablative laser treatment of affected vulvar skin areas.
223904041|NCT06349057|DRUG|reducing anticholinergic burden|In the intraoperative and postoperative periods instead of drugs with high anticholinergic burden; drugs with low burden will be preferred.
223904042|NCT06648304|DRUG|TTYP01 tablets|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
223904043|NCT06648304|DRUG|Placebo (Simulant TTYP01 Tablets)|Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
223904044|NCT04329975|DRUG|Desmopressin|Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.
223904045|NCT05907564|DEVICE|Thrombectomy|Use of Aventus Thrombectomy System to treat pulmonary embolism
223904046|NCT02886312|DEVICE|Supplemental Oxygen Delivery System|
223904047|NCT05195294|BIOLOGICAL|LioCyx-M|HBV antigen specific TCR redirected T cells
223904048|NCT05195294|DRUG|Lenvatinib|12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
223904049|NCT05010681|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223904050|NCT05010681|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223904051|NCT06123312|DIAGNOSTIC_TEST|Tri-modality biopsy|When the lung nodule is visualized by ultrathin bronchoscope (3mm) with RP-EBUS, Tri-modality biopsy is performed.
223904052|NCT05496231|BIOLOGICAL|HPV9 High formulation|3 doses of the high formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
223904053|NCT05496231|BIOLOGICAL|HPV9 Medium formulation|3 doses of the medium formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
223904054|NCT05496231|BIOLOGICAL|HPV9 Low formulation|3 doses of the low formulation of HPV9 investigational adjuvanted vaccine were administered intramuscularly at Day 1, Month 2 and Month 6.
223904055|NCT05496231|BIOLOGICAL|Gardasil 9|3 doses of the marketed HPV vaccine (Gardasil 9) were administered intramuscularly at Day 1, Month 2 and Month 6.
223904056|NCT04835103|BEHAVIORAL|CM|Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation
223904057|NCT04835103|BEHAVIORAL|P/T|Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist
223904058|NCT03711734|OTHER|Acupuncture + Standard of Care|Acupuncture is a nonpharmacologic pain management modality that has been shown to provide superior analgesia for acute pain. This will be combined with our facility's standard of care anesthesia and pain management plan.
223904059|NCT06462443|BEHAVIORAL|RISE for Physicians Program|RISE for Physicians Program. Psychoeducational group program designed to impact resilience, insight, self-compassion, and empowerment
224276974|NCT04478526|BEHAVIORAL|Electronic Cognitive Behavioural Therapy|Weekly sessions of e-CBT through OPTT will consist of approximately 30 slides. Each session is expected to last approximately 50 minutes. The content and format of each weekly online session was designed to mirror live CBT. The slides will highlight a different topic each week and include general information, an overview of skills and homework on that topic. The homework included in each session will be submitted through OPTT and reviewed by the clinicians with personalized feedback provided by clinicians within three days of submission. Weekly homework submission for feedback will be mandatory before being eligible for the next session. Biweekly GAD-7, DASS-42 and Q-LES-SF questionnaires will be completed through OPTT. A second STAI will be completed in the final week of e-CBT treatment.
223904060|NCT06048185|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
223904061|NCT06461923|DEVICE|Insole wearing|The insole-wearing group is instructed to wear the insole gait analysis device as frequently and for as long as possible during outdoor activities. Participants receive feedback during 3rd to 4th week via telephone. Following a period of 6 weeks, an evaluation of the usability and satisfaction of the insole gait analysis device will be conducted.
223904062|NCT04438083|BIOLOGICAL|CTX130|CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
223904063|NCT04571229|DRUG|L-MTP-PE|L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
223904064|NCT05994625|DEVICE|Stream™ Platform|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~Stream™ Platform utilizes the continuous measurements of drain effluent characteristics to generate a Risk Score that is provided to the surgeon. The Risk Score is intended to provide an additional tool for the early diagnosis of anastomotic leakage."
223904065|NCT05994625|DEVICE|Stream™ Platform with Risk Score Omitted|"Stream™ Platform consists of 3 main components: Origin™ , Delta™ Monitor, and Stream™ Application. Origin™ is an inline biosensor system that can be attached inline between an off-the-shelf drainage catheter and reservoir system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) to identify potential anastomotic leaks. The Stream™ Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor).~This version of Stream™ Platform is utilized purely for observational purposes. Therefore, no Risk Score is generated. This allows postoperative monitoring of patients without any influence from the Stream™ Platform."
223904066|NCT05875545|OTHER|Breathing Exercises|Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week
223904067|NCT05875545|OTHER|Pelvic Floor Exercises|Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
223904068|NCT04284969|BEHAVIORAL|PROADAPT program|"* A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~* Pre-operative physical training including strength, endurance and breathing exercises.~* A nutrition activity.~* An activity to educate patients (on nutrition, exercise).~* The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~* A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~* A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery."
223904069|NCT03171129|DEVICE|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
223904070|NCT03171129|DEVICE|High flow Nasal Canula|Oxygen will be administered via nasal canula
223904071|NCT06313021|OTHER|Reliability and Validity Study|Reliability and Validity Study
223904072|NCT06094153|DIETARY_SUPPLEMENT|Placebo|Consume placebo (Maltodextrin) once daily before going to bed for 28 days
223904073|NCT06094153|DIETARY_SUPPLEMENT|HMO 1|Consume HMO 1 (Dietary supplement) once daily before going to bed for 28 days
223904074|NCT06094153|DIETARY_SUPPLEMENT|HMO 2|Consume HMO 2 (Dietary supplement) once daily before going to bed for 28 days
223904075|NCT06482762|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
223904076|NCT05029622|DRUG|Triptorelin Pamoate|Triptorelin 6-month formulation for IM on day 1 and Month 6.
223904077|NCT04084288|OTHER|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
223904078|NCT04084288|DEVICE|Peripheral Nerve Stimulator|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus).
223904079|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Oblique Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Oblique liners according to the approved indications and compatible device.
223904080|NCT05980234|DEVICE|Total Hip Arthroplasty with Longevity IT Offset Liners|Primary or Revision Total Hip Arthroplasty using the Longevity IT Offset liners according to the approved indications and compatible device.
223904081|NCT05363891|DRUG|Natrunix|Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
223904082|NCT05363891|DRUG|Placebo|Placebo
223904083|NCT05012696|DEVICE|Non-invasive ventilation (NIV)|Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.
223904084|NCT05012696|DEVICE|High-flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
223904085|NCT06250803|DEVICE|early pancreatic stent placement (EPSP)|In the EPSP group, a single pig-tail pancreatic stent (5Fr) will be inserted instantly after ERC or EST, and subsequent biliary procedures will proceed as planned. In contrast, in the LPSP group, while keeping the PD guidewire in place, a single pig-tail PD stent (5Fr) will be ultimately placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage.
223904086|NCT03995173|DEVICE|repetitive transcranial magnetic stimulation|rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
224276975|NCT05509088|DEVICE|high flow nasal cannula|Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
224276976|NCT03985046|DRUG|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
223904087|NCT06181461|OTHER|Gong's Mobilization|Group A received Gong's mobilization with routine physical therapy included a 30-45 min session with 15-min TENS. Patients followed daily care instructions, using the affected shoulder in daily activities, and performed pendulum and active shoulder exercises twice a day.
223904088|NCT06181461|OTHER|Kaltenborn Mobilization|Group B will receive Kaltenborn mobilization (Grade III posterior translation) with routine therapy. Posterior translation is applied in 30-sec sets, repeated 15 times over 10 mins, with 10-sec rests. Routine physical therapy includes 30-45 min sessions with 15-min TENS. Patients follow daily care instructions, use the affected shoulder in daily activities, and perform pendulum and active shoulder exercises twice a day.
223904089|NCT03739723|OTHER|Resource allocation to improve surgical learning environments|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific learning environment and resident well-being report, a Wellness Toolkit, coaching webinars, and in-person/virtual conferences to help improve their surgery learning environment and residents' well-being.
223904090|NCT04228419|PROCEDURE|Total Shoulder Arthroplasty|Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
223904091|NCT04228419|PROCEDURE|Reverse Shoulder Arthroplasty|Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
223904092|NCT04319042|PROCEDURE|Immediate Loading|The implant receives an artificial tooth the same day as it is placed.
223904093|NCT04319042|PROCEDURE|Early Loading|The implant receives an artificial tooth 4 weeks after placement.
223904094|NCT05877885|BEHAVIORAL|Targeted Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive training per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform, and includes tasks that emphasize training of sustained attention, salience detection, and dimensions of cognitive control. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
223904095|NCT05877885|BEHAVIORAL|General Cognitive Training Intervention|In this intervention, participants will complete 25-30 minutes of cognitive activities per day, 5 days/week (but up to 7 days/week) for 4 weeks. The training protocol will be delivered via the Posit Science Platform. The intervention protocol will include computerized cognitive activities designed to provide general cognitive stimulation. During the 4 week intervention, participants will have weekly 10-20 minute visits with a Care Manager to provide clinical monitoring of symptoms and structured support to participants.
223904096|NCT06033508|OTHER|exercise with whole body vibration device|exercise with whole body vibration device
223904097|NCT06033508|OTHER|placebo exercise|exercise without vibration on land
223904098|NCT04829877|BEHAVIORAL|Web-based mind-body intervention with HRVB|The web-based mind-body intervention with HRVB contains the following components: 1) Breathing training with HRV biofeedback; 2) 5 different topics will be included ; 3) Home exercise of slow breathing and mindfulness exercise.
223904099|NCT04829877|BEHAVIORAL|Web-based mind-body intervention|The web-based mind-body intervention will receive 5 different topics courses.
223904100|NCT05851963|DEVICE|Sonicare Diamond Clean 9000|Brush teeth with the electric toothbrush 1 daily during the orthodontic treatment
223904101|NCT05851963|DEVICE|HydroSonic Pro|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
223904102|NCT05851963|DEVICE|Oral-B 123|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
223904103|NCT05851963|DEVICE|Curaprox CS 5460|Brush teeth with the electric toothbrush 2 daily during the orthodontic treatment
223904104|NCT05358834|DIETARY_SUPPLEMENT|Melatonin|Oral melatonin administered as a single pill.
223904105|NCT05358834|DIETARY_SUPPLEMENT|Placebo|Oral placebo administered as a single pill.
223904106|NCT06723444|BEHAVIORAL|Learning and Memory Training|"The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context.~Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions)."
223904107|NCT06723444|BEHAVIORAL|Placebo Comparator|The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).
223904108|NCT06717880|DRUG|IBI363 combined with Bevacizumab|"IBI363 will be administrated on Day 1 of every 2 weeks or every 3 weeks, intravenous injection.~Bevacizumab, intravenous injection."
223904109|NCT06717880|DRUG|IBI363 + Furuitinib|IBI363 Q2W or Q3W IV，Furuitinib po
223904110|NCT06822985|DRUG|QL1706|Drug: QL1706 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
223904111|NCT03828799|COMBINATION_PRODUCT|Folfirinox + regorafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
223904112|NCT04091867|DRUG|sEphB4-HSA with chemotherapy|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis. Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).
223904113|NCT04091867|DRUG|Cetuximab|Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window
223904114|NCT04091867|RADIATION|Radiation Therapy|6930 cGy IMRT starting D15-D18
223904115|NCT05524181|OTHER|Telehealth Integrated Primary Care (TIPC)|The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
223904116|NCT05526430|DRUG|Harmine Hydrochloride Capsules|capsules taken orally
224276977|NCT03658434|RADIATION|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
224276978|NCT04013763|OTHER|wheat containing skin care products|stop or continue using wheat containing skin care products
223904117|NCT06778512|OTHER|Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t|Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.
223904118|NCT06210308|PROCEDURE|Data collection from gastric ultrasound|observational study
223904119|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.|1\) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.
223904120|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.|2\) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.
223904121|NCT06340412|DIETARY_SUPPLEMENT|Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.|3\) Sandwich with butter-like dairy product (40g milk fat) without MFGM.
223904122|NCT06398795|PROCEDURE|Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS).|An innovative surgical approach, Dual-port Trans-subclavian Thyroid Endoscopic Surgery (DTS), presents a unique dual-port endoscopic technique for thyroidectomy. DTS significantly reduces postoperative hospital stay, emphasizing its potential for accelerated patient recovery compared to COT.
223904123|NCT06398795|PROCEDURE|Conventional open thyroidectomy (COT)|open thyroidectomy with traditional collar incisions
223904124|NCT05166499|DIETARY_SUPPLEMENT|Hydroxy Methyl Butyrate|Hydroxy Methyl Butyrate
223904125|NCT05166499|DIETARY_SUPPLEMENT|Balanced Amino Acids|Balanced Amino Acids
223904126|NCT05984446|DEVICE|real-rTMS|Each subject will undergo 4 rTMS sessions using a 70-mm figure-eight coil (20Hz for 25 minutes). Target localization will be performed with a stereotaxic neuronavigation system.
223904127|NCT05984446|DEVICE|sham-rTMS|The sham condition will match the real-rTMS protocol, but a sham coil will be used.
223904128|NCT06251687|PROCEDURE|Transbronchial Cryobiopsy，TBLC|Transbronchial lung cryobiopsy (TBLC) is a novel technique that has proved its diagnostic value in various diffuse parenchymal lung diseases
223904129|NCT06251687|PROCEDURE|Transbronchial Lung Biopsy，TBLB|Transbronchial lung biopsy (TBLB) is a relatively safe technique routinely employed by pulmonologists for the diagnosis of diffuse parenchymal lung disease
223904130|NCT04864314|DIETARY_SUPPLEMENT|Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity|Participants in the Experimental group will receive a daily dose of 250 mg of TetraSOD® in a capsule during 90 days. After treatment, the group will stop consumption of TetraSOD® and a wash-out period of three months will start
223904131|NCT04864314|DIETARY_SUPPLEMENT|Sham|Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days. After treatment, the group will stop consumption of placebo and a wash-out period of three months will start
223904132|NCT05622929|BEHAVIORAL|Digitally-enabled Multifaceted Quality Improvement Intervention|"Digitally-enabled multifaceted strategy in addition to access to a RWE platform to provide clinical data. The digitally-enabled multifaceted strategy will include various tools that will provide support to the health professionals responsible for treating ASCVD patients in each center as well as patients, including:~* Knowledge of effective lipid lowering therapies~* Clinical decision support~* Audit and feedback on adherence to optimal clinical management~* Audit and feedback on LDL-C control"
223904133|NCT05622929|BEHAVIORAL|Usual care|Health professionals responsible for treating ASCVD patients in each center will continue to provide usual care to ASCVD patients in addition to provide data through a RWE platform.
223904134|NCT05726279|DEVICE|NIRS based personalized blood pressure management|In lieu of predetermined blood pressure treatment thresholds, an optimal MAP range will be chosen based on limits of autoregulation calculated in real-time for the previous four hours for each participant. Choice of medications and dosing will be left to the primary clinical obstetrics team.
223904135|NCT05384821|DRUG|Vincristine|IV, D1-D22-D43 and D64
223904136|NCT05384821|DRUG|Irinotecan|Oral, 5 days/week during W1,W2,W7 and W8 (D1 to D5, D8 to D12, D43 to D47, D50 to D54)
223904137|NCT05384821|DRUG|Temozolomide|Oral,3 weeks in a row, twice per cycle (D1 to D21, D43 to D63)
223904138|NCT05384821|DRUG|Etoposide|Oral, 3 weeks in a row, twice per cycle (D22 to D42, D64 to D84)
223904139|NCT05384821|DRUG|Cis-Retinoic acid|Oral, 2 weeks in a row, thrice per cycle (D15 to D28, D43 to D56, D71 to D84)
223904140|NCT05851183|DRUG|Vitis Vinifera seed extract medication plus therapeutic lifestyle change|Administer 150mg of Vitis Vinifera seed extract (Entelon®) orally twice a day
223904141|NCT05851183|BEHAVIORAL|Therapeutic lifestyle change only|Implementing TLCs is a critical component of a comprehensive treatment plan for varicose veins. A key aspect of TLCs is the optimization of postural habits. Patients are advised to avoid extended sitting or standing periods, which exert additional pressure on the venous system in the lower extremities and exacerbate venous insufficiency. During rest periods, elevating the legs closer to the heart is recommended because this simple yet effective adjustment promotes venous return and reduces the gravitational burden on the venous valves of the legs. The use of graduated compression stockings during waking hours is another therapeutic lifestyle intervention that is often prescribed for patients with varicose veins. Additional TLCs include maintaining optimal body weight and engaging in regular physical exercise Walking or cycling are often recommended because of their effectiveness in promoting lower limb venous return.
223904142|NCT05897944|OTHER|COPD|A data set consisting of information from COPD and HC groups will be used to experiment with the classification performance of several Machine Learning techniques.
223904143|NCT05509413|DEVICE|DEFLAGYN vaginal gel|DEFLAGYN is a vaginal gel, classified as a medical device, containing silica and citric acid, which binds pathogens, inhibits their spread and exerts an antioxidant effect. It is applied intravaginally (through an applicator) and used for 3 months.
223904144|NCT00540774|DEVICE|detection of oral pathology|detection of oral pathology
224276979|NCT01015963|OTHER|laboratory biomarker analysis|Perform DNA sample analysis
224276980|NCT01887795|DRUG|Erlotinib|
224276981|NCT01887795|DRUG|WBRT|
224276982|NCT04967950|DRUG|Secukinumab 300 MG|Secukinumab 150 mg s.c. with loading dose at baseline, week 1,2,3,4 and then every 4 weeks from week 5 up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, Secukinumab 150 mg will be with a switch to 300 mg.
224276983|NCT04967950|DRUG|Secukinumab 150 MG|Methotrexate 15 mg po. every week up to 12 weeks. After which, if MASEI ultrasound enthesitis score improvement is less than 50%, methotrexate with a switch to Secukinumab 150 mg at 12 weeks.
223904145|NCT04965246|BEHAVIORAL|Physical Activity|The physical activity program will focus on increasing physical activity, starting with a target of 100 minutes per week. The session durations will build over time to 150 minutes per week. Participants will be instructed to walk, or engage in other forms of light-intensity physical activity to achieve these goals. Participants will be instructed on the use of the ratings of perceived exertion scale (6-20). As the participants' health and fitness status improves, frequency, intensity, and session duration will be modified accordingly during weekly support calls. As participants will enter the study engaging in varying levels of physical activity, goals will be responsive to the most recent week's achieved minutes.
223904146|NCT04965246|OTHER|Usual Care|Participants in the usual care group will receive no intervention
223904147|NCT02259218|OTHER|laboratory biomarker analysis|Correlative studies
223904148|NCT06401577|DEVICE|Dexcom Continuous Glucose Monitor (CGM)|Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level
223904149|NCT05208697|BEHAVIORAL|Tele-Harm Reduction|THR is telehealth-enhanced, on-demand services including low-barrier access to antiretrovirals, medications for substance use disorder and hepatitis C treatment. It includes mobile phlebotomy, harm reduction counseling, medication management, telehealth mental health/substance use disorder services-- all delivered via an SSP, integrated with the provision of evidence-based naloxone and injection equipment.
223904150|NCT05208697|OTHER|off-site linkage|standard of care linkage to a Ryan White clinic
223904151|NCT02950766|DRUG|NeoVax|combination of Neoantigen peptides and poly-ICLC
223904152|NCT02950766|DRUG|Ipilimumab|local administration of ipilimumab
223904153|NCT03085810|DRUG|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
223904154|NCT04799015|DRUG|Dexamethasone|Dexamethasone 10mg IV
223904155|NCT04799015|DRUG|Metoclopramide 10mg|Metoclopramide 10mg IV
223904156|NCT05470023|OTHER|OTC Toothpastes or Mouthrinses|OTC Toothpastes or mouthrinses used according to standard of care
223904157|NCT03621371|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
224276984|NCT04967950|DRUG|Methotrexate|methotrexate
223904158|NCT03621371|BEHAVIORAL|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
224276985|NCT05863221|DRUG|ZYNRELEF 200Mg-6Mg Extended-Release Solution|ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
223904159|NCT04532190|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS)
223904160|NCT06302829|OTHER|Dry needling|AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30min
223904161|NCT06302829|OTHER|intramusuar electrical stimulation|Myofascial trigger point would be targeted by direct intramuscular electrical stimulation by using direct electrode placement method, where anode pole and the cathode pole of the stimulator connected to the needles of the MTrPs of the shoulder girdle muscles .AROM 10 repetitions ×2 set×30 sec ,6days\\week, Shoulder strengthening exercises: Isometric pain free (elastic Thera-band) 10 repetitions ×2 set×30 sec ,6days\\week, Maitland mobilization grade 3 and 4 10 repetitions ×2 set×30 sec ,6days\\week Total of 6 session were given each consisting of 30 min
223904162|NCT02109302|PROCEDURE|Blood sample|
223904163|NCT02109302|PROCEDURE|Skin biopsy|
223904164|NCT02109302|OTHER|Questionnaire|
223904165|NCT05200403|DRUG|Crisaborole 2%|The adult caregiver will apply a thin layer of Crisaborole 2% topically on their child participant twice a day for 2 weeks.
223904166|NCT05200403|DRUG|Vehicle treatment|The adult caregiver will apply a thin layer of the vehicle treatment topically on their child participant twice a day for 2 weeks. The vehicle treatment is made of excipients of crisaborole ointment (non-medicated ointment).
223904167|NCT05200403|DEVICE|Accelerometry device for children|Children participants will wear two wrist worn (or wrist worn AND ankle worn for 3 months up to \<2 years) accelerometry devices. Devices will be optional for child participants who have active AD on location of device placement, with a minimum of at least one wrist device needed for enrollment.
223904168|NCT05200403|DEVICE|Accelerometry device for adult caregivers|Adult caregiver participants will wear two accelerometry devices (one on each wrist) and complete daily assessments related to scratching, sleeping habits, pain, AD severity, quality of life, and device comfort questionnaires.
223904169|NCT06520878|DIETARY_SUPPLEMENT|NANO-PSO (pomegranate seed oil)|NANO-PSO administered orally, 2 capsules, equivalent to 640 mg of pomegranate seed oil, every 24 hours in the morning with food.
223904170|NCT06520878|DIETARY_SUPPLEMENT|Placebo|Placebo administered orally, 2 capsules, equivalent to 640 mg of mineral oil, every 24 hours in the morning with food.
223904171|NCT01959607|OTHER|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
223904172|NCT01959607|OTHER|CC|Single use of subject's own cigarette (CC)
223904173|NCT01959607|OTHER|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
224276986|NCT06461442|PROCEDURE|Cryotherapy|Extremely cold liquid (liquid nitrogen) will used by a dermatologist to freeze and destroy abnormal cells in the treatment areas randomized to this treatment.
224276987|NCT06461442|DRUG|5Fluorouracil|Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
224276988|NCT01354470|DRUG|Modafinil|600 mg Modafinil capsule
223904174|NCT06667973|DRUG|Gilteritinib|"Gilteritinib fumarate is an oral, selective FLT3 and AXL inhibitor. It is a type 1 inhibitor, active against both the FLT3-ITD and FLT3-TKD mutations. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3-ITD, FLT3-D835Y, and FLT3-ITD-D835Y, and it induces apoptosis in leukemic cells expressing FLT3-ITD.~Gilteritinib is approved for the treatment of relpased/refractory FLT3-mutated AML after the successfull ADMIRAL trial. In the present study Gilteritinib (120 mg/die) in combination with FLAI will be tested as induction therapy in newly-diagnosed patients."
223904175|NCT03209583|DEVICE|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
223904176|NCT05934448|DRUG|Pembrolizumab|Pembrolizumab via iv, dosage and timing per protocol
223904177|NCT05934448|DRUG|Lymphodepletion Chemotherapy|Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
223904178|NCT05934448|DRUG|Chimeric Antigen Receptor (CAR) Therapy Infusion|Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
223904179|NCT05934448|PROCEDURE|Leukapheresis|manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
223904180|NCT04731961|PROCEDURE|Standard of care (15 Botox injections)|The controls will be given the standard of care of 15 Botox injections.
223904181|NCT04731961|PROCEDURE|Experimental Arm (5 Botox injections)|5 Botox injections will be given, with each injection containing three times the amount of Botox than each of the 15 injections given in the standard of care arm.
223904182|NCT05124769|BEHAVIORAL|Pain Allowing Program (PAllow)|Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \> 40% MVC).
223904183|NCT05124769|BEHAVIORAL|Pain Avoiding Program (PAvoid)|"Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued."
223904184|NCT03974828|DEVICE|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the electronic health record. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
223904185|NCT05864313|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|10 Hz rTMS for 5 seconds over the frontal eye fields with 25 second intertrain interval for 10 trains (500 pulses) at 90% of the resting motor threshold,
223904186|NCT05864313|BEHAVIORAL|Gait training|Subjects will practice stepping on virtual targets with real-time feedback of their foot position displayed on a screen while walking on a treadmill.
223904187|NCT05864313|BEHAVIORAL|Gaze training|Subjects will perform gaze stabilization and gaze shifting exercise via a virtual reality headset.
223904188|NCT05864313|DEVICE|Sham rTMS|Sham rTMS stimulation will produce discharge noise and vibration without stimulating the cerebral cortex.
223904189|NCT06203795|OTHER|Anticoagulation dosing|Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday
223904190|NCT06203795|OTHER|Blood sampling|Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
223904191|NCT06203795|OTHER|Duration of the dialysis session|Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday
223904192|NCT06203795|DEVICE|Choice of the hemodialyzer|Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
223904193|NCT06643663|PROCEDURE|Endodontic Micro-Surgery|Surgery performed using ACM membrane and PRF plug in test group \& without membrane \& PRF in control group.
223904194|NCT05089227|DRUG|"treatment intervention"|for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
223904195|NCT05089227|DRUG|"treatment standard"|during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
223904196|NCT05089227|BIOLOGICAL|biological assessment|CBC, reticulocytes, haptoglobin, LDH, bilirubin
223904197|NCT05671861|DEVICE|Trismus Device Prototype|Device is noninvasive and will be inserted between patient's upper and lower teeth
223904198|NCT05671861|OTHER|Questionnaires|Surveys will be administered to participants
223904199|NCT05671861|OTHER|Mobile Application|A study-specific, accompanying secure mobile application for users to track progress will be created.
223904200|NCT05294991|BEHAVIORAL|Wellness app intervention #1|This is the active intervention group.
223904201|NCT05294991|BEHAVIORAL|Wellness app intervention #2|This is the active comparator/control group.
223904202|NCT05296135|DIAGNOSTIC_TEST|OncoPrism-HNSCC™|OncoPrism-HNSCC™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
223904203|NCT04510311|DRUG|3-[18F]Fluoro-para-hydroxyphenethylguanidine|Single IV injection of 12.0 mCi (+/- 10%) \[18F\]3F-PHPG
223904204|NCT04510311|DRUG|[123I] metaiodobenzylguanidine|Single IV injection of 10.0 mCi \[123I\]MIBG
223904205|NCT04510311|DIAGNOSTIC_TEST|Positron emission tomography/computed tomography scan|Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of \[18F\]3F-PHPG
223904206|NCT04510311|DIAGNOSTIC_TEST|Planar scintigraphy scan|Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of \[123I\]MIBG
223904207|NCT04510311|DIAGNOSTIC_TEST|Single photon emission computed tomography/computed tomography scan|SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of \[123I\]MIBG
224276989|NCT03506087|BEHAVIORAL|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
224276990|NCT03506087|BEHAVIORAL|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
223715650|NCT05650216|DRUG|Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)|"1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity."
223904208|NCT03785964|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
223904209|NCT03785964|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
223904210|NCT05524337|BEHAVIORAL|white noise|"Dr. Harvery Karp's song The Happiest Baby, consisting of intrauterine sounds only, will be used for white noise. The sound will be set to 45 db."
223904211|NCT05524337|BEHAVIORAL|therapeutic touch|In the group where therapeutic touch will be applied, the heel blood collection procedure and the study will be explained to the family, and after the consent is obtained, the therapeutic touch will be applied to the baby 5 minutes before, during and after the procedure.
223904212|NCT05524337|BEHAVIORAL|white noise and therapeutic touch|the group where therapeutic touch and white noise will be applied together, after the family is informed about the procedure, white noise will be listened to 5 minutes before, during and 5 minutes after the heel blood collection, and therapeutic touch steps will be applied during this time.
223904213|NCT06010030|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. Anodal or sham tDCS will be administered.
223904214|NCT06010030|BEHAVIORAL|Speech Therapy|Participants will receive either semantic or phonological focused speech therapy
223904215|NCT03744182|DRUG|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
223904216|NCT03744182|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
223904217|NCT06031298|BIOLOGICAL|Dentin Graft|Dentin graft is a grafting technique of autogenous origin that uses the teeth extracted from the patient for the graft material preparation.
223904218|NCT05039229|OTHER|Nozzles (NZ)|Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
223904219|NCT05039229|OTHER|Cleaning of surfaces (CS)|Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.
223904220|NCT05665686|DEVICE|Relaxation training with device|Relaxation training will be applied with the device.
223904221|NCT05665686|OTHER|Home Exercise|An exercise application including home exercise programs will be performed for six weeks.
223904222|NCT02748941|DEVICE|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~* Ulceration \>2 mm~* Plaque thickness~* GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~* CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~* Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~* Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
223904223|NCT06163690|COMBINATION_PRODUCT|Endourage Targeted Wellness Formula C™, a full hemp flower extract|A hemp-derived formulation designed as a daily use adjunctive therapy to help improve Long COVID symptoms. Endourage Targeted Wellness Formula C™ are used as sublingual drops held under the tongue for 60 to 90 seconds.
223904224|NCT06272006|PROCEDURE|Coronally Positioned Flap with Connective Tissue Graft|his intervention involves surgically repositioning the gum tissue over the exposed tooth root and adding a connective tissue graft. The graft is obtained from the patient's palate and placed in the area of gingival recession to promote tissue regeneration and enhance root coverage. The procedure aims to reduce gingival recession and improve periodontal health.
223904225|NCT06272006|PROCEDURE|Modified Coronally Advanced Tunnel with Connective Tissue Graft|This intervention utilizes a minimally invasive technique to create a tunnel beneath the gum tissue, through which a connective tissue graft is placed. The graft, sourced from the patient's palate, is used to encourage the growth of new gum tissue over the exposed root. This method is designed to minimize trauma and promote faster recovery, aiming to improve root coverage and periodontal outcomes.
223904226|NCT03896685|DRUG|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
223904227|NCT03896685|DRUG|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
223904228|NCT03896685|DRUG|Clofazimine 100 MG Oral Capsule|Clofazimine: 100 mg QD
223904229|NCT03896685|DRUG|Linezolid 600Mg Tab|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
223904230|NCT03896685|DRUG|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
223904231|NCT05883241|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
223904232|NCT05883241|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn during treatment via SAM patch.
223904233|NCT05110716|BEHAVIORAL|Bundle-size 1|In this condition, each choice in the adjusting-amount task produces only a single consequence (e.g., lose $900 in 1 year).
223904234|NCT05110716|BEHAVIORAL|Bundle-size 3|In this condition, each choice in the adjusting-amount task produce a series of three consequences over time. o hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $300 in 1 year, lose $300 in 2 years, lose $300 in 3 years).
223904235|NCT05110716|BEHAVIORAL|Bundle-size 9|In this condition, each choice in the adjusting-amount task produce a series of nine consequences over time. To hold total amount constant across conditions, the $900 available in the bundle-size 1 condition will be distributed equally across all consequences in the series. (e.g., lose $100 in 1 year, lose $100 in 2 years, lose $100 in 3 years...lose $100 in 9 years).
223904236|NCT05796388|DEVICE|Virtual Reality|Both groups will receive standard of care linaclotide 290 mcg.
223904237|NCT05237388|DRUG|Baricitinib|One pill daily
223904238|NCT05237388|DRUG|Placebo|Baricitinib placebo pill
223904239|NCT04117347|DEVICE|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
224276991|NCT00595673|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
223715651|NCT01748084|DRUG|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
223904240|NCT04117347|DEVICE|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
223904241|NCT04117347|DEVICE|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
223904242|NCT06352658|DEVICE|Conventional mandibular advancement device|With a vacuum mahine (Biostar, NY) a 2-mm-thick hard, clear resin sheet was adapted to the cast. The excess material was cut, borders were trimmed and smoothed. Maxillary mandibular casts were mounted by a protrusive the interocclusal record. The appliances were re-placed on the mounted casts to be splinted to form a Monoblock MAD by autopolymerizing acrylic resin at the premolar -molar area.
224276992|NCT02005276|BEHAVIORAL|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
224276993|NCT02005276|BEHAVIORAL|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
223715652|NCT01748084|DRUG|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
223715653|NCT03773991|DIAGNOSTIC_TEST|Lung MRI|Proton Lung Magnetic Resonance Imaging
223904243|NCT06352658|DEVICE|CAD CAM mandibular advancement device|"3D models for the stone casts were constructed with laser scanning machine (accuracy \<20 µm; D500, 3shape).~Maxillary and mandibular casts were rescanned in the achieved 75% advancement position and monoblock device was designed by CAD (computer-aided design) with 3D software (3-matic; Materialise) and printed by"
223904244|NCT06352658|PROCEDURE|Uvuloplatopharyngeoplasty UPPP|uvulopalatopharyngeoplasty UPPP were performed by the same ENT surgeon under GA.
223904245|NCT03046992|DRUG|YH25448|"* Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448"
223904246|NCT05756036|OTHER|None Observational study|Non interventional study
223904247|NCT04817618|DRUG|Placebo|Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
223904248|NCT04817618|DRUG|iptacopan|iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
223904249|NCT03278080|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
223904250|NCT03278080|OTHER|Car-following test|Driving with simulator program for DCV measurement
223904251|NCT03278080|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
223904252|NCT05680012|DIETARY_SUPPLEMENT|Gluten containing snack bar|Ingest snack bars containing 3 grams of gluten every day for 6 weeks.
223904253|NCT04766866|DIAGNOSTIC_TEST|sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation|A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
223904254|NCT02505984|DRUG|Oxytocin|Study participants will be randomized to a placebo or drug group.
223904255|NCT02505984|DRUG|Placebo|Study participants will be randomized to a placebo or drug group.
223904256|NCT03687086|OTHER|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
223904257|NCT03687086|OTHER|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
223715654|NCT03773991|DIAGNOSTIC_TEST|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
223715655|NCT03773991|DIAGNOSTIC_TEST|Chest CT|High-resolution Quantitative Chest CT
223715656|NCT03773991|DIAGNOSTIC_TEST|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
223715657|NCT03773991|DIAGNOSTIC_TEST|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
223904258|NCT05088616|BEHAVIORAL|Virtual Diabetes Wellness Classes and Medically Tailored Meals|Four weeks of virtual diabetes wellness classes and 12 weeks of medically tailored meals.
223904259|NCT05800457|PROCEDURE|Partial synovectomy|Patients in the intervention group will undergo partial synovectomy during total knee replacement surgery
223904260|NCT04749212|DIAGNOSTIC_TEST|serum high-sensitivity Troponin I (TnI) and NT-Pro-Brain Natriuretic Peptide (NT-proBNP)|Both biomarkers will be determined in each patient preoperatively and at postoperative day 1 and day 2.Measurements will not necessarily be taken independently of other measurements, meaning that the addition of the biomarker could be included in routine pre or postoperative day-1 and day 2 blood tests.
223904261|NCT06140069|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders."
223904262|NCT06582329|DRUG|Alfa1 Antitrypsin|Participants will be treated intravenously with A1AT 120 mg/kg bodyweight once a week for 4 weeks (4 total infusions).
223904263|NCT05808140|DRUG|Indocyanine Green|Preoperatively, a single dose of intravenous indocyanine green is administered
223904264|NCT05808140|DEVICE|Fluorescence imaging|Use of a spinal endoscopic fluorescent imaging system to assist surgeons in identifying and protecting nerve roots intraoperatively
223904265|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
223904266|NCT03709121|DRUG|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
223904267|NCT03709121|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
223904268|NCT06851117|COMBINATION_PRODUCT|Proprioceptive Neuromuscular Facilitation (PNF)|Participants in the PNF group will undergo intensive training of the affected limbs for 20 minutes per day, 5 days a week, over a 4-week period. During therapy sessions, the unaffected limb will be constrained using a mitt or cast to encourage focused activation and strengthening of the affected side. The therapy will include repetitive movement patterns designed to enhance strength, flexibility, and coordination.
223904269|NCT06851117|COMBINATION_PRODUCT|Spider Cage Therapy Group|This group will participate in therapy sessions within the Spider Cage for 20 minutes per day, 5 days a week, for 4 weeks. Interventions will involve weight-bearing exercises, movement facilitation, and balance training, utilizing the cage's elastic cords to support and stabilize posture. The goal is to improve gross motor skills, balance, and controlled movement.
223715658|NCT03773991|DIAGNOSTIC_TEST|Pulmonary Function Tests|Spirometry and Plethysmography
223715659|NCT03773991|DIAGNOSTIC_TEST|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
223904270|NCT06851117|DIAGNOSTIC_TEST|Combined PNF and Spider Cage Therapy Group|Participants in this group will receive both PNF and Spider Cage Therapy, with integrated principles and techniques from both approaches. The intensity and duration will be consistent with the individual therapy groups, with sessions held for 20 minutes per day, 5 days a week, over 4 weeks. This combination is expected to enhance functional outcomes by targeting both strength/coordination and balance/postural control.
223904271|NCT05137574|DEVICE|Integrated Pulmonary Index (IPI) monitoring|Integrated Pulmonary Index (IPI) monitor will be applied to the patients, to provide numerical data obtained from the measurements of end-tidal carbon dioxide, respiratory rate, oxygen saturation measured by pulse oximetry (SpO2), and pulse rate.
223904272|NCT05137574|DRUG|propofol|propofol
223904273|NCT05137574|DRUG|ketamine|ketamine
223715660|NCT03773991|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test
223715661|NCT03773991|DIAGNOSTIC_TEST|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
223904274|NCT06847113|OTHER|Physical function|Observe walking speed, both maximal and self-selected, over a 12-months period after knee arthroplasty
223904275|NCT06393114|OTHER|Fermented oat-based product|Participants will incorporate a novel fermented product into their habitual diet for three weeks. In addition, the consumption of dairy and plant-based dairy alternatives is restricted. Cereal product consumption, specifically bread and porridge, is slightly restricted to prevent gastrointestinal symptoms caused by the increased intake of dietary fibre. Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
223904276|NCT06393114|OTHER|Unfermented oat-based product|Participants will incorporate a novel unfermented product into their habitual diet for three weeks. Dietary adjustments and other guidance are consistent with those described during the fermented product intervention.
223904277|NCT06853223|DRUG|Maraviroc|Product will be administered for 300 mg immediately preceding the lung transplant surgery and then will be administered every 12 hours. There will be 7 total doses. The first 3 will be 300 mg doses and the remaining 4 will be 150 mg doses. Maraviroc will be given oral (PO) or by feeding tube (PFT) in crushed format depending on the route availability.
223904278|NCT06853223|DRUG|Placebo|Placebo in 300 and 150 mg formulations Product will be administered every 12 hours for 3 days. The placebo will be matched in appearance and taste to the Maraviroc and is available in PO and liquid (PFT) formulations.
223904279|NCT06849479|PROCEDURE|Aerobic exercise and medical treatment|Aerobic exercise training was done for 30 minutes, day after day (3 sessions weekly) for 6 weeks. Each session started by warming up phase that was walking on treadmill for 5 minutes at 20% of target heart rate. Active phase after warming up was walking on treadmill for 20 min at 50-70 % of target heart rate. And cooling down phase after the active phase of exercise was walking on treadmill for 5 minutes at 20 % of the target heart rate
223904280|NCT06849479|DIETARY_SUPPLEMENT|Medical treatment group|patient received supplement in the form of one capsule daily, that contain iron supplement (10 mg) and multi vitamins (B1=0.6 mg;, B2=0.6 mg; B6=0.6 mg; B12= 1.2 mc and C=30 mg) as well as essential trace elements (Zinc=5 mg; Copper=0.44 mg; Folic acid=200 mc and Biotin=12 mc
223904281|NCT04176601|BEHAVIORAL|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
223904282|NCT05145478|DEVICE|Shockwave Intravascular Lithotripsy (IVL)|Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.
223715662|NCT00595530|DRUG|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~* Patients begin the ketamine infusion at 0.05 mg/kg/hr.~* 4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~  1. patient's pain has not improved to an acceptable level~ 2. side effects remain acceptable~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~* 4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~* Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
223715663|NCT02495298|PROCEDURE|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
223715664|NCT02495298|PROCEDURE|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
223715665|NCT03330730|OTHER|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
223715666|NCT00042289|DRUG|atazanavir/cobicistat|atazanavir/cobicistat 300/150 mg q.d.
223715667|NCT00042289|DRUG|darunavir/ritonavir dosage #1|darunavir/ritonavir twice daily 600/100 mg b.i.d.
223715668|NCT00042289|DRUG|darunavir/ritonavir dosage #2|darunavir/ritonavir twice daily 800/100 mg b.i.d.
223715669|NCT00042289|DRUG|darunavir/ritonavir dosage #3|darunavir/ritonavir twice daily 900/100 mg b.i.d.
223904283|NCT06851611|BIOLOGICAL|COVID-19 vaccine, low dose level|Test article
223904284|NCT06851611|BIOLOGICAL|COVID-19 vaccine, high dose level|Test article
223904285|NCT06851611|OTHER|Nasal Drops|Method of administration of test article
223904286|NCT06851611|OTHER|Nasal Spray|Method of administration of test article
223904287|NCT06850961|DEVICE|Digital health intervention by using a mobile application|A digital health intervention for promoting self-management in patients with COPD by using a mobile application.
223715670|NCT00042289|DRUG|elvitegravir/cobicistat|elvitegravir/cobicistat 150/150 mg q.d.
223715671|NCT00042289|DRUG|dolutegravir|dolutegravir 50 mg q.d.
223715672|NCT00042289|DRUG|tenofovir alafenamide fumarate (TAF)|TAF 25 mg q.d. without cobicistat or ritonavir boosting
223715673|NCT00042289|DRUG|TAF w/cobicistat|TAF 10 mg q.d. with cobicistat
223715674|NCT00042289|DRUG|TAF w/cobicistat or ritonavir|TAF 25 mg q.d. with cobicistat or ritonavir boosting
223715675|NCT00042289|DRUG|efavirenz|efavirenz 600 mg q.d.
223715676|NCT00042289|DRUG|darunavir/cobicistat|darunavir/cobicistat 800/150 mg q.d.
223904288|NCT06850961|OTHER|Feasibilty study and qualitative interview studies|This study is a one group feasibility study including quantitative and qualitative study designs. The investigators will use focus groups and indiviual interviews, as well as Interpersonal Process Recall (IPR) interviews.
223904289|NCT03759431|RADIATION|Vocal-cord Radiotherapy|Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.
223904290|NCT03759431|RADIATION|Complete Larynx Radiotherapy|Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.
223904291|NCT05299671|BEHAVIORAL|Video consultation|During the video visit, a pharmacist will speak with the patient about potential drug-drug interactions between the patient's cancer treatment and the other medications on the list, make recommendations about medication management (which will also be directly communicated to the oncologist), provide education about the patient's new OACD, and answer any questions. The virtual consultation will last about 30 minutes via an electronic device.
223904292|NCT06441123|BIOLOGICAL|Blood Sampling|20 ml of blood (5 tubes of 4 ml) will be collected once.
223904293|NCT04746586|OTHER|Circulating MiRNA indentification|Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
223715677|NCT00042289|DRUG|lopinavir/ritonavir dosage #1|lopinavir/ritonavir 800/200mg b.i.d.
223715678|NCT00042289|DRUG|atazanavir/ritonavir/tenofovir dosage #1|atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
223715679|NCT00042289|DRUG|rifampicin|rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
223715680|NCT00042289|DRUG|ethambutol|ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
223715681|NCT00042289|DRUG|isoniazid|isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
223715682|NCT00042289|DRUG|pyrazinamide|pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
223715683|NCT00042289|DRUG|kanamycin|kanamycin (2nd line TB drug)
223715684|NCT00042289|DRUG|amikacin|amikacin (2nd line TB drug)
223715685|NCT00042289|DRUG|capreomycin|capreomycin (2nd line TB drug)
223715686|NCT00042289|DRUG|moxifloxacin|moxifloxacin (2nd line TB drug)
223715687|NCT00042289|DRUG|levoflaxacin|levofloxacin (2nd line TB drug)
223715688|NCT00042289|DRUG|ofloxacin|ofloxacin (2nd line TB drug)
223715689|NCT00042289|DRUG|ethionamide/prothionamide|ethionamide/prothionamide (2nd line TB drug)
223715690|NCT00042289|DRUG|terizidone/cycloserine|terizidone/cycloserine (2nd line TB drug)
223715691|NCT00042289|DRUG|para-aminosalicylic acid (PAS)|para-aminosalicylic acid (PAS) (2nd line TB drug)
223904294|NCT06380361|DEVICE|BioSpy System|One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.
223715692|NCT00042289|DRUG|high dose INH|high dose INH (2nd line TB drug)
223904295|NCT04290754|BEHAVIORAL|CATCH-IT|Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious.
223904296|NCT04290754|BEHAVIORAL|TEAMS|Teens Achieving Mastery over Stress (TEAMS) is an 8-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
223904297|NCT06851377|GENETIC|Optical Genome Mapping (OGM) and Whole Genome Sequencing (WGS)|After identifying causal SVs via OGM, WGS will determine rearrangement breakpoints and examine nearby genes within 100 kb that may have altered expression due to positional effects.
223904298|NCT06851377|OTHER|Trascriptome analysis|Following genomic characterization results, transcriptome analysis will be performed on patient-derived lymphoblastoid B-cell lines or fibroblasts to investigate the molecular implications of candidate SVs found in the OGM analysis and identify potential transcriptome abnormalities, such as splicing variants, in patients with atypical clinical features.
223904299|NCT06846762|OTHER|This study did not include intervention between the two cohorts|The study is divided into two parts, Part A and Part B. The purpose of Part A is to reveal the proportion of NSCLC patients who are primarily resistant to first-line non-targeted therapy due to the omission of driver genes (especially fusion variations) by DNA-NGS, the median PFS of patients in the first line, and clinical characteristics through synchronous co-testing of DNA and RNA NGS. The purpose of Part B is to compare the difference in ORR between patients with driver gene positivity identified through synchronous co-testing of DNA and RNA NGS who receive and do not receive targeted therapy, with subsequent treatment regimens determined at the discretion of the patients without any intervention measures.
223904300|NCT06845241|DRUG|ICP-490|Specified dose on specified days
223904301|NCT06232915|PROCEDURE|Mechanical ventilation|Mechanical ventilation during surgery
223904302|NCT06842459|OTHER|Geriatric Assessment|"The intervention group will undergo Geriatric Assessment in addition to diabetes usual care.~Usual care for both the Control and Intervention groups will be assured by a diabetologist according to in-use guidelines.~After randomization, a geriatrician will administer a thorough CGA to all participants allocated to the intervention groups. CGA results will be used to diagnoses or drug review; to identify specific treatment goals according to the functional status of the patient and to incorporate Patient-preferred outcome in the management of diabetes and comorbidities. Using the results of the CGA the geriatricians along with the attending diabetologist and additional healthcare professional, if needed, will implement a personalized diagnostic and therapeutic plan of care. Participants in the Control group will receive no additional intervention over and above usual care."
223904303|NCT06846073|COMBINATION_PRODUCT|The combination of intravitreal anti-VEGF and dexamethasone implants injections.|Early combination of intravitreal dexamethasone implant and anti-VEGF injection for the treatment of DME.
223904304|NCT06848829|OTHER|Pre-manepausal women|Compare tear ferning structure between pre-menopause and post-menopause women.
223904305|NCT06849089|PROCEDURE|Transurethral resection of prostate (TURP)|The surgical intervention used to resect the benign adenomatous hyperplastic nodules of the prostate that cause obstruction and consequently lower urinary tract symptoms. The procedure uses a hot loop shaped knife, operated by electrocautery, to cut the obstructing tissues from center towards periphery of the prostate until the prostatic capsule is reached.
223904306|NCT06849089|PROCEDURE|Holmium laser enucleation of prostate|The surgical intervention used to enucleate the benign adenomatous hyperplastic nodules of the prostate that cause obstruction and consequently lower urinary tract symptoms. The procedure uses a laser fiber to dissect the obstructing adenoma from the prostatic capsule starting from the plane in-between the capsule and the adenoma, meaning removal of tissues from periphery towards the center of the prostate.
223904307|NCT06850584|OTHER|Observation|The study was observational and did not involve any intervention.
223904308|NCT06843369|DIAGNOSTIC_TEST|inflammatory markers|Serum amyloid A , cbc and IL-10
223904309|NCT06850324|DRUG|ABL-101 is administered at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour).|The doses of ABL-101 is administered using an IV infusion pump in the arm at 3mL/kg body weight (to a notional maximum of 100kg, rounded to the nearest ml), at the rate of 15 mL/min (900ml/hour). Patients will undergo a 1 hour-imaging with 19F MRI, 16h-36h after end of PFC infusion.
223904310|NCT06849063|DIAGNOSTIC_TEST|magnetic resonance imaging|all participants undergo novel MR sequences, including 3D MRE#DCE-MRI#IVIM-DWI#T1/T2 mapping.
224276994|NCT02005276|BEHAVIORAL|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
224276995|NCT03945058|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
224276996|NCT03945058|DEVICE|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
223715693|NCT00042289|DRUG|bedaquiline|bedaquiline (2nd line TB drug)
223715694|NCT00042289|DRUG|clofazamine|clofazamine (2nd TB drug)
223715695|NCT00042289|DRUG|delamanid|delamanid (2nd line TB drug)
223715696|NCT00042289|DRUG|linezolid|linezolid (2nd line TB drug)
223715697|NCT00042289|DRUG|pretomanid|pretomanid (2nd line TB drug)
223715698|NCT00042289|DRUG|ethinyl estradiol|oral contraceptives formulated with 30-35 μg ethinyl estradiol
223715699|NCT00042289|DRUG|etonogestrel implant|etonogestrel implant contraceptive
223715700|NCT00042289|DRUG|nevirapine|nevirapine 200 mg twice a day
223904311|NCT06847971|PROCEDURE|Flexor hallucis longus tendon transfer|The FHL tendon will be dissected and transected as far distally as possible. The FHL tendon will be transfixed by Krakow's suture being inserted into the distal 3 cm in the stump to ensure adequate length of the graft inserted within the bony tunnel in the calcaneus.A guide wire with eyelet will be inserted in the calcaneum just anterior to the native AT insertion by a distance 2 mm more than the half of the diameter of the transferred tendon to avoid blow up of the posterior wall of the tunnel. A tunnel will be drilled over the guide wire according to the tendon thickness, without penetrating the planter surface of the calcaneum. The threads at the end of FHL tendon suture will be passed through the eyelet of the guide wire. The tendon will be driven into the calcaneal bony tunnel by pulling the guide wire through the plantar aspect of the heel. Then the FHL tendon will be tenodesed into the bone tunnel using a interference screw of the same size or 1 mm larger than the bone tunnel.
223904312|NCT06847971|PROCEDURE|Gastrocnemius augmented Flexor hallucis longus tendon transfer|The gastrocnemius tendon will be refixed to the calcaneal tuberosity using anchors. According to the size of the defect: If the size of the gap was 4-5 cm, an additional gastrocnemius turndown or V-Y flaps will be done. Turn down flap will be achieved by creating 2 cm wide and 5-6 cm long flap from the gastrocnemius tendon. The most distal 1 cm from the proximal stump will be secured along the lateral border of the flap to prevent its separation from the original stump during tensioning and fixation to the calcaneus. V-Y flap will be achieved by having inverted V-shaped incision in the distal part of the gastrocnemius starting proximally and extending the two limbs distally leaving the lateral 1 cm from the original tendon. Then carful advancement of the proximal AT stump distally to reach the calcaneal tuberosity. then Fixation will be achieved by suture anchors. If more than 5 cm gap, tenomyodesis of FHL through the proximal stump of Gastrocnemius muscle will be done.
223904313|NCT06848959|OTHER|No intervention|Pediatric Encephalopathy Science and Prevention Decision Aid Follow-Up Q\&A
223904314|NCT06851676|DIETARY_SUPPLEMENT|water supplemented by calcium|Fonte Fausta® water is a natural mineral water, rich in essential minerals, such as calcium, magnesium, and bicarbonate, which are important for maintaining bone density, muscle function, and overall metabolic health.
223904315|NCT06851676|OTHER|Water (Placebo)|a natural mineral commercially available
223904316|NCT06852027|OTHER|Different Dietary Practices|The aim was to investigate the effects of Gluten-Casein-Free Diet and Feingold Diet on gastrointestinal complaints in children with Autism Spectrum Disorder.
223904317|NCT06031727|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study is about 52 weeks for each subject including a 4 weeks screening period, enrollment/baseline visit, treatment visit and 48 weeks follow-up period.
223904318|NCT05421429|BIOLOGICAL|KN057 doseⅠ|KN057 subcutaneous (SC) injection
223904319|NCT05421429|BIOLOGICAL|KN057 dose Ⅱ|KN057 SC injection
223904320|NCT05421429|BIOLOGICAL|KN057 dose Ⅲ|KN057 SC injection
223904321|NCT05931003|PROCEDURE|Carotid stenting|In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.
223904322|NCT05931003|PROCEDURE|Carotid endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery."
223904323|NCT05427006|DEVICE|Z5-BL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
223904324|NCT05427006|DEVICE|Z5-TL Dental Implants|This is an observational study, collecting data on the use of Z5-BL Dental Implants.
223904325|NCT02896348|DEVICE|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
223904326|NCT02896348|OTHER|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
223715701|NCT00042289|DRUG|amprenavir|amprenavir 1200mg twice a day
223715702|NCT00042289|DRUG|abacavir|abacavir 300mg twice a day
223904327|NCT04162665|RADIATION|Adaptive short course radiation therapy|Radiation must be livered with adaptive planning and MR gating or CBCT breath hold treatment.
223904328|NCT04162665|DRUG|Standard of care chemotherapy regimen|The recommendations are CAPOX, FOLFOX, or FLT.
223904329|NCT06258863|PROCEDURE|incision type|Total mastectomy was performed using one of the four incision types
224276997|NCT05685550|DRUG|Toposide capsules combined with anrotinib and Emvolizumab group|Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
224276998|NCT04429113|DEVICE|Maxillary expansion with conventional Quad Helix bonded on molars.|Maxillary expansion with conventional Quad Helix bonded on molars
223715703|NCT00042289|DRUG|lopinavir/ritonavir dosage #2|lopinavir/ritonavir (Kaletra) 400/100mg twice a day
223715704|NCT00042289|DRUG|indinavir/ritonavir dosage #1|indinavir/ritonavir 800/100mg twice a day
223715705|NCT00042289|DRUG|fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg twice a day
223715706|NCT00042289|DRUG|lopinavir/ritonavir dosage #3|lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
223904330|NCT05247502|BIOLOGICAL|Data observation|At the time of participant inclusion in the study, demographic data and a baseline serum creatinine measurement will be collected. During the patient's ICU stay, the occurrence and duration of any AKI episode will be recorded. Data related to diagnostic examinations of these AKI episodes will also be collected in accordance with practices guidelines. Data related to AKI monitoring will also be collected, including serum creatinine and urea daily follow-up measurements, diuresis, and nephrotoxic use. The patient's need for extrarenal epuration or use of catecholamines will also be recorded. In the 3-month and 12-month.
223904331|NCT05875467|OTHER|SE3 Game|A prototype online game designed to increase environmental health literacy
223528896|NCT01380080|DRUG|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
223528897|NCT01380080|DRUG|Isoniazid|INH 300 mg orally once daily
223904332|NCT05761600|OTHER|Ethnographically-informed group observation|The chief investigator will visit each art therapy group 3-6 times; there will be up to 5 groups recruited. They will record observational data and insights; making use of visual reflective journaling where appropriate. These will later be written up as full field notes.
223904333|NCT05761600|OTHER|Semi-structured Interviews|Individual interviews will take place with all three key stakeholders in group art therapy at different stages of the study. Each interview will have a topic guide to structure the discussion and will combine arts-based methods with conversation to maximise accessibility. Interview location, timing and format (online or in-person) are flexible, and the chief investigator will adapt to the needs of the participants.
223904334|NCT05761600|OTHER|Focus Group|After data collection and initial analysis (likely 3-5 months after final observation and/or interview) a focus group will be held with the art therapist participants. This session will use arts-based engagement to support member checking of the initial results and triangulation of the findings, which is likely to include potential active ingredients in group art therapy and principles of practice with this client group.
223904335|NCT03548428|DRUG|Atezolizumab|1200mg IV every 3 weeks for 4 months
223904336|NCT03548428|RADIATION|SBRT|3 to 5 fractions depending on tumor size
223904337|NCT03392987|GENETIC|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
223904338|NCT02990533|DRUG|Testosterone|
223904339|NCT02990533|DIETARY_SUPPLEMENT|Protein Supplement|
223904340|NCT02990533|OTHER|Placebo Injection|
223528898|NCT06414902|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV
223528899|NCT06270056|DRUG|Misoprostol|Self-administered misoprostol by clients obtaining medication abortion via telemedicine
223528900|NCT04980326|BEHAVIORAL|Doing What Matters (DWM)|The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.
223715707|NCT00042289|DRUG|atazanavir/ritonavir dosage #1|atazanavir/ritonavir 300/100 mg once a day
223715708|NCT00042289|DRUG|didanosine delayed release (Videx® EC)|didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
223715709|NCT00042289|DRUG|emtricitabine|emtricitabine 200 mg once a day
223715710|NCT00042289|DRUG|tenofovir|tenofovir 300 mg once a day
223904341|NCT02990533|OTHER|Placebo supplement|
223904342|NCT03996850|PROCEDURE|Computed Tomography|Undergo SPECT/CT
223904343|NCT03996850|OTHER|Questionnaire Administration|Ancillary studies
223904344|NCT03996850|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223904345|NCT03996850|RADIATION|Technetium Tc-99m Sestamibi|Given IV
224276999|NCT03644043|DEVICE|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
223904346|NCT00882895|PROCEDURE|Stem cell infusion|
223904347|NCT00882895|PROCEDURE|TLI|
223904348|NCT00882895|DRUG|Anti-thymocyte globulin|
223904349|NCT00882895|DRUG|Solumedrol|
223904350|NCT00882895|DRUG|Tacrolimus|
224277000|NCT05150405|DRUG|QLF31907|In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.
223904351|NCT00882895|DRUG|Mycophenolate mofetil|
224277001|NCT00452543|DRUG|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
224277002|NCT00452543|DRUG|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
224277003|NCT00452543|BEHAVIORAL|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
223715711|NCT00042289|DRUG|nelfinavir dosage #1|nelfinavir \[625 mg tablets\] 1250 mg twice a day
223715712|NCT00042289|DRUG|tipranavir/ritonavir|tipranavir/ritonavir 500/200 mg twice a day
223715713|NCT00042289|DRUG|lopinavir/ritonavir dosage #4|lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
223715714|NCT00042289|DRUG|raltegravir|raltegravir 400 mg twice a day
223715715|NCT00042289|DRUG|etravirine|etravirine 200 mg twice a day
223715716|NCT00042289|DRUG|maraviroc|maraviroc 150 mg or 300 mg twice a day
223715717|NCT00042289|DRUG|atazanavir/ritonavir dosage #2|atazanavir/ritonavir 400/100mg once a day
223715718|NCT00042289|DRUG|tenofovir/atazanavir/ritonavir dosage #2|tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
223904352|NCT06281678|DRUG|IBI363|IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
223904353|NCT01922050|DRUG|LEO 43204 Formulation 1|
223904354|NCT01922050|DRUG|LEO 43204 Formulation 2|
223904355|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose X|
223904356|NCT01922050|DRUG|LEO 43204 Formulation 1 Dose Y|
223904357|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose XX|
223904358|NCT01922050|DRUG|LEO 43204 Formulation 2 Dose YY|
223904359|NCT01922050|DRUG|Placebo Formulation 1|
223904360|NCT01922050|DRUG|Placebo Formulation 2|
223904361|NCT04979039|OTHER|analgesia nociception index (ANI) monitoring|The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
223904362|NCT06284694|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|See experimental arm description
223904363|NCT04789837|DRUG|Cilostazol 50 MG|Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule
223904364|NCT04789837|DRUG|Placebo|Placebo tablet twice daily plus Celecoxib 200mg capsule
223904365|NCT05767242|OTHER|Electrophysiological recording|Investigation of early neural markers using electrophysiology at 6-12-24 months
223904366|NCT05767242|BEHAVIORAL|Behavioral assessment|Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
223904367|NCT05332899|BIOLOGICAL|Influenza Virus Type A H3N2 Challenge|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device, by natural exposure to infected participants, or by inhalation from an aerosol generator or nebulizer. Participants will be admitted to the hospital and quarantined for 8 to 12 days for monitoring, and will receive care and supportive treatment as necessary. Participants will be followed for a total of 12 weeks.
223904368|NCT03661645|DRUG|10 mg IV dexamethasone & 6 day oral methylprednisolone taper|"Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone"
223904369|NCT03661645|OTHER|10 mg IV dexamethasone|Drug:10 mg intravenous (IV) dexamethasone
223904370|NCT04781634|BIOLOGICAL|CD19 and CD22 targeted prime CAR-T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
223904371|NCT06561204|DEVICE|FMET|A full-mouth electronic toothbrush
224277004|NCT00452543|DRUG|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
223715719|NCT00042289|DRUG|nelfinavir dosage #2|nelfinavir \[625 mg tablets\] 1875 mg twice a day
223715720|NCT00042289|DRUG|indinavir/ritonavir dosage #2|indinavir/ritonavir 400/100 mg twice a day
223715721|NCT00042289|DRUG|rilpivirine|rilpivirine (25 mg q.d.)
223715722|NCT00042289|DRUG|darunavir/ritonavir dosage #4|darunavir/ritonavir once daily 800/100 mg q.d.
223904372|NCT04745884|DEVICE|Non-invasive bilateral monitoring of ICP waveform|Brain4care non-invasive bilateral monitoring of ICP waveform
223904373|NCT05490875|PROCEDURE|Carotid ultrasound|Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
223904374|NCT05490875|OTHER|Blood draw|This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
223904375|NCT05490875|OTHER|Survey|Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
223904376|NCT04793867|DRUG|Xenon|"Subjects will be scanned on a commercial 3T whole-body MRI scanner equipped with high-performance gradient systems. Natural isotopic abundance or isotopically-enriched xenon gas (\~86% 129Xe, Linde Inc.) will be used for all studies. Subjects will be positioned supine in the scanner with a 129Xe RF coil around their chests. Using conventional proton MRI and a breath-hold acquisition, scout images will be obtained to localize the subject for subsequent 129Xe acquisitions. 129Xe images will be acquired using the same breath-hold maneuver and a pulse sequence, covering the entire lung (acquisition time \<10 s, approximately 3-mm in-plane resolution, 15-mm slice thickness or less). Additional scans (sequences) may be performed. A maximum of 4 doses of 129Xe will be given throughout the study following the calibration dose."
223904377|NCT06075004|PROCEDURE|Periarticular Local Anesthetic Infiltration|Sixty milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg will be deposited by the orthopedic surgeon at the periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure.
223904378|NCT06075004|PROCEDURE|Posterior Periarticular Local Anesthetic Infiltration plus Pericapsular Nerve Group Block|"From a total of forty-five milliliters of 0.25% bupivacaine + 5ug/mL epinephrine and ketorolac 30 mg, 15mL will be deposited by the orthopedic surgeon at the posterior periarticular level under direct vision during surgery. Fascia, subcutaneous tissues, and skin will also be infiltrated with part of the solution before wound closure with the remaining 30mL.~After wound closure, an ultrasound-guided pericapsular nerve group block will be performed by an anesthesiologist by injecting 10mL of 0.5% bupivacaine + 5ug/mL epinephrine in the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle."
223904379|NCT04728451|BEHAVIORAL|Spectacle wear support|Parents of children in the full-time group are provided with encouragement, support, and counseling throughout the study in order to maximize their child's spectacle wear.
223904380|NCT04728451|DEVICE|Spectacles|Children prescribed and provided spectacles with full correction of their refractive error, with the exception of prescriptions with ≥ +1.50D sphere (plus cylinder notation) in the least hyperopic eye, which will be symmetrically reduced by 1.00D
223904381|NCT04971031|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.
223904382|NCT04971031|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.
224277005|NCT05561257|DRUG|Vitamin C|Vitamin C
223904383|NCT05328115|BIOLOGICAL|ALZ-101|Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.
223904384|NCT05328115|OTHER|Placebo|Intramuscular injections of adjuvanted placebo.
223904385|NCT04935710|BEHAVIORAL|COPE2Thrive|Cognitive Behavioral Therapy-based program to help teens deal with anxiety, stress and depression by showing them how to develop skills needed to stop negative thoughts and start thinking and behaving in more positive ways.
223904386|NCT04935710|GENETIC|Usual care|Children at risk who are not randomized to COPE2Thrive at any point of time serve as the control group.
223904387|NCT05648214|DRUG|ALN-PNP - Part A|Administered by subcutaneous (SC) single ascending dose (SAD)
223904388|NCT05648214|DRUG|ALN-PNP - Part B|Administered by SC parallel single dose
223904389|NCT05648214|DRUG|Placebo (PB)|Administered by SC injection
223904390|NCT05511415|DRUG|Oxytocin|Oxytocin solution, 20nM concentration
223904391|NCT05511415|DRUG|Dexmedetomidine|Dexmedetomidine (10-9M to 10-4M)
223904392|NCT04397679|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
223904393|NCT04397679|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
223904394|NCT04397679|DRUG|Temozolomide|Given PO
223904395|NCT04397679|DRUG|Chloroquine|Given PO
223904396|NCT04397679|PROCEDURE|Tumor Treating Fields Therapy (TTF)|Undergo TTF
223904397|NCT06557343|DIAGNOSTIC_TEST|Single Cell Sequencing|Sequencing of all viable single cells present in deep bronchial brushings using transcriptomics to identify what cells are present and what they are doing.
223904398|NCT04005690|DRUG|Cobimetinib|Given PO
223904399|NCT04005690|DRUG|Olaparib|Given PO
223904400|NCT04005690|DRUG|Onvansertib|Given PO
223904401|NCT04005690|DRUG|Azenosertib|Given PO
223904402|NCT04005690|DRUG|Saruparib|Given PO
223904403|NCT04005690|BIOLOGICAL|Tremelimumab|Given IV
223904404|NCT05116189|BIOLOGICAL|Pembrolizumab|IV infusion
223904405|NCT05116189|DRUG|Paclitaxel|IV infusion
223904406|NCT05116189|DRUG|Bevacizumab|IV infusion
223904407|NCT05116189|OTHER|Placebo for pembrolizumab|IV infusion
223904408|NCT05116189|DRUG|Docetaxel|IV infusion
223904409|NCT06108245|BEHAVIORAL|Values Clarification Mobile Application|Participants in the intervention group will be asked to answer a series of values clarification writing prompts twice a day over four weeks.
223904410|NCT06108245|BEHAVIORAL|Self-Reflection Mobile Application|Participants in the psychological placebo group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to clutter and organization.
223904411|NCT05592158|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
223904412|NCT03624517|DRUG|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
223904413|NCT04642820|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
223904414|NCT04642820|DRUG|placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
224277006|NCT03043040|BEHAVIORAL|Telephone follow up|Already described in previous page
224277007|NCT03043040|BEHAVIORAL|Treatment as usual|Already described in previous page
223904415|NCT05167487|DRUG|Cisplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
223904416|NCT05167487|DRUG|Carboplatin|Route of administration: Intravenous infusion. Neoadjuvant chemotherapy is often given 2 to 4 months before surgery.
223904417|NCT04390425|DEVICE|Experimental - Limb Occlusion pressure|This intervention involves lower tourniquet pressure than the standard of care. There is no change to tourniquet time or how the surgery is performed.
224277008|NCT01769222|BIOLOGICAL|Ipilimumab|Given intratumorally
223904418|NCT05454306|DEVICE|Anser Clavicle Pin|The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
223904419|NCT05456542|DIAGNOSTIC_TEST|Cuff Leak Test|Clinicians perform the cuff leak test (CLT) to help optimize extubation. The test requires deflation of the cuff at the end of the endotracheal tube (ETT) and auscultation for air passing around the ETT. If air movement is not audible on auscultation (a failed CLT) there is a potential presence of laryngeal edema (LE) that may cause post-extubation airway obstruction.
223904420|NCT05456542|DRUG|Dexamethasone 4mg|Dexamethasone, will be administered to those patients who fail the CLT in the intervention arm (4mg intravenous every 6 hours for 12-24 hours). Dexamethasone belongs to a class of drugs known as corticosteroids
223904421|NCT06829875|PROCEDURE|wait for outpatient appointment|this is an observational study measuring impact of pain and function at start and end of wait for those waiting for care from outpatient physiotherapy occupations therapy and podiatry
223904422|NCT04557618|DEVICE|Auricular Vagus Nerve Stimulation|Transcutaneous auricular vagal nerve stimulation
223904423|NCT04557618|DEVICE|Sham Auricular Vagus nerve Stimulation|Transcutaneous auricular vagal nerve ear clip applied without current
223904424|NCT05828173|DEVICE|LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)|Vessel preparation of moderately to severely calcified coronary artery lesions prior to stenting allows for full stent expansion and apposition to the vessel wall
223904425|NCT04989595|DEVICE|MyIUS app|Data will be self-reported by participants through the MyIUS app.
223904426|NCT06563154|DIAGNOSTIC_TEST|Exercise Capacity Assessment|To examine the relationship between exercise capacity and physical fitness of dyslipidemia patients and quality of life, cognitive status and health literacy.
224277009|NCT01769222|RADIATION|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
224277010|NCT03024801|DRUG|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
224277011|NCT03024801|DRUG|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
223715723|NCT04653129|PROCEDURE|Autologous Fat Grafting|"* The fat grafts will be harvested from the abdomen or lateral thighs in a closed sterile system, then prepared according to Coleman guidelines. The blood and oil layers are then separated from the adipose tissue.~* The lipoaspirate will be injected based on a technique described by Vaienti et al, by 17-gaug cannula which will be inserted through the skin around the main incision at the nerve repair site, and the fat graft will be injected after closure of the skin."
223904427|NCT06563154|DIAGNOSTIC_TEST|Physical Fitness Assessment|"* 1-Minute Sit-to-Stand Test: Participants will be asked to sit down and stand up for 1 minute without pausing, and the repetition number will be recorded.~* Timed Up-and-Go Test: Participants will be asked to get up, walk a distance of 3 meters, return and sit down again. The time spent during this track will be recorded.~* Peripheral muscle strength assessment: Participants will be asked to resist the resistance by producing maximum isometric force during the movement, and the maximal force will be evaluated with a dynamometer. The quadriceps femoris muscle, shoulder abductor muscles and hand grip strength will be used for the assessment.~* Flexibility assessment: Participants will be asked to reach towards the tips of their toes while sitting. During this time, the distance between the participant's fingertips and toes will be measured."
223904428|NCT06563154|OTHER|Quality of Life Assessment|Participants' quality of life will be assessed with the Turkish version of the Short Form Quality of Life Questionnaire (SF-36). The questionnaire consists of 36 questions that examine quality of life from different perspectives. It examines quality of life in the subcategories of physical function, physical role difficulty, pain, general health, vitality (energy), social function, emotional role difficulty and mental health. The score for each category varies between 0-100, with a high score indicating a good quality of life.
223904429|NCT06563154|OTHER|Physical Activity Assessment|Participants' physical activity level will be assessed with the Turkish version of the International Physical Activity Scale - Short Form (IPAQ-SF). The IPAQ-SF evaluates the physical activities of the participants in the last 7 days based on sitting time, walking time, moderate and vigorous physical activities.
223904430|NCT06563154|OTHER|Cognitive Health Assessment|Participants' cognitive health will be assessed with the with the Turkish version of the Mini Mental State Examine (MMSE). The test is scored between 0-30. Scores of 25 and above are considered normal. A total score of less than 10 indicates severe impairment. Scores between 10-19 indicate moderate dementia. Scores between 19-24 indicate early dementia.
223904431|NCT06563154|OTHER|Health Literacy Assessment|Participants' health literacy will be assessed with the Turkish version of the HLS-EU-47 health literacy survey. The survey consists of 47 questions. Each item is assessed with one of the following options: Very difficult (1), difficult (2), easy (3), very easy (4) and I don't know. A high total score indicates good health literacy. A total score of 0-25 points indicates insufficient health literacy, \>25-33: problematic - limited health literacy, \>33-42: sufficient health literacy, \>42-50: excellent health literacy.
223904432|NCT06562608|DRUG|Anticholinergic Deprescription|per routine clinical care, people in the active arm of the study will undergo deprescription of benztropine or trihexyphenidyl per routine clinical care.
223904433|NCT06562608|DRUG|No Anticholinergic Deprescription|In this arm, no deprescription of benztropine or trihexyphenidyl will occur.
223904434|NCT04820764|DEVICE|CardioMech MVRS|CardioMech MVRS
223904435|NCT00937001|PROCEDURE|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
223904436|NCT04522908|DRUG|Cabozantinib Oral Tablet|Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
223904437|NCT04421989|BEHAVIORAL|Emotion Coaching|Participants randomized to FBT + EC parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The EC intervention is designed to reduce expressed emotion (e.g., critical comments) and increase parental warmth. The intervention includes emotional awareness and emotion regulation skills for parents, and emotion communication skills for parents to use with their teens undergoing FBT including active listening, emotion support, labeling emotions, and coping with emotions. The structure of EC parent group sessions will begin with review of homework as applicable, a didactic component to teach new skills, followed by role plays between parents in the group and interventionist, and live coaching and feedback from the interventionist.
223715724|NCT04653129|PROCEDURE|Primary Nerve Repair|Standard Epineural nerve repairs will be performed with 9/0 nylon sutures, under magnification by an operating microscope.
223715725|NCT01511315|DRUG|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
223904438|NCT04421989|OTHER|Support Group|Participants randomized to FBT + Support Group parent group condition will also receive FBT as part of their standard of care. In addition to FBT, they will receive 10 additional, weekly, parent group sessions (each session is 60 minutes, 6-8 group members), within a 3-month time frame to account for cancellations. The support group will have a facilitator introduce each topic weekly and parents will discuss. The facilitator's role is to ensure the group remains on topic and on time. Weekly discussion topics include: co-morbid medical diagnoses, understanding levels of care in treatment, taking time off from work, and medications.
223904439|NCT06481462|PROCEDURE|Intrathecal Morphine (ITM)|morphine 100 mcg + 12.5 mg bupivacaine + 20 mcg fentanyl
224277012|NCT01849458|DEVICE|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
223715726|NCT00745823|DRUG|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
223715727|NCT00745823|DRUG|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
223715728|NCT00745823|DRUG|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
223715729|NCT02697825|PROCEDURE|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
223715730|NCT01206660|DRUG|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
223715731|NCT01206660|DRUG|placebo|Placebo administered to affected area twice a day for 28 days
223715732|NCT02967744|DRUG|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
223904440|NCT06481462|PROCEDURE|Quadratus Lumborum II (QLB-II) Block|12.5 mg bupivacaine + 20 mcg fentanyl bilateral QLB block (posterior tip 2) 25 cc 0.25% bupivacaine
223904441|NCT05325645|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
223904442|NCT05325645|DRUG|Placebo|Two placebo tablets will be orally administered once weekly for 7weeks.
223904443|NCT06558266|OTHER|Since this was an observational study, no intervention was performed.|Since it is an observational study, only evaluation will be made. Each participant s mental imagery ability will be evaluated with the Movement Imagery Vividness Questionnaire-2 four times, follicular phase, ovulation, luteal phase and menstrual phase. In addition, the pain intensity experienced during menstruation will be evaluated with the Numerical Classification Scale-11, and the symptoms experienced due to menstruation will be evaluated with the Menstruation Symptom Scale.
223904444|NCT06050369|DEVICE|EEG|Recording, from the scalp, the electrophysiological activity of the brain.
223904445|NCT06050369|DEVICE|MRI|Get the anatomical shape of the brain.
223904446|NCT05706103|BEHAVIORAL|Specific skilled motor training|Participants allocated to the skilled motor training group will receive sensorimotor training of the intrinsic muscles of the lumbopelvic region, namely the multifidus, transversus abdominis, and pelvic floor muscles.
223904447|NCT05706103|BEHAVIORAL|General extension training|Participants allocated to the general extension training group will receive general training exercises using the David Back equipment from the Back Unit at Ghent University Hospital
223904448|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 175mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
223904449|NCT05936346|DIETARY_SUPPLEMENT|Salvia haenkei 350mg|The product appears as a soft gel containing the dry extract of Salvia haenkei
223904450|NCT06538207|DRUG|ONO-4578|Specified dose on specified days
223904451|NCT06538207|DRUG|ONO-4538|Specified dose on specified days
223904452|NCT06538207|DRUG|Oxaliplatin|Specified dose on specified days
223904453|NCT06538207|DRUG|Levofolinate|Specified dose on specified days
223904454|NCT06538207|DRUG|Irinotecan|Specified dose on specified days
223904455|NCT06538207|DRUG|Fluorouracil|Specified dose on specified days
223904456|NCT06538207|DRUG|Gemcitabine|Specified dose on specified days
223904457|NCT06538207|DRUG|Nab-Paclitaxel|Specified dose on specified days
223904458|NCT06238726|BEHAVIORAL|Reminder|Shingrix messages via SMS, patient portal, email, and/or another modality
223904459|NCT05727930|BEHAVIORAL|High-intensity, task-specific (i.e., walking) interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
223904460|NCT05727930|BEHAVIORAL|High-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
223904461|NCT05727930|BEHAVIORAL|Low-intensity, task-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
223904462|NCT05727930|BEHAVIORAL|Low-intensity, non-specific physical therapy interventions|Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
223904463|NCT06125054|DRUG|Ketamine|single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
223904464|NCT06125054|DRUG|Placebo|single dose of placebo (0.9% saline solution i.v. over 40 minutes)
223904465|NCT06125054|BEHAVIORAL|real-time fMRI neurofeedback training|Real-time fMRI based neurofeedback over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on an experimental region. The training is repeated three times.
223904466|NCT06125054|BEHAVIORAL|sham real-time fMRI neurofeedback training|Sham real-time fMRI neurofeedback training over 20 minutes where participants are instructed to perform reward imagery. The feedback is based on a control region. The training is repeated three times.
223904467|NCT03138603|DRUG|Metoprolol Tartrate|Patients will be randomly assigned to receive up-to-three intravenous doses of 5mg metoprolol tartrate (over 15-minutes) at the end of their surgical procedure, and a scheduled oral dose regimen of 25mg metoprolol approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
223904468|NCT03138603|DRUG|Placebo|Patients will be randomly assigned to receive up-to-three intravenous doses of a placebo-comparator (over 15-minutes) at the end of their surgical procedure, and scheduled oral dose regimen of a placebo-comparator approximately every 8-hours postoperatively for up to 3-days (or 72 hrs).
223904469|NCT06157580|DRUG|Compound 21|differences in vasodilation to compound 21 in the skin between groups
223904470|NCT06157580|DRUG|Angiotensin II|differences in vasoconstriction to angiotensin II in the skin between groups
223904471|NCT05819996|BEHAVIORAL|Environmental educational campaign|Educational campaign will be conducted to promote participation in indoor air testing.
223904472|NCT06269367|OTHER|NewGait|wearable limb orthotic device
223904473|NCT06269367|OTHER|Control wearable limb orthotic device|wearable limb orthotic device
223904474|NCT04760899|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
223904475|NCT03463044|DRUG|nangibotide|Continous i.v. infusion
223904476|NCT03463044|DRUG|Placebo|Placebo
223904477|NCT02464007|BIOLOGICAL|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
223904478|NCT03779139|PROCEDURE|Intrahepatic islets and islets in the omental pouch|Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
223904479|NCT03779139|PROCEDURE|Intrahepatic islets alone|This is the standard of care procedure. Patients with islet harvest of \>5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
223904480|NCT03779139|OTHER|Normal Volunteers|These individuals will undergo metabolic testing as well as islet cell function testing.
223904481|NCT05192109|BEHAVIORAL|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
223904482|NCT05192109|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
223904483|NCT04498390|DRUG|LY3493269|Administered orally.
223904484|NCT04498390|DRUG|Placebo|Administered orally.
223904485|NCT06375902|BEHAVIORAL|PragmaCom|Cognitive behavioral intervention targeting the ability to understand metaphors
223904486|NCT06082492|DIAGNOSTIC_TEST|18F FDG PET/CT|Additional 18F FDG PET/CT scans during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
223904487|NCT06082492|DIAGNOSTIC_TEST|CT scan|CT of the thoracic region during follow-up visits at 6, 12, 18, 24 and 36 months of follow-up.
223904488|NCT05328856|DEVICE|Hansgrohe prototype/shower head|Start of the shower with warm comfort temperature and usual body cleansing. Then the Vital shower is carried out for a total of 3-5 minutes, followed optionally by another warm shower with 30 seconds or direct transition to a classic cold shower for 30- 60 seconds
223904489|NCT03010059|DRUG|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
223904490|NCT03010059|DRUG|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
223904491|NCT06383013|BIOLOGICAL|BB-101|Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
223904492|NCT06322940|OTHER|250 mL serving size, 3.25% fat content|Milk
223904493|NCT06322940|OTHER|175 g serving size, ≥2% fat content|Yogurt
223904494|NCT06322940|OTHER|50 g serving size, ≥28% fat content|Cheese
223904495|NCT05268120|DRUG|doxycycline 200 mg q.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
223904496|NCT05268120|DRUG|trimethoprim 200mg b.i.d. - rifampicin 600mg b.i.d.|Both first choice treatments in Dutch guideline for MRSA decolonization
223904497|NCT03481075|OTHER|Biomechanical computer program|Fusion assisting software for image-guided intervention
223715733|NCT03922503|PROCEDURE|Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
223904498|NCT03478956|DRUG|Etrolizumab|Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
223904499|NCT04698031|DRUG|Clopidogrel treatment|After randomization, patients will receive clopidogrel 75 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Clopidogrel is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
223904500|NCT04698031|DRUG|Aspirin treatment|After randomization, patients will receive Aspirin 325 mg daily for the duration of the study. The VA Research Pharmacy will dispense similar looking medication with Arm 2 to ensure the double-blind nature of the intervention. Aspirin is FDA approved for secondary prevention of stroke. Follow-up will be for 24 months with repeat brain MRI obtained at 24 months to assess for interval presence of silent brain infarctions.
223904501|NCT06103669|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
223904502|NCT01050036|PROCEDURE|autologous hematopoietic cell transplantation|"1. Autologous peripheral blood stem cell (PBSCs) harvesting~   * After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~  * Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~  * Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~2. Conditioning regimen for autologous HCT~   * Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~  * Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~3. Autologous cell infusion and waiting for engraftment"
223904503|NCT04865289|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
223904504|NCT04865289|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
223904505|NCT04865289|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
223904506|NCT04865289|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
223904507|NCT05752149|DRUG|CRGD-ZW800-1|Intravenous administration of study drug at lesat 2h prior to surgery
223904508|NCT04360252|OTHER|Gracie Diet|"The patient is going to have an encounter with the nutritionist (either face to face or by phone call) and she will provide patient with the requisite nutritional information and will guide patient on how to properly adhere to the diet.~The session is designed to: answer patient questions, educate patients so that patients understand the underlying nutritional concepts that the diet is based upon, support patients by empowering the patients to make healthy nutritional choices consistent with the diet, educate patients regarding the appropriate combinations of healthy foods, and help patients to develop menu samples based on the Gracie Diet when there is interest."
223904509|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
223904510|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
223904511|NCT04603443|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
223904512|NCT04603443|DIETARY_SUPPLEMENT|Protein Control|Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
223904513|NCT04380311|DEVICE|Tacrolimus Dosing Support Tool|The tacrolimus dosing support tool is based on a population pharmacokinetic model that incorporates patient specific factors including age, renal function, and concomitant medications.
223904514|NCT05346757|DIAGNOSTIC_TEST|miRFec test|The miRFec test actually corresponds to the combination of fecal hemoglobin concentration (ie. FIT) and fecal miRNA expression
223904515|NCT06462924|DEVICE|DeepGad|Using the pre-contrast and low-dose Contrast-Enhanced Magnetic Resonance (CE-MRI) images as input and the true full-dose CE-MRI images as the ground truth. the Cycle GAN deep network (DeepGad), was trained to reconstruct the full-dose CE-MRI images from low-dose CE-MRI images.
223904516|NCT06407843|OTHER|Schroth Method|In addition to regular physical therapy, Group A will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Ten sessions total (30 minutes each, five days a week) will be conducted.
223904517|NCT06407843|OTHER|Regular Physical Therapy|Stretching exercises (especially for the muscles on the concave side of the curve) will be part of these regular workouts. Twice day, perform 10 repetitions of a 5-second hold while supine pelvic tilt, twice. Ten sessions total (30 minutes each, five days a week) will be conducted.
223904518|NCT05396040|PROCEDURE|LOLLI METHODE|WEEKLY SCREENING WITH POOLED SALIVA PCR TEST
223904521|NCT03318601|PROCEDURE|Blood taking|"Blood taking in 2 times :~* J0 : 15 mL~* J14 : 5 mL 20 mL in total volume"
223904522|NCT05084209|BEHAVIORAL|Parkinson's medical decision making support|Participants will be asked to view and work through medical decision making support resources. The resources will include information on medical decisions that may occur in Parkinson's disease, and general medical decisions that anyone may need to make (i.e. choosing a medical decision maker). The resources will also include suggestions on how to discuss these decisions.
223904523|NCT06396806|PROCEDURE|indocyanine green fluorescence imaging lymphatic tracing|At the end of routine operation, indocyanine green was used for lymph node tracing, and further lymph node dissection was performed according to the tracer results.
223904524|NCT06201559|DRUG|Albendazole IP 400 mg|Albendazole IP 400 mg tablets will be administered under fed conditions
223904525|NCT06201559|DRUG|Albendazole 400 mg|Albendazole 400 mg tablets will be administered under fed conditions
223904526|NCT03875287|DRUG|Decitabine|"DOSING REGIMEN(S):~Level -1 10mg daily days 1-4~Level 1 10mg daily days 1-5~Level 2 15mg daily days 1-5~Level 3 20mg daily days 1-5~Level 4 25 mg daily days 1-5"
223904527|NCT03875287|DRUG|Cedazuridine|"DOSING REGIMEN(S):~Level -1 100mg daily days 1-4~Level 1 100mg daily days 1-5~Level 2 100mg daily days 1-5~Level 3 100mg daily days 1-5~Level 4 100mg daily days 1-5"
223904528|NCT07062328|DRUG|Recaticimab and Adebrelimab|"Patients would receive Recaticimab (150 mg, sc., q4w) and Adebrelimab (1200 mg, iv., q3w) plus GP chemotherapy in 21day cycles.~Recaticimab and Adebrelimab would be maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years."
223904529|NCT07062328|DRUG|GP chemotherapy|Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle, up to 6 cycles.
223904530|NCT07064421|DIAGNOSTIC_TEST|Magnetoencephalography plus Stereo-electroencephalography/Electrocorticography|Use Magnetoencephalography and Stereo-electroencephalography/Electrocorticography in the preoperative assessment of children with drug-resistant epilepsy, particularly in identifying the seizure focus.
223904531|NCT07064421|DIAGNOSTIC_TEST|Stereo-electroencephalography/Electrocorticography|Use Stereo-electroencephalography/Electrocorticography in the preoperative assessment of children with drug-resistant epilepsy, particularly in identifying the seizure focus.
223904532|NCT06808256|PROCEDURE|the acupuncture therapy|Acupuncture is performed for 3 consecutive days, using filiform needles in the chest, hands, feet area with 20 minutes retention during therapy and using press needle on the forehead which are retained for 3 days and after 3 days the stick needles will be removed. And patient continue to receive standard therapy in accordance with the clinical practice guidelines of the ICU Tangerang Hospital
223904533|NCT06808256|OTHER|Standard therapy|Pharmacological therapy provided by the doctor in charge of anesthesia science patients to the research subjects was in accordance with existing clinical practice guidelines. In the ICU of Tangerang Hospital, the standard therapy given to post-craniotomy patients with mechanical ventilation is analgesic and sedation. This standard therapy is also given according to the patient's clinical condition
224277013|NCT02682108|DEVICE|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
223715734|NCT03922503|PROCEDURE|Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
223904534|NCT07062471|DEVICE|Carotid Intravascular Lithotripsy (IVL)|The Shockwave Medical Intravascular Lithotripsy (IVL) System with the Shockwave SkyRunner Carotid IVL Catheter is intended for lithotripsy- enhanced balloon dilatation of ≥ 3 mm thick calcified lesions in the carotid arteries prior to stenting. Not for use for treating massive exophytic (mushroom-like) or irregular endoluminal carotid calcification, or in the coronary or cerebral arteries.
223904535|NCT07062757|OTHER|no intervention|this group patients receive any medication for edema control.
223904536|NCT07062757|OTHER|lymphatic drainage massage|A total of 10 sessions of lymphatic drainage massage will be applied to this group of patients, starting from the 2nd postoperative day, with 2 sessions per week.
223904537|NCT07062757|DIETARY_SUPPLEMENT|oral melatonin tablet|In this group of patients, the first dose of 10 mg oral melatonin tablet will be given one day prior to the operation, and the patients will continue taking the tablet daily for a total of 21 days.
223904538|NCT07062757|COMBINATION_PRODUCT|both melatonin and lymphatic drainage|In this group of patients, a total of 10 sessions of lymphatic drainage massage will be applied starting from the 2nd postoperative day, with 2 sessions per week, while the first dose of 10 mg oral melatonin tablet will be administered one day prior to the operation, and the patients will continue taking the tablet daily for 21 days.
223904539|NCT07062081|DIAGNOSTIC_TEST|lipid profile|The blood samples were taken to measure lipid profile levels as triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) and VLDL values.
223904540|NCT07063212|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate
223904541|NCT07063212|DRUG|Cetuximab|Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist
223904542|NCT07064057|OTHER|Aerobic exercise combined with the sniff maneuver technique|Aerobic exercises on a stationary bike or electric treadmill three times a week for six week. Five minutes of stretching, concentrated on the main lower limb muscle groups, were followed by a ten-minute warm-up, twenty minutes of training during the first two weeks and thirty minutes during the third to sixth week, and finally, a five-minute cooling-down phase..
223904543|NCT07064057|OTHER|Aerobic exercise|The treadmill was used for both the warm-up and cooling-down phases. Heart rate was kept between 40% and 50% of maximum heart rate for these sessions. (5) To achieve a moderate exertion (rated as 11--13 on the Borg scale) and/or a moderate dyspnea (rated as 3---4 on the modified Borg scale), the intensity of the aerobic training was progressively increased.
223904544|NCT07063342|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
223904545|NCT07063342|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
223904546|NCT07063342|DRUG|Trospium Chloride|Specified dose on specified days
223904547|NCT06638944|BEHAVIORAL|In-person sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions in the clinic and 3 days of home practice per week using the i-Phagia sEMG system. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
223904548|NCT06638944|BEHAVIORAL|Remote sEMG-biofeedback|Participants in this intervention complete a standardized behavioral swallowing rehabilitation protocol for 12 weeks with weekly (once per week) treatment sessions completed remotely (via telehealth) and 3 days of home practice per week. The protocol includes oropharyngeal strength training and skill-based practice exercises. For this group, patients also use the sensor patch and the software guides them on how to complete the exercises and receive feedback.
223904549|NCT06638944|BEHAVIORAL|Standard-of-care treatment|Participants in this intervention will complete the same standardized behavioral swallowing rehabilitation protocol and in the same frequency as the sEMG biofeedback intervention groups but WITHOUT a device. That is, they will complete the protocol for 12 weeks with weekly (once per week) treatment sessions completed in-person and 3 days of home practice per week. For this intervention group, patients use a visual analog scale and a timer as feedback tools, as frequently done in clinical practice where sEMG devices are not widely available.
223904550|NCT05586958|DRUG|Tigulixostat|Xanthine Oxidase Inhibitor
223904551|NCT05586958|DRUG|Placebo|Matching placebo
223904552|NCT06076304|DRUG|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
223904553|NCT06076304|DRUG|Placebo|Placebo for amoxicillin/clavulanate, oral, twice daily for 7 days
223904554|NCT06076304|DRUG|Budesonide nasal spray|Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
223904555|NCT06076304|OTHER|C-reactive protein|Measurement of C-reactive protein level in capillary blood
223904556|NCT06368986|DRUG|VH4011499 Dose A|VH4011499 administered in fasted or fed conditions.
223904557|NCT06368986|DRUG|VH4011499 Dose B|VH4011499 Dose B administered in fasted or fed conditions.
223904558|NCT06953882|DRUG|Ribociclib 400mg|400 mg (2 x 200 mg tablets by mouth) once daily on days 1 to 21 of a 28-day cycle, followed by seven days off ribociclib (Days 22 to 28).
223715735|NCT05328193|BEHAVIORAL|Healthier Families, COVID Edition|Families randomized to this arm with receive12-weekly health coaching calls virtually with their family with topics such as nutrition, physical activity, sleep, and media use.
223904559|NCT06953882|DRUG|Letrozole 2.5mg|Letrozole will be administered as an endocrine therapy. The regimen will differ depending on the demographic of the patient. For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously.
223904560|NCT06953882|DRUG|Anastrazole 1mg|For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously.
223904561|NCT06953882|DRUG|Goserelin 3.6 MG|For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously, concurrently with goserelin 3.6 mg monthly injection.
223904562|NCT06953882|RADIATION|Adjuvant chemotherapy|Adjuvant chemotherapy dose modifications in Arm 2 will be per institutional guidelines and investigator discretion.
223904563|NCT05513833|OTHER|Standard School Screening and Referral|Counties in the control condition will use standard hearing screening and standard referral by school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.
223904564|NCT05513833|OTHER|Enhanced mHealth Screening|The enhanced screening protocol will consist of an mHealth-based hearing screen combined with tympanometry.
223904565|NCT05513833|OTHER|Specialty Telemedicine Referral|The specialty telemedicine referral will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the specialty telemedicine referral and send details asynchronously to an audiologist for consultation.
223904566|NCT05837091|DRUG|Low Sodium Oxybate|Titrated according to standard of care and continued on stable dose for 3 months
223904567|NCT05837091|DIAGNOSTIC_TEST|24-hour polysomnography|Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
223904568|NCT05837091|DEVICE|Nextsense EEG earbuds|Ear buds used to record sleep staging worn for a 24-hours period
223904569|NCT05837091|DEVICE|Axivity device|Wristband that records activity level worn for approximately one month to track sleep and steps/activity.
223904570|NCT02561247|DEVICE|Prismaflex HF20 CRRT Filter|
223904571|NCT02561247|DEVICE|Prismaflex® System 7.10 and 7.20|
223904572|NCT04826003|DRUG|RO7122290|RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
223904573|NCT04826003|DRUG|Cibisatamab|Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
223904574|NCT04826003|DRUG|Obinutuzumab|"Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~\- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab"
223904575|NCT05989802|DIAGNOSTIC_TEST|Oral swab molecular testing|Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.
223904576|NCT05989802|DIAGNOSTIC_TEST|Automated Cough Sound Analysis|Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.
223904577|NCT05989802|DIAGNOSTIC_TEST|Automated Lung Sound Analysis|Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.
223904578|NCT05989802|OTHER|Chest X Ray Computer Aided Detection|Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
223904579|NCT03325855|OTHER|None - Observational|None - Observational
223904580|NCT06505850|DEVICE|Tapered-shaped cuff tracheal tube|Tracheal intubation with a tapered-shaped cuff tube
223904581|NCT06505850|DEVICE|Cylindrical-shaped cuff tracheal tube|Tracheal intubation with a cylindrical-shaped cuff tube
223904582|NCT05825456|PROCEDURE|endoprosthetic reconstruction|This is a type of surgery in which the affected part of the bone and joint is removed, and replaced by a prosthesis.
223904583|NCT05825456|PROCEDURE|Intramedullary nailing|This is a type of surgery in which the affected bone is stabilized by a nail. The affected part could be removed or retained. If removed, the defect is filled with bone cement.
223904584|NCT05825456|PROCEDURE|Open reduction internal fixation with plate and screws|This is a type of surgery in which the affected part of the bone is visualized completely, after the reduction is achieved, the fixation is provided with appropriate plates and screws. Again the affected part could be removed or retained. If removed, the defect is filled with bone cement.
223904585|NCT04803994|DRUG|Atezolizumab|1200 mg atezolizumab intravenously Q3W (max 32 cycles, up to 24 months)
223904586|NCT04803994|DRUG|Bevacizumab|15 mg/kg intravenously Q3W (max 32 cycles, up to 24 months)
223904587|NCT04803994|PROCEDURE|TACE|Locoregional therapy will be performed as a standard-of-care procedure
223904588|NCT01924819|DRUG|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
223904589|NCT01924819|RADIATION|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
223904590|NCT01924819|PROCEDURE|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers \[Siewert Type II and Siewert Type III\] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
223904591|NCT06353204|BEHAVIORAL|Halt-intervention|The Halt-intervention is a Dutch extrajudicial, or diversion, measure for minors (aged 12-17) who committed a minor offence. The intervention can consist of conversations with the Halt-employee, working or learning assignments to learn from the mistakes made or to work on certain skills, such as social skills, and/or apologizing to the victim.
223904592|NCT06360107|OTHER|brief video|brief video about depression
223904593|NCT04858451|DRUG|RESP301|"A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day."
223904594|NCT04418232|COMBINATION_PRODUCT|Alianza Latina|The main components of Alianza Latina are 1) providing primary care providers with education, training and tools for timely dementia diagnosis and optimal treatment and 2) providing Latino dementia patients with enhanced chronic care through bilingual Health Navigators.
223904595|NCT06489197|DRUG|Ivonescimab combined with albumin paclitaxel and cisplatin|Ivonescimab (20mg/kg, intravenous infusion, d1, Q3W) combined with albumin paclitaxel (220mg/m2, intravenous infusion, d1, Q3W) and cisplatin (75mg/m2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months.
223904596|NCT05110924|OTHER|Standard of care|Patients in the treatment arm will receive standard care.
223904597|NCT05110924|OTHER|Monitoring|Patients in the non-treatment arm will be closely monitored: the tumor will be evaluated using non-invasive imaging devices based on multispectral dermoscopy, reflectance confocal microscopy to determine the exact histology and high definition optical coherence tomography for imaging and volume calculation of the BCC.
223904598|NCT05980299|BEHAVIORAL|Individualized Positive Psychosocial Interaction|The intervention involves a brief positive interaction around a preferred activity or personal care routine.
223904599|NCT05826639|PROCEDURE|Temperature-sensitive radiofrequency ablation|Endobiliary radiofrequency ablation prior to ERCP-guided biliary stenting that utilizes a temperature-sensitive endobiliary RFA catheter
223904600|NCT05826639|OTHER|No intervention|No intervention
223904601|NCT06187220|DEVICE|Therapeutic Plasma Exchange (PEX)|Therapeutic plasma exchange with treatment sessions \>=1 replacing varying fractions of patient´s whole plasma with healthy donor plasma
223904602|NCT05772468|DEVICE|Virtual Reality ('VRelax' VR system)|The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
223904603|NCT04945590|BEHAVIORAL|Virtual Intervention Program|Four separate virtual individual and group interviews (via telephone or online), which will be scheduled with the help of champions and leaders of the Latino community who will collaborate as companions to improve the commitment and experience of families.
223904604|NCT06161974|DRUG|Olutasidenib + TMZ|Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
223904605|NCT03199651|OTHER|Best Practice|Receive usual care
223904606|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
223904607|NCT03199651|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
223904608|NCT03199651|OTHER|Laboratory Biomarker Analysis|Correlative studies
223904609|NCT03199651|OTHER|Medical Chart Review|Undergo medical record abstraction
223904610|NCT03199651|OTHER|Quality-of-Life Assessment|Ancillary studies
223904611|NCT03199651|OTHER|Questionnaire Administration|Ancillary studies
223904612|NCT03199651|BEHAVIORAL|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
223904613|NCT06458933|BEHAVIORAL|Sage|Sage is a 12-session manualized weekly intervention delivered to people with borderline personality disorder (BPD) and their intimate partners. The Sage intervention consists of three phases: Phase 1, orientation and safety which focuses on targeting destructive behaviours (e.g., suicide attempts and self harm engagement) by providing couples with safety strategies that target suicide risk/ crisis, education about BPD, the role of emotion dysregulation and intimate relationship dysfunction in maintaining it (\~three sessions). Next, Phase 2, communication and emotion skills entails couples learning communication skills and strategies for identifying, expressing, and regulating emotions (\~five sessions). Lastly, in Phase 3, cognitive skills and intervention termination, couples learn strategies to target negative cognitions that elicit emotion dysregulation and intimate relationship dysfunction (\~four sessions).
223904614|NCT06458933|BEHAVIORAL|Supportive Individual Psychotherapy|Supportive Individual Psychotherapy (SIP) is a comparator in our control condition reflects enhanced usual care (i.e., case management/supportive psychotherapy) for people with BPD. Both people with BPD and partners will receive SIP sessions separately over the course of 12 sessions, delivered by therapists. For both members of the couple, SIP will involve 12 sessions of a specific form of supportive psychotherapy (referred to in other trials as case management; Linehan et al., 2015) that has been successfully used as a standard care control for individual therapy contact in BPD treatment RCTs (Linehan et al., 2015). This intervention involves conducting a needs assessment, providing resources/information (e.g., referrals), offering assistance with problems in living (e.g., eviction), and providing supportive, empathic responses.
223904615|NCT05740137|DEVICE|AI-assisted colonoscopy|The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
223904616|NCT05792839|PROCEDURE|Abdominoplasty with ventral hernia repair versus ventral hernioplasty.|We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
223904617|NCT04521608|BEHAVIORAL|Intervention- Home-based Pulmonary Rehabilitation|Home-based Pulmonary Rehabilitation (PR) with health coaching using a remote system that will allow patients to complete PR at home. The program involves upper and lower extremity exercises, self-report of symptoms (fatigue, breathlessness, physical activity and overall well-being).
223904618|NCT02533765|DRUG|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
223904619|NCT06616532|DRUG|PM8002|Following a predefined dose and date.
223904620|NCT06616532|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 Q3W
223904621|NCT06616532|DRUG|Topotecan|1.25mg/m2/day via IV infusion on Days 1-5 Q3W
223904622|NCT06272903|DRUG|20% benzocaine, topical anesthetic|"Indicated as a topical anesthetic for use on oral mucosa prior to local anesthetic injections, scaling and prophylaxis. Also useful to relieve discomfort associated with taking impressions and intra- oral radiographs.~The benzocaine topical anesthetic will be applied according to standard clinical practice, aiming to provide local anesthesia to the treatment site and minimize discomfort during the procedure (placing elastomeric orthodontic separators)."
223904623|NCT06272903|OTHER|Children's Toothpaste|Strawberry-flavored children's toothpaste available in Dubai, UAE.
223904624|NCT03705806|RADIATION|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
223904625|NCT05734183|OTHER|MIME|Multisensorial IMmersive Experiences
223904626|NCT05734183|OTHER|MIME + tDCS|Multisensorial IMmersive Experiences plus transcranial direct current stimulation
223904627|NCT03663569|DRUG|Spiolto® Respimat®|Drug
223904628|NCT06171386|PROCEDURE|Microneedling|a form of collagen induction therapy
223904629|NCT06171386|PROCEDURE|Dermabrasion|a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization
223904630|NCT04871269|DRUG|Dronabinol|Dronabinol
223904631|NCT04871269|DRUG|Placebo|Placebo
223904632|NCT05982314|BIOLOGICAL|Gamma-PN3|Experimental whole-cell pneumococcal vaccine
223904633|NCT05982314|BIOLOGICAL|Pneumovax-23|Licensed pneumococcal vaccine
223904634|NCT05982314|BIOLOGICAL|Prevenar-13|Licensed pneumococcal vaccine
223904635|NCT05982314|BIOLOGICAL|Placebo|Saline placebo
223904636|NCT04082650|DRUG|vitamin D|4000IU per day
223904637|NCT04082650|OTHER|Placebo|The same doses with vitamin D
223904638|NCT04298983|DRUG|Abemaciclib 150 MG by mouth twice daily|Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.
223904639|NCT04298983|DRUG|Androgen deprivation therapy (ADT)|ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.
223904640|NCT04298983|RADIATION|Radiation Therapy|RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
223904641|NCT04506307|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
223904642|NCT03121404|PROCEDURE|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
223904643|NCT06258330|DRUG|AM003|Bispecific Personalized Aptamer for intratumoral administration
223904644|NCT01526096|DRUG|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
223904645|NCT01526096|DRUG|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
223904646|NCT01526096|PROCEDURE|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
223904647|NCT01526096|DRUG|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
223904648|NCT01526096|PROCEDURE|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
223904649|NCT01526096|DRUG|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
223904650|NCT01526096|DEVICE|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
223904651|NCT06145334|BEHAVIORAL|Veterans Social|Peer-led weekly community-based social groups (16 weeks) that are current treatment at the study site.
223904652|NCT04248725|BEHAVIORAL|E-TIPS|Chronic pain self-management strategies for employed individuals with physical disabilities
223904653|NCT06440889|DEVICE|Bio-Ray Knee Guard|Wear the metal guard (test product) for 1-2 hours during the first week, and then for 6-8 hours thereafter. (minimum for 4 hours)
223904654|NCT05759299|PROCEDURE|Advanced airway management|Advanced airway management with either tracheal intubation or supraglottic airways performed after induction with hypnotic and/or opioid drugs
223904655|NCT02116530|DRUG|Olanzapine|oral
223904656|NCT02116530|DRUG|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
223904657|NCT02116530|DRUG|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
223904658|NCT02116530|OTHER|Placebo|oral
223904659|NCT03766685|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223904660|NCT05553743|BIOLOGICAL|COVID-19 Exposure|Have been or may have been exposed to COVID-19.
223904661|NCT05553743|DRUG|Antibiotic|Have or have not been prescribed one of several commonly used antibiotics including azithromycin, amoxicillin and clavulanic acid, amoxicillin, or nitrofurantoin.
223715736|NCT05328193|BEHAVIORAL|Teaching Kitchen Outreach|Families receiving this intervention will recipe 11-weekly video recipes and groceries delivered to their door.
223904662|NCT06427343|DRUG|High-dose ferric derisomaltose|"After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.~In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not \>700 ng/mL, or if TSAT was not \>40% during follow-up."
223904663|NCT06427343|DRUG|Low-dose ferric derisomaltose|In the low-dose group, participants will receive repeat iron dosing if ferritin \<100 ng/mL or if ferritin 100-300 ng/mL and TSAT \>20% during follow-up.
223904664|NCT04676165|DEVICE|Smart About Meds (SAM)|"SAM generates a patient-friendly list of prescribed and dispensed medications and offers several features:~* Drug information: Patient-friendly monographs that describe treatment indications and the harms/benefits of medications.~* Adherence alerts: Alerts users to non-adherence, such as when they fill prescriptions that were stopped at hospital discharge, don't fill prescribed medications, or buy medications at the incorrect dose.~* Side-effect checker: Provides a list of side effects associated with individual medications and the patient's overall drug profile.~* Rate my med: Allows patients to rate medications and describe experiences with a medication. Patients can view ratings given by users.~* Caregiver connect: Provides patients' caregivers with access to the app.~* Pharmacy connect: Allows patients to connect with their hospital pharmacist to ask questions regarding their medications and adherence alerts.~* Other: pill images, daily pill reminders, weekly dosing schedule"
223904665|NCT05842876|DEVICE|Continuous Renal NIRS Monitoring|Renal oxygenation data collected every 6 seconds
223904666|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|q6 h BP, q6 h Pulse ox, Echo at 24-72h
223904667|NCT05842876|DIAGNOSTIC_TEST|Standard Clinical Care|Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h
223904668|NCT05842876|OTHER|Satisfaction Survey|Survey to assess which method of monitoring is preferred
223904669|NCT02927236|DEVICE|Transcranial magnetic stimulation (TMS)|Theta burst stimulation is a type of TMS.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 active/sham coil will be used.
223904670|NCT04028479|DIAGNOSTIC_TEST|Biomarker Testing (L)|Patients who have received biomarker testing that could affect prognosis or treatment decisions. This generally excludes testing done to assist in the diagnosis of disease or histology where there is no treatment implication from this testing.
223904671|NCT04028479|DRUG|Systemic Treatment (T)|Patients who have received any treatment as part of their care. This refers to systemic treatment, but also allows other non-drug related interventions such as surgery or radiotherapy as part of the longitudinal care of the patient.
223904672|NCT04028479|OTHER|Patient Reported Outcomes (P)|Patients who have provided information about their disease, treatment course, or experience directly to the study using a patient facing tool or device.
223904673|NCT06144697|DRUG|BMS-986465|Specified dose on specified days
223904674|NCT06144697|OTHER|Placebo|Specified dose on specified days
223904675|NCT06144697|DRUG|Pegasys|Specified dose on specified days
223904676|NCT06144697|DRUG|Famotidine|Specified dose on specified days
223904677|NCT05495555|DEVICE|INTREPID® Hybrid tip|INTREPID® Hybrid tip for cataract removal
223904678|NCT00922571|PROCEDURE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
223904679|NCT00922571|DEVICE|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
223904680|NCT06680869|DRUG|Amiodarone Hydrochloride Injection|"The use of a modified treatment protocol by emergency medical services where the initial dose of amiodarone is given after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
223904681|NCT06680869|OTHER|Usual Care Protocol|"The use of a usual care treatment protocol by emergency medical services where the initial dose of amiodarone is given after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt.~If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study."
223904682|NCT01148849|BIOLOGICAL|margetuximab|margetuximab
223904683|NCT06128993|OTHER|Transcoronary cooling and dilution|Transcoronary cooling and dilution
223904684|NCT06128993|OTHER|Standard of care|Routine clinical care
223904685|NCT03656510|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
223715737|NCT01340885|DRUG|Strattera|10-30 mg b.i.d. for 6 weeks
223715738|NCT01340885|DRUG|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
223715739|NCT01340885|OTHER|Placebo|2-6 pills for 6 weeks
223715740|NCT02007694|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
223715741|NCT03283852|GENETIC|blood sample|search for genetic mutations
223715742|NCT03269864|PROCEDURE|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
223904686|NCT03656510|DRUG|Placebo|Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
223904687|NCT05781061|OTHER|Screening for Eligibility|Asynchronous Screening for MA Eligibility
223904688|NCT05243888|DIAGNOSTIC_TEST|self-sampling|eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter
223904689|NCT06044311|DRUG|Vactosertib|200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.
223904690|NCT06044311|DRUG|Standard of Care Chemotherapy|Neoadjuvant chemotherapy treatment as per standard of care.
223904691|NCT06044311|RADIATION|Concurrent Radiation|Neoadjuvant radiation treatment as per standard of care.
223904692|NCT06502561|DRUG|Aramchol meglumine|Aramchol meglumine is a salt form of Aramchol free acid
223904693|NCT06502561|DRUG|Aramchol free acid|Aramchol free acid is a fatty acid-bile acid conjugate
223904694|NCT05312008|DRUG|Intranasal oxytocin|Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
223904695|NCT05312008|DRUG|Intranasal placebo|Initial volume 1 ml; 2 booster volumes of 0.6 mls each, spaced about 1 hour apart
223904696|NCT06352424|DRUG|BI 456906|BI 456906
223904697|NCT06352424|DRUG|BI 1820237|BI 1820237
223904698|NCT06352424|DRUG|Placebo for BI 1820237|Placebo for BI 1820237
223528901|NCT04980326|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.
223715743|NCT03548103|DIETARY_SUPPLEMENT|Green tea extract|Green tea extract 500 mg tid for 16 weeks
223715744|NCT03548103|DIETARY_SUPPLEMENT|Placebo|Placebo tid for 16 weeks
223715745|NCT00003128|BIOLOGICAL|filgrastim|
223715746|NCT00003128|DRUG|ifosfamide|
223715747|NCT00003128|DRUG|paclitaxel|
223715748|NCT04232384|PROCEDURE|Standard Paracentesis|The patients will be asked to lie supine for 10 minutes and no changes in posture will be allowed for this period. Abdominal paracentesis will be done either by blind technique (in case the ascites is clinically detectable) or ultrasonography guided (in cases the ascites is not clinically detectable).
223904699|NCT06352424|DRUG|Placebo for BI 456906|Placebo for BI 456906
223904700|NCT06439043|OTHER|EMDR Psychotherapy|EMDR psychotherapy will be delivered in person by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
223904701|NCT06439043|OTHER|Online EMDR Psychotherapy|Online EMDR Psychotherapy will be delivered online by the psychotherapist to treat symptoms of Major Depressive Disorder, consisting of 12 weekly sessions.
223904702|NCT03896867|DEVICE|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
223904703|NCT03896867|DEVICE|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
223904704|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for > 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for greater than 2 days prior to discharge home
223904705|NCT06545760|BEHAVIORAL|Kangaroo mother care (KMC) support for < 2 days|Admission to the kangaroo mother care (KMC) ward with continued support of kangaroo mother care, breastfeeding, and preterm infant care for less than 2 days prior to discharge home
223904706|NCT05182775|PROCEDURE|Fecal bacteria transplantation|Fecal microbiota transplantation (FMT) refers to the transplantation of functional flora from the feces of a healthy person into the gastrointestinal tract of a patient, thereby reestablishing the intestinal flora with normal function. FMT promotes the treatment of intestinal microecology by eliminating single microorganisms or certain pathogens (such as vaccines and antibiotics) and increasing beneficial bacteria (such as prebiotics and probiotics) to the reconstruction of intestinal microecology. The best treatment indication for FMT is Clostridium difficile infection, which is a treatment choice confirmed by expert consensus and guidelines in many countries and regions. Meanwhile, FMT has been used in the treatment and research of many intestinal microbiome related diseases worldwide.
223904707|NCT04738812|DRUG|Intensified TB treatment (initial phase)|"8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R.~6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg."
223904708|NCT04738812|DRUG|WHO standard TB treatment (initial phase)|8 weeks of RHEZ with FDC.
223904709|NCT05007470|DRUG|VSL #3 112.5 Capsule|VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
223904710|NCT05007470|OTHER|Placebo|100 mg sugar
223904711|NCT05776459|DRUG|AC102 gel|Drug: AC102 Single intratympanic injection
223904712|NCT05776459|DRUG|Prednisolone|Active comparator: Prednisolone Tablets taken daily by mouth
223904713|NCT05776459|OTHER|Placebo Tablets|Placebo Tablets taken daily by mouth
223904714|NCT05776459|OTHER|Placebo gel|Placebo Single intratympanic injection
223904715|NCT06528158|OTHER|sibling group|"The group will be based on a systemic model and led by two child psychiatrists trained in family and multi-family therapy, who will not subsequently be involved in the data analysis. It will consist of 4 sessions of 1h30, spread over a period of 2 months, with a maximum of 8 participants per session. The first 3 sessions will be spaced 15 days apart, and the last session will take place 3 weeks apart from the third session.~The characteristics of the group (frequency, duration, number of sessions and participants) were built on data from the literature as well as on clinical feedback from a first pilot group conducted in January and February 2024 on the Toulouse pediatric unit by the two therapists who will lead the groups during the study."
223904716|NCT03674684|OTHER|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
223904717|NCT03819153|DRUG|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
223904718|NCT03819153|DRUG|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
223904719|NCT02430129|PROCEDURE|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
223904720|NCT02430129|PROCEDURE|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
223904721|NCT02430129|DEVICE|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
223904722|NCT02430129|DEVICE|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
223904723|NCT04219436|PROCEDURE|vertical mattress suturing technique|vertical mattress suturing technique used for flap closure after esthetic crown lengthening
223904724|NCT04219436|PROCEDURE|figure of eight suturing technique|figure of eight suturing technique used for flap closure after esthetic crown lengthening
223904725|NCT06023212|DRUG|Tranexamic Acid|"IV drip of 2 bottles of tranexamic acid (2g) before making incision during surgery；~1g tranexamic acid soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of tranexamic acid 3 times (every 8 hours)within 24 hours after surgery."
223904726|NCT06023212|DRUG|stroke-physiological saline solution (SPSS)|IV drip of 2 bottles of saline before making incision during surgery； saline soaked gauze applied to the wound for 5 minintes before suture； patients were administered IV drip of saline 3 times (every 8 hours)within 24 hours after surgery.
223904727|NCT05745285|OTHER|LLS Program|The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
223904728|NCT00206791|DEVICE|MBCP-Gel (tm)|MBCPGel 5ml
223904729|NCT00206791|DEVICE|MBCP Gel|MBCPGel 5ML
223904730|NCT05043714|BIOLOGICAL|NG-641 in combination with Nivolumab|"NG-641 is a replication competent adenoviral vector producing a bispecific T cell activator (TAc) targeting fibroblast activation protein (FAP) plus immune enhancer genes CXCL9/CXCL10/IFNa2. This can lead to killing of tumor cells and stimulation of immunity against the tumor cells.~Nivolumab is a human monoclonal antibody that targets the PD-1 cluster of differentiation 279 cell surface membrane receptor."
223904731|NCT05790304|DRUG|Camizestrant|Camizestrant 75 mg tablets. Experimental drug.
223904732|NCT04284917|DRUG|Carglumic Acid (Carbaglu®)|"A. Study period: 36 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12).~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12.~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis and methylmalonic acid will be recorded during treatment period."
223904733|NCT06261021|DRUG|Ruxolitinib 1.5% cream|Topical application of Ruxolitinib 1.5% cream
223904734|NCT06261021|PROCEDURE|Application without occlusion in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 1.
223904735|NCT06261021|PROCEDURE|Application under occlusion at night in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 2.
223904736|NCT06261021|PROCEDURE|Application under occlusion at night in Area 1|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion under occlusion at night on Area 1.
223904737|NCT06261021|PROCEDURE|Application without occlusion in Area 2|Apply Ruxolitinib 1.5% cream on the discoid lupus erythematosus lesion without occlusion on Area 2.
223904738|NCT06482216|BIOLOGICAL|Varicella vaccine|lyophilized powder,subcutaneous injection
223904739|NCT04271436|DEVICE|FDG PET/CT|A single dose of 10 mCi FDG will be given by bolus injection approximately 60 minutes prior to the first planned imaging procedure.
223904740|NCT04271436|DEVICE|FLT PET/CT|. A single dose of 10 mCi FLT will be given by bolus injection approximately 80 minutes prior to the first planned imaging procedure.
223904741|NCT04271436|DEVICE|PET/MR|MR imaging will be performed on a Siemens Biograph mMR or an MRI scanner, if the PET/MR is unavailable.
223904742|NCT04271436|DRUG|[F-18] flurothymidine|-Radiopharmaceutical
223904743|NCT03974178|DRUG|Fexinidazole|Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
223904744|NCT05650788|DIAGNOSTIC_TEST|NMR spectrometry|"The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left)."
223904745|NCT05693675|DRUG|Postoperative methadone|Participants will receive intraoperative methadone (0.2 mg/kg ideal body weight intravenously but not exceeding 20mg) followed by oral/IV methadone postoperatively according to the following scheme: A) Opioid naïve patients will receive 5mg twice daily dosage of methadone on postoperative days 1 and 2 followed by 5 mg daily on postoperative days 3, 4, and 5. B) Patients taking opioids preoperatively will continue to receive their regular opioids and additionally receive 5 mg twice a day of methadone on postoperative days 1 and 2, followed by 5 mg per day on days 3, 4 and 5.
223904746|NCT05693675|DRUG|Postoperative placebo|Participants will receive intraoperative methadone intravenously 0.2mg/kg followed by oral placebo postoperatively according to the following scheme: Opioid naïve patients and patients taking opioids preoperatively will receive placebo tablets twice daily on day 1 and day 2 and once daily day 3, 4 and 5. Patients taking preoperative opioids will be able to return to their baseline opioids immediately after surgery.
223904747|NCT05693675|DRUG|Rescue Analgesia|PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case. All patients receive IV intravenous patient-controlled analgesia and rescue opioids which is usual care for postoperative pain.
223904748|NCT05436444|BIOLOGICAL|A/Mallard/Ohio-99/MM4/1989 H10N7|The human challenge virus will be administered intranasally to each participant using a nasal atomizer. A total volume of up to 2 mL will be administered split between both nostrils of each participant.
223904749|NCT03815656|DEVICE|STN alone|DBS stimulation of STN alone
223904750|NCT03815656|DEVICE|GPi alone|DBS stimulation of GPi alone
223904751|NCT03815656|DEVICE|STN + GPi|cooperative DBS stimulation of STN and GPi sites
223904752|NCT03815656|DEVICE|Closed-loop stimulation|adaptive DBS stimulation of STN and/or GPi sites
223904753|NCT04061148|DEVICE|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
223904754|NCT02400229|PROCEDURE|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
223904755|NCT02400229|PROCEDURE|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
223904756|NCT03436368|PROCEDURE|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
223904757|NCT03436368|PROCEDURE|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
223904758|NCT05244239|DRUG|Lurbinectedin|Given IV
223904759|NCT05244239|RADIATION|Palliative Radiation Therapy|Undergo RT
223904760|NCT06494150|DRUG|nab-Sirolimus|nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle
223904761|NCT06494150|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days
223904762|NCT03467191|DRUG|Alcohol|target BAC .08%
223904763|NCT03467191|OTHER|Placebo|placebo beverage
223904764|NCT05979831|DRUG|DS-2325a|Main Phase and Extension Phase: Loading IV dose followed by maintenance SC doses
223904765|NCT05979831|OTHER|Placebo|Main Phase: IV infusion followed by SC doses
223904766|NCT01849146|DRUG|Adavosertib|Given PO
223904767|NCT01849146|RADIATION|Radiation Therapy|Undergo radiation therapy
223904768|NCT01849146|DRUG|Temozolomide|Given PO
223904769|NCT06823648|DEVICE|Arterial blood samplers with needles PICO70 and safePICO syringes|PICO70 is a self-filling syringe for sample volumes in the range of 0.3-1.5 mL. All syringes are delivered with needle cube for safe needle disposal and a standard tip cap to reduce the risk of blood contact during blood mixing and sample transportation. safePICO is a more advanced group of syringes based on the PICO70 family. They contain a gold coated magnetic steel ball facilitating automatic mixing of the blood when being used with the Radiometer ABL 90 with mixing module. The safePICO is a self-filling syringe covering a volume range of 0.7-1.5 mL and includes a vented safe tip cap (VTC), which simplifies removal of air bubbles and avoid the operator to get in contact with the blood, after attachment to the syringe. Some variants of safePICO are delivered with a needle shield device (NSD) to ensure safe removal of the needle.
223528902|NCT04980326|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
223528903|NCT06383338|DRUG|Omeprazole|Sub-therapeutic probe drug administration to measure phenoconversion.
223528904|NCT06383338|DRUG|Dextromethorphan|Sub-therapeutic probe drug administration to measure phenoconversion.
223904770|NCT05473273|DRUG|Endometrin 100Mg Vaginal Insert|Endometrin will start once endometrial thickness is equal or higher to 7 mm with a trilaminar appearance, after at least 10 days and always less than 16 days of estradiol administration. First day of supplementation a dose of 100mg will be administered at of at 1.pm and 9 pm. From the second day and onwards administration will be increased to three times daily, at 6 am, 2 pm and 10 pm
223528905|NCT04584008|DRUG|FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.|According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
223904771|NCT05473273|DRUG|Estradiol Valerate|Estradiol valerate dose will be reduced to 4mg daily at 7 pm during the first two days of vaginal natural micronized progesterone supplementation and increased afterwards to 6 mg daily (2 mg at 10 am and 4 mg at 7 pm).
223904772|NCT04239820|RADIATION|Imaging|MRI and TSPO-PET imaging at baseline and 18 months after baseline
223904773|NCT06605092|OTHER|Emotional stimulation|Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
223904774|NCT06822686|DEVICE|Harvest and injection of stem cells|Stem cells will be harvested from bone marrow aspirate and injected into the fistula tract The stem cells are the device intervention for this trial and we are looking to assess the procedure of harvesting and injecting the stem cells Patients will undergo study questionnaire: Harvey-Bradshaw Index, perianal Crohn's disease activity index, and Short IBD questionnaire will be administered before surgery and then at 6 weeks, 3 and 6 months after stem cell intervention.
223904775|NCT06823934|PROCEDURE|Impacted lower wisdom tooth extraction|One of the most common operations performed in oral surgery is the extraction of lower impacted wisdom teeth. The extraction of impacted third molars causes significant inflammatory changes resulting in edema, trismus and pain. Complications encountered after the extraction of lower impacted wisdom teeth can negatively affect the daily lives of patients. Some of the treatments applied for these complications can be listed as drug use, cold/hot compression, low-dose laser therapy, cryotherapy, autogenous biomaterials such as PRF.
223904776|NCT04508309|BIOLOGICAL|Cecolin®|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine
223715749|NCT04232384|PROCEDURE|Roll Over Paracentesis|Patients with ascites will be rolled over thrice in bed laterally upto 90 degrees on either side (Figure 1) and ascitic fluid sample is drawn within 1 minute of the last rollover. There will be four steps to this i.e roll over to one side at 90 degrees and then 180 degrees to the other side, then back to the first side and then back to the center (to complete three turns). This will be done after the disinfection and cleaning of the anterior abdominal wall have been done and the personnel involved in the procedure are ready for the paracentesis. The ascitic paracentesis will be initiated within one minute of the completion of the turn. One assistant will maintain a stopwatch during this period to ensure compliance with this.
223715750|NCT02052583|PROCEDURE|therapeutic hypothermia at 32 ° C|
223904777|NCT04508309|BIOLOGICAL|Gardasil®|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine
223904778|NCT06518525|OTHER|pilates-based tele-exercises|pilates-based tele-exercises
223904779|NCT06242665|OTHER|Low UPF Meals (Study Provided)|Meals provided through delivery service
223904780|NCT06242665|OTHER|Low UPF Nutritional Guidance|Self-guided instructions from study team.
223904781|NCT06242665|OTHER|Low UPF Snacks (Study Provided)|Low UPF snacks provided to participant
223904782|NCT05196919|BIOLOGICAL|XT-150|XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
223904783|NCT05196919|BIOLOGICAL|Placebo|Phosphate-buffered saline for injection
223904784|NCT05263440|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
223528906|NCT04584008|DRUG|Other Therapy|Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
223528907|NCT05204485|PROCEDURE|Fibular intramedullary nail|The standard manufacturers approved technique will be performed including the use of 2 distal interlocking screws and the use of a minimum of 1 fibula pro tibia fixation screw depending on the patients' anatomical characteristics.
223904785|NCT05546996|DEVICE|FlowSense|"Patients will have one or more existing external ventricular drains (EVDs). Phase B patients will additionally have an accessible (shaved) region of skin \>3 cm x 3 cm overlaying the EVD tubing.~Clinical data to be collected include: 1) total drainage volume1 over the 20-minute measurement period; 2) handheld ultrasound measurement of skin thickness2 over the EVD; and 3) an ICP waveform from a standard-of-care transducer, 4) dimensions (inner diameter and outer diameter) of tunneled catheter. Single patients may be measured multiple times during their admission; each measurement will be considered independent for analysis."
223904786|NCT03737864|BEHAVIORAL|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
223904787|NCT03737864|BEHAVIORAL|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
223904788|NCT06441682|BIOLOGICAL|ARGX-119|Intravenous infusion of ARGX-119
223904789|NCT06441682|OTHER|Placebo|Intravenous infusion of placebo
223904790|NCT05858736|DRUG|AI-061|A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
223904791|NCT06184919|OTHER|Process Mapping: Observations|Direct observations of the POSH clinic visit.
223904792|NCT06184919|OTHER|Process Mapping: Interviews|Semi-structured interviews of patients and providers involved in the POSH clinic.
223904793|NCT06184919|OTHER|Process Mapping: Focus Group|Focus group of providers and staff who conduct the POSH clinic.
223904794|NCT06184919|OTHER|Participatory Design|"Participatory design, also called co-design is a systems engineering approach where the researchers and participants work together in designing the workflow of an intervention. There will be two groups (design teams) of patients/caregivers and healthcare professionals per location, for a total of four groups."
223904795|NCT04015804|OTHER|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
223904796|NCT05573074|DEVICE|Transcranial Photobiomodulator|Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
223904797|NCT05573074|DEVICE|Sham|Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
223904798|NCT05710224|BIOLOGICAL|V181|0.5 mL SC dose of V181
223715751|NCT02052583|PROCEDURE|therapeutic hypothermia at 34 ° C|
223904799|NCT05710224|BIOLOGICAL|Butantan-DV|0.5 mL SC dose of Butantan-DV
223904800|NCT06818370|OTHER|Coconut Oil|The coconut oil application protocol will be explained to the patients in the experimental group and 10 milliliters of coconut oil will be applied to the hair follicles once a week. Alopecia assessment will be done every week.
223904801|NCT06636357|DRUG|50% N2O plus 50% O2|Inhalation of 50% N2O plus 50% O2 for 45 min
223904802|NCT06636357|DRUG|Oxygen (O2)|50% O2 plus 50% air for 45 min
223904803|NCT04673032|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation for treatment of chronic pain
223904804|NCT04012606|DRUG|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
223904805|NCT06672809|BEHAVIORAL|Core Stability Training|Participants in this group undergo core stability training sessions targeting deep stabilizing muscles. The exercises are designed to enhance spinal support and core control by activating the transversus abdominis and other core muscles. Sessions involve the use of a Pilates reformer and other unstable surfaces, fostering proprioceptive engagement and improved muscle coordination. Training is conducted three times per week for eight weeks, with each session lasting 50 minutes.
223904806|NCT06672809|BEHAVIORAL|Aerobic Exercise|Participants in this group engage in aerobic exercise sessions that consist of warm-up, controlled-intensity walking, and a cool-down phase. This intervention serves as a comparative baseline, aiming to improve cardiovascular endurance without specifically targeting core stability. The aerobic routine is adjusted over time to increase exercise intensity, conducted three times per week for eight weeks, with each session lasting 50 minutes.
223904807|NCT04914676|DRUG|Cytarabine|Subjects on this arm will prospectively receive consolidation therapy with cytarabine. Subjects will be treated with 1000 mg/m2 cytarabine intravenously every 12 hours on Days 1-3 of each consolidation cycle. Subjects will receive up to four consolidation cycles.
223715752|NCT02932670|OTHER|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
223715753|NCT02264197|DRUG|BIBX 245 CL - fed|
223715754|NCT02264197|DRUG|BIBX 245 CL- fasted|
223904808|NCT04914676|DRUG|Cytarabine|Subjects on this arm will have received consolidation therapy with cytarabine between 2/1/2017 and 2/1/2019. Subjects will have received 1000 mg/m2 cytarabine intravenously every 12 hours on days 1, 3, and 5 of each consolidation cycle and will have received up to 4 consolidation cycles.
223904809|NCT06779396|DRUG|The triamcinolone acetonide plus ropivacaine group|The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
223904810|NCT06779396|DRUG|The ropivacaine group|The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
223904811|NCT04085510|DEVICE|Contrast-enhanced mammogram|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
223904812|NCT04568902|DRUG|H3B-6545|H3B-6545 oral tablets.
223904813|NCT04568902|DRUG|Antihistamine|Systemic antihistamine oral drug such as fexofenadine, loratadine and cetirizine.
223715755|NCT02955602|DRUG|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
223904814|NCT06159361|BEHAVIORAL|Balance targeted exercises|6-week exercise program, 3 sessions per week (2 sessions in person, 1 session of home exercises. Participants will receive a booklet with information about the home exercises and will receive a text message reminder), each session will last 60 minutes.
223904815|NCT06125808|DRUG|HRO350|Active substance phospholipid esters from herring roe oil (PEHeRo)
223904816|NCT06125808|DRUG|Placebo|Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
223904817|NCT03240016|DRUG|Pembrolizumab|200mg IV D1
223904818|NCT03240016|DRUG|Abraxane|100mg/m\^2 D1 and D8
223904819|NCT05268887|DEVICE|GENUS device (Active Settings)|Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
223904820|NCT05268887|DEVICE|GENUS device (Sham settings)|Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
223904821|NCT05925218|RADIATION|Radiotherapy as per standard of care|Adjuvant Radiotherapy +/- systemic therapy as per standard of care
223904822|NCT05335070|DRUG|Temporo-masseteric Nerve Block|Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
223904823|NCT03913442|DRUG|Colchicine 0.8 mg or 0.6 mg orally once daily|Colchicine 0.8 mg orally once daily for 1.5 months, and then 0.6 mg once daily for the remainder of the time (1.5 months)
223904824|NCT03913442|DRUG|Placebo oral capsule|Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
223904825|NCT04610372|RADIATION|Hypofractionated external beam radiotherapy|5500 cGy/20 fractions delivered 5 days per week over 4 weeks
223904826|NCT04610372|RADIATION|High dose rate brachytherapy|A single fraction of 19 Gy is delivered from an automated afterloading Iridium-192 source via interstitial catheters placed under ultrasound guidance
223904827|NCT04610372|RADIATION|Permanent seed implant|Iodine-125 radioactive seeds are implanted permanently in the prostate in a single procedure under transrectal ultrasound guidance
223904828|NCT04610372|RADIATION|Stereotactic body radiotherapy|External radiation using SABR technology delivers 36.25 Gy to the prostate in 5 fractions given either once weekly for 5 weeks or every second day over 2 weeks.
223904829|NCT06497075|DRUG|Albendazole 400mg|Single oral dose of Albendazole 400mg tablet
223904830|NCT06497075|DRUG|Ivermectin 3 MG|Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
223904831|NCT05037500|DRUG|Decitabine and Cedazuridine|Given PO
223904832|NCT05037500|DRUG|Enzalutamide|Given PO
223904833|NCT00902603|DRUG|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
223904834|NCT05049512|OTHER|Multi-nut OIT|Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
223904835|NCT01697306|DRUG|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
223904836|NCT01697306|DRUG|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
223904837|NCT06392308|OTHER|none intervention|No interventions are administered to either group of patients.
223904838|NCT03518606|DRUG|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
223904839|NCT06536309|DRUG|Sacubitril-valsartan|Sacubitril-valsartan titrated to maximally targeted dose
223904840|NCT06536309|DRUG|Valsartan|Valsartan titrated to maximally targeted dose
223904841|NCT03377647|BEHAVIORAL|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
223904842|NCT03377647|BEHAVIORAL|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
223904843|NCT00950742|DRUG|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
223904844|NCT00950742|DRUG|BIBW 2992|Increased dose cohorts from low dose to MTD
223528908|NCT05204485|PROCEDURE|Open reduction and internal fixation|An open approach (direct lateral or posterolateral incision) will be carried out. The reduction will be performed using standard techniques of clamping and traction. Fixation will be performed after reduction of the fracture with a plate and screw construct. The surgeon will then proceed to perform surgical fixation of other associated fractures or ligament injuries as indicated. This will most often include open reduction and internal fixation of the medial malleolus with screws through a separate medial incision.
223904845|NCT06254924|BEHAVIORAL|QI App Users|QI App users will be asked to complete a daily, 2-question mood and stress survey. They will be encouraged to use the QI App to practice mindfulness skills including meditation, drawing, coloring, breathing, and walking. They will be encouraged to use the QI App to help them participate in asynchronous group running activities.
223904846|NCT06254924|BEHAVIORAL|Parents/Guardians of QI App Users|Parents/Guardians of QI App users will be informed that their child is using the QI App for a 6-week period.
223904847|NCT06176963|COMBINATION_PRODUCT|SB11 PFS|SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
224083522|NCT02342132|DEVICE|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
223528909|NCT04251533|DRUG|alpelisib|300 mg orally, once per day (QD), tablets
223528910|NCT04251533|DRUG|placebo|300 mg orally, once per day (QD), tablets
223904848|NCT03916783|BEHAVIORAL|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL\&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
223904849|NCT03096093|BIOLOGICAL|ACIT-1|Cell suspension
223904850|NCT05343572|DRUG|Plerixafor|A 20mg single dose of PLERIXAFOR is administered subcutaneously the evening prior to scheduled standard of care surgery for women with AS, AE or RIF for peripheral mobilization of stem cells. For subjects weighing \>83 kilogram, the dosing is a single dose of 0.24 milligram per kilogram.
223904851|NCT02652078|DEVICE|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
223904852|NCT03496922|BEHAVIORAL|Experimental Tobacco Marketplace|See arm group description.
223904853|NCT04004416|OTHER|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
223904854|NCT04004416|DRUG|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
223904855|NCT06192550|DEVICE|Profound Matrix™ System|Study subjects will be treated with the Profound Matrix System
223904856|NCT05980117|DRUG|Remimazolam|Remimazolam (1.0mg IV) titrated to modified observer's assessment of sedation score of 3 -4 during cataract surgery.
223904857|NCT05980117|DRUG|Midazolam|Midazolam (0.5-2mg IV) titrated to modified observer's assessment of sedation score of 3 - 4 during cataract surgery.
223904858|NCT05391243|PROCEDURE|LLETZ|Large loop excision of the transformation zone
223904859|NCT06517628|OTHER|Purely observational study on the care and outcomes of participants with cardiovascular disease in pregnancy.|The primary exposure variable is the organization of cardio-obstetrics care which will be defined by annual site surveys and its association with outcomes will be defined by hierarchical models adjusting for patient characteristics.
223904860|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 before process changes 20 mg
223904861|NCT05799183|DRUG|SHR-1210|Subjects will receive treatment SHR-1210 after process changes 20 mg
223904862|NCT05436262|DEVICE|Real-time fMRI with neurofeedback of motor imagery|Participants undergo a real-time fMRI scan during which they are provided feedback regarding the accuracy of their motor imagery performance.
223904863|NCT05512208|DRUG|Avutometinib (VS-6766) + defactinib|"Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle."
223904864|NCT04462276|DRUG|Atezolizumab|fixed dose of 1,200 mg as an IV infusion, on day 1, to be repeated every 3 weeks (Q3W)
223904865|NCT04462276|RADIATION|thoracic radiotherapy (TRT)|30 Gy in 10 fractions
223904866|NCT05299073|DRUG|MB09|Single dose of 35mg SC administered
223904867|NCT05299073|DRUG|US-sourced Xgeva|Single dose of 35mg SC administered
223904868|NCT05299073|DRUG|EU-sourced Xgeva|Single dose of 35mg SC administered
223904869|NCT01763190|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223904870|NCT06547411|DEVICE|PC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group I received pressure control ventilation (PC).
223904871|NCT06547411|DEVICE|VC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group II received volume control ventilation (VC).
223904872|NCT06547411|DEVICE|PRVC Ventilation mode|Patients were randomly assigned to three groups using a random number table and the random remainder grouping method at a ratio of 1:1:1. Group III received pressure-regulated volume control ventilation (PRVC).
223904873|NCT05683223|BEHAVIORAL|Group CBT for Social Anxiety Disorder|Initial CBT will consist of 12 weekly, 2.5-hour group sessions. Later sessions (after session 7) become more individualized as the exposure practices are tailored to the individual participant's concerns. Most often, the exposures are completed outside the group environment. Session content includes various cognitive behavioral strategies tailored to SAD, such as psychoeducation, examining and challenging cognitive distortions, and exposure exercises.
223528911|NCT04251533|DRUG|nab-paclitaxel|100 mg/m\^2 IV infusion, once per day (QD)
223528912|NCT05634538|DEVICE|Robotic-assisted PCI with Corpath GRX® System|The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).
223528913|NCT05634538|PROCEDURE|Standard PCI|Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
223528914|NCT04619797|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
223528915|NCT04619797|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
223715756|NCT02955602|DRUG|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
223904874|NCT05683223|DRUG|Sertraline|Non-responders will initiate sertraline at baseline (week 0) with 25 mg/day followed by a dose increase to 50 mg/day at week 1, 100 mg at week 4, 150 mg at week 6, and 200 mg at week 8. Upward dose titration may be slowed and the dose decreased if necessary due to side effects, but the clinician will attempt to titrate all symptomatic participants up to 200 mg/day if tolerated by week 8, with the last dose increase allowed at week 10. Participants will be assessed at each visit by the study psychiatrist for purposes of dose titration and monitoring. Symptomatic participants unable to reach 200 mg/day of sertraline due to side effects will be maintained in the trial if they are on at least 50 mg/day by week 8; all symptomatic participants will be titrated to their maximally tolerated dose (\< 200 mg/day sertraline). Any participant unable to tolerate sertraline will be discontinued and referred for clinical treatment.
223904875|NCT05683223|BEHAVIORAL|Individual CBT for Social Anxiety Disorder|Participants who show no or only partial response to the initial group CBT will continue with an individual, tailored form of CBT plus adjunctive SSRI. The format of CBT will include
223904876|NCT06455839|BEHAVIORAL|Guided Resipiration Mindfulness Therapy (GRMT)|GRMT provides training in respiratory regulation, mindfulness and relaxation. The GRMT training will begin with a 15-minute introduction to the treatment model, followed by an hour of therapist-guided respiration (i.e., continuous rhythmic expansion of the chest, and relaxed exhalation involving release of all respiratory and peripheral musculature). The final 45 minutes will be used to discuss participant experiences during the GRMT training. GRMT training sessions will occur in-person and in a small group format (\<5 participants each).
223904877|NCT05651139|DEVICE|Electrical Vibration Device|An electrical Vibration Massage device will be used to induce deep tissue vibration stimulation
223904878|NCT03882073|PROCEDURE|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
223904879|NCT03882073|PROCEDURE|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
223904880|NCT04792502|DRUG|Mosunetuzumab|Administered subcutaneously by injection beginning with 5 mg and increasing to 45 mg.
223904881|NCT04792502|DRUG|Lenalidomide|Patients in the augmentation cohort will be dosed continuously, 10 mg orally once daily, with or without food.
223904882|NCT04979351|OTHER|Abdominal Massage|Abdominal massage will be applied twice a day.
223904883|NCT05014295|OTHER|Accessing personal medical records online via online portals|The participants will receive details on accessing personal medical records online via online portals, for each of the major hospital systems
223904884|NCT03418987|OTHER|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
223904885|NCT04469192|OTHER|Cryotherapy|intervention group will receive a 20-minute topical cryotherapy treatment (using Medline Deluxe Cold Pack) The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
223904886|NCT04469192|OTHER|Education|The education portion will consist of a handout that will be provided to each patient describing specific exercises. These exercises include descriptive information along with pictures on ways to improve posture and protect the lower back in pregnancy good posture
223715757|NCT02955602|DRUG|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
223715758|NCT01804621|BEHAVIORAL|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
223715759|NCT05604118|DRUG|Aspirin|1 week of aspirin supplementation prior to sampling
223715760|NCT06962384|PROCEDURE|Posterior release sclerotomy|"* A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.~* The scleral shell was cauterized to eliminate any residual uveal tissue.~* Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.~Posterior Release Sclerotomy Group (PRS Group)~* A posterior sclerotomy (2-3 mm) was created at the posterior pole of the scleral shell using a crescent blade.~* This sclerotomy expanded the intraocular space, reducing intraoperative resistance during implant insertion.~* The spherical implant was gently placed within the expanded scleral shell, ensuring minimal stress on the tissue."
223904887|NCT04502550|DRUG|Propofol|Target effect-site concentration of propofol will be started at 1.4 μg/mL and will be increased by 0.3 μg/mL with reassessment until endpoints are achieved.
223904888|NCT06520657|OTHER|Community Health Worker|Participants are screened for social determinants of health and work with a community health worker for three months to connect them with community and government services to address their family's needs.
223904889|NCT06520657|BEHAVIORAL|Child weight management intervention|This is a 12-week family-based behavioral group intervention to address childhood overweight and obesity.
223904890|NCT06520657|OTHER|Standard of Care referral to resources|One-time referral to resources based on need that families can access independently either by providing electronic referral to or providing written contact information for a community resource.
223904891|NCT02701153|PROCEDURE|Conventional Surgery|Undergo surgery
223904892|NCT02701153|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223904893|NCT02701153|OTHER|Laboratory Biomarker Analysis|Correlative studies
223904894|NCT02701153|OTHER|Questionnaire Administration|Ancillary studies
223904895|NCT00592852|DRUG|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
223904896|NCT05795114|BEHAVIORAL|Reach Out, Stand Strong, Essentials for New Mothers (ROSE) Program|A 5-part interpersonal therapy based intervention
223904897|NCT05078255|DRUG|Semaglutide 1.34 MG/ML [Ozempic]|Semaglutide 1.34 mg/ml
223904898|NCT05078255|DRUG|Glucose-dependent insulinotropic polypeptide (GIP)|GIP
223904899|NCT05078255|OTHER|Semaglutide 1.34 mg/ml placebo|Saline
223904900|NCT05078255|OTHER|GIP placebo|Saline
223904901|NCT05002088|DEVICE|Transcatheter Aortic Valve Replacement|Transcatheter Aortic Valve Replacement for the treatment of a failed surgical aortic valve bioprosthesis, Valve-in-Valve (ViV), in patients who were considered to be at increased risk for redo surgical aortic valve replacement
223904902|NCT04814771|DRUG|[14C] TS-142|Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
223904903|NCT06266312|BEHAVIORAL|A multimodal prehabilitation programme|"1. During the weekly chemotherapy infusion (week 10-20), a supervised moderate-intensity endurance training (MIET) on a cycle ergometer is performed (11x):~   * 5 min. warm-up~  * 35 min. cycling at 40-60% of (HR reserve + resting HR)~  * 5-10 min. cool-down~2. \+ strength training~During week 17-22 a supervised high-intensity interval training + strength training programme is performed (8x):~HITT:~* 3 min warm-up (20W)~* 14 intervals (30sec. work intervals at 60% of WRpeak alternates with 60-sec. rest intervals at 20W) --1 min. cool-down~Muscle strength:~4 exercises (leg press, chest press, abdominal crunch, lateral pulldown), 3 sets, 8-12 repetitions at 60% of 1-RM.~3\) During 4 consultations with a dietician (week 9, 15, 20, 22) nutritional intake is evaluated and advice is given on energy and protein requirements. Patients are advised to use a digital food diary to record their intake for ≥3 days a week."
223715761|NCT06962384|PROCEDURE|Conventional Ball Implantation|"* A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.~* The scleral shell was cauterized to eliminate any residual uveal tissue.~* Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.~* No posterior sclerotomy was performed.~* The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space."
223904904|NCT05495971|DEVICE|NaturalVue Multifocal|EDOF
223904905|NCT04538976|DRUG|Sildenafil|Sildenafil in standard dosage
223904906|NCT04068181|DRUG|Talimogene laherparepvec|Intralesional injection into injectable cutaneous, subcutaneous and nodal legions.
223904907|NCT04068181|DRUG|Pembrolizumab|Intravenous (IV) infusion.
223904908|NCT06090864|DRUG|Chemotherapy|Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.
223904909|NCT06090864|BIOLOGICAL|Cell infusion|ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
223904910|NCT05868876|DRUG|AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion|AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
223904911|NCT05844397|DEVICE|WaveLight EX500 Excimer Laser System|LASIK Refractive Surgery Using Contura with Phorcides
223904912|NCT05844397|DEVICE|VisuMax Surgical Laser|SMILE Refractive Surgery
223904913|NCT05149638|DIAGNOSTIC_TEST|Cosyntropin stimulation test|In this test, Cosyntropin is administered as an intramuscular injection into the arm. Cortisol levels are measured before and after injection. Cosyntropin tests are routine medical tests that are done in doctors' offices to diagnose adrenal insufficiency. Cosyntropin is a synthetic version of a hormone, called ACTH, that is secreted by our bodies to help produce cortisol.
223904914|NCT06104176|BEHAVIORAL|CBT in group|"All subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
223528916|NCT04619797|DRUG|Pemetrexed|Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
223528917|NCT04619797|DRUG|Carboplatin|Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
223528918|NCT04619797|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.
223528919|NCT04619797|DRUG|Tiragolumab Matching Placebo|Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
223528920|NCT04619797|DRUG|Pembrolizumab|Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
223904915|NCT06104176|OTHER|Virtual reality exposure|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
223904916|NCT06104176|BEHAVIORAL|individual CBT|"ll subjects will have 4 sessions of group CBT (one per week) during the first month following their inclusion, and then randomly assigned (ratio 1:1) to VRET group or individual CBT group. Subjects will undergo 4 additional sessions of VRET or individual CBT (one per week) during the second month.~VRET consists on 4 weekly sessions (one per week, for 1 month) of 60 to 90 minutes duration. Each session, consists in 20 to 30 minutes exposure with 10 minutes breaks (2 to 3 exposure per session). Four environments will be used: The home environment, the metro advertising environment , the party environment, and the supermarket environment. Each session corresponds to one environment, previously ordered according to their difficulty for the patient."
223904917|NCT06336083|PROCEDURE|Doppler ultrasound|Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
223904918|NCT05962541|DRUG|PDD-TURBT with hexaminolevulinate (Hexvix®)|In order to undergo PDD-TURBT, all eligible patients in the experimental arm will be administered the photosensitizer hexaminolevulinate (85 mg in 50 ml of phosphate buffered saline, Hexvix®) on an inpatient setting through a urethral catheterization of the participant's bladder. During the PDD-TURBT surgery, the bladder will be illuminated with blue light (wavelength 380-450 nm). The operating rooms of the participant institutions will therefore need to have the specialized equipment consisting in the blue-light source (POWER LED SAPHIRA \[TM\]).
223904919|NCT05962541|DEVICE|Power Led Saphira (TM)|This is a light source based on LED technology. It can be used for both White Light (WL) and fluorescence applications in blue light (i.e., Photodynamic diagnosis PDD) for visualizing tumor lesions during trans-urethral resection of bladder tumors (PPD- TURBT).
223904920|NCT06378294|PROCEDURE|Mastectomy|Adjuvant postmastectomy radiotherapy
223904921|NCT06449586|DRUG|Letermovir|letermovir stops when CMI\>1.5
223904922|NCT06485232|DRUG|Universal BCMA CAR-T|Universal BCMA CAR-T
223904923|NCT06485232|DRUG|Universal CD19 CAR-T|Universal CD19 CAR-T
223904924|NCT06485232|DRUG|Universal BCMA CAR-T; Universal CD19 CAR-T|Universal BCMA CAR-T; Universal CD19 CAR-T
223904925|NCT03029429|DRUG|Theophylline|oral theophylline
223904926|NCT03029429|DRUG|Placebos|oral placebo
223904927|NCT00614146|DEVICE|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
223904928|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
223904929|NCT00614146|PROCEDURE|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
223904930|NCT02375841|BEHAVIORAL|psychometric tests, questionnaires and neurocognitive assessments|
223904931|NCT05575336|OTHER|ADLIFE intervention|"The ADLIFE toolbox will be deployed, used and evaluated in seven healthcare environments to demonstrate the effectiveness of the ADLIFE intervention in clinical real conditions. Patients participating in ADLIFE will have a personalised care plan, created in the ADLIFE toolbox, developed and managed together with their healthcare professionals. PCPMP will be used within clinical sites´ ICT systems to create patient care plans based on most recent clinical data, following clinical evidence. The main task of patients and informal caregivers will be to use the ADLIFE toolbox as part of their healthcare process together with their healthcare professionals.~Patients recruited will use the ADLIFE system during the pilot study for a follow-up period between 3 and 12 months."
223904932|NCT05594901|OTHER|Application of a prognostic score|The CRECOOLT score, for the prospective cohort, will be systematically calculated once week, or at the occurrence of complications, until 60 days after OLT. The therapeutic management of all patients, during both retrospective and prospective periods, will be established by the attending physicians according with routine practice and not dictated by study protocol.
223904933|NCT04770402|OTHER|Acupuncture|12 acupuncture sessions over 10 weeks
223904934|NCT04770402|OTHER|Standard of Care CIPN management|Investigator directed standard of care management of CIPN
223904935|NCT05584930|OTHER|Collection of blood sample|"* Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)"
223904936|NCT04879615|DRUG|Alteplase|Patients will receive standard dose intravenous alteplase (0.9 mg per kilogram, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)
223904937|NCT06033950|DRUG|Finerenone|Oral finerenone.
223904938|NCT06033950|DRUG|Placebo|Matching oral placebo.
223904939|NCT06303518|OTHER|High normal ETCO2: ETCO2 50 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'High Normal ETCO2' (50 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
223904940|NCT06303518|OTHER|Normal ETCO2: ETCO2 40 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Normal ETCO2' (40 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
223904941|NCT06303518|OTHER|Low Normal ETCO2: ETCO2 30 mmHg (+/- 3mmHg)|BIS readings will be recorded continuously at 'Low Normal ETCO2' (30 mmHg +/- 3 mmHg). Each patient will be tested at High normal, normal, and low normal ETCO2 levels in a randomized order.
223715762|NCT00493324|DRUG|alefacept|Intramuscular
223904942|NCT02322203|DIETARY_SUPPLEMENT|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
223904943|NCT05016947|DRUG|Venetoclax|Tablet, taken by mouth
223904944|NCT05016947|DRUG|Dexamethasone|Taken orally
223904945|NCT05016947|DRUG|Inotuzumab Ozogamicin|Intravenous infusion
223904946|NCT05909891|OTHER|Patient training|"A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated."
223904947|NCT04342234|OTHER|data collection of palatal casts and palatal images of cleft patients routinely treated at the institution|data collection of palatal casts and palatal images of cleft patients, using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity
223904948|NCT05194956|PROCEDURE|Intraoral scan|An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
223904949|NCT05194956|PROCEDURE|Alginate impressions|Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
223715763|NCT00493324|DRUG|polyvalent pneumococcal vaccine|Injection
223715764|NCT01068132|DRUG|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
223904950|NCT06419582|DRUG|BHV-7000|BHV-7000 75 mg taken once daily for 21 days
223904951|NCT06419582|DRUG|Placebo|Matching placebo taken once daily for 21 days
223904952|NCT06851741|BEHAVIORAL|Behavioural Activation for depression (BeatIt2)|"It is a structured, time limited, manualised psychological therapy, developed to treat those with learning disabilities and depressive symptoms.~There is an initial training session for carers regarding their role in the treatment, then 12 sessions with the person with a learning disability and their carer, held weekly or fortnightly, spanning approximately 6 months.~Activities are carried out with the individuals with learning disabilities at each session and elements of the intervention are delivered via carers. The three main phases are: i) assessment and socialisation into the intervention and establishing a relationship with the person with the disability, ii) working towards change, and iii) finishing therapy. The first phase includes assessment of the person's pattern of daily activity, barriers and facilitators to engaging in activity, and examining the link between activity and mood. Specific attention is given to the role of communication and how scaffolding can be provid"
223904953|NCT06852118|PROCEDURE|AMM Group: Adductor Magnus Muscle Plane approach + Femoral Nerve Blocks|In the supine position, the femoral nerve block will be conducted using a high-frequency ultrasound probe to identify the femoral nerve just below the fascia iliaca. After proper sterilization, the needle will be advanced in-plane to inject 15 ml bupivacaine 0.5% around the nerve. After performing the femoral nerve block, the adductor magnus muscle plane block will be performed using a low-frequency ultrasound probe positioned 6 cm distal to the inguinal crease to identify the sartorius muscle, femoral artery, femoral vein, and femoral nerve on the deep side of the sartorius muscle, the probe will be slide by about 2-2.5 cm distally, where we could identify the plane between the adductor magnus and the semimembranosus muscles, and after proper sterilization, the needle will be slowly advanced until the needle tip is close to the posterior surface of the AMM, 20 mL of bupivacaine 0.5% will be injected while observing fluid distribution under the posterior surface of the AMM, Then GA.
223904954|NCT06852118|PROCEDURE|SG Group: Sciatic nerve block by sub-gluteal approach + Femoral nerve blocks|While the patient is in the supine position, the femoral nerve block will be conducted using a high-frequency ultrasound probe to identify a cross-sectional view of the femoral nerve just below the fascia iliaca. After proper sterilization, the needle will be advanced in-plane to inject 15 ml bupivacaine 0.5% around the nerve. the patient will be turned on their sides with the operative side uppermost and flexed, the sub-gluteal sciatic nerve will be identified using a low-frequency probe, and then the same needle will be advanced the in-plane to inject 20 ml bupivacaine 0.5% around the nerve., then GA will be conducted as the other group
223904955|NCT06852378|DRUG|Iliopsoas nerve block|Patients will receive an Iliopsoas nerve block using 10 ml of bupivacaine 0.5%.
223904956|NCT06852378|DRUG|Femoral nerve block|Patients will receive femoral nerve block using 10 ml of bupivacaine 0.5%.
223904957|NCT06852066|PROCEDURE|Computer-Assisted Local Anesthesia|"Description: Local anesthesia applied using the SleeperOne5 (Dental Hi Tec, Cholet, France) device, with controlled injection speed (60 seconds).~Drug Used: 2% Articaine with 1:100,000 Epinephrine Needle Type: 35 mm, 30G dental syringe"
223904958|NCT06852066|PROCEDURE|Conventional Local Anesthesia|"Description: Local anesthesia applied using a manual dental syringe, with injection speed manually controlled (30 seconds).~Drug Used: 2% Articaine with 1:100,000 Epinephrine Needle Type: 40 mm, 27G dental syringe"
223904959|NCT06851234|PROCEDURE|osteopathic manipulative medicine|OMM
223904960|NCT06851234|PROCEDURE|The sham light touch will be performed by an investigator not trained in bodywork or a first--year osteopathic medical student.|Participants will lay supine on an OMM table. After the OSE, the investigator will place their hands flat in light contact with the participants' parietal bone regions, then the shoulders, then the sides of the lower ribs, and finally over the trochanters.
223715765|NCT01068132|DRUG|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
223715766|NCT01282892|PROCEDURE|excess of visceral fat|excess of visceral fat
223715767|NCT01282892|PROCEDURE|patients with NAFLD|patients with NAFLD
223904961|NCT05992077|DRUG|Sofosbuvir/Daclatasvir|Patients with a weight \> 25 kg will be treated with a sofosbuvir/daclatasvir combination for 12 weeks with adult dose (400/60 mg), children with a weight between 14 and 25 kg will be treated with the same sofosbuvir/daclatasvir combination with the half adult dose (200/30 mg) for 12 weeks.
223904962|NCT06852079|OTHER|Qurs e Fishar|Qurs e Fishar is a herbal remedy for Hypertension
223904963|NCT06852638|DRUG|[18F]F-RESCA-RCCB6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.
223904964|NCT06852638|DRUG|[18F]F-RESCA-R8B4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.
223904965|NCT06852638|DRUG|[18F]F-RESCA-RD06|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RD06 injection.
223904966|NCT06852638|DRUG|[68Ga]Ga-NOTA-R8B4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.
223904967|NCT06852638|DRUG|[68Ga]Ga-NOTA-RD06|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]RD06 injection.
223904968|NCT06852638|DRUG|[89Zr]Zr-DFO-RB6|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RB6 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
223904969|NCT06852638|DRUG|[89Zr]Zr-DFO-R8B4|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-R8B4 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
223904970|NCT06852638|DRUG|[89Zr]Zr-DFO-RD06|Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RD06 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).
223904971|NCT06851364|DRUG|0.38% Sodium Hyaluronate (SH) Eye Drops|"A lubricant eye drop containing 0.38% sodium hyaluronate (SH), designed to improve tear film stability and ocular surface health in individuals with moderate to severe dry eye disease (DED).~The formulation has a higher viscosity and retention time, potentially offering better symptom relief for evaporative dry eye (EDE)."
223904972|NCT06851364|DRUG|0.18% Sodium Hyaluronate Eye Drops|"A lubricant eye drop containing 0.18% sodium hyaluronate (SH), used to alleviate dry eye symptoms and improve tear film stability.~This formulation has a lower viscosity compared to 0.38% SH, potentially providing faster absorption but with shorter ocular surface retention."
223904973|NCT06851364|DRUG|Normal Saline Eye Drops|"A non-active control treatment consisting of sterile normal saline (0.9% NaCl) used as a placebo comparator.~It provides temporary moisture but lacks the viscoelastic and therapeutic properties of sodium hyaluronate."
223904974|NCT06852911|DIAGNOSTIC_TEST|Chemiluminescent FeNO Analyzer|A novel chemiluminescence FeNO Analyzer has been developed, capable of measuring both FeNO50 and FeNO during tidal breathing. Each participant underwent three testing sessions, with the results averaged, and the sequence of tests was randomized.
223904975|NCT06852911|DIAGNOSTIC_TEST|Electrochemical FeNO Analyzer|Electrochemical FeNO analyzers are employed in clinical settings for the measurement of FeNO50. Each participant underwent three testing sessions, with the results averaged, and the sequence of tests was randomized.
223904976|NCT02715271|PROCEDURE|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
223904977|NCT06852183|OTHER|VR -FME|The VR-FME intervention specifically focuses on improving body representation and the body-self relationship by working on multisensory integration processes and embodied cognition techniques. This is thanks to the combination of immersive virtual reality experiences of body illusion combined with traditional psychological techniques. The experimental group will receive this intervention in addition to the usual treatment, which will continue as usual for the control group. The intervention consists of 8 sessions spread over 4 weeks, with 2 sessions per week.
223904978|NCT02990819|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
223904979|NCT06216886|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
223904980|NCT06216886|DRUG|Sodium Chloride 0.9% for Injection, Preservative Free|intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
223904981|NCT06851845|OTHER|No intervention|Patients will receive medical care in accordance with the routine practice of disease treatment
223904982|NCT06851598|DRUG|25 units botox|25 units of botox injection into ischiocavernosus muscle
223904983|NCT06851598|DRUG|50 units Botox|50 Units botox injection into ischiocavernosus muscle
223904984|NCT06851598|DRUG|75 units Botox|75 units botox injection into ischiocavernosus muscle
223904985|NCT06318520|OTHER|Use of Calcium silicate based resin cement and resin modified glass ionomer cement|Investigators will restore MIH teeth with stainless steel crowns using calcium silicate-based resin cement and resin-modified glass ionomer cement and evaluate their 1-year success.
223904986|NCT06422845|DEVICE|Dissolve AV Peripheral Scoring Drug-coated Balloon|Subjects in the test group are treated with Dissolve AV Peripheral Scoring Drug-coated Balloon
223904987|NCT06843265|DEVICE|Vacuum- Induce Hemorrhage Control|The JADA System is designed for single use only and is composed of medical grade silicone. Its components include an intrauterine loop with protected vacuum pores, a cervical seal with a sealing valve for infusing saline and a vacuum connector port for applying suction. The intrauterine loop is located at the distal end of a tube and contains 20 protected vacuum pores oriented inward along the loop. This shielded design facilitates intracavitary suction by shielding maternal tissue from the vacuum source and prevents clogging of the vacuum pores with tissue or clot.
223904988|NCT04123418|BIOLOGICAL|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
223904989|NCT04123418|DRUG|WHG626|WHG626 will be administered orally in a dose escalation schedule
223904990|NCT05567328|DEVICE|Research FibroScan (FS)|"Exams will be performed with the M or XL probe as per FS recommendations. Same probe must be used for all exams Exploratory exam after patient 151 are performed with adapted view of Research FS~Patients 1 to 90 \& 151 to 190 Exam1 Exploratory exam with the Research FS Exam2 Reference exam with the CE-marked FS~Patients 91 to 130 \& 191 to 230 Exams1\&2 Two consecutive Exploratory exams with the Research FS Exams3\&4 Two consecutive Reference exams with the CE-marked FS~Patients 131 to 150 Exams1\&2 Two consecutive Exploratory exams with automatic function of the Research FS Exam3 Reference exam with the CE-marked FS~Patients 231 to 270 Exams1 (novice operator) Exploratory exam with the Research FS Exams2 (novice operator) Reference exam with the CE-marked FS Exams3 (experienced/expert operator) Exploratory exam with the Research FS Exams4 (experienced/expert operator) Reference exam with the CE-marked FS"
223904991|NCT05446129|DRUG|Ezabenlimab|Ezabenlimab
223904992|NCT05446129|DRUG|BI 765063|BI 765063
223904993|NCT05446129|DRUG|Pembrolizumab|Pembrolizumab
223904994|NCT06333704|BIOLOGICAL|SPIKEVAX Bivalent|No study drug will be administered during this study as this is an observational study.
223904995|NCT06333704|BIOLOGICAL|SPIKEVAX X|No study drug will be administered during this study as this is an observational study.
223904996|NCT04943588|DIAGNOSTIC_TEST|HCV RNA (PCR)|We will test HCV positive patients after treatment to observe if they achieve SVR
223904997|NCT04943588|DIAGNOSTIC_TEST|HCV Antibody test (Point of care)|HCV antibody test used to establish if patients have had or are actively infected with HCV
223904998|NCT04943588|DIAGNOSTIC_TEST|AST/ALT and platelets measurement|AST/ALT and platelets to determine APRI score
223904999|NCT00906997|PROCEDURE|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
223905000|NCT00906997|PROCEDURE|Colonoscopy|Every 10 years, with sedation.
223905001|NCT05011851|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
223905002|NCT02714439|DRUG|Proflavine|Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
223905003|NCT02714439|PROCEDURE|High-Resolution Microendoscopy (HRME)|High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
223905004|NCT04634799|DRUG|TM5614|TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
223905005|NCT04634799|OTHER|Placebo|Matching placebo will be provided and participants will take 6 tablets in the evening for up to 7 days.
223905006|NCT06251752|DIAGNOSTIC_TEST|X-rays: load bearing inferior limbs, lateral knee, axial patella|X-rays at 5 years follow-up minimum
223905007|NCT02831244|DEVICE|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
223905008|NCT05864638|DEVICE|Endovascular treatment|Endovascular treatment, such as mechanical thrombectomy with stent, aspiration catheter or stent assisted by intermediate aspiration catheter, as well as combination of mechanical thrombectomy with intra-arterial thrombolysis
223905009|NCT05208112|DRUG|M6229|Continuous intravenous infusion of M6229, a low-anticoagulant fraction of heparin. Dose-escalation is based on a modified continual reassessment method (mCRM) including escalation with overdose control (EWOC).
223905010|NCT05884476|OTHER|Treatment-as-usual|Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.
223905011|NCT05884476|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|"REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition."
223905012|NCT06253013|DEVICE|Hyfe Smartwatch|Passive recording of audio with detection of explosive sounds. When explosive sounds are detected, a 0.5-1 seconds audio clip is recorded, and run through an algorithm to determine whether or not it is a cough.
223905013|NCT06253013|DEVICE|FitBit Versa 2|Commercial watch with the capability to monitor vital signs including oxygen saturation, respiratory rate and heart rate. Patients will be able to view their data in the FitBit app.
223905014|NCT06253013|DEVICE|Home Spirometer|Patients will be able to perform spirometry testing at home. They will be able to view their data, and it will be uploaded to a dashboard for clinicians.
223905015|NCT06253013|BEHAVIORAL|Audio recording|Patients will be asked to record several sentences which will be analyzed to detect speech patterns that may indicate changes in respiratory conditions.
223905016|NCT05050149|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
223905017|NCT06510842|OTHER|External drainage of intraventricular hemorrhage|An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
223905018|NCT04954573|RADIATION|infrared-A (wIRA)|Local-water filtered infrared-A (wIRA) irradiation
223905019|NCT04083378|PROCEDURE|Ablation Therapy|Undergo standard of care ablation
223905020|NCT04083378|PROCEDURE|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
223905021|NCT04083378|OTHER|Quality-of-Life Assessment|Ancillary studies
223905022|NCT04083378|OTHER|Questionnaire Administration|Ancillary studies
223905023|NCT06580119|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
223905024|NCT06509152|BEHAVIORAL|Theory of mind-based social competence group intervention|"The ToM-SCGI is designed as a group intervention, with 60-minute sessions held weekly, either once or twice, and led by trained therapists. Two caregiver meetings are conducted in the middle and end of the interventions.~The intervention process for each session is as follows:~1. Warm-up Activities(5-10 minutes): review the previous group session and prepare for the current group activities.~2. Theory of Mind Instruction(10-15 minutes): based on the developmental stage of the children's theory of mind, using thought bubbles to teach corresponding elements of theory of mind development.~3. Social Skills Group Games(30-35 minutes): design social scenario-based group games that allow children to practice applying the acquired theory of mind abilities into expressions and applications of theory of mind and social competence.~4. Summary(5-10 minutes): summarize the children's performance in the group and assign homework."
223905025|NCT00769522|BIOLOGICAL|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
223905026|NCT00769522|DRUG|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
223905027|NCT00769522|DRUG|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
223905028|NCT00769522|DRUG|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
223905029|NCT05346042|OTHER|duration infectiousness|is the probability and the duration of being infectious in hospitalized COVID-19 patients, consequently influencing the decision on cessation of isolation
223905030|NCT03624244|DRUG|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
223905031|NCT06209632|BEHAVIORAL|mirror therapy|30 minutes of intervention, twice a week, and a total of 12 weeks
223905032|NCT06209632|DEVICE|contralaterally controlled functional electrical stimulation|30 minutes of intervention, twice a week, and a total of 12 weeks
223905033|NCT06209632|BEHAVIORAL|conventional physiotherapy|50 minutes of intervention, twice a week, and a total of 12 weeks
223905034|NCT05856890|BIOLOGICAL|HepB mAb19|"HepB mAb19 is a human mAb of IgG1kappa isotype that specifically binds to the a determinant of the extracellular loop of the HBV surface antigen (HBsAg)."
223905035|NCT05856890|OTHER|Sterile Saline|Placebo will be normal sterile saline (NaCl 0.9%).
223905036|NCT05136651|BEHAVIORAL|OurRelationship|The OurRelationship Program is an online adaptation of Integrative Behavioral Couple Therapy (IBCT). It consists of 3 modules that couples complete over the course of 6-8 weeks. Couples also receive a 30-minute coaching appointment following completion of each module.
223905037|NCT06559930|OTHER|Traditional Neurological Rehabilitation + Dual Task Focused Training|Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration. Dual-task exercises, an important aspect of post-stroke rehabilitation, target both motor and cognitive functions. Dual tasks are activities that require performing two different tasks at the same time. These types of exercises are used to increase patients' attention, improve coordination, and help them perform daily living activities more effectively.
223905038|NCT06559930|OTHER|Traditional Neurological Rehabilitation|Rehabilitation programs that start early after stroke and continue at regular intervals throughout life support the individual in regaining his quality of life and performing his daily functions. These programs can help patients increase their functional independence, improve their quality of life, and ensure their social integration. Physiotherapy and rehabilitation after stroke increases joint movement, provides independence in activities of daily living, improves balance and coordination, manages pain, supports speech and swallowing skills, provides psychological support, and promotes social integration.
223905039|NCT01828099|DRUG|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.
223905040|NCT01828099|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle
223905041|NCT01828099|DRUG|Cisplatin|Cisplatin was administered by iv infusion at a dose of 75 mg/m\^2 every 21 days for up to 4 cycles.
223905042|NCT01828099|DRUG|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
223905043|NCT06276868|DRUG|Dalcilib+letrozole+HP treatment group|"All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks."
223905044|NCT03785561|OTHER|participation in a health research study|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
223905045|NCT03561961|RADIATION|Moderate Hypo-fractionation|66-68Gy in 25#
223905046|NCT03561961|RADIATION|Extreme Hypo-fractionation|35-36.25 Gy in 5#
223905047|NCT05870319|DRUG|SKB264|intravenous (IV) infusion (Q2W)
223905048|NCT05870319|DRUG|Pemetrexed|500 mg/m2 intravenous (IV) infusion (Q3W)
223905049|NCT05870319|DRUG|Carboplatin|AUC 5 intravenous (IV) infusion (Q3W) 4cycles
223905050|NCT05870319|DRUG|Cisplatin|75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
223905051|NCT06551038|BEHAVIORAL|Primary suicide prevention intervention|Psychoeducation workshop
223905052|NCT06551038|BEHAVIORAL|Art-based control intervention|Slam poetry workshop
223905053|NCT05803980|PROCEDURE|Fecal microbiota transplantation (FMT)|Single FMT infusion via colonoscopy
223905054|NCT05743907|DRUG|DA-2811|DA-2811 Group: DA-2811 + Forxiga placebo
223905055|NCT05743907|DRUG|Forxiga|Forxiga Group: Forxiga + DA-2811 placebo
223715768|NCT02243332|DEVICE|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
223905056|NCT06208748|DRUG|Bezuclastinib in combination with sunitinib|Bezuclastinib in combination with sunitinib (sutent)
223905057|NCT06406140|DRUG|Niacin tablets 500 mg|tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
223715769|NCT02950532|OTHER|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
223905058|NCT00131235|DRUG|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
223905059|NCT00131235|DRUG|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
223905060|NCT00131235|DRUG|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
223905061|NCT03859635|DRUG|Liposomal Bupivacaine|20 ml
223905062|NCT03859635|DRUG|Bupivacaine, 0.25%|10 ml
223905063|NCT03859635|DRUG|Bupivacaine, 0.5%|30 ml
223905064|NCT06481488|DRUG|E2086|E2086 tablets.
223905065|NCT06481488|DRUG|Placebo|E2086 matched placebo tablets.
223905066|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre 2|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre 2
223905067|NCT05597293|DEVICE|Glucose monitoring using FreeStyle Libre pro iQ|Glucose monitoring in patients with type 2 diabetes using FreeStyle Libre pro iQ
223905068|NCT04829188|BEHAVIORAL|Structured Telephone Support (STS)|Structured telephone support (STS) consists of post-discharge assessment, education, and medication reconciliation delivered telephonically by a health plan case manager, home care as needed, and follow-up with the primary care within seven days post-discharge.
223905069|NCT04829188|BEHAVIORAL|Low-intensity Remote Patient Monitoring (RPM-Low)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions are limited to those checking vital signs that indicate worsening of infection. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
223905070|NCT04829188|BEHAVIORAL|High-intensity Remote Patient Monitoring (RPM-High)|Questions are pushed to members multiple times per week for up to 90 days post-discharge. Questions include monitoring vital signs for worsening infection but also ask about factors that would indicate worsening of underlying heart or lung conditions, such as weight gain or shortness of breath. Patient answers to RPM questions trigger High or Medium alerts, which trigger a response by members of the intervention care team.
223905071|NCT04829188|BEHAVIORAL|Standard Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, nurses contact the patient and/or the patients' PCP or specialist to coordinate care and ensure timely follow-up.
223905072|NCT04829188|BEHAVIORAL|Enhanced Response Team|RPM alerts are screened by a nurse-staffed call center. Nurses determine whether emergency care is needed. If not, the call center alerts a multidisciplinary care team that is led by a certified registered nurse practitioner (CRNP). CRNPs, who operate in a palliative care role, have prescribing authority and can modify care plans. In addition to reacting to RPM triggers, team members (e.g., CRNP, social workers, nurses) meet with the patient in-person or virtually in the week after discharge and at least twice more in the next 90 days, conduct assessments and a pharmacy review, develop care plans, and discuss advance directives.
223905073|NCT05427734|DEVICE|WisePath for Adults|Participants assigned to this condition will receive access to the WisePath app for 12 weeks.
223905074|NCT05427734|DEVICE|Active-Control app + electronic wellness resources brochure|Participants assigned to this condition will receive access to Virtual Hope Box, a well-regarded suicide prevention self-help app, for 12 weeks plus an electronic wellness resources brochure.
223905075|NCT05934942|DRUG|Yasmin®|Ethinylestradiol (EE) and Drospirenone (DRSP)
223905076|NCT05934942|DRUG|BI 1358894|BI 1358894
223905077|NCT06096935|OTHER|bood sample|Exome measurements
223905078|NCT03753204|DRUG|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
223905079|NCT06550609|DRUG|Miltefosine Oral Capsule|Miltefosine 3 pill per day during 28 days AND pentamidine inhaled 300 mg / d during 10 dosis
223905080|NCT04208373|DRUG|JNJ-64417184|JNJ 64417184 tablets will be administered orally.
223905081|NCT04208373|DRUG|Itraconazole|Itraconazole capsules will be administered orally
223905082|NCT04208373|DRUG|Etravirine|etravirine tables will be administered orally.
223905083|NCT06507111|DIETARY_SUPPLEMENT|Lab4P|"Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20 and Bifidobacterium animalis subsp. lactis CUL-34 at a dose of 50 billion bacteria per/ day combined with vitamin C (80 mg/day), Vitamin D (400 IU/day) and Zinc (10 mg/day) on a microcrystaline cellulose (MCC) base~Daily dose: 50 billion bacteria per day"
223905084|NCT06507111|OTHER|Placebo|MCC alone
223905085|NCT03905798|DRUG|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
223905086|NCT05257993|DRUG|JPI-547|"* Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split."
223905087|NCT05257993|DRUG|modified FOLFIRINOX|"* After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle"
223905088|NCT05257993|DRUG|Gemcitabine-nab-paclitaxel|"* After IV administration of nab-paclitaxel 125 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle"
223905089|NCT02128802|PROCEDURE|Gastric Bypass|
223905090|NCT02128802|OTHER|Weight Loss Program|
223905091|NCT04949737|BIOLOGICAL|Helicobacter Pylori detection|"Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire."
223905092|NCT05653193|DRUG|Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
223905093|NCT05653193|DRUG|Antifungals as standard of care|Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
223905094|NCT06300762|DEVICE|Superabsorbent dressing application|Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate
223905095|NCT00321048|DEVICE|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
223905096|NCT04433208|DIETARY_SUPPLEMENT|Complex oligosaccharide|Complex oligosaccharide concentrate
223905097|NCT04433208|DIETARY_SUPPLEMENT|Probiotic|Probiotic
223905098|NCT04433208|OTHER|PPI|Over-the-counter proton pump inhibitor (PPI)
223905099|NCT04433208|OTHER|H2 Blocker|Over-the-counter H2 blocker
223905100|NCT06521814|PROCEDURE|REFLECT scoliosis correction system|(i.e. purpose of research) The Globus Reflect scoliosis correction system aims to provide curve correction for scoliosis patients who are still actively growing. Surgical correction is accomplished without spinal fusion, instead utilizing anterior vertebral body tethering. Reflect holds the convexity of the curve in place so that the concavity can grow, thereby harnessing the power of normal spine growth to correct the deformity.
223905101|NCT01817452|DRUG|Trastuzumab|
223905102|NCT01817452|DRUG|Pertuzumab|
223905103|NCT01817452|DRUG|Paclitaxel|
223905104|NCT04742621|PROCEDURE|Liver transplant|Eligibility for liver transplantation will be limited to patients with histologically confirmed metastatic colorectal adenocarcinoma who have achieved stability of liver metastasis on chemotherapy for at least 6 months prior to transplantation. All patients who undergo liver transplantation will start immunosuppressive therapy per protocol. Patients who undergo a successful liver transplant will not receive adjuvant therapy.
223905105|NCT06283537|OTHER|Effect of training method|The effect of the training method given to midwifery students on their episiotomy application skills, satisfaction with the teaching method and self-confidence.
223905106|NCT06073067|RADIATION|GRID therapy|GRID therapy delivers a high dose of radiation to small areas of tumor interleaved with areas that intentionally receive a low dose
223905107|NCT05556915|OTHER|Ultrasound-guided AVF cannulation method|For ultrasound-guided cannulation, the same ultrasound device will be used for all patients (TE5-POC ultrasound MINDRAY® system). The ultrasound device will identify the AVF aspect , the location including the depth (distance from the skin surface) , the vessel diameter and guide the cannulation in real-time. The device will be disinfected between uses and covered with a transparent adhesive film to avoid any direct contact with the patient. Sterile gel will be used for the cannulation.
223905108|NCT05556915|OTHER|Conventional AVF cannulation method|The AVF cannulation is carried out by palpation. This technique consists of manually evaluating the position, direction and depth of the fistula in order to determine the puncture site where the 2-dialysis catheters will be inserted. After local asepsis, the AVF is therefore needled at 2 points 5 cm apart.
223905109|NCT05579210|BEHAVIORAL|Online relapse prevention therapy|Participants in the e-RPT group will receive 10 weekly predesigned online modules. The content of this program will involve interactive therapy modules based on the principles of. On average each module consists of 30 slides and should take approximately 45 minutes to complete. At the end of each module, participants will be assigned homework to be completed and submitted to their respective therapists up to 48 hours before their next weekly session. The therapists will develop personalized feedback by using session-specific therapy feedback templates. These templates ensure that feedback is also more standardized and structured between different patients and therapists. In previous studies, therapists have been able to effectively use these templates to prepare feedback in approximately 15-20 minutes. The contents of each session are outlined on the detailed description section.
223905110|NCT05579210|BEHAVIORAL|Face to face relapse prevention therapy|Participants in the face-to-face intervention will meet with their therapist weekly through Microsoft Teams (video conference). During these 1-hour sessions, therapists will follow the same 10-week structure and content as e-RPT. Though compared to e-RPT, in face-to-face sessions, the homework will be reviewed with the participant, during the session, providing the appropriate feedback. Then the therapists will prepare a weekly patient report of each session for the principal investigator. At the end of each session, participants will receive the same homework as the e-RPT condition which they will receive feedback on during the following face-to-face session. Following the 10-week face-to-face intervention, participants will have the opportunity to join the e-RPT program.
223905111|NCT05430152|DRUG|Low-Dose Naltrexone|"Study drug dosing schedule (LDN):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
223905112|NCT05430152|OTHER|Placebo|"Study drug dosing schedule (Placebo; capsules made to match LDN doses):~* Week 1: 1 mg/day (1 mg cap)~* Week 2: 2 mg/day (two 1 mg caps)~* Week 3: 3 mg/day (three 1mg caps)~* Weeks 4-6: 4.5 mg/day (three 1 mg caps, plus one 1.5 mg cap = 4.5 mg/day)~* Weeks 7-16: 4.5 mg/day (one 4.5 mg cap) OR based on self-titration dosage (one 1mg, 2mg, or 3mg cap)"
223905113|NCT06443489|DRUG|SHR-4849|SHR-4849
223905114|NCT05605509|DRUG|RP-6306|Dose and schedule will be assigned at enrolment
223905115|NCT05605509|DRUG|Gemcitabine|Dose and schedule will be assigned at enrolment
223905116|NCT05605509|DRUG|FOLFIRI Protocol|Irinotecan Leucovorin FU
223905117|NCT05605509|DRUG|Trastuzumab|standard doses q3weekly
223905118|NCT05605509|DRUG|RP-3500|Dose and schedule will be assigned at enrolment
223905119|NCT05998824|BEHAVIORAL|SCD-specific COVID-19 vaccination information (SCVI) video|SCD-specific COVID-19 vaccination information (SCVI) video developed by health care providers with input from a community advisory board of people with sickle cel disease and their caregivers.
223905120|NCT04704544|OTHER|Tele-rheumatology|Participants will receive virtual visits via video conferencing and/or phone.
223905121|NCT06832150|OTHER|sample collection|"Participants may collected their own cheek swabs and will collect their own urine samples.~Clinical professionals at participating sites will collect blood samples."
223905122|NCT06832150|OTHER|Discussing study|Research Nurse/ Suitably qualified Research Site Staff will discuss the study with potential participants
223905123|NCT06832150|OTHER|Seeking consent|Potential participants who wish to give consent will do with a Research Nurse/ Suitably qualified Research Site Staff.
223905124|NCT02987946|DEVICE|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
223905125|NCT02987946|DRUG|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
223905126|NCT06838468|DIAGNOSTIC_TEST|Screening of compensated advance chronic liver disease|"The tests performed will include a general blood analysis to evaluate liver and kidney function, an assessment of the prevalence of metabolic diseases such as obesity, hypertension, or diabetes, an abdominal ultrasound, and elastography to assess liver stiffness.~Another intervention to be studied is whether the request for diagnostic tests to evaluate liver disease, as well as the visit of the hepatologist during hospitalization in the detoxification unit, influences subsequent alcohol abstinence. To this end, abstinence will be assessed six months after admission to the alcohol detoxification unit and compared with a retrospective cohort of patients admitted to the detoxification unit one year ago, in whom no liver disease evaluation was conducted neither information of potencial liver damage was offered by hepatologist and the intervention was carried out only by the psychiatrists responsible for the unit."
223905127|NCT00586391|GENETIC|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10\^7 cells/m\^2~Dose Level 2:~CD19CAR-28zeta - 1 x10\^8 cells/m\^2~Dose Level 3:~CD19CAR-28zeta - 2x10\^8 cells/m\^2"
223905128|NCT00586391|DRUG|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
223905129|NCT06077552|OTHER|pyramidal training by treadmill|pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises
223905130|NCT04715529|DRUG|FZJ-003|Subjects will receive FZJ-003 oral capsules in a dose escalation format.
223905131|NCT04715529|DRUG|Placebo|Subjects will receive placebo oral capsules (matching FZJ-003) in a dose escalation format .
223905132|NCT04781153|PROCEDURE|Periodontal treatment|Periodontal treatment (scaling and rootplaning) with adjunctive chlorhexidine use
223905133|NCT05095532|BIOLOGICAL|Bone marrow-derived mesenchymal stem cells|MSC transplantation
223905134|NCT05095532|OTHER|Placebo|Standard of Care
223905135|NCT05126290|OTHER|Collection of personal and family history from CAFÉ Study participants|Personal medical and genetic history, as well as relevant information about family history, will be collected from participants in the CAFÉ Study through an online data entry system
223905136|NCT05178251|PROCEDURE|appendectomy|appendectomy for acute appendicitis
223905137|NCT06484920|DRUG|ATRA|150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1)
223905138|NCT06484920|DRUG|Pembrolizumab|200mg Q3W pembrolizumab
223905139|NCT03820141|DRUG|Durvalumab|programmed cell death-ligand 1 inhibitor
223905140|NCT03820141|DRUG|Trastuzumab|anti-HER2 monoclonal antibody
223905141|NCT03820141|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
223905142|NCT05681169|OTHER|School-based HPV-counselling and HPV-vaccination.|"1. Scholl-based parental HPV-counselling~2. Scholl-based pupil HPV-counselling~3. Scholl-based HPVV"
223905143|NCT02646384|PROCEDURE|Ovarian tissue cryopreservation|Ovarian tissue will be removed
223905144|NCT06802289|BEHAVIORAL|Mobility promotion|At the Georges-L. Dumont hospital, a patient mobilization program has been introduced on floor 4C that embeds Kinesiologists within care to visit patients daily. A team of Kinesiologists visit the patients daily to promote movement and help them mobilize to the best of their capabilities (e.g., walking, standing, or sitting on the edge of the bed). The investigators propose to continue this individualized model but incorporate activity and frailty measures in males and females older adults.
223905145|NCT03822936|DRUG|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
223905146|NCT03822936|RADIATION|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
223905147|NCT04800211|OTHER|Experimental: Test Product 1|Subjects were instructed to completely replace their cigarettes with the Test Product 1 EVP (Nu Mark LLC, MarkTen® XL Bold CLASSIC)
223905148|NCT04800211|OTHER|Experimental: Test Product 2|Subjects were instructed to completely replace their cigarettes with the Test Product 2 EVP (Nu Mark LLC, MarkTen® XL Bold MENTHOL)
223905149|NCT05849337|BEHAVIORAL|Brief imagery-competing task|Two digital self-guided sessions of a brief digital imagery-competing task. A memory cue followed by playing a computer game with mental rotation instructions.
224277014|NCT04286295|DRUG|Cytisine|Cytisine is a plant-based smoking cessation medication. Cytisine acts by reducing the rewarding effect of nicotine and attenuating nicotine withdrawal symptoms. A recent review concluded that cytisine is the most promising future smoking cessation treatment. Cytisine is inexpensive to produce and is currently priced much lower than other cessation medications. It is well-tolerated by smokers and requires a shorter treatment period than conventional treatments. Because it is plant-based, cytisine may be attractive for smokers who prefer 'natural' medicines. Numerous placebo-controlled studies have demonstrated the safety and efficacy of cytisine. One high-quality pragmatic non-inferiority trial (n = 1310) found that cytisine was superior to nicotine replacement therapy (NRT) in improving self-reported continuous abstinence rates at 1 week, and 1, 2 and 6 months when both groups received minimal behavioural support.
223905150|NCT05849337|BEHAVIORAL|Brief psychoeducation and signposting task|Two digital self-guided sessions and access to psychoeducation and signposting regarding resources for psychological trauma in Iceland.
223905151|NCT05849337|OTHER|Treatment as usual (TAU)|Routine care that participants would otherwise receive if having intrusive memories of traumatic events
223905152|NCT05170841|DRUG|Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg|Administered as one single tablet to be taken every 8 hours
223905153|NCT05170841|DRUG|Tramadol Hydrochloride 100 mg|Administered as two capsules with 50 mg each to be taken every 8 hours
223905154|NCT05170841|DRUG|Placebo|Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
223905155|NCT05742685|BEHAVIORAL|Reinforcement Learning|Participants in the intervention arm will receive up to daily, tailored text messages based on their electronic pill bottle-measured adherence. Given the participants' baseline characteristics and time-varying responses to the messages, a reinforcement learning algorithm will deliver different text messages and adapt over time to determine which type of messaging works best for each individual participant.
223905156|NCT03132948|BEHAVIORAL|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
223905157|NCT04799184|DRUG|Levobupivacaine 0.25% with epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
223905158|NCT04799184|DRUG|Levobupivacaine 0.25% without epinephrine 5 ug/ml|"The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form."
223905159|NCT04872439|DIAGNOSTIC_TEST|Blood sample collection|Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
223905160|NCT03806790|DRUG|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
223905161|NCT03806790|DRUG|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
223905162|NCT05123586|DRUG|LY3361237|Administered SC
223905163|NCT05123586|DRUG|Placebo|Administered SC
223905164|NCT05686278|DEVICE|Bipolar i and cemented stem (Océane+ or Meije)|Hip hemiarthroplasty is a surgical procedure that involves replacing half of the hip joint
223905165|NCT06255951|DRUG|Itraconazole|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.
223905166|NCT06255951|DRUG|Rifampicin|The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.
223905167|NCT05052684|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
223905168|NCT06373601|DEVICE|sirolimus-eluting balloon (Selution)|PCI treatment with DCB, in particular sirolimus coated balloon
223905169|NCT06373601|DEVICE|paclitaxel-eluting balloon (SeQuent Please Neo)|PCI treatment with DCB, in particular paclitaxel coated balloon
223905170|NCT05917119|OTHER|BLT|Bright light therapy delivered via glasses
223905171|NCT05917119|OTHER|s-BLT|sham delivered with bright light therapy glasses to which a neutral density filter has been applied
223905172|NCT01233531|BEHAVIORAL|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
223905173|NCT01233531|BEHAVIORAL|B--No cash transfers|No monthly cash transfers
223905174|NCT06506266|OTHER|HFA-152a|HFA-152a is administered via oral inhalation
223905175|NCT06506266|OTHER|HFA-134a|HFA-134a is administered via oral inhalation
223905176|NCT06506266|OTHER|Radiolabeled saline solution|Radiolabeled saline solution is administered via oral inhalation
223905177|NCT06354712|DRUG|N-Acetyl-Cysteine with Institutional standard care|A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
223905178|NCT06354712|DRUG|Institutional standard care|Benzydamine Mouthwash
223905179|NCT06504628|DIAGNOSTIC_TEST|screening risk for falling and identifiy the risk level low-intermediate-high|"3 key questions: Any posiitve answer to a) Has fallen in the past year? b) Feels unsteady when standing or walking? or c) Worries about falling? prompts to fall severity step.~if no at the three questions= low level of fall-risk Fall severity: fall with injuires, laying on the ground with no capacity to get up, or a visit to emergency room, or loss of conscienciousness/suspected syncope. or Frailty (Clinical Frailty Scale)= if positive, high risk otherwise, 4 meter-walk test: if =\<0.8m/sec= intermediate risk if \>0.8m/sec=intermediate risk"
223905180|NCT06504628|DIAGNOSTIC_TEST|3 mnth-follow-up|patient's phone call, and data collected from electronic medical record
223905181|NCT02328599|PROCEDURE|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
223905182|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
223905183|NCT02328599|PROCEDURE|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
223905184|NCT06465459|PROCEDURE|LAMBRE device implantation|LAMBRE device implantation
223939968|NCT07192874|OTHER|MyMedDiary|myMedDiary is a HIPAA-compliant, researcher-configurable mobile and web-based application designed for real-time dietary, symptom and lifestyle data collection. It was utilized to collect dietary data in an IRB-approved study at Seattle Children's Hospital evaluating the dietary cost burden of gluten-free foods in pediatric patients with celiac disease (submitted for publication). The application enables participants to log meals using barcode scanning, keyword search, and manual entry, including recipe-level data. The backend system stores encrypted data securely in Microsoft Azure, and dietary entries are automatically converted to nutrient data using a standardized reference system. Researchers access de-identified participant data and analytics through a secure online dashboard. The system supports multicenter trials.
223905185|NCT05833269|BEHAVIORAL|Mindfulness and Compassion based Intercare program for parental burnout reduction (IBAP-BP)|The interventions is an adaptation of an 8-week program called Mindfulness and Compassion based Intercare program designed to reduce burnout. The adaptation includes a parental burnout risk and resource balance framework, focusing on factors such as parental perfectionism, low emotional intelligence, lack of parenting practices, excess parental responsibilities, lack of co-parental support, and lack of social support. The program consists of 8 modules with practical and theoretical activities and daily tasks that require 10-30 minutes. The modules cover topics such as mindfulness, coping with stress, empathy, and self-care. Formal meditation practices include body exploration, sitting, movement, walking, eating, acceptance, compassion, and gratitude. The program also includes descriptions and motivation for practices related to identifying values that promote parenting, time management, attentive parenting techniques, and emotional management.
223905186|NCT05833269|BEHAVIORAL|Educational material|On a weekly basis, participants will receive reminder emails highlighting specific risk factors associated with parental burnout. These risk factors include parental perfectionism, low emotional intelligence, lack of parenting practices, excessive responsibilities, and lack of support. Each week, the reminder email will cover a different topic, providing participants with relevant information.
223905187|NCT05833269|BEHAVIORAL|Reminder by email|Every week, participants will receive two reminder emails: one with a list of activities to complete during the week and another containing information about parental burnout. This approach aims to support participants in staying engaged with the program.
223905188|NCT05833269|BEHAVIORAL|Whatsapp support group|The participants will have the option to join a WhatsApp group with 25 other members from the specific group to receive daily greetings, group support, and have general doubts resolved.
223905189|NCT05833269|BEHAVIORAL|Journaling|As part of the mindfulness intervention, participants are required to write in a journal every day with the purpose of cultivating awareness of bodily sensations, emotions, thoughts, and impulses. Each week, the journaling topic focuses on a different area, including pleasant experiences, unpleasant experiences, needs and resources, communication difficulties, and sharing resources. In contrast, the control group's journaling activity involves free writing about everyday issues, thoughts, and ideas.
223905190|NCT05833269|BEHAVIORAL|Guided relaxation excercise|Participants receive a 10 and 20-minute relaxation exercise guide called the Jacobson Progressive Relaxation, which they are expected to practice daily.
223905191|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - Walking|30 minutes of walking or light jogging a day at a moderate intensity for 30 minutes a day, 5 days a week for 12 weeks
223905192|NCT06429813|BEHAVIORAL|Home-Based Exercise Intervention - HIIT Cycling|Four, 4 minute high intensity intervals of exercise, separated by 3 minutes of lower intensity exercise + a 10 minute warm up and 5 minute cool down for 40 minutes a day, 3 days a week for 12 weeks
223905193|NCT05590728|DRUG|Apramycin (EBL-1003)|A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
223905194|NCT02852213|DRUG|AAV2-hAADC|Initially, subjects will be enrolled sequentially into 2 dose groups. 3 subjects will be enrolled in Cohort 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as infusate volume of up to 160μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Cohort 2 may commence after the last subject in Cohort 1 is treated and followed through Month 3 post-op, with approval of the data safety monitoring board (DSMB). Cohort 2 will receive a higher dose (4.2 x 10\^11 vg, 160 uL). Upon DSMB review of Cohort 1/2 results, Cohort 3 (4-12 yo) and 4 (aged \>/= 13 yo) will be dosed (1.6 x 10\^12 vg, 60uL) in 1-2 sites bilaterally in-between the SNc and VTA. Cohort 5 will follow (aged 24-47 months) at 1.3 x 10\^12 vg, 500uL. Final safety and clinical outcome assessments will be performed 1 year post-surgery. Follow-up analysis will be performed for 2 years post-op. Subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates.
223905195|NCT03734679|DEVICE|SurVeil Drug Coated Balloon|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
223905196|NCT06526754|DEVICE|3D-Printed Liver Model|Participants in the 3D Printed Model Group (3DP) will receive surgical planning based on physically developed and validated 3D-printed liver models from Phase One. These models will be used to guide the surgical procedures.
223905197|NCT06526754|PROCEDURE|Digital Simulation-Based Surgical Planning|Participants in the 3D Virtual Model Group (3DV) will receive surgical planning based on digital simulations using the fastest AI-assisted segmentation method with manual adjustments from Phase Two. These digital simulations will be used to guide the surgical procedures.
223905198|NCT04339101|DRUG|Fludarabine|Given via infusion
223905199|NCT04339101|DRUG|Itacitinib Adipate|Given PO
223905200|NCT04339101|DRUG|Melphalan|Given IV
223905201|NCT04339101|OTHER|Quality-of-Life Assessment|Ancillary studies
223905202|NCT04339101|OTHER|Questionnaire Administration|Ancillary studies
223905203|NCT04339101|DRUG|Sirolimus|Given PO
223905204|NCT04339101|DRUG|Tacrolimus|Given IV or PO
223905205|NCT05772104|DRUG|Shugan Jieyu Capsules|Oral, 4 Capsules, BID
223905206|NCT05772104|DRUG|Shugan Jieyu Capsules Placebo|"Drug: Shugan Jieyu Capsules Placebo, Oral，4 capsules，BID~Drug: Placebo, Oral, 1 capsule, BID"
223905207|NCT04198181|PROCEDURE|Surgery|Resective surgery included lobectomy (partial or total brain lobe resection), tuberectomy (epileptogenic tuber resection), and tuberectomy plus (resection of epileptogenic tuber and perituberal gyri). Tuberectomy was typically performed on the epileptogenic tuber within or near an eloquent area. Lobectomy was performed in patients with large epileptogenic tubers in the brain lobes. Multiple lobectomies, tuberectomies, tuberectomies plus, and lobectomy combined with tuberectomy/tuberectomies plus were further performed in patients with multiple epileptogenic tubers.
223939969|NCT07192874|OTHER|Feedback on Gluten Exposure|The MyMedDiary Application will provide feedback on potential gluten exposure when participants input dietary record information into the application.
223939970|NCT07197762|BIOLOGICAL|Trumenba|"Trumenba is a sterile, recombinant vaccine targeting Neisseria meningitidis serogroup B. It contains two lipidated factor H binding protein (fHbp) variants-A05 from subfamily A and B01 from subfamily B-delivered in a 0.5 mL prefilled syringe. Each dose includes 120 µg of protein (60 µg per variant), 0.018 mg polysorbate 80, and 0.25 mg aluminum as AlPO₄, formulated in histidine-buffered saline at pH 6.0.~A single intramuscular dose will be administered in the deltoid."
223905208|NCT06852729|OTHER|Biering-sorenson protocol|"* Students shouldn't perform any vigorous activity a day before assessment.~* Frist, therapist will request from each participant to watch videos to understand how the test should be applied.~* The starting position will be a half prone lying on a plinth with the superior edge of the iliac crest horizontal at the edge of the plinth and the arms crossed over the chest.~* The participant should keep the unsupported upper part of the body.~* The lower limbs will strategically be stabilized with straps.~* The participant will be asked to maintain the upper body in a horizontal position and the timer started.~* The test ends if the participant can maintain the previous position for 4 minutes (240 seconds) or can no longer maintain the set position before 4 minutes elapses. The stop time is recorded.~* There is considerable range of mean fatigue times reported for the Biering-Sørensen test in the literature ranging from 84s to 180s in healthy males."
223905209|NCT06852144|OTHER|clinical practice drug treatment|Observational, prospective and retrospective study, transversal, non-profit, monocentric. All data of patients affected/ afferents to theU.O. of Nuclear Medicine of the IRCCS AOU of Bologna will be collected submitted/ who will undergo a PET/ CT investigation for thyroid pathology or other indication with incidental feedback of thyroid uptake and patients who have They undergo PET/CT with known thyroid disease. Of these patients will be collected the personal data, clinical news, data related to PET/ CT (dedicated software e.g. MIM), biochemical/ laboratory and anatomopathological (for operated patients), any other imaging investigations already performed and to be performed later by normal clinical practice. The medical nuclear images will be evaluated by at least two nuclear medical experts, with qualitative, semi-quantitative and radiometric parameters as far as possible. Patients will be treated according to normal clinical practice.
223905210|NCT06852976|DRUG|0.75% MDI-1228_mesylate gel plus Standard of Care|Approximately 40 subjects will receive 0.75% MDI-1228\_mesylate gel twice daily for 12 weeks.
223905211|NCT06852976|OTHER|Standard of Care Alone|Approximately 20 subjects will receive the standard of care alone including wound cleaning, debribement and other additional care decided by the healthcare provider.
223905212|NCT06851689|DEVICE|Jamar handheld dynamometer|Jamar handheld dynamometer to asses hand grip strength
223905213|NCT06851689|DEVICE|Biodex isokinetics|Biodex isokinetics to asses torque
223905214|NCT06852846|DIAGNOSTIC_TEST|Biological sample|Biomarker test for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-inducible protein of 10 kDa (IP-10), and C-reactive protein
223905215|NCT06852963|DRUG|VP-001|VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.
223905216|NCT06850246|DEVICE|treatment of radiofrequency technology|When operating, first select 470 kHz frequency, CRT resistance probe for deep fat management operation for 10 minutes, and then select CET capacitance mode 470 kHz for superficial fat operation for 6 minutes. Then, select the 940 kHz frequency CET capacitance probe for epidermal tightening operation for 4 minutes. The temperature is set by the energy value. In CRT mode, the energy value is set to 70, and it can reach above 42 ℃ within one minute. In CET mode, the energy value setting is adjusted to 75. The operation mode is to gradually raise the temperature to the midline after partially increasing the temperature at the side of the waist. The technique is mainly to move in a circle and lift to the midline.
223905217|NCT06850246|DEVICE|Placebo|Under the condition that the machine is not turned on, the treatment is performed in the same operation time, mode, and treatment area of the treatment group.
223905218|NCT03985592|BEHAVIORAL|Education|Intervention description provided in elaboration on arms of the study.
223905219|NCT06848543|BEHAVIORAL|Arm 1 Intervention|Arm 1 intervention is weight based taxes on cannabis, where participants make hypothetical purchases under weight based taxes.
223905220|NCT06848543|BEHAVIORAL|Arm 2 Intervention|Arm 2 intervention is price based taxes on cannabis, where participants make hypothetical purchases under price based taxes.
223905221|NCT04922736|DEVICE|UVA-1 Phototherapy|All patients will receive UVA-1 Phototherapy treatments
223905222|NCT06852261|BEHAVIORAL|Scapular-focused exercise|Scapular-focused exercise primarily targets the trapezius muscle, 60 minutes each session, once a week for 12 weeks.
223905223|NCT06852261|BEHAVIORAL|Scapular-focused exercise|Scapular-focused exercise primarily targets the trapezius muscle, 60 minutes each session, once a week for 12 weeks.
223905224|NCT05168306|DEVICE|FreeStyle Libre 2 Flash Glucose Monitoring System|The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older.
223905225|NCT02733159|DRUG|pembrolizumab|anti PD-1
223905226|NCT06850714|DIETARY_SUPPLEMENT|Bifidobacterium breve PRL2020 (Brevicillin®)|Probiotic Bifidobacterium breve PRL2020 (Brevicillin®) at a dose of 20 billion CFU per day (one stick in the morning and one in the evening).
223905227|NCT06850714|DRUG|Amoxicillin or Amoxicillin/Clavulanic Acid|Treatment of Amoxicillin or Amoxicillin/Clavulanic Acid as per medical prescription.
223905228|NCT06113562|PROCEDURE|PFO closure|The participants will receive a onetime closure of a small hole in heart. The procedure usually takes up to an hour. The procedure is done with local anesthesia and conscious sedation. A catheter is inserted into a vein in upper thigh and threaded to heart to deploy the closure device. Either Gore septal occluder or Amplatzer PFO occluder
223905229|NCT06567613|DIAGNOSTIC_TEST|Speech test|The hearing screening ensures normal hearing before enrollment. The speech reception threshold for swiss german mono- and bisyllable words is determined in an adaptive procedure.
223905230|NCT06848660|DEVICE|A rigid cervical collar|The rigid cervical collar is used for spinal motion restriction for 12 weeks for the non-surgical treatment of a stable cervical spine fracture.
224277015|NCT04286295|DRUG|Nicoderm C-Q Transdermal Product|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants will be instructed to apply a new patch each day. They will continue to wear patches for 25 days.
224277016|NCT04286295|DRUG|Nicorette Lozenge Product|Participants in the NRT group will receive Nicorette Lozenges to use during their 25-day quit attempt. They will receive enough lozenges to last for the 25-day treatment period.
224277017|NCT03259113|DEVICE|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
223905231|NCT06851065|DRUG|Luspatercept|As per product lable
223905232|NCT06851065|DRUG|Erythropoiesis-stimulating agents|As per product label
223905233|NCT06568107|BEHAVIORAL|Environmental And Sensory Experience (EASE) intervention|The participant will be exposed to 30 minutes of a still nature image and associated nature sounds (60-80 beats per minute). An brief interview will occur with the legally authorized representative to find out what nature scene would meet the preference of the person living with dementia and persistent vocalizations.
223905234|NCT06122194|DRUG|Drug: PF-07817883|PF-07817883 tablet
223905235|NCT06536374|DRUG|Trimethoprim Tablets|Trimethoprim 150mg is administered once daily for 3 months
223905236|NCT05477056|OTHER|PrecivityAD blood test|Clinician Survey post receipt of PrecivityAD blood test result
223905237|NCT04606030|DEVICE|BioBridge® Collagen Matrix|BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
223905238|NCT04606030|PROCEDURE|Vascularized Lymph Node Transfer (VLNT)|Micro-surgical procedure for vascularized lymph node transfer (VLNT)
223905239|NCT00291525|DEVICE|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
223905240|NCT00291525|DEVICE|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
223905241|NCT05050539|BEHAVIORAL|Low Intensity|5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.
223905242|NCT05050539|BEHAVIORAL|High Intensity|Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
223905243|NCT04376918|DEVICE|Begin with BVGA|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
223905244|NCT04376918|DEVICE|Begin with Face-mask|"Device: BVGA The BVGA enables the direct connection of a bag valve device to a Guedel, eliminating the need for a face mask during ventilation~Other Names:~• Bag Valve Guedel Adaptor Device: Face Mask Classic face mask"
223905245|NCT06217198|BEHAVIORAL|Deprexis|Deprexis is an internet-delivered treatment for depressive symptoms and related functional impairment. The intervention draws from various theoretical frameworks and consists of 12 modules: 10 core content modules and an introductory and summary module. Deprexis is designed to be interactive, includes answering questions and learning techniques and concepts through instruction and examples.
223905246|NCT05464056|BEHAVIORAL|Be Unstoppable in Life Together (BUILT)|Participants will complete weekly sleep, food, and exercise home challenges focused on creating sustainable healthy eating, sleep, and exercise routines. Parents will participate in weekly support calls by UIC and Chicago Park District staff to provide support and accountability. Children will have the opportunity to win small prizes based on completing weekly challenges. The intervention will be co-facilitated by UIC students and Chicago Park District staff and will largely take place on-line. For additional details visit: https://built.ahs.uic.edu.
223905247|NCT02470962|OTHER|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
223905248|NCT06614920|OTHER|Plant-Based Food Provision (with or without food prescription)|"Food Prescription: Participants will bring the food prescription obtained from the nutrition class to Village FREEdge, food pantry at the Freedom Lab, where it will function as a voucher. Each voucher will allow for participants to pick up enough plant-based food for 6 meals per person in their household (with household maximum of 5 people)(enough meals for 3 days- 2 meals per person per day). We expect that participants will pick up food twice per week from Village FREEdge to obtain enough meals to feed each participant's household for 6 days out of the week for up to 1 year.~Without food prescription: Participants will be given plant-based meals from Village FREEdge (up to two meals per day with a maximum of two meals per pick-up) without the use of a food prescription."
223905249|NCT06614920|OTHER|Plant-Based Nutrition Education|"A once weekly classes for a 5-week nutrition course. The parents/guardians would bring their children and any additional household member(s) to the nutrition class, which will organize participants in different classrooms by age (children 4 years, 4-12 years old, 12-14 years old, 14+ years old). Each classrooms will engage in age-appropriate interactive nutrition-based activities. All children below 18 will engage in interactive activities for the full 1.5 hours. Adolescents aged 14 up will join the classroom with adults and listen to a 45 minute lecture and engage in a subsequent 45 minute interactive activity that incorporates content from the lecture. The interactive activities for the children range from creating a fruit and veggie Tik Tok song and performing it, drawing foods on a balanced plate, etc. The interactive activities for participants 14 year old and older range from discussions about fiber in diet, guided plant-based meal preparation, reading nutrition label etc."
223905250|NCT05338060|OTHER|prospective collection of surgical exudates (SEs)|prospective collection of surgical exudates (SEs) from patients who are hospitalized for post-operative recovery from esophagectomy or gastrectomy for gastroesophageal cancer
223905251|NCT05712096|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
223905252|NCT05636995|DIAGNOSTIC_TEST|Aldosterone/Renin Ratio|Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.
223905253|NCT05204888|DEVICE|myAirvo3|For patients assigned to the HFNT intervention group, a myAirvo 3 device will be provided. The myAirvo 3 is for the treatment of spontaneously breathing patients, infant to adult, who would benefit from receiving high flow warmed and humidified respiratory gases. This includes patients who have had upper airways bypassed. The flow may be from 2 - 60 L/min depending on the patient interface. The myAirvo 3 is for patients in homes and long-term care facilities.
223905254|NCT05204888|DEVICE|Pulse oximeter|A pulse oximeter will be provided to measure heart rate and pulse oximetry; subjects will enter and transmit the data on the smartphone once daily before 11AM. Heart rate and pulse oximetry measures will be taken after wearing the device for approximately 2 minutes.
223905255|NCT06455527|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using the 1x1 Mini CT tDCS device. For active tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (29 minutes), and then ramp down (for 30 seconds) at the end. Participants will receive 10 sessions of tDCS over the course of this study on weekdays (M-F).
223905256|NCT06455527|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS will be delivered using the 1x1 Mini CT tDCS device. For sham tDCS, the device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 28 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end. Participants will receive 10 sessions of sham tDCS over the course of this study on weekdays (M-F).
223905257|NCT03908697|DEVICE|Mira monitor comparison to ClearBlue monitor|Testing first morning urine with hormone test sticks at home
223905258|NCT00559156|DIETARY_SUPPLEMENT|arginine/omega-3 fatty acids/nucleotides oral supplement|
223905259|NCT00559156|DRUG|cisplatin|
223905260|NCT00559156|PROCEDURE|adjuvant therapy|
223905261|NCT00559156|RADIATION|radiation therapy|
223905262|NCT05558384|BEHAVIORAL|Aerobic Exercise|"A 15-week standardized aerobic exercise intervention.~* Frequency: 5 days/wk (2 supervised)~* Intensity: 50-59% heart rate reserve~* Time: 40 min/session (ramp up from 25-40 during first 4 weeks)~* Type: Aerobic exercise (e.g. treadmill, walking/jogging, cycling, elliptical)"
223905263|NCT05777070|BEHAVIORAL|Bimanual Cup Stacking Training|Children practices bimanual cup stacking, 15 trials/day for 5 consecutive days
223905264|NCT05509803|BEHAVIORAL|PE Audit and Feedback Tool|The intervention consists of a Physical Education (PE) Audit and Feedback tool, which was adapted from work done through the PE Works program in the New York City Department of Education. A district-level PE program leader in Oakland Unified School District will deliver the tool, which consists of auditing the current status of PE in intervention schools, providing feedback on the status to help improve PE, and providing technical assistance to bring schools up to code and ensure support for PE programming.
223905265|NCT05987813|DEVICE|TENS Unit|Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
223905266|NCT05027074|DRUG|MK-2060|MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion
223905267|NCT05027074|DRUG|Placebo|Normal saline administered via IV infusion
223905268|NCT06461455|DEVICE|Lehfilcon A multifocal for astigmatism contact lenses|Investigational multifocal contact lenses for astigmatism
223905269|NCT06461455|DEVICE|Samfilcon A multifocal for astigmatism contact lenses|Commercially available multifocal contact lenses for astigmatism
223905270|NCT06461455|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfection system
223905271|NCT05252416|DRUG|BLU-222|Oral administration
223905272|NCT05252416|DRUG|Carboplatin|IV Infusion
223905273|NCT05252416|DRUG|Ribociclib|Oral administration
223905274|NCT05252416|DRUG|Fulvestrant|Intra muscular administration
223905275|NCT05899439|OTHER|blood draw|a peripheral blood draw
223905276|NCT05580406|BEHAVIORAL|Outreach messaging|Participants will receive outreach messages via health care system secure messaging and/or phone following a new diagnosis of depression made in primary care if the participant has failed to initiate treatment (pharmacotherapy or psychotherapy) within 30 days of new diagnosis.
223905277|NCT06328036|BIOLOGICAL|Atezolizumab|Given IV
223905278|NCT06328036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223905279|NCT06328036|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223905280|NCT06328036|PROCEDURE|Surgical Procedure|Undergo surgical resection
223905281|NCT06328036|BIOLOGICAL|Tiragolumab|Given IV
223905282|NCT04580680|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|At each participating center, EBP treatments with commercial membranes will be delivered in accordance with local practice and local levels of expertise. Enrolled patients will not receive additional treatments other than those routinely administered in ICUs. Nonetheless, all parameters settings for EBP treatments will be recorded in the web-based registry and analyzed a posteriori to reveal potential correlations with patient outcomes.
223905283|NCT04192435|DRUG|Tranexamic Acid|100mg/ml
223905284|NCT04192435|DRUG|Placebos|Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.
223905285|NCT05263089|OTHER|PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)|"Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s."
223905286|NCT05263089|OTHER|ESTELITE® Alpha; Tokuyama, Tokyo, Japan|The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
223905287|NCT05924789|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
223905288|NCT06175091|DEVICE|alarm management left to the discretion of the nurse|alarm management left to the discretion of the nurse in charge of the patient
223905289|NCT06175091|DEVICE|restrictive alarm use strategy|more restrictive protocol for the use of alarms
223905290|NCT05661448|BEHAVIORAL|Cognitive remediation|The goal of this program is to improve performance on cognitive domains known to hinder functioning. It aims to promote positive attitudes towards learning and facilitate the development of independent learning skills to foster competence and confidence. Another aim is to increase patients' awareness of their cognitive strengths and weaknesses and their own problem solving strategies.
223905291|NCT05661448|BEHAVIORAL|MetaCognitive Training|The metacognitive training (MCT) program is based on the theoretical foundations of cognitive models of schizophrenia but employs a slightly different focus in its therapeutic approach targeting the specific cognitive biases underlying delusions. The modules aim to raise awareness of these biases and prompts participants to critically reflect on and update their problem-solving repertoire.
223905292|NCT05553457|DEVICE|Testing of MyHand-SCI Device|Subjects will attend 1-20 sessions (approximately 90 minutes) to trial the MyHand-SCI device, including a variety of controls and components.
223905293|NCT04534296|OTHER|early mobilization|Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
223905294|NCT04534296|OTHER|routine care|In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
223905295|NCT04575688|DRUG|Exparel|Exparel will be administered by periarticular injection to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
223905296|NCT04575688|DRUG|Bupivicaine|Bupivicaine will be administered by popliteal block to patients undergoing hindfoot osteotomy or fusion, ankle osteotomy or fusion, or ankle fracture repair.
223905297|NCT05540288|DRUG|Nalmefene|"Week 1: 18 mg/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 36 mg/d~2. In the presence of grade 3 ARs, 18 mg/d~3. In the presence of grade 4 ARs, treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the 18mg/d dosage during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the 18mg/d dosage during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the 36mg/d dosage during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the 36mg/d dosage during week 2, the treatment dosage will be decreased at 18mg/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
223528921|NCT05962775|PROCEDURE|Ethanol Sclerotherapy for Endometrioma|2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
223905298|NCT05540288|DRUG|Placebo|"Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately."
223905299|NCT04888689|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223905300|NCT04888689|DEVICE|IMU|"IMU is a portable system of miniaturized inertial sensors for objective, instrumental, ambulatory, and validated analysis of normal and pathological human gait. Each miniaturized inertial sensor (2 cm × 0.7 cm × 0.5 cm) includes a triaxial accelerometer and a triaxial gyroscope.~These four inertial sensors are connected to a box by wires and are numbered 1 to 4. They must be attached - using adhesive tapes - on the participant's shoes."
223905301|NCT05963880|DEVICE|Brachial and Central BP measurements with Mobil-o-Graph NG device (IEM), WatchBP Office device (Microlife), BP+ device (Uscom) and Oscar 2 with SphygmoCor inside device (SunTech)|All participants will have three readings at 1-min interval after a 5-min seated rest with each device. The order in which each device will be tested is randomized.
223939971|NCT07197762|BIOLOGICAL|PENBRAYA|"PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. It consists of two components:~* A lyophilized MenACWY portion (polysaccharides conjugated to tetanus toxoid)~* A liquid MenB portion (two recombinant fHbp variants: A05 and B01) Each 0.5 mL dose contains 20 µg of polysaccharides (5 µg per serogroup), 44 µg tetanus toxoid, 120 µg of MenB protein (60 µg per variant), plus stabilizers and aluminum phosphate.~This will be administered intramuscularly in the deltoid."
223939972|NCT07196150|BEHAVIORAL|Exercise Program|Participants will complete an 8-week supervised exercise program, delivered twice per week. The program includes lumbopelvic stabilization, stretching, and endurance training exercises designed to reduce menstrual pain and improve physical function.
224277018|NCT05046951|BEHAVIORAL|Should I Screen website|The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
223528922|NCT06378008|DRUG|CSPS toothpaste|Toothpaste containing 5.0% weight/weight (w/w) CSPS.
223528923|NCT06378008|DRUG|Regular fluoride toothpaste (Crest Cavity Protection)|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
223528924|NCT04047576|DRUG|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
223905302|NCT04490616|OTHER|rTMS treatment|"A two-site rTMS stimulation delivered by a Magstim unit featuring a double 70 mm cooled coil will be applied.~MCI patients will be randomly assigned to one of the two study groups:~1. RR-Gr will receive 4 weeks of rTMS stimulation of the right temporo-parietal junction (RTPJ) and medial prefrontal cortex (MPFC);~2. PL-Gr will receive sham stimulation of the RTPJ and MPFC during the first 2 weeks followed by 2 weeks of real stimulation. Each week of rTMS treatment will consist of five sessions (50 min, one per day).~For each area target, a total of 2000 pulses at 20Hz, 3-s train duration, and 28-s inter-train interval at 100% motor threshold (MT) will be delivered per session. A fixed intensity of MT will ensure a more consistent spatial spread of TMS effects in subjects' brains not influenced by differences in individual MT. In the sham condition, a sham coil will be used.~Each session lasted for about 60 min including time for set up and 50 min of stimulation."
223905303|NCT04450953|DRUG|Eplerenone 50mg/day (cross over design)|Eplerenone 50mg/day for 6 months followed
223905304|NCT04450953|OTHER|Period without eplerenone (cross over design)|6-month period without eplerenone
223905305|NCT05903547|DEVICE|Dermabond Prineo|For subjects in the Dermabond Prineo group, the Dermabond Prineo system will be applied to the skin for skin closure under manufacturer's guidelines.
223905306|NCT05903547|OTHER|Suture|For subjects in the Suture group, the skin will be closed with the standard subcuticular suture method.
223905307|NCT04487717|DEVICE|nProfiler I Stomach Cancer Assay Kit|nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
223905308|NCT06799559|DRUG|3-6mg QLM1016|3-6mg QLM1016 pluse Aripiprazole dummy oral solution film administered orally once daily for 6 weeks
223905309|NCT06799559|DRUG|10-20 mg Aripiprazole oral solution film|10-20mg Aripiprazole oral solution film plus QLM1016 dummy oral solution film administered orally once daily for 6 weeks.
223905310|NCT06798662|DEVICE|Ultrasound-Guided Pulsed Radiofrequency (PRF)|A high-frequency linear ultrasound transducer will be used for this procedure. The transducer will be placed transversely over the target rib area to obtain a clear visualization of the rib, intercostal muscles, and pleura. The entry point for needle insertion will be selected 1-2 cm inferior to the inferior border of the target rib. Using a 22G radiofrequency (RF) needle, an in-plane approach will be used for needle advancement. The needle will be advanced slowly until it reaches the inferior border of the rib. The needle will then be withdrawn 1-2 mm to ensure the needle tip is positioned adjacent to the intercostal nerve. The RF needle will then be connected to the RF generator for sensory testing. Stimulation parameters will be set at 50 Hz and 0.5-1V. The target location will be considered accurate if stimulation induces pain in the participant. Pulsed radiofrequency treatment will then be administered using the following parameters: voltage of 45V, frequency of 2 Hz, pulse width
223905311|NCT06798662|DEVICE|Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine)|The patient is positioned in either the lateral decubitus or sitting position, with the affected side facing upwards, ensuring adequate exposure of the targeted intercostal region. A high-frequency linear ultrasound transducer is placed transversely over the posterior lateral aspect of the targeted rib, using the vertebral column as a reference point. The transducer is then scanned laterally to identify the target rib, clearly visualizing the rib, intercostal muscles, and pleura. The intercostal nerve appears as a small hyperechoic structure located between the internal and innermost intercostal muscles. The needle is advanced until it contacts the inferior border of the rib. The needle is then slightly withdrawn and positioned between the internal and innermost intercostal muscles to avoid pleural puncture. After negative aspiration, 10 mL of 0.5% ropivacaine (or 133 mg of liposomal bupivacaine) combined with 10 mg of triamcinolone acetonide is injected slowly.
223905312|NCT06798662|DEVICE|Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)|For the Paravertebral (PVB) block, a high-frequency linear ultrasound transducer was placed transversely, parallel to the spinous processes, approximately 2-3 cm lateral to the spinous process of the target thoracic vertebral segment. The position and angle of the transducer were adjusted to clearly visualize the transverse process (TP) and the axial view of the lamina of the target vertebra. In the ultrasound image, the transverse process appeared as a hyperechoic structure, typically with a characteristic acoustic shadow posterior to it. Subsequently, the transducer was slightly slid caudally, causing the transverse process and its acoustic shadow to gradually disappear from view. At this point, the ultrasound image revealed components of the paravertebral space (PVS), including the parietal pleura, the superior costotransverse ligament, and the intercostal fascia, which exhibited a heterogeneous mixed echogenicity. Using an in-plane technique, a puncture needle was advanced from lat
223905313|NCT06798662|DEVICE|Rhomboid Intercostal and Subserratus Plane (RISS) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)|"The RISS block is a composite nerve block technique that involves two injection sites: the inter-rhomboid plane and the sub-serratus plane. The selection of block plane was determined by the patient's specific location of pain.~Rhomboid Intercostal Plane Block (RIPB):~For the Rhomboid Intercostal Plane Block (RIPB), a high-frequency linear ultrasound transducer was initially positioned in a sagittal orientation, medial to the scapular border. It was then slightly rotated to obtain an oblique sagittal view (oblique paramedian sagittal view), located 1-2 cm lateral to the scapular border. Upon obtaining the appropriate ultrasound image, the following anatomical structures were identified sequentially, from superficial to deep: the trapezius muscle, the rhomboid muscles (specifically, the major rhomboid), the intercostal muscles (located between the ribs), the pleura, and the lung. The target injection plane was the fascial plane situated between the rhomboid muscle and the intercostal"
223905314|NCT06798662|DRUG|Drug (famciclovir and gabapentin)|All patients will receive famciclovir and gabapentin. All participants will receive standard antiviral therapy with famciclovir 500 mg orally three times daily for 7 days. Gabapentin will be initiated at a typical starting dose of 300 mg per day, administered in three divided doses. The dosage may be gradually increased, as needed and tolerated, up to a maximum dose of 1800 mg per day.
223905315|NCT06798129|PROCEDURE|extracorporeal blood purification therpay|Extracorporeal blood purification therapy in this study includes intermittent hemodialysis (HD), continuous renal replacement therapy (CRRT), plasma exchange (PE), and hemoperfusion (HP).
223905316|NCT05125029|DRUG|Botulinum toxin|Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
223905317|NCT03662386|PROCEDURE|OCT-A|Optical coherence tomography angiography (OCT-A)
223905318|NCT03662386|PROCEDURE|Visual acuity (ETDRS)|Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
223905319|NCT03828344|BIOLOGICAL|hUC-MSC suspension|Patients will be treated at dose of 0.75×10\^6 cells/kg of body weight (Cohort 1) or 1.5×10\^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
223905320|NCT03828344|BIOLOGICAL|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
223905321|NCT04670679|DRUG|ERAS-601|Administered orally
223905322|NCT04670679|DRUG|Cetuximab|Administered via intravenous infusion
223905323|NCT04670679|DRUG|Pembrolizumab|Administered via intravenous infusion
223905324|NCT06972264|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
223905325|NCT06972264|DRUG|Placebo|Placebo
223905326|NCT05015153|OTHER|Pulmonary rehabilitation (PR)|20 sessions of PR in respiratory rehabilitation centre will be performed over a period of 3 months
223905327|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
223905328|NCT06248411|DRUG|KK2260|KK2260 will be administered intravenously at several dose levels, and after determining MTD, multiple dose regimens will be evaluated in multiple cancer types to target.
223905329|NCT06823375|RADIATION|Radiotherapy|\- SBRT 27.5Gy to 50Gy in 5 fractions on alternate days will be delivered between cycle 3 and 5 to the PVTT and its adjacent lesions.
223905330|NCT06823375|DRUG|Atezolizumab plus Bevacizumab|\- Atezolizumab 1200mg IV and Bevacizumab 15mg/kg IV will be given every 3 weeks, till disease progression, intolerable toxicity, death or withdrawal of consent.
223905331|NCT03824327|PROCEDURE|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
223905332|NCT03824327|DRUG|Papaverine Hydrochloride|Given IV
223905333|NCT03824327|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223905334|NCT02887521|OTHER|education|pulmonary rehabilitation participant manual
223905335|NCT02887521|PROCEDURE|rehabilitation|pulmonary rehabilitation
223905336|NCT02887521|DEVICE|pedometer|receive a pedometer
223905337|NCT02887521|OTHER|education|receive a pamphlet with exercises plus the standard course of care
223905338|NCT02887521|PROCEDURE|surgery|patients undergo surgery
223905339|NCT06188780|DIAGNOSTIC_TEST|urine/blood analysis with IA and LC-GCMS analysis|urine/blood analysis with IA and LC-GCMS analysis
223905340|NCT02112526|DRUG|Acalabrutinib|
223905341|NCT02709161|DEVICE|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
223905342|NCT02709161|DEVICE|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
223905343|NCT05109988|BEHAVIORAL|Breastfeeding telephone support|The intervention consists of four weekly 20-30 minutes telephone-administered counselling sessions on breastfeeding, delivered individually in the first month postpartum for mothers and fathers.
223905344|NCT04785131|OTHER|Prune|daily consumption of 50 grams prune.
223905345|NCT04102176|OTHER|stopping nucleos(t)ide therapy|patients taking nucleoside(t)ide therapy will stop treatment
223905346|NCT04102176|OTHER|Continue nucleos(t)ide analogue|Continue nucleos(t)ide analogue
223905347|NCT05795400|DRUG|Dapagliflozin 10mg Tab|10 mg tablets given once daily, per oral use
223905348|NCT05795400|DRUG|Placebo|tablet of placebo drug dosed once daily
223905349|NCT04965935|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.
223905350|NCT04965935|DRUG|Placebo Matching Dapagliflozin Oral Tablet|Placebo will be administered for 12 weeks.
223905351|NCT03507257|DRUG|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
223905352|NCT03507257|DRUG|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
223905353|NCT03507257|DRUG|Fluorodeoxyglucose|All participants will receive a single bolus intravenous injection of approximately 5 mCi (+/- 10%, 0.5 mCi) of fluorodeoxyglucose. At approximately 30 minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
223905354|NCT05757739|PROCEDURE|Tenex|In the Tenex procedure, the surgeon inserts a special needle into the damaged portion of the tendon under ultrasound guidance. Ultrasonic energy vibrates the damaged tissue and it can be suctioned out. This procedure is done with local anesthesia in surgeon's office.
223905355|NCT06151106|DRUG|Chidamide combined with Duvillisib|Specified dose on specified days
223905356|NCT04672733|BIOLOGICAL|Hizentra|Solution for injection for subcutaneous use
223905357|NCT02397954|DRUG|Avacincaptad Pegol|Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.
223905358|NCT06060522|DIAGNOSTIC_TEST|CT, CBCT|"Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline."
223939973|NCT07196150|BEHAVIORAL|Exercise plus Motor Imagery Training|Participants will complete the same 8-week supervised exercise program as the Exercise Only group. In addition, they will practice kinesthetic motor imagery of the prescribed movements prior to performing them, aiming to enhance motor control and pain modulation.
223905359|NCT05835804|DRUG|GCP intratumoral catheter|After local anaesthesia, intratumoral catheter will be place (one or several depending tumour criteria).The catheter placement could be guided by radiological imaging. Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%. GCP will be administered successively for 8hours, at 20ml/h with a total duration of 24hours. The ITC will be done every 28 days for 6 times maximum in case of good response and tolerance. Nivolumab 240 mg IV will be started 1 to 7 days before the first intratumoral infusion and every 15 days, until progression or 2 until years in case of partial response, complete response or stabilization. Evaluation of tumour size will be done by CT-scan, or MRI 2every 2 months and PET-FDG every 3 months.
223905360|NCT03626220|OTHER|acupuncture|More than five years of experienced certified acupuncturists performed all treatments using the study protocol and administered to all participants. The acupoints selection principle was based on the Bi syndrome(the impediment disease) recorded in the Huangdi's Internal Classic, the Traditional Chinese medicine literature. Disposable sterile stainless steel needles (CASOON, Wuxi Jiajian Medical Instrument Company, Limited., Jiangsu, China) with 0.3mm in diameter and 40mm in length, were inserted into the prespecified acupoints
223905361|NCT05278728|DRUG|Nimotuzumab|200,400,600 or 800mg weekly until progression or AEs
223905362|NCT05278728|DRUG|Irinotecan|180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles
223905363|NCT05387265|DRUG|CX-904|CX-904 is a T-cell engaging bispecific Probody® candidate against Epidermal Growth Factor Receptor (EGFR) and CD3.
223905364|NCT04363164|DRUG|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
223905365|NCT04363164|DRUG|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
223905366|NCT04363164|DRUG|Testosterone enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
223905367|NCT05940740|OTHER|Colorectal-Mobile application|The use of Colorectal-Mobile application by the patients on a daily basis by the researcher will be monitored remotely via the management platform of the usage status of the mobile health application.
223905368|NCT06397586|OTHER|Routine volleyball|MOtor imagery
223905369|NCT02201134|DRUG|sevoflurane|
223905370|NCT05957406|DEVICE|Acumen HPI Smart Alerts and Smart Trends Software|Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.
223905371|NCT05957406|DEVICE|The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff|Device: HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff
223905372|NCT04350359|DEVICE|Variable-dose TTNS Protocol 5 x week|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.
223905373|NCT04350359|DEVICE|Fixed-dose TTNS Protocol|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.
223905374|NCT04350359|DEVICE|Variable-dose TTNS Protocol 2 x week|At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.
224277019|NCT05046951|BEHAVIORAL|Should I Screen print booklet|The Should I Screen print-based education will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.
224277020|NCT03799224|DRUG|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
224277021|NCT03799224|DRUG|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
224277022|NCT03799224|DRUG|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
224277023|NCT00355524|DRUG|TMC114|TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
224277024|NCT00355524|DRUG|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
224277025|NCT01524016|DRUG|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
224277026|NCT00781079|BEHAVIORAL|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
223905375|NCT06988306|BEHAVIORAL|GDM Enhanced|The GDM Enhanced intervention is comprised of HV-delivered, evidence-based modules (10-20 minutes) with facilitator guides. The content prioritizes management and prevention of diabetes through healthy eating, physical activity, and stigma-informed weight management strategies.
223905376|NCT06988306|BEHAVIORAL|Meals|The Meal intervention includes medically tailored meals being provided to participants starting after randomization and tailored to their individual dietary preferences and cultural considerations.
223905377|NCT06676384|DRUG|Oral prednisolone and SoC|Oral prednisolone 0.5 mg/kg per day (maximum, 40 mg/day) for two months, followed by dose tapering by 5mg per day each month for six to nine months. All participants in this arm will receive SoC and oral cotrimoxazole prophylaxis.
223905378|NCT06676384|DRUG|Gut-directed budesonide and SoC|Gut-directed Budesonide 12 mg once daily for nine months and tapered to 9mg once daily for the next three months, 6mg once daily for the next three months and 3mg once daily for the next three months and stopped (total 18 months). All participants in this arm will receive SoC.
223905379|NCT06676384|DRUG|Mycophenolate mofetil (MMF) and SoC|Mycophenolate mofetil (MMF) 1.5g/ day for twelve months, followed by 1g/ day for six months (total 18 months). All participants in this arm will receive SoC.
223905380|NCT06676384|DRUG|Hydroxychloroquine and SoC|Hydroxychloroquine (HCQ) 6.5 mg/kg/day (maximum 400 mg daily) for 24 months. All participants in this arm will receive SoC.
223905381|NCT06676384|DRUG|Non-steroidal mineralocorticoid receptor antagonist and SoC|Generic drug not available currently. All participants in this arm will receive SoC.
223905382|NCT06676384|DRUG|SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)|Maximal labelled or tolerated dose of ACEi/ ARB and a steady dose of SGLT2i (10mg/d of dapagliflozin).
223905384|NCT06874998|BEHAVIORAL|Structured group discussions|"A group-based program for immigrant parents of children aged 0-17, providing essential information on key aspects of family life in Sweden. The intervention consists of five weekly three-hour sessions, combining lectures, group discussions, and interactive exercises, led by a trained group leader and, when necessary, an interpreter.~The following topics are discussed:~* Parenting in a New Country - Adapting to cultural changes and supporting children's integration.~* Education \& Child Development - School system, parental involvement, and learning support.~* Healthcare \& Well-being - Access to healthcare, preventive care, and mental health.~* Parents' Rights \& Responsibilities - Child welfare laws, positive discipline, and social services.~* Parenting Teenagers - Navigating adolescence, peer relationships, and risk prevention."
223905385|NCT06874998|BEHAVIORAL|Unstructured group meeting|"Parents in the control group are asked to participate in a gathering where they will watch two short films from the Swedish Educational Broadcasting Company (UR), followed by a brief discussion. The films have been handpicked by representatives from BRIS and PLUS together with the researchers to create an opportunity for a meeting. The first film A way in - first meeting shows a family from Iran living in Sweden for 1,5 years and explores how one can establish a place in society. In the second film Make new friends it is illustrated how hard it can be to create a new social context. The intention with the short films is not to give a short version of PiS, but to engage parents in the study and the program so they will complete them."
223905386|NCT07027748|DRUG|Naxitamab|Recombinant humanized anti-GD2 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.
223905387|NCT07027748|DRUG|Irinotecan|Topoisomerase Inhibitor, single-dose vial, via intravenous infusion per standard of care
223905388|NCT07027748|DRUG|Temozolomide|Alkylating agent, capsule, via orally (by mouth) per standard of care
223905389|NCT07027748|DRUG|Sargramostim granulocyte-macrophage colony stimulating factor|Recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF), multi-use vial, via subcutaneously (under the skin) injection per standard of care
223905390|NCT07028268|DRUG|SHR-2017、Denosumab placebo|SHR-2017; high dose ；Denosumab placebo
223905391|NCT07028268|DRUG|SHR-2017、Denosumab placebo|SHR-2017; low dose ；Denosumab placebo
223905392|NCT07028268|DRUG|Denosumab；SHR-2017 placebo|Denosumab；SHR-2017 placebo
223905393|NCT07057583|OTHER|Non-Interventional Study|Non-interventional study
223905394|NCT07057544|DEVICE|LBBAP CRT device implantation|Pacing system with a lead implanted in the left bundle branch area will be done.
223905395|NCT07057544|DEVICE|BVP-CRT|Implantation of biventricular device
223905396|NCT06749132|DIAGNOSTIC_TEST|Transthoracic echocardiogram|All study participants will undergo a clinical transthoracic echocardiogram (TTE) performed by certified echocardiography technicians. The TTE includes standard transthoracic examination with acquisition of B-mode, color and spectral Doppler images and videos in line with standard echocardiographic guidelines.
223905397|NCT07062991|OTHER|Kendall Exercises|Kendall exercises which includes: Chin tuck in supine Stretching the cervical extensors Shoulder retraction with theraband Stretching of the pectoralis major muscle Every strengthening exercise will be repeated for 12 repetitions and done for 3 sets and each stretching exercise will be hold for 30 seconds and repeated 3 times. The exercises will be performed three times per week for 4 weeks
223905398|NCT07062991|OTHER|Scapular stabilization exercises|Shoulder shrugs Prone arm lift Stretching of levator scapular Stretching pectoralis minor muscle Each strengthening exercise will be repeated for 15 repetitions of 3 sets and each stretching exercises will be hold for 30 seconds and repeated 3 times. The exercises will be performed three days per week for 4 weeks.
223905399|NCT07064044|OTHER|Conventional Traetment|TENS applied for 10 minutes, Therapeutic ultrasound,Hip abductors and lateral rotators strengthening, Hamstring muscle passive stretching, Isometrics for quadriceps, given thrice a week for 4 weeks .
224277027|NCT05378308|OTHER|Patients with Atrial Fibrillation (AF) or venous thromboembolism (VTE)|Patients with AF or VTE; OAC treatment patterns according to patient demographics, clinical factors, risk stratification, geographic regions, local NOAC medical insurance policy and NOACs availability
224277028|NCT05318755|DRUG|GAHT for transgender men|Testosterone undecanoate
223528925|NCT04047576|DRUG|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
223905400|NCT07064044|OTHER|Muscle Energy Technique and Patellar Inferior Glide|Muscle Energy Technique for Hamstrings and Quadriceps While the patient contract muscle (Hamstring / Quadriceps) the therapist applies a gentle controlled force. After the contraction patient release and the therapist reposition the leg into a new barrier. Intensity of contraction will be 20-25-% of maximum strength. Each contraction will be held for 5-7 seconds, followed by additional passive stretching maintained for 30 and the relaxation patellar inferior glide applied at patella: the examiner applied a gentle downward force on the patella with their right hand, while the left hand controlled the direction of the patella's movement. This will be applied for 3-4 minutes as tolerated by the patient.
223905401|NCT07063472|BEHAVIORAL|Tele- pilates|"Tele-Pilates for (TP) group The TP program included warm-up, main session, and cool-down phases. The session started with warm-up exercises in the form of breathing, spinal twist, cat stretch, arm circles, and abdominal stretching. Each exercise was performed for five repetitions, with each repetition held for 10-15 seconds and followed by a 5-second rest period. The warm-up phase lasted a total of 10 minutes.~Tele-Pilates was supervised by a Pilates professional trainer. Participants engaged in mat-based Pilates exercises. These exercises included roll-up, bug leg, crock leg lying, prone single leg kick, bug roll, knee/lumbar roll, and prone attitude rotation.The session ended with 10-minute cool-down that involved relaxation exercises and stretching."
223905402|NCT07063472|DEVICE|Kinesio taping application for the KT group|Kinesio taping application for the KT group The participant sat upright in a chair, and a piece of kinesiology tape (5 × 5 cm, 3NS, Korea) was used to measure the distance from just above the anus to the upper border of the pelvis. This measured length was then divided by eight, and the tape was cut accordingly. One end of the tape was anchored on the ulnar bone just above the inguinal region. With 25% stretch, the tape was applied diagonally upward and outward, following the contour of the iliac crest over the ilium. The second end was secured to overlap the base of the initial tape. A second strip was applied in a similar manner in the opposite direction over the ilium. KT was applied for over eight weeks, with the tape changed every three days
223905403|NCT07062926|OTHER|Spencer Muscle Energy Technique|Spencer muscle energy technique participants will receive a hot pack for 7-10 minutes followed by their respective treatments, three times a week for four weeks. Group A will undergo Spencer Muscle Energy Technique for 30 minutes
223905404|NCT07062926|OTHER|Post Facilitation Stretch|Post facilitation stretch participants will receive a hot pack for 7-10 minutes followed by their respective treatments, three times a week for four weeks.post facilitation stretching process was repeated 5 times with 10 second interval between each stretch.
223905405|NCT07062068|PROCEDURE|ultrasound guided Brachiocephalic vein and internal jugular vein cannulation in mechanically ventilated ICU patients|"For Arm ( candidates for BCV cannulation ) :~by ultrasound guided we insert Central venous catheter in BCV under complete aseptic condition For Arm ( candidates for IJV cannulation ) by ultrasound guided we insert central venous catheter in IJV under complete aseptic conidtion we do comparison between the 2 arms as regard : 1st pass success rate , complications and failure rate in ventilated patient in ICU ."
223905406|NCT07063615|OTHER|Microbiome-Powered Cream|"Mode of Usage: Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.~Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.~Frequency: Apply twice daily - once after the morning shower and once before bedtime.~Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets."
223905407|NCT07063615|OTHER|Placebo Hair Cream|"Mode of Usage: : Apply a generous amount of the cream to the affected area of the scalp. Gently part the hair using a wide-tooth comb or your fingertips to ensure direct contact with the scalp. Extend slightly beyond affected areas.~Massage the cream gently into the skin until fully absorbed. Do not rinse off after application.~Frequency: Apply twice daily - once after the morning shower and once before bedtime.~Route of Administration: Topical Note Ensure the scalp is completely dry (within 5 minutes of towel-drying post-shower) before applying the cream. At night, ensure the cream is fully absorbed before lying down to avoid transfer to bedding materials like pillows or sheets."
223905408|NCT05673785|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
223905409|NCT05673785|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion
223905410|NCT05673785|DRUG|Doxorubicin|Doxorubicin IV infusion
223905411|NCT05673785|DRUG|Prednisone|Prednisone tablets
223905412|NCT07063927|PROCEDURE|personalized oral instruction form|The investigators will customize the POIF for participants. The POIF will be conceived to have a cover, and participants extraoral photos and intraoral photos will be covered when not conducting oral hygiene, the cover will ensure participants confidentiality. The personalized oral instruction form will be handed to the independent residents along with a hygiene kit comprising the necessary tools to conduct oral hygiene by the second investigator. For dependent residents, the personalized oral instruction form will be handed to the caregivers along with the personalized oral hygiene kit.
223905413|NCT07064304|PROCEDURE|Laser Deepithelialization of Free Gingival Graft|Extraoral deepithelialization of harvested free gingival graft using Er,Cr:YSGG laser (2780 nm, 2.5 W, 83.3 mJ, 30 Hz, 600 μm tip) before placement in gingival recession treatment.
223905414|NCT07064304|PROCEDURE|Scalpel Deepithelialization of Free Gingival Graft|Extraoral deepithelialization of harvested free gingival graft using a 15c surgical scalpel blade before placement in gingival recession treatment.
223905415|NCT07062484|DRUG|Control: gemcitabine, cisplatin, tirelizumab|PD-1 inhibitors combined with chemotherapy
223905416|NCT07062484|DRUG|Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy|PD-1 inhibitors combined with chemoradiotherapy
223939974|NCT07196150|BEHAVIORAL|Exercise plus Pain Neuroscience Education|Participants will complete the same 8-week supervised exercise program as the Exercise Only group. In addition, they will receive weekly face-to-face pain neuroscience education sessions focused on pain neurophysiology, supported with home assignments to reinforce learning.
223939975|NCT07196449|DRUG|Methotrexate|Methotrexate Tab. 2.5 mg (Korea United Pharm)
223939976|NCT07196449|DRUG|Rifampicin|Rifampin Cap. 150 mg (Yuhan Corporation)
223939977|NCT07196449|DRUG|Cyclosporine|Cypol-N Cap. 100 mg (Chong Kun Dang)
223939978|NCT07196384|DEVICE|Spectroscopy system|System that measures the fluorescence intensity in tissue in vivo.
223905417|NCT07063979|DEVICE|Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient|Use of a wearable device, which emits a low-level electric current across 2 small electrodes on the underside of the patient's wrist, stimulating the nerves and sending a signal to the center of the brain that can help suppress nausea/vomiting. A review of the medical literature found studies that found the device to be effective in reducing PONV. It has been studied in the past, but the trials had limitations, not double blinded and no true placebo. We have proposed a true double blind randomized study utilizing a placebo which specifically mimics the actual device as closely as possible to prevent bias and adversely effecting data results. Nor had this device been tested specifically in the postop bariatric surgical patient.
223905418|NCT07063979|DEVICE|A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.|The company who makes the active device created a sham wearable device that looks like the active, and buzzes (to give the feel of stimulation), but does not actual emit a low-leve electrical signal to stimulate the nerves.
223905419|NCT02551068|OTHER|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
223905420|NCT02551068|OTHER|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
223905421|NCT05494593|DRUG|ELAPRASE|Participants will receive 0.5 milligram per kilogram (mg/kg) of body weight of ELAPRASE, intravenous, infusion for 104 weeks.
223905422|NCT05494593|DRUG|Rituximab|Participants will receive 375 milligram per square meter per dose (mg/m\^2/dose) of intravenous rituximab weekly for 4 weeks in 5-week cycle.
223905423|NCT05494593|DRUG|Methotrexate|Participants will receive 0.4 mg/kg of methotrexate by mouth (PO) 3 times per week for 5 weeks in each cycle.
223905424|NCT05494593|DRUG|Intravenous Immunoglobulin (IVIG)|Participants will receive 500 mg/kg of IVIG every 4 weeks in 5-week cycle.
223905425|NCT03487822|BEHAVIORAL|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
223905426|NCT05671653|DRUG|PF-07081532|Experimental oral GLP-1 drug
223905427|NCT05671653|DRUG|Semaglutide|Approved and marketed GLP-1 drug for subcutaneous injection.
223905428|NCT04074135|DRUG|68-Gallium DOTATATE|68-Gallium DOTATATE, to be used in yearly PET/CT research scans
223905429|NCT03749902|DRUG|Oral misoprostol|"* An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~* The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~* If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~* In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
223905430|NCT03749902|DRUG|Oxytocin|"* Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~* The oxytocin group will not receive misoprostol after the membranes have ruptured."
223905431|NCT05098184|BIOLOGICAL|Tumor Infiltrating Lymphocyte|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
223905432|NCT06189495|DRUG|GenSci048|1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
223905433|NCT06189495|DRUG|GenSci048 placebo|"1\. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4\. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)"
223905434|NCT06059014|DRUG|177Lu-PSMA-1 (radiopharmaceutical)|7.4 GBq (or 5.9 GBq in case of lower actvity) of 177Lu-PSMA-1, every 6 weeks for 4 administirations
223528926|NCT06028412|PROCEDURE|Sublobar|"The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group."
223528927|NCT06028412|PROCEDURE|Lobectomy|lobectomy+system lymph node dissection
223528928|NCT05219318|DRUG|Combination PD-1/PD-L1 ICI + VEGFR-TKI|The study will enroll patients achieving an objective response beween the end of the 11th month and the end of the 13th month of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC)
223528929|NCT05219318|OTHER|Treatment pause|Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression
223905435|NCT03617731|DRUG|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
223905436|NCT03617731|DRUG|Bortezomib|all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
223905437|NCT03617731|DRUG|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
223905438|NCT03617731|DRUG|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
223905439|NCT05376111|DRUG|Venetoclax, Azacitidine|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
223905440|NCT06481319|BEHAVIORAL|Infertility Patient Navigator|Assistance with infertility evaluation including scheduling appointments
223905441|NCT03397654|DRUG|Pembrolizumab|Pembrolizumab solution
223905442|NCT03397654|COMBINATION_PRODUCT|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
223905443|NCT06469788|BEHAVIORAL|Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences|Participants will watch video focused on the importance of receipt of updated COVID-19 vaccination in patients with AIRD
223905444|NCT06469788|BEHAVIORAL|Video on the importance of good oral health for patients with AIRD|Participants will watch video on the importance of good oral health in AIRD patients.
223905445|NCT06469788|BEHAVIORAL|Brochure on COVID-19 vaccination in AIRD patients|Participants
223905446|NCT06469788|BEHAVIORAL|Patient Navigation|Participants will receive phone calls from patient navigators to provide support and information for receipt of updated COVID-19 vaccination in patients with AIRD
223905447|NCT06469788|BEHAVIORAL|Brochure on the importance of good oral health in AIRD patients|Participants will receive a brochure on the importance of good oral health in AIRD patients.
223905448|NCT04846933|GENETIC|WGS and RNA sequencing|
223905449|NCT04846933|GENETIC|circulating tumor DNA (ctDNA)|
223905450|NCT04846933|DIAGNOSTIC_TEST|FDG PET/CT imaging|
223905451|NCT01903330|DRUG|ERC1671|Given intradermally
223905452|NCT01903330|DRUG|GM-CSF|Given intradermally
223905453|NCT01903330|DRUG|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
223905454|NCT01903330|DRUG|Oral Control (Sucrose pill)|Given PO
223905455|NCT01903330|DRUG|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
223905456|NCT01903330|DRUG|Bevacizumab/Bevacizumab Biosimilar|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
223905457|NCT05745727|DRUG|PRX-115|Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
223905458|NCT05745727|DRUG|Placebo|Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
223905459|NCT06466915|DRUG|Dexmedetomidine|Group Dex received 1 mcg/kg of dexmedetomidine intra-nasal 10 minutes before the surgical procedure ended.
223905460|NCT06466915|DRUG|Propofol|Group Pofol received 1 mg/kg propofol IV before the extubation.
223905461|NCT04018053|DRUG|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
223905462|NCT04018053|DEVICE|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
223905463|NCT04283149|DEVICE|EVO/EVO+ Visian ICL|The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
223905464|NCT02859038|PROCEDURE|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
223905465|NCT02859038|PROCEDURE|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
223905466|NCT06260254|RADIATION|Railway noise|Low level railway noise, not exceeding 50 dB LAF,max. Thirty six single railway noise events.
223905467|NCT06260254|RADIATION|Low level railway vibration|36 single railway noise events at 0.5 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
223905468|NCT06260254|RADIATION|Intermediate level railway vibration|36 single railway noise events at 0.7 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
223905469|NCT06260254|RADIATION|High level railway vibration|36 single railway noise events at 0.9 mm/s, varying from 11.5 s to 56.9 s in duration. Vibration always occurs concurrently with the noise exposure.
223905470|NCT05275881|DEVICE|Virtual Reality|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the the RV group, The session will be started before the gesture and the patient will wear the helmet throughout the act. In case of pain and / or restlessness, the child will receive analgesics.
223905471|NCT05275881|DRUG|Usual Practices|In each arm, patients will benefit from an EMLA-type local anesthetic cream, pain and anxiety assessment. During the act, the physiological constants will be recorded (Fr, O2 and pulse). In the control group, the child will receive the usual care: nitrous oxide, anxiolytics, opioid analgesics, psychotropic and benzodiazepine
223905472|NCT03982459|BEHAVIORAL|Decision support tool|Internet-Based, interactive decision support tool
223905473|NCT03780829|BEHAVIORAL|hypoxia|intermittent cycles of normoxia-hypoxia
223905474|NCT03780829|BEHAVIORAL|sham hypoxia|intermittent cycles of sham hypoxia
223905475|NCT03780829|DRUG|D-cycloserine|NMDA agonist treatment
223905476|NCT03780829|DRUG|sham-NMDA agonist|sham-NMDA agonist treatment
223905477|NCT03780829|BEHAVIORAL|exercise training|bimanual massed practice training
223905478|NCT06572150|PROCEDURE|Deep Brain Stimulation - Minimal Electrophysiology|Participants will undergo standard work-up and follow-up for DBS, but with minimal intraoperative electrophysiological testing.
223905479|NCT06572150|PROCEDURE|Deep Brain Stimulation - Standard|Participants underwent DBS surgery with standard intraoperative electrophysiological testing.
223905480|NCT03738852|DEVICE|Continuous Glucose Monitor (CGM)|Continuous Glucose Monitor (CGM)
223905481|NCT03738852|DRUG|Insulin|standard insulin regimen
223905482|NCT06617715|BIOLOGICAL|Sinovac PCV13|One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.
223905483|NCT06617715|BIOLOGICAL|Prevnar®|One dose of Prevnar® (0.5 mL) is administered intramuscularly.
223905484|NCT06821685|BIOLOGICAL|autologous decidual-like NK cells|intrauterine infusion
223905485|NCT06818994|DRUG|Psilocybin-assisted Psychotherapy|The intervention will be psilocybin-assisted psychotherapy. The first treatment period will include four preparation sessions with Managing Cancer and Living Meaningfully (CALM) therapy elements. The psilocybin dosing session will take place after these preparation sessions are completed. The dosing session will include an in-person visit lasting approximately 8 hours in which the participant will receive a capsule of psilocybin 25 mg under constant supervision of therapists. The following day, the first integration session will take place and two weeks later the second integration session along with CALM will be conducted. Participants who show a partial response will be offered a second dosing session, entering the second treatment period. The second treatment period includes a second dosing session using the same dose and safety measures as the first one. It will also be followed by an integration session the following day, and a second integration session with CALM two weeks later.
223905486|NCT04474834|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 300 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40 %).
223905487|NCT05056350|OTHER|Questionnaires|Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
223905488|NCT05056350|OTHER|back to work coaching|Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops
223905489|NCT06778460|DRUG|Esketamine-lidocaine group|In the esketamine-lidocaine group, patients received esketamine (0.25 mg/kg) and lidocaine (1.5 mg/kg) at the induction of anesthesia, followed by the continuous infusion of esketamine (0.02 mg/kg∙h) and lidocaine (1.5 mg/kg∙h) until the end of surgery. Postoperatively, the patients received two pumps. One pump delivered a fixed-rate infusion of lidocaine at 1.0 mg.kg-1.h-1 and esketamine at 0.02 mg.kg-1.h-1 infusion for 72 hours. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
223905490|NCT06778460|OTHER|Placebo group|In the conventional analgesia group, patients received the same volume of normal saline instead of lidocaine and esketamine until the end of surgery. Postoperatively, the paitents received two pumps. One pump was the same volume of normal saline instead of lidocaine and esketamine. Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
223905491|NCT02305888|DRUG|LEO 43204|Treatment of actinic keratosis
223905492|NCT02760030|DRUG|Fulvestrant|Given IM
223905493|NCT02760030|OTHER|Laboratory Biomarker Analysis|Correlative studies
223905494|NCT02760030|DRUG|Palbociclib|Given PO
223905495|NCT02760030|OTHER|Questionnaire Administration|Correlative studies
223905496|NCT02760030|DRUG|Aromatase Inhibitors|Given PO
223905497|NCT02483312|BIOLOGICAL|IL-12|
223905498|NCT06232590|DEVICE|Control Lens (comfilcon A)|Multifocal monthly replacement contact lens for 1 month
223905499|NCT06232590|DEVICE|Test Lens (lehfilcon A)|Multifocal monthly replacement contact lens for 1 month
223905500|NCT05174767|DEVICE|AMDS|AMDS Implantation
223905501|NCT02965014|BEHAVIORAL|Face-to-Face Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
223905502|NCT02965014|BEHAVIORAL|mHealth Young Women's CoOp (YWC)|Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
223905503|NCT02965014|BEHAVIORAL|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing (HCT).
223905504|NCT05272735|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|Hepatitis B Vaccine (Recombinant) 20 mcg intramuscular injection at 0-1-6 months
223905505|NCT06530732|PROCEDURE|Deep Cervical lymphatlc-Venous Anastomosis Surgery|Cervical deep lymphatic-venous anastomosis (dcLVA) can promote the flow of cerebrospinal fluid within the glymphatic system. The procedure involves connecting deep cervical lymphatic vessels to veins, reducing pressure on lymph nodes and allowing lymphatic fluid from high-pressure vessels to flow into the lower-pressure venous system. This surgical intervention enhances the clearance of waste in the glymphatic system, particularly amyloid-beta (Aβ) and tau proteins. By facilitating the removal of these AD-associated proteins from the brain, dcLVA can reduce local tissue fibrosis and cervical nerve compression, potentially reversing degenerative changes, slowing disease progression, and improving the quality of life for AD patients.
223905506|NCT06530732|DRUG|Lecanemab|The newly approved anti-beta-amyloid (Aβ) monoclonal antibody Lecanemab can delay AD progression but is only suitable for patients in the early stages. For those with moderate to severe AD, Lecanemab is not effective.
223905507|NCT04404595|BIOLOGICAL|CT041|treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
223905508|NCT05615415|DRUG|PET Tracer|Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.
223905509|NCT05615415|DRUG|MRI Tracer|Injected via intravenous catheter during PET-MR scanning.
223939979|NCT07196384|DRUG|Nivolumab-800CW|Fluorescent tracer
224277029|NCT05318755|DRUG|GAHT for transgender women|Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
224277030|NCT03519438|OTHER|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
224277031|NCT01218035|DRUG|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
223905510|NCT05615415|DEVICE|3T PET/MRI|Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
223905511|NCT06002919|BEHAVIORAL|MindWalk Intervention|The intervention will include: 1) a mindful walking training followed by 2) a prescribed mindful walking regimen, 3) self-reporting of adherence to regimen by the participants using activity logbooks and use of a user-friendly PA tracker (Fitbit) for daily step count, and 4) personalized text messages with reminders and motivational messages for participants to do the mindful walking as prescribed including a weekly check-in call or text message for accountability.
223905512|NCT06540404|OTHER|Pulse traction|The subjects underwent impulse traction of the knee joint in the second degree according to the Kaltenborn concept.
223905513|NCT06540404|OTHER|Continuous traction|The subjects underwent continuous traction of the knee joint in the third degree according to the Kaltenborn concept.
223905514|NCT06540404|OTHER|Sham therapy|The therapist did not use traction force, the knee joint was kept in a flexed position of 40 degrees.
223905515|NCT05464537|OTHER|Unipolar Polarity Switch Left|10-15 Left veins are randomized to Unipolar Polarity Shift, right veins are randomized to CAI-OPR-LAAP
223905516|NCT05464537|OTHER|Unipolar Polarity Switch Right|10-15 cases randomized to CAI-OPR-LAAP on left veins, and Unipolar Polarity Switch on right veins
223905517|NCT05181020|BEHAVIORAL|Maternal Voice Exposure|Main objective of this study is to determine if it is possible to expose preterm infant in a systematic manner to mother's voices before their feeds and to determine if this exposure results in an increase in their oral intake.
223905518|NCT05977348|BEHAVIORAL|Healthy Eating Curriculum|The Healthy Eating (HE) curriculum is designed to provide children with skills needed to develop healthy eating habits. Each lesson builds upon the overall goal of creating a healthy restaurant. Children are taught to identify differences between GO and WHOA foods, recognize the five food groups, and learn to make healthy food choices.
223905519|NCT05977348|BEHAVIORAL|Improving the Classroom Food and Mealtime Environment|"HBP+ Classrooms will receive additional sensory activities for each lesson (e.g., posters, food models, games) designed to improve the classroom food environment and provide repeated exposure to activities and messages about fruits and vegetables. Teachers in HBP+ classrooms will be provided with additional training on strategies shown to increase food acceptance in preschool children (e.g., modeling, encouraging children to try foods without coercion). In addition, HBP+ classrooms will include tasting charts that children will stamp to indicate their liking for each food each week."
223905520|NCT05977348|BEHAVIORAL|Parent Education|Parents in intervention classrooms will be given access to 8 web-based lessons on food parenting and responsive parenting. Topics include: establishing mealtime routines, shopping healthy on a budget; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; the division of responsibility in feeding, and portion control.
223905521|NCT05977348|BEHAVIORAL|ECE Food Acceptance Training|HBP+ early childhood educators (ECEs) will be asked to complete an online, self-paced course on increasing food acceptance in preschool children. Topics will include: repeated exposure to foods; modeling of healthy eating behaviors; addressing picky eating in children; structuring low-stress mealtime environments; and the division of responsibility in feeding.
223905522|NCT06061471|DRUG|AK111|AK111 regimen 1-subcutaneous injection,until week 24.
223905523|NCT06061471|DRUG|AK111|AK111 regimen 2-subcutaneous injection,until week 24.
223905524|NCT06096272|DEVICE|Augment Reality Exergames|Adaptive physical activity AR gaming modules were created in collaboration with physical therapists with expertise in CP and the Augment Therapy app development team. The program will consists of 5 games adapted for children with cerebral palsy.
223905525|NCT05866627|DRUG|Famotidine|Specified dose on specified days
224277032|NCT00006942|DRUG|bryostatin 1|Given IV
224277033|NCT00006942|DRUG|cisplatin|Given IV
223905526|NCT05866627|DRUG|Afimetoran|Specified dose on specified days
223905527|NCT05778851|DEVICE|EsoGuard result|Education slide-set EsoGuard and patient cases including EsoGuard result
223905528|NCT06274593|DEVICE|OCT|Peripapillary angiography (OCT) at baseline and each year during 3 year
223905529|NCT05582785|DIAGNOSTIC_TEST|Hyperfine MRI|Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
223939980|NCT07196384|DRUG|Durvalumab-680LT|Fluorescent tracer
224277034|NCT00006942|OTHER|laboratory biomarker analysis|Correlative studies
224277035|NCT06277076|PROCEDURE|Computer Implant guided Surgery|Dental implant placed using printed guide after a digital planification on a superimposed 3D surface scan and a 3D Cone Beam imaging of the jaw.
224277036|NCT00411268|DRUG|OROS hydromorphone HCI SR (slow release)|
224277037|NCT04346862|DRUG|Acetyl-L-carnitine hydrochloride 500mg|The participants will receive treatment of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
224277038|NCT04346862|DRUG|Placebo|The participants will receive treatment of placebo of Acetyl-L-carnitine hydrochloride 500mg, orally, 3 times a day for 24weeks
224277039|NCT02180230|DEVICE|Shorty implants|Dental implant insertion to maxilla or mandible
223905530|NCT06185660|DRUG|sodium zirconium cyclosilicate (SZC)|sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
223905531|NCT03220035|OTHER|Laboratory Biomarker Analysis|Correlative studies
223905532|NCT03220035|DRUG|Vemurafenib|Given PO
223905533|NCT05490680|DRUG|Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg|Sildenafil Oral Film containing 25 mg, 50 mg, 75 mg or 100 mg sildenafil as citrate, flexible-dose
223905534|NCT05490680|DRUG|Placebo|Placebo Oral Film
223905535|NCT03639883|DRUG|AIV001|Intradermal injection
223905536|NCT06065215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that uses powerful magnets and radio waves to generate detailed images of the body's internal structures. The MRI intervention includes using a specialized MRI machine and lung imaging protocol.
223905537|NCT06065215|DIAGNOSTIC_TEST|Echocardiogram|"An echocardiogram, often called an echo, is a non-invasive medical test that uses high-frequency sound waves (ultrasound) to create real-time images of the heart's structure and function. It provides valuable information about the heart's size, shape, and function."
223905538|NCT06065215|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound is a non-invasive imaging technique that employs high-frequency sound waves (ultrasound) to visualize the structures and conditions of the lungs. It is particularly valuable for diagnosing and monitoring lung-related conditions, such as pneumonia, pleural effusions, and pulmonary edema. The lung ultrasound intervention involves using an ultrasound machine equipped with a specialized probe gently placed on the chest to capture detailed images of the lungs and adjacent structures.
223905539|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
223905540|NCT03162783|DRUG|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
223905541|NCT03162783|DRUG|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
223905542|NCT03595787|PROCEDURE|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
223905543|NCT03649880|DRUG|¹⁸F-Fluoromisonidazole|Given IV
223905544|NCT03649880|PROCEDURE|Computed Tomography|Undergo PET/CT
223905545|NCT03649880|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI or PET/CT
223905546|NCT03649880|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223905547|NCT03649880|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
223905548|NCT06428786|OTHER|Female Sexual Function Index|As part of the study, data on the socio-demographic characteristics of the individuals is collected by means of personal interviews using a questionnaire. The results of laboratory tests required for the diagnosis of PCOS will be taken from hospital records. The Female Sexual Function Index (FSFI), the Beck Depression Inventory and the KF-36 quality of life assessment form will be completed in person and the total scores will be analyzed taking into account four different PCOS phenotypes.
223905549|NCT06289166|DRUG|STSP-0601 for Injection|A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
223905550|NCT02433379|DEVICE|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
224277040|NCT04153786|OTHER|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
223905551|NCT05624125|OTHER|Beetroot juice|Two 70 ml beetroot juice drinks daily for 4 months.
223905552|NCT05624125|OTHER|Placebo|Two 70 ml placebo drinks daily for 4 months.
223905553|NCT05656261|GENETIC|Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys|On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
223905554|NCT06259305|OTHER|Creation of a memory track combined with the baby's heartbeat|This is as described above
223905555|NCT06227338|DRUG|Indocyanine green|"Indocyanine green dye (Diagnostic Green) will be diluted with sterile water and a specific dose-arm (0.125 mg/kg, 0.25 mg/kg, 05 mg/kg, 1 mg/kg, and 2 mg/kg) will be administrated by slow intravenous injection by peripheral venous catheter:~* at induction anaesthesia of the surgical procedure (0.125 mg/kg or 0.25mg/kg), or~* in the hospital room 24 hours before the breast surgery (05 mg/kg, or 1 mg/kg, or 2 mg/kg)."
223905556|NCT06005428|DRUG|CRD-4730|Oral CRD-4730 in capsule form
223905557|NCT06005428|DRUG|Placebo|Placebo to match CRD-4730 in capsule form
223905558|NCT06552299|OTHER|Laypersons|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
223905559|NCT06552299|OTHER|Health-Care Providers|"1. Participants will be asked to draw a 5cm line.~2. Participants will be asked to press a depth measuring device and resuscitation training manikin to depth of 5cm without and with assistance."
223905560|NCT05739864|BIOLOGICAL|FMT|This intervention is represented by the administration, in the recipients' gut, of super - donor microbiota through FMT
223905561|NCT05739864|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
223905562|NCT03504683|BEHAVIORAL|Early TRE|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
223905563|NCT03504683|BEHAVIORAL|Mid-day TRE|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
223905564|NCT03504683|BEHAVIORAL|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
223905565|NCT05700071|DIAGNOSTIC_TEST|MRI|MRI without contrast agent
223905566|NCT06047509|PROCEDURE|Focal Laser Ablation|Removal of cancerous tissue through the direct application of laser energy
223905567|NCT03022942|OTHER|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
223905568|NCT03022942|OTHER|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
223905569|NCT05330767|DEVICE|DermaClose Continuous External Tissue Expander Device|Constant tension and self-tensioning device. Supplied sterile and for single use only.
223905570|NCT05330767|DEVICE|DermaClose XL Continuous External Tissue Expander Device|Intended for large wounds that are greater than 8 cm in width. Constant tension and self-tensioning device. Supplied sterile and for single use only
223905571|NCT05330767|DEVICE|Conventional wound dressings|Wet-to-dry, gauze, and negative pressure wound therapy.
223905572|NCT06218355|OTHER|Intensive Education|Intervention will consist of virtual education and communication through scheduled push notifications
223905573|NCT06218355|OTHER|Enhanced Virtual Care|"Intervention will utilize a telehealth model consisting of pull approach of patient engagement."
223905574|NCT04496895|DIETARY_SUPPLEMENT|Placebo|consume 1 sachet per day for 2 months
223905575|NCT04496895|DIETARY_SUPPLEMENT|orange peel fermentation|consume 1 sachet per day for 2 months
223905576|NCT00248807|DRUG|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
223905577|NCT00248807|OTHER|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
223905578|NCT04347187|DRUG|Anticoagulants|oral anticoagulants, dual or triple antithrombotic theraphy
223905579|NCT06730295|RADIATION|Online adaptive SBRT|Online adaptive SBRT (without PTV expansion margin). The total dose will be 39-42Gy/3 fractions, administered once daily. FBCT and 4DCT will be acquired.
223905580|NCT05658224|BEHAVIORAL|Education on effects of Exercise-induced hypoalgesia from exercise|Educational session with participants
223905581|NCT06083753|DRUG|PIPE-307 Dose A|Subjects will receive daily oral doses of PIPE-307
223905582|NCT06083753|DRUG|PIPE-307 Dose B|Subjects will receive daily oral doses of PIPE-307
223905583|NCT06083753|DRUG|Placebo|Subjects will receive daily oral matching dose of Placebo
223905584|NCT05407792|DRUG|Staphylococcus and Neisseria Tablets|0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
223905585|NCT05407792|OTHER|On-demand treatment|At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment. For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).
223905586|NCT03288948|OTHER|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
223905587|NCT04158934|BIOLOGICAL|ADYNOVI/ADYNOVATE|Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.
223905588|NCT05070728|DRUG|Sham Injector|Intravitreal sham injection
223905589|NCT05070728|DRUG|FAI Insert|"Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle."
223905590|NCT04562441|DRUG|Axitinib|Axitinib: 5 mg bd po Day 1 to Day 28
223905591|NCT04562441|DRUG|Avelumab|Avelumab: 10 mg/kg Day 1 to Day 15 every 4 weeks
223905592|NCT03374241|BIOLOGICAL|HM15211 or Placebo|Long-acting tri-agonist
223905593|NCT05217615|BEHAVIORAL|ezParent|The ezParent Program is a 6-module web-based adaptation of the group-based Chicago Parent Program (CPP). ezParent uses multiple strategies to promote skill development in parents. Each module includes (a) video narrator descriptions of parenting strategies, (b) video vignettes of parents and children as examples of how parenting strategies work, (c) questions following each vignette for parents to reflect upon, (d) interactive activities for parents to complete, (e) knowledge questions to assess parent understanding of the strategies, and (f) practice assignments. To tailor to the former VPT population, developmental tips are included. Parents are instructed to complete the 6 modules over 10-weeks, approximately 1 module every 1.5 weeks. At the end of each module, parents receive a practice assignment linked to the module content. To encourage and support program completion, parents receive automated text messages and badges.
223905594|NCT05217615|BEHAVIORAL|Coaching calls|The purpose of the brief (\~15 min) telephone coaching calls is to provide parents with clarification of program content, encouragement and reinforcement of program completion, and support tailoring of intervention content (ezParent or Active Control)for their child. Coaching calls are guided by a semi-structured script aimed at supporting parent learning and motivation. Calls will be scheduled every week for 10 weeks. Each call will include an opportunity for parents to identify and discuss:(a) questions regarding the materials and content received in their respective groups,(b) identification of potential barriers and strategies to overcome barriers for completion of intervention (ezParent or control) content in their respective group, and (c)follow up on discussion points from previous calls. In both conditions, coaches will have access to a web-based usage portal to guide the discussion.
223905595|NCT05217615|BEHAVIORAL|Active Control|The active control is an adaptation of a web-based application developed in our previous study (R01-HS024273). The program will include general information typically provided during well-child or NICU follow up visits. Six topic areas are: Immunizations, Common Childhood Illnesses, Nutrition, Dental Health, and Indoor and Outdoor Injury Prevention/Safety. The program includes handouts, websites, and resources provided to parents of children in this age group. Parents will be instructed to review each topic over 10-weeks, approximately 1 topic every 1.5 weeks
223905596|NCT06038162|PROCEDURE|Parallel connection|The RRT machine is connected on a separate vascular access (dialysis catheter).
223905597|NCT06038162|PROCEDURE|Integrated connection|A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
223905598|NCT04681339|OTHER|Antibiotic treatment|Antibiotic treatment
224277041|NCT05491850|OTHER|Moderate Physical Activity for Peripheral Diabetic Neuropathy|Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
224277042|NCT00061464|DRUG|pemetrexed|
223905599|NCT04681339|OTHER|No antibiotic treatment|No antibiotic treatment
223905600|NCT04197310|DRUG|Nivolumab|240mg, intravenously, Day 1 and 15 of a 28 day cycle
223905601|NCT04197310|DRUG|Cabozantinib|40mg, orally, Daily for a 28 day cycle
223905602|NCT02589795|BIOLOGICAL|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
223905603|NCT02589795|BIOLOGICAL|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
223905604|NCT02589795|DEVICE|Trigrid Delivery System - Intramuscular|Electroporation
223905605|NCT02589795|DEVICE|Trigrid Delivery System - Intradermal|Electroporation
223905606|NCT05520268|BEHAVIORAL|Conventional music therapy (CMT)|CMT comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and led by a professional music therapist. For PWDs living in a care home, the CMT sessions are implemented as inpatient rehabilitation held at the care home. For PWDs living at home, the CMT sessions are implemented as outpatient rehabilitation held at a local day activity centre.
223905607|NCT05520268|BEHAVIORAL|Digital music rehabilitation (DMR)|DMR comprises both receptive and expressive musical activities (listening and reminiscing to music, singing, and moving to music) held in small groups (8 PWDs/group) for a duration of 10 weeks (2x60 min sessions/week) and implemented using a novel digital music content service called HILDA. In HILDA, there are a number of stand-alone musical programs hosted by a virtual presenter which the PWDs can follow and through which they can interact. The DMR sessions are moderated by an instructor (care home staff member or research assistant). For PWDs living in a care home, the DMR is implemented as live sessions held at the care home using a HILDA box connected to a TV screen and operated via a remote controller by the instructor. For PWDs living at home, the DMR is implemented as virtual sessions using a video communication platform that allows the instructor to stream and control the HILDA service and the participants to see and hear each other and interact.
223905608|NCT03599661|OTHER|Interview|Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
223905609|NCT03599661|OTHER|Questionnaire Administration|All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
223905610|NCT04972929|OTHER|Spinal Manipulation|Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).
223905611|NCT04972929|OTHER|Sham Spinal Manipulation|Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
224277043|NCT00061464|DRUG|gemcitabine|
224277044|NCT00362687|DRUG|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
224277045|NCT00362687|DRUG|FTC alone|emtricitabine 200 mg
224277046|NCT00362687|PROCEDURE|No HAART|No HAART
224277047|NCT04629170|DRUG|SYNB8802|SYNB8802 is formulated as a nonsterile solution intended for oral administration
224277048|NCT04629170|DRUG|Placebo|In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
224277049|NCT02287636|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
223905612|NCT03746964|PROCEDURE|Cardiac MRI|Preoperative cardiac MRI
223905613|NCT03746964|OTHER|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
223905614|NCT04739839|OTHER|survey questionnaire|Questionnaire focusing on low back pain in relation to life style, physical activity level, illness perception and quality of life.
224277050|NCT02287636|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
224277051|NCT02287636|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
224277052|NCT02287636|PROCEDURE|positron emission tomography|Undergo PET/MRI
223905615|NCT05698290|OTHER|HELP Pain Training Program|A training program to teach school providers nonpharmacologic (e.g., cognitive behavioral and mindfulness meditation) strategies to use with students with pain symptoms.
223905616|NCT06548425|OTHER|Smart Phone Based Cardiac Telerehabilitation|"Smart Phone Based Cardiac Telerehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60 % THR and modified borg scale 9 (very light- 13 (somewhat hard) Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
223905617|NCT06548425|OTHER|Center based cardiac Rehabilitation|"Center based cardiac Rehabilitation~Frequency:3 sessions per week for 8 weeks Intensity: 40-60% THR and modified borg scale 9 (very light- 13 (somewhat hard)~Time: Approx. 30 Min Type: Aerobic \& strength Exercises"
223905618|NCT04942613|BEHAVIORAL|Motivational Interviewing Techniques|Motivational Interviewing Techniques including but not limited to open-ended questions, reflection, affirmations, and summary will be used to build participant rapport, support behavior change (physical activity), and facilitate program engagement.
223905619|NCT04942613|OTHER|Physical Therapy Interventions|strengthening, balance, functional activities, stretching, breathing, aerobic endurance exercise
223905620|NCT04942613|OTHER|Education|Education on general health topics which may include the following: basic nutrition, stress reduction, sleep hygiene
223905621|NCT04942613|OTHER|Qualitative Interview|Qualitative interview to explore patient perspectives of the multicomponent telerehabilitation program (physical therapy, biobehavioral interventions, technology, and social support interventions) and how they contribute to program engagement and participation as well as changes in physical activity.
223905622|NCT06146335|PROCEDURE|Kono-S anastomosis (KSa)|antimesenteric functional end-to-end handsewn anastomosis connecting small intestine and colon after surgery
223905623|NCT06146335|PROCEDURE|Side-to-side anastomosis (SSa)|side-to-side anastomosis connecting small intestine and colon after surgery
223905624|NCT04909801|DRUG|Abatacept|Abatacept SC (125 mg) once weekly
223905625|NCT04909801|DRUG|Adalimumab|Adalimumab SC (40 mg) once every 2 weeks
223905626|NCT04909801|DRUG|Methotrexate|Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
223905627|NCT02570373|DRUG|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
223905628|NCT05235113|DEVICE|Tele-Exergame Platform|Subjects will perform exercises remotely twice a week with tele-exergaming platform.
223905629|NCT05235113|DEVICE|No Tele-Exergame Platform|Subjects will perform exercises in the home exercise twice a week without tele-exergaming platform.
223905630|NCT05060315|COMBINATION_PRODUCT|Remunity Pump for Remodulin|Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
223905631|NCT06364631|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.
223905632|NCT06364631|DRUG|Ipilimumab|"The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion.~When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle."
223905633|NCT06364631|DRUG|Pembrolizumab|Pembrolizumab is to be administered as an approximately 30-minute IV infusion.
223905634|NCT06364631|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
223905635|NCT06364631|DRUG|Axitinib|Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.
223905636|NCT06364631|DRUG|Lenvatinib|Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.
223905637|NCT06525571|DRUG|Cysview|Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.
223905638|NCT06525571|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
223905639|NCT05297773|BEHAVIORAL|Aerobic Training Group|The participants will perform continuous cycling at 30%-35% of their heart rate reserve for one month (phase 1: adaptive phase). Then, the intensity will increase every 4-5 weeks (± 5%) up to 80% of heart rate reserve (moderate intensity), depending on the participant's tolerance. An individualized equation establishing the relationship between heart rate, oxygen consumption, and power output will be determined during the cardiorespiratory fitness assessment and used to determine exercise intensity.
223905640|NCT05297773|BEHAVIORAL|Resistance Training Group|Initially, and during the first two weeks of the adaptive phase (1-month), the resistance training group will perform one set of 8-12 repetitions (40%-repetition maximum) of 8 exercises for upper and lower body (squat, leg extension, leg curl, deadlift, plank, dead bug, seated row, shoulder press). Then, in the last two weeks, the participants will perform 2 sets of each exercise (45%-repetition maximum). After the adaptive phase, three sets of each exercise will be performed. The initial load will be 50% -repetition maximum increasing up to a maximum of 70%-repetition maximum at the end of the study. Every 4-5 weeks the load will be reviewed and adjusted according to individual.
223905641|NCT05297773|OTHER|Control group|The control group will perform a weekly stretching/relaxation session for 45 minutes.
223905642|NCT03369223|BIOLOGICAL|BMS-986249|Specified dose on specified days
223905643|NCT03369223|BIOLOGICAL|Nivolumab|Specified dose on specified days
223905644|NCT03369223|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223905645|NCT04872543|DRUG|ASTX727|ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
223905646|NCT06534385|DEVICE|Air purifier|Winix HEPA air purifier
223905647|NCT05574114|RADIATION|Bridging radiotherapy (BRT)|RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).
223905648|NCT05574114|DRUG|Conditioning chemotherapy|Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
223905649|NCT05574114|BIOLOGICAL|CAR T-cell product|Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.
223905650|NCT03725384|DRUG|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
223905651|NCT03725384|DRUG|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
223905652|NCT04550221|BEHAVIORAL|Shauriana|The components of this intervention are: four weekly in-person sessions with a trained peer intervention specialist; optional additional in-person or by phone check-ins after the in-person sessions are delivered; and optional monthly group sessions. The four in-person health education and coaching sessions will be delivered once per week, by trained peer facilitators who identify as GBMSM. These sessions will focus on the following topics: sexual health basics (understanding how HIV and STIs are transmitted, prevented, and diagnosed/treated), relationships (types of relationships we have, characteristics of healthy relationships, communication skills), stress and coping (understanding mental health challenges, adaptive and maladaptive coping strategies), and healthy sexuality and empowerment (understanding sexual orientation and gender identity, challenging stereotypes about GBMSM, making sexual choices).
223905653|NCT06402669|OTHER|Packed Red Blood Cell Administration|Difference in occurrence of mortality in patients transferred versus directly admitted who have packed red blood cell administration in the first four hours of arrival to the hospital.
223905654|NCT04934527|DRUG|Cytotect|"The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12."
223905655|NCT05347745|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.
223905656|NCT04811040|DRUG|Oral Lenacapavir|Tablets administered without regard to food
223905657|NCT04811040|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
223905658|NCT04811040|DRUG|Teropavimab|Administered intravenously
223905659|NCT04811040|DRUG|Zinlirvimab|Administered intravenously
223905660|NCT05274074|BEHAVIORAL|Social LEAF|Social LEAF is an adaptation of the Life Enhancing Activities for Family Caregivers program to focus on social relationships and loneliness. Social LEAF is a six-session group program provided by video-conference that teaches caregivers coping skills to improve social relationships and social connection. Social LEAF is delivered in groups of up to 10 caregivers via videoconference and will consist of six weekly hour-long discussion-based classes to teach positive coping skills around improving social relationships. Each week will focus on a skill from the original LEAF study adapted to the group and social context.
223905661|NCT03670524|OTHER|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
223905662|NCT06530277|BEHAVIORAL|REMINDer (A digital environmental enrichment intervention)|"REMINDer adapts the REMIND program (Nicotra et al., 2022) for telehealth, integrating cognitive, motor, sensory, emotional, and social stimulation through music, dance-based movement, and mindfulness. The program consists of 2 online sessions/week for 60 minutes each over 6 weeks, led by trained facilitators experienced in dance movement therapy and mindfulness exercises. Sessions are divided into welcome/warm-up (10 min), training (40 min), and relaxation/feedback (10 min) phases. Using a structured manual, participants perform exercises that address the program's multimodal stimulation. The REMINDer program is delivered in a group setting via an online videoconferencing system. The intervention, no intervention (AB) group undergoes the training program between t1 and t2 and then resumes their normal lifestyle from t2 to t3. The no intervention, intervention group (BA) maintains its normal lifestyle from t1 to t2 and then participates in the training program from t2 to t3."
223905663|NCT06252597|BEHAVIORAL|education and training|education and training at a regularly scheduled occupational therapy clinic visit will be performed with handouts, verbal education, hands-on training, and video training
223905664|NCT06106607|BEHAVIORAL|Intervention group|"A 20-week intervention with a basic part, including~1. A group session with education about IBD,physical activity and exercise in relation to IBD (definitions, evidence and recommendations). Furthermore, access to a video with general information about IBD, physical activity and exercise~2. Four individual motivational counselling sessions (two physical, two by telephone) with a project nurse. These will involve identifying individual motivation and opportunities for increasing physical activity and behavioral goal setting.~An optional intervention part will follow, including choises between (or all of)~1. A one-hour individual session with a physiotherapist, involving guidance in physical activity and exercise tailored to the individual.~2. Being teamed up with 1-2 'exercise buddies' (other participants from the overall intervention group).~3. Access to 4 short 2-3 minutes videos/'reels' of a physiotherapist explaining and demonstrating beneficial physical exercises."
223905665|NCT03344848|DEVICE|Orion Visual Cortical Prosthesis System|The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
224277053|NCT02287636|PROCEDURE|magnetic resonance imaging|Undergo PET/MRI
223715770|NCT03667261|DEVICE|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
223715771|NCT03667261|DEVICE|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
224277054|NCT00345033|DRUG|Aripiprazole|15-mg dose once a day for 8 weeks
224277055|NCT00345033|DRUG|Placebo|1 tablet placebo dose once a day for 8 weeks
224277056|NCT01828437|DRUG|Pyridoxine plus prednisolone|
223715772|NCT04244331|DIAGNOSTIC_TEST|CCO|Determination of COO in tumor biopsies from patients with GBDD using the Lymph2Cx assay using NanoString tectology
223905666|NCT05706857|BEHAVIORAL|Ultra Fast-track|Patients are extubated in the operating room
223905667|NCT03501576|BIOLOGICAL|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
223905668|NCT05702749|PROCEDURE|Microsurgical resection of VS|Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
223905669|NCT05702749|RADIATION|Stereotactic radiosurgery|Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
223905670|NCT05702749|OTHER|PREHAB|A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
223905671|NCT06044922|DEVICE|24-hour Holter monitoring|Holter monitor is fitted within 2h of ICU admission to acquire a 24-hour electrocardiogram recording
223905672|NCT04101487|OTHER|Cash Transfer|Monthly cash transfers
223905673|NCT04101487|OTHER|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
223905674|NCT06398106|DRUG|Proactive TDM-based dosing of secukinumab|"Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
223905675|NCT06398106|DRUG|Proactive TDM-based dosing of ixekizumab|"Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week"
223905676|NCT06398106|DRUG|Proactive TDM-based dosing of guselkumab|"Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week"
223905677|NCT05562622|DEVICE|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
223905678|NCT05562622|DEVICE|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
223905679|NCT04769310|DEVICE|Cardiac and Brain MRI|"A CMR to evaluate for LA and LAA high-risk features on either a 1.5 or 3 Tesla clinical MR scanner will be used. Gadolinium injection will be administered. Gadolinium is a contrast product that helps define areas of fibrosis in the LA.~High-resolution brain MRI with no contrast will include the following sequences for most accurate assessment of embolic lesions: 3D T1 MPRAGE, 3D FLAIR, DWI, ADC, and SWI"
223905680|NCT06565052|BEHAVIORAL|Prehabilitation Program|A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed.
223905681|NCT05884073|BEHAVIORAL|Circuit-based Resistance Training|Participants will engage in a 12-week circuit-based resistance training program 2-3 times/week. Each supervised session will last about 30 minutes and will consist of 5 resistance exercises. Each exercise will be completed for 1 minute for a total of 5 minutes followed by a 1-minute rest. The circuit will then repeated 3 additional times (total of 4 circuits). All resistance sessions will be supervised by a certified fitness professionals.
223905682|NCT05884073|BEHAVIORAL|Nature-based Walking|Participants will be asked to engage in 30 minutes of self-paced walking in nature 2-3 days/week. Participants will be provided with a list of resources that direct them to walkable nature/green spaces close to their home or workplace.
223905683|NCT03928093|DRUG|Pregabalin|Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
223905684|NCT06851455|OTHER|Cadaveric Workshop on Ultrasound-guided Injections|"Participant physicians will attend a structured cadaveric workshop on ultrasound-guided musculoskeletal injections.~Participants will perform hands-on procedures under expert supervision on lower extremity joints listed as hip, knee and ankle.~For the assessment participants will be asked to complete pre- and post-workshop assessments to measure skill improvement and confidence levels."
223905685|NCT04113603|DIAGNOSTIC_TEST|Urinary malignancy|Single bolus three phase CTU
223905686|NCT04192136|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
223905687|NCT04192136|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule).
223939981|NCT07196956|DEVICE|Low-Frequency Electromagnetic Field Therapy (0.5 Hz)|Active electromagnetic field therapy delivered via a PMT Quattro PRO device (Italy, 2002). Settings: 0.5 Hz frequency, 30 mA intensity, applied for 20 minutes per session to the spinal lesion level (T6-T12) while patient is prone. Followed by 10-minute rest. Administered three times per week for 2 months, in conjunction with a standardized 45-minute physical therapy program (stretching, strengthening, balance, and gait training).
224277057|NCT01828437|DRUG|Prednisolone|
223905688|NCT04192136|OTHER|Exercise Intervention|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands.~On aerobic training days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.~On resistance training days, subjects will be given instructions to complete circuits of resistance exercises. Resistance training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."
223905689|NCT06853002|OTHER|Breathing exercise with spirometry|Breathing exercise with spirometry
223905690|NCT06853002|OTHER|Breathing exercise with deep breathing method|Breathing exercise with deep breathing method
223905691|NCT06848621|DEVICE|40Hz light modulation glasses|A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
223905692|NCT06848621|DEVICE|100Hz light modulation glasses|A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
223905693|NCT06852521|OTHER|Stimulus Properties: Target Location|The location of the target item in the display will be varied across trials (appear left, right, up, or down)
223905694|NCT06852521|OTHER|Stimulus Properties: Distractor Presence|A proportion of all trials will contain a task-irrelevant, singleton distractor defined in a non-target dimension (e.g., color target and motion distractor)
223905695|NCT06852521|OTHER|Stimulus properties: Cue Validity|Varied across trials, the validity of the cue will be determined by the match or mismatch between direction of the visual cue (an arrowhead around the fixation pointing to the right, left, up, or down) and actual target location
223905696|NCT05367102|BEHAVIORAL|Supporting Healthy Relationships program|"The investigator will provide the following 4 activities: 1) marriage and relationship education \[using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)"
223905697|NCT06668623|OTHER|Reiki Group|Remote Reiki application will be performed once a day for 20 minutes for four days by a researcher who has received second level training. No changes will be made to the standard treatment plan of the patients during the application.
223905698|NCT06668623|OTHER|Sham Reiki Group|In the placebo group, the Sham Reiki group will receive remote Reiki application in accordance with the application protocol by a nurse who is not a Reiki practitioner trained by the researcher and has not received any previous training.
223905699|NCT05184738|OTHER|Experimental Treatment, Oligomeric nutritional formula|Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).
223905700|NCT05184738|OTHER|Control Treatment|Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).
223905701|NCT06851715|OTHER|Clinic consultation focused on asthma self-management|The clinic healthcare professionals (HCPs) will be provided with the completed Adolescent Asthma Self-efficacy Questionnaire (AASEQ), which will help identify areas where participants need additional support to improve their asthma self-management skills. Targeted behavioural interventions, developed during the 'ItsMyAsthma' study, will be applied during the clinic consultation to address individual needs.
223905702|NCT06712290|DRUG|celgene|"CTM Boost (CTM Biomedical, Miami, FL) is a decellularized Human Cellular and Tissue Based Allograft (HCT/P) derived from placental connective tissue. It is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is regulated as a minimally-manipulated biologic by the FDA and is marketed as an allograft for homologous use to supplement or replace damaged or inadequate connective tissue. It is administered applied into the tissue via injection.~Participant will undergo a single injection of 2.0cc of the injectable CTM allograft, administered using a 20G needle in the subacromial space. 3mL of ropivacaine will be mixed into the syringe prior to administration of the injection. Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used."
223905703|NCT06712290|DRUG|Corticosteroid|Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or intra-articular (into the joints) use. It may be used to treat many different types of inflammatory conditions. In this study, a 2.0cc dose injection of Kenalog-40 will be administered directly into the subacromial space using a 20G needle. 3mL of ropivacaine will be injected along with the steroid (as part of the same injection). Posttreatment pain control (hydrocodone/acetaminophen #20 5/500 mg) will be used.
223905704|NCT06827743|BEHAVIORAL|feeding behavior education|Two groups will receive personalized sensory integration training, and one group will receive feeding behavior training. Both the caregiver and the child will take part in feeding behavior training. In order for the training to be successful, the therapist, child, and parent cooperation is necessary. Before this training, the children will be evaluated with the Behavioral Pediatric Feeding Assessment Scale and a behavioral training plan will be created according to the children's attitudes and behaviors during feeding. This plan will include organizing feeding times, determining the family's approach to the child's behaviors during feeding, regulating the children's feeding behavior problems with extinguishing and desensitization methods, and organizing the feeding environment, and creating a personalized training plan.
223905705|NCT06827743|BEHAVIORAL|Sensory integration intervention|The sensory integration training given to both groups includes training that includes oral processing skills in particular, as well as training that includes tactile, vestibular, proprioception, and visual stimuli as needed. Children will be supported with sensory stimuli in order to ensure that the child focuses and remains calm. Sensory integration training will be planned by taking into account the Dunn Sensory Profile test results. In this training, different patterned fabrics, plushes, and toys with different surfaces for tactile stimulation will be provided to maintain the child's calmness and focus; swings and exercise balls for vestibular stimulation; and training to provide sensory regulation with proprioceptive approaches. In addition, within the scope of sensory integration training, stimuli will be provided in the oral region according to the children's sensory responses to the texture, taste, and content of foods.
223905706|NCT06342102|PROCEDURE|PENG + LFCN block|The PENG block was performed under ultrasound guidance. After skin disinfection, the needle was advanced between the psoas tendon and pubic ramus where 20 mL of 0.5% ropivacaine were injected. The LFCN block was performed following the PENG block.10 ml of 0.5% ropivacaine were injected near the nerve into the fat-filled flat tunnel (FFFT) located at the level of the superior anterior iliac spine and lateral to the sartorius muscle.
223905707|NCT06342102|PROCEDURE|FIC block|FICB was performed under ultrasound guidance. The needle was advanced above the fascia iliaca and 20 mL of 0.5% ropivacaine were injected
223905708|NCT04075526|DRUG|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
223905709|NCT04075526|DRUG|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
223905710|NCT04075526|OTHER|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
223905711|NCT05452564|DRUG|Baricitinib 2 MG Oral Tablet|Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
223905712|NCT05452564|DRUG|Placebo|Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
223905713|NCT04730583|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion
223905714|NCT04730583|DEVICE|1064nm laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
223905715|NCT04730583|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
223905716|NCT06850909|DEVICE|Microdrop GPS dish|The µDrop GPS® micro-wells dish is specifically designed for oocyte and embryo handling and culture. The sloped concave micro-well bottoms of the µDrop GPS® dish allow oocytes and embryos to settle at a central location away from the well walls. The concave nature of the wells provides the thinnest well bottom possible, helping to reduce refraction and allow for optimal visualization. The wells may reduce droplet collapsing/mixing, offer better orientation/optics, and reduce set-up/observation time.
223905717|NCT06850909|DEVICE|16 well BIRR dish|The 16-Well BIRR Dish is a high-quality 3D culture dish designed for optimal embryo handling and identification in IVF. It features well-numbering (1-16) for clear tracking, a large labeling area, and an expanded working space for better accessibility. Its 16 wells allow for increased wash drops and single embryo culture, reducing the number of dishes needed per IVF cycle. Rigorously tested (MEA+, LAL, and SMA per lot), it ensures safe and efficient embryo culture.
223905718|NCT06851078|DRUG|Levetiracetam IV|1000 mg twice a day during 7 days maximum
223905719|NCT06851078|OTHER|Placebo control|NaCl 0.9% sodium chloride in the same route and method of administration as experimental treatment
223715773|NCT01801891|DEVICE|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
223715774|NCT01801891|OTHER|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
223715775|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.
223905720|NCT06851728|DEVICE|MARPE|treating patients with transverse maxillary deficiency using minis crews supported hybrid hyrax
223905721|NCT04116671|DEVICE|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
223905722|NCT02317887|BIOLOGICAL|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
223905723|NCT06758856|DIETARY_SUPPLEMENT|Trimethylglycine|Betaine anhydrous from sugar beets
223905724|NCT06758856|OTHER|Eggs|3 whole eggs
223905725|NCT06758856|DIETARY_SUPPLEMENT|Cellulose|Cellulose
223905726|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
223905727|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
223905728|NCT03172975|BIOLOGICAL|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
223905729|NCT03172975|BIOLOGICAL|Placebo|Physiological sterile saline solution
223905730|NCT03172975|DRUG|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
223905731|NCT03172975|OTHER|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
223905732|NCT06828393|DRUG|S-1117|S-1117 via subcutaneous or intravenous administration.
223905733|NCT06828393|OTHER|Placebo|Placebo via subcutaneous or intravenous administration.
223905734|NCT05523206|OTHER|No intervention|No intervention
223905735|NCT04263181|PROCEDURE|Peripheral blood draw|"* All cohorts will have peripheral blood drawn at baseline no more than 4 days prior to the first dose of chemotherapy and must also occur before the first dose of chemotherapy~* Cohort 0 or 1 - peripheral blood draw on Day 2~* Cohorts 0, 2, 3, 4 and 5 - peripheral blood draw on Day 3~* Cohort 0 or 1 - peripheral blood draw on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - peripheral blood draw on Cycles 2 or 3 and 4 or 5, Day 28"
223905736|NCT04263181|PROCEDURE|Bone marrow aspirate|"* Cohort 0 or 1 - bone marrow aspirate on Day 14~* Cohort 0 or 1 - bone marrow aspirate on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - bone marrow aspirate on Cycles 2 or 3 and 4 or 5, Day 28"
223905737|NCT04263181|PROCEDURE|Buccal swab|"* Cohort 0 or 1 - buccal swab on Day 35 (at count recovery)~* Cohorts 0, 2, 3, 4, and 5 - buccal swab on Cycle 2 or 3 and 4 or 5, Day 28"
223905738|NCT03626597|DIAGNOSTIC_TEST|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
223905739|NCT03626597|BEHAVIORAL|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling \& referral to care
223905740|NCT03626597|BEHAVIORAL|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling \& referral to care
223905741|NCT06451341|BEHAVIORAL|Acceptability of Intervention Measure (AIM)|"The Acceptability of Intervention Measure (AIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The AIM will measure the extent to which participants believe CAB+RPV LA implementation is acceptable."
223905742|NCT06451341|BEHAVIORAL|Intervention Appropriateness Measure (IAM)|"The Intervention Appropriateness Measure (IAM) questionnaire will be administered at Baseline to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The IAM will measure the extent to which participants believe CAB+RPV LA implementation is appropriate."
223905743|NCT06451341|BEHAVIORAL|Feasibility of Intervention Measure (FIM)|"The Feasibility of Intervention Measure (FIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The FIM will measure the extent to which participants believe CAB+RPV LA implementation is feasible."
223905744|NCT06451341|BEHAVIORAL|HIV Stigma Scale Questionnaire|"The HIV Stigma Scale Questionnaire used in this study is a shortened version of the validated 40-item HIV stigma scale. This 12-item questionnaire measures the same four stigma subscales measured in the original version, for a streamlined approach to collecting this data on personalized stigma, disclosure concerns, concerns with public attitudes and negative self-image.~This will be administered at Baseline, Month 7 and Month 15."
223905745|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The status version will be administered at Baseline, Month 7 and Month 15."
223905746|NCT06451341|BEHAVIORAL|HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)|"The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The change version will be administered at Month 15."
223905747|NCT06451341|BEHAVIORAL|Needs and Barriers Assessment|"The Needs and Barriers Assessment is a questionnaire designed to assess patient participant barriers and social determinants of health, emotional challenges related to antiretroviral therapy, and the impact of switching to CAB+RPV LA treatment.~This will be administered at Baseline, Month 7 and Month 15."
223905748|NCT06451341|BEHAVIORAL|Pre-visit Outreach|Patient participants will be contacted prior to each clinical injection visit for an appointment reminder and a needs assessment.
223905749|NCT06451341|BEHAVIORAL|Qualitative interview|Qualitative interviews will be conducted within thirty days after study completion at Month 15 to further evaluate the participant's experience with the implementation of CAB+RPV LA treatment.
223905750|NCT06451341|BEHAVIORAL|Staff education|Staff participants will participate in Extension for Community Healthcare Outcomes (Project ECHO) educational sessions with topics such as fundamentals of HIV treatment and care, HIV outcomes, delivery of antiretroviral therapies (ART) including long-acting ART, cultural sensitivity, and social determinants of health in rural areas.
223905751|NCT06844006|COMBINATION_PRODUCT|Nudging|Clinicians will be nudged with a prompt, based on remote monitoring data, current medication data, contraindications, in the electronic patient dossier whether further optimization to guideline directed medical therapy (GDMT) is possible.
223905752|NCT06848179|DIAGNOSTIC_TEST|Computer algorithms|Collection of computer algorithms called ausculto® that is designed to perform heart sound analysis to estimate heart rate and heart rate variability
223715776|NCT06372223|DRUG|SPH5030|SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.
223715777|NCT02671396|BEHAVIORAL|Virtual reality based intervention|Virtual reality based balance training
223715778|NCT02671396|BEHAVIORAL|Conventional intervention|Conventional balance training
223715779|NCT04235478|DRUG|Combination Product: triamcinolone and saline|a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
223905753|NCT06848179|BEHAVIORAL|Exercise|Participants will be requested to exercise to raise their HR over the resting range while heart-related physiological signals are collected.
223905754|NCT06841939|OTHER|castor oil|Participants recruited into this group had vaginal examinations conducted and it was confirmed that they were not in labour, Bishop's score was then documented. They were counselled to take 30 ml of castor oil under direct observation by the researcher and the time and date of administration documented. The participants' phone numbers and addresses were also recorded. Participants who fail to achieve labour within 24 hours had a repeat dose of 30 ml of castor oil.
223905755|NCT06841939|OTHER|Water|Participants recruited into this group had vaginal examinations conducted and it was confirmed that they were not in labour, Bishop's score was then documented. They were counselled to take 30 ml of water under direct observation by the researcher and the time and date of administration documented. The participants' phone numbers and addresses were also recorded. Participants who fail to achieve labour within 24 hours had a repeat dose of 30 ml of water.
223905756|NCT06848725|BEHAVIORAL|Data quality development toolkit concerning the medical quality indicators (MQI)|"The toolkit uses a train-the-trainer strategy.~The research team will:~* develop training and support materials for external training providers and delegated staff (champions) from the long-term care facilities~* prepare external training providers within a one 3h session to train champions from the long-term care facilities~* organize an e-mail contact centre for MQI related questions for the participating facilities.~The external training providers will:~\- train the champions in one full day (8h) in-person training session and in 2 online sessions a 4h and 2h to support their co-workers to collect reliable MQI data.~Based on the received training, the champions will:~* provide internal trainings to the care and nursing team,~* perform data quality monitoring,~* provide feedback on data quality and act as a contact person for questions on MQI in their facility."
223905757|NCT06852131|PROCEDURE|open carpal tunnel surgery|open carpal tunnel surgery
223905758|NCT06852131|PROCEDURE|Steroid Injection|triamsinolon injection
223905759|NCT06852131|PROCEDURE|PRP injection|PRP injection
223905760|NCT06851260|PROCEDURE|Fine-dissection of the thymus|In thyroid surgery, precise dissection and preservation of thymus tissue are used to improve the protection of the lower parathyroid gland function and increase the curative effect of the surgery.
223905761|NCT06852482|OTHER|SBE Capacitation (behavioral intervention) for facilitator population|"An intervention is proposed with two training sessions for the tutors of the Pràcticum I, III, and IV courses in the Physiotherapy Degree. The first session will be on January 10, 2024 (3 hours), and the second on February 2, 2024 (2 hours), both at the FCSB facilities of UVic-UCC.~The sessions aim to:~Promote behavior that facilitates learning in Simulation-Based Education (SBE). Provide facilitators with tools and strategies for effective SBE implementation.~Highlight the differences and similarities in SBE across the Pràcticum I, III, and IV courses, based on increasing difficulty.~Training will involve clinical simulation principles, with facilitators experiencing all SBE phases. An actress, later participating in student simulations, will be involved. Scenarios from the courses will be used, supported by a PowerPoint presentation and an information dossier for participants."
223905762|NCT06852482|OTHER|SBE (behavioral intervention) for student population|"Simulation-Based Education Each student in Pràcticum I, III, and V will participate in a simulation session tailored to their course.~Simulations are conducted in groups of five students with the same UVic tutor acting as facilitator. Each simulation follows three phases (prebriefing, simulation, debriefing), with varying emphasis across courses:~Pràcticum I: The prebriefing ensures group confidence. Two volunteer students participate in the simulation. The debriefing is shorter, less focused on outcomes, and highlights learning over errors. Emphasizes guidance for student.~Pràcticum III: Prebriefing and debriefing are equally emphasized. One volunteer student performs the simulation.~Pràcticum V: Cases are more complex, requiring less prebriefing but comprehensive briefing. Students autonomously set session rules. The debriefing is in-depth and focuses on clinical application. One volunteer student performs the simulation, Focuses on autonomy and independent work."
223905763|NCT02043691|DEVICE|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
223905764|NCT02043691|DEVICE|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
223905765|NCT02043691|DEVICE|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
223905766|NCT06852794|OTHER|Survey|The patients will receive questionnaires. The enrolled patients will be asked to provide feedback on the answers they read.
223905767|NCT05174572|PROCEDURE|IMR|Patients undergoing coronary sinus reducer implantation (Reducer) undergo evaluation of the index of microcirculatory resistance (IMR) at the time of implantation, and at 4 months follow-up.
223905768|NCT06052046|DEVICE|TOTAL30 for Astigmatism Contact Lenses|Participants will be refit into TOTAL30 for Astigmatism Contact Lenses and followed for 1 month.
223905769|NCT03851796|BEHAVIORAL|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
223905770|NCT03851796|BEHAVIORAL|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
223905771|NCT04470778|DRUG|BMS-986256|Specified dose on specified days
223905772|NCT04470778|DRUG|Famotidine|Specified dose on specified days
223905773|NCT04470011|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
223715780|NCT03000439|DRUG|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
223905774|NCT04470011|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
223905775|NCT03792919|DRUG|Stop current treatment (anti-HBV neucleos(t)ides)|Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
223905776|NCT03792919|DRUG|Keep current treatment (anti-HBV neucleos(t)ides)|Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
223905777|NCT02677064|OTHER|assessments|All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
223905778|NCT05576077|BIOLOGICAL|TBio-4101|TBio-4101 is an autologous selected and expanded tumor infiltrating lymphocyte (TIL) product generated following ex vivo expansion of tumor reactive TIL population found in tumor harvest. After preparation with non-myeloablative lymphodepletion chemotherapy (cyclophosphamide and fludarabine) followed by low dose radiation,TBio-4101, and IL-2.
223905779|NCT05576077|DRUG|Pembrolizumab|Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
223905780|NCT04362254|DRUG|Spesolimab|Spesolimab
223905781|NCT04568434|DRUG|Olezarsen|Olezarsen was administered by SC injection.
223905782|NCT04568434|DRUG|Placebo|Olezarsen-matching placebo was administered by SC injection.
223905783|NCT05101161|BEHAVIORAL|Neurofeedback|Modulating brain oscillations based on visual neurofeedback
223905784|NCT05469464|DRUG|Orismilast modified release tablets|"Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~* UNI50001~* LEO32731"
223905785|NCT05469464|DRUG|Placebo|Placebo matching tablets
223905786|NCT01542580|DEVICE|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
223905787|NCT01542580|DEVICE|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
223905788|NCT01542580|DEVICE|Vanguard DA 360|Dual-articulation device, only cleared in EU
223905789|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PS bearing|non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
223905790|NCT01542580|DEVICE|Vanguard 360 TiNbN Femur with PSC bearing|constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
223905791|NCT03774758|DIAGNOSTIC_TEST|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
223905792|NCT06044831|BEHAVIORAL|Expanded Population Health Model|This intervention includes the current population health model in addition to expanded programming from a local community organization. The current population health model with Baylor Scott \& White Health and Wellness Center includes access to primary care, general wellness programs such as cooking classes and nutritional counseling, and evidence-based disease management and prevention. The additional programs from a local community organization focus on human essentials integral to improving health and quality of life and include: health and wellness, economic stability, safe and affordable housing, transportation, a sense of belonging, education, and access to fair credit.
223905793|NCT06058936|OTHER|exercises using virtual reality technology|this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
223905794|NCT05618574|DIETARY_SUPPLEMENT|140 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)|The investigators propose to study the benefits nitrite therapeutics, using nitrate-rich beetroot juice to increase serum nitrite. The investigators hypothesize that increased nitrite will improve functional metrics and reduce fatigability in Veterans with long COVID as a result of enhanced skeletal muscle mitochondrial respiration. Participant will receive 140 ml per day of Beet-It nitrate beverage for 16 mmol of nitrate/day for 14 days vs the placebo.
223905795|NCT05618574|DIETARY_SUPPLEMENT|210 ml of nitrate-depleted placebo|Participants randomized to the placebo arm will receive 210 ml of nitrate-depleted beverage (cranberry juice) per day for 14 days.
223905796|NCT05236660|DEVICE|Custom-made shoes: pressure-optimized|Pressure-optimized custom-made shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months.
223905797|NCT05236660|DEVICE|Custom-made indoor shoes: pressure optimized|Pressure-optimized custom-made indoor shoes: evaluated and optimized using in-shoe pressure analysis, and re-evaluated after 6 months. Specifically designed for indoor use.
223905798|NCT05236660|DEVICE|Foot temperature monitoring|Personalised at-home daily foot temperature monitoring at high-risk regions.
223905799|NCT05236660|BEHAVIORAL|Education|Personalised patient education consisting of quantitative feedback on in-shoe pressures, temperature measurements and footwear use and, in addition, motivational interviewing where indicated and needed to improve device use.
223905800|NCT05537948|DRUG|Pitavastatin|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of Pitavastatin: Pitavastatin at visit 0 will be prescribed at a dose of 2 mg, after 1 month in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg.~The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with pitavastatin, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). There will be visits on the 7th, 9th and 12th months."
223939982|NCT07196956|DEVICE|Placebo Electromagnetic Field Therapy|identical-appearing electromagnetic therapy device with no active field output (placebo/sham). Applied for 20 minutes per session to the spinal lesion level (T6-T12) while patient is prone. Followed by 10-minute rest. Administered three times per week for 2 months, in conjunction with the identical standardized 45-minute physical therapy program (stretching, strengthening, balance, and gait training) as the active EMT group.
223905801|NCT05537948|DRUG|PCSK9 inhibitor|"First phase (6 months):~Patients will be randomized 1:1 into 2 groups:~1. pitavastatin monotherapy~2. monotherapy with a PCSK9 inhibitor (evolocumab 140 mg or alirocumab 150 mg once every 2 weeks subcutaneously)~In the group of PCSK9 inhibitors:The lipid profile and safety of the therapy will be assessed in 1, 3 and 6 months after the start of the therapy.~When triglyceride levels rise above 5.7 mmol/l in two consecutive analyzes, the addition of fenofibrate may be considered.~Second phase (6 months):~If the target level of LDL-C is not achieved during monotherapy with a PCSK9 inhibitor, the patient will be asked to continue treatment with combined lipid-lowering therapy (pitavastatin + PCSK9 inhibitor). Pitavastatin will initially be prescribed at a dose of 2 mg, after 1 month. in the absence of side effects against the background of ongoing therapy, the dose will be increased to 4 mg. There will be visits on the 7th, 9th and 12th months."
223905802|NCT04662190|DEVICE|3D printing model/guide.|Orbital decompression surgery will be previously planned and simulated using 3D-printed individualized models. In the operating room, surgery will be assisted with 3D-printed individualized guides.
223905803|NCT04662190|PROCEDURE|Standard surgery|Orbital decompression surgery will be previously planned and simulated using the actual standard methods.
223905804|NCT05020678|BIOLOGICAL|NKX019|NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.
223905805|NCT05907434|DIAGNOSTIC_TEST|Nephrocheck (AKI score)|Early biomarker of AKI
223905806|NCT04533763|BEHAVIORAL|Technology-based Mindful Living program|The program is delivered using web-based group conferencing. During each session, participants are taught new stress management and coping techniques. Each week there is opportunity to apply techniques to real world situations for practice. Participants have a group orientation session, and then meet for 10 weeks. Group sessions last 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post- randomization. Program includes training in mindfulness, cognitive behavioral stress management, relaxation, imagery, prioritizing meaningful activities, communication, and coping strategies. Content is geared toward concerns of cancer survivors.
223905807|NCT04533763|BEHAVIORAL|Technology-based Healthy Lifestyles program|The program is delivered using web-based group conferencing. Sessions include content from the National Cancer Institute, American Cancer Society, and health care providers with expertise in oncology. All content is geared to promoting healthy living among ovarian cancer survivors. Participants have a group orientation session, and then meet for 10 weeks, with group sessions lasting 1.5 - 2 hours. Booster sessions occur approximately 4.5 and 9 months post-randomization. Healthy Lifestyle sessions include topics such as nutrition, exercise, sleep, quality of life, survivorship, and cognitive function with content geared toward concerns of cancer survivors.
223905808|NCT03825757|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
223905809|NCT03825757|DRUG|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
223905810|NCT06308510|OTHER|collection additional peritoneal lavage fluid|collection additional peritoneal lavage fluid
223905811|NCT06080113|RADIATION|Focal Brachytherapy|Targeted focal brachytherapy is an image-guided technique, where the radioactive source is placed only, and directly into the cancerous area of the prostate. The aim is to preserve the normal surrounding prostate gland tissue to limit treatment-related side effects to the adjacent anatomical structures. A multiparametric prostate MRI is used to identify, localize, and delineate the intraprostatic PCa tumour lesion and plan treatment. A specialized MRI-ultrasound image-fusion software combines the MRI-images with dynamic ultrasound performed in the operating room and is used to focally guide the placement of the radioactive source in the prostate cancer (PCa) tumour focus based on focal dosimetry calculations. A safety margin around the tumour is applied where it is possible to account for MRI tumour volume underestimation, microscopic spread, and treatment uncertainties.
223905812|NCT02920229|DRUG|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
223905813|NCT05297500|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-12)
223905814|NCT05049018|OTHER|Traditional Physical Therapy Program|"This intervention included:~* Strengthening and facilitation exercises for the affected upper extremity muscles.~* Stretching and mobilization exercises for the affected upper extremity muscles and joints.~* Postural reactions exercises.~* Facilitation of arm-reaching and arm-hand skills for the affected upper extremity.~* Facilitation of manipulative tasks (grasp and release activities) for the affected upper extremity.~* Training of daily living activities for the upper extremities."
223939983|NCT07196592|BEHAVIORAL|Olfactory stimulation|"Olfactory stimulation were set as follows:~Essential oil types: yuzu, lavender, lemon, and mint. Concentration: 158 μL of essential oil + 50 mL of water. The mixed solution was poured into the test tubes of the olfactory instrument, ensuring that the liquid levels of the four solutions were kept at the same height. Each scent was released for 30 seconds, followed by a 10-second air interval, with each cycle lasting 20 minutes."
224277058|NCT00499824|BEHAVIORAL|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
224277059|NCT00004216|BIOLOGICAL|salmonella VNP20009|
224277060|NCT00004216|DRUG|cefixime|
224277061|NCT00004216|DRUG|ceftriaxone sodium|
223715781|NCT03000439|DRUG|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
223715782|NCT00926276|PROCEDURE|Fundoplication|Fundoplication
224277062|NCT00004216|DRUG|ciprofloxacin|
224277063|NCT00004216|DRUG|trimethoprim-sulfamethoxazole|
224277064|NCT02566096|DRUG|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
223905815|NCT05049018|DEVICE|ArmeoSpring Virtual Reality Device (Upper Extremity Training Device with Virtual Reality Technology)|ArmeoSpring virtual Reality Equipment is a functional upper extremity rehabilitation device that provides specific therapy with augmented feedback. The ArmeoSpring instrument facilitates intensive task-oriented upper extremity therapy after stroke, traumatic brain injury, or other neurological diseases and injuries. It combines adjustable arm support, with augmented feedback and a large 3 D workspace that allows functional therapy exercises in a virtual reality environment.
223905816|NCT03755167|DRUG|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
223905817|NCT06206434|DIAGNOSTIC_TEST|Point of care ultrasonography|Transthoracic echocardiogrpahy followed spinal anesthesia and 5 ml/kg Ringers lactate fluid co-loading
223905818|NCT05725161|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Participants assigned to the ACT group will receive 8 weekly individual ACT sessions guided by a coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
223905819|NCT05725161|BEHAVIORAL|Wait-list control group with psychoeducation materials provided|The wait-list control group will receive care as usual with psychoeducation materials provided during the study period and receive ACT sessions after the study period ends
223905820|NCT04461327|BEHAVIORAL|Painful stimulations of major depressive patients|"All three pain mechanisms will be tested in one session lasting 1h approximately.~The mechanisms are tested in the following order:~1. Aδ and C threshold~2. Wind-up~3. CPM~(more details in detailed description)"
223905821|NCT04461327|BIOLOGICAL|Blood sample|The blood test is made between 2 and 24 hours before the experimental procedure. The biological collection is made to measure medications' concentration if the patient takes antiepileptics and/or lithium, and to measure complete blood count (CBC).
223905822|NCT04461327|DIAGNOSTIC_TEST|Clinical assessment|"A clinical assessment will be made by a trained researcher.~(more details in detailed description)"
223905823|NCT04461327|BEHAVIORAL|Social touch|Stroking
223905824|NCT04592978|BEHAVIORAL|Pain-Alcohol Personalized Feeback Intervention|The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.
223905825|NCT04592978|BEHAVIORAL|Control Personalized Feedback Intervention|The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
223905826|NCT02611518|DRUG|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
223905827|NCT02611518|DRUG|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
223905828|NCT02611518|DRUG|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
223905829|NCT05997914|BEHAVIORAL|Storytelling Intervention|Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
223905830|NCT03449706|DRUG|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
223905831|NCT05485779|DRUG|AQ280|"Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral"
223905832|NCT05485779|DRUG|Placebo|"Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral"
223905833|NCT04670900|PROCEDURE|Tension band wiring or plate fixation|Choice of operative treatment is TBW or PF with a precontoured anatomical plate. The treating surgeon decides if TBW or PF is chosen as operative treatment method. The surgeries are performed according to OTA principles by an experienced surgeon, a trauma fellow or a consultant as approved by the participating hospitals.
223905834|NCT04670900|PROCEDURE|Active non-operative treatment with optional plaster cast|Patients allocated to non-operative treatment are offered a back-slab in 60 degrees of flexion for pain-relief. The back-slab is removed 7-14 days following injury.
223905835|NCT05444907|OTHER|No Intervention / Exposure|No intervention / exposure since this is an observational study
223715783|NCT02786446|DRUG|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
223905836|NCT06335849|BIOLOGICAL|LYB004 25µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
223905837|NCT06335849|BIOLOGICAL|LYB004 50µg|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
223905838|NCT06335849|BIOLOGICAL|SHINGRIX|Subjects will be enrolled and stratified by age (50-59 years and 60-70 years in a 1:1 ratio) and randomized (2:2:1) to receive 25 μg LYB004, 50 μg LYB004 or SHINGRIX. The two-dose immunization schedule will be adopted, that is, LYB004 or SHINGRIX will be intramuscularly injected on Day 0 and Day 60.
223905839|NCT02010242|DRUG|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
223905840|NCT02010242|DRUG|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
223905841|NCT05265715|OTHER|Low AGE diet|"The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)"
223905842|NCT05265715|PROCEDURE|Research blood draw|Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
223905843|NCT06232018|DEVICE|Skin adhesive (Dermabond)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue (DERMABOND ADVANCED®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
223905844|NCT06232018|DEVICE|skin adhesive + polyester mesh (Dermabond prineo)|"* Arthrotomy (deep layer) is repaired using number 1-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* Subcuticular suture is repaired using number 3-0 monofilament absorbable suture (STRATAFIX™ , Ethicon, johnson \& johnson, Somerville, NJ)~* After subticular sutures was done~* 2-octylcyanoacrylate glue + polyester mesh ( DERMABOND PRINEO®, Ethicon, johnson \& johnson, Somerville, NJ) was applied"
223905845|NCT03999593|PROCEDURE|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
223905846|NCT06558604|DRUG|Obinutuzumab|1000 mg/40mL
223905847|NCT06558604|DRUG|Glofitamab|10mg/mL
223905848|NCT06558604|DRUG|Venetoclax Oral Product|10mg, 50mg and 100mg tablets
223905849|NCT06558604|DRUG|Zanubrutinib Oral Capsule|80mg capsules
223905850|NCT06839430|OTHER|hypertonic saline 5% sodium chloride|Hypertonic saline acts as an analgesic by alleviating nociceptive pain from inflamed tissues, which may include bone, connective tissue , synovium , or a combination of these Hypertonic saline results in safe and remarkable outcomes on knee pain, stiffness and function compared with intra-articular dextrose injection
223905851|NCT06839430|OTHER|hypertonic dextrose 20%|A recent study showed the sensorineural analgesic effect of 5% dextrose prolotherapy in the treatment of chronic low back pain ,Therefore, the mechanism of action for dextrose prolotherapy is hypothesized to work through reducing peripheral sensitization and targeting structural dysfunction
223905852|NCT06838858|PROCEDURE|Motor Imagery Training|The study group will receive motor imagery training in addition to control group's exercise program. This process will proceed as follows; In motor imagery training videos taken with a 9-year-old healthy child will be watched.• The content of the videos will include exercises such as ankle dorsiflexion, heel tapping while walking, climbing and descending stairs, walking on a ramp, standing on a ramp, walking on soft ground, and walking on a treadmill.• The patients will watch these videos and then the relaxation, imagination and return to environment phases of motor imagery will be applied respectively.
223905853|NCT06838858|PROCEDURE|Conventional Post-operative Exercises|"This group will receive conventional exercises in the post-op process. The exercises included in the conventional exercise program are;~* Balance board exercises~* Balance disc exercises~* Bosu exercises~* Balance pad exercises~* Wobble board exercises~* Walking on soft ground~* Balance exercises on soft ground~* Apraximations and tractions~* Target angle exercise for ankle~* General standing balance exercises (Eyes open and closed - single foot, double foot)~* Ankle bidirectional ROM~* Ankle bidirectional strengthening~* Exercises to increase foot intrinsic muscle strength and balance~* Functional exercises"
223905854|NCT04706988|OTHER|Treatment of asthma according to GINA guideline|Pharmacological treatment depending on level of control of asthma
223905855|NCT06834204|OTHER|PC2: Primary Care Connect|Primary Care Connect is a health system intervention that includes patient education, electronic medical record optimization, protocolized communication from cancer care team to primary care.
223905856|NCT06397001|DRUG|nL-SAA1-01|Personalized antisense oligonucleotide
223905857|NCT06263114|DIAGNOSTIC_TEST|TruGraf® Liver gene expression panel (GEP)|Test done on blood sample collected during for cause or routine liver biopsy
223905858|NCT06831643|DRUG|Standard Medical treatment|Standard Medical treatment
223905859|NCT06831643|BIOLOGICAL|Therapeutic Plasma Excahnge|Therapeutic Plasma Excahnge
223905860|NCT06564545|RADIATION|TBI|The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223905861|NCT06564545|RADIATION|TMLI|The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
223528930|NCT06637124|DEVICE|Blood Flow Restriction Therapy Device|"Blood Flow Restriction (BFR) therapy involves units use standardized cuffs of varying widths and lengths which are physically attached to the devices and provide the capability of precisely controlling the amount of pressure applied to each limb during exercise or at rest.~We will be using Smart Cuffs® 4.0 which allows for a fast, hassle-free personalized pressure calculation. With the built-in pressure sensor and on-board computer, it will calculate and set the optimal pressure for each participant's limb. There is no need for an external doppler probe or hand pump. Made in the USA, SmartCuffs® are registered with the FDA as a Class 1 Medical Device.~Blood flow restriction therapy is commonly paired with resistive training, so this study will explore the effect of blood flow restriction at rest for patients with osteoarthritis at different restriction levels (50% for first group and 70% for second group)."
223905862|NCT06564545|DRUG|Cyclophosphamide|The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
223905863|NCT06839560|DRUG|Adelumab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy|"1. Adelumab: 1200 mg on Day 1, every 3 weeks (q3w).~2. VEX Metronomic Chemotherapy:~   Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w).~3. Radiotherapy: The interval between radiotherapy and immunotherapy should be within 3 weeks, with no specific order required. Different radiotherapy techniques will be selected based on the size and location of the metastatic lesions:~Stereotactic Body Radiation Therapy (SBRT), Spatially Fractionated Radiation Therapy (SFRT), Low-dose Radiotherapy (LDRT)."
223939984|NCT07196592|BIOLOGICAL|Temporal Interference,TI|"During stimulation, the parameters were set as follows:~Δf=40Hz (2000Hz vs. 2040Hz) 2mA Stimulation duration: 20min We fixed the stimulation protocol and used a standard head to simulate stimulation of the entorhinal region."
223905864|NCT06839560|DRUG|Adelumab+VEX Metronomic Chemotherapy+Delayed Radiotherapy|"1. Adelumab: 1200 mg on Day 1, every 3 weeks (q3w).~2. VEX Metronomic Chemotherapy:~   Vinorelbine: 20 mg orally, every other day, every 3 weeks (q3w). Cyclophosphamide: 50 mg orally, once daily, every 3 weeks (q3w). Capecitabine: 500 mg orally, three times daily, every 3 weeks (q3w).~3. Radiotherapy:~If there is intracranial disease progression but extracranial disease remains stable, the systemic treatment regimen of Adelumab + VEX metronomic chemotherapy will be continued, with the addition of intracranial radiotherapy.~If there is intracranial disease progression and extracranial disease progression, the systemic treatment regimen will be modified, with the addition of intracranial radiotherapy.~The radiotherapy positioning and techniques will be the same as those used in the experimental group."
223905865|NCT05764525|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
223905866|NCT05764525|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
223905867|NCT05591131|OTHER|genetic testing|Undergo genetic testing
223905868|NCT05591131|OTHER|Survey Administration|Complete survey
223905869|NCT05388448|DRUG|Sanfetrinem Cilexetil|"Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.~Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules"
223905870|NCT05388448|DRUG|Rifampicin|Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.
223905871|NCT06378151|OTHER|TLT training|"Emergency clinicians assigned to the intervention group will receive the following training and resources.~1. The TLT Conversation Guide: The structured conversation guide entails discussing patients' values and goals, prognosis, and shared decision-making to use a trial of intensive care. Originally used in ICU settings, we systematically refined the guide to be used in the ED incorporating inputs from patient advisors' and emergency clinicians' inputs.~2. Clinician Training: The clinician training will include a one-hour didactic on research methodologies and serious illness communication skills, followed by a four-hour communication training with trained actors.~3. EHR Documentation: An EHR template for documenting the TLT conversation findings has been developed.~4. Intensivist Communication: A standard template to communicate the TLT conversation findings to the intensivists has been developed."
223905872|NCT03542578|DEVICE|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
223905873|NCT06839885|OTHER|Interventional group|"Patients with primary or secondary unilateral lower extremity lymphedema who have received at least 2 weeks of Complex Decongestive Therapy in the last year and completed treatment at least 3 months ago, and who agreed to participate in the study, were included in the study at Health Sciences University Gaziosmanpasa Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Prior to treatment, all patients were planned to receive education about the treatment to be applied in the form of a home program. The patients were planned to be treated in the hydrotherapy unit during lunch breaks, under the supervision of a volunteer physiotherapist.~After the initial assessments, patients in the study group will perform aquatic exercises in groups of 5 or 7 participants, three times a week for 6 weeks, under the supervision of a physiotherapist.Patients in the intervention group will receive a home exercise program and self-drainage."
223905874|NCT06839885|OTHER|Control group|"Patients with primary or secondary unilateral lower extremity lymphedema who have received at least 2 weeks of Complex Decongestive Therapy in the past year and completed their treatment at least 3 months ago, and who agreed to participate in the study, were included in the study at Health Sciences University Gaziosmanpasa Training and Research Hospital, Department of Physical Medicine and Rehabilitation. Prior to treatment, all patients were planned to receive education about the treatment to be applied in the form of a home program. Patients were planned to be treated in the hydrotherapy unit during lunch breaks under the supervision of a volunteer physiotherapist.~After the initial assessments, patients in the control group will receive a home exercise program and self-drainage."
223905875|NCT03334630|DEVICE|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
223905876|NCT03334630|DEVICE|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
223905877|NCT06442787|DEVICE|conventional splints|only intermediate and final splint will be used during the surgery
223905878|NCT06442787|DEVICE|cutting guides and positioning guides|patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery
223905879|NCT06442787|DEVICE|cutting guides and fixation plates|patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
223905880|NCT06299410|DRUG|ITI-1284 10 mg|ITI-1284 tablet
223905881|NCT06299410|DRUG|ITI-1284 20 mg|ITI-1284 tablet
223905882|NCT05653336|DEVICE|PerQseal® Closure Device System|Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.
223905883|NCT04054050|OTHER|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
223905884|NCT05178888|DRUG|MRTX849|KRAS G12C inhibitor
223905885|NCT05178888|DRUG|Palbociclib|CDK 4 and 6 inhibitor
223905886|NCT04246112|OTHER|Handwriting intervention|children will practice handwriting 5 days p/week, 15-20 minutes p/day for 12 weeks using the movalyzer software program.
223905887|NCT02965755|OTHER|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
223905888|NCT04252573|DEVICE|Chimney Endovascular Aortic Sealing (ChEVAS) System|The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.
223905889|NCT05116514|OTHER|Case management|"Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months"
223905890|NCT06112639|DEVICE|DANCEREX-DTx|"DANCEREX treatment integrates the dance activities with an innovative motivational system into applied game~The patients will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair). In addition, the DANCEREX app involves a game dynamic in which the execution of the rehabilitation sessions feeds a digital book that allows the rehabilitation experience to be placed in a narrative context."
223905891|NCT06112639|DEVICE|Multidimensional dance-based program|Multidimensional dance-based program provided via a digital medicine telerehabilitation platform. The patient will perform the exercises (different dance styles, i.e., Irish Dance, Hip Hop, Cha Cha Cha) independently at home using videos that illustrate the activity to be performed for each treatment session on a mobile device (tablet). The intensity of the exercise will be moderate with a progressive increase in difficulty level over the weeks. The treatment will start with simple dance movements to be performed in a sitting position to proceed with gradually more complex sequences, always to be performed in safe conditions (first seated and then standing, holding onto a chair).
223905892|NCT06112639|DEVICE|Educational Program|Subjects will view educational/informative videos on Tablet. The treatment will be provided via a digital medicine platform.
223905893|NCT03138161|DRUG|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
223905894|NCT03138161|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
223905895|NCT03138161|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
223905896|NCT04833010|OTHER|Cardiopulmonary Exercise Test|Participants will complete a Cardiopulmonary Exercise test on cycle ergometer in which they will perform progressive step-exercise cycling to exhaustion
223905897|NCT04833010|OTHER|Cognitive Performance Test|Cognitive Performance will be tested using a cognition application on an iPad during the Cardiopulmonary Exercise Test.
223905898|NCT04555590|BEHAVIORAL|H-HOPE Intervention|The H-HOPE intervention (Hospital to Home: Optimizing the Preterm Infant's Environment) to promote early infant development and parental engagement. H-HOPE includes ATVV, which provides Auditory (voice), Tactile (moderate touch massage), Visual (eye to eye), and Vestibular (rocking) stimulation with a parent-directed component which provides participatory guidance and social support to engage with their infants.
223905899|NCT03030261|DRUG|Elotuzumab|During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg.
223905900|NCT03030261|DRUG|Pomalidomide|During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
224277065|NCT02642523|DRUG|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
223905901|NCT03030261|DRUG|Dexamethasone|During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
223905902|NCT05249101|DRUG|Ivaltinostat|Ivaltinostat (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate) is a novel anticancer therapeutic candidate that inhibits enzymatic activity of histone deacetylase (HDAC).
223905903|NCT05249101|DRUG|Capecitabine|Capecitabine is labeled for monotherapy for the treatment of adjuvant Dukes' C colon cancer and metastatic colon cancer at a recommended dose of 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest. This dose schedule was effective and tolerable in the first line setting for patients with pancreatic cancer (Cartwright, 2002).
223905904|NCT04019977|OTHER|Nurse Home Visiting Program|Brief nurse home visiting program
223905905|NCT03617679|DRUG|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
224277066|NCT02642523|DRUG|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
224277067|NCT02642523|OTHER|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
223905906|NCT03617679|DRUG|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
223905907|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
223905908|NCT00999856|DEVICE|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
223905909|NCT00999856|DEVICE|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
223905910|NCT00999856|DEVICE|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
223905911|NCT00999856|DEVICE|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
223905912|NCT02234388|OTHER|Observation|There are no interventions associated with this registry as it is purely observational.
223905913|NCT05059639|OTHER|Almond|Consume 2 ounces of almond daily for 8 weeks
223905914|NCT05059639|OTHER|Pretzel|Consume comparative amount of pretzel daily for 8 weeks
223905915|NCT05299242|DRUG|Adalimumab Injection|40mg in 0.8ml preparation in vials from Fresenius Kabi Ltd
223905916|NCT05299242|DRUG|Placebo|Saline \[0.9% NaCl\]
223905917|NCT04777721|BIOLOGICAL|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
223905918|NCT05106491|DEVICE|Synchronized Cardiac Support with the icor kit|Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
223905919|NCT05370040|BIOLOGICAL|AAHI-SC2 Vaccine|AAHI -SC2 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike protein delivered by nanostructured lipid carrier (NLC) Vaccine
223905920|NCT05370040|BIOLOGICAL|AAHI-SC3 Vaccine|AAHI-SC3 self-amplifying RNA (saRNA) against SARS-CoV-2 Spike and nucleocapsid protein delivered by nanostructured lipid carrier (NLC) Vaccine
223905921|NCT05370040|BIOLOGICAL|EUA or approved vaccine|Janssen or Pfizer vaccines (control arm)
223905922|NCT03996291|DRUG|Tolebrutinib|Pharmaceutical form: Film coated tablet Route of administration: Oral
223905923|NCT05205460|DEVICE|Home-based telerehabilitation|A home-based exercise mobile app will be offered combined with the heart rate sensing clothes to each participant in the group of home-based telehealth exercise training program. The mobile app provides auto-feedback of heart rate at each exercise training session through the heart rate sensing clothes and alarm function identifying individuals' appropriate exercise intensity (target heart rate) during their exercise based on their exercise prescription calculated and set up inside the app. After completing each exercise training session, the record of training time and heart rate response is simultaneously uploaded to the cloud system of the medical center through the heart rate sensing clothes. The experienced and well-trained nurse checked the cloud system data to monitor participants' adherence to exercise training. In addition, online communication is enabled using LINE software, which provided a platform for patients and researchers to interact with each other through messaging.
223905924|NCT05205460|BEHAVIORAL|Education and self-exercise|The participants will receive a exercise prescription suggestion. Then, they will maintain their usual lifestyles without exercise reminders.
223905925|NCT05636215|BIOLOGICAL|IBI354|Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
223905926|NCT04534582|DRUG|HLX14|healthy volunteers receive HLX14 (60mg) once
223905927|NCT04534582|DRUG|EU-Prolia®|healthy volunteers receive EU-Prolia® (60mg) once
223528931|NCT06637124|DEVICE|45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.|Patients assigned to group will receive strengthening of the lower limb musculature through moderate intensity resistance training (60% of 1RM) using a 45° leg-press machine, 90°-0° of knee flexion knee extension machine, leg curl machine and calf raise machine.
223905928|NCT04534582|DRUG|US-Prolia®|healthy volunteers receive US-Prolia® (60mg) once
223528932|NCT06638346|OTHER|Shortened FIFA 11+ warm-up exercise program|"The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines."
223905929|NCT04534582|DRUG|CN-Prolia®|healthy volunteers receive CN-Prolia® (60mg) once
223905930|NCT04214184|BEHAVIORAL|Increased sleep duration|Participants will increase their nightly time in bed by 2 hours per night for 4 weeks to target the recommended 7 hours of sleep per night.
223905931|NCT01711190|PROCEDURE|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
223905932|NCT06566378|DEVICE|Buzzy|In children pre-procedure, buzzy was placed under the armpit. The children were made before starting the application. It continued until the end of vaccination procedure.
223905933|NCT06566378|DEVICE|Buzzy (Placed in standard)|In children pre-procedure, buzzy was placed on the arm. The children were made before starting the application. It continued until the end of vaccination procedure.
223905934|NCT04807764|COMBINATION_PRODUCT|Standing transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation during standing followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
223905935|NCT04807764|COMBINATION_PRODUCT|Lying transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation while lying supine on a therapy table followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
223905936|NCT04807764|OTHER|Standing sham transspinal stimulation followed by robotic gait training|Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of sham transspinal stimulation during standing at an intensity where sensation is absent followed by 30 minutes of robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
223905937|NCT03541720|DRUG|18F-DA|18F-DA is an investigational PET radiotracer
223905938|NCT05737303|DRUG|nab-paclitaxel combined with carboplatin|"Nab-Paclitaxel/carboplatin q3weeks Nab-Paclitaxel 260 mg/m² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel/carboplatin weekly Dose-dense Nab-Paclitaxel 100 mg/m2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg/m² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles~Paclitaxel weekly/carboplatin weekly Paclitaxel 60 mg/m2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)"
223905939|NCT05861427|DRUG|Atogepant|Oral Tablet
223905940|NCT05861427|DRUG|Placebo for Atogepant|Oral Tablet
223905941|NCT05931497|DEVICE|whole body hyperthermia|heat will be applied to the participant through a sauna to increase core body temperature
223905942|NCT05370079|BIOLOGICAL|Collection of biological sample (blood and/or CSF)|"Blood sample will be collected one time for each patient:~2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube~If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml)."
223905943|NCT06094062|OTHER|App-based treatment support|The intervention includes a smartphone app that patients will download on their smartphones. Medication intake, symptom course and well-being will be tracked over treatment duration. If symptoms worsen, the pharmacist will contact the patients and counsel them based on their adherence and well-being data. Patients who still have symptoms after the 30 days of treatment will receive a final counseling by the pharmacy, and if necessary will be forwarded to the treating physician.
223905944|NCT05655312|DRUG|[203Pb]VMT01|\[203Pb\]VMT01 is administered intravenous (IV) as an imaging agent for SPECT/CT
223905945|NCT05655312|DRUG|[212Pb]VMT01|Subjects with positive uptake of \[203Pb\]VMT01 will receive a fixed dose of \[212Pb\]VMT01 administered IV every 8 weeks starting at Cycle 1 Day 1.
223905946|NCT05655312|DRUG|Nivolumab|For all combination-therapy cohorts, 480 mg nivolumab will be administered every 4 weeks as an IV infusion.
223905947|NCT05290441|PROCEDURE|None involvement|No EGFR involvement
223905948|NCT01826071|OTHER|Static Stretch|Standing Gastrocnemius Stretch Standing Soleus Stretch Seated Gastrocnemius Stretch Seated Soleus Stretch Hamstring Stretch Quadriceps Stretch (Standing) Quadriceps Stretch (Side Lying)
223905949|NCT01826071|OTHER|Active Elongation|Mini Squat- Double Leg Mini Squat- Single Leg Prone Hip Extension with Knee Flexed 3 Position Straight Leg Raises Quadriceps Myofascial Release Heel Raises (Eccentric Strengthening) Single Leg and Double Leg Gastrocnemius Myofascial Release Calcaneal Glides
223905950|NCT06568081|OTHER|SloMo|SloMo, is a blended digital therapeutic for people who fear harm from others. It is based on cognitive-behavioural therapy for psychosis. An online therapy platform supports the delivery of 11 face-to-face sessions, which are synchronised to a native mobile app for use in daily life. SloMo works by helping people to notice their worries and fast thinking habits, and encourages them to slow down for a moment to find ways of feeling safer.
223905951|NCT01478542|DRUG|Conventional Vincristine|
223905952|NCT01478542|DRUG|Liposomal Vincristine|
223905953|NCT01478542|DRUG|Ricover-scheme rituximab|
223905954|NCT01478542|DRUG|optimised rituximab-schedule|
223905955|NCT04722887|BIOLOGICAL|Alpha-1 15%|Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
223905956|NCT04722887|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion
223905957|NCT03910478|DEVICE|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
223905958|NCT03910478|OTHER|Standard Control Strategy|Standard of care with office-based testing.
224277068|NCT01115933|DEVICE|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
224277069|NCT01830309|DRUG|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
224277070|NCT04536506|OTHER|Bobath Therapy|Bobath group received 45 min of sessions three times weekly for 12 weeks. An individual program was scheduled for each case following pre-assessment. It was targeted to enable normal posture, facilitation of corrective balance and protective responses and development of normal movement patterns
224277071|NCT04536506|OTHER|Vojta technique|Vojta group received the following three times weekly for 12 weeks: 1. Reflex crawling, 2. First stage of reflex turning, 3. Second stage of reflex turning. Stimuli (pressure and stretch) for 30-60 sec were given by using the main stimulus points and auxiliary stimulus points together.
224277072|NCT00959439|DRUG|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
224277073|NCT00959439|DRUG|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
223905959|NCT05043961|PROCEDURE|Palisade sacroiliac joint radiofrequency ablation using 3-tined needles|"Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion."
223905960|NCT04971109|DRUG|TPOXX|Study is based on Animal Regulatory Rule
223905961|NCT04971109|OTHER|TPOXX Placebo|Does not apply
223905962|NCT06568861|DRUG|ALG-097558|Multiple doses of ALG-097558 200 mg (2 x 100 mg tablets)
223905963|NCT03953417|DEVICE|Accelerated intermittent theta-burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left DLPFC using the MagPRo stimulator."
223905964|NCT05293171|DRUG|1.25 mg/kg BL-8040 + BL-8040-matching placebo|Administered via subcutaneous (SC) injection
223905965|NCT05293171|DRUG|2 mg/kg BL-8040|Administered via subcutaneous (SC) injection
223905966|NCT05293171|DRUG|BL-8040-matching placebo|Administered subcutaneous (SC) injection
223905967|NCT05293171|DRUG|400 mg Moxifloxacin (1x400 mg tablet)|Administered orally
223905968|NCT05340062|DEVICE|bedside sonography|TCD and ONSD sonography twice a day per 2 days
223905969|NCT05133739|DEVICE|injection of RHA®4 in Midface|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per cheek (subcutaneous and/or supraperiosteal layer). Touch-up treatment provided at 4 weeks (up to 3.0 mL per cheek)."
223905970|NCT05133739|DEVICE|injection of Comparator Product in Midface|"Comparator product is sterile, biodegradable, colorless gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE.~Up to 3.0 mL injected per cheek (subcutaneous and/or supraperiosteal layer). Touch-up treatment provided at 4 weeks (up to 3.0 mL per cheek)."
223905971|NCT05454839|OTHER|Survey|Interviewer-administered survey
223905972|NCT05454839|OTHER|Focus group|Focus group for selected participants
223905973|NCT04313712|DRUG|ibogaine with magnesium treatment|Participants will receive magnesium sulfate intravenously and ibogaine orally.
223905974|NCT06438159|OTHER|Cardiac rehabilitation with Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is as follows:~* 8 weekly group sessions of 2h30 led by the mindfulness instructor,~* Sessions of around 45 minutes a day to be carried out by the patient, at home, for personal training,~* An intensive day between the 6th and 7th sessions to explore certain practices more intensively, in order to support participants in effectively integrating mindfulness meditation into various life situations."
223905975|NCT06438159|OTHER|Conventional cardiac rehabilitation|The usual cardiac rehabilitation program combines exercise training and therapeutic education workshops, with a daily session for four weeks.
223905976|NCT06577428|DRUG|RAY1225|administered SC
223905977|NCT04844866|GENETIC|MB-CART2019.1|MB-CART2019.1 is designed to effectively target malignant B cells in patients suffering from late stage haematological B-cell malignancies. MB-CART2019.1 consists of autologous cluster of differentiation CD20/CD19 chimeric antigen receptor (CAR) transduced CD4/CD8 enriched T cells, derived from a leukapheresis and processed by using the CliniMACS Prodigy® device.
223905978|NCT04844866|DRUG|R-GemOx or BR plus polatuzumab vedotin|Immunochemotherapy will be administered as per arm description.
223905979|NCT02641639|DRUG|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
223905980|NCT02641639|DRUG|Placebo|Saline for infusion
223905981|NCT06415292|DRUG|Winlevi (clascoterone) 1% cream|Splitface design- Subjects applied Winlevi (clascoterone) cream 1%, twice daily to the randomized half face following cleansing, every morning and evening.
223905982|NCT06835023|DRUG|Ringer lactate (RLS)|50 patients will receive only Ringer Lactat
223905983|NCT06835023|DRUG|Dextran+Ringer Lactat(D+RLS)|50 patients Dextran+RInger Lactat 1:3 ratio
223905984|NCT06540651|OTHER|use of Luminettes ® with active light emission|Spectrum of 400 \< X \< 750 nm assumed active
223905985|NCT06540651|OTHER|use of Luminettes ® with a light emission presumed to have no therapeutic effect|Modification of spectrum parameters for wavelengths covered, with light emission in a spectrum of 560 \< X \< 650 nm assumed to have no therapeutic effect
224277074|NCT05499416|DRUG|Bimekizumab|Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
224277075|NCT03934996|OTHER|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
223905986|NCT05332457|DRUG|Reduced dosage of beta-blocker|"Phase I:~1. CPET performed at trough BB concentration: participants will undergo CPET at least 30 hours after last beta-blocker usage.~2. CPET performed at peak BB concentration : participants will undergo CPET at 3 hours after last beta-blocker usage.~Phase II:~BB dosage will be reduced."
223905987|NCT06061328|BEHAVIORAL|OASIS DA training|The OASIS decision aid is a novel implementation strategy selection tool developed by a multidisciplinary team of experts using machine learning algorithms and user-centered design approaches.
223905988|NCT06061328|BEHAVIORAL|Current DA Tool training|The CFIR-ERIC Matching Tool is a currently available decision aid tool for selecting implementation strategies that is based on expert opinion.
223905989|NCT01712490|DRUG|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
223905990|NCT01712490|DRUG|doxorubicin|Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
223905991|NCT01712490|DRUG|bleomycin|Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
223905992|NCT01712490|DRUG|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
223905993|NCT01712490|DRUG|dacarbazine|Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
223905994|NCT05871970|BIOLOGICAL|TARA-002|All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
223905995|NCT06780683|DRUG|Upadacitinib|"Induction Therapy: The dose of upadacitinib for induction therapy is 45mg once daily for a duration of 8 weeks (for ulcerative colitis) or 12 weeks (for Crohn's disease).~Maintenance Therapy: The dose of upadacitinib for maintenance therapy is 15mg once daily; for patients with refractory, severe, or extensive disease, a maintenance dose of 30mg once daily may be considered."
223905996|NCT04433260|OTHER|Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index|The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
223905997|NCT04433260|OTHER|Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.|Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
223905998|NCT04433260|OTHER|Informed consent|Participants will need to give their consent to participate to the survey after reading PIS
223905999|NCT05681299|DRUG|growth hormone and lirglutide|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects and liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
223906000|NCT05681299|DRUG|growth hormone|GH will be administered as one nightly subcutaneous self-injection at 11pm at a dose of 0.03 mg/kg/day in healthy and 0.5 mg in male and 0.6 mg in female GHD subjects.
223906001|NCT05681299|DRUG|liraglutide|Liraglutide will be administered by subcutaneous injection taken by subjects beginning at a dose at 0.6 mg nightly from 9-11 pm and escalated in 0.6 mg increments weekly as tolerated to a final dose of 1.8 mg nightly.
223906002|NCT05681299|DRUG|Placebo|Placebo will be taken by nightly subcutaneous injection at 9-11 pm.
223906003|NCT04432506|BIOLOGICAL|Anakinra|Given SC
223906004|NCT04432506|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
223906005|NCT04432506|DRUG|Cyclophosphamide|Given IV
223906006|NCT04432506|DRUG|Fludarabine|Given IV
223906007|NCT04986423|DRUG|ZEN003694|72 mg PO QD
223906008|NCT04986423|DRUG|Enzalutamide|160 mg PO QD
223906009|NCT06053086|RADIATION|Treatment ETHOS radiotherapy|• Cohort A: Adaptive RT: PTV = CTV + 2 mm (except for IMC with 5mm), excluding 5mm beneath the skin
223906010|NCT06053086|RADIATION|Conventional IMRT|• Cohort B: IMRT: PTV = CTV + 7mm, excluding 5mm beneath the skin
223906011|NCT06536387|BEHAVIORAL|Storytelling Through Music|Storytelling Through Music is a six-week intervention that combines storytelling, reflective writing, song-writing, and self-care skills to improve emotion regulation through affective and cognitive coping skills.
223906012|NCT05990465|DRUG|Pirtobrutinib|Pirtobrutinib will be administered at 200 mg/day orally starting at least 14 days prior to apheresis as bridging until the start of lymphodepletion and restarted between day 28-120 for up to one year as maintenance post cell infusion.
223906013|NCT05990465|DRUG|LV20.19 CAR T cells|Subjects will receive a dose of 2.5x10\^6 CAR-T cells/kg as a previously identified safe in a Phase 1 protocol at the Medical College of Wisconsin.
223906014|NCT06537544|OTHER|Comprehensive Rehabilitation Program|Pelvic Floor Muscle Strengthening Exercises Core Strengthening Exercises Breathing Exercises Patient education about bladder diary Postural education
223906015|NCT06537544|OTHER|Conventional Pelvic Floor Training|Kegels exercises in different body positions
223906016|NCT03987022|DRUG|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control postoperatively
223906017|NCT03987022|DRUG|Opioids|Use of narcotic for pain control postoperatively
223906018|NCT03987022|OTHER|Ice Packs|Placement of Ice packs on surgical sites postoperatively
223906019|NCT03987022|DRUG|Tylenol|Use of pain medication postoperatively
223906020|NCT03987022|DRUG|Motrin|Use of non-steroidal anti-inflammatory drug for pain control postoperatively
223906021|NCT03987022|DRUG|Dilaudid Injectable Product|Use of narcotic for pain control postoperatively
223906022|NCT03987022|DRUG|Percocet 5Mg-325Mg Tablet|Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
223906023|NCT05617794|DEVICE|Diffusion Optics Technology (DOT) Pattern Spectacle Lens|DOT Pattern Spectacle Lens
223906024|NCT05617794|DEVICE|Control Spectacle Lens|Control Spectacles
223906025|NCT02550522|DEVICE|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
223939985|NCT07196592|COMBINATION_PRODUCT|Olfactory-TI Stimulation|"During stimulation, the parameters were set as follows:~Δf=40Hz (2000Hz vs. 2040Hz) 2mA Stimulation duration: 20min We fixed the stimulation protocol and used a standard head to simulate stimulation of the entorhinal region.~Olfactory stimulation were set as follows:~Essential oil types: yuzu, lavender, lemon, and mint. Concentration: 158 μL of essential oil + 50 mL of water. The mixed solution was poured into the test tubes of the olfactory instrument, ensuring that the liquid levels of the four solutions were kept at the same height. Each scent was released for 30 seconds, followed by a 10-second air interval, with each cycle lasting 20 minutes."
223906026|NCT06554912|PROCEDURE|Lymphatic Decompression|"Patients will be prepared according to standard procedures Clinical examinations, para-clinical assessment and biological tests Patient will be set in angiography room and local anesthesia at the puncture area (femoral vein or brachial vein).~Obtain access to the femoral vein per standard procedures (option for brachial access depending on anatomy based on pre-operative CT, per physician discretion) After setting introducer sheath, catheterism of cardiac cavity will be performed for assess the following standard hemodynamic measures Catheterism of thoracic duct through the subclavian vein will be performed under fluoro guidance and phlebography using contrast Measure TD and central venous pressures Deploy stent under fluoro guidance Standard vascular stent deployed in subclavian vein and into lymphovenous junction Evaluate the procedure with standard phlebography and hemodynamic measures Remove catheters, and temporary compression as standard venous procedures"
223906027|NCT04290806|OTHER|Routine care as per site standard|Physician's choice according to patient's needs. Routine care as per site standard.
223906028|NCT06441773|PROCEDURE|Respiratory Rehabilitation|"An initial assessment is conducted upon admission to personalize the program. This includes:~Clinical examination Spirometry Maximum Inspiratory Pressure (PImax) measurement Multidimensional Dyspnea Profile questionnaire at end of TM6 Exercise Functional Testing Measurement of quadriceps strength and endurance Blood gases Educational interview and shared educational assessment London Chest Activity of Daily Living (LCADL) Tobacco and/or dietary consultation~The respiratory rehabilitation program, performed twice a week, includes:~Exercise training on an ergocycle and treadmill (30 minutes at ventilatory threshold for the ergocycle; 30 minutes at 60-80% walking speed for the treadmill; or dyspnea rated 4-6 on the Borg scale after endurance exercise) Quadriceps muscle strengthening Therapeutic education program Group gymnastics Smoking cessation assistance Socio-psychological and nutritional support"
223906032|NCT06270199|BIOLOGICAL|Control|Standard treatment
223906033|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - three infusions|3 doses of 5 million MSC will be administered
223906034|NCT06270199|BIOLOGICAL|Allogenic fetal mesenchymal stem cells from umbilical cord - six infusions|6 doses of 5 million MSC will be administered
223906035|NCT06079398|DRUG|Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
223906036|NCT06079398|DRUG|Placebo for Navepegritide|Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
223906037|NCT05339035|BEHAVIORAL|Training based on IMB model, motivational interview technique, hippotherapy program|"In the first stage of the research, the Digital Game Addiction Scale for Children will be applied to the entire universe and participants with a digital game addiction score of 73 and above will be determined. According to the criteria of inclusion in the research, students will be informed and those who volunteer to participate in the study will be determined and listed. After the experimental and control groups are determined, the participants will be contacted and data collection forms will be applied. The students in the experimental group will be trained according to the IMB model, the students in the experimental group will be given a 6-session motivational interview program and the students will be taken to the hippotherapy program, which lasts 1 hour once a week for 8 weeks. Hippotherapy applications will be carried out at the horse farm in Amasya, accompanied by expert horsemen."
223906038|NCT04874870|DRUG|Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]|1 injection of 0.58mg will be injected into applicable cord.
224277076|NCT04499378|DIAGNOSTIC_TEST|Lung CT|Computed tomography of the thorax
223715784|NCT02786446|DRUG|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
223906039|NCT04874870|COMBINATION_PRODUCT|Xiaflex + Hand-Based Custom Orthosis|1 injection of 0.58mg will be injected into applicable cord followed by use of hand-based custom orthosis to maintain finger extension
223906040|NCT05162547|DEVICE|NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay|The NeuMoDx™ FluA/FluB/RSV/SARS-CoV-2 Assay (IUO) is a multiplexed, in vitro real-time Polymerase Chain Reaction assay, diagnostic test intended for the simultaneous qualitative detection and differentiation of Influenza A virus (Flu A), Influenza B virus (Flu B), Respiratory Syncytial Virus (RSV) and SARS-CoV-2 RNA
223906041|NCT05855746|DRUG|Colchicine Pill|"Participant receive, in addition to standard of care therapy, six months of colchicine (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization. The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision.~During the six months of the treatment administration, in case of severe adverse reaction (such as nausea and/or diarrhea during five days), a dose reduction could be considered by the investigator: half of the study protocol dose could be accepted (0.5 mg per day in the morning). In case of remaining adverse reactions, the study drug should be stopped."
223939986|NCT07196592|COMBINATION_PRODUCT|Sham Control|"During stimulation, the parameters were set as follows:~Δf=0Hz (2000Hz vs. 2000Hz) 2mA Stimulation duration: 20min.~Olfactory stimulation were set as follows:~Essential oil types: air. lasting 20 minutes."
224277077|NCT00707187|DRUG|Cialis|35 pills of study medication (20 mg)
224277078|NCT05948033|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3."
224277079|NCT04329676|PROCEDURE|Deep Brain Stimulation|Patients with PD who are eligible to bilateral STN DBS surgery and chose to get directSTIM System implanted will be followed over a 6-month period to evaluate changes in their condition.
224277080|NCT04011449|DEVICE|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
223906042|NCT05855746|DRUG|Placebo|"Participant receive, in addition to standard of care therapy, six months of placebo (at a dose of 0.5 mg twice daily, morning and evening) beginning maximum 72 hours post-randomization.~The standard of care is defined according to the European consensus paper as follow: All participants without contraindication receive a betablockers, and heart failure ESC (European Society of Cardiology) guidelines directed medical therapies if LVEF \< 50% (Left Ventricular Ejection Fraction), including ACE (Angiotensin-Converting Enzyme) inhibitors, diuretics if indicated. The choice of the dosage and the drug is left at the investigator decision."
223906043|NCT06304428|OTHER|Deprescribing Care Model|The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)
223906044|NCT06304428|OTHER|Bone Health Service Model|The Bone Health Service Model is designed to provide osteoporosis evaluation and management
223906045|NCT06304428|OTHER|Injury Prevention Service Model|The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
223906046|NCT05832190|OTHER|Standard of care|Patients receiving during 3 months before the surgery usual general dietary recommendations regarding balanced diet comprising legumes and fruits, meat or equivalent, dairy products and starch and bread
223906047|NCT05832190|DIETARY_SUPPLEMENT|Biotin supplement|1 capsule per day of Biotin 450µg during 3 months before the surgery.
223906048|NCT05832190|DIETARY_SUPPLEMENT|Fiber supplement|3 servings per day of PureLean® Fiber, a powdered blend of fibers and prebiotics, during 3 months before the surgery
223906049|NCT06552728|OTHER|Energy Healing|EH derives from the theory that by using the body's biological energy, there can be a therapeutic effect that guides the patient towards a homeostatic state. Preliminary data in chronic pain patients, suggests that EH, delivered by an experienced practitioner, is able to reduce self-reported pain symptoms within minutes. Effects lasting for weeks to months have also been anecdotally reported. For patients with pain, this can result in a reduction of symptoms. Participants will also be presented with sham EH as a control.
223906050|NCT05916417|DEVICE|TMS-fNIRS over the dl-PFC|Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technology. Functional Near Infrared Spectroscopy (fNIRS) is a brain imaging technology that utilizes light.
223906051|NCT02202772|DRUG|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
223906052|NCT02202772|DRUG|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
223906053|NCT02202772|DRUG|Cisplatin|Intravesical installation of Cisplatin for 2hours
223906054|NCT06565572|DRUG|nL-FLVC-001|nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
223906055|NCT06565949|OTHER|Education group|aregivers in the experimental group will be given a detailed and planned training programme on pressure sores. The trainings will be held in a total of four sessions, with twenty minutes in each session, two weeks apart.
223906056|NCT06565949|OTHER|control group|In the first stage of the study, the participants in the experimental and control groups were asked to complete the 'Introductory Information Form' and '' Pressure sore knowledge test' will be completed. In the second stage of the research, no intervention will be made to the caregivers in the control group, and in the last stage of the research, 'Pressure sore knowledge test' will be filled in as post-test data for all participants.
223906057|NCT05017012|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Pembrolizumab (+) Berahyaluronidase alfa is a fixed-dose formulation of pembrolizumab (either Conc1 or Conc2) and berahyaluronidase alfa for SC administration.
223906058|NCT05017012|BIOLOGICAL|Pembrolizumab|Participants will receive pembrolizumab 400 mg IV.
223906059|NCT05017012|DRUG|Pemetrexed|Participants may receive 500 mg/m\^2 IV every 3 weeks (Q3W) Day 1 and Day 22 of Cycles 1 to 18 as background SOC treatment during the study, as applicable to their diagnosis.
223906060|NCT05017012|DRUG|Carboplatin|Participants may receive 5 mg/mL/min IV (nonsquamous) or 6 mg/mL/min IV (squamous) on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
223906061|NCT05017012|DRUG|Paclitaxel|Participants may receive 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
223906062|NCT05017012|DRUG|Nab-paclitaxel|Participants may receive 100 mg/m2 IV on Day 1, 8, and 15 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
223906063|NCT05017012|DRUG|Axitinib|Participants may receive 5 mg orally twice daily continuously as background SOC treatment during the study, as applicable to their diagnosis.
223906064|NCT05017012|DRUG|Cisplatin|Participants may receive 75 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 cycles as background SOC treatment during the study, as applicable to their diagnosis.
223906065|NCT02701829|OTHER|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
223906066|NCT02701829|OTHER|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
223906067|NCT02701829|OTHER|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
223906068|NCT04142606|OTHER|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
223906069|NCT06201884|DEVICE|Early rehabilitation through Adapted Physical Activity|From the day after surgery, 1 to 2 walking sessions with walking platform, lasting 6 to 30 minutes (min-max), will be proposed daily until the day of discharge.
223906070|NCT05797857|OTHER|Exercise Training|A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.
223906071|NCT04929496|PROCEDURE|post-PCI FFR|final invasive physiology measurements after successful stent implantation, followed by functional optimization if physiology indexes remain positive.
223906072|NCT06384222|DRUG|Abiraterone acetate|Given orally
223906073|NCT06384222|DRUG|Prednisone|Given orally
223906074|NCT06384222|DRUG|Hyperpolarized [1-13C] pyruvate (HP 13C)|Given IV
223906075|NCT06384222|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
223906076|NCT06384222|PROCEDURE|Non-investigational radical prostatectomy (RP)|Planned, standard of care surgical procedure occurring outside of this study.
223906077|NCT06384222|PROCEDURE|Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)|Imaging procedure
223906078|NCT05336201|BEHAVIORAL|CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth)|Manualized cognitive remediation intervention that includes 1) skills-based remediation (metacognitive training), 2) parent training, and 3) cognitive behavioral approaches. Intervention targets self-management and goal-setting skill building to promote independence in activities necessary for transition of care.
223906079|NCT02432261|DRUG|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
223906080|NCT02432261|DRUG|Testosterone only gel|Testosterone only gel
223906081|NCT00915759|DEVICE|ProKera|ProKera placed in non-dominant eye after photorefractive keratectomy (PRK)
223906082|NCT00915759|DEVICE|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after photorefractive keratectomy (PRK)
223906083|NCT02260557|DRUG|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
223906084|NCT02260557|DRUG|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
223906085|NCT05756088|DIAGNOSTIC_TEST|Blood draw to measure the levels of dd-cf DNA|Blood draw to measure the levels of dd-cf DNA.
223906086|NCT06786507|DRUG|Ustekinumab 90 mg|Ustekinumab is a human monoclonal IgG1 antibody that blocks the p40 subunit of both IL-12 and IL-23 this antagonistic action inhibits the interaction of these cytokines with the IL-12Rβ1 receptor. The IL-12Rβ1 receptor is found on the surface of NK cells and T cells which reduces inflammation and alters the body's immune response
223906087|NCT06786507|DRUG|Infliximab|Infliximab is a biological therapy/immunotherapy medication designed to stimulate the body's immune system and treat certain diseases. Infliximab is a purified, recombinant DNA-derived chimeric IgG monoclonal antibody protein that contains both murine and human components that inhibit tumor necrosis factor-alpha (TNF-α). TNF-α is a signaling protein involved in acute phase reactions and systemic inflammation. Macrophages, CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons produce TNF-α. This TNF-α inhibition inhibits the inflammatory reaction's cascade, leading to improved disease condition inflammatory bowel disease
223906088|NCT06783738|OTHER|Exercise|The participants will come to our lab twice. In the first visit we will perform a fitness assessment, using a noninvasive, cardiopulmonary exercise testing used routinely to measure fitness in children.
223906089|NCT03602157|BIOLOGICAL|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10\^7, 5x10\^7, 1x10\^8
223906090|NCT03602157|BIOLOGICAL|ALTCAR.CD30 cells|Fixed dose level of 1x10\^8
223906091|NCT03602157|DRUG|Bendamustine|70 mg/m\^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
223906092|NCT03602157|DRUG|Fludarabine|30 mg/m\^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
223715785|NCT02786446|DRUG|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
223906093|NCT06250608|DEVICE|Pulse oximeter, NIRSITX|It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
223906094|NCT06852287|DRUG|chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.|Toripalimab: 240mg ivd d1, q3w; Lenvatinib: 8-12mg po qd (body weight\<60kg, 8mg po qd; body weight ≥ 60kg, 12mg po qd) Chemotherapy by hepatic arterial infusion (GOLD HAIC): d1 oxaliplatin: 100-125mg+gemcitabine: 800-1000mg; q3w.
223906095|NCT04200911|DRUG|Rapamune|Sirolimus 1mg capsules
223906096|NCT06849232|PROCEDURE|Platelet-Rich Plasma (PRP) Injections|wounds were first cleaned with normal saline, followed by the injection of PRP, prepared from the patient's own blood by the hematology department, into the surrounding wound area twice weekly
223906097|NCT04045665|DRUG|Antiplatelet-only strategy|Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
223906098|NCT04045665|DRUG|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-325mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
223906099|NCT04166526|DEVICE|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
224083523|NCT02342132|DEVICE|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
224083524|NCT01446419|DEVICE|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
223906100|NCT04166526|DEVICE|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
223906101|NCT06565624|PROCEDURE|Cotton Swab Nasal Stimulation|Nostril probing for the purpose of producing reflex tearing
223906102|NCT05546385|DEVICE|Partial Rebreathing Device|Partial Rebreathing Device
223906103|NCT05546385|DEVICE|Sham breathing device|Sham breathing device
223906104|NCT03807414|DEVICE|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
223906105|NCT04387305|DRUG|Tranexamic acid injection|Active drug is provided to participants as described based on the TXA arm they are randomized to.
223906106|NCT02740634|DRUG|F-18 AV 1451|Tau binding agent
223906107|NCT02740634|DRUG|C-11 PiB|Amyloid binding agent
223906108|NCT06145646|DEVICE|Muscle warm-up|Passive heating of the vastus lateralis of the right quadriceps will be performed using a microwave device. The device will be set at a power of 150 W and a distance of 10-15 cm from the skin surface for 20 minutes with the purpose of increasing local muscle temperature to 40 ºC.
223906109|NCT06099743|BEHAVIORAL|Psychosocial intervention|Intervention manual and six one-on-one coaching sessions.
223906110|NCT06099743|OTHER|Usual supportive care|Referral to cancer center supportive care services (e.g., social work) as needed, upon request from the patient, caregiver, or clinician.
223906111|NCT06495593|DRUG|Ocrelizumab|Standard ocrelizumab dosing
223906112|NCT06450561|OTHER|cardiovascular event|In this single group observational trial the exposure of interest is a cardiovascular event.
224277081|NCT01294449|DEVICE|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
224277082|NCT01294449|DEVICE|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
224277083|NCT00603512|DRUG|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
224277084|NCT00603512|DRUG|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
224277085|NCT00603512|DRUG|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
224277086|NCT00603512|DRUG|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
224277087|NCT00603512|DRUG|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
224277088|NCT03266055|DIETARY_SUPPLEMENT|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
224277089|NCT03266055|DIETARY_SUPPLEMENT|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
223906113|NCT02657005|DRUG|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
223906114|NCT03866668|DRUG|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
223906115|NCT02724969|BEHAVIORAL|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
223906116|NCT06799429|BEHAVIORAL|Supervised in-person group|Individually prescribed and directed/supervised by a fitness trainer in-person, multi-mode exercise 2 x a week for 30-60 minutes The fitness trainer is with the participant while they exercise.
223906117|NCT06799429|BEHAVIORAL|Monitored distance group|Individually prescribed ulti-mode exercise 2 x a week for 30-60 minutes. Written plan/feedback and support by phone/text or email is provided by a fitness trainer who is not present with the participant when they exercise.
223906118|NCT05193929|DEVICE|OptiPulse™|TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait
223906119|NCT05193929|DEVICE|Standard of Care offloading device|CAM boot
223906120|NCT01346540|DRUG|BIBF 1120|VEGF inhibitor
223906121|NCT01346540|DRUG|Placebo|BIBF 1120 placebo
223906122|NCT05061069|DIAGNOSTIC_TEST|cervical vestibular evoked myogenic potentials (cVEMP)|cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.
224277090|NCT05967936|DRUG|Bupivacaine Injection|evaluation of pain by using two different types of local anesthesia
223906123|NCT04506866|DEVICE|InterStim Micro|Eligible subjects will receive InterStim Micro therapy. Commercial devices will be used within their intended use as described in each geography's approved instructions for use
224277091|NCT00024349|DRUG|fluorouracil|
224277092|NCT00024349|DRUG|mitomycin C|
224277093|NCT00024349|RADIATION|radiation therapy|
224277094|NCT05233787|PROCEDURE|Tailored use of defunctioning stoma after TME|"Tailored use of defunctioning stoma after TME based on a 2-step process:~i) to perform or not a defunctioning stoma according to the personalized risk of anastomotic leakage (defunctioning stoma only if Anastomotic Failure Observed Risk Score=\[2-6\]), ii) to perform an early stoma closure at day 8-12, according to clinical (fever), biological (CRP level days 2 and 4 postoperatively) and radiological postoperative assessment (CT-scan with colonic contrast retrograde enema day 7-8 postoperatively)"
224277095|NCT05233787|PROCEDURE|Systematic use of defunctioning stoma|Systematic use of defunctioning stoma for 2-3 months after TME, according to French national and international guidelines
224277096|NCT05426954|OTHER|Rehabilitation utilizing blood flow restrictive therapy|BFR therapy
224277097|NCT01896505|DRUG|KCP-330|
224277098|NCT02418754|DRUG|REGN2176-3|
223906124|NCT03362476|BEHAVIORAL|Computer-based alcohol reduction intervention|Brief computer-based version of motivation enhancement therapy (MET) used in conjunction with clinician-delivered MET and standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
223906125|NCT03362476|BEHAVIORAL|Brief clinician-delivered MET|Clinician-delivered MET used in conjunction with standard clinical care for current substance users. The brief intervention is focused on goals, cravings, problem-solving and decision-making. The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
223906126|NCT03362476|BEHAVIORAL|Standard of care|Clinicians ask about substance use and provide evidence-based recommendations promoting abstinence.
223906127|NCT05821686|DRUG|Human Interleukin-2 (IL-2) (Proleukin)|All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
223906128|NCT05837286|DEVICE|Oval-8 ® Orthosis|The experimental group will consist of receiving a PIP joint on the day they receive their cortisone injection. The Oval-8 ® will be issued to the subject by an Occupational Therapist to ensure correct fit and comfort as well as given written instructions for night use. The orthosis will be worn at night for 6-week duration. Participants will have 1 follow up phone call or email at the 6-week mark and then 1 follow up phone call or email at the 12 week mark by a member of the research team from the time they received their cortisone injection where the time for resolution of trigger finger symptoms, VAS (Visual Analogue Scale), subjective questionnaire and QuickDASH scores will all be recorded in their medical research file.
223906129|NCT05837286|OTHER|Cortisone injection only|The control group will receive a cortisone injection and be instructed to move their fingers normally
223906130|NCT05711082|OTHER|Précurseur de la dopamine|"In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.~Speech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house."
223906131|NCT05711082|OTHER|antagoniste D2|In the second condition, volunteers will receive Sulpiride 800 mg
223906132|NCT05711082|OTHER|PLACEBO|In the third condition, volunteers will receive placebo
223906133|NCT03893682|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
223906134|NCT05613218|DRUG|Oxygen|"Patients will have nasal cannula or oxygen mask placed as the usual standard of care.~Patients will be screened and randomized in the emergency department to either liberal or restrictive oxygenation after providing informed written consent and oxygen is titrated to the prespecified target range using an automated feedback device (O2MATIC). Consented patients will be randomly allocated to study groups via the web-based system within REDCap. The allocation will be concealed. Time at randomization will be considered as study time zero (T0). All patients will receive usual standard of care except for their O2 management. The intervention will last for 24 h. After 24 h, patients will be switched over to usual care for oxygen therapy. If the treating physician thinks, that the patient need another oxygenation target and it is thought to be harmful to continue with the allocated target, the intervention-phase can be stopped prematurely."
223906135|NCT02333825|PROCEDURE|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
223906136|NCT02333825|OTHER|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
223906137|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go (TUG single-task)|The TUG test is a well-established clinical test of one mobility sequence: rising from an armchair, walking straight ahead, passing a line marked on the floor, turning around, walking back, and sitting down again.
223906138|NCT05893524|DIAGNOSTIC_TEST|Timed Up-and-Go dual-task (TUGdt)|Two dual-task tests including TUG (TUGdt) were carried out: TUGdt naming animals and TUGdt months backwards. The outcomes registered were: time scores for TUG single-task and both TUGdt tests, TUGdt costs (relative time difference between TUG single-task and TUGdt), number of different animals named, number of months recited in correct order, number of animals per 10 s, and number of months per 10 s.
224083525|NCT01446419|DEVICE|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
224277099|NCT02418754|DRUG|Intravitreal Aflibercept Injection (IAI)|
224277100|NCT02171897|PROCEDURE|Osteosynthesis|
224083526|NCT02161159|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
224083527|NCT02308683|DIETARY_SUPPLEMENT|Moringa oleifera|12 weeks supplementation
224277101|NCT02171897|PROCEDURE|Total hip replacement|
224277102|NCT03671343|BEHAVIORAL|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
224277103|NCT04197154|BEHAVIORAL|Threat manipulation (control, no threat)|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin reacts to heat normally and it is safe for them to participate. A skin-sensitivity reading shows participants a scale that is in the green (no danger) zone.
224277104|NCT04197154|BEHAVIORAL|Threat manipulation|Before the start of conditioning, a mock skin-sensitivity test informs participants that their skin is very sensitive and their nerve fibers are very responsive and they may have adverse reactions to the heat-pain application. A skin-sensitivity reading shows participants a scale that is in the red (higher danger) zone.
223906139|NCT05893524|DIAGNOSTIC_TEST|Clinical functional assessment|The diagnostic procedure was part of the clinical routine for patients undergoing memory assessment and involved a geriatrician's careful evaluation of the patient's history and cognitive testing including Mini-Mental State Examination (MMSE), Clock Drawing Test, Verbal Fluency Test, and Trail Making Test A and B. In addition, all participants carried out short versions of the Geriatric Depression Scale and the General Motor Function Assessment Scale, as well as static balance according to the Bohannon Method, and hand grip strength using a dynamometer.
224277105|NCT04197154|BEHAVIORAL|Conditioning of moderate pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned moderate-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to 'baseline' pain of lower intensity."
223906140|NCT03899636|DRUG|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
224277106|NCT04197154|BEHAVIORAL|Conditioning of high pain|"During nocebo trials of the acquisition phase, conditioned stimuli (i.e., on-screen visual cues ON signaling the activation of sham electrical stimulation) are paired to unconditioned high-pain stimuli, to induce a negative association between the activation of electrical stimuli and an increase in pain. During control trials of the acquisition phase, the deactivation of the sham electrical stimulation (i.e., on-screen message OFF) is paired to pain of lower intensity."
223906141|NCT03899636|DEVICE|NanoKnife System|IRE using NanoKnife System
223906142|NCT05191264|OTHER|EQ5D (EuroQol 5 Dimensions)|The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).
223906143|NCT05191264|OTHER|Numerical Rating Scale (NRS)|the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
223906144|NCT05191264|OTHER|evaluated the consumption of analgesics|the consumption of analgesics by step and by dosage will be evaluated.
223906145|NCT06318949|PROCEDURE|blood sampling|If the patient does not object to participating in the study, a blood sample is taken at each visit (an additional tube may be added to a routine blood sample taken for standard care), or a residual blood sample is reused after routine tests have been performed, and data is collected from the medical record.
223906146|NCT06528665|DRUG|ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults|"ZEPOSIA®~* Titration is required for treatment initiation.~* The recommended maintenance dosage is 0.92 mg orally once daily.~* If a dose is missed within the first 2 weeks of treatment, reinitiate with the titration regimen. If a dose is missed after the first 2 weeks of treatment, continue treatment as planned."
223906147|NCT06776887|DEVICE|The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks|"The Wii Fit group will receive the Wii Fit program for 30 minutes in addition to SPTP for 60 minutes, whereas. The intervention was 3 sessions a week for 12 weeks.~The control group will receive standard physical therapy program (SPTP) only 3 sessions a week for 12 weeks ."
223906148|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair with radicular instrumentation|Coronal and accessible radicular pulp tissue are extirpated using rotary files. After proper drying, the paste is placed in the cavity and the canals.
223906149|NCT05336682|PROCEDURE|Lesion Sterilization and Tissue Repair without radicular instrumentation|Only the coronal pulp is removed, the pulpal floor is covered with triple antibiotic paste with propylene glycol mix.
223906150|NCT05336682|PROCEDURE|Conventional pulpectomy|Pulp tissue extirpation is done. Biomechanical preparation is done using rotary files with frequent irrigation with Chlorhexidine. The canals are dried using sterile absorbent paper points followed by obturation by the paste of ZOE.
223906151|NCT02408276|OTHER|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
223906152|NCT06818591|DIAGNOSTIC_TEST|DEXA(Dual-Energy X-ray Absorptiometry)|Followed for up to 20 years
223906153|NCT03171545|BEHAVIORAL|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
223906154|NCT03171545|BEHAVIORAL|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
223906155|NCT06081309|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
223906156|NCT05468151|OTHER|Cold acclimation|The cold water immersions will last 30-60 minutes per day and the volunteers will undergo 2-3 cold immersions per week.
223906157|NCT05468151|OTHER|Intervention Control group - volunteers with obesity|Participants with obesity in the control group will undergo PET/CT scans at baseline and 12 weeks after the first scan.
223906158|NCT05468151|OTHER|Acute cold exposure|All participants (lean and with obesity) will undergo PET/scans after 2 hours of cold exposure to investigate BAT perfusion and BAT glucose uptake.
224083528|NCT01760161|DRUG|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
224277107|NCT04197154|BEHAVIORAL|Extinction|"During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the nocebo and control visual cues (i.e., on-screen messages ON and OFF) to pain stimuli of only lower intensity."
224277108|NCT04974580|DRUG|Nicotine patch|NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
223906159|NCT05458141|BEHAVIORAL|FYA-003|FYA-003: It is a gamified health education module for children aimed at promoting healthy nutrition, physical activity, health hygiene, and infectious diseases risk reduction within the clinically proven app fooya!
223906160|NCT03720613|DRUG|Naldemedine|0.2 mg tablet once a day at any time with or without food
223906161|NCT03720613|DRUG|Lubiprostone|0.024 mg twice a day \[adjust dose based on liver function\]
223906162|NCT03720613|DRUG|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
223906163|NCT06331338|BEHAVIORAL|Decision Cycle for Person-Centered Glycemic Management|It is defined as a purposefully designed holistic care intervention that improve self-management .
223906164|NCT06331338|OTHER|Traditional diabetes self-management education|Traditional diabetes self-management education content focuses more on teaching relevant knowledge and some skills.
223906165|NCT04696757|DRUG|Capecitabine|Capecitabine without surgery
223906166|NCT06302504|BEHAVIORAL|Nature-based mindfulness program|only one arm is included in this study
223906167|NCT05287594|BEHAVIORAL|Integrated Exercise Program|"Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output."
223906168|NCT03926052|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
223906169|NCT03926052|DRUG|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
223906170|NCT06462820|DEVICE|Active SAINT Stimulation|"Participants who are randomly assigned to this group will receive active SAINT targeted to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
223906171|NCT06462820|DEVICE|Sham SAINT Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation targeted to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system with the Cool-B65 A/P coil."
223906172|NCT03164278|BEHAVIORAL|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
223906173|NCT05368974|DRUG|Direct Acting Antivirals|Direct-acting antiviral exposure during documented pregnancy
223906174|NCT05878431|OTHER|Foot Reflexology|"The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~* Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~* Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~* Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application."
223906175|NCT04761861|DRUG|Vildagliptin 50 MG|Vildagliptin 50 MG tablet once daily
223906176|NCT04761861|DRUG|Placebo|Placebo one tablet daily
223906177|NCT04381429|DRUG|A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
223906178|NCT04381429|DRUG|F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)|A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
223906179|NCT06313853|BEHAVIORAL|COACH-Cog|Oncology clinician intervention components: 1) a brief training video (completed once during the duration of the study following enrollment and randomization), 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments Patient/Care partner dyad intervention components: 1) Care partners (and patients if able) will participate in a one-time communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
224083529|NCT01760161|DRUG|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
224083530|NCT03311048|OTHER|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
224277109|NCT04974580|BEHAVIORAL|Phone Counseling|Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
224277110|NCT04974580|BEHAVIORAL|Digital Coaching|Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
223906180|NCT05591326|PROCEDURE|i-PRF application procedure|Local anesthesia will be applied to the area with gingival recession. Before the procedure, the venous blood taken from the patient will be centrifuged at 700 RPM for 3 minutes in glass and non-addition tubes to obtain i-PRF. i-TZF will be taken into a 2 cc injector. In 2020, Özsağır et al. Decortication, that is, microneedling, will be performed with insulin needle tips according to the protocol defined by Dr. Then the prepared i-PRF will be infected to the apical mucogingival junction of the keratinized gingival area. This process will be repeated once a month for 3 months. After the 3rd month, the horizontal and vertical gingival recession values will be evaluated and recorded at the end of 6 months and 1 year.
223906181|NCT05775562|DIAGNOSTIC_TEST|Pre and post dive examinations|"Performing pre-dive examinations:~\- EFR by plethysmography cabin~Realization of the examinations the day of the dive:~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Measurement of circulating bubbles~* ECG~* Venous blood sampling (biological collection)~* Water balance (Δweight/water intake)~* EFR by plethysmography cabin~* Weight measurement~Realization of the examinations the day after the dive:~* Venous blood sample (biological collection)~* Portable Spirometry~* Pulmonary ultrasound~* Cardiac ultrasound~* Weight measurement"
223906182|NCT04929483|DRUG|BIO89-100|Subcutaneous injection
223906183|NCT04929483|DRUG|Placebo|Subcutaneous injection
223906184|NCT03857945|OTHER|Preoperative mobility device(s) training|Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
223906185|NCT05880199|DEVICE|Body surface gastric mapping device|A medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders.
223906186|NCT05169723|BEHAVIORAL|Exertional respiratory activities|participants will perform a series of exertional respiratory activities
223906187|NCT06344741|BEHAVIORAL|Accepted in latent phase|Participants admitted to the delivery room in the latent phase will be included. Routine procedures will be performed.
223906188|NCT06344741|BEHAVIORAL|Accepted in active phase|Participants admitted to the delivery room in the active phase will be included. Routine procedures will be performed.
223906189|NCT03125070|OTHER|Best Practice and Internet site with links to existing resources|Receive usual care
223906190|NCT03125070|OTHER|Internet, Mobile app and Telehealth Intervention|Receive INSPIRE and survivorship care plan
223906191|NCT03125070|OTHER|Survey Administration|Ancillary studies
223906192|NCT06556823|OTHER|CLNDT+ Conventional PT in Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
223906193|NCT06556823|OTHER|CLNDT+ Conventional PT in non Diabetic Population):|The participant will be asked to sit on edge of table with hand behind the back with neutral spine. Then patient will be asked to adopted slump forward thoracic and lumbar spine. Then flex the patient neck passively and extend the patient asymptomatic knee with ankle dorsiflexion passively. Adopt this position for 30 sec and 12 rep will be perform for 3 sets and 4 rep per set. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
223906194|NCT06556823|OTHER|SMWLM+ Conventional PT in Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
223906195|NCT06556823|OTHER|SMWLM+ Conventional PT in non Diabetic Population)|the participant will be asked to adopt side-lying position on their un-effected side, at edge of treatment table. Then The therapist will be applying transverse glide at spinous process towards floor. Other Therapist extended with slight abduction of 10 degrees and hip and knee flexed to 45 degrees. The participant will actively move into SLR with other therapist assistance. If participant feel pain, then ask them to breathe deeply and hold position for 3 sec. Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 10 min 2. Hot pack for 15 min 3. Bridging Exercises (10 rep x 1 Set with 3 sec hold) 4. Ankle pumps (10 rep x 1 Set).
223906196|NCT06059391|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT with donor peripheral blood stem cells
223906197|NCT06059391|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223906198|NCT06059391|DRUG|Granulocyte Colony-Stimulating Factor|Undergo stem cell mobilization with G-CSF
223906199|NCT06059391|DRUG|Hematopoietic Cell Transplantation Conditioning Regimen|Receive pre transplant conditioning
223906200|NCT06059391|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223906201|NCT06059391|PROCEDURE|Pheresis|Undergo apheresis
223906202|NCT06059391|DRUG|Placebo Administration|Given IM
223906203|NCT06059391|DRUG|Stem Cell Mobilization Therapy|Undergo stem cell mobilization with G-CSF
223906204|NCT04200274|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
223906205|NCT04534218|DRUG|Regorafenib|"* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the following cycles: regorafenib will be administered at a 80, 120 or 160 mg daily dose according to toxicity observed with the last dose used in the first cycle."
224277111|NCT01945619|BIOLOGICAL|Trivirus-Specific CTLs|Patients will receive up to 2 x 10\^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
224277112|NCT01325935|DRUG|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
223906206|NCT04534218|DRUG|Cyclophosphamide|50 mg per os, daily, for 6 months
223906207|NCT04534218|DRUG|Capecitabine|625mg/m²/orally twice daily continuously for 6 months
223906208|NCT04534218|DRUG|Aspirin|75 mg orally and daily until progression
223906209|NCT05479552|DIAGNOSTIC_TEST|Syn-One Test|CND Life Sciences is expanding the utility of its diagnostic technology, the Syn-One Test, to pathologically distinguish between early DLB and Alzheimer's disease to prevent misdiagnoses and establish the relationship between progression and α-synuclein deposition by measuring α- synuclein accumulation in patient's nerve fibers using a simple skin punch biopsy.
223906210|NCT06562985|DRUG|BAY3018250 Dose 1|Infusion, single dose
223906211|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, infusion
223906212|NCT06562985|DRUG|Placebo|BAY3018250 matching placebo, injection
223906213|NCT06562985|DRUG|BAY3018250 Dose 2 infusion|Infusion, single dose
223906214|NCT06562985|DRUG|BAY3018250 Dose 2 injection|Injection, single dose
223906215|NCT05763576|DRUG|RO7565020|RO7565020 will be administered by subcutaneous injection or intravenous infusion.
223906216|NCT05763576|OTHER|Placebo|Matching placebo will be administered by subcutaneous injection or intravenous infusion.
223906217|NCT05763576|DRUG|Nucleos(t)ide analogue (NUC) treatment|NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.
223906218|NCT04981522|BEHAVIORAL|Indigenously adapted problem management plus (IA-PM+)|The IA-PM+ manual would be comprised of the following evidence-based techniques: (a) problem solving, (b) stress management, (c) behavioral activation and (d) accessing social support. The IA-PM+ intervention consisting of five sessions, will teach the participants techniques to manage their emotional problems.
223906219|NCT05770687|DRUG|SGLT2 inhibitor|Patients started on SGLT2 inhibitors after PCI for AMI
223906220|NCT04141891|BEHAVIORAL|Driving Decision Aid|Healthwise DDA
223906221|NCT04141891|BEHAVIORAL|Older Drivers Website|National Institute on Aging (NIA) Older Drivers Website
223906222|NCT06454461|DRUG|Upadacitinib 15 MG|Upadacinib 15mg once daily for the 8 weeks after NECS
223906223|NCT04361136|DRUG|Delgocitinib cream|Cream for topical application
223906224|NCT04361136|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
223906225|NCT05514301|DIAGNOSTIC_TEST|Sensitivity of Polydeep vs high experienced endoscopists for colorectal polyp detection|"Both diagnostic interventions will be performed in all patients~1. High definition colonoscopy performed by high experienced endoscopists blinded to Polydeep.~2. Polydeep: a CADe and CADx system. The gold standard will be the histological diagnosis of the lesion."
223906226|NCT04289805|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
223906227|NCT04289805|OTHER|standard-stimulated cohort|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist."
223906228|NCT06216743|DIAGNOSTIC_TEST|MRI and CT|Patients will undergo an additional MRI, cineMRI and CineCT cscan.
223906229|NCT06036420|DEVICE|Flashed Light Therapy|Light flashes will be presented over 60 minutes as 3-millilisecond flashes of white light at 4,000 lux every 20 seconds
223906230|NCT06036420|BEHAVIORAL|Videoconference-delivered Cognitive Behavioral Therapy|Treatment will involve psychoeducation on sleep, circadian rhythms and light exposure, motivational interviewing, advancing of bedtime schedule, time management and coping with poor sleep, sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring for worry.
223906231|NCT05781009|DRUG|Pregnenolone|300mg
224277113|NCT05841693|DRUG|Carbohydrate|The experimental group of patients will consume the carbohydrate rich fluid 2 hours before the elective CD.
224277114|NCT05841693|DRUG|Placebo|The control group will be offered same amount of placebo fluid.
224277115|NCT00156650|DRUG|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
223906232|NCT05781009|DRUG|Placebo|placebo
223906233|NCT04966585|DRUG|Posaconazole Delayed Release Oral Tablet|Three 100mg delayed-release tablets twice a day on the first day, then three 100mg delayed-release tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
223906234|NCT04966585|DRUG|Matching Placebo Tablet|Three matching placebo tablets twice a day on the first day, then three tablets once a day, starting on the second day. Duration of therapy will be 12 weeks.
223906235|NCT04567030|DEVICE|Dental monitoring (DM)|DM is the first APP system used in orthopedics patients in the world,it has been widely used in Asian countries (Taiwan, Hong Kong, Singapore, Japan, etc.) and has been used by 2140 patients so far. DM allows patients to take in-mouth photos at home, and uses AI as a background analysis to evaluate the patient's current oral condition (including oral hygiene and gum status) based on the photo.
223906236|NCT03423667|DRUG|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
223906237|NCT03423667|DRUG|Lactose powder|Placebo comparator.
223906238|NCT04179539|DIAGNOSTIC_TEST|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
224277116|NCT00156650|DRUG|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
224277117|NCT00156650|DRUG|Depo-Medroxyprogesterone|300 mg IM every 3 months
223906239|NCT04179539|DIAGNOSTIC_TEST|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
223906240|NCT05349240|DEVICE|C2 CryoBalloonTM Ablation System.|Cryoablation is used to ablate the tissue under the cryogenic condition. The device is mainly used to destroy the unhealthy tissues.
223906241|NCT06353217|OTHER|Patient Group (Hypoglycemia Prevention Program)|"The Hypoglycemia Prevention Program:~The patient hypoglycemia profile - this is a set of survey questions about hypoglycemia and related aspects of diabetes care. The questions will be administered as an Epic MyChart message sent to the patient in the week prior to the clinic visit, and in the clinic waiting room on a tablet immediately prior to the patient's primary care provider visit."
224277118|NCT05445570|DIAGNOSTIC_TEST|Non-Interventional|This is an observational, non interventional study
223906242|NCT06353217|OTHER|Primary Care Physician Group|The provider hypoglycemia toolkit - this is the report from the patient hypoglycemia profile, which triggers a set of hypoglycemia prevention tools and patient education materials as appropriate. Primary Care Providers will not be exposed to the intervention until all of their patients have completed the Baseline Clinic Visit.
223906243|NCT06353217|OTHER|Clinic Staff Group|Clinic staff will provide the tablet to the participant immediately prior to the patient's primary care provider visit.
223906244|NCT05943288|DEVICE|OIP-1|Olympus Endoscopy Computer-Aided Detection (CADe) system
223906245|NCT05197790|DEVICE|FDA approved pulse oximeter and DOVE device prototype|The objective is to assess reasonable detection of hypoxic episodes
223906246|NCT06418880|DEVICE|AID system with Remote Real-Time CGM|"The Omnipod 5 AID System is comprised of two components:~* Omnipod 5 Pod (insulin infusion pump with SmartAdjust technology)~* Omnipod 5 App (installed on the Controller or smart phone) The Omnipod 5 AID pod is a lightweight, self-adhesive device that the user fills with U-100 rapid-acting insulin and wears directly on their body. The Pod delivers insulin into the user's body through a small flexible tube, called a cannula, based on the commands from the compatible Controller. In the Omnipod 5 AID System, the Pod itself houses the MPC algorithm and communicates directly with the CGM and the Omnipod 5 App. Based on predicted glucose values, the algorithm commands the Pod's insulin delivery through micro-boluses."
223906247|NCT06418880|COMBINATION_PRODUCT|Standard of Care Insulin Therapy + CGM|"This includes the usage of subcutaneous insulin for glucose control. Participants will wear a real-time Continuous Monitoring (CGM) for 10 days or until hospital discharge (if \<10 days).~Treatment decisions will be based on POC testing with consideration of daily evaluation of CGM patterns."
223906248|NCT06162715|DRUG|Tirzepatide|Tirzepatide will be initiated 12 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 6 weeks following an adaptive maximum dose titration protocol. Patients will then complete a final 4 weeks of the study drug.
223906249|NCT06162715|OTHER|Standard of Care post-gastric bypass|Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook. This includes recommendations for 64 oz of fluids per day, ≥60 grams of protein/day, and daily bariatric multivitamins. Patients will continue to have access to dedicated bariatric dietitians, advanced practice providers, and surgeons on an ad hoc basis per patients' request.
223906250|NCT03134755|DRUG|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
223906251|NCT06026514|BIOLOGICAL|B/HPIV3/S-6P|Intranasal vaccine.
223906252|NCT06262412|BEHAVIORAL|Internet-delivered cognitive-behaviour therapy (ICBT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD and strategies to resolve possible ambivalence towards psychological treatment. The main goal of the treatment is to help the young person to stop avoiding anxiety-provoking situations (e.g., going to school or participating in social situations) by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals (e.g., excessive mirror-checking, camouflaging), known as response prevention. Every module also contains homework tasks that are meant to be completed between modules and mainly consist of exposure and response prevention (ERP) tasks based on the young person's individual goals."
223906253|NCT06262412|BEHAVIORAL|Internet-delivered relaxation treatment (IRT)|"The intervention is Internet-delivered and therapist-guided, involving both the adolescent and at least one caregiver. It consists of two separate sets of modules, one for the adolescent and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The first part includes psychoeducation about BDD, how anxiety and stress are major contributors to BDD symptoms, and that targeting and reducing stress will have a beneficial impact on those symptoms. The main goal of the treatment is to teach the young person to relax in order to cope with anxiety and appearance concerns. The intervention mainly consists of a relaxation treatment and includes different relaxation skills such as deep breathing, progressive muscle relaxation, and imagery (cognitive relaxation). Every module also contains homework tasks that are meant to be completed between modules and mainly consist of relaxation tasks."
223906254|NCT06281080|PROCEDURE|En-Bloc Resection of Bladder Tumours|Patients underwent En-Bloc Resection of Bladder Tumours using Agilis Robotic System.
223906255|NCT05397067|BEHAVIORAL|Peer specialist (PS) and vouchers|this participants will receive vouchers from PS
223906256|NCT04737330|DRUG|Secukinumab|Secukinumab 300 mg s.c. at Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, Week 12
224277119|NCT01814358|DIETARY_SUPPLEMENT|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
224277120|NCT01814358|DIETARY_SUPPLEMENT|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
223906257|NCT04737330|DRUG|Placebo|Placebo s.c. at Baseline, Weeks 1, Week 2, Week 3, Week 4, Week 8, Week 12
223906258|NCT05296928|PROCEDURE|laparoscopic incision|laparoscopic umbilical trocar entry pathways
223906259|NCT06367608|DEVICE|ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's dystonia . The ExAblate uses ultrasound to heat a small spot in the brain called globus pallidus internus(GPi). Ultrasound passes through the skin and skull and into the brain to focus on this particular spot.
223906260|NCT06206148|DEVICE|Given novel electronic pain recording device|Patients in this arm will be given a custom-built pain recording device to see if the method of self-reported data collection has any effect on how many data points are collected.
223906261|NCT06206148|OTHER|Given Hand-written pain journal|Patients in this arm will be given a hand-written pain journal to see if the method of self-reported data collection has any effect on how many data points are collected.
223906262|NCT06206148|OTHER|Smartphone app|Patients in this arm will be given a research smartphone with survey app to see if the method of self-reported data collection has any effect on how many data points are collected.
223906263|NCT04560920|OTHER|Availability of contextual PGHD at the visit|Contextual PGD will be available in a display at the visit.
223906264|NCT04231331|DRUG|Ertugliflozin|Ertugliflozin 5mg qd for 12 months
223906265|NCT04231331|DRUG|Placebo|Placebo qd for 12 months
223906266|NCT03760406|PROCEDURE|Opti-VIM targeting in DBS surgery|DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
223906267|NCT03026517|DRUG|Dabrafenib|
223906268|NCT03026517|DRUG|Trametinib|
223906269|NCT03026517|DRUG|Phenformin|
223906270|NCT03746106|DRUG|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.
223906271|NCT03746106|DRUG|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.
223906272|NCT03746106|DIETARY_SUPPLEMENT|Vitamin B1|5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.
223906273|NCT01651403|DRUG|Tenofovir DF|"* Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
223906274|NCT01651403|DRUG|TDF Placebo|"* Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
223906275|NCT03435510|BEHAVIORAL|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
223906276|NCT05236647|DRUG|Morphine|Intravenous morphine infusion compared to subcutaneous morphine infusion
223906277|NCT03100760|DEVICE|13C-urea breath test|Subjects will undergo 13C-urea breath test involving collection of baseline breath samples, nebulization of 13C-urea, and collection of post-nebulization breath samples
224277121|NCT00462839|PROCEDURE|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
223906278|NCT05936827|DIAGNOSTIC_TEST|Ergometry|"Maximal exercise test is performed on a cycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany). The test begins at a workload of 50 W, which is increased by 25 W (males) every 1 min or the test begins with 25 W which is increased by 25 W (females) every 1 min until exhaustion.~The mean workload during the last 4 min of work is calculated and the VO2max is estimated according to the American College of Sports Medicine (American College of Sports Medicine.~ACSM's guidelines for exercise testing and prescription. Sixth edition. Baltimore: Williams \& Wilkins 2000:304). Blood lactate concentration is measured immediately and 1 min after exhaustion from capillary samples (Biosen C-Line Glucose and Lactate analyzer, EKFdiagnostic GmbH, Germany). (Pahkala et al. 2013.)"
223906279|NCT05936827|DIAGNOSTIC_TEST|Ergospirometry|"VO2max is measured using a stationary bicycle ergometer (Ergoline 800 s; VIASYS Healthcare, Germany. For males, the test starts with 100 W which is increased by 25 W every 1 min until volitional exhaustion. For females, the test starts with 50 W which is increased by 25 W every 1 min until volitional exhaustion.~Ventilation and gas exchange (Vyntus CPX, Vyaire Medical Gmbh, Leibnizstrasse, Hoechberg, Germany) are measured during the test. Subject's blood lactate concentration is measured from capillary samples immediately and 1 min after exhaustion (Biosen C-Line Glucose and Lactate analyzer, EKF-diagnostic GmbH, Germany). The heart rate of the participants is followed continuously (CardioSoft GE, CardioSoft V6.51; GE Medical Systems Information Technologies, USA). (Heiskanen et al. 2021.)"
223906280|NCT06999811|BEHAVIORAL|Empowering Pregnant Women and People Receiving medications for opioid use disorder (EMPWR)|EMPWR is evidence-informed, behavioral intervention to address risk factors for fear of opioid withdrawal, craving, and stress, with an adjective mobile application among pregnant women receiving opioid agonist therapies. The goal of EMPWR is to promote medication retention and adherence.
223906281|NCT06999811|OTHER|Medication monitoring (control)|Participants will record the dose and time buprenorphine was taken for two months via REDCap daily diaries, which will be delivered via text.
223906282|NCT05494359|DIAGNOSTIC_TEST|The nitrogen isotope|The nitrogen mass-charge ratio abundances (NMAs) and NMA ratios (NMARs) The nitrogen components of various m/z values in oral gas were detected.
223906283|NCT07039981|DEVICE|Omnipod M system|The Omnipod M system will allow user to use a lower glucose target and improve systems glucose control
223906284|NCT07035327|OTHER|Dual-task training program|"Participants in the intervention group will engage in a dual-task training program, in which resistance training will be incorporated with cognitive tasks.~\- Resistance training: Participants will be instructed to perform the following exercises with proper form: (1) squat to chair, (2) seated unilateral hip flexion, (3) seated unilateral knee extension, (4) standing unilateral knee flexion and (5) bilateral calf raise. The lower limb exercises will be followed by four upper limb exercises: (6) seated elbow flexion, (7) twisting a towel, (8) seated horizontal opening of arms and elbow, (9) seated diagonal opening of arm and elbow.~\- Cognitive task: Subjects will be asked to perform a verbal fluency task or mental arithmetic tasks simultaneously with the resistance training exercises."
223906285|NCT07035327|OTHER|Resistance exercise|Subjects in the control group will perform the resistance exercises only without receiving any cognitive training. Ten-minute warm-up and cool-down sessions will precede and follow each exercise session.
223906286|NCT06254482|DRUG|PTC518|PTC518 will be administered per dose and schedule specified in the arm.
223906287|NCT00636389|DEVICE|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
223906288|NCT00636389|DEVICE|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
223906289|NCT07058792|OTHER|Medjool dates|Medjool dates are a dried fruit.
223906290|NCT07064343|OTHER|Aspirin|Participants are required to complete the training program includes an educational workshops and five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model.
223906291|NCT07064213|BEHAVIORAL|Behavioral: Educational Video|Participants will watch a 2-minute educational video in Hebrew about perineal tears and episiotomy. The video includes information about types and grades of tears, risk factors, prevention strategies, episiotomy use, healing process, and when to seek help. The video is presented on a secure mobile device by the research team before the onset of active labor.
223906292|NCT07063199|DRUG|Daratumumab Injection|"This study adopts a prospective, single arm, open design method. Thirty subjects were enrolled in the study and were treated with CD38 monoclonal antibody (Daratumumab 16mg/kg/w) for 4 weeks.~The first stage is the main research stage (d1-w4), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Daratumumab once a week for 4 weeks to observe the safety and efficacy during treatment.~The second stage (w5-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Daratumumab after treatment."
223906293|NCT07062458|DIAGNOSTIC_TEST|Nipple Sensation Assessment|"the measurement of nipple sensation preservation, will be conducted using the Semmes-Weinstein esthesiometer. The clinician will use the device to touch the nipple and the surrounding quadrants of the skin, applying filaments of increasing calibers (0.07gr, 0.4gr, 2.0gr, 4.0gr, 300gr), and the lightest caliber perceived by the patient will be recorded. This assessment will be conducted at four different times:~* Before surgery, to assess baseline sensation.~* 1 month after surgery.~* 3 months after surgery.~* 6 months after surgery."
223906294|NCT07063082|OTHER|Erythromycin Phonophoresis|The procedures of ultrasound phonophoresis will be as follows: Patients will be positioned comfortably, sitting in a relaxed position. The physiotherapist will explain the treatment procedures to the patient. The device cables will be checked before each session. The treatment will last 5 minutes for each maxillary sinus. The frequency will be set to 1 MHz, and the intensity will be 1 W/Cm2 for the maxillary sinuses. The ultrasound will be pulsed, and the treatment will consist of 12 sessions, 3 days per week.
223906295|NCT07063082|DEVICE|Ultrasound (US)|"Therapeutic US is produced by a transducer composed of a piezoelectric crystal, which converts electric energy into alternating compression and rarefaction of sound waves at a frequency greater than 20 kHz. The amplitude of the US wave is proportional to the displacement of the US transducer head during each half cycle. The amplitude represents the wave energy.~The ultrasound waves penetrate the tissue on the way to the target organ and have two mechanisms of action (thermal and non-thermal), which may potentially work synergistically to reduce nasal symptoms (nasal blockage and secretions)."
224277122|NCT00250705|DRUG|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
223906296|NCT07063082|DRUG|Topical Erythromycin|Erythromycin is a 14-member macrolide originally discovered in the 1950s. It has broad-spectrum antimicrobial action, inhibiting bacterial protein synthesis. studies have shown that erythromycin has immunomodulatory and anti-inflammatory activity independent of its antimicrobial action Erythromycin is a broad-spectrum macrolide antibiotic, wherein its bactericidal effect occurs by the inhibition of protein synthesis. It is used for the treatment of infections affecting the skin and mucosa; it shows immunomodulatory characteristics
224277123|NCT05853783|OTHER|STRATICYTE™ Test|Assessment for risk of progression to oral cancer
223906297|NCT07063082|OTHER|Medical treatment|Saline nasal wash 3 times daily for a month.
223906298|NCT07063953|OTHER|Standard Physical Therapy|Hot pack \& Transcutaneous Electric Nerve Stimulation (TENS) Myofascial Release Mulligan Mobilization with Movement Exercises
224083531|NCT03311048|OTHER|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
223906299|NCT07063953|OTHER|Egoscue Exercises|Warm Up Exercises (5 min) which includes Stretching ,Walking (Forward, Backward, Sideways), Arm Circles, Side bends, March on the spot, Knee lifts, Standing Gluteal Contractions , Sitting heel raises, Isolated hip flexor lifts on a towel, Supine groin stretch on towels, Static back, Sitting Knee Pillow Squeezes, Sitting floor, Progressive supine groin, Supine calf-hamstring stretch with a strap,Foot circles and point flexes, Cool Down and Breathing Exercises
223906300|NCT06934642|DRUG|Tirzepatide|The drug is being studied to better understand the biological effects of tirzepatide on MASLD.
223906301|NCT04362644|DRUG|PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714|Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
223906302|NCT05895136|DRUG|Human albumin|"Human albumin solution is made from pooled human plasma. It is widely used as a plasma-expander in several disease conditions, such as liver cirrhosis and critically ill patients.~ATC-Code: B05AA01"
223906303|NCT05895136|DRUG|Enoxaparin|Enoxaparin is a drug that belongs to the group of anticoagulants. It exerts its antithrombotic activity by binding to antithrombin III (AT III). ATC-Code: B01AB05
223906304|NCT05895136|DRUG|Standard medical treatment|SMT will be considered non-study medication and is not specified in the protocol.
223906305|NCT04732598|DRUG|Paclitaxel + bevacizumab therapy|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV"
223906306|NCT04732598|DRUG|Paclitaxel + bevacizumab + atezolizumab|"The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.~\[Atezolizumab\] 840 mg/body, day 1,15, IV \[Paclitaxel\] 90mg/m\^2, day1,8,15, IV \[Bevacizumab\] 10mg/kg, day1,15, IV"
223906307|NCT05603741|DRUG|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
223906308|NCT05603741|DRUG|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
223906309|NCT03683420|BEHAVIORAL|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
223906310|NCT05327465|OTHER|Aerobic and resistance exercise|Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
223906311|NCT05327465|OTHER|Usual Care|Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
223906312|NCT06562283|OTHER|Thumb test|Thumb adduction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
223906313|NCT06562283|OTHER|Grip test|Muscle contraction gripping test, consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
223906314|NCT06562283|OTHER|Quadriceps Intermittent Fatigue test (QIF test))|Quadriceps muscle contraction test consisting of intermittent, repetitive isometric contractions lasting 5 seconds at incremental percentages of maximum force.
223906315|NCT04974632|PROCEDURE|localization|small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
223906316|NCT04231149|DEVICE|Test product 2|Test catheter 2
223906317|NCT04231149|DEVICE|Test product 3|Test catheter 3
223906318|NCT04231149|DEVICE|Comparator|SpeediCath Flex
223906319|NCT05877976|BEHAVIORAL|Visual Arts Immersion|Museum educators from The Metropolitan Museum of Art (MET) will provide a curriculum including an art immersion program that will select specific works/art in the museum as well as virtually that will help to stimulate self-reflection and prompt connection to their nursing practice. Participants will be asked to sign up for 2 art immersion classes. The first class will be an in-person class at The MET and the second class will be virtual via WebEx. Each class will last 60 minutes.
223906320|NCT05058833|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.
223906321|NCT05058833|DIAGNOSTIC_TEST|Coronary flow reserve and index of microcirculatory dysfunction|Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
223906322|NCT04296097|DEVICE|DBS|Deep Brain Stimulation (DBS) of the parieto-insular region at the level of the right operculum 3 (OP3)
223906323|NCT06436807|DEVICE|Indwelling catheter|The tunneled catheter is an implant product that enables the drainage of effusion accumulations from serous body cavities so that the symptoms caused by an effusion are relieved by draining off the accumulated fluids.
223906324|NCT04271644|BIOLOGICAL|BCMA CAR-T cells|BCMA CAR-T cell therapy
223906325|NCT03982316|BEHAVIORAL|Telehealth Behavioral Migraine Management|1\) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
223906326|NCT05134246|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
223906327|NCT05134246|PROCEDURE|Carotid artery stenting (CAS)|Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
223906328|NCT03916978|BIOLOGICAL|Autologous PRP intra ovarian infusion|Autologous PRP intra ovarian infusion
223906329|NCT03916978|BIOLOGICAL|Autologous PFP intra ovarian infusion|Autologous PFP intra ovarian infusion
223906330|NCT05823220|BEHAVIORAL|Homeless diversion (HD)|Participants will receive services from specialty-trained community health workers and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
223906331|NCT05823220|BEHAVIORAL|Treatment-as-usual (TAU)|Participants will receive a list of community resources they can contact to receive services and will be invited to complete monthly assessments via text and phone to assess their health and housing for 6 months and to share feedback on their experience with the intervention after completion by a text message to a link for the survey
223906332|NCT06207136|OTHER|Mediterranean-style diet|Coaching in the intervention diet group will promote higher consumption of healthier foods and cooking oils, while discouraging processed foods.
223906333|NCT05408793|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
223906334|NCT05520346|DEVICE|Electronic Device for Toilet|Device will be installed on toilet of patients will in hospital to measure all waste output.
223906335|NCT06016387|DRUG|Tucatinib 150 MG|Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
223906336|NCT06016387|DRUG|Trastuzumab|"MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations."
223906337|NCT06016387|DRUG|Capecitabine|Capecitabine is a tumour-activated antineoplastic agent (antimetabolite). The molecular formula for capecitabine is C15H22FN3O6 and has a molecular weight of 359.35 g/mol.
223906338|NCT06016387|RADIATION|Brain & Spinal Radiation|Brain \& Spinal XRT is a treatment for patients with HER2+ metastatic breast cancer and leptomeningeal disease,
223906339|NCT05622812|DEVICE|Restylane Lyft Lidocaine|Treatment for Jawline definition
223906340|NCT05938855|DEVICE|Electrical stimulation and biofeedback with the medical device Phenix Liberty|"The patient will undergo 10 therapeutic functional re-education sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used.~The patients will complete questionnaires at the end of the care Overall, the functional perineal rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 10 sessions between 10 and 12 weeks~* 1 end visit, within the week after the 10th session"
223906341|NCT04359784|BIOLOGICAL|Anakinra|Given IV (previously SC)
224277124|NCT04606017|DRUG|Caltrate Pill|VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
223906342|NCT04359784|PROCEDURE|X-Ray Imaging|Undergo x-ray
223906343|NCT04359784|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223906344|NCT04359784|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
223906345|NCT04359784|PROCEDURE|Bone Marrow Aspiration|Undergo BMA
223906346|NCT04359784|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223906347|NCT04359784|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223906348|NCT04359784|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223906349|NCT06290492|DEVICE|transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
224277125|NCT03944161|DIETARY_SUPPLEMENT|Oral nutrition supplement|Hypercaloric and high protein supplement
223906350|NCT06290492|DEVICE|sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
223906351|NCT05314491|DEVICE|Multigen Plus CCK|Total Knee Arthroplasty
223906352|NCT05314491|DEVICE|AMF TT cones|To fill a proximal tibia or distal femur defect
223906353|NCT04133077|BIOLOGICAL|blood samples collection|Serology and genetic analyses will be performed in patients blood samples
223906354|NCT04453774|DEVICE|Covidfree@home|Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
224083532|NCT00244595|DRUG|candsartan cilexetil|
224083533|NCT00124111|DRUG|pegfilgrastim|
224277126|NCT03944161|OTHER|Nutritional advice|Advice given by the clinician
224277127|NCT06678061|DEVICE|radiofrequency|block of neurolytic retrocrural celiac plexus block
224277128|NCT05676008|BEHAVIORAL|Microdosing of mindfulness|The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
224277129|NCT03129776|DRUG|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
224083534|NCT00124111|DRUG|cyclophosphamide|
224083535|NCT00124111|DRUG|methotrexate|
224083536|NCT00124111|DRUG|5-fluorouracil|
224083537|NCT01228903|DRUG|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
223906355|NCT04711369|DEVICE|Erbium:Yag laser|"Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed."
223906356|NCT04711369|DEVICE|Sham Erbium:Yag laser|"Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use."
223906357|NCT05483933|DRUG|Pegylated Liposomal Doxorubicin + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
223906358|NCT05483933|DRUG|Mirvetuximab + SL-172154|The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
223906359|NCT06308198|DRUG|AGN-151586|Intramuscular Injections
223906360|NCT06308198|DRUG|Placebo|Intramuscular Injections
223906361|NCT06353022|DRUG|Teclistamab|Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
223906362|NCT06353022|DRUG|Talquetamab|Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
223906363|NCT06353022|DRUG|Lenalidomide|"Induction therapy with lenalidomide:~Lenalidomide 25 mg/day oral from Day 1 to Day 21.~Maintenance therapy lenalidomide (administered orally) for finite duration."
223906364|NCT06353022|DRUG|Bortezomib|Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
223906365|NCT06353022|DRUG|Daratumumab|Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
223906366|NCT06353022|DRUG|Dexamethasone|"Induction therapy with Dexamethasone:~cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22"
223906367|NCT05079698|DRUG|177Lu-PSMA-617|Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
223906368|NCT05079698|PROCEDURE|Stereotactic Body Radiotherapy (SBRT)|No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
223906369|NCT03916185|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L Vaccine|10\^6 plaque-forming units (PFU); administered as nose drops
223906370|NCT03916185|BIOLOGICAL|RSV 6120/ΔNS2/1030s Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
223906371|NCT03916185|BIOLOGICAL|RSV 276 Vaccine|10\^5 plaque-forming units (PFU); administered as nose drops
223906372|NCT03916185|BIOLOGICAL|Placebo|Administered as nose drops
223906373|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) + HIKA|Economic empowerment program using animal husbandry for young adolescents and healthy relationship program for parents/couples in same household
223906374|NCT05763719|BEHAVIORAL|Rabbits for Resilience (RFR) only|Economic empowerment program using animal husbandry with young adolescents
223906375|NCT05763719|BEHAVIORAL|HIKA Healthy Relationship Program|Healthy relationship program for parents/couples
223906376|NCT04177953|DRUG|Carboplatin AUC 5|chemotherapy iv
223906377|NCT04177953|DRUG|Cisplatin 75 mg/m2|chemotherapy iv
223906378|NCT04177953|DRUG|Pemetrexed 500 mg/m2|chemotherapy iv
223906379|NCT04177953|BIOLOGICAL|Nivolumab Injection|Human monoclonal antibody
223906380|NCT05840315|DIETARY_SUPPLEMENT|Basic intervention and nutritional intervention|"The training plan is divided into 3 parts with different sub-components. There will be ongoing enrollment until 10 participants have been recruited, after which the next sub-trial will start recruitment. The intervention from the respective sub-trials is described in the individual study phases.~Participants attend one-hour exercise sessions, 2 times/week for 8 weeks, in groups of 4-7 patients, supervised by 2-3 physio therapists.~After completion of the physical intervention all participants are given a nutritional supplement, being a 200ml cocoa(Chokolate milk), containing 7 grams of protein, 24grams of carbohydrates, 5 grams of fat and in total 166 kilocalories. If any participant has lactose intolerance or diabetes, they are advised to bring an egg and a piece of rye bread to secure an equal amount of protein and calories."
223906381|NCT05840315|PROCEDURE|Sit-to-stand|"First subtrial (participants 1-10):~Sit-to-stand-to-sit training: Participants will be instructed to do as many sit-to-stand repetitions as possible without using their arms in a 30 second window, followed by a 30 second rest. This sequence is repeated for a total of 10 sets (a total of 10 minutes). Standard seat height of chair is 46 cm.~Progression/regression: If a participant is unable to do at least 6 repetitions on the first sit-to-stand test, they are allowed to sit on a 6cm airex pillow while performing the exercise. When a single set of 12 chair rises are attained or total amount of repetitions reach 100 in 10 sets on an airex, the participant progresses to sitting on a 6-0,5cm wedge pillow, and again when the participant attains 12 rises, he/she progress to rising from the standard chair height."
223906382|NCT05840315|PROCEDURE|Leg press|"Second subtrial (participants 11-20):~In addition to the above intervention, progressive strength training is performed on a leg press, consisting of 3 sets of 8-12RM. Participants are instructed to do as many repetitions as possible, and the weight is increased if either 12 repetitions are performed on three consecutive sets or a single set or more than 14 repetitions are completed. If fewer than 6 repetitions are performed, the weight is reduced . There is a minimum of one minute break between each set of training on the leg press."
224083538|NCT01228903|OTHER|Placebo|Placebo tablets with no active ingredient
223906383|NCT05840315|PROCEDURE|Hip abduction|"Third subtrial (participants 21-30):~In addition to interventions described in sub-trial 1, Third subtrial will perform progressive strength training for the gluteal muscles is carried out in form of hip abduction, using rubber bands, consisting of 3 sets of 8-12RM using the same procedure as above mentioned for the leg press.~Hip abduction will be performed from a standing position with a straight arm length from a wall, supporting the wall. The participant will be instructed to abduct the hip facing the wall until the foot is in contact with the wall, and then back until it touches the standing leg.~Progression will be placing a rubber band just proximal to the knee with resistances being: yellow= light, red= moderate, blue= heavy.~further progression will be placing the rubber band around the ankles using the same progression as above."
223906384|NCT03571763|OTHER|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
223906385|NCT06057454|DRUG|R-5280|Modified Superior Starch
223906386|NCT06057454|OTHER|Placebo|Food Grade Starch
223906387|NCT00513760|DIETARY_SUPPLEMENT|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
223906388|NCT00513760|DIETARY_SUPPLEMENT|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
223906389|NCT00513760|DIETARY_SUPPLEMENT|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
223906390|NCT05331300|DRUG|LASN01|Escalating single and multiple doses of LASN01
223906391|NCT05331300|DRUG|LASN01|LASN01 will be administered intravenously
223906392|NCT05331300|DRUG|Placebo|Escalating doses of matching placebo
223906393|NCT05331300|DRUG|Placebo|Placebo will be administered intravenously
223906394|NCT00120263|PROCEDURE|Plasma Exchange|
223906395|NCT02476838|PROCEDURE|Hand Transplantation|microvascular VCA transplant
223906396|NCT03832569|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
223906397|NCT06214559|DEVICE|Sérum VERRUPRO|To be applied twice a day
223906398|NCT05816603|DEVICE|Real Soterix Mini-CT tDCS stimulator|Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration.
223906399|NCT05816603|DEVICE|Sham Soterix Mini-CT tDCS stimulator|Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes/day, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up/ramp down will be repeated.
224277130|NCT03129776|DRUG|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
223906400|NCT05422638|BEHAVIORAL|RBSTE|8-week health promotion group focused on supporting coping with racism and empowerment
223906401|NCT05422638|BEHAVIORAL|PCT|8-week health promotion group focused on providing support and facilitating problem solving
223906402|NCT06128655|OTHER|Participation in PFCC-IR|PFCC-IR with the critical care team is standard practice in ICU but it doesn't usually include family members. The intervention for this study is interdisciplinary patient care rounds that include one family member of the patient.
223906403|NCT05128942|DRUG|Tildacerfont|Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
223906404|NCT02844465|DEVICE|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
223906405|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Insomnia|The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
223906406|NCT04936321|BEHAVIORAL|Internet-delivered CBT for Pain Management|The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
223906407|NCT04936321|BEHAVIORAL|Internet-delivered Sleep Education|The program delivers publicly available information about sleep.
223906408|NCT06134752|OTHER|Pulse field ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
223906409|NCT06134752|OTHER|Radiofrequency ablation|Point by point isolation of pulmonary veins and left atrial posterior wall
223906410|NCT06345430|DEVICE|Exopulse Molli-Suit (Wearable Technological Device)|After initial evaluations, patients will receive Exopulse Mollii Suit in a single session for 1 hour. The stimulation level of the electrodes will be automatically generated by the system in accordance with the pain level specified by the patients for their body parts before the application.
223906411|NCT03184233|PROCEDURE|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
223906412|NCT03184233|PROCEDURE|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
223906413|NCT04901988|DRUG|Nivolumab 10 MG/ML|Eligible patients randomised to Arm B will receive 480 mg nivolumab monotherapy 4 weekly via IV infusion for up to 2 years.
223906414|NCT04357873|DRUG|pembrolizumab; vorinostat|"Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations~Vorinostat: 400 mg once daily, until progression"
223906415|NCT04109027|BEHAVIORAL|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
223906416|NCT04109027|BEHAVIORAL|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
223906417|NCT03828786|PROCEDURE|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
223906418|NCT06185985|DRUG|SPN-812|SPN-812 (200mg to 600mg once daily)
223906419|NCT04979572|DRUG|TS-172|"* Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner"
224277131|NCT03602027|DRUG|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
223906420|NCT04979572|DRUG|Placebo|"* Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner"
223906421|NCT03935854|OTHER|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
223906422|NCT04812093|DEVICE|Spectroscopic otoscope measurements|Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
223906423|NCT03142802|DIAGNOSTIC_TEST|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~1. Normal LDCT:~   \- Patient continues on the study (i.e. continued surveillance)~2. Suspicious LDCT:~   \- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~3. Elevated serum tumour markers or other evidence of metastatic disease:~   * Patient goes off study"
223906424|NCT05856448|DRUG|GLPG3667|Capsule
223906425|NCT05856448|DRUG|Placebo|Capsule
223906426|NCT06315335|DRUG|UCB9741|Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.
223906427|NCT06315335|DRUG|Placebo|Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
223906428|NCT06659952|OTHER|HIV-positive heart transplant|Receipt of heart from HIV-positive deceased donor only as part of this study
223906429|NCT03581773|DRUG|Folic Acid|5 mg pr day for 12 weeks
223906430|NCT03581773|DRUG|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
223906431|NCT02460458|DRUG|Von Willebrand Factor|Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.
223906432|NCT06408714|DRUG|Nalmefene Injection|"Subjects in this arm will be administered intravenous nalmefene with a dosing scheme of:~0.5 mg Nalmefene IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 1.0 mg nalmefene will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion."
223906433|NCT06408714|DRUG|Naloxone Injection|"Subjects in this arm will be administered intravenous naloxone with a dosing scheme of:~0.4 mg Naloxone IV~If an adequate response (increase in RR of at least 5 breaths per minute and minimum respiratory rate of 12 breaths per minute or reduction in ETCO2 to 40 mm Hg) is not attained after 2 minutes, an additional 0.4 mg of naloxone will be administered.~If an adequate response is not attained after an additional 2 minutes of observation, naloxone may be administered as a rescue agent at the treating physician's discretion."
223906434|NCT06207994|DEVICE|Narrow TR|The width of the PRICO SpO2 TR is set to 3% SpO2.
223906435|NCT06207994|DEVICE|Shifted TR|The lower and the upper limits of the PRICO SpO2 TR are increased by 1% SpO2.
223906436|NCT05892861|BEHAVIORAL|cognitive stimulation|video education, board games, and 24-hour dietary recall record
223906437|NCT05892861|OTHER|as usual care|history taking, explain data, and discuss how to control healthy condition
223906438|NCT03446391|PROCEDURE|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
223906439|NCT03446391|PROCEDURE|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
223906440|NCT03446391|DEVICE|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
223906441|NCT03952338|OTHER|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
223906442|NCT03952338|OTHER|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
223906443|NCT03996772|DRUG|Apixaban Oral Tablet|Factor Xa Inhibitor
223906444|NCT03996772|DRUG|Dabigatran|Direct Thrombin Inhibitor
223906445|NCT03996772|DRUG|Edoxaban Tablets|Factor Xa Inhibitor
223906446|NCT03996772|DRUG|Rivaroxaban|Factor Xa Inhibitor
223906447|NCT04063592|PROCEDURE|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
223906448|NCT05433454|OTHER|Outreach From Navigators|Navigators are professionals who can provide one-on-one assistance with the Medicaid renewal process. The nature of the outreach will be randomized to participants.
223906449|NCT04046861|DIETARY_SUPPLEMENT|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
223906450|NCT04046861|OTHER|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
223906451|NCT05668260|DEVICE|Biodegradable Stent|A trans-anastomotic biodegradable internal stent (ARCHIMEDES™) will be placed between the main pancreatic duct (MPD) and the enterotomy in the jejunum just after the completion of the posterior suture of duct-to-mucosa. The biodegradable stent will then be shaped according to the angle of the jejunal loop in order to minimise the risk of displacement. The adequate length of the stent will be chosen according to the length of the jejunal loop.
224277132|NCT03602027|DRUG|Gefitinib|Gefitinib 250mg orally daily for three weeks
224277133|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (rabbit)|
223906452|NCT06555484|DEVICE|Cross Over Assignment Supplemental Oxygen and Supplemental Air|"Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned)."
223906453|NCT06543628|DRUG|Tadalafil 5mg|Participants will take tadalafil once daily at a dose of 5 mg for 6 months.
223906454|NCT06543628|DEVICE|LIPUS (Low Intensity Pulsed Ultrasound)|Participants will receive LIPUS treatment applied twice a week for 4 weeks, with the cycle repeated after a 4-week interval without treatment.
223906455|NCT06633835|BIOLOGICAL|protein subunit: Novavax COVID-19 vaccine|Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
223906456|NCT06633835|BIOLOGICAL|Pfizer mRNA COVID-19 vaccine|Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
223906457|NCT05715268|DEVICE|WeB|"Participants will be given WeB devices and trained on the use of these devices for home therapy, including the associated mobile applications. Participants will be given home programs and given a schedule to use the WeB devices at home on their own time. At their standard visit participants will have their WeB device use checked and progressed as the therapist deems appropriate.~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
223906458|NCT05715268|OTHER|Standard pelvic floor physical therapy|"Baseline will consist of a standard PFPT evaluation. Regular visits (tele-video visits or in-person depending on the patients preference) will be scheduled every week for the first 4 weeks and then every other week at the discretion of the therapist. A total of 8-10 visits will be scheduled over the 12 weeks of the study. Participants will be given home exercise programs (as per standard PFPT).~An in-person visit will be scheduled to re-evaluated participants at the 12 week study completion."
223906459|NCT05727618|DRUG|Pituitrin|The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
223906460|NCT05727618|DRUG|normal saline|Intravenous infusion of normal saline at the same dose and speed
223906461|NCT05402436|OTHER|A diagnosis of atypia as part of the English screening programme|An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
223906462|NCT06230848|PROCEDURE|Multisensory Early Oral Administration of Human Milk (M-MILK)|M-MILK is implemented as droplets, at day 3 of life, after every hands-on care, and during the beginning of a full gavage feeding. The infant may be supportively positioned in bed, held skin-to-skin by caregiver, or held/cradled by nurse or caregiver. The nurse draws up 1 mL of milk into the 1-mL syringe from a prepared bottle or enteral feeding syringe. The nurse then proceeds to implement M-MILK while observing the infant's responses closely. The nurse talks to the infant with a soft calm voice while providing gentle touch throughout the intervention. The nurse begins M-MILK by first placing 1-2 drops of milk onto the infant's upper lip, allowing the infant to feel and smell the milk. The nurse gently strokes the infant's lips with a pacifier/swab or infant's fingers. M-MILK will be provided based on infants' responses and cues. M-MILK is concluded if the infant is no longer engaged or has finished the 1 mL of milk.
223906463|NCT06291493|DIAGNOSTIC_TEST|Fingerstick blood draw|Capillary blood specimen collected from two separate fingerstick blood draws.
223906464|NCT06493955|OTHER|Adapted physical activity for 12 months|6 additional months of adapted physical activity after the 6 first months
223906465|NCT06493955|OTHER|Adapted physical activity for 6 months|standard 6-month prescription for adapted physical activity
223906466|NCT06852391|DRUG|Semaglutide Pen Injector|Semaglutide will be delivered by a subcutaneous injection using an injectable pen once weekly. Semaglutide is formulated with 5 approved doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg). Treatment will commence with the lowest dose and will be increased every 4 weeks to the maximum tolerable dose where they will remain for the remainder of the treatment. Participants who are taking the drug will have monthly visits to assess any adverse events, dose titration and drug adherence.
223906467|NCT06852391|BEHAVIORAL|Behavioural Lifestyle Program (BLP)|The BLP will be delivered by the Growing Healthy Weight Management (GHWM) pediatric program at McMaster Children's Hospital. GHWM is a family-based program addressing health behaviours (nutritional pattern and eating behaviours, physical activity, sedentary time and sleep) and physical and mental health issues. In Year 1, the program typically includes 2 group sessions and monthly individualized sessions with the participant and their family. The interdisciplinary weight management team is comprised of a registered dietician, exercise physiologist, kinesiologist, social worker and/or psychologist, general pediatrician and pediatric endocrinologists.
223906468|NCT06851819|RADIATION|radiotherapy|Palliative radiotherapy for oligometastases can be combined with chemoradiotherapy and immunomaintenance therapy period. The investigator determines the number, timing and regimen of oligometastases according to the location, size, symptoms and patient tolerance of oligometastases
223906469|NCT06851819|DRUG|immunechemotherapy|Tislelizumab in Combination With Chemotherapy(etoposide/cisplatin )
223906470|NCT06852703|OTHER|Infection during pregnancy|any bacterial or viral infection acquired during pregnancy
224083539|NCT03885271|OTHER|Hall Technique|The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate
224083540|NCT03885271|OTHER|Formecresol Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
223715786|NCT05246501|OTHER|Simulation|A case scenario with a diagnosis of dementia was used in the study. The scenario consisted of preliminary preparation, implementation and evaluation parts. Psychiatric nursing laboratory practice was applied to the students in the scenario study group. An elderly female standard patient who was diagnosed with dementia took part in the scenario. During this simulation, students were expected to perform mental state examination of the patient, use therapeutic communication techniques and ensure environmental safety.
224083541|NCT06405464|DRUG|VOCABRIA 30Mg Tablet|CAB 30 mg Film-coated tablets
224083542|NCT06405464|DRUG|EDURANT 25Mg Tablet|RPV 25 mg film-coated tablets
224083543|NCT06405464|DRUG|Cabotegravir Injectable Suspension|CAB LA 600 mg prolonged release suspension for injection (3 mL)
223906471|NCT05762133|BEHAVIORAL|African-American Social Support Effectiveness Treatment-Partners alleviating Perinatal Depression (ASSET-PPD)|This proposed novel intervention has four prenatal modules and two postpartum review sessions addressing key correlates of Perinatal Depression (PND) with the largest effect sizes by targeting fathers': 1) prenatal and postpartum family involvement; 2) mental health psychoeducation; 3) interparental communication and relationship skills; and 4) balanced division of family tasks. The intervention is based on the stress-generation and cognitive-behavior theories to frame skill-based individual sessions of didactics, interactive training, and trackable objectives.
223906472|NCT06368765|OTHER|Oral Rehydration Solution (ORS)|Participants will be administered the ORS during one of the study visits
223906473|NCT06368765|OTHER|Water|Participants will be administered water during one of the study visits
223906474|NCT01752491|DRUG|Ascorbate|Intravenous infusion of high-dose ascorbate
223906475|NCT01752491|DRUG|Temozolomide|Oral chemotherapeutic
223906476|NCT01752491|RADIATION|Radiation therapy|External beam radiation therapy
223906477|NCT04245176|BEHAVIORAL|Standard Genetic Counseling|Standard genetic counseling: Standard of care discussion
223906478|NCT04245176|BEHAVIORAL|Quantitative Genetic Counseling|Quantitative genetic counseling: Discussion is guided by tables and graphs.
223906479|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-1|Dynamic Light Therapy
223528933|NCT06638346|OTHER|Brazilian warm-up exercise program|"The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf."
223528934|NCT06641609|DRUG|Dose-Escalation (Phase Ia) CFT8919 capsule|Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.
223906480|NCT05807178|DEVICE|Dynamic Light Therapy Device, LSA-2|Dynamic Light Therapy
223906481|NCT02249442|DRUG|Tipranavir (TPV)|
223906482|NCT02249442|DRUG|Ritonavir (r)|
223906483|NCT01815242|DRUG|nab-Paclitaxel|
223906484|NCT01815242|DRUG|Gemcitabine|
223906485|NCT01815242|DRUG|Carboplatin|
223906486|NCT03049618|OTHER|Laboratory Biomarker Analysis|Correlative studies
223906487|NCT03049618|BIOLOGICAL|Pembrolizumab|Given IV
223906488|NCT03049618|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
223906489|NCT04636151|BEHAVIORAL|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
223906490|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (I)|"1. upper respiratory inflammation (PurInf (I)): Lonicerae Flos 2.4g, Forsythiae Fructus 2.4g, Schizonepetae Herba 2g, Saposhnikoviae Radix 2g, Cicadae Periostracum 1g, Sophorae flavescentis Radix 2.4g, Atractylodis Rhizoma 2g, Angelicae dahuricae Radix 2g, Menthae haplocalycis Herba 2g, Arctii Fructus 2g, Glycyrrhizae Radix 1g~2. high fever (PurInf (II)): Bupleuri Radix 3g, Scutellariae Radix 2.4g, Gypsum fibrosum 4g, Anemarrhenae Rhizoma 3g~3. lower Respiratory system inflammation (PurInf (III)): Scutellariae Radix 2.4g, Coptidis Rhizoma 1g, Phellodendri Cortex 2.4g, Gardeniae Fructus 2.4g, Houttuyniae Herba 4g, Golden Buckwheat 3g"
223906491|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (II)|Platycodi Radix 2.4g, Peucedani Radix 2.4g, Cynanchi stauntonii Rhizoma 2.4g, Asteris Radix 2.4g, Stemonae Radix 2.4g, Lepidii Descurainiae Semen 2.4g, Plantaginis Semen 2.4g
223906492|NCT04790240|DIETARY_SUPPLEMENT|Inflammation (III)|"1. Metabolites, abnormal fluids (PurPhl):~   Citri reticulatae Pericarpium 1.2g, Citri grandis Exocartium rubrum 2g, Aurantii Fructus immaturu 2g, Pinelliae Rhizoma preparatum 2.4g, Arisaematis Rhizoma preparatum 2.4g, Amoni Fructus 1g, Trichosanthis Fructus 2.4g, Fritillatiae cirrhosae Bulbu 2.4g, Poria 2.4g, Rhei Radix et Rhizoma 1g~2. Capillaries circulation disorder (PurClo):~Salviae miltiorrhizae Radix 2.4g, Curcumae Radix 2.4g, Paeoniae Radix rubra 2.4g, Persicae Semen 2.4g, Carthami Flos 2.4g"
223906493|NCT04790240|DRUG|Standard of care|remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
223906494|NCT04114981|RADIATION|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
223906495|NCT04114981|RADIATION|Fractionated Stereotactic Radiosurgery|Undergo FSRS
223906496|NCT04114981|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223906497|NCT04114981|OTHER|Questionnaire Administration|Ancillary studies
223906498|NCT06431256|DRUG|HLD200 methylphenidate hydrochloride capsules|Doses: 20mg capsules
223906499|NCT06431256|DRUG|Placebo HLD200 capsules|Doses: 20mg capsules
223906500|NCT02425982|PROCEDURE|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
223906501|NCT02425982|PROCEDURE|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
223906502|NCT05784753|BEHAVIORAL|HEART Camp|Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).
223528935|NCT06641609|DRUG|Dose-Expansion (Phase Ib) CFT8919 capsule|Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.
223528936|NCT06641609|DRUG|Cohort-Expansion (Phase Ic) CFT8919 capsule|Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
223528937|NCT06638905|DRUG|Babor Ultimate ECM Repair Serum|The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
223906503|NCT05784753|BEHAVIORAL|HEART Camp Connect|Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
223906504|NCT04248257|BEHAVIORAL|PeACE|3 session peer coaching intervention
223906505|NCT04248257|BEHAVIORAL|Community peer coaching|Peer coaching provided by community organizations that support the HBOC community
223906506|NCT06295523|OTHER|Water Spray|Participants will receive water spraying on their body throughout the climate chamber exposure.
223906507|NCT06295523|OTHER|Control|Participants will NOT receive water spraying on their body throughout the climate exposure.
223906508|NCT06559683|OTHER|Sensory Assessment|Patients scheduled for open-heart surgery will receive a deep/superficial parasternal intercostal plane block preoperatively, and sensory block status will be evaluated after 30 minutes.
223906509|NCT06025617|OTHER|Diagnostic evaluation at the Diagnostic Clinic for Functional Disorders|The intervention consists of being examined at the Diagnostic Clinic for Functional Disorders. If an FSD diagnosis is established, the patient receives feed-back of on the FSD diagnosis and patient education about the condition. Subsequently, the clinic provides guidance to the GP regarding recommended management and treatment options tailored to each individual patient.
223906510|NCT06025617|OTHER|Diagnostic as usual|"Diagnostic as usual consists in being referred to be examined at another existing specialist clinic in the secondary sector, as specified by the patient's GP."
223906511|NCT05715086|PROCEDURE|Ureteroscopy|Upfront ureteroscopy
223906512|NCT03611036|OTHER|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
223906513|NCT03611036|OTHER|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
223906514|NCT00882167|OTHER|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
223906515|NCT05977192|BEHAVIORAL|Standard MI|One phone-based MI session
223906516|NCT05977192|BEHAVIORAL|Intensive MI|Four phone-based MI sessions
223906517|NCT05977192|BEHAVIORAL|MOTIVACC|mHealth-based MI
223906518|NCT05977192|BEHAVIORAL|Ecological momentary assessment (EMA) messages|EMA messages focused on vaccinations and health
223906519|NCT05976698|DRUG|LSD 10 μg|0.5 h after the start of each study session the participants will be administered 10 μg LSD per os in the form of vials containing 1ml 20% EtOH (ethanol).
223906520|NCT05976698|DRUG|LSD 20 μg|0.5 h after the start of each study session the participants will be administered 20 μg LSD per os in the form of vials containing 1ml 20% EtOH.
223906521|NCT05976698|DRUG|Placebo|0.5 h after the start of each study session the participants will be administered placebo per os in the form of vials containing 1ml 20% EtOH.
223906522|NCT04908033|DEVICE|pacemaker implantation|pacemaker implantation
223528938|NCT06638905|DRUG|Babor Cure Cream|Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
223906523|NCT05570877|DEVICE|ChitoCare medical Wound Healing Gel|ChitoCare medical Wound Healing Gel is a CE-marked medical device.
223906524|NCT06046001|DEVICE|AirWaze|AirWaze - easy and advanced tools for CBCT guided lung interventions
223906525|NCT05964504|PROCEDURE|Blood Specimen|Blood will be drawn via venipuncture
223906526|NCT05036590|OTHER|control group|The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.
223906527|NCT05036590|OTHER|Intervention group|The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
223906528|NCT05739994|OTHER|Theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered to a location on the head. cTBS consists of 600 low-intensity TMS pulses delivered over 40 seconds in a pattern of 50 Hz triplets delivered at 5 Hz.
223906529|NCT05739994|OTHER|Sham theta burst transcranial magnetic stimulation|Continuous theta burst TMS (cTBS) will be delivered near the head, while an unplugged TMS coil is held at the vertex. No current will be induced in the head with this procedure.
223906530|NCT06393062|DIAGNOSTIC_TEST|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.|Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
223906531|NCT00621114|DEVICE|GamCath® central venous catheter|Choice of central venous catheter type
223906532|NCT00621114|DEVICE|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
223906533|NCT06191900|BIOLOGICAL|Autologous tumor infiltrating lymphocyte injection（GT201）|GT201 treatment for advanced gynecological tumors (advanced cervical cancer)
223528939|NCT06642909|DRUG|Zuberitamab 600mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
223528940|NCT06642909|DRUG|Zuberitamab 1000mg|administered twice with a 2-week interval between each dose (i.e. D1, D15). One treatment cycle is 24 weeks
223906534|NCT05905705|DIAGNOSTIC_TEST|Electroencephalography (EEG)|High-density EEG will be acquired during resting wakefulness before each ECT session.
223528941|NCT06642909|DRUG|cyclosporine|Initial dose of 3.5 mg/kg/d, oral administration, divided into two doses, taken 12 hours apart (Q12h)
223906535|NCT05905705|DIAGNOSTIC_TEST|Quantitative Measurements of Sleep Microstructure|Overnight sleep EEG will be recorded one day before each ECT session using the DREEM device. The DREEM device allows continuous recording of multichannel EEG.
223906536|NCT06047808|BEHAVIORAL|Storytelling Through Music|"Storytelling Through Music is a six-week expressive arts intervention."
223906537|NCT03652740|DRUG|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
223906538|NCT03808831|DEVICE|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
223906539|NCT03808831|DEVICE|Sham fall detection and prevention system|The sham system with record but no alert function
223906540|NCT05382702|OTHER|Test meal description changed|Using a within-subjects crossover design, on two separate mornings participants will eat yogurt described as 'high fat' and 'low fat.' In actuality, the meals will not differ.
223906541|NCT05714020|OTHER|Real rTMS|Repetitive transcranial magnetic stimulation (rTMS) is applied to the primary motor cortex. The protocol consists of 15 minutes of 10Hz stimulation, 10 seconds on, 20 seconds off, at 90% RMT, for a total of 3000 pulses.
223906542|NCT05714020|OTHER|Sham rTMS|A sham coil is also used to mimic the clicking sound of the transcranial magnetic coil and skin stimulation.
223906543|NCT04076618|DEVICE|Vest|Weighted Vest worn \> or = 8 hours per day
223906544|NCT04076618|BEHAVIORAL|Resistance Exercise Training|Structured exercise training 3 days a week
223906545|NCT04076618|BEHAVIORAL|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
223906546|NCT06551285|DIETARY_SUPPLEMENT|Ovapro (Lifepro)|Dietary supplement that contains inositol, vitamin D, zinc, and curcumin.
223906547|NCT06398808|DRUG|Arm1|ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
223906548|NCT06398808|DRUG|Arm 2|ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
223906549|NCT04978480|OTHER|no intervention|There is no intervention. We are only collecting standard of care data.
223906550|NCT05943665|DRUG|MDMA|medication and therapy combined
223906551|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
223906552|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
223906553|NCT04735393|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).
224277134|NCT00260689|BIOLOGICAL|Anti-thymocyte globulin (horse)|
223906554|NCT04735393|DRUG|Placebo Comparator|Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
223906555|NCT04903678|DRUG|Melphalan|Melphalan is performed for intrathecal chemotherapy
223906556|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 1)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²"
223906557|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 2)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²"
223906558|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 3)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²"
223906559|NCT03784625|DRUG|[131I]ICF01012 (therapeutic dose level 4)|"* 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²"
223906560|NCT05796167|DRUG|Pimavanserin|Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks
223906561|NCT05218889|DRUG|surufatinib + camrelizumab + nab-paclitaxel + S-1|"phase 1b: surufatinib 200 or 250 mg/d, qd po; camrelizumab: 200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; S-1: 40mg bid, D1-14, Q3W; DLTs will be evaluated at first cycle;~phase 2: surufatinib RP2D + camrelizumab + nab-paclitaxel + S-1 when evaluated SD, PR or CR after 4-6 cycles (according to RECIST 1.1), followed by maintenance treatment: surufatinib + camrelizumab + S-1"
223906562|NCT05218889|DRUG|nab-paclitaxel + gemcitabine|nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W
223906563|NCT03225677|PROCEDURE|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
223906564|NCT05752071|DEVICE|Gastric electrical stimulation|Mounting of a temporary gastric pacemaker
223906565|NCT03920358|DEVICE|FRED, FRED Jr and FRED X|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
223906566|NCT02270814|DRUG|nab-paclitaxel|
223906567|NCT02270814|DRUG|Cisplatin|
223906568|NCT02270814|DRUG|Carboplatin|
223906569|NCT02270814|BIOLOGICAL|Cetuximab|
223906570|NCT01928394|BIOLOGICAL|Nivolumab|
223906571|NCT01928394|BIOLOGICAL|Ipilimumab|
223906572|NCT01928394|DRUG|Cobimetinib|
224083544|NCT06405464|DRUG|Rilpivirine Injectable Suspension|RPV LA 900 mg prolonged release suspension for injection (3 mL)
224083545|NCT06405464|BIOLOGICAL|Intact proviral DNA assay|HIV-1 latent reservoir size
224083546|NCT06405464|BIOLOGICAL|Full-length sequencing|Proviral DNA
224277135|NCT00260689|DRUG|Cyclosporine|
224277136|NCT00260689|DRUG|Alemtuzumab|
224277137|NCT01858922|DRUG|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
223906573|NCT05719584|OTHER|hypopressive exercises|patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
223906574|NCT05719584|OTHER|pelvic floor muscle training|patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
223906575|NCT06187584|DRUG|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen 0.15mg/kg PO q6
223906576|NCT06187584|DRUG|Acetaminophen|15mg/kg PO q6 hours
223906577|NCT06187584|DRUG|Ibuprofen|10mg/kg PO q6 hours
223906578|NCT05782075|OTHER|Remote biological monitoring by a heart failure nurse|Review of biological results by a nurse (IDE) trained in heart failure monitoring, alongside the cardiologist, at S1, S2, M1, M2 and M3.
223906579|NCT04707625|DRUG|Aflibercept Ophthalmic|Anti-vascular endothelial growth factor intraocular injection
223906580|NCT02342613|BIOLOGICAL|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
223906581|NCT03208049|BEHAVIORAL|Behavioral Therapy (BT)|Behavioral Therapy will regulate time spent in bed based on information collected from sleep diaries during evaluation and treatment. Behavioral therapy is designed to improve sleep quality by matching opportunity for sleep to the amount of average total sleep calculated from sleep diaries. Once the quality of sleep has improved, sleep quantity is gradually increased by slowly increasing sleep opportunity. Stimulus control will strengthen the bed/sleep association by eliminating non-sleep activities from the bedroom.
223906582|NCT03208049|BEHAVIORAL|Cognitive Therapy (CT)|Cognitive Therapy is designed to identify maladaptive beliefs about sleep, challenge their validity, and replace them with more adaptive thinking patterns. This therapy aims to reduce sleep-related worry, anxiety, and fear. The treatment phase of the study lasts six weeks. During treatment, you will meet with a study therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
223906583|NCT05492825|OTHER|Yoga|Each yoga class will follow a standardized structure, allowing participants to easily re-join if they miss classes. Yoga classes will be adapted to the abilities and limitations of each study participant, for example, using a chair for sitting exercises rather than the floor and to assist with balance. Postures (asanas) will target back pain and include mindfulness, relaxation, and breathing practices integral to hatha yoga, with focus on breath-based movement throughout. Each group will have 1-2 yoga instructors and no more than 5 participants per yoga instructor (up to 10 participants/group).
223906584|NCT05492825|OTHER|Physical Therapy|The assessment at the second screening visit by the Physical Medicine \& Rehabilitation physician/Physical Therapy staff will be available to physical therapists in the Electronic Health Record and will guide the type of exercises, to focus on stabilization (strengthening core trunk muscles) and flexion or extension exercises. Sessions are divided into 30 minutes of working directly with a physical therapist and 30 minutes of supervised aerobic exercise (on treadmill or recumbent bike). Participants will receive a guidebook for guiding and recording home practice, based on Saper's guidebook and modified based on feedback from experts and stakeholders for clarity and cultural appropriateness.
223906585|NCT05492825|OTHER|Treatment As Usual|Participants in the Treatment As Usual group will receive routine clinical care. This includes: 1) pain assessment using a 10-point scale, at OTP admission and annual physical exams. This is documented on a templated form in the OTP electronic health record, as well as whether pain is acute vs chronic pain, and a treatment plan (e.g., on-site care, outside primary care clinician, pain management referral). 2) clinical treatment of pain by participants' on-site or outside clinicians. Those patients who receive on-site medical care have the opportunity to address nonpharmacological and pharmacological treatment with onsite physicians and physician assistants, and to receive referral to specialty care including physical therapy and orthopedics at multiple Montefiore locations throughout the Bronx.
223906586|NCT02658253|BIOLOGICAL|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
223906587|NCT02658253|BIOLOGICAL|GLA-SE|2.56 µg of GLA content
223906588|NCT02658253|BIOLOGICAL|Alhydrogel|0.85 mg og Aluminium content
223906589|NCT02658253|BIOLOGICAL|Placebo|0.9% Na cl
223906590|NCT06503497|BIOLOGICAL|chemotherapy sequential CAR-NK cell infusion|In each chemotherapy cycle, patients received 2 intravenous infusions of CAR-NK on days 2 and 3 after each chemotherapy was discontinued.
223906591|NCT06464289|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
224277138|NCT01858922|DRUG|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
223906592|NCT06464289|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation.
223906593|NCT00005095|OTHER|Ca-125|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
223906594|NCT00005095|OTHER|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
223906595|NCT00005095|PROCEDURE|Surgery|Subjects will be assessed for high risk factors.
223906596|NCT05779969|OTHER|Chest CT scan|Comparison of structural damage to the manubriosternal joint (MST) between a population of patients with radiographic axSpA and a control population free of chronic inflammatory rheumatism on chest CT.
223906597|NCT05910775|BEHAVIORAL|Pre and Post Treatment Presentations|A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance
223906598|NCT02520713|GENETIC|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
223906599|NCT03941405|DRUG|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
223906600|NCT06448299|PROCEDURE|TAPB|Patients will receive ultrasound guided bilateral oblique subcostal TAPB using 25 mL bupivacaine 0.25% in each side
223906601|NCT06448299|BIOLOGICAL|ESPB|Patients will receive ultrasound guided bilateral ESPB at T8 level using 25 mL bupivacaine 0.25% in each side
223906602|NCT06394271|DEVICE|EVAR|Catheter based insertion of aortic endograft via iliac or femoral arteries
223906603|NCT02019004|DRUG|Onabotulinum Toxin A|
223906604|NCT02019004|DRUG|Incobotulinum Toxin A|
223906605|NCT05821816|DEVICE|tDCS|Use of Transcranial direct current stimulation for 20 minutes per day, 5 days a week, at 2mA
223906606|NCT05821816|OTHER|Conventional rehabilitative treatment|Physiotherapy treatment consisting in two treatments per day of 40 minutes each
223906607|NCT03231085|DRUG|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
223906608|NCT03950570|DRUG|Abraxane|In patients with relapsed. metastatic breast cancer, ORIN1001 will be administered in combination with Abraxane administered by intravenous infusion.
223906609|NCT03950570|DRUG|ORIN1001|ORIN1001 will be administered as a table as a monotherapy in the dose escalation phase in patients with advanced solid tumors or in combination with Abraxane in patients with relapse, refractory breast cancer
223906610|NCT05679375|DRUG|Intrathecal ketamine|Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine
223906611|NCT05679375|DRUG|Intravenous ketamine|Patients will receive IV Ketamine 0.25mg/kg after spinal
223906612|NCT06005571|PROCEDURE|composite restoration repair by traditional acid etch treatment procedure and adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid and adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
223906613|NCT06005571|PROCEDURE|Composite restoration repair by acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed and the surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was addded to repair the old restoration and restore the carious cavity.
223906614|NCT06005571|PROCEDURE|Composite restoration repair by sandblasting first, then acid etching, silane solution application, and then adhesive.|Recurrent caries surrounding the defective restoration was removed, the old restoration surface were sandblasted, and the tooth and restoration surfaces were coditoned with acid, then silane applied, next adhesive then new repair composite was added to repair the old restoration and restore the carious cavity.
223906615|NCT05408052|PROCEDURE|Dural Puncture Epidural (DPE)|"Using the 18G Tuohy needle in the sitting position, the epidural space will be determined from the L3-L4 or L4-L5 space using the loss-of-resistance method After Dural puncture will be performed using a 25G Whitacre needle from the Tuohy needle to patients in the DPE group and free CSF flow will be observed, but no medication will be applied to the subarachnoid space. Afterwards, epidural catheter will be placed and when the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
223906616|NCT05408052|PROCEDURE|Standart Epidural|"The neuraxial procedure will be performed in the sitting position using the 18G Tuohy needle, in the L3-L4 or L4-L5 range using the loss-of-resistance method.~The epidural catheter will be placed so that it remains 4 to 5 cm in the epidural space. After the catheter is fixed, a test dose of 3 mL will be administered through the catheter to check for intravascular or subarachnoid catheter placement.~An epidural local anesthetic will be administered throughout the catheter for intraoperative analgesia at 0,1% (bupivacaine+fentanyl+ saline) concentration with the NoL monitor guidance."
223906617|NCT04471246|DRUG|Cephalexin|1000 mg PO QID for 7 days
223906618|NCT04471246|DRUG|Cephalexin + placebo|500 mg PO QID plus oral placebo for 7 days
223906619|NCT04254627|DRUG|Etanercept|Etanercept 50 mg weekly injection
223906620|NCT04254627|DRUG|Mifepristone|Mifepristone 300 mg pill
223906621|NCT06444919|DRUG|Capsaicin 179 Mg Cutaneous Patch|patch application for 30 minutes on the painful fingers.
223906622|NCT06444919|DRUG|Capsaicine low dose 0.04 %|patch application for 30 minutes on the painful fingers. the low-dose patch has a similar appearance to the active patch. It allows you to keep the blind, because it also causes reactions at the capsaicin application site (erythema, burning).
224083547|NCT02867761|DRUG|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
223906623|NCT04728334|DRUG|AK117|An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
223906624|NCT05328154|OTHER|Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care|"* Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0 and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Follow-up diary to be completed at months 1 and 12 of the study"
223906625|NCT05328154|DRUG|Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation|"* Inclusion medical consultation~* Inclusion clinical examination~* Calculation of Kauppila score at one year~* Imaging procedures (DXA) at 1 year~* Magnesium dosage: Visit 1: Day 0; Visit 2: Day 0+9 months and Visit 3: Day 0+1 year~* Samples for biological collection and microbiota analysis Visit 1: Day 0 and Visit 3: Day 0+1 year~* Genotyping in Visit 1: Day 0~* Serum CTX dosage in Visit 3: Day 0+1 year~* Cardiovascular investigations (FMD, RHI, FLD, PWV) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of sarcopenia (SARC-F, SPPB, muscle strength and body composition) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Exploration of pain (NPS, BPI, sensitivity/pain thresholds, CPM) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Quality of life component questionnaires (PSQI, HADs, SF-36) in Visit 1: Day 0 and Visit 3: Day 0+1 year~* Magnesium intake for 1 period of 3 months~* Phone call~* Follow-up diary to be completed at months 1, 10, 11 and 12 of the study"
223906626|NCT04234113|DRUG|Nanrilkefusp alfa|A fusion protein which consists of the N-terminal sushi domain of human IL-15 receptor α covalently coupled via a linker of 20 amino acids to human IL-15
223906627|NCT04234113|DRUG|Pembrolizumab|A humanized IgG4 monoclonal antibody with high specificity of binding to the PD-1 receptor
223906628|NCT05182905|DRUG|AZD1390|"Phase 0: AZD1390 administered orally daily for 3 days prior to resection~Phase 1b: AZD1390 administered daily for 5 days concurrently with standard of care radiation therapy"
223906629|NCT06349772|DRUG|Zynrelef|Zynrelef will be injected at the 12mm port site
223906630|NCT06349772|DRUG|Exparel|Exparel will be injected at the 12mm port site
223906631|NCT05610865|OTHER|Control; Standard-of-care management|Patients will undergo conventional wound care management.
223906632|NCT05610865|BIOLOGICAL|Only PRP injection|Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
223906633|NCT05610865|BIOLOGICAL|PRP + SVF injection|Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
223906634|NCT05610865|BIOLOGICAL|PRP + ASCs injection|Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
223906635|NCT06298461|DRUG|KleanLyte|Laxative for colonoscopy bowel preparation
223906636|NCT06298461|DRUG|Bi-PegLyte|Laxative for colonoscopy bowel preparation
223906637|NCT06837974|OTHER|AI guided TIPS|The TIPS procedure will be conducted under the guidance of AI model which was constructed based on the pre-operation enhanced CT images and intra-operation DSA images.
224277139|NCT01557686|BEHAVIORAL|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
224277140|NCT01493596|DRUG|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
224277141|NCT01493596|DRUG|Placebo|An equal volume of water mixed with juice will be administered.
223906638|NCT06837974|OTHER|Artificially blinded TIPS|The TIPS procedure will be conducted based on the experience of operators.
223906639|NCT05911724|OTHER|Group I Healthy|Healthy Subjects
223906640|NCT05911724|DRUG|CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study|Group II: Stable Angina Patients
223906641|NCT05911724|DRUG|HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study|Group III: Heart Failure Patients
224083548|NCT02867761|DRUG|Placebo|27.5/15.6 mcg placebo
223528942|NCT00210132|DRUG|Ropivacaine|"ropivacaine at 7.5 mg/ml: 4 ml + 4 ml of saline solution to obtain 8 ml of a ropivacaine solution at 3.75 mg/ml injected into the intrapleural catheter every 6 hours.~Treatment administration = every 6 hours for 48 hours."
223528943|NCT00210132|DRUG|Reference|8 ml of saline solution will be injected into the intrapleural catheter. Treatment administration = every 6 hours for 48 hours.
223528944|NCT06206265|DRUG|TRYP-0082|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
223715787|NCT05246501|OTHER|No simulation|The students in the control group did not receive simulation training.
223715788|NCT02370160|BIOLOGICAL|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
223906642|NCT06760715|BEHAVIORAL|an interactive m-health self-management|Description: The experimental group will undergo a lifestyle intervention based on the Transtheoretical Model (TTM), utilizing the MOSAC cloud platform. This intervention focuses on self-management to facilitate behavior changes aimed at weight loss and improving Obstructive Sleep Apnea (OSA) of T2DM patients. Key components include self-monitoring, tracking, real-time feedback, and customized weight loss plans, all enhanced by gamification features. The intervention emphasizes a healthy approach to weight loss, promoting a balanced diet, moderate calorie reduction, and increased physical activity, such as step counts. Each stage of the intervention outlines specific objectives, processes, and measures for achieving behavioral change and supporting healthy weight loss.
223906643|NCT06760715|BEHAVIORAL|In the control group|Description: In the control group, standard medical care will continue to be provided along with written educational pamphlets on weight loss and sleep hygiene. The interactive m-health cloud platform will not be offered. However, the results of the three questionnaires administered to each participant will be individually explained, and any questions will be addressed immediately. After the activity concludes, participants may choose to receive the same intervention as the experimental group, if they wish.
223906644|NCT04261686|DEVICE|Covera Vascular Covered Stent|This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent
223906645|NCT06840431|BEHAVIORAL|in-person condition|participants will receive program components in a classroom setting with a trained non-clinical facilitator.
223906646|NCT06840431|BEHAVIORAL|online condition|Participants will receive program components in an asynchronous online format.
223906647|NCT06840431|BEHAVIORAL|self-help condition|Participants will read a self-help book on how to manage their divorce and take a quiz to ensure that the book has been read.
223906648|NCT06083246|OTHER|Hybenix gel|Clinical application of Hybenix gel after professional dental hygiene of peri-implant mucositis sites.
223906649|NCT06083246|OTHER|Chlosite gel|Clinical application of Chlosite gel after professional dental hygiene of peri-implant mucositis sites.
223906650|NCT06831240|OTHER|Local wheelchair service provider questionnaires|The local wheelchair service providers will complete a questionnaire that includes demographic data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
223906651|NCT06831240|OTHER|Global wheelchair service provider questionnaires|The global wheelchair service providers will complete a questionnaire that includes demographic data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
223906652|NCT06831240|OTHER|End-users questionnaires|The end-users will complete a questionnaire that includes demographic and clnical data, to allow us to describe the sample, and a questionnaire about rear anti-tip devices for manual wheelchairs.
223906653|NCT06751355|DEVICE|SkinScan3D camera|The SkinScan3D (SS3D) is a portable, battery-powered imaging prototype which can successfully achieve all-focus, 3D images using low-cost, off-the-shelf components.
223906654|NCT03376646|DEVICE|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
223906655|NCT03376646|DEVICE|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
223906656|NCT03376646|DEVICE|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
223906657|NCT05955924|DRUG|Nicotinamide|Oral nicotinamide (500 mg) twice daily
223906658|NCT05955924|DRUG|Placebo|Matching placebo capsule twice daily
223906659|NCT06839625|BEHAVIORAL|emotional freedom technıque|EFT application
223906660|NCT04987502|OTHER|Virtual Reality|8 sessions of virtual reality with 3D audio and visual rendering
223906661|NCT04987502|BEHAVIORAL|Standard treatment|counselling, relaxation techniques, sound enrichment
223906662|NCT06464146|DRUG|Morphine|oral morphine (0.5 mg / kg)
223906663|NCT06464146|DRUG|IN fentanyl|IN fentanyl (1.5 µg/kg)
223906664|NCT06464146|DRUG|IN ketamine|IN ketamine (1 mg/kg)
223906665|NCT06464146|DRUG|NaCl 0,9 %|Injectable solution used as Placebo of Oral morphine or IN fentanyl/ ketamine.
223906666|NCT06454708|DRUG|Clascoterone Cream 1%|Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
223906667|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC Intravaginally|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
223715789|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions Only|The intervention took a standardized approach to after visit instructions which included a customizable template that would review patients conditions, changes in any medications, and any future labs, imaging, or referrals.
223906668|NCT04815213|BIOLOGICAL|expanded autologous bone marrow derived MSC Laporoscopic|Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary
223906669|NCT04815213|BIOLOGICAL|EV|Extracellular vesicles injection
223906670|NCT06344416|DEVICE|Use of ReX to dispense and monitor solid oral medication therapy.|ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
223906671|NCT03386578|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
223906672|NCT03386578|BEHAVIORAL|Behavioral HIV risk reduction package|Included cohort-appropriate SMS messages.
223906673|NCT03386578|BEHAVIORAL|Enhanced adherence support|Included two-way SMS messaging and tailored counseling with drug level feedback.
223906674|NCT05397431|DRUG|Lanadelumab|Lanadelumab 300 mg, subcutaneous injection every 2 weeks
223906675|NCT00278785|BEHAVIORAL|Brief Motivational Interview|10-20 minute brief motivational interview
223906676|NCT02260856|DEVICE|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
223906677|NCT02260856|PROCEDURE|Percutaneous Drill Epiphysiodesis|
223906678|NCT02260856|PROCEDURE|Percutaneous Screw Epiphysiodesis|
223906679|NCT05902598|DRUG|VSA001 injection|also referred to as ARO-APOC3
223906680|NCT05902598|DRUG|Placebo|Matching VSA001 injection
223906681|NCT05907174|BEHAVIORAL|Siyakhana - P|A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
223906682|NCT05825183|PROCEDURE|Ultrasound-guided manual vaccum|"For managing with miscarriage or termination of pregnancy (TOP) in first trimester loss, ultrasound-guided manual vacuum aspiration (USG-MVA) is one of the treatment options.~The USG-MVA device works by aspirating the uterine content via the cannula into the syringe. Furthermore, product of conception derived from USG-MVA can be sent for karyotyping analysis.~POCs obtained from MVA procedure were rinsed in normal saline thoroughly in the kidney basin to minimize maternal blood. Chorionic villi were considered as a proxy of fetal genetics, appeared to be yellowish in color and tree-projection-like in appearance, floating on the surface of the waterline. Decidua are originated from the mother, appeared substantive in structure and sank in the basin. The two different types of tissues are separated from each other for different testing."
223906683|NCT06461546|DRUG|Imlifidase|"* Imlifidase (POD0, pre-transplantation), imlifidase, 0.25 mg/kg over a period of 15 minutes, prior to transplantation.~* Dose Adjustment Criteria~FC-XM screening and single antigen will be performed after 6 hours of imlifidase infusion, It will take 3 hours to obtain the results, respectively:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - 2nd Imlifidase infusion will be required (imlifidase dose: 0.25mg/Kg).~FC-XM screening and single antigen will be performed after 2 hours of the 2nd Imlifidase infusion:~* NEGATIVE (FC-XM) - renal transplantation will be performed as soon as possible.~* POSITIVE (FC-XM) - The scheduled kidney transplant will be canceled."
223906684|NCT06272279|DEVICE|spinal stimulation-DCS|transcutaneous spinal stimulation by direct current stimulation
223906685|NCT06272279|OTHER|spinal stimulation-sham DCS|sham transcutaneous spinal stimulation by direct current stimulation
223906686|NCT06272279|OTHER|spinal stimulation-EPS|transcutaneous spinal stimulation by electrical pulsed stimulation
223906687|NCT06272279|OTHER|sham spinal stimulation-EPS|sham transcutaneous spinal stimulation by electrical pulsed stimulation
223906688|NCT05705453|DEVICE|Epidural Spinal Cord Stimulation|Stimulation of the spinal cord from the epidural space.
223906689|NCT06802965|PROCEDURE|catheter ablation, left atrial appendage closure|Compare the clinical prognosis of patients with AF underwent the combined procedure of catheter ablation and left atrial appendage closure (LAAC), single catheter ablation and single LAAC.
223906690|NCT05994976|PROCEDURE|Blood samples collection|biomarkers and optional genetic analysis
223906691|NCT05994976|PROCEDURE|Oral samples collection|biomarkers analysis
223906692|NCT05994976|PROCEDURE|Hair samples collection|biomarkers analysis
223906693|NCT05994976|PROCEDURE|Skin samples collection (skin tape strip and/or skin biopsy, and/or skin scraping)|biomarkers analysis
223906694|NCT05994976|PROCEDURE|Skin surface material samples|biomarkers analysis
223906695|NCT05994976|PROCEDURE|Drainage fluid samples collection|biomarkers analysis
223906696|NCT05994976|PROCEDURE|Stool samples collection|biomarkers analysis
223906697|NCT05891288|OTHER|BioCoat® by Premier®|Bioactive pits and fissure sealant
223906698|NCT05891288|OTHER|3M™ Clinpro™ Sealant.|Fluoride releasing pits and fissure sealant
223906699|NCT06318429|BEHAVIORAL|stretching exercise group|stretching exercise group
223906700|NCT05471661|BIOLOGICAL|Pentavalent-specific T cells (penta-STs)|Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose.
223906701|NCT05485194|OTHER|Reducing dimensional changes following tooth extraction|Use of a titanium bone screw for ridge preservation following tooth extraction
223906702|NCT05093842|BEHAVIORAL|Sedentary Behavior Reduction|Participants receive bimonthly behavioral health coaching, a sit-stand desk attachment or table, and an activity prompter if they do not already have one (e.g., fitbit, as needed).
223906703|NCT05093842|BEHAVIORAL|Information on Physical Activity Recommendations during Pregnancy|Participants in the study will receive educational materials provided one time by email about the currently recommended physical activity during pregnancy.
223906704|NCT03796858|DRUG|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
223906705|NCT03796858|DRUG|Placebo|Participants will receive placebo as SC injection.
223906706|NCT04567537|DEVICE|Laser Treatment|Patients will receive three laser treatments at one-month intervals.
223906707|NCT05561439|OTHER|Dosimetric monitoring|Dosimetric monitoring of workers Information retrieved from passive dosimeters results from the years 2019, 2020 and 2021
223906708|NCT06429163|PROCEDURE|Infiltration of the anterior abdominal wall|Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
223906709|NCT06429163|PROCEDURE|Upper hypogastric plexus blockade|At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.
223906710|NCT06822725|OTHER|Control Group|normals without allergy, those with perennial allergic rhinitis
223906711|NCT06822725|PROCEDURE|Chronic rhinosinusitis (CRS) with and without Nasal Polyposis|Those with and without nasal polyps, and those with acute exacerbations
223906712|NCT04386057|DRUG|Hydroxychloroquine Sulfate|HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
223906713|NCT04386057|DRUG|LY3214996|LY3214996-daily oral dosage per protocol per 28 day cycle
223906714|NCT04586855|DIAGNOSTIC_TEST|Diagnostic Ultrasound|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
224083549|NCT02530931|DRUG|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
223906715|NCT04586855|DIAGNOSTIC_TEST|Transnasal Fiberoptic Laryngoscopy|To investigate if Ultrasound imaging can visualize the larynx during NIV and Cough Assist, and be as accurate as laryngoscopy
223906716|NCT06808555|BEHAVIORAL|Pai.ACT Group|"The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated AI algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. Following interactions with the AI chatbot, Pai.ACT provides a stratified mental health support, categorizing into three risk levels:~* Low-risk: Users access self-help ACT digital modules tailored to their specific psychological inflexibility processes.~* Moderate-risk: In addition to the self-help modules, users receive 4-6 sessions of video-conferencing-based ACT interventions (45-60 minutes per session) conducted by our trained counseling team.~* High-risk: Users are directed to specialized mental health services provided by collaborating units."
223906717|NCT06808555|OTHER|Control Group|Both the Pai.ACT intervention group and the control group will receive standard family support through Hong Kong's family and children rehabilitation services, which are administered by government-funded units under the Social Welfare Department. Parents will participate in structured psychoeducation sessions focusing on positive parenting and will have access to peer support groups. Their children will receive individualized training plans tailored for neurodevelopmental conditions, in addition to referrals for speech and occupational therapy.
223906718|NCT03402945|DEVICE|Prevena|Negative-Pressure Wound Management System
223906719|NCT03402945|DRUG|Cefazolin|antibiotic
223906720|NCT03402945|DRUG|Vancomycin|antibiotic
223906721|NCT03402945|OTHER|standard wound dressing|Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
223906722|NCT04782713|OTHER|Completing surveys|Completing surveys at baseline, 3, 6, 9, and 12 months
223906723|NCT03095313|OTHER|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
223906724|NCT06823336|OTHER|Intervention|Participants will be encouraged to engage in independent exercise twice a week for 30 minutes. They will be randomly assigned to a peer-mentor, with whom they will engage in on-on-one exercise once a week for 30 minutes. Between sessions, they will engage in virtual communication with each other for about 30 minutes each week. Each participant-mentor duo will continue this protocol for 6-weeks.
223906725|NCT06823336|OTHER|Control|Participants will be encouraged to engage in exercise three times a week for thirty minutes, over a span of 6-weeks.
223906726|NCT06372860|BEHAVIORAL|Diabetes Prevention Program|"The intervention will be administered by professionally trained, certified health coaches. Phase I consists of four 1-hour DPP-based sessions to be completed during pregnancy. Each session will be pre-recorded and archived on a secure, private mHealth application. Participants will be asked to complete each session on their own time. A health coach will follow up weekly via phone to check on progress and will work with the participant 1-on-1, if needed. Phase I will be completed by week 36 of pregnancy. Prior to delivery, participants are invited to a virtual focus group about their experiences.~Phase II consists of two 1-hour DPP-based sessions to be completed after delivery. Each session will be pre-recorded and archived on the same mHealth application. Participants will begin Phase II within 1 week of delivery with the same health coach. Phase II will be completed by week 12 postpartum. Upon completion, participants are invited to a virtual focus group about their experiences."
223906727|NCT06372860|BEHAVIORAL|Breastfeeding|"Phase I also consists of six (6) breastfeeding videos that are pre-recorded into 15-20 minute sessions and will be available on the mHealth application. Participants will have access to the first 2 sessions by week 28 of pregnancy and need to complete the remaining 4 sessions by week 36 of pregnancy. Each session is taught by an International Board Certified Lactation Consultant (IBCLC).~Participants will receive 1-on-1 lactation support by the same DPP health coach. The health coach is a professionally trained Certified Breastfeeding Specialist (CBS). She will assist participants with any questions related to lactation. If the health coach is unable to help with a specific issue, she will contact the IBCLC-of-record, who will provide assistance to the health coach only. If the health coach or IBCLC deems additional care necessary, the participant will be referred to their primary care physician. The IBCLC will not have direct contact with the study participants."
223906728|NCT06372860|BEHAVIORAL|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
223906729|NCT06103136|DEVICE|Laparoscopic surgery using the Maestro Platform|"Patients scheduled for laparoscopic surgery will be operated on as per standard of care, using standard port, surgical table and instrument placements (following local applicable guidelines), and off-the-shelf surgical equipment. Standard of care surgical technique following local applicable guidelines will be used.~The Maestro Platform may be used to position and hold the scope as well as the retractor in the locations determined by the surgeon during the procedure, with the ability to revert at any time to standard of care (manual minimally invasive surgery) without the usage of the Maestro Platform, or to convert to open surgery."
223906730|NCT03756649|PROCEDURE|Blood Draw|50 ml will be collected
223906731|NCT03756649|PROCEDURE|Urine Collection|50 ml will be collected
224277142|NCT06073886|DEVICE|Active cTBS|600 active cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
223906732|NCT03756649|PROCEDURE|Stool Collection|Three 25 ml tubes will be collected
223906733|NCT06521021|BEHAVIORAL|AVOID|"Behavioral: Home food environment and grocery delivery (AVOID) Participants will receive coaching (Zoom and/or email/text) to modify their home food environment and alter cues to promote healthy food choices~Behavioral: WW Participants assigned to all arms will receive of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
223906734|NCT06521021|BEHAVIORAL|RESIST|"Behavioral: Inhibitory control training (RESIST) Participants assigned to RESIST will receive coaching (Zoom and/or email/text) and gamified inhibitory control training.~Behavioral: WW Participants assigned to all arms will receive coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills."
223906735|NCT03862170|DRUG|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
223906736|NCT03862170|DRUG|Cefazolin|
223906737|NCT03976999|OTHER|Biological collection|"* Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~* Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
223906738|NCT06379971|DRUG|Placebo|Pregnant women are instructed to take the capsules twice per day, 4 placebo capsules at breakfast and 4 placebo capsules at dinner. Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
223906739|NCT06379971|DRUG|Choline|Pregnant women are instructed to take the capsules twice per day, 4 900mg phosphatidylcholine capsules at breakfast and 4 capsules at dinner. Increased awareness Increased awareness of the benefits of choline by obstetricians and pregnant women, as well as our published results from an observational study showing a wide distribution of plasma choline concentration, is a more apt independent variable for analyses.
223906740|NCT06641375|DEVICE|Anti reflux endoscopic theraphy|"o the intervention arm, the area of cardia, along greater curvature will be cleaned first followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC using the H-APC catheter for marking and to prevent excess ablation . After this, the area of cardia, on either side will be injected in sequence using a combination of methylene blue and normal saline using the H-APC catheter jet system using between Effect 30 and Effect 70 on the ErbeJet 2 to raise the mucosa and create a submucosal cushion . Once adequate submucosal cushion is created, the mucosa starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W using the H-APC catheter till golden-brown discoloration of the ablated tissue20~The area of cardia below the Z-line will be treated in a 270-320-degree fashion. Once adequate ablation is achieved and no deeper tissue injury or bleeding is ensured, the procedure will be terminated."
223906741|NCT06641375|OTHER|Endoscopy|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
223906742|NCT06815328|OTHER|Shock Wave Therapy (SWT)|"Focused SWT sessions targeting spastic muscle groups. Parameters include standardized frequency, energy level, and session duration (30 minutes per session, once weekly for 8 weeks). This therapy aims to reduce muscle spasticity, improve joint mobility, and enhance quality of life.~Standard care consisting of physical therapy sessions (e.g., stretching, mobility exercises) and/or prescribed medications for spasticity management. The therapy follows clinical guidelines and is administered with the same frequency and duration (once weekly for 8 weeks) as the experimental intervention."
223906743|NCT06815328|OTHER|Active Comparator - Conventional Therapy|"Standard care consisting of physical therapy sessions (stretching, mobility exercises) and/or prescribed medications for spasticity management.~Follows clinical guidelines and is administered with the same frequency and duration (once weekly for 8 weeks) as the experimental intervention."
223906744|NCT06821828|COMBINATION_PRODUCT|Modified olfactory training device|Participants will use a modified olfactory training device based on expiratory pressure. The advantages of the improved device are as follows: bi-directional airflow, positive pressure and the function of voice prompts and automatic counting.
223906745|NCT06821828|COMBINATION_PRODUCT|Conventional olfactory training device|This device involves four brown glass jars (total volume 5 mL) with one of the four odors in each (1mL each, soaked in cotton pads to prevent spilling). The following odors were used: phenyl ethyl alcohol (PEA): rose, menthol: mint, citronellal: lemon, and eugenol: cloves. All jars were labeled with the odor name.
223906746|NCT02921893|DRUG|Dexamethasone|Given PO
223906747|NCT02921893|DRUG|Ixazomib Citrate|Given PO
223906748|NCT02921893|DRUG|Lenalidomide|Given PO
223906749|NCT02921893|OTHER|Questionnaire Administration|Ancillary studies
223906750|NCT04009447|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
223906751|NCT05944783|DRUG|Dasatinib 100 MG|single dose of 100 mg Dasatinib tablets
223906752|NCT06818682|DRUG|ADT for 9 months and ARTA for 6 months|Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 9 months and ARTA for 6 months
223906753|NCT06818682|DRUG|ADT for 2 years|Radiotherapy to prostate and pelvic nodes (66-68Gy and 50Gy in 25 fractions OR 60-62Gy and 44Gy in 20 fractions OR 36.25-40Gy and 25Gy in 5 fractions) with ADT for 2 years
223906754|NCT05713877|DRUG|Melatonin|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
223906755|NCT05713877|DRUG|Placebo|Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.
223906756|NCT06746662|BEHAVIORAL|Hypnobreastfeeding training and consultancy|"Hypno-breastfeeding Education Group~A counseling program based on hypno-breastfeeding philosophy, where 4-week education content will be presented to pregnant adolescents in their 28-30th week of pregnancy and applications will be made, will be implemented with 4 sessions and 6 follow-up"
223906757|NCT06438965|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.
223906758|NCT06724380|OTHER|unknown health risk situation|a unknown health risk situation detected at anestesiology consult
223906759|NCT06821776|PROCEDURE|Gastric feeding|Subjects will be fed through a feeding tube that empties into the stomach.
223906760|NCT06821776|PROCEDURE|Transpyloric feeding|Subjects will be fed through a feeding tube that passes through the stomach and empties directly into the small intestine.
223906761|NCT06822868|DRUG|CAR T cells|chimeric antigen receptor T cells
223906762|NCT06823700|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|To percutaneously repair the mitral valve via the femoral vein and atrial septum, offering a treatment for symptomatic functional mitral regurgitation through edge-to-edge valve clipping.
223906763|NCT05442359|DRUG|Nano-bio fusion gingival gel|Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
223906764|NCT05442359|DEVICE|stent|Applied as a palatal stent for palatal wound
223906765|NCT05663359|PROCEDURE|EVLA 1940 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
223906766|NCT05663359|PROCEDURE|EVLA 1470 nm|Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
223906767|NCT05147116|OTHER|Sleeping in a tent|Participants will spend 10 consecutive nights of sleeping in a tent
223906768|NCT03127631|BEHAVIORAL|Nutrition|Standardized advice on healthy diet practices.
223906769|NCT03127631|BEHAVIORAL|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
223906770|NCT03127631|BEHAVIORAL|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
223906771|NCT03127631|DRUG|Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
223906772|NCT03127631|DRUG|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater \>130mmHg, or other blood pressure lowering medication as applicable.
223906773|NCT05473676|DEVICE|Robotic Training Period|Participants will engage in robot assisted gait training on at least 5 days/week for at least 30 minutes each day, for a total period of 12 weeks.
223906774|NCT06821438|PROCEDURE|Laparoscopy|Endoscopy
223906775|NCT06823596|DRUG|Efavirenz 600mg|"Efavirenz induces pyroptosis of HIV expressing cells via the CARD8 inflammasome. In contrast to most ART drugs, and in addition to its anti-retroviral effect, EFV also induces intracellular Gag-Pol dimerization and premature HIV protease activation, causing cleavage of the inflammasome protein CARD8. CARD8 activation results in the production of effector molecules that rapidly kill virus-infected cells by pyroptosis. This effect of EFV has been called TACK or T cell activator of cell killing. We aim to harness this effect to reduce residual nonsuppresible viremia (NSV) in people on stable antiretroviral therapy (ART). Participants in this study will receive EFV in addition to their stable ART regimen for two months, during and after which we will monitor plasma HIV RNA and markers of viral persistence and immune activation."
223906776|NCT03843190|BEHAVIORAL|Take of Pounds Sensibly (TOPS)|Dietician-facilitated classes
223906777|NCT03843190|OTHER|Waitlist Control|At end of study, offered peer-led classes to attend.
223906778|NCT06823830|DRUG|Jinfeng Pill|Jinfeng pills were compared with Diane-35 group and Jinfeng pills combined with Diane-35 group were compared with Diane-35 alone.
223906779|NCT06547541|BEHAVIORAL|Exercise|A body weight based resistance training.
223906780|NCT06822634|OTHER|Observational single centre feasibility study|Patients scheduled to undergo standard of care neo. adjuvant radiotherapy prior to surgery.
223906781|NCT04197336|DEVICE|Bariatric Embolization of Arteries with imaging visible Embolics|bariatric embolization will be performed using tiny (100-200 μm), radiopaque (visible on X-ray) beads (referred to as BTG-001933) in order to suppress the body's signals for feeling hungry, which we predict will lead to weight loss.
223906782|NCT06731413|DRUG|Reduced Dose of Chemotherapy and Immunotherapy|Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135 mg/m2 intravenous (IV) every 21 days. Participants with non-squamous histology will receive carboplatin AUC 3 IV every 21 days and pemetrexed 375 mg/m2 IV every 21 days (collectively, induction chemotherapy). Both groups will receive pembrolizumab 200 mg IV every 21 days for a total of up to 35 cycles (Cycles ≥5 are collectively the maintenance portion of treatment) or until disease progression or unacceptable toxicity.
223906783|NCT06701136|DRUG|Sudapyridine|In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.
223906784|NCT06701136|DRUG|Itraconazole|In Study A: Participants will receive itraconazole capsules at 200 mg orally once daily after breakfast during Cycle 2 (D11-D14). An additional dose of itraconazole (200 mg) will be administered after dinner on D11.
223906785|NCT06701136|DRUG|Rifampin|In Study B: Participants will receive rifampin capsules at 600 mg orally once daily under fasting conditions during Cycle 2 (D15-D27).
223906786|NCT05248191|BIOLOGICAL|Capsule fecal microbiota material (cap-FMT)|Cap-FMT consists of Lyophilized FMT administered at 5 x 10\^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10\^12 bacteria.
223906787|NCT05248191|BIOLOGICAL|Colonoscopic fecal microbiota material (colo-FMT)|Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10\^12 bacteria as liquid.
223906788|NCT06817135|OTHER|scapular stabilization exercises|Cools exercise using the Thera-Band, including sidelying external rotation, side-lying forward flexion, prone horizontal abduction with external rotation, and prone extension exercises to promote lower trapezius and middle trapezius activity with minimal activation of the upper trapezius part.
223906789|NCT06817135|OTHER|Muscle Energy Technique|Muscle Energy Technique for the 1.sternocleidomastoid 2. levator scapulae 3. upper trapezius 4. pectoralis major Through mild isometric contractions, it uses the intrinsic energy of a muscle to lengthen it and induce relaxation through autogenic inhibition.
223906790|NCT06817135|OTHER|Advice about the right the breastfeeding ergonomic.|The patients sit with their backs supported with pillows. Don't lean over the infant. Keep the arms supported and feet on the ground.
223906791|NCT06512922|DEVICE|adaptive cognitive training|The intervention was computerized, multi-domain, adaptive cognitive training. Training areas include processing speed, attention, perception, long-term memory, working memory, computation, executive control, reasoning, and problem-solving. Embedded in the Adaptive Cognitive training application is an adaptive algorithm that will help provide each participant with a cognitive training task at the right level of difficulty based on their profile and real-time performance.
223906792|NCT06512922|DEVICE|placebo cognitive training|They received cognitive training tasks of fixed difficulty.
223906793|NCT06510998|BEHAVIORAL|isometric wall exercise|Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)
223906794|NCT06510998|BEHAVIORAL|passive stretching|A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
223906795|NCT06313957|BIOLOGICAL|LUCAR-20SP cells|Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
223906796|NCT00178932|PROCEDURE|genetic analysis|genetic assay of blood sample drawn with patient's consent
223906797|NCT00178932|PROCEDURE|genetic assay|genetic assay of blood sample drawn with patient's consent
223906798|NCT02084381|DEVICE|MCO-Ci 400|hemodialysis
223906799|NCT02084381|DEVICE|Revaclear 400|hemodialysis
223906800|NCT05868382|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
224083550|NCT01121380|DRUG|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
224277143|NCT06073886|DEVICE|Inactive/Sham cTBS|600 inactive, or sham, cTBS pulses will be delivered continuously (3 pulses at 50 hertz (Hz), repeated at 5 Hz, 15 pulses/sec, continuously for 40 seconds) twice/day for 1,200 pulses/day. The MagVenture MagPro active/sham system will be used to enable double blinding by universal serial bus (USB) key in which a current will be delivered through surface electrodes on the skin beneath the coil to mimic the sensory experience of cTBS for active and sham groups.
224277144|NCT06073886|BEHAVIORAL|Imaginal exposure|Personalized recordings about participants' descriptions of triggering or neutral stimuli or activities
223906801|NCT05868382|BIOLOGICAL|mRNA-1010.4|Sterile liquid for injection
223906802|NCT05868382|BIOLOGICAL|mRNA-1010.6|Sterile liquid for injection
223906803|NCT04585815|DRUG|Sasanlimab Prefilled syringe|prefilled syringe
223906804|NCT04585815|DRUG|Encorafenib|capsules
223906805|NCT04585815|DRUG|Binimetinib|tablets
223906806|NCT04585815|DRUG|Sasanlimab|solution supplied in vials
223906807|NCT04585815|DRUG|Axitinib|tablets
223906808|NCT04585815|DRUG|SEA-TGT|solution in vials
223906809|NCT05826288|OTHER|BioIntelliSense BioButton Rechargable|This study uses the BioIntelliSense BioButton Rechargeable for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.
223906810|NCT05826288|OTHER|Memora Health two-way patient engagement platform provided by RC|The Memora Health platform is designed to automate complex care workflows, making them simple for patients and clinicians to navigate. It utilizes a multi-modal communications system that primarily relies on two-way text messaging and artificial intelligence.
224277145|NCT03980210|PROCEDURE|Hyperbaric oxygen therapy|"1. FiO2 0.21 - 1 ATA~2. FiO2 1 - 1 ATA~3. FiO2 1 - 2.5 ATA~4. FiO2 0.21 - 2.5 ATA~5. FiO2 0.21 - 1 ATA"
224277146|NCT04381481|BEHAVIORAL|Experimental Drink: Nutrition claim on fruit drinks|Fruit drink contains a nutrition claim (task 1)
223906811|NCT03753347|BIOLOGICAL|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
223906812|NCT06488248|PROCEDURE|Endoscopic third ventriculostomy (ETV)|The procedure is performed using an endoscope (LOTTA® system, Karl Storz Endoscopes, Germany; Minop®, BBraun, Tuttlingen, Germany or equivalent). The intervention is carried out under general anesthesia, with the procedure typically lasting around 60 minutes.
223906813|NCT06488248|PROCEDURE|Ventriculoperitoneal shunt (VPS)|The procedure entails the insertion of a catheter into both the ventricular system and the peritoneal cavity, connected to a programmable valve that regulates cerebrospinal fluid flow. The choice of programmable valve (Codman Hakim or Codman Certas Programmable Valves, Integra, Plainsboro, USA; Strata valve, Medtronic, Minneapolis, USA; Sophysa, Orsay, France; Miethke proGAV, Aesculap, Tuttlingen, Germany) is at the surgeon's discretion. The preoperative valve setting is preset to a pressure level between 85 - 135 mmH2O. The VPS procedure is conducted under general anesthesia and typically lasts approximately 90-120 minutes.
223906814|NCT03757689|DRUG|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
223906815|NCT03757689|PROCEDURE|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
224083551|NCT01121380|DRUG|1021|1021
224277147|NCT04381481|BEHAVIORAL|Control Drink: No nutrition claim|Fruit drinks does not contain a nutrition claim (task 1)
224277148|NCT04381481|BEHAVIORAL|Experimental snack: Text warning|The snack contains a text warning (task 2)
224277149|NCT04381481|BEHAVIORAL|Experimental snack: Graphic warning|The snack contains a graphic warning (task 2)
223906816|NCT06035445|BEHAVIORAL|In-person adolescent-friendly service (iPAS) intervention|Monthly visits take place in a group setting with sessions led by peer educators. Clinical staff and peer educators are trained in care of adolescents using the Right to Care training materials. During their clinic visit, adolescents are evaluated individually by a healthcare provider and receive their supply of ART. In addition, adolescents participate in scheduled group team-building activities including dancing, sports, music and receive group counseling facilitated by peer educators. Nine group counseling sessions will discuss the topics of: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. The half-day sessions will end with the provision of a meal. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
223906817|NCT06035445|BEHAVIORAL|mHealth (InTSHA) intervention|The InTSHA intervention is based on Got Transition elements (two-way messaging between adolescents and healthcare providers) and the SMART model. The SMART model focuses on modifiable factors of transition preparation through content delivery, facilitated discussions, online meet ups and consultation with the healthcare team. The intervention consists of 9 modules delivered monthly by group chat. The topics of the modules are: HIV disclosure, alcohol and substance abuse, HIV knowledge, ART adherence and HIV resistance, goal setting and career planning, sexual and reproductive health, HIV stigma, healthcare navigation and self-advocacy, and healthy relationships. Outside of scheduled group chat sessions, adolescents have access to the chat group to check in with members, review content of the sessions, or to comment or ask additional questions. After completion of the 9-month intervention, adolescents will transition to adult care in their standard local adult clinic.
223906818|NCT06035445|BEHAVIORAL|Standard of Care|Adolescents in standard of care are seen every three months by clinicians and collect medication monthly at an on-site pharmacy during regular weekdays. Individual counseling delivered by counselors or social workers is available when necessary. Staff at all clinics receive training in adolescent-friendly services (AFS) through the Right to Care training materials.
223906819|NCT06024746|DRUG|Finerenone|Oral finerenone.
223906820|NCT06024746|DRUG|Empagliflozin|Oral empagliflozin.
223906821|NCT06480383|DRUG|ITI-1284 10 mg|ITI-1284 10 mg tablet, taken once daily, sublingual administration.
223906822|NCT06480383|DRUG|ITI-1284 20 mg|ITI-1284 20 mg tablet, taken once daily, sublingual administration.
223906823|NCT06480383|DRUG|Placebo|Matching placebo tablet, taken once daily, sublingual administration
223906824|NCT04182815|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
223906825|NCT00866684|DRUG|Sirolimus|Treatment arm Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day
223906826|NCT00866684|DRUG|Azathioprine|control arm Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
223906827|NCT00866684|DRUG|Mycophenolate|Control arm Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
223906828|NCT00866684|DRUG|Ciclosporin|Control arm Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
223906829|NCT00866684|DRUG|Tacrolimus|Control arm Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
223906830|NCT03808961|DIETARY_SUPPLEMENT|Niacin|100mg tablets twice daily
223906831|NCT03808961|DIETARY_SUPPLEMENT|Niacinamide|100mg tablets twice daily
223906832|NCT03808961|OTHER|Placebo|Placebo tablet twice daily
223906833|NCT05623150|DIAGNOSTIC_TEST|Liver biopsy|Liver biopsy planned as part of routine care. Clinical-biological characterisation with bio collections.
223906834|NCT05121441|DRUG|ARD-101|Twice daily, oral administration
223906835|NCT05121441|DRUG|Placebo|Twice daily, oral administration
223906836|NCT04531917|OTHER|Pain Neuroscience Education|Pain Neuroscience Education (PNE) teaches patients about complex pain mechanisms known to be of importance in pain following breast cancer such as malfunctioning of the endogenous analgesic system and pain memories.
223906837|NCT04531917|OTHER|Behavioural Graded Activity|"Patients in the experimental group will receive a behavioural treatment integrated within the concepts of operant conditioning. The purpose of Behavioural Graded Activity (BGA) is to increase the level of physical activity in the patient's daily lives in a time-contingent manner. On top of that, a healthy behaviour will be positively reinforced to consequently create a withdrawal of the attention towards pain behaviour, which is seen as an unreliable alarm sign in chronic pain patients. The implementation of BGA after PNE is described in the guideline reported by the International Association for the Study of Pain."
223906838|NCT04531917|OTHER|Usual care|The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
223906839|NCT06585566|PROCEDURE|Cortical-shell graft|Retromolar cortical shell graft technique for SABG
224277150|NCT04381481|BEHAVIORAL|Control snack: barcode label|The snack contains a neutral barcode label (task 2)
223906840|NCT06585332|OTHER|Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))|"The voluntary peak cough flow is measured using a pneumotachograph (BTL cardiopoint Spiro, BTL industries), which meets the recommendations of the American Thoracic Society and the European Respiratory Society for range and accuracy in forced expiratory maneuvers.~Maximal expiratory and inspiratory pressures assessments were performed using a flanged rubber mouthpiece connected to a pressure manometer (Micro RPM, Vyaire Medical). Assessments are conducted according to the statements on respiratory muscle testing of the American Thoracic Society and the European Respiratory Society.~Hand grip strength Grip strength is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation), assessment follows recommendation of The American Society of Hand Therapists."
223906841|NCT06820996|OTHER|Cryotherapy|The root canals were irrigated with 2 °C NaOCl solution in cryotherapy group.
224277151|NCT00935623|BIOLOGICAL|Malaria Challenge|Malaria challenge
224277152|NCT01618513|DRUG|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
223906842|NCT06820996|OTHER|Control (Standard treatment)|The root canals were irrigated with 25 °C NaOCl solution in normal group.
223906843|NCT06827808|OTHER|Team based learning|The intervention planned within the scope of the research is a team-based learning method. Students in the intervention group taking the nursing fundamentals course will be formed into small groups in the nursing skills laboratory. The groups will remain the same throughout the six modules. First, students will be asked to solve the iRAT multiple-choice question set prepared on the relevant module skill. Then, students will be provided with the skill repetition in the determined groups. Then, they will be asked to discuss until they reach a consensus as a group and solve the tRAT, which includes the same multiple-choice question set as the iRAT.
223906844|NCT03679650|DRUG|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
223906845|NCT03679650|BIOLOGICAL|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
223906846|NCT03094312|PROCEDURE|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
223906847|NCT04004065|DRUG|Vesleteplirsen|Vesleteplirsen injection, for IV use
223906848|NCT06191159|DEVICE|Scalpel and standard electrocautery or PEAK PlasmaBlade|Scalpel followed by completion of surgery with standard electrocautery or PEAK PlasmaBlade.
223906849|NCT06191159|DEVICE|PEAK PlasmaBlade|PEAK PlasmaBlade for entire surgery.
223906850|NCT06191159|DEVICE|Standard Electrocautery|Standard Electrocautery for entire surgery.
223906851|NCT01221948|DEVICE|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
223906852|NCT00746096|DRUG|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
223906853|NCT00746096|DRUG|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
223906854|NCT06241976|OTHER|Glucose drink|75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)
223906855|NCT06241976|OTHER|Pure orange juice|300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket
223906856|NCT04514471|OTHER|Unventilated filter cigarettes|Currently marketed unventilated cigarettes
223906857|NCT04514471|OTHER|Ventilated filter cigarettes|Currently marketed ventilated cigarettes
223906858|NCT03420482|DRUG|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
223906859|NCT03420482|DRUG|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
223906860|NCT03167216|DRUG|Cromolyn Sodium|Mast cell stabilizer
223906861|NCT03167216|DRUG|Cetirizine Hydrochloride|Histamine receptor antagonist
223906862|NCT05951387|DRUG|dexmedetomidine plus ketamine|titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
223906863|NCT05951387|DRUG|Dexmedetomidine|starting intravenous infusion with dexmedetomidine starting at dose 0.5ug/kg//hr and titrate the dose to achieve full sedation
223906864|NCT03321045|DRUG|[89Zr]-Df-Trastuzumab|\[89Zr\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
223906865|NCT03321045|DIAGNOSTIC_TEST|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
223906866|NCT03876964|DEVICE|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
223906867|NCT06422689|DRUG|Albuterol and budesonide inhalation aerosol|Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
223906868|NCT04295512|BEHAVIORAL|Unstuck and on Target|Unstuck and on Target is a cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. Unstuck and on Target is the first contextually-based executive functioning treatment that targets flexibility, goal-setting and planning through a cognitive behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Unstuck and on Target will be adapted for use in mental health service settings. Mental health therapists will be trained in Unstuck and on Target and deliver to youth and caregivers.
223906869|NCT04707326|DRUG|Dolutegravir / Lamivudine Pill|HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
223906870|NCT00621712|DEVICE|GamCath® central venous catheter|choice of catheter type
223906871|NCT00621712|DEVICE|GamCath Dolphin® Protect central venous catheter|choice of catheter type
223906872|NCT02295306|DEVICE|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
223906873|NCT06510634|OTHER|Endovascular Therapy|"Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices."
223906874|NCT01387711|DRUG|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
223906875|NCT03571581|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 20 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
223906876|NCT05861336|DRUG|Losartan|Losartan will be administered at the dose of 25 mg PO qd starting on Cycle 1 Day 1. If this dose will be tolerated during week 1, escalation to 50 mg PO qd at Cycle 1 Day 8
223906877|NCT05861336|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1, 8 and 15 every 28 days
223906878|NCT05861336|DRUG|Nab paclitaxel|nab-paclitaxel 125 mg/m2 on days 1, 8, and 15
223906879|NCT05861336|RADIATION|Stereotactic Body Radiation Therapy|7 consecutive fractions for a total dose of 35-42 Gy
223906880|NCT02800356|PROCEDURE|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
223906881|NCT05902117|DIAGNOSTIC_TEST|Troponin and Copeptin assay|Collection of an additional blood tube for copeptin determination during blood collection for troponin testing as part of care.
223906882|NCT04564703|DRUG|Iberdomide|IBERDOMIDE (CC220) IN MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
223906883|NCT04288635|BIOLOGICAL|Whole blood samples|Whole blood samples at admission, from day one to three after admission
223906884|NCT03897361|GENETIC|"CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)"|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
223906885|NCT06587412|OTHER|Radial shock waves treatment|Subjects in this group will receive radial shock waves
223906886|NCT06587412|OTHER|Focal Shock Waves treatment|Subjects in this group will receive focal shock waves
223906887|NCT06587412|OTHER|shock waves placebo treatment|Subjects in this group will receive a shock waves placebo treatment with very low energy settings
223906888|NCT05301894|DRUG|NBI-827104|T-type calcium channel blocker.
223906889|NCT01309672|DRUG|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
223906890|NCT01309672|DRUG|Prednisone|5 mg, oral, 5 mg twice daily
223906891|NCT04962061|OTHER|Cognitive Training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
223906892|NCT04962061|OTHER|Aerobic and resistance exercises|Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
223906893|NCT04962061|OTHER|Stretching and Toning|Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
223906894|NCT03338309|OTHER|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
223906895|NCT02336087|DRUG|Gemcitabine Hydrochloride|Given IV
223906896|NCT02336087|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223906897|NCT02336087|DRUG|Metformin Hydrochloride|Given PO
223906898|NCT02336087|DIETARY_SUPPLEMENT|Therapeutic Dietary Intervention|Given PO
223906899|NCT02336087|OTHER|Laboratory Biomarker Analysis|Correlative studies
223906900|NCT02336087|OTHER|Quality-of-Life Assessment|Ancillary studies
224277153|NCT06677632|OTHER|Palmitoylation Enzyme Expression Profiling Study|The expression of 23 zDHHC enzymes will be studied in human post-mortem hippocampi of AD patients and controls that have already been collected from UK brain biobanks. zDHHC enzymes will be analyzed at both mRNA and protein levels by Real Time PCR and Western blotting techniques, respectively
224277154|NCT04784637|DEVICE|Web Simulation Tool (WST)|WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.
223906901|NCT05318898|OTHER|Vegetal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from vegetal protein sources
223906902|NCT05318898|OTHER|Animal protein|Nutritional recommendations will be given to ensure that the patient consumes a regular diet where the protein intake will be mostly from animal protein sources.
223906903|NCT03283722|DEVICE|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
223906904|NCT05623228|COMBINATION_PRODUCT|The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia|The combination of pharmacotherapy and psychotherapy in individuals with schizophrenia and treatment resistant schizophrenia.
223906905|NCT06514040|DRUG|Precedex|Dexmedetomidine (Precedex) is a highly selective alpha 2 adrenoreceptor agonist which produce sedation, anxiolysis, analgesia, and decreasing inflammatory response to anaesthesia and surgical procedure.
223906906|NCT06514040|DRUG|Sumatriptan 25 mg|Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain (as substance -p), nausea, and other symptoms of migraine
223906907|NCT06245083|DRUG|Pyrroloquinoline quinone (PQQ)|Oral supplement taken daily
223906908|NCT06245083|DRUG|Placebo with soybean oil|Oral supplement taken daily
223906909|NCT06405321|DRUG|Conversion or neoadjuvant therapy.|Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.
223906910|NCT05866861|DRUG|CUG252|CUG252 will be administered by subcutaneous injection.
223906911|NCT05866861|DRUG|Placebo|Placebo will be administered by subcutaneous injection.
223906912|NCT05837117|BEHAVIORAL|Patient's Perspective|"Participants will complete a questionnaire about sexual wellbeing, sexual dysfunction, and communication with your provider on this topic.~Participants/Researchers will learn about your attitudes, beliefs, and feelings about sexual well-being"
223906913|NCT05189756|DRUG|Aprepitant 80 mg|Encapsulated capsule of aprepitant 80mg to make it look alike to the placebo.
223906914|NCT05189756|DRUG|Placebo|Encapsulated placebo capsules for optical, acoustical and haptic blinding.
223906915|NCT04895592|DRUG|Dexamethasone|Given PO or IV
223906916|NCT04895592|PROCEDURE|Resection|Undergo surgical resection
223906917|NCT04895592|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223906918|NCT04625725|DRUG|AZD7442|"* Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366"
223906919|NCT04625725|DRUG|Placebo|Single dose (× 2IM injections) of saline placebo on parent study Day 1.
223906920|NCT05409872|DIETARY_SUPPLEMENT|Combination of Epigallocatechin gallate, vitamin D, vitamin B6, and D-Chiro-inositol|The subject takes a combination of 333.35 mg of green tea extract (150 mg of Epigallocatechin gallate), 25 mg of D-Chiro-inositol, 25 mcg of Vitamin D, and 5 mg of Vitamin B6 twice a day for three months.
223906921|NCT05409872|OTHER|Placebo|The subject takes the placebo twice a day for three months.
223906922|NCT05233150|BEHAVIORAL|PriCARE/CARIÑO|PriCARE/CARIÑO is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE/CARIÑO uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE/CARIÑO includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. CARIÑO is the culturally adapted version of PriCARE for Spanish speaking participants.
223906923|NCT05928052|DEVICE|Transcutaneous Biopac Electrical Stimulator|A transcutaneous electrical stimulator sends low levels of electrical current through surface hydrogel electrodes directly to the spinal cord to improve function.
223906924|NCT05825768|DEVICE|Breast MRI|Breast Magnetic Resonance Imaging prior to breast conserving surgery with and without intravenous contrast agent.
223906925|NCT05825768|DIAGNOSTIC_TEST|standard breast imaging|The control group that receives standard preoperative imaging only (breast ultrasound and mammography)
223906926|NCT06487208|OTHER|Use of a digital cognitive aid in order to anticipate a critical situation|Use of a digital cognitive aid in order to anticipate a critical situation
223906927|NCT06487208|OTHER|Placebo|No intervention
223906928|NCT04205305|DRUG|conventional blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
223906929|NCT04205305|DRUG|intensive blood pressure control (labetalol, nicardipine)|After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.
223906930|NCT02808208|BIOLOGICAL|Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|A single topical application of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period.
223906931|NCT02808208|DRUG|Placebo|5-mL of Lactated Ringers solution topical application to the surface of the outflow vein (right next to the fistula) over a five-minute period.
223715790|NCT06021730|BEHAVIORAL|Standardized After Visit Instructions & Teach Back|This intervention included the Standardized After Visit Instructions and included teach back, a process by which patients restate in their own words their understanding of their condition, what was discussed in the visit, and what potential changes were made
223906932|NCT02808208|BIOLOGICAL|Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)|Two topical applications of mesenchymal stem cells derived from own fat biopsy to the surface of the outflow vein (right next to the fistula) over a five-minute period at stage one and two of fistula surgery
223906933|NCT02795858|DRUG|Ramucirumab|
223906934|NCT02795858|DRUG|Somatostatin Analog|
223906935|NCT06242756|PROCEDURE|Bladder catheterization|Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post cesarean section.
223906936|NCT06096103|DIETARY_SUPPLEMENT|placebo|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
223906937|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardized for Iron + Vitamin C|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
223906938|NCT06096103|DIETARY_SUPPLEMENT|Botanical Extract Standardised for Iron|Route: Oral Dosage: 500mg Dosage Form: Capsule Frequency: Once a Day Duration: 60 Days Mode of Usage: Take the capsule once a day with food
223906939|NCT05616247|BEHAVIORAL|ECALC|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention
223906940|NCT05616247|BEHAVIORAL|ECALC Plus Weekly Boosters|Expectancy Challenge Alcohol Literacy Curriculum Cognitive Behavioral Intervention Plus Weekly Booster Content Delivered by Mobile Device
223906941|NCT04947124|DRUG|QLS-101ophthalmic solution 1%|QLS-101ophthalmic solution 1.0%
223906942|NCT04947124|DRUG|QLS-101ophthalmic solution 2%|QLS-101ophthalmic solution 2.0%
223906943|NCT05539365|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given IT
223906944|NCT05539365|PROCEDURE|Biopsy|Undergo biopsy
223906945|NCT05539365|PROCEDURE|Computed Tomography|Undergo CT scan
223906946|NCT05539365|PROCEDURE|Leukapheresis|Undergo leukapheresis
223906947|NCT05539365|BIOLOGICAL|Pembrolizumab|Given IV
223906948|NCT05539365|OTHER|Quality-of-Life Assessment|Ancillary studies
223906949|NCT05295732|DRUG|TMB-001|Topical TMB-001 0.05% QD/BID
223906950|NCT05295732|DRUG|Matching Vehicle|Topical Vehicle
223906951|NCT05665881|DRUG|Ephedrine|vasopressor
223906952|NCT05665881|DRUG|Phenylephrine|vasopressor
223906953|NCT05665881|DRUG|Norepinephrine|vasopressor
223906954|NCT04752657|OTHER|Delayed administration of survey modules|The intervention consists in delaying the administration of the physical function, physical activity, and events survey modules by 2 weeks
223906955|NCT04752657|OTHER|Regular administration of survey modules|The physical function, physical activity, and events survey modules are administered according to the regular pattern
223906956|NCT06112054|DEVICE|Clotild Smart Guidewire System (CSGS)|In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensors) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure
223906957|NCT06799325|BEHAVIORAL|acceptance and commitment therapy based stress management program|The Stress Management Program Based on Acceptance and Commitment Therapy will be applied to the intervention group, consisting of 6 sessions, 1 session per week, and each session lasting 45 minutes.
223906958|NCT06204029|BEHAVIORAL|Everyone can sing|"The choir lessons are taught by a trained choir leader in close collaboration with the teacher in each class. The choir leaders and music teachers at the school also facilitate choir in the morning for selected or all classes. A special AKS pedagogy is developed and based on the inclusive nature of joyful musicking with body and voice. The pedagogy is developed to ensure that everyone is taken care of, so all children regardless of social or cultural background develop social and professional competencies central to a positive school life. The most important elements in this pedagogy include: A co-teacher system; Each student has a choir partner; Discipline in the classroom lessons is maintained by clear, simple, and subtle means."
223906959|NCT05090683|BEHAVIORAL|Mind-body mobile application|Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
223906960|NCT04750252|BIOLOGICAL|StroMel|Autologous MSC
223906961|NCT03028402|PROCEDURE|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
223906962|NCT05698355|OTHER|Telerehabilitation Treatment|Telerehabilitation includes self-massages for pelvic floor muscle, sex education, breathing, myofascial releasing with wand, and pelvic floor relaxing exercises.
223906963|NCT06440395|BEHAVIORAL|Behavioural: Small Steps for Big Changes Diabetes Prevention Program|The 4-week behaviour change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 4-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the YMCA). The supervised session will include brief behavioural counselling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
223906964|NCT05084430|DRUG|M032|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
223906965|NCT05084430|DRUG|Pembrolizumab|Starting at week four, patients will undergo treatment on the same day, and every three weeks thereafter, with intravenous infusion of 200mg of Pembrolizumab . A total of 3 combined doses of Pembrolizumab and M032 will be given.
223906966|NCT02388048|DRUG|Ibrutinib + ofatumumab|
223906967|NCT06534372|PROCEDURE|Open cardiac surgery with sternotomy|Factors affecting the occurrence of chronic pain in patients undergoing open cardiac surgery with sternotomy will be investigated.
223906968|NCT06799572|OTHER|massage|"Hands will be washed with hand soap and rubbed with disinfectant before the procedure.~* The head of the bed is raised by 30°-45° in the incubator.~* The baby is placed face down.~* Vaseline is applied to the hands.~* The 15 minute session will consist of three 5 minute phases. Phase 1 will be tactile stimulation phase, Phase 2 will be kinesthetic stimulation and Phase 3 will be I Love You technique.~* In the tactile stimulation phase, the infant is turned to the prone position and a stroking motion (12 strokes in approximately 5 seconds) will be applied with moderate pressure in 1-minute intervals, from the top of the head to the neck and back to the top of the head, from the neck to the shoulder, from the neck to the shoulder, from the upper back to the waist and back to the upper back, from the thigh to the foot and both legs, from the shoulder to the hand and from both arms to the shoulder.~* In the kinesthetic stimulation phase, the infant is placed in the supine position and eac"
223906969|NCT06455241|OTHER|HABIT (Hand Activities Behavior Intervention)|A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
223906970|NCT06800079|OTHER|EBT|Elastic Band Resistance Training
224277155|NCT04784637|DEVICE|Behavioral Adaptation Module (BAM)|BAM provides on-demand information to the participant primarily on glycemic risks.
224277156|NCT04784637|DEVICE|Auto Titration Module (ATM)|ATM provides recommendations to the participant to periodically update insulin parameters.
223715791|NCT00594438|DEVICE|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
223906971|NCT06597617|BEHAVIORAL|Adapted physical activity with aerobic training [GEA]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on aerobic training. The first 3 sessions will be accompanied, and will take place either by videoconference or face-to-face, depending on the patient's wishes. Thereafter, each 1st session of the following weeks will also be accompanied and carried out either by videoconference or face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) a block of aerobic activity and (iii) a 2-minute cool-down including breathing exercises. Training will take place in 2 phases. The first phase will involve a total of 90 minutes of aerobic training spread over 3 sessions. The second phase will involve a total of 150 minutes of aerobic training over 3 sessions."
223906972|NCT06597617|BEHAVIORAL|Adapted physical activity with strength training [GRM]|"Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on eccentric training. The first 3 sessions will be accompanied and conducted face-to-face. Thereafter, each 1st session of the following weeks will also be accompanied and carried out face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) muscle-strengthening exercises and (iii) a 2-minute cool-down including breathing exercises. The exercises used will mainly involve the lower limbs. Training will take place in 2 phases. The first phase will involve an exposure/adaptation phase to eccentric training. The second phase will involve a gradual increase in intensity."
223906973|NCT04072783|DIAGNOSTIC_TEST|MRI,DTI, functional MRI|"1. Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~2. Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~3. Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
223906974|NCT06230380|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize PTGs during surgery. The surgical field will be visualized with AF as a minimum of two times during surgery on each side of the neck: First upon exposing the undersurface of the thyroid gland, and secondly before removal of a pathological PTG. Also, removed PTGs will be examined ex vivo to document AF pattern.
223906975|NCT06349109|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test (CPET), the gold standard for the assessment of cardiorespiratory fitness, will be used. The Modified Bruce/half Bruce protocol with will be used. In addition, dyspnoea, leg fatigue and general fatigue will be recorded every three minutes at rest, during the test and during the post-test recovery phases using the Modified Borg Scale and blood pressure will be recorded with a sphygmomanometer. The test will be continued until individuals reach the end of the protocol or until the last point at which they wish to stop the test. The test will be terminated if the patient wishes to terminate the test, severe breathlessness, leg fatigue or general fatigue, loss of coordination, progressive chest pain, ST segment elevation or depression of more than 2 mm, oxygen saturation of 80% or less, reaching 85% or more of the predicted heart rate. Oxygen consumption (VO2peak) will be used as the primary outcome measure for cardiorespiratory fitness.
223906976|NCT06349109|OTHER|Atrial-Ventricular Strain Analysis|Atrial-Ventricular strain will be evaluated by a specialist physician using Speckle Tracking Echocardiography. During the evaluation, standard echocardiographic measurements will be made with transthoracic echocardiography. With these measurements, images suitable for strain analysis will be obtained. Deformation analysis will be performed using the speckle tracing method for the appropriate images obtained and hemodynamic parameters obtained by the analysis will be recorded.
223906977|NCT06349109|OTHER|Arterial Stiffness Measurement|Arterial stiffness will be assessed using the pulse wave velocity (PWV) technique with the Mobile-O-GRAPH (TG) (LE.M., Stolberg, Germany), an oscillometer-based device. After the patients have rested sufficiently, measurements will be taken in an upright sitting position in a quiet and sufficiently bright environment at room temperature, with the device manso placed 2-3 cm above the chiibital fossa in the non-dominant upper limb and the arms raised to the level of the heart. Pulse propagation velocity will be calculated in m/sec with the help of a computer. A high velocity data indicates a high level of arterial stiffening and a low velocity data indicates a low level of arterial stiffening.
223906978|NCT06349109|OTHER|Physical Activity Level|Physical activity level will be assessed with the Child Physical Activity Questionnaire.
223906979|NCT06349109|OTHER|Physical Activity Barriers Assesment|"Physical Activity Outcome Expectancies (child survey) and Physical Activity Home Environment Scale (Child) will be used in children, while  Physical activity barriers (Parent) will be used in family members."
223906980|NCT06517394|BEHAVIORAL|Recovering Together after Cardiac Arrest|The intervention will teach resiliency skills (mindfulness, coping, etc.) to dyads and provider anticipatory guidance and resources to manage stressors specific to cardiac arrest. These sessions will take place in person or on Zoom/telephone, depending on the participant's preference and access to technology.
223906981|NCT06300281|BEHAVIORAL|Neuromuscular Exercise|A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization
224277157|NCT04784637|DEVICE|Automated Insulin Delivery (AID) System|The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
223715792|NCT00594438|DEVICE|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
223715793|NCT03055793|OTHER|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
223715794|NCT05738668|OTHER|Description of clinical characteristic|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study."
223715795|NCT03036046|DRUG|F901318 with fluconazole low dose|adverse events
223715796|NCT03036046|DRUG|F901318 with fluconazole high dose|adverse events
223715797|NCT03036046|DRUG|F901318 with posaconazole|adverse events
223715798|NCT01456468|DRUG|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
223715799|NCT01502059|OTHER|Pilates|Pilates training - twice a week (one hour per class) during 90 days
223715800|NCT03296241|DEVICE|laser|
223715801|NCT03296241|DEVICE|sham control|
223906982|NCT06300281|BEHAVIORAL|Aquatic Exercise|The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
223906983|NCT02698579|GENETIC|No interventional drug product utilized in this follow-up study|"Participants received a single IV infusion of Lenti-D Drug Product (also known as elivaldogene autotemcel or eli-cel) in either parent Study ALD-102 or ALD-104.~The objectives of this long-term follow-up study are to assess long-term safety and efficacy following completion of participation in parent studies. Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant are conducted in this study."
223906984|NCT06000657|DRUG|Vemliver tablet|Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)
223906985|NCT06000657|DRUG|Baracross Tablet|Chronic Hepatitis B Patients Who Pretreated with Entecavir continuting treatement with Baracross Tablet
223906986|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of liquid biopsy.
223906987|NCT05032092|DIAGNOSTIC_TEST|Next Generation Sequencing|Molecular analysis of tissue biopsy.
223906988|NCT05032092|GENETIC|Biomarker Monitoring|Biomarker Monitoring of study patients receiving matched therapy.
223715802|NCT02505997|DRUG|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
223715803|NCT02505997|DRUG|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
223715804|NCT01983436|OTHER|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
223715805|NCT00823368|DRUG|STX209|
223715806|NCT05104164|OTHER|Self-myofascial release|At home, the patients performed a daily session, lasting 15 minutes each, over 8 weeks. Patients accessed an ad hoc mobile application designed by the Hemophilia Physiotherapy research group (He-Foam®). This app, accessible from any smartphone, made it possible to watch the videos with all the exercises included in the intervention. The seven exercises under the specific protocol for patients with hemophilic arthropathy were: Self-release of the plantar region of the foot with a foam ball; Release of the posterior region of the leg with the foam roller; Release of the anterior leg region with a foam roller; Release of the hamstrings region with a foam roller; Release of adductor muscles with a foam ball; Release of abductor muscles with a foam roller; Release of pelvic trochanteric muscles with a foam roller
223715807|NCT02917304|BIOLOGICAL|GC3110A vaccine|0.5mL, Intramuscular
223715808|NCT01314573|BEHAVIORAL|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
223906989|NCT02821351|DEVICE|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
223906990|NCT03863457|DRUG|Fluoroglutamine [18F]F-GLN|Evaluate the kinetics and biodistribution of \[18F\]F-GLN in primary and metastatic breast cancer.
223906991|NCT05100212|BIOLOGICAL|cord blood-RBC concentrates|Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 29 weeks of postmenstrual age (29+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).
223906992|NCT05100212|BIOLOGICAL|adult donor RBC concentrates|Patients in the comparator arm are candidates to receive adult donor-RBC units
223906993|NCT04593615|PROCEDURE|ICG near-infrared imaging|Indocyanine green tracer is used to guide laparoscopic D2 lymph node dissection for gastric cancer
223906994|NCT06310252|DIAGNOSTIC_TEST|Opthalmic assessments|"The participants will undergo the following assessments:~1. Pupil size measurement~2. Manifest refraction (no autorefraction)~3. Monocular in both eyes and binocular uncorrected visual acuity (photopic):~   * Distance (4 m)~  * Intermediate (80 cm)~  * Near (40 cm)~4. Monocular best corrected visual acuity (photopic):~   * Distance (4 m)~  * Near (40 cm)~  * Distance-corrected near (40 cm)~5. Monocular and binocular mesopic (with and without glare) and photopic (without glare) contrast sensitivity testing (subgroup)~6. Slit lamp examination~7. Tear breakup time~8. Placido Corneal topography, keratometry and pachymetry~9. Optical coherence tomography including epithelium mapping (subgroup)~10. Applanation intraocular pressure~11. Cycloplegic refraction~12. Dilated fundus examination~13. Wavefront aberrometry (subgroup)~14. Adverse events"
223906995|NCT06296368|BEHAVIORAL|Preference Reporting to Improve Management and Experience (PRIME)|PRIME is a decision support tool that uses best-worst scaling to provide a personalized report to providers and patients of their most important treatment priorities
223906996|NCT05975697|OTHER|Experimental group to be applied FES|"In the first 24 hours after the thrombectomy procedure, the relatives of the patients in the experimental and control groups who meet the inclusion criteria will be informed by the researcher and their consent will be obtained.~FES treatment to the deltoid, triceps, extensor carpi radialis muscles for a total of 10 sessions, 30 minutes twice a day (in the morning and in the evening), for 5 days after the first 24th hour after the thrombectomy procedure in the experimental group patients (Program duration is 15 minutes and resting time is 15 minutes). minutes) will be applied.Patient information form (Appendix 1), Fugl-meyer upper extremity motor assessment scale (Appendix-2) and Quick DASH (Arm, Shoulder and Hand Injury Questionnaire Short Form) (Appendix-3) were given to both groups within the first 24 hours after the thrombectomy procedure. ) will be applied. All patients will be re-evaluated before and on the 5th day after treatment."
223906997|NCT05296005|DRUG|Capecitabine|Given PO
223906998|NCT05296005|DRUG|Docetaxel|Given IV
223906999|NCT05296005|DRUG|Fluorouracil|Given IV
223907000|NCT05296005|DRUG|Leucovorin|Given IV
223907001|NCT05296005|DRUG|Oxaliplatin|Given IV
223907002|NCT05296005|RADIATION|Radiation Therapy|Undergo radiotherapy
223907003|NCT05296005|PROCEDURE|Surgical Procedure|Undergo surgical resection
223907004|NCT05662865|DRUG|SGLT2 inhibitor|SGTL2i (15 mg) once daily
223907005|NCT05662865|OTHER|Controlled, Adaptive Study Diet|An adaptive study diet combined with SGLT2i, which consists of four sequential, 7-day long phases in which dietary carbohydrates are gradually reduced (50% carbs, 30% carbs, 20% carbs, and 10% carbs) based on safety and tolerability to achieve moderate ketosis. All diet phases are isocaloric. All meals are provided on an inpatient unit.
223907006|NCT05873556|BEHAVIORAL|Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)|This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
223907007|NCT05715229|DRUG|Nivolumab|Immunotherapy
223907008|NCT05715229|DRUG|Ipilimumab|Immunotherapy
223907009|NCT05715229|DRUG|Carboplatin|Chemotherapy
223907010|NCT05715229|DRUG|Paclitaxel|Chemotherapy
223907011|NCT05715229|DRUG|Pemetrexed|Chemotherapy
223907012|NCT02470728|OTHER|New Clinical Pathway|
223907013|NCT05906589|DIETARY_SUPPLEMENT|Inulin|The participant will take inulin twice daily over a 14 day period.
223907014|NCT05906589|DIETARY_SUPPLEMENT|Psyllium|The participant will take psyllium twice daily over a 14 day period.
223907015|NCT05906589|DIETARY_SUPPLEMENT|Maltodextrin|The participant will take maltodextrin twice daily over a 14 day period.
223907016|NCT05903482|OTHER|None - observational|Observational
223907017|NCT05356962|BEHAVIORAL|StOP?-protocol|The StOP?-protocol is an intra-operative briefing initiated by the responsible surgeon. When performing a StOP?-protocol, the surgeons inform the team present in the operating room about the Status (St) of the operation, the Objectives (O) of the operations, the potential problems (P) they may meet and encourage the team to ask questions or voice concerns (?). The responsible surgeon announces at the team timeout when they plan to perform the StOP-protocol(s).
223907018|NCT03776253|BEHAVIORAL|Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)|Attend CFS
223907019|NCT03776253|OTHER|Questionnaire Administration|Ancillary studies
223907020|NCT04689256|DEVICE|MR-010|MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
223907021|NCT04939688|RADIATION|Conventional dose AND ultra low-dose CT scanning in the search for cranial lesions|As well as undergoing the usual, conventional radiation dose CT scan, these patients will also undergo ultra low-dose CT scanning in the search for cranial lesions.
223907022|NCT06095375|DRUG|Regorafenib|Cohort A (Adjuvant/Maintenance Phase). The Adjuvant (Maintenance) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level-1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with adjuvant TMZ to evaluate the initial toxicity of regorafenib and TMZ Cohort B (Concomitant Phase) Therapy dose escalation will explore three dose levels of regorafenib (e.g., 80 mg, 120 mg and 160 mg; level -1: regorafenib 40 mg will be evaluated in case of DLT during regorafenib 80 mg) administered in combination with TMZ and RT.
223907023|NCT06095375|DRUG|Temozolomide|"Following a 3+3 design, in cohort A three patients will be administered temozolomide 150-200 mg/m2 for 5 consecutive days every 28 days until 6-12 cycles and regorafenib daily for 21 days, with a 1-week washout period at dose of 80 mg (level 1), 120 mg (level 2), or 160 mg (level 3) (regorafenib 40 mg- level -1). As a general rule, one cycle will last 28 days (day 1-28); however, in the event of treatment prolongation, the cycle period will be extended.~In cohort B,During concomitant therapy phase: temozolomide 75 mg/m2/die for 42 (max 49 days) consecutive days (concomitant with radiation therapy)."
223907024|NCT04512586|PROCEDURE|Conduction System pacing and AV node ablation|See study arm description.
223907025|NCT04512586|PROCEDURE|Atrial fibrillation ablation by pulmonary vein isolation|See study arm description
223907026|NCT05401838|BEHAVIORAL|Group Brief Cognitive-Behavioral Therapy (G-BCBT)|G-BCBT comprises 12, 90 minute sessions organized in three phases: (1) emotion regulation, (2) cognitive flexibility, and (3) relapse prevention. The first session will be a tailored individual session focusing on person-specific crisis response planning and developing the participant's suicide mode. Sessions 2 through 5 feature treatment goal setting, followed by teaching skills in stimulus control, mindfulness, relaxation, a reasons for living task, and survival kit. Sessions 6 through 10 provide opportunities for improving cognitive flexibility via cognitive-behavioral exercises such as ABC worksheets, challenging questions, patterns of problematic thinking worksheets, coping cards, and activity planning. The third phase of treatment focuses on relapse prevention, and encompasses the last two sessions of treatments where group participants demonstrate mastery of the skills learned in treatment and practice successfully navigating a future stressful situation.
223907027|NCT05401838|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Group|DBT comprises 24 weekly group therapy sessions each lasting 90 minutes. DBT sessions include worksheets and skills practice activities. The DBT protocol entails three phases as follows. Phase I (8 weeks) covers a two-week mindfulness orientation and a six-week distress tolerance module. Distress tolerance skill building includes paired muscle relaxation, distraction, and radical acceptance. Phase II (nine weeks) entails a two-week mindfulness module followed by seven weeks of emotion regulation skill building. Emotion regulation content includes a model of describing emotion and a pleasant events checklist. Phase III (7 weeks) includes two-week mindfulness and orientation module, followed by five weeks of interpersonal effectiveness training. Interpersonal effectiveness training approaches include clarifying goals in interpersonal situations, guidelines for keeping relationships, and self-respect. Mindfulness, cutting across modules, addresses review of concepts such as Wise Mind.
223907028|NCT04454450|DIAGNOSTIC_TEST|PET/MRI|Imaging will include research PET/MRI of pelvis within 30 days of multiregion tissue collection.For research PET/MRI - standard volumes of gadolinium contrast and fluorodeoxyglucose (FDG) will be administered.
223907029|NCT04454450|DIAGNOSTIC_TEST|Contrast enhanced CT|Standard of care contrast enhanced CT
223907030|NCT04570956|DRUG|Tamoxifen|Oral Tamoxifen 10 mg/day
223907031|NCT04570956|DRUG|Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day|Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
223907032|NCT04570956|DRUG|Placebo|placebo pill or placebo gel
223907033|NCT04570956|OTHER|Questionnaire Administration|Ancillary studies
223907034|NCT05104463|DRUG|CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107|CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
223907035|NCT04004442|DRUG|Avelumab|Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
223715809|NCT01314573|BEHAVIORAL|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
223715810|NCT02634229|GENETIC|blood sample|
223907036|NCT04004442|DRUG|AVB-S6-500|AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
223907037|NCT05622201|DRUG|Rituximab|Infusion
223907038|NCT03957434|OTHER|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
223907039|NCT01885689|DRUG|clofarabine|Given IV
223907040|NCT01885689|DRUG|melphalan|Given IV
223907041|NCT01885689|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
224277158|NCT01166815|DIETARY_SUPPLEMENT|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
224277159|NCT01166815|OTHER|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
224277160|NCT00535028|DRUG|AER 001|AER 001 25 mgs s.c. once daily for 28 days
223715811|NCT00748501|DRUG|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
223715812|NCT05307419|PROCEDURE|Rectal suction biopsy.|Suction biopsy performed
223715813|NCT05307419|PROCEDURE|Full-thickness rectal biopsy.|Full-thickness biopsy performed
223715814|NCT05238441|BIOLOGICAL|SCTV01E|D0; intramuscular injection
223715815|NCT05238441|BIOLOGICAL|Comirnaty|D0; intramuscular injection
223715816|NCT05238441|BIOLOGICAL|SCTV01E|D180; intramuscular injection
223715817|NCT05238441|BIOLOGICAL|Comirnaty|D180; intramuscular injection
223907042|NCT01885689|DRUG|tacrolimus|Given IV or PO
223907043|NCT01885689|DRUG|sirolimus|Given PO
223907044|NCT01885689|OTHER|Pharmacological Study|Correlative studies
223907045|NCT06647732|DRUG|Zanubrutinib|160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)
223907046|NCT06647732|DRUG|Rituximab|375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
223907047|NCT04967248|OTHER|Alpelisib|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
223907048|NCT04967248|OTHER|Fulvestrant|Prospective observational PASS study. There is no treatment allocation. Patients recruited on or before their first prescribed dose of alpelisib in combination with fulvestrant will be enrolled.
224277161|NCT00535028|DRUG|placebo|sterile saline
224277162|NCT01065389|BEHAVIORAL|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
224277163|NCT01065389|BEHAVIORAL|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
224277164|NCT03090490|OTHER|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
224277165|NCT03090490|OTHER|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
223907049|NCT04484428|DRUG|K-285|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
223907050|NCT04484428|DRUG|Menthol|88 subjects are to be assigned to 1 week dosing, four times a day (QID) (Period 1), and 32 are to be assigned to 3 weeks dosing (Period 1 and Period 2) with 16 subjects each in the two times a day (BID) and QID dosing regimens.
223907051|NCT05267470|DRUG|Bemarituzumab|Intravenous (IV) infusion
223715818|NCT04750148|DIAGNOSTIC_TEST|6-minute walking test|The subject walks as far as possible for 6 minutes along a 30m long corridor.
223907052|NCT05267470|DRUG|Docetaxel|IV infusion
223907053|NCT05267470|DRUG|Pembrolizumab|IV infusion
223907054|NCT05267470|DRUG|Carboplatin|IV infusion
223907055|NCT05267470|DRUG|Paclitaxel|IV infusion
223907056|NCT05267470|DRUG|Nab-paclitaxel|IV infusion
223907057|NCT05796154|DEVICE|ear blood pressure monitor|The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
223907058|NCT06026488|OTHER|Other|real world treatment and survival of DLBCL patients in China
223907059|NCT04480736|DRUG|Placebo|Matching placebo will be administered orally.
223907060|NCT04480736|DRUG|JNJ-64281802 High dose|JNJ-64281802 high dose will be administered orally.
223907061|NCT04480736|DRUG|JNJ-64281802 Medium dose|JNJ-64281802 medium dose will be administered orally.
223907062|NCT04480736|DRUG|JNJ-64281802 Low dose|JNJ-64281802 low dose will be administered orally.
223907063|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen X|JNJ-64281802 dosing regimen X will be administered orally.
223907064|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Y|JNJ-64281802 dosing regimen Y will be administered orally.
223907065|NCT04480736|DRUG|JNJ-64281802 Dosing Regimen Z|JNJ-64281802 dosing regimen Z will be administered orally.
223907066|NCT06254443|OTHER|Enema Bowel preparation|Enema Group (Experimental Group): Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.
223715819|NCT04750148|DIAGNOSTIC_TEST|2-minute walking test|The subject walks as far as possible for 2 minutes along a 30m long corridor.
223907067|NCT06254443|OTHER|PEG Bowel preparation|Oral PEG Group (Control Group): Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
223907068|NCT06475729|DRUG|Citrate-Free Mirikizumab|Administered SC
223907069|NCT03381586|DRUG|ALT-803|Subjects randomized to Group A will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
223907070|NCT05651542|BEHAVIORAL|Comprehensive Self-Management Intervention|In addition to standard care, participants receive content on self-management which includes cognitive behavioral therapy, relaxation, and diet. Weekly phone calls provide support for achieving the sessions goals.
223907071|NCT05651542|OTHER|Control|The control group will receive standard care.
223907072|NCT05894252|OTHER|Walking Interventions|"Participants in the intervention group will be required to complete a 30-minute walk five days a week for 12 weeks. This will be in addition to any regular walking or exercise they are currently doing, which will be assessed via a questionnaire at baseline. In the control group, participants will be asked to continue with their daily routines and usual level of physical activity.~The baseline measurements will be taken before the intervention at week zero. Subsequently, all the participants will attend a virtual meeting (screening visit) to learn about the key aspects of the research, including the required actions of the control and intervention groups, how to use the act watch and report the required data. All participants in the intervention group and the control group will be required to wear acti watches, which will be given to them for free."
223907073|NCT04003454|OTHER|HCV Screening|The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
223907074|NCT06363786|OTHER|Test patches|Patches (incontinence product cut outs) with a low pH formula or control patches without formula.
223907075|NCT06730022|DRUG|MTX-001 (Dermacyte Liquid)|Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
223907076|NCT06772402|GENETIC|GCB-001|GCB-001 is a self-complementary AAV9 carrying a full length human SMN transgenetic product.
223907077|NCT04630470|BEHAVIORAL|massage therapy with lavender oil|massage therapy with lavender oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
223907078|NCT04630470|BEHAVIORAL|massage therapy with baby oil|massage therapy with baby oil-on both lower leg areas, for 10 minutes on each leg, for 4 weeks, three times a week, in the HD sessions
223907079|NCT06066099|DRUG|AP31969|Oral tablets
223907080|NCT06066099|DRUG|Placebo|Oral tablets
223907081|NCT06155305|PROCEDURE|Biopsy|Before initiating neoadjuvant therapy, patients diagnosed with breast cancer undergo a tumor biopsy. The tissue obtained from the biopsy is utilized to establish organoids and conduct drug testing.
223907082|NCT00709527|DRUG|Avacincaptad Pegol|intravitreal injection
223907083|NCT03864601|DRUG|14C-JNJ-56136379|14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
223907084|NCT04738890|BEHAVIORAL|Mindfulness-based cognitive therapy|Mindfulness-based cognitive therapy adapted for parents and carers of children with food allergy (MBCT-PCCFA) offered live online by video-conferencing
223907085|NCT04738890|OTHER|Treatment as usual|Continuance as planned of whatever other treatments or interventions the participants were receiving at the time of recruitment.
223907086|NCT06548646|PROCEDURE|Thoracic Interfascial Plane Block|The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).
223907087|NCT06548646|PROCEDURE|Erector Spinae Plane Block|The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.
223907088|NCT02662712|DRUG|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
223907089|NCT02662712|DRUG|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
223907090|NCT05085457|DIAGNOSTIC_TEST|ExPreS Protocol|the pacient will be submitted to the SBT with T-ayre, with oxygen support that is proprotional to the fraction of inspired oxygen in IMV, during 30 minutes. If the pacient does not show any sign of SBT failure, ExPreS will be calculated. If punctuation is lower than or equal to 44, it indicates weaning failure and the pacient mjust return to MV for 24 hours at least. Punctuation between 45 and 58 must be evaluated if the pacient presents chronic obstructive pulmonary desease (COPD), obesity or heart desease. In this case, the weaning must be continued if there isn't any risck factors. Punctuation higher than or equal 59 indicates that the pacient can be extubated.
223907091|NCT03705078|PROCEDURE|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
223907092|NCT03705078|PROCEDURE|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
223907093|NCT05540704|BEHAVIORAL|iACT|Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.
223907094|NCT05540704|OTHER|Usual Care|Usual care for problems in Type 1 diabetes management
223907095|NCT03825588|BEHAVIORAL|ASAP (As Safe As Possible)|ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
223907096|NCT03825588|BEHAVIORAL|BRITE smart phone app|BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
223907097|NCT03825588|BEHAVIORAL|TAU (treatment as usual)|TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
223907098|NCT04793646|DRUG|N-acetylcysteine syrup|N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months
223907099|NCT04793646|DRUG|Placebo syrup|Placebo syrup 15 mL twice a day for 3 months
223907100|NCT05845931|DIETARY_SUPPLEMENT|Berberine|A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 11 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine concentrations. (Women will undergo the Intervention twice, once in the 1st half and once in the 2nd half of their menstrual cycle.) In addition urine will be collected over the time of 0-10 h after berberine intake and body composition will be measured by bioelectrical impedance analysis (BIA).
223907101|NCT04348318|OTHER|health related personal data extraction from digital medical records|health related personal data extraction from digital medical records (i.e. patient characteristics; start, end and duration of hospitalization and ICU stay; admitted from another hospital, nursing home or comes with emergency medical Service; formal data of written advance directives; data of unwritten advance directive; information on the contents of the advance directives (regarding life-worthy conditions, health care agents, resuscitation, pain management, artificial nutrition, hydration, surgeries, renal replacement, mechanical circulation, mechanical ventilation, pacemaker, administration of blood products, treatment of infections, organ donation, autopsy); patient history; clinical data; therapeutic features; outcome at discharge; knowledge regarding relatives and their level of information about the advance directives; discussion of euthanasia and self-determination of dying.
223907102|NCT03576612|BIOLOGICAL|AdV-tk|Given IT
223907103|NCT03576612|DRUG|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
223907104|NCT03576612|RADIATION|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
223907105|NCT03576612|DRUG|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
223907106|NCT03576612|BIOLOGICAL|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
223907107|NCT03576612|OTHER|Laboratory Biomarker Analysis|correlative studies
223907108|NCT05810012|DRUG|PENG block|10ml of 0.125% isobaric bupivacaine injected
223907109|NCT05810012|DRUG|FICB Block|20ml of 0.125% isobaric bupivacaine injected
223715820|NCT04750148|DIAGNOSTIC_TEST|10-meter walk test|The natural and fast walking speeds of the subject are measured over 10m. This speed is measured by the examiner as well as by the subject (self-tested version).
223907110|NCT05861323|BEHAVIORAL|Comfort Measures Only Time out (CMOT)|This is a brief intensive care unit team (nurse, physician, advanced practice provider, respiratory therapist) intervention to improve communication and care of patients at end of life in the intensive care unit setting.
223907111|NCT06997068|DRUG|Celecoxib|Given PO
223907112|NCT06997068|DRUG|Erlotinib Hydrochloride|Given PO
223907113|NCT06997068|PROCEDURE|Imaging Procedure|Undergo SOC imaging scans
223907114|NCT06997068|OTHER|Interview|Ancillary studies
223907115|NCT06997068|DRUG|Methotrexate|Given PO
223907116|NCT06997068|OTHER|Questionnaire Administration|Ancillary studies
223907117|NCT03011372|DRUG|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
223907118|NCT06674473|DEVICE|With robot assistance|Use a portable isokinetic device
223907119|NCT06674473|BEHAVIORAL|traditional bodyweight rehabilitation|Use traditional bodyweight rehabilitation
223907120|NCT06657950|BEHAVIORAL|Integrative hatha yoga and mindful self-compassion|12 weeks of integrative hatha yoga and mindful self-compassion training
223907121|NCT06999564|BEHAVIORAL|EFT|"EFT involves the following steps:~1. Identification of the problem that is causing the person distress (e.g., fear of childbirth) and scoring or measuring the severity of this problem.~2. Tapping with the fingertips on certain points of the face and body, known as correction (i.e., regulation of the energy system), as well as the expression of an emphatic phrase (related to the person\&amp;#39;s problem and self-acceptance)."
223907122|NCT06875934|DRUG|SHR-1139 Injection|SHR-1139 injection.
223907123|NCT06875934|DRUG|SHR-1139 Injection Placebo|SHR-1139 injection placebo.
223907124|NCT07064382|DEVICE|VR-based multi-dimensional intervention|VR-based multi-dimensional intervention, including LLMs, AI-agents
223907125|NCT07062250|DEVICE|Feasibility and safety of home-based blood count measurement and transfusions|Feasibility and safety of home-based blood count measurement and transfusions in patients with acute myeloid leukemia
223907126|NCT07063719|OTHER|Ophthalmological visit|"Uncorrected visual acuity (UCVA), best-corrected visual acuity (BSCVA), corneal topography, corneal pachymetry, ocular surface pictures (to evaluate disease status of the eye with and without fluorecein), Schirmer's test, Corneal esthesiometry, Tear film break-up time test, Intraocular pressure.~Below is a summary of steps to perform ocular surface pictures of the cornea.~1. Ensure slit lamp cleaning and appropriate magnification and light settings.~2. Ensure comfortable positioning of both the operator and the patient.~3. Examine external orbital structures and adnexa for inflammation, irritation, or lesions.~4. Examine lids and lashes for abnormalities.~5. Examine both bulbar and palpebral conjunctiva for signs of irritation and injection.~6. Examine the cornea for clarity and the presence of any defect.~7. Examine the anterior chamber depth and evaluate abnormalities that might affect its transparency (blood, purulent material, cells and flare).~8. Examine the surface of the iris an"
223907127|NCT07063719|OTHER|Questionnaires|Ocular Surface Disease Index (OSDI) questionnaire, Visual Analog Pain Scale (VAS) questionnaire
223907128|NCT07063719|OTHER|Blood sample collection|Blood samples from RED patients or control group are collected in BD Vacutainer K2 EDTA.
223907129|NCT07063719|OTHER|Impression cytology|Put one drop of oxybuprocaine hydrochloride 0.4% in patients' eyes and wait 10 seconds. Gently apply both side of one sterile nitrocellulose membrane onto the unexposed bulbar conjunctiva, superotemporally, inferotemporally, superonasally, and inferonasally, for approximately 20 seconds, please, keep the eyes separated.
223907130|NCT07063719|OTHER|Tear fluid|One sterile minisponge per eye will be placed over the lids margin at the junction of the lateral and middle thirds of the lower eyelids and kept in place for 2 minutes. During application of sponges the patient needs to look up to facilitate the procedure. To avoid excessive tear reflex, as well as a mild discomfort, it is recommended that patients close their eyes during the collection. Remove sponge using sterile tweezers and put it into empty 0.5mL tube (pierced at the bottom with a sterile needle) placed into another empty 1.5 mL tube and keep it on ice until processing.
223907131|NCT07064447|PROCEDURE|Cholangiopancreatoscopy|Direct cholangiopancreatoscopy by single operator
223907132|NCT07062796|DEVICE|Water Faucet|Access H2OTM faucet is a smart, hand free faucet that is designed for ease water access for physical limitations
223715821|NCT04750148|DIAGNOSTIC_TEST|One leg stance test|The time held in unipodal equilibrium is measured by the examiner.
223907133|NCT07057609|DRUG|Tested Propofol Medium and Long Chain Fat Emulsion Injection (T)|Single-dose intravenous infusion of the test formulation under fasting conditions at 30 μg/kg/min. Infusion time: 30 minutes. Dosage: 900 μg/kg for both administrations
223907134|NCT07057609|DRUG|Reference Propofol Medium and Long Chain Fat Emulsion Injection (R)|Single-dose intravenous infusion of the reference formulation under fasting conditions at 30 μg/kg/min. Infusion time: 30 minutes. Dosage: 900 μg/kg for both administrations
223907135|NCT07063550|OTHER|exposure to microplastic|Microplastic content in cancerous and paracancerous tissues
223907136|NCT07062120|OTHER|Nicotinamide(NAM)(10%)|The active niacinamide form of vitamin B3, NAM is routinely employed as a pigmentation-reducing agent in melasma treatment protocols
223907137|NCT07062120|OTHER|Supramolecular salicylic acid(SSA) (30%)|Salicylic acid, a superficial chemical peel, has been widely used in treating melasma. Breakthroughs in supramolecular design have addressed its irritancy profile through engineered SA complexes with improved water dispersibility
223715822|NCT00592384|DRUG|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
223715823|NCT00592384|DRUG|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
223907138|NCT07062120|OTHER|Supramolecular salicylic acid simulator|the same course of treatment in the same dosage form that does not contain salicylic acid
223907139|NCT07062120|OTHER|Nicotinamide simulator|the same course of treatment in the same dosage form that does not contain nicotinamide
223907140|NCT07064070|BEHAVIORAL|TRUST|The four online modules included: General Communication, Talking about Relationships and Sexual Health, Parental Monitoring, and Check-up and Check-in (content focused on the importance of alone time). Modules were in English, Chinese, or Spanish
223907141|NCT06772701|DIAGNOSTIC_TEST|Mini International Neuropsychiatric Interview|Fathers have Mini International Neuropsychiatric Interview, the standard diagnostic tool for post-natal depression
223907142|NCT06772701|OTHER|EPDS book|PH-Q9, EPDS and socio-demographic questionnaires are completed online at inclusion and 6 to 8 weeks after the birth of child.
223907143|NCT07063264|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|HD-tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes
223907144|NCT07063264|DEVICE|sham high-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
223907145|NCT07064395|OTHER|bright light|Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.
223907146|NCT07063017|OTHER|Post- Isometric Relaxation|Post Isometric Relaxation Technique to Piriformis; Lay the patient in the supine position and have the practitioner stand on the same side as the affected piriformis muscle. Bend the knee of the affected side and place the foot of that side on the lateral aspect of the opposite knee. Have the practitioner push knee medially until meeting the restrictive barrier. Have the patient push against the practitioner's resistance for 3 to 5 seconds, allow for a period of isometric relaxation, then engage a new barrier; repeat three times. Return the patient to a neutral position and reassess using supine or prone piriformis testing.
223907147|NCT07063017|OTHER|Active Release Technique|Patient position is side lying on the sound side. Therapist stands behind the patient. The upper leg must be in flexion on knee and slight extension Now apply pressure with both thumbs on piriformis and ask patient to flex and extend his hip and also external and internal rotation on hip in flexion. The gluteal muscle is taken from a shortened position to a fully lengthened position while the physiotherapist's contact hand holds tension longitudinally along the soft tissue fibers.
223907148|NCT07064434|PROCEDURE|Sacral canal block combined with general anesthesia|"Sacral canal block: The patient lies on their side, with the back perpendicular to the edge of the operating table. The knee joints of the lower limbs are flexed, the thighs are close to the abdomen, and the waist is arched backward as much as possible, resembling a shrimp shape. The space between the sacrum and coccyx of the patient (sacral hiatus) is fully exposed. By using a low-frequency probe (such as 2-5 MHZ), the strong echo of the sacrum, the low echo of the sacral canal, and the echo of the surrounding soft tissues can be clearly seen. At the located sacral hiatus, hold the puncture needle and slowly insert it perpendicularly to the skin. When the puncture needle passes through the sacrococcygeal ligament, there will be a distinct breakthrough sensation, which indicates that the puncture needle has entered the sacral canal. The general depth of needle insertion is about 2 to 3cm. However, the specific depth varies depending on factors such as the patient's body type."
223907149|NCT07064434|PROCEDURE|Simple general anesthesia|General anesthesia: Midazolam (0.2mg/kg), sufentanil (0.2-0.4μg/kg), etomidate (0.15-0.3 mg/kg), and rocuronium (0.6 mg/kg) were induced. After the patient's muscles were completely relaxed, a laryngeal mask was placed. Connect the anesthesia machine and set the ventilator parameters: Vol.Mode, tidal volume 6-8ml/kg, frequency 10-14 times /min, inhalation-exhalation ratio 1:2, and maintain EtCO2 at 35-45mmHg during the operation. Propofol (4-12mg/kg/h) and remifentanil (0.05-2ug/kg/min) were maintained. According to the operation course, rocuronium (0.15mg/kg) and sevoflurane inhalation (1% - 7%) could be administered at a single time. Anesthesiologists adjust the drug infusion rate based on the patient's hemodynamic indicators SBP, MAP, HR and clinical experience. When HR was less than 45 times /min during the operation, atropine was intravenously injected (0.25-0.5mg per time). When MAP is less than 55mmHg and lasts for more than 3 minutes, ephedrine (6-12mg each time) is given.
223907150|NCT04574882|OTHER|Survey|Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
223907151|NCT05874154|PROCEDURE|Tibial nerve selective neurotomy|Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
223907152|NCT05874154|DRUG|Botulinum toxin injection|Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
223907153|NCT03260465|DEVICE|seleXys PC|Total hip arthroplasty using the seleXys PC cup
223907154|NCT03260465|DEVICE|RM|Total hip arthroplasty using the RM cup
223907155|NCT06440694|DRUG|Colchicine 0.5 mg po|Colchicine 0.5 mg po once daily for 180 days.
223907156|NCT06440694|DRUG|Placebo 0.5 mg po|Placebo 0.5 mg po once daily for 180 days.
223907157|NCT04713969|DRUG|Pantoprazole 40mg|Pantoprazole 40mg twice daily
223907158|NCT03369821|DIAGNOSTIC_TEST|Beta Cell Loss and Immune Function|Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
223907159|NCT03369821|OTHER|Immune Function with RNAseq|Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
223528945|NCT06206265|BEHAVIORAL|Psychotherapy|Participants will receive one dose of 25 mg of oral psilocybin on the first dosing day and a second dose of 25mg oral psilocybin on the second dosing day. TRP 8802 will be administered in a comfortable setting under the guidance of the same two therapists from the preparation period. Participants will have an in-person study visit following the resolution of the psychoactive effects of the psilocybin (as determined by the therapists in discussion with the participant) to ensure participant's safety and comfort.
223907160|NCT05752500|BEHAVIORAL|Cognitive Behavioral Intervention for Physical Activity|Interventionist will use cognitive and behavioral techniques to help the participant increase facilitators and decrease barriers to physical activity, particularly barriers such as lack of motivation, depression, and chronic pain. Meetings will occur every other week for 4 months.
223907161|NCT05752500|BEHAVIORAL|Social Support for Physical Activity|This component will leverage the social functionality of the Fitbit app, promoting social support and friendly competition via a moderated Facebook group.
223907162|NCT05752500|BEHAVIORAL|Physical Activity Coaching|The PA coach will meet with the participant to set goals for physical activity (steps) and encourage self-monitoring. Meetings will occur every other week for 4 months.
223907163|NCT05752500|BEHAVIORAL|Brief Advice and Self-Monitoring|Participants will receive a single session with brief advice about increasing physical activity, and instructions on how to use their study-provided FitBit.
223907164|NCT03951480|OTHER|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity \< 2, manipulations will not be continued. The patient being considered as not very symptomatic.
223907165|NCT03951480|DRUG|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
223907166|NCT03079232|DEVICE|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
223907167|NCT03079232|DEVICE|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
223907168|NCT06256510|DRUG|Midazolam|Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15
223907169|NCT06256510|DRUG|Vepdegestrant|Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.
223907170|NCT05412771|PROCEDURE|Hysteroscopy|Samples will be collected from consenting patients undergoing a surgical hysteroscopy for medical purposes
223907171|NCT04141371|DRUG|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
223907172|NCT04141371|DRUG|physiological serum|daily saline infusion over 3 hours during the vasospasm period
223907173|NCT05593900|BEHAVIORAL|Nurse-to-Family Video Chat|A Nurse-To-Family Video Chat will be offered to parents/guardians to virtually connect with their post-transfer nurse; this intervention is changing the behavior of how providers deliver healthcare and how parents/guardians engage in their child's care.
223907174|NCT03669523|DRUG|Denosumab-nivolumab combination|"* Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks"
223907175|NCT05450510|OTHER|Accelerated (ACCEL) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 8-week-long Phase 2 and Phase 3 trainings.
223907176|NCT05450510|OTHER|Slow (SLOW) protocol group|After randomization and initial evaluations, patients will be referred to Physiotherapy and Rehabilitation clinics for a 14-week-long Phase 2 and Phase 3 trainings.
223907177|NCT04228042|DRUG|Infigratinib|Given PO
223907178|NCT04228042|OTHER|Quality-of-Life Assessment|Ancillary studies
223907179|NCT04228042|OTHER|Questionnaire Administration|Ancillary studies
223907180|NCT04228042|PROCEDURE|Surgical Procedure|Undergo surgery
223907181|NCT05790486|BEHAVIORAL|Take a Break plus Nicotine replacement therapy (NRT) Sampling|"Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At week 1 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and facilitate an abstinence goal."
223907182|NCT05790486|BEHAVIORAL|The Comparison|The comparison group will receive Nicotine Replacement Therapy sampling and will be balanced in all variables except the Take a Break Intervention.
223907183|NCT05790486|OTHER|Community Paramedicine Standard Plus Enhanced Implementation Program|Counties randomized to the enhanced program will receive the standard implementation program plus the following enhancements. We will engage and train local implementation champions. The EMS Implementation Champion will go through the Take a Break Intervention but will not receive NRT sampling. The local implementation champions are internal facilitators with additional knowledge and experience related to the electronic referral process. The champions will also be leaders in their county by trying to improve referrals, remind EMS personnel, and distribute feedback on the performance of the county.
223907184|NCT05790486|OTHER|Community Paramedicine Standard Implementation Program|In counties randomized to the standard program, we will engage EMS leaders and train local personnel. The training will be applying the Ask-Advise-Refer model and the use of an eRefer tool in EMS situations and conditions. The EMS will then engage smokers in the field or community to use the Ask-Advise-Refer training to submit electronic referrals with the eRefer tool.
223907185|NCT06246799|DRUG|Tirzepatide|Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.
223907186|NCT06246799|DRUG|Pioglitazone|Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.
223907187|NCT06246799|DRUG|Sitagliptin|Sitagliptin: will be administered as a 100mg dose once daily.
223907188|NCT06246799|DRUG|Metformin HCI XR|Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.
223719345|NCT06840366|OTHER|Lokomat intervention|The intervention will consist of an 8-week motor rehabilitation program, with 3 weekly sessions of 60 minutes each. In the first weeks, joint mobilization and postural control in a sitting position will be worked on, followed by muscle strengthening and balance re-education in a standing position. Subsequently, coordination exercises and assisted walking on different surfaces will be incorporated. In the final phase, independent walking and the integration of functional movements in daily life activities will be encouraged. The program will be adapted to the individual needs of each patient to optimize recovery and improve quality of life.
223907189|NCT04642352|DRUG|superior laryngeal nerve block|A unilateral injection of 2 cc of a 1:1 mixture of 0.25% bupivacaine and Kenalog-40 via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) via a 27 gauge needle to the thyrohyoid space (front of neck, just above larynx/voice box) on the side which exhibited most discomfort/tenderness/cough on palpation. If neither side was uncomfortable, the right side will be used.
223719346|NCT03210818|DEVICE|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
223907190|NCT06011577|DRUG|REL-1017|REL-1017 tablet
223907191|NCT06011577|DRUG|Placebo|Placebo tablet
223907192|NCT03812549|DRUG|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
223907193|NCT03812549|RADIATION|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
223907194|NCT03812549|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
223907195|NCT05623787|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
223907196|NCT06249815|COMBINATION_PRODUCT|Misoprostol 200mcg Tab|ranscervical Foley catheter (silicone, size 20F with 30ml balloon)+Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
223907197|NCT06249815|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
223907198|NCT06618014|DRUG|Toripalimab|Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.
223907199|NCT06618014|DRUG|Docetaxel|Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.
223907200|NCT06618014|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.
223907201|NCT05172843|PROCEDURE|Surgical knee arthroplasty|"Surgery will be performed 3 months from inclusion in the trial (at week 13). The procedure and type of prosthesis and postoperative program will be at the discretion of the involved surgeon and the participating department.~Post-surgical care and rehabilitation will follow current clinical standards."
223907202|NCT05172843|BEHAVIORAL|Supervised weight loss|"The supervised intensive dietary weight loss program will be initiated 3 months from inclusion in the trial (at week 13) and lasts for 12 weeks.~The program includes full meal replacement by a standard liquid energy intake in a supervised dietary program. Participants will attend the nutrition department weekly. They will be weighed on a decimal scale, given nutritional and dietetic instructions by an experienced dietitian and formula diet products are handed in sessions of 1-2 h. The participants will be taught to make diet plans.~Following the 12 weeks intensive dietary weight loss program participants will be scheduled for two booster follow-up sessions with a dietician at weeks 39 and 51."
223907203|NCT03428646|DRUG|Dupilumab|Dupixent 1 dose at Baseline required for eligibility; otherwise, no therapeutic intervention required during the course of the study. In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
223907204|NCT06230861|DIETARY_SUPPLEMENT|Quercetin|Quercetin tablets 500mg 1 x per day
223907205|NCT06230861|OTHER|Placebo|Placebo control 1 x blinded placebo tablet per day
223907206|NCT06778031|DRUG|SHR-A1811|SHR-A1811.
223907207|NCT06778031|DRUG|SHR-1316|SHR-1316.
223907208|NCT06778031|DRUG|SHR-8068|SHR-8068.
223719347|NCT01082120|DRUG|AZD1656|Tablets orally, twice daily for 10 days
223719348|NCT01082120|DRUG|Pioglitazone|Tablet oral single dose for 10 days
223907209|NCT05789394|BIOLOGICAL|Allogeneic Adipose-derived Mesenchymal Stem Cells|Receive IT
223907210|NCT05789394|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223907211|NCT05789394|PROCEDURE|Craniotomy|Undergo craniotomy
223907212|NCT05789394|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223907213|NCT05789394|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir placement for collection of CSF
224277166|NCT03399006|DEVICE|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position \& carried out for measurement of fetal CRL and diagnosis of any major fetal defects
223907214|NCT05956314|DRUG|KM-001 cream 1% 12 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 84 days. IMP will be applied on the plantar surfaces.
223907215|NCT05956314|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed as follows at screening and baseline, abbreviated after that (i.e., on Days 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort):~* The complete physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, gastrointestinal (GI), musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~* Symptom-directed physical examinations will be performed at all other trial visits.~* Height and weight measurement will be performed at screening only. An abbreviated examination including a comprehensive skin examination."
223907216|NCT05956314|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (oral body temperature, pulse, and resting systolic and diastolic blood pressure) will be measured at screening, on Days 1, 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort. Vital signs will be measured in supine position after at least 5 minutes of rest.
223907217|NCT05956314|DIAGNOSTIC_TEST|Serum chemistry|Approx. 5 mL whole blood will be collected after an ≥8 h fast for serum biochemistry assessments during screening, and on Days 1 (baseline), 7, 84 112, 140 or at an ET visit - where applicable, per cohort. Serum chemistry will include assessments of total and direct bilirubin, ALT, AST, gamma-glutamyl transferase (GGT), alkaline phosphatase, glucose (fasting), sodium, potassium, blood urea nitrogen (BUN/Urea), creatinine, chloride, calcium, uric acid, albumin, and total protein.
223907218|NCT05956314|DIAGNOSTIC_TEST|Hematology|Approx. 5 mL whole blood will be collected for complete blood count (CBC) during screening, and on Days 1 (baseline), 7, 84, 112, 140 or at an ET visit - where applicable, per cohort. The CBC assessments will include red blood cells (RBC), haemoglobin, haematocrit, reticulocyte count, platelet count, mean corpuscular haemoglobin (MCH), mean platelet volume (MCV), white blood cells (WBC), neutrophils (absolute \[abs.\]), lymphocytes (abs.), monocytes (abs.), eosinophils (abs.), and basophils (abs.).
223907219|NCT05956314|DIAGNOSTIC_TEST|Serology|Approx. 5 mL whole blood will be collected for serology assessments during screening. Serology will include HbsAg, HbcAb, hepatitis C antibody, and HIV antibody.
223907220|NCT05956314|DIAGNOSTIC_TEST|Urinalysis|General urinalysis will be performed, by dipstick, during screening, and on Days 1 (baseline), 7, and 84, 112, and 140, or at an ET visit - where applicable, per cohort. At least 7 to 10 mL of urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin, urobilinogen, and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated.
223907221|NCT05956314|DIAGNOSTIC_TEST|ECG test|A 12-lead, resting, ECG will be taken for each patient at screening, on Days 1 (baseline), 84, 112, and at day 140 (for Cohort 2), or at an ET visit - Where applicable. The measurement will be taken after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT, and QTc interval and QRS complex. The report will be printed out and signed by the investigator, who will record in the eCRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the patients will be reviewed.
223907222|NCT05956314|DIAGNOSTIC_TEST|Pharmacokinetics Assessments|"Blood samples for PK will be collected during screening (Days -14 to 0) at any time during the visit, or on Day 1 (up to 30 minutes prior to the first dose, if not performed during Screening) and on Day 7 and at End of Treatment (EoT, Cohort 1: Day 84; Cohort 2: Day 112) up to 30 minutes pre-dose and at 1 h, 2 h, 3 h, 6 h (+15 min) post-dose, on Days 28, 42, and 84 (for Cohort 2): 1 sample after the first dose, before the second dose, as late as possible in the visit, at End of Study (EoS, Cohort 1: Day 112; Cohort 2: Day 140), or at an ET visit: at any time during the visit.~* Altogether up to 15 samples, and approx. 30 mL of blood will be drawn for PK at screening or Day 1 and on Days 7, 28, 42, 84, EoT (84/112), and EoS (112/140), or at an ET visit, if applicable.~* Overall, up to a total of 85 mL of blood will be drawn during the trial for blood and PK assessments per patient in Cohort 1, and 95 mL of blood per patient in Cohort 2."
223907223|NCT05956314|DIAGNOSTIC_TEST|Clinical global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator during screening and on Days 1 (baseline, prior to first dosing), 7, 28, 42, 63, 84, 112, 140, and at ET visit - where applicable, per cohort).~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
223907224|NCT05956314|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS) pain scale|"The patient will enter the PPPK- or PC-related pain score (not any pain) using a VAS pain scale in the patient-reported diary, on a weekly basis starting on Day 1 through ET visit, prior to the second administration of the IMP (evening dose) at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The score will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, 140, and at an ET visit - where applicable, per cohort).~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
223939987|NCT07196332|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of homeostatic and circadian mechanisms of human sleep regulation. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
224277167|NCT03399006|DEVICE|Doppler Ultrasound|"measurement of UtA-PI \& UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
224277168|NCT03399006|DEVICE|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
224277169|NCT05762887|OTHER|Probiotic Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The probiotic group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
223907225|NCT05956314|DIAGNOSTIC_TEST|Peak pruritus-numerical rating scale (PP-NRS)|"The peak pruritus severity will be assessed using the PP-NRS, an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The PP-NRS will be entered by the patients on a weekly basis starting on Day 1 through ET visit, preferably after the evening dose, at the same time every time (±1 hour) except for Day 1 (Visit 2, in-clinic visit), where the assessment will be performed pre-dose during the visit.~The scores will be collected on every in-clinic visit during the treatment and follow up periods (Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort).~The PP-NRS was designed to measure peak pruritus, or worst itch, over the previous 24 hours based on the following question: On scale from 0 (no itch) to 10 (worst imaginable itch) how was your worst itch in the past 24 hours?"
223907226|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) as follows:~Since the start of the trial, my overall status has:~from, 1= very much improved to 7= very much worse"
223907227|NCT05956314|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI will be evaluated on Days 1, 7, 28, 42, 63, 84, 112, and 140, or at an ET visit - where applicable, per cohort.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) as follows:~Please rate the severity of your disease right now, from 1= none to 5= very severe"
223907228|NCT05956314|DIAGNOSTIC_TEST|Lesion photography|"High quality photographic documentation of the treated lesions will be performed during Screening and on Days 1, 7, 42, 63, 84, 112, and 140, or at an ET visit before treatment - where applicable, per cohort.~The photographs will be taken under standardised conditions, using imitoMeasure (Ⓒ imito AG 2016-2022)."
223907229|NCT05956314|DRUG|KM-001 cream 1% 16 weeks treatment.|KM-001 1% will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. The patient will use IMP twice a day for 112 days. IMP will be applied on the plantar surfaces.
223907230|NCT05819710|DRUG|TS-142|Single dose of 5 mg of TS-142
223907231|NCT05819710|DRUG|TS-142|Single-dose of 10 mg of TS-142
223907232|NCT05819710|DRUG|Zopiclone|Single-dose of 7.5 mg of zopiclone
223907233|NCT05819710|DRUG|Placebo|Single-dose of placebo
223907234|NCT02759172|BEHAVIORAL|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
223907235|NCT05322239|DEVICE|Intermittent Theta Burst Stimulation|iTBS parameters. A series of 20, 10 s trains will be presented over the course of the \~3.5 min session. Each train will consist of 2 s of stimulation with an 8 s ITI. During the 2 s of stimulation, 10, 50 Hz bursts will be repeated at intervals of 200 ms (5 Hz).
223907236|NCT05322239|DEVICE|Continuous Theta Burst Stimulation|cTBS parameters. A single 600 pulse cTBS train will be delivered during each stimulation session. The train will consist of 50 Hz bursts, repeated at intervals of 200 ms (5 Hz) for 40 sec.
223907237|NCT02773810|OTHER|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
223528946|NCT06094803|BEHAVIORAL|Mindfulness-based Zentangle Program|"Session 1 focuses on Self-awareness and Self-kindness through the Zentangle method. It covers the introduction, basic techniques, and eight steps of Zentangle. Participants practice mindfulness and learn grid and round patterns. Drawing mindfully and interactive sharing are encouraged for engagement and reflection.~Session 2 emphasizes Acceptance and Non-judgmental Attitude. It builds on the previous session, exploring advanced techniques in the Zentangle method. Participants practice mindfulness, learn organic and texturing patterns, create their own artwork, and engage in interactive sharing for reflection."
223528947|NCT04028999|DEVICE|Evaluate the effects of the EO31 shoulder sling in adults post-stoke|Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
223907238|NCT05299723|BEHAVIORAL|BLT Intervention|BLT will be administered via a Luminette 3 light therapy visor. The Luminette 3 is a visor worn above the eyes containing light emitting diode (LEDs) emitting a blue-enriched white light reflecting to the retina at 1,000 lux via a holographic system in order to ensure correct penetration into the eye without impeding vision. This range of light and intensity is sufficient to synchronize the circadian clock.
223907239|NCT05299723|BEHAVIORAL|BLB Intervention|BLB will be administered via orange lenses that filter out short-wavelength blue light, while allowing the other visible spectrum light to pass. The BLB lenses result in a reduction in melanopic irradiance (i.e., the light that affects sleep) of about 85%. The BLB lenses only make the overall light environment about 30% dimmer. Therefore, the BLB lenses are effective in blocking out most of the blue light in the visible environment that impacts sleep, but do not result in drastic overall dimming/darkening of the light environment.
223907240|NCT05299723|BEHAVIORAL|Sleep Hygiene Education|The sleep hygiene education will consist of watching a sleep education video (background on the regulation of sleep, the impacts of insufficient sleep on mental and physical health, etc.) and a sleep hygiene video (providing overview of sleep hygiene approaches).
223528948|NCT05934123|BEHAVIORAL|EMNODN NEC Care Bundle|A care bundle created by the East Midlands Neonatal Operational Delivery Network to guide neonatal services in the region to implement practices that support own mother's milk feeding and other interventions that may reduce the risk of NEC in babies born \<32 weeks' gestational age.
223907241|NCT00696111|DRUG|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
223907242|NCT06093997|OTHER|Massage treatment|The patient sits upright and the neck naturally relaxes. The doctor uses techniques such as pressing and kneading to relax the soft tissues of the neck, and massages points such as FengMen, FengChi, JingJiaji, JianJing,Tianzong and so on. The focus is on using muscle relaxation techniques around the soft tissues of spasms and pain areas to relax the patient's neck and shoulders. All procedures were performed from mild to severe, once a week for 15 minutes each time, for a total of 4 weeks of treatment.
223715824|NCT05872841|DRUG|Recombinant human adenovirus type 5 + TACE|"1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles."
223907243|NCT06093997|OTHER|Cupping|Use a 4-5cm diameter suction cupping for cupping. The treatment area is coated with glycerol, and the cupping is aspirated and adsorbed on the skin. The cupping is slowly pushed along the patient's neck, along the urinary bladder channel of Foot-Taiyang and governor's meridians from top to bottom, repeating back and forth 9 times. Once a week, for a total of 4 weeks of treatment.
223907244|NCT06093997|OTHER|Bloodletting|the doctor takes JianZhongShu, one on the left and one on the right, with a total of 2 acupoints. After disinfecting with 75% alcohol cotton balls, the patient is quickly pricked 5 times with a blood collection needle, and cupping is performed at the needle hole. After 5 minutes, remove the jar, wipe the blood clean, and disinfect the needle hole. Once a week, for a total of 4 weeks of treatment.
223907245|NCT05583006|DRUG|tenofovir alafenamide (TAF)|TAF switch therapy in CHB patients who are unsatisfied to ETV therapy.
223907246|NCT03541512|BEHAVIORAL|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
223907247|NCT03541512|BEHAVIORAL|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
223907248|NCT06851650|OTHER|Rehabilition protocol after rotator cuff repair surgery|adding early scapular strengthening (lower trapezius and serratus anterior) exercise in Rehabilition program after rotator cuff repair surgery
223907249|NCT05725655|OTHER|Thermotherapy|Hot baths directly after an exercise session
224277170|NCT05762887|OTHER|Placebo Group|The 84 participants will participate in a randomized, double-blind, placebo-controlled trial in two arms. The placebo group will consist of 42 patients. These patients will be recruited from the USP Bipolar Disorder Program. This program has an outpatient clinic that offers free medical care to a population of different ethnic groups, with the majority of subjects coming from the middle and lower social classes.
224277171|NCT02991352|DEVICE|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
223907250|NCT06852339|BEHAVIORAL|EAPOC-COPD|The EAPOC-COPD system consists of: 1) a smart phone / tablet app or Personal Computer-based questionnaire which collects information directly from patients upon prompting, up to 1 week before their clinical appointment; and 2) a point-of-care clinical decision support system that wirelessly receives and processes questionnaire data in order to produce a symptom severity/exacerbation risk assessment, medication change recommendation, and COPD action plan, all of which is made available to providers through a prompt, upon opening the patient chart in the existing EMR. Once approved, the personalized COPD action plan is automatically populated within the patient app/portal, enabling anywhere/anytime access for patients. Patients are also provided with educational resources within their app/portal, designed to improve health literacy, inhaler technique, and adherence to their action plan
223907251|NCT06852339|OTHER|Usual Care|Usual care
223907252|NCT06851624|DEVICE|MARPE|treating patients with transverse maxillary deficiency using minis crews supported hybrid hyrax
223907253|NCT05773859|BIOLOGICAL|XP-DC vaccinations|Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
223907254|NCT06852547|DIETARY_SUPPLEMENT|protein|protein
224277172|NCT00867854|OTHER|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
224277173|NCT01669824|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
223907255|NCT02593773|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
223907256|NCT06853028|OTHER|ultrasound measurement|Muscle thickness measurements were performed with the ultrasound device immediately before root canal treatment, 1 week after, and 3 months after the treatment.
223907257|NCT04982419|DEVICE|Remote ischemic preconditioning|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
223907258|NCT04982419|DEVICE|Sham remote ischemic conditioning|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
223907259|NCT04413201|DRUG|Afatinib|Afatinib followed by osimertinib or ICT
223907260|NCT04413201|DRUG|Osimertinib|Osimertinib followed by ICT
223907261|NCT05049850|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
223907262|NCT05929599|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
223907263|NCT05929599|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
223907264|NCT05381103|DIAGNOSTIC_TEST|PSMA-PET and SOC MRI|60 min continuous acquisition of PET data after 3-6 mCI injection of \[68Ga\]P16-093 followed by contrast-CT
223907265|NCT05381103|DIAGNOSTIC_TEST|SOC MRI|Standard of care MRI
223907266|NCT04292379|OTHER|Standard care|Standard procedures and assessments
223907267|NCT04292379|OTHER|Care Bundle|Suicide risk screening tool, mental health assessment tool, follow-up appointment
223907268|NCT05452460|BEHAVIORAL|Mindfulness intervention|"The mindfulness program called Mindfulness-based peak performance (MBPP) will be used in this study. MBPP is a program that consists of eight 60-min training, and a 60-min session weekly for 8-weeks. The MBPP program will include (1) 5 minutes of will start with a brief recap of the preceding session and homework discussion, (2) after which the 5 minutes of a brief story about performance aimed at inducing the learning motivation of the participants; (3) Followed by 20 minutes of a theoretical lecture introducing a new topic and then (4) 25 minutes of mindfulness exercise. (5) Finally, how to apply the mindfulness skills to sports context will be discussed at the end of each session for 5 minutes."
223907269|NCT06012487|DRUG|Low BPV Regimen|Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
223907270|NCT05227742|DRUG|Psilocybin|Participants will receive oral psilocybin once per week for 5 weeks.
223907271|NCT05227742|DRUG|Placebo|Participants will receive inert placebo once per week for 5 weeks.
223907272|NCT06375512|BIOLOGICAL|HZ Vaccine (IN001)|Formulation for injection
224277174|NCT01575041|DIETARY_SUPPLEMENT|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
224277175|NCT01575041|DRUG|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
224277176|NCT01575041|DRUG|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
224277177|NCT00244829|DRUG|imatinib mesylate|
224277178|NCT00244829|PROCEDURE|adjuvant therapy|
224277179|NCT02416934|DRUG|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
223907273|NCT06375512|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) for injection
223907274|NCT06375512|BIOLOGICAL|Shingrix|Sterile suspension for injection
223907275|NCT06258174|DRUG|Pirtobrutinib|Administered orally.
223907276|NCT03860233|DRUG|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
223907277|NCT03860233|DRUG|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
223907278|NCT06192485|OTHER|proactive balance training|20 participants will receive a proactive balance training program
223907279|NCT06192485|OTHER|Reactive balance training|20 participants will receive a Reactive balance training program
223907280|NCT04178798|DRUG|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
223907281|NCT05224154|BEHAVIORAL|Abstinent Contingent (AC) Re-Connect|Participants in this group will be able to unblock highly desired, but non-essential (e.g., social networking, shopping, games) applications contingent on meeting goals for smoking abstinence, as verified by meeting carbon monoxide goals (CO\<=6ppm).
223907282|NCT05224154|BEHAVIORAL|Submission Contingent (SC) Re-Connect|Participants in this group will also be able to unblock their applications, but contingent on submitting CO samples and independent of meeting CO goals for smoking abstinence.
223907283|NCT05098899|GENETIC|MyGeneMyDiet® Recommendations for Weight Management|This group will receive Nutrition and Lifestyle recommendation based on SNPs known to have an impact to body weight and body composition, and responses to physical activity and dietary fat intake
224277180|NCT02416934|DRUG|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
224277181|NCT04203433|DRUG|DLX105-DMP|1mg applied to target lesion
224277182|NCT01020526|DRUG|pregabalin|Oral capsule 75-450 mg/day
224277183|NCT06096350|DEVICE|robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
223907284|NCT05098899|OTHER|Usual Standard of Care for Weight Management|This group will receive the conventional and standard nutrition lifestyle recommendation for weight management
223907285|NCT04839224|DRUG|carbogen|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes.
223907286|NCT04839224|DRUG|phenylephrine|Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
223907287|NCT03839498|DRUG|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
223907288|NCT05815147|DIETARY_SUPPLEMENT|Fortified Powdered Beverage|Participants will be asked to take the fortified powdered beverage everyday for 6 weeks.
223907289|NCT06087588|DRUG|0.9%sodium chloride|PENG sham block with 20ml 0,9% normal saline
223907290|NCT06087588|DRUG|95% ethanol|PENG neurolysis with 2.5ml of 95% ethanol
223907291|NCT05715125|DRUG|Dose A VTX958|Dose A VTX958
223907292|NCT05715125|DRUG|Dose B VTX958|Dose B VTX958
223907293|NCT05715125|DRUG|Placebo|Placebo
223907294|NCT06751485|DRUG|JSKN003|Experimental drug
223907295|NCT06751485|DRUG|Doxorubicin|Active Comparator
223528949|NCT06484166|OTHER|Fullerene cream|Patients are instructed to apply a thin layer of the Fullerene cream third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
223907296|NCT06751485|DRUG|Paclitaxel|Active Comparator
223907297|NCT06751485|DRUG|Topotecan|Active Comparator
223528950|NCT06484166|DRUG|Trolamine (Biafine)|Patients are instructed to apply a thin layer of the Trolamine (Biafine) third a day, starting three days before radiotherapy(RT) and continue until two weeks after treatment. The application should include the whole treatment area. Patients are also advised to not apply the cream within four hours before the RT in order to avoid possible build-up effect. Patients are asked to keep the skin of the radiotherapy area dry and clean and not use other topical agents in the irradiated area.
223907298|NCT06560281|OTHER|Motion Minder Therapy (MoMT)|Motion Minder Therapy (MoMT) total duration is 1 hour a day, 5 days a week for 4 weeks. The treatment is a carefully planned sequence of exercises intended to help children with spastic hemiplegic cerebral palsy develop their fine motor abilities. Activities includes Sticker Sorting, Beads on Parade, Pegboard Activities, Sensory Bins, Sculpture Building, Finger Painting \& Drawing with Different Tools, Musical Instrument Play. Smartwatches that have tactile sensations and auditory indications are used strategically during certain tasks to enhance proprioception and give real-time feedback, making the rehabilitation process vibrant and interesting.
223907299|NCT04263597|DRUG|2'-fucosyllactose|2FL powder will be provided to participants randomized to receive 2FL in packets. They will be instructed to drink this daily by adding the required amount to food or drink. It may also be mixed in standard feeds or mixed with water and administered by enteral tube, whenever applicable.
223528951|NCT05207670|DRUG|Mosunetuzumab (Cohorts A-C)|Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
223528952|NCT05207670|DRUG|Mosunetuzumab (Cohorts D-E)|Participants will receive SC mosunetuzumab for up to 34 cycles
223528953|NCT05207670|DRUG|Tocilizumab|Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
223528954|NCT04317105|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
223528955|NCT04317105|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223528956|NCT04317105|PROCEDURE|Computed Tomography|Undergo a CT scan
223715825|NCT03719885|DEVICE|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
223907300|NCT06198816|OTHER|ultrasound accelerated thrombolysis and venoplasty|IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
223907301|NCT06479148|DEVICE|enVista® Aspire™|Eyes will receive enVista® Aspire™ lenses
223528957|NCT04317105|DRUG|Copanlisib Hydrochloride|Given IV
223528958|NCT04317105|PROCEDURE|Echocardiography Test|Undergo ECHO
223528959|NCT04317105|BIOLOGICAL|Ipilimumab|Given IV
223528960|NCT04317105|BIOLOGICAL|Nivolumab|Given IV
223528961|NCT04317105|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223528962|NCT06303310|OTHER|Gaze Stability Exercises|Group A ( Gaze Stability Exercise+ Routine Physical Therapy) Group A will receive gaze stability exercises consist of 5 structured components for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks.(16)
223907302|NCT06479148|DEVICE|An IOL with a slightly extended depth of focus|Eyes will receive lenses with a slightly extended depth of focus
223907303|NCT06479148|DEVICE|MX60E|Eyes will receive MX60E lenses
223907304|NCT04579900|PROCEDURE|Endoscopy and duodenal biopsy and sampling|All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
223907305|NCT06309433|DIAGNOSTIC_TEST|dual energy x-ray absorptiometry|Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
223907306|NCT05871372|DEVICE|Brain Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care, respectively, The depression cohort will also have deep brain stimulation (DBS) leads implanted as part of their trial. We will deliver stimulation via the DBS and sEEG electrodes. We will adhere to well known safety parameters.
223907307|NCT05871372|DEVICE|sEEG Stimulation|Both patients in the depression and epilepsy cohort will have implanted intracranial stereo-EEG (sEEG) electrodes as part of their clinical trial and regular clinical care. We will deliver stimulation via the sEEG electrodes. We will adhere to well known safety parameters.
223907308|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose A|Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.
223907309|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose B|Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.
223907310|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose C|Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.
223907311|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose D|Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.
223907312|NCT04447040|DRUG|Acetaminophen/naproxen sodium Dose E|Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.
223907313|NCT04447040|DRUG|Placebo|Placebo tablets administered as a single two-tablet dose.
223907314|NCT04169243|BEHAVIORAL|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.
223907315|NCT04169243|OTHER|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
223907316|NCT04115241|DEVICE|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
223907317|NCT04115241|OTHER|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
223907318|NCT06433401|BEHAVIORAL|Transitional care training with brochures, posters and slide training materials|Education at 1 and 2 months after the first interview
223907319|NCT06348680|OTHER|Video assisted episiotomy repair training|Midwifery Intervention The 'video recording' prepared by researchers specialized in the field of midwifery to increase the episiotomy repair skills of midwifery students will be used as training material. The content of the video recording is as follows: control before episiotomy repair, episiotomy repair, subcutaneous suturing, skin suturing, suturing techniques (Continuous, Simple Intermittent, Mattress). After the video recording is completed, it will be restarted and shown to the students in the experimental group continuously throughout the application period. At the end of the application period, students will be re-evaluated.
223907320|NCT06396377|DEVICE|Reborn doll (Therapeutic object - OT)|If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
223907321|NCT05778162|DIAGNOSTIC_TEST|Synovasure® RISC™ Panel|The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments \[CLIA\] Registration No.: 21D0216863) intended to provide indications for diagnosing different types of arthritis that may correspond to higher risk levels for postoperative complications in patients experiencing knee pain and/or inflammation prior to primary knee arthroplasty.
223907322|NCT05622968|DEVICE|Foley catheter|Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
223907323|NCT05622968|DRUG|Intravaginal prostaglandin E2|Insertion of intravaginal Dinoprostone
223907324|NCT06830837|OTHER|Mandala coloring|Eight pre-selected mandala drawings will be printed on separate A4 (21.0 cm × 29.7 cm) papers. After the patients are admitted to the hospital for the surgery process, the patients in the experimental group will be provided with at least 2 hours of mandala coloring per day until the day of their surgery. No intervention will be applied to the control group patients. Studies examining the effect of mandala coloring on reducing psychological symptoms have reported that using a circularly designed pattern in the mandala template, instead of a square design, has a greater effect on symptom management. Therefore, a circular-shaped mandala template will be used. Each participant will be provided with mandala coloring sheets and 12 colored pencils (red, orange, yellow, pink, light green, green, sky blue, blue, purple, brown, reddish-brown, and black) by the researcher.
223907325|NCT01208662|DRUG|Lenalidomide|oral administration
223907326|NCT01208662|DRUG|Bortezomib|intravenous or, following protocol amendment, subcutaneous administration
223907327|NCT01208662|DRUG|Dexamethasone|"oral administration~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
223907328|NCT01208662|PROCEDURE|Autologous Stem Cell Transplant|Autologous refers to stem cells that are harvested from the participant to be a source of new blood cells after high-dose chemotherapy with melphalan.
223907329|NCT01624129|DRUG|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
223528963|NCT06303310|OTHER|Optokinetic Exercises|Group B (Optokinetic Exercises+Routine Physical Therapy) Group B will receive optokinetic exercises for 20 minutes and the routine physical therapy consisting of balance exercises of 20 minute for 5 days a week for 4 weeks
223528964|NCT06303310|OTHER|Routine Physical Therapy|Routine Physical Therapy
223528965|NCT02002715|DRUG|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
223907330|NCT04627246|BIOLOGICAL|Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP-DC vaccine)|"SOC: Subgroup1: intravenous mFOLFIRINOX for twelve 14-day cycles. Subgroup2: intravenous gemcitabine twice, on days 1 and 8, and oral capecitabine for 14 days of 21-day cycles, for eight cycles.~PEP-DC vaccine: At least 5 subcutaneous vaccinations starting on cycle 8 (subgroup1) or cycle 5 (subgroup2) of chemotherapy: Subgroup1: every 4 weeks, on day 3 of every second 14-day cycle, and then every 4 weeks starting from the first nivolumab administration. Subgroup2: Every 3 weeks, on day 9 of each 21-day cycle, and then every 4 weeks starting from the second nivolumab administration.~Nivolumab for a maximal duration of 2 years: intravenous, starting after the last chemotherapy cycle. Administered as flat dose of 240mg every 2 weeks during 14 weeks, then as flat dose of 480 mg every 4 weeks until the last vaccination. Then, as a maintenance therapy at 480 mg every 4 weeks until appearance of new lesions or unacceptable toxicity."
223907331|NCT04903223|DRUG|Rosuvastatin 10mg|Rosuvastatin will be administered to all participants on Study Day #2
223907332|NCT06840327|OTHER|Blood and tissue samples|Blood samples will be taken from catheters placed for the purpose of surgery (arterial and venous catheters), or during routine venipunctures. (D-1 pre-op). Tissue samples will be taken from surgical waste generated by the surgery. They will therefore not require any additional incisions or surgical procedures.
223907333|NCT06840327|OTHER|walking test|The study includes a walking test between D5 and D7.
223907334|NCT02838316|DRUG|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
223907335|NCT06229574|OTHER|virtual reality glasses|The breastfeeding software developed will be applied in this group.
223907336|NCT01957735|DRUG|BP31510 monotherapy|
223907337|NCT01957735|DRUG|BP31510 in combination with chemotherapy|
223907338|NCT06835101|OTHER|Music intervention|"The music group will receive music beginning 20 minutes before spinal anesthesia until the end of surgery."
223907339|NCT06835101|DRUG|Midazolam (sedative)|"The midazolam group will receive increments of midazolam beginning 20 minutes before spinal anesthesia."
223907340|NCT06558227|BIOLOGICAL|ZG005 for Injection|10 mg/kg or 20 mg/kg administered intravenously Q3w
223907341|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
223907342|NCT06558227|BIOLOGICAL|Sintilimab|200 mg administered intravenously Q3w
223907343|NCT06558227|BIOLOGICAL|Bevacizumab|15 mg/kg administered intravenously Q3w
223907344|NCT06834269|DEVICE|Transcranial magnetic stimulation (tSMS)|Transcranial static magnetic stimulation (tSMS) will be delivered simultaneously to both hemispheres, at the motor cortex (M1), via magnets housed in a helmet.
224277184|NCT06096350|DIAGNOSTIC_TEST|hematochemical analysis|Blood samples of patients will be collected from patients in the early morning (7:30-9:00 a.m.) after an overnight fast at T0 and at T1. Sera samples will be separated by centrifugation (3,000 rpm, 10 min, and 4 °C), divided into 0.5 mL aliquots, and rapidly stored at -80 °C. Subjects' and reference samples were thawed just before the diagnostic test.
224277185|NCT06096350|DEVICE|BIA, hand grip|bioimpedentiometric analyses of muscular mass (T0 and T1), muscular force with hand grip
224277186|NCT06096350|DIAGNOSTIC_TEST|nutritional assessment, MNA,|nutritional status assessment will be performed by: body mass index measurements, (height and weight measurements at T0 and at T1); a Mini Nutritional Assessment survey will be administered to patients at admission; a food questionnaire will be administered to patients during from T0 to T1.
223715826|NCT03239288|OTHER|Control digestible carbohydrate|Single serving of control product
223907345|NCT02912078|OTHER|Pocket-warming|Pocket-warming of epidural medication
223907346|NCT02912078|OTHER|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
224277187|NCT06096350|DIAGNOSTIC_TEST|stool sampling|stool will be collected at T0 and at T1
223715827|NCT03239288|OTHER|Test resistant starch type 4|Single serving of test product
223715828|NCT01761890|BEHAVIORAL|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
223715829|NCT01581814|DRUG|Metformin|500 mg of Metformin per 3/die
223715830|NCT01581814|DRUG|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
223907347|NCT04194268|RADIATION|Carbon Ion|12 x 4 Gy (RBE)
223907348|NCT05425784|DEVICE|Lumoral treatment|The investigational Lumoral treatment -device provides a constant and repeatable application which can be done at home and is easily available. All subjects in the study group will receive their own Lumoral treatment -device and Lumorinse-mouth rinse tablets for the complete duration of the study.
223907349|NCT05425784|OTHER|Standard oral hygiene self care|Both groups shall be given oral and written instructions for twice-daily standard oral hygiene self-care.
223907350|NCT06838637|DEVICE|"Spinal COrd NEuromodulation (SCONE) Device"|A non-invasive electrical device that provides transcutaneous spinal cord stimulation (TSCS) to the spinal cord by electrodes connected to a battery-powered source.
223907351|NCT06834854|DRUG|fentanyl|"Induction: After pre-oxygenation with 100% oxygen, anesthesia will be induced with propofol 2mg/kg (1 ampoule contains 200 mg in 20cc syringe), 100 ml of isotonic saline over 15 minutes. Fentanyl 1 mcg/kg (1 ampoule contains 100mcg over 10cc syringe). Cis-atracurium 0.2 mg/kg (1ampoule contains 20mg in 10cc syringe) will be administered and endotracheal intubation will be done~Maintenance: Anesthesia will be maintained with Isoflurane 1-1.5 % in oxygen and air mixture 1:1, and cis-atracurium will be administered in incremental doses of 0.03mg/kg/30min. Another IV cannula will be placed with two infusion pumps of normal saline 50cc and fentanyl infusion 1-2 mcg/kg/hour (max 300 mcg total)."
223939988|NCT07196332|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|In the first week, treatment consists of a 60-minute video individual intervention session; in the second week, participants receive a 30-minute phone call; in the third week, treatment consists of a 45-minute video individual session; the final session consists of a 30-minute phone call. Treatment begins with learning how to alternately tense and relax 14 major muscle groups, and then to use progressively more efficient tensing-relaxing and passive relaxation exercises, with sessions used to teach techniques and problem-solve barriers to its daily use.
224277188|NCT06096350|DIAGNOSTIC_TEST|urine sampling|the first morning urine will be collected at T0 and at T1
224277189|NCT06096350|DEVICE|indirect calorimetry analysis|indirect calorimetry analysis with K5 (COSMED, Italy) during six minute walk test or timed up and go test.
223907352|NCT06834854|DRUG|Lidocaine (drug)|"Induction: After pre-oxygenation with 100% oxygen, anesthesia will be induced with IV propofol 2mg/kg (1 ampoule contains 200 mg in 20cc syringe), lidocaine 2% (1.5 mg/kg (7.5cc bolus dose)), MgSO4 10% (50 mg/kg in 100 ml of isotonic saline over 15 minutes), Cis-atracurium 0.2 mg/kg (1ampoule contains 20mg in 10cc syringe) will be administered and endotracheal intubation will be done.~Maintenance: Anesthesia will be maintained using Isoflurane 1-1.5 % in oxygen and air mixture 1:1, and cis-atracurium will be administered in incremental doses of 0.03 mg/kg/30min. Another IV cannula will be placed with 2 infusion pump one of them containing mixture of (lidocaine 2% 1.5 mg/kg/hour as infusion along with MgSO4 10% in 10-15 mg/kg/hour with 50cc normal saline over 50ml/hour), while the second contains propofol at 6-10 mg/kg/hour."
223907353|NCT05846334|DEVICE|mindfulHeart|'mindfulHeart' is an interactive, self-guided and patient-oriented mHealth intervention for the reduction of stress in patients with IHD and includes automated feedback via visualization of changes in patient reported outcome measures (PROMs).
223907354|NCT05853835|DRUG|LPX-TI641|LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
223907355|NCT06789653|DIAGNOSTIC_TEST|p16INK4a mRNA level assessment|Blood samples will be collected at two time points, plasma samples will be aliquoted, and T cells will be separated and expression of p16INK4a mRNA in peripheral blood T-lymphocytes will be determined
223907356|NCT06789653|DIAGNOSTIC_TEST|organ-specific protein signatures assessment|Blood samples will be collected at two time points, plasma samples will be aliquoted, and organ-specific protein signatures assessment will be determined.
223907357|NCT02302885|OTHER|Blood collection|Blood Collection
223907358|NCT06355713|DEVICE|Magnetic resonance imaging- Positron Emission Tomography (MRI-PET) examination|"An MRI-PET examination will be carried out pre-operatively and at 6 months for the first 20 patients with Essure® and pre-operatively for the first 10 control patients presenting the selection criteria.~The duration of each acquisition will be approximately 2 hours. Upon arrival, participants will be greeted by electroradiography technicians. A venous catheter will be placed in a vein in the right or left arm. Participants will be installed in the hybrid MRI-PET imager. The injection of \[11C\]PK11195 will take place in the MRI-PET acquisition room. Recording of functional neuroimaging data will begin immediately after intravenous injection of \[11C\]PK11195 and will last for 70 minutes in a resting state.~At the end of the examination, the venous catheter will be removed and the visit will be over."
223907359|NCT06355713|BIOLOGICAL|blood sample|"Patients with Essure : Blood sample pre-operatively (20 mL) and at 2 months (10 mL) and 12 months (5 mL).~Control patients : Blood sample pre-operatively (20 mL)"
223907360|NCT06355713|BIOLOGICAL|urine collection|"Patients with Essure : urine collection pre-operatively (10 mL) and at 2 months (10 mL) and 12 months (10 mL).~Control patients : urine collection pre-operatively (10 mL)"
223907361|NCT06355713|BIOLOGICAL|Collection of a lock of hair|Patients with Essure : Collection of a lock of hair pre-operatively and at 12 months Control patients : Collection of a lock of hair pre-operatively
223907362|NCT06355713|OTHER|questionnaire|"Questionnaires pre-operatively (except PGI-I) and at 2, 6, 12 months then twice a year up to 5 years for patients with Essure, and pre-operatively (except PGI-I) and at 2 months for control patients :~* PGI-I: symptom improvement score~* SF-12: quality of life with physical and mental dimension.~* FIQ: quality of life of women with fibromyalgia symptoms~* HADS: anxiety and depressive dimension~* MFI-20: fatigue according to 5 dimensions )~* VAS : pain assessment~* QDSA: assessment of sensory and emotional impact of pain~* FSFI : quality of sexual life~* Higham score"
223907363|NCT04731129|DEVICE|Probe based confocal laser endomicroscopy of the pleura|Every patient referred for medical thoracoscopy will be screened. The pCLE of the pleura will be performed 2 times. First, just before the thoracoscopy, through the Boutin's needle or the thoracentesis catheter and second through the working chanel of the pleuroscope. This last acquisition allows visual control to target the pleural endomicroscopy assessment. These two acquisitions will be compared between each other and with the histological samples of the pleuroscopy.
223907364|NCT06077136|OTHER|whole body vibration|"3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes~* starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~* upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~* coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises."
223907365|NCT06077136|OTHER|standard physical therapy|all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo
223939989|NCT07197541|DRUG|Bleomycin Injection|Bleomycin injection treatment group: local injection treatment, once every 4 weeks.
223939990|NCT07197541|DRUG|Pingyangmycin Injection|Pingyangmycin injection treatment group: local injection treatment, once every 4 weeks.
223939991|NCT07197671|DRUG|90Y-NM600|NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity
223939992|NCT07196202|OTHER|Laid-Back position training|This intervention is a structured training session for pregnant woman on the use of the laid-back breastfeeding position after birth. The training is designed to be delivered in a single, standardized session by the researcher during the last trimester of pregnancy to be applied within the first 24 hours post-cesarean delivery.
223939993|NCT07196202|OTHER|Standard Postpartum Care|Postpartum mothers who receive structured training and support on the laid-back breastfeeding position
223939994|NCT07196774|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
223939995|NCT07196774|DRUG|Docetaxel injection|Docetaxel injection.
223939996|NCT07196774|DRUG|Trastuzumab Injection|Trastuzumab injection.
223939997|NCT07196774|DRUG|Carboplatin for Injection|Carboplatin for injection.
223939998|NCT07196774|DRUG|Pertuzumab Injection|Pertuzumab injection.
223715831|NCT01581814|DRUG|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
223907366|NCT02413970|DEVICE|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
223907367|NCT06180759|DRUG|Intravenous infusion of DMT|A dose rate of 1.2 mg/min will be administered
223907368|NCT06180759|DRUG|Intravenous infusion of ketamine|A dose rate of 1.0 mg/min will be administered
223907369|NCT06180759|DRUG|Intravenous infusion of placebo|A Placebo (saline infusion) will be administered.
223907370|NCT03403257|OTHER|No interventions|No intervention
223907371|NCT06038552|DRUG|imatinib (IM)|Patients with GIST liver metastases were administered an initial IM dose of 400 mg daily, while those with KIT exon 9 mutations received 600-800 mg daily. All patients continued IM indefinitely unless progression or intolerable adverse reactions.
223907372|NCT06038552|PROCEDURE|hepatic resection (HR)|HR The determination of the surgical modality was established subsequent to comprehensive consultations tailored to each patient within the Department of Liver Surgery. The surgical strategy was established in consideration of factors such as the residual liver volume, tumour positioning, and the surgeon's personal preference. Employing an intraoperative ultrasonographic to enhance the precision of operative assessment.
223907373|NCT06038552|PROCEDURE|radiofrequency ablation (RFA)|RFA RFA was executed utilizing the commercially accessible Cool-tip™ RFA system or the RF 2000 system. The electrode was percutaneously inserted through a guide needle under real-time ultrasound guidance.The primary objective of the RFA procedures encompassed the complete elimination of the tumour entity, with a prescribed ablative margin of 0.5 cm meticulously factored in.
223907374|NCT06038552|PROCEDURE|transarterial chemoembolization (TACE)|TACE Under a comprehensive assessment of the hepatic arterial blood supply, a selective catheter was introduced into the segmental or subsegmental arteries that supplied the tumour. The regimen of hepatic arterial infusion chemotherapy included infusion of carboplatin 300 mg, a mixture of 50 mg of epirubicin and 8 mg of mitomycin C, intimately blended with 5 mL of lipiodol. Embolization was finally performed with either absorbable gelatin sponge particles or polyvinyl alcohol particles .
223907375|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
223907376|NCT03404115|DRUG|Reproxalap Ophthalmic Solution (0.1%)|Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
223907377|NCT03404115|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered for approximately twelve weeks.
223907378|NCT05585190|OTHER|Control|No intervention.
223715832|NCT02151591|DRUG|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
223907379|NCT05585190|OTHER|Sit-Stand Desk at Work|Subjects will receive a sit-stand desk at their work location.
223907380|NCT06089967|OTHER|Medical chart review|Clinical data for all enrolled patients will be abstracted from the electronic medical record. This will include but will not be limited to patient demographics, primary disease (site, histology, histologic grade, staging system used, staging, molecular markers), prior cancer treatment, immunotherapy received, time of onset, treatment received for irAEs, and disease response to treatment. Clinical data will be collected for up to one year after discontinuation of cancer immunotherapy treatment.
223907381|NCT05177822|DRUG|Anakinra|Anakinra 100 mg/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment;
223907382|NCT05177822|OTHER|Placebo|0.9% NaCl/0.67 mL daily subcutaneous injection for up to 14 days, including up to 9 days outpatient treatment.
223907383|NCT06803225|DIAGNOSTIC_TEST|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
223907384|NCT04942626|DRUG|Kineret 100 MG in 0.67 ML Prefilled Syringe|Anakinra 100 mg s.c. (Kineret) will be administered from day -10 (i.e. 10 days before initiation of RT) to the last day of RT.
223907385|NCT04942626|DRUG|Capecitabine|Capecitabine will be administered using a 3+3 dose escalation design (500 mg/m2 bid, 650 mg/m2 bid and 825 mg/m2 bid po, respectively) from day 1 to day 40 of RT including weekends.
223907386|NCT04942626|RADIATION|Radiotherapy|PTV: 1.8 Gy to 45 Gy (#28 fractions) to the primary tumor and pelvic lymph nodes; followed by a sequential boost of 1.8 Gy to 9 Gy (#5 fractions) to the gross tumor volume
223715833|NCT03087669|DEVICE|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
223907387|NCT04942626|PROCEDURE|Watch and Wait (cCR) or TME surgery (non-cCR)|Restaging to evaluate tumor response will be conducted 10 weeks after completion of CRT. For patients achieving a clinical complete response (cCR), a Watch and Wait (W\&W) option with close follow-up is scheduled. In case of non-cCR, immediate total mesorectal excision (TME) surgery is recommended. According to the current German S3-guidelines, adjuvant chemotherapy is optional.
223907388|NCT06051227|DRUG|Fentanyl Citrate|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
223715834|NCT03087669|DRUG|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
224277190|NCT00398073|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
223907389|NCT06051227|DRUG|Esketamine|Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
223907390|NCT02405676|DRUG|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
224277191|NCT00398073|DEVICE|The Dermal PowderMed® devices|
224277192|NCT00398073|OTHER|intramuscularly (IM injection)|
223715835|NCT04443725|DRUG|Hydroxychloroquine , Sofosbuvir, daclatasvir|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.
223907391|NCT02405676|DRUG|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
223907392|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
223907393|NCT02405676|DRUG|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
223907394|NCT02405676|DRUG|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
223907395|NCT02405676|DRUG|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
223907396|NCT05705518|DRUG|Systane Complete PF|3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
223907397|NCT05705518|DRUG|Refresh Relieva PF|3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
223907398|NCT05705518|DRUG|Refresh Optive Mega-3 PF|3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
223907399|NCT05705518|DRUG|CVS Health Lubricant Eye Drop (PG 0.6%)|3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
223907400|NCT06410755|DEVICE|Monitoring system using a insole-type gait analyzer|The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
223907401|NCT05603819|DEVICE|EDIT-B|To perform EDIT-B test, questionnaires and 2x0.5 mL whole blood are collected from each patient.
223907402|NCT05433662|BEHAVIORAL|Pandemic Acceptance and Commitment Therapy (Pan-ACT)|Pan-ACT is a 10-session, closed group, transdiagnostic intervention for older adults.
223907403|NCT06132685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223907404|NCT06132685|PROCEDURE|Computed Tomography|Undergo CT scan
223907405|NCT06132685|DRUG|Dexamethasone|Given dexamethasone or IV
223907406|NCT06132685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223907407|NCT06132685|OTHER|Questionnaire Administration|Ancillary studies
223907408|NCT03194971|OTHER|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
223907409|NCT03194971|DEVICE|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
223907410|NCT03802799|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
223907411|NCT03658343|DIAGNOSTIC_TEST|T2* Imaging|T2\* imaging sequences for MRI
223907412|NCT05682560|BIOLOGICAL|REGENECYTE|HPC, Cord Blood
223907413|NCT05682560|BIOLOGICAL|Placebo|Normal Saline
223907414|NCT05712759|OTHER|Influenza-like illness group|"Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.~ILI is defined by fever \> 37,8°C or/and cough or sore throat."
223907415|NCT03299959|DEVICE|Agili-C implant|Agili-C implant
223907416|NCT03299959|PROCEDURE|SSOC|microfracture and/or debridement
223907417|NCT04066205|BEHAVIORAL|SLEEPSAMRT|SLEEPSMART is a web-based intervention that adapted and modified components from the Transdiagnostic Sleep and Circadian intervention for youth and included four cross-cutting components (sleep complaint, education, behavior change and motivation, and goal-setting) that were integrated into each module. To begin the intervention, participants were provided a link to the SLEEPSMART intervention website for one of the above modules and an online sleep coach each week. At the end of each week, children and parents uploaded the weekly activities and goals via the REDCap link and set up a meeting with the sleep coach to review. The modules took 20 to 30 minutes to complete.
223907418|NCT02052882|BIOLOGICAL|romiplostim|
223907419|NCT05713942|DIAGNOSTIC_TEST|The Sport Concussion Assessment Tool 5th Edition (SCAT5)|The SCAT5 is a standardized tool for use by healthcare professionals in the evaluation of individuals 13 years old or older, who are suspected of having sustained a sports-related concussion. It comprises a neuropsychological test battery that assesses attention and memory function through 8 different domains 1) Symptom number, 2) Symptom severity, 3) Orientation, 4) Immediate memory, 5) Concentration, 6) Neurological examination, 7) Balance errors, 8) Delayed recall.
223907420|NCT05713942|DIAGNOSTIC_TEST|The Immediate Post-Concussion Assessment and Cognitive Testing tool version 4 (ImPACT)|The ImPACT is a computer-based neurocognitive test battery that provides an objective measure of neurocognitive functioning as an assessment aid in the management of concussion in individuals ages 12-80 years
223907421|NCT05091879|GENETIC|Multigene pharmacogenomics test|This multigene pharmacogenomics test will report genetic variation for genes that have Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.
223907422|NCT05111613|DEVICE|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)
223907423|NCT05111613|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
223907424|NCT04613505|BEHAVIORAL|Semi-structured interview|Participants will be asked a set of questions as applicable to each phase. Researchers will be able to ask additional questions as they arise within each interview.
223907425|NCT04613505|BEHAVIORAL|Same day consent questionnaire|A questionnaire (yet to be developed) will be administered to participants.
223907426|NCT06766890|BEHAVIORAL|WeJoy+WeHop|School-based CBT (WeJoy) comprises six weekly sessions on psychoeducation, cognitive restructuring, behavioural activation, emotional regulation, and self-monitoring. Exergaming on the interactive floor (WeHop) can gain a sense of autonomy, competence, and relatedness to help them regulate their emotions and maintain positive behaviours according to the Self-Determination Theory. Children participate in the interactive floor games by stepping on various targets and moving in response to the game's rules. Combining task division, cooperation, and taking turns constitutes the collaboration mechanism.
223907427|NCT06765343|DEVICE|Plaque disclosing agent|Dye agent binding to oral biofilm and plaque for visual detection
223907428|NCT06765343|DEVICE|Guided Biofilm Therapy|Utilisation of a air-polishing device conveying a jet of air, water and erythritol powder for plaque debridement on dental surfaces, followed by calculus removal with an ultrasonic scaler
223907429|NCT06765343|DEVICE|Ultrasonic debridement and polishing|Removal of plaque and calculus with an ultrasonic scaler, followed by surface polishing with a rubber cup and abrasive paste
223907430|NCT04070469|DRUG|Amoxicillin|dosage of plasma concentration of amoxicillin
223907431|NCT06053619|OTHER|GaitTrainer and Virtual Reality|"Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR)."
223907432|NCT06517654|DEVICE|EMG-Biofeedback|The Neurotrac® Simplex device will be used for EMG-Biofeedback treatment. As in the muscle strength assessment procedure, the EMG reference electrode will be placed on the patient\&#39;s forearm, and 2 adhesive electrodes in the EMG channel will be placed on the patient\&#39;s perineal muscles. The patient will be asked to contract and relax the pelvic floor muscles at certain intervals in accordance with the visual and auditory stimuli made on the device screen or computer screen. The pelvic floor muscle contraction and rest period will last 5 seconds each. The program will continue for 2 days a week, 25 minutes per session and 8 weeks and will be performed in a clinical environment. During the treatment, the treatment will be visualized for the patient with different imagery. At the end of the games played, the patients'; scores (%), the lowest and highest EMG values will be recorded in mV. The treatment will be applied to the patients in two sessions per week.
223907433|NCT06517654|OTHER|Rebound Therapy|The program will be performed in a clinical environment for 8 weeks, 2 days a week, each session will be 30 minutes. The correct breathing pattern will be taught to the patient before starting the exercises. O2 saturation and maximum heart rate will be checked during the rest periods during the exercises. The maximum heart rate will be calculated with the formula (HRmax = 208 - 0.7 × age), and the exercise will be paused when it exceeds 80%. The patient will be asked to contract the pelvic floor muscles during the exercise. Necessary warnings regarding the preservation of posture will be made throughout the exercises. The exercise intensity will be increased progressively in order to ensure the patient's adaptation to the exercises.
223907434|NCT06517654|OTHER|Home Exercise Program|Home Exercise Program In addition to EMG-Biofeedback Therapy in Group 1, in addition to Rebound Therapy in Group 2, and in Group 3, only a home exercise program will be applied to patients 5 days a week. The exercise program consists of diaphragmatic breathing, piriformis stretching exercise, adductor stretching exercise, gluteal stretching exercise, cat-camel exercise, happy baby position, deep squat exercise, trunk rotator stretching exercises. Each exercise will be repeated 5 times on the right and left, and 20 seconds will be waited for each repetition.
223907435|NCT04385264|DRUG|Hydroxychloroquine|Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)
223907436|NCT04385264|DRUG|Mannitol|Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
223907437|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (in a single-dose vial)-Route of administration:Intramuscular (IM) injection
224277193|NCT04235660|RADIATION|Yttrium-90 Radiation Segmentectomy|This therapy arm involves two separate steps, a planning/mapping arteriogram and a therapy delivery. The planning arteriogram will be performed to confirm arterial anatomy is acceptable for RS (≤2 segment delivery) and that lung shunting is not too high to preclude treatment with RS. Once confirmed, patients will return for RS (within 45 days of mapping). Dose will be calculated based off the desired treatment volume using pre-treatment cross-sectional imaging. The desired segmental dose will be calculated to be ≥ 200Gy. RS will be performed by one of three separate interventional radiologists with experience in radioembolization. Actual administered activity and location of dose administration will be recorded.
223907438|NCT06284915|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection (powder or cake in a single dose glass vial and a clear and colourless solvent in a pre filled syringe for reconstitution-Route of administration:Intramuscular (IM) injection
224083552|NCT04506294|BEHAVIORAL|eScreen system|The eScreen system is composed of a child screening component and a parent information component. The child screening component is delivered via a game-like interface and includes assessment of current pain, PTSS, and functional recovery. Children are asked to play the game at least 3x/week. The parent information component consists of text / email messages sent to parents at least weekly that summarize child ratings and include a link to an online dashboard with additional personalized information for parents.
223907439|NCT06459843|OTHER|pursed lip breathing techniques|Relax your neck and shoulder muscles. For the use of PLB exercise, the intervention will be given every day till the patient discharged from hospital. Patient will perform 5 sets. In each set, 10 times will be included. Then, instruct the patient to take deep breath through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
223907440|NCT06459843|OTHER|coordinated breathing technique|Put one hand on your abdomen. Make your abdomen push out while you breathe in through your nose. Suck in your abdominal muscles. Breathe out using the pursed-lip technique. You should feel your abdomen go down. Repeat three times and rest for two minutes.
223907441|NCT01585805|PROCEDURE|Biopsy|Undergo biopsy
223907442|NCT01585805|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
223907443|NCT01585805|DRUG|Cisplatin|Given IV
223907444|NCT01585805|PROCEDURE|Computed Tomography|Undergo CT
223907445|NCT01585805|DRUG|Gemcitabine|Given IV
223907446|NCT01585805|DRUG|Gemcitabine Hydrochloride|Given IV
223907447|NCT01585805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223907448|NCT01585805|DRUG|Veliparib|Given PO
223907449|NCT06079775|DRUG|Xeruborbactam Oral Prodrug|Experimental
224083553|NCT02990260|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
223907450|NCT06079775|DRUG|Ceftibuten|Experimental
223907451|NCT06079775|DRUG|Xeruborbactam Oral Prodrug Placebo|Placebo Comparator
223907452|NCT06079775|DRUG|Ceftibuten Placebo|Placebo Comparator
223907453|NCT00595049|DRUG|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
223907454|NCT05640479|DRUG|Pregabalin|patients will receive pregabalin capsules (75 mg) will be given 2 h prior to induction of anesthesia and every 12 hours
223907455|NCT05640479|DRUG|Dexmedetomidine|patients will receive dexmedetomidine after induction of GA a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/kg/h
223907456|NCT05418998|BEHAVIORAL|Executive function (EF) training|EF training will involve at-home computer- or tablet based training to improve several EF processes, including divided attention, response inhibition, switching, and working memory updating. Training session duration = 30 min x 3 session/week.
224083554|NCT02990260|DIETARY_SUPPLEMENT|Lynside Wall Basic|yeast cell walls
223907457|NCT06218485|PROCEDURE|Intravascular ultrasound-guided stent implantation after angiography-derived FFR-based decision-making|"The percutaneous coronary intervention will be performed by intravascular ultrasound (IVUS)-guided strategy after angiography-derived FFR-based decision-making:~1. PCI will be performed if angiography-derived FFR ≤0.80 and will be deferred if angiography-derived FFR \>0.80.~2. If PCI is performed, PCI optimization using IVUS will be performed following the recommended criteria: ① Plaque burden at stent edge ≤55%; ② Minimal stent area ≥ 5.5 mm2, or minimal stent area ≥ distal reference lumen area"
223907458|NCT06218485|PROCEDURE|Fractional flow reserve-guided PCI strategy|"The percutaneous coronary intervention will be performed by fractional flow reserve (FFR)-guided strategy:~1. PCI will be performed if FFR ≤0.80 and will be deferred if FFR \>0.80.~2. If PCI is performed, PCI optimization using FFR will be performed following the recommended criteria: ① Post-PCI FFR ≥ 0.88, or ② Post-PCI ΔFFR (\[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05"
223907459|NCT03726047|BEHAVIORAL|Exercise|Subjects will complete 5 minutes of exercise on an ergometer to examine the effects of exercise on retention of a newly learned walking pattern.
223907460|NCT04804293|DEVICE|FDA approved ultrasound system with shear wave elastography capability|The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
223907461|NCT03643744|DRUG|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
223907462|NCT03643744|DRUG|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
223907463|NCT05806021|DRUG|Triamcinolone Acetonide|Intra-articular injection. For each group, the total injected will be 3 ml. For syringes containing triamcinolone acetonide, the missing volume will be filled with 0.9% isotonic saline
223907464|NCT06537596|DRUG|89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)|Single administration of 89Zr-TLX300-CDx
223907465|NCT04443530|DRUG|Ultimaster™ Tansei™ stents|Patients receiving Ultimaster™ Tansei™ stents
223907466|NCT06066983|BEHAVIORAL|DINOSAUR|This intervention aims to treat intolerance of uncertainty and anxiety in young autistic children.
223907467|NCT06066983|OTHER|Psychoeducation|This intervention provides psychoeducation regarding anxiety and autism.
223907468|NCT05096338|OTHER|Social Determinants of Health|We will perform detailed phenotyping of Social Determinants of Health using the National Institute of Minority Health and Health Disparities PhenX SDOH toolkit at baseline.
224083555|NCT02990260|DIETARY_SUPPLEMENT|Placebo|Maize starch and magnesium stearate
224083556|NCT01928160|DRUG|pemetrexed disodium|Given IV
224083557|NCT01928160|DRUG|carboplatin|Given IV
224083558|NCT01928160|DRUG|cisplatin|Given IV
224083559|NCT01928160|DRUG|erlotinib hydrochloride|Given PO
224083560|NCT01928160|OTHER|laboratory biomarker analysis|Correlative studies
223907469|NCT03307863|DRUG|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
223907470|NCT03307863|DRUG|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
223907471|NCT03307863|DRUG|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
223907472|NCT06413654|DRUG|B001|The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP
223907473|NCT06413654|OTHER|Placebo|The subjects will receive IV dose of placebo matched to B001 on Day 1 and Day 15 of the RCP
223907474|NCT06318182|OTHER|Education|Young men who are included in the research sample and agree to participate in the study will be given training within the scope of the health belief model.
223907475|NCT04036253|BIOLOGICAL|Erythropoietin alfa|Prefilled syringes of erythropoietin
223907476|NCT02810197|BEHAVIORAL|Psychopathological assessment|
223907477|NCT02810197|BEHAVIORAL|Neuropsychological assessment|
223907478|NCT02810197|DEVICE|Functional magnetic resonance imaging (fMRI)|
223907479|NCT06524947|BIOLOGICAL|quadrivalent recombinant norovirus vaccine (Pichia pastoris)|"Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate"
223907480|NCT06524947|BIOLOGICAL|quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo|"Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) placebo at a 30-day interval.~Main ingredients: aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate"
223907481|NCT06338709|DEVICE|BariClip® Device Treatment|Device Administration (Implantation)
223907482|NCT01655784|PROCEDURE|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
223907483|NCT01655784|PROCEDURE|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
223907484|NCT06346067|DRUG|Naporafenib|Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor
223907485|NCT06346067|DRUG|Dacarbazine|Dacarbazine IV - Day 1
223715836|NCT04443725|DRUG|Standard of care treatment|Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
223907486|NCT06346067|DRUG|Temozolomide|Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle
223907487|NCT06346067|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
224083561|NCT04492280|DRUG|Hydrocortisone|After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
223907488|NCT06851247|DRUG|Toripalimab|"Fixed dose: 240mg/ time, add 100ml normal saline, intravenous infusion for 30 minutes (not less than 20 minutes, not more than 60 minutes).~The first course of induction chemotherapy (D1) is used on the first day of each cycle, and every 21 days is a course of treatment up to 18 courses or one year.~After intravenous infusion of triplelizumab, GP regimen induction chemotherapy was administered at an interval of 30-60 minutes."
223907489|NCT06851247|DRUG|Anlotinib|"Oral administration before breakfast, 10mg/ time/day, once a day (d1-14), repeated every 3 weeks, using three courses, one week before radiotherapy discontinuation.~Use on the day the first course of induction chemotherapy begins (D1)."
223907490|NCT06851247|DRUG|Gemcitabine|"1000mg/m2, D1, D8, add 0.9% normal saline 500ml, intravenous infusion. Every 21 days is a treatment cycle. If the recovery of toxicity in the subject is not sufficient for the next course of chemotherapy, the start of the next course of chemotherapy may be appropriately delayed, but the delay cannot exceed 21 days.~The treatment was continued for 3 courses."
223907491|NCT06851247|DRUG|Cisplatin|"Induction Chemotherapy: 80mg/m2, D1, add 1000ml 0.9% normal saline, intravenous infusion for 3 hours.~Concurrent Chemoradiotherapy100mg/m2, add 5% glucose 500ml, intravenous drip. Use on the first day of each cycle, every 21 days for a treatment cycle"
223907492|NCT06851247|RADIATION|radiation|IMRT, 33Fx
223907493|NCT06568406|PROCEDURE|Physiotherapy|Examination by a physiotherapist: the first check-up with an examination and a therapeutic intervention with the patient is performed within 24-72 hours after delivery. This is followed by two regular outpatient check-ups by a physiotherapist for the purpose of therapy and education. The second check takes place after 6-8 weeks. And the third check occurs after 10-14 weeks after childbirth. In these three checks, data collection is carried out simultaneously (in order to complete the secondary objective). The patients are examined and monitored by the same physiotherapist.
223907494|NCT06568406|DIAGNOSTIC_TEST|Urogynaecology|Examination by a urogynaecologist this is carried out in the period of 14-18 weeks after childbirth in order to complete the primary objective. Data collection in order to complete the primary objective is done in the period of 14-18 weeks and 12-14 months after delivery (the online method without the need for a physical visit is preferred).
223907495|NCT06852885|OTHER|Meals|The intervention of the Solid'Africa Gemura selective feeding program will be administered as usual for study participants in the two intervention sites. Eligible hospital inpatients will receive three meals a day during their hospital stay, as prescribed by hospital nutritionists for their specific conditions and ordered from Solid'Africa. The Solid'Africa team will prepare the ordered meals in their off-site kitchen in Rusororo and deliver them daily to the hospitals where the meals will be distributed to the study participants. Meal caloric and nutritional content information is standardized except upon request. The normal meal is 575g of food consisting of 2300kCal with 300g of carbohydrates, 175g of protein, and 100g vitamins/minerals. In addition, Solid'Africa will adjust meal content per nutritionist request for specific needs like low salt/sugar, etc.
223907496|NCT06852937|DEVICE|da Vinci SP Surgery System|da Vinci SP Surgery System
224083562|NCT00502190|DEVICE|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
223907497|NCT03703167|DRUG|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
223907498|NCT03703167|DRUG|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 \& 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
223907499|NCT03703167|DRUG|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
223907500|NCT00140322|BEHAVIORAL|Exercise, fall risk reduction|
223907501|NCT03818620|DEVICE|Barco digital dermatoscope device images|Images of skin lesion taken with the Barco dermatoscope by site team member
223907502|NCT03818620|DEVICE|Reference standard dermatoscope device images|Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
223907503|NCT04314778|BEHAVIORAL|social incentive-based gamification|At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
223907504|NCT05807048|DRUG|Daratumumab and Hyaluronidase-fihj|DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.
223907505|NCT05807048|DRUG|Pre-Intervention Medication|"The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~* Acetaminophen 650 to 1,000 mg orally~* Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~* Montelukast 10mg PO prior to DARZALEX FASPRO®.~* Methylprednisolone 100 mg (or equivalent) orally or intravenously"
223907506|NCT05807048|DRUG|Post-Intervention Medication|"The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment."
223907507|NCT06201390|BEHAVIORAL|Sleep consistency|Participants will be asked to maintain a consistent bed- and wake-time.
223907508|NCT06104605|OTHER|Institutional interventions|Intervention will include, but not be limited to, the following: adding a referral option to chiropractic care in the electronic health record (EHR), optimizing referral option, e.g., creating a list of preferred providers. Additional strategies may be added depending on community health center staff engagement prior to implementation.
223907509|NCT06104605|OTHER|PCPs interventions|"Two one-hour interactive grand rounds/lunch seminars that allow for inter-professional learning for PCPs with optional continuing education credits for PCPs.~Short teaching cases involving clinical vignettes developed with local doctors of chiropractic (DCs), information about DCs (e.g., evidence-base for treatments), and logistics of the referral process (e.g., geographic location of community-based DCs who accept Medicaid) sent to participating providers unable to attend the seminars. Additional strategies may be added depending on primary care provider engagement prior to implementation."
223907510|NCT06104605|OTHER|Patient interventions|Printed and electronic educational materials (e.g., brochures) written at a sixth grade reading level in English and Spanish that present chiropractic as a safe and effective evidence-based treatment for LBP. These materials will be written, reviewed, and revised by the researchers with CHC patient input. Additional strategies may be added depending on patient engagement prior to implementation.
223907511|NCT05977621|OTHER|Transrectal ultrasound (TRUS)|Transrectal ultrasound (TRUS) images of the female pelvis
223907512|NCT05099874|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
223907513|NCT06016764|DEVICE|Continuous Theta Burst in Transcranial Magnetic Stimulation|This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia, intellectual disability, and social-emotional impairment in autism
223907514|NCT04428541|OTHER|Questionnaire for visual function assessment of preverbal children|18 items questionnaire
223907515|NCT05841004|DEVICE|Investigational device|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
223907516|NCT05841004|DEVICE|Comparator device|Hollister Infyna Chic, single-use compact catheter.
223907517|NCT06196424|OTHER|study questionnaire to investigate family history|Participants will be given a specific study questionnaire (paper-based) to fill at home, which was specifically designed to collect family history information
223907518|NCT04024020|OTHER|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
224083563|NCT06438081|COMBINATION_PRODUCT|Cook double-balloon catheter|To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
223907519|NCT05646355|BEHAVIORAL|Proactive CRC Screening Outreach|Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.
223907520|NCT05646355|BEHAVIORAL|Usual Care|Participants will not receive additional outreach from the study team regarding CRC screening.
223907521|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening|"The limited cancer screening will include: 1) a complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin); and 4) chest X-ray.~In women, a breast examination, Pap smear/pelvic examination (if \< 70 years old and previously sexually active) and mammogram will be performed, if not conducted in last year.~In men, similarly, prostate examination and PSA testing will be performed, if not conducted in the last year.~All patients will undergo colon cancer screening as per local practice."
223907522|NCT04304651|DIAGNOSTIC_TEST|Limited cancer screening + FDG PET/CT|The limited cancer screening (as described above) in combination with a FDG PET/CT.
223907523|NCT05928013|DIAGNOSTIC_TEST|Neurothesiometer|The 'gold standard' device for Vibration Perception Threshold testing
223907524|NCT05928013|DIAGNOSTIC_TEST|NERVE|The experimental device for Vibration Perception Threshold testing developed by the project team
223907525|NCT05482932|DIAGNOSTIC_TEST|Health-related physical fitness assessment|Participants will complete several questionnaires and perform multiple health-related physical fitness tests
223907526|NCT03541889|DRUG|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
223907527|NCT05422274|DEVICE|Transcranial Pulse Stimulation|A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on improving inattention and hyperactivity .
223907528|NCT04845893|OTHER|Treatment of Ewings Sarcoma of bone according clinical practice (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
223907529|NCT05058924|DRUG|Prophylactic low molecular weight heparin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.
223907530|NCT05058924|DRUG|Low molecular weight heparin and low-dose aspirin|Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
223907531|NCT06040125|BEHAVIORAL|Supervised Circuit Training|16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity/heart rate monitor) will be provided.
223907532|NCT05110508|BEHAVIORAL|Text Based Behavioral Intervention for Physical Activity|Text intervention messaging will be sent through an automated text messaging service programmed by the CM Informatics team, which has been approved by the institution. Participants will be asked to wear Garmin physical activity monitor to provide physical activity information throughout the intervention. The Garmin is worn like a wristwatch. The device is small and non-intrusive. The Garmin device is a consumer wearable that will automatically detect and track activity such as walking, running, and cycling. The text messages incorporate information from the Garmin monitor to support physical activity.
223907533|NCT03967002|PROCEDURE|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~* the second premolars and first premolars,~* the first lower premolars and canines,~* the canines and lateral incisors,~* the lateral incisors and central incisors, and,~* the two lower central incisors."
223907534|NCT04685135|DRUG|MRTX849|21 day cycles
223907535|NCT04685135|DRUG|Docetaxel|21 day cycles
223907536|NCT05832307|OTHER|Existing Influenza Vaccination Practices|Usual care is defined as the existing inpatient influenza vaccination practices that currently exist at a given site.
223907537|NCT05832307|OTHER|Standardized inpatient influenza vaccination program|Intervention A: The basic intervention is the inpatient influenza vaccination program Intervention B: The intensified intervention is the multifaceted influenza vaccination strategy (Intervention A) plus a learning collaborative
223907538|NCT05540353|DEVICE|Transvaginal photobiomodulation|Low light laser therapy applied transvaginally using a small vaginal wand with sterile disposable wand covers. The intervention last 3-5 minutes based on a surface area calculation performed at the beginning of the intervention, and involves a gentle in and out motion of the wand to deliver light energy to the muscles of the pelvic floor.
223907539|NCT05540353|DEVICE|Sham therapy|Use of the same vaginal wand as active arm, but without activation of the machine. The intervention last 3-5 minutes, and involves a gentle in and out motion of the wand to massage the muscles of the pelvic floor, without delivery of light therapy.
223907540|NCT00179855|PROCEDURE|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
223907541|NCT03411096|PROCEDURE|Quadratus lumborum block using ropivacaine|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
223907542|NCT03411096|PROCEDURE|Quadratus lumborum block with normal saline|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
223907543|NCT06527664|DEVICE|custom-made acetabular implant|custom-made acetabular implant produced with additive manufacturing, to fill the bony loss in Paprosky III bone defects
223907544|NCT05826496|OTHER|Exercise|The supervised high-intensity interval training is conducted on bicycle ergometers at 85-95% maximal workload. The high-intensity interval sequences will be separated by two steady state sequences. Blood samples are collected at baseline, 2 min and 60 min post-exercise.
223907545|NCT06222710|PROCEDURE|Pharmacoacupuncture with ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding
223907546|NCT06222710|PROCEDURE|Pharmacoacupuncture without ultrasound guiding|Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
223907547|NCT06306625|DEVICE|Remote ischemic conditioning|A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of four cycles of a 5-min brachial cuff inflation at 200 mmHg followed by a 5-min of cuff deflation, and is started as soon as possible after randomization. The intervention is repeated 12 and 24 hours after inclusion.
223907548|NCT06306625|DEVICE|No remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is performed.
223907549|NCT05888025|BEHAVIORAL|Telephone-Delivered Mindfulness-based Cognitive Therapy (MBCT-T)|MBCT-T will be delivered in groups of four to eight subjects by telephone using a conference line with NYULH WebEx. Participants will receive a workbook containing session content and home practice logs and audio guides for home practice. Subjects will complete individual orientation sessions with the MBCT-T facilitator prior to start of the group sessions. The four subsequent weekly group sessions are approximately 90 minutes long. Participants will be encouraged to practice daily meditation in between group sessions for 20-30 minutes, six days per week
223907550|NCT06640166|DRUG|encorafenib + cetuximab + FOLFIRI|"encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours)."
223715837|NCT04812691|BIOLOGICAL|JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
223907551|NCT06644716|DIAGNOSTIC_TEST|[18F]F-FAPI PET-CT|Each patient will receive a FAPI PET-CT.
223907552|NCT06821516|PROCEDURE|Evaluation of the postoperative analgesic effectiveness of PENG block in participants undergoing total hip arthroplasty under spinal anesthesia|Evaluation of the postoperative analgesic effectiveness of PENG block in participants undergoing total hip arthroplasty under spinal anesthesia
223907553|NCT06821516|PROCEDURE|Evaluation of the postoperative analgesic effectiveness of lumbar erector spinae block in participants undergoing total hip arthroplasty under spinal anesthesia|Evaluation of the postoperative analgesic effectiveness of lumbar erector spinae block in participants undergoing total hip arthroplasty under spinal anesthesia
223907554|NCT06143215|BEHAVIORAL|4 weeks revision|In the literature is described to clinically revise patients in a 4-6 weeks basis, despite this expert recommendation, no previous research has clinically evaluated if 4-8-12 weeks revision times could change diabetic foot reulceration rate.
223907555|NCT06007898|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet.
223907556|NCT02905422|BEHAVIORAL|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
223907557|NCT05214222|DRUG|Anlotinib/Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks"
224083564|NCT01931059|DRUG|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
224083565|NCT01931059|OTHER|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
224083566|NCT05797077|PROCEDURE|Colorectal resection surgery.|Colorectal cancer radical resection combined with liver metastasis resection or ablation.
223715838|NCT01468012|DRUG|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
223715839|NCT01468012|DRUG|Placebo|matched placebo for LCE condition dosed twice daily
223715840|NCT06404216|OTHER|Nordic walking group training|"16 60-minute NW group sessions, twice weekly. Sessions will be led by a qualified healthcare professional and a graduating student.~A social worker (SP) will participate in one weekly session aiming to empower the participants and utilize group dynamics techniques to promote successful continuation of independent walking following the guided period.~Communication throughout the study will be conducted via a WhatsApp forum, to motivate and sustain regular walking during and after the training period. Following 2 months of guidance the group will be launched independently, while keeping remote contact. Same frequency and schedule will be encouraged."
223715841|NCT02888886|OTHER|Questionnaires about food habits and tobacco|
223715842|NCT02888886|OTHER|Spirometry|
223715843|NCT02888886|OTHER|Carotid echography|
223907558|NCT05214222|DRUG|Penpulimab/Chemotherapy|"Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks Post-progression genetic testing, continued treatment: Anlotinib,Penpulimab Anlotinib: Once daily, one capsule per time (10mg for weight \<60KG, 12mg for weight ≥60KG), administered from day 1 to day 14 of each cycle. Two consecutive weeks of treatment followed by one week off, 3 weeks per treatment cycle.~Penpulimab: 200mg, administered on day 1 of each cycle, every 3 weeks."
223907559|NCT05822635|DEVICE|SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System|Observational, prospective study for the clinical utility of the SpyGlass Discover Digital Catheter and the SpyScope DS Catheter during an intraoperative endoscopy procedure.
223907560|NCT01130025|DRUG|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
223907561|NCT01130025|DRUG|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
223907562|NCT04136132|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
223907563|NCT04898075|BEHAVIORAL|Remote Contingency Management (CM) for nicotine abstinence|Participants will be paid increasing amounts of payment for each negative saliva cotinine test.
223907564|NCT04898075|OTHER|Control|Participants will be paid for providing saliva nicotine test, regardless of whether the test is positive or negative.
223907565|NCT06315842|OTHER|Levels of Diagnostic and Therapeutic Intervention tool by Fontecha and col.|During the intervention periods, participating physicians will integrate into their usual clinical practice a tool for adjusting diagnostic and therapeutic intensity designed by Fontecha-Gómez and colleagues. The tool for adjusting the level of diagnostic and therapeutic intensity classifies patients' profiles into 5 groups based on the recommended level of adjustment.
223907566|NCT06315842|OTHER|Usual clinical practice|The participating physicians will carry out the standard clinical practice currently performed in the study centers. This means that during this period, the diagnostic and therapeutic adjustment tool or any similar tool will not be introduced into routine clinical practice.
223907567|NCT04622683|PROCEDURE|Ultrasound|To determine whether ultrasound exposure at the porta hepatis will affect plasma glucose levels. To also determine whether porta hepatic ultrasound exposure will affect plasma glucose levels as well as insulin sensitivity among overweight/obese individuals who have normal glucose tolerance or impaired glucose tolerance (as defined by OGTT.
223715844|NCT02888886|OTHER|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
223715845|NCT04819568|DRUG|Terlipressin|Terlipressin Bolus Max dose 2 mg/24 hr.i.e 0.5 mg qid
223715846|NCT04819568|OTHER|Standard of Care|Standard of Care
223907568|NCT02578550|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
223907569|NCT02578550|DRUG|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
223907570|NCT02578550|DRUG|Darunavir|A single tablet containing darunavir 800 mg will be administered.
223715847|NCT03644212|DRUG|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
223715848|NCT00878423|DRUG|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
223715849|NCT00878423|DRUG|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
223715850|NCT01432080|DRUG|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
223715851|NCT01432080|DRUG|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
223715852|NCT01432080|DRUG|Montelukast|Montelukast 10 mg PO qhs for 3 months
223715853|NCT01432080|DRUG|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
223715854|NCT04506021|DRUG|Bicarbonate Ringer's solution|According to the choices of the patients' immediate family members, patients will be divided into Bicarbonate Ringer's Solution. no Intervention.
223715855|NCT04506021|DRUG|Other Crystalloid|According to the choices of the patients' immediate family members, patients will be divided into other clinical used crystalloid. no Intervention.
223715856|NCT01029626|PROCEDURE|Endoscopy|Realization of an upper GI endoscopy
223715857|NCT00684593|DRUG|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
223715858|NCT00684593|OTHER|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
223907571|NCT02578550|DRUG|Cobicistat|A single table containing cobistat 150 mg will be administered.
223907572|NCT05216406|DIETARY_SUPPLEMENT|5-HTP|CLEANMOOD is an organic 5-Hydroxytryptophan (5-HTP) ingredient.
223907573|NCT05216406|OTHER|Placebo|Maltodextrin capsule
223907574|NCT03617445|DRUG|FMT oral capsule|FMT oral capsules, single dose of 5 capsules
223907575|NCT03617445|DRUG|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 14 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
223907576|NCT03617445|DRUG|FMT oral placebo|Placebo oral capsules, single dose of 5 capsules
223907577|NCT03617445|DRUG|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 14 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
223907578|NCT05485584|DRUG|rSIFN-co Nasal Spray|8 million IU (16 μg)/day; Once daily
223907579|NCT05485584|DRUG|rSIFN-co Nasal Spray|16 million IU (32 μg)/day; Twice daily
223907580|NCT05485584|DRUG|Placebo Nasal Spray|Once daily
223907581|NCT05485584|DRUG|Placebo Nasal Spray|Twice daily
223907582|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 12 μg|CVGBM will be administered as an IM injection.
223907583|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 25 μg|CVGBM will be administered as an IM injection.
223907584|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 50 μg|CVGBM will be administered as an IM injection.
223907585|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 100 μg|CVGBM will be administered as an IM injection.
223907586|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine RDE 100 μg|CVGBM will be administered as an IM injection.
223907587|NCT05938387|BIOLOGICAL|CV09050101 mRNA vaccine (CVGBM) 6 μg|CVGBM will be administered as an IM injection.
223907588|NCT06606197|OTHER|Having sex with other men|Having sex with other men
223907589|NCT04266431|BEHAVIORAL|EMPOWER|Behavioral weight loss intervention
223907590|NCT05769231|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Chatbot|Digital interventions can relieve the worldwide burden of mental disorders. The low set-up costs and barriers of online platforms make digital interventions very cost-effective. By using the Internet as a delivery medium, many people can enjoy unrestricted access to self-help information. Unlike traditional face-to-face intervention, the effects of digital self-help interventions are scalable. The current study attempts to extend the boundary of digital interventions from accommodating didactic and informational content to providing interactive, intelligent, and most importantly, patient-centered conversational agents. AI chatbots can provide suitable recommendations and training materials to users according to their behavioral, mental, and motivational readiness. Since existing AI chatbots are developed for Western societies, a culture-specific Chinese chatbot will fill the research and service gaps.
223907591|NCT06801548|PROCEDURE|Esthetic crown lengthening surgery|Esthetic crown lengthening surgery using mock-up based guide
223907592|NCT06801548|PROCEDURE|Esthetic crown lengthening surgery using Digital guide|Esthetic crown lengthening surgery using digital guide based on DSD and CBCT
223907593|NCT03711474|DRUG|Dexamethasone|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
223907594|NCT03711474|DRUG|Saline|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
223907595|NCT05587972|OTHER|survey|Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic PRO surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks.
223907596|NCT04465344|DEVICE|Implantation of trifocal IOL, Isatis TF (device under investigation)|Patients will be implanted with study IOL in both eyes
223907597|NCT04465344|DEVICE|Implantation of monofocal IOL, Isatis (control device)|Patients will be implanted with Control IOL in both eyes
223907598|NCT06051760|BIOLOGICAL|NV-001|NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.
223907599|NCT04869631|OTHER|The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.|We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.
223907600|NCT06317701|DEVICE|Hypoglossal Nerve Stimulation (HGNS)|Alternative therapy for Obstructive Sleep Apnea
223907601|NCT04275869|OTHER|Healthy Lifestyle|A 3-month internet-based program focusing on the promotion of healthy lifestyles. The treatment protocol comprises 9 modules which incorporate psychological strategies to promote healthy lifestyles by gradually changing eating and physical activity habits.
223907602|NCT06813846|PROCEDURE|Mid-Crestal Sulcular Incision|A long incision over the crest and midway between buccolingual aspect through the gingiva from the site of the distal implant in mesial direction with intra-sulcular incisions in the teeth adjected to the implant site · Following a full or partial thickness flap is raised to establish access to cover screw.
223939999|NCT07195786|PROCEDURE|Expansion-floating Craniotomy|Following craniotomy with bone flap removal, cerebral edema is assessed. The bone flap is then elevated using 2-3 titanium connectors. The elevation height must be sufficient to at least prevent contact between the bone flap and the underlying brain tissue. If cerebral swelling proves less severe than anticipated or begins to subside, the connectors can be loosened minimally invasively after a maximum scalp expansion period of 7-10 days. The elevated bone flap gradually repositions itself. Mild compression is applied using an elastic bandage for fixation, thereby restoring cranial integrity.
224083567|NCT05797077|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
224083568|NCT05797077|DRUG|Capecitabine|Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
224083569|NCT00116766|DEVICE|anti-mosquito plant use|
223715859|NCT01797653|OTHER|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
224083570|NCT00769119|DRUG|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
224083571|NCT00769119|DRUG|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
224083572|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel|
223907603|NCT06813846|PROCEDURE|Split-Finger Procedure|"The surgical technique first designs 3 interlacing fingers over and adjacent to each implant site and will be extended around each adjacent tooth. · A sulcular incision will be made 2 to 3 mm to the palatal side from each tooth with a loop design (at least 2.0-2.5 mm) adjacent to the implant location. · The incisions will then be joined facially with a semicircular incision at the preplanned free tissue margin of the implant crown. · The facial fingers will be elevated to the desired interimplant height for the papillae. The middle palatal finger will then be split and reflected to the respective mesial and distal sides (each is at least 2.0-2.5 mm wide). · The soft tissue maintains its elevated position with a permucosal extension or a final prosthetic abutment that is extended through the soft tissue. · A modified vertical mattress suture will then be used to suture each papilla using 4-0 or 5-0 Gut or Vicryl sutures."
223907604|NCT06813846|PROCEDURE|"I shaped incision"|A Labial horizontal incision with a #15c blade will be performed mesiodistally 0.5-1.0 mm inside from the labial border of the implant. A horizontal incision will also be performed, parallel to the buccal side, on the palatal side, which is in contact with the palatal border line of the implant different from the labial side. Another incision will be done bucco-lingually over the implant midline perpendicular to the horizontal incision lines performed on the labial and palatal sides. The flap will be reflected with care and the implant will be exposed to remove the cover screw. The healing abutment will be connected and both flaps will be folded up alongside the healing abutment intending them to heal without suture.
223907605|NCT04889716|DRUG|mosunetuzumab|1 mg IV on Cycle 1 Day 1; 2 mg IV Cycle 1 Day 8; 60 mg IV Cycle 1 Day 15; 60 mg IV on Cycle 2 Day 1 and then 30 mg IV every 21 days beginning Cycle 2 Day 1 through Cycle 17.
223907606|NCT04889716|DRUG|glofitamab|2.5 mg IV Cycle 1 Day 8; 10 mg IV Cycle 1 Day 15 then 30 mg every 21 days beginning Cycle 2 Day 1 through Cycle 12
223907607|NCT04889716|DRUG|obinutuzumab|1000 mg IV on Cycle 1 Day 1.
223907608|NCT05485766|DRUG|Pembrolizumab|200 mg fixed dose, IV, every 3 weeks (Q3W), on Days 1 of Cycles 1-4
223907609|NCT05485766|DRUG|Paclitaxel|80 mg/m2, IV, weekly, on Days 1, 8, 15 of Cycles 1-4
223907610|NCT05485766|DRUG|Carboplatin|Area under the curve (AUC 1.5), intravenously (IV), weekly, on Days 1, 8, 15 of Cycles 1-4
223907611|NCT05485766|DRUG|Olaparib|300 mg BID (twice daily) orally
223907612|NCT05485766|PROCEDURE|Definitive Surgery|Each subject will undergo definitive surgery 3-6 weeks after conclusion of the last cycle of the neoadjuvant treatment.
223907613|NCT05366712|DEVICE|Stryker Trident® II HA coated cementless acetabula component|New acetabula component.
223907614|NCT06016062|DRUG|RC148 Monotherapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle
223907615|NCT06016062|DRUG|RC148+docetaxel Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； Docetaxel will be administered as an IV infusion on Day 1 of each 3-week cycle.
223907616|NCT06016062|DRUG|RC148+RC48 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle； RC48 will be administered as an IV infusion on Day 1 of each 2-week cycle.
223907617|NCT06016062|DRUG|RC148+RC88 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle； RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle.
223907618|NCT06016062|DRUG|RC148/Bevacizumab+RC88 Combination Therapy|RC148 injection will be administered as an intravenous (IV) infusion on Day 1 of each 3-week cycle; RC88 will be administered as an IV infusion on Day 1 of each 3-week cycle; Bevacizumab will be administered as an IV infusion on Day 1 of each 3-week cycle
223907619|NCT05507814|BEHAVIORAL|Episodic Future Thinking (EFT)|Participants will generate descriptions of vivid positive future events.
223907620|NCT05507814|BEHAVIORAL|Control Episodic Thinking|Participants will generate descriptions of vivid positive future events.
223907621|NCT06821412|DEVICE|ASTERISK System|This intervention uses an experimental socket fabricated by a certified prosthetist. The electronics within the experimental socket are set up with the ASTERISK system, which sends information collected from the EMG sensors to the prosthetic hand wirelessly rather than the current available method of wired control.
223907622|NCT06821412|DEVICE|Wired Configuration|This intervention uses the same experimental socket that is used for the ASTERISK intervention. The prosthesis is set-up with wired EMG control, which is the current available method for EMG-controlled prostheses.
223907623|NCT04001543|DIETARY_SUPPLEMENT|Immunomodulating oral supplementation|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
224083573|NCT02525549|DRUG|Adapalene and Benzoyl Peroxide Gel (Reference)|
223907624|NCT04001543|DIETARY_SUPPLEMENT|Sip feed control|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
223907625|NCT04823923|OTHER|blood sampling for ITK dosage|Blood sample for ITK dosage at visit 1 (1 month +/- 1 week after the start of treatment) and at visit 2 (3 months +/- 1 month after the start of treatment)
223907626|NCT06823622|BEHAVIORAL|Stepstones transition program|"The STEPSTONES transition program is an 8-component intervention designed to support adolescents with chronic conditions transitioning to adult care. It includes: a transition coordinator (TC), education about the condition, phone support, guidance on transitioning to adult care, parental guidance, peer meetings, a personalized transition plan, and the actual transfer to adult care. The intervention is implemented in five steps, starting with outpatient visits and culminating in the transfer to adult care. Delivered via the Mitt vårdmöte digital platform, the program includes the HEADDDSS adolescent health interview and is conducted by trained specialized nurses."
223907627|NCT04260243|OTHER|Experimental-Myofascial + Respiratory rehabilitation|6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
223907628|NCT04260243|OTHER|Sham Myofascial + Respiratory rehabilitation|6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
223907629|NCT03845790|OTHER|Blood and microdialysis samples|Blood and microdialisys pharmacocinetic samples on one of the two antibiotics prescribed in routine use
223907630|NCT04911296|OTHER|Mock-RP|Standard 000 capsule filled with potato starch, enteric-coated with colorant and lubricious coating.
223907631|NCT05627635|BIOLOGICAL|Balstilimab|Given IV
223907632|NCT05627635|BIOLOGICAL|Bevacizumab|Given IV
224083574|NCT02525549|DRUG|Placebo gel|
223907633|NCT05627635|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
223907634|NCT05627635|BIOLOGICAL|Botensilimab|Given IV
223907635|NCT05627635|PROCEDURE|Computed Tomography|Undergo a CT scan
223907636|NCT05627635|DRUG|Fluorouracil|Given IV
223715860|NCT01797653|PROCEDURE|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
223907637|NCT05627635|DRUG|Leucovorin Calcium|Given IV
223907638|NCT05627635|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223907639|NCT05627635|DRUG|Oxaliplatin|Given IV
223907640|NCT05627635|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223907641|NCT05627635|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223907642|NCT03979924|BEHAVIORAL|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,…) in order to strengthen the stretching."
224083575|NCT04167475|DIETARY_SUPPLEMENT|Probiotic capsule|Each probiotic capsule contains 1 x 10\^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
224083576|NCT04167475|DIETARY_SUPPLEMENT|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
224083577|NCT05589285|BIOLOGICAL|Injection of autologous whole blood to the plantar fascia|Patients assigned in this group will have 2 ml of blood withdrawn from a peripheral vein, then mixed with 1 mL Lidocaine 2% for a total of 3mL volume in one syringe. The patient will be asked to lie down in the clinic bed, and the injection will be administered to the plantar fascia by the principal investigator using a sterile technique.
224083578|NCT05589285|DEVICE|Injection of normal saline to the plantar fascia|This will be the control group receiving sham injection. Patients will have 2 ml of blood withdrawn from a peripheral vein for blinding proposes. They will be asked to lie down on the clinic bed, 1 ml of normal saline will be administered under sterile technique by the principal investigator. The blood that was withdrawn initially will be discarded.
223907643|NCT06446817|DEVICE|LuxHighAdd IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
223907644|NCT06446817|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
223907645|NCT06636513|DIETARY_SUPPLEMENT|SMT04 (M3XTRA)|This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on the gut microbiome and relief of IBS symptoms.
223907646|NCT03833921|DRUG|Abiraterone Acetate|1000 mg orally daily until disease progression
223907647|NCT03833921|DRUG|Prednisone|5 mg oral low dose prednisone, twice daily
223907648|NCT06015633|OTHER|No intervention|Observational only
223907649|NCT06821360|DIAGNOSTIC_TEST|C-peptide test|Participants collect a single home finger-prick sample and post to the clinical laboratory for C-peptide analysis (a measure of endogenous insulin production).
223907650|NCT06108687|OTHER|water spray application|cold water kept in the refrigerator at +4 degrees
223907651|NCT00476606|DRUG|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
223907652|NCT00476606|DRUG|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
223907653|NCT00476606|DRUG|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
223907654|NCT04220684|DRUG|Cytarabine Hydrochloride|Given IV
223907655|NCT04220684|DRUG|Fludarabine|Given IV
223907656|NCT04220684|BIOLOGICAL|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given via infusion
223907657|NCT05834712|DEVICE|mobile platform or not mobile platform|Intervention using WeChat
223907658|NCT06295913|DIETARY_SUPPLEMENT|Group 1, hydroxytyrosol-rich extract capsule|Following a two-week washout period, the subjects will receive a bottle containing capsules (Group 1). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol apart from that provided by the capsule.
224083579|NCT01961115|DRUG|Epacadostat|Given PO
224083580|NCT01961115|BIOLOGICAL|MELITAC 12.1 Peptide Vaccine|Given ID/SC
224083581|NCT00003063|BIOLOGICAL|recombinant interferon alfa|
224083582|NCT00003063|DRUG|fluorouracil|
224083583|NCT00003063|DRUG|leucovorin calcium|
224083584|NCT00003063|DRUG|levamisole hydrochloride|
223715861|NCT05130398|BIOLOGICAL|rVSVΔG-ZEBOV-GP, V920|The experimental vaccine is the rVSVΔG-ZEBOV-GP, an Ebola vaccine.
223715862|NCT05130398|DIETARY_SUPPLEMENT|Fibre and equilibrate breakfast and lunch|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days.
224083585|NCT05345925|DEVICE|Moderato|Several algorithms comprising CNT will be delivered by the Moderato Implantable Pulse Generator. Each application will last approximately 3 min with 2 minutes baseline (regular pacing) between them. Hence, each subject will serve as its own control (during pacing) and test (during CNT application). Furthermore, the average control value for the whole group will be compared with the average test values of CNT algorithms at the different ventricular lead locations for efficacy assessments. Stratification of subjects by initial hemodynamic parameters (such as Ejection Fraction, for example) would be possible depending on the total number of subjects in each group.
224083586|NCT00578643|DRUG|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
224083587|NCT00578643|BIOLOGICAL|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
224083588|NCT00578643|DRUG|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
223907659|NCT06295913|DIETARY_SUPPLEMENT|Group 2, capsule of placebo|Following a two-week washout period, the subjects will receive a bottle containing capsules (Placebo) (Group 2). Blood, urine, and fecal samples will be collected from each participant during their stay at the Human Nutrition Unit at the beginning and end of the study. Subjects will be instructed to refrain from consuming products rich in hydroxytyrosol (such as virgin olive oil and olives) and to maintain their usual dietary habits throughout the study. Additionally, olive oil (1L/week) will be provided to each volunteer that will consume during intervention study as the sole source of dietary fat, used for cooking, salad dressing, toasts, etc. in order to control the extra consumption of hydroxytyrosol.
223907660|NCT05679908|DRUG|TNX-1900|Patients will spray TNX-1900 once into each nostril.
223907661|NCT05679908|DRUG|Placebo Nasal Spray|Patients will spray placebo nasal spray once into each nostril.
223907662|NCT06821932|PROCEDURE|Photofunctionalized dental implant surgery|Dental implants subjected to photofunctionalization were placed in the experimental area of the mouth.
223907663|NCT06821932|PROCEDURE|Dental implant surgery|Dental implants not subjected to photofunctionalization were placed in the bone on the contralateral side of the mouth
223907664|NCT06818799|PROCEDURE|Thulium laser en-bloc resection of bladder mass|En-bloc laser technique
223907665|NCT06818799|PROCEDURE|Trans-urethral en-bloc resection of bladder mass|En-bloc technique
223907666|NCT05169762|OTHER|standard treatment|starndard treatment for transgender women
223907667|NCT04744506|DEVICE|Tissue Marker Clip|Tissue Marker Clip to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
223907668|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed in Metastatic Axillary Lymph Node (Before Neoadjuvant Chemotherapy for Breast Cancer)
223907669|NCT04744506|DRUG|Carbon Nanoparticle Suspension Injection|Carbon Nanoparticle Suspension Injection to be Placed around Primary Tumor (Before Neoadjuvant Chemotherapy for Breast Cancer)
223907670|NCT06137677|OTHER|Sweet Snack|A sweet food will be served for the snack
223907671|NCT06137677|OTHER|Savory Snack|A savory food will be served for the snack
223907672|NCT06821906|RADIATION|Stereotactic Radiosurgery|Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 80 Gy
223907673|NCT06821906|RADIATION|Stereotactic Radiosurgery|Frameless Stereotactic Radiosurgery- CyberKnife with a dose of 130 Gy
223907674|NCT04356209|OTHER|e-PRO Intervention|"Statements of symptoms and patients' health status (PROs) will be collected via a web interface, including access and use in patients with burden symptoms.~The platform will include four items concerning 7 side effects of fibrosis of grade \> 2 in breast cancer. Patients will be encouraged to evaluate on a 5-point Likert scale the frequency, the intensity and the repercussions on the daily life of some symptoms during the last 7 days, in particular on:~* general pain~* anxiety~* sadness~* texture of the treated breast~* Patients will also be invited to express themselves on the severity of two other symptoms of their choice, to their worst degree, by listing and rating them on a 5-point scale ranging from None to Very severe Finally, the aesthetic impact will be evaluated by patients on a visual analogue scale (VAS) of 0 to 100mm"
224083589|NCT00578643|DRUG|Fludarabine|"Day -5 through Day -2~30 mg/m\^2"
223528966|NCT06038175|DEVICE|Video Head Impulse Testing|During vHIT testing a commercially available mono-ocular video oculography system will be donned on the patient. (Interacoustics EyeSeeCam vHIT 3rd Generation Tests: VOR of lateral, RALP, \& LARP canals. SW: 3rd generation VE525 software. HW: laptop PC, lightweight monocular video goggles). Subjects will be instructed to maintain fixation at a target from 1 m distance. A study team member will deliver at least 5 head impulses per side (10-20° angle, duration 150-200 ms, peak velocity of \>150°/s) in the horizontal and vertical planes with unpredictable timing and direction. A neurotologist will then evaluate the VOR gain or the ratio of eye velocity over-head velocity. The presence of refixation (catch-up) saccades, either overt or covert, will be evaluated by the study team. In line with previous literature, the vHIT testing will be considered to be abnormal if VOR gain is \<0.8 in the presence of refixation saccades .
223528967|NCT06038175|OTHER|Standard of care neurologic evaluation|A standard neurologic evaluation will be performed including a National Institute of Health Stroke Scale and imaging if symptoms and NIHSS warrant.
223528968|NCT02009267|DEVICE|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
223528969|NCT02009267|PROCEDURE|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
223528970|NCT02009267|PROCEDURE|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
223528971|NCT03584490|OTHER|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
223907675|NCT04356209|DRUG|Pravastatin|All patients will take Pravastatin 40 mg per day (From Day 0 to Month 12).
223907676|NCT05870761|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223907677|NCT05870761|PROCEDURE|Computed Tomography|Undergo MRI/CT
223907678|NCT05870761|BIOLOGICAL|Dostarlimab|Given IV
223907679|NCT05870761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/CT
223907680|NCT05870761|DRUG|Niraparib|Given PO
223940000|NCT07195786|PROCEDURE|decompressive craniectomy|The patient is placed supine with the head rotated contralaterally. A large retroauricular question-mark incision is made in the scalp. Alternatively, a Kempe incision or preauricular incision may be used according to surgeon preference. Meticulous preservation of the superficial temporal artery (STA) is essential during the procedure to prevent ischemic complications in the flap. After elevating the myocutaneous flap to expose the operative field, a fronto-temporo-parietal craniectomy is performed. For unilateral decompressive craniectomy, the bone window should measure at least 15 × 12 cm, extending inferiorly to the floor of the temporal fossa to ensure adequate decompression.
223907681|NCT06529393|PROCEDURE|SHAC block|with the patient in a beach-chair position and with the arm in extension, the subscapularis muscle is stretched posteriorly and becomes easily visible. With external rotation and abduction, the coracobrachialis and the biceps brachii muscles are displaced, allowing the visualization of the interfascial space between the deep lamina of the deltoid muscle fascia and the superficial lamina of the subscapularis fascia.Once the injection into the fascial space is achieved, the investigators can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle. By injecting the pericapsular space, the investigators reach the terminal articular branches indistinctly from their origin. Furthermore, through the Weitbrecht foramen, a natural capsular foramen between the upper and middle glenohumeral ligaments, the investigators also reach the intra-articular space .
223907682|NCT06529393|PROCEDURE|suprascapular nerve block|Patients will be placed in lateral position by using A high - frequency linear ultrasound probe will be placed approximately 2 cm medial to the medial border of the acromion and about 2 cm cranial to the superior margin of the scapular spine until supraspinatus or infraspinatus muscle contractions were elicited. Following negative aspiration,A 21G 10-cm needle will be inserted using an in-plane approach .The tip of the needle will be placed at the floor of the supraspinatus fossa where the nerve has passed .A volume of 15 mL of a mixture of 2% lidocaine (5 mL) and 0.5% levobupivacaine (10 mL) was injected.
223907683|NCT02857933|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
223907684|NCT04666688|DRUG|LYT-200|monoclonal antibody (mAb), targeting galectin-9 protein
223907685|NCT04666688|DRUG|Tislelizumab|anti-PD-1 monoclonal antibody
223907686|NCT04666688|DRUG|Gemcitabine/nab-paclitaxel|chemotherapy
223907687|NCT05263297|OTHER|control group|no intervention will be made.
223907688|NCT05005819|DRUG|[18F] APN-1607|Subjects will undergo PET imaging using \[18F\]APN-1607.
223907689|NCT06821646|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|18F-N-((2-(2-(fluoro-18f)ethoxy)phenyl)methyl)-N-(4-phenoxy-3-pyridinyl) acetamide
223907690|NCT06821646|DIAGNOSTIC_TEST|transcranial magnetic stimulation and electroencephalography(TMS-EEG)|single pulse and paired pulse
223907691|NCT04449198|DRUG|Resveratrol|500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
223907692|NCT04449198|OTHER|Placebo|placebo for 12 weeks
223907693|NCT06357962|OTHER|Semi-permanent acupuncture|These are sessions that last approximately one hour. The selection of points will be based on the energy diagnosis made during the first visit. In some cases, a point may be changed depending on progress. During the session, an interrogation will be conducted to assess symptoms and signs of the condition, and to evaluate if there have been any adverse reactions to the previous session. At the end of the visit, semi-permanent acupuncture will be applied to the selected points.
223907694|NCT06357962|OTHER|Sham of semi-permanent acupuncture|A simulated semi-permanent acupuncture session will be conducted, consisting of specific placebo materials without needles and without stimulation for a few minutes. These points will not correspond to any acupuncture point and will be located on the hands, feet, and back. Stickers without pins will be applied, but never in critical points related to contraction stimulation or cervical ripening.
223907695|NCT04788823|DRUG|Prednisone|Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.
223907696|NCT06822218|DEVICE|high tone power therapy|patients will be assigned into 2 groups with pre and post treatment protocol application. all patients will be thoroughly evaluated before and after treatment protocol application.
223907697|NCT06822218|DEVICE|TENS|These patients will receive TENS with applied frequencies range from 2 to 120 Hz. for 3 times per week for 30 minutes every session during 3 months of intervention in addition to medications.
223907698|NCT06656910|BEHAVIORAL|Self Compassion Group|"A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell."
223907699|NCT03016156|OTHER|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
223907700|NCT03016156|OTHER|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
223907701|NCT06281834|DRUG|Rifapentine|Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.
223907702|NCT06281834|DRUG|Dolutegravir|All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention
223907703|NCT05377957|OTHER|Quality of life questionnaires|Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis
223907704|NCT05377957|OTHER|Discrete choice experiment|Assessment of patient preferences for outcomes of proton therapy and enucleation
223940001|NCT07195786|DRUG|drug conservative therapeutic|Pharmacotherapy for malignant cerebral edema has been implemented according to current guidelines.
223940002|NCT07196098|OTHER|Slow tempo music|Slow tempo music will be played 15 minutes before and during intravitreal injection.
224083590|NCT00578643|DRUG|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
223907705|NCT05377957|OTHER|Shared decision-making analysis|Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)
223907706|NCT05377957|OTHER|Impact of side-effects analysis|Assessment of the impact of side-effects by questionnaire
223907707|NCT04098250|DRUG|Erenumab|a CGRP receptor monoclonal antibody
223907708|NCT04098250|OTHER|Placebo|Placebo
223907709|NCT03221309|OTHER|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
223907710|NCT05015348|OTHER|fish oil with omega-3 PUFA|3.6g per day fish oil with omega-3 PUFA (EPA+DHA)
223907711|NCT05015348|OTHER|placebo|palm oil as placebo
223907712|NCT03574649|DRUG|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223907713|NCT03574649|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223907714|NCT03574649|DRUG|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223907715|NCT03574649|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223907716|NCT03574649|BIOLOGICAL|ETBX-011|adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine
223907717|NCT03574649|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223907718|NCT03574649|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
223907719|NCT03574649|BIOLOGICAL|GI-4000|RAS yeast vaccine
223907720|NCT03574649|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223907721|NCT03574649|DRUG|Aldoxorubicin|INNO-206
223907722|NCT03574649|DRUG|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223907723|NCT03574649|DRUG|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]
223528972|NCT03584490|OTHER|Phone Administration of Questionnaires|This intervention will pilot questionnaire administration over the phone with currently enrolled or previously enrolled participants from the original intervention. This method was used during the COVID-19 pandemic.
223528973|NCT00375713|DRUG|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
223528974|NCT00375713|DRUG|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
223528975|NCT00375713|DRUG|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
224083591|NCT00578643|PROCEDURE|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10\^8/kg recipient weight; for cord blood ≥ 3 X 10\^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10\^/kg CD34+ cells.
224083592|NCT02670603|DRUG|EVONAIL® solution|
223528976|NCT00375713|DRUG|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
223528977|NCT00375713|DRUG|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
223715863|NCT05130398|DIAGNOSTIC_TEST|Active detection and treatment of pathogens|Monthly diagnostic and treatment of childhood infections Active detection and treatment of pathogens.
223907724|NCT03574649|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
223907725|NCT03574649|DRUG|Docetaxel|Docetaxel
223907726|NCT03574649|DRUG|carboplatin|carboplatin
223907727|NCT04083170|DRUG|Fludarabine|Given IV
223907728|NCT04083170|DRUG|Cyclophosphamide|Given IV
223907729|NCT04083170|DRUG|Thiotepa|Given IV
223907730|NCT04083170|RADIATION|Total-Body Irradiation|Undergo TBI
223907731|NCT04083170|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
223907732|NCT04083170|BIOLOGICAL|Dilanubicel|Given IV
223907733|NCT05940558|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
223907734|NCT05485727|OTHER|The Lokomat® Pro Hocoma USA & Conventional physical therapy|Lokomat Consists of robotic gait orthosis and an advanced body weight support system, combined with a Treadmill. (used for gait training) and Conventional Physical Therapy
223907735|NCT05485727|OTHER|Conventional Physical Therapy|Balance Exercises , Gait training, Trunk control, Range of motion exercises for lower limbs
223907736|NCT01236781|DEVICE|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
223907737|NCT01236781|DEVICE|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
223907738|NCT03099135|DRUG|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
223907739|NCT05118074|DIAGNOSTIC_TEST|Creatinine, eGFR|Compare diagnostic tests to reference methods
223907740|NCT04817774|BIOLOGICAL|TX200-TR101|TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A\*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Four, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.
223907741|NCT05951023|DRUG|Eszopiclone 2 mg|Eszopiclone tablet (encapsulated)
223907742|NCT05951023|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Eszopiclone
223940003|NCT07197710|OTHER|video-guided acupuncture imagery treatment (VGAIT)|Unlike traditional acupuncture, VGAIT can be self-administered and does not require physical needle insertion, making it a practical alternative for patients seeking non-invasive pain management.
223940004|NCT07197710|OTHER|Education video|Education video about postoperative precautions
224083593|NCT05112510|OTHER|Observing whether developing distant metastasis or recurrence|The study is a observational study and has no intervention.
223907743|NCT04059185|OTHER|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
223907744|NCT04059185|OTHER|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
223907745|NCT04059185|OTHER|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
223907746|NCT03756662|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
223907747|NCT05174637|DRUG|FDA018-ADC|FDA018-ADC will be administered via IV infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 \~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 \~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
223907748|NCT04283045|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the TA.
223907749|NCT04283045|BEHAVIORAL|JASPER Plus+|"JASPER Plus+ refers to direct instruction of social communication targets of pointing to share, showing gesures, and give to share gestures, and play targets at the child's target play level.~JASPER Plus+ will occur at a table top with repeated trials of instruction until the child can produce the desired behavior on their own."
223907750|NCT04049851|DRUG|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
223907751|NCT04049851|DRUG|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
223907752|NCT04049851|DRUG|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
223907753|NCT06668441|DRUG|Minimally invasive surgery plus low-dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.001mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
223907754|NCT06668441|DRUG|Minimally invasive surgery plus medium dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.003mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
223907755|NCT06668441|DRUG|Minimally invasive surgery plus high dose rhTNK-tPA group|The calculated injection amount of teneplase (teneplase injection amount = volume of hematoma ×0.009mg) was diluted to 1ml with sterile injection water, and injected into the stereotaxically planned puncture path according to the location and size of the hematoma. The pipeline was rinsed with 0.5ml normal saline, and the drainage tube was fixed and closed for 2 hours, so that after the full effect of the drug on the hematoma mass was ensured. Re-open the drain to allow gravity drainage.
223907756|NCT03690115|DRUG|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
223907757|NCT05540262|DRUG|Edaravone|Edaravone injection 30mg three times a day
223907758|NCT05809830|DRUG|LB-100 plus Doxorrubicin|In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin
223907759|NCT05809830|DRUG|Doxorubicin|The control arm in Phase II will be Doxorrubicin alone
223907760|NCT06621849|PROCEDURE|erector spinae plane block|In the erector spinae plane block (group E), an ultrasound-guided block will be performed on the ipsilateral side of the surgery while the patient is in lateral position 3-5 cm from the midline (10). Moving cephalic from the sacrum, we will identify the L5, L4, and L3 transverse processes and erector spinae muscles posteriorly. A 21 G and 70mm length needle will be directed in-plane, and the needle tip will be positioned anterior to the erector spinae muscle at the corner of the transverse process. After the initial saline injection, dissection of the plane will be observed by injecting a total volume of 20 ml composed of 10 micrograms dexmedetomidine in 2ml of normal saline and 18 ml of bupivacaine 0.25%, which is far from the toxic dose (10). Correct placement is defined as the spread of local anesthetic cranially and caudally from the injection point, dissecting the plane between the transverse processes and erector spinae muscles.
223907761|NCT06621849|DRUG|Morphine|patients will receive 5 ml of subcutaneous lidocaine 1% then 3.5 ml of bupivacaine 0.5% and 0.1 mg of morphine in 0.25 ml of normal saline intrathecal
223907762|NCT04540107|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223907763|NCT04540107|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223907764|NCT04540107|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223907765|NCT06063395|PROCEDURE|open surgery on the abdominal aorta by laparotomy|Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
223907766|NCT06106646|DIETARY_SUPPLEMENT|No active intervention in this protocol (previously randomized to Vitamin C)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
223907767|NCT06106646|OTHER|No active intervention in this protocol (previously randomized to Placebo)|In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
223907768|NCT05795816|DRUG|Testofen|Twice daily dose of 1 capsule (300mg per capsule Testofen)
223907769|NCT05795816|DRUG|Microcrystalline cellulose|Twice daily dose of 1 capsule
223907770|NCT03714360|DRUG|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
223907771|NCT03714360|DRUG|Sodium Chloride 0,9%|Sodium Chloride 0,9%
223907772|NCT05064891|PROCEDURE|Ultrasound guided injection|Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
223907773|NCT05778838|DRUG|Midodrine Oral Tablet|Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.
223907774|NCT05584540|BEHAVIORAL|UNTIRE App|Digital therapeutic application
223907775|NCT04107181|DEVICE|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
223907776|NCT04107181|BEHAVIORAL|Interviews only|Healthy volunteer interviews
223907777|NCT06068244|OTHER|3D printed crowns|3D printed crowns
223907778|NCT06068244|OTHER|Zirconia crowns|Nu smile zirconia crowns
223907779|NCT04587453|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 subclass that specifically binds to human interleukin-13 (IL-13) and blocks the interaction with IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
223907780|NCT04587453|DRUG|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
223907781|NCT04587453|OTHER|Topical corticosteroids (TCS)|TCS administered as needed.
223907782|NCT05672108|PROCEDURE|Computed Tomography|Undergo CT
223907783|NCT05672108|DRUG|Ethiodized Oil|Given IA
223907784|NCT05672108|DRUG|Mitomycin|Given IA
223907785|NCT05672108|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
223907786|NCT05672108|DEVICE|Tris-acryl Gelatin Microspheres|Given IA
223907787|NCT05523856|PROCEDURE|Active Surveillance|It consists on monitoring the cancer with regular tests including PSA, blood test and digital rectal examination every 6 months, a magnetic resonance imaging and prostate biopsy at the first year, and based on clinical decision thereafter. If there was a change on the results, the patient is considered for treatment.
223907788|NCT05523856|PROCEDURE|Robot-Assisted Radical Prostatectomy|It consists on the removal of the prostate gland and seminal vesicles with neurovascular preservation whenever anatomically and oncologically possible, with the Da Vinci procedure. Access is made through 5 or 6 small incisions, less than 1 cm. An extended pelvic lymph node dissection is performed when the risk estimation of node involvement is above the 5%. After surgery, the patient will be hospitalized for about 3 days and will probably resume his work activity between 3 and 5 weeks.
223907789|NCT05523856|RADIATION|Intensity-Modulated Radiotherapy|Patients in this group undergo volumetric modulated arc therapy under daily image-guided radiation therapy in the supine position. Radiation is delivered in 2-3 Gy daily fractions, 5 days per week, with a prescription dose of 60-70 Gy to the prostate.
223907790|NCT05523856|RADIATION|Real-time brachytherapy|Patients in this group receive I125 permanent seeds (low dose rate). The images are obtained with a transrectal ultrasound probe and are transferred to a planning system for calculating the number and position of the seeds. The prescrption dose is 145 Gy to the reference isodose (100%).
223907791|NCT05688241|DRUG|Donor-derived ex-vivo expanded EBV Tscm CTL|Cryopreserved cells will be thawed and infused at three time points. Dosing will be 2x10e6 EBV CTLs per kg of body weight. No prior lymphodepletion will be performed.
223907792|NCT01279408|OTHER|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
223907793|NCT06290921|OTHER|Ovulation triggering|Ovulation triggering when women only 2 dominant follicles as opposed to the clinic's standard of 3 follicles or more
224083594|NCT02315924|OTHER|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
224083595|NCT02315924|OTHER|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
224083596|NCT03987204|DRUG|Ivabradine|Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
224083597|NCT03894345|DRUG|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
224083598|NCT04241965|DRUG|OPC-214870|Tablet(s)
223907794|NCT06754241|BEHAVIORAL|conventional nursing care|(1) Preoperative education: An appropriate walking aid was provided for the patient and instructions were given to guide correct use, while isometric muscle exercises were taught. (2) Postoperative care: Six hours after anesthesia recovery, the head of the patient's bed could be elevated as needed, and the patient was instructed to perform ankle pumps (dorsiflexion and plantarflexion of the ankle).(3) Postoperative exercise: One to two days after surgery, following the removal of the drainage tube, the patient was encouraged to continue with ankle pumps and isometric quadriceps contractions, as well as to begin straight-leg raises. (4) Postoperative Day 3: In strict accordance with medical advice and under the guidance of a physiotherapist, patients engaged in continuous passive motion therapy for the affected knee, along with manual knee joint massage. (5) Postoperative Days 5-7: the patient would try to stand with the assistance of a walker, gradually progressing to walking exercises
223907795|NCT06754241|BEHAVIORAL|Intervention Care|(1) Intervention Day 1: (i) All patients in the observation group were provided with an introduction to the study and invited to join the WeChat group for the observation group. (2) Intervention Day 2: Exercise guidance for patients with KOA was shared via the WeChat group.(3) Intervention Day 3: Guidance for emotional regulation was sent to the patients with KOA via the WeChat group.(4) Intervention Week 1: A micro-lesson on KOA-related knowledge was delivered via the WeChat group to deepen patients' understanding. (5) Intervention Week 2: (i) Text instructions and related questions on common conservative treatments for KOA, including topical and oral painkillers, were shared, with correct answers provided the next day.(ii) A micro-lesson on exercise guidance for patients with KOA was uploaded to the WeChat group to reinforce patients' understanding.
223907796|NCT04884308|BIOLOGICAL|BCG TICE Vaccine|Intradermal vaccination with BCG TICE
223907797|NCT06841185|DRUG|HLX13|HLX13 (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
223907798|NCT06841185|DRUG|US-sourced YERVOY®|US-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
223907799|NCT06841185|DRUG|EU-sourced YERVOY®|EU-sourced YERVOY® (3 mg/kg) and nivolumab (1 mg/kg) treatment on the first day of each cycle, every 3 weeks with a total of 4 cycles
223907800|NCT03801876|DRUG|Carboplatin|Given IV
223907801|NCT03801876|PROCEDURE|Esophagectomy|Undergo esophagectomy
223907802|NCT03801876|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223907803|NCT03801876|DRUG|Paclitaxel|Given IV
223907804|NCT03801876|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
223907805|NCT03801876|OTHER|Quality-of-Life Assessment|Ancillary studies
223907806|NCT03801876|OTHER|Questionnaire Administration|Ancillary studies
223907807|NCT03801876|DRUG|FOLFOX regimen|Folinic acid, flurouracil and oxaliplatin
223907808|NCT03801876|DRUG|CAPOX regimen|Capecitabine combined with oxaliplatin
223907809|NCT03801876|DRUG|Docetaxel|Chemotherapy
223907810|NCT03801876|DRUG|5FU|Chemotherapy
223907811|NCT03795675|DEVICE|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
223907812|NCT05005637|DRUG|Anti Tuberculosis Drug|ATT will be given in the form of fixed drug combination (FDC). Each patient will get a regimen of 2RHZE (2 months of FDC intensive phase, which contains of Rifampicin, Isoniazide, Pirazinamide, Ethambutol) + 7RH (7 months of FDC continuation phase, which contains of Rifampicin and Isoniazid). The dosage will be according to body weight, 30-37 kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets, more than 70 kg: 5 tablets. FDC drugs have to be consumed daily during intensive phase and three times a week during continuation phase.
223907813|NCT05005637|DRUG|Methylprednisolone|Selected participants may be prescribed local or systemic immunosuppressants, including oral methylprednisolone, starting at a dosage of 0.8 mg/kg of body weight per day and tapered gradually (e.g., every three days or weekly) based on the severity of intraocular inflammation observed during presentation and follow-up visits.
223907814|NCT06186830|OTHER|Validity and reliability analyses|Validity and reliability analyses will be performed using Cognitive Exercise Therapy Approach Biopsychosocial Questionnaire, Patient Health Questionnaire-9, Patient Health Questionnaire-15, Generalized Anxiety Disorder-7, Short Form-36, Craniomandibular Pain and Disability Inventory, and Mandibular Function Impairment Questionnaire.
223907815|NCT06350266|BEHAVIORAL|Information about healthcare resources|Text messages will be sent following discharge from the emergency department; text may also be modified in the (online and/or printed) discharge summary packet.
223907816|NCT02658825|DRUG|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
223907817|NCT02658825|DRUG|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
223907818|NCT02658825|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
223907819|NCT02658825|DRUG|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
223907820|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
223907821|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
223907822|NCT02658825|DRUG|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
223907823|NCT02658825|DRUG|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
223907824|NCT06505356|PROCEDURE|Prostate biopsy|Transrectal prostate biopsy
223907825|NCT05287633|DRUG|Esomeprazole|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
223907826|NCT05287633|DRUG|Placebo|Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
224083599|NCT04241965|OTHER|Placebo|Tablet(s)
224083600|NCT05965674|PROCEDURE|Sacral Erector Spinae Plane Block|The transducer will be placed 3-4 cm laterally to the second medial sacral crest in order to visualize the intermediate sacral crest. In the interfascial plane, a total of 20 mL of local anesthetic solution (comprised of 10 mL bupivacaine 0.5%, 5 mL lidocaine 2%, and 5 mL normal saline) will be injected between the erector spinae muscles and the intermediate sacral crest. The same procedure will be performed on the contralateral side.
223907827|NCT05479760|OTHER|KP-Led HCV test and treat service|"After completing informed consent procedures, screening procedures will take place to assess eligibility. Clients who are anti-HCV and HCV-RNA positive, but meet one/more ineligible characteristics for simplified treatment will be referred to a hepatologist for treatment initiation.~Participants who are HCV-RNA positive and otherwise eligible will be offered to initiate DAAs at the CBO, followed by telehealth visits at week 4 and 8 and CBO visits at week 12, and week 24. If a visit is requested by the client, it can be conducted through telehealth or in-person at the clinic depending on client preferences. Substance use will be assessed using ASSIST, Retention in care, occurrence of adverse events during treatment, completion of treatment, and SVR achievement will be assessed. Clients who achieve SVR will be retested with HCV-RNA every 3 months to assess HCV re-infection. Clients who do not achieve SVR will be referred for further analysis and treatment."
223907828|NCT05199454|OTHER|Exercise training|Aerobic exercise training using a treadmill or a bike for 12 weeks, 3 times per week, 60 minutes per session.
223907829|NCT06470243|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223907830|NCT06470243|PROCEDURE|Bone Scan|Undergo bone scan
223907831|NCT06470243|DRUG|Cabazitaxel|Given IV
223907832|NCT06470243|DRUG|Carboplatin|Given IV
223907833|NCT06470243|PROCEDURE|Chest Radiography|Undergo chest x-ray
223907834|NCT06470243|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223907835|NCT06470243|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223907836|NCT06470243|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223907837|NCT06470243|DRUG|Prednisone|Given PO
223907838|NCT04618315|DEVICE|Hearing Aids|Receiver-in-the-ear hearing aids.
223907839|NCT06400615|DRUG|AD109|Oral administration at bedtime
223907840|NCT04433338|OTHER|14-day Low Calorie Diet|"Participants will be asked to:~* Use 4 (women) or 5 (men) Modifast meal replacements per day.~* Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~* Daily consume 100 grams of lean meat/fish/meat analogues.~* Daily consume two spoons of liquid oil~* Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks."
223907841|NCT03173235|DIAGNOSTIC_TEST|Plasma level of vitamin D|messurement of plasma level of vitamin D
223907842|NCT05492175|OTHER|robotic practice|According to the group assignment, participants will start from the BMT proximal mode (i.e., forearm pronation-supination movement), and then the distal mode (i.e., wrist flexion-extension movement), and vice versa. Each participant is expected to complete approximately 400 to 600 repetitions of the proximal mode session (i.e., forearm movements) and another 400 to 600 repetitions of the distal mode session (i.e., wrist movements), respectively.
223907843|NCT05492175|OTHER|kinetic exergaming|All of the participants in experimental and comparison groups will practice on the exergaming for 30 minutes per session. To avoid fatigue, the four domains of programs will be provided alternately. Each program will be executed for approximately 5 minutes with warm-up, followed by a 2-minute break between programs, and cool-down. The games will be selected and adapted according to the personal capacity, the occupational role, and the rehabilitation goal of each participant. The investigators will illustrate and guide the participants to play the games and stand next to them to prevent falls from occurring. To increase security, we will place a handrail in front of the participant for support as needed.
223907844|NCT05492175|OTHER|conventional therapy|Participants in control group will receive 30 minutes of therapist-mediated conventional therapy per session. The training protocols of the conventional therapy will use occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their personal needs. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The content of the functional tasks will be decided together by participants and therapists, such as picking up and putting down items in a box, lifting two soft drink bottles, and so on.
223907845|NCT06769282|BEHAVIORAL|Experimental: Intervention (SPARE) plus Treatment as Usual|5 components: (1) Social skills training, including selecting healthy friends and partners, (2) Problem solving with emphasis on positive outcomes of nonaggressive solutions, (3) Awareness of domineering behavior in self and conflict resolution skills, (4) emotion Regulation, and (5) psycho-education on ACEs and trauma. Each session will include 30 minutes of didactic instruction on the component with developmentally engaging activities to illustrate concepts and an individually tailored 15-minute narrative and mindfulness activity, which may address a traumatic memory depending on youth need and receptivity.
223907846|NCT06769282|BEHAVIORAL|Treatment as Usual (TAU)|Treatment As Usual consists of individual, family, occupational, and art therapy, social skills and emotion regulation groups, and therapeutic milieu. All staff and clinicians are trained in the Incredible Years Parenting Program, which aims reduce behavioral problems, enhance children's social and emotional competence, and improve child-parent interactions. Children also receive individualized treatment tailored for their needs (e.g., sleep interventions). Behavioral health needs staff (BHS) facilitate children's skill acquisition and generalization, implement individualized behavior contingency programs, and assist caregivers with parenting strategies via daily check-ins
223907847|NCT05332561|DRUG|Atezolizumab 1200 mg in 20 ML Injection|Arm 1
223907848|NCT05332561|DRUG|Inavolisib|Arm 2
223907849|NCT05332561|DRUG|Ipatasertib|Arm 3
223907850|NCT05332561|DRUG|Olaparib|Arm 4
223907851|NCT05332561|DRUG|Sacituzumab govitecan|Arm 5
223907852|NCT05332561|DRUG|Trastuzumab/pertuzumab|Arm 6
224083601|NCT03845387|DRUG|KDT-3594|oral administration, dose titration
224083602|NCT03845387|DRUG|Pramipexole|ER formulation, oral administration, dose titration
224083603|NCT02858427|BEHAVIORAL|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
223907853|NCT06111365|DEVICE|CHLOE|"the system will provide to the user a CHLOE™ score, which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5"
223907860|NCT03941080|DIAGNOSTIC_TEST|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
223907861|NCT03941080|BEHAVIORAL|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
223907862|NCT03941080|DIAGNOSTIC_TEST|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
223907863|NCT01005823|DRUG|LEO 29102 cream|Twice daily application for 7 days
223907864|NCT01005823|DRUG|LEO 29102 placebo cream|LEO 29102 placebo cream
223907865|NCT05152628|DRUG|Tacrolimus granules|Oral
223907866|NCT05152628|DRUG|Tacrolimus granules|Oral
223907867|NCT05801068|DRUG|Factor Xa Inhibitor|Hold and resume factor Xa inhibitor during perioperative/periprocedural period according to the predefined protocol.
223907868|NCT02211859|DRUG|BI 2536|
223907869|NCT05444881|BEHAVIORAL|Mindfulness-based Intervention (Headspace TM)|"A commercially available mindfulness mobile phone application (HeadspaceTM) will be used. The use of HeadspaceTM in the current protocol is approved by NYSPI Information Technology Services.~An mHealth mindfulness program such as Headspace provides self-paced, guided mindfulness meditations through a website or mobile app (iOS and Android). The program consists of basic meditation courses as well as courses targeting stress management, anxiety, depression, and parenting. Based on the qualitative interviews with parents in Phase I, psychoeducation will be included on mindfulness practice and mental health, emphasizing basic meditation courses, and asking parents to complete daily assignments of 10 to 20 min a day during the 6-week period. As an engagement strategy, every week participants in the intervention group will receive a call or an email or text message (depends on preference; partisans may opt out to receive email/text messages)."
223907870|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
223907871|NCT00619879|DRUG|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~* For children \>/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~* For children \< 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~* Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols\*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
223907872|NCT00619879|OTHER|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
223907873|NCT00619879|RADIATION|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) \< 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~* Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~* Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
223907874|NCT05338606|DRUG|Bimatoprost Sustained Release Implant|Intraocular Implant
223907875|NCT06584721|OTHER|Anti-pronation taping (Low dye taping) + Conventional therapy|"They would be receiving treatment as follow:~Anti-pronation taping (Low dye taping) Applied on alternate days. 3 days / week for 4 weeks.~Conventional Therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsxset1, 10sec hold) 3sessions/ week."
223907876|NCT06584721|OTHER|Short Foot Exercises + Conventional PT|"They would be receiving treatment as follow:~Short foot exercises are used to reduce the foot pronation: Frequency: 30 reps x 1 set, 30 sec hold and 10 sec relaxation for 4 weeks. 3 session/ week).~Short foot Exercises includes a four-week plan, 1- Shortening of foot in Anterior-posterior direction, 2- Increase medial longitudinal arch, 3- Balanced loading in standing, 4- Approximating Head of first, second meta-tarsal and calcaneus with patient in standing (single leg).~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsx1set, 10sec hold) 3sessions/ week."
223907877|NCT06585228|DIAGNOSTIC_TEST|Cardiac Computed Tomography|Cardiac CT acquired during the acute stroke imaging protocol
223907878|NCT06585228|DIAGNOSTIC_TEST|Transesophageal echocardiography|Ultrasound through the oesophagus to assess cardiac structures.
223907879|NCT06585228|DIAGNOSTIC_TEST|Repeated Cardiac Computed Tomography|A second cardiac CT performed after the TEE.
223907880|NCT02538809|OTHER|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
223907881|NCT03911141|BEHAVIORAL|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
223907882|NCT03911141|BEHAVIORAL|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
223907883|NCT05856838|DEVICE|NovaSure ablation|Ablation of the endometrial tissue using the NovaSure device
223907884|NCT05451979|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
223907885|NCT06451835|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).
223907886|NCT04657042|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Four-dimensional MRI of torso
223907887|NCT04578249|OTHER|Blue light-blocking goggles|Participants will be randomly assigned to one of the two intervention groups.
223907888|NCT04578249|OTHER|Clear goggles|Participants will be randomly assigned to one of the two intervention groups.
223907889|NCT04100408|OTHER|Biospecimen Collection|Undergo saliva or buccal mucosa collection
223907890|NCT04100408|OTHER|Laboratory Biomarker Analysis|Correlative studies
223907891|NCT04100408|OTHER|Questionnaire Administration|Ancillary studies
223907892|NCT05333393|BEHAVIORAL|DİABOT (mobile application robot )|Thanks to the trainings given through the mobile application robot developed for pediatric diabetes management, it is aimed to have an effect on the quality of life, diabetes self-management and physiological parameter levels of children with Type 1 diabetes, and to easily obtain the information they need even when they cannot come to the outpatient clinic. In addition, thanks to the application robot, he will be able to create his own exercise program and determine his diet.
223907893|NCT06100666|BEHAVIORAL|Observational Tests|The Sustainable and Healthy Eating Behaviors Scale will be used to assess sustainable eating behaviors, one-day food consumption records will be collected with the 24-hour Dietary Recall method, the International Diet Quality Index and EAT-Lancet Diet Score will be used to assess diet quality, and body weight, height, waist circumference and neck circumference will be measured to determine nutritional status.
223907894|NCT04813055|PROCEDURE|Therapeutic EUS|"1. EUS-guided collection drainage (transgastric or transduodenal, performed by Lumen Apposing Metal Stents or double pigtail stents) and eventual endoscopic necrosectomy~2. EUS-guided biliary drainage (either of the extrahepatic or intrahepatic biliary tree / transduodenal or transgastric / either as access for subsequent rendez-vous or transpapillary stenting OR for transparietal stenting by metal or plastic stents).~3. EUS-guided gallbladder drainage via Lumen Apposing Metal Stents and eventual subsequent EUS-based cholecystolithotomy~4. EUS-guided gastro-jejunostomy through Lumen Apposing Metal Stents~5. EUS-directed ERCP in post-surgical anatomy (by gastro-gastrostomy or entero-enterostomy performed through Lumen Apposing Metal Stents)~6. EUS-guided pancreatic duct drainage"
223907895|NCT04813055|PROCEDURE|Percutaneous Procedures|Procedures involving a percutaneous access to a target region (fluid collection, gallbladder, biliary tree)
223907896|NCT04813055|PROCEDURE|Surgical Interventions|Surgical interventions to obtain a drainage (e.g. surgical necrosectomy, pancreatico-gastrostomy) or the bypass of a stricture (hepatico-jejunostomy or gastro-jejunostomy)
223907897|NCT04813055|PROCEDURE|non-EUS-based endoscopic procedures|Other endoscopic procedures not involving EUS (enteral stenting, Enteroscopy-assisted ERCP)
223907898|NCT05928585|DRUG|HIB210|Experimental monoclonal antibody
223907899|NCT05928585|DRUG|Placebo|Placebo
223907900|NCT05022342|OTHER|alpelisib plus fulvestrant|Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.
223907901|NCT05390281|DIAGNOSTIC_TEST|increase in serum creatinine|any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
223907902|NCT06185413|OTHER|Participatory system dynamics approach|First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
224083604|NCT02858427|BEHAVIORAL|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
224083605|NCT02858427|BEHAVIORAL|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
223907903|NCT06374225|DEVICE|Automated Titration (O2matic)|The patient will receive supplemental oxygen titrated using an autonomous oxygen titration device. The patient will be monitored and vital signs documented by the site's usual SpO2 assessments, but oxygen titration will occur automatically through the O2matic PRO100 device during the intervention period, unless there is a safety concern. The SpO2 range programmed into the PRO100 is 92-94%. The acceptable SpO2 range for the protocol is 90-96%. If a patient requires \>15lpm or other signs of advancing respiratory failure, they will be taken off the autonomous oxygen and transitioned to higher flow oxygen devices or mechanical ventilation per usual clinical care. If the patient is not receiving any supplemental oxygen per the autonomous titration, the clinical team may remove the oxygen delivery device from the patient, but the patient should remain connected to the PRO100 for the duration of the intervention period for data collection and to monitor for new supplemental oxygen needs.
223907904|NCT06601101|DRUG|Insulin|Insulin eye drops in the postoperative prescription for corneal crosslinking
223907905|NCT06601101|DRUG|Placebo eye drops of 0.5% Methylcellulose|Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking
223907906|NCT03085719|DRUG|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
223907907|NCT03085719|RADIATION|Radiation|Radiation is used to shrink the cancer
223907908|NCT04618978|PROCEDURE|PSG and actigraphy recording|"Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record)."
223907909|NCT06229080|DEVICE|NexGel|When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
223907910|NCT00490516|DRUG|ACP-104|200 mg, tablet, BID, 6 weeks
223907911|NCT00490516|DRUG|ACP-104|100 mg, tablet, BID, 6 weeks
223907912|NCT00490516|DRUG|Placebo|placebo, tablet BID, 6 weeks
223907913|NCT06503406|DEVICE|SupraSDRM®|SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.
223907914|NCT06503406|DEVICE|NovoSorb® BTM|NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140
223528978|NCT02756052|DEVICE|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
223715864|NCT05130398|COMBINATION_PRODUCT|Fibre and equilibrate breakfast and lunch plus Active detection and treatment of pathogens|Participants receive fibres and caloric equilibrate diet during breakfast and lunch every day for 21 consecutive days and diagnostic and treatment of childhood infections Active detection and treatment of pathogens every month for 12 months
223907915|NCT04966299|DIETARY_SUPPLEMENT|Eryhtritol|"Eryhtritol-sweetened beverages twice a day (36g erythritol/day) with main meals during 5 weeks~EryClot-Pilot:~Erythritol 50g dissolved in 300mL water administered once per visit~EryClot:~Erythritol 50g dissolved in 300mL water administered once per visit"
223907916|NCT04966299|DIETARY_SUPPLEMENT|Sucrose|Sucrose-sweetened beverages twice a day (25g sucrose/day) with main meals during 5 weeks
223907917|NCT04966299|DIETARY_SUPPLEMENT|Glucose|Glucose 75g dissolved in 300mL water administered once per visit
223907918|NCT04966299|DIETARY_SUPPLEMENT|Fructose|Fructose 25g dissolved in 300mL water administered once per visit
223907919|NCT04966299|DIETARY_SUPPLEMENT|Xylitol|Xylitol 33.5g dissolved in 300mL water administered once per visit
223907920|NCT04966299|DIETARY_SUPPLEMENT|Water|300mL water administered once per visit
223907921|NCT04032847|BIOLOGICAL|ATL001|ATL001 infusion
223907922|NCT04032847|DRUG|Pembrolizumab|Checkpoint inhibitor
223907923|NCT05838196|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed during clinic appointment
223907924|NCT05055648|RADIATION|Photon Radiotherapy|nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
223907925|NCT05055648|RADIATION|Proton Radiotherapy|nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
223907926|NCT06334991|BIOLOGICAL|CD19 t-haNK|"CD19t-haNK erived from the parental NK-92 (aNK) cell line, CD19 t-haNK is a human, allogeneic, NK cell line that has been engineered to express a CAR targeting CD19. Similar to the haNK cell line, CD19 t haNK has also been engineered to produce endoplasmic reticulum-retained IL 2 and the high-affinity (158V) variant of the Fcγ receptor (FcγRIIIa/CD16a), and thereby has enhanced CD16-targeted ADCC capabilities. CD19 t-haNK is similar to PD L1 t-haNK, differing only in the CAR that is expressed (CD19 vs PD-L1).~Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM."
223528979|NCT02756052|DEVICE|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
223715865|NCT05130398|BIOLOGICAL|Chikenpox or Varicella vaccine (VARILRIX)|The active comparator vaccine, a Varicella vaccine (VARILRIX®)
223715866|NCT05130398|OTHER|Placebo|About 30 children do not receive diet, nor active pathogen detection
223715867|NCT00043771|DRUG|Tolvaptan|
223715868|NCT04592315|DRUG|Lipovirtide Injection|Single dosage of Lipovirtide Injection
223907927|NCT03213665|DRUG|Tazemetostat|Given PO
223907928|NCT06395779|BEHAVIORAL|Neuromuscular Exercise Group|A 12-week Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization, balance training, muscle strength, breathing, and functional movement patterns will be created for the participants in Group 1.
224277194|NCT04235660|RADIATION|Stereotactic Body Radiation Therapy|SBRT will be delivered with linear accelerator-based photon beams with either fixed angle non- coplanar fields or dynamic arcs. An internal target volume (ITV) will be generated to account for tumor movement during breathing cycle. Finally, a planning target volume (PTV) will be an expansion of 3- 5mm from the ITV. For Child Pugh A patients, prescription dose will either be 5000cGy in 5 fractions delivered every other day or 4800cGy in 3 fractions delivered twice weekly. For Child Pugh B patients, prescription dose of 4000cGy in 5 fractions delivered every other day. Inverse planning will be used. 95% of the PTV or more will receive at least 100% of the prescription dose. Normal tissue dose constraints for each dose level will be respected with acceptable deviations permitted as outlined in appendix VII. Patients will be seen at least once per week by a clinician to grade toxicities, with on- treatment labs (CBC, CMP, INR) each week.
223907929|NCT06395779|BEHAVIORAL|Dance Therapy Group|Participants in Group 2 will be given dance training by a dance instructor in the gym for 1 hour a day, 2 days a week, for a total of 12 weeks. In dance therapy practices, simple and basic movements are appropriate to the level of the participants, and special attention will be paid to the rhythm of the music not being fast. Latin dances were applied to the participants; selected rumba, merengue, bachata, and salsa movements. Dance therapy will start with a warm-up exercise (10 minutes), then dance exercises will be applied and the activity will end with a cool-down exercise (10 minutes).
223907930|NCT03056573|DEVICE|Transaortic TAVR Implant|Transaortic TAVR implant
223907931|NCT03056573|DEVICE|Subclavian /Axillary TAVR implant|Subclavian /Axillary TAVR implant
223907932|NCT06667037|DEVICE|Ortho-k lenses|Ortho-k lenses will be administered nightly.
223907933|NCT06667037|DRUG|0.01% Atropine|0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.
223907934|NCT04872855|DEVICE|patient with knee arthroplasty|patient with HLS KneeTec cementless and hybrid fixation prosthesis
223907935|NCT04321551|DRUG|Testosterone Cyp 200Mg/Ml Inj (in Oil)|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
223907936|NCT04321551|DRUG|Letrozole|Letrozole is a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1- ylmethylene)dibenzonitrile. Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C17H11N5, and a melting range of 184°C to 185°C. Letrozole is available as 2.5 mg tablets for oral administration.
223907937|NCT06444295|BEHAVIORAL|Activity scheduling|"Participants will engage in activity scheduling in the app (i.e., Activities module). On the first day of using the app, users will create a list of valued/important and avoided activities (e.g., spending time with friends, going to the gym), and then have the option to add alcohol protective behavioral strategies (e.g., adding ice to drinks, alternating alcoholic and nonalcoholic beverages) to activities that the user identifies as being likely to involve drinking. On subsequent days, users will be encouraged to complete at least one activity from their list."
223907938|NCT06444295|BEHAVIORAL|Cognitive restructuring|"Participants will engage in cognitive restructuring in the app (i.e., Thoughts activities). Users first go through an activity involving the identification of maladaptive cognitions and create a list of their maladaptive cognitions. On subsequent days, they engage in a guided in-app activity involving cognitive restructuring of maladaptive cognitions from their list."
223907939|NCT06444295|BEHAVIORAL|Coaching calls|Participants will receive 10-20 minute weekly coaching calls during the app use period (4 total, including coaching provided in the enrollment call). All coaching calls will, at minimum, include a check-in, troubleshooting of technical issues, check-in about experience with symptom self-monitoring, and offers of referrals. Coaching calls in conditions involving activity scheduling will involve assistance with the Activities module. Coaching calls in conditions involving cognitive restructuring will involve assistance with the Thoughts module.
223907940|NCT06444295|BEHAVIORAL|Non-core intervention components|"All participants, regardless of condition, will receive the following non-core THRIVE components.~* 21 days of brief self-report surveys in the app assessing their PTSD symptoms and alcohol use in the prior 24 hours.~* A banner in their app displaying rotating non-personalized encouraging messages from other users. All app users will have the option of submitting encouraging statements to be displayed to all other users. Statements will be vetted by study staff before posting.~* Lists of referral options specific to each recruitment site via the Resources section of the app.~* Answers to frequently asked questions about the study, the study consent form, and contact information for the study team via the Information section of the app.~* One call with a study point person within the first week following randomization to ensure they were able to access the app and troubleshoot access issues"
223907941|NCT05811585|DEVICE|ADEPT|Adhesion Reduction Solution (4% icodextrin solution)
223907942|NCT06559007|DRUG|HRS-5041 dose level 1|Single dose of HRS-5041 orally administered
224277195|NCT03957694|DRUG|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
223907943|NCT06559007|DRUG|HRS-5041 dose level 2|Single dose of HRS-5041 orally administered
224277196|NCT04304209|DRUG|Oxaliplatin|130mg/m2, d1 q3w, in Capeox regimen (100mg/m2 when used cocurrently with radiotherapy), intravenous infusion
224277197|NCT04304209|DRUG|Capecitabine|1000mg/m2, bid, qd1-14, q3w, in Capeox regimen, oral administration
223715869|NCT05758051|PROCEDURE|subtrochanteric valgus osteotomy|subtrochanteric valgus osteotomy
223715870|NCT01001377|DRUG|Cetuximab|Administered by intravenous infusion
223907944|NCT06158607|BEHAVIORAL|Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders|Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.
223907945|NCT06158607|OTHER|Standard of care treatment|Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
223907946|NCT06423339|PROCEDURE|Ultrasound guided Genicular nerve block|Ultrasound guided genicular nerve block
223907947|NCT06423339|PROCEDURE|Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee|Ultrasound guided Interspace between the popliteal artery and the capsule of the popliteal artery and the capsule of the posterior knee
223907948|NCT06423339|PROCEDURE|Adductor canal block|Ultrasound guided sub-sartorial Adductor canal block
223907949|NCT06423339|DRUG|Bupivacaine Hydrochloride|Pupivacaine 0.5% in 20 ml vial
223907950|NCT04656028|GENETIC|Genetic Testing|DNA is extracted using the QIAamp® DNA Blood Mini Kit (Qiagen, Germany). The DNA concentration is measured on a Qubit 4.0 fluorometer (Thermo Fisher Scientific, USA (TFS)). NGS is performed on Nextseq 550 (Illumina, San Diego, CA, USA). The library preparation is performed using the SeqCap EZ Prime Choice Library kit (Roche, Basel, Switzerland). The Roche panel is used, consisting of 244 (CDS + 25 bp padding) genes including LDLR, APOB, and PCSK9. Reads are aligned to the reference genome (GRCh37). Sequencing analysis resultes in fastq files. Data processing is performed with BWA, Picard, bcftools, GATK3 and generally followed the GATK best practices for variant calling. For clinical interpretation, genetic variants with frequencies in the gnomAD database \<0.5% are selected. The pathogenicity of variants is assessed according to the ACMG / AMP2015 guidelines. The identified SNPs are validated by Sanger sequencing (3500 DNA Analyzer, TFS).
223907951|NCT04656028|BEHAVIORAL|Motivational Counseling|"Motivational counseling will be carried out during Visit 2 and in one month after Visit 2 by certified psychologist with taking into account the results of the psychodiagnostic survey conducted at the first and second visits.~The goals of motivational counseling:~1. Increasing motivation for a healthy lifestyle;~2. Increasing adherence to treatment;~3. Increased motivation to invite relatives for cascade screening. Motivational counseling will be carried out using methods of motivational interviewing, transtheoretical model of changes, cognitive-behavioral therapy, extended preventive counseling."
223907952|NCT04656028|DIAGNOSTIC_TEST|Lipid analysis|Assessment of total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, alanine aminotransferase.
223907953|NCT04656028|OTHER|Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet)|All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage. If somebody has an intolerance to atorvastatin, the drug will be replaced with rosuvastatin and vice versa. In case of intolerance to all drugs from the statin group, the patient will be prescribed ezetimibe with a PCSK9 inhibitor (alirocumab / evolocumab). After receiving the results of the lipid spectrum, ALT, if necessary, the lipid-lowering therapy may be corrected.
223907954|NCT04656028|OTHER|Visit 1|"Visit 1: initially (on enrollment) - informed consents signing; lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires. After this visit patients are randomized to groups with or without genetic testing and then randomized to groups with or without motivational counseling.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform, a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
223907955|NCT04656028|OTHER|Visit 2|"Visit 2 (in 2-3 months): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid lowering-therapy and lifestyle; filling all questionnaires. Patients from the group with genetic testing will get the result of this genetic testing. Patients from the group with motivational counseling will get two consultations with a psychologist (motivational counseling on lifestyle modification) during Visit 2 and in one month after Visit 2.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days"
223907956|NCT04656028|OTHER|Visit 3|"Visit 3 (in 3 months after Visit 2): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
223907957|NCT04656028|OTHER|Visit 4|"Visit 4 (in 12 months after Visit 3): lipid blood tests, patient data gathering, and consultation of cardiologist-lipidologist for optimization of lipid-lowering therapy and lifestyle; filling all questionnaires.~Each visit consists of two patient's attendances to the medical center. At the first attendance, it is planned to take blood for analysis, fill out questionnaires; at the second attendance - to perform a consultation with a cardiologist-lipidologist according to the results of blood analysis. The time interval between two attendances is ≤ 7 days."
223907958|NCT05052255|DRUG|RVU120|RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
223907959|NCT05996406|DRUG|Venetoclax|Venetoclax 400mg po qd for 1 year
223907960|NCT05996406|DRUG|Dexamethasone Oral|Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months
223907961|NCT01976182|DRUG|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
223907962|NCT01976182|DRUG|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
223715871|NCT01001377|DRUG|Panitumumab|Administered by intravenous infusion
223715872|NCT03495362|DIETARY_SUPPLEMENT|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223907963|NCT02658279|DRUG|Pembrolizumab|
223907964|NCT06350175|COMBINATION_PRODUCT|Nicotine Replacement Therapy Agent|The NRT Agents-- 21mg nicotine patches (x14) and 2 mg nicotine lozenges (\~210).
223907965|NCT06350175|OTHER|West Virginia Quit Line|Instructional Pamphlets and contact information for the WV QL. A telehealth line set up to assist people of WV to quit smoking.
223907966|NCT04047602|RADIATION|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
223907967|NCT02684227|DRUG|Carboplatin|Given IV
223907968|NCT02684227|DRUG|Enzalutamide|Given PO
223907969|NCT02684227|OTHER|Laboratory Biomarker Analysis|Correlative studies
223907970|NCT02684227|DRUG|Paclitaxel|Given IV
223907971|NCT02684227|OTHER|Pharmacological Study|Correlative studies
223907972|NCT06406075|DEVICE|Lab demo 1.0|During the intervention, transcutaneous spectral data are collected continuously with the Lab demo. Up to 20 whole blood glucose reference values are also collected, as well as interstitial fluid glucose values using a continuous glucose monitoring device. Some participants will attend multiple measurement sessions.
223907973|NCT06509984|DRUG|Apremilast treatment|treatment of apremilast
223907974|NCT04946032|OTHER|Epidural catheter|The epidural catheter length will vary, either 4 cm or 5 cm into the epidural space.
223907975|NCT04351906|DEVICE|ECCO2R|ECCO2R integrated into the multiFiltrate device
223907976|NCT03598894|OTHER|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
223907977|NCT04099472|BEHAVIORAL|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
223907978|NCT04099472|BEHAVIORAL|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
223907979|NCT03606408|DRUG|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
223907980|NCT06110273|BEHAVIORAL|Fit for Duty-mobile|Fit for Duty-mobile participants will receive self-regulatory support and behavior change techniques via an initial core intervention delivered through a native smartphone app (includes connected device data, 10 weekly lessons, weekly tailored feedback) and 4 coaching calls (weeks 1, 4, 8, and 16). App based tailored feedback and messaging will continue through 2 years. Optional 4-week refresher e-campaigns are offered every 6 mos. after the initial core intervention. Participants choose to follow either a Small Changes approach or a Large Changes approach and may choose to switch approaches over the 2 years, if desired.
223907981|NCT06110273|BEHAVIORAL|m-Health Control|Participants receive digital tools and education on weight gain prevention behaviors at baseline.
223907982|NCT05390268|BEHAVIORAL|Mobile app-assisted behavioral treatment|"The app-assisted training group has access to a newly developed app in which they are taught how to handle tics. A new app session is released at each new treatment session and the content of the app videos is comparable to the information and training at face-to-face individual treatment, as defined by the manual Niks to Tics\["
223907983|NCT05390268|OTHER|Mobile app-assisted psychoeducation|The app-assisted educational group has access to a newly developed app in which they receive psychoeducation on tics.
223907984|NCT06244992|DRUG|PTT-936|Eligible patients will receive single-agent PTT-936 administered per orally (PO).
223907985|NCT06244992|DRUG|Combination of PTT-936 and anti-PD-1/L1 therapy|Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
223907986|NCT05995496|OTHER|Fasting state|16 hours of fasting
223907987|NCT05995496|OTHER|Fed state|Fed a standardized meal
223907988|NCT05995496|OTHER|Magnetic Resonance Imaging|Neuroimaging with computational modeling
223907989|NCT04218318|DEVICE|phototherapy|Phototherapy will be commenced for neonates in both groups according to AAP guidelines.Neonates will be treated with intensified overhead blue LEDs phototherapy if they have a TSB level at or above phototherapy threshold. Neonates will be started on intensified 360◦ LED phototherapy if they have TSB level within 50µmol/L below the exchange threshold. The administration of IVIG is indicated in infants with isoimmune hemolytic disease if TSB lies within 34 to 51 micromol/L of the threshold for exchange transfusion and not responding to initial intensified phototherapy.Infants with a TSB concentration above the thresholds for exchange should have immediate intensified 360◦ LED phototherapy, and preparation for exchange transfusion will be started.Infants showed clinical signs of acute bilirubin encephalopathy will have an immediate exchange transfusion.
223907990|NCT01593241|DRUG|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
223907991|NCT01593241|RADIATION|Involved node RT|Involved node RT
223907992|NCT04867278|PROCEDURE|External Beam Radiation (XRT)|Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
223907993|NCT04867278|PROCEDURE|Debridement|Gluteus minimus debridement in the OR
223715873|NCT03495362|OTHER|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223907994|NCT05122793|BEHAVIORAL|Prevention offer|Improvement of outcomes through lifestyle changes and improved health literacy
223907995|NCT06310668|BEHAVIORAL|group cognitive behavioral therapy sessions|12 group CBT sessions based on catching and challenging cognitive errors and behavioral techniques to deal with substance use problems
223907996|NCT05646277|OTHER|e-Consultation|first orthodontic consultation in remote
223907997|NCT05646277|OTHER|Consultation|first orthodontic consultation in face-to-face
223907998|NCT05204329|BIOLOGICAL|MSC Secretome Eye Drops|MSC Secretome eye drop will be dispensed.
223907999|NCT03223090|BEHAVIORAL|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
223908000|NCT03223090|BEHAVIORAL|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
223908001|NCT05203835|DRUG|Acebilustat|By mouth, once a day, 100 mg capsule
223908002|NCT05203835|DRUG|Placebo|Placebo to match acebilustat by mouth, once a day
223908003|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 2 stages|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the experimental group, patients will be treated according to Limoges' treatment algorithm (2 stages)
223908004|NCT06181357|PROCEDURE|Endoscopic lung volume reduction in 1 stage|After the selection process, they will all be hospitalized in order to undergo an endoscopic lung volume reduction with Zephyr® valve under general anesthesia. In the control group, the entire lobe will be treated during one procedure
223908005|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 1|Our current hearing aids which will be programmed to our standard frequency response curve.
223908006|NCT05828017|DEVICE|Hearing Aid - Variation #1 under Program 1|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
223908007|NCT05828017|OTHER|Hearing Aid - Variation #2 under Program 5 - Streaming Only|Our current hearing aids which will be programmed to our standard frequency response curve.
223908008|NCT05828017|OTHER|Hearing Aid - Variation #3 under Program 5 - Streaming Only|Hearing aids that will have the frequency response curve #3 adjusted and fit to the participant's hearing loss.
223908009|NCT05828017|OTHER|Hearing Aid - Variation #4under Program 5 - Streaming Only|Hearing aids that will have the frequency response curve #4 adjusted and fit to the participant's hearing loss.
223908010|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 2|Our current hearing aids which will be programmed to our standard frequency response curve.
223908011|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 2|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
223908012|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 3|Our current hearing aids which will be programmed to our standard frequency response curve.
223908013|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 3|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
223908014|NCT05828017|OTHER|Hearing Aid - Standard Curve under Program 4|Our current hearing aids which will be programmed to our standard frequency response curve.
223908015|NCT05828017|OTHER|Hearing Aid - Variation #1 under Program 4|Hearing aids that will have the frequency response curve #1 adjusted and fit to the participant's hearing loss.
223908016|NCT05828017|OTHER|Unaided|No hearing aids worn at all and participants tested as is.
223908017|NCT04146324|DRUG|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
223908018|NCT06080464|OTHER|VERABAND information|The device, VERABAND™, activity data reports (including a summary broken down by week) will be provided to treating clinicians prior to each patient's follow-up clinic visit.
223908019|NCT06649981|DIETARY_SUPPLEMENT|FMT capsule|"A lyophilized gut microbiota capsule derived from a rigorously screened, healthy, and physically active donor, free of gastrointestinal diseases, antibiotic use, and chronic conditions. The donor diverse microbiome is supported by a nutrient-rich diet and active lifestyle. The lyophilization process preserves microbial integrity, offering a high-potency dose aimed at restoring and optimizing the gut microbiome of older adults.~This intervention is specifically designed for older adults to enhance resilience to stress, cognitive function, muscular strength, and metabolic health. It is part of a controlled clinical study with follow-up assessments at weeks 1, 4, 8, and 20 post-intervention. This targeted approach distinguishes it from other microbiome-based therapies by focusing on comprehensive health benefits for an aging population."
223908020|NCT06649981|DIETARY_SUPPLEMENT|Placebo Capsule(s)|"A placebo capsule will be used in this study to serve as a control, allowing us to objectively assess the true effects of the lyophilized gut microbiota intervention. The use of a placebo is essential to eliminate bias and ensure that any observed outcomes can be confidently attributed to the actual intervention rather than to psychological or other non-specific effects.~The placebo capsule will be identical in appearance, size, shape, and color to the interventional capsule to maintain blinding for both participants and researchers. This ensures that neither group knows which capsule is being administered, thereby preserving the study's integrity and validity by preventing any expectations or beliefs from influencing the results."
223908021|NCT05878080|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
223908022|NCT05996848|DRUG|Cagrilintide|Participants will receive 2.4 mg cagrilintide subcutaneously.
224083606|NCT02858427|BEHAVIORAL|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
224083607|NCT03828487|DEVICE|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
223908023|NCT05996848|DRUG|Semaglutide|Participants will receive 2.4 mg semaglutide subcutaneously.
223908024|NCT05996848|DRUG|Placebo Semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
223908025|NCT05996848|DRUG|Placebo Cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
223908026|NCT02824731|RADIATION|Radiation with protons|
223908027|NCT02824731|RADIATION|Radiation with photons|
223908028|NCT02852655|DRUG|MK-3475|
224083608|NCT03828487|DEVICE|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
224083609|NCT05792514|OTHER|stong,stamp,pyms|STRONG(screening tool for risk of nutritional status and growth) STAMP(screening tool assessment of malnutrition in pediatrics) PYMS
224083610|NCT00375102|PROCEDURE|Acupuncture|
224083611|NCT00375102|BEHAVIORAL|Relaxation Response|
224277198|NCT04304209|DRUG|Sintilimab|200mg, d1 q3w, intravenous infusion
224277199|NCT04304209|RADIATION|radiotherapy|neoadjuvant radiotherapy with 50Gy to GTV, 45Gy to CTV in 25 fractions.
224277200|NCT04304209|PROCEDURE|total mesorectal excision|total mesorectal excision after neoadjuvant treatment
223715874|NCT05928039|BIOLOGICAL|TNFa Antagonist - Infliximab|• Infliximab 5 mg/kg intravenously \[IV\] at weeks 0, 2, 6, then 5 mg/kg every 8 weeks
223908029|NCT05100043|BIOLOGICAL|IL-4 and IFN-γ measurements|Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
223908030|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Gadovist for MRI investigation|Image enhancing contrast agent will be injected to enhance MRI resolution in breast cancer diagnosis
223908031|NCT05989022|DIAGNOSTIC_TEST|Injection of contrast enhancing agent Imeron for B-CT investigation|Image enhancing contrast agent will be injected to enhance B-CT resolution in breast cancer diagnosis
223908032|NCT06827145|DRUG|Vebreltinib|Vebreltinib 100mg oral BID
223908033|NCT06827145|DRUG|Osimertinib|Osimertinib 80mg oral once daily.
223908034|NCT05802160|BEHAVIORAL|Good Start Matters - Parenting intervention|The Good Start Matters - Parenting intervention is a 2-month mobile-Health (mHealth) parenting program that aims to improve parenting practices and child health behaviors among British Columbian families of preschoolers. This intervention uses a familial approach and blends the best practices and evidence to promote positive parenting regarding 3 main areas: nutrition, physical activity, and screen-time; which altogether aim to support the development of healthy habits among young children. The mHealth app releases new material on a weekly basis and participants' engagement with the app takes about 30 minutes per week.
223908035|NCT06806735|OTHER|3D-Pictures|3D-Pictures will be taken of hypertrophic scars and keloids to document them.
223908036|NCT07045337|OTHER|Hybrid Bracing|Hybrid Bracing includes daytime Underarm Brace(UAB) and nighttime Lateral Bending Brace(LBB)
223908037|NCT07045337|OTHER|Conventional fulltime Underarm Bracing|Conventional group includes fulltime Underarm Brace (UAB) only.
223908038|NCT07056101|DEVICE|A conventional dental syringe|The conventional dental syringe (C-K JECT) is a manual, metal aspirating syringe commonly used for local anesthesia administration in dental procedures. In this study, the device is used to perform buccal and intrapapillary infiltration using 4% articaine with 1:100,000 epinephrine. Injections are delivered manually at a standardized rate by the principal investigator. This arm serves as the active comparator to evaluate differences in pain perception between traditional syringe injections and those delivered via a computer-controlled device.
223908039|NCT07056101|DEVICE|GENI High-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system that automates the injection process using pressure feedback to regulate flow. In this arm, the device is set to high-speed mode to deliver the anesthetic solution at the fastest available flow rate. Buccal and intrapapillary infiltration is performed using 4% articaine with 1:100,000 epinephrine. The procedure is carried out by the principal investigator using a standardized technique. Pain perception is assessed following injection to evaluate the impact of delivery speed on patient experience.
223908040|NCT07056101|DEVICE|GENI Moderate-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system designed to regulate flow and pressure during injection using real-time feedback. In this arm, the device is set to moderate-speed mode, delivering anesthetic at an intermediate flow rate. Buccal and intrapapillary infiltration is performed using 4% articaine with 1:100,000 epinephrine. The injection is administered by the principal investigator using a standardized technique. This group is used to assess the impact of moderate-speed delivery on pain perception and physiological response in pediatric patients.
223908041|NCT07056101|DEVICE|GENI Low-Speed Injection|The GENI device is a computer-controlled local anesthesia delivery system that maintains precise control over injection pressure and flow. In this arm, the device is set to low-speed mode, delivering the anesthetic solution at the slowest available rate to minimize tissue pressure and potential discomfort. Buccal and intrapapillary infiltration is administered using 4% articaine with 1:100,000 epinephrine. The injection is performed by the principal investigator using a standardized technique. This group evaluates whether low-speed delivery reduces pain perception and improves patient comfort compared to faster injection speeds and conventional methods.
223908042|NCT07056959|PROCEDURE|Soft tissue substitute for peri-implant phenotype modification|XCM (Mucograft©, Geistlich Pharma® AG, Wolhusen, Switzerland) placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification when
223908043|NCT07056959|PROCEDURE|Control Group - Free gingival graft for soft tissue augmentation|Free gingival graft around implants placed at the time of healing abutment connection and its impact on peri-implant soft tissue phenotype modification
223908044|NCT07062367|DRUG|Propofol|Patients' anesthesia will be maintained by manually adjusted propofol infusion at a rate of 100-250 mic/kg/min for bispectral index (BIS) maintained between 40-60.
223908045|NCT07062367|DRUG|Sevoflurane plus lidocaine infusion|Sevoflurane with monitored anesthesia care (MAC) adjusted to maintain bispectral index (BIS) between 40-60 plus intravenous lidocaine infusion given as 2mg /kg IV bolus before induction then intraoperative infusion by a rate of 2 mg/kg/h until the end of surgery.
223908046|NCT07062367|DRUG|Sevoflurane|Patients will receive sevoflurane with monitored anesthesia care (MAC) adjusted to maintain bispectral index (BIS) between 40-60.
223715875|NCT05928039|BIOLOGICAL|TNFa Antagonist - Adalimumab|• Adalimumab subcutaneously \[SC\] 160 mg at week 0, 80 mg at week 2, then 40 mg every 2 weeks
224083612|NCT03042936|BEHAVIORAL|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
224083613|NCT04228848|OTHER|new triple hop test|New jumping assessment will be performed in all included study groups. This new assessment includes quality evaluation.
224083614|NCT00706017|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224083615|NCT05152290|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224083616|NCT05016804|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223715876|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Ustekinumab|• Ustekinumab \~6 mg/kg IV x1, then 90 mg SC every 8 weeks
223715877|NCT05928039|BIOLOGICAL|Anti-IL12/23 or anti-IL23 - Risankizumab|• Risankizumab 600 mg IV at weeks 0, 4, and 8, then 360 mg SC every 8 weeks
224277201|NCT04304209|OTHER|Watch and wait|Watch and wait for cCR patients after neoadjuvant treatment
223715878|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV|• Vedolizumab 300 mg IV at weeks 0, 2, and 6, then every 8 weeks
223908047|NCT07062809|OTHER|Sub Occipital Myofascial release and (SNAGS).|The patient will instruct to be seated then will turned his head toward direction that will cause his dizziness. when subject will turn his head, The manual therapist will perform a constant PA glide (using his thumbs one over the other) to upper cervical C1 or C2 vertebra (Oriented toward patient's eyeballs). If flexion or extension movement will provoke the dizziness, an anterior glide will apply to the C2 spinous process. If rotation will provoke dizziness, then an anterior glide will be applied to the C1 transverse process.
223908048|NCT07062809|OTHER|Sub Occipital Myofascial release.|When using the technique, the patient will be in Upward-facing position with their head fully aided on the therapist's hands. The therapist will put three middle fingers simply inferior to the nuchal line, raise the tips of the fingers in the direction of the ceiling, and then simply pull them upward.
223908049|NCT07062627|GENETIC|Anbal-cel|"On Day 1 (D1), Anbal-cel will be administered only to subjects who meet the final inclusion/exclusion criteria for Anbal-cel administration before the infusion.~As premedication before Anbal-cel administration, acetaminophen or paracetamol, and diphenhydramine or H1 antihistamine will be given.~Anbal-cel will be administered as a single intravenous infusion on Day 1 within 30 minutes of thawing, at the dose presented in the following table:~Dose: 2x10\^6 (CAR-T cells/kg)\* Maximum 2 x 10\^8 cells"
223908050|NCT07063355|OTHER|Stripping Massage Technique:|"* The back of the neck and shoulder were uncovered.~* Controlled and steady pressure was administered using the thumb along the entirety of the tense trapezius muscle, moving from origin to insertion and perpendicular to the muscle fibers, for approximately 3 minutes, twice weekly over a period of 4 weeks.~* The pressure was progressively raised with each subsequent stroke, based on tolerance level."
223908051|NCT07063355|OTHER|Post-Isometric Relaxation (PIR)|"* During the PIR intervention, the patients rested in a supine position with their necks tilted to the side, away from the affected side, placing the upper trapezius muscle fibers in a stretched position.~* A moderate isometric contraction, around 75% of the patient's maximum effort, was performed by the upper trapezius and maintained for 5 seconds, followed by a 3-second relaxation phase.~* The therapist then gently mobilized the cervical spine to a new range of motion barrier.~* This sequence was repeated four times per session."
223908052|NCT07062536|DRUG|Oxaliplatin, 5FU, leucovorin|Administered as a single regimen every 2weeks
223908053|NCT07062536|DRUG|Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,|Administered alternately every 2weeks
223908054|NCT07062146|OTHER|reiki|Reiki sessions for 30 minutes, on Day-7 before the surgery and on D15 after the surgery
223908055|NCT07062146|OTHER|Sham (No Treatment)|Sham sessions for 30 minutes, on D-7 before the surgery and on D15 after the surgery,
223908056|NCT07062939|OTHER|postural drainage with ACBT|postural drainage and ACBT for 2 times a day for 30 min for 4 weeks.
223908057|NCT07062939|OTHER|flutter with ACBT|flutter with active cycle breathing technique for 30 min. for 4 week and 2 times a day.
223908058|NCT06783933|DIAGNOSTIC_TEST|surgical or interventional validation|surgical or interventional validation
223908059|NCT07062302|DEVICE|photobiomodulation|"The output of the photobiomodulation device is listed as below:~* Irradiation size: 15 cm × 10 cm~* Dual-wavelength: 660 nm + 850 nm~* Optical power density: 10 - 15 mW/cm2~* Dose density: 6J/cm2"
223908060|NCT07063121|BEHAVIORAL|Shadow's Edge mobile app|A mobile application adapted for Colombian youth that uses interactive storytelling, journaling, and emotional regulation activities to promote subjective well-being and resilience.
223908061|NCT07063121|BEHAVIORAL|Guide to Self-Awareness (GSEA)|A printed guide developed to promote emotional insight, mindfulness, self-awareness, and social-emotional skills through structured reflection activities. Designed to be used alongside the Shadow's Edge app.
223908062|NCT07063108|DRUG|Esketamine hydrochloride|Intravenous infusion of esketamine: after induction, a single dose of 0.25 mg/kg before skin incision，and continuous 0.125 mg/kg/h until 30 min before surgery was stopped.
223908063|NCT07063108|DRUG|Saline|after induction, a single intravenous infusion of an equal amount of 0.9% saline before skin incision, followed by a continuous infusion at the same rate as the test group until 30 min before surgical cessation.
223908064|NCT07062523|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 18.5-22.2MBq (0.5-0.6 mCi)/Kg 68Ga-FAPI. Tracer doses of 68Ga- FAPI will be used to image lesions of Sjögren's syndrome by PET/ CT.
223908065|NCT07063524|DEVICE|Electrical stimulation|Electrical stimulation with controlled heat during the intervention
223908066|NCT07062263|DRUG|Trastuzumab|Inj Trastuzumab given in a dose of 8mg/kg intravenously over 90 mins as first dose and subsequent doses at a dose of 6mg/kg intravenously over 30-60 minutes in 3 weekly cycle along with standard of care chemotherapy
223908067|NCT07062263|DRUG|Chemotherapy|Gemcitabine + cisplatin OR Gemcitabine-cisplatin-Nab-Paclitaxel given as a standard of care, chemotherapy as per the institutional guidlines
223908068|NCT04939038|PROCEDURE|Revascularization|Depending on the condition of the patients, patients will have either endovascular or surgical revascularization
223908069|NCT04939038|PROCEDURE|Standard wound care|Standard wound care according to guidelines
223908070|NCT04230681|DRUG|Hydromorphone|Patients will be randomized to one of two opioids for the treatment of post-operative pain.
223908071|NCT04230681|DRUG|Fentanyl|Fentanyl
224083617|NCT05607901|DRUG|Tacrolimus ointment|tacrolimus is an immunosuppressive drug acting as an immunomodulator to assist manage acute flares and reducing the severity of future flares
224083618|NCT05607901|DRUG|Hydrocortisone 1% cream|Topical corticosteroids (TCS) are the cornerstone for the management of AD to which other treatments are compared.
224083619|NCT06419933|OTHER|The SuperKids Program|The SuperKids program will be administered following the manual of the intervention by a trained therapist, as described in the section of intervention/ treatment
224083620|NCT02534636|DRUG|BMS-986165|
224083621|NCT02534636|DRUG|Interferon alpha-2a recombinant|
224083622|NCT02534636|DRUG|Famotidine|
224083623|NCT02534636|OTHER|Placebo|
224083624|NCT05869825|PROCEDURE|High Flow Nasal Canula following extubation|Participants in this group will be randomized to receive High Flow Nasal Cannula support after extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
224277202|NCT01625403|DRUG|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
224277203|NCT01625403|DRUG|standard of care|standard of care for heart failure
223908072|NCT06844526|OTHER|Hoping Exercise|Week 1 Hopping to the sides on two legs (hands-free) 3 × 10 repetitions Hopping to front and back on two legs (hands-free) 3 × 10 repetitions Hopping to the front on two legs (hands-free) 3 × 10 repetitions Week 2 Hopping to the sides on two legs (hands on the chest) 2 × 15 repetitions Hopping to front and back on two legs (hands-free) 2 × 10 repetitions Hopping to the sides on one leg (hands-free) 5 × 4 repetitions Week 3 Hopping to the sides on one leg (hands on the chest) 3 × 10 repetitions Hopping zig-zag on two legs (hands-free) 2 × 10 repetitions Week 4 Hopping zig-zag on one leg (hands-free) 2 × 10 repetitions Hopping through squares on two legs (hands-free) 2 × 10 repetitions Week 5 Hopping in 8-shape on two legs (hands-free) 2 × 10 repetitions Hopping through squares on one leg (hands-free) 2 × 10 repetitions Week 6 Hopping through squares on one leg (hands on the chest) 2 × 10 repetitions Hopping in 8-shape on one leg (hands-free) 2 × 10 repetitions
223908073|NCT06844526|OTHER|Core Stability Exercises|Week 1 Bridging in face-down position 3 × 20 s Bridging in the supine position 3 × 20 s Side bridging (right and left) 3 × 20 s Week 2 Lifting the leg in supine position (knee bent) 3 × 20 repetitions Rising opposite hand and foot in quadriceps 3 × 20 repetitions Cross-crunch abdominal muscles 3 × 20 repetitions Week 3 Bridging on a physioball 3 × 20 repetitions Cobra exercise on a physioball 3 × 20 repetitions Superman exercise 3 × 20 repetitions Week 4 Sit-up on a physioball 3 × 20 repetitions Rotating the trunk in a sitting position using a physioball 3 × 20 repetitions Week 5 Lunge exercise with trunk rotation using a medicine ball 3 × 20 repetitions Bridging on a physioball (leg raising alternately) 3 × 10 repetitions on each leg Week 6 Lunge exercise (back leg on a physioball) 3 × 10 repetitions on each leg Superman exercise (alternately) 3 × 10 repetitions on each side
223908074|NCT01266096|DRUG|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
223908075|NCT07061938|DRUG|ACE1831|ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.
223908076|NCT07061938|DRUG|Lymphodepleting chemotherapy|Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.
223908077|NCT06149338|DEVICE|Macintosh laryngoscope|Macintosh laryngoscope has been the gold standard for endotracheal intubation since the middle of 20th century. During laryngoscopy and direct vision of the vocal cords, an endotracheal tube is passed into the trachea, establishing the airway.
223908078|NCT06149338|DEVICE|Vie Scope|Vie Scope is a laryngoscope, whose function is relied on Seldinger technique. Firstly, bougie is passed through the translucent barrel of Vie Scope under direct vision between the vocal cords and into the trachea. Then, Vie Scope is removed and an endotracheal tube is passed over the bougie, which will be finally removed. The inflation of the endotracheal tube's cuff is followed by ventilation and confirmation of the tube placement.
223908079|NCT06682130|DRUG|Group A：Patients with PR or ctDNA positivity after salvage treatment|"1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15."
223908080|NCT06682130|PROCEDURE|Group B: Patients with CR and ctDNA negative after salvage treatment|Group B patients initiated ASCT treatment directly after evaluating the efficacy of salvage treatment
223908081|NCT06682130|DRUG|Group C: Patients with SD/PD after posterior treatment|"1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial."
223908082|NCT05727761|DRUG|pioglitazone-metformin|Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
223908083|NCT06554847|DRUG|611|subcutaneous injection
223908084|NCT06554847|DRUG|Placebo|subcutaneous injection
223908085|NCT06554847|DRUG|Topical corticosteroid|Topical
224083625|NCT05869825|PROCEDURE|Non-Invasive Positive Pressure Ventilation following extubation|Participants in this group will be randomized to receive NIPPV respiratory support following extubation. The patient will be clinically monitored and respiratory support will be escalated per a specific flow sheet. The patient will remain on this assigned air support method until they are either removed entirely from air support or need to be re-intubated with oxygen.
224277204|NCT03113396|DRUG|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
223528980|NCT05726968|DRUG|Pilocaine 2% (1.5 ml) and 25 ug fentany|"Patients will be randomly allocated into the study groups according to the list of random numbers. The study groups will be as follows:~* Group P1 (N 15): patients assigned to this group will receive intrathecal 30 mg (1.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).~* Group P2 (N 15): patient assigned to this group will receive intrathecal 40 mg (2 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml).~* Group P3 (N 15): patient assigned to this group will receive intrathecal 50 mg (2.5 ml) of prilocaine 2% + 25 ug fentanyl (0.5 ml)."
224277205|NCT03113396|DRUG|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
223528981|NCT04598425|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBTi)|Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
223908086|NCT06904612|DIETARY_SUPPLEMENT|Micronutrient fortified iodized salt|addition of folic acid, B12 and iron to iodized salt to be consumed daily and assess rise in serum levels.
223908087|NCT06628778|DRUG|Dalteparin|Dalteparin thromboprophylaxis administered subcutaneously twice daily (every 12 hours) from enrollment through pediatric intensive care unit discharge
223908088|NCT05619367|DRUG|Odronextamab|
223908089|NCT05868733|DRUG|Day 1 Lower Dose (2×106 pfu)|rVSV∆G-LASV-GPC
223908090|NCT05868733|DRUG|Day 1 Higher Dose (1×107 pfu)|rVSV∆G-LASV-GPC
223908091|NCT05868733|DRUG|Placebo|Placebo
223908092|NCT05467735|OTHER|Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.|Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
223908093|NCT05727670|PROCEDURE|exposure of the tooth crown|surgical exposure of the crown of a retentive tooth
223908094|NCT04173949|DRUG|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
223908095|NCT02065765|BIOLOGICAL|Ramucirumab|Administered intravenously (IV)
223908096|NCT05645757|DRUG|Ertapenem|A 1-beta methyl-carbapenem that is structurally related to beta-lactam antibiotics
223908097|NCT05645757|OTHER|Placebo|Placebo
223908098|NCT05645757|DRUG|WCK 6777|A combination of ertapenem (ERT) and zidebactam (ZID)
223908099|NCT05645757|DRUG|Zidebactam|A betaß-lactamase inhibitor and betaß-lactam enhancer from the diazabicyclooctane (DBO) class
223908100|NCT06342986|DRUG|FT536|FT536 is an allogeneic natural killer (NK)-cell immunotherapy produced from a clonal master humaninduced pluripotent stem cell (iPSC) line.
223908101|NCT06342986|DRUG|Fludarabine|Fludarabine 25 mg/m2 IV given on day -5. Given consecutively with CY.
223908102|NCT06342986|DRUG|CY|CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
223908103|NCT03924635|COMBINATION_PRODUCT|SYMBICORT and salbutamol|SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.
223908104|NCT05238103|COMBINATION_PRODUCT|Corrie Hybrid Cardiac Rehabilitation Program|The Corrie Hybrid Cardiac Rehabilitation Program is a multi-component intervention. It consists of the Corrie smartphone app for cardiovascular health optimization which is paired with wristband device (Apple Watch or Fitbit), Bluetooth-enabled Omron blood pressure monitor and exercise resistance bands. The program also includes individualized treatment plan development, setting health goals and communication with trained Corrie Health Coach. Furthermore, the intervention includes motivational text messages sent to participants throughout the study to aid with risk factor modification.
223908105|NCT00539591|DRUG|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
223908106|NCT00539591|DRUG|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
223908107|NCT00539591|DRUG|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
223528982|NCT05759767|DRUG|Tamsulosin|Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
223528983|NCT05759767|DRUG|Placebo|Children in this group will receive placebo once daily for 3 weeks after ESWL session.
223908108|NCT03937362|DIAGNOSTIC_TEST|First clinical response evaluation (CRE-1)|Consisting of: endoscopy with bite-on-bite biopsies
223908109|NCT03937362|DIAGNOSTIC_TEST|Second clinical response evaluation (CRE-2)|Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
223908110|NCT02398656|DRUG|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
223908111|NCT02398656|DRUG|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
223908112|NCT04765696|OTHER|No intervention is administered|No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.
223908113|NCT01293214|PROCEDURE|Limb transplantation|
223908114|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
223908115|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
224277206|NCT04602741|BEHAVIORAL|A4i Intervention|6 months of the provision of A4i on the individual's own device.
223715879|NCT05928039|BIOLOGICAL|Anti-integrin - Vedolizumab IV and SC|• Vedolizumab 300 mg IV at weeks 0 and 2, then 108 mg SC every 2 weeks
223908116|NCT02038777|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
223908117|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
223908118|NCT02038777|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
223908119|NCT02038777|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
223908120|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
223908121|NCT02038777|DRUG|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
223908122|NCT02038777|DRUG|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
223908123|NCT02038777|DRUG|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
223908124|NCT05811494|DEVICE|Lexo|Lexo is a Robot-Assited Gait device based on an end-effector system that supports the weight of the patient and help him to recover the walking function.
223908125|NCT05811494|DEVICE|Lokomat|Lokomat is a Robot-Assited Gait device based on a fixed exoskeleton that supports the weight of the patient and help him to recover the walking function guiding the hips, knees and feet of the patient while walking.
223908126|NCT05811494|DEVICE|C-Mill|C- Mill is a body weight support treadmill which includes virtual reality. I can provide feedback to the patient, assisting or hindering the gait task.
224277207|NCT03371524|OTHER|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
223908127|NCT05811494|DEVICE|Body-weight support treadmill|Body-weight support treadmill group will receive the same time and intensity of training like the robotic groups but using the treadmill
223528984|NCT00867152|DRUG|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
223715880|NCT01430390|BIOLOGICAL|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
223908128|NCT04299464|DRUG|Placebo|Participants will receive oral placebo for approximately 12 weeks.
223908129|NCT04299464|DRUG|RO7017773|Participants will receive oral RO7017773 for approximately 12 weeks.
223908130|NCT03493425|DRUG|Carboplatin|Given IV
223908131|NCT03493425|DRUG|Cisplatin|Given IV
223908132|NCT03493425|DRUG|Docetaxel|Given IV
223908133|NCT03493425|RADIATION|Image Guided Radiation Therapy|Undergo image guided IMRT
223908134|NCT03493425|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
223908135|NCT03493425|OTHER|Laboratory Biomarker Analysis|Correlative studies
223908136|NCT03493425|OTHER|Questionnaire Administration|Ancillary studies
223908137|NCT03493425|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
223908138|NCT05384756|DRUG|Alemtuzumab|Given IV
223908139|NCT05384756|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
223908140|NCT05384756|RADIATION|Intensity-Modulated Radiation Therapy|Undergo TMLI
223908141|NCT05384756|DRUG|Sirolimus|Medication to prevent the development of graft-versus-host disease (GVHD)
223908142|NCT04223765|DRUG|CAR.k.28|Three dose levels will be evaluated: Dose level 1 (5x10\^5 cells/kg), Dose level 2 (1x10\^6), and dose level 3 (2x10\^6 cells/kg).
223908143|NCT04223765|DRUG|Fludarabine|30 mg/m\^2/day IV for 3 consecutive days
223908144|NCT04223765|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for 3 consecutive days
223908145|NCT04223765|DRUG|Bendamustine|70 mg/m\^2/day administered over 3 consecutive days.
223528985|NCT00867152|DRUG|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
223528986|NCT00867152|DRUG|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
223528987|NCT00867152|DRUG|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
223528988|NCT00867152|DRUG|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
223908146|NCT04972201|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
223908147|NCT06839066|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223908148|NCT06839066|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223908149|NCT06839066|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
224277208|NCT02893163|BEHAVIORAL|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
224277209|NCT02893163|OTHER|Usual Care|Usual Care by Family Doctor
223528989|NCT01722669|DRUG|isoquercetin or quercetin|Single dose PK/PD study
223908150|NCT05359328|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line|Measurement of physiological parameters
223908151|NCT03676192|DRUG|CT-P16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
223908152|NCT03676192|DRUG|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
223908153|NCT06834438|GENETIC|ST002|Single multi-point intra-tumoral injection of ST002, a lentiviral vector designed to drive expression of the NF2 protein product, Merlin.
223908154|NCT05919589|OTHER|Care Integration for Children With Special Health Care Needs|The Evelina London Children's Hospital (ELCH) is planning to integrate care for children with special health care needs (CSHCN) using a package of support, including 1) family support workers to manage care coordination and support parents, and 2) 'navigation' packs outlining key services, for both the services users and providers
223908155|NCT06839118|DRUG|Botox 200 UNT Injection|A concentration of 50U/mL BTX-A is prepared using saline in four syringes: one with 1 mL, one with 0.8 mL, one with 0.7 mL, one with 0.6 mL. This equals a total administration dose of 155U. A total of 155U BTX-A will be injected at day 1 (first day in week 1) by subcutaneous injections according to the PREEMPT protocol.
223908156|NCT06322667|OTHER|No Intervention|This is a non-interventional study.
223908157|NCT06837168|DEVICE|Stainless steel fixed retainer|The Stainless steel fixed orthodontic retainer is fabricated from a 0.0215-inch, five-stranded stainless steel wire
223908158|NCT06837168|DEVICE|3D printed CAD/CAM Chrome cobalt fixed lingual retainers|CAD/CAM Chrome cobalt retainers; will be digitally designed by the dental technician using EXOCAD software. Then, they will be printed by DMP Flex100 metal 3D printer and then will be polished. Also, a projection like extensions will be added at the ends of the retainers to avoid slippage in addition to gingivally directed V notch shaped bend in the retainer to increase the retention in the anterior region
223908159|NCT05268510|DRUG|Pembrolizumab|400 mg Pembrolizumab day 1 Q6W (max. 18 cycles)
223908160|NCT05268510|DRUG|Olaparib|300 mg Olaparib bid. cont. day 1 to 42 (max. 16 cycles)
223908161|NCT05268510|DRUG|mFOLFOX-6|Oxaliplatin 85 mg/m² 2h day 1, 15, 29 plus Leucovorin 400 mg/m² 2h day 1, 15, 29 plus 5-FU 400 mg/m² bolus, followed by 2.400 mg/m² 46h day 1, 15, 29; Q6W, 2 cycles
223908162|NCT05268510|DRUG|CapOX|Oxaliplatin 130 mg/m² 2h day 1,22 plus Capecitabine 1.000 mg/m² bid. day 1-14, 22-35; Q6W, 2 cycles
223908163|NCT06252402|BIOLOGICAL|CMV/HIV-CAR T Cells|Eligible participants will temporarily interrupt their ART regimen for 4 days prior to leukapheresis to prevent residual cell drug levels that could inhibit lentiviral transduction of the T cells during CAR T cewll manufacturing. Participants will resume their ART regimen immediately after leukapheresis. Once the final cell product is released, participants will receive a single intravenous (IV)infusion of autologous CMV/HIV-CAT T cells (defined as Day 0). Up to three doses of CMV/HIV-CAR T cewlls may be explored.
223908164|NCT06836700|PROCEDURE|Mini PCNL|90 Participants underwent MINI PCNL in MIN PCNL arm and 90 Participants underwent Standard PCNL in Standard PCNL arm.
223908165|NCT06840652|DRUG|Baclofen|Safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease. The investigators will administer baclofen in increasing doses up to a maximum dose of 10 mg every 8 hours, evaluating the drug's tolerance and its effectiveness in achieving alcohol abstinence. Baclofen will be administered during the patient's hospitalization for decompensation of their liver disease, in patients followed up as outpatients in hepatology clinics, and in those managed as outpatients by psychiatrists specializing in addiction
223908166|NCT03924414|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
223908167|NCT03924414|OTHER|Placebo|Normal Saline 100 ml (placebo) IV infusion
223908168|NCT06259279|BEHAVIORAL|High intensity high impact exercise intervention|"Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~\- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes."
223908169|NCT05257759|OTHER|Usual care|Standard management offered in the intensive care unit
223908170|NCT05257759|OTHER|Electrostimulation|The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
223908171|NCT05257759|OTHER|Evaluation of the neuromuscular system|"Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition."
223908172|NCT04079218|DRUG|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
223908173|NCT03643107|DRUG|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
223908174|NCT03643107|COMBINATION_PRODUCT|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
223908175|NCT03743532|BEHAVIORAL|E-cigarette Switching|Participants provided with e-cigarette device and nicotine pods and advised to switch from combustible cigarettes to e-cigarettes.
223908176|NCT03743532|BEHAVIORAL|Financial Incentives|Participants earned incentives for carbon monoxide-verified combustible cigarette abstinence.
223908177|NCT05744024|DEVICE|Virtual Reality system|The intervention group 1 will be wearing the 'SyncVR' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, a controller, and a headphone. The SyncVR Relax \& Distract Application (SyncVR R\&D) will be used.
223908178|NCT05744024|OTHER|Headphones|Headphones with audio. The patients will be hearing their preferred audio, chosen by patient to relaxing and to offer distraction, through headphones during wound care.
223908179|NCT04200391|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
223908180|NCT06237218|BEHAVIORAL|COTID program|COTID is a support program for people with Alzheimer's disease, designed to help them remain at home, including their primary caregiver.
223908181|NCT06505187|DRUG|Celecoxib|200mg every 12 hours
223908182|NCT06505187|DRUG|Tylenol|650mg q6h
223908183|NCT06505187|DRUG|Oxycodone|5mg every 6 hours as needed
223908184|NCT06505187|DRUG|placebo|every 12 hours
223908185|NCT02694822|DRUG|Zalifrelimab|An anti-CTLA-4 monoclonal antibody.
223908186|NCT03841773|DRUG|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
223908187|NCT03841773|DRUG|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
223908188|NCT02424617|DRUG|Erlotinib|Participants received erlotinib 150 mg for the 21-day cycle.
223908189|NCT02424617|DRUG|Bemcentinib|Participants received bemcentinib 600 mg on Days 1 and 2 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
223908190|NCT02424617|DRUG|Bemcentinib|"Participants received starting loading dose of bemcentinib 600 mg (200 mg on Days 1, 2 and 3) and bemcentinib 100 mg as daily maintenance dose for the 21-day cycle.~Depending on tolerability and DLT, the loading dose of bemcentinib was escalated to 800mg (400 mg on Days 1 and 2) and bemcentinib 100 mg as daily maintenance for the 21- day cycle and to 1200 mg daily (600 mg on Days 1 and 2, or 400 mg on Days 1, 2 and 3) and bemcentinib 200 mg as daily maintenance for the 21- day cycle)."
223908191|NCT02424617|DRUG|Bemcentinib|Participants received bemcentinib 400 mg on Days 1, 2 and 3 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
223908192|NCT05869539|DRUG|Combination of Tumor-infiltrating lymphocyte transfer with ANV419|"The study uses a personalized IMP (investigational medicinal product), i.e. TIL product in combination with ANV419.~Day 0: Autologous TIL: (minimum 5 x 10\^9 and up to 2x 10\^11 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Intravenous treatment with ANV419 at 243 μg/kg 2 hours after the TIL infusion. Actual body weight will be used to calculate the dose of ANV419.~Day14: Intravenous treatment with ANV419 at 243 μg/kg. Actual body weight will be used to calculate the dose of ANV419."
223908193|NCT02766322|OTHER|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
223908194|NCT02766322|OTHER|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
223908195|NCT02766322|OTHER|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
223908196|NCT02766322|OTHER|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
223908197|NCT05814159|DRUG|Anakinra|sub cutaneous daily injection
224277210|NCT05761392|OTHER|Precise management|The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
224277211|NCT06384482|DRUG|SNC115 injection|SNC115 Injection is DLL3 CART.
224277212|NCT03269955|DRUG|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
224277213|NCT05467540|DEVICE|SPINERY|Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum
224277214|NCT02132650|BEHAVIORAL|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
224277215|NCT02132650|BEHAVIORAL|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
224277216|NCT03555136|DRUG|Vortioxetine|Treatment with vortioxetine as per local SmPC
223908198|NCT05814159|DRUG|Placebo|sub cutaneous daily injection
224277217|NCT00943813|BEHAVIORAL|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
224277218|NCT02169336|DRUG|Intranasal Dexmedetomidine|
224277219|NCT02169336|OTHER|Intranasal Placebo|
224277220|NCT01148225|DRUG|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
224277221|NCT02910687|OTHER|This is an observational study|
224277222|NCT06857045|DEVICE|NOVA intracranial sirolimus-eluting stent system|The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon.
224277223|NCT03434691|DEVICE|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
223908199|NCT06415955|OTHER|None, pure observationnal study|None, pure observationnal study
223908200|NCT01722812|DRUG|Cromoglicate|Twice daily topical treatment for 14 days
223908201|NCT01722812|DRUG|Placebo|Twice daily topical treatment for 14 days
223908202|NCT05912634|PROCEDURE|Conservative TAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
223908203|NCT05912634|PROCEDURE|Extensive TAAD- R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total arch)
223908204|NCT06278558|OTHER|Interviews with a psychologist/psychiatrist|All patients with a high score (≥11) on the HADS anxiety and/or depressive symptoms scale and who are not already receiving known psychological treatment or treatment mentioned in the file will be contacted by telephone by the investigator or a qualified person designated by him/her in order to conduct a telephone interview with the patient and refer him/her to a psychologist or psychiatrist if necessary. The number and percentage of consultations with a psychologist or psychiatrist following this telephone interview will be calculated in order to highlight the benefits of such a practice (HADS assessment + telephone interview with +/- referral) for earlier and easier referral. Depending on the number of patients contacted, consideration may be given to testing the effect of this approach on post-traumatic development.
223908205|NCT04118439|OTHER|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
223908206|NCT05419687|BEHAVIORAL|Training in de-escalating violence|"* Individual educational component through a de-escalating violence training for health care workers (verbal and non-verbal de-escalating techniques)~* Refreshment training in the form of collaborative learning"
223908207|NCT05419687|BEHAVIORAL|Code of conduct delivered via a warning board|A publicly displayed code of conduct (a co-designed set of rules) for both HCWs and clients, delivered via a warning board at the level of the health facilities and secondary hospitals
223908208|NCT01868997|DRUG|teprotumumab|
223908209|NCT01868997|DRUG|normal saline|
223908210|NCT03811886|DRUG|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
223908211|NCT06521866|DRUG|Serplulimab|IV 3 mg/kg on Day 1, q2w
223908212|NCT06521866|DRUG|Chemotherapy|"Induction therapy：Oxaliplatin: 85 mg/m² IV on Day 1 Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours~Maintenance therapy:~Leucovorin (LV): 400 mg/m² IV on Day 1 5-FU: 400 mg/m² IV bolus on Day 1, then 2400 mg/m² continuous IV infusion over 46-48 hours"
223908213|NCT06521866|RADIATION|SABR|SABR: 25-60 Gy/5 Fx
223908214|NCT06521866|DRUG|Targeted therapy|Cetuximab: 400 mg/m² IV on Day 1, then 250 mg/m² IV weekly ; Bevacizumab: 5 mg/kg IV on Day 1
223908215|NCT01960452|BEHAVIORAL|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
223908216|NCT04742075|DRUG|Olaparib + durvalumab + UV1|The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
224083626|NCT00744900|DRUG|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
224083627|NCT06485219|DRUG|11.2 mg/m2 Purinostat Mesylate|Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.
224083628|NCT06485219|DRUG|15 mg/m2 Purinostat Mesylate|Purinostat Mesylate for Injection: Intravenous infusion, The subjects were given intravenous drip injections once on D1, D4, D8 and D11 of each dosing cycle, with a dosing cycle lasting for 21 days. The overall duration of the longest administration period shall not exceed 96 weeks.
224083629|NCT00573001|DRUG|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
223908217|NCT06162390|DRUG|Remifentanil|"Following a sequential allocation scheme, the predetermined Ce of remifentanil for each patient will be determined by the Dixon up-and-down method. The Ce of remifentanil for the first patient will be 4.0 ng/ml, and then the remifentanil Ce will be increased or decreased in 0.5 ng/ml increments for subsequent patients depending on the success or failure of intubation.~The Ce of remifentanil to provide acceptable intubation at low dose neuromuscular blockade, the primary outcome, will be determined by obtaining seven crossovers of patients with acceptable intubation/unacceptable intubation and then calculating the mean of the midpoint doses for each independent pair of patients. According to previous studies that estimated EC50 by Dixon's up-and-down method, 6-8 failure/success crossover pairs are required, so this study aims to collect independent data of 7 pairs of intubation acceptable/unacceptable patients."
223908218|NCT03592693|DRUG|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
223908219|NCT03592693|DRUG|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
223908220|NCT03943004|DRUG|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
223908221|NCT06789315|DRUG|Mycophenolate Mofetil|MMF at a dose of 750 mg twice daily for a period of 28 days,
223908222|NCT06789315|DRUG|Prednisone|Prednisone at a dose of 40 mg for 28 days.
223908223|NCT04533737|BIOLOGICAL|Brodalumab|Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection
223908224|NCT04533737|OTHER|Placebo|The placebo solution is similar to the active guselkumab (Dummy 1) or brodalumab (Dummy 2) solution except that it does not contain any active substance
223908225|NCT04533737|BIOLOGICAL|Guselkumab|Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection
223908226|NCT04273594|DEVICE|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
223908227|NCT06024564|DEVICE|Sonu Acoustic Resonance Therapy|Participants will receive Sonu treatment twice a day for 90 days
223908228|NCT06557512|RADIATION|Hypofractionated Stereotactic Radiosurgery (SRS)|Undergo Hypofractionated Stereotactic Radiosurgery
223908229|NCT06557512|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI
223908230|NCT06557512|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
223908231|NCT05753215|DRUG|Omadacycline Pill|Omadacycline will be administered 300 mg orally daily without the loading dose.
223908232|NCT05753215|DRUG|Standard of Care|Prior to randomization, SOC antibacterial therapy will be selected by the subject's treating physician.
223908233|NCT05649410|OTHER|mobilization with movement and conventional therapy|Mobilization with movement for Flexion, Abduction, Internal rotation, external rotation
223908234|NCT05649410|OTHER|sleeper stretch along with conventional therapy|it will be performed with the patient in side lying on the affected side to stabilize the scapula against the table and both the shoulder and elbow flexed to 90°.In this position, passive Internal Rotation is applied to the affected shoulder by the therapist or patients opposite hand.
223908235|NCT06528184|DIAGNOSTIC_TEST|Self-sampled HPV DNA testing|Participants will be offered HPV DNA testing done through self-sampling (using self-sampling HPV DNA kits to obtain a mid-vaginal swab)
223908236|NCT06528184|DIAGNOSTIC_TEST|Clinician-sampled HPV DNA test|Participants will be offered HPV DNA testing through clinician sampling (clinician-sampling (speculum examination by a nurse to obtain a cervical swab)
223908237|NCT04169893|DRUG|Placebo (fasting)|Participants will receive placebo once in fasting condition
223908238|NCT04169893|DRUG|Placebo (feeding)|Participants will receive placebo once after meal condition
223908239|NCT04169893|DRUG|1 mg of TS-142|Participants will receive 1 mg of TS-142 once in fasting condition
223908240|NCT04169893|DRUG|3 mg of TS-142|Participants will receive 3 mg of TS-142 once in fasting condition
223908241|NCT04169893|DRUG|10 mg of TS-142 (fasting)|Participants will receive 10 mg of TS-142 once in fasting condition
224083630|NCT00573001|DRUG|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
223908242|NCT04169893|DRUG|10 mg of TS-142 (feeding)|Participants will receive 10 mg of TS-142 once after meal condition
223528990|NCT05335434|DEVICE|THOR LX2.3 with LED Lollipop|The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration
223908243|NCT04169893|DRUG|30 mg of TS-142|Participants will receive 30 mg of TS-142 once in fasting condition
223908244|NCT03916276|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
223908245|NCT03916276|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
223908246|NCT03916276|BEHAVIORAL|Behavioral Activation (BA)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
223908247|NCT06568731|DRUG|Danuglipron|Danuglipron oral tablets
223908248|NCT05926739|DEVICE|Electrical stimulation and biofeedback with Phenix Liberty medical device|"12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session"
224083631|NCT00573001|DRUG|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
224083632|NCT00573001|DRUG|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
224083633|NCT01893398|OTHER|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
224083634|NCT06143527|BIOLOGICAL|AlloRx|Cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224083635|NCT01677715|DIETARY_SUPPLEMENT|"Yili Mei Yi Tian active lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
224083636|NCT01677715|DIETARY_SUPPLEMENT|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
224083637|NCT01445678|DRUG|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
224083638|NCT01445678|DRUG|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
224083639|NCT02307370|DEVICE|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
224083640|NCT01744132|BEHAVIORAL|Aim 3: Contract|
224083641|NCT05233956|DEVICE|LNG IUS|Avibela®: Levonorgestrel intrauterine system (LNG IUS) containing 52mg of LNG, released in the uterine cavity at approximately 19mcg per day.
223908249|NCT03825107|OTHER|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
223908250|NCT03825107|OTHER|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
224083642|NCT05233956|DRUG|COCs|FemiplanTM: Combined oral contraceptives in a 21/7 pill package (21 pills of 0.15 mg of LNG and 30 mcg of EE followed by 7 pills containing 75 mg of ferrous fumarate).
224083643|NCT06438822|COMBINATION_PRODUCT|Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil|cadonilimab at a dosage of 6 mg/kg on day 1 combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2 for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m2 for 30 min on day 1 and fluorouracil at a dosage of 2400 mg/m2 for 46 h every 2 weeks.
224083644|NCT06201910|OTHER|Observation of Blood loss|Retrospetive observation of bloodloss and RBC transfusions.
224083645|NCT05992467|BEHAVIORAL|Wellness Enhancement for Caregivers (WECARE)|WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
224083646|NCT06333145|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in adults of different BMI groups undergoing drug-induced sleep endoscopy
224083647|NCT06960174|DEVICE|Virtual reality|If the participant is assigned to the intervention group a 3D virtual model will be constructed. For the intervention group the CT + VR will be reviewed during preoperative planning.
224083648|NCT06961149|PROCEDURE|Chromoendoscopy with indigo carmine solution spray|Patients will undergo chromoendoscopy with spraying indigo carmine.
224083649|NCT06961149|PROCEDURE|Linked-color imaging endoscopy|Patients will undergo Linked-color imaging endoscopy.
224083650|NCT04837417|DIAGNOSTIC_TEST|Pathologic group|"Voluntary Activation level will be determined with the interpolate twitch technique (ITT), both during isometric contractions (knee at 40° flexion) and during isokinetic contraction at angular velocity equal to 100°/s.~Vastus Medialis and Soleous H-reflex will be measured. Cortical excitability and interhemispheric connectivity will be measured through transcranial magnetic stimulation (TMS).~Tests of balance in standing will be performed using the EquiTest platform. Individuals will be requested to perform three different tasks: Sensory Organization test, Adaptation Test upward/downward, Motor Control test backward/forward. Surface electromyography from lower limbs will be recorded.~Through TMS driven by neuronavigation, the cortical representation of the Quadriceps muscle will be studied.~Gait analysis will be performed on a treadmill mounted on force sensors. Participants will walk at increasing velocities from 0.4 m/s to 1.6 m/s. Speed will be increased of 0.2 m/s every 30 s."
224083651|NCT05231213|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
223908251|NCT06568432|DEVICE|CRP+SAA POCT|CRP+SAA POCT will be provided in 20 village clinics in the intervention group
223908252|NCT06506734|OTHER|Questionnaires|"*  Psychosocial Impact of Dental Aesthetics Questionnaire  PMID 24280547~*  Orofacial Esthetic Scale  PMID 30856637~*  Orofacial Esthetic Scale  PMID 34231057~* A photograph of the patient's smile will be sent to 2 dentists who will also assess the presence or absence of dental dyschromia."
223908253|NCT06569095|OTHER|Detection of MDS-SC using MFC|The aim of this study is to investigate the predictive values of MDS-SC determined by MFC for patients with MDS-EB who underwent allotransplantation.
223908254|NCT06384404|OTHER|Questionnaire|PROMIS questionnaire
224083652|NCT05231213|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
224083653|NCT05900115|BEHAVIORAL|Media Ready Parent|The intervention is a web-based resource that provides parents with media literacy and media mediation skills, knowledge about adolescent development and substance use, and practice in high quality parent-child communication.
224083654|NCT05900115|BEHAVIORAL|Active Control Program|The active control is a web-based resource that contains PDFs of medically accurate information about adolescent substance use.
224083655|NCT05906394|PROCEDURE|Posterolateral Fusion|Posterolateral spinal fusion is a neurosurgical or orthopaedic surgical technique that joins two or more vertebrae. This procedure can be performed at any level in the spine (cervical, thoracic, lumbar, or sacral) and prevents any movement between the fused vertebrae.
224083656|NCT05632354|DRUG|Osivelotor|Osivelotor
223908255|NCT06168825|OTHER|Mind Over Matter (MOM)|"Each participant's involvement in the study will include:~* Attending a Pre-Program Orientation which will be held a week before the first MOM Session.~* Completing 5 weekly sessions of MOM~* Completing 2 surveys; one will be given before the start of the intervention (a pre-test) and the other will be given after the last MOM Session (a post-test)~Participants will also have the option to participate in an optional Focus Group session which will occur a week after the last MOM Session ends~Participants will spend about 6 weeks in this study. If they decide to participate in the optional session, they will spend about 7 weeks in this study.~Please note, this entire Intervention will be offered online. There will be no in-person sessions or visits."
223908256|NCT00306215|DRUG|CCX282-B|CCX282-B or placebo capsules
223908257|NCT06569056|DRUG|HRS-8427|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
223908258|NCT06569056|DRUG|Imipenem and Cilastatin Sodium|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
223908259|NCT06569056|DRUG|HRS-8427 placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
223908260|NCT06569056|DRUG|Imipenem and Cilastatin Sodium placebo|Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
223908261|NCT03209973|DRUG|Tislelizumab|Administered as specified in the treatment arm
223908262|NCT03027102|BIOLOGICAL|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
223908263|NCT05754177|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days
223908264|NCT05754177|OTHER|Placebo|Participants in this arm will receive an equivalent placebo for 84 days.
224083657|NCT02796573|BEHAVIORAL|cognitive behavioural therapy|
224083658|NCT04610658|DRUG|Nivolumab|Participants will receive 1 mg/kg Nivolumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 treatment cycles, Nivolumab will be continued at a flat dose of 360 mg.
223908265|NCT02852538|BEHAVIORAL|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
223715881|NCT01430390|DRUG|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
223715882|NCT04851834|DRUG|NTX-301|Oral hypomethylating agent
223908266|NCT05256940|BEHAVIORAL|Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)|Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.
223908267|NCT05256940|OTHER|Enhanced usual care (EUC)|Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
223908268|NCT02622217|BEHAVIORAL|Sleep deprivation|
223908269|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
223908270|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
223908271|NCT05613478|PROCEDURE|Radical surgery|Radical surgery
223908272|NCT05613478|PROCEDURE|Preoperative TACE treatment|TACE treatment before preoperative camrelizumab combined with apatinib mesylate
223908273|NCT05613478|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q3w (at least 6 cycles) after radical surgery
223908274|NCT05613478|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (at least 6 cycles) after radical surgery
224083659|NCT04610658|DRUG|Ipilimumab|Participants will receive 3mg/kg Ipilimumab on Day 1 of each treatment cycle for 4 cycles (induction immunotherapy). After 4 cycles, Ipilimumab will be discontinued.
224277224|NCT03434691|DRUG|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
224083660|NCT04610658|DRUG|Lurbinectedin|Participants will be treated at 1 of 3 dose levels of Lurbinectedin, beginning at 1.5 mg/m\^2 and increasing to 3.2 mg/m\^2 or the Maximum Tolerated Dose (MTD)
224083661|NCT01097772|DEVICE|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
224083662|NCT04183985|DEVICE|Total knee arthroplasty prosthesis|In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
224277225|NCT03671187|OTHER|Exercise|8 week exercise program
224277226|NCT03734458|OTHER|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
224277227|NCT03734458|OTHER|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
224083663|NCT03782454|DIAGNOSTIC_TEST|Blood sampling|Blood samples taken every third hour during the first 48 hours of intensive care
224083664|NCT02644226|OTHER|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
224083665|NCT02644226|OTHER|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
223908275|NCT05305495|DRUG|Empagliflozin 25 MG|Patients who fulfill the inclusion criteria will receive an intravenous dose of 1.0-1.5 mg/kg of furosemide (≤120 mg) and urine output will be monitored for three hours. Those with a urine output \< 300 ml in the first two hours post furosemide administration will receive a single oral dose of 25 mg of empagliflozin. Two hours after taking empagliflozin, patients will receive a second intravenous dose of 1.0-1.5 mg/kg of furosemide with another timed urine collection at three hours. Empagliflozin will then be continued daily for five days or until hospital discharge, unless the treating physician considers this not to be clinically appropriate.
223908276|NCT06106906|BIOLOGICAL|CD19 CAR-T cell infusion|CD19 CAR-T cell intravenous infusion
223908277|NCT05267873|DRUG|Duloxetine, Vortioxetine|Medications for major depressive disorder
223908278|NCT04959552|DEVICE|FreeStyle Libre 2|The FreeStyle Libre 2 Flash Glucose Monitoring
223908279|NCT05219175|DRUG|MDMA Assisted Therapy|"The intervention is MDMA Assisted Therapy focused on PTSD and three experiment sessions with the first session using an initial dose of 100 mg MDMA HCL (\~80 mg MDMA) with supplemental dose of 40 mg MDMA HCL (\~35 mg MDMA). Total dose range for the first session is 100 mg MDMA HCL (\~80 mg MDMA) to 140 mg MDMA HCL (\~115 mg MDMA).The second and third sessions may use an initial dose of 120 mg MDMA HCL (\~100 mg MDMA) with a supplemental dose of 60 mg MDMA HCL (\~50 mg MDMA) for a total dose range of 120 mg MDMA HCL (\~100 mg MDMA) to 180 mg MDMA HCL (\~160 mg MDMA)~Total cumulative dose range for the three sessions is 340mg MDMA HCL (\~280 mg MDMA) to 500 mg MDMA HCL (\~435 mg MDMA)"
224083666|NCT01542645|DRUG|Methadone|Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
224083667|NCT01542645|DRUG|Fentanyl|Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
224083668|NCT01559909|DEVICE|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
224083669|NCT00388947|DEVICE|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
224083670|NCT03547557|DEVICE|Exablate 2000 strappable system|
224083671|NCT04187092|OTHER|KneeBright Group|"The KneeBRIGHT group will use KneeBright device which consists of an EMG biofeedback interface software that guides users through exercise routines. The wireless EMG sensors includes two small electrodes that will be made to stick to the quadriceps muscles both sides. KneeBRIGHT software features a virtual world wherein patients complete challenges controlling the in-game avatar with the EMG units during exercises specific to knee osteoarthritis rehabilitation.~The KneeBRIGHT software will incorporates a variety of exercises for strengthening the quadriceps and will employ algorithms based on the Daily Adjustable Progressive Resistance Exercise (DAPRE) technique, in which the quantity of repetitions performed in these sets is then used to determine the appropriate increase (or possibly decrease) in target resistance for the next sets/sessions."
224083672|NCT04187092|OTHER|Standard Rehabilitation group|Participants in this group will undergo standard clinic based knee rehabilitation. Both groups will perform exact same exercises, however, no KneeBRIGHT device will be used in this group.
224083673|NCT00278876|DRUG|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
224083674|NCT00565994|PROCEDURE|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
224083675|NCT00945919|DRUG|Oxymorphone ER|Rapid Opioid rotation/titration
224083676|NCT01630525|OTHER|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
224083677|NCT01630525|OTHER|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
223908280|NCT04766892|DRUG|mavacamten|mavacamten capsules
224277228|NCT03734458|OTHER|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
224277229|NCT01601353|DEVICE|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
223908281|NCT06348251|BEHAVIORAL|FoodSteps|Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
224277230|NCT04543084|BEHAVIORAL|Logbook|Participants will record practice in a logbook.
224277231|NCT00168558|BIOLOGICAL|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
223715883|NCT04851834|DRUG|Platinum-based Chemotherapy|Standard of care for ovarian and bladder cancer
223715884|NCT04851834|DRUG|Temozolomide|Standard of care for high-grade glioma
223715885|NCT05226663|PROCEDURE|Computed Tomography|Undergo \[18F\]FFT PET/CT
223908282|NCT05879536|DRUG|Tramadol-ondansetron continuous infusion|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
223908283|NCT05879536|DRUG|Ropivacaine via epidural catheter|Analgesia strategy determined by routine use according to protocols, without investigator intervention.
223908284|NCT05069168|DIAGNOSTIC_TEST|Echocardiography before and after TAVR|"Evaluation of severity of aortic stenosis using :peak velocity ,peak and mean pressure gradient and aortic valve area by continuity equation.-Evaluation of left ventricular dimensions ,volumes and systolic function as assessed by ejection fraction (EF) by m-mode and biplane simpson's method at apical 4 and 2 chambers view Speckle tracking echocardiography(STE) Apical four-, three-, and two-chamber views were used to obtain longitudinal and circumferential strain before and follow-up after TAVR.~cardiac CT :Routine full protocol before TAVR for evaluation and Detection and calculation of left ventricular fibrosis using extracellular volume.~Coronary angiography:evaluate the presence of CAD and calculation of syntax score(SS)"
223908285|NCT02294435|DEVICE|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
223908286|NCT02294435|DEVICE|Unitary Manifold|Unitary Manifold Endovascular stent graft system
224083678|NCT01630525|OTHER|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
224083679|NCT00544869|DRUG|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
223908287|NCT04778397|DRUG|Magrolimab|Administered intravenously (IV).
223908288|NCT04778397|DRUG|Venetoclax|Administered orally at a dose of 100 milligrams (mg) on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle (Cycle=28 days).
223908289|NCT04778397|DRUG|Azacitidine|Administered either subcutaneously (SC) or IV, 75 milligrams per square meter (mg/m\^2) on Days 1-7 or Days 1-5, 8 and 9 during every cycle (Cycle=28 days).
223908290|NCT04778397|DRUG|Cytarabine|"Induction: administered continuous infusion, 100 or 200 mg/m\^2 on Days 1-7 (7+3 induction) and if needed Days 1-5 (5+2 induction) during a cycle (Cycle=Up to 42 Days).~Consolidation: administered IV, 1500 or 3000 mg/m\^2 on Days 1, 3, and 5 once every 12 hours for up to 4 cycles."
223908291|NCT04778397|DRUG|Daunorubicin|Administered IV peripherally (IVP), 60 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
223908292|NCT04778397|DRUG|Idarubicin|Administered IV, 12 mg/m\^2 on Days 1-3 (7+3 induction) and if needed Days 1-2 (5+2 induction) during a cycle (Cycle=Up to 42 days).
223908293|NCT04778397|DRUG|Steroidal Eye Drops|Administered per institutional standard during consolidation.
224083680|NCT00239850|BEHAVIORAL|lifestyle changes|
223908294|NCT06011213|BEHAVIORAL|Issuing health risk warning for a heat waves or cold spells|Whenever a health risk warning for a heat waves or cold spells is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
223908295|NCT06011213|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
223908296|NCT06011213|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and ECG
223908297|NCT06011213|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
223908298|NCT04027140|DEVICE|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
223908299|NCT04469712|PROCEDURE|SASI Bipartition|SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus.
223908300|NCT04469712|PROCEDURE|Gastric bypass|A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler.
223908301|NCT04511364|OTHER|Clinical imaging is performed during the 24 and 60 month follow-up visits|X-ray and DXA scan
223908302|NCT04246671|BIOLOGICAL|TAEK-VAC-HerBy|TAEK-VAC-HerBy will be administered intravenously every three weeks with three administrations in total at the dose defined in stage 1. During stage 2, it may also be administered concurrently with a HER2 antibody(ies) (trastuzumab, pertuzumab).
224083681|NCT01903265|DRUG|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
224083682|NCT01903265|DRUG|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
224083683|NCT03607279|PROCEDURE|NGAL|
224083684|NCT03712826|DRUG|Anti-TNF Drug|Crohn patient with antiTNF treatment
224083685|NCT03712826|DRUG|Ustekinumab|Crohn disease with ustekinumab treatment
224083686|NCT04175145|OTHER|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
224083687|NCT00619502|BIOLOGICAL|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
224277232|NCT01906190|BIOLOGICAL|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
223715886|NCT05226663|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
223908303|NCT06045416|PROCEDURE|venous blood puncture|"Venous blood puncture performed at first hospital contact, and at 28 days, 3 month, and 6 months after hospital admission.~Lumbar puncture and joint puncture for the study will be performed if it is indicated due to diagnostic or therapeutic reasons."
223908304|NCT03249090|OTHER|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
223908305|NCT03249090|OTHER|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
223908306|NCT05949281|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine 0.5 mg once-daily
223908307|NCT05949281|DRUG|Placebo|Placebo tablet once-daily
223908308|NCT06368479|DEVICE|iStatis HBsAg Test|Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.
223908309|NCT05690685|DEVICE|Silver I Alginate Non-Woven Dressing (Hydro-Alginate)|"Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver I Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change up-to six-week follow-up period."
223908310|NCT06131281|PROCEDURE|E-TORe|The E-TORe utilizes ESD in addition to APC prior to endoscopic suturing. In this approach, a standardized solution of normal saline or hetastarch mixed with methylene blue and epinephrine is injected into the gastric rim of the GJA outlet. The mucosa is then carefully incised to expose the underlying muscular layer for a width of approximately 1cm around the GJA circumference. Following ESD, APC is then applied to the inner and outer mucosal margins of the ESD tract. Finally, endoscopic sutures are then placed in purse string fashion and cinched closed around a 6mm TTS balloon.
223908311|NCT06131281|PROCEDURE|c-TORe|The c-TORe will be completed utilizing APC prior to endoscopic suturing. In this approach, the gastric rim of the anastomosis is circumferentially ablated using APC (forced APC, flow of 0.8 L/min and power of 30-70 watts) extending an average of 1-2 cm from the outlet. Following ablation, endoscopic sutures are placed in a purse string fashion within the ablated area and the outlet cinched closed over a 6mm through-the scope (TTS) balloon.
223908312|NCT06085547|BEHAVIORAL|General SARS-CoV-2 Communication|SARS-CoV-2 video tutorial is for general consumption and does not include rural-targeted information
224083688|NCT04644848|DIAGNOSTIC_TEST|Ultrasonographical tattooing of suspicious axillary lymph nodes.|"Patients with clinically negative axillae scheduled for sentinel lymph node biopsy (SLNB) will have axillary ultrasonographical imaging of the ipsilateral axilla with a high-frequency linear probe. Suspicious lymph nodes are identified according to any of the following criteria:~* Round shape.~* Cortical thickness \> 3 mm~* Eccentric cortical thickness.~* Loss of hilum.~For each patient, node dimensions and the presence of each of the above-mentioned criteria are recorded. Tattooing of all suspicious nodes is done using I ml of sterile liquid charcoal."
224083689|NCT04644848|PROCEDURE|Sentinel lymph node biopsy|Sentinel node biopsy is performed with peri-areolar subdermal injection of 3 ml methylene blue 5%. The lymphatics are tracked to the first blue lymph node. All blue, enlarged and /or tattooed nodes are separately biopsied and labelled as SLN and/or tattooed node.
224083690|NCT04644848|DIAGNOSTIC_TEST|Histopathological examination of the axillary nodes|"All tattooed nodes are excised and sent to frozen section examination; labelled tattoo node.~All enlarged or blue stained nodes are excised and sent to frozen section examination; labelled sentinel node.~All nodes are bisected and a single 5 um section examined. All frozen section examinations are followed by routine paraffin section examination."
224083691|NCT04644848|PROCEDURE|Further axillary management|Further axillary management is performed as per institutional guidelines. If SLNB is negative, no further surgery is required. Axillary lymph node dissection is performed if sentinel lymph node is positive or not identified. Management of positive SLNB as per the American College Of Surgeons' Oncology Group (ACOSOG) Z0011 protocol is not currently adopted on routine basis at the investigators' institution. In this study, patients with tattooed nodes with positive histopathological findings are offered full axillary dissection even if their sentinel nodes are negative.
224083692|NCT02688517|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
224083693|NCT02688517|OTHER|Laboratory Biomarker Analysis|Correlative studies
224277233|NCT03668457|BEHAVIORAL|Intervention to Patients|"Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app."
224277234|NCT03668457|BEHAVIORAL|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
223715887|NCT05226663|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FFT PET/CT
223908313|NCT06085547|BEHAVIORAL|Rural-Targeted SARS-CoV-2 Communication|SARS-CoV-2 video tutorial includes a two and a half minute video based messaging adjunct meant to enact a rural-targeted framing of health information presented to White rural individuals.
223908314|NCT05157282|DEVICE|TESS|Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
223908315|NCT05157282|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
223908316|NCT05157282|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
223908317|NCT05157282|DEVICE|sham-TESS|Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
223908318|NCT05534945|DRUG|Programmed intermittent epidural bolus 5 ml|patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
223908319|NCT05534945|DRUG|Programmed intermittent epidural bolus 6 ml|patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
223908320|NCT05534945|DRUG|Programmed intermittent epidural bolus 7 ml|patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
223908321|NCT05534945|DRUG|Programmed intermittent epidural bolus 8 ml|patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
223908322|NCT05534945|DRUG|Programmed intermittent epidural bolus 9 ml|patients in this group will receive a programmed epidural intermittent bolus of 9 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
223908323|NCT05534945|DRUG|Programmed intermittent epidural bolus 10 ml|patients in this group will receive a programmed epidural intermittent bolus of 10 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
223908324|NCT02368041|DEVICE|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
223908325|NCT06184984|DIETARY_SUPPLEMENT|Metabolic availability of methionine in mung beans|Each participant will randomly receive 7 different levels of methionine provided as free amino acids and cooked mung beans.
223908326|NCT04110522|OTHER|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
223908327|NCT06849492|DRUG|Camrelizumab|PD-1 inhibitor
223908328|NCT06849492|DRUG|Nab-paclitaxel|chemotherapy
223908329|NCT06849492|DRUG|SKB264|Trop2-ADC
223908330|NCT06849492|DRUG|Lenvatinib|Anti-angiogenic TKI
223908331|NCT06852989|OTHER|Shared book reading intervention|The study group participated in a parent training program focusing on shared interactive reading practices and attended nine read-aloud meetings with their children under the supervision of a trained librarian.
223908332|NCT06850935|OTHER|Centella asiatica extracellular vesicle formulation|Water-based formulation containing purified Centella asiatica extracellular vesicle as main active ingredient. Applied twice daily at two drops per use to the face after face cleansing for 28 consecutive days.
223908333|NCT06851221|DIAGNOSTIC_TEST|beta3 expression|the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor
223908334|NCT06786611|DIAGNOSTIC_TEST|MRI|Based on the different manifestations of facet joints under MRI, and with the help of the characteristic manifestations of the gray value curve of facet joints under different subtypes, the curve of facet joints under the same level is fitted, and finally the accurate evaluation of different subtypes of small joints is achieved.
223908335|NCT04098874|DRUG|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
223908336|NCT04098874|DRUG|Placebo oral tablet|12 weeks postpartum of blinded placebo
223908337|NCT06851975|OTHER|blood sampling|36ml of blood will be taken during a blood sampling performed in standard practice
223908338|NCT06847984|DIETARY_SUPPLEMENT|Curcumin|"Participants were instructed to rinse with 10 mL of mouthwash for~1 minute, once daily for 1 week of each month. This regimen will be repeated monthly for a period of 1 year."
223908339|NCT06847984|OTHER|Chlorohexidine|Participants were instructed to rinse with 10 mL of mouthwash for 1 minute, once daily for 1 week of each month. This regimen will be repeated monthly for a period of 1 year
223908340|NCT05066854|PROCEDURE|integron research|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose."
223908341|NCT05066854|PROCEDURE|usual practice|"Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines."
223908342|NCT06544187|DIAGNOSTIC_TEST|MRS scan|Magnetic Resonance Spectroscopy scan on the thigh
223908343|NCT06544187|DIAGNOSTIC_TEST|CPET|Cardiopulmonary Exercise Test
223908344|NCT06851832|BIOLOGICAL|Recombinant zoster vaccine(CHO cell)(low adjuvant)|The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 50 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
223908345|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell)|"The dosage for each administration is 0.5 mL, containing 50 μg of gE, 0.25 mL of MF59, and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle.~Vaccination Schedule 1: A total of two doses will be given, with the second dose administered 30 days after the first dose.~Vaccination Schedule 2: A total of two doses will be given, with the second dose administered 60 days after the first dose \[only applicable to the Phase II Experimental Vaccine Group B2\]."
224083694|NCT03702725|DRUG|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
224083695|NCT03702725|DRUG|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
224277235|NCT03668457|OTHER|Control|Other: Usual care Usual care for depressive disorder received in mental health units
223908346|NCT06851832|BIOLOGICAL|Zoster Vaccine, Live|"The dosage for each administration is 0.5 mL, containing not less than 4.3 lg PFU of varicella-zoster live virus, administered subcutaneously at the attachment site of the lower edge of the deltoid muscle on the outer side of the upper arm.~A total of one dose will be given. To maintain blinding, the positive control group A1 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 30. The positive control group A2 will receive a placebo on Day 0 and the Zoster Vaccine, Live on Day 60."
223908347|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell)|The dosage for each administration is 0.5 mL, containing 50 μg of gE and the AS01B adjuvant system \[QS-21 (50 μg), MPL (50 μg), DOPC (1 mg), and cholesterol (0.25 mg)\], administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 60 days after the first dose.
223908348|NCT06851832|BIOLOGICAL|Recombinant Zoster Vaccine (CHO cell) (Adjuvant control)|The dosage for each administration is 0.5 mL, containing 0.25 mL of MF59 and 100 μg of CpG1018, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose.
224083696|NCT03702725|DRUG|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
224083697|NCT04993625|PROCEDURE|avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy|Selective Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy In HER-2 positive/Triple Negative Breast Cancer Patients with Excellent Radiologic Response to the Breast and Axilla
224083698|NCT01475734|BIOLOGICAL|albiglutide|subcutaneous injection
224083699|NCT01475734|BIOLOGICAL|placebo|subcutaneous injection
224083700|NCT00771472|DRUG|vorinostat|Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
224083701|NCT01812902|PROCEDURE|Radical Prostatectomy|
224083702|NCT02842931|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
223908349|NCT06851832|BIOLOGICAL|Normal Saline|"The dosage for each administration is 0.5 mL, containing 0.5 mL of NaCl solution, administered intramuscularly into the deltoid muscle. A total of two doses will be given, with the second dose administered 30 days after the first dose (applicable to Phase I clinical trial).~To maintain blinding, subjects in the positive control A1 and positive control A2 groups will receive a placebo on Day 0 (applicable to Phase II clinical trial)."
223908350|NCT06851000|PROCEDURE|ultrasound-guided pulsed radiofrequency|Medication: 0-3months; Pulsed radiofrequency: week 2, 6, 10;
223908351|NCT06851000|PROCEDURE|ultrasound-guided dry needling|Medication: 0-3 months; Dry needling: week 2; Pulsed radiofrequency: week 6, 10;
223908352|NCT06388434|BEHAVIORAL|Protective Arm Balance Response Training|Participants will be trained in the reach to grasp arm balance response while being exposed to unpredictable balance perturbations
223908353|NCT05089877|DEVICE|Surgical Ablation|The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.
223908354|NCT04359654|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Nebulised Dornase alfa 2.5mg bd for 7 days
223908355|NCT05591547|RADIATION|IMRT/VMAT-Based Accelerated Partial Breast Irradiation|The lumpectomy bed will receive a total of 26 Gy in 5 fractions, with 1 fraction delivered per day. Ideally, the course of radiation therapy would be completed over 5 consecutive treatment days. Treatment must begin within 12 weeks of lumpectomy or re-excision of surgical margins and must be completed within 10 calendar days.
223908356|NCT06417853|BIOLOGICAL|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) Injection
223908357|NCT06417853|COMBINATION_PRODUCT|Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA)|12 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
223908358|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA)|25 mcg Influenza A (H7N9) Microarray Patch Delivery System (VXS-1219)
224277236|NCT04580615|DEVICE|CardiacSense1 and capnograph Respiratory rate measurement|Inpatients Subjects with respiratory disease/impairment and Inpatients Subjects with no known respiratory disease/impairment will be measured simultaneously with both CardiacSense1 and capnograph for at least 30 minutes up to 24 hours. During this time capnograph data will be recorded in parallel to CardiacSense1.
223908359|NCT06417853|BIOLOGICAL|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection|7.5 mcg Influenza A (H7N9) with MF59® Injection
223908360|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant)|12 mcg Influenza A (H7N9) with 4 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
223908361|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant)|12 mcg Influenza A (H7N9) with 8 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
223908362|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant)|20 mcg Influenza A (H7N9) with 3.3 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
223908363|NCT06417853|COMBINATION_PRODUCT|Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant)|20 mcg Influenza A (H7N9) with 6.7 mcg QS21 Microarray Patch Delivery System (VXS-1219A)
223908364|NCT06417853|DEVICE|Microarray Patch Delivery System|Vaccine free Microarray Patch Delivery System (VXS-1219U)
224277237|NCT04022941|DRUG|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
224083703|NCT02842931|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
224083704|NCT02842931|DRUG|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
224083705|NCT02842931|DRUG|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
224083706|NCT01601899|DRUG|Stavudine|30 mg po BD if wt \< 60kg, or 40 mg po BD if wt \> 60kg
224083707|NCT01601899|DRUG|Stavudine|20 mg po BD if wt \< 60kg, or 30 mg po BD if wt \> 60kg
224083708|NCT01601899|DRUG|Tenofovir|300 mg po QD
223908365|NCT06845748|OTHER|Physical activity Group|"This intervention consists of a 48-week structured physical activity program designed to counteract age-related muscle decline. Participants assigned to this group will engage in a home-based exercise program, including muscle-strengthening exercises (bodyweight exercises targeting major muscle groups; progressive difficulty based on individual capacity; designed for feasibility in daily life, requiring no specialized equipment) and aerobic exercise (moderate-intensity cardiovascular activity (e.g., brisk walking, cycling); target heart rate between 65-75% of the estimated maximum heart rate).~The program follows guidelines from the American College of Sports Medicine (ACSM) and aims to improve muscle strength, function, and quality of life. It is distinct from other studies as it specifically targets preventing sarcopenia and muscle loss through a practical, home-based, and scalable intervention.~Participants will be monitored through periodic assessments."
223908366|NCT06844448|PROCEDURE|with Biodentine|After the bleeding has stopped, the cavity is flushed with sterile saline and Biodentine (Septodont, Saint-Maur-des-Fossés, France) is mixed according to the manufacturer's instructions. First it is applied directly to the pulp wound using light pressure, and then the entire cavity is filled with it. One week later the superficial 2-3 mm is removed and replaced it with permanent restoration.
223908367|NCT06844448|PROCEDURE|with MTA|After the bleeding has stopped, the cavity is flushed with sterile saline and MTA+ (Cercamed, Stalowa Wola, Poland) is mixed according to the manufacturer's instructions. First it is applied directly to the pulp wound using light pressure, and after its initial setting the cavity is filled with glass ionomer cement. One week later the glass ionomer cement is removed and replaced it with permanent restoration.
223908368|NCT05912608|PROCEDURE|Conservative TAAAD-R|Cardiac arrest will be ensured using antegrade potassium-rich cardioplegia solution delivered directly into the coronary ostium or after coronary sinus cannula insertion, in patients with aortic regurgitation aorta will be resected down to the sinotubular junction and the thrombus located in the false lumen of the aortic root will be removed so that the aortic lesion could be visualized. The commissures will be resuspended using 4-0 or 5-0 sutures reinforced with a Teflon pledget over each commissure. A 4-0 or 5-0 polypropylene suture will be chosen to seal the proximal anastomosis and this suture line will also be used to secure the intima to the adventitia. In patients revealing normal-sized aortic roots associated with poor-quality valve leaflets, concomitant aortic valve replacement with conventional xenograft or mechanical prosthesis will be preferred.
223908369|NCT05912608|PROCEDURE|Extensive TAAAD-R|Patients who experienced dilatation of the sinuses of Valsalva \>4.5 cm in diameter on computed tomography imaging, those with connective tissue disease, or those in whom intimal tears extended into the sinuses, will undergoing replacement of the aortic root using a biologic or mechanical composite valve graft or valve-sparing root reimplantation procedure.Total arch replacement procedures (TARP) will fulfilled with the use of deep hypothermic circulatory arrest and with either antegrade or retrograde cerebral perfusion, maintaining systemic cooling between 19°C to 25°C and depending on the surgeon's practice.TARPs will be carried out using 1- and 4-branch grafts and involved the resection of all the aortic tissue up to the left common carotid artery (total hemiarch) or reimplantation of the innominate trunk only (partial hemiarch).
223908370|NCT06128915|OTHER|vaccine|Vaccination against 20 serotypes of S. pneumoniae
223908371|NCT04530032|OTHER|ketogenic/modified Atkins diet|ketogenic/modified Atkins diet use
223908372|NCT04530032|OTHER|Standard diet|standard (normal) diet use
223908373|NCT06189508|DRUG|NXT007|In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
223908374|NCT06849739|DRUG|biologic therapy(eg:IFX,ADA,UST,VDZ)|This study compares the detection of blood samples from IBD patients after biologic therapy(eg:IFX,ADA,UST,VDZ) using different methods
223908375|NCT06852040|DEVICE|Intraoral induction electrical stimulation therapy|Intraoral induction electrical stimulation therapy (specific method\[13\]: hand-held electrode rods were used to stimulate the mandibular hyoid muscle, digastric muscle, anterior abdomen, and other muscles of the three groups. Parameter setting: the frequency is 80Hz, the wave width is 1ms, the intensity is set to the muscle contraction, each electrical stimulation is 3s, intermittent 10s, 20min/time, 1 time/day, 5 days/week, 4 weeks is limited.
223908376|NCT06852040|DEVICE|tDCS treatment|tDCS treatment (specific method: microcurrent stimulator, stimulation electrode (3 cm×4 cm gelatin sponge), anodic stimulation site is the pharyngeal sensorimotor cortex area (between C3/T3 on the left\[14\], between C4/T4 on the right); the supraorbital area is the site of cathodic stimulation. The direct current intensity is 2.0 mA (20 min/time, 2 times/day) for two treatments (respectively, yin and yang alternating treatment), with an interval of at least 1 h, 5 days/week, and 4 weeks.
224083709|NCT00412477|BIOLOGICAL|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
223715888|NCT06846489|DRUG|Acalabrutinib|100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment.
224083710|NCT01909284|DEVICE|Acupuncture|"* BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~* Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
224083711|NCT01909284|PROCEDURE|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
224083712|NCT03185689|BEHAVIORAL|Effectiveness of an intensified DSME in T2D adult patients|
223715889|NCT06846489|DRUG|Rituximab|375 mg/m² IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months
223715890|NCT03571815|DRUG|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
223715891|NCT03571815|OTHER|WATER ON TEETH|control group
223715892|NCT03950115|DEVICE|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
223908377|NCT06852040|DEVICE|tDCS combined with intraoral induction electrical stimulation|tDCS combined with intraoral induction electrical stimulation. The patients were first treated with tDCS (the method is the same as that of the control group B) for 20 people twice a day and then given intraoral induction stimulation (the specific method is the same as that of the control group A) for 20 minutes, once a day, for 4 weeks.
223908378|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Growth Path|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention aims to support members to explore their relationships, situations, and goals.
223908379|NCT06017414|BEHAVIORAL|Systemic Psychotherapy-informed Listener Training|A self-guided program lasting 5 weeks on the 7 Cups platform. The self-help intervention encourages listeners to explore their relationships, situations, and goals and think about how they would support members working through their own relationships, situations, and goals.
223908380|NCT00540657|DRUG|CCX282-B|250mg capsule, twice daily, 13 weeks
223908381|NCT00540657|DRUG|Placebo|Placebo capsule, twice daily, 13 weeks
223715893|NCT06497621|PROCEDURE|Single step PVS impression|Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
223908382|NCT05263583|DRUG|Sepantronium Bromide|continuous intravenous infusion
223908383|NCT03676894|DEVICE|Sham Fotona SP Dynamis|Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
223908384|NCT03676894|DEVICE|Intravaginal Fotona SP Dynamis|Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
223908385|NCT03676894|DEVICE|Intraurethral Fotona SP Dynamis|Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
223908386|NCT06392230|DRUG|Oral [14C] PF-06821497|A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1
223908387|NCT06392230|DRUG|Oral PF-06821497|A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2
223908388|NCT06392230|DRUG|IV [14C] PF-06821497|A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2
223715894|NCT06497621|PROCEDURE|Conventional two-step PVS impression|Border molding with heavy-body PVS first, followed by wash impression with light-body PVS
223715895|NCT04442867|OTHER|Case management|Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.
223908389|NCT03523572|DRUG|Trastuzumab deruxtecan|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
223908390|NCT03523572|DRUG|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
223908391|NCT06418100|PROCEDURE|The recto intercostal fascial plane block|After ensuring aseptic conditions, the high-frequency linear ultrasound probe was used to detect the rectus abdominis muscle and the 6-7th costal cartilage as described by Tulgar et al. After rotating and shifting the transducer, 6-7th costal cartilages, the rectus abdominis muscle, and intercostal muscles between the cartilages were confirmed. The primary investigator (B.C.) directed the needle tip caudad in the cephalic direction in-plainly, and 20 ml 0,25% bupivacaine was injected bilaterally into the plane between the costal cartilage and the rectus abdominis muscle following negative aspiration.
223908392|NCT05575219|DRUG|Clonidine (without protocolized initiation)|Participants will be observed for dexmedetomidine withdrawal and clonidine will be started at clinician discretion.
223908393|NCT05575219|DRUG|Clonidine (protocolized initiation)|"* Observe participants without initiating clonidine with dexmedetomidine infusion time of 72-119 hours. To wean off dexmedetomidine, decrease the infusion by 25% of the starting dose every 6 hours.~* Begin clonidine at 1 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of 120-144 hours.~* Begin clonidine at 1.5 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion times of 145-167 hours.~* Begin clonidine at 2 mcg/kg enterally every 6 hours for participants with dexmedetomidine infusion time of \>/= 168 hours or with infusion time of 120-167 hours at doses \>/= 1.1 mcg/kg/min.~* If clonidine is started decrease the dexmedetomidine infusion by 25% of the starting dose 1 hour after each dose of clonidine until off (wean every 6 hours)."
223908394|NCT05896033|BEHAVIORAL|Non-Menthol Cigarettes|Ppts will be randomly assigned to a group that receives non-menthol cigarettes
223908395|NCT05896033|BEHAVIORAL|Tobacco Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives tobacco flavored e-cigarettes
223908396|NCT05896033|BEHAVIORAL|Menthol Cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored cigarettes
223908397|NCT05896033|BEHAVIORAL|Menthol Flavored E-cigarettes|Ppts will be randomly assigned to a group that receives menthol flavored e-cigarettes
223908398|NCT05661604|OTHER|No Intervention|This is an observational study to assess the incidence and key disease characteristics of symptomatic acute respiratory viral infections in a high-risk population at risk for poor outcomes. Duration of each participant will be up to 12 months.
224083713|NCT03148730|DEVICE|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
223715896|NCT04442867|OTHER|Social call|Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
223908399|NCT06508632|BEHAVIORAL|Mandala group|Individual mandala activity will be carried out in all sample groups after admission to the clinic where they come to receive outpatient chemotherapy and when they start taking medication. Children will color (paint).
223908400|NCT05709249|DRUG|XLJDOD compound granule|Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.
224083714|NCT00845195|DRUG|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
223908401|NCT05709249|DRUG|placebo (XLJDOD mimetic agent)|The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.
223908402|NCT05507905|BEHAVIORAL|Music|Music associated with dance forms in dance classes.
223908403|NCT05507905|BEHAVIORAL|Dance Classes|Four Different dance forms taught for 6 weeks each
223908404|NCT05566470|DIAGNOSTIC_TEST|Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors|Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
223908405|NCT01805609|BEHAVIORAL|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture \& discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff \& that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
223908406|NCT01805609|BEHAVIORAL|questionnaires|
223908407|NCT05870046|PROCEDURE|Power training in women older than 65 years with pre-sarcopenia|resistance training based on muscle power training, perform the exercises at high speed.
223908408|NCT05870046|PROCEDURE|Multimodal and nonspecific exercises in women older than 65 years with pre-sarcopenia|different exercise modalities are integrated: Aerobic, mobility, strength, balance and coordination exercises.
223908409|NCT04267120|DRUG|Lenvatinib|Lenvatinib will be provided by Merck.
223908410|NCT04267120|DRUG|Pembrolizumab|Merck will provide pembrolizumab
223908411|NCT04267120|PROCEDURE|Research blood collection|-Within 2 weeks prior to first dose of study drug, cycle 4 day 1, and at the off-treatment assessment
223908412|NCT05427253|DRUG|C106 solution|selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist
223908413|NCT05427253|DRUG|Placebo|Placebo for C106 solution
223908414|NCT02315703|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
223908415|NCT02315703|BIOLOGICAL|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10\^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
223908416|NCT02315703|BIOLOGICAL|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
223908417|NCT02315703|BIOLOGICAL|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
223908418|NCT02315703|DRUG|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
223908419|NCT03519178|DRUG|PF-06873600|PF-06873600 tablet for oral dosing
223908420|NCT03519178|DRUG|Endocrine Therapy 1|Endocrine Therapy 1
223908421|NCT03519178|DRUG|Endocrine Therapy 2|Endocrine Therapy 2
223908422|NCT02240238|DRUG|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
223908423|NCT02240238|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
223908424|NCT05496036|DRUG|Pembrolizumab|400mg IV
223908425|NCT04901078|DRUG|KNX100|KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
223908426|NCT02932176|DEVICE|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
223908427|NCT02932176|DEVICE|machine-learning algorithm|
223908428|NCT05586061|DRUG|Disitamab vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, (every 3 weeks) Q3W
223528991|NCT04825600|DIAGNOSTIC_TEST|anti-Toxoplasma gondii IgG and IgM dosage|blood sample performed to check the toxoplasma serological diagnosis
223908429|NCT05586061|DRUG|Tislelizumab|Tislelizumab: 200mg, d1, ivdrip, (every 3 weeks) Q3W
223908430|NCT05586061|DRUG|S1|S-1: 40-60mg (according to patients' body surface area), po, bid, d1-14, discontinued for 7 days.
223908431|NCT04073498|DRUG|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
223908432|NCT04073498|DRUG|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
223908433|NCT06155604|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily
223908434|NCT06155604|DRUG|Standard maintenance therapy|Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
223908435|NCT06244654|DEVICE|Oculus Quest 2 VR virtual reality glasses and wired over-ear headphones|After the VR group comes to the preoperative area and is evaluated, they will be asked to wear VR glasses and headphones. VR glasses and headphones were worn on the patient during peripheral nerve block applications and the operation. At the end of the operation, the VR glasses and headphones were removed and they were taken to the postoperative recovery room.
224277238|NCT04022941|OTHER|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
223528992|NCT04825600|DIAGNOSTIC_TEST|cellular test|blood sample performed to evaluate the anti T. gondii cellular immunity and to compare results to the toxoplasma serological diagnosis
223908436|NCT06244654|OTHER|No VR|After evaluation of the patients taken to the preoperative area, routine peripheral nerve block application was performed without the use of VR glasses. VR glasses were not worn during the operation, as is the routine protocol. At the end of the surgery, they were taken to the postoperative recovery room.
223908437|NCT03291652|DIAGNOSTIC_TEST|DSA/3DRA|DSA/3DRA
223908438|NCT03878407|OTHER|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
223908439|NCT05112809|DEVICE|Cochlear Stimulation System (CSS)|Cochlear stimulation with surround sound and noise cancellation
223908440|NCT03760588|DRUG|Sacubitril/valsartan|Target dose 97/103 mg b.i.d .
223908441|NCT03978078|OTHER|Biological collection|\- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
223908442|NCT06184997|OTHER|INTAKE OF ISOTONIC DRINK|Intake of natural isotonic drink based on 20% Atlantic sea water, mixed with lemon and stevia.
223908443|NCT06184997|OTHER|PLACEBO|Intake of natural mineral water
223908444|NCT04103567|OTHER|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, after neoadjuvant treatment and before surgery.
223908445|NCT06418191|PROCEDURE|Acupressure|Acupressure is a technique that involves applying pressure to specific points on the body. It is based on the same principles as acupuncture but uses pressure from fingers, palms, elbows, or specialized devices instead of needles.
223908446|NCT04834297|OTHER|Prapela SVS mattress|The intervention will be using the Prapela SVS crib mattress to complement non-pharmacological management of NOWS for the purposes of prevention of pharmacological treatment of NOWS
223908447|NCT05997953|OTHER|Edinburgh Postnatal Depression Scale|Edinburgh Postnatal Depression Scale used as screening tool for postpartum depression
223908448|NCT05529901|DEVICE|GORE® CARDIOFORM Septal Occluder|Patients for whom the device is used (implanted or used by not implanted) during the enrollment period of this post-marketing surveillance will be considered eligible for the study
223908449|NCT06513819|BEHAVIORAL|Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique|Delivered by a clinical pharmacist who will employ IMB-MI in informational, participant-centered discussions in which the clinical pharmacist and the participant collaboratively discuss the harms of alcohol use (with or without concurrent use of cannabis) and polypharmacy (specifically neurocognitively active medications), the relationship of these exposures to fall risk and NCEs, and how to mitigate these harms. Together pharmacist and participant will develop a plan for change in alcohol and polypharmacy use, self-monitoring, medications of concern, symptoms, and any additional resources needed. The goal of the intervention being to help patients stop or decrease alcohol use and stop medications in situations where it is safe to do so and agreed upon by the primary provider (but substitutions will be made if necessary).
223908450|NCT06006013|BIOLOGICAL|Pembrolizumab|Given IV
223908451|NCT06006013|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223908452|NCT06006013|DRUG|Cabozantinib S-malate|Given PO
223908453|NCT06006013|PROCEDURE|Computed Tomography|Undergo CT
223908454|NCT06006013|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223908455|NCT04134208|PROCEDURE|Computed Tomography|Undergo PET-CT scan
223908456|NCT04134208|DRUG|Fluciclovine F18|Given IV
223908457|NCT04134208|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
223908458|NCT06642090|BEHAVIORAL|Educational intervention for patients undergoing hemodialysis in Morocco|This is the first educational intervention in Morocco to improve the knowledge, self-care, and biological characteristics of patients undergoing hemodialysis.
223908459|NCT04323553|DIAGNOSTIC_TEST|Pulsed-field gel electrophoresis and whole genome sequencing|Comparison of the two different techniques
223908460|NCT04323553|OTHER|Data collection|Demographic data (age, gender, hospital admission and discharge date, rooms and wards with dates of admission and discharge, hospitalization prior to current hospital stay, discharge destination, outcome, cause of death, travel history, recent hospitalization in an ESBL-high burden region, admission from another healthcare facility, admission from a long-term care facility, occupational or household contact to animals) Clinical data (date of diagnosis of ESBL-producing E. coli carriage, type of infection/colonization with ESBL- producing E. coli, comorbidities, Charlson Comorbidity Index, infectious diseases after detection of ESBL-PE, active open wounds, indwelling vascular devices, urinary catheterization) Treatment data (Immunosuppression, antibiotic therapy, concomitant medication and surgical therapy prior to and during hospital stay) Microbiological data
223908461|NCT04160832|GENETIC|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
223908462|NCT03476343|DEVICE|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
223908463|NCT02901977|DRUG|Ramipril|Antihypertensive therapy
223908464|NCT02901977|DRUG|Doxazosin|Antihypertensive therapy
223908465|NCT04726371|BEHAVIORAL|Generic Best Practices|GBP consists of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention will receive standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition does not represent inferior or substandard practice. As findings occur and as policy leads to adjustments in recommendations during the course of the study, the GBP condition will incorporate recommendations that are appropriate and up-to-date with CDC and state policy.
223908466|NCT04726371|BEHAVIORAL|Tailored Best Practices|TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization.
223908467|NCT03088878|DRUG|Cirmtuzumab (2-16 kg/mg) plus Ibrutinib|Participants will receive escalating doses of cirmtuzumab (2-16 mg/kg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily, starting at week 4.
223908468|NCT03088878|DRUG|Cirmtuzumab (300mg) plus Ibrutinib|Participants will receive cirmtuzumab (300 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
223908469|NCT03088878|DRUG|Cirmtuzumab (600 mg) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
223908470|NCT03088878|DRUG|Cirmtuzumab (RDR) plus ibrutinib|Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 or 560 mg) orally once daily
223908471|NCT03088878|DRUG|Cirmtuzumab plus ibrutinib|Arm A: Participants will receive cirmtuzumab (600 mg) administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter, plus ibrutinib (420 mg) orally once daily.
223908472|NCT03088878|DRUG|Ibrutinib alone|Arm B: Participants will receive ibrutinib (420 mg) orally once daily
223908473|NCT04128761|BEHAVIORAL|Scarcity Narrative|Participants are presented with a hypothetical scarcity narrative and asked to listen and consider the scenario.
223908474|NCT04128761|BEHAVIORAL|Neutral Narrative|Participants are presented with a hypothetical neutral narrative and asked to listen and consider the scenario.
223908475|NCT03831256|DIAGNOSTIC_TEST|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
223908476|NCT03831256|DIAGNOSTIC_TEST|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
223908477|NCT03831256|DIAGNOSTIC_TEST|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
223908478|NCT03831256|DIAGNOSTIC_TEST|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
223908479|NCT05061745|DEVICE|Guided Meditation VR for Wellness|"Selected Modules of Commercially Available Guided Meditation VR presented on Valve Index Headset"
223908480|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment A|Either MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP) or The NeuroStar® System will be used.
223908481|NCT05061745|DEVICE|Accelerated Transcranial Magnetic Stimulation: Treatment B|Either MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) or The NeuroStar® System will be used.
223908482|NCT05432583|BIOLOGICAL|BNT163|Anti-viral ribonucleic acid (RNA) vaccine for active immunization against HSV-2 administered as intramuscular injection
223908483|NCT05432583|OTHER|Placebo|Placebo
223908484|NCT06803810|BEHAVIORAL|P2P Intervention|This group will complete the same study visits as the standard care group with an additional week 3 visit and 6 CPSS-led therapy intervention sessions. These CPSS led sessions will be completed by the end of the 12week study period. At each study visit you will complete questionnaires.
223908485|NCT06794853|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).
223908486|NCT03324477|DRUG|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
223908487|NCT06068946|BIOLOGICAL|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist
223908488|NCT06068946|BIOLOGICAL|Placebo|Placebo comparator
223908489|NCT05297201|DRUG|CPL500036 - low dose|CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
223908490|NCT05297201|DRUG|CPL500036 - high dose|CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
223908491|NCT05297201|DRUG|Placebo|Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
223908492|NCT05197465|OTHER|Questionnaires|Participants will complete pain and quality of life questionnaires. Opioid consumption will also be assessed using validated questionnaires.
223908493|NCT04680715|RADIATION|Per-Operative Radiotherapy technique by Papillon +TM|20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer
223908494|NCT06074120|DEVICE|Low-level laser therapy|Low-level laser therapy would be introduced via a vaginal probe (gain medium: Gallium-Aluminum-Arsenide, wavelength 660nm) for 30 minutes per treatment, once a week, for 8 courses.
223908495|NCT04690582|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
223908496|NCT04690582|BEHAVIORAL|Crisis Response Plan (CRP)|The crisis response plan (CRP) is a collaborative, patient-centered intervention that is typically handwritten on an index cards and focuses on several key components: (1) warning signs, (2) self-regulatory strategies, (3) reasons for living, (4) sources of social support, and (5) professional and crisis services.
224083715|NCT00845195|DRUG|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
223908497|NCT04690582|BEHAVIORAL|Safety Planning Intervention (SPI)|The safety planning intervention (SPI) is a suicide-focused intervention typically handwritten on a pre-printed form that includes the following sections: (1) warning signs, (2) internal coping strategies, (3) people and social settings that provide distraction, (4) people who can offer help, (5) professionals or agencies they can contact during a crisis, and (6) making the environment safe.
223908498|NCT04690582|BEHAVIORAL|Narrative Assessment|"The narrative assessment is a patient-centered assessment approach in which the clinician invites the patient to share the story of a recent crisis or period of intense emotional distress. Patients are asked to identify the thoughts, emotions, and physical sensations experienced in the time leading up to this crisis, as well as the contextual and environmental characteristics surrounding the crisis. Information obtained from the narrative assessment is then used to help formulate a crisis response plan."
223908499|NCT05245006|DRUG|89Zr-DFO-YS5|3 mCi will be administered intravenously
223908500|NCT05245006|BIOLOGICAL|YS5 antibody|20 or 50 mg administered intravenously
223908501|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Computerized tomography (CT)|Imaging which combines a CT scan and a PET scan
223908502|NCT05245006|PROCEDURE|Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)|Imaging which combines an MRI scan and a PET scan
223908503|NCT05974501|DRUG|Dexamethasone|Dexamethasone 10mg administered via IV once postoperatively within 24 hours for pain and swelling
223908504|NCT05974501|DRUG|Acetaminophen|1,000mg administered via tablet every 8 hours for pain during the first 1-2 weeks postoperatively
223908505|NCT05974501|DRUG|Lyrica|Administered via tablet 75mg nightly for pain during the first 1-2 weeks postoperatively
223908506|NCT05974501|DRUG|Celebrex|200mg administered via tablet twice a day for pain and swelling during the first 1-2 weeks postoperatively
223908507|NCT05974501|DRUG|Meloxicam|30mg administered via IV once postoperatively within 24 hours for pain and swelling
223908508|NCT05974501|DRUG|Oxycodone|5mg administered via tablet every 4 hours as needed for pain during the first 1-2 weeks postoperatively
223908509|NCT05974501|DRUG|Ropivacaine|20 milliliters Ropivacaine 0.2% administered via injection perioperatively.
223908510|NCT05487404|DRUG|ADX-629|3 oral doses of ADX-629 600 milligrams
223908511|NCT05487404|DRUG|Placebo|3 oral doses of placebo
223908512|NCT04718896|DRUG|bimekizumab|Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
223908513|NCT06502535|DIETARY_SUPPLEMENT|Inulin|15 g inulin once daily for 4 weeks.
223908514|NCT06502535|DIETARY_SUPPLEMENT|Potassium nitrate and inulin|1300 mg potassium nitrate once daily for 4 weeks and 15 g inulin once daily for 4 weeks.
223908515|NCT04270942|DRUG|teplizumab 1 mg/mL|"Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody).~Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily"
223908516|NCT06144762|BIOLOGICAL|Biological/Vaccine: Blood sample and tissue sample|"During the surgery :~Tissus sample : primary tumor and metastasis blood sample : 3 EDTA tubes ex vivo MRI data"
223908517|NCT05166668|DRUG|Letrozole 2.5mg tablet|letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response
223908518|NCT06123962|PROCEDURE|Collect peripheral blood and bronchoalveolar lavage fluid|"Peripheral venous blood will be collected and stored from the study participants at a total of five time points: Day 0, Day 1, Day 2, Day 3 after admission to the ICU, and the day of ICU discharge/death. The collection will be conducted after assessing the patients' eligibility for ARDS diagnosis. Each time point will involve the collection of one tube of peripheral venous blood, totaling 5 mL per sample.~Within 24 hours after patients' admission to the ICU and meeting the assessment criteria for ARDS diagnosis, bronchoalveolar lavage fluid (BALF) will be collected and retained, totaling 10 mL."
223908519|NCT05958082|BEHAVIORAL|Educational video|The educational intervention will occur with a clinical research coordinator who will be trained to educate on germline testing in prostate cancer.
223908520|NCT06823869|OTHER|musical book|The child will indicate that he wants to play with the musical book. The child will play with toys for 5 minutes before treatment. Once the child is ready, inhaler medication will begin and the treatment will last 10 minutes. The treatment is terminated at the end of the 10th minute. The child's playing time with the toy is approximately 15 minutes.
223908521|NCT06823869|OTHER|musical piano|The child will indicate that he wants to play with the musical piano. The child will play with toys for 5 minutes before treatment. Once the child is ready, inhaler medication will begin and the treatment will last 10 minutes. The treatment is terminated at the end of the 10th minute. The child's playing time with the toy is approximately 15 minutes.
223908522|NCT06823869|OTHER|sham|The child will not play with toys during treatment. Before the treatment, the researcher demonstrates the process on himself with a nebul mask. Treatment begins after the child is ready. The process will take 10 minutes.
223908523|NCT06823427|DRUG|9MW2821|a nectin-4 ADC with MMAE payload
224277239|NCT04065607|PROCEDURE|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
223908524|NCT06823427|DRUG|Toripalimab (JS001 )|anit-PD-1 antibody
223908525|NCT06357169|DEVICE|Venus Glow|two treatments over a one week period. At the first visit they will complete an initial questionnaire regarding current scalp care practices, skin type, and hair type. An initial baseline scalp swab and HairMetrix photography in the two swab sites will be taken at the beginning of this visit. Treatment with the Venus Glow™ device will also occur. To treat, the scalp will be divided into four quadrants. Swab samples will be collected at the first baseline and concurrent treatment session, second treatment session and 3-6 days after the last treatment when participants have returned to their usual cleansing routine.
223908526|NCT06823089|DEVICE|ReNew Hip Implant|Surgical Intervention
223908527|NCT06821529|BIOLOGICAL|ICA07 therapy|4 million iPSC-DAPs will be administrated into the putamen on each side of the brain
223908528|NCT05592275|DRUG|LY3540378|Administered SC
223908529|NCT05592275|DRUG|Placebo|Administered SC
223908530|NCT03898856|DRUG|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
223908531|NCT03898856|DIAGNOSTIC_TEST|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
223908532|NCT05500885|DEVICE|PEMF device, Quantum Tx, Singapore|The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.
223908533|NCT05500885|OTHER|Standard rehabilitation and sham PEMF therapy for CAI|Balance training and muscle strengthening
223908534|NCT06822283|OTHER|transcranial electric stimulation|tTIS is an innovative non-invasive brain stimulation approach, in which two or more independent stimulation channels deliver high-frequency currents in the kHz range (oscillating at f1 and f1 + Δf). These high-frequency currents are assumed to be too high to effectively modulate neuronal activity. Still, by applying a small shift in frequency, they result in a modulated electric field with the envelope oscillating at the low-frequency Δf (target frequency) where the two currents overlap. The peak of the modulated envelope amplitude can be steered towards specific areas located deep in the brain, by tuning the positions of the electrodes and the current ratio across stimulation channels. Here, we applied tTIS via surface electrodes applying a low-intensity (2mA baseline to peak), sub-threshold protocol following the safety guidelines for low-intensity transcranial electric stimulation in humans.
223908535|NCT06755697|OTHER|Intra-articular US-guided hypertonic dextrose injection, IA group|"IA injection: 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected. The ultrasound transducer (L18-4, Philips EPI Q5) is placed transversely over the patient's suprapatellar pouch while the patient lies supine with the knee actively extended and ankle dorsiflexed. The injectate will be injected into the suprapatellar pouch via transverse view, in-plane, lateral-to-medial approach with a 3.8 cm 22-gauge needle under US guidance.~Physical therapy: The physical therapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise (stretching, ROM exercise, and strengthening), three times a week, and will be continued for 4 weeks."
223908536|NCT06755697|OTHER|Extra-articular US-guided injection targeting MRI-positive lesion sites, EA group.|Patients in the EA group will receive MRI examination of the knee without contrast. Detailed physical examinations (PE) will also be done for each subject. The PEs include inspection, palpation for local tenderness and crepitus, signs of effusion, assessment of range of motion, provocative meniscal testing, and ligamentous tests for laxity. A total of 5 ml of 20% dextrose (2ml vitagen in 2ml normal saline and 1ml 1% xylocain) will be injected to the target areas which has been shown abnormal on MRI images with a 3.8 cm 22-gauge needle under US guidance. For lesions of the deep structures or bone marrow lesion, a 7-cm 23 or 21 gauge needles may be used. Same as the IA group, EA hypertonic dextrose injection will be done at the 0, 2nd, and 4th weeks, as well as physical therapy during the first 4 weeks.
223908537|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - curved 11508AAK|11508AAK Miniature straight forward telescope 0-degree set, curved, diameter 3.3 millimeter, length 30 centimeter, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 French., remote eyepiece, fiber optic light transmission incorporated.
223908538|NCT06281730|DEVICE|Karl Storz New Generation Fetoscope - straight 11506AAK|11506AAK Miniature straight forward telescope 0-degree, straight, diameter 3.3 millimeter, length 30 cm, 30,000 pixels, autoclavable, irrigation connector, central working channel 4 french, lateral working channel 3 french, remote eyepiece, fiber optic light transmission incorporated.
223908539|NCT06703151|BEHAVIORAL|CMDs (Cardiometabolic Diseases) Self-Care Manual|1st-5th month: Complete the assessment of self-care ability and biochemical indicators, introduce the (CMDs self-care) teaching material manual, and evaluate the case's referral treatment status from the institution, and provide answers to questions. Played the Monopoly board game 8 times: On average, each community has about 2-3 groups (a group of 4-7 people), each group has a leader (seed teacher) to conduct CMDs health education Q\&A before each board game activity . 6th month: Conduct self-care process assessment in each community. 7th-12th month: Telephone visits are provided every 2 months (3 times in total), each case lasts 5-10 minutes each time.
223908540|NCT06547294|DEVICE|Osprey IV|Utilization of novel needle over catheter commercial insertion device
223908541|NCT06547294|OTHER|Historical Controls|Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
223908542|NCT06295562|DRUG|Atomoxetine 80mg combined with oxybutynin 5mg|Atomoxetine 80mg combined with oxybutynin 5mg
223908543|NCT06295562|DRUG|Venlafaxine 37.5mg|Venlafaxine 37.5mg
223908544|NCT06295562|DRUG|Atomoxetine 80mg combined with trazodone 100mg|Atomoxetine 80mg combined with trazodone 100mg
224083716|NCT05228366|OTHER|Heel warming with mild thermofor group|Heel warming will be applied to the newborns in the ıntervention group 1 with a thermofor containing 34-37C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
224083717|NCT05228366|OTHER|Heel warming with hot thermofor group|Heel warming will be applied to the newborns in the ıntervention group 2 with a thermofor containing 38-40C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service
224277240|NCT00949091|DRUG|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
224277241|NCT01016054|BIOLOGICAL|AGS-8M4|IV infusion
224277242|NCT01016054|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
223715897|NCT02132091|OTHER|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
223908545|NCT06295562|DRUG|Placebo|Placebo tablet
223908546|NCT05951660|BEHAVIORAL|Educational intervention|"Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences."
223908547|NCT05285943|DRUG|Olive oil cream|Olive oil prepared in a base cream to be applied to irradiated areas.
223908548|NCT05285943|DRUG|Betamethasone Valerate Cream|Betamethasone valerate prepared in a base cream to be applied to irradiated areas.
223908549|NCT05285943|OTHER|Base Cream|The base cream used for preparation of both the betamethasone valerate cream and olive cream will be used as a placebo control to be applied to irradiated areas.
223908550|NCT05663047|OTHER|Prevent It 2.0|A free, anonymous, internet-delivered, therapist assisted, cognitive behavioral therapy (CBT) intervention
223908551|NCT05663047|OTHER|Waitlist|Participants in the waitlist control will wait thirteen weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing problematic sexual behavior.
223908552|NCT06167304|OTHER|Technology-implemented exercise therapy|Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.
223908553|NCT06167304|OTHER|Traditional Physical Therapy|Traditional physical therapy per Standard of care.
223908554|NCT06433739|OTHER|standardized algorithm|standardized algorithm for the correct selection of peripheral venous catheters
223908555|NCT06286722|OTHER|Progressive, individualized and structured exercise program|See description under Arms
223908556|NCT06822764|OTHER|observational|observational
223908557|NCT06270550|OTHER|Dynamic Movement Intervention|Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
223908558|NCT06823895|DRUG|Maixuekang capsule|"Single dose group: Participants will be given Maixuekang capsules once, 1g, orally.~Multiple dose group: Participants will receive 1g of Maixuekang capsules orally for 3 days, 3 times a day."
223908559|NCT06822595|DEVICE|Blood flow restriction (BFR) training|Both groups followed an identical 8-week isokinetic training protocol twice weekly. The BFR group performed exercises with arterial occlusion pressure set to 80% of the measured occlusion pressure.
223908560|NCT06822595|DEVICE|Isokinetic training|Both groups followed an identical 8-week isokinetic training protocol twice weekly.
223908561|NCT03449264|BIOLOGICAL|biological collection|"* Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~* Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out."
223908562|NCT06805500|DEVICE|REACTION|Combination of a exoskeleton and gait trainer
224277243|NCT01016054|DRUG|gemcitabine|IV infusion
223908563|NCT06805500|DEVICE|ABLE Regain|Exoskeleton
223908564|NCT06805500|DEVICE|GABLE Core|Gait trainer
223908565|NCT03836066|DRUG|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
223908566|NCT06311175|BEHAVIORAL|Dietary Tracking Prescription|Dietary tracking prescriptions to follow during a digital weight loss intervention.
223908567|NCT06078761|BEHAVIORAL|Healthy Eating Active Lifestyle (HEAL) Program|Evidence-based lifestyle medicine program for cancer survivors
223908568|NCT06446193|DEVICE|NDTx-01|NDTx-01 intervention: Run 'NDTx-01' application on a smartphone 5 times a week, for 6 weeks, 30 sessions in total.
224277244|NCT01016054|DRUG|carboplatin|IV infusion
224277245|NCT02490800|DRUG|Lisavanbulin Phase 1 dose escalation portion|Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
224277246|NCT02490800|DRUG|Lisavanbulin Phase 2a expansion portion|Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
224277247|NCT01513941|DRUG|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
224277248|NCT01513941|DRUG|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
223908569|NCT06446193|BEHAVIORAL|TAU|TAU: Autism Spectrum Disorders(ASD) or Social Communication Disorders(SCD)-related treatment/rehabilitation/education
223908570|NCT05156320|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 was administered every 4 weeks by intravenous (IV) infusion.
223908571|NCT05156320|DRUG|Placebo|Placebo was administered every 4 weeks by intravenous (IV) infusion.
223908572|NCT06816797|OTHER|Cog Fun Ageing intervention|Cog Fun Aging is a group-based intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 10 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
223908573|NCT06816797|OTHER|Cog-Fun Aging Crossover|"In the initial phase of the study (between T0 and T1) this group will receive usual care. Participants are users of regional services where activities for healthy older adults are available. This group will continue going to activities as normal during the initial phase and then participate in the Cog-Fun Aging intervention."
223908574|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based flow imaging|Ultrasound-based flow imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
223908575|NCT05270005|DIAGNOSTIC_TEST|Ultrasound-based strain imaging|Ultrasound-based strain imaging of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
223908576|NCT05270005|DIAGNOSTIC_TEST|Conventional duplex|Conventional duplex measurements of the carotid artery stenosis will be acquired at baseline and two annual follow-up appointments.
223908577|NCT06606353|BEHAVIORAL|Talk-To-Jo|"Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required."
223908578|NCT06823505|OTHER|structured questionnaire|Using the Depression Scale (CES-D), Cancer Self-Efficacy Scale (CASE), Family Peer Relationship Questionnaire (FPRQ), Family Resilience Scale (FRAS) and Parent-Child Relationship Quality Scale
223908579|NCT03382938|DRUG|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
223908580|NCT03382938|DRUG|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
223908581|NCT03382938|DRUG|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
223908582|NCT03382938|OTHER|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
223908583|NCT03004547|OTHER|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
223908584|NCT00179465|DRUG|Tiagabine|Up to 36 mg daily
223908585|NCT00179465|DRUG|Placebo|Placebo
223908586|NCT05826652|OTHER|Single injection subcostal transversus abdominis plane block|Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.
223908587|NCT05826652|OTHER|Multiple injection subcostal transversus abdominis plane block|Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
223908588|NCT05826652|PROCEDURE|Without Block|The patients in this group will not receive block
223908589|NCT06086951|BEHAVIORAL|Pai.ACT Group|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors. The app also offers 4-6 video-based individual ACT sessions with a dedicated counseling team and a referral system for intensive psychological support, all underpinned by empirical evidence from a previous ACT trial in Hong Kong.
223908590|NCT06086951|OTHER|Control Group|Both the Pai.ACT group and the control group will receive conventional familial support offered by the hospital's Children with Complexity Community Support Programme (CCCSP) and allied Non-Governmental Organizations (NGOs). This support encompasses disseminating educational content focused on the management of children's affective and behavioral manifestations.
223908591|NCT05182255|DEVICE|Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered|To aid in maintaining patency of the esophagus in cases of obstruction of the esophagus caused by an esophageal disease and to seal tracheoesophageal fistula.
223908592|NCT06760455|DRUG|BPR-30221616 Injection|BPR-30221616 will be administered by subcutaneous (SC) injection
223908593|NCT06760455|DRUG|Sodium Chloride Injection|Sodium Chloride Injection will be administered by SC injection
223908594|NCT06454344|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-i)|CBT-I is a structured program with a robust empirical evidence supporting its efficacy for improving sleep quality and quantity. The cognitive component of CBT-I teaching individuals how to recognize and change the beliefs they hold about sleep that negatively impact sleep, such as negative thoughts and emotions. The behavioral component includes several strategies to help improve sleep, including: improved sleep hygiene, improving the sleep environment, relaxation training, stimulus control therapy (consistent wake/sleep times, using the bed only for sleep, etc), and sleep restriction. Sleep restriction consists of reducing the time spend in bed initially to increase sleep drive in subsequent nights. Once sleep has improved, the time in bed is gradually increased again.
223908595|NCT05319821|BEHAVIORAL|Receive ECHO training|Active Intervention
223908596|NCT05319821|BEHAVIORAL|Offered ECHO training in year 5|Delayed Intervention
223908597|NCT05738005|OTHER|Tracking Dietary/Supplement Intake on MyFitnessPal smartphone application (app)|Amyloidosis patients will use MyFitnessPal application to track dietary intake and use of herbal/alternative supplements in from week 2-9. Patient's usage of the application and questionnaires completed by the patient at the start, Week 2 and Week 10 will determine feasibility.
223908598|NCT05049239|BEHAVIORAL|Physical training|Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.
224277249|NCT01513941|DRUG|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
224277250|NCT05341154|DRUG|Ketamine Hcl 50Mg/Ml Inj|Patients will be given the active comparator or placebo only once right before the induction of anesthesia.
224277251|NCT02845154|OTHER|bolus purge|complete and uninterrupted purge
224277252|NCT02845154|OTHER|Intermittent purge|intermittent portal purge
224277253|NCT00521508|PROCEDURE|gene transcription and cytometry|samply of 30 ml of blood
223908599|NCT05049239|BEHAVIORAL|Physical training combined with cognitive support.|"Medium-high-intensity physical training 3 times a week, 60 min / time for 12 weeks, consisting of fitness, strength and mobility exercises with a target level of 60-90% of maximum heart rate. Two sessions per week take place in a group led by a physiotherapist and once a week the training consists of self-chosen training individually or in group.~The cognitive support consists of person centred individual occupational therapy with focus on daily time management skills and planning and organisation in daily life, i.e. make time for physical exercise. The number of session during the intervention period depend on the participants needs and is estimated to 4-6 sessions."
223908600|NCT05911308|DRUG|Durvalumab|1,500 mg Durvalumab IV infusion will be given on day 1 of each cycle for 3 cycles.
223908601|NCT05911308|DRUG|Carboplatin|Carboplatin IV infusion will be given on day 1 of each cycle for 3 cycles. The dose will be AUC 5.
223908602|NCT05911308|DRUG|Abequolixron|100 or 120 mg Abequolixron will be administered by mouth twice a day for 5 days followed by 2 days off throughout your treatment (5 days a week for up to 9 weeks).
223908603|NCT05911308|DRUG|Abraxane|100 mg/m2 Abraxane will be given by IV infusion on days 1, 8, and 15 of each cycle for 3 cycles.
223908604|NCT05911308|DRUG|Pemetrexed|500 mg/m2 pemetrexed will be given by IV infusion on day 1 of each cycle for 3 cycles.
223908605|NCT05615389|DRUG|Medicinal Cannabis - C12T12|"Participants randomised to receive C12T12 Ruby Balanced Oil will commence with 0.008ml/kg/day (0.1 mg/kg/day THC) in two divided doses, and titrate up in four steps (increase by 0.008ml/kg/day every four days) over 16 days up to a maintenance dose of 0.04ml/kg/day (0.5mg/kg/day THC) in two divided doses, with a ceiling dose of 2ml/day (25mg/day THC) for participants weighing 50kg or more. The maintenance dose will then be continued from day 17 until day 42.~Down-titration will occur for 16 days after the end of study visit, in the reverse of the up-titration period."
223908606|NCT05615389|DRUG|Medicinal Cannabis - C20T5|Participants randomised to the C20T5 Ruby CBD Oil will receive a matched volume to the C12T12 arm during the up-titration, maintenance, and down-titration phases.
223908607|NCT06126224|DRUG|KarXT|KarXT 20/2 mg (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg (TDD 90/9 mg) KarXT 40/4 mg (TDD 120/12 mg) KarXT 50/5 mg (TDD 150/15 mg) KarXT 66.7/6.67 mg (TDD 200/20 mg)
223908608|NCT06126224|DRUG|Placebo|Placebo Capsules
223908609|NCT05409573|OTHER|double monitoring of EtO2|"A double monitoring of EtO2 will be performed during the procedure of intubation (from the beginning of the preoxygenation to the success of intubation):~* In the pharynx (via a nasopharyngeal catheter) for the needs of the study~* On the facemask (as the practice in the OR)"
223908610|NCT06821763|DRUG|Calcium Hydroxide Intracanal medication|non setting calcium hydroxide(CH) mixed with normal saline and placed as intra canal medicament during first visit of root canal treatment. effectiveness measured after 48hrs, 72hrs and 96hrs
224083718|NCT05228366|OTHER|Ineffective heel warming with thermofor group|Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
224083719|NCT00410176|BEHAVIORAL|sanitation and personal hygiene|
223908611|NCT06821763|DRUG|triple antibiotic paste (TAP)|mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.
223908612|NCT06823687|OTHER|Virtual reality glasses|Virtual reality glasses Beginning 1-2 minute before the start of the procedure, the patients will be watched (5-10 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product.
223908613|NCT03625115|BEHAVIORAL|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
223908614|NCT06535828|DEVICE|AI and mechanic modeling|The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
223908615|NCT06822270|PROCEDURE|open surgery|open surgical methods for treating Pelvi-ureteric Junction Obstruction
223908616|NCT06822270|PROCEDURE|Laparoscopic Pyeloplasty|minimally invasive laparoscopic techniques.
224083720|NCT01653730|DEVICE|Eclipse 3 portable oxygen concentrator|
223715898|NCT02132091|DIETARY_SUPPLEMENT|400 IU Vitamin E|once each day in morning; oral pill form
223715899|NCT02132091|DIETARY_SUPPLEMENT|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
224083721|NCT01653730|DEVICE|EverGo portable oxygen concentrator|
224083722|NCT01653730|DEVICE|iGo portable oxygen concentrator|
224083723|NCT03446495|DRUG|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
224083724|NCT00925600|BIOLOGICAL|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
224083725|NCT00925600|BIOLOGICAL|Placebo|Prefilled syringe for subcutaneous (SC) injection
224083726|NCT04785612|BIOLOGICAL|RSVPreF|A single dose of 120 mcg RSVpreF for intramuscular injection
224083727|NCT04785612|OTHER|Placebo|A single Placebo dose for intramuscular injection to match experimental vaccine
224083728|NCT00646295|DEVICE|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
224083729|NCT06958367|DRUG|Dexmedetomidine|the effect of dexmedetomidine administration on AKI after ascending aortic surgeries requiring CPB in a placebo-controlled randomised controlled trial.
224083730|NCT06958367|DRUG|Normal Saline (Placebo)|Group (B): the control group will receive an infusion of an equivalent volume of a 0.9% saline for the same duration
224083731|NCT00227201|BEHAVIORAL|Self-affirmation intervention|
224083732|NCT01682005|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
223908617|NCT04824885|DEVICE|Chlorhydric acid based acid concentrate for bicarbonate hemodialysis (medical device)|usual dialysate (A + D) for 6 months and then switch to A-D dialysate for the next 6 months
223908618|NCT06823414|OTHER|Video assisted mastectomy|Nipple Skin sparing mastectomy assisted by endoscopic or robotic
223908619|NCT04285814|DIAGNOSTIC_TEST|Whole Fetal Cell (WFC) Testing|Performing WFC testing on blood specimens.
223908620|NCT06646250|DEVICE|NeoDoppler - CE certified|The NeoDoppler is small and light weighed constructed as a single element transducer, that can be gently fixed over the fontanelle. The system is fully compatible for cooccurring use with other intensive care equipment for neonates as well as caregiving from the parents. It is capable of measuring cerebral blood flow at different depths of the brain simultaneously. The Doppler velocity measurements arise from a cylindrical volume of tissue. It is therefore less sensitive to the exact position and angle of the probe over the fontanel to target the vessels of interest than standard hand-held Doppler. This means that the NeoDoppler system may be placed by healthcare professionals who do not have specialized training performing diagnostic ultrasound exams of the cerebral vasculature in neonates.
223908621|NCT04797195|OTHER|CKD-PD app with home monitoring equipment|use home monitoring equipment to measure blood pressure, body weight, and dialysate fluid volume and record in CKD-PD app
223908622|NCT06823258|DRUG|HS-10365|HS-10365 administered orally once at D1
223908623|NCT06609642|BEHAVIORAL|Art application|"First, participants will complete questionnaires that will provide us with their socio-demographic information, their level of knowledge in visual arts and music, as well as their level of eco-anxiety.~Second, participants will use the application on a touchscreen tablet:~1. A member of the research team will give a brief explanation of the application.~2. The participant will use the application on the touchscreen tablet.~3. A member of the research team will be present in the room during the test as an observer.~Third, the participant will answer questions from a member of the research team: impressions of the tool, digital skills and abilities, enablers and barriers to the use of the tool, expectations, needs, and interests in the application."
224083733|NCT01974817|BIOLOGICAL|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
224083734|NCT00061711|DRUG|Hormone Replacement Therapy|
224083735|NCT00061711|DRUG|Cimicifuga racemosa (Black Cohosh)|
224083736|NCT00061711|DRUG|Multibotanical phytoestrogen formula|
224083737|NCT01241500|DRUG|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
224083738|NCT02151825|DIETARY_SUPPLEMENT|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
224083739|NCT02151825|OTHER|Placebo|3 capsules of Maltodextrin per day
224083740|NCT05148026|DRUG|Unfractionated heparin + RCA first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH
224083741|NCT05148026|DRUG|Unfractionated heparin first|Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
224083742|NCT03551548|DRUG|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
224083743|NCT03551548|DRUG|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
223908624|NCT06822556|DIETARY_SUPPLEMENT|Placebo|14 days of supplementation with 25 mg/day hemicellulose crystalline
223908625|NCT06822556|DIETARY_SUPPLEMENT|Tetraselmis chuii|14 days of supplementation with 25 mg/day tetraselmis chuii
223908626|NCT04101357|DRUG|BNT411|intravenous
223908627|NCT04101357|DRUG|Atezolizumab|intravenous
223908628|NCT04101357|DRUG|Carboplatin|intravenous
223908629|NCT04101357|DRUG|Etoposide|intravenous
223908630|NCT05553353|DEVICE|repetitive transcranial magnetic stimulation--Active|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. An active coil will be used to administer the active rTMS.
223908631|NCT05553353|DEVICE|repetitive transcranial magnetic stimulation--Sham|Repetitive transcranial magnetic stimulation (rTMS) is a type of non-invasive brain stimulation. A sham coil will be used to administer the sham rTMS.
223908632|NCT06348329|OTHER|Birth Preparation Training|Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
223908633|NCT06113965|DEVICE|Peripheral Nerve Stimulation|Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity
223908634|NCT04421222|DRUG|EPI-7386 (QD)|Once daily oral dose of EPI-7386
223908635|NCT04421222|DRUG|EPI-7386 (BID)|Twice daily oral dose of EPI-7386
223908636|NCT04421222|DRUG|Abiraterone acetate|Once daily dose of abiraterone acetate
224083744|NCT00594477|RADIATION|IMRT|
224083745|NCT04836949|DEVICE|Shear Wave Elastography of prostate|A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.
224083746|NCT04836949|DEVICE|Conventional Prostate Ultrasound|A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
224083747|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
224083748|NCT01591070|DRUG|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
224083749|NCT01891643|DRUG|Lenalidomide|
224083750|NCT01891643|DRUG|Dexamethasone|
224083751|NCT01891643|BIOLOGICAL|Elotuzumab|
223908637|NCT04421222|DRUG|Apalutamide|Once daily dose of apalutamide
223908638|NCT05255393|OTHER|Questionnaires|"A 13-item questionnaire specific to LEL, developed and validated by investigators at the Mayo Clinic.~The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients.~The EORTC Quality of Life - Cervical Cancer Module."
223908639|NCT02497950|DEVICE|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
223908640|NCT06310551|DRUG|Oral VH4524184|VH4524184 to be taken orally.
223908641|NCT06310551|DRUG|VH4524184 Formulation A SC|Low (\<1mL) starting dose of VH4524184 LAI Formulation A administered subcutaneously.
223908642|NCT06310551|DRUG|Placebo Formulation A SC|Starting dose of Placebo Formulation A administered subcutaneously.
223908643|NCT06310551|DRUG|rHuPH20|Dose of rHuPH20 administered subcutaneously.
223908644|NCT06310551|DRUG|VH4524184 Formulation B SC|Starting dose of VH4524184 LAI Formulation B administered subcutaneously.
223908645|NCT06310551|DRUG|Placebo Formulation B SC|Starting dose of Placebo Formulation B administered subcutaneously.
223908646|NCT06310551|DRUG|VH4524184 Formulation C SC|Starting dose of VH4524184 LAI Formulation C administered subcutaneously.
223908647|NCT06310551|DRUG|Placebo Formulation C SC|Dose of Placebo Formulation C administered subcutaneously.
223908648|NCT06310551|DRUG|VH4524184 Formulation A IM|Starting dose VH4524184 LAI Formulation A administered intramuscularly.
223908649|NCT06310551|DRUG|Placebo Formulation A IM|Dose of Placebo Formulation A administered intramuscularly.
223908650|NCT06310551|DRUG|VH4524184 Formulation B IM|Starting dose VH4524184 LAI Formulation B administered intramuscularly.
223908651|NCT06310551|DRUG|Placebo Formulation B IM|Dose of Placebo Formulation B administered intramuscularly.
223908652|NCT05377281|PROCEDURE|Peripheral Nerve Tissue Implantation|At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epineurium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
223908653|NCT05590689|DRUG|Gliolan|A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
223908654|NCT05590689|RADIATION|Radiodynamic therapy|Radiotherapy will be performed in combination with Gliolan administration
223908655|NCT05394935|OTHER|High-Intensity Exercise|Acute, low-volume HIIT 12x (1min:1min) Working intensity: \>85% heart rate reserve Resting intensity: Active rest
223908656|NCT05394935|OTHER|Moderate-Intensity Exercise|Continuous, MISS 50mins Working intensity: 50-60% heart rate reserve
223908657|NCT06255288|OTHER|SNAK intervention|The intervention consists of structured dialogue, patient information, and a protein supplement. The structured dialogue part of the intervention consists of an A3 poster with illustrations and keywords which will be hanging in the outpatient clinics. The poster will be utilized by nurses, patients, and their relatives to facilitate a dialogue regarding nutrition and wound healing. The patient information part of the intervention consists of a leaflet with easy-to-read information, which patients and their relatives can bring home after their visit to the outpatient clinic. The leaflet will consist of general information as well as food categories and recipes they can use to enhance their daily protein intake. For the protein supplement part of the intervention, the patients will have access to protein supplement beverages while they are in the outpatient clinic waiting room. Furthermore, they will receive prescriptions for protein drinks, that they can pick up at their local pharmacy.
223908658|NCT06082323|DRUG|LT-002-158/Placebo oral tablet(s)|Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
223908659|NCT04028284|DEVICE|HoloLens-guided epidural|To determine whether using the HoloLens tool increases the success of epidural insertion.
223908660|NCT04028284|OTHER|US-guided epidural|traditional thoracic epidural procedure
223908661|NCT00949598|DRUG|letrozole|Given orally
223908662|NCT00949598|DRUG|tamoxifen citrate|Given orally
223908663|NCT03190538|OTHER|No intervention|There will be no specific intervention to these paediatric NASH patient
223908664|NCT05229822|DIAGNOSTIC_TEST|LBP|Determine any presence of LBP in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
223908665|NCT05229822|DIAGNOSTIC_TEST|sCD14-ST|Determine any presence of sCD14-ST in blood serum by ELISA method 1 hour before surgery, 24 and 72 hours after it.
223908666|NCT05229822|DIAGNOSTIC_TEST|16s rRNA|Determine any presence of 16s rRNA in mesenteric lymph nodes by PCR method.
223908667|NCT06077214|DRUG|Treatment with liposomal bupivacaine|Patients will randomly be treated with either liposomal bupivacaine (study drug) after undergoing bariatric surgery.
223908668|NCT06077214|DRUG|Treatment with standard bupivacaine|Patients will randomly be treated with standard bupivacaine after undergoing bariatric surgery.
223908669|NCT05176470|DRUG|Cyclophosphamide|Given IV
223908670|NCT05176470|DRUG|Fludarabine|Given IV
223908671|NCT05176470|BIOLOGICAL|Lifileucel|Given by IV infusion
223908672|NCT05176470|BIOLOGICAL|Pembrolizumab|Given IV
223908673|NCT05176470|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223908674|NCT04075461|PROCEDURE|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
223908675|NCT04075461|PROCEDURE|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
223908676|NCT06045299|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|Aceclidine+Brimonidine combination ophthalmic solution
223908677|NCT06045299|DRUG|Aceclidine ophthalmic solution|Aceclidine ophthalmic solution
223908678|NCT06045299|DRUG|Placebo (Vehicle) ophthalmic solution|Placebo (Vehicle) ophthalmic solution
223908679|NCT03915262|BIOLOGICAL|Search for exocrine pancreatic insufficiency at week 0 and 12|"We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record."
223908680|NCT06536517|DRUG|Methadone|Intra-operative single dose IV Methadone (0.25 mg/kg of ideal body weight)
223908681|NCT06541184|DRUG|Ziconotide [Prialt]|Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
223908682|NCT04016545|DEVICE|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
223908683|NCT06278285|OTHER|Blood GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues
223908684|NCT06278285|OTHER|Blood No treated GLP1|On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.
223908685|NCT04566237|PROCEDURE|Objective Scatter Index (OSI)|On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
223908686|NCT04566237|PROCEDURE|Average Lens Density (ALD)|on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
223908687|NCT06149663|DRUG|LP352|LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.
223908688|NCT06127459|BEHAVIORAL|Parental Guidance|Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).
223908689|NCT06127459|BEHAVIORAL|Virtual Reality Game|Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
223908690|NCT01926080|OTHER|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
223908691|NCT04985955|DRUG|Tofacitinib|Tofacitinib tablet will be administered orally.
223908692|NCT01988883|DRUG|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
223908693|NCT01988883|DRUG|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
223908694|NCT01988883|DRUG|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
223908695|NCT06320171|DEVICE|Non-Invasive neuromodulation|Direct stimulation of the autonomic nervous system was achieved using Program 7 (P7) of the device, with a directional electrode positioned at the level of the C7 spinous process. P7 delivered a biphasic polarity current with oscillatory frequencies ranging from 1.92 to 14.29 Hz and variable intensities between 0.1 and 0.9 mA.
223908696|NCT06320171|OTHER|Placebo|The placebo group followed the same procedure, except that no current was applied during their 20-minute session.
223908697|NCT05724797|DRUG|NRS-033|A single dose of NRS-033 will be administered
223908698|NCT05724797|DRUG|Placebo|A single dose of matching placebo will be administered
223908699|NCT05408975|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
223908700|NCT05408975|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
223908701|NCT05298748|OTHER|Womb sound recordings|"Womb sounds will be chosen from commercially available (Amazon) womb recordings using a recording that most closely resembles the womb including maternal heart rate, fetal heartbeat, respiratory sounds, bowel popping sounds and frequency spectra as described by Parga, Daland 2018 et al."
223908702|NCT04308681|OTHER|BMS-986278 Placebo|Specified Dose on Specified Days
223908703|NCT04308681|DRUG|BMS-986278|Specified Dose on Specified Days
223908704|NCT02070549|DRUG|Trametinib|Given PO
223908705|NCT04819334|OTHER|Composition of Sports Drink|The composition of sport drinks will be manipulated to determine the effect of drink composition on the appearance of ingested water in body fluid.
223908706|NCT05664217|DRUG|NKTR-255 at 1.5 µg/kg|NKTR-255 at 1.5 µg/kg
223908707|NCT05664217|DRUG|NKTR-255 at 3.0 μg/kg|NKTR-255 at 3.0 μg/kg
223908708|NCT05664217|DRUG|NKTR-255 at 3.0/6.0 μg/kg|NKTR-255 at 3.0/6.0 μg/kg
223908709|NCT05664217|OTHER|Placebo Comparator|Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
223908710|NCT03844750|PROCEDURE|Hepatectomy|Undergo liver resection.
223908711|NCT03844750|BIOLOGICAL|Pembrolizumab|Given IV
223908712|NCT03844750|DRUG|Vactosertib|Given orally
223908713|NCT05920863|PROCEDURE|TACE|TACE: pharmorubicin 30mg, oxaliplatin 50mg, cycle 4-5 week.
223908714|NCT05920863|DRUG|Tislelizumab, Lenvatinib|Tislelizumab: 200mg, cycle 3 week. Lenvatinib: weight \<60kg, 8mg/day; weight ≥60kg, 12mg/day.
223908715|NCT05105009|DRUG|Furosemide Injection|"* Furosemide Stress Test ( 1mg/kg in non diuretic users and 1.5 mg/kg in diuretic users).~* Oral creatinine load using 5 grams of creatinine"
223908716|NCT05105009|DRUG|Creatinine Powder|5g of creatinine (Sigma) in 250 ml of water was taken orally
223908717|NCT05105009|DRUG|Iohexol|5 ml iohexol (Omnipaque) intravenously
223908718|NCT06108076|DRUG|Ketone Monoester (KE)|Ketones are a nutritional supplement currently used by athletes for their performance enhancing effects - specifically their cardio-pulmonary benefits
223908719|NCT03822312|DEVICE|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
223908720|NCT03822312|DEVICE|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
223908721|NCT05565820|OTHER|Vamousse Spray 'n' Go|Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
223908722|NCT05565820|DRUG|Nix Creme Rinse Lice Treatment|1% permethrin lotion for topical application.
223908723|NCT03209609|DEVICE|VEST|External support for vein grafts, cobalt chrome braid
223908724|NCT03209609|PROCEDURE|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
223908725|NCT06281041|DRUG|Antiplatelet Agents|Aspirin or clopidogrel
223908726|NCT05086796|BEHAVIORAL|Substance Use Treatment and Recovery Team (START)|"START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor"
223908727|NCT03295721|DRUG|HTX-011|HTX 011 (bupivacaine/meloxicam), 60 mg/1.8 mg by instillation
223908728|NCT03295721|DRUG|Saline Placebo|Saline placebo by instillation
223908729|NCT03295721|DRUG|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg by injection
223908730|NCT03295721|DEVICE|Luer-lock applicator|Applicator for instillation
223908731|NCT03295721|DEVICE|Vial access device|Device for withdrawal of drug product
223908732|NCT05195281|PROCEDURE|Fine Needle Biopsy or Aspiration|A new sampling of the tumor will be performed after 4-6 months of neoadjuvant chemotherapy
223908733|NCT02573779|OTHER|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
223908734|NCT06547216|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
223908735|NCT06021353|DEVICE|UV fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
223908736|NCT06021353|DEVICE|IR fs-Laser|Stationary scanning spot femtosecond laser used for corneal flap creation during refractive surgery
223908737|NCT06021353|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis (LASIK) surgery
223908738|NCT06430333|BEHAVIORAL|Perinatal Understanding of Mindful Awareness for Sleep (PUMAS)|Mindfulness-based sleep program for pregnant women.
223908739|NCT06430333|OTHER|Treatment-as-usual (TAU)|Usual practices from real-world care experiences.
223908740|NCT06190223|PROCEDURE|Anterior cruciate ligament (ACL) reconstruction with a periost-patellar-tendon-bone (PPTB) autograft and a tibial press-fit technique|A longitudinal incision will be performed starting from the central part of the patella. A ruler will be used to mark a tendon thickness of 10mm from the middle of the patellar tendon. Superiorly, the patellar periosteum will be marked with a length of 30-40mm and a width of 10mm. Inferiorly, the tibial tubercle will be marked in a trapezoidal shape with a length of approximately 35mm, a superior narrow base of 10mm and an inferior wider base of 12mm. After extraction, the superior part of the graft will be prepared with reinforced sutures in a whipstitch pattern, while the bone block will be shaped according to the planned tunnel width. After adequate preparation, the femoral end of the graft will be shuttled in with an adjusted fixation device, while the tibial end will be hammered in with a small mallet, in a press-fit fashion, stopping short of the joint surface, but tensioned appropriately. The femoral adjustable device will then be tensioned to ensure proper graft sitting.
223908741|NCT00898638|OTHER|biologic sample preservation procedure|
223908742|NCT00898638|OTHER|medical chart review|
223908743|NCT02393885|DEVICE|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
223908744|NCT06757036|BEHAVIORAL|Laughter Yoga|the group where Laughter Yoga is performed
223908745|NCT06422793|PROCEDURE|No NG tube gastric decompression|Participants in this group will not undergo gastric decompression following orthognathic surgery at our institution.
223908746|NCT04258033|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
223908747|NCT06799975|OTHER|Education|"Patients in the education group will have a meeting with a physiotherapist at the end of the T1 evaluation, which will take place in a suitable room that ensures privacy is maintained. During this meeting, the physiotherapist will provide the patient with advice regarding their return home and will suggest simple exercises to activate/maintain the abdominal and lower back muscles, to be performed at home until the next visit, one month after the surgery. These exercises are part of standard clinical practice and should be routinely performed by patients who undergo lumbar spinal fusion in the period following the surgery. Additionally, the patient will have the opportunity to communicate, via email or phone, with the physiotherapist until the follow-up appointment with the spine surgeon (scheduled for one month later)."
223908748|NCT06799975|OTHER|Usual Care|The usual discharge procedures consist of a brief interview with the neurosurgeon during which instructions are provided on how to manage the first month after the surgery.
223908749|NCT05584553|DEVICE|ToggleLoc 2.9 mm soft tissue device|The ToggleLoc 2.9 mm Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
223908750|NCT05584553|DEVICE|JuggerLoc soft tissue device|The JuggerLoc Soft Tissue devices consist of non-resorbable devices intended to aid in arthroscopic and orthopaedic reconstructive procedures requiring soft tissue to bone fixation.
224083752|NCT00004165|BIOLOGICAL|filgrastim|
224083753|NCT00004165|DRUG|melphalan|
224083754|NCT00004165|PROCEDURE|peripheral blood stem cell transplantation|
223908751|NCT05935228|OTHER|Implementation of the A-DIVA Scale|Phase 2 aims to evaluate the impact of the implementation of the A-DIVA Scale (classification score for difficult intravenous access) on practitioners' approaches to the peripheral venous catheter placement. It consists of a systematic collection of peripheral venous catheter placement practices for quantitative data and a questionnaire of professionals' opinions on the use of the A-DIVA scale for qualitative data. The main objective of this phase is to recognize the potential appearance of changes in practices through the implementation of a tool for evaluating vascular access difficulties
223908752|NCT05935228|OTHER|Implementation of the algorithm composed of the A-DIVA Scale and the new decision-making tree (the A-DIVA Tool) in the centers|"The main objective of this phase is to evaluate the impact of the algorithm on the quality of peripheral venous catheter placement.~• Systematic collection of judgment criteria and socio-demographic and clinical characteristics of patients. Description of the care strategy implemented. Systematic collection of the A-DIVA Scale with identification of the patient's risk group, systematic rating of pain and evaluation of overall comfort."
223908753|NCT05766332|OTHER|Clinical Evaluation|Undergo clinical evaluation
223908754|NCT05766332|OTHER|Electronic Health Record Review|Medical records reviewed
223908755|NCT04786119|DEVICE|CORI Robotics|Knee arthroplasty with robotics assisted surgery using the CORI Robotics System.
223908756|NCT06772506|PROCEDURE|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|non-surgical technique plus splint and ultrasonic device with 200 mg Tetracycline
223908757|NCT06772506|PROCEDURE|Minimally invasive non-surgical technique with mini five and after five minimally invasive instrument plus splint|minimally invasive instruments, with mini five and after five minimally invasive instrument ultrasonic scaler device, conventional radiographic device and periodontal instruments with post-operative 1 gram penicillin for 3 days regulatory Statement: This study does not include an FDA-regulated device intervention, as the tools utilized are not the subject of investigation but are instead employed as part of routine clinical
223908758|NCT04118023|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging Test|MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
223908759|NCT05840354|DEVICE|Magstim Rapid2|"1-4 weeks after administration of the SJI, participants will attend their first rTMS session. rTMS will be delivered using a biphasic stimulator (DuoMag) and a figure-of-eight coil to the corticomotor representation of the first dorsal interosseous muscle contralateral to the side of worst pain. Recording electrodes will be positioned in a belly-tendon montage over the FDI for electromyography recording. The hotspot and resting motor threshold (rMT) of the FDI will be determined and saved using a Brainsight Neuronavigation system to ensure accurate coil repositioning within and between sessions.~The hotspot and rMT will be confirmed and adjusted if needed at each intervention session. Each rTMS session will consist of 40 trains of 5s delivered at 10Hz, at an intensity of 85% of the resting motor threshold for the FDI muscle and an intertrain interval of 25s (total of 2000 stimulations in a 20-minute session)."
223908760|NCT05840354|DEVICE|Placebo D70mm Air Film Coil|Sham intervention will follow same protocol as active rTMS using a sham coil that does not deliver actual magnetic stimulation.
223908761|NCT06431750|OTHER|Secukinumab|This is an observational study, there is no treatment allocation.
223908762|NCT06558825|BEHAVIORAL|Integrated Intervention to Promote PrEP Uptake|Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.
223908763|NCT06558825|OTHER|Standard Treatment Condition|Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
223908764|NCT05406284|PROCEDURE|double kissing nano culotte stenting|patients with true coronary bifurcation lesion treating with double kissing nano culotte stunting technique
223908765|NCT06620770|OTHER|questionnaires|Morisky and SF12 Questionnaires delivery at inclusion, 6, 12 and 18 months
223908766|NCT03325985|BEHAVIORAL|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
223908767|NCT03325985|BEHAVIORAL|Facilitated,outpatient specialty palliative care|In-person or telehealth palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
223908768|NCT05726825|DEVICE|Therapeutic Plasma Exchange (TPE)|"The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure.~Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication.~To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid."
223908769|NCT05892744|DRUG|Sertraline|50-200mg/day
223908770|NCT02831959|DEVICE|NovoTTF-200M device|
223908771|NCT02831959|OTHER|Best Standard of Care|
223908772|NCT06138470|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
223908773|NCT06138470|DIETARY_SUPPLEMENT|Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
223908774|NCT06138470|DIETARY_SUPPLEMENT|Saffron and Scutellaria baicalensis extract|Food supplements are taken during 6 weeks by healthy volunteers
223908775|NCT06138470|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|Food supplements are taken during 6 weeks by healthy volunteers
223908776|NCT04151550|DEVICE|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
223908777|NCT03556293|BEHAVIORAL|AKI Prevention Toolkit|AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
223908778|NCT03556293|BEHAVIORAL|Technical Assistance (TA)|Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
223908779|NCT03556293|BEHAVIORAL|Virtual Learning Collaborative (VLC)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator \[CAC\] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
223908780|NCT03556293|BEHAVIORAL|Automated Surveillance Reporting (ASR)|Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
223908781|NCT05981040|DRUG|ZYIL1 capsules 25 mg and 50 mg Placebo|ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
223908782|NCT05981040|DRUG|ZYIL1 capsules 50 mg and 25 mg Placebo|ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
223908783|NCT05981040|DRUG|ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg|ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
223908784|NCT05981040|DRUG|Matching placebo 25 mg and Matching placebo 50 mg|Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
223908785|NCT06224712|BEHAVIORAL|Arogya Sangama|Using human-centered design, the investigators will work wit the community to develop a prototype Arogya Sangama model to identify methods to bring GPTF and HWC service providers to create ideas, systems, processes, services, and delivery strategies for the GPTFs. They will help identify and prioritize interventions and address barriers to usability. There will also be capacity building of GPTFs to implement the interventions identified.
223908786|NCT06196203|DRUG|AK117|AK117 IV injection
223908787|NCT06196203|DRUG|Placebo|Placebo IV injection
223908788|NCT06196203|DRUG|Azacitidine|Azacitidine SC injection
223908789|NCT04246138|PROCEDURE|alignment types|types of alignment mechanical versus kinematic of TKA to be studied
223908790|NCT03822793|DRUG|Placebo|Patient will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
223908791|NCT03822793|DRUG|Group 1: perfusion of 300 mg Exacyl|Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
223908792|NCT03822793|DRUG|Group 2: perfusion of 500 mg Exacyl|Patient will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
223908793|NCT03822793|DRUG|Group 3: perfusion of 1000 mg Exacyl|Patient will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
223908794|NCT03822793|DRUG|Group 4: perfusion of 3000 mg Exacyl|Patient will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
223908795|NCT05005416|BEHAVIORAL|GOALS Intervention|Weekly treatment sessions are comprised of a graded activity program focused on goal setting in 4 treatment domains: therapeutic exercise, aerobic activity, functional activity, and pain coping skills. Instruction in cognitive behavioral coping skills for pain include: explaining pain (pain neuroscience education), pacing, soliciting positive social support, cognitive restructuring, present mindedness, and symptom self-management planning.
223908796|NCT05005416|BEHAVIORAL|Usual Care Physical Therapy|Usual care will be characterized by extracting the following variables from participants' electronic health record: date of physician referral to physical therapy for neck or low back pain diagnosis (index referral), attendance of at least one PT visit (adherence), dates of first and last PT visits for index referral (duration of care), number of PT visits attended across an 8-week episode of care for the index referral (number of visits), clinic where PT services were provided (service location), and CPT billing codes issued during the episode of care for the index referral (type and frequency of treatments provided).
223908797|NCT05095727|DRUG|mRNA-3745|Sterile frozen liquid dispersion for injection
223908798|NCT05012163|BEHAVIORAL|Reminder|Letter, short message service (SMS) text, phone, and/or email
223908799|NCT05012163|BEHAVIORAL|Financial incentive|Letter, SMS, phone, and/or email
223908800|NCT05012163|BEHAVIORAL|Lottery|Letter, SMS, phone, and/or email
223908801|NCT06412263|PROCEDURE|Routine root canal treatment/ retreatment|It is a routine clinical procedure involving root canal treatment/ retreatment and pain assessment after the treatment
223908802|NCT05986552|BEHAVIORAL|Individual Schema Therapy (IST)|IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
223908803|NCT05986552|BEHAVIORAL|Individual-Group Schema Therapy (IGST)|IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
223908804|NCT04260867|OTHER|Essential Oil|Those randomized to the treatment group will have containers filled with the essential oil of their choice.
223908805|NCT04260867|OTHER|No Essential Oil|Those randomized to the control group will then be given empty single-use handheld aromatherapy containers containing no essential oil.
223908806|NCT04104633|PROCEDURE|Blood samples|30 ml of blood collection
223908807|NCT05584683|DRUG|Amoxicillin potassium clavulanate|LP-001 will be reconstituted and administered as a single dose
223908808|NCT05584683|DRUG|Amoxicillin potassium clavulanate (Augmentin ES-600)|Augmentin ES-600 will be reconstituted and administered as a single dose
223908809|NCT04896580|BEHAVIORAL|Nature based exercise|Participants will engage in three months of moderate intensity PA, consisting of three 50-minute walking sessions per week (5-minute warm-up, 40 minute walk, 5 minute cool-down and stretch) with an exercise physiologist for 12 weeks.
223908810|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Sulfasalazine enteric-coated tablets Cohort A: PBC treatment group: (1) PBC patients with poor response to UDCA after treatment: 30 patients continued to take UDCA(13-15mg/kg), 30 patients took UDCA(13-15mg/kg)+SASP (0.5g orally three times a day), 30 patients took SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected. (2) Newly treated PBC patients: 30 patients took UDCA(13- 15mg/kg) and 30 patients took UDCA(13-15mg/kg)+SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
223908811|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort B:60 cases with hepatitis B cirrhosis were collected from each group, 30 cases continued the current treatment, and 30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
223908812|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort C：Patients with HCV were treated with sulfasalazine Cohort C: 60 cases with hepatitis C cirrhosis were collected，30 cases continued the current treatment(people with hepatitis C cirrhosis continue to take antivirals), and30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
223908813|NCT06293378|DRUG|Sulfasalazine enteric-coated tablets|Cohort D：Patients with alcoholic liver fibrosis/cirrhosis were treated with sulfasalazine 60 cases with alcoholic cirrhosis were collected , 30 cases continued the current treatment and 30 patients were taking SASP (0.5g orally three times a day) for 12 months of follow-up observation. During 12 months of treatment, at the time of enrollment and the 1st/3rd/6th/9th/12th months, the liver function, fecal flora, liver fibrosis and immune related indexes were detected.
223908814|NCT06833879|DEVICE|Activity Tracking Watch|Device includes a wristwatch that tracks physical activity and a data storage unit that transmits data to a central database.
223908815|NCT06827184|DEVICE|Electrical Impedance Tomography|It utilizes electrical impedance tomography to analyze a series of physiological changes in the lungs following treatment
223908816|NCT05015192|DRUG|NH102|tablets, orally
223908817|NCT05015192|DRUG|Placebo|tablets, orally
223908818|NCT06836674|OTHER|Jigsaw|In this learning method, students will be divided into main and expert groups. Then, an expert from each group will come and the student will be provided with expertise in the subject given to him/her by the instructor. After the student has specialized, he/she will return to his/her own group and will provide training to his/her friends on the subject he/she has specialized in under the supervision of the instructor of the course. During the student\&#39;s specialization process on the subject given, the necessary literature support and controls will be provided by the instructor of the course.
223908819|NCT06836674|OTHER|Metaverse|In this learning method, the topics determined on pediatric drug applications will be prepared weekly by the relevant instructor of the course and will be transferred to the metaverse and presented to the student in the form of weekly modules.
223908820|NCT06836674|OTHER|Classical Education|In this learning method, the subjects determined by the instructor will be explained to the students in a laboratory environment by the instructor using a presentation (power point) method.
223908821|NCT06834620|BEHAVIORAL|Rhythmic and Gymnastic Activities-Based School Physical Education Program|A structured, year-long school-based physical education program integrating rhythmic movements, gymnastics, and small equipment exercises designed to enhance motor and physical fitness. The program included 80 sessions (two per week) focusing on rhythmic activities such as twisting, partner balance, animal walks, tumbling, and rope exercises. The intervention aimed to improve strength, flexibility, agility, and cardiovascular endurance compared to traditional physical education classes.
223908822|NCT04975945|DRUG|Ceftriaxone Sodium|Intravenous vs local action
223908823|NCT06837558|DIAGNOSTIC_TEST|fibroblast growth factor 23|"Investigations: including the different following modalititis~A. Laboratory investigations include:~1. Complete blood picture, PT PC INR, RBS Kidney function tests, eGFR Urine analysis, 24 hours' protein in urine~2. Specific laboratory investigations for SLE and lupus nephritis: ANA,AntiDsDNA,C3,C4~3. Laboratory investigations of Bone mineral density predictors Ca, phosphorus, PTH, vitamin D (OH), Alkaline phosphatase, Fibroblast Growth Factor 23 (FGF 23)~B. Imaging studies:~1 - Abdominal ultrasound 2- chest x-ray 3- Echocardiography (in lupus nephritis with activity form) 4- DEXA bone scan~C. Invasive modality:~Renal biopsy of Patients with SLE with lupus nephritis"
223908824|NCT06835816|DIETARY_SUPPLEMENT|Amino acid supplementation (Glavamin, Fresenius Kabi)|Mixture of amino acids (67 g / 500 ml) given intravenously
223908825|NCT05963646|DIAGNOSTIC_TEST|Natural history study|Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.
223908826|NCT06840067|RADIATION|carbon ion radiotherapy (CIRT)|1.CIRT: GTV: Primary tumor visible on imaging and clinical examination, and involved regional lymph nodes identified by CT/MRI (≥1.0 cm) or PET/CT scan. CTV: GTV plus 5mm margin, include posterior peritoneal plexus area and elective node irradiation around the pancreas (ENI). PTV: CTV plus 2.5-5mm margin (depending on the system error of each unit; When pancreatic head cancer is close to the stomach and intestines, the gastrointestinal direction does not expand). ITV: delineated on 4D-CT considering the influence of respiratory activity. Prescription dose: Stratification by measuring the nearest distance between PTV and gastrointestinal tract (≥5mm or \< 5mm); Pancreatic head cancer (distance \< 5mm) : 52.8Gy(RBE)/4.4Gy/12Fx; Pancreatic head, body and tail cancer (≥5mm) : 57.2Gy(RBE)/4.4Gy/13Fx. CIRT was once a day, four or five times a week. 2.Chemotherapy:Gemcitabine 1000mg/m2, intravenous infusion, dl, d8; Q3w . 3.Targeted therapyNituzumab injection 400mg, Qw，at least 4-6 cycles.
224083755|NCT04494009|DRUG|INCMGA00012|INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
223908827|NCT05435638|DIAGNOSTIC_TEST|Serum chemistry|"Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126).~Serum chemistries will include assessment of total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase, glucose, sodium, potassium, blood urea nitrogen (BUN), and creatinine."
223908828|NCT05435638|DIAGNOSTIC_TEST|Hematology|Approximately 5 mL whole blood will be collected after an ≥8 h fast for complete blood count (CBC) during Screening, and on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Arm 2: Day 112) and follow-up EoS visits (Cohort 1: Day 91; Cohort 2: Day 126). The CBC assessment will include a red blood cells (RBC), hemoglobin, hematocrit, platelet count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MCV), white blood cells (WBC), neutrophils (% and abs.), lymphocytes (% and abs.), monocytes (% and abs.), eosinophils (% and abs.), basophils (% and abs.), large unstained cells (% and abs.).
223908829|NCT05435638|DIAGNOSTIC_TEST|Urinalysis|"General urinalysis will be performed, by dipstick, during Screening, on Days 7 and 84 of treatment, at early termination (ET), if required, and at the EoT (Cohort 2: Day 112) and follow-up EoS visits (arm 1: Day 91; Arm 2: Day 126).~Approximately 7-10 mL urine will be collected. Urinalysis will include pH, specific gravity, blood, nitrites, glucose, ketones, protein, bilirubin urobilinogen and leukocytes. A microscopic examination of the urine will be performed only if clinically indicated."
223908830|NCT05435638|DIAGNOSTIC_TEST|Physical Examination|"A complete physical examination will be performed at Screening, at all in-clinic study visits, and at the End of Study visit.~The physical examination will cover a careful assessment of all body systems, including the head, eyes, ears, nose, and throat and the respiratory, cardiovascular, GI, urogenital, musculoskeletal, neurological, dermatological, hematologic/lymphatic, and endocrine systems. Particular attention will be placed on the areas affected by the disease.~• Symptom-directed physical examinations will be performed at all other study visits."
223908831|NCT05435638|DIAGNOSTIC_TEST|Vital Signs|Vital sign measurements (body temperature, pulse and resting systolic and diastolic blood pressure) will be measured at Screening, at all in-clinic study visits, and at the End of Study visit. Vital signs will be measured in supine position after at least five minutes of rest.
223908832|NCT05435638|DIAGNOSTIC_TEST|ECG Test|A 12-lead, resting, digital ECG will be taken for each participant during Screening, on Days 42 and 84 (for both arms), and on day 112 (Arm 2 only), after the patient has been supine for at least 5 min. At minimum, the following ECG parameters will be recorded: heart rate (HR), PR, QT and QRS intervals and QTC. The report will be signed by the Investigator, who will record in the CRF whether it is normal, abnormal but not clinically significant, or abnormal AND clinically significant. In the latter case the eligibility of the participants will be reviewed.
223908833|NCT05435638|DIAGNOSTIC_TEST|PK|"Blood PK analyses will be performed on ≥5ml blood collected in 5-mL K-EDTA CRO coded pre-labeled tubes, refrigerated immediately after collection. Plasma will be separated by centrifugation within 2h, and then frozen at -20C.~Blood samples will be collected pre-dose on Days 0, 7, and 84, as well as pre-dose at EoT (Arm 2: Day 112), and at any point during the in-clinic visit at EoS (Arm 1: Day 91; Arm 2: Day 126)."
223908834|NCT05435638|DIAGNOSTIC_TEST|IGA scoring|"Lesions severity will be assessed using the Investigator's Global Assessment (IGA) scale,which is a 5-point scale (from 0 =no disease to 4=severe disease) based on Simpson et al. 2020, IGA for atopic dermatitis (see Table 4; Simpson et al. 2020).~The IGA score is selected using the descriptors below that best describe the overall appearance of the lesions at a given timepoint. It is not necessary that all characteristics under morphological description are present. Excoriations should not be considered when assessing disease severity."
223908835|NCT05435638|DRUG|KM-001 1% cream 12 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
223715900|NCT04472702|PROCEDURE|cRFA|cRFA intervention will occur under sterile conditions, the patient will be placed in a supine position on a table and a bolster to provide flexion in the treated knee joint. Skin and soft tissues will be anaesthetized with 2 mL 1% lidocaine at each of the three anatomic sites for cRFA, and a introducer needle will then be placed under ultrasound or fluoroscopic guidance to the SLG, SMG, and IMG nerves. Adjustments at these positions will be made when using ultrasound guidance in order to capture the geniculate nerve if the nerve and/or its accompanying vasculature can be directly visualized using greyscale or Doppler modes. When using ultrasound, the physician will note and record whether their positioning of the needle is based on bony landmarks, direct visualization of the nerve, and/or vascularity accompanying the nerve. Once the introducer needle is placed, the cRFA will be placed into the introducer needle.
223715901|NCT04535700|DRUG|Pioglitazone 30 mg|Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital
224083756|NCT04751396|OTHER|Best Practice|Receive standard educational information
224083757|NCT04751396|OTHER|Educational Intervention|Navigate educational tool
224083758|NCT04751396|OTHER|Interview|Participate in interview
224083759|NCT04751396|OTHER|Questionnaire Administration|Complete questionnaire
223715902|NCT04535700|OTHER|standard of care|Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
224083760|NCT04751396|OTHER|Survey Administration|Complete surveys
224083761|NCT04858477|OTHER|Visual estimation of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size
224277254|NCT04755673|OTHER|Atrantil (Medical Food)|All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
224277255|NCT04436133|BIOLOGICAL|Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
224277256|NCT04436133|BIOLOGICAL|9-valent HPV vaccine（Gardasil 9）|Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml per bottle
224277257|NCT01337596|DRUG|LY2951742|Administered subcutaneously
224277258|NCT01337596|DRUG|Placebo|Administered subcutaneously
223908836|NCT05435638|DIAGNOSTIC_TEST|Clinician global impression of severity (CGI-S)|"Lesions severity will be assessed using the CGI-S scale, which is a 5-point scale (from 0= none to 4= very severe) modified from Busner et al. 2007 (30) by the investigator at screening and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The clinician scoring takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms (pain), behaviour, and the impact of the symptoms on the patient's ability to function (ability to walk). investigators will complete the CGI-S at various timepoints based on the question. Please choose the response that best describes your assessment of the disease severity, based upon the totality of information available to you"
223908837|NCT05435638|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"The VAS score will be collected on every in-clinic visit during the treatment period (Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.).~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and~The following parameter will be evaluated on a VAS from 0 (no pain) to 100 (severe intolerable pain) based on the question:~How was your worst pain intensity in the past 24 hours?"
223908838|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of change (PGI-C) scoring|"The PGI-C scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-C will be evaluated using a 7-point scale from 1 (very much improved) to 7 (very much worse) answering the question Since the start of the trial, my overall status has."
223908839|NCT05435638|DIAGNOSTIC_TEST|Patient global impression of severity (PGI-S) scoring|"The PGI-S scale was developed to provide a brief, stand-alone assessment of the patient's view of his/her global functioning prior to and after initiating a trial medication.~The PGIs will be evaluated on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, if applicable.~The PGI-S will be evaluated using a 5-point scale from 1 (none) to 5 (very severe) answering the question Please rate the severity of your disease right now."
223908840|NCT05435638|DIAGNOSTIC_TEST|Lesion photography|High-quality photographic documentation of the treated lesions will be performed on screening, and on Days 0, 7, 28, 42, 63, 84, 91, 112, and 126 (as applicable, per arm), and at ET visit, pre-dose, if applicable.
223908841|NCT05435638|DRUG|KM-001 1% cream 16 weeks treatment|"KM-001 1% cream will be applied to the treated area twice daily for 12 consecutive weeks, 2 gr per treatment, and overall, 4 gr of daily dose.~KM-001 will be supplied in glass jars (30 g) and will be provided to patients with spatulas and polyethylene gloves."
223908842|NCT05332262|DIAGNOSTIC_TEST|Assessment of platelet reactivity|Assessment of platelet reactivity and HPR status will be performed post-PCI. Platelet reactivity will be measured by VerifyNow P2Y12 and HPR status will be defined using a cut-off value of platelet reactivity units (PRU)\>208.
223908843|NCT05332262|DIAGNOSTIC_TEST|Troponin measurement|Measurement of high sensitivity troponin for the assessment for the presence of myocardial infarction/myocardial injury will be performed post-PCI.
223908844|NCT04771897|DRUG|BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
223908845|NCT04771897|DRUG|BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
223908846|NCT04093167|DRUG|Pembrolizumab|Per current Product Monograph/U.S. Drug Label and/or local guidelines.
223908847|NCT06839638|PROCEDURE|100% Trichloroacetic Acid (TCA)|Patients in this group will receive 100% TCA application to xanthelasma lesions using the dipstick method. The surrounding skin will be protected with white soft paraffin to prevent chemical spillage. Post-treatment, Fusidic acid 2% will be applied twice daily for one week. Treatment efficacy will be assessed after six weeks.
223908848|NCT06839638|PROCEDURE|Cryotherapy (Liquid Nitrogen)|Patients in this group will receive cryotherapy using liquid nitrogen. A single freeze-thaw cycle will be performed until a narrow halo of white ice forms around the lesion. Post-treatment care will include Fusidic acid 2% applied twice daily for one week. Treatment efficacy will be assessed after six weeks.
223908849|NCT04760470|OTHER|Technology-assisted upper extremity rehabilitation|Subjects get 6 weeks of technology-assisted upper extremity rehabilitation
224083762|NCT04858477|DEVICE|Napoleon measurement of polyp size|For each colonoscopy, a fellow will first visually estimate the polyp size and then measure the polyp with Napoleon. The Micro-Tech Endoscopic Polyp Measurement Device named Napoleon is a small catheter with a 15mm ruler calibrated at 1mm intervals with 5mm demarcations. It is classified as a Class 1, 510(k) exempt device by the FDA.
224083763|NCT00522067|BIOLOGICAL|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
224083764|NCT03347149|DEVICE|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
224083765|NCT01429571|OTHER|No intervention|No intervention
224083766|NCT06422988|DIETARY_SUPPLEMENT|Probiotics|Any exposure to probiotics in first 14 days of life
224083767|NCT05330208|DRUG|SHR-1816|SHR-1816
224083768|NCT05330208|DRUG|Placebo|Placebo
224083769|NCT02965716|BIOLOGICAL|Pembrolizumab|Given IV
224083770|NCT02965716|BIOLOGICAL|Talimogene Laherparepvec|Given IL
224083771|NCT06530433|DEVICE|CPRCard + TCPR Link App and Web|Application that allows responder to perform CPR with two-way audio communication and one-way video streaming to SCDF Dispatcher
224083772|NCT06530433|DEVICE|CPRCard Only|Control arm with standard care of procedure that Bystander using CPRCard only
224083773|NCT06231745|DRUG|Methotrexate|Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
224277259|NCT01652586|DRUG|dexmedetomidine-remifentanil|
224277260|NCT01652586|DRUG|midazolam-remifentanil|
223908850|NCT05524402|BEHAVIORAL|TOR-C 1|TOR-C 1 is an active intervention, adapted from the original Toolkit for Optimal Recovery program, adjusted for patients with mTBI and anxiety. The TOR-C 1 sessions address mind-body skills, including eliciting the relaxation response (eg, body scan, deep breathing, mindfulness), cognitive-behavioral strategies (eg, reframing), acceptance and commitment skills (eg, acceptance), and skills for returning to activity (eg, goal setting, activity pacing). The format is a 4-week program with weekly sessions and home practice.
223908851|NCT05524402|BEHAVIORAL|TOR-C 2|TOR-C 2 is an active intervention teaching educational information on key modifiable factors relating to recovery after concussion, such as return to activity, the role of nutrition and sleep, and the relationship between concussion and anxiety. The format is a 4-week program delivered over live video with weekly sessions.
223908852|NCT04590196|DRUG|Longvida curcumin|longvida curcumin verdure sciences formulation
223908853|NCT04590196|OTHER|placebo|"Composition of Placebo :~95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide"
224083774|NCT06231745|DRUG|Paroxetine|Paroxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive compulsive disorder (OCD), panic attacks, anxiety or post-traumatic stress disorder (PTSD).
224083775|NCT04047797|DRUG|Ixazomib|Given by mouth
223908854|NCT06374329|OTHER|Interceptive Slow Maxillary Expansion with removable plates|Interceptive Slow Maxillary Expansion with removable plates (see Willems et al 2023) https://doi.org/10.1093/ejo/cjad014
224083776|NCT04047797|DRUG|Ixazomib Citrate|Given by mouth
223908855|NCT06031012|DRUG|CGECC combined with thalidomide|Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
223908856|NCT06031012|DRUG|CGECC alone|Patients received CGECC alone from the beginning of radiotherapy to one week after radiotherapy.
224083777|NCT04047797|BIOLOGICAL|Rituximab|Given Intravenous
224083778|NCT03523351|RADIATION|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
224083779|NCT03523351|DRUG|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
224083780|NCT02013843|BEHAVIORAL|Community-based treatment of overweight and obesity|"Community based treatment of overweight and obese children using the Holbaek-method."
224083781|NCT05933538|DRUG|Cariprazine|The starting dose is 1.5 mg once daily which will be titrated according to the treating psychiatrist who assessing the response with maximum dose of 4.5mg. The dose to be escalated on 2 weekly interval.
223908857|NCT06194110|DIAGNOSTIC_TEST|Ergometric test|Ramp test followed by a step test, both with ergospirometry
223908858|NCT03703908|DRUG|CCX140-B|Orally administered tablet
223908859|NCT05025865|DRUG|Sodium Hyaluronate|Sodium Hyaluronate of molecular weight 35 kDa will be given in capsule form to the study participants.
223908860|NCT05025865|DRUG|Placebo|A placebo will be given in capsule form to study participants.
223908861|NCT06256497|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Revita System is a hydrothermal ablation system, (CE) certified, intended to impart insulin-sensitizing properties to the body via ablation \& rejuvenation of the duodenal mucosa. As an adjunct to diet and exercise, Revita is intended to 1. improve glycemic control in patients with T2D who have preserved pancreatic beta cell function and whose diabetes is inadequately controlled despite oral and/or injectable glucose lowering medications and/or long-acting insulin therapy, 2. Reduce liver fat in patients with T2D and Non-Alcoholic Fatty Liver Disease (NAFLD). The single use Revita Catheter and Line Set are provided sterile and are not implantable or reusable. These disposables are used with the Revita Console an electromechanical device that controls the ablation cycle and submucosal expansion. The Revita System is used in a suitably equipped endoscopy suite. The Catheter contacts the patient's digestive tract for approximately 45-60 minutes.
223908862|NCT05206565|PROCEDURE|Neurotization - Autologous Reconstruction with DIEP/TRAM|"* Transverse Rectus Abdominis Muscle/Deep Inferior Epigastric Artery Flap Harvest - Prior to elevation of flaps in the suprafascial plane from using loupe magnification to identify medial and lateral row of perforators bilaterally, sensory nerves T10-12 are identified and dissected into the muscle bilaterally to prepare for nerve coaptation, nerves are divided at the level of the fascia where they are pure sensory nerves.~* Chest Intercostal Nerve Harvest - During standard of care chest vessel dissection, intercostal nerves T3-4 are identified. After completion of vein coupling it will be determined whether neurotization can be performed or if autograft. Primary nerve coaptation will be performed if there is adequate length for direct end to end apposition.~* Coaptation of nerve or nerve graft endings will be performed using 9-0 nylon suture in an interrupted fashion."
224083782|NCT05933538|COMBINATION_PRODUCT|Treatment as usual|Participants in this will receive either antidepressants including SSRI, SNRI or TCA or for psychotherapy alone or a combination of psychotherapy and antidepressants.
224277261|NCT05405049|DRUG|Morphine hydrochloride|Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.
224083783|NCT00469950|BEHAVIORAL|exercise training|Exercise training in groups
224083784|NCT02633683|DRUG|HORIZANT 600 mg|HORIZANT 600 mg once daily
224083785|NCT01276171|PROCEDURE|Ultrasound|Participants will place arterial line using ultrasound technique
224083786|NCT01276171|PROCEDURE|Doppler|Participants will place arterial line using doppler technique
224083787|NCT01276171|PROCEDURE|Palpation|Participants will place arterial line using Palpation technique
224083788|NCT06099782|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
224083789|NCT06099782|BIOLOGICAL|Pembrolizumab|Administered via IV infusion
224277262|NCT05405049|DRUG|Bupivacain|Group LWI+IPLA will given 30 ml %0,5 bupivacaine+%2 lidocaine infiltration and instillation
223908863|NCT06521801|OTHER|Observation|Observation
223908864|NCT04902508|BEHAVIORAL|Implicit-only|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment.
223908865|NCT04902508|BEHAVIORAL|Explicit-added|Each intervention session will comprise four core activities: sentence imitation, presentation of a model story with production opportunities, and auditory bombardment. Interventionists will also present the rule/pattern guiding the target form.
224083790|NCT03020862|DIETARY_SUPPLEMENT|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
224083791|NCT06399926|DRUG|Pemetrexed injection|Group 1（20mg）:induction stage is 20 mg per 24 hours for 72 hours, every 2 weeks; consolidation stage is 20mg per 24 hours for 72 hours, every 3 weeks.
224083792|NCT06399926|DRUG|Pemetrexed|Group 2（30mg）:induction stage is 30 mg D1，every week.Consolidation stage is 30 mg D1,every 3 weeks.
224083793|NCT02277717|DRUG|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
224083794|NCT01125280|PROCEDURE|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
224083795|NCT01688024|DRUG|Mitomycin C|
224083796|NCT01688024|DRUG|Normal saline|
224083797|NCT00002559|BIOLOGICAL|filgrastim|
224083798|NCT00002559|DRUG|cisplatin|
224083799|NCT00002559|DRUG|ifosfamide|
224083800|NCT00002559|DRUG|paclitaxel|
224083801|NCT05588570|BEHAVIORAL|CAT|Treatment includes 12 sessions: 2 caregiver teach sessions, 4 caregiver coach sessions in the child-directed interaction (CDI) phase, and 6 caregiver coach sessions in the DADS (Describe situation, Approach situation, give Direct command for child to join situation, provide Selective attention based on child's performance) phase. Throughout the 12 sessions, caregivers are coached through exposures in which the child is given the opportunity to slowly encounter anxiety-provoking factors. In the first session, caregivers are provided psychoeducation on anxiety and parenting practices and taught PRIDE (praise, reflect, imitate, describe, enjoy) skills, which are aimed at increasing approach behaviors and decreasing avoidant behaviors. In the CDI phase, caregivers are coached live via Bluetooth headset through the PRIDE and active ignoring skills. In the last 5 sessions, caregivers are coached through the DADS protocol while working up the Fear Hierarchy with the child.
224083802|NCT03723187|OTHER|normal saline|experimental group use normal saline sealing tube
224083803|NCT03723187|OTHER|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
224083804|NCT04691583|OTHER|Fast diet|"Fast diet of High control ：From May 24, 2018, the method of fast diet was adopted on alternate days. According to the dietary records of normal diet, the normal caloric intake of each subject was calculated. Fast diet was carried out according to 2/3, 1/2, 1/3 and 1/4 of the original normal caloric intake.Each caloric stage last for 4 days, and the total cycle of fast diet was 31 days.~Fast diet of Low control ：After the intervention of fast diet of high control, the subjects were allowed to continue the diet fast diet every other day. It was suggested that the daily caloric intake was 600kal/ day for males and 500kal/ day for females."
224083805|NCT01042080|DEVICE|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
224083806|NCT01042080|OTHER|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
224083807|NCT05167773|DEVICE|tonometer|A subject undergoes intraocular pressure measurement with tonometer
224083808|NCT04278326|PROCEDURE|Vaginal Biopsy|"1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear"
224083809|NCT03674151|DEVICE|Silver Nylon dressing|Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound
223908866|NCT06851286|BEHAVIORAL|Laughter Therapy|A laughter yoga session; It is approximately 30 minutes and consists of four parts. These sections; hand clapping and warm-up exercises, deep breathing exercises, childish games and laughter exercises. In each laughter yoga session, the first three parts are the same, but the laughter exercises in the fourth part vary. In the first session of each new group, the introduction of laughter yoga, its purpose and objectives will be discussed. 10 minutes will be allocated for this section in the first session of each group. Therefore, the first session is planned to be 40 minutes in each group and all subsequent sessions are planned to be 30 minutes.
224083810|NCT03674151|DEVICE|Manuka-Honey|Manuka-Honey dressing on split-skin grafted third-degree burn wound
224083811|NCT03674151|DEVICE|Povidone-Iod (PVP-Iod)|Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound
224083812|NCT03674151|DEVICE|Hydrogel|Hydrogel dressing on split-skin grafted third-degree burn wound
224083813|NCT02441790|BEHAVIORAL|Early Active Range of Motion|3-9 days
224083814|NCT02441790|BEHAVIORAL|Standard Immobilization|21-27 days
224083815|NCT04714515|DRUG|Montelukast|An FDA approved medicine to treat asthmatic patients
224083816|NCT04714515|DRUG|Hydroxychloroquine|An FDA approved antiarthritis drug
224083817|NCT04714515|DRUG|Ivermectin|An FDA approved anti-parasitic medicine
224083818|NCT00325078|DRUG|Infliximab|
224083819|NCT04444232|OTHER|Media Intervention|View an educational video
224083820|NCT04444232|OTHER|Survey Administration|Complete survey
224083821|NCT05234580|DRUG|PA9159 nasal spray solution, 10 μg once daily for 14 days|PA9159 of 10 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
224083822|NCT05234580|DRUG|PA9159 nasal spray solution, 20 μg once daily for 14 days|PA9159 of 20 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
224083823|NCT05234580|DRUG|PA9159 nasal spray solution, 40 μg once daily for 14 days|PA9159 of 40 μg is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
224083824|NCT05234580|DRUG|Placebo nasal spray solution without PA9159, once daily for 14 days|Placebo nasal spray solution is delivered intranasally through a metered-dose mechanical spray pump, once daily in the morning for 14 days.
224083825|NCT00926692|OTHER|Blood draw|Subject will have blood draw.
223908867|NCT06851546|PROCEDURE|Nasal 180° Selective Laser Trabeculoplasty (SLT)|The Nasal 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
223908868|NCT06851546|PROCEDURE|Inferior 180° Selective Laser Trabeculoplasty (SLT)|The Inferior 180° Selective Laser Trabeculoplasty (SLT) will be performed on the right eye. As per standard procedure, the laser will initially be set at 0.8 mJ (or 0.4 mJ for heavily pigmented TM). The energy level will then be adjusted in 0.1 mJ increments: increased until micro-bubble formation is observed or decreased if bubbles are noted. The desired endpoint is the production of a few fine 'champagne bubbles' every 2-3 laser spots. Larger gas bubbles and trabecular meshwork blanching will require the operator to titrate the power downwards in 0.1 mJ increments. Prophylactic IOP lowering and anti-inflammatory drops will be left to physician preference.
223908869|NCT06199089|DRUG|CM313 Injection|"Intravenous CM313 administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to experimental group were treated with CD38 monoclonal antibody (CM313: 16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of CM313 after treatment."
223908870|NCT06199089|DRUG|Placebo Injection|"Intravenous Placebo administration~This study adopts a randomized, double-blind, placebo-controlled design method. A total of 45 subjects were randomly assigned to experimental group (CM313, n = 30) and placebo comparator group (Placebo, n = 15) at a ratio of 2:1. Subjects assigned to placebo comparator group were treated with placebo of CM313 once a week for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of placebo of CM313 once a week for 8 weeks to observe the efficacy and safety during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after placebo administration."
223908871|NCT04674826|DRUG|Tralokinumab administered as 1 × X mL with Device A|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
223908872|NCT04674826|DEVICE|Tralokinumab administered as 2 × Y mL with Device B|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
223908873|NCT06849804|PROCEDURE|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|Group E (n=25): Erector spinae plain block group will receive 0.5 ml/kg of 0.25%bupivacaine.
223908874|NCT06849804|PROCEDURE|Caudal Block Anesthesia|Caudal block group will receive 1 ml/kg of 0.25% bupivacaine
223908875|NCT06849804|PROCEDURE|Local infiltration in the wound|Local Infiltration Group will receive 0.2 ml/kg 0.25% bupivacaine
223908876|NCT05181462|DRUG|Carboplatin|Carboplatin Area Under the Curve (AUC) 2 mg/mL/min intravenous (IV) on days 1 and 8/15, in cycles of 3-4 weeks
223908877|NCT05181462|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV on days 1 and 8/15, in cycles of 3-4 weeks
223908878|NCT05181462|DRUG|Nadunolimab|Nadunolimab escalation (DL -1: 0.5 mg/Kg, DL 1: 1 mg/kg, DL 2: 2.5 mg/kg), DL 3: 5 mg/kg IV on days 1 and 8/15, in cycles of 3-4 weeks.
223908879|NCT05995054|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 110 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
223908880|NCT02950259|DRUG|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
223908881|NCT02950259|DRUG|Indomethacin|Indomethacin 25 mg three times a day for 21 days
223908882|NCT02950259|DRUG|Omeprazole|One tablet of omeprazole daily for 21 days
223908883|NCT02950259|DIETARY_SUPPLEMENT|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
223908884|NCT06119646|OTHER|Warm Pads Applied to the Breast|Applying a warm pad to a breast during episiotomy repair
223908885|NCT06003985|OTHER|Gastric Ultrasound Exam|A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
223908886|NCT06232655|DRUG|Cladribine|A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
223908887|NCT06232655|DRUG|Venetoclax|A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
223908888|NCT06232655|DRUG|Azacitidine|Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
223908889|NCT03213873|BEHAVIORAL|HiBalance|Intervention of highly challenging balance training for 10 weeks.
223908890|NCT03213873|BEHAVIORAL|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
224083826|NCT00176293|DRUG|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, \& 5 of each 28-day cycle
224083827|NCT00176293|DRUG|doxorubicin|Doxorubicin 50mg/m\^2 I.V. on day 5
224083828|NCT02266680|BEHAVIORAL|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
224083829|NCT02569060|OTHER|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
224083830|NCT02569060|OTHER|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
224083831|NCT02569060|OTHER|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
224083832|NCT02569060|BEHAVIORAL|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
224083833|NCT03932799|OTHER|Prospective prior authorization (PA) with hard stops in Washington|"Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority."
224083834|NCT03932799|OTHER|Retrospective review (RR) with prescriber notification in Ohio|In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
224083835|NCT03404466|DRUG|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
224083836|NCT01327742|DEVICE|Relay Thoracic Stent-Graft|Device implant
223908891|NCT06806319|DEVICE|single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm|single intervention by Sirolase ® lower power diode laser 970 ± 15 nm (0.5 watts) continuous emission, power =3 watts, fiber 320 μm.single intervention the follow-up until 6 months
223908892|NCT06806319|DEVICE|single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.|single intervention by electrosurgical unit which was kept 38 watts rms ± 5%. The working frequency was adjusted to 1.5 MHz ± 5%.single intervention then follow-up until 6 months
223908893|NCT06651489|DRUG|Guselkumab|Subcutaneous injection of 100 mg at Weeks 0, 4, 12, and 20
223908894|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
223908895|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
223908896|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
224083837|NCT02638636|BEHAVIORAL|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
224083838|NCT01322022|BEHAVIORAL|ParentTraining|5 sessions of individual parent training
224083839|NCT01322022|OTHER|Parent Education|Parent Education to control for time and attention
224083840|NCT04051957|DRUG|Isosorbide Mononitrate|The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
224277263|NCT04922827|DRUG|Infliximab|single intravenous administration of 5 milligrams/kilogram
223908897|NCT01385189|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
223908898|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
223908899|NCT01385189|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
224277264|NCT04922827|OTHER|Standard of Care|Standard of Care
224277265|NCT03506594|DEVICE|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the CAPENERGY device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41°C radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
224277266|NCT01992094|BIOLOGICAL|QIVc|Novartis Investigational Quadrivalent Vaccine
223908900|NCT01385189|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
223908901|NCT04984642|OTHER|diet|have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
223908902|NCT03892824|DEVICE|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
224277267|NCT01992094|BIOLOGICAL|TIV1c|Licensed Influenza Vaccine
224083841|NCT04051957|DRUG|Placebo oral tablet|Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
224083842|NCT01206855|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
224083843|NCT01206855|OTHER|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
224083844|NCT01274247|DRUG|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
224083845|NCT01097629|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
224083846|NCT01097629|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
223908903|NCT06152094|OTHER|BP Activate Letter|"Participants in the BP Activate Letter arm will receive a BP Activate Report that includes personalized details about recent measurements, current medications, and computer-generated medication recommendations that might improve your blood pressure, along with a log for tracking additional SMBP measurements. They will also receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss."
223908904|NCT06152094|OTHER|Control Letter|Participants in the Control Letter arm will receive a cover letter that includes an assessment that BP appears to be uncontrolled, and suggesting a visit with their provider to discuss.
223908905|NCT06454175|BIOLOGICAL|Placebo|immunization schedule：Month 0，Month 2，Month 6
223908906|NCT06454175|BIOLOGICAL|15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)|immunization schedule：Month 0，Month 2，Month 6
223908907|NCT05223088|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
223908908|NCT05223088|DRUG|Apatinib Mesylate|Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
223908909|NCT05223088|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
223908910|NCT05223088|DRUG|Tegafur|Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
224083847|NCT01097629|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
224083848|NCT06273254|DRUG|Sacubitril and Valsartan Tablets 49mg/51mg|Each tablet contains Sacubitril 49 mg and Valsartan 51 mg
224277268|NCT01992094|BIOLOGICAL|TIV2c|Novartis Investigational Vaccine
223908911|NCT06329518|DRUG|Rezafungin|After receipt of Rezafungin, blood samples will be collected at various time points to determine the pharmacokinetics of Rezafungin.
223908912|NCT03042754|DIAGNOSTIC_TEST|XpertMTB/RIF|
224083849|NCT06273254|DRUG|Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)|Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex
224083850|NCT03760484|DRUG|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
224083851|NCT03760484|BIOLOGICAL|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
224277269|NCT01978691|DIETARY_SUPPLEMENT|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
224277270|NCT01978691|DIETARY_SUPPLEMENT|Polydextrose|Studied as a prebiotic
224277271|NCT01978691|OTHER|Placebo|Control
224277272|NCT05740553|DEVICE|ReTrieve Automated Stereognosis System|An automated tactile training system that may help patients recover lost tactile function after brain injury.
223908913|NCT03535545|DRUG|[68Ga]CBP8|Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
223908914|NCT03535545|DIAGNOSTIC_TEST|PET Imaging|All subjects will undergo PET imaging after administration of \[68Ga\]CBP8.
223908915|NCT02361216|DRUG|Ingenol Mebutate|
223908916|NCT02361216|OTHER|Vehicle|Vehicle gel
223908917|NCT02897427|OTHER|Biomarker Analysis|Complete HPV testing
223908918|NCT02897427|PROCEDURE|Biospecimen Collection|Undergo collection of blood and oral gargle samples
223908919|NCT02897427|PROCEDURE|Ultrasonography|Undergo transcervical ultrasonography
224277273|NCT04926701|DRUG|ETD001 single dose|Single ascending doses of inhaled ETD001
224277274|NCT04926701|DRUG|Placebo single dose|Single doses of inhaled placebo
224083852|NCT02592889|DEVICE|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
224083853|NCT02613208|DRUG|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
224083854|NCT02613208|DRUG|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
224083855|NCT01208129|DRUG|NAB001|nail lacquer, once daily, 52 weeks
224083856|NCT01208129|DRUG|Placebo control|nail lacquer, once daily, 52 weeks
224277275|NCT04926701|DRUG|ETD001 multiple twice daily doses|Ascending doses of inhaled ETD001 administered twice daily
223908920|NCT06167200|OTHER|No intervention, study is observational|No intervention, study is observational
224083857|NCT00693199|DRUG|amlodipine|amlodipine 5mg once daily for 28 days
224083858|NCT00693199|DRUG|terazosin|terazosin 2 mg once daily for 28 days
224083859|NCT00693199|DRUG|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
224083860|NCT02321293|DIETARY_SUPPLEMENT|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
224083861|NCT02321293|DRUG|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
224083862|NCT02321293|DRUG|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
224083863|NCT05749757|DEVICE|Acupuncture|For Shangyitang acupoint, the needle will be inserted towards the direction of nasal tip horizontally to a depth of 10-20mm without any manipulation, and a pad will be adhered afterwards. For other acupoints, the needles will be inserted through adhesive pads to 10-20mm. Needles will be lifted, thrust, and twirled for 3 times to achieve deqi sensation, and will be manipulated every ten minutes during 30-minute maintenance.
224083864|NCT05749757|DEVICE|Sham Acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
224083865|NCT01750814|BIOLOGICAL|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
224277276|NCT04926701|DRUG|Placebo multiple twice daily doses|Doses of inhaled placebo administered twice daily
224277277|NCT04926701|DRUG|ETD001 multiple once daily doses|Doses of inhaled ETD001 administered once daily
223528993|NCT06239376|PROCEDURE|GnRHa+AI - AC|"Pre-treatment includes two doses of 3.75 mg GnRH agonist (Diphereline®, Ipsen, France) on days 2-4 of the menstrual cycle and 28 days later, along with daily 2.5 mg Letrozole (Femara®, Novartis, Switzerland) starting from the first agonist injection.~Endometrial preparation in an artificial cycle begins 28 days after the second agonist injection. Patients take 6 mg/day of oral estradiol valerate (Valiera; Abbott) at least 9 days before progesterone. Endometrial thickness is monitored starting on the 10th day. When it reaches ≥7 mm, 400 mg twice times a day of vaginal progesterone (Cyclogest®, Actavis, UK) is initiated. Embryo transfer aligns with progesterone initiation, taking the embryo's stage into account. Luteal phase support comprises oral estradiol valerate 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA."
223528994|NCT06239376|PROCEDURE|Artificial cycle|The endometrium will be prepared using oral estradiol valerate (Valiera; Abbott) 6 mg/day starting from the 2nd to the 4th day of the menstrual cycle. The endometrial thickness will be monitored from day 10th onwards, and vaginal progesterone (Cyclogest®; Actavis) 400 mg twice times a day will be initiated when endometrial thickness reaches ≥7 mm. Estradiol exposure must last for at least 9 days before progesterone administration. Embryo transfer will be scheduled by the time of the initiation of progesterone and embryo stages. Luteal phase support comprises estradiol 4 mg/day and vaginal progesterone 400 mg twice times a day until the 7th week of gestational age (GA), followed by progesterone alone at 400 mg twice times a day up to the 12th week of GA.
223528995|NCT03211416|OTHER|Laboratory Biomarker Analysis|Correlative studies
223528996|NCT03211416|BIOLOGICAL|Pembrolizumab|Given IV
223528997|NCT03211416|DRUG|Sorafenib Tosylate|Given PO
223528998|NCT03140969|DRUG|QR-110|RNA antisense oligonucleotide for intravitreal injection
223528999|NCT03448393|BIOLOGICAL|CD19/CD22 CAR T-Cells|Cluster of differentiation 19 (CD19)/cluster of differentiation 22 (CD22) chimeric antigen receptor (CAR) T-cells will be infused on Day 0 after lymphodepleting chemotherapy regimen.
223529000|NCT03448393|DRUG|Fludarabine|Fludarabine is administered as an intravenous (IV) infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on body surface area (BSA) (25-30 mg/m\^2/dose) on Days -4, -3, -2 or Days -5, -4, -3, -2.
223529001|NCT03448393|DRUG|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the body surface area (BSA), at 900 mg/m\^2/dose after fludarabine infusion on Day -2 or 600 mg/m\^2/dose on Days -3 \& -2.
223908921|NCT06371950|DIETARY_SUPPLEMENT|Probiotic Formula Bacillus subtilis|5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
223908922|NCT06371950|OTHER|Placebo|Placebo
223908923|NCT04954677|OTHER|AI-box|Automatic quality-control system（AI-box）could real-time measure endoscopic inspection completeness, evaluate gastric cleanliness.
223908924|NCT05520593|DIETARY_SUPPLEMENT|Complex Carbohydrate Drink|Patients will drink a complex carbohydrate drink 3 hours before surgery. Drink to be given at the preoperative holding area.
223908925|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group)|Different dose groups
224083866|NCT01750814|BIOLOGICAL|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
224083867|NCT06461598|DRUG|Chemotherapy|All adjuvant chemotherapy for nonmetastatic PDAC was gemcitabine-based (Cycle \>= 1).
224083868|NCT05102526|BEHAVIORAL|"Experimental: Young Millie prevention program, active teachers"|"Prevention program: Young Mili, in collaboration with the teacher"
224083869|NCT05102526|BEHAVIORAL|"Prevention program: Young Mili, non active teachers"|"Prevention program: Young Mili, without the participation of the teacher"
224277278|NCT04926701|DRUG|Placebo multiple once daily doses|Doses of inhaled placebo administered once daily
224277279|NCT00468338|DEVICE|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
224277280|NCT01214239|DRUG|Placebo|once a day
224277281|NCT01214239|DRUG|Linagliptin|once a day
223908926|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group)|Different dose groups
223908927|NCT06757881|BIOLOGICAL|Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）|Different dose groups
224277282|NCT05147740|DRUG|B/F/TAF|50/200/25 mg fixed-dose combination administered orally once daily without regard to food.
223908928|NCT04621643|BEHAVIORAL|digital cognitive behavioral therapy (dCBT-I)|dCBT-I during 9 weeks. Multicomponent intervention that includes the following: psychoeducation about sleep, sleep hygiene, sleep restriction therapy, stimulus control and challenging beliefs and perception about sleep. The digital CBT-I that will be utilized in this study is named Sleep Healthy Using The internet (SHUTi). The intervention is fully automated with no contact with health care personnel, it is interactive and adapts to input from the users. It comprises of the same elements included in face-to-face CBT-I, but the user gains access to a new educational, behavioral or cognitive module each week only after completion of digital sleep diaries. dCBT-I can be accessed on computers or hand-held devices
223908929|NCT04621643|BEHAVIORAL|Digital patient education about insomnia (PE)|Control condition PE during 9 weeks. A digital patient education program that can be accessed on computers or hand-held devices. The information overlaps with that included in the dCBT-I intervention but it does not include any of the interactive features of the dCBT-I intervention and all the information is available from the moment the PE site is opened.
223908930|NCT06356558|OTHER|Educational intervention (VISACT)|The intervention is an implementation strategy called VISACT: VISuAl aids, Coach providers in communication, and Train organizations in health literacy. This strategy will be delivered to patients, providers, and organizations through a novel interactive response platform.
223908931|NCT06496945|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
223908932|NCT06496945|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
223908933|NCT03619980|OTHER|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
223908934|NCT01761305|PROCEDURE|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
223908935|NCT01761305|BEHAVIORAL|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
223908936|NCT01761305|OTHER|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
223908937|NCT03368625|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
223908938|NCT05230914|OTHER|Simplified imaging strategy|NCCT and CTA will be used to screen patients for endovascular treatment
223908939|NCT05230914|OTHER|Standard imaging strategy|NCCT-ASPECTS (pc-ASPECTS), CTA, and CTP will be used to screen patients for endovascular treatment
223908940|NCT06040476|BIOLOGICAL|hUCB|hUCB
223908941|NCT06343610|DIETARY_SUPPLEMENT|Active product|Contains a complex of: Calaguala leaves extract (Polypodium leucotomos), vitamin C (L-ascorbic acid), blood orange fruit extract (Citrus sinensis; red orange extract), vitamin E (alpha-tocopheryl acetate), vitamin A (retinyl palmitate), vitamin D3 cholecalciferol.
223908942|NCT06343610|DIETARY_SUPPLEMENT|Placebo|No active ingredients.
223908943|NCT04687865|OTHER|Biobank|"For each patient included in the study the following samples will be collected at the indicated time points after transplantation:~* Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy.~* Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy.~* Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy.~* Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction."
223908944|NCT03252938|DRUG|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
223908945|NCT03252938|DRUG|Avelumab|Avelumab i.v.
223908946|NCT06345989|PROCEDURE|Alginate impression|Alginate impressions are a traditional method for creating dental moulds which are used in orthodontic records. Plastic trays are sized to fit the upper and lower jaws, and the alginate is mixed into a putty before being placed in the trays. The putty is then used to take detailed impressions of the patient's teeth. To capture an accurate bite registration, the patient bites down on a piece of warmed wax.
223908947|NCT06345989|PROCEDURE|Intraoral scan|Intraoral scanners capture multiple images of the mouth, which are combined to create a three-dimensional model of the patient's upper and lower teeth. The scanning wand is passed methodically over the surface of the teeth to gather all the necessary information, which is displayed in real-time on a computer screen.
223908948|NCT00957047|DRUG|eslicarbazepine acetate|oral tablets
223908949|NCT00957047|DRUG|placebo|once daily placebo comparator
223908950|NCT00957047|DRUG|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
223908951|NCT05475379|BIOLOGICAL|Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT)|"Typhoid Vi-polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) Typhocon will be manufactured by Incepta Vaccine Limited"
224083870|NCT04547322|OTHER|VR application group|During the transfer from the general surgery clinic to the operating room (3-5 minutes) and in the surgery waiting room, the VR aplication group were asked to wear a virtual reality headset (VR BOX 2) and headphones minimizing sound loss (Earpods with Apple Lightning Connector) that are compatible with mobile phones with IOS operating system. The VR headset and the headphones were controlled by a mobile phone (iPhone 7 Plus). The researchers had the patients watch three-dimensional videos (e.g. underwater world, museum trips, forest and park walks, beach trips, and space travel) for 10 minutes with their preferred background and relaxing music.
223908952|NCT05486481|DRUG|Venetoclax|Given orally (PO)
223908953|NCT05486481|DRUG|Dexamethasone|Given PO
223908954|NCT05486481|DRUG|Daratumumab|Given Subcutaneously (SC)
223908955|NCT05486481|DEVICE|Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay|Lab test
223908956|NCT05389332|BEHAVIORAL|Hispanics Skin Cancer intervention|With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.
223908957|NCT05389332|BEHAVIORAL|Control group: physical activity and nutrition for Hispanics|Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
223908958|NCT04331509|OTHER|No Intervention|No Intervention
223908959|NCT05795556|OTHER|Assessing sarcopenia and potential biomarkers of sarcopenia in fall patients|Blood test, body composition (BIA and/or DXA), balance tests (sway), handgrip strength, isometric knee extension strength, chair-rise test, gait-speed, thickness of the thigh muscles (ultrasound), screening for sarcopenia (SARC-F), screening for malnutrition (SNAQ), screening for depression (GDS-15), screening for self-rated health (EQ-5D-5L), frailty (CSHA Frailty Scale)
223908960|NCT05728138|BEHAVIORAL|CMAP Plus CBT|Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
223908961|NCT03069326|DRUG|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
223908962|NCT03069326|DRUG|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
223908963|NCT04000971|OTHER|Integrated Stroke Practice Unit|Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
223908964|NCT04000971|OTHER|Comprehensive or Primary Stroke Center|Primary and secondary outcomes will be assessed at 3, 6, and 12 months.
223908965|NCT05717530|PROCEDURE|wound site local anesthesic infiltration|: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.
224083871|NCT06024525|DEVICE|Paclitaxel-Coated Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
223529002|NCT03448393|PROCEDURE|Apheresis|According to institutional standards.
223529003|NCT03448393|OTHER|Anti-emetic|Prophylaxis and treatment.
223529004|NCT03448393|DRUG|Diphenhydramine|Pre-medication: 0.5-1 mg/kg/dose (maximum 50 mg/dose) by mouth or intravenous over 10-15 minutes.
223529005|NCT03448393|DRUG|Acetaminophen|Pre-medication: 15 mg/kg/dose (maximum 650 mg/dose by mouth).
223908966|NCT05717530|PROCEDURE|Erector spina plane block|Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.
223908967|NCT05270876|DEVICE|Cochlear Implant and sound processor device fitting paradigm or diagnostic/measurement technique|The investigational device will be a new device fitting paradigm or diagnostic/measurement technique implemented for use with the commercially available sound processor and implant.
223908968|NCT05764876|DRUG|Linezolid Oral Tablet|Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.
223908969|NCT05764876|DRUG|Azithromycin Oral Tablet|Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
223908970|NCT03956888|DRUG|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
223529006|NCT03448393|DIAGNOSTIC_TEST|ECG|Pre-cell infusion.
223529007|NCT03448393|DIAGNOSTIC_TEST|ECHO|Pre-cell infusion.
223529008|NCT03448393|DIAGNOSTIC_TEST|MRI Brain|Pre-cell infusion.
223529009|NCT03448393|PROCEDURE|Bone marrow biopsy|Pre-cell infusion.
224083872|NCT06024525|DEVICE|Paclitaxel-Releasing Coronary Balloon Catheters|to Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters in SVD patients
224083873|NCT02987894|DEVICE|ACURATE neo™ Aortic Bioprosthesis|TAVI, transcatheter aortic valve replacement. Transfemoral access.
224083874|NCT03805126|BEHAVIORAL|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
223908971|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - PIOS MC|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
223908972|NCT05437900|PROCEDURE|Pressure Wire guided strategy - PIOS - PW|Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .
223908973|NCT05437900|PROCEDURE|Pressure Microcatheter guided strategy - Standard of care|Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.
224083875|NCT03805126|BEHAVIORAL|Usual Care|Usual care includes consultation with a social worker and a community health worker.
224083876|NCT06337435|OTHER|multi-looped wire|using multi-looped wire as a retainer
224083877|NCT05335889|DEVICE|eButton|The eButton is a wearable camera that takes pictures every 6 seconds of whatever is in front of participants. The recorded data are processed by algorithms to determine food names, volumes, and nutrient value of the consumed food (e.g., grams of carbohydrates). The eButton is a wearable device containing a multicore microprocessor, a rechargeable battery capable of 10-15 hours of continuous operation (upon a flexible choice of battery capacity), a miniSD card for data storage.
224083878|NCT05335889|DEVICE|Continuous Glucose Monitoring (CGM)|The use of this device provides ambulatory glucose profiles, giving graphic and quantitative information on 24-hour glucose patterns. It does not require finger-prick testing for calibration. The system consists of a reader and a sensor (35 mm x 5 mm). The sensor is applied to the back of a person's arm. The sensor automatically measures interstitial glucose at 15-minute intervals during daily activities like work, sleep, eating, and exercise. It is able to store blocks of glucose data for 14 days.
224083879|NCT01496157|DRUG|18F-DCFBC|A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
224083880|NCT03526289|BIOLOGICAL|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
224083881|NCT03526289|OTHER|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
224083882|NCT03233932|DRUG|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
224083883|NCT03233932|DRUG|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
224083884|NCT04288024|BEHAVIORAL|Weight-shifting training|"Postural task: Participants are standing with their weak side on the force plate. During the task, they wight-shift from side to side ranging from 10 to 90 percent of their body weight.~Suprapostural task: Participants hold a tray with their arms beside the body, 90 degrees of elbow flexion. They rotate the tray left and right for 45 degrees respectively.~During their task, participants should weight-shift and rotate the tray at the same time."
223908974|NCT05437900|PROCEDURE|Pressure Wire guided strategy - Standard of care|Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
223908975|NCT05673759|DEVICE|Electroencephalogram (EEG) system|An FDA 510(k) approved EEG/ERP device designed by G-Tec ™ intended for the acquisition, display, analysis, storage, reporting and management of EEG and auditory evoked potentials (AEP) information and uses Bluetooth technology to securely transmit EEG signals to a computer. The device is patient-friendly, and no serious adverse events have occurred to-date in any research or clinical study or in clinical use.
223908976|NCT05673759|BEHAVIORAL|Standard Neuropsychological Testing|Prior to the EEG session, neuropsychological testing will be done to establish a baseline measurement. We administer a full standard neuropsychological battery (45 mins) for all participants which includes the following tests: MOCA (only for older participants), MMSE, CERAD, Phonemic Test and the Category Fluency test, Trails Making Test A and B, BNT, BAI, BDI, PANAS, Ishihara Color Blindness test, and the Snellen Eye Chart.
224277283|NCT01463891|DRUG|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m\^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
223529010|NCT03448393|DIAGNOSTIC_TEST|Cardiac MRI|Screening
223529011|NCT03816891|DRUG|Vixarelimab|solution for injection
224083885|NCT03530384|OTHER|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
224083886|NCT03530384|OTHER|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
224277284|NCT05189691|BEHAVIORAL|walking exercise|Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
223529012|NCT03816891|DRUG|Placebo|solution for injection
224083887|NCT01400932|DRUG|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
224083888|NCT01400932|DRUG|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
224083889|NCT05030714|DIAGNOSTIC_TEST|Visual Field Testing|Visual field testing using the protocol 24-2 and/or 10-2 Threshold Test
224083890|NCT03793439|DRUG|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
224083891|NCT03793439|DIAGNOSTIC_TEST|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
224083892|NCT03793439|GENETIC|RNA Sequencing|RNA sequencing test at baseline and week 16
223908977|NCT05673759|BEHAVIORAL|Additional neuropsychological tests|Younger participants will receive additional testing along with the standard neuropsychological battery including Pittsburgh Sleep Quality Index (PSQI) \[37\] for sleep quality measures, the Test of Memory Malingering (TOMM) for effort measure, Ohio State Traumatic Brain Injury Identification Method questionnaire (OSU-TBI) \[38\] to gather lifetime TBI history, and the Neurobehavioral Symptom Inventory (NBSI) \[39\] for post-concussive symptoms. These additional tests will add an extra fifteen minutes, making the total time for neuropsychological questionnaires 1 hour in younger participants.
223908978|NCT05872204|DRUG|Abemaciclib|150 mg tablet twice daily
223908979|NCT05872204|DRUG|Letrozole|2.5 mg tablet once daily
224083893|NCT03793439|DIAGNOSTIC_TEST|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
224083894|NCT03793439|DRUG|Corticosteroid|Taper corticosteroids starting at week 4
224083895|NCT03793439|DRUG|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
224083896|NCT03244059|BIOLOGICAL|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
224083897|NCT03244059|DRUG|Placebo|An identically appearing placebo infusion.
224083898|NCT04321811|OTHER|Observation of patients with known, suspected, or at risk for COVID-19 infection|Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.
224083899|NCT00221364|DRUG|Mass treatment with oral azithromycin to an entire village|
224083900|NCT04781075|OTHER|Pain Scale|Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)
224083901|NCT04781075|DRUG|Exparel Injectable Product|Given at the beginning of the surgery for post-operative pain management
224083902|NCT04781075|DRUG|Bupivacaine Injection|Given at the beginning of the surgery for post-operative pain management
224083903|NCT04217395|BEHAVIORAL|Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)|"The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, \& Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device."
224083904|NCT01276821|DRUG|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
224083905|NCT01276821|DRUG|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
224083906|NCT02377102|PROCEDURE|Physical Therapy|12 weeks of supervised physical therapy.
224083907|NCT00948961|BIOLOGICAL|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
224083908|NCT00948961|BIOLOGICAL|CDX-1401|
224083909|NCT00948961|BIOLOGICAL|Resiquimod|
224083910|NCT00948961|BIOLOGICAL|poly-ICLC|
224083911|NCT03136939|OTHER|No intervention|No intervention
223908980|NCT04785300|DRUG|Dasatinib|100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles
223908981|NCT04785300|DRUG|Quercetin|Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles
224083912|NCT00270894|DRUG|epirubicin|epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles
224083913|NCT00270894|DRUG|cyclophosphamide|cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles
224083914|NCT00270894|DRUG|docetaxel|docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles
224083915|NCT00270894|DRUG|trastuzumab|trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments
224083916|NCT02758964|OTHER|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
224083917|NCT05802030|OTHER|Plyometric training|Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
224083918|NCT05802030|OTHER|Routine training|Regular tennis training, including normal fitness training, and injury prevention drills
224083919|NCT00868387|OTHER|energy-restricted, CHO-restricted diet|carbohydrate content of the diet \< 40% Frequency: daily Duration: 12 months
224083920|NCT00868387|OTHER|energy-restricted, CHO-rich diet|carbohydrate content of diet \> 55% Frequency: daily Duration: 12 months
224083921|NCT00976430|PROCEDURE|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
224083922|NCT02163070|DIETARY_SUPPLEMENT|whey drink,|consumption of 220 milliliters of whey drink three times a week,
224083923|NCT02163070|DIETARY_SUPPLEMENT|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
224083924|NCT02163070|DIETARY_SUPPLEMENT|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
223908982|NCT06150404|BEHAVIORAL|White Noises and Maternal and/or Paternal voices|"The intervention group will receive white noise and maternal and/or paternal voice for a maximum of 4 hours per day, alternated as follows: 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice, 1-hour break, 1 hour and 30 minutes of white noise, 30 minutes of maternal and/or paternal voice. The intervention is expected to start at 08:00 in the morning and conclude at 13:00 and will be delivered from the day after the enrollment - when the parents provide their voice recording - until the day of discharge.~The device for administering white noise and maternal and/or paternal voice will be placed approximately 30 cm from the head of the infant in the incubator and at the foot of the infant in the open crib.~The volume will be 45 dB for infants in incubators and infants in open cribs."
223908983|NCT06775613|GENETIC|Long-read sequencing|The technology performed belongs to third-generation sequencing strategies and is capable of analysing very long DNA and RNA fragments.
223908984|NCT03336281|DRUG|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
223908985|NCT04824105|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|A repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System will be used to deliver intermittent theta burst to ventromedial prefrontal cortex, and continuous theta burst to pre-supplementary motor area.
223908986|NCT06144281|BEHAVIORAL|Nudge for PHPC NP Referral|The attending and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for home palliative care services upon hospital discharge will be asked to refer their patient for these services.
223908987|NCT06769984|DRUG|SCTT11|SCTT11 dose 1, dose 2, dose 3, dose 4
223908988|NCT06769984|DRUG|Placebo|Placebo dose 1, dose 2, dose 3, dose 4
223908989|NCT06765564|DRUG|iPSC-MNP|Using iPSC-MNP Cells for the Treatment of ALS Patients
223908990|NCT04276532|PROCEDURE|sentinel lymph node sampling (SLN)|"Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus sentinel lymph node sampling (SLN).~1. The principles of surgery procedures and post-operative adjuvant therapies will follow the latest NCCN guidelines；~2. Surgery carried out by laparotomy, laparoscope, or robotic surgery are accepted；~3. Colored dyes including indocyanine green (ICG) (preferred), methylene blue, carbon nanotube for sentinel lymph node are accepted."
223908991|NCT04276532|PROCEDURE|pelvic lymphonodectomy (PLN)|Total hysterectomy with/without bilateral salpingooophorectomy (THBO) plus pelvic lymphonodectomy (PLN) with para-aortic sampling
223908992|NCT06780748|PROCEDURE|Identification rate of sentinel lymph node|To evaluate the identification rate of sentinel lymph nodes (SLNs). The study will compare the identification rates based on different localization techniques for SLN mapping
223908993|NCT06780241|DIAGNOSTIC_TEST|CMR|CMR (with contrast at baseline and non-contrast at follow-up)
223908994|NCT06780241|OTHER|Quality of Life Questionnaire|Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire
223908995|NCT04294641|DRUG|Ibrutinib|140 mg capsules for a dose of 420 mg daily by mouth for up to 12 months.
223908996|NCT04294641|DIAGNOSTIC_TEST|ECG|At screening.
223908997|NCT04294641|DIAGNOSTIC_TEST|PFT's|"Participants should have PFTs if not performed ≤3 months prior to start of study treatment and Cycle 7, Day 1 (6 months).~Optional at Cycle 12, Day 28 (12 months) and Cycle 24, Day 28 (24 months)."
223908998|NCT04294641|DIAGNOSTIC_TEST|CT|Non-contrast CT at baseline and later during the study if clinically indicated.
223908999|NCT04294641|DRUG|Steroid pulse (prednisone)|0.5-2mg/kg/day allowed for clinical disease stabilization during first 4 weeks after starting Ibrutinib.
223909000|NCT04294641|DRUG|Voriconazole|At any dose.
223529013|NCT05262426|BEHAVIORAL|Behavioral: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
223909001|NCT04294641|DRUG|Posaconazole|"As clinically indicated. At doses less than or equal to suspension 200 mg twice a day (BID) if ibrutinib dose modified to 280 mg once daily.~OR Posaconazole suspension 200 mg three times a day (TID) or 400 mg BID if Ibrutinib dose modified to 140 mg once daily.~OR Posaconazole injection intravenous (IV) injection 300 mg once daily; or delayed-release capsules 300 mg once daily if Ibrutinib dose modified to 140 mg once daily.."
223909002|NCT04294641|DRUG|Azithromycin|Treat or prevent bronchiolitis obliterans.
223715903|NCT00766311|OTHER|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
223909003|NCT04294641|DRUG|Montelukast|Treat or prevent bronchiolitis obliterans.
223909004|NCT04294641|DRUG|Budesonide|Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
223909005|NCT04294641|DRUG|Beclomethasone|Treat or prevent gastrointestinal acute graft-versus host disease (GvHD).
223909006|NCT04294641|OTHER|Filgrastim|Neutrophil growth factor permitted per institutional policy
223909007|NCT04294641|OTHER|Pegfilgrastim|Neutrophil growth factor permitted per institutional policy.
223909008|NCT04294641|OTHER|Erythropoietin|Red cell growth factor permitted per institutional policy.
223909009|NCT04294641|OTHER|Transfusions|According to institutional policy.
223909010|NCT04294641|PROCEDURE|Oral/Skin biopsy|Optional. Baseline, Cycle 7, Day 1 (6 months), Cycle 12, Day 28 (12 months) and Cycle 24, Day 28.
223909011|NCT05669612|DIETARY_SUPPLEMENT|Dairy based protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
223529014|NCT05262426|BEHAVIORAL|Enhanced YaCool|Enhanced YaCool is mobile application developed to support transgender women self-management of their gender and sexual health, including PrEP use. YaCool is a passcode-protected app that allows users to personalized text messaged reminders to take PrEP and/or clinic appointments, record PrEP adherence and sexual activity, and track lab tests. The application is set up to provide personalized recommendations for PrEP regimen, confirmed by clinic healthcare staff. Participants will be asked to download Enhanced YaCool to support PrEP use and gender/sexual health self-management between MES-PrEP sessions for 30 days, and thereafter until the end of Month 12 (if desired).
223715904|NCT00766311|OTHER|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
223909012|NCT05669612|DIETARY_SUPPLEMENT|Mixed protein|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
223909013|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 1|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
223909014|NCT05669612|DIETARY_SUPPLEMENT|Plant-based protein 2|Initial bioavailability trial, followed by 2 weeks consumption of product and follow up bioavailability trial
223909015|NCT05752461|DRUG|SHR-2004 injection|low dose subcutaneous injection once
223909016|NCT05752461|DRUG|SHR-2004 injection|medium dose subcutaneous injection once
223909017|NCT05752461|DRUG|SHR-2004 injection|high dose subcutaneous injection once
223909018|NCT05752461|DRUG|Enoxaparin sodium injection|40 mg administered as subcutaneous injection once daily
223909019|NCT04179773|OTHER|Current care study|"Observational study in two parts:~1. Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~2. Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
223909020|NCT04466488|BEHAVIORAL|Choice Architecture|"1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed"
224083925|NCT03088969|OTHER|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
224083926|NCT03026387|BEHAVIORAL|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory."
224083927|NCT01091961|PROCEDURE|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
224083928|NCT05432544|DRUG|SHR-1918|Ascending dose
224277285|NCT05820919|BEHAVIORAL|LOCK Sleep Program|The LOCK sleep program is a program that trains NH staff in a NH frontline staff huddling approach. It is derived from evidence supporting strengths-based learning, systematic observation, relationship-based teamwork, and efficiency. Staff learn how to work together as a team to collaboratively problem-solving about resident sleep challenges (e.g., evidence-based sleep promoting best practices and daytime meaningful activity best practices).
223909021|NCT04870307|OTHER|Dissemination and Implementation Research|Dissemination and Implementation research involves assisting primary care practices to address SARS-CoV-2 testing using evidence-based practices as well as increased testing in mobile-based community settings. The D\&I model also involves Practice Assessment, Academic Detailing, Practice Facilitation, Health Information Technology Support, Performance Feedback and Benchmarking, and a Virtual Learning Community.
223909022|NCT02442115|OTHER|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
223909023|NCT05906784|OTHER|group acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
223909024|NCT05906784|OTHER|Integrative Group Medical Visits|"IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice."
224083929|NCT05432544|DRUG|SHR-1918 placebo|Ascending dose
224083930|NCT05737693|DRUG|Ketamine|Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
224083931|NCT05737693|DRUG|Midazolam|Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
224083932|NCT06800053|BEHAVIORAL|FOCUS ON US|"This intervention will include 5 sessions cover 5 core content areas, represented by the acronym FOCUS. Family involvement (F) Outlook and meaning (O) Coping effectiveness (C) Uncertainty reduction (U) Symptom management (S) Content from every area is presented in the 3 longer in-depth sessions and reinforced in the 2 shorter check-in sessions. FOCUS encourages participants to work as a team, communicate openly, and support one another, and uses skill building (e.g., stress reduction techniques, healthy behaviors), education (e.g., symptom trajectories, information gathering), and problem-solving therapy to address here-and-now issues that impact QOL. The intervention is flexible, allowing more attention to be spent on issues relevant to particular patients/caregivers."
224083933|NCT02172651|DRUG|Vitamin D3|Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
223909025|NCT04142866|DEVICE|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
223909026|NCT04142866|DEVICE|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
223909027|NCT04142866|BEHAVIORAL|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
224083934|NCT02172651|DRUG|Placebo|Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
224083935|NCT03384108|OTHER|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
224083936|NCT03384108|OTHER|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
224083937|NCT06057610|DRUG|SHR-A1811 Injection|SHR-A1811 Injection
224083938|NCT06057610|DRUG|SHR-A1811 Injection ； Pertuzumab Injection|SHR-A1811 Injection ； Pertuzumab Injection
224083939|NCT06057610|DRUG|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection|Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
224083940|NCT06508944|DRUG|vaginal 17 beta-estradiol|"* Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
224083941|NCT06508944|DRUG|Placebo|"* Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."
224083942|NCT06508944|BEHAVIORAL|Behavioral modifications|Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.
224083943|NCT06582147|OTHER|Implementation of social determinants of health screening and referral|WE CARE is a relatively simple, low-intensity intervention that has two key components: (1) screening individuals using the WE CARE SDOH Screener for unmet social needs, and (2) providing individuals who have unmet social needs with SDOH Community Resource sheets
224083944|NCT01431183|BEHAVIORAL|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
224083945|NCT04954807|DIETARY_SUPPLEMENT|human milk fortified|HMF will be given 6 scoops a day
224083946|NCT04954807|DIETARY_SUPPLEMENT|placebo|Placebo will be given six scoops a day
224083947|NCT00182104|DRUG|Warfarin vs ASA|
224083948|NCT04066868|OTHER|Patient-reported outcomes assessment|Patient-reported outcomes are electronically assessed using EORTC QOL measures
224083949|NCT04066868|OTHER|CTCAE rating|CTCAE Ratings are conducted by clinicians
224083950|NCT04066868|OTHER|PRO data is displayed|PRO data is displayed right next to the CTCAE rating
224083951|NCT00605267|DRUG|Tamoxifen|20 mg once daily oral dose
223529015|NCT05262426|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3, 6, 9 and 12. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
224083952|NCT00605267|DRUG|Anastrazole (Arimidex)|1 mg once daily oral dose
224083953|NCT00605267|DRUG|Goserelin acetate (Zoladex)|3.6mg/month depot injection
224083954|NCT03754660|DRUG|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
224083955|NCT03995719|OTHER|Preoperative education|65 patients were instructed to a preoperative stoma-education program
224083956|NCT03995719|OTHER|Postoperative education|73 patients, receiving the same information in postoperative period.
224083957|NCT02939131|BEHAVIORAL|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
224277286|NCT05820919|OTHER|No intervention (control period/baseline data collection)|Each NH serves as its own control. During the control period, baseline data will be collected.
223909028|NCT04605445|PROCEDURE|1 visit root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be completed in the same visit or performed in another visit where cleaning, shaping and root filling procedures, temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
223909029|NCT04605445|PROCEDURE|2 visits root canal treatment (endodontics)|Endodontics (root canal treatment). In the enrolment visit, access, opening and identification of root canals can be performed and a suitable temporization will be placed in the tooth if needed. Root canal treatment can be started, or performed in another visit, lasting 2 visits. In the first visit cleaning and shaping is performed and a medication is put in place in the canals, and the tooth is temporized until the next visit at least one week apart. In the second visit the tooth is root filled and temporization or permanent restoration will be performed. These procedures are part of the normal clinical praxis. No rigid protocol will be implemented, as a pragmatic design was chosen.
223909030|NCT02668692|DRUG|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
223909031|NCT02668692|DRUG|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
223909032|NCT03562832|DRUG|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
223909033|NCT03664700|DEVICE|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
223909034|NCT03514069|DRUG|ruxolitinib|Starting dose ruxolitinib 10 mg twice daily
223909035|NCT03514069|RADIATION|radiation|60gy for 6 weeks
223909036|NCT03514069|DRUG|temozolomide|75mg/m2
223909037|NCT01957722|PROCEDURE|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
223909038|NCT01957722|BIOLOGICAL|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
223909039|NCT04567238|BEHAVIORAL|Mobile contingency management|Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
223909040|NCT04736121|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|Biocompatible resin microspheres are an injectable permanent implant and preferentially placed into the distal microvascular supply of tumors to provide direct irradiation of tissue and destruction of the microvascular bed. Spheres contain yttrium-90 (Y-90) and are a size between 20 and 60 microns in diameter.
223909041|NCT04631744|DRUG|Cabozantinib|Subjects will receive cabozantinib orally at a (starting) dose of 40 mg once daily
223909042|NCT05680272|BEHAVIORAL|empathic communication-based education|The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
223909043|NCT05140434|DIAGNOSTIC_TEST|Exercise test|exercise test on an exercise bike with increasing load
223909044|NCT05140434|DIAGNOSTIC_TEST|Cardiac CT|cardiac CT scan
223909045|NCT04832854|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous (IV) infusion on Day 1 of each 21-day cycle.
223909046|NCT04832854|DRUG|Tiragolumab|Tiragolumab 600 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
223909047|NCT04832854|DRUG|Carboplatin|Carboplatin at initial target area under the concentration curve (AUC) of 5 or 6 mg/mL/min will be administered by IV infusion on Day 1 of each 21-day cycle.
223909048|NCT04832854|DRUG|Cisplatin|Cisplatin at 75 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
223909049|NCT04832854|DRUG|Pemetrexed|Pemetrexed at 500 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
223909050|NCT04832854|DRUG|Gemcitabine|Gemcitabine at 1000 or 1250 mg/m\^2 will be administered by IV infusion on Days 1 and 8 of each 21-day cycle.
223909051|NCT04832854|DRUG|Paclitaxel|Paclitaxel at 175 or 200 mg/m\^2 will be administered by IV infusion on Day 1 of each 21-day cycle.
223909052|NCT04889495|DRUG|Zirabev|Bevacizumab biosimilar
223909053|NCT05128903|DRUG|[18F]DPA714|"Intravenous injection~* Before or within 2 weeks of starting radiation therapy~* Before starting chemotherapy~* 1 year after the start of radiation therapy Timing cont.~* 1.5 to 2 years after the start of radiation therapy"
223909054|NCT02411773|DRUG|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
223909055|NCT02411773|DRUG|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session.
223909056|NCT02411773|BEHAVIORAL|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
223909057|NCT02411773|BEHAVIORAL|Control to Exercise (Stretching)|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
223909058|NCT01627574|BEHAVIORAL|Motivational Intervention|There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.
223909059|NCT01627574|BEHAVIORAL|Didactic Educational Intervention|There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
223909060|NCT05541029|BEHAVIORAL|Live music|Live Music. A board-certified music therapist will provide live music (singing with instrument accompaniment) of child preferred songs, per caregiver report, with the tempo entrained to the child's respiratory rate at intervention start and decreased as needed to facilitate relaxation, with a target tempo of 60-80 beats per minute (BPM). Song choices will be based on patient preferences, per caregiver report, and performed with relaxing characteristics (steady rhythm and volume)
223909061|NCT05541029|BEHAVIORAL|Recorded music|Recorded Music. MP3 players will be loaded with a recorded music playlist of the child's preferred songs, per caregiver report, and connected to two small speakers that are to be placed at either side of the head of the bed. Speakers will be tested with sound level meter and volume control set at 50-60 decibels. A member of the study team will stay at bedside throughout the recorded music condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
223909062|NCT05541029|OTHER|Usual care|Usual Care. A pharmacologic approach to ameliorating stress and pain in MV children is standard of care in CHP's PICU. CHP provides weight-based guidelines to aid clinical decisions on medications for sedation and analgesia. Bedside nurses assess the child's sedation and pain scores once an hour and administered PRN medications as needed, based on clinical judgement, using CHP's PICU weight-based guidelines. For example, if a child has a pain score of \>1-2 above goal, guidelines suggest providing a fentanyl dose of 0.5 mcg/kg and assessing again in 1 hour. We will include usual care as a third condition to explore how our selected biomarkers vary over 20 min. without the addition of any musical stimuli. A member of the study team will stay at bedside throughout the usual care condition. Study team member will log time of session and complete a checklist with open-response option to note relevant information (e.g., Session interruptions from other staff).
223909063|NCT04970446|DRUG|Antibiotics|All patients will receive a one week course of antibiotic therapy.
223909064|NCT04970446|DIETARY_SUPPLEMENT|Dietician designed diet|All patients will be recommended dietary modification 3 weeks prior to, and during, the study.
223909065|NCT04970446|DRUG|FMT|Anaerobically prepared stool. Dosing will vary according to mode of administration.
223909066|NCT04970446|OTHER|Placebo|Placebo will contain food colourant, 0.9% normal saline and glycerol.
223909067|NCT05725564|BEHAVIORAL|FAST (Functional Activity Strength Training)|Daily exercise intervention including functional resistance exercises and personalized coaching.
223909068|NCT05725564|BEHAVIORAL|Band Together|3 times weekly group exercise over Zoom featuring strength and balance exercises for 45 minutes
223909069|NCT05725564|BEHAVIORAL|Behavioral Change Technique|Reminders, education, goal-setting, self-monitoring, and feedback used to encourage participants to increase effort and adherence
223909070|NCT03048331|DEVICE|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
223909071|NCT02608359|DRUG|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
223909072|NCT06485479|BEHAVIORAL|Intervention ads|The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
223909073|NCT06485479|BEHAVIORAL|Control ads|The ads will be on topics unrelated to quitting smoking, formatted as black text on a white field. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
223909074|NCT04892940|DEVICE|Virtual Reality (VR) technique|"The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group."
223909075|NCT04892940|DRUG|Analgesic protocol|"Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively."
223909076|NCT03325296|DRUG|LEO 124249|Ointment containing LEO 124249
223529016|NCT03834363|DRUG|Fentanyl|Fentanylpatch 12 mcg/hr, change patch every three days.
223909077|NCT03325296|OTHER|Ointment vehicle|Ointment without active ingredients
223909078|NCT04721041|OTHER|Washed Microbiota Transplantation (WMT)|Washed microbiota suspension delivered through mid-gut and lower-gut
224083958|NCT02939131|BEHAVIORAL|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
224083959|NCT01291901|BIOLOGICAL|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
223529017|NCT03834363|DRUG|Morphine Retard|Morphine retard capsules 10 mg bid.
223529018|NCT03834363|DRUG|Placebo patch|Placebo patch, change patch every three days.
223909079|NCT04730739|DEVICE|FastFrame External Fixation System - Knee Spanning or Damage Control Kit|The FastFrame External Fixation Systems - Knee Spanning Kit and Damage Control Kit are single-use external fixators that are sterile packed with all required components for convenience of the end user.
223909080|NCT06083662|DRUG|Neratinib Maleate|"* neratinib 240mg po daily~* herzuma 8mg/kg (loading) --\> 6mg/kg q3w"
223909081|NCT06249048|BIOLOGICAL|STX-001|STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.
223909082|NCT06249048|BIOLOGICAL|Keytruda®|Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
223909083|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive dietary counseling
224083960|NCT01291901|BIOLOGICAL|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
224083961|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
224083962|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
224083963|NCT00793793|DRUG|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
224083964|NCT00793793|DRUG|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
224083965|NCT00793793|DRUG|Placebo|
224277287|NCT05909969|OTHER|Pelvi-Fit app Training|This group will receive Pelvic Floor Muscle Strengthening exercises through software application.
224277288|NCT05909969|OTHER|Control|This group will receive Pelvic Floor Muscle Strengthening exercises through instructions and pamphlets describing exercises.
224277289|NCT01049581|PROCEDURE|aquatic therapy|two hours per week, one hour per time, total 12 weeks
223529019|NCT03834363|DRUG|Placebo oral capsule|Placebo oral capsule bid
223529020|NCT05702450|BIOLOGICAL|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
223529021|NCT01587196|DRUG|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
223909084|NCT02176902|BEHAVIORAL|behavioral dietary intervention|Receive guidelines for low-fat diet
223909085|NCT02176902|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO
223909086|NCT02176902|OTHER|laboratory biomarker analysis|Correlative studies
223909087|NCT06481410|DRUG|Methylene Blue Intervention Group|In addition to standard treatment, patients will receive methylene blue intervention. The method is as follows: a loading dose of 2.5 mg/kg administered via micro-pump over 15 minutes, followed by a continuous infusion at a rate of 0.25 mg/kg/hour for 12 hours or until norepinephrine has been continuously discontinued for 4 hours, whichever comes first. If norepinephrine needs to be increased to 0.1 μg/kg/min before the 12-hour period ends, continue using methylene blue until the 12-hour infusion is completed.
223909088|NCT06481410|DRUG|Normal Saline Control Group|In addition to standard treatment, patients will receive a placebo control with normal saline, administered for the same duration as the intervention group.
223909089|NCT03528928|DEVICE|Surface electrical stimulation|Thin electrode with four conductive areas placed over the perineal area.
223909090|NCT06282523|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
223909091|NCT06282523|BEHAVIORAL|HMRP web app|The HMRP web app is a meditation-based web-based app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMRP provides core content, with instruction administered through a curriculum of guided practices. HMRP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
223909092|NCT06565793|DEVICE|Non Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).
224083966|NCT00950170|PROCEDURE|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
224083967|NCT04148092|DRUG|ripretinib|orally administered solid dosage form
224083968|NCT06960746|BEHAVIORAL|lifestyle changing plus CPAP|20 males with metabolic syndrome, sexual impotence (erectile dysfunction), and obstructive sleep apnea will be in this group (CPAP will be applied in this group that will contain 20 males, CPAP will be applied five days weekly during night-sleeping for 4 hours for 12 weeks plus lifestyle changes that will contain 3-session per-week 40-minute treadmill exercising and low-caloric/dietary 12-week restriction.
224083969|NCT06960746|OTHER|CPAP|20 males with metabolic syndrome, sexual impotence (erectile dysfunction), and obstructive sleep apnea will be in this group. in this group CPAP will be applied five days weekly during night-sleeping for 4 hours for 12 weeks
224083970|NCT06959823|DEVICE|Multisensory Pediatric Support Device (MSPSD)|Child-friendly multisensory device providing audio-visual distraction during invasive procedures.
224083971|NCT06960044|PROCEDURE|Procalcitonin-guided antibiotic management|After the randomization, PCT plasma concentration will be dosed and repeated every 24 hours and antimicrobial treatment will be withdrawn as soon as the PCT value will decrease \> 80% of peak value or will fall below 0.25 ng/mL. Patients with a normal baseline PCT value (below 0.25 ng/mL) will start the antimicrobial therapy, as clinically appropriate and PCT plasma concentration will be repeated every 24 hours, as indicated in the protocol. The antimicrobial agents will be managed according to the clinical and radiological evolution of the LRTI.
224083972|NCT06960044|PROCEDURE|Standard of care|Patients assigned to the control group will be treated according to the best standard of care and PCT will not be evaluated for the whole duration of the study.
224083973|NCT06960863|RADIATION|fibroscan|Liver fibrosis and steatosis can be staged using Dimensional ultrasound TE (transient elastography).
224083974|NCT06959836|DEVICE|VIVERE Bovine Pericardial Bioprosthetic Valve|Replacement of the native valve or bioprosthesis
223909093|NCT06565793|DEVICE|Complex PCI|The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).This designation is applied to angioplasty procedures that meet at least one criterion for complexity. The complex angioplasty involved patients with unprotected left coronary common trunk (UT-PCI), the use of rotablator rotary atherectomy (ARota-PCI), the angioplasty of chronic coronary occlusion (CCO-PCI), or the angioplasty of a bifurcation lesion (CBL-PCI).The highly intricate angioplasty procedure was conducted on patients who met at least two criteria indicative of complexity.
223909094|NCT06568094|DRUG|HRS-5041 tablets|HRS-5041 tablets
223909095|NCT06568094|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
223909096|NCT06568094|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
223909097|NCT06568094|DRUG|Docetaxel Injection|Docetaxel Injection
223909098|NCT06568094|DRUG|HRS-1167 tablets|HRS-1167 tablets
223909099|NCT06568094|DRUG|SHR2554 tablets|SHR2554 tablets
223909100|NCT05748015|DIAGNOSTIC_TEST|quantification of sensory and autonomic small nerve fibers by punch skin biopsy|We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.
223909101|NCT05748015|DIAGNOSTIC_TEST|Cardiovascular Reflexes testing|Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.
223909102|NCT05748015|OTHER|Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms|We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score
223909103|NCT05647564|DIAGNOSTIC_TEST|F-fluorodeoxyglucose positron emission tomography (FDG PET)|Imaging scan
223909104|NCT05647564|DIAGNOSTIC_TEST|prostate-specific membrane antigen positron emission tomography (PSMA PET)|Imaging scan
223909105|NCT04858009|DRUG|Cisplatin|Given via HIPEC
223909106|NCT04858009|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC with mitomycin and cisplatin
223909107|NCT04858009|DRUG|Nab-paclitaxel|Given via HIPEC
224083975|NCT06959875|BEHAVIORAL|High-Fidelity Simulation-Based Therapeutic Communication Training|This intervention involves a structured, high-fidelity simulation scenario in a clinical skills lab setting using mannequins and standardized patients. The scenario focuses on communication with a patient experiencing perinatal loss. The session includes pre-briefing, simulation, and debriefing components.
223909108|NCT04858009|PROCEDURE|Computed Tomography|Undergo CT scan
223909109|NCT04858009|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223909110|NCT04858009|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223909111|NCT02369406|DRUG|Nevirapine|
223909112|NCT02369406|DRUG|Kaletra|
223909113|NCT02369406|DRUG|Lamivudine|
223909114|NCT02369406|DRUG|Zidovudine|
223909115|NCT06105567|BEHAVIORAL|Training given according to the health promotion model by applying the Philips 66 technique|The Effect of Education Given According to the Health Promotion Model on Premenstrual Symptoms, Emotional Eating Behavior and Perceived Stress
223909116|NCT03949725|BEHAVIORAL|Hans Kai Program|In Hans Kai, first, participants attend a 2-month Health School to develop the skills necessary to improve their health and wellbeing. The Health School includes sessions on health indicators; nutrition, grocery shopping and meal planning; physical activity; stress, coping, and health (sleep); and primary care through the years. After participants complete the Health School, they form Hans Kai groups (of 3 or more adults) and begin to meet regularly (at least once a month) independently of facilitators, in a self-sustaining model.
223909117|NCT05758493|DIAGNOSTIC_TEST|124I-Evuzamitide|Amyloid reactive protein used as imaging agent to detect systemic amyloidosis
223909118|NCT05738408|BEHAVIORAL|Financial Incentives (FI) and Nicotine Replacement Therapy (NRT)|: In the intervention condition, patients will receive both NRT plus a 12-week program of monetary incentives for verified smoking abstinence that will be implemented by our clinic staff
223909119|NCT06567548|OTHER|control group|An absorbable gelatin sponge is a sterile hemostatic agent primarily composed of purified porcine-derived gelatin. It is widely utilized in surgical procedures to control bleeding
223909120|NCT06567548|OTHER|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is a biomaterial derived from the patient's own blood, utilized primarily in regenerative medicine and surgery due to its rich content of growth factors and its ability to promote healing.
223909121|NCT06567548|OTHER|Albumin Platelet Rich- Fibrin|is an innovative biomaterial that combines the regenerative properties of platelet-rich fibrin (PRF) with the structural and functional benefits of albumin. This mixture is designed to enhance tissue healing and regeneration by utilizing autologous blood components.
223909122|NCT04039581|OTHER|Kinesio Taping|Kinesio Taping (Space Correction).
223909123|NCT04039581|OTHER|Conventional treatment|Therapeutic exercises (active and passive range of motion (ROM) and strengthening exercise ) and TENS (Transcutaneous electrical nerve stimulation) applications
223909124|NCT06429527|BEHAVIORAL|WHOeyes combined with a questionnaire.|The WHOeyes app (a self-administered visual acuity testing app) plus a questionnaire (to ask the patients to go to the hospital if they ever experience ocular discomfort including eye redness, discharge, etc.) will be used for 1-week follow-up after cataract surgery, and only those with significant vision loss based on WHOeye test or with ocular discomfort are advised to return to the hospital for follow-up.
223909125|NCT06346470|OTHER|Web-based breast self examination education|Students in this group will receive web-based breast self-examination education for 6 hours .
223909126|NCT03308877|BEHAVIORAL|BMI|Four 45-minute, brief motivational sessions for substance use
223909127|NCT03308877|BEHAVIORAL|Stadard Care (SC)|Standard procedures at pretrial program + assessement
223909128|NCT02219633|DRUG|LEO 39652 cream|Applied for 21 days
224083976|NCT06959875|BEHAVIORAL|Paper-Pencil Simulation-Based Therapeutic Communication Training|This intervention utilizes a written clinical case scenario related to perinatal loss. Students read the scenario and write appropriate therapeutic communication responses, followed by group discussion and instructor feedback. The focus is on reflection and theoretical integration.
224083977|NCT02983487|PROCEDURE|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
224083978|NCT02983487|PROCEDURE|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
223909129|NCT05233800|BEHAVIORAL|Faster Asleep Smart Speaker Program|Participants will receive a smart speaker device with a pre-loaded Faster Asleep program. Participants will be asked to engage with the program daily, either using the voice-activated speakers or an accompanying smart-phone app. The study duration is six-weeks and is completed individually using fully automated interaction to deliver components of cognitive behavioral therapy for insomnia.
224083979|NCT01254669|BEHAVIORAL|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
224083980|NCT01425385|OTHER|Near infrared spectroscopy monitoring|This is an observational study without interventions
224083981|NCT01425385|OTHER|Autoregulation monitoring|There are no interventions in this observational study
224083982|NCT00437216|DRUG|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
224083983|NCT00437216|DRUG|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
224083984|NCT03129308|DIAGNOSTIC_TEST|Blood Sampling|4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
224083985|NCT00891514|BEHAVIORAL|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
224083986|NCT00891514|BEHAVIORAL|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
224083987|NCT00360347|DRUG|C.E.R.A.|
224083988|NCT01451593|DRUG|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
224083989|NCT01451593|DRUG|Placebo|placebo identical in appearance to active IMP (phenytoin)
223909130|NCT05233800|BEHAVIORAL|Faster Asleep Website|Controls will have access to a website with information about CBT-I and breast cancer survivorship and will be told to engage with the website as desired. The content will be drawn from the education script that is programmed into the phone app accompanying the smart speaker program.
223909131|NCT03757299|DIAGNOSTIC_TEST|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
223909132|NCT06283719|BIOLOGICAL|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
223909133|NCT05823311|DRUG|Lenvatinib, tislelizumab, gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
223909134|NCT05823311|DRUG|Gemcitabine and cisplatin|Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
224083990|NCT06250387|PROCEDURE|Endobronchial ultrasound transbronchial cryobiopsy|"Endobronchial Ultrasound (EBUS) :~EBUS is usually performed under general anesthesia using a laryngeal masque. It has a linear ultrasonography with a 7.5 MHz frequency. The distal part of the endoscope contains a water filled balloon used as a liquid interface, camera, light source and a working channel. The needle is protected by a sheath to prevent working channel damage. The endoscope is connected to a processor that reflects both endobronchial and ultrasound images on a screen.~EBUS - TBNA : EBUS - Transbronchial needle aspiration EBUS - TBCB: EBUS - Transbronchial Cryo Biopsy"
224083991|NCT01718184|PROCEDURE|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
224083992|NCT01718184|PROCEDURE|Sulcoflex intraocular lens implantation|
224083993|NCT05063812|OTHER|Observational|All these patients have been enrolled in the COVID-19 remote patient monitoring program
224083994|NCT00788905|DEVICE|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
223909135|NCT05823922|BEHAVIORAL|Clinician Delivered CBT|Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
223909136|NCT05823922|BEHAVIORAL|Supplemental MAYA App|"The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week"
223909137|NCT06313489|PROCEDURE|Biopsy of EPL tendon and muscle during the operation|Biopsy of EPL tendon and muscle
224083995|NCT00531193|DRUG|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
224083996|NCT00531193|OTHER|[11C]SCH442416|11C\]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. \[11C\]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
224083997|NCT04688294|DRUG|Sacubitril-Valsartan|30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
224083998|NCT04688294|DRUG|Valsartan|30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
224083999|NCT00215007|DRUG|Levofloxacin|
224084000|NCT05504200|OTHER|Bladder and Pelvic Floor Muscle Training|The intervention group will receive 8-weeks of at home PFMT, this will include 3 face-to-face visits, daily text reminders, and a weekly phone call.
224084001|NCT02374866|OTHER|closer monitoring|
224084002|NCT00263263|DEVICE|sirolimus-eluting stent|
224084003|NCT00263263|DEVICE|bare metal stent|
224277290|NCT04681508|DIAGNOSTIC_TEST|Chest CT without contrast enhancement and chest X-ray|Chest CT without contrast enhancement and chest X-ray as supplement to diagnostic abdominal CT
224277291|NCT02578277|DRUG|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
224277292|NCT02578277|DRUG|BMS-955176|BMS-955176
223909138|NCT04895033|BEHAVIORAL|Responsibility condition|During the fMRI scan, participants will complete alcohol purchase task paradigm for hypothetical alcohol rewards under two conditions. In the next-day responsibility condition, we will present a vignette describing a drinking scenario in which participants have a significant activity the next day (e.g., a work, family, or academic obligation the next morning) and participants are asked to imagine they are deciding how much they want to drink in this situation. The control condition will use a vignette describing a typical drinking scenario with no explicit responsibilities the next day
223909139|NCT03787173|DEVICE|Optimized|Inspiratory trigger and Expiratory trigger settings optimized by investigator
224084004|NCT04173741|OTHER|USG measurement|IVC was visualized in the subxiphoid long axis by using convex probe (5-1 MHz). Diameters of IVC was measured 2 cm caudally to the junction of hepatic vein in M-mode. IJV diameter was measured in the short axis by using linear probe (12-5 MHz) and M-mode. IJV visualized in the junction of cricothyroid membrane level and midclavicular line. Maximum and minimum diameter values were measured in the M mode. Distensibility (maximum diameter - minimum diameter / minimum diameter) and collapsibility (maximum diameter - minimum diameter / maximum diameter) indices were calculated after USG measurements were done.
224084005|NCT02631538|DRUG|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
224084006|NCT02631538|DRUG|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
224084007|NCT02631538|DRUG|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
224084008|NCT02631538|DRUG|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
224084009|NCT04677439|DRUG|Flumatinib|600 mg of Flumatinib orally daily for 24 months
224084010|NCT04475692|BEHAVIORAL|Repetitive, task-specific upper limb practice|A self-directed upper limb intervention (implementing a self-selected dose). This intervention uses an adapted upper limb rehabilitation system to support repetitive upper limb training for stroke survivors.
224084011|NCT04475692|OTHER|Conventional care|Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
224084012|NCT06419114|DEVICE|Optical Coherence Tomography|Comparing the localization ability of OCT and R-EBUS in Peripheral Pulmonary Lesions and the predictive ability of lung cancer pathological classification
224084013|NCT02090712|PROCEDURE|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
224084014|NCT05122637|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System with Medtronic React 71 aspiration catheter and a commercially available pump.
224084015|NCT05122637|DEVICE|Standard of Care Aspiration Thrombectomy System|Commercially available aspiration catheter with commercially available aspiration pump
224084016|NCT00123565|DRUG|Hexadecasaccharide (SR123781A)|
224084017|NCT06405672|PROCEDURE|Endotracheal tube with stylet|The obese patients who will be intubated with stylet in laparoscopic sleeve gastrectomy
224084018|NCT06405672|PROCEDURE|Endotracheal tube alone|The obese patients who will be intubated without stylet in laparoscopic sleeve gastrectomy
224084019|NCT00501475|DRUG|NAC Bicarbonate|
224084020|NCT01292655|DRUG|BMS-906024|
224084021|NCT02455401|DRUG|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
223909140|NCT03787173|DEVICE|Automated|Inspiratory trigger and Expiratory trigger settings automatized
223909141|NCT06536647|DIAGNOSTIC_TEST|Contactless measurement of patient vital signs using the VitalsTM system|Contactless measurement of the patient blood pressure, heart rate, respiratory rate, body temperature and SpO2 will be carried out using the VitalsTM platform based on facial video data.
224084022|NCT02455401|DRUG|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
224084023|NCT02455401|DRUG|No remifentanil|Intervention: no remifentanil will be administrated
224084024|NCT02611401|BEHAVIORAL|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
224084025|NCT02611401|BEHAVIORAL|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
224084026|NCT00035204|DRUG|galantamine|
224084027|NCT03900390|PROCEDURE|cross-preconditioning|After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
224084028|NCT02274610|DRUG|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
224084029|NCT02274610|DRUG|Taxotere|Docetaxel
224084030|NCT03501966|DRUG|Acetazolamide|Medical therapy including diet
223715905|NCT00766311|OTHER|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
223715906|NCT00766311|OTHER|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
223715907|NCT00766311|OTHER|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
223715908|NCT00766311|OTHER|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
223909142|NCT03397706|COMBINATION_PRODUCT|VRx-3996 and valganciclovir|second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)
223909143|NCT06419855|DEVICE|Human collagen matrix graft|Is a porous cross-linked human collagen Matrix or Sponge, used as a scaffold in the repair and restoration of dura mater defects, following craniotomy, laminectomy or in general when there is intentional (surgical procedure) or accidental damage to the dura mater.
223909144|NCT06419855|DEVICE|Bovine collagen matrix graft|Is a porous type 1 collagen matrix derived from bovine Achilles tendon, this matrix is absorbed after 8 weeks and is used for the repair and restoration of dura mater defects.
223909145|NCT04748380|OTHER|CRC decision aid pamphlet|A newly developed 8-10 page decision aid pamphlet that discusses:1. Information on CRC; 2. Information about risk and benefits including the 10-year lag-time to benefitting from CRC screening; 3. Information to help patients evaluate CRC screening options (colonoscopy or stool testing); 4. Possible outcomes relevant to LE and health status. In addition, there will be a values clarification exercise
223909146|NCT04748380|OTHER|Home Safety Pamphlet|The home safety information pamphlet is a 2-page fact sheet on home safety tips for older adults, and was designed by the AGS Health in Aging Foundation. It includes information in seven areas to help older adults stay safe in their homes. Areas include but are not limited to fall prevention and safety proofing homes. It has been used successfully in prior studies of DAs as a control intervention
223909147|NCT05742399|DRUG|Hyaluronic acid NanoGel|Hyaluronic acid nanoparticles (2%)
223909148|NCT05742399|DRUG|Placebo gel|conventional gel having the same color, form and packaging
223909149|NCT06271382|OTHER|Acupressure Group|"In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes."
223909150|NCT06271382|OTHER|Sham Acupressure Group|"Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention."
223909151|NCT06271382|OTHER|Foot Ankle Exercise Group|Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
223909152|NCT02523222|DIETARY_SUPPLEMENT|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
223715909|NCT00766311|OTHER|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
223719349|NCT01087398|DRUG|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~* Busulfan 16 mg/kg \>5year - 20 mg/kg \<5year po~* Cyclophosphamide 200 mg/kg iv~* Fludarabine 160 mg/m\^2"
223909153|NCT03125928|DRUG|Atezolizumab|Monoclonal antibody
223909154|NCT03125928|DRUG|Paclitaxel|Chemotherapy
223909155|NCT03125928|DRUG|Trastuzumab|Monoclonal antibody
223909156|NCT03125928|DRUG|Pertuzumab|Monoclonal antibody
223909157|NCT04677738|DIETARY_SUPPLEMENT|B. breve strain|Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve strain in the morning before breakfast for 12 weeks.
224084031|NCT03501966|PROCEDURE|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
224084032|NCT03501966|PROCEDURE|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
224084033|NCT00849667|DRUG|Farletuzumab|Farletuzumab IV infusion.
224084034|NCT00849667|DRUG|Carboplatin|Carboplatin IV infusion.
224084035|NCT00849667|DRUG|Taxane|Taxane (Paclitaxel or Docetaxel) IV infusion.
224084036|NCT00849667|DRUG|Farletuzumab-matched placebo|Farletuzumab-matched placebo IV infusion.
224084037|NCT01821495|BIOLOGICAL|DC-CIK|
224084038|NCT01821495|BIOLOGICAL|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
224277293|NCT02578277|DRUG|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
224277294|NCT03176433|DEVICE|Normothermic Machine Liver Perfusion|Liver Preservation Method
223909158|NCT04677738|DIETARY_SUPPLEMENT|Placebo|Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
223909159|NCT06505512|DIAGNOSTIC_TEST|No intervention|No intervention
223909160|NCT05021497|OTHER|Global Positional Re-education|A series of gentle active movements and postures aimed at realigning joints and stretching shortened muscles. GPR includes 8 therapeutic postures in lying, sitting and standing.
223909161|NCT05021497|OTHER|Conventional Physical Therapy Program|Axial traction will be given for 5 minutes, followed by mobilization of the muscle fascia along with static stretching of the scalene, levator scapulae, upper trapezius, sternocleidomastoid and pectoralis minor muscles.
223909162|NCT06265688|DRUG|CX-2051|Investigational drug monotherapy
223909163|NCT02851095|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
223909164|NCT02851095|DRUG|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
223909165|NCT02851095|DRUG|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
223909166|NCT05393388|DRUG|[18F]AV-1451|\[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
224084039|NCT04827641|OTHER|Severity Grading assessment in children with perioperative unexpected events|Systematic documentation of all unexpected events was carried out by designated team members during daily routine team conferences. Briefly, on-call team members and all other staff reported on any unexpected event that had occurred within the previous 24 hours, after weekends during the past 72 hours. Events included those that had occurred in inpatients, outpatients and in the pediatric emergency department. Data concerning each event included patient demographics, diagnoses, treatments/operations and types of events.
224084040|NCT00553163|BEHAVIORAL|Gut focussed hypnotherapy|Gut focussed hypnotherapy
224084041|NCT00553163|BEHAVIORAL|Control educational sessions|Control educational sessions
224084042|NCT03089957|DRUG|Ulinastatin|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
224084043|NCT03089957|OTHER|Usual care|Usual care in ICU.
224084044|NCT01075880|DRUG|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
224084045|NCT02198248|DRUG|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
224277295|NCT03203642|DRUG|Tesevatinib|Pharmaceutical form: Tablet; Route of administration: orally
224277296|NCT03203642|DRUG|Placebo|Pharmaceutical form: Tablet (identical to tesevatinib); Route of administration: orally
223715910|NCT06365398|DRUG|Heparin|As soon as the sheath was inserted, three different doses of heparin were administered according to the patients group assignment. In the conventional systemic heparinization (Regular-dose) group (The drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 83 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
223909167|NCT06543368|BIOLOGICAL|Intra articular PRP Injection|A total of 20 joints (estimated 10-15 patients) will receive injections, performed at day 0 and 3 weeks, for a total of two injections - two injections have demonstrated superior outcomes to one, and will increase our number of injections to improve the proof of feasibility. All subjects will receive ultrasound-guided intra-articular joint injections by an experienced sports medicine provider after local anesthesia with 1% lidocaine to the extra-articular structures, namely the skin and joint capsule, to increase comfort.
223909168|NCT05125783|OTHER|questionnaire|Completion of the questionnaire by the patient after consultation with the practitioner.
223909169|NCT06483035|DEVICE|Intensive Visual Simulation (IVS)|The IVS system initially makes a video-recording of the intact body part (arm or leg) executing a set of specific movements. These video recordings will be digitally reversed and projected onto a large screen in front of the patient. On the screen, the patient will monitor an intact, life-like extremity in place of the amputated extremity. This digital extremity will then execute the recorded movements in a pre-planned manner. Simultaneously, the patient will follow the digital virtual limb moving on the screen with his/hers amputated arm/leg, which is hidden below the screen. Hence, IVS therapy comprises elements of both movement perception, motor planning, motor execution and visual feedback of two intact limbs moving which are distinctive from classical Mirror-Therapy.
224277297|NCT02042599|DRUG|Sedation with sevoflurane during 48-hr in ICU|
224277298|NCT00265681|BEHAVIORAL|Phone counseling and written materials|
224277299|NCT03095781|DRUG|XL888|Given PO
224277300|NCT03095781|BIOLOGICAL|Pembrolizumab|Given IV
224277301|NCT01050556|OTHER|Placebo|daily, 24 weeks
224277302|NCT01050556|DIETARY_SUPPLEMENT|folic acid|400 ug/d for 12 or 24 weeks
224084046|NCT02198248|DRUG|Glucocorticoids|"Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule."
224084047|NCT03973476|OTHER|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
224277303|NCT01050556|DIETARY_SUPPLEMENT|folic acid|800 µg/d for 12 or 24 weeks
224277304|NCT01050556|DIETARY_SUPPLEMENT|creatine|3 mg/d for 12 weeks
224277305|NCT01050556|DIETARY_SUPPLEMENT|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
224277306|NCT03169816|DRUG|Lorcaserin|Lorcaserin 10mg, twice daily
224277307|NCT03169816|DRUG|Placebo|Matched placebo for lorcaserin condition dosed twice daily
223909170|NCT06483035|OTHER|Usual Care (UC)|"After allocation to UC, the participants continue with their normal treatment as prescribed by their medical doctor or other health professionals. All control participants are offered to complete IVS treatment after the end of the study period. The participants in the control group will therefore be placed on a fictitious waiting list during the study period."
223909171|NCT05434949|DIAGNOSTIC_TEST|Blood test|"Three blood samples to be taken at 08.00, 10.00 and 12.00 on day 1 of the study.~The following day, after an overnight fast, a blood sample will be taken at 8.00, followed by a standardized breakfast provided by the study team at 8.30, and then two further blood samples at 10.00 and 12.00."
223909172|NCT05434949|OTHER|Analyses of samples|C4 will be measured in surplus serum from 30 adult lipid patients before starting on lipid-lowering therapy (either statin of PCSK9 therapy) and then again 3 months after starting on therapy. Blood samples will be collected as part of routine lipid management, no additional samples are required.
223909173|NCT06536491|DRUG|EC-104 high dose|Intravitreal injection
223909174|NCT06536491|DRUG|EC-104 low dose|Intravitreal injection
223909175|NCT06536491|DRUG|Dexamethasone intravitreal implant|Marketed product intravitreal injection
223909176|NCT06522919|BIOLOGICAL|Autologous Dendritic Cell (DC) Vaccine|Induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a maintenance chemotherapy (FTD/TPI plus Bevacizumab) in patients with refractory MSS/pMMR metastatic colorectal cancer.
223909177|NCT06527235|DRUG|ultrasound-guided betamethasone infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 megahertz (MHz) linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of lidocaine injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
223909178|NCT06527235|DRUG|ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall|The perimeniscal injections will be guided by ultrasound with an 18 MHz linear probe under strict aseptic conditions. Doppler will be systematically used before the injection to identify the medial or lateral inferior geniculate artery. The first step will consist of local anesthesia with 2 ml of isotonic saline injected into the subcutaneous tissues and close to the meniscus wall using a 25-gauge needle. Using an in-plane approach, a 21-gauge needle will be positioned under ultrasound guidance in the medial or lateral wall of the meniscus. Once the needle touches the meniscus wall, it will be withdrawn 1 mm, and a 1-ml injection of betamethasone into the meniscus wall will be performed.
223909179|NCT05295602|RADIATION|CT scan|CT of lower leg
223909180|NCT06292728|DEVICE|ENDOPLY System|One endoscopic procedure where the ENDOPLY System is used for endoscopic gastric plication.
223909181|NCT03976154|OTHER|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
224277308|NCT05068284|DRUG|ABBV-154|Intravenous (IV) Infusion; Subcutaneous Injection
224277309|NCT05068284|DRUG|Placebo|Intravenous (IV) infusion; Subcutaneous Injection
224277310|NCT05068284|DRUG|ABBV-154|Subcutaneous Injection
223529022|NCT01629888|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
223529023|NCT01629888|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
223529024|NCT02184286|DRUG|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
223529025|NCT02184286|DRUG|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
223529026|NCT04310657|DIAGNOSTIC_TEST|mNGS|Metagenomics second generation sequencing technology
223529027|NCT04604431|OTHER|iREACH CDS Tool|Pediatric clinicians in the intervention arm will 1) receive the iREACH education module, 2) have the iREACH CDS tool integrated into the EHR templates for use at the 4-, 6-, 9-, 12-month WCC, and 3) will be reminded by EHR-embedded prompts at the 9-month WCC to ask caregivers whether peanuts were introduced and tolerated.
223529028|NCT00285194|DRUG|Allogeneic Islets of Langerhans|
223529029|NCT00285194|DRUG|hOKT3γ1 (Ala-Ala)|
223529030|NCT02888340|OTHER|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
223529031|NCT00643279|DEVICE|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
223529032|NCT00643279|OTHER|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
224277311|NCT05068284|DRUG|Placebo|Subcutaneous Injection
224277312|NCT00327691|DRUG|Atorvastatin|
224277313|NCT02945527|DRUG|Acetazolamide|As described above
224277314|NCT02945527|DRUG|Dexamethasone|As described above
224277315|NCT02304978|BIOLOGICAL|Group CRC|blood samples
224277316|NCT02304978|BIOLOGICAL|Group control|Blood samples
224277317|NCT02710240|DRUG|Indocyanine Green (ICG)|
224277318|NCT02710240|RADIATION|Intraoperative near-infrared (NIR)|
224277319|NCT02371096|DRUG|MabThera (rituximab)|
224277320|NCT02371096|DRUG|RGB-03|
224277321|NCT00004490|DRUG|sodium dichloroacetate|
223909182|NCT06851273|BEHAVIORAL|Guided Self Help Family Based Therapy (GSH FBT)|Each family will participate in ten virtual sessions of GSH FBT with a trained GSH practitioner local to their provincial study site. Parents will meet their coach for a 60-minute onboarding session where the parents/caregivers are familiarized with the video platform used in treatment. Then, the treatment consists of ten virtual 20-minute sessions over 6 months. In GSH FBT, the parents weigh the adolescent patient prior to the session, on the same day as the session, and report the weight to the coach. Throughout treatment, parents have access to an online platform with a series of videos that outline the core components of FBT: the urgency to act, parental empowerment, medical complications, strategies to use during and after mealtime, and how to externalize the illness. In line with GSH approaches, coach-therapists direct parents to watch or review videos and text content rather than directly affecting behavioral change.
223909183|NCT05803473|DEVICE|Dexcom G6 Continuous Glucose Monitoring System (Dexcom Inc., San Diego, USA)|"For CGM-arm subjects, glucose data are obtained by the CGM Dexcom G6 which via an iPhone SE 3 transmits data to the in-hospital diabetes team stations to be displayed on an iPad 9 10.2."
223909184|NCT05803473|DEVICE|FreeStyle Precision Pro Glucometer for glucose POC testing|For the POC-arm subjects, glucose assessment is done by standard ward glucometer.
223909185|NCT06851468|DRUG|Keverprazan|Keverprazan ：Dosage form: tablet；dose：20mg；dosage: 2 times a day；duration: 14 days
223909186|NCT06851468|DRUG|Esomeprazole|Esomeprazole：Dosage form: capsule；dose：40mg；dosage: 2 times a day；duration: 14 days
223909187|NCT06851468|DRUG|Amoxicillin|Amoxicillin：Dosage form: capsule；dose：1g；dosage: 3 times a day；duration: 14 days。
223909188|NCT06851637|BEHAVIORAL|PoET|Participants in the PoET group completed two online training sessions (3 hours each) via Zoom. Group size was about 25-30 people. The sessions included the following positive psychology constructs: happiness, humour, optimism, loving kindness and gratitude on the first day, and hope, self-efficacy, meaningfulness, forgiveness and resilience on the second day.
223909189|NCT05244278|DEVICE|Medtronic-GI genius (CADe system for detecting colorectal polyps)|Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
223909190|NCT06851897|OTHER|perforated 3D printed metal fixed retainer|The key of modification is digitally designing fixed metal retainer which will be custom made for each patient, and 3D metal printing of the fixed retention wire using Metal printer instead of using generic metal wire for all patients.
223909191|NCT06851897|OTHER|conventional fixed retainer|Conventional fixed metal retainer will be used. Multi strand wire will be used
223909192|NCT06096623|BEHAVIORAL|Weekly Survey|Subjects will respond to Electronic patient-reported outcome (ePRO) every week for 8 weeks.
223909193|NCT06484140|BEHAVIORAL|Financial Navigation|During hospitalization, participants will receive needs assessment, and one-on-one cost-related health education with a material booklet. Resource and service referral will be delivered face-to-face or by phone when the navigator identifies unaddressed problems. Within three months after discharge, participants will receive monthly follow-up phone calls and personalized counseling via WeChat.
223909194|NCT06484140|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
223909195|NCT04783766|DRUG|CK-3773274|CK-3773274- Tablets
223909196|NCT04783766|DRUG|Placebo|Placebo- Tablets
223909197|NCT04170881|OTHER|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
223909198|NCT04805658|DIAGNOSTIC_TEST|Clinical examinations|Clinical examinations
223909199|NCT05325099|DRUG|Azacitidine|azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times
223909200|NCT05325099|DRUG|Placebo|Placebo (subcutaneous injection) QOD x 3 times
223715911|NCT06365398|DRUG|Heparin Sodium Injection|In the micro-dose systemic heparinization (Micro-dose) group (the drug is Heparin Sodium Injection 2ml:12500 Units per bottle), systemic heparin was administered by intravenous injection at a dose of 42 Units/Kg. Patients in both the regular dose (83 units/kg) and low dose (42 units/kg) groups were given heparin intravenously once before the procedure of cerebral angiography, and no further heparin infusion was given during the angiography procedure. If the duration of the imaging procedure exceeded 1 hour, an additional 1/2 amount of the first dose of heparin was given.
223715912|NCT06365398|OTHER|No heparinization|No additional heparin was administered via the sheath or arterial route in the no heparinization group.
223715913|NCT05789810|OTHER|Manuel pressure|10-second manual pressure was applied on the insulin injection area.
223909201|NCT05163496|DRUG|Psilocybin (Usona Institute)|PAP + psilocybin 25 mg
223909202|NCT05163496|DRUG|Active placebo|PAP + niacin 250mg
223909203|NCT03871712|BEHAVIORAL|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
223909204|NCT03871712|BEHAVIORAL|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
224084048|NCT05568589|OTHER|Preoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
224277322|NCT02798328|DEVICE|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
224277323|NCT02520453|DRUG|Durvalumab|
224277324|NCT02520453|DRUG|Placebo|
224277325|NCT04779034|OTHER|Measurement of heart rate variability|Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
224277326|NCT00248937|BEHAVIORAL|Positive affect and self-affect induction|
224277327|NCT01947309|DRUG|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
224277328|NCT00806962|DRUG|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
224084049|NCT05568589|OTHER|Intraoperative Interpectoral - Pectoserratus Plane Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
224084050|NCT05568589|OTHER|Non Block|Pain numerical rating scale (numering Rating Scale) at postoperative 1st, 2nd, 6th, 12th and 24th hours in patients, patient recovery scores at 24th hour (QoR15 Turkish version), amount of tramadol used in patient-controlled analgesia, time to first rescue analgesia , adverse events (pneumothorax, nausea, vomiting, pruritus, hematoma, allergic reactions) and hand grip strength on the postoperative 1st day, quality of life, shoulder joint range of motion, and disability level will be measured on the postoperative 10th day.
224084051|NCT04316169|DRUG|Abemaciclib|150 mg b.i.d
224084052|NCT04316169|DRUG|Hydroxychloroquine 200 mg|Dose level: 200 mg b.i.d.
224084053|NCT04316169|DRUG|Faslodex|Cohort B will receive Faslodex.
224084054|NCT04316169|DRUG|Anastrazole|Cohort A will receive anastrazole or letrozole.
224084055|NCT04316169|DRUG|Letrozole|Cohort A will receive anastrazole or letrozole.
224084056|NCT04316169|DRUG|Hydroxychloroquine 400 mg|Dose level: 400 mg. b.i.d.
224084057|NCT04316169|DRUG|Hydroxychloroquine 600 mg|Dose level: 600 mg b.i.d.
224084058|NCT03104842|DRUG|Isatuximab|Antibody Intravenous
224084059|NCT03104842|DRUG|Carfilzomib|Intravenous
224084060|NCT03104842|DRUG|Lenalidomide|Capsel
224084061|NCT03104842|DRUG|Dexamethasone|Capsel
224084062|NCT00546923|DRUG|Venlafaxine XR|
224084063|NCT04536220|DIAGNOSTIC_TEST|Endoscopic Ultrasound (EUS), Fine Needle Aspiration|Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations
224084064|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
224084065|NCT02086331|BEHAVIORAL|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
224084066|NCT02086331|PROCEDURE|Contrast enhanced ultrasound|
224084067|NCT05213988|DIETARY_SUPPLEMENT|Intermittent Fasting|Intermittent fasting meal pattern
224084068|NCT05213988|DRUG|Fibrates|Bezafibrate 400 mg/day
224084069|NCT05213988|DIETARY_SUPPLEMENT|Low-Carbohydrate/High-Protein diet|Low-calorie, low-carbohydrate, high-protein diet
224084070|NCT04278807|PROCEDURE|Regional Anesthesia - Nerve Blocks|Regional Anesthesia and ultrasound-guided nerve blocks
224084071|NCT02950792|DEVICE|ViewRay MRI|ViewRay Magnetic Resonance Imaging
223715914|NCT05789810|OTHER|ShotBlocker|ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
224084072|NCT02950792|RADIATION|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors \< 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors \< 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) \< 20 Gy with V20 \< 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
224084073|NCT02765074|DRUG|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
224084074|NCT02459379|RADIATION|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
224084075|NCT05313542|BEHAVIORAL|Physical Activity|Physical Activity in the format of Self-defence Training
224084076|NCT03329378|DRUG|Docetaxel|Docetaxel 75mg/m2 IV, day 1
224084077|NCT03329378|DRUG|Carboplatin|Carboplatin AUC 6 IV, day 1
224084078|NCT03329378|DRUG|Trastuzumab|Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1
224084079|NCT03329378|DRUG|Pertuzumab|Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1
224084080|NCT03329378|DRUG|Pegfilgrastim|Pegfilgrastim 6mg SC, day 2 Cycled as per arm
224084081|NCT03329378|DRUG|Trastuzumab|Trastuzumab 6mg/kg every 21 days to complete 1 year
224084082|NCT03329378|DRUG|Paclitaxel|Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
224084083|NCT03329378|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 IV day 1
224084084|NCT03329378|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 IV day 1
224084085|NCT03329378|DRUG|Paclitaxel|80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
224084086|NCT00510276|DRUG|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
224084087|NCT00510276|DRUG|Placebo|twice a day, by mouth for 12 weeks
224084088|NCT05490706|BEHAVIORAL|Bodyweight interval exercise|Performing 15 minutes of bodyweight interval exercise after dinner at home by following a video
224084089|NCT05490706|BEHAVIORAL|Walking|Performing a 30 minute minute walk after dinner at home
224084090|NCT03209284|PROCEDURE|transcrestal sinus floor elevation|augmentation procedure with xenograft
224084091|NCT02250209|DRUG|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.
224084092|NCT02250209|DRUG|Capecitabine|"Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles."
224084093|NCT02250209|DRUG|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles."
224084094|NCT06343779|DRUG|Deucrictibant, Placebo|Deucrictibant Soft Capsules for Oral Use
224084095|NCT05375279|PROCEDURE|Lip Salivary Gland Biopsy|Obtaining few salivary glands from the partipants' lip that will be studied using the Congo Red staining method.
224277329|NCT00806962|DEVICE|placebo|intranasal, puff of air, 2 doses, 21 days apart
224084096|NCT04291144|RADIATION|PET-CT using FEOBV|We will inject 300 MBq of 18F-FEOBV in a peripheral vein and scan the internal organs from (0-70 minutes). The patient then rests, and from 180-210min after injection, we will scan the brain on our Siemens High Resolution Research Tomograph.
223909205|NCT05161117|BEHAVIORAL|Virtual reality simulation app for caregiver education|"Using a virtual reality headset/goggles, caregivers will engage with an interactive app experience to identify and mediate fall risk hazards in the inpatient care environment. The app will present a hospital bedroom and bathroom laden with fall risks. As the caregiver progresses through the experience, the caregiver will ambulate (virtually) through the environment with the goal of identifying fall risks inherent within that inpatient setting. Fall risks will be targeted and identified using the app sighting function and after focusing on the fall risk for the allotted marking time, will self-resolve."
224084097|NCT04291144|RADIATION|MRI-scan|All patients will have an MRI scan of the brain. T1-weighted images will be used to assess general anatomy and identify white matter. T2-weighted sequences will be performed to quantify competing brain pathology. Also, we will collect functional MRI data.
224084098|NCT04291144|DIAGNOSTIC_TEST|Cognitive assessment|Full neuropsychometric examination including tests in 5 cognitive domains.
224084099|NCT04291144|DIAGNOSTIC_TEST|Clinical assessment|Age, sex, duration of disease, patient history and full somatic and neurological examinations. Constipation assessed with Rome-III criteria. Evaluation of Rapid Eye Movement (REM) sleep Behaviour Disorder (RBDSQ) questionnaire. Test for orthostatic hypotension, heart rate variability, and deep breathing.
224084100|NCT01349647|BIOLOGICAL|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
224084101|NCT01349647|BIOLOGICAL|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
224084102|NCT02119520|DRUG|Platelet rich fibrin +Atorvastatin|
224084103|NCT02119520|DRUG|Platelet rich fibrin|
224084104|NCT02119520|PROCEDURE|open flap debridement|
224084105|NCT03472508|DRUG|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
224084106|NCT03472508|DRUG|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
224084107|NCT03472508|DRUG|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
224084108|NCT03486392|DRUG|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
223909206|NCT05161117|BEHAVIORAL|online fall prevention education module|Participants in both intervention and control groups will complete a 20 minute online module: Management of the Patient at Risk for Falls, through the MyLearning education platform. Most caregivers would have taken this module during competencies or orientation, but at various times. It will be taken by all participants in this study to serve as a baseline understanding of identifying and caring for patients at risk for falls. Participants will be enrolled in the module by a member of the research team, and learner transcripts will available through MyLearning education to confirm completion.
224084109|NCT03486392|DRUG|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
224084110|NCT03486392|DRUG|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
224084111|NCT03486392|DRUG|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
224084112|NCT03486392|DRUG|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
224084113|NCT04320524|DEVICE|Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention|3 weeks
224084114|NCT00923117|DRUG|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
223909207|NCT05861921|OTHER|Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture|Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
224084115|NCT01560273|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
224084116|NCT01028625|BEHAVIORAL|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
224084117|NCT01028625|OTHER|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
223715915|NCT05789810|OTHER|Control|No intervention was performed to reduce pain and fear.
224084118|NCT00024427|DRUG|fluorouracil|High dose 5-FU
223715916|NCT01461603|DIETARY_SUPPLEMENT|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
224084119|NCT00024427|DRUG|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
223715917|NCT01461603|DIETARY_SUPPLEMENT|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
223909208|NCT04524416|DEVICE|Minimally invasive glaucoma surgery (MIGS)|MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
223909209|NCT01725763|OTHER|Cardiac MRI|
223909210|NCT06823453|BEHAVIORAL|Peer Harm Reduction Support Champion Intervention|This intervention will recruit non-substance-using friends and family members of people who use opioids and live on the West side of Chicago, educate them on harm reduction (HR) tools and services, and train them to become peer HR support champions. They will be asked to recruit one friend or family member who uses opioids to the study, who will also be provided with an educational training on overdose risk reduction and available HR tools and services. The intervention will then facilitate a counselor-led initial conversation between peer HR support champions and their friend or family member who uses opioids, to help establish HR-related support, and will provide all participants with naloxone and fentanyl test strip kits. This intervention will not only provide another mechanism through which people who use opioids can access HR tools and services, thereby reducing logistical barriers to access and preventing overdose, but it should also reduce stigma and increase social support.
223909211|NCT05815745|DEVICE|Pacemaker - Physiological pacing|The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
223909212|NCT05815745|DEVICE|Pacemaker - Right Ventricular pacing|Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
223909213|NCT06823102|OTHER|tDCS|Transcranial direct current stimulation
223909214|NCT06232564|COMBINATION_PRODUCT|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy|Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
223909215|NCT06423820|DRUG|Ondansetron lozenge|Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
223909216|NCT04660539|DRUG|satralizumab|Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
223909217|NCT04660539|DRUG|azathioprine (AZA)|Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
223909218|NCT04660539|DRUG|mycophenolate mofetil (MMF)|Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
223909219|NCT04660539|DRUG|oral corticosteroids|Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
223909220|NCT04249362|DRUG|Durvalumab|All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.
223909221|NCT06052839|DRUG|Pembrolizumab|Immunotherapy that works by helping the immune system to kill cancer cells by targeting and blocking a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
223909222|NCT06052839|DRUG|Carboplatin|A chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
224084120|NCT00024427|DRUG|triacetyluridine|6 grams (12 tablets)
224084121|NCT00355316|OTHER|Blood draw|
223909223|NCT06052839|DRUG|Paclitaxel|A chemotherapeutic agent used as a treatment for various cancers; paclitaxel is a mitotic inhibitor.
223909224|NCT06202105|PROCEDURE|Laparoscopic gastrectomy|Gastrectomy with laparoscopic approach
224084122|NCT06301178|DRUG|Cholecalciferol|Vitamin D has various critical regulatory roles, including inflammatory control, cellular proliferation and differentiation, and wound healing regulation.
224084123|NCT02606994|DRUG|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
224084124|NCT02606994|DRUG|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
224084125|NCT02606994|DRUG|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
224084126|NCT04420364|OTHER|Maintenance or reduction of immunosuppression|Maintenance versus reduction of immunosuppression
224084127|NCT05797714|DRUG|Tenofovir Amibufenamide（TMF）|TMF, 25mg QD, from baseline to 144 weeks
224084128|NCT06460571|OTHER|Standard Cardiac rehabilitation with Delorme technique|Aerobic training will be provided three alternate days a week at 60-70% of maximum heart rate for eight weeks. Resistance training for 3 sets and 10 repetitions (10 lifts with 50%of 10RM, then 75% of 10RM and will progress to 100% of 10RM) will involve seven exercises (abdominal curl ups, bicep curls, triceps extension, back extension, leg curls, side leg raises and knee extensions).
224084129|NCT06460571|OTHER|standard cardiac rehabilitation|The control group (Group B) will undergo standard cardiac rehabilitation (outpatient cardiac rehabilitation) which include walking, cycling and strength training which will have 5-10 minutes warm-up followed by training for 30-45 minutes, concluding with cool-down without the Delorme technique. The control group will not perform any specific training but will be given a diet chart to follow
224084130|NCT00703313|DRUG|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
224084131|NCT00703313|DRUG|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
224084132|NCT00703313|DRUG|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
223715918|NCT04915430|OTHER|Training|
223715919|NCT02109380|BEHAVIORAL|Bed rest|
224084133|NCT04088448|DRUG|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
223715920|NCT03665805|OTHER|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
223715921|NCT06280170|OTHER|Artificial Intelligence platform for case managers|Providers will have access to the Eleos Health mobile AI platform to document their case management encounters.
224084134|NCT04088448|DRUG|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
224084135|NCT00806104|DIETARY_SUPPLEMENT|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
224084136|NCT00806104|DIETARY_SUPPLEMENT|Maltodextrins|Dietary supplementation for 4 weeks
224084137|NCT01440335|DRUG|Oral R,R'-Fenoterol|
223909225|NCT04819243|DRUG|Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab|"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib~* Atezolizumab"
223909226|NCT04819243|DRUG|Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,|"* Palbociclib 125mg~* AI~* GnRH agonist (or ET + CDK4/6 inhibitors + GnRH agonist)~* Talazoparib"
224084138|NCT01440335|DRUG|Oral Racemic Fenoterol|
224084139|NCT05077488|DEVICE|Juvéderm® VOLIFT™ with Lidocaine|Sterile gel in disposable syringe
224084140|NCT02392260|DEVICE|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
224084141|NCT00686816|DIETARY_SUPPLEMENT|Low calorie diet|low calorie diet
224084142|NCT00686816|DIETARY_SUPPLEMENT|Olestra|low calorie Olestra diet
224084143|NCT05928975|OTHER|MT+ PNE with MI|"The manual therapy treatment approach entailed the management of symptoms based on the clinical judgment of the attending physiotherapist. The physiotherapist selectively employed techniques such as spinal mobilization/manipulation, soft tissue massage, supervised exercises and muscle and neural mobilization, while excluding the utilization of electrophysical modalities. The participants will receive 10 Manual Therapy sessions of 30 minutes within a period of 4 weeks.~The pain neuroscience education program is based on previous clinical studies and available educational materials and is enhanced by motivational interviewing techniques. The program consisted of 4 individualized educational sessions, each lasting 30 minutes. All key aspects of pain neurophysiology were explained and discussed. At the end of the first session, participants will be provided with informational handouts to support the educational process."
224084144|NCT05928975|OTHER|MT|"Participants in this group will be given the same MT program as MT + PNE with MI group without the application of PNE."
224084145|NCT05928975|OTHER|Control|The participants in the control group will be provided with written instructions for performing general exercises at home. These exercises will consist of gentle stretching exercises specifically targeting the low back muscles, as well as relief positions and breathing relaxation exercises.
223909227|NCT03655028|BEHAVIORAL|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
224084146|NCT04371367|BIOLOGICAL|avdoralimab|intravenous administration of avdoralimab
224084147|NCT04371367|OTHER|Placebo|intravenous administration of placebo
224084148|NCT00503165|BIOLOGICAL|Menitorix (MenC and Hib conjugate)|
224084149|NCT01736956|PROCEDURE|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
224084150|NCT03784183|OTHER|Cognitive Stimulation (CS)|CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
224084151|NCT00441792|DRUG|Etomidate|Etomidate at induction dose based on weight
224084152|NCT00441792|DRUG|midazolam|Midazolam at induction dose based on weight
223715922|NCT01129817|OTHER|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
223909228|NCT03655028|BEHAVIORAL|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
223909229|NCT05938543|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces an electrical current in neurons and allows for modulation of neural circuitry.~Other Name: iTBS"
223909230|NCT03513302|DIETARY_SUPPLEMENT|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
223909231|NCT03513302|DIETARY_SUPPLEMENT|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
223909232|NCT06449781|DRUG|Lutetium (177Lu) vipivotide tetraxetan|The intervention will consist of a single administration of 7,4 GBq of lutetium (177Lu) vipivotide tetraxetan
224084153|NCT06121414|DEVICE|laserpuncture|laserpuncture use continous wave,dose 2 Joule, 785nm, 50mw
224084154|NCT06121414|DEVICE|Sham Laserpuncture|Sham laser using laserpuncture in off condition
224084155|NCT02005120|DRUG|Bevacizumab|Intrapleural administration of bevacizumab
224084156|NCT02005120|DRUG|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
224084157|NCT05560737|BEHAVIORAL|ODYSSEE-vCHAT|"ODYSSEE-vCHAT consists of:~* Automated digital counselling resources (educational pages, videos, tools, and trackers)~* Chatrooms available 24/7~* Weekly 30-minute presentations and discussions led by a healthcare professional or patient representative~Each aspect was informed by a rotating schedule of 7 weekly self-care themes. Webcasts were recorded and streamed to our private YouTube channel, and associated hyperlinks were shared on the program. Subjects had the option of submitting photographs depicting heart-healthy lifestyles and activities (with no identifying, sensitive, or personal information) to the Gallery Wall.~Subjects were invited by email to access the resources available to them. They logged on to the program using password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) were recorded. Assessments occurred online at baseline, months 4 and 8, and study completion (up to 16 months)."
224277330|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
224277331|NCT00806962|BIOLOGICAL|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
224277332|NCT04834336|DEVICE|inspiratory muscle training device|Inspiratory muscle training will be performed with an inspiratory muscle training device.
224084158|NCT01225341|DRUG|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
224084159|NCT01225341|OTHER|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
224084160|NCT01363687|DEVICE|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
224084161|NCT02224898|BEHAVIORAL|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
224084162|NCT03715426|BEHAVIORAL|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
224277333|NCT04834336|OTHER|Physical training|Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
224277334|NCT01124435|DRUG|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
224277335|NCT00176943|DRUG|Aldara Cream 5%|
224277336|NCT03460990|DRUG|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
223909233|NCT05732779|OTHER|DOT intervention|A mobile health application developed by eMocha Health Inc. facilitates asynchronous mobile video directly observed therapy (DOT) intervention, empowering users to track dose-by-dose medication adherence
223909234|NCT05618587|DRUG|Lithium|Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
223909235|NCT05618587|DRUG|Placebo|Inactive pill
223909236|NCT06285448|DRUG|Lecanemab|Bi-weekly infusions of lecanemab \[exposure\].
223909237|NCT04693533|DRUG|Fremanezumab Prefilled Syringe [Ajovy]|The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
223909238|NCT06387147|DRUG|Gentamicin|Gentamicin 80 mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
223909239|NCT06387147|DRUG|Placebo|Gentamicin placebo (2ml sodium chloride diluted 1/10 in a syringe of 20mL Metronidazole placebo in tablets
223909240|NCT06387147|DRUG|Metronidazole|Métronidazole 500mg 3 times per day during 14 days oral route or nasogastric tube or jejunostomy tube (in the case of an ostomy)
223909241|NCT01167309|DRUG|LEO 27847|First in patient
223909242|NCT04260854|DRUG|Bupivacaine Hydrochloride|Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
223909243|NCT04260854|DRUG|Saline|Normal saline injections.
223909244|NCT05167864|DRUG|Onabotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
223909245|NCT05167864|DRUG|Abobotulinumtoxina for Injection|cosmetic injection into the glabella area (eyebrow area)
223909246|NCT05167864|DRUG|IncobotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
223909247|NCT05167864|DRUG|PrabotulinumtoxinA for Injection|cosmetic injection into the glabella area (eyebrow area)
223909248|NCT05786417|OTHER|Clinician Discretion|Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
223909249|NCT05786417|DRUG|Beta blocker|Selection of the specific BB and initial starting dose will be determined by the treating clinician.
223909250|NCT05786417|DRUG|Calcium channel blocker|Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
223909251|NCT06580171|OTHER|Walking and Remembering Test|Only Walking and Remembering Test will be applied to the group.
224084163|NCT00866099|OTHER|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
224084164|NCT03557567|DIAGNOSTIC_TEST|NGS molecular screening|
224277337|NCT03460990|DRUG|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
224277338|NCT03460990|DRUG|IVA|Participants received IVA orally once daily in the evening.
224277339|NCT03460990|DRUG|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
224277340|NCT03460990|DRUG|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
224277341|NCT01958060|DRUG|BI 1034020|intravenous part
224277342|NCT01958060|DRUG|Placebo to BI 1034020|intravenous part
224277343|NCT03902301|DIETARY_SUPPLEMENT|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
223909252|NCT06570863|OTHER|Antibiotics(doxycycline)|doxycycline 100 mg 2 stat the first day followed by od for 14 days
223909253|NCT06570863|OTHER|Probiotics|Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.
223909254|NCT06570863|OTHER|Metronidazole gel 25%|After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula
223909255|NCT03495180|OTHER|Standard EEG or SSEP|The gamma frequency range (30 -100 Hz) of standard EEG or somatosensory evoked potential (SSEP) correlate with intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
223909256|NCT03852550|OTHER|e-health application|In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
223909257|NCT05204654|OTHER|In-office fabricated appliance|A 0.022 Slot MBT™ second molar mini tube that has been modified to have a 2 mm length will be placed on the maxillary first molar and a 0.018 slot MBT™ maxillary canine bracket will be placed on the maxillary canine, with a 0.016x0.022 stainless-steel wire spanning from the maxillary first molar to the maxillary canine. A bayonet bend will be placed mesial to the molar tube. A curve will be bent into the wire, so that the wire is able to passively rest on the buccal surface of the maxillary canine. A stainless-steel closed coil will span the molar to canine and lay flush to the mesial portion of the molar tube and the distal portion of the canine bracket. The wire will be cinched mesial to the maxillary canine tie-wing and also 2-3 mm distal to the maxillary first molar to ensure that the molar can rotate during treatment, if needed. A stainless-steel tie will be used to secure the wire into the canine bracket. AP correction will be completed following CMA protocol
223909258|NCT05204654|DEVICE|Carriere Motion Appliance|A bar spanning from the maxillary first molar to canine with a ball and socket joint at the molar and a canine pad at the canine. A slight bend is present between the molar and canine bracket. The ball and socket is designed to allow the molar to rotate to -15 degrees along it's longitudinal axis. The appliance claims that it allows for Class II correction with minimal secondary tooth movements when used with mandibular anchorage.
223909259|NCT01836705|DRUG|SAR302503 (TG101348)|"Pharmaceutical form:capsule~Route of administration: oral"
223909260|NCT01836705|DRUG|Placebo SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223909261|NCT01836705|DRUG|Panolosetron|"Pharmaceutical form:solution~Route of administration: intravenous"
223909262|NCT02745860|DRUG|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
223909263|NCT02745860|DRUG|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
223909264|NCT05469789|OTHER|No Intervention|As it is an observational study, no intervention is administered in this study.
223909265|NCT06254534|DIAGNOSTIC_TEST|optic nerve ultrasonography|The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.
223909266|NCT05608109|BEHAVIORAL|Alcohol personalized normative feedback (APNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's drinking compared to other same-university students will include: (a) drinking days per week, (b) average drinks per occasion, (c) drinks per week, and (d) drinking percentile rank.
223909267|NCT05608109|BEHAVIORAL|Social media personalized normative feedback (SMPNF)|Participants will receive individualized feedback based upon their survey responses. Feedback regarding participant's alcohol related content posts on social media and drinking compared to other same-university students will include: (a) alcohol related posting days per week, (b) average alcohol related posting per week, (c) posting percentile rank, (d) drinking days per week, (e) average drinks per week, and (f) drinking percentile rank.
223909268|NCT03974893|OTHER|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
223909269|NCT04868123|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Transcutaneous nerve stimulation (TENS) is a simple home base treatment to manage pain. It involves electrical current applied to the skin through self-adhering electrodes, using a TENS3000 device (TENSPros.com).
223909270|NCT04868123|BEHAVIORAL|Mindfulness Meditation|Mindfulness mediation is a guided mediation process to improve awareness of being present in the moment.
223909271|NCT01804985|DRUG|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
223909272|NCT01804985|DRUG|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
223909273|NCT01804985|DRUG|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
223909274|NCT04089059|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~1. Cordella Sensor~2. Cordella Delivery System~3. myCordella Patient Reader~4. Reader Dock~5. Cordella Calibration Equipment (CalEQ)~6. myCordella Hub~7. Cordella Data Analysis Platform (CDAP)"
223909275|NCT04149990|DRUG|Entresto Pill|NO other interventions
224084165|NCT03544112|BEHAVIORAL|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
224277344|NCT03902301|DIETARY_SUPPLEMENT|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
223909276|NCT06551311|BEHAVIORAL|cycling training exercise|"Participants were randomly allocated to one of three groups: control (CTL), concentric cycling training (CON), or eccentric cycling training (ECC).~CTL: Received standard health education guidance.~CON and ECC: Participants in both the CON and ECC groups engaged in 24 exercise sessions, performed three times per week, lasting between 20 and 30 minutes. Both groups trained on a stationary bicycle, with the CON group performing concentric cycling and the ECC group performing eccentric cycling. The exercise intensity for both groups was set to a rating of perceived exertion (RPE) level of 13. Sessions began at 20 minutes and increased incrementally by 3-5 minutes each week until participants could sustain a 30-minute duration. The initial exercise intensity was set at 50% of the maximal output determined by a cardiopulmonary exercise test, and it was progressively increased by 5-10% of the estimated target power weekly, with adjustments made primarily to maintain an RPE of 13."
223909277|NCT03314688|BEHAVIORAL|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
224277345|NCT02770144|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
223909278|NCT03314688|BEHAVIORAL|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
223909279|NCT00179400|DRUG|Pioglitazone|This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
223909280|NCT00179400|DRUG|Placebo|This was a randomized placebo-controlled crossover study in which subjects received both agents in random order, separated by a wash-out period. Following 10 or 21 days' intervention, subjects underwent a pancreatic clamp study.
223909281|NCT00179400|PROCEDURE|Pancreatic Clamp Study|During the clamp procedure, glucose (a sugar) and insulin were infused with an IV catheter, and blood samples were collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body and are related to glucose metabolism.
223909282|NCT03765619|DRUG|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
223909283|NCT05675735|BEHAVIORAL|Clinic-Level Multidimensional Intervention|The proximal goal of the intervention will be to increase OTP uptake of flexible THD. The intervention addresses facilitators and barriers to THD practices as identified by existing studies as well as those found during the first phase of the current project. The intervention will be designed to address the information gaps, training needs, and beliefs of individuals across the organizations.
224084166|NCT03544112|DRUG|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
224084167|NCT04960085|DEVICE|echocardiography|philips IE33
224277346|NCT02770144|BEHAVIORAL|Access to Referral to Social Services|
224277347|NCT01597453|BEHAVIORAL|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
224277348|NCT00105495|DRUG|Ferriprox (deferiprone)|
224277349|NCT00105495|DRUG|Desferal (deferoxamine)|
223909284|NCT05772520|DRUG|TLL018 tablets|oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
223909285|NCT05572684|DRUG|NC410|NC410 will be given intravenously (IV) every 2 weeks
223909286|NCT05572684|DRUG|pembrolizumab|Pembrolizumab 400mg will be given IV every 6 weeks.
223909287|NCT06288360|DRUG|Camrelizumab|200 mg, intravenously, 20-60 min. 2 times, every 21 days
223909288|NCT06288360|DRUG|Paclitaxel-albumin|260 mg/m² over 30 min, 3 times, every 21 days
223909289|NCT06288360|DRUG|Cisplatin|4 h, 75-80 mg/m², 3 times, every 21 days
223909290|NCT06288360|PROCEDURE|radical surgery|Radical hysterectomy + pelvic lymphadenectomy 士 para-aortic lymphadenectomy
223909291|NCT06402851|DRUG|Anticoagulant Oral|Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
224084168|NCT00712374|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
224084169|NCT04873492|OTHER|Biological sample collection|Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.
224084170|NCT00207467|BEHAVIORAL|Patient-delivered partner treatment|
224277350|NCT03230734|DRUG|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
224277351|NCT03230734|DRUG|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
224277352|NCT05381896|OTHER|Conventional Scoliosis Exercise Program|Program will include breathing exercises, spinal stabilization and strengthening exercises, posture exercises and stretching execises.
224277353|NCT05381896|OTHER|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
224277354|NCT05119660|DEVICE|Intermittent Theta Burst Stimulation|iTBS
224277355|NCT00198224|PROCEDURE|phlebotomy|
223909292|NCT04243070|DIAGNOSTIC_TEST|3-channel Holter ECG recording|3-channel Holter ECG recording for patients undergoing an EPS
224084171|NCT00207467|BEHAVIORAL|Booklet-enhanced partner referral|
224084172|NCT01175798|DRUG|Cholecalciferol|50,000 IU PO weekly x 6 weeks
224084173|NCT03825913|BEHAVIORAL|Exercise Intervention|"Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention."
224084174|NCT03825913|BEHAVIORAL|Wellness Intervention|In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
224084175|NCT05429879|OTHER|Preferred Music Arm|Patients will choose their preferred music to be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
224084176|NCT05429879|OTHER|Classical Music Arm|A standardized playlist of copyright free classical music will be played during the cystoscopy procedure. No music will be played prior to or immediately after the flexible cystoscopy procedure. Music will be delivered via a speaker allowing for communication between the urologist and the patient during the procedure. Aside from addition of music, standard of care will not be impacted.
224084177|NCT00430170|DRUG|Dipyridamole|Dipyridamole 2x200mg 7day per os
224084178|NCT00430170|DRUG|caffeine|caffeine 4mg/kg iv
224084179|NCT05713864|DEVICE|BTL-899|The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.
224084180|NCT05713864|DEVICE|HPM-6000UF|The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
224277356|NCT05610449|DIAGNOSTIC_TEST|Testing Done Simple SARS CoV-2 Antigen Test|Collections of specimens from subjects presenting with Covid-19 like symptoms or known/suspected exposure to SARS CoV-2 via nasal swabs administered by trained medical personnel.
224277357|NCT00139906|DRUG|Bifeprunox|
223715923|NCT01129817|OTHER|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
223715924|NCT00528788|DRUG|doxercalciferol|
224084181|NCT01112332|DEVICE|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
224084182|NCT00888355|DRUG|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
224084183|NCT00888355|DRUG|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
224084184|NCT00222027|PROCEDURE|Collection of treatment-stratefying prognostic factors|
224277358|NCT04284553|OTHER|Order Entry|An alert will display in the electronic health record when the provider orders one of the high-risk medications for an eligible patient.
224277359|NCT04284553|OTHER|Open Encounter|An alert will display in the electronic health record when the provider opens the chart of an eligible patient.
224277360|NCT04284553|OTHER|Follow-up booster Alert|Once the order entry or open encounter alert displays, the provider will have the option to schedule a follow-up message that will be sent 4 weeks after the alert is triggered
224277361|NCT04284553|OTHER|Cold State outreach|An in-basket message will be sent to the eligible provider 2 days before the eligible patient is scheduled for an in-person visit.
223715925|NCT02039492|PROCEDURE|Sympathetic Renal Denervation|
223715926|NCT02039492|DRUG|Treatment with aldactone|
223715927|NCT02643381|DRUG|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
223909293|NCT04243070|DIAGNOSTIC_TEST|12-channel Holter ECG recording|12-channel Holter ECG recording for patients undergoing a routine follow-up
223909294|NCT06153966|DRUG|ION717|ION717 will be administered by IT injection.
223909295|NCT06153966|DRUG|Placebo|Placebo-matching ION717 will be administered by IT injection.
224277362|NCT04284553|OTHER|Simplified|The alert language itself will be simplified.
224277363|NCT04284553|OTHER|Sign-off alert|An alert will display in the electronic health record when the medication is sent to sign-off for providers.
224277364|NCT04284553|OTHER|Pre-commitment|A two-staged pre-commitment electronic health record alert will be used. In the 1st alert, the providers will be prompted to discuss risks of these high-risk medications and share a handout about the risks with their patients, at their own discretion. The second alert will be either an order entry or open encounter alert, depending on the arm the provider is assigned to.
224277365|NCT04284553|OTHER|Different Risks|Risks of the high-risk medications will be framed differently.
224277366|NCT04284553|OTHER|Standard Epic Basic Alert|This alert will be representative of the alerts currently firing in the Atrius system and not incorporate any functionality.
223715928|NCT02643381|DRUG|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
223909296|NCT05874453|OTHER|eye care protocol|The lower conjunctiva of the eye to be treated is opened, 1-2 drops of gel are applied, the eye is closed. Cleaning eye secretions is done with sterile distilled water. A gel containing trehalose, hyaluronic acid and carbomer will be applied every 2-4 hours in accordance with intensive care eye care protocol. In order to determine the exposure keratopathy, staining with Fluorescein Sodium will be performed by the ophthalmologist on days 0, 5 and 10, and a blue light pen will be used for evaluation. In order to determine the degree of dry eye, the Schirmer I test will be performed on the 0th and 10th days
223909297|NCT06235190|DEVICE|Felix NeuroAI Wristband|The Felix NeuroAI Wristband (Felix) is a wrist-worn, noninvasive, transcutaneous neurostimulation system. Using a proprietary artificial intelligence (AI) algorithm, stimulation will be automatically adapted to patient's needs with the goal to provide full day relief of upper limb tremor.
223909298|NCT06235190|DEVICE|Sham Device|The sham device has the same exterior appearance and components as the Felix device and is used the same way (without delivering the treatment).
223909299|NCT01009788|DRUG|ABT-888|Capsules (30-40 mg) taken orally twice a day on days 1-7 of each 28 day cycle
223909300|NCT01009788|DRUG|temozolomide|Capsules (150 mg/m\^2 initially, and 200 mg/m\^2 starting cycle 2 if tolerated) taken orally once a day on days 1 through 5 of a 28 day cycle
223909301|NCT06258681|OTHER|Incentive spirometer|The incentive spirometry group will continue training with Volumetric Triflo. It is asked to exhale at first and then hold their breath for at least 3 seconds after taking as deep a breath as possible.
223909302|NCT06258681|OTHER|Individualized respiratory training group|Participants will be able to practice both inspiratory and expiratory respiratory muscle training in a single breathing cycle.
223909303|NCT03127189|DRUG|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
223909304|NCT03127189|DRUG|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
223909305|NCT06558994|PROCEDURE|Transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo transection of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis.
223909306|NCT06558994|PROCEDURE|Ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis|Half of the patients will undergo ligation of internal spermatic vessels in first stage laparoscopic Fowler-Stephens orchidopexy for intra-abdominal testis
223909307|NCT06350669|DEVICE|Vestibular rehabilitation phone application|The standard vestibular rehabilitation process, with the support of a phone app throughout the process
223909308|NCT04731376|OTHER|Best Practice|Receive standard peri-operative care
223909309|NCT04731376|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223909310|NCT04731376|OTHER|Questionnaire Administration|Ancillary studies; Quality of life questionnaires will be given both preoperatively and at 3-months postoperatively
223909311|NCT04731376|DRUG|Testosterone Cypionate|Given IM
223909312|NCT06051383|OTHER|Self management|"patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months"
223909313|NCT02296684|BIOLOGICAL|MK-3475 (neoadjuvant)|
224084185|NCT06166628|PROCEDURE|Geniculate artery embolization|Femoral arterial access will be obtained under ultrasound guidance. An angiographic catheter will then be advanced to the distal superficial femoral artery. Angiography will be performed to identify the appropriate genicular branches supplying the regions of hyperemia. A microcatheter (1.7-2.4-French) will then be advanced super-selectively into the genicular arteries and 100-300 um EmboSpheres (Merit Medical) will be injected under fluoroscopic guidance. Multiple geniculate arteries may be embolized until neovascularity is no longer seen and pathologic hyperemia is resolved. A repeat lower extremity angiogram will be performed to evaluate for success of embolization and to exclude complication. The catheter and sheath will then be removed, and hemostasis will be achieved using an AngioSeal (Terumo Vascular Interventions) vascular closure device.
223715929|NCT02643381|PROCEDURE|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
223909314|NCT02296684|PROCEDURE|Surgery|Standard of care
223909315|NCT02296684|RADIATION|Intensity modulated radiation therapy|Recommended, standard of care
223909316|NCT02296684|RADIATION|Image-guided radiation therapy|Recommended, standard of care
223909317|NCT02296684|DRUG|Cisplatin|Standard of care
223909318|NCT02296684|BIOLOGICAL|MK-3475 (adjuvant)|
223909319|NCT02296684|PROCEDURE|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
223909320|NCT06390137|DEVICE|Frequency Specific Microcurrent|The participant will receive an FSM treatment of 40 Hz on channel A and 97 Hz on channel B at 200 uamp with alternating current with a sharp square wave slope for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest. The TENS unit will be wrapped in an opaque bag so that the device is indistinguishable from that of the sham treatment.
224277367|NCT04284553|OTHER|Enhanced Alert|An enhanced alert (known as a Best Practice Advisory \[BPA\]) will appear on the provider's electronic health record screen and will contain several standard components such as information about why the medication is dangerous for their patient and an order set that will allow providers to order a gradual dose taper for their patient, order alternative medications, place a referral to a behavioral health specialist, provide instructions on how to make lifestyle modifications to improve patient symptoms, and add patient instructions for how to gradually taper off benzodiazepines and sedative hypnotics, as applicable.
223715930|NCT02643381|DEVICE|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
223909321|NCT06390137|DEVICE|Sham microcurrent treatment|The participant will receive a sham FSM treatment with the machine off wrapped in an opaque bag for 60 minutes with body contact points using a single towel wrapped posteriorly around the back at the level of T10 and the yellow (right side) and black (left side) leads will be attached to a second towel and wrapped anteriorly just below the abdomen and iliac crest.
223909322|NCT05603052|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
223909323|NCT05603052|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
223909324|NCT06514963|DRUG|HRS-9813|Specified dose on specified days
223909325|NCT06514963|DRUG|Placebo|Specified dose on specified days
223909326|NCT04860830|DRUG|BI 425809|BI 425809
223909327|NCT04860830|DRUG|Placebo|Placebo
223909328|NCT06563388|PROCEDURE|Stereotactic Ablative Radiotherapy|Radiation therapy begins after 3 months of Standard of care
223909329|NCT06563388|OTHER|Best Practice|Receive standard of care therapy
223909330|NCT06562933|DEVICE|Sham vacuum|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. The vacuum electrodes will apply continuous vacuum mode for only 10 minutes without delivering interferential current. Following the sham vacuum therapy, a hot pack will be applied to the painful neck area for 20 minutes.
223909331|NCT06562933|DEVICE|Interferential Current Therapy Vacuum Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the vacuum electrodes. After the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
223909332|NCT06562933|DEVICE|Interferential Current Therapy Carbon-silicon Pad Electrodes|Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four carbon-silicon pad electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the carbon-silicon pad electrodes. Following the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
223909333|NCT06556927|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
223909334|NCT05053854|DRUG|Talazoparib|During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
223909335|NCT05858346|BEHAVIORAL|Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders.
223909336|NCT05858346|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|To provide an evidence-based comparison for the TBT condition, the research-supported psychological treatment of CBT for SAD will be used. CBT for SAD demonstrates efficacy in improving SAD symptoms and quality of life for patients with SAD, with durable improvements evidenced at follow-up assessments. CBT for SAD was used as a comparison to TBT in previous preliminary research. CBT for SAD involves several primary components, including: 1) psychoeducation, 2) training in cognitive restructuring, 3) exposures, 4) advanced cognitive restructuring, and 5) termination.
223909337|NCT05326477|BEHAVIORAL|Behavioral weight loss treatment|The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
223909338|NCT06561711|DRUG|Vonoprazan|Potassium competitive acid blocker
223909339|NCT06561711|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223909340|NCT06561711|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
223909341|NCT06561711|DRUG|Minocycline,Metronidazole|Antibiotics for H. pylori eradication
223909342|NCT05835349|DEVICE|transcatheter pulmonary valve implantation (TPVI)|A stent-mounted valve is introduced over a guidewire and positioned in the RVOT, followed by balloon inflation to deploy the valve.
223909343|NCT02489604|DRUG|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
223909344|NCT02489604|DRUG|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
224084186|NCT06166628|PROCEDURE|Genicular nerve phenol nerve ablation|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 2 cc of 6% phenol will be injected at each location with an end target of fascial expansion under the relevant fascial plane.
224084187|NCT06166628|PROCEDURE|Skin infiltration of 2cc of 0.25% bupivacaine at the knee|A high frequency ultrasound probe and anatomic landmarks will be used to identify the location of the genicular nerves as well as the nerves to the vastus lateralis, vastus intermedius and vastus medialis will be identified. Utilizing an in or out of plane approach as necessary, a 25 g spinal needle will be advanced to the appropriate location after skin anesthesia with 1cc of 1% lidocaine. After negative aspiration, 1.5 cc of sterile saline will then be injected at each location.
223715931|NCT06218641|DEVICE|CP - conventional protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of first aligner. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
223719350|NCT01087398|PROCEDURE|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~1. Sibling full match~2. Other related full match~3. Sibling or other related with 1 mismatch antigen~4. Cord Blood~5. Haploidentical"
223909345|NCT03927768|DIAGNOSTIC_TEST|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
223909346|NCT03927768|DIAGNOSTIC_TEST|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
223909347|NCT06454630|DRUG|REGN7508|Administered by single intravenous (IV) dose
223909348|NCT06454630|DRUG|Enoxaparin|Administered by subcutaneous (SC) dose daily through the time of venography (or day 12, whichever is earlier)
223909349|NCT04210947|OTHER|30 rolls per minute(30RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 2 secs. Then comeback from insertion to origin with 2 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
223909350|NCT04210947|OTHER|15 rolls per minute(15RPM)|Participants will start using foam roller from muscle origin to insertion with a speed of 4 secs. Then comeback from insertion to origin with 4 secs. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
223909351|NCT04210947|OTHER|self-determined|Participants will start using foam roller from muscle origin to insertion with self determined-speed. Then comeback from insertion to origin with same pace. With total of 15 repeats x 2 sets per leg. With 30 seconds rest between.
223909352|NCT06335888|DRUG|AzaFol|AzaFol-PET/CT imaging
223909353|NCT06335888|DRUG|FDG|FDG-PET/CT imaging
224084188|NCT04744974|BEHAVIORAL|Diet intervention|Participants will be given dietician counseling on their assigned diet
224084189|NCT03806426|DRUG|Eicosapentaenoic acid free fatty acid (EPA-FFA)|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
224084190|NCT03806426|DRUG|Placebo|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
223909354|NCT05253586|PROCEDURE|Laparoscopic|Surgeon
223909355|NCT05253586|PROCEDURE|Robotic|Versius system
223909356|NCT06767696|OTHER|Cuff pressure measurement|"Intubation tube cuff pressure in cmH2O at 3 different time periods with a cuff manometer (VBM Medizintechnik, GmbH, Germany)~Time periods:~Cuff pressure value measured in neutral position after intubation (cmH2O) - T0 Cuff pressure measurement value after hyperextension (cmH2O) - T1 Cuff pressure measurement value in neutral position after surgical procedure (cmH2O) - T2"
223909357|NCT05832047|DRUG|Plasma solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
223909358|NCT05832047|DRUG|Lactated Ringer solution (4-hour aggressive hydration)|Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.
223909359|NCT05832047|DRUG|8-hour aggressive hydration|If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
223909360|NCT05198635|DEVICE|local cerebral oxygen saturation|minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
223909361|NCT05980923|OTHER|Performing blood thyroid test (TSH, FT4, FT3)|Blood test as above
223909362|NCT05540158|OTHER|Mobile Integrated Health Intervention|"Subjects will have access to on-demand mobile integrated health program for acute symptoms. Subjects will be educated on the nature and capabilities of the MIH community paramedics and will be able to call a hotline for unscheduled visits 24 hours a day, 7 days a week if they wish to be evaluated for acute symptoms or changes in their condition. All visits entail focused history and physical exam with community paramedic, portable diagnostics as indicated, and telehealth visit with a physician"
224084191|NCT04432363|DEVICE|Transcranial direct current stimulation|Direct current application over the scalp to stimulate and change the excitability of the cortical areas underneath the electrodes (in this case left primary motor cortex and left dorsolateral prefrontal cortex).
224084192|NCT00002309|DRUG|Azithromycin|
224084193|NCT04664348|OTHER|Posteroanterior mobilization (neutral)|"Positioning of the patient: Prone position with the lumbar area uncovered.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain.~Both groups: The patient will be provided with a list of exercises focused on improving resistance to mechanical load in the lumbar region. The completion of the exercise will be in the 6 weeks of the duration of the treatment."
223909363|NCT05783635|BEHAVIORAL|Enhanced Usual Care (pre-operative)|The enhanced usual care will receive standard surgical care, and a resource brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources. The resource brochure will be e-mailed to patients or sent via postal mail.
223909364|NCT05783635|BEHAVIORAL|Preoperative Virtual Health Coaching|"Preoperative Virtual Coaching is based on principles of health coaching, collaborative care, and motivational interviewing. Health and educational content is framed using the Health Belief Model. During two sessions, that take place approximately 3 and 5 weeks prior to surgery, the health coach presents alcohol use reduction/abstinence as important for surgical health (rather than addiction or chronic health reasons) and engages participants in discussion and patient-centered goal-setting.~Participants will also receive a brochure including basic information on health, alcohol use withdrawal risks, and treatment/emergency resources."
223909365|NCT05783635|BEHAVIORAL|Usual surgical care (post-operative)|This group will receive standard post-operative care.
224084194|NCT04664348|OTHER|Posteroanterior mobilization (extension)|"Positioning of the patient: Prone position with the lumbar area uncovered. The head of the stretcher will be raised upwards, placing progressively to extend the lumbar region, until the patient communicates the reproduction of its symptoms.~Positioning of the therapist: Stand to one side of the table at the pelvis of the patient.~Explanation of the technique: The contact will be made with the hypothenar eminence on the spinous processes to be treated. The other hand of the physiotherapist will reinforce the grip to obtain greater stability and precision. It will proceed to carry out some posteroanterior pushes of the target vertebrae, in order to desensitize the chosen area. The force exerted and the speed of the technique will be controlled by the therapist. The technique will be finished when the participant let the therapist know when the pain is gone or when the patient no longer refer a decrease on its pain."
224084195|NCT01940614|OTHER|Water deprivation test|Classical water deprivation test alone
224084196|NCT01940614|OTHER|Water deprivation test|classical water deprivation test plus plasma copeptin cut-off levels
224084197|NCT01940614|OTHER|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
224084198|NCT00148746|DRUG|Pimecrolimus|
224084199|NCT00148746|DRUG|Tacrolimus|
224084200|NCT00148746|DRUG|Prednisolone|
224084201|NCT00148746|DRUG|Ciclosporin A|
224084202|NCT00148746|DRUG|Dermatop|
224084203|NCT00888667|OTHER|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
224084204|NCT05050760|DRUG|Camrelizumab|Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
224277368|NCT04148105|DRUG|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
223719351|NCT01087398|DRUG|Cyclosporin, Methotrexate (GVHD prophylaxis)|"* Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~* 10 mg/m\^2 iv day +1 then 6 mg/m\^ iv day +3 and +6 (Not for UCBT)"
224084205|NCT05050760|DRUG|DCF|DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
224084206|NCT05831982|OTHER|Person-centered strength training and nutrition intervention|Focus on high intensity strength training and nutrition intervention with focus on energy and protein intake. Focus on social relations
224084207|NCT05831982|OTHER|Standard training|Training as usual when discharged with a rehabilitation plan.
224084208|NCT00586365|DRUG|Naproxen|500 mg Naproxen twice a day for two weeks
224277369|NCT04148105|OTHER|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
224277370|NCT03703453|DEVICE|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
224277371|NCT05911087|BIOLOGICAL|Phase II:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
224084209|NCT00085280|DRUG|erlotinib hydrochloride|Given orally
224084210|NCT00085280|OTHER|laboratory biomarker analysis|Correlative studies
224084211|NCT03524573|PROCEDURE|Appendectomy|Appendectomy is the surgical removal of the appendix.
224084212|NCT00880360|DRUG|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
224084213|NCT05527457|DRUG|BAY2586116|160 μg BAY2586116 nasal spray application
224084214|NCT05527457|DRUG|Placebo|Placebo (saline) nasal spray application
223909366|NCT05783635|BEHAVIORAL|Postoperative Virtual Health Coaching|Postoperative Virtual Coaching uses the same framework and structure as Preoperative Virtual Coaching. These sessions will be delivered by a health coach using a collaborative, and motivational interviewing-based approach. The goal of these sessions is to promote well-being and help participants maintain alcohol abstinence or reduction long-term (or initiate change in alcohol use if they have not already). These sessions promote low-risk alcohol use, provide education on chronic health effects of heavy alcohol use, and teach skills for coping with or avoiding triggers for alcohol use including coping with stress and mood challenges. These sessions introduce skills to help participants manage alcohol, stress, and mood as they recover from surgery.
223909367|NCT05783635|BEHAVIORAL|On-Track (Post-operative)|"On-Track is a mobile and web-accessible health tool that uses self-monitoring and provision of feedback on progress towards goals to engage participants in self-management of alcohol use and motivate behavior change through increased self-awareness and accountability for health.~The On-Track application includes a) daily tracking of alcohol and other substance use; b) daily tracking of stress, mood, and pain; c) personalized health goals; and d) visual displays of alcohol use, stress, mood, pain, and goal achievement including graphs of trends over time.~On-Track also uses novel monetary and non-monetary incentives to encourage utilization including an escalating monetary incentive schedule for self-monitoring."
223909368|NCT06134440|DIETARY_SUPPLEMENT|Impact Oral®|All patients will follow low-fiber diet according to ERAS protocol during the study period. Patients assigned to the experimental arm will assume also Impact Oral®, an oral nutritional supplement with immune-nutrients (hyper-proteic formula), manufactured and commercialized by Nestlé Health Science S.p.a. It is a liquid drink packaged in a brick of 237 ml. Patients will assume Impact Oral® for 5 days before surgery and 5 day after surgery.
223909369|NCT06770283|DIETARY_SUPPLEMENT|Spirulina tablet|In the Spirulina tablet intervention group, patients will receive oral Spirulina tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
223909370|NCT06770283|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|In the control group, patients will receive oral maltodextrin tablet treatment (2g/day) for at least 3 weeks before liver transplantation.
223909371|NCT02951130|DRUG|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
223909372|NCT02951130|DRUG|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
223909373|NCT05654675|DIAGNOSTIC_TEST|FDG PET/CT|Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.
223909374|NCT03187535|DEVICE|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
223909375|NCT03187535|OTHER|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
223909376|NCT05586490|DEVICE|Multifunctional RehabilitationDevice (MRD)|Multifunctional rehabilitation device to treat mobility and cognitive problems in PwP
223909377|NCT05586490|DEVICE|existing standard rehabilitation device|existing standard rehabilitation device to be used for in-home comparison testing for aim 3
223909378|NCT06565481|OTHER|Measurement Properties (Reliability and Validity) of a Set of Assessments evaluating Physical Function in adult Participants with Hemophilia|"This study evaluates the reliability (Test-Retest) of six health related instruments that assess physical function in people with hemophilia: Short Physical Performance Battery, Unipedal Stance Test, Four Square Step Test, Timed up and Go, 1 kg Arm Lift Test, 30 Second Chair Stand Test. This study is needed to determine the psychometric properties of these six assessments. Validity of these test will be determined with the Short Form 36, the Hemophilia Activities List and the Hemophilia Joint Health Score Methodology: Reliability (Test re-test study and validity (cross sectional study) of the six tests reported in patients with hemophilia.~This intervention contains physiotherapie assessments, however, no drugs nor medical devices."
223909379|NCT03546361|BIOLOGICAL|Autologous Dendritic Cell-Adenovirus CCL21 Vaccine|Given via CT-guided or bronchoscopic IT injection
223909380|NCT03546361|BIOLOGICAL|Pembrolizumab|Given IV
223909381|NCT05506878|DEVICE|NSS-2 BRIDGE|"NBD® will be applied to either the right or left ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.~Once the device is placed, subjects will be asked to perform a pinch test throughout the duration of their time wearing the device. To perform the pinch test subjects must pinch down on the electrodes and ground to ensure the electrodes are still placed in their designated locations and have not come loose."
223909382|NCT05506878|DEVICE|Sham NSS-2 BRIDGE|Sham NBD® will be applied to either the left or right ear in the immediate post-operative setting (PACU). Only a trained and certified research member who has completed the necessary training required by the company will place the device. The individual placing the device will not be involved in any follow up of the subject or any data collection as that researcher will be unblinded to the treatment allocation. The patient, nurses, surgeons, and other members of the research team will all remain blinded to the treatment allocation.
223909383|NCT04145375|DRUG|ZEN003694|Up to 120mg
223909384|NCT04145375|DRUG|Enzalutamide|160mg
224084215|NCT05593848|PROCEDURE|Intratissue Percutaneous Electrolysis|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided Intratissue Percutaneous Electrolysis in the myofascial trigger points of the infraspinatus muscle
224084216|NCT05593848|PROCEDURE|Dry Needling|Each subject will undergo 3 treatment sessions spaced one week apart. Ultrasound-guided dry needling in the myofascial trigger points of the infraspinatus muscle
224084217|NCT02273245|RADIATION|Thoracic aortogram CT|With and without contrast dye
223719352|NCT02108353|DRUG|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
223719353|NCT02108353|DRUG|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
224084218|NCT00521781|DRUG|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
223909385|NCT04593095|OTHER|NeuroN-QI|SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
224084219|NCT00521781|DRUG|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
224084220|NCT00521781|DRUG|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
224084221|NCT00948740|DRUG|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
224084222|NCT03415555|PROCEDURE|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
224084223|NCT03415555|DRUG|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
224084224|NCT03415555|PROCEDURE|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
224084225|NCT03415555|DRUG|paracetamol|Paracetamol will be given i.v. every 6 hours.
224084226|NCT04550026|OTHER|HTP inhalation|Sham inhalation for 30 minutes
224084227|NCT04061083|DEVICE|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
224084228|NCT04061083|DEVICE|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
224084229|NCT03983499|BEHAVIORAL|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
224277372|NCT05911087|BIOLOGICAL|Phase II:SW-BIC-213;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are 2 groups in phase 2 stage, total number 200 subjects who are ≥18 years old. Details as below:~Group 1: (N=100) - SWIM816 25 μg; Group 2: (N=100) - SW-BIC-213 25 μg;"
224277373|NCT05911087|BIOLOGICAL|PhaseIII:SWIM816;SARS-Cov-2;|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
223719354|NCT03876444|DRUG|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
223909386|NCT03914300|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223909387|NCT03914300|DRUG|Cabozantinib S-malate|Given PO
223909388|NCT03914300|PROCEDURE|Computed Tomography|Undergo CT
223909389|NCT03914300|BIOLOGICAL|Ipilimumab|Given IV
224084230|NCT01684462|BIOLOGICAL|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4\~8h, commencing within 12 hours of stroke onset
224084231|NCT01684462|DRUG|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
224084232|NCT01551693|DRUG|STA-9090|
224084233|NCT00138021|DEVICE|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk \& Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
224084234|NCT02841410|OTHER|Magnetic Resonance Imaging|
223719355|NCT03876444|DRUG|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
223719356|NCT01184794|DRUG|levobupivacaine|40 ml over 48 hours
223719357|NCT01938677|RADIATION|Initial Gamma knife radiosurgery|
223909390|NCT03914300|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223909391|NCT03914300|BIOLOGICAL|Nivolumab|Given IV
223909392|NCT06204900|DEVICE|Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during a standard Transforaminal Lumbar Interbody Fusion (TLIF).
223909393|NCT05076266|OTHER|Questionnaire|Complete the survey questions
223909394|NCT05311085|DRUG|Cytisine|"Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)"
223909395|NCT05311085|DRUG|Nicotine delivered via an e-cigarette|Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
223909396|NCT05311085|COMBINATION_PRODUCT|Cytisine plus nicotine delivered via an e-cigarette|"Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco"
223909397|NCT04070573|DRUG|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
223909398|NCT05703191|DEVICE|Nitric Oxide Generator and Delivery System|Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
223909399|NCT06628024|OTHER|Milk|Milk
223909400|NCT06628024|OTHER|Yoghurt|Yoghurt
223909401|NCT06387329|DRUG|Nitrofurantoin 100 MG|No additional information
223909402|NCT06804668|DEVICE|tDCS|The intervention involves a home-based, self-administered application of network-targeted, multifocal transcranial direct current stimulation (tDCS) using the Neuroelectrics® StarStim Home-tES device. Participants will apply the tDCS for 20 minutes each day over seven consecutive days. The device is specifically programmed to target a brain network associated with motor symptom improvement in Parkinson's Disease, based on recent research identifying this network through deep brain stimulation studies.
223909403|NCT05674357|BEHAVIORAL|Individualized Evidence-Based Therapy in Cancer (Patients)|"The intervention will mirror clinical care in psycho-oncology in which the therapist, collaboratively with their supervisor, will choose specific components of the following evidence-based treatments to administer based on the clinical presentation of the patient and referring problem.~* Cognitive Behavioral Therapy (CBT)~* Acceptance Commitment Therapy (ACT)~* Mindfulness-Based Cognitive Therapy (MBCT)~* Mindfulness-Based Stress Reduction (MBSR)~* Meaning-Centered Psychotherapy (MCP)~* Cognitive Behavioral Therapy for Insomnia (CBT-I)~* CBT for pain~* CBT for fatigue~* CBT for nausea"
223909404|NCT05674357|BEHAVIORAL|Training in Individualized Evidence-Based Therapy in Cancer (Therapists)|Enrolled therapist participants will receive training in evidence-based therapies and deliver therapy to patient participants.
223909405|NCT06039852|OTHER|Novel Postural Management Night-time Intervention|"Essential elements and components of PMN-TI:~* Safe and comfortable position to enable sleep~* Positioning to enable UAD overnight~* Quiet breathing unobstructed by base of tongue (i.e. stertor), vocal cords (i.e. stridor) or pooled secretions~* Postural support in lying to achieve comfort, promote symmetry of posture and maximum loadbearing~* Stomach contents reduced or emptied overnight to minimize reflux and associated aspiration risk."
224084235|NCT00971126|DRUG|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
224084236|NCT05009901|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600 mg daily for 8 weeks
224084237|NCT05009901|DRUG|Placebo|Placebo one tablet daily for 8 weeks
224084238|NCT01271140|DRUG|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
224084239|NCT05546619|DRUG|HIPEC+tislelizumab + targeted therapy|Patients with open liver lobe/segment resection, tumor excision, lymph node dissection will receive medication.
224084240|NCT00737139|PROCEDURE|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
224084241|NCT00737139|PROCEDURE|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
223719358|NCT05846191|DIAGNOSTIC_TEST|serum pentraxin 3 and high sensitive CRP|serum pentraxin 3 and high sensitive CRP
223909406|NCT04003246|RADIATION|Thoracic RT and Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\], first dose within 3 days of RT initiation
223719359|NCT01606514|BEHAVIORAL|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
223909407|NCT04003246|DRUG|Consolidative Durvalumab|1500mg every 4 weeks \[Q4W\] intravenous \[IV\] up to one year
223909408|NCT05236062|BEHAVIORAL|Exercise|aerobic and resistance exercise
223909409|NCT05236062|BEHAVIORAL|Attention control|stretching
223909410|NCT06805708|BEHAVIORAL|Sleep hygiene training programme|"A programme focusing on cognitive-behavioural counselling. The programme will be delivered in 12 sessions of 30 minutes each (intensive phase: 1 session per week for 3 weeks; maintenance phase: 1 session every 2 weeks). After each meeting, the research group members will provide a short-written report reflecting the main discussion topics, the degree of participation, and the group's position in the participatory action research cycle. The discussion topics will be:~1. Management of sleep hygiene in schoolchildren, families and teachers:~   * Surveys (quantitative approach)~  * Focus groups (qualitative approach)~  * The study will identify the health assets~2. Educational elements"
224084242|NCT02568358|OTHER|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
223719360|NCT00314392|BEHAVIORAL|Information (behavior)|
224084243|NCT05034900|OTHER|Chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, postural drainage and coughing techniques.
223719361|NCT01765088|DRUG|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
223719362|NCT01765088|DRUG|α-IFN|3mIU (3million) D1，3，5
223719363|NCT02380677|DRUG|CRLX301|
223719364|NCT02414750|DRUG|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
224084244|NCT05034900|DEVICE|Oscillatory Positive Expiratory Pressure (OPEP) device|Shaker® device will be used.
224084245|NCT05086601|PROCEDURE|colorectal cancer surgery|Any surgery for primary tumor of colorectal cancer, including palliative resection, simple bowel stoma and exploratory surgery.
223909411|NCT06804967|DEVICE|virtual reality relaxation headset|No headset will be used
223909412|NCT06804772|OTHER|Investigational Facial Serum #3|Investigational Facial Serum #3 is a placebo comparator
223909413|NCT06804772|OTHER|Investigational Facial Serum #1|Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.
223909414|NCT06804772|OTHER|Investigational Facial Serum #2|Investigational Facial Serum #2 is made with an active comparator.
223909415|NCT06577259|DRUG|BMS-986435|Specified dose on specified days
224084246|NCT00217347|DEVICE|Esophageal Capsule Endoscopy|
224084247|NCT05549115|DRUG|clarithromycin-sensitive(first-line)|esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
224084248|NCT05549115|DRUG|clarithromycin-resistant(first-line)|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
224084249|NCT05549115|DRUG|empirical therapy group first-line|esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
224084250|NCT05549115|DRUG|levofloxacin-sensitive(rescue treatment)|esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
224084251|NCT05549115|DRUG|levofloxacin-resistant(rescue treatment)|esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days
224084252|NCT05549115|DRUG|empirical therapy group rescue treatment|esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
224084253|NCT05223595|DRUG|Gentuximab|Gentuximab: 8mg/kg or 12mg/kg intravenous (IV) infusion administered on Day 1 and 15 of each cycle; Almonertinib: 110 mg orally once daily.
224084254|NCT04801628|DEVICE|Active Tecar|Active Tecar
223909416|NCT05453838|DIETARY_SUPPLEMENT|oral intake of one serving of the original and new product|1\) Intervention type: Dietary Supplement Intervention name: (visits 1, 3 and 5) Reference product Intervention description: Glucose solution 2) Intervention type: Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: : One serving new product 3) Intervention type: : Dietary Supplement Intervention name: (visit 2 or 4) Diabetes specific tube feed Intervention description: One serving original product
223909417|NCT03914742|DRUG|PARP Inhibitor BGB-290|Given PO
223909418|NCT03914742|DRUG|Temozolomide|Given PO
223909419|NCT03914742|PROCEDURE|Therapeutic Conventional Surgery|resection surgery
223909420|NCT06627413|DRUG|Lumateperone Capsule|Lumateperone 42 mg capsule, oral administration
224084255|NCT04801628|DEVICE|Placebo Tecar|Placebo Tecar
224084256|NCT04435223|BIOLOGICAL|biological assays in particular on the lipid metabolism|bioassays carried out on samples already collected and conserved
224084257|NCT02736032|PROCEDURE|Embryo transfer|The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
224084258|NCT02736032|PROCEDURE|Serum Estradiol and Progesterone levels|Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
224084259|NCT02736032|DRUG|GnRH agonist|GnRH agonist given on day 21 of the cycle preceding the embryo transfer
224084260|NCT02736032|DRUG|External Estradiol|Estradiol started on day1 of the cycle for endometrial prepartaion
224084261|NCT02736032|DRUG|Progesterone|progesterone as luteal phase support start after endometrium is well prepared
224084262|NCT02730156|OTHER|Altitude exposure|Altitude exposure
224084263|NCT01631669|DRUG|Celecoxib|200 mg Q 12 hours orally
223909421|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E2 IM injection
223909422|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-E3 IM injection
223909423|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X2 IM injection
223909424|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI X500-X5 IM injection
223909425|NCT06627413|DRUG|Lumateperone LAI|Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
223909426|NCT06805292|OTHER|Acacia catechu|local delivery of acacia catechu gel in patient with chronic periodontitis stage 2
223909427|NCT06805292|OTHER|Low Level Laser Therapy|low-level laser as an adjunctive therapy in patient with chronic periodontitis stage 2
224084264|NCT00130286|DRUG|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
224084265|NCT00130286|DRUG|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
224084266|NCT00626743|DRUG|SK3530 100mg, Placebo, Amlodipine|
223909428|NCT06805292|OTHER|phase 1 therapy chronic periodontitis|patient with chronic periodontitis stage 2 will go for phase one therapy only
223909429|NCT06805292|OTHER|local drug delivary acacia +LLL|pateient with chronic periodontitis treated with LLL +acacia catehu gel
223909430|NCT06572397|DRUG|H-1337 1.0%|ophthalmic solution
223909431|NCT05426395|DRUG|Vitamin B12 2.6 µg|There are four groups of women (n = 20 total) who will receive B12 dosing once daily, including group 1a (sufficient baseline B12, pregnant), group 1b (sufficient baseline B12, non-pregnant), group 1c (insufficient baseline B12, pregnant), and group 1d (insufficient baseline B12, non-pregnant).
223909432|NCT05426395|DRUG|Vitamin B12 10 µg|There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
223909433|NCT05426395|DRUG|Vitamin B12 50 µg|The participants (n = 20 total) will be randomly assigned to receive either a once per day B12 dose or a twice per day B12 dose. The four groups at this dose level include: group 3a (sufficient baseline B12, pregnant, Q12), group 3b (sufficient baseline B12, Q24), group 3c (insufficient baseline B12, pregnant, Q12), group 3d (insufficient baseline B12, Q24).
224084267|NCT03996330|DIAGNOSTIC_TEST|taqman array card|The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
224084268|NCT01815645|BEHAVIORAL|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
224084269|NCT01815645|BEHAVIORAL|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
223909434|NCT06805357|OTHER|Chest Physiotherapy by Rib Cage Compressions (RCC)|Bimanual Rib Cage Compressions (RCC) applied to the thorax only, with patients in a standardized position (supine with the head of the bed elevated to 35 degrees). The intervention is standardized in terms of the direction of force (posterior and downward) and the characteristics of the compression (brief and vigorous compressions at the beginning of expiration).
224084270|NCT03074929|BEHAVIORAL|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
224084271|NCT01361763|DRUG|Dabigatran|110 mg twice daily
223909435|NCT06804148|DEVICE|Myval Transcatheter Heart Valve|The Myval TAVR bioprothesis is a balloon-expandable THV developed by Meril Lifesciences, which has novel operator friendly design features to improve deliverability and aid precise deployment.
223909436|NCT06425536|OTHER|Home use|Home use twice a day
224084272|NCT01361763|DRUG|Antiplatelets|100mg once a day
224084273|NCT00073320|DRUG|Paliperidone Palmitate|
224084274|NCT00165009|DEVICE|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
224084275|NCT02468336|DEVICE|AngioDefender|
224084276|NCT02468336|DEVICE|Ultrasound|
224084277|NCT04240587|DEVICE|TrueTear™ intranasal neurostimulator (ITN)|"The ITN delivers small electrical currents to the inner cavity of the nose, gently activating nerves that stimulate the body's natural tear production system. Those in the ITN active arm will receive the active tips which contain the current from the base to the nasociliary nerve. Those in the ITN sham arm will receive tips without the current."
224084278|NCT04328506|DRUG|CM082 tablet (test product)|Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals
223719365|NCT02414750|DEVICE|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
223909437|NCT04920149|DRUG|Mesalamine|The IMP will be supplied as sachets with slow-releasing granules.
223909438|NCT04920149|DRUG|Placebo|The IMP will be supplied as sachets with slow-releasing granules.
223909439|NCT05062330|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days
223909440|NCT05062330|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered 7 times over two consecutive days
224084279|NCT04328506|DRUG|CM082 tablet (reference product)|Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions
224084280|NCT03674021|OTHER|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
224084281|NCT02154425|PROCEDURE|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
224084282|NCT02154425|BIOLOGICAL|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
224084283|NCT04429126|BEHAVIORAL|Acupressure|Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
223719366|NCT02414750|PROCEDURE|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
223719367|NCT02414750|PROCEDURE|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
223909441|NCT04977869|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
223909442|NCT04977869|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
223909443|NCT05105906|DIAGNOSTIC_TEST|cognitive tests performed|cognitive tests performed
223719368|NCT01598051|DRUG|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
223909444|NCT05552443|DRUG|Hydromorphone 2.5 mcg/kg|2.5 mcg/kg intrathecal
223909445|NCT05552443|DRUG|Hydromorphone 2.75 mcg/kg|2.75 mcg/kg intrathecal
223909446|NCT05552443|DRUG|Hydromorphone 3 mcg/kg|3 mcg/kg intrathecal
223909447|NCT05552443|DRUG|Hydromorphone 3.25 mcg/kg|3.25 mcg/kg intrathecal
223909448|NCT05552443|DRUG|Hydromorphone 3.5 mcg/kg|3.5 mcg/kg intrathecal
224084284|NCT06257914|DIAGNOSTIC_TEST|Catquest-9SF|Measurement of self-assessed visual function with Catquest-9SF, measurement of ocular aberrations with iTrace (Tracey Technologies), and straylight measurements with C-Quant (Oculus)
223719369|NCT02768012|BEHAVIORAL|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
223719370|NCT04069611|OTHER|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
223909449|NCT05552443|DRUG|Hydromorphone 4 mcg/kg|4 mcg/kg intrathecal
223909450|NCT05552443|DRUG|Hydromorphone 4.5 mcg/kg|4.5 mcg/kg intrathecal
223909451|NCT05552443|DRUG|Hydromorphone 5 mcg/kg|5 mcg/kg intrathecal
223909452|NCT05451875|DEVICE|Non-invasive monitoring|Comparison of VitalTracer monitoring devices with invasive and/or non-invasive gold standard reference
223909453|NCT05785546|OTHER|usual care|For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
223909454|NCT05716763|DRUG|Tramadol Hydrochloride 5 MG/ML Oral Solution|50mg (10mL) single dose
223909455|NCT05716763|DRUG|Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))|50mg (20 drops) single dose
223909456|NCT05300035|DRUG|Recombinant human monoclonal antibody (bNAbs)|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of bNAbs (3BNC117LS \& 10-1074LS) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
223909457|NCT05300035|DRUG|Placebo|"1. Initiation of combination ART (1 integrase inhibitor + 2 nucleoside analogue reverse transcriptase inhibitors) with additional dual intravenous infusions of placebo (saline solution) between Day 7 and Day 10.~2. Analytical treatment interruption (ATI), 52 weeks later, if good immunologic and virologic conditions.~3. During ATI, plasma HIV-1 RNA and CD4 monitoring, for a maximum of 48 weeks.~4. ART resumption, if participant encounters at least one ART resumption criteria."
223909458|NCT06033599|OTHER|MORE and MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
223909459|NCT06033599|OTHER|MORE and No MI and NRT|Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
223909460|NCT06033599|OTHER|Support Group and MI and NRT|Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
223909461|NCT06033599|OTHER|Support Group and No MI and NRT|Eight group support group sessions and and nicotine replacement therapy.
223909462|NCT05493241|BEHAVIORAL|Behavioral Activation for Independence in Older Veterans (ACTIVaTE)|6 sessions delivered by a psychology trainee by telehealth will cover the core content of an existing BA model, Brief Behavioral Activation for Depression-Revised (BATD-R), including education on BA and rationale for the intervention, activity monitoring, values exploration, and activity selection and planning. ACTIVaTE will include the following key modifications: 1) modifying background and psychoeducation to focus on maintaining functional independence; 2) tailoring content to Veterans; 3) adapting materials for VVC telehealth delivery; 4) incorporating elements of activity and environmental modification from an OT perspective; and 5) adding content on VA and community resources for older Veterans. Each session is structured similarly, consisting of education or review of concepts, review of homework and troubleshooting challenges, discussion of core content (e.g. values exploration or activity planning/scheduling), and assignment of homework for the next session.
223909463|NCT05493241|OTHER|Usual care|"In this study, both arms will have access to usual care as part of their routine clinical care. Recognizing the heterogeneity of primary care services provided to patients at risk for functional decline, we will minimally standardize the usual care arm by providing a booklet of educational information on maintaining activity to support independence in aging (e.g., an NIH handout Participating in Activities you Enjoy as you Age and information on VA and community recreation programs to stay active) that will be mailed to participants after randomization."
223909464|NCT03414242|OTHER|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
224277374|NCT05911087|BIOLOGICAL|PhaseIII:Pfizer(Pfizer Bivalent vaccine);SARS-Cov-2；|"The study will be performed in people who were previously vaccinated with 2/3 doses of COVID-19 vaccine, with or without previously diagnosed with COVID-19. The interval between the date of last dose and the date of this study vaccination should be 6 to 24 months.~There are two groups in phase 3 stage., total number 600 subjects who are ≥18 years old. Details as below:~Group 1: (N=300) - SWIM816 (≥18 years old ) Group 2: (N=300) -Pfizer Bivalent vaccine (≥18 years old)"
223909465|NCT04572295|DRUG|E7090|E7090 oral tablet.
223909466|NCT04572295|DRUG|Fulvestrant|Fulvestrant intramuscular injection.
223909467|NCT04572295|DRUG|Exemestane|Exemestane oral tablet.
223909468|NCT04446351|DRUG|GSK6097608|GSK6097608 will be administered as an IV infusion.
223909469|NCT04446351|DRUG|Dostarlimab|Dostarlimab will be administered as an IV infusion.
223909470|NCT04446351|DRUG|Cobolimab|Cobolimab will be administered as an IV infusion.
223909471|NCT04446351|DRUG|Belrestotug|Belrestotug will be administered as an IV infusion.
223909472|NCT04132518|DEVICE|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
223909473|NCT03092453|BIOLOGICAL|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
223909474|NCT03092453|DRUG|Cyclophosphamide 300mg/m^2|administered prior to subject's first DC dose
224084285|NCT04934930|DRUG|Bendamustin|Chemotherapy
224084286|NCT04934930|DRUG|Obinutuzumab|Immunotherapy
223715932|NCT06218641|DEVICE|DP - delayed protocol|"All patients will be treated with Biomax Nuvola aligners built based on the individual patient's characteristics. The number of aligners and the number/type of attachments will be chosen on the basis of the individual malocclusions. In this group the attachments will be bonded at the beginning of third aligner, approximately one month after the start of orthodontic treatment. Two different questionnaires will be administered to the enrolled subjects: the italian version of the adapted OHIP-14 questionnaire, and a customized questionnaire.~The questionnaires will be completed at different stages of orthodontic treatment, as following:~* 24 hours after the delivery of the first aligner - start of orthodontic treatment;~* 3 days after the start of orthodontic treatment;~* 7 days after the start of orthodontic treatment;~* 24 hours after delivery of the third clear aligner;~* 3 days after delivery of the third clear aligner;~* 7 days after delivery of the third clear aligner."
224084287|NCT03891550|DRUG|Epclusa|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
224084288|NCT01558063|DRUG|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
224084289|NCT01558063|DRUG|Saline|Single infusion of saline given intravenously over 40 minutes.
223909475|NCT03092453|DRUG|Pembrolizumab|administered 7-8 weeks after subject's last DC dose
224084290|NCT01558063|PROCEDURE|Magnetic Resonance Imaging (MRI)|90-minute scan during the 40-minute infusion.
224084291|NCT02015169|DRUG|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)
224084292|NCT03484715|BEHAVIORAL|Physical Activity Intervention|A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
224084293|NCT00382837|DRUG|Epratuzumab|
223909476|NCT06487104|DEVICE|TrachPhone HME|"Use of TrachPhone HME for humidification of inhaled air in tracheostomized patients.~The TrachPhone HME is an HME specifically designed for tracheostomy patients."
224084294|NCT06000358|PROCEDURE|Bronchoscopic cryotherapy|The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.
224084295|NCT06000358|DRUG|Pembrolizumab|As a standard of care, patients will receive pembrolizumab.
224084296|NCT06000358|DRUG|Platinum based chemotherapy|As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.
224084297|NCT01454804|DRUG|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
224084298|NCT01454804|DRUG|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
224084299|NCT01454804|DRUG|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
224084300|NCT01454804|DRUG|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
224084301|NCT02775032|BEHAVIORAL|Advance care planning conversations between patients and their GP|
224084302|NCT03737162|PROCEDURE|Stent implantation of subclavian artery|Stent implantation of subclavian artery
224084303|NCT01171651|DRUG|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
223909477|NCT06487104|DEVICE|External Humidifier (Usual Care)|Usual care routines using an External Humidifier for humidification of inhaled air in tracheostomized patients.
224084304|NCT01825031|DRUG|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
224084305|NCT01825031|DRUG|Fluconazole|100mg once daily for 12 weeks
224084306|NCT01825031|DRUG|Azithromycin|500mg once daily for 5 days
224084307|NCT01825031|DRUG|Albendazole|a single dose 400mg
224084308|NCT01825031|DRUG|Isoniazid|300mg taken immediately in combination with cotrimoxazole
224084309|NCT01825031|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
224084310|NCT02908516|DRUG|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
224084311|NCT02908516|DRUG|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
224084312|NCT04591054|DEVICE|Extended Vision IOL|Vivity IOL implantation following cataract extraction
224084313|NCT04591054|DEVICE|Neutral Aspheric Monofocal IOL|enVista IOL implantation following cataract extraction
224084314|NCT03143803|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
224084315|NCT03143803|DRUG|Placebo|Similar looking inactive powder
224084316|NCT03957967|OTHER|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
224084317|NCT01486030|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
223909478|NCT06835062|BEHAVIORAL|Recommendations for Enhancing General Well-Being|"* Wear comfortable clothing and lie on your back. Place one hand on your abdomen. As you inhale through your nose, direct your breath towards your hand, and exhale through your mouth.~* In the same position, place one hand on your abdomen, inhale through your nose, and expand your belly under your hand. As you exhale through your mouth, purse your lips and blow out the air from your lungs.~* Engage in brisk walking at least three times a week.~* Perform stretching exercises similar to yoga; try forward bends while standing and sitting.~* Stay active throughout the month; you can dance, swim, or ride a bike.~* Reduce your intake of tea and caffeine.~* Increase your consumption of milk.~* Drink plenty of water.~* Reduce your intake of sugar-rich snacks such as chocolate.~* Prioritize foods rich in calcium, as well as vitamins A, B, and E."
223909479|NCT06835062|OTHER|Clinical Pilates|"In addition to the general well-being recommendations, the Clinical Pilates Group participated in a total of 16 face-to-face, clinically based Pilates exercise training sessions over eight weeks, with two sessions per week, each lasting 50 minutes. The exercise training started at the end of the menstrual cycle.~The clinical Pilates-based exercise program applied to the group was designed by the researcher. The number of repetitions, levels, and variations of the exercises were progressively adjusted by the researcher according to the participants' conditions.~During the first session, the principles of clinical Pilates were explained, following the BASI Pilates method as described by Isacowitz. Participants were taught alignment, breathing, and core engagement techniques."
223909480|NCT06156813|DIAGNOSTIC_TEST|Diagnostic test|Measurements for validity and reliability
223909481|NCT06833619|DEVICE|Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique|Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique
223909482|NCT06836102|DIETARY_SUPPLEMENT|Orange|usage of orange peel extract in gel layer in treatment of epistaxis
223909483|NCT05127980|OTHER|Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments)|Data collection: Participant characteristics (Illness course, complications of primary EBV infection and provided treatments) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
223909484|NCT05127980|OTHER|Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)|Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin) during 12 months (baseline visit and follow-up visits at 3, 6 and 12 months).
223909485|NCT05127980|OTHER|Data collection: Patient reported outcome (Fatigue questionnaires)|Data collection: Patient reported outcome (Fatigue questionnaires) at 6 and 12 months.
223909486|NCT06840418|DRUG|Indocyanine green (ICG) injection for intraoperative lymph node imaging|Injection is performed at the 3 o'clock and 9 o'clock positions of the cervix, with 1 ml on each side, for a total dose of 2 ml. Injection depth: The tracer is injected into the superficial (2 mm) and deep (1 cm) layers, with the superficial injection performed first, followed by the deep injection.
223909487|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support|Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
223909488|NCT05502016|BEHAVIORAL|Family Model Diabetes Self-Management Education and Support (Wait-list)|Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
223909489|NCT04933435|OTHER|Quality of life questionnaires|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)
223909490|NCT00313196|DRUG|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
223909491|NCT04056611|DRUG|JNJ-53718678 250 mg|JNJ-53718678 250 mg will be administered orally.
223909492|NCT04056611|DRUG|Placebo|Matching placebo will be administered orally.
223909493|NCT04056611|DRUG|JNJ-53718678 125 mg|JNJ-53718678 125 mg will be administered orally.
223909494|NCT05864196|RADIATION|Two-Fraction Stereotactic Body Radiation Therapy (SBRT)|Two-fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer.
223909495|NCT05255120|OTHER|Intiensified structured perioperative information|The doctor takes a medical history and examines the patient according to regular routines, but uses the algorithm as support in deciding on the surgical method. After the doctor's visit, the patient must see a research nurse to receive the intensified preoperative information about hysterectomy. This information is designed according to a checklist. The patient can also download a mobile application. The study-specific mobile application (app) contains information about hysterectomy. The information is structured in three parts - Before the Operation, At the Hospital and After the Operation. A timeline describes the activities and events that occur before, around and after the operation. Within each section there are several information links, with eg checklists.
223909496|NCT06651060|BEHAVIORAL|Menu label|Participants will view a sample of items from a restaurant menu, displayed with labels
223909497|NCT03733925|DRUG|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
223909498|NCT05804942|BEHAVIORAL|High glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\>70), 20% fat and 20% protein.
223909499|NCT05804942|BEHAVIORAL|Medium glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:55-70), 20% fat and 20% protein.
223909500|NCT05804942|BEHAVIORAL|Low glycemic index|Composition (by proportion of calories) of meal: 60% carbohydrate (glycemic index:\<55), 20% fat and 20% protein.
223909501|NCT04724499|BEHAVIORAL|High-Intensity Intervals Training|16 week exercise program with stationary bike.
223909502|NCT04724499|OTHER|Attention Control|16 week stretching program.
223909503|NCT00005398|OTHER|There is no intervention|No applicable
223909504|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with a Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with a connective tissue graft harvested from the palate.
224084318|NCT02515149|DEVICE|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
224084319|NCT00643630|DEVICE|Tetrix|Twice daily topical application
224084320|NCT00643630|DEVICE|Tetrix|Twice daily topical application
223715933|NCT05593120|DIAGNOSTIC_TEST|CT-FFR|"In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis 30%-90% data in at least one major epicardial vessel will be referred for CT-FFR. In patients in whom CT-FFR analysis is performed, FFR will be derived for all vessels. CT-FFR will be evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour. The data derived from this test will determine their management strategy."
223909505|NCT06030947|PROCEDURE|Coronally Advanced Flap combined with micro Connective Tissue Graft|Multiple adjacent gingival recession defects will be covered by coronally advanced flap combined with multiple micro connective tissue graft harvested from the palate.
224084321|NCT01694043|OTHER|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
223909506|NCT06030947|DEVICE|Division of the Connective Tissue Graft into multiple micro Connective Tissue Grafts|The harvested connective tissue graft is divided in multiple micro connective tissue grafts with a scalpel blade before being placed on the recipient site.
224084322|NCT01694043|OTHER|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
224084323|NCT01536301|DRUG|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
224084324|NCT01536301|DRUG|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
223909507|NCT06649708|DRUG|HX044|Conventional dose-escalation design with 3+3 cohort size. All administered on a Q3 weekly basis. Dose escalation will be based on the absence of DLTs during the 21-day DLT evaluation after a review of safety data by the Safety Review Escalation Committee. Subjects will continue on study treatment until the subject develops an intolerable toxicity, withdraws consent, develops progression of disease, death, lost to follow-up, start of new anticancer treatment or up to study treatment duration of 24 months, whichever comes first.
223909508|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple palatal micro connective tissue grafts|The connective tissue graft will be harvested from the palate.
223909509|NCT06650072|PROCEDURE|modified coronally advanced tunnel technique combined with multiple tuberosity micro connective tissue grafts|The connective tissue graft will be harvested from the maxillary tuberosity.
224084325|NCT04196114|DEVICE|STIMO-2 device implantation|Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
224084326|NCT04706884|DEVICE|Near infrared spectroscopy|The rSO2 (cerebral oxygen satutation) was continuously monitored by NIRS (Near infrared spectroscopy) with a sensor positioned on the forehead of the patient
224084327|NCT05568771|OTHER|Core Exercises Assisted Injury Prevention Training Program|After the exercises are fully taught to the athletes, the core training program will be applied on 3 non-consecutive days of the week, accompanied by a physiotherapist or athletic trainer, and the warm-up program will be applied before all trainings of the team, except before the match.The core program will take 20-25 minutes, and the warm-up program will take an average of 20-25 minutes. The exercises consist of an average of 45 minutes. This warm-up program includes running exercises, strengthening exercises, balance and proprioception exercises, and plyometric exercises.
224084328|NCT04588103|OTHER|Heat therapy|Lower limb warm water immersion (42 degrees C)
224084329|NCT04588103|OTHER|Exercise training|Moderate-intensity cycling exercise (\~40-59% VO2 reserve)
224084330|NCT06244953|OTHER|TIER-HF-PC|The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
224084331|NCT06244953|OTHER|Usual Care|Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
224084332|NCT00565617|DEVICE|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
224084333|NCT02122627|DRUG|Vitamin D|Colecalciferol 16.800 IU per week
224084334|NCT02122627|DRUG|Placebo|
223715934|NCT05593120|DIAGNOSTIC_TEST|Routine care|All patients in the routine care group will be assessed according to their current conventional pathways that are based upon routine practice in Wuhan Asia Heart Hospital. The trial will encourage the routine and standard assessment and management of all patients (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance).
223715935|NCT02164500|DRUG|Ruxolitinib|
223909510|NCT06651021|DRUG|balcinrenone/dapagliflozin|"Each participant will receive a single dose of balcinrenone/dapagliflozin 40 mg/10 mg capsule on Day 1 under fasted condition.~Each participant will be involved in the study for up to 35 days."
223909511|NCT06650579|DRUG|Abiraterone Acetate|Given abiraterone acetate
223909512|NCT06650579|DRUG|Bicalutamide|Given PO
223909513|NCT06650579|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223909514|NCT06650579|PROCEDURE|Computed Tomography Angiography|Undergo CCTA
224084335|NCT06213428|BIOLOGICAL|Progressive Perfect Probiotic|Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.
224084336|NCT06213428|OTHER|Placebo|Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
223909515|NCT06650579|DRUG|Leuprolide|Given IM or SC
223909516|NCT06650579|DRUG|Prednisone|Given prednisone
223909517|NCT06650579|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
223909518|NCT06650579|DRUG|Relugolix|Given PO
224084337|NCT00737451|BEHAVIORAL|blood sampling|blood sampling 10ml from the study subjects
224084338|NCT00939835|DRUG|Citalopram Hydrobromide|
224084339|NCT00640471|BIOLOGICAL|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
224084340|NCT00640471|DRUG|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
224084341|NCT04113915|DRUG|triple therapy|Effect of treatment on immunity to obtain infection with hepatitis B\&C
224084342|NCT04113915|DRUG|Steroids|Oral or parenteral steroid therapy for ITP
224084343|NCT05489978|BEHAVIORAL|"Cervical Cancer Stigma Reduction Intervention"|"Change in knowledge:~Cervical cancer burden in Nepal, signs and symptoms, preventive measures available, lifestyle modifications, HPV vaccination, early diagnosis, screening, and treatment.~Change in Stigma~1. Para-social contact~   * Video of a person facing cervical cancer what symptoms she got, how she dealt with it, and how she overcame it.~  * Experiences of a cervical cancer survivor so that women personalize the information by relating it to their own life experiences by changing their attitude and behavior.~2. Participatory learning techniques~   * Personal stories: Voluntary self-reflection of any stigma they perceive on cervical cancer or their community perceives cervical cancer.~  * Group Discussion: Discuss the drivers of stigma, facilitators of sigma, types of stigma prevalent in your community, and consequences of stigma.~3. Myths vs facts: Negative attitudes, myths, and misconceptions about cervical cancer will be contraindicated by factual information."
224084344|NCT00000321|DRUG|Desipramine|
224084345|NCT04139876|PROCEDURE|Open Haemorrhoidectomy|Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.
223909519|NCT03774641|DRUG|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
223909520|NCT06650592|OTHER|All patients who were candidates for immediate lymphatic reconstruction (ILR)|All patients who were candidates for immediate lymphatic reconstruction (ILR)
224084346|NCT04139876|PROCEDURE|LigaSure Hemorrhoidectomy|Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
224084347|NCT06322875|PROCEDURE|Recombinant type III humanized collagen solution for injection|Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face
223909521|NCT06467448|DEVICE|EMG Assessement of Recovery of Neuromuscular Function|EMG Train of Four Assessment of Recovery of Neuromuscular Function
223909522|NCT06651411|BEHAVIORAL|STARS (Scalable Technology for Adolescents and youth to Reduce Stress)|"The intervention is a chatbot-based stress management intervention developed by the World Health Organization (WHO). It consists of 10 sessions, which include: Introduction (1), Psychoeducation (2), Emotion Regulation (3, 4), Behavior Activation (5, 6), Managing Problems (7), Thought Challenging (8, 9), and Relapse Prevention (10). Each session consists of psychoeducation and exercise parts. Trained e-helpers contact participants to support them individually weekly.~The effect of the intervention will be compared against a control group that receives basic psychoeducation. The intervention is provided in Lithuanian."
223909523|NCT06651411|BEHAVIORAL|Basic psychoeducation|Basic psychoeducation includes basic information on stress management.
223909524|NCT06581081|BIOLOGICAL|Senl_B19 autologous CAR-T (S1904) treatment|Subjects enrolled in this study will first receive Senl\_B19 autologous CAR-T (S1904) treatment.
223909525|NCT02631746|OTHER|Laboratory Biomarker Analysis|Correlative studies
223909526|NCT02631746|BIOLOGICAL|Nivolumab|Given IV
224084348|NCT06322875|OTHER|SkinCeuticals recombinant humanized collagen (RHC) serum|Subjects received SkinCeuticals recombinant humanized collagen (RHC) serum application on the test side face
224084349|NCT06322875|OTHER|Regular face cream smear|Subjects received Regular face cream smear application on the whole face
224084350|NCT03091309|OTHER|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
224277375|NCT06157853|PROCEDURE|Radiofrequency Microneedling|A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
223909527|NCT02631746|OTHER|Pharmacogenomic Study|Correlative studies
223909528|NCT05456581|BEHAVIORAL|'Scotoma awareness' Training|In the 'scotoma awareness' training, patients will perform visual search and orientation discrimination tasks while an opaque occluder, custom-tailored to overlap each patient's retinal scotoma, is constantly presented on the computer screen.
223909529|NCT05456581|BEHAVIORAL|Control Training|The task will be performed in the control group without the visible scotoma.
223909530|NCT05320718|DRUG|Ropivacaine|20 ml of 0.5% ropivacaine as bolus and a programmed intermittent bolus of 10 ml ropivacaine 0.2% every 2 h after surgery
223909531|NCT03536767|DRUG|AG10|AG10 800mg twice daily, oral administration
223909532|NCT05342493|DRUG|Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution|The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.
223909533|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Scheduled|VSTs will be infused into stem cell transplant recipients on schedule.
223909534|NCT04230356|BIOLOGICAL|Viral Specific T-cells (VSTs) Treatment|VSTs will be infused into stem cell transplant recipients only if viremia is detected.
223909535|NCT02224144|DRUG|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
223909536|NCT02224144|DRUG|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
223909537|NCT02224144|DRUG|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
223909538|NCT05942924|PROCEDURE|Repeated tactile stimulation|See arm
223909539|NCT05942924|PROCEDURE|Selective tactile stimulation|See arm
223909540|NCT06772922|OTHER|Exercise|effect of exercise after three months (comparison of the patient with himself)
223909541|NCT06093217|DEVICE|Artificial Intelligence|AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
223909542|NCT03520790|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
223909543|NCT03520790|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
223909544|NCT03520790|DRUG|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
223909545|NCT03520790|OTHER|Placebo|Placebo
223909546|NCT04181970|OTHER|Quality assessment|There is no intervention on study subjects. A tumor review will be performed by expert centers.
223909547|NCT06378554|DEVICE|Cereset Research|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM). The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
223909548|NCT02700009|BEHAVIORAL|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
224084351|NCT03091309|BEHAVIORAL|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
224084352|NCT03091309|BEHAVIORAL|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
224084353|NCT03091309|BEHAVIORAL|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
224084354|NCT03091309|OTHER|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence \[self-reported using the 5 item Medication Adherence Report Scale (MARS-5)\] and IBD related disease activated \[self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity\].
224084355|NCT03091309|OTHER|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence \[self-reported using the Medication Adherence Report Scale (MARS-5)\], patient trust in physician \[self-reported using the Trust in Physician Scale (TIPS)\], IBD related disease activated \[self-reported using the PRO-2 or 6-Point Mayo Score\], IBD-specific health related quality of life \[self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)\], patient satisfaction \[self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire\]and IBD specific knowledge \[self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire\].
223715936|NCT02193867|DRUG|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
223909549|NCT02700009|OTHER|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
223909550|NCT06246409|BEHAVIORAL|Modernized patient instructions|Patients will be given modernized patient instructions prior to radiotherapy treatment.
223909551|NCT06246409|BEHAVIORAL|Existing patient instructions|Patients will be given the patient instructions currently in use prior to radiotherapy treatment.
223715937|NCT01189903|DRUG|Regorafenib|
223715938|NCT00144053|DRUG|Cisplatin+Vindesine+MMC/ concurrent radiation|
223715939|NCT00144053|DRUG|Irinotecan+Carboplatin/concurrent radiation|
223715940|NCT00144053|DRUG|Paclitaxel+Carboplatin/concurrent radiation|
223909552|NCT04859608|DRUG|Spacing of Eculizumab infusions|Personalized spacing of eculizumab infusions using a pharmacokinetic population model to estimate eculizumab concentration ( a one-week spacing of eculizumab infusion will be decide if predicted eculizumab concentration in the event of spacing is \> 150 mg/L). Spacing of infusion can be decided every 3 months.
223909553|NCT04795661|DRUG|Pembrolizumab|Administered intravenous (IV)
223909554|NCT05210855|DIAGNOSTIC_TEST|CT scan|Scan with classic dose followed by ultra-low dose
223909555|NCT05850351|OTHER|Virtual reality|Virtual reality is a simulated experience that creates a virtual environment to give the user the feeling of an immersive virtual world, using glasses and a handheld device that can track hand movements. Activities that will improve the functional and respiratory capacity of children with cystic fibrosis will be developed and integrated into the virtual reality game.
223909556|NCT05850351|OTHER|Online|Online exercises are physical activities that are performed via a video-conferencing tool. Children will be at their home environment and exercises which will improve their functional and respiratory capacity will be instructed and supervised by a physiotherapist.
223909557|NCT06511245|OTHER|Randomisation|Technique assigned through randomization
223909558|NCT03149822|DRUG|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
223909559|NCT03149822|DRUG|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
223909560|NCT05965830|DEVICE|Diaphragm ultrasound|A single, simultaneous assessment of the diaphragm muscle functioning through dEMG and dUS at the time of spontaneous breathing.
223909561|NCT06453850|DEVICE|Use of FLEXIGO delivery catheter|Use of FLEXIGO delivery catheter for implantation of ventricular pacing lead
223909562|NCT04165720|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
223909563|NCT04544007|DRUG|Poly ICLC|Enrolled participants will receive poly-ICLC 20 mcg/kg/dose twice weekly IM (using Monday/Thursday or Tuesday/Friday schedule if possible).
223909564|NCT05402813|OTHER|Pure Tone Audiometry Assessment|Collection of Pure Tone Audiometry data performed in routine practice during study period
223909565|NCT05402813|OTHER|Quality of Life Questionnaires|Collection of Quality of Life questionnaire's answers during study period
224084356|NCT03083028|PROCEDURE|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
224084357|NCT03083028|PROCEDURE|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
224084358|NCT03390738|DRUG|Nivolumab|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
224084359|NCT00282841|OTHER|ultrasound|single intravenous administration of maximum 1.5 milliliter ultrasound contrast agent (Definity), followed by maximum 15 minutes transcranial insonation using diagnostic ultrasound.
224084360|NCT04812626|DRUG|5-Fluorouracil|Group A: 1ml of 40mg/ml triamcinolone acetonide will be mixed with 1ml of normal saline Group B:1 ml of 40 mg/ml triamcinolone acetonide will be mixed with 1ml of 50 mg/ml FU Five units (0.125ml) of the mixture TAC 40mg/ml and 5-FU 50mg/ml (1:1) i.e. 2.5mg TAC and 3.125mg of 5-FU or TAC 40mg/ml and 2%xylocaine (1:1) i.e. 2.5mg of TAC will be given intralesional with the help of 1ml insulin syringe of 40units, that covers an area of about 0.5X0.5 cm2 of scar, thus, a scar of 1 cm2 will require 4 injections to cover the whole lesion. Each extra area of 0.5x0.5cm2 will be given 5 units of injection of above mixture of drugs. For the larger lesions, dose can be increased but no more than 2ml in each group. Injection will be given at 2 weeks interval for total of 6 sessions (at 0,2, 4, 6,8,10 weeks) Post treatment follow up: at 12 weeks.
224084361|NCT05844215|DIAGNOSTIC_TEST|MMP-9 and TIMP-1|Examine level of serum MMP-9 and TIMP-1
224084362|NCT06539546|OTHER|Yttria stabilized multilayered (YML) zirconia restorations|Yttria stabilized multilayered zirconia restorations were claimed to have high strength and esthetics at the same time but no clinical studies were conducted yet to prove its high esthetic properties
224084363|NCT06539546|OTHER|Lithium disilicate restorations|Lithium disilicate reinforced glass ceramics are considered a gold standard for monolithic esthetic restorations.
224084364|NCT02570269|PROCEDURE|AuraGain|Fiberoptic Intubation
224084365|NCT02570269|PROCEDURE|Slotted Guedeltubus|Fiberoptic Intubation
224084366|NCT01213212|OTHER|Caloric restriction|Caloric restriction.
224084367|NCT01213212|OTHER|No intervention|"Diet ad libitum"
223715941|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
223715942|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
223909566|NCT06793306|OTHER|Age|Breast cancer patients were divided into young breast cancer and non-young breast cancer by age 35
223909567|NCT06793306|OTHER|combination therapy|To observe and compare the difference in diagnosis, combined treatment and prognosis between young and non-young breast cancer
223909568|NCT05806645|OTHER|Risk-guided transition of care intervention delivered through an integrated digital health strategy|Patients will receive transition of care plans that are tailored to their medical profile and risk and embedded within standardized discharge pathways within the EHR- Education and self-management guidance about AKI for patients, Medication guidance based on evidence-based indications for reducing risk of cardiac and kidney outcomes, Recommendations for subsequent laboratory testing of kidney function, proteinuria and electrolytes according to clinical characteristics and risks, Recommendations for timing and nature of PCP follow-up, Information about the patient's AKI and subsequent management provided to PCPs through discharge summary, Recommendations for outpatient Pharmacy follow-up for medication reconciliation and review according to patient risk and medication management gaps, Recommendations for Nephrology referral for high risk patients
224084368|NCT01833884|OTHER|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
224277376|NCT06157853|OTHER|Facial Cleanser|Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
224277377|NCT06157853|OTHER|Facial Moisturizer|Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
223715943|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
223715944|NCT00694785|DRUG|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
223909569|NCT06299124|DRUG|RGT-419B|RGT-419B will be administered orally
224084369|NCT01465308|DIETARY_SUPPLEMENT|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
223715945|NCT04869332|DEVICE|three cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Three screws for internal fixation in the three-screw group, and three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
223715946|NCT04869332|DEVICE|four cancellous screws|All patients with femoral neck fractures will be randomly divided into 2 groups at a ratio of 1:1. Four screws for internal fixation in the four-screw group, and the fourth screw will be implanted in the horizontal direction of the femoral distance on the basis of the three screws.
223715947|NCT04229394|DRUG|2ccPA|"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"
223909570|NCT03674619|PROCEDURE|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
223909571|NCT03674619|BEHAVIORAL|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions altogether) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
223909572|NCT05781711|DRUG|levodopa-carbidopa|levodopa-carbidopa is the standard therapy used in Parkinson's disease
223909573|NCT05781711|DRUG|Metformin|Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
223909574|NCT00279162|DRUG|Calcipotriene/betamethasone gel and ointment|
223909575|NCT00302887|DEVICE|combined ultrasound therapy|
223909576|NCT00302887|PROCEDURE|connective tissue manipulation|
223909577|NCT00449085|PROCEDURE|Electrophysiology|
223909578|NCT00449085|DEVICE|CARTO™ XP EP Navigation System V9|
223909579|NCT03565029|DRUG|XELOX|Capecitabine and Oxaliplatin (4x cycles)
223909580|NCT03565029|RADIATION|Radiotherapy|Pelvic radiotherapy
223909581|NCT01784913|BIOLOGICAL|UV1 synthetic peptide vaccine and GM-CSF|
223909582|NCT05334862|PROCEDURE|8 plate hemiepiphysiodesis|surgical procedure by lateral incision in proximal tibia and distal femur and fixation by using 8 plate and screws.
223909583|NCT05164055|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
223909584|NCT05818553|DRUG|PRAX-562|Once daily oral or G-tube treatment.
223909585|NCT03976544|DRUG|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
223909586|NCT03976544|DRUG|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
223909587|NCT04475640|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223909588|NCT04475640|OTHER|Genetic Testing|Undergo genetic testing
223909589|NCT00898235|GENETIC|clonality analysis|analyze clonality
223909590|NCT00898235|GENETIC|polymerase chain reaction|analyze polymerase chain reaction
223909591|NCT00898235|GENETIC|protein analysis|analyze protein
223909592|NCT00898235|OTHER|biologic sample preservation procedure|preserve biologic samples
223909593|NCT00898235|OTHER|laboratory biomarker analysis|analyze laboratory biomarkers
223909594|NCT00898235|PROCEDURE|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
223909595|NCT00898235|PROCEDURE|quality-of-life assessment|assess quality of life at each follow-up for life
223909596|NCT03006432|DRUG|Oxaliplatin|
223909597|NCT03006432|DRUG|5Fluorouracil bolus|
223909598|NCT03006432|DRUG|5Fluorouracil continu|
223909599|NCT03006432|DRUG|Docetaxel|
223909600|NCT03006432|DRUG|Folinic Acid|
223909601|NCT05608252|DRUG|VS-6766|Taken Orally
223909602|NCT05608252|DRUG|Abemaciclib|Taken Orally
223909603|NCT05608252|DRUG|Fulvestrant|Administered by intramuscular injection
223909604|NCT02262117|OTHER|standard care|No specific medical care
223909605|NCT02262117|DRUG|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
223909606|NCT03374657|BIOLOGICAL|CPK850|In one of 4 dose levels administered via subretinal injection under anesthesia
223909607|NCT03245437|DRUG|Oxytocin nasal spray|nasal spray
223909608|NCT03245437|BEHAVIORAL|Social Cognition Skills Training|Group based training in social cognition skills
223909609|NCT03245437|BEHAVIORAL|Health Management|Group-based training in mental health management
223909610|NCT03245437|DRUG|Placebo nasal spray|placebo condition
224084370|NCT01465308|OTHER|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
224084371|NCT02190019|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
224084372|NCT04193930|DRUG|Letrozole|Oral tablet letrozole 2,5 mg/twice daily for 5 days
224084373|NCT04193930|DRUG|Menotropins|150 IU of highly purified menotropins intramuscular
224084374|NCT04193930|DRUG|recombinant Follicular stimulating hormone|recombinant Follicular stimulating hormone 300- 400 IU
224084375|NCT01232478|BEHAVIORAL|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
223909611|NCT05953038|DRUG|Lysergic Acid Diethylamide Tartrate|D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
223909612|NCT03813862|OTHER|Non-interventional (observational only)|
224084376|NCT03871478|DRUG|Lidocaine|See Arm Description
224084377|NCT03871478|DRUG|Bupivacaine|See Arm Description
224084378|NCT03871478|DRUG|Lidocaine and Bupivacaine|See Arm Description
224084379|NCT02022826|DEVICE|SmartPill Monitoring System|
223909613|NCT06138197|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted hysterectomy following usual surgical technique
223909614|NCT04410731|DRUG|Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy|Single bilateral intra-articular injection of manufactured cell cultured expanded allogeneic BM-MSCs for painful lumbar facet joint arthropathy
223909615|NCT05528939|DEVICE|EndeavorRx|EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
224084380|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 0|"Patients will receive oral ATRA 25 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study.~If a dose limiting toxicity occurs at 25 mg/m2, then the dose will be reduced by 50% to 15 mg/sq m daily in two divided doses."
224084381|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose -1|"Patients will receive oral ATRA 15 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
224084382|NCT06536413|DRUG|All-Trans Retinoic Acid (ATRA) Dose 1|"Patients will receive oral ATRA 45 mg/m2 per day in two divided doses with carfilzomib-based regimens.~Eligible patients will enter the study in cohorts of two with the first cohort treated at Dose 0. To assign a dose to the next cohort of patients, dose escalation/de-escalation according to the trials Bayesian Optimal Interval (BOIN) Design is conducted. In patients who respond and do not have any dose limiting toxicity (DLT), treatment will continue for a total of 6 cycles in the phase II expansion cohort and subsequently transitioned to standard -of-care options. Each cycle will be 28 days. In phase 1b, a minimum of 16 evaluable patients will be recruited and in the second phase a minimum of 26 evaluable patients will be recruited. A minimum of 42 evaluable patients will be recruited in the study."
224084383|NCT01078805|DRUG|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
224084384|NCT03608917|DRUG|Total Glucosides of Paeony(TGP)|Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
224084385|NCT03608917|DEVICE|Narrow band-ultraviolet b（NB-UVB）|phototherapy on treating vitiligo
224084386|NCT03608917|DRUG|Total Glucosides of Paeony(TGP) analogue|Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
224084387|NCT05920967|DRUG|Dexamethasone Palmitate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
224084388|NCT05920967|DRUG|Dexamethasone Sodium Phosphate|a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.
224084389|NCT03911726|RADIATION|Single PET/MR-measurement|A single PET/MR-measurement using \[18F\]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
224084390|NCT05107817|OTHER|Exercise intervention|A ball catching and throwing exercise.
224084391|NCT01609842|OTHER|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
224084392|NCT00804388|PROCEDURE|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
224084393|NCT02910245|DRUG|Mercaptopurine (Purinethol)|
224084394|NCT02910245|DRUG|Placebo|
224084395|NCT02910245|DRUG|Mesalamine|
224084396|NCT02910245|DRUG|Prednisone|
223909616|NCT05528939|OTHER|Control video game|The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
223909617|NCT06414408|DRUG|Doxycycline Pill|200mg Dose
223909618|NCT01726140|PROCEDURE|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be \>200, the patient will stop the treatment.
223909619|NCT01726140|PROCEDURE|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2\>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be \< 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be \>200, the patient will stop the treatment.
223909620|NCT04507841|DRUG|Niraparib|Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
224084397|NCT05767723|DRUG|Dual antiplatelet therapy: Acetylsalicylic acid + ticagrelor OR Acetylsalicylic acid + prasugrel|Acetylsalicylic acid (100 mg/day) + ticagrelor (90 mg twice daily) Or Acetylsalicylic acid (100 mg/day) + prasugrel (10 mg once daily)
224084398|NCT05767723|DRUG|Monotherapy: Ticagrelor alone OR Prasugrel alone|Ticagrelor alone (90 mg twice daily) OR Prasugrel alone (10 mg once daily)
223909621|NCT06806410|DRUG|Liposomal bupivacaine (LB)|our study team wishes to determine effect of liposomal bupivacaine in regional nerve blocks for surgery of the upper extremity (finger, hand, wrist, elbow)
223909622|NCT06806410|DRUG|Dexamethasone|dexamethasone injected in perineural area can extend the regional nerve block
224084399|NCT01251328|PROCEDURE|General anaesthesia|general anaesthesia is performed according to the hospitals standard
224084400|NCT01251328|PROCEDURE|Sedation|Sedation is performed according to the hospitals standard
224084401|NCT00624390|DEVICE|Sepraspray|
224084402|NCT04023955|BEHAVIORAL|Twitter|Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
224084403|NCT01314950|BEHAVIORAL|Home based occupational therapy|"An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs."
224084404|NCT01314950|BEHAVIORAL|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
224084405|NCT02715687|DRUG|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
224084406|NCT02715687|DRUG|Placebo|Will receive 30 days treatment with oral placebo of 200mg
223715948|NCT04229394|DRUG|placebo|"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"
223715949|NCT05771376|OTHER|Qigong exercise program|"The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks."
224084407|NCT02532270|DRUG|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
224084408|NCT02153099|DRUG|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
224084409|NCT02153099|DRUG|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
224084410|NCT06127524|DEVICE|SEM Scanner|Implementation of the SEM Scanner as part of weekly standard skin assessments of sacrum and heels
223909623|NCT03663218|RADIATION|Dose escalation|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
224084411|NCT05558332|BEHAVIORAL|Youth-Nominated Support Teams for CHR|"Intervention for adolescents aimed at preventing, reducing, and/or managing suicidal thoughts and behaviors. YST-CHR is an add on to the treatment and therapy they are already receiving. Study clinicians will administer the adapted YST treatment manual to participants, aimed at improving suicidal risk."
223715950|NCT05771376|OTHER|Home exercise program|"The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks."
224084412|NCT02474329|OTHER|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.org) for every included patient. This assessment will last for 60 minutes, and it will be done once.
224084413|NCT02474329|DEVICE|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
224084414|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 1|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
224084415|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 2|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
224084416|NCT03572530|DRUG|5-Azacytidine (5-AZA) group 3|"5-AZA (12 mg) will be prepared in preservative-free normal saline to a total volume of 1.2ml. 5-AZA will be infused over a minimum of 30 seconds. 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
224084417|NCT05833672|DRUG|Terelizumab|q3w Terelizumab 200mg on day 1 of each cycle
224084418|NCT05833672|DRUG|CapeOx|Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
224084419|NCT06283641|DRUG|Liraglutide|Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
224084420|NCT06028659|OTHER|Coffee|Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
224084421|NCT06028659|OTHER|Water|150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.
224084422|NCT03570112|DRUG|SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg|sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
224084423|NCT01811147|DRUG|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
224084424|NCT03341676|DRUG|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
224084425|NCT03341676|DRUG|Placebo|Sodium Chloride 0.9% w/v solution for injection
224084426|NCT03847142|OTHER|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
224084427|NCT03847142|OTHER|Outpatient primary care|Usual care delivered through the outpatient primary care setting
223715951|NCT02254187|DRUG|Salmeterol capsule - low|
223715952|NCT02254187|DRUG|Salmeterol capsule - high|
223715953|NCT02254187|DRUG|Salmeterol via Serevent® Diskus®|
223715954|NCT02617745|OTHER|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
223715955|NCT00964860|DEVICE|Glide dental floss|Glide waxed dental floss
223715956|NCT05251090|DRUG|ADVATE|50 international units (IU)/kg, a single dose.
223715957|NCT05251090|DRUG|FRSW107|50 IU/kg, a single dose.
223715958|NCT03025477|DRUG|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
223715959|NCT03025477|DRUG|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
223715960|NCT03025477|DRUG|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"* carboplatin (IV) - paclitaxel (IV) (3 cycles)~* Interval surgery~* Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
223715961|NCT03025477|DRUG|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"* Cisplatin (IV) - Epirubicin (IV) (3 cycles)~* Interval surgery :~  * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~ * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
224084428|NCT02630160|DRUG|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
224084429|NCT02630160|OTHER|Physiological Saline|Intraarticular infusion physiological serum
223909624|NCT06807450|PROCEDURE|closure of oro-nasal fistula in cleft palate patients|group I : Oro-nasal fistula will be closed in two layers, nasal layer by closing the fistula margin and turning over of flap and oral layer will be closed using two flap palatoplasty group II; the same procedure with insertion of free graft of buccal pad of fat between oral and nasal layers
224084430|NCT01301430|DRUG|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
224084431|NCT01550497|OTHER|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
224084432|NCT01195337|BEHAVIORAL|PA Prescription Plan|Exercise program and instructions.
224084433|NCT01195337|DEVICE|Pedometer|Step monitor for individual PA progress.
224084434|NCT01195337|BEHAVIORAL|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
224084435|NCT05539846|PROCEDURE|modified blood collection method|The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
224084436|NCT04657835|DEVICE|cardiac Magnetic Resonance Imaging (MRI)|Cardiac magnetic resonance imaging (MRI) will be realized before Coronary Artery Bypass Grafting for assess atrial cardiomyopathy.
224084437|NCT04657835|BIOLOGICAL|Blood sample|Blood sample will be realized (4 tubes of 4ml blood, 16ml in total) before Coronary Artery Bypass Grafting.
224084438|NCT04657835|PROCEDURE|Cardiac muscle biopsy|Cardiac muscle biopsy will be realized during Coronary Artery Bypass Grafting.
224084439|NCT04657835|DEVICE|Holter-electrocardiogram (ECG)|Holter-electrocardiogram (ECG) will be realized 1 year after Coronary Artery Bypass Graftin during 3 days to diagnose the occurrence of atrial fibrillation.
224084440|NCT04657835|OTHER|medical examination|medical examination will be realized 1 year after Coronary Artery Bypass Graftin. Theses datas will collected: events during the follow-up year and evaluation of the Holter-electrocardiogram result.
224084441|NCT06912217|DEVICE|robotic rehabilitation|It is planned to provide a robotic rehabilitation program for patients in the robotic group, in addition to conventional rehabilitation for 4 weeks, with 30 minutes, 3 days a week, focusing only on their dominant upper extremities.
224084442|NCT06912217|DEVICE|Functional Electrical Stimulation|In the FES group, an upper extremity FES bicycle program (ADI) will be applied to the dominant upper extremity and hand, three days a week for 4 weeks.
223715962|NCT05808972|DRUG|Sodium chloride 0.9% (SC)|This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
223715963|NCT05808972|DRUG|Ringer lactate (RL)|The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
224084443|NCT06912217|OTHER|occupational therapy|In the occupational therapy group, patients will receive the planned treatment in addition to conventional rehabilitation for 4 weeks, three days a week, for 30 minutes.
224084444|NCT05589142|BEHAVIORAL|Time Restricted Eating|Eating calories only during a specific feeding window.
224084445|NCT01420510|DRUG|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
224084446|NCT01420510|DRUG|Placebo vaginal gel|Application of a placebo vaginal gel
224084447|NCT01878630|DEVICE|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~* weighing scale (Seca 861 with bluetooth, seca gmbh \& co. kg.)~* blood pressure device (UA767PBT with bluetooth, A\&D Ltd.)~* ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~* patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~* help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~\- electronic patient record (eHealth connect 2.0, T-Systems International)"
224084448|NCT01878630|OTHER|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
224084449|NCT00880750|DRUG|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
224084450|NCT00880750|DRUG|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
224084451|NCT02285179|DRUG|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
224084452|NCT02285179|DRUG|Tamoxifen|daily dose of 20 mg
224084453|NCT01224548|OTHER|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
224084454|NCT01224548|OTHER|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
223715964|NCT05531760|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK-operated eyes
223719371|NCT04069611|OTHER|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
224084455|NCT04091893|BEHAVIORAL|Usual care/wait list|Individuals in this group can continue with their usual care (but receive no museum-based intervention)
224084456|NCT04091893|BEHAVIORAL|Art Rx|Individuals in this group participate in a specialized tour of an art museum
223909625|NCT06806384|OTHER|ExerGame-based Stroke Rehabilitation|The intervention involves training using the Dividat Senso platform (Dividat, Schindellegi, Switzerland), a pressure-sensitive platform (1.13 m × 1.13 m) equipped with 20 sensors. The training includes a series of ExerGames designed to challenge balance, coordination, and cognitive processing speed. These games focus on weight shifting, stepping accuracy, and reaction time, with difficulty levels progressively adjusted based on participant performance. To ensure safety, participants are allowed to use a waist-high parallel bar for support during the exercises. Additionally, participants receive conventional physical therapy methods that do not interfere with the study protocol. These include range-of-motion exercises, upper-limb training, and respiratory training, delivered in 30-minute sessions, five days per week, over a four-week period.
224084457|NCT04091893|BEHAVIORAL|Artful Meditation|Individuals in this group participate in a meditation and art appreciation program at an art museum
224084458|NCT03890809|DRUG|BMS-986165|Oral administration
224084459|NCT02714179|DRUG|Paracetamol was given intravenously in both group at different times|
223909626|NCT06806384|OTHER|General balance exercise for stroke rehabilitation|The intervention consists of a standardized program of balance exercises designed to improve postural control and stability. The program incorporates weight-shifting training performed once daily for 30 minutes, five days per week, over a four-week period. Weight-shifting activities include anterior-posterior and mediolateral movements, with a focus on loading the affected limb. Participants are instructed to adopt a lunge posture for forward-backward movements, maintain parallel foot positioning for lateral movements, and utilize a balance pad to enhance postural stability. A trained therapist adjusts the intensity and difficulty of the exercises to match the individual abilities of each participant, ensuring a personalized and progressive approach.
223909627|NCT06806384|OTHER|Conventional physical therapy for stroke rehabilitation|The intervention includes conventional physical therapy methods that are compatible with the study protocol. These methods consist of range-of-motion exercises, upper-limb training, and respiratory training. The sessions are delivered for 30 minutes per day, five days per week, over a four-week period.
223909628|NCT06541067|DRUG|Posaconazole|"Per Os, on Day 0 of allo-CSH if the patient's condition permits, or after the last dose of immunosuppressor (post-transplant cyclophosphamide) (Day+5 or Day+6 depending on protocols).~On the first day of treatment: 300 mg in the morning (= 3 x 100 mg tablets) and 300 mg in the evening (= 3 x 100 mg tablets), then from day 2 of treatment: 300 mg per day (= 3 x 100 mg tablets) in a single dose"
224084460|NCT03906825|DIETARY_SUPPLEMENT|CEAG|Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
224084461|NCT03906825|DIETARY_SUPPLEMENT|placebo|placebo
224084462|NCT05693584|OTHER|distraction|diverting the patient's attention with virtual reality glasses
224084463|NCT00486486|DRUG|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
224084464|NCT00486486|DRUG|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
224084465|NCT00439855|DRUG|Enoxaparin i.v.|
224084466|NCT00439855|DRUG|unfractionated heparin|
224084467|NCT02265913|DRUG|Acyclovir 5 percent (Perrigo)|
224084468|NCT02265913|DRUG|Acyclovir 5 percent (Reference)|
224084469|NCT02265913|DRUG|Placebo cream|
224084470|NCT01930786|DRUG|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
224084471|NCT04824378|OTHER|No Intervention.|No Intervention.Only learn ICG image features of different label groups
224084472|NCT00030082|DRUG|isolated perfusion|
224084473|NCT00030082|DRUG|melphalan|
224084474|NCT05682014|BEHAVIORAL|Mindful Breastfeeding Program|"A web-based Mindful Breastfeeding Program, which is applied to pregnant women in groups of 5, consisting of 8 sessions, 2 sessions per week for 4 weeks.~Mindful breastfeeding program will consist of breastfeeding education, introduction to the concept of mindfulness, mindful breastfeeding, practical suggestions to pregnant women by the researcher, providing a discussion environment for them to share their experiences, and homework on the content of the program.~A web site with written material, video and audio recordings will be created and presented to the participants as a support element.~In order for them to use mindfulness practices in their daily lives, motivational WhatsApp short messages will be sent by the researcher daily during the training, weekly during the post-training period, and daily in the postpartum period."
224084475|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic retrosigmoid minimally invasive vestibular neurectomy
224084476|NCT04847700|PROCEDURE|Surgical treatment|Endoscopic tenotomy of middle ear muscles
224084477|NCT00483327|DRUG|Megestrol Acetate|
224084478|NCT00239031|DRUG|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
224084479|NCT02087332|DRUG|Prolonged release Torasemide (Britomar)|
224084480|NCT02087332|DRUG|Torasemide (Diuver)|
224084481|NCT01184690|PROCEDURE|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
223909629|NCT02988661|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
223909630|NCT05560165|PROCEDURE|F-18 sodium fluoride PET/CT guided robotic arm assisted injection of combination of local anesthetic and steroids|A surgical aseptic approach will be followed for the procedure. Local anesthesia of the skin and soft tissue at the entry site will be achieved by 1% lignocaine. A 23G lumbar puncture needle will be introduced and the real-time final placement of the needle will be confirmed with low dose CT (40 mA) fused with pre-procedure PET images. After confirming the real-time position, the local anesthetic and steroid injection (0.5ml of 0.5% Bupivacaine per joint and a total dose of 80mg of Methylprednisolone acetate divided equally based on the number of joints to be injected) will be injected intraarticularly and periarticularly around the target joint through the lumbar puncture needle. The skin entry site will be compressed manually to achieve hemostasis. The same procedure will be repeated if multiple joints are to be injected. After the procedure, patient vitals will be observed for thirty minutes in the recovery area and discharged in stable condition.
223715965|NCT05408949|BEHAVIORAL|Single exercise into pain (SEP) program|"* Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program"
223715966|NCT05408949|BEHAVIORAL|Shoulder Symptom Modification Procedure (SSMP)|\[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
223715967|NCT05408949|BEHAVIORAL|Functional Rehabilitation Program|Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
223719372|NCT04069611|PROCEDURE|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
223909631|NCT06374667|PROCEDURE|Y-3 ICO injection|Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.
223909632|NCT06374667|DRUG|Y-3 intravenous injection|Patients included will be given Y-3 intravenous injection for 7 consecutive days.
223909633|NCT06374667|OTHER|Conventional treatment|standard treatment and management according to related guidelines during the entire treatment period
223909634|NCT06270134|OTHER|Bicarbonate|Bicarbonate is added to hemodialysis fluids to correct the metabolic acidosis that arises from kidney failure. Some dialysis units in Canada add bicarbonate to a level of 32 mmol/L, while other units add bicarbonate to a level of 38 mmol/L. It is unknown whether one level is better for people's health.
223909635|NCT05656092|DRUG|HIP0612|Test drug
223909636|NCT05656092|DRUG|HPP2202|Placebo drug
223909637|NCT05656092|DRUG|RLD2204|Reference drug
223909638|NCT05656092|DRUG|HPP2201|Placebo drug
223909639|NCT06805474|OTHER|Observational|Observational
223909640|NCT06185192|DIETARY_SUPPLEMENT|Viome's Precision Nutrition Program (VPNP)|Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
223909641|NCT03223155|DRUG|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
223909642|NCT03223155|DRUG|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
224084482|NCT01184690|PROCEDURE|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
224084483|NCT01746251|DRUG|Afatinib|
224277378|NCT06157853|OTHER|Sunscreen|Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
223719373|NCT01906502|DEVICE|Sensimed Triggerfish|
224277379|NCT04826289|RADIATION|X rays|Radiological assessment of vertical distance between medial and lateral malleolus in normal opulation
224277380|NCT00354562|DRUG|ABT-751|200mg ABT-751 daily for 14 days every 21 days
224084484|NCT04120558|OTHER|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
224084485|NCT04120558|OTHER|Functional mobility tests and questionnaires|"Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
224084486|NCT04217343|DIAGNOSTIC_TEST|Allosure/Allomap/Cytokines testing|All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
224084487|NCT00249574|DRUG|Buprenorphine/naloxone|Human subjects HIV, HCV
224084488|NCT00249574|DRUG|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
224084489|NCT00670007|BIOLOGICAL|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
223909643|NCT03223155|RADIATION|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
223909644|NCT06512337|DRUG|Deucravacitinib|As per product label
223909645|NCT03571789|DEVICE|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
224084490|NCT00618722|DRUG|Deoxycholic Acid Injection|
224084491|NCT00618722|DRUG|Placebo|
224084492|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
224084493|NCT01549301|DRUG|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
224084494|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
224084495|NCT01549301|DRUG|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
224084496|NCT05825248|OTHER|Fine and gross motor treatment only|occupational therapy intervention involving general fine and gross motor activities
224084497|NCT05825248|OTHER|Reflex integration + fine and gross motor treatment|occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
224084498|NCT05949008|DRUG|Metformin Extended Release (ER) Oral Tablet|Metformin ER will be provided as 1000 mg capsules by Qingdao Baheal Pharmaceutical Co., Ltd. In addition to the active ingredient metformin HCl,each tablet contains the following inactive ingredients: Povidone, Sodium Lauryl Sulfate, Magnesium Stearate, Cellulose Acetate, Polyethylene Glycol (PEG 400, PEG 8000), Triacetin, Hypromellose, Titanium Dioxide, Polysorbate 80, Ferrosoferric Oxide, Shellac.
224084499|NCT05949008|DRUG|Placebo|Matching placebo will be provided as 1000 mg capsules
224084500|NCT00624221|PROCEDURE|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
224277381|NCT00354562|DRUG|Placebo|Placebo daily for 14 days every 21 days
224277382|NCT00354562|DRUG|Docetaxel|Standard Docetaxel every 21 days
224277383|NCT04139460|DEVICE|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
224277384|NCT04139460|DEVICE|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
223909646|NCT06807359|DEVICE|Photodynamic Therapy (PDT)|"The PDT treatment is provided with the SpectraCure P18 laser light delivery system.~PDT will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery. The photosensitizer is activated with light of a specific wavelength that is delivered to the tumor via optical fibers. The activated photosensitizer reacts with oxygen to form highly toxic radicals which induce cell death in the tumour.~* Phase 1: Light dose escalation. Three subjects will be treated per dose level (20 - 40 J/cm2). If no dose-limiting toxicities occur, dose will be escalated (20 - 40 J/cm2) until the Recommended Phase 2 Dose (RPD2) is established.~* Phase 2: Cohort expansion with the RPD2."
223909647|NCT06807359|DRUG|Verteporfin Injection|Verteporfin for Injection (VFI), photosensitizing drug, will be administered intravenously at a dose of 15 mg/m2 body surface area.
223909648|NCT06807554|DRUG|Ketamine|In Group K, ketamine 0.25mg/kg diluted in normal saline to a total volume of 40 ml was instilled by the surgeon, 20 ml before starting gall bladder dissection over the surgical site and liver while remaining 20 ml at the end of procedure after securing haemostasis over gall bladder bed and liver.
224084501|NCT05192187|OTHER|Cross-sectional self-report (questionnaires)|"participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~* perceived harmfulness of activities (selection of PHODA-SeV)~* cognitions about lifting and pain~* reasons for avoidance behaviour (lifting)~Standardised questionnaires include~* NRS for pain~* TSK-11~* FABQ~* RMDQ"
224084502|NCT00200057|DEVICE|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
223909649|NCT06807554|DRUG|Bupivacaine|In Group B, bupivacaine at a dose of 2 mg/kg was diluted in normal saline to a total volume of 40 ml. The administration was performed by the surgeon in two stages: the first 20 ml was instilled before starting the gall bladder dissection, applied over the surgical site and liver, while the remaining 20 ml was instilled at the end of the procedure after achieving hemostasis, applied over the gall bladder bed and liver.
223909650|NCT06805747|OTHER|Variable tidal volume ventilation (V-VCV)|Variable tidal volume ventilation (V-VCV) ：The initial tidal volume is set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW), and the maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) are set at 10-20% of the base tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiration to Expiration Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, and Inhaled Oxygen Concentration (FiO2) 41%.
224084503|NCT01235676|BEHAVIORAL|diet|calorie restriction to reduce weight gain
224084504|NCT01235676|BEHAVIORAL|Exercise|Exercise to reduce weight gain
224084505|NCT03396328|BEHAVIORAL|conventional low salt education|conventional low salt education
224084506|NCT03396328|BEHAVIORAL|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
224084507|NCT03048955|DEVICE|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
224084508|NCT03048955|PROCEDURE|Direct decompression Surgery|A surgical procedure - the control
224084509|NCT01533727|DRUG|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
224084510|NCT01533727|DRUG|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
224084511|NCT02243384|PROCEDURE|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
224084512|NCT02243384|PROCEDURE|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
224084513|NCT00120614|BEHAVIORAL|Premature infant behavior and development information|
224084514|NCT00120614|BEHAVIORAL|Parental activities to support premature infant information|
224084515|NCT00510705|OTHER|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
224084516|NCT00510705|OTHER|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
224084517|NCT00510705|OTHER|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
224084518|NCT04968418|DEVICE|APDM OPAL system wearable IMU|The OPAL system contains wearable IMUs with a sampling rate of 128 Hz and a resolution of 17.5 bits. Each IMU has a size of about 44mm 40mm 14mm × × and weighs less than 25 gm.
224084519|NCT03575026|BEHAVIORAL|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
224084520|NCT03575026|BEHAVIORAL|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
224084521|NCT06122402|OTHER|SECURE Care Bundle|The SECURE Care Bundle is a systematic approach to care that includes checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives including CHG dressing and silicone based remover.
224084522|NCT06122402|PROCEDURE|Standart Care|It is applied in routine care in the clinic. There is no standardization and no procedure for checking the skin, assessing risk factors, registering medical adhesive related skin injury and correctly applying and removing medical adhesives. Only CHG dressing is used for central venous catheter care.
224084523|NCT03752125|DIETARY_SUPPLEMENT|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
224084524|NCT03752125|DIETARY_SUPPLEMENT|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
224084525|NCT00778830|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
224084526|NCT00778830|DRUG|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
224084527|NCT00778830|DRUG|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
224084528|NCT04323371|DIAGNOSTIC_TEST|ELISA|Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
224084529|NCT03198143|DRUG|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
224084530|NCT03198143|DRUG|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
224084531|NCT03840876|DEVICE|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
224084532|NCT06956638|OTHER|Non-interventional|Non-interventional study
224084533|NCT03983681|BEHAVIORAL|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
224084534|NCT03983681|BEHAVIORAL|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
224084535|NCT03282747|BEHAVIORAL|no intervention|no intervention
224084536|NCT05038683|BEHAVIORAL|Holbæk Obesity Treatment|"Obesity is a chronic, progressive, severe, recidivistic, and complex disease, which mandates that children and adolescents with overweight or obesity have access to a professional medical healthcare service as other pediatric chronic diseases, implying a lifelong course of treatment. The HOT method is further based on the physiological insight into the endocrine regulation of fat mass; especially on how the body adapts when it is challenged by weight loss. These insights include an understanding where the body shifts into an energy-preserving mode when the individual is initiating weight-reducing actions, such as a reduced caloric intake or an increased level of physical activity, which has numerous impacts on communication and pedagogy.~HOT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
224084537|NCT05038683|BEHAVIORAL|Conventional Obesity Treatment|"Obesity is viewed as a chronic disease that is ultimately thought to result from an imbalance between energy intake and energy expenditure. However, multiple factors, both environmental and genetic, are thought to influence the disease as well. As obesity reflects energy imbalances, the treatment plan should be designed to induce a slightly negative energy balance by focusing on diet, physical activity, and inactivity through behavior change. Taking one step at a time, will in the end lead to the same energy balance result (i.e. weight loss) and will be more sustainable for the participant whose motivation is absolutely pivotal in this process.~COT is administered by healthcare nurses and dietitians at healthcare centers in Danish municipalities. Each treatment will be conducted as face-to-face sessions totalling a range of six to 12 hours for 12 months."
224084538|NCT05424172|BEHAVIORAL|Stage-I, Group 1: Self monitoring using Non-interactive App|Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
224084539|NCT05424172|BEHAVIORAL|Stage-I, Group 2: Self monitoring using Interactive App|Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
223715968|NCT05408949|BEHAVIORAL|EPTL|In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
223719374|NCT01088945|BEHAVIORAL|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
223909651|NCT06805747|OTHER|Pressure-regulated volume-controlled ventilation (PRVC)|Pressure-regulated volume-controlled ventilation (PRVC) ：Initial tidal volume is set at 6-8 ml/kg IBW based on Ideal Body Weight (IBW), peak inspiratory pressure is capped at 30 cmH2O, maximum tidal volume (Vt\_max), and minimum tidal volume (Vt\_min) is set at 10-20% of basal tidal volume (Vt\_base). Respiratory Rate (RR) 12, Inspiratory Breathing Ratio (IBR) 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, and Inhaled Oxygen Concentration (FiO2) 98%.
223909652|NCT06805747|OTHER|Conventional volume-controlled ventilation (C-VCV)|Conventional volume-controlled ventilation (C-VCV) ：The initial tidal volume is set at 6-8 ml/kg IBW based on Ideal Body Weight (IBW), and the maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) are set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiration to Expiration Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, FiO2 98%.
223909653|NCT06805747|OTHER|Pressure-controlled ventilation (PCV)|Pressure-controlled ventilation (PCV)：Set inspiratory pressure level, usually 20 cmH2O initial value, Respiratory Rate 12, Inspiratory to Expiratory Ratio 1:2, Positive End-Expiratory Pressure (PEEP) 5 cm water column, Inhaled Oxygen Concentration (FiO2) 98%.
223909654|NCT06805747|OTHER|Trendelenburg position|Trendelenburg position：Lower the head of the bed by 30 degrees with no more than 15 degrees of lateral tilt.
223909655|NCT06805747|OTHER|Reverse Trendelenburg position|Reverse Trendelenburg position：Elevate the head of the bed by 30 degrees with no more than 15 degrees of lateral tilt.
223909656|NCT03099057|OTHER|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
223909657|NCT03964376|OTHER|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute
223909658|NCT03964376|OTHER|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
223909659|NCT06061159|DRUG|Remimazolam besylate|initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
223909660|NCT06061159|DRUG|Remimazolam besylate|initial dose is based on the findings from the school-age group；adjust dosage is 0.05mg/kg
223909661|NCT04981600|DEVICE|Radiofrequency ablation|Patients in the RF group will be first examined under anesthesia at the beginning of the procedure in lithotomy position. Approximately 3-6 ml of 20 mg/ml Lidocaine (Jetokaine, Adeka İlaç Sanayi, Samsun) solution will be injected between the cushion and the internal anal sphincter to minimize heat conduction to the surrounding tissues during the procedure. The HPR45i probe (F Care Systems, Antwerpen, Belgium) connected to the Rafaelo ® EVRF machine (F Care Systems, Antwerpen, Belgium) will be placed inside the cushion and 25 watts of RF energy will be transmitted. Care will be taken by not exceeding the dentate line caudally. The recommended Joule value for each operation is 1200-3000 J. Then cold is applied on the cushion, reducing the temperature of the tissue and preventing damage to the surrounding tissues. The same procedure will be performed for other pathologic cushions as well.
223909662|NCT04981600|DEVICE|Laser|"The same preoperative preparations will be done for the laser group as well. The NeoV 1470 (neoLaser, Israel) device will be used in this group. Following routine placement of the patient in lithotomy position and determining the cushion to be treated, a 12 W laser beam with a wavelength of 1470nm will be inserted into the cushion above the dentate line and advanced to the apex and approximately 3 laser shots are delivered throughout the course caudally, the number of which can be altered according to the size targeted cushion. Finally the procedure will be completed after gentle cold application.~An enema will be given to the patients in both study groups in the morning of the operation and patients will be discharged with analgesics on the same day."
223909663|NCT05282459|DRUG|Enasidenib mesylat dose escalation|Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
223909664|NCT03421340|DEVICE|DSC|Stone removal without fluoroscopy using the SpyGlass device.
223909665|NCT03421340|DEVICE|ERC|Standard of care stone removal with fluoroscopy.
223909666|NCT05660434|OTHER|Aroma Inhaler with Bergamot essential oil|The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
223909667|NCT04954885|PROCEDURE|Biospecimen Collection|Undergo stool sample
223909668|NCT04954885|OTHER|Physical Performance Testing|Undergo short physical performance battery
223909669|NCT04954885|OTHER|Physical Performance Testing|Perform 6-minute walk test
223909670|NCT04954885|OTHER|Questionnaire Administration|Complete questionnaires
223909671|NCT05743426|OTHER|Survey|Patient Reported Outcome (PRO) questionnaire
223909672|NCT05743426|OTHER|Toxicity Assessments|Toxicity Assessments will be performed using the National Cancer Institute Common Terminology Criteria (NCI-CTCAE).
223909673|NCT05762107|DRUG|Placebo|Subject receives Placebo by subcutaneous injection daily for 28 days
223909674|NCT05762107|DRUG|ZT-01, 7 mg|Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
223909675|NCT05762107|DRUG|ZT-01, 15 mg|Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
223909676|NCT05762107|DRUG|ZT-01, 22 mg|Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
224084540|NCT05424172|BEHAVIORAL|Stage-II, Groups 1a/2a: E-Coaching 1x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
224084541|NCT05424172|BEHAVIORAL|Stage-II, Groups 1b/2b: E-Coaching 2x per month|In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
224084542|NCT06377566|DRUG|Brentuximab vedotin|Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle
224084543|NCT06377566|DRUG|Doxorubicin|Doxorubicin 25 mg/m\^2 IV
224084544|NCT06377566|DRUG|Vinblastine|Vinblastine 6 mg/m\^2 IV
224084545|NCT06377566|DRUG|Dacarbazine|Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle
224084546|NCT06377566|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg IV (flat) on day 1
224084547|NCT06377566|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 IV (days 1 an
224084548|NCT06377566|DRUG|Vinorelbine|Vinblastine 6 mg/m\^2 IV
224084549|NCT06377566|DIAGNOSTIC_TEST|FDG-PET/CT scan|After 2 cycles of therapy, patients will undergo FDG-PET/CT scan
224084550|NCT04259853|PROCEDURE|PCI|Revascularization on non culprit vessel
224084551|NCT06045988|DEVICE|Non-Contact Sleep Quality Monitor System|Residents of long-term care facilities with Alzheimer's or other related dementias will utilize a sleep monitoring device for the four-week period they are involved in the study.
224084552|NCT06208488|DRUG|Gefurulimab PFS-SD|Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
224084553|NCT06208488|DRUG|Gefurulimab AI|Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
224084554|NCT00699179|DRUG|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
224084555|NCT04614792|DEVICE|Transcranial direct current stimulation|Non-invasive brain stimulation or neuromodulation.
224084556|NCT01009957|DRUG|Everolimus|0.75 mg x 2 / day
224084557|NCT06170996|BEHAVIORAL|Internet-based behavioral parent training (I-BPT)|Internet-based behavioural parent training in a group format, 8 sessions over 2 months, delivered by a systematically trained and supervised therapist.
224084558|NCT06350214|BEHAVIORAL|physical activity and nutrition assessment|Assessment of the physical activity and nutrition condition of cancer survivors.
224084559|NCT00872950|DRUG|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
224084560|NCT04931953|OTHER|Intermittent theta burst stimulation (iTBS)|The localisation of the left dorsolateral prefrontal cortex (DLPFC) target will be identified using effective connectivity of the left caudate to identify the maximally-connected locus in the left DLFPC. Following this the iTBS will be administered to the target coordinates identified using the neuronavigation software available with the system. Connectivity-guided iTBS is then administered using a 70mm Double Air Film Coil (Magstim, Whitland, Dyfed, UK), connected to a Magstim Super Rapid-2 Plus-1 stimulator. The administration comprises bursts of 3 pulses at 50Hz with a power of 80% motor threshold at a burst frequency of 5 Hz (i.e., every 200ms) for 2 seconds, repeated every 10 seconds for a total of 190 seconds (600 pulses). Blocks are repeated a total of 3 times, with 5-minute rest intervals between blocks. During left DLPFC stimulation, the TBS coil is held by a support tangentially to the skull, with the axis of the coil angled approximately 90 degrees from the midsagittal axis.
224084561|NCT04931953|OTHER|Sham Intermittent theta burst stimulation (iTBS)|The sham iTBS administration is performed under the same conditions and with an identical protocol and equipment to the full administration, except that it uses a commercially available sham iTBS coil designed for use in double-blind trials. This sham coil looks like the real coil and connects to the iTBS unit but delivers only a very weak and shallow stimulation thus simulating the sounds made by the real iTBS coil.
224084562|NCT03903380|OTHER|Manual Therapy and Usual care exercise protocol for neck pain|Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
224084563|NCT03903380|OTHER|Manual Therapy and Augmented reality exercise protocol|Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
224084564|NCT00945360|DRUG|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
224084565|NCT01929057|PROCEDURE|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
224084566|NCT01929057|PROCEDURE|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
224084567|NCT00221884|PROCEDURE|Ultrasound|
224084568|NCT03168984|DRUG|UCB0942|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use"
224084569|NCT03168984|OTHER|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use"
224084570|NCT00132041|DEVICE|radiofrequency ablation|
223715969|NCT05408949|BEHAVIORAL|HSR|In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
223715970|NCT04885361|BIOLOGICAL|CoVepiT (OSE13E)|Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.
223715971|NCT03053544|DRUG|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
224084571|NCT06133660|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy and Silicone oil removal to distinguish subjects
224084572|NCT05197803|DEVICE|Hearing aid|Participants will complete testing aided and unaided. The hearing aids have been fit to compensate for their hearing loss.
224084573|NCT05422066|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg on day 1,8,15 for 21 days cycles
224084574|NCT05422066|DRUG|Rituximab|Induction Chemotherapy: 375mg/sqm, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
224084575|NCT05422066|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
223715972|NCT03716024|DRUG|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
223715973|NCT03716024|DRUG|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
223719375|NCT06243263|DRUG|Bupivacain|At the end of the surgery, after wound closure, an inferior alveolar nerve block with 2ml bupivacaine 0,5 % will be realized.
223719376|NCT03808493|DRUG|TAK-438 OD|TAK-438 OD tablet
223719377|NCT03808493|DRUG|TAK-438|TAK-438 tablet
223909677|NCT05211596|BEHAVIORAL|Deaf Weight Wise intervention|The DWW intervention consists of groups of 5 subjects who meet together for 16 weeks, 2 hours each week. Group meetings will be held virtually on Zoom. A trained, deaf, ASL-fluent counselor will lead the sessions. Each session includes group sharing, problem solving, discussion of a weight management topic, and goal setting and action planning for the next week. A key principle of DWW is motivational interviewing, in which the counselor acts as a facilitator to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The maintenance phase starts immediately after the 16-week intervention, and consists of two meetings of the original group via Zoom; one at month 3 and one at month 6 of the maintenance period. Counselors also email participants bi-weekly to check in and provide additional support.
223909678|NCT05789316|OTHER|Ototoxicity Screening Protocol|The ototoxicity screening protocol contains a functional and objective component. The functional component is the Hearing Handicap Inventory for the Elderly - Screening Version (HHIE-S). The objective component will be pure tone audiometry. A 2 kHz tone at 40 dB will play through over-the-ear headphones and subjects will indicate whether they heard it.
224084576|NCT05422066|DRUG|Doxorubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
224084577|NCT05422066|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
224084578|NCT05422066|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease, up to 6 cycles.
224084579|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
224084580|NCT01125332|DRUG|Indirect laryngoscopy in the flexible nasofibroscope|
224084581|NCT05429086|DRUG|Remimazolam combined propofol|Remimazolam combined propofol
224084582|NCT05429086|DRUG|Remimazolam|remimazolam only
223529033|NCT05614882|BEHAVIORAL|Written Stroke Education|The written education will be provided in the stroke folder currently in use by the Yale New Haven Health system. This written information is presented in a stroke folder and includes how to respond to the signs of stroke, dialing 9-1-1, following up with a health care provider after hospitalization due to a stroke and the importance of medication management as well as stroke risk factors, healthy eating habits, exercise habits, common changes following a stroke, stroke recurrence and stroke types. After being given two days to review the materials, patients will be asked to complete the stroke knowledge test (SKT). All participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
223529034|NCT05614882|BEHAVIORAL|Verbal Stroke Education|Participants in the verbal education group will be provided with education over two days from therapists including occupational therapy, physical therapy, speech therapy as well as a physician or nurse. The disciplines will present general stroke information including causes, risk factors, prevention, nutrition and exercise recommendations, importance of managing chronic conditions and the significance of medication compliance. After the verbal education topics are presented, the participants will be tested with the stroke knowledge test (SKT) to measure learning. All the participants will receive a health literacy assessment and based on their scores will be categorized into a high health literacy (HHL) or low health literacy group (LHL) prior to randomization.
223529035|NCT03257501|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
223529036|NCT03639402|BEHAVIORAL|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
223529037|NCT06652490|PROCEDURE|Short-axis/out-of-plane approach versus oblique- axis approach for ultrasound-guided internal jugular venous catheter.|"In the group A, The US probe will be placed perpendicular to the venous anatomy in the SAX approach.~In the group B, The US probe will be aligned at 45° angulation with the venous anatomy, and combined with an in plane needle insertion technique. The needle will be advanced from lateral to medial."
223529038|NCT01498861|DRUG|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
223529039|NCT01498861|DRUG|Dolutegravir|Dolutegravir is an experimental HIV drug
223719378|NCT01125865|DEVICE|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
223719379|NCT01125865|DEVICE|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
223909679|NCT05893940|PROCEDURE|Low Intensity Vibration Therapy|Undergo LIMS vibration therapy
223909680|NCT05893940|PROCEDURE|Dual X-ray Absorptiometry|Undergo DEXA scan
223909681|NCT05893940|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223909682|NCT00780494|DRUG|bevacizumab|Intravenous 15 mg/kg
223909683|NCT00780494|DRUG|carboplatin|AUC 6, Intravenously Day 1 every 21 days
223909684|NCT00780494|DRUG|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
224084583|NCT05429086|DRUG|Propofol|propofol only
224084584|NCT01483430|DRUG|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
224084585|NCT01483430|DRUG|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
224084586|NCT01483430|DRUG|Placebo|1 capsule/day (starch), Duration: 8 weeks
224084587|NCT02658422|DRUG|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
224084588|NCT02658422|DRUG|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
224084589|NCT03609619|DRUG|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
224084590|NCT03609619|DRUG|Placebo|Oral doses of Placebo will be administered twice daily, during the treatment period.
223909685|NCT02154412|OTHER|Respiratory Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) \& an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
223529040|NCT01498861|DRUG|Placebo|Placebo is a tablet with no drug in it
223529041|NCT04701554|OTHER|Qigong program|The intervention group received sixteen sessions lasting one hour with different techniques of diaphragmatic breathing, concentration techniques and exercises with smooth and coordinated musculoskeletal movements. The Qigong program was performed by a therapist with more than 10 years of experience.
223909686|NCT04781855|DRUG|Ibrutinib|Given PO
223909687|NCT04781855|BIOLOGICAL|Ipilimumab|Given IV
223909688|NCT04781855|BIOLOGICAL|Nivolumab|Given IV
223909689|NCT05701982|BEHAVIORAL|Every Step Counts-Tai Chi|The intervention is ESC-TC which is a web-based platform (Every Step Counts) to promote walking combined with pain management content, an online Tai Chi video library, and synchronous Tai Chi classes led by an instructor via teleconference. The intervention is delivered remotely.
223909690|NCT05701982|OTHER|Usual Care|Usual Care
223909691|NCT05037461|RADIATION|High-dose-high precision MR-guided radiotherapy|MR-guided radiotherapy as described in the group information
223909692|NCT06135545|COMBINATION_PRODUCT|Bupivacaine Liposome SAPB|Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
223909693|NCT06135545|COMBINATION_PRODUCT|Traditional TPVB|The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
223909694|NCT04382079|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
223909695|NCT04382079|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
223909696|NCT03899649|DRUG|SOC|Standard of Care treatment
223909697|NCT03899649|DEVICE|NanoKnife System|Irreversible Electroporation
223909698|NCT03500731|BIOLOGICAL|CD3/CD19 negative hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
223909699|NCT03500731|DRUG|Rituximab|Transplantation Conditioning
223909700|NCT03500731|DRUG|Alemtuzumab|Transplantation Conditioning
223909701|NCT03500731|DRUG|Fludarabine|Transplantation Conditioning
223529042|NCT04701554|OTHER|Information on healthy lifestyles, physical exercise and dietary recommendations.|The control group received information on healthy lifestyles, physical exercise and dietary recommendations.
223909702|NCT03500731|DRUG|Thiotepa|Transplantation Conditioning
223909703|NCT03500731|DRUG|G-CSF|Transplantation conditioning
223909704|NCT03500731|DRUG|Hydroxyurea|Transplantation Conditioning
223909705|NCT03298945|DRUG|Miralax-Gatorade Prep|2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
224084591|NCT01567098|PROCEDURE|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
224277385|NCT05140668|DEVICE|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization|Comparison between Supraclavicular And Infraclavicular Approach For Ultrasound-Guided Right Subclavian Venous Catheterization
223529043|NCT01942109|DRUG|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
223529044|NCT01942109|DRUG|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
223529045|NCT03183947|PROCEDURE|fMRI|collection of functional brain data for 1 hour per day
223909706|NCT03298945|DRUG|Golytely|4-L split dose Golytely is the current standard prep at the VA
223909707|NCT05384860|DEVICE|Auricular Trauma Protocol (ATP) Acupuncture|Small filiform (needle) like needles use low frequency electrostimulation at eight ear points for 60 minutes while patient is sedated during surgery. All other aspects of the surgical procedure will go as planned according to the hospital's standard of care.
223909708|NCT05384860|OTHER|No Acupuncture Group|This involves not receiving the acupuncture treatment and surgery going entirely as normal according to the hospital's standard of care.
223529046|NCT03183947|BEHAVIORAL|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 \& 4; controls: Days 2 \& 3)
223529047|NCT03183947|OTHER|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
223529048|NCT03183947|OTHER|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
224084592|NCT01358032|BEHAVIORAL|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) \& 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
223909709|NCT06159842|COMBINATION_PRODUCT|Aminolevulinic Acid 20% Topical Solution with Blue Light|Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.
223909710|NCT06485310|OTHER|Teleconsultation for psychological support|Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
223909711|NCT05707481|OTHER|Clinical Pharmacist-Led Educational Intervention|Non Pharmacological management strategies include information related to life style modification, healthy dietary habits, physical activity and stress management techniques. In contrast, pharmacological educational intervention involves disease -related information ( diabetes/hypertension sign and symptoms, risk factor, complications, self-monitoring of blood pressure/glucose, symptoms and management of hypoglycemia/hypotension etc. ) and drug related information ( prescribed drug name, indication, contraindication, adverse effects etc.) as well as importance of adherence to prescribed medication and strategies to minimize DRPs issues. These teaching sessions will be carried out with the help of verbal communication, audio visual demonstration (including charts,pictorial etc) and information leaflets. Furthermore, a copy of educational package would be given to each participant for reference and guidance.
223909712|NCT04128995|PROCEDURE|Advanced Medical Therapy and Bariatric Surgery|Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
223909713|NCT04128995|DRUG|Advanced Medical Therapy|Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes
223909714|NCT04128995|PROCEDURE|Bariatric Surgery|Vertical Sleeve Gastrectomy for youth without type 2 diabetes
223909715|NCT06822192|DEVICE|temporally interfering electrical stimulation|temporally interfering electrical stimulation
223909716|NCT06822647|PROCEDURE|Cervical Length Measurement at the Beginning of the Anatomy Survey|This intervention involves performing a transvaginal ultrasound to measure cervical length at the beginning of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
223909717|NCT06822647|PROCEDURE|Cervical Length Measurement at the End of the Anatomy Survey|This intervention involves performing a transvaginal ultrasound to measure cervical length at the end of the fetal anatomy survey. The procedure includes using both grayscale and sepia-filtered imaging to evaluate adherence to the nine CLEAR criteria for accurate cervical length assessment.
223909718|NCT06342466|DRUG|Bortezomib|Bortezomib 1.3mg/m2 sc weekly
223909719|NCT06342466|DRUG|Pomalidomide|4mg per day taken orally on 1-21 of repeated 28-day cycles
223909720|NCT06342466|DRUG|Dexamethasone|Dexamethasone 20mg-40mg weekly
223909721|NCT03702270|OTHER|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
223715974|NCT04425694|DEVICE|e-EWS system|The e-EWS system is connected to a physiological monitor, which takes various physiological measurements. The system has an auto-charting module, which automatically captures patients' physiological measurements in an electronic chart (e-chart) and calculates their EWS. All the information in the auto-charting module is then wirelessly transferred to a central display in the ward's nurses station. The central display shows patients' status in terms of EWS and issues alerts when any EWS has exceeded a set threshold. The e-EWS system is not only capable of auto-charting but also provides an alert mechanism to help nurses detect early deterioration.
223715975|NCT04346602|OTHER|all treatment about COVID-2019|All patients with COVID-2019 would receive treatment provided by the government and should comply with relevant laws and regulations.
223715976|NCT00867568|DRUG|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
223909722|NCT02413489|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
223909723|NCT05980533|DIAGNOSTIC_TEST|Ultrasound|Ultrasound at hospital discharge and at follow up at 7-10 days
224084593|NCT04278885|DRUG|Lanadelumab|300mg Lanadelumab s.c. administration every 2 weeks
224084594|NCT01081756|DRUG|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
224084595|NCT01081756|DRUG|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
224084596|NCT04552171|BEHAVIORAL|Access to Game Plan app and 24-hour helpline|Game Plan is a web-based application that helps users reflect on their risk for HIV and level of alcohol use, and if interested, make a plan for reducing their sexual risk or drinking.
224084597|NCT00956943|DRUG|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
224084598|NCT00956943|DRUG|placebo|placebo patch
224084599|NCT02663895|DRUG|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
223909724|NCT06806631|OTHER|Video assisted discharge training|The researchers developed a training content by utilizing various sources and consulting expert opinions. DISCERN (quality criteria for consumer health information) tool was used to evaluate the information quality of the educational content and 5 expert opinions were obtained and the educational content was finalized in line with the suggestions. The training content included the problems that patients may experience in the postoperative period, postoperative interventions (movement, breathing and cough exercises), control times, nutrition, do's and don'ts and other nursing care issues. The content of the training video prepared according to the DISCERN scale was found to be sufficient. The training content was then converted into a video training given by the nurse researcher.
224084600|NCT03057366|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
223909725|NCT05062200|DRUG|JNJ-77242113|JNJ-77242113 will be administered as an oral tablet.
223909726|NCT05062200|DRUG|Placebo|Matching placebo will be administered as an oral tablet.
223909727|NCT04415866|BEHAVIORAL|Paced Auditory Serial Addition task (PASAT)|Single and double digits are presented at intervals between 2 and 3 seconds and the participant must add each new digit to the one immediately prior to it. The participants will be asked to indicate by electronic button press whether the sum of the addition is 13 or not. The duration of the PASAT will be two 12-min tasks.
223909728|NCT06006247|DRUG|CVN424 150 mg|Participants will receive 1 CVN424 tablet (150 mg) per day.
223909729|NCT06006247|DRUG|Placebo|Participants will receive 1 matching placebo tablet per day.
223909730|NCT00492817|PROCEDURE|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
223909731|NCT05333029|BIOLOGICAL|Allogeneic mesenchymal stromal cells (MSCs)|Treatment dose 2 x10\^6 cells/kg (+/- 20%)
223909732|NCT05333029|BIOLOGICAL|Extracorporeal photopheresis (ECP)|Blood is collected through an intravenous (IV) line which is connected to an apheresis machine.The machine adds a chemical that makes the white blood cells sensitive to light. Then the machine shines a light on the cells and then returns the blood to the participant
224084601|NCT03057366|DRUG|[14C]-Pevonedistat|\[14C\]-Pevonedistat intravenous infusion.
224084602|NCT03057366|DRUG|Docetaxel|Docetaxel intravenous infusion.
224084603|NCT03057366|DRUG|Carboplatin|Carboplatin intravenous infusion.
223909733|NCT03501524|DEVICE|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
223909734|NCT03501524|DEVICE|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
224084604|NCT03057366|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
224084605|NCT02911688|DRUG|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
223909735|NCT02812524|DRUG|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
223909736|NCT05259150|BEHAVIORAL|Health for Hearts United Planning for Health|Participants (health leaders) receive trainings (three entitled Take Charge of Your Health, Eat Better, \& Move Around More) and plan for their health ministry and cardiovascular health program to congregants.
223909737|NCT05259150|BEHAVIORAL|Health for Hearts United Preparing for Health|Research participants (church congregants) receive cardiovascular health programming prepared by health leaders that includes the following best practices: Individual Goal Setting, Training, Culturally-tailored Materials, Monitoring Tool \& Recognition.
223909738|NCT05259150|BEHAVIORAL|Health for Hearts United Delivery of Health|The Organization (church) uses best practices to implement Heart Health activities (annual plans, achievements, plans for the year and practices).
223909739|NCT05259150|OTHER|Health for Hearts United Comparison Group Health Ministry Development|Participants (health leaders) have meetings to develop the health ministry. Research participants (church congregants) do not receive cardiovascular health program.
224084606|NCT02911688|DRUG|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
223909740|NCT05191121|BEHAVIORAL|FTP Alone|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins).
223909741|NCT05191121|BEHAVIORAL|FTP+Con-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing conventional parameter FES.
223909742|NCT05191121|BEHAVIORAL|FTP+WPHF-FES|Participants will be challenged with training speed, weight, limited therapist support, and context variation (e.g., fine motor activities will vary using objects such as cards, dice, coins). Muscle groups will be stimulated at the same time they would be activated naturally in a pre-injury movement pattern utilizing wide pulse, high frequency parameter FES.
223909743|NCT06808282|OTHER|White chocolate|To determine the effects of white chocolate consumption on risk factors of cardiovascular diseases
223909744|NCT06808282|OTHER|Dark chocolate|To determine the effects of dark chocolate consumption on risk factors of cardiovascular diseases
223909745|NCT06809257|BEHAVIORAL|Exercise|12 week moderately aerobik exercise
224084607|NCT03820245|DIETARY_SUPPLEMENT|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
224084608|NCT03820245|DIETARY_SUPPLEMENT|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
224084609|NCT03820245|DIETARY_SUPPLEMENT|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
224084610|NCT03820245|DIETARY_SUPPLEMENT|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
224084611|NCT00247104|DRUG|Cranberries - Vaccinium macrocarpon|
224277386|NCT00660868|DRUG|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
224277387|NCT01668823|DRUG|HPPH|Given IV
223909746|NCT06569407|OTHER|Online Educational Intervention|An educational program for EBP based on the online learning model was planned to be developed based on the literature and expert opinions. In the program, in line with the literature, the introduction to the EBP, the importance of EBP, EBP steps, clinical research question design in line with PICO, and introduction of EBP databases. It is planned to include topics such as literature search strategies, types of research, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflection of EBP on patient care and clinical decision-making processes, and it is planned to determine the final version of the education content with expert opinions. The program will include recorded videos, slides and documents for each module. The content of the program will be integrated into the Koç University Online Programs Platform by the experts working at Koç University Educational Technologies Unit.
223909747|NCT06569407|OTHER|Educational Booklet|An educational booklet for EBP was planned to be developed based on the literature and expert opinions. The learning objectives and content of the educational booklet to be developed will be created by considering Bloom\&#39;s taxonomy. In line with the literature, it is planned to include topics such as introduction to EBP, importance of EBP, evidence-based practice steps, clinical research question design in line with PICO, introduction of evidence-based databases, literature search strategies, research types, use of scientific research and evidence evaluation tools, introduction of clinical decision support systems, reflections of EBP on patient care and clinical decision-making processes, and finalization of the booklet topics with expert opinions.
224084612|NCT03964584|OTHER|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
224084613|NCT00191672|DRUG|Gemcitabine|
224084614|NCT00191672|DRUG|Paclitaxel|
224084615|NCT00191672|DRUG|Docetaxel|
224084616|NCT05970107|PROCEDURE|Axillary Lymph Node Dissection|"ALND happens after cancer cells are found during a sentinel lymph node biopsy.~ALND can remove lymph nodes located above, below or directly underneath a muscle that runs along the side of the upper chest."
224084617|NCT05970107|PROCEDURE|Axillary Reverse Mapping|Axillary reverse mapping (ARM) is a technique where blue dye is injected into the upper arm at surgery, allowing direct visualization of arm lymphatics and nodes during ALND
224084618|NCT05970107|PROCEDURE|Lymphaticovenous Bypass|Lymphaticovenous bypass/anastomosis (LVB/LVA) involves supramicrosurgery in which the blocked lymphatic vessel of an affected limb is connected to a nearby vein with the aid of ultra-fine instruments and a powerful operating microscope.
224084619|NCT05529563|PROCEDURE|LSG|LSG
224084620|NCT05636631|DEVICE|Chest ultrasound|chest ultrasound as a non invasive, low cost \& bedside device for differentiation \& follow up of lung congestion \& pneumonia
224084621|NCT05855304|OTHER|manual therapy|The leg length was measured while the subjects were lying on their stomachs. Then, by grasping the lateral malleolus, the knees are bent 90 degrees and changes in leg length were observed, the positions of the SI joints were noted. Afterwards, the person
224084622|NCT05855304|OTHER|Kinesiology taping|As part of the tape (kinesio tex brand) kinesio protocol used in this study, the starting position of the kinesio tape is the site of lumbar spine flexion. Kinesio tape was applied transversely to the bilateral sacroiliac joint area as a long I-shaped piece of tape with 80% tension and no tension was applied to the ends of the tape. Another short tape will be adhered to the SI joint with 80% tension at a right angle to the hip, and no tension is applied to the ends of the tape.
224084623|NCT00237679|BEHAVIORAL|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
224084624|NCT00237679|BEHAVIORAL|Unstimulated|No current is generated.
224084625|NCT02312804|DRUG|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
224084626|NCT02312804|DRUG|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
224084627|NCT02312804|DRUG|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
224084628|NCT01182038|DEVICE|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
224084629|NCT00589641|BEHAVIORAL|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
224084630|NCT00589641|BEHAVIORAL|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
224084631|NCT01749384|BIOLOGICAL|Bevacizumab|Given IV
224084632|NCT01749384|OTHER|Laboratory Biomarker Analysis|Correlative studies
224084633|NCT01749384|OTHER|Pharmacological Study|Correlative studies
224084634|NCT01749384|DRUG|Tivantinib|Given PO
224084635|NCT02155933|OTHER|Blood sampling|Blood sampling for later hormone measurements
224084636|NCT04952623|OTHER|Rotator Cuff Related Shoulder Pain E-Learning Program|The RCRSP e-learning program is designed according to the ADDIE Instructional Design Model in light of current literature.
224084637|NCT02327260|BEHAVIORAL|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
224084638|NCT02327260|BEHAVIORAL|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
224084639|NCT05133830|DRUG|Obeticholic acid|OCA will be administered
224084640|NCT05133830|DRUG|Linerixibat|Linerixibat will be administered
224084641|NCT04548557|BIOLOGICAL|intravenous immunoglobulin therapy|It is passive immunization therapy. Plasma therapy is subjected to moderate to severe patients specially, while all effected individuals can take benefit of immunoglobulin therapy because dose of immunoglobulins can be controlled
224084642|NCT04213404|DRUG|Ribociclib|Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle
224084643|NCT04213404|DRUG|Spartalizumab|Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
224084644|NCT01486576|DRUG|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
224084645|NCT01486576|DRUG|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
223909748|NCT06809465|DIETARY_SUPPLEMENT|Bactopral®|Oral Probiotic Bifidobacterium bifidum PRL2010 supplement
223909749|NCT06809465|OTHER|Plcebo|Oral placebo
224084646|NCT05072444|DRUG|QPX7728|beta lactamase inhibitor
224084647|NCT05072444|DRUG|QPX2014|antibiotic
223909750|NCT06256939|OTHER|Therapy BRIDGE Program|A standardized education and coaching intervention will be developed to promote optimal neurodevelopmental outcomes through caregiver empowerment. This pilot study will enroll up to 15 infants with IVH and their caregivers during their NICU stay. These infant-caregiver dyads will receive up to 10 sessions utilizing the Therapy BRIDGE program over a four-month period that spans the hospital to home transition.
223909751|NCT06808295|DRUG|Dexmedetomidine Hydrochloride|drug will be given before induction and anesthetic doses and hemodynamics will be assessed pre- intra and postoperative
223909752|NCT06809413|DRUG|Sitafloxacin|Study medication: Sitafloxacin 100mg QD for 14 days.
223909753|NCT04958486|DRUG|5-Azacytidine and trastuzumab infusion|Patients will receive once weekly 10 mg intraventricular 5-Azacytidine infusions for six consecutive weeks followed by observation in the infusion suite for a minimum of 30 minutes and once weekly 21 mg intraventricular trastuzumab infusions for six consecutive weeks followed by observation for a minimum of 2 hour after each infusion for the first 2 infusions. During this monitoring period, temperature, blood pressure, heart rate, and oxygen saturation will be measured. Patients will also have a neurological examination performed to observe for neurological changes. All patients will undergo an MRI of the brain and total spine with and without gadolinium within 7 days after the final 5-AZA and trastuzumab infusion to determine treatment response and to assess for any signal changes in the brain or spine caused by the infusions and they will have a 30 day and a 90 day follow-up assessment by telephone or in person for assessment of outcome measures and safety
224084648|NCT04523974|PROCEDURE|Preemptive Surgical Intervention and Precise Efficacy Evaluation of CKD-SHPT|"1. Preemptive surgical intervention for CKD-SHPT patients with poor calcium and phosphorus metabolism controlled by drugs;~2. Rapid immunoreactive parathyroid hormone detection technology during peri-operative period."
224084649|NCT03757884|BEHAVIORAL|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
224084650|NCT03757884|BEHAVIORAL|Diagnostic Checklist|Checklist reminder for diagnosis
224084651|NCT03757884|BEHAVIORAL|Noise cancelling headphones|Noise cancelling headphones
224084652|NCT03757884|BEHAVIORAL|Privacy tablescreen|Privacy Tablescreen
224084653|NCT03757884|BEHAVIORAL|Diagnostic assistance application|Diagnostic assistance application
223715977|NCT02923934|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
223909754|NCT06432400|OTHER|Patient questionnaires|Patients questionnaires, on paper and data collection on patients medical file
223909755|NCT05644717|DRUG|Ertugliflozin 5 mg, 15mg|Ertugliflozin 5/15mg once daily in addition to standard of care
223909756|NCT00282516|PROCEDURE|In-home telemonitoring of pediatric patients with persistent asthma|
223909757|NCT05373758|OTHER|Standard of Care treatment strategy|Management of virologic failure on TLD using the Standard of Care strategy
223909758|NCT05373758|OTHER|Individualized Care treatment strategy|Management of virologic failure on TLD using the Individualized Care strategy
223909759|NCT05373758|OTHER|Immediate Switch|Management of virologic failure on TLD using the Immediate Switch strategy
223909760|NCT02575950|DRUG|LEO43204|
223909761|NCT02575950|DRUG|Placebo|
223909762|NCT06853535|DRUG|The ticagrelor|Ticagrelor 90mg should be taken as soon as possible. From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with ticagrelor 90mg twice a day (bid) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given ticagrelor 90mg bid for anti - platelet treatment.
224084654|NCT01734876|BEHAVIORAL|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
224084655|NCT01734876|BEHAVIORAL|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
224277388|NCT01668823|DRUG|photodynamic therapy|Undergo photodynamic therapy with HPPH
224084656|NCT01424592|DEVICE|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
224084657|NCT02151344|BIOLOGICAL|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
224084658|NCT02151344|BIOLOGICAL|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
224277389|NCT01668823|PROCEDURE|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
224277390|NCT02844010|OTHER|weighing|
224277391|NCT02959008|DEVICE|measure TOI and BP|Both groups measure TOI and BP.
224277392|NCT03624855|OTHER|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
224277393|NCT00223938|DRUG|Oral Iron|Oral Iron
224277394|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 1
224277395|NCT00223938|DRUG|sodium ferric gluconate|weekly intravenous injection Dose 2
223529049|NCT03183947|OTHER|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
223529050|NCT05715827|DEVICE|RAS prostatectomy and RAS cholecystectomy|"There are two types of interventions in the study.~Patients indicated for Robotic Assisted Surgery (RAS) for a prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.~Patients indicated for Robotic Assisted Surgery (RAS) for a cholecystectomy will have the RAS surgery using the Medtronic Hugo RAS system."
223909763|NCT06853535|DRUG|The Clopidogrel|From the 2nd to the 21st day, the patient should receive dual anti - platelet therapy with clopidogrel 75mg once a day (qd) combined with aspirin 100mg once a day (qd). From the 22nd to the 90th day, the patient should be given clopidogrel 75mg qd for anti - platelet treatment.
223909764|NCT06853821|OTHER|Comfort Theory Based Care|In the research, this group includes care-based intervention
223909765|NCT06853821|OTHER|Virtual Reality Glasses|In the research, this group includes interventions with virtual reality glasses.
223909766|NCT06853379|BEHAVIORAL|dietary recommendations|. receive dietary recommendations or nonspecific dietary advices such as reducing fluid intake after 6 p.m. The list of dietary advices have been made reviewing literature and consisted in a list of recommended food, not recommended food at evening and not recommended food
223909767|NCT06853379|OTHER|aroma therapy|the case receive aroma therapy
223909768|NCT06855446|BEHAVIORAL|Intervention with social robot NAO|12 session of 30 minutes, one sessione per week with social robot NAO and a therapist, working on social intransitive gestures
223909769|NCT06855446|BEHAVIORAL|Treatment as usual|Psychomotor/behavioral or speech therapy as usual
223909770|NCT06854003|DRUG|Bendamustine|An Alkylating agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard of care.
223909771|NCT06854003|DRUG|Rituximab|An Anti-CD20 antibody, single-use vials, via intravenous infusion per institutional standard of care.
223909772|NCT06854003|DRUG|Cytarabine|An Antineoplastic, single dose vial via intravenous infusion per institutional standard of care.
223909773|NCT06854003|DRUG|Zanubrutinib|A BTK inhibitor, capsule taken orally per protocol.
223909774|NCT06854003|DRUG|Sonrotoclax|A BCL 2 Protein Inhibitor, immediate release tablet, taken orally per protocol.
223909775|NCT06854510|DRUG|Gargle with 2.5% sodium bicarbonate solution during radiotherapy|"In addition to routine oral care, patients received sodium bicarbonate solution gargle therapy from the initiation of radiotherapy until its completion. The treatment protocol is as follows:~For patients with oral mucositis of grade 0 - 1, gargle with a 2.5% sodium bicarbonate solution (for 1 - 2 minutes each time) three times a day and spit out the liquid after each gargle. For patients with oral mucositis of grade ≥ 2, gargle with a 2.5% sodium bicarbonate solution (for 1 - 2 minutes each time) four to five times a day and spit out the liquid after each gargle."
223909776|NCT06854510|DRUG|Gargle with 0.9% sodium chloride solution during radiotherapy|In addition to routine oral care, patients received 0.9% sodium chloride solution gargle therapy from the initiation of radiotherapy until its completion. The treatment protocol is as follows: For patients with oral mucositis of grade 0 - 1, gargle with a 0.9% sodium chloride solution (for 1 - 2 minutes each time) three times a day and spit out the liquid after each gargle. For patients with oral mucositis of grade ≥ 2, gargle with a 0.9% sodium chloride solution (for 1 - 2 minutes each time) four to five times a day and spit out the liquid after each gargle.
223909777|NCT06223139|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
223909778|NCT06811428|DEVICE|A novel device for immobilization of babies undergoing upright LP, the present working name (non-proprietary) for the device is LP Comfort Seat (LPCS)|The participant will be placed in the LPCS for their lumbar puncture procedure
223909779|NCT06811428|OTHER|Standard of Care (SOC)|The patient will be held in the upright position by a human assistant
223909780|NCT06853691|OTHER|glasses-free 3D visual training|"Trail group Conduct 15 minutes of naked-eye 3D vision training. Twice a day, five days a week.~Control groups The subjects watched ordinary 2D videos for 15 minutes each time, all under the same lighting conditions. This was done twice a day, five days a week."
224084659|NCT05136274|DRUG|Medical treatment|The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
224084660|NCT02653950|PROCEDURE|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
224277396|NCT01873339|DRUG|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
223529051|NCT06159309|OTHER|Hyperbaric oxygen therapy|HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
224277397|NCT01873339|DRUG|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
224277398|NCT00673764|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
224277399|NCT00673764|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
224277400|NCT03745417|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
224277401|NCT01636934|DRUG|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
224277402|NCT01636934|OTHER|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
223529052|NCT06640764|PROCEDURE|Total Hip Arthroplasty|Total Hip Arthroplasty with SMS Femoral Stem (Medacta)
223529053|NCT05481697|DIAGNOSTIC_TEST|GRAIL Galleri|A blood test that aims to detect cancers earlier by looking for abnormal DNA shed from cancer cells into the blood.
223529054|NCT06601179|DEVICE|HIFU|high-intensity focused ultrasound treatment of benign prostatic hyperplasia
223529055|NCT03632044|DRUG|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
223529056|NCT03632044|OTHER|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
223909781|NCT06804915|BEHAVIORAL|simulation|"Each team of physician and nurses will participate in 4 scenarios: 2 adult, 2 pediatric. In each scenario, physician and nurses will have a clinical description of the scenario with the age and weight of each patient.~The simulations will be conducted at the clinical simulation laboratory at Jean-Marc Lepage Pavilion of the University of Sherbrooke using high-fidelity mannequins. SimMan 3GPus will be used for adult scenarios and SimJunior for pediatric scenarios, both from Laerdal company. Participants will receive a briefing containing key information about the scenario and the patient just before starting the simulation.~During the scenarios, the physician is expected to prescribe medications by mentioning the name, the dose and the route of administration of every medication. Moreover, if multiple dilution for a medication is possible, the physician is expected to mention the desired dilution."
223909782|NCT06810856|DEVICE|Abilar® Resin Salve|Abilar® Resin Salve is a medical-grade Norway spruce (Picea abies) resin-based topical medical device, classified as a Class IIb medical device in the EU. It is designed for wound care and skin protection, forming a moist healing barrier while exhibiting antimicrobial properties. It contains 10% of medical-grade Picea abies resin.
223909783|NCT06814964|DRUG|Low dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.009 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
223909784|NCT06814964|DRUG|Medium dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.018 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
223909785|NCT06814964|DRUG|High dose group|The calculated injection amount of tenecteplase (tenecteplase injection amount = volume of intraventricular hematoma × 0.027 mg/ml) was diluted to 1ml with sterile injection water, and administered via the EVD.
223909786|NCT06598618|OTHER|Graston technique+ Conventional PT|IASTM technique (graston technique) on iliotibial band. Frequency 2 sessions of stroking with 20 seconds rest in between 3 times/week for 3 consecutive weeks Intensity as tolerated by patient. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps
223909787|NCT06598618|OTHER|Muscle energy technique + Conventional PT|Muscle energy technique (post facilitation stretch) on iliotibial band. Frequency 10 repetitions 3 times/week for 3 consecutive weeks Intensity starting from 50 percent resistance across barrier provided by physiotherapist.. Conventional PT including 1- Therapeutic ultrasound at frequency of 3.5 MHZ for 10 minutes. 2- Stretching exercise of hamstrings. 3-Isometric exercises of Quadriceps.
223909788|NCT04527445|PROCEDURE|Reduced radiation fluoroscopy|See previous information about each arm
223909789|NCT04527445|PROCEDURE|Conventional fluoroscopy|See previous information about each arm
223909790|NCT06813859|OTHER|exercise testing|incremental cycling test on a bicycle ergometer
223909791|NCT06808386|OTHER|Strengthening 2 times per week|This group will consist of participants with patellofemoral pain and will receive treatment twice a week.
223909792|NCT06808386|OTHER|Strengthening 3 times per week|This group will consist of participants with patellofemoral pain and will receive treatment thrice a week.
223909793|NCT06807736|DRUG|Cabotegravir long-acting|3ml intramuscular injection containing 600mg of Cabotegravir
223909794|NCT06807736|DRUG|Tenofovir emtricitabine|Oral tablet taken daily to PrEP HIV infection.
223909795|NCT06807736|DRUG|Dapivirine containing vaginal ring|Intra-vaginal silicone ring containing slow-release Dapivirine, replaced every 28 days
223909796|NCT06814652|DRUG|Trodon® Hemofarm|Consent was taken from each patient prior to the enrollment into the study during the first interview and 2 ml of blood was withdrawal for the CYP2D6 genotyping. After the cesarean section surgery, each patient received one dose of 100mg/2ml Trodon® Hemofarm for treating the postpartum pain and the patients were monitored for 24 hours. Follow-up was performed for each enrolled patient in which the VAS score, blood pressure, heart rate, oxygen saturation and any new effects after 1 hour, 6 hours of tramadol administration were recorded. In addition, after 24 hours evaluations for nocturnal pain, dietary state and bowel movement were performed.
223909797|NCT04564183|OTHER|Sample collection|Blood, Urine, Nail, Hair, Saliva, optional Stool
223909798|NCT04564183|OTHER|Questionnaires|SF-36, Food Frequency, Pulmonary Fibrosis Study questionnaire, COVID questionnaire
223909799|NCT04564183|RADIATION|High resolution CT scan of the chest|Upon enrollment, all participants will undergo single prone volumetric thoracic chest CT scan. This will be performed at full inspiration using a 64-slice CT scanner.
223909800|NCT04564183|DIAGNOSTIC_TEST|Pulmonary Function Test|All recruited participants will undergo a pre-bronchodilator spirometry test and a lung diffusion capacity test, both in accordance with ATS guidelines. Exercise capacity (maximum physical exertion) will be assessed by performing a 6-minute walk test, also according to ATS guidelines.
223909801|NCT06174181|DEVICE|Preservative-free ophtalmic lubricant emulsion|Use of a preservative-free ophtalmic lubricant emulsion continous during 6 months
223909802|NCT06174181|OTHER|Routine treatment|Use of a preservative-free ophtalmic lubricant emulsion after each intravitreal injection during few days
223909803|NCT06657079|DRUG|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days|combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
223909804|NCT06657079|DRUG|Placebo|Saline inhaler
223909805|NCT06807840|OTHER|influenza virus infection|Participants with active influenza virus infection will be enrolled in this study.
223909806|NCT04271046|BEHAVIORAL|STAR-C-VTF|"1. One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study and to acquaint the caregiver with the STAR-VTF components of good dementia care; distribute printed educational material (and links to same material online);~2. Six 30-minute follow-up phone calls with the caregiver following each of the 6 learning modules to review STAR-VTF concepts, and further brainstorm strategies to modify identified activators and consequences with the objective of reducing behavioral symptoms;~3. secure message support, as needed, with the coach to help with personalizing the STAR-VTF curriculum for up to 6 months."
224084661|NCT02653950|PROCEDURE|Traditional septoplasty|septoplasty under direct vision
224084662|NCT04261530|BEHAVIORAL|Self-hypnosis/self-care|
223909807|NCT04271046|BEHAVIORAL|Control|"One 60 minute baseline orientation phone visit with a coach to get verbal consent for participation in the study. Controls will receive usual care from their primary care provider and/or psychiatrist. We will give participants an information package from the Alzheimer's Association including a list of resources. To assist with retention, and to measure responses to secure messages, we will send a template secure message to control dyads once per month in which we remind participants to contact their primary care provider if they have any issues with behavioral and psychological symptoms of dementia. Dyads in the attention control may receive information and training from their primary care provider and the Alzheimer's Association. This attention control is proposed to assess the additional impact of STAR-VTF above treatment as usual. Investigators do not intend to track non-study training receipt in the control arm."
223909808|NCT06807905|DRUG|Heparin anticoagulation|Hemodiafiltration will be performed with heparine anticoagulation
223909809|NCT06807905|DRUG|Citrate anticoagulation|Patient will perform dialysis with citrate anticoagulation
223909810|NCT06548958|PROCEDURE|Second Stem Cell Transplantation (SCT2)|"1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion;~2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
223909811|NCT06651762|PROCEDURE|unilateral Radiofrequency|unilateral genicular nerve cooled radio frequency ablation pre-operative
223909812|NCT06651762|PROCEDURE|bilateral Radiofrequency|bilateral genicular nerve cooled radio frequency ablation pre-operative
223909813|NCT06651762|PROCEDURE|Epidural|Patients will receive epidural anesthesia intra operative and epidural analgesia post-operative
223909814|NCT06814106|DRUG|Enlicitide Chloride|Oral Capsule
223909815|NCT06814106|DRUG|Placebo|Placebo oral capsule matching enlicitide chloride
223909816|NCT03899428|DRUG|Durvalumab|Durvalumab 1500 mg IV (intravenous infusion)
223909817|NCT03899428|DRUG|Sorafenib|Prescribed by physician.
223909818|NCT03899428|DRUG|Lenvatinib|Prescribed by physician.
223909819|NCT03899428|DRUG|Regorafenib|Prescribed by physician.
223909820|NCT03899428|DRUG|Cabozantinib|Prescribed by physician.
223909821|NCT06814366|OTHER|music and white noise intervention|The experimental groups were played a combination of music and white noise through headphones that blocked ambient noise during the surgical procedure. A playlist consisting of the popular songs of the era was prepared in advance. The patient could choose the music they wanted to listen to from the playlist using a hand-held tablet.
223909822|NCT06814366|OTHER|music intervention|The experimental groups were played music a through headphones that blocked ambient noise during the surgical procedure. A playlist consisting of the popular songs of the era was prepared in advance. The patient could choose the music they wanted to listen to from the playlist using a hand-held tablet.
223909823|NCT06817759|DEVICE|Virtual Reality Hypnosis|An intervention program (VRH) that combines VR and hypnosis; Can use it whenever and how much they want. It contains 200 landscapes in VR and 4 different VRH sessions
223909824|NCT06817759|DEVICE|VRH : Beach|Hypnosis session with a VR immersion at the beach; one accompanied session
223909825|NCT06817759|DEVICE|VRH : Forest|Hypnosis session with a VR immersion in forests; one accompanied session
223909826|NCT06817759|DEVICE|VRH : MagicHand|Hypnosis session with a VR immersion with techniques to reduce pain; one accompanied session
223909827|NCT06817759|DEVICE|VRH : SecurityProtection|Hypnosis session with a VR immersion with techniques to reduce anxiety; one accompanied session
223529057|NCT04950439|OTHER|Collect blood sample|A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
223529058|NCT03814044|DEVICE|PEEK Suture Anchors|"Subjects who have undergone hip joint repair using PEEK Suture Anchors:~BIORAPTOR™ Knotless Suture Anchor and SpeedLock Hip Suture Anchor"
223909828|NCT06821295|OTHER|Smart-T Alcohol|The Smart-T Alcohol intervention offers on-demand content and automated contextually tailored messages to reduce alcohol consumption. The intervention period will span eight-weeks (i.e., weeks 2-9), with follow-up assessments occurring at weeks 9, 13, and 26. All participants will complete brief daily smartphone-based surveys for 13 weeks.
223909829|NCT06821295|OTHER|Usual Care|Participants will receive standard shelter-based treatment (Usual Care) along with completing surveys and assessments.
223909830|NCT06677918|DRUG|EP395|Capsule for oral use
223909831|NCT06677918|DRUG|Placebo|Capsule for oral use
223909832|NCT06839664|DRUG|HS-20094 injection|Administered SC
223909833|NCT06839664|DRUG|Placebo injection|Administered SC
223909834|NCT04491617|OTHER|Standard opioid prescribing|Patients are routinely prescribed opioid medications in addition to non-opioids.
223909835|NCT04491617|OTHER|Restrictive opioid prescribing|Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
223909836|NCT04707469|DRUG|Oral semaglutide|Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
223909837|NCT06504836|OTHER|Gait training with biofeedback|Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
223909838|NCT06504836|OTHER|Gait training without biofeedback|Gait training include treadmill and overground walking.
224084663|NCT04261530|BEHAVIORAL|Music/self-care|
224084664|NCT04261530|BEHAVIORAL|Self-care|
224084665|NCT04261530|BEHAVIORAL|Psycho-education|
224084666|NCT02131857|BEHAVIORAL|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
224084667|NCT02457234|BEHAVIORAL|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
224084668|NCT04222829|PROCEDURE|Megadose Shinbaro Pharmacopuncture|"Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints.~Shinbaro is a refined herbal formulation used to treat inflamed lesions and bone diseases."
224084669|NCT05184907|BEHAVIORAL|Remote Motivational Enhancement (RME) Intervention Arm|Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing within 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
223909839|NCT04904146|DIAGNOSTIC_TEST|Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.|The study aims to perform systematic translational sampling of each patient from study start until end-of-study, or at longest for a three year period for each patient. Treatment will be performed according to clinical routine.
223909840|NCT05724433|OTHER|Virtual HF Care|Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
223909841|NCT05724433|OTHER|Routine HF Care|Care as determined by the treating physician
223909842|NCT04487860|DRUG|AS012|oral administration
223909843|NCT04487860|DRUG|Placebo|oral administration
223909844|NCT03627728|DRUG|Regorafenib|regorafenib/placebo
223909845|NCT03627728|OTHER|placebo|regorafenib/placebo
223909846|NCT06850194|PROCEDURE|vertical ramus osteotomy with iliac graft|in the VRO group all patient will undergo vertical ramus osteotomy surgery with iliac graft to correct the sever mandibular defficiency
223909847|NCT06850194|PROCEDURE|bilateral sagittal splitting osteotomy|all patients in this group will undergo to bilateral sagittal split osteotomy to correct the sever mandibular deficiency
223909848|NCT06850948|OTHER|Qualitative|Interviews collected with participants concerning their experience of gender identity healthcare
223909849|NCT06231706|OTHER|Prebiotic-like nut and seed mix|A mixture of nuts, seeds and other plant based ingredients.
223909850|NCT06231706|OTHER|Bread Crouton|A commercially available bread crouton product.
223909851|NCT06231706|DIETARY_SUPPLEMENT|Probiotic capsule|Contains the single strain Lactobacillus rhamnosus GG at 15 billion CFUs per capsule.
223909852|NCT06231706|OTHER|White bread and low fat spread|Consists of 3 slices of bread (providing approx. 55-60g CHO; 3g fibre) + low fat spread (10-15g)
223909853|NCT05338268|BEHAVIORAL|CBT for Loneliness|CBT delivered over the course of 8, \~45 minute sessions delivered via telehealth.
223909854|NCT05338268|BEHAVIORAL|Health Education|Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
223909855|NCT03079921|DRUG|Phentolamine|Physiologic receptor blockade (α1-receptor).
223909856|NCT03079921|DRUG|Propranolol|Physiologic receptor blockade (β2-receptor).
223909857|NCT03079921|DRUG|Placebo|100mL bag of Normal Saline Solution (NSS).
223909858|NCT02482337|PROCEDURE|POEM|POEM procedure in the OR
223909859|NCT05218096|DRUG|ALXN2050|Oral tablet.
223909860|NCT05218096|DRUG|Placebo|Oral tablet.
223909861|NCT04738591|DEVICE|DIABE-TEXT|Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
223909862|NCT03768960|DRUG|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
223909863|NCT05362435|BEHAVIORAL|Physical activity-based wellness programs|Each MKS+ program has 20-25 participants and consists of the following: 12 Week INTENSE PHASE: 1) pre-program information and orientation session, and data collection/testing; 2) core weekly programming with the following three components: a) 45-60 minute exercise class, b) 15-20 minute nutrition and wellness education, and c) 15-30 minute sharing circle; 3) end of program celebration; 4) urban poling sessions; 5) introduction to local healthcare providers as identified as relevant for the group; 6) ongoing online support via private Facebook group; 7) daily pedometer tracking to provide immediate motivational feedback to participants. 6-12 Week FOLLOW-UP PHASE: 1) Program Facilitator contacts participants weekly to encourage healthy activities, address concerns as needed, and record weekly step counts; 2) encourages continued engagement in private Facebook group; 3) 15-30 minute nutrition and wellness education, and c) 15-45 minute sharing circle.
223909864|NCT06683391|BEHAVIORAL|Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment|The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.
224277403|NCT01636934|BEHAVIORAL|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
224277404|NCT01011335|BIOLOGICAL|Monovalent rAT|10, 25, 50 or 100 μg
224277405|NCT01011335|BIOLOGICAL|Monovalent rLukS-PV|10, 25, 50 or 100 μg
224277406|NCT01011335|BIOLOGICAL|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
224277407|NCT01011335|BIOLOGICAL|Placebo with adjuvant|Placebo with adjuvant
224277408|NCT01011335|BIOLOGICAL|Placebo|Placebo saline
224277409|NCT04667936|OTHER|Treatment group|None, solely treatment documentation
224277410|NCT02688296|DEVICE|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
223529059|NCT06671210|DEVICE|Urine and vaginal swab self-control|Each participant provided urine and vaginal swabs for HPV testing.
223529060|NCT06520553|DRUG|BI 1569912 (C-14)|unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
223529061|NCT06520553|DRUG|BI 1569912 (C-13)|\[13C\]- labelled BI 1569912
223529062|NCT06673823|DEVICE|Mirror therapy|Mirror Therapy (MT) is a non-invasive treatment method aimed at addressing unilateral conditions impacting either the upper or lower limbs. This technique involves placing a mirror along the patient's sagittal plane, allowing the reflection of the unaffected limb to visually overlay the affected limb.
223529063|NCT06673823|OTHER|conventional therapy|conventional therapy
223909865|NCT04601064|BEHAVIORAL|Collaborative Care Model|Collaborative care (CC) is an evidence-based model of integrated mental health and substance use disorder care endorsed by the American Psychiatric Association for the integration of mental health and substance use disorder care into primary care settings. CC includes the following components: 1) A collaborative care team of multidisciplinary health care providers consisting of the primary physician, a care manager and a consulting psychiatrist, providing care in a coordinated fashion; 2) A population focus with the team working together to provide care and continuously measure and track health outcomes of a defined population of patients; 3) A measurement-guided approach with systematic use of disease specific patient reported outcome measures, such as symptom rating scales like the PHQ-9 to drive clinical decision making; and 4) Evidence-based practices with the team adapting scientifically proven treatments within an individual clinical context to achieve improved health outcomes.
223909866|NCT06089837|DRUG|EC5026 oral tablet|"2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)"
223909867|NCT06089837|DRUG|Placebo oral tablet|2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
223909868|NCT05269966|BIOLOGICAL|Injection Brolucizumab|"Single-chain antibody fragment (scFv)~Brolucizumab 6 mg was administered by Intravitreal (IVT) injection as per the Prescribing information (PI) and in line with the treating physician's clinical judgement. Patients received loading doses of brolucizumab at Day 0/Visit 1, Week 4/Visit 2 and Week 8/Visit 3. After the loading doses, at Week 16, disease activity assessment (DAA) were performed based on Best Corrected Visual Acuity (BCVA) and Optical Coherence Tomography (OCT) to assess whether the patient required q8w or q12w dosing."
223909869|NCT05193409|DRUG|225 mg BNC210|225 mg BNC210
223909870|NCT05193409|DRUG|675 mg BNC210|675 mg BNC210
223529064|NCT06675786|DEVICE|I.V. House UltraDressing|I.V. House UltraDressing (I.V. House, Inc., St. Louis, MO, USA) will be applied according to the manufacturer's instructions and secured with an anti-slip tape without the need for further taping. It is intended to prevent complications such as catheter-related displacement, phlebitis, infiltration, extravasation, catheter occlusion, and folding of PVCs.
223529065|NCT06675292|OTHER|Survey-based study|The demographic information of individuals with tension-type headaches, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
223529066|NCT06675656|OTHER|DNA extraction from urine, stool and biopsy. Isolation of serum and PBMC from peripheral blood.|DNA extraction from urine, stool and biopsy for microbiome analysis. Isolation of peripheral blood mononuclear cells from peripheral blood for immunophenotypic analysis, and isolation of serum for analysis of cytokines and bacterial metabolites.
223529067|NCT06674564|DIETARY_SUPPLEMENT|Zinc Acetate 50 Mg Oral Capsule|zinc suppose to improve immunity and wound healing after laryngectomy
223529068|NCT06674564|DIETARY_SUPPLEMENT|Probiotic|probiotics lowering infections rates and improving outcomes after surgery
223909871|NCT05193409|DRUG|Placebo|Placebo
223909872|NCT05916495|OTHER|Hybrid care arm|Patients will be evaluated at 3 months via a remote review. This will review the patients-recorded spirometry and a questionnaire developed for this study which asses the patients' symptom burden and medication adherence. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
223909873|NCT05916495|OTHER|Standard of care arm|Patients will be reviewed in clinic at 3 months per the standard of care. All patients participating in the study will be offered remote monitoring (patient facing app+ patient recorded home spirometry).
224084670|NCT05184907|OTHER|Information Only|Participants randomized to the information-only arm will have their CAT-MH, BAM, and PSS screening report results sent to their primary B/N prescriber and will encouraged to set up an appointment with their prescriber within 14 days to discuss the results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
223529069|NCT06675422|DRUG|JY231 injection|Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.
223529070|NCT06673992|OTHER|This study does not involve any interventions|This study does not involve any interventions
223529071|NCT07000331|OTHER|Thoracic expansion exercises|Individuals placed their hands on their lower ribs and then took 3 deep breaths under their hands in a row. After this cycle, individuals rested by taking 3-4 calm breaths. The cycle was repeated 10 times. The individual did this session 4 times a day.
223529072|NCT07000331|OTHER|Physical activity counseling|Individuals were given weekly group phone calls and meetings. Individuals were gradually accustomed to regular walking to increase their daily step count. In the first week, individuals were asked to walk a total of 30-45 minutes per day, at least 4-5 days per week, and to increase the number of steps measured at the beginning by approximately 1000-2000 steps per day to reach at least 6500 steps. In the second week, the expected goal was at least 7500 steps. In the third and fourth weeks, they were asked to reach at least 10000 steps.
223529073|NCT07004647|DRUG|Fludarabine|D-10 to D-2: Fludarabine (25 mg/m2/day) will be administered intravenously for 3 days;D-10 to D-2: Cyclophosphamide (250 mg/m2/day) will be administered intravenously for 3 days.
223909874|NCT05374018|DIAGNOSTIC_TEST|urinary kit for pneumococcus antigen assay|urine test for detection of pneumococcus antigen
223909875|NCT06222502|OTHER|Planning, Reminders, and Micro-Incentives|Participants will schedule planned walks during weekly phone calls with study staff. Participants will receive reminders for planned walks and receive micro-incentives after completion.
224084671|NCT02235506|PROCEDURE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
224084672|NCT02235506|PROCEDURE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
224084673|NCT02235506|DEVICE|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
224084674|NCT02235506|DEVICE|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
224084675|NCT02103686|DRUG|Lyrica|
224084676|NCT02103686|DRUG|Experimental drug|sustained release formulation of pregabalin
223909876|NCT06222502|OTHER|Health Education|"Participants in this group will receive health education tips during weekly phone calls with study staff."
224084677|NCT02103686|DIETARY_SUPPLEMENT|High fat meal|
224084678|NCT02103686|DIETARY_SUPPLEMENT|fasted|
224084679|NCT02201758|DIETARY_SUPPLEMENT|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
223909877|NCT00957684|DRUG|eslicarbazepine acetate|once-daily oral tablet
224084680|NCT02201758|OTHER|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
224084681|NCT04974788|OTHER|Low Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 30% (low intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
224084682|NCT04974788|OTHER|Medium Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 60% (medium intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
224084683|NCT04974788|OTHER|High Intensity Respiratory Muscle Training|Respiratory muscle training will be performed at 80% (high intensity) of the maximum inspiratory pressure, which indicates respiratory muscle strength. The training will consist of 2 sessions in total; Each session will last 15 minutes. There will be a break of at least 30 minutes between training sessions.
224084684|NCT05121402|DRUG|TLL018|a TYK2/JAK1 inhibitor
224084685|NCT05121402|OTHER|Placebo|a TLL018 Placebo
224084686|NCT00430118|DRUG|asparaginase|
224084687|NCT00430118|DRUG|cyclophosphamide|
224084688|NCT00430118|DRUG|cytarabine|
224084689|NCT00430118|DRUG|daunorubicin hydrochloride|
224084690|NCT00430118|DRUG|dexamethasone|
224084691|NCT00430118|DRUG|doxorubicin hydrochloride|
224084692|NCT00430118|DRUG|etoposide|
224084693|NCT00430118|DRUG|ifosfamide|
223529074|NCT07004049|DRUG|Colistin/Polymyxin B + Sulbactam|For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand and Singapore
223529075|NCT07004049|DRUG|Colistin/Polymyxin B + Tigecycline/Eravacycline|For carbapenem-resistant Acintobacter, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand and Singapore
223909878|NCT00957684|DRUG|placebo|once daily placebo comparator
223909879|NCT04662619|OTHER|B. infantis|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU), will be provided to infants once daily for 12 weeks."
223909880|NCT04662619|OTHER|Lactose Placebo|Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.
223909881|NCT04821141|DRUG|Bazedoxifene and Conjugated Estrogens|BZA (20 mg) plus CE (0.45 mg) taken together once daily
223909882|NCT06156072|DIAGNOSTIC_TEST|Ultrasound-guided venipuncture|Venipuncture will be performed using ultrasound to identify the most appropriate vessel and guide the puncture
223909883|NCT05309616|DRUG|Taltz|Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
223909884|NCT04734080|DRUG|Dronabinol 5mg Cap|Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.
223909885|NCT04734080|OTHER|Placebo oral tablet|Non-active placebo
223909886|NCT06233253|OTHER|Best Practice|Receive usual care
223909887|NCT06233253|OTHER|Medical Chart Review|Ancillary studies
223909888|NCT06233253|BEHAVIORAL|Online Mindfulness Meditation|Receive an online mindfulness intervention
223909889|NCT06233253|OTHER|Survey Administration|Ancillary studies
224084694|NCT00430118|DRUG|mercaptopurine|
224084695|NCT00430118|DRUG|methotrexate|
224084696|NCT00430118|DRUG|prednisone|
224084697|NCT00430118|DRUG|thioguanine|
224084698|NCT00430118|DRUG|vincristine sulfate|
224084699|NCT00430118|DRUG|vindesine|
224084700|NCT00430118|RADIATION|radiation therapy|
224084701|NCT04022486|OTHER|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
224084702|NCT02285400|PROCEDURE|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
224084703|NCT03285815|DEVICE|Proton Therapy|
224084704|NCT03045003|BEHAVIORAL|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
224084705|NCT04584177|BEHAVIORAL|Arm-hand BOOST program|The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
223909890|NCT04661397|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.
223909891|NCT04661397|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.
223909892|NCT04661397|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.
223909893|NCT04661397|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.
223909894|NCT05739955|OTHER|Sani24|24-hour continuously acting quaternary ammonium salt disinfectant
223909895|NCT05739955|OTHER|Standard EPA-registered disinfectant|Standard EPA-registered disinfectant
224084706|NCT04584177|BEHAVIORAL|Control program|A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
224084707|NCT05130177|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.
224084708|NCT05130177|DRUG|Domvanalimab|Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
224084709|NCT00770055|OTHER|medical chart review|
224084710|NCT00770055|OTHER|questionnaire administration|
224084711|NCT00770055|OTHER|survey administration|
224084712|NCT00770055|PROCEDURE|psychosocial assessment and care|
224277411|NCT03701711|DRUG|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 8 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
223909896|NCT05739955|OTHER|Routine Disinfection|Routine disinfection at the study hospital
223909897|NCT06451627|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) will be infused at a speed of 0.3mg / kg / h during surgery .
223909898|NCT06451627|DRUG|saline|Saline will be infused at a speed of 0.3mg / kg / h during surgery .
223909899|NCT05199051|COMBINATION_PRODUCT|Gemtuzumab ozogamicine - Cytarabine - Gilteritinib|See Arms description paragraph
223909900|NCT06145620|OTHER|Physiotherapy|The intervention involves the visualization of different videos explaining the performance of lumbar strengthening exercises, measures for back care, and neuroscience pain education.
223909901|NCT05941182|OTHER|online questionnaires|Before and after online questionnaires
223909902|NCT06223451|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation method that can alter the excitability of the motor area by generating a magnetic field through a coil. Low-frequency stimulation (\<1 Hz) applied with rTMS has inhibitory effects. Repetitive transcranial magnetic stimulation has a neurorehabilitative role as it can modulate the excitability of targeted brain areas. Inhibitory repetitive transcranial magnetic stimulation will be applied to 11 patients with unilateral neglect due to ischemic stroke under the supervision of a doctor for a total of 10 sessions over 2 weeks with conventional rehabilitation.Each session will last for 20 minutes,total of 1200 pulses, 1 Hz repetitive transcranial manyetic stimulation over the unaffected left posterior parietal cortex.
224084713|NCT04682158|DRUG|Carboplatin|Given IV
224084714|NCT04682158|RADIATION|3 Dimensional Conformal Radiation Therapy|Undergo 3D CRT
224084715|NCT04682158|DRUG|Propranolol|Subject will be treated with 30 mg po BID Propranolol for up to 6 weeks
223909903|NCT06223451|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Patients in the sham group will receive sham transcranial magnetic stimulation with sham coil for 20 minutes a day, 10 sessions in total, together with conventional rehabilitation.
224084716|NCT04682158|RADIATION|Intensity Modulated Radiation Therapy|Undergo IMRT
224084717|NCT04682158|DRUG|Paclitaxel|Given IV
224084718|NCT06960837|BEHAVIORAL|ultrasound simulation training case-based workshop during resident sim days|Using the CAE Vimedix ultrasound simulator or standardized patient, a patient stem will be read or video shown to an individual participant. The participant will have 10 minutes to discuss the scenario and scan the simulator/patient. Participants will verbalize their findings and receive additional information, including diagnostic tests or point-of-care ultrasound (POCUS) videos, as they proceed through the case. They will be scored using a standardized rubric. For Objective Structured Clinical Exam (OSCE) testing, two independent raters, both with ultrasound fellowship training, one known to the participants and one unknown to the participants, will observe and rate the participant on a simulated POCUS case using the already published OSCE tool. The rater will read a brief standardized stem, and the participant will have 10 minutes to complete the station.
224084719|NCT00896467|OTHER|questionnaire administration|
224277412|NCT03256994|DEVICE|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
223715978|NCT02923934|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
223715979|NCT01523353|BEHAVIORAL|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
223909904|NCT04088838|OTHER|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
223909905|NCT06166680|OTHER|Sleep quality assessment|"The following item will be assessed in all subjects (n=420):~1\. Sleep, through the Pediatric Sleep Questionnaire."
223909906|NCT06166680|OTHER|Anthropometry|"The following items will be assessed in all subjects (n=420):~2\. Anthropometric data : 2.1 Height; 2.2 Weight; 2.3 Maximal mouth opening; 2.4 Maximal mouth opening with tongue to palate (with the Quick Tongue-Tie assessment tool)"
223909907|NCT06166680|OTHER|Tongue strength assessment|"The following items will be assessed in all subjects (n=420):~3\. Tongue pressure (in kPa) exerted against the IOPI (Iowa Oral Performance Instrument) bulb while swallowing.~4\. Tongue peak pressure (i.e., the maximal pressure - Pmax - exerted against the IOPI bulb) during 3 sec. of tongue elevation.~5\. Tongue peak pressure during 3 sec. of tongue protrusion."
223909908|NCT06166680|OTHER|Tongue endurance assessment|"The following items will be assessed in all subjects (n=420):~6\. The tongue endurance (i.e., the time to task failure in maintaining a pressure equal to 50%Pmax against the IOPI bulb) during tongue elevation.~7\. The tongue endurance during tongue protrusion."
223909909|NCT06166680|OTHER|Orofacial praxis assessment|\- The following item will be assessed in a subset of subjects (n=31): 8. Orofacial praxis through the Motricité Bucco-Linguo-Faciale (MBLF) test.
223909910|NCT05364307|OTHER|Prescreener database|Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.
223909911|NCT06031610|PROCEDURE|carotid artery stenting|Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.
223909912|NCT06031610|DRUG|drug therapy|Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
223909913|NCT06105190|DEVICE|Implantation of premium monofocal IOL, LuxSmart (device under investigation)|Patients will be implanted with study IOL in both eyes
223909914|NCT06105190|DEVICE|Implantation of monofocal IOL, LuxGood (control device)|Patients will be implanted with Control IOL in both eyes
223909915|NCT03325946|BEHAVIORAL|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
223909916|NCT03935971|DRUG|Dupilumab|See arm/group description
223909917|NCT06278753|DIAGNOSTIC_TEST|carbon dioxide cystoscopy|Using carbon dioxide medium for filling bladder
223909918|NCT05863156|DIAGNOSTIC_TEST|Right side lying position|In the study, 60 participants were placed in the right side lying position (intervention 1)
223909919|NCT05863156|DIAGNOSTIC_TEST|Semi Fowler|In the study, 60 participants in the semi-sitting position (intervention 2)
223909920|NCT05863156|DIAGNOSTIC_TEST|left side lying position|In the study, 120 participants in the left side lying position (control group).
223909921|NCT03433742|OTHER|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
223909922|NCT04466865|OTHER|Best Case/Worst Case communication tool training|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of kidney disease. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning the intervention is designed to lead to a discussion of participants preferences and consideration of outcomes.~The nephrologist verbally describes the best case, worst case, and most likely outcomes for each treatment option-incorporating rich narrative from clinical experience and translation of probabilistic information-while drawing a diagram of those options. The nephrologist also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
223909923|NCT03505723|DRUG|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
223909924|NCT03505723|DRUG|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
223909925|NCT03505723|OTHER|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
224084720|NCT00896467|PROCEDURE|psychosocial assessment and care|
224084721|NCT00896467|PROCEDURE|quality-of-life assessment|
224084722|NCT04782167|BEHAVIORAL|BRACE|"Balance training,Static balance:~1. Romberg with eye open \& eye close \[30 sec repeat 3 times\]~2. Tandem standing with eye open then with eye close. Right foot front first, then left foot front \[10 Sec repeat 3 times\]~3. Single leg stance 5 repetition with sec.~Static/Dynamic/Anti-cipatory Postural Control:~1. Sit to stand: 5 repetition~2. Functional reach test: forward, sideways \& cross reach, practice 1 min for each~3. TUG test: with distance of 10 feet \& time 10 sec. practice 2 min Cognitive exercises~1\) Count reverse from 50 Repeat with eyes open and close Reps of 30s for each 2) Push wall and reverse count from 20 3) Remember 5 words, Name 5 animals, Repeat 5 words"
224084723|NCT04782167|BEHAVIORAL|Propirioceptive training|1st Phase - Steady phase (1st set: Eyes Open, 2nd set: Eyes Close) Preserve standup position Equally heels up and down Preserve standup on one leg by turns
224084724|NCT01249235|PROCEDURE|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
224084725|NCT03775707|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224084726|NCT03775707|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
224084727|NCT02720757|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
224084728|NCT03169426|DRUG|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
224084729|NCT02606552|DRUG|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
224084730|NCT02606552|DRUG|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
224084731|NCT02606552|DEVICE|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
224084732|NCT02048345|DRUG|Suspension Fasted State|
224084733|NCT02048345|DRUG|Suspension Fed State|
224084734|NCT02048345|DRUG|Solution Fasted State|
224084735|NCT02048345|DRUG|Solution Fed State|
224084736|NCT00883493|DRUG|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
224084737|NCT00883493|DRUG|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
224084738|NCT04324177|OTHER|Demographic data, morbidity data|To detect association between the demographic data of pediatric patients including age ,sex,hospital stay and clinical data including the diagnosis and co morbidity with the outcome of pediatric patients admitted to ICU of Assiut University children hospital
224084739|NCT05674474|DRUG|Vorasidenib|Administered orally as tablets.
224084740|NCT03346174|OTHER|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
224084741|NCT03346174|OTHER|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
224084742|NCT01061931|PROCEDURE|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
224084743|NCT01124565|DRUG|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
224084744|NCT01202461|PROCEDURE|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
224084745|NCT04111614|DRUG|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
224084746|NCT04111614|DRUG|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
224277413|NCT03256994|BEHAVIORAL|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT-FR will incorporate a quality-of-life questionnaire. CIRT-FR will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
224277414|NCT00063830|DRUG|Alicaforsen|
224277415|NCT01031992|DRUG|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
224277416|NCT01031992|DRUG|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
223909926|NCT03505723|OTHER|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
223909927|NCT03170206|DRUG|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
223909928|NCT03170206|DRUG|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
223909929|NCT05831072|BEHAVIORAL|Mindfulness-cognitive oriented group program|Mindfulness-cognitive oriented group program is a 4-week program based on the theory of mindfulness-based cognitive therapy (MBCT). The main elements of MBCT such as mindfulness breathing, raisin meditation for mindful eating, body scan and mindfulness walking are included. In addition to the weekly intervention, participants are also required to do the mindfulness practice at home.
223909930|NCT06822309|PROCEDURE|External Oblique Intercostal Plane Block|The block is performed before skin incision by a specialized anesthetist. With the patient positioned in the supine position with their ipsilateral arm abducted, the skin was sterilized, using the high frequency linear probe (M-Turbo HF 38 transducer 13- 6 MHz) of Fujifilm Sonosite ultrasound is placed over the sixth rib medial to the anterior axillary line approximately in midclavicular line in a parasagittal orientation. A 20-guage needle is inserted in a cephalocaudal direction, and the external oblique intercostal plane was hydro dissected with saline. After hydro dissection, the needle is advanced 1 to 2 cm, and 20 mL of 0.25% bupivacaine (Sunny Pharmaceutical) with 4 mg dexamethasone as an additive was administered. The same procedure will be done at the other side (bilateral external oblique intercostal plane block).
223909931|NCT06822309|DEVICE|Patient controlled analgesia|Patients in group will receive intravenous patient controlled analgesia device 100 ml (Accuafuser 100 mL, basal rate 4 mL/hr., bolus 0.5 mL/time, and lock time 15 minutes) for postoperative pain management that will contain 30 mg morphine (loading dose0.1mg/kg) will be given by infusion over 10 minutes then accuafuser will be connected),8 mg dexamethasone and 8 mg ondansetron diluted in 100 ml saline.
223909932|NCT06812897|OTHER|Sallie (TM) Life U|Testing of Sallie (TM) Life U platform
223909933|NCT06469177|DEVICE|Pain Coach App|Pain Coach App is a mobile application that offers patients undergoing shoulder, hip and knee arthroplasty surgery preoperative educational tools and questionnaires to provide patient specific details to their surgeons for prescribing purposes as well as post operative pain assessment and medication reminders/tracking, problem troubleshooting and a resource library for further pain management tools and education.
223909934|NCT03340051|BEHAVIORAL|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
223909935|NCT03340051|BEHAVIORAL|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
223909936|NCT05412082|RADIATION|Intensity-modulated radiation therapy|MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.
223909937|NCT05412082|DRUG|5-fluorouracil|"5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week."
223909938|NCT05412082|DRUG|Leucovorin|Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
223909939|NCT05412082|DRUG|Oxaliplatin|Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.
223909940|NCT05412082|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.
223909941|NCT05412082|RADIATION|Accelerated Radiation Therapy|"MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~* Dose level -1: 10 Gy delivered in 4 fractions~* Dose level 0: 12 Gy delivered in 4 fractions~* Dose level 1: 14 Gy delivered in 4 fractions~* Dose level 2: 16 Gy in delivered 4 fractions"
223909942|NCT05412082|DRUG|Irinotecan|Irinotecan dose of 180 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
223909943|NCT04882891|DEVICE|Actimyo|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223909944|NCT06390241|DRUG|Avidin-biotin-Dota-90Y|Within 7-8 days after the VABB procedure, 6-10 mg avidin in 1 ml saline will be administered at the site of the occult carcinoma. Subsequently, 90Y DOTA-biotin in the range of 28-57-126 MBq (3 activity levels investigated) will be injected locally immediately after avidin injection.
223909945|NCT04647630|DIAGNOSTIC_TEST|urine test|test for pneumococcal antigen in urine
223909946|NCT06646939|BEHAVIORAL|PT and OT with a simulated environment|Upon admission to the inpatient rehabilitation unit, participants will undergo a physical and occupational therapy evaluation. The evaluations will include the outcome measures chosen to track for this study (10-meter walk test and Quality Indicators). If a patient meets inclusion/exclusion criteria, informed written consent will be obtained. Throughout the patient's stay, therapists will have the opportunity to perform community integration treatments using the simulated environment. This could include activities such as negotiating a curb, crossing a street, or shopping at a marketplace. The therapist will document the amount of time (units billed) spent performing these interventions. The research investigators will not act as a patient's therapist throughout their admission.
223909947|NCT06823570|BEHAVIORAL|Individualized exercise therapy|Patients in the intervention group will receive an individualized exercise training program 3x/week.
223909948|NCT06823570|BEHAVIORAL|Lifestyle recommendations|The lifestyle recommendation group will receive general recommendations such as salt reduction, higher physical activity levels and stress reduction.
223909949|NCT04362085|DRUG|Therapeutic Anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
223719380|NCT05295511|OTHER|Recreational Team Handball programme|All training sessions consisted of a standardized 15-min warm-up (running, coordination, strength, flexibility and balance exercises), followed by 3x15-min periods of recreational team handball matches interspersed by 2-min breaks, performed in an indoor team handball court. The matches were played as small and formal game formats (4v4, 5v5, 6v6 or 7v7).
223909950|NCT06475950|OTHER|"Kid'EM app experimental group"|"In the Kid'EM app experimental group arm, only the application used differs. Visits are organized in the same way as in the controle app arm.~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
223909951|NCT06475950|OTHER|Kid'EM app control group|"Use of control application without guidance for goal setting~Visit 0 (Inclusion) + Visit 1 (V1) : Physical visit~Children are included in the study by the investigator, formalized by signing a consent form.~Parents fill in questionnaires~Visit 2 (when 1st objective is set):~Telephone interview to assess performance and satisfaction levels after the first goal has been set.~Visit 3 (when setting the 2nd goal):~Telephone interview to assess performance and satisfaction levels after the second goal has been set.~Visit 4 (week 14 - end of study): Physical visit~The questionnaires are again completed by the parents, either directly on a tablet or on paper for later input.~Visit 4 bis:~Telephone interview to assess performance and satisfaction levels after the work on the first two objectives.~Visit 5 (focus group, optional post-study visit)"
223909952|NCT05092659|BEHAVIORAL|Patient interview|Each patient included will be interviewed 3 times : before surgery, 3 and 6 months after surgery
223909953|NCT06585358|OTHER|MIPD|This is a non-inverventional study
223909954|NCT06584656|BEHAVIORAL|Aerobic exercise condition|Aerobic session will last 30 min. The average intensity of the aerobic sessions will be 60-70% of the Maximal Heart Rate. Therefore, participant will perform a continuous moderate intensity aerobic bout of exercise on a cycle ergometer.
223909955|NCT06584656|BEHAVIORAL|Resistance exercise condition|Resistance exercise will last 30 min at 4-6 RPE (OMNI-Resistance Exercise Scale of Perceived Exertion from 0-10). The bout of resistance exercise will include a combination of upper and lower body exercises using elastic bands and the participants' body weight as the primary resistance. Eight different exercises will be performed per set, with 40 seconds per exercise, for a total of 3 sets. The exercises are based on basic movement patterns and include: glute bridge, front plank, standing face pull, incline push-up, squat, pallof press, walking lunge and seated shoulder press.
223909956|NCT06828523|BEHAVIORAL|Listener judgements of speech produced in different tasks|Listeners will hear recorded speech of PALS and age-matched speakers across interactive and non-interactive tasks and indicate what they heard by clicking one of four words displayed on the screen. Standard attention checks and minimum performance thresholds (Theodore, 2021) will be used to ensure that listeners are engaged and are able to provide meaningful perceptual judgments.
223909957|NCT06252623|DRUG|Exenatide|Exenatide will be purchased commercially as Bydureon® for subcutaneous injection and administered at 2 mg once a week for 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
223909958|NCT06252623|DRUG|Placebo|Sterile saline will be used as the placebo and administered subcutaneously once a week for 6 weeks.
223909959|NCT05786066|DRUG|Perampanel 6 MG|Perampanel will be administered 2.5 hours before Ketamine infusion
223909960|NCT05786066|DRUG|Ketamine|Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.
223909961|NCT05786066|DRUG|Placebo|Placebo will be administered 2.5 hours before Ketamine infusion
223909962|NCT04403204|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
223909963|NCT04403204|OTHER|DCE-MRI|Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging
223909964|NCT06007781|BIOLOGICAL|Placebo|2 injections - given on Day 1 and the second given between Day 29 - Day 57
223909965|NCT06007781|BIOLOGICAL|HIL-214|2 injections - given on Day 1 and the second given between Day 29 - Day 57
223909966|NCT05525702|DEVICE|VRFS|Participants wear VR headsets and experience immersive virtual environments, where their family members will be present and offer companionship and comfort.
223909967|NCT03442309|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
223909968|NCT03442309|DEVICE|Fluoride Varnishes|Fluoride varnish (FV)
223909969|NCT03442309|DEVICE|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
223909970|NCT04862416|BIOLOGICAL|R0.6C transmission blocking vaccine|Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.
223909971|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 1: low intensity clinician training|"A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted."
223909972|NCT05001009|BEHAVIORAL|Clinician Implementation Strategy Stage 2: high intensity clinician training|"This includes two components:~1. Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~2. A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians."
223909973|NCT05001009|BEHAVIORAL|Low patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website.
223909974|NCT05001009|BEHAVIORAL|High patient engagement|Patients will be sent information about goals of care conversations, including the PREPARE website. Follow-up phone calls to discuss goals of care conversations and the PREPARE website will be made.
223909975|NCT04779320|DRUG|Vedolizumab IV|Vedolizumab IV
223909976|NCT06198517|OTHER|Moxibustion|The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally.
223909977|NCT06198517|OTHER|Symptomatic treatment|The control group received conventional symptomatic treatment.
223909978|NCT05897476|OTHER|ultrasound|brief external ultrasound will be proceed on each patient included searching signs of aortic dissection
223909979|NCT01976286|OTHER|Salicylic Acid Peels|
223909980|NCT01976286|OTHER|Glycolic Acid Peels|
223909981|NCT02807545|BEHAVIORAL|Scoliosis Specific Exercises|
223909982|NCT05207982|BEHAVIORAL|Family Based weight management program|"Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two eating plan education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity."
223909983|NCT04974151|DRUG|Amlodipine besylate|The amlodipine used in this study is a listed product.
223909984|NCT04974151|DRUG|Amlodipine besylate And Folic Acid|The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020.
223909985|NCT04974151|DRUG|5-methyltetrahydrofolate (5-MTHF)|The 5-MTHF used in this study is a listed product.
223909986|NCT04974151|DRUG|Amlodipine placebo|Amlodipine placebos are dummy pills of amlodipine with identical appearance.
224277417|NCT03499366|DIAGNOSTIC_TEST|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
223909987|NCT04974151|DRUG|Amlodipine folic acid placebo|Amlodipine folic acid placebos are dummy pills of amlodipine folic acid with identical appearance.
223909988|NCT04974151|DRUG|5-MTHF Placebos|5-MTHF placebos are the dummy pills of 5-MTHF with identical appearance.
223909989|NCT03608579|DRUG|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
223909990|NCT05239000|OTHER|geriatric co-management|Geriatric co-management involves a consultation with a geriatrician prior to initiating head and neck radiation and chemotherapy.
223909991|NCT05239000|OTHER|geriatric guided supportive care|Geriatric guided supportive care will be carried out by oncologists. After the patient completes the eRFA, an automated report is generated that identifies the patient's geriatric deficits.
223909992|NCT06067945|OTHER|microleakage|prevention of microleakage and secondary carries
223909993|NCT00186147|PROCEDURE|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
223909994|NCT04185246|DRUG|NH002 (Perflutren Lipid Microspheres) Injectable Suspension|NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
223909995|NCT04185246|DIAGNOSTIC_TEST|Echocardiogram|Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.
223909996|NCT04032782|DRUG|HM15136|10 mg/mL as protein in prefilled syringes
224277418|NCT04674150|DEVICE|ARISE with AR|An augmented reality game for mobile devices with AR experiences enabled
224277419|NCT04674150|DEVICE|ARISE without AR|An augmented reality game for mobile devices with AR experiences disabled as an control
224277420|NCT00501332|BIOLOGICAL|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
224277421|NCT02514395|OTHER|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2\[32\] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
224277422|NCT04747795|DRUG|Vitamin C|IV
224277423|NCT04747795|DRUG|Normal saline|IV
223909997|NCT04032782|DRUG|Placebo of HM15136|Placebo in prefilled syringes
223909998|NCT03728608|DEVICE|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
223909999|NCT03728608|DEVICE|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
223910000|NCT04815239|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT)|Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based treatment for BP adults that prevents or delays mood episodes by stabilizing sleep and daily routines.
223910001|NCT04815239|BEHAVIORAL|The Healthy Lifestyle Behavior Intervention (HL)|HL includes structured psychoeducational modules that aim to teach patients about health risks and help them achieve a balanced lifestyle to optimize physical and mental health.
223910002|NCT02329262|BEHAVIORAL|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
223910003|NCT02329262|BEHAVIORAL|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
224084747|NCT06396650|DEVICE|Home-based training|"1. If the participant shows instability in any specific perturbation directions or with excessive body swaying, the participant will practice walking with a cellphone strapped on the chest in-home training. A cellphone App will detect potential excessive body swaying in any directions and prompt the participant with real time audio-visual feedback to reduce sway in the specific directions.~2. If the subject is diagnosed with collapse-related vertical instability, lower-limb muscle strengthening will be emphasized in the training. The subject may work out with a Shuttle Mini-Press, AB Squat machine, Rowing machine, or Upright Row-n-Ride. The Investigators will select one machine appropriate for the subject to take home. The exercise will be 3-5 sets a day and about 15 repetitions per set. In the beginning, the exercise can be slower and with fewer repetitions based on the subject's capability. As the subject progresses, the subject may change from one exercise machine to another."
224084748|NCT06396650|DEVICE|Lab-based training|In the weekly lab-based training session, the subject will do individualized training using the sliding stepping trainer, with a focus on the direction the subject showed higher risks of falling, as identified in the initial assessment. The sliding stepping trainer will generate perturbations of the footplates in those identified risky directions during stepping.
224084749|NCT06494280|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
224084750|NCT06494280|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
224084751|NCT04642846|OTHER|Silver Diamine Fluoride (SDF)|Silver diamine fluoride (SDF) is one of the topical methods for caries arresting. The advantages of using SDF include ease of use, low cost, pain and infection control, minimal requirement of time/training and non-invasive nature of the procedure. SDF can improve oral health, increase access to care and reduce the need for emergency treatment
224084752|NCT01642745|DRUG|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
224084753|NCT01642745|DRUG|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
224084754|NCT01642745|DRUG|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
224084755|NCT00510185|OTHER|systematic coronary intervention|Coronary angiography within 72 hrs
224084756|NCT00510185|OTHER|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
224084757|NCT00716469|DRUG|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
224084758|NCT05347641|DRUG|Penpulimab|"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"
224084759|NCT04205890|DRUG|Ketamine|The ketamine will be injected per the doctor's orders to achieve a dissociative state; dosage varies between 75mg - 1000mg depending on every individual's unique treatment plan.
224084760|NCT00052390|BIOLOGICAL|bevacizumab|
224084761|NCT00052390|DRUG|doxorubicin hydrochloride|
224084762|NCT04040361|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W
224084763|NCT04040361|DRUG|Ramucirumab|Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W
224084764|NCT04040361|PROCEDURE|Surgery|Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
224084765|NCT00836550|BEHAVIORAL|Video|The participants saw a 6 minute video
224084766|NCT00836550|BEHAVIORAL|in-person HIV pre-test counseling|
224084767|NCT01880411|BIOLOGICAL|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
224277424|NCT03310086|DEVICE|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
224084768|NCT00464204|DRUG|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
224084769|NCT00464204|DRUG|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
224084770|NCT00384241|BEHAVIORAL|Induced Stress|Participation in an active coping task by playing a video game against another participant.
224084771|NCT00384241|PROCEDURE|Buccal Swab|One Buccal swab collected from each parent
224277425|NCT03310086|PROCEDURE|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
223910004|NCT04579692|DEVICE|ExAblate Transcranial treatment|Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
223910005|NCT03529396|DRUG|Chloroquine|Standard chloroquine (three days)
223910006|NCT03529396|DRUG|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
223910007|NCT03529396|DRUG|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
223910008|NCT03529396|DRUG|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
223910009|NCT03529396|DRUG|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
223910010|NCT05715814|DRUG|Empagliflozin 25 MG|PO once daily
223910011|NCT04594005|DRUG|abemaciclib+paclitaxel|"Phase 1b: About 3-6 patients enrollment is expected at dose level 1, -1 and -2. Dose reduction will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.~level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 100mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks level-2: abemaciclib 50mg bid, D1-28 / paclitaxel 70mg/m2, IV. D1, 8, 15 Q 4 weeks~Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study."
223910012|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
223910013|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
223910014|NCT06153095|BIOLOGICAL|IMPT-514|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
223910015|NCT05207956|BEHAVIORAL|Behavioral economics strategies|Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
223910016|NCT05207956|OTHER|Electronic platform|Electronic platform to collect data
223910017|NCT02473042|PROCEDURE|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
223910018|NCT02473042|DRUG|Zofran|4 mg by vein for 1 dose.
223910019|NCT02473042|DRUG|Dexamethasone|10 mg by vein for 1 dose.
223910020|NCT02473042|DRUG|Phenergan|6.25 mg by vein for 1 dose.
223910021|NCT02473042|DRUG|Pepcid|10 mg by vein for 1 dose.
223910022|NCT02473042|BEHAVIORAL|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
223910023|NCT06156670|DEVICE|PFO closure|"The operation of endovascular closure of PFO is performed on X-ray angiographic devices with digital processing of X-ray images. Endovascular closure of a PFO will be performed by femoral venous access using the following instruments: diagnostic catheter, diagnostic guidewire, high-stiffness guidewire for delivery system, interatrial septum occluders of PFO, UNI, ASD types.~Preoperative preparation and control of device implantation will be performed using modern echocardiographic equipment."
224084772|NCT05707923|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
223910024|NCT05628584|COMBINATION_PRODUCT|High FODMAP diet with metformin|Controlled High FODMAP diet (15g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
223910025|NCT05628584|COMBINATION_PRODUCT|Low FODMAP diet with metformin|Controlled low FODMAP diet (3g/day) from day 1-10, metformin XR 1000mg daily day 6-10 for each treatment period
223910026|NCT04979377|OTHER|Clinical hyperandrogenism assessment|Modified Ferriman-Gallwey scale
223910027|NCT04979377|DIAGNOSTIC_TEST|Total testosterone (ng/dL)|Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase
223910028|NCT04979377|DIAGNOSTIC_TEST|A1c (%)|High Performance Liquid Chromatography (HPLC)
223910029|NCT04979377|DIAGNOSTIC_TEST|Total cholesterol|Determined by enzymatic methods
223910030|NCT04979377|OTHER|Body mass index (BMI) (kg/m2)|Defined as body weight divided by the square of body height, and expressed in kg/m2
224277426|NCT00003404|RADIATION|Adjuvant Radiotherapy|Adjuvant radiation therapy
224277427|NCT01487434|BEHAVIORAL|Check & Connect|Structured mentoring and case management
223910031|NCT04979377|DIAGNOSTIC_TEST|Frequency of chronic vascular complications [n (%)]|Retinopathy, nephropathy, neuropathy, and macrovascular disease.
224277428|NCT01873781|DRUG|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
223910032|NCT04979377|DIAGNOSTIC_TEST|Polycystic ovary morphology|Sonographic assessment
223910033|NCT04979377|DIAGNOSTIC_TEST|Cardiovascular autonomic reflex tests (CARTs)|Cardioautonomic function assessement by Vital scan HW7-HW6T:
223910034|NCT04979377|DIAGNOSTIC_TEST|Sex hormone-binding globulin (SHBG) (nmol/L)|Circulating SHBG (IQL) at follicular phase
223910035|NCT04979377|DIAGNOSTIC_TEST|Dehydroepiandrosterone-sulphate (IQL) (ng/mL)|Circulating DHEAS (IQL) at follicular phase
223910036|NCT04979377|OTHER|Waist circumference (cm)|Waist circumference measurement made at the top of the iliac crest
223910037|NCT04979377|OTHER|Waist-to-hip ratio|Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)
223910038|NCT04979377|OTHER|Body composition|Vital Scan HW7-HW6T
223910039|NCT04979377|DIAGNOSTIC_TEST|Mean glucose (mg/dL)|Continuous glucose monitoring (GCM) records
223910040|NCT04979377|DIAGNOSTIC_TEST|Time in target range (hours)|Continuous glucose monitoring (GCM) records
223910041|NCT04979377|DIAGNOSTIC_TEST|Time in hyperglycemia (hours)|Continuous glucose monitoring (GCM) records
224277429|NCT00506116|BEHAVIORAL|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
224277430|NCT00506116|BEHAVIORAL|PME practice and record keeping (in diaries)|
223529076|NCT07004049|DRUG|Colistin/Polymyxin B + Meropenem|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia and Singapore
223529077|NCT07004049|DRUG|Ceftazidime-avibactam + Sulbactam|For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand, Singapore and Australia.
223910042|NCT04979377|OTHER|Insulin dose (UI/Kg)|Daily insulin dose divided by body weight
223910043|NCT04979377|OTHER|Insulin sensitivity|Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference
223910044|NCT04979377|DIAGNOSTIC_TEST|High-density lipoprotein (HDL) (mg/dL)|Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+
223529078|NCT07004049|DRUG|Ceftazidime-avibactam + Fosfomycin|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Malaysia, Thailand and Singapore
223529079|NCT07004049|DRUG|Ceftazidime-avibactam|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
223910045|NCT04979377|DIAGNOSTIC_TEST|Low-density lipoprotein (LDL) (mg/dL)|Estimated by the Friedewald's equation.
223910046|NCT04979377|DIAGNOSTIC_TEST|Triglycerides (mg/dL)|Determined by enzymatic methods
223529080|NCT07004049|DRUG|Ceftazidime-avibactam + Aztreonam|For carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
223910047|NCT06503250|DRUG|Atezolizumab|Observational Study
223910048|NCT06503250|DRUG|Bevacizumab|Observational Study
223910049|NCT06503250|RADIATION|Transarterial Chemoembolization|Observational Study
223910050|NCT02275416|DRUG|Ipilimumab|
223529081|NCT07004049|DRUG|Ceftazidime-avibactam + Colistin/Polymyxin B|For carbapenem-resistant Pseudomonas aeruginosa in China, Malaysia, Thailand, Singapore and Europe.
223529082|NCT07004049|DRUG|High-dose meropenem|For carbapenem-resistant Enterobacterales infection in Europe
223529083|NCT07004049|DRUG|Meropenem + Fosfomycin|For carbapenem-resistant Enterobacterales in Europe
223529084|NCT07004049|DRUG|Meropenem-vaborbactam|For carbapenem-resistant Enterobacterales infection in Europe
223910051|NCT02275416|BIOLOGICAL|UV1 vaccine|
223910052|NCT02275416|BIOLOGICAL|GM-CSF|
223910053|NCT06494774|DRUG|BI 1815368|BI 1815368
223910054|NCT06494774|DRUG|Placebo matching BI 1815368|Placebo matching BI 1815368
223910055|NCT05303584|BIOLOGICAL|Ad5-nCoV-IH|The orally aerosolized Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. The Ad5-nCoV vaccine was supplied in 1.5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. 0.1 ml of Ad5-nCoV vaccine will be aerosolized by using Continuous Vapouring System. Then, the aerosolized droplets will be poured into a disposable suction cup and be inhaled by participants through mouth.
223910056|NCT05303584|BIOLOGICAL|Ad5-nCoV-IM|The Ad5-nCoV is a replication defective Ad5 vectored COVID-19 vaccine expressing the full-length spike gene of wide-type SARS-CoV-2, Wuhan-Hu-1. It was supplied in 1·5mL/vial, at a concentration of 1.0 × 1011 viral particles per mL as a liquid formulation. Participants will be administrated 0.5ml（5×1010VP）of Ad5-nCoV vaccine intramuscularly.
223910057|NCT05303584|BIOLOGICAL|CoronaVac|CoronaVac is an inactivated whole-virion vaccine with aluminium hydroxide as the adjuvant, prepared with a novel coronavirus (CZ02 strain) inoculated in African green monkey kidney cells (Vero cells). One dose of CoronaVac contains 3 μg of SARS-CoV-2 virion in a 0.5 mL aqueous suspension for injection with 0.45 mg/mL of aluminium.
223910058|NCT05604274|OTHER|App to monitor stool consistency and symptoms|App to monitor stool consistency and symptoms
223910059|NCT06562257|OTHER|Honey|Honey has a long-standing reputation for promoting wound healing and offers a more economical treatment modality. Nusantara Honey, a GMP-certified product available on the market, met our criteria for quality and safety.
223910060|NCT06562257|OTHER|PHMB Solution|PHMB is an antimicrobial polymer that is effective against intracellular and biofilm forms of S. aureus. PHMB is quite effective in the treatment of wounds in deep neck abscesses.
223910061|NCT03902912|DRUG|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
223910062|NCT05873517|BEHAVIORAL|Immediate Narrative Exposure Therapy (NET)+|The basis of this intervention is adapted Narrative Exposure Therapy (NET)+. All participants receive 4-8 active NET+ sessions, including a psychoeducational session.
224084773|NCT04219228|DIAGNOSTIC_TEST|Ophthalmic examinations|Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.
223529085|NCT07004049|DRUG|Cefiderocol|For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Europe and Australia.
223529086|NCT07004049|DRUG|Ceftolozane-tazobactam|For carbapenem-resistant Pseudomonas aeruginosa in Europe and Australia.
223529087|NCT07004049|DRUG|Ceftolozane-tazobactam + Meropenem|For carbapenem-resistant Pseudomonas aeruginosa in Europe.
223529088|NCT07003464|DRUG|Zanubrutinib|160 mg (2 tablets) BID. Each 4-week period constitutes one treatment cycle.
223910063|NCT05873517|BEHAVIORAL|Waitlist + NET+|Waitlist control group participants receive 1 psychoeducational sessions and will be added to a waitlist; waitlist control group participants randomly selected from the waitlist be offered the opportunity to receive the active intervention (NET+).
223910064|NCT01254864|DRUG|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
223910065|NCT01254864|DRUG|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
223910066|NCT01254864|DRUG|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
223910067|NCT01254864|DRUG|Dasatinib|100 mg by mouth each day of a 28 day cycle.
223910068|NCT03895996|DRUG|AVT001|autologous dendritic cell therapy
223910069|NCT03895996|OTHER|Placebo|matched placebo
223910070|NCT06278194|PROCEDURE|Gasserian Ganglion Radiofrequency Thermocoagulation|Gasserian ganglion radiofrequency thermocoagulation is performed in the operating room under fluoroscopy. In sterile condition, the foramen ovale is shown by the pain management specialist under fluoroscopy guidance. After this condition, the entry of the needle is marked and anaesthetised with local anaesthetic. After the entry of the gasserian ganglion with the radiofrequency needle, 10 cm long, the location is checked with sensory and motor stimulation. If the placement is correct, 70 degrees 70 seconds of radiofrequency thermocoagulation is applied.
223910071|NCT02693509|OTHER|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
224084774|NCT04219228|DEVICE|Wearable devices|Physical activity, light intensity, and visual information will be measured with wearable devices.
224084775|NCT03869814|OTHER|Blood Draw|Blood Draw
224084776|NCT02848937|DEVICE|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca\_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
224084777|NCT02848937|DEVICE|Bath with citrate and Ca_eq|bath with citrate and Ca\_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
224084778|NCT00159094|DRUG|Doxil and Vinorelbine|
224084779|NCT02690909|DEVICE|Redy™ Renal Denervation System|Renal Denervation System
224084780|NCT05431296|DEVICE|Dexcom ONE Continuous Glucose Monitoring System|The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
224084781|NCT02577263|OTHER|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
224084782|NCT04566367|DIAGNOSTIC_TEST|blue laser imaging|The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
224084783|NCT04581720|DEVICE|Train-of-four (TOF)|Give 4 electrical stimulants on the ulnar nerve to see if the 4 responses (T1 \~ T4) of adductor pollicis fade or not. If there's no neuromuscular block, it shows no fade, or it fades. When an operation is over under general anesthesia, we use the ratio of the height of T4 to T1, and the ratio is over 90%, the neuromuscular block is recovered enough to extubation.
224084784|NCT04039997|DEVICE|CPRMeter|teaching resuscitation with application of cpr feedback device
224084785|NCT04039997|OTHER|Manual chest compression|Manual chest compression
224084786|NCT01369121|DRUG|XERECEPT|BID dosing, subcutaneous for 1 year
224084787|NCT02803957|DEVICE|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
224084788|NCT02803957|DEVICE|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
224084789|NCT02862691|DRUG|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
224084790|NCT02862691|DRUG|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
224084791|NCT04719351|BEHAVIORAL|The DIARY mobile application|The mobile application has two main functionalities. First, it will remind the user to report in regular time periods on their mental health status (e.g., sleep disturbances, stress). The assessment is done daily for four weeks. Second, some completed assessments will be combined with a behavioral prompt i.e. short message encouraging the user to engage in one of the strategies that can help coping with stress at work, e.g. remember to take short breaks, exercise in daylight, summarize a day with a colleague after a finished shift.
224084792|NCT04856514|BEHAVIORAL|PEERS|16 week telehealth intervention; parallel teen and parent/caregiver groups; 90 minutes each week.
224084793|NCT00428402|BEHAVIORAL|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
224084794|NCT05729893|OTHER|root canal sealers|different sealer used in obturating root canals (resin and bio ceramic)
224084795|NCT00701714|DRUG|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
224084796|NCT00701714|DRUG|ERYPO|Solution for injection (s.c.)
224084797|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
224084798|NCT02943395|OTHER|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
224084799|NCT00313573|PROCEDURE|management of therapy complications|
224084800|NCT00313573|PROCEDURE|pain therapy|
224277431|NCT00506116|BEHAVIORAL|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
224277432|NCT00506116|PROCEDURE|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
224277433|NCT00996424|DRUG|Acetylcysteine|Inhalation with N-Acetylcysteine
224277434|NCT00996424|DRUG|normal saline|Inhalation with normal saline solution
224277435|NCT03034434|DEVICE|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
224084801|NCT00313573|PROCEDURE|psychosocial assessment and care|
224084802|NCT00313573|PROCEDURE|quality-of-life assessment|
224084803|NCT01731678|PROCEDURE|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
223529089|NCT07003464|DRUG|Obinutuzumab|1000 mg IV (Days 1, 8, 15 of Cycle 1; Day 1 thereafter).Each 4-week period constitutes one treatment cycle.
223529090|NCT07003464|DRUG|Bendamustine|70 mg/m² (Days 1-2 per cycle) for induction only (Cycles 1-4).Each 4-week period constitutes one treatment cycle.
223715980|NCT02221193|OTHER|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
223715981|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
223910072|NCT05260125|DRUG|Ultrasound-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. A linear probe with a frequency of 7-8 MHz on the SonoScape A8 ultrasound device will be used for suprascapular block under ultrasound guidance. the ultrasound probe was placed in the coronal plane over the suprascapular fossa. Suprascapular fossa was scanned from medial to lateral side to identify suprascapular nerve. After identification, solution of suprascapular nerve block will be injected into the area around the nerve under the scanning with in-plane technique with a 22 gauge 90 mm spinal needle."
223910073|NCT05260125|DRUG|Anatomical Landmark-guided Suprascapular Nerve Block|"For suprascapular nerve block, a solution consisting of 5 ml 2% lidocaine, 1 ml Betamethasone dipropionate + Betamethasone sodium phosphate (6.43 mg/ml + 2.63 mg/ml), 4 ml saline will be used.~Injections will be applied to patients in a sitting position and arm by the side. The suprascapular notch projection will be determined using the anatomical landmark technique defined by Dangoisse et al., and then suprascapular nerve block will be applied with a 22 gauge 90 mm spinal needle to the patients"
223715982|NCT01569789|DEVICE|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
223715983|NCT01434069|DRUG|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
223910074|NCT03849651|DRUG|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
223910075|NCT03849651|BIOLOGICAL|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
223910076|NCT03849651|DRUG|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
223910077|NCT03849651|DRUG|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
223910078|NCT03849651|BIOLOGICAL|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
223910079|NCT03849651|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
223910080|NCT03849651|DEVICE|CliniMACS|Cells for infusion are prepared using the CliniMACS
223910081|NCT03849651|BIOLOGICAL|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
223910082|NCT03849651|DRUG|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
223910083|NCT03849651|BIOLOGICAL|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
224277436|NCT01919541|OTHER|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
224277437|NCT01919541|DEVICE|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
224277438|NCT01919541|DEVICE|hyperinsulinemic euglycemic hyperaminoacid clamp|
224277439|NCT01919541|DIETARY_SUPPLEMENT|whey protein supplementation|
224277440|NCT01919541|OTHER|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
224277441|NCT03092596|BEHAVIORAL|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
224277442|NCT03092596|BEHAVIORAL|Patient health navigator-administered screening tool|patient health navigator-administered screener
224277443|NCT03092596|BEHAVIORAL|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
224277444|NCT02321124|OTHER|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
223715984|NCT01434069|DRUG|FOLFIRI Infusion|Standard therapy of FOLFIRI
223719381|NCT02464462|DIETARY_SUPPLEMENT|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
223535194|NCT06541808|OTHER|mechanical Vagus Nerve Stimulation (High Intensity)|The stimulation consists of a combination of normal neck movements, performed in a comfortable supine position, which can selectively stimulate the VN. In particular. The participant will be stimulated supine on a comfortable massage/treatment bed with the experimenter standing at the cranial short side of the bed. All the neck movements will be gently performed with a combination of upper cervical flexion and contralateral lateral flexion to load the intracranial portion of the vagus nerve. The ipsilateral neck rotation will be combined to load the cervical tract of the nerve. Keeping the participant's head in the final movements combination the upper abdomen will be gently moved caudally to load the thoracic tract and intermittent gentle impulses 1 each second will be administered. The stimulation will be provided for 8 consecutive minutes for each side, only once for the experiment duration.
224277445|NCT02321124|BEHAVIORAL|life style advice|We will apply life style advice for four weeks.
223910084|NCT03849651|BIOLOGICAL|CD19+|IV on day 0 and may receive an additional dose on day 1
223910085|NCT03849651|BIOLOGICAL|CD45RA-depleted DLI|infusion IV
223910086|NCT05312983|OTHER|Audiological and vestibular tests|"6h of audiological and vestibular tests divide in 3 sessions :~* Session A : objective audiological tests~* Session B ; subjective audiological tests~* Session C : balance tests."
223910087|NCT05312983|OTHER|Blood sampling|A 10 mL blood sample will be collected during the study.
223910088|NCT05312983|OTHER|neurocognitive self-questionnaire|Four self-questionnaires to fill out to measure sleep quality, memory and emotional state
223910089|NCT02405364|DRUG|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
223910090|NCT04846036|DRUG|Sonlicromanol|Oral administration of sonlicromanol twice daily
223910091|NCT04846036|DRUG|Placebo|Oral administration of matching placebo twice daily
223910092|NCT06180980|DRUG|Pirtobrutinib|Administered orally.
223910093|NCT06273072|DRUG|Metformin hydrochloride extended-release tablets|titrated to 2000 mg once daily
223910094|NCT06273072|DRUG|Visually identical placebo Metformin hydrochloride extended-release tablets|placebo
223910095|NCT05361941|DEVICE|EP Granules with Tobramycin|EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a 2-stage or 1.5 stage revision of an infected total joint.
223910096|NCT05361941|DEVICE|empty voids|Voids are left empty
224277446|NCT05945667|DRUG|Monural|1 sachet, only 1st day of trial
223719382|NCT02464462|OTHER|Placebo|Rice powder pills
223910097|NCT05474027|OTHER|Avoidance of Deliberate Hypotensive Anesthesia|The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
223910098|NCT05474027|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
223910099|NCT04907669|OTHER|Brief contact intervention|"The BCI in this study is a series of structured messages, and messages will be delivered to participants by pushing feeds through WeChat and an iOS/Android application developed for this study. If participants did not use smartphones, messages will be delivered by mobile text messages or by phone calls. Though the final details are yet to be determined by the CBPR study, the investigators expect to structure messages into six components including introduction, greetings for previous complains, mental health promotion, encouragement, and coping strategies, remind of treatment and subsequent visit, and crisis intervention resource.~Noted, the same messages will also be sent to patients' LHSs."
223910100|NCT04241276|DRUG|ATRA|45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle
223910101|NCT04241276|DRUG|Gemcitabine|1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
223910102|NCT04241276|DRUG|nab-paclitaxel|125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle
223910103|NCT03730558|COMBINATION_PRODUCT|aflibercept + FOLFIRI|aflibercept + FOLFIRI
223910104|NCT05266001|DRUG|GM-CSF|same as arm/group description
223910105|NCT05266001|OTHER|Placebo|same as arm/group description
223910106|NCT05703360|DEVICE|Audiovisual Stimulation|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~One or more of the spheres is temporarily highlighted (target). Then all 8 spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using the hand controller, the initially highlighted target(s) among the 8 spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
223910107|NCT01828112|DRUG|Ceritinib|Ceritinib was the investigational treatment and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
223910108|NCT01828112|DRUG|Pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m\^2 every 21 days.
223910109|NCT01828112|DRUG|Docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m\^2 every 21 days.
223910110|NCT04779827|BEHAVIORAL|Online Social Network and Collective Intelligence Intervention|The online network intervention aims to use different configurations of online social networks to optimize the impacts of collective intelligence process to improve individuals' understanding, beliefs, and behavioral choices regarding a variety of health behaviors. Participants will be put into different online networks and respond to health questions while receiving feedback from their network members.
223910111|NCT04779827|BEHAVIORAL|Independent Control|Independent control aims to test the baseline of population understanding of health behaviors and choices. Participants will respond to health questions independently without getting any feedback from others.
224084804|NCT01147614|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
224084805|NCT01147614|BEHAVIORAL|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
224084806|NCT00679458|DRUG|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
224084807|NCT00679458|DRUG|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
224084808|NCT00456313|DRUG|FLIXOTIDE and SERETIDE|comparator
224084809|NCT00720148|DRUG|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
224084810|NCT00638937|DRUG|saracatinib|Given PO
223910112|NCT04745520|DEVICE|Rib fixation|"Rib fixation is performed by a senior surgeon. The patient is under general anesthesia. A thoracotomy focused on the fracture is performed to optimize access to the rib to be repaired. Video-assisted thoracic surgery (VATS) can be performed to better localize rib fractures. Significant muscle division is avoided. Removal of the periosteum is not required. The broken rib segments are approximated with forceps and the medical devices are used to fix the fracture. The medical devices are implemented according to the manufacturers' recommendations. The goal is to stabilize the chest wall. It is not useful to fix all fractures to stabilize the wall. A chest tube can be placed at the end of the operation.~Medical devices~The following medical devices can be used:~* MatrixRIB™, De Puy Synthes Companies, Zuchwill, Switzerland~* STRATOS™, MedXpert GmbH, Heitersheim, Germany~* NiTi Fixing PlatesTM, IAWAI, Yandzhou, China"
224084811|NCT00289640|DRUG|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
223910113|NCT04745520|DRUG|Analgesia|Epidural analgesia is continuing for 24 to 72 hours post-randomization to maximize outcome benefits. Afterwards, paracetamol, NSAID and/or opioid treatment are used according to pain severity. In case of opioid use, morphine treatment is preferred. However, other opioid drugs or doses can be considered to better customize the treatment.
223910114|NCT05342701|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skill intervention (CHAMP) is an intervention strategy that uniquely address differences in children's development. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to development improvement in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP consists of 35 minutes/day X 3-4 days/week for 19 weeks (dose of 1995 - 2240 minutes). Each session will consist of three parts: (a) 3-5 min of motor skill introductory activity, (b) 25 min of motor skill instruction and practice, and (c) 3-5 min motor skill closure activity."
223910115|NCT05326386|BEHAVIORAL|HTN and Medication Adherence|"Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure."
223910116|NCT01842477|PROCEDURE|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
224084812|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
223535195|NCT06541808|OTHER|Sham mechanical Vagus Nerve Stimulation|Participants will be treated with a fake vagus stimulation by letting the operator hold the neck of the participant in one hand and placing the other hand on the abdomen without any stretch on the vagus nerve
223715985|NCT01803373|DRUG|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
223719383|NCT04167202|PROCEDURE|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
223910117|NCT06618092|DEVICE|Relisten|Patients will be attended using Relisten
224084813|NCT00289640|DRUG|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
224084814|NCT02538172|OTHER|T-Track® CMV assay|
224084815|NCT06395844|DRUG|METR-NK cell(Metabolic Remodeling Nature Killer Cells)|The minimum amount of METR-NK cells infused each time should be no less than 7.5×10\^7 cells, Continuous infusion for 2 days constitutes one course, with 4 courses. The infusion is given every 2 weeks.
224084816|NCT01705847|DRUG|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
224084817|NCT01310335|DEVICE|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
224084818|NCT05632679|OTHER|personalized music intervention|participants who are randomly selected to this group will choose three set of music they prefer among the available selection of instrumental music in the application
224084819|NCT05632679|OTHER|selected audio book|participants who are randomly selected to this group will choose one audio book they prefer among the available selection of audio books on the tablet
224084820|NCT01420484|OTHER|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
223910118|NCT01188928|DRUG|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
224084821|NCT02774993|DRUG|Doxycycline|
224084822|NCT02774993|DRUG|placebo|
224084823|NCT03274921|DIAGNOSTIC_TEST|Biological determination|Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
224084824|NCT02649634|BEHAVIORAL|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
224084825|NCT02649634|BEHAVIORAL|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
224084826|NCT03726684|DEVICE|Coding strategy for cochlear implants|Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
224084827|NCT00692367|BEHAVIORAL|Physical Activity|1\. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
224084828|NCT02476318|DEVICE|ArterX Vascular Sealant|
224084829|NCT01911026|OTHER|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
224084830|NCT03498157|BEHAVIORAL|Exercise|The exercise intervention is an at least 2 weeks lasting (till the day surgery is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
224084831|NCT03498157|BEHAVIORAL|Prehabilitation Education|Participate will receive a 2 hour group-based prehabilitation class which will be held at the Penn State Cancer Institute, Hershey
224084832|NCT01318122|DRUG|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
224084833|NCT01318122|DRUG|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
224084834|NCT05999825|BIOLOGICAL|Sm-p80 + GLA-SE Vaccine|30 μg Sm-p80 + 5 μg GLA-SE
224084835|NCT05999825|OTHER|Placebo|0.9% Sterile Normal Saline
224084836|NCT05999825|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
224084837|NCT01486199|OTHER|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
224084838|NCT06077084|OTHER|Physiotherapy|"4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum"
224084839|NCT01262183|DRUG|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
224084840|NCT01262183|DRUG|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
224084841|NCT00453466|BEHAVIORAL|EBW group intervention to empower battered women|
224084842|NCT01777672|BEHAVIORAL|Dietary and oral hygiene recommendations|
224084843|NCT01777672|DIETARY_SUPPLEMENT|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
224084844|NCT01777672|DEVICE|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
223715986|NCT01803373|DRUG|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
223715987|NCT01803373|DRUG|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
223910119|NCT01188928|DRUG|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
223910120|NCT01188928|DRUG|Calcipotriene|Topical suspension once daily for up to 8 weeks.
223910121|NCT01188928|DRUG|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
224084845|NCT01777672|DEVICE|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
224084846|NCT04963829|BIOLOGICAL|gel combined with lemongrass (Cymbopogon citratus) oil at 0.1% concentration|It is a gel that was used in chronic ulcers healing
224084847|NCT04963829|BIOLOGICAL|Collagenase ointment|Participants who were subjected to a standardized treatment (collagenase ointment)
224084848|NCT04963829|BIOLOGICAL|Gel with 10% peel powder of unripe banana|Participants who used a gel made of 10% peel powder of unripe banana (M. sapientum),
224084849|NCT01012492|DRUG|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
224084850|NCT00459069|BIOLOGICAL|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
224084851|NCT02509091|DRUG|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
224084852|NCT01263041|DRUG|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
224084853|NCT01263041|DRUG|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
224084854|NCT02388373|DRUG|Fluticasone 250/formoterol 10|
224084855|NCT02388373|DRUG|Fluticasone 250/salmeterol 25|
224277447|NCT05945667|DIETARY_SUPPLEMENT|UroNext|1 sachet per day for the first 7 days, followed by 7 days break Same scheme to be repeated for 3 months
223910122|NCT04014166|OTHER|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10\^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10\^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10\^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
223910123|NCT02945176|DEVICE|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
223910124|NCT05756686|BEHAVIORAL|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
223715988|NCT01751425|DRUG|Dasatinib|Given PO
223715989|NCT01751425|DRUG|Imatinib Mesylate|Given PO
223910125|NCT05756686|BEHAVIORAL|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
223910126|NCT05244187|DEVICE|OrthoCor Active System|The OrthoCor Active System is a portable (battery operated) non-invasive device that delivers Pulsed Electromagnetic Field (PEMF) therapy for General Use of temporary pain relief, utilizing wraps that position the therapy, such as on the ankle, back, knee, wrist, elbow, shoulder, foot, or neck.
224084856|NCT02388373|DRUG|Fluticasone 125/formoterol 5|
224084857|NCT00844467|BIOLOGICAL|serotypes and resistance|screening patients with invasive pneumococci
224084858|NCT06549244|DIAGNOSTIC_TEST|Maximum Inspiratory Pressure monitoring|Lung volumes, pressures and breathlessness scores to be measured in pre and post operative phase of care on the same day
224084859|NCT02471716|BIOLOGICAL|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks
224084860|NCT01539980|DEVICE|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site
224084861|NCT04759300|DEVICE|C-MAC VS|patients undergoing tracheal intubation using the C-MAC VS
224084862|NCT04759300|DEVICE|C-MAC VL D -blade|patients undergoing intubation using the C-MAC VL D-blade.
224084863|NCT01893567|DRUG|Clobex Spray|
224084864|NCT04660188|OTHER|Multidisciplinary collaborative care arm|Study participants will be cared for by a team of healthcare professionals; an oncologist, a PCP and a pharmacist navigator.
224084865|NCT05951283|DEVICE|Hybrid Closed Loop Insulin Pump|As above
224084866|NCT04013594|DIETARY_SUPPLEMENT|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
224084867|NCT00639080|OTHER|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
224084868|NCT01486862|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
224084869|NCT06282328|DIAGNOSTIC_TEST|HIV test|Bedside rapid capillary HIV test
224277448|NCT05528302|OTHER|Tech-CBT intervention|The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
224277449|NCT00812318|DRUG|GSK1265744 10 mg oral solution|GSK1265744
224277450|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
224277451|NCT00812318|DRUG|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
224277452|NCT01833754|DRUG|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
223715990|NCT01751425|DRUG|Nilotinib|Given PO
223715991|NCT01751425|DRUG|Ruxolitinib|Given PO
223719384|NCT04167202|PROCEDURE|RICE|RICE protocol
223910127|NCT04410328|DRUG|Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care|Participants in the experimental group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally (if they have a feeding tube), 2 times daily starting on the day of enrollment for a total of 2 weeks.
223910128|NCT04410328|OTHER|Standard of care|Participants will receive standard care starting on the day of enrollment for a total of 2 weeks. Standard of care treatment consist of an intravenous Remidesivir 200 mg loading dose and then 100 mg/daily for a total of 4 days for non-intubated patients and 10 days for intubated patients, intravenous/oral decadron 6 mg/daily for 10 days and prophylactic subcutaneous LMWH daily, started on the day of enrollment and for the duration of hospitalization. If the patients are discharged before 10 days, they are prescribed oral decadron 6 mg daily to complete the course of 10 days.
223910129|NCT05383196|DRUG|Onvansertib|oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.
224084870|NCT02239822|PROCEDURE|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks."
224084871|NCT02239822|PROCEDURE|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
223910130|NCT05383196|DRUG|Paclitaxel|once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
223910131|NCT05348395|OTHER|Experimental diet|Participants that successfully complete the run-in phase will participate in the experimental diet for 8 weeks of feeding. The Participants' adherence will be monitored using direct observation, written daily food diaries, and food waste inventory (i.e., participants are trained to estimate portion of uneaten foods). Participants will be asked to eat one meal onsite 2-3 weekdays (e.g., Monday, Wednesday, and Friday), at which time they will receive meals and snacks for the remainder of that day and enough until the next scheduled visit.
223910132|NCT02902055|DRUG|Neuromuscular Blocking Agents|Neuromuscular blockae
223910133|NCT02902055|DRUG|Isotonic saline|Placebo
224084872|NCT05449457|OTHER|2-Octyl cyanoacrylate|Involves closure supplemented by 2-octyl cyanoacrylate (3 layers)
224084873|NCT04285775|DEVICE|Application of device which monitors for bleeding - Blood Warning Technology with Continuous Hemoglobin sensor (BWATCH)|A stand-alone disc-shaped device (approximately 5 cm in diameter and \<1 cm thick) which can be placed over dressings. Once switched on and put in place, continuous monitoring for bleeding takes place. Detection occurs in 2 phases. First, the system monitors for the appearance of fluid in the dressing by detecting a change in capacitance. Next, a light sensor differentiates blood from other fluids by detecting that a unique spectrum of light (525nm) is absorbed, a property unique for hemoglobin. The presence of fresh blood triggers a loud alarm, alerting medical staff to attend to the patient. The device can be used over transparent plastic dressings and does not require direct contact with blood.
223529091|NCT06675838|BEHAVIORAL|Time Management and Procrastination Behavior Management Training|"Intervention Content~Training Program Name: Time Management and Procrastination Behavior Management Training Duration: 3 sessions of 1 hour each, 5-day program Target Audience: Intern Nurses~Training Content:~Fundamentals of Time Management:~Definition and importance of time management. Key principles for effective use of time (prioritization, time blocking, planning).~Understanding Procrastination Behavior:~Definition and reasons for procrastination behavior. Effects of procrastination on student success.~Time Management Strategies:~Task Prioritization: Differentiating between urgent and important tasks. Time Blocking: Completing specific tasks in designated time slots. Daily Planning: Organizing daily tasks and activities.~Managing Procrastination Behavior:~Identification and analysis of procrastination habits. Coping strategies for procrastination (e.g., goal setting, increasing motivation, self-rewarding).~Effective Teaching Techniques:~Presentations and Information Sharing"
223529092|NCT06674590|PROCEDURE|Proprioceptive Neuromuscular Facilitation|PNF of 30 minutes duration will given in a single session. Pelvic anterior elevation and posterior depression of the hemiplegic side. rhythmic initiation slow reversal agonistic reversals Pelvic anterior depression and posterior elevation of the hemiplegic side. The first diagonal (D1): Flexion and extension The second diagonal (D2): Flexion and extension 4 session per week
223529093|NCT06674590|PROCEDURE|Motor Relearning Program|Motor Relearning Programme (MRP) This is a task-oriented approach to help the control of movement, focusing on the relearning of daily activities.
223529094|NCT03077061|PROCEDURE|Open flap debridement|Open flap debridement using saline as irrigation
223529095|NCT03077061|DEVICE|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
223529096|NCT07004231|OTHER|GOUT Buddy, an AI chatbot|"AI Chatbot (GOUT Buddy) offers personalized gout education and awareness tailored to individual needs"
223529097|NCT07005687|OTHER|Stem Cells|MSCs Derived
223715992|NCT03878628|DRUG|Adipose tissue-derived mesenchymal stem cells|CSCC\_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
224084874|NCT01902940|OTHER|Natural History|Assessment of natural history in IBM and CCFDN
224084875|NCT02964156|OTHER|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
224084876|NCT02964156|OTHER|No intervention|No intervention
224084877|NCT06544278|DIETARY_SUPPLEMENT|probiotic product|During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
224084878|NCT06544278|DIETARY_SUPPLEMENT|Maltodextrin|During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
224084879|NCT01995929|PROCEDURE|transnasal functional endoscopy|
224084880|NCT00055666|DRUG|beclomethasone dipropionate|
224084881|NCT05329675|DIETARY_SUPPLEMENT|Sinphar Lipucan Capsule|oral Sinphar Lipucan Capsule 1# (Arm A), 2# (Arm B), or 3# (Arm C)/day for 90 days
224084882|NCT00569257|DRUG|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
224084883|NCT03720457|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
224084884|NCT02978482|DRUG|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
224084885|NCT02978482|DRUG|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
223910134|NCT03403465|OTHER|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
223910135|NCT06038396|DRUG|RC118|Dose A or dose B, Q2W
223910136|NCT06038396|DRUG|Toripalimab|Fixed dose, Q3W
223910137|NCT06038396|DRUG|RC148|Fixed dose, Q3W Other Names: RC148 injection
223910138|NCT06432699|OTHER|micro osteoperforation|one side used for mops while other side will be control in same patient
223910139|NCT06214143|BIOLOGICAL|T3011 high dose|T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
223910140|NCT06214143|BIOLOGICAL|T3011 middle dose|T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
223910141|NCT06214143|BIOLOGICAL|T3011 low dose|T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
223910142|NCT05517811|DIAGNOSTIC_TEST|TEG indices|Blood samples
223910143|NCT04299581|DRUG|Camrelizumab|a PD-1 immune check inhibitor
223910144|NCT04299581|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
224084886|NCT02211261|BIOLOGICAL|PF-06293620|subcutaneous, single dose 0.3 mg/kg
224084887|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
224084888|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
224084889|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
224084890|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 3 mg/kg
224084891|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
223715993|NCT02753868|BEHAVIORAL|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
223715994|NCT02753868|PROCEDURE|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
223910145|NCT02446236|DRUG|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
223910146|NCT02446236|DRUG|Ibrutinib|560 mg PO daily
223910147|NCT02446236|DRUG|Rituximab|375 mg/m2 IV Day 1
223910148|NCT05010668|DRUG|cryoablation|Cryoablation treatment starts at day 0.
223910149|NCT05010668|DRUG|Sintilimab|Sintilimab will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223910150|NCT05010668|DRUG|lenvatinib|Lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
224084892|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous single dose 6 mg/kg
224084893|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous normal saline single dose
224084894|NCT02211261|BIOLOGICAL|PF-06293620|Intravenous infusion single dose 1 mg/kg
224084895|NCT02211261|BIOLOGICAL|Placebo|Intravenous infusion normal saline single dose
224084896|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
224084897|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
224084898|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
224084899|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
224084900|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
224084901|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
224084902|NCT02211261|BIOLOGICAL|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
224084903|NCT02211261|BIOLOGICAL|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
224084904|NCT03387631|DRUG|Artemether-Lumefantrine|
224084905|NCT03002974|DRUG|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
224084906|NCT03002974|DRUG|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
224084907|NCT03002974|DRUG|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
223715995|NCT00596284|BEHAVIORAL|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
223715996|NCT00596284|BEHAVIORAL|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
223715997|NCT00975650|DRUG|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
223910151|NCT03891485|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
223910152|NCT06580600|DIAGNOSTIC_TEST|Point of care respiratory virus testing|"Patients to be randomised to receive OCS based on the the result of the RSV results within their respiratory virus test. This test will be performed as a point of care (POC) test in ED.~This intervention will stratify the randomisation in a 1:1 ratio, to receive OCS or not.~NB) Whilst the respiratory pathogen test is not routine care to determine the OCS prescription, it is frequently used within this setting. Additionally both the receipt (or not the receipt) of OCS is within standard care pathway. For the purpose of the trial OCS = Dexamethasone, which is delivered as oral suspension 300mcg/kg as per standard practice within the local Trust."
223910153|NCT05750589|DRUG|IRX-101|IRX-101 is a novel ocular anti-septic
223910154|NCT05750589|DRUG|Providone-Iodine|5% Providone-Iodine
223910155|NCT04252989|OTHER|data collection|"* Demographic data: age, sex~* Ophthalmological history: refraction of parents, previous refractions~* Ophthalmological data at each examination: intra-ocular pression, objective refraction after fog, cycloplegia with SKIACOL, slit lamp, dilated eye exam, biometrics~* Potential undesirable events (halos, photophobia...)"
223910156|NCT06799689|BEHAVIORAL|esmadem education|"By providing information about Esma-i Husna, the journey of knowing oneself and character building with Esma-i Husna will be emphasized. It will be carried out with the aim of building on 99 names, namely Allah, Rahman and Rahim, and reducing depressive feelings by benefiting from the guidance of these names.In the second session, it will be explained through the names Esma-i Husna, Celal and Cemal in order to manage depressive feelings and contribute to positive coping. The togetherness of pain as well as happiness, ease along with difficulty, joy along with sadness in a balanced life will be discussed with the name Zü'l Celâl ve'l İkram and the study of Journey to perfection through the names Celal and Cemal. The meaning of existence and life in spirit will be discussed through the name Rab, the life cycle will be explained by establishing a relationship with the names Hafıd-Râfi, Kâbıd-Bâsıt, Muız-Müzil. In addition, it will be carried out within the framework of the name Hakim,"
223910157|NCT04301765|DRUG|testosterone 1.62% gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
223910158|NCT04301765|OTHER|placebo gel|The gel will be applied daily by the participants (all participants will be trained in the application process and will be given printed instructions). The intervention will be for 6 months
223910159|NCT03805477|DRUG|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
223910160|NCT06210802|OTHER|Korean version of Defense and Veterans Pain Rating Scale|Defense and Veterans Pain Rating Scale translated into Korean
223910161|NCT06799312|DEVICE|Ipsilesional high frequency rTMS combined with physiotherapy|As mentioned in details in arms description.
223910162|NCT06799312|DEVICE|Contralesional Continuous Burst Theta rTMS (cTBS) + Physiotherapy|As mentioned in details in arms description.
223910163|NCT06799312|DEVICE|Sham rTMS + Physiotherapy|As mentioned in details in arms description.
223910164|NCT03387761|DRUG|Ipilimumab|"For Cohort 1:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~* Day 1: Ipilimumab 3 mg/kg~* Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~* Day 1: Ipilimumab 1 mg/kg~* Days 22: Ipilimumab 1 mg/kg"
223910165|NCT03387761|DRUG|Nivolumab|"For Cohort 1:~* Day 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~* Days 1 and 22: Nivolumab 1 mg/kg~* Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~\- Days 1, 22 and 43: Nivolumab 3 mg/kg"
223910166|NCT06482268|COMBINATION_PRODUCT|Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)|"Investigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents.~Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain."
223910167|NCT06798779|DEVICE|Glasses|The patients will have had their vision corrected with glasses that may contain both spherical and cylindrical corrections. The glasses prescription that offers the best subjective correction of vision are being recorded.
223910168|NCT06798779|DIAGNOSTIC_TEST|Corneal topography|This is a scan of the cornea (front of the eye). This gives us information on how the cornea is refracting light for the patient.
223715998|NCT00975650|DRUG|Androderm® (Positive Control)|QD administration
224084908|NCT03002974|DRUG|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
223715999|NCT00763672|OTHER|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
223716000|NCT00763672|OTHER|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
223716001|NCT06259019|DEVICE|Liquid Biopsy System (LBS)|Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
223716002|NCT01828957|BIOLOGICAL|Pneumostem®|
223716003|NCT01828957|OTHER|Normal Saline|
224084909|NCT01037673|PROCEDURE|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
224084910|NCT01037673|PROCEDURE|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
224084911|NCT05452967|OTHER|Distraction technique|The post operative pediatric patients will be given mobile phone in recovery for plying games and watching cartoons and with the help of this distraction technique will assess that routine rescue analgesia is needed or not
224084912|NCT00887757|DRUG|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
224084913|NCT00887757|DRUG|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
224084914|NCT00124345|DEVICE|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
224084915|NCT01737931|DRUG|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
224084916|NCT01737931|DRUG|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
224084917|NCT02521155|BEHAVIORAL|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
224084918|NCT02288884|DEVICE|Acticoat PostOp|
224084919|NCT02288884|DEVICE|OpSite PostOp|
224084920|NCT04897867|DEVICE|CoolSculpting® Elite System with CoolSculpting® Elite applicators|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
224084921|NCT01814787|OTHER|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI \> 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
224084922|NCT03909958|OTHER|Electroacupuncture+Routine rehabilitation training Group|"Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm\*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group."
224084923|NCT03909958|BEHAVIORAL|Routine rehabilitation training Group|"Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time."
224084924|NCT02242500|PROCEDURE|Coronally Advanced Flap|
224084925|NCT02242500|DEVICE|Mucograft|
223529098|NCT03081390|OTHER|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
223529099|NCT03081390|OTHER|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
223529100|NCT03081390|OTHER|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
223529101|NCT07004595|OTHER|Evaluation of patient frailty|Quality of Life questionnaire
223529102|NCT07010029|DEVICE|Coronary Sinus Reducer|Patients will undergo implantation of Coronary Sinus Reducer
224084926|NCT06226363|DRUG|LNF1901 Monoclonal Antibody Injection|LNF1901，7 dose groups:0.003mg/kg、0.03mg/kg、0.1mg/kg、0.3mg/kg、1mg/kg、2mg/kg、3mg/kg，IV, infusion time 60min±10min, Q3W, until disease progression or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first.
223529103|NCT07009730|PROCEDURE|Bypassing Agents|Cardiopulmonary bypass surgery, pulsatile flow
224084927|NCT02594436|DRUG|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
224084928|NCT00531804|DRUG|gantenerumab|Administered iv at escalating doses (7 cohorts)
224084929|NCT03183128|BIOLOGICAL|SER-109|"SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"
224084930|NCT03183128|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
224084931|NCT00004433|DRUG|pergolide|
224084932|NCT04326530|DEVICE|Pneumopipe® (European patent 12425057.2, Rome, Italy)|Collection of VOCs on a cartridge after that the child has normally breathed in it for 3 min, both at the baseline and at the last visit.
224084933|NCT04326530|OTHER|Other assessments|"* Spirometry, both at the baseline and at the last visit.~* 24-hour urine collection, both at the baseline and at the last visit."
224084934|NCT00389584|DRUG|irinotecan hydrochloride|
224084935|NCT00389584|PROCEDURE|cognitive assessment|
224084936|NCT00389584|PROCEDURE|management of therapy complications|
224084937|NCT00389584|RADIATION|radiation therapy|
224084938|NCT05641532|BEHAVIORAL|Physical activity behavioral intervention in persons newly diagnosed with MS|"1. The newsletters will provide the knowledge, skills, resources, and strategies for promoting physical activity in persons newly diagnosed with MS. These newsletters will be released seven times during the program. The first three newsletters will be released weekly, and the last four will be released every other week.~2. The one-on-one video coaching chats with participants will be conducted via Zoom, which consist of discussion and elaboration of newsletters content, supportive accountability, feedback and encouragement on behavior change. The chats further provide social persuasion for promoting behavior change. The chats are semi-scripted and individualized interventions (\~15 - 30 minutes/chat). The chats will occur seven times during the week when a newsletter is delivered.~3. The intervention includes a pedometer (NL-800 pedometer), a logbook, and a calendar for tracking daily step counts, planning of physical activity, setting goals, and monitoring progress over the program."
224084939|NCT02417389|DRUG|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
223910169|NCT06526364|OTHER|All participants will be asked to provide data and samples for collection and analysis.|"During the first year, data related to demographics, lifestyle, clinical examinations will be collected at baseline, at 6 months (optional) and at 12 months. PROs, cognitive and motor assessments will be performed using the Healios+Me smartphone app. Additionally, participants will be asked to provide biological samples (i.e., blood, cerebrospinal fluid and stool, saliva and hair) and imaging data (if performed as per standard of care). One unscheduled visit may be performed in case the participant comes to the hospital with the occurrence of flare or for a treatment change.~A long-term follow-up (FU, starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term FU medical data are collected either every 6 month or on a yearly basis, and PROs are collected every 6 months. Whether study visits are conducted in 6- or 12-monthly intervals depends on the schedule of the study visits for the Swiss MS cohort (SMSC)."
223910170|NCT05580991|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
223910171|NCT05076513|DRUG|Niraparib|"In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily."
224084940|NCT02417389|DRUG|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
224084941|NCT04941144|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
224084942|NCT00380562|BEHAVIORAL|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
224084943|NCT00845988|DRUG|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
224084944|NCT01234155|BEHAVIORAL|Exercise Training - Interval Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
224084945|NCT01234155|BEHAVIORAL|Exercise - Continuous Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
223716004|NCT05889195|DIAGNOSTIC_TEST|Cxbladder urine test|Cxbladder tests uses mRNA and DNA biomarkers in the urine to direct the management of UC from diagnosis to surveillance for disease recurrence.
223910172|NCT05076513|RADIATION|Radiation therapy|Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
223910173|NCT05983770|DRUG|AT-1501|IV infusions of AT-1501 20 mg/kg over 1 hour.
224084946|NCT01568203|DRUG|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
224084947|NCT01568203|DRUG|Placebo|Matching placebo control for AMG 579 at each dose level
224084948|NCT02705898|BEHAVIORAL|LPA+Fitbit|
224084949|NCT02705898|BEHAVIORAL|HEC|
224084950|NCT02820467|DEVICE|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
224084951|NCT05721066|DIAGNOSTIC_TEST|ClotPro assessment|Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)
224084952|NCT05721066|DIAGNOSTIC_TEST|Laboratory analysis|Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)
223716005|NCT00454883|DRUG|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
223910174|NCT05983770|DRUG|Tacrolimus|Tacrolimus will be administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter.
224084953|NCT05721066|OTHER|Interview|Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
224084954|NCT04297358|DRUG|Hyperbaric oxygen|40 consecutive (5/7) sessions of hyperbaric oxygen
224084955|NCT04391725|PROCEDURE|Periapical surgery with guided tissue regeneration|periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules
223910175|NCT00429364|DRUG|Losartan Potassium|Losartan .3 - 1.4 mg/kg
223910176|NCT00429364|DRUG|Atenolol|Atenolol .5 - 4 mg/kg
223910177|NCT04871529|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223910178|NCT04871529|DRUG|Avelumab|Given IV
223910179|NCT04871529|DRUG|Gemcitabine Hydrochloride|Given IV
223910180|NCT04871529|DRUG|Carboplatin|Given IV
223910181|NCT04681690|OTHER|No intervention, observation only.|Observation only
223910182|NCT05184452|DRUG|PGDM1400LS (5mg/kg, IV)|5 mg/kg to be administered via IV infusion
223910183|NCT05184452|DRUG|PGDM1400LS (20mg/kg, IV)|20 mg/kg to be administered via IV infusion
223910184|NCT05184452|DRUG|PGDM1400LS (20mg/kg, SC)|20 mg/kg to be administered via SC infusion
223910185|NCT05184452|DRUG|PGDM1400LS (40mg/kg, IV)|40 mg/kg to be administered via IV infusion
223910186|NCT05184452|DRUG|PGDM1400LS (40mg/kg, SC)|40 mg/kg to be administered via SC infusion
224084956|NCT04391725|PROCEDURE|Periapical surgery without anyguided tissue regeneration|periapical surgery will be done followed by flap closure
223716006|NCT00571545|BEHAVIORAL|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
223910187|NCT05184452|DRUG|PGDM1400LS (1.4g, IV)|1.4gram to be administered via IV infusion
223910188|NCT05184452|DRUG|PGDM1400LS (1.4g, SC)|1.4gram to be administered via SC infusion
223910189|NCT05184452|DRUG|VRC07-523LS (20mg/kg, IV)|VRC07-523LS 20mg/kg administered via IV infusion
223910190|NCT05184452|DRUG|VRC07-523LS (20mg/kg, SC)|VRC07-523LS 20mg/kg administered via SC infusion
223910191|NCT05184452|DRUG|VRC07-523LS (1.4g, IV)|VRC07-523LS 1.4g administered via IV infusion
223910192|NCT05184452|DRUG|VRC07-523LS (1.4g, SC)|VRC07-523LS 1.4g administered via SC infusion
224084957|NCT00243659|BIOLOGICAL|ReFacto AF|
224084958|NCT02342405|OTHER|80% oxygen|
224084959|NCT02342405|OTHER|30% oxygen|
224084960|NCT00439582|DIETARY_SUPPLEMENT|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
224084961|NCT00439582|DIETARY_SUPPLEMENT|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
223716007|NCT00571545|BEHAVIORAL|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
223716008|NCT03648541|DRUG|Spesolimab|Solution
223716009|NCT01903187|DEVICE|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
223910193|NCT05184452|DRUG|VRC07-523LS (40mg/kg, IV)|VRC07-523LS 40mg/kg administered via IV infusion
224084962|NCT03310970|DRUG|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
224084963|NCT03310970|DRUG|Lidocaine hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
224084964|NCT03310970|DRUG|Lidoderm 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
223910194|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, IV)|PGT121.414.LS 20mg/kg administered via IV infusion
223910195|NCT05184452|DRUG|PGT121.414.LS (20mg/kg, SC)|PGT121.414.LS 20mg/kg administered via SC infusion
223910196|NCT05184452|DRUG|PGT121.414.LS (1.4g, IV)|PGT121.414.LS 1.4g administered via IV infusion
223910197|NCT05184452|DRUG|PGT121.414.LS (1.4g, SC)|PGT121.414.LS 1.4g administered via SC infusion
223910198|NCT05184452|DRUG|PGT121.414.LS (40mg/kg, IV)|PGT121.414.LS 40mg/kg administered via IV infusion
223910199|NCT03923374|DRUG|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
223910200|NCT03923374|DIAGNOSTIC_TEST|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
223910201|NCT03923374|DIAGNOSTIC_TEST|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
223910202|NCT05876533|DEVICE|Cordio HearO|"Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients"
223910203|NCT04772196|DRUG|Vitamin D3|50,000 IU Vitamin D3 weekly for 8 weeks
223910204|NCT02255799|DRUG|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
223910205|NCT02255799|DRUG|Placebo|Placebo capsule once daily for 70 days.
223910206|NCT05247255|DRUG|Active Comparator|QL block with 0.25% ropivacaine
223910207|NCT05247255|DRUG|Placebo Comparator|QL block with saline
223910208|NCT02935478|DEVICE|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
224084965|NCT00028990|DRUG|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
224084966|NCT00028990|DRUG|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
223910209|NCT06773754|OTHER|Five-days-On and Two-days-Off|Take Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir alafenamide five days a week (Five-days-On and Two-days-Off)
223529104|NCT07010861|OTHER|Expressive Art Therapy|As a strategy for coping with trauma, art production creates therapeutic effects on the individual with its sensory and physical aspects (Chapman, 2013; King-West and Hass-Cohen, 2008). When verbal expression is insufficient or carries the risk of re-traumatization, expressive art therapy offers a safe space through non-verbal expression (Talwar, 2007). It is stated that art production is effective in repairing self-integrity ruptures that occur in traumatic experiences (Harris, 2009). Through creative processes, the individual can restructure both internally and externally. Expressive art therapy, especially when applied in a group environment, creates a psychotherapeutic effect by providing participants with the opportunity to express their emotions, imagination and unconscious processes (Malchiodi, 2012; Kim et al., 2021). The commitment and reflective understanding that occur in group psychotherapy are among the factors that give hope and strength (Robb, 2017).
223529105|NCT06624345|PROCEDURE|Inspiratory muscle training|Patients in the IMT group received the intervention using a threshold loading device set at a pressure range of 5-39 cmH₂O. They were instructed to perform six sets of five breaths, totaling 30 breaths, twice daily for six weeks. Additionally, the aerobic exercise regimen included upper limb exercises (raising arms without resistance), a lower limb stepping warm-up, and a walking routine consisting of 5 minutes of slow walking, 2 minutes of brisk walking, and another 5 minutes of slow walking, for a total of 30 minutes per day.
223529106|NCT06624345|PROCEDURE|Control Group|Subjects received routine care.
223529107|NCT06684769|DEVICE|Emdogain® FL|Enamel Matrix Derivatives
223910210|NCT04452721|OTHER|dynamic compression system|It is a harness that the patient wears all day long for an average duration of 1 year, and that remodels the chest by exerting a moderate pressure on it
223529108|NCT06684769|DEVICE|Labrida BioClean®|Oscillating Chitosan Brush
223529109|NCT06690151|BEHAVIORAL|Neurodevelopmental assessment (Bayley-IV)|Assessment of developmental delays through administration of the Bayley-4 test by a neuropsychologist
223716010|NCT01903187|PROCEDURE|Sham|Renal artery angiogram
223716011|NCT06837740|OTHER|Aromatherapy group|Effects of Aromatherapy Interventions
223716012|NCT06837740|OTHER|Aromatherapy with music therapy group|Effects of Music Therapy and Aromatherapy Interventions
223716013|NCT06297928|PROCEDURE|baratric surgery|Participants in this study will undergo bariatric surgery, either gastric bypass or sleeve gastrectomy, based on clinical criteria and consensus from a multidisciplinary team.
223910211|NCT05845502|BIOLOGICAL|SZ003 CAR-NK|Drug: SZ003 CAR-NK In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8 ,2.0×10\^8 and5.0×10\^8 cells. The infusion is given every 2 weeks.
223910212|NCT06665113|DEVICE|taVNS real stimulation|For the real stimulation group, two modified point electrodes will deliver stimulation near the auricular branch of the vagus nerve in the left concha cymba. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs; continuous stimulation for 60 seconds, followed by a 10-second off period, repeated for 30 minutes.
223910213|NCT06665113|DEVICE|taVNS sham stimulation|For the sham stimulation group, two modified point electrodes will deliver stimulation to the earlobes.Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs; continuous stimulation for 60 seconds, followed by a 10-second off period, repeated for 30 minutes.
223910214|NCT06048419|BEHAVIORAL|Home Program|Home program for 6 weeks (1 hr and 15 minutes per week)
223910215|NCT03408665|RADIATION|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
223910216|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
223910217|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
223910218|NCT04996628|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
223910219|NCT05789225|BEHAVIORAL|Fall prevention program|The intervention consists of the fall prevention program for ambulatory and non-ambulatory people with multiple sclerosis. The program is group-based with 8 participants in each group, led by a facilitator, and performed online. It comprises seven two-hour sessions held once a week, and a booster session held four weeks after the seventh session. In addition participants will receive a brochure about falls and fall risk factors.
223910220|NCT05789225|OTHER|Brochure|Control-group participants will receive a brochure about fall risk factors and fall prevention in addition to the standard MS care and rehabilitation.
223910221|NCT05766670|DRUG|Vancomycin Hydrochloride|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
223910222|NCT05766670|DRUG|Gentamicin|The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
223910223|NCT05766670|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
223910224|NCT06263959|DRUG|GST-HG131|GST-HG131 will be administered.
223910225|NCT06263959|DRUG|Placebo to match GST-HG131|Placebo to match GST-HG131 will be administered.
223910226|NCT06296199|OTHER|VR|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to watch and listen with VR headphones to a concert by a group of musicians playing music."
223910227|NCT06296199|OTHER|Music only|"The participant will be seated comfortably in an armchair. The intervention will last 15 minutes. It will take place once.~This group's intervention will be to listen with conventional headphones to a concert by a group of musicians playing music."
223910228|NCT02584647|DRUG|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)-internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
223910229|NCT02584647|DRUG|sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
224084967|NCT00997009|DRUG|paclitaxel|175 mg/m2 IV day 1, every 21 days
223910230|NCT06141733|OTHER|NIRS group|Standard care plus cerebral oxygen saturation monitoring with a dedicated treatment guideline (NIRS-group) during immediate transition (first 15 minutes after birth) and resuscitation.
223910231|NCT03956784|DEVICE|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~* Normal situation~* Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~* Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
223910232|NCT03956784|OTHER|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~1. Immediate complications and warning signs:~   * Tachycardia\> 120 bpm~  * Dyspnea~  * Rectorragies and / or melena~  * Vomiting with or without presence of blood~  * Major abdominal pain (visual analogue scale\> 6/10)~  * Fever\> 38~2. Management to deal with complications: call the service and / or the surgeon~3. Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
223910233|NCT00661141|DRUG|Antizol|
223910234|NCT00661141|DRUG|Placebo|
223910235|NCT00661141|OTHER|Ethanol|oral dose of ethanol (0.5 g/kg)
223910236|NCT06165172|DEVICE|MyoRegulator®|Study participants will receive treatment using the MyoRegulator® device 3 times a week for 2 x 30 minutes per session. The first week of treatment will be followed by a 1-week rest period with no treatments. Treatment sessions will then resume for 4 consecutive weeks, 3 times per week. A follow-up visit will be scheduled 4 weeks after the last treatment session.
224084968|NCT00997009|DRUG|carboplatin|AUC 5 IV day 1 every 21 days
224084969|NCT00997009|DRUG|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
223529110|NCT06690151|OTHER|Biological sampling|"The samples to be collected at delivery will include:~* A 4 ml maternal blood sample in an EDTA tube for lipidomic and metabolomic analyses at delivery~* A 6 ml maternal blood sample in an EDTA tube (2 tubes of 3 ml) for genetic analysis~* A 4 ml venous cord blood sample in an EDTA tube for transcriptomic and epigenetic analysis; and a 2 ml EDTA tube for metabolomic/lipidomic analysis~* Samples from fresh placenta for transcriptomic, epigenetic, metabolomic, and lipidomic analyses~* A meconium sample collected as soon as possible after birth in a dry tube for microbiome analysis~During hospitalization for the cardiac surgery:~* Genome analysis samples will be collected from the father and the infant. These samples will be taken in two EDTA tubes of 3 ml each.~* Perioperative neurobiomarker samples will be collected (one EDTA tube of 500 μL preoperatively and postoperatively on Day 1 and 2).~At 1 month, a stool sample will be collected from the infants for microbiome analysis."
224084970|NCT00516594|PROCEDURE|Diet with polyfructans and viscous fibers or soy protein|
224084971|NCT02613455|PROCEDURE|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
224084972|NCT02613455|DRUG|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
224084973|NCT02613455|DRUG|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
223529111|NCT06690151|BEHAVIORAL|ELFE dietary questionnaire|Questionnaire on diet and lifestyle during pregnancy (only for the mother)
223716014|NCT06848790|PROCEDURE|Calibrated interdental brush|participants will use calibrated interdental brushes
223910237|NCT03804788|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
224084974|NCT01291602|DRUG|NXL104|IV Solution
224084975|NCT01291602|DRUG|CAZ104|IV Solution
224084976|NCT01291602|DRUG|Placebo|IV saline
224084977|NCT03566329|DRUG|Magnesium sulphate|Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
224084978|NCT03566329|DRUG|Lidocaine Hydrochloride|lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
224084979|NCT03566329|DRUG|Normal saline|Normal saline infusion with the same rate of infusion as the study drugs
224084980|NCT01172015|OTHER|blood samples|
224084981|NCT05796986|PROCEDURE|Endovascular procedure of treatment of wide neck saccular cerebral aneurysm|Endovascular different modalities for occlusion of wide neck saccular cerebral aneurysms include stent assisted coiling or balloon assisted coiling or flow diverter or 3D coiling
224084982|NCT00705263|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
224084983|NCT00705263|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
224084984|NCT01752023|DRUG|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
224084985|NCT01752023|DRUG|Cisplatin + Gemcitabine|Active Comparator
224084986|NCT01902732|DEVICE|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
224084987|NCT02628860|DRUG|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
224084988|NCT00018954|DRUG|asparaginase|
224084989|NCT00018954|DRUG|cyclophosphamide|
224084990|NCT00018954|DRUG|cytarabine|
224084991|NCT00018954|DRUG|daunorubicin hydrochloride|
224277453|NCT02934633|BEHAVIORAL|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
223529112|NCT06690151|BEHAVIORAL|Post-Traumatic Stress Questionnaire IES-R (Impact of Event Scale - Revised)|The IES-R is a 22-item self-report measure (for DSM-IV) that assesses subjective distress caused by traumatic events.
223529113|NCT06690151|OTHER|Data collection for the study (Cardiovascular, developemental, fetal, pregnancy, MRI)|"* Cardiovascular follow-up data collection~* Developmental follow-up data collection~* Collection of postoperative brain MRI data, scheduled between Day 5 post-surgery and the end of the hospital stay~* Collection of data on pregnancy exposure, obstetric events, and delivery data.~* Collection of fetal ultrasound data (T2 and T3).~* Collection of fetal echocardiography data (T2 and T3)."
223529114|NCT02438761|DRUG|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
224084992|NCT00018954|DRUG|doxorubicin hydrochloride|
224084993|NCT00018954|DRUG|etoposide|
224084994|NCT00018954|DRUG|ifosfamide|
224084995|NCT00018954|DRUG|mercaptopurine|
224084996|NCT00018954|DRUG|methotrexate|
224084997|NCT00018954|DRUG|prednisone|
224084998|NCT00018954|DRUG|vincristine sulfate|
224084999|NCT00018954|PROCEDURE|conventional surgery|
224085000|NCT00018954|RADIATION|radiation therapy|
224085001|NCT02440581|DRUG|Alendronate|
224085002|NCT02440581|DRUG|Teriparatide|
224085003|NCT02440581|DRUG|Cinacalcet|
224085004|NCT00611494|DRUG|MMF|Gradual optimization of drug dosage, as clinically tolerated.
224085005|NCT00611494|DRUG|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
224085006|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
223529115|NCT07013409|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
223529116|NCT07013409|DIETARY_SUPPLEMENT|Maltodextrin|The trial period of this study is 3 months, and each patient will undergo 4 visits (in month 0, month 1, month 2, and month 3).
223910238|NCT03804788|BEHAVIORAL|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
223910239|NCT02088658|BEHAVIORAL|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
223910240|NCT05650190|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
223910241|NCT05650190|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
223910242|NCT06170437|BEHAVIORAL|Smoke-free home resident intervention|Study staff delivered intervention on how to adopt a smoke free home using a pamphlet
223910243|NCT06170437|BEHAVIORAL|Lay Health Worker coaching|Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
223910244|NCT05662293|OTHER|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part)|Data collection: Major adverse cardiovascular event (MACE) assessment questionnaire (prospective part). The assessment will be done via mail, letter or phone
223910245|NCT05662293|OTHER|Data collection: Quality of Life (QoL) Questionnaire (prospective part)|"Data collection: Quality of Life (QoL) Questionnaire (prospective part). The questionnaire EQ-5D-5L questionnaire will be used to assess quality of life."
223910246|NCT05662293|OTHER|Data collection (retrospective study)|Anonymized search and review of patients electronic health records of the University Hospital of Basel for patients with a reduced LVEF and a concomitant (±1year or after any observation of a reduced LVEF in imaging) diagnosis of arrhythmia known to be causing AiCM.
223910247|NCT05662293|OTHER|Data collection (prospective study database)|Data collection on alcohol consumption, family history, rhythm disorder, hospitalizations, cardiac assessments, adverse events at baseline, 6 months, 1 year, 2 years and 5 years.
223910248|NCT05839262|OTHER|Conventional physical rehabilitation plus Active video games (CPR+AVG)|"In each session a routine of conventional physical rehabilitation and active video games is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR+AVG: Consists of conventional exercises (aerobic, muscle strengthening, postural balance and flexibility) added to a set of interactive video games available for the Nintendo Switch console."
223910249|NCT05839262|OTHER|Conventional physical rehabilitation alone (CPR)|"In each session a routine of conventional exercises is performed. The duration is 10 weeks / 3 sessions per week (30 sessions).~CPR: Conventional exercises (aerobic, muscle strengthening, postural balance and flexibility)."
223910250|NCT04170634|OTHER|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
223910251|NCT06804629|BEHAVIORAL|Moderate-to-High Intensity Resistance Exercise Training|Resistance exercise training was designed in accordance with World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed such that moderate-to-high intensity participants could achieve two sets of 8-12 repetitions of the eight exercises before volitional fatigue, a deterioration in lifting form, or failure to complete a repetition, using loads of approximately 70-80% of their estimated one-repetition maximum. Completed in the following order, the exercises were: barbell back squat, barbell bench press, hexagon bar deadlift, barbell bent over row, dumbbell lunges, seated dumbbell lateral raises, weighted or unweighted abdominal crunches, and seated dumbbell bicep curls. There was one minute of rest between each set, and two minutes of rest between each exercise. If participants could complete two sets of 12 repetitions, load was increased gradually by approximately 5% in the following session.
224085007|NCT04042194|PROCEDURE|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
224085008|NCT04097327|OTHER|Ectoin Dermatitis Cream 7% (EHK02)|Application of Ectoin Dermatitis Cream in accordance with the instructions for use
223529117|NCT06689423|DEVICE|Credo POCT Device|Testing Credo's POCT device for respiratory viruses detection.
223529118|NCT07003698|PROCEDURE|The group without the rectointercostal nerve block|Patients in this group will be administered dexketoprofen 50 mg and tramadol 100 mg intravenously in the intraoperative period. These patients will not receive the rectointercostal nerve block.
223529119|NCT07003698|PROCEDURE|The rectointercostal plane block|The rectointercostal plane block is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position. Additionally, patients in this group will be administered dexketoprofen 50 mg and tramadol 100 mg intravenously in the intraoperative period.
223716015|NCT06541665|DRUG|ONO-4059|Specified dose, once daily
223716016|NCT06541665|DRUG|Rituximab|Specified dose on specified days
223716017|NCT06541665|DRUG|Methotrexate|Specified dose on specified days
223716018|NCT06541665|DRUG|Procarbazine|Specified dose on specified days
223716019|NCT06541665|DRUG|Vincristine|Specified dose on specified days
223716020|NCT04623216|BIOLOGICAL|Sabatolimab|Sabatolimab is a solution in vial for IV infusion
223716021|NCT04623216|DRUG|Azacitidine|Azacitidine comes in Vial for IV infusion or subcutaneous administration
223910252|NCT06804629|BEHAVIORAL|Low Intensity SHAM Resistance Exercise Training Attention Control|The low intensity SHAM condition was matched all features of engagement with the moderate-to-high intensity intervention apart from load, and load progression. Low intensity SHAM participants completed the same program with loads of approximately 20% of their estimated one-repetition maximum. To maintain low intensity, repetitions completed on the main, heavier lifts (i.e., back squat, bench press, deadlift, bent over row) were increased from 10 in one session to 12 in the next; load was then increased by approximately 10% in the following session, and 10 reps were performed again. On the remaining lighter, assistance lifts, eight repetitions were performed per set, then one repetition was added to both sets in each session, and load was increased by the smallest increment possible when two sets of 12 repetitions were performed. Borg's 6-20 rating of perceived exertion scores were used to monitor intensity, such that if scores exceeded 11, load and reps were not progressed.
223910253|NCT06804694|BEHAVIORAL|TECC-T1D3 Program|The TECC-T1D3 program is a twelve-week virtual care intervention designed to support individuals with Type 1 Diabetes (T1D) and Diabetes Distress. The program includes a health coach (HC) and a virtual care team (VCT) of T1D, mental health experts and peer support, offering comprehensive care through various communication channels, including WebEx, phone calls, and text messaging. The program aims to: i. Provide T1D specific mental health and wellbeing support, ii. Provide guidance on how to communicate with others about T1D, manage stigma and ask for help with diabetes management and iii. Facilitate connections with T1D communities. Participants can choose topics of discussion based on their needs and will be directly supported by the HC and indirectly monitored by VCT.
223910254|NCT06804694|OTHER|Education Intervention|The Education Intervention is a low-intensity, education-focused intervention consisting of 10 automated emails over 12 weeks, providing generalized educational messages with links to resources for mental health support and well-being for individuals living with T1D.
223910255|NCT04251481|RADIATION|PET/MRI with FDG|For the PET/MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for both the MRI and PET portions of the examination. The dye for the PET portion will be 18F-fluorodeoxyglucose (FDG). FDG is an FDA-approved radioactive substance (isotope) that contains chemicals that can be traced by PET/MRI. The dye for the MRI portion will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
223910256|NCT04251481|RADIATION|MRI scan without contrast|MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner to scan the neck ; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
223910257|NCT04251481|RADIATION|MRI with gadolinium|For the MRI scans, an intravenous (IV) catheter (thin tube) will be used to administer dyes (contrast) for MR scans. The dye for the MRI will be a gadolinium based contrast medium which is also an FDA-approved substance that makes certain tissues, abnormalities or disease processes more clearly visible on MRI scans. MRI uses a strong magnetic field to create images of the body. Subjects will be asked to lie on a table that will slide into the scanner; Wear earplugs to reduce the noise made by the MRI scanner and lie still throughout the time in the scanner.
223910258|NCT06805968|OTHER|High Intensity Exercise + Placebo|high intensity exercise
223910259|NCT06805968|OTHER|Low Intensity Exercise + Placebo|low intensity exercise
223910260|NCT06578455|DRUG|Cannabidiol (CBD) Powder|66.68 mg CBD per capsule for a total of 400 mg CBD per serving
223910261|NCT06578455|DRUG|Cannabidiol 100 MG/ML [Epidiolex]|100 mg CBD/mL for a total of 400 mg CBD per serving
223910262|NCT06805682|OTHER|Usual Care|Children will be followed using each CPS participating center's usual practices
223910263|NCT06804382|BEHAVIORAL|Academic detailing|Academic detailing is an evidence-based, 1-on-1 outreach education technique intended to promote clinician behavior change. Information gained during earlier focus groups will be used to develop study-specific materials.
223910264|NCT01386138|BEHAVIORAL|Psycho-education|Receive RBT education and peer-support in a group format.
223910265|NCT01386138|BEHAVIORAL|Experimental|Receive RBT education and a pro-active counseling method
223910266|NCT06805864|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab is administered at 200 mg every 3 weeks for the first 2 cycles during Chemo-CIRT, after completion of radiotherapy, the dose is increased to 400 mg and given every 6 weeks for a total of 17 cycles over 2 years.
223910267|NCT06805812|DRUG|Palbociclib|Administered in combination with endocrine therapy
223910268|NCT06805812|DRUG|Ribociclib|Administered in combination with endocrine therapy
223910269|NCT06805812|DRUG|Abemaciclib|Administered in combination with endocrine therapy
223910270|NCT05569772|DRUG|Semaglutide Pen Injector|maintenance dose of 1mg SC once weekly
223716022|NCT04673838|OTHER|neurodevelopmental therapy|Considering the individual needs and wishes of the patient, an exercise program will be created for each patient in accordance with their functional levels and supporting active participation of the person. The treatment program tailored to the patient; It will include weight transfer to the affected side in different positions, functional reaching out activities, stepping forward and walking activities.
223719385|NCT01029795|DRUG|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
223719386|NCT01029795|DRUG|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
223910271|NCT05569772|DRUG|Semaglutide placebo|maintenance dose of 1mg SC once weekly
223910272|NCT05967351|GENETIC|delandistrogene moxeparvovec|No study drug will be administered as part of this study. Eligible participants who received treatment with delandistrogene moxeparvovec during a previous clinical study will be included.
224085009|NCT05190952|DRUG|Bupivacaine|Bupivacaine 0.25% 1ml/kg will be injected subcutaneously by the surgeon before wound closure.
224085010|NCT05190952|DRUG|Ketamine|In addition to bupivacaine, ketamine 1mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and ketamine will be administered using two separate syringes.
223910273|NCT06578117|DEVICE|Vision Training and Learning Task|"Participants will be seated at a computer, and will be shown a random-noise visual stimulus drifting in one of eight directions. Participants will be instructed to indicate the direction of motion they perceive using a Sony Access Controller or a computer keyboard. Sound cues during stimulus presentation will also be used to ensure participants are aware of stimulus onset during the training task.~After several repetitions of this visual training, a second set of visual cues will be presented to evaluate participant's learning of the program. Responses will be provided in the same manner by input from the controller or the keyboard."
223719387|NCT01029795|DRUG|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
223910274|NCT06806124|DEVICE|Elevation Training Mask|The Elevation Training Mask (ETM) 2.0 was used in all 36 training sessions over the 12 weeks of the study with progressive increases in air restriction to simulate altitude training. This methodology of using ETM during exercise was chosen following the study by Porcari et al. The first week, the additional altitude simulation was 914 m and in the second, 1,829 m. These initial 2 weeks served to adjust the use of the ETM during training, as a process of acclimatization to the altitude simulation and airflow restriction. For the period between weeks 3 and 6 (both inclusive) the simulated altitude was 2,743 m, and for weeks 7-12 (both inclusive), the ETM was set to simulate 3658 m altitude.
223910275|NCT06806124|DEVICE|Sham Elevation Training Mask|For the Control Group, the Elevation Training Mask (ETM) 2.0 was used for 12 weeks with the largest openings available and without using the air restriction filters, so that there was little respiratory obstruction and the reduction in air flow was minimal, with the aim of having a simulated ETM treatment
223910276|NCT06336902|BIOLOGICAL|Balstilimab|Given IV
223910277|NCT06336902|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223910278|NCT06336902|BIOLOGICAL|Botensilimab|Given IV
223910279|NCT06336902|PROCEDURE|Computed Tomography|Undergo CT scan
223910280|NCT06336902|OTHER|Dietary Intervention|Undergo FMD
223910281|NCT06336902|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223910282|NCT06336902|DIETARY_SUPPLEMENT|Vitamin C|Given IV
223910283|NCT04706832|DEVICE|Thoracic Splanchnic Magnetic Neuromodulation Therapy|ThorS-MagNT is performed by low-frequency, low-intensity repetitive magnetic stimulation bilaterally around T7-8 intervertebral space twice a day for 5 days with a total 1200 magnetic stimulations per treatment session at 1 Hz.
223910284|NCT06804759|OTHER|Investigational Facial Serum #1|Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.
223910285|NCT06804759|OTHER|Investigational Facial Serum #2|Investigational Facial Serum #2 is made with an active comparator.
223910286|NCT06804759|OTHER|Investigational Facial Serum #3|Investigational Facial Serum #3 is a placebo comparator
223910287|NCT06805799|OTHER|Follow up to Mindfulness RCT using a Still Face Paradigm|Mothers who participated in an RCT of mindfulness to prevent hypertensive disorders of pregnancy and their infants at 6 months of age will attend one session in which they are consented and prepared for the Still Face Paradigm (SFP). The SFP consists of a sequence of three, 2-minute episodes in which the parent and the infant are seated about one meter away from each other. Across a pre-task baseline, task episodes (free play and still-face), and recovery periods, mothers and infants will wear wireless heart rate monitors to assess respiratory sinus arrhythmia and heart rate. At 12 months, mothers will complete lab work to assess cardiovascular risk and infants' growth velocity will be culled from pediatric medical records.
223910288|NCT06804941|BEHAVIORAL|Online transdiagnostic CBT|This treatment is provided through a secure web platform in which psychoeducation, worksheets, and exercises are presented in online modules similar to chapters in a book. Participants will receive weekly written feedback on their work and progress by a therapist who gives gradual access to the treatment modules. The lion's share of the contact between the therapist and the patient thus takes place through messages (similar to email) in the online treatment platform. It is however allowed to also have one to three face-to-face sessions on-site or through video calls to provide technical assistance and therapeutic support in accordance with the treatment model. Core components are: (a) psychoeducation about emotions and CBT, (b) functional analysis, (c) mindfulness practice, (d) breaking dysfunctional emotion-driven behaviors, and (e) exposure exercises.
223910289|NCT06804941|OTHER|Primary care as usual|It is mandatory for primary care services in Stockholm, Sweden, to have staff with adequate competence in the assessment and treatment of common mental disorders. Typically, these patients are handled by general practitioners, psychologists, nurses, or social workers. As this comparator is intended to reflect real routine primary care, the interventions will not be controlled by the research project. We expect that participants allocated to this condition will receive an active treatment.
223910290|NCT06802900|PROCEDURE|Clinical Outcomes and Surgical Insights from Nerve-Sparing Hysterectomy with Uterine Skeletonization for Deep Infiltrative Endometriosis|In this retrospective study, the patents whom underwent nerve sparing modified radical hysterectomy for deeply infiltrating endometriosis with uterine skeletonization technique will be reviewed. The uterine skeletonization technique was developed by the princible investigator (BK) for DIE modified radical hsyterectomy and performed systematically in Basaksehir Cam ve Sakura City Hospital. The detailed surgical steps, surgical data such as operation duration, surgical type (e.g., hysterectomy + salpingo-oophorectomy, excision of parametrial, rectovaginal, or vaginal nodules, and bowel resections), and intraoperative complications (organ injuries, blood transfusions, conversion to open surgery) will be recorded. Early and late postoperative complications (fever, deep vein thrombosis, sepsis, pelvic abscess, genitourinary fistulas, anastomotic leaks, reoperation, vaginal cuff bleeding or abscess, and bladder dysfunction) will also be evaluated.
223910291|NCT06805981|OTHER|telerehabilitation group|Asynchronous exercise videos were sent for follow-up for 8 weeks.
223910292|NCT06805981|OTHER|conventional rehabilitation group|An exercise brochure with exercises to be followed for 8 weeks was given.
223910293|NCT06558188|DRUG|Romosozumab|romosozumab 210 milligrams monthly
223910294|NCT06558188|DRUG|Teriparatide|teriparatide 20 micrograms daily
223910295|NCT06806072|OTHER|Balneotherapy|The intervention consists in 3 weekly sessions of balneotherapy during 4 weeks.
223910296|NCT06804330|PROCEDURE|root canal treatment and intracanal medicament|Root canal biomechanical preparation followed by intracanal placement of intracanal medicament according to the arm
223719388|NCT00861432|OTHER|additive homeopathic treatment|These patients receive additive homeopathic treatment
223910297|NCT06805916|BEHAVIORAL|NAO-Assisted Therapy|The intervention sessions included tasks designed to engage the child in verbal and social interactions, such as naming objects, responding to questions, and performing gestures. The NAO robot provided consistent and predictable feedback, while therapists supported and reinforced appropriate communicative behaviors.
223910298|NCT06805916|BEHAVIORAL|Standard therapeutic|Standard therapeutic approaches included exercises aimed at improving verbal communication and social engagement, such as naming objects, sentence construction, and comprehension tasks. Therapists adapted the intervention to the child's individual communication goals.
223910299|NCT02951091|OTHER|biomarker screening|immunohistochemistry and in situ hybridization
223910300|NCT06246734|BEHAVIORAL|Hasbro Joy for All robot pet companion|The robot pets are stuffed animals (dogs and cats) that have features that make them seem lifelike. For example, the animal toys turn their heads when petted, purr or make puppy sounds, feel warm, have a heartbeat, and go to sleep when they are ignored. They respond to attention and petting like a real pet. The robot pets do not collect information and do not require any maintenance, except a battery. Engagement with the device is at the discretion of participants.
223910301|NCT06804577|OTHER|peanut ball|The experimental group will use peanut balls;
223910302|NCT05740839|BEHAVIORAL|HIIT Exercise Program|Exercise program with stationary bike via the Zoom platform.
223910303|NCT05740839|BEHAVIORAL|Control Group|Usual Activities
223910304|NCT06787209|BEHAVIORAL|Program to improve lumbopelvic function.|"Each individual will receive a weekly session log at the start of the intervention, allowing them to record the total number of sessions performed between in-person visits and the perceived exertion.~In the strengthening phase, both compound and isolated exercises will be performed. These exercises will be of low intensity and maintained for prolonged periods until the patient reaches fatigue or can no longer perform the repetitions correctly. If the patient reaches 40 repetitions, the exercise will be progressed in difficulty. The patient will have one minute of rest after each set.~Each session will include a total of 4 sets focused on the gluteal muscles The speed of execution for each repetition will be between 4-6 seconds. After the strengthening phase, three unilateral static stretches targeting the hip flexors will be performed, each lasting one minute.~The entire program will be performed using bodyweight exercises and adapted exercises that can be done at home."
223910305|NCT06787209|BEHAVIORAL|generic health care|"The patients will receive 10 physiotherapy sessions at the health center throughout 4 weeks.They will be taught active exercises and undergo passive therapies to address their low back pain. Each session will last approximately 30 minutes.~The intervention will therefore be variable depending on the assigned physiotherapist, as there is no standardized protocol for action."
223910306|NCT04047290|DRUG|AK112|AK112 is a PD1/VEGF bispecific antibody.
223910307|NCT05144555|OTHER|Fixed orthodontic treatment with stainless steel brackets|"Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
223910308|NCT05144555|OTHER|Fixed orthodontic treatment with ceramic brackets|"Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment."
223910309|NCT04972942|DRUG|Daratumumab|"Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)"
223910310|NCT05843877|BIOLOGICAL|Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy|Islet cells are isolated from patients healthy pancreatic tissue. Following total pancreatectomy, these autologous cells are injected into the portal vein, to implant in the liver and produce insulin.
223910311|NCT05843877|PROCEDURE|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)|As a standard procedure, the tumor-affected region of the pancreatic head with surrounding tissue and lymph nodes is removed during surgery. Reconstruction is performed by pancreaticojejunostomy.
223910312|NCT04180202|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
223910313|NCT03866967|BIOLOGICAL|AK105|intravenous (IV) infusion
223910314|NCT06533150|OTHER|multiomic profiling|2 aliquots of patients-derived bone tissue specimens (collected as surgical waste from routinely surgeries) will be collected and exploited from proteins and metabolites isolation according to standardized protocol. Then, samples will be digested using Filter-aided sample preparation digestion protocol and analysed by Liquid Chromatography Tandem Mass Spectrometry. Peptides will be loaded on the PepMap 100 C18 trap cartridge, and subsequently separated on an EASY Spray C18 analytical column. The mass spectrometer, equipped with a nanoESI spray source, operates in positive ion polarity and MS/MS mode. Also metabolites will be assessed by LC-MS/MS and will be separated by HPLC. Obtained results will be analyzed by integrated pathway analysis (IPA) to achieve the multiomic profiling of each patient thus identifying druggable targets to be exploited in drug design. The selected biomolecules will be then tested in patient cells using the developed bioink-nanoparticle complex.
223910315|NCT04428203|DRUG|Epidiolex Oral Liquid Product|600 mg Oral solution
223910316|NCT04428203|DRUG|Epidiolex Oral Liquid Product|800 mg oral solution
223910317|NCT04428203|DRUG|Epidiolex Oral Liquid Product|800 mg oral solution
223910318|NCT05280574|DEVICE|Blinded GE Portrait Monitoring|Continuous vital signs will be monitored and recorded by GE Portrait but not available to clinicians.
223910319|NCT05280574|DEVICE|Unblinded GE Portrait Monitoring|Continuous vital signs will be monitored and evaluated by clinicians using GE Portrait.
223910320|NCT04134910|PROCEDURE|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
223910321|NCT05305794|DRUG|Insulin + semaglutide treatment|Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
223910322|NCT05305794|DRUG|Usual insulin treatment|Usual insulin treatment
223910323|NCT05305794|BIOLOGICAL|Biological check-up|at D0, D90 and D180
223910324|NCT05068414|DIAGNOSTIC_TEST|Blood panel|"* Thrombin generation test~* Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~* International Normalized Ratio (if anti-vitamin K therapy is prescribed)~* Platelet aggregation test"
223910325|NCT06394388|BEHAVIORAL|Cuidando juntos|"Caregiver TLC program will be culturally tailored by including a focus on addressing cultural values to promote social connectedness and translated into Spanish (Cuidando Juntos).~Cuidando Juntos consists of 8 modules: stress management; behavioral activation; building resilience; building self-care skills; managing difficult emotions; reducing isolation; and two on understanding and responding to difficult behaviors of the PLWD."
223910326|NCT05877586|OTHER|CLARE app|"CLARE will contain materials on hospital discharge preparation, Covid care, and caregiver self-care, all of which have already been vetted by the DUHS Patient and Family Education department. Existing CLARE teaching on Covid covers isolation; quarantine; home sanitization; and monitoring for Covid symptoms such as cough, fever, fatigue, and shortness of breath. All will be reviewed and amended to reflect the latest CDC guidelines for Covid care at the time of pilot implementation. CLARE will also include reminders on examining the After-Visit-Summary to determine home medications and information on follow-up care.~CLARE will have two sessions of training and support to caregivers that can be delivered before hospital discharge and daily for seven days after discharge."
224085011|NCT05190952|DRUG|Dexamethasone|In addition to bupivacaine, dexamethasone 0.2mg/kg diluted in 10 ml normal saline will be injected subcutaneously by the surgeon before wound closure. Bupivacaine and dexamethsone will be administered using two separate syringes.
223910327|NCT06851884|OTHER|Standard of Care (SOC)|Universal welcome leaflet on patient admission
224085012|NCT05706935|DIAGNOSTIC_TEST|MeMed BV® test|The MeMed BV® test is an automated semiquantitative immunoassay that measures three nonmicrobial (host) proteins (TRAIL, IP-10, and CRP) in serum samples and is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection.
223910328|NCT06851884|OTHER|Video capsules|3 video capsules of 3 minutes each
224085013|NCT04230447|OTHER|No intervention|No intervention
224085014|NCT03430986|DEVICE|JUVÉDERM® VOLUMA® with Lidocaine|Treatment with JUVÉDERM® VOLUMA® with Lidocaine injectable gel with optional treatment 8 weeks later.
224085015|NCT03430986|OTHER|No-treatment control|No treatment during the control period.
224085016|NCT03478384|BEHAVIORAL|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
224085017|NCT05104047|OTHER|Moxibustion - Traditional (Active)|Traditional Moxibustion (Moxa) is a technique in which the herb, artemisia, in a cigar shape (pole moxa) is lit (burned) and applied over specific acupuncture points which follows a specific protocol aimed at reducing neuropathic lower limb pain/discomfort.
224085018|NCT05104047|OTHER|Moxibustion - Smokeless - (Active)|Smokeless Moxibustion uses the same technique as traditional moxa however, the moxa is smokeless. Smokeless moxa allows for use in a broad range of treatment settings. The protocol is aimed at reducing neuropathic lower limb pain/discomfort.
224085019|NCT05104047|OTHER|Placebo Moxibustion|Participants receive Placebo Moxibustion - a protocol that mimics the active protocol but is not active.
224085020|NCT00067210|DEVICE|Head and Neck Cooling System|
224277454|NCT02934633|BEHAVIORAL|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
224277455|NCT04600739|PROCEDURE|TAVI|Replacement of the aortic valve using a biological prosthesis that is inserted via a catheter.
223910329|NCT06851884|OTHER|Cartoon|3 cartoons
223910330|NCT06851884|OTHER|Virtual reality|3 virtual reality programs
223910331|NCT06851884|OTHER|"Set of end-of-life and grief informational and educational tools"|Including a video capsule, a cartoon, and a kit of two leaflets
223910332|NCT06851884|OTHER|Standard of Care (SOC)|Universal welcome leaflet on patient admission
223910333|NCT05466942|DEVICE|Pulse Oximeter, Respiratory Rate, Heart Rate|Measurement of physiological parameters
224085021|NCT00003414|BIOLOGICAL|aldesleukin|
224085022|NCT00003414|BIOLOGICAL|recombinant interferon gamma|
224277456|NCT02459418|DRUG|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
224085023|NCT00003414|DRUG|busulfan|
224085024|NCT00003414|DRUG|cyclophosphamide|
224085025|NCT00003414|DRUG|cyclosporine|
224085026|NCT00003414|PROCEDURE|peripheral blood stem cell transplantation|
224085027|NCT00003414|RADIATION|radiation therapy|
224085028|NCT05775328|OTHER|Intense pulsed light|Already described in the arm/group description
224085029|NCT04590456|OTHER|PEMF|group A received 60 minutes of traditional program physical therapy which consisted of passive range of motion, stretching,proprioception, isotonic and isometric and 20 minutes of placebo treatment using PEMF, while group B received the same traditional physical therapy program given to the control group in addition of 20 minutes of PEMF therapy
224085030|NCT05152381|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224085031|NCT03540186|DIETARY_SUPPLEMENT|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
224085032|NCT03540186|PROCEDURE|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
223910334|NCT06649383|DEVICE|Virtual reality|Participant will try virtual reality glasses with tailormade software films to see if it's possible to use them as distraction during awake surgery. We will measure doses of propofol given, level of anxiety, experience of the patient and surgeons satisfaction.
223910335|NCT06848712|OTHER|Observational Study - No intervention|This is an observational study evaluating brain structural abnormalities in post-COVID headache patients. No experimental intervention is applied.
224277457|NCT02459418|DRUG|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
224277458|NCT05597839|DRUG|DF9001|Immunotherapy agent targeting NK cells.
224277459|NCT05597839|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
223910336|NCT06848504|BEHAVIORAL|MedSMA℞T Mobile|MedSMA℞T Mobile is an innovative mobile digital health intervention that integrates technology-based learning to facilitate family communication and creation of a personalized Family Medication Safety Plan. The Family Medication Safety Plan (FMSP) is a tool for families to record important information about their medications and create a plan for safe use, storage, and disposal. Participants will play MedSMA℞T Mobile for up to 30 minutes at the first study visit.
223910337|NCT06852456|DRUG|Iparomlimab and Tuvonralimab (QL1706)Injection|PD-1/CTLA-4
223910338|NCT06852456|DRUG|Paclitaxel|Chemotherapy
223910339|NCT06852456|DRUG|Cisplatin|Chemotherapy
223910340|NCT04197869|DRUG|Polyethylene Glycol Powder|Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
223910341|NCT06264193|OTHER|hypoxia|The athletes were living in hypoxic rooms, and training was carried out on lowlands.
223910342|NCT00875888|DEVICE|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
223910343|NCT06569043|OTHER|Breakfast Bar|Packaged breakfast bar product available in retail stores
223910344|NCT06575738|DRUG|Injectable semaglutide|Subcutaneous weekly injectable semaglutide
223910345|NCT06575738|BEHAVIORAL|Standard postoperative care|Standard postoperative care consists of behaviorally-focused interventions delivered by the interdisciplinary Bariatric Surgery Center team targeting nutrition, physical activity, sleep, and mental health at standard postoperative intervals.
223910346|NCT06571123|OTHER|İnteractive floor|Interactive floor The interactive floor system includes a computer, camera and projection. With the projection, videos that are ready on the computer are projected on the floor, image processing is done with the camera and it detects whether there is an object on the floor or not and creates effects on the video. For example, on the floor containing colored balloons, the balloons burst with the movement of the child. With this visual mobility, it is aimed to draw the child's attention to another direction.
223910347|NCT06573567|DEVICE|Bioimpedance|Experimental: use overhydration value obtained by bioimpedance analysis to guide fluid management; the measurements will be obtained once per month
223910348|NCT06573567|DEVICE|Control|Placebo Comparator: the measurements will also be obtained once per month, but not revealed to the participants and the care providers
223910349|NCT04180462|OTHER|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
223910350|NCT04180462|OTHER|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
223910351|NCT04180462|OTHER|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
223910352|NCT04180462|OTHER|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
223910353|NCT06432309|DRUG|Opicapone 50 mg|Evaluate the addition of the COMT-I, Opicapone, to the Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
223910354|NCT06432309|DRUG|Duodopa|Evaluate Levodopa-Carbidopa intestinal gel in Parkinson's Disease patients with motor fluctuations.
223910355|NCT06299319|DRUG|Psilocybin|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered twice during the trial, in conjunction with supportive therapy.
223910356|NCT06374147|DEVICE|SVS mattress|The intervention group will receive standard therapy plus continuous SVS stimulation using the Prapela SVS incubator pad. The control group will receive only standard therapy, using an inert pad (identical to the SVS pad, its controller, and green light, but without the transducer and therefore incapable of vibration), in order to mask caregivers. Treatment with the pad will continue until an infant is apnea-free for 3 days and \<2 weeks from anticipated discharge or at the clinician's discretion to discontinue treatment. After ending treatment, clinicians will observe patients 24 hours later and if apnea returns, should re-initiate treatment as needed. At 1 and 2 years of age, parents will be contacted for a brief telephone follow up survey to assess neurological development
223910357|NCT06573554|DEVICE|Total Contact Cast|Knee High Fiber Glass Total contact Cast
223910358|NCT06573554|DEVICE|Posterior Slab|Posterior Slab Knee high non walking
224085033|NCT01962779|OTHER|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
224277460|NCT05597839|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
224277461|NCT02332213|PROCEDURE|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
223910359|NCT06068283|BEHAVIORAL|LOTUS mHealth Intervention Group|A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.
224085034|NCT06477692|DRUG|ENI using IMRT with or without chemotherapy|This study is a phase II single-blinded randomized trial comparing standard ENI with involved nodal radiotherapy. INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
223910360|NCT06068283|BEHAVIORAL|LOTUS Control Group|Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
223910361|NCT05237284|DRUG|SAR443820|Tablet oral
223910362|NCT05237284|DRUG|Placebo|Tablet
223910363|NCT04227483|DRUG|Deflazacort|Deflazacort for 4 months
223910364|NCT04227483|DRUG|Prednisolone|Prednisolone for 4 months
223910365|NCT06241716|PROCEDURE|Ultrasound-assisted localization, US-AS|In the US-AS group, ultrasonic prescan to determine the best intervertebral space, best puncture Angle and best puncture depth. The optimal puncture section considered by the operator was selected to record the best gap, puncture Angle and depth.
223910366|NCT06241716|PROCEDURE|Real-time ultrasound guidance, US-RTG|In the US-RTG group, the optimal puncture section considered by the operator was selected and recorded directly in the plane of the paracentral transverse section, out of the plane of the paracentral sagittal section or in the plane of the paracentral sagittal section for real-time ultrasound guided lumbar epidural anesthesia.
223910367|NCT05522140|BEHAVIORAL|Nature-based social intervention (NBIS)|"Nature-based social prescribing is a multicomponent, multi-level, behaviorally based complex intervention applaied by facilitators after a specific training. It comprises: a psychosocial component and nature-based activities. The psychosocial component is adapted from the group dynamic of Circle of Friends methodolgy focused on loneliness(Jansson A, Pitkälä KH, 2021) adapted to the cultural context of Prague and the target population (partitipants) of adults who lives in Prague. Participants start with an individual session and then meet once a week for two hours for 10 weeks.~At the first meeting together, participants select the nature-based activities they wish to conduct through a co-created menu."
223910368|NCT05522140|BEHAVIORAL|Usual care + menu with nature based activities|Social prescribing as existing in usual care plus a written menu with the list of nature-based activities in the area.
224085035|NCT06477692|RADIATION|INRT|INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)
224085036|NCT06477692|RADIATION|ENI|ENI using IMRT with or without chemotherapy
224085037|NCT04077905|DRUG|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
223910369|NCT05990426|BEHAVIORAL|FAST Intervention|"Participants will alternate fasting days (FAST) with unrestricted eating (OFF, or Feast) days, for one week surrounding the start of each chemotherapy cycle. The participants will fast for two consecutive days in the middle of the ADF week - the day prior to chemotherapy start date, and chemotherapy day 1 for each cycle. Participants will consume regular diet (OFF/Feast) during other days 5-18 of each cycle."
223910370|NCT05987072|DRUG|Sisunatovir|Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state
224085038|NCT04077905|DRUG|Etoposide|100mg/m² ivgtt on day 1
224085039|NCT04077905|DRUG|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
224277462|NCT02332213|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
224277463|NCT02332213|PROCEDURE|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
224277464|NCT02332213|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
223910371|NCT05036122|DEVICE|LabClasp|Non-invasive device that estimates blood \[lactate\] from interstitial fluid via a proprietary algorithm. The device is placed between the first and second knuckle of a finger and gently applies slight pressure to extract interstitial fluid from the skin. Sensors within the device quickly estimate blood \[lactate\] and return a value to the subject via an accompanying tablet within 20 seconds.
223910372|NCT02371135|GENETIC|colonic biopsies|
224277465|NCT02332213|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
224277466|NCT02332213|PROCEDURE|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
224277467|NCT01137734|DEVICE|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
223910373|NCT02371135|GENETIC|questionnaires|
223910374|NCT05842941|DRUG|DNL343|DNL343 is administered orally once daily per day for 24 weeks.
223910375|NCT05842941|DRUG|Matching Placebo|Matching placebo is administered orally once daily per day for 24 weeks.
224085040|NCT02282683|DRUG|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
224085041|NCT04936074|PROCEDURE|Muscle preserving selective laminectomy|Muscle-preserving selective laminectomy differ from traditional laminectomy by the spinous process split that preserves the deep extensor muscles. The bilateral facet joints are not exposed. After the laminectomy is finished the split fragments of the spinous process are sutured together so that the deep extensor muscles are restored.
224085042|NCT04936074|PROCEDURE|Laminectomy with instrumented fusion|A traditional laminectomy is complemented with lateral mass and/or pedicle screws connected with rods.
223910376|NCT06425666|PROCEDURE|Intervention group /arm 1 (Cataract surgery alone)|Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths.
223910377|NCT06425666|PROCEDURE|Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)|After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
224085043|NCT01893333|PROCEDURE|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
223910378|NCT02946736|BEHAVIORAL|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
224085044|NCT01136343|OTHER|lifestyle modified project|education, counseling
224085045|NCT04743180|DEVICE|LUMINOR© Paclitaxel eluting balloon|Patients will be treated with the Luminor paclitaxel eluting balloon
224085046|NCT03186989|DRUG|IONIS MAPTRx|IONIS MAPTRx injections.
224085047|NCT03186989|OTHER|Placebo|Artificial CSF injections.
224085048|NCT03913156|OTHER|B2970 Metabolic Texture Modified Protein Substitute|The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
224085049|NCT05219188|RADIATION|3.7 mS, CT radiation|Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
224085050|NCT04788524|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
224085051|NCT03789227|PROCEDURE|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
224277468|NCT01137734|DEVICE|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
224277469|NCT04665817|DIAGNOSTIC_TEST|CT-QFR|CT-QFR is a novel method for evaluating the functional significance of coronary stenosis. It is calculated by coronary computed tomographic angiography images.
224277470|NCT04665817|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two. angiographic projections.
224277471|NCT04665817|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire is the gold standard for evaluating the functional significance of coronary stenosis.
224277472|NCT00781521|DRUG|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
224277473|NCT02678871|DEVICE|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
224277474|NCT02678871|DEVICE|WATCHMAN|LAA closure with the WATCHMAN device
224277475|NCT01872715|DRUG|Oracea|
223910379|NCT02946736|BEHAVIORAL|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
223910380|NCT06532630|GENETIC|Anti-CD19-CAR-T cells|"Each subject will be infused with single dose of anti-CD19-CAR-T cells.~A classic 3+3 dose escalation will be employed."
224277476|NCT04085471|DIAGNOSTIC_TEST|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
224277477|NCT01404871|DRUG|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including \> 8 weeks at 250 mg/daily
224277478|NCT01404871|DRUG|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including \>8 weeks at max dose 50mg daily
223910381|NCT06532630|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
223910382|NCT06532630|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m2/day intravenously (IV) for 3 days prior to anti-CD19-CAR-T cells infusion.
224085052|NCT04465929|BIOLOGICAL|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
224085053|NCT04152824|BEHAVIORAL|Resilience-Supportive Leadership Training (RESULT)|Platoon leaders receive a 90-minute, in-person training addressing supportive supervisor behaviors and resilience
224085054|NCT01943565|DRUG|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
224277479|NCT01404871|DRUG|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including \>8weeks at 120mg daily
223910383|NCT05933499|DRUG|IV bimagrumab|IV bimagrumab (30mg/kg IV administered at 0, 4, 16, 28, and 40 weeks)
223910384|NCT05933499|DRUG|IV placebo|IV placebo (administered at 0, 4, 16, 28, and 40 weeks)
223910385|NCT05933499|DRUG|Semaglutide|Semaglutide 2.4mg SQ qweek
223910386|NCT05933499|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Elemental calcium 1200 mg + vitamin D3 800 IU PO daily
223910387|NCT05933499|BEHAVIORAL|Lifestyle and nutrition counseling|Lifestyle and nutrition counseling consistent with current guidelines for weight management
223910388|NCT05906069|BEHAVIORAL|ICBT|The intervention will consist in a structured internet-based intervention with 10 modules that will combine cognitive-behavioral techniques to improve obsessive-compulsive symptoms as well as the emotion regulation ability.
223910389|NCT06105580|PROCEDURE|Conduction system pacing|Conduction system pacing implant as a Resynchronization therapy.
223910390|NCT06105580|PROCEDURE|Biventricular pacing|Biventricular pacing implant
223910391|NCT05451303|DEVICE|OralViome Cancer Testing System|The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.
223910392|NCT04571619|BEHAVIORAL|Pain Coping Skills Training (PCST)|The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
223910393|NCT04571619|DRUG|Buprenorphine|At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
223910394|NCT05862129|PROCEDURE|surgical operation|Radical operation for the perianal abscess
223910395|NCT05889247|OTHER|Circulating tumor DNA treatment monitoring|A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)
223910396|NCT05669391|DIAGNOSTIC_TEST|Genomic analysis of antidepressants|Genomic analysis of all antidepressants. Tris EDTA anticoagulation and salting out were used to extract DNA. OD 260/280 was between 1.6-1.8 and the concentration was greater than 50 ng/ μ L。 Using the PCR gene chip detection method and the Asian Screening Array (ASA) chip detection technology of Illumina Company (this chip is the first whole genome SNP chip designed based on the whole genome sequencing data of 9000+East Asian populations, which contains 750000 markers, with 85% of the effective loci), we can obtain the genetic information of polymorphic loci related to the individual differences of drug effects of subjects.
223910397|NCT05308238|BEHAVIORAL|Occupational therapy intervention group|Participants will receive 6 telehealth coaching sessions and 8 brief email or text check-ins over the course of 4 months. Participants will also receive a Fitbit and Engage PD Workbook.
223910398|NCT05308238|BEHAVIORAL|Disease management education group|Participants will receive online educational videos that they can watch at their own convenience over the course of 4 months. There will be up to 6 hours of content, and the links to these online videos will be provided via email. Following completion of the study, individuals in this group will receive an Engage PD Workbook and one OT coaching session, if they choose to.
223910399|NCT02939612|BEHAVIORAL|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
224277480|NCT02340624|BEHAVIORAL|Referral to SmokeFreeMoms, Quitline or Brief intervention|"1. SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~2. The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~3. Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
224277481|NCT03525249|DIETARY_SUPPLEMENT|nutraceutical|Subjects will consume a capsule for eight weeks
224277482|NCT00005887|DRUG|efaproxiral|
224277483|NCT00005887|RADIATION|radiation therapy|
223529120|NCT06729866|PROCEDURE|electrogram guided pulse field ablation|In persistent atrial fibrillation patients, traget electrogram was mapped firstly , pulse field ablation of pulmonary veins, posterior wall of left atrium and target electrogram was ablated, until the atrial fibrillation converted to sinus rythm or stable atrial tachycardia. The mapping and ablation procedure was repeated until AF terminated or no target electrogram was found.
223529121|NCT03557502|OTHER|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
224085055|NCT01943565|DRUG|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
224085056|NCT01943565|DRUG|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
224085057|NCT01943565|DRUG|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
223529122|NCT03557502|OTHER|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
223910400|NCT04170907|OTHER|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
223910401|NCT06210594|COMBINATION_PRODUCT|Mupirocin + Nozin + chlorhexidine gluconate|Education/household supplies + antibiotic + antiseptic regimen
223910402|NCT06210594|BEHAVIORAL|Education + Household supplies|Education/household supplies
223910403|NCT06118502|BEHAVIORAL|Switching to a different medication|Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
223910404|NCT06118502|BEHAVIORAL|Continued use of the same medication|Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
223910405|NCT06118502|BEHAVIORAL|Switching to a harm reduction tobacco product|Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
223910406|NCT03995550|DRUG|LEO 142397|A compound in development by LEO Pharma A/S
223910407|NCT03995550|DRUG|Placebo|Placebo
223910408|NCT04871568|PROCEDURE|Temporary central dialysis catheterization|Placement of temporary central dialysis catheter
223910409|NCT04617678|OTHER|Prehabilitation Program|We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
223910410|NCT05810987|OTHER|RESTORE|"Virtual educational curriculum organized into the following modules:~Module Specific Communication Strategies~1. Introduction~2. Preparing for and introducing a conversation \[Consider personal bias /Building rapport /Ask permission\]~3. Assessing understanding \[Avoid correcting /Open ended questions\]~4. Giving information \[Give a warning shot /Using silence /Wish/worry/wonder\]~5. Explore goals \[Reflective listening /Naming, validating emotion~6. Summarizing and recommending a plan \[Values-based recommendation /Aligning with goals /REMAP (Reframe, Expect emotion, Map goals, Align, Propose plan)\]"
223529123|NCT05972850|BEHAVIORAL|Vivo Heart|Vivo is an online, live, small group fitness program developed for older adults that uses individually tailored dual-tasked (i.e., cognitive-motor) exercises to improve strength, endurance, balance, and cognition and incorporates social engagement. Certified trainers deliver instruction and coaching through an interactive session for 45 min, 2-3 times/week.
223529124|NCT02411851|DRUG|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
223529125|NCT02411851|OTHER|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
223529126|NCT01822379|PROCEDURE|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
223529127|NCT03683082|DRUG|Oxygen supplementation|40% FiO2 via Venturi mask
223529128|NCT03683082|DRUG|Sham O2 (medical air)|Medical air supplementation via Venturi mask
223529129|NCT05715762|BEHAVIORAL|prone postion|ventilation at prone positioning
223529130|NCT05715762|DRUG|NO inhalation|NO inhalation at 20 ppm
223529131|NCT00270387|DRUG|Natrecor (nesiritide)|
223529132|NCT01516476|DRUG|Placebo|Placebo for 12 weeks
223529133|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
223529134|NCT01516476|DRUG|RO6807952|multiple doses for 12 weeks
223529135|NCT01516476|DRUG|liraglutide|liraglutide for 12 weeks
223529136|NCT01447537|OTHER|Exercise + relaxation|Exercise + relaxation
223910411|NCT05810987|BEHAVIORAL|Medical Interaction and Coaching|Skills sessions with standardized patients (SPs) along with coaching feedback.
223910412|NCT05516758|DRUG|Peresolimab|Administered subcutaneously (SC)
223910413|NCT05516758|DRUG|Placebo|Administered SC
223910414|NCT05656105|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
223910415|NCT04666636|DRUG|Placebo|Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
223910416|NCT04666636|DRUG|Mirabegron|Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
224085058|NCT04785365|OTHER|Biological: ATL001|No investigational product will be administered
224085059|NCT01583374|DRUG|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
224085060|NCT01583374|DRUG|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
224085061|NCT01583374|DRUG|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
224085062|NCT02905175|PROCEDURE|blood sample|
224085063|NCT02905175|PROCEDURE|synovial tissue|synoviocytes from synovial tissue
224085064|NCT01292057|DRUG|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
223529137|NCT01447537|OTHER|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
223529138|NCT05604703|DIAGNOSTIC_TEST|Periodontal classification|300 patients will be classified according to 1999 armitage and 2018 new periodontal classification and compared.
223529139|NCT07136038|BEHAVIORAL|Low Energy Availability Screening and Nutrition Support|Athletes will receive screening for low energy availability, strength and body composition assessments and receive nutrition support from a sports dietitian over the competitive season.
223529140|NCT07146555|OTHER|No Interventions|
224085065|NCT01292057|DRUG|Placebo|Placebo to match active drug Aripiprazole for 8 days
224085066|NCT01265524|DRUG|CLP|Oral administration
224085067|NCT01265524|DRUG|Placebo|Oral administration
224085068|NCT00393575|BEHAVIORAL|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
223716023|NCT04673838|OTHER|Lower extremity sensory training|Lower extremity sensory training will only be applied to the Intervention Group for 4 weeks, 3 days a week and 12 sessions in total. In the lower extremity, 3 sets of soft tissue needing, stroking and fascia stretching will be applied on 5 areas as Quadriceps, Hamstring, Gastrosoleus Group, Peroneal muscles, ankle and foot. In addition, sensory stimulation will be applied in the same five regions of the lower extremity with 3 repetitions and 3 sets with a knurled ball, brush and sponge. Lower extremity mobilizations of PANat Therapy approach will be used with traction and gliding applications in all joints in the ankle and foot. Finally, intrinsic muscle stimulation will be performed for 3 minutes with a bottle and towel under the sole of the foot.
224085069|NCT03771742|PROCEDURE|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
224085070|NCT03771742|PROCEDURE|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
224085071|NCT00783588|BIOLOGICAL|ISF35|Subjects participating in this study will receive up to two doses of 1x10\^8, 3x10\^8, or 1x10\^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
224085072|NCT03349814|PROCEDURE|Diagnostic laparoscopy without appendectomy|A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
224085073|NCT03349814|PROCEDURE|Diagnostic laparoscopy with appendectomy|A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
224085074|NCT02711280|DRUG|Sevoflurane|
223716024|NCT03317327|DRUG|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
223716025|NCT03317327|RADIATION|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
223716026|NCT04724018|DRUG|Sacituzumab Govitecan (SG)|Intravenous infusion
223716027|NCT04724018|DRUG|Enfortumab vedotin-ejfv (EV)|Intravenous infusion
224085075|NCT02711280|DRUG|Propofol|
224085076|NCT00460343|OTHER|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
224277484|NCT00564343|OTHER|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
223716028|NCT04724018|DRUG|Pembrolizumab|Intravenous infusion
223716029|NCT04083508|OTHER|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
223716030|NCT02453178|BEHAVIORAL|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
223716031|NCT00915122|RADIATION|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
223716032|NCT04693988|BEHAVIORAL|Case Management|a case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as provide advice about cardiac symptoms and behavioral life style changes
223716033|NCT03880734|DRUG|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
223716034|NCT03880734|OTHER|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
223716035|NCT06072157|DRUG|AK006-IV|Intravenous infusion
223716036|NCT06072157|DRUG|Placebo-IV|Intravenous infusion
223716037|NCT06072157|DRUG|AK006-SC|Subcutaneous
224085077|NCT00460343|OTHER|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
224085078|NCT00384787|BIOLOGICAL|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
224085079|NCT00384787|BIOLOGICAL|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
224085080|NCT02254031|DRUG|bivatuzumab mertansine|
224085081|NCT01034995|DRUG|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
224085082|NCT01034995|DRUG|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
224085083|NCT01034995|DRUG|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
223716038|NCT06072157|DRUG|Placebo-SC|Subcutaneous
223716039|NCT05018975|DRUG|Tazemetostat|Tazemetostat 800mg BID PO dosing for 15 days
223910417|NCT05142384|BEHAVIORAL|Mom-Net|"Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff.~In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later."
224085084|NCT02504229|BIOLOGICAL|autologous dendritic cells co-cultured with cytokine-induced killer cells|
224085085|NCT02504229|DRUG|Gimeracil and Oteracil Porassium Capsules|
224085086|NCT02504229|DRUG|Oxaliplatin|
224085087|NCT02587338|DEVICE|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anodal, right cathodal
224085088|NCT02587338|DEVICE|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
224085089|NCT06536738|PROCEDURE|esophageal repair|The surgery confirmed a secondary esophageal fistula following the anterior cervical surgery. The procedure involved trimming the esophageal tissue around the fistula and repairing the fistula.
224085090|NCT01506882|DRUG|Levetiracetam (LEV)|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use"
224277485|NCT02463630|PROCEDURE|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
224277486|NCT02034448|PROCEDURE|Continuous Renal Replacement Therapy|
224277487|NCT01226251|DEVICE|In vitro chair side test|Colour evaluation of a strip
224277488|NCT04674397|RADIATION|Radioisotope GFR test|
224277489|NCT01616121|OTHER|Usual treatment of patients with developing acute heart failure|
224277490|NCT01616121|DEVICE|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
224277491|NCT01355354|DRUG|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
223529141|NCT07142083|DEVICE|Bioelectrical Impedance Analysis (BCM)|The Body Composition Monitor (BCM) device will be used to perform daily bioelectrical impedance measurements to guide fluid resuscitation in critically ill patients after major surgery. Measurements include extracellular water, intracellular water, total body water, and phase angle. The results will be used to tailor fluid therapy.
223529142|NCT07142083|PROCEDURE|Conventional Fluid Management|Patients in this group will receive fluid therapy based on standard clinical parameters including blood pressure, heart rate, urine output, laboratory values, and physical examination. No bioelectrical impedance measurement will be performed.
223529143|NCT07158775|BIOLOGICAL|BS01|a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP)
223529144|NCT07158775|OTHER|Sham procedure control|Sham procedure without needle
223529145|NCT07159009|DRUG|Biological: GB261|GB261 will be dosed according to the protocol
223529146|NCT07159646|OTHER|exercise interventions|athletic/physical protocol
223529147|NCT07161570|DEVICE|Virtual Reality (VR) Intervention|10-min VR intervention, once a day, everyday for 14 days.
223529148|NCT07161570|DEVICE|Light Box (LB) intervention|30-min LB intervention once a day, everyday for 14 days.
223529149|NCT07160855|DRUG|Misoprostol (given vaginally)|800 micrograms of a single dose of vaginal misoprostol will be given
223529150|NCT07160855|DRUG|Letrozole 5 mg|10 mg oral letrozole for 3 days will be given
223529151|NCT07160855|DRUG|Placebo|oral placebo for three days will be given
223529152|NCT00221858|PROCEDURE|Ultrasound guided blocks|
223529153|NCT07160517|BEHAVIORAL|Visual Pedagogy and Manual Toothbrushing|Participants in this arm will use a manual toothbrush with caregiver support. Visual pedagogy resources will include printed PECS cards illustrating each step of toothbrushing and tactile sensory panels simulating toothbrush bristles, toothpaste texture, and dental floss. Caregivers will be instructed to use these materials daily at home for 3 weeks to improve comprehension, adherence, and cooperation in children with ASD.
223529154|NCT06524180|DEVICE|Telemedicine|a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
223529155|NCT06524180|OTHER|Usual care|Participants will be followed up as usual by face-to-face consultation with the doctors
223529156|NCT06399536|PROCEDURE|Individualized ANH|Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.
223529157|NCT05772546|DRUG|Avatrombopag|Thrombopoietin receptor agonist, tablet taken orally.
223529158|NCT05772546|DRUG|Matching Placebo|Lactose monohydrate, tablet taken orally.
223529159|NCT05938699|DRUG|NCX 470|NCX 470 0.1% vs Placebo
223529160|NCT05938699|DRUG|Placebo|NCX 0.1% vs Placebo
223529161|NCT05684965|DRUG|XTX301|XTX301 monotherapy
223529162|NCT06483802|GENETIC|ASP2016|Intravenous (IV) infusion
223529163|NCT06483802|DRUG|Prednisolone|Oral
223910418|NCT05142384|COMBINATION_PRODUCT|Treatment as Usual/Waitlist|HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
223910419|NCT05043051|DEVICE|Vagal stimulation|Vagal stimulation
223910420|NCT05043051|DEVICE|Sham stimulation|Sham vagal stimulation
223910421|NCT05255237|DRUG|Jaktinib|75mg BID
223910422|NCT05482360|OTHER|PrEP Optimization Interventions|There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders
223910423|NCT04417998|DRUG|18F-FDG|A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
223910424|NCT04417998|DRUG|18F-AV1451|A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
223910425|NCT04417998|DEVICE|Siemens E7 Reconstruction Tool|Software to correct for motion
223910426|NCT06200779|DIAGNOSTIC_TEST|Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test|"Described in Arms section"
224085091|NCT01187537|PROCEDURE|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to \< 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
224085092|NCT01448200|DRUG|PPI-668|capsules
224085093|NCT01448200|DRUG|Placebo|capsules
224085094|NCT02402855|OTHER|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
224085095|NCT02402855|OTHER|Interview with a sociologist|For a sub-group of 40 womens
224085096|NCT02402855|OTHER|No intervention|
224085097|NCT01602588|DRUG|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
224085098|NCT01602588|RADIATION|Radiotherapy|Short Course radiotherapy
224085099|NCT01758510|GENETIC|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\^6 cells/kg, 0.5 X 10\^6 cells/kg, 1 X 10\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\^6 cells/kg dose cohort.
224085100|NCT05079360|DRUG|Sabizabulin|32mg each day by mouth
224085101|NCT05079360|DRUG|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator|Subjects in the Control Treatment Group will receive an ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site until disease progression is observed and confirmed by BICR. The investigator decision of which comparator treatment will be used will be made prior to randomization.
224085102|NCT02436603|BEHAVIORAL|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
224085103|NCT04800731|OTHER|observation no intervention|no intervention
224277492|NCT01355354|DRUG|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
224277493|NCT03303417|DIAGNOSTIC_TEST|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
224277494|NCT03303417|OTHER|Kiwifruit|Kiwifruit
224277495|NCT03303417|OTHER|calorie-matched sugar drink|calorie-matched sugar drink
224277496|NCT06280417|DEVICE|Unreamed intramedullary tibial nail|Fixation of type IIIa tibial fractures by unreamed IMN
223910427|NCT06200779|DRUG|Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)|"Described in Arms section"
223910428|NCT06200779|DRUG|PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-sensitive strain
223910429|NCT06200779|DRUG|PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-sensitive strain
223910430|NCT06200779|DRUG|Bismuth quadruple therapy (Pylera®) for 10 days|Administered to patients randomized to Intervention group and with H. pylori clarithromycin-resistant and levofloxacin-resistant strain
224085104|NCT03741166|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
224085105|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (8 mg/m^2)|
224085106|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2)|
224085107|NCT01302808|COMBINATION_PRODUCT|Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis|
224085108|NCT01302808|COMBINATION_PRODUCT|(Erlotinib plus Romidepsin (8mg/m^2)) + Antiemetic prophylaxis|
224085109|NCT00273000|DRUG|GLP-2|
224277497|NCT01578317|BIOLOGICAL|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
224277498|NCT01578317|BIOLOGICAL|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
224277499|NCT05511441|PROCEDURE|Surgery Without Aspirin Withdraw|Routine Minimally Invasive Thoracic Surgery Without Aspirin Withdraw
224277500|NCT00128141|BEHAVIORAL|Tactile stimulus|four times a day
224277501|NCT00235417|PROCEDURE|Bone marrow transplantation|
224085110|NCT00488787|DRUG|intranasal ketamine|low dose
224085111|NCT00488787|DRUG|intranasal ketamine|medium dose
223910431|NCT05538286|DEVICE|ClearFit implant|The ClearFit implant is an FDA cleared implant in regular use in the United States. The ClearFit implant and other PMMA cranioplasty implants manufactured by Longeviti have been reported to be safe and effective as cranial implants that permit transcranial ultrasound to be performed. The PMMA cranioplasty implant (Longeviti Neuro Solutions, Hunt Valley, MD) is clear, sonolucent, and was recently shown to be safe and effective in transcranial ultrasonography for bypass patency assessment. The ClearFit cranioplasty being used in this study is industry standard of care.
224085112|NCT00488787|DRUG|intranasal ketamine|high dose
223716040|NCT01002222|DRUG|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
223910432|NCT05538286|PROCEDURE|transcranial ultrasonography through sonolucent cranioplasty|The implantation of the ClearFit PMMA sonolucent implant permits TUSC to be performed at the bedside for patients in both the in-patient and outpatient settings. While the patient is an inpatient, the clinical or research teams will attempt to perform TUSC within 1 hour of neuroimaging if that neuroimaging is performed at a time when a trained ultrasound operator is present.
223910433|NCT06565546|OTHER|Opioid pain medication prescribed based on CYP2D6 genotype testing PLUS Acetaminophen and Gabapentin|CYP2D6 genotype testing for assessment of medication metabolism to guide prescription of postoperative pain medication
223910434|NCT06565546|OTHER|Acetaminophen and Gabapentin: standard postoperative pain medications|Participants will receive standard postoperative pain medications
223910435|NCT05278780|OTHER|Screening for eligibility|Asynchronous screening
223910436|NCT02780700|DRUG|Nintedanib|
223910437|NCT02780700|DRUG|Capecitabine|
223910438|NCT04824079|DRUG|Keynatinib|The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
223910439|NCT06406088|DEVICE|EarGenie MVP test|The EarGenie MVP test consists of placing the EarGenie headgear containing light emitting diodes (LEDs) and light detectors on the infant and running the fNIRS tests of sound detection or sound discrimination via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation in temporal and prefrontal regions of the cortex. Automatic analyses are run to determine whether the infant heard the sounds (at levels 35, 50, and 65 dBSPL) or discriminated between two sounds (Ba/Tea, Ba/Bee, or Ba/Ga). The infant will be in a natural sleep or quiet awake state when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
223910440|NCT05925101|BEHAVIORAL|Extinction-only condition|In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
223910441|NCT05925101|BEHAVIORAL|Rate-drop condition|In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
223910442|NCT05925101|BEHAVIORAL|Rate-hold condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
223910443|NCT05925101|BEHAVIORAL|Magnitude-drop condition|In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
223910444|NCT05925101|BEHAVIORAL|Magnitude-hold condition|This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
223910445|NCT05925101|BEHAVIORAL|Quality-drop condition|In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
224085113|NCT00488787|DRUG|placebo|placebo
224085114|NCT03281980|OTHER|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
224085115|NCT03281980|OTHER|Government Intervention (UCT+HE)|fgbfgjhgykghilk
223716041|NCT05512767|OTHER|Best Practice|Undergo self-manual lymphatic drainage
224085116|NCT06053008|OTHER|The relationship between pain perception, temporomandibular joint disorder severity and spine health|The relationship between pain perception, temporomandibular joint disorder severity and spine health
224277502|NCT05908617|OTHER|Video Discharge|Patient will watch a video discharge instructions in addition to the standard paper instructions. They will also take the pre and post test as the control group
223716042|NCT05512767|OTHER|Consensus Auditory-Perceptual Evaluation of Voice|Ancillary studies
223716043|NCT05512767|PROCEDURE|Diagnostic Imaging|Undergo photographs of face and neck
223716044|NCT05512767|OTHER|Lymphedema Management|Undergo skilled lymphedema treatment by a therapist
223716045|NCT05512767|PROCEDURE|Modified Barium Swallow|Undergo swallow study
223910446|NCT05925101|BEHAVIORAL|Quality-hold condition|We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
223910447|NCT05925101|BEHAVIORAL|Rate-drop/quality-increase condition|In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
223910448|NCT03498638|BEHAVIORAL|Couples Therapy|Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
223910449|NCT03498638|OTHER|Control|Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
223910450|NCT05511597|BEHAVIORAL|Split-belt treadmill training|Split-belt walking with various speed ratios between the two legs, applied with random-block practice
223910451|NCT05511597|BEHAVIORAL|Complex task practice|Overground gait flexibility training with added cognitive tasks
223910452|NCT05511597|BEHAVIORAL|Static balance exercise|Mindfulness and breathing combined with static balance exercises
223910453|NCT06487559|DRUG|Livmoniplimab|Intravenous infusion
223910454|NCT06487559|DRUG|Budigalimab|Intravenous infusion
223910455|NCT03980925|DRUG|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin area under the curve (AUC5) Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
223910456|NCT03980925|DRUG|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
223910457|NCT03980925|DRUG|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
223910458|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
223910459|NCT06222671|DRUG|608|608 subcutaneous (SC) injection.
223910460|NCT06222671|DRUG|Placebo|Placebo subcutaneous (SC) injection.
223910461|NCT03367754|OTHER|Placebo|Single dose of Placebo given via intravenous (IV) infusion.
223910462|NCT03367754|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (immunoglobulin \[Ig\] G4 kappa isotype) that binds to PD-1, thus blocking the receptor from binding with its ligands. Single dose of Pembrolizumab 200 mg given via intravenous (IV) infusion.
223910463|NCT06295237|DEVICE|Intellisync+|mechanical ventilator software automatically detecting and adjusting ventilator parameters to control or reduce the number of events.
223910464|NCT02123082|DEVICE|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
223910465|NCT02123082|DEVICE|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
223910466|NCT05386563|PROCEDURE|Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)|"taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart."
224085117|NCT05873985|OTHER|Dynamic tape on experimental group|"The dynamic taping application was carried out in 2 stages. Three I-shaped tapes were cut. In the first stage, the person was asked to perform scapular retraction, and in this position, the tape was placed by applying medium tension to the anterior part of the other deltoid muscle, passing from the anterior part of the deltoid muscle to the upper thoracic region. In the second stage, the participant was asked to do scapular retraction and depression, and while maintaining this position, medium tension was applied to the lower thoracic vertebra starting from the anterior part of the deltoid muscle and the acromion and tape was applied. Afterward, this process was applied on the other side"
224085118|NCT05873985|OTHER|Sham tape on placebo group|"Sham taping was performed in 2 stages. Three I-shaped tapes were cut. Participants were asked to stand in the comfortable position they used during the day. The first tape was adhered from the starting point of the spine of the scapula with the acromion to the junction of the spine of the scapula and the acromion on the other side without any tension. The other two tapes, starting from the beginning and ending points of the first tape, were adhered to the lower thoracic region without any tension"
224085119|NCT00808041|DEVICE|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
224085120|NCT00821678|OTHER|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
223910467|NCT05386563|PROCEDURE|Sham Stimulation|"Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm)."
223910468|NCT05529316|DRUG|Botensilimab|An anti-CTLA-4 monoclonal antibody
223910469|NCT05529316|DRUG|Balstilimab|An anti-PD-1 monoclonal antibody
223910470|NCT05232032|DRUG|Nociceptin Receptor Antagonist|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist. Peak concentrations are achieved 2-4 hours post-administration.
223910471|NCT05232032|DEVICE|Aversive stimuli|As part of the approach/avoidance task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model, DS71, has been safely implemented in studies within Massachusetts General Hospital (Milad et al., 2013).
224085121|NCT04863274|DRUG|atorvastatin|"Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.~Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre."
224085122|NCT00891826|DIETARY_SUPPLEMENT|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
224085123|NCT00891826|DIETARY_SUPPLEMENT|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
224085124|NCT02225548|DRUG|Selegiline|
224085125|NCT02225548|DRUG|Tadalafil|
224085126|NCT03657615|DEVICE|hearing aid fitting|All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
224085127|NCT01439438|DRUG|Topiramate coated tablet|Test formulation
224085128|NCT01439438|DRUG|Topamax® coated tablet|Reference formulation
224085129|NCT02243501|BEHAVIORAL|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
224085130|NCT02002260|DEVICE|Levonorgestrel intrauterine system|
224085131|NCT02002260|DRUG|Combined oral contraceptives|
224085132|NCT05622539|COMBINATION_PRODUCT|CONVENTIONAL ACUTE STROKE MANAGEMENT|Conventional treatment for acute stroke patients, with or without reperfusion treatments
224085133|NCT02091609|OTHER|dental interproximal brush|use of this to maintain oral hygiene
224085134|NCT02091609|OTHER|dental floss|use of this to maintain oral hygiene
224085135|NCT05598502|DEVICE|REBOA, Resuscitative Endovascular Occlusion of the Aorta|The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
224085136|NCT05598502|OTHER|National guidelines|Standard management of postpartum hemorrhage according to Uganda national guidelines
224085137|NCT02159300|BEHAVIORAL|experience brain activity recording|Intervention: experience brain activity recording
224085138|NCT05025215|BEHAVIORAL|Precise Aerosol Inhalation Nursing Program|The precise aerosol inhalation nursing program was based on the traditional oxygen aerosol inhalation treatment, including precise body position care, time control, observation and treatment, evaluation, etc.
224085139|NCT05025215|BEHAVIORAL|Traditional Aerosol Inhalation Nursing Method|The traditional aerosol inhalation nursing method is carried out according to the operation of aerosol inhalation.
224085140|NCT06810375|DRUG|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|preoperative erector spinae block with bupivacaine (Marcaine®)
224085141|NCT06810375|DRUG|Intercostal nerve block|intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)
224085142|NCT01604005|RADIATION|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
223910472|NCT03900221|OTHER|No intervention|No intervention
223910473|NCT03153683|OTHER|Registry|Collect standard of care clot, tissue and arterial blood during standard of care cerebrovascular procedure for lab analysis.
223910474|NCT05903222|OTHER|Non-Interventional|This study is a non-interventional study of all patients previously enrolled in the PALACS trial
223910475|NCT02443961|BIOLOGICAL|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
223716046|NCT05512767|PROCEDURE|Nasopharyngeal Laryngoscopy|Undergo Nasolaryngoscopy
223716047|NCT05512767|DEVICE|Pneumatic Compression Therapy|Undergo compression therapy - Flexitouch Plus System is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides systematic and sequential pressure changes to move fluid to intact lymphatic chains.
223716048|NCT05512767|OTHER|Quality-of-Life Assessment|Ancillary studies
223716049|NCT05512767|OTHER|Questionnaire Administration|Ancillary studies
223910476|NCT03758625|BIOLOGICAL|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
223910477|NCT03758625|BIOLOGICAL|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
223910478|NCT03758625|BIOLOGICAL|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
223910479|NCT03758625|BIOLOGICAL|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
223910480|NCT03758625|BIOLOGICAL|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
223910481|NCT03758625|BIOLOGICAL|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
223910482|NCT02278887|PROCEDURE|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
223910483|NCT02278887|DRUG|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
223910484|NCT02278887|DRUG|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
223910485|NCT02278887|DRUG|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
223910486|NCT02278887|DRUG|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
223910487|NCT05636072|BEHAVIORAL|WISER|Participants will engage in one or more positive psychology well-being tool(s).
223910488|NCT01866163|DRUG|LEO 90100|
223910489|NCT01866163|DRUG|Vehicle|
223910490|NCT05674409|BEHAVIORAL|Brief Family-Involved Treatment (B-FIT)|Brief Family-Involved Treatment (B-FIT) is a manualized, 3-session intervention for Alcohol Use Disorder (AUD). Designed to be implemented in combination with any existing alcohol treatment program, the goals of B-FIT are to (1) increase reinforcement for AUD treatment engagement, (2) increase positive rewards from drinking reductions, and (3) decrease drinking cues by decreasing negative communication and increasing positive communication.
223910491|NCT05674409|BEHAVIORAL|Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD)|Participants will receive 12 sessions of Cognitive Behavioral Therapy for Alcohol Use Disorder (CBT for AUD).
223910492|NCT04715893|OTHER|Ostomy belt|Stealth ostomy belt continuous for eight weeks
223910493|NCT05833867|DRUG|Sacituzumab govitecan|8 mg/kg Sacituzumab Govitecan is to be administered intravenously in 21-day cycles on Day 1 and Day 8; the next cycle should start a minimum of 14 days after the Day 8 dose (i.e., the Day 8 infusion will be counted as the first day of that 14-day period).
223910494|NCT05833867|RADIATION|Adaptive Radiotherapy|Concurrently, participants will receive an individualized tailored plan for radiation therapy.
223910495|NCT05920148|PROCEDURE|Knee arthroplasty|At multiple timepoints (i.e., ± 6 weeks before, and 1 day, 1 week, ± 2 weeks, and ± 6 weeks after surgery) before and after total knee replacement surgery blood will be collected to assess immune functioning
223716050|NCT05512767|OTHER|Voice Handicap Index-10|Ancillary studies
223716051|NCT04779125|PROCEDURE|Gluteus plasty enhanced with Progrip self gripping mesh|Intervention group will be compared to historical patients in a case-control setting. Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
223716052|NCT02147470|DRUG|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
223910496|NCT05843188|DRUG|Hydroxychloroquine|Anti-Inflammatory - antimalarial - aminoquinolines
223910497|NCT05843188|DRUG|Irinotecan|Antineoplastic agent
223910498|NCT05843188|DRUG|Leucovorin|Folic acid derivative
223910499|NCT05843188|DRUG|Fluorouracil|Antineoplastic agent
223910500|NCT05843188|DRUG|Bevacizumab|Antineoplastic agent
223910501|NCT05110989|DEVICE|AtriCure Cryo Nerve Block (cryoNB) Device Family|Use of Atricure Cryo Nerve Block Device Family to generate cryoanalgesia for the management of post operative pain.
223910502|NCT04900350|DRUG|AK117|Subjects receive AK117 intravenously.
223910503|NCT04900350|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
223910504|NCT05130814|DEVICE|blue light photobiomodulation|1 minute irradiation of blue light performed with EmoLED device.
223910505|NCT05130814|PROCEDURE|cleansing|cleaning of the wound area with saline or ringer's lactate
223910506|NCT05130814|COMBINATION_PRODUCT|hyaluronic acid gauze plus polyurethane foam|every 48 hours or as needed
223910507|NCT05130814|DRUG|zinc cream or hyaluronic acid sodium salt + metallic silver|applied to prevent and/or treat the skin maceration of the surrounding area
223910508|NCT05130814|PROCEDURE|topical treatment|topical treatment indicated for that stage of the lesion
224085143|NCT02281591|DRUG|BIA 2-093|Tablets containing 900 mg
224085144|NCT02281591|DRUG|S-licarbazepine|capsules containing 225 mg
223716053|NCT05683964|DRUG|Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]|per standard care
223910509|NCT05130814|PROCEDURE|bandage|"it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system"
223716054|NCT05683964|DIAGNOSTIC_TEST|Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan|Per standard care
223716055|NCT02164825|DRUG|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
223716056|NCT02164825|DRUG|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
223910510|NCT06543303|DRUG|BTV100 Low dose|1% Cevimeline Ophthalmic Solution
223910511|NCT06543303|DRUG|BTV100 Mid dose|2% Cevimeline Ophthalmic Solution
223910512|NCT06543303|DRUG|BTV100 High dose|4% Cevimeline Ophthalmic Solution
223910513|NCT06543303|DRUG|Placebo|Placebo
223910514|NCT06561061|DRUG|zinc sulfate|Dispersible (20 mg) tablet
223910515|NCT06561061|DRUG|Placebo|Dispersible tablet
223910516|NCT05166850|BEHAVIORAL|PICHA7 mHealth program|The PICHA7 mHealth program is first delivered during a health facility visit by a health promoter bedside to a diarrhea patient (adults and child) and their accompanying household members during the time of illness followed by two home visits during the 7-day high risk period for diarrheal disease transmission. The health promoter delivers a pictorial WASH module on how diarrhea can spread, and instructions on handwashing with soap, water treatment, and safe water storage. A diarrhea prevention package is provided containing: a one-month supply of chlorine tablets for water treatment, a soapy water bottle for handwashing, a handwashing station, and a water vessel with a lid and tap to ensure safe water storage. After health facility delivery of the program, patient households receive weekly voice and text messages from the PICHA7 mHealth program over 12 months on the recommended WASH behaviors.
223910517|NCT05166850|OTHER|Standard Arm|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
223910518|NCT05159219|DRUG|Colchicine Pill|Anti-inflammatory
223910519|NCT05159219|OTHER|Placebo|Inert ingredients
223910520|NCT06336122|BEHAVIORAL|Peer Coach Training - Weekly|Peer participants will be contacted by peer coaches on a weekly basis.
223910521|NCT06336122|BEHAVIORAL|Peer Coach Training - Biweekly|Peer participants will be contacted by peer coaches on a bi-weekly basis
223910522|NCT02770222|DRUG|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
223910523|NCT02770222|DRUG|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
223910524|NCT02770222|DRUG|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
223910525|NCT05789173|DRUG|Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)
223910526|NCT05789173|DRUG|Efavirenz, Methadone and Tizanidine|Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
223910527|NCT05776524|DRUG|Nab paclitaxel|125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first
223910528|NCT05776524|DRUG|Gemcitabine|1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion
223910529|NCT05776524|DEVICE|TheraBionic|This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
223910530|NCT03804905|OTHER|No-cost Medications|Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
223910531|NCT06202235|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Both CKD Patients and Healthy Volunteers will undergo Magnetic Resonance Elastography (MRE) to evaluate liver and renal viscoelasticity. For CKD patients, blood tests for creatinine and cystatin C, along with blood pressure measurements, will be taken within a three-day window surrounding the MRE test. Additionally, CKD patients will undergo a renal biopsy to assess the extent of fibrosis
223910532|NCT05071287|OTHER|mHealth + low-fat diet|A restricted total calorie and reduced total fat consumption.
223910533|NCT05071287|OTHER|mHealth + low-carb/ketogenic diet|A low-carb/ketogenic diet
223910534|NCT06019637|OTHER|Onasemnogene Abeparvovec|Retrospective and prospective observational study. There is no treatment allocation.
223910535|NCT06437847|OTHER|Questionnaire|Questionnaire assessing the use of cognitive tests.
223910536|NCT05863052|BIOLOGICAL|Immunotherapy|immunotherapy
223910537|NCT04086121|DRUG|Spesolimab|Solution for SC injection
223910538|NCT05699915|PROCEDURE|Cardiology consultation|"* Electrocardiogram (ECG).~* Echocardiogram: A comprehensive evaluation of systolic and diastolic function, ventricular and atrial geometry will be performed. Special attention will be given to acquire a 3D measurement of left ventricular ejection fraction (LVEF) and to perform deformation imaging of left ventricle (global longitudinal strain (GLS)). The right ventricular function will be evaluated by tricuspid annular plane systolic excursion (TAPSE) and peak systolic velocity S' derived from color coded tissue Doppler imaging (TDI). Diastolic dysfunction will be based on average E/e' ratio \> 15 and left atrial (LA) area \> 30 cm2."
224085145|NCT02281591|DRUG|R-licarbazepine|capsules containing 225 mg
223716057|NCT00489346|DRUG|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
223716058|NCT00489346|DRUG|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
223716059|NCT03600818|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223716060|NCT03600818|DRUG|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223716061|NCT03600818|DRUG|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
223716062|NCT03600818|DRUG|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
223716063|NCT03600818|DRUG|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
223910539|NCT05699915|DIAGNOSTIC_TEST|Chest Computed Tomography (CT) without contrast|Calcium score. This will be performed at baseline, 12 and 24 months. The scans at 12 and 24 months will be combined, if possible, with standard of care scans for cancer treatment.
223910540|NCT05699915|PROCEDURE|Non-invasive endothelial function tests|"* FMD~* PAT~This aspect of the study will only be performed in the patients included by the Antwerp University Hospital due to organizational/practical issues."
223910541|NCT05699915|PROCEDURE|Electrocardiogram|An ECG will be taken prior to each ICI cycle during the first three months of treatment.
223910542|NCT05699915|DIAGNOSTIC_TEST|Extra serum sample (7.5 mL)|An extra serum sample will be taken at baseline, 3, 6, 12, 24 months and in case of sudden cardiac problems. This will subsequently be analysed to determine high-sensitivity troponin I, high-sensitivity troponin T and NT-proBNP.
223716064|NCT03429686|OTHER|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
223910543|NCT05359185|BEHAVIORAL|Family Wellness|https://familywellness.com/
223910544|NCT05359185|BEHAVIORAL|Career Coaching|Individualized career coaching and employment services.
223910545|NCT05359185|BEHAVIORAL|Financial Planning|Individualized financial planning services.
223910546|NCT04759456|OTHER|Remotely-supervised rehabilitation program|Include nutrition, health-related lifestyle and behavioral changes recommendations, and at least 5 times a week 30 minutes of moderate-intensity aerobic training, 10 minutes of inspiratory and expiratory muscle training with breathing device and 10 minutes of oropharyngeal exercise along with individually titrated CPAP therapy
223910547|NCT06402383|BIOLOGICAL|Vaccination Provision|HPV vaccination #1 will be offered by provider at the first visit when the HPV self-sample is collected. HPV Vaccination #2 will be offered at 6 months for HPV negative women and at 12 months for HPV positive women.
223910548|NCT06402383|BIOLOGICAL|Vaccination Provision 2|"HPV vaccination #1 will be offered by the provider after an HPV negative result is received with vaccine #2 given at 3 months after negative test results obtained.~For HPV positive women - vaccination #1 will be offered at 12 months and vaccination #2 will be offered at the 15 month mark."
224085146|NCT03267004|DEVICE|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\]."
224085147|NCT03267004|DEVICE|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\]."
224085148|NCT04699604|DRUG|Levocetirizine Dihydrochloride|At the end of the HILD assessment participants will be randomized to Levocetirizine Dihydrochloride or placebo. Children will be randomized by an investigational pharmacist to add-on either Levocetirizine dihydrochloride/ Xyzal® (UCB, Inc.) immediate release oral solution 2.5mg/5ml (2.5mg in children 6-11 years of age; 5mg in children \>11 years per recommended doses) or placebo to their current asthma regimen.
224085149|NCT04699604|DRUG|Placebo|Placebo
223716065|NCT06044610|OTHER|GENPOP Passive dehydration (75% reduction in fluid intake|Over 24-hours
223716066|NCT06044610|OTHER|GENPOP Ad lib fluid intake|Over 24 hours
223910549|NCT04116996|DEVICE|DEEP BRAIN STIMULATION|NEUROMODULATION
223910550|NCT05874362|OTHER|Diagnosis of depressive episode or post traumatic stress disorder|Clinical diagnosis of depressive episode or post traumatic stress disorder, confirmed
223910551|NCT05874362|OTHER|No diagnosis of depressive episode or post traumatic stress disorder|No elements in clinical assessment for the diagnosis of a depressive episode or post traumatic stress disorder
223910552|NCT03826901|DRUG|delgocitinib|Cream for topical application
223910553|NCT02834390|DRUG|Quizartinib|"\[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21.~\[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19.~\[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19."
224085150|NCT06106594|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
224099234|NCT00848991|DRUG|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
223716067|NCT06044610|OTHER|EXERCISE without fluid replacement|90-min standard cycling exercise trial in heat chamber
223716068|NCT06044610|OTHER|EXERCISE with fluid replacement|90-min standard cycling exercise trial in heat chamber
223716069|NCT04486911|DRUG|Pyrotinib maleate, SHR6390, letrozole|After providing written informed consent, the participants will undergo combined treatment of pyrotinib maleate, CDK4/6 inhibitor SHR6390, and letrozole. The effectiveness of the combined treatment will be evaluated by MRI every two treatment cycles. If the disease progresses, the participant will withdraw from the trial. If the combined treatment has identified effectiveness, the participant will undergo surgical treatment within 4 weeks (over 2 weeks) after termination of the neoadjuvant treatment. The patients will be followed up for 5 years.
224085151|NCT05400187|BEHAVIORAL|Body composition assessment and smart-phone based counselling|"As for the body composition assessment, body fat and muscle thickness, body fat percentage and distribution will be measured and a brief face-to-face counseling soon after the measurement will be implemented to the participants. Body assessment were measured by the InBody 270 (Biospace, Seoul, Korea) device, which provides a convenient way of accurate body fat measurement comparable with those obtained using air displacement plethysmography (ADP) (about 90% precision).~As for the Whatsapp-based counselling and communication session, qualitative dietary counselling will be offered every two weeks through the Whatsapp. One session contains 15 minutes, including the topics like making a balanced diet (55 % glucose, 30 % lipids and 15 % proteins), diversifying food intake, dietary advices and recommendations in healthy eating behaviors (e.g., eat slowly, eat at a regular time, avoid to skip a meal, drink at least 1.5 L of water each day)."
224085152|NCT06716905|DRUG|ACT500 tablets|Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1
224085153|NCT06716905|DRUG|Placebo|Participants will receive placebo matched to ACT500 Tablets.
224085154|NCT06716905|DRUG|ACT500 tablets|Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.
224085155|NCT06716905|DRUG|Placebo|Participants will receive placebo matched to ACT500 Tablets.
224085156|NCT06703554|OTHER|Sage Oil Mouthwash|Sage oil obtained from a local market of herbal products in Egypt. In order to identify chemical composition of sage essential oils and overall purity, Gas Chromatography/ Mass Spectrometry analysis (GC/MS) performed
224085157|NCT06703554|BIOLOGICAL|Chlorohexidine Mouthwash|0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, and sodium saccharin
224085158|NCT05084482|OTHER|Prediction models|The prediction scores are validated by the CAM-ICU scores up to 14 days after ICU admission.
223716070|NCT00486200|DRUG|ASP2151|Oral administration.
224085159|NCT03227809|BEHAVIORAL|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
224085160|NCT03227809|BEHAVIORAL|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
224085161|NCT03475043|BEHAVIORAL|Auditory training: temporal cues|Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
224085162|NCT06899919|DEVICE|Treatment with light compression systeme during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)|Treatment with light compression system during 16-week treatment period (6 medical visits are planned: D0, W2, W4, W8, W12, W16)
224085163|NCT06899919|DEVICE|Light compression system of the mixed leg ulcer stage C6 / C6r of the CEAP classification|Etiological treatment of mixed leg ulcer stage C6 / C6r of the CEAP classification
224085164|NCT06930833|DEVICE|Corsano CardioWatch 287-2|Eligible patients are asked to wear the Corsano CardioWatch 287-2 for 6 days, of which 3 days approximately 2 weeks before the procedure and 3 days approximately 2 months after the procedure.
224085165|NCT02115230|PROCEDURE|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
223716071|NCT00486200|DRUG|valacyclovir|Oral administration of active comparator.
224085166|NCT04768127|OTHER|early aftercare|This group begins the aftercare program immediately after their bariatric surgery.
224085167|NCT04768127|OTHER|mid-term to late aftercare|This group begins the aftercare program 18 months post surgery.
223716072|NCT00486200|DRUG|Placebo|Oral administration of placebo.
224277503|NCT02497079|DEVICE|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
224277504|NCT02497079|DEVICE|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
223716073|NCT05581862|BEHAVIORAL|3 meals+3 snacks|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals and 3 snacks for 3 months
223716074|NCT05581862|BEHAVIORAL|3 meals|All of the 20 subjects consumed an energy restricted weight loos plan with 3 main meals for 3 months
224085168|NCT06865170|PROCEDURE|25 gauge needle|This intervention will observe patients post-procedural pain using a 25 gauge needle
224085169|NCT06865170|PROCEDURE|22 gauge needle|This intervention will observe patients post-procedural pain using a 22 gauge needle
224085170|NCT06865170|PROCEDURE|+/- Ethyl Chloride Topical Aerosol Anesthetic|This intervention will observe patients post-procedural pain when using topical ethyl chloride spray. This will be compared to a placebo spray which will utilize isopropyl alcohol.
223910554|NCT02834390|DRUG|Cytarabine|"\[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5.~\[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5."
223910555|NCT02834390|DRUG|Idarubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2."
223910556|NCT02834390|DRUG|Daunorubicin|"Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3.~\[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2."
223910557|NCT03118518|DEVICE|Cryoablation|Pulmonary vein isolation via ablation with cryoballoon catheter
223910558|NCT03118518|DRUG|Antiarrhythmic drug|Antiarrhythmic drug initiation
223910559|NCT04393207|DRUG|Liposomal bupivacaine (LB)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with liposomal bupivacaine + bupivacaine or with bupivacaine alone.
223910560|NCT04393207|DRUG|Dexamethasone and methylprednisolone (CG)|Transverse abdominis plane block will be performed and the neurofascial plane between the internal oblique and the transverse abdominis will be infiltrated with with bupivacaine alone.
223910561|NCT04393207|DRUG|Control group (Bupivacaine)- (BPG)|Transverse abdominis plane block will be performed with plain bupivacaine
223910563|NCT05839587|PROCEDURE|Robotic TAPP|Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
223910564|NCT05839587|PROCEDURE|Laparoscopic TAPP|Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
223910565|NCT06246084|BEHAVIORAL|Endocrine Therapy Education Program|Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants. The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
223910566|NCT06553157|DRUG|Statin|Statins are drugs known to help lower total cholesterol and reduce the risk of a heart attack or stroke. Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.
223910567|NCT06553157|OTHER|placebo|placebo
223910568|NCT06197360|BEHAVIORAL|Based on BCW Theory of Health Education|Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.
223910569|NCT06197360|BEHAVIORAL|General diabetes health education|Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
223910570|NCT04538742|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
223910571|NCT04538742|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
223910572|NCT04538742|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
223910573|NCT04538742|DRUG|Pertuzumab|Pertuzumab: administered as an IV infusion
223910574|NCT04538742|DRUG|Tucatinib|Tucatinib administered orally (tablet) twice daily
223910575|NCT06587906|OTHER|Pulmonary ultrasound examination|All ultrasound scans were performed by the same anaesthetists. Pulmonary ultrasound examination was performed at two time points for each patient: 20 min before starting mechanical ventilation of the lungs when patients were placed in the supine position(preoperative), 20 min after after surgery end at the time the patient was placed in the supine position (postoperative), before Intubation and after extubation Patientswere scanned in the supine position following the pulmonary ultrasound examination method The thorax was divided by the anterior axillary line, the posterior axillary line, and a horizontal line beneath nipple. Twelve intercostal spaces of each area were scanned and analysed. Aeration loss was assessedby calculating the modified LUS score that is calculated mainly using the amount of B-line The pulmonary ultrasound score of the hemithorax (0-18).
224099235|NCT00848991|DRUG|Propofol|evaulation of propofol for emergence from anesthesia
224099236|NCT06487351|BEHAVIORAL|The adapted PHBI|The adapted intervention is expected to be an online 60-minute video with an educational part about implicit racial bias, its consequences in healthcare inequalities, how to mitigate it, and seven case scenarios (5 minutes each) to train pharmacy interns on aspects related to cultural competency and how and when to use IBMS to reduce the impact of bias on prescribing PrEP for people of color.
224099237|NCT06487351|BEHAVIORAL|The NIH Implicit Bias course|The NIH Implicit Bias course consists of three modules designed to teach users what bias is, how to recognize it, and how to minimize its impact
224099238|NCT02015819|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
224085171|NCT03694392|BIOLOGICAL|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
224085172|NCT03694392|BIOLOGICAL|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent.
224085173|NCT01218607|DRUG|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
224085174|NCT01218607|DRUG|Placebo|Placebo will be taken twice daily for 16 weeks
224085175|NCT06916169|DRUG|AG2304|AG2304, Single-dose Oral Administration
223910576|NCT06234345|DRUG|Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg|Participants randomized to this group will receive 1 capsule per inhalation twice a day
223910577|NCT06234345|DRUG|Comparator - Trimbow®|Participants randomized to this group will receive 2 triggering twice a day
223910578|NCT02998528|BIOLOGICAL|Nivolumab|Specified dose on specified days
223910579|NCT02998528|DRUG|Cisplatin|Specified dose on specified days
223910580|NCT02998528|DRUG|Vinorelbine|Specified dose on specified days
223910581|NCT02998528|DRUG|Gemcitabine|Specified dose on specified days
224085176|NCT06916169|DRUG|AG23041 and AG23042|AG23041/AG23042, Single-dose Oral Administration
224085177|NCT06916936|OTHER|Creamy Richards 100% Peanuts! Creamy Natural Peanut Butter|"Peanut Butter (PB) Group: Participants in this group will receive a daily snack consisting of a personalized portion of smooth peanut butter (Creamy Richards 100% Peanuts! Creamy Natural Peanut Butter) spread between two plain unsalted saltine crackers (Unsalted Tops Premium Saltine Crackers). The amount of peanut butter will be limited to 16g per two crackers, but additional crackers will be provided if the personalized portion exceeds this limit"
224085178|NCT06916936|OTHER|Cadbury Milk Chocolate Spread|"Control (CTL) Group: Participants in this group will receive a daily snack consisting of an isocaloric amount of a nut-free, vegetable oil-based chocolate spread (Cadbury Milk Chocolate) spread between two plain unsalted saltine crackers (Unsalted Tops Premium Saltine Crackers). Similar to the peanut butter group, the chocolate spread will be limited to 16g per two crackers, with additional crackers provided if needed."
223910582|NCT02998528|DRUG|Docetaxel|Specified dose on specified days
223910583|NCT02998528|DRUG|Pemetrexed|Specified dose on specified days
224085179|NCT06916117|DRUG|Neoadjuvant Chemotherapy (NACT)|"Neoadjuvant chemotherapy:~The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.~Concurrent chemoradiotherapy:~Radical dose to the pelvic concurrent with cisplatin.~Consolidative immunotherapy:~Following the completion of chemoradiotherapy, Sintilimab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total of 6 cycles, starting 3-4 weeks after chemoradiotherapy."
224085180|NCT06916975|DRUG|Adebrelimab|Adebrelimab: 1200mg，iv，d1，q3w；
224085181|NCT06916975|DRUG|AG|Gemcitabine: 1000 mg/m² ，iv，d1、d8，q3w； Nab-paclitaxel: 125 mg/m² ，iv，d1、d8，q3w；
224085182|NCT06915415|BEHAVIORAL|Animal-assisted therapy|One group had a live therapy canine included in therapy sessions who was trained to provide comfort measures and promote interaction with autistic children. He is a certified therapy and service dog and knows over 50 commands and is certified in 10 autism service dog tasks. Participants played with him at the beginning of the session. They could choose to play fetch or hide and seek. Participants could say commands to make him do tricks and give him a treat as a reward. The canine would lay at participants' feet while the therapist was working on a skill in the clinic room. The canine would alert to the onset of anxiety and provide comfort measures. Participants could also cue the canine to provide comfort measures or could brush his fur and give him water as a prosocial behavior. Participants ended sessions with either fetch, soccer, or hide and seek.
224085183|NCT06915415|BEHAVIORAL|Behavioral therapy|One group had a toy plush dog included in therapy sessions. The therapist would incorporate the toy plush dog in the seated portion of the session to practice social skills. Participants could brush the toy plush dog, pet it, and hold it during sessions.
224085184|NCT06917300|DEVICE|Virtual Reality|The VR group will be exposed to a unified 15-minute VR video via phone using a VR device and goggles after receiving routine standard care. A 360˚ video with an immersive audio-visual environment describing pre-operative and post-operative experience on the day of the surgery will be provided, by which they can get accustomed to the environment and procedures associated with the surgery. Background audio will be provided through headsets, and the video will be directed by a neurosurgeon filmed using a Max 360 action VR camera. In the video, actors, neurosurgeons, and nurses will re-enact a typical day for a mock patient undergoing surgery, plus routine post-operative care, including the post-operative immediate recovery room and rehabilitation care by neurosurgeons, psychologists, and physiotherapists in the ward. Patients are allowed to move around freely so that they can experience all aspects of the virtual space, and are encouraged to ask questions at the end.
223910584|NCT02998528|DRUG|Carboplatin|Specified dose on specified days
223910585|NCT02998528|DRUG|Paclitaxel|Specified dose on specified days
223910586|NCT02998528|BIOLOGICAL|Ipilimumab|This arm is closed and no longer enrolling patients.
223910587|NCT06439407|DEVICE|SAT-014(Software as Medical Device)|SAT-014(Software as Medical Device) + maintain previous treatment
223910588|NCT03657342|DRUG|Liposomal Cyclosporine A|This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
223910589|NCT03657342|DRUG|standard of care|Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator.
224085185|NCT06916442|DIAGNOSTIC_TEST|PET/CT Imaging with GZMB-targeted tracer|Intravenous administration of GZMB-targeted tracer (150-200 MBq), followed by whole-body PET/CT scan 30\~60 minutes post-injection.
223910590|NCT04345874|BEHAVIORAL|Nutrition technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
223910591|NCT04345874|BEHAVIORAL|Children's environmental health technical assistance|Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
223910592|NCT05913817|BIOLOGICAL|AVT02 (Alvotech Biosimilar to Adalimumab)|Phase IV Study
223910593|NCT04175977|BEHAVIORAL|Aliviado Dementia Care-Hospice Edition QAPI program|Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
223910594|NCT04175977|BEHAVIORAL|Usual Care|Usual care as provided by the hospice agency
223910595|NCT06150339|OTHER|OASIS Walking Intervention|Communication Care Plan, Sit to Stand Activity, Walking Program
223910596|NCT06333639|OTHER|orthopaedic surgery|usual procedures for an orthopaedic surgery
223910597|NCT06333639|OTHER|orthopaedic surgery and fitted with a virtual reality headset|usual procedures for an orthopaedic surgery and fitted with a virtual reality headset
223910598|NCT06420167|DRUG|Dapagliflozin|10mg orally once daily
224085186|NCT06917638|PROCEDURE|implant placment|"* Crestal incision followed by full thickness mucoperiosteal flap elevation.~* Drilling of the implant according to the manufacturer's instructions to reach the final drill corresponding to the implant size.~* Allocation concealment will be broken at this point to assign the patient into one of two groups:~Control Group: osteotomy preparation the same diameter of the implant. Intervention: oversized drilling:Osteotomy preparations will include an extra drill,(0.2mm) wider than the diameter of the implant.~* A smart peg will then be attached to the implant, to measure its stability using Ostell and three readings will be recorded:occlusal buccal and lingual reading.~* A healing collar will then be place over the implant, then simple intrerupted suture~* A standardized digital periapical radiograph will be taken using a radiographic holder and a custom-made radiographic stent to determine the initial crestal bone level."
224085187|NCT06916871|OTHER|The control group will benefit from awareness|During hospitalization in rehabilitation, doctors and nursing staff will transmit information in a linear manner, i.e. explain, possibly argue and answer the patient's questions on topics such as interpreting blood sugar levels, explaining treatment, good practices in terms of diet, physical activity, etc. at the patient's bedside in an unstructured manner based on interactions between patient and caregivers. There is therefore no standard frequency, number of specific sessions, or topics addressed systematically.
224085188|NCT06916871|OTHER|The experimental group will benefit from structured education which will be carried out by the diabetes nurse|During hospitalization in rehabilitation, the experimental group will benefit from structured education which will be carried out by the diabetes nurse at a rate of 3 sessions for patients on oral anti-diabetics and 5 sessions for patients on insulin.
224085189|NCT06916247|BEHAVIORAL|Complex care management program|Intensive outpatient care management program that includes contact from nurses and case managers to help coordinate care, detect clinical red flags, and reduce overall unplanned acute care utilization.
224085190|NCT06916416|DRUG|Pembrolizumab|6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy
224085191|NCT06916962|BEHAVIORAL|Intervention|"Intervention participants will receive cash transfers on the condition of their participation in peer-led TB support meetings (TB Clubs).~Two monthly TB Club meetings will be held in each participating district. Each will aim to provide enhanced education about the TB treatment process, as well as to improve treatment engagement and adherence, foster social support and mitigate TB-related stigma.~Participants will be eligible for a maximum of three cash transfers, amounting to a total of 3,000,000 VND. The first payment of 1,000,000 VND will be made after a participant joins one TB Club, the second payment will be completed after attending a second TB Club, and the third payment will be provided after attendance at their 6th TB Club."
224085192|NCT06915792|DRUG|Labetalol|Labetalol is a beta-blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral labetalol will be initiated at 200mg twice or three times daily and adjusted up to 2400 mg/day as needed for blood pressure control.
223910599|NCT05660863|DRUG|MN-08 24 mg/day|Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
223910600|NCT05660863|DRUG|MN-08 60 mg/day|Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
223910601|NCT03533517|DEVICE|AccuCinch® Ventricular Restoration|AccuCinch® Ventricular Restoration System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
223910602|NCT05122416|DEVICE|FibroScan examination (S)|A FibroScan examination with the Exploratory S probe.
223910603|NCT05122416|DEVICE|FibroScan examination (M)|A FibroScan examination with the Optimized M probe.
223910604|NCT05122416|DEVICE|FibroScan examination (XL)|A FibroScan examination with the Exploratory XL probe.
223910605|NCT05122416|DEVICE|FibroScan examination (Standard M)|A FibroScan examination with the Standard M probe.
224085193|NCT06915792|DRUG|Nifedipine|Nifedipine is a calcium channel blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral extended-release nifedipine will be initiated at 30mg once daily and adjusted up to 120mg/day as needed for blood pressure control.
224085194|NCT06916260|DEVICE|Red Light (PDT)|The intervention is a non invasive and safe practice. By delivering low level wavelength red light to the front part of the head, it can increase blood flow in the area treated and improve functioning of the associated regions, potentially improving symptoms.
223910606|NCT06324344|DEVICE|High-Dose TENS|high-dose TENS device delivers 1 hour of TENS therapy per session.
224085195|NCT06916260|DEVICE|Placebo|The intervention is a non invasive and safe practice. Participants will be wearing a helmet that delivered low level light therapy to the brain, and use it for the same amount of time as the treatment group. These participants will however, not receive the actual light and receive a placebo, so the helmet will be off. This is done to control of any potential positive effects of the therapy.
224085196|NCT06912672|DIAGNOSTIC_TEST|Evaluate the diagnostic performance of EPIPROBE TAGMe DNA Methylation Detection Kit for Urothelial Cancer|The study aims to evaluate the diagnostic performance of the EPIPROBE TAGMe DNA Methylation Detection Kit for the detection of urothelial cancer. This assay utilizes targeted DNA methylation analysis to identify specific epigenetic alterations associated with urothelial malignancies. The performance of the kit will be assessed in terms of sensitivity, specificity, and overall diagnostic accuracy using clinical urine samples from a patient population with hematuria.
224085197|NCT06916273|DRUG|PA9159 Inhalation aerosol, 60 μg one day treatment|single dose of PA9159 (60 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 2 puffs.
224085198|NCT06916273|DRUG|PA9159 Inhalation aerosol, 120 μg one day treatment|single dose of PA9159 (120 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 4 puffs.
224085199|NCT06916273|DRUG|PA9159 Inhalation aerosol, 240 μg one day treatment|single dose of PA9159 (240 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 8 puffs.
224085200|NCT06916273|DRUG|PA9159 Inhalation aerosol, 300 μg one day treatment|single dose of PA9159 (300 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 10 puffs.
224085201|NCT06916273|DRUG|PA9159 Inhalation aerosol, 120 μg 7-day treatment|Repeated doses of PA9159 (120 μg/inhaler spray) i is administered by inhalation through an inhaler via the mouth, with 4 puffs, twice a day.
224085202|NCT06916273|DRUG|Placebo, the same Inhalation aerosol solution without PA9159 active ingredient|Placebo is delivered via the mouth through an inhaler with the same volume as the corresponding PA9159 dose group
224085203|NCT06912880|PROCEDURE|trans obturator tape surgery|Trans-obturator technique is a more beneficial and a less invasive procedure in treatment of SUI when compared with other techiniques. In this technique, a synthetic mesh tape, which is passing bilaterally through the obturator foramen, is placed underneath the mid part of the urethra.
224085204|NCT06917729|OTHER|CardioBreath|Twice a day for ten minutes,5 days during the week CardioBreath app will be based on Prescription section , using breathing technique Ujjayi Pranayama, based on spontaneous respiratory rate of users, gamified to induce the user to improve performance of the exercises reducing the exercises respiratory exercises
224085205|NCT06913374|DRUG|Dexamethasone|given orally at 40 mg per day for two cycles (days1-4, and days 11-14).
224085206|NCT06913374|DRUG|Dexamethasone|given orally at 40 mg per day for three cycles (days1-4, days 11-14, and days 21-24).
224085207|NCT06917391|BEHAVIORAL|Wendyverse VR food marketing experience|"In the Wendyverse VR application (app) participants can order from a Wendy's restaurant, play games, meet with others who may be visiting the Wendyverse, and access codes that can be used to obtain free food at physical restaurants."
223910607|NCT06324344|DEVICE|Low-Dose TENS|low-dose TENS device delivers 6 minutes of TENS therapy per session.
224085208|NCT06917391|BEHAVIORAL|Nikeland VR non-food marketing experience|In Nikeland VR app, participants can play sports, try on apparel, and engage with celebrity athletes.
224085209|NCT06916234|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
224085210|NCT06916234|DRUG|Naproxen Sodium + Codeine Phosphate|Naproxen Sodium + Codeine Phosphate (550mg + 30mg) is a NSAID. It was given to the patients twice a day.
224085211|NCT06915064|DEVICE|Low- level laser- photobiomodulation therapy|Three patients (30%) received treatment on the left side and seven (70%) on the right side. The treatment was carried out using the EPIC X laser (BIOLASE®), which uses a solid-state diode as a semiconductor source of invisible infrared radiation. The therapy was applied to the masticatory muscles (temporal, masseter, internal pterygoid), to trigger points discovered on palpation and to the intra-articular area of the TMJ (posterior portion through the external ear, superior portion and anterior portion). All patients included in the study underwent four sessions of PBMT-LLL for four consecutive weeks. T
224085212|NCT06915519|DIAGNOSTIC_TEST|measure motor strength and perfusion index|measurements of the motor strength and perfusion index in the blocked hand to predict the successfulness of the supraclavicular block at 0, 5, 10 and 15 min post blockage.
224099239|NCT02015819|DRUG|flucytosine|Given orally
224099240|NCT02015819|DRUG|leucovorin calcium|Given orally
223910608|NCT04152096|DRUG|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
223910609|NCT04152096|DRUG|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
223910610|NCT05819268|BEHAVIORAL|ReACT|ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
223910611|NCT05819268|BEHAVIORAL|CATCH-IT|CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
223910612|NCT04808323|DRUG|Capecitabine|825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
223910613|NCT04808323|DEVICE|Initial Dose of Radiation before Dose Escalation|50 Gy over 25 frac.
223910614|NCT04808323|DEVICE|Cohort A: Dose Escalation Radiation|Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
223910615|NCT04808323|DEVICE|Cohort B: Dose Escalation Radiation|Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
223910616|NCT04808323|DEVICE|Cohort C: Dose Escalation Radiation|Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
223910617|NCT04808323|DRUG|FOLFOX|After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
223910618|NCT05783414|BEHAVIORAL|f2f CST|An evidence-based group CST protocol adapted for Hong Kong Chinese culture. It consists of 14 sessions of group activities (group size: 6) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
223910619|NCT05783414|BEHAVIORAL|f2f carer support|Centre-based carer support programme for dementia carers provided in a community care service centre, which provide group education on caring skills, mutual support groups, and group-based self-care training over 6 months.
223910620|NCT05783414|BEHAVIORAL|vCST|A home-based version of f2f CST delivered via an information and communication technology platform (Zoom plus a web-based CST platform). It consists of 14 sessions of group activities (group size: 3) for people with mild to moderate dementia, where participants with similar level of cognitive impairment receive cognitively stimulating social activities twice per week over 7 weeks.
223910621|NCT05783414|BEHAVIORAL|online carer support|A home-based carer support service delivered via an information and communication technology platform (Zoom plus a web-based carer platform). It consists of 4 group sessions (group size: 6) and 3 individual sessions, and 3 optional self-learning sessions over 6 months, with an empowering care management approach to strengthen carer self-efficacy.
223910622|NCT05180058|OTHER|Wrapping + Breastmilk Group|Interventions applied during orogastric tube insertion
223910623|NCT05284409|DRUG|Pethidine|36 patients will receive 0.5 mg/kg Pethidine IVI
223910624|NCT05284409|DRUG|Acetaminophen|36 patients will receive 15 mg/kg Acetaminophen IVI
223910625|NCT05284409|DRUG|Dexamethasone|36 patients will receive 0.1 mg/kg Dexamethasone IVI
223910626|NCT06205160|DEVICE|SOFT ECoG subdural grid electrode|"Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection.~All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making."
223910627|NCT05000515|OTHER|High-resistance inspiratory muscle strength training|Participants will perform inspiratory muscle strength training.
223910628|NCT05000515|OTHER|Aerobic exercise|Participants will perform brisk walking.
223910629|NCT05389878|OTHER|rehabilitation|All patients addressing intemsive inpatient post stroke rehabilitation undergo a shared evidence based Integrated Care pathway that is routinely adopted in all the participating Centres
223910630|NCT05924113|BEHAVIORAL|Latin Dance|Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
223910631|NCT06471582|DIETARY_SUPPLEMENT|Artificially Sweetened Carbohydrate Beverage|Beverage containing 0.7 g carbohydrate/ kg body mass/ h as a 2:1 mixture of glucose and fructose and artificial sweetener
223910632|NCT06471582|DIETARY_SUPPLEMENT|Artificially Sweetened Beverage|Beverage containing no carbohydrates or kilocalories and an artificial sweetener
223910633|NCT03624465|DEVICE|Levita Magnetic Surgical System|Device for use as a surgical tool.
223910634|NCT06504407|BEHAVIORAL|Bingo Educational Game|The intervention involves Bingo games designed to educate African American/Black community members about cancer and clinical trials. During each game, educational facts are shared, and prizes promoting healthy lifestyles are awarded. Led by a Diversity Navigator, the sessions include pre- and post-test surveys to assess knowledge gain and engagement. The intervention also connects participants with needed medical services.
223910635|NCT03213678|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
223910636|NCT03213678|PROCEDURE|Computed Tomography|Undergo CT
223910637|NCT03213678|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
223910638|NCT03213678|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223910639|NCT03213678|DRUG|Samotolisib|Given PO
223910640|NCT03213678|PROCEDURE|X-Ray Imaging|Undergo x-ray
224099241|NCT02015819|OTHER|pharmacological study|Correlative studies
223910641|NCT04224064|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.
223910642|NCT04218851|DRUG|Posaconazole IV|Posaconazole (POS) 6 mg/kg body weight by IV infusion
223910643|NCT04218851|DRUG|Posaconazole PFS|Dosing based on weight-band taken orally
223910644|NCT04218851|DRUG|Posaconazole tablet|POS tablet 300 mg taken orally
223910645|NCT05109468|OTHER|Quality of life questionnaire|to assess the quality of sexual life of patients treated for anal cancer treated with radiotherapy, during their treatment, then 3 months after treatment and, finally, 2 years after cancer diagnosis.
223910646|NCT03742505|DRUG|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
223910647|NCT03742505|OTHER|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
223910648|NCT06492382|DIAGNOSTIC_TEST|Home Oxygen Monitors|Weaning of home oxygen using information gathered from home moniotr devise
224099242|NCT02015819|OTHER|laboratory biomarker analysis|Correlative studies
224099243|NCT05862363|DIETARY_SUPPLEMENT|Microbiota-directed balanced energy protein (MD-BEP)|Prototypes for nutritional interventions that are composed of locally available, affordable, culturally acceptable complementary foods commonly consumed in Bangladesh have recently been developed.
223910649|NCT04785092|PROCEDURE|All Autologous Cartilage Regeneration|All patients will undergo firstly to a blood sampling and then to the arthroscopic debridement of the damage cartilage and subsequently will be harvested the surrounding healthy cartilage The harvested and healthy cartilage will shredded directly in situ with a shaver. This cartilage will then mixed with the patient's own Platelet Concentrate and may be injected directly into the cartilage defect. The Platelet Concentrate stimulates the healing of the cartilage most effectively. At the same time, the Platelet Concentrate will also used to produce autologous fibrin glue, which can be used to fix the applied cartilage chip / Platelet Concentrate product quickly and safely in the damaged cartilage.
223910650|NCT05886933|DRUG|Fexuprazan Hydrochloride|Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet)
223910651|NCT06478979|DEVICE|Neuclare|It is used to stimulate the brain for a certain period of time to assess gait improvement in patients with Idiopathic Normal Pressure Hydrocephalus (iNPH). In this clinical trial, it is used for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH).
223910652|NCT04964310|GENETIC|genetic polymorphism|Observe the genetic polymorphism frequency difference between case and control groups
223910653|NCT01473784|PROCEDURE|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
223910654|NCT01473784|PROCEDURE|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
223910655|NCT05797428|OTHER|logotherapy|The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
223910656|NCT05851144|BEHAVIORAL|Bienestar/Neema Coordinated School Health Program (BN CSHP)|Bienestar/Neema Coordinated School Health Program (BN CSHP), a Texas Education Agency-approved school health curricula, is a multi-prong intervention
223910657|NCT04174495|DIAGNOSTIC_TEST|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
223910658|NCT05825508|DEVICE|ankle robot|home ankle robot and video game
223910659|NCT02313194|DEVICE|Epidural Stimulation|Determine if epidural stimulation can improve motor function
223910660|NCT02313194|DRUG|Buspirone|Determine if the pharmacological agent in combination with the stimulator can improve motor function.
223910661|NCT05226871|DRUG|Palbociclib|oral
223910662|NCT05226871|DRUG|Cetuximab|Intravenous (IV) infusion
223910663|NCT05226871|DRUG|Fulvestrant|Intramuscular (IM)
223910664|NCT05226871|DRUG|Letrozole|oral
223910665|NCT06151184|PROCEDURE|Chiropractic adjustment|6 weeks of chiropractic care, with frequency and type of procedures determined by field clinician after initial examination.
223910666|NCT03517007|OTHER|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
223910667|NCT06249984|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223910668|NCT06249984|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
223910669|NCT06249984|BEHAVIORAL|Smokeless Tobacco Use|Use moist snuff
223910670|NCT06249984|OTHER|Survey Administration|Ancillary studies
223910671|NCT04796324|DRUG|Ixabepilone Injection|Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
223910672|NCT02871167|PROCEDURE|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
223910673|NCT02871167|PROCEDURE|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
223910674|NCT06698549|DRUG|ALG-097558|Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
223910675|NCT06249295|OTHER|oral cryotherapy|The experimental group used drinking water from a water dispenser with regular filter replacement and maintenance, plus a 2x5x7 cm (50 ml) ice lolly module to make ice lollies, and then intervened in the post-surgical period using oral cold therapy (ice lolly in the mouth)
223910676|NCT05137067|DIETARY_SUPPLEMENT|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)|Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.
223910677|NCT05137067|DRUG|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo|Placebo
223910678|NCT05137067|DRUG|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).|Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
223910679|NCT03174275|DRUG|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
223910680|NCT03174275|DRUG|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
223910681|NCT03174275|DRUG|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
223910682|NCT03174275|DRUG|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
223910683|NCT03174275|PROCEDURE|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
223910684|NCT03174275|RADIATION|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
224085213|NCT06917417|BEHAVIORAL|Laughter Therapy|A laughter yoga session; It is approximately 30 minutes and consists of four parts. These sections; hand clapping and warm-up exercises, deep breathing exercises, childish games and laughter exercises. In each laughter yoga session, the first three parts are the same, but the laughter exercises in the fourth part vary. In the first session of each new group, the introduction of laughter yoga, its purpose and objectives will be discussed. 10 minutes will be allocated for this section in the first session of each group. Therefore, the first session is planned to be 40 minutes in each group and all subsequent sessions are planned to be 30 minutes.
224085214|NCT06916884|DRUG|Desloratadine / Betamethasone in fixed dose|1 tablet, once a day of 5 mg / 0.25 mg
224085215|NCT06916884|DRUG|Desloratadine|1 tablet, once a day of 5 mg
223910685|NCT05296889|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Cervical Spinal System is a posterior stabilization for the cervical and upper-thoracic spine. The implants are used for the posterior monosegmental and multisegmental stabilization of the occipitocervical junction and of the cervical and upper thoracic spine.
223910686|NCT06823323|DIETARY_SUPPLEMENT|Lactobacillus johnsonii|It is previously reported Lactobacillus johnsonii #CGMCC29884 in Cell. Animal studies showed it combined with Clostridium sporogenes to produce indolepropionic acid, modulating CD8+ T cell immune quiescence in the tumor microenvironment and sensitizing immunotherapy in CRC, breast cancer, and melanoma. Mager et al. found Lactobacillus johnsonii enhanced CTLA-4 mAb antitumor effects in CRC mouse models. Studies showed it's a typical probiotic widely distributed in various hosts' guts and has long been applied in food and feed industries. Preclinical studies indicated it improved memory through the gut-brain axis, had anti-inflammatory and antibacterial effects, and regulated metabolic diseases. Randomized trials found it effectively inhibited Helicobacter pylori colonization without obvious adverse reactions, suggesting it's a potentially safe and effective treatment.
224085216|NCT06916208|DIETARY_SUPPLEMENT|capsinoid supplementation|Adolescents in the experimental group will receive active capsules containing dihydrocapsiate (bought from Ajinomoto® (Ajinomoto Health \& Nutrition North America, Inc., Japan) 3 times per day, representing 9mg/day all through the duration of the 4-week multidimensional care program.
224085217|NCT06916208|OTHER|Control group (placebo)|Regular multidimensional care 4-week program
223529164|NCT05751434|BEHAVIORAL|Exercise Therapy|The intervention will consist of exercise therapy, individualized, walking delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule, up to 5 individual treatment sessions/week to achieve a cumulative total duration of 225 to 300 mins/wk until the participant's next standard of care prostate biopsy (about 6-12 months).
223910687|NCT06823323|OTHER|Placebo|Placebo
223910688|NCT06821750|BIOLOGICAL|PF-07314470|subcutaneous injection
223910689|NCT06821750|BIOLOGICAL|Placebo for PF-07314470|subcutaneous injection
223910690|NCT06263257|BEHAVIORAL|Mandala Art Therapy|"In art therapy, visual arts (such as drawing, painting, and sculpting) can be used as a tool to facilitate the expression of emotions and enhance coping skills. Naisin and colleagues (2006) reported that a one-hour art therapy session significantly reduced anxiety levels in hospitalized adult oncology patients. The word mandala is now typically associated with circular, geometric designs and often appears in adult coloring books aimed at promoting mindfulness and stress reduction. However, the methodology and theory of Jung related to mandalas are based not only on coloring pre-drawn templates but also on the activity of creating mandalas. The act of creating a mandala is claimed to provide immediate benefits in improving mood. The mandala is expressed as an instantaneous outward expression of the inner world of the person drawing it."
223910691|NCT05631743|BEHAVIORAL|VR-CBT|The therapy is focused on emotion regulation through guided learning in virtual reality. The manual is a modified conventional cognitive behavioral therapy to include these aspects and the suggestions of an advisory committee of Inuit and non-Inuit health service providers (e.g., cultural adaptation).
224085218|NCT00260520|DRUG|Dalteparin|
224085219|NCT06917274|DIETARY_SUPPLEMENT|Banana|A banana is consumed pre-exercise in order to prevent hypoglycemia
224085220|NCT06917274|OTHER|No banana|No banana is consumed pre-exercise
224085221|NCT06915103|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|A pelvic MRI with and without contrast was performed for evaluation of the ovary.
224085222|NCT06915103|PROCEDURE|Salpingo-oophorectomy|Salpingo-oophorectomy procedure was performed on the left ovary.
224085223|NCT05255328|DIETARY_SUPPLEMENT|Glutamine oral supplement|12-18 g /day of glutamine supplementation
224085224|NCT03371797|DRUG|Valsartan, Amlodipine -|"Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker."
224085225|NCT06916351|OTHER|Acupressure|Acupressure will be applied to a total of three points: the 4th point of the Large Intestine Meridian (LI4-Hegu point) and the 6th point of the pericardial meridian (PC6- Nei Guan point), located three fingers above the wrist.
224085226|NCT06916351|OTHER|Sham acupressure|Sham acupressure will be applied to three points parallel to HT7, LI4 and PC6, approximately 1-1.5 cm away from the meridians.
224085227|NCT06916663|BEHAVIORAL|Upper Body Exercise Protocol (UBE)|"Participants randomized to the Upper Body Exercise Group will perform a structured, supervised exercise regimen focused exclusively on the upper extremities and core muscles, while rigorously maintaining foot offloading prescribed for diabetic foot ulcers (DFU). This intervention is delivered face-to-face in hospital-based outpatient rehabilitation centers. Sessions are held three times per week for 12 consecutive weeks (total 36 sessions), with each session lasting 45-60 minutes.~Each UBE session comprises a 10-minute warm-up on an arm ergometer at 40-50% of the participant's heart rate reserve (HRR), followed by a circuit of eight upper body and core exercises."
223719389|NCT02190357|DRUG|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
223910692|NCT05631743|BEHAVIORAL|Self-management|The previously developed commercial VR program involves guided relaxation and meditation techniques.
224085228|NCT06916663|BEHAVIORAL|Combined Non-Weight Bearing Exercise Protocol (CE)|"Participants in the Combined Exercise Group will engage in a structured exercise regimen that integrates upper body, core, and modified lower extremity exercises-all performed in a non-weight bearing or seated position to ensure complete offloading of the affected foot. Sessions are conducted face-to-face in hospital-based rehabilitation centers. Participants attend three sessions per week for 12 weeks (36 sessions total), each lasting 45-60 minutes.~Each session begins with a 10-minute warm-up on an arm ergometer at 40-50% HRR."
224085229|NCT06916663|BEHAVIORAL|Standard Diabetic Foot Ulcer Wound Care (SC)|Participants assigned to the Standard Care Control Group will receive comprehensive DFU wound management in accordance with International Working Group on the Diabetic Foot (IWGDF) guidelines. This includes standard offloading strategies (using Total Contact Cast or removable cast walker), regular weekly wound assessments, and debridement if necessary. Diabetes management education is provided along with routine adjustments and monitoring of the offloading device to ensure proper healing support. No structured exercise intervention is added; however, all aspects of care such as continuous glucose monitoring and vascular assessments will be uniformly applied to allow comparison with the exercise groups.
224085230|NCT06917430|OTHER|No intervention|No intervention.
224085231|NCT06917144|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Stimulation sessions were performed using a YINGCHI M-100 Ultimate device with liquid-cooled figure-8 coils.~Patients attended 10-minute sessions daily for 10 consecutive working days. For rTMS, stimulation was delivered at an excitatory frequency of 10 Hz, targeting the M1, contralateral to the side of pain in the facial region.~Each session consisted of the following steps.~* 10 series: 60 pulses per series (600 pulses in total).~* Rest intervals: 60 seconds between series.~* Intensity: 70% of the resting motor threshold (RMT). RMT was determined using single-pulse stimulation over the M1 region controlling the abductor pollicis brevis muscle, localized via neuronavigation. The threshold was de-fined as the lowest stimulator intensity producing a motor-evoked potential amplitude \>50 µV in at least 5 of 10 trials."
224085232|NCT06917144|DEVICE|Sham Stimulation|"Sham Stimulation:~The same device and protocol used for intervention protocol with Repetitive Transcranial Magnetic Stimulation were used for sham stimulation, but no active stimulation was delivered. The equipment produced identical sounds and appearances, thereby ensuring blinding."
224085233|NCT06915740|OTHER|Exercise|virtual rehabilitation, including endurance exercise, strength training, breathing exercises, patient education, dietary advice
224085234|NCT06917625|DIAGNOSTIC_TEST|Imaging|The participants will be assessed with a brain MRI and will performed a neurophysiological test to evaluate executive functions
224085235|NCT06916403|DRUG|Intravenous Ketamine Infusions|Ketamine will be slowly infused with the routine target dose 1.5-2 mg/kg over 3-4 hours.
224085236|NCT06917209|OTHER|CBT-CD psychotherapy|9 weekly sessions of CBT-CD psychotherapy
224085237|NCT06935526|OTHER|The mobile training program and telephone follow-ups|The study had three phases: pre-test, implementation, and post-test. Data were collected twice, before the intervention and in the third month, using validated scales and a shock management simulation via the mobile training program (M-ICDEP). M-ICDEP included three sections: an educational section, a two-page summary, and a shock management simulation. All sections were shared with the intervention group. After the pre-test, intervention group patients could log in to M-ICDEP anytime using their email and password, accessing content repeatedly during the three-month follow-up. The researcher conducted telephone follow-ups in the second, fifth, and eighth weeks, evaluating patients using the Telephone Calls Monitoring Form. The information given to the patients during the telephone conversation was continued within the limited of the training program prepared within the scope of M-ICDEP.
224277505|NCT02497079|DEVICE|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
224277506|NCT04542915|OTHER|No intervention|No intervention.
224277507|NCT01765270|DRUG|Saxagliptin|one 5-mg saxagliptin tablet daily
224277508|NCT01765270|DRUG|Placebo|5mg placebo tablet daily
224277509|NCT03947398|DEVICE|BLIMP balloon|Using BLIMP balloon to cross lesion
224277510|NCT03947398|DEVICE|Low profile balloon|using low profile balloon to cross lesion
223910693|NCT03040596|DRUG|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
224277511|NCT05274191|DRUG|Pyrotinib Maleate|Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
224277512|NCT05274191|OTHER|standard regimen|standard regimen
224277513|NCT05281172|BEHAVIORAL|Guided Self-Change therapy (GSC)|The GSC program follows a motivational cognitive-behavioral approach designed to minimize resistance in drug behavior changes, prevent relapse risk, and increase motivation to quit. The GSC consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
224277514|NCT05281172|BEHAVIORAL|Psychoeducation program about healthy habits|The psychoeducational program will include talks about healthy habits such as physical activity, relaxation, and sleep hygiene. This intervention consists of 5 weekly sessions of 50 minutes delivered in groups of 20-25 people.
224277515|NCT02093871|DEVICE|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
223910694|NCT03040596|BEHAVIORAL|Standard voice therapy|Standard voice therapy sessions
223910695|NCT05285137|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
223910696|NCT05285137|DRUG|Saline placebo|Sterile normal saline for injection
223716075|NCT05111171|DEVICE|sheath|Senior interventional doctors interpret the CAG results and group according to their clinical experience: (1) No PCI is required, only diagnostic CAG is required, which is group ①6F sheath CAG group; (2) PCI is required, simple lesions are group ②6F sheath PCI group, the 6F sheath is still used for PCI; (3) PCI is required for the complicated disease and use 7F sheath, as the 7F sheath PCI group is the group ③, and the 7F sheath is replaced for PCI.
223910697|NCT04916626|BEHAVIORAL|OPUS YOUNG|OPUS YOUNG is a two year out-patient specialized early intervention service for children and adolescents with a first episode psychosis. The OPUS YOUNG treatment consists of the following elements: modified assertive community treatment, low patients to case manager ratio, cognitive-behavioural case management (CBCM), psycho-educational family treatment including multiple family groups(MFG) and psychoeducational siblings groups, Social Cognition and Interaction Training (SCIT), possible individual Cognitive Behavioural Therapy (CBT) in addition to CBCM, and manual based psychopharmacologic treatment. Additional, special transition support, individual school/employment support, and prevention and treatment of substance abuse.
224085238|NCT06935526|OTHER|Only a two-page summary section of M-ICDEP|The study had three phases: pre-test, implementation, and post-test. Data were collected twice, before the intervention and in the third month, using validated scales and a shock management simulation via the mobile training program (M-ICDEP). M-ICDEP included three sections: an educational section, a two-page summary, and a shock management simulation. Only a two-page summary section were shared with the control group. After the pre-test, control group patients could log in to M-ICDEP anytime using their email and password, accessing the summary section repeatedly during the three-month follow-up. Routine outpatient follow-up was continued for the control group without any other intervention.
224085239|NCT06935266|BIOLOGICAL|TAK-881|TAK-881 SC injection.
224085240|NCT06935266|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
224085241|NCT06936592|DRUG|Ascorbic acid|Ascorbic acid induce gingival healing
224085242|NCT00379860|DRUG|LXR-623|
224085243|NCT03822481|BEHAVIORAL|Mindful Construal Diary|A Mindful Eating Intervention
224085244|NCT05630157|BEHAVIORAL|Unplugged plus gambling component|12 units/lessons of the Unplugged prevention curriculum plus a gambling component including specific gambling contents in units 3-4-5-7-9 and a 13th unit based on probability and mathematical concepts taught through an online simulator
224085245|NCT05018858|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224085246|NCT05840952|DRUG|ALG-097558|single or multiple doses of ALG-097558
224085247|NCT05840952|DRUG|Placebo|single or multiple doses of placebo
224085248|NCT05840952|DRUG|Midazolam|Multiple doses of Midazolam
224085249|NCT05840952|DRUG|Itraconazole|Multiple doses of Itraconazole
224085250|NCT05840952|DRUG|Carbamazepine|Multiple doses of Carbamazepine
223910698|NCT04916626|BEHAVIORAL|Treatment as Usual|The patients allocated to TAU will be offered non-manualized treatment following national Danish guidelines and local guidelines. Treatment is provided by a multidisciplinary team and consists of case-management (no defined upper case load), family support and psychoeducation, in addition to psychopharmacological treatment. In some cases, social skills training and CBT may be offered. In general, office visits take place in outpatient clinics.
224085251|NCT05840952|DRUG|ALG-097558 in solution formulation|ALG-097558 in solution administered in fasted state
224085252|NCT05840952|DRUG|ALG-097558 in tablet formulation|ALG-097558 in tablet administered in fasted and fed state
224085253|NCT03561402|DRUG|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
224085254|NCT04876352|OTHER|Upper limb/handwriting exercises in an immersive virtual reality setting (VR-training)|"Progressively difficult multimodal physiotherapy under the augmented visual feedback induced by the VR. Participants will wear a head-mounted display and their upper limb movements during the training will be captured by a motion tracker. Patients will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) under the augmented visual feedback provided by the use of VR in increasingly wide range of movement; active upper limb multi-joints movements under the augmented visual feedback provided by the use of VR (following trajectories designed in the virtual space - movement involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage in VR context on a tablet and a smartphone.~30 minutes of exercises, 2 times a week, for 8 weeks."
224085255|NCT04876352|OTHER|Upper limb/handwriting exercises in a real setting (RS-training)|"Participants will perform progressively difficult multimodal physiotherapy in a real setting. Participants will be encouraged to perform their upper limb movements during the training in order to perform faster and ampler movements. They will perform: repetition of movements of upper limb single joints (shoulder, elbow and wrist) in increasingly wide range of movement under the feedback provided by therapist; active upper limb multi-joints movements under the feedback provided by the therapist (following trajectories designed on a table or on a blackboard - movements involving shoulder, elbow and wrist joints) and handwriting tasks and touch screen technology usage under the supervision of the therapist.~30 minutes of exercises, 2 times a week, for 8 weeks."
224085256|NCT04876352|OTHER|No intervention|Only baseline evaluations, without longitudinal assessment
223716076|NCT06438068|OTHER|Modern Colon Hydrotherapy plus probiotic product intake|Colonic cleansing through 3 interventions of Modern Colon Hydrotherapy separated by 48 hours. In addition, a daily intake of a product with prebiotic and prebiotic properties for 30 days.
223716077|NCT02124083|DRUG|Vorinostat|Histone deactylase inhibitor
224085257|NCT05539014|OTHER|Data collection|Prospectif data collection
224085258|NCT03990129|DRUG|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
224085259|NCT00376961|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 for cycles 1-6.
224085260|NCT00376961|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
224085261|NCT00376961|DRUG|cyclophosphamide|750 mg/m\^2 on day 1 of cycles 1-6.
224085262|NCT00376961|DRUG|doxorubicin hydrochloride|50 mg/m\^2 on day 1 of cycles 1-6.
224085263|NCT00376961|DRUG|prednisone|100 mg on days 1-5 of cycles 1-6.
224085264|NCT00376961|DRUG|vincristine sulfate|1.4 mg/m\^2 on day 1 of cycles 1-6.
223716078|NCT02837328|DRUG|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
223716079|NCT02837328|DRUG|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
223716080|NCT05055063|DRUG|Belantamab mafodotin|by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
223716081|NCT05546502|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
224085265|NCT02614846|DRUG|Hetrombopag Olamine|
224085266|NCT05237557|BEHAVIORAL|Preoperative nurse dialogue|Performance of a preoperative nurse dialogue prior major visceral surgery
224085267|NCT04920409|OTHER|FAWGT diet|Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
224085268|NCT04920409|OTHER|Usual diet (UD)|Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
224085269|NCT03728088|OTHER|Rating scales concerning non-technical attributes|
224085270|NCT04256967|OTHER|Body and health focused study environment|Students are exposed to lectures, literature, co-students, contexts that provide body and lifestyle awareness beyond the existing exposure of the society in general
224085271|NCT02456584|DRUG|DMPA 150|injectable contraceptive
224085272|NCT02456584|DRUG|DMPA 300|injectable contraceptive
224085273|NCT02456584|DRUG|DMPA 104|injectable contraceptive
224085274|NCT01059448|DRUG|AMG 827|AMG 827 210 mg
224085275|NCT02267486|OTHER|Standard therapy of Alzheimer Dementia (AD)|
224085276|NCT02267486|OTHER|Observation|
223716082|NCT05546502|BIOLOGICAL|Active Comparator|Covovax
224085277|NCT02591615|DRUG|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
224085278|NCT02591615|DRUG|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
224085279|NCT02591615|DRUG|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
223716083|NCT05239247|OTHER|Mckenzie extension exercise|"Hot pack applied on lumbar region for (ten minute). Mckenzie extension exercise performed 02 sets of 05 repetitions with 45 second hold and 15 sec rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
224085280|NCT02591615|DRUG|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
224085281|NCT04306874|DIETARY_SUPPLEMENT|Ensure Max Protein|Liquid shake with 30 g protein per serving
223716084|NCT05239247|OTHER|Eldoa stretch technique|"Hot pack applied on lumbar region for (ten minute). Eldoa stretch performed 02 sets of 05 repetitions with 45 second hold and 15 second rest between each set once a day.~TENS is applied on lumbar region for (ten minutes)."
223716085|NCT05264935|PROCEDURE|Ultrasound-Guided Puncture and Lavage (UGPL)|After local anaesthesia with rapidocain the calcific deposit of the rotator cuff will be punctured and washed out with saline solution.
224085282|NCT04188197|OTHER|JUUL|Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
223716086|NCT00168896|DRUG|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
224085283|NCT02863068|DRUG|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
224085284|NCT02863068|OTHER|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
224277516|NCT01247844|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
223716087|NCT04930965|BEHAVIORAL|Community health worker engagement|3-4 in-person or virtual engagements (individual or group sessions) over 1 month, each engagement lasting 30 minutes to 1 hour
223716088|NCT05561699|DRUG|Penpulimab Combined With CRT|"1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions."
223719390|NCT03217175|DEVICE|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
223719391|NCT03217175|DEVICE|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
224085285|NCT05956457|BEHAVIORAL|Digital Health Coaching Program|Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
224085286|NCT05956457|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
224085287|NCT01091350|DEVICE|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
224085288|NCT01091350|DEVICE|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
223910699|NCT06823206|OTHER|Sensorimotor training with movement representation techniques|Sensorimotor training will be implemented with movement representation techniques using a standardized retraining sequence of a shoulder control exercise during arm elevation with 3 phases: Phase 1: Action Observation Training; Phase 2: Mirror therapy; and Phase 3: Sensorimotor training of the involved arm. Each session will last 60 minutes, with one supervised intervention session over the 12 weeks.
223910700|NCT06772103|PROCEDURE|self-locking biceps tenodesis|The LHB tendon is detached from its origin at the level of the superior labrum. This technique supports the self-locking mechanism of the LHB tendon in the bicipital groove by detaching the tendon from the Y-shaped superior glenoid, including the superior labrum. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
223910701|NCT06772103|PROCEDURE|Biceps Tenodesis with 360 Suture anchor|The LHB tendon is detached from its origin and sutured. Next, the LHB tendon is fixed in the bicipital groove using a 360-loop tenodesis technique with the Knotless FiberTak® biceps implant system. A radiographically visible suture will be attached to the proximal part of the LHB tendon to facilitate subsequent localization of the LHB tendon during imaging (3-0 stainless steel, ethicon).
223910702|NCT05970640|DRUG|BI 3006337|BI 3006337
223910703|NCT05970640|DRUG|Placebo matching BI 3006337|Placebo matching BI 3006337
224085289|NCT04201717|PROCEDURE|laparoscopic assisted left colectomy (extracorporeal anastomosis group)|For patients in the control group, the surgeon uses wound edge protectors to exteriorize the colon through a small incision in the midline of the abdomen. A ruler and methylene blue solution are employed to mark the area for colon resection. This guarantees a 10-cm margin from the tumor. Guided by these markers, the marginal vessels and mesentery are divided outside the body. The method of anastomosis is at the surgeon's discretion. A side-to-side anastomosis (including antiperistaltic, isoperistaltic, or overlapping anastomosis) is recommended. Side-to-end or end-to-end anastomosis (sewn by hand or by inserting a circular stapler through the anus or proximal colon) is also allowed. After completing the anastomosis, the incision is sutured. An abdominal drainage tube is inserted at the end of the operation.
224085290|NCT04201717|PROCEDURE|total laparoscopic left colectomy (intracorporeal anastomosis group)|In the experimental group, the surgeon will use a 10-cm medical suture and methylene blue solution to mark the resection margin. The marginal vessels and mesentery will be divided inside the body. The proximal and distal colons are resected using a 60mm linear laparoscopic stapler. Side-to-side intracorporeal anastomotic techniques like anti-peristaltic, iso-peristaltic, or overlap methods will be applied. Once the anastomosis is completed, the specimen is retrieved. The surgeon can place the specimen in a sterile plastic bag for retrieval. Alternatively, the surgeon can use a disposable incision retraction fixator to protect the wound. An abdominal drainage tube is inserted.
223716089|NCT02710474|BEHAVIORAL|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
223716090|NCT02710474|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
223716091|NCT03045185|PROCEDURE|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
223716092|NCT00757497|BEHAVIORAL|Electrical Polarization|
223910704|NCT04872166|DRUG|BTX-A51|One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
223910705|NCT05882916|DEVICE|HIV self-testing|Oral fluid-based HIV self-test kits for secondary distribution
223910706|NCT05882916|BEHAVIORAL|Behavioral economic 'nudges'|Salient information for men included with the self-test kit on clinic location and hours within their cluster, and pilot-tested messaging on the importance of early ART initiation, and the availability and benefits of PrEP
223910707|NCT03560973|DRUG|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
223910708|NCT03560973|DRUG|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
223910709|NCT04666714|DRUG|Praga formulation|Praga formulation tablet
223910710|NCT04666714|OTHER|Placebo pregabalin 75mg|Placebo pregabalin 75mg tablet
223910711|NCT04666714|OTHER|Placebo Pregabalin 150mg|Placebo Pregabalin 150mg tablet
223910712|NCT04666714|DRUG|Pregabalin 75mg|Pregabalin 75mg tablet
223910713|NCT04666714|DRUG|Pregabalin 150mg|Pregabalin 150mg tablet
223910714|NCT04666714|OTHER|Placebo Praga formulation|Placebo Praga formulation tablet
223910715|NCT05112302|OTHER|Virtual reality|Use of virtual reality goggles during procedure
223910716|NCT03059264|OTHER|Natural history|Longitudinal disease progression
223910717|NCT06142292|BEHAVIORAL|Individual counseling|Individual counseling sessions with a licensed mental health counselor
223910718|NCT06142292|BEHAVIORAL|Group counseling|Group counseling sessions with a licensed mental health counselor
223910719|NCT01820611|DEVICE|Arcos Revision Stem System|Revision Hip System
223910720|NCT06178523|DRUG|Clomiphene Citrate.|Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).
223910721|NCT06178523|DRUG|Sildenafil Citrate|Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).
223910722|NCT06178523|PROCEDURE|Intrauterine Insemination|IUI (Group-B).
223910723|NCT03484819|DRUG|Copanlisib Hydrochloride|Given IV
224085291|NCT00809328|DRUG|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
224085292|NCT03286972|DEVICE|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
224085293|NCT01678976|DRUG|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
223910724|NCT03484819|BIOLOGICAL|Nivolumab|Given IV
223910725|NCT06674954|PROCEDURE|Regional Anesthesia|"After the patients are monitored and in the supine position, after appropriate field sterilization, interscalene brachial plexus block, superficial cervical block, and supraclavicular brachial plexus block will be applied to these patients under ultrasound guidance. Total of 40 ml of local anesthetic solution (20 ml %0.5 bupivacaine + 10 ml %2 lidocaine + 10 ml physiological saline) will be prepared; 15 ml will be used for interscalene brachial plexus block, 10 ml will be used for superficial cervical block, and 15 ml will be used for supraclavicular brachial plexus block.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223910726|NCT06674954|PROCEDURE|General Anesthesia|"Anesthesia induction will be performed with 2.5 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 mcg/kg fentanyl. Maintenance will be achieved with sevoflurane (MAC: 0.9-1.0) and remifentanil (0.05-0.2 mcg/kg/min). Remifentanil titration will be done according to basal heart rate and blood pressure.~Tramadol (100 mg, intravenous) and dexketoprofen (50 mg, intravenous) will be administered intraoperatively as standard to these patients.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223910727|NCT05470218|OTHER|Meal|Liquid mixed meal with different amounts of protein and leucine
224085294|NCT01678976|DRUG|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
224085295|NCT04020744|OTHER|real-time fMRI based neurofeedback from the hippocampus|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
224085296|NCT04020744|OTHER|real-time fMRI based neurofeedback from another brain area|During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
224085297|NCT00907075|BEHAVIORAL|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
224085298|NCT00907075|BEHAVIORAL|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
224085299|NCT06490861|DEVICE|Paragit|Sleeve to quantify symptoms
224085300|NCT04068857|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
224085301|NCT00138216|DRUG|irinotecan hydrochloride|
224085302|NCT00138216|DRUG|temozolomide|
224085303|NCT00138216|DRUG|vincristine sulfate|
224085304|NCT00066690|DRUG|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
224085305|NCT00066690|OTHER|Laboratory Biomarker Analysis|Correlative studies
224085306|NCT00066690|PROCEDURE|Oophorectomy|Undergo bilateral surgical oophorectomy
224085307|NCT00066690|OTHER|Quality-of-Life Assessment|Ancillary studies
224085308|NCT00066690|RADIATION|Radiation Therapy|Undergo ovarian irradiation
223529165|NCT06316947|RADIATION|CHW-delivered intervention|WellShare CHWs will then deliver the brief, approximately 15-minute intervention to the participating parent. The new intervention components will build off existing tobacco education outreach using verbal instruction and images developed by WellShare CHWs and layer in home smoke-free rules, potential biomarker feedback about smoke exposure, and other educational intervention components that align. Additionally there will be pre and post-intervention surveys and urine samples collection for cotinine levels.
223529166|NCT06569758|DRUG|GenSci098|subcutaneous , 5 dose levels(15mg, 45mg, 90mg, 180mg and 270mg) will be assigned.
224085309|NCT00066690|DRUG|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
224085310|NCT00066690|DRUG|Triptorelin|3.75 mg by im injection q28 days for 5 years
223529167|NCT06569758|DRUG|GenSci098 Placebo|In SAD part only one dose of GenSci098 and GenSci098 Placebo to be given, in MAD part, multiple doses of GenSci098 and GenSci098 Placebo will be given.
223529168|NCT03042143|BIOLOGICAL|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
223529169|NCT03042143|BIOLOGICAL|Placebo (Plasma-Lyte 148)|Infusion of placebo
223719392|NCT03217175|DRUG|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
224085311|NCT05256888|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
224085312|NCT05256888|BEHAVIORAL|Healthy lifestyle education|Weekly tips on healthy lifestyle behaviors (e.g., diet, exercise, sleep) for 12 weeks
224277517|NCT03431337|DRUG|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
224085313|NCT01323205|DRUG|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
224277518|NCT03431337|DIETARY_SUPPLEMENT|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
223529170|NCT06406842|OTHER|Cerebral oxygenation index guided hemodynamics management|In the autoregulation group, anesthesiologist will maintain that the cerebral oxygen index value below 0.3. If cerebral oxygen index exceeds the threshold, norepinephrine or phenylephrine will be infused continuously, or arterial partial pressure of oxygen or arterial partial pressure of carbon dioxide will be adjusted to increase regional cerebral oxygen saturation.
223535196|NCT00753532|DIETARY_SUPPLEMENT|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort respectively. In the MRI(+ve) cohort, 62 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 59 were assigned to placebo, taken orally twice a day for a study period of two years. In the MRI(-ve) cohort, 63 subjects received 200 mg softgels of Palm Vitamin E (tocotrienols) and 57 consumed placebo, taken twice a day for a follow up period of 1 year.
223910728|NCT04790058|OTHER|Knowledge translation of the CSRS practice recommendations|The intervention is knowledge translation of the CSRS practice recommendations; the application of the practice recommendations will occur during the patient's ED visit and patients who are eligible for 15-day cardiac rhythm monitoring will have Holter monitor applied at the time of ED discharge. For the secondary objective to validate the accuracy of the ultra-low risk criteria of CSRS and assess for potential improvements in the practice recommendations and the prediction models we will request verbal consent during the index ED visit for addition of cardiac biomarker measurements \[troponin and NT-proBNP\] for patients who did not have such measurements performed as part of routine clinical care, and a 30-day telephone follow-up for serious outcome assessment. Patients who do not consent will be excluded from these portions of the study but included in the health resource utilization and generic patient safety outcome assessment objectives.
223910729|NCT04576715|BEHAVIORAL|TEaM Intervention|"Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up"
224085314|NCT01323205|DRUG|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
224085315|NCT01323205|DRUG|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
224085316|NCT01323205|DRUG|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
224277519|NCT05167045|BEHAVIORAL|Brain Health PRO|The BHSP is an educational program designed to teach about dementia. It aims to provide best available evidence for lifestyle changes that can help lower dementia risk, and to provide specific recommendations for positive lifestyle changes (e.g., physical exercises to try at home, healthy recipes). The program was developed as a collaborative effort by Canadian investigators who have expertise in the different areas of dementia prevention, along with input from older-adult citizen advisors.
224277520|NCT06551129|DRUG|Mavacamten|As prescribed by treating physician
224277521|NCT01128868|DEVICE|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
224277522|NCT01128868|DEVICE|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
223535197|NCT06152848|OTHER|Data and samples collection|Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
223535198|NCT05348967|DIETARY_SUPPLEMENT|TECADRIOL|Food supplement with D-chiro-inositol and alpha-lactalbumin
223535199|NCT06429787|DRUG|Balfaxar|BALFAXAR (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure
223535200|NCT06429787|DRUG|Kcentra|"KCENTRA, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with:~* acute major bleeding or~* need for an urgent surgery/invasive procedure"
223535201|NCT03517358|OTHER|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
223535202|NCT05438121|DEVICE|SeQuent Please Neo|DCB angioplasty will be performed in accordance with the recent recommendations. Specifically, aggressive lesion predilation (balloon-to-artery ratio: 0.8 to 1.2) using either a plain balloon or a scoring balloon will be performed.
223535203|NCT06376825|BEHAVIORAL|MyLife: An internet-based self-help program to reduce burnout|MyLife is a internet-based and Acceptance and Commitment Therapy oriented self-help program to reduce burnout. In this study a tailored to teachers version of the program will be used.
223535204|NCT03906084|PROCEDURE|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
223535205|NCT03906084|PROCEDURE|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
223535206|NCT05516121|DRUG|VLT-015|100 mg single dose, 200 mg single dose, 200 mg single dose once a day for two consecutive days
223535207|NCT06171061|DRUG|Yangxinshi tablet|In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
223535208|NCT06171061|OTHER|Basic medication|The control group will be given basic medication only. The treatment period is 24 weeks.
223529171|NCT04606914|DRUG|mirvetuximab soravtansine (MIRV; IMGN853)|Mirvetuximab soravtansine (also known as IMGN853 and MIRV) is an antibody-drug conjugate (ADC) that consists of a high affinity humanized monoclonal antibody against folate receptor α (FRα, the protein product of the folate receptor 1 \[FOLR1\] gene) that is conjugated to a cytotoxic maytansinoid by the hindered disulfide succinimidyl 4-(pyridin-2-yl)disulfanyl)-2-sulfo-butyrate linker (sulfo-SPDB) linker. FRα is a glycosyl-phosphatidylinositol (GPI)-linked protein, which shows limited normal tissue expression and high expression on the surface of solid tumors, particularly epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (referenced herein collectively as EOC), endometrial cancer, non-small cell lung cancer (NSCLC), and renal cell cancer.
223529172|NCT05288751|BEHAVIORAL|Contingency Management|Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting.
224085317|NCT05190094|DRUG|Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)|A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
223529173|NCT05965310|BEHAVIORAL|Virtual Psychological Intervention: Cognitive Behavioral Therapy|An asynchronous course of pre- and post-operative CBT modules (VPI) will be delivered to patients in Group A as an adjuvant treatment to standard-of-care rehabilitation.
223529174|NCT04985630|DIETARY_SUPPLEMENT|Mitopure|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
223529175|NCT04985630|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice
223529176|NCT04333537|PROCEDURE|Chest Radiography|Undergo chest x-ray
223910730|NCT04576715|BEHAVIORAL|Standard of Care|"Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template"
223910731|NCT04456296|DRUG|Aveed Injectable Product|Testosterone undecanoate administered by intramuscular injections.
224085318|NCT03580616|DRUG|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
223910732|NCT04456296|DRUG|Fortesta|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
223910733|NCT04456296|DRUG|Testim|Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
223910734|NCT04279834|BEHAVIORAL|PAP Treatment|Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.
224085319|NCT03706365|DRUG|Abemaciclib|Administered orally.
224085320|NCT03706365|DRUG|Placebo|Administered orally.
224277523|NCT00963430|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
223529177|NCT04333537|PROCEDURE|Computed Tomography|Undergo SPECT/CT scan and FDG PET/CT or CT
223529178|NCT04333537|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
223910735|NCT04279834|BEHAVIORAL|Sleep Education I|Motivational enhancement plus participant self-monitoring of sleep.
223910736|NCT03106740|DRUG|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
223910737|NCT03106740|DIAGNOSTIC_TEST|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of \[11C\]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
224085321|NCT03706365|DRUG|Abiraterone acetate|Administered orally.
223529179|NCT04333537|DRUG|Imaging Agent|Receive imaging agent via injection
224277524|NCT06382506|DIETARY_SUPPLEMENT|Consumption of Cornbread with Hazelnut Bread|Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.
224277525|NCT00361478|BEHAVIORAL|Exercise and education|Weekly exercise and education program for 8 weeks
223529180|NCT04333537|PROCEDURE|Neck Dissection|Undergo standard elective neck dissection
223529181|NCT04333537|PROCEDURE|Planar Imaging|Undergo planar imaging
223529182|NCT04333537|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223529183|NCT04333537|OTHER|Questionnaire Administration|Ancillary studies
223529184|NCT04333537|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLN biopsy
223910738|NCT03106740|OTHER|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
223910739|NCT04112381|DEVICE|Exablate Model 4000 Type 1.0/1.1|Exablate thalamotomy of non tremor dominant side of the brain
223910740|NCT05970809|DEVICE|SAGA-001 (A)|Use of a novel microneedle and laser device as a treatment for male patten hair loss with additional microwounding.
223910741|NCT05970809|DEVICE|SAGA-001 (B)|Use of a novel microneedle and laser device as a treatment for male patten hair loss without additional microwounding.
224085322|NCT03706365|DRUG|Prednisone|Administered orally.
224277526|NCT00361478|BEHAVIORAL|Education|Written educational material
223529185|NCT04333537|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT scan
223535209|NCT04082130|PROCEDURE|(XCM)+(CAF)|The description of this intervention has been already given before.
223535210|NCT04082130|PROCEDURE|(SCTG)+(CAF)|The description of this intervention has been already given before.
223910742|NCT05532566|OTHER|Allergenic extract|In each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.
224085323|NCT06428890|DIETARY_SUPPLEMENT|Grape Seed Extract|dietary supplements that rich in polyphenolic compounds
224085324|NCT06428890|DIETARY_SUPPLEMENT|Placebo|Starch
223910743|NCT02055833|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
223910744|NCT02055833|OTHER|Nutritional counseling|Nutritional counseling
223910745|NCT04565990|DRUG|Selexipag|Selexipag tablets will be administered orally at all dose strengths (200, 400, 600, 800, 1000, 1200, 1400 and 1600 microgram) twice daily.
223910746|NCT05151302|DIAGNOSTIC_TEST|computer vision symptom scale (CVSS) questionnaire|Subjects working at VDT for \>20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
223910747|NCT04797858|BEHAVIORAL|COVID-19 self-test|5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
223910748|NCT04797858|BEHAVIORAL|COVID-19 test referral|5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
223910749|NCT05334992|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Individual therapy 12 to 16 weeks
223910750|NCT05334992|BEHAVIORAL|Behavior Activation|Individual therapy 12 to 16 weeks
223910751|NCT05910268|BEHAVIORAL|NIATx + ECHO|Project ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
223910752|NCT06220721|DRUG|Nifedipine ER|Initiation of nifedipine ER postpartum at randomly assigned threshold during the first 6 weeks postpartum.
223910753|NCT06860568|OTHER|Retrospective Study|Retrospective Study This study will use a retrospective Test Dataset of eye scans collected by Optina under different study protocols. MHRC H5 Images collected as part of Optina studies CIP-22-003, CIP-22-004, DOC100463 or RWD-24-011 will be reviewed by an Optina Data Analyst and flagged for potential match to the Target Population. Of the flagged images, 40 will be selected and allocated to the Test Dataset. All selected images must have a matching OCT image for review as part of the Reference Data. The Test Dataset will be documented in the CIP-24-015 data spreadsheet and archived in the CIP-24-015 central files.
223910754|NCT05612880|DRUG|androgen receptor signaling inhibitors|Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
223910755|NCT06717126|DRUG|roginolisib|rognolisib
223910756|NCT06717126|DRUG|Investigator choice of standard therapy|Investigator will choose the most appropriate treatment standardly given to patients
223910757|NCT04826471|DEVICE|DermoRelizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
224085325|NCT02594488|DEVICE|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
224085326|NCT03116113|BIOLOGICAL|BIIB112|Administered as specified in the treatment arm.
224085327|NCT06286423|DRUG|Colchicine 0.6 mg|Colchicine treated subjects will take 0.6mg of drug 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of drug 1x per day (or every other day if kidney disease is present) for 76 +/1 days.
223910758|NCT03453528|DRUG|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
223910759|NCT06101511|PROCEDURE|Intraoperative ventilation with individualized high PEEP titrated to the lowest ΔP with RMs|The intervention is intraoperative ventilation using the available ventilator with individualized high PEEP titrated to the lowest ΔP with RMs. After abdominal insufflation, patients randomized to the individualized high PEEP with RMs group will receive a RM followed by a 'decremental PEEP trial'. This is followed by a second RM after which PEEP is set at the level indicated by the decremental PEEP trial
223910760|NCT06789809|DIAGNOSTIC_TEST|Exercise MRI|Exercise stress MRI with ergometer
223910761|NCT06555081|DRUG|Ruxolitinib IR|Tablet
223910762|NCT06555081|DRUG|Ruxolitinib XR|Tablet
223910763|NCT04414722|DRUG|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
223910764|NCT04414722|BIOLOGICAL|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt
223910765|NCT04414722|OTHER|Control Yogurt|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
223910766|NCT06965049|OTHER|Probiotic|Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
223910767|NCT06965049|OTHER|Placebo|Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
224085328|NCT06286423|DRUG|Control/Placebo group|Placebo treated subjects will take 0.6mg of placebo 2x per day (1 time if kidney disease is present) for 14 days, then will take 0.6mg of placebo1x per day (or every other day if kidney disease is present) for 76 +/1 days.
224085329|NCT01286584|DRUG|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
224085330|NCT01286584|DRUG|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
224277527|NCT04783545|DRUG|VLX-1005|VLX-1005 infusion
224277528|NCT04783545|DRUG|Placebo|Placebo infusion
223535211|NCT04594993|DEVICE|INFINITY™ with ADAPTIS™ Technology Total Ankle System|Total Ankle Replacement
223535212|NCT02990702|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
223910768|NCT06965608|BEHAVIORAL|WhatsApp-Based Cancer Prevention Messaging|Participants in this group will receive a structured series of WhatsApp messages containing evidence-based cancer prevention recommendations from the Latin America and Caribbean Code Against Cancer (LAC Code). Messages will be delivered over four weeks, 3 times a week, covering key topics such as smoking cessation, healthy diet, physical activity, and regular screening. Engagement metrics will be tracked to assess feasibility and adherence.
223910769|NCT06965608|BEHAVIORAL|Online Cancer Prevention Workshop for Healthcare Professionals|Healthcare professionals assigned to this group will participate in an online workshop designed to improve their knowledge of the LAC Code and communication strategies for cancer prevention counseling. The workshop includes recorded lectures, interactive modules, and knowledge assessments. Completion rates and participant satisfaction will be measured.
223910770|NCT06965608|BEHAVIORAL|Combined WhatsApp Messaging and Online Workshop|Participants in this group will receive both interventions: WhatsApp messages with cancer prevention recommendations and access to the online workshop. The intervention aims to assess whether a combined approach enhances adherence and impact. Engagement with both interventions will be monitored.
223910771|NCT06143059|DRUG|Ethanol|Sterile, 95% ethanol will be administered through IV infusion
223910772|NCT06143059|DRUG|Saline|Saline is administered as the placebo
223910773|NCT06965855|PROCEDURE|conventional surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with conventional surgery
223910774|NCT06965855|PROCEDURE|piezoelectric surgery|Description: This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with piezoelectric surgery
224085331|NCT06358014|DRUG|Fematon (estradiol/estradiol-norethindrone acetate combination tablet package)+SSRIs|In the combination group, eligible subjects will receive 1 tablet/day of estradiol/estradiol-norethindrone acetate combination tablet for 8 weeks. The estradiol/estradiol-norethindrone acetate combination tablet will be taken orally before bedtime, 1 tablet/day (trade name: Fematon, Abbott Laboratories, USA, this product is a combination package, with estradiol 1 mg in the first 14 days of each treatment cycle, and estradiol 1 mg and norethindrone acetate 10 mg in the last 14 days of each treatment cycle). This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram.
224085332|NCT06358014|DRUG|SSRIs|This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs. During the study, medication doses will be quantitatively adjusted based on the results of each visit assessment combined with drug concentrations.
223910775|NCT06646042|DRUG|ibuzatrelvir|2x 300 mg tablet
223910776|NCT06646042|DRUG|carbamazepine ER|100 mg BID (Day 1-3) 200 mg BID (Day 4-7) 300 mg BID (Day 8-15)
223910777|NCT05520788|GENETIC|precise medicine|During screening stage, all patients should accept next-generation sequencing (NGS) test.
223910778|NCT04222478|OTHER|Specific auriculotherapy|"3 sessions of auriculotherapy with semi-permanent needles on the 6 points according to the protocol of Alimi at one month intervals."
223910779|NCT04222478|OTHER|Non-specific auriculotherapy|3 sessions of auriculotherapy with semi-permanent needles on non-specific points.
223716093|NCT04728399|DIETARY_SUPPLEMENT|Experimental group|Take 1 bag a day with warm boiling water. Intervention: 2g Soybean peptide, 3g CLA and ng protein. They will complete all baseline, 12-weeks, and 24-weeks visits
223910780|NCT06646484|DIAGNOSTIC_TEST|Impedancemetry evaluation|Each patient eligible for the study will, additionally to the standard care, have repeated measure of impedancemetry along their hospital stay ; Theses measure will be compared to the usual measure of hydration and natremia and agreement between clinical status of interest will be discussed.
224085333|NCT02200484|BEHAVIORAL|Combined parent training and obesity prevention program|
224085334|NCT02200484|BEHAVIORAL|Wellness program (active contact control)|
224085335|NCT00006227|DRUG|Paclitaxel|Given IV
224085336|NCT02159807|DRUG|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
224085337|NCT02159807|DRUG|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
223910781|NCT06823739|OTHER|Exercise|This exercise program in PDE group was designed to be performed at home without re-quiring any specialized equipment. It aims to improve physical health, balance, and coor-dination while maintaining muscle strength and flexibility. Patients performed brist walking at least three times a week for a duration of 10 to 30 minutes per session. It also included balance practice and coordination exercises for 10 minutes. These include: Standing on tiptoes, balancing on one foot while holding onto a chair for support, walking in a straight line as if on a narrow beam. Finally, the exercise session ended with a 10-minute cool-down, focusing on relaxing muscles and performing gentle stretches to improve flexibility and reduce tension. All of the exercises were both explained and given in a figured chart, to the patients or the relatives
224085338|NCT04426305|OTHER|community health worker support|usual care by professional primary care providers + emotional support by trained community health worker
224085339|NCT04426305|OTHER|care as usual|care as usual is provided by professional primary care provider
224085340|NCT05495048|PROCEDURE|NOSES VIIIA|totally laparoscopic right hemicolectomy with transvaginal natural orifice specimen extraction
224085341|NCT05495048|PROCEDURE|laparoscopic surgery with mini-laparotomy|laparoscopic right hemicolectomy with trans-abdominal extraction from a mini-laparotomy
224085342|NCT03857789|OTHER|Questionnaire|A 40 question frailty questionnaire.
224085343|NCT01485978|DRUG|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
224085344|NCT01485978|DRUG|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
224277529|NCT02620059|BEHAVIORAL|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
223716094|NCT04728399|DIETARY_SUPPLEMENT|Control group|Take 1 bag a day with warm boiling water. Intervention: 2g+N protein and 3g Soybean oil. They will complete all baseline, 12-weeks, and 24-weeks visits
223719393|NCT03217175|DRUG|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
223719394|NCT03445338|DRUG|K0706|Study
223910782|NCT06823791|DRUG|Furazolidone|esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
224085345|NCT01485978|DRUG|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
224085346|NCT02319902|DEVICE|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
224085347|NCT02319902|DEVICE|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
224085348|NCT03892837|PROCEDURE|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
224085349|NCT03892837|PROCEDURE|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
224085350|NCT05195528|DRUG|Vonoprazan|Orally via capsule
224085351|NCT05195528|DRUG|Placebo|Orally via capsule
224085352|NCT04856592|DEVICE|Boston Scientific Vici® Venous Stent System|The Vici Venous Stent System comprises two components: the implantable endoprosthesis and its stent delivery system, a 9F over-the-wire system available in a 100cm length and compatible with 0.035in (0.89mm) guidewires
224085353|NCT04856592|DEVICE|Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)|The Opticross 35 catheter is designed for use with a guidewire measuring ≤0.035 in (0.89 mm) in diameter and an introducer sheath of 8F (2.67 mm) or larger. The working length of OC35 catheter is 105 cm.
224085354|NCT01552902|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
224085355|NCT01552902|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
224085356|NCT01552902|DRUG|Placebo|Daily oral dosing in the AM for 6 weeks
224085357|NCT00930202|DRUG|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
224085358|NCT01100489|RADIATION|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
224085359|NCT01100489|OTHER|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
224085360|NCT01100489|PROCEDURE|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins \< 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
224085361|NCT05312957|OTHER|erector spinae plane block|Group ESP (Arm 1)The probe was placed craniocaudally in the parasagittal plane approximately 3 cm lateral to the T5 spinous process. The T5 transverse process is detected .When the block needle (Stimuplex B. Braun R, Melsungen, Germany) touched the transverse process, 0.5-1 mL of the 0.9% NaCl test dose was administered between the erector spinae muscle fascia and the vertebral transverse process, and the needle location was confirmed.Then, 20 ml of 0.25% bupivacaine was administered to this area, Group Control (Arm 2) :No intervention
224085362|NCT00878124|DIETARY_SUPPLEMENT|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
224085363|NCT00878124|OTHER|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
224085364|NCT06411093|COMBINATION_PRODUCT|Kinesiology tape wrapping|Place Kinesiology tape between the nail plate and the inflamed periungual granulation tissue in addition to conventional treatment for 3 months
224085365|NCT06411093|DRUG|Conventional treatment including silver nitrate cauterization|Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
224085366|NCT00722293|DRUG|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
224085367|NCT00722293|DRUG|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
224085368|NCT00722293|DRUG|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
224085369|NCT02828176|PROCEDURE|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
224085370|NCT02828176|PROCEDURE|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
224085371|NCT02828176|PROCEDURE|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
224277530|NCT05433259|DEVICE|Overnight orthokeratology|Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
223910783|NCT06823791|DRUG|Clarithromycin|esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + clarithromycin 500 mg bid, for 14 days. After stopping the medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months and 12 months, the experiment stop. If H. pylori is positive, check again after 6 months. If H. pylori is still positive, high-dose dual therapy will be used to resist H. pylori again. After stopping the second medication for 30 days, check the H. pylori again. If H. pylori is negative, check again after 6 months, and the experiment stops. If H. pylori is still positive, check again after 6 months, and the experiment stops.
223910784|NCT06730230|BEHAVIORAL|Remote Patient Monitoring (RPM)-enabled Community Health Worker (CHW) Support|CHWs will implement RPM by being provided with training modules and implementing electronic health record (EHR) support tools for HTN management.
224085372|NCT02828176|PROCEDURE|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
224085373|NCT00452803|DRUG|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
224085374|NCT00452803|DRUG|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
224085375|NCT00452803|RADIATION|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
224085376|NCT05130008|OTHER|Digitally-enabled CHW Care|Patients will be paired with a CHW and be encouraged to wear the arm biosensor continuously, take blood pressure daily, respond to short symptom assessments daily or every other day, complete weekly life quality surveys, watch weekly HF educational videos and engage in digital (e.g., video visit) and phone-based, and in-person CHW interactions. Each participant will have access to the digital platform and CHW staff during their hospitalization and for the 30 days following discharge for a typical study duration of approximately 32-35 days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
223910785|NCT06205602|DRUG|3BNC117-LS|30 mg/kg to be administered via IV at Step 1 (Day 1)
223910786|NCT06205602|DRUG|10-1074-LS|10 mg/kg to be administered intravenously at Step 1 (Day 1)
223910787|NCT06205602|DRUG|Placebo for 3BNC117-LS|0.9% Sodium Chloride Injection to be administered intravenously at Step 1 (Day 1)
223910788|NCT06205602|DRUG|Placebo for 10-1074-LS|0.9% Sodium Chloride Injection) to be administered IV at Step 1 (Day 1)
224085377|NCT05130008|BEHAVIORAL|Usual CHW Care|Patients will be paired with a CHW for 30-days. Participants will complete questionnaires at the time of enrollment and at study end. Participants will also complete exit interviews in-person or via phone after the study ends.
224085378|NCT03742778|BEHAVIORAL|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
224085379|NCT03742778|BEHAVIORAL|Incentivizing exercise|Participants receive bonus incentives for exercising
224085380|NCT02588456|BIOLOGICAL|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
224085381|NCT03006783|PROCEDURE|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
224085382|NCT02064764|DEVICE|Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter|
224085383|NCT02064764|DEVICE|Arctic Front Advance™ Cardiac Cryoablation System|
224085384|NCT06473636|BEHAVIORAL|Mindfulness training|The mindfulness training program consisted of four 45-minute lessons, conducted once a week. After each lesson, participants were required to complete daily homework, which included the mindfulness exercises learned during that week for at least 30 minutes. The mindfulness training program was based on Kabat-Zinn's Mindfulness-Based Stress Reduction and Williams' Mindfulness-Based Cognitive Therapy. Additionally, specific contents of cancer-related mindfulness training were incorporated into this program, such as Anti-cancer Self-healing Power: 8 Lessons in Mindfulness-based Stress Reduction.
224085385|NCT06415305|DRUG|Winlevi (clascoterone) 1% cream|Dosed twice daily (BID)
224085386|NCT02487108|DRUG|TV-46763|TV-46763 will be administered per dose and schedule specified in the arm description.
224085387|NCT02487108|DRUG|Placebo|Placebo matching to TV-46763 will be administered per schedule specified in the arm description.
224085388|NCT05136833|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.
224085389|NCT05136833|BIOLOGICAL|Placebo|Normal saline will be used as a placebo.
223719395|NCT03445338|DRUG|K0706|Study
223910789|NCT06823310|DEVICE|Control (Standard treatment)|Directly printed orthodontic clear aligner without any additions
223910790|NCT06823310|DEVICE|Chitosan|Adding chitosan nanoparticles to directly printed orthodontic clear aligners in vivo to enhance anti- microbial activity against streptococcus mutans.
223910791|NCT05275998|DRUG|TMB-365/TMB-380|Monoclonal antibodies to be given intravenously
223910792|NCT06818383|DEVICE|Rezum therapy|minimal invasive technique for treating BPH
223910793|NCT05269849|DRUG|Sirolimus|Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
224085390|NCT04848077|BEHAVIORAL|Step count increase with the use of a motivational smartphone application|All participants will be given access to an application installed on the participants' own smartphone: the STEPWISE app. The STEPWISE app will encourage participants to increase their long-term physical activity (1 year). Different treatment arms will receive different physical activity goals. Participants will get feedback and support via the smartphone app, that stimulates them to reach their individual physical activity goal (i.e. target percentage increase in stepcount).
224085391|NCT05812911|PROCEDURE|Standard oxygen|"Standard oxygen therapy administered through a Venturi mask allowing a fraction of inspired oxygen (FiO2) setting to maintain a peripheral oxygen saturation (SpO2) ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
224085392|NCT05812911|PROCEDURE|HFNO|"The oxygen therapy will be administered in a semi-sitting position, with a setting of the FiO2 and the oxygen flow rate, to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
223910794|NCT04304144|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
223910795|NCT04304144|DRUG|SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)|According to institutional standard of care.
223910796|NCT04304144|DRUG|Daratumumab|Treatment for AL amyloidosis
223910797|NCT04529070|BEHAVIORAL|Nightmare Rescripting and Rehearsal|This study aims to test the efficacy of an abbreviated version of Imagery Rehearsal Therapy ('Nightmare Rescripting and Rehearsal Therapy' (NRRT)) administered by non-mental health professionals in a Primary Care setting.
224085393|NCT05812911|PROCEDURE|NIV|"Systematic application of NIV using two levels of pressure, pressure support (PS) + positive end-expiratory pressure (PEEP) provided using a dedicated NIV ventilator or a standard ICU ventilator with the  NIV module  through a facial mask. The FiO2 will be set to obtain a SpO2 ≥ 94%.~For medical reasons left to the clinician appreciation (such as a COPD or pulmonary fibrosis or other conditions), a SpO2 ≥ 90% will be accepted."
224085394|NCT06960148|DRUG|CSPR Toothpaste|a commercially available 8% arginine toothpaste
224085395|NCT06960148|DRUG|Colgate Dental Cream Toothpaste|a commercially available fluoride toothpaste
223910798|NCT04529070|BEHAVIORAL|standard of care|standard of care
223910799|NCT05903820|DRUG|Estradiol patch|Transdermal patch of estradiol
223910800|NCT05903820|DRUG|Progesterone|Oral progesterone capsules 100mg/day
223910801|NCT05617040|BIOLOGICAL|ChAdOx1-PCAQ|Recombinant nonreplicating chimpanzee adenovirus Oxford 1 (ChAdOx1) vector encoding 4 prostate cancer antigens: prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4).
223910802|NCT05617040|BIOLOGICAL|MVA-PCAQ|Replication-deficient recombinant Modified Vaccinia virus Ankara (MVA) vector encoding the same prostate cancer antigens as ChAdOx1-PCAQ (prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of prostate 1 (STEAP1), and an oncofoetal antigen (5T4))
223910803|NCT01467180|DEVICE|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
223910804|NCT01467180|DEVICE|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
223910805|NCT06274723|OTHER|Expert|Participants will view a brief description of an expert source.
223910806|NCT06274723|OTHER|Peer|Participants will view a brief description of a peer source.
224085396|NCT06960278|PROCEDURE|Size of aphthous lesions and degree of pain assessed at days 1, 3, and 5.|Size of aphthous lesions and degree of pain assessed at days 1, 3, and 5.
224085397|NCT06960278|PROCEDURE|Control|The dimensions of the lesion were measured by oral medicine specialists using a flexible ruler
224085398|NCT06960278|DEVICE|ALUMSTONE|alum administration via adhesive patches on the healing process of aphthous ulcers
224085399|NCT06960005|OTHER|Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)|Participants will engage in one-hour exercise sessions twice weekly for 26 weeks: one day of RYMA training and one day of ADL-based training
224085400|NCT06960876|PROCEDURE|Therapeutic Ultrasound|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This Group will additionally receive a therapeutic Ultrasound over the maxillary sinus.
224085401|NCT06960876|PROCEDURE|Sinus Massage|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This group will additionally receive, sinus massage (pressure \& milking)
224085402|NCT06960876|PROCEDURE|Control group|All three groups will continue their prescribed steam protocol and medications by the ENT specialist. This group will not receive any other adjunct physical therapy treatment (control group)
224085403|NCT06960304|OTHER|Physical exercise program|Evaluation of AVF maturation using clinical and ultrasound criteria, after applying a structured physical exercise program.
223910807|NCT06274723|OTHER|1 Sided|Participants will view e-cigarette education messages in one-sided.
223910808|NCT06274723|OTHER|2 Sided|Participants will view e-cigarette education messages in two-sided.
223910809|NCT05256654|DRUG|LY3561774|Administered SC
223910810|NCT05256654|DRUG|Placebo|Administered SC
223910811|NCT03981263|DEVICE|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
223910812|NCT03981263|DEVICE|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
223910813|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at Day 4|Participants will undergo an abbreviated physical exam, assessment of concomitant medications, and reassessment for signs/symptoms of TB
223910814|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at Day 4|Peripheral blood samples, including serum, PBMC, and whole blood, are collected from participants. A tongue swab is also collected from each participant.
224085404|NCT06960343|PROCEDURE|magnetic resonance imaging (MRI)|All enrolled patients will be contacted again at a minimum follow-up of 5 years, and an MRI of the operated shoulder will also be performed.
224085405|NCT06960343|OTHER|VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction|All enrolled patients will be contacted again at a minimum follow-up of 5 years, and a clinical evaluation will be performed using the following measurements and scores: VAS, SST, ASES, CMS scores, and strength measurements in external rotation and abduction.
224277531|NCT03886649|DRUG|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
223910815|NCT06585683|DIAGNOSTIC_TEST|Clinical Evaluation at week 26|Participants will undergo another complete physical exam and have their medical (including TB) history, potential TB signs/symptoms, and concomitant medications reassessed. Chest radiography will be obtained for all participants. An assessment of TB outcomes will also be performed.
223910816|NCT06585683|DIAGNOSTIC_TEST|Laboratory Evaluation at week 26|Peripheral blood samples, including serum, PBMC, and whole blood, will be collected. Participants not previously identified as living with HIV will undergo HIV diagnostic testing, while participants living with HIV will have their HIV viral load and CD4+ T-cell count measured.
223910817|NCT04496154|DIETARY_SUPPLEMENT|Omega-3 fatty acids (2.7 g/d, EPA:DHA, 2:1)|Triple Strength Omega-3 from Webber Naturals
223910818|NCT05842135|PROCEDURE|Laparoscopic approach to small bowel obstrcuction|Bowel viability assessment by indocyanine green fluorescent angiography during laparoscopic approach to small bowel obstruction
223910819|NCT06057324|DEVICE|AI-based Apps|Families which will use the digital interactive tools to empower parents in their daily dietary choices.
223910820|NCT06057324|BEHAVIORAL|Mediterranean-based diet toolkit and activities|Families which will receive educational materials and adolescents will perform educational activities.
223910821|NCT06057324|OTHER|Healthy plant-based snacks|Families in which children will include the snacks in their diet.
223910822|NCT06057324|OTHER|AI-based Apps + Mediterranean-based diet toolkit and activities|Families which will use the digital interactive tools and receive educational material, and adolescents will perform educational activities.
223910823|NCT06057324|OTHER|AI-based Apps + Healthy plant-based snacks|Families which will use the digital interactive tools and children will include the snacks in their diet.
223910824|NCT06057324|OTHER|Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will receive educational material, adolescents will perform educational activities, and children will include the snacks in their diet.
223910825|NCT06057324|OTHER|AI-based Apps + Mediterranean-based diet toolkit and activities + Healthy plant-based snacks|Families which will use the digital interactive tools and will receive educational material, children will include the snacks in their diet, and adolescents will perform educational activities.
223910826|NCT05815485|DRUG|Azeliragon|30 mg twice daily for 5 days followed by 20 mg once daily for 5 days or until discharge (whichever is earliest).
223910827|NCT05815485|DRUG|Placebo|Twice daily for 5 days then 1 time daily for 5 days or until discharge (whichever is earliest).
223910828|NCT04470934|DEVICE|SeQuent® SCB drug-coated balloon catheter|"treatment of coronary artery disease with SeQuent® SCB of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
223910829|NCT05946850|PROCEDURE|Caudal analgesia|Caudal analgesia for chronic lumbosacral pain
223910830|NCT06285214|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
223910831|NCT06285214|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
224085406|NCT06959719|PROCEDURE|Air Entrainment - intentional introduction of the atmospheric air into the pleural space.|This intervention is distinct in that it uses a standard 3-way tap, already present in routine pleural drainage procedures, to intentionally introduce atmospheric air into the pleural space in a controlled and repeatable manner. Unlike other studies where air entrainment may occur incidentally or as part of more invasive procedures, this method specifically utilises precise manipulation of the tap handle to allow intermittent air entry, aiming to reduce negative intrapleural pressure and associated pain during fluid drainage. Air entry is carefully controlled, can be repeated up to five times per procedure, and does not interfere with fluid drainage or introduce additional equipment or complexity.
224085407|NCT06960200|DEVICE|Phototherapy|Non-surgical laser therapy (phototherapy)
223910832|NCT06018064|DEVICE|Prone Positioner|An innovative device to allow for infants to be supported while in the prone position
223910833|NCT03268382|DRUG|APR-246|Intravenous infusion
223910834|NCT03268382|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
223910835|NCT06002438|DIETARY_SUPPLEMENT|Whole egg powder|15g daily dose for 24 weeks
223716095|NCT03167190|PROCEDURE|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
223910836|NCT06002438|DIETARY_SUPPLEMENT|Corn powder|15g daily dose for 24 weeks
223910837|NCT06002438|DIETARY_SUPPLEMENT|Supercereal Plus|Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.
223910838|NCT06002438|DIETARY_SUPPLEMENT|Micronutrient sprinkles|To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.
224085408|NCT06960356|OTHER|detect post-traumatic stress disorder|recommendation for follow-up by a professional specializing in child development and/or a complementary medical consultation
224277532|NCT03886649|DRUG|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
223716096|NCT03167190|PROCEDURE|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
223910839|NCT06002438|DRUG|Sulfadoxine pyrimethamine|"Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18.~Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18."
223910840|NCT04576130|DEVICE|Implantable cardioverter defibrillator|Implantation of an ICD for secondary prevention
223910841|NCT05496088|PROCEDURE|Re-PVI only|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
223910842|NCT05496088|PROCEDURE|Re-PVI + substrate ablation|"Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation."
223910843|NCT04302051|DIAGNOSTIC_TEST|Thermo-acuostic image acquisition of liver|Estimation of hepatic fat content with thermo-acoustic device
223910844|NCT04302051|DIAGNOSTIC_TEST|MRI-PDFF estimation of hepatic fat|Estimation of hepatic fat content with MRI
224085409|NCT06960733|DEVICE|Winged plastic stent|Patient with need for stenting of bile duct were randomised for kind of stents. Stents used were either standard plastic stents or stents with winged design. In this Intervention winged stents were used.
224277533|NCT04767087|DRUG|Honey|0.5 gm/Kg/day honey
223910845|NCT05231070|OTHER|TeleSPC|Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
224085410|NCT06960733|DEVICE|Standard plastic stents|Patient with need for stenting of bile duct were randomised for kind of stents. Stents used were either standard plastic stents or stents with winged design. In this Intervention standard plastic stents were used.
224085411|NCT06960798|OTHER|Bio-specimen Collection|Tissue samples will be taken from existing archived collections and sent for further analysis.
224085412|NCT06960798|OTHER|Blood Draw|Blood samples will be collected within the first year of enrollment.
224085413|NCT06961045|PROCEDURE|Guided Inferior Alveolar Nerve Lateralization with Simultaneous Implant Placement|All patients will be operated on under general anesthesia. A para-crestal incision will be done and a mucoperiosteal flap will be reflected exposing the alveolar ridge and the buccal cortex. The surgical guide will be fitted and fixed in place and the outline of the window will be drawn by the aid of the surgical guide using the piezotome then the guide will be removed. Once the osteotomy is completed the bone window will be mobilized for exposure of the neurovascular bundle. The diamond tips will be used for removal of any remaining bone around the nerve. The neurovascular bundle will be dissected and retracted properly. a surgical guide will be inserted for implant osteotomy. The bone block which was removed for the buccal window will be crushed to be particulates and will be mixed with autologous fibrin glue for preparation of sticky bone, the sticky bone will be packed gently in the window area around the neurovascular bundle then will be covered by platelet rich fibrin.
224085414|NCT06960551|OTHER|ınfertility group|"Before starting the project, the couples in the experimental group will be informed about the mobile application. The women will use the mobile application weekly for 3 months.~4 times for at least 15 minutes each. To create motivation for use, women in the experimental group will be asked to motivational notification will be sent via the mobile application."
224085415|NCT06960551|OTHER|control group|Women in the control group will not receive any intervention. After collecting the post-test data in the project, the principle of benefit and equality Taking this into account, women and their husbands participating in the control group will be given the opportunity to use the mobile application free of charge for three months.
224085416|NCT05926219|BEHAVIORAL|Fatiguing Exercise|Volunteers will perform knee extension exercise of the dominant limb while seated in a chair designed for exercise of the knee extensor muscle group. The chair will be equipped with a lever arm, aligned with the axis of rotation of the knee and fixed to the distal shank, 2 centimeters proximal to the ankle joint. The lever arm will be instrumented to provide resistance and measure velocity. The volunteers will perform 3-5 maximum voluntary contractions (MVC) to determine peak torque. Once established, volunteers will rest for 5 minutes before initiating the fatigue protocol, whereby they will perform repeated MVC of the dominant limb against resistance equal to or less than 50% of MVC until range of motion cannot be maintained. Because the goal of this exercise is to uniformly fatigue the quadriceps muscle group, this exercise will be performed continuously. It is expected to take between 1 and 3 minutes to achieve the desired level of fatigue.
224085417|NCT01571063|DRUG|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
224085418|NCT01571063|DRUG|Placebo|Placebo Tbl. p.o.
224085419|NCT00600171|DRUG|GW642444M|GW642444M
224085420|NCT00600171|DRUG|Placebo|Placebo mulit-dose dry powder inhaler
223910846|NCT06559475|PROCEDURE|Super-Bore Thrombosis Aspiration Catheter treatment group|For the subjects randomized to the Super-Bore Thrombosis Aspiration Catheter treatment group, Mechanical thrombectomy will be performed using a Super-Bore 8/7F Thrombosis Aspiration Catheter.
223910847|NCT06559475|PROCEDURE|Conventional thrombectomy device treatment group|For the subjects randomized to the conventional thrombectomy device treatment group, mechanical thrombectomy will be performed using a commonly used thrombectomy devices in clinic, except for Super-Bore 8/7F Thrombosis Aspiration Catheter.
223910848|NCT01961986|PROCEDURE|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
223910849|NCT01961986|PROCEDURE|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
223910850|NCT06147401|PROCEDURE|PENG plus LFCN block|"The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine."
223910851|NCT06147401|PROCEDURE|FIC Block|"The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment."
223910852|NCT06636370|DIAGNOSTIC_TEST|Contrast-enhanced mammography (CEM)|This intervention group receives supplemental screening with CEM after a negative screening result within the Dutch National Breast Cancer Screening program
224085421|NCT02367521|COMBINATION_PRODUCT|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
224277534|NCT04767087|DRUG|Nigella sativa seed|40 mg/Kg/day
224277535|NCT04767087|OTHER|Placebo|empty capsule with sugar water
223716097|NCT03068260|DRUG|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
223716098|NCT03068260|DRUG|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
223716099|NCT03068260|DRUG|Acetaminophen|1 g orally administered postoperatively
223716100|NCT03068260|DRUG|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
223529186|NCT03467243|BEHAVIORAL|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
223529187|NCT03467243|BEHAVIORAL|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
223529188|NCT03467243|BEHAVIORAL|Treatment as usual|TAU is when Veterans continue to receive their usual care.
223529189|NCT03021486|DRUG|Chlorpromazine|Given IV
223529190|NCT03021486|DRUG|Haloperidol|Given IV
223529191|NCT03021486|OTHER|Quality-of-Life Assessment|Ancillary studies
223529192|NCT03021486|OTHER|Questionnaire Administration|Ancillary studies
223529193|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws.
223529194|NCT04843488|PROCEDURE|Guided bone regeneration with a PTFE+collagen membrane|Xenograft bovine spongious bone substitute mixed with autogenous intraorally harvested particulated bone is used and spatially contained with a PTFE membrane secured with Ti pins and screws and covered with a Collagen membrane subsequently.
223529195|NCT00542373|OTHER|Cytology Specimen Collection Procedure|Undergo oral tissue collection
223529196|NCT00542373|PROCEDURE|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
223910853|NCT06636370|DIAGNOSTIC_TEST|Abbreviated MRI (AB-MRI)|This intervention group receives supplemental screening with AB-MRI after a negative screening result within the Dutch National Breast Cancer Screening program
223529197|NCT00542373|PROCEDURE|Diagnostic Procedure|Undergo standard white light headlamp oral examination
223910854|NCT03850457|OTHER|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
223910855|NCT04862234|DRUG|Dulaglutide|A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
223910856|NCT04862234|DRUG|Placebo|A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
223910857|NCT04862234|DEVICE|Continuous glucose monitor (CGM), blinded|Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
223529198|NCT00542373|PROCEDURE|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
223529199|NCT00542373|PROCEDURE|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
223529200|NCT05984849|BEHAVIORAL|vaccination game|A health game to promote HPV vaccination among youth
223529201|NCT06183723|OTHER|Combination of social-behavior model and eHealth|"The study examines how an intervention combining the social-behavior model and eHealth can improve medication adherence among individuals who struggle to follow their medical regimens. The platform offers multiple features including health education, medication reminders, online consultations, chat rooms, news, and Q\&A services.~The intervention and follow-up are based on a 28-day month. The first intervention period runs from the first to the third month post-enrollment, with the introduction of the main features and sharing of health education videos and monthly short films. A follow-up assessment and questionnaire are completed after the third month.~The second intervention period is between the fourth and sixth months and includes similar features, and face-to-face counseling. New health education videos and monthly short films are shared as well. After the sixth month, another assessment is conducted to evaluate the post-intervention effects."
223529202|NCT04887831|DRUG|Trilaciclib|Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
223910858|NCT03500081|DEVICE|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
223910859|NCT04160013|BEHAVIORAL|Discipline education|Discipline education using the Play Nicely program.
223529203|NCT04887831|DRUG|Gemcitabine|Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
223910860|NCT04160013|BEHAVIORAL|Cavity Prevention|Cavity prevention using a 2 page handout.
223910861|NCT03292484|BIOLOGICAL|AR101|AR101
223910862|NCT06142773|DEVICE|Tidal Volume set on ventilator|Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
223910863|NCT06514807|DRUG|Ropeginterferon alfa-2b (BESREMi®)|Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
223910864|NCT06485089|DRUG|tirzepatide|Women taking tirzepatide as part of standard care in the Weight Managment Clinic
223910865|NCT05438407|DRUG|Leniolisib|The doses selected range from 20 to 70 mg BID (resulting in total daily doses ranging from 40 to 140 mg per day) based on weight. The doses will be administered as (a combination of) 10 mg and 30 mg tablets
224277536|NCT00781092|OTHER|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
223529204|NCT04887831|DRUG|Cisplatin|Cisplatin administered IV on Day 1 of each 21-day cycle
223529205|NCT04887831|DRUG|Carboplatin|Carboplatin administered IV on Day 1 of each 21-day cycle
223529206|NCT04887831|DRUG|Avelumab|Avelumab administered IV on Day 1 of each 14-day maintenance cycle
223529207|NCT05041985|DRUG|Diazepam Tablets|Diazepam 5 mg tablet once per day (bedtime) for 7 days
223716101|NCT03068260|DEVICE|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
223716102|NCT03068260|DRUG|Morphine|intravenously administered morphine via PCA-pump
223716103|NCT03068260|DEVICE|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
223719396|NCT03445338|DRUG|K0706|Study
223529212|NCT04760873|DEVICE|cryotherapy|cryotherapy is a freeze spray that will be applied to GAVE for bleeding
223529213|NCT02931097|DEVICE|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
223529214|NCT02931097|DEVICE|Sham stimulation|
223529215|NCT04017767|PROCEDURE|Induced Acute Intermittent Hypoxia (AIH)|AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).
223529216|NCT04017767|DEVICE|AIH mask|Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.
223529217|NCT05264974|BIOLOGICAL|Autologous total tumor mRNA loaded DOTAP liposome vaccine|"All participants will receive three doses of RNA-NP vaccine (1 dose every 2 weeks) intravenously.~The vaccine dose given will be determined by a 3 + 3 design. Participants will be given one of the following vaccine doses:~Dose level 0 (starting dose level): 0.00125 mg/kg mRNA in 0.01875 mg/kg LP; Dose level 1: 0.0025 mg/kg mRNA in 0.0375 mg/kg LP; Dose level 2: 0.005 mg/kg mRNA in 0.075 mg/kg LP; or Dose level 3: 0.01 mg/kg mRNA in 0.15 mg/kg LP~If 3 or more of the initial 6 subjects experience a dose-limiting toxicity, then the initial starting dose will be reduced (dose de-escalation) to 0.000625 mg/kg mRNA encapsulated in 0.009375mg/kg LPs (Dose level -1)."
223529218|NCT03519269|DEVICE|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
223535213|NCT02990702|OTHER|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
223910866|NCT06180317|OTHER|Virtual reality|Participants will view a specific relaxing and distracting scenario using virtual reality (VR) for approximately 7-8 minutes from one minute before the procedure until the end of the procedure. Assessment will be performed with STAI and VAS just before the endometrial biopsy procedure, VAS during the procedure and again with STAI and VAS after the procedure.
223910867|NCT06476392|DRUG|Melatonin 10 MG|2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
223910868|NCT06476392|DRUG|Placebo|2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
223910869|NCT03308578|DRUG|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
223910870|NCT03308578|DRUG|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
223910871|NCT06071234|PROCEDURE|3D reconstruction technology|Preoperative application of 3D reconstruction technology to evaluate the breast blood supply of participants and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to surgery without preoperative evaluation.
223910872|NCT03453567|PROCEDURE|Valve Replacement|Aortic valve replacement
223910873|NCT06804460|BEHAVIORAL|Dietary intervention|The vegan mediterranean diet is mainly composed of whole plant-based foods, similar a una dieta mediterránea, but the animal sources of protein and fat are substituted with plant foods rich in protein and fat. During the vegan diet, participants are supplemented with 1000 µg of cyanocobalamin (vitamin B12) twice a week (Harrison Sports Nutrition, Granada, Spain) to compensate for the deficiency in vitamin B12 intake induced by the vegan diet.
223910874|NCT06805227|OTHER|Kinesiology Tape Application|"Application Area: Applied specifically to the dominant leg, targeting the rectus femoris, vastus medialis, and vastus lateralis muscles.~Tension Level: Applied with a standardized 50% tension. Duration: The tape was kept in place continuously for 30 days. Color: A blue-colored kinesiology tape was used to standardize the intervention and eliminate potential psychological effects of tape color.~Technique: Applied by a licensed physical therapist with expertise in kinesiology taping techniques, certified by the Saudi Commission for Health Specialties."
223910875|NCT06804070|OTHER|Botanical Moisturizer + Unscented Soap|"The intervention includes the use of 2 products:~1. A botanical moisturizer~2. An unscented bar of soap"
223910876|NCT05959616|BIOLOGICAL|Shigella sonnei 53G|Lyophilized S. sonnei 53G strain (Lot 1794)
223910877|NCT05959616|DRUG|Ciprofloxacin 500 mg|Ciprofloxacin (500 mg orally twice daily for three days),
223910878|NCT06617611|PROCEDURE|Surgical intervention and anesthesia|Any surgical procedure
223910879|NCT06806007|DEVICE|Group A|"Each child in the group A will receive the incentive spirometer training , attending three sessions per week for three consecutive months. The duration of the session will be half an hour Set up~1. Begin bothering child sit on the mat or chair.~2. Hold the incentive spirometer in an upright position.~3. The child Breathe out normally.~4. Place the spirometer mouthpiece in child's mouth and ask him to close his / her lips tightly around it.~5. Ask the child to Breathe in through mouth as slowly and deeply as he can,~6. Hold breath for as long as possible, or at least five seconds. Exhale slowly~7. Rest for a few seconds, and then repeat the first five steps at least 10 times every hour you're awake.~8. After each set of 10 deep breaths, ask child cough deeply to clear lungs"
223910880|NCT06806007|OTHER|Group B|"Each child in the group B will receive the oropharyngeal motor training programme , attending three sessions per week for three consecutive months. The duration of the session will be an hour The training programme consisted of 10 individual mobilization exercises involving orofacial and pharyngeal area that required 45 minutes Each exercise had to be repeated for 10 times.~The 10 exercises are:~* Exercise 1: Pushing Up The Tongue~* Exercise 2: Touching Nose~* Exercise 3: Touching Chin~* Exercise 4: Pushing Tongue Right and Left~* Exercise 5: Folding Tongue~* Exercise 6: Clicking the Tongue~* Exercise 7: Pushing Tongue Against Spoon~* Exercise 8: Holding A Spoon~* Exercise 9: Holding Button with Lips~* Exercise 10: Gargling"
224277537|NCT00781092|OTHER|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
223535214|NCT02990702|DRUG|Bupivacaine|
223535215|NCT02990702|DEVICE|Ultrasound|
223716104|NCT05346770|BEHAVIORAL|Behavioral Intervention|A behavioral intervention could include changing the time of day a drug is taken.
224085422|NCT02367521|DEVICE|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
224085423|NCT02104414|DRUG|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
224085424|NCT02104414|DRUG|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
224085425|NCT02104414|DRUG|Normal Saline|30mL Normal Saline
224085426|NCT00542191|DRUG|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
224085427|NCT00542191|PROCEDURE|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
224085428|NCT00542191|RADIATION|Radiotherapy|Standard of care RADIATION THERAPY as indicated
224085429|NCT00469612|DEVICE|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
224085430|NCT05540626|DEVICE|Cala Trio|transcutaneous afferent patterned stimulation (TAPS)
224085431|NCT03258892|OTHER|Educational Intervention|Receive STG
224085432|NCT03258892|OTHER|Quality-of-Life Assessment|Ancillary studies
224085433|NCT03258892|OTHER|Survey Administration|Ancillary studies
224085434|NCT02300493|BEHAVIORAL|Experimental|Asked to weigh themselves
224085435|NCT04324645|OTHER|Noona Software|Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.
223529219|NCT06546787|OTHER|PSYCHOTHERAPY|IPT, was prepared by the researcher who completed the interpersonal relations psychotherapy training.The first interview will be conducted face-to-face in the offices of Koç University Faculty of Nursing. Subsequent sessions will be conducted via Zoom according to the availability of the patients included in the study. The day and time of the interviews will be planned according to the availability of the patients before the interviews. A total of 12 interviews are planned to be conducted with a patient for 40-60 minutes each. Interview intervals will be organized as once a week.
223529220|NCT02496208|PROCEDURE|Biopsy Procedure|Undergo biopsies
223529221|NCT02496208|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223529222|NCT02496208|DRUG|Cabozantinib S-malate|Given PO
223529223|NCT02496208|PROCEDURE|Computed Tomography|Undergo CT scan
223529224|NCT02496208|PROCEDURE|Echocardiography Test|Undergo echocardiography
223529225|NCT02496208|BIOLOGICAL|Ipilimumab|Given IV
223529226|NCT02496208|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224085436|NCT00847327|BEHAVIORAL|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
223529227|NCT02496208|BIOLOGICAL|Nivolumab|Given IV
224277538|NCT01247792|BEHAVIORAL|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
223529228|NCT05267587|RADIATION|Hypofractionated Stereotactic Radiosurgery|Participants will be given hypofractionated stereotactic radiosurgery (fSRS) in 9 Gray Units (Gy) per fraction x 3 consecutive daily fractions (27 Gy total) to the index metastasis that will be resected.
223529229|NCT03977207|DRUG|Levothyroxine Sodium|Thyroid hormone supplement
223529230|NCT03977207|DRUG|Placebos|Placebo oral capsule
223529231|NCT05150470|OTHER|prevention|dental digital fingerprinting
223529232|NCT02499237|DRUG|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
223529233|NCT02499237|DRUG|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
224277539|NCT03068884|DEVICE|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
224277540|NCT03068884|DIETARY_SUPPLEMENT|L-Tyrosine|Administration of 2 grams tyrosine
224277541|NCT03068884|DEVICE|Transcranial direct current stimulation (sham)|Sham tDCS
224277542|NCT03068884|DIETARY_SUPPLEMENT|Cellulose (placebo)|Administration of 2 grams cellulose
223529234|NCT00730327|DEVICE|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
223529235|NCT00730327|OTHER|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
223529236|NCT02705963|DRUG|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
223529237|NCT02705963|DRUG|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
223529238|NCT02705963|DRUG|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
223529239|NCT06153264|OTHER|neurodynamic mobilization exercise|Upper extremity neurodynamic mobilization exercises and upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks.
223910881|NCT06806007|COMBINATION_PRODUCT|Group C|Each child in the group C will receive a combination program of the incentive spirometer training and oropharyngeal motor training programme attending three sessions per week for three consecutive months. The duration of the session will be one hour and half that Will be designed into half an hour for the incentive spirometer training and an hour for the oropharyngeal motor training programme
224085437|NCT00847327|BEHAVIORAL|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
223529240|NCT06153264|OTHER|strengthening exercises|upper extremity strengthening exercises will be applied 10 repetitions a day, 3 days a week for 6 weeks
223529241|NCT04394494|OTHER|Motor Imagery. Imaging doing Extension exercises without actually doing them.|This study will compare imagining doing specific extension based exercises for LBP vs. actually performing the exercises. This intervention will be just imaging doing the exercises.
223529242|NCT04394494|OTHER|Control: Physically performing extension based exercises.|This study will compare imagining doing specific extension based exercises for LBP vs. actually doing them. This intervention will be actually, physically performing the exercises.
223529243|NCT04448951|OTHER|transcriptomics|transcriptomics
224085438|NCT05959473|DEVICE|Idylla EGFR_IUO/3.20 Mutation Test|Clinical Performance Study Protocol for Idylla EGFR\_IUO/3.20 Mutation Test The EGFR\_IUO/3.20 is automated on the Idylla™ Platform, which executes the entire process from sample to result including sample liquefaction, cell lysis, real-time PCR amplification/detection, and data analysis and reporting.
223716105|NCT05346770|DIAGNOSTIC_TEST|Diagnostic Test|A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.
223910882|NCT06804798|DEVICE|Latex metal alloy coated catheter|Metal alloy works as an antiseptic whereby preventing the attachment of biofilm to the catheter lining.
223910883|NCT06804798|DEVICE|conventional latex urinary catheter|Latex catheters prove to be soft, flexible, inexpensive and thermo-sensitive towards body temperature. However, there is a risk of developing CAUTI as bacteria are more susceptible to adhere to latex.
223910884|NCT05317975|BEHAVIORAL|Add-on telerehabilitation and home-based rehabilitation|"1. 12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.~2. Add-on telerehabilitation for instruction and supervision of exercise training"
223910885|NCT05317975|BEHAVIORAL|Home-based rehabilitation alone|12wk home-based rehabilitation including individualized exercise training and inspiratory muscle training with symptoms monitoring. Participants will be provided with a manual and routine telephone follow-up by a case manager.
224085439|NCT05276661|DIETARY_SUPPLEMENT|TAC/Collagen gel|Apply it twice per day for 4 weeks
224085440|NCT05276661|DIETARY_SUPPLEMENT|placebo lotion|Apply it twice per day for 4 weeks
224085441|NCT01699139|DEVICE|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
224085442|NCT01699139|DEVICE|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
224085443|NCT01084551|DRUG|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
223529244|NCT04448951|OTHER|flow-cytometry|peripheral blood myeloid cells and lymphocytes flow-cytometry
223529245|NCT04448951|OTHER|cytokines|peripheral blood cytokine analysis
223529246|NCT03773419|BEHAVIORAL|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
223529247|NCT03773419|BEHAVIORAL|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
223529248|NCT04868422|DEVICE|Telemonitoring via wireless internet-based system|
223529249|NCT02552225|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
223529250|NCT02552225|OTHER|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
223716106|NCT05346770|OTHER|Data Analysis|Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.
224085444|NCT01084551|DRUG|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
224085445|NCT01084551|DRUG|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
224085446|NCT02932787|DEVICE|Height-adjustable workstation|
223529251|NCT03035747|PROCEDURE|conventional surgery|high ligation and stripping of incompetent saphenous veins
223716107|NCT01695590|DRUG|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
223716108|NCT03416946|DEVICE|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
223716109|NCT03416946|OTHER|Traditional|Traditional cutting method
223910886|NCT04818671|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
223910887|NCT05526196|DRUG|Cannabis|Dried flower cannabis cigarette with 22% THC
223910888|NCT05526196|DRUG|Tobacco|Dried flower cigarette with active nicotine
223910889|NCT05526196|DRUG|Cannabis tobacco|Dried flower cigarette with active nicotine and cannabis
224085447|NCT00250510|BEHAVIORAL|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
223529252|NCT03035747|PROCEDURE|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
223529253|NCT03035747|PROCEDURE|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
223529254|NCT03035747|PROCEDURE|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
223910890|NCT05526196|DRUG|Placebo|Dried flower cigarette with both placebo tobacco and cannabis
223910891|NCT01989013|OTHER|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
223910892|NCT05131815|BEHAVIORAL|Virtual group based physical activity (BurnAlong) and Social Media Discussion Board|Participants will engage in two to three virtual physical activity sessions a week through the BurnAlong app for three months with a chosen partner and participate at least twice a week in the research team-mediated social media message board. Additionally, participants will be asked to participate in one live physical activity session per month with an exercise physiologist.
223910893|NCT06457594|OTHER|Questionnaire|EORTC QLQ-INFO25 EORTC QLQ - H\&N43 and EORTC QLQ-C30
223910894|NCT05695222|OTHER|This is not an interventional study|This is not an interventional study
223910895|NCT02567409|DRUG|Berzosertib|Given IV
223910896|NCT02567409|DRUG|Cisplatin|Given IV
223910897|NCT02567409|DRUG|Gemcitabine Hydrochloride|Given IV
223910898|NCT05425420|DRUG|methadone hydrochloride 0.1mg/kg|Single dose of methadone hydrochloride administered via intravenous (IV)
223910899|NCT05603884|DRUG|Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen|"venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC \> 20×109/L"
223910900|NCT06649539|DRUG|Collagenase Clostridium Histolyticum|"4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL"
223910901|NCT06649539|DEVICE|RestoreX|Restorex initiated beginning on post-injection day 3 or as soon as tolerated - 30 min daily, continuing until 6 weeks after final injection of the final CCH series.
223910902|NCT06649539|DRUG|Sildenafil|Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
223910903|NCT01946386|DRUG|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
223910904|NCT01946386|DRUG|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
223910905|NCT01946386|DRUG|LEO 90100 Aerosol, foam, vehicle|
223910906|NCT01946386|DRUG|Daivobet® ointment|
223910907|NCT01946386|DRUG|Dermovate® cream|
224277543|NCT01967901|BEHAVIORAL|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
223529255|NCT03035747|PROCEDURE|phlebectomy|hooks phlebectomy of varicose veins
223529256|NCT00003287|DRUG|FOLFOX regimen|
223529257|NCT00003287|DRUG|fluorouracil|
223529258|NCT00003287|DRUG|leucovorin calcium|
223529259|NCT00003287|DRUG|oxaliplatin|
223529260|NCT02970565|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
223529261|NCT02970565|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
223910908|NCT01946386|DRUG|Synalar® ointment|
223910909|NCT03911739|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
223910910|NCT03911739|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
223910911|NCT06280352|DEVICE|Custom made Total Knee Arthroplasty|Total knee replacement, patient specific custom made total knee Origin (Symbios, Symbios Orthopédie SA, Avenue des Sciences 1, 1400 Yverdon-les-Bains, Switzerland)
223529262|NCT00893802|OTHER|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
223910912|NCT06280352|DEVICE|Functionally aligned robotically assisted total knee arthroplasty|Total knee replacement, Total Knee Implant Triathlon (Stryker, Kalamazoo, Michigan, U.S.) implanted using MAKO Rio Robotic Arm (Stryker), using functional alignment strategy
223910913|NCT06416020|BEHAVIORAL|HC-MOUD Only|MOUD with buprenorphine provided in a hub buprenorphine clinic
223910914|NCT06416020|BEHAVIORAL|BT-MOUD with Buprenorphine|MOUD with buprenorphine provided by a hub buprenorphine provider either in the hub clinic or via telemedicine at a community hub; Recovery Guiding provided to participants
223910915|NCT05032963|BEHAVIORAL|Overnight polysomnography examinations|sleep lab for overnight polysomnography examinations
223910916|NCT01627301|DEVICE|Device-Guided Breathing (DGB)|The RESPeRATE device will be used for 15 minutes of device-guided breathing daily for 8 weeks. The participant places the elastic belt with a respiration sensor around the upper abdomen, and wears earbuds for audio feedback. The device monitors the breathing rate, calculates inspiration and expiration times, and generates a personalized melody of two distinct ascending and descending tones for inhalation versus exhalation. Users effortlessly entrain their breathing pattern with the tones, and the device gradually guides the user to a prolonged expiration time and slower respiratory rate (to \< 10 breaths/minute). The device automatically stores usage data, allowing for quantification of adherence and performance.
224085448|NCT00423059|DRUG|bevacizumab|
223716110|NCT00182286|BEHAVIORAL|Assessment of continuity of care from the patient perspective|
223910917|NCT01627301|DEVICE|Sham DGB|The sham device is identical to the DGB device, except it does not guide respiratory rates to slow down and instead maintains a rate of 14 breaths per minute. The sham device is used for 15 minutes per day for 8 weeks.
223910918|NCT01627301|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|tVNS is a noninvasive method that involves placing a device over the skin overlying the vagus nerve on the neck. The device delivers mild electrical stimulation, using transcutaneous electrical nerve stimulation (TENS) unit. The stimulation is increased until there is a vibration and slight muscle contraction in the lower face or neck. Then the stimulation is delivered for 2 minutes on the left side of the neck, and on the right side of the neck, for a total of 4 minutes. The tVNS device is used twice daily for 8 weeks.
223910919|NCT01627301|DEVICE|Sham tVNS|Sham stimulation is delivered using a device that is identical to the gammaCore device but is programed to deliver a lower frequency that can be felt by the participant but does not actually stimulate the vagus nerve. The sham device is used twice daily for 8 weeks.
223910920|NCT05888376|DEVICE|Vascular access catheter to support dialysis or CRRT|A specialised vascular access catheter to support bi-directional blood flow at high rates to allow extracorporeal removal of toxins by dialysis or CRRT
223910921|NCT06641557|DRUG|200mg of Ikt-148009|4 50mg capsules
223910922|NCT06642441|DRUG|Chemotherapy + vitamin D2|Before the start of treatment and every 3 weeks thereafter, participants will receive a 10 mg dose of vitamin D2 injection until adjuvant chemotherapy is completed. They will receive a standard adjuvant chemotherapy regimen, which includes 10 mg of vitamin D2 injections per cycle during treatment. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
223910923|NCT06642441|DRUG|Chemotherapy|Participants will receive a standard adjuvant chemotherapy treatment regimen for each adjuvant chemotherapy cycle. The dosage of adjuvant chemotherapy drugs can be customized according to the clinical judgment of the doctor.
223910924|NCT06642324|DIAGNOSTIC_TEST|Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing|Histopathology for carcinoma detection, Immunohistochemistry for carcinoma-related protein expression, Real-Time PCR for HPV association and HPV typing, Sequencing for genetic study or mutation analysis.
223910925|NCT06642168|GENETIC|Whole exome sequencing to detect myocardial genetic mutations (SCA group only)|Whole exome sequencing to detect myocardial genetic mutations
223910926|NCT05696197|BEHAVIORAL|Targeted touchscreen training|Participants will practice the Swipe Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants form different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 minutes per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14 seconds. Instruction and answers are also included. Feedback will be provided by means of knowledge of performance. On each training day, participants will receive a reminder on the training tablet.
223910927|NCT05443906|BEHAVIORAL|Home exercise|Exercise to address limitations impacting walking
223910928|NCT03424850|RADIATION|HDR brachytherapy|"* Dose constraints for 21 Gy:~  * Bladder and rectum: V70 \< 1 cc~ * Urethra: V115 \< 1 cc~ * V135: 0%~* Dose constraints for 23 Gy:~  * Bladder and rectum: V65 \< 1 cc~ * Urethra: V105 \< 1 cc~ * V125: 0%~* Dose constraints for 25 Gy:~  * Prostate V100 \>90% (\>95% preferred)~ * Bladder and rectum: V70 \< 1 cc, Dmax \<115%~ * Urethra: V110 \< 1 cc, Dmax \<120%"
223910929|NCT03714815|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
224085449|NCT04024800|BIOLOGICAL|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in \> 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1)."
224085450|NCT04024800|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
223910930|NCT06249555|DRUG|Vedolizumab (VDZ)|Participants will receive VDZ as part of routine care.
223910931|NCT06249555|DRUG|Ustekinumab (UST)|Participants will receive UST as part of routine care.
224277544|NCT03619876|DRUG|Abatacept|125 MG/ML subcutaneous injections
224277545|NCT03619876|DRUG|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
223716111|NCT00182286|BEHAVIORAL|Relationship between continuity of care, patient outcomes, and costs|
223716112|NCT04901936|DRUG|Pegcetacoplan|Complement (C3) inhibitor
223716113|NCT01471171|DRUG|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
223716114|NCT01471171|DRUG|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
223910932|NCT06249555|DRUG|Risankizumab (RISA)|Participants will receive RISA as part of routine care.
223910933|NCT02691078|OTHER|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
223910934|NCT06806683|RADIATION|intensity modulated radiotherapy|intensity modulated radiotherapy
223716115|NCT01320904|PROCEDURE|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
223910935|NCT05983445|DRUG|genakumab|200mg s.c.
223529263|NCT02297516|DRUG|Azzalure or Dysport|Glabellar lines
223716116|NCT01320904|PROCEDURE|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
223910936|NCT05983445|DRUG|placebo for Diprospan|i.m.
223910937|NCT05983445|DRUG|placebo for genakumab|s.c.
223910938|NCT05983445|DRUG|Diprospan|7mg i.m.
223910939|NCT06650319|BIOLOGICAL|intravenous LY-M003|The study was a single intravenous infusion of LY-M003 at a rate of 1 mL per minute.
223910940|NCT06380309|BIOLOGICAL|IDOV-SAFE|Intravenous injection of oncolytic virus concomitant with Triprolizumab and fruquintinib every 3 weeks until tumor progression
223910941|NCT04409457|OTHER|fasting state|16 hours of fasting
223910942|NCT04409457|OTHER|fed state|fed a standardized meal
223910943|NCT04409457|OTHER|magnetic resonance imaging|neuroimaging with computational modeling
223910944|NCT05674851|OTHER|MRI|collection of MRI scans for mathematical model development
223910945|NCT04280458|BEHAVIORAL|Intentive rehabilitation|"Intervention included:~* psychomotor 5 hours/week ±30 minutes~* kinesitherapy 1.5 hour/week ±20 minutes~during 12 months."
223910946|NCT04280458|BEHAVIORAL|Routine care|"Intervention included:~* kinesitherapy 0.5 hour/week ±10 minutes~* psychomotor 30 min/week ±10 minutes during 12 months."
223910947|NCT06731621|DRUG|Psilocybin|"2 dosing sessions 1 week apart, each about 6-8 hours duration~Psilocybin-assisted therapy (PAT), is a psychotherapeutic intervention in which the psychological effects of psilocybin play a significant role. PAT procedures typically involve psychological preparation prior to therapist-supported psilocybin dosing sessions. These sessions are used to establish a therapeutic relationship, inform participants about what to expect, and set expectations for the dosing session. During the psilocybin dosing session, trained therapists support the individual through their experience and psychological integration therapy occurs after the dosing experience. PAT has shown impressive antidepressant effects in people with TRD or severe MDD in at least six modern-era clinical trials (Andersen et al., 2021)."
223910948|NCT03204916|BEHAVIORAL|Discussion|Participate in focus group
223910949|NCT03204916|OTHER|Medical Chart Review|Data abstraction and central review
223910950|NCT03204916|OTHER|Questionnaire Administration|Complete questionnaire
223910951|NCT06088095|OTHER|Mobility group|Patients will be mobilized in accordance with the gradual mobilization procedure 12 hours after the angiography procedure.
223910952|NCT03505008|DRUG|Methotrexate|Route of Administration: Oral
223910953|NCT03505008|DRUG|Adalimumab|Route of Administration: Subcutaneous
223910954|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
223910955|NCT03671044|DRUG|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
223910956|NCT03671044|DRUG|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
223529264|NCT02297516|DEVICE|Restylane or Emervel filler|Facial tissue augmentation
223529265|NCT02297516|DEVICE|Restylane Skinbooster|Facial skin rejuvenation
223716117|NCT00966329|DRUG|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
223910957|NCT04014907|PROCEDURE|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
223910958|NCT06350500|BEHAVIORAL|Patient Navigation|Receive patient navigation
223910959|NCT06350500|OTHER|Questionnaire|Ancillary studies
223910960|NCT06429033|DRUG|PEP (Purified Exosome Product)|Injection of PEP into hypodermis of abdomen
223910961|NCT06068413|DEVICE|CT image-assisted detection software|CT image-assisted detection software can help doctor to diagnosis the focal liver lesion
223910962|NCT04378244|DRUG|DeltaRex-G|"This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced."
224085451|NCT01583478|BIOLOGICAL|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
223529266|NCT03674281|DEVICE|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
223529267|NCT03674281|DEVICE|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
223529268|NCT02329808|PROCEDURE|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
223529269|NCT04781179|BEHAVIORAL|CM-II|It is an intervention of 4 two-hour sessions with a psychologist, MC-II technique
223910963|NCT05701163|OTHER|Abstinence followed by semen sample collection.|Abstinence is the intervention. Semen samples will be collected after abstinence periods.
224085452|NCT02556567|OTHER|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
224085453|NCT01721499|BEHAVIORAL|Nutritional Counseling|weekly group and individual skills training to improve self control and decrease stress.
224085454|NCT01721499|BEHAVIORAL|Mindfulness Intervention|
224085455|NCT01944709|BIOLOGICAL|Dendritic cell application|
224085456|NCT00450944|BIOLOGICAL|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
224085457|NCT00463476|BIOLOGICAL|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right upper arm using 23 gauge needles.
224085458|NCT06228612|DEVICE|vacuum therapy|vacuum therapy :all patients were informed about initial suction sensation and possible appearance of bruising at the application site. Basic vacuum therapy equipment (cangexia, China) was utilized including a manual suction pump, plastic cups of 40 mm diameter with rolled edge, and anti-septic tools.
224085459|NCT06228612|DEVICE|maxillary stabilization splint (MSS)|maxillary stabilization splint (MSS): was constructed for each patient from hard, heat-cured clear acrylic resin and fitted to the maxillary teeth. On the mounted master casts, the vertical dimension was adjusted to provide 3 mm of vertical space between the closest opposing cusps of the maxillary and mandibular teeth.
224085460|NCT06228612|DEVICE|vacuum therapy VT and maxillary stabilization splint (MSS)|vacuum therapy VT and maxillary stabilization splint (MSS): both Basic vacuum therapy and maxillary stabilization splint :Procedures were the same as in group I and II.
224085461|NCT03728387|OTHER|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
224085462|NCT00739284|DEVICE|nephrostomy tube and ureteral stent|
224085463|NCT03360760|DRUG|Doxorubicin|60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
224085464|NCT03360760|DRUG|Cisplatin|100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
224085465|NCT03360760|DRUG|Methotrexate|High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
224085466|NCT03360760|DRUG|Ifosfamide|12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
223716118|NCT00966329|DRUG|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz)."
223716119|NCT02204878|DRUG|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
224085467|NCT03360760|PROCEDURE|definitive surgery|Including limb-sparing procedure and amputation
223719397|NCT03178864|DRUG|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)
223910964|NCT05606900|BEHAVIORAL|addiction-focused eye movements desensitization and reprocessing (AF-EMDR)|AF-EMDR includes desensitization and functional reprocessing of the targeted memory or the moment with lateral eye movements. In each session of the psychotherapy, which will be applied as 3 sessions, a memory or a moment that causes alcohol craving will be practised. The processing will continue until the patient becomes desensitized to the memory or the moment that cause the craving. In the first session, a memory of craving will be discussed, in the second session a current trigger that causes craving, and in the third session, a moment that is thought to cause craving in the future will be focused.
223910965|NCT06193070|OTHER|Educational Intervention|Play virtual misinformation escape room game
223910966|NCT06193070|OTHER|Interview|Ancillary studies
223910967|NCT06193070|OTHER|Survey Administration|Ancillary studies
223910968|NCT06193070|OTHER|Telemedicine|Play virtual misinformation escape room game
223910969|NCT05875519|DRUG|Local anaesthesia with vasocontrictor (Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg)|Mepivacaine hydrochloride 20 mg (2%) + Levonordefrin hydrochloride 0.06 mg
223910970|NCT06452914|DEVICE|Semiconductor Embedded Therapeutic Socks|Semiconductor Embedded Therapeutic Socks
223910971|NCT06452914|DEVICE|Placebo Socks|Socks not containing the Semiconductor Embedded Therapeutic fabric
223910972|NCT04426669|DRUG|Cyclophosphamide|Day -6 and Day -5: Cyclophosphamide 60 mg/kg/dose as a 2 hour intravenous infusion with Mesna 15 mg/kg/dose, 1st dose prior to Cyclophosphamide infusion then at 3,6,9 and 12 hours later.
223910973|NCT04426669|DRUG|Fludarabine|Day -7 to Day -3 : Fludarabine 25 mg/m\^2/dose as a 1 hour intravenous infusion per institutional guidelines once a day for 5 doses beginning on Day -7. Fludarabine will be started approximately 1 to 2 hours after the cyclophosphamide on Day -6 and Day -5.
223910974|NCT04426669|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TIL)|Day 0 : Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes at assigned dose level.
223910975|NCT04426669|DRUG|Aldesleukin|Days 1-4 : Aldesleukin at 720,000 U/kg as an intravenous infusion, every 8 -12 hours but, no more than 24 hours apart as tolerated for up to 6 doses.
223910976|NCT04520139|DRUG|N-Acetyl-Cysteine|Given PO
223910977|NCT04520139|OTHER|Placebo|Given PO
223910978|NCT03989778|DRUG|Vitamin D|Vitamin D supplementation
223910979|NCT05046639|DRUG|10 mL 2% lidocaine|Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine. Crossover treatment 5 days later using image guided sciatic nerve anesthetic block of the contralateral limb with 10 mL preservative-free saline.
223910980|NCT05046639|DRUG|10 mL preservative free saline|"Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL preservative free saline.~Crossover treatment 5 days later using Image guided sciatic nerve anesthetic block of the contralateral limb with an injection of 10 mL 2% lidocaine."
223910981|NCT03697577|DIAGNOSTIC_TEST|CT scans|Patients will undergo CT or PETCT as part of standard of care
223910982|NCT03697577|DIAGNOSTIC_TEST|DEXA scan|Patients will undergo DEXA scan to measure body fat mass (DEXA will be performed only if available)
223529270|NCT04781179|BEHAVIORAL|Psychoeducation|It is an intervention of 4 two-hour sessions with a psychologist, psychoeducation
223529271|NCT06300775|DEVICE|modified hyrax|Appliance used for rapid maxillary expansion
223529272|NCT06300775|DEVICE|quad helix|device use for slow maxillary expansion
223529273|NCT06486909|DIAGNOSTIC_TEST|Cerebrospinal Fluid (CSF) Sample|Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).
223529274|NCT06486909|DIAGNOSTIC_TEST|Blood Serum Sample|Samples for glucose in blood serum will be completed every day, for the first 14 days.
223910983|NCT03276676|DRUG|[18F]FLT|PET exams of \[18F\]FLT will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
223910984|NCT03276676|DRUG|[18F]Fluciclovine|PET exams of \[18F\]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor \> 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (\~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
223910985|NCT01401751|DEVICE|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
223910986|NCT06496581|DRUG|177Lu-PMSA-617|Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.
223910987|NCT06496581|DRUG|Standard of Care|ADT, abiraterone and each ARSI (Apalutamide, Darolutamide, Enzalutamide) will be administrated according to the standard of care
223910988|NCT04753788|DIAGNOSTIC_TEST|PCR|qPCR for T.pallidum
223910989|NCT04753788|DIAGNOSTIC_TEST|LAMP|LAMP assay for T.pallidum
223910990|NCT06799832|DEVICE|urethal perfusion index monitoring|The urethral perfusion index will be monitored using the IKORUS System (Vygon, Écouen, France)
223910991|NCT03362177|BIOLOGICAL|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal/pancreatic cancer.
223910992|NCT03362177|OTHER|Placebo|Placebo Comparator
223910993|NCT06052514|DEVICE|Continuous positive airway pressure|Patients with moderate or severe OSA will be treated with CPAP
223910994|NCT06772584|DRUG|Desmopressin Acetate 0.2 mg Tablets|3 groups of patients one received only desmopressin and group ginkobiloba ablnd group for both
223910995|NCT06772584|DRUG|Ginkgobiloba|Group s take it as treatment of deep sleep in nectornal enuresis
223910996|NCT06014749|PROCEDURE|undergo|regional anesthesia
223910997|NCT06014749|DEVICE|ultrasound|ultrasound guided
223910998|NCT06014749|DRUG|Local anesthetic|local anesthetic
223910999|NCT05175521|OTHER|Eucalyptus Oil Scent|Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
223911000|NCT05175521|OTHER|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
223911001|NCT03650712|DIAGNOSTIC_TEST|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
223911002|NCT03650712|DIAGNOSTIC_TEST|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
223911003|NCT03650712|DIAGNOSTIC_TEST|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
223911004|NCT06024083|BEHAVIORAL|Dialectical Behavior Therapy skills video intervention|A series of 14 animated videos (9 acceptance-oriented and 5 change-oriented skills videos) available in both English and Mandarin Chinese.
223911005|NCT06482359|BIOLOGICAL|coformulated CIC Vaccine|SARS-CoV-2 rS (35 µg) + trivalent hemagglutinin nanoparticle influenza (tNIV) antigen (180 µg; 60 µg per strain) + Matrix-M adjuvant (75 µg)
223911006|NCT06482359|BIOLOGICAL|Fluzone HD trivalent|60 µg per strain of 3 strains (sodium phosphate buffered isotonic sodium chloride solution + formaldehyde and octyl phenol ethoxylate)
224085468|NCT03360760|OTHER|pre surgical chemotherapy|chemotherapy that given before definitive surgery
224085469|NCT02120755|BIOLOGICAL|AmnioClear™ Human Allograft Amniotic Membrane|
223529275|NCT00525421|DRUG|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
223529276|NCT00525421|DRUG|Placebo|
223529277|NCT00366457|DRUG|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
223529278|NCT00366457|DRUG|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
223529279|NCT00366457|DRUG|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
223529280|NCT00822302|DRUG|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
223529281|NCT00822302|DRUG|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
223529282|NCT03690908|OTHER|no intervention (descriptive study)|no intervention (descriptive study)
223529283|NCT05201131|PROCEDURE|Rezum|Rezum
223529284|NCT01310972|OTHER|Registry|Registry
223529285|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Workshop|2 day workshop
223716120|NCT03727529|OTHER|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
223716121|NCT03727529|OTHER|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
223911007|NCT06291350|OTHER|Plaque sampling and stool collection|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
223911008|NCT06291350|OTHER|periodontal examination|Characterization of the periodontal and digestive microbiota (metagenomic analysis), assessment of clinical attachment loss and alveolysis
223911009|NCT05693701|BEHAVIORAL|Implementation Strategy Bundle|Bundle includes multimodal communications to notify donors about high cholesterol and its treatment, website with resources, and an optional care navigator. Resources for their primary care provider will also be disseminated.
223911010|NCT05693701|OTHER|Usual care notification|Carter BloodCare will notify participants of their high cholesterol, potential for genetic causes, and recommendation to see their care provider by sending its routine, standard notification letter. These participants will also be eligible to receive the intervention bundle at the end of the study.
223911011|NCT04741776|BEHAVIORAL|Resilience Enhancement Skills Training|Family therapy
223911012|NCT04741776|BEHAVIORAL|Problem-Solving Individual Therapy|Individual therapy
224085470|NCT00988247|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
224085471|NCT00988247|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
223911013|NCT04089865|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
223911014|NCT05975580|DRUG|Topiramate|Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
223911015|NCT05975580|DRUG|Phentermine|Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
223911016|NCT05975580|DRUG|Placebo|Placebo is an inactive substance.
223529286|NCT05509348|BEHAVIORAL|Phase 1: ADAPT Online|Online curriculum
223716122|NCT05081141|DIAGNOSTIC_TEST|Diagnostic test for HHV8 exposure|Venipuncture for blood sampling
223716123|NCT05386810|BIOLOGICAL|Experimental vaccine|Sabin Inactivated Poliovirus Vaccine (Vero cell) (2.5ml)-investigational vaccine produced by Sinovac Biotech Co., Ltd. Inactivated Sabin poliovirus antigen (per 0.5ml): type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 2.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate,2 - phenoxyethanol for per injection.
223911017|NCT05088694|BEHAVIORAL|Peaceful Coexistence|"The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior."
223911018|NCT03835065|PROCEDURE|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
223911019|NCT03835065|OTHER|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
223529287|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Group|3 in person group sessions
223529288|NCT05509348|BEHAVIORAL|Phase 2: ADAPT Individual|3 sessions in person one on one
223529289|NCT01497197|DRUG|GONAL-f®|GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.
223529290|NCT01497197|DRUG|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
223911020|NCT03835065|OTHER|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
223911021|NCT04874688|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrient supplement|Small Quantity Lipid-based Nutrient Supplement (SQ-LNS) is a food supplement rich in both macro and micronutrients (calories, proteins, fat and multivitamin mix). SQ-LNS is not considered a regulated drug product in Zimbabwe, or by the United States Food and Drug Administration (FDA). It is commercially available for prevention of chronic malnutrition, produced by Nutriset (https://www.nutriset.fr/products/en/enov-nutributter2). Each child will receive a daily sachet of 20g SQ-LNS between 6-12 months of age, consumed directly from the sachet or mixed with porridge.
224085472|NCT01067131|BIOLOGICAL|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
224085473|NCT01067131|BIOLOGICAL|PEV7C9|capsule intravaginal application contains excipient only
224085474|NCT01067131|BIOLOGICAL|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
224085475|NCT01067131|BIOLOGICAL|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
224085476|NCT02661594|DRUG|APD421 5 mg|Therapeutic dose of amisulpride
224085477|NCT02661594|DRUG|APD421 40 mg|Supra-therapeutic dose of amisulpride
224085478|NCT02661594|DRUG|Moxifloxacin|Positive control for assay sensitivity
224085479|NCT02661594|DRUG|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
224085480|NCT01633957|OTHER|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
224085481|NCT01633957|OTHER|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
223911022|NCT04874688|DIETARY_SUPPLEMENT|Provitamin A biofortified maize|Provitamin A Maize Meal is orange maize-meal processed from provitamin A-rich orange maize. PVA maize meal will be sourced from International Maize and Wheat Improvement Centre (CIMMYT). Children in the intervention arm will consume 13g - 128g of pro-vitamin A (PVA) maize meal, with added powders. Each family will receive a monthly ration of 5kg PVA maize and this ration takes into consideration of household sharing. Families with children in the IYCF arm will receive white maize meal.
224085482|NCT04120922|OTHER|calcium carbonate|See arm description
224085483|NCT04120922|OTHER|sevelamer carbonate|See arm description
224085484|NCT05427578|OTHER|fNIRS measurement|measurement using functional near-infrared spectroscopy
224085485|NCT00289913|BIOLOGICAL|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
224085486|NCT00289913|BIOLOGICAL|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
223911023|NCT04874688|DIETARY_SUPPLEMENT|NUA-45 biofortified sugar beans|NUA 45 bean powder is ground from roasted iron and zinc-rich biofortified sugar beans. NUA 45 bean powder will be sourced from Sky Brands Ltd Company. Children will consume a daily dose of 5g - 15g of NUA 45 bean powder added to complementary foods.
223911024|NCT04874688|DIETARY_SUPPLEMENT|Moringa oleifera|Moringa oleifera is an edible plant abundant in dry tropic regions including Zimbabwe. It is known to be rich in micronutrients and has been widely used in Zimbabwe and around the world both as a food and a herb. Moringa oleifera leaf powder, is a dried and ground powder produced from Moringa oleifera leaves using traditional methods. It has been widely used to fortify complementary foods in the African region with the aim of improving micronutrient status. Moringa oleifera leaf powder will be sourced from Lemex Products Company. Children will receive a daily dose of 5g - 15g of Moringa leaf powder added to complementary foods.
224085487|NCT00289913|BIOLOGICAL|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
224085488|NCT04568850|DIAGNOSTIC_TEST|Plasma IgG levels|Plasma IgG levels of subjects who tested reactive for IgG SARS CoV-2 antibodies will be monitored every month for 4 months for IgG levels
224085489|NCT02530645|BEHAVIORAL|OnTrack|
224085490|NCT02530645|BEHAVIORAL|Treatment as Usual|
224085491|NCT02530645|BEHAVIORAL|Brief Motivational Interviewing|
224085492|NCT02141893|BEHAVIORAL|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
224085493|NCT02141893|BEHAVIORAL|CALMA|Family Education Intervention on management of pediatric asthma
224085494|NCT01447238|DEVICE|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
224085495|NCT00956930|RADIATION|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
224085496|NCT00956930|DRUG|Doxorubicin|75mg fixed dose
224085497|NCT00734084|DEVICE|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
224085498|NCT05202626|DIAGNOSTIC_TEST|Nasopharyngeal Endoscopy image-guided Biopsy|For each participant presenting with a suspicious nasopharyngeal lesion, the attending physician will assess the lesion and determine the appropriate biopsy approach. The physician may decide on multiple biopsies from the lesion area, including one sample from within the lesion itself, another from 5-8 mm outside the lesion, and a third from 8-10 mm beyond the lesion. Alternatively, a single biopsy may be deemed sufficient based on the clinical judgment. Each of these specimens will undergo pathological examination to confirm whether they are carcinomatous or non-carcinomatous.
224085499|NCT02779205|PROCEDURE|adipose tissue sample|adipose tissue sample
224085500|NCT03502187|BEHAVIORAL|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about \~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
224099244|NCT05862363|DIETARY_SUPPLEMENT|Ready-to-use supplementary food-balanced energy protein (RUSF-BEP)|RUSF-BEP is composed of rice, lentil, sugar, soybean oil, and skimmed milk powder mixed with vitamin-mineral premix. MD-BEP is composed of chickpea flour, peanut flour, soy flour, green banana pulp, sugar, soybean oil, and vitamin-mineral premix. The results from previous studies support the notion that repair of impaired gut microbial community development could represent a new therapeutic concept for restoring healthy growth. RUSF-BEP will be given to one arm of low-BMI women of reproductive age and low-BMI pregnant women.
224099245|NCT05862363|PROCEDURE|Esophagogastroduodenoscopy (EGD)|Aim 1A consists of performing EGD to women with low-BMI and normal BMI women with function dyspepsia. In order to enroll 30 participants with normal duodenal mucosal histology, we are planning to perform EGD on 100 healthy women (BMI 20-24.9 kg/m2) of childbearing age who have been referred for evaluation of functional dyspepsia. Undernourished low-BMI (\<18.5kg/m2; 18-35 years) women of childbearing age will be enrolled from Bauniabadh and adjacent slum area of Mirpur, Dhaka and EGD will be performed among 60 women. A total of 6-8 biopsy samples from SI and a dry duodenal aspirate will be collected for biopsy, histochemical and immunocytochemical analysis.
223911025|NCT04874688|DIETARY_SUPPLEMENT|Whole egg powder|Egg Powder is hydrolysed non-genetically modified organism (GMO), fine and unflavoured whole egg powder. It is processed with no additives, preservatives, lecithin, added sugar, soy or monosodium glutamate. Egg powder will be sourced from France (A \& D Food Ingredients - distributor in South Africa). Children in the IYCF-plus arm will receive a daily dose of 14g egg powder. A 15% extra amount of egg powder will be provided to families taking into consideration of household sharing. Egg powder will be provided in sealed plastic jars similar to that of peanut butter and households will receive promotion messages to store the powder in a cool, dry place and avoiding contact with water or moisture during use.
223911026|NCT04874688|DIETARY_SUPPLEMENT|White maize meal|Commercial white maize meal will be provided monthly. Infants age 6-8 months will receive 45g (3 tablespoons) daily; infants aged 9-12 months will receive 71g (4.5 tablespoons) daily.
223911027|NCT05660512|PROCEDURE|Intracept Procedure|Radiofrequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
223911028|NCT05577234|OTHER|Animal-assisted intervention|The dog accompanied by the zootherapist will participate in the care of sessions 1 and 2. During these two sessions, the dog will be present with the child in the waiting room until the end of the dental consultation. Session 3 will take place without the dog being present.The usual management with conventional behavioural strategies and possible administration of MEOPA will be implemented during the 3 treatment sessions.
223911029|NCT05577234|BEHAVIORAL|Venham scale modified by Veerkamp|The Venham scale modified by Veerkamp, based on observation of one's behaviour and used in current practice, ranges from 0 (relaxed) to 5 (totally disconnected from the reality of danger).
223911030|NCT03493230|BIOLOGICAL|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
223911031|NCT05499390|DRUG|AK112|Subjects receive AK112 intravenously.
223911032|NCT05499390|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
223911033|NCT06391255|OTHER|scintigraphy|oesophageal and gastric emptying
223911034|NCT06461130|OTHER|Study Group|Group of people doing dual tasks during double-leg cycling training.
223911035|NCT06461130|OTHER|Control Group|The group that received only aerobic exercise.
223911036|NCT03926130|DRUG|Mirikizumab|Administered IV
223911037|NCT03926130|DRUG|Mirikizumab|Administered SC
223911038|NCT03926130|DRUG|Ustekinumab|Administered IV
223911039|NCT03926130|DRUG|Ustekinumab|Administered SC
223911040|NCT03926130|DRUG|Placebo|Administered IV
223911041|NCT03926130|DRUG|Placebo|Administered SC
223911042|NCT03583333|DRUG|IMI/REL FDC|500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
223529291|NCT01497197|BIOLOGICAL|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
223911043|NCT03583333|DRUG|PIP/TAZ FDC|4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
223911044|NCT03583333|DRUG|Linezolid|Open-label 600 mg Linezolid
223911045|NCT05174611|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
223911046|NCT05174611|OTHER|Placebo|Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
223911047|NCT05687890|DRUG|Placebo of SC0062|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
223911048|NCT05687890|DRUG|SC0062 low dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
223529292|NCT04270643|DIETARY_SUPPLEMENT|Vitamin D3|ATC code A11CC05 (cholecalciferol)
223911049|NCT05687890|DRUG|SC0062 medium dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
223911050|NCT05687890|DRUG|SC0062 high dose|Subjects will take two capsules daily of one of those which are SC0062 low dose, SC0062 medium dose, SC0062 high dose or placebo for 24 weeks during the treatment period
223911051|NCT06423040|OTHER|Social Media Chatbot on Physical Activity Education|a social media chatbot was used to provide a continuous and real-time multimedia health education program on physical activity for the older adults, as well as supportive messages and feedbacks.
223911052|NCT05865743|DRUG|SDD|"The intervention group receives SDD treatment additional to standard care, comprising two distinct liquids for oral administration: first the 5 ml amphotericin B suspension (100 mg/ml) and subsequently the 5 ml SDD base for suspension, containing both colistin sulphate (20 mg/ml) and tobramycin sulphate (16 mg/ml).~Patients take the 5 ml amphotericin B, followed by the 5 ml SDD base for suspension, four times daily for one week, starting three days prior to the surgery. On the day of surgery, intake is limited to an early morning and a late evening dose."
223911053|NCT02818426|DRUG|UCPVax|
223911054|NCT06298851|OTHER|Neural Mobilization Group (NMG)|"Femoral nerve gliding: Mobilization of the femoral nerve will performed while the participant in the prone position and the hip hyperextended. Tension will applied by placing the knee in full flexion and the ankle in plantar flexion.~Sciatic nerve gliding: Participants will take turns while sitting with the trunk in thoracic flexion; perform knee extension/dorsiflexion with cervical extension and knee flexion/plantar flexion with cervical flexion. Tension will applied by flexing the hip and dorsiflexing the ankle to the point where stress will felt.~Peroneal nerve gliding: The participant will asked to maintain this position in a supine position by placing the ankle in inversion and plantar flexion. From a starting position consisting of ankle dorsiflexion, knee, and hip extension, the patient will return to the starting position by simultaneously performing ankle plantar flexion and inversion, full knee flexion, and 90 degrees of hip flexion."
223529293|NCT04270643|DIETARY_SUPPLEMENT|Placebo|Ethyl oleate
223529294|NCT03186768|BEHAVIORAL|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
224085501|NCT03502187|DEVICE|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back \& abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
224085502|NCT03502187|BEHAVIORAL|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
224085503|NCT00214461|BIOLOGICAL|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
224085504|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
224085505|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
223911055|NCT06298851|OTHER|Dynamic Stretching Group (DSG)|Exercises will include functional activities that provided dynamic stretching of the hamstrings, quadriceps, hip flexor, extensor, abductor and adductor muscles, and gastrosoleus muscle. All stretching exercises will be performed in two circuits in an area of 15 m2. 4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. This process will be repeated for both extremities.
223911056|NCT06298851|OTHER|Static Stretching Group (SSG)|"Static stretching exercises will be described to the participants as given below:~Standing quadriceps stretch: The participant will stand upright, fold one knee and bring the heel towards the buttock while holding the foot with one hand.~Modified hamstring stretching: The participant will be in a seated position with one leg straight and will place the other foot on the inside of the straight leg and reach forward.~Gastrocnemius stretching: The participant stands with feet 60-90 cm from the wall, leaning against the wall with both hands, keeping the back leg straight and the front leg slightly bent.~Adductor stretching: Participants will be in a sitting position with an erect spine, bending and releasing their knees with the soles of their feet touching.~Lumbar stretching: In a sitting position, participants keep one leg straight and place the other foot on the outside of the straight leg and rotate the body diagonally."
224085506|NCT00214461|BIOLOGICAL|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
224085507|NCT01492673|DRUG|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
224085508|NCT02908100|DRUG|GDC-0853|Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.
224085509|NCT02908100|DRUG|Placebo|Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
224085510|NCT02181933|DRUG|Nevirapine|
224085511|NCT02181933|DRUG|Zidovudine (ZDV)|
224085512|NCT02181933|DRUG|Lamivudine (3TC)|
224085513|NCT01928589|OTHER|PBI with sequential chemotherapy|270 cGy x15
224085514|NCT01928589|OTHER|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
224085515|NCT06343506|DEVICE|Grassroots Ankle Flex|This device can be used in an individual's home, without assistance, allowing more frequent stretching without increased visits to physical therapy. The Ankle Flex device is used to stretch patients into a dorsiflexion position by securing the foot to the base of the device and the shin to the leg strap attached to the pulley system. The patients can then pull the handle of the pulley system, giving them the mechanical advantage to gently mobilize their ankle into dorsiflexion with their foot firmly secured to the base of the device. This can allow for a deeper and more controlled stretch than previous stretching methods done during at home care.
223911057|NCT06365697|DEVICE|Ton-bridge carotid stent|carotid artery stenting with Ton-bridge carotid stent
223911058|NCT06365697|DEVICE|WALLSTENT carotid stent|carotid artery stenting with WALLSTENT carotid stent
223911059|NCT05233189|OTHER|MOOC|"Registrants will be offered a personalized e-education consisting of 3 to 11 modules adapted to the treatment received in childhood by each in the form of a MOOC entitled Cancer in childhood, living well after over a total duration of about 3 to 7 weeks of training."
223911060|NCT05233189|OTHER|No intervention|Patients will be followed up until 18 months only
224085516|NCT06429995|RADIATION|Radiotherapy|
224085517|NCT05182047|DRUG|Butamirate citrate|Butamirate citrate syrup will be administered orally.
224085518|NCT05182047|DRUG|Sinecod|Sinecod syrup will be administered orally.
224085519|NCT05573971|OTHER|with verbal encouragement|Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement
224085520|NCT00400400|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
224085521|NCT00400400|DRUG|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
224085522|NCT00400400|DRUG|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
223529295|NCT06032130|OTHER|Clinical measurements|Optometric measurements
223911061|NCT05723575|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
223911062|NCT05723575|BEHAVIORAL|somatosensory acuity measurement|Somatosensory acuity will be measured through a tactile discrimination task using the corticalmetrics Brain Gauge. Participants lightly press their tongue onto two vibrating probes and report which one vibrated first or with greater amplitude.
223911063|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
223911064|NCT03807401|BEHAVIORAL|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
223911065|NCT03807401|BEHAVIORAL|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
223911066|NCT04948476|OTHER|Standardized Dialysis and Structured Discontinuation (S2D2)|"Prescription to minimize dialysis-induced ischemia~* Cool dialysate (35.0◦C)~* Dialysate sodium of 145mmol/L~* Dialysate calcium of 1.5mmol/L~* Maximum ultrafiltration rate of 10mL/kg/hour (if no weight, maximum is 500mL/hour)~  * Note: If dialysis machines cannot get to the specified values, values closest to these are acceptable.~Structured dialysis discontinuation (all criteria met)~* Most recent pre-dialysis potassium \<6mmo/L and bicarbonate \>12mmol/L~* Most recent urine volume ≥1L/day OR last ultrafiltration on dialysis \<1L/session~* If available, timed urine collection with result for mean creatinine and/or urea clearance \>12mL/min"
223911067|NCT04948476|OTHER|Usual Care|Dialysis prescription ordered by their clinical team. Decisions on dialysis discontinuation will be left to individual clinicians and will not be guided by a standard protocol.
223911068|NCT05513261|DIAGNOSTIC_TEST|High definition colonoscopy (standard colonoscopy) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply the standard colonoscopy without computer-aided colonoscopy (polyDeep)
223911069|NCT05513261|DIAGNOSTIC_TEST|PolyDeep assisted high definition colonoscopy (CAD system) in Adenoma Detection Rate|In the intervention of this arm the investigators will apply polyDeep assisted high definition colonoscopy (CAD system).
223911070|NCT06397443|OTHER|5-day sailing activity|"* Sailing activity (4 h/die)~* Stretching exercises pre and post-sailing activity~* Post-activity debriefing"
223529296|NCT06032130|OTHER|Oculomotor or perceptual therapy|Oculomotor or perceptual visual learning exercices
223529297|NCT00002529|DRUG|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
224085523|NCT00400400|DRUG|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
223911071|NCT04093583|PROCEDURE|Exodontia|Atraumatic exodontia followed by simple suture
223911072|NCT04093583|DRUG|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
223911073|NCT04093583|DEVICE|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
223911074|NCT05623306|DEVICE|PMT Stereoencephalography (SEEG)|For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
223911075|NCT05623306|DEVICE|Vercise Genus™ Deep Brain Stimulation (DBS) System|For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
223911076|NCT03868579|PROCEDURE|Biopsy|Undergo biopsy
223911077|NCT03868579|OTHER|Medical Chart Review|Review medical chart
223911078|NCT03868579|PROCEDURE|Thoracoscopy|Undergo pleuroscopy
223911079|NCT06498687|DRUG|CYR-064|Theophylline Nasal Spray
224085524|NCT01406067|BEHAVIORAL|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
224085525|NCT01406067|BEHAVIORAL|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
223529298|NCT00002529|DRUG|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
223529299|NCT00002529|DRUG|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
223529300|NCT00002529|DRUG|tamoxifen citrate|Tamoxifen 20 mg daily.
223529301|NCT00002529|DRUG|toremifene|Toremifene 60 mg daily.
223529302|NCT00017043|DRUG|ixabepilone|
223529303|NCT01385579|OTHER|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
223529304|NCT02902614|PROCEDURE|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
223529305|NCT02902614|PROCEDURE|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
223529306|NCT03224884|PROCEDURE|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
223529307|NCT03224884|PROCEDURE|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
223529308|NCT00221767|DEVICE|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
223529309|NCT03484104|DIAGNOSTIC_TEST|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
223529310|NCT03944850|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
223911080|NCT03687762|BEHAVIORAL|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
223911081|NCT03687762|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
223911082|NCT03687762|BEHAVIORAL|Behavioral Activation (BA)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
223911083|NCT01569659|DRUG|Lurasidone|80 mg/day for up to 30 weeks
223911084|NCT01569659|DRUG|Lurasidone|Up to 240 mg/day for up to 30 weeks
223911085|NCT05734222|PROCEDURE|A new method of repair of the abdominal wall of mid-lateral postoperative ventral hernias|"1. It is planned to study potential sources of bleeding and hematoma formation during SRM plastic surgery. On this basis, recommendations on the technique of the operation will be formulated.~2. It is supposed to find a way to preserve intercostal neurovascular bundles when performing SRM repair. This should improve the quality of abdominal wall reconstruction by preserving neurovascular bundles of muscles and reducing neuroalgic pain syndrome.~3. It is proposed to develop a method for combining retromuscular and subaponeurotic spaces in the treatment of mid-lateral hernias~4. It is planned to substantiate the effectiveness and expediency of the application of the developed surgical techniques based on the analysis of the immediate and long-term results of treatment."
223911086|NCT05471037|PROCEDURE|Long Biliopancreatic Limb LRYGB|LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
223911087|NCT05471037|PROCEDURE|Short Biliopancreatic Limb LRYGB|Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
223911088|NCT06266299|DRUG|KK2269|KK2269 administered intravenously
223911089|NCT06266299|DRUG|Docetaxel|antineoplastic drug administered intravenously
223911090|NCT03621254|OTHER|[LO-LONG]|Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention (\[LO-LONG\]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.
223911091|NCT03621254|OTHER|[HI-SHORT|One intervention (\[HI-SHORT\]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
223911092|NCT03928002|OTHER|4D Flow magnetic resonance imagery|acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
223911093|NCT03928002|PROCEDURE|Cardiac catheterization|pulmonary vascular resistance calculation ;
223911094|NCT05967390|DEVICE|Transcranial Magnetic Stimulation|One time for each day, lasting for three weeks.
223911095|NCT04980885|DRUG|AK117|Subjects receive AK117 intravenously.
223911096|NCT04980885|DRUG|Azacitidine|Subjects receive Azacitidine subcutaneously.
223911097|NCT05340621|DRUG|OKI-179 + binimetinib|"Phase 1b: With a 3+3 dose escalation design, enrollment in Phase 1b will proceed until the MTD has been defined or the highest dose level has been reached. OKI-179 will be administered on a 4-days-on/3-days-off schedule, while binimetinib will be administered BID continuously.~Phase 2: Patients will be treated with the RP2D."
223911098|NCT03257969|BEHAVIORAL|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
223911099|NCT03257969|BEHAVIORAL|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
224085526|NCT01688050|DEVICE|Zenith® TX2® Low Profile Endovascular Graft|Treatment of Blunt thoracic aortic injuries (BTAIs)
224085527|NCT04870476|BEHAVIORAL|"Internet-delivered treatment: One step at the time"|The guided internet treatment program consists of 11 modules (+ 1 module for relatives) activated consecutively over a period of 14 weeks. The content is written psychoeducation, patient videos, audio exercises and exposure exercises. The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 14 weeks.
223529311|NCT00415636|DRUG|IC83/LY2603618|40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
223529312|NCT00415636|DRUG|IC83/LY2603618|70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
223529313|NCT00415636|DRUG|IC83/LY2603618|105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
224085528|NCT03922854|OTHER|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
224085529|NCT02436460|BIOLOGICAL|AbGn-168H|Humanized monoclonal antibody
224085530|NCT02743247|DRUG|Tacrolimus|
224085531|NCT02743247|DRUG|Mycophenolate mofetil|
224085532|NCT05322213|DRUG|THC|2-Week, once daily, flexible dose, inhaled THC
224085533|NCT05322213|DRUG|Placebo|2-Week, once daily, flexible dose, inhaled placebo
224085534|NCT00949156|PROCEDURE|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
224085535|NCT00003665|BIOLOGICAL|dendritic cell-MART-1 peptide vaccine|
224085536|NCT00003665|BIOLOGICAL|gp100 antigen|
224085537|NCT00003665|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223911102|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout Each Hour|One 5-minute light intensity walking break per hour throughout the 4-hour SB condition
223911103|NCT05316571|BEHAVIORAL|One 15-Minute Standing Bout Each Hour|One 15-minute standing break per hour throughout the 4-hour SB condition
223911104|NCT05316571|BEHAVIORAL|One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour|Two breaks per hour throughout the 4-hour SB condition, alternating between a 5-minute light intensity walking break and a 15-minute standing break
223911105|NCT05316571|BEHAVIORAL|Uninterrupted Sitting|No breaks will be provided throughout the 4-hour SB condition. This will be used as the control condition
223911106|NCT06560502|OTHER|Standard of Care-DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911107|NCT06560502|OTHER|AmnioCore - DFU|Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911108|NCT06560502|OTHER|Amnio Quad-Core - DFU|Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911109|NCT06560502|OTHER|Standard of Care-VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911110|NCT06560502|OTHER|Amnio Tri-Core - VLU|Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911111|NCT06560502|OTHER|AmnioCore Pro|Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911112|NCT06560502|OTHER|Amniocore Pro +|Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
223911113|NCT06017895|DRUG|doxepin solution|2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall
223911114|NCT06017895|OTHER|Placebo|2.0 mL placebo sprayed to the posterior pharyngeal wall
223911115|NCT03824366|DEVICE|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
223911116|NCT03824366|RADIATION|Radiation therapy|-Standard of care
223911117|NCT05526521|DRUG|Dupilumab|Injection solution Subcutaneous
223911118|NCT05561764|DRUG|Imipenem/Cilastatin/Relebactam|Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.
223911119|NCT06560879|BIOLOGICAL|Lactobacillus casei|Lacticaseibacillus casei is a species of Gram-positive anaerobic bacteria found in the intestine and mouth of humans. This lactic acid-producing bacterium is used in the dairy industry in the production of probiotic foods.
224085538|NCT00003665|BIOLOGICAL|tyrosinase peptide|
224085539|NCT06267963|DRUG|Oral [14C]PF-07220060|A single oral dose of \[14C\]PF-07220060, will be administered as a liquid formulation in Cohort 1.
224085540|NCT06267963|DRUG|Oral PF-07220060|A single oral dose of PF-07220060, will be administered as a liquid formulation in Cohort 2.
224085541|NCT06267963|DRUG|IV [14C] PF-07220060|A single IV infusion of \[14C\]PF-07220060 will be administered in Cohort 2 at Tmax after the administration of the unlabeled oral dose.
224085542|NCT03077932|OTHER|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
224085543|NCT05698667|DIAGNOSTIC_TEST|Transoral ultrasound|Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)
224085544|NCT05698667|DIAGNOSTIC_TEST|Transcervical ultrasound|The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.
224085545|NCT00087373|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|Given intratumorally
224085546|NCT00087373|OTHER|laboratory biomarker analysis|Correlative studies
224085547|NCT03429127|OTHER|Normal saline|Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
224085548|NCT03429127|OTHER|Balanced fluid|Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
224085549|NCT04297215|DEVICE|DermaCura® Chitosan based antimicrobial therapeutic clothing|"DermaCura® antimicrobial therapeutic clothing (D\&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
223529314|NCT00415636|DRUG|IC83/LY2603618|150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
223911120|NCT06560879|BIOLOGICAL|Lactobacillus rhamnosus|A live form of a bacterium that makes lactic acid (a substance derived from milk sugars and also made by the body). Lactobacillus rhamnosus GG is given to help with digestion and normal bowel function. In addition, it may help maintain a healthy gastrointestinal tract. It is being studied for the prevention of infections in patients who received donor stem cell transplants and for other conditions.
223911121|NCT06560879|BIOLOGICAL|Bifidobacterium bifidum|B. bifidum is an essential bacteria found in the human intestine. When it is low or absent all together in the human intestine, it is an indication of being in an unhealthy state. Intestinal flora can be improved if someone takes oral B. bifidum. Also, oral B. bifidum is used for other things such as therapy for enteric and hepatic disorders, for activating the immune response, and for preventing some cancers
224085550|NCT04297215|DEVICE|Binamed® silver based antimicrobial therapeutic clothing|"The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
224085551|NCT04297215|DEVICE|Binamed® therapeutic clothing without antimicrobial agents|"The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes."
224085552|NCT00196417|DRUG|Standard heparin (UFH) versus certoparin (LMWH)|
224085553|NCT06419283|PROCEDURE|Middle Cerebral Artery Stent Implantation|Middle Cerebral Artery Stent Implantation
224085554|NCT06419283|DRUG|standard treatment with aspirin.|standard treatment with aspirin.
224085555|NCT05480319|OTHER|EDICARS|The investigators propose to (1) Embed the EDICAS into our hospital information system (HIS) in real-time at ED triage to identify high-risk patients (EDICAS 6+); and (2) Distribute wearable smart wristbands to high-risk patients to augment vital signs monitoring and send alerts based on GBTM results. The detection and intervention components together form the rapid response system, the Emergency Department In-hospital Cardiac Arrest Response System (EDICARS).
224085556|NCT05480319|OTHER|Usual care|Usual care will be assigned to this arm. No additional interventions.
224085557|NCT03642145|DRUG|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
224085558|NCT05442619|PROCEDURE|Venous blood collection|Venous blood will be drawn from newborns.
224085559|NCT02603744|BIOLOGICAL|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
224085560|NCT01160601|DRUG|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve \[AUC\] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
224085561|NCT01160601|DRUG|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
224085562|NCT01351441|BEHAVIORAL|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
223529315|NCT00415636|DRUG|IC83/LY2603618|195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
224085563|NCT01351441|OTHER|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
224085564|NCT01351441|OTHER|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
224085565|NCT01351441|BEHAVIORAL|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
223529316|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
223529317|NCT00415636|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
223529318|NCT01895192|OTHER|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
223529319|NCT06458569|OTHER|Rehabilitation|3-weeks rehabilitation in hospital
223529320|NCT03369808|BIOLOGICAL|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
223529321|NCT03369808|BIOLOGICAL|Phosphate Buffer Solution|0.5ml phosphate buffer solution
223529322|NCT03369808|BIOLOGICAL|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
223529323|NCT03369808|BIOLOGICAL|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
223911122|NCT06560879|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production.The most common form is used in vitamin supplements or tablets
223911123|NCT06152614|BEHAVIORAL|Enhanced Usual Care (EUC)|Enhanced Usual Care (EUC) includes 5 weeks of hypertension classes.
224085566|NCT05837741|DIETARY_SUPPLEMENT|Standard hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement
224085567|NCT05837741|DIETARY_SUPPLEMENT|Leucine-enriched hypercaloric hyperproteic oral nutritional supplement|Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
224085568|NCT00002969|DRUG|paclitaxel|
224085569|NCT00323999|PROCEDURE|Hysteroscopic resection of fibroids, polyps and endometrium.|
224085570|NCT02917460|GENETIC|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
224085571|NCT01858233|BEHAVIORAL|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
224277546|NCT04244799|BEHAVIORAL|Behavioral nudges|"Behavioral nudges include the following:~1. Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~2. Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~3. Sticker of a pair of eyes placed above the handwashing station~4. Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap"
223529324|NCT03369808|BIOLOGICAL|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
223529325|NCT03014635|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
223911124|NCT06152614|BEHAVIORAL|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+)|Food Delivery and Cooking PLUS Aerobic Training (FoRKS+) includes 5 weeks of hypertension classes followed by 11 weeks of home-delivered Mediterranean-style ingredient kits and virtual cooking classes, and an additional 12 weeks of aerobic exercise.
223911125|NCT05372822|PROCEDURE|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
223911126|NCT05372822|PROCEDURE|Sham spinal cord stimulation|No spinal cord stimulation is provided
223911127|NCT05372822|DEVICE|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead"
223911128|NCT05069896|DRUG|Mirikizumab Prefilled Syringe|Administered SC by prefilled syringe
224085572|NCT00536172|DRUG|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
223529326|NCT03014635|BIOLOGICAL|Placebos|Intramuscular injection
223911129|NCT05069896|DRUG|Mirikizumab Autoinjector|Administered SC by autoinjector
223911130|NCT06444698|DIETARY_SUPPLEMENT|cookies that contain 50 grams of quinoa|250 grams of ground quinoa will be mixed with 250 grams of ready-to-use cookie flour and 100 gram of butter, one egg, and 75 gram of chocolate chips will be added. After mixing, the ingredients will be divided into (10) cookies (each cookie will continue 25 grams of quinoa) and bake them in oven for 9-11 mint at 190 °C. The placebo control group will receive cookies that continue the same ingredient but without quinoa and the cookies will look like the experimental group cookies. Cookies delivery will be every 3 to 4 days for each participants.
224085573|NCT00536172|DRUG|Placebo|Placebo distribution matches the active medication.
224085574|NCT03417271|DEVICE|Deep brain stimulation|The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
224085575|NCT01726088|DRUG|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
224085576|NCT04338490|DEVICE|Feedback mannequim|The intervention group received rcp training with their performance being evaluated in real time so that they could correct themselves
224085577|NCT05863715|BEHAVIORAL|Visual Search Cue Type|Participants receive a target color cue (positive), a distractor color cue (negative), or a neutral non-informative cue prior to visual search.
224277547|NCT04244799|BEHAVIORAL|National WASH policy|"The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion."
224277548|NCT03331159|DEVICE|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
224277549|NCT03331159|DEVICE|Homologous Bone|Cage was filled with homologous bone
224277550|NCT04868565|DRUG|Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]|"after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight."
224277551|NCT03301792|BEHAVIORAL|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
224277552|NCT06227429|DRUG|Nitisinone|According to prescription
224277553|NCT05589337|BEHAVIORAL|Baduanjin|The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.
224277554|NCT05589337|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
224277555|NCT06829784|DRUG|TQC2731 injection|TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
224277556|NCT06829784|DRUG|Placebo|Placebo without drug substance.
224277557|NCT05914506|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level
224085578|NCT00212043|DRUG|carboplatin and gemcitabine|
223529327|NCT01910454|BEHAVIORAL|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
223911131|NCT06444698|DIETARY_SUPPLEMENT|cookies without quinoa|The placebo control group will receive cookies that continue the same ingredient of experimental group but without quinoa and the cookies will look like the experimental group cookies.
223911132|NCT04068831|DRUG|Talazoparib|1 mg talazoparib daily
223911133|NCT04068831|DRUG|Avelumab|800 mg avelumab every 2 weeks
223911134|NCT06274944|DEVICE|nasogastric tube placement pH confirmation device|Each participation will get the contents tested by the novel device and the standard of care procedure.
223911135|NCT02793999|DEVICE|Near-Infrared Spectroscopy (NIRS)|
223911136|NCT04288128|PROCEDURE|Lumbar puncture|Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
223911137|NCT04288128|OTHER|Magnetic Resonance Imaging (MRI)|Each participant will undergo scanning at 3 visits (M0, M6 and M12)
224085579|NCT04139122|DRUG|SJP-0132|SJP-0132 is administered as an eye drop
224085580|NCT04139122|DRUG|Placebo|Placebo is administered as an eye drop
224085581|NCT04009928|DEVICE|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
224085582|NCT04009928|DEVICE|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
224085583|NCT04121845|DEVICE|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
223529328|NCT01910454|BEHAVIORAL|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
223529329|NCT01179373|DEVICE|TMS, H coil|TMS, H Coil, High/ Low Frequency
223911138|NCT04999423|DEVICE|LVIS EVO and HydroCoil Embolic System|Stent assisted Coiling
223911139|NCT05791864|GENETIC|TTX-381|One time subretinal dose in study eye
223911140|NCT04820322|OTHER|Fibersym|RS4-type resistant modified wheat starch
223911141|NCT04820322|OTHER|Control cookie|control cookie
224085584|NCT04121845|OTHER|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
223529330|NCT01690273|OTHER|mobility exercise|30 minutes, twice a week
223911142|NCT05677802|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223911143|NCT05677802|OTHER|Medical Chart Review|Undergo medical cart review
223911144|NCT05677802|PROCEDURE|Stress Management Therapy|Receive biobehavioral stress reduction intervention
223911145|NCT05677802|OTHER|Survey Administration|Ancillary studies
223911146|NCT04939649|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.
223911147|NCT04939649|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
223911148|NCT06779032|DIAGNOSTIC_TEST|blood draw|PCR method to see leucocyte telomere length
223911149|NCT06779032|DIAGNOSTIC_TEST|blood draw|PCR method to see p16
223911150|NCT06054971|OTHER|Remote Administration of NSAA|Remote Administration of NSAA
224085585|NCT01424735|DRUG|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
224085586|NCT03568877|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
224085587|NCT03568877|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
224085588|NCT01474694|OTHER|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
224085589|NCT03162848|BEHAVIORAL|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
224085590|NCT00372879|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 800IU bid
224085591|NCT00434525|PROCEDURE|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
224085592|NCT00434525|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy
224085593|NCT04126824|DRUG|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
223911151|NCT04758390|BEHAVIORAL|IMARA (intervention group)|The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
223911152|NCT04758390|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
223911153|NCT05472259|DRUG|Nanoliposomal irinotecan|In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
223911154|NCT05472259|DRUG|5 FU|In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
223911155|NCT05472259|DRUG|Leucovorin|In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
223911156|NCT05472259|DRUG|Oxaliplatin|Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
223911157|NCT03759522|DRUG|DPA-714 PET/MRI|DPA-714 PET/MRI
223911158|NCT05395871|BEHAVIORAL|Behavioural Message|Messaging involving increased salience, increasing positive emotions and information on health consequences
223911159|NCT05395871|BEHAVIORAL|Behavioural Message + Video|Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.
223911160|NCT05395871|OTHER|Usual Care Message|Standard usual care message involving link to non-behavioural science informed video
223911161|NCT06777693|BEHAVIORAL|Unified Protocol|"The Unified Protocol group format involves 12 sessions focusing on goal setting and motivation, understanding emotions, mindful emotion awareness, cognitive flexibility, countering emotionat behaviours, understanding and confronting physical sensations, emotion exposure and relapse prevention.~The UP model directly approaches the patient\&#39;s emotion regulation by focusing on cognitive flexibility, exposure exercises, mindful awareness, acceptance, and other evidence-based therapeutic approaches known from cognitive-behavioural therapy (CBT), emotion-focused therapy (EFT) and mindfulness-based interventions."
223911162|NCT06779097|DRUG|Vunakizumab (IL-17A inhibitor)|Vunakizumab (IL-17A inhibitor)
223911163|NCT00323856|DRUG|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
224085594|NCT04126824|DRUG|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
224085595|NCT04126824|OTHER|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
224085596|NCT04863963|PROCEDURE|Milligan Morgan|Surgical intervention used in case of Goligher's grade III hemorrhoidal disease
224085597|NCT05779163|DRUG|LBL-033 for Injection|Initial dose - MTD; Q2W; intravenous infusion
224085598|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
224085599|NCT01273441|DRUG|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
224085600|NCT03691415|DRUG|BELKYRA Inj.|Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
224085601|NCT00634231|BIOLOGICAL|AdV-tk|
223529331|NCT01690273|OTHER|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
223911164|NCT06071832|OTHER|Instructions for family Zoom session|Within both play and reading conditions, we will manipulate the method of enacting the structured activities with the goal of facilitating different types of grandparent-initiated joint attention.
223911165|NCT06100731|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (FC6, 10-10 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/ out at the beginning and end of the 15-minutes of stimulation over the course of 15 seconds.
224085602|NCT00634231|DRUG|valacyclovir|
224085603|NCT00634231|RADIATION|Radiation|
224085604|NCT02644408|DRUG|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
224085605|NCT02644408|RADIATION|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
224085606|NCT02644408|OTHER|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
224085607|NCT05373238|PROCEDURE|Early discharge|Early discharge
224085608|NCT02351232|DRUG|Liraglutide|
224085609|NCT02351232|DRUG|Placebo|
223529332|NCT02683902|DEVICE|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
223911166|NCT06032455|BEHAVIORAL|Multisystemic therapy|Multisystemic Therapy (MST) is an intensive, evidence-based treatment aimed at preventing out-of-home placement of adolescents with severe behavioural problems. The intervention is home-based and focuses not only on the adolescent, but also on the various systems surrounding the adolescent, such as the family, neighbourhood, school, and friends. MST helps parents increase their parenting competencies such as parental monitoring and find (more) social support in their environment. MST also helps adolescents improve their relationship with their parents, school participation, and social activities, and promotes contact with pro-social peers. These goals are achieved by working together with key figures in the family's environment. MST treatment duration is three to five months. In MST, a family can contact a therapist 24/7.
223911167|NCT06032455|BEHAVIORAL|Multisystemic therapy - intellectual disabilities|Multisystemic therapy - intellectual disabilities (MST-ID) is a specialisation of standard MST (see above), tailored to the needs and skill deficits of families in which the adolescent and/or parent(s) has/have a known or suspected ID. In MST-ID, among others, simplified language and visual support are used, and extra attention is paid to the generalisation of what has been learned in the treatment sessions.
223911168|NCT06634355|DRUG|Sugammadex|In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
223911169|NCT03156465|DEVICE|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
224085610|NCT01693172|BEHAVIORAL|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
224085611|NCT01023984|PROCEDURE|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
224085612|NCT01023984|PROCEDURE|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
224085613|NCT01772667|PROCEDURE|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
224085614|NCT04855994|PROCEDURE|paravertebral block|The investigators performed Paravertebral block to that patient group for postoperative analgesia
224085615|NCT04855994|PROCEDURE|pectoral block|The investigators performed pectoral block to that patient group for postoperative analgesia
224085616|NCT03729882|PROCEDURE|EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.
224085617|NCT03729882|PROCEDURE|Non EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
224085618|NCT04289896|OTHER|Plyometric exercise|"The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions."
224085619|NCT03773302|DRUG|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
224277558|NCT05375669|DEVICE|ISIS IOM System|"The constant-current TES stimulators will be used in this study with a high-precision oscilloscope. The calibration will assess 5-pulse trains with a 4 ms ISI and 100 mA output across a 1000 Ω resistor at 250, 500, and 1000 µs D. Measurements will include actual I and D of each pulse, and actual ISI.~Total intravenous anesthesia (TIVA), surgery and TES MEP monitoring will proceed routinely without modification and normally involves acquiring many MEPs over several hours. The only departure from standard care will be the placement of two small accelerometers and a brief MEP sequence before skin incision to determine chronaxie and compare the effect of an equivalent increase of I or D on MEP amplitude and movement."
224277559|NCT06467825|DRUG|Potassium Supplement|Participants will be given a potassium supplement that will help prevent low blood potassium levels.
224277560|NCT06467825|DRUG|Furosemide 20 MG|Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.
224277561|NCT06467825|DEVICE|Compression Garment|From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.
224277562|NCT05108883|DEVICE|MR-proADM KRYPTOR|MR-proADM ≤ 0.87 nmol/L together with routine clinical evaluation identifies patients with low disease severity who do not need to be hospitalized
224277563|NCT06528756|PROCEDURE|shockwave therapy|ESWT, these will be given using a 15 mm transmitter in mode continuous with pressure at 3 bar, frequency 12Hz and 3000 impacts. The number of sessions will be between 4 - 8 depending on the patient's clinic with a break between sessions of 5 to 10 days.
224277564|NCT06528756|PROCEDURE|Barbotage|"US-PICT will be carried out with 1 session in which the following actions will be carried out:~* First, a suprascapular nerve block will be performed with a corticosteroid and anesthetic (3 ml of bupivacaine) in an ultrasound-guided manner.~* The calcification will then be infiltrated with 5 ml local lidocaine and preloaded physiological saline solution in an ultrasound-guided manner.~* Finally, repeated suctions will be performed with physiological saline solution to extract calcium in an ultrasound-guided way."
223529333|NCT02683902|BEHAVIORAL|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
223911170|NCT04691804|DRUG|Fuzuloparib , Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg) 1000mg Qd,po~3. Prednisone tablets (strength: 5 mg) 5mg, Bid po"
223911171|NCT04691804|DRUG|Fuzuloparib Placebo， Abiraterone acetate and Prednisone|"1. Fuzuloparib capsules Placebo (strength: 50 mg),150mg, Bid,po~2. Abiraterone acetate tablets (strength: 250 mg)1000mg Qd,po~3. Prednisone tablets (strength: 5 mg)5mg, Bid po"
223911172|NCT06587737|DRUG|Colchicine 0.5 MG|colchicine 0.5mg once-daily
223911173|NCT06587737|DRUG|Placebo|matching placebo, lacking active ingredient, once-daily
223911174|NCT05615675|OTHER|Virtual Reality Headset|Patient uses a virtual reality headset and support during prone pain procedure
223911175|NCT04116528|DRUG|Ketamine|0.5mg/kg
223911176|NCT04116528|DRUG|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
223911177|NCT04116528|DRUG|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
223911178|NCT04116203|DRUG|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
224085620|NCT03773302|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
224085621|NCT03773302|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
224085622|NCT05202145|DRUG|ALXN2050|Oral tablet.
224085623|NCT05202145|DRUG|Cyclosporine|Oral capsule.
224085624|NCT05202145|DRUG|Tacrolimus|Oral capsule.
224085625|NCT05202145|DRUG|MMF|Oral tablet.
224085626|NCT04747015|DRUG|Oxytocin|Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation
224085627|NCT04747015|DRUG|Oxytocin|5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
224085628|NCT04747015|PROCEDURE|cervical traction|sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus. Meanwhile (CCT ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end
223911179|NCT04116203|COMBINATION_PRODUCT|Fish Oil and Metformin|Combo of 2 other arms
224085629|NCT06312891|DRUG|Ivabradine|heart rate lowering therapy
224085630|NCT00330187|DRUG|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
223911180|NCT04116203|DIETARY_SUPPLEMENT|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
223911181|NCT02420977|DRUG|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~* Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
223911182|NCT03420339|DRUG|Stimulant|The stimulants used must meet FDA dosage guidelines for age.
223911183|NCT05423522|DRUG|NanoLithium® NP03|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
223911184|NCT05423522|DRUG|Placebo|One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
223911185|NCT06480734|OTHER|symptom-based scoring system (symptom-questionnaire, paper version)|The patients are asked to complete a paper-based questionnaire (symptom-based scoring system, paper version) once a week during and up to 24 weeks following radiotherapy. The patients state and score symptoms potentially associated with pneumonitis, namely cough, shortness of breath and fever. Scoring points are assigned to severity of the symptoms, and sum scores are used to identify pneumonitis. During the radiotherapy course, patients complete the questionnaire prior to regular appointments with a physician. Following radiotherapy, they are contacted by phone (to minimize the number of hospital visits) once a week for completion of the questionnaire. In case of an increase of the total score when compared to baseline, patients receive a follow-up phone call after 3 days, are asked to come to the hospital as outpatients or are admitted to hospital.
223911186|NCT06543810|OTHER|Hula for Parkinson's|A feasibility study for a Hula program for Parkinson's Disease patients.
223911187|NCT05603650|OTHER|Lumineux Oral Essentials rinse|mouthrinse
223911188|NCT05603650|OTHER|Listerine rinse|mouthrinse
224085631|NCT00330187|BEHAVIORAL|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
224085632|NCT00330187|OTHER|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
224085633|NCT03258814|BEHAVIORAL|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
224085634|NCT03258814|BEHAVIORAL|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
224085635|NCT04805086|BIOLOGICAL|MON002|Autologous monocytes
224085636|NCT00271388|DEVICE|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
224085637|NCT01413958|DRUG|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
223911189|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas (BP) with Aspart or Lispro|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.
223911190|NCT04200313|COMBINATION_PRODUCT|Bionic Pancreas with Fiasp (BPFiasp)|iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.
224085638|NCT01413958|DRUG|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
224085639|NCT01413958|DRUG|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
224085640|NCT02817672|BEHAVIORAL|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
224085641|NCT02817672|BEHAVIORAL|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
224085642|NCT05603429|DIAGNOSTIC_TEST|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status|Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
224085643|NCT01900002|OTHER|Laboratory Biomarker Analysis|Correlative studies
224085644|NCT01900002|OTHER|Quality-of-Life Assessment|Ancillary studies
224085645|NCT01900002|DRUG|Sorafenib|Given PO
224085646|NCT01900002|DRUG|Sorafenib Tosylate|Given PO
224085647|NCT01900002|RADIATION|Yttrium Y 90 Glass Microspheres|Given IA
224085648|NCT00754156|DEVICE|ABRA Abdominal Closure System|ABRA Abdominal Closure System
224085649|NCT00754156|DEVICE|V.A.C. Therapy|V.A.C. Therapy Alone
224085650|NCT00754156|DEVICE|KCI ABThera|KCI ABThera
224085651|NCT04475328|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.
224085652|NCT04475328|DRUG|Placebo of AngongNiuhuang pill|This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.
224085653|NCT04475328|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke
224085654|NCT03262415|DEVICE|LabPatch Continuous Glucose Monitoring (CGM)|"1. The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~2. The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm \[0.618\] x 15.7 mm \[0.618\]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~3. A wire that connects the chip to a laptop that continuously captures glucose data."
224085655|NCT04869800|DRUG|CKD-398|Test Drug
223911191|NCT04200313|OTHER|Usual Care (UC)|Using pre-study insulin regimen with the Dexcom G6 CGM
223911192|NCT04200313|OTHER|BP Guidance Insulin Dosing|Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
223911193|NCT06246188|DIAGNOSTIC_TEST|Cardiac MRI using Regadenoson and GE-267|Performing stress-cardiac MRI for clinical diagnostic in adult patients with suspected coronary artery disease
224085656|NCT04869800|DRUG|CKD-501, D745|Reference Drug
224085657|NCT06151561|DRUG|AGN-151586|Intramuscular Injection
224085658|NCT06151561|DRUG|Placebo|Intramuscular Injection
224085659|NCT01751971|DRUG|Inspired oxygen (40%)|Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
224085660|NCT01751971|OTHER|Sham|Medical air with 21% oxygen via venturi mask (15 L/min).
224085661|NCT00453401|DRUG|NB-001|
224085662|NCT04881123|DRUG|SER150|Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
224085663|NCT04881123|DRUG|Placebo|Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)
224085664|NCT06177366|DIAGNOSTIC_TEST|Blood sampling|Blood samples will be collected at diagnosis, in the same time as BOM is performed
224085665|NCT03382509|DRUG|[14C]BI 1467335|Once Daily
224085666|NCT03382509|DRUG|BI 1467335|Twice Daily
224085667|NCT00167258|BEHAVIORAL|Voucher Reinforcement|
224085668|NCT00167258|BEHAVIORAL|Extra Counseling Services|
224085669|NCT00167258|BEHAVIORAL|Voucher Reinforcement + Extra Counseling Services|
224085670|NCT06002503|DRUG|Venezuelan Equine Encephalitis DNA Vaccine|Venezuelan Equine Encephalitis DNA Vaccine Candidate
224085671|NCT06002503|DEVICE|PharmaJet Stratis Needle-free Injection System|Intramuscular Needle-free Injection System (Jet Injector)
224085672|NCT06002503|DEVICE|PharmaJet Tropis Needle-free Injection System|Intradermal Needle-free Injection System (Jet Injector)
224085673|NCT01974609|DRUG|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
224085674|NCT01974609|DRUG|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
224085675|NCT02022449|BEHAVIORAL|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
224099246|NCT05862363|BEHAVIORAL|Counselling and follow-up|Normal BMI pregnant women will be counseled and followed up as per standard guidelines and will be provided routine antenatal care.
224099247|NCT06118528|DEVICE|Blur Obfuscation|Blurring is applied to the RGB images.
224099248|NCT06118528|DEVICE|Cartoon Obfuscation|Cartoonization is applied to the RGB images.
224099249|NCT06118528|DEVICE|Edge Obfuscation|A black background and simple outlines of objects/people are applied to the RGB images.
224099250|NCT06118528|DEVICE|No Obfuscation (raw)|No editing is performed on the RGB images.
224099251|NCT04259515|DRUG|Del Nido|Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
223911194|NCT05675865|DEVICE|cryoablation procedure|ablation procedure for VT using the investigational device
223911195|NCT05091112|PROCEDURE|Spinal surgery|In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.
223911196|NCT05091112|OTHER|Histology|The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
223911197|NCT06605157|BEHAVIORAL|AMUSED|Delivered live by a board-certified music therapist (MT-BC) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. A Multimodal mUSic therapy intervention for Engaging persons with severe Dementia (AMUSED) uses live participant-preferred music and progressively layers singing, touch, and rhythmic instrument playing concurrent with participant behavioral responses. Follows the Clinical Practice Model for Persons with Dementia and implementation strategies that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. Each small group works with the same music therapist throughout the study.
224085676|NCT02606578|OTHER|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.~At your clinical follow-up visits (\~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.~You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
224085677|NCT04749069|DIAGNOSTIC_TEST|Comparison of pain intensity rating scale|Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
224085678|NCT03921996|PROCEDURE|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
224085679|NCT03921996|PROCEDURE|Radical prostatectomy (RP) only|Radical prostatectomy
224085680|NCT02682680|DRUG|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
224085681|NCT02682680|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
223529334|NCT02683902|DEVICE|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
223529335|NCT04653792|DRUG|Pregabalin 75mg|75 mg capsule
223529336|NCT04653792|DEVICE|Placebo|75 mg
223529337|NCT05201807|DEVICE|Dailies Total 1 (DT1)|TEST Lens
223529338|NCT01335607|DRUG|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
224085682|NCT01332448|DRUG|Orlistat 120|Orlistat 120mg tid
224085683|NCT01332448|DRUG|Orlistat 60|Orlistat 60mg tid
224085684|NCT05772637|PROCEDURE|Repeated cystometries with bladder sensations assessment|A second cystometry will be performed to assess bladder sensations reliability. A third cystometry with cognitive task (STROOP test) at the same time will be performed to assess the impact of distractive attentional task on bladder sensations
224085685|NCT05804799|DIAGNOSTIC_TEST|Contrast-enhanced liver CT scan|"The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction."
224085686|NCT01130129|OTHER|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
224085687|NCT00206921|DEVICE|Pulsed dye laser|
224085688|NCT00206921|DEVICE|Intense pulsed light|
224277565|NCT04841915|DIETARY_SUPPLEMENT|High-Protein Diet|Diet consisting of 25E% from assigned protein during eucaloric diet and 35E% from assigned protein during hypocaloric diet
224277566|NCT04841915|BEHAVIORAL|Clinical dietician|Counselling from a clinical dietician bi-weekly until weight loss of 5% is achieved.
224085689|NCT02475889|PROCEDURE|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
224085690|NCT02475889|PROCEDURE|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
224085691|NCT01573910|DRUG|Moxifloxacin ophthalmic solution, 0.5%|
224277567|NCT04841915|BEHAVIORAL|Weight loss|4 weeks eucaloric diet \~13 MJ/day followed by, 20 weeks hypocaloric diet \~9 MJ/day until 5% weight loss is achieved.
224277568|NCT06132724|OTHER|Signal acquisition|"Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days."
224277569|NCT05478187|DEVICE|QWalk Study Group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
224085692|NCT01573910|DRUG|Ofloxacin ophthalmic solution, 0.3%|
224085693|NCT00000943|BIOLOGICAL|Tetanus Toxoid Vaccine|
224085694|NCT00000943|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
224085695|NCT00000943|BIOLOGICAL|HIV-1 Immunogen|
224085696|NCT00000943|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
224277570|NCT05478187|OTHER|Traditional visual cues - Control group|10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
224277571|NCT06384196|BEHAVIORAL|Identity-Based Transdiagnostic Therapy (IBTT)|In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.
224277572|NCT06384196|BEHAVIORAL|Unified Protocol|In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
223911198|NCT06605157|BEHAVIORAL|Reading Aloud|"Delivered live by a trained research assistant (interventionist) 40 min 2x/week for 12 weeks (24 total sessions; 16 total hours) in small groups of 3-5 people. The interventionist will read aloud from age-appropriate books (Chicken Soup for the Golden Soul by Jack Canfield; World of Wonders by Aimee Nezhukumatathil) selected to have sufficient material for all sessions, contain short stories to accommodate for attention span and session length, and offer choice. Follows implementation strategies identical to the music therapy arm (i.e., within the Clinical Practice Model for Persons with Dementia) that promote cognition, attention, familiarity, audibility, structure, autonomy per participants' strengths, interests, preferences, culture, and momentary responses. However, no music (including musical references) is used. Each small group works with the same reading interventionist throughout the study."
223911199|NCT05820490|OTHER|Whole Room Calorimeter|The indirect calorimetry system allows your oxygen / carbon dioxide exchange to be measured, thereby showing the number of calories burned.
223911200|NCT05820490|OTHER|Mixed-Meal Tolerance Test (MMTT)|The MMTT is done to measure how much body handles a mixed meal.This test shake will raise blood sugar and cause the body to produce insulin.
223911201|NCT05820490|OTHER|Core Body Temperature|Participants will be asked to swallow a core body temperature monitor prior to entering the whole room calorimeter. This monitor is used to record participants core body temperature.
223911202|NCT05820490|OTHER|Morningness-Eveningness Questionnaire|Participants will fill out a questionnaire that asks about your preference for morning or evening.
223911203|NCT05820490|PROCEDURE|Muscle Biopsy|Participants will have two skeletal muscle biopsies (one in the evening and one in the morning). This procedure is used to sample muscle cells from the right and left leg Vastus Lateralis (thigh) muscle.
223911204|NCT05820490|OTHER|Serial Blood Sampling|Participants will have blood sampled every hour for 24 hours to assess changes in circulating hormones.
223911205|NCT04380337|DRUG|FOLFOXIRI|Chemotherapy regimen of Oxaliplatin 85mg/m2 , Leucovorin 400 mg/m2 , Irinotecan 165mg/m2 , 5-Fluorouracil
223911206|NCT04380337|DRUG|FOLFOX regimen|Chemotherapy regimen of Oxaliplatin 85mg/m2, Leucovorin 400 mg/m2, 5-Fluorouracil 2400mg/m2
223911207|NCT04380337|DRUG|XELOX|Chemotherapy regimen of Oxaliplatin 130 mg/m2, Capecitabine 1000mg/m2
223911208|NCT04380337|RADIATION|IMRT|Radiotherapy (5 Gy x 5 fractions) with an additional boost fraction (5 Gy x 1 fraction) delivered sequentially
223911209|NCT06368700|DEVICE|Hyalex Knee Cartilage System|Surgical implantation of the Hyalex Knee Cartilage System
223911210|NCT05759819|DEVICE|Standard stenting|The cilostazol-coated BioMimics 3D stent on the delivery system is deployed into the target lesion.
223911211|NCT06489665|DIAGNOSTIC_TEST|Experimental Intervention|Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
223911212|NCT05516602|OTHER|Peer Support|"Peer-led support groups over the weekend will include the following activities:~* Peer leader counselling on oral PrEP and HIV risk reduction~* Peer leader discussion to dispel myths and misconceptions around oral PrEP~* Peer leader sharing of experiences of daily pill taking~* Participants sharing experiences of influencers and barriers to oral PrEP uptake and adherence followed by a discussion by group members.~* 1-2 role plays per support group session."
223911213|NCT04538378|DRUG|Olaparib|Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.
223911214|NCT04538378|DRUG|Durvalumab|Durvalumab will be administered intravenous (IV) into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.
223911215|NCT04538378|DIAGNOSTIC_TEST|EKG|Screening and all cycles Day 1 and Day 15 (+/- 3) days. One cycle is 28 days.
223911216|NCT04538378|PROCEDURE|Tumor biopsy|Baseline and all cycles Day 15 (+/- 3) days. One cycle is 28 days.
223911217|NCT04538378|DIAGNOSTIC_TEST|CT chest, abdomen and pelvis|Screening and baseline and every 8 (+/-1) weeks after start of therapy.
223911218|NCT04538378|DIAGNOSTIC_TEST|MRI chest, abdomen and pelvis|Screening and baseline and every 8 (+/-1) weeks after start of therapy.
223911219|NCT04452851|DEVICE|BREATHE|The on-demand handheld portable noninvasive positive pressure airway device unit generates BiPAP by using a built-in blower which intakes air from the nearby ambient. The BiPAP pressure functions as a virtual stent within the lungs of a user with COPD. The virtual stent opens the passageways within the user lungs. Once opened, the virtual stent facilitates gas exchange in order to relieve dyspnea. By temporarily facilitating this gas exchange, the user will quickly recover from dyspnea in order to resume regular activities.
223911220|NCT04452851|DEVICE|BiPAP|BiPAP stands for Bilevel Positive Airway Pressure, and is very similar in function and design to a CPAP machine (continuous positive airway pressure). A BiPAP machine is a non-invasive form of therapy for patients suffering from sleep apnea.
223911221|NCT04452851|DRUG|COPD Inhaler|Inhaler medication to support quick relief from COPD symptoms
223911222|NCT02676193|BEHAVIORAL|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
223911223|NCT03068689|PROCEDURE|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is \> 185mm HG the cuffs are inflated to 15 mmHG above that level.
223911224|NCT03068689|OTHER|Placebo|Placebo
223911225|NCT05534321|RADIATION|Prophylactic Radiotherapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
224085697|NCT03830216|DEVICE|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
223529339|NCT01335607|DRUG|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
224085698|NCT03830216|DEVICE|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
224085699|NCT03209219|DRUG|Interferon Alfa-2A|3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
224085700|NCT03209219|DRUG|Cyclosporine Pill|100mg， oral, bid
223716124|NCT05386810|BIOLOGICAL|IPV control vaccine|Inactivated Poliovirus Vaccine - control vaccine produced by Sanofi. Inactivated poliovirus antigens: Mahoney strain for type 1 (40DU), MEF-1 strain for type 2 (8DU), Saukett strains for type 3 (32DU) in 0.5 ml mixture of 2- phenoxyethanol,ethanol,formaldehyde,hanks199 medium (containing amino acids, mineral salts, vitamins, glucose, polysorbate 80 and water for injection),hydrochloric acid or sodium hydroxide (for pH value adjustment),trace amounts of antibiotics (neomycin, streptomycin and polymyxin B)for per injection.
223911226|NCT05534321|DRUG|Standard of care systemic therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
224085701|NCT05888974|DIAGNOSTIC_TEST|Cardiac ultrasonography|During the inclusion visit, the patient will receive 3 cardiac ultrasonography. The first one will be performed at the time of the initiation of the 500mL vascular filling (T0), without delaying and the second one after the end of the filling (Tfin). These first two ultrasound are part of standard practice. A third will be performed 20 minutes after the end of the vascular filling (Tfin+20).
224085702|NCT00899340|GENETIC|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
224277573|NCT02370199|DEVICE|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
223911227|NCT03193333|DRUG|PRO-122|Posology: 1 drop every 12 hours for 90 days
224277574|NCT02370199|DRUG|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
224277575|NCT05269316|DRUG|IMP9064|IMP9064 Monotherapy administered for 21 days
224277576|NCT00646763|DRUG|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
223911228|NCT03193333|DRUG|Timolol eye drops|1 drop every 12 hours for 90 days
223911229|NCT03193333|DRUG|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
223911230|NCT03193333|DRUG|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
223911231|NCT03193333|OTHER|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
224085703|NCT00899340|GENETIC|microarray analysis|microarray analysis
224085704|NCT00899340|GENETIC|protein expression analysis|protein expression analysis
224085705|NCT00899340|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
224085706|NCT00899340|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
224085707|NCT06355882|PROCEDURE|Anesthetic infiltration|Application of local dental anesthesia with two cartridges (3,6 mL) for dental procedures (tooth extraction or periodontal treatment) in patients with low cardiac output syndrome.
224085708|NCT01649947|DRUG|Paclitaxel|"Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)"
224277577|NCT00646763|DRUG|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
224277578|NCT05053568|DEVICE|CARTBox|CARTBox performs analysis of cardiac MRI scans. The result is a treatment file that displays optimal targets for left ventricular lead implantation in CRT. This file will be used as an overlay with live fluoroscopy during the implantation procedure in the intervention group.
224277579|NCT03977194|DRUG|Carboplatin|AUC 6 every 4 weeks
224277580|NCT03977194|DRUG|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
224277581|NCT03977194|DRUG|Atezolizumab|1200 mg every 3 weeks
224277582|NCT04467333|OTHER|All lung cancer patients.|There will be no specific interventions. All patients will receive guidelines based therapy of lung cancer and their comorbidities.
224277583|NCT01104181|DEVICE|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
223911232|NCT03193333|OTHER|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
223911233|NCT03193333|DRUG|Krytantek|Posology: 1 drop every 12 hours for 90 days
224085709|NCT01649947|DRUG|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
223911234|NCT06099093|DRUG|18F-DCFPyl|Fluorine-labeled small molecule, via intravenous infusion per protocol.
223911235|NCT06778967|DRUG|GZR18|Administered SC
223911236|NCT06778967|DRUG|semaglutide|Administered SC
223911237|NCT04444518|BEHAVIORAL|VAX-MOM Intervention|The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
223911238|NCT04444518|BEHAVIORAL|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
223911239|NCT04580914|DEVICE|Treatment with IntellaNav StablePoint Ablation Catheter|Patients will be treated with an ablation catheter
223911240|NCT03580356|BIOLOGICAL|Ligelizumab|Liquid in vial
223911241|NCT03580356|BIOLOGICAL|Omalizumab|Lyophilized powder for solution in vial
223911242|NCT03580356|OTHER|Placebo|Liquid in vial
223911243|NCT01540994|RADIATION|Radiation Therapy|Stereotactic Body Radiation Therapy
223911244|NCT03793023|DRUG|Teneligliptin 20mg|
223911245|NCT05709288|DRUG|BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of an hyper active human factor IX mutant(FIX Padua) transgene in liver. The dose of BBM-H901 is 5x10'12 vg/Kg.
223911246|NCT04598932|DEVICE|Brillouin microscopy|The Brillouin clinical instrument is comprised of three parts: a human interface, a laser-scanning confocal microscope, and an etalon-based spectrometer. The human interface is a modified ophthalmic slit-lamp instrument with chin support and headrest. The light source is a single longitudinal mode CW laser at 780 nm. A polarizing beam splitter and quarter-wave plate assembly sends the laser beam to the human interface. To focus light into the eye, a long-working distance microscope objective is used. Brillouin scattered light from the eye is collected with a single-mode optical fiber. For spectral analysis, a two-stage VIPA-etalon spectrometer configured with the cross-axis cascade principle and the spectrum is measured on a EM-CCD camera.
223911247|NCT05715528|DRUG|Obeldesivir|Tablet administered orally without regard to food.
223911248|NCT05715528|DRUG|Obeldesivir Placebo|Tablet administered orally without regard to food.
223911249|NCT06257901|OTHER|Interviews/Focus groups/Participatory workshops|Qualitative study (no intervention delivered)
223911250|NCT06091657|DRUG|Ketamine Hydrochloride|intravenous injection
223911251|NCT04689204|DRUG|CTA30X|CTA30X cell injection by intravenous infusion
223911252|NCT05285202|OTHER|Active TB case finding with linkage to preventive therapy (ACF/TPT)|ACF/TPT in both intervention arms will consist of TB screening by mobile chest X-ray (with artificial intelligence-based reading, followed by confirmatory sputum testing with Xpert MTB/RIF Ultra for participants with abnormal x-rays), and linkage to preventive therapy for those who are TB-negative and eligible for TPT (limited in April 2024 to those with close TB contact or known HIV infection).
224085710|NCT01649947|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
223529340|NCT02857972|DEVICE|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
223529341|NCT00005978|BIOLOGICAL|filgrastim|
223529342|NCT00005978|DRUG|carboplatin|
223529343|NCT00005978|DRUG|etoposide|
223529344|NCT00005978|DRUG|melphalan|
223529345|NCT00005978|PROCEDURE|autologous bone marrow transplantation|
223529346|NCT00005978|PROCEDURE|peripheral blood stem cell transplantation|
223529347|NCT00005978|RADIATION|iobenguane I 131|
223529348|NCT00005978|RADIATION|radiation therapy|
223911253|NCT03944772|DRUG|Osimertinib|Osimertinib given orally at 80 mg once daily
223911254|NCT03944772|DRUG|Savolitinib|Savolitinib will be given orally at 300 mg or 600mg once daily
223911255|NCT03944772|DRUG|Gefitinib|Gefitinib given orally at 250 mg once daily
223911256|NCT03944772|DRUG|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
223911257|NCT03944772|DRUG|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
223911258|NCT03944772|DRUG|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
224085711|NCT01649947|DRUG|Bevacizumab|"Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles."
224085712|NCT03295214|DRUG|Acetaminophen|Acetaminophen given for pain relief
224085713|NCT00124280|DRUG|RAD001|
224085714|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
224085715|NCT00364182|DRUG|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
224277584|NCT00674908|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
224277585|NCT00674908|BIOLOGICAL|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
224277586|NCT02046863|DEVICE|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
224277587|NCT03328390|OTHER|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
224277588|NCT03328390|OTHER|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
224277589|NCT01790308|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
224277590|NCT01790308|DRUG|Liraglutide|CSII for 2\~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
224277591|NCT00835796|DRUG|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
224277592|NCT00835796|DRUG|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
223911259|NCT03944772|DRUG|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
223911260|NCT03944772|DRUG|Alectinib|Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
223911261|NCT03944772|DRUG|Selpercatinib|Selpercatinib given orally at 160mg twice daily
223911262|NCT03944772|DRUG|Selumetinib|Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
223911263|NCT03944772|DRUG|Etoposide|Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
223911264|NCT03944772|DRUG|Cisplatin|Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
223911265|NCT03944772|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
223911266|NCT06574438|BEHAVIORAL|AIFIGA program|receives the Artificial Intelligence Family Involvement Generative Agent (AIFIGA) program and uses it for 3 months
223911267|NCT06002750|OTHER|disease|Do you have dermatomyositis
224085716|NCT05123235|BEHAVIORAL|Physical Activity|the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
224085717|NCT01920802|DRUG|olanzapine|5mg BID up to 4 weeks
224085718|NCT01920802|DRUG|iloperidone|6 mg BID up to 4 weeks
224085719|NCT01920802|DRUG|Placebo|BID up to 4 weeks
224085720|NCT00905957|PROCEDURE|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
224085721|NCT00905957|PROCEDURE|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
224085722|NCT01286493|BIOLOGICAL|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
223911268|NCT06828094|DIETARY_SUPPLEMENT|enteral nutrition|Nutritionally complete liquid diet used in the study to replace all (exclusive enteral nutrition) or half (partial enteral nutrition) of a participants daily energy intake
223911269|NCT06461169|OTHER|stress ball|Patients squeeze the stress ball
224085723|NCT05535647|DRUG|Regorafenib and HAIC|Regorafenib: oral 80mg/day, D1-21, Q28d; HAIC with FOLFOX: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
224085724|NCT05535647|DRUG|FOLFOX|Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
224085725|NCT05086042|DIAGNOSTIC_TEST|Ultrasonography, Magnetic resonance imaging|The cross-sectional area of the median nerve was measured with US and MRI.
224085726|NCT02591264|OTHER|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
223911270|NCT06111768|DRUG|Dapagliflozin|Receipt of 10mg oral dose of dapagliflozin once daily for three days
223911271|NCT04742608|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223911272|NCT04742608|OTHER|Electronic Health Record Review|Medical charts are reviewed
223911273|NCT06593587|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine 120 mcg
224085727|NCT00616135|PROCEDURE|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
224085728|NCT03284450|OTHER|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
224085729|NCT03284450|OTHER|SSRS|The SSRS (Howatson \& Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
223529349|NCT04695990|DRUG|Wenyang Huoxue Decoction|Wenyang Huoxue granules
223911274|NCT06593587|OTHER|Placebo|Placebo
223911275|NCT03536884|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223911276|NCT03536884|DRUG|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
223911277|NCT03536884|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
223911278|NCT06103474|DIAGNOSTIC_TEST|Lumbar Magnetic Resonance Imaging (MRI)|Lumbar Magnetic Resonance Imaging (MRI)
223911279|NCT06826950|OTHER|comprehensive pharmaceutical care|The intervention group received comprehensive pharmaceutical care in addition to standard care. For first-cycle patients, oncology pharmacists conducted patient education, informing them about potential chemotherapy-induced adverse reactions and corresponding management strategies. Patients were instructed on the proper use of antiemetic medications, the recommended frequency of blood routine tests, and the appropriate timing, dosing, and administration of granulocyte colony-stimulating factor (G-CSF) and thrombopoietic agents. A QR code for oncology pharmacist consultation was provided to enable patients to seek advice on medication-related issues encountered outside the hospital.
223911280|NCT06826950|OTHER|Routine pharmaceutical services|The control group received standard care: After the doctor issues the chemotherapy order, the oncology pharmacist only reviews the order to ensure that the chemotherapy regimen and pretreatment regimen during the study are consistent with those of the experimental group. No other interventions are performed.
224085730|NCT06072014|OTHER|Virtual reality|A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia
224085731|NCT04244370|DEVICE|Caterpillar™ Arterial Embolization Device|Placement of the Caterpillar™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
224085732|NCT00135629|BIOLOGICAL|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).|Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).
224085733|NCT00135629|OTHER|Placebo Injection|Placebo Injection
224085734|NCT00135629|PROCEDURE|Venepuncture: 100ml blood sample taken on 12 separate visits|Venepuncture: 100ml blood sample taken on 12 separate visits
224085735|NCT00002948|BIOLOGICAL|filgrastim|
224085736|NCT00002948|DRUG|topotecan hydrochloride|
224085737|NCT00002948|PROCEDURE|bone marrow ablation with stem cell support|
224085738|NCT00002948|PROCEDURE|peripheral blood stem cell transplantation|
224085739|NCT01470677|DRUG|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
223911281|NCT05364788|OTHER|Retrospective tissue sample analysis|Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
223911282|NCT05937308|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
223911283|NCT03224936|DEVICE|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
223911284|NCT04204863|OTHER|collection of patient data|Extract data from the digital medical records, the electroencephalographic and microbiologic database.
223911285|NCT06630897|OTHER|Text Messages|small amounts of digital support will be in the form of text messages
223911286|NCT03489434|BEHAVIORAL|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
223911287|NCT06827210|DEVICE|Optilume DCB|Optilume DCB is a drug-coated balloon catheter designed for the treatment of bulbar urethral strictures. It combines mechanical dilation with localized drug delivery to reduce stricture recurrence and promote urethral healing. The balloon is coated with paclitaxel, an antiproliferative agent, to minimize scar tissue formation and improve treatment outcomes.
223911288|NCT06827210|PROCEDURE|Standard Direct Visual Internal Urethrotomy (DVIU)|Standard Direct Visual Internal Urethrotomy (DVIU), also known as Sachse Internal Urethrotomy, is a minimally invasive endoscopic procedure for treating urethral strictures.
223911289|NCT04931849|DRUG|Avatrombopag|Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
223911290|NCT04667468|BIOLOGICAL|Cold Stored Platelets (CSP)|early infusion of urgent release CSP
223911291|NCT04667468|BIOLOGICAL|Standard Care|standard care including blood and blood component therapy
223911292|NCT03643510|DRUG|Fulvestrant|Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
223911293|NCT03643510|DRUG|Abemaciclib|Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
223911294|NCT05316181|PROCEDURE|HIPEC|HIPEC perfusion, doxorubicin 35mg/m2 \& mitomycin 15 mg/m2, 41.5'C, 90 min.
223911295|NCT05488548|DRUG|EP31670|EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.
223911296|NCT05205486|DRUG|Cefazolin 3gm for Injection USP and Dextrose Injection USP|Cefazolin 3gm for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur once as a 30 minute IV infusion prior to surgery in adult subjects weighing \>/= 120 kg
223911297|NCT06465121|PROCEDURE|peripheral intravenous catheterization performed with ultrasound guidance by a trained nurse|Intravenous catheterization using ultrasound-guidance to allow real-time visualization of target veins in pediatric patients with difficult intravenous access
223911298|NCT06414356|DRUG|Ketamine|Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)
223911299|NCT06414356|DRUG|Magnesium sulfate|Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.
223911300|NCT06414356|DRUG|Ketamine + Magnesium sulfate|Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)
224085740|NCT02905734|DRUG|Nicotine patch|Single administration of an active treatment (nicotine patch)
224085741|NCT02905734|OTHER|placebo patch|Single administration of a placebo treatment
223911301|NCT04250857|DEVICE|HeartStart FRX|Automated External Defibrillator
223911302|NCT06008353|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
223911303|NCT04361487|DEVICE|NOVOSTITCH PRO Meniscal Repair System|Standard of care surgery with in which the meniscus is repaired using NOVOSTITCH PRO
224085742|NCT01261559|DEVICE|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
224085743|NCT02935309|DRUG|Lenvatinib|Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
223911304|NCT05444699|DRUG|Prednisolone Sodium Phosphate|Oral suspension administered 1 mg/kg once a day for three days
223911305|NCT05444699|DRUG|Sugar syrup|Oral suspension administered the same amount in milliliters as experimental product once a day for three days
223911306|NCT05035654|DRUG|LYR-220 Design 1 (Part 1 only)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
223911307|NCT05035654|DRUG|LYR-220 Design 2 (Part 1 and Part 2)|LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
223911308|NCT05035654|DRUG|Bilateral sham procedure control (Part 2)|Bilateral sham procedure control
223911309|NCT05716373|BEHAVIORAL|pain|reiki
223911310|NCT03854500|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
223911311|NCT03854500|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
223911312|NCT05346692|OTHER|Survey Administration|Complete Survey
223911313|NCT05346692|OTHER|Interview|Complete Interview
224085744|NCT02935309|DRUG|Capecitabine|Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
223911314|NCT05346692|OTHER|Text Message-Based Navigation Intervention|Complete mindfulness intervention
223911315|NCT05346692|OTHER|Interview|Complete interview
223911316|NCT05742932|DEVICE|Trauma surgery using Global D's implants.|Major or minor participants who will be treated by an trauma surgery with ORTRAUTEK® or MINITEK/MICROTEK® implant(s).
223911317|NCT06410508|OTHER|Just Do You|"As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the Just Do You trial by Munson et al.(2022), adapted for increased suitability with our clinical population."
223911318|NCT05924074|BIOLOGICAL|Biological sampling|The procedure will consist of an additional bone marrow sample and blood sample
223911319|NCT06804993|DRUG|Transvaginal repair & botulinum toxin type A injection|100 units of lyophilized botulinum toxin type A were diluted in saline to 50 U/mL before the injections. A total of 30 units of type-A botulinum toxin was injected with a 22-G needle evenly divided in 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)
223911320|NCT06804993|PROCEDURE|Transvaginal repair & distilled water injection|A total of 30 units of distilled water was injected with a 22-G needle evenly divided into 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)
223911321|NCT04204083|DEVICE|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe.
223911322|NCT05533814|DRUG|Perampanel|Perampanel tablets.
224085745|NCT02935309|RADIATION|External Radiation Therapy (XRT)|Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
224085746|NCT03869255|PROCEDURE|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
224085747|NCT02773966|RADIATION|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
224085748|NCT02773966|RADIATION|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
224085749|NCT05700266|DRUG|Rivaroxaban|Rivaroxaban (2.5mg orally twice a day for 90 days)
224277593|NCT01388257|PROCEDURE|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
223911323|NCT02675491|DRUG|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
223911324|NCT03426904|DRUG|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
224085750|NCT05700266|DRUG|Clopidogrel|Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)
224085751|NCT05700266|DRUG|Aspirin|Aspirin (100mg once a day for 1 year)
224085752|NCT05700266|OTHER|Risk Factor Management in both arms|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
224085753|NCT03071783|DEVICE|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
224277594|NCT01388257|PROCEDURE|Simple seton drain removal|Patients are simply followed after seton drain removal.
223911325|NCT03426904|DRUG|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
223911326|NCT05877430|DRUG|CJRB-101|In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.
223911327|NCT05877430|DRUG|Pembrolizumab injection|200 mg given by intravenous (IV) infusion once every 3 weeks
223911328|NCT03785834|PROCEDURE|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
223911329|NCT04075318|BIOLOGICAL|UB-312|A synthetic peptide-based vaccine
223911330|NCT04075318|BIOLOGICAL|Placebo|Matching placebo
223911331|NCT04477291|DRUG|CG-806|CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
223911332|NCT06269861|DEVICE|patient transfer scale|patient transfer scale is a device to measure actual weight for critically ill patient who are unable to stand
224085754|NCT04772248|DRUG|Tofacitinib|First eligible prescription for treating rheumatoid arthritis (RA)
224085755|NCT04772248|DRUG|TNF Inhibitor|First eligible prescription for treating rheumatoid arthritis (RA)
224085756|NCT00224536|PROCEDURE|Intracoronary bone marrow cell transfer|
224085757|NCT06120257|PROCEDURE|lithotripsy using Flexible ureteroscope|using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate
224085758|NCT06120257|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate
224277595|NCT00093730|DRUG|BMS-59926|
224277596|NCT05869916|BEHAVIORAL|psychological first aid|The effect of psychological first aid on earthquake victims was measured using the resilience scale and the secondary traumatic stress scale.
223911333|NCT06517719|OTHER|lutetium (177Lu) vipivotide tetraxetan|This is an observational study. There is no treatment allocation. The decision to initiate lutetium vipivotide tetraxetan will be based solely on clinical judgement.
224277597|NCT04202705|DRUG|SYD1875|SYD1875 IV (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
224277598|NCT06428162|OTHER|questionner|three sections questioner including: demographics, reported cases, unreported cases
224277599|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
223911334|NCT06550245|OTHER|Infants observing familiar and unfamiliar racial groups|All infants will see videos of people from familiar and unfamiliar racial backgrounds. Depending on the caregiver's race, infants will be assigned to see people who are from the same racial background as their caregiver (i.e., familiar) and people who are not.
224085759|NCT06120257|PROCEDURE|holmium laser lithotripsy using Karl® Storz MIP set|using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
224085760|NCT03785054|DRUG|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
224085761|NCT03785054|DRUG|Placebo oral capsule|Placebo treatment
224085762|NCT01804231|OTHER|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
224085763|NCT04597476|DIETARY_SUPPLEMENT|Fucoidan|Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
224085764|NCT04597476|OTHER|Placebo( Potato starch)|Potato starch 4.4gram
224085765|NCT00953394|DRUG|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
223911335|NCT05856435|BEHAVIORAL|Chicago Parent Program for Foster Care|The Chicago Parent Program for Foster Care FC consists of a 12-session parent training program that focuses on building caregiver-child relationships, behavioral management strategies, managing caregiver stress, and skill maintenance.
223911336|NCT05018377|PROCEDURE|Racz adhesolysis|adhesiolysis in failed back surgery
223911337|NCT05018377|DEVICE|NAVI adhesolysis|adhesiolysis in failed back surgery
224085766|NCT03680937|OTHER|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
224085767|NCT03680937|OTHER|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
224085768|NCT00963326|OTHER|laboratory biomarker analysis|
224085769|NCT05222633|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.05ml intravitreal injection
223911338|NCT06756178|DRUG|Propofol Group 1|"Postoperative Use:~Bolus: 10-20 mg intravenously as needed for sedation initiation. Continuous infusion: 0.3-0.5 mg/kg/hour to maintain light sedation adjusted based on clinical response."
224085770|NCT05222633|DRUG|Aflibercept|Aflibercept 2.0mg/0.05ml intravitreal injection
224085771|NCT05222633|DRUG|Conbercept|Conbercept 0.5mg/0.05ml intravitreal injection
224085772|NCT02601573|DRUG|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
224085773|NCT02601573|DRUG|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
224277600|NCT01026857|DRUG|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
223716125|NCT05386810|BIOLOGICAL|single-person sIPV control vaccine|"Sabin Inactivated Poliovirus Vaccine (Vero cell) (0.5ml) -control vaccine produced by Sinovac Biotech Co., Ltd.~Inactivated Sabin poliovirus antigen: type 1 (15DU), type 2 (45DU), and type 3 (45DU)in 0.5 ml mixture of medium 199,glycine,formaldehyde,sodium chloride,potassium chloride,calcium chloride,magnesium sulfate,disodium phosphate,sodium dihydrogen phosphate for per injection."
223911339|NCT06756178|DRUG|Remimazolam Intervention|"Postoperative Use:~Initial bolus: 5 mg intravenously upon ICU arrival. Continuous infusion: 0.2-0.3 mg/kg/hour to maintain light sedation with a maximum dose of 0.8 mg/kg/hour.~Rescue sedation with propofol or midazolam will be allowed if patients become agitated or if Remimazolam is ineffective in maintaining target sedation."
223911340|NCT06756178|DRUG|Dexmedetomidine Intervention|"Postoperative Use:~Loading dose: 0.5-1 μg/kg over 10-20 minutes after ICU arrival. Continuous infusion: 0.2-0.7 μg/kg/hour for sedation maintenance, adjusted as needed to maintain light sedation.~Rescue sedation with propofol or midazolam will be administered if Dexmedetomidine fails to maintain adequate sedation or if patients become agitated."
223911341|NCT01821612|DRUG|oxaliplatin|IV
223911342|NCT01821612|DRUG|irinotecan|IV
223911343|NCT01821612|DRUG|leucovorin|IV
223911344|NCT01821612|DRUG|5-fluorouracil|IV
223911345|NCT01821612|DRUG|capecitabine|PO
223911346|NCT01821612|RADIATION|radiation|
224085774|NCT02601573|DRUG|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
224085775|NCT02601573|DRUG|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
224085776|NCT03527576|DRUG|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
224085777|NCT03527576|DRUG|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
224085778|NCT00746499|DRUG|Raltegravir|400mg raltegravir BID x 7 days
224085779|NCT00001757|DRUG|Voriconazole|
224085780|NCT01052857|PROCEDURE|acupuncture|acupuncture application
224277601|NCT01026857|DRUG|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
224277602|NCT01507233|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
224085781|NCT00974220|DRUG|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
223911347|NCT01821612|PROCEDURE|surgery|
223911348|NCT01821612|DRUG|gemcitabine|IV
223911349|NCT02323880|OTHER|Pharmacological Study|Correlative studies
223911350|NCT02323880|DRUG|Selinexor|Given PO
223911351|NCT03278379|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
223911352|NCT00360087|DRUG|Bosentan|
223911353|NCT03812289|OTHER|Quality-of-Life Assessment|Ancillary studies
223911354|NCT03812289|OTHER|Questionnaire Administration|Ancillary studies
223911355|NCT03812289|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223911356|NCT04934072|DRUG|FKS518|subcutaneously by single-use prefilled syringe (PFS)
223911357|NCT04934072|DRUG|US-licensed Prolia (Amgen)|subcutaneously by single-use PFS
223911358|NCT05023096|OTHER|Tobacco product administration and assessment|Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
223911359|NCT04523701|DRUG|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"|"white test (= the administration of SMOFlipid retrograde through the cystic duct)"
223911360|NCT06361251|DEVICE|CRYONOVE (EC14_4osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
223911361|NCT06361251|DEVICE|CRYONOVE (EC05osc)|The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
223911362|NCT02484430|OTHER|Laboratory Biomarker Analysis|Correlative studies
223911363|NCT02484430|OTHER|Pharmacological Study|Correlative studies
224085782|NCT00974220|DRUG|normal saline (placebo)|single dose, 0.9% saline solution
224085783|NCT04968444|OTHER|Physiotherapy|"Physiotherapy helps to restore movement and function when someone is affected by injury, illness or disability. It can also help to reduce your risk of injury or illness in the future.~This can take the form of~* advice and education~* manual therapy~* exercise prescription~* relaxation"
223529350|NCT04695990|DRUG|Wenyang Huoxue placebo|Wenyang Huoxue placebo have an identical appearance and scent as the active treatment granules.
223529351|NCT05738538|DRUG|ziftomenib|
223911364|NCT02484430|DRUG|Sapanisertib|Given PO
223911365|NCT05202951|OTHER|questionnaires|Electronic case report form integrating questionnaires on chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used.
223911366|NCT06746350|DEVICE|Thermotherapy|Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.
223911367|NCT06322212|DIETARY_SUPPLEMENT|Thiamine|Participants will be provided instruction to take one 500 mg capsule of Thiamine (Vitamin B1) each day in the morning for 3-months.
223911368|NCT06322212|OTHER|Placebo|Participants will be provided instruction to take one capsule (placebo) each day in the morning for 3-months.
223911369|NCT03853031|PROCEDURE|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
223911370|NCT03853031|PROCEDURE|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
223911371|NCT03932162|DRUG|Insulin-Like Growth Factor 1|Growth factor protein
223911372|NCT03932162|OTHER|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
223911373|NCT06026306|BEHAVIORAL|Problem Management Plus (PM+)|PM+ consists of five weekly in-person sessions of 90 minutes. The intervention integrates four evidence-based behavioural strategies: arousal reduction using a slow breathing exercise (session 1), problem-solving (session 2), behavioural activation by re-engaging with pleasant and task-oriented activities (session 3) and accessing social support (session 4). Homework practice is scheduled following each session and discussed in the next session. Psychoeducation is delivered in session 1 and relapse prevention is discussed in session
224085784|NCT04968444|OTHER|Back Pain Workshop|Back workshop is an intervention protocol consisting of an educational program and skills acquisition program, including physical exercises. The session is supervised by a specialist physiotherapist.
224085785|NCT00608855|OTHER|questionnaire administration|
224085786|NCT00608855|PROCEDURE|cryosurgery|
224085787|NCT00608855|PROCEDURE|pain therapy|
223529352|NCT01209767|DEVICE|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
223911374|NCT05081934|BEHAVIORAL|A-CRA|12-14 weekly sessions of A-CRA, a behavioral treatment for youth suffering from substance use disorder and co-occurring problems. The average time for a placement within SiS is for boys 5,9 months and for girls 4,5 months. To further adjust A-CRA to the closed institutional care, frequency of sessions may be increased to twice a week. This is to facilitate maintaining of focus in treatment and closely follow treatment progress. Treatment consists of 18 procedures that aim to reduce problematic behaviors and increase constructive behaviors. Example of procedures are functional analysis of substance use behavior, functional analysis of prosocial behavior, increasing prosocial activities, drink/drug refusal, relapse prevention, anger management and caregiver sessions. Procedures are combined and tailored to youth individual goals and needs.
224085788|NCT00608855|PROCEDURE|quality-of-life assessment|
224085789|NCT04569838|DRUG|Bendamustine hydrochloride injection|Bendamustine is a bifunctional alkylating agent. It cross-links DNA single strand and double strand by alkylation,then destroys the function and synthesis of DNA, and makes the DNA and protein, protein and protein cross-linking, has potential to treat various tumors
223911375|NCT05081934|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT. This will be further specified and registered in the initial phase of the study, in collaboration with SiS.
223911376|NCT05058040|DRUG|Sodium Oligomannate Capsules|Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
223911377|NCT06162299|BIOLOGICAL|YS-HBV-002|YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
223911378|NCT06167239|OTHER|Threshold inspiratory muscle trainer or ventilator pressure setting inspiratory muscle training techniques|New techniques to train inspiratory muscles in mechanically ventilated patients
223911379|NCT03394612|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
223911380|NCT03394612|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
223911381|NCT03480776|DRUG|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
223911382|NCT03480776|OTHER|Placebo|One tablet PO daily
224085790|NCT05257512|DRUG|SY-3505|The third-generation ALK TKI
224085791|NCT02921425|BEHAVIORAL|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
223911383|NCT04935619|BEHAVIORAL|Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
223911384|NCT04935619|BEHAVIORAL|Non-Contingency Reinforcement|Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
223911385|NCT04548713|DEVICE|4% EDTA|Sterile Catheter Lock Solution
223911386|NCT04548713|DEVICE|Saline|Saline Lock Solution
223911387|NCT05860413|BEHAVIORAL|Intermittent energy restriction (IER)|During Phase 1 (Weight Loss), participants will follow a very-low energy diet (VLED; 550-800 kcal/d) 2-3 days per week. On other days, participants do not have a specific kcal goal (non-fasting days). After Phase 1, IER participants will be instructed to follow a VLED 1-2 days per week as needed for weight maintenance.
223911388|NCT05860413|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will eat within an 8-hour period most days (at least 5 days per week). All foods and beverages containing calories will be restricted to this 8-hour period but calorie-free beverages (coffee, tea, diet soda, etc.) are allowed at any time. TRE participants will follow healthy eating guidelines for weight loss during Phase 1 but not follow a specific kcal prescription or restrict intake thereafter.
224085792|NCT03135912|DRUG|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
224085793|NCT03135912|DRUG|Placebo|Dosage method of SESC 01, without active ingredients.
224085794|NCT03135912|DRUG|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
224085795|NCT01227967|DRUG|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
224085796|NCT01227967|DRUG|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
224099252|NCT04259515|DRUG|Buckberg|Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
223529353|NCT01209767|PROCEDURE|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
223529354|NCT01209767|OTHER|Control|
224099253|NCT05850234|BIOLOGICAL|GC012F (AZD0120)|GC012F (AZD0120) is a BCMA/CD19 dual CAR product under investigation for the treatment of patients with RRMM.
224099254|NCT05256537|OTHER|Omission of the drug mycophenolate mofetil|Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.
224099255|NCT05722002|DRUG|NSAID|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)"
224099256|NCT05722002|DRUG|Opioid|"Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses"
223911389|NCT04732507|COMBINATION_PRODUCT|1% plain lidocaine and 0.25% plain bupivacaine|A 5- or 10-ml syringe will be filled equally with 1% plain lidocaine and 0.25% plain bupivacaine. A 1.5-inch 25-gauge needle will be attached to the syringe. The needle will be carefully inserted at the first trigger point and 2 mls of the mixed local anesthetic will be infiltrated. At that point, the needle will be carefully inserted into the trigger point based on the group assigned. Once needling is done for the first trigger point, the process will be repeated in exactly the same fashion for the remaining points.
223911390|NCT06194188|DRUG|Subcutaneous injection of CU-20401|Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
223911391|NCT05523869|DRUG|Intravitreal topotecan|Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
223911392|NCT05523869|PROCEDURE|Pars plana vitrectomy with or without scleral buckle|Standard three-port pars plana vitrectomy with or without scleral buckle.
223911393|NCT06614309|OTHER|Acute Placebo Visit|The placebo visit will include 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air.
223911394|NCT06614309|OTHER|Acute Progressive Carbon Dioxide|The progressive carbon dioxide visit will include a 60-minute progressive ramp which includes 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles.
223911395|NCT06614309|OTHER|Acute Intermittent Hypoxia|The intermittent hypoxia exposure visit will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air.
223911396|NCT06614309|OTHER|Training: Progressive Carbon Dioxide Ramping|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the progressive CO2 ramp protocol of 60-minute sessions, which will include 6 cycles of progressive CO2 ramping starting at 0% and progressing up to 10% within 5 minutes immediately followed with 5 minutes of room air breathing in between cycles, for every visit during the 14 days.
223911397|NCT06614309|OTHER|Training: Intermittent Hypoxic Exposure|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will will be given the intermittent hypoxia exposure protocol of 60-minute sessions, which will include 6 cycles breathing 8-12% oxygen (O2) for 5 minutes with a target pulse oximeter saturation of 86-90%, followed by 5 minutes of breathing room air for every visit during the 14 days.
223911398|NCT06614309|OTHER|Training: Placebo Control|Intervention will consist of 6 to 10 study visits (3-5 sessions/week) to be completed within 14 days. Subjects will complete 6 simulated cycles of 5 minutes breathing 21% oxygen from a douglas bag and 5 minutes breathing room air (60 minutes) for every visit during the 14 days.
223716126|NCT03746652|DRUG|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
224099257|NCT05722002|DRUG|Acetaminophen|Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
224099258|NCT05268380|DIAGNOSTIC_TEST|Covid-19, TB and HIV diagnosis|GeneXpert (sputum) will be used to diagnose active TB disease, IGRA will be used to diagnose latent TB infection, PCR will be used to diagnose Covid-19 active infection, HIV rapid test will be used to diagnose HIV seropositivity.
223716127|NCT06084663|DRUG|Apremilast 30 mg Tablets|Each film-coated tablet contains 30 mg of apremilast
223716128|NCT06084663|DRUG|Otezla 30 mg film-coated tablets|Each film-coated tablet contains 30 mg of apremilast
223716129|NCT05993130|OTHER|The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study
223716130|NCT04959903|BIOLOGICAL|Allogeneic T cell progenitors, cultured ex-vivo|Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
223716131|NCT04059783|DRUG|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
224099259|NCT03710109|OTHER|EEG|non-invasive, non-interventional sensor
224099260|NCT05592340|BEHAVIORAL|Exposure to calorie information|Calories for all foods and beverages
224099261|NCT05592340|BEHAVIORAL|Exposure to carbon footprint information|Carbon footprint labels for all foods and beverages
224099262|NCT02038322|DEVICE|The Stork - Conception Aid|
224099263|NCT01591005|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
224099264|NCT01591005|PROCEDURE|endarterectomy|carotid endarterectomy
224099265|NCT01591005|PROCEDURE|carotid stenting|percutaneous transluminal angioplasty and stenting
224099266|NCT01276886|DRUG|antibiotic|
224099267|NCT01276886|PROCEDURE|Colonic resection with or without stoma|
223716132|NCT04343469|PROCEDURE|Bariatric Surgery (RYGB or LSG)|Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
223716133|NCT03879278|DRUG|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
223716134|NCT03478930|DRUG|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
223716135|NCT03478930|DRUG|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
223716136|NCT00044083|OTHER|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
223716137|NCT00044083|DRUG|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
223716138|NCT05304273|DRUG|Mifepristone|Participants with 1st trimester miscarriage will receive for medical termination
223716139|NCT05304273|DRUG|Letrozole|Participants with 1st trimester miscarriage will receive for medical termination
223716140|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
224099268|NCT01075087|DRUG|Placebo|Bilateral TAP block using sterile normal saline.
223911399|NCT04337255|OTHER|Behavioral Dietary intervention ( MIND Diet)|The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.
223911400|NCT04337255|OTHER|Behavioral Usual Care Diet Intervention|The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
224085797|NCT04671836|DRUG|Lorazepam 1Mg Tablet|"1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI."
224085798|NCT04671836|DRUG|Placebo|Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
223911401|NCT04951076|DRUG|BNC210|BNC210 900 mg twice daily (b.i.d.) for 12 weeks
223911402|NCT04951076|DRUG|Placebo|Placebo twice daily (b.i.d.) for 12 weeks
223911403|NCT06274632|BEHAVIORAL|ADELANTE|A manualized problem-solving intervention that addresses barriers to viral suppression in Latinos with HIV. At the patient-level, CHWs use motivational interviewing to facilitate problem-solving skill development around attending HIV care and adherence and establish an individually tailored goal-setting plan. We target emotional well-being and self-management through a rapport with CHW and the integration of an HIV-centered telenovela to facilitate participant reflection on difficult topics for skill-building. The CHW will also link the participant to needed services.
223911404|NCT04866836|COMBINATION_PRODUCT|Radiotherapy|Patients who meet the criteria for enrollment first receive radiotherapy, either IMRT or SBRT, and the relative biological effect dose is\> 40Gy. On the 7th day (±3 days) after radiotherapy, start to give tislelizumab 200 mg, IVD, q3w, and continue the treatment until disease progression, unacceptable toxic radiotherapy, death or meet the description in the protocol Any discontinuation criteria shall be subject to whichever occurs firs
224085799|NCT06078657|DRUG|IBI110+Sintilimab|"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."
223911405|NCT02642471|PROCEDURE|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
224085800|NCT00564993|DRUG|Dobutamin|10\&20 µg/kg/min
224085801|NCT04049825|DRUG|OPB-111077|OPB-111077+bendamustine
224085802|NCT04049825|DRUG|OPB-111077|OPB-111077+rituximab+bendamustine
224277603|NCT01507233|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
224277604|NCT01402128|DIETARY_SUPPLEMENT|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
224277605|NCT01402128|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks
224277606|NCT00651183|DRUG|Pramipexole immediate release|
223716141|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
223911406|NCT04998162|PROCEDURE|SVF injection|Patients with ankle osteoarthritis will be treated with a single injection of 5 cc of SVF (stromal vascular fraction), obtained from patient's abdominal adipose tissue and concentrated through OPTYFAT device. Infiltration of the ankle, occurs from the safest portal, that is, from the antero- medial, between the tibialis anterior and the saphenous vein and nerve at the level of the articular rima.
223716142|NCT01112865|DEVICE|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
224085803|NCT02627040|DEVICE|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
224085804|NCT02627040|DEVICE|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
224085805|NCT05816681|DRUG|DWJ1230|Daewoong Pharmaceutical
224085806|NCT05816681|DRUG|DWB2001|Daewoong Bio
224085807|NCT05064657|PROCEDURE|Bubble blowing method|"The investigators were used Bubble blowing method and ball squeezing method.~To child were used a ball squeezing method during the blood collection process."
224085808|NCT00430144|DRUG|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
224277607|NCT00894842|DRUG|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
224277608|NCT00894842|DRUG|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
224277609|NCT06495580|PROCEDURE|Optic Nerve Stimulation|Anterograde Stimulation of the Optic Neve.
224277610|NCT04025138|OTHER|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)"
223716143|NCT01112865|DEVICE|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
223716144|NCT02656732|BIOLOGICAL|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
223911407|NCT06000046|DEVICE|Automatic image analysis|After referral for suspected prostate cancer, the patient is scanned with magnetic resonance imaging (MRI) in accordance with guidelines of the standardized healthcare pathway. For consenting patients, the images are interpreted in two ways: first, in the conventional manner, i.e., manually by a radiologist, to determine whether clinically significant cancer is suspected. If so, the radiologist will delineate the suspicious lesions. In the second approach, the software will perform the same task as the radiologist, but automatically. If either or both interpretations point to significant cancer, the patient will be sent for targeted biopsy sampling. Histopathologic evaluation of the samples will then determine whether significant cancer is present in each of the targeted lesions (delineated by the radiologist, software, or both).
223911408|NCT04271956|BIOLOGICAL|Tislelizumab|Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
223911409|NCT04271956|DRUG|Zanubrutinib|Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
223911410|NCT04271956|DRUG|Sonrotoclax|"Cycle 1: Sonrotoclax Start Ramp-up to 320 mg QD po Days 1-2 Sonrotoclax 2 mg (2 tabl. at 1mg) Days 3-4 Sonrotoclax 5 mg (1 tabl. at 5mg) Days 5-6 Sonrotoclax 10 mg (2 tabl. at 5mg) Days 7-8 Sonrotoclax 20 mg (1 tabl. at 20mg) Days 9-10 Sonrotoclax 40 mg (2 tabl. at 20mg) Days 11-12 Sonrotoclax 80 mg (1 tabl. at 80mg) Days 13-14 Sonrotoclax 160 mg (2 tabl. at 80mg) Days 15-16 Sonrotoclax 320 mg (4 tabl. at 80mg)~Cycle 2-6: Day 1-21 Sonrotoclax 320 mg QD po"
223911411|NCT04833907|DRUG|rAAV-Olig001-ASPA|Intracerebroventricular administration of a single dose
223911412|NCT04833907|DRUG|Levetiracetam|Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
223911413|NCT04833907|DRUG|Prednisone|Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
223911414|NCT05541276|DRUG|Melatonin|Melatonin for injection 1 mg/mL
223911415|NCT05541276|DRUG|Isotonic sodium chloride solution|Sodium chloride 0.9 % for injection
223911416|NCT05736458|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
223911417|NCT05736458|PROCEDURE|High controllability TMS target|Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
223911418|NCT06513520|BIOLOGICAL|Blood sampling|Additional blood tube collection during routine blood sampling.
223911419|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Active Rehabilitation with Feedback and Exercise Gaming|Patients will undergo 20 session of 45 minutes each with an exoskeleton for upper limb rehabilitation. The assistance provided by the device is adjusted based on the maximum force (as a percentage of the upper limb's weight) the robot needs to exert to assist the patient's movements. Each session will include exercises designed to improve the range of motion (ROM) of the shoulder, elbow, wrist, and enhance hand coordination. The training parameters, such as difficulty level, duration, and visual stimuli, will be adjusted based on the patient's residual abilities. The selected exercises may involve movements of a single joint along one axis, combined movements of a single joint around 2 or 3 axes, selective exercises for the opening and closing hand, or multi-joint exercises. All exercises will be realized with audiovisual feedback.
223911420|NCT06620198|DEVICE|Armeo® Power 2 Exoskeleton - Passive Mobilization without Feedback|Patients will undergo 20 session of 45 minute of a neurorehabilitation intervention with a SHAM treatment under the guidance of the experimental therapist. This will involve passive mobilization using the exoskeleton for the upper limb, without any audiovisual feedback. They will not realize any active movement during the training.
223911421|NCT04224558|DRUG|Mesna|"Stem Cell Mobilization: Infused according to institutional guidelines;~Post-PBSC Infusion Conditioning: Mesna provided with Cytoxan according to institutional protocol."
223911422|NCT04224558|DRUG|Cyclophosphamide|"Stem Cell Mobilization:~Cyclophosphamide (CY) infused intravenously over 1 hour: 50 mg/kg (25 mg/kg/day on 2 consecutive days)"
223911423|NCT04224558|DRUG|Filgrastim|"Stem Cell Mobilization: Filgrastim (G-CSF) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapheresis;~Post-PBSC Infusion Conditioning: Filgrastim administered intravenously 5 mcg/kg IV starting day + 5, continue until ANC of \>1000/μL"
223911424|NCT04224558|PROCEDURE|Apheresis catheter placement|Subjects will require placement of an Apheresis catheter by Intervention Radiologists on the day of collection of stem cells.
223911425|NCT04224558|PROCEDURE|Leukapheresis|Leukapheresis will be performed on a continuous flow separator machine according to institutional guidelines to target 3-8 x 10\^6 CD34+ cells/kg body weight.
223911426|NCT04224558|DRUG|Fludarabine|Preparative/Conditioning Regime Fludarabine given as 30 mg/m2 per dose x 4 days, beginning on day -6.
223911427|NCT04224558|DRUG|Methylprednisolone|Preparative/Conditioning Regime r-ATG pre-medication according to institutional guidelines
223911428|NCT04224558|DRUG|Diphenhydramine|Preparative/Conditioning Regime r-ATG premedication according to institutional guidelines
223911429|NCT04224558|DRUG|Acetaminophen|Preparative/Conditioning Regime r-ATG premedication according to institutional guidlines
223911430|NCT04224558|DRUG|anti-thymocyte globulin (rabbit)|Preparative/Conditioning Regime r-ATG administered intravenously: 2.5 mg/kg/dose IV over 6 hours on specified days (day -6,-4,-2); ); total 3 doses=7.5 mg/kg.
224085809|NCT04840121|DIAGNOSTIC_TEST|AdhesioRT|AdhesioRT, a novel diagnostic genetic assay, developed by ovo R\&D scientists, helps to predict the endometrial receptivity and embryo implantation.
224085810|NCT00899093|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223911431|NCT04224558|DRUG|lymphocyte immune globulin|Preparative/Conditioning Regime In patients who develop severe allergic reactions to rATG (Thymoglobulin), it may be substituted by horse ATG (hATG, ATGAM, Pharmacia \& Upjohn, Kalamazoo, MI). The recommended dose of hATG is 25 mg/kg/day for 3 doses.
223911432|NCT04224558|BIOLOGICAL|Peripheral Blood Stem Cell Infusion|PBSC (peripheral blood stem cell) infusion on day 0 as per institutional guidelines.
223911433|NCT04224558|DRUG|Cytoxan|Post-PBSC Infusion Conditioning Cytoxan infused intravenously: 50mg/kg/day x 2 days. Infused over 2 hours with adequate hydration or according to institutional guidelines.
223911434|NCT04357093|OTHER|Grape seed extract mouthwash|Mouthwash 15% grape seed extract
224085811|NCT00899093|OTHER|Laboratory Biomarker Analysis|Correlative studies
224085812|NCT02036229|DRUG|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
224085813|NCT00643149|DRUG|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
224085814|NCT00643149|DRUG|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
223911435|NCT04357093|OTHER|Sodium fluoride mouthwash|Sodium fluoride mouthwash
223911436|NCT04291560|BEHAVIORAL|Stretching Exercise Intervention|Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
223911437|NCT02229968|DRUG|Amicar (ε-aminocaproic acid)|
223911438|NCT02229968|DRUG|normal saline|
223911439|NCT05728463|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is defined as total or subtotal desection of the gallbladder laparoscopically.
223911440|NCT05825170|DEVICE|FASY L|Subjects will receive FASY L in lips at level of their scar.
223911441|NCT05249114|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
223911442|NCT05249114|DRUG|Lu-177|Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
223911443|NCT06808425|DEVICE|Intervention A|Weighted blanket
223911444|NCT06808425|DRUG|Intervention B|Standard treatment (melatonin)
223911445|NCT05304819|DEVICE|AchilloCordPLUS™ System Implant|AchilloCordPLUS System Implant Set for Acute Achilles Tendon Repair
223911446|NCT06374589|DEVICE|Closed-loop FiO2 controller|Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.
224085815|NCT03403400|BEHAVIORAL|VRWP Group|The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
224085816|NCT03403400|BEHAVIORAL|VRW Group|The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
224277611|NCT04025138|DEVICE|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
223529355|NCT03135860|DRUG|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
223911447|NCT06374589|DEVICE|Conventional|Six hours period where the fraction of inspired oxygen (FiO2) delivered will be manually titrated by clinician based on SpO2 values obtained from the patient.
223911448|NCT06810336|DRUG|Remifentanil|Intravenous Remifentanil
223911449|NCT06810336|DRUG|Methadone|Intravenous Methadone
223911450|NCT04250051|DRUG|Cytarabine|Given IV
223911451|NCT04250051|BIOLOGICAL|Filgrastim|Given SC
223911452|NCT04250051|DRUG|Fludarabine|Given IV
223911453|NCT04250051|DRUG|Fludarabine Phosphate|Given IV
223911454|NCT04250051|DRUG|Ivosidenib|Given PO
223911455|NCT05589792|DRUG|Placebo oral capsule|Placebo before sleep for 3 nights before the study (inclusive)
224085817|NCT01763164|DRUG|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
224085818|NCT01763164|DRUG|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
224099269|NCT01075087|DRUG|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
224099270|NCT01049776|DRUG|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
224099271|NCT01602731|DEVICE|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
224099272|NCT01305499|DRUG|Entinostat days 3, 10|Given orally on days 3, 10
224099273|NCT01305499|DRUG|5AC|
224099274|NCT01305499|DRUG|Entinostat days 10,17|Given orally on days 10, 17
223911456|NCT05589792|DRUG|Acetazolamide|Acetazolamide 250 mg 3 nights before the study at bedtime, Acetazolamide 500 mg for 2 nights before the study (inclusive) at bedtime.
223911457|NCT06810492|DRUG|Ribociclib; abemaciclib; palbociclib; Dalpiciclib|"Neoadjuvant therapy: CDK4/6 inhibitor combined with endocrine, a total of 6 cycles, 1 cycle every 28 days.~CDK4/6 inhibitors (choose one of the following four types):~* Dalpiciclib 125 mg orally once a day d1-21 every 28 days for a cycle (3 weeks/1 week off)~* Palbociclib 125 mg orally once a day, d1-21, every 28 days in cycles (3 weeks/1 week off)~* Abemaciclib 150 mg orally twice daily in 28-day cycles (may be reduced to 100 mg orally twice daily if not tolerated)~* Ribociclib 400 mg orally once a day in a 28-day cycle Endocrine therapy drugs: take according to the label. Premenopausal patients need to be treated for ovarian function suppression."
223911458|NCT06808568|COMBINATION_PRODUCT|STIMULAN VG|
223911459|NCT04745390|RADIATION|Radiation therapy|Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
223911460|NCT02257060|PROCEDURE|Endocardial Ablation|
223911461|NCT00223145|RADIATION|Radiotherapy 70 Gy|Radiotherapy to the prostate
224277612|NCT04025138|OTHER|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
224277613|NCT04025138|OTHER|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
224277614|NCT04025138|BIOLOGICAL|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
224277615|NCT04025138|BIOLOGICAL|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
224277616|NCT03330236|DEVICE|"Anesthetic depth management"|The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
224277617|NCT01625507|BEHAVIORAL|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
224277618|NCT05291052|DRUG|Tislelizumab|Tisleizumab 200 mg intravenously (IV) every 3 weeks (Q3W) ,D1
223529356|NCT01702298|DRUG|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
223529357|NCT01702298|DRUG|Metformin|Participants will continue pre-study dose of metformin tablet(s) \>=1000 per day
223529358|NCT04507204|DRUG|Adhansia XR|Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
223529359|NCT04507204|DRUG|Concerta|An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)
223529360|NCT01162759|BEHAVIORAL|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
223529361|NCT00400686|BIOLOGICAL|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
223529362|NCT00220090|DRUG|dexloxiglumide|
223529363|NCT01752049|DRUG|Topical timolol maleate|"* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient"
224277619|NCT05291052|DRUG|Lenvatinib|Lenvatinib 8 mg (for patient weight \< 60 kg) or 12 mg (for patient weight ≥ 60 kg), orally, QD, D1-21, Q3W
224277620|NCT05291052|DRUG|Oxaliplatin|"Oxaliplatin 130 mg/m2, IV， D1，Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
223529364|NCT01752049|DRUG|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.
223529365|NCT05511948|DRUG|DBI-102|Topical application on dorsal hand and upper volar arm
223529366|NCT05511948|DRUG|Vehicle gel|Inactive comparator
223529367|NCT05511948|DRUG|Hydroquinone Cream|4% Hydroquinone cream, Acella (approved), twice daily for 12 weeks
224277621|NCT05291052|DRUG|Capecitabine|"Capecitabine 1000 mg/m2, orally, BID, D1-14, Q3W~Subjects can receive up to 8 cycles of the XELOX regimen (Oxaliplatin and Capecitabine). For subjects who are intolerant to XELOX regimen or have stable disease or objective response after complete 8 cycles of XELOX regimen, treatment with tisleizumab and lenvatinib will be continued until tumor progression or for a maximum of 2 years."
224277622|NCT03355352|DRUG|Sufentanil|Sufentail sublingual 15ug nanopills
224277623|NCT03788915|BEHAVIORAL|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
223529368|NCT01141530|OTHER|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
223529369|NCT02769104|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
223529370|NCT02769104|DRUG|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
223529371|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled|Each patient will receive 12µg/kg of levosimendan by inhalation over 10 min. During 10h following inhaled dose, plasma concentrations will be measured.
223716145|NCT02656732|PROCEDURE|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
223716146|NCT04762784|DRUG|Tocilizumab|Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.
224085819|NCT03806244|OTHER|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
224277624|NCT03788915|BEHAVIORAL|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
224277625|NCT01901848|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
224277626|NCT01901848|DRUG|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
224277627|NCT01901848|DRUG|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
223716147|NCT04762784|DRUG|Glucocorticoids|Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
223716148|NCT02829528|BEHAVIORAL|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
223716149|NCT02385500|DRUG|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
223716150|NCT02385500|DRUG|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
224277628|NCT01901848|BEHAVIORAL|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
224277629|NCT01901848|BEHAVIORAL|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
224277630|NCT04664816|DRUG|n-3PUFAs Treatment|Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
224277631|NCT04664816|DRUG|Placebo Treatment|Placebo orally, twice a day for at least 12 months.
224277632|NCT00763555|DRUG|CD 2027|Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
224277633|NCT00763555|DRUG|Calcitriol Vehicle|Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
224277634|NCT05824858|DRUG|LY3537982|Administered orally.
223716151|NCT04745130|DRUG|Sintilimab，regofinib，cetuximab|KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
224277635|NCT01563458|DRUG|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
223716152|NCT04745130|DRUG|KRAS BRAF mutant Sintilimab + regafinil|KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
223716153|NCT00028405|DRUG|LS 11(Taporfin Sodium)|
223716154|NCT00028405|DEVICE|Lumaflex Light Delivery Catheter|
223911462|NCT00223145|RADIATION|Radiotherapy 76 Gy|Radiotherapy to the prostate
223911463|NCT00223145|DRUG|Androgen blockade|Duration : 6 months
223911464|NCT05847478|OTHER|Auricular acupressure of traditional Chinese Medicine|"The participants will be randomly assigned to receive the auricular point patch therapy.~The selected acupoints include Shenmen, hungry point, endocrine, stomach, mouth and subcortical. The opaque patch with vaccaria seed is used for acupoint pressing. Pressing the acupoints once a day before and after eating, each time for 1 minute, lasting for 2-3 days, follow up visit once a week. The intervention period is 3 months."
223911465|NCT05847478|BEHAVIORAL|Intermittent low carbohydrate diet|"The participants will be randomly assigned to the intermittent low carbohydrate diet group.~The intermittent carbohydrate diet includes 7 days of low carbohydrate diet within 2 weeks (consecutive or nonconsecutive, carbohydrate intake be controlled as ≤ 50g per day). The study duration is 3 months, including 1-month intervention period and 2-month self-maintenance period."
223911466|NCT05847478|BEHAVIORAL|Health education|Health education is conducted once a week during 3-month intervention for all participants. Health education including the understanding of childhood obesity and cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
223911467|NCT04247802|OTHER|Backwards Walking (BW) programme|A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
223911468|NCT04247802|OTHER|Usual Care|A 12 week physiotherapy exercise programme EXCLUDING backwards walking
223529372|NCT06387862|DRUG|Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous|Each patient will receive 12µg/kg of levosimendan by intravenous (IV) administration over 10 min and at the same timepoints plasma samples will be measured
223529373|NCT02285881|BEHAVIORAL|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
223535216|NCT06644092|OTHER|Investigation of the Effectiveness of Physiotherapy and Rehabilitation After Osteochondral Allograft Transplantation Operation|The treatment protocol to be applied to the patients after surgery was determined. The protocol includes; cold application, game ready device application, CPM device application, patellar mobilization, soft tissue mobilization application, TENS, conventional TENS and NMES application, ultrasound application, stretching exercises, strengthening exercises, mobilization exercises, balance and proprioception exercises, walking training and kinesio taping.
223716155|NCT04191720|OTHER|Weighted blanket|Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
223716156|NCT05223244|DRUG|bupivacaine, triamcinolone, and heparin (BTH)|30mL of 0.5% bupivacaine (5mg/mL), 2mL triamcinolone (10mg/mL), and 2mL Heparin (10,000units/mL)
223716157|NCT05223244|DRUG|dimethyl sulfoxide (DMSO)|50mL of DMSO and 1mL of triamcinolone (10mg/mL)
223716158|NCT04660669|OTHER|ESDM intervention|Early Start Denver Model (ESDM) intervention with remote parental training/ supervision versus intensive ESDM intervention.
223716159|NCT04660669|OTHER|MOOC|Massive Online Open Course: a teaching and learning intervention based on instrumental and interactive teaching situations
223716160|NCT01991691|DEVICE|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
223716161|NCT04073654|PROCEDURE|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
223716162|NCT02505204|OTHER|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
223911469|NCT05015218|DIAGNOSTIC_TEST|Vacular Ultrasound|To visualize the internal jugular veins ( IJVs) a linear transducer with a 5-10 MHz linear probe was placed over the neck, and the IJV was measured just below the bifurcation of the sternal and clavicular heads of the muscle. The IJV measurements were performed on the transverse axis over a single respiratory cycle. Patients with evidence of IJV thrombosis were excluded. IJV measurements included the antero-posterior maximum diameter at the end of expiration (IJVmax), the antero-posterior mimimum diameter/area at the end of inspiration (IJVmin), the IJV collapsibility index (IJV-CI) during spontaneous, quiet, breathing, \[(IJVmax - IJVmin area)/IJVmax\] and the ratio (R) of IJVmax-to-IJV-CI.
223911470|NCT06148012|OTHER|dental implant|"Digital panoramic radiographs taken during the patients' treatment periods (T0, T1) were used in the study. Measurements of marginal bone levels on radiographs were performed using the Image J software. The distance between the most coronal part of the implant neck and the most apical part of the defect caused by marginal bone loss was measured.~Fractal analysis (FA) was conducted on panoramic radiographs (OPG) with a size of 2952x1435 pixels and a depth of 32 bits. FA on these radiographs at T0 and T1 times was performed using the box counting method determined by White and Rudolp with the ImageJ program(23)."
223911471|NCT05158634|OTHER|Evaluations|"Within the scope of the study, the participants will be evaluated for 30 minutes in a single session. The participants' trunk stabilization and endurance, balance, functional mobility, upper extremity endurance, functional health and quality of life will be questioned by questionnaires, scales and tests. Evaluation will begin with a literature-supported demographic data form prepared for the participants.~Assessments to be made are listed below. Trunk Control Measurement Scale (TCMS) Pediatric Balance Scale (PBS) Time Up and Go test (TUG) Trunk Flexor Test (TFT) The Pediatric Outcomes Data Collection Instrument (PODCI)"
223911472|NCT05623462|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
223911473|NCT05623462|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program includes the following:~\- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
223911474|NCT04315610|OTHER|Access to mobile phone application|Under the guidance of healthcare personnel at the Neonatal Intensive Care Department (NICD) at Oslo University Hospital (OUH), parents are trained to assess their infant's condition, regarding circulation, breathing, eating habits, well-being, and more. In addition, before discharge, a baseline assessment of the infant's condition is stored in the application. After discharge, assessments using the application are performed if necessary.
223911475|NCT04315610|OTHER|Treatment as usual|Active comparator group, based on traditional information and follow-up.
223911476|NCT06817837|BEHAVIORAL|hypnosis|Eight hypnosis sessions will be offered to address various issues: sleep disorders, behavioral issues, anxiety, and pain.
223911477|NCT06816537|RADIATION|Low Level Laser Therapy|A low-level medical gallium-aluminum-arsenide (GaAlAs) diode laser device will be used on the 1st permanent molars in the test quadrants
223911478|NCT06816537|OTHER|No Interventions|The handpiece was also held on the placebo treatment side without laser irradiation (fake irradiation) following the same application protocol as the LLLT treatment side.
223911479|NCT06820164|DRUG|Cooled Sodium Chloride Injection|Injection of a solution containing sterile, cooled 0.9% sodium chloride and 1% lidocaine with epinephrine (1:100,000).
223911480|NCT06675227|DIETARY_SUPPLEMENT|electrolyte beverages|Using Electrolyte Beverages as replacement for water to dissolve PEG(2L plan) in bowel preparation process.
224085820|NCT01396369|DRUG|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
223911481|NCT06819761|DIETARY_SUPPLEMENT|Salivarius SALI-10|Lozenge with 10B CFU (Colony Forming Units)
224085821|NCT01396369|DRUG|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
224085822|NCT05158855|DIETARY_SUPPLEMENT|Bacillus subtilis spore extract|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.
224085823|NCT00016458|DRUG|anti-thymocyte globulin|
224085824|NCT00016458|DRUG|cyclophosphamide|
224085825|NCT03883269|DRUG|Erythromycin 4% topical gel formulation|Erythromycin 4% topical gel formulation, BID, 4 weeks
224085826|NCT03883269|DRUG|Clindamycin 1% topical lotion formulation|Clindamycin 1% topical lotion formulation, BID, 4 weeks
224085827|NCT03883269|DRUG|70% topical ethanol solution|70% topical ethanol solution, BID, 4 weeks
224085828|NCT00526201|BEHAVIORAL|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
224085829|NCT00526201|BEHAVIORAL|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
224085830|NCT03458169|DEVICE|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
224085831|NCT03458169|DEVICE|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
224085832|NCT03458169|DEVICE|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
224277636|NCT01563458|DRUG|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
224277637|NCT01563458|DRUG|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
223716163|NCT02505204|OTHER|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
224277638|NCT06133218|OTHER|Mepitel Film|A safetac-based barrier film with a clinically insignificant bolus effect to protect the skin during radiotherapy.
224277639|NCT04936919|DEVICE|BroadBand Light|Treatment arm will receive Broadband light treatment
223911482|NCT06817083|PROCEDURE|E-C Clamp Technique|"The E-C clamp technique involves forming a C with the thumb and index finger around the mask while the remaining fingers form an E to lift the mandible. This technique aims to provide a good seal while opening the airway."
223911483|NCT06817083|PROCEDURE|T-E Technique|"The T-E technique is a variation where the thumb and index finger form a T over the mask while the other fingers provide chin lift and jaw thrust.~This method is designed to optimize airway patency and mask seal. While these techniques are widely taught and practiced, they often fall short in obese patients due to the difficulty in maintaining an adequate seal and achieving sufficient ventilation pressures. Complications such as hypoxemia and gastric insufflation are more common in this population."
224277640|NCT01865929|DEVICE|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
223716164|NCT00037596|DRUG|Gemtuzumab Ozogamicin|
223716165|NCT00037596|DRUG|cytarabine.|
223716166|NCT04077268|OTHER|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
223716167|NCT02031354|DIETARY_SUPPLEMENT|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
223716168|NCT03680690|PROCEDURE|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
224277641|NCT01865929|PROCEDURE|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
223911484|NCT06817083|PROCEDURE|The Hook Technique|e is a novel method for single-hand ventilation that has shown promise in preliminary studies. This technique involves a unique hand positioning that aims to improve mask seal and ventilation efficacy, particularly in patients with challenging airway anatomy. In Hook Technique using the thumb and index finger to form a hook around the mask, creating a more secure and adjustable seal and utilizing the remaining fingers to apply consistent mandibular lift, enhancing airway patency.
224085833|NCT04358757|PROCEDURE|Elective cesarean delivery|scheduled cesarean delivery for maternal / obstetric indications
224085834|NCT01124825|DEVICE|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
223911485|NCT05666193|DEVICE|CBCT Imaging|Subjects are scheduled for two imaging sessions on the Ethos system with the HyperSight CBCT. One session is on the same day as the CT simulation scan for treatment planning. The second session is on the same day as the delivery of ther 21st treatment fraction. If the subject is sent for a mid-treatment FBCT for re-planning, a third HyperSight CBCT imaging session will be scheduled on the same day as the mid-treatment FBCT.
223911486|NCT06855602|DRUG|Chinese herbal medicine formula (S-2196)|During the 2-week intervention, all participants are required to take 150ml of S-2196 decoction (a Chinese herbal medicine formula containing four herbs) twice per day
223911487|NCT06856083|BEHAVIORAL|Gamified Virtual Reality Sports Exercise Program|"Participants in the experimental group will participate in a variety of sports exercises designed in a virtual reality environment utilizing gamification elements to enhance engagement. The intervention will include:~* Structured virtual reality sports sessions guided by specially trained facilitators.~* Use of gamified features such as rewards, points, and friendly competition to stimulate motivation.~* Incorporation of social elements where participants can interact with each other during sessions to foster community and support."
224085835|NCT01124825|DEVICE|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
224085836|NCT00989989|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
224085837|NCT00989989|PROCEDURE|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
224085838|NCT00989989|DRUG|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
224085839|NCT00989989|PROCEDURE|Sham laser photocoagulation|Sham laser treatment administered at day 1.
224085840|NCT00166387|PROCEDURE|Blood draw|A single blood draw.
224085841|NCT00961987|OTHER|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
224085842|NCT00961987|OTHER|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
224085843|NCT03979976|DRUG|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
224085844|NCT01384292|DRUG|NKTR-118|12.5 mg oral tablet once daily
224085845|NCT01384292|DRUG|NKTR-118|25 mg oral tablet once daily
224085846|NCT01384292|DRUG|Placebo|Oral treatment
224085847|NCT03119012|DRUG|Clopidogrel|75mg/day
224085848|NCT03119012|DRUG|Ticagrelor|120mg/day
224085849|NCT03119012|DRUG|Aspirin|100mg/day
224085850|NCT01750255|OTHER|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
224277642|NCT01997684|PROCEDURE|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
223719398|NCT03178864|DRUG|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
224099275|NCT05040191|OTHER|Traditional Education(control)|The application was made on the model that allows nasogastric tube application and the anatomical structure in the nasogastric region is seen. The student can experience the skill of applying a nasogastric tube to the nasogastric or orgastric region on this model. In the nursing skills laboratory, students were given a demonstration of nasogastric tube application on a model.
224099276|NCT05040191|OTHER|Haptic interactive virtual reality simulation training|Haptic interactive virtual reality simulation technology; It functions by using haptic gloves that are interactive, visually enhanced, containing three-dimensional video and animation, wearable by students. This program has been developed by a software developer who is an expert in the field of information technologies, using the unreal program with a nine-generation computer with a game engine. All the necessary steps in the NGT application have been in simulation.
223911488|NCT06856083|BEHAVIORAL|Traditional Sports Exercise Program for Elderly Individuals with Suicidal Thoughts|"participants will engage in a traditional sports exercise program aimed at elderly individuals experiencing suicidal thoughts. The intervention consists of structured physical activity sessions that include a variety of low-impact sports and exercises designed for older adults. These activities will be conducted in a supportive group setting to foster social interaction and community engagement.~The sessions will be led by experienced facilitators who specialize in elderly fitness and mental health. Each session will last approximately 60 minutes and will include a warm-up, the main exercise component, and a cooldown period to promote physical well-being and relaxation. Participants will be encouraged to engage at their own pace, ensuring that individual capabilities and comfort levels are respected."
223911489|NCT06857760|OTHER|Ice cube|ıce cube
223911490|NCT06857760|OTHER|Mouth wash|Mouth wash
223911491|NCT06857760|OTHER|Menthol lozenge|menthol lozenge
223911492|NCT06857708|DEVICE|Cytal® Wound Matrix|This is the only study to use this intervention in necrotizing soft tissue wounds
223911493|NCT06857708|DEVICE|MicroMatrix®|This is the only study to use this intervention in necrotizing soft tissue wounds
223911494|NCT05571267|DRUG|Avacincaptad Pegol|Zimura 2 mg, administered by intravitreal injection
223911495|NCT05571267|DRUG|Avastin|Avastin 1.25 mg, administered by intravitreal injection
223911496|NCT05571267|DRUG|Lucentis|Lucentis 0.5 mg, administered by intravitreal injection
223911497|NCT05571267|DRUG|Eylea|Eylea 2 mg, administered by intravitreal injection
223911498|NCT06856447|DRUG|Coenzyme Q10|"100 mg once daily starting after the first chemotherapy cycle. Patients will receive 12 cycles of the modified FOLFOX-6 regimen with Coenzyme Q10 (100 mg once daily in the morning), starting after the first chemotherapy cycle and continuing until the end of the 12th cycle. Based on McRae (2023), 200 mg/day for 12 weeks reduced TNF-α and IL-6; thus, 100 mg/day for 6 months was selected (one cycle every 2 weeks = 24 weeks).~Supportive care: Includes a 5-HT3 antagonist for nausea prevention and pantoprazole to prevent gastric irritation.~Intervention Details:~Oxaliplatin: Part of the FOLFOX-6 regimen. 5-Fluorouracil (5-FU): Part of the FOLFOX-6 regimen. Leucovorin: Part of the FOLFOX-6 regimen. 5-HT3 Antagonist: Used for nausea prevention. Pantoprazole: Used to prevent gastric irritation."
223911499|NCT06856447|DRUG|Oxaliplatin|Part of the modified FOLFOX-6 chemotherapy regimen
223911500|NCT06856447|DRUG|5-Fluorouracil (5-FU)|Part of the modified FOLFOX-6 chemotherapy regimen.
223911501|NCT06856447|DRUG|5-HT3 Antagonist|Used for nausea prevention during chemotherapy.
223911502|NCT06856447|DRUG|Pantoprazole|Used to prevent gastric irritation during chemotherapy
223911503|NCT06660056|BIOLOGICAL|A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Recurrent or Progressive Gliomas of the Brain|Use of Ommaya capsules
223911504|NCT06218056|DRUG|Cannabidiol (CBD) 800 mg|CBD (400 mg) will be administered orally twice daily in the morning and again in the evening in 4 capsules each containing 100 mg of the active ingredient in the Ananda investigational new drug, ATL5. ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.
223911505|NCT06218056|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. 4 softgel capsules of placebo will be administered to match the capsule number of the active compound, daily in the morning and evening for each of 56 days.
223911506|NCT06824142|OTHER|Evaluate in real-life conditions the effectiveness of an adapted external aid as a tool to support temporal orientation rehabilitation for individuals with Alzheimer's disease or related dementias in|Unlike other interventions, the E3D tool combines an intuitive, user-friendly interface with real-time temporal cues, offering a personalized experience designed to improve cognitive engagement. This external aid is aimed at fostering independence and improving daily functioning by providing clear and consistent information on time-related aspects, such as season, month, day of the week, and current date.
223911507|NCT06825793|DRUG|Semaglutide Subcutaneous Injection|All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.
223911508|NCT04170855|DRUG|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~* A reduction in fractional spot urinary sodium~* An increase in urinary volume~* A \>1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
223911509|NCT04334343|OTHER|Additional Muscle Biopsy Collection|Subjects will be asked if an additional biopsy from an existing incision can be obtained (i.e. additional needle insertion). For each biopsy required in the main MoTrPAC study (NCT03960827), a small needle will be used to inject some numbing medication (similar to what a dentist uses) in your thigh. A small incision (about 1/4 inch) will be made and a special needle will be used to collect 1 or 2 muscle samples (about the size of a pea).
224277643|NCT01997684|PROCEDURE|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
224277644|NCT03844828|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
224277645|NCT04596306|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
224277646|NCT00625326|DRUG|COL-121|75 µg/g COL-121 Ointment
224277647|NCT00625326|DRUG|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
223911510|NCT04199689|BIOLOGICAL|9vHPV Vaccine|9vHPV is an aluminum-adjuvanted recombinant protein vaccine prepared from the highly purified virus-like particles of the recombinant major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 given as a 0.5 mL intramuscular injection.
223911511|NCT04199689|OTHER|Placebo (Saline for Injection)|0.9% sodium chloride given as a 0.5-mL intramuscular injection
223911512|NCT04094610|DRUG|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
223911513|NCT05385575|DRUG|KN056 (0.1mg)|The participants will receive assigned single dose of KN056 on Day 1
223911514|NCT05385575|DRUG|KN056 (0.3mg)|The participants will receive assigned single dose of KN056 on Day 1
223911515|NCT05385575|DRUG|KN056 (1.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
223911516|NCT05385575|DRUG|KN056 (3.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
223911517|NCT05385575|DRUG|KN056 (6.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
223911518|NCT05385575|DRUG|KN056 (12.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
223911519|NCT05385575|DRUG|KN056 (18.0mg)|The participants will receive assigned single dose of KN056 or placebo on Day 1
223911520|NCT06589362|DEVICE|Transcutaneous auricular vagus active nerve stimulation|In the active stimulation, two electrodes are placed in the cymba conchae of one of the ears, an area thought to be exclusively innervated by the auricular branch of the vagus nerve.
223911521|NCT06589362|DEVICE|Transcutaneous auricular vagus sham nerve stimulation|In the sham stimulation, the electrodes are placed on the tail of helix, which is free of vagal innervation.
223911522|NCT06600360|OTHER|Teledentistry|Measuring the accuracy of the mobile photographic method of teledentistry for diagnosis and treatment need in dental caries detection
223911523|NCT06604117|DRUG|Statin|Participants who opt for this group will receive guideline-recommended conventional lipid-lowering therapy. For those with a history of ischemic stroke (IS), myocardial infarction (MI), acute coronary syndrome within the past year, symptomatic peripheral artery disease, or two or more high-risk factors, the target LDL-C level will be set at 1.4 mmol/L. For other IS participants, the LDL-C target will be set at 1.8 mmol/L. All participants will receive moderate-intensity statin therapy as the primary treatment. If LDL-C levels are not adequately controlled, ezetimibe will be added. If lipid levels remain unsatisfactory, the addition of PCSK9 inhibitors will be considered. Moderate-intensity statins are defined as atorvastatin 10-20 mg or rosuvastatin 5-10 mg.
223911524|NCT06604117|DRUG|Probucol|Participants who choose this group will receive Probucol in combination with guideline-recommended lipid-lowering therapy. Specifically, participants in this group will take 0.5 grams of Probucol twice daily alongside the conventional lipid-lowering therapy mentioned in Group 1. The combination of Probucol and conventional therapy aims to further improve lipid profile and address atherosclerosis.
223911525|NCT06825325|OTHER|Music Listening|Selection of Sufi music will be played to the patients before the wound debridement.
223911526|NCT06825130|BEHAVIORAL|Exercise|Participants will attend 30-min training sessions 3 times a week for 12 weeks. The intensity of HIIT will be at 80% HR@VT2 measured in the first week and will increase to 90% in the second week. By week 3, the intensity will reach HR@VT2.
223911527|NCT04024254|DRUG|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
223911528|NCT06825845|DRUG|Zevorcabtagene Autoleucel|Non-intervention
223911529|NCT06397534|OTHER|Education|"In the experimental group, students will be administered the Introduction Characteristics Form, Stoma Care Knowledge Assessment Form (pre-test), and the General Self-Efficacy Scale (pre-test). Subsequently, digital materials (such as stoma care presentation materials and stoma care demonstration videos) will be prepared by the researchers. The video content will be uploaded to the 'Edpuzzle' program, which is accessible via internet connection or downloadable to devices. The video content in the 'Edpuzzle' program will consist of stoma care procedural steps. Following this, students will apply the stoma care skill in the skills laboratory under the supervision of instructors. To reinforce the implementation in the experimental group, online activities such as word clouds and quizzes will be sent. After the implementation and 4 weeks later, the 'Stoma Care Knowledge Assessment Form (post-test)' and the 'General Self-Efficacy Scale (post-test)' will be administered online."
223911530|NCT06296810|DEVICE|aDBS|adaptive deep brain stimulation
223911531|NCT06862076|PROCEDURE|Lung Function Prehabilitation|Participants assigned to the prehabilitation group received personalized exercise prescriptions, including aerobic training, muscle strengthening, and inspiratory muscle training with a threshold device. The prehabilitation program was conducted at the participants' homes for a minimum duration of two weeks. Adherence was monitored through logbook entries and video call evaluations to ensure correct implementation of the prescribed exercises.
223911532|NCT05249543|BEHAVIORAL|Unified protocol|Transdiagnostic cognitive-behavioral therapy
223535217|NCT01659502|DRUG|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
223535218|NCT06605209|DEVICE|Peripheral Balloon-Expandable Covered Stent System|The intervention in this clinical trial involves the Peripheral Balloon-Expandable Covered Stent System. This stent system is specifically designed for the treatment of stenosis and/or occlusion in the common and external iliac arteries.
223911533|NCT05249543|BEHAVIORAL|Diagnosis-specific cognitive-behavioral therapy|Diagnosis-specific cognitive-behavioral therapy
223911534|NCT05221619|DRUG|Nipocalimab|Depending on the dose received at their last administration in the MOM-M281-006 (NCT04119050) study, participants will continue to receive either nipocalimab dose-1 every 2 weeks (Q2W) or nipocalimab dose-2 every 4 weeks (Q4W) by intravenous (IV) infusion.
223911535|NCT06668636|BEHAVIORAL|ED-PATCH|Participants will access ED-PATCH using their personal mobile device and use it to track important information throughout their visit. The summary will be checked by a healthcare provider and corrected, if necessary, before being locked and sent to the patient or caregiver to keep for their own records.
223911536|NCT05220631|BEHAVIORAL|Technology intervention|Older Adult Technology Services (OATS) 5-week technology intervention
223911537|NCT05220631|BEHAVIORAL|Digital Nutrition Intervention|15-week nutrition intervention delivered completely online
223911538|NCT06608199|BIOLOGICAL|pneumococcal disease prevention|2P+1 programme of PCV13
223911539|NCT06745960|DEVICE|electrical muscle stimulation device (EMS gymna)|muscle stimulant device
223911540|NCT06745960|OTHER|physical therapy program|neck exercises
224085851|NCT01750255|OTHER|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
224085852|NCT04205435|BIOLOGICAL|β-globin restored autologous HSC|gene edited autologous hematopoietic stem cells with β-globin restoration
224085853|NCT03378908|BEHAVIORAL|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
224085854|NCT01975168|DEVICE|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
224085855|NCT05993637|OTHER|Examination of propriception|application of the tests used in proprioception assessment to patients by a physiotherapist
224085856|NCT01964235|DRUG|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
224085857|NCT01964235|DRUG|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
223911541|NCT06767761|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
223911542|NCT06767761|DRUG|Insulin Glargine U100 group|Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
223911543|NCT06677541|OTHER|Instructional handout|A handout on how to improve sexual dysfunction/function will be provided
223911544|NCT06677541|DEVICE|Vibrator|An FDA approved vibrator device to improve sexual function will be provided
223911545|NCT01258036|RADIATION|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
223911546|NCT01258036|BIOLOGICAL|Sampling|Urine and blood samples
223911547|NCT01258036|RADIATION|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
223911548|NCT05027529|DEVICE|CytoSorb|An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
223911549|NCT05027529|OTHER|VA-ECMO only|only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
223911550|NCT05312645|DRUG|Diclofenac 1% Topical|2 grams topically four times daily for 2 weeks to posterior cervical spine
224085858|NCT04446364|OTHER|Ethanolic extract of Aloe vera gel cavity disinfectant|Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
224085859|NCT04446364|OTHER|Chlorohexadine|2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
224085860|NCT00755833|DRUG|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
224085861|NCT01770600|OTHER|placebo|placebo pill administered daily for 5 days
224085862|NCT01770600|DRUG|Riperidone|1 mg risperidone administered orally for 5 days
224085863|NCT04992975|OTHER|MRI at 7T|MRI at 7T
223535219|NCT00840333|DRUG|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
223535220|NCT07003477|DIAGNOSTIC_TEST|Detection of peripheral blood biomarkers|Peripheral blood samples were collected from patients suffering from acute stroke. The concentration of the biomarker glial fibrillary acidic protein (GFAP) was then detected. This was aimed at differentiating between hemorrhagic stroke and non - hemorrhagic stroke. Time - concentration curves were constructed, thereby offering a novel potential approach for the rapid identification of stroke types within ambulances.
224085864|NCT01273064|DRUG|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
224085865|NCT01273064|DRUG|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
224085866|NCT01273064|DRUG|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
224085867|NCT01273064|DRUG|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
224085868|NCT03987087|RADIATION|Radiation|"Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy"
224085869|NCT03987087|DRUG|Chemotherapy|EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
224085870|NCT00383045|DRUG|Buprenorphine/Subutex|
224085871|NCT00383045|DRUG|Naltrexone|
224085872|NCT00383045|PROCEDURE|Drug counseling|
224085873|NCT04545255|DEVICE|Shockwave treatment|ED 1000 shockwave generator
223911551|NCT05312645|OTHER|Petroleum Jelly|2 grams topically four times daily for 2 weeks to posterior cervical spine
223911552|NCT06671704|OTHER|Genetic counseling months 4-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 4 to month 15.
223911553|NCT06671704|OTHER|Genetic counseling months 6-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 6 to month 15.
224277648|NCT00625326|DRUG|Placebo|Placebo
224277649|NCT00625326|DRUG|COL-121|150 µg/g COL-121 Ointment
224277650|NCT00625326|DRUG|COL-121|300 µg/g COL-121 Ointment
223911554|NCT06671704|OTHER|Genetic counseling months 8-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 8 to month 15.
224085874|NCT04635865|DEVICE|3D-printed patient-specific plate|"We adopt an in-house approach for designing by surgeons. All patient-specific devices are designed in 3-matic 13.0 (Materialise). Both cutting and transferring guides are then additively manufactured by Fused Deposition Manufacturing (FDM) using ULTEM 1010, or by Stereolithography using MED610 resin (Stratasys Ltd, Eden Prairie, MN, USA). Both ULTEM 1010 and MED610 are FDA cleared biocompatible materials applicable to high-temperature autoclaving.~Patient-specific surgical plates are designed by delineating a plate path on bone surface, then followed by the placement of screw holes. Surgical plates are generated by the built-in command in 3-matic. After that, surgical plates are fabricated by SLM using grade 2 titanium powder."
224085875|NCT04635865|DEVICE|Conventional commercial reconstruction plate|Bone segments will be stabilized using commercial titanium surgical plates (DePuy Synthes, United States), which are bent manually before fastening the screws.\[
224085876|NCT03043833|BEHAVIORAL|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:~* Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~* Lesson 2 presents different strategies to generate realistic cognitions.~* Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~* Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~* Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
224085877|NCT03984058|BEHAVIORAL|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
224085878|NCT05461638|PROCEDURE|Mechanical Alignment and Unrestricted Kinematic Alignment using Medacta GMK Sphere with MyKnee Custom guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Unrestricted KA places the implant in a custom position for each patient, completely matching individual anatomy and restoring natural alignment to that of the prearthritic knee.
224085879|NCT05461638|PROCEDURE|Mechanical Alignment and Restricted Kinematic Alignment using Medacta GMK Sphere with custom cutting guides|MA places the implant in an average position for all patients based on pre-determined definition of acceptable knee alignment and has become the most common surgical approach for TKA and Restricted KA places the implant in a custom position for each patient, closely matching with anatomy and natural alignment of the individual's knee.
224277651|NCT01718730|DEVICE|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
223529374|NCT03301584|OTHER|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
223529375|NCT03301584|OTHER|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
223529376|NCT04781491|BEHAVIORAL|Forest Therapy (Düppeler Forst - Berlin-Wannsee)|Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna
223529377|NCT01744015|BEHAVIORAL|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
223535221|NCT03830398|DRUG|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
223911555|NCT06671704|OTHER|Genetic counseling at months 10-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 10 to month 15.
223911556|NCT06671704|OTHER|Genetic counseling at months 12-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 12 to month 15.
223911557|NCT06671704|OTHER|Genetic counseling at months 14-15|all genetic counselors within the same specialty at the same site will cross over from standard of care to the intervention training starting at month 14 to month 15.
223911558|NCT05926258|DRUG|Chloroprocaine 3% eye gel|ocular surface anesthesia
223911559|NCT05926258|DRUG|Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops|ocular surface anesthesia
223529378|NCT01744015|OTHER|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
223529379|NCT04902040|BIOLOGICAL|Atezolizumab|Given IV
223529380|NCT04902040|DRUG|Avelumab|Given IV
223529381|NCT04902040|BIOLOGICAL|Durvalumab|Given IV
223529382|NCT04902040|BIOLOGICAL|Nivolumab|Given IV
223529383|NCT04902040|BIOLOGICAL|Pembrolizumab|Given IV
223529384|NCT04902040|DRUG|Plinabulin|Given IV
223529385|NCT04902040|RADIATION|Radiation Therapy|Undergo radiation therapy
223529386|NCT01779960|OTHER|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
223529387|NCT01779960|OTHER|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
223529388|NCT01365754|PROCEDURE|standard|fusion
223529389|NCT01365754|PROCEDURE|new|dynamic stabilization
223529390|NCT05809388|BEHAVIORAL|Parent training|"Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing."
223529391|NCT05809388|BEHAVIORAL|Virtual Reality-assisted PT sessions|"The experimental group will follow the same program of CG sample. Parent Training sessions will be conducted by a trained psychologist; each session will last approximately 60 minutes that include:~* 40 minutes of as usual PT session, with exercises, discussions and role-playing.~* 20 minutes of VR screen with which the parents may interact; VR screen will provides instructive, stimulating, interactive, and direct feedbacks exercises to enhance parenting strategies."
223911560|NCT06488495|BEHAVIORAL|Exercise Program|The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
223911561|NCT06488495|BEHAVIORAL|Exercise Program|The exercise intervention includes a six-week program with weekly supervised sessions and daily home-based exercises.
223529392|NCT03580044|COMBINATION_PRODUCT|ATM-AVI|ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours. Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.
223911562|NCT05748613|BEHAVIORAL|Computerized Anxiety Sensitivity Treatment|Brief computerized treatment for anxiety sensitivity
223911563|NCT05748613|BEHAVIORAL|Health Education Control|Brief computerized presentation on healthy behaviors
223911564|NCT03668041|DRUG|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
223911565|NCT03668041|DRUG|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
223911566|NCT03668041|OTHER|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
224277652|NCT01718730|DEVICE|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
223535222|NCT03830398|DRUG|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
223535223|NCT03830398|DRUG|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
223535224|NCT07003373|DRUG|hormone replacement therapy (HRT) group|Estradiol valerate is initiated at 4 mg/day on day 2 of the menstrual cycle and is adjusted to 8 mg/day based on endometrial thickness. Once the endometrial thickness reaches ≥8 mm, progesterone supplementation is started (400 mg vaginal suppositories twice daily and 50 mg intramuscular injections daily) for 5 days before blastocyst transfer.
223535225|NCT04701242|DRUG|Ezetimibe 10mg|comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
223535226|NCT00861549|DRUG|Phencynonate hydrochloride|2mg/tablet
223535227|NCT04712669|DRUG|rodatristat ethyl 300 mg tablet BID|rodatristat ethyl 300 mg tablet + matching placebo tablet twice daily on top of standard of care
223535228|NCT04712669|DRUG|rodatristat ethyl 600 mg BID|2 rodatristat ethyl 300 mg tablets twice daily on top of standard of care
224085880|NCT05789095|OTHER|Rate of torque development testing of knee flexors and knee extensors using a fixated handheld dynamometer (MicroFet 2, Hoggan, Scientific L.L.C., Salt Lake City, USA), sampling rate of 100hz)|"Participants and their parents/guardian receives information about the test procedures. Written informed consent is obtained before clinical examination and testing.~Clinical testing is performed, anthropometric values are obtained and patient reported outcome measure is filled out, before the tests are performed. Cases will receive treatment for their condition and controls a movie ticket as compensation."
223529393|NCT03580044|DRUG|BAT|The comparator treatment in this study is best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT (monotherapy or combination) for each subject must be recorded prior to randomization. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
223529394|NCT05093621|DRUG|Furosemide|Standard of care diuretic
223529395|NCT05093621|DRUG|Torsemide|Standard of care diuretic
223911567|NCT04221464|BIOLOGICAL|biological collection|Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
223911568|NCT04221464|OTHER|Tissues collections|Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression
223911569|NCT04046094|DRUG|Ascorbic Acid|Ascorbic Acid Intravenous
223911570|NCT05039554|BEHAVIORAL|Acceptance and commitment therapy|Intervention will be provided over 12 weeks with weekly 1-hour sessions using a group format with the overall goal to foster psychological flexibility. ACT will assist participants to notice their internal triggers; abandon their attempts to manage these triggers via active avoidance (suppression or other control-based strategies including opioid or other substance use) and to make commitments to engage in behaviors consistent with their chosen values or goals (rather than allowing negative thoughts, feelings, or pain symptoms to dictate behavior).
223911571|NCT05039554|OTHER|Valera Smartphone Application|For those randomized to a cohort with the Valera app, the app (and cellphones if necessary) will be provided. The app is HIPAA compliant and IRB approved. It consists of 2 components: a participant-facing Smartphone Application and a corresponding online Care Manager Dashboard. Smartphones and internet access will be provided as needed for the 12-week study duration.
223911572|NCT05039554|OTHER|Treatment as Usual|TAU for BUP treatment typically consists of regularly scheduled visits every 1-2 months with primary care physicians and/or nurse care managers in Montefiore primary care settings. During these 15-min follow up visits, providers typically inquire about opioid and other substance use, opioid craving, symptoms of opioid withdrawal, and risk of relapse. In addition, at each visit, urine toxicology tests are conducted and providers review results of prior urine toxicology tests with patients. If opioid or other substance use is ongoing, typically providers will intensify treatment, including increasing the frequency of visits, referring to social workers or mental health providers, recommending self-help groups, and/or recommending outpatient drug treatment programs (e.g., individual and group counseling).
224085881|NCT04973943|DIAGNOSTIC_TEST|Donor-derived cell Free DNA|Measurement of dd-cfDNA and comparison against grade of rejection as determined by endomyocardial biopsy, taken simultaneously
224085882|NCT03448588|DIAGNOSTIC_TEST|detection of serum selenium|For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
224085883|NCT00184145|OTHER|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
224085884|NCT00184145|OTHER|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
224085885|NCT02906072|BEHAVIORAL|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
224085886|NCT02906072|BEHAVIORAL|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
224085887|NCT00128466|DRUG|gentamicin|
223529396|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by DPI|Miflonide Breezhaler 200 mcg or Oxodil Aerolizer 12 mcg
223529397|NCT04203472|DEVICE|Budesonid or budesonide/fomoterol administered by MDI|Budiair 200 mcg or Atimos 12 mcg
223529398|NCT04574336|PROCEDURE|Surgical treatment|We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.
224085888|NCT00128466|DRUG|streptomycin|
224085889|NCT04062214|BEHAVIORAL|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
224277653|NCT03766139|BIOLOGICAL|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
223529399|NCT04574336|DEVICE|Non-surgical treatment|Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.
223535229|NCT04712669|DRUG|Placebo|2 matching placebo tablets on top of standard of care
223535230|NCT03802396|DRUG|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
224085890|NCT00280761|DRUG|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
224085891|NCT00280761|DRUG|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
224085892|NCT00280761|PROCEDURE|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
224085893|NCT00280761|RADIATION|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
223529400|NCT00251433|DRUG|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
223911573|NCT05962814|DEVICE|EarGenie MVP test|The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
223911574|NCT04528407|OTHER|Observation without intervention|This study is a follow-up study without intervention.
223911575|NCT04627922|DRUG|N-Acetyl cysteine|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
223911576|NCT04627922|OTHER|Placebo comparator|The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers and cannabis users with current tobacco use disorder will be randomized to receive placebo per day over 8 weeks.
223911577|NCT04627922|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants in both groups will receive 8 weekly cognitive behavioral therapy sessions for substance use disorder targeting both tobacco and cannabis use.
223911578|NCT05961358|PROCEDURE|snapshots or videos of monitor|The mobile device（a phone）was used to obtain the screen image of the monitor, and the arterial blood pressure waveform is extracted by image processing technology.
223911579|NCT05961358|PROCEDURE|Pressure transducer|Arterial catheter were connected to conventional pressure transducers and Flotrac-Vigileo transducers.
223911580|NCT06847750|DIAGNOSTIC_TEST|Elastography Ultrasound|The US imaging protocol will include three parts: (i) gray-scale; (ii) color Doppler, and (iii) Shear-wave elastography (SWE)
223911581|NCT06847750|OTHER|The Localized Scleroderma Quality of Life Instrument (LoSQI )|The questionnaire is a validated disease-specific patient-reported outcome measure that covers different domains (skin sensations, physical functioning, body image and social support, designed for children and adolescents with localized scleroderma
223911582|NCT02865538|DRUG|BAY3427080|
223911583|NCT02865538|DRUG|Placebo (for BAY3427080)|
223911584|NCT06852300|DEVICE|Concussion Assessment Battery|"The conclusion test battery will comprise five assessment designed to evaluate sport-related concussion:~1. Health Questionnaire - Including as assessment of signs and symptoms.~2. Sport Concussion Assessment Tool (SCAT)~3. Vestibular Ocular Motor Screening (VOMS)~4. Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)~5. Postural stability assessment (NeuroCom VSR Sport).~Functional Neuroimaging Functional Near-Infrared Spectroscopy (fNIRS) is a non-invasive neuroimaging technology that measures brain activity by detecting changes in blood oxygenation. The NIRSIT scanner will be employed at each testing session to assess cognitive function using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and postural stability using the NeuroCom VSR Sport system."
223911585|NCT05975268|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|JS005/placebo
223911586|NCT02622438|OTHER|Followed with an initial assessment, 12 months and followed annually corresponding to the usual follow-up of the patient.|
223911587|NCT06804473|PROCEDURE|Exercise|The exercise intensity will range from 60-75% of their maximum heart rate (HRmax), with each session lasting 28 minutes, three times per week. The exercise protocol will involve interval aerobic training consisting of four intervals
224085894|NCT02851914|DRUG|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
224085895|NCT02851914|DRUG|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
224085896|NCT02979210|OTHER|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
223529401|NCT00481936|DRUG|VB6-845|Intravenous infusion once weekly for 4 weeks
223529402|NCT01010464|PROCEDURE|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
223911588|NCT06851923|OTHER|3Tesla magnetic resonance imaging of the healthy human visual system|The present project presents a series of monocentric MRI studies carried out on healthy adult human volunteers. All neuroimaging will be performed at the Cliniques Universitaires Saint-Luc (CUSL, IRM de recherche). Participants will not directly benefit from their participation. All studies will manipulate the visual properties of the experimental stimuli in a within-subject way, and therefore do not rely on any participation group assignation/randomization method. The duration of studies will vary between 3h to 6h, i.e., from 2 to 4x1h30 3Tesla magnetic resonance imaging sessions depending on the experimental design.
224085897|NCT02979210|OTHER|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
224085898|NCT02240043|OTHER|growth hormone secretion|The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
223911589|NCT05979337|BEHAVIORAL|Empowered Relief|"This is a single-session (2-hour) behavioral intervention utilizing pain psychology principles (cognitive-behavioral therapy for pain, pain neuroscience education).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
223911590|NCT05979337|BEHAVIORAL|Health Education (HE)|"This is a single-session (2-hour) health education class reviewing principles of medically indicated self-management of migraine headaches (e.g., consistent dietary and hydration habits, exercise, understanding of and adherence to medical treatment regimens).~Class will take place over zoom and have up to 25 participants. The Zoom classes will not be recorded. Participant will be asked to have the camera on during the entire class for treatment course/class validity. Participants are not required to speak during the class but are welcome to ask questions.~Participants will complete daily diaries for 14 days prior to attending study classes, and another 14 days after completing study classes.~In addition, participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life."
223911591|NCT05979337|BEHAVIORAL|Treatment as Usual|"Participants will complete questionnaires and information about medical and personal history, symptoms, mood, sleep, medication use, and ability to function in daily life. In addition, participants will complete daily diaries for 28 days.~If participants are interested in attending classes that were not part of this group assignment, participants will be invited to do so after completing the 6-month follow-up questionnaire."
223911592|NCT05784714|BEHAVIORAL|NOLA GEM|This is a mobile application that has 6 psychoeducational sessions and related skills, local resources, and a way for participants to track their progress. Further information is in the arm descriptions.
223911593|NCT05290493|DRUG|NB-001|Non-stimulant modulator of metabotropic glutamate receptors (mGluRs)
223911594|NCT05290493|OTHER|Placebo|Matching, inactive placebo
223911595|NCT06211933|PROCEDURE|HIFU intervention|HIFU intervention on non resectable pancreatic lesions at day 0 for each patient included
223911596|NCT05419830|BEHAVIORAL|BBTI|Participants randomized to BBTI will receive 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later, and 20-minute telephone calls after 1 and 3 weeks. BBTI will focus on four behaviors that promote sleep and discussion of homeostatic and circadian mechanisms of human sleep regulation. These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
223911597|NCT05419830|OTHER|PM antihypertensive dosing or Chronotherapy|participants will be asked to switch their conventional once daily non-diuretic antihypertensive to bedtime
224085899|NCT01518595|DRUG|bosentan|pts. will receive bosentan for 3 months
224085900|NCT01518595|DRUG|Placebo|pts. will receive placebo for 3 months
224085901|NCT04494932|PROCEDURE|Self-Locking Tenotomy|Self-locking Tenotomy describes the surgical procedure that will be performed to treat SLAP tears.
223911598|NCT05419830|OTHER|AM antihypertensive dosing|participants will be asked to continue taking their antihypertensive medication within an hour of awakening
223911599|NCT06469359|DEVICE|Nasal tissue-resident memory T and B cells|Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
223911600|NCT06469359|DEVICE|Nasal fluid sampling|Nasal fluid is collected using strip (Hunt Development) in both nostrils
223911601|NCT06469359|DEVICE|Saliva sampling|Saliva is collected using Oracol (Malvern Medical Developments)
223911602|NCT06469359|OTHER|Blood sampling|Isolation of peripheral blood mononuclear cells (PBMC) and serum from blood
223911603|NCT06469359|DIAGNOSTIC_TEST|ELISA|ELISA to measure antibody responses in mucosal fluids and blood
223911604|NCT06469359|DIAGNOSTIC_TEST|Neutralization test|Neutralization test to measure neutralizing antibody responses in mucosal fluids and blood to measure neutralizing antibody responses in mucosal fluids and blood
223911605|NCT06469359|DIAGNOSTIC_TEST|ELISPot|ELISPot to measure cellular responses in blood
223911606|NCT06469359|DIAGNOSTIC_TEST|Transcriptomics|Transcriptomics to quantify the gene expression of immunological markers in blood
223911607|NCT04608318|BIOLOGICAL|Ibrutinib|Cycles 1 - X: 420 mg daily, d1-28 p.o.
224085902|NCT04494932|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat SLAP tears.
224085903|NCT05434039|OTHER|diclofenac phonophoresis|the patients will be in comfortable position and apply diclofenac phonophoresis on upper trapezius and suboccipital muscle by ultrasound device. diclofenac gel was applied circularly with a thickness of 2-3 mm. Then ultrasound with was applied with 1 MHz frequency and 1.5 Wt/cm2 power over the trigger points on the trapezius and suboccipital muscle, for 10 min.
223529403|NCT05619393|DEVICE|Mobilie Bi-planar X-ray Imaging system|on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
223529404|NCT04925141|DRUG|Dasatinib Tablets|Tyrosine Kinase Inhibitor (TKI)
223529405|NCT01241630|PROCEDURE|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
223529406|NCT06446570|DRUG|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
223529407|NCT03690778|DRUG|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
223529408|NCT03690778|DRUG|JLP-1310|administration of JLP-1310
223529409|NCT01664624|DRUG|Roflumilast|Roflumilast tablets
224085904|NCT05434039|OTHER|high power pain threshold ultrasound|the patients will be in comfortable position and The frequency was set to 1 MHz, and the intensity will be increased from 0.5 to 2 until the patient reported an unpleasant sensation. The probe was held there for 4 s; then, the intensity was reduced by 50%, and the probe will be moved over and around the trigger point. This process is done several times for three minutes
224085905|NCT05434039|OTHER|conventional therapy|the patient will receive an active range of motion exercise, stretching and strengthening of all cervical muscles
224085906|NCT00609596|DRUG|GI198745|
224085907|NCT00291551|DEVICE|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
224085908|NCT04666038|DRUG|Pirtobrutinib|Oral Pirtobrutinib
224085909|NCT04666038|DRUG|Idelalisib|Oral
224085910|NCT04666038|DRUG|Bendamustine|IV
224085911|NCT04666038|DRUG|Rituximab|IV
224085912|NCT00855114|DRUG|everolimus|5 mg/day x 7 days by mouth
224085913|NCT00855114|PROCEDURE|therapeutic conventional surgery|Definitive excision of breast cancer tissue
224085914|NCT00406146|DRUG|amodiaquine+artesunate/artemether-lumefantrine|
224085915|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
224085916|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
224085917|NCT05167448|DRUG|ES104|ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
224085918|NCT00006070|DRUG|etanercept (Enbrel)|
224085919|NCT05558150|DRUG|Ilaprazole|Ilaprazole 10mg
224085920|NCT05558150|DRUG|Aceclofenac|Aceclofenac 100mg
224277654|NCT03766139|BIOLOGICAL|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
224277655|NCT02488824|PROCEDURE|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
224277656|NCT06441903|OTHER|Ultrasound|Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
224277657|NCT05811221|DRUG|Esketamine of single injection|Single group: give esketamine 0.75 mg/kg at the time of induction
224277658|NCT05811221|DRUG|Esketamine of Intermittent injection|Intermittent group: give esketamine 0.5mg/kg during anesthesia induction, and during the measuring ring esketamine 0.25mg/kg was given again
224277659|NCT00493064|DRUG|Nicotinic acid|topical eye drops
224277660|NCT00493064|DRUG|Prednisolone acetate|topical eye drops
224277661|NCT01008384|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units taken orally once a week for 8 weeks
224277662|NCT05966311|DEVICE|Percutaneous Ultrasound Gastrostomy|Ultrasound guided placement of gastrostomy tube using the PUMA-G Pediatric System
223529410|NCT01664624|DRUG|Alogliptin|Alogliptin tablets
224085921|NCT00702078|BEHAVIORAL|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
223529411|NCT01664624|DRUG|Exenatide|Exenatide solution
223529412|NCT01664624|DRUG|Placebo to roflumilast|Placebo-matching roflumilast tablets
223529413|NCT01664624|DRUG|Placebo to alogliptin|Placebo-matching alogliptin tablets
223529414|NCT01912014|BEHAVIORAL|Psychosocial support and counselling|
224085922|NCT00702078|BEHAVIORAL|usual care|follow-up according to todays best practice
224085923|NCT04955561|OTHER|Oxygen therapy|Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
224085924|NCT04955561|OTHER|Medical Air|Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
224085925|NCT04955561|OTHER|10L/min O2|Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
224085926|NCT01635790|DRUG|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
224085927|NCT01635790|DRUG|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
224085928|NCT06469060|DRUG|neoadjuvant anti-PD-1 with DOC chemotherapy|"Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1\. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle."
224085929|NCT05154695|DEVICE|LASER|The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.
224085930|NCT05154695|DEVICE|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
224085931|NCT05154695|DRUG|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
224085932|NCT04690010|PROCEDURE|Ambulatory tubeless PCNL|Patients will be discharged the same day of surgery. No nephrostomy tube will be left in place. A ureteral stent on a string may be left for up to 5 days.
224085933|NCT04690010|PROCEDURE|Inpatient PCNL with nephrostomy tube|Patients will be admitted to hospital for 1-3 days. A nephrostomy tube will be placed at the time of surgery that will be removed prior to discharge.
223529415|NCT06186609|DRUG|PD-1 inhibitor 200mg per three to four weeks, for one year|"PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction."
223529416|NCT05253040|OTHER|KEEP Intervention|Educational intervention
223529417|NCT05253040|OTHER|control|booklet from Parkinson's UK
223529418|NCT01941602|DRUG|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
223529419|NCT01941602|PROCEDURE|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
223529420|NCT01206517|DRUG|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
223529421|NCT01206517|DRUG|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
223529422|NCT01206517|DRUG|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
223529423|NCT00865748|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
223716169|NCT05517044|OTHER|Nitrogen tent preacclimatization to high altitude|The participants assigned to the preacclimatization group spend a minimum of six hours during sleep, throughout the acclimatization period (four weeks preceding the expedition) in a nitrogen concentration tent (Hypoxico OHG, Traunstein, Germany) set to an environmental PO2 corresponding to an altitude of 2500 masl, with a progression to 5500 masl within 28 days in steps of 1000 m every seven days. Respiratory Polygraphy is used to detect periodic breathing, SpO2, and heart rate continuously during sleep and is performed before and after the designated preacclimatization period, and repetitively when increasing normobaric hypoxia in the group with nitrogen concentration tent preacclimatization.
223716170|NCT03045315|OTHER|IVF Procedure|
223716171|NCT01211002|RADIATION|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
223716172|NCT01211002|DRUG|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 \~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
223716173|NCT05405374|OTHER|OSTEOAMP|OSTEOAMP SELECT Fibers (derived from human bone allograft) rehydrated with bone marrow aspirate (BMA) and combined with local autogenous graft for use in lumbar interbody fusion of the lumbar spine.
223911608|NCT04608318|BIOLOGICAL|Venetoclax|"Arm VG~Cycle 1: 20 mg (2 tabl. at 10 mg), d22-28 p.o.~Cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28 p.o.~Cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28 p.o.~Arm VI~Cycle 4: 20 mg (2 tabl. at 10 mg), d1-7; 50 mg (1 tabl. at 50 mg), d8-14; 100 mg (1 tabl. at 100 mg), d15-21; 200 mg (2 tabl. at 100 mg), d22-28 p.o.~Cycles 5-15: 400 mg (4 tabl. at 100 mg), d1-28 p.o."
223911609|NCT04608318|BIOLOGICAL|Obinutuzumab|Cycle 1: (100 mg, d1 + 900 mg, d2) or 1000 mg, d1; 1000 mg, d8 + d15 i.v. Cycle 2 - 6: 1000 mg, d1 i.v.
223911610|NCT03428828|DEVICE|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
223911611|NCT03428828|DEVICE|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
223911612|NCT05391737|DIAGNOSTIC_TEST|Echocardiography|Echocardiography after swimming (acute) and at rest (baseline)
223911613|NCT05391737|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Electrocardiogram (ECG) after swimming (acute) and at rest (baseline)
223911614|NCT05391737|DIAGNOSTIC_TEST|Cardiac biomarkers|high sensitive (hs)-Troponin I and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) after swimming (acute) and at rest (baseline)
223716174|NCT05405374|DEVICE|Infuse|The Infuse Bone Graft/Medtronic Interbody Fusion Device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2, known as dibotermin alfa) placed on an absorbable collagen sponge (ACS). rhBMP-2 is the active agent in the Infuse Bone Graft component. The ACS is a soft, white, pliable, absorbent implantable matrix for rhBMP-2.
223911615|NCT05216653|DRUG|Envafolimab|This product is administered by subcutaneous injection. The recommended dose of subcutaneous injection is 150 mg, administered weekly (QW).
223911616|NCT05216653|DRUG|Oxaliplatin|130mg/m2，ivgtt，d1
223911617|NCT05216653|DRUG|Capecitabine|1000mg/m2，po，bid，d1-14
223911618|NCT05216653|RADIATION|Short-course Radiation|Short-course radiotherapy, using three-dimensional conformal or intensity-modulated radiotherapy, the dose is divided into 5Gy/f, the total dose is 25Gy/5f, 1f/d, and the irradiation is completed within 7 days.
224085934|NCT01238692|DRUG|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
223529424|NCT00865748|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
223529425|NCT05749471|DIAGNOSTIC_TEST|ASEX (Arizona Sexual Experience) administration|ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30. Generally, a subject with a total ASEX score of \> 19, any one item with a score of \> 5, or any three items with a score of \> 4 would have sexual dysfunction.
223911619|NCT05216653|PROCEDURE|TME surgery, total mesorectal excision|The surgical method can choose open, laparoscopic or robotic according to the specific condition of the patient.
223911620|NCT05726292|DRUG|Relacorilant|Relacorilant is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is being used in this study as an experimental drug combined with other treatments for prostate cancer.
223911621|NCT05726292|DRUG|Enzalutamide|Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen medication which is used in the treatment of prostate cancer.
223911622|NCT05726292|OTHER|Placebo (Sugar Pill)|This would be a sugar pill consisting of 2 softgels. This is not an experimental drug or treatment.
223911623|NCT05726292|OTHER|Androgen Deprivation Therapy|"All participants in this study, who meet the requirements to participate, will get Androgen Deprivation Therapy (ADT; a form of hormone therapy) continuously before their radical prostatectomy surgery. As part of this study, ADT consists of one injection every 1-3 months. In this study, ADT is a gonadotropin releasing hormone (GnRH) agonists or antagonist; the choice of which brand of ADT to use is up to your treating physician. GnRH agonists and antagonists are drugs that lower the production of androgens (male hormones) in your body. Prostate cancer cells usually require androgens, such as testosterone, to grow.~Androgen Deprivation Therapy (ADT) has been approved by United Stated Food and Drug Administration (US FDA) to treat patients with prostate cancer but is not approved to treat patients prior to prostatectomy."
223911624|NCT05726292|PROCEDURE|Radical Prostatectomy|Radical prostatectomy is surgery to remove the entire prostate gland and surrounding lymph nodes to treat men with localized prostate cancer.
223911625|NCT01743950|DRUG|Bevacizumab|10mg/kg every 2weeks.
223911626|NCT01743950|RADIATION|PRDR|Daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions. In the rare instance of the presence of extensive disease requiring essentially whole brain radiation, a total daily dose of 1.8 Gy delivered in .2 Gy pulses for 23 fractions to a total dose of 41.4 Gy will be utilized.
223911627|NCT04400331|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
223911628|NCT05331729|RADIATION|FMISO-PET Protocol|"* injection of 18F-FMISO~* Monitoring for 2 h~* PET scan (30 min) 2h post injection~* Monitoring for 2h~* PET (30min) 4h post injection~* Discharge of the subject with appropriate recommendations after a PET/CT"
223911629|NCT04615273|DRUG|Lonapegsomatropin|Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
223911630|NCT04615273|OTHER|Placebo|The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.
223911631|NCT04615273|DRUG|Somatropin|Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
223911632|NCT06493188|OTHER|High-fidelity interprofessional simulation|Students will participate in realistic (high-fidelity) interprofessional simulation scenarios to practice and interpret ABG procedures.
223911633|NCT06493188|OTHER|Low-fidelity interprofessional simulation|Students will take part in low-fidelity interprofessional simulation scenarios. Cases will be discussed, and reflection on ABG execution and interpretation will be guided using paper descriptions and clinical files.
223911634|NCT03229057|DRUG|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
223911635|NCT03229057|DRUG|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
224085935|NCT01238692|DRUG|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
224085936|NCT06215833|DRUG|Propofol|All children will undergo anesthesia via Propofol bolus injection in induction then Propofol infusion in maintenance of anesthesia and will be given after total recovery, Cetal suppositories as postoperative analgesia
224085937|NCT06215833|DRUG|Sevoflurane|All children will undergo anesthesia via Sevoflurane will be given during induction then through maintenance of anesthesia and will be given after total recovery, Cetal suppositories as post operative analgesia
223529426|NCT05439733|OTHER|Questionnaire completion|Women will be asked to complete questionnaires 6 weeks after delivery
223529427|NCT04426747|OTHER|No intervention|No intervention
223529428|NCT01775527|OTHER|blood test|
223529429|NCT01846026|DRUG|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
223529430|NCT01846026|DRUG|placebo|
223529431|NCT06310382|DRUG|GH55|GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
223529432|NCT01041261|DIETARY_SUPPLEMENT|BariatrX Essentials 360 Treatment|Medical food
223911636|NCT03229057|DRUG|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
223716175|NCT02713347|BEHAVIORAL|ADAPT Intervention|"The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
223716176|NCT05866172|PROCEDURE|HAIC|hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h)
223716177|NCT05866172|DRUG|Zoledronic acid|Zoledronic acid 4mg iv.drip
223716178|NCT00365911|PROCEDURE|Taking blood sample|A blood sample will be taken.
223716179|NCT00247975|DRUG|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
223716180|NCT03799081|PROCEDURE|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
223716181|NCT04991909|DRUG|HRS4800|HRS4800
223911637|NCT05769283|OTHER|Platelet Rich Plasma|Platelet rich plasma (PRP) is autologous blood which has been centrifuged to separate the supernatant resulting in a solution with high concentration of platelets. It is then injected into the anterior vaginal wall and periclitoral area
223911638|NCT05769283|OTHER|Saline|Normal Saline to be injected into the anterior vaginal wall and periclitoral area
223911639|NCT03677141|DRUG|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
223911640|NCT03677141|DRUG|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
223911641|NCT03677141|DRUG|Rituxumab|Participants will receive rituxumab via IV.
223911642|NCT03677141|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
223911643|NCT03677141|DRUG|Doxorubicin|Participants will receive doxorubicin via IV.
223911644|NCT03677141|DRUG|Vincristine|Participants will receive vincristine via IV.
223911645|NCT03677141|DRUG|Prednisone|Participants will receive oral prednisone.
223911646|NCT03677141|DRUG|Tocilizumab|Participants will receive tocilizumab via IV.
223911647|NCT05498675|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|There is no treatment allocation. Patients administered sacubitril / valsartan oral tablet (Entresto) 200mg 1/day by prescription that have started before inclusion of the patient enrolled into the study and defined as sacubitril/valsartan group.
223911648|NCT05498675|DRUG|ACEI/ARB|"There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan."
223911649|NCT05094271|OTHER|Supplemental Oxygen|Subjects will be instrumented with a nasal cannula to receive 2L/min supplemental oxygen. The oxygen will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
223911650|NCT05094271|DEVICE|Continuous Positive Airway Pressure Machine|Continuous positive airway pressure is a form of positive airway pressure ventilation in which a constant level of pressure greater than atmospheric pressure is continuously applied to the upper respiratory tract of a person.
223911651|NCT05094271|OTHER|Room Air|Subjects will be instrumented with a nasal cannula to receive 2L/min pressurized room air. The room air will be kept at a fixed rate, however, the participant will be titrated to receive a max of 4 liters per min to maintain sats \>90% based on oximetry readings.
223911652|NCT05465239|DEVICE|SurePace Powered Walker User|Participants will be asked to perform one baseline 5-minute trial with the lab's instrumented walker in passive mode (no powered locomotion) and two 5-minute trials with the walker in active mode (powered locomotion).
223716182|NCT04991909|DRUG|Placebo|Placebo
223716183|NCT00968214|GENETIC|polymorphism analysis|
223716184|NCT00968214|OTHER|laboratory biomarker analysis|
223716185|NCT06124560|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
223716186|NCT02179866|DRUG|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
223716187|NCT02168634|DRUG|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
223529433|NCT01029535|DEVICE|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
223529434|NCT01370876|DRUG|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
223716188|NCT02168634|DRUG|Placebo|1cc normal saline, local injection
223529435|NCT05788445|DEVICE|nrTMS treatment|Using the nrTMS treatment coli to stimulation with high frequency
223911653|NCT05834777|DRUG|Icatibant|Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
223716189|NCT01393691|BEHAVIORAL|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
223911654|NCT05834777|DRUG|Placebo|0.9% sodium chloride will be administered as the same rate as icatibant
223911655|NCT05918120|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
223911656|NCT05918120|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
223911657|NCT05457478|OTHER|Medical Device Qardio® smart scale Usage and Evaluation|Weight monitored using a Qardio® smart scale
223911658|NCT05457478|OTHER|Questionnaire Administration|Ancillary studies
223911659|NCT03947697|DEVICE|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
223911660|NCT03947697|DEVICE|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
223911661|NCT03947697|OTHER|Resistance Training|Group will receive exercise training.
223911662|NCT04280276|DIAGNOSTIC_TEST|TruGraf test|To obtain longitudinal TruGraf testing in patients with stable creatinine, high and normal IPV in tacrolimus levels, between 3 and 18 months post-transplant at the University of Maryland post-transplant clinic.
223911663|NCT04743856|BEHAVIORAL|ActiveGOALSv2|13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.
223911664|NCT04743856|BEHAVIORAL|PAT|Participants will receive a physical activity tracker and encouragement to increase activity.
223911665|NCT03018366|DRUG|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
223911666|NCT03018366|DRUG|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
223911667|NCT03018366|DRUG|Progesterone|After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
223911668|NCT03018366|DRUG|Placebo Pill|After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
223911669|NCT03344965|DRUG|Olaparib|olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
223911670|NCT01853631|GENETIC|Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|"Three dose levels will be evaluated.~Group 1: CD19.CAR/28137ζ at 1×10\^6 cells/m\^2 and CD19.CAR/28ζ at 1×10\^6 cells/m\^2~Group 2: CD19.CAR/28137ζ at 5×10\^6 cells/m\^2 and CD19.CAR/28ζ at 5×10\^6 cells/m\^2~Group 3: CD19.CAR/28137ζ at 2×10\^7 cells/m\^2 and CD19.CAR/28ζ at 2×10\^7 cells/m\^2"
223911671|NCT01853631|GENETIC|Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells|The primary goal of the expanded cohort is to further study the safety profiles of CAR-T cells in each of the disease settings, both with or without lymphodepleting chemotherapy given before CAR-T cell infusion.
223911672|NCT04542616|DEVICE|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation|Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.
223911673|NCT05933863|DRUG|PD-(L)1 antibody immunotherapy|The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
223911674|NCT05739253|PROCEDURE|Transcatheter aortic valve replacement|All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
223911675|NCT04842682|BIOLOGICAL|Solo 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
223911676|NCT04842682|BIOLOGICAL|Solo 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
223911677|NCT04842682|BIOLOGICAL|Solo 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid at weeks 0, 4 and 24."
223911678|NCT04842682|BIOLOGICAL|Combi 0.3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
223529436|NCT05788445|DEVICE|nrTMS sham|Using the nrTMS sham coli to stimulation with high frequency
223529437|NCT01195974|DRUG|YASMIN|YASMIN for 21 days
223529438|NCT01195974|DRUG|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
223529439|NCT01195974|OTHER|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
223529440|NCT00360139|DEVICE|Sculptra Injection|
223529441|NCT03218865|DEVICE|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
223529442|NCT03218865|DEVICE|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
223529443|NCT03230214|DIAGNOSTIC_TEST|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
223911679|NCT04842682|BIOLOGICAL|Combi 1 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 1.0 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
223911680|NCT04842682|BIOLOGICAL|Combi 3 group|"CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24."
223911681|NCT04842682|BIOLOGICAL|Late boost CD40 alone|CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
223911682|NCT04842682|BIOLOGICAL|Late boost CD40 adjuvanted|CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
223911683|NCT05423730|OTHER|White Wine|One serving (5 ounces) of white wine daily for 3 weeks
223911684|NCT05423730|OTHER|Grape Juice|One serving (6 ounces) of white grape juice daily for 3 weeks
223911685|NCT06804343|BEHAVIORAL|first aid training|A pre-test will be applied to the participants in a single group before the training. After the training is applied, a post-test will be done and a follow-up will be done at the end of 6 months and a post-test will be applied.
223911686|NCT06805513|COMBINATION_PRODUCT|Tadalafil 5 mg tablets with a digital tool.|The combination product will be a Drug (Tadalafil 5 mg) and Health Survey Assessment (as a mandatory digital tool). Tadalafil 5 mg will be taken orally, 1 tablet daily to use for treatment of erectile dysfunction. This study will be conducted remotely, via video interaction.
223911687|NCT06804733|BEHAVIORAL|12-week individualized aerobic exercise training|After enrollment, subjects directly participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level measured by International Physical Activity Questionnaire (IPAQ), with the exercise intensity being increased every four weeks.
223911688|NCT06804733|BEHAVIORAL|12-week control intervention followed by 12-week aerobic exercise training|After enrollment, subjects first undergo a 12-week control intervention (i.e., routine treatment) and then participate in a 12-week aerobic exercise training program. The training plan provides individualized progressive aerobic training based on their baseline physical activity level IPAQ, with the exercise intensity being increased every four weeks.
223911689|NCT04961593|DRUG|Caspofungin|For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.
223911690|NCT06836921|OTHER|Standard of Care (Investigator Choice)|Participants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.
223911691|NCT06836921|OTHER|MDC visit|"The multidisciplinary clinic visit will use a shared appointment model and will include a specialized team comprising movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist (PT), an occupational therapist (OT), a speech-language pathologist, and a social worker. Care will be delivered in an outpatient setting at a University Hospital. Prior to the initial visit, patients with APS and their care partners will receive a pre-visit questionnaire to identify their top three care priorities.~During the visit, the multidisciplinary team will convene with the patient and their care partner in a single appointment room. The session will begin by addressing each of the priority issues identified by the patient and care partner. The team will collaboratively discuss management strategies, focusing on self-management, and will provide real-time guidance and recommendations. As indicated, hands-on PT and OT evaluatio"
223911692|NCT03184792|DEVICE|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
223911693|NCT03184792|OTHER|Physical therapy|Physical therapy to improve arm and hand functions
223911694|NCT05203445|DRUG|Olaparib|Olaparib 300 mg orally BID
223911695|NCT05203445|DRUG|Pembrolizumab|Pembrolizumab 400 mg intravenously q6weeks
223911696|NCT06434441|PROCEDURE|Autogenous bone augmentation|Maxillary alveolar bone reconstruction
224085938|NCT02049047|DRUG|Everolimus|Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
223911697|NCT06852157|DIAGNOSTIC_TEST|Tissue, diagnostic and prognostic accuracy|"The clinical data and histological samples of patients with a diagnosis of CIN/SIL on cervical biopsies or conization (performed as required by the normal procedure) will be consecutively acquired from all those taken at the Operative Unit of Gynaecology and Physiopathology of Human Reproduction starting from January 2000 and stored at the Operative Unit of Pathological Anatomy and Histology.~Samples fixed in neutral buffered formalin and paraffin added at 50°C will be analysed by repeating histological examination and performing immunohistochemistry for BAG3. All analyses will be performed blinded to the clinical data of the patients and the results of the original examinations. No patients will be examined ex novo, as only paraffin-embedded tissue samples obtained at the time of the initial diagnosis will be analysed."
223911698|NCT02398747|DRUG|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
223911699|NCT05075577|DRUG|Enzalutamide|Daily oral dose of enzalutamide
224085939|NCT03963609|RADIATION|multisclice CT|assessment of the remodeling index by multisclice CT in patients with chronic stable angina
224085940|NCT00214123|RADIATION|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
224085941|NCT03400800|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
223529444|NCT02458235|DRUG|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
223529445|NCT02458235|BIOLOGICAL|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
224085942|NCT03400800|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
224085943|NCT01814163|DRUG|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
224085944|NCT01512264|DEVICE|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
224085945|NCT06335056|BEHAVIORAL|ProudMe|"ProudMe Tech: Regular human/computer interaction (3-5 times per week) to engage in SMART goal-setting, behavior monitoring, and self-reflection as assisted by AI-enabled feedback.~ProudMe Physical Education \[PE\]: 12 lessons to acquire knowledge, skill, and dispositions to improve physical activity, diet, screen-based sedentary behaviors.~ProudMe Cafeteria: Purposely enabling policy and environmental changes in school cafeteria (recognize areas of strengths and weaknesses; set goals and action plans; make changes to improve scores assessed by the Smarter Lunchroom Scorecard).~ProudMe Training: 4-hour implementation training + regular check-in and support (via motivational interviewing techniques)"
224085946|NCT06335056|BEHAVIORAL|Waitlist Control|The waitlist control involves (a) regular physical/health education and lunchroom, (b) professional development training on the overall importance of quality physical/health education, health eating and foot environment. It does not involve AI-assisted behavior management system.
223716190|NCT01393691|BEHAVIORAL|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
223716191|NCT03060538|DRUG|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
223911700|NCT05075577|DRUG|EPI-7386 with Enzalutamide|Daily oral dose of EPI-7386 in combination of enzalutamide
223911701|NCT05168722|OTHER|No interventions|No interventions
223911702|NCT04670874|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
223911703|NCT04670874|OTHER|Questionnaire Administration|Complete quality of life questionnaire
223911704|NCT03673501|DRUG|Ripretinib|Oral KIT/PDGFRA kinase inhibitor
223911705|NCT03673501|DRUG|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
224085947|NCT04433507|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is performed through a standard 5-port technique. After dissection of the greater curvature of the stomach, a narrow tube-like stomach is created after stapling off the lateral aspect of the stomach using a 40 French bougie as a guide.
224085948|NCT04433507|PROCEDURE|Hiatal Hernia repair|Hiatal hernia repair consists in a circumferential dissection of the diaphragmatic crura to achieve an intra abdominal esophageal length of 2-3 cm. The crura will then be closed anteriorly and posteriorly using nonabsorbable sutures.
224085949|NCT03280160|DRUG|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.~After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.~Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).~A treatment cycle will be defined as lasting 28 days"
224085950|NCT03287128|DRUG|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
223716192|NCT03060538|OTHER|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
223716193|NCT00001535|DRUG|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
223716194|NCT05248048|BIOLOGICAL|CAR-T infusion|NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer
223911706|NCT05838027|BEHAVIORAL|Cash Transfer|Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
223911707|NCT04599634|DRUG|Obinutuzumab|Administered intravenously, on Days 1, 2, 8 and 15 of Cycle 1 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg for dose finding phase. For expansion phase, administered on Days 1, 2, 8 and 15 of Cycle 2 at doses escalating from 100mg - 1000mg then on the first day for all subsequent cycles at 1000mg.
223911708|NCT04599634|DRUG|Venetoclax|For follicular lymphoma (FL) patients in dose finding phase, administered orally at a dose of 600mg or 800mg depending on tolerance, daily, cycles 1-12. For MZL (Marginal Zone Lymphoma), MCL (Mantle Cell Lymphoma) or CLL (Chronic Lymphocytic Leukemia) patients in dose finding phase administered at an escalating dose from 20mg-400mg Cycle 1 on days 1-35, and at a dose of 400mg per day for Cycles 2-12. Patients in expansion phase will receive target dose established from dose finding cohorts daily for all 12 cycles.
224085951|NCT02314507|OTHER|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
223716195|NCT04218422|PROCEDURE|Battlefield Acupuncture|Acupuncture at 5 points on the ears
223716196|NCT04218422|PROCEDURE|Sham Acupuncture|Sham acupuncture in 2 points for liver and 1 point for stomach
223716197|NCT00705484|BIOLOGICAL|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
223911709|NCT04599634|DRUG|Magrolimab|Administered intravenously, starting at 1 mg/kg on second day of first cycle then 30mg/kg on days 8, 15 and 22 of cycle 1 and days 1 and 15 of cycles 2-12 for patients in both the dose finding and expansion phases.
223911710|NCT04599634|DRUG|Acetaminophen|Premedication with 650mg acetaminophen 30-60 minutes prior to obinutuzumab doses.
223911711|NCT04599634|DRUG|Diphenhydramine|Premedication with 25-50mg diphenhydramine 30-60 minutes prior to obinutuzumab doses.
223911712|NCT04599634|DRUG|Prednisone/prednisolone|Premedication with 100mg intravenous prednisone/prednisolone 30-60 minutes before obinutuzumab infusion.
223911713|NCT04599634|DRUG|Methylprednisolone|Premedication with intravenous methylprednisolone 80mg 30-60 minutes before obinutuzumab infusion.
224085952|NCT02314507|OTHER|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
223911714|NCT04599634|DIAGNOSTIC_TEST|CT Scan chest/abdomen/pelvis|Screening, baseline, window Cycle -1/pre cycle 1, cycles 6-12; cycles 3-9, end of treatment and follow-up.
223911715|NCT04599634|DIAGNOSTIC_TEST|MRI|Screening, baseline, window Cycle -1/pre cycle 1, cycles 6-12; cycles 3-9, end of treatment and follow-up.
223911716|NCT04599634|DIAGNOSTIC_TEST|18-FDG-PET|Baseline, Cycle -1, Day 1, window Cycle -1/pre cycle 1, cycles 6-12, end of treatment and follow-up.
223911717|NCT04599634|PROCEDURE|Bone Marrow Biopsy|Screening, Cycle 7-12, Day 1 and end of treatment.
223911718|NCT04599634|PROCEDURE|Bone Marrow Aspiration|Screening, Cycle 7-12, Day 1 and end of treatment.
223911719|NCT02671448|BEHAVIORAL|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
223911720|NCT02671448|BEHAVIORAL|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
223911721|NCT02671448|BEHAVIORAL|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
223911722|NCT01878422|DRUG|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
223911723|NCT01878422|DRUG|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
223911724|NCT01878422|DRUG|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
223911725|NCT01878422|DRUG|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
223911726|NCT05969483|DEVICE|pEEG monitoring|pEEG monitoring during PICU admission
223911727|NCT05776875|DRUG|Atezolizumab Injection|Atezolizumab is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma It is a fully humanized, engineered monoclonal antibody of Immunoglobulin G1 (IgG1) isotype against the protein programmed cell death-ligand 1 (PD-L1).
223911728|NCT05776875|DRUG|Bevacizumab|Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
224085953|NCT04880187|DRUG|AXA1125|AXA1125 administered BID with or without food
224085954|NCT04880187|DRUG|Placebo|Matching Placebo administered BID with or without food
224085955|NCT05030688|OTHER|Postoperative analgesia management|Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
224085956|NCT02025296|DEVICE|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
223911729|NCT05776875|COMBINATION_PRODUCT|Transarterial chemoembolization|Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
223911730|NCT05354765|OTHER|blood sample|lymphapheresis before and during treatment, blood sample in CellSave® tubes (15mL) will be taken at baseline and three weeks, and EDTA tubes (15mL) will be taken at baseline, 3 weeks after treatment start and at progression
224085957|NCT02427347|OTHER|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
224085958|NCT02427347|OTHER|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
224277663|NCT04626544|DEVICE|Body-worn inertial sensors|The device typically includes accelerometers that capture body accelerations in three directions (anteroposteriorly, mediolaterally and vertically) and gyrometers that capture rotations (yaw, pitch and roll). The method of measuring gait using body-worn inertial sensors has been found reliable \[15\] and valid \[20\]. This project will use Opal sensors and the Mobility Lab software from the manufacturer APDM (https://www.apdm.com/wearable-sensors/).
224277664|NCT03123978|DRUG|Enzalutamide|Given PO
223911731|NCT05354765|OTHER|blood sample|lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment
223911732|NCT06138977|DEVICE|Powered prosthesis|A powered prosthesis will be used to restore normative leg biomechanics to above-knee amputee participants during different activities of daily life.
223911733|NCT06359002|DRUG|BYON4413|BYON4413 will be administered by IV infusion.
224277665|NCT03123978|DRUG|Niclosamide|Given PO
224277666|NCT00111956|DRUG|Etanercept|
224277667|NCT00111956|DRUG|Placebo|
223911734|NCT05200923|DEVICE|Sacral Neuromodulation|Sacral neuromodulation delivers electrical stimulation to a sacral nerve
223911735|NCT04540068|DRUG|Transforaminal Epidural Injection|Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
224277668|NCT04347525|OTHER|CaCBT based guided self help using Khushi aur Khatoon Manual|CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm
223911736|NCT05422430|BEHAVIORAL|Rebreathing-induced hypoxia|Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.
223911737|NCT05422430|BEHAVIORAL|Spontaneous breathing|Participants will be spontaneously breathing during an oral glucose tolerance test.
223911738|NCT04340505|DRUG|Fluocinolone Acetonide|Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
224085959|NCT03073473|DIAGNOSTIC_TEST|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
224085960|NCT02647073|DEVICE|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
224085961|NCT05490797|OTHER|app based training with conventional therapy|The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.
224085962|NCT05490797|OTHER|conventional therapy|conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
224085963|NCT01232699|BEHAVIORAL|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
224085964|NCT01232699|BEHAVIORAL|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
224085965|NCT01232699|BEHAVIORAL|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
224085966|NCT03240146|DEVICE|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
224085967|NCT04915040|BEHAVIORAL|Behavioral Activation for Depression|Behavioral Activation (BA) is an effective treatment for depression, and its components may increase social connection. Generally, caregivers are with the older adult care recipient on a regular basis and may be able, with the correct training, to help enhance certain features of the Behavioral Activation treatment, even under pandemic restrictions on social contact. Therefore, we propose to (a) integrate \& (b) gather feasibility data for home-based Behavioral Activation + Caregiver
224085968|NCT01859247|DEVICE|rTMS|
224085969|NCT01660217|OTHER|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
224085970|NCT01625520|DRUG|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
224277669|NCT00356824|DRUG|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
224277670|NCT00356824|DRUG|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
224277671|NCT00007761|BEHAVIORAL|Bipolar Disorder Program|
224277672|NCT00007761|BEHAVIORAL|Usual (psychiatric) Care|
223911739|NCT06015659|DRUG|Zentalis|Small molecule inhibitor of the WEE1 tyrosine kinase, tablet taken orally per protocol.
223911740|NCT06015659|DRUG|Gemzar|Nucleoside metabolic inhibitor, per standard care via intravenous infusion.
223911741|NCT03911011|OTHER|Fresh air|Fresh air insufflation of 2 L/min toward mouth/nose.
223911742|NCT05015751|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
223911743|NCT02962076|DRUG|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
223911744|NCT05092984|DRUG|Spironolactone|"77 patients will be treated with spironolactone Mylan 25mg/day for the first 3 months of the study. Dosage adjustment can be performed according to the eGFR (estimated Glomerular Filtration Rate) concentration at baseline and the serum potassium variation.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
223911745|NCT05092984|DRUG|Placebo|"77 patients will be treated with placebo 25mg/day for the first 3 months. At inclusion, a second randomization is automatically performed in the placebo arm to determine patients receiving a dose adjustment during the study to keep the double-blind.~During the last 3 months of the study, all the patients will be treated with spironolactone Mylan 25mg. Dosage adjustment can be performed according to the serum potassium variation."
223911746|NCT04153539|BEHAVIORAL|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
223911747|NCT04153539|BEHAVIORAL|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
223911748|NCT06676995|DEVICE|Transcranial Pulse Stimulation (TPS)|Transcranial Pulse Stimulation (TPS) is a non invasive brain stimulation technology that applies repetitive single high-pressure ultrashort shockwave pulses within the ultrasound frequency range to stimulate the brain. Subjects will receive 12 TPS sessions conducted three times weekly, for about 40 to 50 minutes/day, over four consecutive weeks.
223911749|NCT05023317|BEHAVIORAL|Strengths-based linkage to alcohol care|SLAC is a behavioral intervention designed to link persons with substance use/misuse to care
223911750|NCT05023317|BEHAVIORAL|Usual care|Usual care consists of brief screening and intervention and/or standard referral to alcohol care
223911751|NCT06225843|BIOLOGICAL|Sotevtamab|Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU)
223911752|NCT06225843|COMBINATION_PRODUCT|FOLFOX|FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs folinic acid, fluorouracil, and oxaliplatin.
224277673|NCT00003467|DRUG|carmustine|
224277674|NCT00003467|DRUG|polifeprosan 20 with carmustine implant|
224277675|NCT00003467|PROCEDURE|surgical procedure|
224277676|NCT03258879|PROCEDURE|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
224085971|NCT04340973|DEVICE|Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
223911753|NCT03983954|COMBINATION_PRODUCT|Obinutuzumab, naptumomab estafenatox and durvalumab|"Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion, as pre-treatment.~Dose escalation and MTD Expansion: NAP is given as an intravenous (I.V.) bolus injection at multiple doses.~Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.~Esophageal cohort expansion: NAP is given as an intravenous (I.V.) bolus injection at multiple doses on cycles 1-6 and one dose per cycle starting cycle 7. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle during cycles 1-6, and at a dose of 1500 mg delivered once every 28 days starting cycle 7."
224085972|NCT02893345|BEHAVIORAL|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
223529446|NCT04506684|DEVICE|Investigational RAMware downloaded onto Reveal LINQ device|The study is utilizing an investigational RAMware, either LINQ HF or ALLEVIATE-HF, that will be downloaded onto the subject's market-released Medtronic Reveal LINQ ICM. The investigational RAMware enables the hardware to record and store additional sensor data from which a respiratory rate will be derived.
223911754|NCT03983954|COMBINATION_PRODUCT|Naptumomab estafenatox and durvalumab|NAP was given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab was given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
223911755|NCT03827382|BEHAVIORAL|Lifestyle Intervention|Physical activity program: 3-5 aerobic training sessions (15-40 minutes each) per week, combined with 2 resistance training per week as well as motivational coaching via telephone Nutritional counseling
224085973|NCT02893345|OTHER|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
224085974|NCT01282229|DEVICE|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
224085975|NCT02135380|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
224085976|NCT02135380|BIOLOGICAL|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
224085977|NCT02135380|OTHER|Control|Standard Therapy
224085978|NCT01950832|OTHER|Investigating clinically normal patients with optic coherence tomography|
224085979|NCT03082560|DIAGNOSTIC_TEST|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
223529447|NCT01662206|DIETARY_SUPPLEMENT|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
223529448|NCT01662206|DIETARY_SUPPLEMENT|Placebo|2 capsules daily containing 348.25 mg of potato starch
223529449|NCT04542928|BEHAVIORAL|nurse facilitated face care group|The experimental group is required to receive a nurse leading 50- minute face care group every two week
223529450|NCT03868501|BEHAVIORAL|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
223529451|NCT01336348|DRUG|Prasugrel|60 mg loading dose given orally at presentation
223529452|NCT01336348|DRUG|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
224085980|NCT02635971|PROCEDURE|Transcatheter arterial infusion|
224085981|NCT02635971|PROCEDURE|Intravenous chemotherapy|
224085982|NCT02635971|DRUG|Gemcitabine|
224085983|NCT02635971|DRUG|Oxaliplatin|
224085984|NCT04345666|DRUG|Testosterone cypionate|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
224277677|NCT03258879|PROCEDURE|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
223529453|NCT01489904|BIOLOGICAL|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
223529454|NCT06512532|OTHER|fireworks eye injury|patients presented with eye injury during festivals due to fireworks
223529455|NCT01427491|DEVICE|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
223716198|NCT00705484|DRUG|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
224277678|NCT01838187|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
224277679|NCT01838187|DRUG|Vorinostat|180 mg/m2 orally once daily on days 0 to +13
224277680|NCT06212050|DEVICE|Transcatheter Aortic Valve Implantation|TAVI in patients with severe BAV stenosis using ACURATE neo2
224277681|NCT00848042|DEVICE|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
224277682|NCT02512055|DRUG|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
224085985|NCT04345666|DRUG|Placebos|The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair
224085986|NCT05401266|PROCEDURE|mild hypercapnia|Ventilation parameters were adjusted to achieve and maintain ETCO2 50-55 mmHg until spontaneous respiration was restored
224085987|NCT04146922|OTHER|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
224085988|NCT04146922|OTHER|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
224085989|NCT04515966|DRUG|Methylprednisolone Injection [Solu-Medrol]|A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.
223911756|NCT03331835|BIOLOGICAL|Brodalumab|"Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis."
223911757|NCT03331835|DRUG|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
223911758|NCT05781672|DIAGNOSTIC_TEST|cardiac ultrasound with speckle tracking analysis|"Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography."
223911759|NCT02418832|PROCEDURE|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
223911760|NCT05405387|DRUG|Budesonide EC|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
223911761|NCT05405387|DRUG|Placebo|Subjects will take 3mg of Budesonide or placebo. Dosing will begin on day prior to cell infusion and continue until Day 14 post transplant. Budesonide or placebo will be in capsule formulation. Budesonide or Placebo will be administered orally three times daily (every 8 hours ± 1 hours) with or without food.
224085990|NCT04515966|DEVICE|wrist splint|A standard wrist splint
224085991|NCT05346614|BEHAVIORAL|Lifestyle intervention|Lifestyle coaching will be given on a digital app-based platform. Individuals will receive real-time feedback via a smart scale, activity monitor, and continuous glucose monitor (first 4 weeks, longer if required). Coaching will be focused on gradual behavior change, assisted by digital nudges, one-on-one, and small group coaching sessions. Coaching will include education regarding lifestyle to improve health literacy with respect to diet and diabetes management. Additionally, coaches will guide participants in the implementation of individualized diet and exercise program with varying levels of carbohydrate restriction and caloric deficit.
224085992|NCT04909684|DRUG|Pembrolizumab|The approved doses of 400 mg every 6 weeks (Q6W) and 200 mg every 3 weeks (Q3W) will be decreased to a 300 mg Q6W dose. The approved dose of 150 mg Q3W will be decreased to a 100 mg Q3W dose.
224085993|NCT05936320|BEHAVIORAL|Information leaflets with illustrations about hearing aid functions|The information leaflet contains written information with simple illustrations about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
224085994|NCT05936320|BEHAVIORAL|Information leaflets with only text about hearing aid functions|The information leaflet contains written information about placement in noisy environments, how to use a telecoil and about directional microphones function in hearing aids. The time spent presenting the information leaflet was approximately ten minutes.
224085995|NCT04986787|DEVICE|tACS|a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms
224085996|NCT04986787|DEVICE|TMS|a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain, it will be specifically cerebellar stimulation
223716199|NCT05438394|DRUG|melphalan hydrochloride for injection|Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle
223716200|NCT04220320|DIAGNOSTIC_TEST|Vaginal examination.|Cervical properties as evaluated by a vaginal examination.
223716201|NCT04220320|DIAGNOSTIC_TEST|Transvaginal sonography.|Cervical length as evaluated by a transvaginal sonography.
223911762|NCT03634540|DRUG|Belzutifan|Belzutifan tablets administered orally.
224085997|NCT04986787|DEVICE|TIS|temporal interference stimulation targeted to striatum, a non-invasive brain stimulation technique that allows interaction with endogenous cortical oscillatory rhythms deep in the brain
224085998|NCT03891147|OTHER|Electro-acupuncture|
224085999|NCT04178980|DRUG|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
224086000|NCT00713362|PROCEDURE|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
224086001|NCT00713362|PROCEDURE|chest tube drainage|Chest tube drainage for pneumothroax
224086002|NCT00757731|DRUG|milnacipran|hard capsule
224086003|NCT00757731|DRUG|Placebo|hard capsule
224086004|NCT00996203|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
224086005|NCT00996203|DRUG|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
224086006|NCT04901039|OTHER|Lung ultrasound|Decompensated HF patients will be evaluated at admission and prior to hospital discharge with a range of tools including lung ultrasound imaging
224086007|NCT04901039|OTHER|Echocardiography|Comprehensive echocardiography with evaluation of filling pressures
224086008|NCT04901039|OTHER|Peripheral venous pressure|Assessment of peripheral venous pressure
224086009|NCT04901039|OTHER|Magnetic resonance imaging|Cardiac magnetic resonance imaging
224086010|NCT04901039|OTHER|Pulmonary scintigraphy|Assessment of pulmonary perfusion with scintigraphy
223911763|NCT03634540|DRUG|Cabozantinib|Cabozantinib tablets administered orally.
223911764|NCT00179842|PROCEDURE|Stem Cell Transplant|
223911765|NCT06578052|DRUG|Irinotecan liposome Capecitabine|"Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs."
223911766|NCT05269706|DRUG|Cannabidiol 200mg|Cannabidiol 200mg (twice daily)
223911767|NCT05269706|DRUG|Epidiolex|Epidiolex 400mg (twice daily)
223911768|NCT05269706|DRUG|Cannabidiol 400mg|Cannabidiol 400mg (twice daily)
223911769|NCT05269706|DRUG|Placebo|Matching Placebo (Twice Daily)
223911770|NCT04838405|DRUG|CT-388|Synthetic Peptide
224086011|NCT01745809|PROCEDURE|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
224086012|NCT06454526|BEHAVIORAL|Mindfulness Based Program|Mindfulness Based Program is an 8-week program with a total of 25 hours. The program, which consists of lectures, meditation and sharing areas, consists of the following topics: Six Senses and Pleasure, Mindfulness and Mind, Get Out of the Head and Enter the Body, Compassion, Meeting Challenges, Stress Reactions and Healing, Retreat Silence Day, Neuroplasticity and the Changing Brain and Wise Living.
224086013|NCT03686969|DRUG|Octanorm|Octanorm 0.5g/kg/week
224086014|NCT03686969|OTHER|Placebo|Placebo
224086015|NCT01044563|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
224086016|NCT01044563|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
224086017|NCT02758535|DEVICE|coaxial renal biopsy|In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
224086018|NCT02758535|DEVICE|noncoaxial renal biopsy|In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
224086019|NCT05742555|OTHER|Virtual reality intervention|After the relatives of the patients included in the experimental group are informed about the study, they will be asked to fill in the Participant Information Form, Nottingham Health Profile (NSP) and Warwick-Edinburgh Mental Well-Being Scale (WEMIOÖ) after obtaining their permission. The virtual reality intervention will be applied to the caregivers at a suitable time of the day (when the patient's care and treatment is not intensive, the caregiver wishes). Different nature scenes (sea, forest, stream) with different types of music (classical music, nature sounds, relaxing music) will be watched for 10 minutes, 3 days a week. The application will be made for 4 weeks. At the end of this period, they will be asked to fill the NSP and WEMİOÖ again as a final test.
224086020|NCT01515228|DEVICE|Xience Prime|everolimus-eluting stent implantation
224086021|NCT01515228|DEVICE|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
224086022|NCT00093613|DRUG|sorafenib tosylate|Given PO
224086023|NCT00093613|OTHER|pharmacological study|Correlative studies
224086024|NCT02481635|DRUG|Gemcitabine|
224086025|NCT02481635|DRUG|Nab-paclitaxel|
224086026|NCT02481635|RADIATION|Radiation Therapy|
224086027|NCT02481635|PROCEDURE|Surgical Resection|
224277683|NCT01095523|PROCEDURE|Laparotomy+ HIPEC +/- CRS|
224277684|NCT05690074|DEVICE|Spectra Wave Writer™ Spinal Cord Stimulator System|Device: 5-6-5 Specify electrode Device: Restore Advance Pulse Generator
223529456|NCT01427491|DEVICE|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
223529457|NCT01593540|DEVICE|metal-free interdental brush|one time per day
223529458|NCT01593540|DEVICE|metal-core interdental brush|one time per day
223911771|NCT04838405|DRUG|Placebo|Placebo
223911772|NCT03694145|OTHER|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
223911773|NCT05724745|DIAGNOSTIC_TEST|1. Standard spirometry|Spirometry is performed in two positions (sitting and supine) and three types of breathing (spontaneous, forced and slow).
223911774|NCT05724745|DIAGNOSTIC_TEST|2. 3D dynamic lung MRI at UTE in prone and supine positions|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine before a reversibility test with salbutamol.
223911775|NCT05724745|DRUG|3. Reversibility test with salbutamol|Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
223911776|NCT05724745|DIAGNOSTIC_TEST|4. 3D dynamic lung MRI at UTE in supine and prone position|Dynamic lung MRI is performed for 3D MR spirometry while the subject is lying prone and supine after the bronchodilatator's administration.
223911777|NCT05791435|DEVICE|PneuRIP|Measuring respiratory indices through Respiratory Inductance Plethysmography
224277685|NCT06065124|PROCEDURE|Bariatric surgery strategy|Bariatric surgery including an intensive pre- and postoperative treatment scheme
224277686|NCT05862857|BEHAVIORAL|HIV-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free HIV testing at the local clinic
224277687|NCT05862857|BEHAVIORAL|Multi-disease-focused mobilization|Patrons and employees of drinking venues that are randomized to HIV-focused recruitment will receive a recruitment card offering free health screenings that may include hypertension, diabetes, HIV, malaria (if febrile), and TB (if symptomatic), and pregnancy at the local clinic
223529459|NCT06416813|PROCEDURE|GDMT+DCB|Preventive Intervention on Eligible Vulnerable Plaques Using DCB
223529460|NCT00002237|DRUG|Peldesine|
224086028|NCT01578031|DEVICE|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
223911778|NCT05791435|OTHER|biofeedback to assist with breathing|Measuring respiratory indices through Respiratory Inductance Plethysmography and providing visual biofeedback on a tablet screen
224086029|NCT01578031|OTHER|Usual Care|Usual care.
224086030|NCT06549088|DEVICE|Spatial Frequency Domain Imaging|Resected lung tissue will be removed from the surgical field and labeled with sutures per standard of care. The specimen will then be immediately analyzed using two SFDI devices in the operating room using sterile technique. Each specimen will be recorded up to three times to ensure at least one high fidelity recording is captured. The SFDI data will be analyzed and compared to the official pathology report from the electronic medical record.
224086031|NCT03219073|DEVICE|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
224086032|NCT03219073|DEVICE|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
224086033|NCT03094195|DRUG|EMA401|EMA401
224086034|NCT03094195|DRUG|Placebo|Placebo
224086035|NCT02238847|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
224086036|NCT01988090|DRUG|800 IU Vitamin D Supplement|Standard Dose
224086037|NCT01988090|DRUG|50,000 IU Vitamin D supplement|High Dose
224086038|NCT01119547|OTHER|Exercise in a group|The patient do their individual exercise program in a group.
224086039|NCT01119547|OTHER|Home exercise|The patient exercise their individual program at home during 6 v.
224086040|NCT03632980|DEVICE|"Ablatherm Foc/Dyn or Focal One HIFU treatment"|"Non invasive treatment of localized prostate cancer by High Intensity Focused Ultrasound therapy, endorectal application.~or Non invasive treatment of localized prostate cancer recurrency by High Intensity Focused Ultrasound therapy after radiotherapy failure, endorectal application."
224086041|NCT04870671|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)|Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
224086042|NCT01557829|DEVICE|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
224086043|NCT01557829|DEVICE|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
224086044|NCT03693248|DRUG|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
224086045|NCT00529737|PROCEDURE|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
224086046|NCT00529737|PROCEDURE|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
223911779|NCT03647098|DRUG|Treatment|Treatment decisions guided by molecular profiling and clinical judgment of principal investigators
223911780|NCT03604913|PROCEDURE|Aortic valve sparing operation|Aortic valve sparing instead of replacement during aortic root replacement
223911781|NCT03604913|PROCEDURE|Bentall operation|Aortic root replacement with replacement of aortic valve
223911782|NCT06477146|DRUG|Milk thistle (MT)|MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
224086047|NCT01734317|DEVICE|Mepilex Transfer Ag|A soft silicone wound contact layer.
224086048|NCT01083667|DRUG|Pyrimethamine|Open Label, dose escalating,
224086049|NCT03887130|DRUG|oral vinorelbine|Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles
224086050|NCT03887130|DRUG|Capecitabine|Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
224086051|NCT03887130|DRUG|Gemcitabine 1250 mg/m²|Gemcitabine 1250 mg/m² on day 1 \& day 8
224086052|NCT03887130|DRUG|Gemcitabine 1000 mg/m²|Gemcitabine: 1000 mg/m² on day 1 \& 8
224086053|NCT03887130|DRUG|Paclitaxel|Paclitaxel 175 mg/m² on day 1
224086054|NCT03887130|DRUG|Docetaxel|Docetaxel 75 mg/m² on day 1
224086055|NCT00360399|DRUG|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
224086056|NCT00360399|DRUG|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
224086057|NCT00360399|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
224086058|NCT03611426|DRUG|rhThrombin ( Topical )|Active Substance
224086059|NCT03611426|DRUG|placebo|saline solution
224086060|NCT02581254|DEVICE|Thin Wire Snare|
224086061|NCT02581254|DEVICE|Thick Wire Snare|
224086062|NCT02926703|OTHER|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
224086063|NCT05078125|DEVICE|Holter monitoring|24 hours Holter monitoring
224086064|NCT01709188|BEHAVIORAL|Musical Dual Task Training|
224086065|NCT01709188|BEHAVIORAL|Walking and Talking|
224086066|NCT02039739|DEVICE|Orsiro™ Drug Eluting Stent group|
223911783|NCT06477146|DRUG|Placebo|The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
224086067|NCT06960772|BEHAVIORAL|Flow Ball Intervention|"Participants receive an intensive intervention using the Flow Ball device over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach'"
224086068|NCT06960772|BEHAVIORAL|Straw Phonation Intervention|"Participants receive an intensive intervention using a straw over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach'"
224086069|NCT06960772|BEHAVIORAL|Sham Intervention|"Participants receive an intensive intervention over 3 weeks (a total of 5 hours), consisting of weekly:~* 1 in-person guided session of 30 minutes~* 2 guided online sessions of 15 minutes each (via teleconsult)~* On the remaining 4 days of the week, participants perform independent training at home: 5 minutes, twice daily. This training is recorded using the app 'MyMedicoach' The sham intervention uses breathing exercises through the Flow Ball, no phonation will be involved."
224086070|NCT01439945|DRUG|magnesium oxide|Given PO
224086071|NCT01439945|OTHER|placebo|Given PO
224086072|NCT04082663|DEVICE|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
224086073|NCT06439030|BEHAVIORAL|Recovery program|The practices included in the program are: Cinema Film Screening and Emotion/Thought Sharing, Laughter Yoga Practice, Stress Coping Techniques Training, Progressive Relaxation, Loss/Mourning Process Training, Expressive Art Therapy Practice, Healthy Lifestyle Behaviors Training.
224086074|NCT00981994|BEHAVIORAL|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
224086075|NCT04764552|DIETARY_SUPPLEMENT|Yeahhh Baby Ointment|The ointment consists primarily of coconut oil (98%), with small amounts of herbal ingredients (tanner's bark, slippery root, sweet weed, velvet plant, walnut hulls, kidney root, green ginger, Indian pink, mad dogweed, and nigella seed) thought to reduce inflammation and to promote tissue healing.
224086076|NCT04764552|OTHER|Coconut oil ointment|Coconut oil ointment with a little olive oil.
224086077|NCT05591495|PROCEDURE|laparoscopy in upper abdominal surgical emergencies in adults|evaluation the role of laparoscopy in upper GIT emergencies in adults
224086078|NCT06364995|BEHAVIORAL|Volleyball|Volleyball Specialised Physical Education Intervention is a step-by-step approach to teaching the intervention. Each lesson was conducted as a Warm-up (10 minutes), Basic contents of the PE lesson (25 minutes), and Cool-down (5 minutes). From the learning of basic skills in the first session to the final Combination Practice underhand service, receive, service, pass, spiking, and block, from the simple to the difficult, the intensity of the training is from weak to strong, Allowing participants to build upon a solid foundation toward mastering intricate volleyball maneuvers. Intensity modulation is key to this intervention; training intensity evolves from moderate to vigorous, aligning with the increasing complexity of skills and the physical demand required to execute them proficiently. The curriculum is thoughtfully designed to transition from basic skill execution to complex gameplay, with each lesson introducing new skills or refining existing ones.
224086079|NCT06364995|BEHAVIORAL|Traditional Physical Education|Participants participating in the control group will attend traditional physical education classes following the established physical education syllabus. Participants in the control group will attend four 40-minute classes per week over ten weeks. Each session will consist of a warm-up (10 minutes), the basics of PE (25 minutes), and a cool-down (5 minutes). The duration and intensity of the experimental and control groups were the same, which allowed for a better comparison.
224086080|NCT06314464|DEVICE|Praxis|Praxis' gaze stabilization exercises are delivered via the tablet-based VestAid software that uses the tablet camera to automatically assess compliance in the conduct of vestibulo-ocular reflex exercises. The smooth pursuit, saccade, agility, and dual tasking exercises are delivered in the form of military-themed mixed reality games using the HTC Vive Focus 3 headset.
224086081|NCT06314464|BEHAVIORAL|Supervised cardiovascular exercise|The supervised cardiovascular exercise does not incorporate gaze stabilization exercises (vestibulo-ocular reflex exercises) or smooth pursuit, saccade, agility, and dual tasking exercises.
224086082|NCT03005626|OTHER|Therapeutic education|
224277688|NCT05427123|OTHER|Medication or psychosocial treatment|Youth included in this naturalistic study will be offered medication management from study psychiatrists. The study's Network Oversight Committee, consisting of PI psychiatrists and consultants, has created guidelines on best practice medications, dosing, and adjustments for the study. The Network Oversight Committee will also offer ongoing consultation to study psychiatrists. The treating physician will take these guidelines and recommendations under consideration but will use clinical judgment and have the final say, in consultation with the parents and child, as to what treatments are prescribed. While psychosocial interventions are of interest as a predictor of outcomes, no universal psychotherapy or other psychosocial treatment will be provided by sites. There is no limitation on participant enrollment in psychosocial treatments. Investigators and their clinical partners may offer these interventions based on clinical judgment and availability.
224277689|NCT06258798|RADIATION|Taking a dental X-ray|Dental X-rays taken in patients with indications confirmed by a written referral.
224277690|NCT03329924|OTHER|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
223529461|NCT01627041|DRUG|Cytarabine|Given IV
223529462|NCT01627041|DRUG|Daunorubicin Hydrochloride|Given IV
223529463|NCT01627041|DRUG|Decitabine|Given IV
223529464|NCT01627041|OTHER|Laboratory Biomarker Analysis|Correlative studies
223529465|NCT01627041|OTHER|Pharmacological Study|Correlative studies
223529466|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
223529467|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
223911784|NCT06477146|BEHAVIORAL|Lifestyle Modification|"The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber \>3 grams/serving. Ideally \>5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control."
223911785|NCT06477146|DEVICE|Fibroscan|FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
223911786|NCT06478199|DIAGNOSTIC_TEST|semen analysis|lab invesigation
223911787|NCT03886766|DRUG|Hot-melt extruded amorphous solid dispersion of Efavirenz|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
223911788|NCT03886766|DRUG|Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
223911789|NCT03886766|DRUG|Efavirenz solution|Efavirenz solution, 3 mg, oral administration (product 3)
223911790|NCT05210569|DEVICE|Vivity|Vivity intraocular lens (IOL)
224086083|NCT03005626|OTHER|Standard follow-up|
224086084|NCT00392028|DRUG|ertapenem|
224086085|NCT06401863|OTHER|Shared Decision Making Tool|EHR-integrated SDM for Patients on Oral Anticoagulants and other medications that might increase the risk of hemorrhage
224086086|NCT06090071|DEVICE|LaseMD Laser|The non-ablative fractional 1,927nm Thulium laser will be used in this study. This FDA-approved laser is an innovative device addressing as well as medical as aesthetic and cosmetic indications. The system allows nearly pain free treatments with depth of 200 μm setting multiple microbeams. The stratum corneum stays intact despite superficial ruptures, coagulation zones appear only in the underlying layers of the skin.
224086087|NCT06090071|DEVICE|Sciton Laser|The Sciton Laser uses Broadband light (BBL), also known as intense pulse light, a commonly available and popular treatment to rejuvenate the skin. BBL uses a broad band of noncoherent light waves, ranging from 560 to 1,200 nm, that are absorbed by a number of components in the skin, leading to a reduction in dyschromia, background erythema, telangiectasia, and an increase in collagen production resulting in amelioration of fine lines.
224086088|NCT06090071|DRUG|Phyto A+ Brightening Treatment|Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
224086089|NCT02384811|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
224086090|NCT05145465|OTHER|Telerehabilitation group|"All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not."
224086091|NCT06386328|DRUG|CKD-378, QD, PO|CKD-378, QD, PO
224277691|NCT05676281|BEHAVIORAL|Healthy Together (Control)|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals"
224086092|NCT06055634|GENETIC|genotyping of SIRT1 in chronic obstructive patients|genotyping of SIRT1 in chronic obstructive patients
224086093|NCT02299193|BEHAVIORAL|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
224086094|NCT02299193|BEHAVIORAL|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
224086095|NCT00006417|PROCEDURE|Stem cell transplantation|
223529468|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
223911791|NCT05834478|DEVICE|Transcutaneous Cervical Vagal Nerve Stimulation|Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).
224086096|NCT03109431|BEHAVIORAL|Level 1|"Youth will receive 1-5 text messages per day for at least 12 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
224086097|NCT03109431|BEHAVIORAL|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
224086098|NCT03109431|BEHAVIORAL|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
224086099|NCT03652909|DEVICE|Ascending Hearing Technologies device|Personal Sound Amplification Device
224086100|NCT04924127|DIAGNOSTIC_TEST|Detection of IDH and TERT mutation|Detection of IDH and TERT mutation using frozen glioma tissues
224086101|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling|Nutrition and Mental health counseling with a standardized format included in each session
224086102|NCT05233046|BEHAVIORAL|Nutrition and Mental health counseling with Nourish Carolina|Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
224086103|NCT02107703|DRUG|Abemaciclib|Administered Orally
224086104|NCT02107703|DRUG|Fulvestrant|Administered IM
224086105|NCT02107703|DRUG|Placebo|Administered Orally
224086106|NCT02179632|BEHAVIORAL|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
224086107|NCT01327755|DIETARY_SUPPLEMENT|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
224086108|NCT01327755|OTHER|Placebo|Same number of pills, frequency, and duration as selenium intervention.
224086109|NCT00856310|BIOLOGICAL|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
224086110|NCT01711242|DRUG|Capecitabine|
224086111|NCT01711242|DRUG|Oxaliplatin|
224277692|NCT05676281|BEHAVIORAL|Healthy Together + Promotora Support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)"
224086112|NCT01711242|RADIATION|Radiotherapy|
224086113|NCT04116021|OTHER|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
224086114|NCT04116021|OTHER|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
224086115|NCT04782791|DRUG|Nivolumab plus SOX|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA\>1.50 m2, 60mg. Day 15 to day 21 is the rest period.
224086116|NCT04782791|DRUG|Nivolumab|The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.
224086117|NCT04782791|PROCEDURE|Gastrectomy|A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
224086118|NCT06441877|OTHER|No intervention|There is no intervention, this is an observationnal study.
224086119|NCT04953871|DRUG|TNF Inhibitor|TNF inhibitors are widely used in patients with spondyloarthritis
224086120|NCT05587881|BIOLOGICAL|COVID-19 vaccine(donor)|Donor received COVID-19 vaccine before stem cells collection.
224086121|NCT05587881|BIOLOGICAL|COVID-19 vaccine(patient)|Patient received COVID-19 vaccine before allo-HSCT.
224086122|NCT01484067|DEVICE|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
224086123|NCT00635973|DRUG|Gefitinib (Iressa)|Iressa
223529469|NCT00922363|BIOLOGICAL|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
224086124|NCT03281642|OTHER|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
224086125|NCT03948932|DEVICE|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
224086126|NCT03948932|DEVICE|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
224277693|NCT05676281|BEHAVIORAL|Healthy Together + Parenting Training|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 6-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
223716202|NCT06169384|DEVICE|Endoscopic adenoidectomy|Subjects will be randomly assigned into two groups (30 patient each group): Group A will undergo endoscopic partial adenoidectomy using the 70◦ rigid endoscope trans-orally and shaver (microdebrider) ,by removing the upper (choanal) part only with leaving the lower part of the adenoid .(2) Group B will undergo total adenoidectomy ,by removing all the adenoid lymphoid tissue .
223716203|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
223529470|NCT06034626|PROCEDURE|Intense pulsed light|Each MGD patient underwent three treatment sessions at three-week intervals and three follow-up examinations over the course of treatment.
223529471|NCT06034626|DRUG|0.3% hyaluronic acid eye drops|0.3% hyaluronic acid eye drops (Hialid; Santen, Osaka, Japan) four times a day during the study, including the follow-up period.
223529472|NCT01164826|DRUG|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
223529473|NCT01164826|DRUG|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
223529474|NCT05119816|OTHER|music therapy intervention|Received a customize playlists prepared by a certified music therapist to listening to during KB
223529475|NCT04987372|DRUG|Dexmedetomidine|The use of multimodal painkillers pre, per and postoperative
223716204|NCT04174846|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
223716205|NCT03928496|DRUG|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
223716206|NCT03928496|DRUG|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
223911792|NCT05834478|DEVICE|Sham Stimulation|Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.
223911793|NCT05834478|DRUG|[F-18]Fallypride|\[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
223911794|NCT05583552|DRUG|Imetelstat sodium|Intravenous injection
223911795|NCT06263855|OTHER|CURE|A large language model (LLM) to help clinicians prepare discharge summaries for hospitalized patients.
223911796|NCT02959502|OTHER|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
223911797|NCT02959502|OTHER|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS \&CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
223911798|NCT06214936|OTHER|Benchtop Incubator|half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the benchtop incubator for the remainder of embryo culture
223911799|NCT06214936|OTHER|Box Incubator|half of the mature oocytes will be placed in the benchtop incubator and after ICSI the resulting inseminated oocytes and subsequent embryos will remain in the box incubator for the remainder of embryo culture
223911800|NCT04199871|OTHER|dichoptic 3D movies|dichoptic movies presented on a Nintendo 3DS
223911801|NCT05829343|PROCEDURE|Laparoscopic Left colectomy|Patients are treated with a laparoscopic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
224086127|NCT01690845|DEVICE|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
224086128|NCT01989130|DEVICE|Roche AMPLICOR CT/NG|
224086129|NCT01989130|DEVICE|Cepheid Xpert CT/NG Test|
224086130|NCT00563147|DRUG|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
224086131|NCT04381208|DIAGNOSTIC_TEST|Complete clinical examination|Medical history-taking, physical examination with provocative maneuvers, radiographic imaging (if relevant), and sacroiliac joint block (if indicated), facet joint block (if indicated)
223911802|NCT05829343|PROCEDURE|Robotic left colectomy|Patients are treated with a robotic approach as the standard of care for the treatment of left-sided colonic diverticular disease, depending on the experience of the surgeon or institution.
224086132|NCT03990870|OTHER|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
224086133|NCT03990870|OTHER|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
224086134|NCT02538302|DRUG|Minirin|Minirin 5 to 10 mg daily for 6 months
224086135|NCT02538302|DRUG|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
224086136|NCT05395221|OTHER|Guided Mediation Virtual Reality App|Guided Meditation Virtual Reality App uses over 40 lush environments with 30 hours of guided meditations on Anxiety, Depression, Maternity, Resilience, Sleep, or Zen and 200 relaxing audio tracks using Virtual reality.
224086137|NCT04351802|DIAGNOSTIC_TEST|Lung ultrasound|Focused lung ultrasound examination
224086138|NCT01169779|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224086139|NCT01169779|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
224086140|NCT01169779|DEVICE|Pen auto-injector|
224086141|NCT01169779|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
224277694|NCT05676281|BEHAVIORAL|Healthy Togethers + Parenting Training + Promotora support|"The total number of sessions families will engage with will be negotiated between the Families and their Care providers. This allows for families to receive care while still honoring their constraints, such as the amount of time they can dedicate per week and over the course of the study, to the intervention. The maximum number of possible sessions include:~* 6 Sessions with a Wellness Coach~* 4-8 sessions with a Dietician~* 4-8 sessions of Physical Theraphy~* 1 session during month 1 or 2 Streetwyze Training~* Safety Net Referrals~* 16-20 Promotora (in home case management) Sessions (weekly first 2 months, afterwards at least bi-weekly)~* 8-10 Parenting Sessions with a Family Health Centers Mental Health Provider using the Incredible Years Curriculum"
224277695|NCT05475431|DRUG|The sequential therapy|Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
224277696|NCT05475431|DRUG|The triple therapy|Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
223911803|NCT05454852|OTHER|Survey|Interviewer-administered survey
223911804|NCT05454852|OTHER|Focus group|Focus group for selected participants
223911805|NCT06029452|OTHER|Machine learning algorithm|Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features
224277697|NCT05475431|DRUG|The hybrid therapy|Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
223911806|NCT04214860|DRUG|APR-246|APR-246 4.5 g/day
223911807|NCT04214860|DRUG|Venetoclax|Venetoclax 400 mg once daily
223911808|NCT04214860|DRUG|Azacitidine|Subcutaneous injection, or intravenous infusion
224086142|NCT01169779|DRUG|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c \<8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c \>=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
224277698|NCT05475431|DRUG|The concomitant therapy|Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
224277699|NCT05475431|DRUG|Bismuth-based quadruple therapy|Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
224277700|NCT03346850|DEVICE|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
223911809|NCT05626634|DRUG|LP352, bexicaserin|LP352 6 mg, 9 mg or 12 mg administered three times daily, orally or through G-tube
224277701|NCT03346850|DEVICE|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
223911810|NCT03972202|DIAGNOSTIC_TEST|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
223911811|NCT03972202|DEVICE|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
224086143|NCT01214486|DRUG|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA \< 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
224086144|NCT01989221|DRUG|Sancuso®|Sancuso® (granisetron transdermal system) 3.1 mg/24 hours
224086145|NCT03512548|DRUG|Relacorilant 350mg|Relacorilant 350mg
224086146|NCT03512548|DRUG|Itraconazole|Itraconazole 200 mg
224086147|NCT03512548|DRUG|Relacorilant 300mg|Relacorilant 300mg
223529476|NCT02661152|DRUG|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
223529477|NCT01198587|DRUG|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
223529478|NCT01198587|DRUG|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
223529479|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
223529480|NCT00573768|DRUG|Placebo|Vehicle 2 times daily
223529481|NCT00573768|DRUG|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
223529482|NCT01785030|DRUG|50% Nitrous oxide|
223529483|NCT04470414|DIAGNOSTIC_TEST|IgG antibodies immunoassay|Assessment of IgG level will be done by quantitative assessment of IgG in the serum of recovered persons by Chemiluminescence Immunoassay (CLIA).
223529484|NCT04624984|DRUG|PD-1 inhibitor|PD-1 Inhibitor, intravenous drip, d1.
223911812|NCT03972202|BEHAVIORAL|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
223911813|NCT04991857|OTHER|T-FAME-HF|16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits
223911814|NCT04991857|OTHER|Control group - HF education program|For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
223911815|NCT05988853|OTHER|follow-up of patients|Follow-up of evidence of nosocomial infections of patients in music therapy
223911816|NCT05451108|DEVICE|PCL Pectus Scaffold implantation and autologous fat grafting|A small incision is made in the chest and pre-sternal pocked is defined. Following this, an empty scaffold is implanted at the site of the defect with skin closed directly over it. At the same stage, autologous fat transfer will be performed, harvesting fat from available donor sites such as the thighs and abdomen - depending on scaffold volume and patient morphology. The area will be infiltrated with local anaesthetic tumescent fluid, liposuction performed, and fat transferred to syringes for filtration prior to injection into the scaffold. Fat will not be processed beyond simple filtration to separate liquid from fat to be injected. The scaffold provides structural stability to the chest during the infiltration of the tissue inside the scaffold.
223911817|NCT03485729|DRUG|Dordaviprone (ONC201)|625 mg dordaviprone (ONC201)
223911818|NCT06419660|DRUG|BI 300202|BI 300202
223911819|NCT06419660|DRUG|esomeprazole|esomeprazole
223911820|NCT05573243|OTHER|bonding strategies|The universal adhesive can be bonded using 3 different bonding strategies. Therefore, three bonding strategies will be assigned for 3 arms: etch-and-rinse, selective enamel etching, self-etch
223911821|NCT06462729|DEVICE|LDGraft|LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
223911822|NCT06462729|DEVICE|LDGraft|LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
223911823|NCT06462729|OTHER|Allograft Bone|Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)
223911824|NCT04078568|DRUG|IVIG|IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
223911825|NCT04078568|DRUG|Aspirin|Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
224277702|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
223529485|NCT04624984|DRUG|PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome|PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
223529486|NCT04587492|DRUG|Nusinersen|Treatment with nusinersen
223529487|NCT06467682|OTHER|tele-exercise|The 12-week tele-exercise program will be performed and supported via the USTEP digital platform, with each patient taking part in 3 training sessions per week with a 60-min duration period per training session. There will be personalized training sessions: i) warm-up and warm-down, ii) aerobic exercise, and iii) strength exercises. All tele-exercise program participants, will use wearable-based tracking to assessment the cardio-oxygenation.
223911826|NCT04078568|DRUG|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
223911827|NCT05594368|DEVICE|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT)|Dose escalating stereotactic arrhythmia radioablation to treat ventricular tachycardia (VT) refractory to conventional antiarrhythmic and catheter ablation-based therapy. First patients will be treated with a dose from 25 Gy prescribed to the 65-90% target volume encompassing isodose escalating to a maximum of 32.5 Gy prescribed to the 65-90% isodose.
223911828|NCT04358315|BEHAVIORAL|Behavioral Intervention|Smell or puff e-liquids
223529488|NCT01263327|BIOLOGICAL|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
223529489|NCT06006104|DRUG|HRS-4357 injection|HRS-4357 injection
223529490|NCT00930124|PROCEDURE|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
223529491|NCT00930124|PROCEDURE|Distraction osteogenesis|
224277703|NCT01024777|DRUG|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
223911829|NCT04358315|OTHER|Questionnaire Administration|Ancillary studies
223911830|NCT05912166|BEHAVIORAL|Wakeful Spanish|"Wakeful Spanish is the Spanish-language version of Wakeful, a self-directed 9-week digital mindfulness course closely aligned with traditional 8-week Mindfulness-based Stress Reduction (MBSR) programs. Wakeful makes one new class available to users each week for 9 weeks. Users receive weekly email notifications from Wakeful informing them when a new class is available. Estimated class duration is 1-1.5 hours.~With Wakeful, users can -~1. Write what they observed during meditations.~2. Be guided by videos/audios through breathing exercises and gentle stretching.~3. See what others experienced and their tips for overcoming challenges.~4. Access videos/audios that explain how mindfulness benefits the body and mind.~5. Receive suggestions on meditations to do during the week~6. Set an intention for the week based on class content."
223911831|NCT03083405|DRUG|Opipramol|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
223911832|NCT05912543|PROCEDURE|Titration of FiO2|The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
224086148|NCT05450614|OTHER|Thrive app|The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.
224086149|NCT05450614|BEHAVIORAL|TCCG|In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
224086150|NCT05996796|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
224086151|NCT05996796|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
224086152|NCT02308644|DRUG|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
224086153|NCT00789633|DRUG|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
224086154|NCT00789633|DRUG|Placebo|Matching placebo given orally twice daily
224086155|NCT00789633|DRUG|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
224086156|NCT02144779|BEHAVIORAL|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
224086157|NCT02144779|BEHAVIORAL|Usual Care|usual hospital care, not assigned to palliative care team
224086158|NCT03354689|RADIATION|Scintigraphy|Scintigraphy
224086159|NCT00917436|DRUG|Thiocolchicoside|
224086160|NCT02834910|OTHER|collection of bacterial sample|
223911833|NCT00544414|DRUG|cisplatin|
223911834|NCT00544414|DRUG|docetaxel|
223911835|NCT00544414|DRUG|fluorouracil|
223911836|NCT00544414|DRUG|gemcitabine hydrochloride|
223911837|NCT00544414|DRUG|leucovorin calcium|
223911838|NCT00544414|GENETIC|gene expression analysis|
223911839|NCT00544414|GENETIC|protein expression analysis|
223911840|NCT00544414|OTHER|laboratory biomarker analysis|
223911841|NCT00544414|PROCEDURE|adjuvant therapy|
223911842|NCT00544414|PROCEDURE|biopsy|
223911843|NCT00544414|PROCEDURE|conventional surgery|
223911844|NCT00544414|PROCEDURE|neoadjuvant therapy|
223911845|NCT00544414|PROCEDURE|quality-of-life assessment|
223911846|NCT00544414|RADIATION|radiation therapy|
223911847|NCT06804291|OTHER|Running|Participants were expected to run 6.44 kilometers.
223911848|NCT06804291|OTHER|Cycling|Participants were expected to cycle 39 kilometers
223911849|NCT06804291|OTHER|Rugby|Participants were expected to play in one rugby match.
224086161|NCT01762514|DRUG|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
224086162|NCT01762514|DRUG|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
224086163|NCT01279057|DRUG|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
224086164|NCT01279057|DRUG|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray|Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
224086165|NCT01279057|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
224086166|NCT05731921|BEHAVIORAL|The exercise program with the 'Empathy Dress'|The experimental group will be given an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week, by the researchers.
224086167|NCT00670826|DEVICE|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand \& forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
224086168|NCT00670826|DEVICE|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
224086169|NCT00967265|BEHAVIORAL|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
224086170|NCT00967265|OTHER|Usual care|Usual care
224086171|NCT01196442|OTHER|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
224086172|NCT01196442|OTHER|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
224086173|NCT06130332|DRUG|PD-1 with chemotherapy|"Tirellizumab+Carboplatin+albumin-bound paclitaxel:2 courses Tirellizumab,+Carboplatin+albumin-bound paclitaxel Tirellizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Tirellizumab, Carboplatin, albumin-bound paclitaxel:2 cycles Surgery：Enlarged local excision，excision with the safe margin 1.0-1.5cm away from the original tumor"
224086174|NCT06130332|PROCEDURE|upright surgery|"Surgery：Primary resection，excision with the safe margin 1.0-1.5cm away from the original tumor~selective neck dissection:I II III region neck dissection"
224086175|NCT00287742|DRUG|risperidone|
224086176|NCT01427309|BIOLOGICAL|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
224086177|NCT01427309|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
224086178|NCT01736904|DRUG|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
224086179|NCT01736904|DRUG|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
224086180|NCT03949907|OTHER|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss \>10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
224086181|NCT03949907|OTHER|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
224086182|NCT02750059|DRUG|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
224086183|NCT02750059|DRUG|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
224086184|NCT05714904|DRUG|ZVS101e|ZVS101e is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene.
224086185|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
224086186|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
224086187|NCT00542620|DRUG|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
224086188|NCT00542620|DRUG|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
224086189|NCT00892580|DRUG|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
224086190|NCT03617705|DEVICE|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
224086191|NCT03617705|DEVICE|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
223911850|NCT06804291|OTHER|control group|Participants were asked to refrain from exercise for 24 hours.
223911851|NCT06804980|DRUG|Rosuvastatin (Crestor)|The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.
223911852|NCT06804980|DRUG|Placebo|The patient will take 3 28-day packs of placebo and 2 28-day packs of rosuvastatin. The order in which they take the placebo or rosuvastatin will be assigned at random.
223911853|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily before randomization|"Once-daily subcutaneous injection of a standard prophylactic dose of Enoxaparin 40 mg according to the set schedule:~* 12 hours before the surgery (if applicable) on a postoperative day -1 (POD -1)~* 6-12 hours after the surgery (key injection 1) on the surgery day (POD 0)~* 12 hours after the previous key injection 1 (key injection 2) on the POD 1~* 24 hours after the previous key injection 2 on the POD 2"
223911854|NCT04710732|DRUG|Standard Enoxaparin 40 mg once-daily after randomization|Once-daily subcutaneous injection (every 24 hours) of a standard prophylactic dose of Enoxaparin 40 mg since POD 3 and until discharge
224086192|NCT03617705|DEVICE|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
223911855|NCT04710732|DRUG|Escalated Enoxaparin 30 mg twice-daily after randomization|Twice-daily subcutaneous injection (every 12 hours) of an escalated prophylactic dose of Enoxaparin 30 mg since POD 3 and until discharge
223911856|NCT04710732|DEVICE|Anti-embolic elastic compression stockings|Applied before or just after the surgery and used around the clock until discharge
223911857|NCT04710732|DIAGNOSTIC_TEST|Thrombodynamic test (TD)|"Blood sampling for TD:~* 12 hours after key injection 1 (TD-12) on the POD 1~* 24 hours after key injection 2 (TD-24) on the POD 2~* 24 hours after each daily injection on the POD 4 (TD-4) and POD 5 (TD-5)"
223911858|NCT05848947|DRUG|99mTc-Macro Albumin Aggregate|Technetium-99m macroaggregated-albumin consists of macroaggregated-albumin particles labeled with technetium-99m (99mTc), with a size between 10 and 90 microns in diameter. 99mTc is a gamma emitting radioactive isotope commonly used for diagnostic localization studies.
223911859|NCT06807255|DIAGNOSTIC_TEST|Lactate levels were assessed via a venous blood gas test utilising an IV cannula already placed in the woman's limb upon admission|Lactate levels were assessed via a venous blood gas test utilising an IV cannula already placed in the woman's limb upon admission; subsequent analysis was conducted using rapid processing (under 5 minutes from the pre-test) with the Rapidpoint 500 Systems-Siemens (Siemens, Milano) emogasanalyzer
223911860|NCT05921162|BIOLOGICAL|Gene Therapy product:vMCO-I|Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
223911861|NCT04098666|DRUG|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
223911862|NCT04098666|DRUG|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
223911863|NCT05907252|BEHAVIORAL|Supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
223911864|NCT05907252|BEHAVIORAL|Non-supervised Group-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
223911865|NCT05907252|BEHAVIORAL|Non-supervised Individual-based Intervention|"The intervention will be an 18-week walking program, with 3 times per week on alternative days. A 2-week basic walking practice with 3 sessions per week, 30-45 minutes per session, and without being led by a certified walking trainer. The walking practice will take reference from the exercise procedure recommended by the Healthy Exercise for All Campaign (LCSD, Department of Health, and Physical Fitness Association Hong Kong, China, 2013). Upon completion of the 2-week basic walking practice, participants will enter week-3 to week-18 main walking program, in which the duration of each training session will increase to 45-70 minutes, depending on the levels of training. In the walking programs, the progressive training principle (ACSM, 2009) will be adopted, using 4 levels as prescribed, in which weeks 3 to 6 are Level-1; weeks 7 to 10 are Level-2, weeks 11 to 14 are Level-3, week 15-18 are Level-4."
223911866|NCT06804707|BIOLOGICAL|blood sampling|"This procedure will take place once during the patient's CARPUS first visit (Croix Rousse hospital (Hospice civils de Lyon).~A peripheral venous line of the cathlon 24 G type with tap without tubing will be inserted by a nurse. A blood sample will be taken at the same time to check creatinine levels before the MRI scan and to record the patient's cholesterol levels for the eCRF."
224086193|NCT01284790|DEVICE|Cochlear implants|
224277704|NCT00979212|DRUG|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
224277705|NCT00979212|DRUG|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
224277706|NCT00979212|DRUG|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
224277707|NCT00979212|PROCEDURE|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
223911867|NCT06804707|DEVICE|ultrasound imaging exam|"This procedure takes place once immediately after the intervention 1. The patient will first have an ultrasound acquisition with the clinical ultrasound scanner (\~5 minutes) in order to locate the plaque. An acquisition with the research ultrasound scanner and matrix probe will then be performed for measurement for ultrasound spectroscopy (\~5 minutes).~An injection of 2.4 ml Sonovue followed by 10 ml saline will be performed during acquisition with the research ultrasound scanner for ultrasound localization imaging measurement (\~10 minutes).~The patient must remain under observation (in the waiting room) for 30 minutes after the examination."
223911868|NCT06804707|DEVICE|High resolution MRI plaque exam|"This procedure will take place once during the patient's CARPUS second visit (Pierre Wertheimer hospital (Hospice civils de Lyon)).~The patient is greeted in radiology, and his/her identity and absence of contraindications are verified.~A peripheral venous line of the cathlon 24 G type with tap without tubing will be inserted by a nurse.~Injection of gadolinium and MRI examination of the plaque used in clinical routine."
223911869|NCT06145997|OTHER|Acupuncture therapy|Acupuncture therapy (AT) is delivered by Licensed Acupuncturists (LAcs). Treatment plans are determined according to each patient's presentation and resulting traditional East Asian medicine (TEAM) differential diagnosis. TEAM therapeutics include AT, Chinese herbal medicine (CHM), Kampo herbal medicine, gua sha, tui na, cupping and lifestyle advice. All TEAM therapeutics are allowed in this study because it is a pragmatic, effectiveness study.
223911870|NCT04750941|DRUG|Copanlisib|Copanlisib will be infused intravenously on days 1, 8, 15 of each cycle, over 1 hour, of 28-day cycles.
223911871|NCT04750941|OTHER|Ketogenic Diet|"In cycle 1, patients will first start the ketogenic diet for 7 days (Day -6 to Day 0).~Only the patients who demonstrate compliance and tolerance with the ketogenic diet, as confirmed by pertinent blood and urine tests and a diary of diet, will be allowed to continue the study and start copanlisib on Day 1. The ketogenic diet will continue daily throughout the treatment days.~In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1.~The ketogenic diet will then continue daily throughout the treatment days."
223911872|NCT06805240|DIAGNOSTIC_TEST|Air Charged Catheter ARM Procedure|Normative datasets for traditional measures of anorectal function with an air charged HRAM catheter will be collected in healthy subjects using the IAPWG standardized testing protocol and London classification for ARM measurement.
223911873|NCT06805240|DIAGNOSTIC_TEST|Solid State Catheter ARM Procedure|Normative datasets for traditional measures of anorectal function with a solid state HRAM catheter will be collected in some healthy subjects using the IAPWG standardized testing protocol and London classification for ARM measurement for comparison to the air charged catheter.
223911874|NCT06805110|BEHAVIORAL|Monthly RDT validation during DHIS2 data review meetings|The Nigeria national malaria program will lead monthly RDT validation at selected legal government areas (LGAs). Health facilities will be asked to retain all RDT cassettes performed for the prior month and bring them to a monthly validation meeting. During these meetings, RDT cassettes will be scanned using the HealthPulse application, which will automatically tally the number of RDTs by brand and result. The application will also allow for the entry of aggregated testing data, including the total number of tests conducted and the RDT results recorded in the health facility register. Discrepancies between the HealthPulse data and facility records will be calculated, with a focus on identifying and addressing discrepancies exceeding a designated threshold (e.g., 10%) that takes into account the proportion of cassettes that may have changed results over the past month. Facilities with significant discrepancies may undergo a detailed audit to align RDT cassettes with patient records.
223911875|NCT06805942|DEVICE|Lipiodol (ethiodized oil) injection|Lipiodol will be used as an embolic agent for arterial embolization targeting neovascularity in the plantar fascia to reduce inflammation and pain.
223911876|NCT05835297|OTHER|Physical exercise interventions|Participants will undergo a 12-week multicomponent exercise regimen, twice per week on non-consecutive days for 45-60 min each. The session will be divided into 4 min of warm-up; range of motion exercises of upper and lower extremities, followed by light walking, then 8 min balance exercises, followed by 15 min strength exercises; two sets of 13-15 repetitions maximum of chair rises with progression, two sets of 13-15 repetitions of modified squats (holding a chair backrest if needed) with progression, 2 sets of 20-30 repetitions of seated or 2 sets of 13-15 repetitions of standing calf raises, then 15 min aerobic exercises; five 3-min bouts of walking between two strengthening exercises and/or 2 balance exercises, finally 3 min cool down exercises of light walking and stretching exercises.
223911877|NCT06804356|PROCEDURE|Tendon interposition arthroplasty|Trapeziometacarpal arthroplasty using autologous tendon interposition to fill the space left by resecting affected joint surfaces.
223911878|NCT06804356|PROCEDURE|Poly-L-D-lactic acid implant (RegJoint) interposition arthroplasty|Trapeziometacarpal arthroplasty using poly-L-D-lactic acid implant (RegJoint) interposition to fill the space left by resecting affected joint surfaces.
223911879|NCT06807073|PROCEDURE|Prophylactic defect closure|Endoscopists will use at least one new generation closure device to approximate the healthy mucosal surrounding the submucosal defect to ensure complete defect closure. Adequate apposition of the mucosal defect margins will be achieved when no visible submucosal areas \>3 mm along the closure line are present.
223911880|NCT06807073|PROCEDURE|No prophylactic defect closure|After performing EMR with thermal ablation, prophylactic defect closure will not be performed.
223911881|NCT02839265|DRUG|FLT3 Ligand Therapy (CDX-301)|See Arm 1 descriptions
224086194|NCT05464017|DEVICE|Optimized version of the mHealth screening tool (intervention) using the machine learning approach|"An improvement to the mHealth triage tool using a machine learning approach, optimizing the efficiency of call schedule and the prediction of which patients are most likely to benefit from follow-up care given data collected at the hospital through the Cameroon Trauma Registry, as well as post-discharge phone contact attempts and survey information. The backbone of the estimators is the ensemble machine learning algorithm the Superlearner, which has been applied to medical contexts, including injury and trauma. It is a theory-driven method based on cross-validation, which combines potentially many different learners (e.g., standard regression, tree regression, random forest, neural nets) such that the model chosen (a weighted average of the learners) is asymptotically equivalent to the so called Oracle - the learner that fits optimally for the data-generating distribution. Note, double-robust CV-TMLE versions of this estimator are available as the tmle3mopttx function in tlverse."
224086195|NCT03374280|DRUG|pemetrexed/cisplatin intercalating gefitinib|
224086196|NCT03374280|DRUG|pemetrexed/cisplatin|
224086197|NCT04030078|OTHER|Survey|Questionnaire-based survey
223911882|NCT02839265|RADIATION|Stereotactic Body Radiotherapy (SBRT)|See Arm 1 descriptions
223911883|NCT06314776|OTHER|Usual physiotherapy without Whole-Body Vibration|Manual Therapy, passive and active mobilizations, stretching, respiratory techniques
223911884|NCT06314776|OTHER|Pre-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
223911885|NCT06314776|OTHER|Post-Usual physiotherapy|(GMFM, Test 10M, Test Time Up and Go)
223911886|NCT03635424|DEVICE|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
223911887|NCT06353061|DRUG|Metformin|Patients randomized to the metformin group will start taking metformin within 1 day after group allocation. They will take one tablet of metformin (850 mg) once daily for three consecutive days. Subsequently, they will take metformin orally twice daily throughout the entire external and internal irradiation period, with each administration consisting of one tablet.
223911888|NCT06353061|RADIATION|Radiotherapy|The study requires all subjects to sequentially undergo external beam radiotherapy (EBRT) and intracavitary brachytherapy (BT). All radiotherapy must be completed within 7-8 weeks after treatment initiation. The total prescribed dose EQD2 for EBRT combined with BT should be ≥80 Gy; for subjects with squamous carcinoma with lesions ≤4 cm, the HR-CTV D90 should be ≥80 Gy; for subjects with adenocarcinoma or lesions \>4 cm, it is recommended that HR-CTV D90 should be ≥85 Gy. When the prescribed dose is limited by organs at risk (OAR), priority should be given to covering HR-CTV. The radiotherapy plan in this study is based on image guidance. Imaging scans can use MRI or CT, and the scanning area should extend at least 5 cm above and below the PTV.
223911889|NCT06353061|DRUG|Chemotherapy|The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
223911890|NCT06353061|DIAGNOSTIC_TEST|PET/CT|Using 68Ga-NY104 as a small molecule targeted imaging agent for CA-IX, two CA-IX PET/CT scans will be conducted in patients: one upon enrollment and another one week after randomization.
223911891|NCT04498026|DEVICE|Adherus Dural Sealant System|Adherus Dural Sealant, In situ polymerizing sealant
223911892|NCT04498026|DEVICE|DuraSeal Exact Dural Sealant System|DuraSeal Exact (P080013b)
223911893|NCT05145426|DEVICE|Low Intensity Focused Ultrasound|Application of LIFU
224086198|NCT00849017|BIOLOGICAL|albiglutide|albiglutide weekly injection
224086199|NCT00849017|BIOLOGICAL|albiglutide uptitration|albiglutide uptitration at week 12
224086200|NCT00849017|BIOLOGICAL|placebo|matching albiglutide placebo weekly injection
224086201|NCT04681092|BIOLOGICAL|AKS-452|s.c. or i.m. vaccination
224086202|NCT01941589|DRUG|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
224086203|NCT01941589|DRUG|corticosteroids only|IV corticosteroids only
224086204|NCT02022605|DEVICE|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
224086205|NCT02022605|OTHER|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
224086206|NCT00715130|BEHAVIORAL|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
224086207|NCT03261115|PROCEDURE|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
223911894|NCT06548880|OTHER|Structured exercise program|The intervention applied in this research has an online exercise training conducting with a structured exercise program including different types of exercise which are range of motion, stretching and low intensity aerobic exercises. The exercise program continued with sessions each lasting 60 minutes, once a week for 10 weeks.
223940005|NCT07196826|PROCEDURE|Active Aquatic Therapy|Active Aquatic Therapy involves structured, therapist-guided exercises in a heated hydrotherapy pool (32-34°C). Water buoyancy and resistance reduce spinal load, facilitate movement, and enhance muscle activation. Sessions last 45-60 minutes, 3 times per week for 4 weeks, supervised by licensed physiotherapists. Each session includes warm-up (water marching, arm swings, trunk rotations), main exercises (lumbar spine function, core strengthening, balance, hip abduction, back extensions, aqua walking, arm/leg strengthening), and cool-down (floating, deep breathing, passive stretches). Intensity is monitored using the Borg RPE scale (60-80% max HR). This intervention uniquely uses active engagement in water to reduce pain and improve strength, flexibility, and function, distinguishing it from passive aquatic therapy and land-based physiotherapy.
224086208|NCT05905796|OTHER|Brain Health Assessment|Research interventionists, who will be trained and licensed health practitioners (e.g., social workers), will ask participants about changes in memory or thinking and daily function, screen for depression, and administer a standard cognitive screening test. Research interventionalists will use a standardized note template to document results in the participant's EHR. Research interventionists will notify participants and PCPs if follow-up is recommended.
224086209|NCT02844855|BEHAVIORAL|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
224086210|NCT04279197|DRUG|Fuzheng Huayu Tablet|FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
223911895|NCT06807645|DEVICE|Clinical Trial Intervention Description General Study Setup Objective: To compare the efficacy of using a custom-made prefabricated acrylic splint versus no splint in maintaining premaxillary stabilit|"Clinical Trial Intervention Description General Study Setup Objective: To compare the efficacy of using a custom-made prefabricated acrylic splint versus no splint in maintaining premaxillary stability post-alveolar cleft repair.~Primary Outcome: Premaxillary stability. Secondary Outcomes: Wound healing and complications. Intervention Details~1\. Common Procedures for Both Arms:~Surgical Procedure: All surgical procedures will be conducted under general anesthesia with nasotracheal intubation.~Antibiotic Prophylaxis: A first-generation cephalosporin will be administered prior to incision as per .~Bone Graft Harvesting: Autogenous bone grafts will be harvested from the anterior iliac crest using a pediatric minimally invasive technique with a 2 cm skin incision 1 cm lateral to the iliac crest.~Alveolar Cleft Repair:~Incision and Flap Design: A sulcular incision will be made to develop full thickness mucoperiosteal advancement flaps extending into the cleft with caref"
223911896|NCT06804447|RADIATION|Proton Beam Therapy|Proton Beam Therapy
223911897|NCT04647448|DIAGNOSTIC_TEST|Application of sensor patch|Application of sensor patch to chest to record acoustic signals due to disturbed blood flow.
223911898|NCT04465487|DRUG|REGN6569|Administered by intravenous (IV) infusion
224086211|NCT04279197|DRUG|Vitamin C tablets|Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
224086212|NCT04279197|DRUG|Placebo|Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
224086213|NCT04279197|OTHER|respiratory function rehabilitation training|Health exercise, once a day
224086214|NCT01061008|OTHER|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
224086215|NCT01061008|OTHER|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
224086216|NCT05327699|DRUG|Ketamine|A single intravenous (IV) infusion of ketamine calculated at 0.5mg/kg through an indwelling catheter over a 40-100min period.
224086217|NCT05327699|OTHER|Placebo|A single intravenous (IV) infusion of saline through an indwelling catheter over a 40-100min period.
224086218|NCT06960122|PROCEDURE|Fecal Microbiota Transplant (FMT)|One course of fecal microbiota transplantation (FMT) was administered in addition to standard therapy.
224086219|NCT06960122|OTHER|Standard Therapy|Standard Therapy Alone
224086220|NCT01695421|PROCEDURE|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
224086221|NCT01695421|PROCEDURE|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
224086222|NCT01695421|PROCEDURE|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
224086223|NCT01695421|PROCEDURE|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
224086224|NCT02024971|DRUG|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
224086225|NCT03625388|DRUG|Dasatinib|Film coated tablet contains dasatinib monohydrate
224086226|NCT06437522|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224086227|NCT06437522|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
224086228|NCT04933123|DEVICE|indirect restorative treatment with a glass ceramic|Inlays and onlays of glass ceramic for molars and premolars are adhesively luted.
224086229|NCT01548261|PROCEDURE|Donating oral mucosal cells|Donating oral mucosal cells
224086230|NCT05242822|DRUG|KIN-3248|KIN-3248 will be administered orally once daily in 28-day cycles
224086231|NCT05536375|OTHER|Exhaled breath condensate collection and blood draw|"Venepuncture- 10mls of blood to be collected~and~Exhaled breath condensate (EBC) collection method- this involved breathing in and out through a disposable device (akin to breathing onto cold glass to produce condensate) with an external cooler device. The R Tube starter kit is a complete disposable EBC collection kit and It has been used in many research clinical investigations."
223911899|NCT04465487|DRUG|Cemiplimab|Administered by IV infusion
223911900|NCT04560595|BEHAVIORAL|Caffeine Reduction Manual|We will provide participants with a Guide to Caffeine Reduction and Cessation in order to help the reduce their caffeine use and determine their ratings of treatment acceptability.
223911901|NCT04305444|DRUG|DTRM-555|Oral once-daily administration
223911902|NCT05533190|DEVICE|Wysa AI chatbot mental health app|Wysa is a guided self-help and triaging tool delivered to patients via an app. It includes a chatbot and makes use of a wide range of clinically underpinned modules to provide mental health support.
223911903|NCT06077175|OTHER|hand massage group|Each individual will receive a 10-minute hand massage, 5 minutes for each hand. Since the speed and number of repetitions of the massage movements should be at normal frequency, the massage will be performed at a speed that does not disturb the individual, is not stimulating and has a calming effect, and will not tire the practitioner. In the massage, effleurage (stroking) and friction (circular rubbing) movements will be used, which have a circulation-supporting and tissue-relaxing effect. Evaluations will be made within 30 minutes after the hand massage.
223911904|NCT06443580|OTHER|interoceptive group based intervention|8 week online group intervention aiming to improve interoception.
223911905|NCT05331625|BEHAVIORAL|Offering Additional Resources to Promote Symptom Management|Participants will be offered additional resources to promote symptom management.
223911906|NCT03261011|BIOLOGICAL|AK-104|Subjects will receive AK104 by intravenous administration.
223911907|NCT03314740|DRUG|Paclitaxel|Comparator active compound
223911908|NCT03314740|DRUG|Cediranib|Experimental compound
223911909|NCT03314740|DRUG|Olaparib|Experimental compound
223911910|NCT05814211|DEVICE|Investigational device - newly developed intermittent catheter|Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The investigational device is for single use.
223911911|NCT05814211|DEVICE|Comparator device #1 - SpeediCath Eve|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
223911912|NCT05814211|DEVICE|Comparator device #2 - SpeediCath Compact Plus Female|"During comparator study period, subjects will only receive one of the comparator products. Randomization will decide which one.~Ready-to-use, sterile, hydrophilic coated intermittent female compact catheter (sizes CH12 and CH14) for urinary drainage. The comparator device is for single use."
223911913|NCT02772731|PROCEDURE|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
223911914|NCT02772731|PROCEDURE|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
223911915|NCT06466980|OTHER|Ventilator associated event|Measure of incidence of Ventilator associated event
223911916|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray with reservoir|"Patients will be randomly divided into two groups. Alginate impressions of maxillary dental arches of patients will be taken to obtain casts and produce the customized trays.~Reservoirs 1 mm thick will be created on the facial surfaces of anterior teeth, including the first premolars in the arches, applying a light-cured resin on the casts. The resin layer thickness will be standardized using a thickness gauge (1.5 mm thickness). Then, customized trays will be fabricated with 0.9-mm-thick vinyl acetate sheets using the thermoforming process. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the patients' mouth."
223911917|NCT05605834|OTHER|9.5% hydrogen peroxide bleaching (POLA DAY advanced tooth whitening system, SDI) using a tray without reservoir.|Alginate impressions of maxillary dental arches of patients will be taken to obtain casts to produce the customized trays. Then, customized trays will be fabricated with no space for reservoir, with 0.9-mm-thick vinyl acetate sheets using the thermoforming process applying a light-cured resin on the casts. Trays will be precisely trimmed completely involving tooth surface (1 mm incisal or occlusal to gingival margin), and the adaptation will be verified on the casts. The trays will be placed over teeth to verify the adaptation in the participants' mouths.
223911918|NCT04227288|DRUG|Enstilar Foam|Subjects will be instructed to apply a thin layer on the nail plate, around the nail plate and under the nail plate. The patient will be instructed to apply one application at night immediately before bed and not wash their hands before morning. All subjects who completed the 6-month treatment will be followed for 1 month after discontinuation.
223911919|NCT03707808|DRUG|intratumoral injection of autologous CD1c (BDCA-1)+ myDC|intratumoral injections plus intravenous administration
223911920|NCT03707808|DRUG|Intratumoral injection of ipilimumab and AS01b|Intratumoral injection of ipilimumab and AS01b
223911921|NCT03707808|DRUG|IV nivolumab|Nivolumab administered intravenously
223911922|NCT06033378|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
223911923|NCT05500690|DIETARY_SUPPLEMENT|Folic Acid Tablet|5 mg folic acid supplement
223911924|NCT03979742|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cell|Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)
223911925|NCT03979742|OTHER|Locomotor Training|Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
223911926|NCT00708448|RADIATION|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
223911927|NCT00708448|DRUG|Erlotinib|150 mg/day
223911928|NCT00708448|DRUG|Bevacizumab|15mg/kg q 21 days
223911929|NCT01678872|DRUG|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
223911930|NCT06305013|OTHER|Pulseless electrical activity recognition|The ability of nurses to recognize the pulseless electrical activity in the questionnaire (electronic survey)
223911931|NCT05403086|DRUG|Psilocybin|Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.
223911932|NCT05403086|DRUG|Ketamine|ketamine hydrochloride injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride.
223911933|NCT06752642|PROCEDURE|Implant overdenture|patients received implant overdenture
223911934|NCT04863261|OTHER|Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App|The CHORUS App has been developed as a tool for clinicians to easily visualize important patient information from their smart phones. Relevant information is electronically distributed and placed within the corresponding module in the CHORUS HCP mobile app for iOS and Android.
223911935|NCT05939518|OTHER|Lactated Ringer's Fluid Bolus Response to Low Urinary Output|During the surgical procedure and the subsequent stay in the Post-Anesthesia Care Unit: if the study participant's urine output (UO) remains \<0.3 ml/kg/h for two consecutive hours, an IV bolus of 250 ml of lactated Ringer's solution will be administered over 15 min and repeated every 30 min until the UO reaches \>0.3 ml/kg/h.
223911936|NCT05939518|OTHER|Post-Anesthesia Care Unit Lactated Ringer's Fluid Management Protocol|During their stay in the Post-Anesthesia Care Unit, patients will receive a 1.5 ml/kg/h IV infusion of lactated Ringer's solution.
223911937|NCT05565989|BEHAVIORAL|MBM and II|An initiation to MBM practice (including 4 exercices) and 2 intention implementation exercices are proposed to participants
223911938|NCT05565989|BEHAVIORAL|MI|A motivational Interview will be conducted with participant.
224086232|NCT03289416|COMBINATION_PRODUCT|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
224086233|NCT03289416|COMBINATION_PRODUCT|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
224086234|NCT02326337|DEVICE|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
223911939|NCT06266728|DEVICE|Total30 for Astigmatism Contact Lenses|Participants must be refit into Total30 for Astigmatism Contact Lenses and wear them over the course of this one month study.
223911940|NCT06053190|BEHAVIORAL|Sentence stimulus|"The sentences are designed such that a specific target word is either (a) Plausible (normal), (b) a semantic pragmatic violation, or (c) a morpho-syntactic violation. Example: e.g., Every morning at breakfast, the boys would (A: EAT)/ (B.PLANT )/ (C. EATS ) eggs..."
223911941|NCT06053190|BEHAVIORAL|Speaking style|The sentences will be presented either in A. conversational speaking style, or B. hyper-articulated clear speech style. Clear and conversational speech samples will be elicited from a single male talker. In the conversational speech condition, which will be recorded first, the talker will be instructed to read the sentences as they would in everyday conversation. In the clear speech condition, the talker will be instructed to produce the sentences as if they would if they were talking to a person with hearing loss.
223911942|NCT04724460|DRUG|Long DOAC|Administration of Rivaroxaban for 18 months
223911943|NCT04724460|DRUG|Short DOAC|Administration of Rivaroxaban for 6 months
224086235|NCT02326337|DEVICE|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
224086236|NCT06213909|OTHER|This is a retrospective analysis of health data from inpatient record, no intervention was designed|This is a retrospective analysis of health data from inpatient record, no intervention was designed
224086237|NCT02065739|DRUG|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
224086238|NCT02065739|DRUG|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
224277708|NCT02785627|OTHER|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
224277709|NCT03294616|DEVICE|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
224277710|NCT03483311|OTHER|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
223911944|NCT04167553|DRUG|HM15136|"In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total."
223911945|NCT04167553|DRUG|Placebo|"In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional.~In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total."
224086239|NCT06522776|BEHAVIORAL|Cognitive behavioral therapy|The investigator adapted the manual of psychological intervention based on Cognitive Behavioral Therapy (CBT) which previously was validated in patients with chronic kidney disease. Patients received CBT using a model of six modules, with a time of 60 minutes for each weekly session. For each module, a skill acquisition criterion was used, to know if the participants were putting the techniques into practice in their daily lives and to know if it was pertinent to move on to the next module. Modules were adapted to the needs of each participant. In consequence, the number of sessions was different for each patient. All participants had a follow-up session one month after they finished the psychological therapy. Additionally, a daily self-record of symptoms perception and a short questionnaire on the usefulness of each technique used were sent daily to the participants via a phone text message.
224086240|NCT03479047|DIAGNOSTIC_TEST|assess diaphragmatic displacement (DD) using ultrasonography|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
224086241|NCT02615457|DRUG|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
224086242|NCT01384682|DRUG|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
224086243|NCT04041115|DIETARY_SUPPLEMENT|Non-alcoholic beer|Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
224086244|NCT04041115|OTHER|control|Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
224086245|NCT02780193|DRUG|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
224086246|NCT06499922|PROCEDURE|SURGICAL EXCISION|surgical excision of low grade glioma
224086247|NCT02701673|DRUG|Busulfan|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
224086248|NCT02701673|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
224086249|NCT02701673|DRUG|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
224086250|NCT02701673|DRUG|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
224086251|NCT02701673|DRUG|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
224277711|NCT06496373|BIOLOGICAL|Fixed neoantigen tumor vaccine|Single/Fixed neoantigen mRNA vaccine includes pancreatic cancer driver mutations such as KRAS G12D, G12V, G12R, G12C, etc. Each vaccine has one neoantigen encoded by mRNA. Total of 4 cycles, 3 weeks each cycle.
224277712|NCT06496373|BIOLOGICAL|personalized neoantigen tumor vaccine|personalized neoantigen tumor vaccine include 5-20 neoantigens selected based on WES/RNA-seq of patients' tumor sample during surgery. Total of 9 cycles after finishing the first 4 cycles of fixed neoantigen tumor vaccine.
224277713|NCT06496373|DRUG|PD-1 inhibitor|Toripalimab
224277714|NCT04269993|DRUG|Cannabis: placebo and medium THC/medium CBD|Vaporized cannabis was administered to participants (placebo and medium THC/medium CBD).
224277715|NCT05483907|DRUG|BBT-877|BBT-877 24 weeks + Follow-up 4 weeks
223911946|NCT06015672|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will have two accelerated transcranial magnetic stimulation (TMS) visits. Each TMS visit will be separated by 5 months. During each TMS visit, they will receive four TMS sessions, each separated by 60 minutes of rest.
224086252|NCT02701673|DRUG|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
224086253|NCT02701673|DRUG|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
224277716|NCT05483907|DRUG|Placebo|Placebo 24 weeks + Follow-up 4 weeks
224277717|NCT05903170|DEVICE|360J LifePak Monitor/Defibrillator|The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.
223911947|NCT05668351|RADIATION|SUPR-SABR treatment|SUPR-SABR prescription dose to the PTV\_4000 will be 8 Gy per fraction for five fractions. The prescription dose to PTV\_3625 will be a minimum of 7.25 Gy per fraction for five fractions. SABR will be delivered 2-3 times a week, every other day. There will be a minimum of 40 hours between fractions and maximum of 128 hours between fractions.
223911948|NCT03852758|BEHAVIORAL|Outdoor Exercise|2 outdoor exercise sessions per week
223911949|NCT03852758|BEHAVIORAL|Indoor Exercise|2 indoor exercise sessions per week
223911950|NCT06350981|DRUG|Exparel|20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine
223911951|NCT06350981|DRUG|Bupivacain|Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL
223911952|NCT05730621|DRUG|Sarpogrelate Sustained Release/Aspirin|Aspirin 100mg qd and Sarpogrelate Sustained Release 300mg qd for 12 weeks
223911953|NCT05730621|DRUG|Aspirin|Aspirin 100mg qd for 12 weeks
223911954|NCT04789551|OTHER|Blood Sample|a blood sample will be collected
223911955|NCT05463913|DRUG|18F-FDG|Patients will receive a single intravenous injection of 3 MBq/kg 18F-FDG
223911956|NCT05463913|RADIATION|PET/CT imaging|Patient will undergo 2 CT acquisitions and multiple PET emission scans.
223911957|NCT06212791|BEHAVIORAL|Self- Report Evaluation-Duke Activity Status Index|Complete the Self- Report Evaluation-Duke Activity Status Index
223911958|NCT06212791|BEHAVIORAL|Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire|Complete the Self- Report Evaluation, Atrial Fibrillation Effect on Quality of Life Questionnaire
223911959|NCT06212791|DIAGNOSTIC_TEST|Cardiopulmonary exercise test (CPET)|Cardiopulmonary exercise test (CPET)
223911960|NCT06212791|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Transthoracic echocardiogram at rest and immediately following peak exercise during CPET
223911961|NCT06212791|DIAGNOSTIC_TEST|Ambulatory cardiac rhythm assessment|Ambulatory cardiac rhythm assessment
223911962|NCT06212791|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) study at rest and during two stages of submaximal exercise (ExeCMR)
223911963|NCT06645678|DRUG|Elranatamab|"Elranatamab: Participants will receive SC administration of elranatamab QW or Q2W. The initial doses of elranatamab will be 12mg (C0D1), 32mg (C0D4), and 76mg (C0D8) and will serve as the 2 step-up priming regimen (Cycle 0). Then, 76mg weekly C1-C6 \> then 76mg bi-weekly from C7 for those achieving PR or better \> then 76mg q4weeks from C12 for those achieving CR or better response. If the participant subsequently begins to have an increase of disease burden not yet qualifying as PD according to IMWG criteria, dose intervals will return to weekly dosing.~premedication for Elranatamab: Acetaminophen 650mg (or paracetamol 500mg), Diphenhydramine 25mg (or equivalent), Dexamethasone 20mg (or equivalent).~In case of mezigdomide discontinuation due to reasons other than disease progression, elranatamab continuation +/- dexamethasone will be allowed until loss of response. The administration of elranatamab +/- dexamethasone will continue per study protocol schedule."
223911964|NCT06645678|DRUG|Mezigdomide|"The first day of study treatment dosing with mezigdomide is considered Day 1 of a cycle. (per recommended phase 2 dose, daily \[qd\], D1-21, q 4weeks). Capsules of mezigdomide will be taken by mouth with or without food.~In case of elranatamab discontinuation due to reasons other than disease progression, mezigdomide continuation +/- dexamethasone will be allowed until loss of response. The administration of mezigdomide will continue per study protocol."
223911965|NCT06645678|DRUG|Dexamethasone|"Administered at the dose of 20 mg/day from C1-3, then 10mg/day from C4-6 as a premedication for elranatamab.~(for those \>=75 yrs, with uncontrolled diabetes mellitus, history of intolerance: 10mg/day -\> 5mg/day)"
223911966|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
223911967|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
223911968|NCT06646055|DRUG|AK112, Cadonilimab, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
223911969|NCT06646055|DRUG|AK112, nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
223911970|NCT06646055|DRUG|nab-paclitaxel, gemcitabine|IV infusion, specified dose on specified days.
223911971|NCT06308575|DRUG|Rivoceranib|Given by PO
223911972|NCT05910411|DEVICE|Inelastic compression|Inelastic compression used in the treatment of lymphedema
223911973|NCT05717400|DRUG|Bevacizumab|Given by vein (IV)
223911974|NCT05717400|DRUG|Atezolizumab|Given by vein (IV)
223911975|NCT05717400|DRUG|Sofosbuvir|Given by PO
223911976|NCT05717400|DRUG|Velpatasvir|Given by PO
223911977|NCT05717400|DRUG|Voxilaprevir|Given by PO
223911978|NCT05717400|DRUG|Ribavirin|Given by PO
223911979|NCT06167213|DEVICE|SAPIEN X4 THV|Implantation of the SAPIEN X4 valve
223911980|NCT05505825|DRUG|AK104 IV infusion；Chiauranib oral|AK104 IV infusion once every 3 weeks；Chiauranib once a day oral
223911981|NCT06163274|DEVICE|Placebo Intravaginal Ring A|Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.
223911982|NCT06163274|DEVICE|Placebo Intravaginal Ring B|Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.
224086254|NCT02701673|DRUG|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
223911983|NCT01895842|DRUG|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
223940006|NCT07196826|PROCEDURE|Passive Aquatic Therapy|Passive Aquatic Therapy (Watsu) is a therapist-guided, passive aquatic technique performed in a warm hydrotherapy pool (35°C). The patient floats while the therapist gently moves their body in rhythmic, synchronized patterns, providing massage, stretching, joint mobilization, and acupressure. Sessions last 45-60 minutes, 3 times per week for 4 weeks, and include preparation/floating, cradling with passive movements, passive stretching and mobilization, acupressure, and final relaxation. Neck and knee supports are used for comfort. This intervention uniquely emphasizes passive relaxation and gentle mobilization, making it suitable for patients with severe movement limitations, distinguishing it from active aquatic therapy and conventional land-based physiotherapy.
224086255|NCT02701673|PROCEDURE|Stem Cell Transplant|Stem cell transplant performed on Day 0.
224086256|NCT00955773|DRUG|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
224086257|NCT01577238|DRUG|1% SPL7013 Gel|Vaginal gel, daily for 7 days
224086258|NCT01577238|DRUG|Placebo|Vaginal gel, daily for 7 days
224086259|NCT03931304|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
224086260|NCT00001676|DRUG|SQ Fludarabine|
224086261|NCT00379951|DRUG|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
224086262|NCT04856657|DEVICE|Transcranial alternating current stimulation|The tACS will be applied with a current of 1-2 mA (milliamperes) via two saline soaked electrode sponges (25 cm²) applied to the back of the head. The anode will be located at Oz and the cathode will be located at Cz.
224086263|NCT03992144|DRUG|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
224086264|NCT03992144|DRUG|metronidazole 400mg|400mg of metronidazole an hour before extraction
224086265|NCT03992144|DRUG|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
224086266|NCT00553462|DRUG|carboplatin|
224086267|NCT00553462|DRUG|erlotinib hydrochloride|
224086268|NCT00553462|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
224086269|NCT00553462|RADIATION|radiation therapy|
224086270|NCT03711604|DRUG|Tenalisib|BID Orally
224086271|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
224086272|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
224086273|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
224086274|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
224086275|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
224086276|NCT01137357|DIETARY_SUPPLEMENT|Yoghurt|Intake of yoghurt during 4 weeks
224086277|NCT00130715|DEVICE|Seprafilm Bioresorbable Membrane|
224086278|NCT01869348|BEHAVIORAL|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
224086279|NCT00370201|DRUG|colchicine|
224086280|NCT05460039|OTHER|Dance mediated by tecnhology|A web system and a dance mat are used to stimulate participants to perform dance activities for 8 weeks.
224086281|NCT03075163|PROCEDURE|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
224086282|NCT03075163|DRUG|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
224086283|NCT00397332|DRUG|Alefacept|IM Alefacept
224086284|NCT05119803|DEVICE|Spinal Mouse (IDIAG M360 )|This device is an electronic computer-aided measuring december that measures the range of motion of the spine, evaluates the angle and shape of the spine in the sagittal and frontal planes. The device provides data to the computer via Bluetooth, and the measured curvatures are displayed on the computer screen. The method has no medical risks or dangers. The device has two rotating wheels that follow the spinous protrusions of the spine, and the distance and angle measurements are transferred from the device to the computer.
224086285|NCT05119803|OTHER|Nine Hole Peg Test|The nine-hole peg test is a simple, fast and manual skill test that has been proven to be valid and reliable in measuring upper limb function in Parkinson's patients. While the patient is sitting, he is asked to insert nine sticks into the holes of the test box with nine holes one by one as fast as possible and remove them back when he is finished
224086286|NCT01487369|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
224086287|NCT04704622|DRUG|Ketamine|ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
224086288|NCT04704622|DRUG|Midazolam|midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
224086289|NCT04704622|DRUG|Dexmedetomidine|dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
224086290|NCT00110994|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
224086291|NCT00110994|DRUG|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
224086292|NCT00110994|DRUG|Dacarbazine|Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1
224086293|NCT01361841|DRUG|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
224086294|NCT01361841|DRUG|travoprost, latanoprost and bimatoprost|one drop once a day for life
224086295|NCT06420310|OTHER|exposure to pesticides|based on work exposures to pesticides
224086296|NCT06028633|DRUG|pembrolizumab|pembrolizumab 200mg IV on day 1 for every 3 weeks
224086297|NCT06028633|DRUG|lenvatinib|lenvatinib 8mg taken orally every day
224086298|NCT06028633|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
224086299|NCT06485193|DIAGNOSTIC_TEST|Immunohistochemistry|Immunohistochemical analysis of archived diagnostic tissue samples.
223911984|NCT03631290|BEHAVIORAL|Deprescribing Intervention|"The deprescribing program was implemented as a clinical quality improvement project for patients receiving dialysis. Patients taking specific potentially inappropriate medications (PIMs) were identified in the medical record. The PIMs of interest included gabapentinoids, clonidine, alpha blockers, muscle relaxants, and Z-drugs. If their nephrologist agreed to attempt deprescribing the PIM, either the nephrologist (Provider Only Communication) or a study team member (pharmacist or nurse, Provider/Patient Communication) would engage the patient in discussion about deprescribing. This discussion included patient education materials about the risk of the medication. If the patient agreed, they were provided taper instructions (if indicated) and were followed up at 1 month and 3 months.~The patient was also invited to enroll in a study to be interviewed about the deprescribing decision and experience, and undergo brief assessment of geriatric problems at baseline and at 3 months."
224086300|NCT03986255|PROCEDURE|Lumbar Puncture|"The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point."
224086301|NCT01964404|DRUG|Marijuana|Smoked plant with THC
224086302|NCT01964404|DRUG|Dronabinol|Capsule with THC
224086303|NCT01964404|DRUG|Placebo|Capsule with no active ingredient
224086304|NCT05631912|BIOLOGICAL|Autologous CD19-STAR-T cell|Phase 1 dose escalation (3+3) : dose 1 (1×10\^6 cells/kg) ,dose 2 (3×10\^6 cells/kg) ,dose 3 (1×10\^7 cells/kg); Phase 2 : Appropriate dose
224086305|NCT05631912|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
224086306|NCT05631912|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
224086307|NCT00486447|DEVICE|64 Channel VCT|cardiac CT angiography exam
224086308|NCT02055404|DEVICE|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
224086309|NCT02055404|DEVICE|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
224086310|NCT01299727|BIOLOGICAL|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
224086311|NCT01299727|BIOLOGICAL|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
224086312|NCT01299727|BIOLOGICAL|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
224086313|NCT00932516|BEHAVIORAL|South Beach Diet™ with South Beach Diet™ Products|
224086314|NCT00932516|BEHAVIORAL|South Beach Diet™|
224086315|NCT00932516|BEHAVIORAL|Calorie restricted diet with South Beach Diet™ Products|
224086316|NCT00932516|BEHAVIORAL|Calorie Restricted Diet|
224086317|NCT02247089|OTHER|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
224086318|NCT02247089|OTHER|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
224086319|NCT05110079|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening."
224086320|NCT01773655|OTHER|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
224086321|NCT04297462|DRUG|Oseltamivir 3 days|Non-inferiority study of 3 versus 7-days duration of PEP
224086322|NCT04297462|DRUG|Oseltamivir 7 days|Active comparator
224277718|NCT05903170|DEVICE|200J Philips HeartStart MRx Monitor/Defibrillator|The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.
224277719|NCT02404857|DEVICE|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
224277720|NCT00108979|DRUG|Escitalopram|
224277721|NCT04429867|DRUG|Hydroxychloroquine|Hydroxychloroquine 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
224277722|NCT04429867|DRUG|Placebo|Placebo 400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses
223911985|NCT05695430|BEHAVIORAL|Brief Cognitive Behavioral Therapy for People with Physical Disabilities|12 sessions of of Brief Cognitive Behavioral Therapy that has been adapted for people with physical disabilities will be administered through telehelath.
223911986|NCT04203524|DIAGNOSTIC_TEST|Procalcitonin Levels|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first. A PCT-guided algorithm will be available to guide the management of patients in the PCT group.
223911987|NCT04203524|OTHER|Control|Procalcitonin (PCT) will be measured within 48 hours of admission to the ICU or 48 hours of onset of sepsis (if developed during the ICU stay). In addition, the patients will have daily blood samples taken up to 5 days or until ICU transfer, whichever occurs first.The results of the PCT levels obtained will be blinded and all clinical team members will not be able to access the results.
223911988|NCT05565326|DEVICE|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system|Low field (0.35 T) MR-images of the brain at a MRIdian® linac system using CE marked low-field MR coils as provided by the company will be taken for volunteers in phase I. In phase II and III, after therapy beginning those images will be taken once per week per subject using CE marked low-field MR coils as provided by the company. This is done over the entire course of radiotherapy, which takes between 3 and 6 weeks.
223911989|NCT05656027|DRUG|Aceclidine + Brimonidine|LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
223911990|NCT05656027|DRUG|Aceclidine|LNZ100 Aceclidine ophthalmic solution
223911991|NCT05656027|DRUG|Brimonidine|Brimonidine ophthalmic solution
223911992|NCT03978663|RADIATION|Neoadjuvant radiotherapy|Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
223911993|NCT03473249|DRUG|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
223911994|NCT02879136|DRUG|Methylphenidate|Patient will be randomized to Methylphenidate
223911995|NCT02879136|OTHER|Physical Therapy|All Patients will have standard of care PT used for PD patients
223911996|NCT02879136|DRUG|Atomoxetine|Patient will be randomized to Atomoxetine
223911997|NCT04473378|DEVICE|FreeStyle Libre Pro|The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
223911998|NCT06438029|OTHER|Education group|the students in the experimental group will be trained on disaster and disaster response
223911999|NCT06438029|OTHER|control group|the students in the experimental group will be trained on disaster and disaster response
223912000|NCT03998059|PROCEDURE|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
223912001|NCT05819476|PROCEDURE|OLP-injection|Open-label placebo injections without any active ingredient (5 ml 0.9% saline). All participants will be informed that the administered injections are placebo infusions.
223912002|NCT05819476|OTHER|Scripted Evidence-based treatment rationale|As a second component the intervention will consist of an evidence-based treatment rationale, which will be delivered to patients receiving the intervention prior to the OLP-injections, explaining placebo analgesia in pain in general and specifically in OLP. In the context of OLP treatments this rationale is important in order to create a mental state of positive expectations.
223912003|NCT05819476|OTHER|Experimental model of acute pain|Experimental model of acute pain (simulating wound pain: this installation will apply monophasic, rectangular electrical pulses of 0.5ms duration with alternating polarity at 2 Hz frequency. The current will be increased to target a pain rating of 6 of 10 on the NRS (0 = no pain, 10 = worst imaginable pain). Three further adjustments in current will be made every 5 minutes for the next 15 minutes to compensate for habituation. This final current will be kept constant until the end of the particular experiment).
223912004|NCT06307886|PROCEDURE|Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With manipulator|patients who underwent laparoscopic hysterectomy with using uterine manipulator
223912005|NCT06307886|PROCEDURE|lPatients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy without uterine manipulator|patients who underwent laparoscopic hysterectomy without using uterine manipulator
223912006|NCT06391697|DEVICE|eOPRA Implant System for Transtibial Amputees and Magnetic Bead Tracking System|"The Magnetic Bead Tracking System is an investigational device that consists of pairs of magnetic beads, and a set of magnetic field sensors that measure and track the length of muscles and the speed at which they move in real-time. When the beads are implanted in muscle in the residual limb of an amputee, the muscle length signal is communicated to an investigational, robotic ankle-foot prosthesis.~The e-OPRA is an investigational implant system that lets a lower leg prosthesis attach securely to the remaining tibia bone. The e-OPRA device has been designed so that it can be implanted with an electrode set that consists of an electrical connector and electrodes to allow it to be used with both a neuro-mechanical (powered) prosthesis system, in addition to the standard prosthesis.~The operation to implant these devices will represent a modification of the surgical technique currently employed for standard below knee amputation."
223912007|NCT05943756|BEHAVIORAL|Signature Strengths|The treatment group will complete 6 web-based sessions of Signature Strengths(1 sessions per week for 6 weeks), designed to teach lessons focused on the Aware-Explore-Apply interventional framework. Sessions are approximately 60 minutes long.
223912008|NCT05943756|BEHAVIORAL|TBI Education Course|The control group will complete 6 web-based sessions of a TBI Education Course(1 sessions per week for 6 weeks), designed to teach lessons based on the TBI Model Systems Knowledge Translation Center's fact sheets. Sessions are approximately 60 minutes long.
224086323|NCT00947284|DRUG|nalbuphine plus naloxone|single dose administered intravenously
224086324|NCT00947284|DRUG|nalbuphine plus saline|single dose administered intravenously
224086325|NCT00947284|DRUG|naloxone plus saline|single dose administered intravenously
223912009|NCT05291273|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the Closed Kinetic Chain Upper Extremity Stability Test (CKCUEST). The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
223535231|NCT03802396|DRUG|Placebo|Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
223912010|NCT05291273|DIAGNOSTIC_TEST|Prone Bridge Test|"The prone bridge test also known as the plank or hover measures the muscular endurance of the abdominal muscles. Subjects will start in the down push up position with their feet together and their hands shoulder width apart. When the test starts the subject will push up to the prone bridge position so they are resting on their hands and toes making sure they maintain a straight line from the shoulders through the hips to the knees. The outcome measure will be the time where the subject stay in this position."
223912011|NCT05291273|DIAGNOSTIC_TEST|Measurement of the muscle strength of the shoulder complex|Maximum isometric force of the external and internal rotators and abductors/adductors measured by a dynamometer.
223912012|NCT03858517|DEVICE|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
223912013|NCT03265808|DRUG|allogeneic human mesenchymal stem cells (allo-hMSCs)|Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
223912014|NCT03265808|DRUG|Placebo|Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
223912015|NCT06371157|DRUG|AK104|intravenous
223912016|NCT06371157|DRUG|Lenvatinib|oral
223912017|NCT06371157|PROCEDURE|TACE|TACE (chemo and embolic agent injection into the hepatic artery)
223912018|NCT06371157|OTHER|Placebo for AK104|intravenous
223912019|NCT06371157|OTHER|Placebo for Lenvatinib|oral
223912020|NCT04750538|DEVICE|BreEStim 120|120 BreEStim stimuli will applied for about 10-15 minutes.
223912021|NCT04750538|DEVICE|BreEStim 240|240 BreEStim stimuli will applied for about 20-30 minutes.
223912022|NCT03636243|BIOLOGICAL|Vascularly biological assessment|22.5 ml of blood will be collected at day -15, month 3 and month 12.
223912023|NCT03636243|BIOLOGICAL|Analysis of vasomotor endothelial function|Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system \[Itamar Medical Ltd., Caeserea, Israel\] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
223912024|NCT03636243|BIOLOGICAL|Analysis of arterial compliance|Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' \[Alam Medical, France\] at day -15, month 3 and month 12
223912025|NCT03636243|BIOLOGICAL|Exploration of microcirculation|The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12
223912026|NCT03636243|BIOLOGICAL|Venous Doppler Ultrasound|aneurysm screening at day -15, month 3 and month 12
223912027|NCT03636243|BIOLOGICAL|Arterial pressure measurement|measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12
223912028|NCT03636243|BIOLOGICAL|Intima-Media Thickness measurement|Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
223912029|NCT03636243|BIOLOGICAL|Exploration of neuropathy|non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
223912030|NCT03636243|BEHAVIORAL|level of physical activity|pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
223912031|NCT03636243|OTHER|thoracic scanner|non-injected thoracic scanner visit at month 3
223912032|NCT04934462|PROCEDURE|physiotherapy|Six months physiotherapy aimed at hip stability.
223912033|NCT04934462|PROCEDURE|arthroscopy|Arthroscopic plication of hip joint capsule.
223912034|NCT03647358|DEVICE|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
223912035|NCT03647358|DRUG|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose. (If a holiday is present in the work week, 124I can be administered orally on Day 2, if needed).
223912036|NCT05820516|DEVICE|TricValve implantation|TricValve implantation
223912037|NCT06799208|PROCEDURE|Laparoscopy|Minimal invasive approach. Have peritoneal tissue sparing character . Minimal blood loss . Reduction of postoperative adhesions.
223912038|NCT06783478|BIOLOGICAL|NK cell infusion|Six infusions of 1 x 10⁷/kg of haploidentical NK cells, in vitro expanded and activated.
223912039|NCT06783478|OTHER|Placebo|Six infusions of placebo
223912040|NCT05664958|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block with liposomal bupivacaine and immediate release bupivacaine
223912041|NCT05664958|DRUG|bupivacaine liposome injectable suspension|133 mg liposomal bupivacaine per side.
223912042|NCT05664958|DRUG|bupivacaine|20 ml bupivacaine 0.25% per side.
223912043|NCT05935605|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.
223912044|NCT05935605|DIAGNOSTIC_TEST|Lung ultrasound|A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.
224086326|NCT00537433|OTHER|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
224086327|NCT02529033|DEVICE|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
224086328|NCT00341614|BEHAVIORAL|3-month Exercise Training and Diet Education|
224086329|NCT01589484|DEVICE|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
224086330|NCT04015830|OTHER|electroencephalography (EEG) and event related potentials (ERP)|This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
224086331|NCT00955058|DRUG|OCP|Daily For 3 months
224086332|NCT02185937|DIETARY_SUPPLEMENT|cola|imatinib intake with coca-cola
224086333|NCT02909621|DIETARY_SUPPLEMENT|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
224086334|NCT02909621|OTHER|PLACEBO|
223912045|NCT05674981|DIETARY_SUPPLEMENT|Probiotic group|Two-strain probiotic supplement includes Lactobacillus reuteri ADR-1 (alive) and Lactobacillus rhamnosus GM-020 ( alive).
224086335|NCT01727089|BIOLOGICAL|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
224086336|NCT01727089|BIOLOGICAL|Bevacizumab|Given IV
224086337|NCT01727089|OTHER|Laboratory Biomarker Analysis|Correlative studies
224086338|NCT01727089|OTHER|Pharmacological Study|Correlative studies
223912046|NCT05674981|OTHER|Placebo group|Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
223912047|NCT05707598|PROCEDURE|Laparoscopic surgery|The laparoscopic approach was used for the treatment of clinical T4b colorectal cancer
223940007|NCT07196826|PROCEDURE|Conventional Physiotherapy|Conventional Physiotherapy is a land-based intervention for chronic low back pain, delivered in an outpatient physiotherapy clinic. Sessions last 45 minutes, 3 times per week for 4 weeks, and include hot pack application (10-12 min) to reduce stiffness, electrotherapy (TENS/Interferential, 15 min) for pain modulation, and supervised therapeutic exercises (15-20 min) focusing on lumbar mobility, core stability, and spinal strengthening. Exercises include William's flexion, prone press-ups, cat-cow mobilization, hamstring stretches, pelvic tilts, and abdominal bracing. This intervention emphasizes pain reduction, postural control, and strengthening deep abdominal and paraspinal muscles, distinguishing it from passive and active aquatic therapies, and serves as the standard comparator in this crossover study.
224086339|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
224086340|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
224086341|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
224086342|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
224086343|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
224086344|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
224086345|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
224086346|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
224086347|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
224086348|NCT00944034|BIOLOGICAL|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
224086349|NCT00944034|BIOLOGICAL|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
224086350|NCT00944034|BIOLOGICAL|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
224086351|NCT04627909|OTHER|Robot|The patient interacts with a robot
224086352|NCT04627909|OTHER|Medical Personnel|The patient interacts with medical personnel
224086353|NCT04627909|OTHER|Caregiver|The patient interacts with the caregiver
224086354|NCT06111989|BEHAVIORAL|Neuropsychological testing|The neuropsychological assessment will involve paper and pencil tests, computerized tests (such as reaction time measurements) and a driving simulator.
223912048|NCT06808165|DIAGNOSTIC_TEST|relaxin|The primary source of relaxin in pregnancy is the corpus luteum, but it is also produced in other tissues, such as the decidua and placenta. Importantly, relaxin's pleiotropic effects include endothelial-dependent vasodilation, extracellular matrix remodeling, and potential contributions to placental development. These properties make relaxin a molecule of interest in the context of PAS disorders, where abnormal placental invasion may reflect disruptions in vascular and extracellular matrix regulation. Additionally, recent findings have indicated altCirculating relaxin levels were assessed before routinely storing maternal venous blood and umbilical cord arterial blood samples are anelyzed. This study aimed to compare relaxin levels in umbilical cord and peripheral blood and estimated placental volumes (EPV) between PAS cases and controls. Additionally, subgroup analysis was conducted to evaluate relaxin levels and EPV among PAS subtypes (accreta, increta, and percreta).
223912049|NCT06810648|PROCEDURE|GDFT|Hydration was goal-directed and guided by Stroke Volume Variation (SVV) using the FloTrac/Vigileo monitor, while analgesia was provided with intravenous analgesics.
223912050|NCT06810648|PROCEDURE|GDFT/ED|Hydration was goal-directed and guided by Stroke Volume Variation (SVV) using the FloTrac/Vigileo monitor, while analgesia was administered via epidural analgesics.
223912051|NCT06810648|PROCEDURE|CFT|Patients received conventional fluid therapy (based on heart rate, urine output and mean arterial pressure) and analgesia was provided with intravenous analgesics.
223912052|NCT06810648|PROCEDURE|CFT/ED|Patients received conventional fluid therapy (based on heart rate, urine output and mean arterial pressure) and analgesia was administered via epidural analgesics.
223912053|NCT06808360|BEHAVIORAL|Supportive and Dignified Maternity Care|SDMC is a theory-driven, inclusive service-delivery package which will be developed using the principles of the human-centred design approach. The model will include capacity-building of maternity teams, and the improvement of governance and accountability mechanisms within public health facilities to ensure that all women are treated with compassion and dignity, while also catering for their diverse needs, including disabilities and common mental health conditions. The integration of psychosocial support in routine maternity care will be a unique feature of the intervention package, a principal aim of which is to address the psychological needs of birthing women and their companions.
223912054|NCT06810557|BEHAVIORAL|Optimize Sleep Primary Care (OSPC)|In addition to standard care within Temple University Primary Care (TUPC), two face-to-face zoom sessions and four brief phone follow-ups (two during active treatment and two during maintenance) that focus on using effective behavioral strategies (e.g., goal setting, self-monitoring, positive reinforcement, stimulus control, problem-solving) to enhance children's sleep by approximately one hour/night.
223912055|NCT06810557|OTHER|Enhanced Usual Care|In addition to standard care within Temple University Primary Care (TUPC), the provision of six education contacts regarding children's sleep needs and the benefits of getting a good night's sleep.
223912056|NCT06199505|DRUG|GZR101|Once daily
223912057|NCT06199505|DRUG|insulin degledec/insulin aspart|Once daily or twice daily
223912058|NCT06808529|DEVICE|Pilates exercises and TENS Acupuncture|All performed Pilates exercises for 24 session, 3 sessions per week for (2 consecutive menstrual cycle), each session lasted for 30 minutes in addition to application of TENS acupuncture therapy for 30 minutes, 3 sessions in the first 3 days for (2 consecutive menstrual cycle).
223912059|NCT06808529|DRUG|ibuprofen 400 mg|All took capsules of ibuprofen(400-milligram) and instructed to take them once every eight hours for three days, one day before the start of their menstrual cycle and on the first two days of menstruation for (2 consecutive menstrual cycle).
223912060|NCT04011644|BEHAVIORAL|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
223912061|NCT04011644|BEHAVIORAL|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
223912062|NCT04011644|BEHAVIORAL|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
223940008|NCT07195812|DRUG|Dual Antiplatelet (DAPT) Therapy|aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days
223940009|NCT07195812|DRUG|Rivaroxaban|Rivaroxaban (2.5 mg twice daily) plus aspirin 100 mg daily plus clopidogrel 75 mg daily for 30 days
223940010|NCT07196553|DEVICE|Ultrasound|ultrasound examination
223940011|NCT07197645|DRUG|153Sm-DOTMP|TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that exhibits avid uptake as shown by 99mTcdiphosphonate bone scans undertaken within 60 days of dosing.
223940012|NCT07195903|DEVICE|Angioplasty or stenting|Jugular Vein Stenting
223940013|NCT07197177|PROCEDURE|regional block|We will infiltrate local anesthesia (Bupivicaine 0.25 %), in pectoral plane vs Erecter spine plane, will observe intraoperative morphine consumption, pain scores and Pacu stay.
223940014|NCT07190560|BIOLOGICAL|plasma transfusion : PC-CHIK-V|plasma transfusion , from donation from an individual who has declared a Chikungunya infection for less than 6 months , to a newborn, whose mother has a peripartum chikungunya infection
223940015|NCT07196124|BIOLOGICAL|BCMA/GPRC5D CAR-T|A single infusion of BCMA/GPRC5D CAR-T Injection administered intravenously.
223535232|NCT06629961|PROCEDURE|abutment placement|Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N
223535233|NCT06629961|PROCEDURE|Ti-base placement|Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
224086355|NCT06111989|BEHAVIORAL|On road test|The driving instructor will guide the participant on a standard route, and will evaluate the performance using standard criteria that will focus mainly on traffic safety.
223912063|NCT06570720|BEHAVIORAL|Alcohol-focused Support of Survivors in Sororities Training (ASSIST)|A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
223912064|NCT06809829|PROCEDURE|Immediate Implant Placement|Eight patients undergoing immediate implant placement with the buccal gap filled with doxycycline loaded gelatin nanoparticles along with gelatin sponge (group A) Eight patients undergoing immediate implant placement with the buccal gap filled with doxycycline along with gelatin sponge (group B)
223912065|NCT06569394|DRUG|Broad Spectrum Cannabidiol (bsCBD) 400 mg|Participants in this Arm will take 400 mg of bsCBD daily. Participants will take medication by mouth with food in the morning and evening.
223912066|NCT06569394|DRUG|Placebo|Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
223912067|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fasting condition, 1 tablet at a time, once a day.
223912068|NCT06569381|DRUG|Pirfenidone Modified-Release Tablets|take the tablet under fed condition, 1 tablet at a time, once a day.
223912069|NCT06809634|OTHER|Large Language Model|The intervention in the experimental group is distinguished by the integration of a Large Language Model (LLM)-based interactive platform (ChatGPT) into clinical reasoning training for physical therapy students. Unlike traditional educational approaches, this intervention provides real-time, AI-generated patient interactions, allowing students to actively engage in virtual clinical case simulations.
224086356|NCT04049019|DIAGNOSTIC_TEST|Urine collection through a collecting device (Uridome®) for maximum 1 week|"The child will collect:~* Urine at bedtime before a wet and a dry night.~* Urine during a wet night through a collecting device.~* First morning voided volume following both a wet and a dry night."
224086357|NCT04049019|DIAGNOSTIC_TEST|Urine collection|"The child will collect:~* Urine at bedtime.~* First morning voided volume"
224086358|NCT05874531|DIAGNOSTIC_TEST|End-expiratory occlusion test|15 seconds end-expiratory occlusion
224086359|NCT02714114|OTHER|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
224086360|NCT02714114|OTHER|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
223912070|NCT06809634|OTHER|Conventional|The intervention in the control group follows a traditional case-based learning approach, which is commonly used in physical therapy education. Unlike the experimental group, this training method relies solely on human-led instruction and written case analysis, without the integration of artificial intelligence or interactive digital tools.
223912071|NCT06197503|PROCEDURE|Conduction system pacing|Left bundle branch pacing or His bundle branch pacing
223912072|NCT06197503|PROCEDURE|Right ventricular pacing|Conventional pacing
223912073|NCT06808269|PROCEDURE|Vivalto Dom follow-up|"During the pre-operative consultation, the patient receives a prescription for medication (analgesics and anti-inflammatories) for immediate post-operative pain relief. They also receive a patient information booklet (see appendix 6). On discharge from surgery, the patient returns home with Vivalto Dom in charge of nursing care and follow-up medication.~Vivalto Dom is a homecare structure whose mission is to coordinate the discharge of patients back home, and to ensure continuity of overall care (care and social aspects) between the hospital and the city."
224086361|NCT04272567|DRUG|Norepinephrine|Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
224086362|NCT04272567|DRUG|Normal saline|Simultaneous with subarachnoid block, a bolus of 1ml normal saline was given followed by normal saline infusion
224086363|NCT00649103|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
224086364|NCT00649103|DRUG|Accupril® Tablets 40 mg|40mg, single dose fasting
224086365|NCT03174210|DEVICE|liquid oxygen device (LOD)|This oxygen Supplementation is used in special order
224086366|NCT03174210|DEVICE|portable oxygen concentrator (POC)|This oxygen Supplementation is used in special order
224086367|NCT01570244|DRUG|levonorgestrel|multiple doses
224086368|NCT01570244|DRUG|Ethinylestradiol|multiple doses
224086369|NCT01570244|DRUG|levonorgestrel|multiple doses
224086370|NCT01570244|DRUG|BI 201335|multiple doses
224086371|NCT01570244|DRUG|Ethinylestradiol|multiple doses
224086372|NCT06201052|OTHER|Exercise test|Beep Test for measuring aerobic power
224086373|NCT02266108|BEHAVIORAL|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
224086374|NCT03623789|DRUG|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
224086375|NCT03623789|DRUG|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
224086376|NCT03623789|DRUG|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
224086377|NCT05728788|DRUG|Antitumor drugs|Anthracyclines, immune checkpoint inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors
224086378|NCT01598376|PROCEDURE|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
224086379|NCT01598376|PROCEDURE|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
224086380|NCT00455117|DRUG|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
224086381|NCT04610476|DRUG|Prednisolone|Prednisolone oral 1-5 mg/day
224086382|NCT04610476|DRUG|Sulfasalazine|Sulfasalazine oral 2 x 1000 mg/day
224086383|NCT04610476|DRUG|Leflunomide|Leflunomide oral 20 mg/day
224086384|NCT04610476|DRUG|Methotrexate|Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week
224086385|NCT04610476|DRUG|Tofacitinib|Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day
224086386|NCT04610476|DRUG|Apremilast|Apremilast oral 2 x 30 mg/day/1 x 30 mg/day
223912074|NCT06808269|PROCEDURE|Liberal follow-up|"The pre-operative and operative course (fasting rules, skin preparation, hospitalization, surgery) is the same as for all routine care patients. The patient is informed before surgery that he or she must make an appointment with a nurse for post-operative care at home; a prescription for medication (analgesics and anti-inflammatories) has been given by the anaesthetist for immediate analgesic treatment, and on discharge from hospital he or she receives another prescription from the surgeon for oral relay treatment.~Follow-up at home takes place over 3 days, with a private nurse visiting the patient's home every day.~During the follow-up, the nurse performs clinical monitoring of the following items: pulse, blood pressure, temperature, pain, bleeding, monitoring of the surgical wound, transit, nausea and vomiting. The patient is also guided through the medication protocol."
223912075|NCT05493852|DEVICE|FARAPULSE Pulsed Field Ablation System|Patients diagnosed as paroxysmal atrial fibrillation with indication of ablation will be treated by FARAPULSE Pulsed Field Ablation System.
223912076|NCT06808542|OTHER|No intervention|No intervention
223912077|NCT06809959|DEVICE|In-phase-tACS|21 minutes and 30 seconds of bifocal stimulation at 3 mA peak-to-peak per field, targeting the aIPS and PMv of the lesioned hemisphere. The stimulation is delivered at 24 Hz with the waveforms of both fields aligned in phase. A 10-second ramp-up at the beginning and a 10-second ramp-down at the end are included to ensure participant comfort. The protocol is administered using the Starstim® device with gel-based electrodes, each with a π cm² surface area.
223912078|NCT06809959|DEVICE|Out-of-phase-tACS|21 minutes and 30 seconds of bifocal stimulation at 3 mA peak-to-peak per field over the aIPS and PMv of the lesioned hemisphere at 24 Hz. In this condition, the waveforms of the two fields are shifted by 180°, creating an out-of-phase stimulation pattern. A 10-second ramp-up and ramp-down are included, and the protocol is administered using the Starstim® device with gel-based electrodes, each with a π cm² surface area.
224086387|NCT04610476|DRUG|Etanercept|Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week
224086388|NCT04610476|DRUG|Adalimumab|Adalimumab s.c. 40 mg every 2 weeks
224086389|NCT04610476|DRUG|Infliximab|Infliximab i.v. 5 mg/kg BW every 8 weeks
224086390|NCT04610476|DRUG|Certolizumab pegol|Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks
224086391|NCT04610476|DRUG|Golimumab|Golimumab s.c. 1x 50 mg every 4 weeks
224086392|NCT04610476|DRUG|Abatacept|Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
224086393|NCT04610476|DRUG|Secukinumab|Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
224086394|NCT04610476|DRUG|Ixekizumab|Ixekizumab s.c. 1x 80 mg every 4 weeks
224086395|NCT04610476|DRUG|Ustekinumab|Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
224086396|NCT03176316|DRUG|Naloxone|Naloxone is an opioid antagonist (i.e., a medication used to reverse or reduce the effects of opioids)
224086397|NCT01451619|DRUG|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
224086398|NCT01451619|DRUG|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
224086399|NCT02840331|DRUG|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
224086400|NCT02840331|DEVICE|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
224086401|NCT05770128|PROCEDURE|laparoscope|subserosal manipulation of gallbladder with laparoscope .
224086402|NCT01349140|DRUG|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
224086403|NCT03241446|DRUG|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
224086404|NCT02130414|DRUG|Sandimmun® IV|2 mg/kg IV
224277723|NCT06227351|PROCEDURE|completely limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to the zygoma anatomy-guided approach classification and previously planned surgery using Cone beam C.T lateral window and sinus foor lifting will be decided to be done or not.~After securing the surgical templates in its proper position, sequential osteotomy drilling will be performed in a steady in and out movement under copious sterile saline irrigation.The drills will be entering the maxilla palatally and puncturing the alveolar crest to reach the buccal side.The drills will be visualized through the bony window created until it reaches the zygomatic bone.Sequential drills with the uses of guided tubes,sleeves and keys will be used to guarantee that the implant have been placed in a fully completely guided manner.Afterwards the zygomatic implants will be placed."
224277724|NCT06227351|PROCEDURE|Partially limiting computer generated surgical three-dimensional guide|"Long mid-crestal incision from the right to the left maxillary tuberosity and raising a full -thickness flap to expose the maxilla up to the fronto-zygomatic notch.~According to zygoma anatomy-guided approach classification and previously planned surgery using cone beam C.T.lateral window and sinus floor lifting will be decided to be done or not.After securing the surgical templates,The first drill only will be used using the guide then it will be removed and the other drills will be completed in a free hand without the use of guide to guarantee that the implant will be placed in partially guided manner.Afterwards the zygomatic implants will be placed."
224277725|NCT03287687|DRUG|Carbon dioxide (CO2) gas insufflation|CO2 gas use for insufflation during endoscopy instead of air insufflation
224277726|NCT03287687|DRUG|Air insufflation|Air insufflation is the standard of practice (used in the control arm)
224086405|NCT02130414|DRUG|CyCol® capsules|37.5 mg CyCol® capsules
224086406|NCT00531960|DRUG|Erlotinib|150 mg, PO, daily
224086407|NCT00531960|DRUG|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
224086408|NCT00531960|DRUG|Standard platinum-based chemotherapy|At the discretion of the investigator
224086409|NCT03611439|DIETARY_SUPPLEMENT|ReBuilder|8-component botanical dietary supplement
224086410|NCT03611439|DIETARY_SUPPLEMENT|Placebo|Inactive Placebo Capsule
223912079|NCT06809959|DEVICE|Sham -tACS|21 minutes and 30 seconds of stimulation mimicking the setup of active tACS, with an initial 10-second ramp-up followed by a 10-second ramp-down. The remainder of the session is stimulation-free. This protocol is administered using the Starstim® device and gel-based electrodes with a π cm² surface area, maintaining the same setup as the active conditions to ensure comparability.
223912080|NCT06808659|OTHER|Neural Mobilization|A total of 20 patients were selected in Group A received neural mobilization of sciatic nerves treatment for 3 days a week for 2 weeks
223912081|NCT06808659|OTHER|Stretching|A total of 20 patients were selected in Group B received stretching of piriformis muscle treatment for 3 days a week for 2 weeks
223912082|NCT06810102|OTHER|VIRTUAL REALITY GLASSES|There will be a video screening
223912083|NCT06809855|DRUG|Dexamethasone|single 8mg post-operative intramuscular injection
224086411|NCT04583371|OTHER|MECHANICAL PULMONARY HYPERINFLUATION|For basal aspiration, the patient will be placed in the supine position with the head elevated at 30º, will be submitted to a single aspiration with a size 12 probe (Mark Med), with a vacuum adjusted to -40cmH2O of pressure, with basic asepsis care being maintained for performing the technique. In the participants of the intervention group, the calculation of the ideal tidal volume of each patient will be performed, after which they will be positioned in the same way as baseline aspiration, in assisted-controlled pressure ventilation, increasing 10 cmH2O in inspiratory pressure and, in ventilatory mode. -controlled by volume, we will increase 50% of the tidal volume for a period of 10 minutes, observing the peak that cannot exceed 40 cmH2O in both ventilation modes, and then three aspirations will be performed for 15 seconds and with an interval of 30 seconds.
224086412|NCT01500057|DEVICE|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
224086413|NCT01500057|DEVICE|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
224086414|NCT05003557|OTHER|Questionnaire administration|"3 different questionnaires are going to be administered to each participant,~* concerning the current health situation~* the SF 36~* the IPQ-R questionnaire"
224086415|NCT04142645|DEVICE|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
224086416|NCT05428150|DRUG|Esbriet 267 MG Oral Capsule|Reference Formulation
224086417|NCT05428150|DRUG|EXCL-100, 600 MG Oral Tablet|Test Formulation
223912084|NCT06167746|OTHER|Digital Health Information (DHI)|Digital health information websites.
223912085|NCT06167746|BEHAVIORAL|Virtual Health Coach for You|Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
223912086|NCT05757726|DEVICE|Velocity pAVF system|A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
224086418|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD|Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
223912087|NCT06810232|PROCEDURE|Gastrointestinal endoscopy|Patients will be divided into groups according to general health risk factors detected during preoperative anesthesia evaluation (hypertension, diabetes, asthma, obesity, chronic disease, medication history, immobility, smoking, etc.) and will be evaluated in terms of age, gender, weight and height will be combined to report BMI in kg/m2, alcohol, allergy, ASA, endoscopy site, complications that may develop related to anesthesia and sedation (such as hemodynamic instability, hemoglobin desaturation, pulmonary aspiration and apnea), additional interventions, and hospital stay.
223912088|NCT06809088|BIOLOGICAL|Albumin|Albumin
223912089|NCT06809088|OTHER|Standard Medical Treatment|Standard Medical Treatment
223912090|NCT06808698|OTHER|Determine the gut microbiome at baseline and 12 months.|There is no separate treatment, surgery, or other intervention.
223912091|NCT05130268|DRUG|Dronedarone|Dronedarone 400 mg twice daily in addition to usual care
223912092|NCT06809205|DRUG|Tamsulosin 0.4 mg|administered tamsulosin 0.4 mg
223912093|NCT06809205|DRUG|Tadalafil 5mg|administered tadalafil 5 mg
223912094|NCT06809205|DRUG|Tamsulosin and Tadalafil|administered tamsulosin 0.4 mg plus tadalafil 5 mg
223912095|NCT04842877|DRUG|Valemetostat tosylate|200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
223912096|NCT06804161|DRUG|SGLT2|10 mg
223912097|NCT06804161|DRUG|Placebo|1 tablet
223912098|NCT05215405|DRUG|Venetoclax|"Venetoclax will be administered orally once daily (QD), continuously. Each dose of venetoclax should be taken with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast.~* Day 1 (200 mg equivalent):~  * Patients 20 \< 30 kg will take 70 mg~ * Patients 30 \< 35 kg will take120 mg~ * Patients 35 to 45 kg will take 200 mg~* Day 2 onwards (400 mg equivalent):~  * Patients 20 \< 30 kg will take 170 mg~ * Patients 30 \< 35 kg will take 250 mg~ * Patients 35 to 45 kg will take 400 mg"
223912099|NCT05215405|DRUG|Navitoclax|"Navitoclax will be administered orally once daily, starting on day 3 of cycle 1 and then may start on day 1 for subsequent cycles. Navitoclax should be taken at the same time each day approximately 24 hours apart. Dosing will be based on the recommended phase II dosing as per the phase I data and subsequent dose recommendations.~* Patients 20 \< 45 kg will take 25 mg~* Patients 45 kg or more will take 50 mg"
223912100|NCT06804889|DEVICE|CANNEFF® VAG SUP vaginal suppositories|CANNEFF® VAG SUP vaginal suppositories containing 100 mg cannabidiol - CBD and 6.6 mg hyaluronic acid - HA.
223912101|NCT06804889|DEVICE|Placebo Suppositories|Received placebo vaginal suppositories with identical composition as for Active Comparator, but without both active ingredients (CBD - cannabidiol and HA - hyaluronic acid).
223912102|NCT06806189|DRUG|Lipiodal|Injection of lipiodal for delineation of interface between the removed mouth/throat cancer and the healthy tissue reconstructing the defect for radiation planning.
223912103|NCT06805669|OTHER|Early referral to palliative care|Participant will be referred to palliative care at start of systemic treatment
223912104|NCT06805669|OTHER|Standard Treatment|Participants will be referred to palliative care upon appearance of uncontrollable symptoms.
223912105|NCT06805604|PROCEDURE|Each group was received monolithic ceramic crowns fabricated using different technique|-Different digital techniques used for fabrication of the monolithic ceramic crowns were chosen for the current study, Clinical performance of all crowns regarding; marginal adaptation, fracture of restoration during service, color stability and wear behavior will be evaluated according to Modified United States Public Health Service (USPHS) Criteria at base line (1 week), 3 and 6 months after cementation of crowns.
223912106|NCT06805344|PROCEDURE|Extracorporeal cardiopulmonary resuscitation based approach|ECPR-based approach is defined as ACLS per current guidelines with aim to proceed to in-hospital or out-of-hospital V-A ECMO if ROSC is not achieved before the cannulation.
223912107|NCT06805344|PROCEDURE|Conventional cardiopulmonary resuscitation|CCPR is defined as conventional ACLS per current guidelines without MCS use until sustained ROSC is achieved or the patient pronounced dead.
223912108|NCT06805578|OTHER|Heritage art programme|The 6-week 'Refresh and Reconnect!' programme includes guided gallery tours led by the museum's Care Facilitator volunteers and artist-led hands-on activities based on various art forms (e.g. artist-led dance, art, or drama workshops).
223912109|NCT06081829|DRUG|Ivosidenib|Subjects will take 2 tablets (500 mg total) orally once daily.
223912110|NCT06808776|OTHER|Cancer survivor narrative|"The narrative video intervention has three parts: (1) Cancer experience - the cancer survivor narrates his/her experience with an HPV-related cancer, including diagnosis, treatment, and how cancer affected their personal life or family; (2) Vaccine recommendation - the cancer survivor provides brief information about the safety and effectiveness of the HPV vaccine and recommend that parents get the HPV vaccine for their child to prevent cancers; and (3) Closing message - The sentence HPV vaccine is cancer prevention. Talk to your child's healthcare provider about getting the HPV vaccine during the next clinic visit will appear on the screen."
223912111|NCT06808776|OTHER|Healthy eating tips|A publicly available video about healthy eating tips for families with children.
223912112|NCT06809816|DRUG|Sodium pentaborate pentahydrate|Sodium pentaborate pentahydrate will be administered orally in capsule form, following the standard protocol outlined in the study design.
223912113|NCT06387342|DRUG|Namodenoson 25mg|oral capsule
224086419|NCT05177055|BEHAVIORAL|Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses|Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
224086420|NCT05177055|OTHER|6-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
223912114|NCT06810024|COMBINATION_PRODUCT|Home-based therapy|"The home-based intervention includes the following modules:~1. Management of Stroke Recurrence Risk Factors: Home-based monitoring and management of blood pressure, blood sugar, cholesterol, and medication adherence.~2. Functional Rehabilitation and Daily Living Skills: Home-based physical therapy, rehabilitation exercises, and recovery of daily living skills.~3. Psychological Health and Emotional Management: Home-based counseling and mental health support to address anxiety, depression, and stress.~4. Nutritional and Lifestyle Interventions: At-home guidance on healthy eating, lifestyle changes, and behavior modification to reduce stroke recurrence.~5. Risk and Complication Prevention: Home monitoring to prevent infections and other complications during recovery.~6. Caregiver Empowerment: Home-based caregiver training and support to improve caregiving skills and reduce caregiver stress."
223716207|NCT02765295|DEVICE|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
223912115|NCT06810024|OTHER|Standard Care (in control arm)|"The standard care intervention involves:~Outpatient Visits: Routine follow-up visits to healthcare providers for stroke recovery monitoring, medication management, and adjustments.~Inpatient Rehabilitation: Physical, occupational, and speech therapy delivered in hospital or rehabilitation centers, if required.~Follow-up Appointments: Regular visits with stroke specialists and rehabilitation professionals for ongoing care."
223912116|NCT06564324|DRUG|Taletrectinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met."
223912117|NCT06564324|DRUG|Crizotinib|"Approximately 138 ROS-1TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: Arm A: Taletrectinib monotherapy at 600 mg once daily (QD), continuously; Arm B: Crizotinib monotherapy at 250 mg twice daily (BID), continuously.~Each cycle duration will be 28 days. Participants will be treated until they experience progressive disease (PD) assessed by the blinded Independent Review Committee (BIRC), intolerable toxicity, or another discontinuation criterion is met. Crossover from control group (crizotinib) to taletrectinib is also permitted, at the Investigator's discretion with the Sponsor's approval, for qualifying participants who have experienced objective progression confirmed by the BIRC."
223912118|NCT06809504|BEHAVIORAL|Exercise based intervention|"12 sessions over 4 weeks, 45-minute sessions divided into:~o 15 minutes for physical exercises"
223912119|NCT06809244|OTHER|Exercise|"Strength training as described under arm"
224086421|NCT05695326|BEHAVIORAL|3D printing technology learning program|The study is aimed to evaluate a 3D printing technology learning program for rehabilitation professionals
224086422|NCT05114083|OTHER|symptom assessment|symptom assessment
224086423|NCT03062657|DEVICE|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
224086424|NCT00080847|BIOLOGICAL|oblimersen sodium|Given IV
223912120|NCT06809946|DRUG|injection with 15 mg bevacizumab-800CW before bronchoscopy|Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
223912121|NCT06809946|DRUG|injection with 25 mg bevacizumab-800CW before bronchoscopy|Patients will receive an intravenous administration of 15 mg bevacizumab-800CW before the bronchoscopy procedure. The bronchoscopy will start with high-definition white light bronchoscopy, followed by fluorescence molecular bronchoscoy to observe the fluorescence signal and MDSFR-SFF spectroscopy to quantify the fluores-cence signal in vivo.
224086425|NCT00080847|BIOLOGICAL|rituximab|Given IV
224086426|NCT00080847|DRUG|cyclophosphamide|Given IV
224086427|NCT00080847|DRUG|doxorubicin hydrochloride|Given IV
224086428|NCT00080847|DRUG|vincristine sulfate|Given IV
224086429|NCT00080847|DRUG|prednisone|Given orally
224086430|NCT00080847|OTHER|laboratory biomarker analysis|Correlative studies
224086431|NCT01739426|DEVICE|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
224086432|NCT04874857|OTHER|Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.|Massage application
224086433|NCT04874857|OTHER|Baby oil|Massage application
224086434|NCT01191112|OTHER|Peptide based enteral formula|Sole source nutrition as per HCP
224086435|NCT03585855|OTHER|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
224086436|NCT06091644|DEVICE|AirAngel® 3D printed videolaryngoscope|This is a mannequin study that aims to compare a videolaryngoscope produced with 3D printing with a Storz videolaryngoscope and a Macintosh direct laryngoscope in the hands of inexperienced users in terms of ease of use, glottic imaging and intubation success.
224086437|NCT00457340|DRUG|Atorvastatin 80mg|
224086438|NCT01590342|DRUG|Diclofenac|Diclofenac 75 mg, two doses
224086439|NCT01590342|DRUG|Placebo|Placebo, two doses
224086440|NCT02091180|DRUG|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
224086441|NCT02091180|DRUG|Control|Saline infusion
223912122|NCT06809335|OTHER|Personalized circadian mHealth|SHIFT is a mobile application designed to improve sleep in night shift workers. The SHIFT mobile application is used to collect data from an Apple Watch to assess an individual shift worker's body-clock timing and make personalized recommendations of light exposure schedules that are designed to align the body-clock with the night shift work schedule.
223912123|NCT06810596|PROCEDURE|Insulin infusion protocol|comparing the efficacy of 2 different protocols for glycemic control in diabetic critically ill patients.
223912124|NCT05256381|DRUG|Nanrilkefusp Alfa|Subcutaneous (SC) injection.
223912125|NCT05256381|DRUG|Pembrolizumab|Intravenous (IV) infusion via peripheral or central venous line.
223912126|NCT06808087|PROCEDURE|Transversus abdominis plane blockage|"1. Patient monitoring~2. Preparation of the skin with 10% povidone-iodine and ensuring appropriate draping~3. Placement of a high-frequency linear transducer transversely between the right iliac crest and subcostal margin along the midaxillary line. Structures visualized on ultrasound from superficial to deep include: skin, subcutaneous fat, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum. The TAP block will be performed in the transversus abdominis plane (TAP) between the internal oblique and transversus abdominis muscles.~4. A 23-gauge, 60 mm blunt-tipped needle will be directed toward the TAP, and negative aspiration will be confirmed upon entry into the fascial layer.~5. An injection of 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, will be performed.~6. Visualization of the oval spread of bupivacaine in the TAP."
223912127|NCT06808087|PROCEDURE|Erector spinae plane blockage|"1. Patient monitoring~2. Positioning the patient in the prone position~3. Preparation of the skin with 10% povidone-iodine and ensuring appropriate draping~4. Counting the transverse processes from the sacrum to find the L1 level~5. Placing a low-frequency curvilinear transducer (depth set to 3-5 cm) parasagittally, and identifying the tip of the right transverse process at this level~6. Visualizing the erector spinae muscle overlying the transverse process~7. Inserting a 22G, 80 mm needle between the transverse process and the fascia of the erector spinae muscle~8. Injecting 1 to 3 mL of saline to confirm the separation of the erector spinae muscle fascia from the transverse process after negative aspiration~9. Injecting 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, after another negative aspiration~10. Visualizing the oval spread of bupivacaine over the erector spinae muscle."
223912128|NCT06808087|DRUG|Tramadol|50 mg of tramadol will be administered via IV infusion over 15 minutes in 100 cc of isotonic 0.9% NaCl (normal saline).
223912129|NCT06808893|OTHER|Psychiatric interview and documentary|"Nursing students who interview psychiatric patients will be provided with an Interaction Form to systematically evaluate and record their interviews. This form consists of the following columns: date of interview, duration of interview, duration of interview, verbal/non-verbal statements of the nurse and patient, effective communication technique and evaluation. The duration of the interview is expected to be between 30 and 45 minutes. Another component of the combination is the documentary Us, You, Them prepared by the Federation of Schizophrenia Associations of Turkey, which deals with the life stories of schizophrenia patients and lasts approximately 56 minutes."
223912130|NCT06808893|OTHER|Psychiatric interview|"Nursing students who interview psychiatric patients will be provided with an Interaction Form to systematically evaluate and record their interviews. This form consists of the following columns: date of interview, duration of interview, duration of interview, verbal/non-verbal statements of the nurse and patient, effective communication technique and evaluation. The duration of the interview is expected to be between 30 and 45 minutes."
224086442|NCT04093648|GENETIC|TEGAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10\^7/m2 DL2: 3x10\^7/m2 DL3: 1x10\^8/m2 DL4: 3x10\^8/m2 DL5: 1x10\^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10\^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
223912131|NCT06808347|DRUG|application of the vaginal estrogen cream|patients will apply the vaginal estrogen cream
223912132|NCT06173323|BEHAVIORAL|ImPart - Improving Chronic Kidney Disease Decisional Partnerships|ImPart is a decision support intervention developed and refined in partnership with a advisory group of patients with and caregivers of people living with Chronic Kidney Disease. The program is designed to support decision-making throughout the illness experience.
223912133|NCT06810245|DRUG|PIPE-791|PIPE-791 tablet, taken once daily for 4 weeks
223912134|NCT06810245|DRUG|Placebo|Placebo tablet, taken once daily for 4 weeks
223912135|NCT05697250|OTHER|Laser power settings (Thulium Fiber Laser)|Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
224086443|NCT04093648|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
224086444|NCT04093648|DRUG|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
224086445|NCT01564706|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
224277727|NCT03880149|DIETARY_SUPPLEMENT|Omega-3|Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
224277728|NCT03880149|OTHER|Placebo|Medium-chain triglyceride (MCT) and vitamin E
224277729|NCT05902468|DRUG|Ursodeoxycholic acid|ursodeoxycholic acid 500 mg orally twice daily for 12 weeks
224277730|NCT02614833|BIOLOGICAL|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
224277731|NCT02614833|DRUG|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
224277732|NCT02614833|DRUG|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
223912136|NCT04890067|OTHER|Treatment of Osteosarcoma according the AIEOP/ISG OS 2021 recommendations (includes drugs, surgery, radiotherapy or any other received treatments)|This observational study collects all the treatments received by the patients according according the AIEOP/ISG OS 2021 and therefore includes drug/biological/surgical/ radiotherapy and any other applicable treatments
224277733|NCT04384341|RADIATION|Bone densitometry (BMD)|"Recruitment of haemophilic patients during a routine visit at the haemophilia centre.~Information of the subjects that the study requires a BMD measure for all and a blood sampling for patients only.~After inclusion and exclusion criteria have been checked, the subject can sign the consent.~For all subjects, an appointment will be made for BMD measure.~For patients and controls: BMD will be measured by Dual Energy X-ray Absorptiometry (DXA) technology, on femoral and lumbar spine (L2-L4) sites.~Recruitment of healthy volunteers through registers (Clinical Investigation Centers) and advertisements."
223912137|NCT06350877|BEHAVIORAL|Physical Activity Intervention|The physical activity intervention will be a 6-week supervised program. Participation will involve engaging in a weekly 1-h session provided in-person at the campus athletics and recreation centre. Each 1-h session will include: (1) 30 min of behaviour change coaching; and (2) 30 min of supervised and structured physical activity training. The intervention materials will include a behaviour change workbook for facilitating the 30 min of behaviour change coaching. Each week participants will complete the behaviour change workbook in session with the program trainer, whereby the overarching goal is to introduce and reinforce engagement in behaviour change techniques and to facilitate the learning objectives and experiences for each weekly session.
223912138|NCT02997202|DRUG|gilteritinib|oral
223912139|NCT02997202|DRUG|Placebo|oral
223912140|NCT01199133|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year.
223912141|NCT01199133|DRUG|Placebo tablet|One sublingual tablet daily for one year.
223912142|NCT05637541|DRUG|GST-HG141|The trial consisted of a low-dose group and a high-dose group, each of which was 50mg bid and 100mg bid for 12 or 24 weeks of treatment
223912143|NCT05790655|OTHER|oPRP|Prepared sample from patient's own blood collected and processed. Either PRP or serum is injected into the patient's ovary. All other care is standard for the IVF process
223912144|NCT05790655|OTHER|Placebo- Serum|Patient's serum is injected into ovary instead of PRP as placebo
223912145|NCT03427996|PROCEDURE|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
223912146|NCT05347563|PROCEDURE|Electrical impedance tomography|All change in ventilator settings (mode, tidal volume or inspiratory pressure, Peep, recruitment…)
223912147|NCT04200300|DIAGNOSTIC_TEST|Online questionnaire|Online questionnaire via SoSciSurvey
223912148|NCT05634902|BEHAVIORAL|CME Educational Intervention|The educational materials for physicians include a recorded CME session, a mobile responsive website with the recommended algorithm of care, print materials (posters and note cards) and a dot phrase for dizziness.
223912149|NCT05634902|BEHAVIORAL|Study Developed Educational Materials for Patients|Patient-oriented materials are incorporated into a mobile responsive website with information/instruction about BPPV, and self-management resources; information/instruction on gaze stabilization exercises for vestibular neuritis
224277734|NCT04384341|BIOLOGICAL|Blood sampling for patients only|For patients, fVIII/fIX activity and antigen, thrombin generation potential and plasmatic markers of bone remodelling will be measured centrally.
224277735|NCT06585306|BEHAVIORAL|jaw lift, increasing oxygen flow, mask ventilation, intubation|When patients develop hypoxemia, the above interventions are sequentially employed to improve their oxygenation status.
223912150|NCT05887791|DIETARY_SUPPLEMENT|Collagen hydrolysate|Single dose
223912151|NCT05887791|OTHER|Placebo|Single dose
223912152|NCT06056258|DIETARY_SUPPLEMENT|VL-NL-02|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
223912153|NCT06056258|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken 45±10 mins before sleep (after dinner) for 21 days
223912154|NCT04874948|DRUG|500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043|Single oral administration of 14C-labeled radioactive 500mg BTZ-043
223912155|NCT05684367|BEHAVIORAL|Center-Based Walking Exercise|Each exercise session will begin with a short warm-up followed by 30 min of walking. Participants will initially be instructed to walk at a moderate intensity, equivalent to a 5-6 on Borg category-ratio (CR) scale. Participants will be encouraged to, if possible, incorporate brief periods of vigorous walking (7-8 on CR10 scale) with a goal of achieving at least 10 min of vigorous walking per session.
223912156|NCT05684367|BEHAVIORAL|Home-Based Walking Exercise|Participants will be asked to walk for exercise in their community five days/week. Participants will be instructed to begin with 10-15 minutes of walking exercise/session in the first month of the intervention and to increase exercise duration by five minutes/session each week, facilitating reasonable but steady progress toward the goal of 30 minutes per session.
223912157|NCT06648915|DIAGNOSTIC_TEST|Lipoprotein(a)|Measurement of Lp(a) was performed at the time of entry to the registry. Lp(a) level was measured using immunenephelometric assay
223912158|NCT05013385|DRUG|Spesolimab|Spesolimab
223912159|NCT05013385|DRUG|Placebo|Placebo
223912160|NCT06650514|DRUG|OMO-103|OMO-103 administered at the recommended phase 2 dose (6.5 mg/kg as a weekly intravenous infusion in 28-day cycles).
223912161|NCT06652503|BEHAVIORAL|online mental health coaching|SWAG-R Program: A 6-week Coaching Program Designed for NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency
223912162|NCT06651866|DRUG|D-CMG|"Liposomal mitoxantrone hydrochloride injection (Doxorubicin®): Used after dilution with 250mL of 5% glucose injection (50mg/mL), with an intravenous drip time of at least 60 minutes.~* Level 1: 12mg/m2, IV drip, day 4;~* Level 2: 18mg/m2, IV drip, day 4; Decitabine: 25mg, IV drip, days 1-3; Cytarabine: 10mg/m2, every 12 hours, IV drip, days 4-10; G-CSF: 300 ug, IV drip, days 1-5; Each cycle is 4 weeks, with a total of 2 cycles, and DLT is observed in the first cycle.~Note: Patients who achieve CR (Complete Remission) and PR (Partial Remission) in the first cycle can continue with the original dose for one more cycle, and then the investigator decides whether to continue this regimen or choose another regimen for maintenance therapy; Patients with NR (No Remission) in the first cycle will be withdrawn from this study."
223912163|NCT05726721|OTHER|Treatment as usual, Psychotherapy|The three treament sites will offer psychotherapy as usual. All including elements of cognitive behavioral therapy and some sites also additional elements from either narrative therapy or interpersonal therapy
223912164|NCT05967728|DEVICE|Remote ischemic conditioning (RIC) progammable device|RIC induces brief periods of ischemia-reperfusion in a limb. In our study, this is accomplished using a new device that can be remotely programmed to deliver either true RIC or a sham protocol, with remote monitoring capabilities to track completion of treatment sessions.
223912165|NCT04417166|DRUG|Pembrolizumab|50 mg powder for concentrate for solution for infusion
223912166|NCT04417166|RADIATION|Involved Field Radiation Therapy|"50-54 Gy Involved Field Radiation Therapy (IFRT) as proposed by the International Lymphoma Radiation Oncology Group (ILROG) guidelines. 50 Gy is recommended in patients without primary tumor invasiveness (invasion to adjacent tissue and/or organs), 54 Gy in locally advanced cases (invasion to adjacent tissue and/or organs) or with other risk factors (age \> 60 years, stage II, elevated serum LDH levels).~Intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are recommended but not mandatory; 3-dimensional conformal RT (3D-CRT) is allowed."
223912167|NCT06651957|OTHER|Biospecimen Collection|Specimen swabs will be obtained.
223716208|NCT02765295|DEVICE|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
223912168|NCT06651957|OTHER|Questionnaires|Given to participants
223716209|NCT05673889|DRUG|ARV-471|Experimental
223912169|NCT06653322|DRUG|HR-1703|HR-1703 will be administered by SC injection.
223912170|NCT06653322|DRUG|Placebo|Matching Placebo will be administered by the SC injection.
223912171|NCT03165786|BEHAVIORAL|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
224086446|NCT03746691|DRUG|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
224277736|NCT04309162|OTHER|Soft tissue therapy|Soft tissue therapy consists of various soft tissue manipulating techniques which includes the stroking, percussive and tapping manipulations. The treatment techniques are divided according to the body parts. under this techniques are tapping, flat finger kneading, Stroking, skin rolling etc.
224277737|NCT00115869|BEHAVIORAL|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
224277738|NCT04975451|DRUG|Anlotinib|Anlotinib plus DCb
223716210|NCT05673889|DRUG|Dabigatran etexilate|Probe substrate
223716211|NCT00138580|DRUG|vildagliptin|
223912172|NCT06652971|DRUG|CKD-379|QD, PO
223912173|NCT06652932|OTHER|Low temperature (15°C) group|The exposure group will be exposed to low temperature (15°C) in a chamber for about 2 hours, resting during the whole periods.
224086447|NCT03746691|DRUG|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
224277739|NCT00630578|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
224277740|NCT02448563|BEHAVIORAL|Nutrition and physical activity education|Eight weekly in-person groups
223716212|NCT01577056|DIETARY_SUPPLEMENT|Fish oil capsule|4g Omega capsule for 12 weeks
223716213|NCT01577056|DRUG|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
223716214|NCT04700761|PROCEDURE|Opioid-free anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + single dose of alfentanil for endotracheal intubation Anesthesia maintenance: desflurane (without any opioid) Rescue for hypertension, tachycardia: desflurane and beta blocker/calcium channel blocker
223716215|NCT04700761|PROCEDURE|Opioid-using anesthesia|Anesthesia induction: thiopental, rocuronium, desflurane + continuous infusion of remifentanil (TCI, Minto model) Anesthesia maintenance: desflurane, remifentanil Rescue for hypertension, tachycardia: desflurane, remifantanil and beta blocker/calcium channel blocker
223912174|NCT06652932|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
223912175|NCT05818410|DEVICE|Prosthetic device (Lunaris)|Participants with an amputation will conduct experiments with the prosthetic device
223912176|NCT05818410|OTHER|No prosthetic device|Able-bodied individuals will conduct experiments to enable comparison with the participants with amputation
223912177|NCT05818410|DEVICE|Prosthetic device (Sach foot)|Participants with an amputation will conduct experiments with the prosthetic device
223912178|NCT05573204|DRUG|Obeticholic Acid Oral Tablet|Obeticholic acid used as 10 mg tablet once daily for 6 months
223912179|NCT05573204|DRUG|Vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
223912180|NCT06651697|RADIATION|Radiation therapy|Radiation therapy with full bladder or empty bladder protocols
223912181|NCT03663361|OTHER|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
223912182|NCT03663361|OTHER|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
223912183|NCT06652347|OTHER|Cancer care delivery|Early vs. delayed sharing of GA and OFS diagnostic results and how that sharing affects patient preferences, decision- making, and satisfaction in the context of participants' cancer care.
224086448|NCT05916872|OTHER|experimental group|Patients will receive Proprioceptive Neuromuscular Facilitation (contract-relax) technique with EMS
224086449|NCT05916872|OTHER|control group|Patients will receive conventional therapy.
224086450|NCT05835869|DIAGNOSTIC_TEST|Optical coherence tomography angiography and pattern electroretinogram|Optical coherence tomography angiography is an infrared eye scan that analyzes retinal vascularization and anatomy
224086451|NCT00131846|DRUG|Thiazide diuretics|Any dosage, frequency, and duration
224086452|NCT00131846|DRUG|No diuretics|Any antihypertensive regimen other than diuretics
224086453|NCT05606926|OTHER|physical therapy program|Flexibility exercises to restore joint mobility of soft tissues, Static and dynamic balance exercises, Functional gait training , Functional strengthening exercises will be conducted three times a week, for three consecutive months.
224277741|NCT00147914|DRUG|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
223716216|NCT03140943|DRUG|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
223912184|NCT03844061|DRUG|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
223912185|NCT03844061|DRUG|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
223912186|NCT03844061|OTHER|Placebo Subcutaneous Injection|Normal Saline
223912187|NCT03844061|OTHER|Placebo Infusion|Normal Saline
224086454|NCT05606926|OTHER|whole body vibration (without extra weight vest)|9 minutes of three sets of 3-min semi-squats on the vibration platform. three times a week, for three consecutive months.
223716217|NCT01468363|DEVICE|Dry weight adjustment|Dry weight adjustment according to BCM results
223912188|NCT03844061|DRUG|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
223912189|NCT05265065|BIOLOGICAL|Tozinameran - Standard Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose."
224086455|NCT05606926|OTHER|whole body vibration (with weight vest)|The extra-weight applied in the vest will be calculated as 10% of the child body weight. The vest is designed to allow small bags of sand with different weights that are distributed equally on anterior-posterior and mediolateral plans.
224086456|NCT02456246|PROCEDURE|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
224086457|NCT00252330|DRUG|SR58611A|
224086458|NCT02816957|DRUG|nigella sativ|nigella sativa powder (2 gm/day) for 3 consecutive months.
223912190|NCT05265065|BIOLOGICAL|Tozinameran - Fractional Dose|"Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose."
224277742|NCT00147914|DRUG|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
224277743|NCT03748095|DRUG|pipéracilline/tazobactam|There is not intervention description
224086459|NCT03844009|OTHER|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
224086460|NCT03893045|DRUG|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
224277744|NCT02913755|BEHAVIORAL|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
224277745|NCT04188964|DRUG|Burosumab|Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
224277746|NCT02745600|DEVICE|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
224277747|NCT03474393|OTHER|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
224086461|NCT03893045|DRUG|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
224086462|NCT00834054|PROCEDURE|Double-lung transplantation|Double-lung transplanted patients
224086463|NCT03188952|DIAGNOSTIC_TEST|International Caries Classification and Management System|Caries assessment and management system
224086464|NCT01187992|DRUG|Atorvastatin|80 mg/day
224086465|NCT02510079|BIOLOGICAL|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
224086466|NCT03335540|BIOLOGICAL|Nivolumab|Specified dose on specified day
224086467|NCT03335540|BIOLOGICAL|Relatlimab|Specified dose on specified day
224086468|NCT03335540|BIOLOGICAL|Cabiralizumab|Specified dose on specified day
224086469|NCT03335540|BIOLOGICAL|Ipilimumab|Specified dose on specified day
224086470|NCT03335540|DRUG|IDO1 Inhibitor|Specified dose on specified day
224086471|NCT03335540|RADIATION|Radiation Therapy|Specified dose on specified day
224277748|NCT03720704|DEVICE|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
224277749|NCT02538211|BIOLOGICAL|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
223912191|NCT06616467|BEHAVIORAL|Tummy Time for the prevention of childhood obesity|"A cognitive-behavioral intervention aimed at mothers of infants is presented that aims to increase the practice of TT and maintain a healthy weight in the infant, called \&#34;Tummy Time for the prevention of childhood obesity\&#34;, within the intervention modifiable variables are involved that directly impact the expected results such as: the knowledge and beliefs of the mothers, infant temperament, parental self-efficacy and self-efficacy for the practice of TT.~The intervention lasts 12 weeks from the first contact with the participants and consists of eight sessions broken down as follows: the first session is presented in a face-to-face format with expository, audiovisual and demonstrative means; sessions two, four, five and seven are provided through a text message with use WhatsApp® and the use of visual media. Sessions three, six and eight are delivered via telephone call with the aim of offering feedback on the doubts generated up to that point."
223912192|NCT05749900|DRUG|Trastuzumab+Nivolumab+Gemcitabine+Cisplatin|Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
223912193|NCT06288659|DEVICE|Intraventricular intracranial pressure monitoring|The postoperative management of ICP is guided by quantifiable Intraventricular ICP parameters. The remaining treatments are consistent with those in the control group.
223912194|NCT04233255|DEVICE|Neuromuscular Ultrasound (US)|"Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles."
223912195|NCT04233255|DEVICE|Electrophysiological studies|"Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz."
223912196|NCT04233255|DIAGNOSTIC_TEST|Seum CPK, CK-MM levels, Lactate dehydrogenase and alanine aminotransferase.|measured in U/L using ELISA.
223912197|NCT04548778|DIAGNOSTIC_TEST|BÜHLMANN fPELA assay|BÜHLMANN fPELA assays are immunoassays for the quantitative determination of fecal pancreatic elastase in human stool samples.
223912198|NCT05610319|DRUG|Faricimab|Faricimab will be administered via intravitreal injection.
223912199|NCT06044493|DRUG|Myreptic-N Tablet|Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit
223912200|NCT06044493|DRUG|Mycophenolate mofetil Tablet/Capsule|Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit
224086472|NCT02867397|DRUG|Teysuno (S1) in combination with epirubicin and oxaliplatin|
224086473|NCT00157833|DRUG|Artekin / Coartemther|
224086474|NCT00240760|DRUG|Memantine Hydrochloride|
224086475|NCT03026582|DEVICE|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
224086476|NCT00041678|DRUG|aripiprazole|
224086477|NCT05600075|DRUG|microneedling with topical glycolic acid 35%.|15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
223529492|NCT00844506|DRUG|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
223529493|NCT00844506|DRUG|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
224086478|NCT05600075|DRUG|microneedling with topical human insulin solution.|15 patients will be subjected to microneedling with topical human insulin solution. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
224086479|NCT05392452|DEVICE|CamAPS HX|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
224086480|NCT05392452|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
224086481|NCT05613530|BEHAVIORAL|MAX NEONAT|"Participants use a digital, hand-held, cognitive aid (a mobile application named MAX NEONAT) and the ILCOR 2020 algorithm poster.~This group consists of a resident in pediatrics + 2 midwifes."
224086482|NCT05613530|BEHAVIORAL|standard of care|no cognitive aid but poster/paper only
224086483|NCT05990855|COMBINATION_PRODUCT|eCBTi-obj|eCBTi based on objective sleep measures recorded by the Muse S headband.
224086484|NCT05990855|BEHAVIORAL|eCBTi-subj|eCBTi based on standard subjective sleep measures recorded on the sleep diary.
223529494|NCT01758029|DRUG|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
223529495|NCT02822664|BEHAVIORAL|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
223529496|NCT02822664|BEHAVIORAL|Healthy subjects|cerebral MRI and/or cerebral PET imaging
223529497|NCT02822664|DEVICE|PET/MRI|
223912201|NCT06119503|BEHAVIORAL|Elongating Time HOrizons for Reentry (ETHoR)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in an incarceration free future.
223912202|NCT06119503|BEHAVIORAL|Standardized Episodic Thinking (SET)|In the standardized episodic thinking (SET) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
224086485|NCT05489445|DEVICE|KODEX - EPD|A patient that is already clinically indicated to undergo cryoballoon ablation for atrial fibillation will use the The KODEX - EPD™ Cardiac Imaging and Navigation electrophysiological (EP) System. This is an imaging system which allows the physician real-time visualization of the catheters in a patients heart during the procedure, as well as display of cardiac images of the patients heart in a number of different formats. The KODEX - EPD system used in this study is cleared for commercial use by the FDA and therefore, it's use in this study constitutes as standard clinical use.
224086486|NCT00301171|DRUG|Inhaled Fluticasone|
224086487|NCT03466892|OTHER|Questionnaires and computer paradigm|Patients will complete different scales and also the visual probe task. First, we hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, we hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).
224086488|NCT01078766|OTHER|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
223912203|NCT04829526|OTHER|data collection|Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
223912204|NCT01447719|DRUG|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
223912205|NCT06565611|DRUG|bremelanotide|bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume
223912206|NCT06565611|DRUG|tirzepatide|tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.
224086489|NCT03880201|PROCEDURE|ultrasound guided supraclavicular block|"The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves."
224086490|NCT03880201|DEVICE|Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)|Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
224086491|NCT00865215|DRUG|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
223912207|NCT04488354|COMBINATION_PRODUCT|CLBR001 and SWI019|No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
223912208|NCT02371460|DIETARY_SUPPLEMENT|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
224086492|NCT00865215|DRUG|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
224086493|NCT00579813|DRUG|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
224086494|NCT01567644|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
224086495|NCT04217369|DEVICE|Diabits Predictions|Participants will be able to view predictions of future blood glucose. These predictions will indicate where the participant's blood glucose will travel over the next hour given that the participant's state does not change. Based on this, the participant is expected, but not required to make decisions about their activity, food, and insulin, in order to maintain blood glucose in a healthy range. The intervention does not require a specific method of glucose management, or event that a participant takes any action after viewing a prediction, the intervention is simply to display the prediction.
223529498|NCT01727934|DRUG|Miravirsen sodium|Subcutaneous injection
223529499|NCT04556253|DRUG|AK104|Subjects will receive AK104 by intravenous administration.
223529500|NCT04252014|BEHAVIORAL|Hookah tobacco messages|Messages communicating the risks of hookah tobacco use in 4 thematic areas: health harms, addictiveness, social use, flavorings.
223529501|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
223529502|NCT03313934|COMBINATION_PRODUCT|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
223529503|NCT00151840|DRUG|IVIG-L|
223529504|NCT04798677|DIETARY_SUPPLEMENT|ABBC1 Immunoessential|Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor
223529505|NCT04798677|DIETARY_SUPPLEMENT|Placebo|Powder for dissolution in water, excipents. Lemon flavor
223912209|NCT02371460|COMBINATION_PRODUCT|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
223912210|NCT06648629|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a trans-diagnostic treatment that targets experiential avoidance as an underlying factor common to mental and behavioral health problems. Mindfulness skills and values-guided behavioral action plans are used to decrease experiential avoidance and impact a broad array of psychological symptoms via improved psychological acceptance.
224086496|NCT05435820|DEVICE|Near-infrared Transcranial Laser Therapy|The treatment consists in exposing bilaterally the frontal brain to Transcranial Laser Therapy, which may enhance ATP production in depressed subjects.
224086497|NCT01810679|DEVICE|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
224277750|NCT03632694|BEHAVIORAL|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
224277751|NCT03632694|BEHAVIORAL|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
224277752|NCT02340962|DRUG|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
223912211|NCT06648629|BEHAVIORAL|Brief Alcohol Intervention|The Brief Alcohol Intervention (BI) is a standard intervention for reducing alcohol use in PWH. The BI includes the creation of a drinking agreement, self-monitoring via drinking diary cards, discussion of risky moods/situation, and strategies for managing these moods/situations.
224086498|NCT01854346|BEHAVIORAL|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
224086499|NCT00362973|OTHER|laboratory biomarker analysis|
224086500|NCT00362973|PROCEDURE|needle biopsy|
224086501|NCT00362973|PROCEDURE|positron emission tomography|
224277753|NCT02340962|DRUG|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
224086502|NCT00362973|PROCEDURE|radionuclide imaging|
224086503|NCT00362973|RADIATION|fludeoxyglucose F 18|
224086504|NCT05527990|DEVICE|Multimodal PO|Mixed methods diagnostic accuracy and implementation of multimodal PO
224086505|NCT05394038|OTHER|None，observational study.|observational study
224086506|NCT00914381|BEHAVIORAL|Behavioral therapy|
223529506|NCT01952977|DIETARY_SUPPLEMENT|Test breakfast|
223529507|NCT02456129|DRUG|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
223529508|NCT02456129|DRUG|[14C] Vilaprisan|an intravenous microtracer dose of \[14C\]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
223529509|NCT02456129|OTHER|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
223529510|NCT05437991|DIAGNOSTIC_TEST|Independent morphological quantifications by echo-doppler using ECST method|The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
223529511|NCT03483948|DRUG|HMPL-523|HMPL-523 tablet
223529512|NCT03483948|DRUG|Azacitidine|Azacitidine Injection
223529513|NCT03344484|OTHER|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
223529514|NCT05815602|DRUG|Ebastine|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
223529515|NCT05815602|DRUG|Duspatalin|"Randomized subjects will administer 4 pills of study medication per day during 12 weeks.~Daily administration schedule consists of taking 2 pills in the morning (1 verum, and 1 placebo). In the evening, subjects will take a second dose of both verum and placebo."
223529516|NCT05619237|DEVICE|NanoSALV Catalytic|NanoSALV Catalytic Antimicrobial Wound Dressing Gel is a Health Canada approved medical device for the management of Chronic Wounds.
223529517|NCT03775993|DRUG|Human growth hormone|Administration of growth hormone
223529518|NCT03775993|OTHER|Placebo|Administration of placebo
223912212|NCT05649787|BEHAVIORAL|Supervised aerobic training|Supervised moderate to high-intensity interval aerobic training
223912213|NCT05649787|BEHAVIORAL|Supervised aerobic plus low to moderate-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training
223912214|NCT05649787|BEHAVIORAL|Supervised aerobic plus moderate to high-intensity strength training|Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
223912215|NCT05100628|DRUG|NOX66|"NOX66 800 mg (400 mg suppository twice daily \[BID\]).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
223912216|NCT05100628|DRUG|NOX66|"NOX66 1200 mg daily (600 mg suppository BID).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
223912217|NCT05100628|DRUG|NOX66|"NOX66 1800 mg daily (600 mg suppository thrice daily).~Monotherapy: 7 days of NOX66 followed by 5 days washout. Combination therapy: 7 days of NOX66 followed by 14 days washout in a 21-day cycle, for up to 6 cycles."
223912218|NCT05100628|DRUG|NOX66|MTD of the combination of NOX66 and doxorubicin will be determined in the dose-escalation cohort of the study. The selected dose will be administered in combination with Doxorubicin.
223912219|NCT05100628|DRUG|Doxorubicin|Doxorubicin will be given at 75 mg/m\^2 as an intravenous infusion on Day 2 of the 21-day cycle for up to 6 cycles.
223912220|NCT05606211|OTHER|No intervention|Observational, no intervention
223912221|NCT05671666|DIAGNOSTIC_TEST|Urea cycle flux study|Quantification of ureagenesis
223912222|NCT06568458|DRUG|Nintedanib|Specified Dose on specified days
223912223|NCT06568458|DRUG|BMS 986278|Specified dose on specified days
223912224|NCT03347786|DRUG|10 mg Intra-arterial Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
223912225|NCT03347786|DRUG|20 mg Intra-arterial Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
223912226|NCT05102942|BEHAVIORAL|Attentional Control Training Program|The 268 patients fulfilling the eligibility criteria will be randomized to one of the three groups: Group A: AACTP delivered via a smartphone application + treatment as usual (TAU; n = 134), or Group B: ACTP sham training delivered via a smartphone application + TAU (n = 134) Patients in Group A will receive seven sessions of AACTP (one session per week for seven weeks). Patients in Group B will receive seven sessions of sham training (one session per week for seven weeks).
223912227|NCT03717753|OTHER|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components. Both groups will receive identical postoperative follow-up.
223912228|NCT04791865|BEHAVIORAL|Disclosure intervention|Participants who are assigned to the Sankofa intervention will take part in the process of disclosure (pre-disclosure, disclosure, and post-disclosure phases) with the adherence and disclosure specialist (ADDS).
223912229|NCT04791865|BEHAVIORAL|Usual Care|During the control period, patients and caregivers recruited at the clinics will receive the current practice in the clinic, where the health care provider is expected to assess the caregiver and child readiness for disclosure during clinic appointments and give some information as they think indicated.
223912230|NCT05637684|DEVICE|low intensity pulsed ultrasound|mechanical sound waves
223529519|NCT01297855|DRUG|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
223529520|NCT01297855|DRUG|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
223529521|NCT02906111|DRUG|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
223912231|NCT04567706|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223529522|NCT02906111|PROCEDURE|vaginal surgery|Control Group
223529523|NCT01874392|DRUG|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
223529524|NCT01874392|DEVICE|Artificial Pancreas (AP) device (APS©)|"Device includes:~* OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~* Dexcom® G4® CGM System (CGM) from Dexcom® Corp~* Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
223529525|NCT03014466|BEHAVIORAL|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
223529526|NCT03014466|BEHAVIORAL|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
223529527|NCT02951507|OTHER|O T unilateral attachment|O T unilateral attachment system
223529528|NCT02951507|OTHER|New design of extracoronal attachment system|O T unilateral attachment
223529529|NCT00619775|DEVICE|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
223529530|NCT03121521|DRUG|Melatonin 10 mg|melatonin 10mg daily p.o.
223529531|NCT03121521|DRUG|Placebo|Placebo 10mg daily p.o.
223529532|NCT01864434|DEVICE|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
223529533|NCT01864434|DEVICE|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
223529534|NCT00888147|DIETARY_SUPPLEMENT|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
223529535|NCT04513925|DRUG|Atezolizumab|Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
223529536|NCT04513925|DRUG|Tiragolumab|Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
224086507|NCT03172689|DEVICE|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
223912232|NCT06124014|DEVICE|At-Home Stimulation|The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions.
223912233|NCT06252038|BEHAVIORAL|Zoom Group Video (GV)|Zoom delivery of the DPP. Participants have access to Prevent T2 Curriculum and connected technology to track weight and physical activity.
224086508|NCT02006771|OTHER|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
224086509|NCT02006771|OTHER|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
224086510|NCT02006771|OTHER|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
224086511|NCT02006771|OTHER|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
224086512|NCT03541421|OTHER|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
223912234|NCT06252038|BEHAVIORAL|Self Directed (SD)|Self directed delivery of the DPP. Participants have access to online curriculum, lifestyle coach and connected technology to track weight and physical activity.
223912235|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 Ag Ultra|The LumiraDx SARS-CoV-2 Ag Ultra Test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal swab samples collected from symptomatic individuals within the first twelve days of symptom onset suspected of COVID-19 by their healthcare provider.
224086513|NCT04134494|DEVICE|Ablative Fractional 2940 nm Laser|"* Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~* Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~* Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
224086514|NCT04340050|BIOLOGICAL|anti-SARS-CoV-2 convalescent plasma|Infusion of one unit of anti-SARS-CoV-2 convalescent plasma \~300 mL over 4 hours
224086515|NCT02495727|BEHAVIORAL|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
224086516|NCT02495727|BEHAVIORAL|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
224086517|NCT02495727|BEHAVIORAL|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
224086518|NCT01710930|OTHER|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
224086519|NCT05183919|OTHER|Digital Treatment|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
224086520|NCT01338467|DEVICE|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
223529537|NCT04513925|DRUG|Durvalumab|Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
223529538|NCT04943848|BIOLOGICAL|rHSC-DIPGVax|Off-the-shelf, neoantigen heat shock protein vaccine
223529539|NCT04943848|DRUG|Balstilimab|BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
223529540|NCT04943848|DRUG|Zalifrelimab|ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
223529541|NCT05751759|DRUG|Mitiperstat|Participants receive mitiperstat orally.
223529542|NCT04484818|DRUG|Darolutamide|Given PO
223529543|NCT04484818|DRUG|Goserelin Acetate|Given via injection
223529544|NCT04484818|DRUG|Leuprolide Acetate|Given IV
223529545|NCT04484818|DRUG|Placebo Administration|Given PO
223529546|NCT04484818|OTHER|Quality-of-Life Assessment|Ancillary studies
223529547|NCT04484818|DRUG|Triptorelin|Given via injection
223912236|NCT05728970|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B|The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative detection and differentiation of SARS-CoV-2, Influenza A and/or Influenza B viral antigens from nasal swab samples.
223912237|NCT06738888|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data, thyromental distance, neck circumference, sternomental distance, ratio of height-to-thyromental distance, RHTMD, ratio of height-to-sternomental distance, RHSMD
223912238|NCT03263988|DEVICE|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
223912239|NCT04050410|DRUG|Moxonidine|active drug given as 1 dose
223912240|NCT04050410|DRUG|Placebo|placebo pill given as 1 dose
223912241|NCT05093933|DRUG|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
223912242|NCT05093933|DRUG|Placebo|0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat
223912243|NCT06279533|DRUG|LV232/Placebo|"Drug: LV232 15mg Group:~6 subjects will receive LV232 15mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 40mg Group:~6 subjects will receive LV232 40mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally.~Drug: LV232 60mg Group:~6 subjects will receive LV232 60mg, orally; Other Names:Placebo 2 subjects will receive placebo, orally."
223912244|NCT06279533|DRUG|LV232|"Drug: LV232 20mg Group:~12 subjects will receive LV232 20mg, orally~Drug: LV232 60mg Group:~12 subjects will receive LV232 60mg, orally"
223912245|NCT06820606|DEVICE|Rezum|In the REZUM arm, water vapour treatment will be preformed.
223912246|NCT06820606|DEVICE|UroLift|In the UroLift arm, prostatic urethral lift treatment will be performed.
223912247|NCT05297279|BEHAVIORAL|Home delivery Omega-3 rich Food|The active treatment arm will receive voucher (with a specified amount) weekly home delivery omega-3 rich food for the 12-weeks (3 months) intervention. Participants will be limited to purchasing foods rich in omega-3 only.
224086521|NCT04171609|BEHAVIORAL|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
224086522|NCT00183846|DRUG|irinotecan|
224086523|NCT00183846|PROCEDURE|radiation therapy|
224086524|NCT01096914|PROCEDURE|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
224086525|NCT01096914|PROCEDURE|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
224086526|NCT02976155|OTHER|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
224277754|NCT02340962|DRUG|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
224277755|NCT02789839|PROCEDURE|Blood test|Blood test of 30mL
224277756|NCT02789839|PROCEDURE|Medullar test|Medullar test for 2-5mL and a smear
224277757|NCT03043898|OTHER|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
224277758|NCT03043898|OTHER|Lung sound recording|Lung sounds are recorded using a sensor array.
224277759|NCT01715649|BEHAVIORAL|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
223912248|NCT05297279|BEHAVIORAL|Dietary Motivational Coaching|The active treatment arm will receive weekly personalize dietary couching by a dietary coach on omega-3 rich food for the 12-weeks intervention. Participant will also receive educational materials and guidance about what kind of food to order, how to cook, prepare (recipes) and store omega-3 rich foods.
223912249|NCT05297279|BEHAVIORAL|Home delivery Food|The control treatment arm will receive voucher (with a specified amount) weekly home delivery food (any kind of food) for the 12-weeks (3 months) intervention. Participant will not receive dietary coaching on food choices and will not be limited to purchasing foods rich in omega-3.
223912250|NCT06641336|DEVICE|RehAtt|Each patient received the RehAtt intervention.
223912251|NCT04574583|DRUG|SX-682|SX-682 will be given orally at designated dose twice a day every day
223912252|NCT04574583|DRUG|M7824|Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
223912253|NCT04574583|BIOLOGICAL|MVA-BN-CV301|MVA-BN-CV301 will be given as four subcutaneous injections (4x10\^8 Inf.U/0.5ml twice during Cycle 1 (Days 1 and 15)
224086527|NCT02894229|BEHAVIORAL|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
224086528|NCT02894229|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
224086529|NCT00781365|OTHER|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
224086530|NCT01573312|DRUG|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
224086531|NCT01573312|BIOLOGICAL|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
224086532|NCT03494556|OTHER|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
224086533|NCT05758090|PROCEDURE|NIPE monitor|Procedure/Surgery: NIPE protocol. Give intraoperative fentanyl according to NIPE value. NIPE score 50-70 indicates optimal narcotic effect. NIPE score \> 70 indicated overdosage of narcotic and narcotic should be withheld. NIPE score \< 50 indicates inadequate narcotic and narcotic should be given.
224086534|NCT05758090|PROCEDURE|Control|Procedure/Surgery: Standard protocol. Give intraoperative fentanyl according to vital signs.
223912254|NCT04574583|BIOLOGICAL|recombinant fowlpox viral (FPV)-CV301|FPV-CV301 will be given as one subcutaneous injection (1x10\^9 Inf.U/0.5ml) on Day 1 starting at cycle 2 through cycle 5 (every 4 weeks) then on Day 1 of every 3 cycles (Cycles 8 and Cycle 11).
223912255|NCT06841107|OTHER|Training was provided on spinal health.|Bus drivers were told about the practices they could do during and outside of work hours, and were asked to comply with these practices every day for 3 months.
223912256|NCT06841107|OTHER|Training on spinal health was provided and lumbar region support was applied for 3 months.|Bus drivers were told about the practices they could do during and outside of work hours, and were asked to comply with these practices every day for 3 months. In addition, lumbar region support was used every day during working hours for 3 months.
223912257|NCT03309332|DEVICE|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
224086535|NCT06098638|OTHER|Nutritional recommendation and Faradic stimulation program|proper maternal nutrition and fluid intake during breast-feeding per day for 12 weeks and2 sessions per week, each session 20 minutes, for 12 weeks. Frequency of 65 Hz, and width pulse 300 ms, with contraction time 10 sec and relaxation time 10 sec
224086536|NCT06098638|OTHER|aerobic and resisted exercise for 12 weeks|Each woman in group (B) participated in a moderate exercise program (aerobic+resistive), 3 days/week, for 12 weeks. The session began with 15 minutes of aerobic exercise on a bicycle ergometer, at 60% of heart rate reserve (HRR), with HRR estimated (220-age-resting heart rate). Then, the participant was performed 15 minutes of resistive exercise (two sets of 8-12 repetitions at 75% of one repetition maximum (1-RM) for basic core exercises in the form of hip lifts, knee extension and flexion, crunches, shoulder flexion and extension, elbow flexion and extension with resistance
224086537|NCT00456690|OTHER|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
224086538|NCT01086436|BIOLOGICAL|Rotarix ™|Oral, single dose
224086539|NCT01086436|BIOLOGICAL|Placebo|Oral, single dose
223716218|NCT04664712|DIETARY_SUPPLEMENT|Tendisulfur Pro|Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
223912258|NCT05217589|OTHER|Funny/Amusing Video Clips|Participants watch 5-7 minutes of video clips that are funny/amusing in nature
224086540|NCT05554120|OTHER|Supermarket tobacco sales ban|In 2024, a ban on the sales of tobacco for supermarkets is planned by the Dutch government. Supermarkets accounted for approximately 40% of tobacco outlets in the Netherlands in 2021.
224086541|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
223912259|NCT05217589|OTHER|Horror/Scary Video Clips|Participants watch 5-7 minutes of video clips that are scary in nature
224086542|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
224086543|NCT04586985|DRUG|FTX-6058 - Two Dosing Periods|Subjects will receive FTX-6058
224086544|NCT04586985|DRUG|FTX-6058 / Midazolam Syrup|Subjects will receive FTX-6058 and midazolam syrup
224086545|NCT04586985|DRUG|FTX-6058/placebo oral capsule(s)|Subjects will receive FTX-6058 or matching placebo.
224086546|NCT05734729|DEVICE|EFFIDRAIN|. Effidrain is a progammable, light-weight, portable drain regulator that can control the rate and volume of body fluid being drained, while empowering the user with information on dynamic changes of pressure within the body cavity being drainged. It is able to adapt to existing drainage systems via a standard medical luer taper connector, and comes with a failsafe system to alert users of drainage irregularities.
224086547|NCT05734729|DEVICE|Manual drainage system|drainage systems required manual control and are unautomated; consequent unintended rapid intravascular and extravascular fluid shifts may result in clinical instability.
224086548|NCT00102089|BIOLOGICAL|VRC-HIVADV014-00-VP booster|
224086549|NCT00102089|DRUG|VRC-HIVADV014-00-VP|
224277760|NCT02519543|DRUG|Placebo|Placebo to be given twice daily, once with breakfast and once with supper
224086550|NCT02505529|OTHER|Resistance Exercise Training|Behavioral interventions of resistance exercise
224086551|NCT02505529|OTHER|Mental Imagery|Behavioral intervention of mental imagery
224086552|NCT01089660|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
224086553|NCT01089660|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
224277761|NCT02519543|DRUG|Metformin|Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper
224277762|NCT00600873|DRUG|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
224277763|NCT00841620|PROCEDURE|Haemorrhoidectomy a.m. Milligan|Surgery
223912260|NCT05217589|OTHER|Thrilling/Suspenseful Video Clips|Participants watch 5-7 minutes of video clips that are thrilling/suspenseful in nature
223912261|NCT05900154|BIOLOGICAL|RSVpreF 120 µg|RSVpreF standard dose level
223912262|NCT05900154|BIOLOGICAL|RSVpreF 60 µg|RSVpreF low dose level
223912263|NCT02630121|DRUG|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
223912264|NCT02630121|DRUG|Placebo|Proportion of the subjects with 50% reduction in AHI.
223912265|NCT06257290|BIOLOGICAL|blood sample|at Day 1 - date of patient inclusion at time of VTE diagnosis
223912266|NCT06257290|BIOLOGICAL|blood sample|at 6 months (in the patient follow-up)
223912267|NCT06024993|DEVICE|Flow-controlled ventilation (FCV)|20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)
223912268|NCT06024993|DEVICE|Conventional volume-controlled ventilation (VCV)|20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.
223912269|NCT05904730|DRUG|Axitinib|The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)
223912270|NCT06854302|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance imaging|Observational diagnostic tests will include adenosine-stress perfusion cardiovascular magnetic resonance imaging before undergoing percutaneous coronary intervention.
223912271|NCT06854302|DIAGNOSTIC_TEST|Coronary physiology|Invasive coronary function tests using a diagnostic guidewire (PressureWire-X, Abbott), thermodilution, intravenous or intracoronary infusion of adenosine and intracoronary infusions of acetylcholine.
223912272|NCT06855121|DRUG|Teclistamab|Real-world use and dosing
223912273|NCT06855121|DRUG|Elranatamab|Real-world use and dosing
223912274|NCT06855121|BIOLOGICAL|Ciltacabtagene Autoleucel|Real-world use.
223912275|NCT06855121|DRUG|Talquetamab|Real-world use and dosing
223912276|NCT06855121|BIOLOGICAL|Idecabtagene vicleucel|Real-world use and dosing
223529548|NCT04565457|DEVICE|Research CBCT|Each study participant will receive one additional CBCT scan, with 2D antiscatter grid in place. This is the only intervention in the study, referred as research CBCT scan, and it will be performed on one of the days during the participant's radiation treatment course. This additional research CBCT scan will be used strictly for the objectives of this study. It will not be used as part of the standard clinical care, such as imaging guidance of participant's radiation treatment or diagnostic purposes. To deliver participant's radiation treatment under CBCT guidance, a standard clinical CBCT scan will be acquired, as in standard clinical care protocols.
223912277|NCT06855238|DEVICE|THAITI software|"THAITI is an AI-based software which predicts on the fly personalised TI for late gadolinium enhancement imaging during cardiovascular magnetic resonance scans.~The clinical investigators will be provided by the computer scientists investigators with a software, based on the developed AI model. During the CMR in the experimental group, investigators will input patients' data on the software (e.g. age, sex, dose of contrast…). The software will provide a TI value to be input in the MRI scanner. TI will be set accordingly to the AI prediction. A LGE series of 3 long axis (4-, 2- and 3-chambers view) and a short-axis stack will be acquired.~For all the patients, a doctor expert in CMR will be at the scanner and quality check the images in real time. Every image where the myocardium is not optimally nulled will be repeated with a TI set by the CMR doctor."
223912278|NCT06853769|DRUG|Anlotinib hydrochloride,Penpulimab|Penpulimab 200mg IV D1 Anlotinib 12mg P.O. QD D1-14
223912279|NCT06855316|DEVICE|electromagnetic stimulation|After performing a high-intensity eccentric exercise session, participants will undergo a daily session of transcranial and/or peripheral magnetic stimulation for three days. The objective is to enhance nerve conduction, which, according to the latest theories on DOMS, may be the cause of decreased athletic performance
223912280|NCT06855095|DRUG|Somatostatin analog|Timing of LA-SSA injection prior to PRRT (either 4-6 weeks or 1-7 days).
223912281|NCT06813040|DEVICE|Active rTMS|Repetitive TMS will be applied at 10Hz on the motor cortex. The protocol consists of 2000 pulses per session and an intensity of 90% of the resting motor threshold. There will be 10 sessions with a minimum interval of 24 hours and a maximum of 72 hours. A figure-8 coil will be used.
223912282|NCT06813040|DEVICE|Sham rTMS|The sham TMS will have the same visual and sound characteristics, but without the passage of the magnetic field to the scalp.
223912283|NCT06853509|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223912284|NCT06811064|OTHER|Testimony video|A testimonial video on the experiences of parents of premature babies during the transfer of their newborn from the intensive care unit to the neonatal unit. This video will be performed with the collaboration of the carers and resource parents.
223912285|NCT06852586|DEVICE|conventional nanohybrid composites|Incremental layering technique is used for restoration
223912286|NCT06852586|DEVICE|Bulk fill composites|Single increment in bulk form is applied for restoration
223912287|NCT06853106|OTHER|Waitlist control group|The participants in the waitlist control group will be informed that they are on a waiting list during the intervention period, serving as a no-treatment control. They will receive the sleep intervention (i.e., the digital-based sleep management program) four weeks after the intervention period is completed.
223912288|NCT06853106|BEHAVIORAL|digital-based multimodal sleep management program|The digital-based multimodal sleep management program consists of (1) sleep hygiene education, (2) sleep restriction, and (3) mindfulness breathing exercises. The program is internet-integrated and delivered via Google Meet, with 45-minute weekly sessions over four weeks. To increase participants' adherence to the sleep management program , the course instructor will request the participants to record their daily sleep diaries (time to bed, time to sleep, wake time during sleep and wake time) and sleep journals(practices of sleep hygiene, sleep restriction and mindfulness breathing exercise) in the mobile app for at least five consecutive days each week.
224277764|NCT00841620|PROCEDURE|Stapled anopexy|Surgery
223529549|NCT06434636|DRUG|Transamine 10% IV/IM Solution for Injection|10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within 15 minutes.
223529550|NCT06434636|DRUG|%0.9 Saline|100 cc %0.9 Normal Saline will be injected through the appropriate vascular access within 15 minutes
223529551|NCT05985954|DRUG|Cetuximab|Given by IV (vein)
223529552|NCT05985954|DRUG|Ulixertinib|Given by PO
223912289|NCT06813313|DEVICE|repetitive transcranial magnetic stimulation|A burst of 3 pulses sent at a frequency of 50 Hz, repeated with a frequency of 5 Hz for 2 seconds, followed by an 8-second pause. This sequence is repeated for 59 cycles, totaling 9 minutes and 50 seconds, with a total of 1800 pulses.
223912290|NCT06809452|BEHAVIORAL|Transdiagnostic Oncologic Program|"The Transdiagnostic Oncology Program (TOP) is a 12-month interdisciplinary aftercare program aimed at improving cancer survivors' quality of life by addressing common clinical issues.~In the first three months, participants attended two weekly 1-hour exercise sessions led by physiotherapists. Once a week, this was followed by 1-hour mind-body therapy for stress reduction. A dietitian provided an initial group session on nutrition and advised at least two personal consultations.~Between months 3-6, exercise was reduced to once weekly, with encouragement to continue independent exercise and relaxation. A second informational session on stress and sleep hygiene was given.~After six months, participants continued independently, meeting the family doctor quarterly to evaluate progress.~For the participants who experienced some psychological problems, sessions with a psychologist at an institute specialized for psycho-oncology, were available."
224086554|NCT01879410|DRUG|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
223912291|NCT00758862|DRUG|2% TD1414 Cream|Application 3 times daily for 7 days
223912292|NCT06810284|DRUG|Sildenafil Citrate (IV)|Controlled hypothermia initiated before 6h after birth (servo-controlled 33.5°C during 72h followed by a 12-h rewarming period up to 36.5°C), open-label IV Sildenafil Citrate (Revatio®, 10 mg/12.5 mL, Pfizer) 0.4 mg/kg delivered over 3 hours, followed by a maintenance infusion at 1.6 mg/kg/day for 72h
223912293|NCT06804902|BEHAVIORAL|Monthly RDT Validation Meeting|Health facilities in intervention districts will bring all RDT cassettes performed in their facility and all outpatient registers to a monthly data validation meeting led by the surveillance, monitoring and evaluation officers (CSE). During these meetings, Audere's HealthPulse application will be used to take photos of each facility's RDT cassettes, tallying the total number of RDTs and total by result. The test positivity rates (TPRs) from the registers will be manually entered into the application and compared with the TPR from the RDT photos. Healthcare facilities with a discrepancy above a certain threshold between TPR derived from register data and the TPR derived from the RDT images may be asked to carry out a more detailed audit to better understand the source of discrepant results. If discrepancies are identified, the CSE will determine what corrections are required before entry into the DHIS2.
224086555|NCT01879410|DRUG|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
224086556|NCT01879410|DRUG|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
224086557|NCT01879410|DRUG|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
224086558|NCT04754789|DRUG|Atorvastatin|preloading with high dose statins (atorvastatin 80mg) with loading dose of dual antiplatelet( asprine 300 mg and ticagrelor 180 mg) pre-primary PCI
224086559|NCT04754789|DRUG|Aspirin|Loading dose of dual antiplatelet (asprine 300 mg and ticagrelor 180 mg)
224086560|NCT00417586|DEVICE|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
224086561|NCT02080052|DEVICE|Robot-assisted prostate biopsy|
224086562|NCT02524431|OTHER|Collection of trabecular meshwork tissue during surgery|Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
224086563|NCT06119880|DRUG|Pancreatin Enteric-coated Capsules|pancreatic enzyme replacement therapy
224086564|NCT06119880|OTHER|Routine treatment plan|Routine treatment plan without PERT
223529553|NCT05985954|DRUG|Encorafenib|Given by PO
223529554|NCT06262321|RADIATION|Prophylactic Palliative Radiotherapy|Prophylactic Palliative Radiotherapy
223912294|NCT06810479|DIAGNOSTIC_TEST|Polygraphy|Polygraphy will be caried out at the patients home to evaluate each MRA after 3 monhts
224086565|NCT05274126|BEHAVIORAL|Patient group/Passvers|"Passvers intervention aims at :~* helping patients followed in the centers, presenting a Severe and Persistent Mental Disorder (schizophrenia, mood disorder, autism spectrum disorder, etc.), at risk or in a situation of psychological disability, to enroll in a rehabilitation program towards recovery.~* supporting the emergence and construction of projects by the people themselves, and to accompany them to realize them.~* Encouraging the use of resources in their environment and common law mechanisms (city hall, department, associations, etc.) for better social integration.~* encouraging involvement in care understood as useful tools for the realization of the personal project.~Passvers also aims at :~* promoting a change in professional practices within the team, in favor of recovery-oriented practices based on the concept of engagement or empowerment.~* allowing cooperation between health and social structures aiming at destigmatizing mental illness."
224086566|NCT02616913|OTHER|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
224086567|NCT02616913|OTHER|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
224086568|NCT02616913|OTHER|Placebo|Each subject consumes placebo in one of 3 treatment periods
223912295|NCT06810479|OTHER|Questionaire|"Epworth Sleepiness Scale~o Johns, Murray W. A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale. Sleep, vol. 14, no. 6, 1991, pp. 540-545."
223912296|NCT06810479|OTHER|Questionaire|"Patient experience questionnaire~o Ng, E.T., Perez-Garcia, A., en Lagravère-Vich, M.O. Development and Initial Validation of a Questionnaire to Measure Patient Experience with Oral Appliance Therapy. Journal of Clinical Sleep Medicine, vol. 19, nr. 8, 1 aug. 2023, pp. 1437-1445. doi: 10.5664/jcsm.10562. PMID: 37082817; PMCID: PMC10394373"
224086569|NCT00874198|PROCEDURE|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system \[pressure settings: 30 - 200 mmH20\]
224086570|NCT02803073|DRUG|Testosterone|Testosterone Cypionate Intramuscular injections will be administered weekly
223912297|NCT06810479|OTHER|Question|Patient final choice of preferred MRA
224086571|NCT02803073|DRUG|Normal Saline|Normal Saline Intramuscular injections will be administered weekly
224086572|NCT01676285|DRUG|Metoprolol succinate|
224086573|NCT01676285|DRUG|placebo|
224086574|NCT01200745|DRUG|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
224086575|NCT02009241|OTHER|Pulmonary Rehabilitation|
224086576|NCT05460585|DEVICE|Cerebral oximetry using Rheopatch|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
224086577|NCT05460585|DEVICE|Cerebral oximetry using NIRO-200NX|"On the study visit, baseline demographic data (age and gender, BMI) are collected. In supine position the sensor patches (left and right) of the device are applied to the forehead and the cerebral oxymetry values are recorded during 120sec. The sensor patches are then removed and the patches of the second device are applied on the same position on the forehead and the measurement is carried out as described before. For the first measurement of each sensor, a total of 5 minutes equilibration and sensor output power adjustment is allowed. A total of 10 measurements are taken, 5 with each device.~The volunteer is then placed in Trendelenburg position and another 4 measurements are made (2 with each device) as previously described."
224086578|NCT01361516|OTHER|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
224086579|NCT05859477|DRUG|Nivolumab|360 mg, i.v., every 3 weeks
224086580|NCT05859477|DRUG|Capecitabine|capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle
223912298|NCT06854770|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
223912299|NCT06855407|OTHER|Blood pressure elevation|Increasing systemic blood pressure for measurement of cerebral blood flow changes
223912300|NCT06853951|DRUG|ACE Inhibitors|0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
224086581|NCT05859477|DRUG|Oxaliplatin|130 mg/m², i.v., day 1, every 3 weeks
224086582|NCT03603041|DIETARY_SUPPLEMENT|Whey protein|Participants in the protein arms will receive whey protein daily for 16 weeks.
224086583|NCT03603041|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
224086584|NCT02153762|DRUG|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
224086585|NCT02153762|DRUG|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
224086586|NCT02337803|BEHAVIORAL|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
224086587|NCT02337803|BEHAVIORAL|Usual Care|Will continue daily physical activity and complete surveys online
223912301|NCT06853951|DRUG|β -Blockers|0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
223529555|NCT06388564|DRUG|Axatilimab|Axatilimab will be administered at protocol defined dose.
223529556|NCT06388564|DRUG|Ruxolitinib|Ruxolitinib will be administered at protocol defined dose.
223529557|NCT06388564|DRUG|Corticosteroids|Corticosteroids will be administered at protocol defined dose.
223529558|NCT04067011|DRUG|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
223912302|NCT05655520|DRUG|SAGE-718|Oral softgel lipid capsules
223912303|NCT00783510|BIOLOGICAL|adalimumab|As prescribed by treating physician
223912304|NCT00783510|DRUG|Methotrexate|As prescribed by treating physician
224086588|NCT04525963|OTHER|Preoperative visit of the operating room nurse and patient education|The operating room nurse, who is given intervention training, will visit the patient before the operation. After the oral training of the operating room nurse, a printed booklet will be left for the patient to read.
224086589|NCT02419027|DIETARY_SUPPLEMENT|GI Flora|
224086590|NCT02419027|DIETARY_SUPPLEMENT|Placebo|
224086591|NCT04069663|OTHER|No interventional study|Retrospective data analysis
224086592|NCT04779151|DRUG|Dostarlimab|Substance: immunoglobulin G4 (IgG4) humanized monoclonal antibody (mAb) that binds with high affinity to PD-1 Manufacturer: Tesaro Inc. Dose: 500 mg every 21 days for the first 4 cycles, followed by 1,000 mg every 42 days cycle (ie, Q6W)
224086593|NCT04779151|DRUG|Niraparib|Substance: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) Manufacturer: Tesaro Inc. Dose: Flat-fixed dose (if \<77kg or platelets \<150,000 μL: 200mg; if \>/=77kg and platelets \>/= 150,000μL: 300mg)
224086594|NCT02405533|DIETARY_SUPPLEMENT|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
224086595|NCT02405533|OTHER|Placebo|Placebo supplementation x 12 months
224086596|NCT00481845|DRUG|Vandetanib|300 mg daily
224086597|NCT00481845|DRUG|Anastrozole|1 mg daily
224086598|NCT05708391|DRUG|Realgar-Indigo Naturalis Formulation|"Radiotherapy: after 4 courses of chemotherapy, radiotherapy was started 13 weeks later. The radiotherapy was performed by three-dimensional conformal intensity modulated radiation (IMRT) technique with a dose of 45-50.4 grey, and radiotherapy was performed 5 times per week for 5-6 weeks.~Oral administration of Realgar-Indigo naturalis formula from 1 week before radiotherapy to the whole radiotherapy period.~Dosage: oral, according to body weight, 3 times a day.Because the patient constitution is different, may first start from the half dose, within 3 days gradually increases the dose.In this study, the dosage of Realgar-Indigo naturalis formula (250mg per tablet) was determined according to the patient's weight stage.In each body weight segment, 60 mg/kg realgar-indigo naturalis formula were given according to the upper limit of body weight"
223912305|NCT06588946|DIETARY_SUPPLEMENT|Ketone monoester (KME) supplement|15g of a KME supplement orally consumed 3x daily for 14 days. This dosing protocol raises plasma β-OHB consistently during the waking hours. Oral KME will be provided in opaque bottles labelled A or B to maintain condition blinding. Each bottle will contain a drink providing 15g of a KME supplement: \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (ΔG®, TDeltaS, Oxford, UK).
224086599|NCT05708391|RADIATION|Radiotherapy|Radiotherapy
224086600|NCT04625777|BEHAVIORAL|Mindfulness Based Stress Reduction|"Mindfulness Based Stress Reduction (MBSR) teaches several different kinds of meditation. MBSR is offered as an online course through Duke Integrative Medicine and is based on the national model first developed by Jon Kabat-Zinn at the University of Massachusetts. It includes exercises in awareness of breath, body scans, walking meditation, choiceless open awareness, Loving Kindness Meditation, and bringing awareness to the present moment. The MBSR Distance Learning course consists of 8 weekly sessions via video conference and includes meditation instruction, periods of guided practice, and group discussion."
224086601|NCT04625777|BEHAVIORAL|Daily Examen spiritual practice|"The Daily Examen is a simple but powerful prayer used by Jesuits every day. It takes only 10-15 minutes and can be used to reflect on positive emotions, move past negative emotions, and align one's work with God's work. The Examen directs the person praying to focus on a five-step routine:~1. Become aware of God's presence;~2. Give thanks to God for everything in your life;~3. Review the events of the day guided by the Holy Spirit;~4. Look at what went well or wrong in the past day; if at fault, ask God for forgiveness; and~5. Look toward tomorrow - what one thing should you do? Listen to what God is telling you."
224086602|NCT04625777|BEHAVIORAL|Stress inoculation combination|This intervention includes a combination of stress inoculation and general stress reduction activities focused on physiology, with exercises that bypass the brain and work directly on the body to mitigate the symptoms of stress. This system is based on Stress Inoculation Training, which uses breathing to prepare people in advance for stressful episodes and recovery skills for following such episodes. The techniques include a variety of breathing, blood flow, and tension control methods, as well as ways to conduct deep tissue massage on oneself to release muscle tension. The awareness aspect involves understanding stress biology and learning to spot the symptoms of stress in oneself and others.
224086603|NCT02849639|OTHER|Placebo|Participants will receive educational materials, but will not receive MTM.
224086604|NCT02849639|OTHER|Medication Therapy Management (MTM)|Participants will receive MTM in addition to the educational materials.
224086605|NCT02849639|DRUG|Scopolamine patch|At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
224086606|NCT01958645|DRUG|MEDI8111|MEDI8111 lyophilisate for solution for infusion
224086607|NCT01958645|OTHER|Placebo|Placebo for MEDI8111 saline solution for infusion
224086608|NCT00031031|DRUG|Kanglaite Injection (KLT)|
224086609|NCT01006070|PROCEDURE|kyphoplasty|surgical kyphoplasty
223912306|NCT06588946|DIETARY_SUPPLEMENT|Placebo supplement|50mL taste-match inert calorie-free placebo drink orally consumed 3x daily for 14 days. Oral placebo will be provided in opaque bottles labelled A or B to maintain condition blinding.
223912307|NCT05651503|DIETARY_SUPPLEMENT|Probiotics|In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
224086610|NCT05039060|DIETARY_SUPPLEMENT|Modified MAC diet (3-weeks)|"* Modified MAC diet to adapt reduced energy intake and increased dietary fiber consumption with appropriate nutrients component~* Dr.Kitchen Inc. directly provide home delivery service for the modified MAC diet including multigrain rice, meal kit, and snacks per day in a regular basis"
224086611|NCT00363792|DRUG|Glyceryl trinitrate, azetazolamide|
224086612|NCT05421910|DEVICE|robotic training combined with electrical stimulation|Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
224086613|NCT03850197|DEVICE|EarPopper|"The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
224086614|NCT03850197|DEVICE|Tympanometry|The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.
223529559|NCT04067011|DRUG|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
223912308|NCT05651503|DIETARY_SUPPLEMENT|Placebo tablet|In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
223912309|NCT05826600|DRUG|OMX-0407|Dose escalation, Dose expansion
223912310|NCT06100315|DRUG|Nalbuphine|bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
223912311|NCT06602934|OTHER|Blood samples|Four blood samples will be taken outside standard care for groups A, B, C and D: at inclusion, M6, M18 and M30 (only at inclusion for group C).
223912312|NCT06602934|OTHER|Oropharyngeal swabs|An oropharyngeal swab will be taken to analyze patients\&#39; upper airway microbiome at inclusion, M6, M18 and M30.
223912313|NCT06602934|OTHER|Calcium score (CT scan)|A calcium score will be taken at 30 months, to assess individual cardiovascular risk.
223912314|NCT06602934|OTHER|ECG|Performed at inclusion, M6, M18 and M30
223912315|NCT06602934|OTHER|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test|Cardiopulmonary exercise test, spirometry, plethysmography, pulmonary absorption of carbon monoxide in a single inspiration, and 6-minute walk test: These tests will be performed consecutively for 2 hours at inclusion (6-minute walk test only), at M6 and at M30. These tests will be performed to assess respiratory and cardiac function.
223912316|NCT03904615|DIETARY_SUPPLEMENT|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
223912317|NCT03904615|DIETARY_SUPPLEMENT|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
223912318|NCT03904615|DIETARY_SUPPLEMENT|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
223912319|NCT05111834|BEHAVIORAL|Supervised resistance training plus nutritional endorsement|resistance training 2x per week, nutritional endorsement/therapy based on individual needs
223912320|NCT05111834|BEHAVIORAL|Nutritional endorsement|nutritional endorsement/therapy based on individual needs
223912321|NCT06595719|DIETARY_SUPPLEMENT|Multi-Strain Probiotics|Each sachet of the multi-strain probiotics contain 30 billion CFU of 6 strains which includes Lactobacillus acidophilus BCMC®12130, Lactobacillus casei subsp BCMC®12313, Lactobacillus lactis BCMC®12451, Bifidobacterium bifidum BCMC®02290, Bifidobacterium infantis BCMC®02129, Bifidobacterium longum BCMC®02120
223912322|NCT06595719|DIETARY_SUPPLEMENT|Placebo|Replicate for multi-strain probiotics without any active ingredients
223912323|NCT06815120|DEVICE|Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)|Kidney stone patients and Oncology patients admitted to either the University Hospital Southampton (UHS) or University College London Hospital (UCLH) for management of kidney stones or for the management of urine drainage in ureter will have a novel ureteric stent instead of their planned conventional stent. The novel stent will be removed after 4 weeks (kidney stone patients) or 25 weeks (oncology patients). Recruitment to the cohort of oncology patients will only commence once the results for kidney stones patients have been reviewed.
223912324|NCT06815120|OTHER|Qualitative interview|Kidney stone patients, Oncology patients and doctors will be interviewed about their experience of having a stent, or their experience in managing patients with a stent.
223912325|NCT06813820|DEVICE|Revivent System|BioVentrix has developed the Revivent System to mirror SVR. The Revivent System is used to place permanent cardiac implants to the epicardial surface for the purpose of reconfiguring abnormal cardiac geometry that is contributing to the dysfunction.
223529560|NCT04067011|BIOLOGICAL|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
223940016|NCT07196657|DRUG|Pregabalin|For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.
223940017|NCT07196657|DRUG|Crisugabalin|For the crisugabalin group, therapy will begin at 20 mg twice daily, with a maximum allowable dose of 40 mg twice daily.
223940018|NCT07196228|DEVICE|Intervention Name (Arm 1): Narrow tie-base abutment Intervention Name (Arm 2): Regular tie-base abutment|"Arm 1 - Narrow tie-base abutment~Intervention Name: Narrow tie-base abutment~Intervention Type: Device~Intervention Description: Participants received a subcrestal bone-level dental implant restored with a narrow-diameter tie-base abutment.~Arm 2 - Regular tie-base abutment~Intervention Name: Regular tie-base abutment~Intervention Type: Device~Intervention Description: Participants received a subcrestal bone-level dental implant restored with a regular-diameter tie-base abutment."
223940019|NCT07197450|DRUG|intravenous administration of PTH1-84 mRNA|intravenous administration of PTH1-84 mRNA
223940020|NCT07197437|DEVICE|Hybrid Coat desensitizer|Dental desensitization treatment
223940021|NCT07197437|DEVICE|Single Bond Universal as desensitizer|Dental desensitization treatment
223940022|NCT07197476|BEHAVIORAL|ASSIST Video Intervention|Video intervention for participants: adolescent trauma patient-parent dyads.
223940023|NCT07196436|DEVICE|Energy Recovery Ventilator|A mechanical ventilation system that exchanges stale indoor air with fresh outdoor air while transferring heat and moisture between the incoming and outgoing air streams
223940024|NCT07196436|DEVICE|Portable Air Cleaner|A standalone home device that filters indoor air to remove particulate matter, allergens, and other pollutants
223940025|NCT07196436|DEVICE|Energy Recovery Ventilator (Sham)|A home-installed ERV unit that operates in recirculation mode only, providing no fresh air exchange or heat/moisture transfer, serving as a placebo for study purposes.
223940026|NCT07196436|DEVICE|Portable Air Cleaner (Sham)|A portable air cleaner that appears to operate like an active unit but does not contain a HEPA filter and does not clean the air, serving as a placebo for study purposes
223940027|NCT07197398|OTHER|Spinal block level analysis|Relation of pregnancy - related, maternal and neonatal data to the level of sensory blockade in the whole study group will be assessed. Only cases with 12.5mg of hyperbaric bupivacaine will be included.
223940028|NCT07197398|OTHER|Data collection|Intervention is to retrieve and analyse anonymous perioperative data. After identification of eligible cases, statistical analysis will be performed
223912326|NCT06813560|DIAGNOSTIC_TEST|hair cortisol|To extract cortisol from the hair, the sample is carefully sectioned into segment lengths that will approximate the time period of interest (from the outermost part, if the hair is 3 cm long, the cortisol secreted proportionally by the individual in the last 3 months of life will be extracted). Then, an approximate average weight per sample of 150 mg will be selected. The samples will be individualised and placed in eppendorfs (one for each patient) and sprayed with scissors. After incubation in methanol for 36 hours, the supernatant portion is extracted, which already contains dissolved cortisol. This solution shall be evaporated to dryness, and then the pellet shall be reconstituted with phosphate (PBS). A commercial kit for the quantification of cortisol by immunoassay (ELISA Victor X5) shall be used. The ELISA kit for the detection of cortisol in saliva (ELISA Kits ' Cortisol ELISA Kits Human Cortisol Competitive ELISA Kit ,Invitrogen).
223912327|NCT06813560|DIAGNOSTIC_TEST|salivary cortisol|Three saliva samples will be collected from each subject, at 8:00, 15:00 and 23:00 hours. Before collecting the saliva they will be instructed to rinse their mouth with cold water, without brushing their teeth. They should also not eat or drink in the hour before the sample is taken. Approximately 1 ml of saliva, collected by direct expectoration into an ependymal tube, shall be obtained and the samples shall be stored for 24 hours at 4°C . Subsequently, samples shall be centrifuged at 2 500 rpm/10 min and the supernatant shall be stored at -20 °C until processing by ELISA kit as per the above protocol.
224086615|NCT03850197|DEVICE|Tubomanometry|"Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
224086616|NCT00000655|DRUG|Atovaquone|
223912328|NCT06813560|DIAGNOSTIC_TEST|salivary Oxytocin|The treatment and collection of saliva as a biological sample shall be identical to the protocol described for the determination of cortisol. The determination of oxytocin shall be carried out by the use of ELISA kit for immunoassay (Oxytocin ELISA Kit (ab133050 ABCAM)
223912329|NCT06813560|DIAGNOSTIC_TEST|Bayley-III Child Development Assessment Scales|They are a set of three standardised assessment scales, which assess the cognitive, motor and language development of children aged 1 and 42 months. For our study, we will use only the motor scale, which is composed of two subscales, the gross motor scale and the fine motor scale. This motor scale is composed of 138 items (the gross motor scale is composed of 72 items and the fine motor scale of 66 items) which assess the degree of control of the body, the coordination of large muscle masses and the manipulative ability of hands and fingers. The total administration time of the motor area for 12-month-old children, as in the case of the sample, is between 15 and 20 minutes.
223912330|NCT06813560|DIAGNOSTIC_TEST|Strange Situation|The Strange Situation is a standardised observational procedure in which the child is exposed to two moments of separation from his/her attachment figure, two moments of reunion with the attachment figure and moments in which he/she interacts with an unknown person, specifically 8 episodes (lasting 3 minutes) in which the level of stress provoked in the child increases in intensity as the situation progresses. It is estimated to last around 20 minutes. It is assessed on a 7-point Likert-type scale, so that low scores indicate low frequency and intensity of the behaviour. These responses allow us to identify three types of attachment: secure attachment, insecure-avoidant attachment and insecure-ambivalent attachment. The strange situation only allows us to assess attachment in children between 1 and 2 years of age.
223912331|NCT06813560|DIAGNOSTIC_TEST|Parenting Stress Index (PSI)|It assesses the stress experienced in parenting through several subscales such as parental distress, dysfunctional parent-child interaction and whether the child is a difficult child based on how parents perceive their children's behaviour.
223912332|NCT06813560|DIAGNOSTIC_TEST|Perinatal Risk Inventory|"\- The Perinatal Risk Inventory is a measuring instrument that provides information on the neonatal situation prior to discharge and facilitates an estimate of the biological risk that the child may present from a very early age. The factors that are analysed in this inventory are evaluated with a score from 0 to 3 for each of the factors mentioned above, ranging from a minimum of 0 points to a maximum of 51. The levels of risk were determined as follows:~1. Low Neonatal Risk: 0 to 6 points.~2. Moderate Neonatal Risk: 7 to 9 points.~3. High Neonatal Risk: 10 or more points."
224086617|NCT00000655|DRUG|Sulfamethoxazole-Trimethoprim|
224086618|NCT01756456|DRUG|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
224086619|NCT01756456|DRUG|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
224086620|NCT01756456|OTHER|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
224086621|NCT01303055|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
224086622|NCT01303055|DRUG|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
224086623|NCT01647737|DIETARY_SUPPLEMENT|MighTeaFlow|4-6 times daily
224086624|NCT01647737|DIETARY_SUPPLEMENT|Xylitol|4-6 times daily
224086625|NCT01618760|DRUG|Risperidone Tablet 1 mg|1 mg tablet once a day
224086626|NCT01618760|DRUG|Risperidone|1 mg tablet once a day
224086627|NCT03681444|OTHER|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
224086628|NCT03681444|OTHER|Clear fluid diet|"Patients will be provided with~* Plain water~* Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~* Soup broth (bouillon or consommé)~* Clear sodas, such as ginger ale and Sprite~* Gelatin (Jell-O)~* Tea or coffee with no cream or milk added~* Sports drinks that don't have color"
224086629|NCT03681444|OTHER|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
224086630|NCT03681444|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
224086631|NCT02153502|DRUG|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
223912333|NCT06813560|DIAGNOSTIC_TEST|Neonatal Behavioural Assessment (NBAS)|is an assessment technique that provides a profile of scores that allows us to detect a possible alteration or pathology, but at the same time, within normal parameters, to detect both the potential or 'strong points' and the problems or 'weak points' of the newborn, as well as their peculiar ways of acting and reacting to environmental variables. Therefore, a profile of the child's behavioural characteristics is obtained, which can be considered as a first outline of the child's temperamental traits. It evaluates the behavioural repertoire of the newborn in 28 behavioural items that are assessed according to a 9-point scale. The scale also includes an assessment of neurological status in 18 reflex items, each with a 4-point rating. In the second edition of the NBAS a series of 7 supplementary items were added with the intention of better capturing the degree of fragility and the quality of behaviour of high-risk children.
223912334|NCT06813560|DIAGNOSTIC_TEST|Galvanic Response|Galvanic Response: has the function of measuring the galvanic response of the skin, also known as electrodermal activity (EDA). It is used to record the electrical behaviour of the skin, which varies according to the activity of the sweat glands. This measurement of electrodermal activity is essential for studying the activity of the autonomic nervous system, which controls involuntary body functions such as sweating and heart rate. It will be measured with the BIOPAC MP36R device.
223912335|NCT06813560|DIAGNOSTIC_TEST|electrocardiography (ECG)|"ECG is used as a monitoring target for various cardiovascular conditions. It will be measured with the BIOPAC MP36R device.~P, Q, R, S, T, U waves; QRS complex, PR interval and QT interval and PR segment and ST segment."
224086632|NCT02153502|DRUG|Placebo|Placebo capsules administered twice a day over a 10-week period
224086633|NCT04187235|PROCEDURE|Laparascopic repair of parastomal hernia|Laparascopic repair of parastomal hernia
224086634|NCT01897480|BIOLOGICAL|LY2875358|Administered IV
224086635|NCT01897480|DRUG|Erlotinib|Administered Orally
224086636|NCT02658812|OTHER|Laboratory Biomarker Analysis|Correlative studies
224086637|NCT02658812|BIOLOGICAL|Talimogene Laherparepvec|Given IT
224086638|NCT02758158|DEVICE|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
224086639|NCT00217165|DRUG|taurine|taurine 2mg BID po
224086640|NCT01966549|DRUG|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
224086641|NCT01966549|DRUG|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
224086642|NCT00002162|DRUG|Saquinavir|
224086643|NCT00002162|DRUG|Lamivudine|
224086644|NCT00002162|DRUG|Stavudine|
224086645|NCT00002162|DRUG|Zidovudine|
224086646|NCT00002162|DRUG|Zalcitabine|
224086647|NCT00002162|DRUG|Didanosine|
224086648|NCT03190408|OTHER|Fluids|Fluids Administered in Shock
224086649|NCT02411747|BEHAVIORAL|Testing|
224086650|NCT02411747|BEHAVIORAL|Directed self-regulated simulation training|
224086651|NCT02363075|DRUG|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
224086652|NCT02363075|DRUG|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
224086653|NCT02104284|PROCEDURE|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
224086654|NCT01896960|DRUG|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
224086655|NCT00622895|DRUG|fludarabine phosphate|Given IV
224086656|NCT00622895|DRUG|Mycophenolic Acid|Given PO
224086657|NCT00622895|DRUG|tacrolimus|Given PO
224086658|NCT00622895|RADIATION|total-body irradiation|Undergo TBI
224086659|NCT00622895|PROCEDURE|bone marrow transplantation|Undergo transplantation
224086660|NCT00622895|PROCEDURE|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
224086661|NCT00622895|PROCEDURE|quality-of-life assessment|Ancillary studies
224086662|NCT00622895|OTHER|laboratory biomarker analysis|Correlative studies
224086663|NCT00622895|OTHER|flow cytometry|Correlative studies
224086664|NCT00622895|PROCEDURE|biopsy|Punch biopsy of skin involved with scleroderma
224086665|NCT02381379|DRUG|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
223912336|NCT06813560|DIAGNOSTIC_TEST|Breathing respiratory rate|The transducer is attached to a strap that is placed around the subject's chest, allowing chest movements to be detected during breathing. The strap ensures a secure and comfortable fit for the subject during the measurement process. This transducer is used in conjunction with other BIOPAC components to assess physiological responses. The data obtained from the transducer provides information on respiratory patterns and their relationship to other physiological measures. It will be measured with the BIOPAC MP36R device.
224086666|NCT01740180|OTHER|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF."
224086667|NCT05004545|DRUG|Propofol|Propofol infusion according to body weight will be compared with sevoflurane acording to MAC % to see the lactate level and hemodynamic parameters of CABG patients
224086668|NCT00560755|BIOLOGICAL|ProQuad®|ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
224086669|NCT00848120|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
224086670|NCT02344225|DRUG|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
224086671|NCT02344225|DRUG|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
224086672|NCT02344225|DRUG|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
224086673|NCT05809141|DIAGNOSTIC_TEST|thromboelastography|Thromboelastography (TEG), a whole blood viscoelastic test. TEG detects the clotting time, clotting kinetics and clot stability to more comprehensively evaluate haemostatic status by several parameters, mainly including reactive time (R), kinetic time (K), angle (α), maximum amplitude (MA) and lysis-30 .
224086674|NCT01515033|OTHER|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
224086675|NCT01428466|DRUG|GSK2585823|CLDM1%/BPO3%
224086676|NCT01428466|DRUG|Benzoyl peroxide 3%|Benzoyl peroxide 3%
224086677|NCT01428466|DRUG|Benzoyl peroxide 5%|Benzoyl peroxide 5%
224086678|NCT01428466|OTHER|Vehicle|placebo
224086679|NCT02116621|BEHAVIORAL|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
224086680|NCT02116621|DEVICE|smartphone|
224086681|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
224086682|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
224086683|NCT01455103|BIOLOGICAL|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
224086684|NCT00708370|OTHER|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
224086685|NCT00708370|OTHER|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
224086686|NCT02972320|DRUG|temozolomide|temozolomide maintain therapeutic
224086687|NCT03056105|OTHER|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence-refraining from eye contact as well as verbal and written communication-except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
223912337|NCT06813729|BIOLOGICAL|Shotblocker|The infant was first placed on the examination table. To calm the infant, the mother was asked to hold the infants' hands and talk to him/her. Before the injection, while one nurse held the infants' leg for the injection, Shotblocker® was applied to the skin by the experienced nurse ensuring that the points were in direct contact. Then, the nurse administered the pneumococcal conjugate vaccine (0.5 ml, IM, Vastus Lateralis Site) through the central hole. After each use, the Shotblocker® was disinfected with 70% alcohol before being used on another infant.
224086688|NCT00005724|BEHAVIORAL|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
224086689|NCT00005724|OTHER|Minimal Intervention Group|Dietary Information pamphlets.
224086690|NCT00005724|BEHAVIORAL|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
224086691|NCT05996484|DRUG|Toripalimab|Toripalimab, 240mg, IV., D1, every 3 weeks, 4 cycles.
224086692|NCT05996484|DRUG|Anlotinib hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off, every 3 weeks, 4 cycles.
224086693|NCT05996484|DRUG|Albumin paclitaxel|Albumin paclitaxel, 200-260 mg/m2, IV., D1, every 3 weeks, 4 cycles.
224086694|NCT05996484|DRUG|Cisplatin|Cisplatin, 60-75 mg/m2, IV., D1, every 3 weeks, 4 cycles.
224086695|NCT01983644|DEVICE|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
224086696|NCT01983644|DEVICE|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
224086697|NCT02312973|DRUG|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
224086698|NCT02312973|DRUG|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
224086699|NCT05986942|DRUG|Fentanyl|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
224086700|NCT05986942|DRUG|Dexmedetomidine|In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
223912338|NCT06813729|BIOLOGICAL|Manuel Pressure|The infant was first placed on the examination table. To calm the infant, the mother was asked to hold the infants' hands and talk to him/her. Next, while one nurse held the infants' leg for the injection, 10-second manual pressure was applied on the vaccine injection site by the experienced nurse. Then pneumococcal conjugate vaccine was administered in accordance with the standard injection technique (0.5 ml, IM, Vastus Lateralis Site).
223912339|NCT04466683|RADIATION|Low dose radiation 35 cGy|A dose of 35 cGy of whole thorax irradiation will be delivered at a single timepoint
223912340|NCT04466683|RADIATION|High dose radiation 100 cGy|A dose of 100 cGy of whole thorax irradiation will be delivered at a single timepoint
224086701|NCT03132584|DRUG|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~\- Via IV Day 3"
224086702|NCT03132584|DRUG|Alemtuzumab|"* The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~* Alemtuzumab will be administered as follows:~  * IV Day 1~ * IV Day 2~ * Target dose IV on Day 3 and 4"
224086703|NCT04159883|OTHER|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
224086704|NCT04159883|OTHER|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist's account."
224086705|NCT04086732|PROCEDURE|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
224086706|NCT00961961|DRUG|Lithium / Fluoxetine|Individualized Daily Dosage
224086707|NCT00961961|DRUG|Lithium / Placebo|Individualized Daily Dosage
224086708|NCT03844867|DIETARY_SUPPLEMENT|Filippo Cea and Carmel|"Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds)."
224086709|NCT02452502|DEVICE|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
224086710|NCT00862095|DRUG|Placebo|Every month for 3 months
224086711|NCT00862095|DRUG|Propranolol|target does 80 mg per day for 3 months
224086712|NCT00862095|DRUG|Amitriptyline|Target does of 50 mg per day for 3 months
224086713|NCT00862095|DRUG|Topiramate|Target dose 100 mg a day for 3 months
224086714|NCT01412957|OTHER|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
223912341|NCT06841276|DEVICE|QoLibri Digital Therapy|A personalized program intended for chronic pain patients. It includes digitalized physical and psychological complementary approaches dedicated to symptoms management and quality of life improvement.
223912342|NCT06814704|OTHER|Hypopressive exercises , hot packs, acetaminophen, progressive strengthening exercises|20 subjects combined HE with traditional treatments for low back pain (heat therapy, medication, and progressive strength training).
223912343|NCT06814704|OTHER|heat therapy, pharmacological therapy, progressive strengthening exercises|"Hypopressive exercises :The women were instructed to hold breath with chest extension for approximately 10 seconds before they began to breathe again. Then, using a series of upper and lower limb positions, the subjects were shown how to apply a series of hypopressive postures"
223912344|NCT06814067|DRUG|Pembrolizumab|Two cycles of neoadjuvant pembrolizumab (200mg q3w) followed by radical surgery. Adjuvant radiotherapy/chemoradiotherapy is decided based on pathological risk factors. Fifteen cycles of pembrolizumab (200mg q3w)maintenance therapy was given.
223912345|NCT06814067|DRUG|Ivonescimab|Two cycles of neoadjuvant Ivonescimab (10mg/kg q3w) followed by radical surgery. Adjuvant radiotherapy/chemoradiotherapy is decided based on pathological risk factors. Fifteen cycles of Ivonescimab maintenance therapy (10mg/kg q3w) was given.
223912346|NCT06814067|PROCEDURE|Surgery|Radical surgery
223912347|NCT06814067|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy with/without concurrent cisplatin-based chemotherapy, based on pathologic risk factors.
223912348|NCT06842329|BEHAVIORAL|Halfer Skin Tape Technique|Helfer Skin Tap Technique (HSTT) is a non-pharmacological pain management method that involves a series of gentle taps on the skin prior to an intramuscular injection. This technique is intended to distract the patient from the pain of the injection and reduce perceived pain intensity by stimulating different sensory pathways.
223912349|NCT06842329|BEHAVIORAL|ShotBlocker Technique|ShotBlocker is a non-pharmacological device that applies pressure to the skin at the injection site to disrupt pain signals and reduce the pain perception during intramuscular injections. The pressure stimulates the sensory nerve fibers, which helps block the sharp pain from the needle insertion.
223912350|NCT06842329|OTHER|Standard Intramusculer injection|The control group will receive a standard intramuscular injection without the use of any pain management techniques (such as HSTT or ShotBlocker). This group serves as a baseline to compare the effect
223912351|NCT06814418|PROCEDURE|Non-surgical periodontal treatment|Step I and II of periodontal treatment.
223912352|NCT06814418|PROCEDURE|Injectable Platelet Rich Fibrin (I-PRF)|Infusion of I-PRF in sited with PPD≥5mm.
223912353|NCT06812338|DEVICE|mechanical traction|Participants will receive traction therapy as follows: force will start at 25% of Body weight, gradually increasing until the tolerance for pulling is reached with maximum of 50% of body weight. The session will be 15 minutes long (1min for acceleration, 13 min application, 1min deceleration); it will be intermittent with ratio of 30 s on and 10s off
223912354|NCT06841796|DEVICE|Real time continuous glucose monitor (Stelo)|Real time CGM will be worn continuously for 24 weeks. Participants will be able to see the glucose data from the CGM facilitating changes in nutritional habits and physical activity
223912355|NCT06807034|OTHER|buccal swabs|buccal swabs for microbiota analysis before and after radiotherapy
223912356|NCT06807528|BEHAVIORAL|Intermittent fasting|Participants will follow a 16:8 protocol whereby they will be asked to fast for 16 hours per day and allowed to eat ad-libitum for the remaining 8 hours. While (for feasibility purposes) it will be a requirement that the fasting period include time spent asleep, participants will be allowed some degree of flexibility in the start and end time of their fasting period. This will be performed in order to accommodate participant preferences (sleeping/eating/medication schedules) as best as possible and provide a sense of autonomy. During the non-fasting hours, participants will be permitted to eat ad libitum.
223912357|NCT06807528|BEHAVIORAL|Behavioral Support Strategies|Evidence-based self regulatory health behaviour support techniques including education, ongoing tailored feedback and encouragement, self monitoring tools, and goal setting will be used to help participants adhere to the fasting protocol. These techniques will be implemented via weekly phone calls to allow for coaching (e.g. barrier identification, strategies/action planning to overcome barriers, goal setting) as well as a smartphone app. The smartphone application will provide information pertaining to intermittent fasting including lay summaries of clinical trials as well as infographics related to healthy eating for the ad-libitum eating periods. Tips for healthy eating on a budget and adhering to an intermittent fasting protocol will also be provided. The smartphone app will also feature intermittent fasting start and stop time reminders, hydration reminders, and the ability to set one's individualized fasting schedule and record actual daily fasting windows.
223912358|NCT03309644|OTHER|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
223912359|NCT03309644|OTHER|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
223912360|NCT03434769|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
223912361|NCT03434769|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
223912362|NCT03434769|BIOLOGICAL|CAR-T Cells|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0~Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
223912363|NCT06816082|BEHAVIORAL|Internet delivered acceptance and commitment therapy|7 week long treatment with therapist asynchronous support in mainly text format. Treatment includes for example mindfulness, psychoeducation, values, and self-compassion
223912364|NCT06818240|DEVICE|Active transcranial direct current stimulation|In the active tDCS session, real stimulation was delivered via a current stimulator (DC-STIMULATOR MC, NeuroConn, Germany) using saline-soaked 4×6 cm² electrodes. The anode was positioned over the left-DLPFC identified as F3 according to the 10-20 international EEG system, and the cathode over the right supraorbital ridge.
223912365|NCT06818240|DEVICE|Sham transcranial direct current stimulation|In the Sham tDCS session, Sham stimulation was delivered via a current stimulator (DC-STIMULATOR MC, NeuroConn, Germany) using saline-soaked 4×6 cm² electrodes. The anode was positioned over the left-DLPFC identified as F3 according to the 10-20 international EEG system, and the cathode over the right supraorbital ridge.
223912366|NCT06818617|PROCEDURE|Epidural steroid injection (ESI)|epidural nerve block procedures for patients with spinal conditions such as stenosis or disc herniation
223912367|NCT06819514|DRUG|EXG110 Injection|EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity.
223912368|NCT06816381|DEVICE|Shear wave elastography measurements|Shear wave elastography measurements in kilopascals via ultrasound
223912369|NCT06820645|DRUG|calcium gluconate|3g IV or IO calcium gluconate.
223912370|NCT06820645|DRUG|Control: Placebo|3g of IV or IO saline placebo.
223912371|NCT04669288|DRUG|Azithromycin|"oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging."
223912372|NCT04669288|DRUG|Placebo|"oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging."
224086715|NCT01412957|DRUG|Panitumumab|Administered intravenously
224086716|NCT05011591|OTHER|Swimming economy|Detailed in arm's section
224086717|NCT02965157|BIOLOGICAL|CART20|
224086718|NCT01105390|BIOLOGICAL|rilotumumab|Given IV
224086719|NCT01105390|DRUG|cisplatin|Given IV
224086720|NCT01105390|DRUG|pemetrexed disodium|Given IV
224086721|NCT01105390|OTHER|laboratory biomarker analysis|Correlative studies
224086722|NCT04114305|BEHAVIORAL|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family \& Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
224086723|NCT01784796|BEHAVIORAL|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
224086724|NCT01784796|BEHAVIORAL|Health Education Program|8 week Health Education Program
224086725|NCT01129193|OTHER|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
223912373|NCT06648928|BEHAVIORAL|Clinician Supported PTSD Coach|Combines self-managed PTSD Coach application with four 20-30 minute sessions delivered by a clinician. The app includes modules on learning about PTSD, self-assessment, symptom management, and finding support.
223912374|NCT06648928|BEHAVIORAL|Self Managed PTSD Coach|A widely available mobile application designed to help individuals manage PTSD symptoms available in English and Spanish.
223912375|NCT06857799|PROCEDURE|Light Power Density and Light Duration 40 mW/cm²*1000s|Use light power density and light duration 40 mW/cm²\*1000s treatment
223912376|NCT06857799|PROCEDURE|Light Power Density and Light Duration 80 mW/cm²*1000s|Use light power density and light duration 80 mW/cm²\*1000s treatment
223912377|NCT06855472|OTHER|The MAR method|"The study was conducted in three isolated stations. Two faculty researchers designed the scenarios, while three others supervised training. Medical student investigators recorded blood loss estimates and estimation times.~Before the study, investigators received 20-minute training. Participants and investigators were blinded to actual blood volumes. Group 1 and Group 2 attended a 10-minute briefing, including consent and study introduction.~The study had two phases. In Phase 1, Group 1 used the Visual Estimation (VE) method, while Group 2 received a 2-minute MAR method training before making estimations. In Phase 2, Group 1 was trained in the MAR method and repeated estimations.A data form recorded demographics, blood loss estimates, and estimation times.~Group 1's VE data and Group 2's MAR data were compared between groups, while Group 1's VE and MAR data were analyzed within the group. Combined MAR data from both groups were used to assess the impact of gender, height, and weight."
224086726|NCT01129193|OTHER|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
223529561|NCT03746015|BIOLOGICAL|TDV|TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
223912378|NCT06856538|DRUG|Bupivacain|After the location will be confirmed through hydrodissection of 1 ml on the plane between the rhomboid major and the underlying intercostal muscles after confirming a negative aspiration via a a 22-gauge short bevel sonovisible needle (Spinocan, B. Braun Melsungen AG, Germany) using an in-plane technique then 10 ml of bupivacaine (concentration 0.25%) will be injected. and its spread will be manifested by the hydrodissection and widening of the plane visualized by ultrasound.
223912379|NCT06856538|DEVICE|Ultrasound|A linear US transducer (Phillips-Saronno Italy) was placed vertically 3 cm lateral to the midline to visualize back muscles: the trapezius above, the rhomboid major in the middle, and the erector-spinae muscle on the bottom, as well as the TPs with shimmering pleura in between.
224086727|NCT01129193|OTHER|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
224086728|NCT01129193|DRUG|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
224086729|NCT03885778|DRUG|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
224086730|NCT03120832|BIOLOGICAL|PAN-301-1|
224086731|NCT05939037|DRUG|Zanubrutinib Oral Product|Treatment will consist of Rituximab administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22 only (4 total infusions). The experimental part of the treatment will consist of Zanubrutinib, given once daily 320 mg (4 x 80 mg capsules). Although Zanubrutinib is taken continuously, therapy cycles are calculated per 28 days. Participants will be treated for a minimum of 6 cycles per protocol. Participants who still use Zanubrutinib at the end of study can continue indefinitely until registration and reimbursement in the Netherlands.
223529562|NCT05664191|DRUG|Levosimendan|Infusion at 0.1 µg/kg/min at day 1 and day 8
223529563|NCT05664191|OTHER|Placebo|Glucose 5%, solution for injection ECOFLAC at day 1 and day 8
223535234|NCT06698640|BEHAVIORAL|Automated SMS|Participants will receive automated SMS messages reminding them of their Well-Child Visits. These messages will be standardized and sent at intervals designed to prompt appointment attendance.
224086732|NCT04736654|OTHER|Survey study|Headache Disability Questionnaire (HDQ) will be applied.
223912380|NCT06857812|OTHER|there is no intervention|there is no intervention
223912381|NCT06856200|DRUG|Sirolimus (albumin - bound)|Sirolimus (albumin - bound): Dose escalation, intravenous infusion
224086733|NCT06584916|DRUG|Orforglipron|Administered orally
223912382|NCT06856200|DRUG|Palbociclib|Palbociclib: the dosage is 125 mg, orally once a day. taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
223912383|NCT06856200|DRUG|Fulvestrant|Fulvestrant: the dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
223940029|NCT07197398|OTHER|Sub-group analysis|Relation of pregnancy - related, maternal and neonatal data to the level of sensory blockade in the sub-groups of different height (\<165cm and \>165cm) will also be performed.
223940030|NCT07197788|DEVICE|Endogenex System|The Endogenex System procedure utilizes a catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum.
223940034|NCT07195864|DRUG|PHMB 0.08%|The study population for this study is patients diagnosed with AK treated with 0.8 mg/ml polihexanide as part of the Spanish Medicines in Special Situations program.
223940035|NCT07197879|DEVICE|Dynamic office chair (saddle chair with standard pendulum mechanism)|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
223940036|NCT07197879|DEVICE|Dynamic Office Chair (office swivel chair with integrated newly developed pendulum mechanism)|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
223940037|NCT07196566|PROCEDURE|Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft|Closure was performed using split-thickness buccal and palatal mucosal flaps with a subepithelial palatal connective tissue graft rotated to cove the bony defect and sutured to the buccal periosteum as the first layer, then the buccal mucosa sutured with the palatal one . Clinical evaluations were conducted at regular intervals over a 3-month postoperative period, assessing wound healing, fistula recurrence, pain, facial edema, infection, and donor site morbidity.
223940038|NCT07197515|BEHAVIORAL|Legal Navigation|• Participants will receive monthly outreach from a trained legal navigator over a 6-month period. The legal navigator is a lawyer (Juris Doctor, or JD) who will proactively address specific legal barriers the patient may encounter during treatment. Communication will include phone calls (and if requested, virtual consultations) tailored to patient needs. In between legal outreach periods, patients may call the legal navigator team themselves for legal needs that may arise.
223940039|NCT07195773|DEVICE|rTMS|investigate the effects of repetitive transcranial magnetic stimulation on corticomotor excitability, balance performance, and mobility in patients with Parkinson's disease, and to further explore the effects on corticomotor excitability by single low-frequency and high-frequency repetitive transcranial magnetic stimulation. Participants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, corticomotor excitability, balance, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited.
223940040|NCT06381180|DRUG|Tetrahydrocannabinol|Plant cannabis that will be smoked
223940041|NCT06381180|DRUG|Cannabidiol|Plant cannabidiol that will be smoked
223940042|NCT06381180|DRUG|Placebo|Plant will be smoked.
223940043|NCT03298243|BEHAVIORAL|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
223940044|NCT06121492|DRUG|Branched-chain amino acid|In the BCAA group, participants will receive oral BCAA for 24 weeks, with a daily dosage of approximately 13.68 g/day. Each sachet of BCAA will contain 6.84 g of BCAA (valine 1.82 g, leucine 3.29 g, isoleucine 1.72 g), total protein 17.08 g, carbohydrates 25.48 g, fat 5.66 g, providing 221.2 kcal of energy. Each sachet weighs 52 g and should be mixed with 150 ml of water. Participants will consume 2 sachets daily, one after breakfast and one after dinner.
223940045|NCT06121492|DRUG|Placebo|In the placebo group, BCAA will be replaced with maltodextrin. Each sachet of the placebo will contain a total of 5.93 g of protein, 35.87 g of carbohydrates, 6.00 g of fat, providing 221.2 kcal of energy. Like the BCAA sachets, each placebo sachet will weigh 52 g and should be mixed with 150 ml of water. Participants in the placebo group will consume 2 sachets daily, one after breakfast and one after dinner.
223940046|NCT05778071|COMBINATION_PRODUCT|eneboparatide|Supplied as a solution (concentration of 250 mcg/mL or 500 mcg/mL) in single-patient-use prefilled pens
223940047|NCT05778071|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution (containing the excipient solution for eneboparatide) in single-patient-use prefilled pens
224086734|NCT06584916|DRUG|Placebo|Administered orally
224086735|NCT04722991|DRUG|Runcaciguat (BAY1101042)|Oral dose of runcaciguat
224086736|NCT04722991|OTHER|Placebo|Oral dose of matching placebo
224086737|NCT02084277|DEVICE|Self-ligating brackets (SLB)|
224086738|NCT02084277|DEVICE|Conventional brackets (CB)|
224086739|NCT03063580|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
224086740|NCT03063580|DRUG|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
224086741|NCT05583942|DEVICE|trascutaneous auricular vagus nerve stimulation|The device to be used is the Roscoe Medical TENS 7000, a commercially available handheld electrical pulse generator, and an ear clip to be placed at the left ear for stimulation. Custom-made ear clips with electrode gel will be placed near the entrance to the canal of the ear to provide stimulation to the auricular branch. The handheld electrical pulse generator will be programmed to deliver electrical stimulation pulses to the cymba concha stimulating the auricular branch of the vagus nerve.
224086742|NCT05583942|DEVICE|Sham device|The device will appear to function but no electrical stimulation will be delivered.
224086743|NCT01889849|DRUG|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
224086744|NCT01889849|DRUG|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
224086745|NCT06538701|PROCEDURE|Anterolateral advancement pharyngoplasty|Starting with bilateral tonsillectomy, The palatopharyngeal muscle (PPM) raised and advanced to be fixed to the pterygomandibular raphe, The posterior part of the PPM, together with its attached mucosa, was then advanced superolaterally behind the palatoglossus muscle to be hooked up to the levator veli palatini muscle
223912384|NCT06856928|OTHER|Meal Challenge|The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.
224086746|NCT01163071|DRUG|ABI-011|ABI-011
224086747|NCT00003400|BIOLOGICAL|filgrastim|
224086748|NCT00003400|DRUG|carmustine|
224086749|NCT00003400|DRUG|cisplatin|
224086750|NCT00003400|DRUG|melphalan|
224086751|NCT00003400|DRUG|vinorelbine tartrate|
224086752|NCT00003400|PROCEDURE|peripheral blood stem cell transplantation|
224086753|NCT00413959|DRUG|VELCADE®|1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
224086754|NCT00413959|DRUG|Rituximab|375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
224086755|NCT00413959|DRUG|Cyclophosphamide|400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
224086756|NCT00413959|DRUG|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
224086757|NCT01113970|DRUG|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
224086758|NCT05065398|DRUG|HLX208|450mg bid, take orally
224086759|NCT03057795|DRUG|Brentuximab Vedotin|Given IV
224086760|NCT03057795|OTHER|Laboratory Biomarker Analysis|Correlative studies
224086761|NCT03057795|BIOLOGICAL|Nivolumab|Given IV
224086762|NCT01648231|DRUG|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
224086763|NCT01648231|DRUG|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
224086764|NCT01648231|DRUG|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
224086765|NCT05105178|OTHER|Giving orientation with headphones|During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
224086766|NCT05105178|OTHER|Emergence as usual with headphones|During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
224086767|NCT01531842|PROCEDURE|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
224086768|NCT01370460|DRUG|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
224086769|NCT01370460|DRUG|Placebo|100mL 0.9% sterile saline
224086770|NCT00002744|DRUG|asparaginase|
224086771|NCT00002744|DRUG|cyclophosphamide|
224086772|NCT00002744|DRUG|cytarabine|
224086773|NCT00002744|DRUG|daunorubicin hydrochloride|
224086774|NCT00002744|DRUG|dexamethasone|
224086775|NCT00002744|DRUG|doxorubicin hydrochloride|
224086776|NCT00002744|DRUG|mercaptopurine|
224086777|NCT00002744|DRUG|methotrexate|
224086778|NCT00002744|DRUG|pegaspargase|
224086779|NCT00002744|DRUG|prednisone|
224086780|NCT00002744|DRUG|therapeutic hydrocortisone|
224086781|NCT00002744|DRUG|thioguanine|
224086782|NCT00002744|DRUG|vincristine sulfate|
224086783|NCT00002744|RADIATION|low-LET cobalt-60 gamma ray therapy|
224086784|NCT00002744|RADIATION|low-LET photon therapy|
224086785|NCT04523532|OTHER|Dietary folate and hazelnut oil|Intervention with folate-rich diet and hazelnut oil supplement in capsule
224086786|NCT02576314|DRUG|sofosbuvir and daclatasvir|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
224086787|NCT02576314|DRUG|ledipasvir/sofosbuvir|"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;"
224086788|NCT05902000|DEVICE|Carotid Stenting|Emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first) the extracranial carotid artery lesion will be left to the interventionist discretion.
223912385|NCT06661304|OTHER|Benson Relaxation Exercise|Benson relaxation exercise is based on the patient relaxing their body muscles by focusing on deep breathing and a word that means something to them.
223912386|NCT06661304|OTHER|Ongoing treatment|In addition to their medical treatment and care in the clinics, patients participate in activities such as group activities, leisure time and walking.
223912387|NCT06660719|DRUG|SP-8203|SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)
223912388|NCT06660719|DRUG|Placebo|Placebo will be intravenously administered twice daily (intervals of 12 hours)
223912389|NCT04710355|DEVICE|Spinal cord stimulation|Adhesion of Intellis spinal cord stimulator to the skin of the abdomen for 4 weeks for baseline recording of activity level prior to trial with spinal cord stimulation.
223912390|NCT04472195|OTHER|Simulation Airway Coaching|Airway coaching on laryngoscopy technique for intubation of neonates/infants within 1 hour of case utilizing RCDP simulation technique.
223912391|NCT02636517|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
223912392|NCT04805307|DRUG|CMG901|CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until confirmed Progressive Disease(PD), unacceptable toxicity, initiation of new anti-tumor therapy, withdrawal from the study, or death, whichever occurs first.
223912393|NCT02245867|DRUG|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
223912394|NCT06825052|BEHAVIORAL|Resistance Training with Deloading Periods|Participants performed an 8-week unilateral resistance training program in which training volume and intensity were reduced during weeks 4 and 8 to facilitate recovery and adaptation.
223912395|NCT06825052|BEHAVIORAL|Continuous Resistance Training|Participants followed an 8-week unilateral resistance training program without any deloading periods. Training volume and intensity remained consistent throughout the study.
223912396|NCT05080283|DEVICE|CP1110 Sound Processor System with automated ForwardFocus On (SCAN 2 FF)|Sound Processor
224086789|NCT05902000|PROCEDURE|Thrombectomy|Intracranial thrombectomy is an endovascular procedure. In the experimental group, thrombectomy will be completed with extracranial carotid stenting.
223912397|NCT05080283|DEVICE|Nucleus 7 Sound Processor (model: CP1000) system|Sound Processor
223912398|NCT05080283|DEVICE|CP1110 Sound Processor System with ForwardFocus Off (SCAN 2)|Sound Processor
223912399|NCT03993392|DRUG|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
223912400|NCT03993392|DRUG|SUBLOCADE|300mg subcutaneous injection
224086790|NCT05902000|DRUG|Dual antiplatelet treatment|Dual antiplatelet therapy is administered after 24 hours of imaging follow-up excluding intracranial hemorrhagic complications. Aspirin Enteric-coated Tablets (Bay Aspirin) 100mg once a night+Clopidogrel Sulfate Tablets (Plavix) 75mg once daily. If there is no contraindication, maintain for more than 1 month, then adjust the dosing regimen according to the guidelines.
224086791|NCT05902000|DRUG|Intraoperative Drug Treatment|Tirofiban is used as an adjunct to endovascular therapy. The currently recommended dosing regimen is a combined intra-catheter arterial administration of a loading dose of 0.4 μg/(kg-min) for 30 min (total dose not to exceed 1 mg)， followed by intravenous pumping of 0.1μg/(kg-min) for 24-48h, and adjustment of dosing in conjunction with CT.
224277765|NCT03323450|BEHAVIORAL|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
223912401|NCT04143295|DRUG|Diiodothyropropionic acid (DITPA)|Drug Administration
223912402|NCT06588920|BEHAVIORAL|Cognitive function, gait, and electroencephalogram|Measurement of cognitive function, gait performance, and electroencephalogram
223912403|NCT06409442|OTHER|Standard Physiotherapy Program|Patients with Subacromial Impingement Syndrome (SIS) will receive a 6-week treatment program. Patients will be given a physiotherapy treatment program by a physiotherapist three times a week, and on the other days, patients will practice six selected simple exercises at home.
223912404|NCT06409442|OTHER|Kinesio Taping|In addition to the standard physiotherapy program, kinesio taping (device) will be applied.
223912405|NCT06409442|OTHER|Local Vibration Therapy|In addition to the standard physiotherapy program, local vibration (device) will be applied.
223912406|NCT06841705|DRUG|Vedolizumab 300 MG Injection [Entyvio]|This is a biologic medication to treat colitis
223912407|NCT06841705|DRUG|Prednisone (and methylprednisolone)|This is a steroid
223912408|NCT06841705|DRUG|Prednisone Taper|This is a tapering dose of prednisone
223912409|NCT06841705|OTHER|Placebo Prednisone Capsules|Placebo for Prednisone
223912410|NCT06841705|OTHER|Placebo Vedolizumab|Placebo for Vedolizumab
223912411|NCT06841705|OTHER|Sulfamethoxazole-Trimethoprim|Antibiotic if on \>21 days of steroids
224086792|NCT01508741|DIETARY_SUPPLEMENT|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
224086793|NCT01508741|DIETARY_SUPPLEMENT|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
224086794|NCT00963950|PROCEDURE|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
224086795|NCT00963950|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
224086796|NCT05927883|BEHAVIORAL|Indigenously Adapted Cognitive Behavioral Therapy|IACBTGA will be comprised of 8 weekly sessions. Cognitive and behavioral strategies will be provided in sessions
223912412|NCT06841705|DRUG|Placebo for Sulfamethoxazole-Trimethoprim|Placebo for antibiotic (Sulfamethoxazole-Trimethoprim) Antibiotic. Only if on \>21 days of prednisone/placebo
223912413|NCT05714579|PROCEDURE|Transcatheter Aortic Valve Implantation|"The TAVI procedure is performed transfemorally under local anesthesia most often, or more rarely under general anesthesia via the subclavian or transaortic route. Identification is carried out under fluoroscopy in the cardiac catheterization room. The crossing of the aortic valve allows the establishment of a guide at the bottom of the left ventricle. Aortic valve predilation can be performed. The tightness of the device is checked by an aortography. Sometimes, post-dilation of the implanted bioprosthesis proves necessary, particularly in the event of under-deployment or significant para-prosthetic leakage.~The duration of the intervention is approximately 1 hour."
223912414|NCT05643287|PROCEDURE|Periodontal treatment|Non-surgical periodontal treatment
224086797|NCT01893749|BEHAVIORAL|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
224086798|NCT06076629|OTHER|Low temperature (16#) group|The exposure group will be exposed to low temperature (16#) in a chamber for about 2 hours, resting during the whole periods.
224086799|NCT06076629|OTHER|Moderate temperature (22#) group|The exposure group will be exposed to thermoneutral temperature (22#) in a chamber for about 2 hours, resting during the whole periods.
224086800|NCT06021249|PROCEDURE|Traditional ventilation strategies|"1. Tidal volume：10ml/kg predicted body weight（PBW）；~2. 0 cm H2O positive end expiratory pressure（PEEP）；~3. negative pressure extubation"
224086801|NCT06021249|PROCEDURE|Traditional lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. Ventilator-controlled recruitment manoeuvre；~4. CPAP；~5. negative pressure extubation"
224086802|NCT06021249|PROCEDURE|Innovative lung-protective ventilation strategies|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；~3. positive pressure extubation；~4. postoperative breathing training"
224086803|NCT06021249|PROCEDURE|Lung-protective ventilation|"1. Tidal volume：6ml/kg PBW；~2. 5cmH2O PEEP；"
224086804|NCT06021249|PROCEDURE|negative pressure extubation|The suction tube is inserted into the endotracheal tube, continuous negative pressure suction, and at the same time that the balloon is completely deflated, the suction tube, dental pad and endotracheal intubation are pulled out at the same time, and then the patient is instructed to cough independently and remove sputum.
224086805|NCT06021249|PROCEDURE|positive pressure extubation|The adjustable pressure limiting（APL）was adjusted to 30cm H2O, and after the patient breathed spontaneously until the peak airway pressure reached 30cm H2O, and after maintaining this level for 10s, the balloon was quickly cut off to remove the endotracheal tube, so that the patient had an autonomous coughing action, and then the oral sputum was removed.
224086806|NCT06021249|PROCEDURE|postoperative breathing training|Inhale deeply through the nose, hold the breath for 5s, and then slowly spit out the breath through the mouth, cycle 5-6 times, and inflate the balloon. The above steps need to be performed 15 times within 24 hours after surgery.
224086807|NCT04343651|DRUG|Placebo|Placebo
224277766|NCT04677686|BEHAVIORAL|Bundle of Care|Hair removal with Clipper Glucose Control Preoperative antibiotics Repeat antibiotics after 4 Hours Optimize Body temperature Instrument change for colorectal anastomosis Use of wound protectors Experienced surgeon Preoperative showering
224277767|NCT00105040|DRUG|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
224277768|NCT00105040|OTHER|Placebo (PB)|Oral tablets and oral solution
223716219|NCT04664712|DEVICE|Focused shock wave|We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
223912415|NCT04646395|DRUG|Tafasitamab|200 mg powder for reconstitution with 5 ml water for injection
223912416|NCT04646395|DRUG|Acalabrutinib|100 mg hard gelatin capsules
224277769|NCT03605992|OTHER|Home-based Rehab|This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).
223912417|NCT04758533|BIOLOGICAL|AloCELYVIR|Mesenchymal allogenic cells + ICOVIR-5: 500.000 cells/kg
224086808|NCT04343651|DRUG|Leronlimab (700mg)|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
224086809|NCT02987855|PROCEDURE|Lipoaspiration|Closed syringe harvesting subdermal fat
224086810|NCT02987855|PROCEDURE|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
224086811|NCT02987855|PROCEDURE|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
224277770|NCT03605992|OTHER|CentreRehab|This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
223912418|NCT03794011|DEVICE|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
223912419|NCT06856434|DIETARY_SUPPLEMENT|Lactobacillus plantarum sp Probiotic|Once daily consumption
224086812|NCT04928534|DIAGNOSTIC_TEST|Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination|"1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.~2. Cognitive function tests, including RPQ, MMSE and MoCA.~3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination"
224086813|NCT05906420|DIAGNOSTIC_TEST|ASTRAL prognostic score|ASTRAL prognostic score
224086814|NCT05886725|OTHER|Patients using Step Test Application and Accelerometer|Patients who are scheduled to have surgery at University of Chicago Medical Center (UCMC) who agree to use the step test application and study accelerometer before and after their surgery.
224086815|NCT05917288|BIOLOGICAL|Belimumab|Belimumab will be administered
224086816|NCT05917288|DRUG|Standard of care|Standard of care will be administered
224086817|NCT02246621|DRUG|Abemaciclib|Administered orally
224086818|NCT02246621|DRUG|Anastrozole|Administered orally
224086819|NCT02246621|DRUG|Letrozole|Administered orally
224086820|NCT02246621|DRUG|Placebo|Administered orally
224086821|NCT05585242|BEHAVIORAL|Infertility ACTion Program|Seven 15-minutes videos of Acceptance and commitment therapy adapted for women with infertility with assigned homework and summaries of the videos.
224086822|NCT04849871|RADIATION|External Beam Accelerated Partial Breast Irradiation|APBI simulation must take place no more than 8 weeks from final definitive breast surgery.
223912420|NCT06856434|OTHER|Placebo Group|Group who received a placebo intervention
223912421|NCT06210009|OTHER|DASH-Style Diet|Participants will be randomized to a DASH-style diet
223912422|NCT06210009|OTHER|Western-Style Diet|Participants will be randomized to a Western-style diet
224086823|NCT05829512|OTHER|Validity and reliability study|Face-to-face questionnaire study
224086824|NCT03131817|DEVICE|Activa PC+S Prefrontal|
224086825|NCT02435355|BEHAVIORAL|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
224086826|NCT05308316|OTHER|Sucrose cigarettes|Winston brand cigarettes will be modified by adding a mixture of sucrose to each cigarette at 2 levels so that the amount of total (originally present and added) sugar content in these cigarettes matches median and highest levels found in popular brands analyzed
224086827|NCT03152682|DIETARY_SUPPLEMENT|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
224086828|NCT03152682|OTHER|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
224086829|NCT04186455|DEVICE|proseal|laryngeal mask proseal
224086830|NCT04186455|DEVICE|baska-mask|laryngeal mask baska-mask
224086831|NCT00287625|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation
224277771|NCT03208517|OTHER|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
224277772|NCT01590199|DRUG|RAD001|
223912423|NCT04817176|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|Experimental Arm: The program is a 6-week group, telehealth intervention for older adults with possible MCI. The intervention uses Motivational interviewing and cognitive behavioral therapy strategies to enhance motivation and help participants overcome personal obstacles to following health-behavior recommendations. Specifically, the program examines the use of a Mediterranean ketogenic type of nutrition to target mild cognitive impairment. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
223912424|NCT04817176|OTHER|Ketogenic Nutrition Program|Active Comparator Arm: 6-week group, telehealth intervention for older adults. The intervention is designed to disseminate practical information to help older adults learn how to incorporate healthy Mediterranean ketogenic nutrition into their lifestyle.
224086832|NCT01538238|DRUG|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
224086833|NCT03440593|OTHER|Caloric delivery will target results of IC measurement.|The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
224086834|NCT01459614|DRUG|Gemcitabine|IV on Days 4 and 11
224086835|NCT01459614|DRUG|Taxotere|IV on Days 4 and 11
224086836|NCT01459614|DRUG|Xeloda|orally, twice a day Days 1-14
224086837|NCT01459614|DRUG|Cisplatin|IV Days 4 and 11
224086838|NCT04451707|OTHER|non-cholera Vibrio infection|Epidemiology of patients diagnosed with non-cholera Vibrio infection
224086839|NCT06120530|DRUG|Bupivacaine|Intraperitoneal Bupivicaine without epinephrine 30 mg administered following completion of pelvic organ prolapse repair.
224086840|NCT06120530|OTHER|Saline|Placebo
224086841|NCT05074108|BEHAVIORAL|Pilot study|Aiming for an interaction 6 week course that will discuss many aspects of health and wellness.
224086842|NCT01111266|DEVICE|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
224086843|NCT00376467|DRUG|Imatinib|
224086844|NCT03962985|OTHER|Guided tour at the Montreal Museum of Fine Arts|"* The duration of the participation -3 months~* The duration of the guided tour-45 minutes, each week~* All participants will be asked to fill out some specific online questionnaires during their participations in the study"
224086845|NCT03036527|PROCEDURE|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
224277773|NCT01590199|DRUG|SOM230|
224277774|NCT04698551|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation involved in DPN requests from phasing of parental haplotypes by 3rd generation long-fragment DNA sequencing techniques coupled with targeted sequencing of free circulating DNA from maternal plasma.
223912425|NCT06657248|DEVICE|univation® XF Pro|Primary medial unicompartmental knee arthroplasty
223912426|NCT05100706|DRUG|Continuous adductor canal block (CACB)|Ropivacaine 0.2% infusion through adductor canal catheter
223912427|NCT05100706|DRUG|Sham continuous adductor canal block (ShACB).|NaCl 0.9% infusion through adductor canal catheter
223912428|NCT06586320|DRUG|150% of their routine home dopaminergic medications dose right in the clinic|IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.
223912429|NCT06586320|DEVICE|Evaluation of mathematical models|Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
224277775|NCT04703751|DEVICE|Transcoronary delivery of a pharmacological agent (nitroglycerin) and cell based agent (Cardiocell) using the CIRCULATE Catheter|Investigated device - the CIRCULATE Catheter will be introduced, using a standard radial or femoral access and a typical guiding catheter and typical coronary wire, first into the right coronary artery. After that the one dose of NTG (200µg) will be administered followed by a typical angiographic recording to visualize the vasodilatatory effect of the medication. Then CardioCell in doses of 10mln cells each (6.7mL) will be administered transcoronary to each of the coronary arteries (right coronary artery (RCA), LAD, left circumflex (Cx)). Angiography will be performed routinely before and after each product administration.
223912430|NCT06606262|PROCEDURE|Tonsillotomy|Bilateral partial removal of the palatine tonsils to a level between the pharyngeal pillars and the tonsillar capsule. Surgery will be performed under general anesthesia using monopolar electrocautery.
224086846|NCT03036527|PROCEDURE|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
224086847|NCT03036527|PROCEDURE|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
224086848|NCT03036527|PROCEDURE|Activity-based training + spinal epidural stimulation|combination effect of both locomotor training and/or stand training with epidural stimulation targeting locomotion and/or stand.
224086849|NCT06333873|OTHER|patient-reported outcome|Performance of real-life tests and tasks
224086850|NCT03791333|OTHER|injury severity score|injury severity score of multi trauma patients
224277776|NCT04937998|PROCEDURE|Autologous PRP injection|Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis
224277777|NCT04937998|PROCEDURE|HA injection|Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis
224277778|NCT02174276|DRUG|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
224277779|NCT02174276|BIOLOGICAL|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
224277780|NCT05973331|OTHER|Pancreatic Cancer Risk Model (PRISM)|A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
224086851|NCT02469571|DIETARY_SUPPLEMENT|Winclove 607|multispecies probiotic
224277781|NCT00277030|DRUG|Surfactant|
224277782|NCT00277030|DEVICE|Nasal CPAP|
224277783|NCT01643239|OTHER|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
224277784|NCT01643239|OTHER|Hospital-based mCIT|the mCIT group with individualized intervention
224277785|NCT01643239|OTHER|Hospital-based TR|OT or PT or therapist-based training
224277786|NCT00722839|BIOLOGICAL|PADRE-CMV fusion peptide vaccine|Given subcutaneously
224086852|NCT02469571|DIETARY_SUPPLEMENT|Placebo|Placebo
224086853|NCT01130987|OTHER|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
224086854|NCT01130987|BEHAVIORAL|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
224086855|NCT05352542|BIOLOGICAL|GPC3 Targeting CART Cells|before treatment with GPC3 Targeting CART cells, subjects will receive a conditioning regimen
223912431|NCT06606262|PROCEDURE|Tonsillectomy|"Bilateral extracapsular removal of palatine tonsils. Surgery will be performed under general anesthesia using cold knife dissection."
223912432|NCT06861738|DRUG|Paracetamol (acetaminophen)|oral paracetamol 500mg three times per day
223912433|NCT06861738|DRUG|Paracetamol Placebo|placebo tab three time per day
223912434|NCT06400719|BIOLOGICAL|AVT16|Single intravenous administration of 300mg of AVT16
223912435|NCT02396823|BEHAVIORAL|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
224086856|NCT03135405|BEHAVIORAL|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
224086857|NCT03135405|BEHAVIORAL|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
224086858|NCT03135405|BEHAVIORAL|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
224086859|NCT02761967|BEHAVIORAL|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
224086860|NCT04095767|DEVICE|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters \[DACs\]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
224086861|NCT06617754|BIOLOGICAL|Biologic drugs|Biologic drugs including Mepolizumab, Dupilumab, Omalizumab, Tezepelumab, or future monoclonal antibodies
224086862|NCT06214260|DIAGNOSTIC_TEST|Peripheral blood sample|Peripheral blood will be collected with a 10 ml Ethylenediaminetetra acetic acid (EDTA) tube before surgery during menstrual phase. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
224086863|NCT06214260|DIAGNOSTIC_TEST|Menstrual Blood sample|5ml menstrual blood will be collected before surgery by the women herself. Additionally, participants will be asked with an interview on demographic, surgical, medical, obstetric, gynecological, contraceptive and medication use history which is validated by Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project (WERF EPHect). Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).
224086864|NCT02108925|DRUG|Oxygen|supplementary oxygen during exercise
223912436|NCT06770686|OTHER|Intervention Group|"A nursing care bundle will be applied to patients in the intervention group. The implementation status of the nursing interventions included in the care bundle for each patient will be observed by the researcher and recorded on the Care Bundle Observer Form. Recording of the applications performed on the monitoring form will be encouraged."
224086865|NCT00004160|DRUG|cisplatin|
224086866|NCT00004160|DRUG|gemcitabine hydrochloride|
224086867|NCT00004160|DRUG|paclitaxel|
224086868|NCT00004160|RADIATION|radiation therapy|
223912437|NCT06770686|OTHER|Control Group|They will receive standard care
224086869|NCT03291561|PROCEDURE|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
224086870|NCT03291561|PROCEDURE|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
224086871|NCT03136107|OTHER|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
224086872|NCT03136107|OTHER|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
223912438|NCT05215197|DRUG|intracochlear platelet rich fibrin administration|intracochlear platelet rich fibrin administration during routine cochlear implantation surgery
223912439|NCT02518048|DRUG|LEO 90100 Aerosol foam|
224086873|NCT03283085|DRUG|25 mg Ontamalimab|Ontamalimab SC solution for injection
224277787|NCT00722839|BIOLOGICAL|tetanus-CMV fusion peptide vaccine|Given subcutaneously
224277788|NCT00722839|DRUG|agatolimod sodium|Given subcutaneously
224277789|NCT00001239|DRUG|FLAC with GM-CSF|
223912440|NCT02518048|DRUG|Betesil® 2.25 mg|
223912441|NCT05825079|BEHAVIORAL|Weight-Bearing Feedback|Feedback on how much weight patients are exerting on their crutch/injured lower extremity (measured via Smart Crutch Tip) will be delivered to their mobile phones.
223912442|NCT05825079|DEVICE|Smart Crutch Tip|The device is attached to the crutch and measures how much weight-bearing load is exerted onto its axis. The device is capable of transmitting this data into the patient and physicians' user interface.
224086874|NCT03283085|DRUG|75 mg Ontamalimab|Ontamalimab SC solution for injection
224086875|NCT06613633|DRUG|third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)|Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
224086876|NCT04201080|DRUG|Part A: TRV250-20mg/ml|TRV250 SC Injections
224277790|NCT04149301|DIAGNOSTIC_TEST|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
224086877|NCT04201080|DRUG|Placebo|Placebo SC injections
224086878|NCT04201080|DRUG|Part B: TRV250 Dose 1|Dose 1of3 TRV250
224086879|NCT04201080|DRUG|Part B: TRV250 Dose 2|Dose 2of3 TRV250 SC injections
224086880|NCT04201080|DRUG|Part B: TRV250 Dose 3|Dose 3of3 TRV250 SC injections
223912443|NCT06674408|OTHER|Traditional physical therapy|"Control group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Finger Ladder Exercise, Codman's Pendulum Exercise, Towel Stretch Exercise and Wand Exercises 10 reps x 2 sets per session,~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week of treatment for outcome measures."
223912444|NCT06674408|OTHER|Prioprioceptive group|"Experimental group included Hot pack over shoulder region for 15 mins. Shoulder AP, PA and inferior glides (Maitland) Grade II, III, IV 30 reps x 3 sets per session, Stretching of levator scapula, upper trapezius, pectoralis major and minor with 15 second hold x 3 reps per session, Strengthening of rotator cuff muscles by manual resistance with 10 second hold x 5 reps x 2 sets per muscle per session, Plyometric CKC shoulder exercise 10 seconds each x 5 reps x 2 sets per session, CKC exercise on the ball 10 seconds each x 5 reps x 2 sets per session, Open KC exercises 10 seconds each x 5 reps x 2 sets per session, Hand-eye coordination exercises for 30 minutes/per day for 5x/per week, Hand Function Exercises for 30 minutes/per day for 5x/per week.~Patients were assessed for baseline measurements against outcome measures. Patients were given a total of 10 sessions such that 5 sessions per week for the duration of 02 weeks. All patients were reassessed at the end of the 1st and 2nd week"
223912445|NCT05840965|OTHER|Foot muscle strengthening|"A specific training program emphasizing the neuromuscular recruitment of the plantar intrinsic foot muscles. This will be colloquially referred to as the Foot Core Strengthening Program. The exercises are: short foot exercise, toe spread out, first toe extension, second to fifth toe extension. Simultaneously, neuromuscular electrical stimulation (NMES) will be provided, as 77% of healthy active people struggle performing contractions of the foot muscles."
223912446|NCT05840965|OTHER|Foot orthotics|Custom-made foot orthotics
223912447|NCT06677398|OTHER|Debriefing Method 1|The researchers used a debriefing method that they chose after a virtual simulation
223912448|NCT06677398|OTHER|Debriefing Method VP|The researchers used the debriefing method that virtual patient simulator presents
223912449|NCT06677398|OTHER|Debriefing Method 2|The researchers used a debriefing method that they chose after a virtual simulation
223912450|NCT06862531|BIOLOGICAL|blood sample|A sample of blood (1mL) was taken
223912451|NCT06465108|DRUG|MBX 2109|Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL
223912452|NCT06465108|OTHER|Placebo|Supplied in 1.4 mL water for injection
223912453|NCT06560216|DIETARY_SUPPLEMENT|Apigenin|0.2 mM in freezing medium
223912454|NCT06804746|PROCEDURE|DHOPE-COR-NMP|Resuscitation and viability assessment through the previously published protocol of sequential hypo- and normothermic liver machine perfusion with controlled oxygenated rewarming (DHOPE-COR-NMP) based on a blood-based perfusate.
223912455|NCT06561893|DIETARY_SUPPLEMENT|Broccoli sprouts extract supplementation|Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites
223912456|NCT04508582|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|Imaging of the heart with CMR, without use of contrast agents.
223912457|NCT04508582|DIAGNOSTIC_TEST|Echocardiography|Imaging of the heart with ultrasound.
223912458|NCT04508582|DIAGNOSTIC_TEST|Blood test|Time- matched blood samples will be taken from patients to assess immune cell phenotype and function, paying particular attention to neutrophil and T-cell phenotype. Plasma samples will be collected for the analyses of cardiac specific factors (BNP, troponin) as well as measurement of steroid hormones (progesterone and oestradiol), and soluble inflammatory and anti-inflammatory mediators
223912459|NCT01130519|DRUG|Bevacizumab|Commercially available. Administered by intravenous infusion.
223912460|NCT01130519|DRUG|Erlotinib|Commercially available. Administered orally.
223912461|NCT04889521|OTHER|No intervention|No intervention. Study is cross-sectional observational.
223912462|NCT05165628|COMBINATION_PRODUCT|CYP-006TK|CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing
223912463|NCT05363163|DEVICE|Gana X|Injection in the deep dermis and subcutaneous layer of the buttocks on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
223912464|NCT04484740|DRUG|Gepotidacin|Single oral dose of 1500 mg gepotidacin
223912465|NCT06647862|DRUG|IMM01|IV infusion
223912466|NCT06647862|DRUG|Azacitidine|subcutaneous injection
223912467|NCT06647862|DRUG|Placebo|IV infusion
223912468|NCT06649201|OTHER|Vulvovaginal Symptom Questionnaire|Participants will undergo assessment of vulvovaginal symptoms via the vulvovaginal questionnaire once pre-transplant, six months, and develop months post-transplant.
223912469|NCT06649201|DIAGNOSTIC_TEST|Vaginal Microbiome Evaluation|A vaginal microbiome evaluation will be performed via vaginal exam by a gynecologist with collection of vaginal samples once pre-transplant, six months, and twelve months post-transplant.
224277791|NCT04149301|DIAGNOSTIC_TEST|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
223912470|NCT06572423|PROCEDURE|Personalized ultrafractionated stereotactic adaptive radiotherapy|PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.
223912471|NCT06572423|RADIATION|Volume Modulated Arc Therapy|Use HyperArc technology
223912472|NCT06572423|PROCEDURE|Computed Tomography|Undergo CT simulation for radiation planning
224277792|NCT03975439|DIAGNOSTIC_TEST|Hemoglobin A1C|Finger stick hemoglobin A1C
224277793|NCT03975439|DIAGNOSTIC_TEST|Urinalysis|Urinalysis by dip stick looking for urine protein level
224277794|NCT03975439|DIAGNOSTIC_TEST|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
224277795|NCT02079363|OTHER|No interventions, this is an observational study|
224277796|NCT02132624|BIOLOGICAL|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
224277797|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
224277798|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
224277799|NCT02242734|DRUG|20 mg HC-ER|1-72 hours
223912473|NCT06572423|PROCEDURE|Positron Emission Tomography|Undergo PET
223912474|NCT06572423|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223912475|NCT06572423|OTHER|Best Practice|Undergo standard of care
223912476|NCT06572423|BEHAVIORAL|University of Washington Quality of Life Scale, Version 4|Complete questionnaire
223912477|NCT06572423|BEHAVIORAL|Functional Assessment of Cancer Therapy-Head & Neck|Complete questionnaire
223912478|NCT05676905|DEVICE|Neocement|Bone graft substitutes
223912479|NCT05621187|DEVICE|Pamira ICD lead family|Implantation, measurements and follow-up schedule
223940048|NCT04147884|DEVICE|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
223940049|NCT04064983|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
223940050|NCT06822543|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
223940051|NCT06822543|DRUG|Datopotamab deruxtecan|Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload and a cleavable linker.
223940052|NCT06822543|DRUG|Carboplatin|Carboplatin is a platinum compound chemotherapy used to treat lung cancer with a known safety profile. For more details on specific indications refer to the approved product label.
223940053|NCT03488459|BEHAVIORAL|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
223940054|NCT03488459|BEHAVIORAL|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
223940055|NCT06504290|DRUG|VV119 Placebo （in healthy adult subjects）|"VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days."
223940056|NCT06504290|DRUG|VV119 （in healthy adult subjects）|"VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days."
223940057|NCT06504290|DRUG|VV119(in adult patients with schizophrenia)|VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily, VV119 6 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first three days,take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the forth day to the fifth day , take 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the sixth day to the seventh day , then 3 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
223940058|NCT06504290|DRUG|VV119 Placebo （in adult patients with schizophrenia）|VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily, VV119 6 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first three days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the forth day to the fifth day ,take 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the sixth day to the seventh day, then 3 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
223940059|NCT01727167|DRUG|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
223940060|NCT01727167|OTHER|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
223912480|NCT06466356|OTHER|Psychoeducational Course for Suicide Prevention|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
223912481|NCT06466356|OTHER|Individual therapy session|Baseline variables includes diagnosis using ICD-10 criteria for research and demographic variables such as age, sex, level of education and occupation. Following assessments will be used when including patients for the project: The General self-efficacy scale (GSE) with additional questions related to the theme of the psychoeducational topics, The mental pain questionnaire (MPQ, Alcohol Use Disorders Identification Test (AUDIT), Drug Use Disorders Identification Test (DUDIT) The Patient Health Questionnaire (PHQ-9), GAD-7, The SCS-Checklist and SCI-5. GSE, MPQ and PHQ-9 will be measured after intervention and after 6, 12, 24 and 60 months.
223912482|NCT06466356|OTHER|Treatment as usual|Treatment as usual (TAU) may include the use of psychotropic drugs, in and out-patient treatment, occupational therapy and other interventions the patients physician deem necessary.
223912483|NCT06575465|BEHAVIORAL|Healthy lifestyle nutrition, culture and physical activity workshops|The intervention will include monthly sessions in the community setting of physical activity. In addition, monthly nutrition and culture sessions will be held.
223912484|NCT06575465|OTHER|Usual care|Usual care patients receive in their primary health care
223912485|NCT06576479|DIETARY_SUPPLEMENT|Nutritious Shake|Powder 70 g/d diluted in 237 ml natural water
223912486|NCT06576479|BEHAVIORAL|Nutritional counseling|Specialized nutritional recommendations for CKD
223912487|NCT02539290|BEHAVIORAL|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
224086881|NCT04201080|DRUG|Placebo|Placebo SC injections
224277800|NCT01580046|DRUG|iodixanol|"1. coronary angiography, 32gI/100ml, 40～60 ml once injection~2. left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
224277801|NCT01580046|DRUG|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
224277802|NCT06167850|PROCEDURE|Copenhagen plank|Performing Copenhagen adduction as prevention for adductor injury.
224277803|NCT06125002|DRUG|Diosmin750|The ingestion will occur orally, under monitoring by the responsible investigator.
224277804|NCT06125002|DRUG|Placebo|The ingestion will occur orally, under monitoring by the responsible investigator.
223912488|NCT02539290|PROCEDURE|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
223912489|NCT02539290|PROCEDURE|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
223912490|NCT02539290|BEHAVIORAL|Sexual intercourse|Sexual intercourse on the day of the intervention and the following day
223912491|NCT06385301|OTHER|6-minute walk distance (6MWD) test on ambient air|6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
223940061|NCT03683849|OTHER|Training|One hour of training, twice a week, for six months.
223940062|NCT00837044|DRUG|Treximet|Treximet
223940063|NCT00837044|DRUG|Migraine rescue medication of choice|Migraine rescue medication of choice
223940064|NCT04284839|DRUG|DOAC|Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
223940065|NCT04284839|DRUG|VKA|Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
223940066|NCT02278796|DRUG|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
223940067|NCT02278796|DRUG|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
223940068|NCT06307652|DRUG|balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
223940069|NCT06307652|DRUG|balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg|1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
223940070|NCT06307652|DRUG|dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin|1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
223940071|NCT05547919|RADIATION|18F-PSMA PET/CT|Patients with metastasized gastroenterologic tumors, that exhibit histological PSMA expression, receive an additional 18F-PSMA PET/CT to routine imaging.
223940072|NCT05868837|DRUG|Rituximab|Rituximab 1000 mg IV on RCP days 1 and 15
223940073|NCT05868837|OTHER|Placebo|Placebo 1000 mg IV on RCP days 1 and 15
223940074|NCT04363112|BEHAVIORAL|Mini Kid II|Mini Kid II (Mini International Neuropsychiatric Interview ) is a standardised, hetero mental health questionary for children, according to DSM IV. Mini Kid II will be administered to children between day 3 and 7 during the study.
223940075|NCT04011930|DRUG|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
223912492|NCT06385301|OTHER|6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)
223912493|NCT03154190|OTHER|Best Practice|Receive usual care
224086882|NCT01891071|PROCEDURE|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
223912494|NCT03154190|OTHER|Laboratory Biomarker Analysis|Correlative studies
224086883|NCT02676830|DRUG|K-312 100 mg|Single oral dose
224086884|NCT02676830|DRUG|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
224086885|NCT02038348|DEVICE|PET with 18F-FDOPA|
224086886|NCT00403221|GENETIC|RTVP-1 Gene|"Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp~One dose only followed by a radical prostatectomy 4 weeks later."
224086887|NCT01178645|DRUG|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
224086888|NCT00565331|DRUG|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
224086889|NCT00565331|DRUG|Placebo|saline solution
224086890|NCT00477789|DRUG|allopurinol|
224086891|NCT02808104|DRUG|mazindol|
224086892|NCT00544921|DRUG|GLY-230|
224086893|NCT00544921|OTHER|Placebo|No drug administered
224086894|NCT00109148|DRUG|MK0364|
224277805|NCT05245955|DEVICE|Assessments of the hand sensory function with the ReHapticKnob|During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).
224277806|NCT04070079|DRUG|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
223912495|NCT03154190|PROCEDURE|Supportive Care|Undergo health care coach support
223912496|NCT03154190|OTHER|Survey Administration|Ancillary studies
223912497|NCT01408225|PROCEDURE|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
223912498|NCT06115759|BEHAVIORAL|T-REX Twente precautions|The intervention group receives the new T-REX Twente precautions, allowing for more independent activities through the use of the tube model (keeping elbows close to the sides).
224086895|NCT05070338|BEHAVIORAL|Guideline-Based (Injunctive Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amounts recommended by safety guidelines for these procedures.~For patient safety, Sutter Health recommends prescribing within the ranges below for these procedures. Doing so will also meet best-practice safety guidelines for post-operative opioid prescribing.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]"
224086896|NCT05070338|BEHAVIORAL|Peer-Based (Social Norm) Nudges|"Surgeons in this arm will receive an email with the following content at the end of each month in which at least two of their patients are discharged with an opioid prescription that exceeds the prescribing guideline for the procedure performed.~Dear Dr. \[Name\],~In \[month\], at least XX of your patients were discharged with opioid prescriptions exceeding the amount prescribed by YY% of your peers for these procedures.~YY% of \[specialty\] surgeons at Sutter Health prescribe within the ranges below for these procedures.~We will continue to send you opioid prescribing safety reports.~Sincerely, \[Signature\]~\[Table displaying recommended ranges of 5mg oxycodone tablets for each procedure\]~The ranges of 5mg oxycodone tablets displayed will be the same as the ranges stipulated by the prescribing guidelines, but this nudge will not mention guidelines."
224086897|NCT05111587|OTHER|Questionnaire|Participant must complete a questionnaire about injury during climbing practice in an artificial structure
224086898|NCT03596346|OTHER|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
224086899|NCT03596346|OTHER|Control product without added RI|2 snack bars daily containing 0 g of RI.
224086900|NCT04440462|OTHER|Sugar and water solution|2 ml of a water and sugar solution (3 full-teaspoons of granulated sugar dissolved in half glass of water)
224086901|NCT04440462|OTHER|Sterile water|2 ml of sterile water
224086902|NCT02232256|DRUG|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
224086903|NCT06662214|OTHER|Refined maize flour|Meal made form refined maize flour
224086904|NCT06662214|OTHER|Whole grain flour|Meal made form whole grain maize flour
224086905|NCT05873712|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224086906|NCT05873712|PROCEDURE|Bone Marrow Biopsy|Undergo BM biopsy
223912499|NCT06115759|BEHAVIORAL|Usual (restrictive) sternal precautions|The control group is not allowed to lift, push, or pull for the first 6 weeks. There is little to no evidence for the current strict precautions currently implemented in the department.
223912500|NCT06790953|PROCEDURE|Group- A Conventional Sensed Mouth Wash|"In Group- A Conventional Sensed Mouth Wash will be used for treatment of Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity."
223912501|NCT06790953|PROCEDURE|Group-B Novel Titania nanoparticles enriched Mouth Wash|"In Group-B Novel Titania nanoparticles enriched Mouth wash will be used to treat the Dentin hypersensitivity.~Visual Analogue scoring system will be used to calculate the dentin hypersensitivity."
223912502|NCT06529133|OTHER|Evaluation of postural control|Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
223912503|NCT05083806|DEVICE|Multispectral Optoacoustic Tomography|Non-invasive optoacoustic imaging of muscular structure
223912504|NCT05684484|DRUG|Roflumilast 500 MCG Oral Tablet [DALIRESP]|Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders
223912505|NCT05684484|DRUG|amino salicylic acid|conventional treatment
223912506|NCT06209684|PROCEDURE|Titanium|Spinal stabilization using titanium screws and rods
223912507|NCT06209684|PROCEDURE|Carbofix|Spinal stabilization using CarboFix screws and rods
223912508|NCT00670241|DRUG|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
223529564|NCT06100562|BEHAVIORAL|Adapted Dance Program|"* Participants will attend a 2x/weekly adaptive dance session for 10 weeks. If participants miss a class due to illness or an unexpected event (loss of transportation, family emergency/need) they will receive a video of the content missed and can complete the session at home.~* Each class will start with a 10 min warm-up that will include stretching and motor games.~* Learn a section of choreography every session using action-based intervention for 30 minutes.~* Break for 5 min.~* Improvisation part of class for 10 min.~* Cool-down for 5 min."
223529565|NCT04115631|DRUG|Acalabrutinib|Given PO
223529566|NCT04115631|DRUG|Bendamustine|Given IV
223529567|NCT04115631|DRUG|Bendamustine Hydrochloride|Given IV
223912509|NCT00670241|DRUG|LEO 80185 vehicle|Once daily application
223912510|NCT00670241|DRUG|Tacalcitol ointment|Once daily application
223912511|NCT02361554|DEVICE|Medtronic Percept with SensSight Deep Brain Stimulation System|Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia
223529568|NCT04115631|DRUG|Cytarabine|Given IV
223912512|NCT03183895|DEVICE|Left ventricular restoration|The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.
223912513|NCT05320822|OTHER|Active Rehab (Group 2)|"The Active Rehab protocol builds off of initial chief complaints and duty profile and addresses symptom control followed by a progressive and prescribed integration of activities to full return to duty that should be integrated with the current PRA TBICoE protocols. The specific activity areas in the intervention include low-intensity aerobic exercise that does not exacerbate symptoms, cognition, balance, visual/vestibular, and comfort/ general well-being.~Participants can be progressed daily according to symptom limitations. At least 3-4 sessions each week are recommended based on a trial of sport-related mTBI and other interventions of this type concerning mTBI/concussion. During each phase, low level aerobic exercise that does not significantly exacerbate symptoms, such as nature walks, will be recommended. The additional activity types that may be chosen include cognitive, balance, visual/vestibular, and comfort/general well-being."
223912514|NCT05320822|OTHER|Progressive Return to Activity (Group 1)|Participant will be asked to use symptoms to guide activity from the time of the injury until participant is asymptomatic. Once asymptomatic, participant will begin the PRA TBICoE clinical recommendation. During this time clinicians will document activities in each stage in addition to initial symptom checklist, stage of PRA CoE progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
223912515|NCT04709419|DEVICE|Celliant Diabetic Medical Socks|"Celliant® Diabetic Medical Socks (Celliant Socks) are intended to provide infrared radiation (IR) to increase tissue oxygen thereby increasing blood flow and circulation in the affected area leading to an effect on wound closure outcomes and possible pain reduction."
224086907|NCT05873712|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223529569|NCT04115631|BIOLOGICAL|Rituximab|Given IV
223716220|NCT04993248|OTHER|Dialog Circle|"The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator."
223716221|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
223912516|NCT04709419|DEVICE|Control (placebo) Medical Socks|The Control Sock will be visually identical to the Active Celliant® Sock. The sock will be made of identical materials without the Celliant® components. The Control sock will be 82% standard polyester, 13% Nylon, and 5% Spandex.
223912517|NCT05317234|GENETIC|Whole-exome sequencing|The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
223912518|NCT05683340|DRUG|180mg of ETC-1002(bempedoic acid)|180mg, tablet, once daily, for 12 weeks
223912519|NCT05683340|DRUG|Placebo|placebo, tablet, once daily, for 12 weeks
223912520|NCT05653466|BEHAVIORAL|Adaptive Spacing Condition|"Each of the 200 target words for practice are presented on a schedule determined by an algorithm that relies on the pattern of correct vs. incorrect responses for each item. Items in the active learning state need to be answered correctly a certain number of times before being categorized as learned. Each item must be answered correctly 3 times in a row (immediately, then at one-minute and five-minute intervals) before it is categorized as learned. Then, it will be scheduled at ever-increasing intervals, until answered incorrectly, at which point the item would be returned to the active learning state, requiring three correct responses in a row to return again to the learned expanding interval state."
223912521|NCT05653466|BEHAVIORAL|High-Item Non-Adaptive Spacing Condition|Each of the 200 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
224086908|NCT05873712|DRUG|Cyclophosphamide|Given IV
223529570|NCT05209386|BEHAVIORAL|Dimension-Based Statistical Learning|"Each participant will complete self-paced blocks of stimuli that will first establish a baseline for neural activity and behavioral responses with clear speech, and will then record responses for experimentally manipulated blocks to introduce 1) speech-in-noise and 2) a Canonical-Reverse block to model an accent. Auditory stimuli will be adjusted to a comfortable level for each participant as determined by a calibration process completed by the participant. Each block involves listening to sound via earphones and making a categorical decision between initial consonants (/b/ or /p/) by tapping a button to indicate the word heard by the participant."
223716222|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
223716223|NCT02340975|BIOLOGICAL|MEDI4736|MEDI4736 will be administered by IV infusion.
223529573|NCT06645314|BIOLOGICAL|Group A|3.0 × 10 \^ 9 BST06 cells, intravenous infusion，at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
223529574|NCT06645314|BIOLOGICAL|Group B|3.0 × 10 \^ 10 BST06 cells, intravenous infusion, at least 2 subjects enrolled, up to a maximum of 8 subjects enrolled
223529575|NCT06645431|BEHAVIORAL|Water Intake|Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
223535235|NCT06698640|BEHAVIORAL|Automated SMS + Scheduling Assistance|Participants will receive the same automated SMS messages as in Arm 2, but with the added component of proactive appointment scheduling assistance. This may include options for scheduling directly through the SMS platform or follow-up messages encouraging appointment setting.
223716224|NCT02340975|BIOLOGICAL|Tremelimumab|Tremelimumab will be administered by IV infusion.
223912522|NCT05653466|BEHAVIORAL|Low-Item Non-Adaptive Spacing Condition|Each of the 40 target words for practice are presented in sequential order randomized within blocks, with each word presented once before the list repeats.
223912523|NCT00319033|DRUG|bosentan|
223912524|NCT02829437|OTHER|Treatment for EST|Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
223716225|NCT02340975|BIOLOGICAL|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
223716226|NCT02340975|BIOLOGICAL|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
223912525|NCT05759663|PROCEDURE|MIRRAD|Repair of the diastasis with MIRRAD technique
223912526|NCT05759663|PROCEDURE|Plication of the entire diastasis arm|Plication of the entire diastasis
223912527|NCT04086589|OTHER|Observational study without intervention|Observational study without intervention
223912528|NCT05342415|OTHER|Internally Focused Exercise|While performing the exercises participants will be instructed to focus on the muscle itself.
223912529|NCT05342415|OTHER|Externally Focused Exercise|While performing the exercises participants will be instructed to focus on the external target (towel, target line, etc.)
224086909|NCT05873712|DRUG|Fludarabine|Given IV
224086910|NCT05873712|PROCEDURE|Leukapheresis|Given IV
224086911|NCT05873712|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
224086912|NCT05873712|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
224086913|NCT05873712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224086914|NCT05873712|DRUG|Zanubrutinib|Given PO
224086915|NCT00863577|DRUG|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
224086916|NCT02292771|DRUG|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
223912530|NCT06272734|DEVICE|Reprieve System|"The study is broken into stages:~1. In Stage one, Subjects enrolled in the study received Reprieve System (RS) therapy, a hospital bedside fluid management system designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure. (complete, N=10)~2. In future Stages, Subjects enrolled in the study will receive RS therapy and will be given varying levels of water consumption to challenge the algorithm. Future Stages will also assess new RS hardware and software features."
223912531|NCT02871726|DEVICE|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy.
223912532|NCT02871726|OTHER|TRUS biopsy|Uronav for prostate biopsy.
223912533|NCT03841253|PROCEDURE|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
223912534|NCT03841253|PROCEDURE|Trans-epithelial PTK (retrospective data collection)|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
224086917|NCT02292771|DRUG|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
223912535|NCT03841253|PROCEDURE|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
223912536|NCT03380962|DRUG|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
223912537|NCT02056834|DEVICE|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
223912538|NCT06757946|COMBINATION_PRODUCT|Mulligan Medial/Lateral glide with compression/ decompression technique|"Warm up (10 minutes with hot pack) and cool down exercises for a period of 5 to 10 minutes was given before starting and after the completion of exercises in supervised exercise program in all the groups. The following ergonomical advice were given to all the subjects, Avoid extreme knee bent positions, avoid squatting, crossed-leg sitting, frequent stair climbing or lifting heavy objects, avoid fatiguing postures except for infrequent short durations tasks, change posture frequently and use support where possible and avoid giving excess strain to the knees.~Mulligan mobilisation consisted of Medial glide mobilisation with movement, Lateral glide mobilisation with movement, with active knee flexion (61) depending on the subjects condition. The gliding force was sustained while the patient performed 3 sets of 10 repetitions.~Total 12 treatment sessions was given to each subject with the frequency of 3 sessions per week for 4 consecutive weeks."
223912539|NCT06757946|COMBINATION_PRODUCT|Mulligan Medial/Lateral glide|"Warm up (10 minutes with hot pack) and cool down exercises for a period of 5 to 10 minutes was given before starting and after the completion of exercises in supervised exercise program in all the groups. The following ergonomical advice were given to all the subjects, Avoid extreme knee bent positions, avoid squatting, crossed-leg sitting, frequent stair climbing or lifting heavy objects, avoid fatiguing postures except for infrequent short durations tasks, change posture frequently and use support where possible and avoid giving excess strain to the knees.~Total 12 treatment sessions was given to each subject with the frequency of 3 sessions per week for 4 consecutive weeks. After completing the therapeutic session, post- intervention data of the outcome parameters were taken."
223912540|NCT05816655|DRUG|Fulvestrant plus AI plus ribociclib|Fulvestrant + AI + ribociclib +/- GnRH agonist
223912541|NCT05816655|DRUG|AI plus ribociclib|AI + ribociclib +/- GnRH agonist
223912542|NCT06046053|DRUG|Placebo Vaginal Film with Square Corners|"2 x 2 placebo vaginal film with square corners"
223912543|NCT06046053|DRUG|Placebo Vaginal Film with Rounded Corners|"2 x 2 placebo vaginal film with rounded corners"
223912544|NCT04432116|BEHAVIORAL|virtual reality 1|the subject is in a virtual waiting room, there is no other intervention. The principle of this intervention is to make the subject wait with as little interfering events as possible
223912545|NCT04432116|BEHAVIORAL|virtual reality 2|Subjects are in a virtual environment mimicking a space ship. On the screen there is a red light and subjects wait for this red light to become green. They press on a pad each time the red light becomes green
223912546|NCT06106022|DRUG|Vonoprazan|Administered orally
224086918|NCT02292771|DRUG|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
224086919|NCT02292771|DRUG|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
224086920|NCT01631305|DRUG|Levothyroxine|3 mcg/kg/day
224086921|NCT01631305|OTHER|Calcium magnesia|Placebo.
224086922|NCT00003788|DRUG|carmustine|
223716227|NCT04003012|DRUG|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
223716228|NCT04003012|DRUG|Lidocaine|lidocaine 1%
223716229|NCT02034383|OTHER|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
223716230|NCT02034383|OTHER|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
223912547|NCT03217110|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
224086923|NCT00003788|DRUG|lomustine|
224086924|NCT00003788|DRUG|porfimer sodium|
224086925|NCT00003788|DRUG|procarbazine hydrochloride|
224086926|NCT00003788|PROCEDURE|neoadjuvant therapy|
224086927|NCT00003788|PROCEDURE|surgical procedure|
224086928|NCT00003788|RADIATION|radiation therapy|
224086929|NCT00067652|BEHAVIORAL|Education and awareness about body image issues.|
224277807|NCT04194606|PROCEDURE|Use of radial artery for access for a coronary angiography or intervention|After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
224277808|NCT06417437|DRUG|SSRI|Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
223912548|NCT03217110|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
223912549|NCT05576038|DRUG|L-Tryptophan|L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
223912550|NCT05576038|DRUG|Freedom SimpleCap Powder|Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
223912551|NCT04622774|DRUG|IMGC936|Antibody Drug Conjugate
223912552|NCT06153602|DRUG|Nalbuphine Hydrochloride 10 MG/ML|Nalbuphine(10mg/ml) 0.8 mg intrathecal
223912553|NCT06153602|DRUG|Sodium Chloride 0.9 % in 5 ML Injection|0.9% Sodium Chloride 0.08 ml intrathecal
223716231|NCT02034383|OTHER|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
223716232|NCT02034383|OTHER|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
223716233|NCT02034383|OTHER|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
223912554|NCT06153602|DRUG|Bupivacaine Hydrochloride, Spinal|0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal
223912555|NCT06153602|DRUG|Nalbuphine Hcl 10Mg/Ml Inj|4 mg IV prn for postoperative pain score\>=4 q 6 h
223912556|NCT06153602|DRUG|Acetaminophen 500Mg Tab|1 tab oral prn for postoperative pain score 1-3 q 6 h
223912557|NCT06153602|DRUG|Ondansetron 8mg|8 mg IV prn for nausea or vomiting q 8 h
223912558|NCT05127044|DEVICE|Diffuse Reflectance Spectroscopy|DRS will be used as a non-invasive optical spectroscopy method to collect key biological information from neonatal skin including skin maturity, blood oxygenation, and bilirubin content.
223912559|NCT05127044|DIAGNOSTIC_TEST|BiliChek|BiliChek will be used as a control for determining bilirubin content.
223940076|NCT04011930|DRUG|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
223940077|NCT02078518|OTHER|Questionnaires|
223940078|NCT04566172|BEHAVIORAL|Inspiratory Muscle Training (IMT)|Participants will receive an inspiratory muscle training that they will do leading up to the day of their surgery.
223940079|NCT01746576|OTHER|Use of impedance threshold device during spontaneous ventilation|
223940080|NCT00466037|BIOLOGICAL|Influenza vaccine|
223940081|NCT02945059|PROCEDURE|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
223940082|NCT00357994|DRUG|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
223940083|NCT00357994|DRUG|Placebo gel|
223940084|NCT00357994|DRUG|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
223940085|NCT00357994|DRUG|Placebo (PBO) oral capsules|
223940086|NCT00357994|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
223940087|NCT00357994|DEVICE|PEG tube|percutaneous endoscopic gastrostomy tube
223940088|NCT00357994|DEVICE|J-tube|jejunal tube
223940089|NCT03055598|DRUG|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
223940090|NCT05439837|PROCEDURE|Infraclavicular and subomohoid block|Its blockade of subscapular nerve in the subscapular fossa and axillary nerve as it curves around humeral And blocking of brachial plexuses cord and supra scapular nerve And blocking of the brachial plexuses cord and supra scapular nerve
223940091|NCT05439837|PROCEDURE|Paracoracoid subscapularis plane block|Blocking of suprascapular nerve in supra scapular fossa and axillary nerve as it curves the humeral head
223940092|NCT05866003|DEVICE|Active conventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, an electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
223912560|NCT05400122|DRUG|Vactosertib|Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 \[ALK5\]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
223912561|NCT05400122|DRUG|Fludarabine Phosphate|Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
223912562|NCT05400122|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity.
224086930|NCT06911996|BEHAVIORAL|Virtual Reality|"After obtaining written consent, participants will be asked to complete a brief demographic survey and pre-intervention surveys (content knowledge, and wellbeing surveys). They will then be equipped with a VR headset, Quest 3 (Meta, Inc., Menlo Park, CA) displaying the educational field trip. After the VR field trip, participants will participate in a complementary hands-on science experiment. At the conclusion of the experiment, patients will be asked to complete the post intervention surveys (i.e awe, content knowledge, and wellbeing surveys).~Additionally, for the first 20 participants, 15 participants will be randomly selected and asked to participate in a 5 open-ended question qualitative interview regarding engagement of the lesson. Audio will be recorded via zoom."
224086931|NCT06917131|DIETARY_SUPPLEMENT|Royal Jelly|Participants will receive 2 capsules per day, providing the dosage of 300mg of royal jelly for 2 months (8 weeks).
224086932|NCT06917131|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive 2 capsules per day (containing microcrystalline cellulose and magnesium stearate in colored gelatin capsules capable of masking the appearance of the internal content), at the same time for 2 months.
224086933|NCT06915116|PROCEDURE|Acupuncture|Acupuncture will be delivered by licensed experienced acupuncturists at MSK. The intervention includes 12 treatments of acupuncture over 12 weeks (i.e. one treatment a week) with a +/- 14-day window. When patients experience menses recovery during the treatment period, they have the option to discontinue treatment or continue receiving up to 12 acupuncture sessions for symptom management over 12 weeks.
224086934|NCT06915116|OTHER|No Acupuncture|Will have the option to receive the same acupuncture treatment as the acupuncture group after a 16-week waiting period
224086935|NCT06915558|PROCEDURE|Opioid-Free Anesthesia (OFA)|Opioid-free anesthesia using a multimodal approach, including dexmedetomidine, lidocaine, ketamine, and magnesium sulfate. No intraoperative opioids are administered.
224086936|NCT06915558|PROCEDURE|Opioid-Based Intravenous Anesthesia (OBA-IV)|Standard opioid-based intravenous anesthesia using propofol, remifentanil, and neuromuscular blockade.
224086937|NCT06915558|PROCEDURE|Opioid-Based Inhalational Anesthesia (OBA-Inh)|Standard opioid-based inhalational anesthesia using sevoflurane, remifentanil, and neuromuscular blockade.
224086938|NCT06916949|DIAGNOSTIC_TEST|Electrocardiogram|two leads ECG
224086939|NCT06916949|DIAGNOSTIC_TEST|Pupillometry|During the simulation, automatic pupillometry will be performed on all team members at the following time points: Baseline (T0) During the simulation (T1) End of the simulation (T2) End of the debriefing (T3)
224086940|NCT06916949|DIAGNOSTIC_TEST|Electroencephalogram|EEG monitoring throughout the entire simulation. The EEG recordings will be sampled at: Baseline (T0) During the simulation (T1) End of the debriefing (T2)
224086941|NCT06917157|DRUG|Administration of antibiotics prophylactically at the time of membrane rupture|"Participants will receive the antibiotic regimen:~* Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours~* Day 2: Intravenous Ampicillin 2 g every 6 hours~* Days 3-7: Oral Amoxicillin 500 mg every 8 hours"
224086942|NCT06917157|DRUG|Administration of antibiotics non-prophylactically at 22 weeks|"Participants will receive latency antibiotics starting 22 weeks 0 days:~* Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours~* Day 2: Intravenous Ampicillin 2 g every 6 hours~* Days 3-7: Oral Amoxicillin 500 mg every 8 hours"
224086943|NCT06533592|PROCEDURE|Continous suture technique|Duct-to-duct anastomosis will be performed using continuous suture technique for study group
224086944|NCT06533592|PROCEDURE|Interrupted suture technique|Duct-to-duct anastomosis will be performed using an interrupted suture for control group,
224086945|NCT05799261|PROCEDURE|Control (standard protocol)|The control group will be treated according to standard protocols of the Department of Periodontology of the university of Bern and receive conventional scaling and root planing. Supra- and subgingival hard and soft tissue deposits are being removed by means of hand instruments and ultra-sonic scalers followed by rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists.
224086946|NCT05799261|PROCEDURE|Test (Guided Biofilm management)|"The test group will be treated according to a novel treatment concept (Guided biofilm management, GBM):~1. Staining of all tooth surfaces to detect soft and hard deposits.~2. Removal of supra- and subgingival hard and soft bacterial deposits by means of an erythritol powder air-polishing.~3. If present, the supra- and subgingival hard deposits (e.g. calculus) will be removed by means of a slim ultrasonic tip (Piezon PS, EMS, Nyon Switzerland) without any additional use of hand instruments.~4. Another sub- and supragingival application of erythritol powder air-polishing without any rubber cup polishing. All patients will have 2 visits per year. At each visit outcome measures will be assessed by masked dentists."
224086947|NCT04558593|PROCEDURE|Active surveillance|Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
224086948|NCT04558593|PROCEDURE|Surgery|Per standard of care: partial or full resection of the kidney, imaging annually
224086949|NCT04531722|PROCEDURE|Intraoperative brain microdialysis|Our current standard practice is to use a lateral approach through the middle temporal gyrus to place 3 depth electrodes targeting the hippocampus for intraoperative verification of pathological epileptiform activity prior to resection. Our research protocol will add one FDA approved electrode that has a central cannula for insertion of a microdialysis probe.
224086950|NCT05639569|DEVICE|Ankura™ TAA Stent Graft System|All patients will be implanted with Ankura™ TAA Stent Graft System in accordance with the instructions for use (IFU).
224086951|NCT03706703|DRUG|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
223912563|NCT05400122|DRUG|IL-2|"Proleukin® (aldesleukin) has been shown to possess the biological activities of human native interleukin-2. In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.~The in vivo administration of Proleukin in animals and humans produces multiple immunological effects in a dose dependent manner. These effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. In vivo experiments in murine tumor models have shown inhibition of tumor growth"
223912564|NCT05400122|DRUG|Natural Killer Cells|Adoptive NK cell therapy has demonstrated the potential for cancer immunotherapy in various malignancies with particular potential in hematologic malignancies including acute myeloid leukemia (AML), and colon cancer \[14, 19-23\]. This therapeutic approach is extremely well tolerated in patients even when massive numbers of cells are utilized (\~109 NK cells/kg). In fact, studies suggest that high doses of NK cells are not only well tolerated but have potential to lead to higher levels of efficacy.
223912565|NCT04396145|DIAGNOSTIC_TEST|Subjective Visual Vertical|All subjects will have Virtual SVV before and after the operation
224086952|NCT03706703|DRUG|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
223912566|NCT04665648|DRUG|Nicorandil|6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention
224086953|NCT03706703|DRUG|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
224086954|NCT03706703|DRUG|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
224086955|NCT04828863|BEHAVIORAL|Neurocognitive testing|Participants will undergo a battery of neurocognitive tests that examine intellectual, executive, and adaptive function. The tests will be given remotely via internet-based surveys.
224086956|NCT02274688|BEHAVIORAL|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
224086957|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device|Usage of the Revitive NMES device - 1-6 sessions daily (30 minutes per session).
223912567|NCT04665648|DRUG|Placebo|placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
223912568|NCT01167725|BIOLOGICAL|bevacizumab|Given IV
223912569|NCT01167725|BIOLOGICAL|cetuximab|Given IV
223912570|NCT01167725|DRUG|FOLFIRI regimen|Given IV
223912571|NCT01167725|DRUG|FOLFOX regimen|Given IV
223912572|NCT01167725|DRUG|capecitabine|Given IV
223912573|NCT01167725|DRUG|fluorouracil|Given IV
223912574|NCT01167725|DRUG|irinotecan hydrochloride|Given IV
223912575|NCT01167725|DRUG|leucovorin calcium|Given IV
223912576|NCT01167725|DRUG|mitomycin C|Given intraperitoneally
223912577|NCT01167725|DRUG|oxaliplatin|Given IV
223912578|NCT01167725|PROCEDURE|therapeutic conventional surgery|Patients undergo cytoreductive surgery
224086958|NCT04784962|DEVICE|Revitive Medic Neuromuscular Stimulation Device (Sham)|Usage of the Sham Revitive NMES device - 1-6 sessions daily (30 minutes per session)
224086959|NCT00219115|DRUG|aliskiren|
224086960|NCT05288582|DEVICE|NovaTears|Over-the-counter eye drop
224086961|NCT02379325|BEHAVIORAL|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
224086962|NCT02379325|BEHAVIORAL|pamphlets material|Given pamphlets material on smoking and complication
224086963|NCT03339492|DEVICE|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
224086964|NCT01332708|BEHAVIORAL|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
224086965|NCT01922921|BIOLOGICAL|HER-2/neu Intracellular Domain Protein|Given ID
224086966|NCT01922921|OTHER|Laboratory Biomarker Analysis|Correlative studies
223912579|NCT04723147|DRUG|Carbidopa Levodopa|Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
223912580|NCT04723147|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
224086967|NCT01922921|BIOLOGICAL|Pertuzumab|Given per standard of care
224086968|NCT01922921|OTHER|Placebo|Given PO
224086969|NCT01922921|BIOLOGICAL|Polysaccharide-K|Given PO
224086970|NCT01922921|BIOLOGICAL|Trastuzumab|Given per standard of care
224086971|NCT00709826|DRUG|gemcitabine|Gemcitabine: per package insert.
224086972|NCT00709826|DRUG|placebo|placebo: 100 mg tablets, 400 mg/day
224086973|NCT00709826|DRUG|Erlotinib|Erlotinib - per package insert.
224086974|NCT00709826|DRUG|apricoxib|apricoxib: 100mg tablets, given orally
224086975|NCT02862314|BIOLOGICAL|Blood sample|
224086976|NCT00000979|DRUG|Zidovudine|
224086977|NCT00000979|DRUG|Didanosine|
223912581|NCT05723250|OTHER|Table-based Educational Intervention|Tablet based educational tool with videos about care coordination, cancer knowledge and self-advocacy.
223912582|NCT05509309|BEHAVIORAL|APERS-based model|APERS-assessments followed by in-service training, APERS-feedback and on-site coaching to improve primary school classroom quality for students with ASD/SCC
223912583|NCT05473793|DIETARY_SUPPLEMENT|Dried chicory root particles|The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).
223912584|NCT05473793|OTHER|Placebo|The control arm receives a placebo consisting of rice puff particles.
223912585|NCT01449513|DRUG|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
223912586|NCT01449513|DRUG|Placebo Gel|Gel vehicle of PEP005
223912587|NCT04587024|OTHER|mHealth intervention|Subjects will receive mHealth direct observation of therapy for 12 weeks
223912588|NCT04587024|OTHER|standard of care|Subjects will receive standard of care observation for 12 weeks
223912589|NCT04947735|DEVICE|Novel spectacle lens design|Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia
224086978|NCT04574999|DRUG|Estriol|Gel for vaginal application
224086979|NCT04574999|OTHER|Placebo|Gel for vaginal application
224086980|NCT06075225|DRUG|Ruxolitinib|Ruxolitinib is asministrated with the dose of 5mg bid for 28 days. If no signs of aGvHD, the dose of ruxolitinib is gradually tapered within the following 16 days.
224086981|NCT00746174|DRUG|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
224086982|NCT00746174|DRUG|Placebo|Placebo 1 tablet PO daily for 16 weeks
224277809|NCT06417437|DEVICE|rTMS|Patients will be treated targeting either the traditional brain region or new region.
224277810|NCT06417437|BEHAVIORAL|Neuro-Feedback|Patients under 18 years old will first be considered this treatment before other methods.
224277811|NCT06417437|BEHAVIORAL|Game Regulation|Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
223912590|NCT04947735|DEVICE|Spectacle lenses|Single vision, impact resistant spectacle lenses
223912591|NCT06340178|PROCEDURE|Fluid application during ct-guided lung biopsy|Injection of a small amount of fluid (max. 20 ml sodium chlorid) in the pleural cavity at the biopsy site
223912592|NCT04466098|BIOLOGICAL|Mesenchymal stromal cells|Thawed product containing MSC(300x10\^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
223912593|NCT04466098|OTHER|Placebo|Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
223912594|NCT05637762|OTHER|- EEG video recording or extension of an EEG video recording planned as part of the care - Wearing a connected heart rate and motion recording patch|The study consists of creating a database to develop an algorithm using machine learning methods.
224277812|NCT01889797|BIOLOGICAL|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
223912595|NCT04650568|DEVICE|Autologous Bone Marrow Derived Mesenchymal Stem Cells|Autologous Bone Marrow Derived Mesenchymal Stem Cells injected into the ACL allograft prior to graft implantation.
223912596|NCT04650568|OTHER|Sham incision|Small incision over the site where bone marrow aspirate would have been obtained
223912597|NCT04209595|DRUG|PLX038|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. PLX038 (PEGylated SN38) will be administered as a 1 hour (-10 minutes / +30 minutes) intravenous (IV) infusion on Day 1 of each cycle (21 days).
223912598|NCT04209595|DRUG|Rucaparib|Phase I: Dose escalation will follow the classical 3+3 trial design by Fibonacci sequence. Phase II: Maximum tolerated dose (MTD) identified in phase I. Rucaparib will be given orally at designated dose twice a day on days 5 to 19 of every 21-day cycle.
223912599|NCT04209595|DRUG|Ondansetron|Participants will be recommended to have 8 mg of ondansetron taken with a small meal or snack to prevent nausea and vomiting approximately 30 minutes prior to each dose of rucaparib.
223912600|NCT04667013|DRUG|Tetramethylpyrazine nitrone (TBN) tablet / Placebo|Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.
223912601|NCT06125210|BEHAVIORAL|early bedside rehabilitation|① electrical diaphragm stimulation, ② electrical muscle stimulation, ③ passive limb movement, ④ respiratory rehabilitation.
223912602|NCT06125210|DIETARY_SUPPLEMENT|nutrition program|(1) nutrition department consultation, (2) MDT to develop individualized nutritional pathways, nutrient formulations and use methods, and achieve the target nutritional level within 2 weeks
224086983|NCT03717376|OTHER|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
224086984|NCT01554787|DRUG|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
224086985|NCT01554787|OTHER|Placebo|at a rate of 2.8g three times per day
224086986|NCT03411395|DIETARY_SUPPLEMENT|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
224086987|NCT03411395|OTHER|Placebo drink|Placebo water with carbonation and aroma
224086988|NCT04689230|PROCEDURE|upper eyelid blepharoplasty|upper eyelid blepharoplasty
224086989|NCT00352703|DRUG|Kepivance (Palifermin)|
224086990|NCT02566720|DRUG|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
224277813|NCT01889797|BIOLOGICAL|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
224277814|NCT00569660|DRUG|Azacitidine|75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
224277815|NCT00050076|DRUG|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
224277816|NCT00050076|DRUG|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
224277817|NCT00050076|DRUG|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
224277818|NCT00050076|DRUG|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
224277819|NCT00731991|OTHER|ART|ART to the levator scapulae.
224086991|NCT02566720|PROCEDURE|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
224086992|NCT00193830|PROCEDURE|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
224086993|NCT03346330|DRUG|TRK-750|TRK-750 capsule
224086994|NCT03346330|DRUG|Placebo|Placebo capsule
223912603|NCT06125210|PROCEDURE|tracheotomy|early tracheotomy for special diseases (e.g central nervous system diseases) receiving mechanical ventilation 14-21 days recommended tracheotomy
223912604|NCT03747419|DRUG|Avelumab|Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.
223912605|NCT03747419|RADIATION|Radiation|Cancer treatment that uses ionizing radiation to kill cancer cells.
223912606|NCT05055804|DEVICE|ELG|"The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well."
223912607|NCT04925193|DRUG|Selinexor|Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).
224086995|NCT04159090|DIAGNOSTIC_TEST|F18-PSMA|Patients with moderate or high risk of prostate cancer
224086996|NCT03502512|OTHER|Questionnaire Administration|Ancillary studies
224086997|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
224086998|NCT03502512|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
224086999|NCT02681666|DIETARY_SUPPLEMENT|Dietary intervention|Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
224087000|NCT02681666|BEHAVIORAL|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
223529576|NCT06245863|DEVICE|Negative pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 milliwatts (mW) per laser. Vacuum therapy: 60 mm suction cup, pulsed mode (MP9, 50 pulsations per minute) and pressure of -150 at -350 mbar. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
223529577|NCT06245863|DEVICE|Positive Pressure and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Positive Pressure: Massage with rollers. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
223529578|NCT06245863|DEVICE|Ultrasound and Laser|Synergistic application (single handle) - Laser: Red (660 nm) and infrared (808 nm) lasers, continuous mode, 100 mW per laser. Ultrasound: 1 megahertz (MHz), continuous mode and 1 milliwatts per square centimeter (mW/cm2). The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
223716234|NCT00303784|DRUG|Goserelin|3.6mg implant, in pre-filled syringe
223912608|NCT04925193|DRUG|Pomalidomide|Oral Table
223912609|NCT04925193|DRUG|Daratumumab|Injection
223912610|NCT04925193|DRUG|Carfilzomib|Injection
223912611|NCT04925193|DRUG|Dexamethasone|Oral tablet or injection
224087001|NCT02948361|OTHER|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
224087002|NCT04092842|DEVICE|Silicone prosthesis|Silicone prosthesis
224087003|NCT04092842|PROCEDURE|Usual practice|Usual surgery
224087004|NCT02103140|BEHAVIORAL|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
224087005|NCT02103140|BEHAVIORAL|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
224087006|NCT00008385|OTHER|placebo|Given orally
224087007|NCT00008385|DRUG|selenium|Given orally
224087008|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
224087009|NCT00582556|DRUG|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
224087010|NCT00582556|DRUG|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
224087011|NCT00595231|DRUG|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
224087012|NCT00595231|DRUG|Placebo|0 mg tablets
224087013|NCT01993888|BIOLOGICAL|EVARREST® Fibrin Sealant Patch|
224087014|NCT01993888|OTHER|Standard of Care (SoC)|
224087015|NCT02519114|PROCEDURE|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
224087016|NCT01501903|PROCEDURE|Standard|FNA in a single plane
224087017|NCT01501903|PROCEDURE|Fanning|FNA in multiple planes
224277820|NCT00731991|OTHER|PNF|PNF to the levator scapulae.
224277821|NCT00731991|OTHER|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
223912612|NCT05686525|PROCEDURE|Transurethral Microwave Thermotherapy|TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.
224087018|NCT03993717|BIOLOGICAL|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
224087019|NCT00832819|DRUG|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
224087020|NCT00832819|DRUG|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
224087021|NCT00832819|DRUG|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
223912613|NCT05686525|PROCEDURE|Prostate Artery Embolisation|In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.
223912614|NCT00254423|DRUG|Dasatinib|Given PO
223716235|NCT00303784|DRUG|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
223912615|NCT00254423|OTHER|Laboratory Biomarker Analysis|Correlative studies
223912616|NCT00254423|OTHER|Pharmacological Study|Correlative studies
223912617|NCT00254423|OTHER|Quality-of-Life Assessment|Ancillary studies
223912618|NCT00254423|OTHER|Questionnaire Administration|Ancillary studies
223912619|NCT05416424|OTHER|LIFE program|During the nutritionist visits, subjects will be asked to discuss and evaluate their current diet and will be given recommended dietary changes. The recommended dietary changes include focusing on eating nutrient dense foods, staying consistent with the timing of meals, limiting added sugars, aiming to have balanced meals and snacks, being a mindful eater, and aiming to drink approximately 2 liters of water a day. Additionally, they will review the nutrition survey with the registered dietician. During the office visits with a doctor, subjects will be given exercise counseling. They will be asked to do 150 minutes per week of moderate intensity aerobic activity
223912620|NCT03957902|DRUG|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
223912621|NCT02299999|DRUG|AZD2014|Target: m-TOR
223912622|NCT02299999|DRUG|AZD4547|Target: EGFR
223912623|NCT02299999|DRUG|AZD5363|Target: AKT
223912624|NCT02299999|DRUG|AZD8931|Target: HER2, EGFR
223912625|NCT02299999|DRUG|Selumetinib|Target: MEK
223912626|NCT02299999|DRUG|Vandetanib|Target: VEGF, EGFR
223912627|NCT02299999|DRUG|Bicalutamide|target: Androgen receptor
223912628|NCT02299999|DRUG|Olaparib|Target: PARP
223912629|NCT02299999|DRUG|Anthracyclines|DNA intercalation
223912630|NCT02299999|DRUG|Taxanes|Target: mitotic tubulin and microtubules
224087022|NCT00832819|DRUG|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
224087023|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg twice daily
223912631|NCT02299999|DRUG|cyclophosphamide|Alkylating agents
223912632|NCT02299999|DRUG|DNA intercalators|DNA intercalators
223912633|NCT02299999|DRUG|Methotrexate|DNA intercalators
223912634|NCT02299999|DRUG|vinca alkaloids|Target: mitotic tubulin and microtubules
223912635|NCT02299999|DRUG|Platinum based chemotherapies|Platinum based chemotherapies
223912636|NCT02299999|DRUG|Bevacizumab|Target: VEGF
223912637|NCT02299999|DRUG|Mitomycin C|Alkylating agents
223912638|NCT02299999|DRUG|Eribulin|Microtubule modulator
223912639|NCT02299999|DRUG|MEDI4736|Target: PD-L1
223912640|NCT04451772|DRUG|Elsubrutinib|Capsule; Oral
223912641|NCT04451772|DRUG|Placebo for Elsubrutinib|Capsule; Oral
223912642|NCT04451772|DRUG|Upadacitinib|Film-coated tablet; Oral
223912643|NCT04451772|DRUG|Placebo for Upadacitinib|Film-coated tablet; Oral
224087024|NCT00317044|DRUG|Esomeprazole|Esomeprazole 40 mg once daily
224087025|NCT00317044|DRUG|Placebo|Placebo twice daily
224087026|NCT00320970|DRUG|Candesartan|
224087027|NCT02426814|DEVICE|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
224087028|NCT02426814|BEHAVIORAL|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
224087029|NCT04852640|PROCEDURE|Active Rehabilitation Program (ARP)|The ARP intervention consists of therapeutic exercises designed to increase shoulder strength and endurance using a cluster of common exercises used for the treatment of shoulder pain. Specifically, the ARP program will focus on increasing scapular motor-control through a phasic program of common therapeutic exercises. This concept has been shown in the literature as capable of reducing shoulder pain and improving function in a variety of pathological conditions, however, the effect of this approach to reducing pain and increasing function for symptomatic shoulder instability is unknown. The selection of exercises and application for each exercise included in the ARP is based on recommendations from the literature and will incorporate participant feedback to customize dosages.
223529579|NCT06245863|DEVICE|Laser|Infrared Laser (808 nm), continuous mode, 100 mW. The treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
223529580|NCT06245863|DEVICE|Placebo Laser|Laser: off mode. The placebo treatment was carried out during 20 minutes on the lumbar, thoracic and cervical spine regions. Seven sessions were performed.
223529581|NCT03890094|DRUG|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
223529582|NCT05921786|DEVICE|Electrophysiological system|Electrophysiological system is used for examining voltage variation in biological samples. And multiphoton microscopy is a common type of nonlinear optical microscope.
223529583|NCT05921786|DEVICE|Multiphoton microscope|Multiphoton microscope acquires high-resolution image based on nonlinear optics and can be used for detect biological specimens.
223912644|NCT06280781|DIAGNOSTIC_TEST|MRI Scans|"The regular use of MRI in active surveillance will lead to greater confidence in active surveillance for patients with low and medium risk prostate cancer. This is because such a strategy is likely to detect cancer progression earlier with fewer invasive biopsies. Those patients randomised to the intervention arm will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.~Patients with a visible lesion or medium risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5. In all patients, a targeted biopsy will be carried out if the MRI PRECISE score is \>/=4."
224087030|NCT04852640|PROCEDURE|Nonspecific Passive Intervention (NPI)|The NPI intervention consists of a non-specific treatment approach to shoulder pain that is commonly administered in the clinical setting. Specifically, passive modalities such as ultrasound, massage, and sensory electric stimulation are commonly prescribed in the treatment of shoulder pain to modulate pain. Further, general core strengthening exercises are often implemented. Therefore, the NPI will consist of regularly prescribed passive treatments and general core strengthening exercises, as commonly administered in routine treatment of shoulder pain.
224087031|NCT05421611|BIOLOGICAL|STAMARIL|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent."
224087032|NCT05421611|BIOLOGICAL|SII-YFV|"SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine. The SII-YFV is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF working seed virus.~SII-YFV will be provided in vial presentation for the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with sterile water for injection."
224087033|NCT05742984|DRUG|linaprazan glurate 25 mg QD|"The subjects will receive 25 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
224087034|NCT05742984|DRUG|linaprazan glurate 50 mg QD|"The subjects will receive 50 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
224087035|NCT05742984|DRUG|linaprazan glurate 75 mg QD|"The subjects will receive 75 mg dose in the evening, in a non-fasted condition 30 minutes after the evening meal, for 14 days. Subjects are to follow a standardized food intake schedule.~After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more in the evening (non-fasted)."
224277822|NCT04039360|COMBINATION_PRODUCT|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
223529584|NCT05933811|PROCEDURE|exploratory laparoscopy|Laparoscopic exploration for impalpable maldescended testis in pediatric age group
223529585|NCT05134649|DRUG|OnabotulinumtoxinA|Intramuscular Injection
223529586|NCT05443828|OTHER|Breakfast Control Meal|The participants consumed extruded puff with added vitacel (cellulose) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
223529587|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed bread with added arabynoxylans (AX) as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
223529588|NCT05443828|OTHER|Breakfast Test Meal|The participants consumed extruded puff with added wheat bran as part of the breakfast meal (400 kcal, 12 g fiber) followed by consumption of standardised meal at lunch and dinner . The lunch and dinner did noft contain any intervention products. Blood samples were collected at 14 timepoints drawn (first sample 15 minutes before breakfast, last sample 24 hours after breakfast), during 6 hours after the test breakfast meal and during other 2 hours after standardised lunch.
223535236|NCT06707922|DRUG|Peginterferon α-2b Injection; Tenofovir Alafenamide Fumarate|Peginterferon α-2b Injection, subcutaneous injection, once a week. Tenofovir Alafenamide Fumarate, Oral administration, once a day.
223912645|NCT04565834|GENETIC|SNP (single nucleotide polymorphism) genotyping|"We use TaqMan technique to perform SNP genotyping. The PCR reactions are carried out using the Roche Light Cycler 480 thermal cycler following the protocol recommended by Thermo Fisher Scientific. Then, replication of 10% of the samples is carried out."
223912646|NCT05083754|DRUG|Retifanlimab|Anti-PD-1 Therapy
223912647|NCT05083754|DRUG|Temozolomide|Anti-PD-1 Therapy
223912648|NCT05083754|RADIATION|Radiation Therapy|Standard of Care
223912649|NCT06080698|DRUG|Intravenous Antibiotics|Participants will continue to receive intravenous antibiotics until the completion of the treatment course
223912650|NCT06080698|DRUG|Oral Antibiotics|Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
223912651|NCT04561492|DRUG|[68Ga]Ga-PentixaFor|Tomography by emission of positons (PET) with theradiopharmaceutic \[68Ga\]Ga-PentixaFor
223912652|NCT06106204|OTHER|ROAD Home Intervention|Hospitals randomized to receive the ROAD Home Intervention will undergo (1) a baseline needs assessment to create a customized suite of stewardship strategies, (2) supported decision-making in selecting ROAD Home strategies to implement, and (3) external facilitation following an implementation blueprint.
223912653|NCT06197997|BEHAVIORAL|Chicago Parent Program (CPP)|The Chicago Parent Program (CPP) is a 12-session group-based parenting intervention designed to strengthen parenting skills and parent engagement in children's learning and improve children's social-emotional and behavioral competence.
224087036|NCT05742984|DRUG|linaprazan glurate 25 mg BID|The subjects will receive 25 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
224087037|NCT05742984|DRUG|linaprazan glurate 50 mg BID|The subjects will receive 50 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
224087038|NCT05742984|DRUG|linaprazan glurate 75 mg BID|The subjects will receive 75 mg dose twice daily, in the morning and in the evening for 14 days. Subjects will be fasted for ≥10 hours overnight before dosing on Day 1 and day 14, until 30 minutes post-dose. During fasting, tap water, but no other drinks, are allowed as desired, except for 1 hour before and 30 minutes after dosing. The second daily dose will be administered 30 minutes after the evening meal, i.e. in a non-fasted condition. The subjects are to follow a standardized food intake schedule. After a drug holiday period of either 2, 4 or 6 days, linaprazan glurate will be given once more (in fasted condition in the morning, non-fasted in the evening).
224087039|NCT00379340|RADIATION|3-Dimensional Conformal Radiation Therapy|
224087040|NCT00379340|PROCEDURE|Conventional Surgery|
224087041|NCT00379340|DRUG|Cyclophosphamide|Given IV
223529589|NCT04157335|BIOLOGICAL|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).~For OLE, Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses and every 8 weeks for the rest 5 doses. For the patients on Benralizumab treatment during double blind period, placebo will be dosed at the second dose during OLE."
223529590|NCT04157335|BIOLOGICAL|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
223535237|NCT06715358|BEHAVIORAL|Reintervention|"* SI! Program environment intervention from 2nd grade through all Elementary Education.~* SI! Program classroom intervention in 2nd grade.~* SI! Program classroom intervention in 5th grade."
223912654|NCT05696119|BEHAVIORAL|I-PROTECT|I-PROTECT is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes end-user-targeted information and injury prevention physical and psychological training, specifically tailored for youth handball. The intervention is delivered through a mobile application (I-PROTECT GO) specifically developed for the I-PROTECT project, including coach, player, club administrator, and caregiver modules. Tailored support to implement I-PROTECT is specifically developed for Swedish community youth handball.
223912655|NCT05696119|BEHAVIORAL|Control|"Coaches of youth teams in the control group clubs will be offered currently available injury prevention training (i.e., Redo för Handboll, English: Ready for Handball), accessible online through the Swedish Handball Federation's coach education material."
223912656|NCT04259281|DRUG|GTX-102|antisense oligonucleotide
223912657|NCT04871048|DEVICE|Transcranial direct current stimulation (tDCS) active|Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.
224087042|NCT00379340|BIOLOGICAL|Dactinomycin|Given IV
224087043|NCT00379340|DRUG|Doxorubicin Hydrochloride|Given IV
224087044|NCT00379340|DRUG|Etoposide|Given IV
224087045|NCT00379340|DRUG|Vincristine Sulfate Liposome|Given IV
224087046|NCT06351293|DEVICE|Defyne Treatment in Nasolabial Fold|Defyne will be injected into left or right nasolabial fold, per randomization.
224087047|NCT06351293|DEVICE|RHA3 Treatment in Nasolabial Fold|RHA3 will be injected into left or right nasolabial fold, per randomization.
224087048|NCT04801758|OTHER|Analytical Treatment Interruption|"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."
224087049|NCT05356767|PROCEDURE|Pharmacomechanical thrombolysis|Pharmacomechanical thrombolysis
224087050|NCT05046028|DIETARY_SUPPLEMENT|Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet|ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
224277823|NCT04776304|BEHAVIORAL|Art Therapy|"This is a pilot study in which every participant receives the art therapy intervention arm. There are no waitlist or control arms. Art therapy is one promising intervention that helps service members (SMs) develop a visual voice, using imagery, symbolism, and metaphor to externalize emotions and experiences that they may not be able to express in words. The standardized, integrative mental health and human services approach of the art therapy program at the NICoE utilizes a mask-making directive to explore thoughts, feelings, and experiences of combat and self-understanding. This process is especially relevant to SMs with PTS symptoms who often remember their trauma as an incoherent, fragmented memory that is often predominantly sensory in nature. NICoE researchers have provided preliminary evidence suggesting associations between recurring art themes represented within the masks and individual BH symptoms."
223529591|NCT03162536|DRUG|Nemtabrutinib|Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
223529592|NCT05050162|DRUG|Cisplatin|Given cisplatin IV every 3 weeks
223912658|NCT04871048|DEVICE|Transcranial direct current stimulation (tDCS) non active|The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
223912659|NCT02507141|DEVICE|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
223912660|NCT05920889|DRUG|Semaglutide|0.5mg subcutaneous injection of the drug before or during EVT, and 7 days after the procedure. i.e. patient will receive a total of 2 injections.
223912661|NCT05268081|OTHER|Virtual specialist conferences|"The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic Diabetes Overview to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min)."
223529593|NCT05050162|DRUG|Cisplatin|Given cisplatin IV weekly
223529594|NCT05050162|PROCEDURE|Computed Tomography|Undergo CT scan
223529595|NCT05050162|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223529596|NCT05050162|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223529597|NCT05050162|OTHER|Quality-of-Life Assessment|Ancillary studies
223529598|NCT05050162|OTHER|Questionnaire Administration|Ancillary studies
223529599|NCT05050162|RADIATION|Radiation Therapy|Undergo radiation therapy
223529600|NCT05610163|DRUG|Capecitabine|Given PO
223529601|NCT05610163|DRUG|5-fluorouracil|Given IV
223529602|NCT05610163|DRUG|Leucovorin calcium|Given IV
223529603|NCT05610163|DRUG|Irinotecan|Given IV
224087051|NCT05046028|DIETARY_SUPPLEMENT|ONS without a sensor component and taste + standard diet|Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
223912662|NCT02828358|DRUG|Azacitidine|Given IV
223912663|NCT02828358|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223912664|NCT02828358|PROCEDURE|Computed Tomography|Undergo CT scan
223912665|NCT02828358|DRUG|Cyclophosphamide|Given IV
223912666|NCT02828358|DRUG|Cytarabine|Given IV, SC, IT
223912667|NCT02828358|DRUG|Daunorubicin|Given IV
223912668|NCT02828358|DRUG|Daunorubicin Hydrochloride|Given IV
223912669|NCT02828358|DRUG|Dexamethasone|Given PO, NG, IV
223912670|NCT02828358|PROCEDURE|Echocardiography|Undergo ECHO
223912671|NCT02828358|DRUG|Hydrocortisone Sodium Succinate|Given IT
223912672|NCT02828358|DRUG|Leucovorin|Given PO, IV
223912673|NCT02828358|DRUG|Leucovorin Calcium|Given PO, IV
223912674|NCT02828358|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223912675|NCT02828358|DRUG|Mercaptopurine|Given PO, NG
223912676|NCT02828358|DRUG|Methotrexate|Given IT, IV, PO
223912677|NCT02828358|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223912678|NCT02828358|DRUG|Pegaspargase|Given IV
224087052|NCT05046028|DIETARY_SUPPLEMENT|Standard diet|Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
224087053|NCT02162862|BEHAVIORAL|Behavioral Counseling|
224087054|NCT02162862|DRUG|bupropion-SR|
223912679|NCT02828358|DRUG|Prednisolone|Given PO, NG
224277824|NCT04952168|DRUG|Almonertinib|All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.
223912680|NCT02828358|DRUG|Thioguanine|Given PO, NG
223912681|NCT02828358|DRUG|Vincristine|Given IV
223912682|NCT02828358|DRUG|Vincristine Sulfate|Given IV
224277825|NCT01974362|DEVICE|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
223912683|NCT06520423|PROCEDURE|Urethral stent tube irrigation|During urethroplasty, a Fr3 ureteral catheter will be placed in the reconstructed urethra, with the proximal end extending approximately 2 cm beyond the urethral wound. The distal end will connect to an F6 single-lumen ureter and a urinary bag. On the second postoperative day, the urethra will be irrigated with 5 ml of saline twice daily. This irrigation routine will continue until the catheter is removed.
223912684|NCT06520423|PROCEDURE|Urinary catheter drainage|During urethroplasty, intraurethral retention of urethral catheters is used to drain urine from the bladder.
223912685|NCT06407297|DRUG|UCMSCs|Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
223912686|NCT06407297|DRUG|Placebo|Peripheral intravenous infusion of Placebo
224277826|NCT01974362|DEVICE|Monolithic Zirconia (MZ)|rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer
223912687|NCT04819737|PROCEDURE|SC MRI|SC MRI (Averaged Magnetization Inversion Recovery Acquisitions (AMIRA), standard conventional SC MRI sequences, additional sequences for spinal cord MRI (sagittal-2D or 3D short tau inversion recovery, sagittal-2D or 3D phase-sensitive inversion recovery, 3D magnetization prepared 2 rapid acquisition gradient echoes (MPRAGE)). To evaluate the presences of ongoing inflammation (acute or chronic) in the SC of patients, 3D MPRAGE and 3D fluid-attenuated inversion recovery images after intravenous gadolinium (Gd) contrast administration (0.1 mmol per kg body weight) will be acquired.
223912688|NCT04819737|OTHER|patient questionnaire|12-item multiple sclerosis walking scale (MSWS-12) questionnaire: self-report measure of the impact of MS on the individual's walking ability
223912689|NCT06035354|DRUG|AK120|subcutaneous injection once a week
223912690|NCT06035354|DRUG|AK120|subcutaneous injection once a week
223912691|NCT06035354|DRUG|Placebo|subcutaneous injection once a week.
223912692|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
223912693|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
223912694|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
223912695|NCT06035354|DRUG|Placebo|subcutaneous injection every 2 weeks for 16 weeks then crossover to AK120 Regimen 4 and Regimen 5.
223912696|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks
223912697|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
223912698|NCT06035354|DRUG|AK120|subcutaneous injection every 2 weeks.
223912699|NCT06079255|DEVICE|IscAlert sensor(s) in patient with risk of acute compartment syndrome|of the replanted extremity Insertion of a CO2- and temperature sensor(s) (IscAlert) in the anterior compartment of a lower limb (leg)
223912700|NCT04784494|DEVICE|Magnetic Seizure Theapy (MagPro XP MST)|"MST treatment will be administered over the frontal/vertex cortex using 100 Hz stimulation using the MagPro XP MST with Cool TwinCoil. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~MST treatments will be administered twice a week, for up to 16 treatments. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
223912701|NCT03340675|DRUG|Ifetroban|Weight based, once daily oral ifetroban
224087055|NCT01910792|DEVICE|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
224087056|NCT03632057|DEVICE|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
224087057|NCT03632057|DEVICE|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
224087058|NCT05884866|DRUG|Dapagliflozin 10mg Tab|see arms
224087059|NCT05884866|DRUG|Balcinrenone 50mg Capsule|see arms
224087060|NCT05884866|DRUG|Balcinrenone 100mg Capsule|see arms
224087061|NCT05884866|DRUG|Dapagliflozin matching Placebo|see arms
224087062|NCT05884866|DRUG|Balcinrenone 50mg matching Placebo|see arms
224087063|NCT05884866|DRUG|Balcinrenone 100mg matching Placebo|see arms
224087064|NCT06079502|DEVICE|Neuromuscular Electrical Stimulation|A supervised program of intradialytic NMES of the quadriceps and calf muscles of both lower limbs with different phases, types and current intensity. The electrical stimulation program will included (total time, intensity, contraction-relaxation phase time): a toning program in the first two weeks.
224087065|NCT06079502|OTHER|resistive training program|"Part one: Warming up for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~Part two: The main part is the resistive training for quadriceps and calf muscles from supine position using weights in the form of sand bags for 20 min.~Part three: Cooling down for 5 minutes in the form of lower limbs range of motion (active free) exercise from supine position.~The training parameters:~The exercise training will be done during the first 2 hours of HD session using free leg weights. The patient will assume a supine lying position on the treatment plinth and perform the exercises for every lower limb separately while the other limb will be supported on the plinth by therapist or the patient himself. Resistance will be placed at the malleoli level in the distal third of the leg."
224087066|NCT03089567|DRUG|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
224087067|NCT03089567|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
224087068|NCT06960226|OTHER|Music Listening|Participants listen to selected instrumental music excerpts presented via headphones during designated experimental trials.
224087069|NCT06960226|OTHER|Silence Control|Participants experience periods of silence with no music presented via headphones during designated control trials. This serves as the auditory control condition compared to Music Listening.
224087070|NCT06960226|OTHER|Active Sensorimotor Synchronization|Participants actively synchronize movements (such as foot tapping and/or head nodding) by timing them with the rhythm of the presented music or with a pacing stimulus provided during silent trials.
224087071|NCT06960226|OTHER|Passive Control Task|Participants remain still and do not perform specific instructed synchronized movements during designated control trials. This serves as the motor task control condition compared to Active Sensorimotor Synchronization.
224087072|NCT06960889|OTHER|radiotherapy|Definitive radiotherapy or radiotherapy-based combined modality therapy
224087073|NCT06960889|DRUG|Immunotherapy|Immune checkpoint inhibitors as monotherapy or in combination with other therapies
224087074|NCT06960889|PROCEDURE|surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines|Radical esophagectomy with or without neoadjuvant/adjuvant therapy
224087075|NCT06960512|BEHAVIORAL|Precision Lifestyle Intervention (PLI) group|"1. Device Application: Participants in the intervention group will wear the GX-01S continuous glucose monitoring system, with data transmitted in real-time to a secure cloud platform.~2. Multidisciplinary Management: A specialized team (health managers, nutritionists, endocrinologists, and Counselor) will analyze glucose fluctuations, dietary patterns, sleep health, physical activity and to formulate personalized adjustment plans. Modifications may include meal timing optimization, sleep duration regulation, and exercise frequency adaptations.~3. Telehealth Follow-up: Participants will receive structured guidance via telephone/telemedicine consultations throughout the 28-day intervention period. Type 2 Diabetes Mellitus (T2DM) patient compliance will be systematically monitored and documented.~4. Tailored Recommendations: Evidence-based lifestyle recommendations will be provided post-intervention, informed by quantitative biomarker data and adherence metrics collected."
224087076|NCT06960408|OTHER|sleep hygiene education and progressive relaxation exercise|The study will be conducted with diabetic individuals who come to the endocrine clinic. The study will be conducted for 6 months. Intervention group Individuals who accept the study will be given face-to-face Progressive Relaxation Exercise training by the researcher in the first week of the first month of the study and will be applied. The Progressive Relaxation Exercise application will also be sent to the patient via WhatsApp and will be applied with the researcher via online interviews in the 2nd, 3rd and 4th weeks for 30 minutes 3 days a week (Monday-Wednesday-Friday). From the 2nd month of the study to the end of the 6th month, the patient will be asked to do the Progressive Relaxation Exercise on their own for 30 minutes 3 days a week (Monday, Wednesday, Friday). No intervention will be made to the control group.
224087077|NCT06960785|DEVICE|MEL90 excimer laser - PRESBYOND|"Participants will undergo laser eye surgery in both eyes using the PRESBYOND method. First, a thin flap is created on the surface of the eye using a femtosecond laser. Then, a second laser (excimer laser) reshapes the cornea to improve vision at near, intermediate, and far distances.~The treatment is similar to monovision techniques, where one eye is mainly corrected for distance and the other for near vision. However, PRESBYOND differs by adjusting the depth of focus in each eye individually, allowing the brain to better combine the two images in the intermediate range-this area is called the Blend Zone. This approach helps preserve natural binocular (3D) vision, contrast sensitivity, and depth perception. Most patients adapt well and quickly to this type of correction. The procedure is customized based on each patient's age and eye characteristics."
224277827|NCT01974362|DEVICE|Zirconia-Feldspathic (PVZ)|restore dental implants with a zirconia suprastructure and feldspathic veneers
224277828|NCT01974362|DEVICE|Monolithic Zirconia (FCMZ)|Full contour full arch zirconia rehabilitation
224277829|NCT04792580|DRUG|Lifitegrast 5% Ophthalmic Solution|Used twice a day in both eyes for 4 weeks after a 2 week washout.
224277830|NCT04792580|DRUG|Placebo|Used twice a day in both eyes for 4 weeks after a 2 week washout with the same drops.
224277831|NCT00571480|OTHER|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
223529604|NCT05610163|DRUG|Oxaliplatin|Given IV
223912702|NCT03340675|DRUG|Placebo|Matching oral placebo
223912703|NCT05172232|DIAGNOSTIC_TEST|Dermalyzer|To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
223912704|NCT05332613|BEHAVIORAL|TRE plus SOC|Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
223912705|NCT05332613|BEHAVIORAL|SOC|Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
223912706|NCT05332613|BEHAVIORAL|TRE|Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
223912707|NCT05241210|DEVICE|AI program for colonoscopy|Provides real-time feedback on the endoscopist moniter during colonoscopy.
223912708|NCT06198725|DIETARY_SUPPLEMENT|Trimtab|High fiber group will take Trimtab (a kind of multi bran and high fiber grain compound powder) 60g per day to intake 28g dietary fiber for 12 weeks.
223912709|NCT03919266|PROCEDURE|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
223912710|NCT03919266|PROCEDURE|Control: usual antibiotic treatment|usual antibiotic treatment
223912711|NCT03740282|DEVICE|Lapiplasty|Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
223912712|NCT03632798|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
223912713|NCT03632798|DRUG|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~* Liposomal Doxorubicin;~* Docetaxel;~* Paclitaxel;~* Carboplatin;~* Cisplatin;~* Gemcitabine;~* Topotecan;~* Carboplatin, Gemcitabine;~* Cisplatin, Gemcitabine;~* Carboplatin, Liposomal Doxorubicin;~* Carboplatin, Paclitaxel;~* Carboplatin, Docetaxel."
223912714|NCT01828021|BIOLOGICAL|Margetuximab|Anti-HER2 monoclonal antibody
223912715|NCT03964363|BEHAVIORAL|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
223912716|NCT04943445|DRUG|carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles|Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
223912717|NCT04943445|RADIATION|Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.|Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
223912718|NCT04943445|DRUG|Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.|Consolidation immunotherapy
223912719|NCT06822023|DEVICE|virtual reality mask|Patients will be prepared as per the standard routine clinical care; they will then be wearing the VR mask for 10 minutes. No other study have looked into VR mask prior to cataract surgery
224277832|NCT00571480|OTHER|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
224277833|NCT00571480|OTHER|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
224277834|NCT04966962|DIAGNOSTIC_TEST|serum and urine metabolomics|serum and urine samples will be collected for metabolomics analysis
224277835|NCT03782662|DRUG|Itraconazole|Itraconazole capsules
224277836|NCT03782662|DRUG|Verapamil|Verapamil tablets
224277837|NCT03782662|DRUG|Rifampicin|Rifampicin capsules
223912720|NCT04421846|OTHER|Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
223912721|NCT04421846|OTHER|Blood sampling, cerebrospinal fluid, stool sampling post-mortem cerebral tissues (NA for the Group 3)|Collection of biological samples and clinical/paraclinical data
223912722|NCT04012931|DRUG|Rilpivirine|Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
223912723|NCT04012931|DRUG|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine \[AZT\], abacavir \[ABC\], tenofovir alafenamide \[TAF\], or tenofovir disoproxil fumarate \[TDF\] in combination with emtricitabine \[FTC\] or lamivudine \[3TC\]), whichever are approved and marketed or considered local standard of care for children aged between 2 and \< 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir \[DTG\] or raltegravir) can also be administered in combination with RPV, as appropriate.
223912724|NCT03995394|OTHER|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
223912725|NCT06822296|OTHER|Physical Therapy|Exercises to improve function of children with CP
223912726|NCT06822296|OTHER|Designed rehabilitation program|Program of exercises to enhance function
223912727|NCT06660290|DRUG|0.003% AR-15512 ophthalmic solution|Investigational ophthalmic solution for topical instillation
223912728|NCT06660290|DRUG|REFRESH® Classic ophthalmic solution|Commercially available ophthalmic solution for topical instillation
224277838|NCT03782662|DRUG|Midazolam|Midazolam oromucosal solution
224277839|NCT03782662|DRUG|Placebo for RV521|Placebo for RV521 capsules
224277840|NCT03782662|DRUG|RV521|RV521 capsules
224277841|NCT01134991|DRUG|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
224277842|NCT06449391|DEVICE|RAI|Immediate implantation
223529605|NCT05610163|RADIATION|Long Course Chemoradiotherapy|Receive LCRT
223912729|NCT06756243|OTHER|Hydrogen Ion Water（Shan Shang Water）|Hydrogen Ion Water (also known as Hydrogen-Rich Water or Hydrogen Water) refers to water that contains dissolved hydrogen gas (H₂). Hydrogen gas is a powerful antioxidant that is believed to neutralize free radicals in the body, which may help reduce oxidative stress and improve overall health.
223912730|NCT06756243|DRUG|Budesonide Nasal Spray therapy|Budesonide Nasal Spray: Administered as 2 sprays twice daily (bid).
223912731|NCT04844294|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT is divided into three phrases. In phase I (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills such as relaxation and mindfulness. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
224277843|NCT02261220|BIOLOGICAL|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
224277844|NCT02261220|BIOLOGICAL|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
224277845|NCT03240120|DRUG|Dabigatran etexilate|Pradaxa 150 mg hard capsules
224277846|NCT03240120|DRUG|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
224277847|NCT01937689|DRUG|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
224277848|NCT00881231|DRUG|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
224277849|NCT00881231|DRUG|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
223940093|NCT05866003|DEVICE|Active unconventional tDCS montage plus CCFES|tDCS is a non-invasive brain stimulation technique. A small machine (9-volt battery operated device) will use a weak amount of electric current to stimulate the brain without any invasive procedure. Electrodes, covered in sponges soaked in saline, will be placed over certain parts of your head and held in place using a rubber strap. In addition, An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract.
223940094|NCT05866003|DEVICE|Sham tDCS plus CCFES|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator.
224277850|NCT05595720|DEVICE|hight intenisty laser|7W(LAZR-207)/15W(LAZR-215\&115)HIGH POWER LASER THERAPYUNIT WITH 2 WAVELENGTHMODES,COMBINATION(810+980 NM) AND SINGLE(1064 NM)
224277851|NCT01362192|DEVICE|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~* Spot Size: 5 mm~* Fluence: 13-15 J/cm2~* Pulse Duration: 40 ms~* Epidermal contact-cooling: 5° Celsius"
223529606|NCT05610163|PROCEDURE|Computed Tomography|undergo CT
223529607|NCT05610163|PROCEDURE|Magnetic Resonance Imaging|undergo MRI
223529608|NCT05610163|PROCEDURE|Sigmoidoscopy|undergo sigmoidoscopy
223529609|NCT05610163|PROCEDURE|biopsy|undergo biopsy
223529610|NCT06412120|DRUG|Niraparib|Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
223529611|NCT06103838|DRUG|18F-fluciclovine injection|370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.
223940095|NCT05866003|BEHAVIORAL|CCFES with Occupational Therapy|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator. During the lab visits, all participants will use CCFES to assist hand opening during occupational therapy task practice.
223940096|NCT02915315|DIETARY_SUPPLEMENT|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
223940097|NCT05964023|DEVICE|pBFS rTMS|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
223940098|NCT05964023|DEVICE|5-cm rTMS|"Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be localized by 5-cm rule."
223940099|NCT01343797|OTHER|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
223940100|NCT03842605|OTHER|Strength training|
223940101|NCT05538689|DRUG|Myfembree Oral Product|The study drug Myfembree will be taken orally with water, once daily, at approximately the same time, with or without food. Each tablet of Myfembree contains Relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5 mg.
223940102|NCT06426953|OTHER|No intervention|No intervention
223940103|NCT05549323|DRUG|PF-07054894|Oral
223940104|NCT05549323|DRUG|Placebo|Placebo
223940105|NCT00461019|PROCEDURE|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
223940106|NCT03150875|DRUG|IBI308|Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
223940107|NCT03150875|DRUG|Docetaxel|As 2nd line treatment to subjects with squamous NSCLC
223912732|NCT04844294|BEHAVIORAL|Present-Centered Therapy (PCT)|PCT includes (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions. PCT differs from BCBT in several key ways including less structure (i.e., patients are allowed to have more input into PCT session agendas) and no systematic training in behavioral or cognitive strategies for managing emotions and changing suicide-focused thoughts. PCT will be used as an active comparator because it is an empirically supported treatment for depression and PTSD that also reduces suicidal ideation (Bryan et al., 2016; Resick et al., 2017), but contains unique elements that distinguish the treatment from BCBT.
223912733|NCT04601480|BEHAVIORAL|Choice Architecture Nudge|During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
224087078|NCT06959732|DRUG|zanubrutinib, obinutuzumab,combined with CVP|Zanubrutinib (160 mg, twice daily \[bid\]), obinutuzumab (1000 mg on cycle 1 \[C1\], days 1, 8, and 15; on cycle 2 - 6 \[C 2-6\], day 1), cyclophosphamide (750 mg/㎡ on day 1), vincristine (1.4 mg/㎡, maximum dose 2 mg on day 1), and prednisone tablets (40 mg/㎡ once daily \[qd\] orally on days 1-5) were used every 21 days as a treatment cycle. Six cycles of treatment were completed, and the efficacy was reviewed every two cycles. Patients with PD were excluded from the group. MRD was detected after six cycles. If MRD was negative, routine maintenance therapy was performed (obinutuzumab 1000 mg once every 8 weeks, a total of 12 times). If MRD was positive, Zanubrutinib (160 mg, continuous bid) was added to the conventional maintenance therapy for 12 months.
224087079|NCT01703000|DEVICE|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
224087080|NCT06413004|OTHER|Elimination and re-introduction of CLE or COLAP positive food item(s)|Elimination (4 weeks) and re-introduction (4 weeks) of all CLE or COLAP positive food item(s)
224087081|NCT04918563|DRUG|Nitroglycerin|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
224087082|NCT04918563|DRUG|Acetylcholine|Vasodilatator solution is dropped on the labial surface on the lateral incisor, so it can penetrate through the sulcus.
224087083|NCT03115996|DRUG|REGN3918|Intravenous (IV) or Subcutaneous (SC)
224087084|NCT03115996|DRUG|Placebo|Matching Placebo
224087085|NCT03358914|OTHER|No intervention|Completion of surveys
224087086|NCT04349137|DEVICE|HD-tACS|non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.
224087087|NCT04349137|DEVICE|sham HD-tACS|sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
224087088|NCT03822884|DRUG|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
224087089|NCT02620904|DRUG|Mifepristone|
224277852|NCT03937791|BIOLOGICAL|E7 T Cell Receptor (TCR)|One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
224277853|NCT01259830|DRUG|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
224087090|NCT02620904|DRUG|placebo|
224087091|NCT02633371|DRUG|Oxybutynin 3% gel|
224087092|NCT01742260|PROCEDURE|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
224087093|NCT02557178|BEHAVIORAL|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
224087094|NCT05051956|DRUG|Palbociclib 125mg and Ribociclib 600 mg|Administration of Palbociclib or Ribociclib
224087095|NCT05222321|OTHER|Sensory-Play Based (SenPlay) Intervention|SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through sensory-play based activities such as pushing, pulling, climbing, jumping, crashing, and swinging. These activities are designed to facilitate changes in the child's arousal through providing sensory input to ensure the child is reaching a threshold of moderate to vigorous physical activity. Completed at three time points, once weekly for three weeks.
224087096|NCT05222321|OTHER|Spontaneous, Free Play|Participant engages in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes. Completed at three time points, once weekly for three weeks.
224087097|NCT03420560|BEHAVIORAL|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
224087098|NCT04315467|DRUG|SGM-101|A one-time infusion of SGM-101
224087099|NCT04315467|DEVICE|Near infrared camera imaging system|Near infrared camera imaging system
224087100|NCT00126165|PROCEDURE|radiotherapy|
224087101|NCT05850845|DEVICE|Microscopic hyperspectral imaging system|CTX for idiopathic membranous nephropathy
224277854|NCT01259830|DRUG|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
224277855|NCT04781244|DEVICE|EndWarts® FREEZE|EndWarts® FREEZE is an alternative home cryotherapy device. Patients don't have to go to the hospital to receive treatment for their wart.
224277856|NCT04781244|DEVICE|Liquid nitrogen|Liquid nitrogen is a conventional cryotherapy treatment for cutaneous wart performed by physician at the hospital.
224277857|NCT00376740|DRUG|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
224277858|NCT03552367|OTHER|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
224277859|NCT03552367|OTHER|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
224087102|NCT03908944|DRUG|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
223912734|NCT04601480|BEHAVIORAL|PMP Integration & Nudge|During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
223912735|NCT03717935|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) Supplement|Powder supplement
223912736|NCT03717935|OTHER|Placebo|Powder that will be similar to the essential amino acid supplement
223912737|NCT01437787|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223912738|NCT01437787|DRUG|Placebo|"Pharmaceutical form:capsule~Route of administration: oral"
223912739|NCT03316053|OTHER|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
223912740|NCT01017055|OTHER|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
223912741|NCT04643041|BEHAVIORAL|watch and wait|patients with DNA mismatch repair-deficient or microsatellite instability-high distal rectal cancer accessed pathological complete response after 6 courses of PD-1 monoclonal antibody (200mg/Course/Q3w) therapy and start watch and wait.
223912742|NCT06264453|DRUG|KH001|topical applications of KH001
223912743|NCT06264453|DRUG|Placebo|topical applications of Water for Injection
223912744|NCT06041334|BIOLOGICAL|Collection of a urine sample|Collection of a urine sample for analysis of urinary biomarkers and urinary metabolomics (Inclusion and 1 year)
223912745|NCT06041334|DIAGNOSTIC_TEST|Magnetic Resonance Imaging of the bladder|Magnetic Resonance Imaging of the bladder (10 adults patients only) (Inclusion and 1 year)
224087103|NCT03908944|DRUG|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
224087104|NCT00976144|DRUG|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
224087105|NCT03454373|BEHAVIORAL|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
224277860|NCT02296957|PROCEDURE|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
223912746|NCT06208085|DIETARY_SUPPLEMENT|Avocado|Intervention arm
223912747|NCT06225427|PROCEDURE|Biopsy|Undergo tissue biopsy
223912748|NCT06225427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223912749|NCT06225427|PROCEDURE|Computed Tomography|Undergo CT scan
223912750|NCT06225427|PROCEDURE|Echocardiography|Undergo echocardiography
223912751|NCT06225427|DRUG|Gilteritinib|Given PO
223912752|NCT06225427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223912753|NCT06225427|OTHER|Questionnaire Administration|Ancillary studies
223912754|NCT05862922|DEVICE|Analgesia Nosiception İndex Monitoring|"ANI is a monitor that can be measured continuously and non-invasively. It measures parasympathetic tone - based on electrocardiography - by analyzing minimal changes in heart rate that occur under anesthesia, in the early stages of awakening, and in each respiratory cycle of awake patients. At the end of the measurement, a value between 0-100 is obtained.~Parasympathetic modulation (stress level, e.g., pain) is obtained with a minimum value of 0 and a maximum of 100. ANI values measured in the early period of recovery correlate with pain scores. When compared with hemodynamic parameters, it has been reported that the ANI response is more sensitive to nociceptive stimuli occurring in the intraoperative period."
223912755|NCT06244433|GENETIC|whole genome sequencing|Study of all coding and non-coding sequences in the genome to identify pathogenic allelic variants
223912756|NCT02990338|DRUG|Isatuximab|Pharmaceutical form: solution for infusion Route of administration: intravenous
223912757|NCT02990338|DRUG|Pomalidomide|Pharmaceutical form: capsule Route of administration: oral
223912758|NCT02990338|DRUG|Dexamethasone|Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
223912759|NCT06195553|BEHAVIORAL|STEPPS plus Family Connections|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.
224087106|NCT00972465|DRUG|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
224087107|NCT02051907|DEVICE|KAM1403 Gel|
224087108|NCT02051907|DEVICE|aloevera gel|
224087109|NCT06001567|DRUG|Avatrombopag|Avatrombopag (platelet count \[PLT\] \<40×10\^9/L, 60mg P.O. QD; PLT of 40-75×10\^9/L, 40mg P.O. QD) will be administered to the patients and last 5-10 days. When the PLT reaches ≥100×10\^9/L, the treatment will be discontinued.
224087110|NCT00732173|BEHAVIORAL|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
224277861|NCT03710616|PROCEDURE|Surgeries|Surgical operations plus systematic lymphadenectomies
224277862|NCT02629016|OTHER|Mindfulness|
224277863|NCT02629016|OTHER|Wellness|
224277864|NCT01819064|DRUG|Atropine|intravenous atropine affect on heart rate
223912760|NCT06195553|BEHAVIORAL|STEPPS|The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.
224087111|NCT00732173|BEHAVIORAL|exercise intervention|Undergo SUCCEED lifestyle intervention
224087112|NCT00732173|OTHER|counseling intervention|Undergo SUCCEED lifestyle intervention
224087113|NCT00732173|OTHER|educational intervention|Receive information
224087114|NCT00732173|OTHER|survey administration|Undergo SUCCEED lifestyle intervention
224087115|NCT04484350|DRUG|Labetalol|10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
223912761|NCT00971087|DEVICE|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects undergoing a biopsy procedure will be imaged on the investigational device prior to their procedure.
224087116|NCT04484350|DRUG|Hydralazine|10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
224087117|NCT04484350|DRUG|Enalapril|1.25 - 2.5 mg IV bolus and then q6h PRN.
224087118|NCT00432237|DRUG|MK0974 50 mg|
224087119|NCT00432237|DRUG|MK0974 150 mg|
224087120|NCT00432237|DRUG|MK0974 300 mg|
224087121|NCT00432237|DRUG|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
223912762|NCT04479761|BEHAVIORAL|Visual and Auditory Cues|Within each scene there will be 2 levels of visual input (static or dynamic) combined with 3 levels of sounds (static, none or dynamic). Postural responses to each combination will be evaluated in order to assess the role of generated and natural sounds in postural control and whether static sounds can improve balance within dynamic virtual environments.
224087122|NCT01356381|DRUG|Vildagliptin|Dosage 50mg b.i.d.
224087123|NCT01356381|DRUG|Placebo|50mg bid
224087124|NCT06395493|PROCEDURE|Pilates Group|In this study, the participants in the Pilates group will undergo 2 sessions per week, for 12 consecutive weeks.
224087125|NCT06395493|PROCEDURE|Exercise Group|In this study, the participants in the Exercise group will undergo 2 sessions per week, for 12 consecutive weeks.
224087126|NCT06395493|PROCEDURE|Control Group|The participants in the control group, are those who either opt not to do the exercises or are on the waiting list for physiotherapy intervention. Therefore, they will not undergo any intervention for 12 consecutive weeks.
224087127|NCT03320499|PROCEDURE|echo doppler at the bed|we practise the echo doppler at the patient 's bed
224087128|NCT03320499|PROCEDURE|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
224087129|NCT03426176|DRUG|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
224087130|NCT03426176|DRUG|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
224087131|NCT03426176|DRUG|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
224087132|NCT03426176|DRUG|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
224087133|NCT04847388|DRUG|Substance like alcohol, marijuana, etc.|Cohort study
224087134|NCT04122599|DRUG|Melatonin|Melatonin for prevent post stroke delirium
224087135|NCT05981066|DRUG|Neoantigen vaccine, I.M injection|Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
224087136|NCT03514082|DEVICE|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
224087137|NCT05140057|COMBINATION_PRODUCT|Moviprep|Bowel preparation for small bowel capsule endoscopy - same product for all groups, different administration timings
224087138|NCT05699148|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Triple combination therapy is licensed in the UK for prescription to paediatric patients aged 6 to 11 years. ETI will be started as part of routine clinical care.
223912763|NCT03552471|OTHER|Laboratory Biomarker Analysis|Correlative studies
223912764|NCT03552471|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
224087139|NCT04668508|DRUG|Anlotinib|concurrent using anlotinib combined with radiation plus adjuvant anlotinib after radiotherapy until disease progress or develop into serious adverse events.
224087140|NCT03644628|PROCEDURE|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
224087141|NCT01354132|DRUG|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
223912765|NCT03552471|OTHER|Pharmacokinetic Study|Correlative studies
223912766|NCT03552471|DRUG|Rucaparib Camsylate|Given PO
224087142|NCT01354132|DRUG|Placebo|Placebo tablets are placed in water or juice in the AM and PM
224087143|NCT01362582|DRUG|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
224087144|NCT00603239|DRUG|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
224087145|NCT00603239|DRUG|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
224087146|NCT02508155|BIOLOGICAL|MEDI7352 for IV infusion|MEDI7352 for IV infusion
224087147|NCT02508155|BIOLOGICAL|Placebo for IV infusion|IV Placebo infusion
224277865|NCT00434837|PROCEDURE|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
224277866|NCT00201396|RADIATION|CCRT|Radiation with weekly Cisplatin
224277867|NCT00201396|DRUG|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
224277868|NCT00515216|DRUG|5-fluorouracil|
224277869|NCT00515216|DRUG|Oxaliplatin|
224277870|NCT00515216|DRUG|Leucovorin|
224277871|NCT02937363|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
224277872|NCT02937363|OTHER|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
224277873|NCT00357539|DRUG|Azithromycin (T1225)|
224277874|NCT00464386|DEVICE|Continuous Glucose Monitoring|measure glucose levels on burn patients
224277875|NCT04448041|OTHER|Malnutrition screening|Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
224277876|NCT02557217|DRUG|NP202|Active
224277877|NCT02557217|OTHER|Placebo|Placebo
223912767|NCT06186817|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
223912768|NCT06186817|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
223912769|NCT06186817|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
223912770|NCT06186817|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
224087148|NCT02508155|BIOLOGICAL|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
224087149|NCT02508155|BIOLOGICAL|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
224277878|NCT00172016|DRUG|Zoledronic acid|
224277879|NCT03281096|DRUG|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
224277880|NCT03281096|DRUG|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
224277881|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered IM followed by Electroporation
224277882|NCT02464670|BIOLOGICAL|INO-4202|INO-4202 delivered IM followed by Electroporation
224277883|NCT02464670|BIOLOGICAL|INO-4201|INO-4201 delivered ID followed by Electroporation
224277884|NCT02464670|BIOLOGICAL|INO-4212|INO-4212 delivered IM followed by Electroporation
223529612|NCT06103838|PROCEDURE|18F-FDG PET/CT|All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan
224277885|NCT02464670|BIOLOGICAL|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
224277886|NCT02464670|BIOLOGICAL|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
224277887|NCT04079452|DRUG|Doravirine|Doravirine 100 mg tablet
223912771|NCT04186819|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
224087150|NCT02357420|DRUG|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
224087151|NCT02357420|DRUG|Placebo|Placebo given subcutaneously for 12 weeks.
224087152|NCT01835184|DRUG|cabozantinib-s-malate|Given PO
224087153|NCT01835184|DRUG|vemurafenib|Given PO
224087154|NCT01835184|OTHER|laboratory biomarker analysis|Correlative studies
224087155|NCT01835184|OTHER|pharmacological study|Correlative studies
224087156|NCT01935895|BEHAVIORAL|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
224087157|NCT01068444|DRUG|Pioglitazone|"1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months"
224087158|NCT01068444|DRUG|placebo|placebo 30 mg/d for 6 months
224087159|NCT06391645|DRUG|Nerve Growth Factor|intravenously injection
224087160|NCT00929955|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
224087161|NCT00929955|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
224087162|NCT00929955|DRUG|Placebo|Placebo added to TAU
224087163|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
224087164|NCT02918084|DRUG|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
224087165|NCT03445702|DRUG|Metformin|Metformin 1000mg once
224087166|NCT03445702|DRUG|Placebo|Sugar pill manufactured to mimic metformin 1000mg
224087167|NCT04232826|BIOLOGICAL|single dose of CNCT19|"Dose A: 1.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose B: 2.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide~Dose C: 4.00 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide"
224087168|NCT04233489|BEHAVIORAL|Family Nurture Intervention (FNI)|"FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU)."
224087169|NCT00002113|DRUG|Flucytosine|
224087170|NCT00002113|DRUG|Fluconazole|
224087171|NCT03168516|DEVICE|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
224087172|NCT01113320|DRUG|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
224087173|NCT01113320|DRUG|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
224087174|NCT02852525|DEVICE|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
224087175|NCT00582517|DEVICE|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
224087176|NCT00582517|PROCEDURE|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
223912772|NCT04186819|DIAGNOSTIC_TEST|Positron Emission Tomography scan|imaging test with radioligand
223912773|NCT06476483|BEHAVIORAL|DIALOG+|A person-centred and solution-focused intervention linked to the DIALOG outcome measure (a measure of patient experience and quality of life).
223912774|NCT06476483|BEHAVIORAL|DIALOG|An outcome measure consisting of 11 questions, with 8 related to quality of life and 3 items on treatment satisfaction. Patients can rate their satisfaction on a 7-point scale for each of the 8 life domains and 3 treatment aspects, resulting in scores for both quality of life and treatment satisfaction. The DIALOG scale does not provide any guidance for patient and clinician interactions.
223912775|NCT06105203|PROCEDURE|Robotic-assisted total mesorectal excision|TME will be performed with the assistance of robot in rectal cancer
223912776|NCT06105203|PROCEDURE|laparoscopic-assisted total mesorectal excision|TME will be performed with the assistance of laparoscopy in rectal cancer
223912777|NCT06809426|DRUG|177Lu-LNC1011|75 mCi (2.78 GBq) of 177Lu-LNC1011 Injection intravenously each time, injections every 6 weeks, not to exceed a total of 6 injections.
223912778|NCT06809660|OTHER|Collection of biological samples and clinical data|"* Collection of a hair sample~* Collection of urine~* Collection of stool samples~* Collection of clinical, paraclinical data, and exposure questionnaire"
223912779|NCT04588415|OTHER|Bereavement Virtual Support Group|"Family members who experience loss will be invited to attend a virtual support group (VSG) led by Bereaved Families of Ontario- Ottawa (BFO). In pre-COVID-19 times, BFO presented monthly Support and Share nights with guest speakers, followed by breakout peer support groups for all different types of losses: loss of child, spouse, parent, loss by suicide, etc. These groups are facilitated by trained volunteers with a shared loss and include between 75 and 150 participants. These Support and Share Nights serve as intake sessions- interested participants from the breakout groups can attend Closed Groups where a smaller group of participants (up to 12) explore their grief more deeply. These run over 8-10 consecutive weeks with the same group of participants. They are led by trained facilitators who have experienced similar losses. Each week has a different theme, based on evidence-based components of bereavement support (e.g. writing a letter to the deceased)."
223912780|NCT06818409|DIAGNOSTIC_TEST|The Diagnostic and Statistical Manual of Mental Disorders (DSM) - 5 criteria for delirium diagnosis|Delirium presence will be assessed using DSM-5 criteria twice daily (morning and evening) for three days, after surgery.
223912781|NCT06036147|BEHAVIORAL|Concussion-focused cognitive behavioral therapy|Youth randomized to receive this component will participate in six 30-minute sessions of cf-CBT. The intervention includes modular CBT targeting post-concussive, anxiety and depressive symptoms. In this CBT treatment, the adolescent can be taught coping skills, relaxation strategies, and cognitive strategies to manage their symptoms, while they are encouraged to increase appropriate activation, including pacing of activities. Six sessions from the CHIP Study Cognitive and Behavioral Skills for Concussion Recovery will be chosen by the interventionist based on the youth's goals in the Introduction Session.
223912782|NCT06036147|BEHAVIORAL|Parent skills training|The focus of the PST component is on the use of positive parenting skills as well as helping parents manage their own emotional distress. Parents are taught to set positive recovery expectations, and to use praise or attention to increase their teen's positive coping behaviors and decrease unhelpful coping behaviors. They are also taught positive communication skills to use with their teen, and guided to schedule pleasant events together in order to strengthen the relationship. In-vivo skills practice and feedback are provided to help parents generalize and use PST techniques. Parents randomized to receive this component will participate in six 30-minute sessions of PST, chosen from the CHIP Study Parent Support Skills Training for Concussion recovery based on the parent's goals in the Introduction Session.
223912783|NCT06036147|BEHAVIORAL|Care management|In the CM component, parents are provided support regarding advocating for their child's needs across different contexts in the healthcare system, school and athletic departments (including guidance regarding medication referrals), using applied problem-solving together with the skills coach to address emergent needs. Adolescents can also be involved in CM, if developmentally appropriate based on their age, independence, and interest. Of note, while the CM component engages youth and parents, treatment effects are hypothesized to result from facilitating access to supportive services including medication referrals at the organizational level. Families randomized to receive this component will participate in six 30-minute sessions of CM, following the guidelines in the CHIP Care Management Manual.
223912784|NCT06815809|BEHAVIORAL|Floor-HI (intervention combines floor exposure with floor rise strategies)|"Floor HI training consists of the following three systematic steps~1. Positioning on the floor: Participants are first taught the backward chaining method. This technique involves using nearby furniture as support to move from an upright position to a kneeling position, through prone and side lying positions, and finally to a supine position.~2. Ground hugging: In this phase, participants will assume a position on the floor. They are encouraged to simulate a fall scenario by observing their surroundings while using relaxation techniques. This includes deep breathing exercises.~3. Getting up from the floor: The final phase focuses on teaching participants techniques to recover from a fall, tailored to their individual balance abilities.~The intervention is carried out on printed surfaces that mimic high fall risk surfaces such as icy, cluttered, wet surfaces."
223912785|NCT05304078|BEHAVIORAL|Telehealth Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide (mailed hard copy, USB drive, eBook, and Website access) and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The TASK III nurse will train caregivers how to assess their needs and concerns, and how to use the TASK III Resource Guide containing content and skill-building tip sheets to address their needs and concerns. Caregivers will also receive an American Heart Association brochure about family caregiving, as well as information, support, and referral to community resources.
223912786|NCT05304078|BEHAVIORAL|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure about family caregiving and 8 weekly calls from a nurse, with a booster call a month later (telephone, videoconferencing, or FaceTime). The ISR nurse will provide information, support, and referral to community resources.
223912787|NCT04372433|BIOLOGICAL|IO-202|IO-202 as monotherapy
223912788|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
224087177|NCT04000646|OTHER|standard care|standard care non-pharmacologic interventions during anesthesia induction
224087178|NCT04000646|OTHER|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
224087179|NCT00928070|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg
224087180|NCT00928070|DRUG|Placebo|Placebo sham 4 mg and 8 mg
224277888|NCT04079452|DRUG|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
224277889|NCT03254732|DRUG|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
224277890|NCT03254732|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
223912789|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine + Venetoclax|IO-202 and azacitidine + venetoclax combination therapy
223912790|NCT04372433|BIOLOGICAL|IO-202 and Azacitidine|IO-202 and azacitidine combination therapy
223912791|NCT06070987|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 100 units. The dose range of each target muscle is as below:100 units in rectus femoris.
223912792|NCT06070987|OTHER|BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot after BoNT-A injected in the affected rectus femoris, then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
223912793|NCT06070987|OTHER|None BoNT-A injection and robot therapy|"Wearable overground exoskeleton lower extremity robot system will be used in this study. The robot lower extremity system consisted with bilateral motors for assisting left and right knees, a pelvis belt and chariot system for suspending the device, and thigh and shank cuffs for attaching the exoskeleton links to the user. Patients will wear receive exoskeleton lower extremity robot (do not inject BoNT-A in the affected rectus femoris), then start to do the functional ambulation training to do 1) walking over ground 2) walking with turning, 3) get in and out of chair, 4) crouching and rising, and 5) going up and down stairs."
223912794|NCT04683081|DEVICE|mechanical cervical ripening|mechanical cervical ripening methods have been used to make the cervix more eligible for vaginal delivery
223912795|NCT04391595|DRUG|Abemaciclib|100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
223912796|NCT04391595|DRUG|LY3214996|400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
223912797|NCT03252288|BEHAVIORAL|Reminders|Text of phone-call based reminders to mobile phones
223912798|NCT03252288|BEHAVIORAL|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs \>1 week but within 4 weeks of the scheduled visit
223912799|NCT05013411|OTHER|Qualitative study|Individual interviews and focus groups will be conducted to explore current strengthens and barriers in obtaining patient observations. Views on use of technology in assisting with patient observations will also be discussed and documented.
223912800|NCT05626894|COMBINATION_PRODUCT|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
223912801|NCT05626894|OTHER|Usual Care|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
223912802|NCT06853964|OTHER|AlloMend® Acellular Dermal Matrix allograft|AlloSource, a non-profit supplier of allografts and one of the nation's leading tissue banks, introduced AlloMend® Acellular Dermal Matrix allograft to bring the benefits of regenerative medicine to more patients. cellular allograft matrices, unlike synthetic materials or xenografts, are recognized as human tissue by the body for graft incorporation by the recipient, minimizing the risk of inflammation or rejection. AlloMend® Acellular Dermal Matrix allograft has been shown to incorporate into the surgical site and demonstrates blood vessel infiltration.
223912803|NCT06815094|PROCEDURE|Regional analgesia either CEA or ESP|Ultrasound guided local anesthetic injection in the course of the conducting nerve to decrease pain transmission.
223912804|NCT06841848|DIAGNOSTIC_TEST|Fundoscopic Exam|visualization of the retina using an ophthalmoscope
223912805|NCT06841159|RADIATION|Ultra-fractionated radiation therapy|Radiation therapy will be delivered every 3 weeks on the PULSAR schedule to achieve optimal local control of metastatic cancer and augment the effects of sintilimab.
223535238|NCT06715358|BEHAVIORAL|Late intervention|"* SI! Program environment intervention from 5th grade through all Elementary Education.~* SI! Program classroom intervention in 5th grade."
223912806|NCT06841159|DRUG|Sintilimab|Sintilimab will be given at 200 mg q3w every 3 weeks and schedule to the next day of every pulses of radiation.
223912807|NCT06841159|DRUG|Standard systemic therapy|"First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only).~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events."
223912808|NCT06842745|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
224087181|NCT05401747|OTHER|Healthy lifestyle|Nutrition consultation and teaching: A registered dietitian has the responsibility of teaching and explaining the diet. Plan: One meeting per 12 weeks. The exercise program is based on the Physical Activity Guidelines Advisory Committee and American Heart Association guideline and a modified version of Dose-Responses to Exercise Training study protocol for older adults summarized our weekly plans in detail. Plan: 2 meetings per week. Cognitive enhancement: Participants can select any of the following activities:methods requiring mental activities, physical activity, and social activity, enjoying music and our weekly dance classes (Waltz).
224087182|NCT05543590|DRUG|Plasmapheresis|5 sessions of plasma exchanges
224087183|NCT05543590|OTHER|Blood collection|Blood collection to assess biological markers at baseline, M3 and M12
224087184|NCT05543590|OTHER|Stool samples|Stool samples will be collected from participants at baseline,M3 and M12
224087185|NCT05543590|OTHER|PET scan|PET scan at baseline and M6
224087186|NCT05543590|OTHER|Cycle ergometer stress test|Cycle ergometer stress test at M6
224087187|NCT05543590|OTHER|Questionnaires at baseline|Questionnaires at baseline, M3 and M6
223535239|NCT06717360|DRUG|AG2304T|AG2304T, QD, PO
223912809|NCT06842745|BEHAVIORAL|Speech-Language Therapy (SLT)|"Our SLT protocol draws from two theories and evidence-based cognitive-linguistic frameworks: (1) conversational alignment, which engages priming of lexical and syntactic structures through dialogue and conversation and (2) increased tolerance of memory load in the context of sentence repetition and dialogue tasks. Administration of these tasks will abide by principles of constraint-induced language therapy, i.e., intense treatment schedule and verbal responding only.~All participants will receive SLT."
223912810|NCT05550376|OTHER|Registry|Non-interventional registry
223912811|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~* At least 30 minutes before a period of skin-to-skin care with a caregiver commences (baseline condition).~* Throughout the period of skin-to-skin care, which should continue for a minimum of 1 hour.~* For at least 1 hour after the participant is returned to their incubator (post-intervention condition).~The protocol accounts for a 30 minute washout period between each study epoch. Therefore, at least 30 minutes of study data will be collected for each epoch."
224087188|NCT05543590|OTHER|Medical consultations|Medical consultations
223535240|NCT06717360|DRUG|AG2304R|AG2304R, QD, PO
224087189|NCT02480530|BEHAVIORAL|Individual Feedback|Patient gets feedback reports on adherence weekly.
224087190|NCT02480530|BEHAVIORAL|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
224087191|NCT00191854|DRUG|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
224087192|NCT00191854|DRUG|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
224087193|NCT00191854|DRUG|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
224087194|NCT00191854|DRUG|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
224087195|NCT03377920|DEVICE|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"* pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~* 5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
224087196|NCT00928811|DRUG|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
224087197|NCT00928811|DRUG|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
224087198|NCT05173129|DIAGNOSTIC_TEST|Posture Analysis|Posture analysis and assessment of mechanical properties of posture muscles
224087199|NCT06183008|DRUG|Intravenous immunoglobulin|Each patient will during the 30-week trial period get 3 IVIG courses (each total dose 2g/kg) for three consecutive days
224087200|NCT06183008|DRUG|Placebo|Each patient will during the 30-week trial period get 3 placebo courses (each 0.9% saline similar volume) for three consecutive days
224087201|NCT02415309|DRUG|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
224087202|NCT02415309|DRUG|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
223535241|NCT06719089|DEVICE|Biodegradable double loop ureteral stent|This ureteral stent is based on natural polymers and degrades inside the human body without causing obstruction, avoiding the need of a second surgery for stent removal and minimizing complications related to encrustation and bacterial infections.
223535242|NCT06719089|DEVICE|PolyUrethane Double Loop Ureteral Stent|This ureteral stent is a double J made of 100% polyurethan, heat-sensitive and radiopaque for excellent patient tolerance and high incrustation resistance.
223535243|NCT05578209|DEVICE|intermittent theta burst stimulation|stimulatory protocol
223912812|NCT05588960|DEVICE|Near-infrared spectroscopy monitoring (Masimo O3 Regional Oximeter with Neonatal Sensor)|"Masimo O3 neonatal sensor will be applied:~▪ For 24 hours once the participant reaches 36 weeks corrected gestational age."
223912813|NCT06599723|DRUG|Conventional lumbar steroid injections|Patients will receive conventional lumbar steroid injections.
223912814|NCT06599723|PROCEDURE|Racz catheter|Patients will receive lumbar epidural steroid using Racz catheter.
224087203|NCT02415309|OTHER|Placebo|40 patients will randomly receive a placebo/sugar pill
223912815|NCT05408663|DRUG|EXT608|EXT608 is an investigational drug administered via subcutaneous injection
223912816|NCT05408663|OTHER|Placebo|matching placebo administered via subcutaneous injection
223912817|NCT04142632|PROCEDURE|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
224087204|NCT01767402|BIOLOGICAL|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
224087205|NCT01767402|BIOLOGICAL|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
223912818|NCT06603051|PROCEDURE|Cryoneurolysis|Those randomized to the intervention group (Group B) will receive a standard treatment of Cryoneurolysis to their surgical knee within 7-10 days of their scheduled surgery. Treatment nerves for the procedure will include the anterior femoral cutaneous nerve (AFCN), supra-patellar branch of the saphenous nerve (SPBSN) and infra-patellar branch of the saphenous nerve (IPBSN).
223912819|NCT06590610|DEVICE|Radial pressure wave (RPW) - Intelect RPW2 Chattanooga|RPW treatment on one leg at the Gastrocnemius and NMES electrostimulation on the opposite leg. RPW or NMES treatment on each leg will be randomized prior to application with each device having an equal chance of being placed on the either leg (dominant and non-dominant).
223912820|NCT06593327|BEHAVIORAL|Intensive Prevention Strategy|Providers randomized to the intensive prevention strategy will receive notification about patients with diabetes who have high heart failure risk and recommendations for medical management, e-consultation, or referral to a cardiometabolic risk management program.
223912821|NCT02542631|DEVICE|Bolus Insulin Patch (Calibra Finesse)|
223912822|NCT02542631|DEVICE|Insulin Pen (Novo-Nordisk FlexPen®)|
223912823|NCT05378620|BEHAVIORAL|Project Dulce + Dulce Digital|Project Dulce will consist of a group diabetes self-management program consisting of a 5-week curriculum delivered by a peer educator in Tagalog. The curriculum provides new knowledge as well as skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complication, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants will learn and practice self-management skills, and help one another address family, cultural, or health system barriers to managing your diabetes. Following the 5-week curriculum, participants will be enrolled in the digital texting platform, Dulce Digital, in which they will receive on-going support via text messages derived from the curriculum, medication reminders, and blood glucose monitoring prompts in Tagalog.
223912824|NCT06806891|BEHAVIORAL|Buddhist walking meditation|the participants will be on hemodialyis. they complain restless leg syndrome. the participants will receive Buddhist walking meditation. this program of meditation will be 30 minutes thrice weekly. before and after Buddhist walking meditation .. The number of patients in the group will be 20. the total duration of Buddhist walking meditation will be 12 weeks.
224087206|NCT01767402|BIOLOGICAL|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
224087207|NCT05973370|DRUG|Placebo|Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
224087208|NCT05973370|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.
224087209|NCT00566787|DEVICE|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
224087210|NCT01604746|BIOLOGICAL|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
224087211|NCT02941367|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223912825|NCT02938923|DRUG|Testosterone|Topical testosterone gel 1%
224087212|NCT02941367|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
223529613|NCT05623722|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
223912826|NCT02938923|DRUG|Placebo gel|Inactive skin gel
224087213|NCT02941367|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
224087214|NCT02941367|DRUG|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224087215|NCT02571348|PROCEDURE|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
224087216|NCT05655117|OTHER|AI based eye screening|The application of AI devices i.e Fundus Camera to detect diabetic retinopathy and macular Oedema in diabetics at the primary care centre
224087217|NCT00021983|BIOLOGICAL|BL22 immunotoxin|
223529614|NCT03728478|DRUG|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
223535244|NCT04955041|OTHER|MRI|T2\* MRI
223912827|NCT02938923|BEHAVIORAL|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
223912828|NCT02938923|BEHAVIORAL|Home exercise program|Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
223912829|NCT02938923|BEHAVIORAL|Health Education Modules|30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
223912830|NCT06807684|DEVICE|transcranial magnetic stimulation|The investigators will deliver a type of high frequency rTMS known as intermittent theta burst stimulation (iTBS), 2400 stimulations per session, equally divided between the bilateral IPL and IFG.
223912831|NCT04820036|DIAGNOSTIC_TEST|Insulin Resistance|Insulin resistance: Fasting glucose and insulin will also be measured to calculate Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), as a surrogate of IR
224087218|NCT01841619|DRUG|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
224087219|NCT04807894|DRUG|Vaginal Cream with Applicator|Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.
224087220|NCT06960265|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"Targeting: The left dorsolateral prefrontal cortex (DLPFC) will be the target for treatment.~Equipment: rTMS will be delivered using a Magstim super rapid magnetic stimulator with a 70-mm air-cooled figure-eight-shaped coil. Resting Motor Threshold (rMT) Measurement: rMT is determined through visual twitch responses in the contralateral hand, identifying the minimal intensity needed to elicit thumb movement in 50% of trials.~rTMS will be administered at a frequency of 15Hz, with each pulse at 100% rMT intensity. Sessions include 60 pulses per train, with a 26-second inter-train pause, across 40 trains, totaling 2400 pulses over a 20-minute session."
224087221|NCT06960265|DEVICE|sham for repetitive Transcranial Magnetic Stimulation|The sham group will undergo a placebo procedure using the same rTMS parameters but with a figure-of-eight sham coil, following precedents set by studies on cocaine use disorder treatment (Terraneo et al., 2016).
224087222|NCT06959784|DRUG|semaglutide|The semaglutide intervention group received semaglutide (0.25 mg qw initially, increased to 0.5 mg qw after four weeks) for 24 weeks (6 months).
224087223|NCT06959784|DRUG|Metformin|The metformin control group was treated with metformin (gradually increasing to 1g bid) for 24 weeks (6 months)
224087224|NCT02348099|OTHER|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
224087225|NCT05413811|DRUG|5 Fluorouracil (5 FU) Cream|Intravaginal topical chemotherapy, 5-fluorouracil cream
224087226|NCT05413811|DRUG|Placebo|Intravaginal topical placebo cream
224087227|NCT03962309|OTHER|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
224087228|NCT06555627|BEHAVIORAL|High Protein Breakfast|For 5 days children will receive a high protein breakfast comprised of baked items (i.e. waffles with syrup) and Greek yogurt. The high protein meal will aim for 40% protein, 40% carbohydrates, and 20% fat. Meals will be served with a cup of water.
223529615|NCT03728478|DRUG|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
223529616|NCT03728478|DRUG|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
223529617|NCT03308474|OTHER|Routine care as per site standard.|Physician's choice according to patient's needs.
223529618|NCT01385826|DRUG|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
223529619|NCT01385826|DRUG|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
223535245|NCT02798003|OTHER|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
223535246|NCT00163293|DRUG|Ciclesonide|Ciclesonide metered-dose inhaler
223912832|NCT04820036|BEHAVIORAL|Quality of Life Assessment|Quality of life will be assessed using the Chronic Liver Disease Questionnaire.
223912833|NCT04820036|DIAGNOSTIC_TEST|Liver Function Test|EUS-guided liver biopsy and portal pressure gradient measurement
223912834|NCT04820036|DIAGNOSTIC_TEST|Radiologic features of NASH|Controlled attenuation parameter (CAP) and liver stiffness scores assessed by transient elastography (TE)
223912835|NCT04820036|DIAGNOSTIC_TEST|Serologic features of NASH|Laboratory value assessment of alanine aminotransferase (ALT), liver chemistries, platelet counts, albumin and calculated NAFLD Fibrosis Score (NFS).
223912836|NCT05428007|DRUG|Sarilumab|Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.
224087229|NCT06555627|BEHAVIORAL|Morning Exercise|Exercise Intervention. For 5 days, a 30-min physical activity bout including a 5-minute warm up and cool down will be provided to participants in this group. The aim is for students to achieve an average heart rate above 150 for the session, not including warm up or cool down. To monitor intensity, the participant will wear heart rate monitors around their chest and waist-worn accelerometers.
223912837|NCT05428007|DRUG|Ipilimumab Injection|Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.
223912838|NCT05428007|DRUG|Nivolumab/Relatlimab|The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
223912839|NCT01850888|DRUG|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
223912840|NCT01850888|DRUG|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
223912841|NCT01850888|DRUG|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000).
223912842|NCT01850888|PROCEDURE|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum \> 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum \>2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
223912843|NCT06660888|BEHAVIORAL|• Fatigue Severity Scale (FFS). • Hamilton Rating Scale for Depression (HRSD-17). • Hamilton Anxiety Rating Scale (HAM-A).|"1. Fatigue Severity Scale The FSS is one of the most commonly used fatigue questionnaires in chronic diseases. It measures how fatigue affects motivation, exercise, physical functioning, carrying out duties, work, family, or social life.~2. Hamilton Depression Rating Scale The 17-item Hamilton Depression Rating Scale (HRSD-17) is the most popular depression measure in antidepressant clinical trials.~3. Hamilton Anxiety Rating Scale The HAM-A was one of the first rating scales developed to measure the severity of anxiety symptoms."
223912844|NCT05238311|DRUG|Elranatamab|
224087230|NCT06555627|BEHAVIORAL|High Carb Breakfast|For 5 days children will receive a high carb breakfast that will be comprised of 15% protein, 65% carbohydrates and 20% fat. Total energy content, fat, sugar, fiber, energy density, are similar between the breakfast meals.
224087231|NCT05215184|DEVICE|Zeto WR19 EEG Recording|15 minutes of EEG recording to be obtained from eligible participants
224087232|NCT00511043|DRUG|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
224087233|NCT04119570|BEHAVIORAL|CKD Report Card|The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
224087234|NCT04329390|DRUG|Anticoagulant drugs|Prescription of, or already on oral anticoagulant treatment.
224087235|NCT00544830|DRUG|Bicalutamide|Given PO
224087236|NCT00544830|DRUG|Goserelin Acetate|Given SC
223529620|NCT06100172|DEVICE|Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)|This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS). Use of tAN for pain relief is an attractive alternative to pharmacologic and opioid-based approaches because it is safe and effective and presents no addiction liability.
223529621|NCT06100172|DEVICE|Sham Control Device|This device looks like the active device, but no stimulation will be delivered.
223529622|NCT01559935|DRUG|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
224087237|NCT00544830|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224087238|NCT00544830|OTHER|Laboratory Biomarker Analysis|Correlative studies
224087239|NCT00544830|DRUG|Leuprolide Acetate|Given via injection
224277891|NCT04659668|DEVICE|MMG-23-04-2019|"The dermal filler MMG-23-04-2019 is applied to the female intimate area (intramucosal administration) of vaginal vestibule, vaginal walls, clitoris, G spot."
223912845|NCT06806761|OTHER|Longitudinal prospective cohort study|Description: Patients after stroke who meet the in- and exclusion criteria will be examined up to 6 times during the first 6 months after their stroke.
223529623|NCT01559935|DRUG|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
223529624|NCT01559935|DRUG|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
223912846|NCT05591677|DRUG|D-Cycloserine|D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
223912847|NCT05591677|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
223912848|NCT05602545|OTHER|food consumption in periodontal health and disease|To determine individuals' daily energy and nutrient intakes and the consumption amounts of food groups, food consumption records were kept by the nutritionist for three consecutive days, with one of them was weekend, using the 24-hour recall method. Data on individuals' frequency and amount of consumption of some fermented products were recorded, considering the foods available in our culture and the market.
223912849|NCT01240122|DEVICE|Biotrue MPS|Multi-purpose contact lens care solution
223912850|NCT01240122|DEVICE|Investigational MPS|Multi-purpose contact lens care solution
223912851|NCT04332211|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atmosphere for the treatment of various emergent medical conditions.
223912852|NCT04332211|DRUG|Pseudoephedrine 60 MG|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
223912853|NCT04332211|DRUG|Placebo oral tablet|administer either pseudoephedrine or placebo orally to patients requiring hyperbaric oxygen therapy
223912854|NCT06746792|OTHER|Low-load resistance exercise with blood flow restriction|BFR-RE group performed bilateral leg extension exercises to volitional exhaustion (90 seconds rest between sets, 30% 1RM) with BFR cuffs applied at 60% of limb occlusion pressure.
223912855|NCT06746792|OTHER|High-load resistance exercise|The HL-RE group performed the same exercise to volitional exhaustion (90 seconds rest between sets, 70% 1RM) without BFR cuffs.
223912856|NCT03229083|OTHER|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
223912857|NCT06813612|BEHAVIORAL|cognitive behavioral play intervention|In the CBPI condition, children use dolls and miniature props to engage in play aimed at fostering positive thinking, a key element of quality of life. Each session includes stories on health, emotional well-being, social interactions, and school activities. The researcher demonstrates problem-solving steps, such as identifying and evaluating solutions, repeating this process three times. In each session, the researcher models problem-solving four times and provides at least five positive affirmations. Both the CBPI intervention and the free play control condition are similar, with the researcher using standardized prompts and providing equal time and positive attention. The key difference is that in the CBPI condition, the researcher models positive thinking and problem-solving, while in the free play condition, the researcher follows the child's lead without guiding play.
223912858|NCT06810258|OTHER|Blood sample during native kidney biopsy|blood sample during standard of care visit for a native kidney biopsy (17.5mL)
223912859|NCT06810258|OTHER|Blood sample during renal graft biopsy|blood sample during standard of care visit for a renal graft biopsy (17.5mL)
223912860|NCT06810258|OTHER|Urine sample during renal graft biopsy|Urine sample during standard of care visit for a renal graft biopsy (50mL)
223912861|NCT06810258|OTHER|Urine sample during native kidney biopsy|Urine sample during standard of care visit for a native kidney biopsy (50mL)
223912862|NCT06808906|OTHER|Hand Massage Application|Hand massage was applied for a total of 12 sessions in two weeks. Care was taken to perform the hand massage application outside the treatment and care hours, and it was performed in a quiet environment. The application was started from the same hand in the same patient in each session, and the same clinic nurse massaged all patients. Since the patients were in the intensive care unit, their vital signs were monitored 24. It was carefully monitored whether there was any change in vital signs during the massage. The patient's hand to be applied was placed on the pillow or bed. Clothes covering the upper extremity starting from the elbow area were removed. The patient was placed in a supine or semi-fowler position. The nurse practitioner took a standing position. She started the massage with effleurage, first on the back of the hand, then on the palm, from the fingertips towards the heart direction, placing the thumbs on the area to be treated and applying effleurage 5 times in a half-mo
223912863|NCT06809699|DRUG|Busulfan (Busulfex)|For myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d) For reduced intensity conditioning: (Bu，3.2 mg/kg/d IV -7d\~-5d)
223912864|NCT06809699|DRUG|Cyclophosphamide (CTX)|Cyclophosphamide is only used in myeloablative conditioning (Cy，1.8g/m2, -5d, -4d)
223912865|NCT06809699|DRUG|Fludarabine (Fludara)|For myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d) For reduced intensity conditioning: Fludarabine（Flu，30mg/m2 /d IV -10d\~-5d）
223912866|NCT06809699|DRUG|Semustine (MeCCNU)|For both myeloablative and reduced intensity conditioning: Semustine (MECCNU，250 mg/m2 orally-3d).
223912867|NCT06809023|BEHAVIORAL|Sleep restriction|Participants will be asked to sleep 4h/night
223912868|NCT06812585|DRUG|Metformin (Cidophage®)|Antidiabetic agent used to treat type 2 diabetes, and to prevent type 2 diabetes.
223912869|NCT06812585|OTHER|Usual Care|Active Comparator: Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®) Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
223912870|NCT04984590|DEVICE|IOPCL AMD MAG|The IOPCL MAG (intraocular pseudophakic capsular lens magnifier) consists of a 4.5 mm diameter optic. The central 1.8mm of the anterior surface has a power of 10.0 diopters. This IOPCL MAG will be implanted over an Alcon Model SN60WF or SA60AT intraocular lens to improve near vision.
223912871|NCT04320680|OTHER|description of a lupus patient cohort|description of a lupus patient cohort
223912872|NCT06085820|BEHAVIORAL|Experimental (birth ball)|"It is a large and firm ball made of soft, thick plastic, inflated with air. It can be easily inflated and deflated, washable, available in different sizes (55-65-75 cm in diameter) and strong enough to carry weight up to 136 kg.~When the literature was examined, it was seen that birth balls between 55-75cm were generally used in accordance with the intended use. Appropriate ball size will be determined by the participant's height. In order for the pregnant woman to continue balance exercises, she should be allowed to sit on the round birthing ball with her knees and hips at an angle of approximately 90°, with an upright spine.~birth ball; It is performed in sitting (pelvic rocking movement, forward-backward and right-left rocking, forward-supported sitting, springing movement), kneeling and squatting (hugging the ball and pelvic rocking movement) positions."
223912873|NCT06085820|BEHAVIORAL|Experimental (birth dance)|"Thanks to the birth dance, the expectant mother perceives less pain. In fact, it is known that a change in position is effective in the perception of pain. On the other hand, if the woman focuses on a point other than the pain during the act, it makes it easier for her to perceive the pain less. The low cost of this application increases its usability.~The most appropriate time for the birth dance is from the active phase of the first phase of labor until the end of this phase . The expectant mother dances with rhythmic movements accompanied by soothing and soothing music with the help of a birth supporter (midwife, relative, spouse or partner). Optionally, sacral massage can be added to the birth dance. In fact, in addition to reducing the pain experienced through freedom of movement, upright position and massage, it is also aimed to provide emotional support to the woman."
223912874|NCT04583280|DRUG|Rilematovir|Participants of age group greater than or equal to (\>=) 28 days to less than (\<) 3 months (age group 1) or \>= 3 months to \< 6 months (age group 2) or \>= 6 months to less than or equal to (\<=) 5 years (age group 3) will receive rilematovir orally twice a day (BID) from Days 1 to Day 7 or Day 8.
223912875|NCT04583280|DRUG|Rilematovir X mg/kg|Participants of age group birth at term (after at least 37 weeks of gestation) to \< 28 days (age group 4) will receive rilematovir orally BID from Days 1 to Day 7 or Day 8. The dose is dependent on outcome of the substudy in neonates and following independent data monitoring (IDMC) review and recommendation.
224087240|NCT06325007|DIETARY_SUPPLEMENT|Induction of labor|The study group only will drink a mixture of 60 ml of castor oil mixed with 140 ml of orange juice. Thirty minutes later, in both groups, an extraamniotic single balloon catheter will be inserted above the internal cervical os and filled with 60 mL of normal saline. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
224087241|NCT06509841|OTHER|Electro-acupuncture at the Jiaji points|Adopting treatments for the group that received electro-acupuncture at the Jiaji points, including: ① electro-acupuncture at the Jiaji points with continuous treatment for 8 weeks.
224087242|NCT06509841|OTHER|Electro-acupuncture at the scalp points|Adopting treatments for the group that received electro-acupuncture at the Scalp points, including: ① electro-acupuncture at the Scalp points with continuous treatment for 8 weeks.
224087243|NCT05163886|DRUG|LAM-002A|LAM-002A (apilimod dimesylate) is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, size 0.
224087244|NCT05163886|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, size 0 capsules.
224087248|NCT06542640|DEVICE|Mb-rt-fMRI-NFB|The MRI and TMS interventions described below will yield measures of change in the targeted brain regions in post- relative to pre- intervention comparisons. These change measures will be compared relative to changes in the sham/control group and the HC group. Furthermore, they will be compared to HC to assess improvement or normalization of brain function in the targeted brain regions. In addition, the investigators will examine treatment effects on traditional biomarkers that are likely to be impacted by such interventions: ERP, NP and NLP measures. Here, mindfulness meditation practiced during a real-time fMRI NFB session will be used to bring connectivity changes to brain structures involved in positive psychiatric symptoms (e.g. attenuated psychotic symptoms) in order to to reduce them.
224087249|NCT06542640|DEVICE|Sham mb-rt-fMRI-NFB|Individuals with CHR who are randomly assigned to this arm will receive mb-rt-fMRI-NFB, as do the experimental group, but it will be aimed at a motor cortex location that is not part of the prefrontal neural networks targeted in the experimental group.
224277892|NCT03981809|DIAGNOSTIC_TEST|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
223529625|NCT01559935|DRUG|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
223529626|NCT01559935|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
223529627|NCT01559935|DRUG|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
223912876|NCT04583280|DRUG|Placebo|Participant of age group 1, 2, 3 and 4 will receive matching placebo of rilematovir BID from Days 1 to Day 7 or Day 8 as per assigned age group.
223912877|NCT06675344|DEVICE|Apollo Neuro Device|The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
223912878|NCT06675344|DEVICE|Sham device|The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
223912879|NCT05559866|DEVICE|Apollo ESG with ERBE HAPC|Utilizing two approved devices in combination to assess durability of suturing.
223912880|NCT05559866|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label.
223912881|NCT06248086|DRUG|ASP2802|Intravenous (IV) infusion
223912882|NCT06248086|DRUG|MA-20|IV infusion
223912883|NCT05992246|DIAGNOSTIC_TEST|Ratio of Femoral Vein Diameter to Femoral Artery Diameter|An ultrasound probe will be used to first scan the area of the upper thigh just below the inguinal ligament directing caudally seeking for the femoral vessels. The femoral artery and vein could be observed simultaneously. Under normal conditions, pulsation is an indication of the femoral artery, and its companion is the femoral vein. The mean femoral vein diameter and femoral vein diameter (3-5 diametral lines in different directions) will be measured during cough, crying, or performing the Valsalva maneuvers.
223912884|NCT06793618|OTHER|Z-track technique|In this method, the neonates are in supine position, the skin is moved and held from the injection site 2 to 3 cm to the side or downward using the non- dominant hand, to ensure that blood vessel wasn't penetrated aspiration on the syringe must perceive the injection and then the medication is to be injected slowly. Researcher assistant that is unaware of the injection method performs the recording of the pain intensity and leakage diameter on the observation form.
223912885|NCT03441100|DRUG|IMA202 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
223912886|NCT03441100|DEVICE|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.
223912887|NCT00631475|DRUG|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)"
224277893|NCT04134637|DEVICE|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
223529628|NCT06329635|DRUG|Intrathecal Nicardipine|First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
223912888|NCT05274282|OTHER|Animation Therapy|Stop-motion movie shooting process designed for improving attention skill and regulating hyperactive and impulsive behaviours.
223912889|NCT00303459|DRUG|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
223912890|NCT00303459|DRUG|placebo|Matching bosentan placebo/b.i.d.
223912891|NCT06878898|BEHAVIORAL|Education and mobile phone text-messaging|The investigators piloted a knowledge and mobile text-messaging intervention using a prospective group design, allocating 14 (asthma=8; COPD=6) and 15 (asthma=9; COPD=6) participants to control and intervention groups respectively, after stratifying by type of disease.
223912892|NCT06878898|OTHER|Education only|Participants in the control group only received the educational intervention.
223912893|NCT06879405|OTHER|The Labor Hopscotch|"Labor Hopscotch consists of 4 basic parameters including movement (mobilization), positioning (birth stool, sitting on the toilet, birth ball, birth mat), water therapy and non-pharmacological methods for reducing pain. There are sub-contents for each of these parameters and hopscotch consists of 7 steps in total. Labor Hopscotch Model Steps;~Step 1: Mobilization (squat, pelvic tilt, using stairs, movement) Step 2: Birth Stool (oral fluid support, massage, breathing techniques) Step 3: Sitting on the Toilet (urinating, dim lighting, music) Step 4: Water Therapy (Warm shower, breathing techniques, Squat, oral fluid support) Step 5: Birth Ball (drawing 8 with the birth ball, slow movement techniques) Step 6: Birth Mat (massage, exercise on the mat, quadruped position) Step 7: Alternative Methods (massage, aromatherapy)."
223912894|NCT04452305|PROCEDURE|Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting|Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
223912895|NCT04129554|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.
223912896|NCT04129554|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
223912897|NCT04129554|DRUG|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
224277894|NCT04134637|DRUG|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
224277895|NCT00741754|OTHER|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
224277896|NCT05098951|DEVICE|Acupuncture|Patients with stiffness of joint receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
224277897|NCT00059709|PROCEDURE|Mediated Negotiation Training|
224277898|NCT02786927|DRUG|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
224277899|NCT02786927|DRUG|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
224087250|NCT06542640|DEVICE|rTMS|In previous work, the investigators used a multivariate pattern analysis to identify functional connectivity correlates of negative symptom severity in a schizophrenia (SZ) group. DLPFC-cerebellum hypo-connectivity was strongly correlated with negative symptoms. In a separate SZ cohort, the investigators used rTMS targeting the cerebellum to manipulate this circuit. The rTMS-induced increase in functional connectivity in a cerebellar-midbrain-DLPFC circuit was strongly linked to negative symptom severity reduction. Furthermore, individuals varied in the degree of change in functional connectivity in response to rTMS. This variation strongly predicted variation in post-rTMS symptom severity. The investigators predict that rTMS based intervention, but not sham rTMS, will similarly impact the cerebellar-midbrain-dorsolateral prefrontal cortex (DLPFC) network in the CHR group receiving real but not sham rTMS.
223912898|NCT04129554|DRUG|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
223912899|NCT04129554|DRUG|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
223912900|NCT04129554|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
223912901|NCT04129554|DRUG|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
223912902|NCT01570361|DEVICE|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
223912903|NCT01570361|DRUG|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
223912904|NCT06653634|DRUG|Methotrexate|Gradual withdrawal of the medication
223912905|NCT06653634|DRUG|TNF Inhibitor|Gradual withdrawal of the medication
223912906|NCT06815146|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
223912907|NCT06815146|DIAGNOSTIC_TEST|Quality of Results (QoR-40)|Several rating scales have been developed to measure quality of recovery after surgery and anaesthesia, but the most extensively used is the QoR-40, a 40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain.
223912908|NCT06815146|OTHER|Opioid consuption|Opioid consuption will be recorded from PCA
224087251|NCT06542640|DEVICE|Sham rTMS|Individuals with CHR who are randomly assigned to this arm will receive rTMS, as do the experimental group, but it will be aimed at a motor cortex location that is not part of the prefrontal neural networks targeted in the experimental group.
224087252|NCT05254418|DRUG|dulaglutide injection|All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
224087253|NCT05579717|BEHAVIORAL|Equine Assisted Learning|EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
223912909|NCT06810362|BEHAVIORAL|Cognitive Remediation (CR)|The CR consists of three 1-hour sessions per week of domain-specific computerized exercises, for a period of 12 weeks, totaling 36 hours
223912910|NCT06810362|BEHAVIORAL|Aerobic Exercise|Aerobic exercise consists in two session per week of cycling. Each session lasts for 45 min, with 15 min of warm up pre and post session
223912911|NCT06810362|OTHER|Cognitve Remediation + Aerobic Exercise|Patients performed both CR exercises and cycling
223912912|NCT06812468|DEVICE|Bellus 3D smart application|Bellus3D is a modern multi-digital digicam, 3-D face scanning that captures in an expert grade, complete 3-D face scans with the pressing of an unmarried button in seconds. It takes 10 s to create an excessive decision 3-D face scan. Bellus3D's excessive precision scanning detects the soft tissue parameters and over a hundred facial andmarks. It uses two Infrared structured light VCSEL (vertical-cavity surface-emitting laser) projectors for high-resolution face scanning. The technique of facial scanning by (Bellus3D) and measuring facial index by (Medit) software was performed following manufacture instructions , The patient's head Stabilized and aligned with the center of the face scan software (Bellus 3D) to avoid scan distortion, The head was tilted towards right and then towards left along with the face analog in the scan software combined with upward and downward movement to ensure complete detection and record of facial landmarks. Then the obj 3D file exported to Medit Software.
224087254|NCT06130085|DIETARY_SUPPLEMENT|Partially hydrolyzed formula|Partially hydrolyzed formula given as the milk supplement for cow milk allergy patients after 6 months of strict elimination diet
223912913|NCT06812468|DEVICE|Medit i-700 intraoral scanner|Medit i-700 intra oral scanner was used to measure the teeth dimensions , it has several advantages including that it can capture up to 70 FPS (FRAMES PER SECOND), which is significantly faster than the previous model. It delivers high image resolution for better quality. The Medit i700 offers a remote control mode and a built-in UV-C disinfection function. In this study a zigzage movement was used which more accurate rout for recording all anterior teeth dimensions and surrounding tissue while scanning. In agreement with a previous study, we started from the posterior left area by scanning the occlusal side, then it proceeded toward the posterior right area by following a zigzag movement when the anterior teeth were scanned. After the occlusal area, the palatal/lingual side was scanned from the right to the left area, and then the buccal side was scanned from the posterior left area to the posterior right one,Then the obj 3D file exported to Medit Software.
223912914|NCT06811987|BEHAVIORAL|Instructor-led AI-Triage educational serious game|Participants will use the AI-triage serious game guided by the instructors.
223912915|NCT06811987|BEHAVIORAL|Self play AI-Triage educational serious game|Participants will self-play the AI-Triage serious game during the class.
223912916|NCT05153317|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules or tablets for oral administration.
223912917|NCT05153317|DRUG|IVA|Granules or tablets for oral administration.
223912918|NCT06810635|DIETARY_SUPPLEMENT|Oral Polyphenol Challenge Test / PPPIL|Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)
223912919|NCT06810635|DIAGNOSTIC_TEST|fasting blood sample|Fasting blood sample will be obtained for determination of markers of metabolic health.
223912920|NCT06810635|DIAGNOSTIC_TEST|Fasting urine collection|Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites
223912921|NCT06810635|DIAGNOSTIC_TEST|24 hours urine collection|Subjects collect urine over the entire 24h. for determination of polyphenol metabolites
223912922|NCT06810635|OTHER|Questionnaires|Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.
223912923|NCT06810635|DIAGNOSTIC_TEST|Stool collection|Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.
223912924|NCT06810635|DIAGNOSTIC_TEST|Transit time determination|Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.
223940108|NCT05608070|DRUG|Oxytocin|Oxytocin 30 IU in 500 ml IV at a rate of 5 IU/h (83.33 ml/h). The infusion will be started intra-operative once the uterus is removed and will continue to run until completion of the medication or discharge from PACU criteria are met, whichever occurs first.
223940109|NCT05608070|DRUG|Placebo|0.9% saline infusion at the rate of 83.3 ml/h.
223940110|NCT02893969|BEHAVIORAL|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
223940111|NCT02893969|BEHAVIORAL|Rest|Complete physical rest until asymptomatic.
223940112|NCT04694937|DEVICE|heart rate variabilty measured by pulse oximetry|"Resting HRV will be measured by Pulse Oximeter BM2000A/Shanghai Berry Electronic Tech Co., Ltd. that is validated for this purpose and is approved by FDA. The measurement, at the patient's fingertip, takes 5 minutes. The measurement will be performed twice - at two consecutive visits at the clinic, as part as the routine follow up of the patient every 3 months.~HRV will be correlated to demographic and metabolic parameters between patients. In order to reveal whether HRV can serve as a predictor to metabolic disease progression or improvement, HRV will be correlated to metabolic parametrers in the same patient at two time-points."
223940113|NCT02316301|DRUG|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
223940114|NCT02316301|DRUG|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
223940115|NCT01255514|DRUG|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
223940116|NCT06509607|OTHER|Concentric Lower Limb Training Program|A specially designed 30-minute concentric lower limb training program (squats, lunges and leg extensions) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the coach, 2 days per week for 8 weeks.
223940117|NCT06509607|OTHER|Eccentric Lower Limb Training Program|A specially designed 30-minute eccentric lower limb training program (wall sit, sitting straddle single leg and full squat) conducted by the researchers, before a 90-minute ordinary badminton training session conducted by the same coach, 2 days per week for 6 weeks.
223940118|NCT04061759|OTHER|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
224087255|NCT06118385|DRUG|BEN8744|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
224087256|NCT06118385|DRUG|Matching Placebo|Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
224087257|NCT05317221|OTHER|Not an extra intervention, tissue taken in routine practice will be used.|No extra intervention: using tumour tissue taken during surgery in standard of care.
224087258|NCT01320605|BIOLOGICAL|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
224087259|NCT05547698|PROCEDURE|Off-pump lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.
223912925|NCT06815159|BIOLOGICAL|Identification any tissue markers predictive or favoring early stenosis in AVF for haemodialysis.|"Primary objective~1. Identify any predictive or favoring tissue markers of early stenosis in AVF for hemodialysis.~   Secondary objectives~2. Compare the results on the possible different expression of tissue markers before and during dialysis.~3. Compare the results on the possible different expression of tissue markers between AVFs made with portions of cephalic vein and AVFs made with portions of basilic vein, in order to evaluate whether the different topographic origin of the AVF can influence its duration."
223912926|NCT06431867|OTHER|Guidelines for primary care management of osteoporosis|All usual care of osteoporosis in primary care
223912927|NCT05459701|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once daily for 24 weeks.
223912928|NCT05459701|OTHER|Placebo|Placebo
224087260|NCT05547698|PROCEDURE|Venoarterial ECMO lung transplantation|General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
224087261|NCT05815498|BIOLOGICAL|mRNA-1283.222|Sterile liquid for injection
224087262|NCT05815498|BIOLOGICAL|mRNA-1273.222|Sterile liquid for injection
224087263|NCT05815498|BIOLOGICAL|mRNA-1283.815|Sterile liquid for injection
224087264|NCT05815498|BIOLOGICAL|mRNA-1273.815|Sterile liquid for injection
224087265|NCT03247634|BEHAVIORAL|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
224087266|NCT05223231|DRUG|LBL-019 Injection|initial dose-MTD
224087267|NCT05223231|DRUG|anti-PD-1 antibody injection|provide medicine base on needs
224087268|NCT06498921|OTHER|Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxel|No treatment will be provided to participants in the study. The decision on initiation of darolutamide (Nubeqa, BAY1841788) in combination with ADT and doctaxel and duration of treatment is solely at the discretion of the treating physician, guided by the recommendations outlined in the local product information.
223912929|NCT05158504|OTHER|Motivation|Motivational notifications were sent via SMS message to the nurses in the motivation group (n=30) at 07.00, 12.00 and 16.00 for 21 days.
223912930|NCT04225572|BEHAVIORAL|Physical Therapy: Dependent on Patient's Needs|"Therapeutic exercise:~* ROM: Begin with passive upper extremity ROM and progress to active ROM.~* Strengthening: Progressive upper extremity resistive exercises starting with light weights.~* Aerobic: Select a suitable, individual aerobic exercise program (walking, yoga, etc.) Manual therapy~* Soft tissue mobilization, myofascial release, and stretching of identified tight and stiff tissue.~Lymphedema treatment~* Manual lymph drainage: Gentle lymphatic massage to lymph nodes and vessels by PT for 1-2 weeks. Instruct patient in self MLD to perform 1-2×/day for 10 minutes during the remaining weeks.~* Compression therapy: Gradient compression bandaging for daily wear with activities and exercise for 1-2 weeks. Instruct in self compression bandaging or issue a compression garment to wear with exercise or activity, or with worsening symptoms of AWS (i.e. cording extends down arm) or lymphedema."
223912931|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
224087269|NCT01323478|DRUG|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
224087270|NCT06386510|PROCEDURE|Strength training|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively.
224087271|NCT06386510|PROCEDURE|Cranial nerve non-invasive neuromodulation|For the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group).
224087272|NCT02411448|DRUG|Ramucirumab|Administered IV.
224087273|NCT02411448|DRUG|Placebo|Administered IV.
224087274|NCT02411448|DRUG|Erlotinib|Administered orally.
224087275|NCT02411448|DRUG|Gefitinib|Administered orally.
224087276|NCT02411448|DRUG|Osimertinib|Administered orally.
224087277|NCT05052268|DRUG|XTX202|XTX202 Monotherapy
223912932|NCT01146704|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
223912933|NCT03606512|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.
223912934|NCT03606512|BIOLOGICAL|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
223912935|NCT03606512|BIOLOGICAL|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
223912936|NCT05163041|DRUG|BT7480|Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
223912937|NCT05163041|DRUG|Nivolumab|Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
223912938|NCT06554379|OTHER|Periodontal health and gingivitis|The presence or absence of periodontal disease in the gingiva was determined.
223912939|NCT04646187|BIOLOGICAL|Infliximab|Dosing interval lengthening from 8 to 12 weeks
223912940|NCT04646187|BIOLOGICAL|Adalimumab|Dosing interval lengthening from 2 to 3 weeks
223912941|NCT05513937|DRUG|Nebivolol|Tablets administered orally once daily according instructions provided by Principal Investigator.
223912942|NCT05513937|DRUG|Amlodipine|Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
223912943|NCT04692012|OTHER|FRESH CORNEAL MYOPIC LENTICULE IMPLANTATION|VisuMax femtosecond laser performed flap-cut procedure with an energy cut index of 30 nJ (150nJ), spot and track spacing surface cut of 4.5 μm, side cut 2.0 μm were used to create an intrastromal pocket into the patient's cornea to receive the donor lenticule. The stromal pocket diameter was set 7.6 to 8.0 mm (1 mm larger than the optical zone of the donor lenticule) and cap thickness was set to 130 μm from corneal surface and a 4 mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 4 mm superior incision. Incision position changed according to the position of the highest K values. Current orientation was marked with a sterile skin marker. The lenticule was positioned around the marked center of the cone and flattened out from the surface using a blunt spatula.
223912944|NCT02846545|BIOLOGICAL|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
223912945|NCT02846545|BIOLOGICAL|Placebo|Matching Placebo to golimumab.
223912946|NCT06496997|DRUG|Methylprednisolone|Methylprednisolone at a dose of 1 mg/kg/day (an average dose of 70 mg/day based on 70 kg body weight)
223912947|NCT06496997|DRUG|Dexamethasone|Dexamethasone at an equivalent dose of 13 mg/day
223912948|NCT06496997|DRUG|Hydrocortisone|Hydrocortisone at an equivalent dose of 350 mg/day
223912949|NCT06351397|BEHAVIORAL|Mixed Reality (MR)|"Mixed Reality simulation of medical crisis scenarios.~MR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario"
223912950|NCT06760351|DRUG|TCM Herbal Therapy|Administration of customized herbal formulations for the TCM group, targeting qi and blood regulation. Pulse diagnosis parameters were evaluated monthly to guide treatment adjustments.
223529629|NCT06329635|OTHER|No intervention|"A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel."
223912951|NCT06760351|DRUG|Standard Western Medicine Treatment|Administration of standard Western medical care, including blood transfusions and erythropoiesis-stimulating agents, focusing on hemoglobin restoration and anemia management.
223529630|NCT01916018|OTHER|Clinical and radiologic exams and blood samples|
223529631|NCT01431430|DRUG|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
223912952|NCT04757337|DRUG|Doxorubicin|6 x 3-week cycles corresponding to a maximal duration of 18 weeks
223912953|NCT04757337|DRUG|Cyclophosphamide|Until progression up to 24 months
223912954|NCT04986046|OTHER|Home Plate Lite|Home Plate Lite comprises electronic educational content (e.g. recipes, instructional videos) disbursed at least weekly over six weeks.
223912955|NCT04986046|OTHER|Home Plate|Home Plate comprises six 1.5-hour weekly sessions where parents work together with a study staff member to discuss the learning objectives and prepare the components of a meal, including entrees, side dishes, and desserts.
223912956|NCT04986046|OTHER|Fruit and Vegetable prescription|All families will receive FVRx over two months; FVRx can be redeemed for fresh, frozen, or canned produce at participating retailers in Philadelphia
223940119|NCT04895670|BEHAVIORAL|Empowering Youth Aging out of Foster Care|App that allows storage of health information, and access to reputable health information and community resources.
223940120|NCT02108574|DEVICE|Placebo Filter|
223940121|NCT02108574|DEVICE|Rhinix Nasal Filter|
223940122|NCT00385606|DRUG|gemcitabine|
223940123|NCT00385606|DRUG|prolonged continuous infusion gemcitabine|
223940124|NCT00385606|DRUG|cisplatin|
223940125|NCT00385606|DRUG|rofecoxib|
223529632|NCT01431430|DRUG|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
223529633|NCT04416724|PROCEDURE|Phacoemulsification|Lens removal by Phacoemulsification
223529634|NCT04416724|DEVICE|Selective Laser Trabeculoplasty|Laser application in trabecular meshwork
223529635|NCT05379153|DEVICE|Laser Therapy|Undergo vaginal fractional CO2 laser therapy
223529636|NCT05379153|DEVICE|Sham Intervention|Undergo placebo procedure
223529637|NCT05379153|OTHER|Questionnaire Administration|Ancillary studies
223529638|NCT05379153|OTHER|Quality of Life Assessment|Ancillary studies
223529639|NCT03186898|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224087278|NCT02689323|DEVICE|repeated transcranial magnetic stimulation|
224087279|NCT06325501|DRUG|Misoprostol 200mcg Tab|receiving a preoperative rectal dose of 800 ug of misoprostol half an hour before surgery
224087280|NCT06325501|DRUG|Oxytocin|after the induction of general anaesthesia (GA), an infusion of 40 IU oxytocin in 500 ml normal saline was started at the rate of 250 ml/hour
224087281|NCT05873218|DRUG|Ephedrine|The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.
224087282|NCT05873218|DRUG|Normal Saline Placebo|Placebo will be administered at matching rate.
224087283|NCT02735629|DRUG|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
223912957|NCT03434548|RADIATION|PET imaging|"PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain.~PET imaging Radiation: Radioligand \[¹¹C\]MePPEP Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]IMA107 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain. Radiation: Radioligand \[¹¹C\]MDL100907 Intravenous injection of radioligand in the arm with PET imaging of the brain."
223912958|NCT03434548|OTHER|Multi-modal MRI imaging|Multi-modal MRI imaging
223912959|NCT04113382|DRUG|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
223912960|NCT04113382|DRUG|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol \[PEG\] 3350).
223912961|NCT05899387|PROCEDURE|Swap collection|"Performing the surgery (Mastectomy with or without implant reconstruction; Insertion of Breast implants for control group 3) according to valid standards.~In addition, taking swabs intraoperatively according to protocol from skin and surgical site."
223912962|NCT05899387|PROCEDURE|Seroma punction|Puncturing of a seroma in case of occurence and clinical need
223912963|NCT05899387|PROCEDURE|Blood sampling|Blood sampling at defined time points according to protocol
223912964|NCT05899387|DIAGNOSTIC_TEST|Sonographic correlation Seroma|If a seroma occurs, a sonographic correlation is performed to determine the exact size of the seroma
223912965|NCT06468982|DEVICE|Intra-aortic Balloon Pump|It will be applied to patients with acute myocardial infarction who have elevated troponin levels and recurrent or persistent chest pain at rest, hemodynamic instability, multivascular disease, left main coronary artery disease, and patients with narrow and/or tortuous coronary artery anatomy in whom PCI has failed or is not applicable.
223912966|NCT03509662|DRUG|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
223912967|NCT03509662|DRUG|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
224087284|NCT02735629|DRUG|CX1739 - 600 mg|CX1739 - 600 mg
223912968|NCT03509662|DRUG|Placebos|One group receives a placebo.
223912969|NCT03691298|DEVICE|SUTUREFIX ULTRA Suture Anchor and SUTUREFIX CURVED Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone
223912970|NCT04072861|DRUG|RBT-9|intravenous administration
223912971|NCT02492711|BIOLOGICAL|Margetuximab|15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
223912972|NCT02492711|BIOLOGICAL|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
223912973|NCT02492711|DRUG|Physician's choice of chemotherapy.|Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
224087285|NCT02735629|DRUG|CX1739 - 900 mg|CX1739 - 900 mg
224087286|NCT02735629|DRUG|Placebo|Placebo to 300 mg CX1739
223529640|NCT03186898|PROCEDURE|Computed Tomography|Undergo CT scan
223529641|NCT03186898|OTHER|Laboratory Biomarker Analysis|Correlative studies
223529642|NCT03186898|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224087287|NCT05728879|COMBINATION_PRODUCT|APR-TD011 (RLF-TD011)|APR-TD011 (RLF-TD011) wound cleansing spray (drug/device combination product with a 510k clearance that is commercially marketed in the US for use by or on the order of a physician.
224087288|NCT03399266|DEVICE|Double Balloon catheter for induction of labor|With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
224087289|NCT01538485|DRUG|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
224277900|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
224277901|NCT02786927|OTHER|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
224277902|NCT03559127|PROCEDURE|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
224087290|NCT01451801|BIOLOGICAL|Twinrix|"A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.~Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin."
223912974|NCT06409689|DRUG|Oliceridine fumarate low dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.1 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
223912975|NCT06409689|DRUG|Oliceridine fumarate high dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
223912976|NCT06409689|DRUG|Oliceridine fumarate moderate dose|The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.35 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
223912977|NCT06409689|DRUG|morphine|The first loading dose of morphine was 4 mg in all patients after operation. The PCA dose of the patients was 1 mg, and the locking interval was 6 min. A supplemental dose of 2 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 60 mg.
224087291|NCT01551979|DEVICE|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group."
224087292|NCT02686294|DRUG|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
224087293|NCT02686294|DRUG|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
224087294|NCT00983411|OTHER|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
224087295|NCT04233515|DRUG|Oral anticoagulant|Clinical visit to a physician to assess stroke and bleeding risk and to possibly initiate OAC therapy or refer for left atrial appendage occlusion
224087296|NCT05249946|OTHER|FoodStep - a sustainable health-promoting model for food services and early childhood education and care|The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
224087297|NCT03720132|PROCEDURE|Extensive flushing of the port catheter|The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
224087298|NCT05302687|DIETARY_SUPPLEMENT|Probiotic|This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
224087299|NCT05302687|DIETARY_SUPPLEMENT|placebo|This project aims to evaluate differences in general women's health of women on probiotic and placebo via the use of questionnaire and evaluate differences in immunity of women on probiotic and placebo via blood immunity profiling. To evaluate differences in gut microbiota profiles of women on probiotic and placebo via blood fecal microbiota profiling.
224087300|NCT05306132|DRUG|ASKC202|Dosage Forms: Tablets; Administration: Oral administration
224087301|NCT01826708|BIOLOGICAL|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
223912978|NCT05026346|DIAGNOSTIC_TEST|Pathologic Exercise|"1. In the first phase of the project, a series of 5 active shoulder mobilization exercises characterized by an adequate range of motion will be tested to verify the set up for the video recording.~2. In the second phase shoulder movements will be recorder by a smartphone.~3. A questionnaire will be used and adapted on the basis of which to evaluate the correctness of the exercises performed by each healthy subject / patient. This questionnaire will provide a Clinical Score (CS) which assigns a numerical value to the patient's overall performance for each repetition.~4. The videos of each repetition of exercises performed by the healthy subjects / patients will then be evaluated by two different clinicians, blinded, using the questionnaire.~5. The Artificial Intelligence learning algorithm will be able to output an evaluation score that will be compared with that produced by clinicians."
223912979|NCT06759740|RADIATION|68Ga-DOTA-SEMA|68Ga-DOTA-SEMA is GLP1R imaging agent
224087302|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
224087303|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
224087304|NCT00663741|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
224277903|NCT03559127|PROCEDURE|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
224087305|NCT01590173|DRUG|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
223912980|NCT05959889|OTHER|Placebo|Patients will receive placebo tablets for 4 cycles of AC.
223912981|NCT05959889|DRUG|Montelukast|Patients will receive motelukast 10 mg for 4 cycles of AC.
223912982|NCT06606119|OTHER|Data and tissue collection|Collection of bone marrow, blood, feces, medical record data, and patient response surveys.
223912983|NCT05301348|DEVICE|Photoacoustic Flow Cytometry|Detection of circulating blood clots
223912984|NCT02893358|DRUG|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
223912985|NCT02893358|DRUG|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
223912986|NCT06590623|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.
223912987|NCT06759363|DRUG|Sodium-Butyrate|1000 mg/day of sodium-butyrate
223912988|NCT06759363|DRUG|Calcium Butyrate|1000 mg/day of calcium-butyrate
223912989|NCT05755087|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223912990|NCT05755087|PROCEDURE|Computed Tomography|Undergo CT
223912991|NCT05755087|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223912992|NCT05755087|DRUG|Tegavivint|Given IV
223912993|NCT06600997|DEVICE|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms|Flow Diversion for Endovascular Treatment of Intracranial Aneurysms
223912994|NCT06600997|DEVICE|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms|Conventional endovascular therapy (stent-assisted coiling, balloon-assisted coiling, or coiling) for endovascular treatment of intracranial aneurysms
223912995|NCT06815614|DEVICE|A Photoplethysmography-Based Continuous Automated Non-Invasive Sphygmomanometer|The investigation medical device under evaluation is oCareTM BP 100, a non-invasive continuous blood pressure monitoring system developed by Taiwan Biophotonic Co. (tBPC). The main function is to use a fingerclip sensor to receive PPG signals and collect continuous blood pressure values and uninterruptedly within the initialization time. In this study, according to the latest released ISO 81060-3:2022 standard requirements, non-invasive blood pressure measurement by cuff at the start and the end time points will be used as oCareTM BP 100 start-to-end blood pressure calibration. The A-line invasive arterial catheter blood pressure measurement will be used as a reference invasive BPM equipment. The purpose of the study is to confirm the stability of the investigational medical device under evaluation and its performance of blood pressure change tracking.
224277904|NCT03559127|PROCEDURE|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
224277905|NCT02695927|DEVICE|Computer rehabilitation glasses|
224277906|NCT01801917|DRUG|Placebo|Matching placebo tablet for oral administration
224277907|NCT01801917|DRUG|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
223912996|NCT06526221|DIAGNOSTIC_TEST|Urine isoniazid testing (IsoScreen test)|Developed by Arkansas' Public Health Service in the 1970s, this test detects metabolites of isoniazid, a drug present in drug-susceptible TB regimens. IsoScreen (GFC Diagnostics, UK) is a commercial version of the Arkansas method with reagents enclosed in a plastic vial, into which 2mL of urine can be injected with a syringe. If the urine contains isoniazid, reagents turn purple/blue (suggesting a dose was taken in the last 24 hours or appropriate adherence) or green (suggesting a dose was taken 24-48 hours before or one missed dose). A yellow result (no color change) suggests medication has not been taken for \>48 hours (two or more missed doses).
223912997|NCT05932407|DRUG|Vortioxetine Tablet|Vortioxetine Tablet
223912998|NCT05932407|DRUG|SSRI|SSRI: Selective Serotonin Reuptake Inhibitor
223912999|NCT06309784|PROCEDURE|Drill Guidance System (DGS)|During a standard surgical procedure where a drill/k wire is being inserted the surgeon may choose (in advance) to supplement their drilling with use of the Drill Guidance System. This will be a supplement to normal practice. it is anticipated it will make surgery more accurate, swifter and safer. If however the surgeon is not finding the DGS useful it can be abandoned and standard drilling with X-ray guidance used
223913000|NCT06797830|DEVICE|AllCore|"AllCore360° is a novel core-strengthening machine intervention designed to target trunk muscles through gravity by means of high-intensity constant velocity rotating exercise (allcore360.com).~AllCore360° is systematic, consistent and designed for use over time. The core is strengthened because a patient's core muscles are used in anterior, lateral, and posterior contractions sequentially during a single rotation (Palevo). The patient must resist gravity with the rotation as well as contract and fire isometrically to keep proper posture. Using proper posture, the patient must keep their back straight and neck neutral throughout the length of the intervention without relying on their lower body muscles at all (this is assisted by straps rendering the legs useless and by securing the pelvis in the chair)."
223913001|NCT06818474|BIOLOGICAL|Lanadelumab 300 mg|no other intervention
223913002|NCT06816966|RADIATION|split-course adaptive hypofractionated radiotherapy|Each treatment cycle comprises a solitary radiotherapy session, which allows for its integration with chemotherapy and immunotherapy. The radiotherapy sessions are scheduled at three-week intervals, thereby affording extended recovery periods for normal tissues. An adaptive radiotherapy plan is implemented for each cycle, enabling precise adjustments to the treatment target area in response to the reduction in tumor volume.
224277908|NCT02486614|PROCEDURE|CRRT|citrate based continuous renal replacement therapy
224277909|NCT03180255|COMBINATION_PRODUCT|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
223529643|NCT03186898|OTHER|Quality-of-Life Assessment|Ancillary studies
224087306|NCT01590173|DRUG|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
223529644|NCT03186898|RADIATION|Radiation Therapy|Undergo proton therapy
223913003|NCT06818565|DRUG|Meropenem Injection|Meropenem 2 gm iv TDS
223913004|NCT06818565|DRUG|Ceftazidime-avibactam|Ceftazidime-avibactam 2.5 gm iv TDS
223913005|NCT06818565|DRUG|Teicoplanin|Teicoplanin 400 mg iv BD 3 doses followed by 400mg iv OD
223913006|NCT06816641|PROCEDURE|Surgical Evacuation of Intracerebral Hemorrhage|Surgical Evacuation of Intracerebral Hemorrhage
223913007|NCT06819618|OTHER|Monitoring with Apple Watch|Patients will receive Apple Watch for Monitoring of Biosignals throughout the hospital stay
223913008|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI alone|patients use ventoline pMDI alone
223913009|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer
224087307|NCT01016379|GENETIC|DNA analysis|
224087308|NCT01016379|OTHER|biologic sample preservation procedure|
224087309|NCT01016379|OTHER|laboratory biomarker analysis|
223529645|NCT03186898|RADIATION|Radiation Therapy|Undergo photon therapy
223529646|NCT05335031|DRUG|Ozanimod|As per product label
223529647|NCT05255900|DRUG|Metyrapone Capsules|Exposure to 24 weeks of treatment with metyrapone
223529648|NCT00694590|DRUG|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
223913010|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer
223913011|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber
223913012|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer
223913013|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer
223913014|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer|patient use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer
223913015|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer
223529649|NCT01929603|PROCEDURE|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
223529650|NCT01929603|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
223529651|NCT01929603|DRUG|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
223529652|NCT01596270|DRUG|SAR245409|Pharmaceutical form: tablet Route of administration: oral
223529653|NCT06343623|PROCEDURE|myomucosal resection and direct closure|myomucosal resection and direct closure
223529654|NCT06343623|PROCEDURE|superiorly based flap|superiorly based pharyngeal flap
223535247|NCT00163293|DRUG|Placebo|Ciclesonide placebo-matching metered-dose inhaler
223535248|NCT01821755|BEHAVIORAL|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
223535249|NCT02561962|DRUG|AMG 224|Administered as an IV infusion.
223913016|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the MDI package
224087310|NCT06157385|BEHAVIORAL|Culinary Medicine|The CM group will receive virtually-delivered cooking demonstration videos every week and nutrition education videos every other week. The cooking demonstrations will provide them with visual instructions on how to incorporate lean beef into their diet. The nutrition education videos will be developed using the Nutrition Care Manual from the Academy of Nutrition and Dietetics and will cover the importance of maintaining adequate protein intake and ways to enhance it in the diet.
224087311|NCT06157385|BEHAVIORAL|Control|The CN group will receive virtually-delivered recipes every week centered on lean beef intake.
224087312|NCT03118193|OTHER|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
224087313|NCT03118193|BIOLOGICAL|blood test|one sample of 4mL
224087314|NCT03118193|BIOLOGICAL|Collection of faeces|Collection of faeces by patient at home - optional
224087315|NCT03118193|DEVICE|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
224087316|NCT06182735|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
224087317|NCT02483741|BIOLOGICAL|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
224277910|NCT03180255|OTHER|Placebo|Ocular iontophoretic delivery of a placebo
224277911|NCT04307849|BEHAVIORAL|Adolescent Health Club|Sexual health/HIV-related evidence-based interventions
223913017|NCT06816342|DRUG|Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer|patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the hand-made paper sheet spacer
223913018|NCT06817785|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
223913019|NCT06817785|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
223913020|NCT04181736|DRUG|Guanfacine Tablets|Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
223913021|NCT06818864|DEVICE|Deep Brain Stimulation|Patients will arrive on the morning of surgery to the medical imaging department of the Sunnybrook Hospital. They will have a stereotactic frame attached directly to their skull, after infiltration with local anesthesia. The frame allows precise coordinates to be acquired so that deep brain structures can be targeted with implanted electrodes. The patient will then undergo a CT scan with the frame in place, followed by transport directly to the operating room. The anesthesia team will insert an intravenous line and may use gentle sedation to relax the patient prior to and during the operation, as they will remain awake during the first stage of the operation. In the operating room the patient's head, via the frame, will be attached to the operating room table, and their scalp infiltrated with additional local anesthetic. A skin incision will be made and two burr holeswith approximately 1.4cm in diameter drilled through the skull. A small electrode will identify the optimal spot for ele
223913022|NCT05340569|DIAGNOSTIC_TEST|Whole-body diffusion-weighted magnetic resonance imaging|See arm description.
224087318|NCT02771522|DEVICE|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black \& white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
224087319|NCT01419132|DRUG|Furosemide|125-250 mg furosemide bid
224087320|NCT01419132|DRUG|Furosemide|125-250 mf furosemide bid
224087321|NCT01555229|DEVICE|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
224087322|NCT01555229|DEVICE|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
224087323|NCT06549010|DIAGNOSTIC_TEST|Perimetric test|This study aims to evaluate a novel head-mounted perimeter against the HFA as an alternative method of VF testing. This new perimeter uses a Virtual Reality (VR) headset and a gamified version of VF testing to assess the visual function of healthy eyes and patients.
224087324|NCT00995254|BEHAVIORAL|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
224087325|NCT03281785|OTHER|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
224087326|NCT03281785|OTHER|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
224087327|NCT03281785|OTHER|Pressure support mode (PS)|Pressure support mode (PS)
223535250|NCT01484249|DEVICE|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
223913023|NCT06820398|OTHER|Functional exercise with progressive strength and resistance load|This group will perform functional exercises with progressive strength and resistance load, adjusted based on heart rate.
223913024|NCT06820398|OTHER|Functional exercises without any load|This group will perform functional exercises, without strength or resistance load
223913025|NCT04372797|DEVICE|Diagnostic test|A battery of oculomotor tests
223913026|NCT06816654|OTHER|Data extraction from medical records|Data extraction from medical records
223913027|NCT06816745|PROCEDURE|Modified high flow tracheal oxygen|Modified high-flow tracheal oxygen with flow rates of 40L/min and 60L/min will be performed.
223913028|NCT06816745|PROCEDURE|Standard high flow tracheal oxygen|Standard high-flow tracheal oxygen with flow rates of 40 L/min and 60 L/min will be performed.
223913029|NCT06815796|PROCEDURE|Arthroscopic Loop tenodesis of long head of biceps.|Loop tenodesis of the long head of biceps tendon.
223913030|NCT06815796|PROCEDURE|Anchor Tenodesis of Long head of biceps tendon|Anchor Tenodesis of Long head of biceps tendon
224087328|NCT03539445|DRUG|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
224087329|NCT03539445|DRUG|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
224087330|NCT05083455|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the exposure group
224087331|NCT05083455|DRUG|Enoxaparin|Any enoxaparin dispensing claim is used as the reference group
224087332|NCT05655377|DEVICE|FitMi PD|Exercise using the motion sensing devices and a tablet computer
224087333|NCT05845346|OTHER|Electrotherapy-Transcutaneous Electrical Stimulation (TENS)|Ten electrotherapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
224087334|NCT05845346|OTHER|Massage therapy|Ten massage therapy sessions lasting 20 minutes each were carried out. Techniques such as superficial rubbing, deep rubbing, kneading and gliding pressure were performed on the cervical region.
224087335|NCT05845346|OTHER|Stretching exercises|Ten stretching exercise sessions.The stretching exercise modality performed consisted of passive static stretching with a sequence of 30s-10s-30s-10s.
224087336|NCT05845346|OTHER|Ischaemic Compression Technique|Ten Ischaemic Compression Technique sessions. The execution of the technique is described as follows: after locating a painful point (trigger point), pressure is applied until pain is generated, then a position is sought where the pain disappears, the position of maximum comfort, which is maintained for 90 seconds (sec), after which time the patient is returned to the starting position in a passive manner.
224087337|NCT00000855|DRUG|Zidovudine|
223529655|NCT02969577|BEHAVIORAL|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
223913031|NCT06813586|OTHER|hospital-based registry|"The clinical data collected for each patient will reflect comprehensive multiprofessional clinical insights necessary for diagnostic definition and typically obtained during diagnostic evaluation and/or monitoring visits. In addition to these, instrumental data commonly acquired in clinical practice, such as neuroradiological and electrophysiological information, will also be collected.~For each enrolled subject, a checklist (CRF) will be completed to gather study-related data. These data will be entered into a specific database constructed on the REDCap platform and managed in an anonymized form. Subject enrollment will be conducted progressively.~This data collection will enable monitoring of study progress, including the number of enrolled subjects, completed assessments, and study adherence. Every three months, monitoring will be performed to assess study progress and the achievement of enrollment targets."
223913032|NCT06819553|DRUG|Oral Potassium Citrate|Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones
223913033|NCT06808581|DIAGNOSTIC_TEST|blood test for pro-inflammatory cytokines and ultrasound of the median nerves|Blood test and ultrasound
223913034|NCT06818773|DRUG|Inetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor|A 21-day cycle is used, with the initial dose of inetuximab at 8 mg/kg (IV), followed by 6 mg/kg (IV) on Day 1 of each subsequent cycle. Gemcitabine (1000 mg/m²) + cisplatin (25 mg/m²) are administered in combination on Day 1 and Day 8 of each cycle. The appropriate PD-1/PD-L1 inhibitor will be selected by the investigator based on the patient's specific condition, and its administration will strictly follow the dosing instructions provided in the relevant drug's package insert.
223913035|NCT06816576|OTHER|Emotional Freedom Technique|"Emotional Freedom Technique application; It is an application that works on cognitive and energetic levels. Emotional Freedom Technique Application Instructions~1. Determination of Subjective Units of Disturbance (SUD)~2. Preparation or setup~3. Application of appropriate acupuncture points in order~4. 9-Gamut: An application that allows the two hemispheres of the brain to be stimulated simultaneously~5. Application of appropriate acupuncture points in order again~6. Control of the differentiation in the level of discomfort with Subjective Units of Disturbance again"
224087338|NCT01256177|DRUG|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
223913036|NCT06817148|PROCEDURE|transcatheter aortic valve replacement (TAVR)|percutaneous transcatheter aortic valve replacement
223913037|NCT06817148|PROCEDURE|surgical aortic valve replacement (SAVR)|surgical aortic valve replacement
224087339|NCT01256177|DRUG|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
224087340|NCT01110395|DIAGNOSTIC_TEST|MR Spectroscopy|MR spectroscopy of myocardial
224087341|NCT00113594|DRUG|Olanzapine|
224087342|NCT00442403|DRUG|chloroquine|
224087343|NCT00442403|DRUG|dehydroepiandrosterone sulphate|
224087344|NCT02493569|PROCEDURE|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
224087345|NCT02940067|OTHER|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
224087346|NCT00275431|DRUG|AT-101|Oral
224087347|NCT01933841|DEVICE|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
223529656|NCT02969577|BEHAVIORAL|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
223913038|NCT06817291|PROCEDURE|Laparoscopic endobiliary stent|During laparoscopic gallblader surgery, a quidewire is inserted in the cystic duct, via the common bile duct and advanced into the duodenum. The plastic stent is threaded over the wire and pushed in position, with a catheter. When the stent is crossing the papilla, the wire is first removed, and then the catheter. The procedure is done under x-ray guidance.
224087348|NCT01933841|PROCEDURE|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
224087349|NCT00793767|DRUG|erythropoietin|bolus of 400 IU/kg
224087350|NCT00793767|DRUG|placebo (saline)|i.v
224087351|NCT01111305|DRUG|Reslizumab|
224087352|NCT01111305|DRUG|Diethylcarbamazine|
224087353|NCT01111305|OTHER|Placebo|
224087354|NCT03624946|BIOLOGICAL|Zika Virus Immune Globulin (ZIKV-IG)|Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
224087355|NCT03624946|OTHER|Placebo|Placebo is a normal saline solution (0.9% sodium chloride).
223913039|NCT06817941|BEHAVIORAL|Speech only|Participants will be using a computer-based speech therapy games at home to train their speech clarity for 8 weeks. While playing these games, a webcam will be recording the participant's speech loudness and mouth opening.
224087356|NCT03966326|DRUG|sevoflurane and fentanil|Patients will receive standard general anesthesia
223913040|NCT06817941|BEHAVIORAL|Hand/Arm only|Participants will be using a computer-based therapy games at home to train their hand and arm movement for 8 weeks. While playing these games, a motion detector will be used to measure how quickly and accurately the participants can move their fingers, wrist, and arm.
223913041|NCT06817941|BEHAVIORAL|Speech and arm combined|Participants will be using a computer-based therapy games at home to train their speech clarity and hand/arm movement together for 8 weeks. While playing these games, a webcam will be recording the participant's speech loudness and mouth opening. A motion detector will also be used to measure how quickly and accurately the participants can move their fingers, wrist, and arm.
223913042|NCT06820619|BEHAVIORAL|Social, Emotional, and Ethical Development (SEED) curriculum|In response to fulfilling children's urgent psychosocial needs, the Bodhi Love Foundation (BLF) adapted the Kindness Curriculum for young children in Hong Kong by translating it from English to Chinese and adapting its length and content for implementation in the local kindergarten context. The adapted Kindness Curriculum, renamed as Social, Emotional, and Ethical Development curriculum (SEED), is a two-part program involving teacher training and delivery of SEED. The teacher training is consist of a 12-hour mindfulness course and a 1-day (6 hours) workshop to get familiarized with the understanding and practice of mindfulness, and the details of the SEED Curriculum. The SEED Curriculum involves 8 short sessions of basic techniques in mindfulness with 10 minutes each. In addition, it has 12 mindfulness-based lessons with specific themes for children in K1 and K2. Each lesson lasts for approximately 30-40 minutes.
224087357|NCT03966326|DRUG|sevoflurane and fentanil plus PECS II block|Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
224087358|NCT02909894|OTHER|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
224087359|NCT02909894|OTHER|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
224087360|NCT00818376|OTHER|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
223529657|NCT02969577|OTHER|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
223913043|NCT06817460|PROCEDURE|tran-sumbilical laparoendoscopic single-site surgery|Different types of surgery
223913044|NCT06817460|PROCEDURE|transvaginal natural orifice transluminal endoscopic surgery|Different types of surgery
223913045|NCT06817070|DIAGNOSTIC_TEST|Food Consumption survey|A comprehensive survey was created using Google Forms® to collect sociodemographic, clinical, anthropometric, dietary data, and physical activity information from participants across most Mexican states. All self-administered surveys began with informed consent and were distributed via instant messaging (WhatsApp), social networks (Facebook, Twitter), and email using a snowball sampling method. Sociodemographic data included age, gender, and residence, while anthropometric data covered weight, height, and physical activity. Food intake was assessed using a 48-item semi-quantitative tool based on the National Health and Nutrition Survey 2021, with participants reporting the frequency and quantity of food consumed on a Likert scale. Responses were converted to daily consumption values and caloric intake using the Mexican System of Foods and Equivalents. Foods and beverages were categorized into twelve groups: six healthy (fruits, vegetables, legumes, natural dairy, white meat, nuts, and
223913046|NCT06820775|COMBINATION_PRODUCT|A TRIPLE INTERVENTION NUTRITION AND PHYSICAL ACTIVITY|"Intervention group: Health advice and triple intervention: 15 ml apple cider vinegar diluted in a glass of water before meals, order in the sequence of meals (sequence of food intake: first vegetables, second proteins, third fats and finally carbohydrates) and physical activity immediately after meals.~Description of all interventions:~Patients in both groups: all patients will receive health advice on sports practice from the WHO, Osakidetza and the Basque Government."
224087361|NCT02024984|DRUG|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
223716236|NCT03564314|OTHER|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
223716237|NCT00120835|DRUG|valopicitabine|
223716238|NCT00120835|DRUG|pegylated interferon|
223913047|NCT04555278|DEVICE|Active rTMS|"A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). The intensity of rTMS will be set at 95 % of the first dorsal interosseous (FDI) resting motor threshold (RMT).~Active rTMS will consist of 40 trains of 5 seconds each at 10 Hz (25-s intertrain interval) applied over M1 (on FDI cortical representation), for a total of 2000 stimulations lasting 20 minutes."
223913048|NCT04555278|DEVICE|Sham rTMS|A sham coil will be use (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS (30 min).
223913049|NCT04555278|OTHER|Motor Control Exercises|The rehabilitation program will consist of a 30-minute session of motor control exercises following the rTMS (Active or Sham) intervention. This approach aims to improve spine health through the optimization of spine loading. The first session will be preceded by an individualized evaluation of the participant's abilities and deficiencies to tailor the training program to each participant.
223913050|NCT04861740|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
223913051|NCT04861740|OTHER|Screening Intervention|Autism screening intervention only.
223913052|NCT06657807|BEHAVIORAL|Online CBT|Online CBT targeting anxiety in pediatric asthma
223913053|NCT06657586|OTHER|neuromuscular exercises|The exercise was applied in 18 sessions of 6 weeks.The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
223913054|NCT06657586|OTHER|conservative treatment|The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
223913055|NCT05759039|PROCEDURE|Medial patellofemoral ligament reconstruction|Medial patellofemoral ligament reconstruction
223913056|NCT05759039|PROCEDURE|Tibial tubercle osteotomy|Tibial tubercle osteotomy
223913057|NCT06652659|OTHER|Non-union|Observational study looking prospectively at many different factors that may affect non-union of midshaft clavicle fractures.
223913058|NCT05625204|BEHAVIORAL|Center based attention (stretching only) control|Center based attention (stretching only) control
223913059|NCT05625204|BEHAVIORAL|Center based HIIT|Center based HIIT
223913060|NCT05625204|BEHAVIORAL|Home based HIIT|Home based HIIT
223913061|NCT05735964|DRUG|Indocyanine green|Intravenous and endoluminal dosing
223913062|NCT05489120|OTHER|Consumption of FLAVIS|Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
223913063|NCT06476704|DRUG|Administration of L-TC|Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
223913064|NCT06476704|RADIATION|HFRT alone|"HFRT : 30 Gy in 5 fractions of 6 Gy.~1 fraction per day, 5 days per week."
223913065|NCT06819709|OTHER|Botanical Moisturizer + Oral Supplement + Unscented Soap|"The intervention includes 3 products:~1. A botanical moisturizer~2. An oral supplement containing l-histidine (an amino acid) and antioxidants~3. An unscented bar of soap"
223529658|NCT03812848|OTHER|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
223529659|NCT01017900|PROCEDURE|local excision|surgical excision by orthopaedic surgeon under local anesthesia
223529660|NCT05227157|OTHER|swab with iron sulfate solution|measurement of the intensity of perception of metallic taste by affixing a swab iron sulfate solution 10g/l at 4 places on the tongue depending on the glossopharyngeal nerve: tip of the tongue (right and left); base of the tongue (right and left). Visual analogic Scale (0 to 5)
223913066|NCT05685225|DRUG|Stage 1: Naltrexone/Acetaminophen|Combination
223913067|NCT05685225|DRUG|Stage 1: Naltrexone|Naltrexone alone
223913068|NCT05685225|DRUG|Stage 1: Acetaminophen|Acetaminophen alone
223913069|NCT05685225|DRUG|Stage1: Placebo|Matching placebo
224277912|NCT04307849|OTHER|Wait-list Control|The wait-listed group will begin the intervention after the intervention group
224277913|NCT01514513|DRUG|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
223913070|NCT05685225|DRUG|Stage 2: Naltrxone/Acetaminophen high dose|Combination high dose
223913071|NCT05685225|DRUG|Stage 2: Naltrexone/Acetaminophen medium dose|Combination medium dose
223913072|NCT05685225|DRUG|Stage 2: Naltrxone/Acetaminophen low dose|Combination low dose
223913073|NCT05685225|DRUG|Stage 2: Placebo|Matching Placebo
223913074|NCT06820086|DRUG|Rosuvastatin 20mg|Preventive statin treatment with rosuvastatin 20mg, 1 tablet per day, for healthy individuals with top 20% CAD PRS.
223913075|NCT06820437|OTHER|Low-fidelity (Visually Enhanced Mental Simulation-VEMS) simulation training|Intervention group 1: Low-fidelity (Visually Enhanced Mental Simulation-VEMS) simulation training will be conducted on active external bleeding control management skills of caregivers of elderly individuals. In this intervention poster and cards will be used.
223913076|NCT06820437|OTHER|High-fidelity (simulated patient/standard patient) simulation training|Intervention group 2: High-fidelity (simulated patient/standard patient) simulation training will be conducted for caregivers of elderly individuals in active external bleeding control management skills. Standardized patient who will act as elderly will be used in this intervention.
223913077|NCT06818253|DIETARY_SUPPLEMENT|The Effect of Glycerol Supplements|The main factor that distinguishes this intervention is first of all the dosage of the dietary supplement and the effects on the variables to be analyzed related to physical performance.
224087362|NCT04909528|DEVICE|Low-level tragus stimulation|Frequency: 20Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulation spot: ear tragus; Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
224087363|NCT04909528|DEVICE|Sham stimulation|Frequency: 20 Hz; Pulse width: 0.2 ms; Current is based on the following: Determine the perception threshold (feeling tingling) at the time of baseline information assessment. Because of sensory adaptation, ask the patient 5 minutes later to increase the current by 1-5 mA. Try to find the current level below the discomfort level and above the perception threshold; Stimulate spot: ear lobe. Stimulation time: 30 min in the morning (from 6:00 a.m. to 9:00 a.m.) and 30 min in the evening (from 20:00 p.m. to 23:00 p.m.)
224087364|NCT06075381|COMBINATION_PRODUCT|Pulmonary Expansion Device (PED)|The Pulmonary Expansion Device constitutes an innovative instrumental technique for lung expansion, designed for use in patients with or without an artificial airway. This device is attached to the artificial airway, the oronasal mask, or the patient's mouth. It enables voluntary control through a system of one-way valves that restrict the air's escape from the lungs to the outside. This creates an environment conducive to retaining air within the lungs, thereby increasing intrapulmonary pressure. Additionally, it reduces the risk of pulmonary complications associated with conventional management, employing a strategy free from exogenous application of positive pressure to the airway. This approach doesn't necessitate expensive equipment or electrical power.
223716239|NCT02601391|BEHAVIORAL|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
224087365|NCT06075381|PROCEDURE|Conventional management|The conventional management includes: Adequate postoperative pain control, global postural reeducation, reeducation of breathing pattern, airway hygiene, early mobilization, respiratory and scapular waist exercises, and in patients with evidence of lung atelectasis or mild persistent hypoxemia, conventional management will involve the use of intermittent positive pressure ventilation in the airway.
223913078|NCT02266719|DEVICE|Fenestrated CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
223913079|NCT02266719|DEVICE|Type I - III TAAA|"Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position."
224087366|NCT02700178|OTHER|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
224087367|NCT03871894|OTHER|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on measured energy expenditure by indirect calorimetry (IC) done alternate day till patient on ventilatory support and protein intake 1.5 g/kg IBW/day
224087368|NCT03871894|OTHER|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 35-40 Kcal/Kg IBW/day and 1.5 g protein /Kg IBW/Day till patient on ventilator
223913080|NCT02266719|DEVICE|Arch cohort|Arch branched devices may be designed using one of two configurations: (1) Zone 0 device with two inner antegrade branches for the innominate artery and the left common carotid artery with or without a retrograde left subclavian artery branch and (2) Zone 1-2 device with a single retrograde subclavian artery branch with double or triple wide scallop for the left common carotid artery. These devices are designed for a of proximal landing/fixation zone of at least 20 mm of healthy aortic segment or a previous graft.
224087369|NCT00983567|OTHER|teen web|Min web
224087370|NCT03981159|OTHER|Physical training|Physical training for three months, twice per week (60 minutes per session).
223529661|NCT06035731|OTHER|SOCIO-AESTHETICS care|SOCIO-AESTHETICS well being care performed by qualify person
224087371|NCT03388593|DRUG|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
224087372|NCT03388593|DRUG|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
224087373|NCT00331006|DRUG|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m\^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
224087374|NCT05423405|OTHER|Acupressure|selected acupoint pressure
224087375|NCT05595278|DIAGNOSTIC_TEST|(CBC) ,(NT-proBNP) ,(cTnT)|complete blood count (CBC) including RDW with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) in a cohort of acute myocardial infarction (AMI) patients.
224087376|NCT02543138|DEVICE|Trocar|Closed thoracostomy using the new trocar
223529662|NCT06314347|DIAGNOSTIC_TEST|Figure of 8 walk test|clinical measurement
223529663|NCT05657847|DEVICE|Photon-counting detector-CT|CT scan
223529664|NCT00318617|DRUG|GW510516X|
223529665|NCT01245608|DRUG|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
223529666|NCT05162846|OTHER|Publicly available genetic testing resources|Participants may view the publicly available Michigan Department of Health and Human Services (MDHHS) website as they wish.
223529667|NCT05162846|BEHAVIORAL|Virtual genetics navigator|A mobile-optimized website/online genetic tool developed by investigators from the University of Michigan's Center for Health Communications Research (CHCR).
223913081|NCT06816849|OTHER|Recommended water intake|All participants received personalized consultation from a dietitian on adequate fluid intake and the selection of drinks based on dietary guidelines. They were required to follow the intervention for four months.
223913082|NCT06820749|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 12-week treatment period in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
223913083|NCT06820749|DRUG|Placebo|the placebo comparator of study
223913084|NCT06817343|BIOLOGICAL|Aflibercept (2.0 mg)|PRN IVT Aflibercept
223913085|NCT04622644|DEVICE|Device: clinical investigation microwave device class IIa not marked CE for stroke detection|Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
223913086|NCT06856564|PROCEDURE|Frenectomy|The study involves using a diode laser and scalpel to treat ankyloglossia in cases that are unresponsive to tongue exercises or exhibit severe restrictions. The techniques employed range from simple frenotomy to complex frenuloplasty, depending on the severity of the condition. Electrocautery is frequently used to minimize bleeding, although it may result in scar formation.
223913087|NCT06856785|OTHER|Resonance Tube Voice Therapy in Water|Resonance Tube of 28 cm in length and 9 mm diameter for adults will be submerged into a bowl of water .Both flexible soft walled tubes,glass tubes or straws can be used
223913088|NCT06855589|DRUG|6 months of Eligard|Total of two 3-month injections of a LHRH agonist for total duration of 6 months
223913089|NCT06855589|DRUG|12 months of Eligard|Total of four 3-month injections of a LHRH agonist for total duration of 12 months
223913090|NCT06855589|RADIATION|prostate SBRT or prostate brachytherapy with radiation therapy|Patients may receive prostate stereotactic body radiation therapy or a combination of high-dose rate brachytherapy with radiation therapy; as per the treating physician's preference
223913091|NCT06857838|PROCEDURE|MBBG|The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
224087377|NCT05722184|DIAGNOSTIC_TEST|BactInsight blood culture system|A battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth, in combination with optimized blood culture bottles.
224087378|NCT02542488|OTHER|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI \>35 kg/m2? A: Are you \>50 years old? N: Is your neck circumference \>40cm? G: Is your gender male?"
224087379|NCT02542488|DIAGNOSTIC_TEST|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
224087380|NCT02542488|OTHER|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
224087381|NCT03644290|BEHAVIORAL|Cognitive training|Five sessions of semantic strategy training and face-name association training
224087382|NCT03644290|BEHAVIORAL|Control Condition|Five sessions of active control information and education
223719399|NCT06026761|DEVICE|Skiin garment and pods|"Participants will be asked to wear two pieces of equipment to record physiological data:~1. A Skiin garment that contains IMU and ECG sensors~2. A Cosmed K5 metabolic cart that will record breathing rate data~Participants will then be asked to perform various tasks of daily living (e.g. watching TV, sweeping the floor), general strength exercises (e.g. squats, triceps dips, lunges), and aerobic exercises (e.g. walking, running) as instructed by researchers"
223913092|NCT06857838|PROCEDURE|MB CABG|The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The moderate-to-severe atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
223913093|NCT06857838|PROCEDURE|MB unroof|"The patients with superficial type(depth\<2mm) and short-segement(length\<25mm) of myocardial bridge will be allocated to receive myocardialbridge unroof surgery，when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The MB was superficial and short confirmed by coronory artery CT angiography."
223913094|NCT06291896|DEVICE|MammoWave|"Women undergoing conventional breast screening examination will be asked by the clinical staff if they are interested in taking part in the study.~A short visit should be performed to check the inclusion/exclusion criteria, review demographic data, and the volunteer's medical history. After performing this visit, the volunteers will perform the MammoWave exam on both their breasts.~The exam will be composed of two phases: data acquisition and data processing. During the acquisition, which should take about 8 minutes, the volunteers would be lying down in a prone position, on the bed which is part of MammoWave.~When the acquisition is completed, the data will be processed through a dedicated microwave imaging algorithm. The output will be composed of microwave images, plus parameters describing the images. MammoWave output will also comprise a label obtained using an optimized classification algorithm."
224087383|NCT02310620|BEHAVIORAL|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
224087384|NCT04688203|DRUG|Magnesium Sulfate Injection|will receive IV bolus dose of 40mg/kg magnesium sulfate in 100 ml saline solution over ten minutes then continuous infusion of 10-15mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
223913095|NCT06857578|PROCEDURE|Total revision of Roux-en-Y gastric bypass|"1. The entire previous gastric bypass construction is released from any adhesions and all parts of the small intestine are measured and assessed.~2. All or parts of the first part of the intestine that food reaches after the gastric pouch (so-called Roux) is resected. The reason is that parts of the intestine that are considered to be of poor quality (for example, affected by a lot of adhesions or abnormally dilated) are removed. This can be about 1.5 meters of intestine, which corresponds to 10-25% of the entire length of the small intestine.~   The gastric pouch will be small (\<30 ml).~3. A new gastric bypass construction is constructed where the intestine receiving food from the esophagus (Roux) will be 1 meter, and the small intestine part from the closed stomach at least 1.5 meters.~The remaining length of the small intestine below the jejuno-jejunal anastomosis should be minimum 3 meters."
223913096|NCT06664021|DRUG|Tislelizumab combined with S-1|Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
223913097|NCT06855797|OTHER|Observation|questionnaire
223913098|NCT06661681|BEHAVIORAL|Cognitive Functional Therapy (CFT)|"Cognitive Functional Therapy (CFT) is underpinned by a strong therapeutic alliance, active listening, and motivational interviewing style, covering the following domains:~i) Making sense of pain involves discussing the multidimensional nature of persistent pain, as well as the beliefs, emotions, and behaviors that can perpetuate the vicious cycle of pain and disability.~ii) Exposure with control involves a functional training designed to normalize maladaptive and provocative postural and movement behaviors, where individuals will learn strategies to improve their body awareness and control and modify postures and tasks commonly associated with pain.~iii) Lifestyle change aims to help patients embrace a healthy lifestyle, which will include promoting a gradual increase in physical activity, sleep hygiene counseling, stress management strategies, and social re-engagement."
223913099|NCT06661681|OTHER|Therapeutic exercises group|Each session will include stretching exercises targeting the following muscles i) Upper trapezius; ii) Pectoralis minor; iii) Posterior shoulder region, and strengthening exercises targeting the following muscles i) Lower trapezius, ii) Middle trapezius, iii) Serratus punch exercise, iv) Shoulder external rotators, and v) Shoulder internal rotators.
223913100|NCT06659458|OTHER|blood draw|A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
223913101|NCT06659458|OTHER|Gene sequencing|Subjects will have their DNA sequenced within and around the EGFR gene.
223913102|NCT04408430|DEVICE|Transseptal ViMAC|Transseptal TMVR using balloon-expandable aortic transcatheter valves.
223913103|NCT06657989|BEHAVIORAL|Reactive balance training|Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
223913104|NCT06657989|BEHAVIORAL|Walking|Overground walking
223913105|NCT06663696|DEVICE|Supraflex Cruz Sirolimus-eluting Coronary Stent System|Biodegradable polymer-coated, cobalt-chromium sirolimus-eluting coronary stent
223913106|NCT06354881|DEVICE|Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres|TCD will be used to measure the cerebral blood flow in the middle and posterior cerebral arteries. This will be done at rest and during two sit-stand manoeuvres, whereby the participant will be asked to stand (from a seated position) and stay standing for 1 minute. The participant will then be given time to recover before repeating the manoeuvre. This will occur at the first visit and the follow-up visit 4 weeks after.
223913107|NCT04784299|DEVICE|YVOIRE volume plus|Hyaluronic acid dermal filler
223913108|NCT04784299|DEVICE|Restylane Lyft with Lidocaine|Hyaluronic acid dermal filler
223913109|NCT06164444|OTHER|Intervention: Reusable drapes and gowns|Reusable drapes and gowns used during surgery.
223913110|NCT06164444|OTHER|Comparator: Disposable (single-use) drapes and gowns|Disposable drapes and gowns used during surgery.
223913111|NCT03615664|DRUG|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
223913112|NCT03615664|DRUG|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
223913113|NCT03615664|DRUG|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
223529668|NCT05162846|BEHAVIORAL|Motivational interviewing (MI)|At least 2 phone calls delivered by trained genetic health coaches using motivational interviewing and providing genetic testing information.
223529669|NCT01189721|DRUG|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
223529670|NCT05534867|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 16 mandala coloring pages given to each participant by the researcher for 1 month, 2 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
223913114|NCT03615664|DIAGNOSTIC_TEST|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial"
223913115|NCT03615664|PROCEDURE|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
223913116|NCT05246319|DIAGNOSTIC_TEST|preoperative imaging|evaluation of preoperative imaging (versus nodes observed on pathology)
223913117|NCT06825299|DIAGNOSTIC_TEST|Chest-Tube Insertion|The technique was performed according to a combination of the Chest-Tube Insertion (BTS) guidelines for chest tube insertion and ultrasound (US)-guided technique for chest tube insertion and US-guided pigtail insertion.
224087385|NCT04688203|DRUG|Labetalol Injectable Solution|will receive IV bolus does of labetalol 0.25 mg/kg over ten minutes then continuous infusion of 0.5-1mg/kg/h will be titrated till achieve target mean arterial blood pressure (55-65 mmHg) and will be terminated by the end of surgery.
224277914|NCT01514513|DRUG|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
223529671|NCT06199479|PROCEDURE|MRI Scan|Performed by MRI Scan
223529672|NCT06199479|PROCEDURE|CT Scan|Performed by CT Scan
223913118|NCT05338164|PROCEDURE|cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
223913119|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 4-step milk ladder (muffin, pancake,baked hard cheese, yoghurt/pasteurised cow milk or modified cow milk)
223913120|NCT06664918|OTHER|oral food challenge (OFC)|oral food challenges with subsequent steps of 6-step milk ladder (cookie, muffin, pancake,baked hard cheese, yoghurt, pasteurised cow milk or modified cow milk)
223913121|NCT06824961|OTHER|5-second ventilation pause duration during mechanical CPR|The intervention is a 5-second lasting ventilation pause during mechanical CPR
224087386|NCT02736903|BEHAVIORAL|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
224087387|NCT02736903|BEHAVIORAL|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
224087388|NCT01767584|DRUG|Cephalexin 1g tablets|Reference product
224087389|NCT01767584|DRUG|Cephalexin 1g tablets|Test product
224087390|NCT02052102|RADIATION|Radiation therapy|
224087391|NCT00640094|DRUG|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
224087392|NCT00728065|DIETARY_SUPPLEMENT|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
224087393|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
224087394|NCT00728065|DIETARY_SUPPLEMENT|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
224087395|NCT00728065|DIETARY_SUPPLEMENT|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
224087396|NCT00728065|DIETARY_SUPPLEMENT|Rice milk|Rice milk containing 50g of available carbohydrates
224087397|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
223529673|NCT06199479|PROCEDURE|Biopsy|Standard of Care Biopsy
224087398|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
224087399|NCT00728065|DIETARY_SUPPLEMENT|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
224087400|NCT05428709|BEHAVIORAL|Acute Exercise|Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
224087401|NCT05835414|DEVICE|Adjunctive, midline prefrontal, lower intensity, shorter session, EEG-enhanced, repetitive transcranial magnetic stimulation (eTMS)|Approximately 2000 pulses per session (x30 sessions) of midline prefrontal, repetitive transcranial magnetic stimulation at 50% or less of motor threshold, calibrated via EEG to a resonant alpha frequency of the participant, and given over approximately 12 minutes. Given as an adjunct to standard of care and integrative treatment for TSRD.
223529674|NCT06335212|DEVICE|Single vision and multifocal contact lenses|Cycloplegic central autorefraction was conducted with both Grand Seiko WAM-5500 open-field auto-refractor (Grand Seiko Co Ltd) and OPD OPD-Scan III Wavefront Aberrometer (Marco) on the subjects in the following conditions: (1) no CLs, (2) SVCLs, (3) MFCLs (+2.00D Add), and (4) MFCLs (+4.00D Add). Relative peripheral power profiles were measured using the OPD under the same 4 conditions after cycloplegia.
223529675|NCT02825667|OTHER|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
223529676|NCT01461460|DRUG|TR-701 FA 1200 mg|6 tablet of T-701 FA
223913122|NCT06824961|OTHER|3-second ventilation pause duration during mechanical CPR|The intervention is a 3-second lasting ventilation pause during mechanical CPR
223913123|NCT06825026|BEHAVIORAL|Pragmatic exercise trial|As part of the broader Observatory of the Older Person cohort, we aim to conduct a pragmatic exercise trial in a subgroup of nursing home residents. This trial seeks to evaluate the effectiveness of a concurrent exercise intervention on frailty, functional capacity, independence in activities of daily living and falls rate in real-world settings.
224087402|NCT04024592|DEVICE|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
224087403|NCT02780791|OTHER|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
224087404|NCT02780791|OTHER|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
224087405|NCT00544934|DRUG|GLY-230|125, 250 0r 375 mg bid for 14 days
224087406|NCT00544934|OTHER|Placebo|No drug administered
224087407|NCT04977206|OTHER|Mutual Goal-Setting Education|Nurses will receive both written and verbal instruction on mutual goal-setting with patients using SMART methodology
224087408|NCT01950819|BIOLOGICAL|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
223529677|NCT01461460|DRUG|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
223529678|NCT01461460|DRUG|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
223529679|NCT01461460|DRUG|Placebo|6 placebo tablets
223529680|NCT04635852|DRUG|Fentanyl|
223913124|NCT06825039|DEVICE|Shockwave therapy|Focused ESWT will be applied to the scarred area in the 3 intervention groups. Each group will receive 10 ESWT treatments with a frequency of 1x/week. Energy levels (EFD mJ/mm2) or bar in radial can range between 0.01-0.33 mJ/mm2 (33). Based upon experimental papers, the described energy flux density, frequency and number of shots should activate or modulate the signaling pathways of interest and are used in the treatment of scars.
223913125|NCT06824090|OTHER|Smartphone Addiction Scale-Short Form|Smartphone Addiction Scale-Short Form: In our study, the Smartphone Addiction Scale-Short Form will be filled out in order to evaluate the intensity of smartphone use of students, and the daily duration of smartphone use will be recorded. The scale is a 6-point Likert-type scale consisting of 10 items used to measure the risk of smartphone addiction. Scores obtained from the scale vary between 10-60 and an increase in the score indicates an increased risk for smartphone addiction. The cut-off score of the scale was determined as 31 for men and 33 for women. In the Turkish validity and reliability study, Cronbach's alpha coefficient was found to be 0.86.
223913126|NCT06824090|OTHER|Hand Grip Strength Assessment|Hand grip strength was measured with 'Saehan Hydraulic Hand Dynamometer'. Participants were informed about the correct holding position and use of the instrument. In the measured arm, the position of 90̊ flexion from the elbow joint and completely adjacent to the body was used. The participant's hand was placed in the second grip position of the dynamometer and asked to make the strongest grip he/she could make, right and left measurements were taken.
223913127|NCT06824090|OTHER|Finger Lateral Grip Strength Assessment|Finger lateral grip strength was measured with 'Saehan Hydraulic pinch gauge'. Participants were informed about the correct holding position and use of the instrument. While the participant was sitting on a chair with arms supported, the shoulder was adjacent to the trunk and neutral, the elbow joint was in 90 ̊ flexion, the forearm was neutral, the wrist was in 0-30 ̊ extension and 0-15 ̊ ulnar deviation. Right and left finger lateral grip measurements were taken.
223913128|NCT06824090|OTHER|Myoton Assessment|Myoton PRO device was used to objectively evaluate the biomechanical properties of the hand and wrist muscles such as tone, stiffness and elasticity. Tenar region, flexor carpi radialis, flexor carpi ulnaris, extensor digitorum, extensor carpi radialis and extensor carpi ulnaris muscles were evaluated bilaterally. Three measurements were recorded at one second intervals and the mean value was used for analysis.
223913129|NCT06550726|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Subjects will undergo MRI scanning in our 3T machine with dedicated high resolution sequences (including 2D T1-weighted inversion recovery sequences, 3D FLAIR MRI whole brain, 3D T1-weighted Sagittal MPRAGE; plus other sequences for the clinical purpose of pre-operative planning as per consensus with referring doctor)
223913130|NCT06825533|DIAGNOSTIC_TEST|Fasting blood sugar level|Assess the level of Blood sugar level in fasting conditions at inclusion
223913131|NCT06825533|DIAGNOSTIC_TEST|Glycated hemoglobin|Assess the level of glycated hemoglobin at inclusion
223913132|NCT04689360|DRUG|elamipretide|Elamipretide is an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane.
223913133|NCT06822127|OTHER|CT scan|6 months postop CT scan
223913134|NCT06822127|OTHER|VLASTIC test|Measurement of the elasticity of the facial integument using the VLASTIC cutometer (Volume-based Light Aspiration device for in vivo Soft Tissue Characterization)
223913135|NCT06260033|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223913136|NCT06260033|PROCEDURE|Bone Scan|Undergo bone scan
223913137|NCT06260033|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223913138|NCT06260033|DRUG|F-18 16 Alpha-Fluoroestradiol|Given IV
223913139|NCT06260033|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223913140|NCT06260033|OTHER|Questionnaire Administration|Ancillary studies
223913141|NCT06260033|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223913142|NCT06346873|DEVICE|JOGO|AI driven mobile app and wearable sensors to provide virtual treatments
223913143|NCT06598514|DRUG|Chlorhexidine|Participants will use a 2% chlorhexidine perineal lavage following defecation
223913144|NCT06598514|DRUG|Sterile Water|Participants will use a sterile water perineal lavage following defecation
223913145|NCT06588647|BEHAVIORAL|Improving Participation after Stroke Self-Management Program (IPASS)|The IPASS-R program is a group-based self-management intervention that aims to improve problem-solving, action-planning, and resource utilization skills for improved community living and participation. The Activity-Barriers-Changes-Doing-Evaluation (ABCDE) framework is a user friendly problem-solving and goal setting framework that is used repetitively in each session throughout the program. Participants are guided to identify (1) an activity that they want to improve or re-engage in (A); (2) individual and environmental barriers that hinder their engagement (B); (3) changes that they can make to deal with the barriers and improve their engagement (C); and (4) an action plan to pursue (D). After the action plan, participants come back in the next session and evaluate their performance in following through on their plans (E).
223529681|NCT04635852|DRUG|Immediate release morphine|
223913146|NCT06588647|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP)|The program is facilitated by two trained leaders in small groups in a community setting with individuals who have chronic health problems and will follow the CDSMP protocol. Participants receive education on various health-related topics applicable to a range of chronic conditions, share experiences, and support one another.
224087409|NCT01950819|DRUG|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
223529682|NCT01140204|DEVICE|Implantation of a bare metal stent|Bare Metal Stent
223529683|NCT06448013|DRUG|Venetoclax|Given by PO
223529684|NCT06448013|DRUG|Gemtuzumab|Given by IV
223529685|NCT06448013|DRUG|Ziftomenib|Given by PO
223529686|NCT02553733|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
223529687|NCT02553733|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
223529688|NCT03057704|DRUG|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
223913147|NCT06608316|DEVICE|Intermittent Theta Burst Stimulation|A novel transcranial magnetic stimulation protocol called intermittent theta pulse stimulation (iTBS) effectively mimics the brain's naturally occurring theta rhythms and promotes significant synaptic changes. Compared to traditional stimulation methods, iTBS is more effective at initiating long-term potential (LTP) and produces significant excitatory effects in a shorter period of time.
223913148|NCT06608927|DRUG|Quemliclustat|Administered as specified in the treatment arm
223913149|NCT06608927|DRUG|Placebo|Administered as specified in the treatment arm
223913150|NCT06608927|DRUG|Nab-paclitaxel|Administered as specified in the treatment arm
223913151|NCT06608927|DRUG|Gemcitabine|Administered as specified in the treatment arm
223913152|NCT06604715|DRUG|JNJ-87562761|JNJ-87562761 will be administered.
223913153|NCT06826001|DRUG|topical finasteride|Group A will receive topical finesteride spray 0.25% twice daily for 12 weeks
223913154|NCT06826001|DRUG|Topical minoxidil|Group B will receive topical 5% minoxidal twice daily for 12 weeks
223913155|NCT06825650|OTHER|Questionnaire study|Questionnaire application
223913156|NCT06597604|DEVICE|Intraoperative use of TenaTac in lung surgery|Use of innovative medical device : TenaTac
223913157|NCT06597604|DEVICE|Intraoperative use of usual sealant in lung surgery|Use of the usual scealant as a control
224087410|NCT01950819|DRUG|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
224087411|NCT01950819|DRUG|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
224087412|NCT01152606|DRUG|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
224087413|NCT00495157|BEHAVIORAL|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
224087414|NCT00495157|BEHAVIORAL|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
224087415|NCT00495157|BEHAVIORAL|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
224087416|NCT00030069|DRUG|Calcitriol|
224087417|NCT00030069|DRUG|Dexamethasone|
224087418|NCT00198692|BEHAVIORAL|self-management|
223529689|NCT03057704|DRUG|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
223913158|NCT06599099|DEVICE|Medtronic Percept RC System|"Medtronic Percept RC System includes:~Percept RC neurostimulator SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Directional Lead Kit (with and without marker; 33cm and 42cm lengths) SenSight Extension Kit (with and without marker; 40cm, 60cm, and 95cm lengths) Percept DBS Handset and Communicator Kit (patient programmer) SenSight Extension Tunneler Kit SenSight Burr Hole Device Kit Clinician Programmer Application (application runs on Model CT900 Tablet) Percept RC Recharger Kit Recharge Application Software Clinician Communicator/Telemetry Module"
224087419|NCT03221218|OTHER|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
223913159|NCT06599099|BEHAVIORAL|One Month Blinded Discontinuation Period|The investigators will use blinded discontinuation at 12 months rather than sham control to establish evidence that response is dependent on ongoing DBS. The open-label design allows for personalized optimization of programming settings - a strength of this design as related to our study goals. Although one of the goals of this study is to use neural recordings to inform programming, currently, unblinded programming is needed to maximize response and minimize side effects. Adverse events will be elicited at each study visit using a standardized instrument, the Patient-Rated Inventory of Side Effects (PRISE). In addition to monitoring for adverse events related to surgery and stimulation, the investigators will track quality of life (QOLS), global functioning (SDS), and necessary adjustments of medications. The behavioral changes of the subject based on these scales will provide insight to the intervention levels provided from discontinuing the therapy from the device.
223913160|NCT06592807|OTHER|Perioperative Warm Socks|The socks to be used in the study were provided by the researcher. The socks were suitable for foot sizes 36-45. The socks were white and made of cotton fabric. The socks were sterilized in an autoclave before use. The socks were put on the patients just before the surgery. The socks were heated to 40 degrees with an intravenous fluid warming machine.The socks remained on the patients feet throughout the surgery. After the surgery, the patients socks were removed and new heated socks were put on. The socks were kept on the patients feet for 1 hour. All socks were used for single use.
223913161|NCT06587256|DEVICE|Mouth Tape|A single piece of silicone tape placed vertically over the lips. When positioned properly the participant can still inhale/exhale and cough around the tape if needed, but will tend to keep mouth closed otherwise.
223913162|NCT06590077|OTHER|Aromatherapy|The test intervention is an aromatherapy cosmetic product containing a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
223913163|NCT06590077|OTHER|Control (placebo) group|Juniper essential oil in apricot kernel oil in low concentration with a faint aroma - presentation as a rollerball. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
223913164|NCT01345851|RADIATION|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
223913165|NCT01345851|OTHER|laboratory biomarker analysis|Correlative studies
223913166|NCT01345851|RADIATION|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
223913167|NCT01345851|DRUG|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
223913168|NCT01345851|DRUG|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
223913169|NCT01345851|RADIATION|stereotactic body radiation therapy|Undergo hypofractionated RT
224087420|NCT04810702|OTHER|no intervention|no intervention
224087421|NCT06435702|DRUG|Darolutamide in addition to androgen deprivation therapy|Darolutamide 600mg twice daily. The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration
224087422|NCT06435702|DRUG|androgen deprivation therapy only|The ADT regimen was either a gonadotropin-releasing hormone analog agonist or a gonadotropin-releasing hormone antagonist.The ADT administration type, frequency, and dose were determined by the investigator.
224087423|NCT06545357|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
224087424|NCT04266535|DEVICE|Target controlled infusion|Target controlled infusion vs manually controlled infusion
224087425|NCT05833802|OTHER|virtual anti-cancer drug|the virtual anti-cancer drug was formulation generated by computer modeling and artificial intelligence technology
224087426|NCT04687319|BIOLOGICAL|bronchial mucus collection|mucus resulting from respiratory physiotherapy sessions for patients with cystic fibrosis or COPD, bronchial aspirations resulting from the bronchial fibroscopy programme
223529690|NCT01014871|DRUG|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
223719400|NCT00688974|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
223913170|NCT06598683|OTHER|tDCS|Stimulation in each session will be applied for 20 min by two 5 × 4 cm (20 cm2) saline-soaked sponge electrodes at an intensity of 1.5 mA (0.075 mA/cm2). A gradual ramp up and down of stimulation for 10 s at the beginning and the end of stimulation
223719401|NCT00688974|PROCEDURE|Adjustable gastric band|Laparoscopic adjustable gastric band
223913171|NCT06598683|OTHER|Conventional|ROM exercises for upper and lower extremities, Stretching of agonists, Strengthening of antagonists, Core stability exercises, Static and dynamic balance activities, Gait training, Functional training
223913172|NCT01209572|DEVICE|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
223913173|NCT01209572|DEVICE|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
224087427|NCT01912755|DRUG|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
224087428|NCT01912755|DRUG|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
224087429|NCT00220220|DRUG|olmesartan medoxomil|
224087430|NCT00220220|DRUG|amlodipine|
224087431|NCT02054182|DRUG|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
224087432|NCT05779709|OTHER|exercise|Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.
224087433|NCT05779709|OTHER|Urotherapy|Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
223913174|NCT06530589|OTHER|Tupler's Technique|Patient will wear diastasis rehab splint and will follow Tupler's techniqe protocol for 6 weeks. In the first 2 weeks both elevator and contracting exercises will be performed and after 2 weeks in the 3rd week only contracting exercises will be perform and for these exercises we divide abdomen into 6 floors and will patient have to contract her tummy towards the 3rd to 5th floor in first week, towards the 4th to 5th floor in 2nd week and from 5th to 6th floor in the 3rd week. in the wek 4 to week 6 head lifts will also be started along with contracting exercises from 5th to 6th floor.
224087434|NCT05394415|DRUG|Tislelizumab|The 1st and 2nd doses were administered concurrently with TP regimen chemotherapy, 200 mg each, on D1 and D22 by intravenous infusion. In patients with successful conversion therapy, one dose of 200 mg on D60, was administered sequentially at the time before surgery after radiation therapy, and two doses of immunotherapy, on D150 and 171, were administered 8 weeks after surgery in concurrent with the 3rd and 4th cycles of chemotherapy as adjuvant therapy; in patients with failed conversion, two doses of chemotherapy combined with tislelizumab, on D60 and D81, were administered 2 weeks after the completion of radiation therapy.
223529691|NCT01014871|DRUG|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
223913175|NCT06530589|OTHER|Traditional Exercises|The traditional treatment includes traditional abdominal exercises that patient will be perform for 6 weeks and three times per week with 15 repetitions of each exercise. These exercises includes posterior pelvic tilt' static abdominal contractions', reverse sit up exercise, kegals, russian twist , trunk twist and reverse trunk twist.
223913176|NCT06841081|OTHER|Enhanced Usual Care|Offer written instructions to the patient and refer the patient to their clinical team if they have unresolved issues.
223913177|NCT06841081|OTHER|Super Supporter Support|Assist and troubleshoot with the patient including a practice video visit.
223913178|NCT04810624|BEHAVIORAL|Relapse Prevention and Changing Habits (REACH+)|Psychotherapy
223913179|NCT06841679|DRUG|Utidelone Capsule|UTD2 40 mg/m2/d, po, qd, day 1-5, q3w
223913180|NCT06841679|DRUG|Utidelone Capsule|50 mg/m2/d, po, qd, day 1-5, q3w
223913181|NCT06841679|DRUG|Utidelone Capsule|60 mg/m2/d, po, qd, day 1-5, q3w
223913182|NCT06841679|DRUG|Capecitabine|1000 mg/m2, po, bid, day 1-14, q3w
223913183|NCT06841679|DRUG|Oxaliplatin|130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles
223913184|NCT06841679|DRUG|Utidelone Capsule|UTD2 po, on d1-5, q3w (dose decided after the phase II)
223913185|NCT06841484|PROCEDURE|Arm I (Assistant-Controlled Laparoscopic Instrumentation)|In this group, robotic distal gastrectomy is performed with assistant-controlled laparoscopic instrumentation. The assistant conducts vascular clipping using articulating Hemolock clip appliers (Livsmed) or Challenger® clip appliers (B.Braun). For gastrointestinal anastomosis, the assistant operates an Echelon stapling system (Johnson \& Johnson) via the assistant port. The surgeon controls the robotic console for all other surgical steps. This method utilizes a hybrid approach, combining robotic precision with laparoscopic efficiency.
223913186|NCT06841484|PROCEDURE|Arm II (Assistant-Controlled Laparoscopic Instrumentation)|"In this group, all surgical steps, including vascular clipping and anastomosis, are performed using the robotic system. The surgeon utilizes the Da Vinci Xi system and switches robotic instruments as needed. Vascular clipping is performed with robotic Hemolock or Hemoclip appliers, and anastomosis is conducted using the SureForm robotic stapler. This fully robotic technique eliminates laparoscopic assistance and utilizes only robotic arms for the entire procedure.~Both groups follow the same postoperative care protocols, including standardized pain management and recovery assessments."
223529692|NCT04012450|PROCEDURE|Epidural anesthesia|Performing an epidural anesthesia
223529693|NCT04012450|PROCEDURE|spina-epidural anesthesia|Performing a spina-epidural anesthesia
223913187|NCT06841432|PROCEDURE|adenoidectomy using coblatioion|One hundred and five patients underwent a Coblation-assisted adenoidectomy procedure. The child was positioned in Rose's position, which helped retract the soft palate and improve visibility of the nasopharynx. Two soft rubber catheters were inserted into the patient's mouth, with the distal and proximal ends crossed externally and secured with a clamp. The COBLATOR™ II surgery system Model EC8000-01 was used, with a power setting of nine for ablation and five for coagulation. Under general anesthesia, the adenoidectomy was performed using either a 4 mm, 70-degree angled endoscope inserted orally or a zero-degree endoscope inserted through the nose, providing effective visualization of the nasopharynx. After the procedure, hemostasis was achieved by using a combination of the coagulation and ablation modes.
223913188|NCT06841432|PROCEDURE|adenoidectomy by Suction diathermy|One hundred and five patients underwent a suction diathermy adenoidectomy procedure. The soft palate was gently retracted using two suction catheters, allowing a 70-degree angled endoscope (Storz, Germany) placed in the oropharynx to provide a clear view of the adenoidal tissue and surrounding structures in the nasopharynx. Using a malleable size 10 or 12 French hand-switching suction coagulator, the adenoidal tissue was carefully ablated, starting from the uppermost part. The procedure was completed when the posterior choanae were clearly visible, and the nasopharynx had a smooth, unobstructed appearance. Great care was taken to avoid injuring the Eustachian tube orifice, posterior septum, choanae, inferior turbinate, palate, and posterior pharyngeal wall. Continuous irrigation with saline, either through the mouth or the nose, helped minimize any thermal damage caused by the diathermy machine.
224087435|NCT05394415|DRUG|Paclitaxel|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1 and D22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150, 171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, on D60, 81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
223529694|NCT04856280|BEHAVIORAL|Kinesiological taping|In KT Group, 6 sessions of KT were applied, starting on the 14th day of the menstrual cycle and 2 times a week for 3 weeks until the cycle ended.
223529695|NCT04856280|BEHAVIORAL|Aerobic exercise|In the AE group, walking and climbing stairs were given during the menstrual cycle, 3 days a week, 45 minutes.
223529696|NCT06042946|PROCEDURE|Microsurgical resection of ISCM|Microsurgical resection of ISCM defines the surgical removal of cancerous tumors that have spread to the spinal cord, using advanced microsurgical techniques and equipment like ultrasound, neuromonitoring, ultrasonic aspirator to prevent damage to the spinal cord.
223913189|NCT06843005|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|Based on the assessment of plaque progression after follow-up CCTA examination, patients will be given either intensive treatment or routine treatment.
224087436|NCT05394415|DRUG|Carboplatin|A TP regimen with paclitaxel 135 mg/m\^2 + carboplatin AUC=5 was used, on D1, 22 infused intravenously. Two cycles of adjuvant chemotherapy, on D150,171, were started 8 weeks after surgery in patients with a successful conversion, and 2 cycles of consolidation chemotherapy, D60,81, were started 2 weeks after the end of radiotherapy in patients with unsuccessful conversion therapy.
224087437|NCT05394415|RADIATION|Radiotherapy|Radiotherapy was scheduled to be given on D1 of the 2nd cycle of chemotherapy. The primary lesions and/or lymph nodes in the operation area would be radiated in 2 stages. A dose of 30Gy/12F would be given in the first stage. When 12 Fractions were given, our MDT team would evaluate the regression of the lesions according to CT and MR results. If surgery is feasible, radiotherapy would be stopped for the primary lesions and lymph nodes in the operation area; if not resectable, the 2nd stage of radiotherapy would be given with a dose of 15Gy/6F, totaling to 45Gy/18F to the ESCC lesions. Radiotherapy for all lymph nodes outside the operation area was with DT of 45Gy/18F. All radiotherapy in this study was scheduled to be 2.5Gy/F, 1F/d, 5F/w. The preoperative radiotherapy target area was outlined by the consensus of the thoracic surgeon and radiotherapist.
224087438|NCT01526525|DRUG|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
224087439|NCT01526525|DRUG|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
224087440|NCT01526525|DRUG|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
224087441|NCT01526525|DRUG|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
224087442|NCT01526525|PROCEDURE|sedation|If the patient had sedation score \>2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
224087443|NCT01526525|PROCEDURE|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
224087444|NCT01526525|DRUG|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
224087445|NCT01526525|DRUG|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
224087446|NCT02928952|BEHAVIORAL|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
224087447|NCT05655585|OTHER|Active Release Technique|Participant will be in prone position on a couch with the therapist standing next to the patient. The patient is asked to flex the knee to 90 degree of the involved side. The therapist then applies gentle tension longitudinally to the hamstring muscle along the entire length while the patient actively moves his knee from flexion to extension
224087448|NCT05655585|OTHER|Mulligan Bent Leg Raise|Participant was in supine lying on a high couch with the therapist in standing position lateral to the leg, which is to be stretched. Hip and Knee of the side to be stretched was bent at 90- 90 degree. Investigator places participant's flexed knee over his shoulder such that the popliteal fossa of the knee rest on his shoulder. A distraction (longitudinal traction force along the long axis of femur) was applied at the lower end of femur
224087449|NCT00934076|DRUG|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
224087450|NCT03406533|DRUG|Midazolam|Midazolam is used as a common medication for sedation in all groups.
224087451|NCT03406533|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
223529697|NCT03788044|OTHER|Education|Education + Medication adherence monitoring + Feedback when low adherence
223529698|NCT05842551|COMBINATION_PRODUCT|Prismatic adaptation and electric stimulation|Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group
223719402|NCT03568760|BEHAVIORAL|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
223719403|NCT03568760|BEHAVIORAL|Comprehension training|Reading and hearing comprehension
223913190|NCT06843005|OTHER|Current clinical guidelines|Patients will be treated according to the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.
224087452|NCT03406533|DRUG|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
224087453|NCT03406533|DRUG|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
223719404|NCT01221883|DRUG|Diazepam|Single dose 10mg Diazepam tablet
223719405|NCT04792164|PROCEDURE|Ultra sound guided nerve block|Ultra sound guided nerve block by lidocaine before open inguinal hernia repair.
223913191|NCT04704271|DRUG|Inhaled THC|4 mg inhaled THC
223913192|NCT04704271|DRUG|Placebo|Inhaled placebo (no active cannabinoids)
223913193|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 1|Participants will use their Radicle Rest Placebo Control Form 1 as directed for a period of 6 weeks.
223913194|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 1.1 Usage|Participants will use their Radicle Rest Active Study Product 1.1 as directed for a period of 6 weeks.
223913195|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control Form 2|Participants will use their Radicle Rest Placebo Control Form 2 as directed for a period of 6 weeks.
223913196|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 2.1 Usage|Participants will use their Radicle Rest Active Study Product 2.1 as directed for a period of 6 weeks.
224087454|NCT03406533|DRUG|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
224087455|NCT02553837|BIOLOGICAL|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
224087456|NCT00723957|DRUG|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
224087457|NCT00723957|DRUG|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m\^2
224087458|NCT00723957|DRUG|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
224087459|NCT03325179|OTHER|Thread-embedding Therapy|
223913197|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Placebo Control 4.1.0|Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
223913198|NCT06347744|DIETARY_SUPPLEMENT|Radicle Rest Active Study Product 4.1.1 Usage|Participants will use their Radicle Rest Active Study Product 4.1.1 as directed for a period of 6 weeks.
224087460|NCT01905475|DRUG|POL6326|
224087461|NCT01905475|DRUG|Placebo|
224087462|NCT01007526|OTHER|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
224087463|NCT00612599|DRUG|biphasic insulin aspart|
224087464|NCT01998542|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine with AlloStim(TM) and CRCL
224087465|NCT01998542|BIOLOGICAL|CRCL|autologous tumor-derived chaperone protein mixture
224087466|NCT01998542|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
224087467|NCT01850615|DRUG|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
224087468|NCT01850615|DRUG|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
223719406|NCT04792164|PROCEDURE|Usual infiltration|Usual infiltration by lidocaine before open inguinal hernia repair.
223913199|NCT05940324|DRUG|Ketamine|Ketamine is an FDA-approved dissociative anesthetic.
224087469|NCT04920240|BEHAVIORAL|cleaning and disinfection mode for surfaces with high frequency contact|According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.
224087470|NCT04920240|BEHAVIORAL|Routine procedure|clean the high frequency contact surface like other surfaces
224087471|NCT00706628|DRUG|BIBF 1120|
224087472|NCT00706628|DRUG|BIBW 2992|
224087473|NCT00706628|DRUG|Sequential BIBF 1120 + BIBW 2992|
224087474|NCT02829879|DRUG|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
224087475|NCT02829879|DRUG|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
224087476|NCT02235649|BEHAVIORAL|Social Cognition therapy ( Psychological Therapy)|
224087477|NCT01574534|DEVICE|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
224087478|NCT01574534|DEVICE|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
223529699|NCT02602652|BIOLOGICAL|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
223913200|NCT05940324|DRUG|Naltrexone Pill|Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
224087479|NCT04522492|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy|2 booster sessions of cognitive behavioral therapy (CBT) delivered thru internet to patients previously treated with CBT. First session focus on understanding the symptoms of skin picking and training techniques to reverse the habit. Second session focus on comorbid symptoms of anxiety and depression, training strategies to improve it.
224087480|NCT04522492|OTHER|Quality of life promotion|2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
223719407|NCT01888679|PROCEDURE|Head movement|Head movement in extension, flexion, right and left rotation
223719408|NCT03998033|BIOLOGICAL|ET140202 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
223913201|NCT05940324|OTHER|Placebo pill|An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
224087481|NCT00004373|DRUG|alprazolam|
224087482|NCT01275014|DRUG|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
224087483|NCT01275014|DRUG|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
224087484|NCT00443508|DRUG|adding Certican to therapy|
224087485|NCT00443508|DRUG|reducing Tacrolimus|
224277915|NCT02878408|GENETIC|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
224277916|NCT04043702|DRUG|The intervention being studied|Intervention Other Names have not been specified
224277917|NCT01287715|DRUG|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
224277918|NCT01287715|DRUG|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
224277919|NCT05858775|DEVICE|Pregnolia System|Cervical stiffness assessment with the Pregnolia System at 3 locations on the uterine cervix.
224277920|NCT05700136|BEHAVIORAL|MOMENT|Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
223913202|NCT03245840|DRUG|Budesonide oral suspension|BOS 10 mL twice daily.
223913203|NCT04028414|OTHER|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
223913204|NCT06826274|OTHER|tDCS|Transcranial direct current stimulation
223913205|NCT06825065|BEHAVIORAL|PAPE Protocol|In this intervention, participants perform a warm-up consisting of 3 repetitions at 90% of 1RM. After a 10-minute rest, they perform 3 sets of half-squats at 75% of their 1RM until volitional failure. This protocol is designed to enhance performance through the post-activation potentiation effect.
223913206|NCT06825065|BEHAVIORAL|Control Protocol|In this intervention, participants perform a warm-up consisting of 8 repetitions at 50% of 1RM. After a 4-minute rest, they perform 3 sets of half-squats at 75% of their 1RM until volitional failure. This protocol is used as a baseline for comparison with the PAPE protocol.
223913207|NCT06818838|BIOLOGICAL|LY-M001 injection|LY-M001 injection is administered intravenously as a single dose
223913208|NCT06139978|BEHAVIORAL|ultrasound observation|The relationship between the anteroposterior diameter of the CM and the gestational age and gender
223913209|NCT06820788|OTHER|music therapy|Local music will be played in the patient room 2 hours after the patient is transferred from the postoperative care unit to the clinic, which is the most appropriate time after surgery, when vital signs have stabilized and clinical adaptation has been achieved.
223913210|NCT06824272|OTHER|MOBIL AND ONLINE EDUCATION|The intervention group attended synchronous online sessions twice weekly (2 hours) for four weeks before IVF, with the mobile app available from the first session. During IVF cycles, the app provided scheduled educational content, reminders, creation of lifestyle maps, feedback,counseling scheduling, and daily motivational messages based on hypnofertility principles to enhance support.
224087486|NCT00998439|DEVICE|SeQuent® Please|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
224087487|NCT00998439|DEVICE|SeQuent® II|"* 6 F, 7 F, or 8 F guiding catheters have to be used~* after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~* additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~* Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~* ISR must be predilated with uncoated balloon~* balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~* inflation time has to be ≥ 30 sec~* select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~* each Paclitaxel-eluting balloon catheter is allowed for single use only~* additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~* if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
224087488|NCT04928014|OTHER|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
224087489|NCT01201213|DRUG|local anaesthetic injection|Single bolus of drug for pain relief in early labour
224087490|NCT02866864|OTHER|Animal allergy +|Allergic symptom occurs when subject contact animal
224087491|NCT02866864|OTHER|Animal allergy -|Allergic symptom does not occur when subject contact animal
224087492|NCT05383690|DEVICE|LED bright light treatment device|Subjects will be instructed to use the bright light treatment device, as early as possible, for 30 minutes each morning. These devices will be equipped with monitoring electronics that will enable us to download their daily degree of use. Participants will also be provided with yellow-tinted blue light blocking glasses and will be instructed to wear them starting 2 hours before bedtime if they are viewing LED or liquid-crystal display screens.
224087493|NCT04929990|BEHAVIORAL|Respiratory muscle training|Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
224087494|NCT06218927|OTHER|QoL monitoring|QoL questionnaire
223529700|NCT04047485|DIAGNOSTIC_TEST|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
223913211|NCT01116895|DRUG|LEO 22811|Oral solution
223913212|NCT01116895|DRUG|Placebo|Placebo
223913213|NCT06751680|DEVICE|Rhomboid Intercostal and Subserratus Plane Block|Upon entry, electrocardiogram (ECG), blood pressure, and oxygen saturation were monitored. The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.The RISS block is a composite nerve block technique that involves two injection sites, located in the inter-rhomboid plane and the sub-serratus plane, respectively. The choice of block plane depended on the patient's site of pain.
223529701|NCT04047485|DIAGNOSTIC_TEST|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
223529702|NCT04047485|DIAGNOSTIC_TEST|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
224087495|NCT01199666|OTHER|Text message|text message appointment and immunization reminders
224087496|NCT03557021|DIAGNOSTIC_TEST|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
224087497|NCT00190060|DRUG|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
224087498|NCT00190060|DRUG|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
224087499|NCT04186611|OTHER|early occupational therapy|"The intervention will be the one usually carried out but earlier and on a daily basis. It will consist of the initial assessment and then positioning and/or carrying out activities of daily living.~The daily duration of the intervention will be about 45 minutes to 1 hour. The overall duration of the intervention will be determined according to the objectives and will be at most equal to the time of stay in the intensive care unit."
224087500|NCT03251326|DRUG|Nabilone|Nabilone capsules (4 mg)
224087501|NCT03251326|DRUG|Cannabis|Cigarettes (0.0 and 5.6% THC)
224087502|NCT03251326|DRUG|Propranolol|Propranolol capsules (40mg)
223913214|NCT06751680|DEVICE|PVB block|The patient is placed in the prone position with their arms abducted and internally rotated. Ultrasound equipment (SonoSite Edge II; Fujifilm SonoSite, Bothell, WA, USA) with a linear 13-6 MHz transducer (HFL50x; Fujifilm SonoSite, Bothell, WA, USA) was used. Each nerve block was performed by initially injecting a 5 mL test dose, observing for clinical signs of pain relief in the affected thoracic dermatome, and then injecting the remaining volume of medication after confirmation of the injection site. Patients received ultrasound-guided nerve blocks every 48 hours, for a total of three treatments.After confirming needle tip placement, 10 mL of 0.5% ropivacaine with 10 mg of triamcinolone acetonide was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block. If multiple nerves were involved, the injection sites were spaced one thoracic vertebral segment apart.
223940126|NCT06100185|DEVICE|PeakSleep|The PeakSleepTM is a constant current device which delivers stable stimulation as a function of the impedance measured across the electrodes (e.g. it varies voltage to produce a steady current). The device gradually ramps up the current as the impedance decreases during the stimulation session. The device uses stimulation amplitudes in the range of 100uA to 500uA at each electrode pair. Devices will be configured to deliver 100 stimulation trains over 30 minutes where each train is 6 pulses of 0.75Hz trapezoidal stimulation (each train lasts 8 seconds). The inter-train interval is 10 seconds leading to a total stimulation time of \<14 minutes with a maximum dose of 1mA (500uA per electrode pair).
224087503|NCT03251326|DRUG|Placebo|Placebo capsules
224087504|NCT05740774|DIAGNOSTIC_TEST|3D ultrasound|3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
224087505|NCT04113811|DEVICE|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
224087506|NCT05548478|PROCEDURE|Transepithelial PRK/MMC|transepithelial photorefractive keratectomy (PRK) and mitomycin C addition
224087507|NCT05548478|PROCEDURE|Alcohol-Assisted PRK/MMC|photorefractive keratectomy (PRK) assisted by alchol and mitomycin C addition
224087508|NCT02266433|DRUG|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
224087509|NCT02266433|DRUG|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
224087510|NCT01745757|DRUG|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
224087511|NCT01745757|DRUG|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
224087512|NCT03709563|DIETARY_SUPPLEMENT|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
224087513|NCT03709563|DIETARY_SUPPLEMENT|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
224087514|NCT04525703|BEHAVIORAL|Pathways for Parents after Incarceration|The Pathways for Parents after Incarceration program uses eight key lessons, including topics on effective listening, speaking, and problem-solving skills, lessons on emotion regulation, and issues surrounding family engagement. The program (both classroom and therapeutic peer support) will be offered virtually and weekly for 8 continuous weeks.
224087515|NCT01285349|BEHAVIORAL|Couple HIV/STI prevention intervention|
224087516|NCT01285349|BEHAVIORAL|Couple-based HIV/STI prevention|
224087517|NCT01285349|BEHAVIORAL|Individual HIV/STI prevention|
223719409|NCT01735682|DEVICE|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
224087518|NCT01285349|BEHAVIORAL|Couple Wellness Promotion|
224087519|NCT00268814|DRUG|Diacetylmorphine|Diacetylmorphine (i.v.), daily
224087520|NCT00268814|BEHAVIORAL|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
224087521|NCT00268814|DRUG|Methadone|Methadone (p.o.), daily
224087522|NCT00268814|BEHAVIORAL|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
224087523|NCT03609255|BEHAVIORAL|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
224087524|NCT03609255|BEHAVIORAL|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
224087525|NCT03609255|BEHAVIORAL|Control|An educational handout for sedentary behavior and weekly neutral topic videos
223913215|NCT05166213|OTHER|focus group discussions (FGD)|FGD to explore patients' attitudes/ concerns towards OLP implementation into clinical practice by means of assessment of qualitative information: 1) Patients' attitudes towards clinical usage of OLPs 2) Personal acceptance of OLP intervention 3) Perceived ideas, concerns regarding OLP implementation. Core questions: 1) Attitudes: After all that I told you about placebos, i.e. that there is a concept that patients are openly elucidated that they receive placebos: What does this elicit in you/What is your opinion on this? How do you like the idea? 2) Context of Acceptance: Under which conditions would you personally take placebos knowing that they are placebos? 3) Concerns: Why would you not take openly administered placebos? 4) Ideas for clinical implication: How could an open placebo intervention look like in the hospital? Where could it be possible to receive placebos and how could a placebo intervention in the best manner take place? What would be important from your point of view?
224087526|NCT06231017|DRUG|Adebrelimab + Cetuximab+ Chemotherapy|Adebrelimab:1200 mg, D1, Q2W+Cetuximab:500 mg, D1, Q2W+FOLFOX6(Q2W) or FOLFIRI(Q2W) until PD or resectability or to max 12 cycles
224087527|NCT04304456|OTHER|Treatment|Antimicrobial and other treatment modalities such as source control, vasoactive medications, dialysis
224087528|NCT00712348|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
224087529|NCT02820961|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDAC)
224087530|NCT02820961|DRUG|exemestane|Aromatase inhibitor
224087531|NCT02109237|PROCEDURE|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
224087532|NCT03656913|DIAGNOSTIC_TEST|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
224087533|NCT02848196|RADIATION|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
224087534|NCT06384092|OTHER|Test Sun Protection Cream|Apply directly on the designated site till absorbed.
224087535|NCT06384092|OTHER|Benchmark Sun Protection Cream|Apply directly on the designated site till absorbed.
223913216|NCT06767540|DRUG|Placebo|placebo subcutaneous injection Q2W until week 46.
224087536|NCT02859909|BIOLOGICAL|BT595|
223913217|NCT06767540|DRUG|placebo|placebo subcutaneous injection Q3W until week 45.
223913218|NCT05619432|DEVICE|HMD: Immersive VR|"The device application involves the 3D multiple-object-tracking (3D-MOT) paradigm composed of 8 high-contrast spheres which are adapted to the visual ability of participant (luminosity and size). The initial speed of the spheres is adjustable and determined during the inclusion visit.~STIMULATION:~One or more of the spheres is temporarily cued (target). Then all spheres move for 20 seconds following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. After 20 seconds, the movement stops and the participant is asked to select, using a laser pointer, the initially cued target(s) among the eight spheres. If the selection is correct the speed of the spheres in the next trial is increased. If the selection is incorrect the speed of the spheres in the next trial is decreased.~Based on performance, stimulations will be adjusted to change difficulty level (e.g. changing backgrounds, number of cued balls, etc.)"
224087537|NCT00047658|DRUG|Interferon-gamma 1b|200 mcg, SQ, 3x per week
224087538|NCT00168961|DIETARY_SUPPLEMENT|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
224087539|NCT02602223|DEVICE|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
223913219|NCT05371132|PROCEDURE|Positron Emission Tomography|Undergo PET
223913220|NCT05371132|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223913221|NCT05371132|DRUG|Zirconium Zr 89-Df-Crefmirlimab|Given IV
223913222|NCT05371132|RADIATION|Intensity Modulated Radiation Therapy|IMRT for Lymphoma patients only
224087540|NCT02602223|DEVICE|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
224087541|NCT01375764|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224087542|NCT01375764|DRUG|Ezetimibe|Administered orally once a day
224087543|NCT01375764|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
224087544|NCT04213755|DIAGNOSTIC_TEST|ROTEM|ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
224087545|NCT04070482|OTHER|Tenofovir exposure in utero and during breastfeeding|Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
224277921|NCT02243137|DRUG|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
224277922|NCT02243137|DRUG|prasugrel|Administration: one loading dose (60mg)
224277923|NCT02243137|DRUG|lysine acetylsalicylate|Administration: one dose (450mg iv)
224277924|NCT04761445|OTHER|Straumann Standard Plus implant and JDental care (JD) Octa implant|Two different implant systems were used. The above-mentioned implants share many features in common, such as implant design. They both have a machined implant collar of 1.8 mm.
224277925|NCT00800618|DRUG|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
223719410|NCT01735682|BEHAVIORAL|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
224087546|NCT05286606|BEHAVIORAL|Exercise and Social Groups|"Participants in the exercise program, which will include a 2-3 time a week 30-45-minute group exercise programme over a 3-month period, 2 x three months. The intervention consists of a 30-45-minute exercise programme. The exercise programme is created by the Good Boost AI based on pre-registration questions or premade sessions, these are either generic sessions with options of strength, aerobic flexibility and balance/coordination exercise with intensity adjusted according to the user's feedback.~In this program the intervention content is standardised through the Good Boost exercise program. The standard program involves all users to be registered to a single group and to log on to the group, through, zoom, and the facilitator welcomes them. The group then performs the exercise programme they would like to do guided through the app, and afterwards they all meet on a group chat and get peer support."
223913223|NCT05362721|DIAGNOSTIC_TEST|Pressure-volume loop catheter|The cardiac catheterization procedure will be done according to standard protocol as part of the standard clinical care. This has become the standard of care in any patient in which it feasible and is performed with low risk.
223913224|NCT03655015|PROCEDURE|Lung Tumor Resection|Lung Tumor Resection
223913225|NCT06610994|DEVICE|local vibration apply|Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
223913226|NCT01808911|DRUG|Steroid + cyclophosphamide|
223913227|NCT01808911|DRUG|Steroid + rituximab|
224087547|NCT03436784|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
224087548|NCT03595280|BEHAVIORAL|Hookah tobacco risk messages|Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
224087549|NCT03417050|OTHER|No intervention will take place for this retrospective and observational study.|No intervention will take place for this retrospective and observational study.
224087550|NCT05042739|DIAGNOSTIC_TEST|CAARMS;SIPS; BSABS;|Comprehensive Assessment of At Risk Mental State (CAARMS); Structured Interview for Psychosis-Risk Syndrome (SIPS); Bonn Scale for the Assessment of Basic Symptoms (BSABS);
224087551|NCT01501279|PROCEDURE|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
224087552|NCT03246633|OTHER|Perceptual Training|Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
223913228|NCT06609512|DRUG|Enlicitide|Oral Tablet
223913229|NCT06610474|BEHAVIORAL|"Use of the online Talk to Nathan about Prostate Cancer decision aid"|This decision aid is publicly available at this website in both English or Spanish: https://www.cdc.gov/prostate-cancer/talk-to-nathan/index.html
223913230|NCT06610474|BEHAVIORAL|Use of a standard prostate cancer screening decision aid|The standard decision aid is available here and will be used in either English or Spanish: https://massclearinghouse.ehs.state.ma.us/PROG-CANC/CA1382kit.html
224087553|NCT06540469|DIETARY_SUPPLEMENT|Iodine Supplementation in Whole Course of Treatment with ATDs|Moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken from ATDs treatment starting until 1 year after ATDs withdrawal.
223913231|NCT06610474|BEHAVIORAL|Use of standard prostate cancer education materials|The standard education materials are available from the National Cancer Institute (NCI) website in English or Spanish: https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq
223913232|NCT06832501|OTHER|Henna|The day-care unit of the University of Hacettepe's oncology hospital is being trained by educational nurses on the treatment of patients receiving capecitabine a day before the application of chemotherapy. All the patients were questioned about their individual and disease-related characteristics using the Patient Information Form, and The National Cancer Institute common terminology criteria for adverse events - version 4.03 (NCICTCAE v4.03), EORTC C30 Cancer Quality of Life Scale, and The Hand-Foot Syndrome-14 (HFS-14) were used by face-to-face interview technique.On the 21st day and the 63rd day after the first treatment course, patients who developed hand-foot syndrome constituted the case-control group, including patients who applied henna and patients who did not apply henna.
224087554|NCT06540469|DIETARY_SUPPLEMENT|Iodine Supplementation During Maintenance Treatment with ATDs|Iodine restriction (non-iodized salt and low iodine diet) will be demanded at the early course of ATDs treatment, and moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken when the ATDs dose is titrated down to a maintenance level until 1 year after ATDs withdrawal.
224087555|NCT06540469|DIETARY_SUPPLEMENT|Iodine Restriction in Whole Course of Treatment with ATDs|Iodine restriction (non-iodized salt and low iodine diet) will be demanded from ATDs treatment starting until 1 year after ATDs withdrawal.
224087556|NCT06540469|DRUG|anti-Thyroid Drugs|Individualized methimazole (MMI)
223913233|NCT03240003|BEHAVIORAL|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
223913234|NCT03240003|BEHAVIORAL|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
224087557|NCT06095739|COMBINATION_PRODUCT|DA-OTC-002|"The topical formula of DA-OTC-002 was formed from 2 molecules: an alpha 1 agonist (synephrine) and a TAAR receptor agonist~A 1mL topical application of DA-OTC-002 was applied to a 10cm x 10xm target area of the right side of the scalp of each subject"
224277926|NCT00800618|DRUG|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
224277927|NCT00800618|DRUG|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
224277928|NCT00800618|DRUG|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
223529703|NCT04047485|DIAGNOSTIC_TEST|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
223719411|NCT01735682|BEHAVIORAL|Control|The control treatment involves exercises of the upper limbs.
223913235|NCT03240003|BEHAVIORAL|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
223913236|NCT06658431|BEHAVIORAL|music group therapy|90 minutes music group therapy
223913237|NCT06859944|OTHER|Embryo transfer|Frozen embryo transfer
223913238|NCT06859944|OTHER|Embryo transfer|Frozen Embryo transfer
224087558|NCT03601286|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
224087559|NCT01194440|DRUG|letrozole|Given orally
224087560|NCT01194440|DRUG|zoledronic acid|Given IV
224087561|NCT04058327|DIAGNOSTIC_TEST|neurophysiological tests, blood biomarkers.|Let the patients do neuropsychological tests and detect blood biomarkers.
224087562|NCT03299803|BEHAVIORAL|Men's Healing Pathways|Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
224087563|NCT00854828|PROCEDURE|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
224087564|NCT00854828|OTHER|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
224087565|NCT00004899|BIOLOGICAL|filgrastim|
224087566|NCT00004899|DRUG|busulfan|
224087567|NCT00004899|DRUG|etoposide|
223719412|NCT02047890|DRUG|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
223913239|NCT06658353|DRUG|VC004 Capsules|VC004 Capsules BID
223913240|NCT06658080|DIAGNOSTIC_TEST|organoid drug test|Before initiating therapy, patients diagnosed with metastatic breast cancer patients with hydrothorax and ascite fluid. The hydrothorax and ascite fluid is utilized to establish organoids and conduct drug testing.
223913241|NCT06658301|OTHER|plyometric push up exercises|The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
223913242|NCT06658301|OTHER|swiss ball push up exercises|. The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
223913243|NCT06660615|BEHAVIORAL|MIDWIFE-LED CARE|The birth process will be followed by the same midwife from the beginning of the intrapartum period until the birth of the baby and placenta. In this process, positive respectful maternal care will be included in line with the recommendations of WHO (İsbir \& Sercekuş, 2017).
223913244|NCT06858358|PROCEDURE|Robotic assisted total knee arthroplasty|• ROSA RATKA with Zimmer Biomet Persona Medial Congruent
223913245|NCT06858358|PROCEDURE|Conventional total knee arthroplasty (cTKA)|cTKA with Microport Evolution Medial-Pivot
223913246|NCT06825663|BIOLOGICAL|Blood punction|At each annual visit (+/- 3 months), 4X10 mL blood will be taken (1 dry tube, 1 heparinised tube, 2 EDTA tubes)
223913247|NCT06856135|DRUG|Vedolizumab IV|"Participants will continue to receive vedolizumab IV at the same dose administered at the end of Trial Vedolizumab-2005 (NCT03196427), at a frequency of every 8 weeks.~• Other Names:~* MLN0002~* ENTYVIO~* KYNTELES"
223913248|NCT06069622|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure|24-hour ambulatory blood pressure, blood, and urine will be obtained prior to semaglutide therapy and after 20 weeks of semaglutide therapy.
223913249|NCT06069622|DIETARY_SUPPLEMENT|Liberal salt diet|Participants will be on a liberal salt (about 200 mEq sodium/day) diet for 7 days.
223913250|NCT06859996|BEHAVIORAL|Tools for Rehabilitation and Cognitive Care (On-TRACC)|The On-TRACC intervention is administered one-on-one with a skilled clinician via telehealth and consists of an introductory session followed by 5 treatment sessions. Participants in the On-TRACC intervention will review various health and lifestyle factors that can affect cognitive functioning, learn and practice skills for managing cognitive and emotional symptoms, and develop personalized goals to support optimal cognitive functioning.
224087568|NCT00004899|PROCEDURE|autologous bone marrow transplantation|
224087569|NCT01239355|DRUG|Akt Inhibitor MK2206|Given PO
224087570|NCT01239355|OTHER|Laboratory Biomarker Analysis|Correlative studies
224087571|NCT04957290|DRUG|NOX66|NOX66 800 mg daily (400 mg suppository twice daily \[BID\]).
224087572|NCT04957290|DRUG|NOX66|NOX66 1200 mg daily (600 mg suppository BID).
224087573|NCT04957290|DRUG|NOX66|NOX66 1600 mg daily (800 mg suppository BID).
224087574|NCT04957290|DRUG|NOX66|NOX66 2400 mg daily (1200 mg suppository BID).
224087575|NCT04957290|DRUG|NOX66|NOX66 RP2D
224087576|NCT04957290|RADIATION|EBRT|The dose levels of EBRT will be either 8 Gy as a single fraction, or 20/25 Gy as 5 fractions given over 5 to 10 days.
224087577|NCT03418012|DEVICE|cervical pessary|Intervention: Device: Cervical pessary: After Having excluded a vaginal infection insertion of the cervical pessary (silicone ring) directly after enrollment. After insertion verification of correct fit of the cervical pessary by transvaginal ultrasound. Removal of the pessary at 37+0 weeks of gestation, or before if any unexpected event occurs. Except for the insertion of the pessary the obstetrical management during the remainder of the pregnancy will be usual management.
224087578|NCT03418012|OTHER|Control-Group|Intervention: Other: expectant management: expectant management is usual care; interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
224087579|NCT03410511|OTHER|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
223913251|NCT06859996|BEHAVIORAL|Brain Health psychoeducation|The Brain Health intervention is administered one-on-one with a skilled clinician via telehealth and consists of an introductory session followed by 5 treatment sessions. Participants in the Brain Health psychoeducation treatment will learn about various health and lifestyle factors that can affect brain health and cognitive functioning. In addition, they will be provided with resources and strategies for managing relevant factors and supporting optimal cognitive functioning.
223716240|NCT02482506|BEHAVIORAL|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
223913252|NCT06859671|DRUG|Standard of Care (SOC)|14 days of antifungal therapy after the 1st negative blood culture
223913253|NCT06859671|DRUG|Shortened duration of antifungal therapy|7 days of antifungal therapy after the 1st negative blood culture
224087580|NCT03410511|OTHER|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
224087581|NCT03410511|OTHER|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
223716241|NCT02482506|BEHAVIORAL|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
223716242|NCT06044428|DEVICE|Steadytemp®|Steadytemp® is a clinical thermometer intended to continuously measure axillary temperature and to display relative changes in axillary temperature to the user. The system consists of a sensor patch and a smartphone application, the body temperature measured by the sensor is transmitted via Near-Field-Communication (NFC) and subsequently displayed in the App.
223716243|NCT00816764|BIOLOGICAL|AGS-8M4|IV Infusion
223716244|NCT04219657|BIOLOGICAL|mesenchymal stem cell application|
223716245|NCT04668625|BEHAVIORAL|Participate in a massive musical event|Participate in a massive musical event
223716246|NCT02560571|DEVICE|ultrasound|
223716247|NCT02560571|OTHER|blood test|
223716248|NCT06392620|OTHER|Study Group|n individually planned exercise program including stretching, strengthening, respiratory, aerobic and posture exercises will be applied via video conference method
223716249|NCT00003097|OTHER|preventative dietary intervention|
223716250|NCT01346449|BEHAVIORAL|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
223716251|NCT01346449|BEHAVIORAL|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
223716252|NCT01346449|BEHAVIORAL|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
223716253|NCT01346449|BEHAVIORAL|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
223716254|NCT00848874|BEHAVIORAL|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
223716255|NCT06259747|OTHER|Acutaping|Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application
223716256|NCT06259747|DRUG|Doxylamine and Pyridoxine|traditional medical treatment for nausea and vomiting during pregnancy
223716257|NCT02228460|DRUG|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
223716258|NCT01243892|DEVICE|NuSpin|Device for administration of doses of somatropin.
223716259|NCT01243892|DRUG|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
223913254|NCT04109066|BIOLOGICAL|nivolumab|Specified Dose on Specified days
223913255|NCT04109066|DRUG|paclitaxel (PTX)|Specified dose on Specified days
223913256|NCT04109066|OTHER|nivolumab placebo|Specified dose on Specified days
223913257|NCT04109066|DRUG|anthracycline|Specified dose on Specified days
223913258|NCT04109066|DRUG|cyclophosphamide|Specified dose on Specified days
223913259|NCT04109066|DRUG|Endocrine Therapy|Variable endocrine therapy of investigators choice
224087582|NCT02409238|DRUG|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
224277929|NCT00800618|DRUG|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
223719413|NCT02047890|DRUG|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
223719414|NCT04847505|DIAGNOSTIC_TEST|68Ga-DOTA-TATE|The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.
223719415|NCT04340401|DRUG|SHR-1210|Patients will receive 3 cycles induction CapeOX and SHR-1210
223719416|NCT04340401|DRUG|Oxaliplatin|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
223716260|NCT04473391|DEVICE|Cycle-ergometer training assisted by FES for lower extremities|The intervention consists of FES treatment sessions on a cycle ergometer for the lower extremities. Each subject received 24 sessions lasting 45 minutes each and a frequency of 3 sessions per week. The sessions will be applied by a physiotherapist with experience in electrotherapy. A 6-channel FES device (TrainFES, Biomedical Devices SpA, Chile) will be used, which consists of a stimulator unit of 95x50x30mm and 100g of weight coupled to the motorized cycle ergometer (MOTOmed Viva 2, Reck GmbH., Germany), a remote user interface consisting of an android application for the configuration of the stimulation via Bluetooth 3.1, and an inertial measurement unit positioned on the rotation axis of the cycle ergometer to detect the rotations and trigger the synchronized electrical stimulation according to the stimulation pattern pre-configured for the pedaling exercise
223716261|NCT00119106|DRUG|Tenofovir disoproxil|Antiretroviral
223716262|NCT00119106|DRUG|Placebo|Placebo
223716263|NCT05496062|DEVICE|F&P Toffee Nasal and Toffee Nasal Pillows Masks|F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
223716264|NCT00007865|BIOLOGICAL|rituximab|
223716265|NCT00007865|DRUG|carboplatin|
223716266|NCT00007865|DRUG|etoposide|
223716267|NCT00007865|DRUG|ifosfamide|
223716268|NCT04911881|DRUG|IBI321|Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
223716269|NCT04476069|DRUG|IBUPROFEN|given to children 30 minutes before extraction / orally for one time only
223716270|NCT03066804|DRUG|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
223716271|NCT03066804|DRUG|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
223716272|NCT03066804|DRUG|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
223716273|NCT03066804|DRUG|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
223716274|NCT03066804|DRUG|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
223716275|NCT03066804|DRUG|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
223716276|NCT00740831|DRUG|PGL4001|tablets
223716277|NCT00740831|DRUG|leuprorelin|solution for injection
223716278|NCT00287885|DRUG|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m\^2/day up to dose level 6 of 6.4 mg/m\^2/day
223716279|NCT06172322|DRUG|NTQ1062 with Fulvestrant|"Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle."
223913260|NCT04109066|PROCEDURE|Surgery|Surgery for breast cancer
223913261|NCT06990581|OTHER|regular core exercises|regular core exercises on trunk stability and balance
223913262|NCT06990581|OTHER|specific type of core exercises|specific type of core exercises on trunk stability and balance
223716280|NCT03421665|DEVICE|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
223716281|NCT06313814|DIETARY_SUPPLEMENT|Swanson ginger capsule|"Swanson Ginger Root? gingerols, shogaols, and paradols, and possesses multiple bioactivities, such as antioxidant, anti-inflammatory, and antimicrobial properties.~Ginger is most commonly associated as a culinary spice flavouring to oriental dishes and even the local bakery character biscuit, the gingerbread man. But since ancient times the spice has also been recognized for its health properties, most popular being to settle the stomach, alleviate indigestion and event prevent motion sickness. More recently research has confirmed Ginger's historical effectiveness on digestive health and beyond."
223913263|NCT00165256|OTHER|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
223913264|NCT04513951|DRUG|5Fluorouracil|phase II
223716282|NCT05892471|DRUG|ciprofol injection|Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
223716283|NCT05892471|DRUG|Propofol injection|Patients in propofol group received 1.5 mg/kg propofol for induction of anesthesia
223716284|NCT01530061|OTHER|Egg Breakfast|Egg, Toast and Jelly
223716285|NCT01530061|OTHER|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
223716286|NCT01979445|DRUG|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
223716287|NCT01979445|DRUG|Clopidogrel|Clopidogrel 600 mg single oral dose
223716288|NCT01979445|DRUG|Prasugrel|Prasugrel 60 mg single oral dose
223716289|NCT06229990|DRUG|Furosemide Injection|After taking furosemide at 1.5 mg/kg intravenously, if the urine output exceeds 200 mL within 2 hours, the patients are going to withhold CRRT. But if there is no response, the titration of furosemide to 2.5 mg/kg and 3.5 mg/kg every 6 hours is scheduled according to the urine output \>200 mL in 2 hours (not exceeding 250 mg).
223716290|NCT03982368|DRUG|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
223913265|NCT04513951|DRUG|L-leucovorin|phase II
223913266|NCT04513951|DRUG|Irinotecan|phase II
223913267|NCT04513951|DRUG|Oxaliplatin|phase II
223913268|NCT04513951|DRUG|Cetuximab|phase II
223913269|NCT04513951|DRUG|Avelumab|phase II
223913270|NCT06613243|DRUG|Esketamine 0.2 mg/kg|Esketamine 0.2 mg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
223913271|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.1 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.1 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
223913272|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.15 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.15 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
223913273|NCT06613243|DRUG|Esketamine 0.2 mg/kg + dexmedetomidine 0.2 µg/kg|A mixture of esketamine 0.2 mg/kg and dexmedetomidine 0.2 µg/kg is diluted in 20 ml normal saline and infused over 40 minutes after clamping the umbilical cord.
223913274|NCT00761124|BEHAVIORAL|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
223913275|NCT00761124|BEHAVIORAL|Printed Material|General prostate cancer pamphlet
223913276|NCT06612125|OTHER|volume controlled ventilation|Pediatric patients in the VCV group (n= 30) received volume-controlled ventilation, target tidal volume was set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
223913277|NCT06612125|OTHER|pressure controlled ventilation|Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
223913278|NCT06612125|OTHER|pressure controlled volume grantanteed ventilation|Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
223913279|NCT06612112|OTHER|No Interventions|No Interventions
223913280|NCT04923776|DRUG|Carboplatin|The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
223913281|NCT04923776|DRUG|Etoposide|The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
223913282|NCT04923776|DRUG|Atezolizumab|The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
223913283|NCT04923776|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|This radiotherapy is given within +/-3 days of cycle 2, 10 Gy 3 doses on alternating days. This is not standard of care and considered interventional.
223913284|NCT06566716|DIAGNOSTIC_TEST|CleoDX ovarian cancer test|A diagnostic test to assist in predicting risk of malignancy prior to surgery for patients with an adnexal mass.
223913285|NCT06596902|BEHAVIORAL|Physical Activity|The 12-month intervention will progressively increase in intensity and complexity to teach parents/children more complex sports skills and behavioral techniques, to prepare them to become future team leaders for nutrition education and sports sessions. In addition, the family Olympics events will take place after every 3-month to reinforce progression, social support; progressive improvements: Phase 1: Beginner (months 0-3) will focus on introductory concepts and basic sports skills and will focus on establishing consistent behavioral patterns and social support. Phase 2: Intermediate (months 4-6) will begin to introduce slightly more complex nutrition behavioral concepts and increase difficulty of sport skills, and reinforce behavioral patterns from phase 1. Phase 4: Advanced (months 10-12) will teach parents and children advanced sports skills ; nutrition knowledge so that they may become team leaders to help implement future activity sessions and nutrition education sessions.
223940127|NCT06100185|DEVICE|Sham|Sham is delivered with the same devices which are alternatively configured to deliver a trivially low amplitude (e.g. 100uA) waveform of a different frequency (e.g. 25 Hz) for the same treatment duration. Beyond differences in amplitude and frequency of stimulation, devices will be operated in exactly the same way during sham treatment.
223940128|NCT05117541|OTHER|Interview|Participate in interviews
223940129|NCT05117541|PROCEDURE|Biospecimen Collection|Undergo collection of hair samples
223940130|NCT05117541|OTHER|Electronic Health Record Review|Medical records are reviewed
223940131|NCT06566092|BIOLOGICAL|LN-145/LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
223940132|NCT01079806|DRUG|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
223940133|NCT01079806|DRUG|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
223940134|NCT01972906|DEVICE|moxibustion|apply moxibustion according to traditional Chinese medicine
223940135|NCT01972906|DRUG|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
223940136|NCT04031365|PROCEDURE|Acupuncture|Use of sterile, disposable needles in acupuncture
223940137|NCT04031365|BEHAVIORAL|Cognitive Behavioral Therapy|psychotherapy
223940138|NCT01332552|DRUG|GSK2485852 70 mg|single dose
223940139|NCT01332552|DRUG|GSK2485852 420 mg|single dose
223940140|NCT01332552|DRUG|placebo|single dose
223940141|NCT01332552|DRUG|placebo|Repeat dose, once daily for 3 days
223940142|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
223940143|NCT01332552|DRUG|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
223940144|NCT01332552|DRUG|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
223940145|NCT01332552|DRUG|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
223940146|NCT01332552|DRUG|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
223940147|NCT01332552|DRUG|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
223940148|NCT03732807|DRUG|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
223940149|NCT03732807|DRUG|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
223940150|NCT03732807|DRUG|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
223913286|NCT06615037|OTHER|Assess Hip joint strength by Biodex isokinetic dynamometer (System 4 Pro)|"Assessment of the strength of hip flexors and extensors muscles:~* Participants will be in a supine-lying position, the highest reliability (ICC = 0.90) according to the results of the meta-analysis (Contreras et al., 2021).~* Seat orientation 0°.~* Dynamometer tilt 0° and orientation 0°.~* The axis of the dynamometer on the greater trochanter of the femur.~* The test parameters included a 0-90 degree range of motion.~* During the isokinetic testing movement, the hip was first flexed from a neutral (starting) position to 90° (for hip flexion) and then the direction of the movement was reversed (for hip extension)~* Angular speed at 120°/s which shows excellent reliability (ICC = 95%) with concentric contraction mode (Contreras et al., 2021) ."
223913287|NCT06400602|BEHAVIORAL|Usual ED Care plus Health Coaching|Patients will participate in eight remotely-delivered sessions of health coaching after ED discharge. Patients will receive usual care during their ED visit.
223913288|NCT06400602|BEHAVIORAL|Usual ED Care plus Education|Patients will participate in eight remotely-delivered sessions of education after ED discharge. Patients will receive usual care during their ED visit.
223940151|NCT03732807|DRUG|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
223940152|NCT03732807|DRUG|Placebo|Oral tablets taken QD
224277930|NCT03095755|OTHER|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
224277931|NCT03095755|OTHER|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
223940153|NCT02554006|BEHAVIORAL|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
223940154|NCT02554006|BEHAVIORAL|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
223940155|NCT04388137|OTHER|No intervention.|No intervention.
223940156|NCT01779700|DRUG|Fingolimod|0.5mg each day of 8 week cycle
223940157|NCT01779700|DRUG|placebo|1 tablet each day of 8 week cycle
223940158|NCT05986994|OTHER|Metabolic acidosis|Metabolic acidosis at birth with umbilical cord arterial pH at birth \< 7.12
223940159|NCT05986994|DIAGNOSTIC_TEST|microRNA|Evaluation of microRNA levels
223940160|NCT05986994|OTHER|Hypothermia|Therapeutic induced hypothermia refers to a lowering of the central body temperature for therapeutic purposes
223940161|NCT00019604|PROCEDURE|computed tomography|Scan to assess the effects of ablation.
223940162|NCT00019604|PROCEDURE|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
223940163|NCT00019604|PROCEDURE|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
223940164|NCT00019604|PROCEDURE|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
223940165|NCT00019604|PROCEDURE|radionuclide imaging|Imaging following injection of a radioactive material.
223940166|NCT00019604|PROCEDURE|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
223940167|NCT00019604|RADIATION|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
223940168|NCT00019604|RADIATION|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
223940169|NCT03605732|BEHAVIORAL|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
223940170|NCT03605732|OTHER|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
223940171|NCT03347409|OTHER|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
223940172|NCT03347409|OTHER|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
223940173|NCT03347409|OTHER|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
223940174|NCT02013115|DRUG|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
223940175|NCT04203966|DIAGNOSTIC_TEST|12-item General Health Questionnaire (GHQ-12)|Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
223940176|NCT04203966|DIAGNOSTIC_TEST|WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)|Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
223913289|NCT02728635|OTHER|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
223913290|NCT02728635|PROCEDURE|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
223913291|NCT02728635|OTHER|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
223913292|NCT06513182|OTHER|No Alexis orthopaedic protector|No Alexis orthopaedic protector will be used during the course of the surgery.
223913293|NCT06513182|DEVICE|Alexis orthopaedic protector|Alexis orthopaedic protector will be inserted after making an initial superficial approach to the shoulder.
223913294|NCT06433752|OTHER|No Intervention|No Intervention
223913295|NCT04483739|DRUG|Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
223913296|NCT04483739|DRUG|Isatuximab Carfilzomib Lenalidomide Dexamethasone|Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation
223913297|NCT05122962|DIAGNOSTIC_TEST|Remote Heart Rhythm Monitoring|We will be looking to see if remote heart rhythm monitoring for 30 days at baseline, 12, and 24 months, helps for early identification of adverse cardiac events.
223913298|NCT06864390|PROCEDURE|genicular nerve neurolysis|The superior medial genicular nerve (SMGN), superior lateral genicular nerve (SLGN), and inferior medial genicular nerve (IMGN) will be blocked either by phenol neurolysis or radiofrequency ablation
223913299|NCT06864559|OTHER|To Compare 3 different suture materials used in oral surgery|To compare bacterial colonization, tissue reaction and clinical characteristics such as wound healing and patient postoperative outcomes in 3 different suture materials used in oral surgery.
223913300|NCT06862999|BEHAVIORAL|No Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King's Cross where he or she is an inhabitant as a worker, resident, or visitor. However, this email will not include any promised compensation for future participation in the hypothetical wellbeing study in the neighbourhood. This group serves as the control group to compare the effects of incentives on participation rates.
223913301|NCT06862999|BEHAVIORAL|Financial Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King\&amp;amp;#39;s Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a financial compensation, which is a chance of enter a prize draw to win a 4 X £100 voucher which can be used to purchase goods and services within the King\&amp;amp;#39;s Cross neighbourhood in London.
223913302|NCT06862999|BEHAVIORAL|Social Incentive Email|Participant will receive an email describing a hypothetical experience sampling study that will happen in King\&#39;s Cross where he or she is an inhabitant as a worker, resident, or visitor. This email will include a paragraph that describes a compensation for participation in the future study. The type of compensation that will be offered is a non-financial compensation, which is an invitation to participate in a social event that will be organised by the researchers and the neighbourhood asset manager team at the end of the research project. This event will be exclusive and it will be an opportunity for participants to socialize with other study participants in the neighbourhood. It will also be an opportunity for the study participants to feel they are contributing a change to the neighbourhood and will be able to articulate their views about the wellbeing research findings which is expected to be used to inform future interventions in the neighbourhood.
223913303|NCT06864052|DRUG|Administration of Apixaban|Apixaban 2.5mg BID or Apixaban 5mg BID
223913304|NCT06864052|DRUG|Administration of Edoxaban|Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD
223913305|NCT06863584|DRUG|Lenalidomide (Revlimid)|10mg po for 21 days, followed by a 7-day rest period.
224087583|NCT02409238|BEHAVIORAL|Intensive Lifestyle Intervention|"The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises."
224087584|NCT02409238|BEHAVIORAL|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
224087585|NCT02000947|DRUG|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
224087586|NCT02000947|DRUG|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
223913306|NCT06863584|RADIATION|SBRT|PTV 30Gy/5f and/or PGTV 35Gy/5F.
224087587|NCT02000947|DRUG|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
223913307|NCT06863909|BEHAVIORAL|Journaling|In the journaling condition, participants will be asked to keep a therapy journal twice a day in addition to the content of the cognitve behavioral therapy. At the beginning of the day, patients are to set a daily goal that aligns with their therapy goals (e.g., remaining calm when negative thoughts arise), and at the end of the day, they will reflect on the day itself and the work done on their therapy goals.
223913308|NCT06863909|BEHAVIORAL|Treatment as Usual (TAU)|Patients in this arm receive standard treatment (cognitive behavioral therapy) for their individual diagnosis. The study participation spans a period of 24 sessions (short-term psychotherapy KZT1\&2), during which the severity of symptoms will be assessed at the beginning of each session (duration approx. 2 minutes). Additionally, participants will be asked to answer some questions about basic documentation (diagnoses, symptoms) at the beginning and end of the study (duration approx. 20 minutes).
223913309|NCT06863597|OTHER|Video content|Video content produced by media professionals using expert opinions.
223913310|NCT06863597|OTHER|Written content|Written content produced by healthcare professionals with experience in health education.
223913311|NCT06863597|OTHER|Podcast content|Podcast content created by media experts based on expert opinions.
223913312|NCT06863597|OTHER|Illustration (information leaflet) content|Illustration-based content created by media experts using expert opinions.
223913313|NCT06671184|OTHER|Observations on clinicopathological factors influencing the difficulty of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
223913314|NCT06349980|DRUG|HLX53 (1000mg)|HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
223913315|NCT06349980|DRUG|HLX53 (2000mg)|HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
223913316|NCT06349980|DRUG|HLX10|HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.
223913317|NCT06349980|DRUG|HLX04|HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
223913318|NCT06349980|OTHER|Placebo|Placebo matching HLX53 will be administered by IV infusion on Day 1 of each 21-day cycle.
223913319|NCT06616402|DEVICE|prototype prosthetic group|"These 3 sessions will commence only upon successful completion of the prosthesis safety and reliability tests conducted in the preceding sessions.~For each module combination, a session will be conducted to assess motor performance through the acquisition of spatiotemporal parameters and energy efficiency parameters of gait. Motor performance will be evaluated using functional assessment tests and data will be recorded during the following activities:~* parallel bar walking on flat ground~* parallel bar walking on an inclined surface~* treadmill walking with a safety harness~* stair climbing/descending with a handrail~* standing up and sitting down from a chair within parallel bars At the end of each session, satisfaction questionnaires (ad hoc questionnaire) will be completed. At the end of the experiment, a usability scale for the devices (ad hoc System Usability Scale) will be completed.~Each session is expected to last approximately 2.5 hours."
223913320|NCT03825601|DIAGNOSTIC_TEST|PET with [11C]Flumazenil|7T MRI sequences : TSE, T2w FLAIR GRE-T2\* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
223913321|NCT06611618|OTHER|Muscle power assessment|Isokinetic dynamometry test Stair ascent/descent on instrumented stairs
223913322|NCT06611618|OTHER|Muscle force assessment|Isometric dynamometry (Maximal Voluntary Isometric Contraction)
223913323|NCT06611618|OTHER|Home-based mobility monitoring|Mobility monitoring with wearable sensors
223913324|NCT06611618|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Full lower limb MRI
223913325|NCT06611618|OTHER|Gait assessment|Motion capture, surface EMG and gorund reaction force data
223913326|NCT05970601|DIETARY_SUPPLEMENT|Soup|Intake of a single soup with different sodium chloride and potassium chloride content
223913327|NCT05890105|DRUG|PF-07853578|PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
223913328|NCT05890105|DRUG|Placebo|Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
223913330|NCT06660264|OTHER|Pharmacist Personalized Medication Review (PMR)|Pharmacist-provided review of current medications and assessment of potential medication related problems.
223913331|NCT06660264|OTHER|Discussion of Pharmacogenomic results during the PMR|Return of pharmacogenomic results and discussion of impact on medications.
223913332|NCT06607822|DEVICE|A patient-centered assistant system based on Large-Language Model (LLM)|Participants will engage in a 10-minute medical consultation using LLM model interface embedded in a tablet device before their regular face-to-face consulation with physicians. During the trials, participants could engage in free conversations covering aspects including risk factors, symptoms, diagnosis, examinations, treatment, advice and caution, etc. Participants who have completed the ophthalmic imaging examination will be asked to input results into the assistant model to generate structured reports.
223913333|NCT06608602|OTHER|tidal volume adjustment during surgery|tidal volume adjustment during surgery according to body weight or FVC
224087588|NCT05948215|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
224087589|NCT05948215|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
224087590|NCT00896532|DRUG|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
224087591|NCT00896532|DRUG|Alendronate|Administered orally once a week
223913334|NCT06855693|BEHAVIORAL|Delivering better oral health: an evidence-based toolkit for prevention|"The PHE Delivering Better Oral Health toolkit has been developed with the support of the 4 UK Chief Dental Officers. This is a general population approach to Oral Hygiene advice and includes the following:~Effective toothbrushing with a fluoride toothpaste is important to support oral health. The physical action of brushing removes plaque, which prevents gingivitis and periodontitis, and the fluoride in toothpaste is effective against tooth decay. The following key messages for the population include when and how to brush, specific habits associated with brushing, and, where necessary, assistance with brushing. There may be adaptations of toothbrushes, such as special grip handles, that are helpful to people who have limited manual dexterity."
223913335|NCT06855693|BEHAVIORAL|Mini Mouth Care Matters guide for special Education Settings|"2\. Oral hygiene guidance from a Clinical standard for autistic children and young people and/or those with a learning disability in special educational settings (Mini Mouth Care Matters Special Education Settings resources.~This is a specific approach to providing Oral Hygiene for children with sensory challenges.~This clinical standard supports the vision of universal access whereby everyone receives quality health services that meet their specific needs.~The clinical standard is designed to be used by all those involved in improving health outcomes and quality of life, including eating, speaking and socialising, for autistic children and young people, and those with a learning disability in England.~It is accompanied by a supporting package of tools, resources, and modules to support the delivery of the oral healthcare assessment (either face to face or remote) and to support teams in the development of complementary tailored mouthcare plans."
223913336|NCT06858891|PROCEDURE|Transversus abdominis plane (TAP) block|Under ultrasound guidance, 20 cc of 0.25% bupivacaine was planned to be administered between the internal oblique and transversus abdominis fascial planes on both lateral aspects of the anterior abdominal wall.
223913337|NCT06863948|OTHER|Teribenin method|"Intervention: Terebenin's Method~* Format:~* Duration: 8 weeks, 1 session/week (2-3 hours).~* Group size: 8-12 participants + 1-2 facilitators.~* Structure of Each Session:~* Introduction (10-15 min): Check-in, brief emotional reflection.~* Main Phase (90-120 min): Psychodrama-like enactments, systemic constellation exercises, body-oriented practices, directive interpretation by the therapist.~* Conclusion (15-20 min): Group reflection, integration, feedback.~* Quality Assurance:~* Audio/video recording (with consent) for supervision.~* A standard protocol/manual specifying core techniques"
223913338|NCT06863948|OTHER|Control Interventions|"1\. Active Control (Preferred):~* Group psychotherapy (CBT, Gestalt, or another recognized approach) matching the same 8-week schedule. 2. Waitlist Control (If Active Control Unavailable):~* Participants receive no active intervention during the 8 weeks, then are offered therapy afterward (if applicable)"
223913339|NCT06865235|PROCEDURE|360º goniotomy assisted transluminal trabeculotomy|Open the Schlemm Canal for 360º with a polipropilen 5-0 suture via trabecular meshwork.
223913340|NCT06865235|PROCEDURE|Phacoemulsification|Cataract Surgery
223913341|NCT06865235|PROCEDURE|180º gonioscopy assisted transluminal trabeculotomy|Open the Schlemm Canal for 180º with a polipropilen 5-0 suture via trabecular meshwork.
223913342|NCT06865040|DRUG|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|"Administration in the interventional arm of long-acting inhaled ß-2 mimetics:~FORMOTEROL FUMARATE 12 µg pwd inhalation capsule (FORMOTEROL VIATRIS®), taken twice a day intraoperatively from Day-2 to Day 7."
223913343|NCT06865040|OTHER|Usual treatment|usual treatment
223913344|NCT06863792|OTHER|ChatGPT|Students in the intervention group will answer the questions from the Hypertension Prevention Attitude Scale using ChatGPT.
223913345|NCT06861426|DRUG|Ginkgo Diterpene Lactone Meglumine|The specific administration protocol (including time of initiation, dosage, and treatment duration) should be strictly adhered to as per the physician's prescription and meticulously documented in the case report forms (CRFs).
223913346|NCT02287090|OTHER|Observational Cohort|
223913347|NCT06676891|DRUG|RZ-001|Participants will receive a single intracerebral injection of RZ-001, Recombinant adenovirus harboring the modified ribozyme construct with HSV-tk as a therapeutic transgene
223913348|NCT04505410|OTHER|"A plant based high fiber diet that mimics fasting (FMD) plus advanced therapy"|Patients will do two 5-day cycles of a fasting mimicking diet. They will start the first diet cycle 1 week after initiating a new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
223913349|NCT04505410|DRUG|Advanced therapy only without dietary intervention|Patients in this group will start an advanced therapy and follow a diet solely based on dietary tolerance: new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).
223913350|NCT06592599|DRUG|Toripalimab|Toripalimab will be administered 240 mg intravenously every three weeks in combination with the induction chemotherapy regimen for 3 cycles, and for 9 cycles as adjuvant treatment following radiation as specified in the overall sequential treatment plan.
223913351|NCT06592599|RADIATION|Concurrent Chemoradiation and Adjuvant treatment following Chemoradiation|"Radiation treatment will be initiated 3-6 weeks following day 1 of the last induction cycle using institutional standards of care and support as follows:~Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.~Following the completion of concurrent chemoradiation, capecitabine will be administered using institutional standards of care as follows:~Capecitabine 650 mg/m2 PO BID x 12 months beginning 12 to 16 weeks following the end of radiation treatment. Dose reductions and discontinuance of capecitabine will be according to the standard of care applied at the treating institution.~Adjuvant Toripalimab 240 mg IV q 21d x 9 maximum doses will be initiated concurrently with the initiation of adjuvant capecitabine, beginning 12-16 weeks following the end of radiation."
223913352|NCT06681441|DRUG|QRL-101 Dose A|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
223529704|NCT04047485|DIAGNOSTIC_TEST|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
223529705|NCT04047485|DIAGNOSTIC_TEST|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
223913353|NCT06681441|DRUG|QRL-101 Dose B|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
223913354|NCT06681441|DRUG|Placebo|All participants will receive three single-dose oral administrations in randomized order, scheduled across three separate study visits, with a 7-day washout period between each visit.
223913355|NCT04554940|BIOLOGICAL|vosoritide|Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
223913356|NCT06838221|OTHER|A Before and After study|interactive oral health educational program for children with intellectual disability and their care givers
223913357|NCT06838221|OTHER|before and after study|To evaluate the oral health of a group of children with disability and determine the effectiveness of the interactive oral health education program on oral health of children and care givers' oral health knowledge.
223913358|NCT05769608|DRUG|Placebo|Placebo once daily for 12 weeks
223913359|NCT05769608|DRUG|lorundrostat Dose 1|lorundrostat Dose 1 once daily for 12 weeks
223913360|NCT05769608|DRUG|lorundrostat Dose 2|lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
223913361|NCT04440592|DRUG|MT-7117|MT-7117
223913362|NCT04440592|DRUG|Placebo|Placebo
223913363|NCT02818829|OTHER|Collection of biological samples|Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
223913364|NCT05193019|OTHER|Parenteral antiplatelet agents|Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
223913365|NCT06348316|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
223913366|NCT06348316|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
223913367|NCT02692313|DRUG|Epinephrine|Dose response of epinephrine infusion
223913368|NCT02692313|OTHER|Saline infusion|Placebo
223913369|NCT05826912|DRUG|Atorvastatin Calcium|Capsule, 80 mg/day, with no loading dose, for 28 days
223716291|NCT03982368|DRUG|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
223913370|NCT05826912|DRUG|Minocycline Hydrochloride|Capsule, 200 mg loading dose on Day 1, then 100 mg twice daily for 6 days, then placebo twice daily for 21 days
223913371|NCT05826912|DRUG|Candesartan Cilexetil|Capsule, 8 mg once on Day 1, then 16 mg daily for 27 days
223913372|NCT05826912|DRUG|Placebo|Capsule, 2x/day for 28 days
223913373|NCT06165536|BEHAVIORAL|Resonant voice therapy|Resonant voice therapy is a standard of care procedure for treating phonotraumatic vocal hyperfunction. The full standardized voice therapy program will have a duration of four weeks, each week with one 60-minute therapy session.
223913374|NCT03354728|OTHER|Laboratory Biomarker Analysis|Correlative studies
224087592|NCT00896532|DRUG|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
223529706|NCT04047485|DIAGNOSTIC_TEST|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
223529707|NCT06449118|BEHAVIORAL|Mindfulness Stress Reduction Program|Mindfulness based-Stress Reduction Program an 8-week program
223529708|NCT00062257|DRUG|irofulven|
223716292|NCT03982368|OTHER|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
223529709|NCT02908217|DRUG|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
223529710|NCT02908217|DRUG|Placebo|6 Intravenous infusions of placebo every 4 weeks.
223913375|NCT03354728|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223913376|NCT06834490|DRUG|Mexidol|50 mg/ml IV solution, 250 mg tablets
223913377|NCT06834490|DRUG|Placebo|Placebo IV solution, Placebo tablets
223913378|NCT05099003|PROCEDURE|Biopsy Procedure|Undergo a biopsy
223913379|NCT05099003|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
223913380|NCT05099003|RADIATION|Radiation Therapy|Undergo radiation therapy
223913381|NCT05099003|DRUG|Selinexor|Given orally
223913382|NCT05300503|BEHAVIORAL|Telehome Monitoring|Participants are enrolled into the Telehome Monitoring program
223913383|NCT06347016|DRUG|Plozasiran Injection|ARO-APOC3 Injection
223913384|NCT06347016|DRUG|Placebo|sterile normal saline (0.9% NaCl)
223913385|NCT05215236|OTHER|Opiate Sparing|Subjects will receive non-opiate medications for pain control
223913386|NCT05215236|OTHER|Opiate Based|Subjects will receive opiate based medications for pain control
224087593|NCT00896532|DRUG|Romosozumab|Administered by subcutaneous injection
224087594|NCT00896532|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
224087595|NCT00896532|DRUG|Placebo to Denosumab|Administered by subcutaneous injection Q6M
224087596|NCT00896532|DRUG|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
223913387|NCT00696124|BIOLOGICAL|VM202 2 mg|2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
223913388|NCT00696124|BIOLOGICAL|VM202 4 mg|4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
223913389|NCT00696124|BIOLOGICAL|VM202 8 mg|8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
223913390|NCT00696124|BIOLOGICAL|VM202 16 mg|16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
223913391|NCT03918837|OTHER|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
224087597|NCT02127255|PROCEDURE|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
224087598|NCT02127255|PROCEDURE|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
224087599|NCT04758962|BIOLOGICAL|1 µg CoV2 SAM (LNP)|2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.
224087600|NCT02149810|BEHAVIORAL|Automatic Self Transcending Meditation|as above
224087601|NCT04399083|DIETARY_SUPPLEMENT|Caffeine|"Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL."
224087602|NCT02035826|BEHAVIORAL|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
224087603|NCT01176916|DRUG|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
223913392|NCT03918837|OTHER|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
223913393|NCT06262477|DRUG|BIIB800|Administered as specified in the treatment arm.
223913394|NCT06262477|DRUG|Actemra|Administered as specified in the treatment arm.
223913395|NCT05728502|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
223913396|NCT05728502|DRUG|Standard of Care (SoC)|Dosage at the discretion of the treating physician.
223913397|NCT03173937|BIOLOGICAL|Omidubicel (former CordIn)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn(TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn (TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn(TM) Non-cultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
224087604|NCT01469559|DRUG|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
224087605|NCT01469559|DRUG|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
224087606|NCT02714166|OTHER|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
223913398|NCT03173937|DEVICE|Miltenyi CliniMACS(R) CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device system that is designed for the in vitro enrichment of CD34+ target cells from heterogeneous hematologic cell populations. The process of CD34+ cell selection results in simultaneous passive depletion of donor lymphocytes, potentially obviating the need for immunosuppressive drugs to prevent GVHD.
223913399|NCT04046523|DEVICE|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
223913400|NCT03486873|DRUG|Pembrolizumab|200 or 400 mg IV infusion
223913401|NCT03486873|DRUG|Standard of Care (SOC)|IV infusion or oral tablets
223913402|NCT03486873|DRUG|Lenvatinib|Oral capsules
223913403|NCT03486873|DRUG|Olaparib|300mg or 250mg or 100mg oral tablers
223913404|NCT03486873|DRUG|MK-4280|IV Infusion
223529711|NCT00288145|BEHAVIORAL|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
223529712|NCT03261804|BEHAVIORAL|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
223529713|NCT01143402|DRUG|Dacarbazine|Given IV
223529714|NCT01143402|OTHER|Laboratory Biomarker Analysis|Correlative studies
223529715|NCT01143402|OTHER|Quality-of-Life Assessment|Ancillary studies
223529716|NCT01143402|DRUG|Selumetinib|Given PO
223529717|NCT01143402|DRUG|Temozolomide|Given PO
223529718|NCT04369326|OTHER|Community-Based TPT Initiation|Community-based care delivery model for pediatric tuberculosis evaluation and initiation of preventive therapy
223529719|NCT00441025|DRUG|Alemtuzumab|
223529720|NCT02686944|BIOLOGICAL|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
223529721|NCT02842385|OTHER|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
223529722|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
223529723|NCT00665834|DRUG|placebo|placebo 20 mg from day 0 to (maximum) day 6
223529724|NCT00665834|DRUG|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
223529725|NCT00665834|DRUG|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
223529726|NCT02526290|DEVICE|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
223529727|NCT05095922|DRUG|Heart-Protecting Musk Pill|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)
223529728|NCT05095922|DRUG|Valsartan Capsules|Valsartan Capsules(capsule, 80mg, once a day, 3 months）
223529729|NCT05095922|DRUG|Calcium Dobesilate Capsules|Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)
223529730|NCT02895217|OTHER|ergocycle|
223529731|NCT00823173|BIOLOGICAL|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
223529732|NCT05132972|BIOLOGICAL|Normoxic Allogenic UCMSC|Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10\^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
224087607|NCT02714166|OTHER|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
223529733|NCT05132972|OTHER|Normal saline solution|Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
223529734|NCT04264000|DRUG|platelet-rich plasma|Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
223529735|NCT04264000|DRUG|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
223529736|NCT02259595|DRUG|HPN-07|500-1,500 mg oral capsules administered in a single dose
223529737|NCT02259595|DRUG|NAC|1,200mg NAC administered via oral capsule in single dose
223529738|NCT02259595|DRUG|Placebo|placebo oral capsule
223529739|NCT04928378|OTHER|Descriptive retrospective study|characterization of the diagnosis, management and outcome of patients with osteoarticular infection due to MDR M. tuberculosis in France (MDR IOATB).
223529740|NCT00831883|BEHAVIORAL|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
223529741|NCT00831883|BEHAVIORAL|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
223529742|NCT00925574|DRUG|CNTO 1959; Placebo|
223529743|NCT03624075|OTHER|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
223529744|NCT00918619|DEVICE|Sangustop|Application of Sangustop haemostatic agent on resection area
223529745|NCT00918619|DRUG|Tachosil|Application of Tachosil fibrin sealant on resection area
223529746|NCT00179686|DRUG|CC-5013|
223529747|NCT03464825|OTHER|Specific and progressive balance training|Specific and progressive balance training for the intervention group
223529748|NCT04247438|OTHER|12h and 36h Biofilm formation on PMMA (Palapress®) dentures and samples worn by participants and brushing cycles needed to remove it.|"Capturing the clinical data for biofilm formation on PMMA dentures and samples worn by participants and the number of brushing cycles required to remove this biofilm.~Development of artificial denture biofilm substitute with similar mechanical properties to real denture biofilm."
223529749|NCT02048540|BIOLOGICAL|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
223716293|NCT03776552|OTHER|Rapid weight loss (RWL) program|16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
223529750|NCT02048540|DRUG|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
223529751|NCT02048540|PROCEDURE|Gastrectomy|
223529752|NCT06493526|DRUG|Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids.|Mycophenolate mofetil dose will be optimized to an AUC12 of 60 h.mg/L, thereafter the calcineurin inhibitor will be withdrawn.
223529753|NCT05321290|OTHER|Robotic Therapy Program|
223529754|NCT03860987|DRUG|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
223716294|NCT03776552|OTHER|Gradual weight loss (GWL) program|16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
224087608|NCT00832897|PROCEDURE|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
223529755|NCT03860987|DRUG|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
223529756|NCT03860987|DRUG|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
223529757|NCT03860987|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
223529758|NCT03860987|DRUG|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
224087609|NCT00759070|DRUG|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~\+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
223529759|NCT03860987|PROCEDURE|Radical Prostatectomy|Radical Prostatectomy
223529760|NCT04379570|OTHER|Educational Intervention|Receive online educational information about ET medication
223529761|NCT04379570|OTHER|Text Message-based Navigation Intervention|Receive text messages
223529762|NCT04379570|BEHAVIORAL|Motivational Interviewing|Receive motivational interviewing counseling sessions
223529763|NCT04379570|OTHER|Best Practice|Attend usual care clinic visits
223529764|NCT04379570|OTHER|Questionnaire Administration|Ancillary studies
223529765|NCT04379570|OTHER|Quality-of-Life Assessment|Ancillary studies
223529766|NCT04490681|DRUG|Ertugliflozin|Fixed dose Ertugliflozin (5mg)
223529767|NCT04490681|DRUG|Placebo|Placebo group
223529768|NCT05213741|DEVICE|Autonomous navigation of a magnetic colonoscope|The proposed magnetic-assisted colonoscope system consists of an megnetic field nevigator, magnetic-assisted colonoscope, and image receiving decoder. All participants will receive the magnetic-assisted colonoscopic examination by using this proposed magnetic-assisted colonoscope system
223529769|NCT01965847|BEHAVIORAL|Medication therapy management|
223529770|NCT03622151|OTHER|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
223529771|NCT02706392|OTHER|Laboratory Biomarker Analysis|Correlative studies
223529772|NCT02706392|BIOLOGICAL|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
223529773|NCT02897336|PROCEDURE|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
223529774|NCT02897336|PROCEDURE|interlaminar|interlaminar epidural corticosteroid injection
223529775|NCT05170971|OTHER|fecal microbiota transplantation|The fecal bacteria were transplanted once every 5 days for a total of 4 times
223529776|NCT05073588|OTHER|Indo Mediterranean diet|Mediterranean diet has been shown to be effective in NAFLD adult patients. In India, it is very difficult to follow Mediterranean diet, so one group will be given Indianized version of mediterranean diet.
223529777|NCT05073588|OTHER|Calorie restricted diet|One group will be given diet restricted in calories, which most of the patients follow to lose weight
223529778|NCT02109276|DEVICE|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
223529779|NCT02109276|DEVICE|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
223529780|NCT01447784|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
223529781|NCT01447784|BIOLOGICAL|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
223529782|NCT05452473|OTHER|CDSS-assisted upper GI endoscopy|Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
223529783|NCT05452473|OTHER|no intervention|Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
223529784|NCT00238394|DRUG|cediranib maleate|Given orally
223529785|NCT00238394|OTHER|laboratory biomarker analysis|Correlative studies
223529786|NCT03290027|DRUG|DFD-03|DFD-03 Lotion
223529787|NCT03290027|OTHER|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
223529788|NCT05408845|PROCEDURE|Biopsy Procedure|Undergo a biopsy
223529789|NCT05408845|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223529790|NCT05408845|PROCEDURE|Computed Tomography|Undergo a CT scan
223529791|NCT05408845|DRUG|Docetaxel|Given IV
223529792|NCT05408845|PROCEDURE|Echocardiography Test|Undergo ECHO
223529793|NCT05408845|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223529794|NCT05408845|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223529795|NCT05408845|OTHER|Questionnaire Administration|Ancillary studies
223529796|NCT05408845|BIOLOGICAL|Trastuzumab|Given IV
223529797|NCT05408845|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223529798|NCT05408845|BIOLOGICAL|Trastuzumab Emtansine|Given IV
223529799|NCT01891955|BEHAVIORAL|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
223535251|NCT05729087|BEHAVIORAL|Blended intervention group|"Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session."
223535252|NCT00373542|DRUG|ropinirole CR-RLS|
223535253|NCT05042206|BIOLOGICAL|Cellgram-CKD|Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease
223529800|NCT01891955|BEHAVIORAL|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
223529801|NCT00619866|DRUG|Elagolix|Elagolix tablets administered orally
223529802|NCT00619866|DRUG|placebo|Placebo tablet administered orally
223529803|NCT04570371|BEHAVIORAL|Conversation Guide + Clinical Support|The intervention is a bundled intervention (conversation guide + clinician decision support tools) which promotes the solicitation and use of patient preferences for post-surgical, non-pharmacological pain management strategies.
223529804|NCT05940428|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
223913405|NCT03486873|BIOLOGICAL|MK-4280A|800mg favezelimab + 200mg pembrolizumab IV Infusion
223913406|NCT05746169|OTHER|Health Questionnaires|A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.
223529805|NCT05840913|DRUG|Articaine HCl 4 % / EPINEPHrine 1:100,000 in 1.8 mL Dental Cartridge|Local anesthetic injection for intra- operative pain control
223529806|NCT01283984|DRUG|AZD2115|Single dose, oral inhalation (nebuliser solution)
223529807|NCT01283984|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
223529808|NCT01194596|BEHAVIORAL|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine), will be given in both arms.
223529809|NCT01194596|BEHAVIORAL|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
223529810|NCT00963872|DRUG|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
223529811|NCT00963872|DRUG|fludarabine phosphate|40 mg/m\^2 over 1 hour on Days -6 through -2.
223529812|NCT00963872|RADIATION|Total body irradiation|200 cGy on Day -1
223529813|NCT00963872|BIOLOGICAL|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
223529814|NCT00963872|BIOLOGICAL|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
223529815|NCT00399087|DRUG|Perifosine|Perifosine oral administration
223529816|NCT00399087|DRUG|Docetaxel|IV administration
223913407|NCT05746169|OTHER|Specimen sample collection|Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
223913408|NCT06465719|PROCEDURE|Minimally invasive basal ganglion hematoma evacuation with Tract-based AI Robot Guiding System|Basal ganglion hemorrhage patients will be operated on hematoma puncture and aspiration with Tract-based AI Robot Guiding System
223913409|NCT06465719|DRUG|Patients will be managed with guideline-based medications|Patients will be managed with guideline-based medications without surgery
223913410|NCT05379322|DRUG|Anti-TNF|Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.
223913411|NCT05379322|DRUG|JAK inhibitor|Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
223913412|NCT01815749|BIOLOGICAL|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
223913413|NCT01815749|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
223913414|NCT01815749|OTHER|laboratory biomarker analysis|Correlative studies
223913415|NCT03737669|BIOLOGICAL|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
223913416|NCT03737669|BIOLOGICAL|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
223913417|NCT05313334|BEHAVIORAL|GAMBIT Task|The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
223913418|NCT05224505|BIOLOGICAL|ATA-100 (AAV9 encoding FKRP gene)|Single intravenous infusion on Day 0
223529817|NCT00399087|DRUG|Prednisone|Oral administration
223529818|NCT01098422|DEVICE|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
223529819|NCT01135966|BEHAVIORAL|Conventional resistance training program|Conventional resistance training program is followed.
223529820|NCT01135966|BEHAVIORAL|Whole body vibration resistance training program|WBV training on FITVIBE
223529821|NCT01968980|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
223529822|NCT01968980|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
223529823|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel|
223529824|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
223529825|NCT00567554|DRUG|paclitaxel|
223529826|NCT00567554|DRUG|paclitaxel + everolimus (RAD001)|
223913419|NCT06847854|DRUG|RO7497372|RO7497372 will be administered as IVT injection as per the schedule specified in the arms.
223913420|NCT02792270|OTHER|Caloric Restriction Diet|"Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein."
223913421|NCT05762367|DIAGNOSTIC_TEST|3T MRI with Gadobutrol injection|MRI will be performed in all participants before and after Gadobutrol injection
223913422|NCT04347759|BEHAVIORAL|Coaching Messages|Participants receive real-time self-management coaching messages based on the severity of their symptoms. When participants call, the IVR system will ask them about each of the selected symptoms, and the patient will report symptom presence and severity numerically with the touchtone keypad.
223913423|NCT04347759|BEHAVIORAL|Automated Daily Monitoring|Participants report daily symptoms and symptom severity. There are three categories of severity based on a numeric scale of 1 to 3 for mild symptoms, 4 to 7 for moderate symptoms, and 8 to 10 for severe symptoms.
223913424|NCT06029309|DRUG|Zanubrutinib|"Participants will be administered Zanubrutinib orally (PO) via capsules daily during each 28-day cycle at the following dose levels:~* Phase 1 Dose Level 1: 320 mg~* Phase 1 Dose Level -1: 240 mg~* Phase 2: Recommended dose determined in Phase 1."
223913425|NCT06029309|DRUG|Tafasitamab|"Participants will be administered a 12 mg/kg dose of Tafasitamab intravenously (IV) during each 28-day cycle as follows:~* Early Induction - Cycle 1: Days 1, 4, 8, 15, and 22~* Early Induction - Cycles 2 and 3: Days 1, 8, 15 and 22~* Late Induction - Cycles 4 through 12: Days 1 and 15"
223913426|NCT04972721|OTHER|No treatment given|The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.
224087610|NCT00759070|DRUG|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
224087611|NCT00134628|PROCEDURE|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
224087612|NCT00134628|PROCEDURE|Sham treatment|Normal air under pressure (1.1 ATA)
224087613|NCT03668574|OTHER|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
223913427|NCT05963568|DRUG|Polycap|Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
223913428|NCT05081492|BIOLOGICAL|Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody|Given IT
224087614|NCT03668574|OTHER|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
223529827|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
223529828|NCT00567554|DRUG|epirubicin - cyclophosphamide / docetaxel + lapatinib|
223529829|NCT00283192|DRUG|Sertraline|
223913429|NCT03963518|DRUG|nivolumab monotherapy|nivolumab monotherapy
223913430|NCT03963518|DRUG|nivolumab plus ipilimumab|nivolumab plus ipilimumab
223913431|NCT06838000|BIOLOGICAL|PCV21|Investigational pneumococcal conjugate vaccine
223913432|NCT06838000|BIOLOGICAL|20vPCV|20-valent pneumococcal conjugate vaccine
223913433|NCT06564636|DEVICE|CATALYSTEM|CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty
223913434|NCT03610815|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
223913435|NCT04344613|DEVICE|ABODpoct device|The device has been developed by a consortium including the Université Libre de Bruxelles, research centers (SIRRIS, CER), a private company (CISEO), and the spin-off Antigon S.A..The device includes a reader and a disposable disk (ABOD disk) for testing one patient et a blood bag. Four blood drops from the patient are deposited on one side of the disk and 4 blood drops from the blood bag one the other side. The disk correctly filled is inserted in the reader and after 2 minutes the result is displayed on the screen as a message GO or No GO. In case of incompatibility or any other problem a red Stop message will appear on the screen.
223913436|NCT06452485|OTHER|No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups.|Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
223913437|NCT06141252|DEVICE|Hypothermia|Patients admitted with out-of-hospital cardiac arrest and treated with hypothermia
224087615|NCT02500186|DRUG|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
224087616|NCT02500186|OTHER|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
224087617|NCT03137615|PROCEDURE|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
224087618|NCT03137615|DRUG|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
224087619|NCT01629745|GENETIC|gene expression analysis|
224087620|NCT01629745|OTHER|flow cytometry|
223719417|NCT04340401|DRUG|Capecitabine|CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.
223913438|NCT02153580|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
223913439|NCT02153580|DRUG|Bendamustine Hydrochloride|Given IV
223913440|NCT02153580|DRUG|Cyclophosphamide|Given IV
223913441|NCT02153580|DRUG|Etoposide|Given IV
223913442|NCT02153580|DRUG|Fludarabine Phosphate|Given IV
223913443|NCT05051033|PROCEDURE|Mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery. Mitral surgery will be conducted using general anesthesia and cardiopulmonary bypass. Mitral surgery may be performed via a sternotomy or a right thoracotomy approach with or without robotic assistance. Standard techniques commonly include a ring or band annuloplasty to correct and prevent annular dilatation; leaflet prolapse and redundancy may be corrected by leaflet resection techniques and / or chordal reconstruction.
224087621|NCT01629745|OTHER|laboratory biomarker analysis|
224087622|NCT03158220|BIOLOGICAL|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
223529830|NCT03464773|OTHER|PIUO Pathway|See arm descriptions
223529831|NCT03212729|RADIATION|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
223529832|NCT03212729|PROCEDURE|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
223529833|NCT03949517|DRUG|68-Ga RM2|Radioactive agent
223529834|NCT03949517|DRUG|68-Ga PSMA11|Radioactive agent
223529835|NCT03949517|DEVICE|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
223529836|NCT03949517|PROCEDURE|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
223529837|NCT03558217|DEVICE|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
223529838|NCT03558217|DEVICE|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
223535254|NCT01150357|DRUG|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
223535255|NCT01150357|DRUG|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
223535256|NCT01150357|DRUG|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
223535257|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose|Intravitreally (IVT) injection.
223535258|NCT05850520|DRUG|Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg|Intravitreally (IVT) injection.
223535259|NCT05850520|DRUG|Sham|Sham procedure will be given on visits when an active injection is not planned.
223535260|NCT05850520|DIAGNOSTIC_TEST|Fluorescein|Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
223535261|NCT04312945|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
223535262|NCT04312945|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
223535263|NCT06116175|PROCEDURE|60 degree thermal radiofequency of tennis elbow|under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula
223535264|NCT05471986|DEVICE|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Subjects will have underwent Fundus Photography using FDA approved non-mydriatic fundus cameras compatible with EyeCheckup which are either TOPCON NW400, CANNON CR2, CANNON CR2 Plus or OPTOMED AURORA IQ
223535265|NCT06934681|BEHAVIORAL|Usual Care Group|Participants will receive the standard intervention provided by the healthcare service, which includes recommendations for physical exercise, physical activity, and healthy eating. This intervention is delivered by the Endocrinology and Nutrition Department at Hospital Universitario y Politécnico La Fe and consists of periodic individual follow-ups (at least three in-person visits per year, both pre- and post-bariatric surgery) by specialized medical staff in Endocrinology and licensed Nutrition and Dietetics professionals. Additionally, it includes five preoperative group sessions focusing on various aspects of healthy nutrition, physical exercise, and physical activity.
223913444|NCT05051033|DEVICE|Transcatheter edge-to-edge repair|Patients will be treated with a commercially-approved edge-to-edge mitral repair device. The steerable guide catheter (guide) is inserted into the femoral vein and advanced across the inter-atrial septum using image guided puncture. Fluoroscopic and echocardiographic guidance will be used to visualize the devices and assess the repair. The guide is positioned over the MV and the clip/clasp delivery system is inserted into the guide and positioned over the MV in accordance with the manufacturer's instructions. The delivery catheter is advanced until the clip/clasp emerges from the tip of the guide into the left atrium. The catheter is manipulated using the control handle until the clip/clasp is correctly oriented with respect to the line of coaptation of the mitral valve. The clip/clasp is opened, and advanced across the mitral valve into the left ventricle then pulled back to grasp the leaflets.
223913445|NCT05898854|DRUG|68Ga-FAPi-46|Gastric or gatro-esophageal junction cancer patients undergo 68Ga-FAPi-46 PET/CT at primary staging and at restaging
223913446|NCT06365892|OTHER|open-label placebo|Placebo will be supplied as a 330mg tablet (manufactured by Consolidated Midland Corporation). Patients will take placebo with each oral opioid intake and 3 additional times per day beginning on POD 1.
223913447|NCT06365892|OTHER|Treatment as usual|Each oral opioid dose is a 5mg Oxycodone tablet. Investigator shall never prescribe ibuprofen. Investigator shall always prescribe Tylenol 625mg every 8hrs (PRN).
223913448|NCT02065726|DIETARY_SUPPLEMENT|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
223913449|NCT02065726|OTHER|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
223913450|NCT04635111|DRUG|TURALIO™|This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
223913451|NCT04079972|BEHAVIORAL|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
223913452|NCT04079972|BEHAVIORAL|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
223913453|NCT06475781|DRUG|Mirivadelgat|Selective aldehyde dehydrogenase 2 (ALDH2) activator
223913454|NCT06475781|DRUG|placebo|placebo
223913455|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
223913456|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
223913457|NCT03915678|DRUG|Association atezolizumab + BDB001+ RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
223913458|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
223913459|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
223913460|NCT03915678|DRUG|Association atezolizumab + BDB001 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
223913461|NCT06566456|PROCEDURE|The puncture site is 1.5-2.5 cm proximal to the radial styloid process|The ultrasound-guided radial artery puncture site is1.5-2.5 cm proximal to the radial styloid process
223719418|NCT04340401|RADIATION|Intensity modulated radiotherapy|patients will receive intensity modulated radiotherapy with capecitabine
223719419|NCT04340401|PROCEDURE|Total mesorectal excision|Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
223913462|NCT06566456|PROCEDURE|traditional site|The ultrasound-guided radial artery puncture site is level with the radial styloid process and where the radial artery pulse is most prominent
223913463|NCT04082533|DRUG|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
223913464|NCT04082533|DRUG|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
223913465|NCT05220865|PROCEDURE|Hall Technique|"* Only food scraps or debris will be removed from the caries cavity.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
223913466|NCT05220865|PROCEDURE|Modified Hall Technique|"* Food scraps or debris will be cleaned from the caries cavity and infected soft carious dentin tissue will be excavated with hand instruments.~* The smallest crown size will be selected that covers all cusps and approaches the contact points with a slight springback feel.~* If the contact points are tight, orthodontic elastic separators will be placed through the contacts and the SSC will be placed at the second appointment 3-5 days later.~* The SSC will be loaded with glass ionomer luting cement and placed evenly on the tooth.~* The child will be asked to bite firmly until the crown is pushed down over the tooth.~* If the child is unable or unwilling to bite down on the SSC, finger pressure will be used to seat the crown~* The child will continue to bite on a cotton roll until the cement hardens~* Excess glass ionomer cement will be removed from the crown margins with hand instruments and dental floss."
223913467|NCT06446882|DEVICE|Personalized treatment according to molecular diagnosis with HER2DX|"Patients with HER2DX high-risk disease:~* Neoadjuvant treatment:~  * High HER2DX pCR score: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~ * Medium HER2DX pCR score: carboplatin + paclitaxel per 12-18 (or docetaxel per 4-6 cycles) + trastuzumab +/- pertuzumab per 4-7 cycles.~ * Low HER2DX pCR score: standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice.~* Adjuvant treatment:~  * pCR at surgery; Trastuzumab +/- pertuzumab up to a total of 18 cycles (including neoadjuvant and adjuvant therapy).~ * No pCR at surgery: T-DM1 per 14 cycles.~Patients with HER2DX low-risk disease:~* Neoadjuvant treatment: paclitaxel per 12 weeks + trastuzumab +/- pertuzumab per 4-5 cycles.~* Adjuvant treatment will be according to the pCR status at surgery:~  * pCR at surgery: trastuzumab or no adjuvant treatment.~ * No pCR at surgery: trastuzumab or T-DM1."
223913468|NCT06446882|OTHER|Treatment by physician´s choice, blinded to the diagnostic HER2DX test results|Patients randomized in ARM A will be treated with standard of care neoadjuvant CT regimens and HER2 blockade at the investigator's choice validated by national and/or international guidelines.
223913469|NCT04613310|DIAGNOSTIC_TEST|Rapid Diagnostic Test vs PCR|4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
223913470|NCT06565637|BEHAVIORAL|Promoting Resilience to Improve Disordered Eating|"See description under Arms"
223913471|NCT03682068|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
223913472|NCT03682068|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
223913473|NCT03682068|DRUG|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
223913474|NCT03682068|DRUG|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
223913475|NCT04701411|BIOLOGICAL|Darvadstrocel|Darvadstrocel perilesional injection.
223913476|NCT06260059|DRUG|Empagliflozin 10 MG|Patient will be given 10 mg of Empagliflozin if randomized to the drug arm or will receive placebo drug for 1 year
223913477|NCT06260059|DRUG|Placebo|To patients randomized to the placebo group, a placebo pill will be given
223913478|NCT06959524|DEVICE|Drug Eluting Balloon|AGENT DCB
223913479|NCT06959524|DEVICE|Drug eluting stent|Any commercially available DES used for standard of care.
223913480|NCT06959524|PROCEDURE|Plain old balloon angioplasty|Bifurcation side branch - POBA
223913481|NCT03683251|DRUG|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
223913482|NCT06828055|DRUG|Placebo|Matching Placebo to VK2735
223913483|NCT06828055|DRUG|VK2735|Active Treatment
223913484|NCT04781309|DRUG|NT-I7|NT-I7 is a recombinant human interleukin-7 fused to a hybrid fragment crystallizable region of a human antibody (hyFc). NT-I6 has a molecular weight of 104 kD. The active moiety of NT-I7 is recombinant human interleukin-7 (rhIL-7), containing human IL-7 (amino acids 4 through 155) and exhibiting all known functions of endogenous human IL-7.
223913485|NCT06760819|DRUG|BAY2927088|tablet, oral
223913486|NCT03426891|DRUG|Pembrolizumab|200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
224087623|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
224087624|NCT06548139|DRUG|Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg|Active ingredient: natural full human monoclonal antibody CBB 1 containing 0.5 mg / ml per dose (2.5ml) Ingredients: 25 mM citrate buffer, 125 mM sodium chloride, 0.02% (w / v) polysorbate 20 and water for injection
224087625|NCT06548139|DRUG|Rabies Human Immunoglobulin (HRIG)|Active ingredient: Rabid human immunoglobulin
224087626|NCT06548139|BIOLOGICAL|Lyophilized rabies vaccine for human use (Vero cells)|Active ingredient: inactivated rabies virus fixed poison
223529839|NCT04473560|DEVICE|Catheter-directed thrombectomy|Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
223529840|NCT01923376|DRUG|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
223529841|NCT01923376|DRUG|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
223529842|NCT00314457|DRUG|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
223529843|NCT03018873|OTHER|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
223529844|NCT03124186|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
224087627|NCT00364299|DEVICE|Automatic control of tracheal tube cuff pressure|
224087628|NCT00591695|PROCEDURE|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
224087629|NCT00591695|PROCEDURE|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
224087630|NCT03847285|OTHER|solid organ transplantation|solid organ transplantation: kidney, heart, pancreas, lung and liver transplantation
223529845|NCT05626660|OTHER|Coronary angiography and percutaneous coronary intervention|Coronary angiography and percutaneous coronary intervention via radial approach
223529846|NCT05074914|PROCEDURE|oesophagectomy|removal of oesophagus
223529847|NCT03306550|DRUG|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
223529848|NCT03306550|DRUG|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
223529849|NCT02665377|DRUG|ANP|
223529850|NCT02665377|DRUG|Placebo|
223529851|NCT05636839|RADIATION|UVB treatment|UVB treatment 3 times per week for 10 weeks
223529852|NCT03075228|DEVICE|IntelliCap|Sampling of the small intestine using a samling capsule.
223529853|NCT01527032|DRUG|melphalan, thalidomide and dexamethasone|
224087631|NCT01015833|DRUG|Doxorubicin Hydrochloride|Given IV
223913487|NCT03426891|DRUG|Vorinostat|Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy.
224087632|NCT01015833|OTHER|Laboratory Biomarker Analysis|Correlative studies
224087633|NCT01015833|OTHER|Pharmacogenomic Study|Correlative studies
224087634|NCT01015833|DRUG|Sorafenib Tosylate|Given PO
224087635|NCT02276586|PROCEDURE|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
224087636|NCT02276586|PROCEDURE|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
224087637|NCT01671280|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
224087638|NCT03897543|DRUG|ABX196|ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).
224087639|NCT01419431|PROCEDURE|Laparoscopic resection|Inflammatory response in laparoscopic surgery
224087640|NCT02299960|DEVICE|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
224087641|NCT02299960|DEVICE|NICOM|Non-invasive measurement of cardiac output
224087642|NCT01959165|DRUG|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
224087643|NCT01959165|DRUG|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
224087644|NCT01959165|DRUG|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
223719420|NCT03837106|OTHER|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
223719421|NCT03487276|DRUG|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
224087645|NCT01959165|DRUG|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
224087646|NCT04500704|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
224087647|NCT04500704|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
224087648|NCT03174145|BEHAVIORAL|Positive behaviour|Information about T4P1010 treatment
224087649|NCT03174145|DRUG|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
224087650|NCT03174145|GENETIC|Pharmacogenetic|Blood sample of 10 millilitres maximum
224087651|NCT03174145|OTHER|Questionnaires and diary completion|Personality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
224087652|NCT05815355|DIETARY_SUPPLEMENT|exclusive enteral nutrition treatment group|
224087653|NCT03052803|DEVICE|Fractional flow reserve measure|Comparison of different devices measuring fractional flow reserve
224087654|NCT00180973|DRUG|Hydroxyurea|
224087655|NCT06960486|PROCEDURE|Bedside ultrasound-guided real-time biliary drainage|Bedside ultrasound-guided real-time biliary drainage by emergency surgeon in the frail and high risk elderly patients with severe acute suppurative infection of biliary tract
224087656|NCT06960486|PROCEDURE|traditional appointment ultrasound|Traditional appointment ultrasound
223529854|NCT02128035|PROCEDURE|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
223529855|NCT01474109|DRUG|macitentan 3mg|macitentan 3mg tablet once daily
223529856|NCT01474109|DRUG|macitentan 10mg|macitentan 10mg tablet once daily
223529857|NCT01474109|DRUG|placebo|matching placebo once daily
223529858|NCT00101348|DRUG|erlotinib hydrochloride|Given orally
223529859|NCT00101348|BIOLOGICAL|cetuximab|Given IV
223529860|NCT00101348|BIOLOGICAL|bevacizumab|Given IV
223529861|NCT00101348|OTHER|laboratory biomarker analysis|Correlative studies
223529862|NCT05164471|GENETIC|verbrinacogene setparvovec|FLT180a is a gene therapy intended to increase endogenous FIX production in adults with Hemophilia B
223529863|NCT02589938|OTHER|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
223719422|NCT03487276|DRUG|Placebo|Placebo
224087657|NCT03497845|BIOLOGICAL|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
224087658|NCT03497845|BIOLOGICAL|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
224087659|NCT03497845|BIOLOGICAL|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
224087660|NCT03497845|BIOLOGICAL|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
224087661|NCT03497845|BIOLOGICAL|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
224087662|NCT03497845|BIOLOGICAL|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
223913488|NCT03426891|DRUG|Temozolomide|All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m\^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m\^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
223913489|NCT03426891|RADIATION|Radiotherapy|All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
223913490|NCT05620407|DRUG|Deucravacitinib|Specified dose on specified days
223913491|NCT05620407|OTHER|Placebo|Specified dose on specified days
223913492|NCT04799275|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223913493|NCT04799275|DRUG|Cyclophosphamide|Given IV
223913494|NCT04799275|DRUG|Doxorubicin Hydrochloride|Given IV
224087663|NCT03497845|BIOLOGICAL|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
224087664|NCT01817816|PROCEDURE|Botox_A|
224087665|NCT01817816|PROCEDURE|Botox_B|
224087666|NCT00927563|DRUG|Tolcapone|pill, 100-300mg/day for 8 weeks
224087667|NCT03016780|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
224087668|NCT03016780|OTHER|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
224087669|NCT03215563|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
224087670|NCT03215563|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
224087671|NCT02737865|DRUG|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
224087672|NCT02737865|DEVICE|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
224087673|NCT04208425|BEHAVIORAL|Project Personality|"The intervention includes five components: 1. An introduction to the brain, including a lesson on the concept of neuroplasticity, describing how and why our behaviors are controlled by thoughts and feelings in their brains, which have potential for change; 2. Written testimonials from older youths who describe their beliefs that people's personal traits (e.g., sadness, anxiety) are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits (i.e., a self-persuasion exercise)."
223913495|NCT04799275|DRUG|Oral Azacitidine|Given PO
223529864|NCT02589938|OTHER|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
223913496|NCT04799275|DRUG|Prednisone|Given PO
223913497|NCT04799275|OTHER|Questionnaire Administration|Ancillary studies
223913498|NCT04799275|BIOLOGICAL|Rituximab|Given IV or SC
223913499|NCT04799275|DRUG|Vincristine Sulfate|Given IV
223913500|NCT05843253|DRUG|Ribociclib|Ribociclib PO qd on days 1-21
223913501|NCT05843253|DRUG|Everolimus|Everolimus PO qd on days 1-28
223913502|NCT05843253|DRUG|Temozolomide (TMZ)|Temozolomide PO qd on days 1-5 for the first 13 cycles
223913503|NCT02194738|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223913504|NCT02194738|DRUG|Carboplatin|Given IV
223913505|NCT02194738|DRUG|Cisplatin|Given IV
223913506|NCT02194738|OTHER|Clinical Observation|Undergo observation
223913507|NCT02194738|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223913508|NCT02194738|DRUG|Crizotinib|Given PO
223913509|NCT02194738|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
224087674|NCT04208425|BEHAVIORAL|Sharing Feelings Intervention|The ST SSI is designed to control for nonspecific aspects of intervention, including engagement in a computer program. It includes the same number of reading and writing activities as the web-based growth mindset intervention; it also mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
224087675|NCT01755663|DRUG|Ivabradine and Metoprolol|
224087676|NCT04958538|DRUG|Methotrexate|Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
224087677|NCT03799510|BIOLOGICAL|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
224087678|NCT03799510|DRUG|GLA-SE solution|The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
224087679|NCT02921451|DEVICE|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
223913510|NCT02194738|PROCEDURE|Echocardiography Test|Undergo ECHO
223913511|NCT02194738|DRUG|Erlotinib|Given PO
223913512|NCT02194738|DRUG|Gemcitabine Hydrochloride|Given IV
223913513|NCT02194738|BIOLOGICAL|Nivolumab|Given IV
223913514|NCT02194738|DRUG|Paclitaxel|Given IV
223913515|NCT02194738|BIOLOGICAL|Pembrolizumab|Given IV
223913516|NCT02194738|DRUG|Pemetrexed|Given IV
223913517|NCT02194738|DRUG|Pemetrexed Disodium|Given IV
224087680|NCT04112680|BEHAVIORAL|Debunking Misinformation through Audio Dramas|The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease
224087681|NCT04112680|BEHAVIORAL|Control group audio jingles|The control group will receive audio jingles about exclusive breastfeeding
224087682|NCT01207830|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
223913518|NCT02194738|OTHER|Placebo Administration|Given PO
224087683|NCT04029857|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given standard of care nutritional supplementation
223529865|NCT02589938|OTHER|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
223535266|NCT06934681|BEHAVIORAL|Controlled exercise with telerehabilitation|Participants will receive the same standard care as the control group, including the same number of visits with the physician and nutritionist and participation in group sessions. Additionally, they will follow a structured physical exercise program, tailored to individual capabilities, combining aerobic and strength exercises, which will primarily be carried out at home with the assistance of telerehabilitation. Physical exercise will be structured in different phases: prior to surgery (prehabilitation), after surgery (rehabilitation), with maintenance periods in between.
223913519|NCT02194738|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223913520|NCT00706420|PROCEDURE|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
223913521|NCT00706420|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
223913522|NCT06196684|PROCEDURE|Mitral allograft implantation|Tricuspid valve replacement with mitral valve allograft
223913523|NCT05571319|DRUG|Metformin Extended Release Oral Tablet|Glucophage XR 500 mg
223913524|NCT04716595|DRUG|K-877 ER 0.2 mg/day morning administration (once daily)|K-877 ER 0.2 mg tablet
223913525|NCT04716595|DRUG|K-877 ER 0.2 mg/day evening administration (once daily)|K-877 ER 0.2 mg tablet
223913526|NCT00581633|OTHER|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
223913527|NCT04077723|DRUG|Englumafusp alfa|Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
223913528|NCT04077723|DRUG|Obinutuzumab|"A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III)."
223913529|NCT04077723|DRUG|Glofitamab|A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
223913530|NCT04077723|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
223913531|NCT06847542|DEVICE|Susvimo PDS Implant|Ranizumab will be administered via a PDS implant per the schedule described in the arm.
223913532|NCT06847542|DRUG|Ranibizumab|"Participants will receive ranibizumab delivered through the PDS implant.~Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment."
223913533|NCT04896255|DRUG|peginterferon alpha based regimen|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
223913534|NCT04896255|DRUG|nucleos(t)ide|peginterferon alpha based regimen or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
224087684|NCT04029857|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given Impact Advanced Recovery PO or via feeding tube
224087685|NCT02899156|DRUG|Flumazenil|
224087686|NCT02899156|DRUG|Placebo|0.9% normal saline
224087687|NCT02445833|BEHAVIORAL|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
224087688|NCT00909155|DRUG|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
224087689|NCT00909155|DRUG|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
224087690|NCT05891067|BEHAVIORAL|SterkWerk|Classroom-based intervention program
224087691|NCT05891067|BEHAVIORAL|Treatment-as-usual|Active control group
224087692|NCT01774422|DEVICE|Extracorporeal CO2 removal device|
223913535|NCT06412029|OTHER|Non-Interventional|Non-interventional study
223913536|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
223913537|NCT03228732|DRUG|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
223913538|NCT03228732|DRUG|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
223913539|NCT03228732|DRUG|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
224087693|NCT04392960|DRUG|[18F]Florbetaben|"Patients will undergo on the same day:~* 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient);~* standard assessment of clonal and organ disease;~* echocardiography;~* cardiac magnetic resonance.~All the patients will undergo those evaluations at baseline and 6 months after treatment initiation."
224087694|NCT03787914|PROCEDURE|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
224087695|NCT00412776|DRUG|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
224087696|NCT02730260|BEHAVIORAL|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
224087697|NCT02730260|BEHAVIORAL|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
224087698|NCT00000733|DRUG|Ribavirin|
224087699|NCT04524845|DEVICE|Unloading brace|"Participants underwent one session of gait analysis. The experimental protocol was divided in four conditions, the control condition without brace (NO), and then three conditions with the different braces tested in a randomized order.~For each condition, the participant was fitted with the brace by the same experimenter and equipped with 19/20 retro-reflective markers (without/with brace) on the pelvis and the investigated leg for motion analysis. After a short recording in a fixed standing position (static trial), each participant carried out at least three barefoot walking trials of a few meters long at a self-selected pace. The walking trial was validated if a complete gait cycle occurred on the two 90cm x 90 cm force plates recording the ground reaction forces. After each condition, the participant had to assess knee pain."
223535267|NCT06932276|BEHAVIORAL|"Some things a re better outside"|"Some Things Are Better Outside interventionis designed to encourage participants to voluntarily create a smoke-free home by accepting a norm of never smoking at home, whether indoors or outdoors, such as on balconies. The intervention is delivered over six weeks and consists of four components: an initial mailing of printed materials, a coaching call, and two additional mailings. It is based on five steps to adopting a smoke-free home: 1) deciding on the reasons for creating one, 2) discussing it with family members, 3) choosing a date to go smoke-free, 4) making the home a smoke-free environment, and 5) maintaining it as smoke-free."
223913540|NCT03228732|DRUG|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
223913541|NCT03250975|DRUG|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
223913542|NCT03250975|OTHER|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
223913543|NCT06888765|OTHER|Optical Coherence Tomography (OCT) and Body Composition Analysis|"This observational study included non-invasive diagnostic assessments to evaluate retinal, choroidal, ocular, and body composition parameters. Optical Coherence Tomography (OCT) measured macular and peripapillary retinal parameters, including retinal volume and cup/disc ratio. Enhanced Depth Imaging OCT (EDI-OCT) assessed choroidal thickness and vascularity, while Optical Coherence Tomography Angiography (OCTA) analyzed vessel density and foveal avascular zone (FAZ) metrics.~Optical biometry measured axial length, anterior chamber depth, lens thickness, K1, K2, and central corneal thickness. Autorefractometry and tonometry were part of the routine ophthalmologic examination, including slit-lamp biomicroscopy. Bioelectrical impedance analysis (BIA) assessed body composition, including BMI, fat percentage, muscle mass, and metabolic age. These assessments were for research purposes only, without therapeutic intervention."
223913544|NCT02865408|DIETARY_SUPPLEMENT|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
224087700|NCT04524845|DEVICE|Rebel Reliever (RR)|Rebel Reliever (RR) (Thuasne, Levallois Perret, France)
224087701|NCT04524845|DEVICE|Action Reliever|Action Reliever (AR) (Thuasne, Levallois Perret, France)
224087702|NCT06087757|DRUG|Open Label Clemastine with a blinded randomize withdrawal|Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.
224087703|NCT04749381|COMBINATION_PRODUCT|acupoint with TCM|The acupoint application was made of traditional Chinese medicine (TCM), and the therapeutic effect was produced through the stimulation of TCM drugs and acupoints.
224087704|NCT04749381|COMBINATION_PRODUCT|acupoint with placebo|The placebo acupoint application was made of black beans and honey, which shares the similar shape and smell of the experiment group, applied at the same acupoints.
224087705|NCT05187832|DRUG|AND019 PO QD|AND019 administrated as oral capsule once per day for 28 days for each cycle
224087706|NCT00823641|DRUG|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
224087707|NCT02629731|DEVICE|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
224087708|NCT02787772|PROCEDURE|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
224087709|NCT02269358|DRUG|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
223719423|NCT04920604|OTHER|Face-to-face anesthesia consultation|The anesthesia consultation is carried out in person in accordance with the usual management.
223913545|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
223913546|NCT02865408|DIETARY_SUPPLEMENT|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
223913547|NCT04898010|DEVICE|Selective Cytopheretic Device|The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
223913548|NCT03610750|OTHER|psychiatric medications and evidence-based psychotherapies|Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
223913549|NCT03792425|PROCEDURE|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
223913550|NCT00462696|DRUG|Neoadjuvant chemotherapy|"Neoadjuvant tehrapy as per standard practice :~Patients will be treated with six cycles of neoadjuvant chemotherapy combining epirubicin (75 mg/m² on day 1) and docetaxel (75 mg/m² on day 1), administered every 21 days (Delcambre, 2005; Wenzel, 1999). This treatment regimen is in line with the latest international recommendations (Kaufmann, 2003). The addition of a leukocyte growth factor in cases of grade IV leukopenia and/or treatment postponements due to grade 3-4 toxicity will be authorized with a maximum delay of 2 weeks per cycle. Dose reductions will be authorized in 25% increments for grade 3-4 toxicity~. Systematic surgical excision of the residual lesion (or the initial tumor site) will be performed between 22 and 35 days after the last chemotherapy treatment, in the form of a lumpectomy or mastectomy, depending on the residual tumor. Lymph node dissection will be systematically associated."
223913551|NCT03736707|DEVICE|HFOV|"HFOV + volume guarantee (VG) as the intervention group HFOV was provided only with piston or membrane oscillators capable of delivering true oscillatory pressure with an active expiratory phase (i.e., Acutronic FABIAN-III, SLE 5000, Löwenstein Med LEONI+, or Sensormedics 3100A). Other machines offering high frequency ventilation were excluded. The lung recruitment maneuver was performed as previously described, and lung volume was assessed by chest radiography or lung ultrasound, targeting the right diaphragm at the level of 8th-9th rib (or 7th-8th rib in case of air leak).~Crossover between HFOV and CMV This study allowed infants who failed to respond to their assigned ventilation mode to receive a trial of the alternate mode. Crossover criteria for HFOV-assigned neonates included failure for 3 hours to maintain SpO2 ≥ 50% despite FiO2 of 1.0, PaCO2 \> 60 mmHg for 3 hours, or signs of ventilator-induced cardiac output reduction. Non-responders to HFOV were switched to CMV."
223913552|NCT03736707|DEVICE|CMV|"CMV as the standard group CMV was delivered by time-cycled, pressure-limited ventilators. Only pressure regulated volume control (PRVC) will be provided by any type of neonatal ventilator.~Crossover criteria for CMV-assigned neonates included failure for 3 hours to maintain SpO2 ≥ 50% despite FiO2 of 1.0, PaCO2 \> 60 mmHg for 3 hours, or requiring \> 30 cm H2O PIP to sustain ventilation. Non-responders to CMV were switched to HFOV.~Ventilator settings were adjusted at the discretion of the attending clinician to maintain a SpO2 between 90%-94%, a PaO2 between 50 and 80 mm Hg and a PaCO2 between 35 and 60 mm Hg and a pH between 7.20 and 7.45. PO2 and PCO2 levels were monitored using arterial blood gas analysis and/or transcutaneous monitoring in both groups."
223913553|NCT05365958|BEHAVIORAL|HIV Podcast for Heterosexual African American Adults|"The video podcast will deliver HIV prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study."
223913554|NCT05098158|OTHER|Non-pharmacological pain treatment|Participant selects from telehealth consultation on massage therapy, yoga therapy, chiropractic and physical therapies.
223913555|NCT06001268|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
223913556|NCT06001268|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
223913557|NCT06001268|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
223535268|NCT06937307|DRUG|Droxidopa capsules|Droxidopa is an oral synthetic amino acid that is directly metabolized to norepinephrine by dopa-decarboxylase. It will be administered at an initial dose of 100 mg three times daily, titrated in 100 mg increments every 24 hours based on blood pressure response, up to a maximum of 300 mg three times daily. Doses will be given approximately 4 hours apart during daytime hours, at least 3 hours apart, with a maximum total daily dose of 900 mg. The treatment duration is 28 days. The drug will be over-encapsulated using opaque capsules to maintain the double-blind design.
223535269|NCT06937307|OTHER|Placebo|Matching placebo capsules containing microcrystalline cellulose (from Millipore Sigma) will be over-encapsulated using identical opaque capsules to maintain blinding. Placebo will be administered following the same schedule as the active treatment: three times daily with the same titration protocol based on blood pressure response, for a treatment duration of 28 days. The Columbia University Research Pharmacy will perform over-encapsulation of both active drug and placebo to ensure they are identical in appearance.
223535270|NCT06944639|DEVICE|Membrane Jason MB GmbH Non-cross-linked (NCL)|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
223535271|NCT06944639|DEVICE|Membrane BioMend Extend Glutaraldehyde cross-linked|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
223535272|NCT06944639|DEVICE|Membrane OSSIX Agile Ribose cross-linked (RCL)|The membrane will be stabilized in the oral mucosa using sutures and flowable composite.
223913558|NCT06343298|DRUG|MANP|MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
223913559|NCT06343298|OTHER|Placebo Matched control|This is a placebo matched vehicle - Vehicle minus the active ingredient
223913560|NCT06267248|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
223913561|NCT05691530|DRUG|rDENdelta30/31-7164|The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
224087710|NCT05231083|DEVICE|Genital Nerves Stimulation|Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
224087711|NCT00787787|DRUG|sunitinib malate|Given PO
224087712|NCT00787787|DRUG|capecitabine|Given PO
224087713|NCT00177515|BEHAVIORAL|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
224087714|NCT01468987|DRUG|LY2605541|
224087715|NCT01468987|DRUG|Insulin Glargine|
224087716|NCT01468987|DRUG|Insulin Lispro|
224087717|NCT04920773|OTHER|Guduchi Ghanvati|500 mg of Samshamani vati or Giloy Ghanavati (Aqueous extract of Tinospora cordifolia) twice daily
224087718|NCT04920773|OTHER|Standard guidelines|Practice guidelines to follow physical distancing, respiratory and hand hygiene, wear mask
224087719|NCT04210271|BEHAVIORAL|Buddy self-testing condition|
224087720|NCT04210271|BEHAVIORAL|Control self-screening condition|
224087721|NCT02834949|BEHAVIORAL|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
223913562|NCT05519449|BIOLOGICAL|JANX007|JANX007 is dosed via IV in a 21- or 28-day cycle.
223913563|NCT05519449|DRUG|Darolutamide|Darolutamide is dosed via oral tablets
223913564|NCT06074861|PROCEDURE|Fasting-mimicking diet + non-surgical periodontal therapy|Test group will receive a full-mouth non-surgical periodontal therapy (also named professional mechanical plaque removal-PMPR) and, in the same day (starting at morning), a fasting-mimicking diet (FMD) will be started (for a cycle of 5 days). Other two cycles of FMD will be followed at 45- and 85- days after treatment, respectively.
224087722|NCT02834949|BEHAVIORAL|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
224087723|NCT02834949|BEHAVIORAL|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (\~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
224087724|NCT04234737|BEHAVIORAL|Hypnotherapy|Hypnotherapy
224087725|NCT03247621|BEHAVIORAL|Whatsapp|
224087726|NCT03247621|BEHAVIORAL|Article|
224087727|NCT03247621|BEHAVIORAL|No Phone|
224087728|NCT03135249|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
224087729|NCT05032950|DRUG|Midazolam|Midazolam administered as a single dose on Day 1
224087730|NCT05032950|DRUG|PF-07321332/ritonavir + Midazolam|"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"
224087731|NCT05032950|DRUG|Ritonavir + Midazolam|"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"
224087732|NCT03257189|DEVICE|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
224087733|NCT03257189|DEVICE|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
224087734|NCT03257189|DEVICE|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
224087735|NCT03257189|OTHER|Activity classification|Visual annotation of subject posture and other activities used for reference
224087736|NCT02959814|OTHER|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
224087737|NCT00299988|DRUG|Intravenous Immunoglobulin|
224087738|NCT00299988|OTHER|Placebo|
224087739|NCT06296121|DRUG|BCD-264|IV, 16 mg/kg
224087740|NCT06296121|DRUG|Darzalex|IV, 16 mg/kg
224087741|NCT04928183|OTHER|Carbon monoxide rebreathe|Carbon monoxide exposure to increase blood (Carboxyhemoglobin) COHb safely to \~10%
224087742|NCT04928183|DRUG|Sodium Nitroprusside|Bolus Sodium Nitroprusside (SNP) injection for endothelium-independent vasodilation measure
224087743|NCT04928183|DRUG|Phenylephrine Hydrochloride|Bolus Phenylephrine injection for observe α1-mediated vasoconstriction during mild exercise
224087744|NCT00652184|DRUG|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
224087745|NCT00652184|DRUG|placebo|placebo cream and placebo valaciclovir
224087746|NCT00652184|DRUG|valaciclovir|active valaciclovir
223913565|NCT03598712|DEVICE|Compression by chest bandage urgo K2®|"1. \- Installation of a short stretch belt (urgo K2® kit)~2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~3. \- Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
224087747|NCT01699256|BEHAVIORAL|Guideline implementation as usual|Newsletters and Invitation to Meetings
224087748|NCT01699256|BEHAVIORAL|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
224087749|NCT04965740|DRUG|Cannabis|Recreational Cannabis
224087750|NCT02298114|DEVICE|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
224087751|NCT02298114|OTHER|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
224087752|NCT02334150|DRUG|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
224087753|NCT00525577|DRUG|Placebo|Placebo tablet, once daily
224087754|NCT00525577|DRUG|AGI-1067|75 mg AGI-1067 tablet, once daily
224087755|NCT00525577|DRUG|AGI-1067|150 mg AGI-1067 Tablet, once daily
223719424|NCT04920604|OTHER|Remote anesthesia consultation|"Anesthesia consultation is carried out in teleconsultation via the Téléo web application (audio and video) at the patient's home on a computer or smartphone. This application allows sending and receiving documents identical to those during the face-to-face consultation."
223913566|NCT03598712|PROCEDURE|punctures|Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
223913567|NCT05145010|DRUG|Infigratinib|Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
223913568|NCT05145010|DRUG|Infigratinib|Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
223913569|NCT06200207|DRUG|Ziltivekimab|Zilitivekimab will be administered subcutaneously once-monthly.
223913570|NCT06200207|DRUG|Placebo|Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.
223913571|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.1 Usage|Participants will use their Radicle Relief Active Study Product 1.1 as directed for a period of 6 weeks.
223913572|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 1.2 Usage|Participants will use their Radicle Relief Active Study Product 1.2 as directed for a period of 6 weeks.
223913573|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
224087756|NCT00796588|OTHER|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
224087757|NCT01352481|OTHER|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
224087758|NCT00145444|DRUG|olanzapine|
224087759|NCT00145444|DRUG|ziprasidone|
224087760|NCT01322906|OTHER|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
224087761|NCT01322906|OTHER|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
224087762|NCT01322906|OTHER|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
224087763|NCT06353776|PROCEDURE|conjunctival biopsy after micropulse transscleral laser therapy|"During MicroPulse TLT, all patients received periocular anesthesia, with an injection of 5 to 10 ml of Lidocaine (Xylocaine 5mg/ml ®) to achieve complete anesthesia.~The investigators employed the 810 nm Cyclo G6® Laser in its MicroPulse® mode (Iridex Corporation, Mountain View, CA, USA) and delivered laser energy to the eye using the second-generation MicroPulse P3® probe (Iridex Corporation, Mountain View, CA, USA). The laser was calibrated to generate a power output of 2500 mW, and a MicroPulse duty cycle of 31.3%. The curved end of the probe's footplate (bunny ears) was positioned 0.5 to 1 mm away from the corneoscleral limbus, maintaining a perpendicular orientation to the eyeball.~Following the laser therapy, an immediate conjunctival biopsy measuring 2 \* 2 mm and avoiding the laser-treated region was performed."
224087764|NCT03064464|OTHER|None Intervention|It is observational study, no interventios to any of the three study arms
224087765|NCT00354302|DIETARY_SUPPLEMENT|calcium carbonate|
224087766|NCT00354302|DIETARY_SUPPLEMENT|calcium citrate|
224087767|NCT00354302|DIETARY_SUPPLEMENT|cholecalciferol|
224087768|NCT00354302|DRUG|alendronate sodium|
224087769|NCT00354302|DRUG|calcium gluconate|
224087770|NCT00354302|DRUG|risedronate sodium|
224087771|NCT00354302|OTHER|laboratory biomarker analysis|
224087772|NCT00354302|PROCEDURE|dual x-ray absorptometry|
224087773|NCT04706910|DRUG|18F-DOPA|All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
223913574|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 2.1 Usage|Participants will use their Radicle Relief Active Study Product 2.1 as directed for a period of 6 weeks.
223913575|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
223913576|NCT05837923|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
223913577|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.1 Usage|Participants will use their Radicle Relief Active Study Product 3.1 as directed for a period of 6 weeks.
224087774|NCT04706910|DRUG|Furosemide Injection|Some participants will receive an intravenous injection of furosemide (40mg, single dose)
224087775|NCT00570245|DRUG|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
224087776|NCT00570245|DRUG|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
224087777|NCT01245673|BIOLOGICAL|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
224087778|NCT01245673|OTHER|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.
224087779|NCT01245673|DRUG|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
224087780|NCT01245673|BIOLOGICAL|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF \[+ coinjection of 2mg of Hiltonol®(Poly-ICLC)\]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
224087781|NCT05653375|OTHER|Mindfulness-based psychoeducation program|In this study, a mindfulness-based psychoeducation program was applied to the experimental group, 2 times a week for 4 weeks, with a total of 8 sessions, including methods such as meditation, body scanning, mindful eating, and breathing work. Measurement tools were applied to the experimental and control groups before and after the program.
223529866|NCT05512624|BEHAVIORAL|Common Elements Treatment Approach|"For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion."
223529867|NCT00778427|DRUG|metformin hydrochloride 1000 mg tablets|
223529868|NCT02890875|OTHER|Ethanol lock|
223529869|NCT02890875|OTHER|Heparin lock|
223913578|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.2 Usage|Participants will use their Radicle Relief Active Study Product 3.2 as directed for a period of 6 weeks.
223913579|NCT05837923|DIETARY_SUPPLEMENT|Relief Active Study Product 3.3 Usage|Participants will use their Radicle Relief Active Study Product 3.3 as directed for a period of 6 weeks.
223913580|NCT01154582|DIETARY_SUPPLEMENT|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
223913581|NCT01154582|DIETARY_SUPPLEMENT|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
223913582|NCT06053749|DRUG|Avonex (IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
223913583|NCT06053749|DRUG|Rebif (IFNβ-1-a, Merck Europe B.V.)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
223913584|NCT06053749|DRUG|Extavia (IFNβ-1-b, Novartis Europharm Limited)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
223913585|NCT06053749|DRUG|Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
223913586|NCT06053749|DRUG|Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
223913587|NCT06053749|DRUG|MS disease modifying drugs (MSDMDs)|Information on drug use in hospitals and outpatient clinics are not recorded in the drug registers used in the study and, thus, information on exposure to these medications is not available.
224087782|NCT05653375|OTHER|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
224087783|NCT03404648|DRUG|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
224087784|NCT03404648|DRUG|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
224087785|NCT03404648|DEVICE|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
224087786|NCT04452890|DIAGNOSTIC_TEST|Sonourethrography|Ultrasound of the urethra.
224087787|NCT04531384|DEVICE|robot-assisted rehabilitation intelligent treatment|robot-assisted rehabilitation psychotherapy
224087788|NCT04531384|OTHER|standard psychotherapy treatment|standard treatment at the compulsory isolated detoxification centers and non-compulsory isolated detoxification institutions
223913588|NCT02489617|OTHER|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
223913589|NCT06556745|DRUG|BKR-017|BKR-017 is an oral tablet formulation designed to target delivery of sodium butyrate to the colon via colon-targeting technology.
224277932|NCT05966207|BEHAVIORAL|Individual Cognitive Stimulation|"The Individual Cognitive Stimulation will be conducted by caregivers, with support by the research team. The intervention will span 12 weeks, consisting of three weekly sessions (30 minutes each session), totaling 36 sessions. Caregivers in this study will utilize a previously translated and validated version of Making a Difference 3 - Individual Intervention of Cognitive Stimulation - A manual for caregivers, specifically adapted for the European Portuguese population."
223716295|NCT05283213|DIAGNOSTIC_TEST|Early biomarkers of acute kidney injury|"The biomarkers tested will be:~* creatinine levels \[pre-, post-CC, H6\],~* Plasma NGAL \[Pre-, Post-CC, H6\].~* Urinary NGAL \[H6\]~* Plasma cystatin C \[Pre-CC, Post-CEC \& H6\],~* plasma HI \[pre-, post-CC, H6\],~* plasma IL-6 \[post-CC, H6\],~* uremia \[pre-, post-CC, H6\],~* urinary DKK3 \[pre-CC\],~* urinary CCL-14 \[H6\],~* plasma angiopoietin-2 \[H6\],~* plasma PENK-A \[H6\]~These biomarkers will, if necessary, be corrected for hemodilution or dilution of urine, if any, using \[pre-, post-CC, H6\] protein and \[pre-, post-CC, H6\] creatinine, respectively."
223716296|NCT04899869|OTHER|Faecal microbiota transplantation with active study microbiota first|2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
223716297|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota first|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota
223716298|NCT04899869|OTHER|Faecal microbiota transplantation with inactive autoclaved study microbiota only|2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota
223716299|NCT00687466|DRUG|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
223913590|NCT06140498|BEHAVIORAL|Self-Efficacy Training and Ecological Momentary Assessment|Participants receive 3 self-efficacy trainings per day, combined with Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week
223913591|NCT06140498|BEHAVIORAL|Control intervention: Ecological Momentary Assessment only|Participants receive Ecological Momentary Assessments assessing mood, social contacts, and virtual context 3x/day for one week only
223913592|NCT03451799|OTHER|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
223913593|NCT03451799|RADIATION|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
223913594|NCT03451799|DRUG|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
223913595|NCT04138394|DRUG|Ascorbic Acid|Patients will receive intravenous vitamin C (50 mg/kg every 6 hours for 96 hours).
223913596|NCT04138394|DRUG|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
223913597|NCT06497413|DEVICE|Transcranial Photobiomodulation|The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.
223913598|NCT06497413|DEVICE|Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered|In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
223913599|NCT06634849|DRUG|PTT-4256|Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohorts A1-A4 will receive 10mg, 20mg, 40mg \& 80mg. Following review by SRC, Cohort A5 participants will receive 160mg PTT-4256 daily
223913600|NCT04464707|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
223913601|NCT04464707|DRUG|Placebo|Matching placebo
223913602|NCT04917601|BEHAVIORAL|Evira Care treatment|The intervention aim to examine the effectiveness of using a digital support system (Evira) in treatment of childhood obesity. Through daily weighings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored. Participants can be randomized to either the intervention group or the control group. The control group will receive local standard treatment.
223913603|NCT04917601|BEHAVIORAL|Standard Lifestyle Care|The control group will receive the local standard care of treatment addressing lifestyles for childhood obesity without any restriction in visits or clinical support. This is the current standard care of treatment for childhood obesity.
223913604|NCT05477953|DRUG|Nifurtimox (BAYA2502)|At least 1 dose of nifurtimox
223913605|NCT06109779|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous) Q3W
223913606|NCT06109779|DRUG|Placebo|Placebo IV (intravenous) Q3W
223913607|NCT06109779|DRUG|Capecitabine|Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
223913608|NCT06109779|DRUG|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle
223913609|NCT06109779|DRUG|S-1 [Tegafur/Oteracil/gimeracil]|S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
224277933|NCT00857558|DRUG|saxagliptin|orally administration at 1 mg once a day for 12 weeks
224277934|NCT00857558|DRUG|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
224277935|NCT00857558|DRUG|saxagliptin|orally administration at 5 mg once a day for 12 weeks
224277936|NCT00857558|DRUG|placebo|orally administration once a day for 12 weeks
224277937|NCT02185963|DRUG|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
224087789|NCT05204043|OTHER|Peter Hess® sound massage|The Peter Hess® sound massage uses sound vibrations generated by therapeutic singing bowls. Peter Hess' methods act far from a traumatised area, far from the pain. It will be given on the patient's bed for 30 minutes.
223529870|NCT05997329|OTHER|App for diet record (MyFood)|Patients in the intervention group will record their food intake, tube feeding, nutrition-related symptoms and body weight in the MyFood app in at least three consecutive days in advance of follow-up.The patients will thus be able to keep track of their nutrition status. They will also have access to nutrition tips for how to reach requirements if they struggle to eat sufficiently or relief symptoms that can affect food intake.Healthcare staff at the hospital and outpatient clinics will use MyFood to monitor the patient's nutrition and document this information in the electronic patient record. They will also receive decision support tailored to each individual patient, e.g. recommendations for how to use oral nutrition supplements if the patient's intake of energy or protein is too low. Patients who struggle to fulfill their requirements will receive an additional referral to a registered dietitian for nutrition treatment between week 5 and 11.
223529871|NCT00129857|DRUG|Dexanabinol|
223913610|NCT03713268|DEVICE|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
223913611|NCT05348876|DRUG|Darolutamide (Nubeqa, BAY1841788)|600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
223913612|NCT04960241|PROCEDURE|Homebased telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
223913613|NCT04960241|PROCEDURE|Homebased rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
223913614|NCT04960241|PROCEDURE|No physical rehabilitation|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
223913615|NCT06164678|BEHAVIORAL|OMSC|The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.
223913616|NCT06409624|OTHER|No intervention is planned as part of the study|No intervention is planned as part of the study
223913617|NCT05600426|DRUG|cyclosporine|cyclosporine
223913618|NCT05600426|PROCEDURE|Matched Unrelated Donor Hematopoetic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
223913619|NCT05600426|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
223913620|NCT05600426|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
223913621|NCT05600426|DRUG|Methotrexate|methotrexate
223913622|NCT05600426|DRUG|Fludarabine|fludarabine
223913623|NCT05600426|DRUG|Cyclophosphamide|cyclophosphamide
223913624|NCT05600426|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
223913625|NCT05600426|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
223913626|NCT04265950|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
224087790|NCT05204043|OTHER|Music relaxation Music Care®|The patient chooses his music preferences and receive the music relaxation in bed for 30 minutes.
224087791|NCT05204043|OTHER|Questionnaires|"* State Trait Anxiety Inventory (STAI)~* Pain assessment - Visual Analogic Scale (from 0 to 10)."
224087792|NCT01526083|OTHER|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
224087793|NCT01526083|OTHER|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose"
224087794|NCT05533892|DRUG|Nocardia rubra cell wall skeleton|Nocardia rubra cell wall skeleton (N-CWS) 400μg hypodermic injected every 1 week (Q1W) for 4 weeks, following by N-CWS 400μg hypodermic injected every 4 weeks (Q4W)
224087795|NCT05533892|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
224087796|NCT05533892|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
224087797|NCT05533892|DRUG|Tislelizumab|200mg intravenously every 3 weeks
224087798|NCT01929135|DRUG|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
224277938|NCT05467982|BEHAVIORAL|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness. Subsample of 75 will also receive COVID-specific Integrated Illness Management and Recovery module.
224277939|NCT05467982|BEHAVIORAL|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
224277940|NCT02997722|DRUG|Ketamine|IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
224277941|NCT02997722|DRUG|Normal Saline|IV infusion of 100 ml of normal saline over 45 minutes.
223913627|NCT06055036|BEHAVIORAL|Black Impact Intervention|The Black Impact intervention is an academic-community-government partnership adapted from the Diabetes Prevention Program and American Heart Association Check, Change, Control programs based on stakeholder feedback and to afford incorporation of additional evidence-based strategies for influencing target outcomes. The intervention is a 24-week community-based lifestyle intervention to improve cardiovascular health among Black men. Each participant will be assigned to a group with \>5 participants based on participant proximity to a central community meeting location. Each team will be guided weekly by a health coach who delivers content and coaching around the lifestyle intervention modeled on the diabetes prevention program and check, change, control blood pressure program, a community health worker who helps to address social needs and connects participants to primary care services, and a trainer who leads physical activity. Teams meet for 90 minutes per week.
223529872|NCT01814982|DRUG|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
223913628|NCT06469944|BIOLOGICAL|Pembrolizumab|Administered via intravenous (IV) infusion.
223913629|NCT06469944|BIOLOGICAL|Sacituzumab Tirumotecan (sac-TMT)|Administered via IV infusion.
223913630|NCT06469944|DRUG|Capecitabine|Administered via oral tablet.
223913631|NCT06469944|DRUG|Leucovorin|Administered via IV infusion.
223529873|NCT04005300|DIETARY_SUPPLEMENT|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
223913632|NCT06469944|DRUG|Levoleucovorin|Administered via IV infusion.
223529874|NCT04005300|DIETARY_SUPPLEMENT|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
223913633|NCT06469944|DRUG|5-FU|Administered via IV infusion
223529875|NCT05056766|BEHAVIORAL|questionnaires: Epworth Sleepiness Scale; Pichot fatigue questionnaire.|"Each patient will undergo 3 to 7 polygraphy recordings according usual practice of titration At the same time, Self-questionnaires will be conducted by the patient in order to evaluate Oral appliance efficacy.~Optimal titration of oral appliance will be done according subjectives parameters. (sleepeness Reduction and fatigue Reduction).~Neither the investigator nor the patient will know the polygraphy results (apnea-hypopnea index)"
223913634|NCT05562947|DEVICE|PDS With Ranibizumab (100 mg/mL)|Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100-mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.
223913635|NCT05562947|DRUG|Ranibizumab (10 mg/mL)|Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterward, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44.
223913636|NCT03297723|OTHER|Therapeutic education Programm|"Intervention will include:~* an identification of educational needs and expectations,~* a bilateral agreement between patient and medical staff on the priority skills acquirement,~* a structured educational activities tailored to the patient's need.~* the making of an educational record."
223913637|NCT03304314|DIAGNOSTIC_TEST|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
223913638|NCT06465186|COMBINATION_PRODUCT|Efinopegdutide|Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks
223913639|NCT06465186|COMBINATION_PRODUCT|Placebo|Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.
223913640|NCT05832879|BEHAVIORAL|OUD Telehealth Platform|The platform is intended to encourage engagement in treatment with medications for opioid use disorder (MOUD) through a chat dialogue with users
223716300|NCT00329238|DRUG|Dabigatran|Dabigatran 150 mg BID (twice daily)
223716301|NCT00329238|DRUG|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
223716302|NCT02257008|DRUG|BILR 355 BS|
223913641|NCT05361031|BIOLOGICAL|Engensis (VM202)|Intramuscular injections
223913642|NCT03479268|DRUG|Ibrutinib|Given PO
223913643|NCT03479268|OTHER|Laboratory Biomarker Analysis|Correlative studies
223913644|NCT03479268|DRUG|Pevonedistat|Given IV
223913645|NCT03479268|OTHER|Pharmacokinetic Study|Correlative studies
223913646|NCT03479268|OTHER|Pharmacological Study|Correlative studies
223913647|NCT05672251|PROCEDURE|Biopsy|Undergo biopsy
223913648|NCT05672251|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223913649|NCT05672251|PROCEDURE|Computed Tomography|Undergo PET/CT
223913650|NCT05672251|BIOLOGICAL|Loncastuximab Tesirine|Given IV
223913651|NCT05672251|BIOLOGICAL|Mosunetuzumab|Given IV
223913652|NCT05672251|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223913653|NCT04995341|DEVICE|Investigational ultracompact OCT and OCTA system|Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
223913654|NCT04995341|DEVICE|retinal photographs|retinal photographs with a commercial portable bedside widefield fundus camera system
223913655|NCT03116204|OTHER|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
223913656|NCT02168829|DRUG|Rivaroxaban|
223913657|NCT02168829|DRUG|Acetylsalicylic acid|
223913658|NCT05280184|BEHAVIORAL|Coin2Dose|Behavioral Economics incentive intervention that also combines automated text message reminders to dose for insulin
223913659|NCT04437667|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application. Participants will be instructed to engage in a minimum of 10 hours of gameplay over the holiday period each year. The game will automatically collect for analysis data related to participants' in-game behavior, e.g. time spent playing, scores on knowledge-based mini-games, choices made in the narrative game, components to which the player was exposed. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma; and promote parent-child dialogue.
223913660|NCT04437667|BEHAVIORAL|Control Mobile Phone Game|Independent gameplay of control game. Total respondent burden: participants will be invited to engage in at least 10 hours of gameplay during each long school holiday (November-December).
223913661|NCT04183283|DRUG|LY3526318|Administered orally.
223913662|NCT04183283|DRUG|Placebo|Administered orally.
223913663|NCT06287255|BEHAVIORAL|EIM+|The Exercise is Medicine (EIM) program involves a personalized exercise prescription and wellness coaching component. At the first 1:1 session, participants are provided with a Fitbit and onboarded with Fitabase, allowing for documentation of baseline health behaviors. Over the course of the program, the EIM fitness specialist reviews Fitbit data and progress towards goals, sending push notifications for encouragement and reminders. A personal training session is conducted, followed by sixteen group sessions including up to eight participants. The final session includes updating goals, incorporating Fitbits, and providing an updated exercise prescription. Upon program completion, participants will attend monthly webinars and health coaching sessions at 6- and 12-months post-program. The program aims to help individuals overcome barriers and maintain long-term exercise self-efficacy.
223913664|NCT05718817|DRUG|XEN1101|XEN1101 capsules
223913665|NCT01002235|BIOLOGICAL|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
223913666|NCT01424982|DRUG|Cyclophosphamide|Given IV
223913667|NCT01424982|DRUG|Cytarabine|Given IV
223913668|NCT01424982|DRUG|Dexamethasone|Given IV or PO
223913669|NCT01424982|DRUG|Doxorubicin|Given IV
223913670|NCT01424982|DRUG|Doxorubicin Hydrochloride|Given IV
223913671|NCT01424982|OTHER|Laboratory Biomarker Analysis|Correlative studies
223913672|NCT01424982|DRUG|Methotrexate|Given IV
223913673|NCT01424982|DRUG|Ponatinib|Given PO
223913674|NCT01424982|DRUG|Ponatinib Hydrochloride|Given PO
223716303|NCT02257008|OTHER|Grapefruit juice|
223716304|NCT02257008|DRUG|Nelfinavir|
223716305|NCT02257008|DRUG|Atazanavir|
223716306|NCT02257008|DRUG|Ritonavir|
223913675|NCT01424982|DRUG|Prednisone|Given PO
223913676|NCT01424982|BIOLOGICAL|Rituximab|Given IV
223913677|NCT01424982|DRUG|Vincristine|Given IV
223913678|NCT01424982|DRUG|Vincristine Sulfate|Given IV
223913679|NCT05869682|PROCEDURE|Bright White Light Therapy|Wear AYOpro BWL therapy
223913680|NCT05869682|DRUG|Combination Drug Therapy|Receive SOC ADT combination therapy
223913681|NCT05869682|OTHER|Electronic Health Record Review|Ancillary studies
223913682|NCT05869682|OTHER|Quality-of-Life Assessment|Ancillary studies
223913683|NCT05869682|OTHER|Questionnaire Administration|Ancillary studies
223913684|NCT05574127|BEHAVIORAL|Behavioral Activation|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
224087799|NCT01929135|DRUG|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
224087800|NCT02425098|BIOLOGICAL|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
224087801|NCT02425098|BIOLOGICAL|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
224087802|NCT04421690|BEHAVIORAL|Cognitive Training|Participants (n=15) will complete computerized cognitive training games and activities online 3 times/week for 8 weeks.
224087803|NCT04421690|BEHAVIORAL|Trivia Training|Participants (n=15) will receive computerized trivia questions to answer and submit 3 times/week for 8 weeks.
224087804|NCT02887443|DRUG|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
224087805|NCT02887443|DRUG|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
224087806|NCT02078219|DRUG|RDEA3170|Oral Treatment
224087807|NCT02078219|DRUG|Allopurinol|Oral Treatment
224087808|NCT02078219|DRUG|Placebo|Oral Treatment
224087809|NCT05648474|DIAGNOSTIC_TEST|Somatosensory evoked potential [SSEP] intraoperative monitoring|No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
224087810|NCT03919240|BIOLOGICAL|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
223529876|NCT02532101|DIETARY_SUPPLEMENT|Oil Palm Phenolics|Palm fruit derived phenolics compound
223913685|NCT05574127|BEHAVIORAL|Supportive Psychotherapy|"Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks)."
223913686|NCT06169280|BIOLOGICAL|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 1·50 x 10⁸ NSCs loaded with1·875 x viral particles administered intra-tumorally on Day 0 and Day 15, then every 4 weeks for up to 6 total doses.
223913687|NCT06548594|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
223913688|NCT05278234|BEHAVIORAL|STEPS|Participants will initially meet with a community health worker (CHW) for a 1-hour orientation at the participant's home, a Henry Ford Health System site or the University of Michigan Detroit Center, or virtual. The CHW will show participants how to use the web modules. Participants will be given (or mailed) a wearable activity tracker to use throughout the course of the 7-week program. Each week participants will watch a brief video on the STEPS website; they may also be asked to complete handouts in the workbook. They will have a weekly 30-minute telephone session with the CHW. CHWs will review the weekly topic, help participants practice new skills, and set a related goal. CHWs will screen for social needs and make appropriate community referrals. Participants will set walking goals each week, using step-count data from the physical activity tracker. Participants will track daily step counts.
223913689|NCT05699772|BEHAVIORAL|Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)|The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.
224087811|NCT06550362|DRUG|iron sulfate|Oral iron administration
224087812|NCT06320405|BIOLOGICAL|Axatilimab|Given IV
224087813|NCT06320405|PROCEDURE|Biopsy|Undergo tumor biopsy
223529877|NCT03050190|GENETIC|Therapeutic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
223529878|NCT05235204|PROCEDURE|Removal of Foley Catheter 2 to 3 days post Colovesical Fistula (CVF) repair surgery|According to review of internal clinical practices, the average duration of catheterization after Colovesical Fistula (CVF) repair is 10.8 days after CVF repair. The intervention in this study removes the Foley Catheter at 2 to 3 days post CVF repair.
223529879|NCT02521285|DRUG|Aspirin|Given PO
224087814|NCT06320405|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224087815|NCT06320405|PROCEDURE|Computed Tomography|Undergo CT scan
224087816|NCT06320405|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224087817|NCT06320405|DRUG|Paclitaxel|Given IV
224087818|NCT06320405|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224087819|NCT06320405|BIOLOGICAL|Retifanlimab|Given IV
224087820|NCT05646056|DEVICE|Software|Observation only
224087821|NCT05920798|PROCEDURE|Biopsy|Undergo biopsy
224087822|NCT05920798|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224087823|NCT05920798|PROCEDURE|Computed Tomography|Undergo CT
224087824|NCT05920798|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224087825|NCT05920798|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
224087826|NCT05920798|BIOLOGICAL|Pembrolizumab|Given IV
224087827|NCT05920798|PROCEDURE|Pheresis|Undergo apheresis
224277942|NCT00791986|DEVICE|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
224277943|NCT04317638|OTHER|Lipid profile|3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
224277944|NCT02020109|RADIATION|splenic irradiation|
224277945|NCT03509285|DRUG|Alprazolam Placebo|100 mg lactose tablets
224277946|NCT03509285|DRUG|Cenobamate placebo|Sugar pill manufactured to mimic cenobamate 100 mg tablet
224277947|NCT03509285|DRUG|Alprazolam|0.5 mg and 1.0 mg alprazolam tablets
224277948|NCT03509285|DRUG|Cenobamate|100 mg tablet
224277949|NCT05135624|DRUG|SP16 (6mg)|SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
224277950|NCT05135624|OTHER|Placebo|Placebo will be administered as 2 concurrent, separate 2 mL s.c. injections of sterile water
223913690|NCT05699772|BEHAVIORAL|Brain Health Group (BHG)|The BHG was developed by researchers and clinicians at Baylor Scott \& White Institute for Rehabilitation.
223913691|NCT05762211|DRUG|Pooled allogeneic fecal microbiotherapy|Capsule for oral use
223913692|NCT05762211|DRUG|Placebo|Capsule for oral use
224087828|NCT06957392|BEHAVIORAL|Systematic self-help training program for enhancing social reward|"Based on previous research, this study has made significant innovations and optimizations within the traditional framework of Acceptance and Commitment Therapy (ACT). We have specifically developed a systematic self-help training module aimed at enhancing social reward, which includes components such as social scenario experience, social skills training, and the improvement of social reward sensitivity.~A single-blind randomized controlled trial will be conducted, dividing IGD participants into two groups. The SRI group (Social Reward Intervention group) will receive a psychological self-help training program designed to improve social reward, while the other (Control group) will receive a course introducing general knowledge about Internet Gaming Disorder. Both groups will have identical learning durations and modalities. The self-help training consists of 8 sessions, delivered twice weekly through a blended online and offline learning format, lasting approximately one month."
224087829|NCT06957392|BEHAVIORAL|general knowledge about Internet Gaming Disorder .|"A single-blind randomized controlled trial is conducted. 30 people, assigned to Control group, was provided with standard educational courses introducing general knowledge about Internet Gaming Disorder. Assessments including standardized scales, behavioral tests, and neuroimaging are conducted once before and once after the intervention.~During the course, participants will receive twice-weekly online guidance sessions totaling eight sessions. The entire intervention lasts approximately one month, with follow-up assessments conducted at 3, 6, and 12 months post-intervention."
224087830|NCT02750670|DRUG|Obinutuzumab|Type II anti-CD20 monoclonal antibody
224087831|NCT02750670|DRUG|Gemcitabine|Antineoplastic agent
224087832|NCT02750670|DRUG|Dexamethasone|Corticosteroid
224087833|NCT02750670|DRUG|Cisplatin|Antineoplastic Agent
224087834|NCT00881660|DEVICE|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
224087835|NCT03099733|OTHER|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
224087836|NCT04714372|DRUG|Daratumumab/rHuPH20|Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
224087837|NCT04714372|DRUG|FT538|FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
224087838|NCT04714372|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
224087839|NCT04714372|DRUG|Cyclophosphamide|Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
224087840|NCT01938157|PROCEDURE|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
224087841|NCT01116050|DRUG|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
224087842|NCT01116050|DRUG|Placebo|5 tablets in opque introducer
224087843|NCT01334398|BEHAVIORAL|Health & Wellness|"The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment."
224087844|NCT02126059|BEHAVIORAL|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
224087845|NCT02126059|BEHAVIORAL|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
223913693|NCT05460780|DEVICE|MATTISSE TEC|Tissue engineering chamber MATTISSE
223913694|NCT06805955|OTHER|NDT|"The neurodevelopmental therapy program aimed to reduce muscle tone, improve hand functions, enhance fine motor skills, and support daily living activities such as eating and personal care.~Specific exercises included:~Finger and wrist flexion/extension, Shoulder and elbow stretching and mobilization, PNF exercises, Functional tasks like screw and nut manipulation, Velcro tasks, door handle turning, button pressing, zipper pulling, and laundry peg placement/removal."
223529880|NCT02521285|OTHER|Laboratory Biomarker Analysis|Correlative studies
223529881|NCT02521285|OTHER|Placebo Administration|Given PO
223529882|NCT02521285|OTHER|Questionnaire Administration|Ancillary studies
223529883|NCT01424553|OTHER|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
223529884|NCT00317122|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
223913695|NCT06805955|OTHER|NDT+Hand Robot|"In this group, participants received 25 minutes of hand robot-assisted therapy following neurodevelopmental treatment. After the robot therapy, they performed fine motor skill exercises, including:~Picking up buttons from one container and placing them in another, Opening a loosely closed jar lid using the robot, Stacking checkers pieces on a table, Flipping over and placing cards back on the table, Transferring weighted cubes from one table to another at a different height. These activities aimed to improve fine motor coordination and hand functionality."
223913696|NCT06804434|DRUG|Lidocaine Intravenous Infusion|intravenous lidocaine 10 mg/ml continuous infusion
223913697|NCT06804434|DEVICE|NOL|Intraoperative Nociception Level index monitoring and guided analgesia
223913698|NCT03989141|PROCEDURE|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
223913699|NCT03989141|PROCEDURE|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
223913700|NCT00560651|PROCEDURE|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
223913701|NCT06805760|OTHER|variable tidal volume ventilation (V-VCV)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW).The maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) were set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiratory to Expiratory Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, and Inhaled Oxygen Concentration (FiO2) 41%.
223913702|NCT06805760|OTHER|pressure-regulated volume-controlled ventilation (PRVC)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW), the upper limit of peak inspiratory pressure was 30 cmH2O, the maximum tidal volume (Vt\_max) and the minimum tidal volume (Vt\_min) was set at 10-20% of the base tidal volume (Vt\_base). Respiratory Rate is 12, Inspiration to Expiration Ratio is 1:2, Positive End-Expiratory Pressure (PEEP) is 5cmH2O, and Inhaled Oxygen Concentration (FiO2) is 98%.
223913703|NCT06805760|OTHER|conventional volume-controlled ventilation (C-VCV)|The initial tidal volume was set at 6-8 ml/kg IBW according to the Ideal Body Weight (IBW).The maximum tidal volume (Vt\_max) and minimum tidal volume (Vt\_min) were set at 10-20% of the basal tidal volume (Vt\_base). Respiratory Rate 12. Inspiratory Flow Rate (IFR) 60L/min, Inspiratory to Expiratory Ratio (IER) 1:2, Positive End-Expiratory Pressure (PEEP) 5cm water column, and Inhaled Oxygen Concentration (FiO2) 98%.
223913704|NCT06805760|OTHER|pressure-controlled ventilation (PCV)|The inspiratory pressure level is set, usually with an initial value of 20 cmH2O, a respiratory rate of 12, an inspiratory/expiratory ratio of 1:2, a positive end-expiratory pressure (PEEP) of 5 cm water column, and an inspired oxygen concentration (FiO2) of 98%.
223913705|NCT06804525|DIAGNOSTIC_TEST|CIDI-5|The World Health Organization Composite International Diagnostic Interview-5th (CIDI-5) is a standardized diagnostic tool used to assess the prevalence of mental and substance use disorders over varying time frames (30 days, 12 months, and lifetime) based on the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and International Classification of Diseases 10th edition (ICD-10) . Trained interviewers will administrate selected modules from the Hong Kong version of the CIDI-5 in a computer-assisted personal interview to measure the outcomes.
224087846|NCT02126059|BEHAVIORAL|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
224087847|NCT03069651|OTHER|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
224087848|NCT03592459|DEVICE|Macy Catheter|Undergo placement of Macy catheter
224087849|NCT03592459|PROCEDURE|Pain Therapy|Receive opioids via Macy catheter
224087850|NCT03592459|OTHER|Questionnaire Administration|Ancillary studies
224087851|NCT03592459|OTHER|Survey Administration|Ancillary studies
224087852|NCT00127127|DRUG|vorinostat|vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration
224087853|NCT00482963|DRUG|levonorgestrel, efavirenz|
224087854|NCT05896345|DEVICE|SWL|Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone
224087855|NCT05896345|COMBINATION_PRODUCT|SWL and ODT|Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone
224087856|NCT04693871|DEVICE|Transesophageal ultrasound|Patients with nonvalvular atrial fibrillation underwent radiofrequency ablation combined with left atrial appendage closure and recovered to sinus rhythm after the operation. To study the changes of left atrial organization and function of two groups of patients with different left atrial appendage emptying speeds.
224087857|NCT01401569|BEHAVIORAL|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
224087858|NCT05651646|OTHER|Intervention Arm (STIMFIX)|This is a single-arm prospective multicenter clinical study recruiting 50 subjects who are already undergoing a spinal cord stimulator trial for chronic back pain secondary to failed back surgical syndrome. Each patient who is recruited for spinal cord stimulator trial for their low back pain is informed about the traditional method of managing the leads and the trail lead anchoring system. If the patient agrees for the Stimfix trail lead anchoring clips StimfixTM, then informed consent is taken for anchoring clips usage during the spinal cord stimulator trail.
224087859|NCT05217914|DRUG|Copanlisib (BAY80-6946)|Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
224087860|NCT04575948|DRUG|Moringa Oleifera|Non toxic Moringa extract with antibacterial and antiplaque effect will be used
224087861|NCT04575948|DRUG|Chlorhexidine mouthwash|Commercial 0.12% chlorhexidine digluconate mouthwash twice daily (each morning and before bedtime during the 21-day study period) after intake of food. The patient will be asked to use 15 ml of mouthwash swish it for 60 sec. then expectorate.
224087862|NCT04575948|DRUG|Base formula|Base formula is a negative control
224087863|NCT00585234|OTHER|Digital Photography|Digital Photography
224087864|NCT04363333|DIAGNOSTIC_TEST|Home Sleep Apnea Testing or In-hospital Polysomnography|Home Sleep Apnea Testing or In-hospital Polysomnography will be conducted 4 to 6 months after the Covid-19 diagnosis
224087865|NCT02780076|OTHER|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
224087866|NCT05486403|BEHAVIORAL|Appetite Toolbox Programme|Preschool educators are trained to deliver a bio-behavioural classroom-based programme focusing on building skills in i) appetite awareness, ii) attention/attention control and iii) sensing body cues. The programme is delivered using a combination of interactive story books, classroom props and activities, and mealtime transitions/routines.
224087867|NCT04239846|DRUG|AC-701 Topical Gel 0.3%|AC-701 Topical Gel 0.3%, BID
224087868|NCT04239846|OTHER|Placebo Gel|Placebo Gel, BID
224087869|NCT00102310|DRUG|YM443|
224087870|NCT01239407|BEHAVIORAL|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2\. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3\. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
224087871|NCT03009604|DRUG|Simethicone|Simethicone 40mg oral tablets
224087872|NCT03009604|DRUG|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
224087873|NCT03656965|DRUG|Acyclovir 800 MG|Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
223716307|NCT02528929|DIETARY_SUPPLEMENT|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
224087874|NCT03656965|COMBINATION_PRODUCT|Radiotherapy and chemotherapy|Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
224087875|NCT04047888|OTHER|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
224087876|NCT04047888|OTHER|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
224087877|NCT02684071|DRUG|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
224087878|NCT02684071|DRUG|topotecan|To be administered in conjunction with methotrexate
224087879|NCT02684071|DRUG|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
224087880|NCT02221089|DRUG|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
224087881|NCT02221089|DIETARY_SUPPLEMENT|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
224087882|NCT02221089|OTHER|Placebo|Placebo capsules identical in appearance to Retaron capsules
224087883|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
224087884|NCT01805180|DEVICE|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
224087885|NCT01258920|DRUG|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
224087886|NCT02933918|OTHER|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
223529885|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with propofol|Incremental administration of propofol up to a cummulative full therapeutic dose (2mg/kg) in POH patients investigated for propofol. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.02mg/kg-0.2 mg/kg -0.6 mg/kg -1.2mg/kg).
224087887|NCT03631927|OTHER|Observation|Observation
224087888|NCT05779085|OTHER|Dermocosmetic|Use of daily cleanser to treat facial acne
224087889|NCT04899635|OTHER|In-vitro contractile fatigue protocol|Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
224087890|NCT05739773|OTHER|five-element music therapy|music therapy
224087891|NCT02427282|DEVICE|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
224087892|NCT02427282|DEVICE|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
224087893|NCT05494307|DRUG|Terbutaline|Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks
223529886|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with ketamine|Incremental administration of ketamine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for ketamine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mg/kg -0.1 mg/kg -0.3 mg/kg -0.6mg/kg).
223529887|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with etomidate|Incremental administration of etomidate up to a cummulative full therapeutic dose (0.2mg/kg) in POH patients investigated for etomidate. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.002 mg/kg -0.02 mg/kg -0.06 mg/kg -1.2mg/kg).
223913706|NCT06804525|DIAGNOSTIC_TEST|LHC-CIDI-5|The interviewer will start by asking the respondent's age and significant personal experiences, which is expected to take 15 minutes. Remembering and recording the experiences provide cognitive engagement and information which can further serve as memory cues for respondents in the following screening of CIDI-5. Subsequently, the respondents will proceed to the screening section for CIDI-5 and will refer to the completed calendar from the LHC section when they are asked to report lifetime experience or age-of-onset for mental disorders. Trained interviewers will conduct all interviews in a computer-assisted personal interview. To validate the diagnoses in the LHC-CIDI-5 group, clinical re-interviews for MDD, GAD, and PTSD will be conducted by a trained mental health professional with previous experience using DSM-5.
224087894|NCT05494307|DRUG|Danazol|Orally danazol at a dose of 200 mg twice daily for 16 weeks
224087895|NCT00398112|DRUG|sunitinib malate|Given orally
223913707|NCT06804954|BEHAVIORAL|Online transdiagnostic CBT|This treatment is provided through a secure web platform in which psychoeducation, worksheets, and exercises are presented in online modules similar to chapters in a book. Participants will receive weekly written feedback on their work and progress by a therapist who gives gradual access to the treatment modules. The lion's share of the contact between the therapist and the patient thus takes place through messages (similar to email) in the online treatment platform. It is however allowed to also have one to three face-to-face sessions on-site or through video calls to provide technical assistance and therapeutic support in accordance with the treatment model. Core components are: (a) psychoeducation about emotions and CBT, (b) functional analysis, (c) mindfulness practice, (d) breaking dysfunctional emotion-driven behaviors, and (e) exposure exercises.
224087896|NCT00398112|OTHER|pharmacological study|Correlative studies
224087897|NCT00398112|OTHER|laboratory biomarker analysis|Correlative studies
224087898|NCT05148884|DRUG|NLX-112|NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
224087899|NCT05148884|DRUG|Placebo|Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
224087900|NCT04963478|OTHER|exercise|exercise testing
224087901|NCT01823809|DEVICE|adenosine stress Cardiac Magnetic Resonance Imaging|
224087902|NCT00365989|DEVICE|ExAblate Enhanced Sonication|
224087903|NCT00806221|DRUG|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
224087904|NCT03606382|DIAGNOSTIC_TEST|HostDx Fever Test|HostDx Fever test to distinguish between viral and bacterial infections
224087905|NCT03606382|DIAGNOSTIC_TEST|HostDx Sepsis Test|HostDx Fever test to determine the severity of a presented, suspected infection.
224087906|NCT05028803|DRUG|sodium phenylbutyrate|same as arm/group
224087907|NCT06329934|BEHAVIORAL|Establishment of a hierarchical monitoring and management team|To be specific, the head nurse served as the team leader to conduct comprehensive macro supervision; moreover, there were 3 responsible team leaders and 6 responsible nurses, all of whom had rich clinical nursing experience and solid theoretical knowledge of pressure injury. Consequently, a joint-action mechanism of the head nurse - responsible team leader - responsible nurses was developed to facilitate the unification of the training of nursing content, precautions, etc.
224087908|NCT06329934|BEHAVIORAL|Assessment of pressure injury|Based on the postoperative coma of patients, the Braden assessment scale was applied to effectively evaluate patients from six dimensions of sensory perception, moisture, activity mode, mobility, nutrition, friction, and shear. The total score was 23 points. Patients scoring 13\~14 points were evaluated by Braden once per week; and those scoring ≤12 points were evaluated at a frequency of 3d/ time.
224087909|NCT06329934|BEHAVIORAL|Communication|Through intensive face-to-face communication with family members, timely information on the surgical effect, mechanism of pressure injury, preventive measures, and clinical manifestations through intuitive methods such as PPT and video, family members were taught with basic knowledge of pressure injury, and guided to inform medical staff in a timely manner when patients had symptoms of pressure ulcer. Simultaneously, by case sharing and positive suggestions, family members were supported to alleviate their concerns and improve their coordination with treatment
224087910|NCT06329934|BEHAVIORAL|Intervention for pressure ulcer|For patients with a Braden score of \>14 points, attention should be paid to keeping skin dry and clean, regularly changing bed sheets and bedding (once per day). Patients with Braden score of 13-14 points should be provided with sponge mattresses, increased times of turning over once per 2 hours, and soft pillows or foam dressings at the site of occipital protuberance to relieve pressure and prevent pressure injury. For patients with Braden score ≤12 points, medical staff should repeatedly emphasize to their families the harm of pressure injury to postoperative recovery.
224087911|NCT06329934|BEHAVIORAL|Rehabilitation training|After regaining consciousness with stable vital signs, patients received rehabilitation training following the principle of association of activity and inertia in a regular order. Patients were guided to perform upper limb movements, joint flexion, lower limb flexion and extension, as well as daily training such as washing face, rinsing mouth, and dressing at a frequency of 3\~4 times/d. Moreover, patients were advised to minimize violent behaviors such as laughing and talking loudly
224087912|NCT06329934|BEHAVIORAL|introduction of the current patient's condition to family members|timely introduction of the current patient's condition to family members to alleviate their concerns
224087913|NCT06329934|BEHAVIORAL|maintaining appropriate temperature and humidity in the ward|maintaining appropriate temperature (20 ℃\~22 ℃) and humidity (60.0%\~70.0%) in the ward
224277951|NCT05135624|DRUG|SP16 (12 mg)|SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
223716308|NCT05845151|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET|Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.
224277952|NCT02203578|DRUG|romidepsin|Given IV
224277953|NCT02203578|OTHER|laboratory biomarker analysis|Correlative studies
224277954|NCT05252247|OTHER|Immobilisation|Eight hours prior to attending the immobilisation session, a splint will be fitted to the hand of the participant and remain until the session start.
223716309|NCT03558698|OTHER|Good ventilation|Good ventilation with a low concentration of CO2
223716310|NCT03558698|OTHER|Ventilation CO2|CO2 High and Good ventilation
223913708|NCT06804954|OTHER|Primary care as usual|It is mandatory for primary care services in Stockholm, Sweden, to have staff with adequate competence in the assessment and treatment of common mental disorders. Typically, these patients are handled by general practitioners, psychologists, nurses, or social workers. As this comparator is intended to reflect real routine primary care, the interventions will not be controlled by the research project. We expect that participants allocated to this condition will receive an active treatment.
223913709|NCT05624489|BEHAVIORAL|Engagement Strategies|The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
223913710|NCT06852950|DEVICE|Libre 3 Plus Continuous Glucose Monitor|Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
223913711|NCT06852950|DEVICE|Dexcom G7 Continuous Glucose Monitor|Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
223913712|NCT03904979|OTHER|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
223913713|NCT06207513|PROCEDURE|Suction Circuit Flushing with Chlorhexidine|Patient intubated with an endotracheal tube and on a mechanical ventilator will receive endotracheal suctioning procedure using an open endotracheal suction catheter that is used multiple times during a 12-hour nursing shift. Flushing of the suctioning circuit will be performed with 40 ml of chlorhexidine gluconate 0.2% after every endotracheal suction procedure
223913714|NCT06573203|DEVICE|Non-contact heart rate and respiratory rate monitoring system|Each neonate enrolled underwent four sleep and vital signs monitoring procedures after admission.
223913715|NCT06573203|DEVICE|Mindray ECG monitor|Heart rate and respiratory rate of each enrolled child were monitored after admission.
224087914|NCT06329934|BEHAVIORAL|careful observation of vital signs in patients|careful observation of vital signs such as heart rate, blood oxygen saturation, and blood pressure in patients
224087915|NCT00851903|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
224087916|NCT00851903|DRUG|Sitagliptin|Oral administration. 100mg film-coated tablets.
224087917|NCT00851903|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
224087918|NCT03642184|DRUG|Empagliflozin|Dosage adjustment based on glucose targets . Once daily
223913716|NCT06573203|DEVICE|aEEG|Each enrolled child underwent a 6-hour sleep-wake cycle, quiet sleep, and active sleep monitoring after admission.
223913717|NCT06573203|OTHER|Neonatal Sleep-Wake Assessment Tool (NSWAT) included four dimensions: eye movement, respiratory rate, facial expression and muscle activity.|The study nurses observed and scored the children's sleep-wake status 10 minutes after two meals during the mattress test period, each time for 5 minutes.
223913718|NCT06644300|DRUG|BM230|SC injection
223913719|NCT06644300|DRUG|BM230|SC injection
224087919|NCT03642184|DRUG|Linagliptin|Dosage adjustment based on glucose targets. Once daily
224087920|NCT04792866|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Comparing 3D FLAIR versus Coronal T2-WI MRI in detecting Optic Neuritis
224087921|NCT03960528|PROCEDURE|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
224087922|NCT03960528|PROCEDURE|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
224087923|NCT02318095|DRUG|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
224087924|NCT02318095|RADIATION|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
224277955|NCT05252247|OTHER|Exercise|Eight hours prior to attending the exercise session, the participant will be instructed to perform 150 ballistic finger movements every hour until the session start.
224277956|NCT06599138|DEVICE|Ultrasound-guided maxillary nerve block|Suprazygomatic approach, ultrasound-guided infrazygomatic window, maxillary nerve block for injection of 2 - 5 ml of contrast
223716311|NCT03558698|OTHER|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
223913720|NCT03550170|BEHAVIORAL|Teleconference|This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
224087925|NCT02318095|OTHER|Sugical resection|Surgical resection of the pancreas post radiation therapy
224087926|NCT02318095|DRUG|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
224087927|NCT03817671|OTHER|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
224087928|NCT03817671|OTHER|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
224087929|NCT00686127|DRUG|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
224087930|NCT00686127|DRUG|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
224087931|NCT04271462|OTHER|Comparing two CO2 absorbers in the ventilator circuit|"General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow."
224087932|NCT04275700|PROCEDURE|A-PRP|The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
223716312|NCT03385005|DEVICE|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
223913721|NCT03550170|BEHAVIORAL|Internet|The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
223913722|NCT03550170|BEHAVIORAL|1-to-1, in-person or videoconference|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
223913723|NCT06369142|DEVICE|Intravascular lithotripsy (IVL)|Intravascular lithotripsy (IVL) and ballons with a nominal rated burst pressure of ≤ 18 atm
223913724|NCT06369142|DEVICE|Standard non-IVL methods|Standard non-IVL methods treating severely calcified lesions such as special high, super high and cutting balloons and ablative procedures
223913725|NCT06090279|DEVICE|OmniFlow Breathing Therapy BioFeeback System|FDA approved healthcare gaming system that is used for patients who have difficulty breathing and allows the patients to participate in breathing exercises for pulmonary rehab. Each game usage itself is expected to last 15-20 minutes.
223913726|NCT01775085|BEHAVIORAL|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.
223913727|NCT01775085|BEHAVIORAL|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
223913728|NCT06806956|DRUG|Treatment of severe malaria with rectal artesunate + Artemisinin based Combination Therapy is not inferior to rectal artesunate + injectable artesunate + ACT in terms of effectiveness in remote areas|The Community Health Worker will give rectal artesunate (RAS) +artemisinin based combination Therapy (ACT) to children aged 6 months to less than or equal to 5 years who fail to make the referral trip. Those who make the referral trip will receive injectable artesunate and artemisinin based Combination Therapy for three days. Giving of RAS +ACT is unique to this study. Children with non malaria severe disease will also receive amoxicillin from the community health worker before they are referred to the next level of care
223913729|NCT06261749|OTHER|Voluntary Abdominal Contractions|Abdominal contraction will be taught before exercise. They will be instructed to tighten their abdomen as if they were wearing tight pants and not to hold their breath. The visual biofeedback unit will be placed between the therapy table and the participant's abdominal area and will be used to monitor the contraction of the abdominal muscles. The visual biofeedback inelastic bag will be inflated to 70 mmHg and the participant will be instructed to draw the abdomen in and maintain the position. The participant will be asked to maintain a pressure of 60 mmHg during scapular retraction with visual feedback from an analog pressure gauge. Pressure changes of ± 5 mmHg due to breathing will be allowed. During exercise, the patient will be asked to perform the exercises while maintaining the pressure on the visual biofeedback.
223913730|NCT06261749|OTHER|Exercise|"Exercises;~1. Scapular retraction with arms next to the trunk~2. Scapular retraction with arms abducted at 45 degrees,~3. Scapular retraction with arms 90 degrees abducted,~4. Scapular retraction exercises with arms 120 degrees abducted The exercises will be performed with the shoulder head off the bed. The exercises will be repeated 3 times with 5 seconds rest between repetitions. To reduce the effect of fatigue, 2 minutes rest will be given between exercises. Each exercise will be performed with 3 seconds of concentric, 3 seconds of isometric and 3 seconds of eccentric contraction and muscle activation of UT-LT and SA muscles will be measured during these phases."
223913731|NCT04999111|BIOLOGICAL|Ad26.COV2.S|Participants will receive IM injection of Ad26.COV2.S.
224277957|NCT00899535|GENETIC|DNA analysis|
224277958|NCT00899535|GENETIC|RNA analysis|
224277959|NCT00899535|GENETIC|microarray analysis|
224277960|NCT00899535|GENETIC|mutation analysis|
224277961|NCT00899535|GENETIC|polymorphism analysis|
224277962|NCT00591760|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
224277963|NCT03367780|DEVICE|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
223716313|NCT05370170|BEHAVIORAL|Acupressure and nutritional advices|Teaching using booklets and application of acupressure
223913732|NCT04715685|BEHAVIORAL|40 minute session|The 40 minute session will include all of the content contained in the 20 minute session, but will include a greater explanation of each of the mind and body skills, followed by in vivo practice of each skill with the nurse. Sessions will also include review of home practice for each group.
224087933|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
224087934|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
224087935|NCT02300129|DRUG|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
224087936|NCT02300129|DRUG|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
224087937|NCT06553833|BIOLOGICAL|Allogeneic transfusion|Anemia is treated by administering donor red cells, and bleeding or coagulopathy by plasma, platelets or other donor blood products.
224087938|NCT06553833|OTHER|Patient Blood Management|PBM is a strategy to manage the participants own blood. Its focus is on anemia, bleeding and coagulation management (using predominantly pharmaceutical and technological means).
224087939|NCT05304962|DRUG|RGT-419B|oral capsules
224087940|NCT05304962|DRUG|RGT-419B in combination with hormonal therapy|RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
224087941|NCT05632237|BEHAVIORAL|Family strengthening program|"Phase I: 2-day Family Strengthening Workshop. The specific topics included in the workshop include: emotions, Body Progressive Muscle Relaxation, body stretch, self care, apologizing, routines to promote attachment, teamwork, saving, delayed gratification, anticipating unexpected expenses, identifying family strengths and values.~Phase II: Case management with family strengthening curriculum. Curriculum is delivered over the course of four visits (about 3 months), some of which involve both caregiver and child while others are just for the caregiver. Topics included are using appropriate discipline, effective communication for family problem-solving, and home budgeting."
224087942|NCT06131294|DEVICE|Fluoride Application (Experimental Fluoride Application)|Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
224087943|NCT06131294|DEVICE|Fluor Protector S|Fluor Protector S is applied on white spot lesions.
224087944|NCT02208960|DEVICE|Neonatal Kit|"Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket\_size.html) in a fitted cloth pouch.~7. Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
224087945|NCT02208960|BEHAVIORAL|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~1. Eye contact and talking to children~2. Responsive feeding and caregiving~3. Singing songs, including those with gentle touch"
224087946|NCT04665557|BEHAVIORAL|Dove Confident Me Indonesia Single Session|"Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform."
223716314|NCT05298709|OTHER|Hyperventilation and CO2 challenge|Subjects will also be asked to complete hyperventilation and CO2 breathing tasks based on instruction from the study investigators as described in study arm.
223716315|NCT02903680|DRUG|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
223716316|NCT02903680|DRUG|Placebo group|Normal Saline 0,9% same volume
223913733|NCT04715685|BEHAVIORAL|20 minute session|For participants randomized to the 20 minute session, content will include pain education, followed by brief explanations of each of the mind and body skills, in vivo diaphragmatic breathing practice and demonstration of use of biofeedback card. Sessions will also include review of home practice for each group.
223913734|NCT04715685|BEHAVIORAL|home practice e-health|Participants will be provided and instructed on access to a migraine-specific interactive web portal, Migraine e-Health. This web-based tool actively guides participants in practicing evidence-based mind and body skills. Use of the Migraine -e-Health application for the high dose capitalizes on teaching participants mind and body skills while increasing accessibility due to implementation on mobile devices.
223913735|NCT04715685|BEHAVIORAL|home practice handout|Participants will be given a handout of commercially available free apps relevant to the mind body skills introduced.
223913736|NCT04715685|BEHAVIORAL|phone call|The dose of phone call will occur about 4 weeks following the face-to-face mind and body introduction session and will last approximately 5-10 minutes. The phone call will be used to promote adherence to home-practice and answer questions related to skill use/home practice completion.
224087947|NCT04396977|PROCEDURE|Histamine 10 mg/ml skin prick|Skin prick through 5 µL histamine diHCl (10 mg/ml)
224087948|NCT04396977|PROCEDURE|Placebo (saline) skin prick|Skin prick through 5 µL saline (0.9% NaCl)
224087949|NCT00522392|DRUG|bortezomib|Given IV
224087950|NCT00522392|DRUG|lenalidomide|Given PO
224087951|NCT00522392|DRUG|dexamethasone|Given PO
224087952|NCT02479789|DRUG|Lidocaine|
224087953|NCT02479789|DRUG|Placebo|
224087954|NCT00140803|DRUG|Visudyne|
224087955|NCT00140803|DRUG|Kenalog|
224087956|NCT04891237|BIOLOGICAL|10,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
224087957|NCT04891237|BIOLOGICAL|30,000 MG01 + 10,000 T517|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
224087958|NCT04891237|OTHER|Placebo|The same solution and presentation as the active treatment, but without active ingredients
223716317|NCT05154396|DRUG|Neratinib|Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
223716318|NCT06072898|DRUG|Psilocybin|Psilocybin (\[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate), 25mg PO.
223716319|NCT06072898|OTHER|Microcrystalline cellulose|MCC (excipient), 25mg PO.
224087959|NCT02154594|DRUG|Acacia catechu|
224087960|NCT02154594|DRUG|Chlorhexidine gluconate|
224087961|NCT02154594|OTHER|Distilled water|
224087962|NCT06959940|OTHER|experimental group (gum group)|"After the pregnant woman in the experimental group was admitted to the delivery room, the data collection tools Personal Information Form and Pregnant Follow-up Form were applied. Pregnant women who agreed to participate in the study were given information about chewing gum. Pain, anxiety, fatigue and thirst scales were administered to the pregnant woman before she started chewing gum. The pregnant woman was allowed to chew gum for 15 minutes. At the end of 15 minutes, the measurements were repeated. Applications were repeated as stated above every two hours until the pregnant woman's dilation reached 5 cm. Routine medical treatment of pregnant women continued."
224087963|NCT06961019|OTHER|Sugar support effervescent Tablets|"Dissolve one effervescent tablet in a full glass of water (approximately 200 mL). Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation.~Frequency: Twice a day before the meal Route of Administration: Oral"
224087964|NCT06960369|COMBINATION_PRODUCT|rTMS combined with Live Probiotic tablet|rTMS group received 1 Hz/s, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week.
224087965|NCT06960369|DEVICE|rTMS combined placebo|rTMS group received 1 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
224087966|NCT06960369|DRUG|shamrTMS combined with Live Probiotic tablet|Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz/s, 20 min for 2 week.
224087967|NCT06960369|OTHER|shamrTMS combined placebo group|shamrTMS group received 0 Hz/s, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week.
223716320|NCT06072898|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy in the form of reassurance, integration, and de-escalatory techniques (if needed). Facilitating rapport and a positive environment.
223913737|NCT06346041|BIOLOGICAL|Oncolytic Virus injection(IDOV-SAFETM)|Administered by intravenous injection as single agent.
223913738|NCT04806841|BEHAVIORAL|Motivational intervention|Three group meeting of 60 minutes to help create effective goals and methods on maintaining motivation to exercise regularly. These meetings will help participants create effective goals and methods on maintaining their motivation to exercise regularly. They will then receive a monthly phone call follow-up at months 4-6.
224087968|NCT06960850|DRUG|Propranolol|A set of 154 numbers will receive oxytocin and propranolol once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
224087969|NCT06960850|OTHER|Placebo|A set of 154 numbers will receive oxytocin and placebo once or twice 6 hours apart. the first dose will be from 10 minutes before commencement of oxytocin titration and the second dose will be 6 hours from the first dose if delivery has not taken place.
224087970|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224087971|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
223913739|NCT04806841|OTHER|Control intervention|Participants in the control group will be simply encouraged to exercise at the EPIC center and complete the online surveys. Participants in the control group will receive the skills/tactics at the end of the study.
223913740|NCT04600544|OTHER|Non-interventional|Translational, observational study
223913741|NCT00950638|DRUG|Avacincaptad Pegol|intravitreal injection
223913742|NCT05476900|DRUG|HR19042 Capsules|HR19042 Capsules
224087972|NCT06961409|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224087973|NCT06960499|OTHER|Surveys|No intervention will be carried out in this study; the recruited patients will only complete the questionnaires provided below
224087974|NCT06960109|BEHAVIORAL|A Mindfulness-Based Stress Reduction Program for Pregnant Women with Gestational Diabetes|The Gestational diabetes mellitus(GDM) pregnant women in the intervention group who agreed to participate in the study and completed the pre-test were invited to the WhatsApp group created by the researcher. 3 separate groups were created with a maximum of 11 participants in each group. The days (for example; Group 1: Tuesday, Saturday) on which the program, which will continue for 4 weeks, will be implemented were determined, considering the participants in each group and the times they were available. For each group, the conscious awareness-based stress reduction program for pregnant women with GDM; For 4 weeks, there were 8 sessions, 2 sessions per week, with each session varying in duration, for an average of 45-60 minutes. The program was carried out using the Google Meet application created online by the researcher, and the connection details were shared with the participants via WhatsApp groups. In the implementation of the mindfulness-based stress reduction program for pregnant
224087975|NCT06961188|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nanocrystalline Megestrol Acetate Oral Suspension + Standard Therapy Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 12 weeks (maximum treatment duration: 12 weeks), whichever occurred first.
224087976|NCT06961188|OTHER|Standard Therapy|Standard Therapy
223716321|NCT04090424|DEVICE|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
223913743|NCT06579677|OTHER|Without any intervention|No interventions will be performed.
223913744|NCT06651502|DEVICE|dental implant placement and immediate provisionalization|dental implant placement and immediate temporization
223913745|NCT05611775|DEVICE|Triaxial accelerometer|Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
223913746|NCT05903274|DRUG|JSP191|Subjects will receive intravenous JSP191
223913747|NCT06101277|DEVICE|Ablative local therapy|Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
223913748|NCT04191057|OTHER|Free light chains|Blood samples will be collected and analyzed
223913749|NCT04225585|BEHAVIORAL|CST-PSP|skills training and experiential learning exercises
223913750|NCT04225585|BEHAVIORAL|General health education|general health education intervention that focuses on improving overall health
223913751|NCT06470217|DRUG|tirilizumab with albumin-bound paclitaxel and cisplatin|tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.
223913752|NCT06470217|PROCEDURE|surgery|patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
223529888|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with midazolam|Incremental administration of midazolam up to a cummulative full therapeutic dose (0.05mg/kg) in POH patients investigated for midazolam. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.0005 mg/kg -0.005 mg/kg -0.015 mg/kg -0.03mg/kg).
223529889|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with fentanyl|Incremental administration of fentanyl up to a cummulative full therapeutic dose (1mcg/kg) in POH patients investigated for fentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.01 mcg/kg -0.1 mcg/kg -0.3 mcg/kg -0.6mcg/kg).
223913753|NCT02661932|DRUG|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
223913754|NCT04104360|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
223913755|NCT04104360|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
223913756|NCT03931408|DRUG|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
223913757|NCT03931408|OTHER|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
223913758|NCT03931408|OTHER|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
223913759|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
223913760|NCT01314105|DRUG|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
223913761|NCT01314105|DRUG|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
223913762|NCT06305078|OTHER|Personalized ADHD Medication Experiment|All parent/adolescent dyads will select and complete a medication experiment.
223913763|NCT04117178|DRUG|Donepezil|Adjustment of treatment with donepezil according to serum level.
223913764|NCT04117178|DRUG|Memantine|Adjustment of treatment with memantine according to serum level.
223913765|NCT04117178|DIAGNOSTIC_TEST|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
223913766|NCT04008563|PROCEDURE|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
223913767|NCT04312841|DRUG|Letermovir|Given PO
223913768|NCT06029153|PROCEDURE|Middle meningeal artery embolization|Middle meningeal artery embolization with coil.
223913769|NCT04134559|DRUG|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
223913770|NCT06404905|DRUG|BT02 monoclonal antibody injection|It is expected to include 10-30 patients assigned to dose escalation cohorts.
223913771|NCT04466059|DIAGNOSTIC_TEST|Automated AI-Guided Diagnosis of Hematological Malignancies|In BELUGA, we want to investigate whether the automated analysis of blood (from peripheral blood and bone marrow aspirates) smears and flow-cytometry-based analyses can provide a benefit for diagnostic quality and, ultimately, patient care.
223913772|NCT05136755|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of antidepressant nonresponders with MDD
223913773|NCT05136755|DRUG|Placebo Cap|Use of placebo as a comparator
223913774|NCT03735745|OTHER|Blood collection|30cc of blood will be collected.
223913775|NCT03735745|OTHER|Saliva collection|5cc of saliva will be collected.
223913776|NCT03735745|OTHER|Tissue collection|Up to 10mg of tissue will be collected.
223913777|NCT03735745|OTHER|Surveys|The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
223529890|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with sufentanyl|Incremental administration of sufentanyl up to a cummulative full therapeutic dose (0.1mcg/kg) in POH patients investigated for sufentanyl. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.001 mcg/kg -0.01 mcg/kg -0.03 mcg/kg -0.06µg/kg).
224087977|NCT06960161|DEVICE|Phototherapy|Phototherapy
223913778|NCT05850052|DEVICE|McGrath videolaryngoscope for rapid sequence endotracheal intubation|Visualize a patient's airway to aid placement of tracheal tube with ease.
223913779|NCT05850052|DEVICE|Conventional direct laryngoscopy using a Macintosh blade|Examine a patient's airway to aid placement of tracheal tube with ease.
223913780|NCT03822494|RADIATION|CyberKnife SBRT|Radiation Therapy
223913781|NCT06235320|OTHER|routine clinical treatment of pain with paracetamol or ibuprofen|No intervention beside clinical routine management
223913782|NCT04209543|DRUG|Estetrol|Estetrol oral tablet: administered orally once daily
223913783|NCT04209543|DRUG|Placebo|Placebo oral tablet: administered orally once daily
223913784|NCT04209543|DRUG|Progesterone|Progesterone oral tablet: administered orally once daily
223913785|NCT03640286|DEVICE|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
223913786|NCT05524116|BEHAVIORAL|Mindful Exercise program|In this 8-week intervention, components of Mindful Based Stress Reduction Program will be integrated with strengthening and neuromuscular exercises recommended for knee osteoarthritis. The goal of this program is to train participants how to be mindful during their exercises.
224087978|NCT06961383|BIOLOGICAL|NG01 - Autologous bone marrow derived human stromal cells|NG01 is a cellular therapy product of autologous stromal cells derived from the bone marrow of multiple sclerosis (MS) patients. NG01 is provided as a cell suspension for intrathecal injection.
224087979|NCT06961383|OTHER|Sodium Chloride 0.9%|The placebo for use in the NG01 clinical trial is 0.9% Sodium Chloride Solution for Injection
224087980|NCT06961201|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication.
224087981|NCT06961201|DRUG|standard treatment|standard treatment
223913787|NCT05524116|BEHAVIORAL|Exercise|In this 8-week intervention, participants will be given recommended strengthening and neuromuscular exercises for knee osteoarthritis. Participants in both the intervention and control group will receive these exercises.
223913788|NCT05823948|DRUG|Insulin Icodec|Participants will receive insulin icodec once-weekly subcutaneously into the thigh, upper arm or abdomen.
223913789|NCT06778356|OTHER|Built environment|Participants will complete the study session at a University student center.
223913790|NCT06778356|OTHER|Natural environment|Participants will complete the study session in a nature trail.
223913791|NCT03181516|BIOLOGICAL|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
223913792|NCT03181516|OTHER|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
224087982|NCT06961240|DIAGNOSTIC_TEST|AI-Based Difficult Airway Prediction Model|"The AI-Based Difficult Airway Prediction Model is an artificial intelligence system designed to predict difficult intubation in patients undergoing general anesthesia. It combines clinical data (age, BMI, Mallampati score, mouth opening, thyromental distance, sternomental distance, neck circumference) and anatomical image data. Machine learning (Random Forests, SVM, Gradient Boosting) and deep learning (ANN, CNN) algorithms are used to classify airway difficulty. The model's predictions are compared with clinical assessments by anesthesiologists using Cormack-Lehane grading. The goal is to improve prediction accuracy, enhance airway management, and support clinical decision-making."
224087983|NCT06960824|DRUG|Life-Cycle Pharma Tacrolimus|Patients receiving LCPT Envarsus® \[Life-Cycle Pharma Tacrolimus\] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics (SmPC).
223913793|NCT05180552|DEVICE|HEALiX is an alternative restraint patient safety device|The HEALiX is a rigid, spiral, exoskeleton-like device made of lightweight stainless steel (Austenitic SAE 316 or equivalent) that comes in various sizes to fit different arm lengths circumference of the patient's bicep. After appropriate measuring and following the fit guide, the HEALiX is placed on the patient's arm so that the hand rests on a soft, padded hand cradle. The trajectory of the end hand cradle is at a 30-degree upward angle to prevent peripheral dependent edema. This hand cradle is surrounded by foam to provide increased support for the patient and also to protect the medical team from any injury. A wrist bracelet (wrist assist) goes around the patient's wrist and prevents the patient from removing the device. The spiral exoskeleton holds the arm in a neutral position with contact points with the patient's skin at the upper deltoid region only.
223913794|NCT05180552|DEVICE|soft wrist restraints|Soft wrist restraints are padded cloth restraints that are worn by patients on wrist and secured to bed frame.
223913795|NCT05345509|DRUG|Aricept Tablet|Donepezil Tablet once daily P.O
223913796|NCT05345509|DRUG|IVL3003|Donepezil Long-Acting Injection, once S.C Injection
223913797|NCT05345509|DRUG|IVL3003|Donepezil Long-Acting Injection, once IM Injection
223913798|NCT05974579|DRUG|89Zr-DFO-AP-101|"At Day 0, patients will receive one dose of the radiotracer. A PET/CT scan will be done 2h post-dose.~At 1, 3, 7 and 10 days post-dose, a PET/CT scan will be repeated."
224087984|NCT06960824|PROCEDURE|Kidney transplantation|Kidney transplant patients using the iBox prognostic system (risk prediction system for kidney transplants)
224087985|NCT06961396|DEVICE|Relaxation Technique|utilizing virtual reality and a relaxation technique called diaphragmatic release to treat menstrual pain sufferers
224087986|NCT06961396|DEVICE|Pain treatment|utilizing cold laser and a relaxation technique called diaphragmatic release to treat menstrual pain sufferers
224087987|NCT01388400|OTHER|conventional occupational therapy|upper limb exercises
223913799|NCT04911816|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine, oral, dose escalated (400mg, 800mg, 1200mg) beginning concurrent with mFOLFIRINOX and extending 2 weeks post-operatively. Dose will be assigned to patients using 3+3 Algorithm to identify the Maximum Dose Tolerated.
224087988|NCT01388400|DEVICE|video capture virtual reality|virtual reality delivered uppe limb exercises
224087989|NCT06959979|DRUG|CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)|Evaluation of the response to CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) on selected Medulloblastoma (MB) patient-derived organoids (PDOs).
224087990|NCT06959797|DEVICE|Closed loop|Ypsomed pump (Ypsomed), CamAPS HX application activated, Android smartphone. Freestyle 3 sensors (Abbott)
224087991|NCT06959797|DEVICE|Open loop|Ypsomed pump (Ypsomed). Android smartphone. Freestyle 3 sensors (Abbott)
223913800|NCT06379607|DEVICE|"High Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use higher flow rates.
223913801|NCT06379607|DEVICE|"Low Flow High Flow Nasal Cannula"|High Flow Nasal Cannula will be applied in both experimental groups but different flow rates will be used in each arm; this arm will use lower flow rates.
223913802|NCT03953144|DEVICE|Synapse 3D Lung Modelling|The 3D virtual models provided by Synapse 3D will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
223913803|NCT03953144|DRUG|IC-Green (ICG)|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
223913804|NCT03065231|DEVICE|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
223913805|NCT03065231|DEVICE|Lumbar Drain|
223913806|NCT06018155|OTHER|Spine surgery|Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
223913807|NCT06003608|DEVICE|Fluid biopsy capsule|Ingestion of two SIMBA capsules
223913808|NCT06003608|DRUG|Levodopa-Carbidopa Immediate Release|Single dose, Levodopa-Carbidopa Immediate Release
223913809|NCT03947112|BEHAVIORAL|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and the UngKan-3 Questionnaire, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
223913810|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Auto-Injector (AI).
223716322|NCT04090424|PROCEDURE|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
223913811|NCT05405985|DRUG|Nemolizumab|Nemolizumab with Dual-Chamber Syringe (DCS).
223913812|NCT05927688|BEHAVIORAL|Therapeutic management following access by the physician to his patient's ePROs|Therapeutic management following access by the physician to his patient's ePROs
223913813|NCT04254107|DRUG|SEA-TGT|Given into the vein (IV; intravenously) on Day 1 of each 21-day cycle
223913814|NCT04254107|DRUG|sasanlimab|Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle
223913815|NCT04254107|DRUG|brentuximab vedotin|Given by IV on Day 1 of each 21-day cycle
223913816|NCT06149702|OTHER|Combined intervention: Keep-on-Keep-Up-LITE (KOKU-LITE) programme and dementia and falls prevention leaflet|KOKU-LITE programme will be used by the participants for 6 weeks and outcome assessments will be performed at baseline and 6 weeks of use. Participants will also use dementia and falls prevention leaflet for 6 weeks.
223913817|NCT04880733|PROCEDURE|Acupuncture for pain management|A manualized acupuncture protocol will be performed by a licensed acupuncturist in the patient's emergency department room.
223913818|NCT04880733|OTHER|Usual care for pain management|Patient will receive usual care for pain management.
224087992|NCT01808352|OTHER|Observational|HPTN 073 is an observational study in MSM in the United States
224087993|NCT01596179|BEHAVIORAL|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
224087994|NCT01596179|BEHAVIORAL|Internet access|a netbook computer with internet access is provided to participants on the control arm.
224087995|NCT04888481|DRUG|68Ga-HA-DOTATATE|Tracer injection
224087996|NCT03713190|COMBINATION_PRODUCT|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
224087997|NCT03713190|DRUG|Placebo|A substance without specific pharmacology principles
224087998|NCT00103012|DRUG|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
224087999|NCT00103012|DRUG|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
224088000|NCT00103012|DRUG|Panax ginseng|Panax ginseng 500 mg twice daily
224088001|NCT00970606|DRUG|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
224088002|NCT00970606|DRUG|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
223913819|NCT06166901|DEVICE|AcrySof IQ PanOptix IOL|Trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism, with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
223913820|NCT06166901|DEVICE|AcrySof IQ PanOptix Toric IOL|Toric trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia, who desire near, intermediate and distance vision with increased spectacle independence.
223913821|NCT06806423|PROCEDURE|Immediate Dental Implant Placement without Adjunctive Treatments|Atraumatic extractions using periotomes and anterior forceps. Osteotomy was prepared with a standardized drilling sequence under copious irrigation. ROOTT R-line implants were selected based on socket dimensions. No topical vitamin D3 was applied. Implants were placed into fresh extraction sockets.
223913822|NCT06806423|PROCEDURE|Immediate Dental Implant Placement with Topical Vitamin D Gel Application|The same procedure as the control group, with the addition of sterile topical vitamin D3 (calcitriol) gel applied to both the implant surface and osteotomy site immediately before implant placement.
223913823|NCT06804642|DEVICE|Spinal cord transcutaneous stimulation (scTS)|"scTS mapping: Each intervention session will be approximately 2 hours each which includes time to place the scTS stimulating pads and other sensors as needed. Participants will be asked to train 3 days per week during the intervention periods so that they achieve at least 12 sessions. In instances in which availability is limited or they must cancel a session, the intervention period will need to be extended slightly (up to a maximum of four weeks) so that they can achieve at least 12 sessions (1-month intervention period) or 24 sessions (2-month intervention periods) of training. The main study interventions are described below.~Step-scTS:~Step-scTS is spinal cord transcutaneous stimulation (scTS) targeted for stepping function. The scTS mapping assessment(s) will assist the study team in determining optimized stimulation parameters for each body and f"
223913824|NCT05410587|DEVICE|Fracture Monitor (implantable device class III)|Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.
223913825|NCT06412679|BEHAVIORAL|Life Skills Education|The RESETTLE-IDPs study compares two innovative delivery approaches for a culturally-adapted life skills education (LSE) intervention aimed at improving the mental health and well-being of internally displaced persons in Nigeria. The interventions are distinguished by their mode of delivery (in-person vs. WhatsApp-based), their focus on peer support and skill-building, and their tailoring to the specific needs and challenges of IDP populations.
223913826|NCT06555731|GENETIC|Ultra rapid genome sequencing|DNA extraction from blood sample and whole genome sequencing
223913827|NCT05552508|COMBINATION_PRODUCT|Benralizumab|Participants will receive benralizumab subcutaneously.
223913828|NCT05947331|PROCEDURE|Graded Anderson procedure|In graded Anderson proceduren only recession of yoke muscles is done.
223913829|NCT05947331|PROCEDURE|Kestenbaum procedure|In Kestenbaum procedure, recession of yoke muscles and resection of their antagonists is done based on Parks table for Kestenbaum procedure according to the preoperative amount of head turn.
223716323|NCT04861389|PROCEDURE|Arterial access|Arterial access for primary percutaneous coronary intervention in STEMI patients
223913830|NCT06058910|DIAGNOSTIC_TEST|Bilistick System 2.0 point-of-care testing device|The routine standard-of-care blood sample collection involves a 0.5 milliliter whole blood draw by the heel stick method for bilirubin assessments under current reference clinical methodology for total bilirubin. An additional 0.035 milliliter of whole blood will be collected for measurement in the point-of-care Bilistick System 2.0 (Bilistick point-of-care testing device). The resulting Bilistick System 2.0 data (i.e., total bilirubin) will be recorded, but will not be entered into the patients' electronic medical records or used for any diagnostic or medical decision purposes.
224088003|NCT00430755|DEVICE|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition \[history-taking\] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
224088004|NCT00430755|PROCEDURE|physician taken history|Convential history taking by physicians
224088005|NCT00430755|OTHER|Computer-assisted history taking|
224088006|NCT06108102|OTHER|Presence of stroke, either ischemic or hemorrhagic (intracerebral and subarachnoid)|Presence of ischemic or hemorrhagic stroke confirmed by neuroimaging and clinical diagnosis
224088007|NCT03268356|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure Kit|A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.
224088008|NCT05434884|PROCEDURE|occlusal veneer restorations|"occlusal veneer preparation with circumferential chamfer finish line and proximal slot  proposed modified occlusal veneer design for rehabilitation of moderate level of permanent first molars. OrPatients will receive endocrown restorations for rehabilitation of sever level of permanent first molars"
224088009|NCT05434884|PROCEDURE|endocrown restorations|endocrown restorations
223913831|NCT01917084|OTHER|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
223913832|NCT04787848|DRUG|Relistor Injectable Product|Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
223913833|NCT03938246|DRUG|TVB-2640 25 mg (US)|Oral dose, tablet, daily dosing
224088010|NCT02472457|OTHER|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
224088011|NCT02472457|OTHER|Free Diet|This diet contains no restrictions.
224088012|NCT02005822|DRUG|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
224088013|NCT00956826|DEVICE|Agit Vacuum|With an electrode and a regular vacuum device
224088014|NCT03051633|BEHAVIORAL|Be Under Your Own Influence|School based anti-drug use communications campaign
224088015|NCT00631878|DRUG|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
224088016|NCT02507804|OTHER|Patient diary PROMs|
224088017|NCT02507804|OTHER|Counselling|
224088018|NCT05211336|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV (intravenous) days 1 and 2 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
224088019|NCT05211336|DRUG|Prednisone|Prednisone 100 mg PO (by mouth) daily days 1-7 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
224088020|NCT05211336|DRUG|Lenalidomide|Lenalidomide 10 or 15 mg PO (by mouth) on days 1-14 for 1 cycle (21 days); followed by Lenalidomide 10 or 15 mg PO daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
224088021|NCT05211336|DRUG|Venetoclax|Venetoclax 800 mg PO (by mouth) on days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
224088022|NCT05211336|DRUG|Ibrutinib|Ibrutinib 560 mg PO (by mouth) daily days 1-14 for a maximum of 6 cycles every 21 days (each cycle is 21 days)
224088023|NCT05211336|DRUG|Acetaminophen|650 mg by mouth (PO) daily on days 1 and 2 approximately 30-60 minutes prior to Obinutuzumab infusion.
224088024|NCT05211336|DRUG|Diphenhydramine|50mg by mouth (PO) daily on days 1 and 2 approximately 30-60 minutes prior to Obinutuzumab infusion.
224088025|NCT05211336|OTHER|Peg-filgrastim|6 mg subcutaneous once on day 8 only.
224088026|NCT05211336|DIAGNOSTIC_TEST|CT Scan (chest, abdomen, and pelvis)|To assess sites of disease.
224088027|NCT05211336|DIAGNOSTIC_TEST|MRI|If clinically indicated.
224088028|NCT05211336|DIAGNOSTIC_TEST|18f-FDG-PET|If clinically indicated.
224088029|NCT05211336|DIAGNOSTIC_TEST|PET|If clinically indicated.
224088030|NCT05211336|DIAGNOSTIC_TEST|Lumbar puncture/Ommaya tap|If clinically indicated.
224088031|NCT05211336|DIAGNOSTIC_TEST|Bone marrow aspiration/biopsy|If clinically indicated.
224088032|NCT05211336|COMBINATION_PRODUCT|EKG|To determine eligibility.
224088033|NCT06303622|PROCEDURE|MRI-USG fusion approach|MRI-USG fusion approach prostate biopsy
223913834|NCT03938246|DRUG|TVB-2640 50 mg (US)|Oral dose, tablet, daily dosing
223913835|NCT03938246|DRUG|Placebo (US)|Oral dose, tablet, daily dosing
223913836|NCT03938246|DRUG|TVB-2640 50 mg (China)|Oral dose, tablet, daily dosing
223913837|NCT03938246|DRUG|Placebo (China)|Oral dose, tablet, daily dosing
223913838|NCT03938246|DRUG|TVB-2640 75 mg (US)|Oral dose, tablet, daily dosing
223913839|NCT06109805|OTHER|Gastric cancer|Patients diagnosed with gastric cancer, including early gastric cancer and advanced gastric cancer
223913840|NCT06550401|OTHER|BREAST-Q Physical Well-Being|This BREAST-Q domain measures pain or tightness and difficulty with mobility, such as lifting arms or running. The preoperative survey contains 10 items, whereas the postoperative survey contains 11 items. Values for BREAST-Q subscales are converted to summary scores, ranging from 0 to 100, via Q-Score software. Higher scores correlate with better patient quality of life. 37 This survey is administered as part of standard care for all patients.
223913841|NCT06550401|OTHER|QuickDASH|QuickDASH, also known as the Arm and Shoulder Range of Motion survey within MSK Engage is an 11-item survey that measures physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb. It is currently standard of care for breast cancer surgery patients. It is a valid, reliable, and responsible survey that can be used for clinical and/or research purposes. Higher scores indicate greater disability.
223913842|NCT05379348|OTHER|Cognitive Assessment|Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
223913843|NCT06206486|OTHER|no intervention, observational|This study is observational. No intervention description available.
224088034|NCT06303622|PROCEDURE|Cognitive-guided approach|Cognitive-guided approach prostate biopsy
224088035|NCT01834235|DRUG|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
223913844|NCT06377917|OTHER|Laser Assisted Hatching|Routine assisted hatching procedure will be performed on both groups at the different embryo developmental phases.
223913845|NCT03037242|PROCEDURE|Transtibial pullout technique|Evaluating radographs
223913846|NCT05895929|DRUG|Mepolizumab|In vitro exposure of human nasal epithelial cells to mepolizumab
223913847|NCT06514482|DIAGNOSTIC_TEST|Diagnosis|Diagnosis
223913848|NCT06763224|OTHER|Questionnaire and Physical Exam|The neuropathic pain measured with the Neuropathic pain DN4 Questionnaire (Echelle de la Douleur Neuropathique en 4 questions - Neuropathic Pain Scale in 4 questions) The global pain measured with Visual Analogue Scale (VAS) The patient's permanent functional disability measured with the Oswestry disability index (ODI) The quality of life measured with the questionnaire EuroQol-5 Dimension (EQ-5D-5L)
223913849|NCT03928236|OTHER|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
223913850|NCT03928236|OTHER|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
224088036|NCT01834235|DRUG|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
224088037|NCT01834235|DRUG|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
224088038|NCT01790490|DRUG|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
224088039|NCT01790490|DRUG|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
224088040|NCT01790490|DRUG|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
224088041|NCT05191043|OTHER|Kinesio Taping Technique|Kinesio taping is a thin, stretchy, elastic cotton strip with an acrylic adhesive that is approximately the same thickness as the epidermis of the skin. When the taping method is followed correctly, the tape effects on the muscle by facilitating a weakened muscle or relaxing an over-used muscle,decreasing pain, fatigue and increasing tissue recovery. Kinesio Taping facilitation technique will be used with fifty percent stretch on rhomboids bilaterally.
223913851|NCT04832958|DRUG|99m-TC-PSMA-I&S|"* 99mTc-PSMA-I\&S intravenous injection the day before surgery~* 99mTc-PSMA-I\&S SPECT/CT imaging~* 99mTc-PSMA-RGS to detect an increased count rate at the level of the nodal stations"
223913852|NCT04842513|DRUG|Multipeptide plus XS15|The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
223913853|NCT02785029|DEVICE|OCT|
223913854|NCT03401840|RADIATION|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
223913855|NCT05575882|OTHER|Skin hydration|Skin hydration outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
223913856|NCT05575882|OTHER|Barrier function measurement|TEWL measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
223913857|NCT05575882|OTHER|Potential of hydrogen measurement (pH)|pH measurement outside flare-up areas on an initial dry skin (the same in each visit). Non invasive technique.
223913858|NCT05575882|OTHER|Clinical evaluation of atopic dermatitis|EASI score on each visit. Non invasive technique.
223913859|NCT05575882|OTHER|Quality of life assessment|Cardiff questionnaires to assess quality of life of subjects and their family members.
223913860|NCT05575882|OTHER|Assessment of the effect on itching and sleep disturbances|Visual analogue scale from 0 to 10
223913861|NCT05575882|OTHER|Assessment of the tolerance of the study product or placebo|By collection of Adverse Events (AEs) on daily log and electronic Case Report Form (eCRF).
223913862|NCT04080622|DRUG|Selenium|Selenium 300 µg/day (IV infusion)
224088042|NCT05191043|OTHER|Routine Physical Therapy|"routine physical therapy includes thermotherapy and Transcutaneous electrical nerve stimulation (TENS), the strengthening exercises of lower and middle trapezius, rhomboids and deep neck flexors. Stretching exercises of upper trapezius, pectoralis major and minor. Mobilization of cervicothoracic junction and postural education.~Thermotherapy and transcutaneous electrical nerve stimulation will be used for 10 minutes in each session. Each exercise will be performed in 3 sets of 10 repetitions. Treatment session will have a duration of 30-45 minutes."
224088043|NCT05408689|DEVICE|T1 TENS|The subjects in Group A will received TENS (Burst mode, 9 pulses per burst, pulse frequency =160Hz, burst frequency=2Hz, intensity was set to trigger visible muscular twitches). Two 2 x 3 cm electrodes was attached on T1 level with 2 cm from the spine. Previous study has shown that it was effective to improve the cognitive function in subjects with Alzheimer's disease.
224088044|NCT05408689|DEVICE|Concha TENS|The subjects in Group B will received TENS (25Hz, 0.5mA) on the concha of left outer ear. The electrical stimulation was generated by the portable neurostimulator (Nemos®, Cerbomed, Erlangen, Germany) and was delivered by a titanium electrodes positioning on top of a silicon earplug. Previous study has shown that it was effective to improve the Accelerate extinction memory formation and retention in healthy young adults.
224088045|NCT05408689|DEVICE|Control|The subjects in Group C will receive 30 min sham electrical stimulation on T1 by a placebo-TENS device. The Placebo-TENS was applied by an apparently identical TENS unit. The unit's power indicator light was illuminated, but the unit's electrical circuit had been manually disconnected inside. In order to shape the common mindset, all subjects (except those in the Control group) were informed that they might or might not feel an electrical current, as different stimulation parameters were being applied.
224088046|NCT04271761|OTHER|Non-interventional, post-market, pilot study of Carina Cochlear System|Several objective acoustic measurements will be performed that do not require active participation from the subject.
224088047|NCT01784887|DRUG|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
224088048|NCT05470127|DEVICE|Prostate biopsy needle|Prostate tissue biopsy with a biopsy needle
224088049|NCT04697966|BEHAVIORAL|Mindfulness (Headspace) App|"The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life."
224088050|NCT04697966|BEHAVIORAL|"Active Control Condition (Recharge condition delivered in Headspace app)"|"The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises."
224088051|NCT05261269|DRUG|DAN-222|Administered IV every week to subjects
224088052|NCT05261269|DRUG|Niraparib|Administered orally once daily
223913863|NCT04080622|DRUG|Placebos|NaCl 0,9% (IV infusion)
223913864|NCT06514612|DRUG|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers|STN1013800 (0.1% Oxymetazoline Hydrochloride) eye drops in single dose containers
223913865|NCT06514612|OTHER|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers|Placebo (0% Oxymetazoline Hydrochloride) eye drops in single dose containers
224088053|NCT05167786|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
224088054|NCT05167786|DEVICE|Conventional gait training|Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
223913866|NCT04347200|DRUG|Antiplatelet Drug|single or dual antiplatelets, triple antithrombotic therapy
223913867|NCT05424380|DRUG|GSK3745417|GSK3745417 will be administered
223529891|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with alfentanil|Incremental administration of alfentanil up to a cummulative full therapeutic dose (10mcg/kg) in POH patients investigated for alfentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.1 mcg/kg -1 mcg/kg -3 mcg/kg -6µg/kg).
223913868|NCT05948995|DEVICE|Abduction external rotation brace|Abduction external rotation brace Arm position : Abduction , External rotation
223913869|NCT06135220|DIAGNOSTIC_TEST|New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath.|The collection time will be an average of 7 minutes. As the patient breathes through a mouthpiece, the exhaled breath is lead through the collection device, and an indicative amount af the exhaled air is led into a clear plastic bag. When the plastic bag is fully inflated, it indicates that the minimum required amount of exhaled breath (approximately 30 liters) has passed through the filter.
223716324|NCT02347280|PROCEDURE|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
223716325|NCT02347280|PROCEDURE|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
223913870|NCT03204825|DEVICE|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
223913871|NCT03204825|BEHAVIORAL|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
223913872|NCT03204825|DEVICE|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
223913873|NCT02909686|DIETARY_SUPPLEMENT|Boswellia Serrata|
223913874|NCT02909686|DIETARY_SUPPLEMENT|Curcumin|
223913875|NCT02909686|DIETARY_SUPPLEMENT|Epimedium|
223913876|NCT02909686|DIETARY_SUPPLEMENT|Fisetin|
223913877|NCT02909686|DIETARY_SUPPLEMENT|Luteolin|
223913878|NCT02909686|DIETARY_SUPPLEMENT|Nettle|
223913879|NCT02909686|DIETARY_SUPPLEMENT|Pycnogenol|
223913880|NCT02909686|DIETARY_SUPPLEMENT|Reishi Mushroom|
223913881|NCT02909686|DIETARY_SUPPLEMENT|Resveratrol|
223913882|NCT02909686|DIETARY_SUPPLEMENT|Placebo|
223913883|NCT06342141|DRUG|Empagliflozin 25 milgrams (Mg)|Load dose
223913884|NCT06342141|DRUG|Empagliflozin 10 Mg|Maintenance dose
223716326|NCT04466020|OTHER|Qualitative research interviews to be conducted|None. Qualitative research interviews to be conducted
223716327|NCT02650856|DRUG|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
223716328|NCT02650856|BIOLOGICAL|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
223716329|NCT05087108|DEVICE|OsciPulse system|The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.
223913885|NCT03113435|OTHER|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
223913886|NCT05072691|DIAGNOSTIC_TEST|CSF immunoglobulin (Ig) free light chains (FLC) dosage|CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
223913887|NCT06153212|PROCEDURE|Membrane placement with bone grafting|The diseased dental implant will be cleaned and the bone defect will be filled with bone graft and covered by a membrane.
223913888|NCT05101863|BEHAVIORAL|Motivational interviewing|MI is a goal-oriented style of communication, and focuses on resolving a patient's ambivalence, while eliciting his/her own reasons to change addictive behavior, also known as change talk.
223913889|NCT06099379|DRUG|∆9-tetrahydrocannabinol|Phytocannabinoids from plant inflorescences (CBD and THC dominant) - inhaled
223913890|NCT05268276|OTHER|1-perineal ice-gel pad application|For the study group Immediately after delivery (within 30 minutes to one hour after delivery), an ice gel pad will be applied to perineal trauma. each gel pad will have fixed standardized diameter (an approximately 5 cm width, 23 cm length, and 1.5 cm thickness) and approved by Egyptian ministry of health. It will be kept in the freezer for 45-60 minutes and will be removed when frozen. Then, it will be wrapped in a sterile pad and applied to cover the perineum and anal region.The investigator will provide a clear and concise information through oral and written instructions about the following; 1) The ice gel pad's purpose, benefits, anticipated effects and how to apply it, 2) Apply the ice gel pad on perineum after birth within 30 minutes to an hour, 3) Instruct the women to apply the ice gel pad for about 20 minutes every two hours during the first 24 hours postpartum only
223913891|NCT05268276|OTHER|2-performance of pelvic floor exercises (Kegel exercises)|women will receive instructions to practice pelvic floor exercises (Kegel exercises) and will be asked to perform these exercises from 6 hours postpartum and continue at home till one week. Before applying the technique, the investigator will teach the women how to recognize the accurate muscle, whereby she imagines holding passing gases or trying to stop the flow of urine midstream at the same time. The women will be taught to insert a clean finger into the vagina before practicing the exercises and if the women feeling pressure around her finger, she is on the right track, . The investigator will perform vaginal examination while the woman is doing the pelvic floor exercises (Kegel exercises) to ensure correct use of muscles. The investigator will instruct the women to continue contracting the muscles for about 5 seconds and then to loosen them for 5 seconds and repeat it for five times each set, perform at least five sets per day
223913892|NCT05268276|OTHER|3- perineal warm compresses application|women will be instructed to apply warm compresses on perineal trauma 48 hours postpartum at home. This will be done by using a clean pad soaked in warm water and squeezed to remove excess water then placed gently on the perineum, the warm compresses will be applied for 15 minutes three times per day (every 8 hours), and water in the bowl will be replaced with every application. Women will be asked to apply warm compresses on perineal trauma from 48 hours postpartum till one week.
223913893|NCT05958537|DEVICE|High flow nasal oxygen|Use of High-flow nasal oxygen at 60% 50 L/min.
223529892|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with remifentanil|Incremental administration of remifentanil up to a cummulative full therapeutic dose (0.5mcg/kg) in POH patients investigated for remifentanil. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose, 3/10th of the dose and ultimately 6/10th of the dose (0.005 mcg/kg -0.05 mcg/kg -0.15 mcg/kg -0.3µg/kg).
223529893|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with rocuronium|Incremental administration of rocuronium up to a cummulative full therapeutic dose (0.6mg/kg) in POH patients investigated for rocuronium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.006 mg/kg -0.06 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.18 mg/kg -0.42mg/kg) are administerd under general anesthesia.
223529894|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with atracurium|Incremental administration of atracurium up to a cummulative full therapeutic dose (0.5mg/kg) in POH patients investigated for atracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.005 mg/kg -0.05 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.15 mg/kg -0.35mg/kg) are administered under general anesthesia .
223529895|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with cisatracurium|Incremental administration of cisatracurium up to a cummulative full therapeutic dose (0.15mg/kg) in POH patients investigated for cisatracurium. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.0015 mg/kg -0.015 mg/kg ). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.045 mg/kg -0.105mg/kg) are administered under general anesthesia .
223529896|NCT06065137|DIAGNOSTIC_TEST|Full dose DPT with succinylcholine|Incremental administration of succinylcholine up to a cummulative full therapeutic dose (1mg/kg) in POH patients investigated for succinylcholine. Doses will be administered every 15 minutes starting at 1/100th of the dose, followed by 1/10th of the dose (0.01 mg/kg -0.1 mg/kg). In a second session 3/10th of the dose and ultimately 7/10th of the dose (0.3 mg/kg -0.7mg/kg) are administered under general anesthesia.
223529897|NCT05677048|BEHAVIORAL|Free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing
223529898|NCT05677048|BEHAVIORAL|IGNITE-TX Group|Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator
223529899|NCT05677048|BEHAVIORAL|IGNITE-TX and free genetic testing and counseling group|Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
223529900|NCT06430346|BEHAVIORAL|Exercise|Physical activity and resistance training
223529901|NCT06555419|DRUG|Nusinersen|Administered as specified in the treatment arm.
223529902|NCT06555419|DEVICE|ThecaFlex DRx System|Implanted as specified in the treatment arm.
223913894|NCT06359587|BEHAVIORAL|Laboratory test overuse (LTO) Bundle|"Key Components of the LTO Bundle:~Educational materials, including an online module, clinical decision support tool, provision of lab utilization (Audit and Feedback) reports for healthcare providers.~Patient engagement tools, such as videos and educational infographics. System level implementation tools adapted to the local context, including EMR-based tools and order set changes, etc."
223913895|NCT05395299|PROCEDURE|SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization|Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
223913896|NCT06037668|DEVICE|BVR-100|Experimental self-guided VR intervention for the treatment of SAD
223913897|NCT06037668|DEVICE|BES-100|Active at-home VR intervention comparator
223913898|NCT05766943|DEVICE|Smart Pass ON|Smart Pass filter will be programmed ON in the S-ICD while performing exercise testing.
223913899|NCT05766943|DEVICE|Smart Pass OFF|Smart Pass filter will be programmed OFF in the S-ICD while performing exercise testing.
223913900|NCT05955846|PROCEDURE|cataract surgery|Subjects will undergo surgery to remove cataract (natural cloudy lens) via phacoemulsification implant the IOL Both eyes will be treated one month apart. Subjects will be followed up during 12 months
223913901|NCT05955846|DEVICE|implantation of device IOL FG-80030.1|implant the IOL in both eyes. Both eyes will be treated one month apart. Subjects will be followed up during 12 months
223913902|NCT05825742|DEVICE|Lumoral Treatment|Subjects will receive detailed instructions for the use of Lumoral treatment -device. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day for two months and to keep a diary.
223913903|NCT05825742|OTHER|Standard oral health instructions|Subjects will receive the latest standard oral hygiene instructions according to the Swedish dental association's guidelines.
223913904|NCT03068390|BEHAVIORAL|RICHH Intervention|Whole health cardiovascular disease (CVD) self-care risk reduction intervention
223913905|NCT03068390|BEHAVIORAL|Usual care|Referral to primary care provider
223913906|NCT05099133|DRUG|LEO 138559|LEO 138559 is an antibody given by injection just under the skin.
223913907|NCT05099133|DRUG|LEO 138559 Placebo|LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
223529903|NCT02688959|BEHAVIORAL|Tai Chi|
223913908|NCT05224544|DEVICE|Investigational device|The test product is a urinary catheter for bladder drainage through the urethra. The product is for intermittent use.
223913909|NCT05224544|DEVICE|Comparator|The comparator is a urinary catheter for bladder drainage through the urethra.
223913910|NCT05837169|OTHER|Mindfulness-based stress reduction|The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
223913911|NCT04804540|DRUG|Vedolizumab IV|Vedolizumab IV infusion
223913912|NCT00844415|DRUG|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
223913913|NCT03555422|DRUG|Selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
223529904|NCT02688959|BEHAVIORAL|Exercise|
223913914|NCT03555422|DRUG|Matching placebo for selinexor|Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
223716330|NCT05087108|DEVICE|Reference Therapy 1|The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
223716331|NCT05087108|DEVICE|Refence Therapy 2|The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
223913915|NCT05966181|BEHAVIORAL|experimental group|"Experimental Group-Repetitive Simulation~* First simulation application; It will be done in groups of four with a total of 5 groups (n=20). In each scenario, one student in the group will participate in the role of nurse and three other students will participate as audience. Four students in each group will take part in a standard patient simulation consisting of four different scenarios.~* Second simulation application; It will be carried out with the students in the experimental group about 3-4 weeks after the first simulation. Each student will use one new scenario alone in the second simulation."
223913916|NCT06821659|BIOLOGICAL|anti-CD19 CAR-T cells|UWD-CD19
223913917|NCT06166498|DRUG|SP (Macleods Pharmaceuticals Ltd)|Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine
223913918|NCT06166498|DRUG|AS (Guilin Pharmaceuticals)|Children will receive 4 mg/kg/day for 7 days
223913919|NCT06245135|BEHAVIORAL|TIME at Home|"Sessions involve a 15-minute pre-video safety check and social time; streaming a 1-hour pre-recorded exercise video; and a 15-minute post-video social time. Two trained facilitators run each class, with a maximum group size of 10 people.~The 1-hour exercise videos include a seated warm-up and cooldown, and 40 minutes of functional, self-paced exercises. In the video, 2 healthcare professionals demonstrate a lower and higher difficulty level of each exercise. The program starts with a level 1 video and switches to a level 2 video midway.~A registered healthcare professional, called the healthcare partner, visits select classes and serves as a resource to participants and facilitators."
223913920|NCT06429956|BEHAVIORAL|Mindful emotion awareness|"The mindful emotion awareness module will follow the manual by Barlow et al. (2018). In session 1, the participant will receive psychoeducation about the purpose of mindful emotion awareness (i.e., to cultivate present-focused, non-judgmental attention to one's emotional experiences) and will complete an in-session guided meditation exercise which they will be asked to practice daily using an audio file. In session 2 and 3, two additional exercises are introduced. With mindful mood induction, the participant is instructed to induce emotions and then practice mindful emotion awareness in this context. With anchoring in the present, the participant is taught four steps to help them use mindful emotion awareness to pull themself back to the present whenever they feel an emotional response start to build in their everyday life. For homework, the participant will practice mindful emotion using these exercises and the audio file."
223913921|NCT06429956|BEHAVIORAL|Cognitive flexibility|The cognitive flexibility module will follow the manual by Barlow et al. (2018) which is based on the principles by Beck (1976). In session 1, the participant will be psychoeducated about the purpose of cognitive flexibility (i.e., to encourage flexible thinking through reappraisal of one's automatic thinking), and how their thoughts influence their emotional reactions. For homework, the participant will be asked to monitor their automatic thoughts. In session 2, the participant will be introduced to the technique of cognitive flexibility (i.e., generating other possible interpretations), and this technique will be practiced throughout session 2 and 3. For homework, the participant will continue to monitor their automatic thoughts and generate and record other possible interpretations.
223913922|NCT03406351|OTHER|Observational|Observational deep phenotyping physiological readouts
223913923|NCT04667455|DIAGNOSTIC_TEST|Biomarker analysis at enrolment|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
223913924|NCT04667455|DIAGNOSTIC_TEST|Biomarker analyses throughout the study|Controls will be compared to cases using blood-based biomarker analyses and non-invasive cardiac imaging techniques to improve early diagnosis and risk stratification of cases
223913925|NCT03631173|PROCEDURE|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
223913926|NCT06481540|DEVICE|Expiratory muscle strength training + SpiroGym application|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations coupled with SpiroGym app. per training session for 8 weeks (intensive training period). After this period, participants will perform an additional 16 weeks of maintenance EMST. EMST therapy sessions will be completed at home on two days (minimum) of the participant's choosing each week.
223913927|NCT06481540|DEVICE|Expiratory muscle strength training|Participants will performe an intensive home-based expiratory muscle training programme using an Expiratory Muscle Trainer (EMST150; Aspire Products, LLC, United States), which provide a pressure- threshold range from 30 to 150 cmH20. EMST therapy sessions will be completed at home on 5 days of the patients choosing per week. Participants will be instructed to perform five sets of five forceful expirations per training session for 8 weeks (intensive training period).After this period, participants will perform an additional 16 weeks of maintenance EMST. EMST therapy sessions will be completed at home on two days (minimum) of the participant's choosing each week.
223913928|NCT02473445|DRUG|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
223913929|NCT06250374|PROCEDURE|Bilateral trans-cranial Doppler ultrasound|Velocity measurements in the middle cerebral artery are made using an ultrasound probe applied to the patient's temple during surgery.
223913930|NCT05196854|OTHER|Group 1. Standard Home Blood Pressure Measurement|Measurement of Blood Pressure using Home blood pressure monitor
223913931|NCT05196854|OTHER|Group 2. Hypnosis script prior to home blood pressure measurement|Pre-recorded clinical hypnosis script (approx 5 mins long) used prior to standard home blood pressure measurement. Clinical Hypnosis is used as a non-pharmacological technique for reducing procedural anxiety, distress and discomfort with patients.
223913932|NCT03015532|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), via instillation
223913933|NCT03015532|DRUG|Saline Placebo|Saline placebo via injection
223913934|NCT03015532|DRUG|Bupivicaine HCl|Bupivacaine HCl without epinephrine
223913935|NCT03015532|DRUG|Ropivacaine|Ropivacaine, via injection
223913936|NCT02600208|DEVICE|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
223913937|NCT05970861|DIETARY_SUPPLEMENT|Freeze-dried Mare Milk (Saumal)|Freeze-dried Mare Milk (Saumal) is frequently reported for having therapeutic and dietary properties associated with specific chemical composition and certain physical properties of the product. It contains a total of about 40 biologically active components, the most important of them vitamins A, C, B1, B2, B6, and B12, amino acids, enzymes, and trace elements (low molecular weight peptides, lactalbumins, and globulins). Saumal will be administered to patients at a dose of 25 grams of dry powder per 200 ml of water, 2 times a day, 30 minutes before the meal, for 4 weeks.
223913938|NCT05549479|BEHAVIORAL|Peer Matching|Participants will be matched with a peer based on evidence informed criteria. Partners will independently communicate and support each other around exercise for the duration of the study.
223913939|NCT05549479|BEHAVIORAL|Qualified Exercise Professional Support Sessions|Dyads will participate in weekly virtual sessions with a QEP for 10 weeks. Each session will last up to 1 hour. The QEP (i.e., registered kinesiologist) will provide a tailored exercise program, focusing on aerobic activity for both individuals in the dyad based on personal circumstances, cancer-related characteristics, side effects, current fitness level (consistent with home-based exercise strategies), and personal preferences.
223913940|NCT04710030|DRUG|Valacyclovir hydrochloride 500mg caplet|Active Comparator
223913941|NCT04710030|DRUG|Placebo sugar pill caplet|Placebo Comparator
223913942|NCT06366724|DRUG|Pyridostigmine|"Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)"
224088055|NCT05167786|OTHER|Exploratory Phase - Optimization of Gait Training and Spinal Stimulation|Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
224088056|NCT05019131|BEHAVIORAL|Training|trainings to reduce conscious bias and stress
224088057|NCT05019131|BEHAVIORAL|Peer support and mentorship|facilitated peer and mentorship opportunities
224088058|NCT05019131|BEHAVIORAL|Leadership engagement|Engaged leadership at the county and facility levels
224088059|NCT05019131|BEHAVIORAL|Embedded champions|Facilitate local champions to promote intervention
223913943|NCT06366724|DRUG|Low-Dose Naltrexone|"LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)"
223913944|NCT06366724|OTHER|Placebo|"Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)"
223719425|NCT01464489|DRUG|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
223913945|NCT06435624|DEVICE|intelligent robotic-assisted training|"Using an intelligent robotic-assisted training (IRAT) system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function.~The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd."
223913946|NCT06435624|OTHER|repetitive facilitative exercise|Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
223913947|NCT06435624|OTHER|conventional therapy|Basic training, including passive joint movement and activities of daily living exercise.
223913948|NCT02832505|OTHER|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
224088060|NCT05791292|OTHER|Evaluation|To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
224088061|NCT00720928|DRUG|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
224088062|NCT05723432|DRUG|KD6001|KD6001 will be administered intravenously.
224088063|NCT05723432|DRUG|Toripalimab|Toripalimab will be administered intravenously.
224088064|NCT02733029|DRUG|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
224088065|NCT02733029|DEVICE|contrast enhanced ultrasonography|Injection of intravenous ultrasound contrast
224088066|NCT05220839|PROCEDURE|Type of cerclage procedure Mc Donald|Patients who underwent Mc Donald cervical cerclage will be calculated the area of cervical cerclage area
224088067|NCT01621685|BIOLOGICAL|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
224088068|NCT03575104|DRUG|Daridorexant|Daridorexant will be administered as tablets, orally, once daily in the evening.
224088069|NCT03575104|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
224088070|NCT00332709|DRUG|Letrozole|2.5 mg/day for 3 years
223719426|NCT01464489|DRUG|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
223719427|NCT00002531|DRUG|asparaginase|
224088071|NCT00332709|DRUG|Zoledronic acid|4 mg every 6 months
224088072|NCT04988698|OTHER|none intervention|none intervention
223529905|NCT03655782|BEHAVIORAL|PATH + DigitMemory (DM) neurotraining|Improve visual timing and sensitivity in the dorsal stream. The mTBI subject will sit 57 cm in front of a computer monitor. During the presentation, the bars in the 'fish-shaped' window in the center of the screen formed by a sinusoidal grating, move left or right very briefly. When the screen goes blank, the subject reports which way the center pattern moved by pushing the left or right arrow key. A brief tone is presented after incorrect responses. The program adaptively changes the contrast of the test pattern so that the subject detects motion at lowest contrast possible. A sequence of patterns in each training cycle that are designed to optimally activate magnocellular neurons are shown to the subject. There are two programs, the first measures the contrast needed to see one direction of movement, and the second program measures the contrast needed to see two directions of movement, requiring memory. Both are followed by digit memory exercises.
223913949|NCT06809127|OTHER|Behavioral tasks with MEG recording|The patients will undergo two visits, during which MEG will be recorded in two types of behavioral tasks: motor task and emotion recognition task. One visit will take place before surgery. The second visit will take place after the surgical intervention and the face motor rehabilitation, 3 to 18 months after the 1st visit.
223913950|NCT06810037|BEHAVIORAL|Mindfulness Practice Based on the Solution-Focused Approach|the experimental group received 90 minutes of solution-oriented based mindfulness practices one day a week for eight weeks
223913951|NCT06368206|DEVICE|Investigational device Aktiia G2C|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia G2C.
223913952|NCT06368206|DEVICE|Marketed device used as reference for blood pressure monitoring: double auscultation cuff|Study subjects are asked to stay seated and relaxed while successive measurements are taken with cuff for double auscultation.
223913953|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2|Study subjects are asked to stay seated and relaxed while successive measurements are taken with Aktiia Bracelet G2.
223913954|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric upper-arm cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric upper-arm cuff.
223913955|NCT06368206|DEVICE|Marketed device used as comparative device for blood pressure and pulse rate monitoring: oscillometric wrist cuff|Study subjects are asked to stay seated and relaxed while taking successive measurements with an oscillometric wrist cuff.
223913956|NCT06368206|DEVICE|Marketed device used as reference for pulse rate monitoring: pulse finger oximeter|Study subjects are asked to stay seated and relaxed while successive measurements are taken with pulse finger oximeter.
224088073|NCT03904797|BEHAVIORAL|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|"Participants were primary caregivers (n=149) recruited from a large, urban early intervention program. All caregivers were approached by early intervention staff the month prior to the child's annual evaluation of progress.~Each caregiver confirmed his or her eligibility online by verifying that they were at least 18 years old; could read, write, and speak English or Spanish; had internet access; and had a child between 0-3 years old who had received early intervention for at least 3 months.~Participants enrolled online and provided consent, signed a HIPAA authorization for service record release, and then proceeded to completing a demographic questionnaire and YC-PEM e-PRO to receive an online report of their responses to share with their child's EI team."
224088074|NCT04684420|DRUG|Glucophage® XR RM Test|Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
224088075|NCT04684420|DRUG|Glucophage® XR Reference|Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
224088076|NCT05944536|OTHER|Balance Exercises (BE)|Each exercise was performed with 10 repetitions for both lower limbs.
224088077|NCT05944536|OTHER|BE + Dual Task|Cognitive and motor secondary tasks were given
224088078|NCT05997355|DRUG|Gabapentin 600Mg Tab|A single preoperative dose of gabapentin 600mg
224088079|NCT00008190|BIOLOGICAL|aldesleukin|
224088080|NCT00008190|BIOLOGICAL|filgrastim|
224088081|NCT00008190|DRUG|busulfan|
224088082|NCT00008190|DRUG|cyclophosphamide|
224088083|NCT00008190|DRUG|etoposide|
224088084|NCT00008190|DRUG|melphalan|
224088085|NCT00008190|PROCEDURE|peripheral blood stem cell transplantation|
223529906|NCT05273268|OTHER|Personalized nutrition|Personalized nutrition based on individual traits delivered through mobile device app.
223529907|NCT05273268|OTHER|Generalized nutrition|General nutrition guidelines currently used by USDA.
224088086|NCT05726357|PROCEDURE|vital pulp therapy|removal of the coronal pulp followed by placing a biocompatible material to preserve the vitality of the radicular pulp
223719428|NCT00002531|DRUG|cyclophosphamide|
223913957|NCT06805201|DIETARY_SUPPLEMENT|Gyngerlean|Alpinia galangal (Red Ginger), Kaempferia parviflora (Black Ginger), and Zingiber officinale (Yellow Ginger).
224088087|NCT00254410|DRUG|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
224088088|NCT00254410|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
224088089|NCT00254410|DRUG|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
224277964|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
224088090|NCT00254410|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
224088091|NCT00254410|DRUG|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
224088092|NCT03584763|DIAGNOSTIC_TEST|Umbilical artery Doppler|Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
223529908|NCT04369105|OTHER|Prone position|The patients will be put in prone position while receiving invasive mechanical ventilation and the investigators will monitor changes in mechanical power applied to the respiratory system and compare with supine position
223529909|NCT05432973|PROCEDURE|Percutaneous Electrical Nerve Stimulation|In the PENS treatment, a biphasic continuous waveform current with a frequency of 2 Hz, a pulse width of 50 microseconds and an intensity that produces visible motor responses of the innervated muscles was used, below the patient's pain threshold. The NT6021 Percutaneous Neuromodulation equipment of the Nutek® brand distributed by Fisiolab Ibérica® was used. This equipment has the CE marking, which denotes compliance with the requirements of the legislation of Royal Decree 414/1996 of March 1, which regulates medical devices. B.O.E. of April 24, 1996
223529910|NCT05432973|PROCEDURE|Neurodynamic and manual therapy|"The manual therapy consisted of passive-assisted mobilization and massage therapy of the muscular and fascial tissue, beginning with the cervical area, kneading while asking the patient to rotate the neck and then in the same way along the muscles and soft tissues innervated by the target nerve.~Neurodynamic was performed in a passive-assisted manner, combining the patient's cervical mobilizations with the mobility of the upper limbs adapted to each case."
223716332|NCT05387031|DRUG|Ustekinumab|The initial intravenous (IV) infusion with ustekinumab at baseline was weight-adjusted (260 mg ≤55 kg, 390 mg between 55 and 85 kg, 520 mg ≥85 kg). According to the label, the first subcutaneous (SC) 90 mg induction dose was administered at week 8 followed by a maintenance dose of 90 mg SC every 8 or 12 weeks, at the discretion of the physician. This study evaluated the CD disease activity, obstructive symptoms, and radiographic or endoscopic remission in patients at different follow-up time points, and comprehensively evaluated the efficacy of ustekinumab in relieving stenotic CD and its related factors.
223716333|NCT03111602|OTHER|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
223913958|NCT05667480|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
223913959|NCT05667480|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and pre-recorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
223913960|NCT03245593|OTHER|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
223913961|NCT03245593|OTHER|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
223913962|NCT06806111|PROCEDURE|Suture|Hemostatic sutures at the palatal donor site; 5-0 non-resorbable suspensory mattress sutures will be anchored to the soft tissues apical to the palatal wound area (5-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA).
224088093|NCT06300515|BEHAVIORAL|Control Group (Active Comparator)|During the intervention phase (hospitalization for HSCT and subsequent 8-week outpatient phase following discharge), the control group will participate in a Health Counseling Program (1 time/week) on aspects related to a healthy lifestyle such as reducing sedentary lifestyle, acquiring healthy nutritional habits, the importance sleep, screen use, and how to address barriers related to clinical status. We will adapt the program to the needs and timing of the patient's treatment, providing the content in one session/week orally (e.g. using presentations) and in writing (e.g. through brochures).
223529911|NCT04425239|DRUG|Panitumumab|Continuous administation
223529912|NCT04425239|DRUG|Panitumumab|Intermittent administation
223529913|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (monoacylglycerol form)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
223716334|NCT02528396|DRUG|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
223716335|NCT02528396|DRUG|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
223716336|NCT00917397|DRUG|Sertraline|varies
223716337|NCT00917397|BEHAVIORAL|trauma-focused cognitive behavioural therapy|once a week
223716338|NCT03087643|OTHER|Passive mobilization - PM|
223716339|NCT00000557|BEHAVIORAL|social support|
223716340|NCT02740556|OTHER|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
223719429|NCT00002531|DRUG|cytarabine|
223719430|NCT00002531|DRUG|daunorubicin hydrochloride|
223719431|NCT00002531|DRUG|dexamethasone|
223719432|NCT00002531|DRUG|doxorubicin hydrochloride|
223719433|NCT00002531|DRUG|etoposide|
224088094|NCT06300515|BEHAVIORAL|Intervention Group|"Same as Control Group + exercise program as described below:~Same as Control Group + exercise program as described below:~Hospital ward (during HSCT); and Hospital Gym or online (patients' home) during the outpatient phase. Frequency: 3-5 days/week. Session duration: 30 to 55-60 minutes Aerobic training (5-25 minutes): bicycling, crank-ergometry, circuit-style exercises, and games. Muscle strength training (10-20 minutes): large muscle group exercises (upper/lower limb + trunk exercises) performed as a circuit using body weight or against resistance (against gravity and with body weight, elastic bands, dumbbells, weighted vests, machines), with a wide range of joint mobility and at submaximal/maximum voluntary speed. Inspiratory muscle training will also be performed (5 min daily, using a specific device that creates resistance against inspiration)."
224088095|NCT04226469|PROCEDURE|Tooth movement|The subject's canines will be retracted distally and crevicular fluid is collected
224088096|NCT00689247|DRUG|AZD1305|oral solution, single dose
223913963|NCT06806111|PROCEDURE|Cyanoacrylate bioadhesive|Several drops of a high-viscosity cyanoacrylate bioadhesive will be applied (Cuantum Oral Adhesive, Cuantum Medical Cosmetics S.L., Spain) to create a uniform adhesive layer.
223913964|NCT06806033|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab 7 days prior to the first dose of glofitamab.
223913965|NCT06806033|DRUG|Glofitamab|Participants will receive IV glofitamab, both in combination with gemcitabine and oxaliplatin and as monotherapy, for up to 12 cycles (cycle length = 21 days).
223913966|NCT06806033|DRUG|Gemcitabine|Participants will receive IV gemcitabine in combination with glofitamab and oxaliplatin for up to 8 cycles (cycles length = 21 days).
224088097|NCT00689247|DRUG|AZD1305|iv infusion, single dose
224088098|NCT04329221|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
224088099|NCT04329221|DRUG|Vaseline|Placebo
223913967|NCT06806033|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin in combination with glofitamab and gemcitabine for up to 8 cycles (cycle length = 21 days).
223913968|NCT06810674|BEHAVIORAL|Get out of your head campaign and website 2.0|"The Get out of your head campaign and website were launched in 2022 to improve men's mental health and reduce stigma (Stas et al., 2024). Developed with experts, a communication agency, and the target audience, the campaign included videos, testimonies, and a website with tailored information on mental health, suicide prevention, and help-seeking (www.komuitjekop.be).~The new campaign and updated website will focus specifically on facilitating help-seeking behaviour among men experiencing suicidal thoughts by increasing their perceived need for support. More specifically, the new campaign will aim to enhance the recognition of their suffering, the relevance of seeking and receiving help and changing the perception of suicidal thoughts, namely that these are not fixed or part of life, but instead are changeable and can improve with the correct help."
223913969|NCT06808373|BEHAVIORAL|hypnosis|Hypnosis will be applied to periodontitis patients
223529914|NCT04382027|DIETARY_SUPPLEMENT|Omega-3 + vitamin K2 (ethyl ester)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to an ethyl ester form.~Treatments are randomly assigned on days 0 and 7 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform the two treatments, with a minimum of 6 days between treatments."
223529915|NCT04548648|DRUG|Acalabrutinib|Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
223529916|NCT05151640|DRUG|Nintedanib|Nintedanib
223529917|NCT02781363|OTHER|Thoracic ultrasound|
223529918|NCT02781363|OTHER|CXR|
223529919|NCT01684904|RADIATION|Proton radiation|
224088100|NCT04329221|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
223529920|NCT05231980|DIETARY_SUPPLEMENT|Alpha lipoic acid (ALA)|ALA is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect.
223529921|NCT05231980|DRUG|Pentoxifylline (PTX)|Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
223529922|NCT05231980|DRUG|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
223529923|NCT01121757|DRUG|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
223529924|NCT01121757|DRUG|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
223529925|NCT04168931|DRUG|Trastuzumab|The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
223529926|NCT04106778|DRUG|DMT310|Topical Powder
224088101|NCT00166855|PROCEDURE|dynamic MRI and bone marrow sampling|
224088102|NCT01035190|DRUG|Budesonide|Inhalation, 200 µg/puff
224088103|NCT03480802|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
224088104|NCT03480802|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
224088105|NCT03480802|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
224088106|NCT05378009|BEHAVIORAL|relaxation and physical activity|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose), Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time), physical activity ( five session per the week conducted on treadmill, 30 minutes in the first treatment month and 40 minutes in the second treatment month)
224088107|NCT05378009|BEHAVIORAL|relaxation|This FD women group will include 30 females who will be treated for 8 weeks with oral proton pump inhibitors (taken one time daily with 40 mg pantoprazole-tablet dose) and Benson relaxation daily sessions (twenty minutes at morning time and another 20 minutes at the evening time)
223719434|NCT00002531|DRUG|ifosfamide|
223913970|NCT06808620|OTHER|The group where the peanut ball is used|Before the application, the appropriate ball size for the physical characteristics and comfort of the pregnant women will be determined. Pregnant women will be given 4 different sizes of peanut balls with a diameter of 40, 55, 65 and 75 cm. In order for the pregnant woman to continue her in-bed balance exercises and position changes, she will be allowed to sit on the peanut ball with her knees and hips at an angle of approximately 90° and her spine upright. A 40-55 cm birthing ball will be used for women between 150-160 cm tall, a 65 cm birthing ball for women between 160-170 cm tall, and a 75 cm birthing ball for women between 170-185 cm tall. Position changes with the peanut ball will be carried out in accordance with a position/exercise guide prepared by researchers in line with literature information. The peanut ball will be applied in 6 different positions. These positions to be applied will consist of side-lying positions, semi-sitting pose, forward bending pose and squatting pos
223913971|NCT06196710|DEVICE|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto the vessels.
223913972|NCT06196710|DEVICE|Hemo-clipping|Contact thermocoagulation using a 3.3mm probe, hemo-clips, or both. The use of the bipolar device involves firm mechanical compression and coagulation for about 8 seconds.
223913973|NCT05031832|DIAGNOSTIC_TEST|HIV test|HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status
223913974|NCT05392283|DEVICE|AERO vacuum cupping device|The treatment consists of 5 sessions (approx. 30 min) of vacuum massage. The vacuum pump provided by the device provides a type of vacuum massage, that can be adjusted according to applied suction and air flow. The resulting massage technique provides a type of soft tissue manipulation similar to the ancient traditional medicine technique of cupping. Nonetheless, this automated technique allows for more precise determination of the massage characteristics.
223913975|NCT05970016|DRUG|TCC1727 tablet（1）|TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
223913976|NCT05970016|DRUG|TCC1727 tablet（2）|Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.
223913977|NCT06808191|DEVICE|pulsed electromagnetic currant machine|Pulsed electromagnetic therapy will be delivered at the frequency of 12Hz, with magnetic flux density of 12G. Each treatment session will last for 1 hour, which will be repeated for 14 sessions within 4weeks.
223913978|NCT06808191|OTHER|Placebo|control group will receive intervention by using the same PEMF unit, but the output will be shut off.
223913979|NCT04667572|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
223913980|NCT06808711|OTHER|Buccocéan mouthwash|Normal conditions of use
223913981|NCT06808711|OTHER|Marketed mouthwash|Normal conditions of use
223913982|NCT06810271|BEHAVIORAL|Eccentric resistance exercise|150 maximal, unilateral eccentric contractions of the quadriceps muscles on a computerized dynamometer.
224088108|NCT01409928|DEVICE|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
223529927|NCT04106778|DRUG|Placebo|Placebo Topical Powder
223529928|NCT06643923|OTHER|Exercise|"F (Frequency): 3 days per week, with a total of 24 sessions. I (Intensity): Low to moderate intensity exercises with progression, ensuring no fatigue is induced.~T (Time): Each session will last 30 minutes, over a total period of 8 weeks.~T (Type):~Warm-up exercises Core stabilization exercises: Aimed at improving core stability. Cool-down exercises E (Enjoyment): Gamified exercises, with sessions conducted to music. A (Adherence): A follow-up system will be implemented, including reminder notes and regular sending of session links to ensure compliance."
223529929|NCT06643923|BEHAVIORAL|Urotherapy|The urotherapy education program was developed by an expert physiotherapist and was piloted with the families of children with DMD (16 parents) prior to the study. Pre-test and post-test assessments demonstrated that the knowledge level of DMD families increased after the training. Additionally, results from the satisfaction survey indicated a high level of satisfaction among the families regarding the urotherapy education (Mean satisfaction score: 33.875/35.000, Minimum=28, Maximum=35). Therefore, it was deemed appropriate to deliver the same urotherapy presentation to the DMD families within the scope of this study. The training lasts approximately 1 hour and will be delivered to families via an online method. Each family will receive the education individually, and no group sessions will be conducted.
223529930|NCT03809351|DRUG|[F-18]AV-1451-PET|All study participants will undergo brain imaging with \[F-18\]AV-1451-PET/MRI. \[F-18\]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
223529931|NCT03737292|DRUG|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
223529932|NCT03737292|DRUG|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
223529933|NCT05524012|DIAGNOSTIC_TEST|Blood sample|longitudinal blood samples for CTC monitoring
223913983|NCT04631445|OTHER|Ketogenic Diet|Ketogenic diet (KD) will consist of macros: dietary carbohydrates restricted to \< 30 g/day; daily protein intake will be targeted to 1.5 g/kg/day (targeted to ideal body weight).
223913984|NCT06175754|PROCEDURE|Laser ablation|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser
224088109|NCT05195788|BEHAVIORAL|Cardiac rehabilitation|The cardiac rehabilitation program is based on 3/week exercise training's sessions including aerobic and muscle building exercises. All exercises are individualized, supervised by a certified kinesiologist at the research center, and in line with the latest recommendations for physical activity in individuals with congenital heart disease. Participants are encouraged to do a minimum of 1 supervised session per week at the research center and may, with the agreement of the cardiologist and the kinesiologist, do the other training sessions at home (hybrid program). The characteristics of the activities are recorded with a heart rate sensor. Each session lasts a maximum of 60 minutes in total and includes approximately 30 minutes of aerobic exercise, and approximately 20 minutes of muscle strengthening exercises, with 5 to 10 minutes of warm-up and cool-down.
224088110|NCT03015103|DEVICE|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
224088111|NCT02243228|DRUG|GM-CSF|
224088112|NCT03122626|BEHAVIORAL|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
224088113|NCT02582996|DRUG|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
224088114|NCT02582996|DRUG|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
223529934|NCT05524012|DEVICE|MRI scan|longitudinal MRI scans (non-contrast enhanced)
223529935|NCT04005833|DIAGNOSTIC_TEST|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
223529936|NCT04728113|OTHER|Supportive care visit with questionnaires|5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit
223913985|NCT06175754|PROCEDURE|Laser with Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, laser plus sclerotherapy
223913986|NCT06175754|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy
223913987|NCT06645132|BEHAVIORAL|exercise intervention|Exercise intervention leveraging wearable devices and a custom smartphone application to cue exercise as a reminder during idle time during an inpatient hospital stay, post allogenic bone marrow transplant.
223913988|NCT05415709|DRUG|Carboplatin|Given IV
223913989|NCT05415709|DRUG|Cisplatin|Given IV
223913990|NCT05415709|PROCEDURE|Cytoreductive Surgery|Undergo CRS
223913991|NCT05415709|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
223913992|NCT05415709|DRUG|Paclitaxel|Given IV
223529937|NCT04728113|OTHER|Oncological standard visit|Oncological standard visit
223529938|NCT06530615|PROCEDURE|Bronchoalveolar Lavage (BAL) during Bronchoscopy|Bronchoalveolar Lavage (BAL) is a standard diagnostic tool for the evaluation of lower respiratory tract pathology including respiratory infections and unexplained radiographic pulmonary lesions including lung neoplasia. It is a minimally invasive procedure that involves introduction of the bronchoscope, installation of sterile normal saline into a subsegment of the lung, and suction and collection of the recovered saline for diagnostic evaluation.
223529939|NCT05847621|BEHAVIORAL|Peer recovery coaching with linkage to recovery resources|Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.
223719435|NCT00002531|DRUG|leucovorin calcium|
224088115|NCT02649257|PROCEDURE|cataract surgery|
224088116|NCT02649257|DEVICE|intraocular lens (MC 6125 AS)|
224088117|NCT02649257|DEVICE|capsular tension ring (CTR 13/11)|
224088118|NCT00893516|BIOLOGICAL|CHOP + CD4|
224088119|NCT00893516|DRUG|CHOP|
224088120|NCT05521737|PROCEDURE|Electroacupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. EA is applied for 20 minutes at an alternating frequency of 2 Hz. Acupunctural points are Zusanli (E36), Fenlong (E40), Yinlingquan (B9), Sanyinjiao (B6), Taichong (H3) and Zulinqi (VB41).
223913993|NCT05415709|OTHER|Quality-of-Life Assessment|Ancillary studies
224088121|NCT05521737|PROCEDURE|Sham Acupuncture|Intervention consists of a total of 32 sessions, divided into two intervention cycles, that is, 16 sessions over two months, with a rest period of one month in between. Sham acupuncture will be applied using a nonpuncture device without electrical stimulation at the same acupunctural points as in the EA group.
224088122|NCT04139083|PROCEDURE|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
223913994|NCT05415709|OTHER|Questionnaire Administration|Ancillary studies
223913995|NCT05415709|PROCEDURE|Biospecimen Collection|Undergo stool sample collection
223913996|NCT05415709|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
223913997|NCT05153252|BEHAVIORAL|Morning Exercise|Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
223913998|NCT05153252|BEHAVIORAL|Evening Exercise|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
223913999|NCT06827522|PROCEDURE|Birth Under General Anesthesia|Before anaesthesia, GSR electrodes will be connected and signal recording will be started. After caesarean section, the newborn will be evaluated and GSR signals will be recorded again after the mother wakes up by providing skin-to-skin contact.
224088123|NCT04139083|PROCEDURE|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
224088124|NCT02393911|DIETARY_SUPPLEMENT|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
224088125|NCT00267527|DRUG|CJC 1295|
224088126|NCT00352248|PROCEDURE|Tongue Acupuncture (Procedure)|
223719436|NCT00002531|DRUG|mercaptopurine|
223914000|NCT06827522|PROCEDURE|Birth Under Spinal Anesthesia|GSR electrodes will be connected before anaesthesia, and since the mother will be conscious during caesarean section, the newborn will have skin-to-skin contact with the mother immediately after birth. During this process, GSR signals of the mother and the baby will be recorded.
223914001|NCT03114072|DEVICE|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
223914002|NCT03114072|DEVICE|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
223914003|NCT05977907|DRUG|Pembrolizumab|Pembrolizumab is an investigational drug in this study
223914004|NCT05977907|DRUG|IO102-103|IO102-103 is an investigational drug in this study.
223914005|NCT03890614|OTHER|Ancillary-Correlative - Creation of three-dimensional myeloma organoids using marrow aspirates|Bone marrow aspirates will be collected from participants with hematologic malignancy being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
224088127|NCT05444712|PROCEDURE|Chemotherapy + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
224088128|NCT05444712|PROCEDURE|Chemotherapy + ASCT + follow up|"* Chemotherapy administrated every 3 weeks for 6 cycles according to local investigator's choice based on usual practices.~* An intermediate evaluation will be performed after four cycles by PET-CT (or CT-Scan for non-avid PTCL)~* The fifth or sixth cycles should be used as stem-cell mobilizing chemotherapy for patients with ASCT strategy~* A post-induction evaluation by PET-CT or CT-Scan will be done between 3 and 5 weeks after the last chemotherapy drug administration for all patients~* Patients with in Complete Response after 6 cycles will receive a High Dose Therapy as conditioning regimen before transplantation~* A last evaluation by PET-CT or CT-Scan will be done between 08 and 12 weeks after the post-induction for all patients"
223914006|NCT05868421|BEHAVIORAL|Support Person Coaching Call|Support person participants assigned to the intervention group will additionally receive a 1-call coaching session about 15-25 minutes in duration on how to support their Veteran smoker. The session will be delivered by research staff by phone or video call. Support persons in the intervention group and the control/no intervention group will receive existing written material resources on support strategies to stop smoking, and resources on how to stop smoking by postal mail or email.
223914007|NCT05868421|BEHAVIORAL|SP written materials|Written materials covering tips on effective supportive strategies for smoking cessation
224088129|NCT05858190|PROCEDURE|Parallel Assignment|intervention group: treated with drug eluting balloon（paclitaxel-coated balloon； Orchid, Acotec Scientific Holdings Limited, Beijing, China)； control group :treated with plain old balloon
224088130|NCT03601871|DRUG|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
224088131|NCT03601871|DRUG|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
223529940|NCT05847621|BEHAVIORAL|Usual Care|Participants will be provided with a list of community recovery resources.
223529941|NCT01890330|OTHER|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
223529942|NCT01890330|OTHER|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
223914008|NCT05868421|BEHAVIORAL|Written Smoking Cessation Materials|Written materials on resource and referral information for VHA and non-VHA EBCT options
223914009|NCT03988621|BEHAVIORAL|ViCCY|Virtual Caregiver Coach for You
224088132|NCT03601871|DRUG|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
224088133|NCT00701493|DRUG|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
224088134|NCT05650034|RADIATION|Elective nodal de-escalation arm|Omission of elective nodal irradiation in N0 hemi-neck of well lateralized H\&N SCCs ( pN0 or by PETCT). Dose de-escalation of elective nodal irradiation in N0 hemi-neck of midline H\&N SCCs ( pN0 or by PETCT).
224088135|NCT01774214|PROCEDURE|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
224088136|NCT01774214|PROCEDURE|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
224088137|NCT03695029|DRUG|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
224088138|NCT00751413|DRUG|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
223716341|NCT02740556|DEVICE|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
223716342|NCT02740556|OTHER|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
223716343|NCT02083783|DRUG|TRI102|formulation containing active moiety (amphetamine)
223716344|NCT02083783|OTHER|Placebo|formulation without active moiety
223716345|NCT00149201|DRUG|5-FU continuous infusion|
224088139|NCT03669978|PROCEDURE|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
224088140|NCT04726332|DRUG|XL102|oral doses of XL102
223716346|NCT00149201|DRUG|MTX + 5-FU sequential therapy|
223716347|NCT05514938|DRUG|Polypill|Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.
223716348|NCT05514938|DRUG|Usual Care (individual medications prescribed by primary cardiologist)|Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.
223716349|NCT02287857|DRUG|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
223716350|NCT02287857|DRUG|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
223716351|NCT01546883|DRUG|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
223716352|NCT04179708|OTHER|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
223716353|NCT04179708|OTHER|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
223716354|NCT04746963|DRUG|AXT107 0.1 mg|Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
223529943|NCT01965249|DEVICE|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HR48 mm
223529944|NCT01965249|DEVICE|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
223529945|NCT05834881|BEHAVIORAL|Contingency Management (CM) combined with vocational/educational coaching|Two evidence based practices, CM and vocational/educational coaching, will be combined and delivered by paraprofessional coaches in an intervention named PEERS (Peers Education Empowering Recovery Supports). CM uses positive reinforcement (e.g., chances to win prizes) for clients who abstain from substance use. A standardized and well-validated CM protocol will be used in the proposed study. Vocational/educational coaching assists individuals in completing educational and vocational goals. A workbook developed specifically for vocational/educational coaching in emerging adults will be used in the study.
223529946|NCT06969807|DRUG|Amimestrocel|In the first month (day 1, 14, 28): 1×10E6 cells per kilogram. From the 8th to the 24th week (week 8, 12, 16, 20, 24): 1.5×10E6 cells per kilogram.
223716355|NCT04746963|DRUG|AXT107 0.25 mg|Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
223716356|NCT04746963|DRUG|AXT107 0.5 mg|Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
223716357|NCT04154735|DRUG|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
223719437|NCT00002531|DRUG|methotrexate|
223914010|NCT06649682|DRUG|68Ga-NYM096 PET/CT and 177Lu-NYM096|Patients recruited in this study will undergo 68Ga-NYM096 PET/CT to evaluate the expression of carbonic anhydrase 9. Those with high CA9 expression will undergo 177Lu-NYM096 treatment, starting from 50mCi and increasing to 100mCi, 150mCi, 200mCi at most using a 3+3 design.
223914011|NCT06650098|OTHER|artificial intelligence-supported mobile application|It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\&#39;s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\&#39; diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
223914012|NCT06650098|OTHER|WEB based application|The content plan for the web-based mobile application group will be prepared with technical support as specified. Patients will be able to log in to the mobile application with a username and password that will be defined specifically for them. Patients will be informed about how the website is used during the first meeting. They will be able to access all the information they need about diabetes with the web-based mobile application. Statistical data such as the frequency of individuals visiting the site, which sections they use more often and how much time they spend will be calculated.
223914013|NCT06649994|DEVICE|Active iTBS of the DLPFC|Participants will receive a 3 minutes intermittent Theta Burst Stimulation of the DLPCF of the left hemisphere while not performing any other task
223914014|NCT06649994|DEVICE|Active iTBS of the vmPFC|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vmPFC while not performing any other task
223914015|NCT06649994|DEVICE|iTBS of the vertex (sham)|Participants will receive a 3 minutes active intermittent Theta Burst Stimulation of the vertex while not performing any other task
223914016|NCT06649994|BEHAVIORAL|Computerized inhibitory control training|"Participants will perform the task of the FoodT app for 10 minutes immediately after iTBS (taking advantage of time of maximum brain potentiation, Rossi et al., 2009).~This task pairs high-calorie meals with the no-go cue. Images appear on the left, right or center of the smartphone screen and they must touch it or not (depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses: If the image has a green border around it, you must tap the image and win 1 point. But if the image has a red border around it, you must inhibit the tapping response or you will lose 1 point. Participants must respond as quickly and accurately as possible and improve reaction time.~Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal"
223914017|NCT05283265|BEHAVIORAL|Sentence Type|Subjects read different types of sentences (object-relative, subject -relative and control sentences) to observe how that sentence affects their intracranially recorded neural activity.
223914018|NCT05283265|OTHER|Direct brain stimulation|On some trials the investigators will apply intracranial electrical current through the electrodes implanted in the participants and observe the effect this has on their behavior (which picture they choose at the end of the trial) and the effect this has on their neural activity that the investigators record simultaneously through-out the experiment.
223914019|NCT03887780|DRUG|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
223914020|NCT06203834|DIETARY_SUPPLEMENT|I-Fiber Pearl|Eat 200g for once, and once a day.
223914021|NCT06203834|DIETARY_SUPPLEMENT|placebo|Eat 200g for once, and once a day.
223914022|NCT06650956|OTHER|Integrated HPV and SRH Service Package|"1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school."
224088141|NCT04726332|DRUG|Fulvestrant|fulvestrant 500 mg administered as an intramuscular (IM) injection every 2 weeks for the first 3 doses and then every 4 weeks.
224088142|NCT04726332|DRUG|Abiraterone|abiraterone 1000 mg administered orally once daily.
224088143|NCT04726332|DRUG|Prednisone|prednisone 5 mg administered orally twice daily.
223529947|NCT06967987|DRUG|Bemarituzumab + Flot regimen|"Bemarituzumab (IV administration) over 30 min (+/- 10min) at C1D1 to C8D1 + 15 mg/kg of bodyweight + single additional dose of 7,5 mg/kg at C1D8~\+ FLOT regimen~* Fluorouracil for solution for infusion (IV administration) as a continuous IV infusion approximately 24 hours 2600 mg/m²~* Leucovorin (folinic acid) solution for infusion (IV administration) over 120 min on the first day, 200 mg/m²~* Oxaliplatin concentrate for solution for infusion (IV administration) over 120 min on the first day, 85 mg/m²~* Docetaxel concentrated for solution for infusion (IV administration) over 60 min on the first day, 50 mg/m²"
224088144|NCT02972827|DEVICE|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
224088145|NCT02972827|OTHER|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
224088146|NCT02752828|DRUG|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223914023|NCT06650956|BIOLOGICAL|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
223914024|NCT01585623|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223914025|NCT01585623|DRUG|omeprazol|"Pharmaceutical form:capsule~Route of administration: oral"
223914026|NCT01585623|DRUG|metoprolol|"Pharmaceutical form:tablet~Route of administration: oral"
223914027|NCT01585623|DRUG|midazolam|"Pharmaceutical form:solution~Route of administration: oral"
223914028|NCT03973827|DRUG|ProTrans|Single infusion of 25, 100 or 200 million cells per patient.
223914029|NCT03973827|OTHER|Control|No intervention. Control subjects.
224088147|NCT02752828|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224088148|NCT02752828|DRUG|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
223716358|NCT04154735|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
223914030|NCT06652100|DIAGNOSTIC_TEST|ProNephro AKI (NGAL)|ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.
223914031|NCT06653036|PROCEDURE|Dural puncture epidural|The Dural puncture epidural technique is done by assessing the epidural space using the Touhy needle and puncturing the dura matter with a finer needle.
224088149|NCT06960473|DEVICE|Intravascular Ultrasound|In the IVUS group, the diameter of the reference vessel (the normal segment of the artery distal to the occlusion) is measured using Intravascular Ultrasound (IVUS). Based on the IVUS measurements, an appropriate balloon is selected to dilate the occluded segment.
223716359|NCT04154735|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
223914032|NCT06653036|PROCEDURE|Standard Epidural Technique|The Standard Epidural Technique is usually performed by identifying the epidural space using the loss of resistance technique and threading the epidural catheter in the epidural space for administration of analgesic drugs.
223914033|NCT04629339|DRUG|INCB086550|INCB086550 will be administered orally twice a day.
223914034|NCT05844150|DRUG|PM8002|IV infusion
223914035|NCT05844150|DRUG|Platinum|IV infusion
223914036|NCT05844150|DRUG|Etoposide|IV infusion
223914037|NCT04705519|DRUG|Nab-paclitaxel Combined With Bevacizumab|Nab-paclitaxel 150mg/m2 ，iv drip, d1, Bevacizumab 5mg/kg, iv drip, d1, q2w.
223914038|NCT02488564|DRUG|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
223914039|NCT02488564|DRUG|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
224088150|NCT06960473|DEVICE|Digital Subtraction Angiography|The DSA group patients will have the appropriate balloon dilation selected for the occluded segment based on the DSA measurement results.
224088151|NCT06289569|OTHER|Home telerehabilitation therapy|Occupational therapist prescribed hand/arm exercises will be assigned to patients. Records of each subject's motor tasks, number of repetition and level of performance will be kept. Standard of care home therapy will be performed Monday-Friday for approximately 4 weeks, followed by 4 weeks of application-driven home teletherapy. It is expected that approximately 20 treatments will be finished in 4weeks, however the amount of therapy completed will be recorded to accommodate patients' schedules. Treatment times can be broken up into multiple treatment periods to accommodate patient and caregiver preferences.
223719438|NCT00002531|DRUG|mitoxantrone hydrochloride|
223719439|NCT00002531|DRUG|prednisolone|
224088152|NCT06293703|PROCEDURE|Surgery|Biliopancreatic limb and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length in RYGB
224088153|NCT06462417|DRUG|Arbidol|Arbidol Hydrochloride Tablets 0.2g/d for 2 weeks
224088154|NCT00010231|DIETARY_SUPPLEMENT|calcitriol|
223914040|NCT02488564|DRUG|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
223914041|NCT02488564|DRUG|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
223914042|NCT00302744|DRUG|Psilocybin (drug)|Capsule (.2 mg/kg).
223914043|NCT00302744|OTHER|Niacin|Active Placebo
223914044|NCT00302744|DIAGNOSTIC_TEST|MRI|MRI required for study inclusion for purpose of ruling out metasteses to brain
224088155|NCT00010231|DRUG|dexamethasone|
224088156|NCT02451787|DIETARY_SUPPLEMENT|Vitamin D|2400 units per day for 3 months
224088157|NCT01728779|DRUG|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
224088158|NCT01728779|RADIATION|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
224088159|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
224088160|NCT00814385|BIOLOGICAL|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
223529948|NCT06971796|DEVICE|Inspire UAS System|Participants will be implanted with the Inspire UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
223914045|NCT05562557|BEHAVIORAL|Motivational Enhancement|To encourage intrinsic motivation to engage in fatherhood activities
223914046|NCT05562557|BEHAVIORAL|HERO Dads Fatherhood Program|Fatherhood engagement curriculum to increase awareness, knowledge, and skills for parenting and co-parenting
223914047|NCT05562557|BEHAVIORAL|Contingency Management|To reinforce healthy behaviors, including attendance at services
223914048|NCT05562557|BEHAVIORAL|Case Management|Referrals to treatment, social services, and employment services
223914049|NCT03998527|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
223914050|NCT06059456|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
223914051|NCT06059456|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
223914052|NCT05238519|BEHAVIORAL|Motivational interview (MI)|"The MI intervention is adapted from the CHEERS study intervention (M Health Fairview) found to be effective in promoting lipid screening in patients at increased risk for FH.~Within one month of completion of the baseline survey, a study coordinator, who received training in motivational interview integrity, will conduct a 20-40-minute (depending on participant needs) telephone or virtual (zoom) interview with participants randomized to this arm. Participants will be assessed on their readiness to get their cholesterol checked and discuss with family members the risk of FH."
223914053|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation Randomized)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 4 weeks using a non-invasive brainstem modulation device.
223914054|NCT05580211|DEVICE|Non-invasive brainstem modulation device (stimulation-Open Label)|Study participants will receive \~19-minute treatments twice daily in the clinic setting over 8 weeks using a non-invasive brainstem modulation device.
223914055|NCT03270059|DRUG|Ferumoxytol|Given IV
224088161|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
224088162|NCT00814385|BIOLOGICAL|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
224088163|NCT00814385|BIOLOGICAL|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
224088164|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
224088165|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
224088166|NCT00814385|BIOLOGICAL|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
223914056|NCT03270059|DRUG|Gadolinium|Given IV
223914057|NCT03270059|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224088167|NCT00814385|BIOLOGICAL|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
224088168|NCT05730595|PROCEDURE|lymph node dissection|The extent of lymph node dissection varies between groups
224088169|NCT04822545|OTHER|referral to comprehensive weight management clinic|"Patients will receive a referral for outpatient CWM clinic, with a message sent to the CWM clinic scheduler, prior to hospital discharge.~At six months after discharge, the patient will receive a phone call from the investigators to ascertain whether they were able to go to the CWM clinic and about their experience."
224088170|NCT03843476|DEVICE|Patient Specific Rod|Posterior spinal fusion rod
224088171|NCT06416163|OTHER|Prospective|Collection of prospective data all ready available for participant
224088172|NCT05759884|DRUG|Anti-VEGF|Intravitreous injection of anti-VEGF drugs
224088173|NCT05759884|RADIATION|subthreshold micropulse laser|577nm micropulse laser photocoagulation therapy
224088174|NCT02958943|BEHAVIORAL|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
224088175|NCT02688348|OTHER|Quality-of-Life Assessment|Ancillary studies
224088176|NCT02688348|OTHER|Questionnaire Administration|Ancillary studies
224088177|NCT00624520|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
223529949|NCT04902807|BIOLOGICAL|Collection of samples|Blood, Urine and Stool samples will be collected from the participants.
223529950|NCT05817942|DRUG|Filgotinib|Jyseleca
223529951|NCT04085172|DRUG|Guanfacine hydrochloride (TAK-503)|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.
223716360|NCT04154735|DRUG|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
223914058|NCT05303129|BIOLOGICAL|Blood sampling|Blood sampling for Lymphocyte typing (Neutrophil/Lymphocyte ratio (NLR), CD4+ and CD8+ lymphocyte counts )
223914059|NCT04381299|OTHER|autologous platelet rich plasma|The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
224088178|NCT00624520|OTHER|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
224088179|NCT02204631|OTHER|Head and Neck Educational Handbook|
224088180|NCT04082208|DEVICE|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
224088181|NCT04082208|DEVICE|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
224088182|NCT02492633|BEHAVIORAL|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
223529952|NCT04085172|DRUG|Atomoxetine hydrochloride|Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.
223529953|NCT04085172|OTHER|Placebo|Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.
223716361|NCT04154735|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
223914060|NCT04381299|OTHER|saline solution|The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
223914061|NCT04938726|DIETARY_SUPPLEMENT|Ketone Monoester|Ketone supplement will be taken by mouth at a dose of 15 mL twice per day
223914062|NCT04864353|BEHAVIORAL|RestDep: Internet-delivered intervention targeting residual cognitive symptoms|The intervention is fully digital with weekly telephone guidance. Key intervention elements are 1) psychoeducation, 2) attention training, 3) strategy training. Cognitive domains as attention, memory and executive functions are covered and rumination.
224088183|NCT02492633|BEHAVIORAL|Intervention|"At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~1. A web-based smoking cessation intervention via Facebook~2. Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~3. A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program."
224088184|NCT02698098|DRUG|Methadone|
224088185|NCT04905667|DRUG|GB221|6 mg/kg, single dose, intravenous infusion, 90-100 min
224088186|NCT04905667|DRUG|Herceptin|6 mg/kg, single dose, intravenous infusion, 90-100 min
223914063|NCT06026969|OTHER|Neurodevelopmental assessments and follow-up|All infants included in this study will receive standardized neurodevelopmental assessment and neurological examinations through age 18 months.
223914064|NCT04158739|DRUG|Cytarabine|Given IT
223914065|NCT04158739|BIOLOGICAL|Flotetuzumab|Given IV
224088187|NCT00216723|DRUG|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"
224088188|NCT04106154|BEHAVIORAL|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
224088189|NCT00065143|DRUG|clofarabine|
224088190|NCT00065143|DRUG|Ara-C|
224088191|NCT05774327|OTHER|Foam Roller|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. For 6 weeks, in addition to foot core exercises, myofascial release will be applied with foam roller 2 days a week. Myofascial release application areas; thoracolumbal fascia, iliotibial band, hamstring, gastro-soleus, peroneal, plantar fascia.
224088192|NCT05774327|OTHER|Foot Core Exercises|Participants will be shown 7 different foot core exercises and will be instructed to do 10 repetitions 3 times a day. Foot core exercises; short foot exercise, toe flexion exercise, heel lift exercise,toe abduction exercise, big toe and other toes extension exercise, front swing exercise, back walking exercises. Participants will do the exercises with the researcher two days a week and the other days follow-up will be provided through the online platform.
224088193|NCT01925209|DRUG|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
224088194|NCT01925209|DRUG|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
224088195|NCT02865382|PROCEDURE|white light was used for colonoscopy withdrawal|
224088196|NCT02865382|PROCEDURE|OE mode was used for colonoscopy withdrawal|
224088197|NCT02796755|DRUG|Riluzole|Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
224088198|NCT02796755|DRUG|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
224088199|NCT05014477|PROCEDURE|Removal or leaving of LAA occluders|After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
224088200|NCT02318758|DRUG|UT-15C|sustained release oral treprostinil
223529954|NCT00611663|BIOLOGICAL|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
223529955|NCT00611663|BIOLOGICAL|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
223529956|NCT06157801|BEHAVIORAL|Interview Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
223529957|NCT06157801|BEHAVIORAL|Survey Study|"All study participants will have the following demographic information collected from their medical records:~* Sex (Male/Female/Other)~* Date of birth~* Preferred language (English/Spanish)~* Health insurance status (for example: private insurance, HCHD gold card)~* Cancer diagnosis (if yes: cancer type/organ, date of pathology diagnosis)~* Genetic testing result (gene with pathogenic/likely pathogenic variant)~* Date of genetic testing result~* Date of documented result disclosure."
223529958|NCT06161831|BEHAVIORAL|Text Message/automated phone reminder|Receipt of text message or automated phone reminders notifying when the next HPV vaccine dose is due (either first or second)
223914066|NCT04354129|DRUG|Cutaquig®|Immunoglobulin replacement therapy with subcutaneous injections of Cutaquig® 165 mg/mL at home.
223914067|NCT04539392|OTHER|Questionnaires on sexuality|Panel of questionnaires assessing sexuality, relationship satisfaction, and body image
224088201|NCT02318758|OTHER|ethanol|Absolut 100 vodka
224088202|NCT05640401|DEVICE|Endoscopy guided by mixed reality (HoloLens2TM) (HXtend™ software)|"Included expert gastrointestinal endoscopists performing diagnostic procedures with mixed reality guidance. All the procedures will be performed by using the HoloLens2TM (Microsoft, Redmond, WA, USA), an ergonomic self-contained holographic device.~HoloLens2TM (Microsoft, Redmond, WA, USA) uses HXtend™ developed software (mdconsgroup, Guayaquil, Ecuador) installed and running on Windows holographic OS. The monitors signals are replicated into holograms by an app developed with the unity Software package (Version 2022.1.22, Unity Technologies, San Francisco, CA, USA).~After each procedure, the researchers will evaluate the device performance along with the acceptance and experience of the endoscopists using this technology."
224088203|NCT05764148|BEHAVIORAL|behavioral activation|"Behavioral Activation (BA) is a specific CBT skill. It can be a treatment all by itself, or can be used alongside other CBT skills such as cognitive restructuring.~Behavioral activation helps us understand how behaviors influence emotions, just like cognitive work helps us understand the connection between thoughts and emotions."
224088204|NCT01545960|OTHER|not applicable in this study|No actual interventions will be administered for this study.
223529959|NCT06364540|DRUG|Ketamine|Nebulized ketamine administered at 0.75 mg/kg via BAN
224088205|NCT01561651|OTHER|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
224088206|NCT02002702|DRUG|Serelaxin|Intravenous infusion
223529960|NCT06364540|DRUG|Fentanyl|Nebulized fentanyl administered at 3 mcg/kg via BAN
223716362|NCT04154735|DRUG|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
223719440|NCT00002531|DRUG|teniposide|
224088207|NCT02002702|DRUG|Placebo|Placebo
223914068|NCT06585696|DRUG|CU-20101 treatment for Moderate to Severe Glabellar Striae|"Part I (randomized double-blind controlled study) Study Part 1 consisted of a 1-day baseline/treatment period (randomized and received 1 dose of study treatment) and a 12-week post-treatment follow-up period.~Part II (open-label study) For subjects who completed Part I of the study, they automatically entered Period 2 of the study. To evaluate the safety, efficacy, and immunogenicity of repeated injections of CU-20101 in the treatment of moderate to severe glabellar striae if they meet the criteria for repeat treatment (as shown in Figure 1, at least 12 weeks apart from each test drug injection). If repeat treatment criteria are not met at follow-up, follow-up may continue after 4 weeks until the next treatment is met. The last study treatment was no later than Day 253 ± 7 days (Week 36)."
223914069|NCT06567730|OTHER|Ni-ti Closed-coil Spring|Ni-Ti closed-coil spring is a passive compressed spring made up of super elastic Nickel-titanium. Two eyelets are attached to each side of the coil to facilitate its application. The eyelets will be engaged in the hooks of the second premolar and canine brackets and will apply a force of 150 gm.
223914070|NCT06567730|OTHER|Elastomeric Power chain|Elastomeric power chains are resilient and latex-free orthodontic materials. They are made up of elastic material and consist of many connected rings. Each ring is engaged in a bracket to apply a force of 175-300 gm.
223914071|NCT05981573|DIAGNOSTIC_TEST|Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo|Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Aptamer based Assay
224088208|NCT01845545|OTHER|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
224088209|NCT00150098|BEHAVIORAL|Enhanced HIV risk reduction and HIV vaccine education|
224088210|NCT01316393|OTHER|XER2020|mucoprotective product
224088211|NCT06160401|DRUG|Singletine|Singletine orally administered
224088212|NCT06160401|DRUG|Placebo|Placebo orally administered
224088213|NCT04398732|DRUG|Enbrel|As provided in real world practice
224088214|NCT00166790|DRUG|chemotherapy agents|
224088215|NCT00166790|PROCEDURE|suction curettage|
224088216|NCT01845714|PROCEDURE|Corneal Cross Linking|
224088217|NCT01845714|PROCEDURE|Corneal Cross Linking combined with topoguided PRK|
224088218|NCT00968422|DRUG|ABT-384|3 escalating doses will be administered daily for 21 days
224088219|NCT00968422|DRUG|Matching placebo to ABT-384|Doses will be administered daily for 21 days
224088220|NCT00556426|DEVICE|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
224088221|NCT02113670|OTHER|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
224088222|NCT00002623|DRUG|carboplatin|
224088223|NCT00002623|DRUG|cisplatin|
223529961|NCT05990543|DRUG|Nelmastobart and Capecitabine|"Nelmastobart intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered on Day 1 of each cycle.~Capecitabine is administered orally for two weeks followed by a one-week rest period"
223529962|NCT06136208|DRUG|s.c 25 mg estradiol pellet|Subcutaneous insertion of 25 mg estradiol pellet.
223914072|NCT05981573|DRUG|Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo|Measurement of Methadone and its metabolites in ISF with LC-MS and RMM
223914073|NCT05981573|DEVICE|ISF Extraction Device 2|Up to 15 minute periods of continuous ISF collection for analysis
224088224|NCT00002623|PROCEDURE|conventional surgery|
224088225|NCT00002623|RADIATION|radiation therapy|
224088226|NCT02395991|DRUG|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
224088227|NCT02395991|OTHER|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
224088228|NCT01724957|PROCEDURE|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
224088229|NCT01596257|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
224088230|NCT01596257|DEVICE|CliniMACS|
224088231|NCT00936988|DRUG|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
224088232|NCT05501626|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
224088233|NCT05501626|DEVICE|Sham Theta Burst Stimulation (TBS)|Each session will be comprised of SHAM TBS: intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex totaling 37,800 pulses.
224088234|NCT06487546|DIETARY_SUPPLEMENT|Ergothioneine|This is a 1-arm study in which participants will take ergothioneine daily with dose range of 5 mg to 25 mg daily. Blood levels of ergothioneine will be monitored while taking daily ergothioneine and after ergothioneine is stopped.
223529963|NCT06569797|DIETARY_SUPPLEMENT|oligosaccharides and multiple nutrients|The effect of adding milk oligosaccharides and optimizing multiple nutrients to infant formula on the growth and development of infants aged 0-1 years
224088235|NCT04019366|OTHER|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
224088236|NCT04019366|OTHER|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
224088237|NCT02274337|DRUG|AC0010|patients take avitinib orally once per day at different dose
224088238|NCT06454084|DRUG|Acetylcholine Chloride|Vasodilator solution
223914074|NCT05405556|DIAGNOSTIC_TEST|eGFR reporting|"To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers"
223914075|NCT02106949|DEVICE|SMS contact with patient after discharge in intervention group|
223914076|NCT03914469|BEHAVIORAL|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and up to two semi-structured interviews at 6 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
223914077|NCT04778410|DRUG|Magrolimab|Administered intravenously
224088239|NCT03599180|DEVICE|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
224088240|NCT00237133|DRUG|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
224088241|NCT06526780|PROCEDURE|Bronchscopy|Bronchscopy in critical ill children with airway diseases
224088242|NCT02876692|DEVICE|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
224088243|NCT02427113|OTHER|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
224088244|NCT02427113|OTHER|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
224088245|NCT02714478|DEVICE|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
224088246|NCT02714478|DEVICE|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
224088247|NCT01523483|DRUG|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
224088248|NCT01523483|DRUG|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
224088249|NCT00826735|BEHAVIORAL|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
224088250|NCT05146141|OTHER|Bent-arm throw exercises|The participants will have to perform bent-arm throw exercises 5 minutes before each training session
224088251|NCT05617521|DEVICE|Abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device
224088252|NCT05617521|DEVICE|Loose abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt)|Revive 3-in-1 Postpartum Recovery Support Belt (KeaBabies® Co., CA, USA). An abdominal binder is a kind of elastic abdominal compression device. It will be loosened just prior the procedure.
224088253|NCT01672931|OTHER|Oocyte Measurement|
224088254|NCT04917770|DRUG|Sintilimab in combination with Multimodality Radiotherapy|Participants will be treated with sintilimab in combination with multimodality radiotherapy
224088255|NCT03860948|DRUG|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
224088256|NCT03860948|DRUG|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
224088257|NCT06373874|BEHAVIORAL|Heel blood collection in a newborn simulation model|"The person who will take heel blood in the newborn simulation model can prepare the materials.~Firstly, the blood sample can fill in all the information on the filter paper. Knows where the baby's face should be. It can determine the area where a heel blood sample can be taken.It can gently warm the heel area for a few minutes. The area can be cleaned with alcoholic preparation (cotton/swab, etc.). He can squeeze the heel with his thumb and index finger in front. The other 3 fingers can be rubbed at the back. May stroke the heel three times. The heel can be pierced once with a lancet at a suitable location. He can relax his hand. He can wipe away the first drop of blood. It can create a large thick drop of blood to be collected on filter paper. It can make the drop fill the entire ring on the filter paper with one touch. After the procedure is completed, the heel can be pressed."
224088258|NCT02673333|DRUG|Pembrolizumab|
224088259|NCT00131807|PROCEDURE|Blood Pressure Measurement|
224088260|NCT00131807|PROCEDURE|Questionnaire|
223719441|NCT00002531|DRUG|thioguanine|
223914078|NCT04778410|DRUG|Azacitidine|Administered either subcutaneously or IV, 75 mg/milligram per square (m\^2) on Days 1 to 7 or Days 1 to 5, 8 and 9 during every cycle
223914079|NCT04778410|DRUG|Venetoclax|Administered orally at a dose of 100 mg on Day 1, 200 mg on Day 2, 400 mg on Days 3-28 during Cycle 1, followed by 400 mg on Days 1-28 during every cycle
223914080|NCT04778410|DRUG|Mitoxantrone|Administered intravenously, 8 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
224088261|NCT02347631|DEVICE|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first."
224088262|NCT02347631|DEVICE|Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.|"Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first."
224088263|NCT01509625|DRUG|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
224088264|NCT03448640|DRUG|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
224088265|NCT00393419|BEHAVIORAL|Comprehensive pharmacy care program|
224088266|NCT05859035|DEVICE|KIOS Informational App|"The KIOS informational app will contain a user interface that includes a login page, true/false questions for the user to answer, verified public domain educational information about drug and alcohol use, Likert-type questions regarding the information presented, and a closing Thank You screen."
224088267|NCT03982550|BEHAVIORAL|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
224088268|NCT04375657|COMBINATION_PRODUCT|TRIIM Treatment|Personalized combination of somatropin, metformin, and DHEA
224088269|NCT04375657|COMBINATION_PRODUCT|Active Control|Metformin and DHEA
224088270|NCT00934102|DEVICE|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
224088271|NCT00934102|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
224088272|NCT00934102|DEVICE|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
223716363|NCT04154735|DRUG|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
223914081|NCT04778410|DRUG|Etoposide|Administered intravenously, 100 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
223914082|NCT04778410|DRUG|Cytarabine|Administered intravenously, 1000 mg/m\^2 on Days 1-5 during Cycle 1 to Cycle 3
223716364|NCT02256631|BIOLOGICAL|VRC01|Administered by subcutaneous injection in the thigh
223716365|NCT02256631|BIOLOGICAL|VRC01LS|Administered by subcutaneous injection in the thigh
223716366|NCT02256631|BIOLOGICAL|VRC07-523LS|Administered by subcutaneous injection in the thigh
223716367|NCT01646307|DRUG|Atorvastatin|
223914083|NCT04778410|DRUG|CC-486|Administered orally, 300 mg on Days 1-14 during each cycle
223914084|NCT04060108|DRUG|MDMA|80mg, 120mg, Placebo
223914085|NCT05695820|OTHER|Blood Flow Restriction training|It is a method that involves reducing blood flow to a muscle by the application of an external constricting device, such as a blood pressure cuff or tourniquet, to provide mechanical compression of the underlying blood vessels. BFR is applied aiming to enhance blood pooling in the capillary beds of the limb muscles distal to the tourniquet
223914086|NCT05683132|BEHAVIORAL|Trauma-Informed CBT-I|5 individual sessions incorporating behavioral and cognitive therapy components and trauma-informed adaptations with a trained instructor.
223914087|NCT05683132|BEHAVIORAL|PTSD Psychoeducation|5 individual sessions incorporating psychoeducation about PTSD symptoms with a trained instructor.
223716368|NCT01646307|DRUG|Rosuvastatin|
223716369|NCT04682028|OTHER|professional care|The trained nurses provide professional care for the patients.
223716370|NCT04682028|OTHER|coventional care|nurses provide coventional care for the patients.
223716371|NCT01577680|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
223716372|NCT01577680|DRUG|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
223719442|NCT00002531|DRUG|vincristine sulfate|
223719443|NCT00002531|DRUG|vindesine|
223914088|NCT06541041|DEVICE|Brief intraoperative electrical stimulation|Intraoperative brief electrical stimulation (BES) will be performed using a handheld nerve stimulator (Checkpoint Guardian) to stimulate the donor nerves at 2 mA with a 200 µs pulse duration for 10 minutes per nerve.
223914089|NCT06541041|DEVICE|Temporary Postoperative Peripheral Nerve Stimulation|An implantable temporary peripheral nerve stimulator (SPRINT PNS System) will be placed during the surgery with one lead for each donor nerve. The implantable peripheral nerve stimulator will be programmed to optimize postoperative pain control on an individualized basis. The peripheral nerve stimulator will be explanted after 60 days, as is intended for this device.
223914090|NCT05209984|DRUG|ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg|Participant will receive for two (2) weeks one (01) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsule once daily + one (01) sibutramine placebo capsule 10mg; after that 2 weeks, participants will receive one (01) placebo capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) capsule of ADF sibutramine IR/ topiramate XR 5mg/25mg once daily + one (01) 10mg sibutramine placebo capsule; after this period, they will receive two (02) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 10mg of sibutramine and 50mg of topiramate) + a placebo capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once a day + one (one) 10mg sibutramine placebo capsule, taken once daily, for two (02) additional weeks, on the titration scheme. On the treatment period, will receive one (01) ADF Sibutramine IR/Topiramate XR 15mg/75mg capsule + one (01) Sibutramine IR 15mg placebo capsule (Sibus®) + one (01) Topiramate XR 100mg placebo capsule, once daily, for 52 weeks.
223914091|NCT05209984|DRUG|ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg|Participant will receive for two (02) weeks one (01) capsule of ADF sibutramine IR/topiramate XR 5mg/25mg once daily + one (01) capsule of placebo sibutramine 10mg; after this initial period of 2 weeks, participants will receive (02) ADF sibutramine IR/topiramate XR 5mg/25mg capsules (totaling 10mg of sibutramine and 50mg of topiramate) + one (01) 10mg sibutramine placebo capsule, taken once daily, for two (02) weeks; after this period, they will receive three (03) capsules of ADF sibutramine IR/topiramate XR 5mg/25mg (totaling 15mg of sibutramine and 75mg of topiramate) + one (01) capsule of 10mg sibutramine placebo, taken once daily, for two ( 02) additional weeks, on titration scheme. On the treatment period, will receive one (01) Sibutramine IR 15mg capsule (Sibus®) + one (01) Topiramate XR 100mg capsule + one (01) ADF placebo capsule sibutramine IR/topiramate XR 15mg/75mg, taken once daily, taken once daily, for 52 weeks.
223914092|NCT05209984|DRUG|SIB Group Sibus (Sibutramine) 15mg|Participant will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) 5mg/25mg sibutramine ADF placebo capsule IR/topiramate XR; after this initial period, they will receive for two (02) weeks one (01) 10mg sibutramine capsule + two (02) placebo capsules of ADF sibutramine IR/topiramate XR 5mg/25mg; after this 4-week period, participants will receive one (01) 10mg sibutramine capsule and three (03) ADF sibutramine IR/topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) additional weeks. This corresponds to the titration scheme.On the treatment period, patient will receive one (01) Sibutramine 15mg capsule + one (01) Sibutramine IR/topiramate XR 15mg/75mg placebo capsule + one (01) placebo capsule of Topiramate XR 100mg, taken once daily, for 52 weeks.
223914093|NCT05209984|DRUG|Placebo Group|participants randomized to the Placebo Group will receive for two (02) weeks one (01) 10mg sibutramine placebo capsule + one (01) sibutramine IR/ topiramate XR 5mg/25mg placebo capsule; after this initial period, they will receive one (01) sibutramine 10mg placebo capsule + two (02) sibutramine IR/ topiramate XR 5mg/25mg placebo capsules, taken once daily, for two (02) weeks; after this 4-week period, participants will receive one (01) 10mg sibutramine placebo capsule + three (03) ADF placebo capsules, taken once daily, for two (02) weeks.On the treatment period, patient will receive one (01) Sibutramine 15mg placebo capsule + one (01) ADF sibutramine IR/Topiramate XR 15mg/75mg placebo capsule + one (01) Topiramate XR 100mg placebo capsule, in once daily intake for 52 weeks.
223914094|NCT06082050|DRUG|YOLT-201|Infusion of YOLT-201 at Day 1， Subjects may voluntarily accept the second study drug treatment at the OBD (Optimal Biological Dose) level.
223914095|NCT05308979|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites
223914096|NCT06828484|DRUG|Allergenic Extract Standardized Cat Hair Acetone-Precipitated (AP)|Cat-allergic and non-allergic participants will be exposed to AP Cat in the NAC.
223914097|NCT06038513|DEVICE|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 24 hours
223914098|NCT06822153|DRUG|ET-26 0.8mg/kg(low-dose) group|In a 2:1 ratio, Placebo was administered with normal saline and ET-26 0.8mg/kg for a duration of 60 ±5 seconds.
223914099|NCT06822153|DRUG|ET-26 2.8mg/kg(high dose) group|In a 2:1 ratio, Placebo was administered with normal saline and ET-26 2.8mg/kg for a duration of 60 ±5 seconds.
223914100|NCT05082454|DEVICE|Open repair|Open repair of the aortic heart valve and ascending thoracic aorta
223914101|NCT05282030|DRUG|tolebrutinib|Pharmaceutical form: Film-coated tablets Route of administration: oral
223914102|NCT03944356|DRUG|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
224088273|NCT04285320|DRUG|Intravesical antibiotic instillation|"Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water"
223529964|NCT06569797|DIETARY_SUPPLEMENT|no oligosaccharides and optimizing multiple nutrients|The effect of traditional infant formula milk powder optimized without adding milk oligosaccharides and multiple nutrients on the growth and development of infants aged 0-1 years old.
223529965|NCT06569797|DIETARY_SUPPLEMENT|breastfeeding|The impact of breastfeeding on the growth and development of infants aged 0-1 years old.
223529966|NCT01803633|OTHER|Cheddar cheese|Tillamook medium cheddar cheese brand
224088274|NCT04285320|DRUG|Antibiotic oral suppressive therapy|"In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)"
223914103|NCT04993170|DIAGNOSTIC_TEST|Bleeding assessment tool|The standardized application of the questionnaire serves to identify patients at risk of bleeding at an early stage and to adapt and optimize perioperative coagulation management accordingly by initiating targeted diagnostics and therapy
223914104|NCT06828770|DEVICE|Minima Stent System|Minima Stent System is indicated for use in the treatment of native or acquired pulmonary artery stenoses or coarctation of the aorta in neonates, infants, and children at least 1.5kg in weight.
223914105|NCT04350177|DRUG|IkT-148009|Oral administration gelatin capsule
223914106|NCT04350177|DRUG|Placebo|Oral administration gelatin capsule
223914107|NCT04936178|DRUG|NB003 tablets|NB003 tablets will be administered at assigned doses for escalation phase and RP2D doses for expansion phase orally twice daily for repeated 28-day cycles until discontinuation criteria are met.
223914108|NCT02815150|DIETARY_SUPPLEMENT|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
223914109|NCT05384561|OTHER|Smell training|For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
223914110|NCT05977556|BEHAVIORAL|Combined neuromuscular exercise training and 'sit less, move more' program|"Neuromuscular strength training: The experimental group will receive up to 24 sessions of neuromuscular strength training led by a physical therapist with expertise in geriatrics and movement behaviors. The program includes exercises such as pelvic lifts, lunges, step-ups, squats, and sit-stands. The difficulty level will progressively increase using techniques like manual resistance, dumbbells, and unstable surfaces.~Sedentary behavior intervention: The experimental group will also undergo a sedentary behavior intervention based on social cognitive theory. It involves weekly coaching sessions to enhance self-efficacy in reducing sedentary time and increasing light-intensity activity throughout the day. Participants will be provided with a wrist-worn Fitbit activity monitor for daily feedback and to track adherence to the intervention. The aim is to encourage participants to sit less and move more throughout their waking hours."
223914111|NCT06573619|OTHER|Validation of questionnaire|Validation of questionnaire
223914112|NCT06638996|DIETARY_SUPPLEMENT|CBG Intervention|50 mg CBG Administered
223914113|NCT06638996|OTHER|Placebo Intervention|Participants will be administered a placebo
223914114|NCT05398770|DIETARY_SUPPLEMENT|Vitamin D supplementation (30 µg/d)|The participants will be instructed to take the tablets (vitamin D or placebo) once a day 4 weeks prior to the onset of the non-surgical periodontal treatment (NSPT), and to continue for two weeks after their first NSPT, altogether 6 weeks.
223914115|NCT04860635|DRUG|F14 (sustained release celecoxib)|Celecoxib in BEPO® drug delivery system
223914116|NCT00677365|DRUG|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
223914117|NCT00677365|DRUG|Placebo|same frequency as study drug using the same nebulizer
223914118|NCT03346343|DEVICE|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
223914119|NCT06853574|DRUG|Fluid therapy|Infusion of 8 ml/Kg/30' or 16 ml/kg/60' of fluids.
223914120|NCT06853574|DRUG|Noradrenaline infusion|dosage will be titrated in order to obtain mean arterial pressure target
223914121|NCT06855381|PROCEDURE|the ISBC group, SonoPlex needle and E-catheter|in the ISBC group, a 22G 50 mm SonoPlex needle with an indwelling cannula will be used. The E-catheter will be inserted into the indwelling cannula.
223529967|NCT01803633|OTHER|Vegan cheese|Daiya brand vegan cheese
223529968|NCT06973720|DRUG|MET097|For subcutaneous administration.
223529969|NCT06973720|DRUG|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration.
223529970|NCT06110910|DRUG|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH)|Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) and recombinanthuman growth hormone injection (rhGH) were used.
223529971|NCT06053892|DIAGNOSTIC_TEST|Puncture|Shoulder puncture with the newly designed technique using AR to overlie the US image to the imaged anatomical structures in comparision to standard US and flurosopic-guidance.
223914122|NCT06855381|PROCEDURE|single bolus injection|An ultrasound-guided peripheral nerve block puncture will be performed from the lateral to the medial side of the neck. In this group a 22G 50 mm needle will be used
223529972|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 1|Two doses of the non-adjuvanted HSV formulation 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223529973|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 2|Two doses of the non-adjuvanted HSV formulation 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223914123|NCT04924868|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones
223914124|NCT04924868|DRUG|Placebo|Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
223914125|NCT06854523|DRUG|PCSK9 inhibitor|The patient used Trastuzumab 150mg within 24 hours before or after PCI, and then every two weeks for 12 months
223914126|NCT06854523|DRUG|Statin+ezetimibe|The patient used statins and ezetimibe within 24 hours before or after PCI, and then once a day for 12 months
223914127|NCT06854523|BEHAVIORAL|Blood lipid levels meet the recommended guidelines|Early use of intensified lipid-lowering therapy during hospitalization led to a rapid decrease in blood lipids and met the recommended guidelines.
223914128|NCT06854523|BEHAVIORAL|Blood lipid levels don't meet the recommended guidelines|The patient did not receive intensified lipid-lowering treatment during hospitalization or did not meet the recommended guidelines for blood lipids
223914129|NCT06855108|DRUG|Caffeine citrate oral solution|Caffeine citrate oral solution will be used and administered by enteral route (oral or by gavage tube). The loading dose (20 mg/kg) will be administered once followed by daily doses of 10 mg per kg body weight every 24 hours for two doses. The study Standard Operating Procedures (SOPs) includes details regarding caffeine preparation based on the participant's body weight.
223914130|NCT06855108|DRUG|Oral placebo solution|Identical placebo oral solution
223914131|NCT06853743|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Nicotinamide riboside, 2 capsules of 500mg taken twice daily for 2 years
223914132|NCT06853743|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 capsules twice daily for 2 years
223914133|NCT06854146|DIAGNOSTIC_TEST|gastric cancer|patients diagnosed with gastric cancer
223914134|NCT06854146|DIAGNOSTIC_TEST|healthy|healthy participants
223914135|NCT06854250|PROCEDURE|Prostate cryoablation|Enrolled patients will receive prostate cryoablation within 6 months of starting androgen deprivation therapy.
223914136|NCT06854250|DRUG|Cyclophosphamide (CTX)|Enrolled patients will receive cyclophosphamide (50mg daily) one day after prostate cryoablation and continue for a total of six months.
223914137|NCT06854796|DEVICE|Recombinant collagen gel|The test device uses a recombinant collagen gel developed by Shaanxi Juzi Biotechnology Co., Ltd., which is different from other designs. The main components of recombinant collagen gel are recombinant collagen, disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, water for injection, after the injection, collagen can occupy a place at the injection site to improve the visual aging caused by soft tissue loss, wrinkles and depressions, and the special manufacturing process can ensure that the gel has smoothness and ductility, which helps to achieve a smooth and natural appearance, effectively and gradually improve wrinkles and plump cheeks.
223914138|NCT06854796|DEVICE|collagen implant agent|1\. After the product is injected into the skin, the collagen implant forms a soft mesh structure through condensation, which can make up for skin defects. 2. After implantation of this product, the connective tissue cells around the implantation site will grow into the collagen network structure and gradually form a bionic structure similar to normal tissue. 3. This product is absorbable and degradable. The collagen implant will be gradually decomposed by protease in the body, and the pressure, elongation and hierarchy of the implant site tissue will affect the final degradation and duration.
223914139|NCT06855017|OTHER|create a pillbox day|create a pillbox day based on two separate fictitious prescriptions
223914140|NCT06854211|DRUG|Morphine p.o.|Morphine 50mg PO will be given on sleep study night.
223914141|NCT06854211|DRUG|Placebo|Placebo will be given on the sleep study night.
223914142|NCT06812767|DIAGNOSTIC_TEST|electrocardiography|12 standard leads
224088275|NCT05931783|PROCEDURE|skeletonized harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in skeletonized technique. Thereby, only the artery itself is harvested.
224088276|NCT05931783|PROCEDURE|pedicled harvesting technique|In patients who are randomized to this treatment arm, the left internal thoracic artery will be harvested in pedicled technique. Thereby, the artery will be harvested together with the accompanying veins, the endothoracic fascia and fatty tissue in order to create an 1-2 cm broad pedicle.
224088277|NCT00421876|BEHAVIORAL|multifactorial continued educational - behavioural programme|
224088278|NCT02318784|DRUG|Carfilzomib|
224088279|NCT00203684|DRUG|Flunisolide-HFA|
224088280|NCT01219842|PROCEDURE|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
224088281|NCT01219842|OTHER|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
224088282|NCT03812406|PROCEDURE|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
223719444|NCT00002531|PROCEDURE|allogeneic bone marrow transplantation|
223914143|NCT06812767|DIAGNOSTIC_TEST|analysis for glucose and cholesterol in the capillary blood|express test
224088283|NCT03812406|PROCEDURE|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
223529974|NCT05298254|BIOLOGICAL|Non-adjuvanted HSV formulation 3|Two doses of the non-adjuvanted HSV formulation 3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223529975|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 1|Two doses of the HSV formulation 1 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223914144|NCT06812767|DIAGNOSTIC_TEST|detection of microalbumuria|express test
223914145|NCT06812767|DIAGNOSTIC_TEST|heart ultrasound examination|Ultrasound examination with Lumify Handheld S4-1 Phased Array Ultrasound (Philips)
223914146|NCT06812767|DIAGNOSTIC_TEST|carotid artery ultrasound examination|Ultrasound examination with Lumify Handheld L12-4 Linear Array Ultrasound (Philips)
223914147|NCT06811662|PROCEDURE|mitral valve replacement|complete versus partial preservation of subvavular apparatus during mitral valve replacement
223914148|NCT05974280|DRUG|Alofisel|Alofisel is made up of 'mesenchymal stem cells' from the fat tissue of a donor. Alofisel is a medicine that is used to treat complex anal fistulas in adults with Crohn's disease
223914149|NCT05974280|DRUG|Fat stem cell|mesenchymal stem cells from adipose (fat) tissue injection
223914150|NCT06811402|OTHER|virtual reality|the patient will wear a VR mask during the session
224088284|NCT00000981|DRUG|Fiacitabine|
224088285|NCT02960282|PROCEDURE|Biospecimen Collection|Undergo collection of fecal specimens
224088286|NCT02960282|OTHER|Laboratory Biomarker Analysis|Correlative studies
224088287|NCT00766792|PROCEDURE|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
224088288|NCT00766792|PROCEDURE|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
223529976|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 1|Two doses of the HSV formulation 2 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223529977|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 1|Two doses of the HSV formulation 3 with adjuvant 1 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223914151|NCT06851169|DRUG|Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib)|Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 12 mg, po, qd, was taken orally for 2 consecutive weeks and stopped for 1 week. Anlotinib was stopped 1 week before surgery. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Adjuvant therapy (benmelstobart combined with anlotinib, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 12 mg, po, qd, was taken orally for 2 weeks and stopped for 1 week.
224088289|NCT02304926|DRUG|Simvastatin|simvastatin (40 mg/day) for 4 weeks
224088290|NCT02304926|DRUG|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
224088291|NCT02304926|DRUG|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
224088292|NCT01438645|DEVICE|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
224088293|NCT00848744|DRUG|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
224088294|NCT00848744|DRUG|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
224088295|NCT00792298|DRUG|Suvorexant|oral tablet taken before bedtime
224088296|NCT00792298|DRUG|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
224088297|NCT01361347|DIETARY_SUPPLEMENT|milk|milk for milk allergic children (1:25 dilution, whole milk)
224088298|NCT04737148|OTHER|Mortality scores|Revised Baux, BOBI and FLAMES scores
224088299|NCT04940234|BEHAVIORAL|Exposure to a Photo|We plan to recruit subjects and randomly assign them to one of four treatments. In each treatment arm, the subject will view a photo of a man. We experimentally vary treatment along two dimensions: whether the man is wearing expert vs. layperson attire and whether the man is white vs. black. We will survey participants' beliefs about the actors' educational attainment and perceived quality as measured by subjects' willingness to accept medical advice for non-urgent health issues or participate in a clinical trial being led by the individual in the photo.
224088300|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 pm
224088301|NCT05868785|DIETARY_SUPPLEMENT|Parenteral nutrition|Parenteral nutrition will be administered starting at 8 am
224088302|NCT02732067|OTHER|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
224088303|NCT03649152|DRUG|Propagermanium|Immediate release capsule
224088304|NCT03649152|DRUG|Placebo|Placebo capsule
224088305|NCT05448625|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
224088306|NCT04752202|BEHAVIORAL|Individually balanced elimination/reducing diets|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced elimination/reducing diets, in accordance with the previously performed food sensitivity tests for 6 months. Laboratory tests for type III food sensitivity in the IgG1-3 class using the ELISA method were performed in an accredited medical laboratory. Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
224088307|NCT04752202|BEHAVIORAL|Individually balanced reducing diets (without elimination)|Participants received diets in the range of 1400-1600 kcal/day (with a deficit of about 1000 kcal/day, depending on the resting metabolism and energy expenditure during the day). At the initial visit and every subsequent month, the women received individually balanced reducing diets (without elimination) for 6 months.Diets were designed by a qualified dietitian using the Aliant (Poland) diet calculator. Each diet had the same macronutrient content - 25% protein, 30% fat, and 45% carbohydrate, and met the daily requirements for micro and macro elements for the given age group.
224088308|NCT01405092|DEVICE|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
223529978|NCT05298254|BIOLOGICAL|HSV formulation 1 with adjuvant 2|Two doses of the HSV formulation 1 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223529979|NCT05298254|BIOLOGICAL|HSV formulation 2 with adjuvant 2|Two doses of the HSV formulation 2 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223719445|NCT00002531|PROCEDURE|peripheral blood stem cell transplantation|
224088309|NCT01405092|DEVICE|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
224088310|NCT03719235|OTHER|CBCT|ultra-low dose CBCT
224088311|NCT01812642|DRUG|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
223914152|NCT06851169|DRUG|Cohort 2: Neoadjuvant therapy (benmelstobart only)|Cohort 2: Neoadjuvant therapy (benmelstobart only, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Adjuvant therapy (benmelstobart, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1.
224088312|NCT01812642|OTHER|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
224088313|NCT05447702|DRUG|Camrelizumab|Intravenous (IV) infusion
224088314|NCT05447702|DRUG|Apatinib|po.
224088315|NCT05447702|DRUG|Nab-paclitaxel|IV infusion.
224088316|NCT05447702|DRUG|Epirubicin|IV infusion.
224088317|NCT05447702|DRUG|Cyclophosphamide|IV infusion.
224088318|NCT04354428|DRUG|Ascorbic Acid|Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
223716373|NCT01944696|OTHER|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
223716374|NCT02267083|DRUG|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
223914153|NCT06855420|DEVICE|Vibration on|Sole vibration will be applied by a vibrating insole system for 10 days. Participants will wear the device for at least 4 hours per day.
223914154|NCT06855420|DEVICE|Vibration off|Participants will wear the device with vibration turned off for at least 4 hours per day during 10 days of intervention.
223914155|NCT06853717|BEHAVIORAL|Therapy Together|CIMT consists of retraining the preferred hand by covering the hand with a soft mitt to promote the use of the assisting hand. With consistent practice, a toddler or infant builds the fine and gross motor skills of their assisting hand and bilateral coordination skills.
224088319|NCT04354428|DRUG|Hydroxychloroquine Sulfate|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and folic acid therapy
224088320|NCT04354428|DRUG|Azithromycin|Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
224088321|NCT04354428|DRUG|Folic Acid|Eligible participants in a household will receive folic acid and an additional intervention drug
224088322|NCT04354428|DRUG|Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]|Eligible participants in a household randomized to this study arm will receive lopinavir-ritonavir therapy
224088323|NCT03872492|OTHER|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively."
224088324|NCT03855501|OTHER|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
224088325|NCT03855501|OTHER|Calcium hydroxide|Apexification treatment was done with calcium hydroxide
224088326|NCT05987748|BEHAVIORAL|Exercise training|Mixed exercise training containing strength and endurance elements carried out under supervision
224088327|NCT01639430|OTHER|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
224088328|NCT03291314|DRUG|Axitinib|1\. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
224088329|NCT03291314|DRUG|Avelumab|2\. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
224088330|NCT00224666|DEVICE|Cortex stimulation|
224088331|NCT05688462|OTHER|Data Collection|This is an observational prospective cohort study. Children admitted to ten identified PICUs in the UK with severe TBI with a clinical need for ICP and ABP monitoring will be included for data collection. The database will contain routinely monitored physiological parameters during management of PTBI in PICU. Without disturbing the routine care and management of these patients, investigators aim to collect this data continuously in a bedside laptop equipped with the study software (ICM+, Cambridge Enterprise Ltd, Cambridge, UK). Alongside these physiological parameters, investigators will also collect relevant clinical and demographic data (details below) and follow these patients for up to 12 months post ictus to assess neuro-psychological outcome.
224088332|NCT01393977|PROCEDURE|rehabilitation of limb function|only receive rehabilitation of limb function
224088333|NCT01393977|PROCEDURE|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
224088334|NCT03670459|OTHER|Cawthorne Cooksey exercises|Eye movements and head movements
224088335|NCT03670459|OTHER|Vestibular habituation exercises|Move from a sitting position to flat on the back
223914156|NCT06808815|DRUG|DC-806|administered orally.
223914157|NCT06808815|OTHER|Placebo|administered orally.
223914158|NCT06809556|OTHER|EEG (electroencephalogram) monitoring of Parkinson's patients undergoing deep brain stimulation|Parkinson's patients undergoing deep brain stimulation (DBS) will be monitored with EEG to detect burst suppression signals during surgery and will undergo postoperative cognitive testing for postoperative delirium.
223914159|NCT06853834|DEVICE|Cryobiopsy with liquid nitrogen|Forceps vs Cryo Endobronchial Biopsy
224088336|NCT03670459|OTHER|Balance exercises|Weight Shift Forward and Back
224088337|NCT01770327|BEHAVIORAL|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
224088338|NCT00460980|BEHAVIORAL|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
224088339|NCT04007159|OTHER|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02 milliliters per centimeters square \[mL/cm\^2\] of serum in an individual cell of patch)
224088340|NCT04007159|OTHER|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of lotion in an individual cell of patch)
224088341|NCT04007159|OTHER|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of cream in an individual cell of patch)
224088342|NCT04007159|OTHER|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm\^2 of normal saline in an individual cell of patch)
224088343|NCT02388295|DRUG|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
224088344|NCT02388295|DRUG|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
224088345|NCT03718247|OTHER|Modified Atkins diet|High fat low carbohydrate diet.
224088346|NCT01963481|DRUG|Exemestane|
224088347|NCT01963481|DRUG|Cyclophosphamide|
224088348|NCT04239326|DIAGNOSTIC_TEST|targeted Next Generation Sequencing (tNGS)|The index tests used in this trial will include up to three end-to-end, targeted next generation sequencing (tNGS) solutions for diagnosis of DR-TB. Each solution will include all of the equipment, reagents, and software necessary for handling the entire sequencing workflow, including DNA extraction from processed sputum samples (i.e. sediment), library preparation, sequencing, and data analysis/interpretation for clinical result reporting.
223914160|NCT06853834|DEVICE|Endobronchial Forceps Biopsy|Comparision of forceps and cryo endobronchial biopsy
223914161|NCT06808737|PROCEDURE|Transversus Abdominis Plane Blockage|Patient monitoring will be conducted, followed by the preparation of the skin with 10% povidone-iodine and ensuring appropriate draping. A high-frequency linear transducer will be placed transversely between the right iliac crest and subcostal margin along the midaxillary line. Structures visualized on ultrasound from superficial to deep include: skin, subcutaneous fat, external oblique muscle, internal oblique muscle, transversus abdominis muscle, and peritoneum. The TAP block will be performed in the transversus abdominis plane (TAP) between the internal oblique and transversus abdominis muscles. A 23-gauge, 60 mm blunt-tipped needle will be directed toward the TAP, and negative aspiration will be confirmed upon entry into the fascial layer. An injection of 20 mL of 0.25% bupivacaine, prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline, will be performed, followed by the visualization of the oval spread of bupivacaine in the TAP.
224088349|NCT03240926|DEVICE|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
224088350|NCT04258579|BEHAVIORAL|PROTECT with Technology Augmentation|PROTECT is a therapeutic intervention focused on treating victims of elder abuse who are experiencing depression. PROTECT therapy will be delivered through video. Participants will be provided with a mobile device (iPhone), and a wearable device (smart watch) that will track sleep, mood, steps, and heart rate.
223914162|NCT06853899|DIETARY_SUPPLEMENT|Truology A2|Truology A2 (0.2% Retinaldehyde Serum) - Applied once daily at night after cleansing.
223914163|NCT06853899|DIETARY_SUPPLEMENT|Truology C-Boost|Truology C-Boost - Applied twice daily (morning \& night).
224088351|NCT04924426|PROCEDURE|TTC immersion|TTC immersion
224088352|NCT05432531|DRUG|Anti JAK1,2|Induction of remission of active lupus nephritis
224088353|NCT05432531|DRUG|Cyclophosphamid|Induction of remission of active lupus nephritis
224088354|NCT01510327|DEVICE|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
224088355|NCT01510327|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
224088356|NCT01510327|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
223914164|NCT06853899|DIETARY_SUPPLEMENT|Truology Barrier Restore|Applied twice daily (morning \& night) as the final skincare step.
223914165|NCT06654089|DIETARY_SUPPLEMENT|Emergen-C Core Super Orange Powder|A dietary supplement powder containing vitamin C, zinc, vitamin B6, vitamin B12, folate, and manganese.
223914166|NCT06654089|DIETARY_SUPPLEMENT|Placebo|A study product identical to the test product without active ingredients.
223914167|NCT06654557|OTHER|Placebo beverage, kiwi-strawberry flavor (Part 1 and Part 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose.
223914168|NCT06654557|OTHER|0% carbohydrate electrolyte solution with glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223914169|NCT06654557|OTHER|0% carbohydrate electrolyte solution without glycerol beverage (Part 1 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223914170|NCT06654557|OTHER|1% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223914171|NCT06654557|OTHER|6% carbohydrate electrolyte solution with glycerol beverage (Parts 1 and 2)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223914172|NCT06654557|OTHER|6% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223914173|NCT06654557|OTHER|2% carbohydrate electrolyte solution without glycerol beverage (Part 2 only)|9.3 oz (276 ml) aliquots 3 times for a total of 28 oz (828 ml) over a 35 min period followed by 25 min rest until Time 0 post-dose. Beverage matched to placebo for color and flavor.
223914174|NCT06853405|BEHAVIORAL|Nutrition-related lifestyle group sessions|"In person lifestyle group sessions of 180-minutes per week, directed by a nutritionist, and comprising:~1. 120-minute nutrition education session for preparing healthy meals, followed by a period of social interaction while consuming the meals prepared. Participants will be encouraged to apply the healthy cooking techniques covered in each session in their home context.~2. 60-minute sessions of daily activities to reduce physical inactivity (e.g., walking to the supermarket to buy ingredients, playing traditional games, caring for community gardening, among others)."
223914175|NCT06853405|BEHAVIORAL|Nutrition-related cognitive training|Individualized nutrition-based cognitive training performed remotely, at home on their own. The participants will be invited to perform cognitive training exercises including novel nutrition-related exercises, and watch educational videos promoting nutrition literacy at least twice a week using COGWEB®, an online platform for cognitive training. For those unable to use computer devices, similar exercises will be available in paper-and-pencil format.
223914176|NCT06853405|BEHAVIORAL|Clinical nutrition consultations|A registered nutritionist will conduct individualized clinical nutrition consultations to each participant three times over the course of the study period.
223914177|NCT06813118|DRUG|Clomiphene Citrate and letrozole|clomiphene citrate 100mg once daily along with letrozole 5mg to one group and letrozole 5mg to second group
223914178|NCT06812234|OTHER|DAX Copilot|"* Enrolled in DAX Copilot program.~* Epic Haiku verified and adapted to record visits for DAX.~* Virtual training to add Patient List column to schedule for DAX Note Status, add appropriate smartlinks to note templates (AI-generated history of present illness, physical exam, and assessment and plan).~* In person at-the-elbow support from Children's Epic Support on Site team at initiation and up to 2 additional sessions."
223914179|NCT06812923|DEVICE|transcranial Alternating Current Stimulation (tACS)|tACS, parameters: 15mA、77.5Hz tACS, 20 times (5 times a week, four weeks totally)
223914180|NCT06812923|DEVICE|Sham stimulation|Sham stimulation, matched with real tACS, except for providing electrical stimulation
223914181|NCT06655727|DIAGNOSTIC_TEST|Ultrasound evaluation|No intervention
223914182|NCT06654739|DEVICE|Laser therapy + physiotherapy/exercise protocol|laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
223914183|NCT06654739|DEVICE|Sham Laser therapy + physiotherapy/exercise protocol|sham laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
224088357|NCT01650090|DRUG|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
224088358|NCT05085509|PROCEDURE|US guidance and MB staining|Ultrasound guidance and methylene blue staining
224088359|NCT02076165|BEHAVIORAL|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
224088360|NCT02076165|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
224088361|NCT04387097|DRUG|remifentanil|postoperative drip-infusion of remifentanil
224088362|NCT04477226|DIAGNOSTIC_TEST|Transvaginal ultrasound scan|Transvaginal ultrasound is done to measure the cervical length, as per Fetal Medicine Foundation guidelines
224088363|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
224088364|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX (PG)|5.0 grams of PGX
224088365|NCT00801814|DIETARY_SUPPLEMENT|PolyGlycopleX|7.5 grams of PGX
224088366|NCT00801814|DIETARY_SUPPLEMENT|Control|0g of PGX
224088367|NCT00801814|DIETARY_SUPPLEMENT|Second Control|0g of PGX
224088368|NCT01755988|OTHER|Educational website (in addition to usual care).|
223914184|NCT06811623|PROCEDURE|Laparoscopic Sleeve Gastrectomy with omentopexy|Laparoscopic Sleeve Gastrectomy with omental fixation to the gastric tube
224088369|NCT01755988|OTHER|Website and interactive platform with telemonitoring.|
224088370|NCT01242644|DEVICE|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
223914185|NCT06811623|PROCEDURE|Laparoscopic Sleeve Gastrectomy without omentopexy|Laparoscopic Sleeve Gastrectomy without omental fixation to the gastric tube
223914186|NCT01121588|DRUG|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
223914187|NCT06498128|DRUG|Daridorexant|Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
223914188|NCT06498128|DRUG|Non-orexin receptor antagonist medications for insomnia|Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
223914189|NCT06498128|OTHER|No insomnia medication|No insomnia medication was administered.
223914190|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Baseline|Measurement of rubella IgG antibody levels at baseline
223914191|NCT05923970|DIAGNOSTIC_TEST|Serology to assess cell mediated immune (CMI) response - Baseline|Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.
223914192|NCT05923970|DIAGNOSTIC_TEST|Serology for antibody levels - Post third dose of MMR vaccine|Measurement of rubella IgG antibody levels post third dose of MMR vaccine
223914193|NCT05923970|DIAGNOSTIC_TEST|Serology to assess CMI - Post third dose of MMR vaccine|Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.
223914194|NCT03655080|RADIATION|Radiation therapy|Using the View Ray System
223914195|NCT03655080|DRUG|nab-Paclitaxel|"* Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes"
223914196|NCT06814873|BEHAVIORAL|Neurofeedback|The participants received visual feedback of the processed result of neural signals acquired online.
223914197|NCT06814873|BEHAVIORAL|Sham-feedback|Previously recorded neural signals are processed and presented to participants as if the signals from them are processed online.
223914198|NCT06752174|BIOLOGICAL|sIPV+bOPV|"2+1 sequential immunization program (sIPV-sIPV-bOPV)"
223914199|NCT06752174|BIOLOGICAL|wIPV+bOPV|"2+1 sequential immunization program (wIPV-wIPV-bOPV)"
223914200|NCT06591819|RADIATION|Hypofractionated Whole Pelvis Proton Therapy with Brachytherapy Boost|Brachytherapy boost will be delivered and then whole pelvis proton radiation therapy in 5 fractions.
223914201|NCT06595212|OTHER|multiomic profile to assess genetic and environmental risk factiors|Genomic, epigenetic, proteomic, microbiome, immunology, biomarker, metabolite, pesticide, metal, and metalloid investigations will be conducted. The twins will be followed longitudinally from a clinical perspective, with biological sample collections to assess discordance and identify early disease signatures in unaffected individuals.
223914202|NCT06597253|DEVICE|Lactate sensor|Continuous interstitial fluid lactate monitoring using the non-invasive Nemaura Investigational Lactate Device.
223914203|NCT04750564|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
223914204|NCT04750564|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
223914205|NCT00721149|DEVICE|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
223914206|NCT06803732|OTHER|Observations on postoperative pain intensity|pain intensity was assessed using a standard visual analogue score, with a score of 0 to 10 corresponding to no pain to the most severe pain on operation day, postoperative day 1, postoperative month 1, postoperative month 3
223914207|NCT06613477|DRUG|PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease|Table 3: Digoxin dosing regimen based on optimized Cmin,ss Dose to be given twice daily (mcg/kg/dose) PNA\<30 days 30 days \< PNA \< 180 days eGFR≤40 1.4 1.4 40\<eGFR≤60 1.6 1.6 eGFR\>60 1.9 2.8
224088371|NCT01242644|DEVICE|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
223914208|NCT06863922|DIETARY_SUPPLEMENT|Berberine|Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
223914209|NCT06863922|DIETARY_SUPPLEMENT|Berberine|Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
223914210|NCT06677164|PROCEDURE|Gluteus Maximus strengthening exercise|Maximus strengthening exercise for eight weeks using weight progression tools either elastic band or sand weight by assuming two modes of exercises (clamshell exercise, prone hip extension) with stretching exercise (hamstring, gastrocnemius, soleus, and plantar fascia) 2 sessions per week for 8 weeks
223914211|NCT06677164|DEVICE|high-intensity laser therapy|A 3-phase treatment program will be performed in each session on the plantar fascia area. Treatment of trigger points in phase 1 and 2 by using power of 9 watts, E2C mode for 6 minute of 2 phases. The draining and vascularization-promoting application involve the whole foot sole, starting from the heel area in phase three by using power of 9 watts, CW mode with energy of 100J/cm2.
223914212|NCT04987060|DEVICE|Intrastromal Fresh Human Lenticule Implantation|The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
223914213|NCT02956291|DEVICE|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
223716375|NCT00970970|OTHER|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
223914214|NCT06672107|BEHAVIORAL|Active Driver Training Intervention|simulated driver training focusing on practice of 4 specific driving skills including lane positioning, speed management, collision avoidance, and dashboard attention
223914215|NCT06672107|BEHAVIORAL|Control Intervention|pre-scripted familiarization with driving simulator controls in the absence of any complex driving scenarios, decision making requirements, or feedback pertaining to driving skills
223914216|NCT06619834|BEHAVIORAL|Financial Navigation and Peer Support|A combined intervention of technology-supported financial navigation and peer support: A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks. Participants will also be matched with a Peer Supporter to help improve the participants\&#39; diabetes self-management.
223914217|NCT06619834|BEHAVIORAL|Financial Navigation Only|A professional financial navigator from TailorMed will use the software to assist participants in exploring options to reduce their specific economic barriers to treatment and care, and non-medical social risks.
223914218|NCT06621186|OTHER|No intervention measures|No intervention measures
224088372|NCT01242644|DRUG|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
224088373|NCT02509559|DRUG|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
224088374|NCT02509559|DRUG|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
224088375|NCT02509559|DEVICE|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
224088376|NCT02509559|DEVICE|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
224088377|NCT02509559|DEVICE|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
223914219|NCT07207954|DRUG|LFD-200|2 mL glass vials, as 150 mg/mL concentrated solution
223914220|NCT07207954|OTHER|Placebo|0.9% NaCl
224088378|NCT02509559|DEVICE|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
224088379|NCT02509559|DEVICE|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
224088380|NCT02509559|PROCEDURE|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
224088381|NCT04578002|OTHER|prehospital telemedical triage|Prehospital Triage of Patients with Suspected Stroke Using Onsite Mobile Telemedicine approach (interactive video and audio streaming). In patients with suspected stroke, a prehospital patient evaluation by end-to-end encrypted real-time audio- and video streaming from the pre-hospital setting to an in-hospital stroke physician, located at the University hospital of Basel, is requested and initiated (telestroke-path). The process is supervised and evaluated by an in-hospital stroke physician in real-time. Patients considered having an acute stroke will be directly transferred to cerebral imaging via CT. All other patients will follow conventional stroke path.
224088382|NCT00859859|DEVICE|Vagus Nerve Stimulation|"1. Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~2. Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
224088383|NCT03290339|PROCEDURE|hysterectomy|laparoscopic hysterectomy and vaginal hysterectomy
223719446|NCT00002531|RADIATION|radiation therapy|
223719447|NCT01806545|BIOLOGICAL|SRM003|One time implant (2 SRM003 pieces) on surgery day.
223914221|NCT07207954|DRUG|Oral Prednisone|Tablet
223914222|NCT07207954|OTHER|Placebo|Placebo tablet to match Prednisone
223719448|NCT01806545|OTHER|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
223914223|NCT07207668|PROCEDURE|Open Flap Debridement (OFD)|Standard periodontal surgical procedure involving full-thickness flap elevation, scaling, and root planing to eliminate inflamed tissue and reduce periodontal pocket depth.
223914224|NCT07207668|OTHER|24% EDTA Root Conditioning|Application of 24% neutral pH EDTA gel for 3 minutes on root surfaces to remove the smear layer and expose collagen fibers before closure.
224088384|NCT03631576|BIOLOGICAL|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
224088385|NCT04025593|DRUG|Cyclophosphamide|750mg/m2 day 1
224088386|NCT04025593|DRUG|Rituximab|375mg/m2 day 0
224088387|NCT04025593|DRUG|Doxorubicin|50mg/m2 day 1
224088388|NCT04025593|DRUG|Vincristine|1.4mg/m2, max 2mg day 1
224088389|NCT04025593|DRUG|Prednisone|60mg/m2, max 100mg day 1-5
224088390|NCT04025593|DRUG|Ibrutinib|420mg/day qd
224088391|NCT04025593|DRUG|Lenalidomide|25mg day1-10
224088392|NCT04025593|DRUG|chidamide|20mg day 1,4,8,11
223914225|NCT07207668|BIOLOGICAL|Injectable Platelet-Rich Fibrin (i-PRF)|Autologous platelet concentrate prepared by low-speed centrifugation of venous blood (\~700 rpm, 3 minutes). The upper plasma fraction rich in platelets and leukocytes was aspirated and applied to defect surfaces for approximately 5 minutes before flap closure.
223914226|NCT07207772|DEVICE|Group P-eit|"The Recruitment Maneuver - PEEP Titration - Recruitment Maneuver (RM-T-R) Strategy will be implemented 5 minutes after endotracheal intubation. The patient will receive an RM (peak pressure 50cm H2O, PEEP 25cmH2O, respiratory rate 6 bpm, for 10 cycles) followed by a decremental PEEP titration, during which PEEP is set to 25cm H2O and decreased stepwise by 2cm H2O every 3min until reaching 5 cmH₂O. Meanwhile, the ventilator parameters (tidal volume, respiratory rate, and inspiratory-to-expiratory ratio) will be adjusted back to their pre-recruitment settings. EIT-based optimal PEEP is defined as the crossing point of the overdistension and collapse curves during a decremental PEEP trial."
224088393|NCT04025593|DRUG|decitabine|decitabine 10mg/m2 day-5 to day-1
224088394|NCT05699655|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
224088395|NCT05699655|DRUG|apatinib|Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
224088396|NCT05699655|DRUG|oxaliplatin|Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
224088397|NCT05699655|DRUG|S-1|Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
224088398|NCT00345670|BIOLOGICAL|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
224088399|NCT00345670|BIOLOGICAL|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
224088400|NCT00345670|BIOLOGICAL|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
224088401|NCT03625531|OTHER|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
224088402|NCT03625531|DRUG|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
224088403|NCT03625531|DRUG|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
224088404|NCT03157531|DEVICE|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
224088405|NCT06192979|DRUG|Daratumumab|"Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice."
224088406|NCT06192979|DRUG|Bortezomib|All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
224088407|NCT06192979|DRUG|Dexamethasone|All patients received 20-40 mg oral or intravenous dexamethasone
224088408|NCT06192979|DRUG|Venetoclax|All patients received venetoclax 400mg daily.
224088409|NCT00250692|DRUG|Nitrous Oxide|
224088410|NCT05373550|BEHAVIORAL|Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.|Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
224088411|NCT02937805|DEVICE|Moisturizing vaginal and vulvar sea buckthorn oil cream|
224088412|NCT02937805|DEVICE|Moisturizing vaginal and vulvar cream|
224088413|NCT02544555|PROCEDURE|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
223914227|NCT07207772|DEVICE|Group P-8|In group p-8, mechanical ventilation will be administered in volume-controlled mode with a tidal volume of 8 ml/kg (based on ideal body weight). Additional settings include a PEEP of 8 cmH₂O, FiO₂ of 0.5, an inspiratory-to-expiratory ratio of 1:2, and a respiratory rate of 12 breaths/min. A recruitment maneuver (RM) will be performed 5 minutes after intubation and again after surgery, using the same protocol as in group P-eit. The respiratory rate will be adjusted as needed to maintain end-tidal CO₂ between 35 and 45 mmHg throughout the procedure.
223914228|NCT07207915|OTHER|Observational retrospective cohort study|Observational retrospective cohort study, data collection was performed via structured extraction from electronic medical records: Includingclinical characteristics, metabolic indicators, laboratory parameters, prognosis, and outcomes.
223914229|NCT07207681|DRUG|KXV01 TCR Lentinvivo Injection|KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reactive TCR.
223914230|NCT07207642|BEHAVIORAL|Music intervention - passive listening|Diffusion of familiar music in the bedrooms and living room before bedtime; passive and individual listening.
223914231|NCT07207642|BEHAVIORAL|Audio books intervention - active listening|Dynamic audio book listening, akin to active listening while respecting the rhythm of the evening . This type of listening involves concentrating specifically .
224088414|NCT02544555|PROCEDURE|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
224088415|NCT02649101|DRUG|Thalidomide|Thalidomide tablet 100mg qn po.
224088416|NCT02649101|DRUG|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
224088417|NCT00119340|DRUG|cyclosporine|
224088418|NCT00119340|DRUG|fludarabine phosphate|
224088419|NCT00119340|DRUG|mycophenolate mofetil|
224088420|NCT00119340|PROCEDURE|peripheral blood stem cell transplantation|
224088421|NCT00119340|RADIATION|radiation therapy|
224088422|NCT01290627|DEVICE|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
224088423|NCT01290627|DEVICE|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
224088424|NCT01625806|DRUG|RO4602522|Single oral dose
224088425|NCT01625806|DRUG|ketoconazole|Multiple oral doses
224088426|NCT05533749|DEVICE|GILL eHealth|The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion. The GILL eHealth intervention consists of two parts. Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities. It promotes the prevention, early recognition and treatment of somatic problems. The second part is MyGILL. It provides the basis for drawing up a personalized lifestyle plan. The result of MyGILL is an overview of the performance of patients in different lifestyle areas. The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
224088427|NCT01838044|DRUG|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
224088428|NCT01838044|DRUG|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
223914232|NCT07209007|OTHER|No Intervention: Observational Cohort|This is an observational cohort study with no interventions administered. Skin swabs, stool samples, blood samples, and skin physiological measurements will be collected at baseline, 3, 6, 12, and 24 months after burn injury to investigate longitudinal changes in the skin and gut microbiome.
224088429|NCT05601245|OTHER|High voltage pulsed current|The treatment session duration is 45 minutes (Reverse the polarity after the first 22 minutes)
224088430|NCT05601245|OTHER|Microcurrent therapy|The treatment session duration is 40 minutes.
223719449|NCT03006991|OTHER|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
224088431|NCT04707638|OTHER|No intervention used|No intervention used
224088432|NCT06321692|OTHER|Evaluation of blood levels of biomarkers of cardiac damage|Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
223719450|NCT02116907|DRUG|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
223719451|NCT01267734|DEVICE|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
223914233|NCT07209137|DIETARY_SUPPLEMENT|Dietary Supplement|The supplement is intended to support improvements in skin health, hair strength, nail strength, joint health, and overall well-being.
223914234|NCT07208656|BEHAVIORAL|Medical TV Drama Episode (House M.D.)|Participants in the experimental group will watch a selected episode of the medical drama House M.D. (Season 1, Episode 1), which includes a dramatized storyline relevant to neurocysticercosis. The episode is intended to deliver narrative-based health education. After viewing, participants will complete post-test questionnaires assessing changes in knowledge, motivation, and credibility compared to pre-test results.
223914235|NCT07207707|DRUG|KQB548|Oral KQB548
223914236|NCT07208838|DIAGNOSTIC_TEST|To test visual acuity in 150 Bulgarian patients over 18 years of age using Snellens visual acuity chart and DDIVAT optotypes|The study compares newly developed visual acuity test (DDIVAT) with standart method for visual acuity testing used worldwide
223914237|NCT01586910|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
223914238|NCT01586910|PROCEDURE|Surgical Aortic Valve Replacement (SAVR)|
223914239|NCT01586910|DEVICE|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
223914240|NCT04462302|BEHAVIORAL|Internet-based pain coping skills program|The purpose of this study is to determine if an 8-session Internet-based pain management program can help you better manage your cancer-related pain.
223914241|NCT05667142|DRUG|XEN1101|XEN1101 capsules
223914242|NCT05667142|DRUG|Placebo|Placebo capsules
223914243|NCT06404047|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
223914244|NCT06404047|BEHAVIORAL|Structured Pacing|Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.
223914245|NCT06404047|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
223914246|NCT06404047|OTHER|Usual Care|Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.
223914247|NCT05666518|DRUG|Vericiguat (Verquvo, BAY1021189)|Dosage at the discretion of the treating physician, based on the recommendations written in the product information.
223914248|NCT05666518|DRUG|Standard of care|Dosage at the discretion of the treating physician
223914249|NCT06171724|DIETARY_SUPPLEMENT|Shoden|Shoden® powder is a commercial, dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides. Shoden® powder is manufactured by Arjuna Natural Pvt Ltd, based in Kochi, Kerala, India.
223914250|NCT06280495|DRUG|Oxaliplatin|5 mg/m2 IV on day 1
223914251|NCT06280495|DRUG|Fluorouracil|400 mg/m2 IV bolus on day 1, followed by 2.4 g/m2 continuous IV infusion over 48 hours
223914252|NCT06280495|DRUG|Serplulimab|200 mg IV infusion on day 1
223914253|NCT06280495|DRUG|Bevacizumab|5 mg/kg IV infusion on day 1
223914254|NCT06953505|DIAGNOSTIC_TEST|Ammonia Study Device|Ammonia study device for capillary ammonia measurement
223914255|NCT06952608|DRUG|Ciprofol group|General anesthesia induction and maintenance were performed using ciprofol.
223914256|NCT06952608|DRUG|Propofol group|General anesthesia induction and maintenance were performed using propofol.
223914257|NCT06488859|BEHAVIORAL|Positive Affect Treatment|Sessions 1-8: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects
223914258|NCT06488859|BEHAVIORAL|Positive Affect Treatment and Negative Affect Treatment|Sessions 1-4: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects Sessions 5-8: Exposure therapy to feared or avoided situations, sensations, or memories
223914259|NCT00873951|OTHER|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
223914260|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
223914261|NCT00873951|DIETARY_SUPPLEMENT|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
223914262|NCT00873951|DIETARY_SUPPLEMENT|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
223914263|NCT06433349|OTHER|Survey and interviews|Questionnaires and interviews
223914264|NCT06154382|DRUG|Eltroxin administration|eltroxin administration
223914265|NCT05502315|DRUG|Cabozantinib|40 mg taken orally
223914266|NCT05502315|DRUG|Nivolumab|480 mg by infusion
223719452|NCT01267734|DEVICE|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
223914267|NCT06168305|DEVICE|GENOSS® DES Sirolimus Eluting Coronary Stent System|The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
223914268|NCT06088043|DRUG|TAK-279|Specified drug on specified days.
223914269|NCT06088043|DRUG|Placebo|Specified drug on specified days.
223914270|NCT06088043|DRUG|Apremilast|Specified drug on specified days.
223914271|NCT05624359|DRUG|FA plus ropivacaine|Th group will receive 0.17% FA and 0.5% ropivacaine for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
223914272|NCT05624359|DRUG|ropivacaine alone|The ropivacaine alone group will receive 0.5% ropivacaine alone for pre-emptive scalp infiltration at about 30 min before surgical incision. The assigned solution was injected along the planned surgical incision and pin fixation sites of the Mayfield head holder, using a 22-gauge needle introduced throughout the entire thickness of the scalp at a 45° angle.
223914273|NCT01064440|BIOLOGICAL|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
224088433|NCT03465033|OTHER|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
224088434|NCT05596214|COMBINATION_PRODUCT|Curcumin-Berberine (coptis)|dietary supplement
224088435|NCT05596214|COMBINATION_PRODUCT|Placebo|Placebo
224088436|NCT05851469|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
224088437|NCT02618369|DEVICE|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
224088438|NCT02924701|OTHER|Blood samples, fibroscan and questionaires|
224088439|NCT00295269|DRUG|Mythylprednisolone|
223914274|NCT01064440|BIOLOGICAL|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
223914275|NCT01064440|OTHER|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
223914276|NCT06127030|BEHAVIORAL|Brief behavioral teacher training|A brief behavioral teacher training program that combines individually-tailored stimulus control and contingency management techniques to treat children's behavioral difficulties in two (bi)weekly training sessions of two hours and a third session of one hour in which the training will be evaluated and maintenance training will be provided.
223914277|NCT06127030|BEHAVIORAL|Practice as usual only (PAU)|PAU may include any support or treatment as regularly provided by mental health care centers, schools, school collaborations and/or other organizations, except from pharmacological treatment for children's behavioral difficulties and/or behavioral teacher training/support. PAU can also imply that there is no support or treatment.
224088440|NCT00540891|DRUG|ALFUZOSIN|
224088441|NCT06199167|BEHAVIORAL|Action Observation Therapy|The Action Observation Therapy group watched each ADL activity for two minutes through pre-prepared videos and then repeated the movement they watched for three minutes. In the 15-session treatment, a total of 18 ADL activities.
224088442|NCT06199167|BEHAVIORAL|Photo Observation|The Photo Observation group observed the photographs taken from the video for two minutes and then practised the movement described for three minutes. In the 15-session treatment, a total of 18 ADL activities.
224088443|NCT05241158|BEHAVIORAL|Counselling with visual aid|patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure
224088444|NCT05241158|BEHAVIORAL|Counselling|Patients counselled about the procedure, complications and the post-procedure recovery phase
224088445|NCT04727541|DRUG|Bintrafusp alfa|Neoadjuvant therapy with bintrafusp alfa
223914278|NCT06953440|DRUG|Dexamethasone Sodium Phosphate Injection|Patients will receive 4 milligrams of dexamethasone submucosal injection next to the extraction site.
224088446|NCT03204344|DIETARY_SUPPLEMENT|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
224088447|NCT03204344|OTHER|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
224088448|NCT03284190|PROCEDURE|Surgery|Surgery
224088449|NCT02057133|DRUG|LY2835219|Administered orally.
223719453|NCT01267734|DRUG|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
223914279|NCT06953440|OTHER|Normal Saline (Placebo)|Patients will receive 4 milligrams of normal saline solution next to the extraction site.
224088450|NCT02057133|DRUG|Letrozole|Administered orally.
224088451|NCT02057133|DRUG|Anastrozole|Administered orally.
224088452|NCT02057133|DRUG|Tamoxifen|Administered orally.
224088453|NCT02057133|DRUG|Exemestane|Administered orally.
224088454|NCT02057133|DRUG|Everolimus|Administered orally.
224088455|NCT02057133|DRUG|Trastuzumab|Administered IV infusion.
224088456|NCT02057133|DRUG|LY3023414|Administered orally.
223914280|NCT04108130|OTHER|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
223914281|NCT04108130|PROCEDURE|Intraoperative PEEP (Positive End-Expiratory Pressure) Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
223914282|NCT04108130|OTHER|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
223914283|NCT04108130|PROCEDURE|Postoperative Incentive Spirometry|Participants will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until participant freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
223914284|NCT04108130|BEHAVIORAL|Postoperative Ambulation|Participants will be encouraged to adhere to prescription of early ambulation.
223914285|NCT06118281|DRUG|Ziltivekimab|Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
223914286|NCT06118281|DRUG|Placebo|Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
223914287|NCT03075696|DRUG|Glofitamab|Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
223914288|NCT03075696|DRUG|Obinutuzumab|Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
223914289|NCT03075696|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
223914290|NCT05663710|DRUG|177Lu girentuximab|Given by IV (vein)
223914291|NCT05663710|DRUG|Nivolumab|Given by IV (vein)
223719454|NCT01267734|DRUG|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
223914292|NCT05663710|DRUG|Cabozantinib|Given by PO
223914293|NCT05663710|DRUG|ArabinoFuranosylGuanine [18F]F-AraG|Given by IV (vein)
223914294|NCT04990128|COMBINATION_PRODUCT|Aspire Needle + Emcyte PureBMC|The Aspire Needle will be utilized to extract the bone marrow and the Emcyte PureBMC will be used to concentrate bone marrow aspirate. The final concentrate will be injected into the hip.
223914295|NCT04990128|DRUG|Triamcinolone|40 mg (1 mL) triamcinolone and 4 cc of lidocaine 1% that will be injected into the hip.
223914296|NCT04362839|BIOLOGICAL|Ipilimumab|Given IV
223914297|NCT04362839|BIOLOGICAL|Nivolumab|Given IV
223914298|NCT04362839|DRUG|Regorafenib|Given PO
223914299|NCT06427811|DRUG|Asciminib|Film-coated tablets with 40 mg dose strength taken orally
223914300|NCT06456463|DRUG|Tagraxofusp|Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.
223914301|NCT06456463|DRUG|Venetoclax|Venetoclax will be administered as an oral tablet (400 milligrams \[mg\]) daily, with ramp up in Cycle 1, and should be continued at target dose (400 mg) for the remainder of Cycle 1 and subsequent cycles of 28 days each.
223719455|NCT00001995|DRUG|Rifabutin|
223719456|NCT05432414|DRUG|pomalidomide|Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
223914302|NCT06456463|DRUG|Azacitidine|Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
223719457|NCT05432414|DRUG|Bortezomib|Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
223719458|NCT05432414|DRUG|Dexamethasone|Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
223914303|NCT05507333|DEVICE|pHyph generation II|Daily administration of the Gedea pessary during 6 days
223914304|NCT06794177|OTHER|Variable priority dual task training|Variable priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks
223914305|NCT06794177|OTHER|Fixed priority dual task training|Fixed priority dual task training with balance and walking exercises performed simultaneously with cognitive tasks, twice a week for six weeks
223914306|NCT06794177|OTHER|Single task training|Single task training with balance and walking exercises, twice a week for six weeks
223914307|NCT06957769|OTHER|heat stress|"Heat stress (exposure) will be quantified using validated environmental heat stress indices, including the Universal Thermal Climate Index (UTCI), Wet Bulb Globe Temperature (WBGT) and heat index (HI). The former two indices integrate four key environmental parameters, ambient temperature, relative humidity, solar radiation, and wind speed, to provide a quantified measure of thermal stress. The heat index represents the apparent temperature or how hot it feels to the human body when air temperature is combined with relative humidity.~Indoor heat exposure will be assessed using wearable temperature and humidity loggers, while outdoor environmental data, including temperature, humidity, radiation, and wind speed, will be captured using Kestrel WBGT devices installed in the study area."
223914308|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily
223914309|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Dasatanib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Dasatinib 20mg daily
224088457|NCT02057133|DRUG|Fulvestrant|Administered IM.
223914310|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily
223914311|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 1250mg twice daily Dasatanib 20mg daily
224088458|NCT02057133|DRUG|Pertuzumab|Administered IV infusion.
223914312|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily
223914313|NCT05036226|COMBINATION_PRODUCT|Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib|Hydroxychloroquine 600mg twice daily Metformin 500mg daily for 7 days, then increase to 1000mg daily Sirolimus 0.5mg daily Nelfinavir 2500mg twice daily Dasatanib 20mg daily
223914314|NCT06836284|DEVICE|Digi-physical treatment tool, Evira|A digi-physical treatment tool named Evira will be used to provide behavioral treatment.
223914315|NCT06836284|DRUG|Anti-obesity medication with liraglutide or semaglutide|Anti-obesity medication with liraglutide or semaglutide according to the clinic's standard procedure
223914316|NCT01672255|DRUG|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
223914317|NCT01672255|DRUG|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
223914318|NCT05785624|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified in the respective arms.
223914319|NCT05785624|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arms.
223914320|NCT05505513|DEVICE|percutaneous Utah Slanted Electrode Arrays (pUSEAs)|Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.
223914321|NCT05034835|DEVICE|usual treatment with compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
223914322|NCT05034835|OTHER|usual treatment without compression garments (CERECARE)|For 3 months, the pain will be assessed every week, tolerance and compliance with compression garments will also be monitored. Participants will be reviewed specifically at a follow-up consultation for the 6-month and 1-year study. Various assessments will be carried out during these visits : assessment of pain, range of motion, muscle strength, sensitivity test, assessment of anxiety, depression and even quality of life.
223914323|NCT06236919|BEHAVIORAL|VR cognitive training|The VR cognitive training group will engage in a subset of six games designed to target specific cognitive functions one game will target cognitive flexibility, requiring participants to switch between different tasks and problem-solving strategies quickly. Another game will focus on planning, asking participants to make a series of decisions to achieve a particular goal. Additionally, the Enhance VR group will also engage in games that target reappraisal strategies, working memory, divided and sustained attention, impulsivity, and processing speed.
223914324|NCT06236919|BEHAVIORAL|VR nature exposure relaxation|The control group will be immersed in ten different nature-based VR environments (e.g., forests, lakes, beaches, etc.), where they will tailor its content and perform relaxation exercises (deep breathing techniques).
223914325|NCT06050070|OTHER|FMRI with sham controlled feedback|"During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.~In order to see if the neurofeedback is really helping change the size of the circular pattern, the study team will have a control condition. In this controlled condition, subjects will see the circular pattern change, and the study team will ask participants to try and increase the size, except that the changing size will not actually be determined by your brain activity. This a called a sham condition because the feedback signal is not real."
224088459|NCT02057133|DRUG|Loperamide|Administered orally.
224088460|NCT02057133|DRUG|Endocrine therapy|Endocrine therapy administered orally.
224088461|NCT02678429|DEVICE|Change DBS programming|Patient will change their DBS settings to move from one DBS setting to the other, allowed one hour to adjust to the new setting prior to testing
224088462|NCT04640714|BEHAVIORAL|CONTINUity of care Under Management by Video visits (CONTINUUM-V)|Video visit by nurse practitioner within 3 business days of hospital discharge.
224088463|NCT01541293|DRUG|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
224088464|NCT01541293|DRUG|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
223719459|NCT05205044|DIAGNOSTIC_TEST|Apelin-13, Apelin-36|Serum levels of Apelin-13 and Apelin-36
224088465|NCT01870635|DRUG|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
224088466|NCT01870635|DRUG|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
224088467|NCT02298101|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
224088468|NCT02298101|DEVICE|Aeroneb Solo Adapter|Nebulizer
224088469|NCT02298101|DEVICE|Opti-Mist Plus Nebulizer|Standard jet nebulizer
223719460|NCT01508650|BEHAVIORAL|Usual care|Usual care control group
223719461|NCT01508650|BEHAVIORAL|Rehabilitation intervention|Multi-domain rehabilitation intervention
223719462|NCT02064894|DRUG|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
224088470|NCT02298101|OTHER|Planar scintigraphy|Imaging technique to investigate whole lung deposition
224088471|NCT02298101|OTHER|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
224088472|NCT02298101|OTHER|Spirometry|FEV1, FVC assessment
223914326|NCT06050070|OTHER|FMRI with real time feedback|During the second fMRI, the study will introduce the real time fMRI neurofeedback part of the study. This is where subjects will use the activity from the brain to control the size of the circular pattern viewed in the first two visits. This is real time fMRI because the pattern will change, in real time, based on what the fMRI scan measures in the brain. Participants will be encouraged to make the circular pattern grow in size, just by thinking about it.
223914327|NCT06108544|DRUG|TAK-279|Specified drug on specified days.
223914328|NCT06108544|DRUG|Placebo|Specified drug on specified days.
223914329|NCT06108544|DRUG|Apremilast|Specified drug on specified days.
223914330|NCT05456295|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg below the knee. The design of the proximal cuff will differ between CUFF-A, CUFF-B, CUFF-C, CUFF-D.
223914331|NCT06140836|DRUG|Repotrectinib|Specified dose on specified days
223914332|NCT06140836|DRUG|Crizotinib|Specified dose on specified days
223914333|NCT06315491|DRUG|CBX-12|CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.
223914334|NCT06569368|DRUG|Metronidazole|Given by PO
224088473|NCT00125034|BIOLOGICAL|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m\^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
223914335|NCT05414994|OTHER|Eye swab|This is a simple swab under the eyelids of both eyes
223914336|NCT05734560|DRUG|D2C7-IT|D2C7-IT will be dosed at 166,075 ng in 36 mL.
223914337|NCT05734560|DRUG|2141-V11|2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
223914338|NCT04160910|DRUG|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
223914339|NCT04160910|DRUG|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
223914340|NCT06534983|DRUG|Autogene Cevumeran|Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
224088474|NCT00125034|DRUG|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m\^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m\^2/day IV over 2-4 minutes followed by 600 mg/m\^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
223914341|NCT06534983|DRUG|Nivolumab|Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
223914342|NCT06534983|DRUG|Saline|Saline solution for IV infusion
223914343|NCT06222606|PROCEDURE|Surgery with autofluorescence|In the experimental group, the surgeon will use the EleVision IR camera system (Medtronic, USA) to visualize parathyroid glands during surgery.
223914344|NCT02018692|DIETARY_SUPPLEMENT|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
224088475|NCT00113243|DRUG|adult stem cells|
223914345|NCT02018692|DIETARY_SUPPLEMENT|Placebo:Starch|Starch powder
223914346|NCT05716945|DRUG|Fluorometholone 0.1% Oph Susp|"Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily."
223914347|NCT05716945|DRUG|Dexamethasone 0.1% ophthalmic suspension|Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
223914348|NCT05716945|OTHER|Stop steroids|Half the patients in each study arm will discontinue steroids.
223914349|NCT05606289|BEHAVIORAL|Crisis Intervention Team (CIT) training|Standard 40-hour CIT training given in one week.
223914350|NCT05035082|DRUG|semaglutide|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
223914351|NCT05035082|DRUG|oral glucose-lowering medications (commercially available)|Oral administration The doctor will give a prescription for the medicine and tell how to take it.
223914352|NCT04047030|OTHER|None- Observational Study|No Intervention
223914353|NCT02585323|BEHAVIORAL|Education session, Fitbit/FitViz, PT counselling|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
223914354|NCT02585323|BEHAVIORAL|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
223914355|NCT05702853|DRUG|Cyclophosphamide injection|500 mg/m2 IV over 30-60 minutes +/- 10 minutes before Fludarabine Days -5, -4, - 3
223914356|NCT05702853|DRUG|Fludarabine Injection|30 mg/m2 IV over 30-60 minutes +/- 10 minutes after cyclo- phosphamide infusion Days -5, 4, -3
224088476|NCT00002909|DRUG|chemotherapy|
224088477|NCT00002909|DRUG|oral sodium phenylbutyrate|
224088478|NCT02788864|DRUG|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
223914357|NCT05702853|BIOLOGICAL|CD19-CD34t metabolically programmed CAR transduced T-cells|Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
223914358|NCT05013307|OTHER|CASE|The Clinical Assessment for Sports Exertion (CASE) addresses the physical performance of athletes by quantifying physiological and symptomatic responses to dynamic exertion. It was developed by clinicians at the Baylor Scott and White Sports Concussion Program in an effort to identify specific system impairments in athletes who were unable to successfully demonstrate readiness for return to play protocols.
223914359|NCT06634810|BEHAVIORAL|Self-Management Support|The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.
223914360|NCT06634810|BEHAVIORAL|COPD Education|The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
223914361|NCT06447675|OTHER|Hyperthermic Baths|The intervention will consist of 12 weeks of repeated (2x/day) 20-min body immersions.
223914362|NCT02250937|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
223914363|NCT02250937|DRUG|Busulfan|Given IV
223914364|NCT02250937|DRUG|Cladribine|Given IV
223914365|NCT02250937|DRUG|Fludarabine Phosphate|Given IV
223914366|NCT02250937|OTHER|Laboratory Biomarker Analysis|Correlative studies
223914367|NCT02250937|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
223914368|NCT02250937|OTHER|Pharmacological Study|Correlative studies
223914369|NCT02250937|DRUG|Venetoclax|Given PO
223914370|NCT06377384|OTHER|FLIGHT Intervention|Personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care.
223914371|NCT05070793|BEHAVIORAL|Culturally adapted interpersonal psychotherapy|Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.
223914372|NCT05534438|RADIATION|Stereotactic body radiotherapy|SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)
223914373|NCT02072772|BEHAVIORAL|Positively Smoke Free group treatment|See Arm Description
223914374|NCT02072772|BEHAVIORAL|Standard Care|See Arm Description
223914375|NCT06793215|DRUG|Divarasib|Divarasib will be administered orally QD
223914376|NCT06793215|DRUG|Pembrolizumab|Pembrolizumab will be administered via IV infusion Q3W
224088479|NCT02788864|DRUG|Placebo|"Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
223529980|NCT05298254|BIOLOGICAL|HSV formulation 3 with adjuvant 2|Two doses of the HSV formulation 3 with adjuvant 2 vaccine administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I of the study.
223529981|NCT05298254|DRUG|Placebo|Two doses of Placebo administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part I and Part II of the study.
223529982|NCT05298254|BIOLOGICAL|HSVTI_F1|Two doses of the formulation of the HSVTI\_F1 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
223529983|NCT05298254|BIOLOGICAL|HSVTI_F2|Two doses of the formulation of the HSVTI\_F2 selected from Part I of the study administered intramuscularly in the deltoid region of the non-dominant arm, one each at Day 1 and Day 29, during Part II of the study.
223914377|NCT06793215|DRUG|Pemetrexed|Pemetrexed will be administered via IV infusion Q3W
223914378|NCT06793215|DRUG|Carboplatin|Carboplatin will be administered via IV infusion Q3W
223914379|NCT06793215|DRUG|Cisplatin|Cisplatin will be administered via IV infusion Q3W
223914380|NCT03588299|DRUG|BAY2599023 (DTX201)|Single escalating doses with 4 dose steps; Single intravenous (IV) administration.
223914381|NCT06479655|DRUG|Fentanyl|Intravenous fentanyl infusion with dilution of 10mcg/ml
223914382|NCT06479655|DRUG|Morphine|Intravenous morphine infusion with dilution 1mg/ml
223914383|NCT06251973|BIOLOGICAL|AgenT-797|AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors
223914384|NCT06251973|BIOLOGICAL|Botensilimab|Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody
223914385|NCT06251973|DRUG|Balstilimab|Botensilimab is supplied as a sterile, single-use solution for IV administration
223914386|NCT06251973|DRUG|Ramucirumab|Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
223914387|NCT06251973|DRUG|Paclitaxel|Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
223914388|NCT06666712|DRUG|Topotecan|Topotecan (TPT) is a chemotherapeutic agent that is a topoisomerase inhibitor. This intervention is uniquely distinguished through its administration using an externalized catheter and external microinfusion pump (Convection-Enhanced Delivery)
223914389|NCT06274515|PROCEDURE|Tumor Tissue and Blood Draw|Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
223914390|NCT06961591|BEHAVIORAL|Weight Loss Plus Cooking|"Participants in the eSLD+Chef-ID group will follow a healthy eating plan using the enhanced stoplight diet, meet with a health coach once a month on Zoom® using an iPad®, and aim to get 120 minutes of aerobic activity and 30 minutes of strength exercises each week.~In addition, they will attend in-person cooking classes-twice a month during the first 6 months and once a month for the next 12 months. In these 60-minute classes, instructors will teach cooking skills, and participants will practice on their own or with a partner, depending on their comfort level. They will learn how to safely use kitchen tools and appliances (like ovens, blenders, knives, and measuring cups) and prepare simple meals or snacks."
223914391|NCT06961591|BEHAVIORAL|Traditional Weight Loss|"Participants in the eSLD group will follow a healthy eating plan using the enhanced stoplight diet, meet once a month with a health coach on Zoom® using an iPad®, and aim to get 120 minutes of aerobic activity and 30 minutes of strength exercises each week.~They will also receive short (2-minute) video messages from their coach-twice a month during the first 6 months and once a month after that. These videos will include feedback on their progress, reminders about their goals, and tips to help them stay on track with healthy eating and exercise."
223914392|NCT03475212|BIOLOGICAL|Virus Specific T-cell (VST) infusion|Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (\>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
223914393|NCT06201299|OTHER|Standard Exercise Program|The program content consists of breathing exercises, upper and lower extremity strengthening with theraband and self-walking. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Resistance exercises will be performed as strengthening exercises for the major muscle groups of the upper and lower extremities using medium-hard theraband. Patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
223914394|NCT06201299|OTHER|Chair-based Exercise Program|The program content consists of breathing exercises and chair-supported exercises. Chest, abdominal and lateral basal breathing exercises will be performed 10 times each. Chair exercises are given in the exercise brochure. Exercises are performed with a chair support or sitting on a chair. In addition, patients will be asked to walk 30 minutes a day on flat ground at 60% workload, for periods calculated according to the 6-minute walk test results (land-based walking).
223914395|NCT06562790|BIOLOGICAL|Gamma PN3|500, 1000 or 1500 µg by IM injection on Days 1 and 29
223914396|NCT06562790|BIOLOGICAL|Prevnar|1 dose on Day 1 and saline placebo on Day 29
223914397|NCT06839859|BEHAVIORAL|Family Acceptance Project - Online|a 9-week long online group program for LGBTQ+ youth of color and their parents / caregivers
223914398|NCT06966089|DEVICE|Urinary ExoDx test|A urine sample for ExoDx Study Kit will be collected onsite and shipped to Exosome Diagnostic's laboratory.
223914399|NCT06966089|DIAGNOSTIC_TEST|Transrectal ultrasound-guided prostate biopsy|Participants will be scheduled for transrectal ultrasound-guided prostate biopsy as per the standard diagnostic practice after urinary test.
223914400|NCT06966089|DIAGNOSTIC_TEST|Transperineal 12-core prostate biopsy|Participants will be scheduled for transperineal 12-core prostate biopsy as per the standard diagnostic practice after urinary test.
223914401|NCT05513378|DEVICE|Needle guide|Please see the arm/group description
223914402|NCT06965231|DRUG|Toripalimab combined with Endostar|"1. Neoadjuvant Phase: 2 doses of toripalimab (240 mg IV, Q2W) before surgery.~2. Surgery: Tumor resection within 2 weeks after the last neoadjuvant dose.~3. Adjuvant Phase: 1) Toripalimab: 240 mg IV every 2 weeks (up to 11 cycles); 2) Endostar: 210 mg (72-hour continuous IV infusion) every 4 weeks (up to 6 cycles)."
223914403|NCT06052826|OTHER|Best Practice|Undergo standard of care
223914404|NCT06052826|OTHER|Cognitive Intervention|Receive delirium prevention education
224088480|NCT05419895|BEHAVIORAL|Early Diagnostic Response Model (EDRM)|Use of telehealth capabilities to implement measures and capture and code information related to an autism diagnosis. This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.
223914405|NCT06052826|OTHER|Comprehensive Geriatric Assessment|Undergo geriatric assessment
223914406|NCT06052826|OTHER|Nutritional Intervention|Undergo nutritional optimization
224088481|NCT05272865|DRUG|Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator|Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
223914407|NCT06052826|PROCEDURE|Physical Therapy|Undergo physical function optimization
223914408|NCT06052826|OTHER|Questionnaire Administration|Ancillary studies
224088482|NCT00476580|BEHAVIORAL|Questionnaire|Questions to collect health information specific to Sri Lankans.
224088483|NCT03324360|DRUG|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
224088484|NCT05490420|OTHER|manual lymphatic drainage (MLD)|MLD is a manual technique that is applied to the lymphatic system with a pressure of approximately 40-50mmHg and increases the working speed of lymphatic nodules/collectors. Its main purpose is to support microcirculation by accelerating lymphatic flow and to prevent/remove interstitial fluid accumulation that may cause fascial adhesions.
224088485|NCT01920360|OTHER|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
224088486|NCT01920360|OTHER|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
224088487|NCT01920360|OTHER|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
224088488|NCT02745561|DRUG|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
224088489|NCT02745561|DRUG|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
224088490|NCT02745561|RADIATION|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
223914409|NCT01203839|RADIATION|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
223914410|NCT03981926|OTHER|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
223914411|NCT06966960|BEHAVIORAL|Online RPG adventure games and e-book learning.|Learning obstetric fetal heart rate monitoring technology through online RPG adventure games and e-book learning.
223914412|NCT06966960|BEHAVIORAL|E-book|E-book learning mode for obstetric fetal heart rate monitoring technology.
223914413|NCT06204809|DRUG|PGN-EDODM1 for infusion|Single dose of PGN-EDODM1 by intravenous (IV) infusion
223914414|NCT06204809|OTHER|Placebo|Administered by IV infusion
224088491|NCT05623293|DIAGNOSTIC_TEST|eye - Optcial coherence tomography|pre and postoperative
224088492|NCT02890680|PROCEDURE|Platelet-rich fibrin|
223529984|NCT06515106|BEHAVIORAL|Remote cognitive rehabilitation program|Behavioral: Remote cognitive rehabilitation program Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
223529985|NCT05871437|DRUG|Huaier granule|On the basis of routine clinical treatment/follow-up, take Huaier Granules orally, 10g each time, three times a day, for one year continuously or until disease progression, intolerable toxicity, withdrawal from the study for any reason or death occurs, whichever occurs first.
223914415|NCT03652493|DRUG|Carboplatin|Tumoral evaluation every 3 cycles
223914416|NCT05464069|DEVICE|Nerivio|Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
223914417|NCT05464069|DRUG|Migraine Relief|Any drug for treatment of migraine relief
223529986|NCT06647589|BEHAVIORAL|Acceptance and Commitment Therapy|participants will then receive ACT-based individual therapy weekly for twelve weeks.
223529987|NCT05991427|BIOLOGICAL|Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
223529988|NCT05991427|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted (Shingrix)|2 doses of Shingrix vaccine on Day 0 and Month 4
223529989|NCT05991427|BIOLOGICAL|ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
223914418|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
223914419|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
223914420|NCT00685581|DIETARY_SUPPLEMENT|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
223914421|NCT05832138|BEHAVIORAL|ONLOOP program|Participants will receive ONLOOP program intervention materials: a study invitation letter, personalized health information, and a reminder to complete their guideline-recommended surveillance test(s)
224088493|NCT02890680|PROCEDURE|Control group|
224088494|NCT04485585|DRUG|BR9006-1|* Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose
224088495|NCT04485585|DRUG|BR9006-2|"* Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose"
224088496|NCT01951677|DRUG|HBsAg|Standard hepatitis B vaccine antigen
224088497|NCT01951677|BIOLOGICAL|PreS HBsAg|preS hepatitis B surface antigen
224088498|NCT01951677|BIOLOGICAL|Advax-1(TM)|Adjuvant formulated with vaccine antigen
224088499|NCT01951677|BIOLOGICAL|Advax-2(TM)|Adjuvant formulated with vaccine antigen
224088500|NCT01951677|BIOLOGICAL|Advax-3(TM)|Adjuvant formulated with vaccine antigen
224088501|NCT01951677|BIOLOGICAL|Alum|Adjuvant formulated with vaccine antigen
224088502|NCT05300945|COMBINATION_PRODUCT|HIPEC|HIPEC after gastrectomy with D2 local lymph node dissection.
223914422|NCT05974488|DEVICE|McMurray Enhanced Airway|The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.
223914423|NCT05974488|DEVICE|Nasal Cannula|Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
223529990|NCT05991427|BIOLOGICAL|Shingrix|2 doses of Shingrix vaccine on Day 0 and Month 4
223914424|NCT05673005|DEVICE|MED3000 topical gel|Topical gel that has been shown to improve erectile dysfunction when used as needed.
223914425|NCT02312401|DEVICE|multi-parametric MRI(MP-MRI)|
223914426|NCT02312401|DEVICE|dynamic contrast-enhanced MRI (DCE)|
223914427|NCT02312401|PROCEDURE|biopsy|
223914428|NCT06445972|BIOLOGICAL|Ramucirumab|8 mg/kg IV Infusion
223914429|NCT06445972|DRUG|Paclitaxel|80 mg/M\^2 IV infusion
223914430|NCT06445972|BIOLOGICAL|Sacituzumab Tirumotecan|3 mg/kg or 4 mg/kg IV Infusion
223914431|NCT06445972|DRUG|Rescue Medications|Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications include antihistamines (histamine-1 and histamine-2 receptor antagonists), acetaminophen or equivalent, dexamethasone or equivalent infusion, and steroid mouth wash (dexamethasone or equivalent).
223914432|NCT06452277|DRUG|BAY2927088|Tablet, oral
223914433|NCT06452277|DRUG|Pembrolizumab|Intravenous (IV) infusion
223914434|NCT06452277|DRUG|Cisplatin|IV infusion
223914435|NCT06452277|DRUG|Carboplatin|IV infusion
223914436|NCT06452277|DRUG|Pemetrexed|IV infusion
223914437|NCT04527926|BEHAVIORAL|STEPuP Intervention|"Project STEPup has 4 components designed to address barriers to MAT and EBP adoption: 1) a hub and spoke remotely-supported provider education and training program, 2) addiction teleconsultation support, 3) case management and telepsychiatry support, and 4) a partnership with health system administrators and payers to address administrative and reimbursement related needs."
223914438|NCT04527926|BEHAVIORAL|Usual Care|Standard of Care
223914439|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Atezolizumab + Bevacizumab|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.
223914440|NCT05377034|COMBINATION_PRODUCT|SIRT-Y90 with Placebo (IV)|Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by placebo at every 3 weeks for 18 months.
223914441|NCT05856539|PROCEDURE|Erector spinae plane (ESP) block|ESP block is an opioid-sparing regional anesthetic involving bupivacaine and dexamethasone for lumbar spinal surgery with touted benefits including opioid use reduction and improved pain control.
223529991|NCT05991427|BIOLOGICAL|IH ChAdOx1-VZV|2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
223529992|NCT05991427|BIOLOGICAL|IH saline|2 doses of saline on Day 0 and Month 4
223914442|NCT05244928|OTHER|"The team training program Team Strategies and Tools to Enhance Performance and Patient Safety®"|"Team Strategies and Tools to Enhance Performance and Patient Safety® is a team training program consisting of an evidence-based set of tools designed to develop teamwork skills with the goal of improving quality in healthcare services and providing safer patient care. In this study, selected tools from the Team Strategies and Tools to Enhance Performance and Patient Safety® curriculum have been chosen for implementation over a 4-month period together with a general emphasis on the key principles: communication, leadership, situation monitoring and mutual support. A full day introduction will be held to mark the start of the intervention and each successive month will have a focus on a single key principle with associated tools.~A quasi-experimental, pre- post design, provides the framework for the intervention of the team training program in two clusters including seven ambulance stations, in total."
223914443|NCT04136912|DRUG|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
223914444|NCT04136912|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
223914445|NCT04811560|DRUG|Bleximenib|Bleximenib is administered orally.
223914446|NCT06743152|BEHAVIORAL|Synchronous exercise program|The synchronous exercise group will be conducted online with synchronous supervision under the supervision of a physiotherapist. The exercise program will be performed for 8 weeks, 2 days a week. In the exercise program, 3 sets, 8 repetitions in 1 set will be progressed to 10-12-15-20-25 repetitions according to tolerance. There will be a 1-2 minute rest between sets.
224088503|NCT04553107|BEHAVIORAL|Deprescribing Intervention|An individualized deprescribing intervention will be created by a pharmacist working with a patient to identify harmful, costly, and unnecessary medications to be reduced. The intervention will include a plan and monitoring for up to 3 months to reduce medication use.
223529993|NCT06271915|OTHER|SNAGs - eccentric exercise|intervention done 2 times per week, 45 minutes each session for 4 weeks
223529994|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 1|Investigational RSV vaccine 1 administered intramuscularly on Day 1 and Day 30.
224088504|NCT04553107|BEHAVIORAL|Usual Care|The usual care arm will receive the current standard of care, which includes medication reconciliation by a clinic nurse at the time of their appointment. Nurses review all medications and answer medication-related questions, and refer medication questions to the healthcare provider for further discussion when necessary.
223914447|NCT06743152|BEHAVIORAL|Asynchronous exercise group|The Asynchronous Exercise Group will be conducted with a video-based structured exercise program. For the asynchronous video-based group, a closed channel will be created on Youtube that only patients can access, and the exercises will be uploaded to the system asynchronously. In the asynchronous exercise group, how each exercise is performed will be shown in detail by the physiotherapist in the video content.
223914448|NCT06220851|DIAGNOSTIC_TEST|Handgrip strength|Handgrip strength will be measured by 3 efforts.
223914449|NCT06971744|DRUG|Hydroxychloroquine|3 x 200 milligram tablets twice daily
224088505|NCT03529409|BEHAVIORAL|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
224088506|NCT00777179|DRUG|Vandetanib|Tablet, oral, daily
224088507|NCT00777179|DRUG|Placebo|Placebo
224088508|NCT01497262|DRUG|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
223914450|NCT06971744|DRUG|Nelfinavir|2x 625 milligram tablets twice daily
223914451|NCT06971744|DRUG|Bevacizumab|IV 15 milligram/kilogram every 3 weeks
223914452|NCT05101837|DEVICE|Home program|Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
223914453|NCT06460506|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
223914454|NCT06460506|DRUG|IVA|Granules for oral administration
223914455|NCT06533423|BEHAVIORAL|Newly diagnosed with Inflammatory arthritis - a Self-MAnagement intervention (NISMA)|The NISMA intervention is a flexible intervention and comprises three mandatory individual sessions with a nurse, supplemented by two optional group sessions over a period of 12 months, to provide comprehensive support tailored to each participant's needs. The intervention is grounded in the theoretical framework Social Cognitive Theory and inspired by the questioning techniques in Acceptance and Commitment Therapy (ACT). These methods play a crucial role in helping participants enhance their self-efficacy. The key components of our approach include: a person-centered approach by addressing challenges identified by each participant to foster self-efficacy through targeted problem-solving and goal-setting. This is utilized by interviewing techniques derived from ACT to assist participants in accepting and committing to self-management. The program is designed to last between 6-12 months, allowing for gradual skill development and adaptation.
223914456|NCT00085930|BIOLOGICAL|EBV specific CTLs|CTLs: 2x10e7 cells/m2
223914457|NCT01858896|DRUG|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
223914458|NCT01858896|OTHER|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
224088509|NCT04127201|BEHAVIORAL|en_línea|This is an online adaptation of the LEARN program. A self-help weight control program developed by Kelly Brownell in 2004.
224088510|NCT04127201|BEHAVIORAL|Group therapy|This is a traditional behavioral weight control program
224088511|NCT05610371|DRUG|Lidocaine|The study group underwent hysteroscopy using saline to which 10ml of 2% lidocaine was added to the first 1000 ml. This dose of lidocaine was calculated to allow maximal benefits with minimal potential complications. The maximal dose of lidocaine is 5mg\\kg in adults which translates to 200mg in a 40kg patient. We have set 200 mg as the maximal dose of lidocaine in our study, assuring the dosage is safe. The rest of the procedure following the first 1000ml of saline was completed using saline alone as needed.
224088512|NCT05610371|DRUG|Saline|The control group underwent hysteroscopy using a saline distension medium.
224088513|NCT05438381|PROCEDURE|Atraumatic Restorative Technique (ART)|Glass ionomer capsule (GC, USA)
224088514|NCT05438381|PROCEDURE|SMART Technique|silver diamine fluoride (SDF) then glass ionomer cement capsule (GC, USA)
223914459|NCT05818358|DIETARY_SUPPLEMENT|black beans|¾ cup of cooked black beans
223914460|NCT05818358|DIETARY_SUPPLEMENT|wheat berries|¾ cup of cooked whole wheat grain
223914461|NCT05818358|DIETARY_SUPPLEMENT|white rice|¾ cup of cooked white rice
223914462|NCT05976334|DRUG|[14C] Subasumstat|\[14C\] Subasumstat IV infusion.
223914463|NCT05976334|DRUG|Subasumstat|Subasumstat IV infusion.
223914464|NCT06647576|DEVICE|Spinal Cord Stimulation - In Clinic|Control Group Intervention: In-Person SCS therapy. Device settings, such as pulse width and frequency, will be adjusted during regular clinic visits. Follow-up assessments for pain relief, quality of life, and therapy effectiveness will occur at 1, 3, and 6-month intervals over a 6-month period.
224088515|NCT05430269|OTHER|Faecal bacteriotherapy (FBT)|Enema of 350 ml of standardised mixed transplantate prepared from faeces of 7 healthy donors.
224088516|NCT05430269|OTHER|standard-of-care protocolised treatment of postantibiotic diarhea|standard-of-care protocolised treatment of postantibiotic diarhea
224088517|NCT01705015|BEHAVIORAL|direct feedback about exercise|
224088518|NCT01705015|BEHAVIORAL|PLacebo|UCFit plus encouraged exercise
224088519|NCT04058522|OTHER|Rotator cuff rehabilitation classes|
224088520|NCT04058522|OTHER|Individual Physiotherapy|
224088521|NCT04058522|DRUG|Triamcinolone Injection|Subacromial Injection 40mg/1ml
224088522|NCT01042444|DEVICE|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
224088523|NCT03471325|PROCEDURE|Plaque disclosed with air flow|air polishing with prior plaque disclosing
224088524|NCT03471325|PROCEDURE|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
224088525|NCT03471325|PROCEDURE|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
224088526|NCT03471325|PROCEDURE|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
224088527|NCT06334588|DIAGNOSTIC_TEST|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist
224088528|NCT06334588|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
224088529|NCT06334588|OTHER|Clinical Scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
223914465|NCT06647576|DEVICE|Spinal Cord Stimulation - Neurosphere|Test Group Intervention: Test group participants will receive remote monitoring and therapy adjustments through the Neurosphere™ virtual clinic platform. Participants in test group will have trial and end of trial phases in clinic, but further SCS therapy will be performed through Neurosphere. Clinicians will adjust the SCS device settings, including pulse width and burst frequency, remotely. This intervention allows patients to avoid in-person visits while receiving continuous, personalized care, with follow-up assessments at 1, 3, and 6 months over a 6-month period.
223914466|NCT06306638|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223914467|NCT06306638|PROCEDURE|Computed Tomography|Undergo CT
223914468|NCT06306638|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo EBUS
223914469|NCT06306638|PROCEDURE|Interstitial Photodynamic Therapy|Undergo I-PDT
224088530|NCT06334588|GENETIC|Research of genetic anomalies|For the diagnosis of autism, patients benefit from a a genetic assessment. This is carried out as part of their care
224088531|NCT00308451|DRUG|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
223529995|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 2|Investigational RSV vaccine 2 administered intramuscularly on Day 1 and Day 30.
223914470|NCT06306638|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
223914471|NCT06306638|OTHER|Physical Performance Testing|Ancillary studies
223914472|NCT06306638|OTHER|Questionnaire Administration|Ancillary studies
223914473|NCT06306638|DRUG|Verteporfin|Given IV
223914474|NCT06306638|DEVICE|Laser: ML7710-PDT|Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.
223914475|NCT01291576|PROCEDURE|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
223914476|NCT01291576|PROCEDURE|Rectal nodule excision|Either full thickness excision or rectal shaving
223914477|NCT06574802|PROCEDURE|ERL + air polishing|Er:YAG laser (ERL) plus sub-gingival air polishing treatment
223914478|NCT06574802|PROCEDURE|ERL|ERL treatment
223529996|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 3|Investigational RSV vaccine 3 administered intramuscularly on Day 1 and Day 30.
223719463|NCT02064894|DRUG|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
223914479|NCT06575569|BEHAVIORAL|high-intensity interval training|Patients had no adverse events after 2 weeks of adaptive exercise training and voluntarily continued participants, intensive interval training under the care of specialists for 12 weeks, 30-40 minutes per week, including starting 5-minute warm-up and last 5-minute cooling-off period, during exercise including 4 intervals, 85-95% of maximum heart rate (HR) reserve for 4 minutes, followed by 50-70% of maximum HR reserve for 3 minutes, so cycling 4 times. Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and health education materials pushed by cardiovascular nurses.
223914480|NCT06575569|BEHAVIORAL|Moderate-intensity continuous training|Using routine postoperative care and follow-up, establish WeChat group as contact for postoperative follow-up, no adverse events after 2 weeks of adaptive exercise training and voluntary participants, patients exercise prescription for 12 weeks, 30-40 minutes, including 5 minutes of warm-up and cooling-off period of the last 5 minutes, during exercise intensity is 70-75% maximum heart rate reserve. The warm-up and cooling-off periods can be performed by stretching, flexibility exercises (i. e., neck, shoulders, upper back, hips, and ankles), and medium to low intensity (50-70% heart rate reserve). Specific exercise logs will be issued for patients to record exercise conditions and related exercise data, encouraged to exercise regularly and pushed health education materials by cardiovascular nurses.
223914481|NCT03610789|DEVICE|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
223914482|NCT06572566|OTHER|Non-invasive examination and assessment.|1\) Test the blood and urine components of all subjects to evaluate the damage to kidney function caused by excessive cadmium. 2) Conduct MRI examinations on all subjects to evaluate changes in brain functional connectivity, metabolism, and structure after excessive cadmium exposure. 3) Conduct bone density examinations on all subjects to evaluate changes in bone density after excessive cadmium exposure. (3) Clinical psychiatric assessment: All subjects will be assessed on their mental and psychological conditions such as pain, cognitive function, depression, anxiety, mania, sleep quality, and suicide risk.
223914483|NCT04547959|DEVICE|cervical interbody cage C-CURVE|ACDF: Anterior Cervical Discectomy and Fusion with a C-CURVE cage
224088532|NCT03132402|DIAGNOSTIC_TEST|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
224088533|NCT01779284|DRUG|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
224088534|NCT01779284|DRUG|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
224088535|NCT02567526|BEHAVIORAL|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
224088536|NCT04113967|OTHER|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
224088537|NCT03863314|DEVICE|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
224088538|NCT03863314|OTHER|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
223914484|NCT06008860|DRUG|Experimental: Primary Cohort|Astepro (azelastine) is a second generation antihistamine, as well as an anti-inflammatory and mast cell stabilizer8. It is available as a 0.1% and 0.15% nasal spray by prescription in the USA and over-the-counter in the European Union (EU). Dosing for adults and adolescents 12 years and older is 1 or 2 sprays per nostril twice daily (0.1%) or 2 sprays per nostril once daily (0.15%)9. It is approved by the FDA for treatment of seasonal allergic rhinitis symptoms (rhinorrhea, sneezing, and nasal pruritus) in adults and children 2 years and older, perennial allergic rhinitis in adults and children ages 6 months and older, and the symptoms of vasomotor rhinitis (rhinorrhea, nasal congestion and postnasal drip) in adults and adolescents 12 years and older9.
223529997|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 4|Investigational RSV vaccine 4 administered intramuscularly on Day 1 and Day 30.
223914485|NCT06008860|OTHER|Placebo Comparator: Primary Cohort - Placebo|A Placebo will be provided by Bayer which features similar color and packaging as azelastine.
223914486|NCT01659606|BIOLOGICAL|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
223914487|NCT01659606|DRUG|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
223914488|NCT01659606|DRUG|Cyclosporins|
223914489|NCT01659606|DRUG|Mycophenolate mofetil|
223914490|NCT01659606|DRUG|Tacrolimus|
223914491|NCT06424587|BEHAVIORAL|Music intervention|: In addition to the routine practice of the clinic, the pediatric patients in this group listened to music through headphones for 20 minutes just before the procedure to reduce the child's anxiety and fear. The therapeutic effect of music was used. Before the study, children between the ages of 6 and 12 who were inpatients at the clinic were asked what music they most liked to listen to, what kind of music they liked, and what their favorite artists and songs were. The music was selected based on the children's answers. In addition, the researcher added children's songs by a musician named Banu Kanıbelli
223914492|NCT04980872|DRUG|Miransertib|Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.
223914493|NCT05285358|DRUG|Cisplatin|Given IV
223914494|NCT05285358|DRUG|Gemcitabine|Given IV
223914495|NCT05285358|DRUG|Nab-paclitaxel|Given via PIPAC
223529998|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 5|Investigational RSV vaccine 5 administered intramuscularly on Day 1 and Day 30.
223529999|NCT06573281|BIOLOGICAL|Investigational RSV vaccine 6|Investigational RSV vaccine 6 administered intramuscularly on Day 1.
223530000|NCT06573281|DRUG|Placebo|Placebo administered intramuscularly on Day 1 and Day 30 and for RSV\_Group F placebo administered only on Day 30.
223914496|NCT05285358|OTHER|Quality-of-Life Assessment|Ancillary studies
223914497|NCT05285358|OTHER|Questionnaire Administration|Ancillary studies
223914498|NCT04890236|DRUG|Duvelisib|Given PO
223914499|NCT04890236|BIOLOGICAL|Tisagenlecleucel|Given via infusion
223914500|NCT04019535|DEVICE|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
223914501|NCT06462482|DRUG|Nandrolone Decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
223914502|NCT06462482|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
223914503|NCT05591924|PROCEDURE|Phelebotomy|Collection of 10mL of heparin anticoagulated blood, 10mL of EDTA anticoagulated blood, and 3mL of blood in a PAX gene tube
223914504|NCT05591924|PROCEDURE|Broncheoalveolar Lavage|Bronchioalveolar lavage fluid (BALF) samples will be obtained from participants who are mechanically ventilated, and a bronchoscopy is indicated as part of routine clinical care. The BALF will be collected by a qualified ICU physician using standard clinical practice. Briefly, patients will receive appropriate sedation and analgesia, a flexible video-bronchoscope will be inserted into the patient's airway, and bronchial segments will be identified. The bronchoscope will be wedged in the most appropriate lung segment and 40-100mL of sterile normal saline (NS) as clinically indicated, will be injected into the bronchoscope port with using a 50mL syringe. Next, the instilled NS (i.e.: lavage fluid) will be collected in a sterile container using gentle suction. The BALF will then be partitioned and sent to clinical laboratories, and the remaining BALF (10-20mL) will be used in the ESTABLISH research study.
223914505|NCT05591924|PROCEDURE|Tracheal Aspirate|Tracheal Aspirate (TA) will be obtained from participants who have an endotracheal tube or a tracheostomy in situ at the time of ICU admission through out the ICU admission on the study days, as long as distal airway access is available.
223914506|NCT05591924|PROCEDURE|Rectal Swab|A Rectal will be obtained at the time of ICU admission and on all study days during the ICU admission
223914507|NCT04161885|DRUG|Venetoclax|Tablet; Oral
223914508|NCT04161885|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
223530001|NCT06088667|OTHER|Fascial mobilization group|In addition to the rehabilitation given to the control group, the fascial release group will be treated with the Graston device to the superficial and deep fascia of the neck and shoulder muscles, biceps and triceps brachii muscles and forearm compartments for 4 weeks.
223530002|NCT05624528|DRUG|Tolcapone|catechol-O-methyl transferase inhibitor
223914509|NCT04161885|OTHER|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
223914510|NCT03169972|BIOLOGICAL|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
223914511|NCT05670236|DRUG|Lidocaine Hydrochloride|10 mL of 1% lidocaine hydrochloride for each intraarticular knee injection
223530003|NCT05624528|DRUG|Placebo|Pill that contains no medicine
223719464|NCT02064894|DRUG|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
223719465|NCT05830292|DEVICE|Diffuse reflectance spectroscopy (DRS) probe|The spectroscopic DRS probe, either sterilised or covered with a sterile probe cover, will be used on the tissue as part of the patient's operation, inside the body itself.
223719466|NCT03472404|PROCEDURE|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
223914512|NCT04030533|DRUG|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
223914513|NCT04030533|DRUG|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
223914514|NCT04030533|DRUG|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
223914515|NCT04030533|DRUG|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
223914516|NCT04030533|DRUG|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
224088539|NCT03437447|DRUG|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
224088540|NCT03437447|DRUG|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
224088541|NCT06424496|OTHER|Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression|Quazi-Experimental study (pre/post design) to assess the Effect of Targeted Health Education Program on Nurses' Awareness About Postpartum Depression
224088542|NCT03778437|PROCEDURE|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
224088543|NCT03778437|PROCEDURE|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
224088544|NCT03778437|PROCEDURE|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
224088545|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
224088546|NCT00484315|DEVICE|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
224088547|NCT04899583|DEVICE|Sirolimus Coated Balloon Catheter|a Sirolimus Coated Balloon Catheter designed and produced by Acotec
224088548|NCT04899583|DEVICE|a Paclitaxel Coated Balloon Catheter|a Paclitaxel Coated Balloon Catheter(trade name:Bingo)
224088549|NCT02652039|OTHER|Questionnaires|Questionnaires
224088550|NCT00943683|DRUG|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
224088551|NCT00943683|DRUG|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
224088552|NCT03505437|OTHER|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
223914517|NCT05333068|PROCEDURE|PCI revascularization strategy based on combined FFR and OCT assessment|PCI revascularization strategy based on combined FFR and OCT assessment All FFR ≤ 0.75 and Vulnerable plaque will be treated. VP defined as TCFA ( cap thickness ≤ 75 micron); Ruptured plaque; or Plaque erosion with \> 70 % AS or MLA \< 2.5 mm2.
223914518|NCT05333068|PROCEDURE|PCI revascularization strategy based FFR assessment|PCI revascularization strategy based FFR assessment (all lesions with FFR≤0.80 will be treated)
223914519|NCT03869190|DRUG|Atezolizumab|"For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
223914520|NCT03869190|DRUG|Enfortumab Vedotin|Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
223914521|NCT03869190|DRUG|Niraparib|Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
223914522|NCT03869190|DRUG|Magrolimab (Hu5F9-G4)|Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
223914523|NCT03869190|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
223914524|NCT03869190|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
223914525|NCT03869190|DRUG|Tocilizumab|Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
223914526|NCT03869190|DRUG|Cisplatin|Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
224088553|NCT03505437|OTHER|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
224088554|NCT01597102|OTHER|No interventions|No intervention is planned in this study
224088555|NCT01963494|BEHAVIORAL|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
224088556|NCT01963494|BEHAVIORAL|Individual planning intervention|Target persons form action plans on their own.
224088557|NCT01963494|BEHAVIORAL|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
224088558|NCT04796519|PROCEDURE|Total knee arthroplasty|Surgical procedure
223914527|NCT03869190|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
223914528|NCT04117100|PROCEDURE|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
223914529|NCT05057052|DRUG|Sintilimab|Sintilimab plus regorafenib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
223914530|NCT05057052|DRUG|Regorafenib|Regorafenib will be initiated on day 14 after cryoablation. Regorafenib 80 mg was given orally once daily on days 1-21 of a 28-day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223914531|NCT05057052|COMBINATION_PRODUCT|US/CT-guided Percutaneous Cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
223914532|NCT04134754|OTHER|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
223914533|NCT02437136|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACs)
223914534|NCT02437136|DRUG|pembrolizumab|A selective humanized monoclonal antibody (mAb)
223914535|NCT06280378|DRUG|KL003 Cell Injection Drug Product|Administered by intravenous infusion after myeloablative conditioning with busulfan.
223914536|NCT01862315|DRUG|Floxuridine (FUDR)|
223914537|NCT01862315|DRUG|dexamethasone|
223914538|NCT01862315|DRUG|Gemcitabine|
223914539|NCT01862315|DRUG|Oxaliplatin|
223914540|NCT01862315|OTHER|MRI|
223914541|NCT01862315|OTHER|Research blood draws|These are optional
223914542|NCT03974022|DRUG|Sunvozertinib|Daily dose of Sunvozertinib
223914543|NCT04526886|OTHER|Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy|Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
223914544|NCT04722913|DIAGNOSTIC_TEST|Photogrametry , flexion rotation (FRT) test, Diagnosis of CGH according diagnostic criteria of the Cervicogenic Headache International Study Group (CHISG)|"Photogrammetry is the science and technology of obtaining reliable information about physical objects and the environment through the process of recording, measuring and interpreting photographic images and patterns of electromagnetic radiant imagery and other phenomena.~Flexion rotation (FRT) test:~FRT is a manual examination technique with high sensitivity and specificity. It is performed with the patient in supine by passively taking the cervical spine into full flexion. End-range cervical flexion imparts ligamentous tension that impedes movement at vertebral segments below C2.7 Maintaining the flexion position, the patient's head is then rotated to each side until the patient reports pain or the operator determines that end of motion has been achieved. It is then determined if a restriction in ROM is present."
223719467|NCT03472404|PROCEDURE|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
223719468|NCT02536040|DRUG|38% diammine silver fluoride|treatment of cavity with study agent
223914545|NCT02393794|DRUG|Romidepsin|Histone deacetylase inhibitor
223914546|NCT02393794|DRUG|Cisplatin|Platinum compound
223914547|NCT02393794|DRUG|Nivolumab|Monoclonal antibody, checkpoint inhibitor
223914548|NCT06772129|OTHER|Aromatherapy|Studies have been reviewed and no lavender aromatherapy has been found to be used for delirium.
224277965|NCT04018690|BEHAVIORAL|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K\&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
224277966|NCT01820962|PROCEDURE|heparin|when not in use CVCs are locked with heparin
223719469|NCT02536040|OTHER|Water|Fluoride free, distilled water
224277967|NCT01820962|PROCEDURE|concentrated citrate|when not in use the CVC is locked with concentrated citrate
224277968|NCT04777305|OTHER|Physical activity training|Participants will be randomized into either one of three intervention groups (aerobic training, resistance training, or combined training comprised of resistance and aerobic training) and a control group. Training is described in the arm description section.
224277969|NCT00575601|DRUG|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
223719470|NCT01851616|DIETARY_SUPPLEMENT|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
223719471|NCT01851616|DIETARY_SUPPLEMENT|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
223914549|NCT06179524|BIOLOGICAL|CAR-T-19 cell injection|The functional component of CAR-T-19 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.
223914550|NCT02827838|BIOLOGICAL|Durvalumab|Given IV
223914551|NCT02827838|OTHER|Laboratory Biomarker Analysis|Correlative studies
223914552|NCT02827838|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223914553|NCT03654131|DEVICE|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
223914554|NCT03654131|RADIATION|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
223914555|NCT05627726|DEVICE|PelviSense-assisted pelvic floor muscle training group|The PelviSense consists of a high-precision, oval-shaped, wearable EMG sensor that displays electrical activity measured in PFMs on the user's mobile device. The reusable, wearable EMG sensor is non-invasive and can be attached to the user's perineal region. The mobile app provides real-time muscular feedback, displayed as EMG waveforms in microvolts. The mobile app can store data for up to 7 days, allowing participants to monitor their progress over the last 7 days in a graphical format.
223914556|NCT05627726|OTHER|Active comparator|Pelvic floor muscle training (PFMT) alone group: Women allocated to the PFMT alone group will perform unassisted PFMT. Exercise parameters, technique, and progression will be similar to those for the PelviSense-assisted PFMT group, but exercises will be performed without the PelviSense.
223914557|NCT05709145|OTHER|Written recommendation|"Patients in the intervention group will receive a report of the colonoscopy that will include a written recommendation that the colonoscopy should be repeated within1 year.~The colonoscopy report will included that an adequate intestinal cleansing has not been achieved and therefore it is an invalid exploration. Additionally, a written recommendation indicating that the colonoscopy should be repeated within1 year will be included in the colonoscopy report. This recommendation is addressed both to the clinician who requested the colonoscopy and to the patient himself."
223914558|NCT05885256|DIAGNOSTIC_TEST|Amending current standard trauma order set|Blood draw happens as part of routine clinical care for all trauma activations. As part of the study, we will use existing blood that is drawn as part of routine clinical care, or when necessary, draw additional blood to obtain samples at 0, 3, 6, 12, 18, and 24 hours assessing ionized calcium, serum calcium, and magnesium. We will strive to have draws occur within +/- 1 hour of the goal times. However, given that the blood draws will be performed by way of the clinical team and the unpredictable nature of trauma care, missed draws or draws out of the goal time frame will not be considered protocol violations
223914559|NCT05799625|BEHAVIORAL|StepOne Smartphone Application|This smartphone application provides a 14-day program that delivers the core components of smoking cessation (i.e., counseling, education) and takes advantage of pandemic-accelerated acceptance of virtual care, videoconferencing, remote monitoring, and social networking. The program seeks to move participants from the pre-action stage (not interested in quitting) to the action stage (intention to quit) and incorporates daily reminders, gamification, and models of habit formation to engage users.
223914560|NCT01545999|OTHER|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
223914561|NCT05432791|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223914562|NCT05432791|PROCEDURE|Bone Scan|Undergo bone scan
223719472|NCT01089062|DRUG|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
223719473|NCT01089062|DRUG|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
223719474|NCT01089062|DRUG|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
223719475|NCT01089062|DRUG|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
223914563|NCT05432791|PROCEDURE|Computed Tomography|Undergo CT scan
223914564|NCT05432791|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223914565|NCT05432791|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223914566|NCT05432791|DRUG|Olaparib|Given PO
224088559|NCT01646359|DEVICE|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
224088560|NCT01646359|DEVICE|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
224088561|NCT03306654|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
224088562|NCT04492904|OTHER|Home-use Test and Follow-up Questionnaire|Prospective tracking of changes in taste and smell acuity, and related changes in appetite, enjoyment of food and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
224088563|NCT01551745|BIOLOGICAL|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
224088564|NCT01551745|DRUG|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
224088565|NCT06287879|DIAGNOSTIC_TEST|Dry eye examination|"1. Lacrimal river height~2. tear break-up time~3. tear-film lipid layer thickness~4. meibomian glands two-dimensional digital infrared images"
224088566|NCT04334382|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight \< 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of \>20.
224088567|NCT04334382|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
224088568|NCT04695509|DRUG|"moderate propofol sedation (Bispectral index monitoring 70-90; The Richmond Agitation and Sedation scale (RASS) -2 - -3"|Two peripheral venous blood catheters are placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, noninvasive blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol light-moderate sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting the enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
224277970|NCT03795012|DRUG|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
223914567|NCT05432791|DRUG|Pazopanib|Given PO
224277971|NCT01825694|BEHAVIORAL|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
223914568|NCT05432791|DRUG|Temozolomide|Given PO
223914569|NCT05432791|DRUG|Trabectedin|Given IV
223914570|NCT05432791|PROCEDURE|Transthoracic Echocardiography Test|Undergo TTE
223914571|NCT06678464|OTHER|Moiz MM|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
223914572|NCT06678464|OTHER|Moiz XL|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day Route of Administration: Topical"
223914573|NCT06678464|OTHER|Moiz LMF 48|"Mode of Usage: After cleansing, apply liberally onto the skin and gently massage until fully absorbed.~Manufactured By: Dermalogics Marketed By: Glowderma Lab Private Limited Frequency: Twice a Day or as often as needed Route of Administration: Topical"
223914574|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223914575|NCT05255094|BIOLOGICAL|AK102|Administered AK102 by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223914576|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223914577|NCT05255094|DRUG|Placebo|Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
223914578|NCT05492422|DEVICE|Central Executive Training (CET)|Central Executive Training (CET)
223914579|NCT05492422|BEHAVIORAL|Behavioral Parent Training (BPT)|Behavioral Parent Training (BPT)
223914580|NCT06179303|DRUG|Abemaciclib|Given PO
223914581|NCT06179303|DRUG|Anastrozole|Given PO
223914582|NCT06179303|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223914583|NCT06179303|PROCEDURE|Computed Tomography|Undergo PET/CT
223914584|NCT06179303|PROCEDURE|Diagnostic Imaging Testing|Undergo clinical imaging for tumor assessment
223914585|NCT06179303|DRUG|Exemestane|Given PO
223914586|NCT06179303|OTHER|Fludeoxyglucose F-18|Given IV
223914587|NCT06179303|DRUG|Fluorine F 18 Fluoro Furanyl Norprogesterone|Given IV
223914588|NCT06179303|DRUG|Fulvestrant|Given IM injection
223914589|NCT06179303|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given GnRH analog
223914590|NCT06179303|DRUG|Letrozole|Given PO
223914591|NCT06179303|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223914592|NCT06179303|DRUG|Tamoxifen|Given PO
223914593|NCT06179303|DRUG|Therapeutic Estradiol|Given PO
223914594|NCT06779266|PROCEDURE|Suturing|Endoscopic Suturing is a technique of the wound closure after advanced endoscopic third-space resections in the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
223914595|NCT06779266|PROCEDURE|Clipping|Clipping is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the through-the-scope clips are delivered to the site through the working canal. The arms of the clip are properly put on the both sides of the defect and the clip is closed to seal the margins. The procedure may be repeated along the resection site for complete closure.
223914596|NCT06779266|PROCEDURE|No closure|The resection site after endoscopic submucosal dissection was left open, without additional closure.
223914597|NCT03695016|BEHAVIORAL|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
223914598|NCT06778837|DEVICE|Wearable devices to detect lymphedema|All participants will undergo measurement of the upper extremities to test the validity and safety of wearable sensors to measure lymphedema.
223914599|NCT04079530|DRUG|K-877 IR 0.2 mg/day|K-877 IR 0.1 mg tablet
223914600|NCT04079530|DRUG|K-877 CR 0.4 mg/day|K-877 CR 0.4 mg tablet
223914601|NCT04079530|DRUG|K-877 CR 0.8 mg/day|Two K-877 CR 0.4 mg tablet
223914602|NCT06547489|DRUG|Zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
223914603|NCT05571696|BEHAVIORAL|Immune Strength|Immune Strength is a 12 week online program that provides content, strategies, and guidance on how to improve your immune system and increase your mental wellbeing, with a focus on stress, sleep, nutrition, and exercise. In addition to the online program, each participant will be paired with a Cleveland Clinic Coach who will communicate with the participant via email. The Coach will help guide the participant throughout the program and provide encouragement and guidance for making behavior changes for making a more resilient immune system.
223914604|NCT01726257|DEVICE|Nellix System|Subjects in this study will receive a Nellix Endovascular Sealing System as part of their intervention.
223914605|NCT05051397|BIOLOGICAL|HYPERCAPNIA|Controlled moderate hypercapnia PaCO2 50mmHg under general anesthesia with mechanical ventilation
223914606|NCT05051397|BIOLOGICAL|NORMOCAPNIA|Controlled normocapnia PaCO2 40mmHg under general anesthesia with mechanical ventilation
223914607|NCT05313308|DRUG|Midazolam|Midazolam oromucosal solution
223914608|NCT04282980|DRUG|DCC-2618|Oral kinase inhibitor
223914609|NCT05308966|OTHER|Data collection|Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
223914610|NCT06242834|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223914611|NCT06242834|PROCEDURE|Computed Tomography|Undergo CT scan
223914612|NCT06242834|PROCEDURE|Echocardiography|Undergo echocardiography
223914613|NCT06242834|BIOLOGICAL|Pembrolizumab|Given IV
223914614|NCT06242834|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223914615|NCT06242834|DRUG|Tazemetostat|Given PO
223914616|NCT05794139|DRUG|NMD670|Tablets
223914617|NCT05794139|DRUG|Placebo|Tablets
223914618|NCT06804512|DEVICE|Visual Occlusion Goggles|The visual occlusion goggles alternate between sight and visual occlusion in a regular and programmable pattern. Based on the electrical properties of the goggles, they are also able to have the tint adjusted instead of blacking out entirely for the occlusion times during the programmed timings.
223914619|NCT06804512|BEHAVIORAL|Balance Beam Walking|Participants will walk on a treadmill mounted balance beam to assess their balance
224088569|NCT04695509|DRUG|"deep propofol sedation (BIS 60-70, The Richmond Agitation and Sedation scale (RASS) -4)"|Two peripheral venous blood catheter is placed after admission in the operation room and venous blood sample is taken (10 ml). Complete monitoring of vital functions is provided (pulse oximetry, blood pressure, electrocardiography, bispectral index monitoring). Doctor anesthesiologist performs regional anesthesia and propofol deep sedation starts. The second blood sample (10 ml) is taken 35-40 minutes after the start of propofol sedation. The third blood sample (10 ml) is taken after emergence from propofol sedation (10-15 minutes after propofol discontinuation). Blood samples are centrifuged and received plasma is frozen at a temperature of -20 C\*. After 26 patients are recruited, the blood plasma is analyzed by conducting enzyme-linked immunosorbent assay (ELISA) of neuromediators (Dopamine, serotonin, Gamma-aminobutyric acid (GABA), acetylcholine, noradrenaline).
224088570|NCT01253603|DRUG|QAW039 capsules once daily for 28 days|
224088571|NCT01253603|DRUG|Placebo to QAW039 capsules once daily for 28 days|
224088572|NCT01253603|DRUG|Fluticasone propionate inhaler twice daily for 28 days|
224088573|NCT00914693|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
224088574|NCT05360550|DRUG|LSP-5415|pregnancy prevention
224088575|NCT03152942|DRUG|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
224088576|NCT03152942|DRUG|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
223914620|NCT06805487|BIOLOGICAL|TetraVax-DV-TV003 (TV003)|0.5 ml of TV003 delivered via subcutaneous injection. TV003 contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN2/4Δ30(ME), 10\^3.3 PFU/mL of rDEN3Δ30/31- 7164 and 10\^3.3 PFU/mL of rDEN4Δ30
223914621|NCT06805487|BIOLOGICAL|Plasmalyte|0.5 mL of PlasmaLyte delivered via subcutaneous injection
223914622|NCT06805487|BIOLOGICAL|Challenge virus ZIKV-SJRP/2016-184|0.5 ml of ZIKV-SJRP/2016-184 delivered via subcutaneous injection. ZIKV-SJRP/2016-184 contains a dose of 10\^2 plaque-forming units (PFU).
223914623|NCT06804564|OTHER|Cold Water Immersion (CWI)|Standard immersion baths with temperature monitoring and ice supplementation. Lower limbs immersed up to the hip. Water temperature maintained at 10-12°C. Duration: 15 minutes per session. Participants perform active ankle flexion/extension to promote circulation.
223914624|NCT06804564|OTHER|Hot Water Immersion (HWI)|Controlled immersion baths. Lower limbs immersed up to the hip. Water temperature maintained at 40°C. Duration: 15 minutes per session.
223914625|NCT06804564|OTHER|Simulated Laser Therapy|Deactivated low-level laser therapy (LLLT) device. Applicator positioned over quadriceps muscle belly. Duration: 15 minutes, with no active laser output to simulate treatment conditions.
223914626|NCT06551519|OTHER|ofatumumab|This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
223914627|NCT06551519|OTHER|DMT category 1|This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
223914628|NCT02572141|DRUG|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
224088577|NCT00631631|DRUG|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
224088578|NCT05253456|PROCEDURE|Derma -Dartos Flap for second layer closure|usage of Derma -Dartos Flap for second layer closure of a distal penile hypospadias in circumcised patients
224088579|NCT04713761|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with MPM received surgical treatment (PD/EPP) after neoadjuvant therapy. Patients who were unable to operate or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Toripalimab 240mg, Carboplatin AUC5+ pemetrexed 500 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
224088580|NCT00749190|DRUG|BI 10773|
224088581|NCT00749190|DRUG|placebo|
223719476|NCT00884312|DRUG|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
223719477|NCT00224042|DRUG|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
223719478|NCT00224042|DRUG|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
224088582|NCT00749190|DRUG|sitagliptin|
224088583|NCT05200793|DRUG|Empagliflozin 25 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
223914629|NCT02572141|DRUG|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
224088584|NCT05200793|DRUG|Linagliptin 10 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
224088585|NCT05200793|DRUG|Metformin 1500 mg|This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)
223914630|NCT06498635|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223914631|NCT06498635|PROCEDURE|Computed Tomography|Undergo CT
223914632|NCT06498635|BIOLOGICAL|Durvalumab|Given IV
223914633|NCT06498635|OTHER|Patient Observation|Undergo active surveillance
223914634|NCT06498635|OTHER|Questionnaire Administration|Ancillary studies
223914635|NCT05401227|DRUG|Ketamine|Ketamine during an MRI
223914636|NCT05401227|DRUG|Ts-134|4 days of TS-134 20 mg
223914637|NCT05401227|DRUG|Placebo|4 days of placebo TS-134
224088586|NCT01652924|DEVICE|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
223914638|NCT05929859|BEHAVIORAL|Speech Motor Chaining|Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.
223914639|NCT03836495|DIETARY_SUPPLEMENT|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
223914640|NCT03571386|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
223914641|NCT03571386|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
223914642|NCT06479096|OTHER|Brush / Espresso Mild Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
223914643|NCT06479096|OTHER|Brush / Espresso Intense Prototype|Subjects will brush and rinse with their assigned mouthwash twice daily.
223914644|NCT06479096|OTHER|Brush / Fresh Breath Oral Rinse|Subjects will brush and rinse with their assigned mouthwash twice daily.
223914645|NCT06479096|OTHER|Brush / Hydroalcohol|Subjects will brush and rinse with their assigned mouthwash twice daily.
223914646|NCT05526443|DRUG|all approved chemotherapeutic agents from second line|all approved chemotherapeutic agents from second line
223914647|NCT02161783|DRUG|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
223914648|NCT02161783|DRUG|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
223914649|NCT02161783|RADIATION|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
223914650|NCT02161783|BIOLOGICAL|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
223914651|NCT06066567|DEVICE|Interferential current stimulation|IF Current parameters will be applied as follow: Amplitude modulated frequency (AMF) 30Hz, Autosweep-5 sec, Dose-15 minutes, type of current dynamic vector field (Mitra, 2006), three days per week over four weeks (Corrêa et al., 2016) and current intensity will be increased gradually, according to the subject's condition
223914652|NCT06066567|OTHER|Draw- In exercises,,|From prone position, participants will lay face down on the bed and flexed their hips and knees at 0°. A PBU will be positioned below the pubis symphysis with the decreasing edge consistent with the ASIS and will be overstated to 70 mmHg. The participants will be trained to gently draw in the lower part of the abdomen under the navel. In addition, while maintaining the neutral pelvic position, the movement of the upper part of the abdomen will be restricted so that the pressure will be decreased by approximately 10 mmHg. The participants will maintain this position for 10 s
223914653|NCT06551012|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Participants will consume 2 x 70 ml bottles of nitrate-rich beetroot juice for a 7 day period prior to exercise testing
223914654|NCT06551012|DIETARY_SUPPLEMENT|Beetroot juice with nitrate extracted|Participants will consume 2 x 70 ml bottles of beetroot juice with nitrate extracted for a 7 day period prior to exercise testing
223914655|NCT04311632|BIOLOGICAL|TCD601|Investigational Product
224088587|NCT01652924|DEVICE|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
224088588|NCT04957459|OTHER|No intervention|No intervention
223914656|NCT04311632|DRUG|Tacrolimus (TAC)|Standard of Care Concomitant Immunosuppression
223914657|NCT04311632|DRUG|Corticosteroids (CS)|Standard of Care Concomitant Immunosuppression
223914658|NCT04311632|DRUG|Mycophenolate Mofetil (MMF)|Standard of Care Concomitant Immunosuppression
224088589|NCT05853471|DRUG|[18F]MC225|All participants will undergo a PET scan with \[18F\]MC225. No pharmaceutical effects are expected and the study will exclusively have a diagnostic purpose. However, since \[18F\]MC225 is a new PET tracer, it is included in pharmaceutical studies and any study performed with \[18F\]MC225 will be automatically be registered as intervention study.
223914659|NCT04311632|DRUG|ATG|Standard of Care induction therapy in solid organ transplantation
223914660|NCT06040801|BEHAVIORAL|Frailty intervention measures|"Providing management and recommendations based on the specific impairment domain.~Assessment domain:~* Functional status~* Nutrition~* Comorbidity~* Mobility/Falls~* Mood~* Cognition~* Polypharmacy~* Social support."
223914661|NCT06370585|DRUG|PRO-229|\- Dexpanthenol 2% and sodium hyaluronate 0.15% ophthalmic solution.
223914662|NCT06370585|DRUG|Lagricel® Ofteno PF|\- Sodium hyaluronate 0.4%. Ophthalmic solution.
223914663|NCT04632225|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
223914664|NCT04632225|OTHER|Placebo|Injectable liquid
223914665|NCT06753578|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT); Quality of Life (QOL); Mild Cognitive Impairment (MCI); cognitive function; elderly; psychological flexibility.
223914666|NCT06753578|BEHAVIORAL|standard care|standard care
223914667|NCT04605159|BIOLOGICAL|RSV MAT|One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
223914668|NCT04605159|DRUG|Placebo|One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
223914669|NCT05387525|DRUG|Tirbanibulin (Klisyri®) 10 mg/g ointment|Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).
223914670|NCT05387525|DRUG|Diclofenac Sodium 3% Gel|Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
223914671|NCT01982890|OTHER|Control|No intervention as this group is simply followed prospectively.
223914672|NCT06256640|DEVICE|Mandibular advancement Device|Intra oral appliances and more specifically Mandibular Advance Devices (MAD) are one of the established alternatives to treat OSA. Oral appliances and MAD are often used interchangeably but we prefer to call them MAD as it is more descriptive of its mechanism of action. MAD are placed in the mouth to temporarily advance and stabilize the lower jaw forward in order to keep the airway open during sleep.
223914673|NCT06765031|DIAGNOSTIC_TEST|Furosemide|Furosemide will be administered intravenously in the form of a push at a dose of 1 mg/kg to furosemide-naïve patients who meet the inclusion criteria and at a dose of 1.5 mg/kg to patients exposed to furosemide.
223914674|NCT06768346|DEVICE|Hyperthermia will be delivered in combination with each instillation using the Combat BRS system|The Combat BRS system is a temperature controlled fluid recirculation system for the delivery of hyperthermic intravesical chemotherapy. The chemotherapy fluid is circulated in a closed system and warmed by an external isolated dry system using a novel innovative laminated aluminium foil heat exchanger with a small priming volume.
223914675|NCT04968366|BIOLOGICAL|Autologous dendritic cells pulsed with multiple neoantigen peptides.|Each dosage of Dendritic Cells (DC) vaccine contains 2-10 million DC cells, loaded with 5-20 tumor neoantigen peptides. DC vaccine will be administered (i.d) around lymph nodes of the groin and Axillary at 2nd, 3rd, 4th, 7th and 11th week after the completion of concurrent Temozolomide chemoradiation. After 5 injections, the investigator will review subject's tolerance and compliance; and, decide whether to administer more DC vaccines up to 8 injections. For certain patients with good tolerance and clinical response of the DC vaccine, peripheral blood is extracted after completion of Temozolomide adjuvant chemotherapy to assess the patient's immune response. According to the result, investigators will decide whether to perform 1-2 more treatment cycles (5-8 injections/cycle) to strengthen the effectiveness
223914676|NCT04968366|DRUG|Temozolomide adjuvant chemotherapy|Temozolomide is administered as the standard-of-care adjuvant chemotherapy, in combination with the DC vaccines to treat the enrolled patients.
223914677|NCT06305117|OTHER|Distraction strategy|Distraction strategy combining the use of virtual reality and music
223914678|NCT05248802|DRUG|Placebo caplet of DLBS2411|1 caplet of placebo DLBS2411, twice daily
223914679|NCT05248802|DRUG|DLBS2411|1 caplet of DLBS2411 250 mg, twice daily
223940177|NCT05897905|BEHAVIORAL|Personalised, holistic follow-up appointments underpinned by self determination theory|"Appointment 1 (two weeks after discharge):~* Address participants knowledge gaps as regards their stroke, medication and secondary prevention.~* Detailed biopsychosocial review.~* Understand participant priorities and jointly set goals.~* Agreeing onward referrals if needed.~* Written summary sent to GP with copy to participant.~Appointment 2 (six weeks):~* Review priorities identified in post stroke review checklist.~* Review goals and plans from first appointment.~* Address any new or persistent information gaps.~* Review hidden impairments that may be impacting on return to work, activities of daily living, relationships or general well-being.~* Agreeing onward referrals and action plan.~* Written summary and plan sent to GP."
224088590|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
224088591|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
224088592|NCT00355121|BIOLOGICAL|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
223719479|NCT04051762|DEVICE|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
223716376|NCT05292508|DIAGNOSTIC_TEST|C-reactive Protein Rapid Diagnostic Test|In the intervention arm in addition to Usual Standard of Care, CRP Testing will be performed. In this test, health worker at health post will prick the finger of the patient using a lancet device following aseptic precautions. A very small drop (10 microliters) of whole blood will be obtained. This will be added to specimen dilution buffer. Then the sample will be mixed by inverting the tube upside down 10-15 times. Then the yellow dip area of the dipstick will be placed into the diluted sample. It will be held there until the liquid rises to the result area by capillary action. The the dipstick is removed from the solution and placed in a horizontal position. The timer will be started and result will be interpreted in 5 minutes. Treatment decision making regarding the use of antimicrobials will be conducted with the help of CRP test results and other clinical features.
223914680|NCT03477435|BEHAVIORAL|Staff training and academic detailing|Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
223914681|NCT02787031|PROCEDURE|Neuraxial anesthesia|
223914682|NCT02787031|PROCEDURE|General anesthesia|
223914683|NCT06402864|RADIATION|contact X-ray brachytherapy (CXB)|3 fractions of contact X-ray brachytherapy (CXB) every two weeks before neoadjuvant chemo radiotherapy (nCRT).
223914684|NCT04278339|OTHER|Evoked Related Potentials|Evoked Related Potentials are measured by means of electroencephalography. During this measure, 2 informatic task will be performed to evaluated evoked related potentials.
223914685|NCT06083766|BEHAVIORAL|hormone therapy|Determine how gender affirming hormone therapy affects muscle physiology
223914686|NCT05663801|DRUG|Use of Bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and patients will be given 30 mL of 0.25% bupivacaine hydrochloride and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
223914687|NCT05663801|DRUG|use of Ketamine as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL of 0.25% bupivacaine hydrochloride plus ketamine hydrochloride (1 mg/kg) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
223914688|NCT05663801|DRUG|Use of Magnesium Sulfate as adjuvants to bupivacaine in pectoral nerve block in mastectomy|Pectoral nerve block will be performed and Patients will be given 30 mL 0.25% Bupivacaine hydrochloride plus Magnesium Sulfate ( 28 ml Bupivacaine 0.25% plus 2ml magnesium sulfate 50%) and It will be divided into 10 mL injected between the 2 pectoral muscles on the interfascial plane, and 20 mL will be injected between the pectoralis minor and the serratus anterior muscles
223940178|NCT06509412|DEVICE|LANAP surgical protocol using ND:YAG 1064 laser|A free running pulsed, 1064 nm wavelength-specific ND:YAG laser (Light walker AT)\* with an attached 320 µm diameter optical glass fiber attached to a metallic hand piece with a flexible tip, which will be set at 3:4 -watt average power, 20 HZ, and a 100-600 µs pulse duration
223940179|NCT06509412|DEVICE|LANAP surgical protocol using diode 940 laser|Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm was attached with a power average set at 0.5-1 watt, in continuous mode, and 20 HZ
223940180|NCT06509412|PROCEDURE|Scaling and root planing (SRP)|Scaling and root planing (SRP) using ultrasonic device (Woodpecker USD-P Led Ultrasonic Scaler Ende) at moderate setting and with appropriate tips and also hand curettes will be used for root planning.
223716377|NCT02929667|DRUG|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
223716378|NCT02929667|DRUG|Placebo|Standard 6 weeks titration.
223940181|NCT05271994|PROCEDURE|endoscopic biliary drainage|endoscopic biliary drainage
223940182|NCT05150093|PROCEDURE|Deep Brain Stimulation|Clinically indicated DBS treatment for dystonia or tremor with simultaneous research electrocorticography (ECoG).
223940183|NCT05616494|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
223940184|NCT05561556|DIETARY_SUPPLEMENT|MitoQ|One 20mg capsule daily for 8 weeks
223940185|NCT03441490|BEHAVIORAL|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
223940186|NCT03441490|BEHAVIORAL|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
223940187|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
223940188|NCT03441490|BEHAVIORAL|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
223940189|NCT01115140|DRUG|metformin plus placebo|metformin 850 mg cp, 2 cps daily
223940190|NCT01115140|DRUG|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
223940191|NCT01115140|DRUG|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
223940192|NCT01115140|DRUG|placebo alone|placebo cp, 2 cps daily
223940193|NCT01697228|DIETARY_SUPPLEMENT|Vitamin D|
223940194|NCT00853255|BIOLOGICAL|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
223940195|NCT05081804|DIETARY_SUPPLEMENT|Carbohydrate Preoperative Drink|Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
223940196|NCT04569526|DEVICE|use of intraoperative ultrasound|Ultrasonography guided brain lesions resection intra operatively for good localization
224088593|NCT03035760|DRUG|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
223914689|NCT06515691|PROCEDURE|M-TAPA block|After the wound closure is completed and the patient is still under genaral anesthesia the M-TAPA block ill be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed in a sagittal position at the costochondral junction at the level of the 9th and 10th ribs. After the rib and the external oblique, internal oblique, and transversus abdominis muscles are visualized on USG, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline between the internal oblique and transversus abdominis muscles. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine ®) will be applied on each side. The total volume will be 60 ml.
223914690|NCT06515691|PROCEDURE|Postoperative pain management|ibuprofen 400mg (Ibuprofen-PF®) intravenous (IV), and tramadol (Contramal®) 100 mg IV will be administered to all patients 20 minutes before wound closure. After surgery, Ibuprofen 400 mg will be given three times a day. A patient-controlled analgesia (PCA) system containing 10 mcg/ml fentanyl will be provided to all patients without continuous infusion. Patients can administer boluses of 0.35 mcg/kg with a 15-minute lockout period and a maximum dose of 100 mcg per hour. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV tramadol (Contramal®) 100 mg will be given as a rescue analgesic.
223914691|NCT06228248|OTHER|metagenomics|Feces used for metagenomic testing
223914692|NCT03718637|BIOLOGICAL|Smith & Nephew Bioinductive Implant|A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.
223914693|NCT03718637|PROCEDURE|Lateral Epicondylectomy|This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
223914694|NCT03718637|RADIATION|Ultrasound Imaging|An ultrasound will be performed on each patient both preoperatively and at 6 months.
223914695|NCT05832281|DRUG|Purysis CBD|Participants will receive Purysis, or synthetic CBD, which will be compared to placebo
223914696|NCT05832281|DRUG|Placebo|Placebo for Purysis
223914697|NCT04165772|DRUG|TSR-042 or Dostarlimab|Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
223914698|NCT04165772|DRUG|capecitabine or 5-FU|Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative.
223914699|NCT04165772|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
223914700|NCT06401954|DEVICE|High-intensity focused electromagnetic therapy|"High-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is set to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
224088594|NCT01796002|DRUG|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
224088595|NCT01796002|DRUG|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
224088596|NCT04420130|DRUG|Camrelizumab|Camrelizumab was administered 200mg iv every 3 weeks
224088597|NCT04420130|DRUG|Chemotherapy|The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
224088598|NCT04420130|PROCEDURE|Ablation|First give pancreatic cancer patients with liver metastases to ablation of liver metastases
224088599|NCT04942392|DEVICE|Digital dance for PD|The digital dance class was held via Zoom. The class was scheduled once a week for 60 min and consisted of 10 sessions. A professional, certified Dance for PD and experienced dance instructor was teaching the dance class. The dance classes followed the Dance for PD protocol yet was adjusted to fit the digital zoom format.
224088600|NCT04751942|DEVICE|Non-compressive Bioactive Garment|patients will be assigned to wear the non-compressive bioactive garment following total knee arthroplasty
224088601|NCT04751942|DEVICE|thrombo-embolic deterrent|patients will be randomized to wear the gold standard TED hose following total knee arthroplasty
224088602|NCT04964011|OTHER|Board game intervention|In this study, the two groups, the Board game group (12-week board game intervention) and Health promotion group (12-week general health promotion intervention).
224277972|NCT01584882|BEHAVIORAL|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
224277973|NCT00363857|DRUG|Ropinirole|
224277974|NCT03359720|OTHER|no intervention survey|survey
224277975|NCT03064620|BIOLOGICAL|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
224277976|NCT00078923|DIETARY_SUPPLEMENT|soy isoflavones|
224277977|NCT00078923|PROCEDURE|neoadjuvant therapy|Prostatectomy or Brachytherapy
224088603|NCT02367950|BEHAVIORAL|Exercise|10 exercise sessions with a personal trainer
224088604|NCT05307458|DRUG|Buprenorphine/naloxone|Participants will receive gradually increasing doses of buprenorphine while tapering down on their methadone dose.
224277978|NCT00078923|OTHER|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
224277979|NCT02897934|DRUG|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
224277980|NCT00991692|OTHER|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
224277981|NCT04506619|OTHER|No Intervention|This is a non-interventional study.
224277982|NCT01102127|DEVICE|Elastography|Performance of US, elastography and FNA.
224277983|NCT01833169|DRUG|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
224277984|NCT03380325|DRUG|Iloprost infusion|Iloprost is a stable prostacyclin analogue
224277985|NCT02664350|GENETIC|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
224277986|NCT02664350|BEHAVIORAL|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
224277987|NCT02664350|BEHAVIORAL|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
223914701|NCT06401954|BEHAVIORAL|Foot core training|"Foot core training will consist of 4 exercises with 10 repetitions per set and 3 sets per session for each exercise.~Twice a week for a total of six weeks."
223914702|NCT06401954|DEVICE|Sham high-intensity focused electromagnetic therapy|"Sham high-intensity focused electromagnetic therapy is applied to intrinsic foot muscles, the intensity is unable to stimulate muscle contraction.~20 minutes of intervention, twice a week, and a total of 6 weeks"
223914703|NCT04881461|DRUG|5-grass mix SLIT-drops|Sublingual allergy immunotherapy drops, for daily administration
223914704|NCT04881461|DRUG|Placebo|Placebo
223914705|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL and r/r CTCL
223914706|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r ATLL
223716379|NCT04335097|DEVICE|Biosensors|Sensor that detect vital signs
223914707|NCT04362007|DRUG|ASTX660|Treatment of ASTX660 for r/r PTCL
223716380|NCT00727428|BIOLOGICAL|FluLaval® TF|One IM injection.
223914708|NCT06022965|OTHER|Best Practice|Receive SOC
223914709|NCT06022965|OTHER|Comprehensive Geriatric Assessment|Complete CARG-GA
223914710|NCT06022965|OTHER|Electronic Health Record Review|Ancillary studies
223914711|NCT06022965|OTHER|Questionnaire Administration|Ancillary studies
223914712|NCT06022965|OTHER|Supportive Care|Receive GA-based interventions
223914713|NCT06022965|OTHER|Telemedicine|Receive GA-based interventions via telemedicine
223914714|NCT06780098|BIOLOGICAL|R-DXD|IV Infusion
223914715|NCT06780098|BIOLOGICAL|I-DXD|IV Infusion
223914716|NCT06780098|DRUG|Docetaxel|IV Infusion
223914717|NCT06604468|DIAGNOSTIC_TEST|Thoracic bioimpedance tomography|Data collection using a thoracic bioimpedance tomography device
223914718|NCT05265299|DRUG|Aspirin 81mg|Aspirin 81mg once daily
223914719|NCT05265299|DRUG|Aspirin 162 mg|Aspirin 162 mg once daily
223914720|NCT05265299|DRUG|Aspirin 325mg|Aspirin 325mg once daily
223940197|NCT03813524|DEVICE|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
223940198|NCT01354145|DRUG|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
223940199|NCT01354145|DRUG|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
223940200|NCT03703414|DIAGNOSTIC_TEST|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
223940201|NCT00734578|DRUG|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
223940202|NCT00734578|DRUG|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
223940203|NCT00734578|DRUG|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
223940204|NCT03735459|BEHAVIORAL|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
223940205|NCT06829199|BIOLOGICAL|Pembrolizumab|Neoadjuvant therapy - 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 24 weeks Adjuvant therapy - 200 mg IV infusion Q3W or 400 mg IV infusion every 6 weeks (Q6W) for up to approximately 30 weeks.
223940206|NCT06829199|DRUG|Paclitaxel|80 mg/m\^2 by IV infusion every week for up to 12 weeks.
223940207|NCT06829199|DRUG|Carboplatin|AUC 1.5 mg/mL/min by IV infusion every week for up to 12 weeks.
223940208|NCT06829199|DRUG|Doxorubicin (hydrochloride)|60 mg/m\^2 by IV infusion Q3W for up to 12 weeks.
223940209|NCT06829199|BIOLOGICAL|Boserolimab|30 mg by IV infusion every 6 weeks (Q6W) for up to 12 Weeks.
223940210|NCT06829199|DRUG|Epirubicin Hydrochloride|90 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.
223940211|NCT06829199|DRUG|Cyclophosphamide|600 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.
223940212|NCT06829199|DRUG|Capecitabine|1000 mg/m\^2 to 1250 mg/m\^2 by oral administration twice a day (2 weeks on and 1 week off) for up to approximately 24 weeks.
223940213|NCT06829199|DRUG|Olaparib (if approved/available locally)|300 mg by oral administration twice a day for up to approximately 52 weeks.
223940214|NCT02085941|DEVICE|Cryoablation|Cryoablation using 17G Galil cryoprobe
223940215|NCT02085941|DEVICE|Biopsy|Biopsy using 18G Temno core biopsy needle
223940216|NCT02761499|DEVICE|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
223940217|NCT05051826|OTHER|Resistance training that combines water and land|"Device: Swimmers in the experimental group received resistance training in water for 12 weeks, and the resistance training in the experimental group was divided into 3 categories:Resistance palm and resistance umbrella, resistance suit.~Device: The swimmers in the experimental group underwent core strength training on land for 12 weeks, and the resistance training in the experimental group was divided into 4 types of resistance zones: Swiss ball, medicine ball and drive zone.The combination of two resistance training methods can improve teenagers' swimming performance."
223940218|NCT06640842|DIAGNOSTIC_TEST|A combination of various test and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy in brain health in midlife.|Participants will be asked to complete a blood draw, 5-lead ECG, MRI, a series of cognitive assessments, dietary assessments, monitor sleep and physical activity and DXA scan.
223914721|NCT06813482|BEHAVIORAL|Digitally enabled cardiac rehabilitation|"The intervention consists of an 8-week remotely delivered cardiac rehabilitation program. It includes an initial assessment during week 1, six weeks of participation in a digitally enabled cardiac rehabilitation (DeCR) program (weeks 2-7), and a final assessment in week 8. Participants will utilize a digital mobile application and receive weekly telehealth consultations with a cardiac nurse. The program is designed to facilitate behavior change and improve outcomes through the following modalities:~1. Telehealth - individualized coaching delivered via telephone by a cardiac nurse, to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~2. Mobile application (called SmartCR) and nurse web portal - for remote monitoring and personalized care planning. The app monitors health and physical activity, has prompted tasks and delivers education via video, audio and written articles."
223914722|NCT06813482|BEHAVIORAL|F2F-CR|Traditional Face-to-face cardiac rehabilitation
223914723|NCT06813482|BEHAVIORAL|Usual Care Group|Usual Care - eligible for cardiac rehabilitation and who unlikely participated in any formal cardiac rehabilitation program
223914724|NCT06813209|DEVICE|tDCS|For true tDCS, the technique will be performed with the anode over the right dorsolateral prefrontal cortex and the cathode over the left dorsolateral prefrontal cortex, positioned at F4 and F3, respectively, according to the International 10/20 Electrode Placement System. The current intensity will be set to 2 milliamperes (mA) for 20 minutes over five consecutive days.
223914725|NCT06813209|DEVICE|tVNS|For true tVNS stimulation, the technique will be performed with the electrodes positioned on the upper concha of the left ear, using gel for better current distribution.
223914726|NCT06596018|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy using 6MV-X rays, administered once a day for three consecutive days.
223914727|NCT06596018|DRUG|Chemotherapy|Continue to follow the original chemotherapy regimen（anthracycline and/or taxane based regimens）
223914728|NCT06106529|DRUG|Oxybutynin|Oxybutynin 5 mg twice per day for 6 weeks
223530004|NCT06643871|OTHER|Adapted physical activity program involving connected bikes|The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
223914729|NCT06106529|DRUG|Venlafaxine|Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
223914730|NCT06358040|DEVICE|Opioid-Dispensing Device|Addinex Opioid-Dispensing Device
223914731|NCT06358040|OTHER|App|Addinex App
223914732|NCT06358040|OTHER|Standard Opioid Pill Bottle|Standard Opioid Pill Bottle
223914733|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Adductor Canal Block|0.25% 15-20ml bupivacaine (local anesthestic) delivered as part of the adductor canal block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the adductor canal block
223914734|NCT06590402|DRUG|Bupivacaine, Dexamethasone in Anterior Femoral Cutaneous Nerve Block|10 ml of 0.25% bupivacaine (local anesthetic) delivered as part of the anterior femoral cutaneous nerve block with 2 mg preservative-free dexamethasone (corticosteroid) delivered as part of the anterior femoral cutaneous nerve block
223914735|NCT06813521|OTHER|NaP1%+VitCG3% leave-on lotion (formula 1256103)|leave-on lotion
224088605|NCT04011202|BEHAVIORAL|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for the duration of their inpatient stay. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
223914736|NCT06813521|OTHER|vehicle (formula 1256145)|vehicle lotion
223914737|NCT06813521|OTHER|reference Octopirox 0.25% (formula 1256149).|lotion reference Octopirox 0.25%
223914738|NCT04068792|OTHER|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
224088606|NCT05535764|DRUG|Pegylated interferon alpha2a|PegINFa will be given once every 2 weeks by subcutaneous administration in the abdomen or thigh.
223716381|NCT05163236|DIAGNOSTIC_TEST|Positive fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
223914739|NCT04068792|DRUG|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.
223914740|NCT04068792|DRUG|JNJ-53718678 2.5 mg/kg|JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.
223914741|NCT04068792|DRUG|JNJ-53718678 3 mg/kg|JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
224088607|NCT04941196|DRUG|Anplag (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
224088608|NCT04941196|DRUG|Brilinta (Ticagrelor 90 mg)|Ticagrelor 90 mg Immediate Release tablet
224088609|NCT03892161|DRUG|Darunavir/ritonavir 800/100 mg tablet|Standard dose DRV/r administered
224088610|NCT03892161|DRUG|Rifampicin 600mg QD tablet and DTG 50mg BD|Rifampicin and DTG added
224277988|NCT02664350|GENETIC|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
224277989|NCT02004717|DRUG|DS-8895a|
224277990|NCT01959802|PROCEDURE|Vitrectomy|
224277991|NCT00002116|DRUG|Cidofovir|
224277992|NCT01407484|DRUG|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
224277993|NCT01407484|DRUG|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
224277994|NCT03422224|DIAGNOSTIC_TEST|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
223914742|NCT04068792|DRUG|JNJ-53718678 4.5 mg/kg|JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
223914743|NCT06815666|PROCEDURE|Bronchoscopy & Metastasectomy|Routine bronchoscopy and standard of care metastasectomy
223914744|NCT06565247|DRUG|[18F]PSMA-PET|Pre-surgical imaging using \[18F\]PSMA-PET at Umea University Hospital, 3.5 MBq/kg, i.v. injection.
223914745|NCT06565247|DEVICE|MRI sequences optimized for prostate cancer examinations|T2-WI, T1-WI, DCE and DWI at Umea University Hospital and at Skåne University Hospital
223914746|NCT00317486|DRUG|bosentan|
223914747|NCT02556281|BIOLOGICAL|Blood sampling|Blood sampling is done for patient with colorectal cancer
223914748|NCT06605170|OTHER|Questionnaire|Translate and culturally adapt the original English version of the traumatic injuries distress scale to Turkish
223914749|NCT06592248|DEVICE|Coc Knee|Implementation of a ceramic on ceramic knee prosthesis
223914750|NCT05127109|COMBINATION_PRODUCT|Nutrition Ecosystem pathway|"1. parenteral nutrition initiated within 72 hours of operative intervention~   * Provided as clinically appropriate: Ensure Enlive, Ensure High-Protein, Nepro with Carb-Steady/ProSource Gelatein Plus, and/or ProSource Gelatein Plus~2. metabolic cart assessments to determine resting energy expenditure (REE) and guide registered dietitians (RDs)~   * Q-NRG Metabolic Cart (Indirect Calorimeter) and Quark RMR Metabolic Cart (Indirect Calorimeter)~  * BWA 2.0 Advanced Bioelectric Impedance Spectroscopy (BIS)~  * Philips Lumify L12-4 broadband linear array transducer ultrasound~3. expedited delivery of oral nutrition supplements and~4. a team-based approach on proper documentation of nutrition delivery and intake"
223914751|NCT05127109|OTHER|Comparator|retrospective cohort of 300 historical matched control subjects
223914752|NCT03663205|DRUG|Tislelizumab|Administered intravenously
223914753|NCT03663205|DRUG|Cisplatin|Administered intravenously
223914754|NCT03663205|DRUG|Carboplatin|Administered intravenously
224277995|NCT05721157|OTHER|AI-enabled Chest X-ray-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
224277996|NCT00105157|DRUG|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
223914755|NCT03663205|DRUG|Pemetrexed|Administered intravenously
223914756|NCT00517153|DRUG|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
223914757|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.
224277997|NCT00105157|DRUG|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
223914758|NCT02577354|DEVICE|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
223914759|NCT03693014|RADIATION|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
223914760|NCT03693014|BIOLOGICAL|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
223914761|NCT05123612|BEHAVIORAL|Fiber|Additional 20 grams of fiber/day.
223914762|NCT05123612|BEHAVIORAL|Fermented Foods|6 servings of fermented foods/day
223914763|NCT04875429|DEVICE|Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2|Endovascular aneurysm repair
223914764|NCT05125731|BEHAVIORAL|Parental absence|Parent does not accompany the child during dental treatment
223914765|NCT05125731|BEHAVIORAL|Parental visual support|The parent does not accompany the child during the dental treatment but watches behind the glass and is seen by the child.
223914766|NCT05125731|BEHAVIORAL|Parental presence|Parent accompanies the child during dental treatment
223914767|NCT06658002|DRUG|Cyclosporine A|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
223914768|NCT06658002|OTHER|Placebo Comparator: Placebo|Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
224277998|NCT00105157|DRUG|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
224277999|NCT00105157|DRUG|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
223914769|NCT04637984|BEHAVIORAL|PREP2 algorithm|A) PREP2. It combines clinical measures and neurological biomarkers in the initial days after stroke: 1) SAFE score (day 3), which is the sum of shoulder abduction and finger extension strength in the paretic upper limb using the Medical Research Council (MRC); 2) NIH Stroke Scale (day 3); 3) transcranial magnetic stimulation (day 3-7) to determine the presence of MEPs in the paretic arm. According with the aforementioned measures, 4 categories of upper limb recovery will be identified: EXCELLENT, GOOD, LIMITED and POOR.
223914770|NCT05887089|OTHER|drone transport|additional transport of samples at room temperature by drone (departure from the CHU Amiens-Picardie, 1 hour flight in the CHU Amiens-Picardie air perimeter, return to the CHU Amiens-Picardie)
223914771|NCT05589155|OTHER|Mobile health application|Intervention will be with mobile health application
223914772|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 2 doses alternate timing|Evaluate 2 doses of the 9-valent HPV vaccine across a 12-month period following the 1st dose among 27-45-year-old females.
223914773|NCT05672927|BIOLOGICAL|9-valent HPV vaccine, 3 doses standard timing|This will be the comparison group for the 2-dose group.
223914774|NCT06818162|OTHER|normative data|Ultra sonography of ulnar nerve along its course to obtain normative values for the CSA
223914775|NCT06843122|BIOLOGICAL|A - Allogenic ADSC cells in fibrin solution - two times administration ADSC/ASC|ADSC/ASC will be administered twice, at two-week intervals - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed every week, up to V6 visit (up to 6 weeks after V0).
223914776|NCT06843122|BIOLOGICAL|B - Allogenic ADSC cells in fibrin solution - one time administration of ADSC/ASC, one time of placebo|ADSC/ASC will be administered once, at the time of the second application patients will receive a placebo - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed weekly, up to V6 visit (up to 6 weeks after V0)
223914777|NCT06843122|OTHER|C - Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface.|Placebo will be administered twice, at two-week intervals - during V0 and V2 visits The first dose will be administered one week after the randomisation visit. Control visits after administration will be performed every week, up to V6 visit (up to 6 weeks after V0).
223914778|NCT06842225|OTHER|reduced physical activity|Each participant will undergo a three-week study. For the first week (day -7 to day 0), participants will be instructed to maintain their normal level of physical activity. For the second week (day 0 to day 7), the reduced physical activity (RPA) week, participants' schedules will be examined, and strategies designed to reduce steps (by at least 2000 steps) and physical activity (by taking elevators and short-cuts, etc.) by increasing sitting time \>10%. To assist in reducing walking and increased sitting, participants will be given seated electric scooters to use whenever they normally walk. The scooters will be returned on the third week (day 7 to day 14), and participants will be instructed to resume their normal physical activity. During the entire three weeks, participants will wear a continuous glucose monitor (CGM) and a physical activity monitor (ActivPal).
223914779|NCT06859710|DRUG|Placebo|Vaporized Placebo
224088611|NCT06089447|BEHAVIORAL|A story based intervention called 'The Shadow of Tallystick Valley'|'The Shadows of Tallystick Valley' is a story based intervention for CYP aged 7 - 14 years aimed at supporting the psychological wellbeing and resilience of those affected by familial substance misuse. It has been designed by Book of Beasties, a developer of games and educational content, in collaboration with the charity Change Grow Live, who support those experiencing substance misuse and CYP affected by familial substance misuse in the UK. The wellbeing resource harnesses protective factors, such as respectful and caring conversations with professionals (Wangansteen and Westby, 2019), to facilitate a safe and supportive environment aimed towards understanding the CYPs experience, support their psychological wellbeing and building resilience and coping skills. It uses fictional narratives, including characters that represent particular topics which act as drivers for engagement.
223914780|NCT06859710|DRUG|THC|Vaporized THC (20 mg)
223914781|NCT06859710|DRUG|CBD 20 mg|Vaporized CBD (20 mg)
223914782|NCT06859710|DRUG|CBD 40 mg|Vaporized CBD (40 mg)
223914783|NCT06859710|DRUG|CBD 80 mg|Vaporized CBD (80 mg)
223914784|NCT06859723|DRUG|Placebo Comparator: Placebo|Placebo
224088612|NCT06253039|OTHER|Repeated sprint|"* The group will endure four weeks (8 sessions) of the assigned training program in addition to the regular swimming training.~* Data collection sessions: All groups will be evaluated before and after the supervised training period in three testing sessions in normoxia separated by at least 24 hours within 7 days.~* Training sessions: will be performed in the ski ergometer and consist of 4 sets of 5x6s all-out sprints with 24s and 5 min of passive rest between the sprints and sets, respectively."
224088613|NCT05624463|BEHAVIORAL|Modified intubation protocol|1\. Turn on the electromyography (EMG) monitor and connect the EMG monitor to the patient as the patient is anesthetized; 2. View the vocal cords with video laryngoscope and intubate the patient with the EMG endotracheal tube; 3. Check the EMG monitor to confirm the correct contact between the electrodes and vocal cords; 4. Adjust the tube to achieve proper and stable contact between the electrodes and vocal cords; 5. Tape the EMG endotracheal tube at the midline and position the patient.
223914785|NCT06859723|DRUG|Low dose THC|Smoked low dose THC
223914786|NCT06859723|DRUG|High dose THC|Smoked high dose THC
223914787|NCT06989710|DIETARY_SUPPLEMENT|Placebo control 7.1.0|Participants will use their placebo control 7.1.0 as directed for a period of 6 weeks.
223914788|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.1.1 usage|Participants will use their Radicle Health Active Study Product 7.1.1 as directed for a period of 6 weeks.
223914789|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.1.2 usage|Participants will use their Radicle Health Active Study Product 7.1.2 as directed for a period of 6 weeks.
223914790|NCT06989710|DIETARY_SUPPLEMENT|Placebo control 7.2.0|Participants will use their placebo control 7.2.0 as directed for a period of 6 weeks.
223914791|NCT06989710|DIETARY_SUPPLEMENT|Health Active Product 7.2.1 usage|Participants will use their Radicle Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
223914792|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for breast cancer per local standard.
223914793|NCT05754658|OTHER|Standard of Care|Drugs routinely administered for prostate cancer per local standard.
223914794|NCT06864910|DEVICE|anodal transcranial Direct Current Stimulation|Transcranial direct current stimulation was administered following standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures . None of the participants reported significant adverse effects.
223914795|NCT06863532|DRUG|Cofrogliptin+SGLT2i+Metformin|The cofrogliptin add-on group will continue their existing SGLT2i plus metformin regimen and dosing, with the add-on of cofrogliptin over 24 weeks of triple combined therapy.
223914796|NCT06863532|DRUG|Metformin dose escalation|The metformin dose escalation group will have their metformin dose gradually increased to the target dose.
223914797|NCT06671054|DRUG|AP1189, 40 mg|AP1189 tablets for oral use
223914798|NCT06671054|DRUG|AP1189, 70 mg|AP1189 tablets for oral use
223914799|NCT06671054|DRUG|AP1189, 100 mg|AP1189 tablets for oral use
223914800|NCT06671054|DRUG|AP1189 matching placebo|AP1189 tablets for oral use
223914801|NCT06997146|BIOLOGICAL|Blood and Urine Sampling|Collection of 10 mL of blood (separated into aliquots for RNA-seq and metabolomic analysis) and 5 mL of urine from participants at various timepoints during sleep and wakefulness. These samples will be used to analyze biomarkers and dysregulated biological pathways related to CCHS.
223914802|NCT06997146|DEVICE|Polysomnography|Participants will undergo polysomnography to assess sleep patterns and respiratory function during sleep. This will help evaluate any sleep-related breathing abnormalities in patients with CCHS and compare them with healthy controls.
223914803|NCT06997146|OTHER|lung function tests|spirometry, ventilatory response to CO2
223914804|NCT06999642|DIETARY_SUPPLEMENT|GI Health Placebo Control|Participants will use their GI Health Placebo Control as directed for a period of 6 weeks.
223914805|NCT06999642|DIETARY_SUPPLEMENT|GI Health Active Product|Participants will use their GI Health Active Product as directed for a period of 6 weeks.
223914806|NCT06999655|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
223914807|NCT06999655|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.
223914808|NCT06999655|DIETARY_SUPPLEMENT|Energy Active Product 2|Participants will use their Energy Active Product 2 as directed for a period of 6 weeks.
223914809|NCT06596044|BEHAVIORAL|VA BIC|VA BIC is a suicide prevention strategy that is designed to meet the needs of Veterans who receive acute psychiatric treatment. VA BIC can be delivered by a trained mental health provider (e.g., mental health nurse, social worker, psychologist, psychiatrist). VA BIC includes two synergistic elements to support the patient after a mental health discharge. The elements include a brief educational session, where the patient receives a one-on-one, one-hour, personalized educational session on suicide prevention. The session incorporates aspects of motivational interviewing. The patient then receives 7 regular follow-up contacts that are conducted by the interventionist. Here the interventionist monitors symptoms, assesses treatment adherence, reviews the safety plan, and assists the patient with engaging in steps to promote their well-being. The sessions incorporate aspects of motivational interviewing. Of note patients in this arm will also receive standard care.
223914810|NCT06596044|OTHER|Standard Care|Regardless of study assignment, all patients will have access to standard care provided upon mental health discharge in non-VA settings. VA staff will also follow standard procedures for mitigating risk including placing Veterans on high risk list when clinically appropriate.
223914811|NCT04206787|DRUG|Afatinib|drug
223914812|NCT06670196|DRUG|SKB264|4mg/kg, intravenous (IV) infusion
223914813|NCT06670196|DRUG|Osimertinib|80mg, QD
223914814|NCT05224869|DEVICE|Medical Device Usage and Evaluation|Undergo hydrogel rectal spacer placement
223914815|NCT05224869|PROCEDURE|CT simulation|CT simulation of radiation treatment planning 2-7 days after hydrogel placement
223914816|NCT05224869|PROCEDURE|Stereotactic body radiation therapy|SBRT in 5 fractions over 1 week, 7 days after CT simulation
223716382|NCT05163236|DIAGNOSTIC_TEST|Negative fecal immunochemical test (FIT)|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
223914817|NCT05224869|RADIATION|Brachytherapy|one month after completing SBRT
223914818|NCT05224869|PROCEDURE|Post-implant dosimetry scan|one month after brachytherapy
223914819|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography; laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed immediately after ERCP with ES under general anesthesia.
223914820|NCT06676241|PROCEDURE|endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy|Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis no earlier than 7 days after ERCP
223914821|NCT06677502|DRUG|Cerebrolysin|Patients were randomized into two groups: CBL - patients treated with cerebrolysin at the daily dose of 50 mL, and K - control patients treated without cerebrolysin. Cerebrolysin was administrated intravenously on the day the delirium was detected and then for seven consecutive days.
223914822|NCT06677502|OTHER|Saline Solution - IV|Patients enrolled in group K received the infusion of 0.9% Saline solution at a volume of 250 mL.
223914823|NCT06675942|DEVICE|Oscillation and Lung Expansion|The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.
224088614|NCT05624463|BEHAVIORAL|Conventional intubation protocol|1\. Intubate the patient with the EMG endotracheal tube and note depth; 2. Position patient and verify the position via Glottic Exam or Respiratory Variation; 3. Fix tube position.
223914824|NCT06675942|DEVICE|High-frequency chest wall oscillation|High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.
223914825|NCT05097885|OTHER|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
223914826|NCT05117008|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
223914827|NCT05832086|BEHAVIORAL|Fasting Mimicking Diet (FMD)|Consume the FMD (Xentigen, L-Nutra, Los Angeles, CA) for 5 days every monthly cycle for 6 cycles total in 6 months.
223914828|NCT05832086|BEHAVIORAL|Standard Anti-Cancer Diet|Will receive standard of care diet and exercise recommendations from the study dietitian. The diet advice will be consistent with the American Cancer Society for cancer survivors and exercise recommendation of a goal of 150 minutes/week of cardiovascular exercise and weight resistance training at least twice a week.
223914829|NCT04195984|DEVICE|Mi-thos® valve and transapical delivery system|Transcatheter mitral valve replacement system
223914830|NCT04497428|BEHAVIORAL|Adaptation|Sensorimotor adaptation in speech
223914831|NCT04497428|OTHER|cTBS|continuous theta-burst stimulation
223914832|NCT06398470|DIAGNOSTIC_TEST|NeuroSAFE procedure|Frozen section analysis of the posterolateral surface of the prostate to guide nerve sparing decisions.
223914833|NCT06398470|DIAGNOSTIC_TEST|LaserSAFE procedure|The LaserSAFE procedure is performed using an FCM called the Histolog® scanner developed by Samantree® which can be placed within the operating room. The Histolog® scanner produces digital images with high, micrometre-range resolution and enables the visualization of tissue microstructures down to the cellular level.
223914834|NCT04751903|BEHAVIORAL|oral motor stimulation|Oral motor stimulation (OMS) is defined as the sensorial stimulation of cheek, lip, jaw, upper-lower gum, internal cheek, tongue and soft palate that affects the physiology of oropharyngeal mechanisms and develops feeding functions.It took 15 minutes to apply the OMS by lightly touching their cheeks, lips, gums, and tongue with fingertips for the first 12 minutes, followed by letting the infant suck on a pacifier for the remaining 3 minutes. OMS used as an alternative or supplementary early intervention strategy to develop oral feeding skills in preterm infants.
223914835|NCT04575883|DEVICE|MedBIKE HIIT|Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
223914836|NCT06853392|COMBINATION_PRODUCT|Demineralized freeze dried allograft with collagen sponge|Demineralized freeze dried allograft,filling 2/3 of the socket covered with collagen sponge ,six months, one time
223914837|NCT06853392|COMBINATION_PRODUCT|autogenous dentin graft with collagen sponge|autogenous mineralized dentin graft, filling 2/3 of the socket covered with collagen sponge , six months, one time
223914838|NCT05646680|PROCEDURE|two step adnexectomy|instead of standard resection of salpinx and ovary, they are now separately excised
223914839|NCT05045820|DEVICE|needling acupuncture|"Acupuncture treatment will both main and supplementary acupoints. Main points include GB30; ST36; LI11- LI4, GB34-SP6; LR3, SP10, DU24, DU20, Yin Tang, Ear Shen Men which are chosen based on the unique clinical features of sickle pain. The remaining individualized acupoints will be selected and manipulated with manual acupuncture with appropriate needling techniques based on the individual Syndrome (reinforce or reduce or Non reinforce or reduce) that is determined by TCM diagnosis."
223914840|NCT05045820|DEVICE|laser acupuncture|Laser acupuncture device VitaLaser 650 (Lhasa OMS, Weymouth, MA or similar) will be positioned 1-2cm over all of the same acupoints used in verum acupuncture treatment above. No palpation is administered prior to positioning the device and there is no physical contact between device and skin.
223914842|NCT02266615|GENETIC|Biobanking of biomaterial for future genetic research.|
223914843|NCT06392945|DEVICE|Cognitive Treadmill Walking Training with Rhythmic Auditory Cueing (CTW+RAC) group|Participants in the CTW+RAC group participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. To increase adaptability to rhythmic auditory cueing prior to cognitive treadmill walking training, participants are required to keep stepping on their feet while listening to the auditory cueing using a metronome program (Metronome APP) for 5 minutes of warm up. Then they start walking on a treadmill with a target speed and perform a cognitive task concurrently while listening rhythmic auditory cueing. According to previous research, the target treadmill speed at week 1, week 2, week 3, and week 4 is gradually increased from 90%, 100%, 110%, to 120% baseline walking speed of comfortable walking on the ground. The beat of rhythmic auditory cueing using the Metronome APP on the smartphone is set at 110% of baseline cadence of comfortable walking on the ground based on a previous study in individuals with stroke.
223914844|NCT06392945|DEVICE|Cognitive Treadmill Walking Training (CTW) group|Participants in the CTW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed and perform a cognitive task concurrently without rhythmic auditory cueing. Same cognitive training and target treadmill speed will be used as the CTW+RAC group during cognitive dual-task treadmill walking. Three cognitive training programs will be the verbal fluency, arithmetic, and visual distinguish tasks. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the 10 meters walk test at week 4.
223530014|NCT05363527|BIOLOGICAL|Endotoxin|Endotoxin
223530015|NCT05363527|BIOLOGICAL|Placebo|Placebo
223530016|NCT03636022|OTHER|VR System|Use of virtual reality to deliver exposure therapy
223914845|NCT06392945|DEVICE|Treadmill Walking Training (TW)|Participants in the TW group will participate in 12-session programs administered for 30 minutes each session, 3 times per week for 4 weeks. They will start stepping on the ground at comfortable pace for 5 minutes of warm up. Then they will start walking on a treadmill with a target speed only, without concurrent performing a cognitive task and no listening rhythmic auditory cueing. Same target treadmill speed will be used as the other two groups during treadmill walking. The target treadmill speed will be gradually increased from 90% at week 1, to 100% at week 2, to 110% at week 3, to 120% baseline walking speed of comfortable walking on the ground.
223530017|NCT03636022|OTHER|Control|Use of conventional delivery of exposure therapy
223914846|NCT05138848|BEHAVIORAL|Time in Bed Restriction|Participants will undergo a 4-week sleep intervention that includes specified in- and out-of-bed times as well as a restriction to their habitual time in bed (average sleep opportunity including naps). This will be truncated equally at the beginning and end of the night.
223914847|NCT05138848|BEHAVIORAL|Sleep Schedule|Participants will maintain their typical sleep schedule for 4-weeks.
223914848|NCT06331364|OTHER|electronic clinical decision support tool (eCDST) diagnostic plan|Participants will be followed for 30 days from enrollment to record clinical outcomes and any antimicrobials used. Analyses will compare clinical outcomes and antimicrobial use between the intervention arm and usual care.
223914849|NCT03946358|BIOLOGICAL|Blood sample collection|"Four blood samples will be collected at:~* baseline~* 2 months from inclusion (+/- 1 week)~* 4 months from inclusion (+/- 1 week)~* the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
223914850|NCT03946358|PROCEDURE|Tumor biopsies|A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan
223914851|NCT03946358|OTHER|CT scan|"A CT scan will be planned~* at baseline~* at tumor evaluation visit (8 weeks)~* every 8 weeks (+/- 1 week)~* at end of treatment visit."
223914852|NCT03946358|DRUG|Atezolizumab|"Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
223914853|NCT03946358|DRUG|UCPVax|"Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)."
223914854|NCT01944332|PROCEDURE|gamete treatment|Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
223914855|NCT06622252|OTHER|13-week session program|The newly designed intervention was split into three major components - Healthy Literacy, Caregiver Wellness, and Culturally Competent Care and is delivered throughout a 13-session program delivered via Zoom. Sessions are guided by a psychologist, nutritionist, spirituality specialist, social worker, case coordinator, oncologist and traditional Chinese medicine practitioner. Sessions are intended for caregivers specifically, however, other members of the family may join if they choose to.
223914856|NCT06869460|RADIATION|Stereotactic Body Radiotherapy/Radiosurgery|Stereotactic Body Radiotherapy/Radiosurgery
223940219|NCT05678725|DEVICE|tACS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as the stimulation electrode, while the return electrode placed on the right shoulder . The dose was at 2mA, 20Hz for 20 minutes.
223940220|NCT05678725|DEVICE|tDCS|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The dose was at 2mA for 20 minutes.
223940221|NCT05678725|DEVICE|sham|used round electrodes（area:3.14cm2） and the montage of a bifrontal setup with C3 as stimulation and C4 as return electrodes. The stimulation lasted for 20 minutes and included a 10-second ramp-up and 10-second ramp-down.
223940222|NCT04468737|BEHAVIORAL|Bowel preparation|Observe patients who undergo bowel preparation by enema or irrigation
223940223|NCT04163562|DRUG|INP20|Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
223530018|NCT04950153|BEHAVIORAL|Peer navigation|Peer navigators will navigate youth with HIV to provide assistance and support to optimize adherence to antiretroviral treatment (ART)
223530019|NCT04950153|BEHAVIORAL|SMS Text messaging|Short Message System (SMS) text messages to remind and encourage youth to adhere to their ART
223940224|NCT04163562|DRUG|Placebo|Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
223940225|NCT04514952|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
223940226|NCT04278989|DRUG|Anti-tumor B|1,200 mg, three times a day for seven to 28 days (dependent on scheduled surgery).
223940227|NCT04725916|OTHER|Showering|Patients will be instructed to shower after surgery with drains in place
223530020|NCT04950153|BEHAVIORAL|Social Media Engagement|HIV testing outreach using social media platforms to promote HIV testing.
223530021|NCT04950153|BEHAVIORAL|Testing Peer Navigation|Peer navigators will conduct HIV testing outreach and linkage to care to at-risk youth
223530022|NCT06367855|DRUG|Dexamethasone|long-acting corticosteroid IV route
223914857|NCT06871150|DEVICE|Flotrac sensor|"Traditional management of hemodynamic parameters and intraoperative fluids without the aid of predictive tools based on artificial intelligence.~Possibility of having advanced hemodynamic analysis tools such as SV (stroke volume), SVV (stroke volume variation), PPV (pulse pressure variation), CO (cardiac output).~The anesthetist will decide whether to administer fluids, vasopressors, or other pharmacological interventions to maintain hemodynamic stability basing on clinical hemodynamic parameters derived from pulse contour systems, in accordance with a specific flowchart.~Interventions will be applied when blood pressure decreases, or clinical signs of instability are observed"
223914858|NCT06871150|DEVICE|HPI|"The Hypotension Prediction Index (HPI) is an advanced arterial waveform analysis algorithm that uses machine learning to predict hypotensive episodes (defined as mean arterial pressure \[MAP\] \< 65 mmHg) five minutes in advance, achieving high sensitivity and specificity. This technology is based on patient demographic data (e.g., age, height, weight) and hemodynamic parameters derived from arterial waveform analysis.~* HPI uses demographic information and hemodynamic signals obtained via a radial arterial catheter.~* The signals are analyzed using Edwards Lifesciences' Acumen IQ software, which has been further developed to include prediction of hypotensive episodes.~The algorithm provides a numerical value (0-100) reflecting the risk of imminent hypotension. An HPI value above 85 signals a high likelihood of hypotension.~The system also provides advanced hemodynamic data, including cardiac output, dynamic arterial elastance, dP/dtmax (systolic slope), and stroke volume."
223940228|NCT04725916|OTHER|Restriction of Showering|Patients will be restricted from showering post operatively if they have drains in place
223940229|NCT06950450|BEHAVIORAL|EMOTİONAL FREE TECHNIQUE|"Intervention Group Procedure Steps:~Pre-Procedure:~Nursing students in the intervention group will be informed about Emotional Freedom Techniques (EFT), and after explaining the purpose and method of the study, their consent will be obtained using the Volunteer Consent Form.~They will be asked to complete the Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI) (state-trait version) forms.~Afterwards, information about EFT will be provided, including how to perform the technique and how to carry out the tapping procedure. After a discussion that is expected to last about 20 minutes, the EFT session will begin. Before the procedure, nursing students will complete the Descriptive Information Form, the State-Trait Anxiety Inventory (STAI-I), and the VAS score forms.~1\. EFT Procedure Sequence: Nursing students who meet the inclusion criteria, including first-year nursing students with no previous clinical experience, will have an initial meeting before their first clinic"
223940230|NCT05357820|DRUG|AB-106, Itraconazole|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17
223530023|NCT06367855|DRUG|Normal saline|normal saline
223940231|NCT05357820|DRUG|AB-106, Rifampicin|single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
223530024|NCT05360888|BEHAVIORAL|Tools for Life|Tools for Life focuses on empowering youth to learn more about their culture and their identity.
223530025|NCT05360888|BEHAVIORAL|Tools for Life + MISN|Tools for Life focuses on empowering youth to learn more about their culture and their identity. MISN focuses on helping youth get support from their community and social networks.
223940232|NCT05106361|BEHAVIORAL|MOSAIC Plus|"Those in the experimental arm will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
223940233|NCT05106361|BEHAVIORAL|MOSAIC|Those in the active comparator will receive a mentor mother intervention named Mother AdvocateS In the Community (MOSAIC). This does not include the IPT component.
223940234|NCT06013995|DRUG|BMS-986326|Specified dose on specified days
223940235|NCT06013995|OTHER|Placebo for BMS-986326|Specified dose on specified days
223940236|NCT05418868|DRUG|Cabotegravir 200 mg/mL|CAB 200 mg/mL will be administered.
223940237|NCT05418868|DRUG|Cabotegravir >=400 mg/mL|CAB \>=400 mg/mL will be administered by IM or SC injection.
223940238|NCT05418868|DRUG|Cabotegravir Formulation I|CAB Formulation I will be administered by IM injection.
223940239|NCT05418868|DRUG|CAB Formulation J|CAB Formulation J will be administered by IM injection.
223940240|NCT05418868|DRUG|rHuPH20|rHuPH20 will be administered.
223940241|NCT05418868|DRUG|RPV|RPV will be administered by IM injection.
223940242|NCT03168750|DEVICE|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
223940243|NCT05462912|DEVICE|custom foot orthotic|The goal of this study is to find out whether the use of software generated custom-made orthopedic foot orthoses improves pain in the long term.
223914859|NCT06871150|DEVICE|HPI-AFM|"HPI: Provides a predictive index (from 0 to 100) based on real-time hemodynamic data, indicating the probability of the patient developing a hypotensive episode (MAP \< 65 mmHg) within the next 10-15 minutes.~AFM: In addition to hypotension prediction, continuously monitors parameters such as stroke volume and cardiac output, providing indications for optimal fluid administration. It is programmed to suggest the quantity and the speed of fluid administration based on real-time data and patient conditions.~In conjunction with the HPI system, the AFM suggests administering a specific fluid volume to correct the patient's hemodynamic status.~The AFM uses a predictive algorithm to calculate the patient's response to fluid administration, enabling anesthetists to dynamically adjust therapy.~The AFM system is based on assisted clinical decisions, where anesthetist receive algorithm-based AI recommendations to proactively administer fluids, avoiding the traditional reactive approach."
223914860|NCT06866743|OTHER|There will be no intervention.|This research focuses on examining seasonal variations in kidney function among postmenopausal females. As an observational study, our approach is non-interventional.
223914861|NCT06097637|OTHER|underwater endoscopic mucosal resection|underwater endoscopic mucosal resection achieves similar rates of complete resection with comparable safety, with lower rates of recurrence and fewer repeat procedures.
223914862|NCT06097637|OTHER|hot snare polypectomy|Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
223914863|NCT05310097|BEHAVIORAL|CPT|CPT will be delivered over the course of 12 one-hour weekly sessions (maximum of 18 weeks to complete treatment). Participants will have the option of receiving CPT in-person or via videoconferencing.
223914864|NCT05310097|BEHAVIORAL|MS|The MS protocol consists of eight strategies: categorization, evaluation, application, cue-based reminders, practice remembering, attention recruitment, praising recall, and repetitions.
223914865|NCT06479629|DRUG|Piracetam|800mg oral tablet of Piracetam three times every day for 3 months
223914866|NCT06479629|DRUG|Placebo|starch tablet
223914867|NCT04192591|DEVICE|Superion™ IDS device|The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
223914868|NCT00862017|DIETARY_SUPPLEMENT|MSg supplementation|
223914869|NCT00862017|DIETARY_SUPPLEMENT|NaCl supplementation|
223914870|NCT07034261|DEVICE|Blinded Continuous Glucose Monitoring Device|Subjects will be asked to wear blinded continuous glucose monitoring device for 14 days.
223914871|NCT06710119|OTHER|Visual Feedback|Visual feedback of foot loading during gait.
224088615|NCT05624463|BEHAVIORAL|Early resumption of oral intake|Patients will drink 30-50ml of normal temperature water after Steward scores ≥ 4 at PACU. If patients swallow successfully and have no significant discomfort symptoms, physicians will guide patients to resume drinking and eating gradually.
224088616|NCT05624463|BEHAVIORAL|Delayed resumption of oral intake|Patients will resume drinking water 6h after the operation at ward. Before patients resume oral drinking, they will be provided 10ml/kg 5% glucose saline intravenously.
224088617|NCT03033771|DEVICE|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
223530026|NCT05301127|DEVICE|spinal-epidural device|received combined spinal-epidural-general anesthesia.
223530027|NCT06420063|BIOLOGICAL|CD123/CD33 CART|"The intervention in this clinical trial involves a novel approach using CD22/123-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD33/123-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD33/123-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD33/123 CAR-T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
223914872|NCT07136493|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples for ctDNA testing
223530029|NCT04918407|DRUG|Empagliflozin 25 MG|25 mg
224088618|NCT00851071|BEHAVIORAL|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
224088619|NCT05664984|BEHAVIORAL|1-face-to-face|The cognitive rehabilitation intervention consists of 45-minute sessions, 2 days a week for 12 weeks. The same rehabilitation intervention program was applied to both groups by face-to-face or tele-rehabilitation method. The main purpose of the study is to see the effectiveness of cognitive rehabilitation intervention in the elderly with amnestic mild cognitive impairment and to compare the two methods.
224088620|NCT05664984|BEHAVIORAL|2-tele rehabilitation|2-tele rehabilitation
223530030|NCT04918407|DRUG|Insulin|Insulin
223530031|NCT03189719|BIOLOGICAL|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
223530032|NCT03189719|DRUG|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
223530033|NCT03189719|DRUG|Cisplatin|80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
223530034|NCT03189719|DRUG|5-FU|800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
223914873|NCT07136493|PROCEDURE|Biospecimen Collection|Undergo possible collection of tissue
223914874|NCT07136493|OTHER|Electronic Health Record Review|Ancillary studies
223914875|NCT07136493|OTHER|Survey Administration|Ancillary studies
223914876|NCT06880991|OTHER|Arm 1|Participant completion of questionnaires and participation in focus group(s) and/or interview sessions.
223914877|NCT06704100|DRUG|Fosamprenavir Calcium & Sodium Alginate|1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID
223914878|NCT06704100|OTHER|Placebo|15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate
223914879|NCT06688058|BIOLOGICAL|V540D|Experimental vaccine and adjuvant administered via intramuscular (IM) injection
223914880|NCT06688058|BIOLOGICAL|GARDASIL®9|Suspension administered via IM injection
223914881|NCT07041541|PROCEDURE|Esthetic Crown Lengthening|Conventional Esthetic Crown Lengthening
223914882|NCT07041541|PROCEDURE|Esthetic Crown Lengthening using GingivalStat approach|Esthetic Crown Lengthening using GingivalStat approach (composite stops)
223914883|NCT06883240|DRUG|Von Willebrand Factor Concentrates|Used according to local labeling or local treatment guidelines.
223914884|NCT06883240|DRUG|Von Willebrand Factor Concentrates and Factor VIII Concentrates|Used according to local labeling or local treatment guidelines.
223914885|NCT06883240|DRUG|Factor VIII Concentrates|Used according to local labeling or local treatment guidelines.
223914886|NCT06883240|DRUG|Recombinant Activated Factor VII|Used according to local labeling or local treatment guidelines.
223914887|NCT06883240|DRUG|Activated Prothrombin Complex Concentrate|Used according to local labeling or local treatment guidelines.
223914888|NCT07037758|DRUG|Tarlatamab|Administered as an IV infusion.
223914889|NCT07037758|DRUG|AB248|Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.
223914890|NCT05562830|BIOLOGICAL|Zilovertamab vedotin|Administered via intravenous (IV) infusion on day 1 and day 8 of Q3W cycles
223914891|NCT05562830|BIOLOGICAL|Pembrolizumab|Administered via IV infusion on Day 1 of each 6 week cycle.
223914892|NCT05562830|BIOLOGICAL|MK-3120|Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.
224278000|NCT01821157|PROCEDURE|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
223530035|NCT05853718|DRUG|Tenofovir Alafenamide Tablets|Take 25mg TAF daily from week 28-32 of gestation until delivery
223530036|NCT02684162|BIOLOGICAL|Donor Lymphocytes|Given IV
223530037|NCT02684162|DRUG|Guadecitabine|Given SC
223530038|NCT02684162|OTHER|Laboratory Biomarker Analysis|Correlative studies
223914893|NCT07032545|OTHER|Broccoli microgreen (BMG)|All participants will consume one serving size (one cup, \~57 gram) of raw BMG daily for 2-week period of time.
223914894|NCT07038798|DEVICE|Brainsway H1-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H1-coil.
223914895|NCT07038798|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H4-coil.
223914896|NCT07038798|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 6-week course of 20 dTMS stimulation session using the Brainsway H7-coil.
223914897|NCT06888154|OTHER|compress application with heated saline|Covering intestines with sterile gauze soaked in 36°C heated saline during surgery to prevent drying and reduce infection risk
223914898|NCT07050264|OTHER|Simulated burn injury via application of absorbent and impermeable material over 60% of the body|Simulated burn injury via application of absorbent and impermeable material over 60% of the body
223914899|NCT07050017|BEHAVIORAL|The study will investigate how different amounts of protein (0 g, 15 g, and 30 g) in post-exercise beverages affect appetite and energy intake following endurance exercise.|The study will investigate how different amounts of protein (carbohydrate control drink : 0 g, reguler milk : 15 g, and high-protein milk : 30 g) in post-exercise beverages affect appetite and energy intake following endurance exercise.
223914900|NCT06664775|BIOLOGICAL|TachoSil|Adjunct to hemostasis
223914901|NCT06664775|BIOLOGICAL|Surgicel Original|Adjunct to hemostasis
223530039|NCT03340116|PROCEDURE|Burn surgery|Burn surgery including wound debridement, skin grafting
223530040|NCT03340116|DIAGNOSTIC_TEST|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
223914902|NCT07047404|DRUG|BP1.4979|selective dopamine D3 partial agonist
223914903|NCT07047404|DRUG|Placebo|matching placebo of BP1.4979 30mg tablet
223914904|NCT07046845|DIETARY_SUPPLEMENT|Perelel Prenatal Vitamin|Daily Perelel prenatal vitamin supplement throughout pregnancy
223914905|NCT07046845|DIETARY_SUPPLEMENT|Generic Prenatal Vitamin|Daily generic prenatal vitamin supplement throughout pregnancy.
223914906|NCT06788912|BIOLOGICAL|Pembrolizumab (neoadjuvant)|Before surgery neoadjuvant Pembrolizumab 200 mg by intravenous (IV) infusion on day 1 of each 21-day cycle for 4 cycles
223914907|NCT06788912|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
223914908|NCT06788912|DRUG|Gemcitabine|In squamous tumors Gemcitabine 1000 mg/m\^2 by IV infusion on day 1 and day 8 of each 21-day cycle for 4 cycles.
223914909|NCT06788912|DRUG|Pemetrexed|In nonsquamous tumors Pemetrexed 500 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles
223530041|NCT05310435|DEVICE|Single volume measurement with ESD|Single volume measurement with Edema Stocking device
223914910|NCT06788912|DRUG|Sacituzumab tirumotecan|Sacituzumab tirumotecan 4 mg/kg by IV infusion on day 1 of each 14-day cycle for up to 6 cycles
223914911|NCT06788912|DRUG|H1 receptor antagonist|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
223914912|NCT06788912|DRUG|H2 receptor antagonist|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
223914913|NCT06788912|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication before Sacituzumab tirumotecan infusion per approved product label
223914914|NCT06788912|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication 8 -10 mg before Sacituzumab tirumotecan infusion per approved product label
223914915|NCT06788912|DRUG|Carboplatin|AUC 5 mg/mL min or AUC 6 mg/mL min by IV infusion on day 1 of each 21-day cycle for 4 cycles
223914916|NCT06788912|BIOLOGICAL|Pembrolizumab (adjuvant)|After surgery adjuvant Pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for 13 cycles
223914917|NCT06788912|DRUG|Paclitaxel|Paclitaxel 175 or 200 mg/m\^2 by IV infusion on day 1 of each 21-day cycle for 4 cycles.
223530042|NCT05310435|DEVICE|Single volume measurement with WDV|Single volume measurement with water displacement volumetry method
223914918|NCT06788912|DRUG|Steroid mouthwash (dexamethasone or equivalent)|Administered orally as rescue medication 2-5 mL 4 times daily
223914919|NCT06752096|PROCEDURE|cerebral angiography, arterial embolization, thrombectomy|This intervention will be conducted using robotic navigation.
223914920|NCT06752096|DEVICE|Cerebral angiogram using robotic device|Diagnostic cerebral angiogram will be performed using a robot to navigate guidewires and catheters to target vessels.
224278001|NCT01821157|PROCEDURE|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
224278002|NCT05040139|PROCEDURE|Malone Procedure|Surgical procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, the procedure is performed under general anesthesia. The surgeon bring the end of the appendix (or a tubulized segment of the ileum) out through the abdominal wall. The appendix is opened and sutured to the abdominal skin.
224278003|NCT05040139|PROCEDURE|Percutaneous endoscopic caecostomy|Endoscopic procedure performed to obtain a percutaneous caecal access for the administration of antegrade colonic enemas. Briefly, a coloscopy is performed to reach the caecum. The cutaneous location of the caecostomy is determined by transillumination of the caecum. A caecopexy is performed with 3 anchors at the chosen location. A specific pig-tail catheter (Chait catheter) is placed percutaneously into the caecum in the center of the 3 anchors.
224278004|NCT05290233|BEHAVIORAL|TRE + Exercise|"We will compare the effects of TRE combined with resistance exercise versus TRE combined with aerobic training.~Other Names:~resistance training endurance exercise"
224278005|NCT03544840|OTHER|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
224278006|NCT00386646|DRUG|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
224278007|NCT05995873|DEVICE|unilateral transcranial photobiomodulation|An 810nM LED at 240mW/cm2 is placed at either F3 or F4 for 4 minutes.
223530043|NCT05310435|DEVICE|Single circumference measurement with tape measure|Single circumference measurement with tape measure
223530044|NCT05310435|DEVICE|Continuous volume measurement with ESD|Continuous volume measurement with Edema Stocking device
223914921|NCT06752096|DEVICE|Meningioma embolization using robotic device.|Meningioma tumors will be embolized using a robot to navigate catheters and wires to the target vessels to the tumor.
223914922|NCT06752096|DEVICE|Mechanical thrombectomy for stroke using a robotic device.|Mechanical thrombectomy procedure will use a robot to navigate catheters, guidewires, and thrombectomy devices to the target vessel.
223914923|NCT06898606|DRUG|Psilocybin and Psilocyn|Oral dose administered via Psilocybe mushrooms material batch-assayed by LC-MS to standardize psilocybin and psilocyn content.
223914924|NCT06898606|DRUG|Placebo|Matching capsules, once daily for 4 weeks (-14 to +14 days).
223914925|NCT06898606|BEHAVIORAL|Psychotherapy-assisted session|Same manualized procedures as Arm 1.
223914926|NCT06898606|DRUG|Fluoxetine|20 mg/day for 4 weeks (-14 to +14 days relative to dosing day).
223914927|NCT06899061|DRUG|Saruparib|"Module 1:~Period 2: participants will receive saruparib orally once daily from Day 1 to Day 9. On Day 5 saruparib will be administered orally in combination with the cocktail of substrates.~Period 3: participants will receive saruparib orally once daily for up to 3 cycles of 28 days each.~Module 2:~Period 1 and Period 2: participants will receive a single oral dose of DC or RC saruparib.~Period 3: participants will receive an oral dose of rabeprazole twice daily from Day 1 to 3, and a single oral dose of rabeprazole prior to DC saruparib on Day 4.~Period 4: participants will receive an oral dose of RC saruparib daily for 3 cycles."
223914928|NCT06899061|DRUG|Digoxin|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
223914929|NCT06899061|DRUG|Furosemide|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
223914930|NCT06899061|DRUG|Metformin Hydrochloride|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
223914931|NCT06899061|DRUG|Rosuvastatin|"Period 1: participants will receive a single oral dose of a cocktail of substrates (digoxin, furosemide, metformin hydrochloride, and rosuvastatin) on Day 1.~Period 2: participants will receive a single oral dose of the cocktail of substrates in combination with saruparib on Day 5."
223914932|NCT06899061|DRUG|Rabeprazole|Period 3: Participants will receive two doses of rabeprazole per day from Day 1 to 3. On Day 4, participants will receive a dose of rabeprazole followed by DC saruparib.
223530045|NCT05023018|DRUG|NEO100|NEO100 is a purified form of perillyl alcohol.
223530046|NCT03762018|DRUG|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
223530047|NCT03762018|DRUG|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
223914933|NCT06721156|DRUG|MK-1167|MK-1167 oral capsule
223914934|NCT06721156|DRUG|Placebo|Placebo oral capsule
223914935|NCT06795048|DRUG|Faricimab|Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.
223914936|NCT04958239|DRUG|BI 765179|BI 765179
223914937|NCT04958239|DRUG|Ezabenlimab|Ezabenlimab
223914938|NCT04958239|DRUG|Pembrolizumab|Pembrolizumab
223914939|NCT06423430|DEVICE|Sham-stimulation|Sham-stimulation
223914940|NCT06423430|DEVICE|Active-stimulation|Active DBS
223914941|NCT06810310|DRUG|Psilocybin (high dose)|PEX010 is the psilocybin produced by Filament
223914942|NCT06810310|DRUG|psilocybin (low dose)|1mg psilocybin, produced by Filament
223914943|NCT06753123|BEHAVIORAL|A workplace-based depression intervention for low-wage hospital workers|This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.
223914944|NCT06897930|BIOLOGICAL|AZD0120|Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
223914945|NCT06897930|DRUG|Cyclophosphamide|Lymphodepletion - specified dose prior to receiving AZD0120
223914946|NCT06897930|DRUG|Fludarabine|Lymphodepletion - specified dose prior to receiving AZD0120
223914947|NCT06779617|DEVICE|SEPSys|The SEPSys Score is a clinical decision support tool for predicting the risk of developing sepsis in the next 4 hours. The SEPSys Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
223914948|NCT06779617|DEVICE|RESCUE|The RESCUE Score is a clinical decision support tool for predicting the risk of patient experiencing clinical deterioration (cardiac arrest, rapid response team call, death, or unplanned increase in care) in the next 4 hours. The RESCUE Score produces a 1-4, color-coded risk, where 4 (red) is the highest risk and 1 (green) is the lowest risk.
223914949|NCT06693908|DRUG|Vixarelimab|Vixarelimab will be administered as per the schedule specified.
223914950|NCT07071285|BEHAVIORAL|E-Book|Breastfeeding eBook learning mode.
223914951|NCT07071285|BEHAVIORAL|face-to-face teaching|face-to-face teaching of breastfeeding
223914952|NCT03891251|OTHER|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
223914953|NCT06780085|BIOLOGICAL|Raludotatug Deruxtecan|IV Infusion
223914954|NCT06780085|BIOLOGICAL|Ifinatamab Deruxtecan|IV Infusion
223914955|NCT06780085|DRUG|Docetetaxel|IV Infusion
224278008|NCT04680780|OTHER|Ketogenic diet|Patients will follow a classical ketogenic diet for 3 months
224278009|NCT04680780|OTHER|3-days water-fasting|Patients will perform water fasting on 3 consecutive days within the first 14 days of each of the 3 months. In one of the 3 months they are - if required - allowed to split the 3 days into periods of 1 and 2 days. On all other days of the intervention period they are allowed to eat ad libitum.
223914956|NCT06919081|DRUG|Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome|Eye Drops
223914957|NCT06919081|OTHER|Vehicle Control|Eye Drops
223914958|NCT06853678|DRUG|Adebrelimab|1200mg,d1,iv,q3w
223914959|NCT06853678|DRUG|Selinexor|40mg,twice weekly,d1, d3,oral,q3w
223914960|NCT06853678|DRUG|Nab-paclitaxel|100mg/m2,d1,d8,d15,iv,q3w
223914961|NCT06608797|BEHAVIORAL|Learning and memory training|The experimental group will receive memory retraining exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 training sessions).
223914962|NCT06608797|BEHAVIORAL|Sham Comparator|The sham comparator group will receive sham memory exercises administered on a laptop computer via Zoom Health twice a week for five weeks (10 placebo control sessions).
223914963|NCT04960709|DRUG|Durvalumab|Anti- PD-L1 Antibody
223914964|NCT04960709|DRUG|Tremelimumab|Human IgG2 mAb
223914965|NCT04960709|DRUG|Enfortumab Vedotin|Nectin-4-directed antibody and microtubule inhibitor conjugate
223914966|NCT04960709|PROCEDURE|Radical Cystectomy|For cisplatin-ineligible or cisplatin-refusal patients
223914967|NCT06537999|DRUG|DNTH103|"* Day 1: IV loading dose~* Week 1 to Week 15: DNTH103 administered SC every 2 weeks"
223914968|NCT06537999|DRUG|Placebo|"* Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks"
223914969|NCT06780111|BIOLOGICAL|Pembrolizumab|IV infusion
223914970|NCT06780111|BIOLOGICAL|I-DXd|IV infusion
223914971|NCT06780111|DRUG|Leucovorin|IV infusion
223914972|NCT06780111|DRUG|Levoleucovorin|IV infusion
223914973|NCT06780111|DRUG|5-Fluorouracil (5-FU)|IV Infusion
223914974|NCT06780111|DRUG|Oxaliplatin|IV infusion
223914975|NCT02039401|BIOLOGICAL|VM202|
223914976|NCT06529614|OTHER|In-situ detection for Micro-RNA|a new in-situ detection methods for Micro-RNA
223914977|NCT07076212|DRUG|Liposomal Irinotecan|50 mg/m2 will be administered on Day 1 of a 2-week cycle
223914978|NCT07076212|DRUG|Oxaliplatin|60 mg/m2 will be administered on Day 1 of a 2-week cycle
223914979|NCT07076212|DRUG|5-Fluorouracil|5-fluorouracil (2400 mg/m2 over 46 hours) will begin administration on Day 1 of a 2-week cycle
223914980|NCT07076212|DRUG|Leucovorin|400 mg/m2 will be administered on Day 1 of a 2-week cycle
223914981|NCT07076212|DRUG|Gemcitabine (mg/m²)|1000 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
223914982|NCT07076212|DRUG|Nab-paclitaxel|125 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
223914983|NCT07076212|DRUG|Cisplatin|25 mg/m2 will be administered on Day 1 and Day 15 of a 4-week cycle
223914984|NCT06842433|OTHER|General healthy diet|General healthy diet based on national health dietary guidelines.
224278010|NCT04680780|OTHER|Control|Patients are allowed to eat ad libitum, but will be advised that low salt intake (\< 5-7 g/day) and sufficient fluid intake (\>3 l/day) which is considered beneficial in ADPKD.
224278011|NCT00002592|BIOLOGICAL|c-myb antisense oligonucleotide G4460|
224278012|NCT00002592|BIOLOGICAL|filgrastim|
224088621|NCT04207047|DEVICE|Genius|"The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic."
224088622|NCT04207047|DEVICE|eC02|The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
223914985|NCT06842433|OTHER|Personalized diet|Personalized diet will be based on an algorithm considering the individuals' postprandial glucose, triglycerides and inflammation markers to each of the three study meals in the characterization phase (Phase I) matched with established knowledge about the effects of specific foods on such metabolic parameters.
223914986|NCT07083596|OTHER|Experimental: Probiotic with LcS|Probiotic drink with LcS will be consumed once per day for four weeks
223914987|NCT07083596|OTHER|Control|Brochure containing recommendations to improve constipation will be provided at end of study.
223914988|NCT07079865|DEVICE|SPRINT PNS modulation system|Participants will receive treatment using the commercially available SPRINT PNS system. Their pain levels will be assessed using qualified scales including NRS and BPI and their quality of life using the PROMIS scale.
223914989|NCT07086079|DRUG|DOR/ISL|Oral tablet
223914990|NCT03057054|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
223914991|NCT03057054|BIOLOGICAL|Lactobacillus plantarum strain 299|Given PO or via NJ, NG or G tube
223914992|NCT03057054|BIOLOGICAL|Lactobacillus plantarum strain 299v|Given PO or via NJ, NG or G tube
223914993|NCT03057054|OTHER|Placebo Administration|Given PO or via NJ, NG or G tube
223914994|NCT05675527|BIOLOGICAL|Low-dose PRP|Injection
223914995|NCT05675527|BIOLOGICAL|High-dose PRP|Injection
223914996|NCT05675527|OTHER|Saline|Injection
223914997|NCT05973630|BIOLOGICAL|ATA-200|single intravenous infusion
223914998|NCT06746402|DRUG|BMS-986278|Specified dose on specified days
223914999|NCT06746402|DRUG|Placebo|Specified dose on specified days
223915000|NCT06746402|DRUG|Moxifloxacin|Specified dose on specified days
223915001|NCT06662500|DEVICE|Intravascular Lithotripsy|The Shockwave Intravascular Lithotripsy (IVL) System with the Shockwave Javelin Coronary Catheter is intended to treat calcified stenosis, including calcified stenoses that are anticipated to exhibit resistance to balloon crossing, full dilatation or subsequent uniform coronary stent expansion.
224278013|NCT00002592|DRUG|busulfan|
224278014|NCT00002592|DRUG|cyclophosphamide|
224278015|NCT00002592|PROCEDURE|autologous bone marrow transplantation|
224278016|NCT00002592|PROCEDURE|in vitro-treated bone marrow transplantation|
223915002|NCT06647459|DIAGNOSTIC_TEST|EP Study|To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.
223915004|NCT06804317|OTHER|telerehabilitation|"Exercise-based interventions were conducted twice weekly for three months via videoconferencing on Microsoft Teams. The program included various components:~Aerobic and strength training, Flexibility, Balance and coordination"
223915005|NCT07085572|DRUG|Cemiplimab|350 mg IV Q3W
223915006|NCT05618782|DRUG|LEVI-04|LEVI-04, a fully human chimeric fusion protein that combines the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75 NTR), for the treatment of chronic pain.
223915007|NCT05618782|OTHER|Placebo|Saline vehicle
223915008|NCT06730100|PROCEDURE|Biopsy Procedure|Undergo biopsy
223915009|NCT06730100|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223915010|NCT06730100|PROCEDURE|Computed Tomography|Undergo CT scan
223915011|NCT06730100|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223915012|NCT06730100|DRUG|pH Low Insertion Peptide-exatecan Conjugate CBX-12|Given IV
223915013|NCT06730100|PROCEDURE|X-Ray Imaging|Undergo chest x-rays
223915014|NCT06904391|OTHER|Educational Intervention|Receive access to SWOG APP Clinical Research workshop. Receive The Advanced Practice Provider Clinical Trials Research Manual
223915015|NCT06904391|OTHER|Behavioral Intervention|Complete mentorship intervention
223915016|NCT06904391|OTHER|Survey Administration|Ancillary studies
223915017|NCT06904391|OTHER|Interview|Ancillary studies
224278017|NCT03581162|DIAGNOSTIC_TEST|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
224278018|NCT01237080|DEVICE|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
224278019|NCT01237080|DEVICE|Fastrach|The Fastrach is an intubation laryngeal mask.
224278020|NCT02141048|BEHAVIORAL|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
224278021|NCT04117893|DRUG|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
224088623|NCT04207047|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
224088624|NCT04207047|DEVICE|LaseMD|The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
223915018|NCT06148935|DRUG|Vericiguat (Verquvo, BAY1021189)|Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol
223915019|NCT06805448|DRUG|MSC|Allogeneic adipose-derived mesenchymal stromal / stem cells in 10% DMSO
223915020|NCT06805448|DRUG|Saline Water (Control)|Isotonic sterile saline water
223915021|NCT06805123|OTHER|Early feeding|Begin drinking water 2 hours after the procedure. If no complications occur 2 hours after starting water intake, progress to a liquid diet. If no abnormalities are observed after the liquid diet, transition to a soft diet for the next meal.
224088625|NCT04207047|DEVICE|LaseMD Flex|There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
224088626|NCT00171860|DRUG|imatinib mesylate|
224088627|NCT02488122|OTHER|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
224088628|NCT02488122|OTHER|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
224088629|NCT02369081|DRUG|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
224088630|NCT02369081|DRUG|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
224088631|NCT02369081|DRUG|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
224088632|NCT02369081|DRUG|Placebo|Placebo treatment for 12 weeks.
224088633|NCT03162679|BEHAVIORAL|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
224088634|NCT01474655|PROCEDURE|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
224088635|NCT00974987|RADIATION|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
224088636|NCT00974987|RADIATION|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
223915022|NCT06805123|OTHER|Late feeding|Maintain fasting on the day of the procedure. Begin a liquid diet 24 hours after the procedure. If no complications occur after starting the liquid diet, transition to a soft diet at the next meal.
224088637|NCT00974987|DRUG|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
224088638|NCT00814242|PROCEDURE|surgical resection|radical resection performed in patinets with HCC.
224088639|NCT00814242|PROCEDURE|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
224278022|NCT04117893|DRUG|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 3.5 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
224278023|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients|"Completion by patients of a 28-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
224278024|NCT06229158|OTHER|Sexual satisfaction questionnaire for patients' life partner|"Completion by the patients' life partner of a 30-item ad-hoc questionnaire evaluating their sexual satisfaction, alone or with the help of one of the researchers.~Each item is rated using a Likert-type scale from 1 to 5. The maximum score is 140, the minimum score is 28. A low score reflects a good level of sexual satisfaction.~Participants who have agreed to take part in the qualitative part of the study will be contacted within a few days of inclusion to arrange an appointment for a semi-structured individual interview."
224278025|NCT04624594|OTHER|Artificial Intelligence Feedback|AI mobile application provides feedback to participants randomized to artificial intelligence group.
223915023|NCT06790706|DRUG|DOMVANALIMAB + ZIMBERELIMAB|Patients will be treated with intravenous Domvanalimab at flat dose of 1200 mg + intravenous Zimberelimab at flat dose of 360 mg, administered every 3 weeks (Q3W, one cycle = 3 weeks).
224278026|NCT04624594|OTHER|Physical Therapist Feedback|PT provides feedback to participants randomized to physical therapist group.
224278027|NCT01714141|BEHAVIORAL|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
224278028|NCT01714141|BEHAVIORAL|Asthma education active control|
223530048|NCT03762018|DRUG|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
223530049|NCT03762018|DRUG|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
223915024|NCT06790706|DRUG|DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4|Patients will be treated with intravenous Domvanalimab at flat doses of 1600 mg + intravenous Zimberelimab at flat dose of 480 mg, administered every 4 weeks (Q4W), together with an induction treatment of intravenous FOLFOX-4 (Oxaliplatin 85 mg/m2 IV, L-folinic acid 200 mg/m2 IV, and fluorouracil 400 mg/m2 IV bolus on Day 1, fluorouracil 2400 mg/m2 IV continuous infusion over 46-48 hours starting on Day 1) given every 2 weeks, for 4 months (one cycle = 4 weeks).
223915025|NCT06747585|DRUG|ALE.P02|ALE.P02, will be administered by IV infusion according to the assigned arms.
223915026|NCT06058455|BEHAVIORAL|IDEA3 Sexual Assault Resistance Intervention|Internet-delivered EAAA (IDEA3), adapted from an in-person sexual assault resistance education intervention: Enhanced Assess, Acknowledge, Act (EAAA) intervention that was found in a randomized trial to reduce sexual assault victimization by about 50% at follow-up. IDEA3 designed for female identifying university students and focuses on resisting sexual assault committed by males in 4, 3-hour units: 1-ASSESS builds ability to detect risk with male acquaintances and develop risk reduction strategies. 2-ACKNOWLEDGE explores overcoming emotional barriers preventing women from acknowledging risk and employing effective resistance strategies with males. 3-ACT shows effectiveness of resistance strategies and teaches verbal and physical self-defense in common situations. 4-RELATIONSHIPS \& SEXUALITY adapts the Our Whole Lives curriculum to increase women's comfort in talking about sex/sexuality and identify sexual values/desires.
223915027|NCT06058455|BEHAVIORAL|Consent Workshop|Participant pairs assigned to the control arm will receive a 60-minute session consisting of a 60-min interactive, virtual consent workshop. The workshop will include information on a) what consent is, including the idea that consent is about bodily autonomy and applies to interactions beyond sex, b) how to give and ask for consent, and c) examples of what it looks like to ask for and give/not give consent. This presentation will be given by a well-trained Research Assistant.
223915028|NCT07094932|DRUG|TBD09|TBD09 will be administered orally
223915029|NCT07094932|DRUG|Placebo|Placebo will be administered orally
223915030|NCT06877416|OTHER|Non-intervention research|Non-intervention research
223915031|NCT07102160|DEVICE|Aspiration thrombectomy system|The Cleaner Vac® Thrombectomy System is a percutaneous mechanical aspiration thrombectomy device designed for the removal of fresh, soft thrombi and emboli from the peripheral venous vasculature. The system includes an aspiration canister with integrated pump, an 18F aspiration catheter, a handpiece with aspiration control lever, a dilator, and an optional flushing adapter. The device operates via controlled suction to extract thrombus and restore venous patency.
223915032|NCT07087600|OTHER|Automatic lateralization therapy|Program the bed to vary angle and time continuously during the intervention
223915033|NCT07087600|OTHER|Supine Positioning|In this intervention, participants will be positioned in the supine position with the head of the bed elevated at 30°
223915034|NCT06352528|DRUG|Repotrectinib|Specified dose on specified days
223915035|NCT01812369|DRUG|GEMCITABINE CISPLATINE|
223915036|NCT01812369|DRUG|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
223915037|NCT07103135|DEVICE|MagVenture X100 Pro transcranial magnetic stimulation system|The study intervention involves the use of the MagVenture X100 Pro transcranial magnetic stimulation system to deliver accelerated intermittent theta burst stimulation (aiTBS) to personalized targets within the somato-cognitive action network (SCAN) and action motor network (AMN) for the treatment of chronic pain.
223915038|NCT06394739|DEVICE|Thrombectomy|RevCore Thrombectomy to treat in-stent thrombosis
223915039|NCT06843291|GENETIC|Genetic Testing for hematological malignancies|combined skin punch biopsy/BM aspiration technique, followed by NGS and OGM.
223915040|NCT06564142|DRUG|Povetacicept|Subcutaneous injection administration.
223530050|NCT06488846|OTHER|INVITE-Home|Curriculum to train Treatment Buddies, selected by the people with HIV, to administer LAI-ART at home with supervision of a Study Nurse.
223530051|NCT06488846|OTHER|Clinic-Administered LAI-ART|People with HIV who continue to receive LAI-ART in clinic
223530052|NCT06488846|OTHER|Oral ART|Oral ART
223915041|NCT06564142|DRUG|Placebo (matched to Povetacicept)|Placebo matched to Povetacicept subcutaneous injection administration.
223915042|NCT04603807|DRUG|Entrectinib|Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.
223915043|NCT04603807|DRUG|Crizotinib|Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
223915044|NCT06919224|OTHER|mHealth app + booklets|A mHealth app that has patient facing guidelines and engaging content and a booklet with the guidelines that are made to be patient-facing.
223940244|NCT05590494|PROCEDURE|Ultrasonic tenotomy|Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
223940245|NCT04115423|DRUG|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
223940246|NCT04115423|DRUG|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
223940247|NCT04811924|DRUG|Application of 0.02% MMC over 60 seconds post corneal crosslinking.|Topical application of 0.02% MMC on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after MMC application.
223940248|NCT04811924|DRUG|Corneal crosslinking without the application of 0.02% MMC|Topical application of placebo on the surface of the cornea post CXL. The surface of the eye is washed thoroughly with Balanced Salt Solution (BSS) over 1 minute after placebo application.
223940249|NCT01499316|PROCEDURE|High Flow oxygen|10 minute shigh flow oxygen
223915045|NCT06916429|OTHER|Psychotherapeutic treatment|"The psychotherapeutic treatment will reflect the therapy practices that characterize the Danish primary sector.~Treatment: Clients are referred by their GP to receive up to 12 individual psychotherapy sessions, typically of 50-60 minutes' duration. For clients with depression and anxiety as referral reason, it is possible to get a supplementary referral by the GP ensuring 12 more sessions, totaling 24 sessions of therapy.~Procedure: Due to the Danish primary sector having relative freedom in method of choice, the psychologist carries out the psychotherapy according to the treatment principles they consider the most relevant, without clauses regarding specific models of therapy or manualization. The therapists register the therapeutic approaches and interventions used in each course of therapy on The Multitheoretical List of Therapeutic Interventions (MULTI-30)at the end of each treatment."
223915046|NCT06916429|OTHER|Waiting List for Psychotherapeutic Treatment|"Treatment: During the waiting list period, clients will not receive any psychotherapeutic treatment for their mental health issues in the Danish primary sector. However, their general practitioner may refer them to appropriate psychiatric treatment if their mental condition worsens and requires immediate treatment.~Procedure: Clients in the waiting list group will fill in questionnaires on their symptom development during the waiting period. They will complete the same set of predictor and outcome questionnaires as the psychotherapy group."
223915047|NCT07106203|BEHAVIORAL|Pursed-Lip Breathing (PLB)|Children in the intervention group will receive Pursed-Lip Breathing exercises twice daily for three days under nurse supervision. Exercises will be applied using playful techniques with a toy (e.g., saxophone ball). Physiological parameters will be measured before and after each session.
223915048|NCT07127783|BEHAVIORAL|Active Recovery|Participants will receive postoperative instructions to follow an active recovery protocol focused on increasing activity level, core strength exercises, and pelvic floor exercises focused on urinary and bowel symptoms. Exercises are to be completed twice per day for the 12 weeks following surgery.
223915049|NCT07127783|BEHAVIORAL|Standard Postoperative Instructions|Standard of care postoperative instructions covering incision care, pain control, dietary instructions, and emergency precautions. Also includes guidelines regarding pelvic rest and lifting restrictions.
223915050|NCT07130812|OTHER|blood flow restriction|The SAGA blood flow restriction tourniquet system will be used for each training sessions for the rowers within the light load restriction group. The 4 inch-wide tourniquet will be applied to both upper thighs during the strength and endurance exercises. Tourniquet setting will be determined as the pressure needed to achieve 40-80% arterial occlusion to the extremity (as measured by the SAGA BFR unit). The SAGA units provides a consistent amount of pressure to the extremity throughout the ROM of the exercise. The settings will be determined at baseline and then recalibrated weekly.
223915051|NCT07130812|OTHER|Heavy load resistance training|For the resistance prescription, rowers will do strengthening exercises at 70-80% 1 RM. Exercises will be performed in series following 6 sets by 5 reps, with 120 seconds of rest between sets for each exercise.
223915052|NCT07135895|DEVICE|Artix Thrombectomy System|Treatment of lower extremity arterial occlusions using the Artix Thrombectomy System.
223530053|NCT05860673|PROCEDURE|mini invasive scoliosis surgery|"The minimally invasive technique, involves two small median skin incisions that allow the deep structures to be exposed. The muscle fibers are separated from the bony insertion by the process of subperiosteal skeletonization. The Investigators then proceed with the arthrectomy of the levels to be instrumented and the infiltration of pedicle screw pairs of the appropriate caliber according to the free-hand technique. After amplioscopic control of proper screw placement, osteotomies of the posterior elements are performed to facilitate correction of the metameres."
223915053|NCT06934044|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle.
223915054|NCT06934044|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
223915055|NCT06580457|BEHAVIORAL|Personal Causal Model + Personalized Feedback|Receive a personal causal model of one's personalized causes of substance use/urges, along with a 1-hour, live clinical feedback session to suggest how to apply these insights to one's own recovery.
223915056|NCT06931951|PROCEDURE|Knee Pharmacoacupuncture|Physician choose the adequate type and dose of pharmacoacupuncture and needle type
223915057|NCT06931951|PROCEDURE|Oriental medicine integrated treatment|Physician choose the integrated oriental medicine treatment other than herbal acupuncture.
223915058|NCT03734029|DRUG|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
223915059|NCT03734029|DRUG|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
223915060|NCT03734029|DRUG|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
223915061|NCT03734029|DRUG|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
224088640|NCT02846103|OTHER|Biological samples|blood and tumor tissue samples
223915062|NCT03734029|DRUG|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
223915063|NCT03734029|DRUG|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
223915064|NCT04510051|DRUG|Cyclophosphamide|Given IV
223915065|NCT04510051|DRUG|Fludarabine|Given IV
223915066|NCT04510051|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given intraventricularly
223915067|NCT06945458|DRUG|KT-621|Oral drug
223940250|NCT01499316|PROCEDURE|Room Air|Room air breathing
223940251|NCT00753493|DRUG|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
223940252|NCT03274076|DRUG|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
223940253|NCT03274076|DRUG|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
223940254|NCT02230137|BEHAVIORAL|Text message arm|Text message sent before each injection of insulin
223940255|NCT02150616|BEHAVIORAL|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
223940256|NCT02150616|BEHAVIORAL|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
223940257|NCT02150616|DRUG|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
223716383|NCT05163236|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT) not performed|We evaluated CRCs screening campaign from January 1, 2016 to December 31, 2017, and interval cancers within two years after a negative test, and five years for post-colonoscopy interval cancers.
223716384|NCT00361569|DRUG|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
223915068|NCT06946888|BEHAVIORAL|Acupressure|Participants in this group will receive instruction on how to perform self-acupressure targeting two specific acupoints on the hands: Shenmen and Neiguan. The acupressure protocol includes pressing each acupoint approximately 15 times (about 30 seconds), with a total of four acupoints per session (both hands), for approximately 2 minutes per session. Pressure should be applied until a sensation of soreness, numbness, fullness, or slight pain is felt (equivalent to about 3 kg of pressure). Participants are asked to perform self-acupressure twice daily (once in the afternoon and once before bedtime, adjustable based on personal schedule) for a total of 2 weeks. They will record their practice using a daily log and continue to complete psychological and emotional outcome questionnaires weekly over a 2-month follow-up period.
223915069|NCT06445946|DRUG|Metformin|Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
223915070|NCT06445946|DRUG|Insulin|Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
223915071|NCT07149207|DRUG|Indocyanine Green (ICG)|Dose: 5 mg/kg IV injection prior to surgery
223915072|NCT06949553|OTHER|No study intervention|No visits or examinations, laboratory tests or procedures are mandated or required for this study. Patients will be recruited through a registry if patients who had participated in previous OASIS trials. After this referral, the study is conducted entirely electronically.
223915073|NCT07150117|BEHAVIORAL|Exercise|A supervised 12-week cycling-based aerobic exercise intervention performed twice per week.
223915074|NCT07154732|DEVICE|Transcranial photobiomodulation (active)|During the active stimulation period, participants completed 11 sessions of active stimulation within 11 days in their own homes. The stimulation duration per session was 9-12 minutes, administered once daily.
223915075|NCT07154732|DEVICE|Transcranial photobiomodulation (sham)|During the sham stimulation period, participants completed 11 sessions of sham stimulation in their own homes within 11 days, with the same stimulation frequency and duration as the active stimulation group. The intervention was delivered at the same target area and wavelength; the intensity was matched to that of the active stimulation during the first 30 seconds and the last 30 seconds of each session, while no intervention was applied in the intermediate period.
223915076|NCT07156955|BEHAVIORAL|Electrical stimulation cue|A single 30-minute session is provided. Electrodes are attached to the cubital fossa, and stimulation is delivered at a frequency that increases up to 70 Hz as the elbow joint approaches the target angle. Target angles are set between 0 degrees and 120 degrees, based on each participant's available range of motion determined during the initial assessment. Participants adjust their elbow joint angle to match the provided target angle using feedback from the electrical stimulation. When the elbow joint angle matches the target angle, the maximum frequency is applied to the cubital fossa. Participants match their elbow joint angle to the target angle based on the given frequency.
223915077|NCT07156955|BEHAVIORAL|Visual stimulation cue|A single 30-minute session is provided. The difference between the current elbow joint angle and the pre-set target angle is displayed on a screen using two colored needles (a red needle for the target angle and a black needle for the current elbow joint angle). The target angle is set within each participant's available range of motion based on the initial assessment. Participants continue the intervention by adjusting their elbow angle using the visual feedback. When the elbow joint angle matches the target angle, the two needles overlap. Based on this visual cue, participants adjust their elbow joint angle to match the target angle.
223915078|NCT07156955|BEHAVIORAL|No cue|A single 30-minute session is provided. The target angle is determined within each participant's available range of motion based on the initial assessment. Throughout the session, participants receive verbal feedback from the assessor and adjust their elbow joint angle accordingly to match the target angle.
223915081|NCT07161765|DEVICE|Rectal Expulsion Device (RED)|"Enrolled participants will complete surveys prior a standard of care visit at the University of Michigan.~Gastroenterology staff will perform the RED device at the time of a participant's anorectal manometry appointment."
223915082|NCT07162584|DRUG|Oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
223915083|NCT07162584|DRUG|Placebo|intranasal administration of placebo (24 IU)
223915084|NCT07168044|BEHAVIORAL|CAN-DO|usual programing offered as part of the congregate meal program plus 18 weekly group education sessions related to CVD risk reduction and nutrition.
223915085|NCT07173504|OTHER|Intermittent enteral nutrition|Participants will receive intermittent enteral nutrition in four separate portions between 8:00 a.m. and 8:00 p.m. Each portion will be administered over a one-hour period.
223915086|NCT07170202|OTHER|Mindfulness Smartphone Application|A mindfulness mobile health smartphone application that has mindfulness information and practice videos.
223940258|NCT02150616|DRUG|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
223716385|NCT00361569|DRUG|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
223716386|NCT00361569|OTHER|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
223716387|NCT00361569|OTHER|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
223716388|NCT05353166|DRUG|REGN5381|Single dose administered via IV infusion
223716389|NCT05353166|DRUG|Matching Placebo|Single dose administered via IV infusion
223716390|NCT02639065|DRUG|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
223716391|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
223716392|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
223915087|NCT07159386|OTHER|EHR alert|Diagnoses of MASLD (based on ICD 9/10 code) in a patient's EHR history, visit, or problem list, will cue a non-interruptive alert to appear and prompt clinicians to use the integrated EPIC© FIB-4 calculation SmartPhrase. The tool displays the FIB-4 risk score, the advanced fibrosis risk, and the clinical guidance. LSM by ultrasound with elastography will be recommended for patients with FIB-4 \>1.3 (FIB-4 \>2.0 if age \>65) and the decision support will urge clinicians to order US with elastography through the SmartSet. LSM results will be documented in the EHR and categorized as low-risk MASLD (LSM \<8 kPa) or advanced fibrosis (LSM \>8 kPa). Results will be disseminated to the ordering PCPs and the patients. PCPs will receive information on patient counseling for MASLD, and the expanding roles of weight loss, reduced alcohol use, and exercise on disease management. PCPs will be encouraged to refer patients with advanced fibrosis to a hepatology specialist, in accordance with guidelines.
223915088|NCT07187453|BEHAVIORAL|Personalized Oral Hygiene Advice using AI assisted mHealth Tool by Non-Dental Personnel|The intervention involve the delivering personalized oral hygiene advice using AI assisted gum disease screening tool by non-dental personnel social workers. Our proposed intervention involve AI to assist in the self-detection of gum disease, and emphasizes the use of mHealth for disease prevention and monitoring. Moreover, the proposed project focuses on providing personalized oral hygiene instruction, which can be utilized or provided by non-dental personnel volunteers. This combination of AI, mHealth, and personalized instruction in addition with regular service of non-dental personnel volunteers is a novel approach in managing periodontal health among older adults.
223915089|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Placebo Product (PP)|1 capsule (placebo)
223915090|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Active Control (AC)|1 capsule (melatonin)
223915091|NCT07200167|DIETARY_SUPPLEMENT|21 days of intervention with Test Product (TP)|1 capsule (valerian root extract)
223915092|NCT07200076|PROCEDURE|Quadratus Lumborum (QL) Block|"In the QLB-2 approach, a needle will be inserted in-plane from anterior to posterior, directed towards the posterior QL muscle border, and a 20 ml solution of 0.25% ropivacaine will be injected.~For the QLB-3 approach, the needle will be inserted in-plane from anterior to posterior, traversing the QL muscle's proper fascia to target the plane between the QL and PM muscles, and a 20 ml solution of 0.25% ropivacaine will be injected."
223915093|NCT07202182|BEHAVIORAL|Creative Drama-Based Stress Management Program|A creative drama-based stress management program is an intervention that aims to reduce nursing students' stress levels and increase their coping and emotional intelligence skills.
223915094|NCT07202182|BEHAVIORAL|Training|In the study, the control group will receive training on a topic different from the experimental intervention for three weeks. This method aims to prevent any loss of motivation that might result from the control group not receiving any training. It also helps determine whether the effects observed in the experimental group are due solely to the creative drama-based stress management program or to the overall training process.
223915095|NCT07202273|RADIATION|simulation-free, single-fraction palliative radiation therapy|Radiation will be delivered in a single fraction. The recommended prescription dose is 8 Gy with external beam radiation therapy.
223915096|NCT07200973|BEHAVIORAL|Adapted LINK LA Peer Navigator|Our study will adapt the LINK LA peer navigation intervention (NCT01406626) for the current context (e.g., HIV care provision, substance use risk environments, etc.) and measure its effects on participants' HIV and substance care engagement.
224278029|NCT02212457|BIOLOGICAL|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB\_0\_2 Group.
223530054|NCT05860673|PROCEDURE|posterior spinal fusion technique|"The standard open technique involves a longitudinal incision along the midline extended along the entire thoracolumbar spine, the paravertebral muscles are incised and spread apart to expose the posterior vertebral structures, in a stretch extending more than 30 cm. The series of facetectomies are performed first, and then pairs of pedicle screws are infixed freehand.~After performing the osteotomies necessary to mobilize the vertebral metameres at the apex of the deformity, correction by derotation maneuvers is continued, and the obtained correction is fixed with pre-shaped bars that are then connected to the screws and tightened to the nuts by dynamometric technique. Almost all vertebral levels of the thoracolumbar tract are included in the arthrodesis"
223530055|NCT03012880|BIOLOGICAL|Daratumumab|Given IV
223530056|NCT03012880|DRUG|Dexamethasone|Given PO
223530057|NCT03012880|DRUG|Ixazomib Citrate|Given PO
223530058|NCT03012880|OTHER|Laboratory Biomarker Analysis|Correlative studies
223530059|NCT03012880|DRUG|Lenalidomide|Given PO
223530060|NCT03012880|OTHER|Questionnaire Administration|Ancillary studies
223915097|NCT07198334|OTHER|Heat acclimation|Passive heat acclimation was designed to induce adaptation in participants through 14 consecutive days of controlled 5-minute whole-body immersion in water at 45°C.
223940259|NCT00975585|DEVICE|senofilcon A|soft contact lens, 2-week replacement indicated
223940260|NCT00975585|DEVICE|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
224088641|NCT05010460|DRUG|Roxadustat|orally 100mg every other day for 5-8 days prior to CABG
224088642|NCT05010460|DRUG|Placebo|orally 100mg every other day for 5-8 days prior to CABG
224088643|NCT01902979|BEHAVIORAL|Lifestyle intervention|
224278030|NCT02212457|OTHER|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group, Month 2 in ABCWY\_0\_6 Group and ABCWY\_0\_11 Group and Month 6 in ABCWY\_0\_1 Group.
224278031|NCT02212457|BIOLOGICAL|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY\_0\_1 Group, Month 1 and 12 in Group ABCWY\_0\_6 Group and ABCWY\_0\_2\_6 Group , Month 0 and 6 in ABCWY\_0\_11 Group and Month 6 and 12 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
224278032|NCT02212457|BIOLOGICAL|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY\_0\_1 Group, Month 0 and 6 in ABCWY\_0\_6 Group, Month 1 and 12 in ABCWY\_0\_11 Group, Month 0, 2 and 6 in ABCWY\_0\_2\_6 Group, Month 0 and 2 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
223530061|NCT04527744|PROCEDURE|the injection of onabotulinumtoxinA at different point|For experimental group, Three units of onabotulinumtoxinA (BTX-A) per site (90 hemifaces) will be initially injected at the Yonsei point. For control group，the same dose of BTX will be injected into the levator labii superioris alaeque nasi muscle, and the injection point is located 3 to 5 mm lateral to each nostril, which was a classical injection point of this treatment.
223915098|NCT07198542|DEVICE|gammaCore Sapphire|This intervention utilizes transcutaneous cervical Vagus Nerve Stimulation (tcVNS). A conductive gel is applied to the device's stimulation surfaces. The device is then placed on the neck over the vagus nerve. The daily treatment protocol consists of three consecutive 2-minute stimulations on the left side of the neck, with a 30-60 second interval between each stimulation. After a brief rest of approximately one minute, the same procedure is repeated on the right side of the neck. The total daily session duration is approximately 20 minutes. Stimulation intensity is individually titrated for each participant to a level that is perceptible but not painful. This regimen is administered once daily for 10 sessions over a 2-week period.
223915099|NCT07198542|DEVICE|Nurosym|This intervention utilizes transcutaneous auricular Vagus Nerve Stimulation (taVNS). The device consists of an earpiece electrode that is clipped onto the left tragus. A small amount of water is applied to the skin for conductivity. The daily treatment protocol consists of one continuous 30-minute stimulation session. Stimulation intensity is individually titrated for each participant to a level that is perceptible but not painful. This regimen is administered once daily for 10 sessions over a 2-week period.
223915100|NCT07199660|BEHAVIORAL|Human-developed negative body image warning|Participants will view a message about the risk of social media use contributing to negative body. The message was developed by humans without using artificial intelligence.
223915101|NCT07199660|BEHAVIORAL|Voluntary warning|Participants will view a message suggesting user take a break from scrolling on social media. The message was developed by humans without using artificial intelligence.
223915102|NCT07199660|BEHAVIORAL|Human-developed depression and anxiety warning|Participants will view a message about the risk of social media use contributing to depression and anxiety. The message was developed by humans without using artificial intelligence.
223530062|NCT04471311|PROCEDURE|Sub-lay mesh supported closure|A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above the arcuate line, posterior layer is reinforced suturing the peritoneum and the posterior rectus sheath; below the arcuate line, the posterior layer is reinforced suturing the peritoneum and the trasversalis fascia. Anterior layer is re-established suturing the anterior rectus sheath. A 3 cm BIO-A Mesh strip is sutureless placed between the posterior rectus sheath and the rectus muscle with an overlap of 1,5 cm at each side. In laparotomies \>20 cm two stripes of 15 cm each is designed. The midline anterior rectus sheath is closed using a running slowly absorbable suture , covering the mesh.
223530063|NCT04471311|DEVICE|BIO-A (GORE) mesh|3 cm BIO-A Mesh strip
223915103|NCT07199660|BEHAVIORAL|Human-developed addiction warning|Participants will view a message warning that social media can be addictive. The message was developed by humans without using artificial intelligence.
223915104|NCT07199660|BEHAVIORAL|Human-developed sleep warning|Participants will view a message that social media use can contribute to poor sleep quality. The message was developed by humans without using artificial intelligence.
223915105|NCT07199660|BEHAVIORAL|Human-developed mental health harms to young people warning|Participants will view a message about the risk of social media use contributing to mental health harms for some young people. The message was developed by humans without using artificial intelligence.
223915106|NCT07199660|BEHAVIORAL|Human-developed warning that social media has not been proven safe|Participants will view a message warning that the use of social media has not been proven safe for young people. The message was developed by humans without using artificial intelligence.
223915107|NCT07199660|BEHAVIORAL|Control message|Participants will view a message about encouraging seatbelt use while traveling in a vehicle.
223915108|NCT07199660|BEHAVIORAL|California's proposed social media warning|Participants will view a message warning about the harms of social media use that mirrors the language the state of California has proposed for mandatory social media warnings.
223915109|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed depression and anxiety warning|Participants will view a message about the risk of social media use contributing to depression and anxiety. The message was developed using artificial intelligence.
223915110|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed negative body image warning|Participants will view a message about the risk of social media use contributing to negative body. The message was developed using artificial intelligence
223915111|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed addiction warning|Participants will view a message warning that social media can be addictive. The message was developed using artificial intelligence.
223915112|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed sleep warning|Participants will view a message that social media use can contribute to poor sleep quality. The message was developed using artificial intelligence.
223915113|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed mental health harms to young people warning|Participants will view a message about the risk of social media use contributing to mental health harms for some young people. The message was developed using artificial intelligence.
224278033|NCT00420095|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
224278034|NCT00420095|DRUG|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
224278035|NCT05211505|DEVICE|WO 2707|Intravaginal application once daily for 1 week, then twice per week until visit 3 (day 38).
224278036|NCT02455947|OTHER|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
224278037|NCT00393705|DRUG|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
224278038|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
224278039|NCT00393705|DRUG|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
224278040|NCT00393705|DRUG|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
224278041|NCT00016653|DRUG|Creatine Monohydrate|
224278042|NCT00016653|DRUG|Glutamine|
223530064|NCT07002723|DRUG|Esketamine combined with dexmedetomidine|After successful neuraxial anesthesia, 0.125mg/kg esketamine and 0.3ug/kg dexmedetomidine are diluted into 30ml of normal saline and continuously pumped for 20 minutes, then connected to a micropump: 15ug/kg/h esketamine 0.02ug/kg/h dexmedetomidine to 96ml saline, continuous amount: 2ml/h, continuous pumping for 48h.
223530065|NCT07002723|DRUG|Normal saline|After successful neuraxial anesthesia, 30ml of normal saline was continuously pumped for 20 minutes, followed by a micropump: 96ml of saline, continuous amount: 2ml/h for 48h.
223530066|NCT06680479|BIOLOGICAL|CH505 TF chTrimer|Stabilized CH505 TF chTrimer, 300 mcg
223530067|NCT06680479|BIOLOGICAL|3M-052-AF|3 mcg
223530068|NCT06680479|BIOLOGICAL|Aluminum Hydroxide Suspension|500 mcg
223530069|NCT06680479|OTHER|Sodium Chloride for Injection|Sodium chloride for injection, 0.9% USP volume-matched placebo injection.
223915114|NCT07199660|BEHAVIORAL|Artificial-intelligence-developed warning that social media has not been proven safe|Participants will view a message warning that the use of social media has not been proven safe for young people. The message was developed using artificial intelligence.
223915115|NCT07203053|DRUG|Tarlatamab|"Protocol treatment consists of tarlatamab, administered as an intravenous (i.v.) infusion:~* 1 mg on day 1 (C1D1),~* 10 mg on day 8 (C1D8) and~* 10 mg on day 15 (C1D15),~* then 10 mg every two weeks (Q2W) until disease progression according to RECIST v1.1 criteria, unacceptable toxicity, or patient decision, whichever comes first."
223915116|NCT07201363|DIAGNOSTIC_TEST|Biomarkers of inflammation and fibrosis in pre-procedural serum blood samples|In all patients, peripheral venous blood samples will be collected before the TAVI procedure for analysis and calculation of prespecified inflammatory and fibrosis biomarkers. In a subpopulation of 40 individuals, four specific microRNAs (miR-21, miR-29b, miR-155, and miR-146b) will be additionally analysed. The level of each biomarker will be correlated with rates of new-onset TAVI-related CDs and compared between patients with detected and patients without detected new-onset CDs.
223915117|NCT07201363|DIAGNOSTIC_TEST|Transthoracic echocardiography with myocardial deformation analysis and staging according to the extent of cardiac damage related to AS|The echocardiographic stage of extravalvular cardiac damage related to AS and myocardial deformation parameters will be analysed in each patient before TAVI procedure and compared between the group with detected new-onset CDs and the group without new-onset CDs with a goal to examine their predictive value for the development of TAVI-related CDs.
223915118|NCT07198139|DRUG|CDI-988|Antiviral to treat norovirus
223915119|NCT07198139|DRUG|Placebo|Matching placebo
223915120|NCT07198139|OTHER|Snow Mountain Virus|Challenge with Snow Mountain Virus
223915121|NCT07207941|DIETARY_SUPPLEMENT|Hexbio|HEXBIO MCP Granule probiotics (Lactobacillus acidophilus, L. casei, L. lactis, Bifidobacterium bifidum, B. infantis, B. longum), one sachet twice daily for 3 months.
223915122|NCT07207941|OTHER|Placebo|Matching placebo sachets, identical in appearance and schedule
223915123|NCT07208890|DEVICE|Methotrexate Iontophoresis/a low-intensity electric current|: Application of methotrexate solution via iontophoresis using a low-intensity electric current (5-10 mA) for 15 minutes per session, once weekly for 4 weeks, then biweekly for another 4 weeks
223915124|NCT07209111|DRUG|MK-1084|Oral administration
223915125|NCT07209111|BIOLOGICAL|Cetuximab|Intravenous administration
223915126|NCT07207577|OTHER|Maximal incremental exercise test|Participants will perform a symptom-limited maximal incremental exercise test on a cycle ergometer.
223915127|NCT07207421|PROCEDURE|Ultra-Fast-Track Anesthesia|General anesthesia for cardiac surgery followed by planned extubation in the operating room or within the first postoperative hour before ICU transfer.
223915128|NCT07207421|PROCEDURE|Standart care anesthesia|Extubation will be targeted in the ICU according to respiratory effort.
223915129|NCT07207876|DRUG|Ceftriaxon|Ceftriaxone will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider
223915130|NCT07207876|DRUG|Benzathine penicillin G|Benzathine penicillin G will not be provided as part of the study. Pregnant participants will receive these drugs as prescribed outside the study by their non-study clinical care provider
223915131|NCT07209046|DIETARY_SUPPLEMENT|UltraFlora® Triplebiotic|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of probiotic ( UltraFlora® Triplebiotics, 2 capsules/day) are taken daily with a glass of water.
223915132|NCT07209046|DIETARY_SUPPLEMENT|Placebo|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of placebo (2 capsule/day) are taken daily with a glass of water.
223915133|NCT07208799|DRUG|Dexamethasone|single dose of dexamethasone 8 mg (2 mL) administered submucosally at the surgical site 30 minutes before incision.
223915134|NCT07208799|DRUG|Methylprednisolone (Corticosteroid)|a single dose of methylprednisolone 40 mg (2 mL) will be administered submucosally at the surgical site 30 minutes before incision.
224278043|NCT05886803|OTHER|Spontaneous ventilation test|The purpose is to mimic ventilation conditions after extubation and thus to help the clinician predict the outcome of an extubation decision.
223915135|NCT07208981|DRUG|Orelabrutinib|Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Orelabrutinib (150 mg, d1-d28). Maintenance phase (a total of 24 cycles, each cycle lasting 28 days), Orelabrutinib (150 mg, d1-d28). Patients who achieve complete remission (CR) or partial remission (PR) after 6 cycles will decide whether to undergo maintenance therapy based on the investigator's choice.
223915136|NCT07208981|DRUG|Zebetuzumab|Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Zebetuzumab (375 mg/m2, d1/C1-C6).
223915137|NCT07208981|DRUG|Lenalidomide|Induction treatment phase (a total of 6 cycles, each cycle lasting 28 days), Lenalidomide (20 mg, d1-d21).
223915138|NCT07208981|DRUG|Bendamustine + Rituximab|Treatment period (a total of 6 cycles, each cycle lasting 28 days), Bendamustine (90 mg/m2, d1-2), Rituximab (375 mg/m2, d1/C1-6).
223915139|NCT07208214|DIAGNOSTIC_TEST|TXI|"Participants allocated to the TXI group undergo withdrawal using Texture and Colour Enhancement Imaging, while those in the Dye group receive withdrawal with Dye chromoendoscopy. Both procedures follow standardized protocols outlined in the study design."
223530070|NCT03766672|DIAGNOSTIC_TEST|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
223530071|NCT04569084|DRUG|MT-1186|Oral edaravone
223915140|NCT07207694|BEHAVIORAL|WhatsApp-based education group|Participants in the intervention group will receive the same routine face-to-face diabetes education and insulin injection training as the control group, plus a structured WhatsApp-based educational program. The WhatsApp intervention will be delivered over four weeks and include booklets/brochures, photos, and videos on diabetes definition and symptoms, complications, recognition and management of hypoglycemia and hyperglycemia, foot care, nutrition, exercise, oral antidiabetic and insulin therapy, and insulin injection demonstration. Participants' questions will be answered through WhatsApp to provide interactive support.
223915141|NCT07207694|BEHAVIORAL|Active Comparator: Routine Education|Participants in the control group will receive routine face-to-face diabetes education and insulin injection training provided during hospitalization. The education is delivered verbally to patients and their caregivers by the clinical staff. After the follow-up period and data collection are completed, participants in the control group will also be offered access to the WhatsApp-based educational materials used in the intervention group.
223915142|NCT07207499|OTHER|"control group (standard regulation device)"|"Evaluate the time spent in the emergency room of patients referred to the emergency room by the standard regulation system"
223915143|NCT07207499|OTHER|"intervention group Access to Care Service SAS"|Evaluate the time spent in the emergency room of patients referred to the emergency room by the Emergency Care Access Service (SAS)
223915144|NCT07208032|PROCEDURE|Irregular Pulsed Radiofrequency (STP)|Flouroscopic guided irregular pulsed Radiofrequency (STP) for dorsal root ganglion
223915145|NCT07208032|PROCEDURE|regular pulsed Radiofrequency|Fluoroscopic guided regular pulsed Radiofrequency for the dorsal root ganglion
223915146|NCT07207356|DEVICE|true transcutaneous pulsed radiofrequency|participants will receive ultrasound guidance to localize the target cervical nerve root (e.g., C5-C7) before treatment. A high-frequency linear transducer will be used with the patient in a sitting position. Transcutaneous pulsed radiofrequency (TCPRF) will be applied using the StimOn™ Pain Relief System (GM2439, Gimer Medical Co., Ltd, Taiwan; FDA 510(k) No. K213802). The device delivers a 500-kHz symmetric biphasic sine wave at 2 Hz with a 25-ms pulse. Each session lasts 30 minutes, divided into two 15-minute phases, with treatment administered 3 times per week for 4 weeks (12 sessions in total).
223915147|NCT07207356|DEVICE|Sham device|participants will receive ultrasound guidance to localize the target cervical nerve root (e.g., C5-C7) before treatment. A high-frequency linear transducer will be used with the patient in a sitting position. Sham device will be applied. No active current will be delivered. Each session lasts 30 minutes, divided into two 15-minute phases, with treatment administered 3 times per week for 4 weeks (12 sessions in total).
223915148|NCT07208162|BEHAVIORAL|5+1 Adapted, early-stage dyadic care planning intervention|The intervention group will receive the adapted SHARE Dyadic program, consisting of five, 60-90-minute curriculum-guided sessions with a SHARE Counselor, plus one optional family session.
223915149|NCT07208162|BEHAVIORAL|Counseling session and printed resources|Control group participants will receive a treatment as usual equivalent: a single, standardized educational and resource session with a packet of information.
223915150|NCT07209098|DEVICE|Cardiac Contractility Modulation (CCM)|CCM is a therapy delivered via the Optimizer System, which is implanted in eligible heart failure patients. The device delivers non-excitatory electrical signals to the heart during the absolute refractory period, enhancing the strength of cardiac contractions without increasing myocardial oxygen consumption.
223915151|NCT07207811|DRUG|NNC6019-0001|NNC6019-0001 will be administered IV.
223530072|NCT04569084|DRUG|Placebo|Oral
223716393|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
223915152|NCT07207811|DRUG|Placebo (NNC6019-0001)|Placebo matched to NNC6019-0001 will be administered IV.
223915153|NCT07207798|PROCEDURE|Epidural Electrical Stimulation|Epidural Electrical Stimulation (EES) is a medical technology that involves delivering controlled electrical impulses to the spinal cord through electrodes implanted in the epidural space-the area between the outermost membrane of the spinal cord (dura mater) and the vertebrae. This technique aims to modulate the activity of spinal neural networks, thereby regulating neurological functions and promoting functional recovery, particularly in individuals with spinal cord injuries or certain neurological disorders.
223915154|NCT07207798|PROCEDURE|Standard Rehabilitation Therapy|A structured, multidisciplinary rehabilitation program designed to improve motor function, mobility, and independence in participants with paralysis. The therapy typically includes physical Therapy and occupational Therapy.
223915155|NCT07207798|RADIATION|positron emission tomography-computed tomography (PET-CT)|PET-CT is an advanced hybrid imaging modality that combines metabolic information from positron emission tomography with anatomical details from computed tomography.
223915156|NCT07207798|RADIATION|Diffusion Tensor Imaging (DTI)|DTI is an advanced MRI technique that maps white matter tracts by measuring the directionality (anisotropy) and magnitude of water molecule diffusion in neural tissues. It provides quantitative metrics of fibers.
223915157|NCT07207798|PROCEDURE|Somatosensory Evoked Potentials (SEPs)|SEPs are electrophysiological responses recorded from the central or peripheral nervous system following electrical stimulation of sensory nerves. They assess the functional integrity of somatosensory pathways.
223530073|NCT00978458|DRUG|temozolomide|Given orally
223530074|NCT00978458|RADIATION|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
223530075|NCT00978458|RADIATION|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
223530076|NCT07020429|DRUG|Huanjingjian decoction|Participants will receive the traditional Chinese herbal formulation Huanjingjian decoction, administered at a dose of one vial (10 ml) twice daily, taken 30 minutes after breakfast and dinner. The intervention will commence immediately following the cessation of menstruation and will continue until the onset of the subsequent menstrual period. Upon the completion of each menstrual cycle, the treatment will be resumed. Each treatment course spans 28 days, with a total of three consecutive cycles administered.
223716394|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
223915158|NCT07207798|PROCEDURE|Motor Evoked Potentials (MEPs)|MEPs are electrophysiological responses elicited by transcranial magnetic stimulation or electrical stimulation of the motor cortex, recorded from peripheral muscles or the spinal cord. They evaluate the integrity of corticospinal tracts.
224088644|NCT01565980|BEHAVIORAL|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
224088645|NCT01565980|BEHAVIORAL|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
224088646|NCT05827757|BIOLOGICAL|autologous adipose-derived mesenchymal stem cell transplantation|Transplant 100 million autologous adipose-derived mesenchymal stem cells at Day 0 and Day 90
224088647|NCT04144439|DRUG|GABA|Gamma amino butyric acid
223915159|NCT07208682|PROCEDURE|retropubic hydrodissection|subjects would receive retropubic hydrodissection prior to passage of the trocars. A total of 60cc of sterile injectable saline would be injected in the retropubic space with a 20g spinal needle along the anticipated path of the trocar.
223915160|NCT07208864|DIAGNOSTIC_TEST|AI-assisted EGGIM scoring|Endoscopists will evaluate the videos with the assistance of the AI system via EGGIM score.
224088648|NCT01233206|DRUG|Metformin|Metformin pre-treatment and co-administration
224088649|NCT01233206|DRUG|Placebo administration|Placebo pre-treatment and co-administration
224088650|NCT00382031|DRUG|Zalutumumab|Individual dose titration weekly i.v doses
224088651|NCT00382031|OTHER|Control|Best Supportive Care
224088652|NCT03639948|DRUG|Carboplatin|Intravenous solution
224088653|NCT03639948|DRUG|Docetaxel|Intravenous solution
223530077|NCT07020429|DRUG|Hormone replacement therapy|Participants will begin oral administration of Utrogestan (estradiol valerate) on the 5th day of menstruation at a dose of 1 mg daily for 21 consecutive days. Starting from day 17 of treatment, medroxyprogesterone acetate will be added at a dose of 10 mg per day.
223915161|NCT07208864|DIAGNOSTIC_TEST|Conventional EGGIM scoring|Endoscopists will evaluate the videos without the assistance of the AI system via EGGIM score.
223915162|NCT07208461|BIOLOGICAL|Low dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
223915163|NCT07208461|BIOLOGICAL|Low dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
223915164|NCT07208461|BIOLOGICAL|Middle dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
224088654|NCT03639948|DRUG|Pembrolizumab|Intravenous solution
223915165|NCT07208461|BIOLOGICAL|Middle dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
223915166|NCT07208461|BIOLOGICAL|High dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
224088655|NCT03639948|DRUG|Pegfilgrastim|Injectable product
224088656|NCT00054587|BIOLOGICAL|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
223915167|NCT07208461|BIOLOGICAL|High dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
223915168|NCT07208461|BIOLOGICAL|Placebo|0.5 mL 0.9% sodium chloride (normal saline) injection per dose
223915169|NCT07208786|DEVICE|PEVT|"PEVT Procedures~After the anastomosis is completed and endoscopy confirms that the anastomotic site is intact and without bleeding, the following procedures are carried out immediately (usually within 30 minutes after the completion of the anastomosis):~1. EVT device selection: Use an open-pore polyurethane sponge (OPPS) connected to a 16Fr nasogastric tube, with the sponge cut to a size of 2 cm × 3 cm.~2. Placement method: Insert the sponge through the anus to the anastomotic site in the intestinal lumen, set the negative pressure to low intensity (-50 to -100 mmHg), and connect to an external negative pressure suction device for continuous suction."
224088657|NCT00054587|DRUG|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
224088658|NCT00054587|DRUG|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
224088659|NCT00054587|DRUG|Epirubicin|100 mg/m², D1 and every 3 weeks
224088660|NCT00054587|DRUG|Fluorouracil|500 mg/m², D1 and every 3 weeks
224088661|NCT05617287|DIETARY_SUPPLEMENT|Semaine Menopause Supplement|Synergistic Dietary Supplement
224088662|NCT00715975|DRUG|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
224088663|NCT00715975|DRUG|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
224088664|NCT06929182|OTHER|"non-high risk thrombotic APS patients treated with DOAC"|There is no specific intervention in this study. Routine care data will be collected from patients with a 'non-high-risk' APS profile who are currently being treated with DOACs or have been in the past.
224088665|NCT06916104|OTHER|search for respiratory allergies|analyses in terms of biotherapy and respiratory allergy
224088666|NCT06917118|DRUG|Oxycodone 5mg taken first|10 pills of 5mg oxycodone Q4hrs as needed
224088667|NCT06917118|DRUG|Acetaminophen|30 pills of 500mg acetaminophen Q4hrs
224088668|NCT06917118|DRUG|Naproxen Tablets, 500 mg|30 pills of 500mg naproxen Q4hrs
224088669|NCT06917118|DRUG|OxyCODONE 5 mg Oral Tablet|Only used for breakthrough pain
224088670|NCT06261736|OTHER|Prophylactic antibiotics|These participants will be given a single dose of an oral antibiotic prior to the procedure.
224088671|NCT06261736|OTHER|No antibiotics|These participants will not be given an antibiotic prior to the procedure.
224278044|NCT00310674|BIOLOGICAL|Meningococcal C Conjugate Vaccine|
224278045|NCT05518331|DRUG|avatrombopag|Avatrombopag, 40-60 mg (body weight \< 80 kg, 40 mg per day; body weight \> 80 kg, 60 mg per day) orally once daily for at least 3 months and followed up for 3 months to determine hematological response and evaluate the drug security.
223915170|NCT07207902|BEHAVIORAL|Explainer video|2 minute explainer video on treatment options
223915171|NCT07207837|OTHER|Stress Ball Use|The stress ball suppresses most of the nerves and muscles around the wrist and hand, which are directly connected to the brain, and stimulates the nerves and muscles. This mechanism reduces the release of stress hormones and regulates blood pressure by providing relaxation and relaxation (Dinis \& Sousa, 2023; Soltani et al., 2023). Stress ball, which is easy to apply, inexpensive, has no side effects on the patient, and is an effective method in physical and emotional recovery, is an intervention that can be preferred in nursing practices (Gezginci, Iyigun, Kibar, \& Bedir, 2018; Kasar, Erzincanli, \& Akbas, 2020). Stress ball application is effective on pain, anxiety and vital signs in different patient groups (Genç, Korkmaz, \& Akkurt, 2022; Gezginci, Iyigun, Kibar, \& Bedir, 2018; Karatas \& Gezginci, 2023), but no randomised controlled study has been found in which stress ball application was performed in intensive care patients.
223915172|NCT07208630|DEVICE|Instrument-assisted soft tissue mobilization|IASTM will be delivered using stainless-steel instruments with beveled edges, applied to the target muscle groups for approximately 20 minutes per session, two times per week, over four weeks. A licensed physical therapist trained in IASTM will perform the procedure. Lubricant will be applied to the skin, and strokes will be delivered in multiple directions with pressure adapted to patient tolerance.
223915173|NCT07208630|BEHAVIORAL|Traditional physical therapy|The control group will receive a traditional physical therapy program focusing on strength, balance, flexibility, and functional mobility training, combined with simple cognitive stimulation tasks. Sessions will last 30 minutes, two times per week, for four weeks, supervised by a licensed physical therapist.
223915174|NCT07209150|DRUG|antibiotic prophylaxis|we will compare varying durations of antibiotic prophylaxis prior to prostate enucleation surgery
223915175|NCT07207629|DIAGNOSTIC_TEST|Transthoracic Echocardiography measurements|TTE will be performed before, just after and 15 minutes after a blood donation, with measurement of aortic VTI, E wave, e' wave, A wave and left ventricle global longitudinal strain
223940261|NCT05491135|BIOLOGICAL|HMB002|The solution containing microbeads will be infused manually into the peritoneal cavity under ultrasound guidance, with usually a 50ml syringe, as a single infusion or several infusions, to achieve in excess of 25 million hepatocytes per kilogram of the body weight.
223940262|NCT00310973|BEHAVIORAL|Social Network Intervention|
223940263|NCT04379557|PROCEDURE|Catheter Ablation|Catheter Ablation is a procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias
223940264|NCT00651859|DRUG|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
223940265|NCT00651859|DRUG|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
223530078|NCT07020429|DRUG|Placebo|Participants will take the placebo oral solution at a dose of 10 mL twice daily (30 minutes after breakfast and dinner). The placebo intervention will commence immediately after the cessation of menstruation and will continue until the onset of the subsequent menstrual period. At the completion of each menstrual cycle, the treatment will be resumed. Each treatment course will last for 28 days, with a total of three consecutive cycles administered.
223940266|NCT00651859|DRUG|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
223940267|NCT03014518|OTHER|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
223940268|NCT03014518|OTHER|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
223940269|NCT05276999|OTHER|Healthcare provider education|Mix of training and educational activities within the district continuing medical education system targeting community health workers and frontline providers focused on the importance of sore throat and it's link to RHD, clinical guidelines to differentiate patients at high or low risk for GAS pharyngitis and guideline based care for treating GAS pharyngitis
223940270|NCT05276999|OTHER|Community Awareness campaign|A district wide public health campaign to increase community awareness of sore throat, including school based education, VHT community sensitization, education of parents and patients, radio messaging, posters, signs and billboards.
223940271|NCT00683800|DRUG|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
223940272|NCT00683800|DRUG|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
223940273|NCT04053270|DRUG|Afamelanotide|16mg subcutaneous implant
223940274|NCT04053270|DRUG|Placebo|Placebo subcutaneous implant
223530079|NCT07158645|OTHER|Medical Food Tri-betahydroxybutyrin|Medical Food Containing Tri-betahydroxybutyrin
223716395|NCT03673215|DRUG|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
223915176|NCT07207512|BEHAVIORAL|Emotion-Focused Therapy for Grief|"The EFT intervention will follow the model described in EFT for grief. Its main goal is to transform core emotional pain (e.g., chronic shame) by activating change-inducing emotions (e.g., assertive anger), a process described as changing emotion with emotion. This work takes place within a safe and supportive therapeutic relationship, characterized by the therapist's empathic, accepting, and compassionate stance. Therapists remain attuned to emotional markers (e.g., self-criticism, unfinished business) that signal opportunities for targeted work on specific affective problems, which are usually addressed through experiential tasks such as the Empty-Chair for Unfinished Business. Although EFT is transdiagnostic, grief work has certain distinctive features, such as the central role of experiencing grief-related sadness and fostering a sense of connection with the deceased."
223915177|NCT07207512|BEHAVIORAL|Self-help intervention based on EFT|The self-help intervention consists of 10 written exercises designed to address different aspects of grief. These include psychoeducation, emotional regulation, focusing on bodily awareness, softening self-criticism, reducing avoidance, managing anxiety and fear, clarifying confusing emotional reactions, processing trauma, imaginal dialogues with the deceased, and cultivating compassion.
223915178|NCT07208422|BEHAVIORAL|Video-based Task-specific Training|Video-based self-administered TST
223915179|NCT07208422|BEHAVIORAL|Manual-based Task-specific Training|Manual-based self-administered TST
223915180|NCT07209059|DRUG|Nivolumab|Monoclonal antibody targeting PD-1; administered in combination regimens
223915181|NCT07209059|OTHER|N-EACOPD-14|14-day regimen. Combination of Nivolumab with Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, and Dacarbazine; given for 2 cycles as initial therapy.
223915182|NCT07209059|OTHER|N-AVD|Combination of Nivolumab with Doxorubicin, Vinblastine, and Dacarbazine; used as de-escalated therapy after negative interim PET (2 cycles).
223915183|NCT07209072|BEHAVIORAL|Street medicine follow up|This intervention will use electronic health record builds to automatically send a referral to a street medicine clinic, who will attempt to contact the patient within 2 weeks.
223915184|NCT07207889|DRUG|morphine chlorhydrate in intrasite gel|The use of Morphine gel to treat painfull perineal radiodermatitis is new. None clinical study was conducted to explore the efficacy of the morphine gel as local analgesic for these cutaneous toxicity due to radiotherapy
223915185|NCT07208097|PROCEDURE|Stereotactic thrombolysis with Tenecteplase|Stereotactic thrombolysis with Tenecteplase for ICH is a minimally invasive method for evacuation hematoma. The hematoma puncture target is identified via CT imaging before surgery. After local anesthesia and sedation, stereotactic minimally invasive surgery is performed with the Leksell stereotactic frame. A postoperative CT scan is immediately conducted to confirm the absence of intracranial rebleeding before administering tenecteplase into the hematoma. Tenecteplase is fully diluted in 2 mL of saline and injected into the hematoma cavity via an irrigation catheter. The drainage tube is clamped for 1 hour before opening (early opening is permitted if necessary). The single dose of TNK is 0.5 mg and can be administered with a maximum of 2 dose in every 24 hours. The target hematoma clearance criteria is: residual hematoma volume ≤10 mL or ≤20% of the initial volume.
223915186|NCT07207434|DRUG|Oral Vancomycin|Oral vancomycin in capsule form will be administered three times daily for 5 days at 250mg per dose. Because oral vancomycin is a non-absorbable antibiotic, the likelihood of systemic absorption is minimal and therefore, it is not associated with the adverse events attributable to the intravenous formulation
223915187|NCT07207434|DRUG|VE818|VE818 is an 11-strain bacterial consortium rationally designed by Vedanta Biosciences Inc., to displace enteropathogens and reduce intestinal inflammation in pregnant women.
223915188|NCT07207434|DRUG|Placebo|Enteric capsules filled with approximately 400mg of microcrystalline cellulose (bulking agent)
224088672|NCT06911359|DRUG|Participants are given Ibuprofen 400 mg to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.|The other group is given a placebo when they receive their dextrose prolotherapy (DPT) injection
223915189|NCT07207967|OTHER|END INSPIRATORY PAUSE DURING CONTROLLED VENTILATION|PATIENTS WILL BE VENTILATED WITH END-INSPIRATORY PAUSE AND HIGH INSPIRATORY FLOW DURING CONTROLED VENTILATION
223915190|NCT07207967|OTHER|NO PAUSE VENTILATION|PATIENTS WILL BE VENTILATED IN VOLUME CONTROLLED VENTILATION WITHOUT END-INSPIRATORY PAUSE
223915191|NCT07208526|DRUG|GOLP regimen|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
223915192|NCT07208526|PROCEDURE|Surgery|R0 resection
223915193|NCT07208526|DIAGNOSTIC_TEST|TDTP-RECIST|Treatment selection between continued GOLP therapy and surgical R0 resection based on TDTP-RECIST criteria.
223915194|NCT07208760|DRUG|Single dose of 1800 mg L9LS SC (12mL)|A human monoclonal antibody to protect against Plasmodium falciparum.
223915195|NCT07208760|OTHER|Placebo 12 mL SC|Normal saline.
223915196|NCT07208760|DRUG|Single dose of 225 mg L9LS SC (1.5mL)|A human monoclonal antibody to protect against Plasmodium falciparum.
223915197|NCT07208760|OTHER|Placebo 1.5 mL SC|Normal saline.
223915198|NCT07207460|PROCEDURE|Comparison of three different injection techniques using hydrodissection with 5% dextrose in the treatment of CTS|Comparison of three different injection techniques with D5W
223716396|NCT03673215|DRUG|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
223716397|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
224088673|NCT06911359|DRUG|Participants are given a placebo to take for 7 days on the day they receive a dextrose prolotherapy (DPT) injection. These procedures are repeated every 3-5 weeks for a total of 3 times.|The other group is given Ibuprofen when they receive their dextrose prolotherapy (DPT) injection
224088674|NCT06915649|PROCEDURE|Amygdalo-Hippocampectomy|"This technique is characterized by specific hallmarks that distinguish it from other approaches, including the Yasargil technique and newer minimally invasive methods. It integrates precise anatomical targeting with optimized surgical pathways to enhance outcomes in patients with those pathologies. The approach of the choroidal fissure will be explained in the article.~By addressing limitations observed in traditional techniques, it aims to minimize neurological deficits while achieving better seizure control."
224088675|NCT01468311|PROCEDURE|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
224088676|NCT01468311|DRUG|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
224088677|NCT01468311|RADIATION|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
223915199|NCT07208396|OTHER|Upper cervical mobilization|"All patients in group A will receive Grades I and II mobilizations in the first two sessions to reduce pain. In subsequent sessions, patients will receive Grades III and IV mobilizations; typically will be utilized to stretch the joint capsule and passive tissues, which provide stability to the joint, thereby increasing ROM. Maitland usually performs treatment techniques in an oscillatory manner. These oscillations can be performed with different amplitudes in different positions in the range of movement.~The mobilizations will be delivered in the prone position. The duration of mobilization will be 30-s bouts given for three sets. The therapist places a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand will be placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force will be directed dorsally from the shoulder until the therapist"
223915200|NCT07208396|OTHER|Integrated neuromuscular inhibition technique|"An integrated approach to myofascial trigger point release is achieved by combining several manual therapy techniques under the name INIT (Integrated Neuromuscular Inhibition Technique). The technique combines MET and SCS with ischemic compression in one coordinated technique .~First, intermittent compression(IC) was initiated by using the thumb and index finger to apply a pincer grip to the TrP in the middle of the UT.~Second, the strain counter strain (SCS) began by applying pressure to the trigger point . The participants' heads were passively flexed laterally to the affected side. and then asked the patient about pain.~Third, the MET begins with one of the investigator's hands stabilizing the affected shoulder and the other on the head side. The participant was asked to move the stabilized shoulder and head in the direction of the other. This contraction lasted 7 seconds and had a maximum voluntary contraction of 20%. After that, the muscle was lengthened for 30 seconds"
223915201|NCT07208396|OTHER|Conventional treatment|"1. Hot packs Hot pack will be applied at the beginning of the treatment session for all patients participated in the study. The participants will be in prone lying position. The neck and upper thoracic region will be exposed. The hot pack then will be applied for 10 minutes on cervical and upper thoracic region.~2. Dynamic neck exercise: Dynamic neck exercises include lifting head up with the chin tucked in from supine lying for neck flexion, lifting head backwards in prone lying for neck extension lifting head sideways from pillow in side lying position for neck side flexion which will be also repeated for the other side.~3. Isometric Neck Exercises The exercises will be performed in sitting position, by holding the theraband directly forwards for neck flexion, backwards for neck extension and obliquely towards right and left and by crossing over the band for neck side flexion and rotation. All these will be done for all patients participated in the study for about 5-10 repetition"
223915202|NCT07208409|DEVICE|14 Fr chest tube|Chest tube size of 14Fr will be inserted
223915203|NCT07208409|DEVICE|12 Fr chest tube|Chest tube of 12 Fr will be inserted
224088678|NCT01468311|RADIATION|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
224088679|NCT03684655|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
224088680|NCT04533711|BEHAVIORAL|OA-PCP Intervention|The OA-PCP intervention includes brief physical activity (PA) counseling delivered via phone by a PA Coach trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA Coach will ask participants about their current physical activity level and work with them to set physical activity goals. Then, after the first call, participants in this group will receive a call about two weeks later, then at about 3 months, 6 months, 9 months and 12 months later. During these calls, the PA coach will ask participants' about their progress toward PA goals and work with them to address any barriers or challenges. The coach will also help participants to identify any programs or resources that may help them to achieve their PA goals. Participants in this group will be asked to wear a wrist-worn monitor to help them track their PA during the intervention period. Also, if participants approve, the coach will use an online program to view their PA data.
223716398|NCT03673215|DRUG|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
223716399|NCT03673215|DRUG|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
223915204|NCT07208409|DEVICE|8 Fr chest tube|Chest tube size of 8Fr will be inserted
223915205|NCT07208591|DRUG|STSA-1002 injection|basal treatment + STASA-1002 intravenous infusion
223915206|NCT07208591|DRUG|STSA-1002 Injection Placebo|basal treatment + STSA-1002 Injection Placebo
223915207|NCT07208110|OTHER|Exposed to trauma|Patients exposed to trauma previous to the admission to the ICU.
223915208|NCT07208110|OTHER|Not exposed|Patients not exposed to trauma previous to the admission to the ICU.
223915209|NCT07207980|BEHAVIORAL|CREDOenAP intervention|Intervention program with intensive lifestyle counseling, added to standard pharmacological treatment subsequently adjusted according to clinical needs and outcomes. The intervention will last 6 months and consists of biweekly in-person and telephone visits. Patients will follow a personalized dietary plan with carbohydrate restriction, based on the recommendations of the American Diabetes Association; engage in moderate and accessible physical activity; implement circadian rhythm regularization; and receive psychological counseling and support.
223915210|NCT07208604|DEVICE|Quantitative refractive crosslinking|Non-invasive corneal cross-linking device delivering controlled UV light through a contact lens platform for biomechanical stabilization of the cornea.
223915211|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 1
223915212|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 2
223915213|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 3
223915214|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 4
223915215|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 5
223915216|NCT07207408|BIOLOGICAL|rF1V-1018|Regimen 6
223915217|NCT07208617|DEVICE|RED-light device using LED light source|The light source type of red light is LED light source.
223915218|NCT07208617|DEVICE|Control|Fake light, with a light source power that is one-tenth of that of real LED light
223915219|NCT07209306|OTHER|Experimental: Self-Help Plus and booster session|"The SH+ programme, developed by WHO is a five-session stress management course. Supervised non-specialist facilitators will deliver it in a group setting in person. SH+ is intended to be transdiagnostic, easily adaptable to different cultures and languages and both meaningful and safe for people with and without mental disorders.~Booster session:~The booster session of SH+ will be provided individually to participants in an online format. It will last approximately 45 minutes, and it will contain a summary of the main contents of the five sessions. The booster session has been developed according to WHO manuals and will be delivered by a trained facilitator.~All participants in the three arms will receive ECAU that will include an information flyer about locally available services for migrants (education, health, social and legal support), and may include community care, social/legal support, etc."
223915220|NCT07209306|OTHER|Doing What Matters in Times of Stress and booster session|Arm Description: The DWM program has been developed by WHO as a stress management guide for coping with adversity. DWM contains the same content as the SH+ illustrated guide, training the five basic stress management skills with standalone audio. Additionally, participants are guided by a briefly trained helper. In this study, the DWM program will be delivered individually as an online guided intervention. The DWM intervention has been adapted for use on a smartphone or other device with internet access. In the online application tool, a new module (i.e., section) is released every week so participants will be asked to go through the entire DWM intervention within five weeks, with guidance from a helper through brief we brief weekly phone or text-based contacts of approximately 15 minutes. Booster session: The booster session will be provided online individually. It has been developed according to the WHO manual, and it contains a summary of the main contents of the online sessions.
223915221|NCT07209306|OTHER|Psychological Placebo|Psychological placebo will consist of a phone call or online meetings with a helper, of the same duration of the DWM sessions. In the first part of the call participants will be reminded about locally available social, health, legal and education services. In the second part of the call participants will choose a discussion topic from topics presented in a list prepared by the research team . Additional session: The additional session of psychological placebo will be provided individually in an online format. It will contain neutral contents and will be facilitated by a helper. It will have the same duration as the booster sessions.
223915222|NCT07208045|BEHAVIORAL|Es tu juego: decide bien (IYG)|Affective-sexual education for adolescents through an gamified online and school-based program.
223915223|NCT06372314|DRUG|Total parenteral nutrition (TPN): this is total nutrition provided by central vein.|isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
223915224|NCT06450444|DEVICE|PRIMUS|The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
223915225|NCT06428097|DRUG|Levothyroxine|Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
223915226|NCT06428097|DRUG|Normal saline|Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
223915227|NCT03367156|DRUG|Dexamethasone|Given PO
223915228|NCT03367156|OTHER|Placebo|Given PO
223915229|NCT03367156|OTHER|Questionnaire Administration|Ancillary studies
223716400|NCT02201485|DEVICE|Stent|
223716401|NCT02201485|DEVICE|Balloon|
223716402|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
223716403|NCT02124330|DIETARY_SUPPLEMENT|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
223716404|NCT02124330|DIETARY_SUPPLEMENT|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
223716405|NCT02094183|OTHER|GLP-1|GLP-1
223716406|NCT02094183|DIETARY_SUPPLEMENT|low calorie diet|low calorie diet
223915230|NCT05843578|DRUG|AGMB-129|Oral capsule
223915231|NCT05843578|DRUG|Placebo|Matching oral capsule
223915232|NCT05507437|BIOLOGICAL|TIN816 70 mg lyophilisate powder|Recombinant human CD39 enzyme
224088681|NCT04533711|BEHAVIORAL|Attention Control|"This group will receive an intervention in the same dose (e.g., number and duration of phone calls and emails) as the OA-PCP group, but the content will not be PA-specific. During the first call, the Coach will discuss 2 topics, for which the amount of content parallels call #1 for the OA-PCP: What is OA? OA Diagnosis and OA Risk Factors. During the second call, the Coach will discuss the topic of Health Care Providers and Overview of OA Treatment Guidelines. Call topics for 3, 6, 9 and 12- month follow-up calls will be: Pain Medications, Mechanical Treatments (e.g., knee braces, footwear, joint protection), Complimentary and Alternative Therapies and discussion of OA and Mental Health, Sleep and Fatigue."
224088682|NCT04265066|DIAGNOSTIC_TEST|microcirculation|measurement of microcirculation
223915233|NCT05507437|OTHER|Placebo|0.9% sterile sodium chloride solution
223915234|NCT05454566|GENETIC|ICM-203|Intra-articular injection
223915235|NCT05895981|DEVICE|G132 system, Beijing PINS Medical Co., China|Neuromodulation was performed according to the usual protocol
223915236|NCT04276805|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|a non-invasive and safe technique that transiently enhances brain GABA and noradrenaline levels.
223915237|NCT04276805|BEHAVIORAL|cognitive training|A program of regular mental activities purported to maintain or improve one's cognitive abilities.
223915238|NCT06952595|BEHAVIORAL|five exercises prescribed and taught to carers and participants|Up to five exercises prescribed and taught to carers and participants in an acute hospital setting fort hem to continue to practice as able.
223915239|NCT06954181|DRUG|Voltaren® Schmerzgel forte; 2.32% (Test Product)|Voltaren® Schmerzgel forte; 2.32% containing 2.32% Diclofenac-N-Ethylethanamin.
223915240|NCT06835712|OTHER|The virtual reality|During the PIK application, 3D visual and audio videos of the beach will be played with an Oculus Go brand virtual reality (VR) headset until the procedure is completed. The video that starts at the beginning of the procedure is planned to last approximately 2-3 minutes during the application. During this time, patients will be asked to close their eyes and take a comfortable position. The VR headset will be disinfected after each application and used on the other patient.
224088683|NCT05390216|PROCEDURE|Partial capsule decortication|The anterior wall of the capsule was removed during the operation.
224088684|NCT02029976|BEHAVIORAL|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
224088685|NCT02029976|BEHAVIORAL|Mailed monthly newsletters|Newsletters
224088686|NCT04617808|OTHER|Questionnaire|"The regulatory scheme applied to all investigative centers is as follows:~* Call from Center 15 by a major patient for secondary headache no traumatic. (i.e. not having been the victim of a head trauma during the 48 hours preceding the call)~* Detection of the pattern of non-traumatic headache, by the regulatory assistant medical with registration of the word cephareg in the medical regulation software in order to alert the regulator about the possible inclusion of the patient~* If possible, patient information on the collection of their data for research and possibility of opposing~* Filling of a medical questionnaire by the regulating doctor~* Weekly collection of medical questionnaires by investigating doctors"
224088687|NCT04025632|DRUG|zilucoplan|Daily subcutaneous (SC) inection
223719480|NCT04058145|DRUG|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
223915241|NCT06835712|OTHER|The guided imagery|Patients in this group will be played an audio clip that helps them imagine walking on a beach and gives instructions during the walk until the procedure is completed, using an MP3 player and headphones. The audio clip aims to activate the imagination of patients by allowing them to use their senses. For example, the temperature of the sun (feeling), the texture of the sand (touching), the color of the sea (seeing), the sound of the waves (hearing), and the smell of the sea (smell) are some examples of this. The audio clip will be voiced by a professional voice artist with good diction. It is planned that the audio clip will be played for approximately 2-3 minutes during the application. During this time, patients will be allowed to close their eyes and take a comfortable position. The headphones of the MP3 player will be disinfected after each application and used on the other patient.
223915242|NCT06964269|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Study intervention is twice weekly injections of Acthar Gel via single-dose pre-filled SelfJect injector for 12 weeks.
224088688|NCT04025632|OTHER|Placebo|Daily subcutaneous (SC) inection
224088689|NCT00565630|DEVICE|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
224088690|NCT01413269|RADIATION|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
224278046|NCT06265753|OTHER|Gastrocinemius Function Massage|The purpose of gastrocnemius massage is to alleviate muscle stiffness in the gastrocnemius muscle and enhance mobility in the foot and ankle of the individuals involved. During the GFM application, the patient assumes a prone posture on a suitable treatment bed. The therapist positions themselves behind the patient's side and secures the patient's foot between their hip and ilium.The therapist firmly holds the gastrocnemius muscle using both hands and applies pressure to the ankle, causing it to move in the direction of dorsiflexion. Simultaneously, the therapist applies mobilisation in the cranial direction, following the same path as the gastrocnemius muscle fibres, using both hands. Afterwards, the therapist gently pulls the arm and trunk backwards until the foot and gastrocnemius muscle become relaxed. The application is sustained in a rhythmic manner . We will apply this massage aproximately 10 min to experimental group.
224278047|NCT06265753|OTHER|Sham application|The sham application was conducted when the patient was lying face down, with the hands placed on the gastrocnemius muscle without any movement. We will apply this application aproximately 10 min to experimental group.
224278048|NCT04734704|PROCEDURE|skin swabs at lesional and non-lesional sites|It will be examined in patients skin swabs sampled at lesional and non-lesional sites
224278049|NCT04734704|PROCEDURE|skin swabs on skin|It will be examined in patients skin swabs sampled on skin
224278050|NCT03473002|OTHER|Placebo|0.9% Sodium Chloride
223915243|NCT04756856|OTHER|Muscle-target oral nutritional supplementation|Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
223915244|NCT05279729|OTHER|Mobile health application|Intervention will be with two different mobile health (mHealth) applications, Weight Watchers and Healthi app (formerly iTrackBites)
223915245|NCT06177977|DEVICE|SS-HH-OCT|The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.
224088691|NCT06518629|OTHER|Photobiomodulation with low power laser|All groups will undergo in-office whitening treatment with 35% hydrogen peroxide (Whitness HP, FGM, Joinville, SC, Brazil). Three whitening sessions will be carried out, considering a seven-day interval between sessions.
223530080|NCT07159711|DIAGNOSTIC_TEST|Seismofit|"Seismofit® is a 3 x 5 x 1.5 cm Class I medical device manufactured by Ventriject, which utilizes SCG principles and machine learning to estimate an individual's fitness. It is afixed to a patient's sternum with an adhesive patch. It measures the amplitude and timing of vibrations on the chest using accelerometers. The device then averages the data collected over 45 seconds to create the SCG. From the SCG, several maxima and minima (fiducial points) are identified, which correlate to the opening and closing of the mitral and aortic valves. Features of the SCG, including the timing, frequency, amplitude, and variability of these points, are then incorporated into an algorithm that also considers patient height, weight, age, and sex to calculate the VO2 peak.~Data is transmitted via Bluetooth to an allocated smartphone app."
223530081|NCT07161518|DEVICE|Low-intensity transcranial ultrasound|Active (focused) ultrasound
223915246|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)|Given via ICT delivery
223915247|NCT04214392|BIOLOGICAL|Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)|Given via ICT/ICV dual delivery
223915248|NCT06129994|OTHER|Observational|Participants will complete an in-person baseline study visit with fasting blood draw, medical and health history, anthropometrics and vital signs, and surveys. If participants are not currently using a CGM, one will be placed. The LifeData study mobile app will be installed on the participant's smartphone. Over the two-week home monitoring period, participants will be asked to wear the CGM and respond to EMA questions three times daily. After the end of the home monitoring period, a remote visit will be performed in which the CGM will be removed by the study participant at home; the study team will obtain all data available from the CGM and insulin pump (if available); and surveys will be collected.
223915249|NCT06352918|OTHER|Palmar grasp reflex stimulation|This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
223915250|NCT04893291|DEVICE|Everolimus Eluting Stent|Patients assigned to this Arm will have an EES implanted after pre-dilatation, the angiography will be conducted as standard of care
224088692|NCT03442803|DEVICE|Target-Controlled Infusion|Propofol Target-Controlled Infusion
224088693|NCT03429478|OTHER|Preoperative application of a bluetooth enabled Headphones.|A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.
224088694|NCT01827891|PROCEDURE|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at \< 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
223530082|NCT07161518|DEVICE|Low-intensity transcranial ultrasound|Sham (unfocused) ultrasound
223915251|NCT04893291|DEVICE|Sirolimus Coated Balloon|Patients assigned to this Arm will be treated with Magic Touch Drug Coated Balloon (DCB) after pre-dilatation, the angiography will be conducted as standard of care
224088695|NCT05798052|BEHAVIORAL|Psychological stressors added to simulated clinical scenarios.|In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
224088696|NCT01524991|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 \& 8 (all cycles)
224088697|NCT01524991|DRUG|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
224088698|NCT01524991|DRUG|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
224088699|NCT05277974|DRUG|inj bupivicain|In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
224088700|NCT05876351|DRUG|Eculizumab|Weight-based doses of Eculizumab will be administered intravenously as an induction dose followed by maintenance dose at Day 8, 15, or 29 depending on weight; then every 2 or 3 weeks, depending upon weight.
224278051|NCT03473002|BIOLOGICAL|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
224278052|NCT05937126|DIAGNOSTIC_TEST|FilmArray Pneumonia Panel|FDA-approved/cleared molecular, multiplex device that rapidly identifies viruses, bacteria, and antimicrobial resistance genes in sputum-like and bronchoalveolar lavage (BAL)-like specimens obtained from individuals with signs of a lower respiratory tract infection.
223530083|NCT07161518|DRUG|Propofol|Intravenous propofol administration
223915252|NCT05443568|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223915253|NCT06473779|COMBINATION_PRODUCT|Tezepelumab|IMP. Subcutaneous injection. Unit dose strengths 210 mg.
223915254|NCT06473779|COMBINATION_PRODUCT|Budesonide/formoterol|AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation
223915255|NCT06473779|COMBINATION_PRODUCT|Albuterol/budesonide (AIRSUPRA®)|AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.
223915256|NCT06473779|COMBINATION_PRODUCT|Mannitol|NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules
223915257|NCT06473779|COMBINATION_PRODUCT|Salbutamol|AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation
223915258|NCT04036045|OTHER|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
223915259|NCT04036045|OTHER|Echocardiogram|Patients will have an echocardiogram at four time points during the study
223915260|NCT04036045|OTHER|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
223915261|NCT05092152|DRUG|Esketamine|2 mg per kilogram of body weight
223915262|NCT05092152|DRUG|Propofol|1.5 mg per kilogram of body weight
223915263|NCT03972150|DRUG|BI 836880|Solution for infusion
223915264|NCT03972150|DRUG|BI 754091|Solution for infusion
223915265|NCT06143514|OTHER|No intervention|No intervention
223915266|NCT06411080|DIAGNOSTIC_TEST|Ultrasound evaluation of fluid tolerance|Lung ultrasound for the assessment of B-line artifact and pleural effusion combined with abdominal ultrasound for VExUS assessment. The imaging study will be reviewed by an expert for will generate a report with interpretation regarding the risk of fluid administration. The assessment will be performed at baseline and after 48 hours after randomization.
223915267|NCT05784402|DRUG|Semaglutide J|Participants will receive oral semglutide J at dose level 1 and 3 in treatment sequence A and C; and at dose level 2 and 4 in treatment sequence B and D.
223915268|NCT05784402|DRUG|Semaglutide C|Participants will receive oral semglutide C in treatment sequence A and B; and at semglutide C at 2x dose level in treatment sequence C and D.
223915269|NCT04221893|RADIATION|Radiation Therapy (RT)|Undergo radiation therapy
223915270|NCT05761743|DIAGNOSTIC_TEST|Urine and Blood Test|Urine N-telopeptide and serum osteocalcin
223915271|NCT01154608|DRUG|Creon|
223915272|NCT01154608|OTHER|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
223915273|NCT06243744|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
223915274|NCT06352788|DEVICE|Modular Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will use a modular design that includes a full length foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg just below the knee.
223915275|NCT06352788|DEVICE|Mono Carbon Fiber Custom Dynamic Orthosis (CDO)|The CDO will use a mono design that includes a full length foot plate, a posterior carbon fiber strut, and a proximal cuff that wraps around the leg just below the knee.
223915276|NCT06035523|DEVICE|Endoform™ Antibacterial|Application of Endoform™ Antibacterial
223915277|NCT06035523|DEVICE|Endoform™ Natural|Application of Endoform™ Natural
223940275|NCT00093353|DRUG|cefixime|
223940276|NCT00093353|DRUG|irinotecan hydrochloride|
223940277|NCT00093353|DRUG|temozolomide|
223940278|NCT02247375|DRUG|Low dose of BIIL 284 BS tablets|
223940279|NCT02247375|DRUG|High dose of BIIL 284 BS tablets|
223940280|NCT02247375|DRUG|Placebo|
223940281|NCT00203554|GENETIC|Poly methylmetacrylate, PMMA|
223940282|NCT04941703|DRUG|Magnesium Citrate plus probiotic|296 ml magnesium citrate
223940283|NCT03305445|DRUG|Ipilimumab|Ipilimumab (1mg/kg)
223940284|NCT03305445|DRUG|Nivolumab|Nivolumab (3mg/kg)
223940285|NCT06016400|DRUG|Alfacalcidol Oral Solution|Alfacalcidol Oral Solution 1ug a day
223940286|NCT06016400|DRUG|Placebo|Placebo
223940287|NCT03773471|BEHAVIORAL|Mobile Health App|ArthritisPower App
223940288|NCT00022165|DIETARY_SUPPLEMENT|selenium|
223940289|NCT04318691|BIOLOGICAL|Blood sampling|Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.
223940290|NCT04318691|PROCEDURE|Bronchoalveolar lavage|Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
223940291|NCT01953692|BIOLOGICAL|Pembrolizumab|IV infusion
223940292|NCT01953692|DRUG|Lenalidomide 20 mg|oral capsule
223940293|NCT01953692|DRUG|Lenalidomide 25 mg|oral capsule
223940294|NCT06369220|DIAGNOSTIC_TEST|cobas® liat CT/NG/MG nucleic acid test|The cobas® CT/NG/MG nucleic acid test for use on the cobas® Liat® System is an investigational, automated, qualitative in vitro nucleic acid diagnostic test that utilizes real-time polymerase chain reaction (PCR) for the direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG) nucleic acid in male/female urine and vaginal swabs (clinician-collected and self-collected) in cobas® PCR Media.
223940295|NCT06369220|OTHER|Standard of Care (SOC): Clinician's Standard Practice|Standard of care (SOC) is defined as the traditional/typical diagnosis and treatment steps in practice recommended by the CDC guidelines that rely upon clinical syndromic presentations and/or external laboratory testing.
223940296|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^4 pfu delivered intramuscularly
223940297|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^5 pfu delivered intramuscularly
223940298|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^6 pfu delivered intramuscularly
223940299|NCT04794218|DRUG|rVSV∆G-LASV-GPC|2 × 10\^7 pfu delivered intramuscularly
223915278|NCT06035523|DEVICE|Symphony™|Application of Symphony™
223915279|NCT06077383|DIETARY_SUPPLEMENT|Weizmania Coagulans BC99|Probiotics group subjects take probiotics every day for 8 weeks.
223915280|NCT05300048|DRUG|Serabelisib|serabelisib administered orally
223719481|NCT04058145|DRUG|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
223915281|NCT05300048|OTHER|Insulin Suppressing Diet|3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
223915282|NCT05300048|DRUG|Nab paclitaxel|nab-paclitaxel administered intravenously weekly
223915283|NCT05672381|PROCEDURE|Lower extremity and/or upper extremity surgery|Lower extremity and/or upper extremity surgery
223915284|NCT05143229|DRUG|Alpelisib|PI3K inhibitor
223915285|NCT05143229|DRUG|Sacituzumab govitecan|Trop-2-directed antibody and topoisomerase inhibitor drug conjugate
223915286|NCT01878617|RADIATION|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
223915287|NCT01878617|DRUG|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
223915288|NCT01878617|DRUG|Cisplatin|ROA: IV
223915289|NCT01878617|DRUG|Vincristine|ROA: IV
223915290|NCT01878617|DRUG|Vismodegib|ROA: Orally (PO)
223915291|NCT01878617|DRUG|Pemetrexed|ROA: IV
223915292|NCT01878617|DRUG|Gemcitabine|ROA: IV
223915293|NCT01878617|OTHER|Aerobic Training|
224088701|NCT03320655|OTHER|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
223530084|NCT05913687|DIAGNOSTIC_TEST|AIDP|Machine learning algorithm of imaging data
223530085|NCT07158697|BEHAVIORAL|HcELP_CMM|The intervention consists of two phases. Phase 1 is an initial individualized, face-to-face meeting to collaboratively set goals and develop action plan (week 1) and Phase 2 is an ongoing, personalized online support delivered by WeChat platform utilizing the official account, chat function, and synchronized online videos to integrate and sustain healthy lifestyle (weekly, week 2-12). Phase 1 covers 4 core steps: 1) assess symptom burden and lifestyle behaviors; 2) generate and analysis symptom burden and lifestyle report; 3) empowerment-based therapeutic person-centered health communication; and 4) behavior commitment. Phase 2 covers two modules: 1) integrate healthy behaviors to long-term lifestyle, and 2) sustain healthy lifestyle behaviors.
223915294|NCT01878617|OTHER|Neurocognitive Remediation|
223915295|NCT05415397|DRUG|Celecoxib 400mg|Celecoxib add-on (400mg daily) add-on to treatment as usual (standard antidepressant treatment)
223915296|NCT05415397|DRUG|Placebo|Placebo add-on to treatment as usual (standard antidepressant treatment)
223915297|NCT06483334|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion at different dose levels
223915298|NCT06483334|BIOLOGICAL|Enfortumab Vedotin|IV infusion at different dose levels
223915299|NCT06483334|BIOLOGICAL|Pembrolizumab|200 mg IV infusion
223915300|NCT04906460|DRUG|WVE-N531|WVE-N531 is an antisense oligonucleotide (ASO)
223915301|NCT06347003|DRUG|Plozasiran Injection|ARO-APOC3 Injection
223915302|NCT06347003|DRUG|Placebo|sterile normal saline (0.9% NaCl)
223915303|NCT05882357|DRUG|ELX/TEZ/IVA|Fixed-dose combination granules for oral administration.
223915304|NCT05882357|DRUG|IVA|Granules for oral administration
223915305|NCT06524128|DEVICE|Dreeft wheels (EPPUR company)|The braking system (Dreeft wheels) is installed directly on the participant's wheelchair, by a trained occupational therapist. The Dreeft wheels are supplied for a period of 1 month.
223915306|NCT02861573|BIOLOGICAL|Pembrolizumab 200 mg|IV Q3W
223915307|NCT02861573|DRUG|Olaparib 400 mg|Eight 50-mg capsules PO BID
223915308|NCT02861573|DRUG|Docetaxel 75 mg/m^2|IV Q3W
223915309|NCT02861573|DRUG|Prednisone 5 mg|One 5-mg tablet PO BID
223915310|NCT02861573|DRUG|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
223915311|NCT02861573|OTHER|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
223915312|NCT02861573|DRUG|Olaparib 300 mg|Two 150-mg tablets PO BID
223915313|NCT02861573|DRUG|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
223915314|NCT02861573|DRUG|Lenvatinib|20 mg PO QD
223915315|NCT02861573|BIOLOGICAL|Pembrolizumab/Vibostolimab coformulation|IV Q3W
223915316|NCT02861573|DRUG|Carboplatin|IV Q3W
223915317|NCT02861573|DRUG|Etoposide|IV on Days 1, 2 and 3 of each cycle
223915318|NCT02861573|BIOLOGICAL|Belzutifan 120mg|PO QD
223915319|NCT03633708|DRUG|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
223915320|NCT04499534|BIOLOGICAL|Seasonal influenza vaccine|To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination
223915321|NCT05284747|DRUG|Evolocumab|Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
223915322|NCT05284747|DRUG|Routine Lipid Management|Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
224278053|NCT05937126|DIAGNOSTIC_TEST|Culture and antimicrobial susceptibility testing|Standard of care Gram stain, culture and other clinically ordered tests will be performed per standard practice.
223915323|NCT05879991|DRUG|zongertinib (C-14)|Oral solution
223915324|NCT05879991|DRUG|zongertinib|Film-coated tablet
223915325|NCT05879991|DRUG|zongertinib (C-14)|Solution for infusion
223915326|NCT03594734|BEHAVIORAL|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
223915327|NCT03594734|OTHER|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
223915328|NCT06158022|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223915329|NCT06158022|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223915330|NCT03438747|DEVICE|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
223915331|NCT03438747|OTHER|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
223915332|NCT05636176|DRUG|Ziltivekimab|Ziltivekimab subcutaneous (s.c.) injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
223915333|NCT05636176|DRUG|Placebo|Ziltivekimab placebo s.c. injection in a pre-filled syringe or a pen-injector once-monthly for up to 4 years.
224278054|NCT03675763|OTHER|Manual treatment|Craniosacral therapy protocol.
223915334|NCT06159543|BEHAVIORAL|Mango|1.5 cups/day of mango for 12 weeks
223915335|NCT05232253|DEVICE|Cystoelastometer - Urodynamics Testing|The non-invasive cystoelastometer device connects to the drainage end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device a pressure measurement is recorded and stored in the device along with the time and date. The remaining urine is then evacuated through the catheter and device and the cystoelastometer records the volume of urine evacuated. The measurement(s) of bladder pressure and volume as well as the time and date can later be transmitted wirelessly to a smart phone that contains an app for the device.
223915336|NCT05205512|OTHER|Exercise Intervention|Maintain current levels of physical activity
223915337|NCT05205512|OTHER|Questionnaire Administration|Ancillary studies
223915338|NCT05205512|OTHER|Telemedicine|Participate in telehealth exercise intervention
223940300|NCT04794218|OTHER|Placebo/Diluent|N/A delivered intramuscularly
223940301|NCT03552276|DRUG|SUNPG18_07 I (Tildrakizumab 200 mg)|injection
223940302|NCT03552276|DRUG|SUNPG18_07 II (Tildrakizumab 100 mg)|injection
223940303|NCT01644994|COMBINATION_PRODUCT|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
223940304|NCT01401218|OTHER|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
223940305|NCT00176202|DRUG|Divalproex Sodium|Divalproex sodium is a mood stabilizer
223940306|NCT00176202|DRUG|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
223940307|NCT01964781|DRUG|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
223940308|NCT01964781|DRUG|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
223940309|NCT01964781|DRUG|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
223940310|NCT01964781|DRUG|tranexamic acid plus saline|
223940311|NCT01964781|DRUG|saline|
223940312|NCT00378300|DRUG|Oral Probiotics|
223940313|NCT05657210|GENETIC|Mutation|
223940314|NCT04623554|BEHAVIORAL|Prehabilitation program|The prehabilitation program includes combined high-intensity interval training on a cycle ergometer and machine-based resistance exercise of large muscle groups supervised by a physiotherapist. Exercise sessions will take place in physiotherapy departments at local hospitals or in municipality rehabilitation centres 3 times a week during the neoadjuvant chemotherapy period and ending in the week before breast surgery (maximum estimated 29 weeks depending on number of chemotherapy cycles, dose delays and time of breast surgery). Participants will be screened for psychological distress four times and in case of moderate-severe distress be advised to visit the local Cancer Society Support Center where participants will be assessed and offered free services based on their psychosocial needs and available offers. Participation will be monitored.
223940315|NCT05957510|DRUG|Serplulimab|serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
223940316|NCT05957510|DRUG|SOC|the treatment recommended by the investigator
223940317|NCT04362826|BIOLOGICAL|Novel probiotic|Investigational novel probiotic
223940318|NCT04362826|OTHER|Placebo|Placebo for probiotic
223940319|NCT06227494|BEHAVIORAL|Fiber Intervention|Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.
223530086|NCT07158697|BEHAVIORAL|Usual care-maintain daily lifestyle|"Participants in this group will continue with their normal daily lifestyle. WeChat-based follow-up will be performed weekly in the first 4 weeks and bi-weekly in the next 8 weeks. Each follow-up will last for 20 minutes. Follow-up communications will include: (1) general well-being assessments using brief, non-intrusive inquiries (e.g., How have participants felt overall in the past week/two weeks?); (2) disease management monitoring through standardized question tracking significant changes in their underlying diseases, intentionally avoiding exploration of intervention-targeted lifestyle behaviors (e.g., Have participants experienced notable changes in their health status or disease management approach since last contact?); and (3) addressing disease-related inquiries. For any questions inquired by participants in the control group, general advice will be given for ethical consideration."
223530089|NCT06233448|DEVICE|Indirect cardiometry|Measurements of thorathic fluid content
223530090|NCT04972838|BEHAVIORAL|Remaking Recess (RR)|Remaking Recess is a flexible, school-based social engagement intervention for students with autism and their peers. The research team will work with school personnel to deliver RR during recess. RR is tailored based on the needs of schools, students, and staff.
223915339|NCT06320015|BEHAVIORAL|Substance Misuse Assistance Response Team (SMART)|The study intervention is engagement with a Substance Misuse Assistance Response Team (SMART) community health worker-peer recovery specialist (PCHW). SMART PCHWs engage ED patients with substance use disorders and facilitates ED services provision and linkages to outpatient care. Services provided include supporting ED initiation of buprenorphine, harm reduction services, social services (transportation, housing assistance, etc.), and engagement in peer recovery, behavioral health services, and addiction treatment services. Services are provided at the time of the ED visit. A subgroup of patients is provided short term case management and outpatient services navigation depending on PCHW caseload availability and individual needs.
223915340|NCT06320015|OTHER|Usual Care Group|Patient not seen by a SMART community health worker in the emergency department. Care and treatment referral at discretion of emergency department treating team.
223915341|NCT05320406|RADIATION|Radiation therapy|Undergo radiation therapy
223915342|NCT05320406|DRUG|Leuprolide|Given IM or SC
223915343|NCT05320406|DRUG|Relugolix|Given PO
223915344|NCT03058588|GENETIC|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
223915345|NCT05558059|DEVICE|Handheld Optical Coherence Tomography with OCT Angiography|"OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image.~OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients."
223915346|NCT06418204|OTHER|Non-interventional Study|Non-interventional study
223915347|NCT05176093|BIOLOGICAL|Engensis|Lyophilized biologic to be reconstituted containing Engensis
223915348|NCT05176093|OTHER|Placebo|Injectable Liquid
223915349|NCT05835986|DRUG|RO7507062|RO7507062 solution for injection will be administered SC as specified in each treatment part (arm).
223915350|NCT05835986|DRUG|Tocilizumab|When applicable, tocilizumab solution for infusion will be administered intravenously at 8 milligram per kilogram (mg/kg) for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
223915351|NCT06752278|DRUG|Pilocarpine|Pilocarpine is a muscarinic agonist
223915352|NCT06752278|DRUG|artificial tears|artificial tears used for the treatment of Dry eye
223915353|NCT06347380|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
223915354|NCT04007848|DRUG|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
223915355|NCT04007848|DRUG|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
223915356|NCT04706507|DRUG|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
223915357|NCT06810206|OTHER|Bilateral Ultrasound Guidance M-TAPA|transversus abdominis, internal oblique, and external oblique muscles will be identified on the costochondral angle in the sagittal plane at the 10th costal margin. deep angle will be given to the costochondral angle at the edge of the 10th costa with the probe in the sagittal direction to view the lower surface of the costal cartilage in the midline. The needle will be inserted in the cranial direction using the in-plane technique, and the needle tip will be moved to the posterior aspect of the 10th costal cartilage, and saline (5 ml) will be injected to confirm the location by observing dissection between internal oblique muscle and transversus abdominis muscle under the 10th costal cartilage, and local anesthetic will be injected into the lower surface of the chondrium. The local anesthetic to be used is bupivacaine 0.25% with Ultrasound Siemens® ACUSON X300 portable scanner with a high frequency linear transducer (10 MHz) using A Quincke 22 G . x 3½ in. (0.7x88 mm) A spinal needle
223940320|NCT06227494|BEHAVIORAL|Standard Weight Loss Education|Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.
223530091|NCT05272384|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223530092|NCT05272384|PROCEDURE|Computed Tomography|Undergo PET/CT
223915358|NCT06810206|PROCEDURE|Bilateral Ultrasound Guidance EOIPB|"The patients will be positioned in the supine position with the ipsilateral arm in abduction. The transducer will be positioned in a cephalad to caudad parasagittal plane at the anterior axillary line at the level of the sixth and seventh ribs in line with the xiphoid process. Using the in-plane technique, the needle will be advanced from cephalad to caudad until the tip lies in the plane between the external oblique muscle and intercostal muscles between the sixth and seventh ribs. Following hydro-dissection with 2 ml of 0.9% saline to confirm the correct needle tip position, LA injection will be given. The same procedure will then be repeated on the contralateral~* Local anesthetics to be injected: iBupivacaine (0.25%)~* Dose : 25ml on each side~* Device to be used: Ultrasound Siemens® ACUSON X300 portable scanner with a high-frequency linear transducer (10 MHz) that is covered in sterile plastic.~* Needle to be used : A Quincke 22 G . x 3½ inch (0.7x88 mm) spinal needle"
223915359|NCT06810115|OTHER|Viral PCR test|Viral PCR test regardles of symptoms
223915360|NCT06809478|PROCEDURE|Pulpotomy using Chitosan liquid|"1. After complete hemostasis, a cotton pellet damp with chitosan liquid will be applied and gently placed over the pulp stumps for 5 minutes and removed. Then, a thick mix of zinc oxide and eugenol will be placed and gently condensed into the pulp chamber by a moistened cotton pellet.~2. Tooth will be restored with stainless steel crown."
223915361|NCT06809478|PROCEDURE|Pulpotomy using Formocresol|"1. After complete hemostasis, a cotton pellet damp with formocresol will be applied and gently placed over the pulp stumps for 5 minutes and removed. Then, a thick mix of zinc oxide and eugenol will be placed and gently condensed into the pulp chamber by a moistened cotton pellet.~2. Tooth will be restored with stainless steel crown."
223915362|NCT06122168|OTHER|Mandala|verbal interview, standard health care, sheet of paper showing a mandala to be colored at will
223915363|NCT06122168|OTHER|Standard care|verbal interview and standard health care
223915364|NCT06805045|PROCEDURE|augmented reality|To provide augmented reality (AR) guidance during robotic-assisted and laparoscopic surgeries, by overlaying the preoperative 3D virtual anatomical models to intraoperative surgical images (3D AR guidance).
223915365|NCT06808724|PROCEDURE|implant with ozonated oil|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Ozonated oil (Surgy O3) will be applied to the implant surface and then the implant will be inserted into the prepared osteotomy site. A 3 mm high transepithelial abutment will be then screwed using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
223915366|NCT06808724|PROCEDURE|non-activated implant|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. In the control group, the implant will be inserted without any treatment. A 3 mm high transepithelial abutment will be then attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
223915367|NCT06808724|PROCEDURE|implant with plasma activation|Following local anesthesia (mepivacaine HCl 2% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills. Implant will undergo vacuum-plasma activation immediately before insertion (Plasma X Motion, Megagen, Gyeongbuk, South Korea) and then it will be inserted into the prepared osteotomy site. A transepithelial abutment will then be attached using a torque wrench, tightened to 30 Ncm. Single monofilament synthetic polypropylene 4.0 sutures will be used to close the flaps.
223915368|NCT06650891|DRUG|Quercetin|oral quercetin prior to surgery
223915369|NCT06650891|OTHER|Placebo|capsule identical looking to quercetin
223915370|NCT04205604|DRUG|18F-Fluoro Dopa Imaging|Imaging with 18F-Fluoro Dopa PET Imaging
223915371|NCT06653114|OTHER|Education in Chronic Musculoskeletal Pain|Improving Knowledge and Skills in Chronic Musculoskeletal Pain (Assessment and Management)
223915372|NCT06653114|OTHER|Education in Communication Skills|Developing Communication Skills (Empathy, Motivational Interviewing, Shared Decision-making)
223915373|NCT06114628|DRUG|Ganfeborole|Oral daily dosage of 20mg.
223915374|NCT06114628|DRUG|BTZ-043|Oral daily dosage of 1000mg.
223915375|NCT06114628|DRUG|Bedaquiline (B)|Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
223915376|NCT06114628|DRUG|Delamanid (D)|Oral daily dosage of 300mg.
223915377|NCT06114628|DRUG|Pretomanid (Pa)|Oral daily dosage of 200mg.
223915378|NCT06114628|DRUG|Moxifloxacin (M)|Oral daily dosage of 400mg.
223915379|NCT06114628|DRUG|Linezolid (L)|Oral daily dosage of 600mg for the first 8 weeks.
223915380|NCT06114628|DRUG|Pyrazinamide (Z)|Oral daily dosage of 1200mg-2000mg depending on weight.
223915381|NCT06114628|DRUG|Rifampicin (R)|Oral daily dosage of 450mg-750mg depending on weight.
223915382|NCT06114628|DRUG|Isoniazid (H)|Oral daily dosage of 225mg-375mg depending on weight.
223915383|NCT06114628|DRUG|Ethambutol (E)|Oral daily dosage of 825mg-1375mg depending on weight.
223915384|NCT06114628|DRUG|Delpazolid (DZD)|Oral daily dosage of 1200mg
223915385|NCT06114628|DRUG|Quabodepistat (Q)|Oral daily dosage of 30mg
223915386|NCT06086496|DEVICE|GENOSS® DES Sirolimus Eluting Coronary Stent System|The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
223915387|NCT06310161|DEVICE|Bright light|Bright light treatment will consist of using the Re-timer device 3 times per week during dialysis sessions for 4 weeks. The Re-timer is worn like a pair of glasses and contains light emitting diodes mounted on the lower portion of the frame. The Re-timer emits blue-green 500 nm light with an intensity of \~500 lux lm/m2. Participants will be instructed to use the device for 60 minutes at the beginning of each dialysis session.
224278055|NCT05702905|DRUG|Metformin Hydrochloride 500 MG|Metformin oral tablet (500mg per tablet) will be administered in a dose increasing mode: the initial dose will be 500mg twice daily, which will be increased to 1000mg twice daily after two weeks, and then maintained until the end of treatment in total 12 weeks.
223530093|NCT05272384|DRUG|Decitabine and Cedazuridine|Given PO
223530094|NCT05272384|BIOLOGICAL|Nivolumab|Given IV
223530095|NCT05272384|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223915388|NCT06310161|DEVICE|Dim Light|Dim light treatment will use non-light emitting glasses that look identical to Re-Timer for 4 weeks at each dialysis session following baseline assessments. Participants will use the device for 60 minutes at the beginning of their dialysis session.
223915389|NCT03026816|DEVICE|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
223915390|NCT06512883|DRUG|Benralizumab|Benralizumab will be administered as SC injection on Q4W.
223915391|NCT04513054|GENETIC|Blood collection for genetic analysis|Blood collection for genetic analysis
223915392|NCT06604208|DEVICE|Binaural Beats|"The binaural beat device is a health product that is not classified as a medical device. It functions similarly to a music box, providing different frequencies through physiological and psychological induction. This process offers binaural beat information to the Reticular Activating System (RAS) for potential changes in consciousness. The binaural beat frequencies are designed to match the brainwave frequency of light sleep, specifically 3.4 Hz (θ waves), with a base frequency of 440 Hz. The device uses three types of background music-piano music, light music, and string music-as experimental materials.~The binaural beat device offers three modes, allowing users to select different modes based on their comfort and listening preferences. This study requires that the binaural beats be listened to for at least 30 minutes. The device has a built-in app for continuous playback, so users can connect the power and listen throughout the night."
223915393|NCT06604208|DEVICE|Placebo|Placebo
223915394|NCT06828016|OTHER|foot reflexology|foot reflexology, each session lasting 45 minutes to 1 hour
223915395|NCT06828016|OTHER|usual foot care|usual foot care, with each session lasting 45 minutes to 1 hour
224088702|NCT03320655|OTHER|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
224088703|NCT00770848|DRUG|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
224088704|NCT00770848|DRUG|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
224088705|NCT00770848|DRUG|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
224088706|NCT00770848|DRUG|Placebo|Placebo
224088707|NCT00770848|DRUG|Prednisone|5 mg orally BID
224088708|NCT00192374|BIOLOGICAL|CAIV-T, Liquid|
224088709|NCT05395676|DEVICE|Exergame home training programme|Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
223530096|NCT03283007|DRUG|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
223915396|NCT03866837|DIETARY_SUPPLEMENT|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
223915397|NCT03866837|DIETARY_SUPPLEMENT|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
223915398|NCT03866837|DIETARY_SUPPLEMENT|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg \[(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg\].
223915399|NCT03770416|DRUG|Ibrutinib|Given PO
224088710|NCT00391599|PROCEDURE|enema|
224088711|NCT03455673|DIAGNOSTIC_TEST|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (\> 270 ng/ml) = 1"
224088712|NCT01898156|DRUG|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
224088713|NCT04646148|BEHAVIORAL|Yoga classes|All participants are invited to attend weekly yoga classes.
224088714|NCT03276741|DIETARY_SUPPLEMENT|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
223530097|NCT03283007|DRUG|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
223530098|NCT06127199|DEVICE|Ovaprene|Non-hormonal intravaginal ring
223530099|NCT02466919|DRUG|Pantoprazole|H. pylori eradication therapy
223530100|NCT02466919|DRUG|Amoxicillin|H. pylori eradication therapy
223530101|NCT02466919|DRUG|Metronidazole|H. pylori eradication therapy
223915400|NCT03770416|BIOLOGICAL|Nivolumab|Given IV
223915401|NCT06828159|DIETARY_SUPPLEMENT|Wild blueberry|Freeze-dried wild blueberry powder 25g/day
223915402|NCT06828159|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for calories and no polyphenols
224088715|NCT06337201|DEVICE|Test of the application Min Memoria|Focus group interviews will be conducted to reach healthcare professionals' experiences using a written life story in daily care. Then, the information from the written life story will be transferred to the application, and the healthcare professionals will test a digital life story (the application) in daily care instead. Observation studies will be conducted to observe the use of the digital life story. What can be seen in the communication and the interaction, and in what situations is the digital life story used?
224088716|NCT04755829|DEVICE|BreathX test for breath VOCs|Breath samples are collected into an ultra-clean bag and breath VOCs are analyzed with GC-SAW.
224088717|NCT00006449|DRUG|naltrexone (Revia)|
223915403|NCT03235440|BEHAVIORAL|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
223915404|NCT03318159|DRUG|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
223915405|NCT06212193|DEVICE|Trillium™|Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement
223915406|NCT06741007|PROCEDURE|Retroperitoneal pelvic lymphatic and uterine vessel dissection|ICG injection to cervix uteri at 3 and 9 o'clock followed by laparoscopic dissection of retroperitoneal space to detect uterine vessels (uterine arteries, SUVs and DUVs) bilaterally in addition to detect the location and biopsy of SLN stained by ICG.
223915407|NCT05422885|DRUG|Dasatinib|Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks
223915408|NCT05422885|DRUG|Quercetin|Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
223915409|NCT04619173|OTHER|Thoracic manipulation|hot pack ,transcutaneous electrical nerve stimulation and manipulation along with stretching'
223915410|NCT04619173|OTHER|Conventional physical therapy Program|hot pack ,transcutaneous electrical nerve stimulation and stretching
223915411|NCT06854172|BEHAVIORAL|Mindfulness based self-compassion training|Self-compassion training is a program that aims to help individuals develop a kind, understanding and tolerant approach towards themselves. In this training, individuals learn to be more compassionate towards themselves and to share. This training can help manage negative emotional states such as stress, anxiety and stress and can lead to a healthier internal balance. When combined with mindfulness techniques, self-compassion training allows individuals to accept the moment and develop a more compassionate approach towards themselves. It is thought that this training will be applied to the experimental group to develop parents' feelings of self-compassion and positively affect the parameters of caregiver burden, self-efficacy and emotion regulation designed in the study.
223915412|NCT06854276|DRUG|SSS06|SSS06 is a highly glycosylated, long-acting recombinant protein product produced through recombinant gene technology by introducing site-specific mutations into the rHuEPO gene.
223915413|NCT06854276|DRUG|rhEPO|a recombinant human erythropoietin injection.
223915414|NCT06854679|RADIATION|Radiotherapy dose escalation|All patients will receive 45Gy in 25# to mesorectum and elective nodal volumes, and 52.5Gy in 25# as standard to primary gross tumour volume which includes primary tumour, visible nodal disease and extramural vascular invasion if present. Boost dose escalation to a maximum of 60Gy will be delivered to patients with ongoing visible disease from week 2 of treatment onwards.
224088718|NCT00006449|BEHAVIORAL|broad spectrum treatment|
224088719|NCT00006449|BEHAVIORAL|motivational enhancement therapy|
224088720|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation A|
224088721|NCT02141061|DRUG|Telapristone Acetate, Proellex 12 mg Formulation B|
224088722|NCT06549361|OTHER|No interventions need to be specified for this study|No interventions need to be specified for this study
224088723|NCT05749835|OTHER|Thoracic Manipulation and Sustained Natural Apophyseal Glides and conventional therapy|After the segmental mobility examination of thoracic spine, the therapist will apply a high-velocity, end range screw thrust to a restricted segment of the thoracic spine as described by Maitland.
224088724|NCT05749835|OTHER|Sustained Natural Apophyseal Glides and conventional therapy|Position of therapist: stands beside the patient, while his\\her head is cradled between your body and your right forearm (when you stand at his\\her right side). Gentle pressure is now applied in a ventral direction on the spinous process of C7 while the skull remains still due to the control of your right forearm. (The really gentle moving force to do this comes from your left arm via the thenar eminence over the little finger on the spine of C7).
224088725|NCT03226990|OTHER|impression technique|impression technique with and without wax spacer
224088726|NCT04355013|DEVICE|Core emperature monitoring|Monitoring core temperatures with probes placed in the arterial outlet and venous inlet of extracorporeal pump, pulmonary artery, bladder, nasopharinx and forehead using a doublé-sensor probe
224088727|NCT01838057|DEVICE|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
224088728|NCT01838057|OTHER|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
224278056|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL|Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and increased to 1.0mg QW after another 4 weeks, and then maintained 1.0mg until the end of treatment in total 12 weeks.
224278057|NCT05702905|DRUG|Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|Both Semaglutide injection and Metformin oral tablet will be administered as described above.
223530102|NCT02466919|DRUG|Levofloxacin|H. pylori eradication therapy
223915415|NCT06855303|OTHER|Muscle Energy Teqnique using post isometric relaxation (PIR) principle|The contralateral leg may be either flexed or may lie straight on the plinth. The affected leg will be flexed at both the hip and knee joints, and then slowly straightened by the therapist until the restriction barrier is identified. The limb will be moved a little away from the restriction barrier and the isometric contraction against resistance is introduced. The patients will be asked to resist the movement with no more than 25% of strength. The contraction will be held for 7-10 seconds followed by complete relaxation of the limb. On exhalation, the knee joint will be straightened (extended) towards its new barrier, and through that barrier a stretch will be applied and maintained for 30 seconds. 3 repetitions
223915416|NCT06855303|OTHER|Muscle Energy Teqnique using receprocal inhibition (RI) principle|The supine patient will ask to fully flex the hip and knee on the affected side. The affected leg will then be slowly straightened by the therapist until the restriction barrier is identified. The calf of the affected leg will then be placed on the practitioner's shoulder that stands facing the head of the table on the side of the affected leg. Then the patient will be asked to attempt to straighten the lower leg utilizing the antagonists to hamstrings, employing approximately 20 percent of the strength of the quadriceps. This will be resisted by the practitioner for 5 to 7 seconds. Appropriate breathing instructions will be given. On exhalation, the knee joint will be straightened (extended) towards its new barrier and through that barrier a stretch will be applied and maintained for 30 seconds. 3 repetitions)four repetition
223915417|NCT06855303|OTHER|Conventional Treatment group|This group will receive a 10 minutes application of high-frequency TENS. Hot moist pack: The patient will be made to lay in a supine position with the affected knee in slight flexion A hot moist pack will be applied around the knee for 15 minutes. Ankle pumps, Heel slides, Open chain knee flexion and extension exercises, Straight leg raise, Quad isometrics and Calf stretch. All these exercises were given 10 repetitions x1 set, three days/week
223915418|NCT06812676|DEVICE|Virtual Reality Goggles|The VR group will be given a VR headset to wear during the nasal endoscopic procedure at the clinic.
223915419|NCT06420687|DEVICE|Clinically prescribed prosthesis|Clinically prescribed prosthesis:
223915420|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + 1-DOF|1-DOF wrist rotation and1-DOF hand
223915421|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Wrist flexion +1-DOF|2-DOF wrist (rotation and flexion) and 1-DOF hand
223915422|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + Multi DOF hand|1-DOF wrist rotation and multi-DOF hand
223915423|NCT06420687|DEVICE|Experimental prosthesis - Wrist rotation + wrist flexion + Multi DOF hand|2-DOF wrist (rotation and flexion) and multi-DOF hand
223915424|NCT06811792|PROCEDURE|Intrathecal Therapy|Patients who underwent at least one lumbar puncture and spinal canal administration of glucocorticoids during hospitalisation were classified as receiving intrathecal (IT) therapy. Dexamethasone was the glucocorticoid administered intrathecally at a dose of 5 mg per administration. All patients also received oral or intravenous anti-TB regimens, which included at least isoniazid and rifampicin for drug-sensitive TBM cases. Patients diagnosed with or suspected of having drug-resistant TBM who required second-line anti-TB drugs were excluded from the study.
223915425|NCT06813144|OTHER|inspiratory muscle exercise|Inspiratory muscle training will be given with or without smart adaptor.
223915426|NCT05236764|DEVICE|CliniMACS|Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
223915427|NCT06854978|OTHER|RETHA|The study will enroll up to 10 participants with stroke who will be paired with trained therapists to receive R3THA telerehabilitation. The participants with stroke will participate in 7 training sessions. The training includes hand and arm exercises.
223915428|NCT06806202|DRUG|conventional 2% lignocaine at room temperature|This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar nerve blocks (IANB) in mandibular permanent molars
223915429|NCT06806202|DRUG|pre-warmed 2% lignocaine at 42°C|This study aims to compare the effectiveness of warm 2% lignocaine (lidocaine) versus conventional room temperature 2% lignocaine for achieving successful inferior alveolar nerve blocks (IANB) in mandibular permanent molars
223915430|NCT06812702|OTHER|Observational|Observational
223915431|NCT06812702|PROCEDURE|Skin Biopsy|Participants may consent to additional skin biopsy at baseline and at the one-year follow-up. Skin will be taken paravertebrally at approximately the C8 level.
223915432|NCT06808503|BEHAVIORAL|NIMH Clinical Pathway|Complete the implemented workflow and tools for suicide risk screening, assessment, safety planning and follow-up.
224088729|NCT04200612|BEHAVIORAL|Equine-Assisted Psychotherapy|Equine-Assisted Psychotherapy (EAP) involves working on the psychological goals set between the client and the mental health professional. This is done through the experiential interactions between the clients and the horse. This experiential aspect is vital as it allows clients to process the emotions, thoughts and behaviors that were expressed during sessions with the horse.
224088730|NCT04200612|BEHAVIORAL|Equine-Assisted Activities|Simple interactions with the horses that does not necessarily involve any goals being set between the client and the personnel handling the session. These can involve activities such as grooming or petting of the horse.
223530103|NCT02466919|DRUG|Clarithromycin|H. pylori eradication therapy
223530104|NCT05916040|DEVICE|Radiotherapy with MRIdian with simultaneous integrated boost|radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost
223530105|NCT05916040|OTHER|Questionnaires before, during and after radiotherapy|"Questionnaires consisting of 3 quality of life scales and 1 mental state scale:~* EORTC QLQ-C30~* EORTC QLQ-CR29~* Low Anterior Resection Syndrome Score (LARS) questionnaire~* Hospital Anxiety and Depression Scale (HADS) questionnaire"
223530106|NCT03737136|DRUG|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
223530107|NCT05553249|BEHAVIORAL|Written Exposure Therapy|Virtual, group-based Written Exposure Therapy
223530108|NCT04630808|DRUG|NCX 470 0.1%|NCX 470 Ophthalmic Solution, 0.1%
223530109|NCT04630808|DRUG|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005%
224088731|NCT04200612|OTHER|Placebo-control group|This group will only be watching movies related to horses and they are told that this is another form of EAP even though this is not the case. This type of intervention has not been known to provide any therapeutic effect relevant to the study and thus is used as the placebo-control.
223915433|NCT06812364|PROCEDURE|one level ESPB|Ultrasound will be sagittal placed against the target vertebral level T7 vertebrae in the lateral or sitting position and moved in approximately 3-cm lateral to the spinous process. The Erector Spinae muscle and transverse process will be then identified, and a blunted tip ,100mm, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) will be advanced, using the in-plane approach, in caudal -to- cephalad direction, through the inter fascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 3 ml normal saline to confirm the correct needle tip position. The block will be performed bilaterally by injecting 60 mL of 0.25% bupivacaine (30mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the T7 vertebrae
223915434|NCT06812364|PROCEDURE|two level ESPB|"The target vertebral levels are T5 transverse process (at the level of Sternal Angle, above T7 by tow vertebra)(19) and T10 transverse process (at the level of Xiphisternal Junction, below T7 by 3 vertebrae).~The block will be performed bilaterally by injecting 60mL of 0.25% bupivacaine (15mL into each of four site) into the fascial plane between the deep surface of the Erector Spinae muscle and the bilateral transverse processes of the thoracic vertebrae 5 and 10 (at the most lateral part of the transverse process) in the same technique."
223915435|NCT06852716|OTHER|Health education based on BCW theory|The intervention stage lasted for 3 months. The intervention measures in the intervention stage were as follows: stimulate the motivation to change (M), guide and motivate MCI patients to establish the health belief of insisting on long-term home oxygen therapy, and strengthen the importance and necessity of self-management; Training in behavioural change (C) Dissemination and presentation of knowledge manuals; Guide patients to correctly understand the definition, causes, clinical manifestations and hazards of COPD and MCI related diseases to improve their cognition and prevention awareness of the disease; Create a behavior change environment (O), provide a platform for patient communication, share and demonstrate home oxygen therapy skills, and improve long-term home oxygen therapy compliance. Along with the Visit stage: Collect relevant data during the patient's outpatient visit or home visit to understand the patient's long-term home oxygen therapy situation.
223915436|NCT06852716|OTHER|Routine health education|(1) Give disease-related knowledge guidance according to nursing routine; (2) Guide patients and their families to standardize oxygen inhalation and ensure that patients correctly master oxygen inhalation operation methods; (3) Patiently answer patients' doubts about the disease, encourage patients to treat the disease with a positive attitude, and establish a good relationship of trust with patients and their families.
223915437|NCT06813183|OTHER|The palmar grasping reflex|"In the experimental group, the baby is monitored under a radiant heater before the procedure. After the infant's initial physiologic parameters and NIPS are recorded, the palmar grasp reflex is stimulated just before the procedure begins. The palmar grasp reflex can be stimulated by moving an object distally across the palm of the hand. In newborns, the right hand is more dominant than the left hand in the palmar grasp reflex ( Fagard et al., 2017). The researcher will stimulate the palmar grasp reflex by moving the index finger distally along the palm of the infant's right hand. The reflex stimulation will be continued until the end of the 5th minute.~Physiologic parameters will be scored by the investigator and a second nurse with at least 5 years of experience in neonatal intensive care and recorded on the follow-up form by scoring the pain levels 1 minute before (0 min), during, 2 and 5 min after the heel pricking procedure in the neonates in the NIPS intervention groups via the be"
223915438|NCT06854926|BEHAVIORAL|Helping relationship from significant others|Helping relationship from significant others is the intervention of this study. We will use four strategies, including warning mechanisms, target setting, encouragement, and feedback.
223915439|NCT06854926|BEHAVIORAL|Usual team|Patients of this team accept usual care
223915440|NCT06854848|BIOLOGICAL|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223915441|NCT06854848|BIOLOGICAL|urine sample|10 ml
224088732|NCT04274439|OTHER|Internet-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.
224088733|NCT04274439|OTHER|Online Booklet|An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
224088734|NCT00003956|DRUG|fluorouracil|
224088735|NCT00003956|DRUG|leucovorin calcium|
224088736|NCT00003956|DRUG|lonafarnib|
224278058|NCT05702905|BEHAVIORAL|calorie-restricted diet|All subjects after randomization will be reviewed and evaluated by a nutritionist, and then will receive diet guidance. The clinical nutritionist will develop a written nutrition plan for each subject. The nutrition plan of this study adopted the method of calorie restriction diet (CRD) to develop a diet, which required 83.68 kJ/kg of energy per day, 1.2 g/kg of protein per day, 40%\~55% of carbohydrate energy supply ratio, and 20%\~30% of fat energy supply ratio, to ensure the intake of vegetables, fruits and other rich dietary fiber, and drinking more than 1.5 L per day. The nutritionist will explain the method of food exchange in detail to enrich the food types of patients. The diet diary will be distributed to each subject, and the subjects will be required to make a return visit once every four weeks, return the diet diary each time, and receive guidance according to their compliance.
223530110|NCT06011187|PROCEDURE|Routine care|Fluid administration will be given per routine care MAP between 65 - 70 mmHg
224088737|NCT03011229|DEVICE|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
224088738|NCT03011229|DEVICE|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
224088739|NCT03224286|DEVICE|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
223530111|NCT06011187|DEVICE|AFM|AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg
223915442|NCT06854263|DEVICE|skin marking for radiotherapy treatment|skin marking for radiotherapy treatment
223915443|NCT06854666|OTHER|effectiveness of platelet-rich plasma (PRP) in treating lateral epicondylar tendinopathy (LET)|"The intervention involves the administration of PRP (platelet-rich plasma), L-PRP (leukocyte-rich platelet-rich plasma), and saline according to a protocol developed for patients with lateral epicondylitis (EPi lat). The intervention includes specific parameters such as centrifugation speed and dual injection to the painful site, which is repeated after one week.~Following the procedure, treatment continues with a rehabilitation program, including the use of an orthosis. The orthosis serves as support during the recovery process after the injection. The rehabilitation program and the use of the orthosis aim to improve joint function and reduce pain, supporting tissue healing and regeneration."
223915444|NCT06854887|DEVICE|digital breast tomosynthesis and mammography|tomosynthesis is 3D image for the breast mammography is 2D image for the breast
223915445|NCT06853600|DIETARY_SUPPLEMENT|Rhodiola Rosea Capsules|One of the most practical and accessible options for mitigating the occurrence of mental fatigue is the strategic use of nutritional supplements. Several nutritional supplements have been shown to reduce behavioural or subjective markers of mental fatigue, including caffeine, creatine, panax ginseng, and various vitamins or minerals. Among these, Rhodiola Rosea (RR), a supplement with purported adaptogenic and ergogenic properties, has gained attention. Several randomized controlled trials have reported reductions in mental fatigue after RR supplementation without adverse effects. The main objective of this study was to explore the effects of four days of Golden Root Extract (RR) supplementation on mental fatigue, visuo-cognitive processing, strength performance, and perceived exertion in young, healthy individuals.
223915446|NCT04084574|BEHAVIORAL|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
224088740|NCT00004255|BIOLOGICAL|anti-thymocyte globulin|
223530112|NCT04795531|DRUG|Insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
223915447|NCT06812273|BEHAVIORAL|STM Training|This condition consists of an up/down spectral-temporal modulations (STM) presented both in quiet and with competing background noise
223915448|NCT06812273|BEHAVIORAL|Speech Training|Participants will train on the identification of three sets of speech stimuli of increasing linguistic complexity: individual phonemes (vowels), spondaic words, and matrix sentences.
223915449|NCT06812273|BEHAVIORAL|Mixed Training|This condition involves both the STM and the speech training, described above, and an additional module training localization.
224088741|NCT00004255|BIOLOGICAL|filgrastim|
224088742|NCT00004255|DRUG|cyclophosphamide|
224088743|NCT00004255|DRUG|fludarabine phosphate|
224088744|NCT00004255|DRUG|methylprednisolone|
224088745|NCT00004255|DRUG|tacrolimus|
223915450|NCT06812273|BEHAVIORAL|Gamified Training|"This uses auditory training within a game experience where players control a game avatar (the wisp) that appears to fly through a landscape. Players were asked to help the wisp avoid obstacles or choose from among options based on a variety of sound cues."
223915451|NCT06812273|BEHAVIORAL|Foraging Training|This adds a component to the game where participants navigate the wisp to the location on the screen that relates to the target stimulus. The concept here is that searching for targets with manual movements, ecologically stimulates sensori-motor loops where the actions of the participants generates the auditory stimuli that are heard.
223915452|NCT06654960|DRUG|HRS9531 injection|HRS9531 injection single dose.
224088746|NCT00004255|PROCEDURE|allogeneic bone marrow transplantation|
224088747|NCT00004255|PROCEDURE|in vitro-treated bone marrow transplantation|
223530113|NCT04795531|DRUG|Placebo insulin icodec|"You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
223530114|NCT04795531|DRUG|Insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
224088748|NCT00004255|RADIATION|radiation therapy|
224088749|NCT06959953|OTHER|Low-cost model|The primary structure of a low-cost training model fashioned from an old portable 3-drawer organizer unit repurposed to serve as the foundation for the training apparatus. This training apparatus will act as the experimental arm to compare it to the Airway Part-Task Trainer in FBTI.
224088750|NCT06959953|OTHER|Airway Part-task Trainer|Training using Airway Part-Task Trainer
224088751|NCT02204904|GENETIC|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
224088752|NCT05567562|COMBINATION_PRODUCT|dual anti-platelet therapy|dual anti-platelet therapy
224088753|NCT05567562|DRUG|Placebo|Placebo
224088754|NCT00408005|DRUG|Asparaginase|Given IM or IV
223530115|NCT04795531|DRUG|Placebo insulin degludec|"You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections"
224088755|NCT00408005|DRUG|Cyclophosphamide|Given IV
224088756|NCT00408005|DRUG|Cytarabine|Given IT, IV, or SC
224088757|NCT00408005|DRUG|Daunorubicin Hydrochloride|Given IV
224088758|NCT00408005|DRUG|Dexamethasone|Given IV or PO
224088759|NCT00408005|DRUG|Doxorubicin Hydrochloride|Given IV
224088760|NCT00408005|OTHER|Laboratory Biomarker Analysis|Correlative studies
224088761|NCT00408005|DRUG|Leucovorin Calcium|Given PO
224088762|NCT00408005|DRUG|Mercaptopurine|Given PO
224088763|NCT00408005|DRUG|Methotrexate|Given IT or PO
224088764|NCT00408005|DRUG|Nelarabine|Given IV
224088765|NCT00408005|DRUG|Pegaspargase|Given IM or IV
223915453|NCT06654960|DRUG|Metformin Hydrochloride tablets|Metformin Hydrochloride tablets 500mg.
223915454|NCT06812182|BEHAVIORAL|nurse guided clinical pathway|"Educational training sessions were provided to care providers for one week. Pre-operative; counseling and education of patient for chest physiotherapy, using spirometry, bowel preparation, early mobilization and how to predict common complications with learning to cooperate with nurses. Emphasis on patients to co-operate postoperatively was strongly stressed in spite of the pain and weakness.~Intra-operative: Optimal fluid management, short acting anesthetics, regional analgesia, opioids-sparing anesthesia, small incisions, avoiding drains, maintaining normothermia, venous thrombo-embolism \[VTE\] prophylaxis and antibiotic prophylaxis were routinely done.~Post-operative: Early oral nutrition, optimal fluid management, multimodal non-opioid analgesia, postoperative nausea and vomiting PONV prophylaxis, stimulation of gut motility, early removal of catheters and drains, early mobilization, chest physiotherapy and using spirometry effectively."
223915455|NCT06854198|OTHER|Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry|Participants will be called and offered a screening appointment. At the appointment, visual acuity, OCT, color fundus photography, tonometry, and visual field testing will be performed. The images will be assessed for abnormalities. Participants meeting referral criteria will be referred for a comprehensive eye examination with an eye care provider.
223915456|NCT06854198|OTHER|Educational Brochure|A brochure about glaucoma screening will be mailed to participants. The brochure will include contact information of a staff member who can schedule an appointment for a comprehensive eye examination.
223915457|NCT06808334|OTHER|CLAIR|Subject will have retinal images obtained and uploaded to CLAiR Software. Subjects are not directly in contact with CLAiR software. There is no medical intervention.
223915458|NCT06811246|DRUG|Islatravir (ISL)|Oral administration of a single dose in period 1 and period 2
223915459|NCT06811246|DRUG|Lamivudine (3TC)|Oral administration of multiple daily doses for 27 days
223915460|NCT06812624|OTHER|There is no intervention in this study.|This study is planned as a retrospective cross sectional study. Only the information of the patients will be used.
223915461|NCT06654596|DRUG|Telitacicept 240mg|Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.
223915462|NCT06654596|DRUG|Glucocorticoid|Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
223915463|NCT06810791|DRUG|HVA|Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 14. Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.
223915464|NCT06810791|DRUG|VA|VEN is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from day 3 to day 28, and AZA (75 mg/m2) is given subcutaneously from day 1 to 7.
223915465|NCT06810791|DRUG|Standard Chemotherapy|Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is given by venous drip daily at 60mg/m2, from day 1-3, combined with Ara-C at 100mg/m2 by continuously venous drip from day 1-7.
223915466|NCT06811753|PROCEDURE|robotic surgery|minimally invasive surgery
223915467|NCT06811883|DEVICE|LIGHTBACK|This group will perform a standard 20-minute warm-up, and the LIGHTBACK protocol is also included.
223915468|NCT06811883|DEVICE|Placebo|This group will perform a standard 20-minute warm-up, but the LIGHTBACK protocol is not included and a similar placebo is used.
223915469|NCT03492424|DEVICE|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
223915470|NCT03872401|DRUG|Evolocumab|Administered subcutaneously using an autoinjector pen.
223915471|NCT03872401|DRUG|Placebo|Administered subcutaneously using an autoinjector pen.
223915472|NCT04257461|DRUG|Fluoropyrimidine|Monotherapy: 12 cycles of 5FU or 8 cycles of Capecitabine. The choice of fluoropyrimidine must be specified prior to randomisation.
223915473|NCT04257461|DRUG|Oxaliplatin|Bichemotherapy: Oxaliplatine combined with Fluoropyrimidine.
223915474|NCT06108479|DRUG|DF6215|Immunotherapy (cytokine) targeting effector cells.
223915475|NCT06108479|DRUG|pembrolizumab|Anti-PD-1 immunotherapy agent
223915476|NCT06108479|DRUG|KEYTRUDA®|Anti-PD-1 immunotherapy agent
223915477|NCT03495128|OTHER|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
223530116|NCT05272878|DRUG|IRBESARTAN, tablet, 150 mg|IRBESARTAN will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
223915478|NCT03495128|OTHER|Reconditioning|daily resistance training (for 3 days) on one leg
223915479|NCT04784416|DEVICE|Active tPBM-2.0|The NIR continuous wave (average irradiance = 300 mW/cm2) will be used. The duration or irradiation will be for \~11 minutes (666 seconds).
223915480|NCT04784416|DEVICE|Sham tPBM-2.0|"The sham mode (0 mW/cm2) will be used. The duration or sham irradiation will be for \~11 minutes (666 seconds)."
223915481|NCT04784416|DRUG|18F-MK-6240|PET tracer to be injected prior to PET imaging session, which will occur during baseline assessments
223915482|NCT06617416|DRUG|Cadonilimab (AK104)|AK104 ivgtt Q3W
223915483|NCT06617416|DRUG|Sugemalimab|1200mg Q3W
223915484|NCT06508567|RADIATION|High Dose Rate Brachytherapy|2 fractions of MRI-guided HDR Brachytherapy (13Gy each) delivered over 14 days (± 7 days).
223915485|NCT03595202|DRUG|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
223915486|NCT03595202|DRUG|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
223915487|NCT05388812|OTHER|Treatment As Usual Vocational Rehabilitation (TAU-VR)|TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job
224088766|NCT00408005|DRUG|Prednisone|Given IV or PO
224088767|NCT00408005|RADIATION|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
224088768|NCT00408005|DRUG|Thioguanine|Given PO
224088769|NCT00408005|DRUG|Vincristine Sulfate|Given IV
224088770|NCT00962845|DRUG|hydroxychloroquine|200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
224088771|NCT06475300|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224088772|NCT06475300|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
223915488|NCT05388812|OTHER|Individual Placement and Support (IPS)|The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
223915489|NCT04502186|BEHAVIORAL|Raising Our Spirits Together|Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
223915490|NCT04502186|OTHER|Enhanced Control Condition|The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
223915491|NCT06313060|DIETARY_SUPPLEMENT|Coca-cola|200 ml of Coca-Cola will be administered and must be ingested within a maximum of 10 minutes
223915492|NCT03233854|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
224088773|NCT04809766|BIOLOGICAL|Autologous Mesothelin-specific TCR-T Cells|Receive FH-TCR Tᴍsʟɴ IV
224088774|NCT04809766|DRUG|Cyclophosphamide|Given IV
224088775|NCT04809766|DRUG|Fludarabine|Given IV
224088776|NCT04809766|DRUG|Bendamustine|Given IV
224088777|NCT04526106|DRUG|RLY-4008|RLY-4008 is an oral inhibitor of FGFR2
224088778|NCT03155997|DRUG|Abemaciclib|Administered orally.
224088779|NCT03155997|DRUG|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
224088780|NCT01848145|DRUG|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of \>= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE \>= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
224088781|NCT04067518|BIOLOGICAL|SHP674|SHP674: powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m\^2: 2500 IU/m\^2 every 14 days if BSA \<0.6 m\^2: 82.5 IU/kg every 14 days
224278059|NCT05702905|BEHAVIORAL|physical exercise|All subjects after randomization will be reviewed and evaluated by a trainer, and then will receive guidance of physical exercise.The trainer will formulate an exercise plan for each subject. The exercise plan consists of 30 minutes of moderate and low intensity continuous aerobic exercise every day, with a frequency of 5-7 days/week. The form of exercise can be determined according to personal hobbies, such as fast walking, jogging, climbing, swimming, etc. The exercise diary will be distributed to each subject, and the subjects are required to make a return visit once every four weeks, return the exercise diary each time, and the trainer will provide guidance to the subjects according to their compliance.
223915493|NCT03233854|DRUG|Cyclophosphamide|Given IV
223915494|NCT03233854|DRUG|Fludarabine Phosphate|Given IV
223915495|NCT03233854|OTHER|Laboratory Biomarker Analysis|Correlative studies
224088782|NCT01743833|OTHER|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
224088783|NCT01743833|OTHER|Scapular High Velocity, Low Amplitude Thrust Maneuver|
224088784|NCT00505947|DRUG|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
224088785|NCT00505947|DRUG|placebo|placebo 5 mg/Kg body weight by intravenous infusion
224088786|NCT01781455|DRUG|BBI503|
224088787|NCT04508387|PROCEDURE|Group HH (heated-humidified)|Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.
224088788|NCT00862251|DRUG|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
224088789|NCT00862251|DRUG|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
224088790|NCT00862251|DRUG|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
224088791|NCT00862251|DRUG|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
224088792|NCT00241332|DRUG|fentanyl|
224088793|NCT05265767|BIOLOGICAL|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene|Auto CD34+PBSC transduced with a lentiviral vector encoding a novel coagulation factor VIII transgene administered by IV infusion following conditioning regimen.
224088794|NCT00675025|DRUG|Donepezil hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
224088795|NCT00294944|DRUG|Idazoxan|
224278060|NCT03393780|DRUG|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
224278061|NCT04516187|DIAGNOSTIC_TEST|signs and symptoms, blood tests|signs and symptoms as observed by the treating physician + blood tests (CRP, Procalcitonin, White blood cell count)
223915496|NCT03233854|OTHER|Questionnaire Administration|Ancillary studies
223915497|NCT03233854|DRUG|NKTR-255|Given IV
223915498|NCT06774664|BIOLOGICAL|SCTC21C|Drug: SCTC21C Administered SC
223915499|NCT04175470|DRUG|Bevacizumab|10 mg/kg intravenously every three weeks
223915500|NCT04175470|DIETARY_SUPPLEMENT|Tocotrienol|Capsules, 300 mg orally three times daily
223915501|NCT02215265|DRUG|Cisplatin|Chemotherapy
223915502|NCT02215265|RADIATION|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
223915503|NCT05335122|DRUG|OTX-TIC low dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
223915504|NCT05335122|DRUG|OTX-TIC high dose Travoprost Intracameral Implant|OTX-TIC implant is injected into the anterior chamber of the eye.
223915505|NCT05335122|DRUG|Durysta, Bimatoprost Intracameral Implant 10 µg|Durysta is injected into the anterior chamber of the eye.
223915506|NCT06754852|DRUG|HMB-002 (Part A)|HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.
223915507|NCT06754852|DRUG|HMB-002 (Part B)|HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.
223915508|NCT06220162|DRUG|chidamide in combination with venetoclax and azacitidine (VAC)|Enrolled patients were given chidamide 10 mg every day on days 1-14, azacitidine 75mg/m2 every day on days 1-7, and oral venetoclax began at 100mg on day 1 and increased stepwise over 3 days to reach the target dose of 400mg (100mg, 200mg, and 400mg) on days 1-28. Dose adjustments for concomitant venetoclax with CYP3A4 inhibitors were made according to the literature.
223915509|NCT02944968|DEVICE|THERMOCOOL SMARTTOUCH® SF-5D catheter|
223915510|NCT04663204|DRUG|Sparsentan|Target dose of 400 mg daily
223915511|NCT03686748|BEHAVIORAL|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
223915512|NCT03686748|BEHAVIORAL|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
223915513|NCT05732272|DRUG|Bupropion|150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
223915514|NCT05296746|DRUG|Ribociclib (neoadjuvant)|Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
223915515|NCT05296746|DRUG|Chemotherapy (adjuvant)|Adjuvant chemotherapy. 3 regimens are permitted.
223915516|NCT05296746|DRUG|Ribociclib (adjuvant)|Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
223915517|NCT06430918|OTHER|physical examination, questionnaires and inventories|Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
223915518|NCT05875506|DRUG|Ozone gel|(Ozene; Premier Research Labs, lp, 3500-b Wadley pl, Austin, TX, USA. 78728) applied in dry socket
223915519|NCT05875506|DRUG|doxycycline hyclate saturated chitosan dressing|doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
223915520|NCT03307915|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
223915521|NCT03307915|BIOLOGICAL|MVA-Mosaic|Participants will receive MVA-Mosaic 10\^8 pfu as IM injection at Weeks 24 and 36.
223915522|NCT03307915|BIOLOGICAL|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
223915523|NCT03307915|DRUG|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
224088796|NCT01799876|PROCEDURE|Autologous Cell|
224088797|NCT01799876|PROCEDURE|Standard microfracture arthroscopic surgery|
224088798|NCT00773487|OTHER|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
224088799|NCT02371850|DRUG|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
224088800|NCT00050102|DRUG|MDX-010 (CTLA-4)|
224088801|NCT01296048|DEVICE|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
224088802|NCT02692625|DIETARY_SUPPLEMENT|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
224088803|NCT02692625|DIETARY_SUPPLEMENT|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
224088804|NCT04225325|COMBINATION_PRODUCT|SYMTUZA|DESCOVY+REZOLSTA
224278062|NCT00327587|DRUG|Valsartan + amlodipine|
224278063|NCT00327587|DRUG|Valsartan + HCTZ|
224278064|NCT00327587|DRUG|Amlodipine + HCTZ|
224278065|NCT00327587|DRUG|Valsartan + amlodipine + HCTZ|
223915524|NCT06815380|OTHER|No Intervention|This is non-interventional study.
223915525|NCT06842394|OTHER|Adaptive E-learning|An adaptive e-learning program comprising 13 modules each unfolding and testing the learners knowledge and ability to assess own competence regarding specific acute and time critical medical patient conditions.
223915526|NCT06814457|PROCEDURE|a nursing care bundle on oral intake|a nursing care bundle on oral intake will be started the day after their successful extubation and extend for 14th days. Additionally, the participants will be provided with a brief education on safe swallowing.
223915527|NCT06815549|DRUG|Fluorothiazinone, tablets 300 mg|patients will receive Fluorothiazinone, tablets 300 mg at a dose 1200 mg/day (2 tablets twice a day) for 14 days
223915528|NCT06815549|DRUG|Nitrofurantoin 100 MG|Comparison arm patients will receive Nitrofurantoin in accordance with the instructions for medical use.
223915529|NCT06814522|DRUG|Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate|25 mg, single dose of synthetic psilocybin
223915530|NCT06814379|BEHAVIORAL|Rehabilitation|"30-60 minutes. A total of 3 session/week at home. 4 weeks.~* Warm-up.~* Aerobic: walking (20-25 minutes).~* Strength: (25-30 minutes).~* Cooling.~* Education: WHO recommendations."
223915531|NCT06814379|BEHAVIORAL|Virtual reality based rehabilitation|"30-60 minutes. A total of 3 session/week (2 sessions at home and 1 session at the University of Granada). 4 weeks.~The 2 sessions at home will be the same as the sessions in the rehabilitation group (group 2).~The session at the University of Granada will be done with virtual reality (Nintendo Switch) and will follow the same outline as the rest of the sessions:~* Warm-up.~* Aerobic: walking (20-25 minutes).~* Strength: (25-30 minutes).~* Cooling.~* Education: WHO recommendations."
223915532|NCT06815679|DRUG|salbutamol 2.5 mg via vibrating mesh nebulizer (VMN)|To evaluate the patient's respiratory effort, the pressure-time product (PTPes) and the delta of Pes oscillations during inspiration (∆ Pes) will be obtained from the analysis of the Pes curve. Global and regional pulmonary tidal volumes will be evaluated with Electrical Impedance Tomography
223915533|NCT06808867|DIETARY_SUPPLEMENT|Placebo|Eligible subjects will receive Placebo to take daily for six weeks
223915534|NCT06808867|DIETARY_SUPPLEMENT|Dietary Supplement with Active Ingredient Blend|Eligible subjects will receive Active supplement to take daily for six weeks
223915535|NCT06842290|PROCEDURE|Botulinum toxin-A injection|Botulinum toxin-A Injection Mentalis muscle in lower anterior teeth
223915536|NCT06842290|PROCEDURE|Coronally advanced flap|Coronally Advanced Flap andDe-epithelized Free Gingival Graft
223915537|NCT06842810|DIAGNOSTIC_TEST|Serum FGF21 measurement by Enzyme- linked immunosorbent assay (ELISA)|Venous 5 ml blood will be collected, then centrifugation at the speed of 2000-3000 rpm for 20-min., supernatant will be collected and stored at -20°C for later analysis then tha sample will be tested for fibroblast growth factor 21
223915538|NCT06841965|DRUG|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
223915539|NCT06777576|DEVICE|Hands-free exoskeleton|"A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces."
223915540|NCT02905331|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
223915541|NCT02905331|DRUG|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
223915542|NCT01385202|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
223915543|NCT03368729|DRUG|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
223915544|NCT03368729|DRUG|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
223915545|NCT05677594|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|Magnetic resonance imaging of the entire body from skull base through distal thighs/knees without contrast material
223915546|NCT06594497|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
223915547|NCT06594497|OTHER|Conventional Physiotherapy + Kinesthetic motor imagery training|Conventional Physiotherapy + Kinesthetic motor imagery training
224088805|NCT04225325|COMBINATION_PRODUCT|DESCOVY+DOLUTEGRAVIR|DESCOVY+DOLUTEGRAVIR
223530117|NCT05272878|DRUG|Placebo, tablet, 150 mg|Placebo will be introduced at 150 mg orally one daily, with a progressive increase to 300 mg a day, at 7 days or 2 months follow-up visit.Treatment will be continued for 12 months, unless a side effect would occur.
224088806|NCT04225325|COMBINATION_PRODUCT|SYMTUZA+DOLUTEGRAVIR|DESCOVY+REZOLSTA+DTG
224088807|NCT02033356|PROCEDURE|Adductor canal block with lidocaine 1%|US-guided adductor canal block
224088808|NCT02033356|DRUG|Lidocaine|
224088809|NCT01403909|DEVICE|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
224088810|NCT01403909|PROCEDURE|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
224088811|NCT00891995|DEVICE|Closed loop|Closed loop therapy for up to 4 to 6 days
224278066|NCT01240850|DRUG|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
224278067|NCT01240850|DRUG|Prednisone|
224278068|NCT03185741|BEHAVIORAL|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
224278069|NCT03185741|BEHAVIORAL|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
223915548|NCT03681262|DEVICE|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
223915549|NCT03681262|DEVICE|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
223915550|NCT06753747|DRUG|Palbociclib|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle.
223915551|NCT06753747|DRUG|Afatinib(30mg)|Afatinib will be administered orally at a dose of 30 mg once daily (QD) in each 4-week cycle.
223915552|NCT06753747|DRUG|Afatinib(40mg)|Afatinib will be administered orally at a dose of 40 mg once daily (QD) in each 4-week cycle.
223915553|NCT06753747|DRUG|Afatinib(RP2D)|In the Phase 2 study, the recommended Phase 2 dose (RP2D) of Afatinib, determined during the Phase 1b portion, will be utilized.
223915554|NCT05774665|DRUG|Omega 3|Omega-3 fatty acid enriched for eicosapentaenoic acid (EPA)
223915555|NCT05774665|OTHER|Placebo|Placebo consisting of soybean oil (about 54% omega-6 and 6% omega-3, but no EPA or docosahexaenoic acid (DHA)).
223915556|NCT06408038|OTHER|For each patient included, the samples described below will be collected:|"* A single blood sample will be taken before initiation of the metastatic treatment line. The volume of total blood sampled is 34mL.~* A tumour sample (FFPE block already archived) from a metastasis (other than bone) if available or, failing this, from the primary breast tumour, will be sent to the sponsor in order to meet the objectives of the study.~Once the blood sample has been taken, patients will have completed their participation in the study."
223915557|NCT06590441|DEVICE|Myopia control spectacles|Myopia control spectacles fitted with temperature sensors
223915558|NCT04102111|DRUG|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
223915559|NCT04102111|DRUG|Placebo|Participants will receive oral tablets of matching placebo twice daily.
223915560|NCT06553131|DEVICE|Neuromuscular Transmission Monitoring|A neuromuscular transmission module connected to electrodes applied to the skin and positioned to provide stimulation of a single nerve and monitor the muscular response to nerve stimulation
223915561|NCT05862298|DIAGNOSTIC_TEST|venous excess ultrasound score|Venous congestion is classified into 4 grades. If the Inferior vena cava is not plethoric, there is deemed to be no congestion (grade 0), and further Doppler examination is not performed. When the IVC is plethoric but there are no severely abnormal waveforms (defined as S-wave reversal on hepatic, \>50% pulsatility on portal, and a monophasic pattern on intrarenal Doppler), congestion is considered to be mild (grade 1). Plethoric IVC with at least 1 severely abnormal pattern is considered to be moderate congestion (grade 2), while 2 or more abnormal Doppler patterns constitute severe congestion (grade 3)
223915562|NCT06982131|DRUG|RO7795081|RO7795081 will be administered orally during Periods 3, 4, and 5, according to the protocol.
223915563|NCT06982131|DRUG|Placebo|Placebo will be administered orally during Periods 3, 4, and 5, according to the protocol.
223915564|NCT06982131|DRUG|Rosuvastatin|A single 10 mg dose of rosuvastatin (ROS) will be taken on Day 1 of Period 1 and on Day 1 of Period 4.
224278070|NCT05348928|DEVICE|Continuous glucose monitoring device|Continuous glucose monitoring device
223915565|NCT06982131|DRUG|Pitavastatin|A single 1 mg dose of pitavastatin (PIT) will be taken on Day 1 of Period 2 and on Day 1 of Period 5.
223915566|NCT05727280|BEHAVIORAL|Progressive Relaxation Exercise Practices|The intervention planned within the scope of the research are the Progressive Relaxation Exercise application. Patients in the intervention group undergoing open heart surgery will be given training on progressive relaxation exercise in the patient's room the day before the surgery. Correct breathing techniques will be taught and the relaxation exercises will be performed by using audio recordings. Afterwards, the relaxation exercise will be provided to the patient to practice the progressive relaxation exercise with mp3 accompaniment. After open heart surgery, progressive relaxation exercise will be applied to the patient on the 1st, 2nd and 3rd days of his admission to the service. The patient will be asked to perform the progressive relaxation exercise twice a day, once during the day and once in the evening.
223915567|NCT06440304|DRUG|Fosfomycin|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
223915568|NCT06440304|DRUG|Eravacycline|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
223915569|NCT06440304|DRUG|ampicillin/sulbactam|Patients will be randomly divided according to a predetermined randomization table Upon arrival of a positive microbiological finding on A. baumannii, patient will be randomised to one of groups (Colistin with Unasyn OR Colistin with Xerava OR Colistin with Fosfomycin
223915570|NCT06815770|DRUG|Terlipressin Injectable Product|Terlipressin Injectable Product
223915571|NCT06605339|BEHAVIORAL|Virtual Reality|Virtual Reality Distraction
223915572|NCT06655870|DRUG|mRNA-0184|SC injection
224088812|NCT00891995|DEVICE|Home glucose monitoring|Standard diabetes management using a home glucose meter.
224088813|NCT00891995|DEVICE|Insulin pump|Insulin pump use for 2 years
224278071|NCT05348928|OTHER|Laboratory plasma glucose concentration determination|Laboratory plasma glucose concentration determination
224088814|NCT00891995|DEVICE|Continuous glucose monitor|Continuous glucose monitor use for 2 years
224088815|NCT04755556|OTHER|home based intensive bimanual training|Home Based Intensive Bimanual Training with Routine Physical Therapy bimanual training includes. functional activities play with ball, make a dough, make beads, make blocks .Routine Physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
224088816|NCT04755556|OTHER|Routine Physical Therapy|Routine physical Therapy includes stretching spastic muscles, EMS, normalizing muscle tone.
224088817|NCT02054702|DRUG|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
224088818|NCT02054702|DRUG|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
224088819|NCT02898480|PROCEDURE|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
224088820|NCT05510960|OTHER|Video game & Robotic surgery simulator success|"A questionnaire was administered to all participants, asking about their demographic information, surgical experience, hobbies, and previous video game playing experiences.~After the questionnaire, the participants were asked to play the Temple Run (Imangi Studios, NC, USA) and Piano Tiles 2™ mobile games for one month. At the end of the period, with the da Vinci® Skills Simulator™ for one hour, all participants performed four different robotic surgery simulator tasks (Camera Targeting 1, Energy Switching 1, Ring \& Rail 2, Vertical Defect Suturing) that require the ability to apply basic robotic surgery rules and measure surgical skills."
223530118|NCT04043286|DEVICE|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
223915573|NCT06606249|BEHAVIORAL|Self-Help Plus (SH+)|"Self-Help Plus is a novel, brief, low-intensity intervention, recently developed by the World Health Organization (WHO) and intended to help people with and without mental disorders cope with distress stemming from diverse types of adversity.The key components of the program are based on acceptance and commitment therapy (ACT), a distinct form of cognitive-behavioural therapy. SH+ draws on ACT techniques of coping with stress, compassion and acceptance toward oneself and others, and living following one's values.~An online version called Doing what matters in times of stress is available as an illustrated guide and pre-recorded audio."
223915574|NCT06606249|BEHAVIORAL|Psychological First Aid (PFA)|Psychological First Aid (PFA) is also developed by the WHO and is a general supportive intervention, aimed at listening and understanding the needs and concerns of people, providing support without pressuring them to talk.
223915575|NCT06655220|DRUG|Metformin hydrochloride|Metformin hydrochloride
223915576|NCT06655220|DRUG|BI 1815368|BI 1815368
223915577|NCT06655428|DEVICE|Endobronchial Therman Liquid Ablation (ETLA)|The ETLA System is a minimally invasive bronchoscopic treatment designed to deliver heated normal saline to targeted emphysematous lung regions with hyperinflation to cause tissue ablation and subsequent volume reduction as a means for treating emphysema. The ETLA procedures will be performed under general anesthesia. Each procedure will be limited to treatment in a single lung, with either unilateral or bilateral treatment over the two procedures.
223915578|NCT05638360|DRUG|Ru Yi Jin Huang Powder|Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
223915579|NCT05638360|DRUG|Placebo|Each patch contains 13g starch and 10c.c. water.
224088821|NCT05448118|DIAGNOSTIC_TEST|Virtual POC Toxicology Test|Providers and patients will use Saliva Toxicology test at the point of care during virtual care visits.
224088822|NCT01884792|OTHER|Sitting OGTT|
224088823|NCT01884792|OTHER|Standing OGTT|
224278072|NCT02174185|BEHAVIORAL|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
224278073|NCT02208336|OTHER|medical chart review|Ancillary studies
224278074|NCT06301269|OTHER||
224278075|NCT04156737|DEVICE|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
223530119|NCT00280202|PROCEDURE|Biopsy of the major carinal area|Biopsy performed intraoperatively
223530120|NCT00280202|PROCEDURE|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
223915580|NCT06808763|OTHER|Knee Rehabilitation Exercise Program|"Rehabilitation Program Description:~The rehabilitation program was designed to restore knee function and strength progressively in football players recovering from anterior cruciate ligament (ACL) injuries. Key elements of the program are detailed below:~Program Components:~Session Structure:~Each session lasted 60 to 90 minutes. Sessions were performed multiple times weekly, progressively adjusted throughout the program.~Session Breakdown:~Warm-Up and Jump Exercises (Part 1):~Focused on preparing the body for physical activity and improving jump dynamics.~Dynamic Exercises (Part 2):~Included drop-jumps, side-hops, and crossover-hops for dynamic knee stabilization and balance.~Strength Exercises:~Targeted muscle groups included hamstrings, quadriceps, and calves. Exercises consisted of one-legged leg press, eccentric leg press, squats, one-legged squats on a balance mat, one-legged leg curls, Nordic hamstring, one-legged toe-raises, and lunge exercises.~Resistance training was i"
224088824|NCT01884792|OTHER|Sitting CGM|
224088825|NCT01884792|OTHER|Standing CGM|
224088826|NCT00887458|DRUG|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
224088827|NCT00887458|DRUG|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
224278076|NCT04156737|DEVICE|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
224278077|NCT00033527|DRUG|INS316|
224278078|NCT00033527|OTHER|sputum cytology|
224278079|NCT05704491|DIAGNOSTIC_TEST|artificial intelligence (AI) algorithm of the MONA DR model|A 45-degree fundus image is taken for each eye and patient using the Crystalvue NFC 600. The fundus photographs are then analyzed using the MONA DR model and classified for presence of diabetic retinopathy.
224278080|NCT01898845|DRUG|LEE011|
223530121|NCT00280202|PROCEDURE|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
223530122|NCT00280202|PROCEDURE|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
223915581|NCT04159012|DEVICE|Transcranial direct current stimulation|"A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4)."
223915582|NCT06756529|OTHER|hand massage|Hand massage was applied to the patients before surgery, on the morning of surgery and after surgery.
223915583|NCT06817746|BEHAVIORAL|FIRRST|FIRRST is based on the principles of Naturalistic Developmental Behavioral Interventions (NDBIs), and more specifically on the principles of Infant Start and iBASIS. FIRRST targets ASD prodromes including diminished eye contact, diminished communicative intent, diminished social orientation, and unusual pattern of object exploration. Additionally, it also targets motor immaturity, frequent in infants at risk for ASD. FIRRST is a systemic approach, integrated within the family dynamics and culture. The program will address the five elements identified in efficacious very early intervention: 1) parent involvement, 2) frequency and length of intervention, 3) individualized, developmentally appropriate activities, 4) beginning the interventions as early as possible, and 5) increasing parental sensitivity and responsivity to infant cues. FIRRST will be delivered by experienced licensed health professionals trained by the developer of the intervention.
223915584|NCT06817746|BEHAVIORAL|Parent Education|Families will receive written educational material focused on supporting child development and targeting ASD specific immaturities and atypicalities. Additionally, parent education families will receive counseling once per month for 6 months delivered by a licensed health professional aiming at supporting the family well being and helping the family to connect with the local public health services.
223915585|NCT06818175|PROCEDURE|Ultrsound Guided Hydrodissection of the Thoracolumbar Fascia|The injection of a fluid solution to separate facial or tissue layers in the body. Usually guided by ultrasound.
223915586|NCT06818175|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|The therapeutic application of manually guided forces by an osteopathic physician (US Usage) to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. OMT employs a variety of techniques.
223915587|NCT06816680|PROCEDURE|APF + FGG|In APF + FGG technique, a split- thickness flap was prepared and apically positioned using 5-0 (PDS\*II, Polydioxanone, ETHICON) or 6-0 (PROLENE, ETHICON) sutures for flap stabilization. To eliminate muscle and frenum attachment at recipient site, vestibuloplasty and a periosteal incision were performed. A 4 mm or 6 mm healing abutment was then screwed onto the implants. FGG was harvested from palate in a 7-8 mm width and trimmed to an even thickness of 1 to 1.5 mm. A resorbable hemostatic sponge (Spongostan, Ethicon, Johnson \& Johnson) was placed at donor site for wound coverage. For graft fixation, a loop suture with 6-0 (PROLENE, ETHICON) was first placed at the center of recipient site, additional sutures were added to enhance stabilization.
223915588|NCT06816680|PROCEDURE|PPF group|For the PPF group, the palatal sliding flap was a modified version of modified roll technique, as described in previous cohort study. Unlike the original technique, the crestal incision was placed 5 mm palatally from the border of keratinized tissue to allow for KMW redistribution, and a partially split-thickness flap was harvested from palatal connective tissue graft (CTG). Following buccal pouch flap preparation, a slight APF was required in cases with limited vestibular depth. When the palatal pedicle CTG was rolled in buccal pouch flap, a loop suture with 6-0 (PROLENE, ETHICON) was used for flap stabilization.
223915589|NCT06608407|BIOLOGICAL|PRP group|After the completion of hysteroscopic adhesiolysis, recruited participants will be randomized to one of the two treatment groups by computer-generated numbers: Immediately administer uterine perfusion with PRP after surgery, and administered PRP perfusion during hysteroscopy at 4 and 8 weeks after hysteroscopic adhesiolysis, A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery. Control group without PRP treatment.
223915590|NCT03958539|DEVICE|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
223915591|NCT06411054|DEVICE|Acu-TENS|After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair. A pulse rate of 120 Hz, current of 4-12mA, and pulse width of 300µS will be delivered continually for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed).
224088828|NCT02844127|PROCEDURE|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
224278081|NCT05421039|BEHAVIORAL|Exposure to unintended injuries|"After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers"
223530123|NCT00280202|PROCEDURE|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
224088829|NCT03803527|PROCEDURE|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
224088830|NCT03180892|OTHER|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
224088831|NCT01453881|DEVICE|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
224088832|NCT01453881|DEVICE|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
224088833|NCT00129064|BEHAVIORAL|Electronic referral system|
224088834|NCT02673255|BIOLOGICAL|Tetanus and Diphtheria (Td) Vaccine|
224088835|NCT05024006|DRUG|Remdesivir|Two intravenous loading doses, then daily infusion for 10 days
224088836|NCT05024006|DRUG|Hydroxychloroquine|Two oral loading doses, then orally twice daily for 10 days
223915592|NCT06411054|DEVICE|Sham acu-TENS|"After cleaning the acupoints with alcohol, electrode pads (HC-ROUND-32 2.0) will be placed on the acupoints SP6, ST36, LI4, LR3, according to the locations described in the Standard International Acupuncture Nomenclature. The electrode pads will be connected to a TENS machine (MTRP-00003), in which ipsilateral LI4 and SP36, SP6 and LR3 serve a pair.~In the sham acu-TENS, TENS pads will be placed on the same acupoints, connected to the machine, but without electric current. The pads will be stuck on the acupoints for 45 minutes (i.e. from 15 minutes before starting the MVA to 15 minutes after the procedure has completed)."
223915593|NCT06817733|PROCEDURE|Transurethral Thermal Vaporization of the Prostate|After anesthesia, the patient is placed in the lithotomy position, and standard aseptic preparation and draping are performed. A cystoscope and a transrectal ultrasound (TRUS) probe are inserted. Following real-time image fusion and localization according to the preoperative plan, needles are inserted to deliver thermal vaporization to the prostate. Each needle treatment lasts 8 seconds, and the entire procedure is completed within 200 seconds after activation of the needle pathway.
224088837|NCT05024006|DRUG|Lopinavir / Ritonavir|Orally twice daily for 14 days
224088838|NCT05024006|DRUG|Interferon beta-1a|Daily injection for 6 days
224088839|NCT05024006|DRUG|Acalabrutinib|Orally twice daily for 10 days
224088840|NCT03067090|DEVICE|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
224088841|NCT05131061|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT imaging|68Ga-Pentixafor PET/CT imaging
224088842|NCT06422182|DRUG|Bupivacain 25% (Erector Spinae Plane Block)|Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
224088843|NCT06422182|DRUG|Morphine (Intravenous patient-controlled analgesia)|Patients received intravenous patient-controlled analgesia (IV-PCA) by morphine
224088844|NCT05264350|DEVICE|Sialic acid nasal spray|The nasal spray will be self administered twice daily for 8 weeks.
224088845|NCT05264350|DEVICE|Isotonic Saline Nasal Spray|The nasal spray will be self administered twice daily for 8 weeks.
224088846|NCT00109473|DRUG|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
224088847|NCT00109473|DRUG|cortecosteroid|As prescribed by the referring gastroenterologist
223915594|NCT06816914|DRUG|NALIRIFOX|Patient in upfront surgery arm will receive operation followed by adjuvant chemotherapy with NALIRIFOX; patient in experimental arm will receive neoadjuvant NALIRIFOX followed by operation than adjuvant NALIRIFOX after operation.
223915595|NCT06596980|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
223915596|NCT05439200|DEVICE|Asynchronous 3D movies|3D movies streamed at home for viewing on a handheld lenticular 3D screen
223915597|NCT05439200|DEVICE|Patching|Adhesive patch to cover the fellow eye
224088848|NCT03870841|DRUG|PC945|PC945, nebulized
224088849|NCT02718859|BIOLOGICAL|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
224088850|NCT02718859|PROCEDURE|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
224088851|NCT04236544|BEHAVIORAL|PExMS and DECIMS-Wiki|The intervention consists of an information provision on immunotherapies as a combination of factual and experiential information. PExMS is a multimedia website providing patient experiences with MS in everyday life and with therapies illustrated by video, audio and text files of 48 persons with multiple sclerosis. The development of the intervention followed largely recommendation for standardised qualitative research provided by international DIPEx (Database of Individual Patients' Experience of illness) association, which use standardised qualitative research methods to provide 'balanced' information from original interview data. Data for the website was generated in a qualitative interview study with relapsing remitting multiple sclerosis patients across Germany. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies.
224088852|NCT04236544|BEHAVIORAL|DECIMS-Wiki|The active comparator is DECIMS-Wiki, which is an evidence-based online information platform. It is considered to be excellent factual information about immunotherapies for multiple sclerosis.
224088853|NCT05679414|DIAGNOSTIC_TEST|RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes|Venous blood sample
224088854|NCT00047346|DRUG|erlotinib hydrochloride|Given PO
224088855|NCT00047346|OTHER|pharmacological study|Correlative studies
224088856|NCT00047346|OTHER|laboratory biomarker analysis|Correlative studies
224088857|NCT00379327|PROCEDURE|Acupuncture|Acupuncture administered in last three weeks of pregnancy
224088858|NCT00379327|DEVICE|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
224088859|NCT02673229|DRUG|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
223915598|NCT05566964|DEVICE|ME&MGopen smartphone application|Smartphone application includes digital tests and e-questionnaires
223915599|NCT06642662|DIAGNOSTIC_TEST|Somascan 5.0|This observational study will test patient plasma using the SomaScan platform, a highly multiplexed proteomic tool that uses SOMAmers (Slow Off-rate Modified Aptamers) to bind with high specificity and affinity to preselected proteins to quantify levels. SomaScan v5.0 quantifies 10,778 clinically relevant human proteins, with several thousand proteins linked to inflammation and immune system functions, across a wide range of concentrations (\>10 logs) with high sensitivity (\<1 pg/mL) and reproducibility (median coefficient of variation \< 5%). Individual protein concentrations are transformed into a corresponding SOMAmer concentration and quantified using a DNA microarray read-out.
223915600|NCT04282811|DRUG|Venetoclax|Patients treated with venetoclax-based regimens outside clinical trials in Italy
223915601|NCT05818462|DIAGNOSTIC_TEST|Uroflow testing|Uroflowmetry is a test that measures the volume of urine released from the body, the speed with which it is released, and how long the release takes.
223915602|NCT05818462|DIAGNOSTIC_TEST|Bladder Scan|Bladder scan measures ultrasonic reflections within the patient's body to differentiate the urinary bladder from the surrounding tissue. In this case, it is used to detect the volume of urine in the bladder.
223915603|NCT05818462|OTHER|Dysfunctional Voiding Scoring System Survey|The Dysfunctional Voiding Symptom Score to provide accurate and objective numerical, grading of voiding behaviors of children.
223915604|NCT05818462|DIAGNOSTIC_TEST|DEXA Scan of pelvis and sacral spine|DEXA (dual x-ray absorptiometry) scans measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip and the spine.
223915605|NCT05818462|DIAGNOSTIC_TEST|Urine tests for specific biomarkers|Urine tests for specific biomarkers (ATP, NGF, BNDF and urine proteomic screening).
223915606|NCT05070247|DRUG|TAK-500|TAK-500 intravenous infusion.
223915607|NCT05070247|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
223915608|NCT06429631|DEVICE|mobile application on telephone|"when patient discharge from the hospital, mobile application downloaded their telephone. then researcher give feedback about patients CIC outputs.~also mobile application include 2 animations, videos, frequently asked questions and ask the expert section."
223915609|NCT06606808|DRUG|Risankizumab-800CW 4.5 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
223915610|NCT06606808|DRUG|Risankizumab-800CW 15 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
223915611|NCT06606808|DRUG|Risankizumab-800CW 25 mg|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
223915612|NCT06606808|DRUG|Risankizumab-800CW optimal dose|Risankizumab-800CW will be administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure will be performed to enable the visualisation and detection of fluorescence signals.
223915613|NCT04325815|DEVICE|CADDIE- Computer Aided (AI) Device used in Endoscopy|"1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation"
223915614|NCT04763772|DIAGNOSTIC_TEST|Body Fat Distribution Imaging Report|Those randomized to body fat distribution imaging will be scanned on a 1.5 Tesla Siemens Aera MRI scanner (Siemens, Erlangen, Germany), located in the Center for Advanced Heart and Vascular Care using a 6-minute dual-echo Dixon Vibe protocol providing a water and fat separated volumetric data set covering neck to knees, and a multiecho Dixon acquisition for proton density fat fraction assessment in the liver. Images of the liver will be acquired using a 16-channel SENSE extra large Torso coil and images from the rest of the body will be acquired using the body coil. Volumetric imaging datasets of the body derived by MRI will be generated and adipose tissue/fat depots will be quantified: abdominal subcutaneous compartment (ASAT), visceral compartment (VAT), and hips and buttocks (lower body fat); proton density fat fraction of the liver (i.e. hepatic steatosis) as well as the quality of lean (skeletal muscle) including muscle volume and degree of fat infiltration.
223915615|NCT04763772|DIAGNOSTIC_TEST|Basic Weight Information|Body weight and body mass index
223915616|NCT04763772|BEHAVIORAL|Patient Provided|Body weight/fat distribution information will be provided directly to the patient
223915617|NCT04763772|BEHAVIORAL|Physician Provided|Body weight/fat distribution information will be provided directly to the physician
223915618|NCT03898583|DRUG|Microarray patch A|Microarray patch
223915619|NCT03898583|DRUG|Microarray patch B|Microarray patch
224088860|NCT02673229|DRUG|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
223915620|NCT03898583|DRUG|Placebo|Microarray patch vehicle
223915621|NCT03898583|DRUG|Daivobet|Daivobet Gel
223915622|NCT06861491|BEHAVIORAL|Non-pharmacological|This intervention will be provided by student pharmacists. It will focus on lifestyle modifications, adherence, and education of disease state.
223915623|NCT06860282|DRUG|Remdesivir|Intravenous remdesivir 100 mg
223915624|NCT06860282|DRUG|CX2101A|CX2101A enteric-coated tablet
223915625|NCT06860282|DRUG|Placebo|CX2101A placebo enteric-coated tablet
223915626|NCT06861140|DIETARY_SUPPLEMENT|Tryptophan 25mg/kg bodyweight|Tryptophan is supplemented during the treatment of chronic pouchitis with pro- and antibiotics
223915627|NCT06861140|OTHER|Placebo|standard treatment of chronic pouchitis using pro- and antibiotics.
223915628|NCT06862921|OTHER|Control|fawler position using a standard tourniquet
223915629|NCT06861036|PROCEDURE|Biospecimen|"* 1 or 2 tumoral specimen (depending on the size of the tumor)~* 1 specimen of the healthy oral mucosa~* 1 leucoplakia specimen if applicable.~The biospecimens will be collected at the time of the surgery organised for the standard routine medical care."
223915630|NCT06861036|PROCEDURE|Blood sampling|Blood sampling (6 mL), taken from a routine biological exam.
224088861|NCT01371461|DRUG|Paroxetine|
223530124|NCT00280202|PROCEDURE|Analysis of lymph nodes|Tissues banked for future analysis
224088862|NCT05239845|DIETARY_SUPPLEMENT|Prebiotic|The bioactive ingredients used in this study include bovine milk fat globule membrane (MFGM), bovine lactoferrin and a prebiotic blend of polydextrose and galactooligosaccharides (PDX/GOS).
223915631|NCT06860919|OTHER|Follow-up of the patients during 3 years|"Evaluation of PTSD prevalence, anxiety-depressive state, quality of life, look for a correlation between their clinical history and PTSD.~Analysis of the nutritional, gastrointestinal and respiratory status."
223915632|NCT06860412|BEHAVIORAL|Animal Assisted Intervention|This is a multimodal group intervention program that simultaneously carries out health education activities, physical activities, emotional activities and social interactions through the integration of a psychoeducational intervention and animal-assisted therapy for elderly people with unwanted loneliness.
223915633|NCT06860412|BEHAVIORAL|Psychoeducational Intervention as Usual|This psychoeducational intervention is a multimodal group intervention program that simultaneously carries out health education activities, physical activities, emotional activities and social interactions for elderly people with unwanted loneliness.
223915634|NCT06861023|OTHER|Patients who have undergone extensive nail resection with reconstruction|The investigators studied a population of 10 patients who underwent nail and nail matrix excision surgery as part of the treatment of subungual melanoma, as well as the reconstruction, the investigators opted for. The specific intervention of this study is based on late postoperative questions (after 3 months)
223915635|NCT04474574|DEVICE|Simultaneous recording of nocturnal SpO2|The intervention will consist in performing a simultaneous recording of nocturnal SpO2 and pulse rate for at least 4 hours with 3 different devices.
223915636|NCT06859892|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine 0.4 μg/kg and esketamine 0.2 mg/kg is infused over 10 minutes before anesthesia induction. Dexmedetomidine 0.20 μg/kg/h and esketamine 0.10 mg/kg/h is then infused until 60 minutes before the expected end of surgery. Patient-controlled intravenous analgesia is established with 100 μg dexmedetomidine, 50 mg esketamine, and 100 μg sufentanil, diluted to 100 mL with normal saline, and programmed to deliver 2-mL boluses with a lock-out interval of 8 minutes and background infusion rate at 1 mL/h for up to 72 hours after surgery.
223915637|NCT06859892|DRUG|Placebo|Placebo (normal saline) is administered in the same rate and volume as that in the dexmedetomidine-esketamine group. Patient-controlled intravenous analgesia is established with 100 μg sufentanil, diluted to 100 mL with normal saline, and programmed to deliver 2-mL boluses with a lock-out interval of 8 minutes and background infusion rate at 1 mL/h for up to 72 hours after surgery.
223915638|NCT06858592|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Dancers will then individually be screened for somatic dysfunctions (SD) by a physician and VCOM OMS-III student doctor under their direct supervision. OMS-III student investigators will receive training and be assessed on their abilities before performing OMT on subjects. This will take place at the dancers' place of practice in a private area equipped with an OMM table. The areas to be screened include the lumbar spine, hips, knees, ankles, and feet. All diagnoses in these areas will be documented with specific notation for the area of greatest restriction on paper. After making a diagnosis or multiple diagnoses, the dancer will be treated utilizing OMT for 15 minutes starting with the area of greatest restriction in the lower body by the OMS-III student doctor under direct supervision of a physician, should an adverse event take place. The type of treatment(s) used will be at the discretion of the supervising physician and the VCOM student doctor. They may use any OMT technique, exc
223915639|NCT06855667|BIOLOGICAL|Plasma Exchange|3 to 5 sessions alternate day
223915640|NCT06855667|DRUG|Steroid|Steroid
223915641|NCT06855667|DIETARY_SUPPLEMENT|Diet|Diet
223915642|NCT04707768|DRUG|Vadadustat|oral tablets
223915643|NCT04707768|DRUG|Mircera®|intravenous administration
223915644|NCT06860217|OTHER|Robotic Nipple-Sparing Mastectomy|Patient will undergo to nipple sparing mastectomy and breast reconstruction, conducted using robot
223915645|NCT06668363|BEHAVIORAL|Treat4All|An alcohol reduction evidence-based intervention integrated with HIV status-neutral counseling
223915646|NCT06668363|BEHAVIORAL|Standard of care (control arm)|Sexual risk reduction counseling
223915647|NCT06860009|BEHAVIORAL|Multicomponent psychological intervention|The multicomponent intervention starts with 8 sessions of ACT (Acceptance and commitment therapy) once a week. After four weeks, patients start with graded activity and frequent napping. After eight weeks in the intervention period, patients will have consults with an IBD psychologist every two weeks. The intervention period is 14 weeks in total.
224088863|NCT05239845|OTHER|Control|Maltodextrin
224278082|NCT04083326|DEVICE|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
223915648|NCT06860009|BEHAVIORAL|Early start|Patients in the early group immediately start with the multicomponent psychological intervention
223915649|NCT06860009|BEHAVIORAL|Late start (after 28 weeks)|Patients in the late intervention group will wait 28 weeks before starting the intervention
223915650|NCT06862141|DEVICE|bendable suction ureteral access sheath|flexible ureteroscopy will be done using bendable suction ureteral access sheath
223915651|NCT06862141|DEVICE|conventional suction ureteral access sheath|flexible ureteroscopy will be done using conventional suction ureteral access sheath
223915652|NCT06860841|DRUG|D-Chiro-Inositol Combined with Metformin|D-chiro-Inositol will be administered for 14 days,1 cp after lunch and 1 cp after dinner in addition to preexisting metformin therapy
224088864|NCT04212000|DRUG|Levoketoconazole|Levoketoconazole tablet
224088865|NCT04212000|DRUG|Ketoconazole|Ketoconazole tablet
224088866|NCT00499109|DRUG|Docetaxel|"GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days"
224088867|NCT00499109|DRUG|Vinorelbine|DV Group: 35 mg/m\^2 on days 1 and 15
223530125|NCT05917002|DEVICE|Real TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system).
223915653|NCT06860841|DRUG|Placebo in combination with metformin|placebo will be administerd for 14 days, 1 cp after lunch and 1 cp after dinner in addition to pre-existing metformin therapy
223915654|NCT06862258|PROCEDURE|Shehata technique|For patients whose intra-abdominal testicle cannot easily reach the contralateral internal inguinal ring due to a short testicular pedicle, the Shehata procedure will be performed. This technique involves a two-stage laparoscopic orchidopexy that preserves the testicular vessels. In the first stage, the intra-abdominal testicle is fixed above the contralateral iliac crest using prolene vascular suture. Twelve weeks later, a second procedure is performed to position the testicle lower. This approach ensures the preservation of the testicular vessels, vas deferens, and overall circulation.
224088868|NCT00499109|DRUG|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
223915655|NCT06860659|DRUG|0.28% Sodium Hyaluronate , preservative free eye drops|0.28% Sodium Hyaluronate , preservative free eye drops
223915656|NCT06860659|DRUG|0.18% Sodium Hyaluronate , preservative free eye drops|0.18% Sodium Hyaluronate , preservative free eye drops
223915657|NCT06862856|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|This is a PET scan with flotufolastat F 18 injection.
223915658|NCT06857409|PROCEDURE|pulsed radiofrequency|All patients will be monitored with electrocardiography, non-invasive blood pressure, and peripheral oxygen saturation, and peripheral intravenous vascular access will be performed before the procedure. Patients will be placed in a sitting position. The physician will stand behind the patient for the posterior approach. The skin area to be injected will be prepared and covered in a sterile manner using a povidone-iodine-based solution. The operator will use ultrasound (a TOSHIBA Aplio 500 Ultrasound) guidance to perform suprascapular nerve radiofrequency. The suprascapular notch will be visualized. A twenty-two gauge, 10 cm long, and 10 mm active-tipped radiofrequency cannula will be introduced to the suprascapular notch. Motor stimulation will be performed at 2 Hz at a setting of 1 V, and sensory stimulation will be performed at 50 Hz at a setting of 0.5 V. After the needle tip confirmation, pulsed radiofrequency will be applied to the suprascapular nerve for 360 seconds.
223915659|NCT06860438|DRUG|Vasoconstrictor Agents|vasopressor agents will be started in patients with sepsis who will not improved using the resuscitation fluids
223915660|NCT06862739|COMBINATION_PRODUCT|Empagliflozin+Linagliptin+Metformin|Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients
223915661|NCT06861959|DEVICE|Device: Volume-Controlled Ventilation (VCV)|Tidal volume: 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
223915662|NCT06861959|DEVICE|Device: Pressure-Controlled Ventilation (PCV)|Initial peak inspiratory pressure adjusted to deliver a tidal volume of 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
223915663|NCT06861959|DEVICE|Device: Pressure-Controlled Volume-Guaranteed Ventilation (PCV-VG)|Pressure-controlled mode with volume guarantee to maintain a tidal volume of 8 mL/kg of ideal body weight Respiratory rate adjusted to maintain an end-tidal CO₂ (EtCO₂) level of 30-35 mmHg Inspiratory-expiratory ratio: 1:2 PEEP: 5 cmH₂O Mechanical ventilation was provided using a Datex-Ohmeda Avance Anesthesia Machine (GE Healthcare, USA) Measurements were taken at four predefined time points (T1-T4)
223915664|NCT05115682|BEHAVIORAL|High-intensity Intermittent Exercise|The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
223915665|NCT06666296|BEHAVIORAL|Digital collection of recipes|The digital recipe collection is created for private use. This collection contains recipes for every meal of the day to ensure a Planetary Health Diet throughout the day. This includes digital weekly plans with corresponding dishes, including shopping lists, to simplify implementation in everyday life. This enables participants to make quick meal choices and simplify their shopping. Employees are encouraged to use this digital recipe collection to prepare their meals over a defined period of time. In addition, the kitchen management of the university hospital will be asked to assist with the creation of the recipes. The project benefits from the experience of the kitchen staff. Popular recipes can be used across projects.
223915666|NCT06666296|BEHAVIORAL|E-Mail-Newsletter|"The e-mail newsletter contains information on the Planetary Health Diet (background, urgency, goals, etc.). Regular contact by e-mail enables a fast, uncomplicated and personal exchange with the participants, uncomplicated and personal exchange with the participants. The e-mail support encourages participants to actively engage with the topic. The newsletter is supplemented by instructional kitchen videos (one person cooks a recipe from the recipe collection), checklists (e.g. How sustainable am I already acting?), tasks (e.g. three possible measures for a more sustainable diet) or food information (e.g. seasonal plan for fruit and vegetables). This provides participants with important information at regular intervals and ensures compliance."
224088869|NCT00499109|DRUG|Gemcitabine|"GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
224088870|NCT06110052|OTHER|prospective follow up|compare preoperative and postoperative visual analog scale VAS of maximum perceived pain in ladies with OMAs
223530126|NCT05917002|DEVICE|Sham TBS to mPFC|This will be delivered with the Magventure MagPro System; (double blinded using the integrated active sham system). The Magventure MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
223915667|NCT06666296|BEHAVIORAL|digital/hybrid teaching kitchen|Recipes, cooking techniques, shopping tips and recommendations for implementing the Planetary Health Diet are taught in the digital/hybrid teaching kitchen. The focus here is on fun, good taste and interesting experiences. A shared experience can be created through such cooking events. The teaching kitchen events can be supplemented by the participation of the kitchen management in order to benefit from their special cooking skills and wealth of experience. The positive aspect of the digital training kitchen is the easy access to information, as this does not have to be read, but is conveyed visually.
223915668|NCT06666296|BEHAVIORAL|Digital events (digital cafés)|"Events are planned that will be set up via the digital café for in-depth discussions and exchanges about the content. Fixed dates are planned at which the study participants can meet digitally. In this protected setting, the topics of the study will be discussed in a convivial atmosphere. The personal exchange enables a deeper examination of the topic. The online events give participants the opportunity to interact directly with the study coordinators and other participants in order to effectively and sustainably change the participants' perception and awareness of sustainable nutrition through the various intervention points."
223915669|NCT06666296|BEHAVIORAL|Social-Media|A dedicated Instagram account for this project will be created for the center, where valuable content on the Planetary Health Diet will be shared regularly. The test subjects can also use this platform to exchange information.
223915670|NCT04708834|DRUG|Troriluzole (BHV-4157)|200 mg daily first 2 weeks, 280 daily following first 2 weeks
223915671|NCT05956574|BEHAVIORAL|Nutrigenomix, personalized dietary plan|Personalized dietary plan.
223915672|NCT05956574|BEHAVIORAL|Physical Activity|Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.
224088871|NCT03417440|OTHER|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
224088872|NCT03417440|OTHER|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity-a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
224088873|NCT03417440|OTHER|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
224088874|NCT03417440|OTHER|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
224088875|NCT05926427|DRUG|Orelabrutinib|150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
224088876|NCT05926427|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
224088877|NCT05926427|DRUG|Chemotherapy|Not specified, recommended regimen according to histopathologic type
224088878|NCT05936762|DEVICE|Neoial HC|Patients with severe knee osteoarthritis were enrolled in the clinical study and treated with 3 injections of 40 mg NEOIAL HC (HA sodium salt at 2% with two molecular weights 20% with pm at 400 kD and 80% between 1200 and 1500 kD t + collagen) at a distance of 1 week from each other, followed by a fourth infiltration of the same product at a distance of 1 month from the third.Patients were followed up with baseline clinical evaluation, reporting of adverse events after each single infiltration and subsequently at the end of treatment, 3, 6 months follow-up.
224088879|NCT06020794|BEHAVIORAL|Exercise|quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
224088880|NCT06020794|BIOLOGICAL|LP-PRP|The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
224088881|NCT00923429|PROCEDURE|Stay-active care|No other treatment than the stay-active care
224088882|NCT00923429|PROCEDURE|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
223915673|NCT05956574|BEHAVIORAL|Behavioral counseling|Review behavioral counseling videos and participate in worksheets to assist with behavioral change.
223915674|NCT05956574|BEHAVIORAL|Standard Dietary plan|Receive a standard dietary plan
223915675|NCT03579836|DRUG|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
223915676|NCT03579836|COMBINATION_PRODUCT|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
223915677|NCT04293523|DRUG|ELOCTA|Extended half-life factor VIII product
224088883|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
224088884|NCT00923429|PROCEDURE|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
224088885|NCT04004949|OTHER|Assessment of scapular balance angle and upper extremity sensorimotor function|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores \& scapular balance angle test (SBA).
224088886|NCT03304522|DRUG|VX-150|Participants received VX-150 1250 milligrams (mg) once daily (qd) orally for 6 weeks.
224088887|NCT03304522|DRUG|Placebo|Participants received placebo matched to VX-150 for 6 weeks.
224088888|NCT05479903|PROCEDURE|acupuncture|Manual acupuncture or electro-acupuncture by experienced acupuncturists for patients
223915678|NCT04975607|BEHAVIORAL|Music Therapy|The three live music therapy sessions will be provided after lung transplant. All three music therapy sessions will employ a variety of data-based interventions to address pain, anxiety, and improve relaxation. Music therapy interventions may include patient preferred live music, active music listening, singing or other active music-making, and guided breathing and relaxation.
223915679|NCT06752473|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
223915680|NCT06614738|OTHER|Sampling of feces and duodenal fluids|"* Blood sampling (plasmotheque and serotheque): 2 tubes (EDTA (5mL) and dry (5mL)) during hospitalization~* Fecal sampling (fecal library): A stool sample (approx. 2g) will be taken 48 hours before the endoscopy at home for outpatient or during hospitalization~* Duodenal aspiration fluid (6-10 mL in total): before and after mucosal lavage with sterile isotonic saline on the day of endoscopy.~* Food and Lifestyle Questionnaire (FFQ) during inclusion"
223915681|NCT06781034|OTHER|None, pure observational study|None, pure observational study
223915682|NCT06781554|DEVICE|MD-Small Joints Collagen Medical Device|The infiltrations will be performed using 2.5ml syringes and 26 gauge/13mm needles under complete aseptic conditions. The first 3 infiltrations will be carried out at both intra- and peri-articular levels by injecting MD-Small Joints Collagen Medical Device into the trapeziometacarpal joint until a counter-pressure is felt, preventing further penetration of the liquid; the remaining quantity (usually about 1ml) will be injected at the peri-articular level by retracting the needle tip. The fourth and fifth infiltrations will be performed only at the peri-articular level.
223915683|NCT06862167|PROCEDURE|Desarda's technique|Patients will undergo Desarda's technique.
223915684|NCT06862167|PROCEDURE|Lichtenstein's technique|Patients will undergo Lichtenstein's technique.
224088889|NCT05479903|BEHAVIORAL|computerized cognitive training system|One-on-one cognitive training by an experienced cognitive therapist, combined with an existing computerized cognitive training system
224278083|NCT01614262|OTHER|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
223915685|NCT06781164|DEVICE|telemedicine|Recording of the ear of each patient with an ear problem
223915686|NCT06857630|OTHER|Observational|Postoperative acute kidney injury and hemoglobin level relationship observation
223915687|NCT06661421|DEVICE|Dry Needling|This intervention combines Dry Needling Therapy (DNT) with routine physical therapy for children with spastic cerebral palsy. The experimental group will receive DNT alongside physical therapy, while the control group will undergo only physical therapy. Routine Physical Therapy includes a warm-up, stretching, and strengthening exercises like hamstring stretches and squats, adjusted over a month with increasing intensity. Dry Needling targets the gastrocnemius muscle using a fast-in, fast-out technique with sterile needles, applied weekly for 10 weeks. This combined approach aims to reduce spasticity, improve mobility, and enhance range of motion, distinguishing it from standard therapies.
223915688|NCT06661421|OTHER|Cerebral Palsy conventional Treatment|Sessions will include a 5-minute warm-up, stretching, and strengthening exercises. Hamstring stretches will be done with the child supine, one leg flat, and the opposite hip flexed to 90°. Active knee extension will be held for 5 seconds, followed by a 40-second assisted stretch, repeated five times. If a short psoas is detected, a prone psoas stretch will involve assisted hip extension for 5 seconds, followed by a 40-second hold, repeated five times. Strengthening exercises like squats, heel rises, and step-ups with a loaded backpack will target the lower extremities. The program will last one month, with three sessions per week, focusing on hamstring stretches and progressive resistance exercises.
223940321|NCT01328496|DRUG|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
224088890|NCT05479903|BEHAVIORAL|aerobic exercise|Patients are trained by experienced physical therapists with the help of elastic bands and physical therapy devices
224088891|NCT05479903|BEHAVIORAL|tranditional cognitive training|One-on-one cognitive training with an experienced cognitive therapist, combined with traditional cognitive training methods (e.g., balls, cards, counting, daily conversation, etc.)
224088892|NCT05479903|OTHER|Conventional treatment|Treatment of underlying disease and stroke according to guidelines, as well as necessary care and rehabilitation
224088893|NCT01114789|OTHER|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
224088894|NCT00756548|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
224088895|NCT00756548|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
224088896|NCT03696329|DRUG|Tetrabenazine Tablets 25 mg|
224278084|NCT00948792|PROCEDURE|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
224278085|NCT00948792|PROCEDURE|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
224278086|NCT00654641|PROCEDURE|Negative pressure wound closure|Applying negative pressure to primary wound closure
224278087|NCT00654641|PROCEDURE|Standard wound closure|Standard wound closure
224278088|NCT03724682|DEVICE|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
224088897|NCT01736046|RADIATION|CT Enterography|"Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
224088898|NCT03314506|OTHER|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
224088899|NCT02013544|DRUG|Placebo|
224088900|NCT02013544|DRUG|Prasterone (DHEA)|
224088901|NCT02785809|OTHER|Pausing oral contraceptive|
224088902|NCT04741373|DIETARY_SUPPLEMENT|oral nutritional supplements|oral nutritional supplements, 400-600kcal/day;
224088903|NCT04741373|BEHAVIORAL|rehabilitation exercise|Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
224088904|NCT04741373|OTHER|health education|Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
224088905|NCT00238264|RADIATION|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
224088906|NCT05503355|DRUG|BST-236|"In part 1: During the induction (in combination with venetoclax), the BST-236 doses are:~In cohort 1 - 2.3 g/m2/d X6 days In cohort 2 - 2.3 g/m2/d X6 days In cohort 3 - 4.5 g/m2/d X6 days In cohort 4 - 4.5 g/m2/d X6 days In cohort 5 - 4.5 g/m2/d X6 days In part 1: During maintenances (for responding patients) the BST-236 dose- 4.5 g/m2/d X6 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
223915689|NCT04807881|DRUG|Keynatinib|All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
223915690|NCT06669611|DRUG|Camrelizumab combined GP chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.
224088907|NCT05503355|DRUG|venetoclax|"In part 1: During the induction (in combination with BST-236), the venetoclax doses are:~In cohort 1 - 200 mg QD X 7 days In cohort 2 - 400 mg QD X 7 days In cohort 3 - 200 mg QD X 7 days In cohort 4 - 400 mg QD X 7 days In cohort 5 - 200 mg QD X 14 days In part 2, the dose chosen as safe and efficacious for induction in part 1 will be used"
224088908|NCT02557087|DRUG|Hyoscine|
224088909|NCT02557087|DRUG|Pethidine|
223915691|NCT06669611|DRUG|Camrelizumab combined TPC chemotherapy|Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
223915692|NCT06669091|DRUG|Ecopipam tablet|A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
224088910|NCT01247857|DRUG|Ropivacaine 30 mg|"Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
224088911|NCT01247857|DRUG|Ropivacaine 30 mg|"intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
224088912|NCT01247857|DRUG|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
224088913|NCT00474916|DRUG|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
224088914|NCT00474916|DRUG|Placebo|Normal Saline given as dose escalation for placebo
224088915|NCT02036320|DEVICE|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
224088916|NCT00701987|DRUG|ALS-357|Topical application of ALS-357
224088917|NCT00456703|OTHER|intraoperative fluid management|fluid restriction
224278089|NCT03365791|BIOLOGICAL|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
224088918|NCT00456703|OTHER|fluid restriction|restriction of fluids
224088919|NCT05484193|DRUG|GnRH agonist|GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
224088920|NCT05484193|DRUG|Progesterone|vaginal progesterone for luteal phase support
224088921|NCT03013465|OTHER|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
224088922|NCT03013465|OTHER|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
224088923|NCT01008345|DRUG|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
223530127|NCT06334497|DRUG|Letermovir|"480mg (2X240mg- tablets) of Letermovir given orally once a day until the treatment success or the treatment failure, up to 12 weeks. In case of co-administration with cyclosporine A, the dosage of Letermovir will be reduced."
223530128|NCT06334497|DRUG|Valganciclovir|"Valganciclovir 900 mg (2X450 mg-tablets) twice a day until the treatment success or the treatment failure, up to 12 weeks. In case of impaired renal function, the dosage of valganciclovir will be reduced."
223915693|NCT06670092|OTHER|Vojta Therapy|"The intervention is carried out using Vojta therapy for one month, with one session per day, 5 days a week. This therapy is carried out by an expert physiotherapist. Vojta therapy is a non-experimental, painless, non-invasive therapy with no adverse effects, which is based on triggering repeated motor reactions or innate movement patterns (reflex locomotion patterns) in the trunk and limbs based on defined stimuli and starting from specific postures.~Both groups will undertake a pre-treatment assessment, a post-treatment assessment at the end of the one-month intervention period, and a final follow-up assessment one month after the end of the intervention."
223915694|NCT06670092|OTHER|No intervetion|No intervetion group
223915695|NCT06668961|DRUG|SI-B001|Administration by intravenous infusion
224088924|NCT00723684|OTHER|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
224088925|NCT00723684|OTHER|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
224088926|NCT00885365|DRUG|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
224088927|NCT00885365|DRUG|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
224088928|NCT03030963|OTHER|Equal ratio ventilation(ERV)|Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
224088929|NCT03030963|OTHER|"I:E Ratio 1:2"|Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
224088930|NCT00417872|DRUG|Nitazoxanide|
223530129|NCT06334497|DRUG|Letermovir placebo|"480mg (2X240mg- tablets) of Letermovir placebo given orally once a day until the treatment success or the treatment failure, up to 12 weeks"
223530130|NCT05842031|BEHAVIORAL|Quality of Life Questionnaires|Identify what interventions may be helpful in improving quality of life.
223530131|NCT05842031|BEHAVIORAL|Patient Educational Needs|Identify what interventions may be helpful in improving patient educational needs
223530132|NCT05842031|BEHAVIORAL|Symptom Management|Identify what interventions may be helpful in improving symptom management Improve symptom management
223530133|NCT05568862|DIAGNOSTIC_TEST|Doppler ultrasound, Urodynamic assessment.|The patients included in the study group were given 600 cc of water in the morning and the Doppler ultrasound was performed 30 minutes later
223530134|NCT05568862|DIAGNOSTIC_TEST|Urodynamic assessment.|A transurethral double lumen catheter was used to measure intravesical pressure in the urodynamic unit for the patients in the study group immediately after the use of the Doppler USG
223530135|NCT01323192|DRUG|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
223915696|NCT06668961|DRUG|SI-B003|Administration by intravenous infusion
223915697|NCT05876039|DRUG|Initial remifentanil effect-site concentration|Different initial remifentanil effect-site concentration
223915698|NCT04691323|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
224088931|NCT00417872|DRUG|Metronidazole|
224088932|NCT02133417|DEVICE|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
224088933|NCT01982825|BEHAVIORAL|Online intervention arm|See online intervention arm
224088934|NCT01982825|BEHAVIORAL|Online control arm|See online control arm
224088935|NCT03102229|OTHER|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
224088936|NCT03102229|OTHER|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
224278090|NCT03365791|BIOLOGICAL|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
224278091|NCT03693950|BIOLOGICAL|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
224278092|NCT03693950|BIOLOGICAL|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
224278093|NCT03900234|OTHER|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
223530136|NCT01323192|DRUG|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
223530137|NCT01019265|DRUG|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
223530138|NCT05165472|OTHER|Quadri-pulse theta burst stimulation|High frequency transcranial quadri-pulse theta burst stimulation prior to hand motor function training
223530139|NCT02398331|OTHER|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
223915699|NCT03525587|OTHER|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
223915700|NCT06258811|DRUG|albumin paclitaxel, cispatin, tislelizumab|Neoadjuvant immunochemotherapy (2 cycles, and 21 days each cycle, 260mg/m2 albumin paclitaxel intravenously on day 1 and day 22, with 75mg/m2 of cisplatin and 200mg of tislelizumab) + radical surgery + adjuvant therapy (radiation/chemoradiation followed by 200mg of tislelizumab, every 3 weeks for one year)
223915701|NCT03117972|DRUG|FOLFOXIRI|12 cycles
223915702|NCT03117972|DRUG|FOLFOX|12 cycles
223915703|NCT03117972|DRUG|FOLFIRI|12 cycles
223915704|NCT03117972|DRUG|Bevacizumab|12 cycles
223915705|NCT03117972|DRUG|LV5FU2|Maintenance chemotherapy
223915706|NCT03117972|DRUG|Capecitabine|Maintenance chemotherapy
223719482|NCT04635215|DEVICE|Sensura Mio Bodyfit technology ostomy pouches|The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
223915707|NCT04857827|DRUG|QLS-101|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
223915708|NCT04857827|DRUG|Timolol maleate PF 0.5% ophthalmic solution|Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
224088937|NCT05196893|BEHAVIORAL|Link Intervention|Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
224088938|NCT04850560|BIOLOGICAL|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine|CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
224088939|NCT04281797|DIAGNOSTIC_TEST|Intestinal microbiome new generation sequencing|Fecal samples collected at baseline pre-transplant and post-transplant, new generation 16s RNA sequencing performed.
224088940|NCT06190587|DIETARY_SUPPLEMENT|Goji Berry|As a functional food goji berry contains 19 amino acids, 21 minerals, a wide range of carotenoids (β-Carotene, Neoxanthin, Cryptoxanthin, Zeaxanthin), polysaccharides, flavonoids, phytosterols, vitamin A, C and E.
224088941|NCT00065026|BEHAVIORAL|Physical activity opportunities for low-income women|
224088942|NCT03628157|OTHER|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
224088943|NCT01923025|DRUG|RO5545965|Single dose
223915709|NCT06865157|OTHER|Healthy Wallet|The Healthy Wallet program is a mobile-based initiative designed to promote healthy eating among low-income families by incentivizing the purchase of fruits and vegetables at open markets. Over a two-month period, 30 families received monthly benefits to use at a designated open market.
223915710|NCT05562739|DIETARY_SUPPLEMENT|Postbiotic|multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.
223915711|NCT05562739|DIETARY_SUPPLEMENT|Placebo|Matching placebo in a form of a capsule for 6 weeks.
224088944|NCT04097548|BEHAVIORAL|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
224088945|NCT00006430|BIOLOGICAL|Autologous dendritic cells transfected with amplified tumor RNA|
224088946|NCT05266404|DRUG|Dapagliflozin/sitagliptin FDC|Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
224088947|NCT05266404|DRUG|Sitagliptin|Subjects will receive 100 mg single dose of Sitagliptin orally.
223915712|NCT06616311|DEVICE|Radiofrequency microneedling|The target population is skin of color patients with melasma. Patients will receive 5 consecutive RFMN treatments over a period of 5 months.
223915713|NCT04078152|DRUG|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
223915714|NCT05827874|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
223915715|NCT05827874|BIOLOGICAL|Tdap|Tdap will be administered as an IM injection.
223915716|NCT05827874|BIOLOGICAL|PPSV23|PPSV23 will be administered as an IM injection.
223915717|NCT02510235|DEVICE|Lubricin|Lubricin 150 µg/ml eye drops
223915718|NCT02510235|DEVICE|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
223915719|NCT06608992|DRUG|SURGICEL® Powder|SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
223915720|NCT06370702|OTHER|Handgrip Exercises|Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
224088948|NCT05266404|DRUG|Dapagliflozin|Subjects will receive 10 mg single dose of Dapagliflozin orally.
224088949|NCT04513691|DIAGNOSTIC_TEST|EOS Calculator|Neonatal Early-Onset Sepsis Risk Calculator which is a tool that determines the risk of EOS for a particular newborn by looking at maternal risk factors and the newborn's clinical picture as opposed to just laboratory tests alone
224278094|NCT02726841|PROCEDURE|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
224278095|NCT02726841|PROCEDURE|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
224278096|NCT02642809|DRUG|Pembrolizumab|
224278097|NCT02642809|RADIATION|Brachytherapy|
224278098|NCT02642809|PROCEDURE|Endoscopic biopsy|
224278099|NCT02642809|PROCEDURE|Computed tomography-guided biopsy|
224278100|NCT02642809|PROCEDURE|Peripheral blood collection|
224278101|NCT03973151|DRUG|HL-085|HL-085 is one MEK inhibitor.
223530140|NCT06835036|OTHER|Exercise Treatment|In this study, a functional exercise programme will be performed 3 days a week for 8 weeks in three cycles as previously recommended. This programme consisted of a 5-minute warm-up and a 45-minute exercise phase.
223530141|NCT05558644|OTHER|single arm for all patients|"* tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery."
223915721|NCT06071286|PROCEDURE|Blood samples|Patients with suspected advanced OC, based on preoperative imaging/clinical evaluation, will undergo blood samples in different timepoints
223915722|NCT06674681|DIAGNOSTIC_TEST|HPV Self-Collection|HPV self-collection program for in-clinic and mailed cervical cancer screening.
223915723|NCT05694169|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
223915724|NCT05640375|DRUG|Methylprednisolone|Single dose, 1 mg/kg
223915725|NCT06549023|PROCEDURE|Single-session panretinal PRP (SS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
223915726|NCT06549023|PROCEDURE|Multiple-session panretinal PRP (MS-PRP)|Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
223915727|NCT05966805|BEHAVIORAL|Exercise training group|12-Week Exercise intervention on mentaL, metabolic, physicaL, spiritual, social, and occupational well-being among shift-working acute care NURSE
223915728|NCT05966805|BEHAVIORAL|Wait-List Control Group|Control group
223915729|NCT00450216|DRUG|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
223915730|NCT00450216|DRUG|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
223915731|NCT05699837|DEVICE|Audio or visual alpha (10Hz) stimulation|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights, to deliver rhythmic 10Hz or non-rhythmic stimulation
223915732|NCT05623774|DRUG|Imatinib Mesylate|400mg tablet
223915733|NCT05623774|DRUG|IkT-001Pro|100mg or 400mg tablet
223915734|NCT05466838|DRUG|PERT at discharge|Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
223915735|NCT05466838|OTHER|Standard of Care|Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
223915736|NCT06608420|OTHER|Gradient Boosting Survival Analysis (GBSA),|It is a non-deep learning method that effectively addresses data scarcity issues. GBSA adapts the gradient boosting machine algorithm for survival analysis, particularly accommodating censored data. In survival analysis, patients are represented by a triplet (xi, δi, Ti), where xi is the feature vector, Ti is the time to event, and δi indicates whether the observation is censored. Our goal is to estimate the survival function S(t), representing the probability of a patient surviving beyond time t, and the hazard function λ(t), indicating the instantaneous probability of an event occurring at time t.
223915737|NCT06608420|OTHER|Concordance index|The survival model performance will be evaluated using the concordance index (c-index), a metric particularly suited for survival analysis. The c-index assesses the predictive accuracy of our model by comparing predicted and observed event times. A high c-index indicates that our model effectively predicts the order of patient hazard given its input features.
223915738|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation|Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)
223915739|NCT05016531|DEVICE|Low Intensity Focused Ultrasonic Stimulation Frequency|Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)
223915740|NCT05819931|DEVICE|Mechanical In-Exsufflator treatment|"The Mechanical In-Exsufflator (MIE) is a device that alternately inhales and exhales air and amplifies the respiratory cycles in flow and pressure. 15 breathing cycles (about 3 minutes) are recommended each day.~Patients will practice the MIE daily independently and/or carried out by his physiotherapist (PT) during PT sessions.~The MIE is prescribed by the neurologist or pulmonologist and is covered by social security in France. It is gifted by an external service provider.~The Peak-Flow Cough is considered as the standardized score retaining the best of 3 consecutive measurements by Peak-Flow, a small portable device for personal use, which measures the maximum expiratory flow reached by the patient at the moment when the breath is most powerful.~The patient is his own control. At baseline, the patient will be treated as usual. He will be asked to read the Peak-Flow Cough measures. The PT will also perform the Peak flow measurement at each patient visit."
223915741|NCT04898400|PROCEDURE|endoscopy sleeve gastroplasty|endoscopic procedure for weight loss
223915742|NCT06746857|DEVICE|repetitive transcranial magnetic stimulation|Bilateral dorsolateral prefrontal cortex Intermitten Theta Burst Stimulation to
223915743|NCT06856824|PROCEDURE|injection in the bicipital groove guided by anatomic landmarks|Anatomical landmark-guided puncture involves patient positioning and palpation, whereas ultrasound-guided involves identifying the biceps tendon's axis and inserting the needle parallel to the transducer.
223915744|NCT06856824|PROCEDURE|injection in the bicipital groove guided by ultrasound|Anatomical landmark-guided puncture involves patient positioning and palpation, whereas ultrasound-guided involves identifying the biceps tendon's axis and inserting the needle parallel to the transducer.
223915745|NCT06857162|BEHAVIORAL|Positioninng during Cs|"1. Group A (N=72): Immediate Supine Position (Control):~   Immediately after administering spinal anesthesia, participants will be placed in a supine position. To reduce the risk of aortocaval compression, a slight left lateral tilt (approximately 15 degrees) will be applied. This is the traditional positioning method and serves as the control group for comparison.~2. Group В (N=72): Sitting Position:~   After spinal anesthesia, participants will be positioned in a sitting position with the ack supported at a 90-degree angle for the first 2 minutes. Knees will be bent, and feet will be supported.~3. Group С (N=72): Semi-Sitting Position:~After spinal anesthesia, participants will be positioned in a semi-sitting position with the back supported at the back supported at for the first 2 minutes.~Similar to the sitting position, knees and feet will be flat."
223915746|NCT06862180|OTHER|Meal replacement therapy|A serving of Contro Eazy Now is equivalent to 5 scoops (50g) contains 26.5g of carbohydrate, 10g of protein and 8.9g of fat. It supplies 215kcal of energy per serving
223915747|NCT06861218|DRUG|pemetrexed|The pemetrexed is administrated by intrathecal injection with a dose of 50mg, once per week for 4 weeks, followed by every four weeks thereafter. The cerebrospinal fluid(CSF) samples are collected every 4 weeks and the cytology examination will be performed. If CSF cytology was negative, CSF cytology was tested again 1 week later. Two negative tests were considered as negative CSF cytology. If the cytology of cerebrospinal fluid was negative after 4 consecutive intrathecal injections, the intrathecal injection should be stopped. If positive, continue to give a intrathecal injection every 4 weeks until CSF cytology is negative. If CSF cytological positivity or worsening of neurological symptoms occurs again during discontinuation, or if new symptoms appear, the intrathecal injection should be resumed every 4 weeks.
223915748|NCT06861218|DRUG|vometinib|double dose of vometinib (160mg)
224088950|NCT02706938|OTHER|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
224088951|NCT02706938|OTHER|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
224088952|NCT02324166|DRUG|Cefazolin|cephalosporin antibiotic
224088953|NCT02324166|DRUG|Lidocaine|local anesthetic
224088954|NCT04713943|DIETARY_SUPPLEMENT|>Your< Iron Syrup|Once daily dose of \>Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
224088955|NCT04713943|OTHER|Placebo|Once daily dose of placebo syrup for 12 weeks
224088956|NCT02703857|DRUG|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
224088957|NCT01447394|BIOLOGICAL|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
224088958|NCT01447394|BIOLOGICAL|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
224088959|NCT01447394|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
224088960|NCT01908595|DRUG|M518101|
224088961|NCT01461681|PROCEDURE|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
224088962|NCT05314673|DRUG|Preoperative Intra-lesional Bevacizumab Injection in primary pterygium|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture Any intraoperative complication was noted and was treated accordingly. All patients received dexamethasone + tobramycin eye drops postoperatively 4 times a day in the 1st week. The eye drops were tapered over 4 weeks.~Patients were examined 30 days before bevacizumab injection (D-30), before surgery (day 0: D0) and then at D7, M1, M3, and M6 after surgery."
224088963|NCT05314673|PROCEDURE|pterygium surgery without adjunctive therapy|"The surgical technique featured:~subconjunctival anesthetic (lidocaine 2%) injection 5 mm from limbus; excision of the pterygium, starting from its head, followed by pterygium body removal; exposition of a triangular-shaped bare scleral bed (3-4 mm) conjunctival autograft stitched limbus to limbus with 10/0 vicryl suture"
224088964|NCT04675047|OTHER|no intervention for healthy control|observational study - no intervention
224088965|NCT00697957|BEHAVIORAL|Exercise|Progressive impact exercise
224088966|NCT03838484|DRUG|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
224088967|NCT03838484|DRUG|Placebo patch|Placebo skin patch will be applied to the skin.
223716407|NCT06556537|DEVICE|Face-to-face and video-assisted training|"During the first phase, the intervention group will receive face-to-face training over 12 weeks. Each session will last 60 minutes, and there will be five sessions per week, with three supervised and two unsupervised.~In the second phase, there will be 60 work sessions, divided into blocks of four weeks on three occasions, with one month of exercise and two months of non-exercise over the remaining 9 months. This phase will be conducted via video assistance. Each session will include a warm-up of 10-15 minutes, a main part of 20-40 minutes, and a cool-down of 10-15 minutes."
223716408|NCT00481078|DRUG|vorinostat|Given PO
223716409|NCT00481078|DRUG|paclitaxel|Given IV
223915749|NCT06861114|DIAGNOSTIC_TEST|Urine proteomics|Patients with hepatocellular carcinoma amenable to radical resection were included according to the inclusion exclusion criteria, and preoperative urine and postoperative urine from consecutive patients were collected at the marker time (before receiving postoperative adjuvant therapy after radical surgery for hepatocellular carcinoma) and at the longitudinal time (at the time point of 3 months after radical surgery), and the different samples were preprocessed, followed by mass spectrometry-based urinary proteomics to detect the differences in urinary proteins, and the data were recorded to compare the differences.
224088968|NCT05191160|OTHER|Soy Milk|250 mL, single-serve shelf-stable pack (Alpro Soya) 100 Kcal, 8g of soy protein
224088969|NCT05191160|OTHER|Cow's Milk|250 mL, single-serve shelf-stable pack (Organic Meadows) 130 Kcal, 8g of casein/whey protein
224088970|NCT05191160|OTHER|Sugar Sweetened Beverages|355 mL, single-serve cans 130-140 Kcal, 0g of protein
224088971|NCT00813995|DRUG|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
224088972|NCT00813995|DRUG|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
224088973|NCT03824301|DEVICE|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
224088974|NCT03824301|DEVICE|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
224088975|NCT06363162|DIAGNOSTIC_TEST|Immunohistochemistry or genetic test|Perform two diagnostic methods on the same sample
224088976|NCT02507349|BEHAVIORAL|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
223530142|NCT02390895|PROCEDURE|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
223915750|NCT06861803|DRUG|Letrozole tablets|The intervention in this study is ovulation induction using letrozole, an aromatase inhibitor commonly used in women with polycystic ovary syndrome (PCOS) to stimulate ovulation. Participants will receive letrozole at an initial dose of 2.5 mg/day for five days, starting on day 3 of the menstrual cycle. If ovulation is not achieved, the dose will be incrementally increased up to a maximum of 7.5 mg/day over a maximum of three cycles. Ovulation will be monitored through serial transvaginal ultrasounds to assess follicular development, and confirmed by measuring mid-luteal serum progesterone levels (\>3 ng/mL). Based on the response to letrozole, participants will be classified as either letrozole-sensitive (ovulatory) or letrozole-resistant (anovulatory) to identify potential predictors of resistance and improve individualized treatment strategies for PCOS-related infertility.
223915751|NCT06862843|OTHER|Collecting questionnaires and biological samples|For each family member will be collected a 3-days food diary, a food frequencies questionnaire and a questionnaire assessing the adherence to the mediterranean diet. Additionally, a blood sample for trascriptomic analysis and a fecal sample for gut microbiota analysis will be collected
223915752|NCT06861179|DRUG|The formulation of Compound Phellinus igniarius decoction|The formulation of Compound Phellinus igniarius decoction is manufactured by Hangzhou Qianjifang Technology Co., Ltd, the composition includes Phellinus igniarius 12g, jujube 3g, wolfberry 3g, tangerine peel 1g. The dosage regimen was as follows: 4 Packs of the formulation of Compound Phellinus igniarius decoction (Phellinus igniarius Herbal Decoction Pieces) + 1 Pack of the formulation of Compound Phellinus igniarius decoction(Excipients) per day, administered twice daily throughout the entire course of radiotherapy until its completion.
223915753|NCT06596668|DRUG|bomedemstat|Oral tablet
223915754|NCT06596668|DRUG|carbamazepine|Oral extended-release capsule
224088977|NCT02507349|BEHAVIORAL|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
224088978|NCT05497726|PROCEDURE|Sentinel lymph node detection using intravenous bevacizumab-800CW|Sentinel lymph node detection using intravenous bevacizumab-800CW
224088979|NCT03124225|DRUG|DMARD|
224088980|NCT03476044|DRUG|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
224088981|NCT03476044|DRUG|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
224088982|NCT01982591|OTHER|laboratory biomarker analysis|Correlative studies
224088983|NCT01982591|OTHER|questionnaire administration|Ancillary studies
224088984|NCT03618030|DRUG|PRC-063 oral capsules|Daily dose
224088985|NCT03618030|DRUG|Placebo oral capsules|Daily dose
224088986|NCT02082197|DRUG|ABT-SLV176|ABT-SLV176 administered daily
224088987|NCT01583348|PROCEDURE|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
224088988|NCT04060615|PROCEDURE|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
224088989|NCT02612870|DEVICE|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
224088990|NCT02612870|DEVICE|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
223530143|NCT04019002|DRUG|Hyperpolarized 13C Pyruvate|Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution via intravenous injection over a period of about 1 minute once prior to each research magnetic resonance imaging procedure.
223716410|NCT00481078|DRUG|carboplatin|Given IV
224088991|NCT02612870|DEVICE|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
224088992|NCT02612870|DEVICE|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
224088993|NCT02612870|DEVICE|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
224278102|NCT05259956|BEHAVIORAL|Schroth based scoliosis specific exercise|The intervention is set to be delivered in a one-hour Schroth-based exercise session, with the frequency of twice a week for five weeks. The exercise consists of active auto-correction in 3D, stabilizing the corrected posture, and training in ADL.
224278103|NCT05259956|BEHAVIORAL|"3 plus 1 multidimensional exercise therapy"|The intervention is set to be delivered in a 90-minute exercise session, with a frequency of twice a week for five weeks. The exercise consists of a one-hour Schroth-based exercise session and an additional 30-minute manipulative therapy of pelvic asymmetry.
223716411|NCT00481078|OTHER|placebo|Given PO
223716412|NCT00481078|OTHER|laboratory biomarker analysis|Correlative studies
223716413|NCT01558271|DRUG|LY2189265|
223716414|NCT01558271|DRUG|Placebo|
223716415|NCT01558271|DRUG|Liraglutide|
223915755|NCT06587607|BEHAVIORAL|VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.|VA CALM is a 9 week mindfulness curriculum typically delivered at a once/week module pace in group settings during sessions that last approximately 60-90 minutes. Module topics include: Program Introduction, Why mindfulness, Perception, What Makes Something a Pleasant Experience?, Being Stuck, Getting Unstuck, Communication, Mindfulness in Daily Life, and Today is the First Dat of the Rest of Your Life.
223915756|NCT06592742|BEHAVIORAL|Pulmonary rehabilitation (alone)|The Pulmonary Rehabilitation (PR) program for the control group includes daily aerobic exercises such as treadmill walking or cycling for 20-30 minutes at moderate intensity, tailored to improve cardiovascular fitness and respiratory function. Strength training focuses on major muscle groups with resistance exercises lasting 15-20 minutes, promoting muscle strength and endurance. Airway clearance techniques are performed for 15-20 minutes daily, using methods like chest physiotherapy or positive expiratory pressure (PEP) to clear mucus from the lungs. Breathing exercises, including diaphragmatic and pursed-lip breathing, are practiced for 10-15 minutes to improve breathing efficiency. Participants also receive education on disease management and nutritional support to meet caloric needs.
223915757|NCT06592742|BEHAVIORAL|Intervention group (PR + PMR)|The intervention group will follow a Pulmonary Rehabilitation (PR) program combined with Progressive Muscle Relaxation (PMR). Daily aerobic exercises like treadmill walking or cycling will be performed for 20-30 minutes at moderate intensity, improving cardiovascular fitness and lung function. Strength training for major muscle groups will be included, with 15-20 minutes of resistance exercises to enhance muscle strength. Airway clearance techniques, such as chest physiotherapy or PEP, will help clear mucus from the lungs in daily 15-20 minute sessions. Breathing exercises, including diaphragmatic and pursed-lip breathing, will be practiced for 10-15 minutes to improve breathing efficiency. The PMR component involves daily 20-30 minute guided sessions to reduce stress and anxiety through muscle relaxation techniques.
223915758|NCT06673082|DRUG|Oral zinc supplementation|Oral Zinc will be supplemented to the interventional group on a dose of 30 mg elemental zinc/day.
223915759|NCT06673082|OTHER|Placebo|Oral
223915760|NCT06590870|DRUG|Fentanyl|The fentanyl solution for administration will be prepared by diluting 2 mL of fentanyl 50 µg/mL with 8 mL of normal saline (bacteriostatic 0.9% sodium chloride) for a fentanyl solution of 10 µg/mL.
223915761|NCT06590870|DRUG|Normal saline|The normal saline solution for administration will be bacteriostatic 0.9% sodium chloride.
223915762|NCT06863896|PROCEDURE|Hartmann's reversal|Colostomy reversal with laparoscopic technique after Hartmann's procedure ( procto-sigmoidectomy with end colostomy)
223915763|NCT06863363|DRUG|PEG-rhGH Injection + Semaglutide Injection|"Polyethylene Glycol Recombinant Human Growth Hormone Injection (PEG-rhGH Injection), 54 IU/9.0 mg/1.0 mL/amp.; Subcutaneous injection using pen-injector, once weekly at a dose of 2 mg per week (weeks 1-40).~Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including dosage escalation period (W1-W16): starting dose 0.25 mg, increasing every 4 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and maintenance treatment period (W17-W40): at a dose of 2.4 mg for 24 weeks"
223915764|NCT06863363|DRUG|Semaglutide Injection|Semaglutide Injection, 0.68 mg/mL，1.5 mL；1.34 mg/mL，1.5 mL；1.34 mg/mL，3 mL；2.27 mg/mL，3 mL；3.2 mg/mL，3 mL; Subcutaneous injection once weekly using pre-filled pen including dosage escalation period (W1-W16): starting dose 0.25 mg, increasing every 4 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and maintenance treatment period (W17-W40): at a dose of 2.4 mg for 24 weeks
223915765|NCT06865196|BEHAVIORAL|Positive Parenting Seminar Series|Selected Teen Triple P Positive Parenting Seminar Series Delivered Through Telehealth
223915766|NCT06863935|DIETARY_SUPPLEMENT|High-dose omega-3 PUFA supplementation|High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy
223915767|NCT06863935|DIETARY_SUPPLEMENT|High-dose omega-3 PUFA supplementation|High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy
223915768|NCT06219616|DIAGNOSTIC_TEST|BKV immune monitoring|Blood will be drawn and investigated for BKV-specific T cell response.
223915769|NCT06769802|BEHAVIORAL|Experimental|"The children in this group and their mothers will be informed about the research and their written consent will be obtained. The scale will be filled in before the application. Before the application, Nebul will introduce the teddy bear to the mother and child. The teddy bear cannot be washed because it contains an electronic device. Therefore, it will be disinfected with a solution containing 60-70% alcohol before and after use. The recorded voice will then be played to the child and mother. Then, routine nebulizer treatment will be applied and the second audio recording will be played at the end of the treatment. The researcher will be with the child.~At the end of the nebulizer treatment, after the mask is removed, the Child Fear Scale and the Child Anxiety Scale-State Scale will be filled out. The Child Fear Scale will be filled in by both the mother and the nurse and the average will be taken."
224088994|NCT02684305|DRUG|Administration of Propess|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
224278104|NCT01652963|OTHER|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
224278105|NCT03590834|BEHAVIORAL|Center-based Intervention|"1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks"
224278106|NCT03590834|BEHAVIORAL|Home-based Intervention|"1. Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~2. Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~3. 16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~4. Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
224278107|NCT03590834|BEHAVIORAL|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
224278108|NCT05419817|DRUG|pembrolizumab|Pembrolizumab is an immunotherapy (monoclonal antibodies) that will be given at a dosage of 200 mg IV, on Day 1 of each 21 day treatment cycle
224278109|NCT05419817|DRUG|Sitravatinib|A small molecule inhibitor of multiple tyrosine kinases that will be taken at a dosage of 100 mg orally, every day
223915770|NCT06769802|BEHAVIORAL|Control|The children in this group and their parents will be informed about the research and their written consent will be obtained. Scales will be filled in before application. Children in this group will receive routine nebulizer treatment and routine application will be performed. At the end of the treatment, the scales will be filled in again.
223915771|NCT06767995|DEVICE|Flexible fiberoptic bronchoscopy|If Flexible Intubation Video Endoscope® (FIVE) will be used, the appropriate endotracheal tube is loaded into the bronchoscope and made ready. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started when the FFB started to pass through the patient's mouth/nose, and as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, the stopwatch was stopped and this time was recorded as the successful intubation time. The time between passing FFB through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. The endotracheal tube passage time was defined as the intubation time minus the best glottic visualization time and recorded. Complications during the procedure were recorded.
223940322|NCT02463214|OTHER|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
224278110|NCT03610919|DRUG|Nasal Sprays|Intranasal administration of 24 international units per dose.
224278111|NCT01465568|DRUG|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
224278112|NCT01465568|DRUG|bisphosphonates|continue present bisphosphonate treatment
224278113|NCT01393951|BIOLOGICAL|ASP7374|subcutaneous and intramuscular
223940323|NCT06004765|DRUG|Lenalidomide|10mg/d \*21 days, 28 days for 1 course
223940324|NCT06004765|DRUG|Azacitidine|75mg/m2/d\*5 days, 28 days for 1 course
223940325|NCT06465888|OTHER|egg whites|Participants will eat four egg whites daily for the 4-week study
223940326|NCT06465888|OTHER|whole eggs|Participants will eat two eggs daily for the 4-week study
223940327|NCT06465888|OTHER|Omega-3 eggs|Participants will eat two Christopher Farms omega-3 fortified eggs daily for the 4-week study.
223940328|NCT06465888|OTHER|egg yolk|Participants will eat four egg yolks daily for the 4-week study
223940329|NCT03695601|OTHER|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
223940330|NCT02899221|RADIATION|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
223940331|NCT02899221|PROCEDURE|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
223940332|NCT02899221|OTHER|Laboratory Biomarker Analysis|Correlative studies
223940333|NCT05886582|DRUG|Rotigotine Transdermal System [Neupro]|Neupro® 2mg/24h transdermal patches for the first seven days, followed by the target 4mg dose for the subsequent 35 days (five weeks) of dosing up to the follow-up assessments, followed by two days of 2mg/24h ramp-down dose.
223940334|NCT05886582|DRUG|Placebo|Placebo drug
223940335|NCT05071300|DRUG|Eplontersen|Eplontersen will be administered by SC injection.
223940336|NCT03307616|BIOLOGICAL|Ipilimumab|Given IV
223940337|NCT03307616|BIOLOGICAL|Nivolumab|Given IV
223940338|NCT03307616|RADIATION|Radiation Therapy|Undergo radiation therapy
223940339|NCT04175938|DEVICE|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
223940340|NCT01886872|DRUG|Bendamustine Hydrochloride|Given IV
223940341|NCT01886872|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223940342|NCT01886872|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223940343|NCT01886872|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223940344|NCT01886872|PROCEDURE|Computed Tomography|Undergo CT
223940345|NCT01886872|DRUG|Ibrutinib|Given PO
223940346|NCT01886872|OTHER|Laboratory Biomarker Analysis|Correlative studies
223940347|NCT01886872|OTHER|Quality-of-Life Assessment|Ancillary studies
223940348|NCT01886872|BIOLOGICAL|Rituximab|Given IV
223940349|NCT04261894|BEHAVIORAL|OPTIMIZE|The study intervention is implementation of the OPTIMIZE perinatal care checklist with patient navigation support. The checklist will contain perinatal care components to be assessed for each participant. Specifically, the checklist will be built into the electronic health record as a secure digital record of: (1) the participant's adherence to the recommended prenatal and postpartum visit schedule, (2) the completion of procedures and processes in a participant's prenatal and postpartum standard care plan, and (3) the completion of processes to address social determinants of health, along with completion of referrals to appropriate support resources. The OPTIMIZE checklist will also include records of patient navigation review, engagement, and tracking of barrier status and resolution
223915772|NCT06767995|DEVICE|Glidescope|If GlideScope® Titanium is to be used, a 50-60° angle is applied with the appropriate stylet, and the appropriate one from 3 pediatric blade sizes is selected according to the clinical experience of the relevant practitioner. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started as soon as the videolaryngoscope started to pass through the patient's mouth, and the stopwatch was stopped as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, and this time was recorded as the successful intubation time. The time between passing the videolaryngoscope through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. Endotracheal tube transit time was defined as intubation time minus best glottic visualization time and recorded. Complications during the procedure were recorded.
223915773|NCT05347069|DRUG|Aspirin|Aspirin 100 mg/day
223915774|NCT05347069|DRUG|No aspirin|No aspirin administered
223915775|NCT06252779|DEVICE|Plasma therapy equipment|The host of this product contains a high-voltage generator that can generate high-voltage electrical energy and deliver it to the treatment head. The air supply mechanism sends air to the ionization chamber inside the treatment head, which is ionized under the action of high-voltage electricity to generate thermal plasma, forming a particle flow mainly composed of active nitric oxide (pNO), which is then sprayed out from the nozzle of the treatment head to the target tissue of the human body. PNO particles can alter skin permeability, allowing them to act on specific parts of the body after transdermal absorption on the surface of the body.The patient will receive 14 days of treatment, with 20 minutes per day.
223915776|NCT06252779|DEVICE|Fake therapeutic device|False stimuli with the same appearance and pattern as Plasma therapy equipment.The patient will receive 14 days of treatment, with 20 minutes per day.
223915777|NCT03248479|DRUG|Magrolimab|Administered intravenously
223915778|NCT03248479|DRUG|Azacitidine|Administered according to region-specific drug labeling either subcutaneously or intravenously
223915779|NCT06170814|OTHER|Exercise|Exercise will be done for approximately 40 minutes, 3 days a week for 6 weeks. Ramps, obstacle jumping, stairs and tracks will be built to improve walking and balance functions. One group will be given external focus stimuli, the other group will be given internal focus stimuli.
223915780|NCT04980924|OTHER|no intervention|no intervention
223915781|NCT06253871|DRUG|IAM1363|Oral, immediate release capsules of IAM1363
223915782|NCT04262830|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging (MRI)|Cardiac magnetic resonance imaging will be performed to evaluate cardiac remodeling, function, and tissue characteristics
223915783|NCT04262830|OTHER|Accelerometer physical activity monitoring|Measurement of physical activity using hip-worn accelerometer.
224088995|NCT02684305|DEVICE|balloon|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
224088996|NCT02684305|DRUG|Intravenous oxytocin infusion|"1. History taking and physical examination including cervical length~2. Eligibility assessment~3. Explanation regarding the study protocol~4. Signed informed consent (at VAS\<3)~5. Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
224088997|NCT02909868|DEVICE|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
224088998|NCT01851538|OTHER|Observational study; no intervention.|
224088999|NCT00860470|DIETARY_SUPPLEMENT|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
223915784|NCT06862882|BEHAVIORAL|Community-Based Primary Health Care|Mediation between citizens and health workers to allow an orderly and appropriate use of social and health services
223915785|NCT06858722|DRUG|ripertamab|On Day 1 of the treatment period, an intravenous infusion of Ripertamab at a dose of 375 mg/m² body surface area will be administered.
223915786|NCT06858722|DRUG|Placebo|On Day 1 of the treatment period, an intravenous infusion of Placebo at a dose of 375 mg/m² body surface area will be administered.
223915787|NCT06858852|DRUG|ET-26HCl 0.8mg/kg group|The initial dose was 0.8 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)
223915788|NCT06858852|DRUG|Etomidate Injectable Product 0.3mg/kg group|The initial dose was 0.3 mg/kg administered as a single IV infusion over a period of 1 minute ±5 seconds. If needed, up to 50% of the starting dose was increased (30-seconds ± 5-seconds bolus)
223915789|NCT06856642|OTHER|Conservative Physical Therapy|"Transcutaneous Electrical Nerve Stimulation (TENS):It is an electrotherapy modality commonly used in pain management. Conventional TENS will be applied to our patients. The frequency of Conventional TENS will be 50 Hz, the pulse duration will be 80 µs, the amplitude will be of mild to moderate intensity as perceived by the patient, and the duration will be 20 minutes.~Hot Pack:It is a superficial heat therapy method commonly used to reduce muscle spasms, increase circulation, and alleviate pain.The packs, which are kept in hydrocollator tanks, will be applied at a temperature that will not harm the patient.The application time is 20 minutes.~Therapeutic Ultrasound:This method, which uses sound waves to support tissue healing, creates heating and healing effects in deep tissues and is commonly used to reduce pain and relieve muscle spasmsThe frequency of the applied ultrasound will be 1 MHz, with an intensity of 1.5 W/cm², and it will be applied for 8 minutes in continuous mode"
223915790|NCT06856642|OTHER|Abdominal Draw-in Manuever|Starting Position: The patient lies in a supine position with knees bent and feet flat on the ground. The neck and spine are kept in a neutral position. Breath Control: The patient focuses on abdominal expansion while inhaling and flattening the abdomen while exhaling. Transversus Abdominis Activation: The patient attempts to draw the abdominal muscles inward (pulling the navel toward the spine). During this movement, care should be taken to avoid pressing the lower back against the ground or contracting the hip muscles. The goal is to activate only the deep abdominal muscles. Checking for Proper Muscle Activation: The patient can place their fingertips on the lower abdominal region (just above the pelvic bone) to feel whether the transversus abdominis muscle is activating correctly. Maintaining the Position: The patient holds this activation for 5-10 seconds while continuing to breathe naturally, then relaxes. Muscles should be fully relaxed between repetitions.
223915791|NCT06856642|OTHER|Real-Time Ultrasound Biofeedback with Abdominal Draw-In Manuever|The patient, who has been instructed on the abdominal drawing-in exercise, assumes a supine position with knees bent. The ultrasound screen is positioned so that both the practitioner and the patient can see it. The researcher places the linear ultrasound probe on the patient's transversus abdominis muscle to obtain an image, which is then shown to the patient for awareness. The patient is instructed to keep their eyes on the screen and follow their muscle activity throughout the exercise. During the exercise, the patient's muscle is displayed on the screen, and they are asked to hold the contraction at its maximum level for 10 seconds. After the contraction phase, the patient is instructed to relax and rest for 2 minutes. The treatment is completed with a total of 10 repetitions.
223915792|NCT05565209|OTHER|SA brief descriptive name used to refer to the intervention(s) studied|Details that can be made public about the intervention
223915793|NCT06860997|DIAGNOSTIC_TEST|Tissue Doppler Imaging (TDI) S' Wave Echocardiography|This intervention involves bedside echocardiographic assessment using TDI S' wave velocity to evaluate its diagnostic accuracy for acute coronary syndrome (ACS) in patients presenting with acute chest pain in the emergency department (ED).
223915794|NCT06672666|DRUG|Hemp Derived Cannabidiol Extract|Participants will be given the study drug in a titrated method of 50-150mgs per day for 4 weeks
223915795|NCT06672666|DRUG|Placebo|Partcipants will be given placebo substance to be taken with titrated instructions that mimic IP dispensing method daily for 4 weeks
223915796|NCT06671262|RADIATION|SBRT|Target the primary tumor region with a single dose of 8Gy, or deliver a dose of 3Gy to the axillary lymph nodes, administered once a day for three consecutive days.
223915797|NCT06671262|DRUG|Immuno-chemotherapy|Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by epirubicin, cyclophosphamide, and toripalimab for another four cycles.
223915798|NCT04066881|BIOLOGICAL|Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|"1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant."
223915799|NCT04066881|BIOLOGICAL|Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|"1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional)."
223915800|NCT04066881|BIOLOGICAL|Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Sodium Chloride (NaCl) for injection, 0.9%
223915801|NCT04066881|DRUG|Control PrEP:TDF/FTC once daily (weeks 0-26)|Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
223915802|NCT04066881|DRUG|Experimental PrEP:TAF/FTC once daily (weeks 0-26)|Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
223915803|NCT06155916|DRUG|Pregabalin|Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.
223915804|NCT06606665|OTHER|Cognitive skills test|Cognitive skills; It will be evaluated with the Montreal Cognitive Assessment Scale.
223915805|NCT06606665|OTHER|Reaction time test|Reaction time; It will be evaluated with the 12-Red Square Test on the App-coo test application via tablet.
223915806|NCT06606665|OTHER|Quality of life assessment|Quality of life assessment; It will be evaluated with the Nottingham Health Profile.
223915807|NCT06606665|OTHER|Lower extremity muscle strength assessment|Lower extremity muscle strength assessment; It will be evaluated with a 30-second sit-and-stand test.
223915808|NCT06606665|OTHER|Hand grip strength measurement test|Hand grip strength measurement test; It will be evaluated with a dynamometer.
223915809|NCT06606665|OTHER|Pulmonary function assessment|Pulmonary function assessment; It will be evaluated by spirometry.
223915810|NCT06606665|OTHER|Balance assessment|Balance assessment will be done with the Wii Fit Balance Board.
223915811|NCT06290583|DRUG|Bupivacaine|Spinal anesthesia with standard dose of bupivacaine
223915812|NCT06290583|DRUG|Prilocaine|Spinal anesthesia with 50 mg dose of Prilocaine.
223915813|NCT06544863|OTHER|Data collection and blood sample|In addition to collecting medical data, additional blood samples will be collected in order to create a biological collection and identify biomarkers associated with the occurrence of cirrhosis-related complications, progression to TH and follow-up.
223915814|NCT06857123|BEHAVIORAL|Exercise with Rest|Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include two 45 minute rest periods between exercises and take about two and a half hours.
224278114|NCT02511860|DIETARY_SUPPLEMENT|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
224089000|NCT00860470|DIETARY_SUPPLEMENT|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
224089001|NCT06016816|PROCEDURE|Bilateral endoscopic sphenopalatine ganglion block|After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal,
224089002|NCT06016816|PROCEDURE|placebo|Placebo group (group:2) will be administered 4 cc saline. aspects will be evaluated.
224089003|NCT03689192|BIOLOGICAL|ARG1-18,19,20|300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
224089004|NCT00357773|DRUG|Azithromycin (T1225)|
224089005|NCT00135057|DRUG|insulin glulisine|
224089006|NCT00135057|DRUG|insulin glargine|
223940350|NCT04941482|BEHAVIORAL|Periodic health check program for post-stroke|The stroke survivors were assessed for their physical and mental health, recurrence risks, and harmful behaviors at 0, 1, 3, and 6 months using specific scales.
223940351|NCT04941482|BEHAVIORAL|Guiding the appropriate rehabilitation exercises|The appropriate rehabilitation exercises were designed and guided for each patient, and they were followed up by the daily online report.
224089007|NCT03184844|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
224089008|NCT04972877|OTHER|Treatment group protocol|"For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group."
224089009|NCT04972877|OTHER|Control group protocol|"For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes."
224089010|NCT03023904|BIOLOGICAL|Nivolumab|Given IV
224089011|NCT03023904|OTHER|Laboratory Biomarker Analysis|Correlative studies
224089012|NCT06448793|DRUG|Approved Non-small Cell Lung Cancer (NSCLC) therapies|As prescribed by treating physician
224089013|NCT02759042|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
224089014|NCT01105637|BEHAVIORAL|Augmented Exercise Program|12 week (3 x per week) exercise prescription
224089015|NCT02700984|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
224089016|NCT02700984|PROCEDURE|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
224089017|NCT00733525|BEHAVIORAL|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
224089018|NCT00733525|DRUG|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
224089019|NCT00733525|BEHAVIORAL|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
224089020|NCT01211808|DRUG|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
224089021|NCT01211808|DRUG|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
224089022|NCT00619008|OTHER|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
224089023|NCT00619008|OTHER|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
224089024|NCT00619008|OTHER|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
224089025|NCT05265650|DRUG|BO-112 in combination with ablative radiotherapy (SABR) and nivolumab|Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
224089026|NCT05265650|PROCEDURE|Tissue Biopsies|Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
223940352|NCT04941482|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will carry out on post-stroke patients in the first three months (one time per week in the first month and one time per the second and third month). This intervention method aims to discover and resolve patient's conflicts by a standardized communication skill to improve their mental health and change negative behaviors.
223940353|NCT04941482|DEVICE|Functional near-infrared spectroscopy|The fNIRS devices served as an effective monitoring and therapeutic tool, evaluating the evolution of neural activity and stroke rehabilitation and recovery. Moreover, the cortex hemodynamic measurement by fNIRS could detect various mental disorders such as depression, anxiety, schizophrenia early through cognitive tasks.
223940354|NCT05966155|OTHER|Pharmacogenetic testing|Genetic testing of CYP2D6 and CYP2C19
223940355|NCT05966155|OTHER|Clinical decisions support|Prescribing recommendations to the provider based on the pharmacogenetic testing results
223940356|NCT02743819|DRUG|Pembrolizumab|Pembrolizumab given every 3 weeks (200 mg) by IV infusion.
223940357|NCT02743819|DRUG|Ipilimumab|Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.
223940358|NCT05985915|DRUG|Ianalumab (VAY736)|Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use
224089027|NCT01543347|DRUG|Temocillin|Antibiotic treatment
224089028|NCT02648386|PROCEDURE|Laparoscopic surgery|Completely resected rectal tumor.
224278115|NCT02511860|DIETARY_SUPPLEMENT|Placebo|Methylcellulose (inert) tablet taken as placebo
224089029|NCT02648386|DEVICE|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
223915815|NCT06857123|BEHAVIORAL|Exercise without Rest|Participants in this arm exercise 3 times a week for 12 weeks. Exercise program consists of warm-up, strengthening exercises of the lower major extremity muscle groups, and aerobic training using a treadmill. These sessions include minimal resting periods between exercises and take about one hour.
224089030|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
224089031|NCT02648386|BIOLOGICAL|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
223915816|NCT06547632|DEVICE|ClearPetra Ureteral access sheath|Patients will be randomly assigned (1:1) to vacuum-assisted (ClearPetra) or traditional approach group for retrograde intrarenal surgery according to standard of care.
223915817|NCT06618898|OTHER|online questionnaire|The online questionnaire includes demographic data: age, gender, instrument (oboe, flute, clarinet, bassoon, and cello), years of service, number of services in the last six months and specific questions about orofacial pain, sleep bruxism, stress experiences, and sleep quality.
223915818|NCT06867744|PROCEDURE|Extracapsular Supradiscal Subperiosteal Surgical Procedure for Temporomandibular Joint Internal Derangement Correction|Patients in a supine extended position with nasotracheal intubation; oral intubation in such cases is not suitable as it makes dissection and disc repositioning difficult and compromises the surgery results. Periauricular incision with postauricular extension; after infiltration with noradrenaline 1/200000 solution with or without zylocaine which gives better exposure and better aesthetic results. Dissection down the wound till reach the temporal fascia starting posteriorlay till the fascia blended with the zygomatic arch anteriorly; identification of temporal root of zygomatic arch using fine dissector followed by subperiosteal dissection of zygomatic arch till five mm anterior to the articular eminence of TMJ. Accurate identification of TMJ followed by meticulous subperiosteal dissection of superior margin of TMJ capsule then the dissection continued posteriorly till posterior margin; no need to dissect the bilaminar zone, and the dissection continued anteriorly down the skull base t
224089032|NCT04833439|OTHER|Fasting Mimicking Diet|Low-caloric, low-protein, plant-based diet regiment for 3 days
224089033|NCT02557061|PROCEDURE|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
224089034|NCT02557061|BIOLOGICAL|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
224089035|NCT05807009|OTHER|core exercise|the patients will receive seven exercises performed in crook lying and side lying position on exercise mats. Cushions were used to allow the participants to be comfortable in all positions. The exercises in the crook lying position were core activation with breathing, single-leg lift with knees bent, single-leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight.
223716416|NCT05332665|DEVICE|AS-OCT|Anterior segment optical coherence tomography (AS OCT) is an imaging device that can acquire an anterior segment image using a noncontact method with the patient in a sitting position. This device provides reproducible and quantitative measurements of the AC angle and other anterior segment parameters.
223716417|NCT05332665|PROCEDURE|YAG laser PI|medical procedure which uses a laser device to create a hole in the iris, thereby allowing aqueous humor to traverse directly from the posterior to the anterior chamber and, consequently, relieve a pupillary block
223915819|NCT06867302|DRUG|Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML)|An infusion given all through intraoperative time
224089036|NCT05807009|OTHER|traditional therapy|the patients will receive : an active warm-up including low intensity movements and dynamic stretching; choreographed aerobic training, progressing gradually from low to moderate intensity; and a cool-down involving low intensity movements, and dynamic and static stretching
224089037|NCT01348802|BEHAVIORAL|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
224089038|NCT01348802|BEHAVIORAL|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
224089039|NCT00014092|BIOLOGICAL|aldesleukin|
224089040|NCT00014092|BIOLOGICAL|recombinant interferon alfa|
224089041|NCT00014092|BIOLOGICAL|sargramostim|
224089042|NCT00014092|DRUG|temozolomide|
224089043|NCT05784207|OTHER|Radiomics model to classify between IPF with UIP pattern and ILDs without UIP pattern|The aim is to evaluate the performance of AI with the performance of doctors
224089044|NCT00850252|DEVICE|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
223915820|NCT06867302|DRUG|Dexmedetomidine Injection [Precedex]|Single dose given 15 minutes before end of surgery
224089045|NCT01079767|DRUG|temsirolimus|
224089046|NCT01748799|DRUG|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
224089047|NCT01748799|DRUG|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
223915821|NCT06865638|PROCEDURE|Intraoperative leak testing|◦After anastomosis was completed, the integrity of anastomosis was tested intraoperatively. The methods include directly observing the integrity of the anastomosis under gastroscopy, immersing the anastomosis in 500 - 1000 mL of warm saline and temporarily occluding the distal end, filling the anastomotic bowel with air, and injecting 60 mL of methylene blue through colonoscopy. Wrapping a white gauze pad around the anastomosis and observing for methylene blue leakage.
224089048|NCT03705481|DEVICE|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
223716418|NCT01845831|DRUG|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
223915822|NCT06867419|RADIATION|Transient Elastography|participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.
223915823|NCT06866002|OTHER|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
223915824|NCT06866002|OTHER|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (arterial stiffness) for the patients of the subgroup and others questionnaires.
223915825|NCT06866808|OTHER|talocrural MWM and Therapeutic US|Mobilization with movement alongwith the therapeutic ultrasound
223915826|NCT06866808|OTHER|Conventional physiotherapy|Ankle isometrics, calf stretches, icing
223915827|NCT06867315|DEVICE|steep pulse therapy system|"1. Use steep pulse system to ablate the transitional zone of the prostate to treat BPH~2. The steep pulse generator employs irreversible electroporation technology, which involves inserting electrodes into the tumor and delivering high-voltage electrical pulses to create nanoscale permanent pores on the lipid bilayer of tumor cell membranes. This disrupts the intracellular balance and induces cell apoptosis"
223915828|NCT06867315|DRUG|Tamsulosin Hydrochloride|"1. use Tamsulosin Hydrochloride Sustained-Release Capsules to treat BPH~2. the brand name is Harnal®~3. the specification is 0.2mg per capsule"
223915829|NCT06867224|DEVICE|Shame TUS-vmPFC|The sham stimulation protocol maintained identical parameter settings to the active treatment group with equivalent application of ultrasound coupling gel at the left vmPFC site localized via the FP1 electrode. Crucially, the ultrasound transducer's output trigger was disabled during sham sessions, ensuring identical device operation procedures without acoustic energy delivery. Participants received daily 15-minute sham sessions matching the active group's 10-day treatment schedule.
223915830|NCT06867224|DEVICE|Active TUS-vmPFC|Participants in the active stimulation group will receive the transcranial ultrasound stimulation (TUS) targeted the left ventromededial prefrontal cortex (vmPFC), localized via the FP1 electrode position of the International 10-20 EEG system. The TUS will be delivered in the form of pulsed sinusoidal waves, with a fundamental frequency of 0.5 MHz and an intensity of 8 W/cm² (spatial peak pulse average intensity \[Isppa\]). The pulse duration will be 500 microseconds, and the sonication bursts will consist of 50 tone bursts per session, with a duty cycle of 5%. Each burst (pulse repetition frequency: 100 Hz) was followed by an 8-second inter-burst interval, yielding a total session duration of 15 minutes. Participants underwent one daily session for 10 consecutive days.
223915831|NCT06866418|DEVICE|1. Phagenyx® System Group Patients|Patients who have undergone Pharyngeal Electrical Stimulation (PES) treatment for severe dysphagia using the Phagenyx® System
223915832|NCT06866977|DRUG|Oncolytic virus VRT106|VRT106, IV
223915833|NCT06866977|DRUG|Chemotherapy|21 days/cycle
223915834|NCT06864702|BEHAVIORAL|Whether the patient received diagnosis and treatment at Zhujiang Hospital of Southern Medical University and retained medical images such as abdominal|The construction of a deep learning model for semantic segmentation of images during laparoscopic hepatobiliary and pancreatic surgery, focusing on classifying surgical stages, anatomical structures, surgical instruments, and surgical gestures, along with the validation of model performance (Intersection over Union, Dice score, accuracy, precision, recall, and F1 score).
223915835|NCT06863077|PROCEDURE|MCL Pie-Crusting|Percutaneous MCL Pie-Crusting
223915836|NCT06863064|DRUG|Dexmedetomidine|During the surgery, target-controlled infusion (TCI) pumps were used, employing the Dyck model for continuous infusion of propofol, with the target plasma concentration maintained at 0.2 ng/ml. Postoperatively, propofol was infused at a rate of 0.2-0.4 mcg/kg/hr according to the intensive care unit's protocol, until the patient had the endotracheal tube removed.
223915837|NCT06863064|DRUG|Normal Saline|During the surgery, equal volumes of saline were injected. After the surgery, the patient was transferred to the intensive care unit, where propofol was continuously infused at a rate of 0.2-0.4 mcg/kg/hr according to the ICU protocol, until the endotracheal tube was removed.
223915838|NCT06342921|DRUG|15 mg ADC189|Use only once during the whole study.
223915839|NCT06342921|DRUG|45 mg ADC189|Use only once during the whole study.
223915840|NCT06342921|DRUG|Placebo|Use only once during the whole study.
224089049|NCT00473876|DRUG|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
224089050|NCT00473876|DRUG|Matched Placebo (Capsules)|Similar dosing regime as active comparator
224089051|NCT03911622|DEVICE|MRI|medical device that is used as an imaging tool for soft tissues
223915841|NCT06865300|DRUG|Lidocain 40 mg|We injected 40 mg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.
223915842|NCT06865300|DRUG|lidocain 1 mg/kg|We injected 1 mg/kg lidocain before rocuronium injection. Then we recorded pain score by using visual analog scale.
223915843|NCT06865300|DRUG|serum physiologic|We injected serum physiologic before rocuronium injection. Then we recorded pain score by using visual analog scale.
223915844|NCT03030066|DRUG|DS-1001b|Generic not assigned
223915845|NCT05439018|OTHER|Integrated Neuromuscular inhibition|Integrated Neuromuscular Inhibition in addition to traditional treatment will be received three times a week for eight weeks. Integrated Neuromuscular Inhibition will be contain three combined manual treatment ( ischemic compression , strain counter strain , Muscle energy technique ) traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
223915846|NCT05439018|OTHER|traditional treatment|traditional treatment will be received three times a week for eight weeks . traditional treatment in Form of stretching and strenghthening of cervical muscles and postural advices
223915847|NCT06624631|OTHER|Adherence support strategy a|Monthly SMS reminders
223915848|NCT06624631|OTHER|Adherence support strategy b|Community Health Promoters' (CHPs) monthly reminder home visits
223915849|NCT06624631|OTHER|Adherence support strategy c|No monthly reminders
223915850|NCT06676826|DEVICE|Infrabony defects will be filled with a volume-stable collagen matrix (VCMX)|Infrabony defects will be filled with a volume-stable collagen matrix
223915851|NCT06676826|DEVICE|Infrabony defects will be filled treated with a deproteinized bovine bone mineral with 10% collagen|Infrabony defects will be filled with with a deproteinized bovine bone mineral with 10% collagen
223915852|NCT06676111|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
223915853|NCT06676111|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (W0, W4, W8)
223915854|NCT07011732|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
223915855|NCT07011732|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
223915856|NCT07011732|DRUG|Placebo|Specified dose on specified days
223915857|NCT07014462|DRUG|Dexamethasone plus Venetoclax-based Low-Intensity Therapy|Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or low-dose cytarabine, per treating physician's discretion. In addition, participants will receive dexamethasone administered orally at 10 mg twice daily on days 1-3 of cycles 1 and 2, and 20 mg orally on day 1 of cycles 3 through 6. This intervention is being studied to evaluate whether the addition of dexamethasone improves tolerability and clinical outcomes in patients unfit for intensive chemotherapy.
223915858|NCT06619860|DRUG|VX-993|Tablets for oral administration.
223915859|NCT06619860|DRUG|Pregabalin|Capsules for oral administration.
223915860|NCT06619860|DRUG|Placebo (matched to pregabalin)|Placebo matched to pregabalin for oral administration.
223716419|NCT01845831|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
223915861|NCT06619860|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
223915862|NCT07011706|DRUG|ATI-045|ATI-045 group
223915863|NCT07011706|DRUG|Placebo|Placebo group
223915864|NCT07017673|DRUG|Ivonescimab|Drug: Ivonescimab Dose: 20 mg/kg Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
223915865|NCT07017673|DRUG|Carboplatin|Drug: Carboplatin Dose: AUC6 Route: IV infusion Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
223915866|NCT07017673|DRUG|Docetaxel|Drug: Docetaxel Dose: 75 mg/m\^2 Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)
223915867|NCT05183646|DRUG|DMX-200|DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.
223915868|NCT05183646|DRUG|Placebo|Patients will receive 120 mg capsules of Placebo twice daily
223915869|NCT07018102|OTHER|Trunk Control Care Program|"1. The intervention group underwent a 4-week bedside trunk control care module intervention based on routine care in a rehabilitation ward.~2. trunk control care module: combine the care strategies of arm training, butterfly technique, shoulder control, diaphragmatic breathing and body awareness, practice twice a day, each time for 20-30 minutes, and can be adjusted according to the patient's condition."
223915870|NCT02940613|BEHAVIORAL|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
223915871|NCT05990166|OTHER|Mineral-enriched powder|Mineral-enriched powder Mineral-enriched powder to allow for at-home fortification of beverages with 5 mg of ferrous iron and 10 mg of zinc sulfate monohydrate
223915872|NCT05990166|OTHER|Placebo powder|Placebo powder which is identical to the mineral- enriched powder, but does not contain the active ingredients (ferrous iron and zinc sulfate monohydrate)
223940359|NCT05985915|OTHER|Placebo|Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use
223940360|NCT05869734|BEHAVIORAL|Sleep health promotion|We will provide sleep hygiene related adjustments in the intervention group A; and brief behavioral treatment for insomnia (BBTI) in the intervention group B.
223940361|NCT05869734|BEHAVIORAL|Urologic health promotion|We will provide information related to urologic health promotion in three groups (2 experimental groups and 1 comparison group).
223940362|NCT05869734|BEHAVIORAL|Pelvic floor muscle training|We will provide information related to pelvic floor muscle training in three groups (2 experimental groups and 1 comparison group).
223940363|NCT05948813|DRUG|TY-9591|The dose of TY-9591 tablet is 160 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
223940364|NCT05948813|DRUG|Osimertinib|The dose of Osimertinib is 80 mg once daily. A cycle of treatment is defined as 21 days of once daily treatment until meet the of discontinuation criteria.
223915873|NCT01475786|BIOLOGICAL|Low Dose: 16 mg Engensis (VM202)|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
223915874|NCT01475786|BIOLOGICAL|High Dose: 32 mg Engensis (VM202)|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
223915875|NCT01475786|OTHER|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
223915876|NCT06628401|BEHAVIORAL|Educational information (Control)|Information packs will be developed for participants outlining the importance of a control group in research studies to maximise compliance. Participants will receive a £10 gift voucher weekly that they can spend at selected retailers of their choosing.
223915877|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, excluding fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
223915878|NCT06628401|BEHAVIORAL|Educational information (Increasing F&V intake + Juice)|Information packs will be developed to support participants in increasing their intake of whole fruits and vegetables, including fruit juice. The information packs will be developed using published guidance from the UK government, expert panels, and regulatory bodies. The packs will be co-developed with the public to ensure the guidance is appropriate for its target audience. Participants will also receive a £10 supermarket voucher weekly to purchase fruit and vegetables.
223915879|NCT07024316|DRUG|ATL-001 (Ciclopirox oral solution)|Daily administration of oral ATL-001
223915880|NCT05484635|PROCEDURE|Diagnostic laparoscopy and inguinal mesh removal|Surgical examination and treatment of groin pain following inguinal hernia surgery by surgical exploration with a laparoscope or removal of mesh laparoscopically
223915881|NCT05484635|PROCEDURE|Diagnostic laparoscopy|Surgical examination through laparoscopy without removal of mesh
223915882|NCT07025447|BEHAVIORAL|Familia Bora|"Familia Bora is a couples-based group parenting program that takes place in a preferred location within the community among participants. Twelve couples will be enrolled in each village and form one parenting group. CHWs will be trained to deliver the intervention.~The program will involve 17 group sessions. Each session is expected to last 1.5 hours and will be delivered weekly for approximately 5 months. Each session will focus on various topics, including responsive caregiving, positive discipline, managing emotions and stress management, child nutrition, couples' communication, non-violent conflict resolution strategies in relationships, gender equity, and early child care and education. In addition to the weekly group parenting sessions, CHWs will be encouraged to conduct home visits to engage couples who miss sessions, reinforce key messages, and provide extra support for caregivers and children as needed."
223915883|NCT07026448|DIETARY_SUPPLEMENT|Energy Placebo Control|Participants will use their Energy Placebo Control as directed for a period of 6 weeks.
223915884|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks.
223915885|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 2|Participants will use their Energy Active Product 2 as directed for a period of 6 weeks.
223915886|NCT07026448|DIETARY_SUPPLEMENT|Energy Active Product 3|Participants will use their Energy Active Product 3 as directed for a period of 6 weeks.
223915887|NCT07024823|DRUG|AZD4248|AZD4248 will be administered orally.
223915888|NCT07024823|DRUG|Placebo|Placebo will be administered orally.
223915889|NCT07024823|DRUG|AZD4248|AZD4248 will be administered via IV infusion.
223915890|NCT07024823|DRUG|Placebo|Placebo will be administered via IV infusion.
223915891|NCT03591003|DIAGNOSTIC_TEST|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
223915892|NCT07029568|DRUG|NNC0705-0001|NNC0705-0001 will be administered orally.
223915893|NCT07029568|DRUG|Placebo|Placebo matching NNC0705-0001 will be administered orally.
223915894|NCT06185205|DRUG|Accelerated partial breast irradiation|High Dose Rate treatment delivery
223915895|NCT07025811|DRUG|Vevye®|Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.
223915896|NCT07025811|DRUG|Xiidra®|Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.
223915897|NCT06703333|COMBINATION_PRODUCT|Extracorporeal photopheresis (ECP)|"* Months 1-3: One ECP cycle (two-consecutive days) every other week for 3 months (12 procedures).~* Months 4-6: One ECP cycle every month for 3 months (6 procedures).~* Total: 18 procedures (within 6 months \~24 weeks)."
223915898|NCT06876363|GENETIC|EN-374|Single dose of EN-374 administered by intravenous infusion after mobilization and followed by enrichment
223915899|NCT06879652|OTHER|Increasing Dairy intake|The prediabetic and overweight participants aged 14-17 and 60-75 years consuming ≤1 serving of dairy per day who are assigned to the intervention group will consume 3 servings of dairy (milk, yogurt, cheese) before each meal throughout a day for 24 weeks.
223915900|NCT07208435|BEHAVIORAL|Web-Based Therapeutic Exercise Program|Participants complete an 8-week web-based therapeutic exercise program via Physitrack, with 30-45 minute sessions twice weekly. The program targets core strengthening, spinal mobility, posture correction, and pain reduction. Exercises progress weekly from basic core engagement and breathing techniques to advanced trunk control, dynamic movements, and integration. The platform provides instructional videos, reminders, educational content, and self-monitoring tools to enhance adherence, engagement, and self-management.
223940365|NCT05980481|DRUG|RC48-ADC（2.5mg/kg）|2.5 mg/kg intravenous infusion every 2 weeks
223940366|NCT05980481|DRUG|Trastuzumab|First load dose is 8.0mg , then 6.0 mg/kg intravenous infusion every 3 weeks
223940367|NCT05980481|DRUG|Toripalimab|3.0 mg/kg intravenous infusion every 2 weeks
223915901|NCT07208435|BEHAVIORAL|Traditional Home Exercise Program|Participants follow a 6-week traditional home exercise program with 30-40 minute sessions, twice weekly. The program focuses on flexibility, basic trunk and core strengthening, balance, and ergonomic practice. Exercises progress weekly, including cat-cow stretches, pelvic tilts, glute bridges, partial curl-ups, bird-dog, lunges, and posture training. Participants perform exercises independently at home using printed instructions, aiming to reduce pain, improve spinal mobility, and enhance functional outcomes.
223915902|NCT07208539|DRUG|Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1|The cohort A (borderline resectable) and cohort B (locally advanced) both received treatment with gemcitabine, albumin paclitaxel (administered on days 1, 8, and 15, with 4 weeks as one cycle) and adalimumab (administered once every 4 weeks, with 4 weeks as one cycle). After completing 2 cycles of treatment, they were sequentially given liposomal irinotecan combined with 5-FU/LV, oxaliplatin (administered once every 2 weeks, with 4 weeks as one cycle) and adalimumab (administered once every 4 weeks, with 4 weeks as one cycle). After completing 2 cycles of sequential treatment, surgical evaluation was conducted: for patients who could undergo radical surgical resection, surgery was performed within 2-4 weeks after the end of the conversion treatment stage, and the postoperative treatment plan was selected based on the investigator's judgment; for patients who could not undergo radical surgical resection, subsequent treatment plans could be selected based on the investigator's judgment.
223915903|NCT07209202|OTHER|High fructose meal|Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein.
223915904|NCT07209202|OTHER|Low fructose meal|55% total carbohydrate (6% fructose), 30% fat, 15% protein.
223915905|NCT07209202|OTHER|13C labeled fructose, oral|Tracer amount of 13C labeled fructose administered orally in the meals.
223915906|NCT07209202|OTHER|13C labeled fructose, intravenous|Tracer amount of 13C fructose administered intravenously
223915907|NCT07207746|BEHAVIORAL|Behavioral: Music Listening|Participants listened to slow-tempo instrumental classical music (40-60 dB) via headphones during the entire urodynamic procedure.
224089052|NCT05233358|PROCEDURE|Hepatic Artery Infusion Chemotherapy|HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
223915908|NCT07208942|DEVICE|Rectal Stimulation|"The stimulation balloon was lubricated with paraffin oil and inserted until the distal end of the balloon was 10 cm from the anal verge, so as to eliminate the influence of different stimulation sites on the subjects.~At the start of stimulation, the dilatable balloon was rapidly inflated to 60/80 mL, with a stimulation duration of 150 milliseconds. Concurrently with stimulation, the onset time of stimulation was marked on the electroencephalogram (EEG), and the time window for cortical potentials evoked by rapid rectal balloon distension stimulation was recorded. During the experiment, 35 stimulations were administered to the subjects; however, the first and last stimulations were excluded due to setup issues with the precision inflation-deflation control device for the intestinal balloon. Each stimulation was delivered as a 150-millisecond inflation pulse, providing 35 identical rectal stimulations. The inter-stimulus interval was randomly set to 12 ± 4 seconds, and EEG signals were"
223915909|NCT07209176|OTHER|Provider-level|The provider level component will involve an email to each of the genitourinary medical oncologists at Johns Hopkins with their NGS testing rate from preliminary data and compare this rate to the mean. The initial email will also include the 2025 ASCO guideline recommending somatic testing in virtually all metastatic prostate cancer patients. Providers who do not have baseline NGS testing rates available will also be emailed. Providers will subsequently be emailed their updated NGS testing rate at the conclusion of the study period.
223915910|NCT07209176|OTHER|Provider-level and patient-level|In addition to the provider component, patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing. The email will be sent by the MyChart Recruitment Innovation team. Those without email on file will have the same message and attachment sent via mail by our study coordinator.
224089053|NCT05233358|PROCEDURE|Transarterial Chemoembolization|"Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles."
224089054|NCT05233358|DRUG|Regorafenib|Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
224278116|NCT06349096|DEVICE|Alma Harmony|The ClearLift is a class IIb medical device, High Power Q-switched (QS) 1064nm Nd:YAG laser module in the Harmony system. It has a targeted laser module for the non-invasive removal of various colored tattoos, as well as deep and superficial benign pigmented lesions, wrinkles, fine lines, and skin tightening.
224278117|NCT04318769|BEHAVIORAL|AFFIRM|AFFIRM is an 8-session manualized group coping skills intervention focused on reducing sexual risk behaviours and psychosocial distress among SGMY. AFFIRM is delivered by two facilitators (primarily social workers and peers) through a combination of education and rehearsal (i.e., simulation of real-life experiences) in a manner that affirms participants' sexual and gender minority identities and experiences.
224278118|NCT02129062|DRUG|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
224278119|NCT02129062|OTHER|Laboratory Biomarker Analysis|Correlative studies
224278120|NCT02773940|DEVICE|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
224278121|NCT04505735|DRUG|11C-PiB|Pittsburgh Compound-B (11C-PiB) is a diagnostic imaging agent that binds to beta-amyloid plaques and allows them to be viewed using positron emission tomography (PET) imaging.
223915911|NCT07208383|OTHER|Questionnaire|Questionnaire to examine awareness, knowledge, and help-seeking behaviors among gynecological patients and the general public
223915912|NCT07208149|DRUG|MR001 Bispecific Antibody for Injection|Intravenous infusion
223915913|NCT07207603|OTHER|No intervention|No intervention
223915914|NCT07208994|OTHER|Description|No intervention
223915915|NCT07209124|OTHER|Experimental: Intervention 1 (AB): Engagement in Motion-Based Activities (Wii & Magic Table)|Group to receive treatment/intervention in the AB schedule - Wii first and then magic table
223915916|NCT07209124|OTHER|Experimental: Intervention 2 (BA): Engagement in Motion-Based Activities (Magic Table BA)|Group go receive treatment in the BA schedule -- magic table first and then Wii
223915917|NCT07207395|DRUG|JBI-802|LSD1/HDAC6 Inhibitor
223915918|NCT07207395|DRUG|Pembrolizumab|PD-1
223915919|NCT07209293|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Transesophageal echocardiography images will be taken prior to and post oral gastric suction.
223915920|NCT07208019|OTHER|Acupuncture|Electroacupuncture group: After local routine disinfection.Select the main acupoints of bilateral frontoparietal line (MS2), Tianzhu (BL10), Fengchi (GB20), blood supply, parietal midline (MS5), and parietal midline (MS8). Connect the wires of the electroacupuncture instrument to the same side of the bilateral frontoparietal line(MS2) and Tianzhu acupoint (BL10), and perform head electroacupuncture treatment on both sides with a pair on each side.There are two groups of electroacupuncture, with a continuous frequency of 100Hz, and each electroacupuncture stimulation lasts for 30 minutes. After enrollment, treatment will be conducted 5 times a week for 8 weeks.
223915921|NCT07208019|OTHER|Acupuncture|Sham electroacupuncture group: After local routine disinfection. Choose the same acupoints as the electroacupuncture group, but use a specially designed electroacupuncture instrument that cannot output current, with only indicator lights or parameter displays when in use.
223915922|NCT07208318|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
223915923|NCT07207850|BEHAVIORAL|Parents Helping Parents program|Our innovative vaping cessation program will include two key components: 1) online training for parents and their offspring, and 2) parent-helping-parent coach sessions. Parents and children in the control setting will receive no treatments during the intervention (Baseline to Month 3). Dyads will be provided online training materials after the 6 month follow up.
223915924|NCT07208916|DIETARY_SUPPLEMENT|Grape Powder|All participants will consume two 36g packets of grape powder (mixed with water) daily for two, 2-week periods during the study. Participants will mix pre-measured grape powder with water and drink twice a day (once in the morning and in the afternoon/evening) for two weeks.
223915925|NCT07208071|OTHER|Augmented reality headset use|Use of a Microsoft HoloLens 2 headset with augmented reality assistance
223915926|NCT07208825|DEVICE|rTMS|2 weeks starting period (10 treatment days) followed by 5 treatment once a month.
223915927|NCT07208825|OTHER|Basic physical therapy treatment|10 sessions with physical (or occupational) therapist with special education for treating CRPS
223915928|NCT07208825|OTHER|Functional neurology|4 to 6 sessions with specialized OMT-physical therapist who will aim to improve the neurological deficits of the CRPS patient
223915929|NCT07208825|DRUG|Optimizing the medication|Aim is to optimize the medication of the CRPS patient according the the medication guidelines
223915930|NCT07209215|DRUG|Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)|Use of Signatera Genome ultra-sensitive ctDNA blood test post-total neoadjuvant therapy (TNT) for ctDNA-informed treatment management of early-stage rectal cancer.
223915931|NCT07207733|DEVICE|PcyCare: Self-Directed Education Platform for Pregnant Women|This intervention involves the use of the PcyCare self-directed education platform by pregnant women for one week. Participants will access educational modules on nutrition, pregnancy warning signs, mental health, and childbirth preparation. The platform includes interactive content, instructional videos, and quizzes to enhance participants' understanding. Data on ease of use, satisfaction, and increased understanding will be collected through questionnaires. In addition, midwives/practicing midwives and information technology/media experts will assess the quality of the platform's content and features through expert reviews to evaluate the platform's suitability and improvements before wider trials.
223915932|NCT07207382|DRUG|MTA group|MTA group is considered the control group
223915933|NCT07207382|DRUG|Premixed Bioceramic material|Premixed Bioceramic material is test group B
223915934|NCT07207382|DRUG|Treated Dentin Matrix|Treated Dentin Matrix is test group C
223915935|NCT07207369|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
223915936|NCT07207369|DEVICE|Saline Control|Intradermal Injections
223915937|NCT07208773|DRUG|YL201|YL201 will be administered as IV infusion
223915938|NCT07208773|DRUG|Ivonescimab|Ivonescimab will be administered as IV infusion.
223915939|NCT07208851|BEHAVIORAL|Problem Management Plus booster session|A 60-minute session designed to refresh participants on the PM+ strategies (diaphragmatic breathing, problem management, behavioral activation, strengthening social support). Session consists of practicing strategies and developing plans for the future.
223915940|NCT07209228|BEHAVIORAL|Haptic-Integrated Interactive Virtual Reality Experience|Participants will use haptic gloves to interact with the virtual reality experience
223915941|NCT07209228|BEHAVIORAL|Traditional Virtual Reality Experience (Hand Controllers)|Participants will use traditional hand controllers to interact with the virtual reality experience
223915942|NCT07208500|PROCEDURE|RIPC|Inflate a standard blood pressure cuff on one upper arm to 200 mmHg, maintain this pressure for 5 minutes, then deflate the cuff and keep it deflated for another 5 minutes. Repeat this process for 4 cycles.
223915943|NCT07207590|OTHER|web-based gamification application|Subject review and case analysis will be performed through a web-based gamification application on postpartum hemorrhage management, which will be prepared and developed by the game developer.
223915944|NCT07207590|OTHER|control group: traditional classroom learning techniques|Students in the control group will be taught topic review and case analysis using traditional classroom learning techniques
223915945|NCT07208903|BEHAVIORAL|focus group discussions|"These sessions will address:~* emotional reactions to the disclosure of the result~* perceptions and representations of the disease and its treatment~* the impact on the parent-child relationship~* the lived experience of neonatal screening and the perception of the support provided"
223915946|NCT07208903|BEHAVIORAL|Interview with the psychologist|"These sessions will address:~* emotional reactions to the disclosure of the result~* perceptions and representations of the disease and its treatment~* the impact on the parent-child relationship~* the lived experience of neonatal screening and the perception of the support provided"
223915947|NCT07208188|DEVICE|Transcutaneous spinal cord stimulation (tESCS) active group|Participants in the active arm will receive 60 min of tESCS alongside the conventional occupation therapy, 20 sessions for 4 weeks, 5 times per week
223915948|NCT07208188|DEVICE|Sham transcutaneous spinal cord stimulation (tESCS)|The control group will receive only 1 min of tESCS while doing conventional occupational therapy for 60 min. Number of session 20, 4 weeks, 5 times a week
223915949|NCT07209163|DRUG|Tazemetostat|Tazemetostat 800mg, twice once daily (BID), orally
223915950|NCT07209163|DRUG|Linperlisib|"In Phase I, BOIN design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of Linperlisib: 60 mg once daily (QD) and 60 mg QD, orally.~In Phase II, BOP2 design will be adopted to enroll around 24 participants, aiming to evaluate the efficacy and safety of Tazemetostat with Linperlisib RP2D in patients with peripheral T-cell lymphoma with co-RHOA/TET2mut."
223915951|NCT07209163|DRUG|Golidocitinib|"In Phase I, BOIN design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of Lgolidocitinib: 150 mg every other day (QOD) and 150 mg QD, orally.~In Phase II, BOP2 design will be adopted to enroll around 24 participants, aiming to evaluate the efficacy and safety of Tazemetostat with Golidocitinib RP2D in patients with peripheral T-cell lymphoma without co-RHOA/TET2mut."
223915952|NCT07208240|DRUG|Tb-PSMA-I&T (Tb-PSMA)|Terbium-161 produce beta emission with the addition of Auger electrons which have higher linear energy transfer and a very short range. By that it has the potential to improve local and distal (micro-metastatic disease) efficacy with a similar safety profile. It will be given to patients with high risk locally advanced prostate cancer prior to Radical prostatectomy
223915953|NCT07208708|OTHER|Scalloped margin retainer|Patient satisfaction was assessed during 2 weeks of whitening with a scalloped orthodontic retainer. Colour change, TS and IG were also measured. No studies have evaluated the effect of different margin designs in orthodontic retainers used in for tooth bleaching. Therefore, the present study aimed to clinically assess the impact of scalloped and straight margin design in orthodontic retainers employed for at-home bleaching, considering patient satisfaction, bleaching efficacy, tooth sensitivity (TS), and gingival irritation (GI).
223915954|NCT07208708|OTHER|Straight orthodontic retainer|Patient satisfaction was assessed during two weeks of whitening with a straight orthodontic retainer. Colour change, TS and IG were also measured. No studies have evaluated the effect of different margin designs in orthodontic retainers used in for tooth bleaching. Therefore, the present study aimed to clinically assess the impact of scalloped and straight margin design in orthodontic retainers employed for at-home bleaching, considering patient satisfaction, bleaching efficacy, tooth sensitivity (TS), and gingival irritation (GI). The null hypotheses were that no significant differences would be observed in: (1) patient satisfaction, (2) bleaching efficacy, (3) tooth sensitivity, and (4) gingival irritation, when different margin designs are used in orthodontic retainers for at-home tooth bleaching.
223915955|NCT07208279|DIETARY_SUPPLEMENT|Axolt Brain Supplement|https://axoltbrain.com/ Axolt is a brain health supplement. It includes native ingredients, formulated to help the brain perform at its best.
223915956|NCT07208279|DIETARY_SUPPLEMENT|Bolero - Flavored Drink Placebo|The control group will be asked to consume 1 packet of Bolero flavored water mix hydration enhancement also in about 16 oz of water once a day for 45 days.
223915957|NCT07208474|OTHER|Laughter yoga|Laugher yoga
223915958|NCT07209020|DEVICE|HealiAid Collagen Wound Dressing|Within the surgery procedure, the tumor is completely removed and the wounds are cleaned properly before applying the HealiAid Collagen Wound Dressing. HealiAid is soft and pliable. It can be adjusted to the size of the wound, and it is recommended to apply one to four pieces per wound. HealiAid Collagen Wound Dressing will be kept in place until absorbed completely.
223915959|NCT07208175|OTHER|Ultrasound-Guided Peripheral Intravenous Catheter Insertion|In this arm, PIVC insertion is performed by oncology nurses who have completed a structured ultrasound training program. Nurses use real-time ultrasound imaging to identify and select a suitable vein, guide the advancement of the catheter, and confirm placement. This method contrasts with the standard touch-and-feel approach by incorporating ultrasound technology and specialized nurse training to improve first-time insertion success and reduce complications.
223915960|NCT07208175|OTHER|Traditional Peripheral Intravenous Catheter Insertion|PIVC insertion performed by oncology nurses using the conventional touch-and-feel landmark technique, relying on visual inspection and palpation of veins. Represents current standard clinical practice in oncology.
223915961|NCT07208812|PROCEDURE|Conventional open -tray impression|Primary impression with irreversible hydrocolloid, custom tray with open window, and final impression with silicone material around impression copings to fabricate a 3D-printed implant overdenture
223915962|NCT07208812|PROCEDURE|Functionally generated reline impression|Interim prosthesis relieved and reline impression taken during centric closure with border molding, scanned to construct a 3D-printed implant overdenture
223915963|NCT07208812|PROCEDURE|Mucostatic base with functional borders impression|Intraoral scan of edentulous arch, 3D-printed baseplates for occlusion rim, functional border molding, and digital workflow to fabricate 3D-printed implant overdenture
223940368|NCT05980481|DRUG|Oxaliplatin（130mg/m2 ）|130mg/m2 intravenous infusion Q3W
223716420|NCT01845831|DRUG|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
223716421|NCT01845831|DRUG|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
223716422|NCT01845831|DRUG|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
223716423|NCT01845831|DRUG|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
223716424|NCT00760097|DEVICE|Transcranial direct stimulation|sessions of 20 minutes each
223915964|NCT07208305|DRUG|Olanzapine|Oral olanzapine (2.5mg per night, oral, 30 minutes before taking opioids on the first day of treatment), for 7 consecutive days.
223915965|NCT07208305|DRUG|Metoclopramide|Metoclopramide (10mg/ time, orally, 3 times a day) was taken orally for 7 days.
223915966|NCT07208266|BEHAVIORAL|contingency management|Participants with opioid use disorder admitted to the inpatient addiction management unit will receive a contingency management (CM) program as a behavioral intervention. The program consists of providing positive reinforcement (small rewards or incentives) contingent upon objective evidence of desired behaviors, primarily drug abstinence verified by urine toxicology screening. The intervention will be delivered throughout the inpatient stay (approximately two weeks). Participants' adherence and abstinence will be monitored, and rewards will be adjusted based on performance.
223915967|NCT07209267|DRUG|Antiretroviral Therapy (ART)|"Antiretroviral Therapy (ART): A treatment regimen for HIV infection that uses a combination of antiretroviral drugs to suppress viral replication, reduce HIV-related morbidity, and prevent transmission.~In Step 1, participants will continue their current ART regimen for 26 weeks.~In Step 2, participants will interrupt ART.~In Step 3, participants will restart ART treatment early if they meet the ART restart criteria before the end of Step 2 (24-week maximum). Otherwise, they will resume ART at the end of Step 2."
223915968|NCT07209267|DRUG|Baricitinib (LY3009104) 2 mg|"Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients.~During Step 1, Baricitinib will be taken at a dose of 2 mg orally daily for 26 weeks.~During Step 2, Baricitinib alone will be continued at a dose of 2 mg orally daily for up to an additional 24 weeks"
223915969|NCT07207447|PROCEDURE|Improving the stability and re-fixation with different modalities|Improving the stability and re-fixation with different modalities such as exchange plate with longer plate, intramedullary nailing, exchange nailing with larger diameter, plating over nail or dynamization of intramedullary nail.
223915970|NCT07207447|PROCEDURE|Re-fixation with biological stimulation|Re-fixation with biological stimulation such as bone grafting, either with plate and bone graft, plate over nail and graft, or with external fixation with LRS or Ilizarov and grafting in one stage or two stages.
223915971|NCT07207447|PROCEDURE|complex care with non-union resection and bone reconstruction|complex care with non-union resection and bone reconstruction, including resection of the non-union and dealing with the defect with bone transport, either direct transport or staged with cement spacer and later bone transport, Masquelet technique or acute compression and lengthening with another osteotomy.
223915972|NCT07207447|PROCEDURE|Amputation|Amputation with consideration of prosthesis.
223915973|NCT07208370|OTHER|clinical assessment|standraized clinical evaluation to assess disease sevirity and progration
223915974|NCT07208929|RADIATION|MRI|Brain and Spinal Cord MRI
223915975|NCT07208201|PROCEDURE|bronchoscopy|"BAL is performed with the fiberoptic bronchoscope in a wedge position within the selected bronchopulmonary segment.~The total instilled volume of normal saline should be no less than 100 ml and should not exceed 300 ml.~Three to five sequentially instilled aliquots are generally withdrawn after each aliquot instillation.~For optimal sampling of distal airspaces, the total volume (pooled aliquots) retrieved should be greater than or equal to 30% of the total instilled volume.~A total volume of retrieved fluid less than 30% may provide a misleading cell differential, especially if total retrieved volume is less than 10% of total instilled volume.~If less than 5% of each instilled aliquot volume is recovered during the procedure due to retention of most of the fluid in the lavaged segment, the procedure should be aborted to avoid increased risk of tissue disruption and/or inflammatory mediator release due to overdistention of the lavaged segment."
223915976|NCT07208136|DRUG|JMKX005425|JMKX005425 administered orally.
223915977|NCT07208734|DEVICE|Transcranial Alternating Current Stimulation (tACS)|Gamma TranscraniaThis intervention uses a personalized transcranial alternating current stimulation (tACS) protocol specifically designed for older adults with cognitive impairment. Unlike standard brain stimulation approaches, this protocol is individualized through artificial intelligence-based modeling of each participant's brain imaging data to optimize electric field distribution. The study will evaluate both safety and effectiveness in a multicenter randomized controlled trial.l Alternating Current Stimulation (tACS)
223915978|NCT07208734|OTHER|AI-based Cognitive Training|This intervention provides a personalized cognitive training program tailored to multiple cognitive domains. Using algorithm-based task matching, the system delivers training exercises adapted to each participant's cognitive profile. The program is designed to target memory, attention, executive function, and language, and will be validated through a multicenter randomized controlled trial.
223915979|NCT07208734|OTHER|Sham intervention|The sham stimulation group will undergo the same setup procedures as the active tACS group, including electrode placement and device operation. However, no effective current will be delivered beyond an initial brief sensation, ensuring participants cannot distinguish sham from active stimulation. This allows blinding of participants and investigators to treatment allocation.
223940369|NCT05980481|DRUG|Capecitabine（1000mg/m2）|1000mg/m2 per os Q3W
223716425|NCT04959916|BEHAVIORAL|Group Metacognitive Therapy|Group Meta-Cognitive Therapy (Group-MCT) will consist of six weekly sessions delivered by two trained trainee clinical psychologists over 1-1.5 hours. The aims of the intervention are to help participants develop knowledge that can facilitate control of worry, rumination and attention, and to modify the metacognitive beliefs that maintain these unhelpful patterns of thinking. The treatment follows a manual that has been previously evaluated in the treatment of cardiac patients suffering from anxiety and depression. Sessions include group discussions, experiential learning and homework tasks that participants will be expected to complete between sessions.
223716426|NCT02172768|OTHER|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
223716427|NCT02172768|OTHER|daily dosing|micafungin daily for 8 days
223716428|NCT02172768|DRUG|micafungin|
223716429|NCT01988688|DEVICE|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
224089055|NCT05233358|DRUG|Immune Checkpoint Inhibitors|Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
224089056|NCT05066685|OTHER|All participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
224089057|NCT00348140|DRUG|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
224089058|NCT00348140|DRUG|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
223915980|NCT07208721|BEHAVIORAL|The Key to Emotional Balance|"The Key to Emotional Balance (KBA) program consists of eight sessions, each lasting 40-50 minutes, and aims to help participants develop emotional balance. The first session introduces the individual, introduces group rules, provides information about the program, and supports the client in identifying and expressing their emotions. The second session encourages the client to assess their energy-time intensity in their current and future balance models and, if deviations occur, to restructure them. The third session will help participants recognize their abilities in coping with bipolar illness and its symptoms and to use these abilities effectively. They will also be encouraged to identify factors that hinder their ability to use their abilities and focus on their developed abilities. The fourth session will focus on developing a positive perspective, enabling them to approach bipolar illness and its symptoms from a positive perspective. The fifth session will support participants"
223915981|NCT07207655|OTHER|HPV Card Game|HPV Card Game Group: Twenty individuals in the intervention group will receive HPV education using the card game method.
223915982|NCT07207473|BEHAVIORAL|Behavioral strategy program X plus Y|Brief 4 session education program with sleep specialist focused on behavioral strategies for improving use of sleep apnea therapy. Tests behavioral strategy program X plus Y.
223915983|NCT07207473|BEHAVIORAL|Behavioral strategy program X|Brief 4 session education program with sleep specialist focused on behavioral strategies for improving use of sleep apnea therapy Tests behavioral strategy X.
223915984|NCT07208955|PROCEDURE|heat application|Heat application in the early postoperative period affects gastrointestinal function and mental well-being
223915985|NCT07208955|PROCEDURE|abdominal massage|Abdominal massage administered in the early postoperative period has an effect on gastrointestinal function and mental well-being.
223915986|NCT07208955|OTHER|control group|control group
224089059|NCT00348140|OTHER|Placebo|Placebo
224089060|NCT00516919|DRUG|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
224089061|NCT00516919|BEHAVIORAL|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
224089062|NCT01872455|DIETARY_SUPPLEMENT|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
224089063|NCT01872455|DIETARY_SUPPLEMENT|Usual diet|Usual diet of the patients
224278122|NCT03738787|PROCEDURE|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
224278123|NCT03738787|PROCEDURE|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
224278124|NCT06181253|OTHER|Preoperative education|The intervention will be an instructional video describing proper walking technique particularly up flights of stairs for patients to do at home. This will be shown at preoperative surgical clinic and will be available for access at home from patient's cell phones. The video is currently in production at BMC. Additionally, text reminders will be sent daily to remind patients to walk at home.
224278125|NCT06181253|BEHAVIORAL|Moderate aerobic exercise|Participants will be encouraged to compete 140-150 minutes of moderate aerobic exercise per week- achieved by two walking sessions per day 10-11 minutes in length (realistic/achievable goal)
223915987|NCT07208448|DEVICE|Voll Degradable Shoulder Spacer|Voll Degradable Shoulder Spacer
223915988|NCT07209241|BIOLOGICAL|CART-EGFR-IL13Ra2 T cells|CART-EGFR-IL13Ra2 cells are autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2.
223915989|NCT07207538|OTHER|Other: Strength physical exercise programme|12 multi-joint strength exercises will be developed. Participants will be taught the rating scale of perceived exertion (RPE) based on the number of repetitions in reserve (RIR). Participants will be asked that during the performance of each of the exercises they must perceive an effort between 7-8 within the overall score of the scale (0-10; 0 = no effort at all and 10 = cannot perform one more repetition, i.e. maximal effort). When subjects perform the 12 repetitions with lower perceived exertion than the set effort in two consecutive sessions with full range of motion the training load will be increased by about 2-10% following the American College of Sports Medicine guidelines and reassessed using the RIR-based RPE. Patients in the usual treatment group will continue to participate in their existing rehabilitation programmes, but will not be included in the strength training programme.
224089064|NCT02489370|DEVICE|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
224089065|NCT03371355|DRUG|Placebo|Placebo (Matched with ISIS 703802)
224089066|NCT03371355|DRUG|ISIS 703802 40 mg|ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
224278126|NCT06181253|OTHER|Text messages|Text reminders will be sent daily to remind patients to walk at home.
224278127|NCT06181253|BEHAVIORAL|Pedometer|Participants will be encouraged to walk 10,000 steps daily which will be tracked with a pedometer
223915990|NCT07207538|OTHER|Other: Normal life|Description: Normal life and carry out all the activities they have been doing previously.
224089067|NCT03371355|DRUG|ISIS 703802 80 mg|ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
224089068|NCT03371355|DRUG|ISIS 703802 20 mg|ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
224089069|NCT02059876|DRUG|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
223915991|NCT07208695|DRUG|Antiplatelet or Anticoagulant Drugs|The goal of this observational study is to assess the effect of postoperative continuous use of standard-dose oral antiplatelet (e.g., aspirin, clopidogrel) or anticoagulant drugs (e.g., warfarin, direct oral anticoagulants) on key postoperative outcomes in patients with primary lower extremity varicose veins who have undergone endovenous radiofrequency ablation (RFA) of the great saphenous vein. Unlike studies focusing on preoperative medication adjustment or single-drug cohorts, this study specifically targets routine postoperative medication use without protocol-mandated dose changes, and distinguishes between two major classes of antithrombotic agents while including a non-user control group. The main questions it aims to answer are: 1) Whether postoperative oral antiplatelet/anticoagulant use correlates with increased 30-day bleeding risk (defined by standardized criteria: minor = localized ecchymosis needing no intervention; major = bleeding requiring transfusion or surgical hemo
223915992|NCT07209254|OTHER|High-touch blood pressure management|Twelve weeks of text-based home blood pressure monitoring with BP self-management and team-based care
223915993|NCT07209254|OTHER|Low-touch blood pressure management|10 days of text-based home blood pressure monitoring
223915994|NCT07208344|BIOLOGICAL|Intravenous infusion of mononuclear cells from umbilical cord blood|When performing cell infusion, it is essential to use an infusion set and follow the standard blood transfusion procedures. Before, during, and after the infusion, monitor the patient's body temperature, pulse, breathing, and blood pressure. When infusing cells, first flush the tube with 20-30 ml of 0.9% sodium chloride, and start the infusion at a rate of 20-30 drops per minute. After half an hour, if there are no adverse reactions, increase the rate to 30-50 drops per minute. During the cell infusion process, gently shake the cell bag once every 15 minutes. After the infusion is completed, flush the cell preservation bag with 20 ml of 0.9% sodium chloride and gently shake it. After that, use 0.9% sodium chloride to rinse the infusion set to remove the cells completely, to ensure the quantity of cell infusion.
223915995|NCT07208344|DRUG|Conventional medical treatment：donepezil, rivastigmine or galantamine|The treatment is carried out using drugs such as cholinesterase inhibitors (ChEI) which are suitable for mild to moderate Alzheimer's disease. For example, donepezil, rivastigmine, galantamine, etc. The frequency and dosage of drug administration should be in accordance with the instructions provided by the drug manufacturer.The patient should maintain the stability of the medication regimen throughout the entire study period.
223915996|NCT07209280|OTHER|Cannulated Bone Bolt® Screw System|Patients treated with the Cannulated Bone Bolt® screw system for Lateral Compression Type -1 (LC-1) fractures.
223915997|NCT07209280|OTHER|Standard Cannulated Screw System|Patients treated with the Standard Cannulated Screw System for Lateral Compression Type -1 (LC-1) fractures.
223915998|NCT07207824|DRUG|Active Comparator: BCG induction and maintenance|"Drug: Bacillus Calmette-Guerin Immunotherapy treatment approved by NMPA for patients with high-risk non-muscle invasive bladder cancer~Other Names:~BCG"
223915999|NCT07207824|DRUG|DV + BCG induction and maintenance|"Drug: Disitamab vedotin(RC48) •An antibody-drug conjugates (ADCs) targeting HER2, has been approved in China for chemotherapy-refractory advanced UC with HER2-expression.~Other Names:~• RC48, DV~Drug: Bacillus Calmette-Guerin Immunotherapy treatment approved by NMPA for patients with high-risk non-muscle invasive bladder cancer~Other Names:~BCG"
223916000|NCT07208253|DRUG|Bupivacaine + Dexamethasone|20 mg bupivacaine (4 mL of 0.5%) combined with 8 mg dexamethasone, sprayed locally over the mesh and surrounding tissues after placement during laparoscopic TEP hernioplasty.
223916001|NCT07207785|DRUG|Pirtobrutinib|Patients will receive pirtrobrutinib at a starting dose of 200 mg once daily (q.d). All treatment will be administered orally and a cycle will be defined as 28 days in length and should be maintained regardless of dose interruptions. Treatment is meant to be administered until tumor progression, unacceptable adverse event, or patient decision for interruption.
223916002|NCT07208006|DRUG|Standard Lipid-Lowering Therapy|Participants will receive lipid-lowering therapy according to current clinical guidelines. Treatment will be initiated with statins. Based on follow-up lipid levels, ezetimibe may be added, and PCSK9 inhibitor therapy may be considered if LDL-C goals are not met.
223940370|NCT05980481|DRUG|RC48-ADC（2.0mg/kg）|2.0 mg/kg intravenous infusion every 2 weeks
223940371|NCT05980481|DRUG|Capecitabine（750mg/m2）|750mg/m2 per os Q3W
223940372|NCT05980481|DRUG|Oxaliplatin（100mg/m2 ）|100mg/m2 intravenous infusion Q3W
223940373|NCT05003414|DEVICE|GMK Sphere cementless Knee Replacement|Performance of Total Knee Arthroplasty (TKA) with GMK Sphere cementless Knee Replacement
223940374|NCT04605055|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
223940375|NCT04605055|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein.
223940376|NCT01553942|DRUG|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
223940377|NCT01553942|RADIATION|Radiation|Daily, Monday-Friday
223940378|NCT01553942|DRUG|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
223940379|NCT01553942|DRUG|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
223940380|NCT01553942|PROCEDURE|Surgery|Surgery to remove tumor
223940381|NCT04638478|OTHER|PRECODE-MRI|Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy
223940382|NCT06421675|DRUG|Elranatamab injection|Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
223940383|NCT05874414|DRUG|GNS561 + Trametinib|GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
223916003|NCT07208006|DRUG|Early Intensive Lipid-Lowering Therapy (PCSK9 Inhibitor)|Participants will receive early intensive lipid-lowering therapy with a PCSK9 monoclonal antibody, initiated during the index hospitalization, in addition to statins. Ezetimibe may be added if clinically indicated. The PCSK9 inhibitor will be administered regardless of baseline lipid levels.
224089070|NCT04795479|DRUG|Relacorilant|Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily
224089071|NCT04795479|DRUG|Placebo to relacorilant|Placebo to relacorilant capsule by mouth once daily
224089072|NCT04795479|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet by mouth
224089073|NCT06064760|BEHAVIORAL|Psychoeducational Workshop on Personal Strengths and Emotional Competences to Improve the Psychological Wellbeing and Quality of Life of Grandparents Caring for Their Grandchildren|"The intervention is a psychoeducational group workshop (6-8 participants). It includes 5 sessions of, approximately, 90 minutes. In addition, 3 months after the end of the workshop, a follow-up call will be organized with the participants. Due to the Covid-19 pandemic, the workshop will be held online.~The sessions are:~* Session 1: Defining my role as grandparent.~* Session 2: Deepening my relationships.~* Session 3: Growing as grandparent.~* Session 4: Discovering my emotional world.~* Session 5: Caring for others and caring for myself."
224089074|NCT06213662|DRUG|Botulinum toxin type A for injection|Botulinum toxin was injected into the upper esophageal sphincter of each patient
224089075|NCT02619422|OTHER|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
223916004|NCT07208058|DRUG|Plonmarlimab|Subjects will receive Plonmarlimab 10 mg/kg by intravenous injection once weekly from Week 1 to Week 3, and Plonmarlimab 6 mg/kg by intravenous injection once weekly from Week 4 to Week 8 (10 mg/kg QW×3 + 6 mg/kg QW×5).
223916005|NCT07208227|OTHER|Face Cream RV4983A LA3365|Cosmetic face cream product applied once a day on face, neck and neckline.
223916006|NCT07209033|DEVICE|FlexiOss®|Bone reconstruction with FlexiOss® biocomposite.
223916007|NCT07209033|PROCEDURE|Allogenic human bone grafting|Implantation of allogenic human bone graft.
223916008|NCT07207993|OTHER|Fitness app for self-efficacy|AI-driven personalized exercise prescription via a fitness app. This targets self-efficacy.
223916009|NCT07207993|OTHER|Social network via app for social support|Participants will be provided access to a social network via app. This targets social support.
223916010|NCT07207993|OTHER|Health education app targeting outcome expectations|Participants are provided with an app-based health education. This targets outcome expectations.
224089076|NCT03386084|DEVICE|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
223719483|NCT03214965|BEHAVIORAL|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
223719484|NCT00840450|DRUG|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
223916011|NCT07207616|OTHER|educational intervention for nursing|A quasi-experimental study was carried out between February and October 2023 in the Valencian Community. This non-randomized intervention followed the TREND guidelines and targeted nurses registered in one of the three official nursing colleges of the region. The educational intervention included an asynchronous online phase hosted on a Google Sites platform, where participants accessed interactive learning materials and completed a pre-test. This was followed by a four-hour in-person session that included a brief theoretical review and hands-on workshops practicing various ALS techniques. A post-intervention test was administered immediately afterward. The intervention led to a noticeable improvement in ALS knowledge, demonstrating its effectiveness.
223916012|NCT07208357|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
224089077|NCT06546865|DEVICE|22F Sheath Size|Participants in this group will have the 22F sheath size used in their procedure.
224089078|NCT06546865|DEVICE|26F Sheath Size|Participants in this group will have the 26F sheath size used in their procedure.
224089079|NCT01997151|BEHAVIORAL|Healthy Pregnancy: Step by Step|
224089080|NCT02868892|DRUG|Pemetrexed|Pemetrexed 500 mg/m2
224089081|NCT01662648|DRUG|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
224089082|NCT01106924|OTHER|Probiotic|daily probiotic consumption
224089083|NCT01106924|OTHER|Placebo|daily placebo consumption
224089084|NCT02669979|OTHER|Intervention|Professional oral care
224089085|NCT02633540|RADIATION|IMRT Radiation|Radiation to Larynx
224089086|NCT02131844|OTHER|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
224089087|NCT02131844|OTHER|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
224278128|NCT05450991|PROCEDURE|Pull through|Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
223916013|NCT07208357|DRUG|Pregabalin with toludesvenlafaxine|In the pregabalin with toludesvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Toludesvenlafaxine will be administered at 40 mg daily initially. If the initial dose is well-tolerated, the dose could be further escalated by 40 mg per day after 7 days, up to a maximum of 160 mg per day. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and toludesvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
223916014|NCT07208084|BEHAVIORAL|Project SOAR Awakenings arm|Four Project SOAR Awakenings sessions will be conducted electronically (Zoom) by experts in a group format (12-18 participants/group) with Black American women diagnosed with breast cancer. The Strong Black Woman concept and other culturally curated topics will be discussed as they apply to group members' experience of breast cancer. All women in the study will receive a care box with resources for Black American women diagnosed with breast cancer.
223916015|NCT07208084|BEHAVIORAL|Project SOAR comparison group|Black American women diagnosed with breast cancer in this arm will receive a care box with resources for Black American women diagnosed with breast cancer.
223916016|NCT05848739|DRUG|ST316|IV
223916017|NCT05848739|DRUG|FOLFIRI regimen & bevacizumab|"FOLFIRI: Days 1 and 15 of each 28-day cycle:~* irinotecan 180 mg/m2 IV over 90 minutes concurrently with~* leucovorin 400 mg/m2 IV over 2 hours, and then~* 5-FU bolus 400mg/m2 (up to 15 min infusion)~* 5-FU 2400 mg/m2 IV over 46 hours~* bevacizumab should be administered as 5mg/kg."
223916018|NCT05848739|DRUG|Fruquintinib|5 mg once a day for the first 21 days of a 28-day cycle
223916019|NCT05848739|DRUG|Lonsurf & bevacizumab|Lonsurf 35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 day bevacizumab 5 mg/kg on days 1 and 15. ST316
224089088|NCT05086679|DEVICE|Compression Stockings with 25-30 mm Hg pressure|The group will have compression stockings with 25-30 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
223716430|NCT05532761|OTHER|self-administered questionnaires|"In order to describe the experience of CAR-T cell therapy of DLBCL patients, a pharmaceutical follow-up is carried out the day before the injection (baseline) and at 1, 3, 6, 9, 12 and 18 months. These follow-ups consist of interviews with the patient and the delivery of self-administered questionnaires. The interviews will investigate drug consumption, the use of self-medication and complementary alternative therapies and the adverse effects of interest. The self-questionnaires will focus on exploring multidimensional quality of life, social and professional life, anxiety-depression or uncertainty tolerance through internationally validated questionnaires.~No supplementary visits will be needed : interviews with the research team will occur at the end of hematologic consultations."
223716431|NCT00221403|DRUG|Risperidone oral solution|liquid, BID dosing.
223716432|NCT00221403|DRUG|Valproate Oral Solution|liquid, BID dosing.
223716433|NCT00221403|OTHER|Placebo|liquid, BID dosing.
223716434|NCT05045131|PROCEDURE|Left atrial combined pulmonary vein isolation and posterior wall isolation|
223716435|NCT00415831|DRUG|ELC200 (carbidopa+levodopa+entacapone)|
223716436|NCT03501459|DRUG|Rituximab|
223716437|NCT04566679|DIETARY_SUPPLEMENT|Dibuzin|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
223716438|NCT04566679|DIETARY_SUPPLEMENT|placebo|2-week run-in phase (weeks 1-2) followed by 8-week treatment period (weeks 3-10) and 4-week follow-up phase (weeks 11-14)
223719485|NCT04566328|DRUG|Bortezomib|Given SC
223719486|NCT04566328|BIOLOGICAL|Daratumumab and Hyaluronidase-fihj|Given SC
223916020|NCT06952738|OTHER|Not applicable- observational study|The investigators are only looking to see the rate of positivity of the cultures as well as what the organisms that are found in the cultures are.
223916021|NCT05505578|BEHAVIORAL|GamerFit Condition|Participants receive a Fitbit device, the GamerFit app on their mobile device, exergaming console and games (Nintendo Switch) (where applicable), and follow a 12-week exergaming curriculum provided by the app. Physical activity (PA) increases during the intervention up to 60 minutes/session. Other interventional aspects include weekly reminders, exercise and health related video materials, and weekly telehealth sessions with an intervention coach.
223916022|NCT05505578|BEHAVIORAL|Comparator Condition|Participants receive a Fitbit device, instructions on how to use it, and a booklet of healthy tips. They also get weekly reminders to charge, sync, and review their Fitbit data.
223916023|NCT04290403|DEVICE|Pull Ups|Participants will be asked to wear pull-ups continence products for the duration of four weeks
223916024|NCT04290403|DEVICE|Styled Briefs with tapes|Participants will be asked to wear styled briefs with tapes for the duration of four weeks
223916025|NCT06003595|OTHER|Data collection on patient reported long-term outcome of SSRF hardware removal|One prospective follow-up visit will be performed. On this visit the patient reported long-term outcome will be documented through a health survey.
223916026|NCT05989269|OTHER|Modified lab reporting|If appropriateness of culturing i.e., clinical criteria for pneumonia testing does not meet the algorithm AND there is growth of one or more organism(s) that are not considered normal upper respiratory flora, during the intervention period, the result will be modified to reflect the likelihood of asymptomatic colonization.
223916027|NCT06495658|DIETARY_SUPPLEMENT|Prebiotic|Participants will be asked to take a daily dose of prebiotic supplement for 8 weeks.
223916028|NCT06876246|BEHAVIORAL|Family Check-Up Online|The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication.
223916029|NCT06876246|BEHAVIORAL|FCU Online with Telehealth Coaching|This intervention is the Family Check-Up Online plus telehealth support from a parenting coach. The Family Check-Up Online is a digital intervention that includes an assessment, computer-generated feedback, and intervention modules that focus on improving family relationships and parenting skills in order to reduce child mental health problems and to improve child self-regulation. These modules include Healthy Behaviors for Stressful Times, Positive Parenting, Rules and Consequences, Supporting School Success, and Communication. A coach based at the child's school meets with caregivers via telehealth modality to provide motivation and to help caregivers tailor the content of the modules to their specific child and family's needs.
223916030|NCT05247034|DIETARY_SUPPLEMENT|Cocoa|Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.
223916031|NCT05247034|OTHER|Placebo|Each capsule contains 500 mg of methylcellulose
223916032|NCT05679232|DEVICE|Hydrogel coating|hydrogel coating applied to implant's surfaces during cementless hip revision arthroplasty
223916033|NCT05679232|PROCEDURE|Control|standard cementless hip revision arthroplasty
223916034|NCT04464564|DRUG|AVP-786|oral capsules
223916035|NCT04464564|DRUG|Placebo|oral capsules
223916036|NCT06803537|OTHER|Fiber-reinforced composite|short fiber-reinforced composite used as base covered by conventional composite
223916037|NCT06803537|OTHER|indirect lab composite|indirect lab processed resin composite inlay restorations
223916038|NCT06803537|OTHER|Conventional resin composite|conventional microhybrid resin composite posterior restorations
223916039|NCT06571968|DEVICE|fully guided stent|All surgical procedures with drills were done through the stent., the implant was picked up from the implant holder and then installed, still with the surgical guide in situ, by using the ratchet and ratchet connector at a motor speed of 20 rpm, followed by cover screw placement without the need for sutures.
223916040|NCT06571968|DEVICE|semiguided stent|"The first osteotomy was performed with the surgical guide in situ using a 1.95 mm pilot-drill. Successive color coded implant drills were used to prepare implant osteotomies. When using each twist drill, a removable sleeve having a diameter to coincide with the drill and inserted into the sleeve of the surgical guide.~The stereo lithographic guide template was removed and the receptor sites were irrigated with saline solution then the final drill of the implant system 3.5 mm diameter was used to finalize the osteotomy. The implant was gripped with the placement aid, released from the implant holder by 1/4 turn and manually inserted into the prepared implant site using a finger placement tool or hand ratchet. A torque of 45 N cm should not be exceeded during insertion procedure and cover screws were screwed over it."
223916041|NCT04511052|DIETARY_SUPPLEMENT|Probiotic|Daily intake of 10 x 10\^9 CFU of a proprietary strain for a total duration of 10 weeks
223916042|NCT04511052|OTHER|Placebo|1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks
223916043|NCT04511052|DIETARY_SUPPLEMENT|Carotenoid supplement|1 capsule daily containing \~20 mg of total carotenoids for a total duration of 10 weeks
223916044|NCT04337619|BEHAVIORAL|Behavioral Treatment|Standard Behavioral Weight Loss Treatment (remotely delivered)
223916045|NCT04337619|BEHAVIORAL|Mindful Acceptance|Integration of acceptance and willingness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
223916046|NCT04337619|BEHAVIORAL|Values|Integration of values clarification and awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
224089089|NCT05086679|DEVICE|Compression stockings with up to <=10 mm Hg pressure|The group will have compression stockings with up to 10 mm Hg pressure. All the participants' size for compression stocking will be measured at the first visit. Three points will be measured: below and above their knees and above their ankle. Subsequently, Right Arian Farmed Co (Tehran, Iran) will provide compression stockings for patients based on their sizes. Participants will be asked to use compression stockings as long as they could (ideal would be the majority of the time they are upright). In addition, a CD included some videos and booklets about instructions on how to wear CS and how to keep them will be provided for the participants with their compression stockings.
223916047|NCT04337619|BEHAVIORAL|Mindful Awareness|Integration of mindfulness and present-moment awareness skills into Standard Behavioral Weight Loss Treatment (remotely delivered).
223916048|NCT06537648|BEHAVIORAL|Decreasing Alzheimer's Risk Through oNline Choreographed Exercise - Down Syndrome Program|Adults with Down syndrome will be asked to attend 35 minute, remotely delivered (Zoom®) group dance sessions twice weekly across 12 weeks. All sessions will be directed by an instructor experienced in leading 35 minute, group remote exercise sessions for individuals with intellectual disability as part of the ongoing exercise program for individuals with intellectual disability offered by the Division for Physical Activity and Weight Management.
224089090|NCT05086679|BEHAVIORAL|Lifestyle modification|All patients will receive standard treatment of VVS despite their randomization(drink 2-3 liters of fluids, consume 10 grams 120 mmol/day of sodium chloride, and practice counter-pressure maneuvers (squatting, leg crossing, handgrip, and arm-tensing))
223916049|NCT06427590|DRUG|ASC47|single subcutaneous injection of ASC47
223916050|NCT06427590|DRUG|Matching placebo|single subcutaneous injection of Placebo
223916051|NCT06318533|DRUG|anti-CD19 CAR NK cells|Patients will receive Fludarabine (30mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3, followed by Anti-CD19 CAR NK cells infusion.
223916052|NCT06963489|OTHER|Not applicable- observational study|Intervention is not applicable
223716439|NCT05548816|OTHER|Handheld Dynamometer , Special tests and Modified DASH questionarre .|A mix of tools , special tests and questionarre to help in confirming the diagnosis of subacromial impingement.
223719487|NCT04566328|DRUG|Dexamethasone|Given PO
223719488|NCT04566328|DRUG|Lenalidomide|Given PO
223916053|NCT03505710|DRUG|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
223916054|NCT06965101|RADIATION|Radiotherapy to the spine in a single appointment|8Gy/ 1# to be delivered to all participants using a single posterior direct field.
224089091|NCT06354933|DIAGNOSTIC_TEST|Neurological Soft Signs|Neurological Soft Signs score according to the Heidelberg Manual
224089092|NCT04048512|PROCEDURE|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
223719489|NCT04566328|OTHER|Quality-of-Life Assessment|Ancillary studies
224089093|NCT04048512|PROCEDURE|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
224089094|NCT02984462|PROCEDURE|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
224089095|NCT00619957|DRUG|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
224089096|NCT00619957|DRUG|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
223916055|NCT06965439|BEHAVIORAL|AI-delivered emotional wellbeing support|Participants in this arm will complete four 20-minute sessions with an AI-powered chatbot designed to deliver CBT-based emotional wellbeing support. The chatbot provides conversational guidance using techniques such as cognitive restructuring, behavioural activation, and emotion validation. Sessions are delivered via Zoom, and participants receive structured homework after each session to reinforce learning. The chatbot was not custom-built for this study but is an existing tool provided to NUS students as part of their digital mental health benefits.
223916056|NCT06965439|OTHER|Neutral writing tasks|Participants in this arm will complete four 20-minute sessions of neutral writing tasks unrelated to mental health. Prompts include writing factually about daily routines or describing an object in detail. The content is emotionally neutral to act as a comparison for the chatbot intervention. Sessions are conducted online via Zoom.
223916057|NCT05647044|DEVICE|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
223916058|NCT05647044|DEVICE|placebo intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) will be delivered with the Magventure MagProX100 with MagOption stimulation and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo. The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
223916059|NCT06115395|DEVICE|non- invasive ventilator|Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
223916060|NCT06115395|DEVICE|fiber-optic bronchoscopy|Group 2 (hypoxemic patients who will undergo conventional bronchoscopy under conventional o2 therapy without NIV ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
223916061|NCT06115395|DEVICE|non- invasive ventilator|Group 3 (non- hypoxemic patients who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
224089097|NCT02628925|DEVICE|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
224089098|NCT00807950|DRUG|Simvastatin|
224089099|NCT01508455|DRUG|Dexmedetomidine|
224089100|NCT01508455|DRUG|Midazolam|
224089101|NCT01508455|DRUG|Fentanyl|
224089102|NCT01508455|DRUG|Morphine|
224089103|NCT05249049|DEVICE|e-OPRA Implant System for Transtibial Amputees|The e-OPRA System for transtibial use consists of an anchorage element (Fixture), which is surgically inserted in the medullary canal of the amputated skeleton of the lower limb. The skin penetrating e-Abutment is then inserted and secured with the e-Abutment screw. To allow the system to be used with an external neuro-mechanical prosthesis, soft tissues from the distal limb are preserved incorporated into the residual limb. Muscle electrodes are then placed in the neuro-muscular constructs. After a rehabilitation program, in everyday use, the implanted e-OPRA device will be used by the patient with the Axor TC and their commercially available prosthesis. However, the modified version of the implant will allow the patient to use a powered neuro-mechanical prosthesis during specified testing scenarios.
224089104|NCT01739751|DEVICE|pedometers|portable device that estimate the number of steps walked daily
224089105|NCT02292212|DEVICE|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
223719490|NCT00617123|DRUG|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
223719491|NCT00617123|DRUG|Placebo|matching placebo oral tablet
224089106|NCT01946815|DRUG|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
224089107|NCT05351658|DEVICE|KronoSafe® System|All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
223719492|NCT00461045|DRUG|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
224089108|NCT00080197|DRUG|E7070|
224089109|NCT03587532|DIAGNOSTIC_TEST|Indocyanine green angiography|ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.
224089110|NCT03587532|DIAGNOSTIC_TEST|Hemodynamic evaluation|Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.
223719493|NCT00133952|DRUG|Ruboxistaurin|Administered orally
223719494|NCT00133952|DRUG|Placebo|Administered orally
223916062|NCT06115395|DEVICE|fiber-optic bronchoscopy|Group 4 (non- hypoxemic patients who will undergo conventional bronchoscopy without non- invasive ventilation{NIV) will be on conventional oxygen therapy throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
223916063|NCT01907789|OTHER|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
223916064|NCT01907789|PROCEDURE|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
223916065|NCT01907789|PROCEDURE|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
223916066|NCT01907789|BEHAVIORAL|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
223916067|NCT01907789|PROCEDURE|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
223916068|NCT01907789|BEHAVIORAL|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
223916069|NCT03304717|DRUG|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
223916070|NCT03304717|OTHER|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
223916071|NCT05735652|DEVICE|SpaceOAR Hydrogel|The SpaceOAR System is an in-situ formed absorbable hydrogel that is administered transperineally (with transrectal ultrasound guidance) between the prostate and rectum
223916072|NCT04866940|OTHER|Sequences test|the realization of preliminary acquisitions to validate the feasibility of clinical or cognitive research protocols
223916073|NCT06574035|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
223916074|NCT06574035|BEHAVIORAL|Exercise|Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
223916075|NCT06574035|BEHAVIORAL|Group Discussions - Ongoing Support|Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
223916076|NCT06639516|DIETARY_SUPPLEMENT|Bifidobacterium longum|Bifidobacterium longum
223916077|NCT06639516|DIETARY_SUPPLEMENT|Placebo|Placebo
223916078|NCT06639516|COMBINATION_PRODUCT|Standard clinical treatment|Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
223916079|NCT05934487|DEVICE|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)"
223916080|NCT04276935|OTHER|Interview|Participate in cognitive interview
223916081|NCT04276935|OTHER|Quality-of-Life Assessment|Ancillary studies
223916082|NCT04276935|OTHER|Questionnaire Administration|Ancillary studies
224089111|NCT03587532|DIAGNOSTIC_TEST|Biological and pathological markers of ischemia|"* Systemic and local capillary lactate on blood samples~* Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~* Pathological analyses of the biopsies at 3 ROI"
224089112|NCT04455711|DRUG|Lidocaine Iv|Bolus dose of 1.5 mg/kg lidocaine was injected immediate after operation.
223719495|NCT04303819|DRUG|Exenatide treatment|12 weeks of exenatide injection, 5 μg twice a day by subcutaneous injection for 4 weeks, followed by 10 μg twice a day for 8 weeks, as recommended by the drug manufacturer.
223719496|NCT06122896|OTHER|Screening Blood Tests|Carbohydrate antigen (CA) 19-9, and Hemoglobin A1C (HbA1c) per standard-of-care.
223916083|NCT04506424|OTHER|CT Guided Cochlear Implant Programming|Flat Panel (high resolution) CT scans of the temporal bones, including the inner ears, will be obtained. The research team will use the scans to generate custom cochlear implant (CI) programs for use by the participants.
223916084|NCT05660629|OTHER|Mulligan Mobilization|Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
223916085|NCT04801381|PROCEDURE|Aquablation therapy|Aquablation is carried out with the AQUABEAM Robotic System®, PROCEPT BioRobotics, Redwood City, CA, USA
223916086|NCT04801381|PROCEDURE|Transurethral laser enucleation|Transurethral laser enucleation is performed according to the standard established at the respective test center. Included laser techniques: Holmium laser (HoLEP) and Thulium laser (ThuLEP).
223916087|NCT06804720|BEHAVIORAL|Mindfulness based Self compassion|All participants in the test group completed the 8-week MBCL (Mindfulness-Based Compassionate Living) training, consisting of 2-hour sessions per week, in accordance with the MBCL training protocol. Training was conducted by one expert periodontist who is also an internationally certified MBCL instructor
223916088|NCT06805266|DRUG|Vortioxetine (tablet)|Vortioxetine will be used with the aim of treating freezing of gait in subjects with Parkinson Disease and depressive symptoms
223916089|NCT05860114|DRUG|Givinostat|"Drug: ITF2357 Givinostat 10mg/mL Dose: 10mg/mL; Dosage form: oral suspension~On days 1 and 13 givinostat was administered in the morning, following an overnight fasting of at least 8 hours and subjects remained fasted until at least 4 hours post-dose. Moreover the subjects were in a semi-recumbent position and remained semi-recumbent until at least 4 hours post-dose.No fluids were allowed from 1 hour before dosing until 2 hours post-dose. Water was provided ad libitum at all other times.~From Day 5 to Day 12, subjects received givinostat 50 mg as oral suspension, twice a day, in the morning and in the evening."
223916090|NCT05079269|OTHER|Crystalloid Solutions|As above
223916091|NCT06168019|OTHER|Exposures|COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
223916092|NCT05492448|DIETARY_SUPPLEMENT|Placebo|Subjects take one pack containing maltodextrin twice daily after breakfast and dinner.
223916093|NCT05492448|DIETARY_SUPPLEMENT|L. salivarius AP-32 and L. reuteri GL-104|Subjects take one pack containing L. salivarius AP-32 and L. reuteri GL-104 twice daily after breakfast and dinner.
223916094|NCT05492448|DIETARY_SUPPLEMENT|L. reuteri GL-104|Subjects take one pack containing L. reuteri GL-104 twice daily after breakfast and dinner.
223916095|NCT06375655|BEHAVIORAL|Team2BF|Team2BF includes 3-4 breastfeeding-supportive messages per time interval, sent weekly from 28 weeks gestation through delivery, daily through 2 weeks postpartum, weekly from 2 to 10 weeks, and then monthly to one year. Other maternal health topics are not addressed.
223916096|NCT06375655|BEHAVIORAL|Bright By Text|Bright By Text sends 2-4 messages per week from the first trimester through and beyond one year postpartum about a wide range of maternal and child health topics as outlined on their website; 8 messages are specifically about breastfeeding.
223916097|NCT05361408|DRUG|Zoledronic acid, once|Intravenous infusion of 5mg zoledronic acid, once
223916098|NCT05361408|DRUG|Zoledronic acid, twice|Intravenous infusion of 5mg zoledronic acid for 6month interval, twice
223916099|NCT05339477|OTHER|Accelerometer measurement|Study personnel will initiate an accelerometer and inform the patient to wear the accelerometer with an elastic belt on their right hip during waking hours for seven consecutive days. Moreover, patients are instructed to register their wear time in an activity diary in paper form. In addition, patients will register their working hours, if relevant. After seven days, patients send back the accelerometer and diary in a pre-paid envelope. The same procedure is repeated at the second follow-up visit at 1 year.
223916100|NCT04734730|DRUG|Abiraterone Acetate|Given PO
223916101|NCT04734730|DRUG|Bicalutamide|Given PO
223916102|NCT04734730|DRUG|Degarelix|Given SC
223916103|NCT04734730|DRUG|Goserelin Acetate|Given SC
223916104|NCT04734730|DRUG|Leuprolide Acetate|Given IM
223916105|NCT04734730|DRUG|Prednisone|Given PO
223916106|NCT04734730|OTHER|Questionnaire Administration|Ancillary studies
223916107|NCT04734730|DRUG|Talazoparib|Given PO
223916108|NCT03021395|DRUG|Decitabine|Decitabine at a dose of 20mg/㎡/d on day 1-5.
223916109|NCT01736059|DRUG|CD34+ bone marrow stem cells intravitreal|
223916110|NCT04950894|DEVICE|Hypoglossal Nerve Stimulation|Hypoglossal Nerve Stimulation started at Month 1 compared to no Stimulation (Control group will start stimulation at M7+1Day)
223916111|NCT03868826|PROCEDURE|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
223916112|NCT06809322|DRUG|Vorasidenib|Vorasidinib will be administered orally once daily at a dose of 40 mg in continuous 28-day cycles
223916113|NCT06809322|DRUG|Vorasidenib Placebo|Matched oral vorasidenib placebo will be administered once daily in continuous 28-day cycles
223916114|NCT03778801|DIAGNOSTIC_TEST|kinesiophobia|The investigators assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
223916115|NCT05908409|DRUG|IDP-121|IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
223916116|NCT06813326|PROCEDURE|catheter insertion|success of catheter insertion
223916117|NCT06853977|BEHAVIORAL|Cognitive tasks|Cognitive tasks performed during intracerebral voltammetric recordings
224089113|NCT04455711|DRUG|Remifentanil|Continuous infusion of remifentanil 1.5 ng/ml until extubation
224089114|NCT04385173|DRUG|B7-H3 CAR-T|The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T
224089115|NCT04385173|DRUG|Temozolomide|Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.
224089116|NCT01014403|DRUG|enoxaparin|Enoxaparin 30 mg sq q 12 hours
224089117|NCT01014403|DRUG|placebo|vehicle
224089118|NCT05488860|DRUG|Triamcinolone acetonide(scar)/5-ALA(others)|For scar, the drug is triamcinolone acetonide.
224089119|NCT05488860|PROCEDURE|Piezoelectric drived microneedling|Piezoelectric drived microneedling
223916118|NCT06811961|BEHAVIORAL|Exercise|Patients with lipedema will perform group exercises consisting of warm-up, loading and cool-down periods of 40-50 minutes, 2 days a week for 6 weeks, and strengthening exercises applied to the muscles around the hips and knee extensors with elastic resistance bands, determined according to the effort level perceived by the patient, 3 sets of 10 repetitions, 2 days a week for 6 weeks.
224089120|NCT05488860|DRUG|5-ALA (a photosensitizer for photodynamic therapy).|For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
224089121|NCT03092050|BEHAVIORAL|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
224089122|NCT03092050|BEHAVIORAL|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
224089123|NCT01970163|OTHER|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
223916119|NCT06811961|BEHAVIORAL|Physical activity|The control group will be given recommendations regarding lipedema and physical activity level.
223916120|NCT06813287|DIAGNOSTIC_TEST|Electroencephalography (EEG)|Recording of electrical activity in the brain
223916121|NCT06813287|DEVICE|Upper extremity robot|Used for training and objective assessment (kinematics)
223916122|NCT06811077|OTHER|individual coaching|in addition to group therapeutic education, the patient participates to individual coaching session and answers several Patient Reported Outcome to assess his wellbeing
223916123|NCT05327647|DRUG|Bicalutamide|Induction intravesical BCG with bicalutamide 150 mg for 90 days
223916124|NCT05327647|BIOLOGICAL|Control Arm|Induction BCG
223916125|NCT06826053|OTHER|Therapeutic position|each newborn was given four different therapeutic positions in sequence.
224278129|NCT00516087|BIOLOGICAL|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2"
223916126|NCT06826053|OTHER|Therapeutic position + smell breast milk|each newborn will be given four different therapeutic positions in sequence and will be made to smell the scent of breast milk.
223916127|NCT05839509|DRUG|GH001|GH001 administered via inhalation
224089124|NCT01970163|OTHER|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
224278130|NCT06616077|DRUG|Micronized Progesterone 600 mg|Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
224278131|NCT06616077|DRUG|mifepristone 200 mg|Post ovulatory single oral administration (LH+2, LH peak=LH+0)
224278132|NCT06616077|DRUG|Oral Placebo Tablet|Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
224278133|NCT06616077|DRUG|Placebo Vaginal|Cocoa butter
224278134|NCT01643434|DRUG|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
224278135|NCT01643434|DRUG|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
224278136|NCT00890942|DRUG|naloxone|naloxone 0.4mg.(1 ml) intramuscular
224278137|NCT00890942|DRUG|normal saline|normal saline 1 ml IM
224278138|NCT00349401|DRUG|ketorolac|
224278139|NCT00349401|DRUG|morphine|
224278140|NCT02722616|DEVICE|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
223719497|NCT06122896|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
223719498|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Imaging|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
223916128|NCT06006585|DRUG|BI 771716|BI 771716
223916129|NCT04105114|DRUG|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
223916130|NCT04105114|DEVICE|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
223916131|NCT04105114|DEVICE|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
223916132|NCT04105114|DEVICE|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
223916133|NCT04105114|DEVICE|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
223916134|NCT04105114|DEVICE|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
223916135|NCT05003245|DRUG|HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection|0.05mL solution at a 4-week interval for intravitreal injection
223916136|NCT05003245|DRUG|Lucentis|0.05mL solution at a 4-week interval for intravitreal injection
223916137|NCT05597267|DEVICE|MIRIA Laser|4-6 experimental treatments at 4-6 weeks intervals
223916138|NCT00942877|DRUG|AZD2171|Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS).
223916139|NCT06455085|BEHAVIORAL|Augmented-Fracture Liaison Service Arm|Patients are contacted by a patient navigator (serving as the liaison) and referred to a bone health clinician.
223916140|NCT06455085|BEHAVIORAL|Enhanced Usual Care Arm|Patients will be mailed education materials and encouraged to follow up with their primary care physician.
223916141|NCT06094621|OTHER|Survey|For the patients who underwent a pre-operative virtual visit, data will be collected through semi-structured interviews conducted by trained research personnel. The interviews will be conducted in a one-on-one format, either in-person or via telephone, according to the participant's preference.
223916142|NCT05586308|BEHAVIORAL|Text-massaging suport|Text-messaging quitting support program (i.e., This is Quitting) is an evidence-based, free mobile program from Truth Initiative designed to help young people quit vaping. The program is fully automated and interactive. To establish or reinforce perceived social norms and social support around quitting, a majority of messages come from other users who have submitted them to the program.
223916143|NCT05586308|BEHAVIORAL|Financial incentive|"1. Participants will earn $3 for each saliva cotinine sample submission regardless of positive or negative results after the quit day (an assessments at Week 6, Week 8, Week 10, and Week 12, during the abstinence phase)~2. Participants will earn additional escalating rewards for each negative sample- $7 for Week 6, $12 for Week 8, $17 for Week 10, and $22 for Week 12 (2 months after the target quit date). The bonus starts at $7 and increase by $5 for each subsequent negative cotinine sample (i.e., $7, $12, $17, and $22).~3. A reset contingency will be used. That is the reward amount will be returned back to original $7 if there is a missing or positive saliva cotinine sample"
223916144|NCT05586308|BEHAVIORAL|Media literacy|Media literacy e-learning lessons cover topics regarding what e-cigarettes are and how they work, how nicotine and nicotine addiction affects the brain and behavior, how to prepare to quit vaping, developing a quit plan and how to deal with cravings and relapse. The program focuses on changing knowledge, attitudes and beliefs related to e-cigarette use, as well as emphasizing vaping related media literacy.
223916145|NCT06815276|OTHER|Exercise|core muscle training
224089125|NCT01970163|OTHER|Conventional Care Dressings|"Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~* If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~* Hydrogels can also be used if the wound is in need of moisture.~* For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion."
224089126|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
224089127|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
224089128|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
223719499|NCT06122896|COMBINATION_PRODUCT|Magnetic Resonance Cholangiopancreatography|Annually and per National Comprehensive Cancer Network Guidelines (NCCN) guidelines.
223916146|NCT06813989|OTHER|carotid ultrasound|The investigator will perform a carotid ultrasound just 2 cm before the carotid bulb and measure the corrected flow time and flow using Doppler and pulse wave analysis. The corrected carotid flow time will be calculated according to Bazett's equation.
223916147|NCT06813534|DEVICE|Intravascular Ultrasound guided PCI|Intra-coronary ultrasound
223916148|NCT06841900|DEVICE|Cochlear Implantation|Standard cochlear implantation
223916149|NCT06808841|DRUG|Sufentanil injection|Different concentrations of sufentanil were administered to three different subgroups of patients in the same way
223916150|NCT06808841|DRUG|Placebo|Placebo
223916151|NCT06809998|DRUG|Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).|Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).
223916152|NCT06809998|OTHER|Band-Aid|Band-Aid
224089129|NCT01791855|DRUG|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
224089130|NCT04935983|OTHER|High CHO|Diet with high carbohydrate content
224089131|NCT04935983|OTHER|Low CHO|Diet with low carbohydrate content
224089132|NCT02254915|DEVICE|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
224089133|NCT02254915|DRUG|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
224278141|NCT02722616|DEVICE|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
223719500|NCT05091749|BIOLOGICAL|blood samples|troponin measurement
223719501|NCT03264261|DEVICE|robotic training|robotic training, 3 times/week for 6 weeks
224089134|NCT01881646|RADIATION|Positron emission tomography (PET) using [11C]PBR28|
224089135|NCT00772447|DRUG|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
224089136|NCT00772447|DRUG|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~\- 1 g every 6 hours or 2 g every 8 hours"
224089137|NCT02147873|DRUG|birinapant|
224089138|NCT02147873|DRUG|Azacitidine|
224089139|NCT02147873|DRUG|Placebo|
224089140|NCT00650858|DRUG|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
223916153|NCT06813937|DEVICE|Procedure: Peripheral Magnetic Stimulation (PMS)|PMS is a non-invasive neuromodulation technique used to treat chronic pain. Procedure starts with sensory mapping, localisation of the hotspot and detection of sensory threshold. Then two protocols of PMS are implemented: 5 blocks of PMS of varying frequency and 1 block of rPMS.
223916154|NCT06813937|OTHER|Electroencephalography (EEG)|EEG is a technique commonly used for the registration of brain activity. The procedure is non-invasive, electrodes are placed on the scalp of the participants. The recording is made simultaneously with the PMS.
223916155|NCT06812728|DRUG|mFOLFIRINOX|Neoadjuvant chemotherapy
223916156|NCT06812728|DRUG|mFolfox6|Neoadjuvant chemotherapy
223916157|NCT06841302|OTHER|Fibromyalgia Agents|All study participants were enrolled in a combined treatment program consisting of both a structured aerobic exercise program (swimming, cycling, or brisk walking for at least three days a week, with each session lasting two hours) and a pharmacological treatment regimen. Patients who did not adhere to the prescribed treatment regimen or who discontinued follow-up were excluded from the study.
223916158|NCT06812962|OTHER|Online quiz competition|The intervention and control students participated in an online quiz game on tobacco and healthy eating topics, respectively. Each day, students could answer a maximum of 5 questions randomly selected from the respective pool of questions by the platform. The students logged onto the online platform and played the quiz competition on weekdays for 4 weeks (i.e. total of 20 days).
224089141|NCT03688217|BEHAVIORAL|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
224089142|NCT03688217|BEHAVIORAL|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
224089143|NCT03163420|DRUG|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
224089144|NCT03163420|OTHER|Placebo|Fructose
224089145|NCT01957137|DEVICE|InterStim® (Device Programming)|
224089146|NCT02497001|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler \[MDI\])
224278142|NCT02722616|DRUG|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
224278143|NCT02086344|PROCEDURE|PBS|TLH plus PBS
224278144|NCT02086344|PROCEDURE|TLH _adnexal preservation|TLH without PBS
224278145|NCT04167696|BIOLOGICAL|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
224278146|NCT04167696|DRUG|ENDOXAN|administered as preconditioning chemotherapy
223916159|NCT06811025|DRUG|Contezolid|Contezolid 800mg once daily (QD) for 7 days;
223916160|NCT06811025|DRUG|Linezolid (LZD)|Linezolid 600mg once daily (QD) for 7 days.
223916161|NCT06813768|DEVICE|Microfractured adipose tissue injection and plug placement|surgery + infiltration of micro-fractured autologous adipose tissue at the level of the internal orifice and placement of a biological prosthesis
224278147|NCT04167696|DRUG|Fludara|administered as preconditioning chemotherapy
223916162|NCT06811701|PROCEDURE|Scalp nerve block|Patient in this group will receive a scalp nerve block using bupivacaine before skull pin fixation to manage to pain.
223916163|NCT06811701|DRUG|Opioid Anesthetics|Patient in this group will receive IV opioid for pain management before skull pin fixation
224278148|NCT01923311|DRUG|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
223719502|NCT03264261|DEVICE|treadmill training|treadmill training only, 3 times/week for 6 weeks
223916164|NCT06811701|PROCEDURE|Local Anesthetic Injection|"Patients in this group will receive a local anesthetic (such as lidocaine) injection at the pin site before skull pin fixation."
224089147|NCT02497001|DRUG|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
224089148|NCT02497001|DRUG|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
224089149|NCT02497001|DRUG|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
224089150|NCT05587283|DRUG|Experimental: Low dose LABTHERA-001 capsule|Low dose LABTHERA-001 capsule, 0.2 x 10\^9 CFU/capsule with excipients.
224089151|NCT05587283|DRUG|Experimental: Medium dose LABTHERA-001 capsule|Medium dose LABTHERA-001 capsule, 1 x 10\^9 CFU/capsule with excipients.
223719503|NCT00299104|DRUG|folate|Intravenous repeating dose
223719504|NCT00299104|DRUG|methotrexate|Oral or parenteral repeating dose
224089152|NCT05587283|DRUG|Experimental: High dose LABTHERA-001 capsule|High dose LABTHERA-001 capsule, 5 x 10\^9 CFU/capsule with excipients.
224089153|NCT05587283|OTHER|Placebo Comparator: Low dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
224089154|NCT05587283|OTHER|Placebo Comparator: Medium dose Placebo capsule|Medium dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
224089155|NCT05587283|OTHER|Placebo Comparator: High dose Placebo capsule|High dose Placebo capsule, filled with excipients; Lactose, and magnesium stearate.
224089156|NCT03898063|BEHAVIORAL|90 DAYS film|the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.
224089157|NCT03898063|BEHAVIORAL|HIV pamphlet on disclosure|A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
223916165|NCT06813625|BEHAVIORAL|Shared book reading intervention|The intervention involved us pairing each teen DS with a college student to form a duo. Each group consists of one person with DS and at least one college student who will work together throughout the shared reading intervention. A weekly event hosted by a graduate student. It begins with ice-breaking activities such as color and music games to promote social interaction between participants. After the game, participants chose from a selection of 20 books suitable for different age groups. They can choose their own reading method, such as reading aloud or assigning roles, and are encouraged to share experiences in their own duos or in a large group of multiple duos. The session ends with a sharing and reflection activity where participants can discuss what they have read and plan for the next session.
223916166|NCT06811688|OTHER|Two mobile applications: Brushout and Brush teeth reminder applications|These applications were adjusted to send notifications twice daily in the morning and night as reminders to practice oral hygiene.
223916167|NCT06842862|DEVICE|GGED|This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
223916168|NCT06814990|DIAGNOSTIC_TEST|Cardiac MRI|Additional to standard clinical practice Patients will receive a cardiac magnetic resonance imaging without contrast. Measured parameters are enddoastolic and endsystolic volume (in ml oder ml/body surface area (BSA)), stroke volume (in ml) of right and left ventricle absolute and relatvie to body surface area (BSA), ejection fraction in % of right and left ventricle, myocardial Strain in % of right and left ventricle if applicable. T1 and T2 relaxation times are obtained and aortic and pulmonary artery flow parameters are measured.
223719505|NCT00299104|DRUG|methylprednisolone|Intravenous repeating dose
223916169|NCT06814990|DIAGNOSTIC_TEST|Blood samples|We will take additional blood samples for the analysis of markers of bacterial translocation (e.g. LBP, EndoCAb, 16S rRNA), detection of bacterial markers (bacterial extracellular vesicles), inflammatory markers (e.g. IL-1ß, TNF-α, TGF-ß, IL-6, CXCL8, IL1-RA, IL-10, IL-18) and monocyte/macrophage activation markers (sCD14, sCD163, sCD87, sCD206), bile acids (including TCA, GCA, GCDCA, TCDCA, TLCA, GLCA, TDCA, GDCA, CA, CDCA, UDCA, DCA, TUDCA, LCA), lipids and lipoproteins (triglyerides, cholesterol, LDL/HDL cholesterol), coagulation factors (e.g. VWF, ADAMTS13, fibrinogen), markers of cardiac remodeling (e.g. NT-proBNP; troponin, VEGF-D, cleaved Gasdermin D, HMGB1) and Immunophenotyping of monocytes/macrophages, T and B cells (e.g. CD14, CD16, MERTK, CD4, CD127, CD25, TREM1/2).
223916170|NCT06814990|DIAGNOSTIC_TEST|Echocardiography|Patients will receive an extended echocardiographic protocol. In addition to standard clinical parameters, we will collect study specific parameters such as LV EF in %, global longitudinal strain in %, septal e' velocity (cm/s), E/e' ratio, left atrial volume index (LAVI) (in ml/m2), tricuspid regurgitation velocities (m/s).
223916171|NCT06814223|DRUG|• Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously. • Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA|"Patients with an elevated risk of infection will be randomly assigned to two groups using stratification for new catheter placement versus catheter replacement. Fifty percent of the high-risk patients will receive prophylactic antibiotics targeting gram-positive and gram-negative bacteria. The antibiotic regimen will include:~* Cefamezine (2 grams) and gentamicin (80 mg) administered intravenously.~* Patients with penicillin allergies, a history of methicillin-resistant Staphylococcus aureus (MRSA) infection, or known MRSA colonization will receive vancomycin (2 grams)."
223916172|NCT06813950|OTHER|Physical activity|The intervention group will participate in a 10-week structured physical activity program consisting of 120 minutes of supervised exercise per week, led by a team of physiotherapists and physical activity professionals. Meanwhile, the control group will not participate in any organized physical activity program but will continue with their usual activities.
223916173|NCT06815510|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Patients will be followed up to find out any of these complications: pulmonary, hemodynamic complications, temperature disturbances, or pain
223916174|NCT06814808|OTHER|Conventional Therapy|All three groups will receive a conventional physiotherapy program (TENS, therapeutic ultrasound, hot pack) 5 times a week for 4 weeks and the same exercise program 3 days a week for 4 weeks.
223916175|NCT06814808|OTHER|Ischemic Compression Group|The ischemic compression group will receive ischemic compression therapy for the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles.
223916176|NCT06814808|OTHER|Strain-Counter Strain|The strain counterstrain technique will be applied to the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles.
223916177|NCT06814808|OTHER|Integrated Neuromuscular Inhibition Technique (INIT)|This group will be subjected to INIT for the upper trapezius, levator scapulae, splenius capitis, and lower trapezius muscles, 3 sessions per week for 4 weeks (12 sessions in total).
223916178|NCT06841601|OTHER|topical anesthetic gel|gels applied directly to the mucous membranes to provide localized relief of pain by numbing the area. They typically contain active ingredients such as lidocaine, benzocaine, or prilocaine, which work by blocking nerve signals to reduce sensation and discomfort
223916179|NCT06841601|OTHER|Vibration|The vibration generated by the Buzzy device functions as a non-pharmacological agent that can reduce pain perception in children based on the principles of the Gate Control Theory of Pain.
223916180|NCT06841601|OTHER|Cold pack|cold packs are also provided by the Buzzy device. they act as non-pharmacological agents that can reduce pain perception in children based on the Gate Control Theory of Pain.
224089158|NCT04937010|PROCEDURE|Occipital nerve stimulator implant|Implantation of occipital nerve stimulator and different stimulation parameters
224278149|NCT01923311|DRUG|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
223719506|NCT00299104|DRUG|placebo|Intravenous repeating dose
223719507|NCT00299104|DRUG|rituximab|Intravenous repeating dose
223719508|NCT06120387|PROCEDURE|Radical surgery|Radical nephroureterectomy
224089159|NCT03706573|DRUG|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
223916181|NCT06841367|OTHER|Mindfulness-based stress reduction training|It is expected that improvements in physiological parameters and anxiety levels will be observed in the preeclampsia group with awareness-based stress reduction training.
223916182|NCT06841068|BIOLOGICAL|Amniotic fluid or placental CD117 stem cells|CD117 (c-Kit) positive stem cells, extracted from ethical fetal sources such as amniotic fluid and placental tissue.
223916183|NCT06841263|OTHER|Not applicable- observational study|Not applicable - observational study
223916184|NCT06842186|DRUG|WVE-007|Stereopure siRNA oligonucleotide
223916185|NCT06841237|OTHER|Xiang Lei Ointment plus Clinical standard treatment protocols|A therapy for chronic wound healing
223916186|NCT06841237|OTHER|Clinical standard treatment protocols|A therapy for chronic wound healing
224089160|NCT03684135|OTHER|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
224089161|NCT02347904|DRUG|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
224089162|NCT03711903|DRUG|Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).|The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
224089163|NCT03711903|DRUG|0.9% Sodium-chloride|normal saline
224089164|NCT02949830|DRUG|Givosiran|Givosiran by subcutaneous (SC) injection.
224089165|NCT00054132|BIOLOGICAL|Bevacizumab|Given IV
224089166|NCT00054132|DRUG|Erlotinib Hydrochloride|Given PO
223916187|NCT04305366|OTHER|Tissue collection|Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
223916188|NCT04860765|DEVICE|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
224089167|NCT00054132|OTHER|Laboratory Biomarker Analysis|Correlative studies
224278150|NCT02031237|RADIATION|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
223916189|NCT06790589|DRUG|Levothyroxine Oral Tablet [Synthroid]|"Round, colour coded, scored tablet debossed with SYNTHROID on one side and potency on the other side."
223916190|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with glucose|The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of glucose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
223916191|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with fructose|Description: The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of fructose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
223916192|NCT06751862|DIETARY_SUPPLEMENT|150g of fat with sucrose|The subjects will receive 460 ml of cream (high fat load - 150g of fat in total) with fruit tea sweetened with 50 g of sucrose. Two and four hours later they will receive again fruit tea sweetened with the same sugar as at time 0 h. During the day, the subjects will not receive any food and they will be allowed to drink only water or fruit tea.
223916193|NCT06751862|DIETARY_SUPPLEMENT|Short-term (7 days) fructose restriction|Subjects will receive a package of glucose and selected foods without fructose to supplement their diet. For seven days they then will adhere to the diet without fructose and keep the detailed dietary record.
223916194|NCT06594055|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring is a wearable device that continuously collects glucose data from interstitial fluid.
223916195|NCT06594055|DEVICE|Self-monitoring blood glucose|The control group used self-monitoring blood glucose (SMBG) for two weeks with a manual food diary, followed by diet education. They then repeated SMBG with a food diary three months later, with a final follow-up at the 6-month mark.
223916196|NCT06594055|DEVICE|AI food camera|The AI food camera automatically detects the contents and nutritional information of foods.
223916197|NCT06594055|DEVICE|Food diary|A food diary is a record in which the user manually writes down the consumed foods and their amounts.
223916198|NCT04370834|BIOLOGICAL|Tocilizumab|Given IV
224089168|NCT03955094|DEVICE|Intubation via AMBU® AURAGAIN™|Success rate of paediatric intubation through AMBU® AURAGAIN™
224089169|NCT01290887|DRUG|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
224089170|NCT02920060|DRUG|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
224089171|NCT02920060|DRUG|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
224089172|NCT03316352|PROCEDURE|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
224089173|NCT03316352|PROCEDURE|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
224089174|NCT03316352|DEVICE|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
223716440|NCT02339935|BEHAVIORAL|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
223916199|NCT06355986|BEHAVIORAL|Alert-based computerized decision support|An on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the provider that his or her patient is at risk for stroke due to AF, and that there is no order for anticoagulation. Clinicians who receive the computer alert will have three options: 1) access an order template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence-based clinical practice guidelines to learn more about stroke prevention in AF, or 3) continue with order entry after providing an explanation for why anticoagulation was not prescribed.
223916200|NCT06592989|DRUG|sorafenib, gefitinib|Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.
223916201|NCT05032066|DRUG|HZN-825|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
223916202|NCT05032066|DRUG|Placebo|"Core Phase: Participants will receive HZN-825 300 mg QD, HZN-825 300 mg BID or matching placebo orally in the morning and evening with a meal for 52 weeks according to randomization schema.~Extension Phase: Participants who received matching placebo in the Core Phase will receive open-label HZN-825 150 mg orally in the morning and evening with a meal for 52 weeks."
223916203|NCT04093921|BEHAVIORAL|MET-based therapy|see previous
223916204|NCT04093921|BEHAVIORAL|Standard Care|To include all recommended outpatient treatments
224278151|NCT02031237|RADIATION|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
223916205|NCT02782676|DEVICE|Investigational Healon5 OVD|ophthalmic viscosurgical device
223916206|NCT02782676|DEVICE|Healon5 OVD|ophthalmic viscosurgical device
223916207|NCT06597786|OTHER|Exercise therapy|Patients will receive a study kit which includes a smart watch (for monitoring of mobility / lifestyle patterns), heart rate monitor, blood pressure cuff, scale, and e-tablet. Patients may receive a treadmill to perform exercise therapy sessions. The treadmills and study kits are MSK owned equipment that will be deployed to the patients' homes and returned at the end of the study.
223916208|NCT03334695|BIOLOGICAL|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.
223916209|NCT03334695|DRUG|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
223916210|NCT02641730|DRUG|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
223916211|NCT02641730|DRUG|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
223916212|NCT02874742|DRUG|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
223916213|NCT02874742|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
223916214|NCT02874742|DRUG|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
223916215|NCT02874742|DRUG|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
223916216|NCT04245956|PROCEDURE|Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire|The intervention consists of measuring a series of hemodynamic indices in a stenosed coronary using a pressure wire, immediately before and after transcatheter mitral valve repair using the percutaneous edge-to-edge MitraClip system in patients with severe mitral insufficiency and concomitant intermediate coronary artery stenosis.
223916217|NCT03589547|DRUG|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
223916218|NCT03589547|RADIATION|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~\*3 fractions are allowed for centrally located tumors"
223916219|NCT06746025|BEHAVIORAL|Quit Center cessation program|Lifestyle modifications based on the Quit Center cessation program.
223916220|NCT06813196|BEHAVIORAL|Forest Bathing|Forest bathing intervention is a group structured psychosocial intervention. Its core therapeutic element is its nature-based activities that took place in an outdoor green space. During the session, participants would be guided by a trained forest therapy guide to engage in nature-based activities, such as walking in the woods, listening to the nature, and interacting with objects in the nature through different sensations.
223716441|NCT02339935|OTHER|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
223916221|NCT06813196|BEHAVIORAL|Art activity|Art activity intervention is a group semi-structured psychosocial intervention. Its main therapeutic element is its engagement in art-based activites. During the session, participants would be guided in individual or collaborative art activities of different forms, such as painting, paper arts, and dried flower art, by an experienced interventionist in an activity room.
224089175|NCT03316352|DRUG|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
224089176|NCT01811511|DIETARY_SUPPLEMENT|Chungkookjang|
224089177|NCT01811511|DIETARY_SUPPLEMENT|Placebo|
224089178|NCT02886299|DRUG|Fenofibrate|
224089179|NCT02886299|DRUG|Simvastatin|
223716442|NCT02745444|DIETARY_SUPPLEMENT|low-calorie formula diet|
224089180|NCT03436173|DRUG|Fluoxetine|Fluoxetine 10 mg/2.5 ml mixed with water
223916222|NCT06808919|OTHER|Whole Body Vibration Exercise|The participants underwent a prescribed exercise protocol involving both static and dynamic exercises on the designated platform. Specifically, static squats at a 30º angle, dynamic deep squats ranging from 30 to 60º, toe raises, weight transfer maneuvers during squats, as well as static and dynamic squat exercises performed unilaterally were implemented as part of the program
223916223|NCT06808919|OTHER|Aerobic Exercise|The participants assigned to the aerobic exercise group were directed to engage in running activity on a conventional treadmill. The participants engaged in aerobic exercise, specifically moderate-to-high-intensity running at 65-80% of their maximal heart rate, for durations of 30-45 minutes per session, three times weekly. Heart rate was monitored with a portable pulse oximetry device.
224089181|NCT03436173|OTHER|Peppermint syrup|Liquid peppermint syrup measured to the equivalent volume and mixed with water
223916224|NCT06808919|OTHER|Strengthening Exercise|Strengthening group, participants engaged in various lower extremity strengthening activities such as straight leg raises, abduction and adduction movements, knee flexion-extension, ankle plantar-dorsiflexion exercises. These exercises were performed both on a bed and in standing positions, utilizing resistance exercise bands.
224089182|NCT04725279|PROCEDURE|Rehabilitation Treatment: Physiotherapy, Electrotherapy or Exercises at home|The 67 patients attended the rehabilitation consultation where, after taking the anamnesis, they began to perform balance tests with a stabilometric platform and those patients with associated neck pain, with cervical motion sensors. Treatment with conventional physiotherapy, electrotherapy or exercises at home was prescribed as appropriate to each one. 3 months later, the patients were examined again in consultation, using a new anamnesis, the platform and the sensors.
224089183|NCT00578357|BEHAVIORAL|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
224089184|NCT01795547|DRUG|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
224089185|NCT01795547|DRUG|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
223916225|NCT06810830|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (iCBT)|A structured 7-week program focusing on cognitive restructuring, stress management, and emotional regulation.
223916226|NCT06810830|BEHAVIORAL|Internet-Based EMDR Flash Technique (iEMDR-FT)|A 3-session protocol adapted to minimize re-exposure to distressing cancer-related memories through rapid bilateral stimulation and positive imagery.
223916227|NCT06808958|BEHAVIORAL|Experimental (Bathtub Bath) Group|The newborn's eyes will be covered with a phototherapy eye patch and placed in the baby's jeans and the treatment will be started. The position (face down and back down) is changed every two hours. And phototherapy is paused every three hours for feeding. Therefore, the bath will be given half an hour after the phototherapy application is completed before the two phototherapy sessions. The physiological parameters of the newborns will be evaluated 0 minutes before the bath. Then the bathtub bath application will be started. The bath application will be completed in a time not exceeding 5 minutes. Physiological parameters, stress and comfort will be assessed 15 minutes after bathing. Then, 15 minutes after starting the phototherapy session and 15 minutes before ending the phototherapy session, physiological parameters, stress and comfort will be assessed. The measured physiological parameters (respiratory rate, heart rate, oxygen saturation and body temperature), stress and comfort scor
223916228|NCT06814626|DIETARY_SUPPLEMENT|12-week nutritional intervention with Friliver dispensing|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
223916229|NCT06814626|OTHER|12-week nutritional intervention with personalized diet|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
224089186|NCT05112796|PROCEDURE|Class I extractions sites received immediate implants using the Vestibular Socket Therapy|A 1-cm-long vestibular access incision was made using a 15c blade 3 to 4 mm apical to the mucogingival junction at the related socket. A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision
224089187|NCT05112796|PROCEDURE|class I extractions sites received immediate implants using the Partial Extraction Therapy|the hopeless tooth was decoronated 1 mm coronal to the gingival margin using a diamond bur. Then, the facial root segment was separated from the rest of the root using a Lindemann bur in gentle mesiodistal sweeping strokes from the gingival margin to the apex of the root, aiming to separate the palatal and the labial root segments.
224089188|NCT04790227|DEVICE|MRI|MRI
224278152|NCT02031237|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
224278153|NCT02031237|DEVICE|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
224278154|NCT00825864|DRUG|diclofenac drops|one drop 4 times a day for 3 months
224278155|NCT00825864|DRUG|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
224278156|NCT04963608|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
224278157|NCT01110317|DRUG|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
224278158|NCT00973934|DEVICE|Magstim Theta|
224278159|NCT00973934|DEVICE|Thymatron System IV|
224278160|NCT00757679|DRUG|Milnacipran|capsules
224278161|NCT00757679|DRUG|Placebo|capsules
224278162|NCT00772616|DRUG|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
224278163|NCT00772616|DRUG|Sufentanil|dosage according to usual criteria
224278164|NCT00006102|DRUG|becatecarin|
224089189|NCT04738357|DRUG|HSK21542|HSK21542：1 µg/kg
224089190|NCT04738357|DRUG|Placebo|Placebo
224089191|NCT02532348|OTHER|Blood samples|Blood samples
223916230|NCT06814626|OTHER|12-week nutritional intervention with diet diary to report foods eaten.|After TIPS placement patients of the treatment group receive a 12-week nutritional intervention that includes a personalized diet, Friliver dispensing (Dompé; 2 sachets 3 times a day) and a diet diary to report the quantity and quality of the foods eaten every single day.
223916231|NCT06812572|DEVICE|Visibly Vision Test|The Visibly Vision Test is used as a digital self-administered device to measure visual acuity and to subjectively measure refractive value for a patient's eye to determine the optical prescription for the conditions of myopia and astigmatism
223916232|NCT03969563|BEHAVIORAL|Mindfulness-based Stress Reduction|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
223916233|NCT03969563|BEHAVIORAL|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
223916234|NCT05633147|DRUG|Linaprazan glurate|"Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days."
223916235|NCT05633147|DRUG|Drug drug interaction (DDI) - Clarithromycin (Part I)|Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).
223916236|NCT05633147|DRUG|Drug drug interaction (DDI) - Midazolam (Part 2)|Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
223916237|NCT06587945|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral Nicotinamide Riboside, 2g daily for 4 weeks followed by 1g daily for 16 weeks
224089192|NCT00382148|DRUG|omalizumab|SC repeating dose
224089193|NCT02870725|BEHAVIORAL|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
224089194|NCT05485207|DRUG|Transvaginal botulinum toxin A (BTA) injection|Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
224089195|NCT02764541|DRUG|Letrozole|
224089196|NCT02764541|DRUG|Tamoxifen|
224278165|NCT04296201|DEVICE|DMA treatment|Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
223916238|NCT06587945|OTHER|Placebo|Matched placebo
223916239|NCT06587945|PROCEDURE|Vitrectomy and Gas tamponade|Standard of care Vitrectomy surgery for retinal reattachment
223916240|NCT06595628|PROCEDURE|Lichtenstein Mesh-Based Hernioplasty|This is a tension-free hernioplasty procedure that uses a synthetic mesh to reinforce the inguinal canal floor. The mesh is fixed to the inguinal ligament and internal oblique aponeurosis, creating a barrier to prevent hernia recurrence. It is considered the gold standard for inguinal hernia repair and is widely used for its effectiveness in reducing recurrence rates and postoperative complications.
223916241|NCT06595628|PROCEDURE|Combined Modified Guarnieri-Desarda Tissue-Based Hernioplasty|This technique combines elements of the Guarnieri and Desarda tissue-based repairs. It does not involve the use of synthetic mesh, relying instead on the patient's own tissues to reinforce the inguinal canal. The Guarnieri technique reshapes the internal ring to improve the inguinal canal's shutter mechanism, while the Desarda technique reinforces the posterior wall using the external oblique aponeurosis. This approach aims to preserve natural anatomy and minimize complications associated with mesh use.
223916242|NCT06813495|BEHAVIORAL|Eastern Principles Acceptance and Commitment Therapy for Nurses and Nursing Aids (EPACT NNA)|The EPACT intervention will be group-based with 5-10 participants per group. The group-based format has been shown to be an effective delivery method for NNAs (O'Brien, et al., 2019b). The EPACT protocol is comprised of two 2.5-hour sessions spaced one week apart.
223916243|NCT06813495|BEHAVIORAL|Acceptance and Commitment Therapy for Nurses and Nursing Aids (ACT NNA)|The ACT for NNA intervention has been previously tested for NNAs. It contains only the six core processes identified above and omits the added EPACT components of acceptance of suffering, common humanity, impermanence, self- and other-compassion, and non-self-attachment. It will be delivered in a similar group-based format of 5-10 participants in two 2.5 -hour sessions.
223916244|NCT06814899|DRUG|Fosfomycin|In this retrospective study, the investigators want to analyze the medical records of all patients admitted to the Lecco ASST from 04/01/2020 to 12/31/2023 treated with IV fosfomycin in order to evaluate different clinical outcomes.
224089197|NCT02764541|DRUG|Palbociclib|
224089198|NCT02764541|DRUG|Endocrine Therapy|
224089199|NCT02536248|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
224089200|NCT02536248|DRUG|Placebo|Placebo for 6 weeks
224089201|NCT06071611|OTHER|Experimental: Oxygen-Ozone (O2-O3)|Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).
224089202|NCT06071611|OTHER|Active Comparator: Oxygen (O2)|Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).
224089203|NCT06071611|OTHER|Placebo Comparator: Placebo (Air)|Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
224089204|NCT01552343|DRUG|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
224089205|NCT01552343|DRUG|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
224089206|NCT04608214|DRUG|Alisporivir|Administration of alisporivir at the dose of 600 mg p.o. BID from D1 to D14 to patients and standard of care (SOC).
224089207|NCT04608214|OTHER|Standard of care (SOC)|Locally accepted regimen protocols for patient care and select agents based on the underlying diagnosis and the severity of COVID 19 (excepting e.g. azithromycin and other antibiotics listed as prohibited medications)
224278166|NCT05934357|OTHER|Fiber|The intervention treatment will contain fiber.
224278167|NCT05934357|OTHER|Control|The control treatment will contain corn meal.
223916245|NCT06813300|PROCEDURE|Electrophysiological recordings|Addition of electrophysiological recordings performed during cognitive tasks passation in patients undergoing DBS: in pre-op, per-op, peri-op and post-op setting
223916246|NCT06811337|PROCEDURE|Open Sinus Elevation|Open Sinus Elevation
223916247|NCT06811337|PROCEDURE|Closed Sinus Elevation|Closed Sinus Elevation
224089208|NCT04492566|DEVICE|Automated Insulin Delivery|"Participants will use the Automated Insulin Delivery (AID) iAPS system for 48-60 hours in a medically supervised session.~For subjects who wish to continue use of the system, they will be offered the option of continuing use of the system at home in an extension phase, for the rest of their pregnancy."
224089209|NCT01569581|BIOLOGICAL|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
224089210|NCT01569581|BIOLOGICAL|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
224089211|NCT01569581|BIOLOGICAL|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
224089212|NCT01569581|BIOLOGICAL|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
224089213|NCT05685940|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of risankizumab.
224089214|NCT05685940|PROCEDURE|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
224089215|NCT02040142|PROCEDURE|HIPEC|
224089216|NCT02040142|DRUG|Mitomycin C|
224089217|NCT04912960|DEVICE|Mechanical ventilation|Optimum PEEP
224089218|NCT06365619|DRUG|Ipilimumab|Two cycles of neoadjuvant ipilimumab prior to surgical resection.
224089219|NCT06365619|DRUG|Nivolumab|two cycles of neoadjuvant nivolumab prior to surgical resection.
224089220|NCT00743808|OTHER|quality improvement|3-phase quality improvement intervention
224089221|NCT05635890|OTHER|Cawthorne Cooksey exercise protocol|Cawthorne Cooksey exercise protocol
224089222|NCT05635890|OTHER|conventional vestibular rehabilitation|conventional vestibular rehabilitation
224089223|NCT04653493|BIOLOGICAL|CD19 CAR engineered autologous T-cells|"Given IV~Following preconditioning with lymphodepleting chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) T cells as a single or split dose (day 0, 1 and 2, CAR cells will be intravenously infused at the 10%, 30% and 60% ratio respectively). Dosing of CD19 CAR-T cells will follow a dose-escalation schema, with dose changes based on dose-limiting toxicities."
224089224|NCT04653493|DRUG|Cyclophosphamide|Given IV
224089225|NCT04653493|DRUG|Fludarabine|Given IV
224089226|NCT04653493|DRUG|Mesna|Given IV
223916248|NCT06589726|DRUG|Placebo|Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
223916249|NCT06589726|DRUG|Moxifloxacin|Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
223916250|NCT06589726|DRUG|Enpatoran low dose|Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
224278168|NCT00945334|DRUG|Neomycin|500 mg po bid for 14 days
224278169|NCT00945334|DRUG|Placebo|placebo for 14 days tid
224278170|NCT00945334|DRUG|Rifaximin|550 mg po tid
224278171|NCT00332124|DRUG|Choline|900 mg every day until birth of infant
224278172|NCT00332124|DIETARY_SUPPLEMENT|Placebo|Corn oil every day in place of choline
224278173|NCT04451980|PROCEDURE|Subcutaneous adipose tissue biopsy|Percutaneous adipose tissue biopsy
223916251|NCT06589726|DRUG|Enpatoran high dose|Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
223916252|NCT06769204|DRUG|EMLA SPRAY|2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure
224089227|NCT05359393|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"Patients will receive tislelizumab in combination with neoadjuvant radiotherapy and chemotherapy, and will be evaluated 2-3 weeks after completion of the treatment. Those patients who achieve complete clinical regression of the lesion can choose observation, but for those without CCR, surgical resection (TME of the primary lesion, surgical resection of metastases or other destructive local treatment) will be applied. Patients will continue to receive tislelizumab for one year after surgery or during observation.~For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx.~Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w x6, i.v). Chemotherapy adopts CAPEOX plan, including Capecitabine(1000mg/m2 bid, d1-14, p.o) and oxaliplatin(130mg/m2, d1, i.v)."
224089228|NCT03052647|DEVICE|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
224089229|NCT03052647|DEVICE|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
224089230|NCT02330419|DRUG|Placebo|Placebo capsules will contain microcrystalline cellulose (Medisca). Placebo and active medication will be provided in capsules that are an exact match in color, so as to make the placebo and active medication indistinguishable from each other.
224089231|NCT02330419|DRUG|Naltrexone|REVIA is a white, crystalline compound. The hydrochloride salt is soluble in water to the extent of about 100 mg/mL. REVIA is available in scored film-coated tablets containing 50 mg of naltrexone hydrochloride.
224089232|NCT02330419|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist
224278174|NCT04451980|RADIATION|CT scan|CT scan of chest and abdomen without contrast
224278175|NCT04451980|DIAGNOSTIC_TEST|Oral glucose tolerance test|Ingestion of 75g of oral glucose syrup and measurement of blood glucose and insulin at time 0, 15 min, 30 min, 60 min, 90 min, and 120 min.
224278176|NCT04451980|DIAGNOSTIC_TEST|Blood collection|Fasting blood collection for plasma cytokines and T cell phenotypes.
224278177|NCT01713088|OTHER|Multisystemic therapy|
224089233|NCT02330419|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers:|Urine samples will be collected weekly and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours).
224089234|NCT02330419|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measure that will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection
224089235|NCT02330419|DIAGNOSTIC_TEST|Dried Blood Spot (DSB) Testing for Phosphatidylethanol|Phosphatidylethanol (PEth)-a phospholipid formed only in the presence of alcohol-is a novel, direct biochemical marker of alcohol that has shown high (\>95%) sensitivity and specificity to detect heavy drinking over a period of 2-3 weeks in several studies of dependent patients and abstainers. DSB samples will be collected at enrollment, weeks 3, 6, 9, 12, and post-treatment visits at month 1, 3, and 6.
224089236|NCT02330419|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments are SMS texts to collect data on alcohol consumption, number of drinks on drinking days, and targeted medication administration prior to anticipated drinking sessions. Messages will use short-hand notations to maintain participant confidentiality
223916253|NCT06769204|DRUG|Placebo|2 puffs of saline into the cervix and cervical canal 5 minutes before the procedure
223916254|NCT06769776|OTHER|No Drain i.e. Omission of abdominal drain placement|Omission of abdominal drain placement in intervention arm. The No-drain arm will be compared to drain arm
223916255|NCT06768840|DRUG|Baricitinib|oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A
223916256|NCT06768840|DRUG|oral mini pulse|pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
223916257|NCT06768840|RADIATION|Narrow Band UVB Treatment|narrowband ultraviolet rays B phototherapy two sessions per week
223916258|NCT06603519|DIETARY_SUPPLEMENT|Modified Plant-Based Mediterranean Diet|Two-week dietary intervention after the participants' scheduled colonoscopy consisting of vegetarian high-fiber meals. These meals are designed to provide a substantial intake of dietary fiber through a variety of plant-based foods, including whole grains, legumes, fruits, vegetables, nuts, and seeds. Meals will be delivered bi-weekly, and compliance will be monitored through regular check-ins with a study dietitian.
223916259|NCT04741230|DEVICE|Gebauer Lenticule|The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
223916260|NCT06655636|DEVICE|Device tuned to Assistance|The device spring components will be tuned to produce an assistive supination torque on the forearm.
223916261|NCT06655636|DEVICE|Device tuned to Sham (Slack Springs)|The device spring components will be tuned to slack springs to serve as a placebo. The user will think they are receiving forces but in reality the device will not be providing any forces.
223916262|NCT06655636|DEVICE|Device tuned to Anti-Assistance|The device spring components will be tuned to produce a resistive supination torque on the forearm.
224089237|NCT06494579|DRUG|Lamivudine|Lamivudine is used in the management of human immunodeficiency virus (HIV) and Hepatitis B Virus. It is being repurposed here to assess if this can improve response to cancer immunotherapy
224089238|NCT06494579|DRUG|PD-L1 Blocker|PD-1 or PD-L1 blocking antibodies; there are around a dozen of these FDA approved for varying indications, and whatever is administered to a patient as standard of care (FDA APPROVED) will be continued in the patients and administered in combination with lamivudine.
224089239|NCT04535193|DRUG|18F-mFBG for intravenous administration|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
224089240|NCT00183690|PROCEDURE|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
224089241|NCT00183690|PROCEDURE|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
224089242|NCT06286462|OTHER|Cancer Tracking System (CATSystem)|The CATSystem provider dashboard highlights patients with overdue services or those in need of outreach and sends automated, customized texts to support screening and treatment follow-up per national guidelines. Points of intervention and alerts include: cervical cancer screening and treatment counseling, initial and follow up cervical cancer screening per national guidelines, treatment for precancer and cancer, referral tracking and follow up. In addition, the CATSystem can securely store images of the cervix taken with colposcopes to allow for remote expert consultation if needed to correctly diagnose a patient or can be reviewed at clinical team meetings for input. Primary goals of the CATSystem are to increase rates of guideline-adherent cervical cancer screening/ rescreening and improve guideline-adherent treatment, referral, and follow-up rates of women with positive screens.
223916263|NCT06654206|OTHER|Exercise|"Supervised strength exercise sessions: There will be two sessions per week, each lasting 50 minutes. Each session will consist of three distinct parts:~Warm-up: 10 minutes of global strength and aerobic exercises at 6/10 on the Rating Perceived Exertion (RPE) scale.~Strength training: 6 strength exercises targeting the major muscle groups, lasting 30 minutes. The initial load will be set at 70% of the estimated 1-RM (assessed in the first session and based on the individual patient). When the participant is able to complete 3 sets of 12 repetitions with the established weight in two consecutive sessions, the weight will be increased by 10%. The exercises will be performed in a circuit format with 30 seconds of rest between exercises and 90 seconds of rest between sets.~Cool-down/stretching: 10 minutes of a combination of breathing exercises and stretching for the major muscle groups.~Promotion of physical activity: Participants"
224278178|NCT01713088|OTHER|YOT (usual services)|
224278179|NCT06467578|DEVICE|Breezing Portable Indirect Calorimeter|Indirect calorimeter with face mask and smartphone compatible application
224278180|NCT03471988|DRUG|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
223716443|NCT02745444|DIETARY_SUPPLEMENT|protein-restricted diet|
223916264|NCT06654206|OTHER|Home exercise|Participants will complete three weekly home training sessions that will not coincide with supervised training days. Each session will last 20 minutes, they will complete two sets of five exercises, with one minute of work and one minute of rest.
223916265|NCT06043531|OTHER|Experimental: EVOO|Subjects will consume 50g of cold pressed EVOO per day for 28 days.
223916266|NCT06493994|OTHER|transaxillary (TAX) transcatheter aortic valve replacement|Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).
223916267|NCT04370431|DRUG|TTYP01 single ascending doses|TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
223916268|NCT04370431|DRUG|Placebo|Placebo control for Part A of the study
223916269|NCT04370431|DRUG|TTYP01, 60 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
223916270|NCT04370431|DRUG|TTYP01, 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet)
223916271|NCT04370431|DRUG|Radicut® (ampoule), 30 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
223916272|NCT04370431|DRUG|Radicut® (bag) , 60 mg|An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
223916273|NCT04370431|DRUG|TTYP01, up to 120 mg|TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
223916274|NCT02326974|DRUG|T-DM1|Neoadjuvant treatment is for a total of 18 weeks.
223916275|NCT02326974|DRUG|Pertuzumab|Neoadjuvant treatment is for a total of 18 weeks.
223916276|NCT02326974|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
223916277|NCT06788821|DIAGNOSTIC_TEST|Description of the trend of major thyroid ultrasound biometric parameters|Use of prenatal ultrasonography for diagnosis and prognostic guidance in suspected fetal thyroid changes.
223916278|NCT06798636|DRUG|Psilocybin 5 mg with cognitive behavioural therapy intervention|This is an oral 5mg psilocybin dose preceding a mental imagery rescripting procedure
223916279|NCT06798636|DRUG|Placebo with cognitive behavioural therapy intervention|This is an oral placebo comparator preceding a mental imagery rescripting procedure
223916280|NCT04186650|BIOLOGICAL|COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin|Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
223916281|NCT06819774|DRUG|Cetirizine Hydrochloride Injection|The subjects received a single dose of 1-2 ml of the injection of cetirizine hydrochloride (administered by intravenous push) and a 1 ml dose of the injection simulant of diphenhydramine hydrochloride (administered by deep intramuscular injection), both as a simulation of a single administration.
223916282|NCT06819774|DRUG|Diphenhydramine Hydrochloride Injection|The subjects received 1 ml of the injection of Diphenhydramine Hydrochloride (for deep intramuscular injection) and 1 ml of the injection of Simulated Cetirizine Hydrochloride (administered by rapid intravenous injection over 1 to 2 minutes), each as a single dose.
223916283|NCT06820931|DRUG|Xuandi Ziyin Mixture|Treatment is given only with the hospital preparation 'Xuandi Ziyin Mixture' with a dosage of 30ml per administration three times a day.
223916284|NCT06816030|DRUG|MK-4482|Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.
223916285|NCT06819917|OTHER|Identification of liver fibrosis biomarkers|"Patients will be recruited in the study using 2 different approaches. The first is patients who are referred to clinical centers as part of an existing assessment where a decision to perform a liver biopsy has been made (routine biopsy). This decision can be based on standard liver function tests AST, ALT, FIB-4 (performed up to 8 months before biopsy), fibroscan (performed up to 6 months before biopsy) or other factors.~In addition, patients F0-F2 who underwent a biopsy within the last 6 months but at least 1 month ago, can be recalled to join the study. If patients agree to participate in the study, they will be recalled to the site for a blood draw and ultrasound scan."
223916286|NCT06820541|DEVICE|Double plastic pigtail stent plus fully covered self-expandable metal stent|After contrast injection, the cystic duct orifice will be detected. Using a sphincterotome, a 0.035-inch hydrophilic angled guidewire will be negotiated into the gallbladder. Dilation of the cystic duct will be performed using standard devices designed for biliary intervention, including pneumatic dilators or dilation progressive catheters. After dilation, a 7Fr plastic, double pigtail stent, length of 12 or 15 cm, will be deployed across the papilla. Finally, a fully-covered self-expandable metal stent will be placed alongside the gallbladder drainage for biliary drainage.
223916287|NCT06820541|DEVICE|Fully covered self-expandable metal stent|After biliary cannulation, a fully covered self-expandable metal stent will be placed for biliary drainage
223916288|NCT06817317|OTHER|Model Based Training|experimental group
223916289|NCT06817317|OTHER|Peer and Self-Learning Group|experimental group
223916290|NCT06819241|BEHAVIORAL|AI chatbot support|Integrating the practice of self-monitoring of HBP with the use of AI chatbot responses. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.
223916291|NCT06819241|BEHAVIORAL|telemonitoring and case management|Combining self-monitoring of HBP with telemonitoring and case management. This arm includes reminders for patients to monitor their BP and take antihypertensive medications, and involves tracking BP readings over time and offering feedback. Moreover, this arm offers physician-endorsed guidance on modifying the dosage of antihypertensive medication and implementing lifestyle adjustments. It offers education on hypertension and the potential side effects of medication, as well as assistance with medication refills and scheduling appointments.
224278181|NCT03471988|DRUG|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
223716444|NCT00110838|PROCEDURE|Supplementation with fish oil versus placebo|
223916292|NCT06820801|OTHER|pelvic floor muscles strength and function|using pressure perineometer to evaluate pelvic floor muscles strength and using PFDI to evaluate pelvic floor muscles function
223916293|NCT06820918|DEVICE|Bottle PEP|Home respiratory physiotherapy using the PEP bottle for a minimum of 10 minutes to a maximum of 30 minutes, twice a day (morning and evening), every day for 30 days
223916294|NCT06816355|PROCEDURE|Orchiectomy|CPT:54520
223916295|NCT06816355|PROCEDURE|Hysterectomy|CPT:1013911
223916296|NCT06816355|PROCEDURE|Augmentation mammoplasty|CPT:19325
223916297|NCT04173247|DEVICE|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
223916298|NCT04173247|OTHER|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
223916299|NCT06818318|OTHER|Temporomandibular disorder|Fonseca's Anamnestic Index was used for TMJ dysfunction. The diagnostic accuracy of the Fonseca's Anamnestic Index was found to be high in identifying pain-related and intra-articular TMDs, and the cut-off point was set as 25 points. A score of 25 and above was accepted as the presence of TMD.
223916300|NCT06818318|OTHER|Smartphone Addiction Scale-Short Form|In our study, the Smartphone Addiction Scale-Short Form will be filled out in order to evaluate the intensity of smartphone use of students, and the daily duration of smartphone use will be recorded. The Smartphone Addiction Scale-Short Form is a 6-point Likert-type scale consisting of 10 items used to measure the risk of smartphone addiction. Scores obtained from the scale vary between 10-60, and an increase in the score indicates an increased risk for smartphone addiction. Although the scale does not have a cut-off score in our country, it was determined as 31 for men and 33 for women in the Korean sample.
223916301|NCT06818318|OTHER|Neck Disability Index|The Neck Disability Index was used to assess the disability caused by neck pain. This questionnaire consists of ten items, four of which are related to subjective symptoms (pain intensity, headache, concentration, sleep) and six of which are related to activities of daily living (self-care, lifting, reading, work, driving and leisure activities). Scale scoring ranges from 0-40.
223916302|NCT06818318|OTHER|Temporomandibular Joint Pain|Numeric Pain Scale is a simple, reliable and short-term method commonly used in the clinic to measure pain intensity. It is a very reliable method in the evaluation of pharmacological and nonpharmacological treatments that reduce pain. The patient is told that the most severe pain he/she experiences is 10, and if he/she has no pain, the pain intensity is 0. The participant was asked to say a number between 0 and 10 corresponding to the intensity of pain felt in the TMJ region.
223916303|NCT06818318|OTHER|Anterior posture of the head|The anterior posture of the head was assessed with the Craniovertebral angle using a goniometer. The Craniovertebral angle was measured in degrees as the angle between the horizontal plane and the 7th cervical vertebra and the ear hole.
223916304|NCT06818318|OTHER|Pressure Pain Threshold Assessment|In our study, the pressure pain threshold measurement of the dominant and non-dominant side masseter and tenar muscles was evaluated with Baseline manual algometer.
223916305|NCT02561611|BEHAVIORAL|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
224089243|NCT04418856|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
224089244|NCT04418856|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
224089245|NCT05764967|OTHER|Low Dye Taping|The augmented low-Dye technique, involves applying a device consisting of a spur and mini-stirrups to the foot and then adding reverse sixes and calcaneal slings to an anchor on the distal one-third of the leg. A rigid 38-mm sports tape with zinc oxide adhesive is used for all of the taping procedures.
224278184|NCT01435824|DRUG|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
223716445|NCT04778930|OTHER|Physical Therapy|"FACE-TO FACE SESSIONS: approximately 90 minutes of Goal-directed training (activities for the activation of the muscles of the trunk, pelvis and lower limbs; and training of activities will be carried out in a functional and meaningful context, aimed at specific functional objectives, according to the interests of each participant and agreed with the participants and their families) and gait training on the treadmill for 20 minutes.~TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation."
223716446|NCT04778930|OTHER|THERAPEUTIC EDUCATION PROGRAM|TELEHEALTH THERAPEUTIC EDUCATION PROGRAM: Session 1: Concept and causes of CP, together with the general objectives and guidelines of the program. Session 2: The family-centered model; Sessions 3, 4 and 5: Actions Observation Therapy; Session 6: Program Evaluation.
223716447|NCT00967590|DRUG|RO5036505|380mg iv infusion once weekly for 8 weeks
223716448|NCT00967590|DRUG|placebo|iv infusion once weekly for 8 weeks
223716449|NCT04355520|DRUG|TQ-B3525|TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
223719509|NCT06120387|RADIATION|Kidney sparing surgery+Postoperative radiotheray|Kidney sparing surgery+Postoperative radiotheray
223916306|NCT06795555|BEHAVIORAL|Virtual reality food exposure|Patients in this condition are exposed to a virtual kitchen environment once/day, for 5 consecutive days (from Monday, day 1, to Friday, day 5). Each session lasts 5 minutes. The VR environment was specifically developed by the study team (Natali et al, 2024) and it consists of a kitchen with foods of different calorie contents. Patients are invited to explore the environment; they can freely move, open the cupboards and the fridge, and grab and hold the foods. Participants can choose to interact with one of three versions of the virtual kitchen environment: a) a kitchen alone, b) a kitchen with a virtual pet which participants can interact with (and aimed at inducing positive mood) and c) a kitchen with a compassionate avatar which motivates the participant to face food-related fears.
224089246|NCT05764967|OTHER|Temporary Felt Insoles|A temporary orthosis is fabricated from 7-mm orthopedic felt.The subject stands on his or her template while the TTR pointer is attached to the medial tibial plateau of the leg using a Velcro strap. An outline of the position of the device on the tibial plateau is drawn onto the skin with an indelible ink pen to allow for accurate relocation between all trials. TTR is measured in relaxed calcaneal stance while the subject wearing shoes. Measurements are recorded onto a data-collection sheet. Each measurement performes twice. The subject are given orthosis inserted into the shoe. All shoes are visually assessed to ensure that they will not induce pronation or internal rotation.
224089247|NCT03198689|DRUG|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
224089248|NCT05761964|BEHAVIORAL|Harmony & Health|Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
224089249|NCT05761964|BEHAVIORAL|Health Education|Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
224089250|NCT05341921|BEHAVIORAL|Alternate Nostril Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
224089251|NCT05341921|BEHAVIORAL|Bhramari Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
224089252|NCT05341921|BEHAVIORAL|Sheetali Breathing|Utilizing Pranayama (deep breathing technique) in normotensive and hypertensive women in 3rd trimester of pregnancy
224089253|NCT03710447|OTHER|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
224089254|NCT03710447|OTHER|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
224089255|NCT03710447|OTHER|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
224089256|NCT03710447|OTHER|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
224089257|NCT05187377|DRUG|Growth Hormone|Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.
224089258|NCT05187377|DRUG|Saline|Placebo (saline) will be administered subcutaneously once daily.
224089259|NCT03183362|DEVICE|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
224089260|NCT03183362|DEVICE|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
224089261|NCT06542146|DIETARY_SUPPLEMENT|Mediterranean diet|The Mediterranean diet is consisting of fruits, vegetables , legumes, whole grains, nuts, and olive oil as the main source ofdietary fat
224089262|NCT06542146|DIETARY_SUPPLEMENT|Usual diet|Usual diet including routine diet we already eat
224089263|NCT03542058|DRUG|Carvedilol|Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
224278185|NCT01435824|DRUG|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
224278186|NCT02040519|BEHAVIORAL|Filling out voiding diaries.|
223916307|NCT06795555|BEHAVIORAL|Virtual Reality Nature Exposure|"Patients in this condition complete a session of VR exposure to a natural scenario (from the NatureTreksVR app) for 5 consecutive days (from Monday to Friday), one session/day. Each session lasts 5 minutes. Participants can choose exposure to one of three different natural environments, at the start of each session: a white sand beach (Blue Ocean), a snowy mountain (White Winter), or a forest in autumn foliage (Red Fall)."
223916308|NCT06820632|BEHAVIORAL|Enhanced physical education|"The Enhanced physical education is based on the Health and Physical Education (HPE) Curriculum Framework developed by the Bhutanese Ministry of Education and well-document in the 2022 edition, www.education.gov.bt. The enhanced PE group will follow closely the description of the HPE curriculum and receive two 90-minute sessions weekly for 5 months. According to the HEP curriculum, the enhanced PE program incorporate both PE with socio-emotional competencies, such as self-regulation, self- and social-awareness, empathy-building exercises, and cooperation activities."
223916309|NCT06820632|BEHAVIORAL|HPE Standard curriculum|Health and physical education (HPE) standard curriculum includes roughly one hour per week of general physical education, typically involving activities like football and basketball.
223916310|NCT06821308|DEVICE|Implant placement|Each patient received 4 implants to support a bar supported overdenture. One implant is commercially available, 3 implants were experimentally made by the manufacturer for this study. The implants were similar in macro-desing, surface and platform shift but differ in microthread design and implant-abutment connection.
223916311|NCT06819345|OTHER|Survey form|PPE15 (Picker Patient Experience Questionnaire) at all visit of the study KDQOL-SF (Kidney Disease Quality Of Life -short form) at inclusion and 3 months after initiation of RRT ou 24 months after inclusion SDMQ9 (Shared Decision Making Questionnaire): at inclusion and 3 months after receiving information related to RRT SDRS (Score Decision Regret Scale) : 3 months after initiation of RRT ou 24 months after inclusion HLS EU 16 (Health Literacy Survey) : at inclusion or 3 months after information on RRT
223916312|NCT06817447|PROCEDURE|Pulmonary vein isolation plus cavo-tricuspid isthmus ablation|For those who are randomized to CTI+CPVI Arm, additional CPVI should be performed after finishing CTI ablation. CPVI could be performed using open-irrigated contact-force catheter, cryoballoon catheter or pulse-field ablation catheter. The endpoint is defined as both entrance and exit block in the pulmonary veins.
223916313|NCT06817447|PROCEDURE|Cavo-tricuspid isthmus ablation|"In periprocedural period, all antiarrhythmic drugs were discontinued for at least 5 half-lives and amiodarone for 2 months before the procedure. An electrophysiological study was performed after overnight fasting and mild sedated state with administration of intravenous midazolam and fentanyl.~CTI ablation should be performed under the CARTO or Ensite electroanatomic mapping system using an open-irrigated contact-force ablation catheter. Radiofrequency should be delivered at 30-50 W with a contact-force between 5-30 g in a point-by-point fashion until the CTI line is completed. Touch-up radiofrequency should be performed as needed. The endpoint of ablation is termination of AFL, if present, and the demonstration of bidirectional block across the CTI by using differential pacing."
223916314|NCT06816953|DIAGNOSTIC_TEST|HEAD-US|HEAD-US for evaluate haemophilic arthropathy in 6 joints. (Elbow, Knee, Ankle)
223916315|NCT06816953|DIAGNOSTIC_TEST|Urinary carboxy-terminal cross linked telopeptide of type II collagen|Cartilage biomarker represent cartilage degradation
223916316|NCT06816953|DIAGNOSTIC_TEST|Inflammatory markers|Inflammatory markers included CBC, Ferritin, ESR, CRP
223916317|NCT06817551|DRUG|Dexamethasone|\*Please see description for dexamethasone + supportive care arm.
223916318|NCT06817551|OTHER|Supportive Care|\*Please see description for supportive care arm.
223916319|NCT06814210|DEVICE|Cerebral Embolic Protection|Subjects will undergo M-TEER following placement of the cerebral embolic protection device.
224089264|NCT03644160|BEHAVIORAL|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
224089265|NCT00033865|BEHAVIORAL|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
224089266|NCT01438008|DRUG|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
224278187|NCT03239496|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
224278188|NCT03239496|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
223916320|NCT06818305|DRUG|Finerenone (BAY 94-8862)|"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Finerenone (10mg/d or 20mg/d)."
223916321|NCT06818305|DRUG|Empagliflozin 10 mg|"Adjusting lifestyle and managing underlying conditions according to the Chronic Kidney Disease Early Screening, Diagnosis, and Prevention Guidelines (2022 Edition) + Empagliflozin (10mg/d)."
224278189|NCT05507996|DRUG|Recombinant adeno-associated virus administration|The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
224278190|NCT00275275|DRUG|Requip PR|Requip 24-Hour once a day for one month
224278191|NCT00275275|DRUG|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
223716450|NCT04355520|DRUG|Fulvestrant injection|Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle. Each cycle is 28 days.
223716451|NCT03253497|DRUG|Chlorobenzene Liquid|before induction will be used for oropharynx
223916322|NCT06817486|OTHER|RUNNİNG TRAİNİNG|Running training It was performed between 08:00 and 10:00 for morning running and between 18:00 and 20:00 for evening running (Bessot et al., 2014). The exercise intensity of each child in the running group was determined as the 50% heart rate (HR) according to the Karvonen formula (target pulse: (220-age-basal pulse) × intensity) + basal pulse). HR was determined via a telemetric heart rate monitor (PolarM400, Finland) during the first week of running training. Environmental conditions are known to influence the degree of airway epithelial disruption during high-intensity exercise (Boukelia et al., 2017). Therefore, all the participants performed continuous running exercise on a football field in Kelkit/Gümüşhane/Turkey (altitude: 1373 m). It was performed for 50 minutes (including 10 min warm-up and cool-down), 3 days a week, for 8 weeks at the set target heart rate. Each session was supervised by trainers. Running included approximately 10 minutes of warm-up and cool-down with stati
223916323|NCT06817486|PROCEDURE|TRAİNİNG|RUNNING TRAINING WAS DONE
223916324|NCT06818279|DRUG|Dabigatran|Dabigatran 150 mg BD fixed dose to be given for duration of 6 months.
223916325|NCT06818279|DRUG|Enoxaparin|Enoxaparin . Treatment would be given with 1 mg /Kg (100IU/Kg) dose s/c twice daily for 6 months.
223916326|NCT06819982|OTHER|BCM2.0|The BCM2.0 programme provides occupational therapy sessions and assistive devices to support older people who want to age in place.
223916327|NCT06818760|DIAGNOSTIC_TEST|Masimo Smart Wristband|Continuous wear of Masimo Smart Wristband
224089267|NCT01438008|DRUG|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
224089268|NCT04735003|DEVICE|Transcatheter tricuspid valve interventions|Transcatheter repair or replacement to treat tricuspid regurgitation
224089269|NCT02667145|OTHER|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
224089270|NCT03804385|PROCEDURE|intercostal tube|surgical operation
224089271|NCT02293122|OTHER|Observational|Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F\&A Specular Microscope.
224089272|NCT01813890|DRUG|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
224089273|NCT01813890|DRUG|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
224089274|NCT01813890|DRUG|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
224089275|NCT06250140|DEVICE|Tie up device|The recurrence rate of internal hemorrhoids in different treatment methods
224089276|NCT02071433|PROCEDURE|Saphenous nerve blockade|
224089277|NCT02071433|PROCEDURE|Femoral nerve blockade|
224089278|NCT04311658|DRUG|Isosorbide Mononitrate 40 MG|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
224089279|NCT04311658|DRUG|Placebo|one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
224089280|NCT01556984|OTHER|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
224089281|NCT01457183|DEVICE|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
224089282|NCT04439123|DRUG|Capivasertib|Given PO
224089283|NCT02229201|DRUG|Propofol|4-6 mg/kg/h during anaesthesia
224089284|NCT02229201|DRUG|Sevoflurane|0.8 MAC
224089285|NCT03939013|DIAGNOSTIC_TEST|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
224089286|NCT02230176|DRUG|Sunitinib|
224089287|NCT02230176|DRUG|177Lu-DOTA0-Tyr3-Octreotate|
224089288|NCT05042830|PROCEDURE|Blood sampling|Blood samples will be taken by puncture of the antecubital vein for peripheral blood mononuclear cells (PBMCs) isolation, cytokines measurement, and flow cytometry analysis
224089289|NCT05042830|PROCEDURE|Nasal biopsies|Nasal biopsies will be taken from the lower fringe of the inferior turbinate, approximately 1-2cm from the anterior curved edge for RNA sequencing and confocal microscopy staining
224089290|NCT05042830|BIOLOGICAL|Nasal specimen collection|Nasal specimen collection will be conducted. Nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)) will be obtained.
224278192|NCT00117806|BEHAVIORAL|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
223916329|NCT06816485|DEVICE|PTV (Percutaneous Transcatheter Valvuloplasty) Balloon|Minimally invasive medical procedure used to replace a diseased aortic valve without the need for open-heart surgery. It is commonly used to treat severe aortic stenosis, a condition in which the aortic valve becomes narrowed and restricts blood flow from the heart to the rest of the body.
223916330|NCT06817811|DRUG|Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica)|One tablet of the test drug was given orally under fasting condition
223916331|NCT06817811|DRUG|Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia)|One tablet of the reference drug was given orally under fasting condition
223916333|NCT06656754|OTHER|Isometric Reaching|"The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation"
223916334|NCT06476600|DRUG|Dexmedetomidine injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
223916335|NCT06476600|DRUG|Nalbuphine Injection|All the eligible patients will undergo general anaesthesia for their elective surgeries (Laparoscopic Cholecystectomies). For the induction and maintenance of anaesthesia the participants will be randomised in a 1:1 ratio to receive either a standard opioid-based anaesthesia (by Nalbuphine) or opioid-free anaesthesia (by Dexmedetomidine) treatment protocols.
223916336|NCT01855633|DEVICE|Traditional Theta burst stimulation (TBS)|
223916337|NCT01855633|DEVICE|Modified TBS rTMS|
223916338|NCT01855633|DEVICE|Sham rTMS|
223916339|NCT06653556|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
223916340|NCT06478693|DRUG|MT-303|MT-303
223916341|NCT04801368|DRUG|Randomization of two local anesthetics.|Patients will be blinded and randomized to two different arms. One receiving ropivacaine, one receiving liposomal bupivacaine.
223916342|NCT05302219|OTHER|Respiratory rate|The participant alternates respiratory rates of 30, 15 and 7.5 breaths/min. Breathe each frequency for 2 minutes with a one-minute break.
223916343|NCT05302219|OTHER|Tidal volume|The participant alternates tidal volumes of approx. 2, 1 and 0.5 litres. Breathe each tidal volume for 2 minutes with a one-minute break.
223916344|NCT05302219|OTHER|Apnea|The participant simulates three apneic pauses lasting 1 minute with a two-minute break.
223916345|NCT06651463|OTHER|Videorecording|Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
223916346|NCT05043064|PROCEDURE|Wet lab tasks|Robotic-assisted internal thoracic artery harvesting, mitral annulus sutures placement and atrial closure in porcine model
223916347|NCT06820736|DEVICE|Drain|A drain is a small flexible tube that is placed next to where the spine was operated upon.
223916348|NCT06815978|DIAGNOSTIC_TEST|DXA|Dual energy X-ray absorptiometry
223916349|NCT06815978|DIAGNOSTIC_TEST|ultrasonography|ultrasonography
223916350|NCT06815978|DIAGNOSTIC_TEST|indirect calorimetry|indirect calorimetry
223916351|NCT06815978|DIAGNOSTIC_TEST|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
223916352|NCT06815978|DIAGNOSTIC_TEST|bioimpedentiometry|bioimpedentiometry
223916353|NCT06857318|BIOLOGICAL|Colostrum Nasal Spray|24 hours use of nasal spray of colostrum from MERS-CoV positive camels- 6 doses total
223916354|NCT06857318|OTHER|Water for injection|24 hours use of a nasal spray of water for injection- 6 doses total
223916355|NCT06855888|PROCEDURE|Modified Blumgart suture method|During pancreaticoduodenectomy, the modified Blumgart suture method is used for pancreaticojejunostomy. For anastomosis, 5-0PDS is used for pancreatic duct mucosal anastomosis, and 3-0 or 4-0 monofilament non-absorbable suture is used for pancreaticojejunal mattress anastomosis.
223916356|NCT06855888|PROCEDURE|Three-sided mattress suture|At the time of pancreaticoduodenectomy, the three-sided mattress suture is used as the pancreaticojejunostomy method. In addition to the conventional Blumgart modified suture, the three-sided mattress suture method adds a mattress anastomosis with 3-0 or 4-0 monofilament non-absorbable suture to the cranial and caudal sides of the pancreaticojejunostomy site.
223916357|NCT06816238|OTHER|Interactive education|interactive education based on a medical knowledge model, utilizing intelligent medical agents and interactive Q\&A
223916358|NCT06816238|OTHER|Traditional health education|traditional health education methods without the use of the interactive medical model and intelligent Q\&A system
223916359|NCT05224440|BEHAVIORAL|Veteran Sponsorship Initiative|Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
223916360|NCT04924400|BEHAVIORAL|CHIP Program|"GHP members randomized to the intervention arm will participate in the following activities:~* Attend 2 group meetings per week over 6 weeks, followed by one group meeting per week for 6 weeks (12 weeks total); each meeting will last about one hour. CHIP classes for weeks 1-4 and week 12 require in-person attendance, while week 5-11 classes can be attended either virtually or in-person.~* Receive a copy of The Optimal Diet, The Official CHIP Cookbook.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey"
223916361|NCT04924400|BEHAVIORAL|Usual Care|"GHP members assigned to the control arm will receive the routine standard of care for GHP members. Members will receive a summary of diabetes-related benefits available to members with type 2 diabetes.~The following data will be collected at weeks 1,12 and 26:~* Biometrics: Weight, BMI, waist circumference, systolic and diastolic blood pressure~* Biomarkers (blood tests): HbA1c, LDL-C~* Psychometrics: Wellbeing360 survey"
223916362|NCT06663189|DRUG|treatment withdrawal|Patients will STOP their DMT
223916363|NCT06663189|DRUG|Usual DMT continuation|Patients will continue their DMT during the trial as usual : Interferon-β (IFN-β), glatiramer acetate, dimethyl fumarate, teriflunomide or diroximel fumarate
223916364|NCT06663189|OTHER|MRI|Cerebral+spinal cord enhanced MRI (M0) Cerebral enhanced MRI (M6, Relapse early visit) Unenhanced cerebral MRI (M12, M18, M24, Relapse distant visit
223916365|NCT06663189|BEHAVIORAL|Quality of Life questionnaires|EQ-5D5L: EuroQol-5-Dimension 5 levels Burden of Treatment Questionnaire (BTQ self-administered questionnaires) Hospital Anxiety and Depression (HAD) questionnaire
223916366|NCT06663189|OTHER|Disability evaluation tests|EDSS: Expanded Disability Status Scale 25Foot/Walk 9-HPT:Nine Hole Peg Test
223916367|NCT06825221|DIETARY_SUPPLEMENT|Oral Nutrition supplement|Participants received normal diet and in the interventional group received package of immune formula 2 meals per day for 10-14 days prior surgery.
223916368|NCT06826248|DRUG|Darqeen Capsule|Effect of Darqeen capsule on Thyroid hormones
223530144|NCT06958237|DEVICE|salicylic acid wart patches|"The wart patches contain the auxiliary therapeutic substance salicylic acid at a concentration of 40%, which causes chemical exfoliation, removing the exfoliated skin. Salicylic acid softens the keratinised skin, making it easier to remove. The remedial process leads to the removal of the wart by exfoliation. The wart should disappear after about 7 days of using the patch. The treatment can be prolonged up to 21 days.~The wart patch is intended for the treatment of common warts and plantar warts. The mechanism of action of the product is the barrier and protective action of the patch, reducing the possibility of spreading viral infection and, as an auxiliary, to exfoliate keratinised epidermis, accelerating the skin renewal process."
223530145|NCT02296476|DRUG|Birabresib|Administered orally in a fasted state once daily.
223716452|NCT00067665|OTHER|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
223716453|NCT01480752|DRUG|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
223916369|NCT06824883|DRUG|Immunochemotherapy|"P-P-GemOx regimen Sintilimab 200mg iv D1; Pegaspargase 3750U im D1; GemOx regimen: Gemcitabine 1000mg/m2 iv D1, Oxaliplatin 100mg/m2 iv D1 This regimen is administered every 3 weeks.~For patients with stage I-II (localized) disease:~A sandwich approach incorporating radiotherapy is employed. Patients initially receive 2 cycles of the P-P-GemOx regimen. If the interim evaluation demonstrates a complete response (CR) or partial response (PR), patients will proceed to intensity-modulated radiotherapy (IMRT). Following radiotherapy, an additional 2 cycles of the P-P-GemOx regimen are administered.~For patients with stage III-IV (advanced) disease. Patients are planned to receive 6 cycles of the P-P-GemOx regimen. For those achieving CR or PR following 6 cycles of immunochemotherapy, subsequent treatment options include autologous hematopoietic stem cell transplantation (auto-HSCT) or PD-1 monoclonal antibody maintenance therapy, determined based on age and overall physical condition."
223916370|NCT06824454|DRUG|Dipyridamole 75 MG|Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.
223916371|NCT04424316|BIOLOGICAL|RSVpreF|RSV vaccine (RSVpreF)
223916372|NCT04424316|BIOLOGICAL|Placebo|Placebo
223916373|NCT06816290|OTHER|"This research uses a qualitative method called photovoice. Participants express their experience of being a nursing student in a foreign country through visuals and share their feelings and"|"Photovoice is a participant-centered research method that allows participants to convey their experiences through visual data. This method is particularly used to understand social issues and the challenges individuals face. Participants take photos that they find meaningful related to the research topic and express their feelings, thoughts, and experiences through these images.~In this study, the Photovoice method is used to visualize the experiences of being a nursing student in a foreign country. Participants share their cultural adaptation, educational processes, personal challenges, and overall life experiences through photos taken with their smartphones. The photos are then analyzed in-depth during face-to-face interviews with the participants, where they discuss the meaning of the photo, the reason for choosing it, and their personal experiences."
223916374|NCT06280560|PROCEDURE|Controlled Ovarian Stimulation + Luteal Phase Support|Short COS protocol with GnRH antagonist followed by progesterone supplementation. Will be initiated after a negative vaginal ultrasonographic scans to define ovarian quiescence, on days 1 and 2 of the menstrual period. For ovarian stimulation, 150-225 UI /day of FSHrec (GONAL F) will be administered along or in combination with 75 UI/day of HMG (Menopur). From day 6 onwards, HMG/FSHrec will be administered on an individual basis according to the serum E2 levels and transvaginal ovarian ultrasound scans and GnRH antagonist (Orgalutran) 0.25 mg /day is introduced as soon as a follicle of 14 mms diameter has achieved. hCGrec (6500 IU, Ovitrelle) will be administered when 7 or 8 follicles with a maximum diameter of \>17-18 mms will observed. 400 mg of micronized vaginal progesterone will be administered (200 mg twice a day vaginal route), during 5 days. An endometrial biopsy and a blood sample will be obtained 7 days after hCG administration (hCH+7)
224278193|NCT00117806|BEHAVIORAL|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
224278194|NCT02415387|BIOLOGICAL|typhoid vaccine|Given IM
224278195|NCT02415387|OTHER|Placebo|Given IM
223530146|NCT01301677|DRUG|Hydrocortisone|Hydrocortisone liquid formulation
223530147|NCT01301677|DRUG|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
223530148|NCT01301677|DRUG|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
223716454|NCT01480752|DRUG|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
223530149|NCT06796101|DEVICE|Vagus Nerve Stimulation|In the study, CE certified vagus nerve stimulation device Vagustim will be used. Transcutaneous auricular vagus nerve stimulation will be applied bilaterally. The stimulation pulse width is 300 microseconds, frequency is 10 Hz and will be applied biphasically for 20 minutes.
223716455|NCT01480752|DRUG|no injection|inject nothing after inferior alveolar injection and before root canal therapy
223716456|NCT06504784|DIETARY_SUPPLEMENT|Dietary Fiber Mixture|10g/day of dietary fibre mixture - a mixture of oligo-and polysaccharides
223716457|NCT06504784|OTHER|Placebo|10g/day of placebo (glucose)
223716458|NCT03282643|DRUG|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
223916375|NCT06280560|PROCEDURE|Hormonal Replacement Therapy programmed artificial cycle|6 mg of oestradiol orally administered starting the first day of the menstrual period, followed by an endometrial scan 10-days later, and when a 7 mms triple line endometrium has seen by vaginal ultrasound scan, 800 mg of micronized vaginal progesterone (400 mg twice a day vaginal route), during five days, will be added to the oestrogen therapy. An endometrial biopsy and a blood sample will be obtained on day 5 of progesterone administration (P+5)
223916376|NCT06280560|PROCEDURE|Natural Cycle (NC)|No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
223916377|NCT06280560|PROCEDURE|Endometrial receptivity reference group|Recruited among women belonging to the oocyte donation program and will follow the procedures described above for the Natural Cycle group. No hormonal stimulation. From day 6 of the menstrual period, follicular growth will be evaluated. As soon as a follicle reaches 17mm in diameter, ovulation test strips will be provided to assess LH levels in the first morning urine. The participant will report the positive and will be scheduled for sampling seven days later. An endometrial biopsy and a blood sample will be obtained 7 days after LH peak (LH+7)
223916378|NCT06265207|OTHER|Virtual reality|Before the mammography, a 20-minute relaxing video featuring nature and forest views will be watched with VR SHINECON 360 degree glasses. Since it is seen in the literature that watching a video for 20 minutes provides effective results, the video viewing time was determined as 20 minutes.
223916379|NCT06265207|OTHER|routine maintenance|routine maintenance
224089291|NCT05042830|PROCEDURE|Mucosal RNA sampling|A 10 cm nasal curette will be used (Rhino-Probe, Arlington Scientific, USA). The curette is brought to lie against the mid-inferior portion of the inferior turbinate under direct visualisation. The curette is rubbed against the mucosal surface, going outwards. To ensure successful sample acquisition, this motion will be repeated 2-3 times
223530150|NCT06796101|OTHER|Controlled breathing exercises|"A controlled breathing exercise group will continue for a total of 2 weeks and will receive 10 sessions of 20 minutes per day.~The thoracic expansion exercise will be performed in 10 repetitions. In each intervention session, 2 sets of nadi shodhana pranayama consisting of 8 respiratory cycles will be applied to the patients, with a 2-minute rest period between the sets. Kapalabhati will be practised for 3 minutes, with 15 quick breaths in 10 seconds followed by a 20-second break (a total of 30 breaths per minute). In each session, 2 sets of bhramari pranayama consisting of 10 breathing cycles will be performed at a low respiratory rate, with a 1-minute rest period between sets. The physiological sigh exercise involves the first inspiration phase being 1 second, the second phase 0.25 seconds, and the exhalation 2 seconds for 3 minutes."
223530151|NCT00442702|DRUG|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
223716459|NCT03282643|DRUG|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
223716460|NCT03282643|DRUG|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
223716461|NCT02779829|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number SR15-40-Z12-006.
223716462|NCT02368015|OTHER|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
223716463|NCT02368015|DRUG|cefazolin|
223716464|NCT00514111|DRUG|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
223716465|NCT02487667|DEVICE|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
223716466|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
223716467|NCT01130454|DEVICE|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
223716468|NCT02887638|OTHER|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~* Analysis of the sitting-posture profile:~  o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~* Analysis of the dural profile before and after the provoking task:~  o Determination of the dural sensitivity by the use of the slump-test~* Analysis of the pain profile before and after the provoking task:~  * Determination of pressure pain sensitivity by the use of pressure algometry~ * Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
223716469|NCT02610725|OTHER|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
223719510|NCT05465044|OTHER|Twice-weekly hemodialysis with incremental crossover to thrice-weekly schedule|50% of the eligible participants will be assigned to twice-weekly hemodialysis for up to 12 months with incremental crossover to thrice-weekly hemodialysis as indicated.
223719511|NCT05465044|OTHER|Thrice-Weekly Hemodialysis|50% of the eligible participants will be assigned to outright thrice-weekly hemodialysis, which will be continuation of the initial thrice-weekly schedule during the run-in period, without the option to switch to less frequent dialysis schedule representing the standard of care.
223530152|NCT00442702|DRUG|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
223530153|NCT01746524|DEVICE|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
223530154|NCT05068349|DRUG|Butylphthalide|Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
223530155|NCT04257019|OTHER|Lavender oil|Inhalation of Lavender oil
223530156|NCT04257019|OTHER|Almond oil|Inhalation of Almond oil
223916380|NCT06819124|BEHAVIORAL|Structured Communicative Interaction|"Two interlocutors, one with ALS and their caregiver will work together. Each participant in the pair will view the same set of words on their screens. After one second, one of the words will be highlighted on the speaker's screen, they will say the word in the phrase Click on the \_\_\_\_ this time, and the listener will click on it. After the listener has made their selection, both participants will receive feedback on trial success."
223916381|NCT06819124|BEHAVIORAL|Unstructured communicative interaction|"Two interlocutors, one with ALS and their caregiver will work together. The pairs will be presented with two different versions of the same picture with eight differences chosen to elicit the same target segments (e.g., hid, ship, net). These pictures will be modified from the LUCID corpus. In total, pairs will complete four picture sets per session. Pairs will be given 5 minutes for each picture set."
223916382|NCT06820892|OTHER|Survey|The study utilised a 16-item questionnaire to evaluate the quality of information received during antenatal diagnosis consultations and its congruence with subsequent experiences following birth and hospitalisation of the infant. The questionnaire encompassed seven questions pertaining to consultation arrangements, including duration, frequency and unit visits, six questions addressing the received information, and three questions exploring the long-term outcomes of the child.
223916383|NCT06816602|BEHAVIORAL|education|Receiving structured education
223916384|NCT06819384|OTHER|Movement Pattern Training|The group A Movement Pattern Training 2set each set 20 repition lasting for eight weeks.
223916385|NCT06819384|OTHER|propioceptive neuromuscular facilitation|The group B propioceptive neuromuscular facilitation 2set each set 20 repition lasting for eight weeks.
223916386|NCT06816407|DRUG|Prucalopride 2mg|Prucalopride 2mg taken preoperatively
223916387|NCT06816407|DRUG|Prucalopride 4mg|Prucalopride 4mg taken preoperatively
223916388|NCT06816407|OTHER|Standard Care|Standard Supportive care
223916389|NCT03752892|OTHER|intervention -1-leg cycle training|partitioned aerobic exercise training
223916390|NCT03752892|OTHER|usual care - 2-leg cycle training|conventional aerobic exercise training
223916391|NCT06825923|OTHER|Clinical and Endotypic Assessmen|This observational study involves a detailed clinical and endotypic assessment of patients diagnosed with Obstructive Sleep Apnea (OSA). Assessments include polysomnography (PSG) to measure sleep patterns and disturbances, drug-induced sleep endoscopy (DISE) to evaluate upper airway obstruction, and various biomarker analyses to characterize endotypic traits. The study aims to collect comprehensive phenotypic and endotypic data to develop predictive models for OSA patient characterization and management.
223916392|NCT06824025|DRUG|lidocaine group ( nebulized lidocaine + saline) total volume 4 ml|nebulization of 60 mg lidocaine in 4ml saline 0.9%
223916393|NCT06826222|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Participants will complete two interventions: sodium bicarbonate (SB) and placebo (PL). In the SB condition, participants will receive 0.3 g/kg SB, while in the PL condition, they will receive 0.03 g/kg table salt, administered double-blind.
223916394|NCT06826222|DIETARY_SUPPLEMENT|Sodium Chloride|Participants will complete two interventions: sodium bicarbonate (SB) and placebo (PL). In the SB condition, participants will receive 0.3 g/kg SB, while in the PL condition, they will receive 0.03 g/kg table salt, administered double-blind.
223916395|NCT06820268|DRUG|XS-04 tablet|Each treatment cycle is 28 days, with continuous oral administration, twice daily.
223530157|NCT04257019|OTHER|Water|Inhalation of water
223530158|NCT01248325|DRUG|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
223530159|NCT01248325|DRUG|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
223530160|NCT05604261|DRUG|Anaprazole sodium 40 mg|Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
223916396|NCT06824558|OTHER|primiparous pregnant woman following virgin mary|It is thought that the application of the motherwort during birth shortens the duration of labor and reduces pain and fear during birth. In the study, the pregnant women in the intervention group watched the opening of the motherwort in water during birth.
223916397|NCT06824558|OTHER|primiparous pregnant|Only midwifery care was applied to pregnant women in the control group.
223916398|NCT06825156|DRUG|Empagliflozin 10 MG|Patients receive 10mg Empagliflozin(SLGT-2i) daily from 3 days prior to surgery untill 2 days post-surgery which includes day of surgery.
224278196|NCT06531642|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days|Within 2 hours of ED admission after inclusion criteria is met, administer 1st dose of Protonix (pantoprazole) 40mg, then followed by 40mg q12hrs for 2 additional days.
224278197|NCT06531642|DRUG|Protonix (pantoprazole) 40 mg q 24 hrs for 2 days|Administer 1st dose of 40mg Protonix (pantoprazole) at the usual timing (current practice: in the intensive care unit), then followed by 40mg daily for 2 additional days.
223916399|NCT06604975|PROCEDURE|Measure of Basal Copeptin level|"Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation"
223916400|NCT06604975|PROCEDURE|Measure of arginine-stimulated copeptin|The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.
223940384|NCT05115864|DEVICE|PFMT with device|The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
224089292|NCT05042830|PROCEDURE|Intranasal challenge|The extract of birch pollen (Allergopharma, Vienna, Austria) will be freshly diluted in a 0.9 percent sterile sodium chloride solution and administered by means of a metered pump. The allergen will be administered supplying 15 μl per puff to both nostrils. Azelastine nasal spray or desloratadine 5mg will be given if the patient suffers from nasal or eye symptoms after the challenge. Equivalent amount of saline without allergens will be given to the control group.
224089293|NCT05042830|PROCEDURE|Skin prick test|"In order to evaluate the patient's sensitization profile at the screening visit, a regular skin prick test will be conducted with commercial birch pollen extract and a panel of allergens used in routine diagnosis in the allergy clinic of the ear, nose, and throat (ENT) department.~Titrated skin prick test: Titrated skin prick test (SPT) to birch pollen extract is conducted by using increasing dilutions up to 1:100 000. As a result, it is possible to determine the lowest concentration that leads in a skin reaction."
224089294|NCT05042830|PROCEDURE|Peak Nasal Inspiratory Flow (PNIF)|The functionality and convenience of the PNIF presents a rare opportunity to rapidly obtain objective measurements of nasal peak inspiratory flow. It was also validated during other nasal allergen challenge as a study tool
224089295|NCT05042830|BIOLOGICAL|Pregnancy test|In female patients, a regular urine pregnancy test will rule out pregnancy. The test will be conducted at the screening visit before the first skin prick test and then once a month afterwards.
224089296|NCT00386906|PROCEDURE|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
224089297|NCT04591392|DEVICE|reSept ASD Occluder|Transcatheter closure of secundum ASD using a permanent implant
224089298|NCT05281757|DEVICE|posterior stabilization for the cervical spine|The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
224089299|NCT03952559|DRUG|Baricitinib|Administered orally
224089300|NCT03952559|DRUG|Placebo|Administered orally
224089301|NCT03952559|DRUG|Topical corticosteroid|Administered as standard-of-care
224089302|NCT06199076|DRUG|Oxytocin nasal spray|The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
224089303|NCT02867306|DRUG|ASP1707|Oral
224089304|NCT02867306|DRUG|methotrexate (MTX)|Oral
224089305|NCT05327322|BEHAVIORAL|Glycemic load|Participants will be provided food to meet GL prescription for the duration of the trial.
224089306|NCT05327322|BEHAVIORAL|Calorie restriction|Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
224089307|NCT05327322|BEHAVIORAL|Behavioral support|All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
224089308|NCT04895306|DRUG|Testosterone Cypionate|Weekly intramuscular administration of testosterone at a dose of 3 mg
224089309|NCT04895306|DRUG|Placebo|Weekly intramuscular administration of Placebo
224089310|NCT04555941|DEVICE|intermittent theta burst stimulation|active or Sham iTBS will be given to the AD/MCI patient
224089311|NCT05406323|BEHAVIORAL|Web-Based Fall Prevention Program|"Health education: This intervention consisted of seven health issues which are Fall among elderly, fall risk factors,  fall prevention interventions-exercise,  fall prevention interventions-healthy diet,  fall prevention interventions- drug use, fall prevention interventions- vision, fear of falling.~Exercise: This intervention is the exercise that is a combination of balance and strengthening exercises (8 exercise). Participants will do the exercises at least three days a week (along 6 week).~Safe home environment: This intervention is aimed at providing a fall-safe home environment for the participants. In this context, the participants will watch the video on creating a safe home environment for falling. Participants will also be asked to answer the Home Safety Check Form for Falls to make their home more fall-proof. In this form, according to the answers given by the participants, suggestions will be given to prevent the risks of falling in the home environment."
224089312|NCT05937412|OTHER|Alcohol sterilization|Sterilizing skin using alcohol
224089313|NCT05937412|OTHER|Honey sterilization|Sterilizing skin using honey
224089314|NCT05943704|DIETARY_SUPPLEMENT|beef broth|It indicates if the child has allergy of Beef or not.
223916401|NCT06604975|PROCEDURE|IRM|"Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment."
223916402|NCT06604975|BEHAVIORAL|Water reduction at home|Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
223940385|NCT04909203|DEVICE|iKinnect2.0|iKinnect2.0 is a paired mobile phone app for use on both Android and iOS operating systems by youth with conduct disorders and their parents.
223940386|NCT04909203|DEVICE|Active Control App|Mobile phone app for use on both Android and iOS operating systems for GPS tracking of other persons.
223940387|NCT06344481|DEVICE|Surgical (Hyalex Cartilage Knee Implant)|Implantation of Hyalex Cartilage Knee Implant.
223940388|NCT06193590|DEVICE|Carevix|Cervical stabilization device that uses vacuum
223940389|NCT06193590|DEVICE|Tenaculum|standard of care cervical stabilization device
223940390|NCT04205903|DRUG|Nilotinib|Given PO
223940391|NCT04205903|DRUG|Nilotinib Hydrochloride Monohydrate|Given PO on cycle 1 Days 7, 14, 15 once a day 24 hours prior to the paclitaxel infusion and again 30 minutes prior to the paclitaxel infusion on days 8, 15.
223940392|NCT04205903|DRUG|Paclitaxel|Given IV weekly on days 1, 8, 15, of every 21 days, at a starting dose of 80mg/m2
223940393|NCT04205903|OTHER|Questionnaire Administration|Ancillary studies
223940394|NCT02811510|DRUG|Placebo|Placebo pill (no active cannabinoids)
223940395|NCT02811510|DRUG|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
223940396|NCT04233567|DRUG|Infigratinib|Given PO
223940397|NCT03584711|COMBINATION_PRODUCT|FOLFOX + panitumumab|"FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment"
223940398|NCT06192433|DEVICE|High-frequency repetitive transcranial magnetic stimulation (40Hz)|Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
223940399|NCT06192433|DEVICE|Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)|Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
223940400|NCT04594564|PROCEDURE|Total hip arthroplasty with Delta TT cup|Total hip arthroplasty using Delta TT cup and ceramic bearings
223940401|NCT05302115|DEVICE|S-ICD|Implantation of an S-ICD
223940402|NCT04815993|DRUG|SYN-020 delayed release capsule|SYN-020, is an opaque, white, size 3 HPMC capsule for oral administration containing enteric-coated, delayed-release pellets.
223940403|NCT06787469|OTHER|Resin Cement|Bioactive self adhesive resin cement (SHOFU BeautiLink) used to cement indirect restorations to endodontically treated molars.
223940404|NCT06787469|OTHER|Resin Cement|Self adhesive resin cement
223940405|NCT06477653|BIOLOGICAL|dupilumab|Dupilumab is an interleukin-4 receptor alpha antagonist. Dosing for an individual will be determined based on the nature of their residual symptoms and the FDA-approved dosing for that indication.
223940406|NCT06285864|BEHAVIORAL|Interoception-based intervention|Intervention will include body awareness, sensorial, and relaxation exercises, plus homework.
223940407|NCT05896865|RADIATION|Whole breast / chest wall & regional lymph node irradiation|Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
223940408|NCT05896865|RADIATION|Internal mammary or supraclavicular lymph node boost|Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
223940409|NCT06052332|RADIATION|Short course radiotherapy|Patients will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy.
223940410|NCT06052332|DRUG|Adjuvant chemotherapy (optional)|The choice of the adjuvant chemotherapy is to the investigator's discretion.
223940411|NCT06052332|PROCEDURE|Total mesorectal excision|"Surgery must be performed according to the principles of total mesorectal excision. A watch \& wait approach is allowed for those subjects who have clinical complete response according to the local assessment."
223916403|NCT05148117|DIAGNOSTIC_TEST|Suspected Sepsis Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
223941434|NCT02481466|BEHAVIORAL|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
223530161|NCT05604261|DRUG|Anaprazole sodium 60 mg|Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
223530162|NCT05604261|DRUG|Rabeprazole sodium 20 mg|Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
223530163|NCT00313560|DRUG|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
223530164|NCT06628570|DIAGNOSTIC_TEST|HRA + Biopsy|High-Resolution Anoscopy, or HRA, is a standard of care procedure for screening and detection of premalignant lesions of the anus. Using a small, thin round tube called an anoscope, the anal canal is examined with a high-resolution magnifying instrument called a colposcope. The application of a mildly acidic liquid on the anal canal facilitates the evaluation of abnormal tissue such as anal dysplasia. Biopsies for histological confirmation of disease will be taken. Biopsies' reporting will follow the terminology, criteria, and recommendations of the Lower Anogenital Squamous Terminology (LAST) project. Histology results will be reported as benign, condyloma acuminatum, AIN grades 1-3, or cancer. For the proposed project, aHSIL+ will be defined as AIN2 (p16 block-positive), AIN3, and cancer at the HRA encounter. All other cases will be classified as \<aHSIL, including benign, condyloma acuminatum, and AIN1
223530165|NCT06628570|DIAGNOSTIC_TEST|Anal Cytology|Anal cytology collection (swab samples) will be performed as part of the standard of care during this study. The collected cells, suspended in the SurePath liquid-based medium, will be placed on a slide and microscopically examined by a board-certified pathologist. The sample will then be interpreted using the Bethesda System: negative for intraepithelial lesion or malignancy (NILM), ASCUS, LSIL, ASC-H, or HSIL. Pathologists interpreting the anal cytology will be blinded from hrHPV testing and biopsy histology.
223530166|NCT06628570|DIAGNOSTIC_TEST|Genotyping of anal hrHPV infection|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. To identify the infecting HPV genotype, DNA will be extracted from swab samples collected with the MagNA Pure LC DNA Isolation Kit III and an LC MagNA Pure system (Roche Diagnostics GmbH, Mannheim, Germany), followed by HPV typing using the TypeSeq assay, a laboratory prepared high-throughput next-generation sequencing assay developed by NCI will be performed as described. The assay uses three sequential PCR steps resulting in barcoded L1 amplicons sequenced and submitted to a bioinformatics pipeline for typing. This TypeSeq assay qualitatively detects and identifies 51 HPV genotypes (HPV types 3, 6, 11, 13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, and 114), including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)
223530167|NCT06628570|DIAGNOSTIC_TEST|CINtec®PLUS|Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. Dual immunostaining with p16/Ki-67 will be performed on the residual cytologic specimen by Roche MTM Laboratories (Heidelberg, Germany), using the CINtec®PLUS Kit according to the manufacturer's instructions. The anal cytology material will be stained with a mouse monoclonal antibody directed against human p16INKa (p16) protein (clone E6H4) and recombinant rabbit monoclonal antibody directed against human Ki-67 protein (clone 274-11AC3V1), using the BenchMark ULTRA instrument (Ventana Roche). Samples with insufficient cellularity will be excluded from the evaluation. A trained cytotechnologist will review all cases for cells staining positively with both markers. A slide will be considered positive if 1 or more squamous epithelial cell(s) stained positive for both p16 and Ki-67 and dual stain-positive cells will be semi-quantitatively assessed (0, 1, 2-5, 6-50, \>50).
223530168|NCT05505461|DRUG|neoadjuvant Radiation plus SOX and PD-1 antibody|"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."
223530169|NCT04073056|DRUG|Bupivacaine|Bupivacaine Hcl 0.25% Inj
223530170|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 4-7 days per week
223530171|NCT02194387|DIETARY_SUPPLEMENT|Dietary Intervention|Record dietary intake 1 day per week
223916404|NCT05148117|DIAGNOSTIC_TEST|Control Group - Diagnostic Measurements|Blood samples (7.5ml) will be collected in cell free DNA collection tubes cfDNA will be extracted with the use of MagMAX cell free DNA isolation kit. Quantitative PCR will determine the total cfDNA. cfDNA (5micro litr) will be subjected to bisulphide conversion with use of EZ DNA methylation kit (Zymo research). We will perform digital PCR for interrogating bisulphide treated cfDNA for FMA 101A locus with the use of Quant Studio 3D digital PCR system. Copy numbers of unmethylated FAM 101A locus as determined by d PCR in the sample will be expressed as the copy numbers of cardiomyocyte specific cfDNA per plasma volume.Inflammatory markers IL-6.IL-8, IL 1-18 and C-reactive protein (CRP) will be measured using commercial assays. Speckle tracking imaging will be used to obtain tissue displacement, velocity, strain, and strain rate in radial longitudinal and circumferential planes EF and FS will be determined by conventional methods.
223916405|NCT03761017|BIOLOGICAL|Lorigerlimab|Bispecific DART protein binding PD-1 and CTLA-4
223916406|NCT00560118|DRUG|fotemustine|
223916407|NCT06589791|OTHER|No treatment given|Online self-completion survey
223916408|NCT06817681|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Ingestion of gelatin capsules containing 0.4 g/kg body weight of sodium bicarbonate (NaHCO3) followed by 90 minutes of rest. Continuous high intensity cycling to be performed following 90-minute resting measures.
223916409|NCT06817681|OTHER|Placebo (Sodium Chloride)|Ingestion of gelatin capsules containing 0.4 g/kg body weight of sodium chloride (NaCl) followed by 90 minutes of rest. Continuous high intensity cycling to be performed following 90-minute resting measures.
223916410|NCT06590129|PROCEDURE|hydrodissection of median nerve|Ultrasound guided hydrodissection of median nerve in carpal tunnel with 5% dextrose solution
223916411|NCT06590129|OTHER|Physiotherapy|5-20 sessions in rehabilitation area with physical media: paraffin glove (10 coats for 15min), mobilizations of wrist and fingers, strectching of wrist and fingers tendons/muscles, muscle stregthening whit isometric or isotonic excercises to intrinsic muscles of the hand an forearm, and occupational therapy with techniques for sensory return, nerve and tendon sliding techniques, activities aimed at improving basic hand functions and work simulation activities.
223916412|NCT06600880|DEVICE|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
223916413|NCT06600880|DRUG|Lumason|New packages of Lumason microbubbles will be shipped from Bracco Diagnostics Inc. and will be used in conjunction with the ultrasound transducer to temporarily open the BBB. Lumason microbubbles will be freshly activated before treatment sonication and will be drawn using a 10-ml syringe to reach the desired dosage of 0.1mL/kg right before the intravenous injection.
223916414|NCT06600880|OTHER|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|"A high-resolution MRI (with and without gadolinium (Dotarem) contrast agent) will be acquired prior to BBB opening on the GE SIGNATM Premier (3T) (same scanner as in the NHP study) for pre-treatment planning and screening purposes. Then, a second MRI (with and without gadolinium) will be acquired and read by a Board-Certified Radiologist immediately after the treatment sonication in order to assess the BBB opening and safety. Finally, a final follow-up MRI (with and without gadolinium) will be conducted 3 days (±1 day) after the treatment to confirm BBB closing and/or safety. This will be read by a Board-Certified Radiologist as well.~All MRI procedures will be performed at the CUIMC/Neurological Institute of New York."
223916415|NCT06600880|RADIATION|Positron Emission Tomography (PET)|A first PET/CT scan with Amyvid (18F-Florbetapir) and MK-6240 (F18-Florquinitau) tracers will be performed on the SIEMENS Biograph 64 to assess the baseline amyloid plaque load and tau load before the treatment, respectively. Finally, two follow-up PET/CT scans will be conducted 3 weeks (±1 week) and 3 months (±2 weeks) post-treatment to assess amyloid plaque load (using Amyvid) and tau load (using MK-6240).
223916416|NCT06600880|DRUG|Amyvid|Amyloid PET tracer Amyvid (18F- Florbetapir) will be stored in their original container with proper radiation shielding at 25 °C and only handled by properly trained personnel in the handling and administration of radioactive materials, which requires employing proper radiation protection procedures.
224080461|NCT04995874|DIETARY_SUPPLEMENT|KOKOPlus protein and micronutrient powder|KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.
224080462|NCT02488304|RADIATION|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2."
224080463|NCT04507087|BEHAVIORAL|Documentary|A 20-minute documentary about the health, environmental, and animal welfare consequences of eating meat and animal products
224080464|NCT04507087|BEHAVIORAL|Control|"A 20-minute unrelated video (a motivational talk entitled Listening to shame)"
224080465|NCT03006809|BIOLOGICAL|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
224080466|NCT03006809|OTHER|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
224080467|NCT02144272|DRUG|LY3114062 SC|LY3114062 administered SC.
224080468|NCT02144272|DRUG|Placebo|Placebo administered SC.
224080469|NCT02144272|DRUG|LY3114062 IV|LY3114062 administered IV.
224080470|NCT04226794|DEVICE|a-tDCS|Anodal Transcranial direct current stimulation (tDCS) stimulation. Anode will be allocated at DLPFC right and cathode at DLPFC left. The stimulation will occur for 20 min in the intensity of 2 milliampere (mA).
223530172|NCT02194387|OTHER|Internet-Based Intervention|Receive email coaching
223530173|NCT02194387|OTHER|Internet-Based Intervention|Participate in social networking
223530174|NCT02194387|OTHER|Laboratory Biomarker Analysis|Correlative studies
223530175|NCT02194387|OTHER|Questionnaire Administration|Ancillary studies
223916417|NCT06600880|DRUG|MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
223916418|NCT06600880|DRUG|Dotarem|FDA-approved medication. Dotarem will be handled in accordance with the CUMC Research Pharmacy procedures and NYP policy P168, Version 4. Dotarem will be used according to its labeling. 0.2 ml/kg.
223916419|NCT06600880|DIAGNOSTIC_TEST|Blood draw|Blood samples will be collected through an intravenous catheter or a finger prick during screening, on the day of the FUS treatment and the follow up examinations (week 3 and month 3). These samples will be processed to assess any blood content changes induced by the focused ultrasound treatment.
223916420|NCT06600880|DEVICE|UR5e|Universal Robots robotic arm used for the accurate positioning of the neuronavigation-guided single-element focused ultrasound transducer with respect to the patient's head.
223916421|NCT06600880|DIAGNOSTIC_TEST|Urine test|Urine test required following the MRI and PET Centers policy used clinically for pregnancy screening
223916422|NCT06601127|DRUG|Tiprogrel|Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
223916423|NCT06601127|DRUG|Tiprogrel|Drug: Tiprogrel and Aspirin Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.
223916424|NCT06601127|DRUG|Clopidogrel|Day 1, loading dose of Clopidogrel and loading dose of aspirin; Day 2-21, daily maintenance dose of Clopidogrel and daily maintenance dose of aspirin; D22-90: daily maintenance dose of Clopidogrel.
223916425|NCT06597682|DRUG|Prednisone|Total 4 weeks of treatment
223916426|NCT06597682|DRUG|Budesonide/Formoterol|Total 8 weeks of treatment
223916427|NCT06597682|DRUG|Vitamin C combined with Coenzyme Q10 oral treatment|Total 4 weeks of treatment
223916428|NCT06597682|DRUG|Montelukast tablets oral treatment|Total 8 weeks of treatment
223916429|NCT06594757|PROCEDURE|Toothbrushing with triple-headed manual toothbrush|Toothbrushing with triple-headed manual toothbrush
223916430|NCT06594757|PROCEDURE|Toothbrushing with standard manual toothbrush|Toothbrushing with tstandard manual toothbrush
223916431|NCT06444594|DRUG|TRPM8 Agonist|menthol gel 4-10%
223916432|NCT06444594|DRUG|TRPV1 Agonist|camphor gel 5-20%
223916433|NCT06444594|DRUG|TRPV4 Agonist|capsaicin gel 0.05-1%%
223916434|NCT06444594|DRUG|TRPM8, TRPV4, TRPV1 Agonists|menthol (4-10%), capsaicin (0.05-1%), camphor (5-20%)
223916435|NCT06444594|OTHER|Vehicle gel|Inactive vehicle gel
223916436|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose
223916437|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, single dose
223916438|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, three times daily for a total of 8 days
223916439|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, six times daily for a total of 8 days
224278198|NCT06276699|PROCEDURE|1.Isometric exercise 2.combined conservative treatment|Exercise programs will be taught to patients with details by an experienced physiotherapist at the beginning of the study. Cervical Traction Patient will sit upright posture on a chair. Mechanical traction will be applied. It includes placement of a halo device around the neck, then the harness will be attached to the machine that applies traction force through-out the treatment, the device is controlled by the control panel. Intermittent mechanical traction will be applied for 10 minutes in which pull for 10 seconds and 5 seconds rest will be applied. Neural mobilization will be carried out using Butler's approach. The subject will be positioned in supine, and the median nerve will be mobilized using a slider.
223530176|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
223530177|NCT02194387|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
223719512|NCT06831175|DRUG|Camrelizumab|Camrelizumab was administered 200mg IV every 3 weeks.
223916440|NCT06597422|DRUG|STSP-0902 Placebo|Eye drop, multiple doses
223916441|NCT06597422|DRUG|STSP-0902 ophthalmic solution|Eye drop, single dose, tear samples will be collected
223916442|NCT06586970|BEHAVIORAL|Meals + RD services|Registered dietitians (RD) will provide tailored dietitian counseling and nutrition education
223916443|NCT06586970|BEHAVIORAL|Meals + OT services|Occupational therapists (OT) will provide tailored home safety recommendations and fall prevention education/strategies
223916444|NCT06586970|BEHAVIORAL|Meals + RD + OT services|A combination of tailored registered dietitian and occupational therapy services will be provided
223916445|NCT00412607|DEVICE|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
223916446|NCT06857305|DRUG|Eribulin biweekly regimen|Eribulin biweekly regimen
223916447|NCT06857305|DRUG|Eribulin standard regimen|Eribulin standard regimen
223916448|NCT06820359|OTHER|Bowel Preparation|Individuals will perform a bowel preparation using a Fleet saline enema.
223916449|NCT06820359|OTHER|No bowel preparation|Subjects will not be required to perform bowel preparation before surgery.
223916450|NCT04265807|DEVICE|Active Remote Ischemic Conditioning|A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
224080471|NCT04226794|BEHAVIORAL|Nutritional Counseling|Presentation delivered through video clip during 20 minutes based on Cognitive Behavioral Therapy interventions
223716470|NCT01714011|DRUG|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
223916451|NCT04265807|DEVICE|Sham Remote Ischemic Conditioning|The control group will have a sham package opened at the bedside as soon as feasible after ED arrival. This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device. Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
223916452|NCT06599528|DRUG|T-R (Test-Reference drug)|T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
223916453|NCT06599528|DRUG|R-T (Reference-Test drug)|R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
223916454|NCT06878014|PROCEDURE|Spinal Anesthesia (bupivacaine)|Patients were positioned in sitting position on operating table, interspinous space was identified using anatomical landmarks (intercristal line) and palpation. Entire procedure was conducted with aseptic technique, puncture site was prepared with izopropyl alcohol solution. Skin was anesthetized with subcutaneous injection of 1% lidocaine. Spinal puncture was achieved using median or paramedian technique with 27G pencil-point spinal needle. After confirmation of free flow of cerebrospinal fluid 15 mg of 0,5% bupivacaine was administered intrathecaly. Block level was assessed by lack of sensation to alcohol swab in periumbilical area and complete motor block (Bromage 3).
223916455|NCT06878014|DRUG|Postoperative pain management with acetaminophen|Postoperatively patients received 1,0g of paracetamol every 6 hours,
223916456|NCT06878014|DEVICE|PCA IV Oxycodone|All patients were equipped with PCA capable syringe pump (Perfusor Space, B. Braun) with 40 milligrams of oxycodone. Care provider explained thoroughly how to operate the device and educated about possible adverse effects.
223716471|NCT01714011|DRUG|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
223716472|NCT04048928|BEHAVIORAL|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
223716473|NCT00003105|BIOLOGICAL|filgrastim|
223716474|NCT00003105|DRUG|cisplatin|
223716475|NCT00003105|DRUG|doxorubicin hydrochloride|
223916457|NCT06878014|DRUG|Postoperative pain management with dexketoprofen|Postoperatively patients received 50mg of dexketoprofen intravenously every 8 hours.
223916458|NCT06878014|DRUG|Postoperative pain management with metamizole|Postoperatively patients received 1,0g of metamizole intravenously every 6 hours.
223916459|NCT06878014|DRUG|Preemptive Analgesics|After securing intravenous line each patient received preemptive analgesia with 1,0g paracetamol and 1,0g metamizole.
223916460|NCT06878014|DEVICE|Patient monitor|Postoperatively each patient's vital signs were monitored continuously using patient monitor for 48 hours.
224080472|NCT04226794|COMBINATION_PRODUCT|a-tDCS and nutritional counseling|a-tDCS + Nutritional Counseling
224080473|NCT04226794|COMBINATION_PRODUCT|s-tDCS and nutritional counseling|s-tDCS + Nutritional Counseling
224080474|NCT06530784|PROCEDURE|Cryoablation|After the completion of screening, the subjects received cryoablation treatment
224080475|NCT06530784|DRUG|PD-1 antibody and bevacizumab|Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
223716476|NCT00003105|DRUG|gemcitabine hydrochloride|
223716477|NCT00003105|DRUG|ifosfamide|
223716478|NCT00003105|DRUG|paclitaxel|
223716479|NCT04075760|PROCEDURE|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
223716480|NCT04075760|DRUG|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \> 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
223716481|NCT01297660|OTHER|Video-urodynamic examination|
223716482|NCT00826943|DRUG|Cetirizine|Cetirizine 10 mg tab daily x 7 days
223716483|NCT00826943|DRUG|Levocetirizine|5 mg tab daily x 7 days
224080476|NCT05112887|OTHER|Osteopathic Manipulative Therapy|Osteopathic Manipulative Therapy is a type of hands-on manipulative medicine where the physician uses their hands and knowledge of anatomy to encourage the human body to reattain homeostasis.
224278199|NCT04760587|BEHAVIORAL|smart devices in adolescent weight control|The study will apply mobile phone applications and smart watches to understand the relationship between weight control behaviors and weight control health outcome in adolescent.
224278200|NCT00319787|DRUG|Iressa|
224278201|NCT04619199|DIAGNOSTIC_TEST|Blood sample|Blood sample performed at the inclusion and during the follow-up.
224278202|NCT04231409|DEVICE|Boston Scientific Spectra WaveWriter SCS System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
224278203|NCT05251506|DEVICE|laser lancing device or lancet for blood glucose level measurement|Subjects measure blood glucose level using laser lancing device (LMT-1000) and lancet for 2 months each.
224278204|NCT01474915|DRUG|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
223716484|NCT00826943|DRUG|Placebo|Placebo tablet daily x 7 days
223916461|NCT06597981|BEHAVIORAL|Dyadic empowerment-based sport stacking|For the intervention group, the care dyads will receive an 18-week dyadic empowerment-based sport stacking program, which is divided into two phases: the active phase (weeks 1-12) and the maintenance phase (weeks 13-18). In the active phase, the care dyads will engage in three online sessions in small groups (3-5 dyads/group) and three check-up/support sessions. Three online sessions will be scheduled at weeks 1, 3, and 9 during the 12-week active phase. They will also be required to engage in self-practice at home for at least 30 minutes per day, five times per week during this time according to their training schedule. In the maintenance phase, there will be three online sessions in small groups (3-5 dyads/group). Three online sessions will be scheduled at weeks 13, 16, and 18. The dyads will continue their self-practice at home (at least 30 minutes/day, five times/week) for 6 weeks.
223916462|NCT06597981|OTHER|Basic education|Participants in the control group will receive basic education on dementia caregiving, which will comprise three group-based (3-5 dyads/group) online meetings in the same schedule as the intervention group (1st, 3rd, 9th week).
224080477|NCT04304131|DIAGNOSTIC_TEST|Earlytect Colon Cancer|A diagnostic device measuring syndecan 2 methylation status in stool DNA to detect colorectal cancer
224278205|NCT01474915|DRUG|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
224278206|NCT01474915|DRUG|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
224278207|NCT01474915|DRUG|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
224278208|NCT02339415|DRUG|Edoxaban 30mg daily|
224278209|NCT02339415|DRUG|Matching placebo|
224278210|NCT01765751|PROCEDURE|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
224278211|NCT01665651|DRUG|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
224278212|NCT01665651|DRUG|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
224278213|NCT01665651|DRUG|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
223716485|NCT01348165|DRUG|BI 137882|Powder for oral solution
224080478|NCT02647151|DRUG|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
224278214|NCT01665651|DRUG|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
224278215|NCT05246787|BEHAVIORAL|breastfeeding|nonphamacological methods
223716486|NCT01348165|DRUG|Placebo|Powder for oral solution
223716487|NCT04191031|DEVICE|ioveraº|Cryoneurolysis
223716488|NCT04191031|DEVICE|ioveraº sham|ioveraº sham
223716489|NCT00074152|DRUG|chemotherapy|Given within 10 weeks after surgery.
223716490|NCT00074152|RADIATION|radiation therapy|Given within 6 months after surgery
223716491|NCT01696825|DRUG|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
223716492|NCT01696825|DRUG|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
223716493|NCT01696825|DRUG|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
223716494|NCT01595997|DRUG|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
223716495|NCT02416401|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
223916463|NCT05181748|BIOLOGICAL|Autologous platelet rich plasma|Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
223916464|NCT06597500|DRUG|GSK3923868|GSK3923868 will be administered.
223916465|NCT06597500|DRUG|Itraconazole|Itraconazole will be administered.
223916466|NCT05070741|BEHAVIORAL|Heat Therapy|Subjects will undergo 12 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 4 weeks. Subjects will be immersed up to the shoulder in a 40°C hot tub until rectal temperature (Tre) increases by 1°C (\~20 minutes). Subjects will then remain in the water bath submerged to waist level to maintain Tre between 38.5 and 39.0°C for another 30 minutes (approx. total time submerged \~50 minutes). Following hot water immersion, subjects will be monitored for another 10 min, or until Tre falls below 38.5°C. Core temperature will be monitored using either 1) a rectal probe with sterile disposable sheaths or 2) a sterile disposable rectal thermistor probe (401 A/C, Advanced Industrial Systems, Inc., Harrods Creek, KY) to be inserted \~1 inch past the anal sphincter (inserted by participant). Heart rate and blood pressure will be monitored throughout the treatment. Subjects will be continually monitored and removed from the hot bath if Tre exceeds 39.5°C.
223916467|NCT06842992|DRUG|NH102|5 mg twice daily over 6 weeks, followed by a 1-week tapering period.
223916468|NCT06842992|DRUG|NH102|10 mg twice daily over 6 weeks, followed by a 1-week tapering period.
223916469|NCT06842992|DRUG|NH102|15 mg twice daily over 6 weeks, followed by a 1-week tapering period.
223916470|NCT06842992|DRUG|Duloxetine Hydrochloride Enteric-coated Capsule|30 mg twice daily for 6 weeks, followed by a 1-week tapering period.
223916471|NCT06842992|DRUG|Placebo|Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.
223916472|NCT06843135|DEVICE|Ventricular pacing|Participants will undergo conductionsystem pacing and right ventricular pacing in a randomized sequence, each for six months. After each phase, patients will undergo a CMR scan and advanced ECG imaging
223916473|NCT06842069|BEHAVIORAL|Decision Aid Supported Education|Dialysis Education
224080479|NCT02647151|DRUG|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
224080480|NCT06101576|PROCEDURE|TUIP|Patient who underwent transurethral incision of the prostate (TUIP) using electrical current or laser beam.
224080481|NCT06101576|PROCEDURE|TURP|Patient who underwent transurethral resection of the prostate (TURP) using momopolar or bipolar current.
224080482|NCT06101576|PROCEDURE|Prostate Vaporization|Patient who underwent vaporization of the prostate using plasma or laser energy (GreenLight PVP and Thulium vaporization of the prostate).
224080483|NCT06101576|PROCEDURE|AEEP|Patient who underwent anatomical endoscopic enucleation of the prostate (AEEP) using Holmium, Thulium or GreenLight laser or bipolar current.
224080484|NCT05302323|OTHER|Disposable Drape|Disposable surgical drapes, consisting of 6 pieces, were used as a set during surgery
224080485|NCT05302323|OTHER|Reusable Drape|Reusable surgical drapes, consisting of 6 pieces, were used as a set during surgery
224080486|NCT02020044|OTHER|Endothelial Keratoplasty|
224080487|NCT00332956|BIOLOGICAL|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
224080488|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
224080489|NCT00332956|BIOLOGICAL|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
224080490|NCT00332956|BIOLOGICAL|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
224080491|NCT04749394|DRUG|Camrelizumab, PD-1 monoclonal antibody|Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
224080492|NCT04749394|DRUG|Apatinib, VEGFR2 antibody|Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
224080493|NCT02550028|DRUG|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
224080494|NCT02550028|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
224080495|NCT00135603|DRUG|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
224080496|NCT00135603|PROCEDURE|appendectomy|ablation of the appendix by laparotomy or laparoscopy
224080497|NCT00721487|DRUG|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
224080498|NCT05869006|BEHAVIORAL|Designed SIA Instrument Supported Interpersonal Relations-Based Group Practice|Group Practice
224278216|NCT05246787|COMBINATION_PRODUCT|Breastfeeding and Shotblocker|combined Breastfeeding and Shotblocker device
224278217|NCT05246787|DEVICE|shotblocker|it is a small plastic tool
224278218|NCT01263886|DRUG|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
224278219|NCT01263886|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
223916474|NCT06842069|BEHAVIORAL|Dialysis Education for Urgent Dialysis Start Patient|"Education provided in two consequtive educational session. During first 30-minute session, the aim of the training program was explained with an overview of CKD, sparing time for potential patient questions. The second training day was scheduled according to patients' agenda and their next hemodialysis session.~Second Interview: RRT options were explained in the 30-minute , followed by interactive discussion with patients, ensuring that patients understood the information. When the training was completed, a guidebook (Treatment Options in Kidney Failure-Conscious Choice, Conscious Start) was distributed to participants. The third interview date and time was scheduled with the patients in the DTSEP group."
223916475|NCT06841783|PROCEDURE|nerve block|ultrasound guided nerve block
223916476|NCT05786040|PROCEDURE|Biopsy|Undergo biopsy
223916477|NCT05786040|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223916478|NCT05786040|PROCEDURE|Computed Tomography|Undergo CT
223916479|NCT05786040|PROCEDURE|Positron Emission Tomography|Undergo PET
223916480|NCT05786040|BIOLOGICAL|Rituximab|Given IV or SC
223916481|NCT05786040|BIOLOGICAL|Tafasitamab|Given IV
223916482|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with polyphenol supplement (PPS)|Test meal with polyphenol supplement
223916483|NCT05326503|DIETARY_SUPPLEMENT|Meal matrix with placebo|Test meal with placebo (maltodextrin) supplement
223916484|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with PPS|Test drink with polyphenol supplement
223916485|NCT05326503|DIETARY_SUPPLEMENT|No meal matrix with placebo|Test drink with placebo (maltodextrin) supplement
223916486|NCT05657795|DEVICE|Closed-loop automated oxygen control (Oxygenie, SLE6000)|The OxyGenie closed-loop oxygen saturation monitoring software (SLE) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
223916487|NCT05443685|DRUG|ADX-629|"Particpants 10-50 years old will be administered ADX-629 250 mg tablets twice daily.~Participants 5-9 years old will be administered ADX-629 125 mg tablets twice daily."
223716496|NCT02416401|OTHER|Commercially available computerized training|
223916488|NCT05670782|DRUG|KM-819|Participants will receive oral doses of KM-819 once-daily
223916489|NCT05670782|DRUG|Placebo|Participants will receive matching placebo once-daily
223916490|NCT06824766|OTHER|Visual Analogue Scale|The pain intensity of the participants will be assessed using the Visual Analogue Scale, which is a simple, reliable and short-term method commonly used to measure pain intensity in the clinic. The participant is told that the most severe pain he/she experiences is 10 and if there is no pain, the pain intensity is 0. The participant will be asked to tick a number between 0 and 10 corresponding to the intensity of pain felt in the masticatory muscles at rest and during chewing.
223916491|NCT06824766|OTHER|Autonomic nervous system activity assessment|All participants included in the study will undergo a 5-minute test with the Polar H10 chest strap device for autonomic nervous system activity assessment (heart rate variability assessment). The data obtained after the measurement will be analysed with Kubios software. Stress index (cardiovascular system stress), PNS index (parasympathetic nervous system dominance), SNS index (sympathetic nervous system dominance), LF power (sympathetic activity), HF power (parasympathetic activity) and LF/HF ratio (sympathetic/parasympathetic balance) parameters will be used in the evaluation of HRV in Kubios programme.
223916492|NCT06824766|OTHER|Masticatory muscles assessment|The Myoton PRO device will be used to objectively assess the biomechanical properties of the participants' masticatory muscles such as tone, stiffness and elasticity. The masseter and temporalis muscles will be evaluated bilaterally in the sitting position. Three measurements will be recorded at one second intervals and the average value will be used for analysis.
223916493|NCT06824753|OTHER|oxygenator and tubing set blood transfusion|blood from the oxygenator and tubing set was collected into a 1000 cc Ringer lactate bag, originally used as the pump's priming solution, under sterile conditions using a roller pump
223916494|NCT06819033|DEVICE|PBM Therapy|patients will receive PBM therapy using the Biolase Epic pro laser. An average power of 0.6w (peak power = 80w, rep. rate= 20Hz). Each aphthous ulcer will be irradiated one time for a total of 30 seconds via continuous wave.
223916495|NCT06819033|DRUG|Maalox plus Benadryl|1:1 mixture of Maalox and Benadryl will be applied to the ulcer as needed for pain. Applications typically will be applied before eating to form a dissolvable oral band-aid that lasts for up to 30 minutes. 10 milliliters of 1:1 Maalox: Benadryl solution will be provided to the family. During the presenting appointment, the patient/family will be shown how to use the 1:1 Maalox: Benadryl solution. It will be applied topically with no rinsing needed.
223916496|NCT06825689|DEVICE|Self-sampling with urine|Urine is self-collected at home using a urine sample cup.
224080499|NCT05869006|BEHAVIORAL|Placebo group practice|The placebo control group application was carried out simultaneously with the intervention group application, and the group application without active curative content was applied.
224080500|NCT03562663|DEVICE|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
224080501|NCT03562663|DEVICE|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
224080502|NCT03926676|OTHER|grandio blocks|nano hybrid composite blocks
224080503|NCT03926676|OTHER|emax|ceramic blocks
224080504|NCT05035680|BIOLOGICAL|Unadjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection
224080505|NCT05035680|BIOLOGICAL|SWE adjuvant mixed with unadjuvanted seasonal influenza vaccine shortly before dosing (SWE + QIV)|Single 0.8 mL IM injection
223716497|NCT01063868|DRUG|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
223716498|NCT01063868|DRUG|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
224080506|NCT05035680|BIOLOGICAL|MF59 adjuvanted seasonal influenza vaccine|Single 0.5 mL IM injection of MF59 adjuvanted seasonal influenza vaccine
224080507|NCT05870904|OTHER|Dry Needling|"Dry Needling includes the insertion of a fine, strong filiform needle without presentation of any pain relieving medicine.~Ischemic pressure is usually applied to trigger point, in what is known as trigger point therapy, where enough continuous pressure is applied to a trigger point within a tolerable measure of pain, and as discomfort is decreased, extra pressure is gradually applied"
224080508|NCT03658226|BEHAVIORAL|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
224080509|NCT01831128|DEVICE|ASV Treatment|
224080510|NCT02224235|DRUG|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
223716499|NCT05492344|OTHER|Personalized ventilation|"Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings:~* Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O)~* Tidal volume: 6 to 8 mL/kg predicted body weight (PBW)~* Daily prone positioning~LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol.~Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings:~* PEEP ≥ 15 cm H2O~* Tidal volume: 4 to 6 mL/kg PBW~* Daily recruitment maneuver"
223716500|NCT05492344|OTHER|Standard care|"Patient who are randomized in the control group will receive standard care~* Tidal volume: 6 mL/kg PBW~* PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study~* Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg"
223716501|NCT07008664|OTHER|Epigenetic Signature Assay|Up to 15 ml of blood will be collected from each patient at various time points throughout their 5 years of participation. DNA extraction, bisulfite conversion and analysis of epigenetic markers through PCR or next-generation sequencing will be performed. An epigenetic signature assay will then be identified.
224080511|NCT02224235|DEVICE|Resolute Integrity DES|Resolute Integrity DES
223916497|NCT06825689|DEVICE|Self-sampling with swab|A vaginal cell sample is self-collected at home using a swab and collection tube.
223916498|NCT06825689|DEVICE|In-clinic Pap/HPV co-testing|Cervico-vaginal cell samples are collected by a clinician during a Pap smear/HPV co-test appointment.
224080512|NCT02224235|DEVICE|COBRA PzF|
224080513|NCT02224235|DRUG|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
224080514|NCT01002092|DRUG|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
224080515|NCT01002092|DRUG|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
223719513|NCT06831175|DRUG|Apatinib|Apatinib was administered 250 mg PO QD.
223916499|NCT06818526|DEVICE|Huandao Conditioning Application|"Mobile Application Intervention: Huandao Conditioning App for Allergic Rhinitis Treatment~Type: Software Application (Mobile App) Purpose: Energy balancing therapy based on traditional Chinese medicine meridian theory Application Method: Self-administered via smartphone Duration: 5-10 minutes per session"
223916500|NCT06818526|DEVICE|Placebo Huandao Conditioning App|"Mobile Application Intervention: Placebo Huandao Conditioning App for Allergic Rhinitis Treatment~Type: Software Application (Mobile App) Purpose: Energy balancing therapy based on traditional Chinese medicine meridian theory Application Method: Self-administered via smartphone Duration: 5-10 minutes per session"
223916501|NCT06826235|OTHER|3 dates at the breakfast meal in the diet program|Participants in the intervention group will consume 3 dates at the breakfast meal in the diet program.
224080516|NCT05042427|OTHER|Pregnancy Weight Management Health Literacy Questionnaire|Give questionnaires to check the weight management health literacy level of primigravida women.
223719514|NCT06831175|DRUG|mitotane|Mitotane is administered orally and plasma concentration was measured. The target steady-state plasma concentration is 14-20 mg/L.
223916502|NCT06264232|DEVICE|Cataract Surgery|Bilateral removal of age related cataractous lenses with the implantation of intraocular lenses to improve visual acuity.
223916503|NCT06173349|DRUG|PLZ4-coated paclitaxel loaded micelles (PPM)|Given PLZ4-coated paclitaxel loaded micelles intravesically
223916504|NCT05195034|DRUG|Dexmedetomidine|The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with continuous infusion at a rate of 0.2 µg/kg/hour until the end of dural closure.
223916505|NCT05195034|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
223916506|NCT03995979|OTHER|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
223916507|NCT06147232|DRUG|Sotagliflozin|Sodium-glucose-co-transporter 1 and 2 inhibitor
223916508|NCT06147232|DRUG|Placebo|Placebo tablet
224080517|NCT05886062|OTHER|Motor Imagery to Facilitate Sensorimotor Re-Learning Training|In order to motor imagery to facilitate sensorimotor re-learning training will be given for 20 minutes a day, 3 days a week, for a total of 8 weeks. Basketball-specific movement patterns will be used (squat, single leg jump, side stepping, standing on one leg, squat on one leg, etc.). Exercises will be started from easy and progressed to more advanced levels. During the exercise, the person will not only be physically active, but will be asked to dynamically visualize the determined scenario. Thus, a holistic exercise program will be applied both physically and psychologically.
224080518|NCT05886062|OTHER|Control Group|They will only continue their routine basketball technical-tactical training.
224080519|NCT02012556|DRUG|Tesamorelin|
224080520|NCT04512833|RADIATION|Cyberknife stereotactic body radiation therapy|A total dose of 45-54 Gy in 5-10 fractions was given according to the location of lesions for small HCC patients with decompensated cirrhosis.
224278220|NCT03577886|DRUG|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
224278221|NCT03577886|DRUG|Placebo|Phosphate Buffer Diluent oral solution
223916509|NCT04823689|PROCEDURE|reductions|"Two reduction techniques are compared: dorsal decubitus and ventral decubitus reduction. The dorsal decubitus reduction consists in placing the patient in the dorsal position and achieving reduction by traction maneuvers on the luxated upper limb. This maneuver generally requires procedural sedation. A mild traction of the traumatized limb in the axis is performed, with slight external rotation and progressive abduction. In the absence of reduction at this stage, this gesture is completed by a flexion adduction of the limb. A counterweight is then made by a rolled sheet and passed under the armpit of the patient.~The ventral decubitus reduction consists in placing the patient in the ventral position. The luxated limb is positioned in pendulum and the line of contact with the stretcher must pass through the mid-clavicular line. The humeral head is brought to the scapula."
223916510|NCT02768844|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
223916511|NCT02768844|OTHER|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
223916512|NCT04170374|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
223916513|NCT04170374|OTHER|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
223916514|NCT06144411|OTHER|prevalence of preoperative malnutrition|prevalence of preoperative malnutrition
223916515|NCT06594783|OTHER|Carvedilol plus endoscopic variceal ligation|Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
223916516|NCT06594783|DRUG|Carvedilol alone|Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
223916517|NCT06667960|DRUG|JK06|Biparatopic anti-5T4 antibody
223916518|NCT06610955|OTHER|High intensity interval training|After a 10 minutes warm up exercise, participants will exercise with a bicycle ergometry device at 80% of their maximum heart rate for 4 minutes, and the active recovery period will be 3 minutes (4x4 minutes). During the recovery period, the participant will exercise with the Ergoline bicycle ergometry system for 4 sets at 60% of their maximum heart rate for 3 minutes. A total of 45 minutes exercise session will be completed with a 10 minutes cool down exercise. Exercise will be done 5 days a week for a total of 8 weeks. In the first 4 weeks, exercise will be done at 80% intensity, and in the following weeks, the exercise intensity will be increased by 5% each week, respectively, to 85%, 90%, 95%, and 100% in the last week.
223916519|NCT06610955|OTHER|Moderate intensity continuous training|Following a 10 minutes warm up exercise, participants will exercise continuously for 30 minutes at 65% of their maximum heart rate with the Ergoline bicycle ergometry system. A 5 minutes cool down exercise will end the 45 minutes exercise session. The exercise duration is 5 days a week for a total of 8 weeks.
223916520|NCT06610903|DRUG|Hemay005|In the first cycle, 15mg (1 tablet/person) was given on an empty stomach for Hemay005-T1 or Hemay005-T2, and the second cycle was crossed over
223916521|NCT06667232|OTHER|Single-pulse stimulation|Investigators use single-pulse electrical stimulations at 1Hz to elicit cortico-cortical evoked potentials
223916522|NCT06667232|OTHER|Paired-pulse stimulation|The repetitive delivery of pairs of stimulation pulses is DES patten with a 5-50 ms interval between each pulse, constitutes repetitive paired-pulse stimulation.
223916523|NCT06667232|OTHER|Stepwise frequency stimulation|Stepwise incremental stimulation ranging from 5 Hz to 145 Hz following a cyclic pattern.
223916524|NCT06667232|OTHER|Burst stimulation|Burst stimulation pattern consisting of short bursts delivered once a second and an intraburst frequency of 50 Hz, 100 Hz, 150 Hz, 175 Hz and 200 Hz
223916525|NCT06668597|BEHAVIORAL|Motivational educational program to improve sleep quality in OSA patients through adherence to CPAP|Phase 1 (Pre-adaptation Psychoeducation): The participant will be shown, within two days prior to the home visit by the provider, which usually takes place within three days of the visit with the pulmonologist, the necessary materials (device, masks, and tubing), along with an educational video on the topic of OSA (duration 25 minutes); Phase 2 (Motivational Interview): Following the first night of titration and use of the CPAP, the participant will be contacted by phone for a brief motivational interview (duration 25 minutes); Phase 3 (Psychological Support Interview): One week after the provider's intervention and the start of the CPAP adaptation period, the participant will be contacted again for a support interview regarding the adaptation process to CPAP (duration 40 minutes). The first week of adaptation is considered a high-risk period for abandonment of device use; Phase 4 (Monitoring Interview): Two weeks after the provider's intervention and the start o
223916526|NCT06609486|DEVICE|Blood pressure measurement group|"In this study, the protocol applied to automatic electronic blood pressure system module BN1 for performance evaluation is ISO's proposed ISO 81060-2:2018 Non-invasive sphygmomanometers- Part2: Clinical investment of internal automatic measurement type. The initial BP measurement is performed alternately, measuring the blood pressure by the measurer and the test device once each, and measuring blood pressure by the measurer four times by the observer and three times by the test device."
223916527|NCT06609083|DRUG|THC 30mg|High dose of THC (30 mg)
223916528|NCT06609083|DRUG|THC 5mg|Low dose of THC (5 mg)
223916529|NCT06609083|DRUG|THC 0mg|Placebo dose of THC (0 mg)
223916530|NCT06609083|DRUG|Cigarette Full Nicotine|Full nicotine cigarette
223916531|NCT06609083|DRUG|Cigarette Reduced Nicotine|Reduced nicotine cigarette
223916532|NCT05825989|BEHAVIORAL|Healthy Beat Acupunch Regimen|The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
223916533|NCT06858631|BEHAVIORAL|Physical Aerobic Exercise|30-minute net aerobic exercise sessions at moderate intensity (3-5 METS, 60%-70% of maximum heart rate) three times per week. Walking, cycling, or swimming, with the option to alternate activities to enhance adherence to the program. Each session will include 10 minutes of warm-up (gradual increase in intensity); 30 minutes of aerobic exercise and 10 minutes of cool-down (gradual reduction of intensity and optional stretching). Total weekly exercise duration will be 150 minutes
223716502|NCT07011329|RADIATION|Changes in the brain MTP parameters after radiotherapy|Our study explores the changes in brain MTP parameters and their correlation with clinical cognitive scores before and after chemotherapy and/or radiotherapy in patients with NPC. We investigates MRI-derived multiparametric imaging biomarkers (MTP) as predictive biomarkers for chemotherapy/radiotherapy-induced cognitive decline in nasopharyngeal carcinoma, aiming to optimize neurotoxicity risk stratification and guide personalized neuroprotective interventions in precision oncology.
224080521|NCT04157387|OTHER|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
224080522|NCT04157387|OTHER|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
223916534|NCT06661369|OTHER|Sensory Perceptual Motor Training on Group|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
223916535|NCT06661369|OTHER|Sensory Perceptual Motor Training on Individual|"1. Sensory Input~   * Wheelbarrow walks, swimming, and drying off.~2. Proprioceptive~   * Climbing, pushing, pulling, and carrying heavy objects.~3. Vestibular~   * Swinging, trampolining, and playground games.~4. Tactile~   * Stereognosis training, textured paths, and messy play (mud, sand).~5. Motor Planning~   * Statue spinning, crawling through/under objects, and quick movements.~6. Balance and Posture~   * Various balance positions (e.g., hands and knees).~7. Ocular Control~   * Catching and tossing balls.~8. Bilateral Coordination~   * Activities using both sides of the body (e.g., stick ball).~9. Visual-Spatial~   * Walking, stair climbing, and puzzles.~10. Fine Motor Skills~    * Puzzles, bead stringing, and drawing.~11. Gross Motor~    * Standing, walking, running, and throwing games."
223916536|NCT06858930|PROCEDURE|ACL footprint localization after preoperative navigation executed by robotic arm|Anterior cruciate ligament (ACL) reconstruction is performed using the preoperative navigation of Naton Robotics, followed by random assignment to either robotic surgery or traditional manual surgery. The difference between the two lies in whether the localization of the ACL footprint is performed by a human or by the robotic arm. The surgical technique is standardized as double-bundle reconstruction.
223916537|NCT06858930|PROCEDURE|ACL footprint localization after preoperative navigation executed by rmanual execution|Anterior cruciate ligament (ACL) reconstruction is performed using the preoperative navigation of Naton Robotics, followed by random assignment to either robotic surgery or traditional manual surgery. The difference between the two lies in whether the localization of the ACL footprint is performed by a human or by the robotic arm. The surgical technique is standardized as double-bundle reconstruction.
224080523|NCT03037281|DIAGNOSTIC_TEST|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
224080524|NCT02118376|DRUG|Exenatide|5ug bid,Subcutaneous injection
224080525|NCT01864785|PROCEDURE|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
224080526|NCT01864785|PROCEDURE|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
224080527|NCT02393391|DEVICE|Neuroelectrics STARSTIM|
224080528|NCT02847754|OTHER|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
224080529|NCT00688909|DRUG|letrozole|2.5 mg daily by mouth for 6 months
224080530|NCT02008825|DEVICE|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
224080531|NCT02008825|DEVICE|Usual non suction Bougie|Usual non suction Bougie
224080532|NCT01220414|DRUG|Naltrexone, then placebo|50 mg of naltrexone
223716503|NCT06759389|DEVICE|Resuscitation (Ventor)|Resuscitation with the Ventor device
224080533|NCT01220414|DRUG|Placebo, then Naltrexone|sugar pill
224080534|NCT03190187|OTHER|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
223716504|NCT07010796|DEVICE|Alma Prime X|Alma Prime x is a platform that provides applicators for radiofrequency and ultrasound.
224080535|NCT03190187|OTHER|Sham manipulation|Patients will receive simulated spinal manipulation without force application
224080536|NCT01340521|DRUG|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
224080537|NCT00578123|BEHAVIORAL|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
224080538|NCT02988102|OTHER|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
224080539|NCT00445887|OTHER|Laboratory Biomarker Analysis|Correlative studies
224080540|NCT00445887|DRUG|Levonorgestrel|Given orally
224080541|NCT00445887|OTHER|Placebo|Given orally
224080542|NCT01860560|DEVICE|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
224080543|NCT01860560|DEVICE|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
224080544|NCT05756725|OTHER|Practice-Level Implementation Strategies|The intervention is implementation of new population health management tools that may better leverage patient navigation and other staff resources to ensure timely abnormal follow up of breast and colorectal cancer screening. The research team will work with CHCs to select implementation strategies that will best facilitate integration of the new tools into practice. The team will use electronic health record data (analyzed at the population level) to determine the impact of the new tools on screening outcomes and qualitative data from up to 3 staff and 2 patients per CHC to evaluate integration of the tools into practice.
224080545|NCT00003632|BIOLOGICAL|filgrastim|
224080546|NCT00003632|DRUG|carmustine|
224080547|NCT00003632|DRUG|cytarabine|
224080548|NCT00003632|DRUG|etoposide|
223916538|NCT06856408|BEHAVIORAL|FinnPog|The aim of the study is to find out how intervention affects the early childhood educators' self-efficacy teamwork and the changes in children's behavioral challenges. This RCT study has two parallel groups where teams of the daycare centres are randomized to intervention or control group. The research data is collected using electronic surveys and interviews.
223916539|NCT06859450|DRUG|Levofloxacin|Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.
223716505|NCT07012603|OTHER|External oblique and rectus abdominis plane (EXORA) block|Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20 mL of bupivacaine 0.25%.
223716506|NCT07012603|OTHER|Sham block|Patients will receive a sham block using 20 mL of normal saline as a control group.
223716507|NCT07016204|BEHAVIORAL|Cognitive-Behavioral Therapy|A structured 12-week psychotherapy protocol targeting maladaptive appearance-related beliefs and behaviors in individuals with Body Dysmorphic Disorder (BDD). The intervention involves individual sessions once per week (60 minutes) and incorporates techniques such as psychoeducation, cognitive restructuring, exposure and response prevention (ERP), mindfulness, and attentional retraining.
223716508|NCT07014501|OTHER|High altitude|Altitude above 3500 meters.
223916540|NCT06859450|DRUG|Placebo|Add-on treatment of inhaled Levofloxacin 240mg twice daily or placebo (saline) twice daily for up to 3 days while admitted.
223916541|NCT06859905|OTHER|blood flow restriction training|"Position of the patient The vascular occlusion pressure required for the full blockage of upper extremity blood flow will be measured at rest, with the individual relaxed in a sitting position(Sieljacks et al., 2018).~Position of the of the cuff during BFRT~Placing a 5 to 6 cm wide cuff on the more proximal part of the affected upper limb, it should be around the bulk of biceps muscle above the cubital fossa .~BFRT Cuff Pressure The upper arm external pressure of the cuff (100-130 mmHg) will be selected concerning the subject's resting blood pressure as described previously by Yasuda et al. 2008 (Yasuda et al., 2008).~BFRT exercises prescription~1. Exercise frequency and duration~   -The study group (BFRT G) will be subjected to supervised exercises with low-load blood flow restriction training LIBFR (three days per week for 8 weeks),~2. Exercise intensity -Low load blood flow restriction training LIBFR (20%-40% of 10 repetition maximum (10 RM) BFR training for the study group,"
223916542|NCT06859905|OTHER|regular exercises|"the routine rehabilitation will be applied 3 times per week for 8 weeks, including the following training~1. Appropriate neurodevelopmental techniques as needed by each patient~2. Progressive resistance exercise for muscles in the affected upper extremity using sandbags, free weights, or elastic resistance bands according to each patient's abilities~3. prolonged stretching using splints if needed~4. Functional electrical stimulation (FES)"
223916543|NCT06855953|DIETARY_SUPPLEMENT|Vitamin K|Participants receive 0.5 mg/day phylloquinone orally for 12 weeks
223916544|NCT06855953|DIETARY_SUPPLEMENT|Placebo|Participants receive daily placebo for 12 weeks
223716509|NCT07014501|OTHER|Medium altitude|Altitude between 3500 meters and 1500 meters.
223916545|NCT06856486|DIETARY_SUPPLEMENT|Sulforaphan Smart®|Fasting volunteers will intake the Sulforaphan Smart® pill, and blood and urine samples will be taken at the beginning of the intervention (Time 0 hours, before intake the pill), and 6 and 24 hours after its intake the pills (Time 6 hours and Time 24 hours) to measure the biomarkers related to the bioavailability of GSL/ITCs.
223916546|NCT06856655|DEVICE|Scorpion Portal Vein Access Kit|Procedure/Surgery: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
223916547|NCT06860152|DEVICE|Cochlear implant|Cochlear implant
223916548|NCT06857552|OTHER|Visual biofeedback using transperineal ultrasound (TPUS)|The intervention (study) arm will recieve coached maternal pushing via transperineal ultrasound (US) with visual biofeedback
224080549|NCT00003632|DRUG|melphalan|
224080550|NCT00003632|DRUG|methotrexate|
224080551|NCT00003632|PROCEDURE|peripheral blood stem cell transplantation|
224080552|NCT00700180|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
224080553|NCT00700180|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
224080554|NCT00700180|DRUG|Carboplatin-based chemotherapy|As prescribed
224080555|NCT02977104|OTHER|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
224080556|NCT06265844|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224080557|NCT06265844|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223716510|NCT07014501|OTHER|Low altitude group|Altitude below 1500 meters.
224080558|NCT06265844|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223916549|NCT06859190|DRUG|estazolam 1-2 mg|oral estazolam 1-2 mg daily at bedtime for 8 weeks.
223916550|NCT06859190|PROCEDURE|Auricular pressure bean combined with electroacupuncture|Electroacupuncture treatment will be performed on seven acupoints, including Baihui (GV20), Shenting (GV24), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), and Sanyinjiao (SP6). Each session lasts for 30 minutes and is conducted twice a week.In addition, auricular point seed-pressing therapy will be applied to bilateral auricular points related to insomnia (Shenmen, Heart, and Sympathetic). Each auricular point will be pressed for 1 minute, three times a day. The total treatment course is eight weeks.
223916551|NCT06858293|BEHAVIORAL|Mental Imagery Open Chain|Participants will receive a paper packet with instructions to imagine themselves performing seated maximal leg extension exercises. They will be instructed to imagine the feeling of the exercise for 5 seconds, rest for 5 seconds, and repeat this 50 times with a 2-minute rest period after the 25th repetition. They will also be asked to keep track of the exercises with tallies on a table within the packet and also to record on this table if they did not complete the exercises for that day. The participant is asked to perform the exercises on five consecutive days.
224080559|NCT05025566|DIAGNOSTIC_TEST|Cognitive (behavioural and neurophysiological) screening|"Cognitive disorders are attested at the behavioral level by the psychologist specialized in neuropsychology who makes the patient take a standardized battery of specific psychometric tests. This assessment thus makes it possible to obtain behavioral data such as reaction time, error rates and modeling parameters.~The electroencephalogram (EEG) consists of collecting the signal of the brain's bioelectrical activity by means of electrodes placed on the scalp. The EEG is used to determine the cerebral functioning underlying cognitive functions by performing it simultaneously with the behavioral tasks of the neuropsychological assessment, thus obtaining a neurophysiological phenotyping of cognitive disorders."
224080560|NCT03934788|DEVICE|oxysoft (olifilcon C)|subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.
224080561|NCT03934788|DEVICE|Si-Hy (olifilcon B)|subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
224080562|NCT02408692|DRUG|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of \<25 kg/m2 will have completed study participation.
224080563|NCT02408692|DRUG|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
224080564|NCT06154967|RADIATION|tereotactic body radiotherapy|In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used
224080565|NCT03569202|DEVICE|Piiloset Trehalose Emulsion Eye Drops|Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
224080566|NCT03569202|DEVICE|Control Eye Drops|Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
224080567|NCT02439580|DIETARY_SUPPLEMENT|Annona muricata extract|ethanol-soluble fraction of water extract
224080568|NCT02439580|DIETARY_SUPPLEMENT|Placebo|maltose
224080569|NCT00337233|PROCEDURE|yoga therapy|10 week yoga class
224080570|NCT02684721|OTHER|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
224080571|NCT00727363|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
224080572|NCT00727363|DIETARY_SUPPLEMENT|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
223530178|NCT03949023|PROCEDURE|Standard of Care Cerebral Angiogram Group|"Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration)."
223530179|NCT06775860|DRUG|ICP-332 Tablets|ICP-332 will be administered as tablet
223530180|NCT06775860|DRUG|ICP-332 Placebo Tablets|ICP-332 Placebo will be administered as tablet
223716511|NCT07014410|DRUG|pyrotinib dalpiciclib letrozole|ER positive HER2 positive advanced breast cancer patients are given pyrotinib+dalpiciclib+letrozole
223716512|NCT07015372|BEHAVIORAL|Laughter Yoga|Laughter yoga intervention including clapping, breathing, childlike play, and laughter exercises, delivered in 8 sessions over 4 weeks to reduce stress and burnout and improve general health among psychiatric nurses.
223716513|NCT07014930|DRUG|Control session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling.
223716514|NCT07014930|DRUG|Inhibition session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 50 mg of fluvoxamine for 7 consecutive days (CYP2C19 inhibitor).
223716515|NCT07014930|DRUG|Induction session|Plasma and urine sampling as well as the determination of the blood OH-omeprazole/omeprazole ratio at baseline by capillary blood sampling, with prior administration of 600 mg of rifampicin for 10 consecutive days (CYP2C19 inducer).
223716516|NCT07016568|DEVICE|Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)|The AAJT-S is a non-invasive, externally applied medical device designed to achieve temporary occlusion of the abdominal aorta and inferior vena cava by inflating a pneumatic bladder to 250 mmHg. In this study, the device will be used as a temporizing measure for patients with severe postpartum hemorrhage unresponsive to standard uterotonics and balloon tamponade. The device will be applied horizontally over the upper abdomen and inflated using a built-in pressure gauge. The intended effect is to reduce pelvic blood flow and allow time for mobilization of surgical resources and blood transfusion. Maximum application time will not exceed 60 minutes, in accordance with established safety guidelines.
223716517|NCT07014423|PROCEDURE|The Pulsed Field Ablation to Isolate the Pulmonary Vein with the utilization of FARAVIEW mapping software.|Pulmonary Vein Isolation with the additional use of the FARAVIEW mapping system (The additional mapping approach)
223716518|NCT07014423|PROCEDURE|The Pulsed Field Ablation to Isolate the Pulmonary Vein without the utilization of FARAVIEW mapping software.|Pulmonary Vein Isolation without the use of the FARAVIEW mapping system.
223916552|NCT06858293|BEHAVIORAL|Mental Imagery Closed Chain|Participants will receive a paper packet with instructions to imagine themselves performing maximal standing squat exercises. They will be instructed to imagine the feeling of the exercise for 5 seconds, rest for 5 seconds, and repeat this 50 times with a 2-minute rest period after the 25th repetition. They will also be asked to keep track of the exercises with tallies on a table within the packet and also to record on this table if they did not complete the exercises for that day. The participant is asked to perform the exercises on five consecutive days.
223916553|NCT06858605|OTHER|Kaltenborn-Evjenth Orthopedic Manual Therapy (KEOMT)|Kaltenborn's biomechanical approach to diagnosis and treatment emphasizes ergonomic principles and trial-based techniques. His mobilization methods, classified into Grades I-III, target pain relief (Grades I-II) and joint hypomobility (Grade III) by enhancing glide and tissue elasticity. The Kaltenborn-Evjenth Orthopedic Manual Therapy (KEOMT) further refines this approach using arthrokinematic principles to restore physiological joint motion based on the concave-convex rule.
223916554|NCT03582033|DRUG|SEA-BCMA|Given into the vein (IV; intravenously)
223916555|NCT03582033|DRUG|dexamethasone|Given by mouth (orally) or by IV
223916556|NCT03582033|DRUG|pomalidomide|Given orally
223916557|NCT06353529|DRUG|Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution|2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
223916558|NCT06353529|DRUG|Placebo|2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
223916559|NCT06353529|DRUG|Sham Comparator|Participants receive no additional study injections
223916560|NCT04631016|DRUG|Tozorakimab|Participants will receive SC injection of tozorakimab as stated in arm description.
223916561|NCT04631016|OTHER|Placebo|Participants will receive SC injection of placebo as stated in arm description.
223916562|NCT06669806|DEVICE|TIPS Stent Graft|a covered TIPS stent graft
223916563|NCT06668935|DEVICE|To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists|All subjects will then begin use of their prescribed GLP-1 or combination GIP/GLP-1 medication in accordance with the HCP's instructions. Subjects will be titrated to their maximum tolerable dose per the medication's approved titration schedule and according to their HCP's standard of care between Visits 2 and 3.
223916564|NCT06670963|DRUG|Iron|Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
223916565|NCT06670963|DRUG|EPO|Epoetin alfa 50 units/kg IV 3 times weekly
223916566|NCT06670963|DRUG|0.9 % NaCl|Volume of 0.9% NaCl identical as volume of medications used in experimental arm
223916567|NCT06669234|DRUG|ALN-F1202|Administered per the protocol
223916568|NCT06669234|DRUG|Matching Placebo|Administered per the protocol
223916569|NCT06669416|BEHAVIORAL|Taste Alteration Self-Assessment|The nurse-led intervention involves using a valid/reliable TA assessment tool (Chemotherapy-induced Taste Alterations Scale (CiTAS) and teaching the patient to select assessment-driven interventions to manage TA symptoms.
223916570|NCT06669416|BEHAVIORAL|Taste Alternation Self-Management|The nurse-led intervention involves teaching the patient to use the assessments and the evidence-based Patient Education Sheet to select assessment-driven interventions to manage their symptoms. Data will be collected about the specific actions prescribed in the teaching tool and to identify which interventions were used and their overall impact.
223916571|NCT06669663|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Participants will receive Pimonidazole (non-CTIMP) prior to their surgery for OG cancer and then undergo intra-operative sampling.
223916572|NCT06248515|DRUG|Sacituzumab govitecan-hziy|10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles
223916573|NCT05512039|DRUG|Botox 50 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
224080573|NCT00890838|DIETARY_SUPPLEMENT|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
223916574|NCT05512039|DRUG|Botox 100 Unit Injection|Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
223916575|NCT03812614|BEHAVIORAL|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
223916576|NCT03812614|BEHAVIORAL|I-DSMES|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSME sessions, case management contacts with CHW throughout the duration of the 6-month intervention, and guidance on how to prepare for and participate in healthcare appointments.
223916577|NCT02695940|DRUG|LEO 124249 ointment 30 mg/g|
223916578|NCT02695940|OTHER|LEO 124249 ointment vehicle|
223916579|NCT04628585|OTHER|Safety and efficacy assessments|Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
223916580|NCT06310005|DRUG|BI 3006337|BI 3006337
223916581|NCT06310005|DRUG|Placebo|Placebo
223916582|NCT05890131|OTHER|Digital letter|A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
223916583|NCT06207708|OTHER|questionnaires QLQ-FA12, Mini Nutritional Assessment Short Form, Nutritional Risk Screening, diet questionnaire of frequency, ,body mass index measurement|the patient is administered with questionnaires focused on diet, fatigue, nutrition screening and on body mass index at the beginning and at the end pf particle therapy radiation treatment
223916584|NCT06207708|DIAGNOSTIC_TEST|blood biomarkers|as per clinical routine, hemoglobin, lymphocytes, albumin and NLR will be collected
223916585|NCT05205161|DRUG|AZD0466|All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
223916586|NCT05453929|DRUG|Rocuronium for deep NMB|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
223916587|NCT05453929|DRUG|Rocuronium for moderate NMB|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
223916588|NCT05419050|DRUG|denosumab|monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis
223916589|NCT06746311|DRUG|HT-101|Single dose of HT-101 administered subcutaneously.
223916590|NCT06746311|DRUG|HT-101|Multiple dose of HT-101 administered subcutaneously.
223916591|NCT06746311|DRUG|Placebo|Placebo, containing no active ingredient, administered subcutaneouly
223916592|NCT06454227|PROCEDURE|Subcutaneous washing|subcutaneous washing with chlorhexidine gluconate prior to skin closure
223916593|NCT06454227|PROCEDURE|no subcutaneous washing|no washing
223916594|NCT06612723|OTHER|high-intensity gait training|Individuals will perform up to 40 minutes of walking practice during 60 minute sessions while targeting heart rates of at least 70% heart rate reserve.
223916595|NCT06612723|BEHAVIORAL|Physical activity coaching|Individuals will receive feedback on the minutes of walking activity performed on non-training days and provided coaching strategies to increase this metric.
223916596|NCT04681638|DRUG|Pathogen-Reduced Plasma|The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
223916597|NCT04681638|DRUG|Crystalloid Solutions|The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
223916598|NCT06288386|DEVICE|GrandioSO Heavy Flow|Attachment will be performed with GrandioSO Heavy Flow.
224278222|NCT01085448|OTHER|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
223916599|NCT06288386|DEVICE|Filtek Z350XT Flowable|Attachment will be performed with Filtek Z350XT Flowable.
223916600|NCT06177613|PROCEDURE|Blank culture transfer|A maximum of 0.1 ml of gassed embryo culture medium preheated to 37°C is injected into the uterine cavity transcervically using an embryo transfer catheter placed just beyond the internal os, two to 3 days before transfer of the thawed embryo
223716519|NCT07014449|DRUG|WBC100 QD|WBC100 will be administered orally as capsules once daily in 28-day cycles. The dose-escalation phase follows an accelerated titration combined with the traditional '3+3' design.
223916601|NCT06177613|PROCEDURE|Sham transfer|An intermediate transfer step is added two or three days before the planned transfer of the frozen embryo but with an empty catheter.
223916602|NCT01420770|DRUG|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
223916603|NCT06612346|DEVICE|Minimally Invasive Micro Trabeculostomy|The MINT system is a surgical device designed to create a trabeculostomy within the eye.
223916604|NCT06612151|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
223916605|NCT06612151|DRUG|topotecan hydrochloride for injection|Topotecan hydrochloride will be administered intravenously per prescribing information.
224080574|NCT02415712|DRUG|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
223916606|NCT06612229|PROCEDURE|Conservative surgical treatment of liver echinococcosis, verification of occult biliary fistulas and their elimination by weaving and using medical cyanoacrylate glue|In conservative surgical operations for liver echinococcosis, the biliary fistula is identified, onto which a U-shaped suture is applied, after which medical cyanoacrylate glue is applied between the suture stitches to the fibrous capsule in the fistula area and the suture threads are tied.
223916607|NCT06611891|DRUG|68Ga-DOTATOC|Slow direct intravenous injection
223916608|NCT06611644|OTHER|Erector Spinae Plane Block|Patients in this group will receive an Erector Spinae Plane (ESP) block in addition to standard postoperative care. The ESP block will be performed under ultrasound guidance. A needle will be advanced in-plane or out-of-plane, targeting the lateral aspect of the T6 transverse process. Local anesthetic (20 to 30 ml) will be injected into the fascial plane between the erector spinae muscle and the transverse process. This block is intended to provide postoperative analgesia by blocking the transmission of pain through the thoracic spinal nerves.
224080575|NCT01668654|DRUG|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
224080576|NCT01526668|BEHAVIORAL|Follow-up strategy|Comparison of different follow-up strategies
224080577|NCT01526668|BEHAVIORAL|No contact after discharge|
224080578|NCT03335085|DRUG|Oxytocin|
224080579|NCT03335085|OTHER|Placebo|
224080580|NCT04557384|DRUG|Ramucirumab|Administered SC
224080581|NCT05590598|COMBINATION_PRODUCT|Azelastine + Mometazone, nasal spray|140 mcg + 50 mcg/dose (Sandoz d.d., Slovenia), one actuation in each nostril twice daily, morning and evening (recommended interval between administrations is approximately 12 hours), for 14 consecutive days.
223530181|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.
223530182|NCT05728658|DRUG|ICP-248|Eligible patients will receive ICP-248 orally as specified in the treatment arm.
223530183|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
223530184|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
223530185|NCT05728658|DRUG|ICP-248 +Rituximab|Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.
223530186|NCT05728658|DRUG|ICP-248+Orelabrutinib|Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.
223530187|NCT05728658|DRUG|ICP-248+Orelabrutinib+Rituximab|Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.
223719515|NCT06836349|OTHER|Early active motion training after operated FPL injury|Early active motion training after operated FPL injury
223916609|NCT06611644|OTHER|SPSIPB blcok|Patients in this group will receive a Serratus Posterior Superior Intercostal Plane (SPSIP) block along with standard postoperative care. The SPSIP block will be performed under ultrasound guidance, where the needle is advanced between the second and third ribs towards the medial aspect of the scapula. Local anesthetic 20 to 30 ml) will be injected into the fascial plane between the serratus posterior superior muscle and the intercostal muscles after confirming needle placement with hydrodissection using 1-2 ml of saline. This block is intended to provide broad analgesia across the upper thoracic dermatomes, from C3 to T7, to control postoperative pain.
224080582|NCT05590598|COMBINATION_PRODUCT|Momat Rhino Advance|140 µg + 50 µg/dose - one actuation into each nostril twice daily - morning and evening (interval between administrations is 12 hrs), corresponding to 560 µg/day of azelastine and 200 µg/day of mometasone for 14 consecutive days
224080583|NCT02456350|DRUG|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
224080584|NCT02456350|DRUG|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
224080585|NCT02456350|BIOLOGICAL|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
224080586|NCT02617810|DRUG|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
223719516|NCT06836349|OTHER|Immobilisation in plaster cast 4 weeks after operated FPL injury|Immobilisation in plaster cast 4 weeks after operated FPL injury
224080587|NCT02617810|DRUG|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
224080588|NCT02617810|DRUG|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
224080589|NCT06098859|PROCEDURE|Thoracic epidural analgesia|Thoracic epidural analgesia was started preoperatively and rest posoperative 48 hours
224080590|NCT06098859|PROCEDURE|Erector spinae plane block|Erector spinae plane block was applied preoperatively using local anesthetic
224080591|NCT02397473|DRUG|Galcanezumab|Administered SC
224080592|NCT02397473|DRUG|Placebo|Administered SC
224080593|NCT05340205|DRUG|Tranexamic acid|Patients will receive 1 gm tranexamic acid diluted in 20 ml of Glucose 5% 15 minutes prior to skin incision and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following delivery of the baby.
224278223|NCT05751876|DRUG|Dienogest|Dienogest 2mg was prescribed once per day orally
223530191|NCT05850416|OTHER|mGlide-Care|Mhealth mediated model of HTN care with self-monitoring and medication management
223530192|NCT05850416|OTHER|Usual Care +|Usual Care with self-monitoring support
223530193|NCT06523504|DEVICE|DIMS|wear DIMS ,and use placebo,once nightly, both eye
223530194|NCT06523504|DRUG|The 0.02% ATP Group|wear SP, and use 0.02%ATP eye drops, once nightly, both eye
223530195|NCT06523504|DRUG|The 0.04% ATP Group|wear SP, and use 0.04%ATP eye drops, once nightly, both eye
223530196|NCT06523504|COMBINATION_PRODUCT|0.02%ATP+DIMS|wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
223530197|NCT06523504|COMBINATION_PRODUCT|0.04%ATP+DIMS|wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
223530198|NCT02964377|DRUG|(+)- Epicatechin|
223530199|NCT03184753|BIOLOGICAL|OC-IgT cells|Autologous human OC-IgT cells.
223916610|NCT06611644|OTHER|Control|Patients in the control group will receive standard postoperative pain management without any regional block intervention. This will include the administration of systemic analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics will be administered as needed based on the patient's pain level. Pain management will be conducted according to the standard protocol followed for breast surgery patients.
223916611|NCT06612866|DIETARY_SUPPLEMENT|Keratin hydrolysate|The clinical study will be conducted in two phases. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Kera-Diet® ingredient and at determining the overall absorption peak of the tested ingredient. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human skin cell and intestinal epithelial cell cultures.
223916612|NCT06611605|BEHAVIORAL|Storytelling with metaphor toys|"There is evidence of the effectiveness of various methods such as using different types of balls as tactile stimulation and active distraction methods during the management of pain, anxiety, and fear, watching cartoons, using virtual reality (VR) as a method of distracting attention, and using virtual reality hypnosis (VRH). However, no scientific study has been found on storytelling with a metaphoric toy during venous blood collection.~Before the children in the intervention group start the blood collection process, the story will be told to the child by the researcher in the waiting room of Akdeniz University Hospital Blood Collection Unit. The child and the parent will be together during the story telling. Expert opinions were received from five academics who completed their doctorate in Child Health and Disease Nursing for the content of the story."
223916613|NCT04076956|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
223916614|NCT06457958|DRUG|Sevoflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
223916615|NCT06457958|DRUG|Desflurane Group|"Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR."
223916616|NCT05864040|DEVICE|Bitrack System-assisted laparoscopic radical/simple nephrectomy|Robot-Assisted Laparoscopic Transperitoneal Radical/Simple Nephrectomy is performed under general anesthesia. Using blunt dissection, the inferior pole of the kidney is lifted, and ureter and gonadal veins released from fat and connective tissue. The ureter is dissected caudally and sectioned after being sealed with a distal endoscopic clip. Dissection proceeds along the psoas muscle with anterior elevation of the ureter and lower renal pole towards the hilium. Main hilar are circumferentially dissected and sectioned and the kidney is entirely mobilized and released. Gerota´s capsule and suprarenal gland may be preserved if oncologically safe. Once the specimen is completely released, a laparoscopic bag is introduced by the assistant and the specimen entrapped. The robot is undocked, gas evacuated from the abdomen and specimen retrieved.
223916617|NCT06234410|RADIATION|Computed tomography coronary angiography (CTCA)|Single CTCA scan prior to kidney transplantation
223916618|NCT05852808|DRUG|Intra-articular steroid injections|"The patient will be placed in prone position and the facet joints will be imaged by pa-radiation path with attention to radiation protection. 20 mg Kenacort + 1 ml Bupivacain (2.5 mg/ml) will be injected into the affected facet joints. The patient is monitored after the intervention for another 30 minutes before leaving the hospital. In order to track the pain level, the patient will be instructed to keep a pain diary. The patient will be contacted via telephone 72h after the intervention and asked about the pain level.~The intervention is finished after one consultation."
223916619|NCT05852808|RADIATION|Low-dose radiation therapy|The treatment consists of an informing consultation, a planning CT scan and a series of 10 radiation sessions delivered over 3.5 weeks ( = 12 visits in total). The clinical target volume (CTV) will be defined based on the MRI and SPECT/CT. Planning target volume (PTV) will be expanded in all directions by 0.5 cm beyond the CTV. Patients will be treated in a supine position with minimum 6 MV photons and a 3D-technique or volumetric modulated arc therapy (VMAT)-technique. A kilovolt (kV) and in exception a cone-beam CT will be performed before each treatment for positioning accuracy. A dose of 0.5 Gy x 10 fractions (3 times per week) will be delivered over 3.5 weeks. Each radiotherapy treatment session takes approximately 15 minutes. If a second radiotherapy series will be done (NRS 4-10 at visit 4), the radiotherapy dose und fractionation will be the same as the first series.
223916620|NCT02768038|OTHER|Observational|Blood, stool ja biopsy specimens
223716520|NCT07014384|DEVICE|Anodal and cathodal ctDCS|CtDCS will be delivered using an DC-stimulator and two saline-soaked sponge electrodes: one electrode placed 3 cm lateral to the right of the inion, the other electrode on the right buccinator muscle. A 2 mA current will be delivered through these electrodes for a duration of 20 minutes with a 8-second fade-in and fade-out.
223719517|NCT02654743|DIETARY_SUPPLEMENT|Sulforaphane|Children with ASD will receive Sulforaphane in this study
223916621|NCT06600438|DEVICE|Slow-SPEED app|Gamified motivational smartphone app
224080594|NCT05340205|DRUG|Misoprostol|"Patients will receive 400 microgram misoprostol which will be inserted inside the uterus near the cornu after delivery of the placenta and a slow IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h).~."
223916622|NCT06599268|BEHAVIORAL|Survey using a questionnaire.|"Questionnaire to assess the barriers and enablers for women reaching top executive positions in pharmaceutical companies and pharmacies~The following sections will be considered:~* General Characteristics of the Participants~* Work-related characteristics~* Barriers faced by women to reach top executive positions (Likert scale)~* Enablers for women to reach top executive positions (Likert scale)~* Conception of women in the pharmaceutical sector (Likert scale)"
224080595|NCT05340205|DRUG|Oxytocin|Patients will receive an IV bolus of 5 IU oxytocin and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby.
223916623|NCT04945239|BEHAVIORAL|Amplification of Positivity Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
223916624|NCT04945239|BEHAVIORAL|Stress Management Training (6 Sessions)|6 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for activity exercises designed to decrease stress.
223916625|NCT04761770|OTHER|Geriatric assessment (GA) pre-transplant|Assessment of comorbidities, polypharmacy, and functional, nutritional, and psychosocial impairment.
223916626|NCT04761770|DRUG|conditioning regimen|"Based on the Geriatric assessment.~1. HCT-CI/Age ≤4 AND no IADL impairment (less vulnerable/fit) -\> Myeloablative (MA) regimen~2. HCT-CI/Age \>4 AND/OR any IADL impairment (more vulnerable) -\> Reduced-intensity (RIC)/Nonmyeloablative (NMA) regimen"
223916627|NCT04761770|PROCEDURE|Allogeneic CD34+ selected stem cells|Stem cells are collected as per institutional guidelines. CD34+ enriched stem cells will be obtained using the FDA approved reagents from Miltenyi, according to the instruction manual.
223916628|NCT06598670|OTHER|tDCS|tDCS will be applied to the M1 area for 20 minutes with 5x7 cm electrodes. The intervention will be applied for eight weeks on alternate days
223916629|NCT06598670|OTHER|Conventional treatment|Breathing exercises will be performed
223916630|NCT06860958|DRUG|Fluoxetine|Fluoxetine is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs)
223916631|NCT06860958|DRUG|Roflumilast|Roflumilast is the first drug targeting PDE4 that was marketed for treatment of chronic obstructive pulmonary disease (COPD) with relatively weak potency inducing nausea and vomiting
223530200|NCT06477003|DEVICE|Multispectral Optoacoustic Tomography|The MSOT device will be used to take images of the tumor or affected lymph nodes of patients with head and neck squamous cell carcinoma.
223530201|NCT06477003|PROCEDURE|Temperature Measurement|The temperature of the skin will be measured prior to and after MSOT imaging.
223530202|NCT04534075|BIOLOGICAL|Capsules containing either dietary fiber or placebo|The participants are invited to eat 15 capsules per day. The capsules either contain dietary fiber from psyllium husk or placebo.
223916632|NCT06860958|DRUG|Placebo|Placebo
223916633|NCT06604156|DEVICE|EEG monitoring|During gastrointestinal endoscopy, electroencephalogram (EEG) monitoring will be conducted using qCON and qNOX technologies to assess patients\&amp;amp;#39; sedation and analgesia status while they undergo painless gastrointestinal endoscopy. This will be combined with visual assessments (such as cough reflex, respiratory depression, and limb movement) and clinical physiological monitoring (including vital signs and pulse oximetry) to explore and establish a stable and optimal depth of sedation for anesthesia.
223916634|NCT01999361|DRUG|Myfortic|treatment with myfortic
223916635|NCT06316882|DIAGNOSTIC_TEST|Screening endoscopy|We perform upper endoscopy, when the patient authorizes it, during their screening colonoscopy
223530203|NCT06579664|DEVICE|iTBS|Participants in active group will receive iTBS stimulation in 50-Hz triplets at 5 Hz for 600 seconds per session (2 seconds on and 8 seconds off) at 90% of their resting motor threshold to the left dorsolateral prefrontal cortex (DLPFC).Each intervention day includes 4 sessions (1800 pulses/session) of stimulation delivering a total of 7200 active pulses. This treatment protocol will be conducted 15 consecutive days.
223916636|NCT05211050|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.
223916637|NCT05211050|DRUG|Sumatriptan|10 min infusion of 4 mg sumatriptan.
223916638|NCT05211050|DRUG|Saline|10 min infusion of isotonic saline (placebo).
224080596|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
223716521|NCT07014384|DEVICE|Sham stimulation|The tDCS procedure will be identical to the active (anodal and cathodal) stimulation condition, but stimulation will cease after 30 seconds.
223716522|NCT07014592|DEVICE|stimulating probes and electrodes|Subdural electrodes and/or ball tip probes will be used intraoperatively to provide electrical stimulation to the brain.
223716523|NCT06714929|BEHAVIORAL|Hydration|Clusters of schools will sequentially be exposed to the intervention in a stepped-wedge fashion. The intervention is a 4-month community participatory school-based hydration intervention that includes provision of refillable water bottles in schools with hydration stations in addition to: 1) social marketing, 2) behavioral reinforcement, and 3) education and outreach.
223716524|NCT05232110|DRUG|Pozelimab|
223716525|NCT06627751|BIOLOGICAL|Mezigdomide|Given PO
223716526|NCT06627751|DRUG|Carfilzomib|Given IV
223716527|NCT06627751|DRUG|Dexamethasone|Given PO
223719518|NCT00598104|DRUG|QAX576|
223916639|NCT03419052|BEHAVIORAL|Speed of processing training|Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) which tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.
223916640|NCT03419052|BEHAVIORAL|MIND foods|"The MIND diet (created by the Rush Aging \& Memory group) specifically emphasizes foods high in polyphenols such as berries, nuts, cocoa, black beans, olive oil, and green leafy vegetables. Participants select these foods from the digital study application and receive them through home delivery."
223916641|NCT03419052|BEHAVIORAL|Cognitive training control|Control training is provided by the Internet-based BrainHQ program from Posit Science, Inc.These are inert games such as tic-tac-toe, connect 4, battleship, etc.
224080597|NCT02274285|BIOLOGICAL|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
224080598|NCT02274285|BIOLOGICAL|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
223916642|NCT03419052|BEHAVIORAL|Control foods|Foods contain low polyphenols. Participants select these foods from the digital study application and receive them through home delivery.
223916643|NCT06859619|OTHER|Peripheral venous blood sample|Peripheral venous blood sampling for IgG serology against leishmaniasis, leptospirosis, brucellosis, Q fever, rickettsiosis, tularemia, psittacosis, Lyme disease, tick-borne encephalitis, hantavirus, hepatitis E virus, dengue virus, Zika virus, Chikungunya virus, West Nile virus, Usutu virus, Toscana virus, Crimean-Congo hemorrhagic fever virus.
223916644|NCT02361658|OTHER|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
223916645|NCT02361658|OTHER|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
223916646|NCT02361658|OTHER|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
223916647|NCT05123027|BEHAVIORAL|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|Participants will meet with the PILOT Peer consistently throughout the 6 months of study participation.
223916648|NCT05123027|BEHAVIORAL|Treatment As Usual Peer|Participants will receive recovery resources and standard of care procedures specific to the Emergency Department.
223916649|NCT06593847|BEHAVIORAL|Single-session VR exposure intervention|VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.
223916650|NCT06598644|OTHER|Cervical SNAGS (C3-C7) + Conventional PT|Cervical SNAGS at C3-C7 with active movements of lateral flexion and rotation with overpressure at the end range. .Frequency: 10 reps 3 times/week for 3 consecutive weeks Intensity: starting from 20% to 50% resistance across barrier provided by Physical therapist Conventional PT including 1-hot pack for 10 minutes 2-Cervical Stretchings for levator scapulae and sternocleidomastoid 3-cervical isometric exercises, 4. Cervical Range of motion exercises
224080599|NCT06342869|PROCEDURE|Anesthesia|application of different anesthesia techniques
224080600|NCT02529579|OTHER|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
224080601|NCT02529579|DRUG|Gemcitabine|standard Gemcitabine therapy
224080602|NCT05422872|OTHER|Delphi study|A Delphi study will be conducted with several rounds up to expert consensus.
224278224|NCT04837079|OTHER|Clinical observational study|Clinical observational study
223716528|NCT06627751|PROCEDURE|Echocardiography|Undergo ECHO
223716529|NCT06627751|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223716530|NCT06627751|PROCEDURE|Computed Tomography|Undergo PET/CT
223716531|NCT06627751|PROCEDURE|Computed Tomography Assisted Biopsy|Undergo CT guided tumor Biopsy
223716532|NCT06627751|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration biopsy
223916651|NCT06598644|OTHER|IASTM (ergon) + Conventional PT|IASTM, ergon applied at levator scapulae and sternocleidomastoid muscle, with 30 strokes at an angle. After that icing done at the levator scapulae and sternocleidomastoid muscle for 5-10 minutes using cold pack.
223916652|NCT06678542|DRUG|GP681 tablet|GP681 tablet, 20 mg, single oral dose in each Group.
223916653|NCT06678542|DRUG|GP681 Powder for Oral Suspension|GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.
224080603|NCT01990157|DRUG|TAB08|Weekly intravenous administration in escalating doses.
223916654|NCT04362774|DEVICE|ORBERA365|Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)
224080604|NCT03372239|DRUG|Indoximod base formulation|Specified dose on specified days
223916655|NCT06862466|OTHER|Education intervention|Knowledge, Attitude, and Practice Questionnaire (KAPQ) Regarding Renal Nutrition will be used to collect the data at baseline, after the intervention, and three months follow-up, which is adjusted for clustering.
223916656|NCT06864364|OTHER|CGM feedback visualization|The subject will have CGM feedback visualization
223916657|NCT06864364|DIETARY_SUPPLEMENT|milk supplemented with mulberry leaves extract|milk supplemented with mulberry leaves extract
223916658|NCT06864364|OTHER|blinded CGM feedback visualization|The subject will have blinded CGM feedback visualization
224080605|NCT03372239|DRUG|Indoximod HCL (salt) formulation|Specified dose on specified days
224080606|NCT03372239|OTHER|Placebo|Specified dose on specified days
224080607|NCT04280354|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
224080608|NCT04280354|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
224080609|NCT03256045|DRUG|Carfilzomib|Given IV
224080610|NCT03256045|OTHER|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
224080611|NCT03256045|DRUG|Dexamethasone|Given PO
224278225|NCT05898113|OTHER|EXTRA VIRGIN OLIVE OIL|Participants will consume a daily amount of extra virgin olive oil. Can consume the oil either raw or cooked
224278226|NCT05898113|OTHER|OLIVE OIL LOW POLYPHENOL|Participants will consume a daily amount of olive oil low polyphenol. Can consume the oil either raw or cooked
224278227|NCT05982184|OTHER|Music|Patient preferred music listened to through earpieces or headphones using patients' own hardware and software.
224278228|NCT00468871|DRUG|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
224278229|NCT00468871|DRUG|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
224278230|NCT00277043|DRUG|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
223716533|NCT06627751|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223719519|NCT00598104|DRUG|Placebo|
223916659|NCT05921201|BEHAVIORAL|Relax, Reflect, and Empower mobile application|Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
223916660|NCT03735979|DRUG|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
223916661|NCT03735979|DRUG|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (\~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
223916662|NCT03735979|DRUG|Placebo|IV placebo solution
223916663|NCT06862544|DEVICE|Smartwatch (Withings Scanwatch 2)|All-day monitoring of patients via smartwatch and migraine diary app
223916664|NCT06861192|DRUG|Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy|On the 1st to 5th day, Fasudil hydrochloride (10mg of fasudil hydrochloride) was treated, and on the 5th day, PD-1 monoclonal antibody (triprilizumab, 3mg/kg, intravenous drip) was treated. The treatment was repeated every 21 days for a total of 4 times
223916665|NCT06861192|DRUG|Placebo combined with androgen deprivation therapy|Days 1 to 5 were treated with placebo (0.9% sodium chloride 10mg), and days 5 were treated with placebo (0.9% sodium chloride 3mg/kg). The treatment was repeated every 21 days for a total of 4 times.
223916666|NCT06861192|PROCEDURE|radical prostatectomy|Radical prostatectomy was performed 3 weeks (±7 days) after the treatment cycle
223916667|NCT06618872|DIAGNOSTIC_TEST|PET/CT with RO958 (experimental)|the participant will have 2 PET (one with an experimental radiotracer- Tau PET), one with a standard radiotracer (amyloid-PET)
223916668|NCT02531542|DEVICE|Echocardiography according to the READ method.|"* Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~* A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
223916669|NCT06865846|DEVICE|TeleMedBot|The patient will receive a questionnaire daily containing a list of questions about blood pressure and heart rate. For this purpose, a messaging application will be installed on the patients' smartphones before the study begins. All patients will be instructed and trained to use the application. Every day at 12 noon, patients will receive a questionnaire containing 2 questions. Patients can start, pause, and continue answering for 12 hours before the next questionnaire appears. For security reasons, no personal data of patients is entered or saved in the program. The research physician will receive daily information about the patient's self-monitoring results and make decisions about the need to adjust therapy.
223916670|NCT06868095|OTHER|Surgical resection|Histologically confirmed EOCRC
223916671|NCT06867250|DIAGNOSTIC_TEST|The patients' periodontal clinical parameters were recorded. PISF samples were collected, and the evaluations of 25(OH)D and LL-37 were conducted using enzyme-linked immunosorbent assay.|In vitro studies have shown that vitamin D promotes the release of antimicrobial peptides from gingival epithelial cells, no clinical research has specifically examined its effect on LL-37 levels in peri-implant tissue diseases. This study seeks to investigate the relationship between vitamin D levels in peri-implant sulcus fluid and clinical parameters in individuals with both peri-implant health and disease. Additionally, it aims to assess the correlation between vitamin D and the antimicrobial peptide LL-37.
223916672|NCT05112900|BEHAVIORAL|Text Messaging (TM)|\[see arm/group descriptions\]
223916673|NCT05112900|BEHAVIORAL|Text Messaging + Health Navigation (TM+HN)|\[see arm/group descriptions\]
223916674|NCT06867952|DIETARY_SUPPLEMENT|Vitamin K2 plus vitamin D3|Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.
223916675|NCT06867952|DIETARY_SUPPLEMENT|Vitamin K2 plus vitamin D3|Intervention: Vitamin K2 (menaquinone-7), 100-200 µg/day plus vitamin D3 (800- 1000 IU/day) for 6-9 months.
223916676|NCT06866587|OTHER|exercise therapy|Priorities of the treatment included care and interventions to avoid inappropriate neck positions and to provide a regular exercise program for neck muscles and ergonomics training (ergonomic arrangements for desk setup, reading position, computer and mobile phone use, handcrafts, television watching, and pillow height). Of note, patients were advised to avoid cold exposure, particularly in the neck area (air-conditioned environments, wet hair, and holding the hair dryer too close to the scalp). Patients that did not show improvement after training and regular exercise were initiated on medical treatment after the second week and were given myorelaxant gel and oral tablets (diclofenac sodium) for the neck area.
223916677|NCT06865508|DEVICE|Laser therapy|Laser therapy was administered using a low-level laser device with the following parameters: \[ wavelength 980 nm810, power 500mw, and duration 90 seconds (30second for each 3 sides\].
223916678|NCT06865508|DEVICE|zinc oxide eugenol dressing.|zinc oxide eugenol dressing.
223916679|NCT04930783|DRUG|CDX-301|Administered as an injection given underneath the skin
223916680|NCT04930783|BIOLOGICAL|NEOVAX|Personalized neoantigen vaccine administered as an injection given underneath the skin
223916681|NCT04930783|DRUG|Nivolumab|Administered intravenously (IV)
223916682|NCT04930783|DRUG|Pembrolizumab|Administered intravenously (IV)
224080612|NCT03256045|OTHER|Laboratory Biomarker Analysis|Correlative studies
224080613|NCT03256045|DRUG|Panobinostat|Given PO
224080614|NCT01448395|DRUG|[14C]NXL104|500mg/100mL intravenous solution
224080615|NCT01244256|DRUG|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
224080616|NCT01244256|DRUG|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
224080617|NCT05202457|PROCEDURE|Elective surgery|Patient undergoing elective or urgent surgery
223716534|NCT06627751|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
223916683|NCT06865833|OTHER|Tai Chi and Relaxation Intervention|"This Tai Chi and Relaxation Intervention specifically targets adolescents with chronic somatoform disorders, utilizing a combination of mind-body practices designed to reduce pain and alleviate psychological distress. The intervention is distinct in the following ways:~Target Population: It focuses specifically on adolescents aged 12-19 years experiencing unexplained physical symptoms, such as chronic pain, headaches, and fatigue, that are not attributable to any identifiable medical condition.~Non-pharmacological Approach: Unlike traditional medical treatments that may involve medications or invasive procedures, this intervention is entirely non-medical, aiming to address both the physical and psychological aspects of chronic somatoform disorders without using drugs.~Structured Workshops: The intervention consists of weekly Tai Chi and relaxation workshops (1 hour 15 minutes per session) over a 5-week period. The approach emphasizes gentle, controlled movements, relaxation techniqu"
223916684|NCT04621006|DIAGNOSTIC_TEST|Continuously assessment of disease activity|Continuous measures of disease activity and activity in the contact activation system.
223916685|NCT06674980|OTHER|Standard of Care - DFU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223916686|NCT06674980|OTHER|AM/Single - DFU|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223916687|NCT06674980|OTHER|AM/Double - DFU|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223916688|NCT06674980|OTHER|Standard of Care - VLU|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223916689|NCT06674980|OTHER|AM/Single - VLU|Participants will receive weekly applications of AM/Single and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223916690|NCT06674980|OTHER|AM/Double - VLU|Participants will receive weekly applications of AM/Double and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223916691|NCT05958927|OTHER|tear test and eye measurement|tear test and eye measurement
223916692|NCT06071013|DRUG|Nintedanib, gefitinib, erlotinib, afatinib, osimertinib|"Nintedanib is a multiple tyrosine kinase inhibitor that can bind competitively to the ATP-binding pocket of these receptors and block intracellular signaling, which is critical for the proliferation and migration.~Gefitinib, erlotinib and afatinib are the first- and second- generation of EGFR tyrosine kinase inhibitors that reversibly and irreversibly inhibit the binding of ATP to the phosphate-binding loop of ATP binding site in the kinase domain of EGFR, leading to the inhibition of cell proliferation and induction of apoptosis of cancer cells."
223916693|NCT06613516|DRUG|Capivasertib|Capivasertib is a selective inhibitor of the kinase activity of the serine/threonine Akt/PKB pathway that may potentially provide clinical benefit over a range of therapeutic indications. Capivasertib comes in capsule form in two forms; 160mg or 200mg
223916694|NCT06662305|BEHAVIORAL|Kick-Nic! mobile phone application|The Kick-Nic! app has seven modules that cover core CBT strategies using skills, graphic illustrations, and interactive components to help adolescents quit using e-cigarettes.
223916695|NCT06662305|BEHAVIORAL|NCI Quit Vaping website|The NCI webpage provides quitting tobacco resources for youth, including for e-cigarettes. The information provided is similar to the CBT skills modeled by the Kick-Nic! app.
223916696|NCT06681558|DEVICE|Group Nasal Cannula|"Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a conventional oxygen mask.~The nasal cannula is a device that provides oxygen to patients through the nasal passages."
223916697|NCT06681558|DEVICE|Group Procedural Oxygen Mask|Oxygen administered during the endoscopic retrograde cholangiopancreatography (ERCP) procedure will be delivered through a Procedural Oxygen Mask (POM® ELITE MF). The procedural oxygen mask is a device that covers both the mouth and nose to deliver oxygen to the patient. Its reservoir feature increases the concentration of delivered oxygen
223916698|NCT06609421|OTHER|Informative Appointment|The only intervention involving the participants is non-clinical, which is an extra 30-minute informative telephone appointment added to the standard care consultation schedule of interested IVF patients where they will be presented with a digital consent PDF form to sign by a study nurse or clinically trained research personnel. Participants will be in the study for 24-30 months. During this time their discarded, unfertilised oocytes and follicular fluid collected during routine oocyte retrieval along with information from their electronic medical records will be collected and analysed.
223916699|NCT06669338|OTHER|Music therapy|patients listen to music for 20 minutes with headphones before colonoscopy.
223916700|NCT06669338|OTHER|listen to white noise|patients listen to white noise with headphones for 20 minutes before colonoscopy.
223916701|NCT06669338|OTHER|listen to hospital ambient sound|patients listen to recorded ambient sound for 20 minutes with headphones before colonoscopy.
223916702|NCT06157086|OTHER|ofatumumab|There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol
223916703|NCT04956549|BEHAVIORAL|Physical activity program|Supervised group sessions will be held twice per week for approximately 52 weeks. Each physical activity session will last slightly approximately 80 minutes and will consist of aerobic, strength, flexibility, and balance training. The 80 minutes of activity consists of a 5 minute warm-up, 45 minutes of aerobic training, 15 minutes of strength training, 10 minutes of balance training, and a 5 minute cool-down. The physical activity group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations.
224080618|NCT03094000|BEHAVIORAL|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
223916704|NCT04956549|BEHAVIORAL|Successful Aging|The successful aging group will be based on a low-intensity activity program and a healthy aging educational component. Sessions will be approximately 60 minutes in duration and will occur once per week for the first 6 months and then every other week for the remainder 6 months of the study. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
223916705|NCT05849610|DRUG|Daratumumab|Daratumumab will be administered by SC injection.
224080619|NCT03094000|BEHAVIORAL|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
223916706|NCT05849610|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area (BSA) at baseline and will be administered by subcutaneous (SC) injection.
223916707|NCT05849610|DRUG|Lenalidomide|Lenalidomide will be administered by oral route.
223916708|NCT05849610|DRUG|Teclistamab|Teclistamab will be administered by SC injection.
223916709|NCT05849610|DRUG|Talquetamab|Talquetamab will be administered by subcutaneous (SC) injection.
224080620|NCT00127751|BEHAVIORAL|Enhance health lifestyle changes and medication compliance|
224080621|NCT02765282|DEVICE|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
224080622|NCT00002550|DRUG|cisplatin|
224080623|NCT00002550|DRUG|etoposide|
224080624|NCT00002550|PROCEDURE|conventional surgery|
223916710|NCT04745962|DEVICE|Slimscope|Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.
224080625|NCT00002550|RADIATION|radiation therapy|
224080626|NCT00254566|OTHER|Moxifloxacin Placebo|1 capsule once daily for 5 days
224080627|NCT00254566|DRUG|Moxifloxacin|1 X 400mg capsule once daily for 5 days
224080628|NCT00254566|OTHER|Azithromycin SR Placebo|single dose, oral.
224080629|NCT00254566|DRUG|Azithromycin SR|single dose 2.0 g oral
224080630|NCT05310214|OTHER|Acupuncture|"Treatment with ACP will be performed by inserting sterile acupuncture needles 0.25 x 13 mm into the acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji , for the treatment of chronic non-specific low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~In order to increase the effectiveness of blinding for both groups, in this study the model was adopted: combined simulated control. In this case, Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. Thus, in the ACP group, the placebo LACP (without dosemetry) will be applied to these 4 points together with the real treatment."
224080631|NCT05310214|OTHER|Laser acupuncture|"The use of LACP (808 nm wavelength, 100 mW, energy 6 J per acp point), on acupoints BL23 (Shenshu), BL25 (Dachangshu), BL40 (Weizhong), BL62 (Qixue), SI3 (Houxi) and Jiaji will be used as a treatment for nonspecific chronic low back pain. Interventions will last one hour, and will happen twice a week for 5 weeks.~Sham acupuncture points will be used to simulate the treatment, as follows: i) Arms: 3 cm above the lateral epicondyle of the elbow, ii) Lumbar spine: Iliac crest on the same line as the greater trochanter of the femur. These sham points will be inserted superficially so that the depth is sufficient to keep them fixed during the experiment, without individuals reporting the dequi."
224080632|NCT00059202|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic Acid 28-30 mg/kg/day in divided doses
224080633|NCT00059202|DRUG|Placebo|Placebo for Urso
224080634|NCT03378479|DRUG|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)
223716535|NCT03598751|DRUG|BCD-085|120 mg / 2 mL subcutaneously
223916711|NCT05687344|DRUG|Nifedipine ER|Postpartum BP treatment to \<140/90 mmHg
223916712|NCT06854497|DIAGNOSTIC_TEST|MMSE (Mini-Mental State Examination),NIHSS (NIH Stroke Scale) and mRS (Mordified Rankin Score), Confusion Assessment Methods (CAM), PSQI Pittsburgh Sleep Quality Index, Respiratory polygraphy|Respiratory polygraphy will be performed during acute stroke period, to evaluate the relationship between sleep apnea and stroke evolution.
223916713|NCT00319111|DRUG|bosentan|"Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)"
223916714|NCT06087952|OTHER|Randomised treatment advice (discontinue vs continue after 3 months)|Randomisation to continue or discontinue anticoagulant therapy in 1:1 ratio stratified on risk category of L-TRRiP and VTE-BLEED score
223916715|NCT06087952|DIAGNOSTIC_TEST|VTE-BLEED score|Predict bleeding risk during extended anticoagulant treatment (high or low) using the VTE-BLEED score
223916716|NCT06087952|DIAGNOSTIC_TEST|L-TRRiP score|Predict VTE recurrence risk after anticoagulant discontinuation (high, intermediate or low) using the L-TRRiP score
223916717|NCT06087952|OTHER|Advise to continue anticoagulant treatment after 3 months|Advise to continue anticoagulant treatment after 3 months for patients with high VTE recurrence and low bleeding risk
223916718|NCT06087952|OTHER|Advise to discontinue anticoagulant treatment after 3 months|Advise to discontinue anticoagulant treatment after 3 months for patients with low VTE recurrence risk
224080635|NCT03378479|OTHER|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
223916719|NCT06746961|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|5mg/kg , iv, q3w
223916720|NCT06746961|DRUG|Lenvatinib|8 mg or 12 mg QD via oral capsule
224080636|NCT03567148|PROCEDURE|PRF|Applying to the palatal wounds
224080637|NCT03567148|PROCEDURE|Essix retainer|Applying to the palatal wounds
224080638|NCT03567148|PROCEDURE|Ozone therapy|Applying to the palatal wounds
223916721|NCT01601808|DRUG|Placebo|Orally once a day, continuously throughout the study
223916722|NCT01601808|DRUG|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
223916723|NCT06858254|BIOLOGICAL|Autologous mesenchymal stem cells|"1. Participant's blood is drawn at the start of each visit.~2. Bone marrow aspirate is drawn from the posterior aspect of the pelvis and is subsequently harvested and processed.~3. The following procedures are administered in a crossover design (Day 0 and 6 months):~   * Intranasal bone marrow aspirate administration (INA BMAC) OR Sham INA~  * Intravenous bone marrow aspirate administration (IV BMA) OR Sham IVA~4. At 12 months, all participants receive IV BMA + INA BMAC"
223916724|NCT02243852|DRUG|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
223916725|NCT06868680|BEHAVIORAL|Balance Program|A comprehensive program of tailored exercise therapy, educational content spanning a variety of topics related to balance improvement and fall prevention, a personalized clinical approach to improving balance, and access to a board-certified health coach and physical therapist.
224080639|NCT03567148|PROCEDURE|LLLT|Applying to the palatal wounds
224080640|NCT03567148|PROCEDURE|Collagen fleece|Applying to the palatal wounds
224080641|NCT00358657|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
224080642|NCT00358657|DRUG|Cyclophosphamide|Given IV
224080643|NCT00358657|DRUG|Fludarabine Phosphate|Given IV
224080644|NCT00358657|OTHER|Laboratory Biomarker Analysis|Correlative studies
224080645|NCT00358657|DRUG|Mycophenolate Mofetil|Given PO
224080646|NCT00358657|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
224278231|NCT00277043|DRUG|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
223916726|NCT06868680|OTHER|Educational Reading Content|Informational articles on reducing risk for falls.
223916727|NCT06869395|OTHER|Questionnaire|"The responses obtained will be recorded as follows:~\- Referred to a dentist~\- Referred to a physician~\- Prescribed an over the counter (OTC) preparation~\- Prescribed an OTC preparation and referred to a dentist or a physician~\- Wanted to see the patient~\- Other answers: ……….."
224080647|NCT00358657|DRUG|Sirolimus|Given PO
223916728|NCT05386589|DRUG|Molnupiravir|Four 200 mg capsules administered orally as a single dose
223916729|NCT06868069|DIAGNOSTIC_TEST|Diagnostic tests and questionnaires|Assessment of office blood pressure, orthostatic hypotension, 24-hour ambulatory blood pressure, frailty
223916730|NCT06868342|PROCEDURE|High-frequency nerve conduction block|A high-frequency nerve conduction block applied to a muscular branch of the tibial nerve and assessed by intraoperative EMG, performed before the nerve is cut as a part of a standard tibial neurectomy for focal spasticity.
223916731|NCT06867861|DIETARY_SUPPLEMENT|Fiber|Psyllium fiber supplement capsules, 2g soluble fiber per capsule. They will be instructed to take 4 capsules twice daily for a total of 16g supplemental soluble fiber per day. This will be continued throughout pregnancy.
223916732|NCT03167164|BIOLOGICAL|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
223916733|NCT03167164|BIOLOGICAL|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
223916734|NCT03167164|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223916735|NCT03167164|DRUG|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
223916736|NCT03167164|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
224080648|NCT00358657|DRUG|Tacrolimus|Given IV or PO
224080649|NCT00358657|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
224080650|NCT00079378|DRUG|decitabine|Given IV
224080651|NCT00079378|DRUG|valproic acid|Given orally
224080652|NCT00079378|OTHER|pharmacological study|Correlative studies
224080653|NCT00079378|OTHER|laboratory biomarker analysis|Correlative studies
224080654|NCT00348621|PROCEDURE|Visual impairment intervention program|enhanced access to eye care services
224080655|NCT01044966|DRUG|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
224080656|NCT05773677|DIETARY_SUPPLEMENT|Specific Diet|"A specific diet will be developed for each patient, which will also take into account any food allergies or intolerances.~Each diet will be then eventually modified and revised throughout the pregnancy, according to the evolution of the same."
224080657|NCT03047499|DRUG|Botulinum toxin type A|Botulinum toxin type-A injection
224278232|NCT06378567|DIETARY_SUPPLEMENT|Dietary supplement liquid shot beverage products|Participants will use their product as instructed for 3 of the 4 study weeks
224278233|NCT05131516|DIAGNOSTIC_TEST|Alveolar recrutment maneuver|alveolar recruitment maneuver (30 mmHg for 30 seconds)
224278234|NCT04979923|DRUG|Lidocaine|Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
224278235|NCT00676741|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224278236|NCT00676741|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224278237|NCT00676741|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224278238|NCT03380416|OTHER|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
223716536|NCT03598751|DRUG|Placebo|2 mL
223716537|NCT05237687|DRUG|Sirolimus|Patients will be randomly assigned to sirolimus or standard of care
223916737|NCT03167164|DRUG|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223916738|NCT03167164|DRUG|Leucovorin|Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
223916739|NCT03167164|DRUG|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
223916740|NCT03167164|DRUG|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
223916741|NCT03167164|RADIATION|Stereotactic Body Radiation Therapy|radiation
223916742|NCT03167164|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223916743|NCT03167164|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
223916744|NCT03167164|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-MUC1
223916745|NCT03167164|BIOLOGICAL|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
223916746|NCT03167164|BIOLOGICAL|haNK|NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
223916747|NCT06755762|OTHER|Organoid 3D culture|Investigate different normal cells (lung, bone, soft tissue, liver, etc) as metastatic organs to simulate the behaviors of CTCs in metastatic sites
223916748|NCT06872957|DEVICE|Surface Electromyography Noraxon MiniDTS system|Trapezius muscle activities of 19 healthy individuals were measured with surface EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) in the ascending, stationary and descending phases of the wall slide exercise under different head posture conditions: natural head posture and corrected head posture.
223916749|NCT06871826|DRUG|TIMP2 level|different TIMP2 level after on-pump cardiac surgery
223916750|NCT06873282|BIOLOGICAL|TB/Flu-05E|Participants will receive single intranasal injection of TB/Flu-05E vaccine in 0.5 ml, containing 7.7 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the TB10.4 and HspX antigens of M. tuberculosis
223916751|NCT06873282|OTHER|Placebo|Participants will receive single intranasal injection of physiological buffer in 0.5 ml
223916752|NCT06867562|DRUG|Paclitaxel Lipid Suspension|The formulation consists of uniformly sized (\< 100 nm) particles of Paclitaxel suspended in a lipid-based formulation. The advantage of such a Lipid-Based formulation of Paclitaxel is an improvement of the safety profile by eliminating excipients, Cremophor and ethanol which are present in conventional Paclitaxel formulations (Taxol®).
223916753|NCT06867562|DRUG|Conventional paclitaxel or Taxol|Conventional formulation with detergent Cremophor and alcohol
223916754|NCT06868862|OTHER|Exercise|Two Exercise Modalities: HIIE and MICE
223916755|NCT06869980|PROCEDURE|mitral valve replacement through limited right anterior thoractomy|The incision is placed just lateral to the nipple over the fourth intercostal space (above the nipple in men and in the inframammary crease in most women) 6-10 cm in length, the pectoralis muscles are mobilized for fourth intercostal space thoracic entry-The pericardium is opened 2-cm ventral to the phrenic nerve under direct vision and carried cephalad to the aortic reflection. The anterior edge of the pericardium is tacked to incision edges using silk sutures-To initiate cardiopulmonary bypass, Cannulation of the femoral artery and femoral vein should be prior to mediastinal dissection-. The ascending aorta occluded with an external clamp. This aortic clamp passed through the thoracotomy incision if we use the aortic cross clamp and the anterograde cardioplegia delivered through a standard cardioplegia cannula secured with purse-string sutures in the ascending aorta.
223716538|NCT00009997|BIOLOGICAL|trastuzumab|
223716539|NCT00009997|DRUG|cyclophosphamide|
223716540|NCT00009997|DRUG|doxorubicin hydrochloride|
223716541|NCT00009997|DRUG|paclitaxel|
223716542|NCT00009997|DRUG|tamoxifen citrate|
223716543|NCT00009997|PROCEDURE|conventional surgery|
223716544|NCT05869422|DIETARY_SUPPLEMENT|Iron|60 ± 5 days of daily oral iron supplementation.
223716545|NCT05869422|OTHER|Placebo|60 ± 5 days of daily oral placebo intake.
223716546|NCT06507046|PROCEDURE|Total knee replacement|Mechanical or Personalized alignment
223716547|NCT06456424|BIOLOGICAL|Phage therapy|Bacteriophage cocktail consisting of phages BP13 and J1P3
223916756|NCT06869980|PROCEDURE|mitral valve replacement through median sterntomy|The incision is begun approximately 2 cm below the sternal notch and extended approximately 2 cm beyond the distal tip of the xiphoid process and is usually extended with the electrocautery down to the sternal periosteum. A midline approach can be ensured by careful attention to the insertion points of the pectoralis major muscles onto the sternum; the incision should lie directly midway between these insertion points.After sternotomy, the pericardium is opened; the heart is cannulated for cardiopulmonary bypass. Arterial inflow is established by cannulation of the distal ascending aorta near the pericardial reflection. Double venous cannulation of the venae cavae by way of the right atrium is generally employed. In most adults a size 32 Fr cannula in the superior vena cava and a size 34-38 Fr cannula in the inferior vena cava provide excellent venous drainage and easy fit. Encircling of the venae cavae and their generous mobilization aid in the subsequent exposure of the mitral valve.
223916757|NCT06871137|OTHER|Welfare Benefits Advice (WBA)|Appointment offered to receive financial advice from a Welfare Benefits Advisor (WBA) co-located with routine 6-8 week newborn health checks
223916758|NCT06871137|OTHER|Usual care|No intervention, existing London Borough of Tower Hamlets 'service as usual'
223916759|NCT06681870|DRUG|ASP1893|Intravenous infusion
223916760|NCT06625658|DEVICE|Direct printed clear aligners|chang aligner every 10 days
223916761|NCT05564208|DRUG|elafibranor|Oral Tablet
223916762|NCT05564208|DRUG|elafibranor|Oral Tablet
223916763|NCT06875544|OTHER|Beautifil F00|Beautifil F00 is bioactive giomer resin composite.
223916764|NCT06875544|OTHER|G-aenial Universal Injectable Flowable Composite|Nanohybrid resin composite is a type of restorative material that features nano-sized fillers as a main component
223916765|NCT06628180|DEVICE|LIFU|Application of low-intensity focused ultrasound for neuromodulation
223916766|NCT06628180|DEVICE|Sham LIFU|Sham application of LIFU - will appear the same to participants.
223916767|NCT04743973|DEVICE|Muse S™ Headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
224278239|NCT03380416|OTHER|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
224080658|NCT03762304|OTHER|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
223916768|NCT05654662|DRUG|Corsodyl Original Dentifrice|It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million \[ppm\] Fluoride ion \[F\])
223916769|NCT05654662|DRUG|Colgate Cavity Protection Dentifrice|It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)
223916770|NCT05225792|BEHAVIORAL|Promis Physical Function Questionnaire|Patient reported physical function outcomes
223916771|NCT05225792|BEHAVIORAL|L Test|Performance based measure assessing general physical function and balance ability.
223916772|NCT05225792|BEHAVIORAL|Narrowing Beam Walking Test|Subjects attempt to walk along 4 progressively narrower beam segments with their arms crossed over their chest.
223916773|NCT05225792|BEHAVIORAL|PEQ-A|Survey on confidence, stumbles and falls.
224080659|NCT05661201|DRUG|NEROFE|weekly doses of NEROFE (48-288 mg/m2) (dose level 1: 96 mg/m2, dose level -1: 48 mg/m2, dose level 2: 192 mg/m2, dose level 3: 288 mg/m2), intravenously over 60 minutes
224080660|NCT05661201|DRUG|Doxorubicin|weekly doses of 8 mg/m2 (fixed dose), intravenous push over 3 mins;
224080661|NCT02658448|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
224080662|NCT03106779|DRUG|Asciminib|40 mg tablets was taken orally twice a day (BID)
224278240|NCT00292591|DRUG|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
224278241|NCT00292591|DRUG|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
224278242|NCT00442650|DRUG|Efalizumab|
224278243|NCT02431624|DRUG|BTDS|
224278244|NCT05376137|DEVICE|continuous positive airway pressure (CPAP)|CPAP comfort settings will be modified in the active group to be personalized to each participant
223916774|NCT06624527|OTHER|Psychoeducation based on Cognitive Behavioral Therapy|A psycho-educational application based on Cognitive Behavior Therapy consisting of a total of 8 sessions prepared by the researcher.
223916775|NCT06695780|OTHER|survey on eating behavior, physical activity and health status|Participatory research: participants will carry out surveys, functional tests and urine and blood sampling completely independently
223916776|NCT06630260|DRUG|Avutometinib|Supplied as 0.8mg capsules.
223916777|NCT06630260|DRUG|Defactinib|Supplied as 200mg tablets.
224278245|NCT03756337|DEVICE|Neuro 1 & Neuro 2|participant common fitting map used for tests
223916778|NCT06630260|DRUG|Temozolomide|Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.
223916779|NCT06687070|DRUG|APG -2449|Orally once a day(QD), every 28 days as a cycle.
223916780|NCT06687070|DRUG|PLD|Injected on the first day of each cycle, every 28 days as a cycle.
223916781|NCT06875596|OTHER|Control: Exercise Program|The entire program begins with an assessment of scapulohumeral rhythm using a digital inclinometer, isometric strength testing, range of motion measurements, the Y-Balance Upper Quarter Test, and the Closed Kinetic Chain Upper Extremity Stability Test. The exercise program for the experimental group lasts eight weeks and is divided into four two-week phases with four sets of exercises targeting the dominant upper extremity only. After the initial assessment, participants will undergo scapular positioning correction for the dominant extremity. They are then introduced to the first set of exercises for the first two weeks. The handball players will be given an exercise sheet explaining each exercise, which they will complete daily after completing their assigned ten minutes of exercise. They will also be given two resistance bands to provide resistance during the assigned exercises. One band is for upper scapular rotation, while the other is for resisting
224080663|NCT03106779|DRUG|Bosutinib|500 mg tablets was taken orally once daily (QD)
224080664|NCT06044168|DIETARY_SUPPLEMENT|Dietary Supplement: Leucine|150mg/kg body mass/day
224080665|NCT05207228|BEHAVIORAL|CBT4CBT|Cognitive behavioral treatment through the web CBT4CBT
224080666|NCT06097897|DEVICE|SVO-ID|Combined scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) for imaging of the eye
224080667|NCT02288247|DRUG|Enzalutamide|Oral
224080668|NCT02288247|DRUG|Docetaxel|intravenous infusion
224080669|NCT02288247|DRUG|Prednisolone|Oral
224080670|NCT02288247|DRUG|Placebo|Oral
224080671|NCT06395090|BIOLOGICAL|Pembrolizumab|IV infusion
224080672|NCT06395090|BIOLOGICAL|Favezelimab|IV infusion
224080673|NCT06395090|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
224080674|NCT06395090|BIOLOGICAL|Vibostolimab|IV infusion
224080675|NCT06395090|BIOLOGICAL|Pembrolizumab/Vibostolimab|IV infusion
224278246|NCT03756337|DEVICE|Neuro 2 & Neuro 1|participant common fitting map used for tests
224278247|NCT03429049|DRUG|CNTX-4975-05|Receiving CNTX-4975-05 injection
224278248|NCT03429049|DRUG|Placebo|Receiving Placebo injection
224278249|NCT05739734|DRUG|CRIS100|local application of CRIS100
224278250|NCT05139758|DIAGNOSTIC_TEST|Biodex Balane System|The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
224278251|NCT03609242|BEHAVIORAL|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
224278252|NCT02685696|DEVICE|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
224278253|NCT02685696|DEVICE|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
223716548|NCT04147221|DRUG|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
223716549|NCT04086147|DRUG|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
223716550|NCT04086147|DRUG|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
223716551|NCT01730391|OTHER|Data collection|Collection of demographic data and vaccination history
223716552|NCT01730391|OTHER|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
223716553|NCT03834961|DRUG|Larotrectinib Sulfate|Given PO or via NG or G tube
223716554|NCT03275376|DRUG|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
223716555|NCT03275376|DRUG|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
223716556|NCT02625272|PROCEDURE|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
223716557|NCT03092154|DRUG|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
223716558|NCT06298110|BIOLOGICAL|Platelets Rich plasma of the same patient|on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
223716559|NCT03578861|OTHER|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
223716560|NCT02885012|DRUG|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
223719520|NCT04496271|DEVICE|RIC (Receiver in channel)- device|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
223719521|NCT00003931|GENETIC|reverse transcriptase-polymerase chain reaction|
223916782|NCT06875596|OTHER|Experimental: Exercise Program|Participants in the active control group will begin the program in the same manner as the experimental group, beginning with scapulohumeral rhythm assessments using a digital inclinometer, isometric strength testing, range of motion measurements, the Y-Balance Upper Quarter Test, and the Closed Kinetic Chain Upper Extremity Stability Test. They will also follow an eight-week exercise program divided into four two-week phases with four sets of exercises targeting the dominant upper extremity only. The key difference is that the control group will not focus on correcting scapular position for upward rotation during the exercises. Specifically, they will skip the upward rotation exercises at the beginning of each set and will not incorporate the acquired upward rotation control into other movement exercises. You will also be given a resistance band to provide resistance during the assigned exercises.
223916783|NCT06872853|OTHER|diagnosis, surgery, drugs for rare neoplasms|diagnostic and surgical procedures, drugs (pharmacological active substance, dose, regimen)
223916784|NCT06873971|DRUG|Topical estrogen therapy based on estriol (E3)|Patients will use low-dose isolated topical estrogen therapy in the form of estriol 1mg/g vaginal cream (Generic), with disposable, individualized vaginal applicators pre-set at the recommended dosage of 5g/dose each. Initially, they will use it for 14 consecutive nights, and then use it 2 times a week, always during the night, on Mondays and Thursdays, for 16 consecutive weeks from the start of the research. The treatment will be provided in fractions for each 30-day period and will always be delivered after each laser session, along with a leaflet containing usage, storage, and application instructions for the vaginal cream. The patients will be monitored through a messaging app, reinforcing the instructions and the days of application correctly.
223916785|NCT06873971|RADIATION|Laser Er:YAG On|All participants in the group will undergo 3 applications of the Er:YAG laser with an interval of 4-5 weeks between them. The intimate laser session consists of 2 stages, using a PS03-fractional tip: the internal stage (vaginal canal) and the external stage (region of the vestibule and introitus).
223916786|NCT06873971|RADIATION|Laser Er:YAG Off|All participants in the group will undergo 3 applications of the Er:YAG laser with the device turned off, with an interval of 4-5 weeks between them. The intimate laser session consists of 2 stages, using a PS03 fractional tip: the internal stage (vaginal canal) and the external stage (vestibule and introitus region).
223916787|NCT06693518|DRUG|Treatment B|Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
223916788|NCT06693518|DRUG|Treatment A|Dabigatran Etexilate 150 mg
224080676|NCT03345186|OTHER|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
224080677|NCT05506397|OTHER|Acupressure|Acupressure is a technique based on stimulating certain points on the body with stimulation methods such as hands and fingers.
224080678|NCT04623645|DEVICE|ultrasound technique|evaluate the effect of ultrasound guided technique for block of internal branch of superior laryngeal nerve
223916789|NCT03386513|DRUG|IMGN632|CD123-targeted ADC
223916790|NCT06460467|DEVICE|scintigraphy of 177Lu-DOTATATE|The medical device under study is a hybrid wide-field CZT solid-state camera, the VERITON-CT ™ camera.
223916791|NCT02639754|BEHAVIORAL|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
223916792|NCT02639754|BEHAVIORAL|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
223916793|NCT06396689|DIETARY_SUPPLEMENT|Synbiotic|The capsule contains Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, and Bifidobacterium bifidum R0071 (3 billion bacteria per capsule), as well as zinc oxide, potato starch fructooligosaccharides, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
223916794|NCT06396689|DIETARY_SUPPLEMENT|Placebo|The capsule contains zinc oxide, coating agent, methyl hydroxypropyl cellulose, anti-caking agent and magnesium stearat
223916795|NCT05418140|OTHER|Ultrasound diagnosis of adenomyosis|The diagnosis of adenomyosis will be made using transvaginal ultrasound scan (TVS) (2D and 3D Ultrasound and applying Morphological Uterus Sonographic Assessment (MUSA) criteria (Van den Bosch et al, 2015).
224080679|NCT05566002|DIAGNOSTIC_TEST|Right heart catheterization|RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
224080680|NCT04652804|BEHAVIORAL|Low intensity HCV treatment adherence support|A 28-day supply of medication will be dispensed to participants at entry, 4 weeks, and 8 weeks. Participants will receive standard adherence counseling at entry and every refill pickup/home or field delivery. Participants will have access to all of the services available at the ICC including facilitated linkage to referrals as needed. Site staff will routinely track clients who miss refill appointments in real-time using standard tracking measurements
224080681|NCT04652804|BEHAVIORAL|Medium intensity HCV treatment adherence support|The medium intensity intervention will include standard of care dispensation of a 28-day supply of medication at entry, 4 weeks and 8 weeks. Participants will be assigned to a patient navigator (PN) and receive tailored patient navigation support for medication reminders, picking up medication refills (or home or field delivery of study medications), overcoming barriers as well as service linkage. Participant will be contacted by the PN at least once every two weeks.
224278254|NCT02491996|BEHAVIORAL|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
224278255|NCT00164255|DRUG|sulfadoxine/pyrimethamine|
224278256|NCT00164255|DRUG|sulfadoxine/pyrimethamine plus artesunate|
224278257|NCT01723150|DRUG|Ciprofloxacin|
224278258|NCT01723150|DRUG|Ceftriaxone|
223530204|NCT06579664|DEVICE|sham iTBS|Participants in the sham group will receive sham iTBS stimulation, which will use the same stimulation parameters, dosage, and duration as the active group, but will employ a sham coil. The sham coil is identical in appearance to the real stimulus coil and simulate the sound of a real stimulus, but do not produce a real stimulus.
223916796|NCT05560724|DEVICE|Transcranial direct current stimulation (tDCS)|Anodal stimulation or sham
223916797|NCT06293911|OTHER|Biorepair Plus Parodontgel Intensive|The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
223916798|NCT06293911|OTHER|Placebo gel|The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
223916799|NCT06696300|OTHER|Classical Physiotherapy Group|"Classical physiotherapy group (CF) will be treated face to face for 30 sessions in total, 3 days a week, 10 weeks. Hotpack, Ultrasound, TENS and Basic Exercises will be applied to the CF group. Hotpack will be applied superficially to the lumbar region for 15 minutes. Ultrasound 1MHz- 1.5 Wt/cm2 will be applied to the lumbar region. TENS 50 Hz will be applied for 15 minutes, leaving the painful area in the middle. Basic exercises will be applied as 8-12 repetitions, 2 sets. The number of repetitions and sets will be increased as the tolerance of the patients increases.~Pelvic tilt exercises Supine hip flexor stretch Supine lumbar extensor stretch Crunches Cat-Camel Exercises"
223916800|NCT06696300|OTHER|Foundation Inspiratory Muscle Training in Addition to Classical Physiotherapy|In addition to Classical Physiotherapy, Foundation Inspiratory Muscle Training (IKE) will be treated face to face for 30 sessions, 3 days a week, 10 weeks. On other days, IKE will be applied at home for 15 minutes in the morning and evening for a total of 30 minutes and will be followed up with a diary. IKE will be applied with a device that can load with threshold pressure. The IKE group will continue the exercise program for 10 weeks. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be asked. As tolerance increases, the consecutive respiratory cycle will be increased. The intensity will be adjusted by taking weekly MIP measurements. Daily monitoring forms will be created for each participant to ensure exercise follow-up.
224278259|NCT01723150|DRUG|Trimethoprim/sulfamethoxazole|
224278260|NCT01723150|DRUG|Ertapenem|
224080682|NCT04652804|BEHAVIORAL|High intensity HCV treatment adherence support|The high intensity intervention will involve patient-centered DOT with flexibility in terms of the frequency of pickup and the site of DOT (ICC, field-based) with a minimum of at least 1 observed dose per week. Participants in this arm will also receive PN support for overcoming barriers and service linkage similar to participants in Arm 2. The main differences between Arms 2 and 3 are: (i) medications will not be dispensed for more than one week at a time (to coincide with opioid agonist therapy (OAT) dosing, where applicable); and (ii) ≥1 dose/week will be observed.
224080683|NCT04911946|OTHER|Questionnaire|After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
224080684|NCT01571115|BEHAVIORAL|Physical Exercise|
224080685|NCT01526109|BEHAVIORAL|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
223940412|NCT06052332|COMBINATION_PRODUCT|Total neoadjuvant therapy|"The choice of the TNT is left to the investigator's discretion.~If RAPIDO:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 18 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If RAPIDO light:~* SCRT (5 fractions of 5 Gy), followed by~* Up to 12 weeks of oxaliplatin based chemotherapy (mFOLFOX6 or CAPOX)~If OPRA with induction chemotherapy:~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX), followed by~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine)~If OPRA with consolidation chemotherapy:~* CRT (25-28 fractions of 1.8-2.0 Gy each +/- a boost to the primary tumour and involved lymph nodes, for a total of 50-56 Gy of radiation combined with either continuous infusion ﬂuorouracil or capecitabine) followed by~* Up to 16 weeks of oxaliplatin-based chemotherapy (mFOLFOX6 or CAPOX)"
224080686|NCT01526109|BEHAVIORAL|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
224080687|NCT01526109|BEHAVIORAL|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
224080688|NCT03634800|DRUG|Nivolumab 240mg|Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.
224080689|NCT03634800|RADIATION|Radiation therapy|Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.
224080690|NCT04543214|OTHER|Enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response after surgery. It benefits patient by reducing complications and enhancing recovery and saves resources for the health care system. In this concept, surgeons work collaboratively with anesthesiologist, nurses, nutritionists and physical therapists to develop and manage the perioperative care.
224080691|NCT06073392|OTHER|Educational video|Educational video in animation mode
224080692|NCT01491256|DRUG|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
224080693|NCT01491256|DRUG|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
223916801|NCT06696300|OTHER|Functional Inspiratory Muscle Training Group in Addition to Classical Physiotherapy|Functional Inspiratory Muscle Training Group will receive functional inspiratory muscle training in addition to classical physiotherapy, 3 days a week, 10 weeks, 30 sessions in total, face-to-face treatment. On other days, foundation-ICE will be applied at home for 15 minutes in the morning and evening, for a total of 30 minutes, and will be followed with a diary. The same protocol will be applied with the foundation IKE group for teaching the respiratory cycle in the first 4 weeks, and resisted breathing will be worked simultaneously with the exercises in Table 2 in the last 6 weeks. The exercise program will be continued for a total of 10 weeks, including F-ICE, foundation IKE for the first 4 weeks, and F-ICE for 6 weeks thereafter. The intensity of the exercise will be adjusted to 40-50% MIP for the exercise group. After 10 consecutive respiratory cycles, 3-4 respiratory controls will be requested. As tolerance increases, the number of consecutive respiratory cycles will be increase
223916802|NCT06696794|DRUG|Mitomycin C (MMC)|When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (mitomycin) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
223916803|NCT06696794|DRUG|Normal Saline (Placebo)|When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (Normal Saline) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
223916804|NCT03116061|OTHER|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
224080694|NCT06067880|OTHER|Cancer-related Unilateral|This group included patients who have used only contraction type LVs.
224080695|NCT06067880|OTHER|Normal + Ectasis LVs|This group included patients who had only non- contraction type LVs.
224080696|NCT00138697|DRUG|IVIG-L|
223719522|NCT01657669|DRUG|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
224080697|NCT00049088|DRUG|docetaxel|Given IV
224080698|NCT00049088|BIOLOGICAL|bevacizumab|Given IV
224080699|NCT00049088|OTHER|laboratory biomarker analysis|Correlative studies
224080700|NCT00049088|OTHER|pharmacological study|Correlative studies
224080701|NCT02750787|OTHER|Nutritional Study Product|Two 220 ml servings per day
224080702|NCT00929071|DEVICE|Evolence|Injectable collagen
224080703|NCT00929071|DEVICE|Lidocaine|admix anesthetic
224080704|NCT00929071|DRUG|topical anesthetic|
224080705|NCT03856255|DEVICE|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
224080706|NCT02995304|DRUG|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
224080707|NCT02995304|DRUG|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
224080708|NCT02995304|DRUG|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
224080709|NCT03130790|DRUG|Varlitinib|300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
224080710|NCT03130790|DRUG|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
224080711|NCT03130790|DRUG|Placebo|oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
224080712|NCT03130790|DRUG|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
224080713|NCT04206878|DIAGNOSTIC_TEST|Point-of-care birth test|Collect quantitative data through clinical chart and form abstractions; collect qualitative data through in-depth interviews with caregivers, health workers and policymakers
223719523|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)|100 mg subcutaneous (s.c) once
223916805|NCT06397820|DEVICE|Percutaneous coronary intervention (PCI)|Revascularization by percutaneous coronary intervention for vessels with decreased PET-derived flow indexes
223916806|NCT03165955|DRUG|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
223916807|NCT06699199|DRUG|Silver diamine Fluoride 38%|"Intervention is the application of Silver diamine fluoride 38% to children Group in arm 1 (Arm 1): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth~SDF: (Silver diamine fluoride 38% is a material used for arresting caries lesions in primary and permanent teeth)~\- SDF Product generic name and information (E-SDF: it is a 1-step Technique) - The 38% SDF solution comprised a blend of silver, fluoride, and ammonia at a total concentration of 38%."
224080714|NCT01325103|PROCEDURE|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
224080715|NCT01793415|DRUG|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
224080716|NCT01793415|OTHER|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
224080717|NCT03616431|DIAGNOSTIC_TEST|Pancreo-KIT breath test|"Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive)."
224278261|NCT06021106|OTHER|Breathing exercise application with virtual reality glasses|In adapting breathing exercises to virtual reality glasses; The exercise video was first shot by the researcher in front of a green screen. Then, a 3D background design was made by a software developer, a 360-degree printout was taken, and it was converted into a form that can be viewed with glasses. The exercise video is prepared as 20 minutes. Exercises were performed at patients' homes through home visits. A total of 24 sessions of exercises were performed three days a week.
224278262|NCT06021106|OTHER|routine treatment and care|routine treatment and care
224278263|NCT04030013|OTHER|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
223916808|NCT06699199|DRUG|Silver diamine fluoride- potassium iodide|"Intervention is the application of Silver diamine fluoride 38% + potassium iodide to children Group in arm 2 (Arm 2): children will receive Silver diamine fluoride 38% application for 1 min to arrest primary teeth, Followed by an second minute of potassium iodide solution application~\- SDF Product generic name and information (Riva-star: it is a 2-step Technique) 30-35% SDF solution (1st step) comprised a blend of silver, fluoride, and ammonia applied in combination with a second application of potassium iodide solution (2nd step)"
223916809|NCT06701357|DRUG|CR-CHOP+PD1 inhibitor|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； PD1 200mg D1
223916810|NCT06701357|DRUG|CR-CHOP + Orelabrutinib|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Orelabrutinib 150mg/qd D1-21
223916811|NCT06701357|DRUG|CR-CHOP + decitabine|Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Decitabine 10mg/m2 D-5 - -1
223916812|NCT06634004|OTHER|BOLD MRI|The study will utilize the MRI diagnostic reactivity test to evaluate cerebrovascular reactivity in patients with moyamoya and healthy controls. All participants (patients and controls) receive the same diagnostic scan, and there is no cross-over, factorial, or sequential nature to the study.
223916813|NCT05305560|DRUG|Ivermectin Tablets|Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.
223916814|NCT05305560|DRUG|Matching placebo tablets|Daily placebo tablets intake for 28 days
224080718|NCT04845412|DIAGNOSTIC_TEST|Hearing screening tests|"Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device."
224080719|NCT03008395|BEHAVIORAL|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
224080720|NCT03008395|OTHER|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
224080721|NCT01521273|OTHER|Bean varieties|10 x 50 g/ arm
224278264|NCT00079521|PROCEDURE|Therapeutic Touch|
224278265|NCT00661921|BIOLOGICAL|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
224278266|NCT00661921|BIOLOGICAL|Placebo|AMG 108 volume matching placebo
224278267|NCT04654234|DEVICE|Total body PET/CT (uExplorer)|A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.
223719524|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)|200 mg subcutaneous (s.c) once
223719525|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)|300 mg subcutaneous (s.c) once
223719526|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
223719527|NCT05588908|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)|one s.c. injection of SSGJ-613 once, on Day 1.
223916815|NCT06874101|DEVICE|Activated ROAM System with User Feedback|The activated ROAM device will provide the user with daily information about their oxygen therapy usage and pulse oximetry.
223916816|NCT06874101|DEVICE|Sham Comparator|The sham comparator is a ROAM device that monitors oxygen usage, but keeps the usage details blind to the user.
223916817|NCT06693635|DIAGNOSTIC_TEST|Implant planning|The implant planning will be carried out using various software programs. The AI assistance provided by each software will be evaluated.
223916818|NCT06701955|OTHER|Questionnaire and Physical Exam|self administered questionnaires
223916819|NCT06876324|BEHAVIORAL|HealthMPowerment App|A mobile health app designed to facilitate increased PrEP use and adherence among AYAs
223916820|NCT06877507|DEVICE|Gastroscopy|Gastroscopy for all included patients
223916821|NCT06877507|DIAGNOSTIC_TEST|Gas Chromatography - Mass Spectrometry|Using a patient's exhaled breath test with Gas Chromatography - Mass Spectrometry
223916822|NCT06616623|BIOLOGICAL|Atezolizumab|Given IV
223916823|NCT06616623|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
223916824|NCT06616623|PROCEDURE|Computed Tomography|Undergo CT
223916825|NCT06616623|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223916826|NCT06616623|DRUG|Vismodegib|Given PO
223916827|NCT04499521|DEVICE|BrachyGel VHPS|Packing system for administering brachytherapy in cervical cancer patients
223916828|NCT04503694|DRUG|Nivolumab 10 MG/ML Intravenous Solution|"Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~* On day 1 and 15, during the Induction treatment~* On day 29, 43 and 57, during the Consolidation treatment"
224278268|NCT04882137|BEHAVIORAL|Education plus Coaching|Providers in Intervention group will receive standard education (1.5 hr CME), a tip sheet on how to manage side effects for quick reference and a number to directly reach a provider experienced with managing etonogestrel side effects with questions regarding how to manage side effects.
224278269|NCT02902887|DEVICE|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
223719528|NCT05588908|DRUG|Compound Betamethasone Injection (phase II)|1 mL i.m. once on Day 1
223916829|NCT04503694|DRUG|Regorafenib 30 MG Oral Tablet|"Regorafenib will be administered orally once a day at a dose of 60 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~* From day 1 to 14, during the Induction treatment~* From day 29 to 49, during the Consolidation treatment"
223916830|NCT04503694|RADIATION|Radiotherapy|All study subjects will receive 5 daily fractions of radiotherapy. Each fraction will consist of 5 Gy for a total dose of 25 Gy. Radiotherapy is to start on day 22 and to finish on day 26.
223916831|NCT04503694|PROCEDURE|Surgery|Subject will undergo surgical resection of the primary tumour in the rectum between day 74 and 87. Surgery must be performed according to the principles of total mesorectal excision as described by Heald et al. The type of surgical approach (low anterior resection or abdominoperineal resection, etc.) will be left to the discretion of the treating surgeon.
223916832|NCT04503694|PROCEDURE|Non-operative Management|"Subjects who achieve cCR after pre-operative treatment can, after discussion with the local investigator, decline surgery and opt for a non-operative management. cCR will need to be confirmed between day 67 and 74 by the following procedures per local practise:~* Digital rectal examination~* Rectal endoscopy~* Rectal MRI Subjects who achieve near cCR at the first assessment time point after pre-operative treatment, can be re-assessed 6 to 8 weeks later with the same procedures. If cCR is diagnosed, they can opt for watch \& wait, otherwise they would need to undergo surgical resection.~Subjects who opt for a non-operative management will be followed for tumour recurrence and survival for 5 years after end of treatment visit. Follow-up for these subjects will be more intensive than that for subjects undergoing surgery"
223940413|NCT03684993|DRUG|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
223940414|NCT03684993|DRUG|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
223940415|NCT03684993|DRUG|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
223940416|NCT04633148|DRUG|Cyclophosphamide (Non-IMP)|Intravenous infusion for 3 days
223940417|NCT04633148|DRUG|Fludarabine (Non-IMP)|Intravenous infusion for 3 days
223940418|NCT04633148|DRUG|UniCAR02-T-pPSMA|Intravenous Infusion for 21 days
223940419|NCT04633148|DRUG|UniCAR02-T (IMP)|Intravenous infusion of single dose
223940420|NCT00003459|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
223940421|NCT03088800|DRUG|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
223940422|NCT03088800|DRUG|APAP|Oral APAP at 15mg/kg dose
223940423|NCT06067776|BIOLOGICAL|Cetuximab|Given IV
223940424|NCT06067776|DRUG|Osimertinib|Given PO
223940425|NCT06067776|DRUG|Tucatinib|Given PO
223940426|NCT06487702|DRUG|fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium|"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"
223940427|NCT03582475|DRUG|Carboplatin|Given IV
223940428|NCT03582475|DRUG|Cisplatin|Given IV
223940429|NCT03582475|DRUG|Docetaxel|Given IV
223940430|NCT03582475|DRUG|Etoposide|Given IV
223940431|NCT03582475|BIOLOGICAL|Pembrolizumab|Given IV
223940432|NCT04346875|PROCEDURE|Regularly changing of dressing|Conventional dressing
223940433|NCT04346875|PROCEDURE|No application|No dressing change
223940434|NCT03363945|BIOLOGICAL|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
223940435|NCT01706159|DRUG|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
223716561|NCT06830369|DEVICE|HypnoVR|In the intervention group, after extubation, patients will receive IVR with HypnoVR®, twice-a-day over two to five days. The product consists of HypnoVR® virtual reality software and HypnoVR® Compagnon remote control software. HypnoVR® is a CE-marked class 1 medical device, developed and marketed by HypnoVR SAS, an ISO 13484:2016 and ISO 27001:2017 certified company. The device works with a virtual reality headset, a personal audio device and a mobile terminal. The investigators will only use sessions of 10 to 20 minutes. For each type of session, a visual universe, a musical atmosphere and a male or female voice are defined. Typically, the scenarios include 3 phases: preparation, hypnosis and return. We will use the following sessions: anxiety, pain, rehabilitation.
223716562|NCT06830369|OTHER|usual health care|usual health care
223916833|NCT06876051|BEHAVIORAL|Relaxation & Breastfeeding Education|"Pregnant women in this group will be trained in 10 individual interactive sessions, focusing on relaxation techniques and breastfeeding including:~1. Diaphragmatic breathing~2. Progressive muscle relaxation (PMR) - tailored for pregnant women.~3. Guided imagery~4. the analysis of the concept of stress and stress management strategies for pregnancy including Cognitive-behavioral approach (CBT principles)~5. Mindfulness-based pregnancy adaptation including positive thinking and wellbeing during pregnancy .~6. Pregnancy stages.~7. Benefits of breastfeeding.~8. Breastfeeding guide and practical applications.~9. Labor stages and childbirth preparation.~10. Newborn and infant needs at home Every relaxation technique training will last 20 minutes practice in every session Additionally pregnant women will be practiced at least 3 times weekly during pregnancy"
223916834|NCT06876051|BEHAVIORAL|Active comparator|"Participants in this group will receive only interactive online education, focusing exclusively on breastfeeding and newborn care. The Programme included ten remote sessions:~1. Pregnancy stages.~2. Benefits of breastfeeding.~3. Skin-to-skin contact and rooming-in during the first days.~4. The role of breastfeeding in maternal emotional well-being.~5. Breastfeeding guide and practical applications.~6. Maternal nutrition during breastfeeding.~7. Common breastfeeding challenges.~8. The father's role in breastfeeding support.~9. Labor stages and childbirth preparation~10. Newborn and infant needs at home."
223716563|NCT01174303|DRUG|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
223716564|NCT01174303|DRUG|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
223716565|NCT02529345|DEVICE|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
223716566|NCT02290561|PROCEDURE|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
223716567|NCT02290561|DEVICE|MRI|
223716568|NCT02290561|DEVICE|high intensity focused ultrasound (HIFU)|
223716569|NCT02894918|DRUG|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
223716570|NCT00438698|OTHER|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
223716571|NCT00438698|OTHER|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
223716572|NCT05412654|DIETARY_SUPPLEMENT|High potassium water|High potassium water Potassium 6.2 mg/100ml
223716573|NCT05412654|DIETARY_SUPPLEMENT|Control low potassium water|Control water Potassium 0.2 mg/100ml
223716574|NCT01883830|DEVICE|gaming therapy (Xbox)|
223716575|NCT01883830|DEVICE|Dynamic balance platform (Biodex)|
223716576|NCT05798832|OTHER|Virtually reality training group|BLS Training with VR
223716577|NCT05798832|OTHER|Traditional training group|BLS Training with Traditional
223716578|NCT05489510|COMBINATION_PRODUCT|Pulsed or continuous lighting|The cross-linking procedures will be performed on an outpatient basis using the PXL Platinum 330 System (UVA light source and riboflavin solution).
223716579|NCT01354977|DRUG|Resveratrol|1,000mg twice daily for 28 days
223716580|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
223716581|NCT03478358|DRUG|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
223940436|NCT01706159|DRUG|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
223940437|NCT04505358|DRUG|PU-AD|active vs placebo
223940438|NCT04505358|DRUG|Placebo|active vs placebo
223940439|NCT06212297|GENETIC|LX101|Subretinal administration of LX101 to the contralateral, previously uninjected eye
223940440|NCT06212479|DIAGNOSTIC_TEST|MRI Scan|Whole Body MRI Scan
223940441|NCT04816955|BEHAVIORAL|Dietary recommendations|Dietary recommendations, with increasing additional behavioural/practical advice or no dietary recommendations
223716582|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
223716583|NCT03478358|DRUG|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
223716584|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and amino acids (lysine and arginine).
223716585|NCT03478358|DRUG|3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)|The patients were intravenously injected with 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine).
223716586|NCT00651794|BEHAVIORAL|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
223716587|NCT00651794|BEHAVIORAL|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
223916835|NCT06876051|OTHER|control group|This group will received only standard prenatal and postnatal care at a Baby-Friendly Hospital, which adheres to WHO and UNICEF guidelines for breastfeeding support. They did not participate in additional structured educational programs or relaxation training.
223916836|NCT06726850|DRUG|Placebo|In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
223916837|NCT06726850|DRUG|GS1-144|In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
223716588|NCT00651794|BEHAVIORAL|Skills practice with low-fidelity mannequin|
223916838|NCT06721572|DEVICE|TEA|Active TEA or sham TEA will be self-administered at home over two daily treatment sessions of 30 minutes each in the morning and evening. Active TEA will be delivered through an active stimulation acupoint that has previously shown to reduce abdominal pain in other patient populations. Sham TEA will be administered at a different point a few cm away from the active site and that has been shown to be ineffective in reducing pain. Other than the location, the anatomical location, application of TEA and sham will be identical. The device will be programmed by the study team to generate fixed frequency, pulse width, and time on/time off during the pulsed stimulation. The subject is only able to change the stimulation output in a range from 0-10 milliampere.
223916839|NCT06648564|PROCEDURE|Bone regenerative surgery with a bone graft substitute and a resorbable membrane|Dental implants with a diagnosis peri-implantitis were treated with regenerative surgery.
223716589|NCT00651794|BEHAVIORAL|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
223716590|NCT02644733|PROCEDURE|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
223916840|NCT05525104|DEVICE|Narcotrend Monitor (MT MonitorTechnik, Hannover, Germany)|"This trial is designed to investigate the additional value of Density Spectral Array monitoring, on the speed of emergence after general anaesthesia. We will compare traditional general anaesthesia with sevoflurane using a MAC value and subjective clinical parameters to the objective and continuous approach using DSA depth of hypnosis. The investigational product is the validated Narcotrend monitor, an electroencephalographic monitor, that is regularly used in anaesthesia practice in the Sophia children's hospital and will be used according to intended purpose. The extended version as used in the operating room in the Sophia Children's hospital offers a diversity of diagrams including Density Spectral Array.~The electroencephalographic Narcotrend monitor records frontal EEG-activity. Standard paediatric ECG electrodes are used for EEG registration"
223916841|NCT06346704|OTHER|Digital HealthTechnology|Subject will wear the Syde® for 1 month every 6 months
223916842|NCT06602466|DRUG|Test toothpaste|0.454% Stannous Fluoride, 0.3% Zinc Chloride,1% Alumina toothpaste containing 1100 parts per million (ppm) fluoride.
223916843|NCT06602466|DRUG|Colgate Cavity Protection Toothpaste|Commercial toothpaste containing 1450 ppm fluoride.
223916844|NCT06882434|BEHAVIORAL|Local intervention program|"HI-HOPE Project introduces a three-phase intervention program Phase 1: Active Mind \& Body (12 Weeks) Focus: Cognitive enhancement, depression relief, and music-based movement therapy.~Delivery: Certified community instructors. Schedule: 1 session/week, 2 hours per session (total 12 sessions). Supplementary Exercise: High-intensity training by professional coaches (1 session/week, 1 hour per session).~Phase 2: Complete Senior Wellness (12 Weeks) Focus: Comprehensive functional improvement covering all six ICOPE domains. Delivery: Certified community instructors. Schedule: 1 session/week, 2 hours per session (total 12 sessions). Supplementary Exercise: High-intensity training by professional coaches (1 session/week, 1 hour per session).~Phase 3: Advanced Exercise Training (12 Weeks) Focus: Strengthening self-care abilities and increasing acceptance of medical interventions.~Delivery: Professional exercise coaches. Schedule: 2 sessions/week, 1 hour per session (total 24 sessions)."
223940442|NCT01121965|PROCEDURE|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
223940443|NCT00553332|DRUG|selumetinib|Given orally
223940444|NCT00553332|OTHER|laboratory biomarker analysis|Correlative studies
223940445|NCT06178952|DEVICE|Transcranial pulse stimulation Verum|Participants are slated to undergo a total of five TPS sessions over a 10-day interval. Each stimulation session will endure approximately 30 minutes and will be administered once daily.
224080722|NCT04835285|DIAGNOSTIC_TEST|Npf.|3T MRI and 1,5 T MRI scanners. For myocardium, pancreas and pituitary gland iron overload
224080723|NCT01851408|DRUG|sorafenib tosylate|Given orally
224080724|NCT01851408|DRUG|temsirolimus|Given IV
224080725|NCT03690310|BIOLOGICAL|Anti-CD19 CAR NK Cells|Anti-CD19 CAR NK Cells injection
223716591|NCT02644733|PROCEDURE|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
223716592|NCT03600545|OTHER|Brain Fitness App|Brain exercises using an iPAD
224080726|NCT05210179|BIOLOGICAL|TURKOVAC-Dollvet|TURKOVAC-Dollvet vaccines produced by Dollvet Veterinary Vaccine Pharmaceutical Biological Substance Production Industry Co., Ltd.
224080727|NCT05210179|BIOLOGICAL|TURKOVAC-Koçak|TURKOVAC-Koçak vaccines produced by Koçak Farma Pharmaceutical and Chemical Industry Co., Ltd.
224080728|NCT00883675|DRUG|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
224080729|NCT00197197|DRUG|GW873140|
224080730|NCT04743557|DRUG|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 pre-mRNA
224080731|NCT03333070|DIETARY_SUPPLEMENT|probiotic - Lactobacillus reuteri|The treated arm will receive 5 drops per day for 48 weeks
224080732|NCT03333070|OTHER|placebo - with no active ingredient|The control arm will receive 5 drops per day for 48 weeks
224080733|NCT06548763|DRUG|Topotecan|1.4mg/㎡, orally administered, d1-5
224080734|NCT06548763|DRUG|Toripalimab|240mg, intravenous drip, d1, q3w
224080735|NCT02776241|OTHER|water|
224080736|NCT03884400|PROCEDURE|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
224080737|NCT00984750|DRUG|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
224080738|NCT00984750|DRUG|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
223916845|NCT06882434|BEHAVIORAL|Referral Process|"Self-referral tracking (1-2 weeks): Participants able to visit referral sites independently will be followed up to confirm completion.~Barrier assessment: If unable to attend, interviews will identify obstacles (e.g., transport, finances, willingness).~Transportation support: Solutions include volunteer transport with fuel subsidies, local transport networks, and government-assisted group referrals.~Financial assistance: Eligibility for social welfare aid will be assessed, with support for applications.~Personal willingness \& health literacy: Health education will address concerns about treatment or social stigma.~Telehealth consultations: Remote specialist consultations will be provided if in-person visits are not possible.~Hospital-based referral support: Group hospital visits will be arranged for those with referral difficulties.~Monthly tracking: Referral completion rates and outcomes will be monitored (e.g., treatments, assistive devices, social services)."
224080739|NCT00364689|DRUG|Rifaximin|
224080740|NCT00364689|DRUG|Lactulose|
224080741|NCT00364689|OTHER|Placebo|
224080742|NCT00841737|OTHER|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
224080743|NCT00841737|OTHER|Control Group|In the control group the depression is treated as usual with the conventional treatment.
224080744|NCT04545905|DIAGNOSTIC_TEST|ANC surveillance|Clinic-based testing of all pregnant women during antenatal care visits.
224080745|NCT04553211|BEHAVIORAL|EPT|Expedited Partner Therapy (EPT) involves provision of empiric oral antibiotic therapy to the recent sexual partners of an individual diagnosed with gonorrhea and/or chlamydia infection.
224080746|NCT05611957|DRUG|LY3437943|Administered SC.
224080747|NCT05325775|DRUG|ACER-801 50 mg BID|50 mg BID (twice daily)
224080748|NCT05325775|DRUG|ACER-801 100 mg BID|100 mg BID (twice daily)
224080749|NCT05325775|DRUG|ACER-801 200 mg BID|200 mg BID (twice daily)
224080750|NCT05325775|DRUG|Placebo|Placebo
224080751|NCT00276575|BIOLOGICAL|bevacizumab|
224080752|NCT00276575|DRUG|erlotinib hydrochloride|
224080753|NCT00276575|DRUG|everolimus|
224080754|NCT03887299|COMBINATION_PRODUCT|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
224278270|NCT04814459|OTHER|HOP-UP-PT Program|Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
224278271|NCT04380675|OTHER|Music|Music listening during ESWL
224278272|NCT04865484|PROCEDURE|Surgical resection|Surgical resection of fibrostenotic area (\>4cm)
223716593|NCT05715034|BEHAVIORAL|Compassionate Care|Single-session web-based program
223716594|NCT05715034|BEHAVIORAL|Relaxing with Nature|Single-session web-based program
223716595|NCT03718585|OTHER|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
223716596|NCT01495117|DRUG|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
224080755|NCT03887299|OTHER|Standard Wound Care|Wound care will be administered as standard protocol in our institution
224080756|NCT03473561|DRUG|Racecadotril plus ORS|"1.5 mg/kg of Racecadotril will be administered, 3 times daily, via the oral route (in addition to standard treatment i.e. oral rehydration solution).~In infants less than 9 kg: one 10 mg sachet 3 times daily. In infants from 9 kg to \< 13 kg: two 10 mg sachets 3 times daily. In children from 13 kg to 27 kg: one 30 mg sachet 3 times daily. In children of more than 27 kg: two 30 mg sachets 3 times daily."
224080757|NCT02760082|OTHER|Qualitative evaluation|
224080758|NCT04095169|DIAGNOSTIC_TEST|Complement C3d test (blood sample)|Evaluation of C3d levels in EDTA samples from participants
224080759|NCT00191451|DRUG|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
224080760|NCT00191451|DRUG|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
224080761|NCT00191451|DRUG|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
224080762|NCT00003160|DRUG|paclitaxel|
224080763|NCT02755194|OTHER|No intervention|This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
224080764|NCT02441504|OTHER|Low intensity Exercise|aerobic exercise training using walking and running
224080765|NCT05565963|OTHER|Virtual reality exercise intervention|The experimental group received VR exercise sessions for 75-90 minutes, twice a week for a duration of 12 weeks.
224080766|NCT03650998|DRUG|Ropivacaine|See arm description
224080767|NCT03650998|DRUG|Saline|See arm description
224080768|NCT01114529|DRUG|Everolimus|Early CNI to everolimus conversion
224080769|NCT01114529|DRUG|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
224080770|NCT00592475|DRUG|conivaptan|IV
224080771|NCT00592475|DRUG|Placebo|IV
224080772|NCT06240910|OTHER|Neurodynamics|Neuro dynamics involving Stretching and gliding of the Sciatic nerve (performing each exercise for 30 s at a slow and comfortable pace of 1 repetition per \~3-4 s. The participants rested for 60 s between each exercise.
224080773|NCT06240910|OTHER|Aerobic training|Aerobic exercise will involve warm-up by stretching and flexibility exercises for 5 minutes, Treadmill walking for 6 minutes, and Stationary bicycle for 6 minutes
224080774|NCT00356031|DRUG|Bevacizumab|Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
224278273|NCT04865484|PROCEDURE|Endoscopic stricturotomy|Endoscopic stricturotomy of fibrostenotic area (≤4cm)
223916846|NCT06882434|BEHAVIORAL|Telehealth Education & Digital Integration|"Live-streamed health education across multiple community sites.~Digital health platforms for real-time intervention monitoring and professional feedback:~Polypharmacy management via medication usage tracking and pharmacist analysis. Nutritional assessment with dietitian recommendations. Health consultations provided remotely by specialists based on screening results."
223916847|NCT04678856|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
223916848|NCT04678856|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
223916849|NCT06809751|DRUG|melatonin 3mg|In this group, participants will be randomly assigned to take 3 mg tablets of melatonin twice a day for 1 month.
223916850|NCT06809751|DRUG|Placebo Drug|The placebo is also prepared in the form of tablets with similar packaging as melatonin by the pharmaceutical company. Participants will be randomly assigned to take placebo with the same frequency and duration as melatonin (twice a day for 1 month).
223916851|NCT06809075|PROCEDURE|hematopoietic precursor transplantation (TPHa)|An apheresis is performed on the patients and a selection of CD34 hematopoietic progenitors is performed. Subsequently, conditioning is performed with cyclophosphamide, thymoglobulin, corticosteroids and rituximab to subsequently infuse the hematopoietic precursors.
224278274|NCT04865484|PROCEDURE|Strictureplasty|Strictureplasty of fibrostenotic area (≤4cm)
223916852|NCT06811142|DRUG|Botulinum Toxin Type A (BoNT-A)|This intervention involves the early administration of botulinum toxin type A (BoNT-A) within the first 12 weeks after a cerebrovascular event. The injections target muscles affected by spasticity, aiming to reduce abnormal tone, prevent contractures, and improve functional mobility. BoNT-A works by blocking acetylcholine release at the neuromuscular junction, resulting in muscle relaxation. Ultrasound guidance or anatomical landmarks will be used for accurate injection. This early intervention capitalizes on the neuroplastic window and is combined with standard rehabilitation to enhance motor recovery and prevent long-term complications.
223916853|NCT06857604|OTHER|Biological samples|Immunological Screening and Genetic analysis
223916854|NCT04351256|DRUG|Durvalumab Injection [Imfinzi]|Durvalumab fixed dose of 1,500 mg
223916855|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) conventionally|Conventionally fractionated TRT consisting of 30 x 2 Gy (60 Gy) within 6 weeks
223916856|NCT04351256|RADIATION|Thoracic Radiotherapy (TRT) hypofractionated|Hypofractionated TRT consisting of 20 x 2,75 Gy (55 Gy) within 4 weeks
223916857|NCT04905238|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure
223916858|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
223916859|NCT04751851|BEHAVIORAL|Long duration withdrawal programme with ACT|"* 10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.~* 8 individual weekly ACT sessions. The ACT programme includes mindfulness, acceptance and thoughts defusion exercises, identification of personal values and promotion of actions committed to these values. It also includes sleep restriction, a component of CBT for insomnia, used in this protocol to carry out committed-actions, according to the principles of ACT."
223916860|NCT04751851|BEHAVIORAL|Medium duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 6 weeks.
223916861|NCT04751851|BEHAVIORAL|Long duration withdrawal programme without ACT|10 interviews of withdrawal monitoring and psychological support during a taper programme of 18 weeks.
223916862|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Palbociclib|Continuation of CDK4/6 inhibitor Palbociclib
223916863|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Palbociclib|Discontinuation of CDK4/6 inhibitor Palbociclib
223916864|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor -Palbociclib|Continuation of CDK4/6 inhibitor -Palbociclib
223916865|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor -Palbociclib|Discontinuation of CDK4/6 inhibitor -Palbociclib
223916866|NCT06207734|DRUG|Continuation of CDK4/6 inhibitor Abemaciclib|Continuation of CDK4/6 inhibitor Abemaciclib
223916867|NCT06207734|DRUG|Discontinuation of CDK4/6 inhibitor Abemaciclib|Discontinuation of CDK4/6 inhibitor Abemaciclib
223916868|NCT04637282|DRUG|PLX-200|15 mg/mL oral solution of experimental drug
223916869|NCT04637282|DRUG|Placebo|Taste and color-matched drug-free solution
223916870|NCT01504789|BEHAVIORAL|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
223916871|NCT01504789|BEHAVIORAL|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
224278275|NCT04449536|DRUG|Mesna|Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
224278276|NCT01891812|DRUG|Nitrous oxide 50%|
224278277|NCT00144833|DRUG|fosamprenavir/ritonavir (700mg/100mg BID)|
224278278|NCT00144833|DRUG|fosamprenavir/ritonavir (1400mg/100mg BID)|
224278279|NCT00144833|DRUG|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
224278280|NCT04689100|DRUG|JMT101|Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
224278281|NCT04689100|DRUG|JMT101|IV infusion Q2W (28-day cycles)
224278282|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Quadriceps Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using only the tendon portion of the quadriceps tendon (without bone fragments) in this group.
223716597|NCT01495117|DRUG|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
224278283|NCT06617559|PROCEDURE|Anterior Cruciate Ligament Reconstruction with Hamstring Autograft|The investigators will perform all-inside anterior cruciate ligament reconstruction using the hamstring tendon as a graft in this group.
224278284|NCT06394115|DEVICE|Ostomy pouch|Ostomy pouch coated with novel technology
223716598|NCT04638933|OTHER|No intervention|No intervention
223716599|NCT00949520|OTHER|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
223716600|NCT00949520|OTHER|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
223916872|NCT01504789|BEHAVIORAL|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
223916873|NCT01504789|BEHAVIORAL|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
223916874|NCT04671303|DRUG|Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate|"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."
223916875|NCT04705220|DIETARY_SUPPLEMENT|MERIVA® Tablets|The treatment corresponds to 1 g / day of experimental product (corresponding to about 200 mg of curcuminoids).
223916876|NCT04705220|OTHER|Placebo Tablets|The composition of placebo includes the same components of the treatment tablets, except for the active substance.
223916877|NCT05930509|DEVICE|Non-invasive transcranial direct current stimulation (tDCS)|Electrical stimulation
223916878|NCT05163639|PROCEDURE|Non-invasive pairing of cortical and spinal stimulation|Transcranial magnetic stimulation (TMS) threshold, Transcutaneous spinal cord stimulation (TSCS) threshold, and peripheral and central motor conduction times will be determined. In the active intervention, two TMS pulse intensities will be tested: 90% and 120% of motor threshold. Two conditioning TSCS pulse intensities will be tested: 50% and 90% of response threshold. Single TSCS pulses will be delivered timed to arrive in the cervical spinal cord at a range of intervals from 30ms before to 30ms after the TMS pulse. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
223916879|NCT05163639|PROCEDURE|Intraoperative pairing of cortical and spinal stimulation|The surgeon will position spinal cord electrodes on the epidural surface one level rostral (typically C4/C5) to the site of myelopathy. Spinal and cortical thresholds will be determined. Investigator will then test the immediate effects of paired stimulation by stimulating the cortex at 120% of threshold and the spinal cord at 90% of threshold at various latencies relative to the time of synchronous convergence. The control intervention will include cortical only (120%) spinal only (90%) and non-convergent latency pairing stimulation.
223940446|NCT06178952|DEVICE|Transcranial pulse stimulation Sham|Placebo treatment will be performed using the same medical device, handpiece and treatment paradigm as in the verum treatment with one difference: the standoff device at the end of the handpiece. This device is designed to replicate the appearance, feel, and sound of the verum system, while omitting the transmission of any pulses.
223940447|NCT06363617|OTHER|FLI|Health professionals will use the FLI test in their clinical practice
224278285|NCT01841060|PROCEDURE|Percutaneous radiofrequency ablation (RFA)|Computed tomography (CT) was used to treat tumors under general anesthesia. Thoracic epidural anesthesia was administered in case of contraindication to general anesthesia mostly due to poor respiratory function. All patients were treated with the same multitine electrodes (LeVeen; Boston Scientific, Nattick. MA) measuring 3, 3.5, or 4 cm in diameter and at least 10 mm larger than the diameter of the target tumor. Multiple overlapping ablations were performed, when needed, in different parts of the tumor in order to cover the entire volume.
223716601|NCT03724760|OTHER|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
223716602|NCT02140372|DRUG|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
223716603|NCT03973996|DIETARY_SUPPLEMENT|Green Tea Extract|A gummy confection with catechin-rich green tea extract (1 g/d)
223716604|NCT03973996|DIETARY_SUPPLEMENT|Placebo|A matched gummy confection formulated without green tea extract
223716605|NCT02469298|DRUG|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
223716606|NCT02469298|DRUG|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
223716607|NCT02469298|DRUG|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
223716608|NCT02469298|DRUG|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
223716609|NCT04249583|BIOLOGICAL|botulinum toxin|neuromodulator to be injected in the GL region
223716610|NCT04249583|BIOLOGICAL|Placebo|Placebo to be injected in the GL area
223716611|NCT04388618|OTHER|NHANES smell and taste tests|participants will be asked to smell 8 cards of different odors and submit your choices in a given card, and so for 3 different taste tips (salty, bitter and neutral). participants will be asked to submit his choices in a given card as well. Then participants photograph those cards and send it via WhatsApp to a given number to be collected
223716612|NCT06058481|DEVICE|Blockbuster|The investigator inserted the BlockBuster in Group A patients.
223716613|NCT06058481|DEVICE|Proseal-LMA|The investigator inserted the Proseal-LMA in Group B patients.
223716614|NCT06158789|PROCEDURE|MR guided low intensity focused ultrasound|Low intensity focused ultrasound opens the blood brain barrier
223716615|NCT02562053|DRUG|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
224278286|NCT03879486|OTHER|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
224278287|NCT04458168|BEHAVIORAL|Use of Purposeful app|"Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment."
224278288|NCT01467596|DEVICE|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
224278289|NCT06058364|DIETARY_SUPPLEMENT|Intervention 1 - Triglyceride|Triglyceride (1 softgel each morning with a glass of water)
224278290|NCT06058364|DIETARY_SUPPLEMENT|Intervention 2 - Placebo|Placebo (1 softgel each morning with a glass of water)
224278291|NCT00915434|DRUG|JNJ-31001074|
224278292|NCT00462891|OTHER|IT System|
224278293|NCT00736918|BEHAVIORAL|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
224278294|NCT00736918|OTHER|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
223916880|NCT05163639|PROCEDURE|Non-invasive repeated pairing of cortical and spinal stimulation (SCAP)|Thresholds will be determined as above. Immediately prior to repetitive pairing, a set of 12 TMS pulses will be delivered at 120% threshold to measure the baseline cortical MEP. Likewise, a set of 12 TSCS pulses will be delivered at 120% of threshold to establish the baseline spinal MEP. For each session, baseline maximal pinch dynamometry will be determined. Immediately after the SCAP protocol is completed, response to TMS, TSCS, and maximal pinch dynamometry will be measured again every 10 minutes over the subsequent hour. The control conditions will include TMS only TSCS only and non-convergent pairing latency pairing stimulation.
223916881|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)|Intraoperative: Spinal and cortical thresholds will be determined. Immediately prior to repetitive pairing, a set of 12 baseline cortical pulses and 12 baseline spinal pulses will be delivered at 120% threshold. SCAP protocol will be applied, both of which have been successful at inducing lasting effects in the rat. After pairing, cortical stimulation at 120% of threshold and spinal cord stimulation at 120% threshold will be repeated every 10 minutes for the duration of surgery. In a subset of patients repeated pairing will be conducted with a latency that investigator does not expect will induce SCAP, or with electrodes placed over the ventral epidural surface. The control intervention will include repeated pairing at a non-convergent latency, as well as pairing of cortical stimulation with ventral epidural stimulation.
224278295|NCT01731249|BIOLOGICAL|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
224278296|NCT01731249|BIOLOGICAL|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
224278297|NCT04897113|PROCEDURE|plasma exchange with albumin|plasma exchange with albumin, two per week, 110% of the circulating plasma volume
224278298|NCT04897113|PROCEDURE|plasma exchange without albumin|plasma exchange without albumin, two per week, 110% of the circulating plasma volume
224278299|NCT00440622|DRUG|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
224278300|NCT00440622|DRUG|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
224278301|NCT00440622|DRUG|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
224278302|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
224278303|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
224278304|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
224278305|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
224278306|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
224278307|NCT00856713|DRUG|NRL972|Single intravenous dose of 2 mg NRL972
224278308|NCT00653159|DEVICE|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
224278309|NCT00653159|DEVICE|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
224278310|NCT05680779|OTHER|ultrasound-guided percutaneous neuromodulation|It´s an intervention of physiotherapy
224278311|NCT05680779|OTHER|dry needling|It´s an intervention of physiotherapy
224278312|NCT00963651|DEVICE|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
223530205|NCT05169346|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
223916882|NCT05163639|PROCEDURE|Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region|As per the intervention 'Intraoperative repeated pairing of cortical and spinal stimulation (SCAP)' targeted at or below myelopathic region.
223916883|NCT06517082|OTHER|Artificial Intelligence|Ambient AI software intervention is implemented into the providers workflow. The software incorporates Automated Speech Recognition technology with Large Language Models to generate clinical documentation in real-time.
223916884|NCT05713006|DRUG|Alectinib Oral Product|Alectinib is administered with a sequential dose escalation every 21 days from 300 to 600mg twice daily in the phase 1 portion. In phase 2, patients received an investigator-chosen dose based on the PK analysis.
223916885|NCT06088381|OTHER|Experimental Observation|Patients on the experimental arm will be under observation only.
223916886|NCT06088381|OTHER|Observation per Standard of Care|The low-risk group of patients will be observed per standard of care.
223916887|NCT06088381|RADIATION|Adjuvant Treatment per Standard of Care|The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)
223916888|NCT06088381|DIAGNOSTIC_TEST|Circulating Tumor DNA test (ctDNA test)|Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
223916889|NCT06790368|BIOLOGICAL|VENOX|Treatment with allergy vaccine against Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
223916890|NCT04729933|DEVICE|V-Wave Shunt Placement|After the MitraClip Placement and after final screening, the existing transseptal puncture used for MitraClip placement is used to place the V-WAVE Shunt device.
223916891|NCT06834386|OTHER|Best Practice|Receive standard of care
224278313|NCT05258630|BEHAVIORAL|Diabetes Homeless Medication Support (D-Homes)|There will be 10 sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool to the patient's needs/goals and tailored diabetes education as needed.
224278314|NCT05258630|BEHAVIORAL|Enhanced usual care|Trained diabetes wellness coaches will provide an approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will read these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
224278315|NCT01926275|DEVICE|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
223916892|NCT06834386|OTHER|Electronic Health Record Review|Ancillary studies
223916893|NCT06834386|OTHER|Interview|Ancillary studies
224278316|NCT01926275|DEVICE|NPPV|noninvasive positive pressure ventilation
224278317|NCT01926275|DEVICE|IMT|inspiratory muscle training
223916894|NCT06834386|OTHER|Questionnaire Administration|Ancillary studies
223916895|NCT06834386|DRUG|Suvorexant|Given PO
223916896|NCT06953635|PROCEDURE|Quadratus Lumborum (QL) Block|"The intervention arm will receive bilateral quadratus lumborum blocks in the preoperative holding area prior to surgery. The syringe will contain a total of 60 mL of 0.25% Ropivacaine with 4 mg of Decadron. The anesthesiology pain team provider will administer 30 mL on the left side and 30 mL on the right side of the abdominal wall. The patient will receive one injection site per flank. During the procedure, the patient is placed in the left and then right lateral decubitus position and the ultrasound probe is placed above the iliac crest at the mid axillary line. The pain team provider will move the probe posteriorly to identify the shamrock sign. Under ultrasound guidance, a needle is inserted in an in- plane approach through the quadratus lumborum (QL) muscle until reaching the middle of the thoracolumbar fascia layer between QL and psoas muscle. After negative aspiration for blood, injection will allow the spread of local anesthetic between the QL and psoas muscle on each side."
223916897|NCT06953635|PROCEDURE|Placebo|"The placebo control group will receive the same quadratus lumborum (QL) block procedure as the intervention group, with the only difference being the injection of 60 mL of saline instead of local anesthetic. The anesthesiology team will administer 30 mL on each side of the abdominal wall, with one injection site per flank. The patient will be positioned in the left and right lateral decubitus positions, and the ultrasound probe will be placed above the iliac crest at the mid-axillary line to identify the shamrock sign. The needle will be inserted through the QL muscle to the thoracolumbar fascia layer, between the QL and psoas muscle. After negative aspiration for blood, saline will be injected, allowing spread between the QL and psoas muscle on each side."
223916898|NCT06953362|DEVICE|Direct Neural Electrical Stimulation|We are not delivering treatment in this study. Direct neural electrical stimulation is being administered to determine its effect on neural circuit activity and connectivity.
223916899|NCT04804605|DRUG|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%|ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
223916900|NCT02914483|BEHAVIORAL|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
223916901|NCT02914483|BEHAVIORAL|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
223530206|NCT05169346|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
223716616|NCT02562053|DRUG|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
224278318|NCT03666481|BEHAVIORAL|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
224278319|NCT04405908|BIOLOGICAL|SCB-2019|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
223916902|NCT02914483|DIAGNOSTIC_TEST|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
223916903|NCT05425615|DEVICE|Transcranial Magnetic Stimulation|Deymed DuoMag XT-100 rTMS
223916904|NCT04389957|OTHER|Veterans Affairs Endoscopy Quality Improvement Program (VA-EQuIP)|We created an innovative informatics framework for centralized reporting of colonoscopy quality across the VA, facilitating the implementation of the VA Endoscopy Quality Improvement Program (VA-EQuIP). The VA-EQuIP quality dashboard (updated at 6 month intervals) provided adenoma detection rates (ADR), bowel preparation quality, and cecal intubation rate to every facility.This initiative directly addressed the OIG's recommendations and the VA's urgent need for evidence-based colonoscopy quality measurement and reporting. Through VA-EQuIP, we provided bi-annual audits and feedback on colonoscopy quality for VA sites and endoscopists, along with individual provider benchmarking against local and national performance standards. Additionally, we organized collaborative learning sessions led by national experts in colonoscopy training and quality. These sessions focused on shared learning, featuring lectures, discussions, skill-building activities, and work on quality improvement projects.
223916905|NCT06167655|DEVICE|Neurostimulator|Neurostimulation system that applies stimulation to nerve pathways in the head associated with migraine symptoms.
223916906|NCT06813001|OTHER|ACT-based nursing intervention|ACT-based nursing intervention is a 1:1 single online session with a nurse, which takes about 60 minutes followed by a daily self-monitoring survey for one week, which encourages patients to practice ACT.
223916907|NCT06815406|PROCEDURE|Endoscopic Mucosal Resection (EMR)|atients assigned to this arm will undergo Endoscopic Mucosal Resection (EMR), a standard endoscopic technique that involves the resection of colorectal Laterally Spreading Tumors - Granular type (LST-G) using a diathermic snare with submucosal injection. The procedure may be performed en bloc or in a piecemeal fashion, depending on lesion size and characteristics. EMR is widely accepted for lesions with low submucosal invasion risk but has a higher recurrence rate than ESD.
224278320|NCT04405908|BIOLOGICAL|SCB-2019 with AS03 adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with AS03 adjuvant.
223916908|NCT06815406|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Patients assigned to this arm will undergo Endoscopic Submucosal Dissection (ESD), an advanced endoscopic technique that allows for en bloc resection of large colorectal Laterally Spreading Tumors - Granular type (LST-G). The procedure involves the use of specialized knives to dissect the submucosal layer, ensuring complete resection with histologically clear margins (R0 resection). ESD has been associated with lower recurrence rates but requires a high level of expertise, longer procedural times, and carries a higher risk of complications.
224278321|NCT04405908|BIOLOGICAL|SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant|SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22), and administered with CpG 1018 plus Alum adjuvant.
224278322|NCT04405908|BIOLOGICAL|SCB-2019 with Alum adjuvant|SCB-2019 intramuscular vaccinations at 9 µg twice (on Day 1 and Day 22), and administered with Alum adjuvant.
224278323|NCT00363155|DRUG|KRN7000|
224278324|NCT02893995|DRUG|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
224278325|NCT02893995|DRUG|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
224278326|NCT00836147|DRUG|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
224278327|NCT00836147|DRUG|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
224278328|NCT00109837|BIOLOGICAL|filgrastim|As needed per physician discretion
224278329|NCT00109837|DRUG|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
224278330|NCT00109837|DRUG|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
224278331|NCT00109837|DRUG|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
223716617|NCT02562053|DRUG|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
223716618|NCT02562053|DRUG|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
224278332|NCT00109837|DRUG|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
223916909|NCT06040840|PROCEDURE|BAX|Injection of 30 mL of lidocaine (10 mg/ml) around the median, radial, ulnar and musculocutaneous nerves.
223916910|NCT06040840|PROCEDURE|Tourniquet|Inflation pressure 75 to 100 mmHg above the patient's systolic blood pressure.
223916911|NCT06040840|DRUG|Lidocaine|Axillary block with Lidocaine (10 mg/ml).
223916912|NCT06040840|PROCEDURE|WALANT|"Preparation of a mixture of 20 ml of lidocaine (10 mg/ml) with epinephrine (0.005 mg/ml) + 3 ml Na bicarbonate (84 mg/ml) + 17 ml sterile normal saline.~The ultrasound probe will be placed to obtain a transverse image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 5 ml of the solution posterior and then anterior to the median nerve under the annular carpal ligament.~Then the ultrasound probe will be placed to obtain a longitudinal image of the median nerve at the wrist. With an in-plane technique, a 50mm ultrasound needle (Ultraplex 360°, B Braun, Melsungen, Germany) will be advanced to achieve a spread of 15 ml of the solution anterior to the median nerve towards the carpal tunnel.~At last, a local infiltration with 5 ml of the solution will be performed around the surgical incision."
223916913|NCT06040840|DRUG|Lidocaine + Epinephrine|WALANT technique with lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine.
223916914|NCT05599724|OTHER|Biocollection|"For the FERTITHEQUE, will be collected:~* Clinical characteristics~* Biological characteristics measured as part of the usual follow-up~* consultation n°2 : DNA~* consultation n°2 : plasma~* consultation n°2 : serum~* consultation n°2 : vaginal microbiota~* consultation n°3 : follicular fluid (puncture fluid)~* consultation n°4 : plasma~* consultation n°4 : vaginal microbiota."
223916915|NCT06056011|DEVICE|Connex CSVM with Timmy3 module|Connex Vital Signs Monitor with the Timmy3 Investigational module
223916916|NCT06602141|PROCEDURE|Muscle Biopsy|This procedure is used to sample muscle cells from the leg Vastus Lateralis (thigh) muscle.
223916917|NCT06602141|PROCEDURE|Adipose Biopsy|This procedure is used to sample fat tissue from the abdomen (belly).
224080775|NCT00356031|RADIATION|Radiation Therapy|External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
224080776|NCT00356031|PROCEDURE|Surgery|Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
224080777|NCT00449514|DRUG|tamoxifen|
224080778|NCT00449514|DRUG|clomiphene citrate|
224080779|NCT06205108|DEVICE|taVNS stimulation|Non-invasive stimulation of the auricular branch of the vagus nerve (cymba conchae). Research device from tVNS technologies.
224080780|NCT06205108|DEVICE|sham stimulation|Non-invasive stimulation of the ear lob (not innervated by the vagus nerve). Research device from tVNS technologies.
224080781|NCT05361629|PROCEDURE|Intralesional steroid administration|Treatment by administering steroids into the lesion
224080782|NCT05361629|PROCEDURE|Intraoperative cavity steroid administration|Treatment by administering steroids into the surgical cavity
224080783|NCT05637554|PROCEDURE|Laparoscopic appendectomy using clipping.|Laparoscopic appendectomy using clipping to secure the base of the appendix.
224080784|NCT05637554|PROCEDURE|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.|Laparoscopic appendectomy using extracorporeal ligation to secure the base of the appendix.
223916918|NCT06602141|OTHER|Glucose Clamp|In this test, we will measure the effect of insulin by giving you insulin and glucose (sugar) intravenously through an IV line in your arm.
223916919|NCT06602141|OTHER|Accelerometer|The tri-axial accelerometer measure activity and uses those values to estimate the number of calories burned based on your height, weight, age, and gender. The monitor also evaluates physical effort and the body's response to different activities.
223916920|NCT06602141|OTHER|Endurance Exercise|Visit the study site 3 times a week to engage in endurance exercise training for approximately 12 weeks. Each session will last approximately 75 minutes, and exercise group can choose to use either a stationary bike or a treadmill to complete the training.
223916921|NCT06602141|OTHER|Physical activity/ dietary habits|Visit the study site bi-weekly to get weight measurements and speak to the study team about weight maintenance and participant physical activity/dietary habits.
224080785|NCT06520189|DEVICE|F-18 FDGPET/CT|F-18 FDGPET/CT oncology protocol for lung cancer patients
224080786|NCT04507984|DIAGNOSTIC_TEST|Genetic analysis|After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
224278333|NCT00109837|DRUG|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
224080787|NCT04507984|DIAGNOSTIC_TEST|Lipid levels measurement|Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
224080788|NCT06193941|DIAGNOSTIC_TEST|RT-qPCR|RT-qPCR
224080789|NCT04615637|DEVICE|MEG recordings|"1. Classical MEG recordings (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli).~2. MEG recordings with our OPM He4 prototype (patient at rest, normal subjects stimulated with visual, motor, somesthesic and auditory stimuli)."
224080790|NCT00813397|DEVICE|Sepraspray|Max. 10g of Sepraspray
224080791|NCT06217120|DRUG|Colchicine|Colchicine 0.5 mg daily
224080792|NCT06217120|DRUG|Placebo|Placebo once daily
224080793|NCT06001944|OTHER|Blood flow restriction|The BFR training group will be given detailed information about the technique and discussed possible side effects.The American Association of Sports Physicians (ACSM) recommends that at least 65% of 1 maximum repetition, similar to high-intensity exercise, 8-12 repetitions of resistant weight lifting strength training, can be used with low loads such as 20% to 30% of the maximum 1 repetition in therapy to caste hypertrophy and strength.
224278334|NCT00109837|DRUG|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC \< 3,000
224278335|NCT00109837|DRUG|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
223716619|NCT01661296|OTHER|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
223716620|NCT01661296|DRUG|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
223916922|NCT06602141|OTHER|Heavy Water Labeling Period|Participants in both control groups will be required to drink heavy water, which is ordinary water that is enriched with deuterium (stable, non-radioactive isotope) and called deuterium-labeled water, for 12 weeks.
223916923|NCT04977271|DRUG|Venlafaxine|The Immediate Release generic formulation of this drug will be used due to its ability to be crushed for those patients who rely on parenteral administration of medications.
223916924|NCT06588140|DEVICE|Duplicated refitted complete denture made from conventionally heat-cured polymethyl methacrylate.|The duplication of a refitted complete removable denture will be performed using conventional heat-cured polymethyl methacrylate through the conventional heat-cured polymerization technique.
223916925|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM pink polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed separately with pink polymethyl methacrylate resin, and the teeth are printed as a single unit using tooth-colored resin, followed by the assembly of the two components.
223916926|NCT06588140|DEVICE|Duplicated refitted complete denture made from 3D-printed CAD/CAM white polymethylmethacrylate acrylic resin.|The duplication of a refitted complete removable denture will be performed using a 3D-printed CAD/CAM technique, where the denture base is printed as a single unit using tooth-colored resin, and the denture flange will be veneered with pink polymethyl methacrylate resin.
223916927|NCT04258566|DEVICE|Optical Molecular Imaging|Tracks and localizes intrahepatic lesions
223916928|NCT04258566|RADIATION|Indocyanine Green|Fluorescent dye used for visualization of cells and tissue
223916929|NCT03404791|DRUG|TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per participant.
223916930|NCT04468672|BEHAVIORAL|Portion size|The amount of food served (g) at the first two meals of each day. These amounts will vary across 4 weeks.
223916931|NCT06336772|DEVICE|Restylane Shaype|Half (50%) of study participants will receive Restylane Shaype for the treatment of mild to severe chin retrusion
223916932|NCT06336772|DEVICE|Juvéderm Volux|Half (50%) of study participants will receive Juvéderm Volux for the treatment of mild to severe chin retrusion
223916933|NCT05460871|DRUG|Pregabalin 75mg|participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
223716621|NCT00275990|DEVICE|rheolytic thrombectomy with direct stenting|
223716622|NCT00275990|DEVICE|direct stenting|
223716623|NCT06301685|BEHAVIORAL|Routine therapy|The study lasts 10 days for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
223916934|NCT06814912|OTHER|Survey using a questionnaire|virtual reality headset is added during treatment administration. Patient must complete a survey at the end of treatment administration and virtual headset use.
223916935|NCT06814314|DIAGNOSTIC_TEST|Transcriptomic investigation|Transcriptomic investigation followed by ontology classification
223916936|NCT06815133|DRUG|Zilbrysq|Zilbrysq is a medicine used to treat generalized myasthenia gravis anti-AChR (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against a protein called the acetylcholine receptor. It is given as a subcutaneous injection (under the skin) once daily in a prefilled syringe that can be self-injected, and the dose depends on the patient's body weight. There are 3 available doses: 16.6 mg/0.416 mL for patients weighing less than 56 kg (123 lbs); 23 mg/0.574 mL for patients between 56 kg and less than 77 kg (123-170 lbs); and 32.4 mg/0.81 mL for patients weighing 77 kg and above (\>170 lbs). This can be injected into the abdomen, front of the thighs, and back of the upper arms (only if administered by a caregiver),
223916937|NCT04142307|DEVICE|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
223916938|NCT04142307|DEVICE|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
223916939|NCT06302933|BIOLOGICAL|Blood sampling|Blood samples collected from children followed in the Pediacam III ANRS12225 cohort
223916940|NCT05830201|BEHAVIORAL|No Dog Present|Dog is not present during pin removal
223916941|NCT05830201|BEHAVIORAL|Dog is Present|Dog is present during pin removal
223716624|NCT06301685|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223716625|NCT06301685|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. once a day.
223916942|NCT05493280|DEVICE|MOXI|Patients will receive treatment using f1927 devices and will be treated over the affected areas, once each month for a total of three months.
223916943|NCT04614948|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
223916944|NCT04614948|OTHER|Placebo|Placebo will be administered as IM injection on Day 1 and Day 57.
223916945|NCT00964392|PROCEDURE|Atrial fibrillation ablation|Radiofrequency ablation
223916946|NCT06581029|OTHER|The multidimensional peer victimization scale (PVS)|The multidimensional peer victimization scale (PVS), a self-report scale for children and adolescents, was used to assess the victimization
223916947|NCT06657196|OTHER|No Intervention: Observational Cohort|No intervention.
223916948|NCT05378373|BEHAVIORAL|Garmin, Pattern Health App|Wearable sensors will deliver individualized feedback to participants according to their assigned intervention
223916949|NCT06807502|DEVICE|The DM/DIV ScreenCell is the experimental product studied during this research|The product is not used directly on the subject, but on a blood sample taken from the participant.
223916950|NCT06806306|PROCEDURE|LASIK|Laser-assisted in situ keratomileusis is one of the most widely performed refractive surgeries for correcting myopia, hyperopia, and astigmatism
223916951|NCT06002100|OTHER|fNIRS measurement|Kernel Flow2 measurements.
223916952|NCT06638203|OTHER|The 2-hour Exemplary Leadership Course (ELC)|"This two-hour course, based on the Five Exemplary Leadership Model, aims to refresh participants' theoretical understanding of leadership while providing insights into effective leader-follower interactions through practical scenarios. The session will begin with an exploration of the nature of leadership, including its philosophical and historical context. The significance of leadership in nursing will be emphasized, highlighting its impact on education, clinical practice, and the profession overall. Participants will examine the key roles of nurse leaders, focusing on modeling the way, inspiring a shared vision, challenging the process, enabling others to act, and encouraging the heart. Content Outline:~1. The Nature and Definition of Leadership (5 minutes)~2. Leadership and Its Importance in Nursing (15 minutes)~3. Transformational Leadership and Its Components (40 minutes)~4. Positive Leader-Follower Interactions (15 minutes)~5. Case Study Discussions (45 minutes)"
223916953|NCT06638203|OTHER|The NurseLead in Progress Game|Developed collaboratively by the author and a company, this unpublished game focuses on role-playing leader-follower interactions to navigate scenarios effectively. Designed for five students per session, the game consists of five sections, lasting approximately one hour, with each section corresponding to one of the Five Practices of Exemplary Leadership. In each section, one student takes on the role of leader while the other four act as followers. The main objective is to guide a newly appointed charge nurse in making sound decisions when facing challenges to achieve key goals. Following the game, a debriefing session will allow participants to analyze responses with experts. Performance will not be formally evaluated, as the game serves as a learning experience, enabling students to lead and engage as followers. This activity aims to activate the experiential learning phase of Kolb's Learning Model.
223916954|NCT03498521|DRUG|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
223916955|NCT03498521|DRUG|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
223916956|NCT03498521|DRUG|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
223916957|NCT03498521|DRUG|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
224278336|NCT00109837|DRUG|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
224278337|NCT00109837|DRUG|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
224278338|NCT00109837|DRUG|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
224278339|NCT00109837|DRUG|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
223716626|NCT01230944|PROCEDURE|Laparoscopic Nissen fundoplication|
223716627|NCT01230944|PROCEDURE|Open Nissen fundoplication|
223716628|NCT01664533|DRUG|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
224278340|NCT00109837|DRUG|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
224278341|NCT00109837|DRUG|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
224278342|NCT00109837|RADIATION|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
224278343|NCT00109837|DRUG|allopurinol|300 mg/d PO Days 1-7
224278344|NCT00109837|DRUG|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
223716629|NCT04910802|BIOLOGICAL|Gardasil9|Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.
223716630|NCT04070274|PROCEDURE|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
223716631|NCT04911530|OTHER|no intervention|no intervention
223916958|NCT03498521|DRUG|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
223916959|NCT03498521|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
223916960|NCT03498521|DRUG|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
223916961|NCT03498521|DRUG|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
223916962|NCT03498521|DRUG|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
223916963|NCT03498521|DRUG|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
223916964|NCT03498521|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
223916965|NCT03498521|DRUG|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
223916966|NCT03498521|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
223916967|NCT03498521|DRUG|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
223916968|NCT03498521|DRUG|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
223916969|NCT03498521|DRUG|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
223916970|NCT03498521|DRUG|Ivosidenib|Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
223916971|NCT03498521|DRUG|Pemigatinib|Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
223916972|NCT06631079|BIOLOGICAL|NECVAX-NEO1|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
224080794|NCT06001944|OTHER|Multimodal rehabilitation|"Patients with LDT will be informed that the condition will be gradually resolved with adequate rest and time.~Exercise Training will consist of 3 phases.The goal is to protect the injured tissue from stress during the first phase of rehabilitation during the protective phase but not to restrict its function. In this phase, the use of counterforce breys, cold application, cyriax physiotherapy, Mill's manipulation, elbow mobilization and stretching to the wrist extensors will be applied. The program will be created taking into account the principle of proximal stability for distal mobility during the reinforcement phase. The rotator manchet will be added to the program. It will be active first in the exercise and then progresses resistantly according to the condition of the patient. After distal strengthening, the dress will be transferred to stabilization exercises where flexion and extension reveal simultaneous contraction."
224080795|NCT06549751|BIOLOGICAL|MT-601|Cellular Therapy
223716632|NCT06094569|PROCEDURE|Endovascular Therapy|Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
223716633|NCT00804791|OTHER|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
223716634|NCT00804791|OTHER|Unisol 4 Saline Solution|saline solution for irrigating the cornea
223716635|NCT02708160|DRUG|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
223716636|NCT02708160|DRUG|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
223716637|NCT02708160|DRUG|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
223916973|NCT05088759|BEHAVIORAL|Alert|The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
223916974|NCT05818475|OTHER|Angiography-guided PCI|Non-culprit lesion treatment will be based on visual estimation by angiography. The evaluation of PCI result will be also based only on angiography.
223916975|NCT05818475|OTHER|Angiography-derived FFR PCI indication and planning|Non-culprit lesion treatment will be based on angiography-derived FFR result. In case of positive assessment, PCI will be planned according to the virtual PCI plan based on the physiology pullback curve.
224080796|NCT02965079|DEVICE|ECCO2R|The ECCO2R system was developed from the principle of ECMO systems by underscoring the importance of carbon dioxide elimination rather than direct improvement of oxygenation in some patients. The circuit of the ECCO2R system can be set up in venovenous (VV) or arteriovenous (AV). For VV setup, a low flow pump is used to maintain a low extracorporeal flow rate using only 20-30 % of cardiac output. The ECCO2R system does not provide complete pulmonary function as it can achieve only limited oxygenation but provides predominantly carbon dioxide removal. As neither VV nor AV circuit allows full cardiopulmonary bypass, the system provides respiratory function but no cardiac support
224080797|NCT00132730|DRUG|MK-0873 2.5 mg|
224080798|NCT00132730|DRUG|MK-0873 1.25 mg|
224080799|NCT00132730|DRUG|MK-0873 0.75 mg|
224080800|NCT00132730|DRUG|Placebo to MK-0873|
224080801|NCT00132730|DRUG|Usual Care|
224080802|NCT05215366|DIAGNOSTIC_TEST|copeptin biomarker in children with febrile seizures|biomarkers increase in children with febrile seizures
224080803|NCT04318405|DRUG|Iron isomaltoside 1000|Observation of real-life treatment with iron isomaltoside 1000 / Iron Derisomaltose 1000
224080804|NCT04196660|BEHAVIORAL|Labor Dance|The pregnant women and their spouses were trained about the labor dance in the prenatal training without disclosing any information regarding the delivery and labor pain. The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music (on a YouTube channel named Ohgertam Jugrefem) in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing. During the active phase of labor, the pregnant women in the DPMG danced with the midwives who were attendant in the delivery room and who were monitoring the pregnant women's status.
224080805|NCT06547970|OTHER|Educational intervension|an educational intervention about the disease, symptoms \& how to deal with these symptoms, foot care, life style like sport and nutritional advices
224080806|NCT05957172|DEVICE|ZOLL Arrhythmia Management System|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity, and body posture (biometric data)
224080807|NCT01554579|DRUG|Gefapixant|BID
224080808|NCT01554579|DRUG|Sugar Pill|Placebo
224080809|NCT04882176|DRUG|LM-061|The subjects in each dose level will be administered single oral dose of LM-061 tablet on C0D1, and washout for 5 days. After that, the subjects will be administered multiple oral doses once daily (QD) in continuous 28 days (4 weeks) per treatment cycle, until meet the treatment termination criteria, including disease progression or unaccepted toxicity, etc. After obtaining MTD/RP2D, the Safety Review Committee (SRC) may combine the data of safety, PK, and preliminary efficacy to explore other dosing schedules (such as 3 weeks on and 1 week off).
223716638|NCT03961581|BEHAVIORAL|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
223716639|NCT01504035|DEVICE|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
223716640|NCT01504035|DEVICE|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
223716641|NCT04625309|OTHER|Adaptive sports|This will be the number of hours per week the subjects actively partake in adaptive sports teams.
223716642|NCT00290888|PROCEDURE|Acromioplasty|
223716643|NCT00977899|BIOLOGICAL|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
223716644|NCT02566434|DIETARY_SUPPLEMENT|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
223719529|NCT05588908|OTHER|Placebo (phase II)|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
223916976|NCT05564637|DRUG|Treprostinil|30mcg (5 breaths) of inhaled treprostinil will be administered during the RHC procedure and patients will be initiated on outpatient inhaled treprostinil therapy for 3-months with gradual up titration to target dose as per standard clinical practice.
224080810|NCT03979326|PROCEDURE|Static stretching|Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
224080811|NCT02623335|OTHER|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
224080812|NCT04871503|DEVICE|BTL-899 Buttocks|The treatment administration phase in both study groups will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 will be applied over the gluteal area.
223916977|NCT05564637|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC) while exercising|A procedure to measure how well or poorly your heart is pumping and to measure the pressures in the heart and lungs. A catheter will be inserted into a vein and artery in order to take the measurements and this will be conducted while exercising on a supine cycle ergometer. Various measurements will be taken during periods of rest and exercise.
223916978|NCT05564637|DIAGNOSTIC_TEST|Optional Muscle Biopsy|A sample of muscle tissue will be collected and analyzed for the ability of the cells to utilize oxygen.
223916979|NCT06128252|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in tablets of 1.0 gram of taurine powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
223916980|NCT06128252|BIOLOGICAL|Serplulimab|Serplulimab
223916981|NCT06128252|DRUG|XELOX regimen|Oxaliplatin + capecitabine
223916982|NCT06128252|DIETARY_SUPPLEMENT|Placebo|Taurine placebo in tablets of 1.0 gram of starch powder. Dosage: 3.0 gram/day. Frequency: 3 time/day.
223916983|NCT06594796|BEHAVIORAL|Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)|One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
223916984|NCT06876688|DRUG|Relma-cel Followed by Tislelizumab|Enrolled patients with relapsed/refractory (R/R) CNSL will receive Relma-cel infusion, followed by treatment with Tislelizumab (200mg, IV, q4w, for 12 months) starting at 35 days post-infusion. BTK inhibitors will be used in combination as needed.
223916985|NCT06876298|DIAGNOSTIC_TEST|- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.|\- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.
223916986|NCT06351761|DEVICE|Investigational Device (Withings SCT02) 30 second Electrocardiogram recording|30 second ECG recording with investigational device (Withings SCT02)
223916987|NCT06351761|DEVICE|Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording|30 second ECG recording with reference device (Schiller Cardiovit FT-1)
223916988|NCT06290999|DIAGNOSTIC_TEST|multifrequential admittancemetry|"Every participant of the study have to complete an Ear, Nose and Throat examination included a conventional audiometry, and a multifrequential admittancemetry.~if radio-interventional venous stenting is not indicated, an multifrequential admittancemetry will also be performed 3 months after the procedure."
223916989|NCT06308445|DRUG|Rapamycin|This is a 2-dose rapamycin safety study, with a target through level of 3 to \<5 ng/ml for the first 3 months and 5-8 ng/ml for the next 3 months for each of the included patients. To avoid the possible cumulative effect, the two treatment phases will be separated by a 3-weeks wash-out period.
223916990|NCT06651658|PROCEDURE|Pleural embolisation|Administration of pleural blood patch with tandem needle technique
224080813|NCT03739528|DRUG|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
224080814|NCT03739528|DRUG|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
223716645|NCT04010487|GENETIC|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
224080815|NCT04355598|DRUG|Lidocaine-Prilocaine cream|2 mL of the Lidocaine-Prilocaine cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
224080816|NCT04355598|DRUG|glyceryl trinitrate cream|2 mL of the glyceryl trinitrate cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
223716646|NCT01954550|BEHAVIORAL|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
223716647|NCT01954550|BEHAVIORAL|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
223716648|NCT00468325|PROCEDURE|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
223916991|NCT04062565|DRUG|Treprostinil Injectable Product|Injection
223916992|NCT04062565|DRUG|Riociguat Pill|Tablet
223916993|NCT06653127|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients. Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence.
223916994|NCT06652672|PROCEDURE|Organ-sparing surgery|Endoscopy-assisted laparoscopic/robotic wedge resection and sentinel lymph node biopsy using submucosal injection of ICG.
223916995|NCT06652672|PROCEDURE|Standard of care segmental resection|Standard of care segmental resection of the affected part of the colon including removal of regional lymph nodes.
223916996|NCT06652425|OTHER|Low temperature (15°C) group|The exposure group will be exposed to low temperature (15°C) in a chamber for about 2 hours, resting during the whole periods.
223916997|NCT06652425|OTHER|Moderate temperature (22°C) group|The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
223916998|NCT06814548|OTHER|ICIs(Immune checkpoint inhibitors)|N
223916999|NCT06814249|OTHER|ligation of pancreatic stump with a quantified force|After severing the pancreas, the pancreas was ligated at 5 mm from the pancreatic stump with a quantified force.
223716649|NCT00468325|PROCEDURE|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
223917000|NCT06814249|OTHER|Manual suturing or stapling closure.|Handle the pancreatic stump according to conventional methods (manual suturing or stapling closure).
223917001|NCT01196715|DRUG|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
223917002|NCT01196715|DRUG|Filgrastim|300 mcg vials twice a week, 3-4 days apart
223917003|NCT01196715|PROCEDURE|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
223917004|NCT04055012|DRUG|Metformin|500mg tabs of Metformin Extended Release
223917005|NCT04055012|DRUG|Placebo|Placebo Tabs
223917006|NCT05960032|DRUG|Zavegepant|Participants receiving single dose of Zavegepant 10 mg
223917007|NCT04375891|RADIATION|Radiation Therapy|30 Gy in 10 fractions of 3 Gy each
224278345|NCT04587258|BEHAVIORAL|Informational videos and social media campaigns encouraging cancer screening.|Informational videos will be made using community members and will be played in the Blackstone Valley Health Center, as well as posted on social media platforms, such as Facebook and Instagram. These videos will encourage at risk populations in the selected areas to visit their physicians to discuss the possibility of undergoing screening procedures for either breast or colorectal cancer. Data will then be collected about the rates of screening and will be compared to the screening rates from the time period of March 9th 2020 to May 31st 2020, with the goal of increasing screening rates by 25%.
223716650|NCT00468325|PROCEDURE|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
223917008|NCT04375891|RADIATION|Radiofrequency Ablation (RFA)|Radiofrequency Ablation (RFA) / Vertebral Augmentation
223917009|NCT06631092|BIOLOGICAL|Oral DNA Vaccine|Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine
223917010|NCT05501808|PROCEDURE|cerasmart|the patient received a crown made of cerasmart ceramic
223917011|NCT05501808|PROCEDURE|enamic|the patient received a crown made of enamic ceramic
223917012|NCT06806345|DEVICE|Hyperbaric oxygen therapy|Hyperbaric Oxygen Therapy (HBOT):(Haux, Starmed 2300, Germany). A multichamper Double-lock, divided into Main chamber and Antichamber, with omega Ω-shape and all safety and CE-Certificate,
223917013|NCT06806345|DRUG|Hypoglycemic Drug|"Metformin reduces serum glucose level by several different mechanisms without increasing insulin secretion.it increases the effects of insulin so it is termed insulin sensitizer ,metformin also suppresses the endogenous glucose production by the liver ,which is mainly due to a reduction in the rate of gluconeogenesis and asmall effect on glycogenolysis. Moreover, metformin activates the enzyme adenosine monophosphate kinase (AMPK) resulting in the inhibition of key enzymes involved in gluconeogenesis and glycogen synthesis in the liver while stimulating insulin signaling and glucose transport in muscles"
223917014|NCT05259943|DRUG|Psilocybin first|Participants will receive 8 doses of 2mg psilocybin.
223917015|NCT05259943|DRUG|Placebo first|Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
223917016|NCT05883956|DRUG|Subcutaneous azacitidine|Subcutaneous azacitidine, 75mg/m2, 7 days
223917017|NCT05883956|DRUG|Oral decitabine/cedazuridine|Oral decitabine 35mg/cedazuridine 100mg, once daily, 5 days
223917018|NCT03188692|BIOLOGICAL|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
223917019|NCT06005948|OTHER|exercise|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks
223917020|NCT06005948|OTHER|control|No intervention will be made.
223917021|NCT01474122|DRUG|Macitentan 3 mg|Macitentan 3-mg tablet once daily
223917022|NCT01474122|DRUG|Macitentan 10 mg|Macitentan 10-mg tablet once daily
223917023|NCT01474122|DRUG|Placebo|Placebo tablet matching macitentan tablet, once daily
223917024|NCT06589635|DRUG|ADC-189 and Itraconazole|"Part 1:~Day 1, fasting condition, 45 mg ADC189, administered orally~Part 2:~Day 22, 200 mg itraconazole bid, taken orally after meals. Day 23-Day 25, 200 mg itraconazole was taken orally after meals. Day 26, 45 mg ADC-189 and 200 mg itraconazole was taken orally after meals. Day 27-Day 39, 200 mg itraconazole was taken orally after meals."
223917025|NCT05830799|DRUG|Drug Drug Interaction|The intervention phase consists of 3 periods: in period 1, the pharmacokinetics (PK) of all substrates will be evaluated in the absence of C21, in period 2, a potential inhibitory effect of C21 on the substrates be evaluated, and in period 3, the net effect of potential C21-mediated induction and inhibition on the substrates will be evaluated
223940448|NCT04340752|DRUG|Indocyanine Green|ICG is an injectable fluorescent pigment that binds to proteins in the blood and allows surgery teams to view blood vessels with greater precision. The ICG will not affect the course of the operative or postoperative period, and will be injected intravenously prior to the actual repair
223940449|NCT03775486|DRUG|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
223940450|NCT03775486|DRUG|Placebo for Olaparib|Matching tablet
223940451|NCT03775486|DRUG|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
224278346|NCT05752565|DEVICE|SenseWear armband device|"Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life"
224080817|NCT04355598|DRUG|placebo cream|2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
224278347|NCT02205502|DRUG|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
224278348|NCT02205502|DRUG|Normal saline|
224278349|NCT00498316|PROCEDURE|Cord Blood Infusion|Cord blood transplantation performed on day 0.
224278350|NCT00498316|DRUG|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
224278351|NCT00498316|DRUG|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
223917026|NCT06811259|OTHER|Virtual reality (in experimental group)|Virtual reality application is performed with virtual reality glasses. Virtual reality glasses are a simulation model that provides participants with the opportunity to communicate with a dynamic environment created by computers and gives them a sense of reality. Virtual reality glasses, which have a mechanism compatible with smart phones, allow videos downloaded to mobile phones or watched directly via the internet to be viewed at a 360-degree angle. The two lenses on the device provide panoramic viewing by dividing the image into two equal parts. The bands on the front of the device that fits the face are flexible and prevent the device from slipping from the face. The buckles on the back are adjustable and provide ease of use. Thanks to the proximity sensor on the device, images can be zoomed in and out to obtain a clearer image. Thanks to the device holder on the sides, the phone can be easily placed and removed from the device. Again, videos can be advanced or changed with the tou
224080818|NCT03038646|DRUG|MIN-101|
224080819|NCT06070948|DRUG|Venetoclax|Oral; Tablet
224080820|NCT06112041|DRUG|ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin|RC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin
224080821|NCT02945956|DRUG|Entecavir|The subjects will be taking 1 Entecavir tablet per day for 96 weeks.
224080822|NCT02945956|DRUG|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
223917027|NCT06811259|OTHER|Standart care|Women in the control group will receive only standard care during colposcopy
224080823|NCT02710409|BIOLOGICAL|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
224080824|NCT02710409|BIOLOGICAL|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
224080825|NCT02710409|BIOLOGICAL|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
224080826|NCT05941819|DEVICE|ARC-IM Thoracic System implantation|Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
224080827|NCT04982081|BIOLOGICAL|hiPSC-CM therapy|20 patients with congestive heart failure who met the inclusion and exclusion criteria will be recruited. After being fully informed and signed the informed consent, the patients will be randomly divided into two dosage groups: 100 million cells (10 patients) and 400 million cells (10 patients). Human iPSC-derived cardiomyocytes will be injected into the myocardium through a transcatheter endocardial injection system.
224080828|NCT05049603|DRUG|Atorvastatin 20mg|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
224080829|NCT05049603|OTHER|Placebo|One tablet/day, given approximately at 10 pm, after dinner and before going to bed, for 24 weeks
224080830|NCT05091320|DRUG|Mechanical thrombectomy|Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke
224080831|NCT05091320|DRUG|medical treatment|medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
224080832|NCT01046695|DEVICE|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
224278352|NCT00498316|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
224278353|NCT00498316|OTHER|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
224278354|NCT00498316|DRUG|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are \> 55 and \< 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
223917028|NCT06290895|OTHER|women having had a second IVF cycle with AOA|The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.
223917029|NCT06594900|BEHAVIORAL|resistance training intervention|"The RT intervention focuses on knee extensor muscles, following current guidelines. Children will attend two supervised 1-hour sessions per week, proven sufficient for adaptations. Trained coaches and a scientific assistant, supported by master students, will document the sessions. Sessions are spaced 48 hours apart, totaling 40 over 20 weeks, with eight sessions between PRE and MID.~Each session has three phases: warm-up, strength, and coordination. Warm-up involves whole-body games to increase heart rate and prepare for strength training. The strength phase, documented for effort and adjustments, includes squats, lunges, and step-ups, with intensity changes over time. Four sets of 8-12 repetitions per exercise are performed, aiming for strength increase and hypertrophy. Movements are done with great effort but not until voluntary failure.~The coordination phase focuses on age-appropriate strength and motor skills through a circuit of challenges."
224278355|NCT00498316|DRUG|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are \>1 and \< 55 years old. Patients \>55 but \< 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
224278356|NCT00498316|RADIATION|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
224278357|NCT00498316|DRUG|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are \>1 and \< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
224278358|NCT00498316|DRUG|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
224278359|NCT00498316|DRUG|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
223716651|NCT01458652|DRUG|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
223716652|NCT06293807|DRUG|Xylocaine 2 % with 1:100,000 epinephrine|Local anesthetic used during dental procedures
223917030|NCT06603025|OTHER|chewing gum|Preoperative intervention group patients will chew sugarless gum for at least 30 minutes 30-60 minutes before surgery. The gum will be removed before going to the operating room.
223917031|NCT06767644|OTHER|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
224278360|NCT00498316|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is \> 2.5 x 109/L.
224278361|NCT03690089|DRUG|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
224278362|NCT03690089|OTHER|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
224278363|NCT01545739|DEVICE|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
224278364|NCT01848210|DRUG|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
224278365|NCT01848210|DRUG|Placebo|Coumarin + troxerutin placebo-matching tablets
224278366|NCT05455164|DIETARY_SUPPLEMENT|Isomalto Oligosaccharide|all of the subjects were given eucaloric prepared meal which contain high protein and DF (contain 25-30 gram DF and protein content between 30-40% of total macronutrient distribution range)
224278367|NCT00381849|DRUG|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
224278368|NCT00381849|DRUG|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
224278369|NCT04970498|DIAGNOSTIC_TEST|MRI|MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
223716653|NCT06293807|DRUG|Bupivicaine 0.5% with 1:200,000 epinephrine|Local anesthetic used during dental procedures
223917032|NCT06767644|OTHER|no music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
223917033|NCT06605417|GENETIC|Methylomics|Methylomics analysis of FFPE blocks and frozen tissues
223917034|NCT06605417|GENETIC|RNA sequencing|RNA sequencing of FFPE blocks and frozen tissues
223917035|NCT06605417|GENETIC|Spatial transcriptomics|Spatial transcriptomics of FFPE blocks and frozen tissues
223917036|NCT06605417|GENETIC|Liquid biopsy|cfDNA characterization extracted from blood/saliva
223917037|NCT03652272|BEHAVIORAL|EMC2|"1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
223917038|NCT06698250|DRUG|Zanzalintinib|Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.
223917039|NCT06698250|DRUG|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)
223917040|NCT06698250|DRUG|Tremelimumab|Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells
223917041|NCT06810063|OTHER|Assessment only, no intervention|Participants in this study complete two visits to test the agreement of telehealth and in person assessments of arm and hand movement.
223917042|NCT06817434|DRUG|Revascularization/Conservative management|Revascularization/Conservative management
223917043|NCT06820255|DRUG|Platinum + Gemcitabine|Eligible patients will be treated with platinum-based chemotherapy (i.e. cisplatin + gemcitabine or carboplatin + gemcitabine).
223917044|NCT06820255|DRUG|Avelumab first-line maintenance|Patients with stable disease or tumor response after treatment with platinum-based chemotherapy will start treatment with avelumab 800 mg fat dose Q2 weeks until progression of disease or unacceptable toxicity
223917045|NCT06820255|DIAGNOSTIC_TEST|NGS test for DDR alterations|All patients will be tested for DDR alterations on tumor tissue.
223917046|NCT06817954|PROCEDURE|endoscopic-assisted mastectomy and immediate breast reconstruction|endoscopic-assisted mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
223917047|NCT06817954|PROCEDURE|mastectomy and immediate breast reconstruction|conventional mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer
223917048|NCT06821165|OTHER|Dr. Goniometer Application|The Dr. Goniometer application is a digital tool used for measuring elbow flexion range of motion (ROM). In this study, participants' elbow flexion ROM will be assessed using both the Dr. Goniometer application and a manual goniometer. Measurements will be taken twice by two different raters to evaluate the validity and reliability of the digital application compared to the manual goniometer.
223917049|NCT05985382|OTHER|Lower Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
224278370|NCT04970498|DIAGNOSTIC_TEST|blood routine test|The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.
224278371|NCT00160745|DRUG|Rosuvastatin|
223716654|NCT06293807|OTHER|Placebo|0.9% Normal Saline solution used in place of local anesthetic
223917050|NCT05985382|OTHER|Upper Body Resistance Exercise|Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
223917051|NCT06818292|BIOLOGICAL|Liraglutide|0.6 mg of the pre-filled solutions from pen-injector Liraglutide (GLP-1 Agonist)
223917052|NCT06818292|BIOLOGICAL|Placebo|0.1 mL NaCl
223917053|NCT06819462|DRUG|Inhaled Placebo|Inhalation of drugs was started within 24 hours after the screening of patients. Both groups inhaled with vibrating mesh spray twice a day for 3 days. The NS group inhaled with normal saline .
223917054|NCT06819462|DRUG|inhaled corticosteroids and other asthma drugs|Inhalation of drugs was started within 24 hours after the screening of patients. Both groups used vibrating mesh spray twice a day for 3 days. The Polymyxin E group inhaled polymyxin， 75 mg bid.
223917055|NCT06817694|BEHAVIORAL|Cognitive-behavioral group therapy|The intervention consists of a 4-week cognitive-behavioral group therapy. Each session is given online and will last 90-minutes. The intervention has been adapted to the population of women with a cancer and a BRCA1/2 mutation from a behavioral-cognitive therapy for fear of cancer recurrence that already exists and has already been proven effective.
223716655|NCT02734940|DRUG|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
223716656|NCT02734940|DRUG|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
223716657|NCT02734940|DRUG|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
223716658|NCT02734940|DRUG|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
223716659|NCT02734940|DRUG|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
223719530|NCT03974425|DRUG|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
224278372|NCT01710605|BIOLOGICAL|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
224278373|NCT03474328|DEVICE|AlcoChange|Smartphone app and breathalyser
224278374|NCT02992457|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily.
224278375|NCT02992457|DRUG|Ribavirin|Ribavirin 1000-1200 mg daily
224278376|NCT02992457|DRUG|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
224278377|NCT02992457|DRUG|Simeprevir|Olysio once daily.
224278378|NCT02992457|DRUG|Daclatasvir|Dakla once daily for three months.
224080833|NCT05275569|PROCEDURE|True acupuncture + standard antiemetic treatment|"Participants will receive electroacupuncture once daily from day 1 to day 4. The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy."
223917056|NCT06818448|DEVICE|Rotator cuff repair with the SINEFIX|Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
223917057|NCT06818448|DEVICE|Rotator cuff repair with comparator device|Treatment of rotator cuff lesions with the conventional surgical technique (comparator device)
223917058|NCT06219369|PROCEDURE|Group T|"SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique."
223917059|NCT06820294|OTHER|No intervention|As per widely adopted clinical research practice for case reviews of de-identified, anonymised data, no explicit consent of participants (or their legal guardians) would be required for this study other than the consent they provided at biopsy (from which the whole genome sequencing data is derived) for researchers to access their notes (as documented on hospital consent form).
223917060|NCT06816316|PROCEDURE|external angular dermoid cysts surgical removal|"Skin incision was done below the eyebrow, subcutaneous and orbicularis dissection was done to remove the cysts. Upon accidental opening of the cyst then removal of the cyst walls and its contents from the surgical field as much as possible was done.~At this step, in group (A) only saline was used to wash the surgical field from any remnants. In group (B) the surgical field was cleaned with a gauze soaked with ethyl alcohol 70%. Then closure of the wound in both groups."
223917061|NCT06818916|DRUG|Hetrombopag|Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
223917062|NCT06816719|DRUG|Treatment A: JW0106 1 tablet + C2101 1 tablet|"* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101~* Administration orally with 150 mL of water under fasting conditions"
223917063|NCT06816719|DRUG|Treatment B: JW0107 1 tablet|"* Administration alone of 1 tablet of JW0107~* Administration orally with 150 mL of water under fasting conditions"
223917064|NCT04576741|BEHAVIORAL|bMBI standard practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).
223917065|NCT04576741|BEHAVIORAL|bMBI shorter more frequent practice|This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).
223917066|NCT06817369|OTHER|Exercises given with internal focus instructions|Both groups of girl volleyball players will be given 5 exercises. Exercise 1: Hands-free vertical jump (the movement of an individual jumping from a certain point and then jumping back to the same point) Exercise 2: Training in catching and throwing the ball thrown by the physiotherapist while the individual remains stationary for 30 seconds in the lunge position Exercise 3: Weight transfer on balance beam Exercise 4: Stretching the hamstring and trunk muscles / Bending the trunk while standing upright and touching the toes to the ground exercise Exercise 5: Exercise used in Wall Catch Coordination test Each exercise will be 3 sets of 10 repetitions / 1-2 minutes of rest between each set.
223940452|NCT03775486|DRUG|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
223940453|NCT03775486|DRUG|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
223940454|NCT03775486|DRUG|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
223940455|NCT03775486|DRUG|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
223940456|NCT03775486|DRUG|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
223940457|NCT06648122|OTHER|laboratory results|evaluation of laboratory results (hemogram results:WBC, RBC, Hematocrit, Monocyte count, Neutrophil count, Lymphocyte count, Platelet count, PDW, MPV, MLR, NLR, NMR, PLR, PMR, PNR, PWR, SII)
223940458|NCT06346093|PROCEDURE|Fecal Microbiota Transplantation Capsules|FMT Capsules in Combination with Chemotherapy and Anti-PD1/PD-L1 Therapy
223940459|NCT06346093|PROCEDURE|Placebo|Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules
223940460|NCT04119063|DEVICE|powered orthosis|Novel powered leg brace to provide assistance during walking.
223940461|NCT03199404|DEVICE|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
223940462|NCT06061744|OTHER|Minimally invasive surgery|laparoscopic or robotic surgical approach for the treatment of gallbladder cancer
223940463|NCT06576076|BEHAVIORAL|Contingency management for cannabis abstinence|Those randomized to the abstinence condition (CB-Abst) will be incentivized using an escalating reinforcement schedule for eight weeks of cannabis abstinence.
223940464|NCT02055742|DEVICE|illumigene CT and NG assays, illumipro-10|
223940465|NCT04562675|BEHAVIORAL|LHA intervention|For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.
223940466|NCT04562675|OTHER|brochure-only|brochure-only for control group (CG)
223940467|NCT06492304|BIOLOGICAL|CTX131|CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
223917067|NCT06817369|OTHER|Exercises given with external focus instructions|Both groups of girl volleyball players will be given 5 exercises. Exercise 1: Hands-free vertical jump (the movement of an individual jumping from a certain point and then jumping back to the same point) Exercise 2: Training in catching and throwing the ball thrown by the physiotherapist while the individual remains stationary for 30 seconds in the lunge position Exercise 3: Weight transfer on balance beam Exercise 4: Stretching the hamstring and trunk muscles / Bending the trunk while standing upright and touching the toes to the ground exercise Exercise 5: Exercise used in Wall Catch Coordination test Each exercise will be 3 sets of 10 repetitions / 1-2 minutes of rest between each set.
224278379|NCT02992457|DRUG|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
223716660|NCT02551757|DEVICE|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
223716661|NCT02551757|DEVICE|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
223716662|NCT03766633|DIAGNOSTIC_TEST|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
223716663|NCT06337331|DRUG|Venetoclax|400mg/day PO Days -8 to -2
223716664|NCT06337331|DRUG|Decitabine|20mg/m2/day IV Days -7 to -3
223716665|NCT06337331|DRUG|Fludarabine|30mg/m2/day IV Days -7 to -3
223716666|NCT06337331|DRUG|Busulfan|3.2mg/kg/day IV Days -5 to -4
223716667|NCT06337331|RADIATION|Total Body Irradiation|200cGy Day -2
223716668|NCT05884723|DIETARY_SUPPLEMENT|Ketogenic Diet|4-week preoperative well-formulated very low carbohydrate isocaloric diet consisting of 50g net daily carbohydrates and 1.5g/kg protein with the remaining energy needs consisting of primarily mono- and polyunsaturated fats
223716669|NCT05894928|DRUG|LOXO-783|Administered orally.
223716670|NCT05894928|DRUG|Cholestyramine|Administered orally.
223716671|NCT05124964|OTHER|PedsQL 4.0 Scale|The PedsQL 4.0 Generic Core Scale contains 23 items that measures physical (eight items), emotional (five items), social (five items), and school (five items) functions. The Scale comprises parallel patient self-report and parent proxy-report formats. The items are reverse-scored and trans- formed to a 0-100 scale according to the instructions, and higher scores indicate a better HRQOL. PedsQL 4.0 will be evaluated at baseline, yearly through 3 years post-enrollment.
223716672|NCT05124964|OTHER|Short Form-36|Altogether, 36 questions with standardized response choices were organized into eight scales, including physical functioning (PF), role limitations as a result of physical health problems (RP), body pain (BP), general health perceptions (GH), vitality (VT), social functioning (SF), role limitations as a result of emotional problems (RE), and general mental health (MH). Additionally, reported health transition (HT) was used to evaluate general health changes during the previous year. The raw scores were converted to a 0-100 scale according to the instructions, and higher scores indicated a better HRQOL. Physical component score (PCS) and mental component score (MCS) were also calculated. SF-36 will be evaluated at baseline, yearly through 3 years post-enrollment.
223716673|NCT05124964|OTHER|Chinese Wechsler Intelligence Scale for Children|The intelligence of the child was tested by the China-Wechsler Intelligence Scale for Children (C-WISC), which was revised by Gong and Cai at Hunan Medical University. The C-WISC consists of 11 individual tests that include six verbal tests \[Information (I), Comprehend (C), Sorting (S), Arithmetic (A), Vocabulary (V), and Digit symbol (D)\] and five performance tests \[Picture Completing (PC), Picture Arrangement (PA), Block Pattern (BP), Object Assembly (OA), and Coding (CD)\]. Based on individual testing, vocabulary scores (V), procedure scores (P), and full scores (F) were obtained. Furthermore, the VIQ, PIQ, and full intelligence quotient (FIQ) were calculated progressively . C-WISC will be evaluated at baseline, yearly through 3 years post-enrollment.
223716674|NCT05137106|OTHER|Active Dry Needling|All participants in this group received an ADN session with an intramuscular insertion of a 25 mm X 0.22 mm acupuncture needle into the infraspinatus muscle. The dry needling was performed with the rapid entry and exit technique.
223716675|NCT05137106|OTHER|Sham Dry needling|All participants in this group received one session of SDN with a 25 mm X 0.22 mm acupuncture needle over the infraspinatus region. To ensure that the blunt needles did not puncture the skin during the experimental session (and for patient comfort), each needle was individually cut and polished and checked for sharpness against the investigator's fingertip. As a precaution against infection, each patient was treated with a separate dummy needle.
223716676|NCT01785550|OTHER|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
223716677|NCT01995240|DRUG|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
223716678|NCT04287244|DEVICE|Transcutaneous Spinal Direct Current Stimulation|tSDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
223716679|NCT01894191|PROCEDURE|Air insufflation|Insufflation during colonoscopy including insertion phase
223716680|NCT01894191|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
223716681|NCT01894191|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
224278380|NCT02992457|DRUG|Sofosbuvir and Ledipasvir|Once daily for three months
224278381|NCT02992457|DRUG|Salvage therapy|three months in repeated treatment failure
224080834|NCT05275569|PROCEDURE|Sham acupuncture + standard antiemetic treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation. They will receive fosaprepitant 150 mg intravenous IV + palonosetron 0.25 mg IV + dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post-chemotherapy(the antiemetic drugs are the same as the true acupuncture group)."
223530207|NCT05548647|BEHAVIORAL|Behavioral Treatment|All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh \< 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.
223917068|NCT06820684|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol will be delivered as follows:~1. Touching and applying gentle pressure to the participant's upper shoulder area (this is called Thoracic inlet direct myofascial release)~2. Touching and applying gentle pressure to the participant's midsection and abdomen (this is called Abdominal diaphragm direct myofascial release)~3. Touching and applying gentle pressure to the participant's pelvis and sacrum (this is called Muscle Energy or Counterstrain, if indicated).~4. Touching and applying gentle pressure to the participant's hips and hamstrings (this is called muscle energy) and will be done in 3 repeated rounds of 5 seconds each.~5. Touching and applying gentle pressure to the backs of the participant's knees (this is called open popliteal fossa with direct myofascial release)~6. Touching and applying gentle pressure to the participant's feet, moving them back and forth in 10 rhythmic pulses (this is called Pedal Pump)"
223917069|NCT06820502|PROCEDURE|Transurethral Resection of Prostate (TURP)|"TURP:~Transurethral resection of the prostate remains the criterion standard therapy for obstructive prostatic hypertrophy and is both the surgical treatment of choice and the standard of care when medication fails. It improves obstructive voiding symptoms and urinary flow rate with success rates ranging from 85 to 90% ."
223917070|NCT06820502|PROCEDURE|Transurethral Resection Of Bladder Tumor|"TURBT:~Trans-urethral resection of bladder tumor (TURBT), performed endoscopically, is the firstline procedure for diagnosis, staging, and treatment of visible bladder tumors,"
223917071|NCT05536245|OTHER|Questionnaire|To prevalence of psychological, physical and sexual violence suffered or committed in a population of patients suffering from one or more addictions
224080835|NCT03072160|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks.
224080836|NCT02280213|DEVICE|MIL|Direct laryngoscopy 1
224080837|NCT02280213|DEVICE|MAC|Direct laryngoscopy 2
224080838|NCT02280213|DEVICE|WIS|Direct laryngoscopy 3
224080839|NCT02280213|DEVICE|PHIL|Direct laryngoscopy 4
224080840|NCT03992625|DEVICE|Deep Brain Stimulation|High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders
224080841|NCT01091571|DRUG|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
224080842|NCT01091571|DRUG|Placebo|Placebo twice daily during seven consecutive days
224080843|NCT01091571|OTHER|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
224080844|NCT02287727|OTHER|Laboratory Biomarker Analysis|Correlative studies
223530208|NCT05548647|DRUG|Placebo|An inactive saline solution administered via subcutaneous injection
223530209|NCT05548647|DRUG|Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]|Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss
223716682|NCT01993654|PROCEDURE|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
224080845|NCT02287727|DRUG|Regorafenib|Given PO
224080846|NCT01450982|DRUG|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
224080847|NCT01835119|DRUG|gum|gum
224080848|NCT02648126|PROCEDURE|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
224080849|NCT02338687|DIETARY_SUPPLEMENT|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
224080850|NCT02338687|BEHAVIORAL|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
224080851|NCT04282031|DRUG|BPI-1178|BPI-1178 once daily on Days 1 to 21 of a 28-day cycle
224080852|NCT04282031|DRUG|Fulvestrant|Fulvestrant 500mg intramuscularly on Days 1 and 15 of Cycle 1, and on Day 1 of Cycle 2 and beyond
224080853|NCT04282031|DRUG|Letrozole|Letrozole 2.5 mg once daily of a 28-day cycle
224080854|NCT04282031|DRUG|BPI-1178|BPI-1178 once daily of a 28-day cycle
224080855|NCT00828282|DRUG|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
224080856|NCT00309322|DRUG|Phentolamine Mesylate (NV-101)|
224080857|NCT06549387|PROCEDURE|Corneal cross linking|Applying UVA irradiation to the cornea after soaking with riboflavin
224080858|NCT03067909|OTHER|CIED surgery|
224080859|NCT03176082|OTHER|Mailed Reminders with Fecal Immunochemical Testing kits|
224080860|NCT03176082|OTHER|Reminder letter only|
223530210|NCT05581485|DRUG|Dexmetedomedine infusion|Patients received a loading dose of dexmedetomidine at 1 µg/kg over 10 minutes, followed by a continuous infusion at 1 µg/kg/h throughout the procedure. This regimen was combined with TIVA (propofol) and THRIVE to support spontaneous breathing during endoscopic laryngeal surgery.
223917072|NCT03818178|DIETARY_SUPPLEMENT|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
223917073|NCT03818178|DIETARY_SUPPLEMENT|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
223917074|NCT03818178|OTHER|Saline|All participants will serve as their own controls with a saline infusion study day.
223917075|NCT06365684|DRUG|Sodium zirconium cyclosilicate|In the case of hyperkalemia patients will be treated with Sodium zirconium cyclosilicate to allow the continuation of potassium enriched diet. In case hyperkalemia arises in the control group, patients will be treated with Sodium zirconium cyclosilicate as well.
223917076|NCT06656377|BEHAVIORAL|exercise intervention|A total of 25 prediabetic adults of either gender will participate in the study they will engage in exercise at intensities of 50%, 60%, 70%, or 80% of their predicted maximum heart rate (PMHR). In duration they will exercise for 15, 30, 45 and 60 minutes, and in timing protocol they will exercise at various time points after having breakfast. Blood samples were collected at four time points i.e. at fasting, pre-exercise and post-exercise at 30 and 60 minutes to measure glucose, insulin, and C-peptide levels.
223917077|NCT06657729|OTHER|Succiometry|Assessement of sucking performance by measuring pressures (suction, crushing) with a succiometer every 10 days. This instrument consists of a standard silicone teat for premature newborns, which is connected via two silicone tubes to pressure micro-sensors. These pressure sensors measure the child's sucking activity on the teat. This activity is characterised by suction and crushing movements. It is a non-nutritive sucking activity (no fluid is delivered). Sucking performance is recorded during a period of calm awakening of the infant and over a period of 5 minutes, and is part of routine care since non-nutritive sucking is a common practice in neonatal unit. The first measurement will be taken in the first week of life and then every 7-10 days until discharge from the neonatal unit.
223917078|NCT06656507|PROCEDURE|Quadro Iliac Plane Block (QIPB)|The Quadro Iliac Plane Block (QIPB) will be performed pre-awakening in patients undergoing lumbar vertebra surgeries. Using a low-frequency convex ultrasound transducer (2-6 MHz), the spinal process will be identified at the L3 level in a prone-positioned patient. The transducer will be moved laterally to locate the transverse process within the erector spinae muscle and then rotated to the parasagittal plane to identify the Quadratus Lumborum Muscle (QLM) attachment to the iliac crest. A 22G x 100 mm block needle will be advanced under ultrasound guidance, and 50 mg (0.25%) bupivacaine will be injected bilaterally into the fascia beneath the QLM. This technique is designed to provide effective postoperative pain control by blocking the nerves in the quadratus lumborum plane.
223917079|NCT06656507|PROCEDURE|Erector Spinae Plane Block (ESP)|The Erector Spinae Plane Block (ESP) will also be performed pre-awakening. A linear ultrasound probe will be placed transversely at the level of the L3 vertebra to visualize the transverse process. A block needle will be advanced under ultrasound guidance until it touches the transverse process, after which the needle will be withdrawn 1 mm. Fifty milligrams (0.25%) bupivacaine will then be administered bilaterally. The ESP block aims to provide postoperative analgesia by blocking sensory nerves in the erector spinae plane.
224080861|NCT01949363|DRUG|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
224080862|NCT01535079|DRUG|Placebo|Single administration
224080863|NCT01535079|DRUG|Ibuprofen 35 mg|Single administration
224080864|NCT01535079|DRUG|Ibuprofen 25 mg|Single administration
223530211|NCT05581485|PROCEDURE|Ultrasound-Guided Superior Laryngeal Nerve Block (SLNB)|Following anesthesia induction, patients received bilateral ultrasound-guided superior laryngeal nerve blocks using 5 mL of 1% lidocaine per side. This intervention was combined with total intravenous anesthesia (TIVA) using propofol and high-flow nasal oxygenation (THRIVE) to maintain spontaneous respiration during endoscopic laryngeal surgery.
224080865|NCT01535079|DRUG|Ibuprofen 15 mg|Single administration
224080866|NCT01535079|DRUG|Strefen|Single administration
224080867|NCT00097357|DRUG|Apixaban|Tablets, Oral, 12 +/- 2 days
224080868|NCT00097357|DRUG|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
224080869|NCT00097357|DRUG|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
224080870|NCT00097357|DRUG|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
223716683|NCT02710565|OTHER|Cohort|Obtaining additional EBUS TBNA samples for cell culture
223716684|NCT00902408|DIETARY_SUPPLEMENT|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
224080871|NCT00097357|DRUG|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
223719531|NCT00847379|DRUG|Ataluren|Ataluren oral powder for suspension will be administered as per dose and schedule specified in the arm.
223719532|NCT02672865|DRUG|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
224080872|NCT04924855|OTHER|Blood sampling (4 per year)|Blood sampling (4 per year)
224278382|NCT02976051|RADIATION|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
224278383|NCT01089530|BEHAVIORAL|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
224278384|NCT01053091|BEHAVIORAL|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
224278385|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
223917080|NCT06656078|OTHER|1. WORKING MEMORY TASK:|Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.
223917081|NCT06656078|OTHER|2. VISUAL AND VERBAL FLUENCY TASK|Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
223917082|NCT06656078|OTHER|3. MOTOR TASK:|Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
224080873|NCT04528121|OTHER|CoDuSe balance training and step square exercises|"The standardized intervention targeted visual, somatosensory, and vestibular aspects of balance and will be included with balance exercises~Examples of core stability exercises as follows: in supine position with knees bent, slowly slide one heel forward to straighten leg; and, in four-point kneeling position, slide one foot in a straight line away from the body and lift the leg off the floor.~Examples of dual-task exercises as walking while turning one's head and juggling a balloon.~Examples of sensory strategies as standing and walking on uneven surfaces and standing with eyes closed."
224080874|NCT04528121|OTHER|conventional balance training|static and dynamic balance training exercises from sitting, standing and ambulation activities
224080875|NCT01356004|DRUG|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
224080876|NCT01356004|DRUG|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
224080877|NCT03359135|OTHER|Rehabilitation|Rehabilitation during 4 weeks
224080878|NCT03359135|DEVICE|Compression Garment|Rehabilitation associated to wearing CG during 4 weeks
224080879|NCT03709381|DRUG|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
224080880|NCT03709381|DRUG|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
224080881|NCT01985672|PROCEDURE|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
224080882|NCT00408694|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
224278386|NCT00162682|PROCEDURE|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
224278387|NCT04219358|DRUG|Vehicle Gel Base|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water."
224278388|NCT04219358|DRUG|Imiquimod 5% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%."
223917083|NCT06657677|DIETARY_SUPPLEMENT|40mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
224080883|NCT00408694|BIOLOGICAL|Bevacizumab|Given IV
224278389|NCT04219358|DRUG|Imiquimod 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form."
224278390|NCT04219358|DRUG|Imiquimod nanoencapsulated 0,05% gel|"Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%"
224278391|NCT04219358|DRUG|Lip sunscreen 30 Sun Protector Factor (SPF)|Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
224278392|NCT04219358|DRUG|Dexpanthenol|"Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon.~Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair."
223917084|NCT06657677|DIETARY_SUPPLEMENT|100mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
224080884|NCT00408694|DRUG|Cisplatin|Given IV
224080885|NCT00408694|DRUG|Fluorouracil|Given IV
224080886|NCT00408694|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224080887|NCT01727895|DIETARY_SUPPLEMENT|Beta-glucan (Glucan #300®)|
224080888|NCT04479800|DRUG|ASTX660|Form: capsule; Route of administration: oral
224080889|NCT01265771|DEVICE|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
224080890|NCT01265771|DEVICE|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
224080891|NCT04001855|OTHER|Dilute vinegar (acetic acid)|Dilute vinegar baths or gauze soaks
224080892|NCT04001855|OTHER|Dilute bleach|Dilute bleach baths or gauze soaks
224080893|NCT04537689|BIOLOGICAL|Ixekizumab|Ixekizumab for 6 months, given 160mg at weeks 0, followed by 80mg at 2, 4, 6, 8, 10 and 12, then 4 weekly till 6 months. Given subcutaneously.
224080894|NCT04537689|DRUG|Methotrexate|Oral tablet up to 15mg per week
224080895|NCT04537689|DRUG|Cyclosporin A|Oral capsule up to 200mg per day
224080896|NCT04537689|DRUG|Acitretin|Oral capsule up to 25mg per day
224080897|NCT00004914|BIOLOGICAL|epoetin alfa|
224080898|NCT00004914|PROCEDURE|physical therapy|
224080899|NCT00727207|DRUG|everolimus|
224278393|NCT01118819|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
223917085|NCT06657677|DIETARY_SUPPLEMENT|180mg oral iron dosing|Participants will receive a single morning oral dose of iron as Fe57-labelled ferrous sulfate
223917086|NCT00364637|DRUG|Sevoflurane (Volatile Anesthetic)|
223917087|NCT00364637|DRUG|Total intravenous anesthesia|
223917088|NCT05754515|PROCEDURE|target controlled infusion (TCI) group|"Patients in the TCI group will be anesthetized with propofol and remifentanil throughout the operation.~Patients included in the inhalation anesthesia group will be anesthetized with desflurane and remifentanil with a bispectral index of 40-60 throughout the operation."
223917089|NCT06812598|DRUG|Letermovir (0-24w）|Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 24 weeks post-transplant (approximately 170 days).
224080900|NCT03895125|BEHAVIORAL|[year1] dual-task training with task priority strategy|postural focus: focus mainly on postural performances while dual-tasking suprapostural focus: focus mainly on suprapostural performances while dual-tasking
224080901|NCT03895125|BEHAVIORAL|[year2-3] dual-task training with internal and external focus|internal focus: focus mainly on body movements external focus: focus mainly on object in the environment
224080902|NCT02429531|BIOLOGICAL|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
224080903|NCT02429531|BIOLOGICAL|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
224080904|NCT01180803|DEVICE|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
224080905|NCT01180803|DEVICE|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
224278394|NCT02048696|OTHER|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
224278395|NCT04060134|OTHER|SimpliDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
224278396|NCT04060134|OTHER|AlloDerm HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
224278397|NCT04060134|OTHER|AlloMax HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
223917090|NCT06812598|DRUG|Letermovir (0-14w）|Patients will begin receiving prophylactic treatment with domestically produced letermovir from day 0 to day 28 post-allo-HSCT, at a dose of 480 mg, administered orally once daily. If used in combination with cyclosporine, the dose should be reduced to 240 mg once daily. The treatment will continue until 14 weeks post-transplant (approximately 100 days).
223917091|NCT06811597|PROCEDURE|Voco Meron Conventional Glass Ionomer|The right molars were bonded with Meron
223917092|NCT06811597|PROCEDURE|High-Q-Bond Band™ self-adhesive resin cement.|The left mandibular first molars were bonded with FSM High-Q-Bond Band™ self-adhesive resin cement.
224080906|NCT00666926|DRUG|PF00562271|125 mg twice daily \[BID\] with food, tablet
224080907|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
224080908|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
224080909|NCT00666926|DRUG|PF00562271|125 mg BID with food, tablet
224080910|NCT02883244|DEVICE|Soft-Picks Advanced|Soft-picks Advanced will be used once a day to clean interdental sites at home.
224080911|NCT02883244|DEVICE|Floss|Floss will be used once a day to clean interdental sites at home.
224080912|NCT05481866|OTHER|Oropharyngeal administration of colostrum|The intervention group will be given 0.2ml colostrum for oropharyngeal administration every 3 hours.
224080913|NCT05481866|OTHER|Oropharyngeal administration of sterile water|The control group will be given 0.2ml sterile water for oropharyngeal administration every 3 hours.
223917093|NCT06807879|BEHAVIORAL|Modified Otago Exercise with Routine care Physical therapy|"To improve the efficacy of the balance improvement intervention, we modified the OEP by incorporating the additional walking, recommended by the OEP guidelines, into a single exercise session and conducting it as a group exercise program in accordance with a previous meta-analysis (Chiu et al., 2021) . As shown in Figure 1, the modified-OEP group intervention consisted of 15 min of walking followed by a 30 min Otago Exercise Program consisting of balance and strength training, followed by another 15 min of walking. The 15 min walking was accomplished through continuous walking at an individual pace in the \~15m training room. Participants were asked to walk 15 m, make a U-turn towards the left side, walk 15 m, then make a U-turn towards the right side at the next turning point, in order to achieve an equivalent effect on the promoted benefit of symmetry when turning left and right.~This was repeated until the session was complete."
224080914|NCT05008094|DIAGNOSTIC_TEST|Whole-exome sequencing|Whole-exome sequencing with the focus on Parkinson's disease loci.
224080915|NCT05008094|DIAGNOSTIC_TEST|Microbiota sequencing|Next generation sequencing of microbiota from stool and saliva samples.
224080916|NCT05008094|DIAGNOSTIC_TEST|Magnetic resonance imaging|Magnetic resonance imaging of the brain focused on detection of free water in Substantia Nigra using a novel protocol.
224080917|NCT05008094|DIAGNOSTIC_TEST|Transcranial ultrasound and Electroencephalography|Transcranial ultrasound of Substantia Nigra, as well as high resolution EEG.
224080918|NCT05008094|DIAGNOSTIC_TEST|ELISA (Enzyme-Linked Immunosorbent Assay)|ELISA (Enzyme-Linked Immunosorbent Assay) will be used to assess the inflammatory state, glial functions, and disease progression will also be determined through specific markers in the participant's serum and plasma samples
224278398|NCT04060134|OTHER|FlexHD HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
224278399|NCT04060134|OTHER|DermACELL HADM|Human acellular dermal matrices are used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
224278400|NCT00387517|DRUG|Aliskiren/HCTZ|
223917094|NCT06807879|BEHAVIORAL|Routine Care Physical Therapy|The routine care physical therapy session typically involves a variety of exercises aimed at general strengthening, stretching, and basic gait training. 1 hour of standard physiotherapy exercises focusing on general strengthening, stretching, and basic gait training. The session included a combination of exercises aimed at general strengthening, such as core stability exercises, muscle-strengthening exercises with weights or resistance bands and functional movements like squats and lunges. Stretching exercises targeting key muscle groups like hamstrings will be incorporated to improve flexibility and range of motion. Gait training will focus on activities like side lunges, step-ups, and balance exercises to enhance walking ability and postural control. Additionally, the plan emphasized progressive challenges incorporating a mix of static and dynamic balance exercises using tools like foam pads or balance boards.
223716685|NCT01166113|DRUG|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
223917095|NCT06651164|DIAGNOSTIC_TEST|psychosocial risk screening|"* combined tablet-based screening questionnaire for psychosomatic screening and social service screening~* in case of positive psychosomatic or social service screening subsequent psychosomatic and / or social service consultation"
223917096|NCT04813172|BEHAVIORAL|Symptom Assessment|"Examine the symptomatology of head and neck cancer patients undergoing treatment that includes radiation by completing the M.D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN), the Brief Pain Index (BPI)and the Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H\&N). They will also be asked to complete the Hearing Handicap Inventory for Adults - Screening (HHIA-S) and the Tinnitus Handicap Inventory - Screening (THI-S) as well as the Flourishing Measure.~Each patient enrolled will be followed by a nurse and speech-language pathologist, twice a week, throughout their treatment (from start until 3-month post completion) All assessments are collected on a secure Ipad through REDcap database. If any significant changes occur, within 2 points from their last assessment, the nurse will notify the oncology physician and provide plan of care to avoid emergency room or hospital visit."
223917097|NCT06855992|DEVICE|Laser|60-minute 635 nm red laser intervention 3 times per week for 8 weeks
223917098|NCT06855992|DEVICE|Red Light|60-minute red light sham intervention three times per week for 8 weeks
223917099|NCT06819163|DIETARY_SUPPLEMENT|Berry leaf extract|The study foresees the intake of 2 capsules per day during 12 weeks
223716686|NCT00208611|DIETARY_SUPPLEMENT|Vitamin B12 Supplementation|1000 micrograms daily
223917100|NCT06819163|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 12 weeks
223917101|NCT06819501|DEVICE|hyperbaric oxygenation treatment|Administration of 100% oxygen at a pressure of 2.0ATA once daily for 60-90 minutes for a total of 30-40 times.
223917102|NCT06819501|BEHAVIORAL|routine care|Administration of pressurised ice gloves 30 minutes before, during, and 30 minutes after administering paclitaxel chemotherapy drugs.
223917103|NCT03239613|OTHER|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
223917104|NCT06988215|OTHER|Kinesiology Taping with Exercise|Real kinesiology taping is applied to the suprahyoid region in three directions (from the hyoid bone to the clavicle, to the sternum, and horizontally). Taping is renewed every three days. Participants also perform effortful swallowing and oromotor exercises daily (5 sets of 10 repetitions) for 6 weeks.
223917105|NCT06988215|OTHER|Placebo Taping with Exercise|Non-therapeutic kinesiology taping with no tension is applied to the suprahyoid region to mimic the appearance of the therapeutic tape. Participants perform the same daily swallowing and oromotor exercises as the intervention group for 6 weeks
223917106|NCT06857292|DRUG|Telpegfilgrastim|"Experimental group: Patients were subcutaneously injected with Telpegfilgrastim 33μg/kg (maximum dose ≤2mg) 24h after chemotherapy, 21 days for one chemotherapy cycle, and only one chemotherapy cycle was observed.~Pharmacokinetic determination: Among them, 8 patients underwent pharmacokinetic determination. The pharmacokinetic sampling time points were blood samples taken before administration, 12 h, 24 h, 48 h, 120h, 168 h, 336 h, 480h after administration. A total of 8 blood samples were collected, and the pharmacokinetic characteristics of the experimental drugs were analyzed by ELISA."
223917107|NCT06410157|BEHAVIORAL|Daily practice|Participants will be asked to undergo daily mindfulness practice while regulating (either increase or decrease) heart rate oscillation.
223917108|NCT04532177|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
223917109|NCT06855979|OTHER|Food with high antioxidant potential|The dietary intervention using fruit and nut bars with high antioxidant activity will last 1 month. Before and after the procedure, oxidative-antioxidant markers in the blood and intestinal microflora in the stool will be determined.
223917110|NCT06857721|DEVICE|Intraoral Scanners|Intraoral scanners for pediatric patients
223716687|NCT03875885|BEHAVIORAL|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
224080919|NCT05008094|DIAGNOSTIC_TEST|Fluorescent correlation spectroscopy (FCS)|Fluorescent correlation spectroscopy (FCS), more specifically, ThT fluctuating intensity fluorescent analysis (FIFA) will be used to determine the existence of pathological conformation protein forms and their relation to the disease's grade and therapy.
224080920|NCT04177719|DRUG|Oxytocin|oxytocin will be given intranasally. The order of administration will be counterbalanced
224080921|NCT04177719|DRUG|Placebo|Saline placebo will be given intranasally. The order of administration will be counterbalanced
224278401|NCT05965817|DRUG|SGM-101 op top of ICG|SGM-101 op top of ICG
223917111|NCT06855901|DEVICE|Ultra-longterm EEG monitoring at home by means of a scubscalp electrode implant.|"Subjects with uncontrolled seizures previously investigated in outpatients epilepsy clinics and for whom an admission to the Epilepsy Monitoring Unit is indicated by clinical practice, will be screened for eligibility.~Implantation of subcutaneous EEG electrodes will be done at each Research Unit by a neurosurgeon/surgeon. The implantation procedure will consist of placing subcutaneously the electrode contacts over the site of the suspected seizure focus as defined by a previous Video-EEG and neuroimaging evaluations. Surgical procedures will be performed under local anesthesia. If the device is well-tolerated, all the subjects will proceed to the extended home monitoring study, which is the core of the study protocol. The aim of the extended study is to assess sensitivity of seizure detection of sqEEG in comparison to subject's home diary, and the tolerability and safety of sqEEG in a period of 6 months."
223917112|NCT06857331|PROCEDURE|Erector Spinae Plane Block using 0.2% ropivacaine|Bilateral thoracic ESP block on the day of the transplantation with a subsequent catheterization will be suggested for the patients. In case of their written consent for the participation in the study this procedure will be performed on the day of the operation. 0.2% ropivacaine is going to be used throughout all the perioperative period.
223917113|NCT06856876|OTHER|Multidisciplinary Care Team (MDCT) Approach|A personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines.
223917114|NCT06856876|OTHER|Standard Breast Cancer Therapy|Breast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated.
223917115|NCT06856980|PROCEDURE|Suture button fixation|Patients undergoing suture button fixation of syndesmosis injury.
223917116|NCT06856980|PROCEDURE|Syndesmotic screw fixation|Patients undergoing syndesmotic screw fixation of syndesmosis injury.
224080922|NCT06386848|DRUG|Botulinum toxin|Botulinum toxin doses injected in dystonia
224278402|NCT01134341|DRUG|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
224278403|NCT01134341|DRUG|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
224278404|NCT01134341|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
224278405|NCT01134341|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
223530212|NCT06490718|DRUG|USG ESPB|"After obtaining the appropriate sonographic window, under strict aseptic precautions, the block needle is inserted in the plane of the US beam in a caudad to cranial direction until the tip is in contact with the transverse process (TP) at its lateral aspect. A test bolus of 0.9% saline (1-2 ml) is injected and sonographic evidence of erector spinae muscle displacement (posterior) from the underlying TP is sought to ensure that the tip of the block needle is indeed at the erector spinae muscle plane. The study drug from the 25 ml syringe with the label 'study drug for ESPB' (containing either 25 ml of 0.5% ropivacaine with 1:200,000 adrenaline or 0.9% saline depending on the group allocation) is injected in small aliquots over a minute. The anaesthesiologist performing the block and the patient is blinded to the group allocation.~Successful injection reveals a clearly delineated posterior displacement of the erector spinae muscle."
223530213|NCT06490718|DRUG|Intravenous Infusion|"Following ultrasound-guided erector spinae plane block (USG ESPB), patients will be transferred to the operating room. General anesthesia (GA) will be administered according to a standardized protocol.~Study Drug Infusion:~Immediately after securing the airway, an intravenous infusion from a 50 ml syringe labeled study drug for IVI will commence. The study drug contains either 30 ml of 2% lidocaine or 0.9% saline, depending on group allocation. The infusion begins with a bolus rate of 0.1 ml/kg over 10 minutes and continues at 0.1 ml/kg/hr until surgical wound closure."
223530214|NCT06304857|DRUG|Dapagliflozin|10 mg tablet q.d
223917117|NCT06855823|DRUG|Golicitinib combined with Pomadomide|golidoctinib 150 mgqd, pomalidomide 2mg/3mg/4mgqd
223917118|NCT06856603|RADIATION|stereotactic radiation therapy in ablative doses to each metastatic site|Stereotactic ablative radiation therapy will be utilized for each metastatic site in patients with 6 to 10 sites of metastasis (persistent or progressive disease).
223917119|NCT06820112|OTHER|mechanical ventilation|patients who received mechanical ventilation
224080923|NCT00880256|BEHAVIORAL|mindfulness-based stress reduction|An 8-week course in mindfulness training
224080924|NCT05963763|BEHAVIORAL|Career Navigator Coaching|"The Career Navigator will support participants with a tailored approach to reach career and financial goals through one or more of the following services, in addition to referrals to other external services (community-based organizations) as needed for 6 months:~1. Career pathway navigation~2. Employee benefit maximization~3. Financial literacy and wealth building~4. Services funds for resources that mitigate specific barriers or needs."
224080925|NCT03649295|OTHER|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
224278406|NCT02603549|OTHER|Pituitary panel will be drawn pre-op and post-op for all patients.|
224278407|NCT00114595|DRUG|eicosapentaenoic acid|
224278408|NCT02550587|BEHAVIORAL|satisfaction|anesthesia satisfaction rates
223917120|NCT06818981|DRUG|8mg dexamethasone|Minimal research exists on how to treat pain, odynophagia, and dysphagia in sleep surgery patients. One study by Williams et al. evaluated the use of a one-time dose of intravenous or intramuscular dose of steroids versus placebo after uvulopalatopharyngoplasty but did not find a clinically significant difference between the two groups postoperatively. However this study mentioned that their current intervention was too short and that a longer-term steroid intervention could be beneficial. This is the goal of this intervention.
223917121|NCT06816888|OTHER|No Prompt|Presence and type of message included in the prompt will be randomized
223917122|NCT06816888|OTHER|Prompt 1|Presence and type of message included in the prompt will be randomized
223917123|NCT06816888|OTHER|Prompt 2|Presence and type of message included in the prompt will be randomized
223917124|NCT06818578|PROCEDURE|Lesion Sterilization and Tissue Repair Therapy|LSTR treatment is a minimally invasive, cost-effective, and easy-to-apply procedure for necrotic primary teeth, with a focus on disinfection with an antibiotic mixture without the need for root canal instrumentation.
223917125|NCT06818578|DRUG|Different Antibiotic Combinations|Clinical and Radiographic Success of Different Antibiotic Combinations (evaluating whether the alternative 3Mix-MP combination of clindamycin instead of minocycline is as effective as the standard 3Mix-MP formulation) in Lesion Sterilization and Tissue Repair Therapy
223917126|NCT06818890|DEVICE|Definitive abutment base|Definite abutment base, this is a two-piece definitive abutment where the base is connected to the implant as soon as it is placed.This abutment will allow the tissues around the implant to heal undisturbed, thus, establishing a good and healthy periimplant soft and hard tissue with long-term stability.
223917127|NCT06818890|DEVICE|Conventional Healing Abutment|A healing abutment of different diameters (4.3, 5, 6 mm) and heights (1.5, 3 mm) is placed on the day of the surgery, and the flaps are sutured around them to allow for tissue healing around the abutment to create an optimum emergence profile and tissue cuff around the implant and definitive abutment.
223917128|NCT06855615|DRUG|Mixtard® 30 TDS|The clinical use of TDS premixed human insulin (PHI) is unclear. In contrast, biphasic insulin analogue given thrice daily is a well-proven, safe and suitable alternative to an intensified insulin regimen.
223917129|NCT06855615|DRUG|Insulatard® once daily and thrice daily prandial Actrapid®|Basal bolus regimen is considered a physiological form of treatment and the standard of care in clinical practice but the multiple daily injections often lead to poor compliance.
223917130|NCT06856811|PROCEDURE|tmj lavage with ringer lactate solution|tmj lavage using 150ml ringer lactate in symptomatic side of unilateral anterior disc displacement with reduction
223917131|NCT06660875|DRUG|Serratus posterior superior intercostal plane block|Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
223917132|NCT06660875|DRUG|Interscalene brachial plexus block and superficial cervical plexus block|İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
224080926|NCT03649295|OTHER|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
224080927|NCT04871711|DRUG|Delgocitinib cream|Cream for topical application
224080928|NCT04871711|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream\> except that it does not contain any active ingredient.
224080929|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|20 minutes exposure
224080930|NCT00229307|BEHAVIORAL|Prolonged Exposure (PE) therapy|40 minutes exposure
224080931|NCT03467646|PROCEDURE|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
224080932|NCT03467646|PROCEDURE|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
224080933|NCT03467646|PROCEDURE|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
224080934|NCT00028912|DRUG|bortezomib|
224080935|NCT00028912|DRUG|carboplatin|
224080936|NCT04887493|DRUG|Misoprostol|Misoprostol 25µg will be used for both the study arms
224278409|NCT00081172|RADIATION|lutetium Lu 177 monoclonal antibody J591|
224278410|NCT03473067|BEHAVIORAL|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
224278411|NCT03473067|OTHER|Capacity Building|Schools will participate in teacher training and parent training.
224278412|NCT06471478|COMBINATION_PRODUCT|intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion|patients received intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion for decresing donor specific antibodies.
224278413|NCT00695383|BEHAVIORAL|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
224278414|NCT00695383|BEHAVIORAL|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
224278415|NCT06380257|OTHER|Observational study methods|Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.
223530215|NCT06304857|DRUG|Placebo|tablet matching dapagliflozin 10 mg q.d
223530216|NCT03558126|DEVICE|silicone tube|
223530217|NCT06466395|DRUG|Venetoclax|Given by PO
224278416|NCT02076776|BEHAVIORAL|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
224278417|NCT02076776|BEHAVIORAL|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
224278418|NCT02076776|BEHAVIORAL|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
224278419|NCT00745134|DRUG|Capecitabine|Given PO
223530218|NCT06466395|DRUG|Hyper-CVAD|Given by IV
223530219|NCT05494086|PROCEDURE|DPLDG|Dual-port laparoscopic distal gastrectomy
223530220|NCT05494086|PROCEDURE|LDG|Laparoscopic distal gastrectomy
223530221|NCT06021600|DRUG|Cladribine|Given by PO and Given by IV (vein)
223530222|NCT03371719|DRUG|Apalutamide|Given PO
223917133|NCT06659861|OTHER|RV3278B-OS0386|Cosmetic product to be applied twice a day on the face during the whole study
223917134|NCT06659861|OTHER|RV4632A-RY1845|Cosmetic product to be applied in the event of facial skin discomfort only
223917135|NCT06662682|OTHER|Whole-Body Vibration|The intervention (IC) will be specified as a five-minute Whole-Body Vibration session. The WBV take place on a side alternating vibration plate (Wellengang, Germany). The patients stand barefoot on the vibration plate on a prescribed position. In this position the amplitude will be 6-7mm. The WBV protocol contains mobilizing sequences with lower frequencies and activating sequences with higher frequencies
223917136|NCT06662682|OTHER|Control Condition|Non-intervention control condition
223917137|NCT06663813|BEHAVIORAL|Educational Intervention|Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.
223917138|NCT06659536|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device|Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar URO device using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the symptomatic treatment of urge incontinence in adults with overactive bladder in accordance with the approved labelling.
223917139|NCT06662019|DRUG|N-IP-00001 inhalation solution|Multiple ascending dose (MAD) study. Over the 2 dosing days participants will receive a total of 6 inhaled doses of 5 ml of N-IP-00001 at increasing concentrations, ranging from 0.5mg/ml to 16mg/ml (total volume loaded in the nebuliser is 6 ml per dose).
223917140|NCT06662019|DRUG|0.9% NaCl isotonic saline solution|Nebulized treatment consisting of 0.9% saline solution.
223917141|NCT06661083|DIETARY_SUPPLEMENT|EGCG, FA, HA, B12|EGCG + FA + HA + B12 (1 cps /die)
224080937|NCT04159038|OTHER|Intervention Group|The immediate intervention group will receive training on how to identify children at risk for developmental disabilities and how to refer to Early Intervention/Early Childhood Special Education.
224278420|NCT00745134|DIETARY_SUPPLEMENT|Curcumin|Given PO
223530223|NCT03371719|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223917142|NCT04214834|DRUG|Morphine|The dose interval for morphine will be either every 3 or 4 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
223917143|NCT04214834|DRUG|Methadone|The dose interval for methadone will be every 8 or 12 hours, per hospital practice. Clinical teams are asked to wean study drug at least every 24 hours.
223917144|NCT03349801|OTHER|No intervention|According to clinical practice.
223917145|NCT04947137|DRUG|Tc99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
223917146|NCT05464251|OTHER|Prospective chart review of subjects diagnosed with spinal epidural abscess|Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
223917147|NCT06498388|OTHER|Stiffness measurement by visco-elastography|Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
223917148|NCT01692366|DRUG|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
223917149|NCT04472013|OTHER|Data collection from lumbar puncture|Cerebro spinal fluid (CSF) will be acquired by lumbar puncture and sent for routine analysis including CSF chemistry, cytology and microbiology. Targeted CSF proteomics using OLINK Proximity Extension Assay (PEA) technology to assess a potential CNS-contribution of the disease will be performed.
223917150|NCT04472013|OTHER|Data collection from blood draw|Plasma samples will be acquired for plasma cytokine proteomics using CyTOF (mass cytometry analysis) technology.
223917151|NCT04472013|OTHER|CNS magnetic resonance imaging (MRI) imaging|3Tesla magnetic resonance imaging (MRI) will be performed to document early/manifest encephalitic changes in COVID-19 patients.
223917152|NCT04472013|OTHER|Microscopy of defined brain regions on autopsy specimens|High dimensional, microglia-centric CODEX fluorescent microscopy of defined brain regions on autopsy specimens will be acquired from medulla oblongata, cortex, cerebellum, and olfactory bulb. A brain-specific CODEX panel for the assessment of the immune microenvironment was implemented, with inclusion of a wide array of myeloid/microglia markers, T-cell markers, and a few neuronal markers. All the antibodies have been validated and tested in formalin-fixed tissues of different zones of glioblastoma tumors including invading tumor periphery. The Panel will be modified to include the viral entry receptors, CD147, ACE2 and TMPRSS2. Presence of SARS-CoV-2 virus particles will be assessed by qPCR, andMultiplexed Ion Beam Imaging (MIBI) technology will be used to visualize tropism of virus to specific cellular brain compartments.
224080938|NCT04159038|OTHER|Control group|The control group will continue usual WIC care.
224080939|NCT06778018|DIETARY_SUPPLEMENT|Lotus Seed|Regimen supplemented with 200 mg/kg of Lotus Seed capsules for 12-month randomized controlled trial.
224080940|NCT06778018|DIETARY_SUPPLEMENT|Placebo|Regimen supplemented with 200 mg/kg of Starch capsules for 12-month randomized controlled trial.
224080941|NCT04741269|DIAGNOSTIC_TEST|Find a link between lack of knee flexion and meniscal posterior luxation fixed|"Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways.~Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift."
224080942|NCT03757832|DEVICE|Liver Imaging|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality.
224080943|NCT03682315|DEVICE|Biphasic phycogenic biomaterial|Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
224278421|NCT00745134|OTHER|Laboratory Biomarker Analysis|Correlative studies
224278422|NCT00745134|OTHER|Pharmacological Study|Optional correlative studies
224278423|NCT00745134|OTHER|Placebo|Given PO
224278424|NCT00745134|OTHER|Quality-of-Life Assessment|Ancillary studies
223530224|NCT03371719|OTHER|Placebo Administration|Given PO
223530225|NCT01813383|OTHER|There is not any intervention|
223530226|NCT06523803|DRUG|ZW171|Administered per protocol requirements
223530227|NCT01644591|OTHER|Quality-of-Life Assessment|Ancillary studies
223530228|NCT01644591|OTHER|Questionnaire Administration|Ancillary studies
223917153|NCT06299683|BEHAVIORAL|Psychosocial Treatment|The psychosocial self-management intervention consists of 8 weekly 50-minute individual visits with an assigned trained therapist. Sessions follow a structured protocol that has been developed with the patient population and tested in a prior study. Treatment modules are individualized and include topics such as pain coping strategies, relaxation training, education on IC/BPS, and communication strategies.
223917154|NCT06299683|OTHER|Pelvic Floor Physical Therapy|The pelvic floor physical therapy condition consists of 10 weekly 45-minute individual visits with an assigned trained physical therapist. In IC/BPS, pelvic floor physical therapy (PT) uses manual manipulation to release localized muscle tension, trigger points, and correct other scars and restrictions to reduce pain and urgency symptoms. Specific techniques will include external connective tissue manipulation to the abdominal wall, back, buttocks and thighs, myofascial trigger point release, and internal transvaginal/transrectal treatment of the soft tissues of the pelvic floor with connective tissue and myofascial manipulation to pelvic floor musculature
223917155|NCT06583213|PROCEDURE|Fractional Spinal Anaesthesia.|An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).
223917156|NCT06583213|PROCEDURE|Conventional Spinal Anaesthesia|"Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes."
223917157|NCT06819540|BEHAVIORAL|Mindfulness-Based Stress Reduction Programme|Mindfulness involves paying attention to what is occurring in the present moment, noticing the particularity of that attention, and accepting without judgement all states of awareness. Mindfulness is important in moving individuals away from automatic thoughts, habits and unhealthy patterns of behaviour, and therefore can play an important role in promoting conscious and self-affirmed behavioural regulation, which has long been associated with enhancing well-being. Mindfulness is a way of regulating one's self, thoughts and awareness. It has been demonstrated to enhance the ability to remain present in the moment, arising through purposeful, momentary, non-judgemental attention to experience. Recently mindfulness appears to have a positive impact on helping people overcome addiction and psychological problems and providing effective techniques to manage them
223917158|NCT03617237|OTHER|Retrospective Populations|"All patients who are currently treated by any physician at the University of Texas Southwestern campus Aston Clinic, Seay Clinic, PHHS Clinic, Moncrief Radiation Oncology, St. Paul West Campus Radiation Oncology, East Radiation Oncology Clinic will be included in the registry. The data from the charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number.~1. The research involves no more than minimal risk to the subjects.~2. The waiver will not adversely affect the rights and welfare of the subjects.~3. The research could not practicably be carried out without the waiver.~4. Whenever appropriate, the subjects will be provided with additional pertinent information after participation."
223917159|NCT06660446|OTHER|Exercise|The lymphoma unit of the Donostia University Hospital (HUD) is part of the Onkofrail project that analyzes the impact of a physical activity in older cancer patients. The Onkofrail study has included everything type of solid tumors and very diverse treatments, which is a limitation methodology that could condition the analysis of the results. Therefore, the need of proposing a new PE project in a homogeneous population such as that of people with lymphoma, the most prevalent hemopathy in our environment, which has a great survival, but present important adverse effects secondary to treatment systemic.
223917160|NCT03884101|DRUG|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
223917161|NCT03884101|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
223917162|NCT03884101|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
223917163|NCT03884101|DRUG|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
223917164|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel one time a day during Day 3-Day 12.
224278425|NCT00745134|RADIATION|Radiation Therapy|Undergo radiation therapy
224278426|NCT04773509|PROCEDURE|Paravertebral block|Randomly selected patients of the PVB group are performed PVB with 0.2% ropivacaine on both sides.
224278427|NCT05436132|BEHAVIORAL|VR and AR oral healthcare curriculum training|HCWs in the VR/AR group received 2.5 hours VR and AR oral healthcare curriculum training. VR oral care training system was training the standard oral healthcare procedure for different physical and oral conditions in elderly people.AR oral care training system was training for the manual Bass brushing technique.
223530229|NCT01644591|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223530230|NCT04746898|OTHER|Virtual Reality Training|Students received their basic life support application training through virtual reality glasses with special software.
223530231|NCT04746898|OTHER|High Fidelity Simulation Training|Students received their basic life support application training through high fidelity simulator mannequins.
223530232|NCT04746898|OTHER|Low Fidelity Simulation Training|Students received their basic life support application training through low fidelity simulator mannequins.
223530233|NCT03772535|DIAGNOSTIC_TEST|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
223530234|NCT05473065|DEVICE|Multiaxial Prosthetic Foot Emulator|Participants will walk in the laboratory with the multiaxial Prosthetic Foot Emulator (PFE) in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.
223716688|NCT03875885|BEHAVIORAL|CONTROL|This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
224080944|NCT03682315|DEVICE|Xenograft bovine hydroxyapatite|Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
224080945|NCT03473132|DRUG|four factor prothrombin complex concentrate|After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
224080946|NCT04186026|OTHER|Saline + saline|Double saline infusion followed by an ad libitum meal
224080947|NCT04186026|OTHER|Neurotensin + saline|Neurotensin + saline infusion followed by an ad libitum meal
224080948|NCT04186026|OTHER|GLP-1 + saline|GLP-1 + saline infusion followed by an ad libitum meal
224080949|NCT04186026|OTHER|GLP-1 + Neurotensin|GLP-1 + Neurotensin infusion followed by an ad libitum meal
224080950|NCT01055535|DRUG|Microplasmin|125 µg intravitreal injection
224080951|NCT03778086|PROCEDURE|gonioscopy|gonioscopic observation and grading of iridocorneal angle
224080952|NCT05365165|DRUG|Sevoflurane|Sevoflurane will be applied during aortic cross- clamping in cardiac surgery
224080953|NCT00347828|DRUG|Moxifloxacin ophthalmic solution 0.5%|
224080954|NCT00347828|DRUG|Gatifloxacin ophthalmic solution 0.3%|
224080955|NCT04947176|DIETARY_SUPPLEMENT|Supplement|200mg C15:0 once daily
224080956|NCT04947176|OTHER|Placebo|Matching placebo once daily
224080957|NCT03463590|DEVICE|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
224080958|NCT02183519|DRUG|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
224080959|NCT02183519|OTHER|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
224080960|NCT04291755|DRUG|Pembrolizumab Injection|Any checkpoint inhibitor is acceptable
224080961|NCT01612715|OTHER|Segmental Allergen Challenge|segmental allergen challenge
224080962|NCT01831960|DRUG|cortexolone 17α-propionate|
224080963|NCT02541773|DEVICE|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
224080964|NCT03961360|DRUG|Aspirin 81 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
224080965|NCT03961360|DRUG|Aspirin 162 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
224080966|NCT00006247|DRUG|semaxanib|
224080967|NCT03542201|OTHER|PLS|Participants will have to read standard textual information about the conducted systematic review (approximately 500 words)
224080968|NCT03542201|OTHER|Blogshot|Participants will have to read the blogshot information about the results of the Cochrane systematic review (approximately 100 words)
224080969|NCT03863626|OTHER|Frusemide IV shots|"giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)"
224080970|NCT03863626|OTHER|Frusemide IV infusion|"giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade"
223716689|NCT01265732|DRUG|PF-04191834|single dose, 100mg, dispersion
224080971|NCT04945798|OTHER|OMT|OMT: direct myofascial release for the triplanar diagnonosis to the OA, thoracic outlet, respiratory diaphragm and pelvic diaphragm concluding with a pedal pump for 120 seconds
224080972|NCT03754907|PROCEDURE|Endocutter stapler|Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson \& Johnson K.K., Tokyo, Japan)
224080973|NCT03754907|PROCEDURE|suture material|absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
224080974|NCT04448990|DEVICE|TENS eco 2 Transauricular vagal nerve stimulation|"Auricular electrical stimulation will be applied bilaterally using Transcutaneous Electrical Nerve Stimulation device TENS eco 2 (Schwa-Medico, Pierenkemper GmbH, Ehringshausen, Germany).~tVNS will be applied bilaterally using electrical square impulses delivered in blocks of 9 impulses with a frequency of 100 Hz and a pulse width of 200 μs emitted twice per second resulting in mixed frequency pattern of 100 Hz/2 Hz with the current intensity, that will be individually adjusted for each ear separately until the maximal tVNS intensity, which is not uncomfortable or painful, will be achieved."
224080975|NCT04448990|DEVICE|Sham TENS eco 2|Sham
224080976|NCT01653041|DRUG|Everolimus|
224080977|NCT01401504|DRUG|ASP3026|oral
224080978|NCT04804592|DEVICE|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
224080979|NCT04804592|DEVICE|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
224080980|NCT04804592|DEVICE|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
224080981|NCT06233695|DRUG|Potassium sparing diuretic|Starting Spironolactone or Eplerenone at the time of enrollment.
224080982|NCT02058602|OTHER|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
223716690|NCT01265732|DRUG|PF-04191834|single dose, 100mg, suspension
224080983|NCT06066892|PROCEDURE|Impression techniques|3 types of impression techniques for all on four
224080984|NCT01032148|DRUG|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
224080985|NCT01397578|DRUG|MABT5102A|Repeating subcutaneous injection
224080986|NCT01397578|DRUG|MABT5102A|Repeating intravenous infusion
224080987|NCT01397578|DRUG|placebo|Repeating subcutaneous injection
224080988|NCT01397578|DRUG|placebo|Repeating intravenous infusion
224080989|NCT02528240|PROCEDURE|EMS|
223917165|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo one time a day during Day 3-Day 12.
223716691|NCT01265732|DRUG|PF-04191834|single dose, 300mg, suspension
223716692|NCT00205738|DRUG|Risperidone, Olanzapine|
223917166|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 2 times a day during Day 3-Day 12.
223917167|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 2 times a day during Day 3-Day 12.
223917168|NCT06824948|DRUG|Timolol Maleate Gel|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with 0.5% timolol maleate gel 3 times a day during Day 3-Day 12.
223917169|NCT06824948|DRUG|Placebo|A 2-day washout phase follows 1 dose on Day 1, the subjects are applied with placebo 3 times a day during Day 3-Day 12.
223917170|NCT06267716|PROCEDURE|PENG block|preoperative ultrasound-guided pericapsular nerve group block
223917171|NCT06267716|PROCEDURE|IPB|preoperative ultrasound-guided iliopsoas plane block
223917172|NCT06818500|OTHER|high-fat meal|Participants will report fasted and consume two Jimmy Dean breakfast bowls (sausage).
223917173|NCT06818500|OTHER|Stress|Participants will report fasted and undergo a mental stress task.
223917174|NCT03370913|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
223917175|NCT06816277|PROCEDURE|Desbridamiento de periimplantitis|"The implant with the most severe involvement was selected, although the treatment was performed on all implants, to prevent patients with more affected implants from having greater statistical relevance.~The peri-implant surgical treatment was performed under local infiltrative anesthesia with 4% articaine with 1:100,000 adrenaline. Debridement was performed using ultrasound with irrigation, complemented using curettes. Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded. It was sutured with 4/0 monofilament in a pre-assembled 3/8 s"
223917176|NCT06816277|DRUG|Aplicación de melatonina|Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded.
223917177|NCT06816277|OTHER|Placebo application|Treatment with melatonin or placebo was applied through computer block randomization. To achieve blinding, a different code was assigned to the group applying 1.9 mg of melatonin (A) and to the control group (B) applying placebo (dextrinomaltose 2 mg) powder and the samples and records were coded.
223917178|NCT05521477|DIETARY_SUPPLEMENT|SLAB51|One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
223917179|NCT06825962|OTHER|Water intake|Water ingested to fully replace sweat losses during exercise.
223917180|NCT06825962|OTHER|Water restriction|Water restriction to induce hypohydration of \~3% body mass through sweat losses during exercise.
223917181|NCT06824220|DEVICE|High-Flow Tracheal Oxygen|High-Flow Tracheal Oxygen is the use of high oxygen flows in tracheostomized patients. Unlike conventional oxygen therapy which is performed through siliconized nasal prongs, this is done through a connector directly on the tracheostomy tube.
223917182|NCT06826339|OTHER|ACApatch™|Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223917183|NCT06826339|OTHER|caregraFT™|Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223917184|NCT06826339|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223917185|NCT06825286|DRUG|Bupivacaine|Patients received general anesthesia and bilateral ultrasound guided transmuscular quadratus lumborum block wilh (20 ml bupivacaine 0.25%).
223917186|NCT06825286|DRUG|Bupivacaine and Dexmedetomidinc) group|Patients received general anesthesia and bilateral ultrasound guided transmuscular quadratus lumborum block with (20ml Bupivacaine 0.25%) + (Dexmedetomidine Imic/kg)
223940468|NCT03844919|DEVICE|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
224080990|NCT02528240|DEVICE|+ occlusive membrane|
224080991|NCT02528240|DEVICE|conebeam CT|
224278428|NCT05436132|BEHAVIORAL|traditional teaching methods oral healthcare curriculum|HCWs in the control group received 2.5 hours traditional teaching methods of oral healthcare curriculum training.
223716693|NCT01120301|DEVICE|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
224278429|NCT03747185|OTHER|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
223917187|NCT06817824|OTHER|Su-jok therapy|"Su Jok therapy was developed by South Korean scientist Professor Woo Jae Woo (1942-2010) in 1986. In Korean language, 'Su' means hand and 'Jok' means foot (Friman \& Chelala, 2016; Ivanov 2018; Woo 1987, 1991, 2000, 2002, 2007; Sharma \& Sharma, 2015). In Su Jok therapy, it is argued that there are reflection points of the body in the hands and feet and that these points activate every organ and part of the body like a remote control (Woo 1987, 1991, 2000, 2002, 2007; Şimşek \& Alpar, 2020).~Holistic approaches, energy flow and meridians form the basis of Su Jok therapy (Ivanov, 2018; Seth, 2013). Su Jok is an integrated therapy method that includes many tried and trusted methods of oriental medicine (Ponni, 2011; Rodríguez et al., 2018; Seth, 2013). In particular, it is similar in content to practices such as acupuncture and acupressure, which are approaches expressed by the same philosophy (Ivanov 2018; Ponni, 2011; Rodríguez et al., 2018)."
223917188|NCT06825117|DIETARY_SUPPLEMENT|OMNi-BiOTiC® 41167|The probiotic OMNi-BiOTiC® 41167 consists of 3g of 3 x 10\^9 CFU total L. gasseri W15, L. plantarum W1, L. plantarum W21, B. lactis W51, L. acidophilus W70 and L. reuteri W192 per sachet of which two are to be taken each day. Additional non-probiotic components are cranberry-extract (0.01g), D-mannose (0,4 g), vitamin D (2,25µg), maize starch and hydrolyzed rice protein. All the strains in OMNi-BiOTiC® 41167 are specifically tested and selected for their inhibition potential against the known most common uropathogens like the uropathogenic Escherichia coli (UPEC), Klebsiella pneumonia, Proteus mirabilis and Entercoccus faecalis.
223917189|NCT06825117|DIETARY_SUPPLEMENT|Placebo|The placebo consists of all components of OMNi-BiOTiC® 41167, except the probiotic bacteria, cranberry-extract, D-mannose and vitamin D. It has the same smell, taste and texture as the OMNi-BiOTiC® 41167.
223917190|NCT06826300|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
223917191|NCT06826300|OTHER|Placebo|Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
223940469|NCT03844919|BEHAVIORAL|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
223940470|NCT02019459|OTHER|Very low nicotine content cigarettes|
223940471|NCT02019459|OTHER|standard nicotine content cigarettes|
223716694|NCT05014763|PROCEDURE|connective tissue graft|Connective tissue graft surgery will be done for increasing soft tissue volume. In this methods connective tissue will be harvested from lateral palate or tuberosity area.
223716695|NCT02821182|RADIATION|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h."
223940472|NCT00002748|BIOLOGICAL|gene-modified tumor cell vaccine therapy|
223940473|NCT00002748|BIOLOGICAL|interleukin-2 gene|
223940474|NCT04420767|DEVICE|tDCS|Individuals undergo 20min daily sessions receiving actual tDCS to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
223940475|NCT04420767|DEVICE|Sham brain stimulation|Individuals undergo 20min daily sessions receiving sham stimulation to the brain (to the right DLPFC: dorsolateral prefrontal cortex)
223940476|NCT04420767|BEHAVIORAL|Go-No GO task|During the brain stimulation sessions, all individuals will be asked to perform a 10 min-computerized task related to inhibitory control (Go-No Go)
223940477|NCT06101875|OTHER|Health Coach (Health coaching)|Patients will be assigned a health coach and be eligible to 8 times, 1 hour sessions over a 12 week period. The health coach will use techniques to increase their ability to self-manage, motivation levels and commitment to change their behaviour.
223940478|NCT06101875|OTHER|Digital Toolkit (Control)|This is an online website, unsupervised, 12-week self-management programme.
223940479|NCT00767741|DEVICE|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
223940480|NCT01847534|OTHER|Supplemental PN|
223940481|NCT01847534|OTHER|Standard Care|
223940482|NCT05473416|OTHER|McKenzie back extension exercise|McKenzie's back extension exercise consists; start with your belly facing down on the mat. Angle your legs in line with your hips, point your toes, and breathe into the next movement. Gently bending your elbows, push yourself up off the floor, until you feel the extension in your back. Be mindful not to lock your elbows as you support your weight with your hands and wrists for 10 seconds. Take deep inhales and exhales as you move in and out of the pose. Patients will be performed these activities under the supervision of physiotherapist.
223940483|NCT05473416|OTHER|Pilates pelvic tilt exercise|Pilates pelvic tilt exercise consists; lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Pull your belly button in toward your spine, pushing your pelvis up toward the ceiling. Tighten your gluteus and hip muscles as you tilt your pelvis forward. Hold for 10 seconds.
223940484|NCT05473416|OTHER|Baseline treatment|Postural guidelines + proper lifting technique + stretch break Rest
223940485|NCT02235298|DRUG|Dapagliflozin|5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
223940486|NCT02235298|DRUG|Metformin|500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
223940487|NCT02235298|DRUG|Placebo|Placebo pill taken once daily to mimic Dapagliflozin
223940488|NCT01553487|OTHER|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
223940489|NCT01333605|DRUG|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
223940490|NCT06191458|DRUG|Primaquine|Primaquine 0.5 mg/kg (Government Pharmaceutical Organization, Thailand) will be given once daily with food for 14 days. This is the dose recommended by the World Health Organization for radical cure of P. vivax in tropical regions. Doses will be directly supervised (DOT).
223940491|NCT06350760|BEHAVIORAL|Active control condition|The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021.
223917192|NCT06825975|DEVICE|Hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
223917193|NCT06825078|DEVICE|multiparametric MRI|"An MRI scan will be performed within 2 weeks of the discovery of a solid lung nodule ≥ 5mm on the screening scan.~When a follow-up scan is indicated, an MRI will be repeated on the same day as the follow-up scan.~The MRI sequences that will be performed are: SpiraleVibe UTE, T1map, T2 map and Diffusion.~A synthetic scanner image will be generated from the UTE morphological MRI image using a generative artificial intelligence (GAN) model."
223917194|NCT00160732|DRUG|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
223917195|NCT00160732|PROCEDURE|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
223917196|NCT06825507|BEHAVIORAL|Lifestyle-based mental health care|Participants in the LSC will access a stepped care treatment consisting of 3 steps, including self-help multicomponent LM treatment (Step 1), guided self-help based on the LM approach and low-intensity cognitive behavioural therapy for depression (Step 2), and specialist mental health services (Step 3).
223917197|NCT06825507|OTHER|Care-as-usual|Participants in the CAU will receive their baseline depressive symptom severity via text message following randomisation, and they will have unrestricted access to mental health services based on their needs and preferences, such as pharmacological treatments, psychological treatments, and complementary and alternative medicine.
223917198|NCT06824909|DEVICE|ROSE-AI diagnostic system|"All samples were obtained due to the necessity for disease treatment and in accordance with routine clinical workflows. After the pathological diagnoses were confirmed by the pathology departments of the hospitals affiliated with the respective endoscopic centers, the eligible pancreatic puncture Diff-Quik stained smears were borrowed and transferred to Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University. There, the self-developed Zhiying Shunxi system was used to capture corresponding traditional light microscope RGB images. After the imaging was completed, all specimens were returned to the endoscopic centers from which they originated. Using the RGB images as input, an artificial intelligence algorithm was developed to assist in differentiating solid pancreatic lesions."
223917199|NCT03169634|PROCEDURE|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
223917200|NCT03169634|PROCEDURE|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
223917201|NCT03169634|PROCEDURE|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
223917202|NCT04906824|DEVICE|great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing|VascuCel implantation in order to perform great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
223917203|NCT06507072|BEHAVIORAL|Adaptive Rock Climbing Program|Twelve week rock climbing program. The program will take place once per week over the course of twelve weeks.
223917204|NCT06241495|OTHER|Placebo|Placebo oil will be applied to the individuals included in the study. During the semen sample giving process, coconut oil (placebo) will be applied with a diffuser.
223716696|NCT03269942|PROCEDURE|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
223716697|NCT03269942|PROCEDURE|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
223716698|NCT00299455|DRUG|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
223917205|NCT06241495|OTHER|Aromatherapy|Aromatherapy will be applied to the individuals included in the study. During the semen sample giving process, lavender oil will be applied with a diffuser.
223917206|NCT05983055|DRUG|Dexamethasone 20mg|Periarticular dexamethasone injection
223917207|NCT06823011|DIAGNOSTIC_TEST|blood collection|Blood was collected from the study group and the control group at 10 am in the morning on an empty stomach.
223940492|NCT06350760|BEHAVIORAL|PROCARE-I+ 8-session|The active control condition will be based on PROCARE protocol, which was put into practice in PROCARE-I, in 2021. In addition, PROCARE-I+ adds additional modules, which allow adolescents to be provided with tools to address the risk factors they present.
223716699|NCT00299455|DRUG|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
223716700|NCT02702505|BIOLOGICAL|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
223716701|NCT02702505|OTHER|ProRoot MTA|Control group
223716702|NCT00569569|DRUG|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
223716703|NCT03740061|DIAGNOSTIC_TEST|Ultrasonographic assessment of muscle|Ultrasonographic assessment of quadriceps muscle
223716704|NCT03999372|BIOLOGICAL|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
223716705|NCT03999372|OTHER|ICSI|Normal ICSI procedure
223716706|NCT02397278|DRUG|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
223940493|NCT02744066|DEVICE|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
223940494|NCT03163563|DEVICE|Easywarm|Warming blanket
223940495|NCT03163563|DEVICE|BairHugger|Patient warming mattress with continuous warm air.
223940496|NCT04571437|DRUG|Capecitabine|Capecitabine metronomic combined with Letrozole
223940497|NCT04571437|DRUG|Letrozole 2.5mg|Letrozole daily alone
224080992|NCT04044833|BEHAVIORAL|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
224080993|NCT00212147|DRUG|General anesthesia with nitrous oxide|
224080994|NCT00212147|DRUG|General anesthesia without nitrous oxide|
224080995|NCT00935389|DRUG|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
224080996|NCT04230863|BEHAVIORAL|Neuroplasticity-based Computerized Cognitive Remediation|"The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization."
224080997|NCT05911646|OTHER|OSA-18 Survey|"OSA 18 is an 18-item questionnaire that uses a Likert-type scoring system to collect information about 5 subscales that are considered to be elements in quality of life: sleep disturbance, physical symptoms, emotional symptoms, daytime function, and caregiver concerns. On the basis of this information, a summary score is calculated and scores are divided into three categories:~Mild (40-60), moderate (61-80) and severe \>81."
224080998|NCT05911646|OTHER|Decisional Conflict (DCS)|The DCS is a 16-item survey in which participants are asked to respond to statements related to their decision on a five-point ordinal Likert scale: 0) strongly agree, 1) agree, 2) neither agree nor disagree, 3) disagree, and 4) strongly disagree. Scores are summed, divided by 16, and multiplied by 25. Scores range from 0, signifying that the respondent has complete certainty about the best choice, to 100, which signifies that the respondent feels extremely uncertain about the best choice.
223917208|NCT04298450|BEHAVIORAL|Active SMS Intervention|Welcome message letting participant know they will be contacted to book an appointment, followed by appointment reminders and other clinic information, psychoeducational materials, and a distress check-in with two-way feedback to their care team, all sent by SMS/text message at the participant's preferred time of day. If they indicate that they are in high distress, or they request, their care provider will be notified and asked to reach out to them. They will also receive crisis resources.The intervention will continue until the patient attends the first consultation appointment, or for up to 30 days if the patient does not attend, which reflects the program's practice of closing referrals for non-attending patients.
223917209|NCT04298450|BEHAVIORAL|Sham SMS|Single welcome message letting participant know they will be contacted to book an appointment.
223917210|NCT04633538|DEVICE|6MWT smartphone app|Use of smartphone app to measure 6 minute walk test (6MWT)
223917211|NCT06610045|OTHER|No intervention|No specific intervention is assess in this study.
223917212|NCT01027728|DRUG|CCX 354-C|"* Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
223917213|NCT05969223|DRUG|Risankizumab|Subcutaneous injection
223917214|NCT05969223|DRUG|Placebo for Risankizumab|Subcutaneous injection
223917215|NCT02595424|DRUG|Capecitabine|Given PO
223917216|NCT02595424|DRUG|Carboplatin|Given IV
224080999|NCT01733017|BEHAVIORAL|Sodium reduction|Teaching and skill building to reduce dietary sodium
224081000|NCT01733017|DIETARY_SUPPLEMENT|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
223917217|NCT02595424|DRUG|Cisplatin|Given IV
223917218|NCT02595424|DRUG|Etoposide|Given IV
223917219|NCT02595424|OTHER|Laboratory Biomarker Analysis|Correlative studies
223917220|NCT02595424|DRUG|Temozolomide|Given PO
223917221|NCT06745466|DRUG|ganirelix acetate|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration. Women will self-administer subcutaneous injections (0.25 mg/day in 0.5 ml of normal saline) of the GnRH antagonist ganirelix acetate (Antagon, Organon, Inc., West Orange, New Jersey,) every day for \~12-15 days (starting on day \~2-4 of the menstrual cycle). Testing will occur on day 3-4 and day14-15 of using Antagon.
224081001|NCT01733017|DIETARY_SUPPLEMENT|rice bran oil capsules|placebo capsules
224081002|NCT01733017|BEHAVIORAL|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
223917222|NCT05061017|DRUG|Pixatimod|Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.
223917223|NCT05061017|DRUG|Nivolumab|Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer
223917224|NCT05061017|DRUG|Cyclophosphamide (low dose)|Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
223917225|NCT05057468|DRUG|Cyclosporine|2.5-5 mg orally for 3 months
224081003|NCT00695565|DRUG|Placebo Gel|TID x 12 weeks
224081004|NCT00695565|DRUG|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
224081005|NCT02312492|OTHER|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
224081006|NCT02312492|OTHER|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
224081007|NCT02312492|OTHER|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
224081008|NCT02288273|DRUG|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
224081009|NCT02288273|DRUG|Placebo|Placebo
224081010|NCT03084640|DRUG|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
224081011|NCT03084640|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
224081012|NCT03084640|DRUG|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
224081013|NCT02419508|DRUG|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
224081014|NCT02419508|DRUG|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
224081015|NCT02419508|DRUG|Prostaglandin analogue|
224081016|NCT03110900|DRUG|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
224081017|NCT03110900|DRUG|Loxapine|loxapine + placebo
223917226|NCT05057468|DRUG|Rituximab|375 mg/ m2 weekly dose for a maximum of 4 weeks
223917227|NCT06219668|PROCEDURE|Omentopexy group|Omentopexy and Clips on staple line during LSG
223917228|NCT04992299|BEHAVIORAL|Mindfulness-Based Intervention|6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
223917229|NCT04992299|BEHAVIORAL|Cognitive-Behavioral Therapy|6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
223719533|NCT00531323|DRUG|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
223917230|NCT04992299|BEHAVIORAL|Health Education|6-week health education didactic program of 6 weekly 1 hour group sessions
224081018|NCT00163332|DRUG|Ciclesonide|
224081019|NCT06501664|DRUG|liposomal irinotecan|Liposomal irinotecan 70 mg/m²
224081020|NCT06501664|DRUG|5-FU|5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h
224081021|NCT06501664|DRUG|LV|LV 400 mg/m²
224081022|NCT06501664|DRUG|Irinotecan|Irinotecan 180 mg/m²
224081023|NCT04583397|OTHER|radio frequency electromagnetic fields|Exposure system delivers emissions comparable to those from a WiFi access Point close to the bed or sham (no exposure)
223917231|NCT02938520|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
223917232|NCT02938520|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
223917233|NCT02938520|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
223917234|NCT02938520|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
223716707|NCT05541120|DEVICE|Remote Patient Monitoring|Remote patient monitoring as the intervention is defined as a tablet and Bluetooth-enabled glucometer technology that collects point-of-care (POC) blood glucose data from a patient outside of a traditional clinical setting, and securely transmits this data to Epic for review and potential intervention.
223917235|NCT02938520|DRUG|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
223917236|NCT02938520|DRUG|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
223917237|NCT04101916|DEVICE|Paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 12 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
223917238|NCT04101916|DEVICE|Sham paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
223917239|NCT06420830|PROCEDURE|SAPIEN 3 Ultra RESILIA Valve|Patients with severe aortic stenosis undergoing transarterial TAVR with the SAPIEN 3 Ultra RESILIA valve.
223917240|NCT05500040|BEHAVIORAL|Multimodal Rehabilitation|The rehabilitation measure is based on the biopsychosocial ICF model of the WHO. A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
223917241|NCT04831086|DRUG|Steroid Drug|Steroids doses will be optimized in the intervention group according the risk based on predictive models
223917242|NCT04831086|DRUG|Tocolytic Agents|Tocolysis duration will be optimized in the intervention group according the risk based on predictive models
223917243|NCT06605482|OTHER|Patient Reported Outcome Measures|Participants will complete the following outcome measures American Shoulder and Elbow Surgeons Evaluation Questionnaire - upper limb function score 12-Item Short Form Survey - general health questionnaire
224278430|NCT03747185|OTHER|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
224278431|NCT02430207|PROCEDURE|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
224278432|NCT02430207|PROCEDURE|temporary pacing subclavian vein|
224278433|NCT06009588|DEVICE|self-expandable valves|patients undergoing TAVR use self-expandable valves
224278434|NCT06009588|DEVICE|balloon-expandable valves|patients undergoing TAVR use balloon-expandable valves
224278435|NCT04292015|DIAGNOSTIC_TEST|Optos ultra-widefield retinal imaging (Optos California)|retinal imaging device
224278436|NCT03731728|BEHAVIORAL|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
224278437|NCT03731728|BEHAVIORAL|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
224278438|NCT03698487|OTHER|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
224278439|NCT03727698|DEVICE|MR Linac|MR guided radiotherapy treatment
224278440|NCT05919745|DRUG|Ibuprofen 600 mg|Preoperative delivery of ibuprofen per os.
224278441|NCT05919745|DRUG|Placebo|Preoperative delivery of placebo per os.
223917244|NCT06605482|OTHER|Range of Motion|Shoulder and Elbow Range of Motion collected at the time of radiographic union
223917245|NCT06605131|DRUG|GP+Toripalimab+CCRT|"1\. Induction Chemotherapy (GP Regimen combined with Toripalimab):~1. GP Regimen Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Toripalimab: For patients weighing ≥ 40 kg: 240 mg on Day 1; For patients weighing less than 40 kg: 3 mg/kg; every 3 weeks for 3 cycles.~2\. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
223917246|NCT06605131|DRUG|GP+CCRT|"1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles"
223917247|NCT04499638|DEVICE|Peripheral vascular catheters|Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
223917248|NCT06608303|DRUG|Topical Human Granulocyte Macrophage Stimulating Factor Gel|Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.
223917249|NCT06608303|DRUG|Saline (NaCl 0,9 %) (placebo)|placebo
223917250|NCT06608693|OTHER|PNF stretching|Subjects lay supine on a treatment table, holding one knee to the chest and letting the other leg extend freely toward the floor at the end of the table. This protocol was adapted from previous studies. The hip joint was carefully and gradually lowered towards the floor, with the knee flexing at a 90-degree angle until the individual experienced a mild stretching sensation (Visual analog scale:4-6). Then, the subject performed a sub-maximal voluntary isometric contraction by utilizing the flexor muscles for 20 seconds while resisting the applied force exerted by an examiner through the utilization of a hand-held dynamometer (K-Force Muscle Control). The examiner proceeded to passively manipulate the leg to achieve the desired range of motion (ROM), maintaining it for 20 seconds. This process was repeated six times for each limb. The patient rested for 2 minutes before applying the same technique to the other side.
223917251|NCT06608693|OTHER|Static stretching group|While the patient was lying supine, the hip and knee joints on the non-stretch side were kept in 90⸰ flexion. A sandbag was positioned on the side to be stretched, specifically proximal to the patella, in order to induce a moderate sensation of stretching in the patient. Subsequently, a force was exerted in the direction of hip extension for a duration of 30 seconds. Afterward, the patient was instructed to relax. This process was repeated a total of six times, with a designated 20-second rest period between each repetition. The patient took a two-minute rest before the same technique was applied to the other side. There was no specific order on which side to apply the technique.
223917252|NCT05057572|DRUG|Carvedilol|\- Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.
223917253|NCT05057572|DRUG|Standard Medical Treatment|"* Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)"
223917254|NCT05904691|DRUG|OCU-10-C-110 for Injection|OCU-10-C-110 for Injection in one of 3 doses
223917255|NCT06585917|DEVICE|7F Thin-Walled Sheath|The 7F Thin-Walled Sheath is used during coronary intervention procedures via distal radial artery access. This device has a smaller outer diameter compared to traditional 7F sheaths, designed to reduce the risk of vascular complications while allowing for the performance of complex coronary interventions.
223917256|NCT06585917|DEVICE|6F Thin-Walled Sheath|The 6F Thin-Walled Sheath is the standard device used in coronary intervention procedures via distal radial artery access. It is employed as a control in this study to compare its efficacy and safety against the 7F Thin-Walled Sheath.
223917257|NCT06501794|DEVICE|Quantitative measurement of eye movements|Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
223917258|NCT06826144|PROCEDURE|remote ischemic conditioning|Remote ischemic conditioning (RIC) is applied to the contralateral upper limb, consisting of 5 cycles per session, 2 sessions per day. Each cycle includes 5 minutes of ischemia followed by 5 minutes of reperfusion. The pressure used to occlude the brachial artery is set at 200 mmHg or exceeds baseline systolic pressure by 35 mmHg (intervention group).At least 4 sessions of actual RIC treatment before the procedure.Continued RIC treatment for a minimum of 4 weeks postoperatively.
223917259|NCT06826144|PROCEDURE|Sham treatment|Remote ischemic conditioning (RIC) is applied to the contralateral upper limb, consisting of 5 cycles per session, 2 sessions per day. Each cycle includes 5 minutes of ischemia followed by 5 minutes of reperfusion. The pressure used to occlude the brachial artery is set at 20 mmHg.At least 4 sessions of sham RIC treatment before the procedure.Continued sham RIC treatment for a minimum of 4 weeks postoperatively.
223917260|NCT06597071|OTHER|NeuraLight PD|NeuraLight software-based platform for PD patients
223917261|NCT06597071|OTHER|NeuraLight PSP|NeuraLight software-based platform for PSP patients
223917262|NCT06597071|OTHER|NeuraLight MSA|NeuraLight software-based platform for MSA patients
223917263|NCT06597071|OTHER|NeuraLight|NeuraLight software-based platform
223917264|NCT06589297|DIAGNOSTIC_TEST|Modified Rankin scale|Acute stroke patients will undergo modified rankin scale
223917265|NCT06825169|BIOLOGICAL|NCR101 injection|Subjects will receive one NCR101 injection in Single Ascending Dose（SAD）and receive 4 NCR101 injections in Multiple Ascending Dose(SAD).
224278442|NCT05919745|DRUG|Acetaminophen|Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
224278443|NCT00894933|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
223917266|NCT06820346|OTHER|Manual and instrumental evaluation of hip adduction|The intervention consists of a new manual test for assessing iliotibial band (ITB) tension and hip abductor extensibility. The patient lies supine on the edge of a treatment table with the non-tested leg flexed at the hip and knee, stabilizing the pelvis. The tested leg remains extended. The examiner stabilizes the non-tested leg with one hand and adducts the tested leg until a resistance is felt, ensuring no pain. The hip adduction angle is visually assessed and recorded. A subset of participants also undergoes the modified Ober test for comparison. Inertial motion sensors are used to validate the accuracy of visual assessments. The primary outcomes include intra-rater and inter-rater reliability, while secondary outcomes evaluate the test's accuracy and pelvic movement reduction.
223917267|NCT06599333|BEHAVIORAL|Adherence to Care|"Questionnaire to assess the perception and readiness of patients in Lebanon towards the effectiveness of digital marketing strategies to improve their adherence to medications they take chronically~The following sections will be considered:~* General Characteristics of the Participants~* Medical and medication history~* Assessment of adherence to chronic medications (Likert scale)~* Digital Marketing Strategies to improve adherence to chronic medications (Likert scale)~* Perceived barriers to adopting digital marketing strategies in Lebanon (Likert scale)"
223917268|NCT06825637|DEVICE|Kandoo|Kandoo is an app that allows patients to track their activities in an engaging and gamified platform.
223917269|NCT06825429|PROCEDURE|exercise programme for group with ECOG 0-1|exercise programme for group with ECOG 2
223917270|NCT06825429|PROCEDURE|exercise programme for ECOG 2 group|this intervention shall be proportionated to the ECOG status of the group
223917271|NCT06597344|DRUG|Gepotidacin|Gepotidacin will be administered.
223917272|NCT06603441|DIAGNOSTIC_TEST|Samsung Galaxy Watch|Samsung Galaxy Watch technology to monitor sleep patterns, oxygen saturation, PPG, and heart rate variability amongst other physiologic parameters.
223917273|NCT06599359|BEHAVIORAL|BLISS Questionnaire|"After extensive literature review and review from the IRB of the Lebanese University. A questionnaire was developed to assess the Intention to leave, job stress, burnout, and job satisfaction among pharmacists in Lebanon~The following sections will be considered:~* Socio-economic characteristics~* Work-related characteristics~* Job stress assessment (Likert scale)~* Burnout assessment (Likert scale)~* Intention to Leave assessment (Likert scale)"
223917274|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 48-hour course of antibiotics.
223917275|NCT06002607|OTHER|Antibiotic duration|The patient will be enrolled in a 7 day course of antibiotics.
223917276|NCT05106036|OTHER|Clinical Support Decision Tool|Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
223917277|NCT06597409|OTHER|Standard PR|(Aerobic exercise, PLB, ACBT, Education)
223917278|NCT06597409|OTHER|Standard PR plus Respiratory Muscle Stretching (RMS)|Standard PR plus Respiratory Muscle Stretching (RMS)
223917279|NCT06819436|DRUG|Dexamethasone|Intravenous dexamethasone 8mg given to participants before spinal anesthesia
223917280|NCT06819436|OTHER|Placebo|Intravenous placebo given to the participants before spinal anesthesia
223917281|NCT05875922|DEVICE|IOL implantation experimental (ISOPURE 1.2.3.)|Implantation of premium monofocal IOL ISOPURE 1.2.3.
223716708|NCT04503902|DRUG|Donafenib Tosilate Tablets|In the dose exploration phase (phase I)，three doses of Donafenib tosylate tablets \[100 mg once a day (QD); 100 mg twice a day (BID); 200 mg, BID\] will be explored. In the dose expansion phase (phase II), patients will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
223917282|NCT05875922|DEVICE|IOL implantation active comparator (TECNIS Eyhance)|Implantation of EDOF IOL TECNIS Eyhance
223917283|NCT06663969|OTHER|Temporal Interference|Researchers applied temporal interference (TI) stimulation to the deep brain nuclei of patients who had undergone SEEG monitoring, recording changes in electrical activity detected by SEEG.
223917284|NCT06377215|DEVICE|Open-source master hearing aid|The investigators will administer the intervention by fitting the device to the participant's audiometric profile. Testing will be counter-balanced across conditions with half the conditions requiring no intervention and the other half with the intervention.
223917285|NCT06670716|OTHER|Examination by a speech therapist|MASTcz test
223917286|NCT06670716|DIAGNOSTIC_TEST|Cognitive examination|ALBA test, PICNIR test
223917287|NCT06670716|OTHER|Examination of delirium|CAM-ICU and ICDSC questionnaire
224081024|NCT02674438|OTHER|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~1. Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores (EHMRG30-ST), where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~2. Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48-72 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
224081025|NCT04103801|DIETARY_SUPPLEMENT|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
223716709|NCT04503902|DRUG|Toripalimab Injection|JS001 will be administrated by intravenous (i.v.) infusion once every 21 days
223716710|NCT03744091|DRUG|P1|10 mg or 20 mg of THC:THCa
223716711|NCT06293404|DRUG|Bupivacain|7.5 mg Bupivacaine hydrochloride (0.5% heavy Marcaine) will be used on spinal anesthesia. (each group)
223716712|NCT01991210|DRUG|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
223716713|NCT01991210|DRUG|PLD|PLD will be administered at a dose of 40 mg/m\^2 IV every 4 weeks.
223917288|NCT06670716|OTHER|History taking|The first page includes several sections: personal information, pre-stroke history, time-related data, neurological deficit data, radiological evaluation, pre-admission and admission treatment, and a medical examination focused on motor and speech impairments. The third page will document the physician's delirium examination and the speech therapy assessment. A questionnaire will be given to the relatives or close persons of the patients to fill out in order to collect systematic personal and pre-stroke anamnestic data and to assess the presence of dementia signs before the stroke using the Blessed Dementia Scale (BDS) questionnaire. All pages of the record form and the Questionnaire for Relatives are included in the appendices.
223917289|NCT04882839|COMBINATION_PRODUCT|psychotherapy assisted psilocybin|psychotherapy for patients while under the influence of psilocybin
223917290|NCT05652010|DEVICE|New 2-piece Coupling|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with new 50mm Ø coupling.
223917291|NCT05652010|DEVICE|SenSura Mio Click|Flat or concave baseplate. SenSura Mio Click maxi bag (open, wide outlet) with 50mm Ø coupling.
223917292|NCT04727242|DRUG|Gemcitabine|Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
223917293|NCT04727242|DRUG|Dacarbazine|Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV
223917294|NCT04727242|PROCEDURE|Cytoreductive Surgery|Surgery for cancer removal
223917295|NCT04727242|BEHAVIORAL|Functional Assessment of Cancer Therapy (FACT) G questionnaire|Preoperative and Postoperative FACT G questionnaire to assess QoL
223917296|NCT04727242|PROCEDURE|Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan|Radiologic imaging after Cycle 3 and 6 and at each follow up visit
223530235|NCT05473065|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with the commercial prosthetic study feet in three foot modes corresponding to commercial prosthetic study feet. Walking conditions will include self-selected comfortable, slow, and fast speeds, inclines, cross slopes, and uneven terrain.~Additionally, participants will be fit with one of the commercial prosthetic study feet and wear it at home and in the community for approximately one week. Participants will return to the laboratory to follow-up testing, and will complete the community trial with each of the three commercial prosthetic study feet."
223530236|NCT04134260|DRUG|Apalutamide|Given PO
223530237|NCT04134260|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223530238|NCT04134260|PROCEDURE|Bone Scan|Undergo bone scan
223917297|NCT04727242|DRUG|Gadolinium|Contrast Agent
223917298|NCT03209791|OTHER|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
224081026|NCT05683444|DRUG|Octreotide infusion|Octreotide infusion for 2,5 hours. 300 ng/kg/min bolus was given for the first 15 minutes and then a continuous infusion of 100 ng/kg/min for the remaining 135 minutes.
224081027|NCT05683444|DRUG|Saline infusion|Saline Infusion
224278444|NCT05103449|OTHER|Video Coaching|Video-based coaching sessions after salpingectomy 1 and 2
224278445|NCT01359579|DRUG|varespladib methyl|Single oral 500 mg dose
224278446|NCT00631007|DRUG|INT131 besylate|Once-daily, oral
224278447|NCT00631007|DRUG|Pioglitazone HCl|Once-daily, oral
224278448|NCT00631007|DRUG|Placebo|Once-daily, oral
223530239|NCT04134260|PROCEDURE|Computed Tomography|Undergo CT
223530240|NCT04134260|DRUG|Hormone Therapy|Receive hormone therapy
223530241|NCT04134260|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223530242|NCT04134260|PROCEDURE|Positron Emission Tomography|Undergo PET
223530243|NCT04134260|OTHER|Quality-of-Life Assessment|Ancillary studies
223530244|NCT04134260|OTHER|Questionnaire Administration|Ancillary studies
223530245|NCT04134260|RADIATION|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
223530246|NCT05470478|DEVICE|Mobile neural decoding platform (mobile iBCI)|An embedded neural signal processor device will be evaluated for its ability to provide accurate and reliable closed-loop control in a home-based brain-computer interface.
223917299|NCT03989089|DRUG|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
223917300|NCT06421324|BEHAVIORAL|Health reccommendations|Patients are given recommendations according to their risk group, based on the model which already predicted health indicators. This information will be sent to the patient's treating physician so that treatment and recommendations are aligned with the clinical care practice based on the European Code of Cancer guidelines, the H. pylori best practices guidelines and European GIM guidelines
223917301|NCT04843527|DEVICE|FreeStyle Libre System|FreeStyle Libre Flash Glucose Monitoring System
223917302|NCT04843527|DEVICE|FreeStyle Libre System plus food app|FreeStyle Libre Flash Glucose Monitoring System and Smartphone Food Logging application
223917303|NCT05417828|DEVICE|Emulation of Active Daily Living tasks with a robotic device (SPINDLE)|SPINDLE will provide an assistive and resistive force to aid in rehabilitating the subject's upper limb
223917304|NCT06086613|DRUG|AGA2115|"In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection."
223917305|NCT06086613|DRUG|Placebo|"In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection."
224278449|NCT04615533|OTHER|Frail older adults, assessment|Frail'BESTest, Clinical Frailty Scale, Mini BESTest, Berg Balance Scale, Tinnetti Balance and gait sacale
224278450|NCT00683787|DRUG|docetaxel|Given IV once every 3 weeks
224278451|NCT00683787|DRUG|vandetanib|Oral vandetanib once daily
224278452|NCT03010852|BEHAVIORAL|Focused incentive spirometer education and monitoring|
224278453|NCT04167618|DRUG|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
223917306|NCT06085404|PROCEDURE|Blood sample|Patients will be enrolled starting right after Ethics Committee approval. Samples will be taken during surgery that will take place in the operating rooms of oncological gynecology.
223917307|NCT06442241|BIOLOGICAL|LYB005 low dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917308|NCT06442241|BIOLOGICAL|LYB005 middle dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917309|NCT06442241|BIOLOGICAL|LYB005 high dose without adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917310|NCT06442241|BIOLOGICAL|LYB005 low dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917311|NCT06442241|BIOLOGICAL|LYB005 middle dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917312|NCT06442241|BIOLOGICAL|LYB005 high dose with adjuvant|Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917313|NCT06442241|BIOLOGICAL|Placebo|0.9% sodium chloride injection. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917314|NCT06442241|BIOLOGICAL|Positive control|AREXVY. Dosage forms and strengths: Solution for injection. Administer a single dose (0.5 mL) as an intramuscular injection.
223917315|NCT05894096|DEVICE|Cold Atmospheric Plasma Jet Treatment|Application of Colf Atmospheric Plasma Jet on the wound
223917316|NCT05894096|DEVICE|Alginate Patch|Application of Alginate Patches on the wound
223917317|NCT06234995|DRUG|Levodopa|Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
223917318|NCT06234995|DEVICE|Clinical DBS Setting|Deep brain stimulation performed with the patients' optimized clinical setting.
223917319|NCT06234995|DEVICE|Sham DBS|Deep brain stimulation performed with sham stimulation.
223917320|NCT06234995|DEVICE|DBS Setting Maximizing Prefrontal Activation|Deep brain stimulation performed to maximize the activation of the prefrontal cortico-STN projections.
223917321|NCT06234995|DEVICE|DBS Setting Minimizing Prefrontal Activation|Deep brain stimulation performed to minimize the activation of the prefrontal cortico-STN projections.
224081028|NCT00502216|DRUG|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
224081029|NCT00502216|DRUG|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
224081030|NCT02549482|OTHER|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
224089315|NCT06936059|DEVICE|Mixed Reality based analgesic therapy|"The intervention is a single 15 min MR therapy. The MR therapy is consisted of MR device and software. The model of MR device used is Pico Neo 3 Pro. The software run on the MR device delivers two types of contents: 1) A 7min of computer-generated 360 video of underwater scene with therapeutic music to distract patients' attention on pain and make patients passively relax. 2) An 8min guided relaxation in which patients are transported to seaside with narrative to achieve image and breathing relaxation.~And the placebo-group used the same non-mixed reality(Non-MR) scenario to treat patients, although the scenario is completely identical, it is not presented in a mixed reality scenario. It only presents the scene in normal display mode."
224089316|NCT04172883|OTHER|Treatment arm|All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
224089317|NCT00002120|DRUG|Trimetrexate glucuronate|
224089318|NCT00002120|DRUG|Trimethoprim|
224089319|NCT00002120|DRUG|Sulfamethoxazole|
224089320|NCT00002120|DRUG|Dapsone|
223716714|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be guided by a physiotherapist.
223917322|NCT06530381|OTHER|Pilates Exercises With Face-to-Face|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed face to face.
223917323|NCT06530381|OTHER|Pilates Exercises With Telerehabilitation|The exercise program includes a warm-up period; exercises performed in the supine position, bridge, side-lying position, prone position, quadripedal position and sitting positions, and a cool-down period. Exercises are performed as telerehabilitation.
223917324|NCT04729751|DRUG|Maralixibat|"Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL)~* 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base~* 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base"
223917325|NCT03267563|BEHAVIORAL|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
223917326|NCT03267563|BEHAVIORAL|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
223917327|NCT03267563|BEHAVIORAL|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
223917328|NCT06391710|DRUG|HRS9531|subcutaneous
223917329|NCT06391710|DRUG|Placebo|subcutaneous
224089321|NCT00002120|DRUG|Leucovorin calcium|
224089322|NCT01997463|DRUG|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
224089323|NCT03426098|DEVICE|Secret RF|A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
224278454|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
223917330|NCT05868460|DEVICE|High intensity laser|patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.
223917331|NCT05868460|OTHER|traditional physical therapy exercise program|passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.
223917332|NCT05868460|DEVICE|placebo High intensity laser|patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
223917333|NCT06827769|DIAGNOSTIC_TEST|serum zinc and magnesium|participants will be subjected to laboratory investigations (complete blood picture, liver and kidney function tests, Prothrombin time, international normalized ratio (INR), serum zinc, and magnesium).
223917334|NCT05741294|DRUG|Tirbanibulin 2.5 mg ointment|Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
223917335|NCT06607237|DEVICE|DM-28|1 drop in each eye, 4 to 6 times per day
223917336|NCT04736810|BIOLOGICAL|AK105|IV infusion
224089324|NCT04257760|BEHAVIORAL|Palliative Care consultation outside standard of care|The ALS patients and their caregivers will receive a consultation with a palliative care physician. This will take approximately one hour and occur in their location of choice (ie. often the patient's home). Subsequent palliative care consultations will occur at the discretion of the ALS patient and the palliative care physician.
224089325|NCT01870739|DRUG|sacubitril/valsartan (LCZ696)|200 mg tablets
224089326|NCT01870739|DRUG|olmesartan|
224089327|NCT01870739|OTHER|placebo to sacubitril/valsartan (LCZ696)|placebo
224278455|NCT01288391|DRUG|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
223530247|NCT03122184|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
223716715|NCT05981417|OTHER|Therapeutic exercise|Therapeutic exercise sessions will be performed at home.
223917337|NCT04736810|DRUG|Cisplatin|IV infusion
223917338|NCT04736810|DRUG|Gemcitabine|IV infusion
223917339|NCT04736810|DRUG|Anlotinib hydrochloride|Oral administration
223917340|NCT06593197|COMBINATION_PRODUCT|Apremilast with NB-UVB|Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
223917341|NCT06593197|DEVICE|NB-UVB|NBUVB only will be given twice per week for 8 months
223917342|NCT06600100|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
223940498|NCT00623337|BEHAVIORAL|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy \& 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify \& refer sick babies
223940499|NCT02170337|DRUG|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
224089328|NCT01870739|OTHER|placebo to olmesartan|placebo
224089329|NCT01870739|DRUG|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
224089330|NCT00327522|BIOLOGICAL|pneumococcal vaccine|
224089331|NCT01384214|BIOLOGICAL|botulinum toxin Type A|750 U at Visit 1
224089332|NCT01986062|DRUG|AR11|
224089333|NCT01986062|DRUG|Placebo|
224278456|NCT01780480|DRUG|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
223940500|NCT02170337|DRUG|Placebo|Contains no active drug
223940501|NCT00874588|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
223940502|NCT01475110|DRUG|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
224089334|NCT03538743|DRUG|Placebo|Tablet, 0 mg, twice daily, 28 days
224089335|NCT03538743|DRUG|PF-06882961|Tablet, 15 mg twice daily, 28 days
224089336|NCT03538743|DRUG|PF-06882961|Tablet, 50 mg twice daily, 28 days
224089337|NCT03538743|DRUG|PF-06882961|Tablet, 150 mg twice daily, 28 days
224089338|NCT03538743|DRUG|PF-06882961|Tablet, 300 mg twice daily, 28 days
224089339|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 5, 28 days
224089340|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 6, 28 days
224089341|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 7, 28 days
224089342|NCT03538743|DRUG|PF-06882961|Tablet, dose TBD, twice daily, Cohort 8, 28 days
223716716|NCT01158300|DRUG|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
223917343|NCT06600100|BEHAVIORAL|Placebo Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation, Rossi et al., 2009). Images appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, or lose 1 point. Participants must respond as quickly and accurately as possible. Here, three separate categories of non-food items (stationery, flowers and clothing) would be Go signal (associated with green 100%), No-Go signal (associated with red 100%) and control (50% red 50% green) respectively.
223917344|NCT06586606|DRUG|MK-1708|Oral administration
223917345|NCT06586606|DRUG|Itraconazole|Oral administration
223917346|NCT06861348|DRUG|Inotuzumab Ozogamicin±Donor Lymphocyte Infusion|"Participants will receive Ino±DLI regimen:~* ① InO induction dose: the first cycle: 0.8mg/m2, intravenous infusion, d1; 0.5 mg/m2, intravenous infusion, d8, d15;~* ② If CR/CRi was reached after induction, the second cycle :0.5mg/m2, intravenous infusion, d1, d8，d15; If CR/CRi is not reached, Cycle 2 :0.8mg/m2, IV infusion, d1; 0.5 mg/m2, intravenous infusion, d8, d15;~* ③DLI dose: CD3 positive cells 1x10\^7/kg; DLI indication: no previous grade III-IV aGVHD, negative HLALOSS test and no present aGVHD and cGVHD;~* Lumbar puncture: cytarabine 50mg+dexamethasone 5mg+methotrexate 10mg, intrathecal injection, once a month after remission, a total of 4-6 courses of treatment."
223917347|NCT04852601|OTHER|ToolboxDetect|The clinician or staff member will identify the patient by either scanning a barcode or entering his/her name, age and medical record number on an administrative screen (allowing for proper routing of test results). After completing the test, a 'submit' button will automatically generate a secure HL7 message, sharing 1) a binary classification of the results ('impaired cognition' or 'normal function'), 2) the quantitative ToolboxDetect score, and 3) brief clinical decision support to rule out any reversible causes. These results will be linked to a discrete, queriable, Epic SmartData element. As patients undergo multiple AWVs over time, ToolboxDetect quantitative scores will be displayed in Epic Synopsis Activity, a graphical display that can visualize trend data (e.g. patient vitals) and calculate a percentage change from the prior year. This will allow a clinician to establish a patient's own baseline (instead of using normative data only) for reference.
223917348|NCT06862440|DEVICE|Kegg|Fertility status monitor
223917349|NCT06861322|BEHAVIORAL|Short Foot Exercise|"* Description: Short Foot Exercise is a therapeutic exercise designed to strengthen intrinsic foot muscles and improve medial longitudinal arch stability.~* Procedure: Participants will perform Short Foot Exercise twice daily, five times per week for four weeks. The exercise consists of progressive phases, starting with basic foot activation and advancing to resistance-based strengthening using bands.~* Purpose: To determine if strengthening the foot's intrinsic muscles positively impacts knee pain, muscle function, and balance in individuals with flexible flatfoot."
224089343|NCT02828800|OTHER|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith \& Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
224089344|NCT02608918|DRUG|BMS-955176|
224089345|NCT02786823|DIETARY_SUPPLEMENT|Folic acid|tab. Folic acid 5 mg
224089346|NCT02786823|DIETARY_SUPPLEMENT|Vitamin B12|tab. Vitamin B12 500 mcg
224089347|NCT02786823|DRUG|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~1. Sulfonylurea~2. Metformin~3. Metformin plus Sulfonylurea"
224089348|NCT06357650|OTHER|No intervention. This is an observational study|This is an observational study. Hence there is no intervention
224089349|NCT03664128|OTHER|Coping with Anxiety through Living Mindfully (CALM) Pregnancy|Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants); no intervention for other participants
224089350|NCT05402826|DIETARY_SUPPLEMENT|Oral zinc + vitamin E|In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.
224089351|NCT05402826|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive placebo pills before and after surgery.
223716717|NCT02381288|DRUG|TAK-448|TAK-448 solution for subcutaneous injection
223716718|NCT02381288|DRUG|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
223716719|NCT01578460|DEVICE|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
223716720|NCT01578460|DEVICE|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
223716721|NCT00657527|DRUG|Rosuvastatin|
223917350|NCT06861322|BEHAVIORAL|Conventional Physical Therapy|"* Description: Standard non-invasive physical therapy aimed at reducing knee pain, improving muscle relaxation, and enhancing lower limb function.~* Procedure: Participants will receive twice-weekly conventional physical therapy for ten minutes per session over four weeks. Treatment includes soft tissue mobilization, muscle relaxation techniques, and neuromuscular stimulation, as appropriate for knee pain relief.~* Purpose: To evaluate its effectiveness as a standalone treatment compared to the addition of Short Foot Exercise."
223917351|NCT06859567|OTHER|Evaluation|Comparison of the 6-minute walk test and Chester step test, one of the aerobic capacity tests
223917352|NCT03853434|PROCEDURE|Embolization|Angiographic embolization
223917353|NCT06858189|BEHAVIORAL|Walk-and-talk therapy|During the 10-week intervention, clients and therapists will engage in walk-and-talk therapy outdoors in natural settings during weekly therapy sessions. In addition, therapists will work with clients to set realistic goals for increased nature-based physical activity outside of the therapy setting. Therapists will check in with clients weekly regarding their progress and assist with goal revision, barrier planning, and self-monitoring.
223917354|NCT06857617|BIOLOGICAL|(Part C) MET097|"Participants will receive 13 once-weekly subcutaneous injections of MET097 as follows:~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 1.2mg~* 12 once-weekly doses of 0.6mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 1.6 mg~* 12 once-weekly doses of 0.8 mg followed by a 13th dose of 3.2 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 2.0 mg~* 12 once-weekly doses of 1.0 mg followed by a 13th dose of 4.0 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 2.4 mg~* 12 once-weekly doses of 1.2 mg followed by a 13th dose of 4.8 mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 2.4mg~* Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 4.8mg"
223917355|NCT06857617|BIOLOGICAL|(Part C) Placebo|Participants will receive 13 once-weekly subcutaneous injections of matching placebo
223917356|NCT06858917|PROCEDURE|Ganglion Impar Block|Block of the ganglion impar is performed by injecting a mixture of steroid and local anaesthetic in front of the sacrococcygeal joint. This procedure is performed in a sterile operating theatre under ultrasound and/or fluoroscopic (X-ray) guidance. Radiopaque agents are also used during the procedure to confirm the location.
223917357|NCT06858917|PROCEDURE|Sacral Erector Spinae Plane Block|The sacral erector spina plan block is performed with ultrasound guidance by injecting a high volume mixture of local anaesthetic and steroid into the fascia under the erector spina muscles in the sacral region.
223917358|NCT06859112|OTHER|logotherapy focused psychoeducation|8 sessions of online individual logotherapy focused psychoeducation program
223917359|NCT06856941|DEVICE|cerebello-spinal direct current stimulation|Cerebello-spinal direct current stimulation is an electrical stimulus in the cerebellum as well as in the spinal cord that is used to improve functional mobility. To our knowledge, this is the first study to use this setup in individuals with Parkinsons disease.
224089352|NCT04640766|DEVICE|PRISM|"The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on no-consecutive days. Each session will last approximately 30 minutes."
224089353|NCT00630331|BIOLOGICAL|Cell culture-derived influenza vaccine|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
224089354|NCT00630331|BIOLOGICAL|Egg-derived influenza virus vaccine|One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
224089355|NCT00630331|BIOLOGICAL|Placebo|One dose (0.5 mL) of phosphate buffered solution.
224089356|NCT00667615|DRUG|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
224089357|NCT01827384|DRUG|Adavosertib|Given by mouth (PO)
224089358|NCT01827384|DRUG|Carboplatin|Given intravenous (IV)
224089359|NCT01827384|DRUG|Everolimus|Given by mouth (PO)
224089360|NCT01827384|DRUG|Temozolomide|Given by mouth (PO)
224089361|NCT01827384|DRUG|Trametinib|Given by mouth (PO)
224089362|NCT01827384|DRUG|Veliparib|Given by mouth (PO)
223530248|NCT03122184|BEHAVIORAL|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
223530249|NCT05248594|DRUG|HEMLIBRA|Emicizumab (Hemlibra, also known as ACE910 and RO5534262) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
223716722|NCT00657527|BEHAVIORAL|Cholesterol lowering diet|
224089363|NCT02368327|BIOLOGICAL|Fluad|
224089364|NCT02368327|BIOLOGICAL|Fendrix|
223716723|NCT01397084|DRUG|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
223716724|NCT05533021|OTHER|Training and Consultancy|In order to facilitate the transition to motherhood, theory-based training and counseling was provided to primiparous mothers on self and infant care.
223917360|NCT06856941|DEVICE|sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation involves masking, where the total duration of stimulation is thirty seconds, which is sufficient to mimic the sensation of stimulation but without neuromodulatory effects
223917361|NCT06858943|PROCEDURE|arthroscopic meniscus reconstruction using a tendon autograft|arthroscopic meniscus reconstruction using a tendon autograft
224089365|NCT02368327|BIOLOGICAL|Placebo|
224089366|NCT00584961|OTHER|non-interventional|non-interventional
224089367|NCT00317460|OTHER|Physician Management|Standard physician care
224089368|NCT00317460|BEHAVIORAL|Counseling|Physician Management and Counseling
224089369|NCT01110252|DRUG|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
224089370|NCT01110252|PROCEDURE|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
224089371|NCT01110252|GENETIC|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
224089372|NCT05660304|DEVICE|Cortico-cortical paired associative stimulation|Two brain areas will be stimulated with transcranial magnetic stimulation pulses. The pulses will be delivered with a time difference, on other words, one pulse after another.
224089373|NCT05660304|DEVICE|Sham cortico-cortical paired associative stimulation|Two brain areas will be stimulated with sham transcranial magnetic stimulation. The sham pulses will be delivered with a time difference, on other words, one pulse after another.
224089374|NCT02944019|DRUG|Edoxaban|Prescribed according to approved label
224278457|NCT01780480|DRUG|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
223917362|NCT06861816|OTHER|incentive spirometer and walking with dog|End stage renal diseased adolescents (numbering twenty) will trained by incentive spirometer 30 min during the sessions of dialysis three applications weekly for 12 weeks. they will additionally walked freely with a dog 30 min three times weekly (in opposite days of hemodialysis). The duration of this trial will be 12 weeks.
223917363|NCT06861816|OTHER|training by incentive spirometer only|End stage renal diseased adolescents (numbering twenty) will trained by incentive spirometer 30 min during the sessions of dialysis three applications weekly for 12 weeks.
223917364|NCT06862492|DEVICE|Open surgical cut down technique|"The technique was performed following the descriptions of Farhadi et al. The infant was positioned in 30° (Trendelenburg's position), with a roll under his shoulders for neck extension and rotated to contralateral side of the surgical side to expose the incision site. Incision was done under sedation and pulse oximeter to monitor the oxygen saturation during the technique.~Under complete aseptic technique, a small transverse incision 1cm was made on triangle bordered by the clavicle inferiorly and by the sternal and clavicular heads of the sternomastoid muscle medially and laterally. With blunt dissection we separate the two heads of the sternomastoid exposing the internal jugular vein .~Then internal jugular vein cut down was performed and catheter inserted through it, all internal jugular vein venotomies were repaired as needed by 6/0 Polypropylene (Prolene®) suture and the wound was closed by absorbable polyglactin (Vicryl) suture"
223917365|NCT06862492|DEVICE|Modified Seldinger's technique|After proximal and distal control of the vein, a 24-G. cannula was carefully inserted directly to the internal jugular vein . The guidewire was inserted through the cannula, then the cannula was removed. A size 4-5 French short length catheter was passed and brought out through the guidewire, then the guidewire was removed. The wound was closed after the correct catheter position and good haemostasis was obtained; the area was covered with sterile dressing.
223917366|NCT06862492|DEVICE|Closed Ultrasound guided CVC insertion|Ultrasound probe was connected to ultrasound unit and focused with ultrasonic gel and wrapped in a sterile plastic sheath. By wrapping the transducer in a sterile sheath, the probe place perpendicular to the long axis of the vessel, standard US two-dimensional (2D) imaging was used to visualize the vein in the short-axis view as a circle. Catheterization was performed under continuous dynamic observation of real-time 2D images. Insertion needle was advanced through the skin under US guidance into the internal jugular vein . A guidewire was then placed through the needle into the vein, and the needle was removed. Then catheter was inserted over the wire into internal jugular vein .
223917367|NCT01396408|DRUG|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
223917368|NCT01396408|DRUG|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
223917369|NCT06862830|OTHER|Virtual reality video|Virtual reality video: luna park, carousels, space, zoo, safari, dinosaurs, sightseeing, role-play
223917370|NCT06861400|BEHAVIORAL|Self-Reflective Resilience-Recovery Activity Promotion Training|Self-Reflective Resilience-Recovery Activity Promotion Training (SRR-RAPT) promotes finding positive meaning in stressors by building self-awareness of the coping and regulatory responses used to manage them; evaluating those responses; adapting them based upon their perceived effectiveness; and developing a plan for managing similar stressors in the future based on what can be learned from the current situation. In addition to prompting self-monitoring and active reflection on stressors and coping responses, SRR-RAPT encourages practicing recovery activities that permit a person's stressor induced strain level to return to baseline. SRR-RAPT is administered daily for 8 consecutive days.
223917371|NCT06861907|DEVICE|Virtual Reality|Virtual Reality Modules created to simulate HAZWOPER PowerPoint scenarios
224278458|NCT01780480|PROCEDURE|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
223530250|NCT00830531|DRUG|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
223530251|NCT00830531|DRUG|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
223917372|NCT04159610|DRUG|WO3970|Application of cream to each axilla
223917373|NCT04159610|DRUG|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
223917374|NCT05535816|DIAGNOSTIC_TEST|Ultrasound|Before completing retrograde intrarenal surgery, a complete endoscopic examination will be performed along with ultrasound instead of fluoroscopy by the same endourologist to determine the size of the largest residual fragment.
223917375|NCT05570734|BEHAVIORAL|LUNA Care Coordination|Participants in this group will have 6 or more 30-minute care coordination sessions with the LUNA Care Coordinator. The LUNA Care Coordinator will assist with appointments and referrals, medications, and assist with accessing the health education videos. They will work closely with the participant's primary care provider and the LUNA Behavioral Health Provider.
223917376|NCT05570734|BEHAVIORAL|LUNA Behavioral Health|Participants in this group will have 6 or more 30-minute behavioral health sessions with the LUNA Behavioral Health Provider. The LUNA Behavioral Health Provider will screen and address life stressors, social support, and health care use. The purpose of these sessions is to check on participant's progress with their care plan. The behavioral health sessions will involve discussion of issues that may interfere with optimal diabetes self-management. The LUNA Behavioral Health Provider will help participants overcome any potential barriers to managing their diabetes by setting goals and helping to address life stress or other issues that may be interfering with their diabetes self-management.
224278459|NCT00470860|BEHAVIORAL|Participation in LOFTS online tutorial|
224278460|NCT02518217|BEHAVIORAL|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
223530252|NCT01300026|DRUG|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
223530253|NCT03232788|PROCEDURE|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
223917377|NCT05570734|BEHAVIORAL|Health Education Videos|Participants in this group will have access to eight 20 to 30-minute health education video sessions with corresponding print material and activities to reinforce what they learn. The health education videos focus on medication adherence, self-monitoring, stress and coping, nutrition, physical activity and culturally driven beliefs and values.
224278461|NCT02518217|BEHAVIORAL|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
224278462|NCT02518217|BEHAVIORAL|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
223917378|NCT05570734|BEHAVIORAL|Virtual Integrated Visits|Participants in this group will have two virtual integrated visits with the LUNA care team. Through video conferencing, they will meet at the same time with the LUNA Care Coordinator, the LUNA Behavioral Health Provider, and their primary care provider to ensure an integrated care plan.
223917379|NCT00674882|OTHER|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
223917380|NCT04122677|DEVICE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
223917381|NCT06997835|BEHAVIORAL|Control group：The interactive management nursing model on the wechat platform|The intervention subjects of the control group: targeted at the pregnant and postpartum women themselves. Specifically, conduct routine outpatient prenatal examinations and health education for pregnant women. Regularly receive health education and pregnancy guidance intervention provided by the wechat platform. It includes: ① Setting specific wechat ringtones, 60-second voice messages and picture reminders every day; ② Basic knowledge education every Monday ③ Dietary guidance is provided every Tuesday. ④ Exercise guidance every Wednesday ⑤ Guidance on blood glucose monitoring every Thursday; Weight guidance is provided every Friday.
223917382|NCT06997835|BEHAVIORAL|Intervention group：Family-centered early care intervention|"The intervention subjects of the intervention group were parturients and their primary caregivers (spouses and parents).~The specific measures are as follows:~1. Establish a family-centered healthcare team (FCC) It includes one chief physician, two attending physicians, one diabetes specialist nurse, two responsible nurses, one psychotherapist, and one nutritionist. The organization members will conduct FCC concept learning and knowledge training.~2. Interactive management nursing model on the wechat platform~   * Set specific wechat ringtones, 60-second voice messages and picture reminders every day;~     * Basic knowledge education every Monday; ③. Dietary guidance every Tuesday;~       ④. Exercise guidance every Wednesday;~       ⑤ Guidance on blood glucose monitoring every Thursday;~       ⑥. Weight guidance every Friday;~       ⑦. Strengthen home care guidance every Saturday and Sunday."
223917383|NCT04163991|DRUG|VIB4920|liquid for IV infusion following dilution in normal saline
223917384|NCT04163991|DRUG|Placebo|0.9% saline for IV infusion
224278463|NCT01658202|DRUG|V0116 transdermal patch (Test treatment )|
223917385|NCT06997536|PROCEDURE|Ilioinguinal/iliohypogastric Nerve Block|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
223917386|NCT06997536|PROCEDURE|Transversus abdominis plane (TAP) block|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
223917387|NCT06997536|PROCEDURE|Quadratus Lumborum Block (QLB)|The aim of this study is to compare the analgesic efficacy of IL/IH block, TAP block, and QLB applied in inguinal hernia cases operated under spinal anesthesia, with each other and with a control group that did not receive any additional block to spinal anesthesia.
224089375|NCT04707755|OTHER|Motor imagery technique|"The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs."
224089376|NCT04707755|OTHER|Conventional Physical Therapy|It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
224278464|NCT01658202|DRUG|Nicotine transdermal patch (Reference Treatment )|
224089377|NCT01416363|DRUG|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
224089378|NCT01416363|DRUG|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
224089379|NCT01416363|DRUG|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
224089380|NCT00804115|DRUG|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
224089381|NCT06043440|DRUG|Oxygen|Active nocturnal oxygen concentrator
224089382|NCT05536323|DRUG|Remimazolam bolus|Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years
224089383|NCT05536323|DRUG|Remimazolam continuous|Remimazolam 12 mg/kg/hr
224278465|NCT04638270|BIOLOGICAL|anti-CD19 FasT CAR-T cells|Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) for 3 days prior to cell infusion.
224278466|NCT05744700|DIETARY_SUPPLEMENT|Inulinase|Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
224278467|NCT05744700|DIETARY_SUPPLEMENT|Maltodextrin placebo|Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
223530254|NCT03232788|DEVICE|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
223530255|NCT03232788|DEVICE|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
224278468|NCT04027881|BEHAVIORAL|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
224278469|NCT02553655|PROCEDURE|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
223917388|NCT03372057|DRUG|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
223917389|NCT03372057|DRUG|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
223917390|NCT03372057|DRUG|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).
223917391|NCT02475161|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
223917392|NCT02475161|DRUG|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
224278470|NCT02553655|PROCEDURE|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
224278471|NCT02553655|PROCEDURE|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
224278472|NCT02397213|DRUG|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
224278473|NCT02397213|DRUG|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
223917393|NCT06351215|DRUG|Methadone group|5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg
223917394|NCT06351215|DRUG|Placebo|sugar pill that is identical look-alike to study drug
223917395|NCT05342974|DRUG|Atorvastatin|Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.
223917396|NCT05342974|DRUG|Misoprostol|On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
223917397|NCT05272163|BEHAVIORAL|Stimulus Type|Targets can be specific or categorical
223917398|NCT05272163|BEHAVIORAL|Target Presence|There is or is not a target present on each trial
223917399|NCT05272163|BEHAVIORAL|Checklist|In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
223917400|NCT05611372|DRUG|Rasagiline|1 mg rasagiline
223917401|NCT04961840|OTHER|No Intervention|This is a non-interventional study.
223917402|NCT05495360|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|twice daily serving of the study product
223917403|NCT05953740|DRUG|MK-5720|IM injection
223917404|NCT05953740|DRUG|Placebo to MK-5720|Placebo IM Injection matched to MK-5720
223917405|NCT05953740|DRUG|MK-8189|Oral Tablet
223917406|NCT05953740|DRUG|Placebo to MK-8189|Placebo oral tablet matched to MK-8189
223917407|NCT06473103|DEVICE|Two photon fluorescence microscopy imaging|Excised tissues will be imaged with two photon fluorescence microscopy prior to submission for histological processing.
223917408|NCT03880955|DEVICE|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
223917409|NCT04567316|DRUG|[14C]-radiolabelled BI 1358894|Part 1
223917410|NCT04567316|DRUG|BI 1358894|Part 2
223917411|NCT06609655|OTHER|no intervention studied, it&#39;s a databank|"The AgeTeQ database Arts, health and new information and communication technologies has three objectives.~The first is to preserve the data collected as part of the research projects carried out by the AgeTeQ laboratory.~The second objective of the database is to use the information provided by the recorded data to fuel reflection, test new research hypotheses and thus open up new avenues of research for the Arts, Health and New Information and Communication Technologies research team.~The third objective is to share the AgeTeQ database with the scientific community on a non-commercial basis, to improve access to data on the themes of arts, health and new technologies, and to increase knowledge and enable the development of research in these fields."
223917412|NCT05755191|DRUG|NEU-411|Oral Doses
223917413|NCT05755191|DRUG|Placebo|Oral Doses
223917414|NCT05458622|BIOLOGICAL|Blood sample|"\- Total volume of blood (on each sampling occasion): 54,5mL.~* Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~* Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points."
223917415|NCT05458622|BIOLOGICAL|Urine sample|\- Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
223917416|NCT05458622|BIOLOGICAL|Saliva sample|\- Saliva: will be collect in special container for saliva microbiome and methylation;
223917417|NCT05458622|BIOLOGICAL|Stood sample|\- Stool: One sample for microbiome to be sent to the biobank, frozen at -80 °C
223917418|NCT05458622|PROCEDURE|Tissue sample|"\- Tissue samples for organ-specific manifestations:~* Kidney tissue in lupus nephritis: one small fragment of the fresh kidney biopsy will be stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Skin tissue (at selected centers) from inflamed lesion and non-inflamed skin from the gluteal region will be obtained through punch biopsy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Synovial tissue (at selected centers) will be obtained through ultrasound-directed arthroscopy and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment.~* Aspirate from swollen lymph nodes (at selected centers) will be obtained and stored in a 10% dimethyl sulfoxide (DMSO) solution (slow freezing to -80 °C) until shipment."
223917419|NCT04214418|DRUG|Cobimetinib|(40-60 mg) orally once daily (morning) on days 1-21 of each 28-day selective small molecule inhibitor for MEK1 and MEK2
223917420|NCT04214418|DRUG|Hydroxychloroquine|(600mg) orally twice daily on days 1-28 of each 28-day cycle
223917421|NCT04214418|DRUG|Atezolizumab|840 mg IV on Days 1 and 15 of each cycle humanized IgG1 monoclonal antibody (MAb)
223917422|NCT05112939|DRUG|RPV LA|RPV LA will be administered at different formulations.
223917423|NCT05112939|DRUG|CAB LA|CAB LA will be administered at formulation 3.
223917424|NCT06474260|BEHAVIORAL|"One All Intervention"|"One-all is a Three-year curriculum targeted at specific outcomes for each yearfacilitated by young people from the community. The facilitators are inducted througha rigorous facilitators programme of three to five months' length. The facilitators areencouraged to adapt the program to their needs and provide the programme incustomized forms appropriate and as required for the communities. The interventionhas thus far been provided to the fishermen communities in Chennai and anecdotalfield evidence suggest, gains in the intended goals. After these experiences theintervention was being tried amongst the tribal adolescents in Gudalur. One-alltargets to provide the undermentioned skills to achieve the mentioned Goals andSkills:~* self-management • understanding feelings~* social awareness • conflict resolution~* relationship skills • empathy building~* self-awareness Skills •nurturing interpersonal relationships~* identity building • awareness about gender stereotypes"
223917425|NCT05197855|DEVICE|Deem 3 Headband|The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.
223917426|NCT04312399|PROCEDURE|blood take|Blood is taken to analyse degradation products of the metabolism of amyloid
223917427|NCT05146284|DRUG|PXL770|Tablet
223917428|NCT06452329|DRUG|Nivolumab|As prescribed by treating physician
223917429|NCT05441618|DEVICE|Lyoplant®|replacement and extension of connective tissue structures in neurosurgery
223917430|NCT05281276|DRUG|chidamide|During the run-in period, the patients will take a single dose of chidamide on Day 3. In a 28-day treatment cycle, the dosing schedule is four/six table (20/30mg) BIW .
223917431|NCT05281276|DRUG|celecoxib|During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
223917432|NCT06856772|DRUG|Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Participants will be instructed to take their Statin daily at approx. 8PM-12AM.
223917433|NCT06856772|DRUG|Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Participants will be instructed to take their statin upon awakening/or with their breakfast (approx. 6AM-10AM).
223917434|NCT06331065|OTHER|Information session on mindfulness meditation and questionnaires|"The information session on mindfulness meditation is an information meeting on the PROMIND study opened to all hospital professionals from the 8 participating departments, i.e. the intervention and control groups.~During this information session, it is specified that it is desirable for the non-intervention groups to maintain their usual practice (or non-practice) during the study, without starting a new practice of mindfulness meditation.~Before this meeting, the baseline questionnaires are administered. Immediately after this time, the questionnaire on representations of mindfulness meditation is administered."
223940503|NCT04039776|DIAGNOSTIC_TEST|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
223940504|NCT02454959|DEVICE|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
224089384|NCT03170752|BEHAVIORAL|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
224089385|NCT03720171|DEVICE|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
223917435|NCT06331065|DEVICE|Mindfulness meditation experimentation, practice program, questionnaires, individual interview and focus group|"After randomization, a mindfulness meditation trial session is offered to all professionals in the intervention group follow by the questionnaire on representations of mindfulness meditation administration.~Then, interdepartmental focus groups is conducted with leaders. The following mindfulness meditation program consists of 10 1-hour sessions within 15 days, in groups of up to 15 professionals, conducted at the participants' place and time of work, by a certified mindfulness meditation trainer with a recommended daily practice of 10-20 minutes with the possibility of a longer duration, and an audio guidance tool adapted to the study.~After the program, and 3 months later, questionnaires are administered for both groups.~For the intervention group, individual interviews, and inter-departmental focus groups (leaders) are carried out at the end of the intervention, and intra-departmental focus groups are conducted 3 months after the end."
223917436|NCT06862973|DIAGNOSTIC_TEST|Digital Occlusal Analysis Using Medit i700 and OccluSense in Single-Tooth Implant Restorations|This study differs from other research through the comparison of two advanced digital occlusal analysis methods-OccluSense system and MEDIT i700 intraoral scanner-to measure occlusal force distribution both before and after the insertion of single-tooth implant restorations in the posterior segment. Unlike research based upon the use of articulation paper, this study employs pressure-sensitive sensor technology (OccluSense) and scanner-based occlusion analysis (MEDIT i700) to quantitatively measure occlusal contacts and force intensity using CloudCompare and ImageJ. With the analysis of the variations that take place within the pre-and-post implant occlusion, the study provides an understanding of occlusal adaptation and how to optimize occlusal adjustments to prevent implant overload and complications, differing from the research that has previously lacked both digital force mapping and longitudinal occlusal analysis.
223917437|NCT06540768|OTHER|Therapeutic Normothermia Group|Maintenance of a body temperature between 35 and 37 degrees Celsius using conservative and pharmacological interventions for 72 hours.
223917438|NCT06862063|DIAGNOSTIC_TEST|Genetic testing|Each eligible patient will undergo a blood sample to perform a genetic analysis through Next Generation Sequencing (NGS) technique in order to analyze a high number of genes involved in the structure/function of connective tissue
223917439|NCT06864455|BEHAVIORAL|Guided Imagery Meditation|Audio meditation by Sheri Menelli, for 10-14minutes
223917440|NCT06864455|BEHAVIORAL|Religious Recitation|listen to Surah Ar-Rahman for 14 minutes
223917441|NCT06864455|BEHAVIORAL|Infant Video with Music|10 minutes of slides show of infant's image and video
223917442|NCT06864455|BEHAVIORAL|Distraction with News and Media|10 minutes of phone use
223917443|NCT06864455|BEHAVIORAL|Control|All participants will ask to sit for 10minutes . Minimum distraction will be applied such as minimal or no chatting.
223917444|NCT01850849|DRUG|LEO 39652 cream|
223917445|NCT01850849|DRUG|cream vehicle|
223917446|NCT05941377|OTHER|blood pressure lowering|For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.
223917447|NCT06542653|PROCEDURE|PCI|successful percutaneous coronary intervention (PCI) in Coronary chronic total occlusions (CTOs) patients
223917448|NCT06542653|DRUG|OMT|optimal medical therapy (OMT) in CTO patients, such as aspirin 1td, ACEI/ARB 1td, β blocker 1td, statin 1td.
223917449|NCT02293954|PROCEDURE|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
223917450|NCT02293954|PROCEDURE|positron emission tomography|Undergo PET
223917451|NCT02293954|OTHER|laboratory biomarker analysis|Correlative studies
223917452|NCT02293954|OTHER|pharmacological study|Correlative studies
223917453|NCT02293954|DRUG|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
223917454|NCT05475678|DRUG|（Carrelizumab + TCb） regimen|Carrelizumab +docetaxel + carboplatin regimen
223917455|NCT05475678|DRUG|TCb regimen|docetaxel + carboplatin regimen
223917456|NCT04869488|DRUG|Fluzoparib|Fluzoparib Orally twice daily（Cohort 1、Cohort 4）
223917457|NCT04869488|DRUG|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|Enzalutamide OR abiraterone acetate Orally once daily（Cohort 1）
223917458|NCT04869488|DRUG|Fluzoparib Combined With Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily（Cohort 2、Cohort 3、Cohort 4）
223917459|NCT03717623|DRUG|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
223530256|NCT04697849|BEHAVIORAL|Cognitive Rehabilitation and Exposure/Sorting Therapy|Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) provides training in compensatory cognitive strategies to address the executive dysfunction typical of individuals with HD, then helps reduce the distress associated with discarding items via exposure therapy.
223917460|NCT06607029|DRUG|the opioid-based control group|Intraoperative analgesia will be administered with conventional opioid drugs such as sufentanil and remifentanil.
223917461|NCT06607029|DRUG|the opioid-free anesthesia group|The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
223917462|NCT06862479|PROCEDURE|Endoscopic management of fistulas with stents or vacum therapy|A prospective registry of patients who develop fistulas after oncologic surgery on the stomach or esophagus as well as those after bariatric surgery and managed endoscopically with stents or endoscopic vacuum therapy will be evaluated to assess and compare the efficacy and safety of the Luso-Cor versus conventional partially or fully covered metallic stents or bariatric stents or endoscopic vacuum therapy.
223917463|NCT03532672|OTHER|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice). The participants will fast for another 10 hours during daily activities.
223917464|NCT06676267|PROCEDURE|Laparoscopic surgery|The laparoscopic surgery system is applied to gynecology and 5G remote surgical treatment.
223917465|NCT05557578|DRUG|Tislelizumab combined with GEMOX (GOT) regimen|Tislelizumab 200mg on day 1；Gemcitabine 1000mg/m2 on day 1、8；Oxaliplatin 135mg/m2 on day 1；cycle 3 weeks
224089386|NCT01404663|BIOLOGICAL|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
223917466|NCT06250855|DEVICE|Mini Toric IOL|Adults (males and females) ≥18 years with cataract and pre-existing corneal astigmatism who have undergone monocular or binocular Mini Toric Ready implantation after cataract surgery in which the cataract lens was removed by phacoemulsification, with circular capsulorhexis, leaving the posterior capsule intact.
223917467|NCT04452500|DRUG|CORT108297|CORT108297- 180mg daily for 7 days
223716725|NCT06507891|DRUG|TQ-A3334 tablets|TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.
223917468|NCT04452500|DRUG|Placebo|Placebo- 180mg daily for 7 days
223917469|NCT05255133|OTHER|Liquid biopsies|Blood sampling will be done at regular intervals
223917470|NCT05255133|OTHER|Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)|Scans will be done at regular intervals
223917471|NCT04635059|DRUG|Pacritinib|Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
223917472|NCT06876792|DEVICE|electrical impedance tomography|Respiratory drive assessed by flow index measured by electrical impedance tomography.
223917473|NCT04175327|DEVICE|CardioCel implantation|treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
223917474|NCT04938609|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
223917475|NCT04938609|RADIATION|Stereotactic Body Radiation Therapy (5 days)|8Gy x 3 (Mon-Fri) GTV+3mm
223917476|NCT04938609|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
223917477|NCT06527300|DRUG|NHWD-870 HCl|Administered P.O.
223917478|NCT06275984|OTHER|online CPR-AED training|"The online CPR-AED training consists of successfully completing the online training course. To access the course, interested persons must register on a Moodle environment platform, with free and open access, through the following link: https://register.magnore.com/registre-curs-de-reanimacio -cardiopulmonary-dea/~Online training takes 3-4h and the participant will have access for 1 month (7x24h)."
224089387|NCT01629615|DRUG|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
224089388|NCT03327233|DEVICE|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
223917479|NCT06609460|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
223917480|NCT06609460|COMBINATION_PRODUCT|Placebo|Placebo to match
223917481|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
223917482|NCT00640822|DRUG|Tacalcitol Ointment|Once daily application for up to 8 weeks
223917483|NCT00640822|DRUG|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
223917484|NCT05531058|BEHAVIORAL|AI-driven Vaccine Communicator|The intervention will include five modules web-based psychoeducation programme (two module sessions weekly, each module lasts for 15-20 minutes) and interact with an MI communication skills-based AI, digital assistant.
223917485|NCT05531058|BEHAVIORAL|Self-learning of COVID-19 vaccine knowledge|Participants in the control group will be given HK government websites in COVID-19 vaccine and invite to join the online examination in relation to Covid-19 vaccine knowledge (using multiple choices questions similar to the intervention group), and this is to ensure that participants from the control group also use time to search relevant information of covid-19 vaccines, also this is to control the time effects.
223917486|NCT03011034|DRUG|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
223917487|NCT03011034|DRUG|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
223917488|NCT04699773|PROCEDURE|LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
223917489|NCT04699773|RADIATION|Hypofractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
223917490|NCT04564209|OTHER|Info Viz for Health|During the intervention, health care providers provide HIV-related health education using a mobile app that contains a bilingual database of relevant infographics.
223917491|NCT05650996|BEHAVIORAL|ADL/Cast Care instruction|Participants in the experimental group will watch a video instructing them on early ADL participation after DRF fracture treated in a cast and cast care. Participants in the experimental group will also receive a handout on ADL participation and cast care.
223917492|NCT05650996|BEHAVIORAL|Cast Care Instruction|Participants in the control group will watch a video instructing them on cast care. Participants in the control group will receive a handout on cast care.
223917493|NCT06679153|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461 Ophthalmic Solution, 1.0%, for up to 28 days
223917494|NCT06679153|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461 Ophthalmic Solution, 0.5%, for up to 28 days
223917495|NCT06679153|DRUG|Prednisolone acetate|Prednisolone acetate, 1%, for up to 28 days
223917496|NCT06544941|DEVICE|Smart Bassinet|The SNOO will respond to a crying or fussing infant in order to soothe and calm it down.
223917497|NCT06544941|DEVICE|HALO|The HALO is a commercially available bassinet
223917498|NCT05844956|DRUG|DZD8586|Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
223917499|NCT05727085|OTHER|All pregnant women with a twin pregnancy and the offspring|No intervention
223917500|NCT06870162|BEHAVIORAL|Pain Disengagement Training|The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.
223917501|NCT05098379|BEHAVIORAL|Tele-Rehabilitation Home Exercise Program|"Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences."
223917502|NCT06869772|PROCEDURE|Closure of sternotomy|In group I, spreading of BW on the sternal surfaces by digital pressure immediately after sternotomy and before closing the chest. In group II ORC will be cut and laid along the sternotomy over the intramedullary area immediately after sternotomy and it will be removed before closing the chest.
223917503|NCT06671730|BEHAVIORAL|8-Week Telehealth-based Occupational Therapy Program|The telehealth-based OT program will be grounded in SDT. The program will be designed to help BC survivors transition from recovery after surgery to achieving levels of aerobic PA and MSE that are recommended according to each participants' specific treatment course and desired outcomes. Participants will engage in eight once-weekly OT sessions with a licensed occupational therapist via Zoom-lasting for up to about an hour. Each session will teach psychoeducational and skill-building techniques that support decreasing functional limitations associated with BC and BC treatment as well as improving behavioral skill sets necessary for maintenance of aerobic PA and MSE. Participants will receive study-provided exercise equipment and a fitness tracker (Fitbit Charge 6) for use engaging in greater amounts of aerobic PA and MSE (keeping these materials post-study)
223917504|NCT06001125|DRUG|Methotrexate|Methotrexate 20 mg PO weekly
223917505|NCT02911805|BEHAVIORAL|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
223917506|NCT02911805|BEHAVIORAL|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
223917507|NCT06677970|DRUG|BP lowering drugs (nicardipine, labetalol, urapidil)|After successful reperfusion, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.
224278474|NCT06065865|BEHAVIORAL|Guidance document|"The main intervention of interest is the guidance document, which is explained under 'Arms'. Within the treatment trajectory, that is based on the guidance document, the participants can receive a combination of NIKA, and parent and child can both get EMDR-therapy. The therapies are combined in one treatment trajectory.~NIKA consists of 5 weekly sessions during which participants are videotaped by a trained therapist. The therapist will provide personalized feedback to the parent, which is focused on reducing disrupted parenting behavior and increasing sensitive parenting behavior. EMDR is a brief trauma therapy (in this trial a maximum of six 90-min sessions for the parent and a maximum of six 60-min sessions for the child) aimed at reducing the negative load of the memories of traumatic events. Both parent and child can receive this therapy. During the weekly sessions, the participant is asked to bring the traumatic event to mind while the therapist provides a distracting task."
223917508|NCT06677970|DRUG|BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil)|After successful reperfusion, appropriate BP raising (20% increase in SBP, maximum of 180 from baseline SBP) are administered.
223917509|NCT06873711|BIOLOGICAL|vedolizumab|Intravenous injection of VDZ (300mg/time) at weeks 0, 2, and 6, followed by intravenous injection of the same dose of VDZ every 8 weeks to maintain treatment.
223917510|NCT06885996|DRUG|Psilocybin|See treatment arm description.
223917511|NCT06752512|DEVICE|Remote Patient Monitoring|24/7 remote patient monitoring with a wearable thermometer
223917512|NCT06873048|DEVICE|Control Contact Lens (stenfilcon A Sphere)|One week of wear
223917513|NCT06873048|DEVICE|Test Contact Lens (stenfilcon A Toric)|One week of wear
223917514|NCT06872619|DEVICE|PROSTest|Multianalyte Algorithm Analysis of circulating prostate cancer transcripts
223719534|NCT00531323|DRUG|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
223719535|NCT05094583|BEHAVIORAL|Use of SmokeFree app|Intervention Arm
223917515|NCT06867783|DEVICE|coquille|"Modalities: Elaboration of the personalized care project, follow-up parents-child single family, multi-family therapy (MFT).~Frequency: MFT weekly, bi-familial observation weekly for one month, single-parent child-parent monitoring weekly for five months, MFT father-child bimonthly for six months, three co-parents, three child psychiatric consultations to develop the personalized collaborative care project"
223940505|NCT02454959|DEVICE|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
223716726|NCT06507891|DRUG|TQ-A3334 tablets + Anlotinib capsules|"TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."
223917516|NCT06871163|PROCEDURE|inspiratory muscle training|Volunteers allocated to the Sham group will receive proton pump inhibitor medication at a standard dose of 20 mg Participants will perform home-based IMT with a moderate load set at 50% of maximal inspiratory pressure (PImáx), adjusted weekly during in-person sessions at LACAP-UFPE. Training will use the Powerbreathe® Classic Light device, provided to participants for the study duration. The protocol includes three cycles of 10 explosive respiratory incursions, with one-minute rest intervals, performed twice daily for eight weeks. Participants will record perceived exertion (Borg scale) and any occurrences in a training log.
223917517|NCT06871163|PROCEDURE|inspiratory muscle training (IMT) combined with manual techniques for the lower esophageal sphincter (MTLES) and diaphragmatic release (DRT)|"Volunteers allocated to the group will receive proton pump inhibitor medication at a standard dose of 20 mg.~The IMT protocol will be the same as in Group 1. Intervention: IMT Combined with Manual Techniques (MTLES \& DRT) The IMT protocol follows Group 1. DRT (Rocha et al., 2015) involves manual traction during inspiration and deepened contact during expiration, applied in two sets of ten deep breaths. MTLES (Eguaras et al., 2019) is performed with the patient seated, applying epigastric pressure to access the lower esophageal sphincter through coordinated flexion-inspiration and extension-expiration for 5 minutes."
223917518|NCT06871163|PROCEDURE|Controle|Volunteers allocated to the Sham group will receive proton pump inhibitor medication at a standard dose of 20 mg, as prescribed for other participants. They will undergo a simulated treatment protocol, including inspiratory muscle training (IMT) without load to mimic device use and manual techniques where the therapist places hands on the intervention area without performing actual manipulation.
223917519|NCT06871345|OTHER|Semi-structured interviews SCID|"Structured Clinical Interview for DSM-5 Personality Disorder (SCID) :~The SCID is a 90-item semi-structured interview, covering all 10 categories of personality disorder as described in the DSM-5. Each item is rated on a three-point scale: absent, subclinical level and present."
223917520|NCT06871345|OTHER|Self-report questionnaires|Participants will complete a battery of self-report questionnaires, assessing emotional dysregulation (including SRD, the primary endpoint), childhood adversity, anxiety, depression, and premenstrual symptoms.
223917521|NCT06871345|OTHER|Cognitive assessment|"Cognitive assessment, coupled with the recording of physiological parameters (Biopac).~Participants will complete a battery of neuropsychological tests targeting emotional processes. These tests will make it possible to evaluate the hot component of executive functioning, i.e. specifically involved in the processing of socio-emotional information. Autobiographical verbal fluences and the emotional Hayling test will be used to measure initiation and inhibition processes, respectively."
224089389|NCT03952260|OTHER|Fasting time for clear fluid prior to anaesthesia|"This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery."
224089390|NCT00895830|DRUG|APD405|IV
224089391|NCT00895830|DRUG|Placebo|IV
224089392|NCT04946266|PROCEDURE|Surgical intervention|Surgical intervention with collection of tissue material
224089393|NCT01370967|OTHER|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
224089394|NCT01370967|OTHER|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
224089395|NCT01370967|OTHER|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
224089396|NCT03623867|DRUG|Secukinumab|Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
224089397|NCT03623867|DRUG|Placebo|Subject will take placebo once weekly in week 0-4, and once monthly till week 48
224089398|NCT00288574|DRUG|Fluoxetine|
224089399|NCT00288574|DRUG|Placebo|
224089400|NCT04888663|DRUG|Trastuzumab + Ramucirumab + Paclitaxel|For both Phase Ib and II: Trastuzumab 4 mg/kg (loading dose) followed by 2 mg/kg on Days 1, 8, 15 and 22, and ramucirumab 8 mg/kg on Days 1 and 15, as well as paclitaxel will be administered intravenously in a 4-week cycle (every 28 days) For Phase Ib, Paclitaxel 80 or 70 mg/m2 (according to dose level) will be administered on Days 1, 8, 15 For Phase II, paclitaxel at RP2D (80 or 70 mg/m2) will be administered on Days 1, 8, 15 of each cycle
223716727|NCT01540240|DRUG|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
224089401|NCT01260103|DRUG|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
224089402|NCT01260103|DRUG|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
224089403|NCT03883737|OTHER|PNM|an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)
224089404|NCT04336904|DRUG|Favipiravir|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
223716728|NCT01540240|DRUG|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
223917522|NCT06871345|OTHER|Momentary Ecological Assessment (EMA)|A momentary ecological evaluation protocol will be proposed between visits V1 and V4 in order to assess the emotional and symptomatic dynamics in a context of daily life. During two menstrual cycles, subjects will be invited, via their smartphone, to take daily semi-random readings (indicated by SMS) of their subjective (4 times/day), but also spontaneous emotional experiences
223917523|NCT06870747|DEVICE|use of Transcutaneous electrical neurostimulation|in this study we would like to use for the first time TENS device during non surgical periodontal therapy
223917524|NCT06870747|DEVICE|no TENS during non-surgical periodontal therapy|patients in the control group are going to have non surgical periodontal therapy without TENS
223917525|NCT06869668|OTHER|Correlation|Correlation between outcomes
223917526|NCT06871657|PROCEDURE|Sinus lift using osseodensification technique|Osseodensification dislocates existing bone into trabeculated space by using a bur that turns in anti-clockwise direction. The procedure itself is not part of the research, but is the intervention of interest to the study.
223917527|NCT06871657|PROCEDURE|Sinus lift using the osseocondensation technique|This procedure is performed by using osteotome hand instruments. The procedure itself is not part of the research, but is the intervention of interest to the study.
223917528|NCT06873100|DRUG|Upadacitinib|Upadacitinib is an oral Janus kinase (JAK) inhibitor used in this study to treat patients with relapsing polychondritis. The drug is administered at a dose of 15 mg once daily for a duration of 24 weeks.
223917529|NCT06873100|DRUG|corticosteroids and immunosuppressants|Corticosteroids combined with immunosuppressants is a conventional treatment for relapsing polychondritis. In this study, it serves as the control arm against Upadacitinib for the treatment of relapsing polychondritis. Dosing is tailored to the individual patient's condition, with the selection of different types of corticosteroids and immunosuppressive agents based on the specific needs of the patient's clinical profile.
223917530|NCT01438853|BIOLOGICAL|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
224089405|NCT04336904|OTHER|Placebo|"Dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.~Where the subject has experienced an adverse event related to liver injury of grade≥3 (NCI CTCAE v5.0), the dose is to be reduced to 600mg BID. It is at the discretion of the investigator whether or not to perform dose reduction based on how the subject is benefiting from study treatment. The subject should be discontinued from treatment if he/she re-experiences any adverse event related to liver injury of grade≥3 after dose reduction"
224089406|NCT01955707|DRUG|natalizumab|Administered as described in the treatment arm
224089407|NCT01955707|DRUG|Placebo|Matched placebo
224089408|NCT02487875|OTHER|rehabilitation|
224089409|NCT01714466|DRUG|NER1006|
223917531|NCT01438853|DRUG|Placebo|Single intravenous dose of saline control
223917532|NCT06684288|PROCEDURE|Access flap surgery|Granulation tissue attached to the alveolar bone was excised to ensure complete access and optimal visibility of the root surfaces. In addition, instrumentation was performed using a combination of ultrasonic and hand instruments, and no alveolar bone modification was undertaken during the flap procedure. Subsequently, the mucoperiosteal flap was repositioned and primarily closed with proximal simple sutures employing monofilament suture material (5/0 Propilen, Dogsan, Türkiye). Patients were given post-operative recommendations; however, no medication was prescribed.
223917533|NCT06681987|BEHAVIORAL|simulation training|One group of students will practice computer-based simulation for pre-eclampsia and eclampsia case management skills using a high-fidelity simulator (n = 15) (subgroups n=3), while the other group will practice with a low-fidelity model (n = 15; subgroups n=3). In the first stage, the case will be written for the high-fidelity simulator and will be submitted to the opinions of experts in the field. After the necessary arrangements are made, the groups will be randomized and allocated. In the second stage, the experimental group will be presented with a virtual reality simulator, and the control group will be presented with a case example of preeclampsia and eclampsia with a low-level simulator. In order to evaluate and increase the teamwork skills of the students in the experimental and control groups, the students will be divided into subgroups of three.
223917534|NCT02624050|DRUG|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
223917535|NCT02624050|DRUG|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
224089410|NCT01714466|DRUG|MOVIPREP|
224089411|NCT03551587|DEVICE|Vibringe|The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
224089412|NCT01817790|DRUG|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
223716729|NCT04030611|DIAGNOSTIC_TEST|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
224089413|NCT01817790|DRUG|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
224089414|NCT01671345|BEHAVIORAL|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
224089415|NCT01671345|BEHAVIORAL|Control|Attention control
224089416|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) lower dose formulation vaccine|1 dose of RSV (GSK3389245A) lower dose formulation vaccine administered intramuscularly at Day 1.
224089417|NCT03636906|BIOLOGICAL|RSV (GSK3389245A) higher dose formulation vaccine|2 doses of RSV (GSK3389245A) higher dose formulation vaccine administered intramuscularly, at Day 1 and Day 31.
223917536|NCT03685110|DEVICE|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
223917537|NCT06690983|DIAGNOSTIC_TEST|18F-S16/T807|Each subject receive a single intravenous injection of 18F-S16/T807, and undergo PET/CT or MRI imaging within the specificed time.
223917538|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Paravertebral Block performed with a 20 ml injection of Ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaine 3,75 mg/ml/side
223917539|NCT04546113|PROCEDURE|Ultrasound-guided Bilateral Erector Spinae plane Block performed with a 20 ml injection ropivacaine 3,75 mg/ml/side|Bilateral injection of 20 ml of Ropivacaine 3,75 mg/ml/side
223917540|NCT06623331|OTHER|AI-enhanced endoscopy training|Endoscopists trained in AI-enhanced environment. Their quality indicators are measured after completing training, without additional AI enhancement.
223917541|NCT06623331|OTHER|Conventional endoscopy training|Endoscopists trained conventionally
223917542|NCT06179953|OTHER|NAO intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts."
223917543|NCT06179953|OTHER|Traditional intervention|"The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts."
223917544|NCT06874231|OTHER|Neuroimaging|The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples
223917545|NCT06875674|DIETARY_SUPPLEMENT|supplementation with control strawberry|control strawberry supplementation (100 grams/day) for 30 days
223917546|NCT06875674|DIETARY_SUPPLEMENT|supplementation with biofortified strawberry|selenium biofortified strawberry supplementation (100 grams/day) for 30 days
223917547|NCT06875674|DIETARY_SUPPLEMENT|supplementation with selenium in tablet|selenium supplementation in tablet (100 micrograms/day) for 30 days
223917548|NCT05934136|BEHAVIORAL|My Healthy Brain 1|My Healthy Brain 1 is an 8-week group program delivered via 90-minute Zoom meetings led by a clinical psychologist. It provides education on the link between dementia and lifestyle factors, including poor exercise, sleep, diet/nutrition, mental and social stimulation, alcohol, and smoking. My Healthy Brain 1 participants learn evidence-based mindfulness and behavior change skills to address common barriers to healthy habits, such as stress and setting achievable goals. My Healthy Brain 1 participants wear an activity watch to monitor lifestyle changes during the program.
223940506|NCT01603836|BIOLOGICAL|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
224089418|NCT03636906|BIOLOGICAL|GSK's multicomponent meningococcal B vaccine|3 doses of GSK's multicomponent meningococcal B vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
224089419|NCT03636906|BIOLOGICAL|Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine|3 doses of Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 1, Day 61 and end of RSV season 1, depending on the vaccination schedule.
224089420|NCT03636906|BIOLOGICAL|GSK's pneumococcal polysaccharide conjugate vaccine|3 doses of GSK's pneumococcal polysaccharide conjugate vaccine administered intramuscularly, at Day 61, Day 121 and at the end of RSV season 1, or at Day 31, Day 61 and end of RSV season 1, depending on the vaccination schedule.
224089421|NCT03636906|BIOLOGICAL|GSK's meningococcal group A, C, W-135 and Y conjugate vaccine|2 doses of GSK's meningococcal group A, C, W-135 and Y conjugate vaccine administered intramuscularly, at Day 61 and at the end of RSV season 1, or at Day 31 and end of RSV season 1, depending on the vaccination schedule.
224089422|NCT03636906|DRUG|Placebo|1 dose or 2 doses of Placebo administered intramuscularly at Day 31, or at Day 1 and Day 31, or at Day 1 and Day 61, or at Day 31 and Day 121, depending on the vaccination schedule.
224089423|NCT05333094|OTHER|Brackets|"Levelling and alignment for the bonded teeth through following the wire sequence: 0.014 NiTi, 16 NiTi, 0.016×0.022 NiTi and 0.017×0.025 StSt. (Wires from American Orthodontics)~• After levelling and aligning is completed the patient will be referred for the uptake of post intervention records; a standardized dental photograph and CBCT after 6- 9 months)"
223719536|NCT01561170|DEVICE|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
223940507|NCT04745676|BEHAVIORAL|Telehealth|Telehealth ACP intervention advance care planning intervention
223917549|NCT05934136|BEHAVIORAL|My Healthy Brain 2|My Healthy Brain 2 condition controls for the effect of time spent and support/feedback from the group and interventionist. Participants in My Healthy Brain 2 will receive education on lifestyle, brain health, and cognitive decline symptoms in addition to usual care as determined by their medical team. Each weekly session will focus on a different topic: 1) lifestyle and brain health, 2) physical activity, 3) sleep, 4) nutrition, 5) medical adherence, 6) cognitive health, 7) social support, and 8) a program overview. My Healthy Brain 2 is conducted in the same format as My Healthy Brain 1 (8 weekly Zoom sessions, 90 minutes each), but does not include behavior change strategies. My Healthy Brain 2 participants wear an activity watch to monitor lifestyle changes during the program.
224089424|NCT01301989|BEHAVIORAL|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
224089425|NCT01301989|OTHER|Sleep Education Control|"The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers"
224089426|NCT04815837|BEHAVIORAL|Intervention|"1. Viewing a video promoting Human Papillomavirus (HPV) vaccination: participants will watch a 5-minute online video promoting MSM's uptake of HPV vaccination. In the video, a peer MSM discussed about the risk of contracting HPV and having anal cancers among MSM, severe consequences of HPV-related diseases, as well as the benefits of HPV vaccination. He also demonstrated the procedures of taking up HPV vaccination in the collaborative private clinics, which portrayed caring, privacy guaranteed, and non-judgmental environment.~2. Receiving the discount coupons: each participant will be given a discount coupon. By using the coupon, one can enjoy a 10% discount for taking up three doses of HPV vaccines at a collaborating private clinic.~3. Visiting the project webpage: Participants can assess the project webpage by scanning the QR code on the discount coupon.~4. Follow-up reminders: participants received five reminders at Month 1, 2, 4, 6, \& 8."
224089427|NCT02065544|BEHAVIORAL|behavioral weight loss and exercise|Weight loss and exercise counseling
223917550|NCT06118554|OTHER|Irrigation head position|Patients irrigated their sinuses with once daily 2 mg mometasone using 240 mL NeilMed sinus rinse bottles for 8 weeks. The only factor that varied between groups was the head position patients irrigated in.
223917551|NCT06875336|DIAGNOSTIC_TEST|biomarker analysis|"PAXgene blood for RNA will be collected and stored. Results from these additional examinations are not included in the treatment monitoring of the patient concerned. If M. tuberculosis can be cultivated, strains will be stored for genotyping and whole genome sequencing. Serum biomarkers will be tested using commercially available kits.~In addition, TAM-TB assays will be performed from samples stored at each time-point. For this purpose, PBMCs will be collected and frozen using well-established protocols."
224089428|NCT04817501|OTHER|Taking 5 ml of venous blood at different time intervals|
224089429|NCT04817501|OTHER|Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any|
223917552|NCT06873906|PROCEDURE|Deep Parasternal intercostal plane block|Patients will receive bilateral deep parasternal plane block using, 1mg/kg of 0.25% bupivacaine on each side under ultrasound guidance. The total dose of bupivacaine amounting to 2 mg/kg.
224089430|NCT04093596|GENETIC|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
224089431|NCT04093596|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
224089432|NCT04093596|DRUG|Fludarabine|Chemotherapy for lymphodepletion
224089433|NCT04093596|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
224089434|NCT04093596|DRUG|Nirogacestat|a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
223719537|NCT01561170|DEVICE|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
223917553|NCT06873906|PROCEDURE|Erector Spinae Plane Block|Patients will receive bilateral erector spinae plane block using, 1 mg/kg of 0.25% bupivacaine will be administered on each side under ultrasound guidance. The total dose of bupivacaine amounted to 2 mg/kg
223917554|NCT06873906|DRUG|conventional analgesic regimen|"Anesthesia will be induced with IV ketamine, 2 mg/kg, fentanyl, 2 µg/kg, and rocuronium 0.9 mg/kg, administered to facilitate endotracheal intubation.~Maintenance of anesthesia will be achieved by isoflurane at an end tidal concentration of 1-1.5% in FiO2 of 0.5, intravenous fentanyl at a dose of 1 µg/kg in incremental dosage, and intravenous rocuronium 0.15 mg/kg administration according to nerve stimulator."
223917555|NCT06875817|OTHER|Feldenkrais exercises|Feldenkrais exercises focused on pain, improving mobility, and disability.
223917556|NCT06875817|OTHER|Standard physical therapy interventions|"* Knee Isometrics: Isometric exercises targeting the quadriceps and hamstrings, performed for 10 minutes, twice a week.~* Knee Mobilization~* Transcutaneous Electric Nerve Stimulation (TENS).~* Heating Pad Duration: 30-minute sessions, conducted twice a week for 4 weeks."
223917557|NCT06874387|OTHER|Hypoxia, intermittent|Moderate-Intensity Aerobic Exercise (\~60-70% of maximum heart rate) and Intermittent Hypoxia (maintained between 80-90% during hypoxic phases)
223917558|NCT06874387|OTHER|physical exercise|Moderate-Intensity Aerobic Exercise (\~60-70% of maximum heart rate)
223917559|NCT06874387|OTHER|Sham (No Treatment) hypoxia|Exposure to normoxic air (FiO₂ \~20.9%) instead of actual hypoxia.
223917560|NCT06870825|DEVICE|High-intensity Magnetic Field Muscle Stimulation|"1. The procedure is performed for 20 min., 1k/d, 5k/week, a total of 14 times (rehabilitation duration 14 days).~2. Parameters: applied parameters according to the manufacturer's specified program for muscle stimulation: muscle strengthening program~3. Stimulation site: quadriceps femoris muscle, applied above the motor point approximately 60% of the distance from the upper medial border of the patella to the anterior upper wing of the iliac bone.~4. device: BLT Super Inductive System~   * Along with muscle stimulation techniques, all subjects will undergo a standardized outpatient rehabilitation plan."
223917561|NCT06870825|DEVICE|Transcutaneous Neuromuscular Electrical Stimulation|"1. the procedure is performed for 20 min., 1k/d, 5k/week, a total of 14 times (rehab. duration 14 days).~2. Parameters: applied parameters according to the manufacturer's specified program for muscle stimulation (EMS, P3)~3. Stimulation site: quadriceps femoris muscle, applied above the motor point.~4. device: ITO ES-5200~   * Along with muscle stimulation techniques, all subjects will undergo a standardized outpatient rehabilitation plan."
223917562|NCT06874634|DRUG|Human serum albumin injection|Infusion of human albumin injection into patients with abdominal sepsis admitted to the ICU
223917563|NCT05815667|BEHAVIORAL|Individualised Active Communication Education (I-ACE)|The swedish I-ACE consists of five modules with different themes, all with sections of information alternated with reflective tasks. The participants are assigned one module each week and provided with weekly feedback from a health care professional on their work, before being assigned the next module.
223917564|NCT03904576|DRUG|BI 1358894|Film-coated tablet
223917565|NCT03904576|DRUG|Placebo|Film-coated tablet
223917566|NCT05516576|DEVICE|endomina®|Endoscopic gastroplasty
223917567|NCT06124690|DEVICE|Catheter ablation|Pulmonary vein isolation and ablation of low voltage areas.
223917568|NCT04807777|DRUG|Ruxolitinib|Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
223917569|NCT03279978|DRUG|BI 730357|BI 730357 film-coated tablet
223917570|NCT03279978|DRUG|Placebo|Placebo
223917571|NCT03279978|DRUG|Midazolam|Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed
223917572|NCT06874036|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is a procedure to see the ascending, transverse, decending, sigmoid, rectum of colon parts
223917573|NCT06873893|PROCEDURE|Midpoint transverse process block|This group will receive a volume of 20ml of bupivacaine 0.5% at midpoint of the line between the posterior border of the transverse process of T4 and the pleura ( injection will be deep to the posterior aspect of the vertebral transverse process but superficial to the superior costotransverse ligament )
223917574|NCT06873893|PROCEDURE|Pectoral Nerve Block|This group will receive a volume of 10ml of bupivacaine 0.5% will be injected between the pectoralis major and pectoralis minor muscle then another 10ml bupivacaine will be injected between pectoralis minor and serratus anterior muscle
223917575|NCT04330040|DRUG|Olaparib|Tablet
223917576|NCT05906199|DRUG|Renexin CR 200/160mg|Single oral administration of Renexin CR 200/160mg, QD
223917577|NCT05906199|DRUG|Aspirin 100mg|Single oral administration of Aspirin 100mg, QD
223917578|NCT05700760|BEHAVIORAL|ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns)|Evidence-based 5 session psychosocial intervention that has been found to prevent \~50% of postpartum depression among low-income, at risk women.
223917579|NCT05700760|BEHAVIORAL|Enhanced Care as Usual (CAU)|Usual care at the study site does not include postpartum depression prevention. Instead, HFHS clinics try to screen for PPD that has already occurred and refer women for mental health care. Screening for existing PPD at these clinics primarily relies on the EPDS (10+), Perinatal women who score 10+ on the EPDS are referred for mental health services. Services received depends on follow-up, severity, and the mental health wait list. Our study will exclude women meeting criteria for likely current major depressive episode at baseline and assist them in obtaining mental health care. Enhanced CAU consists of usual care + monitoring and emergency referral, as is required to fulfill ethical obligations to trial participants.
223917580|NCT03745716|DRUG|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
223917581|NCT03745716|DRUG|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (\< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
223917582|NCT06701318|DEVICE|Ultrasound shear wave elastography|An ultrasound machine (GE LogiQ S8) equipped with SWE technology will be used. A high-frequency linear transducer will be used and The machine settings will be optimized for musculoskeletal applications.
223917583|NCT06700733|DEVICE|PEEK prosthesis|For the PP, The PEEK framework will be constructed, the fit of the PEEK framework will be verified intraorally, and the final screw-retained prosthesis will be constructed of PMMA teeth and a visiolign pink composite estimating the gingival tissue.
223917584|NCT06700733|DEVICE|Titanium prosthesis|For the TP, the framework will be milled from Ti blocks according to the virtual design of the final prosthesis framework. PMMA teeth then will be cemented, and the final prosthesis will be screwed.
223917585|NCT03236935|DRUG|L-NMMA|pan-nitric oxide synthase inhibitor
223530257|NCT04697849|BEHAVIORAL|Case Management|Case Management (CM). CM is the most widely available and utilized intervention for HD and is considered standard of care. This form of treatment involves managing the functional, housing, and legal ramifications of HD. Additionally, CM often involves assistance with economic, health, and social resources while providing support for the client.
223917586|NCT03236935|DRUG|Pembrolizumab|PD-1 inhibitor
223530258|NCT02835690|BIOLOGICAL|Pembrolizumab|IV infusion
223917587|NCT00626795|DRUG|TD1414 2% cream|BID 7 days
223917588|NCT00626795|DRUG|TD1414 2% cream|TID 7 days
223917589|NCT00626795|DRUG|Bactroban® (mupirocin) 2% cream|BID 7 days
223917590|NCT06632613|DRUG|ENN0403 capsules, low dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at low dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
223917591|NCT06632613|DRUG|ENN0403 capsules, high dose|ENN0403 capsules will be orally administered once a day for 5 consecutive days at high dose based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the placebo capsules will be administrated through a nasogastric tube/oral gastric tube.
223917592|NCT06632613|DRUG|Placebo|Placebo capsules will be orally administered once a day for 5 consecutive days based on the standard treatment after cardiac surgery. If the subject is unable to swallow the investigational product autonomously, the capsules will be administrated through a nasogastric tube/oral gastric tube.
223917593|NCT04539808|DRUG|Capecitabine|Given PO
223917594|NCT04539808|DRUG|Fluorouracil|Given IV
223917595|NCT04539808|DRUG|Irinotecan Hydrochloride|Given IV
223917596|NCT04539808|DRUG|Leucovorin Calcium|Given IV
223917597|NCT04539808|DRUG|Losartan Potassium|Given PO
223917598|NCT04539808|DRUG|Oxaliplatin|Given IV
223917599|NCT04539808|RADIATION|Radiation Therapy|Undergo short-course or long-course RT
223917600|NCT04539808|PROCEDURE|Resection|Undergo surgical resection
223917601|NCT04539808|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
223917602|NCT04539808|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223917603|NCT06879054|OTHER|Healthy lifestyle education|Healthy lifestyle education via nutritional educational modules from the Gaples Institute.
223917604|NCT06878755|OTHER|Promoting Assertive Communication among Teens (PACT)|See Arm Description
223917605|NCT06878755|OTHER|Healthy Minds|See Arm Description
223940508|NCT04745676|BEHAVIORAL|Control|For the control arm, no telehealth visit will be scheduled.
223940509|NCT02610413|OTHER|Laboratory Biomarker Analysis|Correlative studies
223940510|NCT04241835|DRUG|Tazemetostat|"Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity."
223940511|NCT06730932|DRUG|JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)|"Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol"
223940512|NCT05859711|DRUG|thyme honey mouth rinse|oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy. (Charalambous et al.,2017)
223940513|NCT05859711|DRUG|saline mouth rinse|saline mouth rinse 3 times per day starting in the 4th week of radiotherapy and for one month after completion of radiotherapy
223940514|NCT06300086|BEHAVIORAL|Electronically delivered nudging letters to patients with CKD|"Patients in the active arm will receive a digital nudge letter as part of the study. The nudge letter will be delivered at baseline. Letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD randomized to not receive digital nudge letters (usual care)."
223716730|NCT03120416|BEHAVIORAL|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
223917606|NCT03998488|DRUG|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
223917607|NCT03998488|DIETARY_SUPPLEMENT|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon (approximately 5 grams) of psyllium husk powder twice a day (morning and night) for 8 weeks, beginning 3 days prior to Week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
223917608|NCT06882993|DIAGNOSTIC_TEST|Panenteric capsule endoscopy|Panenteric capsule endoscopy
223917609|NCT06882993|DIAGNOSTIC_TEST|Ileocolonoscopy|Endoscopic examination of the colon and terminal ileum after bowel preparation.
223917610|NCT06882993|DIAGNOSTIC_TEST|MRI enterography|MRI of the small bowel
223917611|NCT06882993|DIAGNOSTIC_TEST|Small bowel capsule endoscopy|Capsule endoscopy of the small bowel
223917612|NCT01756300|DEVICE|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
224089435|NCT04633590|BEHAVIORAL|Home-based exergaming|Participants will undertake one of two 6-week training interventions. In both groups participants will be asked to train 3 times per week (18 sessions total), during which adherence to the training will be measured. To monitor adherence to training and training load (exercise completion, exercise duration and heart rate achieved during workouts) throughout the 6 weeks participants will be given a heart rate monitor.
224089436|NCT05876559|OTHER|Joyuus Self-care Mobile App|Joyuus is an innovative self-care mobile tool designed to address the needs of underserved women who are at greater risk for adverse postpartum outcomes. It provides the appropriate information, knowledge, and skills to improve postpartum health through self-care, and identifies when it is appropriate to seek care.
223917613|NCT03247309|BIOLOGICAL|IMA201 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
223917614|NCT03247309|DIAGNOSTIC_TEST|IMADetect®|IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only.
223917615|NCT06884241|DIETARY_SUPPLEMENT|Probiotic supplementation|The intervention consists of a 6-week supplementation with a specific combination of probiotics: Lactiplantibacillus plantarum P17630 49x109, Lacticaseibacillus paracasei I1688 1x109, Ligilactobacillus salivarius I1794 25x106. All participants were given a gluten-free, low FODMAPs diet. After 4 weeks (T1), foods containing gluten were reintroduced in the diet of all participants (at least 6 g/day of gluten), while the reduced FODMAP content was maintained
224089437|NCT05876559|OTHER|Standard Care|Standard care is access to typical resources women have access to during postpartum and does not include the Joyuus intervention.
224089438|NCT06170645|OTHER|APA program|An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.
224089439|NCT06170645|OTHER|Active transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
224089440|NCT06170645|OTHER|Sham transcutaneous VNS|After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
224089441|NCT02348515|PROCEDURE|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
224089442|NCT02348515|PROCEDURE|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
224089443|NCT02348515|PROCEDURE|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
224089444|NCT02348515|PROCEDURE|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
224089445|NCT02348515|PROCEDURE|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
224089446|NCT03493360|OTHER|Visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at their back in a mirror for visual feedback.
224089447|NCT03493360|OTHER|No visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at a mirror that is covered and no visual feedback is provided.
224089448|NCT02719340|PROCEDURE|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
224278475|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
224278476|NCT01152918|BEHAVIORAL|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
223716731|NCT04082312|OTHER|No intervention|No intervention
223716732|NCT05448053|PROCEDURE|Ilizarov|Ilizarov fixation in open type III pediatric and adolescent tibial shaft fractures
223716733|NCT06140784|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
223917616|NCT06884241|OTHER|Placebo|"The participants received placebo for 6 weeks. Placebo was identical in appearance, texture, taste, and packaging to the probiotic treatment. All participants were given a gluten-free, low FODMAPs diet.~After 4 weeks (T1), foods containing gluten were reintroduced in the diet of all participants (at least 6 g/day of gluten), while the reduced FODMAP content was maintained"
223917617|NCT06722092|BEHAVIORAL|VR-based script training|The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.
223917618|NCT06722092|BEHAVIORAL|Conventional script training|The flow of training is identical to the VR condition, except that photos depicting the scenarios and prerecorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.
223530259|NCT06551220|DRUG|Trastuzumab Deruxtecan|The patients received Trastuzumab Deruxtecan at a dose of 5.4 mg/kg every 3 weeks until disease progression or unacceptable adverse effects occurred.
223917619|NCT06872736|DEVICE|WeFun-wearable activated|1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the experimental group will have the wearable's experimental movement functions activated.
223917620|NCT06872736|DEVICE|WeFun-wearable desactivated|1 month daily routine program with weekly visits in natural environments (home, community, etc) together with WeFun-weareable to increase spontaneous use of the upper limb in children with UCP during activities of daily life and leisure. Activities are priorized by Canadian Occupational Performance Measure and Goal Atteinment Scale. Programs are designed together with a transdisciplinary team, acting as consultants. Children in the control group will not have experimental functions in their wearables.
223917621|NCT06732713|OTHER|Swiss Ball|Swiss ball exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes , 3 to 4 sessions per week for 8 weeks
223917622|NCT06732713|OTHER|Frenkel exercise|Frenkel exercises will be performed in supine, sitting and standing position for about 25 to 30 minutes, 3 to 4 sessions per week for 8 weeks
223917623|NCT06735976|DEVICE|PAVM Embolization|This study consists of one group. All participants will undergo PAVM embolization with a LOBO™ device.
223917624|NCT06735976|DEVICE|PAVM Embolization with a LOBO™ device|Participants will undergo PAVM embolization with the LOBO™ device per standard of care.
223917625|NCT06740136|OTHER|Exercise|Muscle induced-damage eccentric exercise
223917626|NCT06739174|DEVICE|Confidence Be 1-Piece Closed Bag|Active Chamber Filter - Circle Shape
223917627|NCT06739174|DEVICE|Confidence Natural 1-Piece Closed Bag|Protective Filter - Circle Shape
223917628|NCT06739174|DEVICE|Confidence Be go 1-Piece Closed Bag|Active Chamber Filter - Hexagon Shape
223716734|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
223917629|NCT06738589|DEVICE|non-invasive ventilation|Non-invasive ventilation adds positive pressure to the upper airway via a mask on the face.
223917630|NCT06738030|DEVICE|Transcranial current stimulation|The transcranial alternating current stimulation is delivered during the speech stimulus and the current matches the envelope of the target speech
223917631|NCT06738030|BEHAVIORAL|Auditory training|An at-home auditory training program that adaptively and interactively trains the listener in degraded speech, cognitive skills, and communication strategies
223917632|NCT06870604|PROCEDURE|do open surgery|Open surgery was performed in patients undergoing gastric perforation
223917633|NCT06870604|PROCEDURE|do laparoscopic surgery|Laparoscopic surgery was performed in patients undergoing gastric perforation
223917634|NCT06734299|OTHER|Sunscreen A|Sunscreen A will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
223917635|NCT06734299|OTHER|Sunscreen B|Sunscreen B will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
223917636|NCT06734299|OTHER|Sunscreen C|Sunscreen C will be applied to both lower legs (between the knee and ankle) and then her full face to the randomly assigned participants at Visit1, Visit 2, and Visit 3.
224278477|NCT01152918|BEHAVIORAL|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
224278478|NCT01152918|BEHAVIORAL|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
223530260|NCT05761821|DEVICE|Leadless pacemaker|All enrolled patients were implanted with leadless pacemaker.
224278479|NCT01152918|BEHAVIORAL|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
224278480|NCT01152918|BEHAVIORAL|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
224278481|NCT05788276|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin active tablets
223530261|NCT00710593|BIOLOGICAL|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
223530262|NCT04490278|OTHER|Medical Record Review - Inpatient Treatment|Patient characteristics, medical history, and information regarding their inpatient treatment from the electronic medical record
224278482|NCT05788276|DRUG|Placebo|Matched placebo tablets
223530263|NCT04490278|OTHER|Online Questionnaires|Patients will complete online questionnaires related to their physical, cognitive and mental health function and inquire about current treatments. The multiprofessional CoV-PICS clinic practitioners will evaluate their responses and, combined with information obtained during their virtual visits, formulate a suggested treatment plan and needed referrals.
223917637|NCT06735638|PROCEDURE|OTC MIE Esophagectomy|"Consenting patients will undergo minimally invasive esophagectomy (MIE) using the Out of the Cage (OTC) robotic-assisted technique. The procedure will follow the exact standard steps of traditional VATS/RATS esophagectomy, except the thoracic ports will be placed in the subcostal plane. The number of ports (1-4) will be determined based on the patient and case characteristics.~The Da Vinci Xi® surgical system will be used to perform the thoracic portion of the esophagectomy through subcostal ports using the standard technique. Once the procedure is completed, the robotic arms and ports will be removed from the chest, and figure-of-8 stitches with non-absorbable sutures will be placed to close the diaphragm at the port sites. A 24 Fr soft chest tube will be left in place, as per standard VATS/RATS esophagectomy protocols. Incisions will be closed in the standard manner."
223917638|NCT06735846|DEVICE|Guide wire|Insert the distal end of the guide wire into the introducer sheath and enter the blood vessel through the introducer sheath;5.Insert the catheter directly into the blood vessel through the guide wire, and when the catheter reaches the target position, exit the guide wire.
223917639|NCT06735105|DIAGNOSTIC_TEST|Scanning parameter|Based on abdominal scanning, TSE-DWI,ZOOMIT DWI and EPI-DWI scans were performed, and the study was divided into two steps according to the nanomotion criteria. The first step was self-controlled, which was divided into experimental group and control group. The experimental group included TSE-DWI,ZOOMit DWI, and the control group included EPI-DWI. Then the image quality was evaluated by subjective and objective evaluation indexes. In the second step, the three DWI stages were performed separately by four diagnosticians, with an interval of 1 month, and statistical analysis was performed at the end.
223917640|NCT06743412|OTHER|Regular music listening|Regular listening of self-selected music sung in Italian language during the hospital stay and after discharge till the follow-up visit after 3 months.
223917641|NCT06739434|GENETIC|GCB-002|GCB-002 is a self-complementary AAV9 carrying a full length human MECP2 transgenetic product.
223917642|NCT06754618|DEVICE|Delfi|Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
223917643|NCT06857019|OTHER|"Endotracheal Tube Position Anomaly Alerting System"|"The Endotracheal Tube Position Anomaly Alerting System (ETPAAS) is designed to assist healthcare providers in managing patients receiving mechanical ventilation via an endotracheal tube. This system integrates an artificial intelligence (AI) algorithm that automatically evaluates the appropriateness of endotracheal tube positioning whenever a patient's chest X-ray is uploaded. If the system detects that the distance between the endotracheal tube tip and the carina falls outside the optimal range, it promptly alerts healthcare providers, enabling timely intervention to correct the tube position and enhance patient safety."
223917644|NCT03441971|DEVICE|GORE PV1|Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).
223917645|NCT06812936|DRUG|Acetaminophen|"This intervention involves the administration of acetaminophen 500mg tablets, taken up to three times within the first 24 hours following archwire insertion to manage pain associated with orthodontic treatment. Acetaminophen is a centrally acting analgesic that reduces pain without significantly affecting tooth movement, making it a preferred choice for pain relief in orthodontic patients. Participants will be instructed to record their pain levels using a visual analog scale (VAS) over a five-day period post-bonding to assess the effectiveness of this treatment."
223917646|NCT06812936|PROCEDURE|Acupressure|This intervention involves the application of acupressure to two specific acupressure points: Jaw Chariot (St 6) and Facial Beauty (St 36). Participants will be trained to apply firm pressure to these points up to five times within the first 24 hours after archwire insertion to alleviate orthodontic pain. Acupressure is a non-invasive therapy based on traditional Chinese medicine that aims to stimulate the body's natural healing processes and promote pain relief by balancing energy flow. Participants will be instructed to record their pain levels using a visual analog scale (VAS) over the first five days post-bonding to assess its effectiveness.
223917647|NCT06811779|DRUG|Sodium Hypochlorite|Sodium hypochlorite used in 5% concentration for disinfection
223917648|NCT06811779|DRUG|Chlorhexidine|Chlorhexidine 0.2% concentration for disinfection
223917649|NCT03990883|DEVICE|Princess Filler Lidocaine|correction of nasolabial folds
223917650|NCT06877117|BEHAVIORAL|Pictorial Framing|Visual aids illustrating collimation benefits
223917651|NCT06877117|BEHAVIORAL|Traffic Light Color Coding Framing|Decision cues using color-based risk indicators
223917652|NCT04479514|OTHER|Warm Baths or Showers|Daily warm baths or showers
223917653|NCT04479514|OTHER|Moisturizer|moisturizers applied daily immediately after bathing
223917654|NCT04479514|DRUG|SPF 30 or Higher Suncreen|Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.
223917655|NCT04479514|OTHER|Sun Protective Clothing|Sun protective clothing worn when outdoors
223917656|NCT04479514|BEHAVIORAL|Limited Sun Exposure|Limit sun exposure during peak hours of 10am-4pm
223530264|NCT03279653|PROCEDURE|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
223917657|NCT04479514|OTHER|Dilute bleach baths|Warm 10-15 minute dilute bleach baths every other day
223530265|NCT01695603|DEVICE|Intellivent|
223530266|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
223917658|NCT05288452|BEHAVIORAL|Digital Health Coaching|The digital health coaching intervention program involves an evidence-based curriculum and one-on-one support to promote positive health behaviors and patient self-management of diabetes.
223917659|NCT05288452|DIETARY_SUPPLEMENT|Food Box Delivery|The food box intervention component will consist of biweekly food boxes delivered directly to participants over the course of 6 months. The food boxes will contain shelf-stable groceries that adhere to ADA nutritional guidelines for individuals with T2DM.
223917660|NCT05288452|BEHAVIORAL|Remote Patient Monitoring (RPM)|The RPM team will instruct the participants to monitor blood glucose levels 3 times daily. Glucose levels will be monitored 8 a.m. to 5 p.m.Monday to Friday. Data summaries will be reviewed bi-monthly with RNs and pharmacists. Participants will be provided with a glucometer, test strips, and mobile divide to record their blood glucose levels.
223917661|NCT05288452|BEHAVIORAL|Diabetes Education Class|The diabetes education class will be administered by a certified diabetes educator.
223917662|NCT06048250|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223917663|NCT06048250|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223917664|NCT06048250|PROCEDURE|Computed Tomography|Undergo CT
223917665|NCT06048250|BIOLOGICAL|Mezigdomide|Receive PO
223917666|NCT06048250|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223917667|NCT05131347|BEHAVIORAL|motor intervention|Children in the motor intervention group will receive motor skills training based on motor learning theory. Movement activities include playing on trampoline and tilt board, walking on knees, toes and heels, creeping and crawling under different obstacles, jumping forward and backward, driving scooter board, playing balance devices, hopping, and visual motor coordinated movement. These activities are designed from easy to complex.
223917668|NCT05131347|BEHAVIORAL|cognitive intervention|Children in the cognitive intervention group will receive cognitive training. The activities consist of 12 exercises with progressive cognitive demands at 10 levels to improve cognitive functions such as attention, cognitive flexibility, inhibitory control, and working memory.
223917669|NCT06954545|BEHAVIORAL|Healthy Kids Programme|Our intervention was prepared by adopting an interactive curriculum shaped on role-play with visual materials and toy models of foods appropriate for the age of the children
223917670|NCT06953947|PROCEDURE|Costoclavicular block|"The costoclavicular block was first described by Karmakar et al. in 2015. It is a type of brachial plexus block that targets the three cords located lateral to the axillary artery within the costoclavicular space. The costoclavicular space is defined as the area between the middle third of the clavicle and the anterior thoracic wall. Within this space, the cords of the brachial plexus are situated lateral to the axillary artery, positioned between the pectoralis major, subclavius, and serratus anterior muscles.~In contrast to the traditional infraclavicular approach, the cords in the costoclavicular block are located more superficially and are more consistently clustered lateral to the axillary artery, which may facilitate visualization and needle targeting. After the needle is placed between the three cords under ultrasound guidance, the local anesthetic (20 mL of 0.25% bupivacaine) is injected."
223917671|NCT06953947|PROCEDURE|Interscalene block|Originally described by Etienne in 1925, the technique was later refined into its modern clinical form by Alon Winnie in 1970. The interscalene approach, primarily preferred for shoulder surgeries, aims to target the upper roots of the brachial plexus (C5-C7). In interscalene block, a needle is placed under ultrasound guidance around the upper and middle trunks of the brachial plexus, which pass through the space between the anterior and middle scalene muscles, and the local anesthetic (20 mL of 0.25% bupivacaine) is injected while its spread is observed.
223917672|NCT06953947|DRUG|Costoclavicular block|In costoclavicular block, the course of the three cords of the brachial plexus is visualized under ultrasound guidance, adjacent to the brachial artery beneath the clavicle. Subsequently, after the needle is placed under ultrasound guidance between the three cords, 20 mL of 0.25% bupivacaine is injected as the local anesthetic.
223917673|NCT06953947|DRUG|Interscalene Nerve Block|In interscalene block, using an ultrasound probe placed on the neck, the course of the brachial plexus trunks between the anterior and middle scalene muscles is visualized. Then, after the needle is inserted under ultrasound guidance between the anterior and middle scalene muscles, 20 mL of 0.25% bupivacaine is injected as the local anesthetic.
223917674|NCT05860829|BEHAVIORAL|Educational|Caregivers of children with ASD will be sampled that are enrolled in Autism specialized Schools or centers. Tools and group education sessions will be developed in Urdu, English and Sindhi language. A caregiver education program session will be conducted by a practicing dentist and a registered dietitian in Urdu1 and English. Considering the ease of caregivers, cost-effectiveness and managing flexible hours, tele-health will be practiced for education program. A post-test will be conducted to assess the impact of the educational program on the knowledge of caregivers.
223917675|NCT04427007|DEVICE|Moisture Management Liner|A prototype prosthetic liner designed to reduce and/or remove moisture and heat that builds up on the limb.
223917676|NCT04427007|DEVICE|Control Liner|The participant's usual prosthetic liner
223917677|NCT05937100|DRUG|Formocresol|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
223917678|NCT05937100|DRUG|Biodentine|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
224278483|NCT05615376|DEVICE|ECG application|The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.
223917679|NCT05937100|DRUG|Hyaluronic acid gel|Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
223917680|NCT06292091|DRUG|Captopril 12.5 Mg|12.5 mg of captopril
223917681|NCT06292091|DRUG|Sodium bicarbonate 4 G|4 g of sodium bicarbonate
223917682|NCT06292091|DRUG|Torsemide 20 MG|20 mg of torsemide
223917683|NCT05124405|OTHER|Fitbit|wearable activity tracker
223917684|NCT05124405|OTHER|Continuous Glucose Monitor|wearable activity tracker
223917685|NCT05947422|DIAGNOSTIC_TEST|High resolution CT Chest|"CT chest in our institution will be done with standard high resolution protocol . No I.V contrast will be given. Scans will be obtained during full inspiration in supine position from the thoracic inlet to the level of the diaphragm.~Patients with CT chest performed outside our institution will be reviewed in DICOM format and assessed for its compatibility to be integrated into the computer-based analysis software."
224089449|NCT02617238|OTHER|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
224089450|NCT06625086|OTHER|Convensional exercises|Exercises will be provided to individuals in the Self-Guided Exercise group through a brochure.
224089451|NCT06625086|OTHER|Supervised exercises|Exercises will be administered to individuals with PFPS under the supervision of a physiotherapist.
224089452|NCT06625086|OTHER|Web based exercises|The exercises will be administered to participants through a web-based application.
224089453|NCT04596891|BEHAVIORAL|Psychotherapy|Eight sessions of exposure therapy combined with mindfulness delivered via videoconferencing platform.
224089454|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 180 mg/day
223917686|NCT05947422|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed using standard techniques according to ATS-ERS criteria 2019 . Spirometry device (Zan 300, NSPIRE HEALTH GMBH Co.) will be used. Percentage predicted values (%pred) will be calculated based on reference values for healthy adults. All patients will be required to undergo spirometry in a reproducible way, and the best values will be reported. Spirometry should meet international acceptability and repeatability standards
223917687|NCT06563713|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 0 following protocol requirements
223917688|NCT06563713|DRUG|Placebo|Subjects will receive the administration dose on Day 0 following protocol requirements
223917689|NCT04919629|BIOLOGICAL|Bevacizumab|Given IV
223530267|NCT02829996|DRUG|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
223716735|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
223917690|NCT04919629|PROCEDURE|Biopsy|Undergo tumor biopsy
223917691|NCT04919629|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223917692|NCT04919629|DRUG|Pegcetacoplan|Given IV and SC
223917693|NCT04919629|BIOLOGICAL|Pembrolizumab|Given IV
223917694|NCT04919629|OTHER|Questionnaire Administration|Ancillary studies
223917695|NCT05191823|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
224089455|NCT05218668|DRUG|Fasudil (WP-0512)|Oral fasudil up to 300 mg/day
224089456|NCT04838873|PROCEDURE|Open radical cystectomy|Standard open radical cystectomy and urinary diversion
224089457|NCT04838873|PROCEDURE|Laparoscopic-assisted radical cystectomy|Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion
223917696|NCT05191823|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
223917697|NCT06639633|OTHER|Anatomy Training with Enlarged %100 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 100% magnification on a 3D printer for 60 minutes.
224278484|NCT05615376|DEVICE|12 lead ECG|The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
224278485|NCT01507207|PROCEDURE|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
224278486|NCT04776005|OTHER|Data collection|Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
224278487|NCT03105193|DRUG|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
224278488|NCT03105193|DRUG|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
224278489|NCT03105193|DRUG|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
224278490|NCT03105193|DRUG|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
224278491|NCT01617551|DRUG|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
223917698|NCT06639633|OTHER|Anatomy Training with Enlarged %50 3D Printed Carpal Model Group|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 30 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 50% magnification on a 3D printer for 60 minutes.
223917699|NCT06639633|OTHER|Anatomy Training with Conventional Carpal Models|After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. They will then have a 60 minutes practical lesson with a standard sized printed model.
223917700|NCT04998305|DRUG|TJ-68|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of TJ-68 for three times per day before meals. It will be administered by dissolving 2.5 g of TJ-68 powder in 1 oz. of lukewarm water.
223917701|NCT04998305|DRUG|Placebo|For two periods (one period = 2 weeks) during the 11-week participation, participants will take 2.5 g of placebo for three times per day before meals. It will be administered by dissolving 2.5 g of the placebo powder in 1 oz. of lukewarm water.
223917702|NCT05357768|OTHER|data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue|"Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification."
223917703|NCT03489122|BEHAVIORAL|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
223917704|NCT03489122|BEHAVIORAL|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
223917705|NCT04510740|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
223917706|NCT06772090|BIOLOGICAL|Lactobacillus and Bifidobacterium|"Each lot of Lactobacillus and Bifidobacterium and placebo capsules to be used in this study will undergo bioburden testing (tested as per USP \<61\>) to ensure that each lot has:~* Not more than 2000 colony forming unit (CFU) of contaminating (other than the seven strains of bacteria used in the Lactobacillus and Bifidobacterium capsules) aerobic bacteria per gram or dose (whichever is greater);~* Not more than 200 CFU of yeasts and molds per gram or dose (whichever is greater); and~* No bile-tolerant Gram-negative bacteria, Escherichia coli, Salmonella species (in 10 gm), Pseudomonas aeruginosa, Staphylococcus aureus, and Clostridium species per gram or dose (whichever is greater; tested as per USP\<62\>)."
223917707|NCT06772090|OTHER|Placebo|Placebo capsule manufactured in same facility as experimental capsule.
223917708|NCT00147056|DEVICE|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
224278492|NCT01961258|OTHER|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
224278493|NCT02638519|OTHER|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
224278494|NCT02638519|OTHER|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
224278495|NCT02638519|DRUG|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
224278496|NCT02638519|DEVICE|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
223530268|NCT02829996|DRUG|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
223530269|NCT02829996|DRUG|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
223917709|NCT05942339|DEVICE|Procedure/Surgery|The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
223917710|NCT06262347|BEHAVIORAL|Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME)|The TOME intervention is a modified version of the personally-tailored opioid overdose prevention education and naloxone distribution (PTOEND) intervention (Winhusen et al. Evaluation of a personally-tailored opioid overdose prevention education and naloxone distribution intervention to promote harm reduction and treatment readiness in individuals actively using illicit opioids. Drug Alcohol Depend. Nov 1 2020;216:108265). Modifications include updating the knowledge assessment/education to reflect changes in the drug supply (i.e., the current high prevalence of fentanyl and increasing prevalence of xylazine) and the addition of items specific to pregnancy. Like PTOEND, TOME is a computer-guided intervention which utilizes REDCap to complete assessments and automatically generate personally-tailored feedback reports.
223917711|NCT06262347|BEHAVIORAL|Control|Participants randomized to the control condition will be offered three SAMHSA handouts.
223917712|NCT05562310|DRUG|Total parenteral nutrition (TPN). This is total nutrition provided by central vein.|phenylalanine, methionine and histidine intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
223917713|NCT03674723|OTHER|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
223917714|NCT06573047|OTHER|kinesotape|a- Kinesio-tape: cure tape (made in Korea) made from 100% gentle cotton fibre and 100% medical grade acrylic adhesive. its Hypoallergenic, water-resistant and does not limit range of motion (ROM), it is come with different colours and sizes. Kinesio Tape is safe enough for a baby's sensitive skin, and gentle enough for aging individuals, flexible enough for rehabilitation, durable enough to support working muscle, joint or ligament and strong enough for athletes at any level.
223917715|NCT06573047|BEHAVIORAL|Chest physiotherapy exercises|selected chest physiotherapy exercise three times per week for two weeks, each session will be about 20 minute which will include the following exercise ( huffing , coughing , percussion,and postural drainage)
223917716|NCT06397768|BIOLOGICAL|RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
223917717|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223917718|NCT06397768|BIOLOGICAL|Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223917719|NCT06397768|BIOLOGICAL|Hepatitis B vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223917720|NCT06397768|BIOLOGICAL|Streptococcus pneumoniae vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223917721|NCT06397768|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form:Oral solution-Route of administration:Oral
223917722|NCT06397768|BIOLOGICAL|Measles, mumps, and rubella vaccine|Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular
223917723|NCT06397768|BIOLOGICAL|Varicella virus vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular
223917724|NCT06397768|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
223917725|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-6 (il-6) concentration in blood serum|Measurement of fasting interleukin-6 (il-6) concentration in fasting venous blood serum
223917726|NCT06793085|DIAGNOSTIC_TEST|Measurement of fasting tumor necrosis factor α (TNF-α) concentration|Measurement of fasting tumor necrosis factor α concentration in fasting venous blood serum
223917727|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-18 (il-18) concentration|Measurement of interleukin-18 (il-18) concentration in fasting venous blood serum
223917728|NCT06793085|DIAGNOSTIC_TEST|Measurement of interleukin-4 (il-4) concentration|Measurement of interleukin-4 (il-4) concentration in fasting venous blood plasma
223917729|NCT04536012|BEHAVIORAL|Gamification and Social Incentives|Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
223917730|NCT05059002|DEVICE|Physiological signal monitoring and seizure detection|Data collection and as an adjunct to other methods of seizure monitoring
223917731|NCT03364127|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
223917732|NCT03364127|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
223917733|NCT06421376|DRUG|Cardonilizumab|Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
223917734|NCT06421376|RADIATION|Chemoradiotherapy ±immunotherapy|"Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles"
223917735|NCT06421376|PROCEDURE|Radical surgery|Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
223530270|NCT02829996|DRUG|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
223530271|NCT05314660|DRUG|38 % silver diamine fluoride|Application of 38% SDF on carious dentine lesions.
223530272|NCT05314660|PROCEDURE|Atraumatic restorative technique|Hand excavation of carious dentine followed by application of Glass ionomer
223530273|NCT05314660|PROCEDURE|Ultra conservative dentistry|Removal of soft dentine and enlarging of cavity to control bio film
223716736|NCT06140784|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
223716737|NCT02198274|DRUG|BIBH 1|100 mg/week
223716738|NCT04934397|OTHER|Study Infant Formula|Powdered partially hydrolyzed whey (WPH) based infant formula with oligosaccharides
223917736|NCT05972577|OTHER|Health Promotion and Education|Undergo GO!
223917737|NCT05972577|OTHER|Medical Device Usage and Evaluation|Wear accelerometer
224278497|NCT02807441|DRUG|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
224278498|NCT03300908|BEHAVIORAL|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
224278499|NCT03300908|BEHAVIORAL|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
224278500|NCT03992547|OTHER|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
224278501|NCT04417647|DEVICE|VZ powder (purified clinoptilolite)|VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).
224278502|NCT04417647|PROCEDURE|Standard of care (SoC)|wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.
224278503|NCT04964674|BEHAVIORAL|Behavioral Measurement|Take measurements of behavioral performance
224278504|NCT01074645|DRUG|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
223917738|NCT05972577|OTHER|Quality-of-Life Assessment|Complete quality of life assessments and diary entries
223917739|NCT05972577|OTHER|Questionnaire Administration|Complete questionnaires
223917740|NCT06651840|PROCEDURE|"bipolar diathermy Standard technique."|"The bipolar technique for group A:~A bipolar with straight blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
223917741|NCT06651840|PROCEDURE|coblation technique.|"The coblation technique for group B:~An coblator with tonsillar blade will be used with a footplate-operated switch to control the coagulation time, and the length, width and depth of penetration of the thermal power.~The lesion will be coagulated in a distal-to-proximal direction to achieve a uniform gray-white coagulation zone in the lesion and surrounding tissue. Multiple ablations at the same area should be avoided to avoid septal perforation. After finishing coagulation small gauze impregnated with antibiotic ointment will be applied for 2 hours postoperatively."
223917742|NCT03709966|DEVICE|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
223917743|NCT03709966|BEHAVIORAL|Routine|Physical activity promotion supported by a kinesiologist
223917744|NCT05988918|DRUG|ESK981|160 mg, PO, Once daily 5 days on and 2 days off
223917745|NCT06356285|BEHAVIORAL|Presentation of Antimicrobial Resistance|Participants will be presented with a poster containing information about antibiotics, each intervention poster will have a different name at the top, representing a new way to frame antimicrobial resistance.
223917746|NCT05598034|DEVICE|Left DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the left DLPFC brain region to deliver a mild, tolerable electric current.
223917747|NCT05598034|DEVICE|Right DLPFC tDCS|This intervention involves placing non-invasive scalp-electrodes over the right DLPFC brain region to deliver a mild, tolerable electric current.
223917748|NCT05598034|BEHAVIORAL|Cognitive task|Participants will be asked to perform a 2-back working memory mental task alongside administered tDCS
223917749|NCT06854029|DRUG|Cabotegravir Injection|Long-acting injection (LAI) Prep + X-RB treatment initiated in jail or prison.
223917750|NCT06854029|DRUG|Cabotegravir Pill|Oral PrEP + SL-B treatment initiated in jail or prison.
223917751|NCT06854029|DRUG|Buprenorphine injection|Long-acting injection (LAI) Prep + X-RB treatment initiated in jail or prison.
223917752|NCT06854029|DRUG|Buprenorphine Pill|Oral PrEP + SL-B treatment initiated in jail or prison.
223917753|NCT02800512|PROCEDURE|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
224278505|NCT06283836|DRUG|Dexmedetomidine|monitored anesthesia care (sedation)
224278506|NCT06283836|DRUG|Remifentanil|monitored anesthesia care (sedation)
224278507|NCT01280344|DRUG|Saline Solution for Injection|Intravenous (IV)
224278508|NCT01280344|DRUG|Ipamorelin|Intravenous (IV)
224278509|NCT01752530|OTHER|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
224278510|NCT01752530|OTHER|Treatment as usual|Treatment as usual at the clinic
224278511|NCT06490406|BEHAVIORAL|Multimodal intervention (communication and education simulations) for EG1|"In summary, students in EG1 received the following multimodal intervention flow: 1) Health communication training, 2) Structured educational simulation using standardized patients (SPs), and 3) simulation feedback and self-assessment using a systematic guide that included the health literacy practices."
224278512|NCT02996019|DRUG|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
224278513|NCT02996019|DEVICE|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
223917754|NCT02800512|PROCEDURE|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally-by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
223917755|NCT06813573|BIOLOGICAL|blood sampling|A maximum of 4 tubes of 10ml will be collected: at baseline (before cycle 1), before each cycle (from 2 to 6 included), at the end of the treatment, and in case of relapse during follow-up period
224089458|NCT03370393|BEHAVIORAL|Pathways for African-Americans' Success (PAAS)|PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of African Americans (AA), with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
224089459|NCT06759792|OTHER|eye hand coordination exercises|exercises to improve eye hand coordination post strabismus surgery
224089460|NCT06771895|BEHAVIORAL|Combined exercise and nutritional intervention|The intervention consists of a combined exercise and nutritional intervention. All subjects will perform 20 weeks of supervised resistance and endurance type exercise training 2 to 3 days per week. The dietary intervention aims to attain a diet that comprises sufficient protein and is otherwise in line with the Dutch Healthy Diet guidelines. In support, subjects will consume a daily high protein multi-nutrient supplement which will be ingested pre-sleep. There will be an additional supplement intake moment following each training session.
224089461|NCT06900452|DIETARY_SUPPLEMENT|0.5 serving of pistachios|"The equivalent of 0.5 servings (15g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 15g pistachio, 35g muesli base, 150g full fat natural yoghurt, 15g unsalted butter (melted), 10g unflavoured whey powder"
224089462|NCT06900452|DIETARY_SUPPLEMENT|1 serving of pistachios|"The equivalent of 1 serving (30g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 30g pistachio, 35g muesli base, 150g full fat natural yoghurt, 10g unsalted butter (melted), 5g unflavoured whey powder"
224089463|NCT06900452|DIETARY_SUPPLEMENT|2 servings of pistachios|"The equivalent of 2 servings (60g) of shelled, roasted pistachio nuts, crushed and mixed into a muesli-based breakfast meal for consumption.~Ingredients: 60g pistachios, 25g muesli base, 150g low fat natural yoghurt"
224089464|NCT06900452|DIETARY_SUPPLEMENT|Placebo|Macronutrient-matched placebo breakfast meal. Ingredients: 40g muesli base, 150g full fat natural yoghurt, 25g unsalted butter (melted), 15g unflavoured whey powder
224089465|NCT06755879|BEHAVIORAL|digital game-based learning activity|learning interventions to prevent surgical site infections with a digital game-based learning activity
224089466|NCT06755879|BEHAVIORAL|traditional method|Evaluation of the effectiveness of students' learning of interventions to prevent surgical site infections in the theoretical course taught by traditional method
224089467|NCT06855082|BEHAVIORAL|stoma self-care apps|This study uses a stoma self-care app, accessed through LINE official account, a communication software commonly used by Chinese people, as an intervention measure to integrate technology acceptance and task technology adaptation models to explore the correlation of each aspect and its impact on self-care ability and quality of life. Whether the factors and task technology adaptability will affect the willingness and usage behavior of enterostomy patients, the research subjects can effectively improve their self-care ability, quality of life, usage willingness, and usage behavior after intervention.
224089468|NCT06855082|BEHAVIORAL|Traditional Education Receive colostomy health education manual with oral instruction|conventional
224089469|NCT06901284|DIAGNOSTIC_TEST|Graded Exercise Test|"Participants will perform a graded exercise test on either a cycle ergometer or treadmill. The testing protocol will begin with a 5- 10 min warm-up of either cycling or running/walking at the participants preferred pace.~If the graded exercise test is on a bike, exercise will begin at wattage that elicits \~50% of their heart rate max, HRmax = 208 - 0.7 × age and increase by either 10W, 15W, or 20W every two minutes in a stepwise fashion until symptom limitation. The step of the wattage increase will be at the discretion of the investigators.~If the graded exercise test is on a treadmill, the test will begin at a speed that elicits \~50% of predicted HRmax. Following, the speed of the treadmill will increase 0.5 mph (0.8 km/hr) every two minutes in a stepwise fashion until symptom limitation. If the participant maxes out the speed of the treadmill, we will increase the grade 2% every 2-minutes until symptom limitation."
224099277|NCT05040191|OTHER|Haptic interactive computer-based simulation training|"Clinical tvr (tactile simulator) produced by a foreign commercial company used in nursing education was used. Clinical tvr simulation applications can be accessed online or downloaded to a computer. This simulator; It functions by using an interactive, visually enhanced 2D, animated, haptic arm that can be held by students like a pen. It includes applications such as nasogastric tube placement, urinary bladder catheter placement, heart massage. These applications can be realized through both mouse and haptic arm computer input devices. clinical tvr; It is a simulator that incorporates the enhanced benefits of haptic feedback through the use of haptic technology. This simulator provides a near-realistic sensory experience where the learner can practice a skill as it actually is. Computer-based simulation with haptic interaction was used in this study with the haptic arm in NGT application skill."
223917756|NCT06814834|DRUG|Oral dissolution therapy|Patients received guidance for oral potassium-sodium-hydrogen-citrate (6:6:3:5) at a dosage of twenty milliequivalents three times every day, along with a daily fluid intake of two to three liters and a food plan to restrict protein and sodium consumption for a maximum of three months.
223917757|NCT06814834|PROCEDURE|Extracorporeal shock wave lithotripsy|Patients received extracorporeal shock wave lithotripsy utilizing a Dornier lithotripter equipped with an integrated ultrasound for stone localization. If the patient required additional sessions, up to a maximum of four sessions, at a rate of 60-90 shocks per minute, the period between sessions was three weeks.
223917758|NCT06814834|PROCEDURE|Oral dissolution therapy + extracorporeal shock wave lithotripsy|Patients received a combination of oral dissolution therapy and extracorporeal shock wave lithotripsy.
223917759|NCT06815016|OTHER|Reflexology ,mulligan mobilization and conventional|Reflexology is a systematic practice in which applying some pressure to any particular points on the feet and hands give impacts on the health of related parts of the body as (Knee reflex point, Pituitary reflex point, Entire spine, Liver reflex area, Thyroid reflex area ) Mulligan's Mobilization with Movement (MWM) apply accessory gliding force combined with active movement as (Lateral glide MWM for flexion / extension, Medial glide MWM for flexion / extension, Self-medial glide MWM for knee flexion/extension: home exercise)
223917760|NCT06815016|OTHER|reflexology and conventional|Reflexology as (Knee reflex point, Pituitary reflex point, Entire spine, Liver reflex area, Thyroid reflex area ) and conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
223917761|NCT06815016|OTHER|mulligan mobilization and conventional|Mulligan mobilization as (Lateral glide MWM for flexion / extension, Medial glide MWM for flexion / extension, Self-medial glide MWM for knee flexion/extension: home exercise) and conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
223917762|NCT06815016|OTHER|Conventional treatment|Conventional methods as (Transcutaneous Electrical Nerve Stimulation (TENS), Ultrasound Therapy and exercises) treatment.
223917763|NCT06813222|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10 mg
223530274|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1 hour. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
223530275|NCT05080764|COMBINATION_PRODUCT|1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 1h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
223917764|NCT06841380|OTHER|sesame-based oil|15min of oil pulling with 15ml sesame-based oil for 8 weeks
223917765|NCT06841380|OTHER|distilled water|15min rinsing with 15ml distilled water for 8 weeks
223917766|NCT04802876|DRUG|Spartalizumab|Spartalizumab (PDR001) 400mg will be given intravenously every 28 days
223917767|NCT04802876|DRUG|Tislelizumab|Tislelizumab 300mg will be given intravenously every 28 days
223917768|NCT02095691|DEVICE|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
223917769|NCT06756191|DRUG|Combination therapy group|Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
223917770|NCT06756191|DRUG|Liposomal Amphotericin B|Liposomal amphotericin B (AmBisome®) alone
223917771|NCT03476369|DRUG|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
223917772|NCT03476369|DRUG|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
223917773|NCT02724540|DEVICE|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
223917774|NCT02724540|COMBINATION_PRODUCT|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
223917775|NCT02724540|COMBINATION_PRODUCT|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
223917776|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered as a single dose IV infusion or subcutaneous injection
223917777|NCT06050915|DRUG|DISC-3405|DISC-3405 is administered in multiple ascending doses as an IV infusion or subcutaneous injection
223917778|NCT06050915|DRUG|Placebo|Placebo is administered as a single dose IV infusion or subcutaneous injection
223917779|NCT06050915|DRUG|Placebo|Placebo is administered in multiple ascending doses as an IV infusion or subcutaneous injection
223917780|NCT06598865|OTHER|adapted physical activity|After the initial training in adapted physical activity (APA), patients will receive regular support from an APA instructor, and they will be asked to participate in 3 sessions per week of APA, if possible in a Sport-Health center close to their home, for the entire duration of the study. The content of the additional APA sessions (up to 2 additional sessions per week) can be discussed with the APA instructor. They will also be asked to return to the study center for a visit at 3 months (Visit 3) to assess the effect of the APA conducted during this period
223917781|NCT06585839|BEHAVIORAL|Digital coaching solution to improve childbirth experience|Intervention provides coaching to improve the childbirth experience and offers comprehensive perinatal mental health support to pregnant and postpartum women. It features emotion tracking and exercise customization functionality, along with an avatar-based platform. The app includes digital psychotherapy exercises and psychoeducation. These core elements are complemented by exercises in mindfulness, relaxation, and self-soothing.
223917782|NCT06585839|OTHER|Application for the control group|Application for the control group including surveys.
224099278|NCT00994617|DRUG|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
224099279|NCT00994617|DRUG|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
224099280|NCT04460703|OTHER|Control message|2/15 of the sample will be assigned to the pure control group, which is a passage on the costs and benefits of bird feeding.
224099281|NCT04460703|OTHER|Baseline message|3/15 of the sample will be assigned to a control group with a message about the effectiveness and safety of vaccines.
224099282|NCT04460703|OTHER|Personal freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting people's personal freedom and by working together to get enough people vaccinated society can preserve its personal freedom.
223917783|NCT06595706|DRUG|Lucid-21-302|Capsule containing a small molecule inhibitor of hypercitrullination
223917784|NCT06595706|DRUG|Placebo|Capsule containing only Silicified Microcrystalline Cellulose
223917785|NCT00887198|DRUG|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
223917786|NCT00887198|DRUG|Placebo|4 placebo tablets per day taken orally.
223917787|NCT00887198|DRUG|Prednisone|5 mg tablet orally twice daily.
223917788|NCT06807060|BEHAVIORAL|'Light, activity and sleep in my daily life' intervention|"The intervention is complex in that it considers multiple factors (e.g., light-related behaviour, physical activity and sleep behaviour) and multiple components (e.g., cognitive goal setting and implementation).~The intervention is delivered as a web-based course on a digital learning platform. Course material is placed in nine modules covering electric lighting, daylight, physical activity outdoors and sleep. Besides online material, the course includes a test kit containing light bulbs, a sleep mask, a checklist for the room inventory, a cap, a notebook, and a sleep diary. The purpose of the test kit is to encourage experimentation and provide handouts and printed copies to facilitate the completion of assignments."
223917789|NCT06587516|BEHAVIORAL|Neuromuscular Warmup Program|This intervention consists of a structured warm-up routine specifically designed to enhance neuromuscular function and balance. The program includes exercises such as two way forward lunge, single-leg balance, multidirectional lunges, single-leg hops forward and backward, and single-leg calf raises. Each exercise is aimed at improving proprioception, dynamic stability, and lower limb strength.
223917790|NCT06587516|BEHAVIORAL|Traditional Warmup Program|This intervention involves a conventional warm-up program. It includes general stretching exercises and light jogging intended to prepare the body for physical activity.
224278514|NCT02996019|DEVICE|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
223917791|NCT02394626|PROCEDURE|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
223917792|NCT02394626|PROCEDURE|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
223917793|NCT06050720|DEVICE|Apne-Scan DC1 device|The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
223917794|NCT05007080|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as intramuscular (IM) injection.
223917795|NCT05340348|OTHER|Blood samples (36 mL) + fecal samples + hair sample|Blood samples at inclusion, 2 years later and/or if relapse, fecal samples at inclusion and every years for 5 years, hair sample at inclusion
223917796|NCT06589271|BIOLOGICAL|human umbilical cord mesenchymal stem cell suspension|2 \* 10\^7 cells (2ml)
223917797|NCT06589271|PROCEDURE|total endoscopic extraction of lumbar nucleus pulposus|hUC-MSCs are injected into the opposite side of the minimally invasive surgical site immediately after surgery, and the puncture needle remains for 1 minute after injection and then pull out to prevent cell suspension leakage
223917798|NCT06668792|DRUG|BCD-248|subcutaneously
223917799|NCT00319046|DRUG|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
223917800|NCT05819502|DRUG|Restylane line of injectables|Restylane fillers are manufactured by Q-Med AB, part of the Galderma Group.
223917801|NCT06571812|DEVICE|TSX|Treatment of tooth loss with TSX dental implants
223917802|NCT05147584|DEVICE|Dual fetal oxygen sensors|Placement of both internal and external fetal oxygen sensors
223917803|NCT03967379|BEHAVIORAL|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
223917804|NCT03967379|OTHER|Enhanced Standard Care|Standard of care administered by the institution
223917805|NCT03329937|DRUG|Niraparib|Niraparib is a potent, orally active, highly selective poly adenosine diphosphate (\[ADP\]-ribose) polymerase 1 (PARP1) and PARP2 inhibitor. It will be supplied as 100 mg capsules and will be administered at starting dose of 200 mg PO daily throughout 28 days for 2 cycles (each cycle is 28 days), with the potential for an additional 4 cycles (maximum total of 6 cycles) at the assigned dose and schedule.
223917806|NCT05814432|DRUG|Single high dose of liposomal amphotericin B|Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
223917807|NCT05814432|DRUG|L-AmB standard dose|Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
223917808|NCT04664959|DRUG|SB16 (Proposed Denosumab Biosimilar)|"Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.~At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously."
223917809|NCT04664959|DRUG|Prolia® (Denosumab)|Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.
223917810|NCT04782752|RADIATION|Radiation: Varying Doses of RT|3+3 radiation dose escalation model to see the maximum tolerated dose
223917811|NCT05269888|OTHER|Blood Test 1|"Blood test 1 - At 12 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
223917812|NCT05269888|OTHER|Blood Test 2|"Blood test 2 - At 18 months (+3months) from the date of 1st Covid-19 vaccine:~Anti-SARS-CoV-2 S1/S2/N IgG antibody Roche, T-SPOT® COVID SARS-CoV-2, Full Blood Count, Serum Immunoglobulins, Anti-VZV titres"
224278515|NCT02347319|DRUG|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
224278516|NCT02347319|DRUG|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
224278517|NCT02347319|DRUG|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
223917813|NCT05840237|OTHER|"Anhydrous Enol-Oxaloacetate, a Medical Food"|"Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food"
223917814|NCT05840237|OTHER|White Rice Flour|"Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food"
223917815|NCT01223352|DRUG|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
223917816|NCT06291207|DRUG|AD-224A|PO, Once daily, 8weeks
223917817|NCT06291207|DRUG|AD-224B|PO, Once daily, 8weeks
223917818|NCT06291207|DRUG|AD-224C|PO, Once daily, 8weeks
223917819|NCT06291207|DRUG|Placebo of AD-224A|PO, Once daily, 8weeks
223917820|NCT06291207|DRUG|Placebo of AD-224B|PO, Once daily, 8weeks
224089470|NCT06901284|DIAGNOSTIC_TEST|Graded Hypoxia Exercise Test|"Participants will perform a single constant work rate exercise tests during graded hypoxia. They will be outfitted with either a facemask or mouthpiece connected to a uni-directional breathing valve. During inspiration, subjects will breathe from a closed-system Douglas bag balloon reservoir (\~200 L) connected to the value on the inspired side via air-tight clean-bor tubing.~The participant will complete the same mode of exercise as they did during visit 1, either bike or treadmill. The resistance on the bike or incline of the treadmill will be set to elicit an intensity equivalent to \~50% of their V̇O2max determined during visit 1. Participants will complete 5-minute stages over a range of FiO2 values. The exercise test will begin in an FiO2=0.21 (i.e. room air). Following this first 5-min stage the FiO2 will increase to 0.25, afterwards, participants will complete another stage at FiO2=0.21 and then decrease in a stepwise fashion every 5-minutes."
223716739|NCT00560976|DRUG|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
223719538|NCT02279563|DRUG|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
223917821|NCT06291207|DRUG|Placebo of AD-224C|PO, Once daily, 8weeks
223917822|NCT04632433|DRUG|Cemiplimab|350 mg every 3 weeks
223917823|NCT04965766|DRUG|U3-1402|U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
223917824|NCT04217603|DEVICE|Continuous positive airway pressure (CPAP) device|Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle
223917825|NCT04217603|DEVICE|Sham-continuous positive airway pressure (CPAP) device|An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
223917826|NCT03754465|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
224089471|NCT04981223|DEVICE|ExactVu|clinical micro-ultrasound, imaging Device, Manufacturer; Exact Imaging
224089472|NCT04280081|DRUG|Selpercatinib|Administered orally
224089473|NCT06621394|OTHER|nutritional intervention|nutritional intervention to mediterranean diet
224089474|NCT06621394|BEHAVIORAL|Mindful Eating|intervention regarding mindful eating, e.g. attention while eating, apprechiation of food
224089475|NCT06621394|OTHER|Attention Control|Befreinding Control Group: Provision of same amout of time and attention, without having an intervention, e.g. talking about hobbies and interests, playing card games
224089476|NCT06927778|OTHER|Exercise|Individualised corrective exercise protocols based on Functional Movement Screening
224089477|NCT05026905|DRUG|Gemcitabine 1000 mg|Gemcitabine 800mg/m2 in N/S 250ml over 30 minutes (or fixed dose rate 10 mg/m2/min) IV infusion on day 1 repeated every 14 days.
224089478|NCT05026905|DRUG|Nab paclitaxel|Nab-paclitaxel 125mg/m2 over 30 minutes IV infusion on day 1 repeated every 14 days, followed by Gemcitabine
224089479|NCT05026905|DRUG|S1|"S-1 orally 60-100 mg/day day 1 to 7 on in a 2-week cycle. The dose of S-1 is defined as follows:~* BSA \< 1.25 m2: 60 mg/day~* 1.25 m2 ≤ BSA \< 1.5 m2: 80 mg/day~* BSA ≥ 1.5 m2: 100 mg/day"
223917827|NCT03754465|PROCEDURE|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
224089480|NCT05026905|DRUG|leucovorin|leucovorin 30mg BID day 1 to 7 on in a 2-week cycle
223719539|NCT02279563|DRUG|Dymista™ Nasal Spray|
223917828|NCT04623775|BIOLOGICAL|Nivolumab|Specified dose on specified days
223917829|NCT04623775|BIOLOGICAL|Relatlimab|Specified dose on specified days
223917830|NCT04623775|DRUG|Carboplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
223917831|NCT04623775|DRUG|Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
223917832|NCT04623775|DRUG|Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
224089481|NCT05026905|DRUG|Oxaliplatin|Oxaliplatin 75mg/m2 in 250 mL of D5W over 120 minutes IV infusion on day 1 repeated every 14 days
224089482|NCT00289679|DEVICE|Hip prosthesis revision|
224089483|NCT06782269|PROCEDURE|ankle fusion|fusion of ankle joint
224278518|NCT05505305|BEHAVIORAL|Time-restricted eating and high-intensity interval training|Maximal daily eating window of 10 hours and high-intensity interval training (three weekly, unsupervised, aerobic exercise sessions performed at \> 90 % heart rate maximum). Each exercise session will last for 33-38 minutes. Participants will receive digital follow-up once weekly. The intervention period will be seven weeks,
224278519|NCT03239977|BEHAVIORAL|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
224278520|NCT03239977|BEHAVIORAL|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
224278521|NCT05258851|DRUG|Ceftazidime-avibactam|Experimental
223719540|NCT02279563|DRUG|Placebo|
223917833|NCT04623775|DRUG|Nab-Paclitaxel|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
223917834|NCT04623775|DRUG|Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
223917835|NCT01950234|DRUG|ACTH|Acthar gel
223917836|NCT01950234|DRUG|Placebo|Placebo
223917837|NCT06814938|DRUG|Semaglutide|2.4 mg subcutaneous weekly
224278522|NCT05258851|DRUG|Colistin|Control
223719541|NCT00001006|DRUG|AS-101|
223917838|NCT06814938|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient administered subcutaneous weekly
223917839|NCT06815523|OTHER|Machine learning and logistic regression for the training/testing cohort and validation cohort|Machine learning and logistic regression for the validation cohort
223917840|NCT06810986|BEHAVIORAL|16-week digital intervention|"Participants will be enrolled in a 16-week programme with the aim to manage T2DM through lifestyle adjustments. Participants will be given online support by their personal health coach with additional support from a dietitian or clinician in the study if required.~Each participant will receive personalised recommendations for blood glucose monitoring schedule, diet and physical activity. Participants are required to log their blood glucose, diet and physical activity in the BruHealth application. Participants will review their progress with their health coach via video consultation on a regular basis. Additionally, participants will also participate in a structured diabetes self-management education course."
223917841|NCT06810388|OTHER|Health education intervention program based on a family-centered empowerment model|Three sessions of approximately 15-30 min each are conducted within 3 d of the child's admission to the hospital, from the fourth day to the day before discharge, and on the day before discharge. The researcher or charge nurse assesses the caregivers' mastery every week using uniform evaluation criteria and adjusts the topic or number of interventions within each phase based on mastery, with the final intervention content and timeline remaining unchanged.Health education includes: providing family caregivers of children with malignant tumors with knowledge of the disease, guidance on dietary care, instruction on how to recognize symptoms, guidance on medication, post-implantation precautions at the port of infusion, knowledge of blood markers, monitoring of the disease, and emergency treatment.
223917842|NCT06810388|OTHER|Implementation of routine care measures|"Routine nursing care and current health education content will be provided, including the following: introduction to the department's environment, rules, and regulations; admission counselling; examination guidance; distribution of health education brochures; ongoing education on daily care, medication management, and health practices during hospitalisation; guidance on daily care, medication management, and health education by the nurse in charge; proactive support and communication by medical staff, including resolving questions and sharing caregiver experience; and discharge instructions with follow-up schedules for chemotherapy.~Participants in the control group are offered an FCEM-based intervention regimen on their second admission (at the beginning of the second course of treatment), which is appropriately adapted to the control group's second chemotherapy treatment."
223917843|NCT06808139|PROCEDURE|Plasma-Rich Platelet Graft|The clot was extracted from the tube, separated from red blood cells, and gently compressed between two surgical swabs to obtain a soft and resistant membrane. The Snodgrass technique was carried out for all patients, with a suitable size catheter (8-12-Fr), repair was carried out by a continuous layer of polyglycolic suture (Vicryl) size 6/0, covered by an interrupted second layer. In group A, after finishing the Snodgrass TIPU, a PRP sheet coverage was applied over urethroplasty and secured by Vicryl 7/0, and finally the skin sutured directly without any covering layers
223917844|NCT06808139|PROCEDURE|Dartos Flap|preputial dartos flap will be used
223940515|NCT06300086|BEHAVIORAL|Electronically delivered nudging letter to associated GPs of patients with CKD|"The associated GPs of the patients in the active arm will receive one digital nudge letter as part of the study. The nudge letter will be delivered at baseline. The letters will be delivered through the official, mandatory Danish electronic letter system.~The control arm will consist of patients with CKD whose associated GP was randomized to not receive a digital nudge letter (usual care)."
223940516|NCT05047263|DRUG|Finerenone (BAY94-8862)|Tablet, 10 mg or 20 mg, once daily (OD), oral
223940517|NCT05047263|DRUG|Placebo|Tablet, once daily, oral
223940518|NCT01156155|RADIATION|Digital xray of jaw and teeth|one time xray of jaw and teeth
223940519|NCT01156155|PROCEDURE|Blood draw|Three to four tablespoons of blood drawn.
223940520|NCT01156155|OTHER|questionnaires|completed questionnaires regarding patient's health and functional ability.
223940521|NCT01156155|PROCEDURE|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
223940522|NCT01156155|OTHER|Bilateral digital xray of hands|One time digital xray of hands
223940523|NCT05931510|OTHER|Myofscual release|I will apply myofascial release on group A patients and observse its effects on shin splint
223940524|NCT05931510|OTHER|Post isometric relaxation.|I will apply post isonetric relaxation on group b patients and observe effects on shin splint
223719542|NCT05199129|DRUG|HCP1904-3|Take once daily for 8 weeks orally
223719543|NCT05199129|DRUG|RLD2001-1|Take once daily for 8 weeks orally
223917845|NCT06807827|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
223917846|NCT06807827|OTHER|Basic Education|Basic Education about lifestyle Modification(Provide guidance on how to maintain a healthy lifestyle, including balanced diet, exercise and regular sleep patterns). General Knowledge advancement. General knowledge about disease and medicine. Pill planner will be provided to keep them adherent to their medication. General Medication counselling.
223917847|NCT06502782|DIAGNOSTIC_TEST|digital assesment|Gingival recession sites were scanned with an intraoral optical surface scanner, and STL images were recorded. The images were imported into image analysis software. The depth, width and area of gingival recession were calculated using Autocat program.
223917848|NCT03419260|OTHER|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
223917849|NCT06065280|DRUG|Empagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
223917850|NCT06065280|DRUG|Dapagliflozin 10 MG|Each group will be divided into 2 subgroups one on Empagliflozin and the other one on Dapagliflozin 10 MG daily.
223917851|NCT06656052|OTHER|1. working memory task.|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants will be asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher.
223917852|NCT06656052|OTHER|2. Visual and Verbal Fluency Task|Stroop colour word test (modified Stroop test): participants will be asked to name the colour of ink that each word is printed in. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.
223917853|NCT06656052|OTHER|3. Motor Task|Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
223917854|NCT06656169|DRUG|Subcutaneous polyvidone collagen|Use collagen-polyvidone at a dose of 0.2 ml, applied to the affected area of the hand.
224089484|NCT01052649|OTHER|Blood sampling|
224089485|NCT06916130|DRUG|AD-120A|Administered before the breakfast during 7 days, Oral, Tablet
224089486|NCT06916130|DRUG|AD-120|Administered before the breakfast during 7 days, Oral, Tablet
224089487|NCT06916572|OTHER|Scapular stabilization exercises|"Individuals in the Scapular Stabilization group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. The treatment of individuals in this group included scapular stabilization exercises in addition to conventional treatment. Scapular stabilization exercises were planned to be applied only on the days of the session. Each of the exercises was applied as 10 repetitions and 2 sets.~Conventional treatment included an exercise program consisting of Wand, Codman, finger ladder and rotator cuff strengthening exercises, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities."
223917855|NCT06656169|OTHER|saline solution|administer saline solution at a dose of 0.2 ml, applied to the affected area of the hand.
223917856|NCT06656676|BEHAVIORAL|WePrEP: A shared decision-making tool|WePrEP will be bilingual, both patient- and provider-facing, stored on the provider's electronic device (and will have the capability to integrate with electronic health records in the future to enable scalability), and easily accessible during in-person or virtual patient-provider encounters. WePrEP is designed to present pertinent PrEP information to transgender women and their PrEP service providers to stimulate discussions about PrEP choice and support adherence (once a PrEP strategy has been chosen). We hypothesize that this will ensure selection of the ideal PrEP method and improve subsequent adherence.
224089488|NCT06916572|OTHER|Scapular PNF|"Physiotherapy and rehabilitation program was applied to the individuals in the PNF group for 6 weeks, 3 days a week, as in the Scapular Stabilization group. In addition to conventional treatment, scapular PNF approaches were added to the treatment of individuals in this group.~The scapular PNF patterns of anterior elevation - posterior depression and anterior depression - posterior elevation were applied with rhythmic initiation, repeated contractions (stretches) and rhythmic stabilization techniques with 10 repetitions of each technique.~Conventional treatment included an exercise program consisting of Wand, Codman, finger ladder and rotator cuff strengthening exercises, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities."
224089489|NCT06915168|OTHER|Informational Intervention|Given CIPN DecisionAid
224089490|NCT06915168|OTHER|Survey Administration|Ancillary studies
223917857|NCT06656676|BEHAVIORAL|Active comparator: CDC recommendations for discussing PrEP|Standard of care recommendations to discuss PrEP with potential end-users, endorsed by the CDC.
223917858|NCT06807476|OTHER|Validity and reliability|"The scale consists of 40 items and four sub-dimensions, and is scored according to a 5-point Likert rating scale (ranging from Strongly Disagree (Score = 1 point) to Strongly Agree (Score = 5 points)). The scale evaluates the healthy/patient individual's readiness attitude level towards acupuncture, personal beliefs, preferences and experiences. The score received per sub-dimension varies between a minimum of 10 and a maximum of 50 points. The average cut-off score per sub-dimension is 25. The higher the score (above the average cut-off score), the more open the healthy/patient individual is to acupuncture. Sub-dimensions:~Sub-Dimension 1 (Items 1-10): Willingness to Try Acupuncture Sub-Dimension 2 (Items 11-20): Belief in the Effectiveness of Acupuncture Sub-Dimension 3 (Items 21-30): Comfort in the Acupuncture Sub-Dimension 4 (Items 31-40): Concerns and Preferences"
224099283|NCT04460703|OTHER|Economic freedom message|1/15 of the sample will be assigned to this intervention, which is a message about how COVID-19 is limiting peoples's economic freedom and by working together to get enough people vaccinated society can preserve its economic freedom.
224099284|NCT04460703|OTHER|Self-interest message|1/15 of the sample will be assigned to this intervention, which is a message that COVID-19 presents a real danger to one's health, even if one is young and healthy. Getting vaccinated against COVID-19 is the best way to prevent oneself from getting sick.
223917859|NCT06656325|DEVICE|Erchonia® FX405|"Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit."
223917860|NCT06656325|DEVICE|Placebo Laser|"Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit."
223917861|NCT06656026|DRUG|ZSP1273 granules|Oral
223917862|NCT06368050|BEHAVIORAL|practice structure intervention|practice structure intervention
223917863|NCT06061575|DRUG|Acetaminophen|fever will be managed with acetaminophen
223917864|NCT06061575|DRUG|Ibuprofen|fever will be managed with ibuprofen
223917865|NCT06838572|PROCEDURE|Skin cooling to 20°C|According to the group, copper parts at a constant temperature of 20°C were placed on the superficial skin of the brachial plexus for 15 minutes.
223917866|NCT06838572|PROCEDURE|Skin cooling to 15°C|According to the group, copper parts at a constant temperature of 15°C were placed on the superficial skin of the brachial plexus for 15 minutes.
223917867|NCT06838572|PROCEDURE|Skin cooling to 8°C|According to the group, copper parts at a constant temperature of 8°C were placed on the superficial skin of the brachial plexus for 15 minutes.
223917868|NCT06838572|PROCEDURE|No skin cooling|According to the group, copper parts at room temperature (23°C) were placed on the superficial skin of the brachial plexus for 15 minutes.
223917869|NCT06810401|PROCEDURE|Debridement of implant surface with titanium curettes and irrigation with sterile saline solution|All patients in both groups received non-surgical treatment of peri-implantitis involving the debridement of hard- and soft accumulations on implant surfaces using titanium curettes (Titanium Implant Scaler 204SD, Hu-Friedy) for 15 minutes, followed by irrigation with sterile saline solution
224089491|NCT06916650|DEVICE|High-Intensity Laser Therapy (HILT)|Nd:YAG laser (1064 nm) applied to anterior, lateral, posterior glenohumeral joint aspects. Three-phase protocol per session: (1) 10 J/cm² @ 10 Hz; (2) 12 J/cm² @ 2000 Hz; (3) 10 J/cm² @ 15 Hz. Total energy \~1200 J/session. Frequency: 2 sessions/week for 6 weeks (12 sessions total). Delivered by trained PTs.
223719544|NCT05063487|OTHER|Return of recent classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a recent classification (i.e., having acquired an HIV infection within the last year) will be returned to study participants during a scheduled 1-month visit following initial HIV diagnosis.
223917870|NCT06806553|BEHAVIORAL|Constraint-Induced Movement Therapy (CIMT) With Motor Relearning Program (MRP)|"Intensive training sessions of 3 hours/day for 6 weeks, focusing on functional tasks with the paretic arm while constraining the unaffected arm using a mitt or sling. Implement a constraint on the non-paretic arm to encourage increased use of the affected arm in daily activities. Use shaping techniques to gradually increase the complexity and difficulty of tasks performed with the affected arm (Rahman, 2016).~MRP: Standard physiotherapy sessions of 1 hour/day for 6 weeks, including exercises for both affected and unaffected arm. Focus on improving strength, range of motion, and coordination through repetitive task practice, neuromuscular re-education and compensatory strategies (Brkić, 2016; Ghrouz et al., 2023)."
224089492|NCT06916650|DRUG|Ultrasound-Guided Intra-articular Corticosteroid Injection|Single injection into the glenohumeral joint under ultrasound guidance. Consists of 40 mg methylprednisolone acetate combined with 4 ml of 1% lidocaine hydrochloride. Delivered at baseline by an experienced orthopedic physician.
224089493|NCT06916650|BEHAVIORAL|Manual Therapy|Skilled hands-on techniques including glenohumeral joint mobilizations (Maitland grades III-IV), posterior capsule stretching, scapular mobilization, and soft tissue techniques targeting restricted tissues. Session duration: \~30 minutes. Frequency: 2 sessions/week for 6 weeks (12 sessions total). Delivered by PTs specialized in manual therapy.
224089494|NCT06916650|BEHAVIORAL|Standard Exercise Program|Standardized program including pendulum exercises, active-assisted range of motion exercises (e.g., wand, wall climbs), stretching (e.g., cross-body, sleeper stretch), and progressive resistive exercises using resistance bands. Includes supervised instruction/progression and a daily home exercise program component. Supervised instruction frequency: 2 sessions/week for first 6 weeks, then 1 session/week for next 6 weeks (total 18 supervised sessions over 12 weeks). Delivered by trained PTs.
224089495|NCT06915350|OTHER|maspin ( mammary serine protease inhibitor)|Maspin is an immunohistochemical marker to detect the prognosis of colorectal carcinoma
224089496|NCT06916611|OTHER|Cardiac Magnetic Resonance Imaging|This study included patients who were diagnosed with HFpEF and had completed CMR.
224089497|NCT06915701|DIETARY_SUPPLEMENT|Will take vitamin E 800mg/day|Patients with deficient vitamin E intake (\<15mg/day), who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus vitamin E 800mg/day.
224089498|NCT06915701|DRUG|Will take 200mg/day magnesium oxide placebo.|Patients with RA deficient in vitamin E intake (\<15mg/day) , who are treated with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) plus the consumption of magnesium oxide 200mg/day in placebo form.
224099285|NCT04460703|OTHER|Community interest message|1/15 of the sample will be assigned to this intervention, which is a message about the dangers of COVID-19 to the health of loved ones. The more people who get vaccinated against COVID-19, the lower the risk that one's loved ones will get sick. Society must work together and all get vaccinated.
223719545|NCT05063487|OTHER|Return of long-term classification|As part of routine HIV case-based surveillance in Rwanda, blood samples are collected for recency testing on the Rapid Test for Recent Infection (RTRI) assay and viral load testing for all newly diagnosed people living with HIV. Results of a long-term classification (i.e., having acquired an HIV infection more than one year ago) will be returned to study participants during the scheduled 1-month visit following initial HIV diagnosis.
223917871|NCT06806553|BEHAVIORAL|Bobath Therapy|The first step in the Bobath approach is a thorough assessment of the individual's movement patterns, muscle tone, strength, coordination, and functional abilities. This assessment helps in identifying specific impairments and setting goals for treatment. Bobath therapists use specific handling techniques to facilitate normal movement patterns and inhibit abnormal muscle tone. These hands-on techniques aim to promote efficient movement and improve motor control. The Bobath approach emphasizes task-oriented training, where functional activities relevant to the individual's daily life are incorporated into therapy sessions. This helps in improving motor skills in a context that is meaningful to the individual (Grozdek Čovčić et al., 2022; Kuciel et al., 2021).
223917872|NCT06811558|BIOLOGICAL|Ixekizumab|injected with ixekizumab
223917873|NCT06811558|BIOLOGICAL|Secukizumab|injected with secukizumab
223917874|NCT06594120|BEHAVIORAL|Multimodal rehabilitation with additional work specific training|The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
223917875|NCT06765304|BEHAVIORAL|Transtheoretical education intervention group|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
223917876|NCT06765304|BEHAVIORAL|Preconceptional Period Healthy Life Behaviours Classical Education Intervention Group|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
223917877|NCT06765304|BEHAVIORAL|Placebo|The trainings will take place in eight consecutive sessions (two sessions per week) over four weeks. Sessions will last 60 minutes. The content of the training will be designed under the title of Week 1 - Planning, Week 2 - Preparation, Week 3 - Action, Week 4 - Sustaining.
223917878|NCT06769568|DRUG|reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia|reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia
223917879|NCT06161584|DRUG|Pegcetacoplan|Administered intravitreally (IVT) in eyes with geographic atrophy (GA)
223917880|NCT05590455|DRUG|Adalimumab Injection|one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
223917881|NCT04979455|OTHER|Core temperature monitoring|Core temperature will be monitored on the day of exercise
223917882|NCT04979455|BEHAVIORAL|Questionnaires|Questionnaires will be completed at baseline and on the day of exercise
223917883|NCT04979455|OTHER|Heart rate monitoring|Heart rate will be monitored on the day of exercise
223917884|NCT04979455|OTHER|Urine collection|Urine samples will be collected at baseline and on the day of exercise
223917885|NCT04979455|OTHER|Sleep monitoring|Sleep will be monitored at baseline and on the day of exercise
223917886|NCT04979455|OTHER|Blood collection|Blood samples will be completed at baseline
223917887|NCT04979455|OTHER|Saliva collection|Saliva samples will be collected at baseline and on the day of exercise
223917888|NCT04979455|OTHER|Throat swab collection|Throat swab samples will be collected at baseline and on the day of exercise
223917889|NCT04979455|OTHER|Stool collection|Stool samples will be collected at baseline and on the day of exercise
223917890|NCT06816225|OTHER|Actigraphy|Actigraphy is a validated complementary means of diagnosis, the gold standard for the assessment of circadian rhythm.
223917891|NCT06816225|OTHER|Schedule of Growing Skills II|Assessment scale for skills in child development from 0 to 6 years.
223917892|NCT06816225|OTHER|Questionnaire Children Sleep habits|Questionnaire for assessing sleep habits, validated for the Portuguese population (4) which allows us to understand the sleep hygiene habits of the child
223917893|NCT06816225|OTHER|Melatonin evaluation|Melatonin will be measured in the first-morning urine and it is considered to be a good marker of plasma MLT level since its concentration is highly correlated with nocturnal plasma melatonin.
223917894|NCT06816810|DRUG|Hydroxychloroquine (HCQ)|The intervention involves hydroxychloroquine (HCQ), administered orally in 200 mg tablets, with a dosing schedule of 200 mg twice daily (400 mg per day). The treatment duration is 48 weeks, after which participants will enter a 4-week safety follow-up period. HCQ will be taken alongside stable doses of Parkinson's disease (PD) medications, with no anticipated changes during the study. Monitoring for adverse events, laboratory assessments, and efficacy evaluations will occur regularly throughout the 12-month period. The study does not include a placebo group or other treatment arms.
223917895|NCT06820762|DRUG|irinotecan liposome(II) plus Ivonescimab via intravenously (IV) Q3W for 4-6 cycles, followed by Ivonescimab until disease progression or intolerable toxicity|"Drug: ivonescimab 20mg/kg, IV, D1, Q3W~Other Names:~AK112 Drug: irinotecan liposome(II) 70mg/m\^2, IV, D1, Q3W"
223917896|NCT06815991|DRUG|MIB-725|MIB-725 is a modified precursor of the NAD+ biosynthetic pathway.
223719546|NCT01023932|DEVICE|Cochlear Implants|
223917897|NCT06606327|DRUG|Diazoxide, 3 mg/kg per dose|Insulin anti-secretagogue taken for 8 doses over 4 days
223917898|NCT06608030|DRUG|Esketamine|A single dose of 0.3mg / kg esketamine during induction of anesthesia.
223917899|NCT06608030|DRUG|normal saline|Receiving the same volume of normal saline during induction of anesthesia.
223917900|NCT06608186|DRUG|Cetrorelix drug|a drug injection daily sc. from day 5 of stimulation till hCG trigger day
223917901|NCT06608186|DRUG|Drospirenone drug|A drug drospirenone in the form of 1 tablet / d from day 5 of stimulation till hCG trigger day
223917902|NCT06608641|DRUG|Endoxifen enteric-coated tablet (8 mg)|Patients will continue treatment with their initial randomized medication for 3 weeks
223917903|NCT06608641|DRUG|Placebo Tablets|Patients will be treated with Endoxifen Placebo Tablets for 21 days
223917904|NCT04803604|BEHAVIORAL|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, lay coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training as well as monthly follow-up.
223917905|NCT06606886|DRUG|Tablet Metformin (Group A)|Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year
223917906|NCT06606886|DRUG|Tablet Hydroxyurea (Group B)|Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
223917907|NCT06607939|DRUG|ORB-021|ORB-021 is dosed via IV infusion
223917908|NCT05016856|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System|A personalized and adaptive text message reminder system.
223917909|NCT05016856|BEHAVIORAL|Standard Reminder System (Active Control)|A typical text message reminder system.
223917910|NCT04866641|DRUG|T-1201 Injection 100 mg Kit|T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
223917911|NCT05883345|DIAGNOSTIC_TEST|Serum blood test for Helicobacter pylori immunoglobulin G, pepsinogen, and gastrin-17 levels|Endoscopic biopsy
223917912|NCT04902872|DRUG|CBX-12|CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
223917913|NCT01582867|DEVICE|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B\_HC01"
223917914|NCT05614206|BEHAVIORAL|Behavioral intervention based on Applied Behavior Analysis principles|"Intervention sessions are conducted by licensed therapists with a training in applied behavior analysis or behavior analysts. One-to-one interventions for 3 h/week are carried out over a period of 5 months.~The intervention focused on two target symptoms, imitation and joint attention, as two of the pivotal skills in early development. Behavior analytic techniques are used, including discrete trial, shaping for positive reinforcement, systematic prompting and fading procedures, and reinforcement procedures, according to the published manual.~Imitation sessions start with imitation recognition and imitation of familiar actions (gestural and object imitation) and end with the imitation of novel actions. Joint attention evolvs from initiating requests (starting with gaze shift with the child looking away from an interesting object to the adult and back) to coordination of gaze shift, vocalization and gestures through reaching, and pointing and showing behaviors."
223917915|NCT06346171|BEHAVIORAL|Virtual Reality Integrative Psychotherapy|"Music therapy: Weightless by Marconi Union plays continuously, bridging VR distraction and psychotherapy.~Before: Patients pick a VR scene (-13 to -10 min), learn VR navigation, and practice 4-7-8 breathing with a VR flower for grounding and resilience (-10 to -9 min). They continue 4-7-8 doing Progressive Muscle Relaxation (4+7 contraction, 8 relaxation), moving from lower body to facial muscles (-8 to -5 min). Values and commitment to action are discussed (-4 to -2 min), emphasizing present-focused thoughts and acceptance (-1 min).~During: Mindfulness and relaxation are encouraged, with PMR during intense moments. Empowerment and procedural feedback are provided (0 to 30/45 min).~After: Debriefing normalizes the experience, reinforcing proactive health actions (35 to 50 min)."
223917916|NCT06346171|DEVICE|Virtual Reality Distraction|"Software: Nature Treks VR nature environments. Hardware: dedicated head-mounted VR display (Oculus Rift S.) powered by a high-end computer (Laptop with at least GTX 1080 graphics card, both with processing units that lower the bottleneck chances); minimum specifications should facilitate presence while limiting cybersickness by ensuring refresh rates beyound 85 frames/second.~Music therapy: Weightless by Marconi Union plays continuously, facilitating sensorial distraction while also allowing blinding.~Although the psychotherapist will interact with the patient, the dialogue will exclude psychotherapic approaches. The dialogue is designed to be neutral, resembling a comprehensive tutorial for the VR experience. This serves as a comparator to assess the added value of integrating psychotherapeutic techniques within the VR experience."
223917917|NCT02050906|BEHAVIORAL|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
223917918|NCT02050906|BEHAVIORAL|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
223917919|NCT02050906|OTHER|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
223917920|NCT02050906|BEHAVIORAL|telephone based counseling|Undergo behavioral activity and nutritional counseling
223917921|NCT02050906|PROCEDURE|quality-of-life assessment|Ancillary studies
223917922|NCT02050906|OTHER|questionnaire administration|Ancillary studies
223917923|NCT06589687|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of Cesarean delivery under neuraxial anesthetic.
223917924|NCT04807751|DRUG|Delgocitinib cream|Cream for topical application
223917925|NCT04807751|DRUG|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
223917926|NCT06592053|PROCEDURE|Breast Cancer Surgery Pain|Factors affecting the occurrence of chronic pain in patients undergoing elective mastectomy surgery will be investigated.
223917927|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Escalation)|Dose escalation for ACM-CpG monotherapy administered via intramuscular injection will similarly be conducted using traditional 3+3 dose escalation. Three dose levels have been planned. If the patient experiences a DLT or two Grade ≥ 2 drug-related toxicity, the dose level will be expanded according to a 3+3 design. The safety and tolerability of each dose level will be assessed by the study team after all patients enrolled in the dose level have been followed for at least 21 days after the first dose of the ACM-CpG (DLT observation period). Once the MTD is reached, the RP2D will be determined.
223530276|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|"The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3 hours. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).~Other Names:~ALA-PDT, Ameluz®-PDT"
223917928|NCT06587295|DRUG|Intramuscular ACM-CpG Monotherapy (Expansion)|Patients will be administered ACM-CpG monotherapy at a dose determined in the dose escalation phase.
223917929|NCT06030076|DRUG|Tildrakizumab|As provided in real-world clinical practice.
223917930|NCT06588803|OTHER|No intervention, only for observational studies|No intervention, only for observational studies
223917931|NCT06593210|BIOLOGICAL|Adjuvant, non-live RSV vaccine|One dose of arexvy vaccine to transplant recipients.
223917932|NCT06470022|DEVICE|Medtronic Evolut FX|TAVI performed with Medtronic Evolut FX
223917933|NCT06470022|DEVICE|Edwards Sapien 3 Ultra Resilia|TAVI performed with Edwards Sapien 3 Ultra Resilia
223917934|NCT06824571|DIETARY_SUPPLEMENT|High-Dose Taurine Supplementation (6g)|Participants will receive taurine supplementation at a high dose of 6g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of high-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
223917935|NCT06824571|DIETARY_SUPPLEMENT|Medium-Dose Taurine Supplementation (4g)|Participants will receive taurine supplementation at a medium dose of 4g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of medium-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
223917936|NCT06824571|DIETARY_SUPPLEMENT|Low-Dose Taurine Supplementation (1g)|Participants will receive taurine supplementation at a low dose of 1g. The taurine will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention is designed to evaluate the effects of low-dose taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
223917937|NCT06824571|DIETARY_SUPPLEMENT|Placebo (0g Taurine)|Participants will receive a placebo, consisting of an inactive substance (0g taurine). The placebo will be provided in powder form, dissolved in water, and administered 30 minutes prior to exercise. This intervention serves as a control arm to evaluate the effects of taurine supplementation on exercise performance, fatigue resistance, and recovery under high-temperature and high-humidity conditions.
223917938|NCT06601673|BEHAVIORAL|Cognitive training|The intervention consists of computer-based cognitive training in the areas of attention, processing speed, memory, emotional intelligence, reasoning and orientation. The training takes place under supervision for 120 minutes a day from the first to the fifth postoperative day.
223917939|NCT06601673|BEHAVIORAL|Listen to audio book|Here, an audio book is listened to for 2h daily for the first five postoperative days (or until discharge from hospital if earlier). The audio book is brought and set up by study staff.
223917940|NCT05869487|RADIATION|Dual-energy X-ray absorptiometry|Whole body x-ray absorptiometry
223917941|NCT06820983|OTHER|adult questionnary for parents of children aged 8 to 13|Quality of life questionnaire for parents of children aged 8 to 13
223917942|NCT06820983|OTHER|Quality of life questionnaire for children aged 8 to 13|Quality of life questionnaire for children aged 8 to 13
223917943|NCT06820983|OTHER|Quality of life questionnaire for adolescents aged 14 to 17|Quality of life questionnaire for adolescents aged 14 to 17
224089499|NCT06915935|RADIATION|dualenergy X-ray absorptiometry|Dual-energy X-ray Absorptiometry (DXA) is an accurate, safe, and rapid bone mineral density measurement method that is widely used in the diagnosis of osteoporosis and the assessment of fracture risk. The principle is based on the difference in absorption of different energy X-rays in bone and soft tissue, and bone mineral content (BMC) and bone mineral density (BMD) are obtained through mathematical calculations. DXA is commonly used to measure bone mineral density in the lumbar spine, femoral neck, and forearm, and to assess the degree of osteoporosis using a T score, where T ≤ -2.5 is defined as osteoporosis. Due to the advantages of high precision, low radiation dose and convenient operation, DXA is considered as the gold standard for clinical bone mineral density detection.
223917944|NCT06820983|OTHER|Quality of life questionnaire for adults|Quality of life questionnaire for adults
223917945|NCT06820983|OTHER|A satisfaction adherence questionnaire|A satisfaction adherence questionnaire will also be distributed to patients after several months' use of oscillating PEP
224089500|NCT06917040|DEVICE|Spatial repellant emanator|Spatial emanator with an active ingredient Transfluthrin (C15H12Cl2F4O2, 110mg, EPA registered number 432-1588).
224089501|NCT06916793|DRUG|CKD-843 dose#1|IM injection every 3 months for 12 months
224089502|NCT06916793|DRUG|CKD-843 dose#2|IM injection every 3 months for 12 months
223719547|NCT00003499|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223719548|NCT03859193|BEHAVIORAL|Nutritional Video|A 10 - 15 minute video
223719549|NCT06505668|DRUG|Atenolol 25 mg|Patients will be receiving Atenolol 25mg OD for 2 months.
223917946|NCT06274853|DRUG|GS-441524|Oral GS-441524 capsules
223917947|NCT06274853|DRUG|Placebo|Placebo capsules
223917948|NCT06816589|BEHAVIORAL|ChatGPT-based job coaching|Using ChatGPT for creating job resumes, discussing job types, preparing and practicing for job interviews, writing job descriptions for individuals with Asperger's syndrome, and discussing workplace social interactions
223917949|NCT06820567|DRUG|Dapagliflozin (DAPA)|patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients
223917950|NCT06820567|DRUG|Placebo|type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks
224278523|NCT02861027|PROCEDURE|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
223917951|NCT06603766|DRUG|IV Magnesium Sulfate|MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.
224089503|NCT06916793|DRUG|Placebo of CKD-843 dose|IM injection every 3 months for 12 months
224089504|NCT06916793|DRUG|Dutasteride Capsules|oral, once daily, 12 months
224089505|NCT06916793|DRUG|Placebo of Dutasteride Capsule|oral, once daily, 12 months
224089506|NCT06917443|OTHER|Abdominally targeted exercises|The interventional exercise regimen will include specific abdominally targeted exercises postulated to increase blood flow to the intestine and decrease inflammation.
224278524|NCT02861027|PROCEDURE|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
223719550|NCT06505668|DRUG|Ivabradine 10mg|Patients will be receiving Ivabradine 5mg BD for 2 months.
223917952|NCT06603766|DRUG|Inhalational magnesium sulfate|It gives us the same mechanism of action as IV MgSO4 with less side effects.
223917953|NCT06598657|OTHER|Mobilization with Movement MWM|Mobilization with Movement MWM of Talocrural joint in non-weight bearing position to improve Dorsiflexion Range of Motion (3 sets of 6 repetitions were applied, with a 1-minute break between sets/3 times a week) and conventional therapy which includes stretching, strengthening, balance training exercise.
224089507|NCT06917443|OTHER|General exercises|Generally recommended exercises, without particular attention to the abdomen
224089508|NCT06498986|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224089509|NCT06498986|DRUG|Osimertinib Mesylate Tablets|Oral administration, 80mg daily for a cycle of 3 weeks.
224089510|NCT06935708|DRUG|Intrathecal Morphine|In Spinal group, 25 G or 27 G pencil point needle, depending on the preference of the anesthesiologist, will be inserted at L2-L3 or L3-L4 intervertebral space and 300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.
224099286|NCT04460703|OTHER|Economic benefit message|1/15 of the sample will be assigned to this group, which is a message about how COVID-19 is wreaking havoc on the economy and the only way to strengthen the economy is to work together to get enough people vaccinated.
224099287|NCT04460703|OTHER|Guilt message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and society must work together to get enough people vaccinated. Then it asks the participant to imagine the guilt they will feel if they don't get vaccinated and spread the disease.
224099288|NCT04460703|OTHER|Embarrassment message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the embarrassment they will feel if they don't get vaccinated and spread the disease.
224099289|NCT04460703|OTHER|Anger message|1/15 of the sample will be assigned to this message. The message is about the danger that COVID-19 presents to the health of one's family and community. The best way to protect them is by getting vaccinated and by working together to make sure that enough people get vaccinated. Then it asks the participant to imagine the anger they will feel if they don't get vaccinated and spread the disease.
224099290|NCT04460703|OTHER|Trust in science message|1/15 of the sample will be assigned to this message about how getting vaccinated against COVID-19 is the most effective way of protecting one's community. Vaccination is backed by science. If one doesn't get vaccinated that means that one doesn't understand how infections are spread or who ignores science.
224099291|NCT04460703|OTHER|Not bravery message|1/15 of the sample will be assigned to this message which describes how firefighters, doctors, and front line medical workers are brave. Those who choose not to get vaccinated against COVID-19 are not brave.
224099292|NCT04681326|DEVICE|biological prosthesis|retro-muscular positioning of a swine dermal collagen prosthesis
224099293|NCT03425903|DEVICE|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
224099294|NCT05732129|DRUG|Fluzoparib|150mg,orally, bid (days 1-7) every 2 weeks
224099295|NCT05732129|DRUG|Irinotecan|30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
224099296|NCT00932997|BEHAVIORAL|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
224099297|NCT00932997|OTHER|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
224099298|NCT00932997|OTHER|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
224099299|NCT00932997|OTHER|questionnaire administration|Baseline and 9 months after enrollment and intervention
224099300|NCT00932997|PROCEDURE|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
224278525|NCT01454440|DRUG|Eptifibatide|Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure) vs placebo.
224278526|NCT00996437|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
223716740|NCT02322034|OTHER|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
223917954|NCT06598657|OTHER|Conventional Treatment|"* Stretches of Hamstrings, Gastrocnemius, Soleus and hip adductors with duration of 20 sec hold/ 5 reps and Frequency: 3 times/week. Stretches will be performed passively~* Strengthening exercises of Quadriceps and abdominal muscles three times a week.~* Static balance exercises including single leg balance, tandem stance, weight shifting with Duration: 10 sec hold/ 5 reps Frequency: 3 times/week"
223917955|NCT05271097|OTHER|MyLink2Care app full functionality|Participants will be shown how to download the app and use the assessment tool.
223917956|NCT05271097|OTHER|MyLink2Care app major intervention features inactivated|Participants will be shown how to download the app and use the assessment tool.
223917957|NCT06586541|OTHER|Participation in attending team rounds|Family members can participate both in-person and virtually, which can vary daily if desired. If the family member wishes to participate in-person, they will be invited to be present when the team rounds in the ICU. If the family member wishes to participate virtually, they will be provided with a personalized link by email to attend rounds.
223917958|NCT06602375|OTHER|Standard care|The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.
223940525|NCT04502472|BIOLOGICAL|Convalescent plasma transfusion|Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.
223940526|NCT02378779|OTHER|Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)|The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
223940527|NCT02378779|OTHER|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
224278527|NCT00996437|DRUG|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
224278528|NCT04443569|DRUG|Lidocaine patch|Lidocaine patch to be placed in post-operative recovery area and used in addition to routine post-cesarean delivery pain management
224278529|NCT04443569|OTHER|Placebo patch|A placebo patch will be placed superior to the Pfannenstiel incision in the same manner as the lidocaine patch treatment group.
224278530|NCT02882269|DRUG|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
223940528|NCT02378779|OTHER|Humour|Use the humour to approach the subject of premature ejaculation
223940529|NCT02378779|OTHER|Take the drama out|Take the drama out to approach the subject of premature ejaculation
223940530|NCT02378779|OTHER|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
223940531|NCT02378779|OTHER|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
223940532|NCT02378779|OTHER|Help to verbalize|Help for the patient to speak about premature ejaculation
223940533|NCT04444804|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Dosage at the discretion of the treating physician
223940534|NCT04444804|DRUG|LMWH and Phenprocoumon|Dosage at the discretion of the treating physician
223940535|NCT03829436|DRUG|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
223940536|NCT03829436|DRUG|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
223940537|NCT03829436|DRUG|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
223940538|NCT03829436|DRUG|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
223940539|NCT05111951|BEHAVIORAL|Mobile health-delivered physical exercise and support for physical activity|Mobile health-delivered physical exercise sessions, prescription of an individual exercise-regime and support for physical activity through behavior change techniques.
223940540|NCT05111951|BEHAVIORAL|Mobile health-delivered behavior change techniques.|Mobile health-delivered behavior change techniques following the core elements of the Swedish model for physical activity on prescription.
223940541|NCT05986305|BEHAVIORAL|Go Act|Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
223940542|NCT05986305|BEHAVIORAL|Peer|During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
223917959|NCT06602375|OTHER|Physical Therapy (PT)|Participants randomized to this group will receive individualized, tailored courses of physical therapy care. Interventions may be directed at the temporomandibular, cervical, and/or scapulothoracic regions based on subject clinical presentation and impairments. Manual therapy joint and soft tissue mobilizations may be used to address pain, mobility, and motor control. Motor control exercises may be used to promote relaxation, improve range of motion, and appropriate postures. Strengthening exercise, primarily directed to the cervical and scapulothoracic regions, may be implemented as appropriate. Stretching exercise may be used to address pain and mobility deficits. The interventions are intentionally pragmatic; study participants will receive treatment as they are comfortable and as recommended by the treating therapist.
223917960|NCT06824935|PROCEDURE|Anesthesia|The study planned to investigate the anesthesia requirements and frequency and the risk factors that play a role in the anesthesia of patients who had completed preoperative anesthesia evaluation and were going to undergo outpatient cataract surgery.
223917961|NCT06592183|BEHAVIORAL|Smart-phone based, self-driven speech rehabilitation|Participants will perform the speech exercises for 60 min per day. Participants may complete the speech exercises all at once or split them into several sessions. Thus, participants assigned to the intervention group will use the application for 30-60 min daily, 5 days per week, for 4 consecutive weeks.
223917962|NCT06824792|DRUG|Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE.|Quasar is a biologically-informed multi-agent system developed based on multi-omics and multi-modal data. By integrating multidimensional information such as patients' demographic, clinical, and omics data (including DNA genotyping, whole-exome sequencing, transcriptome sequencing, etc.), it prioritizes standard treatment plans and recommends the optimal personalized treatment plan. Including targeted drugs, chemotherapy, immunotherapy approved by China CDE.
223917963|NCT06824844|DRUG|artificial tear eyedrops|The intervention group and control group were treated with artificial tear eyedrops four times a day.
223917964|NCT06824844|DRUG|0.05% cyclosporine eyedrops|The intervention group was treated twice a day.
223917965|NCT06604637|OTHER|Non-invasive transcutaneous auricular vagus nerve stimulation (taVNS)|taVNS will be applied for a total of 12 sessions, 20 minutes each session, 3 days/week.
223917966|NCT06816862|DEVICE|SYMPHONY™ OCT System|Internal fixation system for surgical stabilisation of upper spine instabilities
223917967|NCT06819358|DEVICE|Transcranial Magnetic Stimulation|Patients in Group A will receive 2 weeks (10800 Hz daily, 5 days×2) of TMS treatment, while patients in Group B will receive sham stimulation with the same frequency. After a 4-week washout period, the two groups cross over. Patients in Group A will receive sham stimulation, and patients in Group B will receive TMS treatment for 2 weeks (10800 Hz daily, 5 days×2).
223917968|NCT05416385|OTHER|Carotid Contrast Enhanced Ultrasound|Carotid Contrast-Enhanced Ultrasound (CEUS), a diagnostic ultrasound enhancing agent that opacifies the blood to delineate the vessel walls.
223917969|NCT05757791|DRUG|Empagliflozin|The full duration of therapy will be six-weeks. The route of administration will be oral. The starting dose of the medication will be 10mg daily for the first 14 days of the study, with a dose escalation to 25mg for the last 28 days of the study.
223917970|NCT06609538|OTHER|Control Group|Receives standard preoperative instructions and propofol or ketamine infusion.
223917971|NCT06609538|OTHER|Suggestion Group|Receives positive preoperative suggestions and propofol or ketamine infusion.
223917972|NCT04556526|BIOLOGICAL|Ad26.ZEBOV|Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
223917973|NCT04556526|BIOLOGICAL|MVA-BN-Filo|Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
223917974|NCT06859229|DEVICE|Innovative technology pathway for gait neurorehabilitation|Participants will be assigned to either an advanced or traditional training pathway based on the protocol. The innovative tehcnology pathway for gait rehabilitation will incorporate devices such as exoskeletons, virtual reality systems, and body-weight suspension (BWS) devices to enhance gait rehabilitation. At the end of the training period, participants will undergo follow-up evaluation tests to assess outcomes.
223917975|NCT06859229|OTHER|Conventional gait rehabilitation strategy|The control group will undergo a traditional rehabilitation program that follows standard clinical protocols for gait recovery. This program will include conventional therapeutic exercises aimed at improving strength, balance, coordination, and functional mobility
223940543|NCT00121849|BIOLOGICAL|Leish-111f + MPL-SE vaccine|
223940544|NCT00177177|DRUG|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
223940545|NCT02338024|BEHAVIORAL|Modified Antiretroviral Treatment Access Study intervention|
223940546|NCT01203293|BEHAVIORAL|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
223940547|NCT01203293|BEHAVIORAL|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
223940548|NCT03102034|BIOLOGICAL|D46/NS2/N/ΔM2-2-HindIII|10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
223940549|NCT03102034|BIOLOGICAL|Placebo|Isotonic diluent; administered as nose drops
223940550|NCT00986375|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
223940551|NCT00986375|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
223940552|NCT00843934|DRUG|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
223940553|NCT00843934|DRUG|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
223917976|NCT06859580|DRUG|Zoledronic acid 4 mg|Product name/EU MP number: Zoledronic Acid Oresund Pharma 4 mg/100 ml infusionsvätska, lösning/PRD8924813 (Test) Substance (name/ code): ZOLEDRONIC ACID/SUB00176MIG Strength: Zoledronic Acid 0.04mg Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 52486 / SE Modified in relation to MA: No Max Dosage: mg milligram(s) Duration of use: Week
223917977|NCT06859580|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|"Product name/EU MP number: Natriumklorid Baxter ClearFlex 9 mg/ml,infusionsvæske, opløsning/PRD456031 (Placebo) Substance (name/ code): SODIUM CHLORIDE/SUB12581MIG Strength: Sodium Chloride 0.9g / 100mL Pharmaceutical form: SOLUTION FOR INFUSION Route of administration: INFUSIÓN INTRAVENOSA Marketing authorisation status (MA number, MS where authorised etc): 32466 / DK Modified in relation to MA: No Max Dosage: ml millilitre(s) Duration of use: Week"
223917978|NCT06859801|DEVICE|Percutaneous Ablation|Percutaneous ablation is a minimally invasive alternative therapy for metastatic bone disease and can be used for destruction of nerves mediating pain signals, tumor destruction, decompression, or inhibition of tumor growth.
223917979|NCT06859801|RADIATION|Radiation Therapy|Radiation therapy (RT) is a widely accepted treatment for painful bone metastases and provides palliation of pain for patients.
223917980|NCT06859086|PROCEDURE|class II restoration|A class II cavity will be prepared after local anesthesia has been given as requierd . Rubber dam isolation will be done. Sectional matricing and wedging will be done. Followed by placement of restorative material according to the randomization sequence.
223917981|NCT06858618|COMBINATION_PRODUCT|FCN-338 + Azacitidine|FCN-338 (400 or 600 mg, PO, QD, D1-28) combined with azacitidine (75mg/m², SC, QD, D1-7), 28 days/cycle
223917982|NCT06858618|COMBINATION_PRODUCT|FCN-338 + erythromycin+ Ara-C|"Induction phase: FCN-338(600 mg, QD, D1-14) , erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7) for 1 to 2 cycles.~Consolidation phase: FCN-338(600 mg, QD, D1-14) ,Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles Maintenance phase:FCN-338(600 mg, QD, D1-14) , azacitidine (50 mg/m², SC, QD, D1-5) for the first 12 cycles and FCN-338 (600 mg, QD, D1-14) alone for the rest 12 cycles"
223530277|NCT05080764|COMBINATION_PRODUCT|3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The treatment field (whole face excluding the periocular area) will be cleansed with gauze soaked with ethanol or isopropanol. Afterwards, approximately 1 tube of study medication will be applied as a thin layer. After drug application, subjects should stay inside for 3h. Post incubation, red light illumination with BF-RhodoLED® will be performed according to the lamps user manual until a total light energy of 37 J/cm2 was applied. To cover the whole face 2 illuminations will be required which can either be performed subsequentially or in parallel (with 2 lamps).
223530278|NCT02266303|OTHER|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
223530279|NCT00089492|DRUG|Optimized Background ARVs|As prescribed
223917983|NCT06826170|RADIATION|hypofractionated radiosurgery|The total dose will be 25 Gy, delivered in 5 fractions, in 5 consecutive days
223917984|NCT06859255|DIAGNOSTIC_TEST|MRI|The patients will be undergo to a MRI without contrast after 1 month from the procedure/surgery to test the hwmodynamic performance 4d flow in the implanted valve
223917985|NCT06857747|DRUG|Capecitabine|metronomic capecitabine, 500 mg, tid， po
223917986|NCT06857747|DRUG|Vinorelbine|metronomic vinorelbine, 40mg/d, TIW1, po
223917987|NCT06857747|DRUG|Etoposide|metronomic etoposide, 50mg/d, po
223917988|NCT06856512|OTHER|Remote ischaemic preconditioning|The dialysis protocol integrates a sequence of five ischaemia/reperfusion blocks applied to the upper limb. Each block consists of a 5-minute period of cuff inflation at a supra-systolic pressure individualized to each patient-20 mmHg above the limb occlusion pressure-followed by a 25-minute period of cuff deflation. This intervention begins 30 minutes after the start of dialysis and is referred to as hemodialysis remote ischaemic preconditioning (HD-rIPC).
223917989|NCT06856512|OTHER|Exercise|The exercise protocol consists of five sequential bouts of physical activity, initiated 30 minutes after the start of dialysis. Each bout comprises a 5-minute cycling exercise at moderate intensity, corresponding to a Borg Scale rating of 12-14, followed by a 25-minute passive recovery phase. This structured intervention is referred to as hemodialysis exercise (HD-EX).
223917990|NCT06856512|OTHER|standard dialysis|The hemodialysis control condition (HD-CONT) consists of standard hemodialysis treatment without the integration of any additional interventions, such as exercise or ischaemia/reperfusion protocols.
223917991|NCT06655480|DRUG|[ARNI + SGLTi + AMR]|Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet
223917992|NCT06655480|DRUG|[SGLTi + previously taken RAAS blocker]|Empagliflozin 10mg tablet, previously taken RAAS inhibitor
223917993|NCT06856395|OTHER|intervention group|Robotic distraction during vaccination process
223917994|NCT06858423|DRUG|Budesonide buffered with 0.9% isotonic saline.|120 patients received budesonide buffered with 0.9% isotonic saline.
223917995|NCT06858423|DRUG|Fluticasone propionate nasal spray.|120 patients received fluticasone propionate nasal spray.
223917996|NCT06858423|OTHER|0.9% saline for nasal irrigation.|120 patients used 0.9% saline for nasal irrigation.
223917997|NCT06857734|DRUG|Vitamin B Complex|group of vit. B will recieve as an oral capsules for 4 days preoperative , and infusion of vitamin B complex 1ml diluted in 100 ml normal saline administered intravenously after anathesia induction .
223530280|NCT00089492|DRUG|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
223530281|NCT00089492|DRUG|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
223530282|NCT06484582|OTHER|workers|This study will be conducted as a face-to-face survey. Surveys will be created with Google Forms and will be filled out by the physiotherapist according to the participant's response.
223917998|NCT06857734|DRUG|vitamin C|group of vitamin C will recieve 1000 mg as an oral capsule for 4 days and infusion at dose of 50 mg/kg diluted in 100 ml normal saline administered iv after induction of anathesia .
223917999|NCT06857734|DRUG|Placebo|patients will recieve placebo tablets with identical regimen preoperative and a placebo infusion of 100 ml normal saline after induction of anathesia ,prepared with identical appearance and taste by the pharmacist according to the randomization group.
223918000|NCT06859216|BEHAVIORAL|AI-Generated Plain Language Summaries|Participants receive standard ophthalmology notes plus an AI-generated summary that explains medical information in simpler language. Each summary is reviewed by an ophthalmologist for accuracy before being given to the participant. The goal is to help participants better understand their diagnosis, treatment plan, and follow-up instructions.
223918001|NCT06857916|OTHER|Traditional|Traditional rehabilitation course will occur.
223918002|NCT06857916|OTHER|cycle with biofeedback|Individuals will receive biofeedback about their power production and power symmetry while participating in a 32 minute recumbent cycling session in inpatient rehabilitation facility.
223918003|NCT05309785|DRUG|Invokana 300 mg and 100 mg tablet|"Substudy 1 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 12+2 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12+2 weeks (phase 2) and then stopped. If not tolerated, the dose will be reduced to 100 mg until the end of follow-up.~Each phase of 12 weeks is followed by a 2-week window to ascertain surrogate efficacy outcomes.~Substudy 2 Patients who fulfill the inclusion criteria and consent to participate will receive canagliflozin 100 mg po daily for 9 days."
223918004|NCT06859749|OTHER|Education|"Students will be given a question-answer application. In order to perform the Escape game for students, 4 stations were prepared in the skills laboratory: Pulse, Respiration-Oxygen Saturation, Blood Pressure, Body Temperature. Separate scenarios will be prepared for each station."
223918005|NCT06858449|DIETARY_SUPPLEMENT|Whey protein (20 grams)|20 grams of whey protein
223918006|NCT06858449|DIETARY_SUPPLEMENT|Whey protein (60 grams)|60 grams of whey protein.
223918007|NCT06663657|OTHER|Cognitive Sensorimotor Exercises|Patients in group A will receive cognitive sensorimotor exercises for 30 minutes, sessions for 5 days per week for 8 weeks.
223918008|NCT06663657|OTHER|Task Oriented Training group|Patients in group B will receive task oriented training for 30 minutes, sessions for 5 days per week for 8 weeks.
223918009|NCT06659445|DRUG|ONL1204 Opthalmic solution|Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
223918010|NCT06659445|DRUG|Avacincaptad Pegol intravitreal solution|Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection
223918011|NCT06659445|OTHER|Sham|Sham injection
223918012|NCT06664528|DIAGNOSTIC_TEST|ECHOCARDIOGRAPHY|A complete echocardiographic exam will be performed during each cardio-oncologic evaluation.
223918013|NCT06664528|DIAGNOSTIC_TEST|ELECTROCARDIOGRAPHY (ECG)|An ECG tracing will be obtained during each cardio-oncologic evaluation.
223918014|NCT06664528|DIAGNOSTIC_TEST|LABORATORY TESTS|The cardiac biomarkers high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be dosed according to the current recommendations of Cardio-Oncology Guidelines.
223918015|NCT06669182|DEVICE|Intermittent Theta-Burst Transcranial Magnetic Stimulation|50Hz, stimulation intensity of 100% RMT, duration of 40s as a group of stimulation, 600 stimulation pulses, repeated stimulation of bilateral cerebellar dentate nuclei, with a 5-minute interval between each group, 1200 stimulation pulses per site, 5 times a week, treatment for 4 weeks, then treat once a week for 8 weeks.
223918016|NCT06669104|DEVICE|Medtronic Hugo™ surgical robotic system|undergoing robotic thoracic surgery by the Medtronic Hugo™ surgical robotic system
223918017|NCT06228781|PROCEDURE|Autologous haemopoietic stem cell transplantation|"Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).~Stem cell mobilization with cyclophosphamide 2g/m2 and filgrastim 10 ug/kg/d x 5 day.~Stem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg/kg ; fludarabine 30mg/m2 or cladribine 10mg ；cytarabine 1-2g/m2 or idarubicin 8mg/m2；cyclophosphamide 40mg/kg followed by CD34 selected autologous hematopoietic stem cell transplant."
223918018|NCT05834673|OTHER|SMS messages|Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)
223918019|NCT05834673|OTHER|Telephone-based support calls|Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.
223918020|NCT05834673|OTHER|GP Education|Education of GPs on the European Society of Cardiology (ESC) guidelines and Guideline Directed Management Therapy
223918021|NCT06984367|OTHER|socio-technical intervention|A daily cognitive stimulation at home with specific software (Brainer) and 1 group session per week. Furthermore, each participant will receive the NAO robot at home.
223918022|NCT06984367|OTHER|Usual care|The subjects will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises, as they would do outside the framework of the experiment. In any case, they will be free to read and do the proposed exercises.
223918023|NCT02506673|DEVICE|Zeiss, Cinema ProMED (audiovisual equipment)|
223918024|NCT02506673|DRUG|Midazolam|
223918025|NCT02506673|DEVICE|Skin Conductance Monitor|
223918026|NCT06613009|DRUG|IBI3009|Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3009)
223918027|NCT04344158|DRUG|AK105 Injection|AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.
223918028|NCT04344158|DRUG|Anlotinib Hydrochloride Capsules|Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
223918029|NCT04344158|DRUG|Sorafenib Tosylate Tablets|Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.
223918030|NCT03033641|DEVICE|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
223940554|NCT00785200|OTHER|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
223940555|NCT00785200|OTHER|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
223716741|NCT01121237|DRUG|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
223918031|NCT05943821|DRUG|Allopurinol 200 mg|The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
223918032|NCT05943821|DRUG|Optional intervention|"Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels \>5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up."
223918033|NCT05868577|DRUG|Corticosteroid injection (CSI) with local anesthetic (LA)|The PI will then administer the injection using an infracalcaneal needle peppering
223918034|NCT05868577|DRUG|Local anesthetic (LA) with Saline injection|The PI will then administer the injection using an infracalcaneal needle peppering
223918035|NCT05692011|DEVICE|blood purification(PS)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with PS membrane, 24 hours per day, for 3 consecutive days
223918036|NCT05692011|DEVICE|blood purification(AN69ST)|After the sepsis patients were enrolled, they were treated with blood purification in CVVH mode with AN69ST membrane, 24 hours per day, for 3 consecutive days
223918037|NCT04967599|BEHAVIORAL|Phenotype Feedback Intervention|Online session providing information on health-related risk associated with alcohol consumption and alcohol metabolism gene variations plus personalized feedback on flushing phenotype and associated risks.
223918038|NCT04967599|BEHAVIORAL|Genotype Feedback Intervention|Online session providing personalized feedback on alcohol metabolism genotypes and associated health-related risks.
223918039|NCT05666947|OTHER|Home-based exercise|Eight weeks of home-based exercise programs
223918040|NCT04369911|PROCEDURE|Acupuncture|Acupuncture treatments will be separated by a minimum of two days and a maximum of 14 days. Treatment sessions will be identical for both groups. Standard, sterile stainless-steel, disposable needles will be inserted at acupuncture points with a total of 18 needles for each treatment session. The depth of the needle will be approximately 10-20 millimeters. Needles will be left in place for 30 minutes.
223918041|NCT05567978|PROCEDURE|pupillometry index|Admission to the intensive care unit, measurement of pupillometry index every 4 hours for 7 days or at extubation of brain damaged patients
223918042|NCT00194298|PROCEDURE|FDG-PET Imaging|
223918043|NCT03782818|DRUG|Olaparib|Olaparib up to 300 mg BID for 24 weeks
223918044|NCT06814951|PROCEDURE|TAR Method|Patients selected for the intervention group will undergo thoracoabdominal rebalancing management such as abdominal supports and/or in the ileocostal space, inspiratory assistance, release of the shoulder girdle, thoracic balance, release of the pectoralis major and deltoid muscles together with aspiration if necessary.
223918045|NCT06814951|PROCEDURE|Conventional physiotherapy|Patients selected for the control group (conventional physiotherapy) will be exposed to respiratory physiotherapy techniques such as vibrocompression, manual passive expiratory therapy, acceleration of expiratory flow, fractional inspiration in times, diaphragmatic breaths and aspiration when necessary.
223918046|NCT05636085|DEVICE|Mainz Biomed Colorectal Cancer Screening Test|There is no intervention.
223918047|NCT05198648|OTHER|Trigeminal cardiac reflex|Trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
223918048|NCT05198648|OTHER|Non-trigeminal cardiac reflex|No trigeminal cardiac reflex occurred during the cerebellopontine angle tumor surgery.
223940556|NCT03019835|DRUG|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
223940557|NCT03019835|OTHER|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
223940558|NCT00347204|DRUG|ketorolac (Acular LS)|
223940559|NCT00347204|DRUG|Nepafenac (Nevanac)|
223940560|NCT05606484|OTHER|Exercise with non-immersive virtual reality|Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
223716742|NCT05155059|DEVICE|MagStim|Bursts of three at 50Hz with an inter burst interval of 200 ms will be given for 190 seconds and this session will be repeated 3 times with 20 minutes between each session in one day. The set of 3 sessions will be repeated 5 times in 5 consecutive days.
223716743|NCT05155059|OTHER|Sham Comparator|Sham TMS stimulation using a sham coil
223719551|NCT05199012|DIETARY_SUPPLEMENT|Black pepper extract|Subjects will be randomized to receive either the placebo or active (black pepper extract) in a 1:1
223719552|NCT00002098|DRUG|Lentinan|
223940561|NCT05606484|OTHER|Exercise with a static pedal|Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
223940562|NCT01022125|DRUG|TMC435|
223940563|NCT02587169|DRUG|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
223918049|NCT06827548|DEVICE|vagal nerve stimulation|"Cervical neck electrodes used in this part of the study will include the multi electrode array (MEA). The MEA can be placed on either side of the neck over the area of the vagus nerve to record any electrical activity that might occur during the baseline period.~Two ECG electrodes are placed either one on each arm or on the chest for measurement of the electrocardiogram (ECG).~Three ECG electrodes are placed on the abdomen in a line parallel to the longitudinal axis of the stomach to record the electrogastrogram (EGG).~A onetime baseline recording will be made for 20 minutes after which the subject will be discharged from the study."
223918050|NCT06786962|DEVICE|Virtual reality Hypnosis|"The experimental group of 22 participants consists of a hypnosis intervention using a virtual reality device (HypnoVR®).~Participants are seated in a quiet area of the unit:~They choose a visual scenario from among 3 proposals, guaranteeing the conditions of a restorative environment. During each session, the same script (support mode) is spoken and the same music (serenity program with soothing tones) is associated with the script. Each participant is fitted with a virtual reality mask and a headset with active noise reduction."
223918051|NCT06786962|OTHER|Control arm (SEQ):|"Restoration time~Participants are seated in a quiet area of the unit. The control group of 21 participants consists of a break with the following instructions and suggestions:~Take advantage of this break, this time just for you, to recharge your batteries. Sit in this armchair and I suggest you think of something pleasant and comfortable."
223918052|NCT06729762|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation, microwave ablation, laser ablation
223918053|NCT06003582|OTHER|Infant Parent Support|Therapeutic Intervention
223918054|NCT02934282|DRUG|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
223918055|NCT01286766|DRUG|DCS (docetaxel with cisplatin with TS-1)|"1. S-1: 70 mg/m2 #2 bid PO, D1-14~2. Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~3. Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
223918056|NCT01286766|DRUG|DCF (docetaxel with cisplatin with 5-FU)|"1. 5-FU: 1,000 mg/m2 CI, D1-3~2. Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~3. Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~   * Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~  * treatment is repeated until 4 cycles"
223918057|NCT05451693|BEHAVIORAL|Outreach-ER|The intervention is similar to other care intervention/support programs such as REACH or New York University Caregiver Intervention (NYCUI). The Intervention is designed to be delivered over phone/virtual and in-home and will be conducted by Amplio, LLC consultants.
223918058|NCT06608914|DRUG|Nandrolone decanoate|Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
223918059|NCT06608914|DRUG|Saline|Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
223918060|NCT02044484|BEHAVIORAL|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
223918061|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia with AI chatbot|digital cognitive behavioral therapy for insomnia with two-way interactive, intelligent, and patient-centered conversational agents
223918062|NCT06593262|BEHAVIORAL|app-based digital cognitive behavioral therapy for insomnia without AI chatbot|digital cognitive behavioral therapy for insomnia without two-way interactive, intelligent, and patient-centered conversational agents
223918063|NCT06862726|DRUG|Anti Xa dosage|VKA: quadriseparable tablet Apixaban: 5 mg twice daily or 2.5 twice daily Rivaroxaban: 20 mg once a day or 15 mg once a day
223918064|NCT06862726|DRUG|Dosage of PT-INR|This arm contain 40 pateints treated by VKA,. PT-INR dosage will be performed.
223918065|NCT06593457|DRUG|IP|NX-5948 oral
223918066|NCT06593457|DRUG|Matching Placebo|Fluconazole
223918067|NCT06862427|BEHAVIORAL|Healthy Lifestyle Application (Traditional Chinese Version)|A firefighter-oriented Healthy Lifestyle Application (Traditional Chinese Version)
223918068|NCT06861465|BEHAVIORAL|Online Mind-Body Wellness Program|Online program (mindful movement, meditation, breathwork)
223918069|NCT06861465|BEHAVIORAL|Online Mind-Body Wellness Program + Nutritional Counselling|Online program (mindful movement, meditation, breathwork) + nutrition counselling
223918070|NCT06588907|DRUG|Bupivacaine Hydrochloride|After preparing the infraclavicular block site, a 22-gauge needle, guided by ultrasound, will be placed in the 6-7 o'clock position in the same plane as the ultrasound probe. Subsequently, lateral, medial, and posterior cords described as hypoechoic nerve fascicles within hyperechoic structures will be identified. Initially, 2 mL of saline will be administered to confirm proper spread. Once confirmed, 20 mL of 0.25% bupivacaine (prepared by diluting 10 mL of 0.5% bupivacaine with 10 mL of normal saline) will be injected in fractional doses with intermittent negative aspiration. Fifteen minutes after this procedure, anesthesia depth will be assessed using a cold-hot test, followed by reduction and application of the cast.
223719553|NCT00002098|DRUG|Didanosine|
223719554|NCT02042183|DRUG|Lubiprostone|12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1
223940564|NCT01259557|DRUG|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
223719555|NCT02042183|DRUG|Placebo|0 mcg soft capsules of placebo for oral administration
223719556|NCT01727297|DEVICE|REVEAL Implantable Cardiac Monitor|
223918071|NCT06588907|DRUG|Ketamine|Until the recovery period, patients will be closely monitored by an experienced doctor or nurse during sedation. Emergency equipment will be readily available in case of any complications. The following protocol will be used for procedural sedation-analgesia (PSA): Ketamine will be administered intravenously at a dose of 0.5-1 mg/kg. Patients with Numeric Rating Scale (NRS) scores above 5 may receive additional doses of 0.25-1 mg/kg, repeated every 5 to 10 minutes as needed.
223918072|NCT06860672|GENETIC|Dual vector DNA base editor|The base editor is delivered using a dual vector adeno-associated virus (AAV) system and introduced into the child via intrathecal injection to correct the mutated CHD3 gene. The vital signs of the child will be closely monitored during treatment to assess possible acute adverse effects. The child will be followed up regularly after treatment to monitor the success of gene editing and the neurodevelopmental improvement of the child. Possible long-term adverse events will be closely monitored to assess the safety of the treatment.
223918073|NCT06861842|DRUG|Theralite®|Reference
223918074|NCT06861842|DRUG|Actilitio®|Test
223918075|NCT06862349|DRUG|Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
223918076|NCT06862349|DRUG|Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist.|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
223918077|NCT06862414|DEVICE|Smartphone-based deep learning system|The smartphone-based deep learning system was trained using a dataset of over 50,000 white-light macroscopic images collected between 2006 and 2013 to develop the YOLOv7 model. Lesions were categorized into three referral grades: benign (green), potentially malignant (yellow), and malignant (red).
223918078|NCT06860698|OTHER|E-cig use|Based on e-cigarette usage, participants will be divided into those who used e-cigarettes and those who did not use e-cigarettes
223918079|NCT06860854|PROCEDURE|Epidural Analgesia|"The eligible patients will have their vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery measured directly before the administration of ELA. They will be also asked to rate their level of pain on the visual analogue scale (VAS).~The specific method and drug regimen for ELA will be determined by the attending anesthesiologist. The mode of administration (continuous infusion, intermittent bolus, or patient-controlled epidural analgesia) will be recorded along with the anesthetic agents used for future subgroup analysis.~The vital signs, the Doppler velocities and VAS score will be recorded after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor."
223918080|NCT06856694|OTHER|NLP+AI Report|A NLP model will extract key content from consultations and AI (Chat GPT) will summarize that information. Reports including the top sentences by NLP probability for key content areas will be generated and will be provided to patients and providers within approximately 72 hours after each case. In both arms, a follow up phone call will allow for clarification any concepts that was inadequately communicated during the consultation. This call will be audio recorded and qualitatively assessed to determine whether deficiencies in risk communication observed in the consultation were rectified.
224099301|NCT00932997|PROCEDURE|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
224099302|NCT03903757|OTHER|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
224099303|NCT00813748|DRUG|Xolair|
224099304|NCT03678974|BEHAVIORAL|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
224099305|NCT00283387|DRUG|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
224099306|NCT00283387|DRUG|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
224099307|NCT01495871|DIETARY_SUPPLEMENT|Amino Acids|15 grams amino acids two times per day for 6 weeks
224099308|NCT01495871|DIETARY_SUPPLEMENT|Placebo of inert compounds|Placebo two times per day for 6 weeks
224099309|NCT01495871|DIETARY_SUPPLEMENT|Valine|2.5 grams valine supplementation two times a day for 6 weeks
224099310|NCT06329388|DIETARY_SUPPLEMENT|TruHeight Growth Protein Shake|Participants will be administered two scoops of TruHeight Growth Protein Shake, mixed with 12-16 fluid ounces of water, once daily, five times per week for six months. The supplement is intended to support growth patterns in children by providing essential nutrients that contribute to bone development and overall growth.
223719557|NCT02084654|DRUG|Exenatide 5 and 10 mcg 2 times a day|
223719558|NCT02084654|DRUG|placebo|
223719559|NCT02864498|DRUG|DS107|
224278531|NCT02882269|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
224278532|NCT00392457|DRUG|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
224278533|NCT00392457|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
223918081|NCT06668025|OTHER|MxA tests|Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.
223918082|NCT06668025|OTHER|MxA feedback|MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.
223918083|NCT06668025|OTHER|Follow-up at Day 30|A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.
223918084|NCT06860334|DRUG|Favipiravir|6-fluoro-3-hydroxypyrazine-2-carboxamide, T-705
224278534|NCT05041114|DEVICE|Motor Neuroprosthesis|Type of implantable brain computer interface
224278535|NCT05178914|PROCEDURE|Treatment adaptation|Patients will benefit from intensified treatment or de escalation treatment according to the result of the index of microcirculatory resistance
224278536|NCT04122781|DEVICE|Novel K-wire fixation devices|The patients received surgery using novel K-wire fixation devices
224278537|NCT01876238|OTHER|T-PAT|
223918085|NCT06860334|DRUG|Ribavin|1-3,4-dihydroxy-5-1,2,4-triazole-3-carboxamide
223918086|NCT06860334|OTHER|Optimised Standard of Care|Optimised standard of care will include treatment per national guidelines for CCHF case management in Turkiye and Iraq, and any other supportive medication or therapies as required.
223918087|NCT06856109|DIAGNOSTIC_TEST|68Ga-Pentikra PET/CT Scan|68Ga-Pentikra Injection, Intravenous, administered at 0.05 mCi/kg by weight.
223918088|NCT06861166|DRUG|Geranium wilfordii combined with androgen deprivation treatment|Geranium wilfordii 15g decoction (Geranium 15g, decocted by the decocting machine in the decocting room of the pharmacy Department of the hospital) was taken orally, 200mL/ time, once/day, for 3 months + continuous androgen deprivation treatment
223918089|NCT06861166|DRUG|Androgen deprivation treatment|Continuous androgen deprivation therapy
224278538|NCT01876238|OTHER|Surveys|Pre-test and posttest surveys and questionnaires
223530283|NCT03766984|DRUG|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
223530284|NCT03766984|DRUG|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
223530285|NCT03766984|DRUG|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
223530286|NCT02194790|BEHAVIORAL|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
223719560|NCT02864498|DRUG|Placebo|
223918090|NCT06861166|PROCEDURE|radical prostatectomy|After completion of treatment, radical prostatectomy was performed 3 weeks later (±7 days).
223918091|NCT06861296|BEHAVIORAL|Intervention Group|(Flipped Learning Model Based Training Group)-Arm Description: This group will receive training on postpartum hemorrhage management using the reverse learning
223918092|NCT06666361|OTHER|Experimental Group|"The experimental group participates in the Mobio Health Multimedia Hypertension Promotion Program, which includes a hypertension education manual and a mobile health (m-health) intervention aimed at enhancing participants' health literacy and promoting healthy behaviors. In the first week, participants receive the health-education manual on-site, with face-to-face explanations and guidance on using mobile resources, such as text messaging, provided by the Sub-Investigator.~The mobile health intervention transforms the manual's content into six video units, each covering a specific topic, and these videos are continuously pushed over a two-month period. Distributed through LINE@, the official LINE account of the nursing platform, participants can easily access information via the chat menu at the bottom of the screen. This setup improves accessibility, making it convenient for participants to locate and use essential health information directly from the chat window."
223940565|NCT06064669|DRUG|Metformin pretreatment before ovarian stimulation|The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
223940566|NCT06064669|DRUG|Placebo pretreatment before ovarian stimulation|The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
223940567|NCT06064669|DRUG|Metformin pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
223940568|NCT06064669|DRUG|Placebo pretreatment before endometrial preparation for frozen embryo transfer|After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
223918093|NCT06666361|OTHER|control group|The control group received one copy of the same health education manual as the experimental group. The sub-Investigator only explained how to use the manual, and afterwards, no face-to-face teaching or m-Health interventions were conducted. After the experiment concluded, the m-Health program used by the experimental group would be provided to the control group.
223918094|NCT04675034|DRUG|MEDI7352|Participants will receive SC injection of MEDI7352 as stated in arm description.
223918095|NCT04675034|OTHER|Placebo|Participants will receive SC injection of placebo as stated in arm description.
223918096|NCT02954939|DRUG|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
223918097|NCT02954939|DRUG|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
223918098|NCT06269926|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP consists of skill-based therapy sessions completed weekly for 12 weeks. Participants are oriented to CBT and set individualized goals (sessions #1-3) before focusing on cognitive and behavior skill building including physical activity, pacing, relaxation training, and cognitive restructuring (#4-10) then focusing on maintenance and discharge planning (#11-12). It will be completed in Maryland in an online real-time audio/video virtual group therapy format.
223918099|NCT03494959|DRUG|Pentaglobin|Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.
223918100|NCT06664957|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants in this arm will receive 400 mg of Vitamin C, administered as two 100 mg tablets in the morning and two 100 mg tablets in the evening, for a total of 12 months. The intervention aims to support antioxidant defense and improve clinical outcomes in COPD patients.
223918101|NCT06664957|OTHER|Placebo|Participants in this group will receive a placebo, identical in appearance to the active nutrient supplement (Vitamin C) tablets, with no active ingredients. The placebo will be administered as two tablets in the morning and two tablets in the evening (four tablets per day) for a duration of 12 months, serving as a control to compare the effects of the active intervention.
223918102|NCT06666855|DRUG|DE-117B Eye Drops|Investigational Product: 0.002% DE-117B Eye Drops
223918103|NCT06666855|DRUG|Latanoprost|Active Control: 0.005% Latanoprost Eye Drops
223918104|NCT06614218|DEVICE|Minimally Invasive Micro Sclerostomy|The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.
223918105|NCT05433103|OTHER|Low-Load Exercise with Blood Flow Restriction|Participants in the BFR group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training with at least 60% blood flow occlusion. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
223918106|NCT05433103|OTHER|Low-Load Exercise Control Group|Participants in the Control group will attend a 10-week, twice weekly intervention exercise session combining low-load resistance training. Standard education regarding the importance of exercise for people with MS will also be provided. All participants will also be asked to practice a home exercise program focusing on functional tasks one time a week.
223918107|NCT05275556|DEVICE|Computer-Assisted Detection (CADe) Device|The CADe Device uses artificial intelligence to aid in identifying colorectal polyps during High Definition White Light Endoscopy (HD-WLE) based colonoscopies. This device connects the Gastroenterologist's colonoscopy video output source to the main monitor and highlights the regions of interest where the device detects a potential lesion. The CADe Device overlays graphical markers onto video from the endoscope camera and does not perform further processing to the endoscope video signal. This device is not intended to replace clinical decision making.
223918108|NCT06670027|OTHER|Family voice|Group A receives the family voice
223918109|NCT06670027|OTHER|Nature sound|Group B receives the nature sound.
223918110|NCT05545449|BEHAVIORAL|PrEP Peer Mentor Program|Five PrEP peer mentors will provide outreach, education, and referral for HIV pre-exposure prophylaxis. Peer mentors have received training on HIV, PrEP, family planning, adolescent development, peer support, and action planning. Interactions will include 1:1 informal interactions as well as planned group outreach interactions.
223918111|NCT05243966|DEVICE|Myriad Matrix™ and Myriad Morcells™|Ovine forestomach matrix sheet graft and morselized extracellular matrix
223918112|NCT04870359|PROCEDURE|Pre-emptive increase of immunosuppressive treatments|"1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day."
223918113|NCT04870359|DRUG|Prednisolone and/or AZA/MMF|Prednisolone and/or AZA/MMF
223918114|NCT05809986|OTHER|Ofatumumab|There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
223918115|NCT02637609|OTHER|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
223918116|NCT02637609|OTHER|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
223918117|NCT06488573|BEHAVIORAL|Nutritional intervention|7 individual sessions + 8 small group sessions
223918118|NCT05440084|PROCEDURE|Chronic total occlusion percutaneous coronary intervention|Chronic total occlusion percutaneous coronary intervention
223918119|NCT06854367|DEVICE|TBS|Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neurostimulation that uses focused magnetic field pulses to directly stimulate cortical neurons. Theta burst stimulation (TBS) is a briefer form of patterned rTMS that has been shown to be effective against major depressive disorder. Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.
223918120|NCT05807724|OTHER|Phone-based fall-prevention strategy|Written education material and Phone-Based Fall-Prevention Strategy
223918121|NCT05807724|OTHER|Home-visit fall prevention strategy|Written education material and Home visit-Based Fall-Prevention Strategy
223918122|NCT04409795|DRUG|Metformin Extended Release Oral Tablet|Initial oral hypoglycemic agent added to existing insulin treatment
224089511|NCT06935708|PROCEDURE|Epidural Analgesia|Epidural analgesia with levobupivacaine and fentanyl mixture. For intraoperative intermittent analgesia, Epidural group will be given a loading dose of 5-10 milliliters of a mixture of 10 micrograms per milliliter (μg/mL) of fentanyl (Fentanyl Piramal Critical Care, 50 mcg/ml) and 0.25% levobupivacaine (Levobupivakain Kabi 5 mg/ml), followed by intermittent 4-5 mL boluses as needed throughout the surgery. Postoperative continuous epidural analgesia in the epidural group will consist of 2 μg/mL fentanyl added to 0.1 % levobupivacaine at the rate 5-8 mL/h during the first 24 hours after surgery.
224089512|NCT06934278|DRUG|Pooled human plasma|Infusion of pooled human plasma (Octaplas, 10 mL/kg, max 400 mL) over 1 hour after induction of general anaesthesia
223918123|NCT04409795|DRUG|Sitagliptin|Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
223918124|NCT06112340|DRUG|linsitinib|Study medication taken twice daily by mouth
223918125|NCT06865066|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy with acceptance commitment therapy components
223918126|NCT06865326|OTHER|Standardized CTEPH Screening Protocol|Implementation of a standardized screening algorithm for early detection of CTEPH in patients after Acute Pulmonary Embolism (APE) and establishment of optimized referral of patients to specialized centers.
224089513|NCT06934278|DRUG|Placebo|Infusion of cryst (Octaplas, 10 mL/kg, max 400 mL) over 1 hour after induction of general anaesthesia
223918127|NCT04889066|RADIATION|Stereotactic Radiation Therapy|"24-27 Gy in 3 fractions- one plan, given once every other day with first cycle of Durvalumab for comparator arm. 24-27 Gy in 3 pulses- each pulse of radiation re-planned, given once every 4 weeks with each Durvalumab for experimental arm."
223918128|NCT04889066|DRUG|Durvalumab|Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1 (CD279) and CD80 (B7-1). MEDI4736 is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. MEDI4736 contains a triple mutation in the constant domain of the Ig G1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
223918129|NCT06863623|OTHER|İmmersive Virtaul Reality Applications|To apply immersive virtual reality applications (Scenarios)
223918130|NCT06863623|OTHER|Relaxing Videos|To watch relaxing videos including pictures and sounds prepared by researcher
223918131|NCT06863987|DRUG|Valsartan Oral Solution|"Valsartan oral solution, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning).~The dose administered is based on the subject's weight at the V1 visit:~Halve dose:~\<35 kg: 7 mL (equivalent to valsartan 20 mg);~* 35 kg: 13 mL (equivalent to valsartan 40 mg).~Full dose:~\<35 kg: 13 mL (equivalent to valsartan 40 mg);~* 35 kg: 27 mL (equivalent to valsartan 80 mg)."
223918132|NCT06863987|DRUG|Placebo|"placebo, taken by mouth, once daily. It is recommended that the medication be administered at the same time each day (e.g., in the morning).~The dose administered is based on the subject's weight at the V1 visit:~Full dose:~\<35 kg: 13 mL ;~* 35 kg: 27 mL .~Placebo dosing during elution phase:~\<35 kg: 7 mL;~* 35 kg: 13 mL."
223918133|NCT06865261|DIETARY_SUPPLEMENT|Bioarginina C|Bioarginine®C oral vials is a dietary supplement based on L-arginine and liposomal Vitamin C that is useful for making an integrative share of L-arginine and Vitamin C. Liposomal Vitamin C is a particular type of Vitamin C produced through an innovative technology that optimizes and amplifies its absorption.
223918134|NCT06865261|DIETARY_SUPPLEMENT|Placebo|Vials containing placebo were made to be indistinguishable in appearance from active treatment
223918135|NCT06864377|OTHER|Quality of life questionnair|The questionnaire used is the Abdominal Hernia Q, which is specific to ventral hernias. Patients will receive the questionnaire at baseline and at 1, 3, 6, and 12 months after ventral hernia repair. If treated conservatively, the questionnaire will be administered at 1, 3, 6, and 12 months after completing the baseline questionnaire.
223918136|NCT06860581|DIETARY_SUPPLEMENT|Intervention (Sanprobi®Stress)|The composition of lyophilized strains of Bifidobacterium longum Rosell®-175 and Lactobacillus helveticus Rosell®-52 (trade name: Sanprobi®Stress; manufacturer: Sanprobi sp. z o.o. sp. k., Szczecin, Poland) was placed in capsules, the shell of which consisted of hydroxypropylmethylcellulose. The total bacterial content per capsule was 3x109 CFU. Filling substances were potato starch and magnesium stearate. The weight of the capsule was 420 mg. Dosage: 1 capsule/day for 12 weeks.
223918137|NCT06860581|OTHER|Placebo|Filling substances were only potato starch and magnesium stearate.
224089514|NCT03463772|PROCEDURE|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
224278539|NCT03715686|PROCEDURE|wire localization|Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
223918138|NCT06861595|DEVICE|accuvein|intravenous route with accuvein
223918139|NCT06861595|OTHER|with out accuvein|intravenous route with out accuvein
223918140|NCT06862154|DRUG|IV Analgesia- Fentanyl|Patients receive intravenous fentanyl at a dose of 1 mcg/kg, diluted in 100 mL normal saline, administered as a single dose for systemic analgesia. This intervention aims to control acute pain in hip fracture patients before surgical intervention.
223918141|NCT06862154|PROCEDURE|Femoral Nerve Block|Patients undergo an ultrasound-guided, single-injection femoral nerve block with 20 mL of 0.5% bupivacaine. This regional anesthesia technique targets the femoral nerve, providing effective pain relief while reducing opioid requirements.
223918142|NCT06615843|DEVICE|Participants will receive post-emergency gynecological follow-up at home using a connected health app|The app will facilitate data collection and communication, including logging of vital signs, symptoms (such as pain, bleeding, and vomiting), and uploading of test results. Medical professionals will review the health data twice daily and provide care instructions through instant messaging. The app will also alert the medical team of any urgent updates or deviations from expected health patterns
223918143|NCT06617195|OTHER|Exercise|Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle
223918144|NCT01907126|BEHAVIORAL|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
223918145|NCT01907126|BEHAVIORAL|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
223918146|NCT04603911|DRUG|Liposomal bupivacaine|The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
223918147|NCT04603911|DRUG|Bupivacaine, epinephrine, dexamethasone, and clonidine|The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
223918148|NCT05563584|BEHAVIORAL|Super Rehab|A 12-month healthcare-delivered lifestyle intervention involving exercise and nutritional support
223918149|NCT06862895|OTHER|chest physiotherapy|Chest Physiotherapy is including various techniques, in this study classical CPT was used to be applied to participants
223918150|NCT06864663|DRUG|nerve block with bupivacaine 0.25%|ultrasound guided adductor canal block and interspace between the popliteal artery and the knee capsule using bupivacaine 0.25%
223918151|NCT06864663|DRUG|Nerve Block with bupivacaine 0.25%|ultrasound guided combined adductor canal block and genicular nerve block using bupivacaine 0.25%
223918152|NCT06858410|DRUG|lorlatinib|Eligible patients will be registered to receive oral lorlatinib 100mg qd for 36 months during the treatment phase.
223918153|NCT06858410|OTHER|concurrent/sequential platinum-based chemoradiotherapy|The choice of chemotherapy and will be determined by the investigator prior to treatment allocation and the radiotherapy also according to the clinical therapy regimen decided by the investigator.
223918154|NCT06768983|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|10 sessions of remotely delivered CBT; each session is about 45 minutes in length. The aim of the sessions is to cultivate skills that promote activity and reduce fatigue and its impact on daily activities.
223918155|NCT04856384|OTHER|synchronisation abilities|The study contains 1 descriptive and 3 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, with period and phase auditory manipulations
223918156|NCT05008055|DRUG|Capivasertib|Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
224278540|NCT03203772|OTHER|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
224278541|NCT02576717|DRUG|RPC1063|
224278542|NCT06416852|DRUG|18F-Alfatide Injection|A single dose of (0.1\~0.15）±0.015 mCi/kg IV injection of 18F-Alfatide. The patients will be intravenously injected with 18F-Alfatide Injection and undergo PET/CT scan at 60 min±10 min after the injection.
223716744|NCT02786797|BEHAVIORAL|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
223918157|NCT06343051|DEVICE|USCOM|Device that measures how much blood is being pumped in and out of the heart.
223918158|NCT06610890|DRUG|Hemay005|One 15mg tablet, four tablets at a time
223918159|NCT06610890|DRUG|Midazolam maleate|One 15mg tablet, one tablet at a time
223918160|NCT06503679|DRUG|LY4100511 (DC-853) Dose 1|Administered orally
223918161|NCT06503679|DRUG|LY4100511 (DC-853) Dose 2|Administered orally
223918162|NCT06503679|DRUG|LY4100511 (DC-853) Dose 3|Administered orally
223918163|NCT06503679|DRUG|Midazolam|Administered orally
223918164|NCT06503679|DRUG|Repaglinide|Administered orally
223918165|NCT06503679|DRUG|Digoxin|Administered orally
223918166|NCT06503679|DRUG|Rosuvastatin|Administered orally
223918167|NCT06667336|PROCEDURE|intermittent suction|This suction was applied only as needed to clear secretions
223918168|NCT06667336|PROCEDURE|continuous suction|The suction catheter was inserted at the start of laryngoscopy and maintained in the oropharynx until the moment of ETT delivery.
223918169|NCT03873402|BIOLOGICAL|Nivolumab|Specified dose on specified days
223918170|NCT03873402|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223918171|NCT03873402|OTHER|Ipilimumab placebo|Specified dose on specified days
223918172|NCT04155710|BIOLOGICAL|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
223918173|NCT04155710|DRUG|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
223918174|NCT04155710|DRUG|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
223918175|NCT04155710|DRUG|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
223918176|NCT04007055|DIAGNOSTIC_TEST|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
223918177|NCT04007055|DRUG|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
223918178|NCT04679389|DRUG|Placebo|administered orally or enterally
223918179|NCT04679389|DRUG|Acetazolamide|administered orally or enterally
223918180|NCT05296122|DEVICE|TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation.|The main purpose with the study is to investigate safety and feasibility of the TRANBERG® laser applicators when used in MR-guided laser thermal ablation of brain lesions using the TRANBERG® Thermal Therapy System and TRANBERG® Thermoguide Workstation together with SmartTwist™ MR Hand Drill with the SmartTip™ MR Drill Kit for MR-guided laser thermal ablation of brain lesions.
223918181|NCT05152472|DRUG|Atezolizumab 1200 mg|(Intravenous administration)
223918182|NCT05152472|DRUG|Imatinib 400 MG|(Per os)
223918183|NCT06861088|DRUG|Isoquercetin|Isoquercetin with vitamin C and vitamin B3 capsules
223918184|NCT06861088|DRUG|Placebo|Placebo
223918185|NCT06861374|DRUG|Bivalirudin|"For rescued PCI, do not recommend to include patient who's ACT is more than 350s.~If fibrinolysis is successful, monitor ACT and wait till it's lower than 350s before randomization.~Monitor ACT before angiography, (1) if ACT\<180, bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (2) if 180s\<ACT\<225s, bivalirudin 0.5mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI; (3) if ACT\>225s, bivalirudin intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. (4) ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s, intravenous injection of 0.3 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds."
223918186|NCT06861374|DRUG|Unfractionated heparin|(1)If ACT\<180s, administer an intravenous bolus of unfractionated heparin at 70 U/kg before coronary angiography, with a maximum total dose of 6000U. (2)If 180\<ACT\<225s, administer an intravenous bolus of unfractionated heparin at 60 U/kg before coronary angiography, with a maximum total dose of 4000U. (3)If ACT\>225s, proceed directly with PCI and maintain 225s\<ACT\<350s.
223918187|NCT06862245|DRUG|T received propofol at a dose of 2-2.5 mg/kg based on total body weight|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group T received propofol at a dose of 2-2.5 mg/kg based on total body weight. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison.
223918188|NCT06862245|DRUG|Group L received propofol at 2-2,5mg/kg dose based on le|A total of 120 patients undergoing general anesthesia for urological surgeries at our hospital were included in the study. Patients were randomized into two groups (Group T/Group L). All patients were taken to the operating room, and in addition to routine monitoring, BIS and SedLine monitoring were provided. All patients received 1 mcg/kg of fentanyl. Group L received propofol at 2-2,5mg/kg dose based on lean body weight, which was calculated from CT imaging by a radiologist. Propofol was administered at a rate of 100 mg/min. The laryngeal mask will be placed once an adequate depth of anesthesia is achieved. All data were recorded at 2-minute intervals for 6 minutes before and after induction. The collected data were statistically analyzed for comparison
223918189|NCT06864572|DIAGNOSTIC_TEST|P17-079, P16-093, or P15-041 PET/CT|P17-079, P16-093, or P15-041 PET/CT
223918190|NCT06860620|DRUG|Zinc supplementation plus standard treatment|children were given 5 mg of elemental zinc sulfate as a single daily dose for children less than 4 years of age and 10 mg for children more than 4 years of age for a total duration of 6 months, along with standard therapy.
223918191|NCT06862778|DIAGNOSTIC_TEST|SERS|Spectroscopic assessment of serum samples from healthy and diabetic patients to identify characteristics for diagnosis.
223918192|NCT05662306|DRUG|Aripiprazole Lauroxil|1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.
223918193|NCT05662306|BEHAVIORAL|Computerized cognitive and functional skills training|Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.
223918194|NCT06858215|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised lay counsellors in primary health care clinics. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the counsellor helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
223918195|NCT04099732|DRUG|Rosuvastatin|Tablet
223918196|NCT04099732|DRUG|BI 1358894|Tablet
223918197|NCT04099732|DEVICE|Dabigatran etexilate|Capsule
224089515|NCT03463772|DRUG|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
224089516|NCT00168350|DRUG|memantine|
224099311|NCT02762058|DEVICE|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
223918198|NCT04822350|DRUG|Avelumab|As provided in real world practice
223918199|NCT06617338|DIAGNOSTIC_TEST|CT scan unilateral knee|Intervention given to the Active Comparator arm
223918200|NCT06617338|DIAGNOSTIC_TEST|CT scan bilateral knee|Intervention given to the Experimental Arm
223918201|NCT06616142|DRUG|[18F]CETO tracer|PET/CT with para-chloro-2-\[18F\]fluoroethyl-etomidate (\[18F\]CETO) has a high specificity for the steroidogenic enzymes CYP11B1 and CYP11B2, present in the adrenal cortex, and has more favourable tracer characteristics compared to \[11C\]metomidate. Results obtained with this novel tracer seem promising, but its potential value in the subtyping of PA needs to be further established.
223918202|NCT06616142|DRUG|Dexamethasone oral|Pre-treatment of dexamethasone prior to 18F CETO PET/CT scan
223918203|NCT06616142|PROCEDURE|Adrenal vein sampling|Adrenl vein sampling
223918204|NCT05257603|BEHAVIORAL|RPCW|Psychosocial intervention that includes two in-person group sessions two weeks apart and two on-line units during the intervening two weeks. Behavioral training, educational materials, discussions and videos, as well as interactive online materials are included to increase awareness of sexual assault cues, dating and drinking protective behavioral strategies, barriers to defending oneself, and saying no to hazardous drinking and sexual advances.
223918205|NCT05257603|BEHAVIORAL|HEC|Health Education time and attention control that includes two in-person sessions two weeks apart and two on-line units during the intervening two weeks. The in-person sessions cover stress management and sleep, while the online units cover nutrition and physical activity. The in-person and online sessions are designed to foster discussion and be interactive.
223918206|NCT05291507|DEVICE|Muse MRgFUS System|The intended use of the device is to thermally ablate breast tissue under magnetic resonance image guidance. The thermal ablation is performed non-invasively using extracorporeal focused ultrasound.
223918207|NCT04882904|DEVICE|Actimyo°|Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223918208|NCT06091163|BEHAVIORAL|Ketogenic Diet|"A Ketogenic Diet (KD) is a high-fat and very low-carbohydrate intake. Participants will follow a modified KD (estimated 20-50g carbohydrates/day based on a 2000 kcal diet) without energy restriction. Participants will test for ketosis in their morning urine at least twice a week to monitor adherence.~To support adherence in people with depression, delivered pre-prepared KD meals (3 meals per day) and additional ketogenic snacks will be sent to participants. A registered dietitian will provide weekly 30-minute nutritional counselling sessions. The dietitian will schedule appointments and assess the participants' experience with adhering to the KD diet, troubleshoot as required, give guidance on how to prevent or overcome side effects of KD diets, and keep record of participants' ketosis level and suicide risk."
223918209|NCT06091163|BEHAVIORAL|Phytonutrient Diet|Participants in the control group will receive the same degree of dietetic input and be told that their diet is a modified fat and phytonutrient diet. The photo diet aims to increase vegetable consumption, reduce saturated fat intake and increase poly- and mono-unsaturated fat intake. Participants in the control group will receive food vouchers (£20 every two weeks) to help purchase these items. This aims to be a plausible placebo dietary treatment for depression. There is no clear evidence that these manipulations will change depression severity. The dietitian will create written materials to explain the diet and suggest foods by colour with supporting recipe suggestions.
224089517|NCT02366000|OTHER|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
224089518|NCT06198686|DRUG|Nalmefene|Opioid antagonist
224089519|NCT03219164|DRUG|AZLI|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
224089520|NCT03219164|DRUG|Placebo|Administered via the PARI Altera® Nebulizer System. Participants \< 2 years will receive via the SmartMask® Baby, 2 to \< 6 years via the SmartMask Kids® and \> 6 years via the nebulizer mouthpiece.
224089521|NCT01142414|BIOLOGICAL|panitumumab|
224089522|NCT01142414|DRUG|cisplatin|
224089523|NCT01142414|DRUG|fluorouracil|
224089524|NCT01142414|OTHER|laboratory biomarker analysis|
224089525|NCT01142414|PROCEDURE|adjuvant therapy|
224089526|NCT01142414|PROCEDURE|quality-of-life assessment|
224089527|NCT01142414|RADIATION|3-dimensional conformal radiation therapy|
224089528|NCT01142414|RADIATION|intensity-modulated radiation therapy|
224089529|NCT03733912|OTHER|Phthalate metabolites measurement|To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
224089530|NCT00295945|DRUG|fentanyl citrate|
224089531|NCT00295945|DRUG|hydromorphone hydrochloride|
224089532|NCT00295945|DRUG|ropivacaine hydrochloride|
224089533|NCT04643184|OTHER|Management Program|Joint management between the geriatric and cardiology team of the geriatric syndromes and heart failure. Education of the patient and their caregiver, preparing them for the transition of care.
224089534|NCT02303054|PROCEDURE|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
224089535|NCT05219565|DEVICE|Attractive Targeted Sugar Bait (ATSB)|An ATSB is a A4-sized panel containing thickened fruit syrup laced with a neonicotinoid insecticide, dinotefuran. The syrup-insecticide mixture is covered with a protective membrane that allows mosquitoes to feed through the membrane while preventing non-target organisms from feeding. This device is designed to attract and kill mosquitoes.
224089536|NCT04387292|PROCEDURE|Ophthalmologic exam|"* Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)"
223716745|NCT02786797|BEHAVIORAL|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
223716746|NCT02853604|DRUG|ADXS11-001|
223716747|NCT02853604|DRUG|Placebo|
223716748|NCT05278767|OTHER|E-Mobile Education and Counselling|The patients in the experimental group received e-mobile training and consultancy services with the mobile application developed specifically for bariatric surgery that started before the operation and lasted for 3 months.
223716749|NCT04213079|DEVICE|re-adaptation of the vestibulo-ocular reflex|The VOR will be readapted by activating velocity storage with full-field optokinetic motion at 5°/s in a set direction while the head is oscillated with a set frequency and direction. The readaptation training will be conducted in repeated modules, each lasting for 1-5 min. The expected duration of daily sessions varies from 30 to 90 min. A day's session will be terminated if patient no longer feel symptoms of MdDS.
223716750|NCT04213079|DEVICE|Habituation of velocity storage of the vestibulo-ocular reflex|The central (velocity storage) time constant will be reduced by inducing cancellation of two velocity storage-mediated responses: OKN and the VOR. Sinusoidal rotation at 0.017 Hz (1 revolution/min) in darkness advances the slow phase eye velocity of the VOR by 32º. In contrast, the OKN at this frequency has no phase advancement. Thus, to counteract the VOR by OKN, the optokinetic stimulus should be set to 32º phase advance the out of phased head rotation stimulus. Since the conflict stimulus is expected to be overwhelming to patients at higher chair velocities, subjects will be first trained with a 10°/s stimulus. In a previous study, no complaints were reported when subjects were tested at such low velocities. Preliminary testing show signs of symptom improvement when the peak velocity reached 30°/s to 40°/s.
223918210|NCT06862505|PROCEDURE|Biopsy|Biopsy of soft tissue were taken randomly at 8 or 16 weeks to compare soft tissue
223918211|NCT06862297|DEVICE|Ultrasonic Jaw Tracking Device|"This study investigates the effectiveness of the Ultrasonic Jaw Tracking Device, a novel non-invasive diagnostic tool designed to monitor dynamic jaw movements during sleep. The device is equipped with advanced ultrasonic sensors and proprietary algorithms to track jaw position and motion in real time.~The intervention involves placing the device on the participant's mandible during polysomnography (PSG) sessions to simultaneously measure jaw movement data alongside standard PSG parameters. The primary goal is to evaluate the accuracy and efficacy of the device in detecting sleep-related conditions such as obstructive sleep apnea (OSA) compared to traditional PSG metrics."
223918212|NCT06671171|DEVICE|Apple Watch Series 9|"Participants will wear Apple Watch Series 9 during cardiopulmonary exercise test (in Visit 1), 1-week study period and 6-Minute walk distance test (in Visit 2) to have assessment of maximal oxygen uptake and pre- and post-SaO2.~During 1-week study period, participants will measure their oxygen saturation once daily with a medical-grade pulse oximeter while wearing the smartwatch continuously."
223918213|NCT06671197|DEVICE|Pulmonary vein isolation|Pulsed field ablation
224089537|NCT06378827|DRUG|Dexmedetomidine|Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
224089538|NCT06060301|DRUG|sulfasalazine 500 MG|The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
224089539|NCT06060301|DRUG|corticosteroids|The patients will use topical corticosteroids 4 times per day.
224089540|NCT04847128|BEHAVIORAL|Chronic aerobic exercise|Participants in the experimental group will exercise more than 30 minutes each time and 3 times weekly for 8 weeks. The chronic aerobic exercise in the present trial is running. The heart rate is required to 60% -85% of the maximum heart rate during exercise. Maximum heart rate = 220 - age.
224089541|NCT02355301|PROCEDURE|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
224089542|NCT00129025|PROCEDURE|Hypofractionated radiotherapy|
224089543|NCT02592005|OTHER|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
223716751|NCT00652405|DIETARY_SUPPLEMENT|alcohol|250 ml of white wine (13% vol; \~25 gram of alcohol per day)
223716752|NCT00652405|DIETARY_SUPPLEMENT|Placebo|250 ml of mineral water (Brand name: Vittel)
223716753|NCT03719521|OTHER|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
223716754|NCT04343261|BIOLOGICAL|Convalescent Plasma|treatment with 2 Units of convalescent plasma
223716755|NCT04278638|RADIATION|IORT|IORT in surgery of laryngocarcinoma
223716756|NCT04278638|PROCEDURE|surgery|total laryngectomy or hemilaryngectomy
223716757|NCT04278638|RADIATION|External radiotherapy|External radiotherapy
223918214|NCT06671197|DEVICE|Pulmonary vein isolation+posterior left atrial wall line+superior vena cava isolation|Pulsed field ablation
223918215|NCT06671106|OTHER|toothbrushing|manual toothbrush (meridol)
223918216|NCT06671106|OTHER|flossing|dental floss (meridol)
223918217|NCT06671106|DEVICE|Toothpaste Product|amine and zinc lactate - containing toothpaste (meridol Gum Protection)
223918218|NCT06671106|DEVICE|Mouthrinse|amine and zinc lactate - containing mouthrinse (meridol Gum Protection)
223918219|NCT06671340|DRUG|Dorzagliatin|chronic treatment with dorzagliatin for 4 weeks (50mg twice daily or 75mg twice daily, oral)
224089544|NCT01000103|DEVICE|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
224089545|NCT01000103|DEVICE|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
224089546|NCT02338843|DRUG|LJPC-501|Treatment arm
224089547|NCT02338843|DRUG|Placebo|PBO
224089548|NCT04085432|OTHER|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
223918220|NCT06678945|PROCEDURE|Bar-Clip attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.
224089549|NCT00023322|DRUG|Peginterferon Alpha-2a|Treatment
224089550|NCT02226484|DRUG|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
224089551|NCT06108661|PROCEDURE|Conventional Physical Therapy|"Moist heat therapy for 10 minutes for 3 times per week (alternatively) for 2 weeks.~TENS was applied for 15 minutes, 3 times per week (alternatively) for 2 weeks. Stretching protocol for deep lumbar spinal muscles was employed. The frequency was 3 times per week (alternatively) for 2 weeks."
223918221|NCT06678945|PROCEDURE|Bar- OT Equator attachment|The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
223918222|NCT05932342|BEHAVIORAL|Integrated program of cognitive remediation, physical exercise and socially stimulating activity|"Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport."
223918223|NCT06678516|DIETARY_SUPPLEMENT|Intermittent fasting|Participants are asked to abstain from any form of fasting or calorie restriction in one month of the study (which is also a pre-fasting washout for those volunteers that might be performing forms of fasting before the study) and then start with one month of intermittent fasting, with daily fasting duration from 7:30 to 18:30. Food is abstained from during fasting, only water and zero-calorie drinks like black coffee and unsweetened tea are allowed.
223918224|NCT06678906|BEHAVIORAL|Intervention arm|All patients in the intervention group will benefit from the standard information phase on physical activity and sedentary behavior, as well as personalized support for behavior change in the form of a serious game and remote coaching.
223918225|NCT06323044|OTHER|Best Practice|Receive usual care
223918226|NCT06323044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223918227|NCT06323044|OTHER|Electronic Health Record Review|Ancillary studies
223918228|NCT06323044|OTHER|Interview|Ancillary studies
223918229|NCT06323044|OTHER|Medical Device Usage and Evaluation|Receive MedSupport intervention
223918230|NCT06323044|OTHER|Medical Device Usage and Evaluation|Use MEMS device
223918231|NCT06323044|OTHER|Survey Administration|Ancillary studies
223918232|NCT04959695|BEHAVIORAL|PE Coach|PE Coach is a treatment companion mobile application designed with features to support the tasks of prolonged exposure psychotherapy and the homework between sessions.
224089552|NCT06108661|PROCEDURE|Slump Stretching|Slump stretching will be performed with the patient in the long sitting position with the patient's feet against the wall to assure the ankle remained in 0 degree dorsiflexion. The therapist will apply over pressure to the cervical spine flexion to the point where the patient's symptoms will be reproduced. The position will be held for 30 s. A total of 5 repetitions will be completed.
224089553|NCT06108661|PROCEDURE|ELDOA|"ELDOA will be performed as per the tolerance of the patient (Max hold time=60sec) for 2 weeks (alternatively). For L4/L5 spinal segment patient sits on the floor, arms at the side legs relaxed.~For L5/S1 segment the patient lies on his or her side with torso perpendicular to a wall with the sitz bone pressing into the wall. The patient swing the legs up so that he or she is lying on his or her back with the legs perpendicular up the wall and the sitz bone pressing into the wall. The arms are lying by the sides."
224089554|NCT06123156|DRUG|Sildenafil|Sildénafil during 10 months (50mg daily), start 30 days after surgery
224089555|NCT06123156|OTHER|Placebo|1 platelet during 10 months (daily), start 30 days after surgery
224089556|NCT02828267|BEHAVIORAL|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
224089557|NCT02828267|BEHAVIORAL|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
223918233|NCT04959695|BEHAVIORAL|Prolonged exposure without PE Coach|Standard PE treatment protocol without PE Coach
223918234|NCT06867692|OTHER|Aerobic Exercise|"Warm-Up (5 minutes): Marching in Place: 2 minutes of marching to elevate heart rate. Arm Circles: 1 minute of small and large arm circles. Side Steps with Arm Swings: 2 minutes of stepping side to side with gentle arm swings. Main Exercise Routine (35 minutes): Walking/Jogging Intervals: 10 minutes alternating between 1 minute of walking and 1 minute of jogging. Jumping rope: 10 minutes of rope jumping. As a pre-determined routine to maintain consistency. Aerobic Games: 10 minutes of structured games like:~1. Simon Says: Incorporating aerobic movements like jumping jacks, running in place, etc.~2. Obstacle Course: Pre-planned course involving stepping over objects, crawling, and balancing. Ball Activities: 5 minutes of activities such as throwing and catching, or dribbling a ball around cones.~3. Cool Down (5 minutes) Stretching: Gentle stretching of major muscle groups, holding each stretch for 20-30 seconds."
223918235|NCT06867692|OTHER|Light Physical Activity Plan|"Warm-Up (5 minutes): Gentle Walking: 2 minutes at a slow pace. Light Arm Movements: 1 minute of gently moving arms up and down. Side Steps: 2 minutes of gentle side stepping.~2\. Main Activity Routine (35 minutes): Stretching Exercises: 10 minutes of gentle stretching, focusing on flexibility. Balance Activities: 10 minutes of activities such as: Standing on One Leg: Holding balance for 10-15 seconds on each leg. Heel-to-Toe Walking: Walking in a straight line, placing the heel of one foot directly in front of the toes of the other foot. 3. Light Coordination Games: 10 minutes of low-intensity activities like: Passing a Ball: Gently passing a ball back and forth with a partner. Basic Catch and Throw: Simple throw and catch exercises with a soft ball. Guided Relaxation: 5 minutes of guided relaxation techniques, including deep breathing and visualization. 4. Cool Down (5 minutes) Gentle Stretching: Stretching major muscle groups, holding each stretch for 20-30 second"
223918236|NCT06867029|PROCEDURE|Onlay Mesh|to compare between two techniques of mesh placement in uncomplicated ventral hernias, onlay (mesh on external oblique) versus sublay (mesh in the retromuscular space).
223530287|NCT01424800|DEVICE|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
223918237|NCT06867146|DRUG|Three-drug chemotherapy group|Three-drug chemotherapy group, mFOLFIRINOX, including 5-fluorouracil, leucovorin, oxaliplatin and irinotecan.
223918238|NCT06867146|DRUG|two-drug chemotherapy group|two-drug chemotherapy group, including gemcitabine-based combination regimens (predominately gemcitabine/nab-paclitaxel or gemcitabine/capecitabine)
223918239|NCT06867549|DRUG|Propofol|Targeted propofol infusion in TRD patients will induce sedation. Dosage of propofol is determined based upon EEG markers and treatment arm.
223918240|NCT06867549|DIAGNOSTIC_TEST|Electroencephalography (EEG)|EEG will be recorded during propofol infusion and during overnight sleep. Sleep EEG data will be acquired for a minimum of one night prior to the first sedation session, providing a baseline measure. Additional overnight sleep recordings will be performed on day of sedation and subsequent nights.
223918241|NCT06867549|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Trained staff will provide evaluation and up to 3 follow up appointments of BBTI for all participants. These will be done remotely to assess behavioral approaches to improve overall sleep habits.
223918242|NCT06866860|OTHER|Implant surgical guide with internal irrigation|"* Virtual surgical plan will be completed in the implant planning software (BlueSky plan, BlueSky Bio, USA), and the implant type, position, and sleeve height will be adjusted.~* The entry point of the surgical drill into the alveolar bone will be identified.~* An irrigation channel will be added, directed toward the entry point of the drill and adjusted to have the same diameter as the irrigation system tube."
223918243|NCT06866860|OTHER|Conventional implant surgical guide with external irrigation|Virtual surgical plan will be completed in the implant planning software (BlueSky plan, BlueSky Bio, USA), and the implant type, position, and sleeve height will be adjusted. Conventional guide will be printed
223918244|NCT06865352|BIOLOGICAL|HSCT donor leukemia-specific cytotoxic T-cells|donor T-cells stimulated with patient leukemia blasts
223918245|NCT06866327|BEHAVIORAL|Piano lessons|The program consists of 12-weekly piano lessons, alternating small group lessons and individual lessons each week. Individual lessons reinforce and help personalize what is instructed during group lessons. Lessons are tailored to help older adults with memory challenges learn note reading, finger positioning, and song playing. Participants are asked to practice at home in between lessons for 10 minutes per day, 5 times per week, with a keyboard and bench provided.
223918246|NCT06866327|BEHAVIORAL|Music Lessons|The program consists of 12-weekly music lessons, alternating small group lessons and individual lessons each week. Individual lessons reinforce and help personalize what is instructed during group lessons. Lessons are tailored to help older adults with memory challenges learn various instruments, engage in group playing during group lessons, and engage in music appreciation activities. Participants are asked to practice at home in between lessons for 10 minutes per day, 5 times per week, with instruments provided.
223918247|NCT06866392|DIAGNOSTIC_TEST|photoelectric detection|Methylation test and colposcopic biopsy was performed in the conventional group, and clinical follow-up was performed according to the methylation results; in the experimental group, methylation test and colposcopic biopsy and OITS was performed, and clinical follow-up was performed according to the methylation results and OITS results.
223918248|NCT06619093|OTHER|blood sampling|3 additional citrate tubes (2.7mL)
223918249|NCT05744895|DEVICE|Device: Robotic MAKO total knee|Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
223918250|NCT05744895|DEVICE|FocusMotion knee brace|Focusmotion knee brace measures range of motion during exercises
223918251|NCT05744895|DEVICE|Fitbit tracking device|Fitbit will measure patients steps, HR, and sleep
223918252|NCT05744895|DEVICE|FocusMotion app|Will survey patients with PROMS
223918253|NCT06483308|RADIATION|Radiotherapy|Radiotherapy using 30Gy in 6 fractions (alternate days) over 12 days.
223918254|NCT05412758|DIETARY_SUPPLEMENT|Oral Stimulant Drink|For the AROMA 1 study patients will be requested to consume a nutrient drink (approximately 200 ml) that includes natural ingredients found within a typical human diet. Following consumption of the drink, serial breath tests will be performed to determine varying levels of VOC production in breath
223918255|NCT03771612|DRUG|Naproxen|Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
223918256|NCT03771612|DRUG|Placebos|Half of the participants will be randomly assigned to receive a placebo pill twice daily
223918257|NCT00001481|DRUG|Estradiol|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
223918258|NCT00001481|OTHER|Placebo|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
223918259|NCT00001481|DRUG|Progesterone|To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
223918260|NCT06681077|PROCEDURE|Community Health Education|Receive I CAN intervention
223918261|NCT06681077|OTHER|Survey Administration|Ancillary studies
223918262|NCT06681766|DRUG|Nomlabofusp|Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
223918263|NCT06681766|DRUG|Placebo|The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
224278543|NCT06416852|DRUG|18F-FDG Injection|A single dose of 5～10mCi IV injection of 18F-FDG. The patients will be intravenously injected with 18F-FDG Injection and undergo PET/CT scan at 40 min±10 min after the injection.
223918264|NCT06484400|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a well-established psychological treatment that focuses on identifying, understanding, and changing negative thinking and behavior patterns. The intervention involves structured sessions where participants are taught strategies to alter detrimental thoughts and behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, CBT will be delivered in 12 one-hour weekly sessions conducted in person and on a one-on-one basis. This intervention is designed to reduce symptoms of depression and anxiety through cognitive restructuring and behavioral adaptations.
223918265|NCT06484400|BEHAVIORAL|Ericksonian Hypnotehrapy|Ericksonian Hypnotherapy is a form of psychotherapy using clinical hypnosis and indirect suggestion to modify unconscious behaviors and thought patterns. Named after Dr. Milton H. Erickson, this therapeutic approach emphasizes adaptability and utilizes the patient's own experiences and internal resources for healing. The therapy is known for its effectiveness in addressing anxiety and depression by encouraging flexibility in perception and behavior. Like CBT, this intervention will be administered over 12 one-hour sessions, each conducted in person and tailored to the individual's unique psychological landscape.
223918266|NCT05997082|OTHER|Mindfulness Self-Compassion Course|This course is designed to reduce burnout and compassion fatigue among specialist rehabilitation providers. Course materials are adapted from the Center for Mindful Self-Compassion (CMSC).
223918267|NCT05334355|OTHER|Family history of hypertension|Presence or absence of a family history of hypertension in a cross sectional study design.
223918268|NCT06854068|DEVICE|laser treatment|In the laser treatment groups, the Fotona LightWalker® Erbium laser (2,940 nm) will be used, with each session lasting five minutes. During treatment, the energy density will be set to 20 J/cm², and the laser tip will be held perpendicular to the target area, applied in continuous and contact modes.
223918269|NCT06854068|DEVICE|application of desensitizing agent|"Mix the product for 15 s. Apply in a thin layer on treatment area(s) with aid of a microbrush, with no rinsing or removal"
223918270|NCT06854068|OTHER|Placebo|"Simulation of a single layer application (15s) , with the aid of a microbrush, on the surface of the tooth and with no rinsing or removal."
223918271|NCT03350516|DIETARY_SUPPLEMENT|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
223918272|NCT03350516|DIETARY_SUPPLEMENT|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
223918273|NCT06225232|DRUG|Psilocybin combined with Psychotherapy|The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy. Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
223918274|NCT03581071|DRUG|TS-143|
223918275|NCT06376474|DRUG|Hemay005|15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
223918276|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C1|Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.
223918277|NCT05447338|PROCEDURE|Maitland C2|Maitland central posterior-anterior passive joint mobilization at C2: The patient will lie prone, the therapist behind the patient's head, with both thumbs will apply a central force on the spinous process of C2. The duration of the application will be up to five applications of 10 to 30 seconds in duration, depending on clinical judgment.
223918278|NCT05447338|PROCEDURE|SNAG C1|Sustained natural apophyseal slippage (SNAG) will be applied e.g. in the case of wanting to improve the left rotation. The therapist performs a sustained anterior glide to the C1 transverse process on the left. The participant will be seated, simultaneously rotating their head to the left while holding the SNAG. The glide of C1 will be maintained by the therapist until the participant's head returns to the neutral starting position. The same will be done, but in the opposite direction to improve the right rotation.
223918279|NCT05447338|PROCEDURE|Specific joint mobilization post muscle inhibition on C2|The therapist rotates the head to the right side until the final sensation of the movement is noted, either due to pain or muscular tension. From this position, the therapist asks the patient to rotate the head to the left side while offering resistance with both hands in the opposite direction, in such a way as to generate an isometric contraction of the rotator muscles of the head to the left. The therapist then asks the patient to hold the position for 6 seconds. Subsequently, the therapist with the finger in the transverse process of C1, pushes it in the postero-anterior direction and simultaneously (with the contratome hand) rotates the patient's head to the right. The technique is repeated until the ROM improves, always taking into account the patient's tolerance.
223940569|NCT05871658|BEHAVIORAL|electroacupuncture|electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
223940570|NCT03391024|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
223940571|NCT00167921|DRUG|Premarin® Vaginal Cream|
223940572|NCT00167921|DRUG|Premarin® oral tablets|
223940573|NCT03132298|OTHER|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
223530288|NCT05804929|OTHER|Observation without intervention|Observation of food intake, body composition, microbiota, genetics, metabolic rate, metabolomics.
223918280|NCT05447338|PROCEDURE|Myofascial inductions; Suboccipital induction|The therapist places his hands under the patient's head in such a way that he can palpate the spinous processes of the cervical vertebrae with his fingers. Next, slowly bring your fingers up until they contact the occipital condyles. At this time he should gently move his fingers downward, thus finding the space between the condyles and the spinous process of the axis. Next, flexing the metacarpophalangeal joints to 90°, slowly elevate the skull. The therapist's hands should remain together and the base of the skull should rest on their palms. The therapist should apply pressure with the index, middle and ring fingers of each hand. This pressure should be maintained for a few minutes until a release of the fascia is noted. In the last phase of the technique, the therapist, without releasing the pressure, opens his hands and slowly brings his head back.
223918281|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 1|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought
223918282|NCT05447338|PROCEDURE|Myofascial inductions; Horizontal induction of the TMJ.|The therapist places the middle fingers of both hands on the lingual aspect of the lower molar teeth and then gently presses towards the table. This pressure must be maintained for a minimum of 90 to 120 seconds. Afterwards, the therapist, very attentive to the changes in the direction of the fascial restriction, follows the release movement.
223918283|NCT05447338|PROCEDURE|Myofascial inductions; Posterior elongation of the cervical fascia in the supine position|Position of the patient, lying on the stretcher in the supine position. Therapist position: Sitting at the head of the table. Technique: With one of his hands, the therapist supports the patient's head on the occipital area and slowly brings it to flexo-elevation. With the other hand, he contacts the mass of the paravertebral muscles, placing the thumb on one side of the spine and the proximal interphalangeal joint of the index finger in flexion on the other. While one hand holds the head position, the other performs a downward vertical slide. The maneuver is repeated between 3 and 7 times in a slow and progressive manner.
223918284|NCT05447338|PROCEDURE|Myofascial induction; Angle of the scapula|Position of the patient, supine position, with the arm resting along the trunk. Position of the therapist, standing or sitting at the head of the table. The therapist places one of his hands under the shoulder blade, embracing the lower angle with the fingertips and bringing it slightly cranially. This maneuver frees access to the superior angle of the scapula, which makes it easier for the index and middle fingers of the other hand to contact the insertion of the angle. More sustained pressure is applied to this point, while the hand placed on the scapula moves in the direction of release.
223918285|NCT05447338|PROCEDURE|Myofascial induction sternocleidomastoid muscles|Objective, release the myofascial restrictions of the fascia of the SCM muscle. Position of the patient, supine position with the head near the upper edge of the stretcher. Therapist position. sitting at the head of the stretcher. Technique: The therapist, with one hand placed on the occipital region, gently rotates the patient's head. The other hand places it on the mass of the SCM muscle with the thumb at the point of insertion on the mastoid process. While one hand applies the rotational movement and a slight extension of the head, the other performs a transverse slide over the zone of restriction in the SCM muscle. A longitudinal sliding movement of the SCM muscle can be made between the thumb and forefinger of the executing hand.
223918286|NCT05447338|PROCEDURE|Myofascial induction of pectoralis major and minor|Objective, release the fascia of the pectoralis major and minor muscle. Position of the patient, supine position, with the arm abducted to about 120 degrees. Position of the therapist, standing next to the patient, at head height. Technique: with his cranial hand, the therapist holds the patient's arm, and with the caudal hand, placed in a prone position, contacts the space between pectoralis major and ribs. This contact is made with the fingertips. The pressure should be maintained for about 5 minutes. As the release occurs, both of the therapist's hands must adjust to the direction of the changes. When detecting the restriction in the pectoralis minor, the penetration should be deepened with the hand, sliding it over the ribs. Contact and restraints with the pectoralis minor and major are often particularly painful, forcing the therapist to apply controlled force.
223918287|NCT05447338|PROCEDURE|Myofascial induction; upper trapezius|Objective, release the myofascial restrictions of the upper trapezius. Position of the patient, supine, with the elbow flexed and the hand resting on the abdomen, and the arm in a slight abduction. Therapist position, sitting at the head of the table. Technique: The therapist places his hand on the patient's shoulder so that he can grasp the fibers of the upper trapezius between the index, middle, and ring fingers above and the thumb below. Subsequently, he exerts gentle and sustained pressure overcoming three restraining barriers.
223918288|NCT05447338|PROCEDURE|Myofascial induction, of the fascia of the subscapularis muscle|Position of the patient, supine, with the arm raised about 90-160 degrees, depending on the degree of movement restriction. Therapist position, standing at the head of the table. Phase A With his cranial hand, the therapist holds the patient's arm and performs very gentle traction. The palm of the caudal hand, thumb up, is placed on the outer edge of the scapula, as close as possible to the glenohumeral joint. A slight traction is performed with both hands in opposite directions, subsequently following the direction of release. Phase B, The thumb of the caudal hand slightly invades the space between the inner aspect of the scapula and the thorax. The rest of the application is performed as in phase A. Phase C, the therapist places his caudal hand in a prone position and slowly penetrates the aforementioned space with the tips of the fingers. sustained for a time ranging between 90 seconds and 5 minutes, following the release stages.
223940574|NCT03132298|OTHER|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
223940575|NCT03298789|OTHER|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
223918289|NCT05447338|PROCEDURE|Intraoral myofascial induction of the masseter|Position of the patient, supine position, on the stretcher without the pillow. Position of the therapist, sitting at the head of the table. Technique: The therapist, with the index of his hand, contacts the masseter just below the zygomatic arch and inside the mouth. To ensure proper contact on the masseter, the patient is asked to attempt to close the mouth. Once the muscle is correctly located, the patient should immediately relax the masseter. Next, the therapist compresses the masseter between his index finger and thumb. You have to wait long enough for the release to occur. Sometimes both hands are used by placing the forefinger of the other hand on the outer surface.
223918290|NCT05447338|PROCEDURE|Deep myofascial induction of the external pterygoid|"Objective, release the myofascial restrictions and recover the functional coordination of the external pterygoid muscles.~Position of the patient, supine position, on the stretcher without the pillow. Therapist position, sitting at the head of the table. Technique: The therapist palpates the temporomandibular joint with the index or middle finger of one hand. With the index finger of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs."
223918291|NCT05447338|PROCEDURE|Intraoral mifascial induction of the internal pterygoid|Objective, release the restrictions of the internal pterygoid fascia. Position of the patient, supine position on the stretcher. Therapist position, sitting laterally at the head of the stretcher and looking at the patient. Technique: Therapist palpates the TMJ with the index or middle finger of one hand. With the index of the other hand, he contacts the pterygoid inside the mouth and maintains pressure until release occurs. You have to wait three consecutive releases.
223918292|NCT05447338|PROCEDURE|Myofascial inductions; Synchronization of the temporal bones PHASE 2|The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought.
223918293|NCT04031209|DEVICE|G7 Acetabular System|All patients will receive G7 Acetabular System
223918294|NCT05693337|DEVICE|Forward Looking Infrared Radar (FLIR) thermal imaging|The FLIR camera will collect temperature recordings pre-procedure and 5 minutes post-procedure, which will be used to calculate a delta T to assess achievement of a successful sympathetic block.
223918295|NCT06189170|DRUG|KP405|Experimental drug
223918296|NCT06189170|DRUG|Placebo|Placebo
224089558|NCT02828267|BEHAVIORAL|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
224089559|NCT00601978|DRUG|carbidopa/levodopa|
224089560|NCT00601978|DRUG|Carbidopa/Levodopa/Entacapone|
224089561|NCT06121128|PROCEDURE|Inspiratory Muscle Training (IMT)|"The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week."
224089562|NCT06121128|PROCEDURE|Normal Breathing|No IMT performed
224089563|NCT05168618|BIOLOGICAL|Atezolizumab|Given IV
224089564|NCT05168618|DRUG|Cabozantinib S-malate|Given PO
224089565|NCT00150189|BEHAVIORAL|Sucrose|
223530289|NCT02117011|OTHER|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
223530290|NCT04750421|DEVICE|Transillumination Venolux®|Transillumination Venolux® method was used on the other half of the face before injections to visualize veins.
223530291|NCT06102395|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
223530292|NCT06102395|DRUG|Cisplatin|Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
223530293|NCT06102395|DRUG|Carboplatin|Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
223530294|NCT06102395|DRUG|Nedaplatin|Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
223530295|NCT06102395|DRUG|Nab paclitaxel|Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
223530296|NCT06102395|DRUG|Docetaxel|Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
224089566|NCT03265587|OTHER|No intervention|No intervention
224089567|NCT05890703|DRUG|IMP2 (lidocaine-23%-tetracaine-7% gel)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
223530297|NCT06102395|DRUG|Liposomal paclitaxel|Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
223530298|NCT06102395|DRUG|Fluorouracil|Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
223530299|NCT03186638|DRUG|Ibuprofen|Given PO
223530300|NCT03186638|OTHER|Placebo|Given PO
223530301|NCT03186638|OTHER|Questionnaire Administration|Ancillary studies
223530302|NCT00948350|PROCEDURE|awake intubation|two anesthesia techniques
223530303|NCT01055145|DRUG|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
223530304|NCT03237806|DRUG|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
223530305|NCT03237806|DRUG|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
223918297|NCT05104983|DRUG|Sirolimus|The investigational drug product to be used in this study is sirolimus, provided in oral suspension.
223918298|NCT05104983|DRUG|Placebo|Matching placebo
223918299|NCT05473637|DIAGNOSTIC_TEST|MRI|Patients will repeat study-protocol MRI at baseline (enrollment) and at least once in 1 year or 2 years follow-up (depends on availability).
223918300|NCT04711759|DEVICE|High flow nasal cannula|High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.
223918301|NCT04711759|DEVICE|Standard oxygen therapy|Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.
223918302|NCT06622135|DEVICE|Tasso Lancet Device|blood samples will be obtained from all participants using Tasso device
223918303|NCT06618859|BEHAVIORAL|Time-restricted eating|Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
223918304|NCT06618859|BEHAVIORAL|Active control|Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
223918305|NCT05211869|BEHAVIORAL|T1D-CATCH|"As defined by the CDC, a CHW is a frontline public health worker who is a trusted member of a community or who has a thorough understanding of the community being served, and leverages this unique position to link health systems, social services, and communities. CHWs engender trust with patients by having direct community and lived experience, offering specific support and empathy that may be difficult for other diabetes care professionals to provide. In addition, CHWs have firsthand understanding of cultural barriers to traditional western healthcare and can promote patient-centered culturally-relevant care. They enhance team-based care by helping providers with extra outreach, social needs management, time-consuming tasks, and aligning patient-provider priorities.~CHWs in this project will provide social needs assessment and management, introduction to diabetes technologies, and support for onboarding to technology."
223918306|NCT06870227|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform emergency eclampsia in labour
223918307|NCT06866626|BEHAVIORAL|Theory-Based Nutrition Education Intervention to Improve Infant and Young Child Feeding Practices and WASH Practices Among Turkana Caregivers|This nutrition education intervention was designed following the DESIGN procedure, informed by the Theory of Planned Behavior, and employed health literacy principles. The nutrition education sessions were held Monday through Saturday for a total of 8 weeks in a community building. This nutrition education intervention had 4 modules, module one covered the recommended breastfeeding practices, including early initiation of breastfeeding, exclusive breastfeeding and continued breastfeeding. The second module was on the young child feeding practices, with a focus on the quality and quantity of the child's meal. The third module entailed WASH practices such as disinfection of drinking water, harms of open defecation, and other personal and household hygiene practices. The fourth module served as a comprehensive review of all previous modules.
223940576|NCT03298789|OTHER|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
223940577|NCT03619642|OTHER|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
223940578|NCT05162716|DEVICE|Single-chamber pacemaker implantation with left bundle branch area pacing|A prepectoral single-chamber pacemaker is implanted with a 3830 (Medtronic) IS-1 pacing lead screwed via the right ventricle in the deep interventricular septum in order to capture the left Purkinje system on the left ventricular endocardial side.
223940579|NCT00034489|DRUG|pemetrexed|
223940580|NCT00034489|DRUG|gemcitabine|
223940581|NCT00196521|DEVICE|Tension-free vaginal tape obturator system|
223940582|NCT01044888|DRUG|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
223530306|NCT04363346|DRUG|FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.
223530307|NCT01478425|DEVICE|Lipidic Microemulsion|Topical nasal, twice a day
223530308|NCT01478425|DEVICE|Saline|Topical Nasal, twice a day
223530309|NCT00000720|DRUG|Globulin, Immune|
223530310|NCT00000720|DRUG|Zidovudine|
223940583|NCT03358433|OTHER|Exercise|
223940584|NCT01767350|PROCEDURE|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
223940585|NCT04693949|OTHER|NAC|Pretreatment of zirconia RBFDP with nanostructured alumina coating after milling of RBFDP's framework
223940586|NCT04693949|OTHER|APA|Air-borne particle abrasion of zirconia RBFDPs prior to bonding
223940587|NCT05481905|DRUG|ENX-101|Adjunctive treatment to current antiseizure medication
223940588|NCT04776096|DRUG|Bepotastine Besilate 1.5% PF|Bepotastine besilate 1,5% Preservative free ophthalmic solution
223940589|NCT04776096|DRUG|Olopatadine Hydrochloride 0.2% BAK|Olopatadine hydrochloride 0.2% with BAK as preservative
223940590|NCT03293914|BEHAVIORAL|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
223530311|NCT02748447|DEVICE|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
223918308|NCT06866626|DIETARY_SUPPLEMENT|Harvest Lentil Vegetable Blend|Harvest Lentil Vegetable Blend is a dehydrated supplemental food produced from natural ingredients namely, rice, carrots, lentils and onions. This product was prepared by mixing it with water and boiling the mixture for approximately 25-35 minutes to a mid-consistency. In this study we implemented a blanket supplementary feeding program where all the recruited children in the intervention group received a meal of Harvest Lentil Vegetable Blend. The feeding program was on-site, and participating children aged 6-12 months received three-quarters of a cup of the supplemental food, (\~ 52 kcal/d). Children aged 13-23 months received 1 cup of the supplemental food (∼69 kcal/d), whereas children aged 24-59 months received 2 cups of the supplemental food (∼138 kcal/d). The feeding was implemented for 6 days a week (Monday through Saturday) for a total of eight weeks.
223918309|NCT06871358|DRUG|Atorvastatin 80mg|80 mg of Atorvastatin are loading in first medical contact (Emergency Department) before primary PCI
223918310|NCT06871358|DRUG|Placebo|Only given a loading DAPT without loading Atorvastatin 80 mg
223918311|NCT06869655|DEVICE|Threshold Loading device|threshold loading device for diaphragmatic resistance training
223918312|NCT06869655|DEVICE|Volumes Oriented Spirometry|group B will receive this interentions
223918313|NCT06870955|PROCEDURE|using biomimetic abutments|The subjects recieved the biomimetic healing abutments during the second-stage surgery, and the biomimetic prosthetic abutments were used to complete the implant restoration.
223918314|NCT06867432|DRUG|Combination Product：t: SIRT-Y90 +HAIC+Atezolizumab + Bevacizumab|"Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.~HAIC：administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks."
223918315|NCT06867237|DEVICE|Suction cuff pressure|Use the device to do continuous management of suction cuff pressure and subglottic irrigation suction
223530312|NCT03787654|DEVICE|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60\~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
223918316|NCT06865625|BEHAVIORAL|mobile application|In this study, unlike similar studies in the literature, participants were grouped based on their oral hygiene status.
223918317|NCT06865625|BEHAVIORAL|traditional oral hygiene motivation|The group demonstrating the brushing technique on a braces model
223918318|NCT06871085|DEVICE|Stability Sock|Use of a stability sock
223918319|NCT06866561|OTHER|aerobic exercise|The exercise group participated in a supervised aerobic exercise program consisting of walking on a treadmill for 30 minutes per day, 3 days per week, at an intensity of 40-60% of maximal heart rate for 4 weeks. Additionally, they were shown an exercise program at the initial assessment that included balance, posture, and endurance exercises using body weight and weights to be performed 3 days a week, with 3 sets of 10 repetitions. The control group did not participate in any exercise program.
223918320|NCT06866561|OTHER|cholecalciferol|Participants were prescribed 2000 IU of vitamin D (cholecalciferol) daily for 12 weeks.
223918321|NCT06866561|OTHER|calcium carbonate|Participants were prescribed 1200 mg of calcium carbonate daily for 12 weeks.
223918322|NCT06866483|BEHAVIORAL|Social media recruitment|Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment
223918323|NCT06866483|BEHAVIORAL|Self-Assessment|Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups
223918324|NCT06866483|BEHAVIORAL|Follow-up|Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis
223918325|NCT06871371|DEVICE|Sevoflurane (Volatile Anesthetic)|Both groups will be given sevoflurane and one group will be given low current anesthesia and the other group will be given medium flow anesthesia.
223918326|NCT06871371|DEVICE|low- medium flow anesthetic machine|The study aims to compare the effects of low and normal flow sevoflurane anesthesia on the frontal QRS-T angle and cerebral oxygenation in laparoscopic cholecystectomy surgery.
223918327|NCT06871007|DRUG|Nivolumab|Nivolumab 40 mg on Day 2 is added to dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R).Standard guidelines for conducting the DA-EPOCH-R protocol will be used.
223918328|NCT06868888|OTHER|Blood collection|Erythrocyte osmotic deformability was evaluated via osmotic gradient ektacytometry.
223918329|NCT06868888|OTHER|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary Exercise Testing (CPET) is a non-invasive assessment that evaluates the integrated function of the cardiovascular, pulmonary, and muscular systems during exercise.
223918330|NCT06871566|OTHER|Artificial Intelligence-Supported Occupational Therapy Program|The AI-supported occupational therapy program was individually implemented by an occupational therapist over 8 weeks, with 2 sessions per week, each lasting 45 minutes. A touchscreen tablet, touch pen, and external camera were utilized during the sessions. At the beginning of the program, technological devices and artificial intelligence tools were introduced to the children. For the goals and detailed intervention program of the 8-week schedule
223918331|NCT06869993|DIETARY_SUPPLEMENT|Meal Kit plus Mobile Culinary Medicine Education|This intervention will involve four phases: (1) a baseline assessment; (2) a 7-day monitoring phase, (3) a 30-day intervention phase in which all households receive weekly meal kits delivered to their home in addition to mobile culinary medicine education; and (4) a follow-up assessment.
223918332|NCT06868732|DRUG|JSKN016|Administered intravenously according to protocol.
223918333|NCT06868732|DRUG|Carboplatin|AUC 4, Q3W, administered intravenously according to protocol.
223918334|NCT06868732|DRUG|Furmonertinib Mesylate|160mg, qd, administered according to protocol.
223918335|NCT06868732|DRUG|Ivonescimab|20mg/kg, Q3W, administered intravenously according to protocol.
223918336|NCT06868732|DRUG|Docetaxel|60mg/m\^2, Q3W, administered intravenously according to protocol.
223918337|NCT06868732|DRUG|Tislelizumab|200mg, Q3W, administered intravenously according to protocol.
223918338|NCT06868732|DRUG|Pembrolizumab|200mg, Q3W, administered intravenously according to protocol.
224089568|NCT05890703|DRUG|IMP1 (EMLA 5% cream)|Applied in a 2 mm thick even layer for 30 minutes on the ulcer with an occlusive dressing. During the second treatment the same dose is applied. Immediately after removal of the occlusive dressing, the rest of the preparation will be removed and sharp debridement will be performed. In order to minimise bias in this crossover trial, the localisation of start (most distal part of Wound) of sharp debridement and the sequence of sharp debridement (if more than one wound; from the largest to the smallest) is defined in the first visit.
224089569|NCT04691661|DRUG|Radotinib HCl 50 mg|Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.
224089570|NCT04691661|DRUG|Placebo|Placebo
224089571|NCT01136551|DRUG|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
224089572|NCT00909272|PROCEDURE|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
224089573|NCT00909272|PROCEDURE|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
224089574|NCT02639377|DRUG|Chlorhexidine gluconate|
224089575|NCT02639377|DRUG|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
224089576|NCT01542307|BIOLOGICAL|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
223918339|NCT06872801|DEVICE|High-Flow Nasal Cannula|To compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD.
223918340|NCT06872801|DEVICE|Noninvasive Ventilation|to compare the effects of NIV (Trilogy Evo®) and HFNC (myAirvo2®) in patients with chronic hypercapnic COPD
223918341|NCT06872281|DEVICE|Fractional bipolar radiofrequency|The treatment group will receive a single treatment of intravaginal fractional bipolar radiofrequency therapy.
223918342|NCT06872281|DEVICE|Sham device|The sham group will receive treatment with a specialized sham device that mimics the treatment group's equipment. There are no differences in the design of the tip device, the auditory signal (beeping), or the pulse count display.
223918343|NCT06873243|BEHAVIORAL|Learning Health System Approach|Our intervention will be informed by the framework for designing LHSs developed by The Health Foundation and the updated framework for developing and evaluating complex evaluations commissioned by the UK Medical Research Council and National Institute for Health Research.The updated framework considers not only if an intervention is effective, but also whether the intervention is acceptable, implementable, cost-effective, scalable, and transferrable across contexts. The trial will encompass three of the four key components of complex intervention design: Development of an intervention Assessment of feasibility of the intervention, and Evaluation of the intervention. . We anticipate that a Plan Do Study Act (PDSA) cycle of quality improvement will be most suited to the Thai context as this approach is currently being promoted by the Thai Ministry of Public Health.
223918344|NCT06681103|BEHAVIORAL|Personalized Normative Feedback|Those participating in this condition will receive a personalised brief report which summarises the results of their initial assessment. The PONF will comprise the following elements: (1) Details of the main gambling and trading activities performed, including frequency of engagement and amount of money spent; (2) Scores on the criteria of pathological trading and/or PGSI (pathological gambling), together with an interpretation of the results and the level of severity; (3) Summary of the areas (financial, emotional, etc.) that the participant has indicated as being affected by gambling or trading. All results will be accompanied by graphs enabling participants to compare their scores with the average scores of the Spanish population of the same sex and age range. To prevent an increase in behaviour in participants whose frequency or intensity of gambling/trading is below the norm, as recommended by Newall et al. (2023), the normative data will include extreme averages and percentages
224089577|NCT01542307|BIOLOGICAL|Room air|Placebo
224089578|NCT03222271|DEVICE|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
224089579|NCT02790229|OTHER|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
223918345|NCT06871800|OTHER|blood withdrawal|10 ml of blood, two 5 ml tubes suitable for serum isolation. Blood collection will be done at admission in the rehabilitation department (T0), after completing 50% of their rehabilitation program (T1), and at discharge (T2)
223918346|NCT06873087|DRUG|İsotretinoin|Isotretinoin treatment at a dose of 0.3 mg/kg/day for 3 months
223918347|NCT06871618|OTHER|Retrospective|Retrospective Operative risk in patients undergoing instrumental abortion
223918348|NCT06871852|OTHER|a video-based physiotherapy and exercise program.|Video-Based Intervention Group: Participants in this group will receive videos detailing migraine triggers, precautionary measures, and a physiotherapy and exercise program. Each exercise will be thoroughly explained by a physiotherapist in the videos, enabling participants to perform the exercises correctly by following the verbal and visual instructions.
223918349|NCT06871852|OTHER|brochure-based physiotherapy and exercise program.|"Brochure-Based Intervention Group: Participants in this group will be provided with brochures that include information on migraine triggers, precautionary measures, and rehabilitation exercises accompanied by visual aids. The exercises will be detailed with written instructions and illustrations.~Exercise Program: The exercise program will include self-massage techniques for specific muscle groups, self C1-C2 joint mobilization, cervical region exercises, cognitive exercises, and progressive relaxation exercises for the back and face."
223918350|NCT06872554|OTHER|Supervised exercise training|The intervention will consist of a 12-week multicomponent training program. This program will include exercises focused on strength training, mobility, stretching, and breathing. Throughout the 12 weeks, there will be a progressive increase in training volume-understood as the number of sets and repetitions performed-and in intensity, defined as the difficulty involved in performing the exercises. After each training session, data will be collected on the perceived effort and the pain in the area affected by the abdominal hernia.
223918351|NCT06872554|OTHER|Non supervised exercise training|The intervention will consist of a 12-week multicomponent training program. This program will include exercises focused on strength training, mobility, stretching, and breathing. Throughout the 12 weeks, there will be a progressive increase in training volume-understood as the number of sets and repetitions performed-and in intensity, defined as the difficulty involved in performing the exercises. After each training session, data will be collected on the perceived effort and the pain in the area affected by the abdominal hernia. This program will be realized for the participants at home, with the use of a specified training App, without the supervision of a sport science professional.
223918352|NCT06873347|DEVICE|Procedure type|"• Patients undergoing one of the following surgeries:~* Supra cervical hysterectomy~* Total hysterectomy~* Breast conserving surgeries: B-plastic + periareolar mastopexy~* Breast conserving surgeries: segmental resection"
223918353|NCT06873347|DEVICE||"• A dataset from procedure types other than the above mentioned to the type unknown is assigned to this type."
223918354|NCT06872333|DRUG|Alemtuzumab|Alemtuzumab (Campath) will be administered IV over 2 hours on day -8 to day -4.
223918355|NCT06872333|RADIATION|Total Body Irradiation|400 cGy in 2 split fractions will be administered per Department of RadiationOncology SOPs.
223918356|NCT06872333|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines
223918357|NCT06872333|DRUG|Thymoglobulin|"ATG will be administered IV every 24 hours beginning on day -8 for all patients.~Dosing will be model-based using Bayesian methodology13,14,15. Total doses and total number of doses (1-4 doses) will be determined based on absolute lymphocyte count and weight."
223918358|NCT06872333|DRUG|Fludarabine|Fludarabine will be administered IV over 1 hour every 24 hours on day -5 to day - 2. The daily dose of fludarabine will be determined by model-based dosing utilizing Bayesian methodology with a cumulative area under the curve (cAUC) of 20 mg\*hr/L (range 18-22 mg\*hr/L).
223918359|NCT06872333|DRUG|Busulfan|Busulfan dosing and administration and therapeutic drug monitoring (TDM) per institutional guidelines. Initial busulfan dosing will be determined by model-based dosing utilizing Bayesian methods with a cumulative area under the curve (cAUC) of 75 mg\*hr/L.
223918360|NCT06872333|DRUG|Thiotepa|Thiotepa will be administered at a dose 5 mg/kg IV every 12 hours on day - 7 over 2 hours. Patients will undergo thiotepa skin care per institutional guidelines
223918361|NCT06872333|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered at a dose of 14.5 mg/kg over 2 hours IV daily on days -6 and -5. Cyclophosphamide dosing is calculated based on actual body weight (ABW).~For Arm D - Cyclophosphamide 50 mg/kg IV will be administered over 2 hours on days +3 and~+4. Cyclophosphamide dosing for post-transplant is calculated based on ideal body weight (IBW) unless patient weighs less than IBW, in which case actual body weight (ABW) will be used."
223918362|NCT06872333|DRUG|Sirolimus|Patients on Arm A and Arm D will receive sirolimus; beginning on day -3 and continuing until day +180 for patients on Arm A or beginning on day +5 and continuing until 1 year post transplant for patients on Arm D.
223918363|NCT06872333|DRUG|Tacrolimus|Patients on Arm B and Arm C will receive tacrolimus, beginning on day -3 and continuing until day +180. Tacrolimus dosing and monitoring will be per institutional guidelines.
223940591|NCT06264583|OTHER|HDV screening|1\. Analyze the rate of HDV-testing and evaluate the prevalence of HDV-infection by testing.
223940592|NCT02448524|DEVICE|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
223530313|NCT03787654|DEVICE|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
223918364|NCT06872333|DRUG|Mycophenolate Mofetil|MMF will begin on day -3 (Arm A, B \& C) or day +5 (Arm D). Patients treated on adult service will receive 15 mg/kg (max 1500 mg/dose) given every 12 hours, rounded to nearest 250 mg. Patients on pediatric service will receive 15 mg/kg (max 1000 mg/dose) given every 8 hours. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. MMF will be stopped at day +30 (Arms A, B \& C) or day +35 (Arm D) or 7 days after engraftment, whichever day is later, if no acute GVHD.
223918365|NCT06871605|PROCEDURE|ultrasound-guided transversalis fascia plane block|With the patient in the lateral decubitus position, an 8-12 Hz linear ultrasound (US) probe is placed transversely over the iliac crest. The external oblique (EO), internal oblique (IO) and transversus abdominis (TA) muscles are identified so that the abdominal muscles are in the field of view. The TA muscle is then advanced posteriorly until it tapers to the thoracolumbar fascia with its aponeurosis adjacent to the quadratus lumborum (QL) muscle. The 22 gauge block needle is advanced in plane with the US probe. After placing the needle tip in the virtual triangular plane between the posterior edge of the TA muscle, the QL and the underlying transversalis fascia, 4 mL of 0.5% bupivacaine + 2 mL of a total of 8 mg dexamethasone + 4 mL of saline are injected for a total volume of 10 mL.
223918366|NCT06871605|PROCEDURE|ultrasound-guided ilioinguinal and iliohypogastric nerve block group|With the patient in the supine position, an 8-12 Hz linear ultrasound (US) probe is placed medial and cephalal to the anterior superior iliac spine (ASIS), transversely between the ASIS and the umbilicus. The external oblique (EO), internal oblique (IO) and transversus abdominis (TA) muscles are identified so that the abdominal muscles are in the field of view. The II-IH nerves are hyperechogenic in the fascial plane between the IO and TA muscles. A 22 gauge block needle is advanced in plane with the US probe. When the needle tip is advanced to the II and IH nerves, 4 mL of 0.5% bupivacaine + 2 mL total 8 mg dexamethasone + 4 mL saline is injected for a total volume of 10 mL.
223918367|NCT06623630|DRUG|Cyclophosphamide|Standard of care
223918368|NCT06623630|DRUG|Ciltacabtagene Autoleucel|Standard of care
223918369|NCT06623630|RADIATION|Total body irradiation|Radiation doses delivered to the entire body
223918370|NCT06626308|OTHER|brain functional MRI|visual protocol stimulation during brain functional MRI
223530314|NCT03787654|DRUG|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
223918371|NCT05488522|BIOLOGICAL|SBRT + atezolizumab and bevacizumab|"Stereotactic Body Radiotherapy (SBRT) is a radiation procedure that delivers precise doses of radiation in fractions. See following section for more information on the schedule, dose, volume, and simulation of SBRT.~Atezolizumab is an FDA-approved immune checkpoint inhibitor that is used in the treatment of advanced HCC. It is administered as a flat-dose 1200 mg intravenous infusion every three weeks.~Bevacizumab is an FDA-approved anti-VEGF monoclonal antibody that is used in the treatment of advanced HCC in combination with atezolizumab. It is administered as a weight-based dose of 15 mg/kg intravenous infusion every 3 weeks."
223918372|NCT06862570|DRUG|2% lignocaine with epinephrine 1.8 ml(36mg/ml lignocaine HCL, epinephrine bitartrate 0.0324mg/ml)|2% lignocaine with epinephrine 1.8 ml(36mg/ml lignocaine HCL, epinephrine bitartrate 0.0324mg/ml)
223918373|NCT06862570|DRUG|4% Articaine with epinephrine 1.7 ml (40mg/ml Articaine HCL, epinephrine bitartrate 0.018 mg/ml)|4% Articaine with epinephrine 1.7 ml (40mg/ml Articaine HCL, epinephrine bitartrate 0.018 mg/ml)
223918374|NCT05589363|DRUG|ABC block with bupivacaine/liposomal bupivacaine|Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
223918375|NCT05589363|DRUG|ABC block with saline|Patients will be randomized to receive an ABC block using normal saline
223918376|NCT06676189|DEVICE|total knee arthroplasty with medial pivot polyethylene|total knee arthroplasty with medial pivot polyethylene
223918377|NCT06676189|DEVICE|total knee arthroplasty with ultra-congruent polyethylene|total knee arthroplasty with ultra-congruent polyethylene
223530315|NCT01263119|DRUG|Warfarin|10-mg warfarin oral dose
223530316|NCT01263119|DRUG|LY2216684|18-mg LY2216684 oral dose
223530317|NCT02385071|DRUG|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
223530318|NCT02385071|DRUG|Treatment B|Treatment B (3\*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
223918378|NCT06624956|DRUG|glucose, insulin, and potassium (GIK)|"GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV."
223918379|NCT06624956|DRUG|Crystalloid Infusion|placebo
223918380|NCT06675539|DIAGNOSTIC_TEST|French version PAWSS|French version of the Prediction of Alcohol Withdrawal Severity Scale
223918381|NCT04114136|DRUG|Nivolumab or Pembrolizumab (dependent upon approved indication)|Anti-PD-1 mAb (monoclonal antibody)
223918382|NCT04114136|DRUG|Metformin|Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
223918383|NCT04114136|DRUG|Rosiglitazone|A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
223918384|NCT06613763|DRUG|RAY1225|Administered SC
223918385|NCT06269809|PROCEDURE|Temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
223918386|NCT06269809|PROCEDURE|No temporary clipping of the uterine arteries and the utero-ovarian ligmants.|Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
224278544|NCT04635332|BEHAVIORAL|Food literacy and physical activity promotion interactive group sessions + Developed health promotion intervention materials (booklet)|"Information, skills training, goal setting and feedback interactive group sessions to improve food literacy aimed at increasing consumption of fruits and vegetables~Information, skills training, goal setting and feedback interactive group sessions to increase engagement in moderate physical activity~Information and skills training to increase ability to evaluate nutrition information~In general, focus will be on increasing knowledge, skills and self-efficacy to develop a lifelong healthy and gastronomic relationship with food and physical activity."
223530319|NCT02385071|DRUG|Treatment C|Treatment C (3\*50 mg dispersible SMV tablets dispersed in water under fed conditions).
223918387|NCT00760630|DEVICE|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
223918388|NCT06445465|DRUG|[18F]MNI-1216|\[18F\]MNI-1216 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of α-synuclein deposits.
223918389|NCT06363747|OTHER|Very Low Calorie Diet|Optifast is a medically supervised very low-calorie diet (VLCD) diet that safely induces caloric restriction
223918390|NCT02781883|DRUG|BP1001 in combination with Ventoclax plus decitabine|BP1001 in combination with Ventoclax plus decitabine
224089580|NCT02790229|OTHER|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
224278545|NCT04635332|BEHAVIORAL|Developed health promotion intervention materials (booklet).|In the control arm, participants will only be given the developed intervention materials (designed in form of the usual awareness programs). No group sessions will be conducted
224278546|NCT05647707|DIETARY_SUPPLEMENT|L-Carnitine|The 36 patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose of 50 mg/kg IV every 8 h.
224278547|NCT03843515|DRUG|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
223530320|NCT02385071|DRUG|Treatment D|\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fed conditions.
223530321|NCT02385071|DRUG|Treatment E|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3\*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
223530322|NCT02385071|DRUG|Treatment F|3\*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3\*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
223530323|NCT03101800|DRUG|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
223530324|NCT03101800|DRUG|Azathioprine|Standard weight based azathioprine dosage
223918391|NCT02781883|DRUG|BP1001 plus decitabine|BP1001 plus decitabine in ventoclax intolerant or resistant subjects
223918392|NCT06684028|DRUG|68Ga-FAPI-JNU|Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
223918393|NCT05625646|OTHER|quality assurance program|The program consists of an online quiz using a multiple choice questionnaire (MCQ) design. The participants are expected to complete the online MCQ at 3, 6, 9, and 12 months following baseline. The MCQ includes still-pictures and video sequences of the 10 application specific POCUS examinations from the course curriculum. Through 15-20 questions, the quiz tests the OSAUS dimentions Each question has four possible answers of which up to three answers are correct. Each MCQ will have ten questions pertaining to pathologies within the ten applications of the curriculum. Further, there will be five to ten questions relating to image recognition, image optimisation, ultrasound artifacts. Once each MCQ is finalized, the participating GP's will receive feed-back on the answers with suggestions for improvement and guidance toward continuing self-directed learning.
223918394|NCT06622590|BIOLOGICAL|QIV|Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
224089581|NCT04578210|BIOLOGICAL|T memory cells and NK cells|Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
224089582|NCT03335501|DEVICE|Insulin pump|The participant's insulin pump will be used to infuse insulin
224089583|NCT03335501|DEVICE|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
224278548|NCT00006371|DRUG|aminoglutethimide|
224278549|NCT00006371|DRUG|ketoconazole|
224278550|NCT00006371|DRUG|therapeutic hydrocortisone|
224278551|NCT00399893|DRUG|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
224278552|NCT00399893|DRUG|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
224278553|NCT01363011|DRUG|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
224278554|NCT01363011|DRUG|COBI|COBI 150 mg tablet administered with food orally once daily
223918395|NCT06622590|BIOLOGICAL|QIV control|Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
223918396|NCT06874673|DRUG|Pronase|During the colonoscopy procedure on participants in Group A, when colitis with mucosal mucus impeding visualization is encountered, the gastroenterologist uses a solution of pronase (200 U/mL) delivered through the endoscope's biopsy forceps to irrigate the affected area. Images are captured before and after the irrigation, and a score for improvement in mucosal clarity is assigned. The location of the lesion, irrigation time, and volume of fluid used are recorded. During endoscope withdrawal, the same area is reassessed for improvement in clarity, and the disease activity is evaluated. Biopsy specimens are taken from the most severe inflammation site for histopathological examination.
223918397|NCT06874673|DRUG|Saline (NaCl 0,9 %) (placebo)|During the colonoscopy procedure on participants in Group B, when colitis with mucosal mucus impeding visualization is encountered, the gastroenterologist uses saline delivered through the endoscope's biopsy forceps to irrigate the affected area. Images are captured before and after the irrigation, and a score for improvement in mucosal clarity is assigned. The location of the lesion, irrigation time, and volume of fluid used are recorded. During endoscope withdrawal, the same area is reassessed for improvement in clarity, and the disease activity is evaluated. Biopsy specimens are taken from the most severe inflammation site for histopathological examination.
223918398|NCT06874218|DEVICE|prefabricated CAD-CAM Zirconia crowns according to Egyptian sizes.|compare prefabricated zirconia crowns according to the Egyptian crown sizes with the international standard zirconia crowns sizes for primary upper central incisors
223918399|NCT03812913|BEHAVIORAL|psychological evaluation|"* Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~* Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
223918400|NCT05807958|DEVICE|Skin Prick Automated Test|A skin prick automated test will be performed in each participant.
223918401|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
223918402|NCT02919917|DRUG|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
223918403|NCT06002386|DEVICE|Vsling|Implantable ventricular repair device
223716758|NCT01007773|DRUG|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
223918404|NCT06363591|PROCEDURE|Surgery|Wise or wide excision
223918405|NCT06363591|OTHER|No Surgery|No wide local excision
223918406|NCT05347771|DRUG|Dupilumab|Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
223918407|NCT05347771|DRUG|Placebo|The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
223918408|NCT02905110|DRUG|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
223918409|NCT02905110|DRUG|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
223918410|NCT02905110|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
223918411|NCT04827251|DIETARY_SUPPLEMENT|Coffee|"Participants will receive Nespresso coffee maker Essenza model. The coffee Nespresso blend voluto will be provided (caffeinated and decaffeinated). The patients will have to take four cups of espresso per day (three cups a day for patients aged 65 and over)."
223918412|NCT05276219|DRUG|Furosemide Injection|A diuretic (iv furosemide) strategy for decongestion in acute heart failure
223918413|NCT05276219|DRUG|Isosorbide Dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure
223918414|NCT05276219|DRUG|Furosemide and isosorbide dinitrate|Vasodilation (iv isosorbide dinitrate) strategy for decongestion in acute heart failure AND A diuretic (iv furosemide) strategy for decongestion in acute heart failure
224099312|NCT02762058|PROCEDURE|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
223918415|NCT06872255|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"All procedures will be performed by an experienced endoscopist, with a sufficient experience in third space endoscopy (at least 100 POEMs) under general anesthesia (internal preoperative examination is necessary) with a high-definition endoscope, fitted with a plastic distal attachment. Before the procedure, the patients will be administered intravenous antibiotics. Exclusively CO2 will be used for insufflation. POEM will be performed in a similar way as in patients with achalasia - the procedure consists of 4 steps: (1) mucosal incision and tunnel entry, (2) submucosal tunneling, (3) myotomy, and (4) closure of the mucosal entry with endoscopic clips or other closure devices. Perioperative protocol might differ according the usual way of performing POEM in a given center."
223918416|NCT06627075|PROCEDURE|Surface Guided RadioTherapy (SGRT) without mask|"Firstly, patients are positioned in a vacuum mattress that moulds their head, neck and shoulders for a reference scan.~During the treatment sessions, patients are positioned according to the reference scan, using the surface camera system.~Once the observed offsets have been applied, the patient's surface is captured. Treatment can then begin, with continuous monitoring of displacements by the surface camera system. Automatic beam interruption is provided during treatment in the event of motion detection exceeding the standard tolerance threshold (\>3 mm).~If the use of a thermoformed mask during your treatment prove necessary, for whatever reason, will not result in a halt to the research.~Patients receive between 10 and a max of 35 radiotherapy sessions. The follow-up period begins after the last radiotherapy session, and patients are assessed at 4 or 6 weeks and at 3 months by a radiotherapist."
223918417|NCT06072924|BEHAVIORAL|Isotonic Endurance Exercise|Pressing tongue against a pressure sensor at the set number of repetitions per session (individualized per participant) 3 times per day
223918418|NCT06072924|BEHAVIORAL|Sham Exercise|Pressing tongue against pressure sensor at a low threshold (1-15kPa) 30x/day
223716759|NCT01007773|DRUG|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP \< 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
223716760|NCT01007773|DRUG|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
223918419|NCT00591175|BEHAVIORAL|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
223918420|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
223918421|NCT00591175|BEHAVIORAL|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
223918422|NCT06817564|BEHAVIORAL|AI-PEF|Participants will follow a 12-week walking program with five 30-minute sessions per week, progressively increasing intensity based on heart rate and effort indices. Garmin fitness trackers will monitor adherence and intensity. Remote guidance will support participants via weekly digital health messages on the LINE app, offering personalized feedback, goal reinforcement, and lifestyle recommendations. Participants will also receiThese AI feedback implementations will be tailored to complement the in-person education and will include reminders of the individualized goals set during the remote exercise intervention and consultation . The digital component will also offer a platform for patients to share their progress and seek further guidance during the scheduled in-person consultation. The use of digital AI feedback aligns with the trend of integrating technology into healthcare services, providing a convenient and accessible modality for supporting parents engaging in regular exercise.
223918423|NCT06817564|BEHAVIORAL|Theory-based digital exercise|The theory-based digital exercise group will follow the same in-person clinic visits and walking program as AI-PEF but without AI-driven feedback
223918424|NCT06817564|BEHAVIORAL|Active Control|Participants in the active control group will receive standard TBI care, including Garmin-based self-monitoring and routine clinic visits at baseline (T0), 3 months (T1), and 6 months (T2). These visits will include general health education and recommendations on daily physical activity. No personalized or digital exercise strategies will be provided. Participants completing the 6-month protocol will have the option to access the AI-PEF program after the study.
223918425|NCT05215054|DEVICE|Gana V®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
223918426|NCT05215054|DEVICE|Sculptra®|Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).
223918427|NCT02272309|PROCEDURE|EEG and EP measurement|
223918428|NCT02296229|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223918429|NCT02296229|OTHER|quality-of-life assessment|Ancillary studies
223918430|NCT02296229|OTHER|laboratory biomarker analysis|Correlative studies
223918431|NCT02296229|DRUG|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
223918432|NCT04165733|DIAGNOSTIC_TEST|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
223918433|NCT06695728|OTHER|exercise|It consists of exercises to be done with the exoskeleton. These are; jumping exercise, squat, sit-stand and forward bending exercises.
223918434|NCT06694584|BEHAVIORAL|Tea(m)Time|Tea(m)Time is divided into two phases, starting with the qualification of team leaders. This starts with knowledge transfer about healthy leadership, resilience, occupational health and safety, posture work, psychological empowerment, agile management and the role of the manager. The team leaders also learn various moderation/coaching techniques. The qualification is followed by the implementation of Tea(m)Time. The teams start each hour with self-reflection. This is followed by a stress assessment and prioritization. The teams then work on the problems identified and look for solutions together.
224099313|NCT00982605|PROCEDURE|EBUS_TBNA|EBUS during bronchoscopy
223716761|NCT01007773|DRUG|Propofol|Propofol will be titrated to an ICP \< 20 mm Hg until achievement of sustained ICP control.
223716762|NCT02123121|DRUG|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
223716763|NCT02123121|DRUG|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
223716764|NCT02123121|OTHER|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
223716765|NCT02123121|OTHER|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
223716766|NCT03000140|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
223716767|NCT03000140|BEHAVIORAL|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
223716768|NCT01154855|PROCEDURE|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
223716769|NCT02250170|DRUG|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
223716770|NCT05275400|DRUG|Insulin Efsitora Alfa|Administered SC
223716771|NCT05275400|DRUG|Insulin Degludec|Administered SC
223716772|NCT04000490|OTHER|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
223716773|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
223716774|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Standard treatment
223716775|NCT02585960|BIOLOGICAL|PEGylated Recombinant Factor VIII|Intensified treatment
223716776|NCT02783625|DRUG|Romidepsin|
223716777|NCT02783625|DRUG|Bortezomib|
223716778|NCT02783625|DRUG|duvelisib|
223716779|NCT00822783|DRUG|Omalizumab|
223918435|NCT06695494|DIAGNOSTIC_TEST|Gene panel array|Blood sample collection for gene panel testing
223918436|NCT06695494|OTHER|Blood Sample Collection|Blood sample collection for research purposes
223918437|NCT06695013|DRUG|zanubrutinib|zanubrutinib 160 mg BID orally
223918438|NCT06695013|DRUG|CAR-T|CAR-T Cell therapy
223918439|NCT06695013|RADIATION|Bridging radiotherapy|For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.
223918440|NCT06695013|DRUG|Tislelizumab|200mg IV Q3-4W
223918441|NCT06691490|DEVICE|Transcranial Magnetic Stimulation Sham|cTBS over SMA and cTBS over precuneus (control site)
223918442|NCT06688123|DRUG|SHR-3167|Dose level 1.
223918443|NCT06688123|DRUG|SHR-3167|Dose level 2.
223918444|NCT06688123|DRUG|Insulin glargine|Dose level 3.
223918445|NCT06688227|OTHER|Isolated Core Stability Program|The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
223918446|NCT06688227|OTHER|Integrated Core Stability Program|"An individualized protocol was designed for these cricketers targeting static and dynamic core stability, with integration of balance, endurance and power component.~Tranversusabdominis and multifidus strengthening is combined with upper extremity motions to work on the fast bowling action i.e throwing of the players.~At the same time lower extremity balance and strengthening is also included to ensure the high speed of sprint."
223918447|NCT06689540|BIOLOGICAL|MTS105|"MTS105 is a combination of mRNA, which encodes a therapeutic protein, and its delivery vehicle, a lipid nanoparticle (LNP). The starting dose is estimated based on the Minimal Anticipated Biological Effect Level (MABEL) derived from non-clinical studies.~A starting dose of 0.05 μg/kg was proposed for this study; following dose strength for escalation are: 0.5 μg/kg, 3.0 μg/kg, 15 μg/kg, 30 μg/kg, 45 μg/kg."
223918448|NCT04717700|DRUG|Selinexor 20 MG Oral Tablet|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
223716780|NCT00822783|DRUG|Placebo|
223716781|NCT03639935|DRUG|Rucaparib|Rucaparib 600 mg PO BID days 1-28
223716782|NCT03639935|DRUG|Nivolumab|Nivolumab 240 mg IV days 1 and 15
223716783|NCT01050712|DRUG|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
223716784|NCT01050712|DRUG|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
223716785|NCT06533787|DEVICE|Echocardiography|Functional echocardiography assessment
223716786|NCT02683161|DRUG|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
224099314|NCT00827489|DRUG|HTC-867|
223716787|NCT02683161|BEHAVIORAL|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
223716788|NCT02683161|BEHAVIORAL|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
223719561|NCT05823129|BEHAVIORAL|Tele-rehabilitation caregiver empowerment enhanced post- discharge rehabilitation directive|The intervention group will receive an implemented TUG test-based telerehabilitation program. The TUG test-based telerehabilitation involves patients routinely doing two TUG tests by themselves twice daily. Each patient will be provided with a unique link to the TUGstopwatch, a prerecorded video outlining instructions on how to properly conduct a TUG test, and support and guidance for patients and caregivers throughout the study period.
223918449|NCT04717700|DRUG|Bortezomib Injection|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
223918450|NCT04717700|DRUG|Lenalidomide capsule|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
223918451|NCT04717700|DRUG|Dexamethasone Oral|Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
223918452|NCT06877806|OTHER|Core exercise|The experimental treatment had a total of 18 introductory courses lasting 30 minutes each. The treatment included exercises to increase the mobility and strength of the neck, shoulders, pelvis and hips, and anti-flexion, anti-extension and rotation exercises were used to stabilize the spine. McGill curl-up was performed during each treatment for all 6 weeks. In the first two weeks, the subjects did general and introductory exercises (all positioned planks, plank walking, forearm cranes, plank pad forearms, etc.). Week 3 and 4 with additional movements and rotations (alternating hand and foot board holding, superman posture, faceplate switches, etc.). During the fifth and sixth weeks, the exercises were performed on unstable surfaces (one-handed board, ball stirring pot, feet raised sideboard, etc.). The intensity of those training courses was individual, but each one started at submaximal.
223918453|NCT06876311|DEVICE|Anterior Cervical Interbody Fusion|Standard Anterior Cervical Interbody Fusion with Stand-alone Cervical Cages
223918454|NCT06876311|DEVICE|Anterior lumbar Interbody Fusion|Standard Anterior Lumbar Interbody Fusion with Stand-Alone Lumbar Cages
223918455|NCT06876311|DEVICE|Lateral Lumbar Interbody Fusion|Standard Lateral Lumbar Interbody Fusion with Stand-alone Lumbar cage
223716789|NCT06193252|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
223716790|NCT06333613|DEVICE|ACUVUE OASYS® 1-DAY with HydraLuxe™ TECHNOLOGY (AO1D)|Test Lens
223716791|NCT02228629|DEVICE|CrocsRx Medical Silver cloud clogs|
223716792|NCT04251169|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30-minute intravenous (IV) infusion every 3 weeks beginning in Cycle 1
223716793|NCT04251169|DRUG|Paclitaxel|Paclitaxel will be administered at the 80 mg/m2 dose via 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of every 21-day cycle (beginning in Cycle 2). On days of scheduled infusions of pembrolizumab and paclitaxel (i.e., Day 1 of every cycle), paclitaxel is to be administered after infusion of pembrolizumab
223918456|NCT06695767|BEHAVIORAL|Neurobehavioral therapy|Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.
223918457|NCT06871878|OTHER|PRACTISE Physiotherapy Intervention|The PRACTISE programme is a 16-week personalised physiotherapy programme, incorporating tele-rehabilitation, which aims to support individuals to achieve optimal dose of exercise to improve motor and functional outcomes after stroke. There are three core components to the intervention: goal setting, exercise and a supported self-management approach. PRACTISE comprises of nine therapist supported sessions: five in person, home-based rehabilitation sessions (weeks 1-4, two visits in week 1) and four telephone or video consultations (Near Me) (weeks 6, 8, 12 and 16), a simple self-management workbook (with space to record personal goals, action plans and progress) to develop skills for self-management, and a personalised online exercise programme delivered through the Giraffe platform five times per week.
224099315|NCT00827489|OTHER|Placebo|
224099316|NCT02176486|DRUG|Ixazomib|Ixazomib capsules.
224099317|NCT02176486|DRUG|Placebo|Ixazomib placebo-matching capsules.
224099318|NCT03268798|DEVICE|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
224099319|NCT00872066|DEVICE|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
224278555|NCT01363011|DRUG|ATV|ATV 300 mg tablet administered orally once daily
224278556|NCT01363011|DRUG|DRV|DRV 800 mg tablet administered orally once daily
224278557|NCT01363011|DRUG|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
224278558|NCT01205893|DEVICE|Neovasc Reducer|Implantation of the Reducer
224278559|NCT01205893|DEVICE|Control|Control - No device implanted
223716794|NCT00548223|DRUG|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid\*1year
223716795|NCT00548223|DRUG|placebo|Capsule, 0.18g, 2#, Bid\*1year
223716796|NCT00307411|DRUG|Growth hormone|
223716797|NCT03616600|OTHER|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
223716798|NCT05787275|OTHER|diaphragmatic positioning|Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
223716799|NCT05787275|OTHER|incentive spirometer|Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
223918458|NCT06885892|PROCEDURE|Posterior Tibial Artery Perforator-Pedicled Propeller Flaps|Posterior tibial artery perforator-pedicled propeller flaps are feasible, safe, and effective procedure in the reconstruction of the defects in the lower leg.
223918459|NCT06885892|PROCEDURE|Perforator-Pedicled Propeller Flaps|Posterior Tibial Artery Perforator-Pedicled Propeller Flaps
223918460|NCT06882330|BEHAVIORAL|Dialectical behavior therapy|A complex psychotherapy program for patients with borderline personality disorder.
223918461|NCT06878651|DEVICE|The Whole Body Vibration|Whole Body Vibration device may positively affect balance, dual-tasking and gait parameters by increasing the sensory input received under the sole in individuals diagnosed with diabetic foot. In individuals diagnosed with diabetic foot, the sensory/vibration perception threshold of individuals decreases due to the disease, so the balance of individuals is impaired. This may cause these individuals to experience gait disturbances in daily life. There are almost no studies in the literature on the use of whole body vibration for this patient group. This study will discuss the applicability of whole body vibration in the clinic for individuals diagnosed with diabetic foot and that it can be an additional adjunct to treatment.
223918462|NCT06879353|DRUG|Tranexamic Acid (TXA)|A single intravenous dose of tranexamic acid (15 mg/kg) was administered before surgery to assess its efficacy in reducing perioperative blood loss and the need for transfusion.
223918463|NCT06879353|DRUG|Placebo|An equal volume of intravenous normal saline was administered as a placebo before surgery to compare outcomes with the tranexamic acid group.
223918464|NCT06725212|DEVICE|Water Vapor Thermal Ablation|The water vapor thermal ablation system injects thermal energy in the form of water vapor into the hyperplastic prostate tissue in controlled doses. The injected water vapor quickly disperses through the gaps between tissue cells. When water vapor comes into contact with tissue, it cools and condenses immediately. The stored heat energy is released, denaturing the cell membrane, causing cell death and eventually being absorbed or shed by the body and excreted through urination, thus improving the lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
223918465|NCT06725212|DEVICE|Cystoscopy|Cystoscopy is a procedure that allows the doctor to examine the lining of patient's bladder and the tube that carries urine out of the body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into the bladder.
223918466|NCT06744829|DEVICE|Balloon placement and inflation and removal of the Balloon|STELLA Endogastric ballon will be inserted into the stomach and inflated with sterile saline solution and will remain in place for 6 months. After which the device will be removed
223918467|NCT06740695|BEHAVIORAL|Education group|"The training materials were prepared in line with the researchers and expert opinions were obtained. Trainings will be given for two weeks. After the trainings are completed, reminder information will be sent to the pregnant women via text messages every other day to inform them that the trainings are continuing. Reminder information prepared as text messages will be sent to the pregnant women's mobile phones. 4 weeks after the first training, the same training will be reminded again via WhatsApp as a summary training by emphasizing key points.~The trainings will be carried out by an expert researcher in the field. In the training content prepared in line with WhatsApp, the risks that may be seen during pregnancy and Gestational Diabetes Mellitus;~* Sensitivity perception and Seriousness perception, perceived risks that may be seen during pregnancy~* Health motivation perception, the pregnant woman's beliefs and practices regarding being healthy,~* Benefit perception, pregnancy follow"
223918468|NCT06734676|DEVICE|Intermittent theta burst stimulation (iTBS)|iTBS: 90% RMT, 50Hz intraburst frequency, 3 pulses per burst, 5Hz interburst frequency, 2 seconds on/8 seconds off, totaling 1800 pulses over approximately 10 minutes. Each day includes 4 iTBS sessions (1800 pulses per session) with 50-minute intervals, totaling 7200 pulses per day for 14 consecutive days (100800 pulses total).
223918469|NCT06734871|DRUG|CAR T cells|chimeric antigen receptor T cells
223918470|NCT06742606|BIOLOGICAL|Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab|"All the patients will be treated according to guidelines of ECCO/ESPGHAN and will be followed up regularly for 12 months by assessment~• response to treatment Frequency of relapses,~Regular assessment will be:~Clinically every 2 to 4 weeks at gastroenterology outpatient clinic by using activity scoring systems:~pediatric Ulcerative Colitis Activity Index pediatric Chron's Disease Activity Index~Laboratory follow up will done at weeks 12,24,36,48 of starting or changing to other biological by doing inflammatory markers( CBC, ESR, CRP, albumin. At the end of study(week 48) each patient will be reassessed by:~Disease activity:~Laboratory Endoscopy will be repeated at week 48 of starting or changing to other biological to assess effect of biologicals on reach mucosal healing."
223940593|NCT02448524|DEVICE|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
223940594|NCT04863677|BEHAVIORAL|High Intensity Interval Training(HIIT）|Last 12 weeks (3 sessions per week)
223940595|NCT04863677|BEHAVIORAL|Moderate Intensity Continuous Training(MICT）|Moderate Intensity Continuous Training(MICT）
223940596|NCT00171769|DRUG|Certoparin|
224099320|NCT00872066|DEVICE|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
223716800|NCT05787275|OTHER|Control|Traditional medical treatment
223940597|NCT05309200|DRUG|OCE-205|The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
223940598|NCT05309200|DRUG|Placebo|Placebo to match OCE-205 is a sterile solution to be used for intravenous infusion.
223940599|NCT03693066|OTHER|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
223716801|NCT03576560|OTHER|Retrospective Chart Review|Retrospective Chart Review
223716802|NCT05873257|DEVICE|Biatain Fiber Ag applied to participants|Intervention involving a wound gelling fiber dressing with silver
223716803|NCT04960644|DRUG|MTX|MTX (5-10 mg/day,Dmax 10mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
223716804|NCT04960644|DRUG|Corticosteroid|corticosteroid Methylprednisolone 1 mg/kg/day was given for 10 days and then the dosage was gradually reduced according to patient's response
223716805|NCT04177004|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
223716806|NCT04177004|DRUG|Cyclophosphamide|Given IV
223918471|NCT06736626|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents (DES), which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of DES, and received a subsequent course of dual antiplatelet therapy (DAPT), as clinically indicated.
223918472|NCT06742463|DRUG|Venetoclax|BCL-2 inhibitor
223918473|NCT06742463|DRUG|homoharringtonine|alkaloid
223918474|NCT06742463|DRUG|Cytarabine (Ara-C)|Metabolic antagonist.
223918475|NCT06742463|DRUG|G-CSF|Granulocyte colony-stimulating factor
223918476|NCT02934867|OTHER|Protocol phone advice|Protocol phone advice
223918477|NCT02934867|OTHER|Usual phone advice|Usual phone advice
223918478|NCT06743945|DRUG|POLA-R-CHP|Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
223918479|NCT01651000|DRUG|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
223918480|NCT01651000|OTHER|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
223918481|NCT06738693|PROCEDURE|External Fixation|External fixation involves the stabilization of unstable intra-articular distal radius fractures using an external fixator. The procedure is performed under anesthesia, with fixator pins placed percutaneously into the proximal and distal fragments of the radius. Postoperative care includes regular cleaning of pin tracts, early mobilization exercises for adjacent joints, and fixator removal upon radiological confirmation of fracture healing, typically between 6 to 8 weeks post-surgery.
223918482|NCT06738693|PROCEDURE|Open Reduction and Internal Fixation (ORIF) with Volar Locking Plate|ORIF using a volar locking plate is performed to anatomically reduce and stabilize unstable intra-articular distal radius fractures. The procedure is conducted under anesthesia, involving an open approach through the volar aspect of the wrist. The volar locking plate is secured with screws to provide rigid fixation, enabling early mobilization. Postoperative follow-up includes evaluation of functional outcomes, union rates, and potential complications.
223918483|NCT06737003|DEVICE|Nasal high frequency oscillatory ventilation|NHFOV was administered using the SLE 6000 device manufactured by Wipro GE Healthcare Private Limited in Bengaluru, Karnataka. The initial amplitude was set at 25 cm H2O and adjusted to a maximum of 35 cm H2O based on clinical response. The frequency was set at 12 Hz. The mean airway pressure (MAP) was initiated at 6 cmH2O and titrated up to 10 cmH2O based on clinical assessment. The I:E ratio was maintained between 1:1 to 1:2 in cases of air trapping, using nasal prongs •
223918484|NCT06737003|DEVICE|Vapotherm Group|The Hi-VNI Vapotherm was administered using the Vapotherm device, manufactured by Vapotherm, INC, USA. Initially, the flow rate was set at 4 L/min and adjusted accordingly to achieve the desired clinical outcome, with a maximum flow rate of 8 L/min when necessary. The temperature was maintained at 36-37°C, and the FiO2 was adjusted as required to attain the target SpO2 range of 90% to 94%، using soft nasal cannula interface
223918485|NCT06737003|DEVICE|Nasal CPAP Group|CPAP therapy was administered using the MEDIN CNO device, developed by medin Medical Innovations GmbH in Olching, Germany. The initial pressure was set at 5 cmH2O and adjusted accordingly to achieve the desired clinical outcome, with a maximum pressure of 8 cmH2O. This approach aimed to maintain the target oxygen saturation (SpO2) levels between 90% and 94%، using bi-nasal with midline prongs
223918486|NCT06739967|BEHAVIORAL|Behavioral Treatment|"The SLT intervention will be entirely administered online through a web-based platform. While each of the treatments will engage semantics, phonology, and orthography, the protocols will be tailored relative to the characteristics of each PPA variant. Patients with svPPA and lvPPA will undergo a lexical retrieval training (LRT) intervention implemented using a training cascade.~Patients with nfvPPA will undergo Video-implemented Script Training (VISTA), a choral reading approach training accurate production of functional scripts. The method is based on that implemented in American-English individuals with PPA and aims at improving grammar and motor aspects of speech production by taking advantage of repetitive practice and automaticity."
224089584|NCT03335501|OTHER|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
224089585|NCT00550628|GENETIC|DNA methylation analysis|
223716807|NCT04177004|DRUG|Etoposide|Given IV
223918487|NCT06738550|DIETARY_SUPPLEMENT|inulin|In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided
224089586|NCT00550628|GENETIC|fluorescence in situ hybridization|
223918488|NCT06738550|DRUG|Lactulose oral solution|In the patients of the experimental group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours
223918489|NCT06741059|OTHER|Transkutanöz Elektriksel Sinir Stimülasyonu - TENS|Transcutaneous Electrical Nerve Stimulation (TENS) has gained popularity in recent years as a non-invasive method for pain management. TENS works by modulating nerve stimulation through low-frequency electrical currents applied to the skin, reducing pain perception. Its potential effectiveness in alleviating menstrual pain has drawn increasing attention as an alternative treatment option
224089587|NCT00550628|GENETIC|gene expression analysis|
223716808|NCT04177004|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
223716809|NCT04177004|DRUG|Goat Milk|Given human lysozyme goat milk PO
223716810|NCT04177004|BIOLOGICAL|Palifermin|Given IV
223716811|NCT04177004|DRUG|Sirolimus|Given PO
223918490|NCT06741540|OTHER|tDCS|"Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that modulates cortical excitability by applying a weak direct current through electrodes placed on the scalp. This technique usually lasts for 20-30 minutes and can affect brain function by altering cortical excitability, local cerebral blood flow, synaptic plasticity, and the balance of cortical excitation/inhibition.~tDCS is widely used in clinical settings and has shown some clinical efficacy in treating common psychiatric and neurological disorders. It is also used to improve motor, perceptual, and cognitive processes, as well as to treat a variety of neurological and psychiatric diseases."
223918491|NCT06893432|DEVICE|hearing aids|Hearing aids are a common intervention method used to address age-related hearing loss, providing amplified sound to improve hearing clarity and communication abilities for elderly individuals.
223918492|NCT06855628|OTHER|[6,6-²H₂]-Glucose|\[6,6-²H₂\]-Glucose is a stable isotope-labeled glucose used as a metabolic tracer. It is administered orally to assess glucose metabolism using Deuterium Metabolic Imaging (DMI).
223918493|NCT06818084|COMBINATION_PRODUCT|TAVR+GDMT|"The patient will undergo transcatheter aortic valve replacement on the basis of guideline-directed medical therapy with The VitaFlow™ system.~The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve."
223918494|NCT06818084|COMBINATION_PRODUCT|SAVR+GDMT|The patient will undergo conventional surgical aortic valve replacement on the basis of guideline-directed medical therapy.
223918495|NCT06269913|OTHER|FeSC|Iron/yeast complex
223918496|NCT05174650|DRUG|Atezolizumab|Infusion i.v. of atezolizumab on day 1 of a 3-week cycle, first infusion rate over 60 minutes, subsequent infusion rates 30 minutes if tolerated for a maximum of 20 cycles in total
223918497|NCT05174650|DRUG|Derazantinib|Oral intake of 300 mg derazantinib continuously on day 1 to day 21 of a 3-week cycle for a maximum of 20 cycles in total
223918498|NCT04198129|DRUG|Antibiotic treatment (Unasyn or Cleocin)|Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
223918499|NCT04198129|DRUG|Antibiotic treatment (Augmentin or Cleocin)|the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
223918500|NCT04198129|OTHER|Control Group|Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
223918501|NCT06543667|BIOLOGICAL|Limbal Stem Cell Derived Exosomes Eye Drop|Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
223918502|NCT04338581|BIOLOGICAL|AMG 714|anti-IL-15 monoclonal antibody (Anti-IL-15 MAB)
223918503|NCT04338581|BIOLOGICAL|Placebo|Placebo for AMG 714
223918504|NCT04338581|PROCEDURE|nbUVB phototherapy|Participants will undergo narrow band ultraviolet B (nbUVB) phototherapy if their total body Vitiligo Area Scoring Index (T-VASI) does not improve by ≥ 25% at Week 24 compared to Week 0. Phototherapy will be administered in accordance with the Vitiligo Working Group expert recommendations.
223918505|NCT06317038|DEVICE|Total 30 Contact Lens|Patients will be give a contact lens for 1 month
223918506|NCT06949462|OTHER|PEAR|"Participants in the intervention arm will receive anaesthesia risk counselling through the PEAR (Patient Education of Anaesthesia Risks) chatbot prior to their face-to-face consultation with an anaesthetist. PEAR is a multilingual, AI-powered conversational tool designed to provide personalized, interactive education on anaesthesia-related procedures, risks, and safety information.~The chatbot delivers content aligned with institutional guidelines and allows patients to explore topics at their own pace, ask questions in natural language, and revisit information as needed. After completing the chatbot interaction, patients proceed with their standard preoperative consultation, where any further questions are addressed by the anaesthetist.~This approach is designed to enhance patient understanding, reduce anxiety, and optimize the in-person consultation by preparing patients in advance."
223716812|NCT04177004|DRUG|Tacrolimus|Given IV and PO
223716813|NCT05345197|DRUG|emicizumab|This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
223716814|NCT06962956|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Brush two times a day for 1 minute with manual toothbrush
223716815|NCT06962956|DRUG|0.454% Stannous Fluoride Dentifrice|Brush two times a day for 1 minute with manual toothbrush
224089588|NCT00550628|GENETIC|polymerase chain reaction|
224089589|NCT00550628|GENETIC|protein expression analysis|
223716816|NCT06962956|DRUG|0.454% Stannous Fluoride Dentifrice|Brush two times a day for 2 minutes with electric toothbrush
223716817|NCT05847842|PROCEDURE|Anterior quadratus lumborum block|20 mL of 0.25% bupivacaine will be given
224089590|NCT00550628|GENETIC|reverse transcriptase-polymerase chain reaction|
224089591|NCT00550628|OTHER|diagnostic laboratory biomarker analysis|
224089592|NCT00550628|OTHER|immunoenzyme technique|
224089593|NCT00550628|OTHER|immunohistochemistry staining method|
224089594|NCT00550628|PROCEDURE|biopsy|
224089595|NCT00550628|PROCEDURE|therapeutic conventional surgery|
224089596|NCT00550628|RADIATION|fludeoxyglucose F 18|
224099321|NCT00527202|DRUG|botulinum toxin A|Botulinum toxin A versus saline in parallel groups
224099322|NCT00728416|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
223716818|NCT05847842|PROCEDURE|Transversus abdominis plane block|20 mL of 0.25% bupivacaine will be given
224099323|NCT00728416|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
224278560|NCT01368302|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
224278561|NCT00585260|DRUG|mannitol|indirect mannitol challenge
223716819|NCT05847842|PROCEDURE|Local infiltration|20 mL of 0.25% bupivacaine will be given
223918507|NCT06954298|BEHAVIORAL|supervised lifestyle modification|Supervised lifestyle intervention will consist of regular exercise (3x a week), nutritional counselling (weekly), cognitive bahavioural therapy (monthly).
223918508|NCT06953713|PROCEDURE|gallbladder extraction umbilical|extracting gallbladder via umbilical port site
223918509|NCT06953713|PROCEDURE|extracting gallbladder via epigastric port|extracting gallbladder via epigastric port
223918510|NCT06953739|DRUG|P-GEMD|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (12 mg/m2) on day 1, every 3 weeks; Drug: Pegaspargase Pegaspargase(3750 IU) on day 2, every 3 weeks; Drug: Gemcitabine Gemcitabine (1000 mg/m2) on day 1, every 3 weeks; Drug: Etoposide Etoposide (65 mg/m2) on day 2-4, every 3 weeks. Drug: Dexamethasone Dexamethasone (40 mg/d) will be taken orally from day 1-4, every 3 weeks; Patients \> 65 years of age may be adjusted according to the investigator's decision.
223918511|NCT06953739|DRUG|P-Gemox|Drug: Pegaspargase Pegaspargase(2000-2500 IU/m2) on day 1, every 3 weeks; Drug: Gemcitabine Gemcitabine (1000 mg/m2) on day 1 and day 8, every 3 weeks; Drug: Oxaliplatin Oxaliplatin (130mg/m2) on day 1, every 3 weeks; Patients \> 65 years of age may be adjusted according to the investigator's decision.
223918512|NCT06744504|DRUG|cytarabine|Cytarabine combined with daunorubicin was used for induction therapy. According to the different doses of cytarabine, it was divided into standard dose group and intermediate dose group.In addition, high doses of cytarabine are also used for post-remission treatment.
223918513|NCT06744504|DRUG|daunorubicin|combined with cytarabine and used for induction therapy
223918514|NCT06744504|DRUG|idarubicin|combined with cytarabine and cyclophosphamide and used for post-remission treatment
223918515|NCT06744504|DRUG|cyclophosphamide|combined with cytarabine and idarubicin and used for post-remission treatment
223918516|NCT04756076|DIAGNOSTIC_TEST|Metal level measurements|Measure multiple metal levels
223918517|NCT06952777|OTHER|Non-adhesive capacitively-coupled sensors|Non-adhesive capacitively-coupled sensors which can detect signals of the magnitude of the fetal heart rate and information about fetal movements.
223918518|NCT02267993|DRUG|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of \< 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
223918519|NCT05182463|DRUG|Peginterferon Alfa-2B|Different usage of peginterferon Alfa-2B and/or Nucleos(t)ide analogs in arm/group descriptions are depended on the wishes of the patient and the advice of the attending doctor.
223918520|NCT05182463|DRUG|Nucleoside Analogs|Nucleos(t)ide analogs refer to one of the first-line drugs, including ETV, TDF and TAF.
223918521|NCT06151236|DRUG|Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination|Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
223918522|NCT04633278|DRUG|CMP-001|Subjects will receive CMP-001 10mg weekly for 2 doses after which CMP-001 will be administered every 3 weeks. The first dose of CMP-001 may be administered subcutaneously (SC) or Intratumorally (IT) at the discretion of Investigator. All subsequent doses will be injected intratumorally every 3 weeks (Q3W).
223918523|NCT04633278|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV is administered Q3W.
223918524|NCT06055322|BEHAVIORAL|Adapted Dialectical Behavior Therapy|DBT includes skills training groups, unlike other suicide-specific treatments, with modules on distress tolerance, emotion regulation, interpersonal effectiveness, and mindfulness (Linehan, 2014)
224278562|NCT00278174|BIOLOGICAL|recombinant interferon alpha-1b|
223918525|NCT03636490|BEHAVIORAL|Psychological Stress Intervention|All enrolled participants who attended the laboratory visit underwent stress-inducing tasks (psychological stress) using validated research tools. Participants performed a 5-minute computer Stroop Color Test and a 5-minute verbal Mental Arithmetic Task. The research assistant asked the participant to work as quickly and accurately as possible for both tasks.
223918526|NCT05977673|DRUG|Tislelizumab|Tislelizumab 200mg IV day1
223918527|NCT04149600|PROCEDURE|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
223918528|NCT06385106|DEVICE|Real repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session.
223918529|NCT06385106|DEVICE|Sham repetitive transcranial magnetic stimulation|The target brain region for stimulation was the left dorsolateral prefrontal lobe. The intensity of the stimulation was 80% of the resting motor threshold (MT) of each subject. In the target brain region, we applied 40 stimuli at a frequency of 20 Hz and the MT for 1600 pulses per session. The patients were applied with the coil angled away from the head to reproduce the noise of the stimulation as well as some local sensation
223918530|NCT02246127|DRUG|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
224278563|NCT02754284|BIOLOGICAL|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
224278564|NCT02754284|BIOLOGICAL|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
224278565|NCT03105817|DEVICE|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
224278566|NCT00680069|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
224278567|NCT05022368|DEVICE|LabraGuard|Protection of the lips and the oral commissure during transoral procedures
223918531|NCT02246127|DRUG|STZ-5FU|"0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops."
223918532|NCT05257772|DEVICE|AV Delay Optimised RV Pacing|AV Delay Optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems) and Echo to assess LVOT gradient change.
223918533|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
223918534|NCT04063891|DEVICE|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
223918535|NCT06952829|OTHER|evaluation of intravenous access of patients with Adult-Difficult IntraVenous Access (A-DIVA) score prior to puncturing subject|The patient's intravenous access will be evaluated using the A-DIVA score by the study nurse at the time of admission, prior to venipuncture performed by the care nurse
223918536|NCT06952829|OTHER|evaluation of intravenous access of patients with modified Adult-Difficult IntraVenous access(A-DIVA modified) score prior to puncturing subject|The patient's intravenous access will be evaluated using the A-DIVA-m score by the study nurse at the time of admission, prior to venipuncture performed by the care nurse
223918537|NCT05438862|PROCEDURE|State of art aortic valve surgery|Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
223918538|NCT05370352|BEHAVIORAL|Standard smoking cessation treatment|Standard smoking cessation treatment (behavioural and pharmacotherapy) provided by Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation
223918539|NCT05370352|BEHAVIORAL|Personalised chat messaging|Personalised chat messaging focusing on smoking relapse prevention for 3 months from randomisation. A trained counsellor will interact with a participant individually and provide relapse prevention advice via WhatsApp. The participant can also access a supportive chatbot in WhatsApp, which will provide on-demand smoking relapse prevention support when the counsellor is not available (e.g., during nighttime).
223918540|NCT05370352|BEHAVIORAL|SMS text messaging|SMS text messaging on generic information about the harms of smoking and the benefits of quitting for 3 months from randomisation.
223918541|NCT03107416|PROCEDURE|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
223918542|NCT03107416|DRUG|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
223918543|NCT04726293|DIETARY_SUPPLEMENT|Mango|Mango beverage -1 cup fresh mango equivalent, twice a day for 4 weeks
223918544|NCT04726293|DIETARY_SUPPLEMENT|Control|control beverage 1 cup, twice a day for 4 weeks
223918545|NCT05117151|DIAGNOSTIC_TEST|hypotension prediction index|monitor intraoperative hypotension prediction index as well as hemodynamic variables to exam the ability in predicting hypotension events of each variable
223918546|NCT03417531|DIETARY_SUPPLEMENT|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
223918547|NCT03417531|DIETARY_SUPPLEMENT|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
223918548|NCT03417531|PROCEDURE|Active Exercise|Program includes five strength exercises that can be easily performed at home
223918549|NCT03417531|PROCEDURE|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
224278568|NCT04874896|DIETARY_SUPPLEMENT|Microbiota autotransplantation|Patients received microbiota autotransplantation in capsules (1g per day) for 6 months
224278569|NCT04874896|DIETARY_SUPPLEMENT|Control|Patients will not received microbiota autotransplantation in capsules and will received usual medical care
224278570|NCT01955512|DRUG|Clopidogrel|Clopidogrel 75mg daily for 7 days
223918550|NCT06890091|OTHER|Fatigue assessment|Fatigue score measured by the EORTC QLQ-FA 12 fatigue self-assessment scale
223918551|NCT04158024|OTHER|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
223918552|NCT04342572|DRUG|Melphalan|-The drug is commerically available
223918553|NCT06962033|BEHAVIORAL|Opioid Agonist Therapy|Opioid Agonist Therapy (OAT) as HIV prevention
224278571|NCT01955512|DRUG|Placebo|Matched placebo
224278572|NCT03920306|DRUG|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
223716820|NCT01651039|DRUG|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
223716821|NCT01651039|DRUG|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
223918554|NCT06470984|BEHAVIORAL|Educational intervention|Professional development program provided online to small groups of professional nurse leaders via an educational platform over a 6-week period.
223918555|NCT01144455|DRUG|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
223918556|NCT01144455|DRUG|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
223918557|NCT01144455|DRUG|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
223918558|NCT03664453|DRUG|omaveloxolone|Omaveloxolone 50 mg capsules
223918559|NCT00488072|DRUG|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
223918560|NCT00488072|DRUG|Placebo|One placebo tablet by mouth daily.
223940600|NCT03693066|OTHER|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
223940601|NCT03693066|OTHER|Control|
223940602|NCT04798066|BIOLOGICAL|HB-adMSCs|Autologous adipose derived mesenchymal stem cells
224278573|NCT00000555|DRUG|estrogen replacement therapy|
224278574|NCT00000555|DRUG|estrogens, conjugated|
224278575|NCT00000555|DRUG|progesterone|
224278576|NCT00000555|DRUG|hormone replacement therapy|
223918561|NCT06469034|DEVICE|conventional ultrasound|The operators in the control group will perform the procedure by visualizing the conventional ultrasound images displayed directly on the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. To standardize the approach, the ultrasound machine will be placed just to the right of the patient and operators will be asked to stand at the head of the patient and perform the procedure on the patient's internal jugular vein. Each operator could determine the height of the surgical table, and the posture during the procedure that will be most familiar to him/her to increase the success rate. Every procedure will be recorded by focusing on the participant's hands and faces.
223918562|NCT06469034|DEVICE|Head-mounted display ultrasound|In the HMD group, the ultrasound machine will be located behind the operator to remove the distraction, and the operator will not be allowed to see the ultrasound screen during the procedure. Images from the MR ultrasound machine will be transmitted to HMD via a novel connection developed specifically for this purpose. The operator will wear a pair of HMD and perform the procedure by visualizing the ultrasound images displayed on their HMD screen instead of the ultrasound screen. Each operator will perform an internal jugular vein cannulation via the short-axis approach. Every procedure will be recorded by focusing on the participant's hands and faces.
223918563|NCT06136936|DEVICE|CT-156-C-001|CT-156 is a digital therapeutic (DTx) under development to treat patients 18 years of age and older with a diagnosis of schizophrenia under standard of care therapy who are on antipsychotic medication and not currently experiencing acute hallucinations or delusions.
223918564|NCT05657639|DRUG|CAV Regimen|Cladribine 5 mg/m2/day , cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
223918565|NCT05657639|DRUG|MEC Regimen|Mitoxantrone 8mg/m2 d1-5, etoposide 100mg/m2 d1-5, cytarabine 1g/m2 d1-5
223918566|NCT03775161|DEVICE|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
224278577|NCT00000555|DRUG|supplementation, food|
224278578|NCT00000555|DRUG|ascorbic acid|
224278579|NCT00000555|DRUG|vitamin e|
224278580|NCT02428582|DEVICE|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
223530325|NCT02328495|DRUG|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
223716822|NCT01651039|DRUG|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
223716823|NCT02059395|OTHER|Mastery based learning|Participants are allowed to follow the course content at their own speed
223918567|NCT06965166|PROCEDURE|PCD-CT|Participants undergo PCD-CT scan on study
223918568|NCT06751394|DRUG|PD-1 antibody (Toripalimab)|PD-1 antibody: (Toripalimab): 240mg q3w
223918569|NCT06751394|DRUG|Capecitabine|Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy
223918570|NCT06751394|DRUG|Oxaliplatin|130 mg/m² q3w
223918571|NCT06751394|DRUG|Irinotecan|200 mg/m² q3w
224278581|NCT02428582|DEVICE|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
224278582|NCT00148720|DRUG|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
224278583|NCT03153787|OTHER|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
223716824|NCT02059395|OTHER|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
223918572|NCT06751394|RADIATION|Radiation|45-50Gy/25Fx or 30Gy/15Fx
223918573|NCT06751394|PROCEDURE|surgery|The type of surgery will depend on the site of recurrence and the involvement of adjacent structures, which will be determined by the surgeons.
223716825|NCT00788567|DRUG|mycophenolate mofetil|1
223716826|NCT03730571|DEVICE|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
223716827|NCT02252913|DRUG|Volitinib|oral administration
223716828|NCT02252913|DRUG|Docetaxel|intravenous injection
223918574|NCT05623189|DRUG|HTD1801|HTD1801,1250 mg, BID
223918575|NCT05623189|DRUG|Placebo|Placebo, BID
223918576|NCT06964932|DIETARY_SUPPLEMENT|Probiotc|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
224278584|NCT02644798|OTHER|Baseline-recorded data recorded|Baseline-recorded data recorded. Peripheral blood samples were drawn.
224278585|NCT03558620|PROCEDURE|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
224278586|NCT02051595|OTHER|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
224278587|NCT05999279|BEHAVIORAL|Survey|Developed questionnaire to assess the literacy of patients + another survey to assess their preferences regarding traditional versus digital pharmaceutical care
224278588|NCT02265406|DRUG|Anti-Infective Agents|
224278589|NCT02265406|DRUG|Placebo|
224278590|NCT05331391|BEHAVIORAL|Brief mobile SMART Exercise Support Program|Patients will receive 1) a brief SMART Exercise individual face-to-face session; 2) a theory-based instant messaging (WhatsApp/WeChat) and telephone-delivered health coaching on a 2-stage tapering schedule. Stage 1 (week 1 to 6): daily messages and two biweekly phone calls for exercise habit formation. Stage 2 (week 7 to 12): messages twice a week and monthly phone calls for exercise habit maintenance.
223918577|NCT06964932|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
224278591|NCT00715091|DRUG|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
224278592|NCT00715091|DRUG|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
224278593|NCT01032460|DEVICE|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
224278594|NCT01032460|DEVICE|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
224278595|NCT01032460|DEVICE|intubate with the Airtraq device|intubate with the Airtraq device
224278596|NCT02154724|DEVICE|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
223530326|NCT02328495|OTHER|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
223918578|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~* 14mg/ms day +1 and +8~* 10mg/ms day +1 and +8~* 8mg/ms day +1 and +8~CHOEP-21~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
223918579|NCT02223208|DRUG|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~* Romidepsin dose according to phase I iv day +1 and +8~* Doxorubicin 50 mg/ms iv day +1 or +2,~* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1 or +2,~* Cyclophosphamide 750 mg/ms iv day +1 or +2~* Etoposide 100mg/ms iv from day +1 to +3 or from day +2 to +4~* Prednisone100 mg orally from days +1 to +5 or from days +2 to +6~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --\> AUTO-SCT, PR --\> ALLO-SCT)"
223918580|NCT06224088|OTHER|VV ECMO|treatment with VV ECMO in the ICU
223918581|NCT05184114|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance, Blood Tests|Imaging, blood investigations (white cell count, C-reactive protein, NT-proBNP, lactate dehydrogenase and high sensitivity troponin)
223918582|NCT06239259|OTHER|Questionare As described in Secondary Outcomes|All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
223716829|NCT01671800|DRUG|Botulinum Type B|
223716830|NCT01671800|DRUG|Placebo|
223918583|NCT02107105|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
223918584|NCT02107105|OTHER|Questionnaire Administration|Complete quality of life questionnaire
223918585|NCT02358187|BIOLOGICAL|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
223918586|NCT03907020|DIETARY_SUPPLEMENT|Barley|Assessing the metabolic availability of lysine in barley.
224278597|NCT02154724|DEVICE|DBS|The aDBS s applied for two hous in DBS modality.
224278598|NCT01593072|DRUG|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
224278599|NCT01593072|OTHER|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
224278600|NCT00900016|GENETIC|protein expression analysis|
224278601|NCT00900016|GENETIC|western blotting|
224278602|NCT00900016|OTHER|immunohistochemistry staining method|
224278603|NCT00900016|OTHER|immunologic technique|
223530327|NCT06295419|OTHER|dual task|cerebral palsy and healthy controls will be evaluated dual task conditions
223530328|NCT06295419|OTHER|single task|cerebral palsy and healthy controls will be evaluated single task conditions
223716831|NCT00134082|BIOLOGICAL|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10\^8 cells per dose. The first dose was given on Day +1.
223716832|NCT00134082|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is \>= 1000/mcL.
224278604|NCT00900016|OTHER|laboratory biomarker analysis|
224278605|NCT05516888|PROCEDURE|radiofrequency of gasserian ganglion|radiofrequency ablation of the gasserian ganglion
224278606|NCT05516888|PROCEDURE|radiofrequency of the peripheral trigeminal branches|radiofrequency of the peripheral trigeminal branches ( maxillary, mandibular, supraorbital)
224278607|NCT01917435|DEVICE|video-stylet|
224278608|NCT01917435|DEVICE|fiberoptic bronchoscope|
224278609|NCT06446388|DRUG|QLS31905|Administered as an intravenous infusion.
224278610|NCT06446388|DRUG|Oxaliplatin|130 mg/m2, intravenous infusion, D1, up to 8 cycles.
224278611|NCT06446388|DRUG|Capecitabine|1000 mg/m2, oral, bid, D1-D14
224278612|NCT06446388|DRUG|Gemcitabine|1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
224278613|NCT06446388|DRUG|Cisplatin|25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
224278614|NCT06446388|DRUG|QL1706|5 mg/kg, intravenous infusion,D1
224278615|NCT06446388|DRUG|Chemotherapy drug|Standard chemotherapy recommended by guidelines.
224278616|NCT03498599|BEHAVIORAL|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
223918587|NCT03525639|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
223918588|NCT05015868|DIAGNOSTIC_TEST|Standard of care|"Enrollment of patients afferent to our Center with cryptogenic drug-resistant epilepsy with onset in pediatric age, subject to informed consent;~* acquisition and updating of Electroencephalogram polygraphic data of wakefulness and sleep and neuroradiological data (previous negative brain magnetic resonance imaging);~* execution of a complete neuropsychological assessment for the classification of cognitive aspects and evaluation of executive functions;~* execution of genetic tests through Next generation sequencing epilepsies panel or exome sequencing"
223918589|NCT05015868|DIAGNOSTIC_TEST|Functional magnetic resonance imaging-Electroencephalogram combined analysis|"A functional brain magnetic resonance imaging is executed analysing blood oxygenation level dependent signal.~During the functional recording, a contemporary electroencephalogram is registered in order to analyse the space-time relationship between the epileptic discharges and the bold abnormalities."
223918590|NCT05015868|DIAGNOSTIC_TEST|High density- electroencephalogram or 7 Tesla magnetic resonance imaging|"In the event that neither the cause nor the epileptogenic area has been identified, we will evaluate the execution of further tests, such as:~* execution of High Density-electroencephalogram recording at IRCCS Medea di Conegliano (TV, Italy) (approximately 3 patients / year) for a further electrophysiological definition;~* 7 Tesla brain magnetic resonance imaging performed at IRCCS Stella Maris in Calambrone (PI, italy) (approximately 3 patients / year expected), to obtain greater spatial resolution and better neuroradiological definition."
223918591|NCT00527410|DRUG|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
223918592|NCT06236503|BEHAVIORAL|Real Stimulation|"Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months."
223918593|NCT06236503|BEHAVIORAL|Placebo Stimulation|Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
223918594|NCT06134258|OTHER|mixed meal test|mixed meal test after fasting
223918595|NCT06298838|DEVICE|AURA10® Specimen PET/CT imager|The AURA10 PET-CT specimen imager detects and measures the electron density distribution of a specimen and the radiotracer distribution within a specimen. The function of the system is to acquire and visualize PET and CT images of a specimen, based on which a healthcare professional can rapidly verify whether the correct tissue has been resected. It can be used in any condition that requires resection surgery to visualize the resected specimen. The device is automated and semi-quantitative, i.e., qualitative regarding visualization of structure and radiotracer distribution and quantitative regarding tissue density (Hounsfield units) and radiotracer uptake in the specimen (Bq/ml). The type of specimen required is resected tissue from a patient undergoing resection surgery.
223918596|NCT03596801|BIOLOGICAL|RSV 6120/∆NS1|Delivered as nose drops
223530329|NCT01151267|OTHER|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation \>97% and end tidal CO2 at 35-45mmHg.
223530330|NCT01151267|DEVICE|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
223530331|NCT04015388|DEVICE|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
223530332|NCT04219410|PROCEDURE|Fully minimally invasive esophagectomy|Esophagectomy using a novel fully minimally invasive approach
223530333|NCT02672995|RADIATION|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5\~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5\~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
223716833|NCT00134082|BIOLOGICAL|Rituximab|375 mg/m\^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
223716834|NCT00134082|DRUG|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
223716835|NCT05045248|DRUG|Apraclonidine Hcl 0.5% Oph Soln|Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
223716836|NCT00006161|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
223716837|NCT00006161|PROCEDURE|Distal Splenorenal Shunt|
223716838|NCT01488370|DEVICE|Endotracheal intubation|Endotracheal intubation
223716839|NCT00463112|DRUG|Sibutramine|
223530334|NCT02672995|DRUG|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
223530335|NCT03481439|OTHER|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
223530336|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
223530337|NCT00678704|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
223530338|NCT00678704|DRUG|Placebo|Placebo tablet prior to intercourse on demand
223716840|NCT05075122|BIOLOGICAL|UV1|UV1 vaccination (300 μg) UV1 vaccination will be applied in a dense schedule with three vaccinations during one week before initiation of pembrolizumab, followed by 5 additional vaccinations every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14)
223716841|NCT05075122|DRUG|Sargramostim for Injection|75 μg GM-CSF as adjuvant per vaccination. Applied in a dense schedule with three injections during one week before initiation of pembrolizumab, followed by 5 additional injections every 3 weeks on d1 of each cycle (5 cycles in total, duration of treatment will be 13 weeks in total, regular EOT at week 14).
223716842|NCT05075122|DRUG|Pembrolizumab injection|200mg flat dose iv every 3 weeks. Pembrolizumab will be administered beyond the EOT visit at physician discretion until disease progression and up to a maximum of two years (standard of care)
223716843|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
223716844|NCT05341193|DRUG|Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab|"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
223716845|NCT01830270|DRUG|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
223716846|NCT01830270|DRUG|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
223918597|NCT03596801|BIOLOGICAL|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
223918598|NCT03596801|BIOLOGICAL|Placebo|Delivered as nose drops
223918599|NCT05374538|DRUG|VIC-1911|VIC-1911 tablets for oral administration
223918600|NCT05374538|DRUG|sotorasib|Sotorasib tablets for oral administration
223530339|NCT06255353|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223530340|NCT06255353|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
223719562|NCT04080401|DEVICE|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
223918601|NCT04587674|DEVICE|Spinal Cord Stimulation|Lead(s) and Implant Pulse Generator
223918602|NCT05807997|OTHER|Refusal of ICU admission.|patients aged 18--99 who were presented to the general intensive care unit from January 2018 to the end of December 2023 and were not admitted.
223918603|NCT04877444|DEVICE|Duck Duck Punch|"Duck Duck Punch (DDP) is an interactive computer game deliberately designed to enhance UE movement quality via individualized progressive movement practice. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. The goal 'dose' of DDP will be 200 repetitions."
224278617|NCT03498599|BEHAVIORAL|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
223918604|NCT04877444|BEHAVIORAL|Aerobic exercise|Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. The target intensity of aerobic exercise is 70% heart rate reserve. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
223918605|NCT04877444|BEHAVIORAL|Lower extremity stretching|Subjects will perform 15 minutes of lower extremity stretching. Following aerobic exercise subject will play an upper extremity rehabilitation game called Duck Duck Punch.
223918606|NCT05672368|DEVICE|Robot-Assisted Surgery|Undergo surgery using the da Vinci SP device
223918607|NCT06494098|PROCEDURE|Nasoalveolar Molding|presurgical orthopedics
223918608|NCT06494098|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch and nose
223918609|NCT06614270|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine and Cyclophosphamide for conditioning. Multiple doses of anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.
223918610|NCT06811519|DIAGNOSTIC_TEST|Body Composition Analyzer (ACCUNIQ BC720)|Body Composition Analyzer (ACCUNIQ BC720)
223918611|NCT06655818|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
223918612|NCT06655818|DRUG|Dostarlimab|Dostarlimab will be administered.
223918613|NCT06817096|DRUG|Nitazoxanide 600Mg Oral Tablet / placebo oral tablet|1 tablet every 12 hours
224278618|NCT00407745|DRUG|placebo|Placebo
224278619|NCT00407745|DRUG|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
224278620|NCT02581072|DRUG|SB204 4%|Applied topically once
224278621|NCT02581072|DRUG|SB204 8% or 12%|Applied once topically
224278622|NCT02581072|DRUG|Vehicle|Applied topically once
224278623|NCT05270928|DRUG|IBI346|IBI346 Antibody and IBI346 CAR-T cell injection
224278624|NCT06175429|DIAGNOSTIC_TEST|Physical performance testing|Assessment of physical performance using established clinical tests and scoring systems
223918614|NCT06816134|DRUG|TmBU conditioning Regimen|TmBU conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT) : Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT)：Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
223918615|NCT06816134|DRUG|mBUCY conditioning regimen|mBUCY conditioning Regimen and GVHD Prophylaxis of Haploid transplantation (Haplo-HSCT) and unrelated donor transplantation (UDT): Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG) or GVHD Prophylaxis of Matched Sibling Donor Hematopoietic Stem Cell Transplantation (MSD-HSCT)：Cyclosporine A (CsA) + short-term low-dose methotrexate (MTX), then stem cells are infused into patient's blood.
223940603|NCT03875066|OTHER|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
223940604|NCT03875066|OTHER|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
223940605|NCT01797666|DRUG|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
223940606|NCT05609149|PROCEDURE|total mesorectal excision|patients must underwent total mesorectal excision
223940607|NCT05818150|DEVICE|Embosphere Microspheres|Embolic Agent: Embosphere Microspheres
224278625|NCT06175429|DIAGNOSTIC_TEST|Breath sampling and VOC analysis|Sampling of exhaled breath and using Proton-transfer-reaction time-of-flight mass spectrometry (PTR-TOF) for VOC quantification.
224278626|NCT06175429|DIAGNOSTIC_TEST|Muscle ultrasound|Quantitative and qualitative assessment of different limb skeletal muscles using non-invasive ultrasound.
224278627|NCT06175429|DIAGNOSTIC_TEST|Blood-based biomarker analysis|Blood sampling and assessment of different blood-based biomarkers of muscle integrity using Enzyme-linked Immunosorbent Assay (ELISA) and Electrochemiluminescence Immunoassay (ECLIA)
224278628|NCT03968731|OTHER|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
224278629|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|250 mg
224278630|NCT01510860|DRUG|UDCA (Ursodeoxycholic acid)|500 mg
224278631|NCT01397981|BEHAVIORAL|Gait retraining|Changing the kinematics of walking
224278632|NCT05176379|DRUG|Fluconazole 150 mg|A single acute 150 mg dose
223716847|NCT01830270|DRUG|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
223716848|NCT01830270|PROCEDURE|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
223716849|NCT06085378|DRUG|Urinary Kallidinogenase for injection|The 0.15 peptide nucleic acids(PNA) unit of Eurecrine for injection was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days
223940608|NCT05818150|DRUG|Corticosteroid injection|Corticosteroid injection
223940609|NCT06465966|DEVICE|iRAI|Ionizing-radiation photo acoustic imaging (iRAI) is a method of collecting images from inside the body using acoustic (sound) waves. Researchers will collect iRAI during a participant's radiation treatments. Researchers will use this imaging to examine the delivery and dose of the radiation to the participant's prostate. Researchers will also compare the delivery and dose calculated from iRAI to the expected doses that were calculated from CT images which are done as standard of care.
223940610|NCT06810505|DRUG|Atogepant|Oral tablet
223940611|NCT06810505|DRUG|Placebo for Atogepant|Oral tablet
223940612|NCT04870255|DEVICE|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
223940613|NCT04870255|DEVICE|Dorsomedial Prefrontal Cortex (DMPFC)|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
223940614|NCT04870255|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
223940615|NCT04840433|DEVICE|MACE|Using magnetically assisted capsule endoscopy to examine oesophagus and stomach
223940616|NCT00942981|DRUG|PET|Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.
223940617|NCT07119801|DEVICE|Radial Extracorporeal Shock Wave Therapy|rESWT will be administered to the FCU and FCR muscles two days per week over a period of four weeks (8 sessions in total). The point of application will be selected as the center of the muscle belly for both the FCU and FCR. Each muscle will receive 2000 shocks using a 15 mm applicator tip at a frequency of 5 Hz. The treatment will be conducted at an intensity of 60 mJ (1 bar), with an energy flux density of 0.340 mJ/mm².
223918616|NCT06813599|OTHER|Neurodevelopmental Technique on Gait Pattern in Children With Spastic Diplegic Cerebral Palsy|"Each child of group A received a designed NDT program, attending three sessions per week for two consecutive months. The internationally recognized neurodevelopmental therapy (NDT) intervention will be used, consisting chiefly of three components:~1\. Exercise training: the therapist is goal-oriented and works with the child to make a family exercise plan. The plan is developed based on specific activities of the children in the family. The plan is designed step by step, and all tasks allow the child to reach a functional goal. Having set an exercise target, the child is able to achieve the goal as his/her exercise ability increases. Subsequently, the difficulty level of the task is increased or the environment altered, so the infant continues to face challenges to exercise ability. In the process of implementing the training plan, the therapist should pay attention to the degree of completion and quality of child movements, making corrections and offering guidance twice weekly."
223918617|NCT06813599|OTHER|Motor Planning Exercises on Gait Pattern in Children With Spastic Diplegic Cerebral Palsy|"Each child of group B will receive a designed motor planning program, attending three sessions per week for two consecutive months. Practicing skills will help children with poor motor planning ability become more confident. There are many things we can do to help children improve their motor planning. Using simple language, Thinking about all the different steps to complete a sequence of steps can be difficult for children with motor planning difficulties so we should keep language simple to help them better understand what they need to do to complete a task.~Breaking new skills down into smaller steps, Guiding the child through a task by providing one instruction at a time. This will help them to better follow instructions and reduce anxiety over learning a new skill. Starting with the simplest movement first, Practice the individual movements that make up a task, gradually increasing the degree of difficulty as your child gains confidence in the simpler movements."
223918618|NCT06818188|OTHER|Turning based specific training with rhythmic auditory stimulation (RAS)|"The study involved an experimental group that underwent a 6-week turning-based training with rhythmic auditory stimulation (TBST-RAS), performed three times a week on alternate days. The purpose was to improve motor control and walking abilities through rhythmic auditory cues, specifically adjusting the metronome's beat to the patient's cadence.~Week 1: Patients performed turning exercises around a cone and walking with visual cues at 5% rhythmic auditory cue intensity, with rest periods.~Weeks 2-3: The intensity of rhythmic auditory cues increased to 10%, and patients engaged in cone turning, figure-of-eight walking, and walking with visual cues, with rest breaks in between.~Weeks 4-5: Rhythmic auditory cue intensity increased to 15%. Exercises included cone turning, figure-of-eight walking, walking with visual cues, multidirectional stepping, and rest periods.~Week 6: The final week involved exercises with a further increase in rhythmic auditory cue intensity to 20%. The exercise"
223918619|NCT06818188|OTHER|Turning based specific training without rhythmic auditory stimulation (RAS)|"The control group underwent 6 weeks of turning-based specific training without rhythmic auditory stimulation (TBST), performed three times a week on alternate days. The training followed this pattern:~Week 1: Patients began with cone turning for 5 minutes, followed by 2 minutes of rest. Then, they walked with visual cues for 5 minutes, also without rhythmic auditory stimulation.~Weeks 2-3: The exercises continued with cone turning and figure-of-eight walking for 5 minutes each, with 2-minute rest periods in between. Patients also walked with visual cues for 5 minutes without RAS.~Weeks 4-5: The exercises included cone turning, figure-of-eight walking, walking with visual cues, and multidirectional stepping (forward, backward, laterally), all for 5 minutes each, with rest periods between exercises.~Week 6: In the final week, the duration of cone turning and figure-of-eight walking was reduced to 3 minutes, but the exercises still had 2-minute rest periods in between. Patients also p"
223918620|NCT06816511|PROCEDURE|magnetic resonance-guided focused ultrasound surgery, MRgFUS|Magnetic Resonance-Guided Focused Ultrasound Surgery The clinical symptoms, brain imaging, and cognitive function status were followed up for 2 years before and after surgery.
223918621|NCT06816628|OTHER|comedy therapy|After patients came to the clinic after transplantation surgery and their condition was stable, 10-minute Turkish comedy films prepared by the researchers were shown.
224278633|NCT01219452|BIOLOGICAL|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
224278634|NCT02644161|PROCEDURE|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
223530341|NCT06255353|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223530342|NCT04047446|DRUG|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
223530343|NCT04047446|DRUG|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
223716850|NCT06085378|OTHER|Placebo|The 0.15 peptide nucleic acids(PNA) unit of placebo was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day. The solvent can be increased and/or slowed down according to the patient's condition for 10 consecutive days, while receiving clinical routine treatment for 10 days.
223716851|NCT02587260|DRUG|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
223716852|NCT02587260|DRUG|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
223716853|NCT02587260|DRUG|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
223716854|NCT02126917|DRUG|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
223716855|NCT02126917|DRUG|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
223716856|NCT02126917|DRUG|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
223716857|NCT03727269|OTHER|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
223716858|NCT03727269|OTHER|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~1. Knack Maneuver (Ashton -Miller 1998, 2008)~2. Pelvic floor strengthening: kegel Exercise.~3. -Lumbo-Pelvic Stabilization Exercise.~4. Functional Training/ PFM Contraction during ADL~5. Correction of biomechanical/structural deformities"
223716859|NCT00166478|DRUG|Exisulind Therapy|
223716860|NCT04556162|DIAGNOSTIC_TEST|fractional sodium excretion|fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.
223716861|NCT04556162|OTHER|risk subgroups|subgroup analysis will be performed to identify the patient groups at risk for sodium depletion
223716862|NCT01552200|PROCEDURE|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
223716863|NCT01552200|PROCEDURE|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
223716864|NCT03146013|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
223716865|NCT00720538|DRUG|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
223716866|NCT00720538|DRUG|placebo|placebo capsules
223716867|NCT01591759|DRUG|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
223918622|NCT06817798|OTHER|Specific foot mobility|Specific mobility of the foot, performed bilaterally.
223918623|NCT06592443|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
223918624|NCT06592443|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
224278635|NCT02644161|PROCEDURE|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
223716868|NCT01591759|DRUG|Placebo|Placebo arm of single-blind study
223716869|NCT00309114|PROCEDURE|bacterial interference|
223716870|NCT04388878|DRUG|PF-07054894|Participants will receive oral ascending doses
223716871|NCT04388878|DRUG|Placebo|Participants will receive matching placebo
223716872|NCT02054091|DIETARY_SUPPLEMENT|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
223716873|NCT04353271|DRUG|Hydroxychloroquine|Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.
223716874|NCT04353271|OTHER|Placebo|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.
223716875|NCT00284583|DRUG|Injection of Steroid into Foot|
223716876|NCT00284583|DRUG|Injection of Alcohol into Foot|
223716877|NCT00284583|DRUG|Injection of Lidocaine into Foot|
223716878|NCT02284984|DRUG|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
223716879|NCT03675477|DRUG|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).
223716880|NCT03675477|DRUG|Placebo|Placebo Oral Tablet
223918625|NCT06592443|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
223918626|NCT06657690|DRUG|Irinotecan liposome|Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
223918627|NCT06657690|DRUG|S-1|S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
223918628|NCT06657105|DRUG|EE/LNG|EE/LNG tablet will be administered orally.
223918629|NCT06657105|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
223918630|NCT06286800|DEVICE|Transcranial direct current stimulation (tDCS) with OT|Weak direct current (0.5-2 mA) will be delivered for up to 20 minutes through surface electrodes which will be positioned using the ptDCS montage. The current will be increased and decreased ramp-like at the beginning and end of the 20-minute stimulation to lessen the itchy/numb skin sensation and decrease the likelihood of an innocuous phosphene-like visual phenomenon. The stimulation will be delivered during the first 20 minutes of occupational therapy targeted to the more affected upper extremity.
223918631|NCT06286800|DEVICE|Sham tDCS with OT|Same procedure and montage as with the active stimulation but the current will be increased then decreased ramp-like and switched off after 20 seconds instead of the 20 minutes to elicit the same cutaneous sensation as the other stimulation conditions. \[69\] This short length of stimulation is documented to elicit sensations comparable to those of real stimulation. With this procedure, subjects were unable to differentiate between tDCS and sham stimulation in our and other previous studies.
223918632|NCT04966637|OTHER|COPD cohort|as this a retrospective descriptive study no intervention will be administered to study participants
223918633|NCT06857201|PROCEDURE|Left Bundle Branch Area Pacing|LBBAP is performed during permanent pacemaker implantation post-TAVR.
223918634|NCT06857201|PROCEDURE|Right Ventricular Pacing|RVP is performed during permanent pacemaker implantation post-TAVR.
223918635|NCT06664203|PROCEDURE|Selective turuncus block with 25 ml bupivacain|A high-frequency linear ultrasound (USG) probe will be used to locate the C7 transverse process, which will serve as a sonoanatomic landmark. Once the C5 ventral ramus is identified at the C7 transverse process level, the linear probe will be slightly caudally angled to visualize the C6 ventral ramus. The area where the superior trunk is formed by C5 and C6 will be examined with the USG probe until the superior trunk is visualized. Below the superior trunk, the middle trunk and the C8 ventral ramus will be visible. In Group 1, a total of 23 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used as the local anesthetic mixture, totaling 25ml. 7ml of the local anesthetic mixture will be injected into the superior trunk, the middle trunk for an additional 8 ml. The probe will then be directed caudally to obtain an optimal view of the lower trunk, where 10 ml of the same mixture will be injected close to the lower trunk.
223918636|NCT06664203|PROCEDURE|Selective turuncus block with 15 ml bupivacain|In Group 2, 13 ml of 0.5% bupivacaine plus 2 ml (8 mg dexamethasone) will be used, totaling 15 ml. In Group 2, 5 ml of the local anesthetic mixture will be injected into the superior trunk, followed by 5 ml into the middle trunk and 5 ml into the lower trunk, as in Group II.
223918637|NCT06661031|BEHAVIORAL|Motivational Enhancement Therapy plus Ecological Momentary Intervention|Two Motivational Enhancement Therapy (MET) sessions (1st, \~45 minutes; 2nd, \~30 minutes) between counselor and participant occur one week apart. MET sessions are personalized, interactive, face-to-face, and delivered according to a manual. MET session discussion topics include triggers for cannabis use, life goals/values, and development of a change plan. Participants then complete a 2-week Ecological Momentary Intervention (EMI) period. Survey prompts are sent 4x/day (3x/day at quasi-randomized times, 1x/day at fixed time; \~2 mins each) that ask about the participant's recent cannabis use. Depending on answers reported, the participant can receive tailored messages that support their self-efficacy and prompt use of coping strategies.
223918638|NCT06661031|BEHAVIORAL|Enhanced Usual Care|Participants meet with a study counselor 1-on-1 via videoconference to review a brochure containing cannabis information and treatment resources.
223918639|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Synergy ZFR00).
223918640|NCT06658119|PROCEDURE|cataract surgery|The participants will receive femtosecond laser-assisted cataract surgery and implant an extended depth-of-focus intraocular lens (Tecnis Symfony ZXR00).
223918641|NCT06658197|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg) plus mechanical thrombectomy
223918642|NCT06658197|DRUG|Alteplase|Alteplase 0.9 mg/kg administered as 10% bolus +90% infusion/1 hour (maximum dose 90mg) plus mechanical thrombectomy
223918643|NCT06663098|DRUG|Atezolizumab|1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase
223918644|NCT06663098|DRUG|Carboplatin|AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase
223918645|NCT06663098|DRUG|Etoposide|80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days
223918646|NCT06619275|DRUG|Ripretinib|Switch-Control Tyrosine Kinase Inhibitor
223918647|NCT06777745|OTHER|Model-assisted breast examination application|Designed for the development of self-examination skills, this model is in the shape of a female upper body with medium-sized breasts. Thanks to its ergonomic design, it can be worn easily and offers a comfortable use. Made of high quality, dermatologically tested and tactile silicone material. This model, which reflects all the details of the skin realistically, has a structure suitable for standing and lying examination. For educational use, there are 2 benign tumours, 4 malignant tumours and 2 typical anomalies. This model allows for practical explanation of all stages of breast examination such as determining the area to be examined, manual examination of the area, examination method, nipple examination and detection of malignant formations in the breast.
223918648|NCT05763901|DIAGNOSTIC_TEST|Clinical tests and motor control evaluation using Inertial Measurement Units|Each patient is evaluated using clinical tests (Movement ABC2, Test of Motor Competence), a screening questionnaire (DCD-Q), and wearable Inertial Measurement Units to assess balance and motor control during a Natural Walking and Tandem Walking test.
223716881|NCT01163175|OTHER|Ruminant trans fats|"Consumption of the 4 experimental diets:~1. a diet rich in ruminant TFA (8 g/day);~2. a diet moderately rich in ruminant TFA (4 g/day);~3. a diet rich in industrial TFA (8 g/d);~4. a control diet (minimal dietary TFA of industrial and ruminant sources)."
223716882|NCT06204146|BEHAVIORAL|massage|stressn level and preterm growth
223716883|NCT00696722|DRUG|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
223716884|NCT00696722|DRUG|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
223716885|NCT04924322|DRUG|Enoxaparin|Enoxaparin is a LMWH produced from UFH that exerts its anticoagulant effects by binding to and inducing a conformational change in antithrombin to accelerate the inactivation of factor Xa and thrombin. Age-specified dose of enoxaparin will be administered within 24 hours after insertion of the CVC with the dose subsequently adjusted to pre-specified anti-Xa target.
223716886|NCT03652012|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
223716887|NCT02199366|PROCEDURE|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
223716888|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection30mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (30mg/m2)
223716889|NCT05941585|DRUG|HomoharringtonineD1-D7(2mg/m2/day)|Homoharringtonine intravenous infusion on D1-D7,2mg/m2/day in a 4-week treatment cycle.
223716890|NCT05941585|DRUG|Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)|Venetoclax d4-d12 (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day)in a 4-week treatment cycle.
223716891|NCT05941585|DRUG|Cytarabine(standard-dose:d1-d7100mg/m2/day)|Cytarabine intravenous infusion on d1-d7 ,100mg/m2/day
223716892|NCT05941585|DRUG|Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2)|d1-d4100mg/m2/day, d5-d7 1g/m2
223716893|NCT05941585|DRUG|Mitoxantrone hydrochloride liposome injection24mg/m2|Mitoxantrone hydrochloride liposome intravenous infusion on day 1 (24mg/m2)
223716894|NCT05393895|DRUG|CSF-1|One drop bilaterally twice daily for at least 6 weeks
223716895|NCT05393895|DRUG|Vehicle|One drop bilaterally twice daily for at least 6 weeks
223716896|NCT02696603|BEHAVIORAL|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
223716897|NCT02696603|BEHAVIORAL|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
223918649|NCT03901534|DEVICE|Continuous positive airway pressure (CPAP) therapy|Standard, clinically used CPAP therapy. CPAP will be prescribed by the participants' clinician provider and not by the study investigators.
223918650|NCT03901534|DEVICE|Nox A1 Recorder|Non-invasive, body-worn, sleep recording device for nocturnal polysomnography.
223716898|NCT02696603|BEHAVIORAL|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
223918651|NCT03327714|BEHAVIORAL|Mindfulness and compassion|
223918652|NCT05161819|DEVICE|Repetitive transcranial magnetic stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
223918653|NCT05161819|DEVICE|Sham stimulation|High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
223918654|NCT06814769|DEVICE|hyaluronic acid|intra-articular administration
223716899|NCT02696603|BEHAVIORAL|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test \[Corsi, P.M. (1972)\] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
223716900|NCT02696603|BEHAVIORAL|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
223716901|NCT02696603|BEHAVIORAL|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
223716902|NCT02696603|OTHER|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
223716903|NCT04740190|DRUG|Talazoparib|low dose whole brain radiation, followed by combination talazoparib and carboplatin
223716904|NCT04124757|OTHER|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
223918655|NCT06407739|OTHER|Three-Phase Physical Therapy Intervention|Phase 1: It include subtalar and talocrural joint mobilization in the supine position along with stretching and home education Stage 2: It include subtalar and talocrural joint mobilization in the supine position along with Kinesiotaping and functional exercises Phase 3: this phase include balance and propioceptive training aling with along with strengthening exercises of peroneal and tibialis anterior
223918656|NCT06258707|DEVICE|LuxBoost IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
223918657|NCT06258707|DEVICE|LuxGood IOL|Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
224089597|NCT03918512|OTHER|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~* Demographical and clinical characteristics at baseline~* Consolidated version of the CSS-48 questionnaire~* Lumbar pain numeric rating scale (NRS)~* Radicular pain NRS~* Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~* Oswestry Disability Index (ODI)~* Fukushima LSS Scale 25 (FLS-25)~* 12-Item Short Form Health Survey (SF-12)~* Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
223918658|NCT06823154|DRUG|Amoxicillin|Prospective cohort study of patients presenting to the ED with a reported BLA. (1) Allergy history and risk assessment, (2) Oral provocation challenge (if eligible), and (3) Post-discharge follow-up (if received OPC or referred to allergy).
223918659|NCT06823154|OTHER|Study questionnaire|"In the first component of the study, research staff will survey patients for history pertinent to their BLA label. This includes questions regarding any prior evaluations, patients' perception of their allergy label, and clinical details of allergy history. The latter involves an allergy history risk assessment, which will screen patient for high-risk features (eg, new maculopapular rash within 2 hours of administering antibiotic). Presence of any high-risk features will disqualify the patient from subsequent study components.~Finally, the questionnaire will screen for presence of any clinical confounders that would preclude administration of the OPC (eg, use of antihistamines within prior 72 hours)."
224089598|NCT02332252|DEVICE|Scalpel|Skin incision performed with a scalpel during cesarean section.
224089599|NCT02332252|DEVICE|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
224089600|NCT02332252|PROCEDURE|Skin incision|
224089601|NCT00476138|DRUG|Epigallocatechin-gallate|
224089602|NCT00937235|DRUG|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
224089603|NCT00937235|BEHAVIORAL|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
224089604|NCT00937235|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
223918660|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
223918661|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
223918662|NCT04074733|DIAGNOSTIC_TEST|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
223918663|NCT06825767|DEVICE|Conventional Treatment|Conventional treatment including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg for 4 weeks, 3 days a week for 4 weeks in 24 patients
224089605|NCT02948894|DEVICE|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
224089606|NCT00419250|DRUG|lenalidomide|
224089607|NCT00419250|DRUG|lenalidomide|
223716905|NCT05051722|DIAGNOSTIC_TEST|Vaginal Fluid Collection|A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.
223918664|NCT06825767|DEVICE|conventional treatment and high-intensity laser therapy(HILT)|Conventional treatment and HILT including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg and HILT for 4 weeks, 3 days a week for 4 weeks in 24 patients .
223918665|NCT06825767|DEVICE|conventional treatment and low-intensity laser therapy (LLLT)|Conventional treatment and LLLT including hotpack therapy, Transcutaneous Electrical Nerve Stimulation (TENS), joint range of motion exercises, straight leg lifting exercises, quadriceps strengthening exercises, pillow squeezing exercises, balance exercises on one leg and LLLT for 4 weeks, 3 days a week for 4 weeks in 24 patients.
224089608|NCT00419250|DRUG|lenalidomide|
224089609|NCT00419250|DRUG|lenalidomide|
224089610|NCT00419250|DRUG|lenalidomide|
224089611|NCT03522545|BIOLOGICAL|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
223716906|NCT05051722|DIAGNOSTIC_TEST|Blood Collection|A blood sample will be collected from each participant prior to undergoing any exams or procedures.
223716907|NCT05537883|DRUG|Liposomal bupivacaine|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
223716908|NCT05537883|DRUG|Bupivacaine Injection|Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
224089612|NCT03522545|BIOLOGICAL|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
224089613|NCT03783195|OTHER|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
224089614|NCT06548321|DIAGNOSTIC_TEST|Extracorporeal Shockwave Therapy|" The ESTW machine is turned on and the instrument, or shockwave gun, is pressed against the affected area. Rapid impulses are then delivered to the patient. Treatment typically lasts between 5 and 15 minutes. While this treatment can be uncomfortable for some, most do not experience any pain.~Once treatment is completed, patients should do their best to physical activity… higher levels of energy Shockwaves into deeper tissue locations… ESWT therapies can help treat neurological disorders like multiple sclerosis and the effects of stroke."
224089615|NCT06252116|DRUG|Pregabalin group|Pregabalin group
224089616|NCT06252116|DRUG|Duloxetine group|Duloxetine group
224089617|NCT03115931|OTHER|no intervention|no intervention
224089618|NCT01793792|DEVICE|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
224089619|NCT01185847|DRUG|RO5083945|intravenously, until disease progression
224089620|NCT01185847|DRUG|cisplatin|standard treatment, up to 6 cycles
223530344|NCT04390282|BEHAVIORAL|Application-based support system|All participants (experimental and control group) will be invited to a separate appointment at the vascular open clinic at baseline and after three months and measured regarding weight, blood pressure, Ankle Brachial Pressure Index, six minutes walking test and pain. To calculate the estimate 10-year risk of manifesting clinical cardiovascular disease, the Framingham Risk Score will be used. Further, a questionnaire will be answered at baseline and after three months containing the instruments, VascuQoL-6, Health Education Impact Questionnaire and Medication Adherence Report Scale-5.
223918666|NCT06826040|DRUG|SKB445 for injection|SKB445 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
223918667|NCT06819267|OTHER|Horizontal Plyometric Group|"Group A~* Duration: A 30-minute treatment session for four weeks.~* Frequency: Two to three sessions per week.~* Warm-up: 5 minutes following the FITT principle (Frequency, Intensity, Time, Type).~* Warm-up Components:~* 5 minutes of moderate to high-intensity cardiovascular warm-up.~* Exercise Components (30 minutes per session):~* Horizontal ankle jumps\| Long jumps \| Diagonal obstacle jumps~* Intensity: Moderate to high."
223918668|NCT06819267|OTHER|Vertical Plyometric Group|"Group B~* Duration: A 30-minute treatment session for four weeks.~* Frequency: Two to three sessions per week.~* Warm-up: 5 minutes following the FITT principle (Frequency, Intensity, Time, Type).~* Warm-up Components:~* 5 minutes of moderate to high-intensity cardiovascular warm-up.~* Exercise Components (30 minutes per session):~* Vertical ankle jumps~* Counter movement jump~* Front obstacle jumps"
223918669|NCT06825104|DEVICE|Volta AF-Xplorer|Dispersion ablation strategy guided by Volta Medical AI-software targeting areas of spatiotemporal dispersed electrograms
223918670|NCT06825104|PROCEDURE|Dispersion ablation + PVI|TAILORED-AF index procedure: Dispersion ablation + PVI
223918671|NCT06825104|PROCEDURE|PVI|TAILORED-AF index procedure: PVI only
223918672|NCT06306898|OTHER|Endotracheal Intubation|Ventilation with an endotracheal tube
223918673|NCT06306898|OTHER|Laryngeal tube|Ventilation with an laryngeal tube
223918674|NCT06306898|OTHER|Laryngeal mask|Ventilation with an laryngeal mask
223918675|NCT06306898|OTHER|I-Gel-Laryngeal Mask|Ventilation with an I-Gel-laryngeal mask
223918676|NCT01653678|DIETARY_SUPPLEMENT|Vitamin D-3 (cholecalciferol), 2000 IU|
223918677|NCT01653678|DRUG|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
224278636|NCT02644161|DRUG|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
223530345|NCT02367456|DRUG|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
223918678|NCT01653678|DIETARY_SUPPLEMENT|Vitamin D placebo|
223530346|NCT02367456|DRUG|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
223918679|NCT01653678|DRUG|Fish oil placebo|
223918680|NCT06824116|BEHAVIORAL|Exercise|Training on a bicycle ergometer was performed four times a week for 3 weeks for 45 min. The exercise intensity corresponded to 50%-60% of maximal oxygen uptake (VO2max).
223918681|NCT06824116|BEHAVIORAL|Exercise|Training on a bicycle ergometer was performed four times a week for 3 weeks for 45 min. The exercise intensity corresponded to 70 - 80% of maximal oxygen uptake (VO2max).
223918682|NCT06662435|BEHAVIORAL|GYNCOG|"Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day.~Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include:~Double Decision: This exercise tests your ability to quickly identify and choose between two options.~Eye for Detail: It challenges participants to spot small differences between two similar images.~Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours."
223918683|NCT06825819|BIOLOGICAL|Subjects with and without Long COVID|To collect biospecimens (matched stool \& blood) samples from 400 people with and without long COVID (200 participants/group) to understand how COVID-induced dysbiosis impacts symptom severity, immune suppression, and gut barrier dysfunction both ex vivo and in vitro.
223918684|NCT06825858|DRUG|KH658|KH658: AAV vector containing a coding sequence for an anti-VEGF protein
224278637|NCT02644161|OTHER|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
223716909|NCT04034446|BIOLOGICAL|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
223918685|NCT06825936|OTHER|Diet intervention|For participants assigned to the intervention arm, the dietary intervention consists of: a) pre-cooked Asian-Mediterranean meals: participants will receive free meals, two meals a day, five days a week, and b) pre-packed nuts, 30g a day, five days a week, during the intervention period. Additionally, participants will receive a dietary consultation session at baseline and every four weeks.
223918686|NCT06825936|OTHER|Control|For participants assigned to the control arm, they will receive a leaflet with dietary advice based on national guidelines at baseline.
223918687|NCT06825949|DEVICE|Hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
223918688|NCT06824324|DRUG|intramuscular Botulinum Toxin|A thirty units of Botulinum toxin A was injected intramuscularly in Triger zone of patient with myofascial pain syndrome
223918689|NCT06824779|DRUG|Flu Vaccine|Vaccination against FLU by one of FLU vaccines in the french market
224089621|NCT01185847|DRUG|gemcitabine|standard treatment, up to 6 cycles
224278638|NCT02644161|PROCEDURE|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
223530347|NCT04089410|DEVICE|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
223918690|NCT06824779|BIOLOGICAL|Biological samples|"Before and after the FLU vaccination, according the french recommendations, the following samples will be collected :~Nasal fluid sampling Saliva sampling Blood samples Nasal cell sampling"
223530348|NCT04089410|DEVICE|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
223530349|NCT04089410|OTHER|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
223918691|NCT06665724|DRUG|5-Aminolevulinic acid Hydrochloride (Gliolan®)|Patients will receive 5-Aminolevulinic acid hydrochloride via oral administration (20 mg/kg) 6-8 hours before CV01 treatment.
223918692|NCT06665724|DEVICE|CV01|Ultrasound will be delivered 6-8 hours after administration of 5-aminolevulinic acid hydrochloride. A total of 12 fields will be treated (10 treatment sites across the hemisphere with 2 additional treatments over areas of increased enhancement).
223918693|NCT06823999|DRUG|Ascorbic acid (Vitamin C)|In the study, acute ischemic stroke patients will receiving vitamin C 4 gram perday for 4 days.
223918694|NCT06823999|OTHER|Normal Saline (Placebo)|Particiapnts receiving normal saline 20 ml perday for 4 days
223918695|NCT06664827|DEVICE|Delfi PTS Blood Flow Restriction Tourniquet System|In Houston Methodist rehabilitation clinics these devices are used as standard of care for BFR therapy in many post-operative treatments. General guidelines suggest using ranges between 30% - 80% of limb occlusion pressure (LOP). In our previous research efforts involving BFR the investigators have adhered to these guidelines and experienced no adverse events while observing these ranges to be well tolerated by subjects.
223918696|NCT05189236|PROCEDURE|Control Group (Only Algorithm of Febrile Neutropenia Management)|"Common Procedure Steps~1. The child is admitted to the unit and evaluated.~2. The objective of the study is explained to the children and children's parents, and their consent is obtained after they have read and signed the informed consent form.~3. The inclusion and exclusion criteria are evaluated.~4. The group of the child to be included in the study is determined in accordance with the randomization order.~5. The first section of the patient information and follow-up form is filled out.~6. The algorithm of Febrile Neutropenia Management is applied. The room temperature is kept constant at 21-24 degrees.~Procedure Steps for Control Group:~1. Common procedure steps are followed.~2. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
223530350|NCT04089410|OTHER|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
223530351|NCT04089410|OTHER|Autonomic Balance, Orthostatic and Hypoxic tolerance|"1. Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~2. Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~3. The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
223716910|NCT04530773|BEHAVIORAL|Watch VR movies/ Play VR games|The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.
223716911|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing high dose of the drug substance.
223940618|NCT07119801|OTHER|Conventional rehabilitation|Conventional rehabilitation will be administered for 1-2 hours daily, 5 days a week, for 12 weeks. It will include range of motion exercises, stretching exercises, progressive resistive exercises, positioning, postural control, weight shifting, balance, gait training, occupational therapy, and speech-language therapy according to the patient's needs.
223940619|NCT04491292|OTHER|Questionnaire Administration|Complete questionnaires
223940620|NCT06979076|DRUG|MS-553, DS1|Oral, Dose Schedule 1
224089622|NCT01185847|DRUG|pemetrexed|standard treatment, up to 6 cycles
223530352|NCT04089410|OTHER|Psychological Testing|"1. Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~2. Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~3. Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~4. Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
223530353|NCT04089410|OTHER|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
223530354|NCT05950321|PROCEDURE|Paramedian cervical epidural steroid injection|For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
223716912|NCT05039515|DRUG|IPN60130|Immediate-release capsule containing low dose of the drug substance.
223716913|NCT05039515|DRUG|Placebo|Placebo will be supplied as powder filled hard capsules
223940621|NCT06979076|DRUG|MS-553, DS2|Oral, Dose Schedule 2
223940622|NCT05775848|DRUG|BBP-418 (ribitol)|The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.
223940623|NCT05775848|OTHER|Placebo|A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
223940624|NCT06341452|DEVICE|Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control|Patients will be treated for 12 weeks thrice weekly Hemodialysis or Hemodiafiltration sessions resulting in 36 sessions per patient.
223940625|NCT06977828|DRUG|tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy|After receiving 4 cycles of tislelizumab combined with anlotinib and platinum-based doublet chemotherapy, the subjects will be evaluated by a multidisciplinary team (MDT) to determine whether to proceed with radical surgical resection. The surgery will be performed within 3 to 7 weeks after the last neoadjuvant treatment. Postoperatively, patients will be divided into two subgroups based on the pathological results: For patients with postoperative pathological pCR, tislelizumab monotherapy will be used for maintenance treatment; For patients with postoperative pathological non-pCR, tislelizumab combined with anlotinib will be used for maintenance treatment. Both groups will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor therapy, death, or other situations specified in the protocol that require treatment cessation, whichever occurs first. The maximum treatment duration is 12 months
223940626|NCT06608849|OTHER|Blood samples|Blood sampling for proteomics and transcriptomics, suPAR measurement \&amp; isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \&amp; urea
223940627|NCT06608849|OTHER|Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms|Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
223940628|NCT06445023|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
223940629|NCT06445023|BIOLOGICAL|Matching placebo|Matching placebo Subcutaneous Administration
223940630|NCT04825613|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells
223940631|NCT04440280|DRUG|N-acetyl cysteine (NAC) 10% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
223940632|NCT04440280|DRUG|N-acetyl cysteine (NAC) 20% solution|N-acetyl cysteine is a sterile, unpreserved eye drop containing 20% (200 mg/mL) of acetylcysteine.
223940633|NCT04440280|DRUG|Visine Dry Eye Relief eye drops|Visine Tears Dry Eye Relief artificial tears ophthalmic solution
223940634|NCT05023070|DRUG|Cannabidiol|Cannabidiol 200 mg
223940635|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
223940636|NCT05023070|DRUG|Cannabidiol|Epidiolex 400 mg
223940637|NCT05023070|DRUG|Cannabidiol|Cannabidiol 400 mg
223940638|NCT06980805|DRUG|IMVT-1402|Dose 1 or Dose 2 SC QW
223940639|NCT06980805|DRUG|Placebo|Matching Placebo SC QW
223940640|NCT04226248|DRUG|Rivastigmine Transdermal System|Rivastigmine Trandermal Patches applied once a day for up to 12 months
223940641|NCT04226248|OTHER|Placebo Transdermal System|Placebo Trandermal Patches applied once a day for up to 12 months
223940642|NCT06782451|PROCEDURE|Surgery or biopsy|A part of the tumor sample collected during the surgery or the biopsy performed as part of routine patient care will be used for the research.
223940643|NCT06782451|PROCEDURE|Blood sample|38 mL of blood will be taken for the study.
223940644|NCT06593717|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
223940645|NCT06593717|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
223918697|NCT05189236|PROCEDURE|Experimental Group (Algorithm of Febrile Neutropenia Management+Cold Steam)|"Procedure Steps for Experiment Group:~1. Common procedure steps are followed.~2. Cold steam is continuously applied until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative).~3. The body temperature of the child are recorded in the second section of the Patient Information and Follow-up Form from the time the patient is admitted until the fever is kept under control (until the discharge criteria are met, - 72 hours without fever and the culture result is negative)."
223918698|NCT06665737|DRUG|Early receiving G-CSF group|Early receiving G-CSF group will be given within 72 hours post chemotherapy
223918699|NCT06665737|DRUG|Late receiving G-CSF group|Late receiving G-CSF group will be given after 72 hours post chemotherapy
223918700|NCT06824636|OTHER|a personalized diet plan was prepared according to the calculated requirements of each patient by two expert dietitians|Oral enteral nutrition products were added to the diet if the daily calorie and/or protein requirements could not be met by the diet. All of the patients underwent follow-up visits (4th and 8th weeks) after the initial assessment on admission. Each visit (0, 4th and 8th weeks) included screening of the nutritional status and food consumption, and measurements of body mass index (BMI), muscle mass, muscle strength, gait speed, serum albumin and serum C-reactive protein (CRP). Anthropometric measurements, muscle strength, physical performance, and the physical exercise plan were assessed.
223918701|NCT06825728|DRUG|Different doses of Metoprolol.|The control group received 23.75mg/d of metoprolol, and the experimental group received the maximum tolerable dose of metoprolol.
223918702|NCT02405221|BIOLOGICAL|TA-CIN (arm)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
223918703|NCT02405221|BIOLOGICAL|TA-CIN (thigh)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
224278639|NCT05583110|DRUG|Tucatinib|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
223530355|NCT05950321|PROCEDURE|Selective nerve root pulsed radiofrequency|For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
223530356|NCT04975620|DEVICE|Fine needle biopsy|Taking biopsy from solid pancreatobiliary mass lesions with 8 back and forth movement of the needle within the lesion with slow withdrawal of the stylet
223716914|NCT05373784|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual into the gastrointestinal tract of another individual. This is currently an accepted method of treatment for recurrent colitis secondary to Clostridium difficile infection refractory to antibiotics/medical management. FMT can be delivered via capsule endoscopy or via colonoscopy. In this study, it will be administered via colonoscopy.
223918704|NCT06824597|BEHAVIORAL|Baby-friendly hospital initiative training program|"The Baby-Friendly Hospital Training Program is a critical intervention to improve maternal and infant health outcomes by promoting and supporting breastfeeding worldwide. It empowers the maternity nurses in this study to create an environment that prioritizes the needs of mothers and babies, ensuring the best possible start to life. It will be conducted for eight sessions (theoretical and practical), each session for about 20-30 minutes. It will include the importance of early initiation of breastfeeding, skin-to-skin contact immediately after birth, the importance of exclusive and continued breastfeeding, positions of breastfeeding, the importance of avoiding pre-lacteal feeds and unnecessary supplementation, advantages of rooming-in, and how to manage common breast and nipple conditions.~The researcher will design an Arabic booklet and distribute it to the nurses at the first session as a guide to reinforce the teaching"
223719563|NCT04080401|OTHER|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
223918705|NCT06824298|OTHER|TENS|"Before surgery: The socio-demographic data of the patients will be recorded. During surgery: After patients are taken to the operating room and anesthesia is induced, TENS electrodes will be attached to the paravertebral muscles at the level of Lumbar vertebrae 2, 3 and Sacral Vertebrae 2, 3. After the surgery is completed, TENS will be activated before the patient is woken up.~TENS settings: In modulation type, medium intensity contractions will be given at a frequency ranging from 60-80 Hertz to 1-5 Hertz, with a current rate ranging from 50-100 microseconds to 150-200 microseconds.~After surgery: TENS will continue to be applied to patients in the recovery room for 30 minutes after the surgery. Patients will be evaluated by researchers in terms of pain and comfort associated with bladder tenesmus at 0, 15 and 30 minutes in the recovery room and at 6, 12 and 24 hours in the postoperative ward."
223918706|NCT05008172|PROCEDURE|Splenic Artery Embolization|The decision for proximal or distal (selective) embolization is at the discretion of the Interventional Radiologist. For patients with angiographically evident injury, the choice of embolization site will be left to the discretion of the operator. For patients without angiographically evident injury, proximal splenic embolization will be performed with approved materials (coils or plugs for most patients) within the main splenic artery. The embolization endpoint will be hemostasis in the main splenic artery.
223918707|NCT06817525|DRUG|6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group A： Albumin-bound paclitaxe (260 mg/m²,d 1)+Carboplatin (AUC=5, d 1)+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"
223918708|NCT06817525|DRUG|6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group B: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15)+Carboplatin (AUC=5, d 1 )+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"
223918709|NCT06817525|DRUG|6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group C： Albumin-bound paclitaxe (260 mg/m²,d 1, 6 cycles)+Carboplatin (AUC=5,d 1, 6 cycles)+Camrelizumab (200 mg, , d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"
223918710|NCT06817525|DRUG|6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 ( d 1)+5*Bevacizumab ( d 1)|"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group D: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15,6 cycles)+Carboplatin (AUC=5, d 1, 6 cycles)+Camrelizumab (200 mg, d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"
223918711|NCT06819150|OTHER|Newborn bathing|The babies in the experimental group will have a bathtub bath before starting phototherapy treatment.
223716915|NCT03665051|PROCEDURE|Muscle Tissue Biopsy|A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
223918712|NCT06818942|OTHER|Observations on preoperative and intraoperative factors influencing the difficulty of surgery|Age, body mass index, gender, inflammatory indicators, previous history of abdominal surgery, underlying disease
223918713|NCT04616924|DRUG|RHB-204|RHB-204
223918714|NCT04616924|DRUG|Placebo|Matching placebo to RHB-204
223918715|NCT06825676|BEHAVIORAL|CKD Patient Management Based on Guidelines|"1. Lifestyle Education: smoking cessation, physical activity, healthy eating, and weight management.~2. Pharmacological Treatment: Implement targeted and guideline-based pharmacological treatment plans for patients with different comorbidities, such as the use of RAAS inhibitors (RASi), SGLT2 inhibitors, statins, and other medications.~3. Risk Factor Management: Effectively manage risk factors such as hypertension, diabetes, and dyslipidemia, and regularly reassess these factors.~4. Risk Assessment: Perform risk assessments for CKD patients based on eGFR and UACR, and implement graded management according to the results.~4、Referral Management: Refer patients with eGFR \< 30 ml/min/1.73m² or severe proteinuria.~5、CKD Patient Management Checklist: Community doctors should complete the CKD patient management checklist in a standardized manner, including records of risk factors, dynamic kidney function, and follow-up plans."
223918716|NCT06824922|BEHAVIORAL|"Be yourself, educational intervention with chatbot to promote self-determined motivation and prevent adolescent pregnancy: pilot trial protocol"|"The Be Yourself educational intervention stands out for its focus on self-determined motivation and teen pregnancy prevention. Unlike traditional interventions, which focus on transmitting information, this intervention promotes adolescent autonomy in making responsible sexual decisions. It uses interactive technology such as a web page and a chatbot, which provide personalized follow-up and reinforcement activities between sessions, encouraging active participation. It also employs competency-based learning, which strengthens practical and emotional skills, such as effective communication and problem solving. Sessions include role-plays and practical activities to apply what has been learned. This comprehensive approach and the use of digital platforms distinguish Be Yourself from other interventions, offering continuous and personalized accompaniment to reinforce learning throughout the process."
223918717|NCT06824922|OTHER|Conventional Sex Education|For the CG, two theoretical sessions are planned. In the first, an orientation on adolescent sexual health will be provided through a one-hour PowerPoint presentation. Topics of anatomy, physiology, biological changes in adolescence and contraceptive methods will be addressed, highlighting their proper use and the prevention of adolescent pregnancy. The second session, also lasting one hour, will develop sexual health self-care skills, discussing the importance of self-care, self-respect and informed decision making. There will be a question and answer session to address concerns and reflect on how self-care contributes to a healthy and safe sexual life.
223918718|NCT06824441|BEHAVIORAL|Age- and Role-Specific Questionnaire Administration|"Participants will be assigned a sequence number upon eligibility confirmation. The intervention consists of completing a series of questionnaires, as follows:~Child/AYA/Caregiver Group:~Pre-clinic Visit: 3 questionnaires (approximately 15-20 minutes total). Post-clinic Visit: 2 questionnaires (approximately 5-10 minutes total).~Clinician Group:~Post-clinic Visit: 2 questionnaires (approximately 5 minutes total)."
223918719|NCT06823284|DRUG|Esflurbiprofen Topical System|The total of two TK-254RX per day for 5 days (one patch applied to left and right lower leg above ankle)
223918720|NCT06823284|DRUG|Flurbiprofen tablet|3 tablets per day for 4 days
223530357|NCT03379974|DRUG|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
223530358|NCT03379974|BEHAVIORAL|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
223918721|NCT06231927|BEHAVIORAL|The Skills for Life Adjustment and Resilience (SOLAR) program|The SOLAR program is a 5-session intervention program that aims to introduce participants necessary recovery skills after a traumatic event resulting in a subclinical distress. During the program, participants will be given workbooks including the topics for skill development for recovery and adjustment. At each session, they will discuss these topics with the study coaches.
223918722|NCT06253234|BIOLOGICAL|personalized dendritic cell injection ZSNeo-DC1.1|Sequence A: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 3 weeks as a dosing cycle, a total of 6 dosing cycles Sequence B: For the first 3 cycles, 1 week as a dosing cycle, the next 3 cycles, 2 weeks as a dosing cycle, a total of 6 dosing cycles
223918723|NCT06605586|DRUG|Tasquinimod|treatment with tasquinimod capsules once daily
223918724|NCT06608173|BEHAVIORAL|radKIDS2.0 Safety and Empowerment Education Program|radKIDS® uses activity-based skill training to help elementary aged children develop personal safety boundaries, critical thinking skills for responding to threats of danger, age-appropriate coping strategies for dealing with current and past victimization, self-assertiveness and physical skills for self-defense, communication skills for reporting incidences to parents/adults, and increasing child self-worth-the program's cornerstone for personal safety and healthy development for elementary students.
223918725|NCT06608433|DRUG|semaglutide|semaglutide/Rybelsus will be administered as a single oral dose
223918726|NCT06608433|DRUG|Placebo|Placebo pills will be administered as a single oral dose
223918727|NCT03409718|DEVICE|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
223918728|NCT06587841|DEVICE|Spinal COrd NEuromodulation™ (SCONE™) for transcutaneous spinal cord stimulation (TSCS)|The SCONE™ class II investigational device is a non-invasive central nervous system (CNS) stimulator (electrical continence device) designed to provide transcutaneous spinal cord stimulation for the improvement of symptoms of bladder dysfunction associated with centrally-mediated NLUTD.
223918729|NCT06598345|BEHAVIORAL|Routine Pet Fish Care|Participants in the Routine Group will be provided specific instructions for coupling the daily and weekly fish care and diabetes care throughout the 12-week intervention They will also be told to monitor BG four times daily, review BG readings with their parent weekly and document the BG checks and weekly reviews on their device's software.
223918730|NCT06598345|BEHAVIORAL|Collaborative Communication|Parents and participants in the Collaborative Communication group will be given recommendations for how to conduct weekly meetings in a collaborative approach based on a modified version of the Minute Meeting protocol.
223918731|NCT06825988|DEVICE|Grasp|Grasp system (hardware and mobile application) during first 6 postsurgical weeks of rehabilitation. Subjects are instructed to report pain through squeezing the hardware in 3 different levels regulaly during the day, and, in addition enter answers to questions on patient reported outcome meassures (sleep quality, overall well-being, use of medication, appetit, physical activity) and register exercise time into the mobile application.
223918732|NCT06824038|BEHAVIORAL|nutritional counseling|"Nutritional counseling based on the nutritional assessment of each patient. Each patient will receive a package of:~i. A booklet that contains the whole instructions and dietary records to help in remembering information and record their application of the plan.~ii. A tailored diet menu adjusted according to the required calories of the patient calculated by the Harris Benedict equation, considering the patient preferences, individualized requirements and with choices suitable for different economic classes."
223918733|NCT06593769|DIETARY_SUPPLEMENT|whey-protein microgel|The product used in this study is a liquid 125 mL whey protein microgel (WPM) formulation that will be delivered in a ready-to-drink formulation. The WPM is dairy based and, aside from milk and lactose, no other allergens are present Whey proteins and caseinates are two major fractions of cow milk proteins.
224089623|NCT00951821|BEHAVIORAL|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
224089624|NCT00951821|BEHAVIORAL|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
223918734|NCT06593769|OTHER|Placebo|Water (isovoloumous amount)
223918735|NCT06594744|PROCEDURE|Endoscopic variceal ligation|EVL will be performed and repeated every 3 to 4 weeks until the EVs are eradicated. Following this, patients will undergo regular upper gastrointestinal endoscopic surveillance, initially every three months for a total of two sessions, then every six months for a total of two sessions, and subsequently annually. If EVs are found to recur during surveillance, additional EVL will be performed every 3 to 4 weeks until the varices are again eradicated endoscopically.
223918736|NCT06594744|DRUG|Carvedilol|The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
223918737|NCT06587529|BEHAVIORAL|The Set Me Free Project's (SMFP) READY to Stand (RTS)© Curriculum|Students will receive the Ready to Stand (RTS)© programming over six school days, spread over six weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
223918738|NCT06600074|BEHAVIORAL|Back care advice|All patients in both groups will be advised to use proper lifting techniques, avoid prolonged sitting or standing, maintain a healthy weight, quit smoking, practice good posture, take breaks, spread housekeeping duties over the whole week, and sleep in supportive positions.
224089625|NCT05637255|DRUG|SYL1801|1 drop in the eligible eye
223918739|NCT06600074|OTHER|Postural correction exercises|All patients in both groups will be instructed to perform postural correction exercise. They will be performed from different positions (crock lying, supine lying, supine, sitting and standing position). They will lie in crock lying position for example and the physical therapist will instruct them to do chin in , open out ribs through costal breathing, contract abdominal muscles, contract glutei, hold for 6 seconds and relax and repeat 10 times.
223918740|NCT06600074|OTHER|Retro-walking|Patients in the experimental group only will practice walking backward on a treadmill, starting with a 5-minute warm-up at a self-selected speed, then gradually increasing speed from 1.2 to 1.6 m/s based on comfort and progress.
223918741|NCT06599931|DEVICE|tACS Transcranial alternating stimulation|session of 20 minutes
223918742|NCT06097494|OTHER|No intervention|Observational analysis of usual care only.
223918743|NCT06588595|DRUG|Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.
223918744|NCT06588595|DRUG|Aspirin plus clopidogrel|After at least 30 days of DAPT \[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.
223918745|NCT06589765|DRUG|HRS-7535 tablet|HRS-7535 tablet
223918746|NCT06589765|DRUG|dapagliflozin tablet|dapagliflozin tablet
223918747|NCT06587464|OTHER|No Intervention|This is a non-interventional study.
223918748|NCT06601842|DEVICE|ICP monitoring|ICP monitoring
223918749|NCT06591728|DIETARY_SUPPLEMENT|Oral PCA|Administration of 1,000 mg BID of oral PCA in individuals with knee prosthetic joint infection prior to revision surgery
223918750|NCT06589128|DIETARY_SUPPLEMENT|Astaxanthin Oral Capsule|Once daily supplementation of oral astaxanthin capsule for 24 weeks
223918751|NCT06589128|DIETARY_SUPPLEMENT|Placebo|Once daily supplementation of olive oil capsule for 24 weeks
223719564|NCT04309539|PROCEDURE|Fascia iliaca block|"A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia."
223918752|NCT04861636|BEHAVIORAL|HealthTRAC|Behavioral weight management intervention targeting emotion regulation skill building. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
223918753|NCT04861636|BEHAVIORAL|SBWC|Behavioral intervention focused on behavioral weight control. Intervention components will be delivered in 27.5 hours of direct contact time across 12 months. All adolescents will be assessed prior to randomization (baseline), immediately following the intervention (4 months), upon completion of maintenance sessions (12 months) and 18 months after the start of intervention.
223918754|NCT04571736|OTHER|access to the internet information platform|This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
223918755|NCT06203327|OTHER|Esophagogastroscopy (OLGA 0-Ⅰ)|Surveillance endoscopies at years 3-5.
223918756|NCT06203327|OTHER|Esophagogastroscopy (OLGA II)|Surveillance endoscopies at years 2-3.
223918757|NCT06203327|OTHER|Esophagogastroscopy (OLGA III-IV)|Surveillance endoscopies every year.
223918758|NCT06842446|DIAGNOSTIC_TEST|POC D-dimer|POC D-dimer will be compared to laboratory D-dimer in hospital setting and used in a machine learning model
223918759|NCT06842446|DIAGNOSTIC_TEST|POC ultrasound|Point of care (POC) ultrasound performed by ED physicians compared to ultrasound performed by radiologist. POC ultrasound 3 point examination performed by ED physician will be compared with POC ultrasound full leg examination performed by ED physician.
223918760|NCT06842446|DIAGNOSTIC_TEST|Machine learning model|The DSS will be compared to the usual strategy. It will also be estimated how many participants where DVT could have been excluded without ultrasound.
223918761|NCT06842914|OTHER|postural training|postural training
223918762|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (250 mg/kg)|250 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
223918763|NCT05757193|DIETARY_SUPPLEMENT|DeltaG (500 mg/kg)|500 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
223918764|NCT05997979|DRUG|Capsaicin 8% patch|Patients will receive Capsaicin 8% patch at the inclusion of the study and three months later if it is necessary (persistant pain). Qutenza should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
223918765|NCT05997979|DEVICE|Hydrocolloid dressing|Patients will receive Hydrocolloid dressing at the inclusion of the study and three months later if it is necessary (persistant pain). Hydrocolloid dressing should be applied to intact, non-irritated, dry skin, and during 30 minutes for the feet or 60 minutes for other areas of the body.
223918766|NCT06824831|DRUG|Patients receive microporous polysaccharide hemospheres.|Patients were randomized to receive microporous polysaccharide hemospheres, after mastectomy was done.
223918767|NCT06824831|DRUG|Patients DO NOT receive microporous polysaccharide hemospheres.|Patients were randomized to NOT receive microporous polysaccharide hemispheres after mastectomy was done.
223918768|NCT06825351|BEHAVIORAL|Psychological First Aid versus Dialectal behavioral Intervention|"PFA is an immediate, supportive intervention aimed at helping individuals in distress. It focuses on providing emotional support and practical assistance in the aftermath of a crisis.~Key Components:~Safety and Comfort: Ensuring that participants feel safe and secure in their environment.~Active Listening: Engaging in empathetic listening to validate participants' feelings and experiences.~Assessment of Needs: Identifying immediate needs and concerns, including emotional and practical aspects.~Information and Resources: Providing clear information about available resources, such as mental health services and coping strategies.~Encouragement of Social Support: Guiding participants to connect with friends, family, or support groups."
223918769|NCT06611098|DEVICE|Viscosupplements|intra-articular injection
223918770|NCT04819191|BEHAVIORAL|SHARING Choices|SHARING Choices is a multicomponent communication intervention to proactively engage family members or friends and to support advance care planning in primary care
223918771|NCT06610747|PROCEDURE|Home-based Care Monitoring|For participants in the home-based care group, home service appointments will be scheduled during the 'pro re nada' (PRN) treatment phase. Participants will receive a home self-administered visual acuity tester and a self-administered Home OCT to use at home every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. The results of the visual acuity and OCT measurements will be transmitted to the clinician at the hospital. An online discussion between the clinician and the participant will be held. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
223918772|NCT06610747|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|Each eye will receive three to five q4week loading anti-VEGF injections of aflibercept (2-mg, EYLEA®) after enrollment to complete the initial loading phase of 5 doses. Each eye will then be treated according to the PRN treatment protocol described in the study protocol.
223918773|NCT06610747|PROCEDURE|Laser Treatment|Panretinal photocoagulation (PRP) may be administered if deemed necessary by the investigator, typically for high-risk proliferative diabetic retinopathy (PDR). However, individuals are not eligible for this study if it is expected that they will require PRP within 6 months at the time of enrollment. In general, PRP should not be given to study participants with less than high risk PDR. For previously untreated eyes exhibiting PDR with high-risk characteristics, PRP should be administered promptly, while it can be considered, although generally not recommended, for persons with non-high-risk PDR or severe non-PDR who are being monitored monthly in this protocol. Focal/grid laser typically should be withheld until sometime after the final visit.
223918774|NCT06610747|PROCEDURE|Standard Hospital/clinic-based Care Monitoring|For participants in the standard Hospital/clinic-based group, hospital service appointments will be scheduled during the \&amp;amp;amp;#39;pro re nada\&amp;amp;amp;#39; (PRN) treatment phase. Participants will be instructed to return to the clinic for hospital-based visual acuity examinations and standard OCT measurements every 4 weeks after the 5th injection through 48 weeks, and then as needed per the DME treatment regimen protocol provided in the protocol. A discussion between the clinician and the participant will be held in clinic. Reports will be sent to the participant after each visit. In the event that the study coordinator is unable to contact the participant, a total of three phone call attempts will be made. Any failure to keep an appointment will be communicated to the participant.
223918775|NCT06611228|OTHER|Multidomain Interventions|Multidomain Interventions The intervention group will receive a personalized MDI approach from a multidisciplinary team, including a digital coach, physiotherapist, clinical nutrition expert, neuropsychologist, geriatrician, and nurse. This approach will encompass physical activity program, nutritional interventions, cognitive training and stimulation, medication reconciliation, coaching on the use of technological supports, and group activities. Environmental modifications at home will also be proposed
223918776|NCT06611007|DRUG|embolization therapy|Hand arterial embolization with Lipiodol in emulsion with iodinated contrast agent
223918777|NCT06855069|DRUG|HS-20089|HS-20089 dose 1
223918778|NCT06855069|DRUG|Paclitaxel|Paclitaxel dose 2
223918779|NCT06855069|DRUG|Doxorubicin|Doxorubicin dose 3
223918780|NCT06855069|DRUG|Topotecan|Topotecan dose 4
223918781|NCT06841146|PROCEDURE|routine cesarean section|cesarean section
223918782|NCT04560179|DRUG|Tobramycin solution for inhalation 78mg dose|Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
223918783|NCT04560179|DRUG|Tobramycin solution for inhalation 150mg dose|Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
223918784|NCT04560179|DRUG|Tobramycin solution for inhalation 216mg dose|Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
223918785|NCT04560179|DRUG|Tobramycin solution for inhalation 300mg dose|Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
223918786|NCT04602611|OTHER|Oncology Nurse Navigation|Providing the subject with the service of navigation (ONN) performed under LCI Patient Navigation Program (LPNP), led by a registered oncology nurse.
223918787|NCT06858072|OTHER|Instrument assissted soft tissue mobilization(IASTM)|IASTM (Instrument-Assisted Soft Tissue Mobilization) in four specific body areas. The quadratus lumborum, posterior fascia, sacrum, hip lateral rotators, and hamstring bilaterally were these areas. The subjects were asked to kneel directly on the bed to stimulate the lumbar posterior muscles erector spinae (iliocostalis, longissimus), lumborum, and multifidus. At the same time, the IASTM treatment was applied to the rear fascia. The same treatment was applied to the sacrum while the subject kneeled on the bed. For hip lateral rotators, the IASTM treatment was applied to the gluteus maximus and gluteus medius while kneeling in a prone position with knee and hip flexion. Similarly, for the hamstring bilaterally, the IASTM treatment was applied to the biceps femoris, semitendinosus, and semimembranosus while in a prone position. The instrument was used for about 20 seconds in a direction parallel to the muscle fibers being treated and then for an additional 20 sec perpendicular to fibres
223918788|NCT06858072|OTHER|Transverse friction massage|patient was lying prone while the therapist administered a transverse friction massage to the affected area. Before the massage, the therapist cleansed and dried the place to be treated, ensuring it was free of dirt or debris. The therapist used their palpation skills to locate the site of pain and apply the massage technique accordingly. The therapist performed the transverse friction massage using their thumb to apply pressure across the muscle fiber, with each repetition lasting for two minutes
223918789|NCT06858748|OTHER|Observational|This is a 24-month observational study in adults in three disease domains, consisting of screening visit, baseline visit, quarterly telemonitoring visit and end of monitoring period
223918790|NCT06860048|DEVICE|Arm sleeve|Randomised to wear arm sleeve on left or right
223918791|NCT06858176|OTHER|No intervention was implemented in this observational study|No intervention was implemented in this observational study
224089626|NCT01417676|RADIATION|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
223918792|NCT06860126|BEHAVIORAL|Intergenerational Activity Program: This indicates a program that involves activities designed for interaction between older adults and younger participants|"Engage in 90-minute intergenerational interaction sessions, three times a week for three months, in a controlled indoor environment.~* Spend the first 45 minutes actively interacting with a younger participant in pairs, collaborating on activities of interest to the senior.~* Participate in group activities such as book reading, puzzles, joke-telling, and sharing experiences for the remaining 45 minutes.~* Attend 36 sessions held on odd days in the main hall of the Neshat Center.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
223918793|NCT06860126|BEHAVIORAL|Yoga and Mindfulness Sessions|"Participate in 90-minute intergenerational yoga sessions, three times a week for three months, in a gym setting.~* Perform modified yoga exercises suitable for seniors, including:~* 20 minutes of warm-up with stretching and joint rotations.~* 50 minutes of main exercises (asanas and pranayama).~* 20 minutes of relaxation and meditation (Shavasana).~* Attend sessions on odd days at 9 AM in the Neshat Center yoga hall.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
223918794|NCT06860126|BEHAVIORAL|Physical Exercise and Storytelling|"Engage in 60-minute light aerobic exercises, three times a week for three months, in a park setting.~* Follow warm-up and aerobic exercises led by a senior fitness instructor.~* Spend 30 minutes in a friendly group discussion, sharing experiences and memories with younger participants.~* Attend sessions on even days at 9 AM in Mashhad's Mellat Park.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
223918795|NCT06860126|BEHAVIORAL|Outdoor Interaction Games|"Participate in 90-minute intergenerational interaction sessions, three times a week for three months, in a park setting.~* Engage in non-exercise activities such as group discussions, storytelling, and sharing experiences with younger participants.~* Attend sessions on even days at 9 AM in Mashhad's Mellat Park.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
223918796|NCT06860126|BEHAVIORAL|Social Visits to Nursing Homes|"Engage in 90-minute intergenerational interaction sessions, three times a week for three months, in a nursing home setting.~* Participate in non-exercise activities such as group discussions, storytelling, and sharing experiences with younger participants.~* Attend sessions on odd days at 9 AM in the nursing home.~* Gender Representation:~* 60 participants (30 women and 30 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population.~* 60 younger participants (30 women and 30 men) with an average age of 21.45 ± 0.35 years, selected through purposive sampling from Mashhad's Islamic Azad University."
223918797|NCT06860126|OTHER|control group|"Continue with their daily routines without participating in any intergenerational interaction or structured activities.~* No specific interventions or programs are provided.~* Gender Representation:~* 78 participants (39 women and 39 men) aged 60 and above, selected through stratified random sampling from Mashhad's elderly population."
223918798|NCT06859060|BEHAVIORAL|BRIDGES Healthcare Manager Intervention|A culturally adapted, multilevel intervention consisting of monthly 60-minute sessions over a 12-month period. Sessions will be conducted by graduate clinical psychology students acting as healthcare managers. The intervention focuses on care coordination, patient activation, and reducing provider stigma to improve access to preventive primary care services.
223918799|NCT06859060|OTHER|Enhanced Treatment as Usual (ETAU)|Participants will continue to receive standard psychiatric care, including routine visits with their mental health providers at the designated clinical sites. They will also receive a booklet with information on how best to link with primary care providers. This ensures that participants are aware of available resources and basic health care recommendations, but does not include any active follow-up or intervention components.
223918800|NCT06858267|BEHAVIORAL|PeSSKi questionnaire survey|The control group will only receive the questionnaire without meditation. The PeSSKi questionnaire survey will be receive in 4 time point, First questionnaire will sent via email after the appointment for the surgery is scheduled. The second PeSSKi questionnaire survey will share via email at halfway point to the surgery. The third questionnaire survey will be done immediately before the day of surgery in person to assess how anxious the patient is. The final questionnaire survey will be done 1 week postoperatively to assess how much pain the patient is still in after the quantity of analgesic usage logged throughout the week.
223918801|NCT06858267|BEHAVIORAL|Meditation Video|"The experimental group pediatric patients selected for this study and their parents will be receiving meditation and PeSSKi (Perceived Stress Scale for Kids) questionnaire. The ideal meditation schedule will be 3-5 meditations per week for 5 minutes beginning 3 weeks before surgery. This will provide a dose-response relationship of meditation to anxiety and postoperative pain for data analysis. The Patient and their parents will open the link, enter their assigned number, and follow the guided meditation embedded in the Qualtrics. This will track how many times and for how long the patients are following the regimen.~The questionnaire has eleven questions on a five-point scale ranging from Not at all to A lot. An example of the meditation video questionnaire is linked here:~https://augusta.qualtrics.com/jfe/form/SV\_3DeFFKdJVupMJQq (experimental group) https://augusta.qualtrics.com/jfe/form/SV\_2b2DZ9x16jY9IzQ (PeSSKi questionnaire)"
223918802|NCT06860191|DRUG|Root Canal Sealants|In this study, different irrigation agitation methods and different root canal sealers will be compared.
223918803|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Guava Consumption|Participants eat a defined portion of guava.
223918804|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Pineapple Consumption|Participants consumed fresh-cut pineapple purchased from street vendors. Health outcomes, including potential microbial contamination and GI symptoms, were assessed for five days after consumption.
224089627|NCT06146894|PROCEDURE|Single obturation technique (Bioceramic Sealer)|Root canal will be obturated using single cone technique using Bioceramic Sealer
223918805|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Watermelon Consumption|Fresh-Cut Watermelon Consumption Description: Participants consumed fresh-cut watermelon obtained from street vendors. GI symptoms and microbial contamination effects were monitored for five days following consumption.
223918806|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Guava Consumption (With Gastric Acidity)|Same as intervention 2, but in participants with acidity
223918807|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Pineapple Consumption (With Gastric Acidity)|Same as intervention 3, but in participants with acidity.
223918808|NCT06858046|DIETARY_SUPPLEMENT|Fresh-Cut Watermelon Consumption (With Gastric Acidity)|Same as intervention 4, but in participants with acidity.
223918809|NCT06858371|BEHAVIORAL|AI Depression Literacy and Support Training|"The intervention consists of two AI-based chatbots designed to enhance depression literacy, reduce stigma, and improve confidence in supporting others with depression.~AI Depression Education Teacher - This chatbot provides interactive psychoeducation on depression, covering symptoms, causes, treatments, and ways to support others. Participants engage in a structured conversation to enhance their understanding and receive real-time feedback.~AI Depression Patient Simulation (Beibei) - Participants interact with a simulated individual experiencing depression to practice empathetic communication and support strategies. Through guided conversations, they learn to recognize depressive symptoms, offer emotional support, and encourage help-seeking.~This two-phase intervention provides both knowledge and practical experience in a safe, interactive environment. Participants will engage with both chatbots sequentially within a one-hour session."
223918810|NCT06858371|BEHAVIORAL|AI Depression Literacy Education|This intervention consists of interaction with an AI chatbot, i.e., AI Depression Education Teacher, which provides interactive psychoeducation on depression, covering symptoms, causes, treatments, and ways to support others.
223918811|NCT06858371|BEHAVIORAL|Psychoeducation Material Group|"The intervention contains standard psychoeducation materials about depression. Participants will be directed to:~A depression-related article - Provides general information about depression, including its symptoms, causes, and treatment options.~A video describing the lived experience of a depression patient - Shares a personal story to help participants understand the real-life impact of depression."
223918812|NCT06855914|PROCEDURE|surgerical repair|surgical repair of AVF aneurysm
223918813|NCT06858202|BEHAVIORAL|Mindfulness Intervention|Guided meditation or guided expressive writing
223918814|NCT06858202|BEHAVIORAL|Non-mindfulness Intervention|Standard inpatient and outpatient resources available for Huntsman Cancer Institute patients through social work and the Wellness and Integrative Health Center. Participants will be encouraged to ask their providers for more information or if appropriate more consults to the appropriate resources if interested.
223918815|NCT06664125|DRUG|JMKX003002 will be administered orally|tablets for oral administration.
223918816|NCT06664125|DRUG|Sevelamer carbonate|tablets for oral administration.
223918817|NCT06010836|BEHAVIORAL|Script guided conversation|Patients getting script guided intervention of 3 domains in the preoperative period
223918818|NCT05505942|BEHAVIORAL|LPA Sessions|"A study interventionist will conduct phone/video sessions and provide information regarding the acute and long-term psychological and physical benefits of increasing PA. Participants will be introduced to the concept of utilizing brief bouts of PA as a coping strategy for managing emotions and urges to drink alcohol in-the-moment. Participants will also be given information on the public health guidelines for PA (and how these translate into step counts) as well as how to determine if their PA is moderate intensity (e.g., measuring heart rate and identifying rate of perceived exertion). Study clinicians will also orient participants to the proper use of the Fitbit activity tracker and tips for self-monitoring step counts with the tracker and on the app and/or website."
223918819|NCT05505942|OTHER|Fitbit Only|Interventionists will provide participants information about the proper use of the Fitbit activity tracker and offer tips for self-monitoring step counts with the tracker and on the app and/or website.
223918820|NCT04496752|DEVICE|DCTclock|Cognitive Test
223918821|NCT06134076|OTHER|Unfermented chickpea|Frozen meals containing 100 g unfermented chickpeas
223918822|NCT06134076|OTHER|Fermented chickpea|Frozen meals containing 100 g fermented chickpeas
223918823|NCT06988384|OTHER|Bike fitting|Participants underwent bike fitting using the idmatch system, which utilizes three-dimensional motion capture to optimize rider position.
223918824|NCT04866472|DEVICE|video-laryngoscope and GlideRite Rigid Stylet|Once subject is in the operating room, standard monitoring will be instituted including nerve stimulator. Induction will follow standard practice.Once full muscle relaxation is confirmed with a train of four of 0/4 laryngoscopy will be preformed using a video-laryngoscope (VLS) with a #3 blade for women and a #4 blade men. Endotracheal intubation will be performed using a #7 endotracheal tube in women and # 8 in men using the GlideRite Rigid Stylet. The stylet will be shaped to the curvature of the blade of the VLS and lubricated with a water-based lubricant. After successful tracheal intubation the circuit will be connected and ventilation confirmed with capnography and auscultation.
223918825|NCT04866472|DEVICE|video-laryngoscope and TCI Articulating Introducer Device|In the operating room, standard monitoring will be instituted including nerve simulator. Induction will follow standard practice. Once full muscle relaxation is achieved (train of four of 0/4) laryngoscopy will be performed using a video-laryngoscope (VLS) using a #3 blade in women and a #4 blade in men. A #7 endotracheal tube will be used for women and a #8 for men. Endotracheal intubation will be performed by placing the tube on the back of the TCI articulating introducer, after shaft is lubricated with a water based lubricant. The tip of the TCI articulating introducer will be maneuvered into the trachea and advanced until the green zone of the introducer shaft is adjacent to the glottis. The handle of the articulating introducer will then be removed and the ETT will be advanced over the articulating introducer and into the trachea via Seldinger's technique. Once in place the respiratory circuit will be connected and confirmed with capnography and auscultation.
223918826|NCT06612047|PROCEDURE|Prostate biopsy|All patients were required to underwent transperineal prostate biopsy (Systemetic + Targeted) and have corresponding pathological diagnosis results.
224089628|NCT06146894|PROCEDURE|lateral condensation technique (Bioceramic Sealer)|Root canal will be obturated using lateral condensation technique using Bioceramic Sealer
224089629|NCT06146894|PROCEDURE|Warm Vertical condensation technique (Bioceramic Sealer)|Root canal will be obturated using vertical condensation technique using Bioceramic Sealer
223918827|NCT04524689|DRUG|SAR408701 (Tusamitamab ravtansine)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
223918828|NCT04524689|DRUG|Pembrolizumab|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
223918829|NCT04524689|DRUG|Cisplatin|Pharmaceutical form: Lyophilized powder for reconstitution in solution Route of administration: Intravenous
223918830|NCT04524689|DRUG|Carboplatin|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
223918831|NCT04524689|DRUG|Pemetrexed|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
223918832|NCT06149273|BEHAVIORAL|Sleep School|Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.
223918833|NCT06149273|BEHAVIORAL|Treatment as usual|Oral and written information about improving sleep habits given by an educated nurse.
223918834|NCT06118853|BEHAVIORAL|yoga or gentle massage plus standard treatment for HSCT|The yoga sessions will be conducted at the patient's bedside, using one or more of the following techniques: gentle stretches (asanas), guided relaxation (savasana), slow and deep diaphragmatic breathing (pranayama), and meditative exercises focusing on natural breathing or visualization of a soothing place (dhyana). From these techniques, the integrative therapist will choose what best suits the patient for each session, based on their psychophysical state and symptoms presented, as there can be many variations during HSCT. Gentle massage is characterized by soft touches using light pressure, primarily using the palm of the hand, with a slow and steady rhythm across the entire body. It can be performed over clothing or even over the bedsheet and blanket.
223918835|NCT06299150|OTHER|IPS e.max CAD|CAD CAM Restoration
223918836|NCT06157411|BEHAVIORAL|Mindful Eating Intervention (AC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Mindful eating program: group sessions one evening a week (8x2h) and home exercises (30 min/day).~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1~Focus groups: Each participant will be asked to describe the program and talk about their perceptions and feelings, as well as the potential changes in behavior they have observed in their daily life."
223918837|NCT06157411|BEHAVIORAL|Conventional Dietetic Intervention (DC group)|"Screening visit: Patients will meet with a doctor, a dietician, a teacher of adapted physical activity or a psychologist.~Visit 0: Following 24 to 72 hours of reflection, the investigator will confirm the patient's understanding of the study, and those expressing verbal willingness will be randomized into the two groups.~Visit 1: Participants will be weighed and required to fill out eight questionnaires on a secure platform.~Visit 2: visit identical to visit 1~Follow-up group session: To assess each person's progress according to their needs, resources, difficulties, life plans, and initial expectations.~Visit 3: visit identical to visit 1"
223918838|NCT05210374|DRUG|Disulfiram|"To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day"
223918839|NCT05210374|DRUG|Copper Gluconate|"To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles"
223918840|NCT05210374|DRUG|Liposomal Doxorubicin (Doxil)|"To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles"
223530363|NCT00842621|PROCEDURE|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
223530364|NCT00842621|OTHER|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
223918841|NCT03971955|OTHER|Mixed Meal Test|a standard liquid mixed meal will be administered to the participant. The test meal with 1 kcal/ml and with the following caloric distribution Protein: 25%, Carbohydrate: 53%, Fat: 22% is given at a dose of 6 mL per kilogram body weight. Maximum dose is 360 mL and it will be ingested over 5 minutes. Blood samples will be taken 10 min prior to ingestion (t=-10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 minutes.
223918842|NCT03971955|OTHER|Dual Energy X-Ray Absorptiometry (DEXA)|DEXA Scans will be performed to obtain body composition measures (body fat and estimated muscle mass) using a General Electric (GE) Lunar iDXA whole-body scanner.
223918843|NCT03971955|PROCEDURE|Adipose Tissue Biopsy|The abdominal skin 6-10 cm lateral to the umbilicus will be cleansed with chlorhexidine. A sterile drape is placed, and the skin and adipose tissue will be anesthetized using Lidocaine. A 3-4 mm Mercedes Liposuction cannula will be inserted for aspiration of up to 2g of adipose tissue.
224089630|NCT06146894|PROCEDURE|lateral condensation technique (AH Plus Sealer)|Root canal will be obturated using lateral condensation technique using AH plus Sealer
224089631|NCT06146894|PROCEDURE|Warm Vertical condensation technique (AH plus Sealer)|Root canal will be obturated using vertical condensation technique using AH plus Sealer
223918844|NCT02705859|DRUG|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
224089632|NCT04764435|OTHER|Physician ownership|"The intervention or exposure is whether the dialysis facility was owned by a physician in 2017"
223918845|NCT02705859|DRUG|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
224089633|NCT04764435|OTHER|Large dialysis organization ownership|"The intervention or exposure is whether the dialysis facility was owned by a large dialysis organization in 2017"
223918846|NCT04704869|BIOLOGICAL|Cryoprecipitate|Cryoprecipitate is a blood product high in fibrinogen. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
224089634|NCT05679206|DIAGNOSTIC_TEST|Echocardiography images|"Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient"
224089635|NCT05679206|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring|Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
224089636|NCT05507957|DIAGNOSTIC_TEST|direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment|-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
224089637|NCT00004479|DRUG|midodrine|
224089638|NCT04954482|OTHER|No Intervention|This is an observation study, with no intervention
224089639|NCT02185521|OTHER|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
223530365|NCT02369536|DIETARY_SUPPLEMENT|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
223530366|NCT02369536|DIETARY_SUPPLEMENT|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
223530367|NCT06418958|DEVICE|Red Light|Light Curing with Red Light
223530368|NCT06418958|DEVICE|Blue Light|Light Curing with Blue Light
223530369|NCT04573972|BEHAVIORAL|Social Incentive|Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
223918847|NCT04704869|BIOLOGICAL|Red Blood Cells|RBCs are utilized as part of the Massive Transfusion protocol for hemorrhage control.
223918848|NCT04704869|BIOLOGICAL|Plasma|Plasma is utilized as part of the Massive Transfusion protocol for hemorrhage control.
223918849|NCT04704869|BIOLOGICAL|Platelets|Platelets are utilized as part of the Massive Transfusion protocol for hemorrhage control.
223530370|NCT04573972|BEHAVIORAL|Standard Incentive|Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
223918850|NCT04704869|BIOLOGICAL|Whole Blood|Whole Blood is utilized as part of the Massive Transfusion protocol for hemorrhage control.
223918851|NCT06605001|OTHER|Delay of Gratification|Children will complete a delay of gratification task with 1 of 2 rewards
224089640|NCT03856957|DEVICE|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
224089641|NCT03856957|DEVICE|control|colonoscopy without endocuff
224089642|NCT04006184|OTHER|Chart review|Retrospective review of medical records at a single site with six physicians
224089643|NCT00185861|DRUG|Arsenic Trioxide|
224089644|NCT00185861|PROCEDURE|Stereotactic radiosurgery|
224089645|NCT04379752|DEVICE|Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment|Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
224089646|NCT03294993|DEVICE|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
224089647|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
224089648|NCT00333216|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
224089649|NCT00333216|OTHER|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
224089650|NCT05317767|BIOLOGICAL|Flu-M [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
224089651|NCT05317767|BIOLOGICAL|Inactivated Split Influenza Vaccine|solution for intramuscular injection, 0.5 ml
224089652|NCT05641350|BEHAVIORAL|Barlow's Unified Protocol|Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.
224089653|NCT04222283|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|At BSL all the participants will be switched from a booster containing regimen (ritonavir or cobicistat) to TAF/FTC/BIC (BIKTARVY).
224089654|NCT01341457|DRUG|LY2603618|Administered intravenously
224089655|NCT01341457|DRUG|Gemcitabine|Administered intravenously
223918852|NCT04905914|DRUG|ATRN-119|ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
223716916|NCT03665051|OTHER|Maximal Oxygen Consumption (V02max)|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
223918853|NCT03662022|DRUG|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
223918854|NCT06164106|BEHAVIORAL|Virtual Crisis Response Planning|Individuals complete a chat-based experimental collaborative suicide intervention virtually.
223918855|NCT06164106|BEHAVIORAL|In-Person Crisis Response Planning|Individuals complete a collaborative suicide intervention in-person.
223918856|NCT06164106|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
223918857|NCT06650163|PROCEDURE|Advanced Magnetic Resonance Imaging|Undergo advanced MRI
223918858|NCT06650163|PROCEDURE|Brain Surgery|Undergo brain surgery
223918859|NCT06650163|OTHER|Electronic Health Record Review|Ancillary studies
223918860|NCT06650163|PROCEDURE|Immuno-Positron Emission Tomography Scan|Undergo immuno-PET
223918861|NCT06650163|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223918862|NCT06650163|PROCEDURE|Stereotactic Biopsy|Undergo stereotactic image-guided biopsy
223918863|NCT06650163|DIAGNOSTIC_TEST|Zirconium Zr 89 Crefmirlimab Berdoxam|Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
223918864|NCT06599190|OTHER|pelvic floor exercises, nutritional instructions|They will receive nutritional instructions and pelvic floor muscle exercises three sessions/week for 3 months.
223918865|NCT06599190|OTHER|abdominal hypopressive exercises, pelvic floor exercises, nutritional instructions|consists of 25 female athletes. They will receive the same treatment for the control group and abdominal hypopressive exercises three sessions/week of 30 mins per week for 3 months.
223918866|NCT03681912|BEHAVIORAL|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 45-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
223918867|NCT03681912|BEHAVIORAL|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
223918868|NCT03681912|BEHAVIORAL|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
223918869|NCT06665477|DEVICE|Restylane Volyme|Subjects in Restylane Volyme treatment group will receive treatment on Day 1 and optiponal treatment 1 month later.
223918870|NCT03893903|DRUG|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
223918871|NCT03893903|DRUG|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
223918872|NCT06858059|OTHER|psychological intervention|All participants of the lighthouse parenting programme will engage in the full program over a period of five weeks, divided into ten sessions. The 5 group interventions will occur once a week for 1.5 hours. During this time, the psychotherapist will disseminate psychological knowledge and skills pertinent to parenting, after which the group members will engage in practice exercises and discourse. Subsequently, one individual session will be conducted each week for one hour.
223918873|NCT06859437|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain Placebo|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~One capsule of placebo orally per a day during the entire period of antibiotic therapy."
223918874|NCT06859437|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain LP299v|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~One capsule of LP299v orally per a day during the entire period of antibiotic therapy."
223918875|NCT06862817|DRUG|Aloe vera gel|Aloe vera mouthgel not only as a potent agent for prevention mucositis, but also as a prevention of candidiasis in patients undergoing radiotherapy of head and neck with its antifungal and immunomodulation properties
223918876|NCT06862817|DRUG|Benzydamine Hydrochloride 0.15% Oral gel|. Benzydamine's mechanisms of action are rooted in its anti-inflammatory, anesthetic, and analgesic properties. It has been shown to reduce the synthesis of TNF-α, IL-1β and prostaglandins while also acting as an antioxidant by scavenging reactive oxygen species (ROS) benzydamine inhibits leukocyte-endothelial interactions, thereby decreasing neutrophil degranulation, and helps mitigate histamine-induced vasodilation and vascular permeability.
223918877|NCT06862817|DRUG|bioadhesive gel|bioadhesive These polymers increase viscosity through a liquid-to-semi-solid phase transition, improving retention at the administration site and providing a sustained release profile ,Mucoadhesive Dosage Forms These dosage forms are typically employed to administer medications to epithelial surfaces, including the buccal cavity, sublingual area, oral cavity, eyes, nasal passages, vagina, and lungs
223918878|NCT02526368|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
223918879|NCT02526368|DRUG|Hyperpolarized 13C,15N2-urea|Given IV
223918880|NCT02526368|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223918881|NCT06861556|PROCEDURE|Ultrasound guided Transversus Abdominis Plane block with 0.2ml/kg bupivacaine 0.25%|The operator applied a linear ultrasound probe transversally to the mid-axillary line between the costal margin and iliac crest. Landmarks were then identified as three muscles layers beneath the subcutaneous tissue; from external to internal lay respectively the external oblique muscle (EO), the internal oblique muscle (IO) and the transversus abdominis (TA). The needle was inserted in plane from the iliac crest level on the midaxillary line advancing towards the midline to the fascia laying between the IO and the TA muscles until pop detection. A clear aspiration ruled out vascular effraction. Finally, the space between the two muscle planes was hydrodissected with the bupivacaine.The end goal was visualizing the IO moving upward leaving room to a hypoechoic lens-shaped local anesthetic distribution.
223918882|NCT06861556|PROCEDURE|Ultrasound-guided Quadratus Lumborum block with 0.2ml/kg bupivacaine 0.25%|The patient was laid in a lateral decubitus position. The operator applied the probe transversally on the iliac crest directing the indicator to display the back muscles encompassed by the thoracolumbar fascia (TLF).The intended image was spotted by the emergence of the transverse process L4, delimiting the stem of a shamrock-like shape. Quadratus lumborum (QL) muscle represented the upper leaf of the shamrock, and psoas major (PM) and erector spinae (ES) stood respectively for the anterior and posterior leaves. The needle was inserted in plane from the postero-median lumbar wall directed antero-laterally with tip aiming at the posterior border of the QL muscle adjacent to the ES muscles. Pop detection indicated the middle TLF where the local anesthetic would spread, homogenous and resistance-free
223918883|NCT06858956|DRUG|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors|Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
223918884|NCT04490109|BIOLOGICAL|B244|B244 suspension
223918885|NCT04490109|BIOLOGICAL|Vehicle|Vehicle suspension
223918886|NCT06437223|DRUG|Tonabersat|Tonabersat 40mg. Two tablets per day
223918887|NCT06437223|DRUG|Placebo|Placebo 40mg, Two tablets per day
223918888|NCT06614205|DIAGNOSTIC_TEST|tumoral dosimetry by scintigraphy|The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment
223918889|NCT04791579|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic
223918890|NCT04791579|DRUG|Placebo|Placebo pill
223918891|NCT06779825|COMBINATION_PRODUCT|fMRI Neurofeedback attention task|Neurofeedback is an attentive task where participants are shown their real-time brain signals while in the scanner with the use of a representation, such as a rocket moving towards a portal. Participants are able to increase this brain signal by more purposefully engaging certain brain regions, and this is reflected in the representation that they see. Ultimately, this study is interested in whether neurofeedback can replicate the effects of stimulant medication in ADHD.
223918892|NCT04323397|DEVICE|Non-invasive ventilation|Intervention nasal high frequency oscillatory ventilation (nHFOV) and nasal synchronized intermittent positive pressure ventilation (nSIPPV) were generated by neonatal ventilators (SLE6000 infant ventilators, United Kingdom) using bi-nasal prongs (RAM cannula, NEOTECH®, USA) or the nasal mask of the same type for both ventilation modes. The size of the prongs was determined by the infant's weight. The largest possible prongs were used, with a snug fit to avoid leakage. Pacifier for preterm and term neonate (Jollypop™, USA) was taken to avoid leakage from the mouth. The disposable ventilator circuit (Fisher \& Paykel RT268™, Evaqua Dual Limb Infant Breathing Circuit Kit with Evaqua 2 Technology and Pressure Line, Flow \> 4L/min, New Zealand) was used. The initial NIV setting was (7) described in arm description. (above)
223918893|NCT05138510|BEHAVIORAL|Focus Group|"Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred.~We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material.~Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison."
223918894|NCT06350539|OTHER|Biological Sample Collection|Excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
223918895|NCT06478173|BEHAVIORAL|Exercise training|Exercise training will be performed as supervised small sided soccer games (3v3 to 7v7) 3 times a week for 14 weeks. Each session will last \~1 hour. Patients allocated to soccer training will undergo a ramp-up phase consisting of walking soccer training during weeks 1 and 2, after which normal soccer training will be applied from weeks 3 to 14.
223918896|NCT06865365|DRUG|Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions|Liraglutide daily (0.6-3.0mg, highest tolerable dose) as additional preoperative method for weight loss
223918897|NCT06865365|BEHAVIORAL|Dietologic measures and lifestyle optimization for weight loss|all subjects will receive dietary measures and lifestyle opitmization suggestions in order to drop weight preoperatively.
223918898|NCT06865378|PROCEDURE|Carbon dioxide (CO2) gas insufflation|Artificial pneumoperitoneum created by the Trendelenburg position and carbon dioxide (CO2) insufflation, which is widely used in laparoscopic procedures, frequently leads to physiological changes such as postoperative nausea and vomiting (PONV) and pain. Therefore, the currently limited usable parameters PI and PVI will be evaluated in correlation with end tidal CO2 in continuous monitoring.
223918899|NCT06857110|PROCEDURE|ultrasound-guided supracondylar block of the radial nerve|75 mg of intramuscular diclofenac will be administered, or 1 gram of oral acetaminophen in case of contraindications for the administration of Non-Steroidal Anti-inflammatory Drugs
223918900|NCT06857110|PROCEDURE|hematoma block|The orthopedic surgeon will perform a hematoma block before closed reduction. Intramuscular diclofenac (75 mg) or oral acetaminophen (1 g) will be administered if NSAIDs are contraindicated. With the patient in a supine position, the fracture site will be identified through palpation. After antisepsis with 2% chlorhexidine gluconate, a 10 cc syringe with a 21-gauge needle will be inserted to aspirate and confirm placement over the fracture hematoma. Then, 1% lidocaine (2 mg/kg) without epinephrine will be infiltrated. A 10-minute waiting period will be observed before performing closed reduction maneuvers.
223918901|NCT06857110|DRUG|5 mg of intramuscular diclofenac|the orthopedic surgeon on duty will perform the hematoma block prior to closed reduction in the procedure room as follows: 75 mg of intramuscular diclofenac will be administered
223918902|NCT06856369|PROCEDURE|Platelet rich fibrin|sub-gingival administration of platelet rich fibrin following open flap surgery
223918903|NCT06856369|DRUG|Metformin hydrochloride powder|subgingival administration of 1% Metformin Hydrochloride gel with platelet rich fibrin following open flap surgery
223530371|NCT03005392|OTHER|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
223530372|NCT05322278|OTHER|Data collection|No interventions
223918904|NCT06856369|DRUG|alendronate sodium powder|subgingival administration of 1% Alendronate gel with platelet rich fibrin following open flap surgery
223918905|NCT05520060|OTHER|Physical support|Pharmacological and non-pharmacological methods in pain management, Mobilization, Position preferred by the woman, Fluid and nutritional support, Massage applications, Sacral pressure, Listening to music, Breathing and relaxation exercises
223918906|NCT05520060|OTHER|Psychospiritual support|Effective communication, Encouragement to speak up and express fears, Support for faith-oriented practices
223918907|NCT05520060|OTHER|Environmental and sociocultural support|egulating the temperature, light and sound of the room, Environment that promotes respect for privacy, Reducing environmental noise, Information, Social support, Talking about cultural practices, Social support
224278640|NCT05583110|DRUG|Trastuzumab|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
223918908|NCT05520060|OTHER|Routine care|Admission to the delivery room, preparation for birth, delivery, postpartum care, etc.
223918909|NCT06860061|PROCEDURE|Laser refractive surgery|"This prospective comparative interventional study will enroll patients with low and moderate myopia who seek laser vision correction at Sohag Center for LASIK and Corneal Surgeries, Sohag, Egypt. Eyes included will be divided into 3 groups according to the type of refractive surgery used (conventional LASIK, Femto-LASIK and PRK) and each group will be subdivided into 2 groups according to the degree of myopia (low and moderate).~All patients will be subjected to routine comprehensive preoperative examinations including manifest uncorrected distant visual acuity (UCDVA), best corrected distant visual acuity (BCDVA), slit-lamp examination, intraocular pressure, and fundus examination.~Corneal topography and corneal aberrometry will be performed on all patients using Sirius's Scheimpflug-Placido topography (CSO, Florence, Italy). The CSO topography system analyzes a total of 6144 corneal points of a corneal area within a circular annulus outlined by an inner radius of 0.33 mm and an outer"
223918910|NCT06861725|OTHER|Silver Diamine Fluoride (SDF)|"Silver Diamine Fluoride has been used extensively around the globe for decades. Advantage Arrest silver diamine fluoride 38% will change how you offer your patients the protection they deserve.~Advantage Arrest:~Provides immediate relief from dentinal hypersensitivity Kills pathogenic organisms Hardens softened dentin making it more acid and abrasion resistant Does not stain sound dentin or enamel Can provide important clinical feedback due to its potential to stain visible or hidden lesions Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity."
223918911|NCT06861725|OTHER|VOCO Fissurit|Transparent Light-cured pits and fissure sealant, with high stability and good adhesion to enamel
224278641|NCT05583110|DRUG|Vinorelbine|"Run-in Phase:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg intravenous (IV) or 600 mg subcutaneous (SC) every 3 weeks.~* Oral vinorelbine: 50 mg/m2 (in the first cycle) and 60 mg/m2 (in the following cycles if no dose limiting toxicity \[DLT\] is seen) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg twice a day (BID) on a continuous dosing schedule.~Following patients in the phase II:~* Trastuzumab either IV or SC: 8 mg/kg IV loading dose (if necessary), followed by 6 mg/kg IV or 600 mg SC every 3 weeks.~* Oral vinorelbine: 50 mg/m2 or 60 mg/m2 (based on the run-in phase results) on days 1 and 8, every 3 weeks.~* Oral tucatinib 300 mg BID on a continuous dosing schedule."
223716917|NCT05427461|OTHER|Blood samples will be collected at different times.|"For patients with localized leiomyosarcoma, samples will be collected:~* At Baseline.~* Before surgery (for patients who have had neoadjuvant treatment (external radiotherapy and/or chemotherapy)).~* After surgery.~* At each control visit.~* At local or metastatic recurrence (or at 24 months post inclusion if no progression).~For patients with metastatic leiomyosarcoma, samples will be collected:~* At Baseline.~* At each therapeutic line.~* At progression (or at 24 months post inclusion if no progression)."
223716918|NCT03217357|DEVICE|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
223716919|NCT01594671|DRUG|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
223716920|NCT01594671|DRUG|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
223716921|NCT01594671|OTHER|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
223716922|NCT01328431|OTHER|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
223716923|NCT02796469|DRUG|Pentoxifylline|
223716924|NCT02796469|DRUG|Corticosteroid|
223918912|NCT06862661|OTHER|Daily Tips and Advice on the use of LactApp m-health tool throughout the breastfeeding journey.|A tool to track breastfeeding frequency, duration, and baby's weight and offers access to a community forum for peer support along with direct consultations with lactation experts.
223918913|NCT06862193|BEHAVIORAL|HealthyMoms4MentalHealth|The intervention is a mobile application targeting women during the perinatal period, aiming to promote mental wellbeing.
223918914|NCT06442774|OTHER|Mobile application|"The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS)."
223918915|NCT06442774|OTHER|Monitoring via wearable|Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
223918916|NCT06864117|OTHER|Body position during urodynamics|"The group defines the body position in which the first and second measurements are taken.~Group A: sitting, lying down (s/l). Group B: lying down, sitting (l/s). According to the ICS standard, the third measurement is always taken in a sitting position."
223918917|NCT06863389|PROCEDURE|Chen's U-suture technique|Initially, an approximately 2 cm cut edge of the pancreas remnant was mobilized and a incision of the jejunal loop was conducted slightly shorter than the pancreatic remnant. Using dual-needle 3-0 prolene suture for anastomosis, needle A went through the entire intestinal wall from the posterior wall about 1.5 cm away from the resection margin of the jejunum loop, then went through the superior boarder of the pancreas from posterior to anterior. To suture the anterior wall of the jejunum loop, the stitch next entered from the resection margin of the jejunum loop and kept it within the seromuscular layer from proximal to distal, and got out from about 1.5 cm away from the resection margin. Needle B repeated the aforementioned procedures with a parallel distance about 1.0 cm between needle A. Generally, the whole anastomosis needed two to four identical stitches. The stitches should overlap each other to reduce pancreatic leakage. Once all the stitches were finished and tighte
223918918|NCT06863389|PROCEDURE|invagination|Firstly, using 3-0 silk sutures, the pancreatic capsule and the serosa of the jejunal loop were anastomosed interruptedly to constitute the posterior outer layer of the anastomosis. Secondly, a jejunotomy with an appropriate size was performed and the inner layer (including posterior and anterior) of invagination was formed by two 5-0 prolene sutures with a continuous running between the pancreatic parenchyma and the full-thickness jejunum. Thirdly, the anterior outer layer was sutured in line with the first step.
224278642|NCT01685359|DRUG|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
223716925|NCT02796469|DRUG|Placebo|
223716926|NCT02975687|BIOLOGICAL|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
223716927|NCT00018031|DRUG|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
223716928|NCT00018031|DRUG|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
223716929|NCT01644539|DIETARY_SUPPLEMENT|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
224089656|NCT05766722|DEVICE|DORA AI|Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
224089657|NCT01676831|DRUG|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
224089658|NCT01676831|DRUG|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
224089659|NCT00999830|DRUG|IPH2101|One infusion of IPH2101 every 4 weeks
224089660|NCT00003200|DRUG|Taxotere|
224089661|NCT00003200|RADIATION|Radiation therapy|
224089662|NCT02850848|DRUG|Entigin Film Coated Tablet 0.5mg|
224089663|NCT02850848|DRUG|(Baraclude 0.5mg Tablets|
224089664|NCT02590029|BEHAVIORAL|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
224089665|NCT02590029|BEHAVIORAL|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
224089666|NCT02590029|BEHAVIORAL|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
223918919|NCT06863389|PROCEDURE|Duct-to-Mucosa|Briefly, Duct-to-Mucosa should make a opening matched to the pancreatic duct and was also performed by two layers. One was the outer layer in both the anterior and posterior walls of the anastomosis which were formed by interrupted 3-0 silk sutures betweent the pancreatic capsule and the jejunal serosa. The other was the inner layer performed in eight to twelve stitches from pancreatic duct to jejunal mucosa with 5-0 prolene sutures.
224089667|NCT03422484|OTHER|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
224089668|NCT00004386|GENETIC|recombinant adenovirus containing the ornithine transcarbamylase gene|
224089669|NCT05555810|PROCEDURE|clipping or ligation of the cystic duct and the cystic artery in Laparoscopic cholecystectomy|The investigators will make a comparison between clipping and ligation of cystic duct and cystic artery during Laparoscopic cholecystectomy and trying to know advantages and disadvantages of each technique .
224089670|NCT01918254|DRUG|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
224089671|NCT01918254|DRUG|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
224089672|NCT01918254|DRUG|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
224089673|NCT02609581|DRUG|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
224089674|NCT02979756|PROCEDURE|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
223918920|NCT06864741|BEHAVIORAL|Virtual reality guided motor rehabilitation|Custom rehabilitation exercises running on a Meta Quest 2/3S/3 head mounted virtual reality display.
223918921|NCT06520072|BEHAVIORAL|Children Eating Well (CHEW) mobile app|"The target users of the CHEW app are parents/guardians of preschool aged children. The purpose of the CHEW app is to provide parents/guardians with easy, practical ways to improve nutrition and wellness among their preschool-aged children. The app provides guided goal setting and tracking tools. Parents/guardians set goals related to their preschool-aged children focused on nutrition, physical activity, sleep behaviors and parenting styles. The parents/guardians can also to set goals for themselves for behaviors related to nutrition, physical activity, sleep, and stress. The app does not have features that target children as users.~The CHEW app was developed by the study team and can be downloaded for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). After downloading the CHEW app, enrolled participants must enter the Access Code provided by the study team in order to unlock the app and use it."
224089675|NCT03124459|DRUG|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
224089676|NCT03124459|DRUG|Placebo|Recombinant fusion protein or buffer solution
224089677|NCT01116193|DRUG|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
224089678|NCT04640727|PROCEDURE|open reduction|A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.
224089679|NCT04640727|PROCEDURE|closed reduction|we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
224089680|NCT00576771|PROCEDURE|PSV|Pressure Support Ventilation
224089681|NCT00576771|PROCEDURE|NAVA|Neurally Adjusted Ventilatory Assist
223716930|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
223918922|NCT06520072|BEHAVIORAL|Beanstalk mobile app|"Beanstack is free commercially-available mobile app that provides goal setting and tracking tools similar to the CHEW app, but focused on a different topic, specifically encouraging parents/guardians to read to their preschool children more frequently. In the case that a parent/guardian is not able to successfully download Beanstack to their mobile device, as a backup alternative they will be asked to use a similar free commercially-available mobile application called Bookroo.~Beanstack is available to the public for mobile devices (phones or tablets) at no cost in the Apple App Store (iOS/Apple) and the Google Play Store (Android). Bookroo is a web-based application that users access via the mobile device's web browser and looks and functions like a regular mobile application. It should work on any mobile device with a browser and data/wifi access,"
223918923|NCT06865404|PROCEDURE|PIFPB block|The ultrasound probe will be positioned parallel and 2-3 cm lateral from the midline in the 4th or 5th intercostal space. The needle will be inserted in-plane in a cauda-cranial direction until the tip of the needle reaches the plane of the fascia between the pectoralis major muscle and the external intercostal muscles. A 20 ml volume of bupivacaine 0.25% will be injected on each side.
223918924|NCT06865404|PROCEDURE|PIRSB Block|After the PIFPB is performed with the same position and probe, a bilateral posterior rectus sheath block (PRSB) will be conducted. The probe will be placed 2-3 cm next to the xiphoid in the epigastric region and parallel to the costal margin. The needle will be inserted into the plane between the rectus abdominal muscle and its posterior sheath. After verifying needle placement, 10 ml of bupivacaine 0.25% will be injected on each side.
223918925|NCT06865404|PROCEDURE|PIEOB block|After the PIFPB is performed with the same position and probe, an external oblique block will be used to place the linear array ultrasound probe between the midclavicular line and the anterior axillary line at the level of the 6th rib, with the direction mark pointing to the cephalad. The probe will be rotated on the slightly medial cranial end, and the caudal end will be lateral to produce a mesial sagittal oblique view and a short-axis view of the ribs. The following structures will be identified from superficial to deep layers: subcutaneous tissue, external oblique muscle, intercostal muscles, pleura, and lung. After determining the thoracic fascial space between the external oblique muscle and the intercostal muscles, bupivacaine 20 mL will be slowly injected into the space with a nerve block needle at the head side of the 6th rib horizontally near the mid axillary line. The block will be repeated in the same way on the other side.
223918926|NCT06756841|DEVICE|PEF treatment|PEF energy delivery via endoscope
223918927|NCT02853500|DEVICE|TriNav|TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
223918928|NCT02853500|DEVICE|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
224089682|NCT00576771|PROCEDURE|patient-controlled|assisted controlled MV through a button
223530373|NCT03186547|DRUG|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
223530374|NCT03186547|PROCEDURE|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
223530375|NCT00046072|DRUG|E5564|
223918929|NCT02853500|DRUG|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
223918930|NCT06540547|BEHAVIORAL|MomMA Intervention|Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
223918931|NCT03817983|DIAGNOSTIC_TEST|MRE review for evidence of axSpA in SIJs|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease
223918932|NCT03817983|DIAGNOSTIC_TEST|Clinical assessment and dedicated MRI of the spine and pelvis|Clinical assessment and dedicated MRI of the spine and pelvis to assess for evidence of axSpA
223918933|NCT06069427|BEHAVIORAL|Sprint interval training (SIT)|The SIT protocol consists of 4 repeated 30-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 4-minute warm-up consisting of unloaded pedalling. Each sprint will be followed by 4 minutes of unloaded pedalling.
223716931|NCT01644539|DIETARY_SUPPLEMENT|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
223716932|NCT00769392|DRUG|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
224089683|NCT04647110|DRUG|crizotinib|as provided in real world practice
224089684|NCT04647110|DRUG|alectinib|as provided in real world practice
224089685|NCT04647110|DRUG|brigatinib|as provided in real world practice
224089686|NCT04647110|DRUG|ceritinib|as provided in real world practice
224089687|NCT04647110|DRUG|lorlatinib|as provided in real world practice
224089688|NCT03751293|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
224089689|NCT01740336|DRUG|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
223918934|NCT06069427|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT|The REHIT protocol consists of 2 repeated 20-second, 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass on a stationary bicycle. The first sprint will be preceded by a 2-minute warm-up consisting of unloaded pedalling. The first sprint will be followed by 3 minutes of unloaded pedalling, and the second sprint will be followed by 4 minutes of unloaded pedalling.
223918935|NCT06069427|BEHAVIORAL|No-exercise control (CON)|The control condition will involve seated rest for a period equivalent to the other interventions.
223716933|NCT00769392|DRUG|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
223716934|NCT00769392|DRUG|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
223716935|NCT00769392|DRUG|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
223716936|NCT01463488|DRUG|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
223716937|NCT01463488|DRUG|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
223716938|NCT01521546|DRUG|eplerenone|25mg tablet, once daily by mouth for 12 months
223716939|NCT01521546|DRUG|placebo|one tablet by mouth daily for 12 months
223716940|NCT02158273|DRUG|Sugar Pill|145 mg/day, oral pill, 9 days
223716941|NCT02158273|DRUG|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
223716942|NCT00286312|DRUG|Atorvastatin|
223716943|NCT02296320|DRUG|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
223716944|NCT02296320|OTHER|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
223716945|NCT06185283|DIAGNOSTIC_TEST|panoramic x-ray|Long cone paralleling technique and a film holder designed specifically for implant imaging were used for intraoral radiograph. To maintain the same film- implant distance and cone implant distance, a modification were carried out for the film holder. This modification is a hole drilled exactly above the implant fixture so the distance were maintained during subsequent film exposures. Through this modification, standardized radiographs were achieved.
223716946|NCT01667029|DRUG|Sulfasalazine|
223716947|NCT01667029|DRUG|placebo|
223716948|NCT02609269|OTHER|Decipher Cancer Classifier|The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA
223716949|NCT01341145|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
223716950|NCT01341145|BEHAVIORAL|Relaxation|12-week progressive muscle relaxation program (active control)
223918936|NCT03744676|BIOLOGICAL|lisocabtagene maraleucel|lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
224278643|NCT01201759|DRUG|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
224278644|NCT01201759|DRUG|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
224278645|NCT00491907|DRUG|folic acid 5mg/day|
223716951|NCT03244215|DIAGNOSTIC_TEST|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
223716952|NCT03244215|DIAGNOSTIC_TEST|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
223716953|NCT03244215|OTHER|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
223716954|NCT00820690|DRUG|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
223716955|NCT00820690|DRUG|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
223716956|NCT00820690|DRUG|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
223716957|NCT00820690|PROCEDURE|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
223918937|NCT06997614|OTHER|Conventional group|The conventional group adhered to conventional nutritional management methods and training
223918938|NCT06997614|OTHER|evidence-based nursing group|The study group implemented the EBN-based protocol alongside structured training
223918939|NCT05394857|DRUG|SHR-1314|SHR-1314 subcutaneously
223716958|NCT02899793|DRUG|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
223716959|NCT03310021|BIOLOGICAL|Andexanet alfa|fXa inhibitor antidote
223918940|NCT06664892|RADIATION|Ultra-hypofractionated radiation|RT, delivered via external beam, 5.2 Gy per fraction for 5 fractions following BCS and neoadjuvant or adjuvant chemotherapy. Specific adjuvant/neoadjuvant therapies are at the discretion of the treating Medical Oncologist.
223918941|NCT03967158|DEVICE|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
224278646|NCT00989209|DRUG|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
223716960|NCT03310021|DRUG|Apixaban|factor Xa inhibitor
223716961|NCT03310021|DRUG|Rivaroxaban|factor Xa inhibitor
223716962|NCT03310021|DRUG|Edoxaban|factor Xa inhibitor
223716963|NCT03310021|DRUG|Placebo|Placebo
224089690|NCT01740336|DRUG|Placebo|Placebo matching to GDC-0941
223918942|NCT06172894|DRUG|APN401|APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
223918943|NCT06388824|DRUG|normal saline|Patients undergoing surgical abortion received a single injection of 5ml 0.9% normal saline after the beginning of surgery
223918944|NCT06388824|DRUG|Esketamine|Patients undergoing surgical abortion received a single injection of 0.2mg/kg esketamine after the beginning of surgery
223918945|NCT06084195|BIOLOGICAL|Blood sample and tissue sample|"During the surgery :~* Tissus sample : primary tumor and metastasis~* blood sample : 3 EDTA tubes~* ex vivo MRI data"
223918946|NCT04905095|OTHER|EWS|Early Warning Score will be implemented in the computer system of the nursing station which belong to this intervention group. When the nurses enter the vital signs of the patients into the system, the EWS will be automatically calculated and an alarm will be displayed if an intervention is necessary, which is protocolized.
223918947|NCT04905095|OTHER|usual clinical care|Nurses perform their clinical monitoring activities as usual. EWS will not be implemented in their nursing station
223918948|NCT03479255|BEHAVIORAL|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patients from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent matters related to their care.
223918949|NCT03479255|BEHAVIORAL|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
223918950|NCT04649099|DEVICE|Leaflex™ Performer|A transfemoral catheter designed to treat calcific aortic stenosis by scoring the calcification in the aortic valve leaflets.
223918951|NCT06746519|DRUG|BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine|The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.
223918952|NCT04724928|RADIATION|Metastasis directed therapy (MDT)|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Concurrently, the oligometastasis will be treated with stereotactic body radiotherapy or metastasectomy.
223918953|NCT04724928|DRUG|Immunotherapy|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards immunotherapy will be initiated and regular follow up will be performed.
223918954|NCT04724928|PROCEDURE|Standard of care|Patient receives standard of care therapy with either radical cystectomy with pelvic lymph node dissection or trimodality therapy (consisting of a visible complete TURb and radio chemotherapy). Afterwards regular follow up is performed.
223918955|NCT05827965|BEHAVIORAL|education and drug adjustement|education of the patients (lifestyle) and adjustement of glucocorticoid replacement schedule
223918956|NCT04599569|DEVICE|indirect calorimetry|indirect calorimetry with and without renal replacement therapy
223918957|NCT05990335|BEHAVIORAL|mHealth application (custom)|Smartphone based application designed to engage user executive functions
223918958|NCT06857786|DRUG|Drug: CT041 autologous CAR T-cell injection|The planned dose of satri-cel in this trial was 2.5 × 108 cells, single infusion. The trial will start with a safety run-in phase, which is defined from the day of infusion to the 28th day after infusion for the first 6 participants. The type, grade, incidence rate, and outcome of adverse events during the safety run-in phase will be summarized and assessed by the investigator and collaborator (CARsgen Therapeutics Co., Ltd). The investigator and collaborator could discuss and assess whether the lower or higher doses should be explored based on the based on the safety and tolerability, cellular metabolic characteristics, and benefit-risk profile. If no dose adjustment is required, satri-cel dose will continue to be 2.5 × 108 cells for the rest of the participants.
224089691|NCT01740336|DRUG|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
223940646|NCT06593717|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
224278647|NCT00989209|PROCEDURE|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
224278648|NCT03191708|DIAGNOSTIC_TEST|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
224278649|NCT02227459|DRUG|ND-L02-s0201 Injection|
224278650|NCT00500006|DRUG|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
223918959|NCT06857071|BEHAVIORAL|Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention|"The E-SNRHT intervention will recruit people newly diagnosed with HIV as seeds, briefly remind them of HIV transmission risks and how HIV spreads through networks, and ask them to recruit people in their expanded social networks (i.e., anyone they know) who they think might benefit from being tested for HIV, regardless of whether or not they have engaged in any HIV risk behaviors together. By including expanded social networks, E-SNRHT aims to broaden the reach of HIV testing to people who are reluctant to participate in risk partner recruitment and/or to seek clinic testing. Network members recruited by a seed will also be asked to recruit additional people they know using the same education and recruitment instructions provided to seeds. All network members will be tested for HIV and provided with pre- and post-test counseling, all participants diagnosed with HIV will be referred to care, and all participants who test negative will be referred to 3-month follow-up HIV testing."
223918960|NCT06475339|OTHER|30/30 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.
223918961|NCT06475339|OTHER|30/20 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.
224278651|NCT00500006|DRUG|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
223918962|NCT06475339|OTHER|40/30 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.
223918963|NCT06475339|OTHER|20/12 work/rest cycle|Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.
223918964|NCT06856070|OTHER|(Group A: Preformed Bioflx crown)|"prepartion:1.The mesiodistal width of the tooth will be measured using calipers and a closely fitted crown will be selected based on the measurements.~2\. The tooth will be prepared similarly to stainless steel crowns (SSCs):~* Occlusal reduction of approximately 1-1.5 mm will be done using a diamond bur.Mesial and distal reduction of no more than 1 mm will be performed using a No. 169L diamond bur.Depending on the tooth anatomy, either no buccal and lingual reduction will be needed, or a minimal reduction will be done.~  3.All sharp line angles and corners will be smoothed to ensure proper crown fit.~  4.The crown will be checked for proper fit before cementation. It will be positioned to extend 1 mm below the gingival margin.~  5.The crown will be cemented using luting glass ionomer cement (GIC). The crown will be held with firm, constant pressure until the cement sets initially.~  6.The marginal fit will be evaluated, and necessary adjustments will be made. 7.The occlusion will be checked,"
223918965|NCT06856070|OTHER|(Group B: Preformed Zirconia crown)|1\. Crown Selection: The mesiodistal dimension of the corresponding tooth will be measured . to select the appropriate size.2. Occlusal Reduction: The marginal ridge of adjacent teeth will be used as a reference point and a 1.5-2 mm of occlusal reduction will be performed to allow proper crown seating.3. Bucco-Lingual Reduction: The bucco-lingual wall will be reduced by approximately 1-1.5 mm using a flame-shaped diamond bur.4. Interproximal Reduction: 1 mm of interproximal reduction will be performed using a flame-shaped diamond bur such as a .368 or .330 tapered carbide bur.5. Feather Margin Preparation: Subgingival reduction of 1-2 mm will be done using a flame-shaped diamond bur, creating a feathered margin to achieve a passive fit.6. Trial Fitting of the Crown: The crown will be tried in to ensure proper adaptation. until the crown fits passively and extends sub gingivally by 1-2 mm wit.7. Glass ionomer cement will be used for cementation.
223918966|NCT06859840|DEVICE|LIDAR|Using the LIDAR model to assist in image interpretation, patients with positive results are recalled for further examination based on the LIDAR output information and the original image interpretation, to obtain pathological results and long-term follow-up.
223918967|NCT06856304|PROCEDURE|laparoscopic disconnection of the hernia sac|disconnection of the hernial sac at the level of the internal ring using hook diathermy with sweeping the vas and the vessels away till completely separating them from the edges of the sac, then narrowing of the internal ring by appling a vicryl 3/0 suture between the ilipubic tract and the transverse arch of the transversus abdominus muscle
223918968|NCT06856304|PROCEDURE|Percutaneous internal ring suturing|A single umbilical trocar was placed through a supraumbilical incision, and then the surgeon stood on the same side of the hernia. To choose the location for the needle puncture, the position of the IIR was assessed by pressing the inguinal region from the outside with the tip of a forceps. Under laparoscopic-guided vision, the previously prepared 18-gauge injection needle threaded with the monofilament suture was introduced into the abdominal wall through a skin puncture at the lateral edge of the internal ring. With the movements of the tip of the needle, the thread passed under the peritoneum, over the lateral half of the IIR. The thread was pushed through the barrel of the needle into the abdominal cavity and eventually made a loop. The needle was pulled out, leaving the loop of the thread inside the abdomen by hanging the loop on the endoscope this prevented the extraction of the loop with the needle and thus prevented repeating this step. Next, the thread loop was pulled out of t
223918969|NCT06859489|DEVICE|Active aGeing And Personalised service's Ecosystem (AGAPE)|"The experimental protocol is structured into two phases:~Phase 1 (pre-pilot) - Preliminary assessment of the functionality and usability of the AGAPE platform by older adults and caregivers, divided into:~Living lab: Three sessions to progressively explore and test the platform and its services, including workshop activities.~Testing phase: Use of the platform in the home environment of older adults for one month.~Phase 2 (pilot study) - Evaluation of the platform's impact on the daily lives of older adults, caregivers, and care organizations, with a 12-month involvement for each user."
224278652|NCT04330911|PROCEDURE|Aerobic Exercise|Exercise loading is determined by increasing the heart rate. This loading calculated by Karvonen formulas (maximum %80 of Heart Rate)
224278653|NCT02297750|PROCEDURE|double-wire technique in patients undergoing ERCP with biliary cannulation|
224278654|NCT02297750|PROCEDURE|single-wire technique in patients undergoing ERCP with biliary cannulation|
224278655|NCT06161142|DIAGNOSTIC_TEST|Second alkaline phosphatase measurement|(2-4 weeks after the 1st measurement)
224278656|NCT06161142|DIAGNOSTIC_TEST|Extended laboratory diagnostics|Laboratory testing investigating features that support the diagnosis of hypophosphatasia or exclude it by indicating secondary hypophosphatasemia for other reasons (including parameters such as serum calcium, inorganic serum phosphate, vitamin B6, vitamin B12, folic acid, bone-specific alkaline phosphatase, vitamin D3, and more).
223716964|NCT04999176|DRUG|Rivaroxaban|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
223716965|NCT04999176|DRUG|Enoxaparin|Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.
223716966|NCT06282146|PROCEDURE|transcranial magnetic stimulation|non-invasive form of brain stimulation
223716967|NCT01275040|OTHER|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
223716968|NCT01275040|OTHER|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
223716969|NCT05737732|DEVICE|Circadian Effective Lighting|Participants will receive lighting with a spectrum of 300K, 500 lux to the eye level between 7:00am and 10:00am in the morning, and hospital lighting (\<100lux) during the afternoon between 10:00am and 6:00pm. In the evening this group of participants will receive lighting with a spectrum of 3000K, \<50lux at eye light level between 6:00PM and bedtime.
223716970|NCT05737732|DEVICE|Circadian Ineffective Lightning (CIL)|Participants will receive lower lighting levels in the morning (lighting with A spectrum of 300k, \<50lux to the eye level between 7:00am and 10:00am) and the same lighting levels throughout the rest of the day.
223716971|NCT00719108|BIOLOGICAL|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
223716972|NCT00719108|BIOLOGICAL|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
223716973|NCT06324370|DIETARY_SUPPLEMENT|Virgin Coconut Oil|"Virgin Coconut Oil (VCO) will be administered with 240 mL water and standardized food during dosing periods.While the participant is standing up, each dose will be administered orally with at least 240 mL of water and standardized meal after an overnight fast of at least 10 hours on each occasion. The time of dosing will be recorded to the nearest minute in the case report form (CRF).~No other liquid or solid food intake is permitted during this time. Fluid intake will be ad libitum 4 hours post-dose. There will be a washout interval of 7 days between the single- and multiple-dose studies.~Participants will not be permitted to take any prescribed medication or over-the-counter products (including vitamins and herbal supplements) within 14 days prior to dosing or during the course of the study."
223716974|NCT02423993|BEHAVIORAL|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
223716975|NCT02423993|DEVICE|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
223918970|NCT06861972|PROCEDURE|Caesarean Hysterectomy|Caesarean delivery followed by hysterectomy
223918971|NCT06861972|PROCEDURE|Conservative management|Focal myometrium resection of the area of diseased myometrium after delivery
223918972|NCT06862310|OTHER|yogurt intervention|daily probiotics dose of 3 × 108 CFU (95% confidence interval \[CI\]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day)
223918973|NCT06862024|BEHAVIORAL|Deep Breathing and Cough Exercise Skills|Ability to apply deep breathing and cough exercise skills will be examined.
223918974|NCT06862024|BEHAVIORAL|Satisfaction with the training method|The level of satisfaction with the training provided will be determined with the PechaKucha presentation.
223918975|NCT06615661|DEVICE|C-Rex Instrument|The C-Rex Instrument is a manual ophthalmic surgical instrument used for ab interno goniotomy and inner wall trabeculotomy.
223918976|NCT06203106|OTHER|Biological Sample Collection|Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).
223918977|NCT03003533|GENETIC|SPK-8011|A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
223918978|NCT06679348|OTHER|walking exercise on treadmill|The study included two intervention groups, consisting of participants who met the inclusion criteria and adhered to the experimental procedures. One group will do treadmill walking exercises, while the other will do treadmill walking exercises using virtual reality (VR). Both interventions were conducted in a single session, with each group participating in a 20-minute walking exercise session at a moderate intensity, as identified by other studies.
223918979|NCT06679348|OTHER|Treadmill walking exercise using VR|Walking on the treadmill with the Free Run game on the Nintendo Wii allows users to walk at 5 miles per hour for 20 minutes. The user gets on the Wii Balance Board and starts walking in the virtual environment after running the application. The application detects the user's movements and controls the progress of the virtual character. During this experience, users increase their motivation by encountering various landscapes while tracking their performance and getting information about the calories they spend. This setup provides a fun, game-like atmosphere for a realistic walking experience.
223918980|NCT06677996|DRUG|varegacestat|Experimental intervention
223918981|NCT06677996|DRUG|Itraconazole (200 mg)|Intervention to evaluate DDI with experimental intervention
223918982|NCT06333223|DIETARY_SUPPLEMENT|Mixture of (Poly)phenols and a probiotic supplement|Mixture of (Poly)phenols and a probiotic supplement
223918983|NCT06333223|DIETARY_SUPPLEMENT|Placebo comparator|Mixture of (Poly)phenols and a placebo maltodextrin comparator
223716976|NCT02423993|DEVICE|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
223716977|NCT02423993|PROCEDURE|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
223716978|NCT02423993|PROCEDURE|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
223716979|NCT02423993|PROCEDURE|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
223716980|NCT02423993|PROCEDURE|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
223716981|NCT04292483|DRUG|Nitric Oxide|Inhaled vasodilator to increase pulmonary capillary perfusion
223716982|NCT00001071|DRUG|Filgrastim|
223716983|NCT04372082|OTHER|Standard of care (SOC)|SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen…) during the whole study duration
223716984|NCT04372082|DRUG|Hydroxychloroquine|200 mg x 3 per day during 10 days in addition to SOC
223918984|NCT04024059|BEHAVIORAL|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
223918985|NCT04024059|BEHAVIORAL|Contingency Management for abstinence|Incentives contingent on opiate abstinence
223918986|NCT03384537|COMBINATION_PRODUCT|Listerine total care zero|reducing intra-oral cariogenic microorganism.
223918987|NCT03384537|COMBINATION_PRODUCT|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
223918988|NCT05496140|BEHAVIORAL|CLS-R-FUERTE|The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
223918989|NCT05541484|DRUG|SGLT2 inhibitor|See above.
223918990|NCT05541484|DEVICE|Biosense Breath Ketone Analyzer|The hand-held device tests ketones in exhaled breath
223918991|NCT06622031|PROCEDURE|Transjugular intrahepatic portosystemic shunt|A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.
223918992|NCT06622031|DRUG|Lenvatinib|12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg
223918993|NCT06622031|DRUG|PD-1 inhibitor|Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)
223918994|NCT05698368|BEHAVIORAL|Mindset intervention|Participants receive a digital mindset intervention to improve mindsets about osteoarthritis and exercise.
223918995|NCT05698368|OTHER|Active comparator|Participants receive a series of osteoarthritis education videos and reflective questions that matches the digital mindset intervention in duration and attention.
223918996|NCT06869629|PROCEDURE|Targeted axillary dissection|Known metastases are marked before surgery and removed together with a sentinel lymph node biopsy
223918997|NCT06868992|PROCEDURE|Bariatric surgery (Sleeve Gastrectomy or Gastric Bypass)|Patients undergoin bariatric surgery with simultaneous liver biopsy to analyze MAMs alterations in liver and PBMCs. Follow-up assessments at 6 and 12 months.
223918998|NCT06870448|DRUG|Methyprednisolone sodium succinate|Methylprednisolone at a dose of 2 mg/kg/day for 3 consecutive days, with a maximum daily dose of 160 mg (4 vials, 40 mg per vial, Hanhui Pharmaceutical Co., Ltd.). The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug be administered before arterial access closure.
223918999|NCT06870448|DRUG|Placebo|Placebo for 3 consecutive days, with a maximum daily dose of 4 vials (Hanhui Pharmaceutical Co., Ltd.)
223919000|NCT06868901|PROCEDURE|Standard angioplasty + drug-eluting balloon technique|Treatment of restenosis of hemodialysis vascular access via the standard angioplasty + drug-eluting balloon technique
223919001|NCT06868901|PROCEDURE|Atherectomy + drug-eluting balloon|Treatment of restenosis of hemodialysis vascular access via the atherectomy + drug-eluting balloon technique
223919002|NCT06870643|OTHER|Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks|Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks.
223919003|NCT06870708|PROCEDURE|arthroscopic repair of partial rotator cuff tear using the conversion versus the transtendon technique|arthroscopic repair of partial rotator cuff tear using the conversion versus the transtendon technique
223940647|NCT06593717|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
224089692|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted at femoral triangle apex|In group 1, the adductor canal catheter is inserted at femoral triangle apex (the proximal end of the adductor canal).
223919004|NCT06869200|DEVICE|Concentrated Growth Factor (CGF) Intra-articular Injection|"Preparation Method: The CGF is prepared using an autologous platelet-rich preparation kit specifically designed to concentrate growth factors from the patient's own blood. The process involves a specialized centrifugation technique that yields a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and other bioactive molecules.~Rationale: This intervention leverages the body's natural healing response by utilizing autologous growth factors to enhance the repair of cartilage and other joint tissues affected by osteoarthritis. The high concentration of bioactive molecules in CGF is believed to provide a more potent therapeutic effect compared to other platelet-rich therapies."
223919005|NCT06869200|DEVICE|Platelet-Rich Plasma (PRP) Intra-articular Injection|"Preparation Method: The PRP is prepared using a disposable PRP preparation device that separates and concentrates platelets from the patient's blood. This process enriches the plasma with platelets and associated growth factors.~Rationale: PRP has been widely used in clinical practice for its ability to promote tissue healing and reduce inflammation in osteoarthritis. It serves as an active comparator in this study, allowing for a direct comparison of the therapeutic efficacy and safety profile of CGF against a well-established treatment modality."
223919006|NCT06870409|DRUG|Bacteriophage|"Complex drug of 3-4 virulent phages to each type of bacteria, active against:~* Staphylococcus spp. \[Staphylococcus aureus, CoNS (S. epidermidis, S. haemolyticus, S. hominis, S. warneri, S. capitis)\].~* Streptococcus spp. \[Streptococcus viridans (Str. mutans, Str. sanguis, Str. mitis, Str. cristatus, Str. gordonii, Str. oralis, Str. salivarius), Gemella hemolysans, Str. bovis (Str. gallolyticus), Str. constellatus, Str. anginosus, Str. agalactiae\].~* Enterococcus spp. \[E. faecalis, E. faecium\].~* Non-HACEK \[E. coli, A. baumanii, K. pneumoniae, P. aeruginosa\]"
223919007|NCT06868407|BEHAVIORAL|Psychoeducation about Suicide Crisis Resources (Control Intervention)|The active control intervention includes psychoeducation about suicide crisis services, with a particular focus on breaking down myths and barriers to using suicide crisis services use.
223919008|NCT06868407|BEHAVIORAL|Experimental: Self-Guided Electronic Safety Plan Intervention|This is a modified version of the E-SPI first created by Methi and colleagues (2024) which was originally adapted from the six primary steps of the Stanely-Brown safety plan (identifying warning signs, internal coping strategies, social distractions, non-professional crisis contacts, professional crisis resources, suicidal means restriction). Modifications to the E-SPI were based on pilot-study participant feedback and feedback from a youth focus group. The intervention was updated in accordance with pilot-study participant feedback and feedback from subsequent youth interviews. Modification examples include updated instruction wording to reduce ambiguity, updated illustrations, and increased accessibility for participants with reading-based learning disabilities.
223919009|NCT06869109|DIAGNOSTIC_TEST|serum cxcl10|serum blood sample to measure the cxcl10
223919010|NCT06869109|DIAGNOSTIC_TEST|serum crp|blood sample to measure crp
224089693|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15*2 cm above the location|In group 2, the adductor canal catheter is inserted femur length/15\*2 cm above the location where the nerve block performed in group 1.
224089694|NCT04206150|PROCEDURE|the three different sites of continous adductor canal block: the adductor canal catheter is inserted femur length/15 cm below the location|In group 3, the adductor canal catheter is inserted femur length/15 cm below the location where the nerve block performed in group 1.
224278657|NCT06161142|DIAGNOSTIC_TEST|Symptom and clinical findings checklist for hypophosphatasia|Checklist including numerous symptoms and clinical findings regarding the musculoskeletal system and non-musculoskeletal body parts
223716985|NCT04372082|DRUG|Association of diltiazem and niclosamide|niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
223919011|NCT06869759|BEHAVIORAL|Implementation strategy - Health Promotion and Education-based intervention|Firstly, three broad strategies will be implemented in the intervention arm (use of advisory boards, sensitization, and linkage to care). The advisory board meetings will be held every month to discuss the progress and receive their feedback. Secondly, orientation and capacity building will be done by onsite coaching to community health workers at the health facility level on BSE. Those trained health workers will frequently capacitate FCHVs during monthly meetings. Then, FCHV will visit the community to be aware of BSE as well as they will be involved in a stigma reduction campaign. Sensitization to FCHVs through orientation and capacity building by providing 3 batch training to selected 3 wards, then FCHVs aware and practice the skills of BSE to the recruited participants during home visit and Thirdly, the suspected and identified cases will be linked by strengthening the referral mechanism of the health system and CHWs reminders for follow-up to cases.
224089695|NCT04372095|PROCEDURE|oral smears|oral smears
224089696|NCT03220412|BEHAVIORAL|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
224089697|NCT04561349|OTHER|Task oriented training|Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
224089698|NCT04561349|OTHER|Conventional rehabilitation treatment|"Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised."
224089699|NCT03290014|DIAGNOSTIC_TEST|polysomnography|Monitoring of brain activity and respiratory variables during sleep
224089700|NCT03290014|DIAGNOSTIC_TEST|Actigraphy|monitoring daily physical activity for 7 days
224089701|NCT03290014|DIAGNOSTIC_TEST|Osler test|Evaluation of subjects´ ability to remain awake
224089702|NCT01717638|BIOLOGICAL|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
224089703|NCT01717638|BIOLOGICAL|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
224278658|NCT06161142|DIAGNOSTIC_TEST|SF-36|Quality of life questionnaire
223919012|NCT06871332|OTHER|Progressive relaxation exercise group|Patients in the intervention group performed progressive relaxation exercise for 20 minutes before femoral sheath removal.
223919013|NCT06868771|OTHER|topical treatment with the pre- and postbiotic study preparation and niacinamide 4% and one with the 10% urea-based preparation.|Application of the topical preparation in both groups will be performed twice a day for a total duration of 3 months.
223919014|NCT06869928|OTHER|PIUO Pathway|see arm description.
223919015|NCT06869005|OTHER|BARF scale|"BARF Scale, validated in paediatrics, is graduated from 0 to 10 and shows 6 increasingly nauseous faces. A child/adolescent will be considered at risk of NV if he/she declares a score greater than or equal to 4 out of 10 on at least one of the 4 observation times.~This scale can be used by the child him/herself, from the age of 4; or by a close adult, usually present at the child's side during treatment."
223919016|NCT06869811|DEVICE|LAA Closurse|LAA Closure + DOAC or OAC
223919017|NCT06871098|OTHER|Hip Hinge Instruction|The participant will be instructed to perform a hip hinge movement based on their current understanding and ability. This initial movement assessment will serve as a baseline measure to analyze the participant's natural hip hinge mechanics before any intervention. The purpose of this assessment is to determine whether the implementation of the Founder Exercise intervention leads to significant changes in the kinematics of the hip hinge movement.
223919018|NCT06867133|DEVICE|Electrophysiological rehabilitation|"On the basis of treatment in the control group, postoperative electrophysiological rehabilitation services were started for 30 minutes each time, once a day, for 6 consecutive days as one course of treatment, for a total of one course of treatment. The patch is located at the projection site of the lower abdomen uterus as shown in the figure, simulating bioelectric stimulation parameters: biphasic pulse current, frequency 2Hz, pulse width 3ms.~Simultaneously conducting family health education, including but not limited to:~1. Guidance on postoperative physical recovery after abortion: provide advice on postoperative care, nutrition, activity, and personal hygiene;~2. Introduction to contraceptive methods: Introduce the advantages and disadvantages of various contraceptive methods, and help patients choose the most suitable contraceptive method for themselves;~3. Other related health education: including fertility planning and the best time to conceive again."
223919019|NCT06865976|PROCEDURE|Non-Surgical Intervention|For non-surgical treatment of peri-implant mucositis, granulation tissues were removed by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA) during mechanical debridement under local anesthesia
223919020|NCT06865976|PROCEDURE|Surgical peri-implant therapy|In cases requiring surgical intervention for peri-implantitis, mucoperiosteal flaps were elevated on both vestibular and oral aspects after administration of local anesthesia (articaine with epinephrine 1:200,000) to expose the peri-implant defect. Granulation tissue from the bony defect area was meticulously excised using by titanium curettes (Hu-Friedy, Titanium Implant Scaler Mini-Five, Chicago, IL, USA).
223919021|NCT06865976|PROCEDURE|Second stage surgery|Healthy peri-implant mucosa samples were obtained during the second-stage surgery of implant placement procedures. These samples consisted of incisional biopsies of peri-implant mucosa in direct contact with the implant surface.
223919022|NCT06867276|DEVICE|Excimer laser|Excimer laser patients undergo ultraviolet b phototherapy treatments at a physical medicine clinic twice a week for four weeks. The device uses a 308nm beam of coherent light, with six spot sizes to avoid healthy skin. The radiation exposure time is 10 minutes, with a maximum dose of 0.65 J/cm². Personal protection standards include wearing protective eyewear for the retina and choroid, as they absorb visible light radiation, which can cause keratoconjunctivitis or cataracts. The thermal effect of the laser can cause superficial carbonization of the epidermis, phlyctens, or erythema, so non-flammable gloves are recommended.
223919023|NCT06867276|DEVICE|Bioptron Pro 1|Patients undergone Bioptron light treatment twice weekly for four weeks at a physical medicine clinic. The treatment is administered by a physiatrist following the manufacturer's user guide. Patients sit in a comfortable chair with their hand on an armrest, holding the Bioptron light probe at a 90° angle for 10 minutes.
223919024|NCT06867172|DIAGNOSTIC_TEST|computerized tomography|Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.
223919025|NCT06867172|DIAGNOSTIC_TEST|Endosonography (EUS)|EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.
223919026|NCT06865703|OTHER|diaphragmatic release technique|The participant lay in the supine position and the therapist stood at the participant's head, the therapist passed his hands (the hypothenar and the lateral 3 fingers) under the costal cartilage of the seventh to the tenth ribs bilaterally, with the therapist's forearm aligned up toward the subject's shoulder. Then, the therapist quietly drew the diaphragm in and upward during the inspiratory phase. The therapist then went deeply with both hands toward the inner costal margin during the expiratory phase to resist the rebounding movement of the thoracic cage. The depth of this manual contact was progressively increased in subsequent respiratory cycles. The maneuver was repeated in 4 sets, each of which consisted of 5 deep breaths with 2-min intervals in between if needed
223919027|NCT06865703|OTHER|rib raising technique in group A|• The patient is in supine position and therapist hand under the thorax The fingertips take up contact with the angular costae and move it up and in lateral traction and maintained and this will repeated until all ribs on the side are mobilized. This movement will be repeated several times until perceives an improvement in the rib flexibility
223919028|NCT06865703|OTHER|THORACIC LYMPHATIC PUMP TECHNIGUE|"* Patient in the supine position and therapist will stand the participant's head, facing The therapist places the thenar eminence of each hand to the pectoral region and infra clavicular and the other fingers were spread around the thoracic cage and angled toward the body's side to create consistent, compressive force across the thoracic cage The participant was then allowed to breathe in deeply and breath out. The therapist slowly reduced the compressive force and withdrew the participant.~* During breath out rhythmic oscillatory compression in the posterior and caudal direction was applied to the chest wall.~* By the end of the expiratory phase, the compressive force was maintained, and ask to take another deep breath. In this way, the participant encountered some resistance equivalent to the chest-wall movement during inspiration. The maneuver was repeated for 5 respiratory cycles, then hands to allow for full inspiration."
223716986|NCT05328063|OTHER|Control group|"All subjects will carry out a gluteus maximus strengthening work out. The exercises should be performed at a frequency of 3 times/week and with a dosage of 3 sets of 8 repetitions.~1-4 Weeks: 1. Bilateral gluteal bridge: Supine decubitus with knees and hips bent and feet supported. To raise the pelvis until the knees are flexed to 90° and then returns to the starting position. 2.Clam shell: Lateral decubitus with knees and hips bent to 45º, working leg placed on top of the other. Separate this knee while feet remain in contact using a medium density Theraband on the distal thighs. Bilateral work. 3. Side-Step: Bipedestation with Knees and hips bent. The exercise then consists of two steps taken in one direction followed by two steps in the opposite direction to return to the starting position. The elastic band shall be placed above the knees.~4-8 Weeks: 1.Unilateral gluteal bridge. 2 Clam shell: hips bents to 60º. 3. Side-Step: placing the elastic band over the ankles"
223716987|NCT05328063|OTHER|Intervention group|"All subjects will receive a specific program of manual therapy on the hip joint. 10 sessions of manual therapy will be applied during 8 weeks, 1 session per week, except the first week when two sessions will be applied.~The protocol consists of passive manual joint therapy at low speed on the hip, applying each mobilization in 3 series of 10 repetitions. It also includes muscle stretching, performing 3 series and holding the stretch for 25 seconds.~Manual therapy includes: 1. Anteroposterior (AP) and posteroanterior (PA) displacement of the hip. 2. Lateromedial and mediolateral displacement of the hip. 3. Distraction of the long axis/traction of the hip. 4. Lower slip in internal rotation (IR) and external rotation (ER) of the hip. 5. Iliopsoas stretch. 6. Piriformis stretch.To perform the protocol, the patient shall be placed in the supine decubitus position.~In addition to the same gluteus maximus strengthening programme used for the control group."
223716988|NCT00025363|DRUG|vincristine sulfate|Given IV
223919029|NCT06868121|OTHER|OMGYES.com|OMGYES.com is an interactive website that offers information, video tutorials, interviews, tips, and resources to explore female sexual pleasure through groundbreaking research that's told through the real-life experiences of women of all ages and life stages.
223716989|NCT00025363|DRUG|irinotecan hydrochloride|Given IV
223919030|NCT06868043|DEVICE|FiberSense System|FiberSense system, a novel CGM system using interstitial fluid (ISF) glucose as an indicator of blood glucose levels by diabetic patients
223919031|NCT06865911|OTHER|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infiltration of cold tumescent solution at 4 C for lipoplasty.
223919032|NCT06865911|OTHER|Warm saline|Infiltration of warm tumescent solution at body temperature for lipoplasty.
223919033|NCT06865911|PROCEDURE|Liposuction of the arms|Infiltration of tumescent solution in both arms, VASER fat emulsification then power-assisted liposuction of the arms.
223919034|NCT06866470|BEHAVIORAL|relaxation group|exercise group
223919035|NCT06865690|OTHER|Eductional training program|"Arms and Interventions~Arms:~VAK Learning Model Group:~Description: Participants in this group will receive an educational program based on Fleming's VAK (Visual, Auditory, Kinesthetic) learning model. The program will tailor teaching methods to participants' sensory preferences (visual, auditory, or kinesthetic).~Kolb Learning Cycle Group:~Description: Participants in this group will receive an educational program based on Kolb's Experiential Learning Cycle. The program will emphasize experiential learning through concrete experiences, reflective observation, abstract conceptualization, and active experimentation.~Interventions:~VAK Educational Training Program:~Description: A structured CPR training program designed to align with participants' sensory preferences (visual, auditory, or kinesthetic). The program includes:~Visual components: Demonstrations, diagrams, and videos.~Auditory components: Verbal instructions, discussions, and feedback.~Kinesthetic components: Hands-on"
223919036|NCT06866197|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
224089704|NCT03071718|OTHER|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
223919037|NCT06867198|DIETARY_SUPPLEMENT|Peanuts|43 g of peanut butter (1 snack cup) 3 x/week, 42 g of dry roasted peanuts (1/3 of a cup) 3x/week, or 56 g of peanut flour 1x/week for 6 months.
223919038|NCT06869486|OTHER|Exercise|"A cardiopulmonary exercise test in a treadmill will be performed after an overnight fasting. Gas exchange, heart rate, and muscle oxygen saturation levels will be assessed continuously during the entire test. Blood pressure and rate of perceived exertion will be recorded prior the end of each stage whereas blood glucose concentration will be assessed before and after the test. All the hemodynamic parameters will be assessed at rest to standardize the cardio-metabolic condition of the participants prior to exercise testing.~Maximal exertion will be requested from all participants except elders, in whom a submaximal test will be applied, following the guidelines provided by the American College of Sports Medicine. From this trial, maximal oxygen uptake, ventilatory thresholds/dynamics, chronotropic and inotropic response, and metabolic flexibility will be examined. A trained exercise physiologist will supervise all the tests and validate the obtained data."
223919039|NCT06869486|OTHER|Bioelectrical Impedance|Bioelectrical impedance analysis will be used to estimate body compartments through a mechanism of resistance and reactance (InBody 770, KOR) . The compartments measured include body cell mass, fat mass, extracellular tissue, lean mass, muscle mass, visceral adipose tissue area, phase angle, among others.
224089705|NCT03071718|OTHER|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
223716990|NCT00025363|DRUG|cyclophosphamide|Given IV
223716991|NCT00025363|DRUG|doxorubicin hydrochloride|Given IV
223716992|NCT00025363|DRUG|ifosfamide|Given IV
223716993|NCT00025363|DRUG|etoposide|Given IV
223716994|NCT00025363|DRUG|tirapazamine|Given IV
223716995|NCT00025363|BIOLOGICAL|filgrastim|Given SC
223716996|NCT00025363|BIOLOGICAL|sargramostim|Given SC
223716997|NCT00025363|OTHER|pharmacological study|Correlative studies
223716998|NCT00025363|OTHER|pharmacogenomic studies|Correlative studies
223716999|NCT00025363|OTHER|laboratory biomarker analysis|Correlative studies
223717000|NCT01128556|DRUG|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
223717001|NCT01128556|DRUG|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
223717002|NCT01822795|PROCEDURE|Lung volume reduction coïl treatment|
223717003|NCT01822795|OTHER|Regular medical treatment|
223717004|NCT01100671|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
223717005|NCT02158234|DRUG|Cisplatin|Cisplatin 15 mg/m\^2 prior to each fraction
223919040|NCT06869486|GENETIC|Micronucleus Assay|The frequency of micronuclei, nuclear buds, basal cells, binucleated cells, condensed chromatin cells, karyorrhexis, karyolysis, and pyknosis will be determined through microscopic examination of exfoliated oral mucosal cells from each participant.
223919041|NCT06869486|BEHAVIORAL|Physical activity and sedentary time|Physical activity and sedentary time will be assessed through the Spanish version of the International Questionnaire of Physical activity. In half of the analyzed subjects a wearable device (Fitbit luxe, Fit bit Inc) will be also used to record daily steps, energy expenditure and heart rate patterns.
223919042|NCT06869486|BEHAVIORAL|Sleep|Insomnia severity index, sleep quality, somnolence and chronotype will be subjectively assessed in all participants, using validated scales such as the Pittsburgh, Epworth and ISI questionnaires. In half of the participants, sleep quality will be tracked by wearing a Fit band luxe device in the wrist.
223919043|NCT06869486|BIOLOGICAL|blood sampling|"The concentrations of glucose, glycated hemoglobin, and lipid profile will be determined through serum analysis using a blood chemistry analyzer (Spin120, Spinreact, ESP). Serum samples will be obtained by centrifuging peripheral venous blood samples (4-6 mL) collected in Vacutainer tubes at 2500 rpm for 10 minutes. From the same serum samples, circulating levels of insulin, ovarian hormones (estradiol and progesterone), insulin-like growth factor 1 (IGF-1), and vascular endothelial growth factor (VEGF) will be assessed using enzyme-linked immunosorbent assays (ELISA) on a microplate reader (iMark, BIORAD, USA), following the specifications provided by each kit manufacturer (Biotechne, USA; AccuBind, GUA).~Glucose, insulin and triglyceride values obtained from the blood chemistry analyzer and ELISA assays will be used to calculate the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and the triglyceride-glucose index."
223919044|NCT06869486|BEHAVIORAL|psychometrics|Perceived stress will be obtained from the Perceived Stress Scale adapted for Mexican population. Additionally, depression and anxiety scores will be obtained from the Becks Depression Inventory, validated in Mexican adults. Ruminative thinking will be assessed through the short version of the Ruminative Responses Scale and substance abuse will be examined through the 10-items Drug Abuse Screening Test. Social media disorder and screen time will be also investigated from the Social Media Disorder Test and a cell-phone screen capture.
223919045|NCT06869486|BEHAVIORAL|Nutritional Supplement|"A semi quantitative food frequency questionnaire will be applied to collect data about macronutrient intake and supplements consumption. Hierarchical consumption of each food groups will be also assessed.~Last meal consumed prior to exercise testing will be also recorded in conjunction with fasting time."
223919046|NCT06869486|GENETIC|Genotyping|The P10L polymorphism of the OPN4 gene, previously associated with chronic insomnia and severe daytime sleepiness in the Mexican population will be determined using RFLP-PCR assays. DNA will be extracted from previously collected blood samples (4 ml) using the Master Pure DNA purification kit from Epicentre (Illumina Inc., US).
223919047|NCT06868810|OTHER|Injection of hypertonic saline|Injection 10 mL of 10% NaCl through central venous catheter
223919048|NCT06868810|OTHER|Injection of 5% NaHCO3|Injection of 5% NaHCO3 through central venous catheter
223919049|NCT03022071|OTHER|Cognitive behavior therapy|In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
223919050|NCT03649971|DRUG|Guselkumab|Guselkumab SC will be administered every 4 weeks.
223919051|NCT03649971|DRUG|Placebo|Placebo SC will be administered every 4 weeks.
223919052|NCT05907616|BEHAVIORAL|Produce purchase incentive|Participants will be provided with a specific incentive amount per month for 10 months to purchase produce, nutrition education sessions and will be sent text message reminders to redeem their incentives every month and to provide them with nutrition tips.
223919053|NCT05974358|PROCEDURE|Kono-S anastomosis|Kono et al. described a new operative technique that could reduce the rate of post-operative recurrence: a termino-terminal ileocolonic anastomosis, anti-mesenteric, with a supporting column to prevent distortion and anastomotic stenosis (Kono-S anastomosis).
223919054|NCT05974358|PROCEDURE|Conventional anastomosis for ileocolonicresection of Crohn's disease|conventional anastomosis for ileocolonicresection of Crohn's disease
223919055|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device + PRF|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed followed by application of PRF clots and membrane. Then, the flap will be closed and sutured.
223919056|NCT06679283|PROCEDURE|Open flap debridement with a chemo-electric device alone (control)|The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed. Then the flap will be closed and sutured.
223919057|NCT00817193|BEHAVIORAL|Physical Activity|Physical Activity program
223919058|NCT00817193|BEHAVIORAL|Wellness|Wellness program
223919059|NCT05954546|DRUG|Enco+bini|Patients with BRAF mutant + receiving encorafenib and binimetinib combination treatment
223919060|NCT06261112|OTHER|kaleidescope|used to kaleideskope
223717006|NCT02158234|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
223717007|NCT06556589|BEHAVIORAL|Collaborative Care|Collaborative care components include patient-centered team care, population-based care, measurement-based treatment to target, evidence-based care, and accountable care.
223717008|NCT02331342|DEVICE|NICOM cardiac output measurement|
223717009|NCT02331342|DEVICE|Innocor cardiac output measurement|
224089706|NCT00135421|DRUG|Pexacerfont|Tablets \& Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
223919061|NCT04106830|DRUG|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
223919062|NCT06872541|DRUG|Clopidogrel|Clopidogrel 75 mg uma vez ao dia durante 14 dias
223919063|NCT06871956|DIAGNOSTIC_TEST|PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma|PMRA and Shapley-Based Machine Learning for Predicting Lymph Node Metastasis in Central Subregions of Clinically Node-Negative Papillary Thyroid Microcarcinoma: A Prospective Multicenter Validation and Development of a Web Calculator
223919064|NCT06872385|OTHER|Answering a questionnaire|The subject have to answer an online questionnaire about her perceptions on menopause and opinion on treatments for the condition
223919065|NCT06872307|BEHAVIORAL|RAMP-It-Up Initiation, Adherence, and Retention Intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)-delivered by trained interventionists-to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills
223919066|NCT06873607|DEVICE|mobile app|Mobile application content: general information about rheumatoid arthritis (causes, symptoms, treatment), lifestyle changes, coping strategies for symptoms, nutrition and exercise recommendations, and daily life considerations.
223919067|NCT06873607|OTHER|Control (Standard treatment)|Routine medical check-ups and the information provided during these visits
223919068|NCT06863714|DRUG|peritonsillar bupivacaine injection|Peritonsillar injection was superficially administered to the superior and inferior peritonsillar regions in a volume of 2-5 ml. A 23 Gouge needle syringe was used for injection. A 0.5% Bupivacaine was administered at a dose of 1 mg/kg (maximum dose of 25 mg)
224089707|NCT00135421|DRUG|Escitalopram|Tablets \& Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
224089708|NCT00135421|DRUG|Placebo|Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
224089709|NCT03815890|DRUG|Nivolumab|2 courses 240 mg flat dose
224089710|NCT03815890|DRUG|Ipilimumab|single dose ipilimumab (1mg/kg) at day 1
224278659|NCT06161142|DIAGNOSTIC_TEST|Short physical performance battery (SPPB) score|The short physical performance battery is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older or disease-affected people. The scores range from 0 (worst performance) to 12 (best performance). The SPPB has been shown to have predictive validity showing a gradient of risk for mortality, nursing home admission, and disability.
223919069|NCT06867471|DIETARY_SUPPLEMENT|Ketone Diol, R-1,3-butanediol (Ketone-IQ)|Effect variables will be measured on the last day of treatment with Ketone-IQ
223919070|NCT06867471|OTHER|Placebo drink|Effect variables will be measured on the last day of treatment with Placebo
223919071|NCT06866015|OTHER|Activation-socialization intervention programme|"The proposed A-S IP (Author, 2021) includes 40 activities of three domains focusing mainly on the social-psychological level of education: the Laughter Therapy Concept (13), the Reminiscence Therapy Concept (13), and the Cognitive and Social Skills Stimulation Intervention Concept (14).~The implementation of the A-S IP activities was designed for a time period of four weeks during weekdays. In the Hriňovčan care facility for older adults, mainly in the common room, two activities were implemented daily during the morning and afternoon hours reserved for this purpose. Morning activities (active) were from 10:00 to 11:00 a.m., and afternoon activities (passive) were from 1:00 to 2:00 p.m. The application of the activities was strictly determined and organised according to a time-thematic schedule that applied rules. The participants participated in group activities, and their participation was voluntary."
223919072|NCT06867159|PROCEDURE|Autogenic Inhibition (AI) MET (Post Facilitation Stretch)|"Autogenic Inhibition (AI) MET (Post Facilitation Stretch)~1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.~2. The patient contracts the muscle isometrically, using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.~3. On release of the effort, a rapid stretch is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.~4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more."
224089711|NCT03815890|DRUG|Ipilimumab|two courses ipilimumab (1mg/kg) at day 1 and 21
224089712|NCT04637087|OTHER|Atrial fibrillation risk electronic health record alert|Electronic health record best practice alert which displays patient's 5-year risk of developing atrial fibrillation
224089713|NCT00006981|BIOLOGICAL|SS1(dsFv)-PE38 immunotoxin|
224089714|NCT03638492|PROCEDURE|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
224089715|NCT03638492|PROCEDURE|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
224089716|NCT00687453|DRUG|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
224089717|NCT00687453|DRUG|NPH twice-daily|Addition of morning NPH to bedtime NPH
224278660|NCT06161142|DIAGNOSTIC_TEST|Physical examination|A full rheumatological examination will be performed.
224089718|NCT06959927|OTHER|Standard Care Group|"Patients in this group received conventional hemodialysis care, including:~Continuous monitoring of vital signs (blood pressure, respiratory rate, pulse, heart rhythm); Supplemental oxygen therapy as needed; Instruction on effective coughing techniques; Strict fluid and electrolyte management; Metabolic support therapies; Positional adjustments (upright posture with lower limb dependency); Environmental regulation (temperature: 22-24°C; humidity: 50-60%); Individualized dietary counseling."
223919073|NCT06867159|PROCEDURE|Reciprocal Inhibition (RI) MET|"Reciprocal Inhibition (RI) MET~1. The shortened muscle (Tensor Fascia Latae) is placed in a mid-range position about halfway between a fully stretched and a fully relaxed state.~2. The patient contracts the antagonist muscles (hip adductors), using a maximum degree of effort for 5-10 seconds while the effort is resisted completely.~3. On release of the effort, a rapid stretch to TFL is made to a new barrier, without any 'bounce', and this is held for at least 10 seconds.~4. The patient relaxes for approximately 20 seconds and the procedure is repeated between three and five times more."
223919074|NCT06870929|DEVICE|The Photogrammetry-assisted intraoral scanning|The Photogrammetry-assisted intraoral scanning; will be executed using the MUA-compatible ioConnect ® photogrammetry system components exactly in the same sequence as recommended by the manufacturer
223530376|NCT02418091|BEHAVIORAL|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
223919075|NCT06870929|DEVICE|The modified approach of splinting-assisted intraoral scanning|The scan bodies will be mounted over the MUA and loosely connected with a power chain before the Medit scanner single-shot scanning procedure. Using the additional scan option in the Medit scanner software, another single-shot scan will be obtained and superimposed to the first scan yielding a color map that reflects the accuracy of the obtained scan and directs a highly precise final scan.
223919076|NCT06870929|DEVICE|Simple splinting-assisted intraoral scanning|The Medit i600 direct intraoral classical scans will be obtained while applying only a basic simple splinting
223919077|NCT06869616|OTHER|Cognitive Remediation|10 patients will undergo a rehabilitative training (Cognitive Remediation), already published and demonstrated to be feasible for patients with schizophrenia. This program includes domain-specific neurocognitive exercises aimed at training specific cognitive areas known to be impaired in schizophrenia. The treatment plan includes 15 45-minutes sessions.
223919078|NCT06868940|DEVICE|wearable multi-channel ECG acquisition devices|If patients do not meet the exclusion criteria, they will wear the wearable multi-channel ECG device for 7 days after enrollment, followed by a myocardial SPECT examination; there is no specific order for these examinations. After enrollment, baseline information of the patients (such as age, gender, height, weight, etc.), comorbidities (such as hypertension, diabetes, hyperlipidemia, chronic kidney disease, etc.), and auxiliary examination data (such as complete blood count, biochemistry, cardiac injury markers, BNP, echocardiography, wearable multi-channel ECG device data, SPECT-related examination data, such as ST-segment, total load score, total rest score, etc.) will be collected. The endpoint of this study is to evaluate the sensitivity, specificity, and accuracy of the wearable multi-channel ECG device in assessing myocardial ischemia in CHD.
224089719|NCT06959927|OTHER|Risk-Stratified Management Group|"Patients in this group received standard care plus targeted risk management interventions:~System Enhancement:~Standardized nursing protocols and accountability frameworks Competency-based staff training (emergency response, fluid management) Individualized care plans (e.g., intensified glycemic control for diabetics, optimized BP monitoring for hypertensives)~Risk Stratification:~Admission assessments and follow-up evaluations to identify high-risk patients Hemodynamic monitoring with alert thresholds for early deterioration detection Strict pharmacological supervision and fluid balance protocols~Environmental Modification:~Optimized dialysis unit conditions (temperature: 22-24°C; humidity: 50-60%) Dedicated cardiac care zones for HF patients~Quality Control:~Quarterly audits of critical care domains (patient education, vital signs documentation, protocol compliance, satisfaction metrics) Corrective actions for identified deficiencies"
224089720|NCT05591781|DEVICE|high frequency chest wall oscillation with vest system|Patients were assigned to 2 groups with pre- and post- treatment protocol application. All patients were thoroughly evaluated before and after treatment protocol application.
224089721|NCT05591781|DEVICE|Lung flute (OPEP)|. Thirty patients (Group B) received Lung flute (OPEP) in addition to their prescribed medication, 3 times per week twice a day for three successive weeks
224089722|NCT06630117|BIOLOGICAL|V330|Intramuscular injection
224089723|NCT06630117|BIOLOGICAL|Placebo|Intramuscular injection
224089724|NCT02651090|DRUG|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
224089725|NCT02145962|DEVICE|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
224089726|NCT02145962|DEVICE|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
224089727|NCT00419796|DRUG|Lumiracoxib|
224089728|NCT00434967|DRUG|Candesartan cilexetil|32 mg oral tablet
224089729|NCT00434967|DRUG|Hydrochlorothiazide|25 mg oral tablet
224089730|NCT00434967|DRUG|Candesartan/HCT 32/25 mg|
224089731|NCT04929639|OTHER|measurment of intraabdominal surgery|Immediately after intubation, while the patient is lying in the supine position, an intra-abdominal measurement will be made from the bladder catheter and recorded. Then, after the surgical site antisepsis, when the trocar required for the operation is placed by the general surgeon, another measurement will be made from the trocar port. Measurements will be recorded.
224089732|NCT03542838|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
224089733|NCT03542838|DRUG|Saline|Saline is a normal physiological solution
224089734|NCT02372617|PROCEDURE|periacetabular osteotomy|
224089735|NCT04701125|DEVICE|selective head-neck cooling using PolarCap system|Players receiving selective head-neck cooling after SRC
224089736|NCT02309463|DRUG|Endothelin receptor antagonist therapy|
224089737|NCT06959966|COMBINATION_PRODUCT|Placebo|Starch capsule, 4 grams, two capsules per day for six months.
223919079|NCT06869096|PROCEDURE|Intraoperative area irrigation|After colorectal cancer surgery, flush the surgical area with chlorhexidine solution 1 minute before suturing the skin. According to abdominal cavity contamination, bleeding and tumor invasion to determine the flushing time and flush fluid volume. If the abdominal cavity infection is more serious or exudate more, the flushing time can be relatively prolonged. At last, there were no obvious blood residue, tissue fragments and suppurative secretions in abdominal cavity. Ensure that the surgical field of vision is clear, the surface of each organ is smooth, and there is no abnormal exudate.
223919080|NCT06870695|PROCEDURE|Electrocautery|Patients undergoing standard surgical de-epithelization with electrocautery.
224089738|NCT06959966|COMBINATION_PRODUCT|Oligo Fucoidan|Oligo fucoidan capsule, 4 grams, two capsules per day for six months.
223919081|NCT06870695|PROCEDURE|Surgical blade by scalpel|Patients undergoing standard surgical de-epithelization using surgical blade by scalpel.
223919082|NCT06869538|OTHER|Exercise|For the Pilates exercises, a Pilates instructor created movements (squeeze mini ball, stretch hoop, circle with large ball, back and forth with large ball, and squat) in the gymnasium of the pregnancy school for 8 weeks, 2 days a week. Auxiliary equipment (mini ball, resistance band, Pilates ring) was used. Kegel exercises were performed 4 days a week, 3 sessions a day for 8 weeks.
223919083|NCT06871033|DRUG|TAP block with neostigmine|40 patients will receive postoperative TAP block with 20ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline) and 500 microgram neostigmine for each side.
223919084|NCT06871033|DRUG|TAP block with Ketamine|40 patients will receive postoperative TAP block with 20 ml 0.25% plain bupivacaine (10ml 0.5% bupivacaine added to 10ml normal saline) and 0.5 mg/kg ketamine for each side.
223919085|NCT06870942|DRUG|Maintenance first-line treatment plus radiation therapy|Maintenance first-line treatment plus radiation therapy
224089739|NCT01586988|BEHAVIORAL|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
224089740|NCT01430351|DRUG|Mefloquine|Given PO
224089741|NCT01430351|DRUG|Memantine Hydrochloride|Given PO
224089742|NCT01430351|DRUG|Metformin Hydrochloride|Given PO
224089743|NCT01430351|DRUG|Temozolomide|Given PO
224089744|NCT01018355|DEVICE|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
224089745|NCT02145494|RADIATION|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
224089746|NCT02660125|PROCEDURE|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
224089747|NCT01830530|DRUG|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
223919086|NCT06870370|DRUG|propranolol|This group Will receive propranolol intravenously at a dose of 1 mg every 6 h for 7 days, and doses will be held if heart rate less than 60 bpm, mean arterial pressure less than 65 mmHg
223919087|NCT06870370|DRUG|normal saline IV|This group Will receive 1ml of sterile 0.9% normal saline IV every 6 hours for 7 days
223919088|NCT06862804|BEHAVIORAL|practical group training|It is understood how important the issue is when it is considered that supporting these families, especially mothers, both socially and psychologically can be important in alleviating the difficulties they experience and that mothers with children with autism are in a risk group in terms of receiving this support. The research was designed considering that the applied training we will provide will be effective in increasing social support and developing self-compassion for the primary caregivers of children and will reduce the level of depressive symptoms.
223919089|NCT06862804|BEHAVIORAL|practical group training|practical group training
224089748|NCT01830530|DRUG|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
224089749|NCT01830530|DRUG|placebo|two tablets daily in the morning
224089750|NCT00501228|DRUG|Filgrastim|5 mg/kg ID Once Daily x 1 Week
224089751|NCT04472728|DRUG|BIO101|BIO101 capsules
224089752|NCT04472728|DRUG|Placebo|placebo capsules
224089753|NCT03585140|OTHER|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
224089754|NCT03585140|OTHER|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
224089755|NCT03585140|DRUG|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
224089756|NCT03585140|DRUG|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
224089757|NCT03804684|DIAGNOSTIC_TEST|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
224089758|NCT03804684|DIAGNOSTIC_TEST|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
224278661|NCT06161142|DIAGNOSTIC_TEST|Recording of vital signs|(including body temperature, blood pressure, heart rate)
224278662|NCT06161142|DIAGNOSTIC_TEST|Bioelectrical Impedance Analysis|A body composition measurement by BIA (Bioelectrical Impedance Analysis \[proportional mass of muscle, water and fat in kg\]) will be performed.
224278663|NCT06161142|DIAGNOSTIC_TEST|Genetic testing of the alkaline phosphatase gene|Investigation of mutations regarding the alkaline phosphatase gene
223919090|NCT03884439|DRUG|Infliximab [infliximab biosimilar 3]|\<Crohn's disease\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. \<Ulcerative colitis\> The usual dose is 5 mg as Infliximab \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
223919091|NCT04700774|BEHAVIORAL|Behavioral activation|Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
223919092|NCT05418647|OTHER|high dialysate Na|high dialysate sodium (Na = 141 mmol/L) for 8 weeks
224089759|NCT02221544|DEVICE|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
224089760|NCT02221544|DEVICE|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
224089761|NCT02221544|DEVICE|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
224089762|NCT02221544|DEVICE|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
224089763|NCT01756274|DEVICE|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
224089764|NCT01756274|DEVICE|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
224089765|NCT01756274|DEVICE|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
224089766|NCT04008732|DRUG|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
223919093|NCT05418647|OTHER|low dialysate Na|low dialysate sodium (Na = 136 mmol/L) for 8 weeks
223919094|NCT06871813|BEHAVIORAL|combined the CDIO model with escape room pedagogy|consisting of 16 hours of theoretical instruction delivered in a classroom setting during the first two months, followed by 8 hours of practical skills training in the third month. Practical training covered four core competencies: cardiopulmonary resuscitation (CPR), closed intravenous transfusion, micro-infusion pump operation, and cardiac monitoring operation. The experimental group followed the same syllabus, incorporating an innovative teaching strategy that combined the CDIO model with escape room pedagogy.
224089767|NCT04008732|DRUG|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
224089768|NCT04008732|DRUG|Nitro Pohl|to be dosed intravenously in Part 2 of the study
224089769|NCT02241473|OTHER|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
224089770|NCT05255003|BIOLOGICAL|Enoxaparin|"I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
224089771|NCT05255003|BIOLOGICAL|Dalteparin|"I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation"
223919095|NCT06873503|PROCEDURE|Bracket removal using a Weingart plier with the mouth open|The brackets will be removed using a Weingart plier. The patient will be asked to keep his mouth open during this procedure.
223919096|NCT06873503|PROCEDURE|Biting on a cotton roll during brakcet removal|The brackets will be removed using a Weingart plier. During this procedure, the patient will be asked to bite on a cotton roll.
223919097|NCT06873269|OTHER|Baseline assessment|demographic information (age, gender, ethnicity), relevant medical, surgical and oncological history (number and types of previous treatments), clinical assessment (including Child Pugh score, BCLC stage), functional assessment (ECOG performance status), baseline laboratory findings (liver and kidney function, AFP tumor marker,..), date of diagnosis, baseline imaging characteristics (number, size, location of lesions, portal vein thrombosis, TNM stage) and if available histopathological diagnosis (grade of differentiation, microvascular invasion).
223919098|NCT06873269|RADIATION|holmium-166 radioembolization|Characteristics of treatment: treatment date, predicted target dose in Gy, predicted non-target dose in Gy, target volume in mL, whole liver volume in mL, administered activity in GBq, tumor absorbed dose, normal liver-absorbed dose Aim of TARE: palliative or curative/downstaging
223919099|NCT06873269|OTHER|Follow-up phase|"The following data on the performed monitoring after the procedure with clinical assessment, imaging modalities and blood samples as determined by the center, will be collected retrospectively:~* Response: tumor response on imaging, tumor marker (AFP levels) at 3, 6 and 12 months after Ho166-TARE, and thereafter every 6 months until last follow-up or death, date of progression, time to progression after treatment~* Toxicity and safety: side effects, adverse events, hepatic function parameters, presence of ascites or hepatic encephalopathy~* Survival: date of last follow-up or death"
223919100|NCT06873490|DEVICE|Electric stimulation removabel device|The device will be used to stimulate orthodontic tooth movement through a specific design used to deliver the current to the mucosa around the teeth being retracted.
223919101|NCT06873490|PROCEDURE|Traditional retraction method.|In this intervention, the upper anterior teeth will be retracted together backward using the traditional retraction method. No acceleration devices will be used in conjunction with this procedure.
223919102|NCT06871514|OTHER|2-DECIDE intervention: decision support for cardiovascular risk management|"The 2-DECIDE intervention consists of:~* Training of healthcare providers in implementing shared decision-making during clinical consultations.~* At least one initial extended outpatient consultation with a trained physician to ensure adequate time for actual understanding of treatment options.~* Decision support based on U-prevent~* Clear communication to the patient is provided in an easily comprehensible format, including pre-visit information, and a post-visit handout of the information and decisions made using the U-prevent medical device. Additionally, the general practitioner receives a letter detailing the outcome and rationale of the shared decision, along with the individual estimates that have informed the treatment choice."
223919103|NCT06871514|OTHER|No Intervention: usual care|Usual care
223919104|NCT06685146|OTHER|Glucagon Infusion|A 240 minutes infusion of glucagon (10 ng/kg/min)
223919105|NCT06685146|OTHER|Glucose clamp|A 240 minutes infusion of 20 % w/v glucose. The infusion rate of glucose will be adjusted continuously to match the levels of glucose measured on the glucagon study day.
223919106|NCT06682520|OTHER|Postpartum NEST-Rural Program (Hospital based service model)|NEST-Rural services will include 3-5 nurse encounters and, if indicated, up to 3 social work encounters with mothers and their infants in the postpartum period, postpartum remote blood pressure monitoring, breastfeeding support, infant weight checks, linking mothers and infants to needed social, behavioral, and health-related resources, and integration of service delivery with healthcare providers.
223919107|NCT06684119|DEVICE|Electrical Impedance Tomography positive end-expiratory pressure titration|A PEEP titration will occur for the patient with the PEEP increased by 2 cm H2O every 2 minutes until a maximum PEEP of 20 or three steps (+ 6 cm H2O) above the set clinical PEEP. The PEEP will then be decreased by 2 cmH2O every 2 minutes until a minimum PEEP of 6 cmH2O or three steps (- 6 cm H2O) below their clinical PEEP.
223919108|NCT06684639|BIOLOGICAL|GD2-CAR-T cell|Split intravenous infusion of GD2-CAR-T cells \[dose escalating infusion of (1-100)x10\^6 GD2-CAR-T cells/kg\]
223919109|NCT06684080|OTHER|A care bundle|"1. Risk evaluation for PPH and Reserve plan;~2. Assess blood loss using Estimated Blood Loss Form and amnion fluid collection drape;~3. Satisfy any of the following conditions: i. If the estimated blood loss reaches 500ml but is less than 1000ml, and any of the following abnormal indicators are present; ii. If the estimated blood loss reaches 1000ml, no other indicators need to be considered: 1） Lack of uterine contractions 2） Persistent bleeding 3）Shock index (heart rate/systolic blood pressure) was greater than 0.9 Initiate the following protocols①, ②, ③, ④~   * Maintain uterus tone (Administration of Oxytocin and second-line medications to promote uterine contraction)~     * Intravenous infusion ③ Administered tranexamic acid ④ Multi-methods and Multi-disciplinary"
223530377|NCT01517984|DRUG|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
223530378|NCT01517984|DRUG|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
223530379|NCT05188989|DRUG|TPN171H 2.5mg group|TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
223530380|NCT05188989|DRUG|TPN171H 5mg group|TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
223530381|NCT05188989|DRUG|TPN171H 10mg group|TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
223530382|NCT05188989|DRUG|Placebo group|Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
223530383|NCT04817150|PROCEDURE|Laparoscopic ventral mesh rectopexy|Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore
223530384|NCT00926614|DRUG|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
223530385|NCT00926614|DRUG|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
223919110|NCT06492642|OTHER|Patient Education for Chronic Low Back Pain|"Patient education on chronic low back pain (LBP), including:~Day 5: Basic LBP education, types of LBP, red flags; Day 8: LBP guideline recommendations re: imaging; Day 11: LBP guideline recommendations re: use of rehabilitation services, sitting and standing desks; Day 14: LBP guideline recommendations re:pharmacologic management; Day 17: LBP guideline recommendations re: injections and surgery."
223919111|NCT06688214|OTHER|Kinesio Taping treatment|Therapeutic KT application administered to patients in group A. The KT treatment was completed in compliance with Kase's recommended methodology for rotator cuff tendinitis/impingement. Initially, an inhibitory approach was used to apply a supraspinatus Y-strip from its insertion to its origin. The measurement of the strip's length was taken from the acromion to the scapular spine. The base of the strip was later applied to the tuberculum major while the patient was seated; the superior tale of the Y-strip was then terminated at the superomedial angle of the scapula, passing between the middle and superior fibers of the trapezius with light tension (% 15-25); the shoulder was then extended, adducted, and internally rotated with cervical contralateral bending; the final portion of the tape (2.5-5 cm) was applied painlessly.
223919112|NCT06688214|OTHER|Scapular Stabilization Exercises|"Participants in Group B engage in a twice-weekly, supervised SSE exercise program that is based on the clinical decision algorithm that has been recommended by an expert panel. The goal of scapular orientation training was to normalize the scapula's resting posture and enhance proprioception. Subsequently, three scapular control exercises were executed: a closed kinetic chain exercise known as the unilateral bench press, bilateral shoulder flexion up to 60°, and a scapular control exercise including bilateral shoulder retraction and extension in the prone position. There was no discomfort involved in performing the exercises, and each session may consist of no more than four exercises. The dosage and progressions were based on the objectives of each exercise; each exercise was performed 8-10 times with a 5- to 10-second hold in between, and there was a 30-to 1-minute rest period."
223919113|NCT06688721|DEVICE|Driving a bus equipped with EDA|Eco-driving assistance (EDA) systems is a technology integrated into vehicles that helps drivers to optimize fuel efficiency and reduce emissions by providing real-time feedback and guidance on driving behaviors. The system typically analyzes several driving behaviours that are measured using different captors and sensors. These systems aim to reduce the overall carbon footprint of driving, leading to cost savings for the public transport company and reduced environmental impact.
223919114|NCT06686927|DRUG|corticosteroids combined with immunoglobulin and romiplostim|"Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month."
223919115|NCT06690112|PROCEDURE|Arm I (Drainage tube removal)|During gastrectomy, a drainage tube is placed within the abdominal cavity. In Arm I (the intervention group), the drainage tube will be removed at the bedside. This procedure is a simple intervention that does not require local anesthesia and involves the removal of the drainage tube by cutting the nylon suture.
223919116|NCT03547271|BIOLOGICAL|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
223919117|NCT03547271|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
223919118|NCT03547271|BIOLOGICAL|DTaP-IPV-HB-Hib vaccine|Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
223919119|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (13-valent)|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
223919120|NCT03547271|BIOLOGICAL|Pneumococcal vaccine (10-valent)|Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
223919121|NCT03547271|BIOLOGICAL|MMR vaccine|Measles, mumps, and rubella vaccine
223919122|NCT06686173|OTHER|None-placebo|This is one kind descriptive study. The different donor groups made the cohorts different: the parous female donor and young male donor
223919123|NCT06686173|OTHER|non-intervention study|This study is one kind of non intervention study
224089772|NCT05255003|BIOLOGICAL|Tinzaparin|"I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation"
224089773|NCT01147926|DRUG|Placebo|Placebo matched to Prucalopride tablet orally once daily.
224089774|NCT01147926|DRUG|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (\<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
224089775|NCT05799014|PROCEDURE|CT-guided percutaneous lung biopsy|The participants would undergo CT-guided percutaneous lung biopsy.
223919124|NCT06686173|OTHER|donor selection|the intervention of this study was the different donor groups: the parous female donor and young male donor. All the patients involved in this study were treated by the combination of ATG and PTCy
223919125|NCT06060535|BEHAVIORAL|Suicide Attempt Risk Model Care Pathway|The suicide attempt risk model uses documented histories of medical and psychiatric diagnoses, medications, and health service utilization to predict risk of a suicide attempt in the 90 days following an outpatient visit in behavioral health clinics.
223919126|NCT02785991|PROCEDURE|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
223919127|NCT04835363|OTHER|Early Occupational Therapy intervention|four-week OT intervention program for patients who have suffered a stroke with the aim of improving the functional result and facilitating the return home by providing knowledge about specific care and neurorehabilitation.
223919128|NCT03118037|DEVICE|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
224089776|NCT05799014|PROCEDURE|Percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology|The participants would undergo percutaneous lung biopsy guided by electromagnetic navigation real-time positioning technology.
224089777|NCT01784835|OTHER|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
224089778|NCT01784835|OTHER|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
224089779|NCT01217502|BEHAVIORAL|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
223919129|NCT06691685|DRUG|ESO-T01 Injection|ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
223919130|NCT06686147|DIAGNOSTIC_TEST|Assessment of Joint Range of Motion|Joint range of motion (ROM) measurements will be conducted to assess the specific ranges of motion of participants' joints.
223919131|NCT06666465|OTHER|Operating Room Environment Experienced by Patients Wearing Virtual Reality Glasses Before Surgery The Effect of Surgery Experience on Surgical Fear Level and Care Perceptions|The video, which will be shot for patients to experience the operating environment, will include premedication, an operating room and a post-operative care unit. In the video, the operating room environment will be recorded by the researcher with a voice introduction. The image was shot with a 360-degree camera (Insta 360 One X2), edited with an application program (Insta 360 Studio) and then uploaded to the YouTube VR Pro application as a secret video. The video will be shown to the glasses via an Android phone on the internet via YouTube. People wearing glasses at the screening will be able to look in any direction they want thanks to the 360-degree video. They will be able to watch the video again if they want.
223919132|NCT06623149|BEHAVIORAL|Non-Surgical Intervention|"After referral from the general practitioner to the orthopedic department, the patient is offered a 3-month non-operative treatment program. The conservative program consists of several elements that are offered on an individual basis. The program consists of 3 main elements:~* Patient education/information~* Specialized exercise supervised by a physiotherapist~* Weight loss counseling with a dietician"
223717010|NCT03638609|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
223919133|NCT06623149|PROCEDURE|Current practice|After referral from the general practitioner to the orthopedic department, the patient is assessed by an orthopedic surgeon in the out-patient clinic according to standard practice with a focus on symptoms, history, physical examination, radiography, and an appraisal of the patient's expectations. If an indication for knee arthroplasty is found, the patient is offered knee arthroplasty, and if the patient accepts the offer, he/she is scheduled according to usual practice. If a patient declines the offer, the patient is informed that the hospital cannot offer any additional service, and the patient is referred back to primary care.
223717011|NCT03158896|BIOLOGICAL|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
223919134|NCT06391372|DRUG|estriol cream|1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
223919135|NCT02833831|DRUG|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
223919136|NCT02833831|DRUG|Placebo|Matching Placebo will be administered.
223919137|NCT02833831|DRUG|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
223919138|NCT06872502|BEHAVIORAL|Mindfulness-Based Meditation (Integral Meditation - IM)|The intervention consists of 12 in-person mindfulness-based meditation sessions over a period of six weeks, with each session lasting one hour, twice per week. The practice, called Integral Meditation (IM), includes focused breathing, body relaxation, emotional awareness, and acceptance exercises.
223919139|NCT06874569|PROCEDURE|TAP Block:|TAP Block: A linear high-frequency probe (6-13 MHz) was placed transversely along the midaxillary line to visualize the external oblique, internal oblique, and transversus abdominis muscles. Using an in-plane approach, a 21G SonoPlex, STIM (PAJUNK, Germany), was advanced, and after hydro-dissection with 1-2 mL saline, 20 mL of 0.25% bupivacaine (Marcaine, AstraZeneca, Sweden) was injected into the plane between the internal oblique and transversus abdominis muscles.
223919140|NCT06874569|PROCEDURE|TFP Block:|TFP Block: With a linear probe, the transversalis fascia was identified between the internal oblique and transversus abdominis muscles. An in-plane technique was used to insert a 21G needle, and following confirmation of correct placement with hydro-dissection, 20 mL of 0.25% bupivacaine was administered bilaterally.
223919141|NCT06874569|PROCEDURE|QLB:|QLB: A low-frequency curvilinear probe (2-5 MHz) was used to identify the quadratus lumborum muscle and adjacent structures. The needle was advanced in-plane until it reached the targeted region adjacent to the quadratus lumborum, where after hydro-dissection, 20 mL of 0.25% bupivacaine was injected bilaterally.
223919142|NCT06873646|COMBINATION_PRODUCT|Tri-Gnate Alginate Dressing|Patient will receive dressing product (Tri-Gnate Alginate) for the management of wound. The product will be put on every alternate day. Wound condition will be monitored from T0 - T6.
223919143|NCT06873646|COMBINATION_PRODUCT|Dressing product from Manuka honey|Patient will receive other type of dressing product (Manuka honey product) for the management of wound. The product will be put on every alternate day. Wound condition will be monitored from T0 - T6.
223919144|NCT06873646|COMBINATION_PRODUCT|Bactigras + Dermacyn|Patient will receive standard dressing product (bactigras + dermacyn) for the management of wound. The product will be changed everyday. Wound condition will be monitored from T0 - T6 on alternate day basis.
223919145|NCT06875219|DRUG|Luspatercept (ACE-536)|Luspatercept (ACE-536)
223919146|NCT06875492|COMBINATION_PRODUCT|HMME-PDT|Twice HMME-PDT, and the treatment interval is 2 to 3 months.
223919147|NCT06875492|DEVICE|PDL|Prior PDL treatment history.
224089780|NCT01217502|BEHAVIORAL|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
224089781|NCT00363831|DRUG|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
224089782|NCT01474590|DRUG|Epiduo/Tactuo|topical to the face, once daily in the evening
224089783|NCT01474590|OTHER|vehicle gel|topical to the face, once daily in the evening
224089784|NCT01474590|DRUG|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
224278664|NCT05341804|BEHAVIORAL|cognitive and balance dual task training|a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software
223919148|NCT06627036|DEVICE|Dermatoscope|For participants in the dermoscopy group, the marking will also be done preoperatively with a marker pen, but the lesion borders will be determined using a dermatoscope. A peripheral margin based on BAD guidelines will be marked similarly.
223919149|NCT06246344|RADIATION|Adaptive Boost Radiotherapy|"The choice of adaptive protocol and delivery system is based on individual tumor characteristics, patient anatomy and institutional capabilities. This approach provides flexibility in treatment planning while adhering to evidence-based dose constraints. Adaptive radiotherapy is delivered using one of the following advanced platforms: the Elekta Unity MRI Linac (MR-guided) or Varian Ethos (CBCT-guided), or the United Imaging uRT-linac 506c (FBCT-guided).~ART Option 1 (simultaneous integrated boost, SIB):~GTVp+GTVn: A total dose of 60-65 Gy delivered in 25 fractions using a simultaneous integrated boost approach.~CTV: A total dose of 45-50 Gy delivered in 25 fractions.~ART Option 2 (sequential boost, SB) GTVp+GTVn: An initial hypofractionated boost with a total dose of either 9-12 Gy delivered in 3 fractions or 10 Gy delivered in 2 fractions.~CTV: Followed by standard fractionation delivering 45-50 Gy in 25 fractions."
224278665|NCT05341804|BEHAVIORAL|balance training|Includes static balance, dynamic balance and strength training
224278666|NCT04627571|DRUG|Cenegermin Ophthalmic Solution [Oxervate]|An 8-week course of topical cenegermin eye drops given 6 times daily would be started in the affected eye, in conjunction with the pre-existing medical treatment for neurotrophic keratopathy. Patients will be followed-up at 4 weeks, 6 weeks, 8 weeks, 3 months, 6 months, 9 months and 12 months (±2 weeks at each time point) after treatment. At each visit, patients will be assessed to determine the corneal epithelial defect and corneal sensation.
223717012|NCT05235555|DEVICE|Transcatheter heart valve (THV) with CE approval|TAVI trough femoral access or alternative routes
223717013|NCT02046161|PROCEDURE|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
223717014|NCT02385942|DEVICE|Smart phone|"* measure the Live assessed wound size and the transmitted Smart phone-based wound size~* determine dressing materials using Smart phone-based tele-consultation"
223717015|NCT02933606|DRUG|BNC210|
223717016|NCT02933606|DRUG|Placebo|
223717017|NCT02221687|DIETARY_SUPPLEMENT|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
223717018|NCT02221687|DIETARY_SUPPLEMENT|Control formula|Standard milk formula without pre and probiotic
223717019|NCT01193595|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
223717020|NCT01193595|DRUG|bevacizumab|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
223717021|NCT01061411|DRUG|Dalteparin|Given SC
223919150|NCT06246344|RADIATION|Long course non-ART radiotherapy|Conventional long-course radiotherapy administered in a non-adaptive manner without dose escalation. Treatment will be targeted to the pelvic lymphatic drainage region only. A total dose of 45-50 Gy will be delivered in 25 fractions over the course of treatment.
223919151|NCT06246344|DRUG|Concurrent chemotherapy|Capecitabine (825 mg/m2, po, twice daily)
223919152|NCT06246344|DRUG|Consolidation Chemotherapy|Following the completion of concurrent chemoradiotherapy, consolidation chemotherapy will commence 7 to 10 days later. Patients will receive two cycles of the CAPEOX regimen. Each cycle comprises: Capecitabine: 1.0 g/m² administered orally twice daily on days 1 through 14, and Oxaliplatin: 130 mg/m² administered intravenously on day 1.
223919153|NCT06246344|PROCEDURE|Total mesorectal excision (TME) surgery|Total mesorectal excision surgery
223919154|NCT06450626|OTHER|Listening Music Intervention|Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
223919155|NCT06684691|OTHER|Intervention group|The escape room game will be applied to the students in the intervention group after the theoretical training.
223919156|NCT06684691|OTHER|Control group|The escape room game will not be applied to the students in the control group after the theoretical training.
223919157|NCT06624566|OTHER|Experimental: Implementation of an intensive therapeutic group exercise program in the neurorehabilitation process|Description: The variables will be measured prior to group assignment The age and sex variables and the satisfaction survey will be measured at the beginning of the program, the other variables at 20 sessions, at 40 sessions, at 60 sessions and/or at hospital discharge. Before the patient starts the program, he/she is classified in group A - patients who have seated trunk control for at least 2 minutes (with supervision) and no standing control (Berg scale item 3.3) - or in group B - patients who have standing trunk control for 2 minutes (with supervision) (Berg scale item 2.3). There is a maximum of 4 patients per group with 1 physiotherapist per group.. There is a maximum of 4 patients per group with 1 physiotherapist per group.. The difference with respect to the usual treatment of the neurorehabilitation service of the HMS is that in the EINTER program, strength and endurance exercises will be implemented in addition to the usual care plan
223919158|NCT05645276|DRUG|AK129 IV infusion|AK129 is administered intravenously according to the frequency and dosage of administration at different stages.
223919159|NCT05960786|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband to determine effectiveness in providing temporary relief to symptoms of vertigo.
223919160|NCT05960786|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband sham to determine effectiveness in providing temporary relief to symptoms of vertigo.
223919161|NCT06004440|DEVICE|Ion Endoluminal System|Subjects will under a planned procedure with the Ion Endoluminal System
223940648|NCT06593717|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
223919162|NCT06161324|OTHER|PFM exercises program through the Mobile app in cooperation with the superficial sensor|"The mobile app will offer a personalized progressive protocol to the user based on his needs, via 12 levels of games(from the easiest to the hardest).The cooperating PFM superficial sensor will indicate the activity of the PFMs during the contraction.Νο face-to-face meetings will be incurred between participants and therapist.~Participants will follow a program for 12 weeks(3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).Endurance training will involve slow velocity contraction and speed training will involve quick (i.e.1 sec duration) strong contractions.Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)."
223919163|NCT06161324|OTHER|Face-to face PFM exercises program in Healthcare environment|"The therapy will include face-to-face meetings weekly, regarding the progress of the treatment and its smooth transition (intra-vaginally assessment when it needs, correction, encouragement, motivation, etc).~Participants will follow a personalized progressive PFM exercise program for 12 weeks (3 times weekly, 1-5 sessions daily, each session's duration approximately 20 minutes).The endurance training will involve slow velocity contraction and the speed training will involve quick (i.e.1 sec duration) strong contractions. The Knack maneuver training will contain a pre-contraction before the increment of the intra-abdominal pressure during coughing. The exercise positions will change every 2 weeks.It will be followed the order of supine, side, prone, quadruped support, sitting and standing position"
223919164|NCT06161324|OTHER|PFM exercises program via home-leaflet(without suprevision)|"The participants of the CG will be advised to follow a personalized PFM exercise program at home based on their 1st meeting assessment. They will receive a comprehensive leaflet, with instructions and images about the PFM exercises at home. The PFM exercise program will last 12 weeks (3 times weekly, 1-5 sessions daily), without meetings, guidance and supervision by the physiotherapist. Similarly to the other two intervention groups, the program will contain endurance training (slow velocity contraction), speed training (quick contractions), Knack maneuver training (pre-contraction before coughing), and changing positions every 2 weeks (supine, side, prone, quadruped support, sitting and standing position)"
223919165|NCT06693921|PROCEDURE|AI/guided block graft|The allo-dentin tooth graft will be prepared by placing a dentin block from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template.
223919166|NCT06693921|PROCEDURE|AI/guided shell graft|The allo-dentin shell graft will be prepared by placing a dentin shell from extracted teeth in the trim template and trimming with round burs to the planned dimension under the guidance of the template
223919167|NCT06630143|OTHER|Combined Virtual and Clinical Simulation|Participants will complete a preeclampsia case scenario through virtual simulation first and then engage in a clinical simulation involving the same case. This sequential intervention is designed to reinforce knowledge and skills.
223919168|NCT06630143|OTHER|virtual simulation|Participants will complete the preeclampsia case scenario using the vSim® platform, allowing them to engage in virtual clinical decision-making.
224278667|NCT04045808|OTHER|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
224278668|NCT03136562|DIAGNOSTIC_TEST|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
224278669|NCT03681938|PROCEDURE|Autograft|Autograft
224278670|NCT05128136|DEVICE|Impact of ring size on adherence|The study design is a randomized, open-label, parallel group 3-way crossover study comparing adherence, preference and overall acceptability of 3 different-sized placebo IVRs (IVRs A, B and C) in 24 US couples. At enrollment, each couple will be randomly assigned to 1 of 6 sequences of IVR use: A-B-C, A-C-B, B-A-C, B-C-A, C-A-B or C-B-A. Each couple will use each of the 3 IVRs (IVRs A, B and C) for 30 days per IVR, 90 days total.
224278671|NCT06377007|DEVICE|IOLMaster 700 (Carl Zeiss Meditec AG)|Subjects will undergo measurements with the IOLMaster 700 device.
224278672|NCT06377007|DEVICE|Argos (Alcon Laboratories, Inc.)|Subjects will undergo measurements with the Argos device.
224278673|NCT01994915|OTHER|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
224278674|NCT03243591|OTHER|Livionex gel|Brushing area of mucositis with gel
223717022|NCT01061411|OTHER|Pharmacological Study|Correlative studies
223717023|NCT01061411|DRUG|Sunitinib Malate|Given PO
223717024|NCT04259567|DEVICE|Cytokine absorption|Use of CytoSorb absorber
223919169|NCT06691750|DEVICE|Barbed suture|Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.
223919170|NCT06691750|DEVICE|Conventional smooth suture|Size 1 smooth multifilament absorbable polyglactin suture.
223919171|NCT06686381|PROCEDURE|Maximum TURBT|Total removal of the bladder tumor through TURBT
223919172|NCT06686381|DRUG|Chemotherapy + Immunotherapy Induction|Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)
223919173|NCT06686381|RADIATION|Radiotherapy|Hypofractionated radiotherapy: 20 fractions, 55 Grays
223919174|NCT06686381|DRUG|Immunotherapy Maintenance|Maintenance Avelumab every 2 weeks for 12 months
223919175|NCT06686381|OTHER|Watchful waiting with supportive care|1 year watch and wait
223919176|NCT06686082|DRUG|Biologics|The ultrasonic changes of synovitis and enthesitis were observed after 12 weeks of treatment with biologic agents
223919177|NCT05269992|OTHER|Real food products|As per arm/group descriptions.
223919178|NCT01536938|DRUG|LEO 90100|
223919179|NCT01536938|DRUG|Calcipotriol|
224278675|NCT03243591|OTHER|Aquafresh gel|Aquafresh gel
223919180|NCT01536938|DRUG|Betamethasone|
223919181|NCT06870435|BIOLOGICAL|Blood, nasopharyngeal swab and saliva|Collect blood, nasopharyngeal swab and saliva samples from participants.
223919182|NCT06870435|DIAGNOSTIC_TEST|EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA|Detect EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA for all participants.
223919183|NCT06870435|DIAGNOSTIC_TEST|Novel screening biomarkers|Next-generation sequencing for EBV and castoff cells using nasopharyngeal swabs, etc..
223919184|NCT06870435|DIAGNOSTIC_TEST|Endoscopic examinations with or without biopsy|High-risk participants will refer to endoscopic examinations with or without biopsy
223919185|NCT06224855|DRUG|DXC006|"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."
223919186|NCT06868394|RADIATION|radiotherapy|The impact of previous radiotherapy exposure was studied on developing second primary malignancies.
223919187|NCT06868394|OTHER|No intervention|This group received no radiotherapy
223919188|NCT06872476|OTHER|bed bath|
223919189|NCT06872476|OTHER|bed bath with heat|
223919190|NCT06868472|PROCEDURE|Prehabilitation|"The waiting time until the operation is about 6 weeks. The intervention is carried out during this time:~The intervention group receives a brochure with an evidence-based exercise program for the shoulder and shoulder girdle. The brochure contains pages in which the patient documents how the exercises are carried out. The exercise program is supplemented by information in the form of a video/Power Point presentation on: Anatomy/function, pain management, hospitalization and subsequent rehabilitation.~After 2 and after 4 weeks, the physiotherapist who has explained the exercise program will contact you by telephone/zoom."
223919191|NCT06868472|PROCEDURE|Control|The control group receives a leaflet with general information for the period up to the operation (e.g. buy water-resistant plasters, arrange post-op physiotherapy appointments).
223919192|NCT06872398|OTHER|Blood and saliva sampling|"Physical and biological evaluation at inclusion visit V0 and at follow up visit V1 (after 1 year).~the biological evaluation includes blood and saliva sampling at the 2 visits."
223919193|NCT06873399|DIAGNOSTIC_TEST|MS-39|The MS-39 (Costruzione Strumenti Oftalmici, Firenze, Italy) is a device for anterior segment analysis of the eye, which combines Placido disc corneal topography and high-resolution SD-OCT. The device provides information on pachymetry, elevation, curvature, and dioptric power of both corneal surfaces. To obtain corneal topography, 22 Placido disc rings are emanated from a laser emitted diode (LED) light source at 635 nanometres (nm). The central 10 millimetres of the anterior corneal surface are covered. Epithelial thickness maps are calculated for different sectors (central, paracentral inferior/superior/nasal/temporal).
223717025|NCT04746339|DRUG|Apixaban 2.5 MG|Apixaban 2.5mg twice daily for 30 days
223717026|NCT04746339|DRUG|Placebo|placebo twice daily for 30 days
223717027|NCT00592215|DRUG|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
223717028|NCT04511104|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
223919194|NCT06872970|PROCEDURE|Open reduction of femoral neck fractures and internal fixation by dynamic hip screws|Open reduction of femoral neck using watson jones or smith peterson approach fractures then fixation of fractures by dynamic hip screws
223919195|NCT06872970|PROCEDURE|Open reduction of femoral neck fractures using watson jones or smith peterson approachand internal fixation by cannulated screws and medial buttress plate|Open reduction of femoral neck fractures then fixation of fractures by cannulated screws and medial buttress plate
223919196|NCT06698757|BIOLOGICAL|Sintilimab|Subjects were enrolled and received Sintilimab at a dose of 200 mg, administered via intravenous infusion on the first day of each cycle, with each cycle lasting 3 weeks (Q3W)
223919197|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®)|ADM (Novomatrix®) will be used alone
223919198|NCT06634043|PROCEDURE|Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF|ADM in combination with L-Prf will be applied
223919199|NCT04998422|DRUG|HG381|HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
223919200|NCT04159519|DRUG|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
223919201|NCT04159519|DRUG|Fasenra®|Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
223717029|NCT04511104|OTHER|Standard of Care|Standard of care rehabilitation
223717030|NCT03312101|OTHER|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
223919202|NCT04159519|DRUG|Ventolin®|Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
223919203|NCT04918316|OTHER|Corneal gas permeable lens|Fit in corneal gas permeable contact lens first.
224089785|NCT01474590|DRUG|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
224089786|NCT01708031|OTHER|physiological signals|
224089787|NCT01958957|DRUG|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
224089788|NCT01305512|DRUG|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
223717031|NCT06310538|BEHAVIORAL|kou sha|Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
223919204|NCT06874686|PROCEDURE|Minimally invasive laparoscopic pull-through surgery|"Pediatric patients diagnosed with Hirschsprung's Disease from 2017-2023 at the National Children's Hospital underwent two minimally invasive procedures: conventional laparoscopic pull-through (CLP) and single-incision laparoscopic pull-through (SILPS).~CLP involves three to five small incisions for trocars, allowing laparoscopic visualization and instrument access. Pneumoperitoneum is established, and the aganglionic colon segment is identified and mobilized using laparoscopic energy devices. The rectum is dissected circumferentially to preserve mesenteric blood supply, and a transanal approach is used to excise the diseased segment, followed by coloanal anastomosis with absorbable sutures.~SILPS follows the same principles but is performed through a single umbilical incision using a multi-port device for all instruments. This technique offers benefits like reduced scarring and less postoperative pain but requires advanced laparoscopic skills due to instrument crowding."
223919205|NCT05430230|DRUG|Naproxen 500 Mg|naproxen tablets
223919206|NCT05430230|DRUG|Placebo|lactose NF
223919207|NCT06413355|DRUG|[F-18]-FAPI-74|A positron-emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo expression of FAP with positron emission tomography (PET/CT).
223919208|NCT06871540|OTHER|Probiotic Agent|Patients in the test group were instructed to take one tablet immediately after tooth brushing (before bedtime) once daily for 30 consecutive days. Probiotic was administered in tablets containing 1x109 cfu/g S. salivarius K12.
223919209|NCT06871540|OTHER|Non-Surgical Intervention|Patients in the control group received non-surgical periodontal treatment only.
223919210|NCT06871761|DRUG|HR17031 injection|HR17031 injection
224278676|NCT01186016|BEHAVIORAL|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
224278677|NCT01186016|BEHAVIORAL|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
224278678|NCT02660541|DEVICE|Betafoam|Comparison between 2 medical devices
223919211|NCT06871761|DRUG|insulin glargine|insulin glargine
223919212|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 1|Investigational varicella vaccine of Lot 1 administered subcutaneously.
223919213|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 2|Investigational varicella vaccine of Lot 2 administered subcutaneously.
223919214|NCT06740630|BIOLOGICAL|Investigational varicella vaccine_Lot 3|Investigational varicella vaccine of Lot 3 administered subcutaneously.
223919215|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 1|Marketed varicella vaccine of Lot 1 administered subcutaneously.
223919216|NCT06740630|BIOLOGICAL|Marketed varicella vaccine_Lot 2|Marketed varicella vaccine of Lot 2 administered subcutaneously.
223919217|NCT06740630|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
223717032|NCT06310538|DRUG|Hongjin Xiaojie Capsules|The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
223717033|NCT05086848|DRUG|Irinotecan liposome、5-fluorouracil、Leucovorin|Irinotecan liposome、5-fluorouracil、Leucovorin
223919218|NCT06740630|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
223919219|NCT06740630|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223919220|NCT06740630|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223919221|NCT06740630|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine) co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223919222|NCT06739317|RADIATION|Radiation|Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
223919223|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
223919224|NCT06739317|DRUG|First line therapy|Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
224278679|NCT02660541|DEVICE|Allevyn Silver Dressing|Comparison between 2 medical devices
223919225|NCT06739317|PROCEDURE|operation|If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.
223940649|NCT06593717|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
224278680|NCT02118987|DRUG|Omalizumab|
224278681|NCT01529554|DRUG|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
224278682|NCT01529554|DRUG|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
223919226|NCT06739109|PROCEDURE|Therapy-guided internet-based treatment program|eBA is a guided internet-based treatment for problematic alcohol use, based on cognitive behavioural therapy and motivational interview. The patients get access to self-help modules with information, questionnaires, and tools useful in a process of reducing alcohol use. Questionnaires measuring changes in alcohol use, illicit drug use, physical and mental health, and quality of life are frequently answered. These questionnaires are an integrated part of the treatment program and are used by the therapist to monitor and adjust the treatment according to each patient. The patients use the results from the questionnaires to assess whether the treatment is helpful reaching the treatment goal. The patients are guided by a therapist, and they communicate using a system for written messages in the treatment program and/ or guided by telephone.
223919227|NCT06885762|DRUG|efgartigimod|efgartigimod 20 mg/kg was administered via intravenous infusion on day 1 and day 5 of the treatment period only.
223919228|NCT06751290|DRUG|Cyproheptadine|Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
223919229|NCT06751290|BEHAVIORAL|Nutritional Counseling|This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic nutritional guidance on high-calorie foods.
223919230|NCT06751290|BEHAVIORAL|Behavioral Counseling|This includes in person counseling by a provider once in office for up to 15 minutes as well as standardized hand out with basic behavioral guidance.
223919231|NCT06751134|DRUG|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
223919232|NCT06748287|DEVICE|iGrow Hair Growth System|has a helmet-design and headphones to allow for hands-free use and music listening capabilities. Treatment is 25 minutes every other day. three to four times per week for 4 months.
223919233|NCT06748287|DEVICE|Capillus352|has a similar design to a salon hair dryer which hovers over the head to allow for hand-free use. Treatment is 12 minutes, three times per week for 4 months.
223919234|NCT06748287|DEVICE|HairMax Ultima 12 Lasercomb|is comb-like device with hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 8 minutes three times per week for 4 months.
223717034|NCT04279457|DEVICE|DyeVert Plus System|The DyeVert Plus System also contains a reusable Contrast Monitoring Wireless Display (CMW) which communicates with the Dye-Vert Plus Disposable to allow real-time monitoring and display of contrast volumes manually injected compared to a predefined, physician-entered contrast usage threshold throughout the procedure. At the end of the procedure, the CMW displays total procedure contrast volume used (mL), % of physician specified limit , total procedure contrast volume saved (mL), and % contrast saved
223919235|NCT06748287|DEVICE|HairMax Laserband 82|is headband design device which has unique hair-parting teeth to aid in delivery of light therapy directly to the scalp. Treatment is 90-second treatments three times per week for 4 months.
223919236|NCT06744101|RADIATION|Evaluate the effectiveness of Diffusion Weighted MRI (DWI) in detecting breast lesions.|Assess the sensitivity, specificity, and diagnostic accuracy of DWI compared to Ultrasonography (USG) for benign and malignant lesions.
223919237|NCT06744101|RADIATION|Compare Sensitivity and Specificity of DWI and USG|Analyze which modality performs better in lesion detection based on sensitivity and specificity.
223919238|NCT06418347|DRUG|Alpha lipoic acid|"Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects."
223919239|NCT06418347|DRUG|Letrozole|Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
223919240|NCT06738329|OTHER|Carrageenan gummy sweet|Gummy sweet containing carrageenan and agar as the gelling agents.
223919241|NCT06738329|OTHER|Carrageenan and inulin gummy sweet|Gummy sweet containing agar and carrageenan as gelling agents, with added inulin.
223919242|NCT06738329|OTHER|Placebo agar agar gummy|Gummy sweet containing agar as gelling agents.
223940650|NCT06593717|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
224278683|NCT00818298|DRUG|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
224278684|NCT04525898|DRUG|Methadone|The methadone group will receive an intravenous dose of methadone at induction of anesthesia (0.15 mg/kg ideal body weight (IBW)
223717035|NCT04279457|OTHER|Standardized hydration protocol|hydration protocol based up on the Poseidon protocol
223530386|NCT02234193|DEVICE|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
223919243|NCT06747650|BEHAVIORAL|Dialectical Behavior Therapy for Adolescents|Standard of care (SOC) DBT-A includes approximately six weeks of pretreatment, and approximately six months of DBT-A skills group, individual therapy, and 24/7 phone coaching. During pre-treatment, clients are oriented to the DBT-A model and client commitment to treatment is established. After approximately six weeks, the client enters DBT-A skills group along with their caregiver. This skills group meets weekly for 1.5 hours and clinicians explain the five main DBT-A skills (mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness, and walking the middle path) via PowerPoints and discussion. Clients and their caregivers are assigned weekly homework. At the same time, teens are completing weekly 1-hour individual therapy sessions where they are utilizing the skills learned in group. Both teens and caregivers have access to what DBT-A calls 24/7 phone coaching. This phone coaching is 24/7 access to a therapist when a crisis is arising.
223919244|NCT02765412|OTHER|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
224089789|NCT03939234|COMBINATION_PRODUCT|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
223919245|NCT02765412|OTHER|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
223919246|NCT02765412|OTHER|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
223919247|NCT02765412|OTHER|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precision. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
223919248|NCT05031494|DRUG|YH003|YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
223919249|NCT05031494|DRUG|Toripalimab|Toripalimab will be administered at a dose of 240 mg every 3 weeks.
224089790|NCT00486603|DRUG|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
223919250|NCT05031494|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered each 21-day cycle.
224089791|NCT00486603|DRUG|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
224089792|NCT00486603|OTHER|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
224089793|NCT00486603|RADIATION|Radiation|Radiation during the first six weeks of treatment Monday-Friday
224089794|NCT00367211|DRUG|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
224089795|NCT00367211|DRUG|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
224089796|NCT04939857|DRUG|Trimetazidine|The experimental group will be treated with trimetazidine, and the control group will not be intervened
224089797|NCT05075668|DEVICE|CPAP face mask|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
224089798|NCT05075668|DEVICE|High flow nasal cannula (HFNC)|Two types of CPAP therapy for OSA support are compared; CPAP face mask vs HFNC at different flow rates
223919251|NCT05031494|DRUG|Gemcitabine|Gemcitabine will be administrated each 21-day cycle.
224089799|NCT00747487|DRUG|Idebenone|Idebenone 900 mg/day
224089800|NCT00747487|DRUG|Placebo|Placebo
224089801|NCT05069584|PROCEDURE|Biopsy|patient must have a biopsy for his prostate cancer
224089802|NCT05340972|DIAGNOSTIC_TEST|MEESSI score|The score aimed to predict the AHF patient's future in the month following management for ED
223530387|NCT02234193|PROCEDURE|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
223530388|NCT04782921|DEVICE|Xenogenic bone graft material|After access to the periodontal defect via straight incision in vestibulum, at the mucogingival border or short releasing incision on adjacent tooth, Gel 40 (a mixture of collagen gel and xenogenic bone particles) or Gen-Os (pure xenogenic bone particles) will be inserted.
223530389|NCT00056823|DRUG|rhuFab V2 (ranibizumab)|
223530390|NCT04252209|OTHER|natural herbs of coconut, aloe vera, and pepperint|mixture of herbal oils of coconut, peppermint, aloe vera
224089803|NCT00331305|BEHAVIORAL|Supervised Exercise|
224089804|NCT00331305|BEHAVIORAL|Home-Based Exercise|
224089805|NCT00331305|DRUG|Sertraline (Zoloft)|
224089806|NCT00331305|DRUG|Placebo Pill|
224089807|NCT00037648|DRUG|Anakinra|anakinra
224089808|NCT00037648|DRUG|Placebo|placebo
224089809|NCT01670994|BIOLOGICAL|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
224089810|NCT02494570|DRUG|nab-Sirolimus|Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.
224278685|NCT01500005|DRUG|Baby D3 drops|2000-4000 iu per day
223717036|NCT05751265|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks . Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
223717037|NCT05751265|DRUG|5Fu|Participants will receive 5-FU, 2.4 g/m2，bid，d1-d14，q3w
223717038|NCT05751265|DRUG|Paclitaxel injection|Participants will receive paclitaxel 135 mg/m2 ivgtt q2w or 175mg/m2 q3w
223919252|NCT06877390|OTHER|conventional drug and exercise rehabilitation|patients in the control group received antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel, once a day), β-blocker (25-100 mg of metoprolol, twice a day, with the dose adjusted based on the patient's heart rate) and statins (10-20 mg of rosuvastatin, every night). In addition, the patients received exercise rehabilitation (e.g. aerobic, resistance and flexibility training) for 30-60 min, 3-5 times/week.
223919253|NCT06877390|DEVICE|EECP-based rehabilitation regimen|Patients in the rehabilitation group received the same medication and exercise rehabilitation as the control group during the trial period after undergoing DCB-based PCI DCBs; in addition, they were provided with EECP treatment after 7 days of medication. The treatment adopted a P-ECP/TI EECP device with a pressure setting of 0.020-0.035 MPa. Based on patients' actual tolerance, the treatment pressure and inflation and exhaust times were adjusted to a diastolic/systolic blood pressure ratio of \>1.2 and a diastolic/systolic pressure area of 1.5-2.0. The treatment was applied daily for 1 hour, 6 days a week, for a total of 36 hours.
223919254|NCT06883071|PROCEDURE|Endoscopic ultrasound (EUS)-guided spring plug combined with ECI|Group A: Spring plug combined with ECI under the guidance of endoscopic ultrasound (EUS): Spring plug was placed to limit the flow of varicose veins by EUS, and then tissue glue was injected under EUS to block the varicose veins. Group B: Titanium clip plus EUS-guided spring plug placement to limit the flow combined with ECI: After partial titanium clip flow limitation under endoscopy, spring coil combined with tissue glue injection was placed in the varicose veins by judging the inflow and outflow tracts under the guidance of ultrasound (EUS).
223919255|NCT06883071|PROCEDURE|Titanium clip plus EUS-guided spring plug placement for flow limiting combined with ECI|Group A: Spring plug combined with ECI under the guidance of endoscopic ultrasound (EUS): Spring plug was placed to limit the flow of varicose veins by EUS, and then tissue glue was injected under EUS to block the varicose veins. Group B: Titanium clip plus EUS-guided spring plug placement to limit the flow combined with ECI: After partial titanium clip flow limitation under endoscopy, spring coil combined with tissue glue injection was placed in the varicose veins by judging the inflow and outflow tracts under the guidance of ultrasound (EUS).
223919256|NCT06736951|OTHER|MMSH (Multi-Modal Sleep Hygiene) Bundle|Focus on Noise Reduce Noise Perception, Reduce Hallway Noise, Reduce Noise in Rooms Focus on Light Reduce Lights at Night, Increase Light in Day, Reduce Light Perception Focus on Staff-Patient Interactions Delirium Screening, Avoid Care Procedures at Night, Z-time Plan \&amp; Prep Focus on Daytime Activity Increased Mobility, Increase Patient Engagement Focus on Medications Pain Management, Medication Monitoring, Continue pharmacy protocols, Timing of Medications/Monitoring Labs
223919257|NCT06889909|DRUG|Trelagliptin 100 mg|Trelagliptin 100 mg was administered orally once weekly before breakfast on the same day of the week.
223919258|NCT06889909|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg was administered orally once daily.
223919259|NCT06894251|DIETARY_SUPPLEMENT|LIMICOL® NG|All subjects will consume 2 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V2, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 1 tablet in the evening during dinner. If a dose is missed, 2 tablets can be taken at the next dose.
223919260|NCT06894732|PROCEDURE|Rotary induced abortion|Rotary induced abortion under ultrasonic monitoring was performed with intravenous anesthesia.
223919261|NCT06893497|DEVICE|Low Level Laser Therapy|In this study, which had more patients than other studies, different parameters were evaluated to determine the protocol of LLL therapy. These parameters were the cause of IAN injury, number of sessions, time of treatment start and period of follow-up.
223919262|NCT06750861|DRUG|QL1706|QL1706+AG
224278686|NCT00065949|DRUG|magnesium sulfate|
224278687|NCT00214682|DRUG|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
223717039|NCT02920385|DRUG|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
223717040|NCT02920385|DRUG|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
223717041|NCT02920385|DRUG|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
223717042|NCT02920385|DRUG|Placebo|Oral administration once daily together with semaglutide
223717043|NCT03834441|OTHER|Oral HRSN screening|Verbal screening delivered by an RA
223717044|NCT03834441|OTHER|Written HRSN screening|Patient completes written screen on iPad.
223717045|NCT01930266|DIETARY_SUPPLEMENT|Experimental|
223717046|NCT01930266|BEHAVIORAL|Active comparator|
224278688|NCT00214682|BEHAVIORAL|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
223919263|NCT06742372|OTHER|combined inspiratory and aerobic exercise training|combined inspiratory and aerobic exercise training will be performed in healthy individuals
223919264|NCT06742372|OTHER|aerobic exercise training|aerobic exercise training will be performed in healthy individuals
223919265|NCT06748872|DRUG|Lymphodepletion|Cylcophosamide and Fludarabine
223919266|NCT06748872|BIOLOGICAL|TCR-T cells (MDG1015)|TCR-T cells (MDG1015)
223919267|NCT06748469|PROCEDURE|The duration of the intervention will be 240 seconds|Dorsal Root Ganglion pulsed radiofrequency 240sec
223919268|NCT06748469|PROCEDURE|Dorsal Root Ganglion pulsed radiofrequency 480sec|The duration of the intervention will be 480 seconds
223919269|NCT06751069|BEHAVIORAL|Home-based Pulmonary Rehab|Participants are expected to engage in the home-based PR routine five to six days a week for the entire 12-week study period. The PR routine begins with slow upper body and timed breathing exercises, followed by two slow balance walks for 6 minutes each. The total exercise time is 24 minutes a day followed by a 4-minute mindful breathing meditation/cool down. Exercises may be modified or repeated according to baseline activity level and as conditioning improves.
224089811|NCT01802359|DRUG|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
224089812|NCT00837187|DRUG|Intravenous dexmedetomidine|100 ug
224089813|NCT00837187|DRUG|Intranasal dexmedetomidine|100 ug
224089814|NCT04267640|BIOLOGICAL|AMG0001|AMG0001 is a DNA Plasmid encoding hepatocyte growth factor (HGF) administered intramuscularly
224089815|NCT04267640|BIOLOGICAL|Placebo|Matching placebo
224089816|NCT03110588|DRUG|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
224089817|NCT03110588|DRUG|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
224089818|NCT01295125|DEVICE|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
224089819|NCT01295125|PROCEDURE|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
224089820|NCT06487013|DEVICE|ArcBlate Focused Ultrasound Ablation System|MR-guided High Intensity Focused Ultrasound (MRgHIFU)
224089821|NCT06487013|OTHER|Sham MRgHIFU treatment|Sham MRgHIFU treatment
223919270|NCT06755684|DRUG|Befotertinib combined Bevacizumab|Befotertinib combined Bevacizumab
223919271|NCT06755684|DRUG|Befotertinib combined platinum-based double chemotherapy|Befotertinib combined platinum-based double chemotherapy
223919272|NCT06751797|OTHER|No intervention|No intervention
224089822|NCT05729841|OTHER|Ocean row|the Talisker Whisky Atlantic Challenge annual ocean rowing race.
224089823|NCT00003558|DRUG|carboplatin|
224089824|NCT00003558|DRUG|etoposide|
224089825|NCT00003558|DRUG|fluorouracil|
224089826|NCT00003558|DRUG|leucovorin calcium|
223919273|NCT06752005|BEHAVIORAL|Intervention Group|One of the investigators created a randomization sequence using a simple random numbers table and determined the groups. Another researcher assigned premature infants to the study groups according to the order of hospitalization in the unit, and the same researcher also applied the intervention. Thus, each infant experienced all three positions in a crossover design by the end of the study. Infants in all three groups were positioned for two hours in each posture, totaling six hours by the end of the study. Immediately after positioning in each posture, and at 1, 30, 60, 90, and 120 minutes, heart rate and oxygen saturation (SpO₂) values were recorded from bedside monitors, and respiratory rate was counted over one minute. Comfort and stress scores were assessed immediately after positioning (1 minute) and at 60 and 120 minutes. The Premature Infant Comfort Scale (PICS) was used to assess comfort, while the Neonatal Stress Scale (NSS) was used to evaluate stress.
224089827|NCT00003558|DRUG|paclitaxel|
224089828|NCT03182439|DEVICE|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
224089829|NCT03182439|DEVICE|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
224089830|NCT03182439|DEVICE|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
224089831|NCT03182439|DEVICE|Apple Watch|Apple Watch Heart Rate Monitoring Device
224089832|NCT05229939|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
224089833|NCT01488253|DRUG|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
224089834|NCT01488253|DRUG|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
224089835|NCT01561664|OTHER|muscle and fat biopsy|muscle and fat biopsy
224089836|NCT02575430|OTHER|No treatment: retrospective chart review|
224089837|NCT01841632|DRUG|MultiStem|
224089838|NCT01855256|DRUG|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
224089839|NCT01855256|DRUG|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
224089840|NCT05207150|DEVICE|LINQII/Apple Watch Series 6|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear an Apple Watch Series 6 for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (Apple Watch) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
223717047|NCT06557447|DIAGNOSTIC_TEST|Immunological and microbiological sample of peri-implant crevicular fluid; clinical evaluation|"Immunological sample collection involves placing a Periopaper strip in the peri-implantar sulcus for 30 seconds. If sample is contaminated with blood, sample will be discarded and another sample will be collected (a different surface of the same implant/tooth can be used).~Microbiological sample collection involves collecting subgingival dental plaque by sliding the end of the STERILE curette (Gracey) inside the peri-implant sulcus. In case of slight bleeding following the first sample, dry the site again before collection. In case of profuse bleeding, collect a sample from another site (by site mean mesial/buccal/distal/lingual) of the same implant.~Both immunological and microbiological samples will be sent for respective laboratories for the analysis.~Clinical evaluation will assess presence of dental plaque, bleeding on probing and gingival status."
223717048|NCT02871414|BEHAVIORAL|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
223919274|NCT06740318|OTHER|Motivational enhancement therapy|The intervention consists of three motivational interviews with the focus to enhance the participants motivation to enter treatment of alcohol use disorder. the interviews are structured and based on the model Motivational enhancement therapy.
223919275|NCT06826092|DRUG|Metformin Pill|Metformin 500mg TID、FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy
223919276|NCT06826092|DRUG|FOLFIRI plus target therapy only|FOLFIRI (Leucovorin (LV), 200 mg/m2, 2-hour infusion, 5-FU, 2,800 mg/m2, 46-hour infusion, Irinotecan (IRI), 180 mg/m2, 2-hour infusion) plus target therapy
223919277|NCT06776679|DRUG|[14C]-BGB-16673|Administered orally as suspension in lipid vehicle
223919278|NCT04868877|DRUG|MCLA-129|full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
223919279|NCT04868877|DRUG|Osimertinib|Approved, 3rd-generation EGFR-TKI
223919280|NCT04868877|DRUG|Chemotherapy|administrated by IV infusion
223919281|NCT05900895|DRUG|Olaparib|Participants will be treated with olaparib at the approved doses for the treatment of subtypes of breast cancer or at reduced dose/frequency for participants with moderate renal impairment.
223919282|NCT05900895|DRUG|17b-estradiol|17b-estradiol will be taken orally three times per day.
223919283|NCT05267639|DEVICE|Power Knee|Newest version of the commercially-available Power Knee developed by Ossur.
223919284|NCT06628687|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
223919285|NCT05743231|PROCEDURE|interpectoral area block + serratus anterior area block group|The interpectoral and serratus anterior area blocks will be applied immediately after general anesthesia is given to the participants under ultrasound guidance. 30 ml of 0.25% bupivacaine will be used for two blocks.
223919286|NCT06562712|PROCEDURE|Conventional management|Patients will be subjected to conventional management for placenta accreta spectrum.
223919287|NCT06562712|PROCEDURE|Bilateral internal iliac artery balloon occlusion|Patients will be subjected to bilateral internal iliac artery balloon occlusion for placenta accreta spectrum.
223717049|NCT02871414|BEHAVIORAL|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
223919288|NCT05515497|DEVICE|BMT4me 2.0 app|The BMT4me app was designed by AWRI RISI developers and has been through multiple phases of stakeholder testing. The app is a virtual assistant for caregivers, allowing for medication record keeping, medication and refill reminders, symptom tracking, and a word and picture journal. All data is secured on the individuals password protected phone.
223919289|NCT06427434|OTHER|Strengthening and stretching exercises to the back and abdominal muscles|Strengthening and stretching exercises to the back and abdominal muscles will be performed for 30 min, three times per week for 4 weeks.
223919290|NCT06427434|OTHER|Modified Lumbar Sustained Natural Apophyseal Glide|Modified Sustained Natural Apophyseal Glide will be applied on the affected lumbar level for 30 sec three times per week for 4 weeks.
223919291|NCT05620875|DIAGNOSTIC_TEST|Cerebral injury markers|Blood tests at given time points perioperatively.
223919292|NCT05620875|DIAGNOSTIC_TEST|Cerebral oximetry index|Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy
223919293|NCT05715255|BEHAVIORAL|Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)|Participants randomized to the adaptive intervention are telephoned weekly and asked to enter by pin-pad or voice the severity of the PRO-CTCAE items on a 0-4 scale, with 0 being none and 4 being very severe. Participants are mailed the Symptom Management and Survivorship Handbook in their preferred language (English or Spanish). Survivors who rated any item at moderate or higher (2-4) will be referred by the ATSM to read the corresponding chapters in the Handbook and given a call back in 24 hours to inquire about the severity of the reported symptom, whether it has improved or worsened, and whether the participant reported it to their HCP, or the HCP has contacted the survivor. Participants that report elevated symptoms for two consecutive weeks are rerandomized to continue the ATSM alone or continue the ATSM with TIP-C added for 8 weeks. TIP-C is delivered by a masters prepared counselor with cancer expertise via weekly 30-minute phone calls using interpersonal techniques.
223919294|NCT05715255|BEHAVIORAL|Active control comparator|Survivors in the active control will receive weekly AVR assessments of PROCTCAE symptoms, and summary of these assessments will be sent securely to HCPs. Survivors will not receive the Handbook and will not be prompted by the AVR to contact HCPs unless the symptoms are severe.
223919295|NCT04083534|DRUG|REGN5459|Administered by intravenous (IV) infusion
223919296|NCT03697408|DRUG|Itacitinib|A JAK 1 selective small molecule inhibitor
223919297|NCT03697408|DRUG|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
223919298|NCT06752746|DRUG|9MW3011|Multiple dose
223717050|NCT01245621|BEHAVIORAL|Later entry group|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
223530391|NCT04252209|OTHER|carboxy methyl cellulose|a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
223717051|NCT01245621|BEHAVIORAL|Early palliative care intervention|"1. Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~2. Comprehensive Palliative Care Team Assessment \& Management Plan."
223717052|NCT01427972|DRUG|LY2623091|Administered orally
223717053|NCT01427972|DRUG|Eplerenone|Administered orally
223919299|NCT04244175|DRUG|Placebo|Participants received CVL-865 matched placebo tablets orally twice a day (BID) during the Treatment Period.
223919300|NCT04244175|DRUG|CVL-865|Participants received CVL-865 tablets orally twice a day (BID) up to the maximum dose of 7.5 mg BID or 25 mg BID during the Treatment Period.
223919301|NCT05624138|DRUG|Placebo tablets|12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
223919302|NCT05624138|DRUG|Ketotifen Oral Tablet|ketotifen is a potent anti histaminic drug that may prevent oxaliplatin induced peripheral neuropathy and mucositis and will be administered 2 mg daily along with the 12 cycles of modified Folfox-6 regimen
223919303|NCT06281756|BEHAVIORAL|Cognitive Behavioral Treatment for Insomnia (CBT-I)|Subjects will receive therapy for 8 weeks
223919304|NCT06281756|DRUG|Trazodone|Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
224089841|NCT05207150|DEVICE|LINQII/SkyLabs CART-I ring|LINQ II will be implanted and in the first 3 months it will send alerts to participants' smartphones if it detects an AF episode longer than 30 minutes. After 3 months, participants will wear a SkyLabs CART-I ring for another 3 months. The LINQ II ICM will continue to detect and record AF episodes and will be used to validate the AF detection accuracy by the wearable devices but it will no longer send alerts during AF episodes. Instead, the wearable device (CART-I ring) will send a real-time alert to participants during AF episodes longer than 30 minutes and participants will use the appropriate smartphone app to acknowledge they have received the alert.
224089842|NCT00869297|OTHER|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
224089843|NCT00869297|OTHER|Control|Fluids titrated at discretion of anesthesiologist.
224089844|NCT04337957|OTHER|geriatric nephrology|Collection of the geriatrician's opinion
224089845|NCT01824979|DEVICE|CPAP mask ( Pilairo)|
224089846|NCT01824979|PROCEDURE|Other CPAP mask|
224089847|NCT03373019|DRUG|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
224089848|NCT03807531|DEVICE|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
224089849|NCT00292084|DRUG|Celgosivir|
224089850|NCT04899648|BEHAVIORAL|Behavioral Intervention Group|Behavioral intervention: (a) form groups and choose peer leaders; (b) train peer leaders on 16 core classes based on diabetes prevention program curriculum; (c) support and motivate peer leaders to lead intervention in their group; (d) monitoring of the interventions.
224278689|NCT00214682|BEHAVIORAL|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
224278690|NCT00214682|DRUG|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
223919305|NCT06281756|OTHER|Placebo|Non-remitting subjects will receive placebo for 8 weeks
223919306|NCT04845529|DEVICE|transcranial direct current stimulation (tDCS)|We will apply tDCS to the patients' brains for 20 minutes at the intensity of 1.5mA. Each patient will undergo the three sessions (separated by at least 24h to minimize carry-over effects), in a pseudo-randomized order across patients.
223919307|NCT04957576|BEHAVIORAL|Visuo-tactile stimulation|The patient will place both hands on a table in front of him/her, seeing only the left one disown. A visuo-tactile stimulation will be done, with the right (out of view, but perceiving the tactile stimulation) and left (in full view, but with somato-sensory deficits, therefore not feeling the stimulation) hands touched with a paintbrush for five minutes.
223919308|NCT06496061|DRUG|Norepinephrine|Norepinephrine infusion with 0.05 mg/kg/h
223919309|NCT06496061|PROCEDURE|Leg wrapping|Elastic leg wrapping
223530392|NCT01500317|DRUG|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
223530393|NCT01500317|DRUG|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
223530394|NCT01500317|DRUG|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
223530395|NCT00335829|BIOLOGICAL|bevacizumab|
223530396|NCT00335829|DRUG|chemotherapy|
223530397|NCT00335829|DRUG|embolization therapy|
223919310|NCT01508390|RADIATION|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
223919311|NCT06420440|PROCEDURE|Hepatic arterial infusion chemotherapy|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days)
223919312|NCT06420440|DRUG|Lenvatinib|Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued approximately two weeks before surgery, Oral 8 mg or 12mg once a day depending body weight).
223919313|NCT06420440|DRUG|Tislelizumab|Patients in the neoadjuvant therapy group received two cycles of Tislelizumab therapy before surgery (First treatment with Tislelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)
223919314|NCT06420440|PROCEDURE|Liver resection|Patients in the neoadjuvant therapy group were evaluated for tumor status and surgical safety after neoadjuvant therapy, and eligible patients subsequently underwent surgical resection. Patients in the direct surgery group underwent liver resection.
223919315|NCT06420440|DRUG|Tislelizumab|Given the high risk of postoperative recurrence, patients in both groups received adjuvant Tis therapy (every 21 days for 8 cycles) starting about one month after surgery.
223919316|NCT06315023|DEVICE|DETOUR System|Percutaneous Transmural Arterial Bypass Therapy using the DETOUR™ System
223919317|NCT04595331|DEVICE|Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection|Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
223919318|NCT03710772|DRUG|Cyclophosphamide|Given IV
223919319|NCT03710772|DRUG|Cytarabine|Given IV
223919320|NCT03710772|DRUG|Dexamethasone|Given PO or IV
223919321|NCT03710772|DRUG|Doxorubicin Hydrochloride|Given IV
223919322|NCT03710772|DRUG|Ibrutinib|Given PO
223919323|NCT03710772|DRUG|Methotrexate|Given IV
223919324|NCT03710772|BIOLOGICAL|Rituximab|Given IV
223919325|NCT03710772|DRUG|Venetoclax|Given PO
223919326|NCT03710772|DRUG|Vincristine Sulfate|Given IV
223919327|NCT05794399|DRUG|Rivaroxaban|"Intervention Group:~The patients in the intervention group will be treated with Rivaroxaban 20 mg once daily with the evening meal in patients with a CrCl \>50 mL/min OR 15 mg in cases of moderate-to-severe renal impairment dose with the dosing of once daily with the evening meal in patients with a CrCl ≤50 mL/min. The patient in the intervention group will be requested for follow-up after 3 months of commencing the treatment or whenever the signs and symptoms of bleeding events are noted."
223919328|NCT05794399|DRUG|Warfarin|"Control Group:~The patients in the control group will be treated with Warfarin. The dose will be started with 5 mg and will be titrated based on the International Normalized Ratio (INR) which will be targeted at the range of 2.0 to 3.0. The dual antiplatelet duration will be based on the latest guidelines. The patients will be asked for frequent INR monitoring on an OPD basis until the INR is within the therapeutic range, after which patients will be asked for monthly follow-up INR reports. The patients in the control group will not be treated with heparin or low molecular weight heparin before the INR is maintained in the therapeutic range."
223919329|NCT06784141|BEHAVIORAL|personalized Cognitive Behavior Therapy including third-wave|In the personalized CBT, patients first complete 21 days of EMA with six assessment points daily to assess relevant processes of CPP models. Person-specific networks are estimated based on the EMA data. A network-based algorithm indicates the treatment target. The individual CBT modules are selected for the participants from a matching matrix that contains experts' module recommendations for specific treatment targets. After that, participants will receive one out of ten CBT modules addressing their treatment target. All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behavior Therapy, Acceptance and Commitment Therapy or Mindful Selfcompassion.
223919330|NCT06784141|BEHAVIORAL|standardized Cognitive Behavior Therapy including third-wave|The standardized CBT intervention is manual-based and contains five sessions of cognitive behavioral therapy. Based on the evaluated manual from EFFECT Back, a short version with 5 modules is used: attention control, relaxation techniques, behavioral activation, cognitive strategies, and consolidation.
223919331|NCT02313623|PROCEDURE|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
224278691|NCT00214682|BEHAVIORAL|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
223919332|NCT05064514|DEVICE|Transcatheter Tricuspid Valved Stent Graft|All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.
223530398|NCT00335829|PROCEDURE|hepatic artery infusion|
223530399|NCT06641011|DEVICE|Immediate restoration (resin- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by resin-based fissure sealant
223530400|NCT06641011|DEVICE|Immediate restoration (GI- based) after blot-drying silver fluoride application|Blot-drying silver fluoride with cotton pellet followed by glass ionomer-based fissure sealant
223530401|NCT06641011|DEVICE|Immediate restoration (Resin based) after rinsing silver fluoride application|Rinsing silver fluoride off followed by resin-based fissure sealant
223530402|NCT06641011|DEVICE|Immediate restoration (GIC) after rinsing silver fluoride application|Rinsing silver fluoride off and blot-drying of fissures followed by glass ionomer-based fissure sealant
223919333|NCT05757492|DRUG|CHS-006 (anti-TIGIT)|Arm A participants will receive CHS-006 administered via IV Q3W.
223919334|NCT05757492|DRUG|toripalimab (anti-PD-1)|Arm B participants will receive toripalimab administered via IV Q3W.
223919335|NCT04707183|DRUG|Lidocaine IV Infusion|Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.
223919336|NCT04707183|DRUG|2% Lidocaine via ESPB|10 ml of 2% lidocaine will be infused through ESPB in treatment group
223919337|NCT05909644|DRUG|Omaveloxolone|Omaveloxolone Capsules, 150 mg, administered orally
223919338|NCT05909644|DRUG|Efavirenz|Efavirenz Tablet, 600 mg, administered orally once daily
223919339|NCT06299267|OTHER|dual task conditions|dual task conditions on manual skill tests
223919340|NCT04472897|DRUG|GSK2556286|GSK2556286 will be administered.
223919341|NCT04472897|DRUG|Placebo|Placebo will be administered
223919342|NCT04591002|DRUG|Osimertinib 80 MG|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. Osimertinib will be administered orally as one 80 mg tablet once a day (1 cycle is 28 days). Cycles are repeated until disease progression, unacceptable toxicity, or until 1 year after the initiation of osimertinib administration.
223919343|NCT05723835|DRUG|Somapacitan|Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.
223919344|NCT05280925|BEHAVIORAL|Episodic Future Thinking|Participants will be prompted three times daily to think vividly about personally meaningful future events.
223919345|NCT05280925|BEHAVIORAL|Healthy Information Thinking|Participants will be prompted three times daily to think about their responses to informational health vignettes.
223919346|NCT05447078|DRUG|Immulina TM|Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
223919347|NCT05447078|DIETARY_SUPPLEMENT|Placebo|Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.
223919348|NCT04725383|DRUG|amitriptyline|Amitriptyline is a tricyclic antidepressant being studied off-label here for repetitive behaviors in autism spectrum disorders.
223919349|NCT04521153|DRUG|Camrelizumab|Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery
223919350|NCT04521153|DRUG|Apatinib Mesylate|Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery
223919351|NCT04521153|PROCEDURE|Radical surgery|Radical surgery
223919352|NCT03781089|DRUG|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K \< 4.0 mEq/L, and patiromer will be discontinued if K \< 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
223919353|NCT04092634|DEVICE|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
223919354|NCT04092634|DEVICE|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
223919355|NCT04202835|DRUG|Cyclophosphamide|Post Transplant Cyclophosphamide
223919356|NCT04202835|DRUG|Anti-Thymocyte globulin (rabbit)|Anti-Thymocyte Globulin (rabbit, Thymoglobulin)
223919357|NCT02238808|DRUG|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
223919358|NCT06957886|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
223919359|NCT06957886|DRUG|Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel|Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
223919360|NCT03994471|DRUG|XyloCore Low Strenght, XyloCore Medium Strenght, XyloCore High Strenght|XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine
223919361|NCT03994471|DRUG|1.36%, 1.5%, 2.27%, 2.5%, 3.86%, 2.25% Glucose PD Solution|Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.
223919362|NCT06550375|DEVICE|TECNIS Odyssey IOL|Implantation with the TECNIS Odyssey IOL
223919363|NCT06958783|OTHER|Blood lipid monitoring in breast cancer patients during chemotherapy|This intervention is distinguished by its prospective design, enrollment of a clearly defined cohort of adult female patients with newly diagnosed early-stage breast cancer (stage IB-IIIB), administration of a uniform chemotherapy regimen (doxorubicin, cyclophosphamide, paclitaxel), and standardized monitoring of fasting lipid profiles at four precisely scheduled timepoints: pre-chemotherapy, pre-paclitaxel, post-paclitaxel, and three months post-chemotherapy completion
223919364|NCT00756639|RADIATION|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
223530403|NCT06641011|DEVICE|Resin based fissure sealant restoration one week after silver fluoride (AgF) application|Resin based fissure sealant restoration one week after silver fluoride (AgF) application
224278692|NCT00214682|BEHAVIORAL|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
224278693|NCT05892731|OTHER|with depression|age-related hearing loss with depression
224278694|NCT05892731|OTHER|without depression|age-related hearing loss without depression
223919365|NCT00756639|OTHER|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
223919366|NCT05635617|PROCEDURE|Lower Extremity Surgery|Patients 18 years of age or older with high energy lower extremity fractures. Provision of informed consent.
223919367|NCT05856968|PROCEDURE|continuous subcutaneous tissue closure|The use of continuous subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
223919368|NCT05856968|PROCEDURE|Interrupted subcutaneous tissue closure|The use of interrupted subcutaneous tissue closure to determine which closure results in a lower rate of surgical site infection.
223919369|NCT04487041|BIOLOGICAL|Standard dose influenza vaccination|Single 0.5 ml injection administered intramuscularly into participant's deltoid muscle
223919370|NCT04487041|BIOLOGICAL|High dose influenza vaccination|4 times more concentrated single 0.7 ml injection administered intramuscularly into participant's deltoid muscle
224278695|NCT03890757|OTHER|ultrasound guided paravertebral or serratus anterior block|"Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site"
224278696|NCT01098539|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
224278697|NCT01098539|DRUG|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
224278698|NCT04136067|DRUG|NNC0268-0965|One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
223919371|NCT05770375|DRUG|MDMA 40mg|MDMA 40mg
223919372|NCT05770375|DRUG|MDMA 80mg|MDMA 80mg
223919373|NCT05770375|DRUG|MDMA 120mg|MDMA 120mg
223919374|NCT06058897|OTHER|MRI|MRI examinations will be conducted on the 3T MRI technical platform. During the MRI examination, images reflecting the integrity of the LC (quantification of neuromelanin as well as its functional connections with the different brain regions (resting functional MRI) will be acquired. High-resolution T1 and T2 weighted images of the the entire brain will also be acquired for the volumetry of cerebral areas.
223919375|NCT06058897|OTHER|eye-tracking|Eye tracking examinations will be conducted using an EyeBrain medical device (class IIa) developed by Suricog. This eye tracker will be installed in a box, in an experimental room. The eye tracker is combined with a computer to present visual cognitive tasks. Pupillary dilation/constriction measurements will be acquired at rest (when fixing a cross presented on the screen) and during the performance of different cognitive tasks (exploration and processing of scenes visuals, reading texts, making saccades or anti-saccades when presenting visual targets). These pupillary measurements will then be linked to the memorization of the stimuli presented, this recognition being tested at the end of the exam.
223919376|NCT06058897|OTHER|cognitive exams|Cognitive measures will be acquired during an evaluation session through interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare (Covirtua Cognition software). Some exercises will test cognitive systems a priori dependent on NA release (episodic memory, working memory, selective attention, selective inhibition, planning) and other a priori independent of NA (semantic memory: categorization, naming).
223919377|NCT06095271|DIAGNOSTIC_TEST|serum Neurofilament Filament Light chain (sNfL) monitoring|the intervention consist of a blood draw and providing the sNfL information to the treating physician
224278699|NCT04136067|DRUG|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
224278700|NCT02104258|OTHER|Physiotherapy ASPETAR|Standardized physiotherapy protocol
224278701|NCT02104258|OTHER|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
224278702|NCT04348955|BEHAVIORAL|Women between 18 and 70 years old with an adjuvant breast cancer histologically characterized|"Quality of life and anxiety questionnaires before the course of chemotherapy (C1 and C4).~Touch-Massage during the course of chemotherapy (from C1 to C3) Anxiety questionnaire at the end of the course of chemotherapy (from C1 to C3)"
224278703|NCT00721955|DRUG|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
223919378|NCT05554107|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists and/or physicians with special interest in POTS.
223919379|NCT06448312|DRUG|SKB264|IV Infusion
223919380|NCT06448312|DRUG|Pembrolizumab|IV Infusion
223919381|NCT06548698|OTHER|escape room|Nursing students in the intervention group analyzed the breast cancer surgery case with the escape room experience.
223919382|NCT06114680|DEVICE|CochSyn test prototype|The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.
223919383|NCT06114680|DEVICE|Universal Smart Box (USB)|Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
223919384|NCT06283108|DEVICE|Standard Child Life Preparation and Support + Meta Quest 2 VR headset with Gurney Journey (a mixed reality experience)|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental or gastrointestinal procedure. Child life specialist's will utilize Gurney Journey as part of their support for induction. Gurney Journey is a mixed reality experience, using the Meta Quest 2 VR headset that was designed to mitigate patient anxiety during transport from pre-admission rooms to the procedure room/operating room for surgical procedures.
223919385|NCT06283108|BEHAVIORAL|Standard Child Life Preparation and Support|Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure.
223919386|NCT06963242|DEVICE|Dynamic Navigation System for Implant Placement Using Bone Screws as Landmarks|This study uses a dynamic navigation system for implant placement in fully edentulous patients requiring full arch prosthesis rehabilitation. The system incorporates bone screws (placed as reference points on the jaw arch) to guide the accurate placement of implants. Unlike traditional freehand implant placement, this dynamic navigation system aims to minimize deviation from the planned implant positions while also reducing the time required for the surgical procedure. The results will be compared to a group where landmarks are based on remaining teeth to assess accuracy and time efficiency of the system.
223919387|NCT06963242|DEVICE|Dynamic Navigation System for Implant Placement Using Remaining Teeth as Landmarks|In this arm, participants will undergo implant placement using a dynamic navigation system, where the reference points for implant positioning are based on the remaining teeth to be extracted. This approach, in contrast to the bone screw method used in Group 1, relies on the teeth that will be removed as landmarks to guide the accuracy of implant placement. The primary goal is to evaluate the accuracy of the implant placement and the time required for the procedure using this method. The results from this group will be compared to those from Group 1, where bone screws are placed as reference points, to assess the accuracy and time efficiency of both approaches.
223919388|NCT06817109|DEVICE|interactive technological intervention for improvement of mental health symptoms in Primary Care users Health|Intervention based on cognitive and behavioral techniques, such as psychoeducation on anxiety, depression and insomnia; muscle relaxation and breathing techniques; sleep hygiene techniques, behavioral activation and mindfulness techniques
223919389|NCT06661733|DRUG|AZD5462|Participants will receive AZD5462 orally.
223919390|NCT06777771|OTHER|Reformer pilates exercises|The reformer pilates exercises session will start with 5 minutes of warm-up exercises, continue with resistance exercises for 20 minutes, and end with 5 minutes of cool-down exercises. The springs of the reformer pilates device will be adjusted to create mild fatigue in the first week and will be gradually increased to create moderate fatigue in the following weeks. Reformer pilates sessions will consist of 15-20 different exercises with 12-15 repetitions, including all major muscle groups. These sessions will also include exercises that strengthen the pelvic floor muscles. Reformer pilates sessions will be applied twice a week for 6 weeks, a total of 12 sessions. Apart from this, they will be asked to walk for at least 30 minutes a day, at least 3 days a week.
223919391|NCT02163694|DRUG|Veliparib Placebo|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
223919392|NCT02163694|DRUG|Veliparib|Supplied as 40 mg, 50 mg, or 100 mg capsules for oral administration twice daily (BID) on Days -2 through 5 of a 21-day cycle.
223919393|NCT02163694|DRUG|Carboplatin|Administered intravenously over approximately 15 to 30 minutes at an area under the curve (AUC) of 6 mg/mL/min immediately following paclitaxel infusion on Day 1 of every cycle. The duration of carboplatin infusion may be lengthened according to institutional guidelines.
223919394|NCT02163694|DRUG|Paclitaxel|Administered by intravenous infusion over approximately 1 hour at a dose of 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle. Paclitaxel is to be infused prior to carboplatin on Day 1. Dosing of veliparib/placebo is to be completed before the carboplatin or paclitaxel infusions.
223919395|NCT05659147|DIAGNOSTIC_TEST|Research MRI without administration of intravenous secretin|Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
223530404|NCT06641011|DEVICE|GI- based fissure sealant restoration one week after silver fluoride (AgF) application|GI- based fissure sealant restoration one week after silver fluoride (AgF) application
223530405|NCT04846179|DIETARY_SUPPLEMENT|Ginkgo biloba extract|Patients recruited to Ginkgo Biloba Extract (GBE) group will be advised to take Webber Natural Ginkgo Biloba 120 mg soft gel, 1 tablet twice a day for 4 months.
223919396|NCT05659147|DIAGNOSTIC_TEST|Research MRI with administration of intravenous secretin|Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
223919397|NCT05659147|GENETIC|Genetic Sequencing|Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
223919398|NCT05659147|DIAGNOSTIC_TEST|Blood Tests|Research blood draw (for markers of pancreatic endocrine insufficiency)
223919399|NCT05659147|DIAGNOSTIC_TEST|Stool Tests|Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
224278704|NCT00721955|DRUG|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
224278705|NCT00721955|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
224278706|NCT00490321|DEVICE|VentrAssistTM Left Ventricular Assist Device|
224278707|NCT02297087|GENETIC|Standard of care based on target(s) identified via GWS.|
224278708|NCT04959032|DRUG|Lumateperone 42 mg|Lumateperone 42 mg capsules administered orally, once daily.
224278709|NCT04959032|DRUG|Placebo|Matching capsules administered orally, once daily.
224278710|NCT05036005|DRUG|Ontruzant|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
224278711|NCT05036005|DRUG|Chemotherapy|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
223919400|NCT05659147|OTHER|Survey Completion|Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
224278712|NCT05036005|DRUG|Pertuzumab|All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
224278713|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally in a single dose.
224278714|NCT04791345|DRUG|Methylprednisone|12 mg of methylprednisone (3 pills of 4 mg each) administered orally every 24 hours during 3 days.
223919401|NCT05659147|DIAGNOSTIC_TEST|Endoscopic pancreatic function tests (ePFTs)|At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
223919402|NCT05659147|DRUG|Secretin|"Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg).~Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI.~Participants in Aim 4 will receive two doses (1 during each MRI).~Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study."
223919403|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Test Arm|Use of single vision, impact-resistant spectacle lenses may reduce the rate of progression of juvenile myopia
223919404|NCT06034327|DEVICE|Single vision, impact-resistant spectacle lenses; Control Arm|Single vision, impact-resistant spectacle lenses
223919405|NCT06825572|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
223919406|NCT06663631|DRUG|chlorpromazine and promethazine|C+P were diluted to 50 ml saline solution and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
223919407|NCT06663631|DRUG|Placebo group|50 ml saline solution was set as placebo and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
223919408|NCT06663631|PROCEDURE|endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
223919409|NCT06663631|DRUG|rt-PA|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
224089851|NCT01592994|BEHAVIORAL|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
224089852|NCT00004054|DRUG|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
224089853|NCT00004054|DRUG|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
224278715|NCT04791345|DRUG|Deflazacort|30 mg of deflazacort (1 pill) administered orally in a single dose.
224089854|NCT00004054|DRUG|etoposide|50 mg/m\^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
224089855|NCT00004054|DRUG|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
224278716|NCT04791345|DRUG|Dexamethasone|4 mg of dexamethasone (1 pill) administered orally in a single dose.
224278717|NCT04791345|DRUG|Dexamethasone|2 mg of dexamethasone (1/2 pill) administered orally every 12 hours during 5 days.
224278718|NCT02368262|OTHER|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
224278719|NCT02368262|PROCEDURE|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
224278720|NCT06240065|OTHER|Green bean puree|Green bean puree as a proxy for fiber-foods
224278721|NCT00083772|DRUG|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
224278722|NCT06394492|DRUG|SHR-A1921|SHR-A1921 dose 1
224278723|NCT06394492|DRUG|Doxorubicin|Doxorubicin dose 2
224278724|NCT06394492|DRUG|Paclitaxel|Paclitaxel dose 3
224278725|NCT06394492|DRUG|Topotecan|Topotecan dose 4
223530406|NCT04609982|DEVICE|ear plugs|giving half of the patients ear plugs
223530407|NCT06276647|BEHAVIORAL|HOME|The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
223530408|NCT03624725|PROCEDURE|modified BII+Braun|modified BII+Braun digestive tract reconstruction
224278726|NCT04800926|DEVICE|Xavier wheelchair controller|Controlling a wheelchair using the Xavier surface EMG system
224278727|NCT03417739|DRUG|BVD-523|ERK1 and ERK2 inhibitor
224089856|NCT00004054|DRUG|paclitaxel|135 mg/m\^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
224278728|NCT02884986|DRUG|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
224278729|NCT02884986|DRUG|Placebo|120mg of placebo
224278730|NCT03397667|OTHER|ABC ANSWERS|Primary Care plus ABC ANSWERS
224278731|NCT03397667|OTHER|Control|Primary Care as usual
224278732|NCT05301816|DEVICE|Spinal Cord Stimulator (SCS)|Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
224278733|NCT03926416|BIOLOGICAL|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
224278734|NCT03926416|BIOLOGICAL|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
223919410|NCT06663072|DRUG|Fulvestrant|"Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses."
223919411|NCT06663072|DRUG|177Lu-DOTATATE|"Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles."
223919412|NCT06666179|BIOLOGICAL|low dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
223919413|NCT06666179|BIOLOGICAL|adjuvanted low dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
223919414|NCT06666179|BIOLOGICAL|high dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
223919415|NCT06666179|BIOLOGICAL|adjuvanted high dose SCB-1019T|Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T)
224089857|NCT00004054|DRUG|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
224278735|NCT05469958|OTHER|Hypothermia prevention bundle|pre-warming of the patient for 10 minutes with forced air blankets before the surgery starts, which will be maintained during surgery and during the immediate postoperative period, the intravenous perfusions will be warmed up to 38 Celsius degree (ºC) and the environmental temperature will be controlled at 21 Celsius degree (ºC) during surgery
224278736|NCT05469958|OTHER|Conventional care|the patient will be attended with textile blankets on patient demand
224278737|NCT02134639|PROCEDURE|68Ga-DOTATOC PET-CT Imaging|
224278738|NCT04902963|DEVICE|PE tube|Gelatin mixed with antibiotic and steroid ear drop to create a rigid device that maintains a lumen, acting as an intermediate-duration bioabsorbable ear tube.
223919416|NCT06666179|OTHER|Placebo|0.9% NaCl saline placebo
223919417|NCT06825611|DEVICE|Momentum Application|A mobile application to scan and predict spinal curvature. The application monitors curvature and track changes over time.
224278739|NCT01055886|DRUG|nicotine patch|Nicotine patch, 7-21 mg.
224278740|NCT01055886|DRUG|placebo patch|placebo patch used from weeks 4-6
224278741|NCT06622486|DRUG|EGL-001|IV administration
224278742|NCT04325516|BEHAVIORAL|Daily activities|"Participants will perform four tasks in a randomized order:~* sit to stand~* dorsi flexion of the foot~* knee extension~* hip extension"
224278743|NCT00428155|DEVICE|closure device placement|
223530409|NCT04497714|DIAGNOSTIC_TEST|Ultrasonic image collection|Ultrasonic image collection,consist of three static images and one dynamic image
223530410|NCT02219152|DRUG|tranexamic acid|
223919418|NCT06826183|DEVICE|REVEAL Linq device|Implantable loop recorder
223919419|NCT06497764|DEVICE|Vibrational Anesthesia (VA) Device|The half of the patient's scalp randomized to receive VA during PRP treatment will receive VA via the Buzzy bee-striped personal. The device is powered by two AAA batteries and is indicated for use for pain reduction. It uses the Melzack and Wall's Gait Control theory, which states that activation of non-nociceptive fibers can interfere with signals from pain fibers to inhibit overall sensation of pain.
224089858|NCT00004054|RADIATION|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
224089859|NCT00004054|DRUG|warfarin|To keep international normalized ratio (INR) \> 1.5 and \< 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
224089860|NCT02547623|DRUG|Dexamethasone|depot intracameral
224089861|NCT02547623|DRUG|Prednisolone|Prednisolone eye drops 1%
224278744|NCT03430635|PROCEDURE|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
224278745|NCT03467737|OTHER|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
224278746|NCT03467737|OTHER|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
224278747|NCT03467737|OTHER|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
224278748|NCT03467737|OTHER|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
224278749|NCT03467737|OTHER|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
223919420|NCT06497764|PROCEDURE|PRP Treatment|PRP (a needle-related procedure) will be delivered per routine standard of care.
223919421|NCT03610906|PROCEDURE|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
223919422|NCT06842095|OTHER|Transcranial Alternating Current Stimulation (beta-tACS)|"The study intervention is transcranial alternating current stimulation (tACS).~The electrode montage will include one electrode positioned on the scalp over the left or right motor cortex (either C3 or C4 using the international 10-20 EEG system), depending on the location of the stroke, and a second electrode over posterior area (Pz). A low intensity of stimulation (max. 4 mA peak to peak amplitude) will be used for up to 30 minutes in total (delivered in short bouts of up to 5 seconds based on the timing of movement of the upper limb)."
223919423|NCT06842095|OTHER|Transcranial Alternating Current Stimulation (sham)|The comparator is sham stimulation. Stimulation is delivered for a very short duration or timed in such a way relative to movement to mimic the scalp sensations of the active stimulation without delivering stimulation that would be anticipated to impact relevant brain activity rhythms.
223919424|NCT06842277|BIOLOGICAL|Injectable albumin platelets rich fibrin|Using injectable albumin platelets rich fibrin which is minimally invasive non surgical technique with autogenous , slow degradable and rich in leukocytes and growth factors material .
223919425|NCT06841497|OTHER|Dolabi|herbal remedy for DM II
223919426|NCT06147336|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, fixated within the inter-atrial septum.
223919427|NCT06392867|DEVICE|intermittent theta-burst stimulation (iTBS)|"iTBS treatment will be performed as comprising 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train-interval of 8 seconds. Repeat trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20) which equals the standard number of pulses in a daily iTBS treatment session, as approved by the FDA. The stimulation site over the left DLPFC will be determined using the international 10-20 system for EEG electrodes corresponding to the F3 location. 20 daily treatment sessions will be performed from Mondays to Fridays for four weeks for all included patients.~Treatments will be performed at the brain stimulation laboratory at the Hong Kong Polytechnic University. Stimulation will be delivered using a MagPro X100 model (details about MagPro X100: magventure.com/en\_eur/products/magpro-x100/ ) and a Cool-B65 A/P Butterfly Coil is used in this study."
223919428|NCT05888532|DRUG|Copper-64 labeled Granzyme B (64Cu-GRIP B)|Given IV prior to imaging
223919429|NCT05888532|PROCEDURE|Positron Emission Tomography (PET)|Imaging procedure
224089862|NCT05877131|DRUG|Levobupivacaine|To evaluate the efficacy of low-dose levobupivacaine (0.125%) (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
224089863|NCT05877131|DRUG|Ropivacaine|To evaluate the efficacy of low-dose ropivacaine (0.2) in avoiding hemodynamic changes after performing regional analgesia in pregnant women in labor and preventing changes in fetal heart rate and cardiotocographic recording.
223919430|NCT06668116|DRUG|Ropivacaine 0,1%|"The study uses ropivacaine for nerve blocks, starting at 0.1% concentration and capped at 0.5% for safety. Concentration adjustments are made based on each participant's response 60 minutes post-injection:~* Increase by 0.025% if pain reduction is \<50%~* Increase by 0.025% if reduction is 50-75% without sensory/motor block~* Decrease by 0.025% if reduction is 50-75% with sensory/motor block~* Decrease by 0.025% if reduction is \>75%. Pain is assessed using a Numerical Rating Scale. The study employs Dixon's up-and-down method for five cycles to determine the optimal concentration for effective pain relief without significant numbness or weakness."
224089864|NCT01795651|PROCEDURE|identification of take-home message of lecture|
223919431|NCT06668116|OTHER|NaCl (placebo)|0.9 % NaCl solution (saline) injection
223919432|NCT06611358|OTHER|Kinesiology Taping and Exercise|Individuals meeting the inclusion criteria will receive kinesio taping applied to the temporomandibular joint by a physiotherapist every three days for two weeks. The kinesio tape will be applied along the origin-insertion line with zero tension. In addition to the kinesio taping, participants will follow a exercise program prescribed three days a week. This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol
224278750|NCT03467737|OTHER|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
224278751|NCT02399891|OTHER|Quality Assurance Implementation|
224278752|NCT02399891|OTHER|Standard of Care|
223530411|NCT02219152|DRUG|saline|
223717054|NCT02859168|BEHAVIORAL|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
223919433|NCT06611358|OTHER|Convansionel Exercise|This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol.
224089865|NCT05612919|OTHER|Red blood cell from umbilical cord blood|"Patients will receive a volume of 15-20 ml/kg of red blood cell from umbilical cord blood (UCB-RBC). The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient. The UCB-RBC bags will contain a minimum volume of 20 mL of RBC, with a haematocrit of about 60% and an acceptable residual leucocyte content of \<106/mm3.~Product validation is currently under development."
223919434|NCT06855758|DRUG|terlipressin|Terlipressin was given prior to the opening of the graft circulation (with the possibility of reperfusion hypotension) when the blood pressure is suboptimal and does not respond well to dobutamine or fluid volume resuscitation. 1 mg terlipressin + 100 ml of sodium chloride injections was given for intravenous infusion.
223919435|NCT06148181|DRUG|ABBV-141|Infusion; intravenous (IV)
223919436|NCT06148181|DRUG|Placebo for ABBV-141|Infusion; IV
223919437|NCT06148181|DRUG|ABBV-141|Injection; subcutaneous (SC)
223919438|NCT06148181|DRUG|Placebo for ABBV-141|Injection; SC
223919439|NCT06650475|PROCEDURE|Using low or standart pressure|Written consent will be obtained before the randomized study. Randomization will be done on the computer using a software program. Participants will be divided into two groups. Patients in Group S will undergo laparoscopy under standard pressures (12-16 mmHg) in laparoscopic surgery, while patients in Group L will undergo laparoscopy under low pressure (8-10 mm Hg).
223919440|NCT06862050|BEHAVIORAL|BREATHE Free Curriculum|Curriculum will teach practices: love, perspective, prudence, hope, humility, forgiveness, spirituality, self-control, teamworking, perseverance, gratitude, and joy.
223919441|NCT06863467|DRUG|Intravenous Gemini|Single ascending intravenous dose infused once over 10-15 minutes.
223919442|NCT06863467|DRUG|Intravenous placebo|Intravenous sugar solution infused in a single dose over 10-15 minutes.
223919443|NCT06864767|OTHER|Neuro-sensory Motor Developmental Assessment|The test used to assess children's development levels evaluates the child's development in six parameters: gross motor function, fine motor function, neurological status, infant movement patterns, postural development and sensory-motor function (tactile, proprioceptive, ocular and vestibular systems) on a scale of 1 to 5. High scores are interpreted as motor dysfunction.
223919444|NCT06864767|OTHER|Functional Oral Intake Scale|It is a scale consisting of a total of 7 levels and two sections, developed by Crary et al. to indicate the functional oral intake of patients with dysphagia. A higher score indicates a better nutritional level.
223919445|NCT06864767|OTHER|Behavioral Pediatrics Feeding Assessment Scale|The scale used to determine eating problems in children evaluates both the child's nutritional status and the parents' feelings about the child's nutritional status. It consists of 35 items in total and is scored from 1 to 5. High scores indicate problematic eating behaviors and habits.
223919446|NCT06864767|OTHER|Pediatric Quality of Life Inventory|The PedsQL assesses health-related quality of life in children ages 2 to 18 years with chronic illnesses from both the child's and parents' perspectives. It consists of 25 items and 3 categories (About My Child's Neuromuscular Disease, Communication, About Our Family Resources). The Neuromuscular Module was used to assess the quality of life of the children in our study and was answered by the parents only. The scale is scored from 0 to 4, with higher scores indicating better quality of life.
223919447|NCT06863207|DEVICE|Percutaneous electrical nerve field stimulation|Percutaneously nerve stimulator applied to the external auricle weekly for several consecutive weeks of therapy
223919448|NCT06863207|BEHAVIORAL|Hypnotherapy|Gut-directed hypnotherapy delivered via audio recordings
223919449|NCT06863493|DRUG|SFA002|SFA002 760mg
223919450|NCT06863493|DRUG|Otezla|Oral Otezla 30mg
223919451|NCT06863493|DRUG|Placebo|Placebo will be matched to whichever drug is assigned when randomized
223919452|NCT06864611|BEHAVIORAL|Pre-Game Safety Huddles|Before every regular season game, participating teams in league randomized to the Pre-Game Safety Huddle condition will hold brief Pre-Game Safety Huddles. Pre-Game Safety Huddles have three core components: (1) Gather (Athletes, coaches, officials, and other stakeholders come together before the start of the game); (2) Share (Opinion leaders (coaches, referees) affirm the importance of seeking care for suspected concussion, and (3) Repeat (Process is repeated before every game)
223919453|NCT06864247|OTHER|No Intervention: Observational Cohort|No intervention
223919454|NCT06863454|DIAGNOSTIC_TEST|Trichoscopy|Trichoscopy will be done on patients with PV disease activity and remission
223919455|NCT06672679|BEHAVIORAL|Juntos|6 week family-based intervention
223919456|NCT06672679|BEHAVIORAL|Resource guide|Active control arm will receive a resource guide
223919457|NCT06859931|DRUG|TQB3702 Tablets|TQB3702 is a selective kinase inhibitor.
223717055|NCT02859168|DEVICE|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
223919458|NCT06859931|DRUG|TQB3702 Tablets+TQB3702 Placebo|TQB3702 is a selective kinase inhibitor； A placebo is a simulated drug whose physical properties, such as appearance, size, color, dosage form, weight, taste, and odor are substantially the same as the test drug, but cannot contain the active ingredients of the test drug.
223919459|NCT06859931|DRUG|TQB3702 Placebo|TQB3702 Placebo without drug substance.
223717056|NCT01015209|DEVICE|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
223919460|NCT06857097|PROCEDURE|single anastomosis sleeve jejunal bypass|sleeve was created starting devascularization of greater gastric curve 6 cm proximal to pylorus. Devascularization was done via either a harmonic scalpel or a ligasure device. Dissection was continued proximally till reaching the left diaphragmatic crus. Afterwards that the stomach was resected along the greater curvature via an endostapler over a 36-Fr bougie. After creating the sleeve, two meters of the small bowel were counted starting from the ligament of Treitz, and an antecolic isoperistaltic gastrojejunostomy (4-cm wide) was created with the antrum via linear stapler, and the anterior wall defect was closed by sutures.
223919461|NCT06857097|PROCEDURE|One anastomosis gastric bypass|dissection started just distal to the crows' foot till reaching the lesser sac. A long narrow gastric pouch was created by the endostapler. After that, a longitudinal gastrojejunostomy (4-cm wide) was created at 200 cm distal to the Treitz ligament as the SASJ group.
223919462|NCT06858969|DRUG|Treatment group|Chidamide+XELOX + Bevacizumab+PD-1
223717057|NCT06468566|DIAGNOSTIC_TEST|Ultrasound light scattering imaging equipment|Radiologists use ultrasound light scattering imaging to evaluate the benign and malignant nature of breast nodules
223717058|NCT06059794|OTHER|PUQE score|The Pregnancy-Unique Quantification of Emesis (PUQE) is a scoring system to quantify the severity of nausea and vomiting of pregnancy (NVP). Based on quantification of the 3 physical symptoms of NVP (nausea, vomiting and retching)
223919463|NCT06858969|DRUG|Standard-of-care control group|XELOX + Bevacizumab+PD-1
223919464|NCT06859814|PROCEDURE|urinary catheterization|urine samples for culture and sensitivity will be collected in patients having urinary tract infection and we will use sterile container 50cc for urine sampling culture on blood or macconkey medium for detection type of organism .
223919465|NCT06856096|DIAGNOSTIC_TEST|PET/MRI|PET/MR imaging using an integrated TOF PET/MR scanner (Signa, GE Healthcare, WI, USA)
223919466|NCT06854354|BEHAVIORAL|HPV Prevention Vaccine|The educational intervention was implemented through a private Facebook group, facilitating access to HPV vaccine information. A user guide was provided and profiles were verified for authenticity using a non-duplicity algorithm. Prior to access, mothers completed questionnaires to assess their knowledge, beliefs and acceptance. The intervention lasted four weeks and included four modules with videos, handouts and infographics. The first session provided information on HPV, its transmission and prevention. The second highlighted the benefits of the vaccine and debunked myths. The third showed testimonials from mothers who had their daughters vaccinated. The last session was a videoconference with group dynamics to resolve doubts. The sessions were held weekly and access and duration were monitored within the group. After finishing, the group was temporarily closed to avoid biases in the second measurement, allowing free access to the contents.
223919467|NCT06854354|OTHER|Placebo|The CG did not have an educational intervention, nor the use of any placebo, the test instruments were applied and a month after this, they were invited to a virtual platform where they were asked to answer again the measurement instruments, once obtained the filling of the questionnaires they were invited and provided the user guide that allowed them to participate and learn about the Facebook group, as well as view the educational materials, to obtain the same benefits as the GE
223919468|NCT06859151|OTHER|Reproductive tract microbiota|Reproductive tract microbiota
223919469|NCT02926690|DRUG|OTS167PO|Single arm, no competitor
223919470|NCT06860425|OTHER|RestoreMe|Comprehensive mobile device application
223919471|NCT06671041|DRUG|Preservative Free eye drop|Participants were required to use a lubricating eye drop
223919472|NCT06671535|DEVICE|Polymethylmethacrylate membrane|A polymethylmethacrylate hollow fiber membrane (PMMA membrane) has unique properties including the uniform structure and the adsorption property.
223919473|NCT06671535|DEVICE|polysulfone membranes|Dialyzers containing polysulfone membranes are widely used for modern dialysis therapies as they allow efficient removal of a broad spectrum of uremic toxins.
223919474|NCT06860711|DRUG|NSAIDs|IV formulation: ketorolac 0.5mg/kg/dose, 15mg maximum, no more than 8 doses total PO formulation: ibuprofen suspension 10mg/kg/dose, 400mg maximum Total duration (IV + PO) will not exceed 5 days.
224089866|NCT05612919|OTHER|Red blood cell from adult donor|"Patients will receive a volume of 15-20 ml/kg of red blood cell from adult donor according to standard guidelines.~The transfusion will be prescribed and administered with all the routine safety measures carried out by the nurses to ensure compatibility between the administered RBC and the patient.~Blood samples are irradiated according to standard practise."
224089867|NCT05782829|DIETARY_SUPPLEMENT|L-tyrosine supplementation|L-Tyrosine supplementation before surgery for inguinal hernia under general anaesthesia
224089868|NCT05782829|DIETARY_SUPPLEMENT|Placebo supplementation|Placebo supplementation before surgery for inguinal hernia under general anaesthesia
224089869|NCT04336163|DEVICE|Optical Coherence Tomography|Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
223717059|NCT06059794|OTHER|GAD-7|"The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include not at all, several days, more than half the days and nearly every day"
223919475|NCT06860711|DRUG|Placebo|IV or PO medication, compounded to have similar look, consistency and taste to the corresponding medications
223919476|NCT06861361|DEVICE|Myval balloon-expandable THV Series|Patients receive Myval balloon-expandable THV Series (TAVR)
223919477|NCT06861361|DEVICE|Surgical bioprosthetic valve|Patients receive any surgical bioprosthetic valve commercially available at the clinical investigation site (SAVR)
223919478|NCT01993810|DRUG|Carboplatin|Given IV
223919479|NCT01993810|DRUG|Cisplatin|Given IV
223919480|NCT01993810|BIOLOGICAL|Durvalumab|Given IV
223919481|NCT01993810|DRUG|Etoposide|Given IV
223919482|NCT01993810|DRUG|Paclitaxel|Given IV
223919483|NCT01993810|DRUG|Pemetrexed Disodium|Given IV
223919484|NCT01993810|RADIATION|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
223919485|NCT01993810|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
223919486|NCT01993810|OTHER|Quality-of-Life Assessment|Ancillary studies
223919487|NCT01993810|OTHER|Questionnaire Administration|Ancillary studies
223919488|NCT01768013|DRUG|LEO 90105|Once daily for four weeks
223919489|NCT06666725|OTHER|Menu label|Participants will select food items from three restaurant menus, displayed with labels as specified by their assigned group
223919490|NCT06337942|PROCEDURE|Bladder Transplantation|A bladder transplantation will be performed. The bladder will be recovered from a brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the recipient's ureter(s) to the new bladder.
223919491|NCT06337942|PROCEDURE|Combined Kidney and Bladder Transplantation|For patients who qualify for a combined kidney and bladder transplant, both a kidney and a bladder transplant will be performed. Both kidney and bladder allografts will be recovered from the same brain-dead human donor. The connections that will be made will include connections between donor and recipient blood vessels, the bladder transplant and the recipient urethra, and the kidney transplant ureter to the transplanted bladder. If the recipient has continued urine output, new connections between the native ureters and the transplanted bladder will also be made.
224099324|NCT00296322|DRUG|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
224099325|NCT03613428|DRUG|Ruxolitinib|Dose escalation up to 80 mg administered orally
223919492|NCT06827353|DRUG|maintenance therapy with bevacizumab|Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received bevacizumab after chemotherapy.
223919493|NCT06827353|DRUG|maintenance therapy with niraparib|Maintenance therapy after platine-based chemotherapy in non-mutated advanced ovarian cancer is unclear. Arm of patients that received niraparib after chemotherapy.
223919494|NCT06119074|OTHER|Gifted Savings|Gifted Savings assets will be in the form of cash, Bitcoin, and/or stock. Participants will receive identical asset portfolios. The asset mix will be determined by Gifted Savings. Participants will not have any control over the assets they receive, nor the proportion of each in their account. After registration on the Gifted Savings website, participants can immediately withdraw $100 USD if they choose. Then, for each of the first two years, participants may withdraw up to $500 USD for an emergency (self-attested) if the value of the account is 50% or more of its value 30 days prior and the account has sufficient funds to fulfill the request. Two years post-enrollment, participants may withdraw the entire value of their GS account or continue holding the assets in their GS account (in perpetuity or until the GS non-profit ceases to exist). GS funds are unconditional; there are no restrictions or limitations on how the money can be spent.
223919495|NCT06674811|OTHER|Wearing Smartwatch|Patients and their caregivers will be asked to start wearing a smartwatch prior to surgery and continuing to wear it for one year following surgery at all times except when bathing or swimming, eating, undergoing a procedure, or if refusing to wear them. The smartwatches collect motor activity by minutes spent being sedentary, active, or highly active, heart rate, and sleep duration and stages. Data from the smartwatches syncs with Garmin connect using Fitabase to allow the study team to review the data.
223919496|NCT06674811|OTHER|Patient Report Outcomes|To obtain patient-reported outcomes (PROs), questionnaires will be administered at time of enrollment, in the two weeks prior to surgery if applicable, and at 1, 2, 4, 8, 12, 16, 20, 24, 34, 44, and 54 weeks postoperatively. Questionnaires can be completed electronically, over the telephone or in person. The PedsQL Cancer Module and Patient Health Questionnaire depression scale (PHQ-9) will be utilized for questionnaires.
223919497|NCT06674811|OTHER|Blood Draw|When patients are having blood drawn as part of their regular care, extra blood may be drawn for this study. Participants may opt out of this. Blood draws will occur preoperatively and at intervals postoperatively for proteomic, metabolomic, and exposomic testing.
223919498|NCT06674811|OTHER|Clinical Data Review|Clinical data will be collected and stored in a database by study staff. This includes patient demographics, diagnosis characteristics including staging and risk group, treatment characteristics, and outcomes including length of stay following surgical intervention, readmissions, surgical complications including surgical site infection, time off therapy/time to resumption of chemotherapy.
223919499|NCT06674018|DIETARY_SUPPLEMENT|Indole-3-propionic acid|A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
223919500|NCT06674018|DIETARY_SUPPLEMENT|Placebo|Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.
223919501|NCT05948657|DIAGNOSTIC_TEST|PSMA-PET CT|Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
223919502|NCT05717725|PROCEDURE|Pulsed-field ablation|Patients will receive catheter ablation, i.e. pulmonary vein isolation by means of pulsed-field energy
223919503|NCT05717725|PROCEDURE|Sham procedure|Patients will receive sham procedure, no ablation.
223919504|NCT06363045|DEVICE|NIDEK TONOREF III|The auto ref/kerato/tono/pachymeter TONOREF III is a medical device which measures objective refractive errors, corneal curvature radius, intraocular pressure and corneal thickness of the patient's eye.
223919505|NCT06363045|DEVICE|Haag-Streit, PERKINS HAND-HELD APPLANATION TONOMETER|Haag-Streit Goldmann Manual Tonometer measures intraocular pressure to aid in the screening and diagnosis of glaucoma
223919506|NCT06363045|DEVICE|NIDEK CEM-530|Nidek CEM-530 is a non-contact ophthalmic microscope, optical pachymeter, and camera used for examination of the corneal endothelium and for measurement of the thickness of the cornea.
223919507|NCT06859034|DRUG|injection of dextrose 10% in retrodiscal tissues|group 1 will recieve 10% dextrose in retrodiscal tissues
223919508|NCT06859034|DRUG|injection of dextrose 25% in retrodiscal tissues|group 2 will recieve 25% dextrose
223919509|NCT06864520|DIETARY_SUPPLEMENT|GAMMA-AMINOBUTYRIC ACID - GABA|Food supplement based on GABA and Melissa extract
223919510|NCT06864520|OTHER|Placebo|Placebo based on microcrystalline cellulose, rice bran, bitter cocoa powder
223919511|NCT06668909|DEVICE|WaveLight® EX500|Phorcidies Planned Contoura LASIK
223919512|NCT06677242|DIAGNOSTIC_TEST|Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing|These are additional tests, added to the observational study to collect information on tumor characteristics and to pursue early detection of this diagnosis.
223919513|NCT04661137|DRUG|Selinexor 60 MG|Selinexor 60 mg PO on days 1, 8 and 15
223919514|NCT04661137|DRUG|Selinexor 80 MG|Selinexor 80 mg PO on days 1, 8 and 15
223919515|NCT04661137|DRUG|Selinexor 100 MG|Selinexor 100 mg PO on days 1, 8, 15 and 22
223919516|NCT04661137|DRUG|Carfilzomib|56 mg/m2 IV on days 1, 8 and 15
223919517|NCT04661137|DRUG|Pomalidomide|4 mg PO daily for 21 days
223919518|NCT04661137|DRUG|Daratumumab|16 mg/kg IV days 1, 8, 15 and 22 for cycles 1-2; days 1 and 15 for cycles 3-6; day 1 for cycle 7 and on
223919519|NCT04661137|DRUG|Dexamethasone|20 mg if ≥ 75 years old and 40 mg if \< 75 years old on days 1, 8, 15 and 22
223919520|NCT04414215|BEHAVIORAL|Emotional working memory training|Participants will complete an emotional working memory n-back training program that progressively increases difficulty and has been shown to enhance prefrontal activity in a non-psychiatric sample
223919521|NCT04414215|BEHAVIORAL|Placebo working memory training|Working memory training that does not involve emotional stimuli using an N-back training program
224099326|NCT03613428|DRUG|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
224099327|NCT03613428|DRUG|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
224099328|NCT05078814|OTHER|Observational research|Observational research
224099329|NCT00838487|OTHER|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
223919522|NCT06672588|DEVICE|Magnetic Seizure Therapy (MST)|MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
223717060|NCT03685968|DEVICE|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
223717061|NCT00799422|DEVICE|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
223919523|NCT06672588|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q or MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
223919524|NCT05256641|DRUG|Acalabrutinib|Given PO
223919525|NCT05274919|DEVICE|Philips Achieva 7T MRI|Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
223717062|NCT00799422|DEVICE|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
223919526|NCT05274919|DEVICE|X-ray (optional)|Optional X-ray scan to assess the safety for undergoing an MR examination.
223919527|NCT05274919|COMBINATION_PRODUCT|Additional contrast injection|Contrast agent administration for the additional 7T scan (optional).
223919528|NCT05274919|OTHER|Question list|Questionnaire for contra-indications for an MR examination.
223919529|NCT06586164|BEHAVIORAL|Targeted Cognitive Training|TCT is a computer-based cognitive training program in which participants train on progressively more difficult auditory processing exercises in order to improve speed, accuracy and fidelity of auditory information processing in order to generate gains in cognition and functioning.
223919530|NCT06590480|BIOLOGICAL|RP1|Genetically modified Herpes Simplex Type 1 Virus
223919531|NCT06590480|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
224099330|NCT00838487|OTHER|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
224099331|NCT02625038|DEVICE|EUDAMED CIV-14-03-011940|
224099332|NCT04698928|DEVICE|Theta burst stimulation|Theta burst stimulation over SMA. 3 section per day, for 5 days, total 15 sections.
224099333|NCT04629729|DRUG|FT819|Experimental Interventional Therapy
224099334|NCT04629729|DRUG|Cyclophosphamide|Lympho-conditioning agent
224099335|NCT04629729|DRUG|Fludarabine|Lympho-conditioning agent
224099336|NCT04629729|DRUG|IL-2|Biologic response modifier
224099337|NCT04629729|DRUG|Bendamustine|Lympho-conditioning agent
224099338|NCT04273724|OTHER|Targeted Interventions for Impairments Identified During Geriatric Assessment|Participants will be referred for specific evidence-based interventions based on impairments identified during a baseline comprehensive geriatric assessment.
224099339|NCT06075823|DEVICE|TEER|transcatheter edge-to-edge mitral valve repair for significant mitral regurgitation
224099340|NCT06075823|OTHER|Optimal Medical Therapy|optimal heart failure management of ATTR-CM
224099341|NCT03591887|BIOLOGICAL|ABY-035|ABY-035 solution for injection
224099342|NCT03591887|BIOLOGICAL|Placebo|Placebo to ABY-035 solution for injection
224099343|NCT01787071|OTHER|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
224099344|NCT04036825|DIETARY_SUPPLEMENT|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
224099345|NCT04036825|DIETARY_SUPPLEMENT|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
224099346|NCT01667848|DEVICE|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
224099347|NCT01667848|DEVICE|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
224099348|NCT03547050|OTHER|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
224099349|NCT03547050|OTHER|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
224099350|NCT00030784|DRUG|ifosfamide|
224099351|NCT00030784|DRUG|pegylated liposomal doxorubicin hydrochloride|
224099352|NCT01642355|BEHAVIORAL|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
224099353|NCT01642355|BEHAVIORAL|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
224099354|NCT03252782|DEVICE|Herbst Appliance|Acrylic Splint Herbst Appliance
224099355|NCT03252782|DEVICE|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
224099356|NCT03571464|DEVICE|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
224099357|NCT04460430|DRUG|Neratinib + endocrine therapy|Neratinib plus Fulvestrant, Exemestane or Tamoxifen
223919532|NCT06020027|BEHAVIORAL|Water is K'é|Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
223919533|NCT06866769|DIAGNOSTIC_TEST|CTA|The levels of biomarkers are determined before (within 30 days prior to the procedure) and after the implantation of the stent (24-48 hours, 1 month, 3 months, 6 months, and at 1 year), along with the performance of a contrast-enhanced ultrasound. Additionally, a follow-up CT angiography is performed to validate the concordance, that is, to assess if there are changes in the biomarker values determined one month after the implantation of the stent compared to the baseline values that may suggest the presence of complications (endoleaks, infection, thrombosis, etc.).
223919534|NCT06615115|OTHER|Exercise|All participants will perform a total body stretching exercise for 10 minutes, followed by 10 minutes of obstacle course navigation, 10 minutes of balance training (including tandem walking, balance board exercises, single-leg balance, and two-legged reaching exercises), and will conclude with 10 minutes of strength training exercises.
223717063|NCT00799422|DEVICE|Clear Care|Commercially marketed contact lens solution for contact lens care
223717064|NCT00799422|DEVICE|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
223919535|NCT05256472|DRUG|AK104|anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
223919536|NCT05256472|DRUG|axitinib|an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally
223919537|NCT06676371|PROCEDURE|Conventional hemiarch replacement|Conventional open hemiarch replacement
223919538|NCT06676371|PROCEDURE|E-vita® Open Neo; Artivion|E-vita® Open Neo is a hybrid stent graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk Technique.
223919539|NCT06676371|PROCEDURE|Thoraflex Hybrid; Terumo|The Thoraflex Hybrid is a device system designed to repair a weakened and bulging section (aneurysm) and/or a tear in the lining (dissection) of the aorta behind the heart (aortic arch). The system includes a polyester graft section that reinforces a weakened section of the blood vessel, a connected stented section (nitinol wire frame on polyester graft material) that holds the artery open, and a delivery catheter that is used to place the device. The polyester graft and stented sections are coated with a protein substance taken from animal body parts (gelatin) to seal the implant and prevent blood from leaking out.
223919540|NCT06138184|BEHAVIORAL|Anticoagulation Educational Materials|This includes new web-based patient educational materials that have been developed prior to the start of the study
223919541|NCT06138184|BEHAVIORAL|Control Group: Standard of Care|This will be the current practice for patient education
223940651|NCT06593717|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
223940652|NCT06593717|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning.
223940653|NCT06602453|DRUG|GDC-8264|GDC-8264 will be administered as per pre-defined regimen.
224099358|NCT00356915|DRUG|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
224099359|NCT00356915|DRUG|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
224099360|NCT00356915|DRUG|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
223717065|NCT04614220|BEHAVIORAL|Presence of Family member|The correlation between presence of the Family member and the consent for regional anaesthesia for Caesarean Section
223717066|NCT05160103|OTHER|Cosmetic Formulations|Topical emulsions containing anti-aging ingredients
223940654|NCT06602453|DRUG|Placebo|Placebo will be administered as per pre-defined regimen.
223940655|NCT06811454|BEHAVIORAL|MINDSET|Participants randomized to MINDSET will receive a text message at their preferred time each day for 8 weeks containing a link to the 15-minute audio content. At the end of each week (on day 7), participants will receive a second link to the weekly survey in the text. Participants will be able to play the audio content on their device by clicking the first link and access the weekly survey by clicking the second.
223940656|NCT06811454|BEHAVIORAL|Enhanced Usual Care (EUC)|Participants will receive a 1-page brochure summarizing publicly available information on depression self-care strategies via text each week for 8 weeks on the same day they receive the text message containing a link to the weekly survey (day 7). This information will come from the Facing Forward: Life After Cancer Treatment booklet from the National Cancer Institute.38 Weekly topics will include: 1) Reducing stress; 2) Coping with stress; 3) Coping with depression; 4) Feeling angry; 5) Feeling alone; 6) Finding meaning after treatment; 7) Social relationships; and 8) Seeking support. These materials do not include any content on mindfulness or cognitive therapy.
223940657|NCT06098651|DRUG|DCR-STAT3|DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion.
223940658|NCT06660433|DEVICE|Point-of-care respiratory test platform|A point-of-care respiratory multiplex testing platform situated within a long-term care facility to provide rapid test results
223940659|NCT06660433|OTHER|Existing respiratory virus testing platform|Currently used respiratory virus testing platforms
223940660|NCT05867602|DRUG|Albumin|intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
223940661|NCT03581136|DEVICE|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
223717067|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
223919542|NCT03856528|OTHER|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
223919543|NCT06805188|OTHER|Acupuncture|"The intervention was performed by two licensed acupuncturists with at least 10 years of clinical experience who received two weeks of training in standardized intervention methods prior to the trial. Acupoints location refers to the WHO Standard Acupuncture Point Locations in the Western Pacific Region (WHO Standard)〔41〕.The acupuncture group will receive the following acupoints (Figure 3, Table 2): the affected side of Chize(LU5), Quchi (LI11), Dubi (ST35), Fengshi (GB31), and Xiyangguan (GB33).~Needling was performed with 0.30mm x 40mm disposable Huatuo brand sterile acupuncture needles.After the needles were inserted, needle manipulation was performed at all acupuncture points to achieve the sensations of soreness, numbness, distension, and heaviness.Each acupoint was manipulated for about 30 seconds, and the acupuncture treatment was performed for one 30-minute session."
223919544|NCT06805188|OTHER|Sham acupuncture|The device's sham needling operation mimics real needling through appearance and tactile sensation, making it difficult for patients to distinguish, meeting the requirement of blinding and effectively controlling the patients' cognitive bias towards the type of intervention. Patients in the sham acupuncture group received this sham acupuncture intervention, which was designed to ensure that only the actual biological effects of acupuncture differed between the experimental group and the control group, and to exclude the psychological implication effects caused by the patients' expectation effects or the operation itself, so as to enhance the scientific validity and reliability of the research results.
223919545|NCT05428852|OTHER|Laboratory Biomarker Analysis|Correlative Studies
223919546|NCT05428852|OTHER|Neurocognitive Assessment|NRG-CC
223919547|NCT05428852|OTHER|Questionnaire Administration|Ancillary studies
223919548|NCT05428852|DEVICE|Fitbit|Fitbit Activity Tracking
223919549|NCT05428852|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo ketogenic diet
223919550|NCT04393350|DRUG|Lenvatinib|Given PO
223919551|NCT04393350|DRUG|Lenvatinib Mesylate|Given PO
223919552|NCT04393350|BIOLOGICAL|Pembrolizumab|Given IV
223919553|NCT04393350|OTHER|Quality-of-Life Assessment|Ancillary studies
223919554|NCT04393350|OTHER|Questionnaire Administration|Ancillary studies
223919555|NCT06174428|DEVICE|Oral/Throat cancer test|The Oral/Throat cancer test is intended for the qualitative detection of molecular features (human genes, microbial species and functions) associated with Oral Squamous Cell Carcinoma (OSCC) or OroPharyngeal Squamous Cell Carcinoma (OPSCC) in saliva samples from adults with a suspicion of cancer. A positive result from CDOT may indicate the presence of OSCC or OPSCC. The device is intended as a diagnostic aid for clinicians when assessing patients with suspected OSCC or OPSCC who may benefit from follow-up diagnosis and treatment. The device is not intended for a definitive diagnosis.
223919556|NCT06770335|BEHAVIORAL|THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Full intervention|A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm include the full intervention.
223919557|NCT06770335|BEHAVIORAL|THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Cognitive rehabilitation only|A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm includes the cognitive rehabilitation only.
223919558|NCT06014580|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
224099361|NCT00509106|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
224099362|NCT00509106|DRUG|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
224099363|NCT00509106|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
223717068|NCT00530946|DRUG|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
223717069|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
223717070|NCT00530946|DRUG|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
223919559|NCT01315106|DEVICE|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
223919560|NCT05454514|DEVICE|HiDO medication adherence platform|The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.
223919561|NCT05454514|DEVICE|Automated Medication Platform with Video Observation|There is no drug intervention. The device elicits increases adherence of medications.
223919562|NCT05454514|OTHER|Time on Task|"Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score."
223919563|NCT04825288|BIOLOGICAL|XB2001 or Placebo|XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
223919564|NCT06870357|DRUG|propofol|Fifteen minutes after the subarachnoid block, propofol was pumped in at a rate of 20 mg/kg/h with a micro pump, and the pumping rate was reduced to 10 mg/kg/h after 1 min. The infusion was stopped when the consciousness disappeared, and the time of the disappearance of consciousness was observed (time of the disappearance of eyelash reflex).
223919565|NCT06869382|DRUG|Foster BDP/Formoterol|Foster is a combination therapy containing beclometasone dipropionate (an inhaled corticosteroid, or ICS) and formoterol fumarate (a long-acting beta-agonist, or LABA), which is used for managing asthma and chronic obstructive pulmonary disease (COPD).
223919566|NCT06869382|DRUG|Omalizimab|Omalizumab is a monoclonal antibody that specifically targets immunoglobulin E (IgE), a key mediator in allergic asthma. By binding to free IgE in the bloodstream, omalizumab prevents it from attaching to FcεRI receptors on mast cells and basophils, inhibiting the allergic inflammatory cascade that contributes to asthma exacerbations and bronchoconstriction. This intervention is particularly useful in patients with severe allergic asthma, who have high levels of IgE and have not responded well to conventional therapies such as inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).
223919567|NCT06868550|BEHAVIORAL|Comprehensive Oral Health Promotion Program|The principal investigator will carry out all treatment procedures, and the patients will be randomly assigned to any of them.
223919568|NCT06870318|OTHER|No intervention; Observational study|OptiMoM-NForte is meta-analysis study (observational secondary use of data), the investigators will analyze data from the OptiMoM and NForte trials. No interventions form part of this study.
223919569|NCT05323487|DRUG|Bumetanide Injection|Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
223919570|NCT06870305|OTHER|MBTP : Mindflulness based training for psychosis|The group-based mindfulness programme is called MBTP (Mindfulness based training for psychosis). The MBTP programme consists of 5 sessions over a period of one month (2 sessions in the first week, then one session a week). Each session lasts approximately 1h30 and is carried out in a group of 5 participants. The sessions cover informal and formal mindfulness tasks, elements of psycho-education on emotions, meditation exercises on emotions, and thought defusion and acceptance tasks. Participants are encouraged to meditate at home between sessions.
223919571|NCT06866457|OTHER|Audio hypnosis|"Audio hypnosis via a digital recording (Ellis Traumgeschichte) accessible via QR code"
223919572|NCT06866665|DRUG|Anticoagulation Monotherapy|Participants in the anticoagulation monotherapy group will receive apixaban 5 mg twice daily during the study period.
223919573|NCT06866665|DRUG|Combination therapy|Participants in the combination therapy group will receive clopiogrel 75 mg daily and apixaban 5 mg twice daily during the study period.
223919574|NCT06866795|DRUG|GT-220F capsule|GT-220F capsule for oral administration
223919575|NCT06869525|BEHAVIORAL|Acupuncture|Dingchuan, Shanzhong, Tiantu, Feishu, Kongji, after obtaining qi, connect the electric needle (continuous wave, The frequency was 2Hz, the current intensity was 1\~5mA, and the current intensity was gradually increased according to patient tolerance), and the treatment was 30min.
223919576|NCT06869525|BEHAVIORAL|Sham Acupuncture|Dingchuan, Shanzhong, Tiantu, Feishu, hole the most points open 5\~10mm, shallow piercing through the skin, connected with the electric needle but no electricity, treatment 30min.
223919577|NCT06870266|DRUG|Nafarelin nasal spray|NAFARLIN 200 MCG X2 DAY
223919578|NCT06870266|DRUG|Utrogestan®|UTROGESTAN 200 MG X2 DAY
223919579|NCT06869239|DRUG|Etoposide + cisplatin/carboplatin|Four courses of intravenous cisplatin (75 mg/m² of body surface area on day 1 or divided into 3 days of each cycle) or carboplatin (area under the curve of 5 mg/mL per min on day 1 of each cycle) and intravenous etoposide (100 mg/m² of body surface area on days 1-3) every 3 weeks
223919580|NCT06869239|RADIATION|Thoracic radiotherapy|High-dose, accelerated, hyperfractionated, twice-daily thoracic radiotherapy (54 Gy in 30 fractions) concurrent with chemotherapy initiated at the beginning of cycles 1-3
223919581|NCT06869239|RADIATION|Prophylactic cranial irradiation (PCI)|PCI (25Gy in 10 fractions, once daily over two weeks) 3-4 weeks post-chemoradiotherapy for patients achieving PR or CR
223919582|NCT06869239|DRUG|PD-L1 inhibitor|Maintenance therapy with PD-L1 inhibitors (Durvalumab 1500 mg Q4W or Atezolizumab 1200 mg Q3W or Sugemalimab 1200 mg Q3W or Adebrelimab 1200 mg Q3W) post-PCI until disease progression, death, or intolerable toxicity, up to 2 years
223919583|NCT06870669|BEHAVIORAL|progressive relaxation exercise|We will use progressive relaxation exercises to investigate the potential effects on first year nursing students' whose in the preclinical period of education.
223919584|NCT06870110|DEVICE|Bias Modification Biofeedback|The device uses EEG-based bias modification biofeedback intended to reduce attention to drug-related cues and increase attention to non-drug pleasant scenes. Specifically, the device measures perceptual biases from Event-Related Potential biomarkers related to Substance Use Disorders.
223919585|NCT06869863|BIOLOGICAL|Medicinal product MediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparation of solution for injection in patients with severe spermatogenesis disorders|Human mesenchymal stromal cell secretion1 containing vascular endothelial growth factor (VEGF)2 ≥ 5,0 нг
223919586|NCT06869863|OTHER|Clostilbegit (clomiphene) 50 mg 1 tablet x 1 p a day - 3 months, Triovit - 1 tablet x 1 p a day - 3 months, Folic acid - 1 tablet x 1 p a day - 3 months.|Combination treatment recommended by standards
223919587|NCT05708105|DIAGNOSTIC_TEST|Cerebral near-infrared spectroscopy|Continuous cerebral NIRS will be monitored using the INVOS 5100C or 7100 Cerebral Oximeter (Medtronic, Minneapolis, MN, USA), initiated as early as feasible after birth or postnatal consent and continued until 48 hours of age. Neonatal sensors applied over a light-permeable barrier will be placed on the right or left side of forehead, like the methods used in our pilot study and in line with our clinical protocol. The continuous parameters recorded for this study using cerebral NIRS will include CrSO2 and COIx.
223919588|NCT05708105|DIAGNOSTIC_TEST|Functional echocardiography|"The first echocardiogram will be completed as soon as possible after consent and \< 24 hours of age in all cases. This will be to capture markers of early low systemic blood flow and document patent ductus arteriosus and its size, as known to be associated with IVH.~The second scan will be performed at the end of the monitoring period, between 48-60 hours of age. This scan is planned to record the change in LVO from baseline (re-perfusion), which has been postulated to relate to development of IVH."
223919589|NCT05708105|DIAGNOSTIC_TEST|Head Ultrasound|HUS will be paired with both echocardiograms. The first HUS will document baseline IVH status (paired with the first ECHO). The final HUS will be performed between days 4-7 of age, as per the standard clinical practice by site radiology service and will be used to confirm the final IVH status.
223919590|NCT06681545|OTHER|one to one interviews and or focus groups|one to one interviews and or focus groups
223919591|NCT06151730|OTHER|Non-Interventional Study|Non-interventional study
223919592|NCT06803498|PROCEDURE|Receipt of significant resuscitation intervention at birth|Receipt of CPAP, PPV, intubation, or CPR at birth in a hospital delivery room
223919593|NCT06886516|DRUG|Apixaban|A factor Xa inhibitor, 2.5 and 5 mg tablets, by mouth per protocol.
223919594|NCT06786312|DRUG|Apatinib|250mg, P.O, qd, 21 days per cycle;
223919595|NCT06786312|DRUG|Adebrelimab|20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;
223919596|NCT06786312|DRUG|Etoposide Injection|100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.
223919597|NCT06786312|DRUG|Carboplatin Injection|Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.
223919598|NCT06886217|BEHAVIORAL|Collaborative Life Skills dHealth tool (CLS-D)|The purpose of this adapted intervention is to integrate digital health (dHealth) technology into the Collaborative Life Skills Program (CLS), an established, school-based behavioral intervention for students with ADHD, to make the program accessible to schools that serve students from low-socioeconomic (SES) backgrounds. Existing evidence-based interventions for students with ADHD are often inaccessible in schools with limited resources to support implementation. By adapting CLS to include a dHealth tool-CLS-D-researchers aim to improve the feasibility of intervention implementation in schools with limited resources and mitigate disparities in access to evidence-based interventions among students with ADHD who are from low-SES backgrounds.
223919599|NCT06361225|DIAGNOSTIC_TEST|evaluation with RUSH protocol|Daily evaluation of the patient via ultrasound using the RUSH protocol
223919600|NCT06857773|DRUG|Intra arterial infusion Floxuridine (FUDR) combined with systemic therapy|Floxuridine is administered via the hepatic arterial infusion pump directly to the hepatic artery with a continous flowrate for a period of 2 weeks. Intra arterial infusion of FUDR is combined with systemic therapy (FOLFOX/FOLFIRI) intravenously. Administration of FUDR via the chemopump is every 4 weeks and systemic therapy is administered every 2 weeks.
223919601|NCT06857773|DEVICE|Hepatic arterial infusion pump (HAIP)|The HAIP (pump) is implanted during surgery combined with resection of the primary tumor before start of induction treatment with Floxuridine and concomitant systemic therapy
224089870|NCT05503290|BEHAVIORAL|Lullaby Project|Our proposed intervention is the randomized participation of pregnant individuals with epilepsy in the Lullaby Project coordinated by a musical institution in Toronto. The Lullaby Project is an initiative first created by Carnegie Hall's Weill Music Institute. In this program, pregnant women and/or new mothers are paired with professional musicians to compose and write personal lullabies for their child(ren). Since its inception in 2011, the project has expanded globally and have helped numerous families write original lullabies for their newborns. The Lullaby intervention is unlike traditional music therapy as patients are actively participating in the creative song-writing process, not singularly in passive listening. Through sessions, participants will be given an opportunity to share experiences, experiment with musical arrangements, write lyrics, and receive positive feedback from the musician.
224089871|NCT03983551|DRUG|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
224089872|NCT03983551|DRUG|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
224099364|NCT03124043|OTHER|Livongo for Diabetes program|See description in arm/group description.
224099365|NCT02213718|DRUG|Desflurane|desflurane (7%-8% end-tidal concentration)
223919602|NCT06857773|DRUG|Systemic therapy (standard of care)|Patient included in the control arm will receive systemic therapy according to standard clinical practice. Induction therapy regimens include: CAPOX (3 weekly) or FOLFOX/FOLFIRI/FOLFOXIRI (2weekly) with optional addition of Bevacizumab (2 weekly)
223919603|NCT06856382|DIAGNOSTIC_TEST|gastric cancer|Patients diagnosed with gastric cancer by pathological biopsy.
223919604|NCT06185777|BEHAVIORAL|Exercise oncology counseling and referal|Identification \& brief consultation Screening: Needs assessment for exercise therapy Information / educational talk Consultation with the patient Risk assessment (with physician clearance) Consultation Referral to exercise therapy
224099366|NCT02213718|DRUG|propofol|propofol (TCI:3.5-4.0μg/min)
224099367|NCT02213718|DRUG|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
224099368|NCT00551707|DRUG|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
224099369|NCT00551707|DRUG|prednisolone|prednisolone (2.7 mg)
224099370|NCT00551707|DRUG|dipyridamole|dipyridamole 360 mg
224099371|NCT00551707|DRUG|placebo|placebo
224099372|NCT00551707|DRUG|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
224099373|NCT00488631|BIOLOGICAL|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
224089873|NCT06196502|OTHER|Gentle Human Touch (GHT)|Gentle touch is a touch technique that provides a kind of relaxation in premature babies, reduces behavioral stress and motor activities of babies and is effective in their positive behavior. GHT Hepatitis-B vaccine will start 5 minutes before the application and continue during and after the procedure. It is planned to take 10 minutes in total. The researcher will place one hand on the baby's head and the other hand on the baby's lower abdomen, covering the waist and hips, for 10 minutes.
223919605|NCT06668012|DEVICE|Palomacare® vaginal gel is a medical device with CE class IIa.|"The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days.~In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid.~Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not."
223919606|NCT03233646|DEVICE|Retinal and Choroidal Imaging|Non-invasive OCT, OCTA, and UWF fundus photography of retina
224278753|NCT05625269|OTHER|Education|The first session of the individual training will be held for the patients in the intervention group on the first day of the service hospitalization, covering the issues related to the procedure and the hospital process. Afterwards, the second session of individual education will be held the day before discharge on issues related to the patient's home care, such as treatment site care, nutrition, exercise, medication and symptom management. In addition to the patients, their families will also participate in the training sessions. The training will be given face-to-face in a quiet environment to increase intelligibility in patients' rooms. The patients will be given a booklet and magnet prepared by the researcher in addition to the oral explanation.
224278754|NCT00506012|DRUG|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
224278755|NCT03447444|OTHER|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
224278756|NCT01589601|BEHAVIORAL|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
224278757|NCT01589601|BEHAVIORAL|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
224278758|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
223919607|NCT04567056|DIAGNOSTIC_TEST|Blood sample|A separate blood sample will be taken for methylation-analyses
223919608|NCT06755866|DIAGNOSTIC_TEST|The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer|Chest MRI scan outside of standard treatment options
223919609|NCT06753487|PROCEDURE|Myofacial Release|"Manual Myofascial Release:~Control group will receive 3- 5 repetitions of Manual Myofascial Release in Piriformis muscle i.e giving ischemic pressure on muscle directly for 90 secs and then release."
223919610|NCT06753487|PROCEDURE|Facilitated positional release technique|"FPRT:~Treatment group will receive 5 repetitions of FACILITATED POSITIONAL RELEASE technique i.e applying pressure over tender area of muscle while maintaining specific postion"
223919611|NCT06593691|OTHER|conventional treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise
224089874|NCT06196502|OTHER|Kangaroo Care|"Kangaroo care will be provided to randomly selected volunteer moms in their own gynecological ward rooms, where they will have skin-to-skin contact with their babies while maintaining their privacy. Kangaroo care is a strategy that promotes bonding and engagement between a mother and her infant by allowing skin-to-skin contact with the newborn's face facing the mother and only the diaper remaining.~The infant is positioned such that his or her shoulders are totally on the mother's chest, ensuring the baby's airway is open. To avoid heat loss while the baby is in skin-to-skin contact with his mother, a tiny blanket will be placed on his back and a beanie will be placed on his head. Kangaroo care will begin 5 minutes before the Hepatitis-B vaccine is administered and will continue throughout the operation. It is estimated that it will take 10 minutes in total."
224089875|NCT06196502|OTHER|Lactation|Breastfeeding will become standard medical practice. Breastfeeding will start as soon as the baby is given the vaccination and continue throughout the process.
224278759|NCT00726895|DRUG|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
223919612|NCT06593691|OTHER|Conventional treatment + multi-wave locked system laser treatment|Hot Pack, TENS, therapeutic ultrasound, and exercise + multi-wave locked system laser treatment
223919613|NCT06872762|BEHAVIORAL|Exercise|Exercise for 90 minutes (cycling) while minimizing thermal strain
224278760|NCT04265287|OTHER|Data collection|Demographic, clinical, microbiological, critical care support and management data will be collected.
224278761|NCT04066257|DRUG|Tegoprazan|Tegoprazan 50 mg tablet
224278762|NCT04066257|DRUG|Metronidazole|Metronidazole 250 mg tablet
224278763|NCT04066257|DRUG|Tetracycline|Tetracycline hydrochloride 250 mg capsule
224278764|NCT04066257|DRUG|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
224278765|NCT02910596|DRUG|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
224278766|NCT02910596|DEVICE|early bladder training|early bladder training start on 3rd - 5thpostoperative day
224278767|NCT02910596|OTHER|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
224278768|NCT02910596|OTHER|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
223919614|NCT06872762|BEHAVIORAL|Heat strain|Exercise for 90 minutes (cycling) while maximizing thermal strain
223919615|NCT06873594|PROCEDURE|three-ports laparoscopic cholecystectomy|in this arm, laparoscopic cholecystectomy will be done with three ports
223919616|NCT06873594|PROCEDURE|four-port laparoscopic cholecystectomy|in this arm, laparoscopic cholecystectomy will be done with four ports
223919617|NCT06871748|OTHER|Low FODMAP Diet|A standardized diet containing low levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs), designed to reduce bloating and gastrointestinal symptoms. Meals are pre-prepared, calorie-matched, and visually identical to those in the high FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence monitored through food diaries and photos.
223919618|NCT06871748|OTHER|High FODMAP Diet|A standardized diet containing high levels of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) to assess its impact on bloating and gastrointestinal symptoms. Meals are calorie-matched and visually identical to those in the low FODMAP group to maintain blinding. Participants will consume three main meals and one snack daily for two weeks, with adherence tracked through food diaries and photos.
223919619|NCT06873126|COMBINATION_PRODUCT|Counselling sessions|The study provides insights into the use of awareness counselling sessions for physical activity promotion, which may have a significant impact on physical activity education, promotion, practice and policy making and will be more effective to ensure adherence to activity among young adults.
223919620|NCT06869369|OTHER|Turkish PNE4Kids|"Participants in the intervention group will receive 'Turkish PNE4Kids Programme'. The PNE4Kids program was developed based on the book Explain pain by Butler and Moseley and includes an explanation and reassurance on the cause of pain, a brief summary of relevant pain mechanisms, and the integral role of psychosocial and physical factors in precipitating and maintaining pain. This programme has been translated and validated in Turkish children."
223919621|NCT06873165|DIETARY_SUPPLEMENT|Probiotics|1 capsule(with three different dosage) per day for 12 weeks
223919622|NCT06873165|DIETARY_SUPPLEMENT|Placebo|1 capsule per day for 12weeks
223919623|NCT01884961|OTHER|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
223919624|NCT06867068|DRUG|Midazolam Hydrochloride|Short-acting sedative. Benzodiazepine. Gamma-aminobutyric acid (GABA) inhibitor
223919625|NCT06867068|DRUG|Fentanyl|Synthetic opioid drug used as an analgesic.
223919626|NCT06867068|DRUG|Ketamine|General Anesthetic. N-methyl-D-aspartate (NMDA) receptor agonist
223919627|NCT06867068|DRUG|Propofol injection|General Anesthetic. GABA receptor modulator and calcium channel blocker
223919628|NCT06867068|DRUG|Nitrous oxide|Modulates a wide range of ligand-gated ion channels and inhibits NMDA receptor-mediated currents
223919629|NCT06681194|DRUG|Silver Nitrate|"See Silver nitrate only study arm"
223919630|NCT06681194|DRUG|triamcinolone|"See Triamcinolone only study arm"
223919631|NCT06681194|DRUG|Silver nitrate + triamcinolone|"See Combination group study arm"
223919632|NCT06624592|DRUG|Sevoflurane|Subjects will receive standard of care anesthesia Sevoflurane, with intravenous push Dexmedetomidine
223919633|NCT06624592|DRUG|Isoflurane|Subjects will receive standard of care anesthesia Isoflurane
223919634|NCT06860269|DRUG|Randomization + Blinatumomab + chemotherapy|Rando 1 : BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 4 cycles (first cycle starts with 9 µg/day for 7 days)
223919635|NCT06860269|OTHER|Randomization + Standard frontline T-ALL chemotherapy backbone|Rando 3 : standard of care
223919636|NCT06860269|DRUG|Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone|Rando 3 : ISA will be given at 10 mg/kg IV for a maximum of 28 infusions starting at induction up to maintenance phase.
224278769|NCT04874363|OTHER|no intervention|no intervention
223919637|NCT06860269|DRUG|Randomization + Blinatumomab + Ponatinib + chemotherapy|"Rando 2 :~* PONA will be given at 45 mg/day PO during 2 cycles, 30 mg/day during 2 additional cycles, and 15 mg/day during maintenance phase or after alloHSCT~* BLINA will be given at 28 µg/day IVC from D1 to D28 for 2 to 5 cycles (first cycle starts with 9 µg/day for 7 days). Patients allografted will receive two courses before transplant."
223919638|NCT06860269|OTHER|Randomization 1 + Allo HSCT|Rando 1 : standard of care - Allogeneic Hematopoietic Stem Cell Transplantation
223919639|NCT06860269|OTHER|Randomization 2 + Allo HSCT|Rando 2 : standard of care
223919640|NCT05196347|DRUG|Dapagliflozin|In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.
223919641|NCT06682702|OTHER|DNS Group|ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions. Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
223919642|NCT06682702|OTHER|Schroth Group|ISST Schroth exercises are a model of exercise aimed at correcting scoliosis in three dimensions.
223919643|NCT05584202|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
223919644|NCT05584202|OTHER|Placebo|0.9% sodium chloride
223919645|NCT02991313|DEVICE|Endocardial Ablation Procedure|
223919646|NCT06874777|OTHER|Aromatherapy group|It is known that aromatherapy is used in symptom management in chronic diseases. When the literature is examined, it is seen that aromatherapy application is effective in relieving anxiety and fatigue in cardiovascular diseases. Currently, there is no symptom management method other than pharmacological treatment that is widely used or recommended by health professionals for ICD patients. The literature review reveals that there is no study examining the effect of lavender oil aromatherapy in relieving anxiety and fatigue in individuals with ICD implantation. In this context, the aim of this study is to determine the effect of aromatherapy applied by inhaling two drops for two minutes before going to bed for one month on anxiety and fatigue levels in individuals with ICD implantation.
223919647|NCT06630611|BIOLOGICAL|NMA-LD regimen|The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
223919648|NCT06630611|BIOLOGICAL|Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion|On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
224089876|NCT01634932|OTHER|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
223919649|NCT06630611|BIOLOGICAL|High dose IL-2|"Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration."
223919650|NCT06630611|BIOLOGICAL|IL-2 analog|"Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg."
223919651|NCT06691165|OTHER|Low oxygen therapy (LOT)|"Participants will breathe variable concentrations of inspired oxygen, carbon dioxide, and nitrogen. The concentrations will be adjusted on a breath-by-breath basis to maintain end-tidal targets.~Each daily session of the intervention will consist of forty 1-minute intervals. Each 1-minute interval will consist of 40 seconds of hypercapnic hypoxia, increasing the partial pressure of end-tidal carbon dioxide by +4 mmHg and decreasing the partial pressure of end-tidal oxygen to 45 mmHg, followed by 20 seconds in simulated room air to return to baseline carbon dioxide and oxygen levels."
223919652|NCT06688396|DEVICE|Mobile 6L AI-EKG Screening|"Participants (probands) with DCM will invite their first-degree relatives to undergo DCM screening procedures.~Probands and first-degree relatives will complete a mobile 6L AI-EKG which will be transmitted to a mobile app and interpreted by the AI-EKG algorithm. Results will be shared electronically or verbally to the participant.~If available, the probands clinical 12L EKGs will be obtained if recorded within 30 days of their Kardia 6L recording.~All participating FDR will be encouraged to pursue cardiac screening per ACC/AHA recommendations. Study staff will obtain echocardiogram results up to 6 months of participant enrollment."
223919653|NCT03788369|PROCEDURE|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
223919654|NCT02933762|DRUG|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
223919655|NCT02933762|DRUG|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
223919656|NCT06871982|BEHAVIORAL|PNF+ PBI|Parents of participating students assigned to the PNF+ PBI condition will receive an email invitation to sign up for a Parent-Based Intervention app. This app features six personalized normative feedback (PNF) quizzes and provides tailored videos and readings based on responses to these quizzes. Parents will create an account and complete the first PNF quiz, after which they will immediately receive their initial set of tailored content. They can then explore additional app content at their convenience, including access to five more quizzes that will yield further customized reading lists and access to a general resource library. For approximately six weeks, parents will receive weekly app notifications and email reminders alerting them to additional unengaged content (e.g., PNF quizzes, readings). Parents in this condition will maintain access to the app throughout their student's first year of college.
223919657|NCT06871982|BEHAVIORAL|SNMC+ PBI|Parents of participating students randomized to this condition will receive a series of 6 emails (delivered weekly) in August and September. Each email will include risk-reducing normative facts and a relevant tip for communicating with students about alcohol-related risks.
223919658|NCT06871982|BEHAVIORAL|PH+ PBI|Parents of participating students randomized to this condition will receive an email introducing the PBI including a link to access the Handbook online. Parents can explore the Handbook at their own pace.
223919659|NCT06872827|DRUG|Herbal toothpaste|Intervention
223919660|NCT06872580|DRUG|QLS1209|Levels of QLS1209 will be explored in dose escalation, and determine the maximum tolerated dose.
223919661|NCT06872580|DRUG|QLS1209|Every 21 days is one cycle.1-3 dose levels of QLS1209 will be explored in dose optimization, and determine the recommended dose (RD) of QLS1209 and evaluate the preliminary anti-tumor activity of QLS1209.
223919662|NCT06873425|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
223919663|NCT06873425|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
224089877|NCT01634932|OTHER|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
224089878|NCT01634932|OTHER|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
224089879|NCT01880307|DRUG|Azathioprine|
224089880|NCT01880307|DRUG|Infliximab|
224089881|NCT01880307|DRUG|Prednisolon|
224089882|NCT03573167|BEHAVIORAL|In-Person Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.
224089883|NCT03573167|BEHAVIORAL|Mobile Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
224089884|NCT04490889|DIAGNOSTIC_TEST|NiPGT-A|NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
224089885|NCT01221857|DRUG|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
224089886|NCT06318884|DRUG|SCTB35 injection|SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and another appropriate dose of SCTB35 will be applied for the dose-expansion cohorts.
224089887|NCT04430907|BIOLOGICAL|HPV 9-valent Vaccine, Recombinant|"After consent, participants will complete an intake survey confirming eligibility. Participants will also complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions.~After survey completion, the participant will be asked if they would like to be administered the HPV vaccine, Gardasil 9. If participants do not agree, they will be contacted 1-week later for the follow-up survey. If participants do agree, the project coordinator will notify the study physician, who will place an order for the vaccine. The vaccine will be administered to the patient prior to discharge from the hospital. Participants will be contacted 1-week later for the follow-up survey."
224278770|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 1|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
224278771|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 2|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
223530412|NCT05069519|BEHAVIORAL|Personalized Smartwatch|"Participants will continue with standard care, but will receive a Fitbit and be encouraged to participate in at least 150 min. moderate-to-vigorous physical activity (5 sessions aerobic exercise, 30 min. per session; and 2 sessions of strength training) per week if their body condition allows throughout the intervention period. The previously established daily and weekly exercise prescription will be offered to participants based on their previous week Fitbit data.~PA improvements will be tailored over time based on each participant's previous week PA and they will be encouraged to increase PA by 5-10 min/week if possible depending on specific situations. Participants will save each workout and synchronize the Fitbit PA data to its app where they only share daily data and receive weekly personalized exercise prescriptions established in pilot studies."
223530413|NCT05069519|BEHAVIORAL|Facebook Health Education|Participants assigned to this condition will receive a Fitbit smartwatch, continue with standard care, but will receive health education tips developed in the investigators' previous studies from a private Facebook group in which only group members and researchers can access. Additionally, the investigators will track login counts, analyze their post activity and online sentiments via texting mining and natural language processing, and then offer weekly personalized feedback based on the data to facilitate social support
223919664|NCT06871644|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of
223919665|NCT06873074|PROCEDURE|anterior long segment cervical fixation|
224089888|NCT01577862|DRUG|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
224089889|NCT01577862|DRUG|Rifampicin|600 mg every 12 hours intravenously
224089890|NCT04201743|DRUG|Acellular amniotic membrane derived allograft injection (NuDYN)|Injectable acellular amniotic membrane derived allograft (NuDYN) through routine follow-up with physical examination, pain, function and quality of life measurements and compare dose effects (1 mL versus 2 mL of NuDYN injection) in the treatment of knee osteoarthritis.
224278772|NCT04432207|BIOLOGICAL|IMU-201 (administered as PD1-Vaxx) - Regimen 3|IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
223530414|NCT03326908|DEVICE|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
223530415|NCT02927444|BIOLOGICAL|NBP606|A single intramuscular injection into the thigh
223919666|NCT06873074|PROCEDURE|posterior long segment cervical fixation|
223919667|NCT06873074|PROCEDURE|combined anterior and posterior fixation|
223919668|NCT06287268|OTHER|eltrombopag|This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
223919669|NCT06680271|OTHER|Remote exercise|The intervention group will consist of 25 subjects receiving a multicomponent physical exercise intervention (aerobic, strength, flexibility, and neuromotor) delivered by a physical therapist via the Microsoft Teams platform
224089891|NCT05011487|DRUG|Osimertinib|80mg/qd oral for 60 days
224089892|NCT05011487|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
224089893|NCT05011487|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin on Day 1 of every 3-week cycle for 2 cycles
224089894|NCT02563301|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
224278773|NCT04432207|DRUG|Atezolizumab|Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
224278774|NCT04432207|DRUG|Standard of care chemotherapy|Chemotherapy to be administered according to the prescribing information.
224278775|NCT01041209|BEHAVIORAL|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
224278776|NCT01041209|BEHAVIORAL|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
224278777|NCT06519747|DEVICE|Cardiac monitoring device|Portable, up to 14 days of monitoring
223530416|NCT02927444|BIOLOGICAL|Prevnar13|A single intramuscular injection into the thigh
223919670|NCT06680271|OTHER|Home exercise|The control group will consist of 25 subjects receiving traditional physical therapy at home from a physical therapist.
223919671|NCT06124664|DIAGNOSTIC_TEST|Radionuclide venography|With the patient in an upright position, 370 MBq of 99mTc pertechnetate is injected into one of the dorsal veins of the foot after applying a tourniquet in the area of the ankle joint. Then, with the help of a gamma camera detector, the movement of the radiopharmaceutical is monitored in the following segments: tibial (muscular-venous pump of the lower leg), popliteal, femoral and iliocaval. To study the evacuation function of the muscular-venous pump (MVP) of the leg, using an analytical computer program, areas of interest are identified in the tendon, muscle parts of the veins of the leg and the popliteal vein. The time of evacuation of the radiopharmaceutical from the MVP of the leg is estimated - the average transport time of the isotope.
224089895|NCT02198833|BIOLOGICAL|Urine Culture|Obtain urine culture every third day
224089896|NCT02198833|DEVICE|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
224089897|NCT02198833|DEVICE|Scanning Electron Microscopy|Houston Site Only
223530417|NCT06467240|PROCEDURE|hybrid rapid maxillary expander assisted with Micro-osteo perforation (MOPs)|patients with constricted maxillary will applied for hybrid expansion and group of them will assisted by Micro-osteo perforation (MOPs)
223919672|NCT06124664|DIAGNOSTIC_TEST|single-photon emission computed tomography|"SPECT of the pelvic veins with in vivo-labelled red blood cells (RBCs). For radionuclide assessment of the state of the pelvic veins, 2 ml of Perfotech solution is injected into the cubital vein for subsequent labeling of red blood cells in vivo. In 20 minutes. 370 MBq of 99mTc-pertechnetate is injected into one of the veins of the dorsum of the foot and radionuclide venoscintigraphy is performed according to the method presented above. 20 minutes after the administration of the radiopharmaceutical and the venography, SPECT of the pelvic veins is performed. Tomography of the distribution of labeled erythrocytes in the pelvic veins is carried out in a circular orbit with the gamma camera detector rotated 360°. The analysis of the obtained information is carried out using the standard ECT Protocol software package, which allows obtaining sections in 3 projections (sagittal, transversal and coronal) with a slice step of 8 mm."
223919673|NCT04296955|OTHER|Motivational interview as a new health communication intervention|Same as intervention name
223919674|NCT06696677|DIAGNOSTIC_TEST|CT|CT measurment of small bowel
223919675|NCT06696677|PROCEDURE|Measuring the small instestine length using pre-marked laparoscopic graspers|Intra-operatively, the surgeon will assess the length of the small intestine using a 5-cm marked laparoscopic graspers to accurately assess the whole small intestine length.
223919676|NCT06698107|BEHAVIORAL|Childbirth education programme|"The intervention framework is underpinned by a converging of salutogenic and self-efficacy perspectives, aiming to enhance mothers' ability to adapt to new motherhood life despite stressors, and to address the question, How do teenage mothers stay well despite stressful events of transition to motherhood? The intervention consists of six sessions: three of which will be provided in the antenatal period and the other three in the postpartum period. The sessions contain two individual face-to-face educations (each lasting 60-90 minutes), two phone calls (each lasting 30 minutes), and two group discussion sessions (each lasting 90-120 minutes), as supported by the existing evidence."
223919677|NCT06698107|OTHER|Usual Care|The control group will receive the usual maternity care.
223919678|NCT06229119|DEVICE|Implantable Collamer Lens|The EVO ICL lens is intended to be placed entirely within the posterior chamber directly behind the iris and in front of the anterior capsule of the human crystalline lens. When correctly positioned, the EVO ICL lens functions as a refractive element to optically reduce moderate to high myopia with or without astigmatism.
223919679|NCT06482138|PROCEDURE|Biopsy and Cytobrush|Collection of olfactory cleft biopsies and cytobrushes
223919680|NCT00329836|OTHER|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
223919681|NCT06135506|PROCEDURE|free-hand ridge splitting|Midcrestal incision will be followed by reflection of full thickness flap. Midcrestal cut without vertical osteotomy will be done using piezosurgery unit, and then the cut will be extended deep to the implant length. The ridge will be expanded progressively using bone wedges. Dental implant fixtures will be placed stably with 1 mm minimal thickness of buccal bone plate. Surgical site will be completely closed, and wound edges will be sutured in a tension-free way.
223919682|NCT06135506|PROCEDURE|AI/guided ridge splitting|"The patient specific guides will be placed and fixed by monocortical osteosynthesis screws at the pre-planned positions at the labial buccal mucosa.~A midcrestal cut will be performed on the crest of alveolar ridge guided by the guide slits. The cuts will be expanded progressively using bone wedges through the guide slits gradually lateralize and expand the labial alveolar plate of bone, so the labial cortex will move through the intentionally created micro gap till it touches the fitting aspect of the patient specific guide. Implant drills will be inserted through the guiding holes in the surgical guide and the implant osteotomy sites will be prepared. Finally, implants will be inserted in the osteotomy sites using torque-wrench in a self-tapping fashion engaging palatal and basal bone for primary stability."
223919683|NCT06697964|OTHER|HRA|High resolution anoscopy to help evaluate anal conditions such as precancerous lesions
223919684|NCT05074056|DRUG|Ketorolac|We will administer intraoperative ketorlac.
223919685|NCT04252482|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 12 weeks
223919686|NCT03475134|OTHER|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
223919687|NCT03475134|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223919688|NCT03475134|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223919689|NCT03475134|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
223919690|NCT03475134|DRUG|Nivolumab|Nivolumab will be administered for maximum 24 months as follows: first year: 240 mg every 2 weeks; second year: 480 mg every 4 weeks.
223919691|NCT05939401|OTHER|Biopsies|Biopsies and blood samples will be taken at time of diagnosis or recurrence
223919692|NCT01106183|DIETARY_SUPPLEMENT|transfer factor|capsules, 2 per day by mouth for 7 weeks.
223919693|NCT01106183|DIETARY_SUPPLEMENT|Placebo|cornstarch, 2 capsules per day by mouth.
223919694|NCT05407376|OTHER|Produce prescription (weekly produce delivery)|Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
223919695|NCT06701721|DRUG|THN391 MAD|Route of administration- IVT injection
223919696|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort A: Short duration NET. Patients in this cohort can be treated with NET up to 8weeks (\<= 8 weeks)
223919697|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort B: Intermediate duration NET. Patients in this cohort can be treated with NET \> 8weeks but \<=24 weeks
223919698|NCT06806930|DRUG|Neoadjuvant endocrine therapy|Cohort C: Extended duration NET. Patients in this cohort can be treated with NET \>24 weeks but \<= 52 weeks
224089898|NCT02198833|PROCEDURE|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
224089899|NCT02198833|PROCEDURE|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
224099374|NCT00488631|BIOLOGICAL|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
223919699|NCT06807892|OTHER|Synergistic management|In synergistic management, exercises are carried out in a synergistic way: 40 minutes of exercises involving both physical and cognitive stimulation.
224278778|NCT01610024|DIETARY_SUPPLEMENT|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
223919700|NCT06807892|OTHER|Sequential management|In sequential management, exercises are performed sequentially: 20 minutes of physical exercises and 20 minutes of cognitive exercises.
223919701|NCT02461134|DRUG|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
223919702|NCT06700460|DEVICE|Laser-assisted in Situ Keratomileusis|LASIK
223919703|NCT06700460|DEVICE|Implantable Collamer Lens placement|EVO ICL
223919704|NCT06701526|DRUG|Eptinezumab|Solution for infusion
223919705|NCT04761198|DRUG|Etigilimab|IV infusion of IV etigilimab every 2 weeks
223919706|NCT04761198|DRUG|Nivolumab|IV infusion of nivolumab every 2 weeks
223919707|NCT02994927|DRUG|Avacopan|"Avacopan 30 mg twice daily orally for 52 weeks (364 days):~\- Three 10 mg avacopan capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone-matching placebo tapering regimen over 20 weeks (140 days):~* Prednisone-matching placebo capsules equivalent to 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to a protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone-matching placebo dose of 30 mg per day."
223919708|NCT02994927|DRUG|Prednisone|"Avacopan-matching placebo twice daily orally for 52 weeks (364 days):~\- Three avacopan-matching placebo capsules in the morning, preferably with food, and three in the evening, preferably with food, approximately 12 hours after the morning dose.~Oral prednisone tapering regimen over 20 weeks (140 days):~* Prednisone 60 mg per day if the subject's body weight was ≥55 kg, or 45 mg per day if the subject's body weight was \<55 kg, starting on Day 1 with tapering according to the protocol-specified schedule.~* Adolescents who weighed ≤37 kg started at a prednisone dose of 30 mg per day."
223919709|NCT02994927|DRUG|Cyclophosphamide|Orally or intravenously administered
223919710|NCT02994927|BIOLOGICAL|Rituximab|Intravenously administered
223919711|NCT02994927|DRUG|Azathioprine|Orally administered
223919712|NCT06634160|DIAGNOSTIC_TEST|Fibroscan|Evaluation of the prevalence of steatosis by measuring ultrasound attenuation with Fibroscan® (non-invasive method, at a distance from a meal (3h fasting)).
223530422|NCT04373369|DRUG|Vorolanib|Vorolanib is administered orally at a dose of 200 mg on Days 1 through 21 of each 21-day cycle.
223919713|NCT06634160|OTHER|Sample collection|20 mL whole blood sample
223919714|NCT05846464|DEVICE|Meta Quest 2|The Meta/Oculus Quest (along with the SignWave software) delivers an immersive audio/visual-based game environment where the users hand is created and displayed in the virtual environment and matches target gestures to the beat of the music.
223919715|NCT06632990|DRUG|BMS-984923|oral capsules once or twice daily
223530423|NCT04373369|DRUG|Atezolizumab|Atezolizumab is administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
223530424|NCT04961957|DEVICE|Waterproof padding|Apply waterproof padding to allow for normal bathing and water activities
223530425|NCT04961957|DEVICE|Non-waterproof padding|Apply standard padding that does not allow for normal bathing and water activities
223919716|NCT06632990|DRUG|Midazolam|midazolam, oral, 2mg administered before study drug and after study drug
223919717|NCT06632990|DRUG|Caffeine|Caffeine, oral, 100mg administered before study drug and after study drug
223919718|NCT06632990|DRUG|dextromethorphan|dextromethorphan, oral, 30mg administered before study drug and after study drug
223919719|NCT06632418|DRUG|RhPDGF-BB|0.3 mg/mL rhPDGF-BB
223919720|NCT06633445|PROCEDURE|botulinum toxin type A injection in lateral pterygoid muscle|"* Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle."
223530426|NCT05763121|DRUG|Dexpramipexole Dihydrochloride|oral administration of dexpramipexole tablet
223530427|NCT05763121|DRUG|Placebo|oral administration of placebo tablet
223530428|NCT06352151|OTHER|Routine Physiotherapy Group|Children with Down syndrome who receive routine physical therapy treatment in special education centers will undergo evaluation after eight weeks of treatment, followed by a control evaluation after 12 weeks.
223919721|NCT06633445|PROCEDURE|botox injection in lateral pterygoid muscle|"* A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound."
223940662|NCT06608940|DRUG|BC3402|BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
223940663|NCT06608940|DRUG|Durvalumab|Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
223940664|NCT06608940|DRUG|Tremelimumab|Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
223940665|NCT06986200|PROCEDURE|Chest Compressions|Performing chest compressions in full firefighter's personal protcetion equipment
223940666|NCT06986200|PROCEDURE|One minute rotation intervall|Chest compressions using a one minute rotation intervall
223530429|NCT06352151|OTHER|Orofacial Treatment Group|"The orofacial treatment group receives therapeutic orofacial treatment in addition to routine physiotherapy treatment. Each week, one or two target exercises will be taught to the child with Down syndrome, and the exercises will gradually increase throughout the process. Parental involvement will be encouraged during the treatment to ensure active participation in therapy.~The goals of the therapy are as follows:~First Goal: Nasal hygiene and Sleep hygiene education~Second Goal: Nasal Breathing Exercise Training~Third Goal: Creating Awareness of Tongue Resting Position~Fourth Goal: Creating Lip Position Awareness - Lip Exercises~Goal Five: Chewing Muscle Exercises~Sixth Goal: Strengthening the Soft Palate~Seventh Goal: Reshaping Correct Swallowing"
223530430|NCT06352151|OTHER|Therapeutic Yoga Group|The therapeutic yoga group receives therapeutic yoga treatment and routine physiotherapy treatment. Children with Down syndrome will be given yoga exercises suitable for their age.
223919722|NCT06822322|PROCEDURE|Percutaneous Coronary Angioplasty|"A Percutaneous Coronary Intervention is used in both arms, with the drug Zotarolimus for stenting strategy and Paclitaxel for balloon strategy.~Coronary guide wires are passed into both the distal main vessel (distal MV) and side branch (SB) and predilation of MV on a 1:1 basis is required.~The device component dilates the vessel lumen by Percutaneous Transluminal Coronary Angioplasty (PTCA), while the drug is intended to reduce the proliferative response associated with restenosis."
223919723|NCT06822322|DEVICE|Stepwise Provisional Stent Strategy|In the stepwise provisional stent strategy, stenting of the MV is undertaken with a wire jailed in the SB. Then, non-compliant balloons sized to the diameter of the distal MV and SB are sequentially inflated at high pressure, and then simultaneously at low pressure (kissing balloon inflation ; KBI).
224099375|NCT00488631|BIOLOGICAL|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
224099376|NCT00488631|BIOLOGICAL|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
224099377|NCT03502746|DRUG|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
224099378|NCT03502746|DRUG|Ramucirumab|8mg/kg, IV over 60 minutes.
224099379|NCT01400646|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
224099380|NCT01400646|DRUG|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
224099381|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
224099382|NCT01400646|DRUG|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
224099383|NCT01400646|DRUG|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
224099384|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
223919724|NCT06822322|DEVICE|Drug Coated Balloon Strategy|In the drug coated balloon (DCB) strategy, SB is prepared with a balloon at a 1:1 diameter, followed with a 1:1 sized DCB inflation for 60 seconds at nominal pressure. Then, MV is re-evaluated and treated with DCB at nominal pressure only, sized 1:1 with the proximal MV, for 60 seconds.
223940667|NCT06986200|PROCEDURE|Two minute rotation intervall|Chest compressions using a two minute rotation intervall
223530431|NCT04153292|DEVICE|SAPIEN M3 valve and dock|During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
223940668|NCT06498960|DEVICE|CereVasc eShunt System|"The eShunt System consists of the following components:~* eShunt Implant~* eShunt Delivery Catheter and Transfer Tool~* eShunt Anchor"
223940669|NCT06498960|DEVICE|VP Shunt|Control arm - VP shunt
223940670|NCT06817889|DRUG|Remdesivir|Given IV
223940671|NCT06817889|OTHER|Survey Administration|Ancillary studies
223940672|NCT06817889|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223940673|NCT06817889|PROCEDURE|Nasal Swab|Undergo nasal swabs
223940674|NCT06586437|BEHAVIORAL|Clinical Assessments|The participant will undergo a battery of clinical assessments to identify the upper extremity motor performance, sensory acuity, and ability to complete activities of daily living. Tests 1-5 will be completed separately for each hand. All participants will be video recorded while completing these assessments. The recordings will be used for grading tasks and data analysis: Box and Blocks, 9-hold peg board, Test of Arm Selective Control, Sensory Acuity Testing, KINARM End-Point Lab Sensory Test, Section GG of the inpatient Rehabilitaion Facility-Patient Assessment Instrument, NEURO-QOL Upper Extremity Function Scale, Edinburgh Handed Inventory
223940675|NCT06586437|BEHAVIORAL|Brain-Spinal Cord fMRI|Resting state, brain-spinal cord activity, spinal cord microstructure, magnetic resonance spectroscopy
223940676|NCT06586437|BEHAVIORAL|Hoffmann Reflex Assessments|Hmax 20-50 stimulations of increasing intensity. Next, the participant will sit quietly as 10 stimulations will be delivered at the participant's Hmax with an interstimulus interval of 15 seconds. Subsequently, stimulations at the participant's Hmax will be applied as the participants produce a contraction of 10-20% of their maximum voluntary contraction (MVC). The target contraction level will be shown in real-time based on the FCR EMG activity. The participant maintains their EMG activity at the target level for 6.5 seconds as 10 stimulations are delivered at the participants Hmax.
223940677|NCT06586437|BEHAVIORAL|MEG Imaging|Resting state, somatosensory, isometric force matching, entrainment
223940678|NCT06586437|BEHAVIORAL|Transcutaneous Current Stimulation|Cortical stimulation, spinal cord stimulation - sham and stim
223940679|NCT06593756|DEVICE|Transthoracic Echocardiography|Transthoracic echocardiography (TTE) is used for intermittent non-invasive stroke volume (SV) measurements. It is calculated by multiplication of left ventricular out flow tract (LVOT) and LVOT velocity time integral (VTI), obtained in a parasternal long axis view and apical five chamber view, respectively.
223940680|NCT06593756|DEVICE|Uncalibrated Pulse Contour Analysis|Pulse Contour Analysis allows an automated and continuous measurement of stroke volume (SV). Its underlying principle is that the integral of the systolic arterial pressure curve directly correlates with stroke volume.
223919725|NCT06822322|DEVICE|Cross-Over Stepwise Provisional Stent Strategy|Following Drug Coated Balloon treatment in the Main vessel (MV) in the Drug Coated Balloon Arm, if the result is unacceptable in the MV, with either TIMI\>3 flow and/or dissection propagation, MV stenting is mandatory followed with Kissing Balloon Inflation (KBI), where non-compliant balloons sized to the diameter of the distal main and side branch are sequentially inflated at high pressure, and then simultaneously at low pressure. If the cross-over stent implantation in the MV is used, a further SB treatment with either DCB or stent implantation is used, according to operator preference.
223919726|NCT06802939|DEVICE|rTMS|RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
223919727|NCT03875339|BEHAVIORAL|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
223919728|NCT03533257|DRUG|AMX0035|Combination Therapy of PB and TURSO
223919729|NCT03533257|DRUG|Placebo|Placebo
223919730|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|"Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)"
223919731|NCT06619717|PROCEDURE|Hyperbaric Oxygen Therapy|Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes
223919732|NCT06406452|DEVICE|Bioresorbable Tracheobronchial Splint|"Subjects will have several imaging and bronchoscopic studies and the placement of the splint will require an open-chest surgery to implant the airway splint (s).~The Materialise Bioresorbable Tracheobronchial Splint is designed for an individual subject based on Computed Tomography (CT) scans taken using a specific scan protocol. Based on these 3D models, a pre-operative plan is discussed between the Materialise engineering team and the treating surgeon(s) to determine the locations and required dimensions of the splint(s). Each subject may receive up to four splints positioned on subject's trachea or mainstem bronchi.~Subjects will also have several follow-up visits, and parents will be expected to regularly fill out questionnaires."
223919733|NCT06105164|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher."
224278779|NCT04478240|BEHAVIORAL|PeerLearning.net|"PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group."
224278780|NCT02005939|DIETARY_SUPPLEMENT|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
224278781|NCT06679712|PROCEDURE|Transbronchial PDT lung tumor ablation|Transbronchial photodynamic therapy ablation for peripheral lung cancer
224278782|NCT05685017|DIAGNOSTIC_TEST|Nur Aisiyah Widjaja|Blood analysis for ICAM-1, VCAM-1, blood fasting insulin, lipid profile, fasting blood glucose and adiponectin investigation
224278783|NCT04039490|DEVICE|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
224278784|NCT02609516|OTHER|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
223530432|NCT05837676|BEHAVIORAL|Problem Solving Training for Concussion|PST-Concussion is a combined treatment consisting of brief problem-solving training, standard concussion education, motivational interviewing, goal-setting, and compensatory cognitive strategies.
223530433|NCT05837676|OTHER|Treatment as usual|Patients assigned to TAU will receive the care that they and their providers determine is necessary to best manage their presenting concerns.
223530434|NCT04710264|OTHER|AURORA-Rec|Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.
223919734|NCT06105164|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows for selective external manipulation of neural activity in a non-invasive manner. During rTMS a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field, which in turn induces electrical current in neurons and allows for modulation of neural circuitry.~Intermittent theta burst stimulation (iTBS) consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses (82), will be applied to the target. Cerebellar stimulation will be applied to the targets at 100% of aMT or 35% maximal stimulator output, whichever is higher.~Sham is achieved by using a coil with a magnetic shield preventing magnetic field from reaching the head."
223919735|NCT05967416|BIOLOGICAL|SIRPant-M|Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection
223919736|NCT05967416|RADIATION|External-beam radiotherapy (XRT)|Radiotherapy given by external beam to the IT-injected lesion only
224278785|NCT05970614|OTHER|Eye masks and ear plugs|Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
224278786|NCT05753813|DRUG|Phexxi|intravaginal gel twice weekly for 4 weeks.
223919737|NCT05339269|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy is performed by the same surgical team.
223919738|NCT06871709|COMBINATION_PRODUCT|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
223919739|NCT06871709|OTHER|MTA-Anglus|Mineral Trioxide Aggregate (MTA) has been the gold standard material for primary tooth pulpotomy. MTA has antimicrobial properties, excellent sealing ability, is biocompatible and has a dentinogenic effect on pulp tissue by stimulating the release of cytokines from bone cells, which promotes hard tissue formation. Furthermore, MTA maintains pulp tissue integrity while having no cytotoxic effects. Nevertheless, the clinical application of MTA has been limited due to some properties such as its long setting time, difficulty in its handling, being washed out, discoloration, and increased cost. These urged the search for an alternative pulpotomy material to MTA
223919740|NCT06868498|OTHER|A semester-long course for training of students as CHWs with additional EMPOWER training for delivering a brief trans-diagnostic psychosocial intervention.|Students will participate in a special topics course resulting in a CHW certification with the state of Texas. The course will focus on behavioral activation interventions. Undergraduate Bachelor of Social Work (BSWs) students will then be deployed to the health system as certified CHWs with mental health training to provide a sufficient level of care for many, and an entry point to clinical care for those who have needs that are currently unaddressed.
223919741|NCT06592482|DRUG|AZD0780|"A single A dose of AZD0780 will be administered in the morning on Day 1 under fasted condition. Study intervention will be administered orally with approximately 240 mL of water."
223919742|NCT06011876|OTHER|Acute Intermittent Hypoxia (AIH)|AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
223919743|NCT06011876|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
223919744|NCT06011876|OTHER|Sham AIH|A single session of sham AIH with episodes of normal room air (21% O2).
223919745|NCT03493542|BIOLOGICAL|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
224089900|NCT03931655|DIAGNOSTIC_TEST|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
224089901|NCT05210595|DRUG|Clopidogrel 75 mg|75 mg/day as maintenance dose.
224089902|NCT05210595|DRUG|Ticagrelor 60mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
224089903|NCT05210595|DRUG|Ticagrelor 45 mg|In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
224089904|NCT00004396|DRUG|heme arginate|
224089905|NCT00004396|DRUG|tin mesoporphyrin|
224089906|NCT01911858|DEVICE|Askina Calgitrol Paste|
224089907|NCT05621356|OTHER|A nasal fluid Basophil Activation Test (BAT)|a BAT technique for monitoring the inhibitory effect of nasal fluid on basophil activation.
223530435|NCT04732260|DRUG|Letermovir|"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."
223530436|NCT05456139|BEHAVIORAL|Treatment as Usual|"Families in the Treatment as Usual (TAU) condition will receive usual care and EI services in their community, which will be tracked with the BSRC Intervention History Form. Because all families join My Baby Navigator and will be screened by the SoCo CheckUp, families in both conditions will have access to the Seamless Path for Families which includes online tools about social communication developmental milestones. Families will also have access to Autism Navigator About Autism in Toddlers, the ASD Video Glossary, and the Autism Navigator How-to Guide for Families, a self-guided online course."
224089908|NCT03311672|DRUG|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
224089909|NCT03311672|DRUG|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
224089910|NCT03311672|RADIATION|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
224089911|NCT06257212|DRUG|BCG vaccine (Danish strain 1331)|Intradermal BCG vaccine (0.1 ml) + subcutaneous saline at inclusion and after 3 months.
224278787|NCT03354208|OTHER|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
224089912|NCT06257212|DRUG|MMR Vaccine|Subcutaneous MMR vaccine (0.5ml) + intradermal saline at inclusion and after 3 months.
224089913|NCT06257212|DRUG|Placebo|Subcutaneous saline + intradermal saline at inclusion and after 3 months.
224089914|NCT01186393|BEHAVIORAL|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
224089915|NCT01186393|BEHAVIORAL|Low Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
224089916|NCT01186393|BEHAVIORAL|High Glycemic Index|Diets will be energy-restricted (\~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
224089917|NCT03268629|BEHAVIORAL|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
224089918|NCT03268629|BEHAVIORAL|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
224089919|NCT01885780|DEVICE|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
224089920|NCT05785195|DEVICE|Nitric Oxide Generation and Delivery System|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
224089921|NCT01886118|PROCEDURE|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
224089922|NCT01886118|OTHER|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
223919746|NCT06277141|BEHAVIORAL|Standard message|Participants will receive standard messaging based on the Cancer Association of South Africa (CANSA) recommendation on breast cancer screening and a reminder to screen for breast cancer.
223919747|NCT06277141|BEHAVIORAL|Radiology booking site link.|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site.
223919748|NCT06277141|BEHAVIORAL|Radiology practice telephone numbers|Participants will receive a reminder to screen for breast cancer together with a list and telephone numbers of radiology practices
223919749|NCT06277141|BEHAVIORAL|Radiology site link and telephone numbers|Participants will receive a reminder to screen for breast cancer with a direct online link to a radiology practice booking site and a list and telephone numbers of radiology practices
223919750|NCT05159700|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day.
223919751|NCT04831320|DRUG|nab-paclitaxel|Supplied by Celgene Corporation
224089923|NCT01886118|OTHER|Conventional media culture|embryos are cultured in conventional media
223919752|NCT04831320|DRUG|Nivolumab|Supplied by Bristol-Myers Squibb
223919753|NCT06045819|BIOLOGICAL|Blood sampling for venetoclax drug dosage (venous puncture)|8 blood samples for venetoclax and azole antifungal drugs identification and dosage will be taken by venous and capillary punctures throughout management of patients
224089924|NCT00457496|BEHAVIORAL|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
224089925|NCT01686568|DRUG|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
224089926|NCT01686568|DRUG|placebo|
224099385|NCT01400646|DRUG|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
224099386|NCT03147027|PROCEDURE|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
224099387|NCT03147027|OTHER|medication|medication to prevent sustained VT and ICD therapies
224099388|NCT04987593|DIETARY_SUPPLEMENT|Probiotics|Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
224099389|NCT05288088|DIAGNOSTIC_TEST|No intervention|This is an observational study
224099390|NCT03693872|DRUG|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
224099391|NCT03693872|DRUG|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
224099392|NCT04808687|DRUG|Nab paclitaxel and S-1|Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
224099393|NCT01539629|DEVICE|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
224099394|NCT05762341|OTHER|PRESSURE INJURY PREVENTION TRAINING|PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
224099395|NCT01088425|OTHER|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
224099396|NCT05330520|PROCEDURE|"Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement"|when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
224099397|NCT03578406|DRUG|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
224099398|NCT03489213|OTHER|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
224099399|NCT03489213|BEHAVIORAL|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
224099400|NCT03489213|OTHER|Laboratory Biomarker Analysis|Correlative studies
224099401|NCT03489213|DIETARY_SUPPLEMENT|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
224099402|NCT03489213|OTHER|Questionnaire Administration|Ancillary studies
224099403|NCT06010810|DRUG|3 % Topical Tranexamic Acid|Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months
224099404|NCT06010810|DRUG|4% Topical Hidroquinone|Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
224099405|NCT00927485|DRUG|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
224099406|NCT00927485|OTHER|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
224278788|NCT00265785|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
224278789|NCT04791488|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy protocol
224278790|NCT04791488|PROCEDURE|Diving simulation|Hyperbaric chamber diving simulation protocol
224278791|NCT00404053|DRUG|Clopidogrel|
224278792|NCT03607045|DEVICE|headless screw|headless screw group
223919754|NCT05980494|DRUG|normal Saline|normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours
223919755|NCT05980494|DEVICE|lung ultrasound|Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified
223919756|NCT05980494|DEVICE|inferior vena cava measurements|The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.
223919757|NCT05980494|DIAGNOSTIC_TEST|passive leg raising test (PLRT)|"Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line)."
223919758|NCT05980494|DEVICE|pulse pressure variation|patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
223919759|NCT06692335|PROCEDURE|High-Intensity Focused Ultrasound (HIFU)|The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.
223919760|NCT06692335|PROCEDURE|myomectomy|Laparoscopic or open or hysteroscopic myomectomy will be performed.
223919761|NCT06457737|DEVICE|IPS Empress Direct|Resin composite will be heated and used to lute a ceramic partial coverage restoration.
223919762|NCT06457737|DEVICE|Bisco Duo-Link Universal|Dual cure adhesive resin cement will be used to lute a ceramic partial coverage restoration.
223919763|NCT06688292|DRUG|Taneasy 600mg granules|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, plumonary emphysema,mucoviscidosis and bronchiectasis.
223919764|NCT06688292|DRUG|Actein effervescent 600mg|Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.
223919765|NCT04093869|BEHAVIORAL|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
223919766|NCT04093869|BEHAVIORAL|Standard of Care plus Education (SOC-ED)|The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
223919767|NCT06688201|OTHER|Other neurosurgical techniques|Those include open craniotomy, small skull window microsurgery, and endoscopic surgery. The attending clinician is required to consider which type of craniotomy or other procedure according to the expertise and availability at the hospital.
223919768|NCT06688201|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
223919769|NCT06687304|DEVICE|Light enhancement|Light recipe that mimics the varying daylight of the day
223919770|NCT06873464|OTHER|Three cycles of tDCS combined with motor tasks|"Three cycles of 2 weeks duration each combining tDCS and motor task.~Initial Assessment (V0): Collect demographic data and EDSS, MFIS, MSQOL-54, and BBS results.~First Cycle: 2 weeks, Monday to Friday, with a weekend break. Post-First Cycle Assessment (V1): Reassess MFIS, MSQOL-54, and BBS. Washout Period: 1 month without tDCS. Second Cycle: 2 weeks, Monday to Friday, with a weekend break. Final Assessment after Second Cycle (V2): Reassess MFIS, MSQOL-54, and BBS. Washout Period: 1 month. Third Cycle: 2 weeks. Final Assessment after Third Cycle (V3): Reassess MFIS, MSQOL-54, and BBS."
224278793|NCT03401918|DIAGNOSTIC_TEST|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
224278794|NCT03401918|DRUG|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
224099407|NCT00927485|OTHER|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
224278795|NCT03267927|DEVICE|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
223919771|NCT06873464|OTHER|Two cycles of tDCS combined with motor tasks|"Initial assessment (V0): Prior to the first tDCS cycle, demographic data and results from the EDSS, MFIS, MSQOL-54, and BBS scales will be collected.~First cycle: 2 weeks Post-first cycle assessment (V1): Reassess MFIS, MSQOL-54, and BBS scales. Washout period: 1 month without tDCS treatment. Second cycle: 2 weeks, with sessions from Monday to Friday and a weekend break. Final assessment (V2): After the second cycle, reassess MFIS, MSQOL-54, and BBS scales.~Follow-up assessment (V3): 45 days after treatment completion."
223919772|NCT04271189|DRUG|Metformin-Sitagliptin-Empaglifozin-Pioglitazone|1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
223919773|NCT04271189|DRUG|Standard of care|Usual medical care to treat diabetes.
223919774|NCT06702371|BEHAVIORAL|Mindset Intervention|"The EMBody intervention contains seven short documentary-style films and paired reflection activities across three modules.~Module 1: Introducing Mindsets (Film 1: A New normal; Film 2: What is a Mindset?; Film 3: Your Body is Capable; Film 4: How to Choose Your Mindset).~Module 2: Challenges and Setbacks (Film 5: Living with Uncertainty; Film 6: The Long and Winding Road).~Module 3: Looking to the Future (Film 7: Opportunities Emerge)."
223919775|NCT06699056|DEVICE|15-minutes of sitting during COR ECG Acquistion|"Participants will follow a standardized protocol during a 15-minute seated session using the Peerbridge COR™ device. Participants will sit comfortably in an upright chair with a straight back; armrests are optional. Their feet must remain flat on the floor with legs uncrossed to ensure unobstructed blood flow and a stable posture. Arms should be relaxed and placed in their lap, on a flat surface (e.g., table), or on the armrest, ensuring they are not tensed or elevated. Participants will maintain a straight back with relaxed shoulders throughout the session.~To begin, participants will press the Event Button on the Peerbridge COR™ mobile device, marking the start of the session. They will remain seated in this position for 15 minutes. At the end of the session, participants will press the Event Button again to mark the conclusion of the seated event. This protocol ensures consistent data collection across all participants."
223919776|NCT06699654|OTHER|Placebo gel|A gel without active Spirulina components applied as a control intervention.
223919777|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Gel|A conventional Spirulina gel formulation applied as a periodontal therapy.
223919778|NCT06699654|DIETARY_SUPPLEMENT|Spirulina Nanoparticles Gel|A novel Spirulina nanoparticles gel formulation applied as a periodontal therapy.
223919779|NCT06699940|DEVICE|Transcranial Magnetic Stimulation|Patients between the age of 12-21 received TMS treatment for MDD disorder.
223919780|NCT06867614|PROCEDURE|Total laparoscopic hysterectomy|Removal of uterus and cervix by laparoscope
223919781|NCT06504043|DRUG|HST101|HST101 is a novel anti-PCSK9 fusion protein
223919782|NCT06194227|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive in-person high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
223919783|NCT06194227|BEHAVIORAL|Traditional Yoga|Participants will perform in-person controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
223919784|NCT04274361|DRUG|Ketamine|Ketamine infusion
223919785|NCT04274361|DRUG|Placebo|Placebo infusion
223919786|NCT05399381|DEVICE|Transcranial alternating current stimulation (tACS)|Non-invasive, multi-electrode transcranial alternating current stimulation (tACS) over frontal and parietal brain areas.
223919787|NCT01159782|OTHER|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
223919788|NCT03250676|DRUG|H3B-6545|Oral capsules by mouth once daily
223919789|NCT06880120|DEVICE|Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing|This intervention involves the use of Seismocardiography (SCG) and Gyrocardiography (GCG) Diagnostic Testing, a non-invasive technique that records mechanical vibrations of the chest caused by heart activity using high-precision accelerometers and gyroscopes. Unlike traditional imaging techniques such as coronary artery calcium computed tomography (CAC-CT), coronary computed tomography angiography (CCTA), and invasive coronary angiography (ICA), this method does not require radiation exposure (unlike CAC-CT and CCTA), is completely non-invasive and does not require contrast agents (unlike ICA), and provides real-time cardiac mechanical activity measurements rather than anatomical imaging.
223919790|NCT00733122|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
223919791|NCT06880380|BIOLOGICAL|HIV-CAR-T|Intravenous Infusion of CAR-T Cells
223919792|NCT06879366|DRUG|Aloe vera gel|10% aloe-vera gel will be prepared under well-controlled laboratory checks
223919793|NCT06879366|DRUG|Benzydamine Hydrochloride 0.15% Oral gel|Benzydamine Hydrochloride 0.15% Oral gel
223919794|NCT06880224|BEHAVIORAL|Testing Peer navigation|Peer navigators will promote HIV testing in YMSM and linkage to care if HIV-positive
223919795|NCT06880224|BEHAVIORAL|PrEP Intervention|Motivational-interviewing to promote uptake of PrEP among those who test HIV-negative
223919796|NCT06880224|BEHAVIORAL|Treatment Peer Navigation|Peer navigators will provide assistance and support to youth with HIV to optimize adherence to ART
223919797|NCT06880224|BEHAVIORAL|Social Media Outreach|Social media outreach to identify youth at risk for HIV
223919798|NCT06880224|BEHAVIORAL|SMS Test messaging|Text (SMS) messages to remind and encourage youth to adhere to their ART
223919799|NCT06880224|OTHER|Adherence standard of care|Standard of care HIV treatment adherence
223919800|NCT06879496|DRUG|Oral ketamin|Patients will be received oral ketamine before operation
223919801|NCT06879496|DRUG|Oral Midazolam|Patients will be received oral Midazolam
224099408|NCT00927485|OTHER|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
224099409|NCT00927485|OTHER|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
223919802|NCT06879496|DRUG|Oral dexmedetomidine|Patients will be received oral dexmedetomidine
223919803|NCT06877325|BEHAVIORAL|PFMT|The training is divided into three phases. The first phase is the foundation phase (Weeks 1-4), which primarily activates the pelvic floor muscles. Strengthening Phase (Weeks 5-8): Builds muscular endurance and control by increasing contraction duration. Consolidation Phase (Weeks 9-12): Enhances overall stability and strength through functional movements.
223919804|NCT06877325|BEHAVIORAL|QGPFMT|The training is divided into three phases: Foundation Phase (Weeks 1-4): Focuses on breath regulation and activation to promote energy flow and awaken the pelvic floor muscles. Strengthening Phase (Weeks 5-8): Combines core stability training to enhance muscle strength and flexibility. Consolidation Phase (Weeks 9-12): This phase strengthens core control while incorporating standing meditation and breathing exercises to harmonize body and mind, improving overall stability and endurance.
223919805|NCT06877325|BEHAVIORAL|Qigong|"The training is divided into three phases. The first phase (Weeks 1-4) focuses on breathing regulation and relaxation to enhance blood circulation and promote body recovery. Strengthening Phase (Weeks 5-8): Utilizes Dao Yin techniques to improve flexibility and stimulate energy flow. Consolidation Phase (Weeks 9-12): Emphasizes overall enhancement and core strengthening and incorporates extended deep breathing meditation to harmonize body and mind."
223919806|NCT06876831|OTHER|Shared decision making for LDCT (3 potential outcomes LDCT on discharge, scheduled date of LDCT, or Lung Cancer Screening referral)|These interventions will be facilitated as an inpatient
223919807|NCT06876831|BEHAVIORAL|Inpatient Tobacco Cessation Counseling (Handouts, NYC Quits number, Medication Recommendations to primary team, Smoking cessation referral)|Active smokers only will received inpatient tobacco cessation counseling/risk reduction
223919808|NCT06878599|COMBINATION_PRODUCT|Hyaluronic Acid (HA)|Adding Hyaluronic acid to dexamethasone as intratympanic injection
223719565|NCT04309539|PROCEDURE|combined LFCN block with PENG block|With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
223919809|NCT06878599|DRUG|Dexamethasone|Intratympanic injection of Dexamethasone
223919810|NCT06875999|BEHAVIORAL|animal assisted therapy|The Children's Emotional Indicator Scale (Facial expression, Vocalization, Activity, Interaction and Cooperation Level) will be used to provide a simple, objective and consistent method to determine children's emotional behavior during stressful medical procedures. The FLACC scale will be used for pain. In addition, all physiological parameters including pulse rate, saturation value and respiration will be measured and recorded with a pulse oximeter device. Animal assisted therapy will be applied to the participants in the study group to reduce the stress of the children. In animal-assisted therapy, the child will be shown a fish in a glass bowl and a red fish song will accompany the process. In the study, participant children will be randomly assigned to intervention and control groups.
223919811|NCT06878105|OTHER|Data collection on interventions performs as per medical routine|No intervention other than routine medical practice
223919812|NCT06876987|OTHER|Routine care|Receiving routine care.
223919813|NCT06876987|OTHER|Retraining Program|Retraining program using a mobile-based training system.
223919814|NCT06879925|BEHAVIORAL|QI-GONG and control|QIGONG
223919815|NCT06877000|OTHER|VITIQOL questionnaire|16 questions questionnaire measure effect of vitiligo on quality of life
223919816|NCT05630014|BEHAVIORAL|Aliviado DSD Caregiving Mastery Program|Family caregiver intervention consisting of mHealth-app based educational videos and articles; caregiver-administered assessment tools and care plans; and motivational push notification reminders and encouragements.
223919817|NCT06708663|DRUG|HX009+IN10018|"The 7.5 mg/kg dose group will first enroll 3 to 6 subjects, and if the 7.5 mg/kg dose group is tolerable, then 3 to 6 subjects will continue to be enrolled into the 10 mg/kg dose group; if the 7.5 mg/kg dose group is not tolerable, a decision will be made to add a new, lower dose group after discussion between the sponsor and the investigator; in addition, based on the available study data, the sponsor and the investigator will discuss and decide whether to add an unplanned dose group or an exploratory group and decide on the appropriate recommended dose (RP2D) for the Phase IIa study.~IN10018 is fixed dose at 100mg daily."
223919818|NCT06715436|DIETARY_SUPPLEMENT|Mediterranean Diet|The MedDiet will be planned according to the Mediterranean diet pyramid
223919819|NCT06715436|DIETARY_SUPPLEMENT|Ketogenic Diet|Modified Atkins diet with a maximum of 20 g of carbohydrates per day.
223919820|NCT06715436|DIETARY_SUPPLEMENT|Control group|The control group will be asked to continue their dietary and lifestyle habits
223919821|NCT06714071|DIAGNOSTIC_TEST|CRP and Albumin and coagulation profile|CRP and Albumin and coagulation profile
224089927|NCT01516827|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
224089928|NCT02978222|BIOLOGICAL|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
224089929|NCT02978222|DRUG|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
224089930|NCT02034487|OTHER|retrospective data collection|
224089931|NCT03614572|BEHAVIORAL|Group MI|refer to the arm description
224089932|NCT01379625|DRUG|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
224089933|NCT03972072|OTHER|Pre-defined MR-linac based IGRT and plan adaptation protocol|daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
223919822|NCT06712992|DEVICE|Trans-spinal Direct Current Stimulation|Physiomed- IONOSON-Expert, Germany will be used to deliver SHAM direct current, The Physiomed- IONOSON-Expert, Germany is Two-channel electrotherapy including 21 currents, including direct current. The tsDCS electrodes will be rectangular pieces of saline-soaked synthetic sponge (7 × 8 cm, 56 cm2), to minimize chemical reactions at the electrode-skin interface. The anode will be placed over the spinous process of the eighth thoracic vertebra (T8) and the cathode will be placed on the second lumbar vertebra (L2) according to a modeling study which demonstrated that this configuration had a relevant impact on the distribution of the induced electric field (EF) in the lumbosacral spinal cord for the efficacy of tsDCS.
223919823|NCT06712992|OTHER|Conventional Exercises|"1. Isometric exercises of spine~   * Hollowing in abdominals.~  * Isometric for back extensors.~2. Bridging exercises.~3. Graded active flexion exercises of spine~4. Graded active extension exercises of spine"
223919824|NCT06712992|DRUG|SHAM Trans-spinal Direct current stimulation|"For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions.~These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs ."
223919825|NCT06881160|DIAGNOSTIC_TEST|mi-RNA analysis|To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.
223919826|NCT06882122|DRUG|Atogepant 60 mg|Atogepant 60 mg daily for 3 months
223919827|NCT06881212|BEHAVIORAL|THERAPEUTIC APPROACH TRAINING|"This study focuses on pre- and post-operative training for open-heart surgery patients, aiming to reduce anxiety, agitation, and discomfort during intubation and recovery.~In the meeting phase, the nurse introduces herself, explains the research, and obtains written/verbal consent. The patient's anxiety level is assessed.~In the study phase, patients are informed about the surgical process, breathing exercises, Intensive Care Unit conditions, and postoperative care. They are encouraged to express fears and concerns to improve psychological preparedness.~Key topics include:~Fasting before surgery Breathing exercises to ease extubation Use of mechanical ventilation Intensive Care Unit environment \& pain management Early mobilization \& recovery timeline Patients receive guidance on their role in recovery, ensuring better adaptation and reduced distress post-surgery."
224089934|NCT03972072|DIAGNOSTIC_TEST|salivary flow measurements|baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
224089935|NCT01614964|DRUG|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
224089936|NCT01614964|DRUG|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
224089937|NCT00541983|DRUG|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
224089938|NCT00541983|DRUG|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
224089939|NCT00888238|DRUG|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
224089940|NCT00888238|DRUG|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
224089941|NCT05673538|DRUG|TT-00973-MS tablets treatment|The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
224089942|NCT01755832|PROCEDURE|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
224089943|NCT00331435|PROCEDURE|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
224089944|NCT04600167|DRUG|Isoniazid and Rifapentine (INH-RPT)|Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
224089945|NCT04600167|DRUG|Placebo|Participants in the control group will receive placebo once weekly for 12 weeks
224089946|NCT00061256|DRUG|Alendronate|
224089947|NCT00061256|DRUG|Calcium carbonate|
224089948|NCT00061256|DRUG|Vitamin D|
224089949|NCT06301360|BEHAVIORAL|Internet based Emotional Awareness and Expression Therapy (I-EAET)|"In I-EAET with therapist support, the therapist and participants communicate asynchronous using written messages. The therapist gives feedback each week on home-work assignments and is available on demand for support.~In I-EAET without therapist support, the participants works with home-work assignments on their own and only have technical support."
224089950|NCT04673058|PROCEDURE|Spinal Manipulation|Intervention will be administered twice a week for 3 weeks. Each treatment session will be given in 20-minute sessions consisting of 10 minutes of manual examination and 10 minutes of manual treatment.
224089951|NCT04673058|PROCEDURE|Sham Manipulation|The practitioner will primarily identify the areas where somatic dysfunction is detected and keep the application away from these areas. The patient will be positioned for treatment as in active therapy, but once in the lock position, a lower thrust will be given by releasing some back from the position.
224089952|NCT03254173|DRUG|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
224089953|NCT03254173|DRUG|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
224089954|NCT03482869|DIAGNOSTIC_TEST|walking ability|Included patients will perform a 6 min walk test
223530437|NCT05456139|BEHAVIORAL|Early Social Interaction Mobile Coaching (ESI-MC)|The ESI-MC coach will offer 24 weekly sessions for the 6-month ESI-MC condition. The parent will be the focus of training. Each session includes: setting the stage to develop that session's agenda; intervention implementation with these coaching steps: a) review the target, b) use guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to support caregiver reflection and independence in the activity, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and summarize plans for deliberate practice between sessions. Families will be invited to participate in the online Autism Navigator How-To Guide, a self-guided online course and companion to the online group education meetings to engage families in the content of the online course and provide support through interaction with other families. Families will also participate in TAU usual care and EI services in their community.
223919828|NCT06881095|PROCEDURE|socket shield technique group (study group)|"immediate implant installation with socket shield technique: After administration of local anesthesia, the root will be sectioned in a mesio-distal direction along its long axis, sectioning divided the tooth root into one facial third and two palatal thirds.~Periotomes will then be inserted between the palatal root section and the alveolar socket wall to sever the PDL and this section of root was then carefully delivered so as not to disturb the facial root section, the remaining root section was then reduced coronally to 1 mm above the alveolar crest.~The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants, and the root section was checked for immobility with a sharp probe.~After completion of the previous steps, the tooth root here will be known as the socket- shield (SS). An osteotomy was then sequentially prepared according to manufacturer"
223919829|NCT06881095|PROCEDURE|conventional immediate implant without socket shield technique|• After administration of local anesthesia, atraumatic tooth extraction by extraction forceps and Periotomes, an osteotomy was then sequentially prepared according to manufacturer instructions and a suitable implant then inserted and placement of cover screw. However, the soft tissue contour formed after healing may need some modification prior to impression taking. Suturing around the healing abutment, suture will be removed one week post surgically and then healing abutment and final prosthetic loading will be done after 4-6 months.
223919830|NCT06881628|DRUG|Tranexamic Acid and vitamin K|"Tranxemic acid (1 g loading dose followed by 3 g maintenance dose over 24- 48 hours) and intravenous injection (10 mg daily of vitamin K for 24-48 h) along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."
223919831|NCT06881628|DRUG|Placebo|"Intravenous saline over 24-48 hours along with initial management of airway management, hemodynamic stabilization, octreotide analogue, PPI, antibiotics, and endoscopy to control UGIB in cirrhotic patients.~Patients will be followed up after 5 days and 6 weeks to assess the rate of rebleeding, need for blood transfusion, hospital stay, adverse effects, and mortality rate."
223919832|NCT06881485|OTHER|Very Low Calorie Diet|This is a parallel multicentric longitudinal randomized controlled trial in which prospective data will be collected from the electronic health record. The inclusion and exclusion criteria will be checked and afterwards patients will be randomized to (unblinded) medication only or combination with VLCKD. Both arms include NB and lifestyle changes for 26 weeks but the patients belonging to the experimental arm must follow a VLCKD in the first 10 weeks on top of it. Like the other arm, the remaining 16 weeks will consist of NB combined with lifestyle interventions. Afterwards there is a follow-up extension of 26 weeks.
223919833|NCT06879769|OTHER|Metoprolol I.V.|The participant will receive intravenous Metoprolol (up to 15 mg) during the CT examination, administered directly at the CT table prior to CCTA.
223919834|NCT06879769|OTHER|Metoprolol I.V. and 1 hour waiting.|The Participant will rest in the waiting room for 1h and then receive intravenous Metoprolol, up to 15 mg.
223919835|NCT06879769|OTHER|Music Intervention, Seloken (Recordati) orally and Metoprolol I.V.|The participant will receive Seloken (Metoprolol) according to clinical routine (up to 100 mg) and Metoprolol I.V. (up to 15 mg). The participant will also receive noise-canceling headphones and an iPad (or their own device) to select calming music and listen to it one hour before and during the CT scan.
224089955|NCT01032629|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily
224089956|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
224089957|NCT01032629|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
224089958|NCT02236689|PROCEDURE|Non operative|no surgical intervention
224089959|NCT02236689|PROCEDURE|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
224089960|NCT04751721|BIOLOGICAL|CoronoVac Vaccine|CoronaVac vaccines will be inoculated in 2 doses with an interval of 24 days.
224099410|NCT03607227|DRUG|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
224099411|NCT03607227|DRUG|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
224099412|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
224099413|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: hesperidin|2 capsules hesperidin
224099414|NCT03734510|DIETARY_SUPPLEMENT|Dietary Supplement: flaxseed|30 g flaxseed
224099415|NCT03734510|OTHER|control|no supplementation
224099416|NCT04619576|BEHAVIORAL|Occupational health workers|Questionnaire online
223530438|NCT02254863|BIOLOGICAL|DUOC-01|Intrathecal administration of DUOC-01
223719566|NCT06506383|OTHER|No Intervention as this is an ecological study|No Intervention as this is an ecological study
223719567|NCT06652334|PROCEDURE|Spinal anesthesia|20 patients undergoing spinal anesthesia
223530441|NCT06295809|BIOLOGICAL|Pembrolizumab|IV Infusion
223530442|NCT06295809|BIOLOGICAL|Intismeran autogene|IM injection
223719568|NCT06652334|PROCEDURE|Erector spinae plane block|20 patients undergoing erector spinae plane block
223919836|NCT06878781|OTHER|High carbohydrate challenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 479.6 kcal; Carbohydrate, 83.6%; Lipids, 12.4%, and Protein, 4.0% (70 g of hot cake, 100 g of mango, 270 ml of peach nectar, and 40 g of strawberry jam). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
223530443|NCT06295809|PROCEDURE|Surgery|Local resection of cancerous lesions of the skin
223919837|NCT06878781|OTHER|High lipid challenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 1043.4 kcal; Carbohydrate, 4.9%; Lipids, 86.8%, and Protein, 8.3% (60 g of manchego cheese, 25 g of egg, white, dried, 24 g of bacon, 5 ml of oil, 65 g of cream cheese, 70 g of cream, and 16 g of poblano pepper). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
223919838|NCT06878781|OTHER|High proteinchallenge|Capillary blood samples will be obtained in the morning after an overnight 8-hour fasting; then, an indirect fasting calorimetry will be performed. After the indirect calorimetry, the metabolic and hormonal response to the test meal is performed. The nutritional composition of the standardized meal is shown below. Energy, 441.3 kcal; Carbohydrate, 1.6%; Lipids, 5.1%, and Protein, 93.3% (2 scoop Isopure Zero Carb, 180 g of chicken breast, 20 g of lettuce and 24 g of ham turkey breast). The food challenge should be consumed within 15 minutes. After 5 minutes of rest, indirect calorimetry will be postprandially, lasting 30 minutes. Capillary blood shall be obtained at the following times: 15-30-45-60-90 and 120 min after ingestion of food.
223919839|NCT06880718|DRUG|Brixadi (Injectable Buprenorphine)|Brixadi comes in several doses and can be administered on a weekly or monthly basis. For clinical reasons (i.e., each patient will already be on a stable dose of MOUD in a setting without significant illicit opioid use), the monthly injection will be used. The approximately equivalent to the 300mg Sublocade dose is 96mg of Brixadi. The maximum dose is 128mg. Brixadi can be administered in the abdomen, buttocks, or triceps. Participants in the Brixadi treatment arm will be given one or more Brixadi injections each month prior to release from prison and each month after release. They can continue to receive the medication after the conclusion of the trial. Brixadi is covered by most Medicaid health insurances in the state of Rhode Island.
223919840|NCT06880718|DRUG|Sublocade|Sublocade is a 100mg or 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. Participants in the Sublocade treatment arm will be given monthly Sublocade injections, as clinically indicated, each month prior to release from prison and each month after release. They can continue to receive the medication after the conclusion of the trial. Sublocade is covered by most Medicaid health insurances in the state of Rhode Island. The standard dosing schedule is two months of 300mg followed by monthly 100mg injections. To maximize real-world generalizability, the medication dosing will be determined by clinical indication of the provider who will have the flexibility to provide medication dosing based on their clinical acumen and/or shared decision-making.
223919841|NCT06881199|OTHER|Complete denture with a metallic Co-Cr casted palate|Complete denture with a metallic Co-Cr casted palatal material
223919842|NCT06881199|OTHER|Complete denture with an acrylic palate|Complete denture with an acrylic palatal material
223919843|NCT06881706|OTHER|medical nutrition therapy|Medical nutrition treatment was planned for all participants with metabolic syndrome. A diet plan was created considering age, gender, blood findings and nutritional habits. Individuals with MetS were given a weight loss diet planned at the basal energy level calculated with the Harris-Benedict equation and applied for 8 weeks. Individuals who applied the weight loss diet were targeted to lose at least 5% of their initial weight at the end of 8 weeks. Individuals who strictly followed the given medical nutrition treatment and achieved the targeted weight loss formed the intervention group, and individuals who did not follow the medical nutrition treatment formed the control group. At the end of the 8 weeks, all parameters, blood pressure and anthropometric measurements of all individuals who participated in the study and retrospective 24-hour food consumption records were recorded again and the study was concluded.
223919844|NCT06880913|BIOLOGICAL|Nanobody-Based CD19/CD22 Tandem Dual CAR-T|"Phase I: Patients will receive a single infusion of autologous CD19/CD22 dual CAR-T cells at one of three dose levels (0.3 × 10⁶ cells/kg, 1.0 × 10⁶ cells/kg, or 2.0 × 10⁶ cells/kg) following fludarabine (25-30mg/m2\*3d) and cyclophosphamide (250-300mg/m2\*3d) (FC) lymphodepleting chemotherapy.~Phase II: Patients will receive autologous CD19/CD22 dual CAR-T cells at the RP2D following FC lymphodepleting chemotherapy."
223919845|NCT06876090|DIAGNOSTIC_TEST|Sarcopenia tests (for muscle mass, muscle function, physical performance)|We are not aware of any other study performing sarcopenia tests in GDM (or in pregnancy in general), with the aim of assessing sarcopenia prevalence in GDM/pregnancy, and related possible adverse pregnancy outcomes.
223919846|NCT06876090|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The OGTT, in combination with the sarcopenia tests, will allow to explore the relationships between the glucometabolic condition and the muscle quality in the pregnant women, either with GDM or with normal glucose tolerance.
223919847|NCT06876090|OTHER|Montreal Cognitive Assessment|The MoCA questionnaire, in combination with the sarcopenia tests, will allow to explore the relationships between the cognitive function the presence of the sarcopenia syndrome in the pregnant women, either with GDM or with normal glucose tolerance.
223919848|NCT06715540|DRUG|BCD-261, dose 1|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
223919849|NCT06715540|DRUG|BCD-261, dose 2|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
223530444|NCT05723640|DRUG|177Lu-LNC1004 Injection group 1 radionuclide therapy|The treatment regimen will consist of a single dose 30mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
223530445|NCT05723640|DRUG|177Lu-LNC1004 Injection group 2 radionuclide therapy|The treatment regimen will consist of a single dose 60mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
223919850|NCT06715540|DRUG|BCD-261, dose 3|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
224278796|NCT03267927|DEVICE|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
223919851|NCT06715540|DRUG|BCD-261, dose 4|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
223919852|NCT06715540|DRUG|BCD-261, dose 5|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
223919853|NCT06715540|DRUG|BCD-261, dose 6|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
223919854|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials
224089961|NCT04378777|PROCEDURE|Biological sample collection|During patient hospitalization: Nasal secretion samples by nasal swabs (for non-intubated patients), whole blood (blood draw/phlebotomy) and sputum secretions by endotracheal aspiration (for intubated patients) will be obtained to proceed with immunologic analysis of samples. DNA will be collected from whole blood at enrollment for genetic analysis (e.g., genome-wide association study \[GWAS\]). After hospital discharge: Collection of biologic samples (involving nasal swabs and blood draw/phlebotomy) will occur up to 12 months.
224089962|NCT04378777|PROCEDURE|Data Collection: Clinical Care Assessments|Baseline data and assessments obtained as part of ongoing clinical care will be collected throughout hospitalization for COVID-19. After hospital discharge, clinical status and activity assessments will occur up to 12 months.
224089963|NCT06185855|OTHER|Retrospective Ultrasonographic Data Analysis|The intervention involves a detailed retrospective analysis of ultrasonographic data from patients who underwent breast lesion surgery. The study focuses on developing a quantitative nomogram model, which integrates patient age and significant sonographic characteristics of breast lesions. The purpose is to differentiate breast lesions and assess their malignancy in a non-invasive, accurate manner. This analysis uses data collected from January 2020 to June 2023, including clinical and ultrasound examination records from patients who met the inclusion criteria. The intervention does not involve any direct patient interaction or new diagnostic procedures.
223919855|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose X|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
224099417|NCT04109040|DEVICE|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
224099418|NCT05531240|PROCEDURE|Prostate Artery Embolization|Prostate Artery Embolization (PAE) is performed by experienced interventional radiologists. The method involves catheterization of the prostate vessels superselectively with two to three French microcatheters. PAE is performed with microspheres of 250 to 400 µm in size.
224099419|NCT05531240|PROCEDURE|Transurethral Prostate Resection (TURP)|Under general/regional anesthesia, a resectoscope is inserted into the urethra that carries an electric metal loop (monopolar or bipolar diathermy) that is used to cut and extract the prostate tissue.
224278797|NCT03267927|DEVICE|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
224278798|NCT00089427|DRUG|IL13-PE38QQR|
223919856|NCT06715540|DRUG|BCD-261, pre-specified therapeautic dose Y|Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes
223919857|NCT06705790|BEHAVIORAL|Pelvic Floor Muscle Training|Pelvic floor muscle training 5x/week for 12-weeks
224278799|NCT00089427|PROCEDURE|Surgery for placement|
224278800|NCT00089427|PROCEDURE|Radiation therapy|
224278801|NCT00089427|DRUG|Temozolomide with radiation therapy|
224278802|NCT05222360|OTHER|Education|3 educational sessions about body image and nutrition
224278803|NCT00051831|DRUG|Emtricitabine|Will be administered as one 200-mg capsule orally daily
224278804|NCT00051831|DRUG|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
224278805|NCT00051831|DRUG|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
224278806|NCT00051831|DRUG|Saquinavir|Will be administered as five hard gel capsules orally twice daily
224278807|NCT00051831|DRUG|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
224278808|NCT00052520|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
223919858|NCT06704919|DEVICE|Use of conduit cages and fibergraft BG Putty|Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
223919859|NCT06705088|DRUG|SUVN-I6107|SUVN-I6107 Tablet
223919860|NCT06705088|DRUG|Placebo|A look-alike tablet with no active ingredient.
223919861|NCT06705907|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|Intervention targeting academic executive functioning
223919862|NCT06705907|BEHAVIORAL|Building Essential Social Skills for Teens (BESST)|Intervention targeting social skills
224099420|NCT01948752|OTHER|Nutrition information on menus|
224099421|NCT01874483|DRUG|Placebo|placebo
224099422|NCT01874483|DRUG|BI 187004|BI 187004, dose 2
224099423|NCT01874483|DRUG|BI 187004|BI 187004, dose 4
224099424|NCT01874483|DRUG|BI 187004|BI 187004, dose 5
224099425|NCT01874483|DRUG|BI 187004|BI 187004, dose 6
224099426|NCT01874483|DRUG|BI 187004|BI 187004, dose 7
224099427|NCT01874483|DRUG|BI 187004|BI 187004, dose 1
224099428|NCT01874483|DRUG|BI 187004|BI 187004, dose 3
224099429|NCT03885297|DRUG|Saxenda|Obesity pharmacotherapy
224099430|NCT03885297|OTHER|Lifestyle modification|Tier 3 NHS weight management
224099431|NCT03885297|DIAGNOSTIC_TEST|Metabolomics|Small molecule intermediates and products of metabolism
224099432|NCT03885297|DIAGNOSTIC_TEST|miRNA|Small non-coding RNA molecules
224099433|NCT04304677|DEVICE|Percutaneous coronary intervention|"1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES"
224099434|NCT02534337|DRUG|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
223919863|NCT06714344|DEVICE|KITGuideMe: W61-MD41-AIT, version 1.0.0|"We are planning to conduct a prospective, 1:1 randomized study within the HM program.~Randomization occurs at the level of network physicians. Network physicians participating in the study are randomly assigned to either the AMPEL group (access to the module) or the non-AMPEL group (no access to the module) using a permuted block randomization scheme to ensure that there are the same number of patients in each study arm. Logical checks within the module ensure that once a network physician is assigned to an arm, he or she remains in that arm for the remainder of the stud"
223919864|NCT06719856|DRUG|18-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
223919865|NCT06883331|PROCEDURE|intermaxillary fixation using IMF screws|"IMF screws will be placed at the junction of the attached and alveolar mucosa, after verifying the root position on the orthopantomogram (OPG) radiograph. One screw in each quadrant was sufficient; all IMF screws will be placed with the patient under local anesthesia or general anesthesia . Cortical perforation with a 1.5-mm drill bit under copious irrigation will be performed or by self-drilling IMF screws and the IMF screws will be tightened on the drilled hole.~After IMFS placement, intraoperative IMF will be achieved by passing round, stainless steel wires through the screw head to achieve satisfactory occlusion."
224089964|NCT06249750|DRUG|Immunotherapy|Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
224089965|NCT06249750|DRUG|Targeted therapy|Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
224089966|NCT06249750|DEVICE|Hyperthermia|"Thermal stimulation is a rapidly developing physiotherapeutic tool, which is playing an increasingly important role in the field of comprehensive tumor therapy due to its unique low adverse effects and high compatibility. A large number of clinical studies have shown that the addition of heat stress to multimodal tumor therapy does not significantly increase toxicity and side effects, and the combination of heat stress with other therapies can have the effect of 1+1\>2. ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h."
224089967|NCT05527002|OTHER|Satisfaction of patients after medical and surgical treatment for thoracic endometriosis|"It is a retrospectively evaluation of cases of thoracic endometriosis in our clinic over the last 20 years, based on the review of medical records and on outpatient follow-up visits.~The questionnaire are filled in routinely by patients attending the endometriosis center of this institute every 6 months. We will collect data relating to these questionnaires referring prospectively to the study period.~If the questionnaires have not already been filled in by the patient, she will be contacted to fill them in, after signing the informed consent of the study."
224089968|NCT00661583|DRUG|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
224089969|NCT00661583|DRUG|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
224089970|NCT00661583|DRUG|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
224089971|NCT04814979|DEVICE|Low-intensity pulsed ultrasound (LIPUS)|Low-intensity pulsed ultrasound (LIPUS) consists of frequencies usually ranging from 0.75- 1.5 MHz at intensities \<100mW/cm² (usually about 30mW/cm²) and usually pulsed at 1:4. The transducer head is strapped or otherwise held in place and remains stationary for treatment periods in the region of 20 minutes. Again, US medium is used for efficient sound transfer to deeper tissues. This modality was approved by the FDA in the United States in 1994 for the accelerated healing of fresh fractures and then approved by the same body in 2000 for the treatment of established non-union fractures. The studies presented to the FDA demonstrated that LIPUS had a positive effect during all three main stages of fracture healing, i.e. inflammatory, reparative and remodelling by enhancing angiogenesis, chondrogenesis and osteogenesis.
224278809|NCT00052520|BIOLOGICAL|aldesleukin|Given SC
224278810|NCT00052520|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
224278811|NCT00052520|PROCEDURE|allogeneic bone marrow transplantation|Undergo transplantation
224278812|NCT00052520|OTHER|laboratory biomarker analysis|Correlative studies
224278813|NCT00052520|GENETIC|gene expression analysis|Correlative studies
224278814|NCT00052520|OTHER|immunologic technique|Correlative studies
224278815|NCT00052520|OTHER|flow cytometry|Correlative studies
224278816|NCT00052520|GENETIC|polymerase chain reaction|Correlative studies
224278817|NCT00052520|GENETIC|cytogenetic analysis|Correlative studies
224278818|NCT00052520|OTHER|staining method|Correlative studies
224278819|NCT02464241|OTHER|only examination|
224278820|NCT03211455|DRUG|Lidocaine|intravenous lidocaine versus placebo
224089972|NCT04814979|OTHER|Routine physical therapy|"Gentle hamstrings stretching for 15 seconds 3 times a day. Flexibility of these muscle reduces stress to the lumbar region thus enhances the spino-pelvic rhythm (lumbar motion/pelvic motion). Strengthening of abdominal muscles (transversus abdominis and internal oblique). Training of these stability muscles in the lumbar spine provides a solid foundation for the individuals to integrate them into their functional movement patterns. Exercises focusing on these muscles have been shown to significantly decrease pain and disability in people with spondylolysis. Each exercise will be performed as 3 sets of 10 repetitions on alternate days."
224089973|NCT01392833|DRUG|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
224089974|NCT01392833|DRUG|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
224089975|NCT01392833|DRUG|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
224089976|NCT05116657|DIAGNOSTIC_TEST|Nasal Lavage and Oral Wash|"* Nasal Lavage: The nasal lavage will be performed using a spray technique. Using a disposable metered-dose inhaler (100 µl per spray), room temperature saline will be sprayed in one nostril while the other nostril is closed. After 5 sprays, the subject will gently exhale through the lavaged nostril and the fluid will be collected in a specimen cup. The procedure will be repeated a minimum of 8 times and a maximum of 15 times in each nostril. After collection, the sample will be placed on ice and processed within 2 hours.~* Oral Rinse: Oral samples will be collected using a standardized procedure in accordance with the Manual of Procedures for Human Microbiome Project.Study participants will rinse their mouth (swish/gargle) with 15 mL sterile normal saline for 1 min, and will expectorate the contents of the mouth into a 50 mL centrifuge tube. Sample should be kept cold on ice until processing."
224089977|NCT02216565|OTHER|Hospitalization in specialized neuro-vascular unit|
224089978|NCT02216565|DRUG|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
224089979|NCT02216565|OTHER|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
224089980|NCT02216565|PROCEDURE|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
224089981|NCT05411302|OTHER|Mental health supportive text messages|Text4Support program was developed based on knowledge from randomized controlled trials conducted in Ireland and Alberta and from evaluations of the Text4Mood program. The diagnostic-specific approach is based on an analysis of service data, which suggested that diagnostic clusters for individuals accessing mental health services into 6 categories: mood disorders, anxiety disorders, schizophrenia and other psychotic disorders, substance use disorders, adjustment disorders and personality disorders. Thus, text message content will focus on 2 dimensions. General range includes messages of self-care, social support, hope, affirmation, and recovery. Specific content will focus on managing symptoms related to the conditions described above. As a component of scalability and inclusiveness, text message content can also be customized based on end-user characteristics. We will explore content that is sensitive to needs based on age group, cultural identity and gender identity.
224089982|NCT04629560|DRUG|Miracle Fruit|one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
224089983|NCT03751111|DRUG|Naloxone|Naloxone at an sublingual dose of 0.4 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
224089984|NCT03751111|DRUG|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
224089985|NCT00899652|GENETIC|Southern blotting|
224089986|NCT00899652|GENETIC|chromosomal translocation analysis|
224089987|NCT00899652|GENETIC|cytogenetic analysis|
224089988|NCT00899652|GENETIC|gene rearrangement analysis|
224089989|NCT00899652|GENETIC|mutation analysis|
224089990|NCT00854646|DRUG|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
224089991|NCT03393026|DRUG|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
224278821|NCT03211455|DRUG|isotonic saline|intravenous isotonic saline
224278822|NCT06028646|DEVICE|Dynamic Airway CT scan (DA-CT)|Patient will be asked to perform movements during the scan.
224278823|NCT00311649|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|
224278824|NCT06048887|DRUG|CRN04894 Oral Solution|CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
224278825|NCT06048887|DRUG|Placebo Oral Solution|Placebo
224278826|NCT01720849|DRUG|Fampyra|The will be given as per normal patient treatment plan
224278827|NCT03222037|DEVICE|senofilcon A|Acuvue Oasys 1-Day
224278828|NCT03222037|DEVICE|Control|Trial Frame with best spherocylindrical refraction (SCR)
223530446|NCT05723640|DRUG|177Lu-LNC1004 Injection group 3 radionuclide therapy|The treatment regimen will consist of a single dose 80mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
224278829|NCT04445233|DEVICE|COVID-19 IgM-IgG Rapid Test|Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
223530447|NCT05723640|DRUG|177Lu-LNC1004 Injection group 4 radionuclide therapy|The treatment regimen will consist of a single dose 100mCi intravenous administration of 177Lu-LNC1004 Injection per 6-week cycle, for a total of 2 cycles, the dose per cycle will be fixed.
224278830|NCT05478928|OTHER|Dynamic dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
223919866|NCT06883331|PROCEDURE|intermaxillary fixation using IMF screws with surgical guide|"The patient's CBCT images in DICOM format will be converted into stereolithographic (STL) images using the segmentation software.~The converted CBCT STL images will be integrated to obtain the exact tooth morphology Virtual surgical planning (VSP) will be carried out using software to select the exact position of IMF screws placement away from any vital, anatomical or tooth structure.~these locations will be incorporated into the patients specific IMF surgical guides as access holes to direct the IMF screws drill.~Guide will be constructed with a thickness of 2-3 mm and printed using Photopolymer Resin® (Form labs) in the CAD/CAM 3- dimensional (3D) printer"
224278831|NCT05478928|DEVICE|Fixed dose dynamic MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
224278832|NCT05478928|OTHER|Static Dry needling|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point for 120 seconds.
224278833|NCT05478928|DEVICE|Fixed dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).
224278834|NCT05478928|DEVICE|Algorithm-based dose static MEP|Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. The therapy will be done statically, at 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed. Treatment will finish when the patient does not refer any discomfort for a period longer than 60 seconds. Total dose in mC will be registered.
224278835|NCT05478928|OTHER|Placebo|An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly up to 3 mm deep into the upper trapezius trigger point for 120 seconds.
224278836|NCT06266754|BIOLOGICAL|Oral polio vaccine|Standard oral polio vaccine
223719569|NCT03425877|DEVICE|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
223919867|NCT06883474|OTHER|Osteosclerotic Changes on Computed Tomography|Osteosclerotic Changes on Computed Tomography
223919868|NCT06884891|DRUG|QL2108 injection|300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W);subcutaneous injection
223919869|NCT06884891|DRUG|Dupixent®|300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W); subcutaneous injection
224278837|NCT06266754|OTHER|Placebo|Saline 0.9%
224278838|NCT06678477|DEVICE|3D device|Use 3D machine to generate the 3D image
224278839|NCT00559741|BIOLOGICAL|cetuximab|
224278840|NCT00559741|DRUG|fluorouracil|
224278841|NCT00559741|DRUG|irinotecan hydrochloride|
223919870|NCT06882629|BEHAVIORAL|'Speaking at school, a matter of doing' combined with VR homework exercises|The treatment in this study consists of behavioral therapy for selective mutism (with the protocol 'Speaking at school, a matter of doing') with the addition of the VR homework exercises. The protocol consists of 10 steps that help the child to gain confidence while speaking at school. For every treatment step there are VR homework exercises available. Families receive a VR headset for the duration of the study. Parents are instructed to work on the VR homework exercises at least once a week and encouraged to work on the VR homework exercises several times a week.
223919871|NCT06882304|OTHER|orthodontic treatment|young adult after orthodontic treatment
224278842|NCT00559741|DRUG|leucovorin calcium|
224278843|NCT00559741|OTHER|pharmacological study|
224278844|NCT03743259|DRUG|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
224278845|NCT03743259|DRUG|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
224278846|NCT03743259|DRUG|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3\~1mL once in this study.
224278847|NCT05735158|BIOLOGICAL|KB105|Replication-defective, non-integrating HSV-1 vector expressing TGM1 formulated as a topical gel
224278848|NCT05735158|OTHER|Placebo|Visually matched excipient gel
224278849|NCT01195155|DIETARY_SUPPLEMENT|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
224278850|NCT05397795|DRUG|10000 IU hCG (Choriomon5000 IU; IBSA)|10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
224278851|NCT05397795|DRUG|Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)|GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.
224278852|NCT04546269|PROCEDURE|Fully-guided vs. conventionally guided implant placement|Patients randomized to implant placement planned virtually based on a CBCT and a surface scan vs. implant placement based on a wax-up on gypsum casts
224278853|NCT00496262|BIOLOGICAL|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
224278854|NCT05787392|BEHAVIORAL|Chamas cha MamaToto program|Chamas is a community health volunteer (CHV)-led group programme that engages women during pregnancy and the first 1000 days of their child's life. The strategy focuses on promoting maternal, newborn, and child health (MNCH) by providing health education, peer support, and opportunities to access financial capital, all while addressing inequities that perpetuate poor outcomes.
224278855|NCT03022539|RADIATION|Repeat CT scan|
224278856|NCT05907655|DRUG|Nitroglycerin 0.3 MG|Sublingual nitroglycerin will be used to provoke spontaneous-like migraine attacks in migraine patients. A dose of 0.9 mg of sublingual nitroglycerin will be used. The same dose will be administrated to controls.
224278857|NCT05907655|DIAGNOSTIC_TEST|MRI|The following brain MRI sequences will be acquired before and after nitroglycerin administration: fluid attenuated inversion recovery (FLAIR), 3D T1-weighted inversion recovery prepared gradient echo, diffusion weighted sequence and 3D susceptibility weighted images.
223919872|NCT06883058|BEHAVIORAL|Caregivers-patients support intervention for advanced cancer (CASA)|The Caregivers-Patients Support Intervention for Advanced Cancer (CASA) will be delivered to patients and caregivers. The sessions follow a protocol and will be held weekly or bi-weekly for a total of 5 sessions.
223919873|NCT06883058|BEHAVIORAL|Placebo|Usual care will be provided to participants in the control group. The usual care consists of symptom management once a week and 5 sessions.
223919874|NCT06883266|DEVICE|transcranial direct current stimulation (tDCS)|2 mA will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
223919875|NCT06883266|DEVICE|Sham (No Treatment)|For 30 seconds, the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex
223919876|NCT06883799|OTHER|Without intervention.|Without intervention
223919877|NCT06884787|DRUG|Conventional nanohybrid multishade composite|Teeth will be restored with conventional multi shade nanohybrid Resin Based Composite (RBC) filtek Z350Xt,3M ESPE, San Paul, MN, USA
223919878|NCT06884787|DRUG|Single shade nanohybrid composite|Teeth will be restored with One-shade Resin Based Composite (Omnichroma, Tokuyama Dental, Tokio, Japan)
223919879|NCT06879223|BEHAVIORAL|Oral Health Educational Program|Providing the children with an educational program through a data show presentation when and how to brush their teeth, causes of dental caries and how to prevent its occurrence. A flyer will be distributed including simple language about preventive measure of dental caries and schedule of teeth brushing to ensure retention of information.
223919880|NCT06879990|BEHAVIORAL|Retrograde normal saline irrigation|Retrograde normal saline irrigation during supine Mini percutaneous nephrolithotomy
223919881|NCT06879990|BEHAVIORAL|Without Retrograde normal saline irrigation|Without Retrograde normal saline irrigation during supine Mini percutaneous nephrolithotomy
224089992|NCT05814445|OTHER|Neuromuscular exercise program|Participants will complete a neuromuscular program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and training to improve hip and knee muscles strength, proprioception, and core stability.
224089993|NCT05814445|OTHER|Institutional exercise program|Participants will complete an institutional exercise program during 22 weeks. The program consist of isotonic open and closed kinetic chain exercises for the hip and knee, and concentric and eccentric knee exercises.
224278858|NCT05907655|DIAGNOSTIC_TEST|Blood sampling|Plasma levels of neuropeptides involed in migraine will be measured using commercially available enzyme-linked immune-sorbent assay (ELISA) kits. All ELISA will be performed by the same experienced technician who will be blinded for the clinical diagnosis.
223919882|NCT06882564|DRUG|resveratrol mouthwash|"the participants where instruct to rinse their mouth twice daily with 10 ml of assigned mouthwash for 60 seconds for 7 days. There is currently no published research on the use of resveratrol as a mouthwash for halitosis treatment.~This study aims to fill this gap by evaluating its effectiveness in reducing oral malodor through antibacterial action and the potential of volatile sulfur compounds ( VSCs)"
224278859|NCT05907655|DEVICE|Sleep profiler|Sleep architecture will be investigated using the Sleep Profiler. Sleep Profiler is medical device with CE mark which is produced by Advanced Brain Monitoring and distributed throughout Italy exclusively by Medigas. Sleep staging will be automatically performed for 30-second epochs throughout a dedicated software and a standardized and validated procedure. Frontopolar EEG signal waveforms will be visually inspected to confirm the accuracy of the auto-staging.
224278860|NCT05884255|DRUG|Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide|Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide
224278861|NCT05884255|DRUG|long-acting Octreotide.|High-dose long-acting Octreotide.
224278862|NCT06338423|DEVICE|vacuum mattress|vacuum mattresses used to better positioning of the patient
224278863|NCT06338423|OTHER|Standard Mattress|Standard Mattress
224278864|NCT04389645|DIAGNOSTIC_TEST|IP-10 in CDS protocol|Dynamic IP-10 measurements in hospitalized COVID-19 positive patients
224278865|NCT03547817|DEVICE|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
224278866|NCT04502849|PROCEDURE|Bypass surgery|Creating a bypass with graft or vein.
224278867|NCT04502849|PROCEDURE|Endovascular angioplasty/stenting|Performing an angioplasty with or without stenting in stenosis.
224278868|NCT04502849|PROCEDURE|Hybrid surgery|Performing an angioplasty with or without stenting in stenosis and creating a bypass with graft or vein.
223919883|NCT06882564|DRUG|Chlorhexidine mouthwash (0.2%)|The second group will given chlorhexidine 0.2% mouthwash as an active comparator, and will asked to rinse with 10 ml of undiluted mouthwash for 60 seconds twice per day for 7 days, and will instructed to refrain from eating and drinking for 30 min after rinsing.
223919884|NCT06882564|DRUG|Placebo|the third group will given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 seconds twice daily for 7 days and will be instructed to refrain from eating and drinking for 30 min after rinsing.
223530448|NCT04873362|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
223919885|NCT06881121|PROCEDURE|Fast-track protocol for hip fracture fixation|Fast-track protocol implication on mortality and morbidities in hip fracture fixation
223919886|NCT06882083|PROCEDURE|paravertebral block|A single-dose bilateral paravertebral block will be administered under ultrasound guidance before the induction of general anesthesia. The block will be performed at an appropriate thoracic level using 20 mL of 0.25% bupivacaine as the local anesthetic.
224089994|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
224089995|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
224089996|NCT02765659|BEHAVIORAL|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
223530449|NCT04873362|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
223919887|NCT06884007|BEHAVIORAL|Telepsychiatric Parent Training Program|This study involves a telepsychiatric parent training program for caregivers of children with ADHD. The program includes 9 sessions, each addressing specific topics related to managing ADHD-related behaviors and enhancing parenting strategies. Sessions are primarily delivered through a telepsychiatric platform, such as video conferencing (e.g., Zoom), with additional support provided through text-based communication via platforms like WhatsApp, and, when necessary, follow-up phone calls. The content covers behavior management techniques, stress coping strategies, and skills for managing emotional and behavioral issues in children with ADHD. This intervention is designed to provide accessible, flexible support to caregivers, enhancing their ability to manage their child's condition.
223919888|NCT06884007|OTHER|Routine Treatment|Routine treatment and services (no intervention, participants continue with their usual care)
223919889|NCT03830918|BIOLOGICAL|Atezolizumab|Given IV
223919890|NCT03830918|DRUG|Niraparib|Given PO
223919891|NCT03830918|OTHER|Quality-of-Life Assessment|Ancillary studies
223919892|NCT03830918|OTHER|Questionnaire Administration|Ancillary studies
223919893|NCT03830918|DRUG|Temozolomide|Given PO
223919894|NCT04768777|BEHAVIORAL|Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)|The current behavioral intervention consists of two primary components; an internet website and one-on-one video chats with a behavioral coach. The internet website involves content delivered through interactive video courses.The interactive video courses are based on elements of social cognitive theory. Each course consists of an introduction, the primary content, and a take home message.The interactive courses include embedded, supplementary options such as videos on content and worksheets related to the topic.A pedometer is provided for tracking steps, and these steps will be entered into the website so progress can be monitored. The chats support adherence to the intervention,discussion of website material,supportive accountability,and reporting of adverse events/injuries. The chats are conducted face-to-face through an online videoconferencing platform. There are a total of 12 chats over 16 weeks. Chats occur on weeks 1-8, 10-11, 13 and16.
223919895|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
223919896|NCT06716645|DRUG|Robitussin Maximum Strength Cough and Chest Congestion DM|Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
223919897|NCT06716645|DRUG|Robitussin Maximum Strength Nighttime Cough DM|Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
223919898|NCT06715462|DRUG|N0750|N0750 caps + Cymbalta placebo caps + Lyrica placebo caps
224089997|NCT04095455|PROCEDURE|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
224278869|NCT04502849|DRUG|Vitamin E|100 mg Vitamin E per os 1 per day (1 month).
224278870|NCT04502849|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound of lower limbs arteries.
224278871|NCT04502849|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for apoptosis and endothelial dysfunction markers.
224278872|NCT04502849|DIAGNOSTIC_TEST|Arterial wall sampling|Arterial wall sampling for apoptosis markers.
224278873|NCT06678776|PROCEDURE|surgery|Explore the relationship between breast fascia development and surgical processes by repeatedly observing surgical videos of endoscopic mastectomy and reduction mammaplasty.
223530450|NCT04873362|DRUG|Placebo|Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
223919899|NCT06715462|DRUG|Cymbalta®|Cymbalta® caps + N0750 placebo caps + Lyrica placebo caps
223919900|NCT06715462|DRUG|Lyrica®|Lyrica® caps + N0750 placebo caps + Cymbalta placebo caps
223919901|NCT06719037|PROCEDURE|Endo-Surgi Plus endoscopic surgery|Endo-Surgi Plus endoscopic surgery, as a new type of percutaneous endoscopic lumbar discectomy (PELD), features a larger working channel and represents an optimized single-channel endoscopic technique. However, it still has the limitations inherent in single-channel endoscopy.
224089998|NCT04095455|DRUG|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
223919902|NCT06719037|PROCEDURE|Unilateral biportal endoscopic surgery|Unilateral biportal endoscopic discectomy (UBE) is characterized by its separate endoscopic and working channels, and the ability to use traditional open instruments, making it a convenient and versatile technique. It is a commonly used spinal endoscopic surgery in clinical practice.
224089999|NCT04095455|DRUG|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
224090000|NCT03841552|DEVICE|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
224278874|NCT04674982|DEVICE|a vibrating device|vibrating device (Mini vibrator, 8.5 cm, 92-100 Hz)
224278875|NCT00176930|BIOLOGICAL|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
224278876|NCT00176930|DRUG|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
223919903|NCT06719037|PROCEDURE|Microdiscectomy|Microdiscectomy (MD) is a mature minimally invasive technique that uses a microscope to treat lumbar spinal stenosis. As early as 1999, prospective randomized controlled studies confirmed that it has equally excellent clinical efficacy compared to open surgery, with less surgical trauma. It is currently the classic minimally invasive surgical approach for treating lumbar spinal stenosis.
223919904|NCT06717659|OTHER|probiotic supplementation intervention|probiotic supplementation will be administered, while participants continue undergoing routine pulmonary rehabilitation therapy
223919905|NCT06717659|OTHER|standard pulmonnary rehabilitation|undergo routine pulmonary rehabilitation without probiotics intervention
223919906|NCT06722430|DRUG|Icalcaprant|Oral capsule
223919907|NCT06722430|DRUG|Itraconazole (ITZ)|Oral capsule
223919908|NCT06724705|DIETARY_SUPPLEMENT|Lactose|Participants receive lactose to determine whether it changes gut microbial hydrogen production
223919909|NCT06724705|DIETARY_SUPPLEMENT|Sucrose|Participants will consume sucrose which they will consume as a placebo
223919910|NCT06724705|DEVICE|Wear smart underwear|Participants will wear the smart underwear device to measure the microbiome activity index
223919911|NCT06886971|OTHER|The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access|The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access to that choice through the deployment of the SLAT team. HIV-ASSIST is an interactive tool that offers clinicians comprehensive, individualized validated patient-specific ARV decision support along with evidence-based supporting educational material. The free online, interactive tool is designed to augment interpretation of current HIV clinical practice guidelines (CPG).It will be included in the CHOICE counseling providing participants with patient-centered approach, specifically addresses the patient's expressed needs, problems, issues and concerns with a goal of providing accurate and unbiased information on available choices. After CHOICE counseling, if the participant chooses LAI-ART, the participant is referred to the SAVVY LAI-ART access team (SLAT) to facilitate access.
223919912|NCT06883188|DRUG|talc powder|intrapleural instillation of talc slurry
223919913|NCT06883188|BIOLOGICAL|patient's own venous blood|intrapleural instillation of patient's own venous blood
223919914|NCT06887478|OTHER|Exercise|A progressive resistance exercise program focusing on strengthening the flexor hallucis longus (FHL) muscle in elderly participants.
223919915|NCT06881719|DEVICE|The Adventures of Apollo & Rosetta|"The new APP The Adventures of Apollo and Rosetta consists of 7 exercises (1. Explorer; 2. Deciphering codes; 3. Particle accelerator tunnel; and 4. Leaping asteroids, - 5. Galactic art; 6. Stellar Laboratory; 7. Challenge of opposites).~The training program provides for the application of 36 mini-game sessions lasting 15-20 minutes each (alternating the first 4 and the last 3 games) over 12 weeks (the child must practice 3 times a week).~The training via APP can be administered in the first sessions on an outpatient basis, then it can be delegated to parents who take care of the exercises 3 times a week (20-15-20 minutes). A work diary will be kept monitoring the progress of the activities."
223919916|NCT06882759|OTHER|No intervention (observational study)|This is an observational study. No intervention.
223919917|NCT06879782|DRUG|Drug placebo|Instill one drop of the eye solution in each eye, twice a day (morning and evening, approximately 12 hours apart), for a treatment period of 12 weeks.
223919918|NCT06879951|OTHER|Participants are not assigned an intervention as part of the study.|Participants are not assigned an intervention as part of the study.
223919919|NCT06886438|PROCEDURE|RVS|Revascularization
223919920|NCT06886438|PROCEDURE|L-PRF|Regenerative endodontic procedure with L-PRF application
223919921|NCT06886438|PROCEDURE|i-PRF|Regenerative endodontic procedure with i-PRF application
223919922|NCT06886386|DEVICE|Trans-spinal direct current stimulation|Patients with a neurological level above T10 will receive cervical tsDCS (anode electrode at C7, and the cathode electrode on the right shoulder). Patients with a neurological level from T10 onwards will receive thoracic tsDCS (anode electrode at T10, and the cathode electrode at the iliac crest). (i) Experimental group (active tsDCS): electrical stimulator (Neuroconn/Germany) connected to a pair of saline-soaked sponge electrodes (35 cm²) with a current intensity of 2.5 mA for 20 minutes. (ii) Control group (sham tsDCS) with electrodes positioned at the same locations as active tsDCS, for 30 seconds (the setup will remain for the full 20 minutes). Thus, patients will experience the initial sensations at the stimulated site, without inducing an effect. Physical therapy will be performed during tsDCS (45 minutes), based on scientific evidence, considering patient preferences, and respecting motor learning theory and neuroplasticity principles, focusing on motor function recovery.
224278877|NCT00176930|RADIATION|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
224278878|NCT00176930|DRUG|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
224278879|NCT00176930|DRUG|Equine ATG (ATGAM)|UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
224278880|NCT00176930|BIOLOGICAL|CD4+/CD25+ cells|On days -2, patients will receive CD4+/CD25+ cells intravenously.
224278881|NCT02724826|BEHAVIORAL|Qigong therapy|Medical qigong
223919923|NCT06718179|DRUG|Short duration of aspirin and prasugrel|aspirin 75 mg/day for 1 months plus prasugrel 10 mg/day (5 mg/day) for 1 year, followed by lifelong aspirin 75 mg/day after 1 year
223919924|NCT06718179|DRUG|Conventional duration of aspirin and prasugrel|aspirin 75 mg/day lifelong plus prasugrel 10 mg/day (5 mg/day) for 1 year
223919925|NCT06718699|OTHER|resistance exercise tests|One 1RM and three RTF tests (5-8RM, 9-12RM, 13-16RM) on seven resistance training devices
223919926|NCT06885775|DEVICE|DXP01|PCL Dermal Filler
223919927|NCT06885775|DEVICE|Juvederm ULTRA 3|HA Dermal filler
223919928|NCT06725576|PROCEDURE|Ablation|Thyroid ablation performed under ultrasound guidance to treat low-risk papillary thyroid carcinoma.
223919929|NCT06726343|DEVICE|Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
224278882|NCT02724826|BEHAVIORAL|Exercise therapy|Regular exercise
224278883|NCT01940263|DIETARY_SUPPLEMENT|Anthocyanin|
224278884|NCT01940263|DIETARY_SUPPLEMENT|Placebo|
223919930|NCT06726343|DEVICE|Investigational Fetal Monitoring Device|Fetal monitoring device is a multi-parameter maternal fetal monitor that is intended to monitor, store, display, transmit, and generate alarms for non-invasive and invasive clinical parameters of pregnant women and fetuses (singleton and twin), during the antepartum, intrapartum, and postpartum period.
223919931|NCT04780581|DRUG|Dexamethasone|6 mg/24h - 10 days
223919932|NCT04780581|DRUG|Methylprednisolone|250 mg/ 24h - 3 days
223919933|NCT06727240|DEVICE|Intervention|The interventional device is a coupling device intended to prevent mechanical complications during peripheral intravenous infusions. While control will not receive the device.
224090001|NCT03841552|OTHER|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
224090002|NCT00452712|PROCEDURE|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
224090003|NCT00815646|DRUG|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
224090004|NCT00751894|DRUG|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
224090005|NCT00006131|DRUG|Valacyclovir|
224090006|NCT00799526|PROCEDURE|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
224090007|NCT00799526|PROCEDURE|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
224278885|NCT02221817|PROCEDURE|Trochanter bursa injections|
224278886|NCT02221817|DEVICE|Ultrasound|
224278887|NCT06616441|DRUG|Bupivacaine|Group (A) only will receive intra-peritoneal 40 ml bupivacaine 0.2%, after laparoscopic procedure before removing trocars.
224278888|NCT00585312|DRUG|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
224278889|NCT00585312|DRUG|Placebo|Masked, placebo comparator
224090008|NCT04052841|PROCEDURE|Thermal pulsation|Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
224090009|NCT04052841|PROCEDURE|Intense pulsed light therapy|Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.
224090010|NCT04052841|PROCEDURE|Manual warm compresses|Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
224090011|NCT00868790|DRUG|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
224090012|NCT00868790|DRUG|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
224090013|NCT00868790|DRUG|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
224090014|NCT00868790|DRUG|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
224090015|NCT01968941|RADIATION|Stereotactic Body Radiotherapy (SBRT)|
224090016|NCT01968941|RADIATION|Conventional Radiotherapy (CRT)|
224278890|NCT06166758|BEHAVIORAL|Educational Video|Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
224278891|NCT03858023|OTHER|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
223919934|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction|"The SR group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks. Each session lasted approximately 60 minutes and was conducted by the same therapist.~After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests. Before rehabilitation involving kinesiotherapy (two weeks post-surgery), the following measurements were conducted:~Height and body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation~After the rehabilitation the following measurements and assessments were conducted:~Body weight Thigh circumference measurements Assessment of muscle and tendon stiffness Body composition evaluation Evaluation of the strength of knee extensor and flexor muscles under isokinetic conditions Evaluation of knee extensor strength under inertial conditions Postural stability assessment"
224090017|NCT02291211|DRUG|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
224278892|NCT05796596|BEHAVIORAL|Experimental: Virtual Reality (VR) distraction|Children in the VR distraction group will begin interacting with the virtual environment (VE) 2 minutes prior to the skin prick test and will continue playing throughout. The VR environment is a game in which the child draw a 360 degree image.
224278893|NCT05796596|BEHAVIORAL|Active Comparator: Distraction by the book|In the book distraction group, the child will be invited to find and count animals in various landscapes. The book will be given 2 minutes prior to the skin prick test and continued reading throughout.
223717071|NCT05679583|RADIATION|Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy|"1. Preoperative Stereotactic body radiation therapy (SBRT) For the gross pancreatic cancer lesion, 30 Gy/5 fx will be prescribed considering respiratory movement. And 20 Gy/5 fx will be prescribed to the triangle operation area including the common hepatic artery, celiac artery, and portal vein.~2. Pancreatic resection Surgical resection will be performed 2-4 weeks after the end of radiation therapy. The surgical method and resection range depend on the surgeon's judgment at the time of surgery.~3. Adjuvant Chemotherapy Adjuvant chemotherapy will be given under the judgment of the oncologist from 4 weeks after surgical resection, considering the pathological findings (R0 or R1 resection status, etc.) and the patient's medical condition. Adjuvant chemotherapy includes gemcitabine alone, gemcitabine plus capecitabine combination therapy, and mFOLFIRINOX."
223717072|NCT02946528|DEVICE|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
223919935|NCT06726044|OTHER|Standard rehabilitaion after ACL reconstruction plus inertial exercises|"The SR+I group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks including inertial exercises. Each session lasted approximately 70 minutes and was conducted by the same therapist.~Subjects also performed inertial exercises from the fifth week of rehabilitation. These exercises were conducted on an InerKnee. The inertial exercises protocol included: knee extension exercises performed in a seated position for the operated leg, 4 sets of exercises, each lasting 15 seconds individually, adjusted resistance to maintain a 1-second extension cycle, passive rest periods of 2 minutes between sets After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests the same as in SR group."
223919936|NCT06706206|OTHER|Observational trial|"Observational clinical trial. Participants will undergo cardiovascular risk assessment (clinical and blood tests) and coronary CT angiogram.~These results will be compared to a control population without haemophilia (recruited as part of a different clinical trial)."
223919937|NCT06727721|BIOLOGICAL|mesenchymal stem cells with OCN-19|The patient received mesenchymal stem cells with OCN-19 three times
223919938|NCT06727721|BIOLOGICAL|Mesenchymal stem cells|Ordinary mesenchymal stem cells were given
223919939|NCT06727721|BIOLOGICAL|albumin injection|Placebo
223919940|NCT06881420|PROCEDURE|BASIS technique|Balloon AngioplaSty with the dIstal protection of Stent retriever
224090018|NCT03254056|PROCEDURE|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
224090019|NCT03254056|PROCEDURE|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
224090020|NCT01231412|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
224090021|NCT01231412|DRUG|Cyclosporine|Given PO or IV
224090022|NCT01231412|DRUG|Fludarabine Phosphate|Given IV
223717073|NCT02946528|DEVICE|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
223717074|NCT04764279|DIETARY_SUPPLEMENT|OPTIFAST dietary supplement|Participants will use Optifast Nutrition Supplement as previously described
223717075|NCT00622284|DRUG|Placebo identical to BI 1356 5mg|Placebo tablet once daily
223717076|NCT00622284|DRUG|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
223717077|NCT00622284|DRUG|BI 1356|5mg, once daily in the morning for 104 weeks
223919941|NCT06889272|OTHER|blood transfusion|Red blood cell suspension replacement during surgery
223919942|NCT06730438|DEVICE|Transcranial Pulse Stimulation|Patients will receive TPS once a day for five days a week, each session will be separated from the previous one by 24h. Each stimulation and assessment session will be performed at the same hour of the day, in the morning preferably, to maximize the probability of observing responses to stimuli. Patients will be managed in a quiete room with stable light and temperature.
223919943|NCT06730373|DRUG|Disitamab Vedotin|2.5 mg/kg IV every 3 weeks
223919944|NCT06730373|DRUG|Sintilimab|200 mg IV every 3 weeks
224090023|NCT01231412|DRUG|Mycophenolate Mofetil|Given PO
224090024|NCT01231412|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
224090025|NCT01231412|DRUG|Sirolimus|Given PO
224090026|NCT01231412|RADIATION|Total-Body Irradiation|Undergo TBI
224099435|NCT02534337|DRUG|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
224099436|NCT05223101|DRUG|Telminone 80 mg|Single administration of telmisartan 80 mg
224099437|NCT05223101|DRUG|Drug: Micardis 80 mg|Single administration of telmisartan 80 mg
224099438|NCT05152355|DRUG|Budesonide 200 microgram/Puff, HFA MDI|Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
224099439|NCT05152355|DRUG|Budesonide 100 microgram/Actuation Powder for Inhalation|Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
224099440|NCT04227444|DIAGNOSTIC_TEST|Hologram|"Patient undergoing elective anatomical resection for lung cancer will receive standard preoperative CT scan of the chest (as usual); CT images will be subsequently elaborated by a Holographic computer to generate 3D images (holograms).Two radiologists and two thoracic surgeons will analyze CT images in a standard modality and report number of artery and vein branches for the lobe to be resected, moreover they will report every anatomical variation, according to the normal anatomy.~After that, the same two radiologists and thoracic surgeons will analyze 3D images by the use of Microsoft Hololens and perform the same analysis as quoted above.~For each review of the exam performed will be written a digitally signed clinical report to certify the timing of the evaluation and to be able to trace the analysis and any subsequent modifications of the interpretation of the CT images results."
224099441|NCT02680288|DRUG|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
224099442|NCT02680288|DRUG|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
223919945|NCT06730373|DRUG|S-1|40-60 mg BID for 14 days, every 3 weeks
223919946|NCT06730373|DRUG|Trastuzumab|First load dose is 8.0mg/kg , then 6.0 mg/kg IV every 3 weeks
223919947|NCT06730373|DRUG|Oxaliplatin|130 mg/m2 Q3W
223919948|NCT06730373|DRUG|Capecitabine|1000 mg/m² Q3W
223919949|NCT06730373|DRUG|5-FU|800 mg/m²
223919950|NCT06730373|DRUG|Cisplatin|80 mg/m²
223919951|NCT06634394|DRUG|APVO436|Infusion drug administered as a 4 hour infusion.
224090027|NCT04416802|COMBINATION_PRODUCT|autologous platelet-rich plasma and low-intensity extracorporeal shockwave therapy|"The patient who encounters sexual dysfunction and visits our Outpatient Department (OPD) could enter this trial if he meets the inclusion criteria and exclusion criteria.~1. To fill the questionnaires of International index of erectile function (IIEF) and erectile hardness score (EHS) before starting treatment.~2. Li-ESWT treatment weekly for three weeks and PRP injection at the same day after the last Li-ESWT treatment.~3. Coming back at the fourth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~4. Li-ESWT treatment weekly for three weeks starts on fifth week and PRP injection at the same day after the last Li-ESWT treatment.~5. Coming back at the eighth week and check is there any side effect and fill the questionnaires of IIEF and EHS.~6. Coming back at the twelfth week and check is there any side effect and fill the questionnaires of IIEF and EHS."
224090028|NCT04680117|OTHER|Blood collection|"Blood collection with samples of 15ml max by subject (case or control) at J0, M6 and M12:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
224090029|NCT04680117|OTHER|Saliva sample|Saliva sample by subject at J0
224090030|NCT04680117|OTHER|Nasal|Nasal brushing by subject at J0
224090031|NCT02149225|DRUG|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
224090032|NCT02149225|DRUG|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
224090033|NCT02086019|DRUG|Conservative Arm|crossover to angiogram only if predefined criteria met
224090034|NCT02086019|PROCEDURE|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
224090035|NCT05106530|DIAGNOSTIC_TEST|Holter, ECG|Incidence of arrhythmias in Holter monitoring among coronary artery ectasia patients as compared to normal coronary artery patients.
224090036|NCT03499730|DRUG|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
223717078|NCT00622284|DRUG|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
223919952|NCT06634394|DRUG|Venetoclax|Oral tablet given on days 1 through 22, of a 28 day cycle.
223919953|NCT06634394|DRUG|Azacitidine|Intravenous infusion given on days 1-8 of a 28 day cycle
223919954|NCT06729424|DEVICE|Digital patient education program|The education consists of 8 modules including main themes within osteoporosis, with content aiming to promote behavioural changes including psychoeducation and behavioural activation.
223919955|NCT06889532|PROCEDURE|Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.|Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.
224090037|NCT03305640|PROCEDURE|acetabular fracture surgery|acetabular fracture surgery
224099443|NCT02680288|OTHER|Oral Placebo|Oral inert treatment
224099444|NCT05076968|PROCEDURE|Complete denture fabrication|Patient satisfaction was assessed regarding dentures fabricated by students and specialists after 8 weeks of delivery
223530451|NCT04873362|DRUG|Trastuzumab|Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
223717079|NCT03493074|DIAGNOSTIC_TEST|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
223717080|NCT00916942|DRUG|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
223919956|NCT06142409|DIETARY_SUPPLEMENT|Enzyme containing lozenge|Lozenge containing multiple enzyme combination
223919957|NCT06853704|PROCEDURE|papillary unit advancement|"collagen matrix augmentation in papilla area using tunneling technique, up to my knowledge, it's the first time to use collagen matrix in treating papilla, in less invasive approach, only though tunneling with no primary and secondary incisions.~so, the technique is designed to be less invasive, maximizing papillary blood supply.~and to use xeno collagen matrix instead of connective tissue graft used in previous study. so \~ less morbidity, less postoperative pain with no Donar graft site ."
223919958|NCT06723613|BEHAVIORAL|Exercise group|"Primiparous mothers assigned to the exercise group will attend classes in groups of 8-10. Mothers will be given 1 hour (120 minutes) of exercises to increase breast milk three times a week for 6 weeks. The total training time is 18 hours. Each session will include 60 minutes of warm-up and stretching exercises and 30 minutes of relaxation exercises.~Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF), LATCH-Breastfeeding Record System, IMDAT: Breast milk intake level assessment tool scales will be applied to mothers before exercise (8th week after birth) and after exercise (14th week)."
223717081|NCT00916942|DRUG|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
223717082|NCT02647814|BEHAVIORAL|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
223919959|NCT05636397|DIETARY_SUPPLEMENT|L-Citrulline|Citrulline is a nonessential amino acid made in the small intestine, occurs naturally in the body, and is believed to help reduce inflammation.L-CIT is a part of the urea cycle, produced as a by-product along with nitric oxide (NO).
223919960|NCT06891976|OTHER|Acupressure therapy|It will be applied to the first experimental group, three times per week for 3 weeks, with each session lasting 30 minutes. Each woman will receive a brief explanation about acupressure therapy and its effects to ensure her confidence and cooperation. Before starting, participants will be asked to empty their bladder for relaxation and assume a prone position. The therapy involves applying prolonged, slow, firm pressure with both thumbs on five key points (BL20, GV3, GB30, GB34, and BL25), which are commonly used for low back pain. Each point will receive three cycles of one-minute pressure followed by one minute of relaxation.
223919961|NCT06891976|OTHER|kinesio tape|It will be applied to the second experimental group, for 3 weeks. The tape, 5cm wide and 0.5mm thick, will be fixed in a standing lumbar flexion position on clean, grease-free skin. Four I-shaped bands, each 0.5mm in width, will be applied. The first 5cm of tape will be carefully placed on the skin without stretching, while the middle portion will be stretched 1-2 inches (50%). Two bands will be applied horizontally, and two more will be placed vertically along the lumbar spine, from the lower iliac crest to the upper twelfth rib. The tape will be rubbed to warm the adhesive, ensuring proper adhesion. It will be replaced every 3 days for 3 weeks.
223919962|NCT06891976|DRUG|Non-steroidal anti-inflammatory drugs|All the three groups will receive 400mg of Non-steroidal Anti-Inflammatory Drugs (Ibuprofen) once a day on the treatment days two hours before the session.
223919963|NCT06741319|BEHAVIORAL|Demographic characteristics|"* Gender identity~* Sex assigned at birth~* Age~* Address~* History of study enrollment(s)"
223919964|NCT06741319|BEHAVIORAL|Social and sexual behaviors|"* Places where clients go for shopping, dining out, exercise, entertainment~* Places where clients meet their sexual partner(s)~* Places where clients obtain condoms and lubricants~* Social networking and other online services clients regularly use and purposes of using~* Lifetime and current sexual practices and condom use~* Number and types of sexual partners~* Self-perceived HIV risk level~* Disclosure of HIV or sexual orientation status"
223919965|NCT06741319|BEHAVIORAL|Psychosocial characteristics|"* Sexual orientation~* Educational level~* Occupation and income~* Attitude towards and use of HIV testing and sexual health services~* Use of injecting drugs, recreational drugs, and alcohol"
223919966|NCT06741319|BEHAVIORAL|Clinical characteristics|"* Medical history, including gender dysphoria and hormone therapy~* HIV counseling and testing~* Diagnosis and treatment of sexually transmitted diseases (STD)~* Sample collection information~* Laboratory results~* Gender dysphoria and mental health history~* Body hair pattern~* Bridging therapy~* Fertility and reproductive issues~* Gender transition effects"
223919967|NCT06741319|BEHAVIORAL|Referral and linkage to care for HIV-positive clients|"* Health insurance scheme~* Initiation and continuation of antiretroviral treatment"
224099445|NCT04107220|DRUG|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
224099446|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
224099447|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
224099448|NCT02615301|DIETARY_SUPPLEMENT|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
224099449|NCT02615301|DIETARY_SUPPLEMENT|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
224099450|NCT04194177|OTHER|mechanical ventilation during robotic surgery|protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg
224099451|NCT01985321|DRUG|ethanol/glycolic acid solution|ethanol/glycolic acid solution
224099452|NCT01985321|DRUG|Placebo/Ethanol|ethanol solution
224099453|NCT03578705|DEVICE|"Electrical Impedance Myography unit or EIM"|
224099454|NCT00016315|DRUG|carboplatin|
224099455|NCT00016315|DRUG|gemcitabine hydrochloride|
224099456|NCT00016315|DRUG|paclitaxel|
224099457|NCT00016315|RADIATION|radiation therapy|
224099458|NCT00167622|PROCEDURE|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
224099459|NCT00167622|PROCEDURE|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
224099460|NCT02201940|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
224099461|NCT02201940|DRUG|Placebo|Tablet administered orally once daily
223919968|NCT06741319|BEHAVIORAL|Characteristics associated with service implementation|\- Facilitators, barriers, feasibility and acceptability of and satisfaction with service implementation as identified by clients and healthcare providers
224090038|NCT03377634|BEHAVIORAL|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
224090039|NCT02797119|DRUG|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
224090040|NCT02797119|DRUG|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
224090041|NCT02797119|DRUG|Saline Solution (TA0)|
224278894|NCT03716323|DEVICE|immediate premolar implant with xenograft and allograft|"* A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
224090044|NCT01264939|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
224090045|NCT01264939|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
224278895|NCT00190450|BIOLOGICAL|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
224278896|NCT02463838|OTHER|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
224278897|NCT04096339|OTHER|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
224278898|NCT04096339|OTHER|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
224278899|NCT05409352|BEHAVIORAL|Self-administered acupressure|Participants will receive training of self-acupressure on the 5 standard acupoints by a trained traditional Chinese medicine (TCM) practitioner, have return-demonstration, be assessed by the practitioner with the use of a competency checklist, and be instructed to perform self-acupressure on the standard acupoints once a day. A follow-up visit will be conducted to reinforce learning, in which participants will demonstrate the acupressure technique while the practitioner observes and provides feedback, including suggestions for technique adjustments if necessary. The practitioner will recommend 2 additional acupoints from the list of optional acupoints based on the patients' sensitivity to acupoint stimulation and preference. Daily duration of self-practice will range from 8-10 minutes depending on the semi-individualized protocol (5 standard + 2 optional acupoints).
224278900|NCT05409352|BEHAVIORAL|Aerobic exercise|Participants will receive verbal and written information from a trained exercise specialist about the specific advice of the desired exercise frequency (3x/week), duration (30 min each time), and intensity (moderate determined by rating of 12 to 14 on the Borg Rating of Perceived Exertion scale). The exercise specialist will demonstrate how to perform walking at moderate intensity indoors and outdoors, followed by return-demonstration of the patient. Education on safety precautions and walk schedule planning will be provided. Competency check will be performed to assess participants' ability to self-monitor and self-regular exercise intensity using Borg Scale. One week after the start of the program, the exercise specialist will conduct a 1-hour follow-up visit to supervise the patient's walking session and assess whether there is any additional advice needed.
224278901|NCT04857151|BEHAVIORAL|App based mindfulness program (ABMP)|App based mindfulness program (ABMP)
224278902|NCT06808646|DRUG|pitavastatin|Single oral administration
224278903|NCT06808646|DRUG|pitavastatin single dose combined with ceftobiprole|Single oral pitavastatin co-administered with IV ceftobiprole
224278904|NCT00828022|BIOLOGICAL|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
224278905|NCT03380130|DRUG|Nivolumab|An anti-programmed death 1 monoclonal antibody
224278906|NCT03380130|DEVICE|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
223717083|NCT00880009|DRUG|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
223717084|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
223717085|NCT00880009|DRUG|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
223919969|NCT06739135|BEHAVIORAL|Visual feedback training|Visual feedback training to modify use of the accelerator pedal when driving in a driving simulator, to reduce the % of time driving with the pedal pushed down more than 9 degrees
224090046|NCT01264939|DRUG|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
224090047|NCT01264939|DRUG|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
224090048|NCT00764725|DRUG|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
224090049|NCT00764725|BIOLOGICAL|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
224090050|NCT01099228|OTHER|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
224090051|NCT01099228|OTHER|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
223919970|NCT06739200|PROCEDURE|Platelet-Rich Fibrin (PRF) Membrane|The Platelet-Rich Fibrin (PRF) membrane is a biocompatible material derived from the participant's own blood and prepared through centrifugation. It is applied at the surgical site during periapical surgery to promote tissue regeneration, enhance wound healing, and reduce postoperative swelling and pain. Unlike synthetic materials, PRF is autologous and does not require additional chemical additives or processing. This study aims to evaluate its effectiveness in improving recovery outcomes compared to surgery without PRF membrane placement.
223919971|NCT06889155|DRUG|Oxytocin|10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.
223919972|NCT06887998|DRUG|Gabapentin 600 mg capsules|21 patients will receive 600 mg oral gabapentin one hour before induction.
223919973|NCT06887998|DRUG|Gabapentin 400 mg capsules|21 patients will receive 400 mg oral gabapentin one hour before induction.
223919974|NCT06887998|DRUG|Placebo|21 patients will receive placepo one hour before induction.
223919975|NCT06747078|OTHER|Neurodevelopmental Therapy (NDT) + Core Stabilization Training|In addition to the neurodevelopmental treatment of 30 minutes per day, 3 sessions per week, and a total of 24 sessions, core stabilization training was applied 3 sessions per week for 8 weeks and a total of 24 sessions. The core stabilization training session lasted 30 minutes.
223919976|NCT06747078|OTHER|Neurodevelopmental therapy + Balance Exercises|In addition to NDT, which is 30 minutes per day, 3 sessions per week and 24 sessions in total, balance training was applied 3 sessions per week for 8 weeks and 24 sessions in total. The balance exercise session lasted 30 minutes.
223919977|NCT06747078|OTHER|Neurodevelopmental therapy|NDT was applied for 60 minutes per day, 3 sessions per week, for 8 weeks and a total of 24 sessions.
223919978|NCT06588842|OTHER|Cluster Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets and 15-second rests after repetitions three and six.
223919979|NCT06588842|OTHER|Traditional Set Resistance Training|Participants will receive a total of 24 in-person training sessions using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets.
223919980|NCT06748846|DEVICE|Physiotherapy + Occupational therapy + Focal Muscle Vibration|\- Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. -Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. -SMV (15 minutes): Administered during the last part of each physiotherapy session. Experimental Group: SMV is applied to the trapezius (middle/descending fibers) and quadratus lumborum bilaterally at 80 Hz with an amplitude of 0.5 mm.
223919981|NCT06748846|DEVICE|Physiotherapy + Occupational therapy + Sham Focal Muscle Vibration|Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. SMV (15 minutes): Administered during the last part of each physiotherapy session. Control Group: Sham SMV using disconnected terminals produces sound but no vibration, ensuring blinding.
223919982|NCT06746740|BEHAVIORAL|Exercise|Adapted with input from phase 1
223919983|NCT06755528|DRUG|Chitosan|The participants will receive medications for fallopian tube adhesions (Chitosan (glucosamine (GIcN) and N-acetylglucosamine (GIcNAc) units,1 tablet per day) as prescribed by the gynecologist
223919984|NCT06755528|DEVICE|shockwave therapy|The participants will receive shockwave with the following parameters: sonic pulses characterized by: high peak pressure, up to 100 mpa (500 bar) or even more, rapid rise in pressure (\<10 ns), short duration (\<10 μs) and a broad range of frequency. The energy flux density was 0.09 to 0.16 mJ/mm2; with a frequency of 5 Hz and 2000 impulses, i session per week for 4 weeks.
223919985|NCT06755008|PROCEDURE|bronchial fibroscopy|2 bronchial biopsies will be taken during bronchial fibroscopy
223919986|NCT06755164|OTHER|Simultaneous aerobic and cognitive training (SIM)|The SIMULTANEOUS Group (SIM) will undergo15 minutes of stretching and preparatory mobilization + 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic and cognitive training, 5 minutes cool-down) + 15 minutes of mobilization and deep breathing (total: 70 minutes). Patients will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick.
223919987|NCT06755164|OTHER|Sequential aerobic and cognitive training (SEQ)|The SEQUENTIAL Group (SEQ) will undergo 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic training, 5 minutes cool-down), + 30 minutes of cognitive training (total: 70 minutes). Patients will perform the cognitive training after the aerobic training, sited on a desk using a computer and a joystick.
224099462|NCT00749086|DEVICE|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
224099463|NCT00749086|PROCEDURE|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
224099464|NCT05102474|OTHER|Polysomnography (PSG)|PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.
224099465|NCT03162718|BEHAVIORAL|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
224099466|NCT03953118|DRUG|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
223717086|NCT01099553|OTHER|Educational video|Instructions to view an educational video about preparing for a colonoscopy
223717087|NCT01099553|OTHER|Written instructions|Written instructions on preparing for a colonoscopy
223717088|NCT02469922|DEVICE|Positron emission tomography|
224099467|NCT03953118|DRUG|Placebo Oral|Oral placebo tablet
223919988|NCT06753721|DRUG|Doxorubicin liposome combined with CapOX and Bevacizumab|Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
223919989|NCT06754033|DIAGNOSTIC_TEST|Interventional group I|Intervention Details: Participants in this arm will receive a Ganglion Impar Block, a minimally invasive injection aimed at blocking pain signals from the coccyx region (Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance). Participants in this arm will receive a Ganglion Impar Block, a minimally invasive procedure involving the administration of Triamcinolone Acetate (a corticosteroid) and Bupivacaine (a local anesthetic). This is intended to block pain signals originating from the coccyx region. The procedure will be conducted under fluoroscopic guidance to ensure precise delivery. The injection will be complemented by a structured physical therapy program, including heat therapy, ultrasound, posture training, core strengthening exercises, and mobility activities to improve pain relief and functional capacity.
223919990|NCT06754033|COMBINATION_PRODUCT|Interventional group II|Intervention Details: Participants in this arm will receive a Caudal Epidural Steroid Injection Caudal Epidural Steroid Injection using Triamcinolone Acetate (40 mg), Bupivacaine (0.25%), and Normal Saline (6 mL) administered with a 22G Spinal Needle under Fluoroscopic Guidance), designed to deliver anti-inflammatory medication directly to the epidural space, thereby reducing inflammation and pain. This will also be paired with a tailored physical therapy program, focusing on similar modalities as in Arm 1, including heat therapy, ultrasound, posture training, and strengthening exercises. The objective is to enhance pain relief and functional recovery in the context of coccydynia.
223919991|NCT06769581|PROCEDURE|Infraclavicular Brachial Plexus Blocks|Lateral sagittal technique infraclavicular brachial plexus block
223919992|NCT06759584|DRUG|Dexamethasone|To Compare clinical outcome of dexamethasone phonophoresis in a (continuous and pulsed) maneuver for management of Temporomandibular Disorders
223919993|NCT06756438|OTHER|Study product|Anti-itching, anti-replapse and repairing treatment. Emollient.
223919994|NCT06756438|OTHER|Placebo|Emollient
223919995|NCT06757543|DEVICE|Video laryngoscopy|Video laryngoscopy with C-MAC (Karl Storz, Tuttlingen, Germany)
223919996|NCT06757543|DEVICE|Direct laryngoscopy with standard laryngoscope|Direct laryngoscopy with standard laryngoscope
223919997|NCT06762691|DEVICE|MyCRO Band|A 3D-printed cranial remolding orthosis
223919998|NCT06762691|DEVICE|Traditional CRO|A traditionally manufactured cranial remolding orthosis such as the Orthomerica Starband
223919999|NCT00243087|DRUG|BI 2536|
223920000|NCT06839599|DRUG|CMTS4520 (dietary fiber probiotics)|CMTS4520 is a synbiotic formulation containing a standardized ratio of plant-derived prebiotics and clinically validated probiotic strains. Participants will receive 4 weeks of CMTS4520 daily for chronic diarrhoea.
223920001|NCT06839599|DRUG|Placebo|Capsules with matching volume and consistent appearance to CMTS4520.
223920002|NCT06845930|DRUG|Rectal Diclofenac|Rectal diclofenac, 100mg administered immediately after skin closure then 12 hourly for 24 hours.
223920003|NCT06845930|DRUG|Intramuscular diclofenac|Intramuscular diclofenac, 7mg administered immediately after skin closure then 12 hourly for 24 hours.
223920004|NCT06671392|DRUG|DWC202405|5/20mg, 1 tablet, Oral, Once a day
223920005|NCT06671392|DRUG|DWC202405, DWC202314|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
223920006|NCT06671392|DRUG|DWC202405, DWC202314P|5/20mg + 1.5mg, 1 tablet, Oral, Once a day
223920007|NCT06671392|DRUG|DWC202313, DWC202314|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
223920008|NCT06671392|DRUG|DWC202313, DWC202314P|10/40mg + 1.5mg, 1 tablet, Oral, Once a day
223920009|NCT06885515|DIAGNOSTIC_TEST|leukocyte telomere length (LTL) will be measured using the Telomere Restriction Fragment (TRF) Analysis method|genomic DNA (2-5 µg) is digested overnight at 37°C with HinfI restriction endonuclease. Fragments are being separated on an agarose gel, transferred to a Hybond N+ membrane. The membrane is being hybridized over night at 50°C with a 5' end-labeled (AACCCT)3 oligonucleotide probe and with ladder probe of 1Kb ladder. Following membrane washes the membrane is exposed to PhosphoImager. The mean telomere length is calculated by the computer program Telotool \[19-20\]. TRF analysis will be conducted at the laboratory of Prof. Yehuda Tzfati at the Hebrew University, which is highly experienced in the field of telomere biology and in telomere length analysis. Blood samples will be taken once from each participant. no genetic sequencing will be performed as part of this study.
223920010|NCT05920330|OTHER|Nasal Plug|Please see the arm description for details.
223717089|NCT02469922|RADIATION|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
223717090|NCT02771093|DRUG|Trelagliptin|Trelagliptin 100 mg tablet
223920011|NCT06811818|OTHER|complete denture with bilateral balanced occlusion|Participants in this group will be given complete dentures with bilateral balanced occlusion
223920012|NCT06811818|OTHER|complete denture with lingualized occlusion|Participants in this group will be given complete dentures with lingualized occlusion
223920013|NCT06654128|DIAGNOSTIC_TEST|artificial intelligence|patients will undergo tandem colonoscopy with artificial intelligence
223920014|NCT06842251|OTHER|Rotary Crown Down Technique|Root canal treatment with rotary instrument is done using crown down approach and post endodontic pain measured after 4,12,24,48 hours.
223920015|NCT06842251|OTHER|Manual Step Back Technique|Root canal treatment with manual instruments using step back technique and post endodontic pain measured at 4,12,24,48 hours .
223920016|NCT06810154|BIOLOGICAL|Multi-strain probiotics|Infants will be started on probiotics (Bifidobacterium and Lacticaseibacillus) with enetral feed.
223920017|NCT06811649|DIAGNOSTIC_TEST|Ultrasound guided injection with local anaestethic|"Experimental treatment consists of ultrasound assessment combined with palpatory assessment to identify the most suitable space for epidural catheter insertion.~The conventional neuroaxial technique relies on palpation of the spinous processes and iliac crests to recognize the midline and height of the lumbar interspace to be used to perform a neuroaxial block.~With the echo-assisted technique, in aid of the conventional technique, a preprocedure (Prepuncture) is performed for the purpose of combining classic anatomical findings with useful sonographic findings that should improve the success of the neuroaxial technique."
223920018|NCT06866730|DEVICE|Serious game|Serious game in which participants manipulate instrumented toys
224278907|NCT01362673|DRUG|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
223717091|NCT02771093|DRUG|Alogliptin|Alogliptin 25 mg tablet
223920019|NCT06888245|OTHER|Non-animated Menstruation Education|Providing menstruation education to female secondary school students with Powerpoint support without animation.
223920020|NCT06888245|OTHER|Animated Menstruation Education|Providing menstruation education to female secondary school students with Powerpoint and animation support.
223920021|NCT06890052|OTHER|Targeted exercise program|Participants in the active comparator group will perform 25 sessions of isolated lumbar extension resistance exercise (ILEX) using a new machine-based device equipped with a pelvic restraint system to ensure targeted conditioning of the paraspinal muscles. The exercise will be supplemented by visual biofeedback displayed on a computer screen. A detailed protocol will be followed, incorporating an individualized, diagnosis-based range of motion and progressive resistance overload. The supervised 16-week program consists of two sessions per week for the first nine weeks, followed by one session per week for the remaining seven weeks.
223920022|NCT06890052|OTHER|Targeted exercise as part of an integrative therapy program|"Participants in the experimental group will perform 25 sessions of isolated lumbar extension resistance exercise (ILEX) using a new machine-based device equipped with a pelvic restraint system to ensure targeted conditioning of the paraspinal muscles. The exercise will be supplemented by visual biofeedback displayed on a computer screen.~A detailed protocol will be followed, incorporating an individualized, diagnosis-based range of motion and progressive resistance overload.~The supervised 16-week program consists of two sessions per week for the first nine weeks, followed by one session per week for the remaining seven weeks.~Each session is supplemented with general exercises for the back and trunk muscles (e.g., lat pulldown, abdominal crunch). In addition, participants will receive at least five sessions of therapy, which may include joint mobilization, tissue treatment, stress management, and other therapeutic modalities."
223920023|NCT06762639|BEHAVIORAL|Personalized Sleep Prehabilitation (PSP)|"Sleep prehabilitation will consist of usual care prehabilitation (exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care) with the addition of sleep support. This support will consist of:~* Brief behavioural treatment for insomnia~* Sleep hygiene~* Behaviour change support (e.g., goal-setting, use of a wearable tracker to modify behaviour)"
223920024|NCT06762639|BEHAVIORAL|Standard of Care Prehabilitation|Exercise, nutritional support, psychosocial support, education, smoking cessation support, and/or medical care delivered by regulated health professionals included Kinesiologists, Dietitians, Clinical Psychologists, etc.
223920025|NCT06744166|DEVICE|TENS-WAA|Patients assigned to the TENS-WAA group will receive transcutaneous electrical nerve stimulation based on Wrist-Ankle Acupuncture theory for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. According to the principles of WAA, two pairs of TENS-WAA (Wuxi Jiajian Medical Device Co., Ltd.) electrode pads will be placed on the upper area 2 and 3 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis. Upper area 3 is between the edge of the radius and the radial artery. Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reach the maximum tolerable level without causing pain.
223920026|NCT06744166|DEVICE|Sham (No Treatment)|Patients assigned to the sham TENS-WAA group will receive sham stimulation for a duration of 30 minutes after anesthesia induction, as well as at 8 hours and 24 hours postoperatively. Researchers will attach the electrode patches at the same location, set the parameters to the same frequency, pulse width, and minimum current intensity as the TENS-WAA group, but do not activate the device, leaving it in place for 30 minutes at each time point.
223920027|NCT06750640|DIAGNOSTIC_TEST|Infrared thermography|A thermograph (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) was used to record thermal images. The infrared camera was fixed on a tripod 1 m away from the subject to ensure that no shaking movements or vibrations occurred during the recording of thermal images. MDD related acupoints on the inner and outer sides of the limbs were detected. Appropriate body position was selected according to the different parts to be detected. Using the automatic interval saving shooting mode, one thermal picture was taken at 10-s intervals, 3 pictures were taken for each subject.
223920028|NCT06744244|DIAGNOSTIC_TEST|Olfactory Testing|Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.
224090052|NCT01972321|OTHER|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~1. Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~2. Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~3. Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
224099468|NCT05653908|OTHER|StudentMood|StudentMood is an app that uses ecological momentary assessment method to asses mood and other mental health corelates. Participants will have to complete the application (the mood wheel, heart rate and other behavioral data as well as standardized scales) daily throughout the entire semester
224099469|NCT01413386|DEVICE|biliary stent|palliative treatment for malignant patients
223530452|NCT06493318|PROCEDURE|Dorsal ligamentoplasty reinforced with an internal brace|After a longitudinal dorsal incision of the wrist, an ECRB (extensor carpi radialis brevis) or palmaris longus hemi-tendon is harvested. The scapholunate positioning is adjusted using joystick pins. A 2.5 mm blind tunnel is made in the lunate and two 2.5 mm blind tunnels are made in the proximal and distal poles of the scaphoid. The tendon graft is threaded using a fiberloop and reinforced with suture tape. The graft is fixed in the proximal pole of the scaphoid with a swive-lock anchor (Arthrex®), then in the lunate, and finally fixed in the distal pole of the scaphoid by the same method. An anti-rotation scapho-capitate pin is then placed. This is maintained for 6 weeks during post-operative immobilization with a wrist orthosis. Rehabilitation begins after the pin is removed.
223530453|NCT05189665|PROCEDURE|Extraperitoneal high sacral ligament suspension surgery|The extraperitoneal high sacral ligament suspension surgery is to shorten the bilateral uterosacral ligaments .
223920029|NCT06744244|DIAGNOSTIC_TEST|Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)|Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.
223920030|NCT06744244|DIAGNOSTIC_TEST|Video-EEG|The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).
223920031|NCT06744244|DIAGNOSTIC_TEST|fMRI|Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.
223920032|NCT06744244|DIAGNOSTIC_TEST|Neurodevelopment assessment|Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.
223920033|NCT06817018|DIETARY_SUPPLEMENT|Placebo|Placebo (Sabinsa)
223920034|NCT06817018|DRUG|Ginger|Ginger root extract
223920035|NCT04835935|OTHER|microbiome pattern|microbiome pattern in neonatal period
223920036|NCT03937661|BIOLOGICAL|PRP|Autologous PRP intra ovarian infusion
223920037|NCT03937661|BIOLOGICAL|Placebo|Autologous PFP intra ovarian infusion
223920038|NCT06625619|OTHER|Non-Interventional Study|Non-interventional study
223920039|NCT06825624|DRUG|HS-20093|administered as an IV infusion
223920040|NCT06825624|DRUG|Bevacizumab|administered as an IV infusion
223920041|NCT06825624|DRUG|5-FU|administered as an IV infusion
223920042|NCT06825624|DRUG|Leucovorin|administered as an IV infusion
223920043|NCT06825624|DRUG|Capecitabine|administered orally
223920044|NCT06825624|DRUG|Oxaliplatin|administered as an IV infusion
223920045|NCT06871475|BIOLOGICAL|sticky bone with coronally advanced flap|using sticky bone with coronally advanced flap in treating the gingival recession
223920046|NCT06871475|PROCEDURE|coronally advanced flap|using coronally advanced flap alone in treating gingival recession
223920047|NCT06815731|PROCEDURE|lateral laparoscopic suspension (LLS)|lateral laparoscopic suspension (LLS)
223920048|NCT06815731|PROCEDURE|Sacropexy without posterior mesh fixation on the puborrectalis muscle|Sacropexy without posterior mesh fixation on the puborrectalis muscle
223920049|NCT06754722|OTHER|App to guide self-acupressure|The intervention is delivered via a mobile health app. EnergyPoints app, on iOS and Android, educates and guides use of acupressure rituals to self-manage fatigue and sleep disturbances. The intervention involves using the app daily for 6 weeks. A follow-along format guides correct point stimulation for two acupressure rituals (stimulating and relaxing). The app synchronizes symptom self-reports with fitness tracker (e.g., an Apple Watch or Fitbit) sleep and activity data, allowing evaluation of response to acupressure. The dashboard provides options to tailor the rituals and pressing time (½, 1 or 2 min. per point) according to symptom experience, lifestyle, and schedule. Individuals can choose to use enhancements such as aromatherapy (including an instructional safety video), relaxing music, and/or visuals during each ritual and connect with other users via the social engagement feature.
223920050|NCT06725186|BEHAVIORAL|RELAX|The RELAX intervention is a social-emotional intervention consisting of 8 weekly, 1.5 hr sessions and a booster session 1 month and 6 months after the completion of RELAX. During the first 60 minutes of RELAX sessions, parents and adolescents meet separately; during the last 30 minutes combined parent-adolescent discussion and problem-solving activities take place. RELAX is structured such that parents learn emotion regulation/coping skills the week prior to them being taught to the adolescents. Group sessions will involve both didactics and discussion of topics including psychoeducation, basic cognitive/behavioral principles, emotional awareness, emotion regulation strategies, parent emotion socialization practices, coping skills, conflict management strategies, and communication skills.
223920051|NCT06725186|BEHAVIORAL|Psychoeducational Materials|Infographics with information on emotion regulation development, emotion regulation strategies, and strategies for managing interpersonal conflict, including when different strategies are more or less effective will be provided to participants via email.
223920052|NCT06869733|OTHER|Scooping Mobilization|Group A treated with only scooping mobilization with frequency of 2 to 3 times in a week for consecutive 4 weeks.
223920053|NCT06869733|OTHER|Scooping Mobilization with Scapulothoracic mobilization|Group B treated with scooping mobilization with scapulothoracic mobilization, which was given 2 to 3 times in a week for consecutive 4 weeks.
223920054|NCT06856356|PROCEDURE|Robot-assisted surgery|Orthopedic surgeons perform total knee arthroplasty using an orthopedic joint surgery navigation system
223920055|NCT06856356|PROCEDURE|Conventional total knee arthroplasty|Orthopedic surgeons perform total knee arthroplasty using a 4 in 1 osteotomy guide
224099470|NCT05897541|DRUG|S-217622|Administered as a tablet.
224099471|NCT05897541|DRUG|Placebo|Administered as a tablet.
223920056|NCT06876701|DRUG|Bevacizumab|Evaluation of the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
223920057|NCT06859021|OTHER|follow up call|A follow-up call is made to the patient 30 days (+ 5 days) after inclusion to check for the occurrence of an Major Cardio Vascular Event.
223920058|NCT06876155|PROCEDURE|Arm 1: The anaesthesiologically performed, ultrasound-guided, 4 quadrant-TAP block ( a combination of a lateral with a subcostal TAP block bilaterally)|Injection of a total of 60 ml ropivacaine 0.2% into the target compartment (2x 20 ml laterally, 2x 10 ml subcostally)
223920059|NCT06876155|PROCEDURE|Arm2: The surgically performed, laparoscopic landmark-based assisted TAP block|Injection of a total of 6 x 10 ml = 60 ml ropivacaine 0.2% into the target compartment (at 3 defined puncture sides bilaterally: at the anterior axillary line at 2 different, fixed heights and at the midclavicular line subcostally)
223920060|NCT06815458|OTHER|Nursing education|Mind mapping based learning
223920061|NCT06814535|DRUG|Botulinum Toxin A / Botulinum Toxin A|Botulinum toxin type A
223920062|NCT06814535|DRUG|Platelet rich plasma|Plasma that contains concentrated platelets
223920063|NCT06814535|DRUG|Saline -- placebo comparator|Physiological saline .9 %
223920064|NCT06856967|DRUG|Nirsevimab|Evaluation of drug exposure in cases and controls
223920065|NCT06760299|OTHER|%25 tension Kinesio tape|"I shaped Kinesio tape application with 25% tension"
223920066|NCT06760299|OTHER|75% tension Kinesio tape|"I shaped Kinesio tape application with 75% tension"
223920067|NCT06813170|DIETARY_SUPPLEMENT|Metarecod|Policaptil Gel Retard: Metarecod®. The medical device will be given as 1 sachet twice daily
223920068|NCT06813170|OTHER|Diet|Diet program will be planned to achieve a ≥8% body weight relative reduction over 12 months and tailored calculating a 20% caloric relative decrease from habitual energy intake, corresponding to an average energy deficit of approximately 500 kcal/daily (approximately a total of 1,200-1,500/daily Kcal for women and 1,500-1,800/daily Kcal for men), with \<30% of total calories from fat (\<10% from satured fats) and at least 15% of total calories from proteins. For carbohydrate intake, low glycemic index food will be preferred to high glycemic index food, to prevent higher post prandial glycemic excursions
223920069|NCT06940739|BIOLOGICAL|IOV-3001|IOV-3001 will be administered as a single dose by IV infusion, which will be administered in a hospital setting.
223920070|NCT06143046|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223920071|NCT06143046|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223920072|NCT06783829|DRUG|SHR4394|SHR4394
223920073|NCT06551545|DIETARY_SUPPLEMENT|Tryptophan intake|There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1
223920074|NCT06087783|DIETARY_SUPPLEMENT|Experimental product - Fortifit® Powder|Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
223920075|NCT06087783|OTHER|Standard of care|Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
223920076|NCT06257056|DEVICE|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain
223920077|NCT03417284|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HSCT
223920078|NCT03417284|BIOLOGICAL|Filgrastim-sndz|Given SC
223920079|NCT03417284|DRUG|Melphalan Hydrochloride|Given IV
223920080|NCT05132400|BEHAVIORAL|Psychological-informed Physical Therapy (PiPT) Training|An approach designed to incorporate the concepts of cognitive behavioral therapy (CBT) for pain management into routine clinical PT practice in order to modify maladaptive responses associated with chronicity. The goal of PiPT is to promote a fast and optimal recovery by removing psychological obstacles, obviating the need for referral to a psychologist and facilitating triage to other health professionals in a timely manner when needed. PiPT training includes education about the neuropsychology of pain, patient communication skills, and identification of psychosocial risk factors for chronicity and treatment approaches that include reassurance, relaxation, and psycho-behavioral reactivation.
223920081|NCT05954832|DIAGNOSTIC_TEST|Echocardiography|Echocardiography and Clearsight BP measurements before, immediately after anesthesia induction and after intubation (for 20 min)
223920082|NCT05942417|PROCEDURE|Echoguided percutaneous neuromodulation plus exercise|This group is taking the EPNM and the exercise program
223920083|NCT05942417|PROCEDURE|Strength program|This group is taking the exercise program
223920084|NCT06308380|PROCEDURE|Specific protocol of rehabilitation exercise|Specific protocol of rehabilitation exercise
223920085|NCT06308380|PROCEDURE|Short gastrocnemius surgery.|During surgery, a partial release of the gastrocnemius muscle tendon is performed to relieve tension and allow greater range of motion. This procedure is typically performed on an outpatient basis and under local or regional anesthesia, which allows for a quicker recovery compared to more invasive surgeries.
223920086|NCT06339190|DIAGNOSTIC_TEST|Venepuncture|A single blood draw at the time of presentation to clinic or whilst an inpatient.
223920087|NCT04887467|DRUG|Apomorphine|"Assigned Interventions:~* blood sampling~* blood collection~* systolic, diastolic, mean blood pressure and heart rate measure"
223920088|NCT03811405|DEVICE|Active biphasic pulse stimulation---Home Settings|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
223920089|NCT03811405|DEVICE|Active biphasic pulse stimulation---VIN Biphasic|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
223920090|NCT03811405|DEVICE|Active biphasic pulse stimulation---Stimulator Off|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
223920091|NCT06174701|BEHAVIORAL|Problem Solving Therapy (PST)|PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
223920092|NCT06174701|BEHAVIORAL|Enhanced Usual Care|"Participants in the control arm will receive enhanced usual care. They will receive additional mental health education in the form of educational handouts mailed or emailed to them."
223920093|NCT06200896|DEVICE|Self Forming Magnets used to Create A Compression Anastomosis|Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.
223920094|NCT05660486|OTHER|Aromatherapy|Participants in this group will receive 2-3 drops of 100% pure Lavandula angustifolia essential oil applied to a surgical mask pre-procedure for aromatherapy.
223920095|NCT05660486|OTHER|Placebo|Participants in this group will receive 2-3 drops of water applied to a surgical mask pre-procedure.
223920096|NCT01663831|OTHER|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
223920097|NCT05527418|DRUG|Dasatinib|Dasatinib monotherapy 70 mg/day, during 16 weeks.
223920098|NCT05527418|DRUG|Placebo|Placebo during 16 weeks.
223920099|NCT05564325|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
223920100|NCT05564325|DEVICE|Standard of care guidewire (different models may be used)|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
223920101|NCT06295263|OTHER|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers|Handwriting, gait, speech, eye movements, biological samples (blood, urine, stool, saliva, etc.), images, EEG, and other relevant markers in all experimental and control groups
223920102|NCT03938090|DEVICE|Optimised MultiSite Pacing|The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
223920103|NCT03938090|DEVICE|Standard biventricular pacing|Conventional programming settings using biventricular pacing will be used
223920104|NCT05299346|OTHER|Follow up|Comprehensive follow up in dedicated follow up unit
223920105|NCT06172374|GENETIC|Sano Genetics Testing Kit|Genetic testing spit collection tubes for DNA testing
223920106|NCT05862909|OTHER|CHD-specific web-based emotion regulation intervention|CHD-specific web-based emotion regulation intervention with ten video-based sessions covering emotional challenges of CHD and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in the daily life of patients with CHD, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
224099472|NCT00937222|DIETARY_SUPPLEMENT|Peanuts and peanut butter|Peanuts and peanut butter
223920107|NCT05862909|OTHER|General web-based emotion regulation intervention|General web-based emotion regulation intervention with ten video-based sessions covering topics related to emotional awareness and effective emotion regulation strategies (i.e., reappraisal, acceptance, problem solving, distraction, rumination, avoidance, suppression). To integrate the intervention into emotional experiences occurring in daily life, the sessions are supported by everyday emotion regulation exercises using an ecological momentary intervention.
223920108|NCT04611113|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
223920109|NCT04611113|DIETARY_SUPPLEMENT|Control Nutritional Support|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement. The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
223920110|NCT05768958|OTHER|Exercise|45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.
223920111|NCT05768958|OTHER|Control|45 min rest during the same time period as the exercise bout on exercise study visits.
223920112|NCT04769817|OTHER|177Lu-PSMA|Lu-PSMA will be administered as a standard-of-care procedure following assessment of suitability by a nuclear medicine physician and managed in close collaboration with the patient's medical oncologist.
223920113|NCT06099405|BEHAVIORAL|High-speed, Cognitive Challenge Yoga|Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.
223920114|NCT06099405|BEHAVIORAL|Traditional yoga|Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
223920115|NCT05055011|OTHER|Electronic Health Record Review|Review of medical records
223920116|NCT05055011|OTHER|Survey Administration|Complete survey
223920117|NCT03031262|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
223920118|NCT03031262|DRUG|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
223920119|NCT05803109|OTHER|AVIVA-PURE-CocoPull-Organic-made in USA|virgin cold pressed coconut oil with Peppermint essential oil
223920120|NCT06959251|DIETARY_SUPPLEMENT|Glycine|Patients will receive for 6 months an oral supplement of 0.5 g/kg/day glycine, up to 25 g/day, divided in three daily intakes.
223920121|NCT06959251|DIETARY_SUPPLEMENT|Magnesium+thiamine|Patients will receive for 6 months an oral supplement of up to 400 mg/day, according to age, of elementary magnesium (formulated as magnesium citrate) plus up to 10 mg/day of thiamine (formulated as benfotiamine), divided in three daily intakes.
223920122|NCT06959251|OTHER|Placebo|Patients will receive for 6 months placebo (sugar glass), in a similar daily amount as in experimental arms, and divided in three daily intakes.
223530454|NCT05189665|PROCEDURE|Sacrospinous ligament fixation|The sacrospinous ligament fixation surgery is to open the front and back peritoneum through the vagina and shorten the bilateral uterosacral ligaments.
223920123|NCT06833034|PROCEDURE|The novel surgical method|Additional bone removal in intended direction for tooth movement
223920124|NCT06833034|PROCEDURE|The conventional surgical method|The conventional method to use surgery
223920125|NCT02246374|DEVICE|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
223920126|NCT02632175|BIOLOGICAL|Adalimumab|every other week or weekly subcutaneous injection
223920127|NCT05284097|DRUG|Ad26.ZEBOV, MVA-BN-Filo|"Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus"
223920128|NCT04864899|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging (CMR)|Imaging
223920129|NCT04864899|DIAGNOSTIC_TEST|Blood test|Blood investigation
223920130|NCT04864899|DIAGNOSTIC_TEST|6-minute walk test|Correlating the cardiac MRI parameters with functional capacity
223530455|NCT01542892|OTHER|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
223530456|NCT01542892|DIETARY_SUPPLEMENT|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
223530457|NCT00455702|DRUG|d-cycloserine|50mg dose d-cycloserine v placebo
223530458|NCT04378868|DRUG|Antibiotics, cefuroxime and metronidazole|Patient receives antibiotics while waiting appendectomy
223530459|NCT04378868|DRUG|No antibiotics|No antibiotics are given while waiting surgery.
223530460|NCT04378868|OTHER|urgent schedule|Patients can wait up to 8 hours for surgery.
223530461|NCT04378868|OTHER|less urgent schedule|Patients can wait up to 24 hours for surgery.
223920131|NCT05311176|BIOLOGICAL|IMU-131|IMU-131 will be administered intramuscularly into the deltoid region of the arm on Day 1, 15, 29 and 57 and then every 63 days until disease progression or treatment discontinuation.
223920132|NCT05311176|DRUG|Ramucirumab plus Paclitaxel|Chemotherapy to be administered every 3 weeks (Q3W) starting on Day 1.
223920133|NCT05311176|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered every 3 weeks (Q3W) starting on Day 1 until disease progression or treatment discontinuation.
223920134|NCT05698615|BEHAVIORAL|Chess training|"The chess training, which takes place as a measure for CRT with the children and adolescents, is carried out by the concept of the Munich Chess Academy. The concept applied here, Chess according to the King's Plan, represents a holistic concept. Especially prepared for children and adolescents, theoretical aspects are illustrated in games and exercises."
223920135|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 5-6mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
223920136|NCT06490627|DRUG|Thalidomide|"Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 7-8mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period."
223920137|NCT04166799|DEVICE|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
223920138|NCT05877053|DRUG|CK-4021586|CK-4021586
223920139|NCT05877053|DRUG|Placebo for CK-4021586|Placebo for CK-4021586
223920140|NCT02115295|DRUG|Cladribine|Given IV
223920141|NCT02115295|DRUG|Cytarabine|Given IV
223920142|NCT02115295|DRUG|Gilteritinib|Given PO
223920143|NCT02115295|DRUG|Idarubicin|Given IV
223920144|NCT02115295|OTHER|Laboratory Biomarker Analysis|Correlative studies
223920145|NCT02115295|DRUG|Midostaurin|Given PO
223920146|NCT02115295|DRUG|Venetoclax|Given PO
223920147|NCT00641381|DRUG|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
223920148|NCT00641381|DRUG|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
223920149|NCT00641381|DRUG|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
223920150|NCT00641381|OTHER|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
223920151|NCT00641381|PROCEDURE|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
223920152|NCT00641381|PROCEDURE|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
223920153|NCT06562348|OTHER|Standard of care|Patients will be offered palliative systemic treatment according to standard of care. Response evaluation will be performed with the imaging-based RECIST according to standard guidelines. Treatment pauses according to institutional guidelines. Blood samples will be analyzed retrospectively to evaluate ctDNA.
223920154|NCT06562348|OTHER|ctDNA-RECIST guided palliative systemic treatment|"Patients are offered palliative systemic treatment according to standard of care. Response evaluation will be performed using ctDNA-RECIST.~ctDNA is measured before start of treatment. If the baseline sample is ctDNA negative the patient is transferred to an observational cohort, and sampling procedures continues as in the standard arm. If the baseline sample is ctDNA positive the patient continues in the ctDNA-RECIST guided arm. Treatment response is evaluated according to ctDNA-RECIST, and further sampling follows a predefined decision schedule."
224099473|NCT01130922|DRUG|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
224099474|NCT01130922|DRUG|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
224099475|NCT00424398|DRUG|Bepreve|sterile ophthalmic solution
223920155|NCT05825937|DEVICE|ClearSight System|Patients having either elective cardiac surgery or elective neurointerventional surgery will have blood pressure monitored by the ClearSight device, along with the standard of care radial arterial line, throughout their surgery. The arterial line will be placed on the radial artery contralateral to the upper arm blood pressure cuff. The ClearSight device will then be placed on the third finger of the hand ipsilateral to the radial arterial line.
223920156|NCT06550050|BEHAVIORAL|Radiation|Standard of care
223920157|NCT04734197|DRUG|SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)|combination of a topical immunosuppressant and a topical corticosteroid solution
223920158|NCT04734197|DRUG|Mycophenolic Acid 0.1%|topical immunosuppressant
223530462|NCT01038323|OTHER|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
223920159|NCT04734197|DRUG|Mycophenolic Acid 0.3%|topical immunosuppressant
223920160|NCT04734197|DRUG|Betamethasone Sodium Phosphate 0.01%|topical corticosteroid solution
223920161|NCT04734197|DRUG|Placebo Comparator: Vehicle|topical vehicle solution
223920162|NCT04734197|DRUG|Cyclosporine 0.05% Ophthalmic Emulsion|topical ophthalmic emulsion
223920163|NCT04734197|DRUG|Lifitegrast 5% Ophthalmic Solution|topical ophthalmic solution
223920164|NCT02521103|DEVICE|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
223920165|NCT01098955|BEHAVIORAL|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
223920166|NCT01098955|BEHAVIORAL|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
223920167|NCT01098955|DRUG|Varenicline|2 mg daily for 12 weeks
223920168|NCT04028401|DRUG|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
223920169|NCT05354531|PROCEDURE|anterior subcutaneous internal fixator ( INFIX)|INFIX was invented based upon the same biomechanical principle as the traditional external fixator, but it is placed subcutaneously. It proved to be stiffer than the traditional external fixator, and at the same time eliminates the open pin tracts, which increased the infection rate and nursing care
223920170|NCT04198870|DEVICE|MitraClip™ device implantation|Transcatheter repair of the mitral valve using MitraClip™ device
223920171|NCT04198870|PROCEDURE|Mitral Valve Repair Surgery|Surgical repair of the mitral valve
223920172|NCT05583513|DIAGNOSTIC_TEST|MLHFQ (Minnesota Living with Heart Failure Questionnaire)|The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
223920173|NCT05583513|DIAGNOSTIC_TEST|KCCQ (the Kansas City Cardiomyopathy Questionnaire)|The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
223920174|NCT06962735|DEVICE|real-time continuous glucose monitor|Individuals who switched from using isCGM to rtCGM
223920175|NCT05190679|OTHER|None/Observational Studies|This is an observational study and there is no intervention.
223920176|NCT01709292|DRUG|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
224099476|NCT00424398|DRUG|Placebo|sterile ophthalmic solution
224099477|NCT00424398|DRUG|Bepotastine Besilate|sterile ophthalmic solution
224099478|NCT01023789|DEVICE|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
224099479|NCT02533089|OTHER|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
224099480|NCT01284803|BEHAVIORAL|an educational intervention|To elaborate an educational program for the management of depression in primary care
224099481|NCT04268719|DIAGNOSTIC_TEST|wireless pH capsule recording|wireless pH capsule recording for up to 96 hours
224099482|NCT00095563|DRUG|lapatinib ditosylate|Given orally
224099483|NCT00095563|OTHER|laboratory biomarker analysis|Correlative studies
224099484|NCT05974306|DEVICE|implantable loop recorder|Implantation of an implantable loop recorder
224099485|NCT05841940|DRUG|[14C]HLX208|Carbon-14 labeled HLX208
224099486|NCT04846114|PROCEDURE|Dental implant surgery|
224099487|NCT02335502|DEVICE|Implantation with the commercially available Axium neurostimulator|
224099488|NCT00898092|GENETIC|microarray analysis|
224099489|NCT00898092|GENETIC|molecular genetic technique|
224099490|NCT00898092|GENETIC|mutation analysis|
224099491|NCT00898092|GENETIC|polymerase chain reaction|
224099492|NCT00898092|GENETIC|reverse transcriptase-polymerase chain reaction|
224099493|NCT00898092|OTHER|diagnostic laboratory biomarker analysis|
224099494|NCT00166348|BEHAVIORAL|Cognitive Group Therapy|
224099495|NCT03589001|OTHER|Activity modification|Activity modification, exercises and gradual return to sport
224099496|NCT05303740|DRUG|Anlotinib|This is an observational study.
224099497|NCT00056199|DRUG|EYE001|
224099498|NCT02034123|DRUG|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
224099499|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
224099500|NCT00401440|DRUG|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
224099501|NCT00246259|DRUG|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
224278908|NCT01362673|DRUG|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
223920177|NCT01709292|DRUG|Vemurafenib (Post Surgery) - Group A + C|"Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.~Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B."
224278909|NCT01362673|DRUG|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
223530463|NCT01038323|BEHAVIORAL|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
223920178|NCT01709292|OTHER|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
223920179|NCT05909709|DRUG|Alocyte low dose|"Low dose containing 0.2 - 1.0 x 10\^11 particles and 3-10x10\^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used."
223920180|NCT05909709|DRUG|Alocyte medium dose|"Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used."
223920181|NCT05909709|DRUG|Alocyte high dose|"High dose containing 1.0 - 5.0 x 10\^11 particles and 15-50x10\^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used."
223530464|NCT01038323|DRUG|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
223920182|NCT06305143|DRUG|Conbercept|participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.
223920183|NCT06511219|DEVICE|maxillary segmental distalization|maxillary segmental distalization using skeletal anchored digitally printed appliances
223940681|NCT06593756|DEVICE|Transpulmonary Thermodilution/Calibrated Pulse Contour Analysis|Transpulmonary thermodilution (TPTD) involves the administration of a cold saline bolus into a central venous catheter. A special thermistor catheter placed in the femoral or brachial artery detects the successive changes in blood temperature. The resulting heat dissipation curve is analyzed to estimate stroke volume, cardiac output and other hemodynamic variables such as intrathoracic thermal volume (ITTV), pulmonary thermal volume (PTV), global end-diastolic volume (GEDV), intrathoracic blood volume (ITBV) and extravascular lung water (EVLW). Intermittent TPTD-derived cardiac output measurements (typically performed 1-3x/d) are used to calibrate pulse contour analysis.
223530465|NCT04164927|OTHER|Manual Lymphatic Drainage|"1. Lymphatic correction method was used via the KinesioTaping® to patients group.~2. Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~3. Control group received only physiotherapy treatment."
223530466|NCT04164927|OTHER|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
223530467|NCT04164927|OTHER|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
223530468|NCT06143189|OTHER|Hosting conditions|"Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments."
223530469|NCT06143189|OTHER|Hospital Clowns|"The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes."
223530470|NCT02105129|DRUG|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
223530471|NCT02105129|DRUG|Placebo|Oral administration
223530472|NCT02143882|DRUG|Fluenz|Live attenuated influenza vaccine
224278910|NCT01362673|DRUG|Placebo|Oral single dose as matching placebo
223530473|NCT00384943|BEHAVIORAL|Moderate-intensity Exercise|
224278911|NCT01362673|DRUG|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
224278912|NCT01362673|DRUG|Placebo|Oral multiple doses as matching placebo for 12 days
224278913|NCT01311427|BEHAVIORAL|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
223920184|NCT06635642|BEHAVIORAL|Dichotic Interaural Intensity Difference (DIID) Training|A total of five trials will be presented in a sequence and there will be 10 sequences per training session. Each of the 25 consonant-vowel-consonant words or digits 1 through 10 (excluding 7) will be presented to each ear during the session. The pairs will be randomized every time, and a word will never be paired with itself. After a sequence is completed, the difficulty of the task will be adjusted, in real time, based on performance on the prior task. If the child scored 4 or 5 of 5 correct in the poorer ear, then the IID will be decreased by 2 dB making the task more difficult. If the child scores 0, 1, or 2 of 5 correct, then the IID will be increased by 2 dB making the task easier. Last, if the child scores 3 of 5 correct, then the IID will remain unchanged for the next sequence.
223920185|NCT06313632|DRUG|Bupivacaine injection|Erector spinae plane block with bupivacaine (0.5%) 30 mL once
223920186|NCT06313632|DRUG|Placebo|ESP with matching saline placebo
223920187|NCT06313632|OTHER|Monitored Anesthesia Care|Standard monitored anesthesia care
223920188|NCT05709782|PROCEDURE|Spine Radiosurgery|scan
223920189|NCT05709782|DEVICE|Magnetic Resonance imaging|scan
223920190|NCT05709782|RADIATION|MR-LINAC|scan
223920191|NCT04220203|DRUG|Tucatinib|300 mg orally two times per day
223920192|NCT04220203|DRUG|Capecitabine|1000 mg/m\^2 orally two times per day on Days 1-14 of each 21-day cycle
223920193|NCT04220203|DRUG|Trastuzumab|Loading dose of 8 mg/kg into the vein (IV; intravenously), followed by 6 mg/kg IV once per 21-day cycle
223920194|NCT01473485|DEVICE|ExAblate Transcranial System|MR Guided Focused Ultrasound
223920195|NCT05941988|PROCEDURE|pre grafting partial maxillary expansion with post grafting expansion|pre grafting partial maxillary expansion then anterior iliac grafting followed by 2 months period for consolidation then post grafting expansion till full arch alignment
223920196|NCT05178849|OTHER|Hypnosis|Hypnosis
223920197|NCT05178849|DRUG|Local anesthetic|For the local anesthesic, the doctor uses in both arms of the study a 20 ml vial of lidocaine hydrochloride without adrenaline for injection dosed at 2%.
223920198|NCT06802653|DIAGNOSTIC_TEST|not provided|
223920199|NCT06390657|OTHER|Planning CT, MRI|"SBRT-PATHY and CARBON-PATHY planning is performed for study purposes only. Patients will be treated according to standard radiotherapy as per institutional policies.~The planning images (CT, MRI) will be anonymized and used for planning purposes only."
223940682|NCT06593756|DEVICE|Esophageal Doppler|In esophageal Doppler, a thin ultrasound probe, coated with aqueous ultrasound gel, is orally or nasally inserted into the esophagus and orientated towards the aorta. By emission and detection of continuous wave Doppler signals, real time spectral waveforms of red blood cell velocity in the aorta are obtained, from which cardiac indices can be derived.
224099502|NCT00246259|DRUG|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
224099503|NCT05971797|BEHAVIORAL|REBT|During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
224099504|NCT00465257|DRUG|artesunate + amodiaquine|
224099505|NCT05347615|PROCEDURE|IOL Implantation:EDOF lens|A EDOF lens is implanted in the dominant eye
224099506|NCT05347615|PROCEDURE|IOL Implantation: Monofocal lens|A monofocal lens is implanted in the non dominant eye.
224099507|NCT04193683|OTHER|Myofascial Release Technique|Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.
224099508|NCT04193683|OTHER|Sham-Ultrasound|Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
224099509|NCT04275427|DEVICE|LA-400 laser acupuncture|low level laser
224099510|NCT01411787|BEHAVIORAL|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
224099511|NCT00199004|DRUG|Cyclophosphamide|
224099512|NCT00199004|DRUG|Dexamethasone / Prednisolone|
224099513|NCT00199004|DRUG|Vincristine|
224099514|NCT00199004|DRUG|Daunorubicin|
224099515|NCT00199004|DRUG|Asparaginase|
224099516|NCT00199004|DRUG|Methotrexate|
224099517|NCT00199004|DRUG|Cytarabine|
224099518|NCT00199004|DRUG|Mercaptopurine|
224099519|NCT00199004|DRUG|G-CSF|
224099520|NCT00199004|DRUG|Vindesine|
224099521|NCT00199004|DRUG|VP16|
224099522|NCT00199004|DRUG|Adriamycin|
224099523|NCT00199004|DRUG|Thioguanine|
224099524|NCT00199004|DRUG|VM26|
224099525|NCT00199004|DRUG|Rituximab|
224099526|NCT00199004|PROCEDURE|CNS irradiation|
224099527|NCT00199004|PROCEDURE|Mediastinal irradiation (if residual TU)|
224099528|NCT00199004|PROCEDURE|Stem cell transplantation|
224099529|NCT01271686|DRUG|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
224099530|NCT00717730|DIETARY_SUPPLEMENT|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
224099531|NCT00717730|DIETARY_SUPPLEMENT|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
224099532|NCT00717730|DIETARY_SUPPLEMENT|Placebo|Placebo with no active ingredients
224099533|NCT00717730|DIETARY_SUPPLEMENT|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
224099534|NCT03133767|DRUG|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
224099535|NCT03133767|DRUG|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
224099536|NCT06329050|DRUG|Losartan|Administration of Losartan tablets(50 mg)
223920200|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
223920201|NCT06419595|BEHAVIORAL|Behavioral: Screening and Support for Youth (SASY) Multi-component Platform: includes screening, feedback, single session intervention, and resource information|Description: Description: Participants who interact with a QR code and express interest in participating will be randomized to receive either: 1) recruitment from a Research Coordinator (standard research staff approach) or 2) recruitment from an EYE for Prevention Youth Researcher. The process of consent, screening, providing feedback, and offering access to a Single Session Intervention and information on additional resources (per scoring on the screening into Tier 1 (low risk/normal), 2 (moderate/at risk), or 3 (high/clinical risk): Tier 1 = screening+feedback; Tier 2=screening+feedback+SSI; Tier 3=screening+feedback+SSI+resource information) will be the same in each group. The randomization is simply changing who provides the process and platform to the participant.
223920202|NCT03932032|BEHAVIORAL|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
223920203|NCT03932032|BEHAVIORAL|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
223920204|NCT05701098|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.
223920205|NCT03834818|BEHAVIORAL|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~* Download the Medable App~* Register to the study~* Validated Questionnaires~* Active Task~Every Day~* 9:00 a.m. Daily Questions~* 9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~* Day 1 Pre-Surgery~* 1-Week Post Operation~* 2-Weeks Post Operation~* 1-Month Post Operation~* 3-Months Post Operation~* 6-Months Post Operation"
223920206|NCT04549116|DRUG|Progesterone-IBSA Injectable Solution|Progesterone-IBSA 25mg, twice daily (BID) SC Injection every 12 hours
223920207|NCT04549116|DRUG|Progesterone Vaginal Gel with Applicator|Crinone 8%, 90 mg, QD intravaginally
223920208|NCT04549116|DRUG|Placebo Vaginal gel with applicator|Vaginal gel Placebo, once daily (QD) intravaginally
223920209|NCT04549116|DRUG|Placebo injectable solution|Placebo injectable solution, BID SC Injection every 12 hours
223920210|NCT04310423|DRUG|Placebo|Matched to endotoxin
223920211|NCT04310423|BIOLOGICAL|Endotoxin|Bolus dose of 0.8 ng/kg
223920212|NCT05836688|BEHAVIORAL|Goal-Focused Emotion-Regulation Therapy (GET)|Patients will be asked to identify value-derived goals (i.e., goals for the most important domains of one's life) and ones sufficiently important to sustain movement toward them in the short-term future. Patients will discuss their goal possibilities, providing a forum to ensure that goals are manageable and consistent with identified values. Patients will learn strategies to refine their goals (e.g., approaching goals rather than avoiding obstacles, defining markers of progress), generate pathways to goals, and address potential obstacles and blockages. The overall goal is to enhance self-regulation through improved goal navigation skills, improved sense of meaning and purpose, and better ability to regulate specific emotional responses.
223920213|NCT05836688|BEHAVIORAL|Individual Supportive Listening|ISL sessions will be matched in terms of time and attention. Supportive therapy will be non-directive and will primarily reinforce a patient's ability to manage stressors through attentively listening and encouraging expression of thoughts and feelings, assisting the individual to gain a greater understanding of their situation and alternatives, and helping to buttress the individual's self-esteem and resilience. This will be delivered in the same manner as GET (individually) and is a common, non-directive control method in intervention research.
223530474|NCT06560892|DRUG|Bupivacaine injection|patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
223920214|NCT04215952|BEHAVIORAL|Semantic Feature Analysis Treatment|On each treatment trial, the clinician will show the participant with aphasia a pictured object and ask them to name it. The clinician will then guide the participant in verbally generating semantic features for the target, using a chart that specifies five kinds of features: group, use/action, properties, location, and personal associations. When the participant cannot generate a given feature, cueing or other assistance will be provided. After feature generation, the clinician will ask the participant to name the picture again and provide cueing if needed. The clinician will then review the generated features and ask the participant to name the item once more, with cueing if needed. Finally, the clinician will ask the participant to say a sentence containing the target word and provide cueing if needed. Treatment will then proceed to the next item. Participants will receive approximately 20 hours of treatment on each of three 10-item lists, for a total of 60 hours of treatment.
223920215|NCT06082986|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants received ustekinumab as per their routine clinical practice.
223920216|NCT02399124|DEVICE|PROSENSE™|single arm, open label, PROSENSE™ treatment
223920217|NCT04850729|OTHER|non-intervention|non-intervention
224099537|NCT06329050|DRUG|Placebo|Administration of Placebo tablets
224090053|NCT01972321|BEHAVIORAL|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
223920218|NCT04227379|BEHAVIORAL|Intervention 1- DSMS+|Participants in this group were signed up for an interactive, patient-centered, and customizable diabetes self-management support texting intervention (DSMS+). This arm received the same daily educational content as the DSMS arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging th
223920219|NCT04227379|BEHAVIORAL|Comparison - DSMS|"Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Self-Management Support (DSMS), comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSMS messages could not be customized. There was no interactive content for the DSMS arm other than a once monthly message asking whether the messages had been helpful."
223920220|NCT02436941|RADIATION|Proton or Photon|
223920221|NCT06778122|DEVICE|High efficiency particulate air filtration system (nightly administration)|Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with active filters (HyperHEPA technology). Dose adjustments are permitted in the study where noise disturbance is an issue for participants. The air filtration therapy will be delivered in doses decreasing sequentially in terms of speed mode. Participants will be instructed to keep doors and windows of the bedroom closed during each session at night, and to follow a similar bedtime routine.
223920222|NCT06778122|DEVICE|High efficiency particulate air filtration system (nightly and daily administration)|Portable air purifier set up with active filters (HyperHEPA technology) is continuously in operation (24 hours for 14 days) at 275 m³/h in bedrooms with the door and windows closed. During this open-labell phase, the participants will be asked to remain in the bedroom for as long as possible and to keep an activity log for the outdoor locations. Dose adjustments are permitted.
223920223|NCT06778122|DEVICE|Air filtration system without filters (sham)|Portable air purifier is programmed to provide a dose of filtered air at 275 m³/h nightly for at least 7 hours consecutive within a time window between 10:00 p.m. and 10:00 a.m. Air purifier is set up with a sham filter, which is identical in appearance and noise as the HyperHEPA filter (active filter) when the air purifier is in operation. Dose adjustments are permitted in the study where noise disturbance is an issue for participants.
223920224|NCT05036018|DEVICE|ACURATE neo2|The ACURATE neo2 valve will be implanted using a two-step mechanism during transfemoral transcatheter aortic valve implantation (TAVI). Balloon predilatation will be recommended in the ACURATE neo 2 valve group.
223920225|NCT05036018|PROCEDURE|minimalist approach|Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.
223920226|NCT05036018|DEVICE|CoreValve Evolut Pro, Pro+ and FX|The Evolut Pro, Pro+ or FX valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.
223920227|NCT05036018|PROCEDURE|Standard of care|Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
223920228|NCT06150716|DRUG|ION356|Administered as intrathecal (IT) injection.
223920229|NCT06848465|RADIATION|Low Dose Radiotherapy|10 Gy in 5 fractions, 15 Gy in 3 fractions, 20 Gy in 10 fractions respectively in three Cohorts from Day1
223920230|NCT06848465|RADIATION|Short course Radiotherapy|25 Gy in 5 fractions from Day1
223920231|NCT06848465|DRUG|XELOX|Oxaliplatin: 130mg/m2 IV Q3W on day 1 of each cycle. Capecitabine: 1000mg/m2 Q3W Dose of 1000mg/m2 on day 1-14 of each cycle.
223920232|NCT06848465|DRUG|Tislelizumab|200mg IV Q3W on day 1 of each cycle.
224090054|NCT01972321|OTHER|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
224099538|NCT00730340|PROCEDURE|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
224099539|NCT00730340|PROCEDURE|Tonsillectomy with open fossa|SOP for a tonsillectomy.
224099540|NCT00206141|DRUG|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
224099541|NCT00814931|DRUG|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
224099542|NCT00814931|DRUG|Placebo|matching oral liquid suspension placebo twice a day for 8 days
224099543|NCT02380131|DRUG|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
223920233|NCT06848907|DRUG|ganzhixiao capsule|Ganzhixiao Capsule is mainly composed of Bupleurum chinense, Herba Artemisiae, Polygonum cuspidatum, Rhubarb and Hawthorn.Take 3 capsules each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.
224278914|NCT01311427|BEHAVIORAL|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
224278915|NCT03011060|PROCEDURE|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
223920234|NCT06848907|DRUG|placebo capsule|Take 3 palcebo capsule each in the morning, afternoon, and evening, and swallow with warm water after meals for 16 weeks.All participants in the trial were required to have a low-fat diet and engage in aerobic exercise for 150 minutes per week.
223920235|NCT06462638|OTHER|Neurobehavioral states and physiological parameters evaluation|"Each individual infant included in the study will be assessed 3 times a week for at least two weeks: specifically, two detections of neurobehavioral states in response to interaction with the mother, two detections with the father, and two detections with the nurse(s) will be made.~For each infant involved in the study, an audio/video recording of cradle movements and vocalizations will be made at 3 different consecutive times (5 minutes each): baseline; recording during interaction with either parent or nurse; post-interaction assessment.~The parent or nurse is asked to interact freely with the baby, choosing whether to use voice and touch or only one of the sensory stimulation channels. During the interactions, parents and nurse will in turn be assessed relative to some basic physiological parameters through the use of a band applied to the chest; the infant's physiological parameters during the 3 times will also be recorded."
223920236|NCT06462638|OTHER|Maternal vocal pitch evaluation to assess depressive/anxious state|"Regarding the assessment of any depressive/anxious states of the mother, as an additional support to the self-report questionnaires the maternal vocal pitch will be specifically assessed through the Talking about software (AI algorithm applied to maternal postpartum depression research)."
223920237|NCT05650619|OTHER|Biospecimen collection|Specimens that may be collected include urine, blood, saliva, kidney tissue, etc. Biospecimens will be collected to establish the RESOLVE biobank.
223920238|NCT05650619|OTHER|Data collection|Data collection for all groups
223920239|NCT06966427|DEVICE|Dosing Guidance System to be used with both time and amount of insulin as input|Any insulin dosing event manually logged by the participant, the DGS will receive the time and amount of the dose as input
223920240|NCT06966427|DEVICE|Dosing Guidance System to be used with only time of insulin as input|any insulin dosing event manually logged by the participant, the DGS will receive only the time of the dose as input
223920241|NCT05512650|DEVICE|Virtual Reality Meditation|Participants will be set up in the VR equipment. They will engage and follow along with a 10-20 minute guided meditation through the VR. The meditation program may include simulated movement, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
223920242|NCT05512650|DEVICE|Non-VR Meditation|Participants will engage and follow along with a 10-20 minute guided meditation on a computer screen placed before them. The meditation program may include simulated movement visuals, relaxing music, and the voice of a meditation guide. The research team member will supervise the session, ensuring safety of the subject is maintained.
223920243|NCT03964441|BIOLOGICAL|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
223920244|NCT03964441|BIOLOGICAL|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
223920245|NCT03964441|OTHER|Parent interviews (optional organizational study)|Interview with a sociologist or psychologist to explore perceptions of ES and the impact of the results, expectations regarding certain types of results not currently available, the emotional situation, and position regarding the continuation of the pregnancy At 4 different times: at inclusion, at the time of the CGA-array results, at the time of the ES results and at a distance from the ES results
223920246|NCT03964441|OTHER|parent questionnaire (optional organizational study)|To evaluate the experience, perceptions, the impact of the analyses on the decision, satisfaction and concerns regarding the ES and its results, opinions on certain types of results not currently available, as well as anxiety and possible psychological distress At 4 different points in time: at inclusion, at the delivery of the CGA-array results, at the delivery of the ES results and at a distance from the delivery of the ES results
223920247|NCT03964441|OTHER|professional interviews (optional organizational study)|interview to understand how the decision is formed
223920248|NCT03964441|OTHER|Focus group for professionals (optional organizational study)|interview to specify whether variants of unknown significance) VUS will potentially be returned to the clinicians, or even to the patient via the clinician.
223920249|NCT06055608|DRUG|Sirolimus|Participants in Group 1 will transition to sirolimus therapy on day 14 (+/- 5 days) - weight \<40 kg will receive 3mg/m\^ 2, with maintenance dose of 1 mg/m\^2 divided BID - weight \>= 40kg will receive 6mg/m\^ 2, with maintenance dose of 2 mg daily
223920250|NCT06055608|BIOLOGICAL|Belatacept|Belatacept will be administered as an intravenous infusion over 30 minutes. The belatacept dose for the study is 10 mg/kg on post-operative day (POD) 1, 5, 14, 28, 56, 84 for the first 3 months, followed by 5 mg/kg every 4 weeks (+/-4 days), starting on month 4 until month 24
224278916|NCT03011060|DRUG|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
224278917|NCT06677827|DRUG|Bupivacaine|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25% only bilateral
224278918|NCT06677827|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|External Oblique Intercostal plane block technique with 20 ml bupivacaine 0.25%+200 mg magnesium sulphate bilateral
224278919|NCT02241694|OTHER|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
224278920|NCT02226991|DRUG|Tipranavir|
224278921|NCT02226991|DRUG|Ritonavir|
223920251|NCT06055608|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil-MMF will be initiated at 600 mg/m\^2 BID until tacrolimus is at therapeutic levels, then 450 mg/m\^2 BID
224090055|NCT04028037|PROCEDURE|FTPGT treated patients|"The recipient bed will be prepared according to Langer\&Langer modified technique. Intrasulcular incision will be performed from at least one tooth mesial and one tooth distal to the tooth with gingival recession, without vertical incisions.A split-thickness flap will be raised.The harvest of palatal graft will be done using FTPG technique. An incision, parallel to the gingival margin, deep to the bone, will be made. At the center of this incision, a U shaped one about 1-2mm deep will made, with the convex side towards the palatine vault.The width of the U incision will be equal to the width of the GR and the length will be 1mm greater.A split-thickness dissection of the area surrounding the U shaped incision will be done.The graft will be removed by detaching it from the bony surface.The graft will be made up of an apico-lateral portion of connective tissue and periosteum, and of a full-thickness central part.The palatal graft will be adapted to the recipient site and sutured."
224090056|NCT04028037|PROCEDURE|CAF+SCTG treated patients|According to De Sanctis \& Zucchelli, a tension-free trapezoidal flap will be elevated by the split-full-split technique and the anatomic papillae will be de-epithelialized. A 1-mm thick SCTG will be harvested from the palate as epithelialized graft. The height of the graft was equal to the distance between the buccal bone crest and the CEJ. After epithelium removal, the graft was positioned and sutured 1mm apical to the cement-enamel junction with 5-0 resorbable sutures . The SCTG will then be covered by the tension-free coronally positioned flap, sutured about 2mm over the CEJ by 5-0 silk sutures.
224090057|NCT01488006|DEVICE|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
224090058|NCT01957956|OTHER|Laboratory Biomarker Analysis|Correlative studies
224090059|NCT01957956|BIOLOGICAL|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
224090060|NCT01957956|DRUG|Temozolomide|Given PO
224090061|NCT05878028|COMBINATION_PRODUCT|L-TIL, Tislelizumab, Docetaxel|PD1 positive lymphocytes were collect, isolated, and expanded from peripheral blood, then infused back into the patient's body. Besides this, Tislelizumab and Docetaxel were used as combination therapy.
224090062|NCT03384329|DRUG|Resveratrol Pill|Resveratrol 500 mg
224090063|NCT03384329|DRUG|Placebos|Placebo Pills
224090064|NCT01961427|DIETARY_SUPPLEMENT|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
224090065|NCT01961427|DIETARY_SUPPLEMENT|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
224090066|NCT01167608|OTHER|No Intervention. This is a cross-sectional survey study.|No intervention.
224090067|NCT03181113|DRUG|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
224090068|NCT03181113|DRUG|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
224090069|NCT06543771|DIAGNOSTIC_TEST|Safety Test ABO and ABTest Card®|Pre transfusional control with the Safety Test ABO device (reference device) and the ABTest Card® device (comparator).
224090070|NCT00032084|BEHAVIORAL|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
224090071|NCT00032084|DRUG|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
224090072|NCT00032084|DRUG|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
224090073|NCT00032084|PROCEDURE|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
224090074|NCT03670030|DRUG|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
224090075|NCT04103866|DEVICE|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
223530475|NCT06560892|DRUG|Dexmedetomidine injection|Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
223530476|NCT00737360|DRUG|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
223920252|NCT06055608|DRUG|Tacrolimus (Group1)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels. Participants in Group 1 will be transitioned to sirolimus 2-4 weeks post-transplant
223920253|NCT06055608|DRUG|Anti-Thymocyte Globulin (ATG)|Participants will receive induction therapy with anti-thymocyte globulin (1.5 mg/kg/dose, maximum 125 mg) starting intraoperatively on day 0 and continuing on days 2 and 3 (total dose 4.5 mg/kg). Total dose may be extended to 6 mg/kg over 1-2 days for delayed graft function
223920254|NCT06055608|DRUG|Tacrolimus (Group 2)|Participants will receive Prograf® (tacrolimus), or generic, initiated at 0.1 mg/kg BID within 48 hours of transplantation to attain target trough levels
224090076|NCT00003490|BIOLOGICAL|sargramostim|
224090077|NCT00003490|DRUG|cyclophosphamide|
224090078|NCT00003490|DRUG|prednisone|
224090079|NCT00003490|DRUG|vincristine sulfate|
224090080|NCT01306760|DRUG|Ketamine|Ketamine used as the anaesthetic during ECT.
224090081|NCT01306760|DRUG|Propofol|The standard anaesthetic used for ECT.
224090082|NCT01722461|DEVICE|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
224090083|NCT01722461|DEVICE|Sham treatment|Ulthera System delivering no ultrasound energy
224090084|NCT02284165|OTHER|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
224090085|NCT00944827|DIETARY_SUPPLEMENT|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
224278922|NCT02226991|DRUG|Efavirenz|
223920255|NCT05367037|DEVICE|PhysioVP|The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.
223920256|NCT05367037|DEVICE|DDD-VPA|In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
223920257|NCT06510816|DRUG|ANX007|Form: solution for injection; Route of Administration: IVT injection
223920258|NCT06510816|OTHER|Sham Administration|Form and Route of Administration: to mimic IVT injection (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to stimulate the pressure of an injection).
223530477|NCT05603637|PROCEDURE|Catheter ablation using SmartTouch radiofrequency ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using radiofrequency energy with SmatTouch ablation catheter (Biosense Webster, USA)
223920259|NCT06093061|COMBINATION_PRODUCT|CCRT with Maintenance Tislelizumab and Metronomic Capecitabine|"CCRT: Radiotherapy will be delivered once daily, for 5 days per week, over 6 to 7 weeks. During RT, cisplatin will be administered either 100 mg/m2 3-weekly or 40 mg/m2 weekly, IV infusion (physician's choice).~Maintenance: Tislelizumab 200mg, day 1 per 3-week cycle, intravenous (IV) infusion and capecitabine 650 mg/m2, days 1-21 per 3-week cycle, bidaily, oral, for a total of 12 months (17 cycles)."
223920260|NCT06303128|DRUG|Amoxicillin 250 MG|Liquid amoxicillin 250mg PO
223920261|NCT06303128|DRUG|Placebo|Given prior to amoxicillin 250mg in one-dose group
223920262|NCT06303128|DRUG|Amoxicillin 62.5mg|Given first in two-dose group, liquid amoxicillin 62.5mg PO
223920263|NCT06303128|DRUG|Amoxicillin 187.5mg|Given second in two-dose group, liquid amoxicillin 187.5mg PO
223920264|NCT05852990|COMBINATION_PRODUCT|Glutamine plus L. reuteri|Glutamine plus Lactobacillus reueri twice daily for up to 6 weeks or death
223920265|NCT04842149|DIETARY_SUPPLEMENT|Bif195 capsules|1 capsule daily for 8 weeks
223920266|NCT04842149|DIETARY_SUPPLEMENT|Placebo capsules|1 capsule daily for 8 weeks
223920267|NCT05952141|BEHAVIORAL|Clinic Outreach|A member of the pathology team will contact the referring clinic to communicate the readiness of results.
223920268|NCT05952141|BEHAVIORAL|Enhanced Outreach|A member of the pathology team will contact both the referring clinic and the patient directly to communicate the readiness of results.
223920269|NCT05952141|BEHAVIORAL|Low-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging.
223920270|NCT05952141|BEHAVIORAL|High-Touch Strategy|Patient will be sent asynchronous text messaging reminders related to the importance of timely care using framed messaging in combination with synchronous telephone-based patient navigation.
223920271|NCT06499415|DRUG|5FU-Calcipotriol|topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
223920272|NCT06499415|DRUG|5-FU 50 MG/ML Topical Cream|topical 5FU, twice daily, 7 days a week, during 4 weeks
223920273|NCT06702631|DRUG|Nitrous oxide|After a no-drug control period, subjects will inhale nitrous oxide, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration is reached. During the drug condition, subjects will receive low-dose nitrous oxide (% corresponding to Minimum Alveolar Concentration).
223920274|NCT06702631|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
223920275|NCT06605443|DEVICE|Breath analyzer|The study subject will be advised to sit quietly for minimum 10 minutes prior the sampling to avoid temporal changes in levels of volatile organic compunds (VOCs) related to body movement or try to avoid abrupt changes in body posture. Then, he/she will be asked to blow in the breath analyzer in order to obtain the exhaled VOCs profile.
223920276|NCT06605443|DEVICE|Skin patch|A skin patch will be placed in the anterior part of the patient's arm for the obtention of the skin VOCs profile (estimated sampling time of around 1 h). These profiles will be recorded with a dedicated software and analyzed using standard statistical methods.
223920277|NCT06605443|GENETIC|Liquid biopsy|Circulating free tumor DNA (cfDNA) will be extracted from patient's blood and analyzed to detect mutations in BRAF and other prognostic genes.
223920278|NCT06592703|DRUG|Adipose tissue-derived Mesenchymal Stromal Cells|repeated allogenic ASCs IT injections
223920279|NCT05932628|OTHER|This study will observe participants who receive a supported self management approach for thumb base osteoarthritis but it is not an interventional study.|Participants will receive an occupational or physiotherapist led supported self-management programme, which equates to normal NHS care, having been adopted by the sites involved. This involves education, progressive exercises and hand splints if required. The educational materials used, and a minimum number of appointments will be consistent across the study sites. Additional treatments for coexisting conditions will be provided, additional stepped care for thumb base osteoarthritis will also be recorded.
223920280|NCT06602778|OTHER|Biomarkers / blood|Analysis of routine biochemical parameters
224090086|NCT00944827|DIETARY_SUPPLEMENT|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
223530478|NCT05603637|PROCEDURE|Catheter ablation using Farawave pulsed-field ablation catheter|Patients will undergo catheter ablation for atrial fibrillation, i.e. pulmonary vein isolation, using pulsed-field energy with Farawave ablation catheter (Boston Scientific, USA)
223920281|NCT06602778|OTHER|Questionnaire|Physical activity level will be assessed using the International Physical Activity Questionnaire Short Form (IPQI) and sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The data to be obtained from blood will be obtained by selecting blood samples that will be sent to biological waste.
223920282|NCT06654843|BEHAVIORAL|Comparator Arm|In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.
223920283|NCT06654843|BEHAVIORAL|Enhanced intervention arm|"In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.~In addition to childcare, Arm C will also receive peer support activities. Peer support activities will consist of group volunteer activities at food pantries, free deliveries of food pantry groceries, and group play dates at local playgrounds. A Community Champion will also facilitate group text messages."
223920284|NCT05450133|OTHER|Systemic inflammatory index|neutrophil count x platelet count/lymphocyte count
224278923|NCT01049464|DRUG|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
224278924|NCT01049464|DRUG|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
224278925|NCT03718039|DRUG|HTX-011|HTX-011 (bupivacaine/meloxicam), up to but not to exceed 60 mg/1.8 mg, via instillation.
223530479|NCT03495401|DIETARY_SUPPLEMENT|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
223530480|NCT03495401|DIETARY_SUPPLEMENT|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
223920285|NCT05450133|OTHER|BASDAI|Bath Ankylosing Spondylitis Disease Activity Index includes six questions which includes the following six parameters: fatigue, spinal pain, peripheral joint pain, attachment point inflammation, and duration and severity of morning stiffness. A total score, ranging from 0 to 10, was calculated according to the patients' responses to six questions, with a higher score indicating more severe illness.
223920286|NCT05450133|OTHER|ASDAS-ESR|The ASDAS-ESR is deduced using formula that is chosen by the ASAS group. ASDAS-ESR is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte sedimentation rate (mm/h).
223920287|NCT05450133|OTHER|ASDAS-CRP|The ASDAS-CRP is deduced using formula that is chosen by the ASAS group. ASDAS-CRP is calculated with the answers of spinal, peripheral pain, morning stiffness on BASDAI, the patient global assessment, and erythrocyte C-reactive protein (mg/dl).
223920288|NCT05450133|OTHER|MASES|It is used to evaluate the sensitivity of enthesis points by palpation in patients with ankylosing spondylitis. Scoring is done by giving 1 point for sensitive areas and 0 points if there is no sensitivity on the fifth lumbar spinous process, bilateral first and seventh costochondral joints, iliac crystals, posterior and anterior iliac spines, attachment sites of achilles tendon to the calcaneus.
223920289|NCT02375802|BIOLOGICAL|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
223920290|NCT02375802|DRUG|Adipose-derived stromal cells|
223920291|NCT05755997|DRUG|Cerebrolysin|40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
223920292|NCT05755997|DRUG|0.9 % NaCl|100 ml 0.9% NaCl per day for 4 days every month for 1 year
223920293|NCT06820125|DEVICE|Cognitive rehabilitation: CG group|60 minutes of cognitive training with a computerized device
223920294|NCT06820125|DEVICE|Motor rehabilitation: MG group|60 minutes of robot-assisted gait training with the G-EO System
223920295|NCT06820125|DEVICE|Combined rehabilitation: CbG group|30 minutes of cognitive training with a computerized device + 30 minutes of robot-assisted gait training with the G-EO System. To mitigate the effects of fatigue in sequential training, the patients included in this group will undergo the cognitive (treatment CG) and motor (treatment MG) sessions in a counterbalanced order (half of the participants will follow the CG-MG sequence, and the other half will follow the MG-CG sequence). Five-minute breaks will be provided between the cognitive and motor sessions.
223920296|NCT06817577|DRUG|NG004|repeated intrathecal injections of NG004
223920297|NCT06817057|DEVICE|Virtual Reality headset + headphones|The intervention involves patient use of a Virtual Reality headset (the Oculus Quest 2) and headphones (Beats Ep Wired On-Ear) during their wide-awake hand operation.
223920298|NCT06891664|PROCEDURE|Day surgery regimen for patients|The protocol includes admission on the evening of Day -1 and the execution of the surgery on the morning of Day 0 under general anesthesia. The surgery will be performed with the aid of the Da Vinci Single-port robotic system with extraperitoneal access.
223920299|NCT06891664|OTHER|Ordinary management|Management of patients undergoing robotic radical prostatectomy in an inpatient setting based on a minimum of two nights of hospitalization
223920300|NCT04241666|DIAGNOSTIC_TEST|renal scintigraphy|Technetium-99m-dimercaptosuccinic acid scintigraphy of both kidneys
223920301|NCT04241666|DIAGNOSTIC_TEST|renal doppler sonography|doppler ultrasound of both kidneys
223920302|NCT06600386|OTHER|Alveolar recruitement|PEEP after alveolar reruitment maneuvres
223920303|NCT06600386|OTHER|Standard PEEP|PEEP 5 cmH2O
223920304|NCT06667167|DRUG|Induction Carboplatin|Induction phase of carboplatin+etoposide+pembrolizumab followed by maintenance of Pembrolizumab+sacituzumab govitecan
223920305|NCT06696638|DEVICE|EIT-guided Phigh settings during APRV|The Phigh level selected for the patients in the Intervention group was the intercept point of cumulated collapse and overdistension percentage curves, providing the best compromise between collapsed and overdistended lung.
223920306|NCT02670395|DRUG|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
223920307|NCT02670395|DRUG|Placebo|Placebo solution will be administered orally.
223920308|NCT06283706|OTHER|Tryptophan|There are 7 different tryptophan test levels ranging from 0.5, 2, 4, 6, 8, 10, 12 mg.kg-1.day.1
224090087|NCT05396209|PROCEDURE|Hydrated Amniotic Membrane Plug|Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole
224278926|NCT03718039|DEVICE|Luer Lock applicator|Applicator for instillation.
223920309|NCT00503971|DRUG|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
223530481|NCT01082939|DRUG|Fludarabine|25 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
224278927|NCT03718039|DEVICE|Vial access device|Device for withdrawal of drug product.
223920310|NCT04984421|BEHAVIORAL|Healthy School Start|The Healthy School Start program is a universal 4-component family support program for children starting school (5-7 years of age) promoting healthy dietary habits and physical activity in the home environment to prevent childhood obesity and parents' risk of developing type 2 diabetes. It is targeting both children and parents.
223920311|NCT05725837|DRUG|Paroxetine|Paroxetine, 40mg/day, once a day, for 05 consecutive days or 24 hours after shock resolution
223920312|NCT05592223|DRUG|BCG Vaccine USP|2x10\^6 cfu Tice® BCG (ID)
223920313|NCT05592223|DRUG|Isoniazid|INH in the dose of 300 mg for three days post BCG injection.
223920314|NCT05592223|DRUG|Rifampin|RIF in the dose of 600 mg for seven days post BCG injection.
223920315|NCT06607913|OTHER|Exercise|The participants will exercise 2 days a week for 16 weeks. The exercises will include 4 movements: squats, shoulder press, seated row, and bicep curl focusing on internal load and contraction velocity.
223920316|NCT06601452|DRUG|a compound prescription of Chinese medicine|The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
223920317|NCT06860464|BEHAVIORAL|Remote Ischemic Condtioning (RIC)|See descriptions under arm/group descriptions. RIC is delivered for 5 intervention visits. Visits 1 is the baseline assessment visit, and visits 2-6 are RIC plus training visits.
223920318|NCT06860464|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 5 intervention visits. Visits 1 is the baseline assessment visit, and visits 2-6 are Sham plus training visits.
223920319|NCT06860464|BEHAVIORAL|Balance training|All participants will undergo training on a balance board, learning to hold the board level within the 5- degree horizontal range. Participants perform the balance task for 15, 30-second trials per day at visits 2-6.
223920320|NCT06028776|BEHAVIORAL|MS Ballroom Fitness|A personalized dance-based concept focusing on balance, walking capacity, and well-being.
223920321|NCT06409741|PROCEDURE|Biliary sphincterotomy|"ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge.~The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.~For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary.~If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up."
223920322|NCT06860399|DRUG|Vardenafil|Oral Vardenafil
223920323|NCT06860399|DRUG|Sildenafil|Oral Sildenafil
224278928|NCT03718039|DRUG|aprepitant|Aprepitant, three single doses of aprepitant will be administered orally.
223920324|NCT06862271|PROCEDURE|Group 1 ( Caudal block group )|In the caudal block group, after the induction of caudal block with investigations, 0.2% bupivacaine will be applied to the epidural space in a volume of 0.8 mL/kg and a maximum of 20 mL will be injected into the epidural space and the surgical incision will be made at the 15th minute. For participants after surgery, Pediatric Anesthesia Emergence Delirium (PAED), Face Leg Activity Cry Consolability (FLACC) scales will be recorded, and for parental satisfaction, the LIKERT scale will be used. In addition, the child's walking time, first urination time, and need for additional painkillers will be questioned and recorded.
223530482|NCT01082939|DRUG|Cyclophosphamide|250 mg/m\^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
223530483|NCT01082939|DRUG|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
223530484|NCT01082939|DRUG|Rituximab|"Cycle 1 (Week 1): 375 mg/m\^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m\^2/day IV on Day 2 over 4- 6 hours"
223920325|NCT06862271|PROCEDURE|Group 2 (Penile block and IV Fentanyl group)|In the penile block and IV fentanyl group, 1 µg/kg fentanyl will be administered by the investigations and 5 minutes later, penile block will be performed using 0.25% bupivacaine at a dose of 0.2 mL/kg. For participants after surgery, Pediatric Anesthesia Emergence Delirium (PAED), Face Leg Activity Cry Consolability (FLACC) scales will be recorded, and for parental satisfaction, the LIKERT scale will be used. In addition, the child's walking time, first urination time, and need for additional painkillers will be questioned and recorded.
223920326|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 1|Patients in the first dose level will receive a cell dose of 1×10\^6 cells/kg.
223920327|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 2|Patients in the second dose level will receive a cell dose of 2×10\^6 cells/kg.
223920328|NCT06862388|BIOLOGICAL|Device: Phase Ⅰ Dose Level 3|Patients in the third dose level will receive a cell dose of 4×10\^6 cells/kg. Based on these findings, the maximum tolerated dose (MTD) will be determined.
223920329|NCT06862388|BIOLOGICAL|Device: Phase II MTD in Phase I|This group subjects received the MTD obtained in phase I.
223920330|NCT06862388|BIOLOGICAL|Device: Phase II lower than the MTD in Phase I|This group subjects received a dose lower than the MTD
223920331|NCT03285620|DRUG|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
223920332|NCT03285620|DRUG|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
223530485|NCT00862940|DRUG|Memantine|10 mg tablets twice daily
223530486|NCT00862940|DRUG|Placebo|Tablets twice daily
223920333|NCT03919032|OTHER|This is an observational study without intervention|This is an observational study without intervention
223530487|NCT01846312|OTHER|No treatment given|The participants will not receive any treatment.
223530488|NCT02343185|OTHER|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
223530489|NCT02343185|OTHER|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
223530490|NCT06500455|PROCEDURE|Computed Tomography|Undergo CT
223530491|NCT06500455|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRS
223920334|NCT06615674|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
223920335|NCT06997354|DIAGNOSTIC_TEST|Questionnaire|The parents have to complete a questionnaire
223920336|NCT06021678|DRUG|EX103 injection|Administered as specified in the treatment arm.
223920337|NCT06449183|DIAGNOSTIC_TEST|VIDAS® TBI Test [GFAP and UCH-L1 assays]|The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
223920338|NCT05836012|BIOLOGICAL|HIL-214|2 injections - given at 4 months and the second at 6 months of age.
223920339|NCT05836012|BIOLOGICAL|Placebo|2 injections - given at 4 months and the second at 6 months of age.
223920340|NCT04497558|DIAGNOSTIC_TEST|Endometrium biopsy|In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
224278929|NCT05694130|DRUG|Prednisolone|Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
224278930|NCT05694130|DRUG|Tacrolimus|Oral Tacrolimus 1-2mg twice daily for 12 weeks.
224278931|NCT00879684|BIOLOGICAL|CVX-060|Weekly, intravenous dose
224278932|NCT01684280|GENETIC|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
224278933|NCT01224457|DRUG|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
224278934|NCT03993639|DRUG|Pegfilgrastim|Single dose of SC administration
224278935|NCT04118946|BIOLOGICAL|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
224278936|NCT06396507|DRUG|Permethrin Solution|permethrin 5 % solution
224278937|NCT06396507|DRUG|Sulfur|Sulfur 10%+ vaseline 90 % ointment
224278938|NCT02391233|BEHAVIORAL|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
224278939|NCT02391233|BEHAVIORAL|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
224278940|NCT06873698|BEHAVIORAL|Neuro-behavioral Therapy|Neuro-behavioral therapy (NBT) is an evidence-based, multi-modality, time-limited, whole-person therapy, delivered in one hour, weekly, individual appointments. NBT has been used to treat epilepsy, nonepileptic (functional) seizures, and motor functional neurological disorder (mFND).
224278941|NCT06873698|OTHER|Standard Medical Care (SMC)|Standard Medical Care (SMC) involves the routine care received by the participant. SMC may include any of the following evaluation and followup appointments with neurology, physiatry, psychiatry, psychology, mental health, rehabilitation (e.g., Physical Therapy, Occupational Therapy, Speech and Language Therapy), primary care, among other specialists.
224278942|NCT04511208|DEVICE|Cooling Vest|Evaluate that wearing a cooling vest during surgery reduces surgeons' mean-body temperature and preserves their cognitive performance.
223530492|NCT06500455|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223530493|NCT06500455|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223530494|NCT02239237|DRUG|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
223920341|NCT03438552|RADIATION|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
223920342|NCT06543238|OTHER|Breastfeeding card game group|Breastfeeding card game group: Breastfeeding education will be given to 30 primiparous pregnant women in the intervention group using the card game method twice, two weeks apart.
224278943|NCT04511208|DEVICE|Without cooling vest|Evaluate surgeons' mean-body temperature and cognitive performance without cooling vest.
224278944|NCT00113061|PROCEDURE|Exercise|
224278945|NCT04485208|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the anterior cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
223920343|NCT05572658|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223920344|NCT05572658|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223920345|NCT05752474|BEHAVIORAL|Exercise|Physical therapy targeting flexibility, strength, and endurance will be delivered at the participant's home, center-based, or virtually via a twice-weekly (on average) schedule to provide a total of about 6-8 sessions during the 3-4 week study period. Participants will be asked to participate in self-directed exercise for at least 30 minutes per day for 4 or more days per week.
223920346|NCT05752474|BEHAVIORAL|Nutrition|One-hour virtual group nutrition education classes will be held once per week by a dietitian, focusing on optimal protein intake (1.2 grams per kg of body weight) for lean body mass preservation (from food sources and oral nutritional supplements) and muscle gain. Participants will also receive oral nutritional supplements (20-30 grams of protein/day provided by our study team).
223920347|NCT05752474|BEHAVIORAL|Meditation|One-hour virtual group meditation sessions will be held once per week by an experienced meditation teacher. Classes will focus on breathing techniques, yoga, and mindful meditation practices. Participants will be asked to participate in self-directed meditation for at least 12 minutes daily.
223920348|NCT05752474|BEHAVIORAL|Cognitive Behavioral Intervention|A 30-min telephone-based session with individual patients will take place to deliver cognitive behavioral strategies once per week by a professionally trained clinician. These strategies include education about frailty and surgery, increasing positive beliefs of the benefits of exercise and nutrition, discussing barriers, setting individualized goals for surgery and recovery, developing a detailed exercise and nutrition plan (including logistics), self-monitoring of progress using weekly exercise, diet, and meditation logs, and enhancing self-efficacy through the celebration of small wins.
224278946|NCT04883450|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
224278947|NCT05543395|BEHAVIORAL|Domestic Violence Questionnaire|Domestic Violence Questionnaire
223530495|NCT06120790|OTHER|3 Oz water screen|Patient will consume 3 oz of water continuously without stopping and then will be monitored for one minute post completion. Patient will complete this twice in the same session.
223530496|NCT04876911|BEHAVIORAL|Simulated Presence Therapy|A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
223530497|NCT05657158|OTHER|Brolucizumab|Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included
223920349|NCT03865992|DIETARY_SUPPLEMENT|Curcumin|Given capsules for oral administration
223920350|NCT03865992|OTHER|Placebo|Given capsules for oral administration
223920351|NCT03865992|OTHER|Nanoemulsion|Given nanoemulsion curcumin PO
223920352|NCT03865992|OTHER|Quality-of-Life Assessment|Ancillary studies
223920353|NCT03865992|BEHAVIORAL|Questionnaire|Ancillary studies
223920354|NCT03640858|DEVICE|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
223920355|NCT06865274|PROCEDURE|Blood draw for the laboratory assessment|Blood draw of approximately 5 ml of peripheral venous blood (collected in EDTA) will be collected for DNA extraction and genetic analysis limited to the research of FCG3A polymorphisms
223940683|NCT06593756|DEVICE|Bioreactance|Bioreactance is a noninvasive hemodynamic monitoring technique, in which four double electrode sensors are placed on the skin of the chest. A high frequency sine wave is transmitted across the thorax. Pulsatile flow in the aorta causes phase shifts and amplitude changes of this signal, which are measured across the different electrodes and used to compute cardiac output.
224090088|NCT05396209|PROCEDURE|ILM filling|The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole
224090089|NCT05396209|PROCEDURE|Conventional ILM peeling|Peeling with complete removal of the internal limiting membrane within the vascular arch
224090090|NCT00257634|DRUG|dexamethasone to injury site|
224278948|NCT00912522|DEVICE|TMS|TRANSCRANIAL MAGNETIC STIMULATION
224278949|NCT04826250|PROCEDURE|Timing of medication|Either morning or nighttime medication
223530498|NCT04637529|DRUG|S (+) - Ibuprofen|S (+) - Ibuprofen + placebo of Ibuvix®
223530499|NCT04637529|DRUG|Ibuvix® - ibuprofen|Ibuvix® + placebo of S(+) - Ibuprofen
223530500|NCT04644952|OTHER|Electronic Health Record Review|Review of medical records
224278950|NCT03241836|DIAGNOSTIC_TEST|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
224278951|NCT04634630|GENETIC|Exposure to lung cancer stem cells|The exposure to lung cancer stem cells was measure as the percentage of Aldehyde dehydrogenase (ALDH) on all viable cells extracted from surgically resected tumor specimens
224278952|NCT04726215|DRUG|[18F]F AraG|PET imaging agent specific to activated T cells
223920356|NCT06864325|OTHER|VR-training|The VR gaming experience is based on the commercial rhythm game Beat Saber, featuring songs by Queen with varying rhythms and tempos. Players receive visual stimuli in the form of colored square blocks and must slice them in time with the music using the corresponding right or left hand. The blocks must be cut with a lightsaber of the same color. To ensure the safety of older adults, heart rate and energy expenditure were monitored throughout each session, while oxygen saturation was assessed before and after the exercises. Participants playe the game in comfortable conditions: the game loaded directly into the headset and VR glasses synchronized with portable screens to allow monitoring and assistance if needed. Before each session, the headset was adjusted to fit the participant's head dimensions, and corrective glasses were provided if required. The VR setup included a Meta Quest 2 headset with goggles and user-friendly controllers equipped with sensors (Meta Platforms, U.S.).
223920357|NCT06863831|DRUG|Yishen Qutong Granules|The patent prescription of Professor Feng Li, the head of the Department of Traditional Chinese Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences.
223920358|NCT06863831|DRUG|Yishen Qutong Simulant Granules|Yishen Qutong Simulant Granules is a preparation with one-tenth the dosage of Yishen Qutong Granules.
223920359|NCT06864182|DRUG|CX2101A tablet|CX2101A tablet
223920360|NCT06864182|DRUG|CX2101A placebo tablet|CX2101A placebo tablet
223920361|NCT06864182|DRUG|CX2101A enteric-coated tablet|CX2101A enteric-coated tablet
223920362|NCT06864182|DRUG|CX2101A placebo enteric-coated tablet|CX2101A placebo enteric-coated tablet
223920363|NCT06864923|OTHER|Hot foot bath application group|The intervention group will receive hot foot baths for three consecutive nights starting from the second day of hospitalization. The foot bath will be applied one hour before the patient goes to bed at night. The foot tub will be filled with hot water to approximately 20 cm above the patient's ankle and the temperature of the water will be measured with a water thermometer. The temperature of the water will be kept stable at 41-42°C. This application will be done for 20 minutes. The sleep and fatigue levels of the patients will be measured with measurement tools in the morning (3 times) following each application.
223920364|NCT06863350|DEVICE|patent foramen ovale closure|patent foramen ovale closure
223920365|NCT06864312|DRUG|continuous infusion of levobupivacaine|patients one arm of this study will receive a postoperative continuous infusion of levobupivacaine
223920366|NCT06864312|DRUG|oxycodone|A timed weight appropriate dose of oxycodone will be administered 16 hours postoperatively
223920367|NCT06863675|DEVICE|HAL lenses for children with strabismus|It has been shown that peripheral segmented defocus spectacles can slow myopia progression. The Essilor® Stellest™ lens has been designed with an exclusive and pioneering technology called HALT (Highly Aspherical Lenslet Target). The HALT technology is made of a constellation of 1,021 invisible lenslets. This constellation creates a signal in front of the retina that acts as a shield against eye elongation and, therefore, myopia progression. Studies suggest that children are tolerable against these glasses, and the lenses can slow down myopia progression by 67% on average, compared to single vision lenses, when worn 12 hours a day. It can be considered as one of the best available myopia control spectacle lens designs, being superior to progressive addition and bifocal lenses.
223530501|NCT03558789|BIOLOGICAL|bovine lactoferrin|mouthwash
223530502|NCT04358237|DRUG|Lurbinectedin|"Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device."
223530503|NCT04358237|DRUG|Pembrolizumab|Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
223530504|NCT05794646|OTHER|Hybrid effectiveness-implementation study type 2|Diagnosis of hepatitis C; Assessment of hepatic fibrosis; Treatment of hepatitis C; Assessment of psychological disorders and treatment or referral.
223530505|NCT06325514|DIAGNOSTIC_TEST|Artificial intelligence based program|the AI based program is based on image analysis
223530506|NCT05852938|DRUG|BION-1301|BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.
223530507|NCT05852938|DRUG|Placebo|Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.
223530508|NCT05712187|DRUG|ALTO-100|ALTO-100 tablet BID
223530509|NCT05712187|DRUG|Placebo|Placebo tablet BID
223530510|NCT05053152|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223530511|NCT05053152|PROCEDURE|Bone Scan|Undergo bone scan
223530512|NCT05053152|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223530513|NCT05053152|OTHER|Fluciclovine F18|Given fluciclovine F18
223530514|NCT05053152|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI and/or PET/MRI
223530515|NCT05053152|DRUG|Placebo Administration|Given PO
223530516|NCT05053152|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and/or PET/MRI
223530517|NCT05053152|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT or PET/MRI
223530518|NCT05053152|DRUG|Relugolix|Given PO
223530519|NCT05053152|RADIATION|Stereotactic Body Radiation Therapy|Undergo SABR
223530520|NCT05573308|DEVICE|Clear Aligners with Dental Monitoring|Dental Monitoring™ (DM ™). This digital technology software allows orthodontists to monitor patients remotely through continuous analytics using control vision technology, metaheuristics, and artificial intelligence.31 This app utilizes a patented artificial intelligence machine learning algorithm to calculate 3-dimensional (3D) tooth movements from intraoral photos and videos that patients capture using their smartphone cameras.
223530521|NCT05573308|DEVICE|Clear Aligners|Removabale orthodontics appliances
223530522|NCT05552859|DRUG|Insulin glargine 300 U/mL|Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
223530523|NCT05552859|DRUG|Insulin degludec 100 U/mL|Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
223717092|NCT02398760|OTHER|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
223920368|NCT06863675|DEVICE|SVL for children with strabismus|SVL for children with strabismus
223920369|NCT06864884|DRUG|ARC-001|Gel formulation containing investigational anesthetic.
223920370|NCT06864884|DRUG|Placebo gel|Gel that contains no active ingredients.
223920371|NCT06863415|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
223920372|NCT06863415|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
223920373|NCT06864897|DEVICE|Total hip prothesis|Total hip prothesis with a Delta-TT cup, H MAX S Stem and a ceramic liner
223920374|NCT06864897|DEVICE|Total hip prosthesis|Total hip prosthesis with a Delta TT cup, H MAX S stem and polyethylene liner
223920375|NCT06864793|DRUG|QL1012D|A single Subcutaneous injection, 225IU
223920376|NCT06864793|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
223920377|NCT06863688|DEVICE|Tourniquet|Tourniquets will be applied to the thigh of the operative extremity during operative fixation of ankle fractures.
223920378|NCT06863688|OTHER|No Tourniquet|No tourniquet will be inflated on the operative extremity during the operative fixation of ankle fractures.
223920379|NCT06864078|DEVICE|IUD Insertion during Cesarean Section|to evaluate the analgesic effect of diclofenac potassium and lidocaine gel applied to the posterior vaginal fornix before IUD insertion in women who had previously undergone cesarean section. By assessing the efficacy of this pain management strategy, this study seeks to contribute to the optimization of IUD insertion protocols, improving patient comfort and increasing the acceptance of this highly effective contraceptive method.
224090091|NCT00737529|DRUG|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
224090092|NCT03065829|BEHAVIORAL|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
224090093|NCT03065829|BEHAVIORAL|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
224278953|NCT04547036|DEVICE|XEN45|Up to 140 consecutive patients with preoperatively recorded endothelial cell counts will be summoned to a consecutive endothelial cell count record and measurement of central corneal thickness postoperatively.
224278954|NCT01634854|DRUG|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
224278955|NCT01634854|DRUG|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
224278956|NCT01169038|DRUG|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
224278957|NCT01488448|DRUG|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
224278958|NCT01488448|DRUG|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
223920380|NCT06864078|DRUG|lidocaine gel and diclofenac potassium tablets|lidocaine gel and diclofenac potassium tablets
223920381|NCT06864078|DRUG|Placebo|Placebo
223920382|NCT06865183|BEHAVIORAL|Positive Parenting Seminar Series|Selected Child Triple P Positive Parenting Seminar Series Delivered Through Telehealth
223920383|NCT06863181|DEVICE|Radiofrequency ablation|Genicular nerve neurolysis with heat
224090094|NCT04957563|BEHAVIORAL|olfactory rehabilitation|treatment for improve olfactory function
224278959|NCT05683808|DRUG|Apixaban|Open label
223920384|NCT06342726|DEVICE|PAX Warming Blanket|Electric resistive active external warming blanket
223920385|NCT06342726|DEVICE|Passive insulation|3-layered wrapping model
223920386|NCT06388642|DRUG|Afamelanotide 16mg implant|afamelanotide 16mg implant will be administered to each patient during the study.
223920387|NCT05977751|DEVICE|FemBloc|Treatment for women who desire non-surgical permanent birth control by occlusion of the fallopian tubes.
224090095|NCT06217250|PROCEDURE|Traditional EMR|Conventional EMR with thermal ablation of resection margins: initial submucosal injection of saline and methylene blue and subsequent piecemeal resection with 10- or 15-mm diathermic snare with subsequent thermal ablation of resection margins with snare tip soft coagulation.Nevertheless, this technique is associated with the emergence of serious adverse events (SAEs), including delayed bleeding (PPB), electrocautery-induced post-polipectomy syndrome (PPS), and perforation(4).
224090096|NCT06217250|PROCEDURE|"the cold snare (CO), underwater technique (W), and the use of submucosal lift (L) in both study arms"|"The cold-EMR technique, as opposed to the conventional approach, employs a specialized snare that enables tissue transection without the need for electrical current, particularly in appropriately selected lesions. This approach yields the same efficacy outcome as the conventional procedure but offers the advantage of reducing the risks associated with polypectomy, which are often secondary to the use of diathermic current. Subsequently, the lesion fragments are retrieved for histological examination. Furthermore, the use of underwater setting, as demonstrated for hot EMR, could improve the effectiveness of cold-EMR."
224278960|NCT02329431|BEHAVIORAL|activation curriculum|psychosocial activation curriculum
224278961|NCT02329431|BEHAVIORAL|support group|parent directed support group
224278962|NCT01475487|PROCEDURE|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
224278963|NCT00219986|DRUG|Potent HAART during acute or early HIV-1 infection|
223717093|NCT02289339|DEVICE|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
223717094|NCT01646762|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223717095|NCT01646762|OTHER|Laboratory Biomarker Analysis|Correlative studies
223717096|NCT02412618|DRUG|Mifepristone|Progesterone antagonist
223717097|NCT02412618|DRUG|Misoprostol|Prostaglandin E1
223717098|NCT02412618|DIETARY_SUPPLEMENT|Placebo|Tasteless, odorless, sugar based pill
223920388|NCT06676839|OTHER|the complete ICOPE program|"The participant benefits from a personalized intervention, including 1) a screening to be repeated every 6 months, based on the use of the ICOPE tool, allowing an assessment of the 6 functions necessary for an autonomous lifestyle; 2) a comprehensive assessment step for the 6 functions 3) a personalized intervention step aimed at correcting the trajectory of functional decline, based on the participants' preferences; 4) a follow-up step for this intervention.~Participants will benefit from telephone follow-up 1.5 months after the start of the program and between each annual visit to support them in implementing their personalized intervention plan.~At each contact, the ICOPE nurse reviews the participant's implementation of the personalized intervention plan recommendations and their adherence to the program.~The results of the assessment and the proposed intervention are communicated and discussed with the primary care physician and a summary letter is also sent."
223920389|NCT06677606|PROCEDURE|PENG block|The ultra sound transducer will be placed in a transverse orientation, medial and caudal to the anterosuperior iliac spine in order to identify the anteroinferior iliac spine, the iliopubic eminence and the psoas tendon. Using an in-plane technique and a lateral-to-medial direction, the block needle will be advanced until its tip will be positioned on the periosteum dorsal to the psoas tendon. The LA (20mL of bupivacaine 0.5%) will be injected following negative aspiration.. The accurate position of the needle was confirmed by hydro dissection and spread under the illo-psoas muscle
224090097|NCT01145560|DRUG|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
224090098|NCT01145560|DRUG|Placebo|Placebo
224090099|NCT01724892|DRUG|Dexamethasone|
224090100|NCT01724892|DRUG|Loteprednol etabonate|
224090101|NCT01339455|PROCEDURE|AHSCT|"AHSCT Procedure:~1. Mobilization and Harvesting:~   * Cyclophosphamide~  * Rituximab~  * GSCF~  * Dexamethasone~  * Apheresis~2. Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~   * Cyclophosphamide~  * MESNA~  * Rabbit ATG~  * Rituximab~  * Methylprednisolone~  * Stem Cell infusion~  * GSCF"
224090102|NCT06041555|OTHER|3 MRI sequences (T2*, IVIM and Multi Echo-Gradient), without injection, are performed|Generate 3D maps of intra-tumoral hypoxia and characterize their evolution during treatment thanks to the establishment of a prospective database of MRI sequences
224278964|NCT02386761|DRUG|Single Ascending Dose (SAD)|
224278965|NCT02386761|DRUG|Multiple Ascending Dose (MAD)|
224278966|NCT06233539|OTHER|Observational research without intervention|Observational research without intervention
224278967|NCT03761706|BEHAVIORAL|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
224278968|NCT03761706|OTHER|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
224278969|NCT03785691|DRUG|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
224278970|NCT03785691|DRUG|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
224278971|NCT03785691|DRUG|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
224278972|NCT01732679|OTHER|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
224278973|NCT00378027|DRUG|Fondaparinux|Administer Fondaparinux Risk Stratify
224278974|NCT01920750|BIOLOGICAL|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
224278975|NCT01920750|BIOLOGICAL|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
224278976|NCT01920750|OTHER|Mock Antigen|Physiological saline
224278977|NCT01129323|DRUG|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
224278978|NCT03774199|DEVICE|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
224278979|NCT05868824|OTHER|Blood sample|A blood sample for assessing cytokines will be performed at baseline and at follow-up visit 3 months after initiation of treatment. The blood sample will be performed as part of blood tests done for standard AD follow up.
224278980|NCT02971787|DIETARY_SUPPLEMENT|Probiotics|Day 1-21: 2 capsules per day
224278981|NCT02971787|DIETARY_SUPPLEMENT|Salt|Day 8-21: 10 tablets à 600 mg per day
224278982|NCT06024382|OTHER|twin block|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
224278983|NCT06024382|OTHER|twin block combined with low level laser|2 parallel groups one is treated with twin block and the other is treated with twin block combined with low level laser therapy
224278984|NCT01977456|DRUG|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
223920390|NCT06677606|PROCEDURE|PAI block|LA infiltration will be carried out using a total dose of 150mg of bupivacaine and a total volume of 60mL. The admixture (consisting of 60mL of bupivacaine 0.25% and 30mg of ketorolac) will be loaded into two 30mL syringes at the beginning of surgery. After insertion of the acetabular component (and before insertion of the femoral stem), the surgeon will infiltrate the deep tissues (ie, anterior and posterior capsules, gluteus minimus and medius muscles, supraacetabular region, area around the anterior inferior iliac spine, and quadratus femoris muscle all the while avoiding the deep hip external rotator muscle group in order to prevent sciatic nerve block) with the first 30mL syringe. Before wound closure, the gluteus maximus muscle, iliotibial band, subcutaneous tissues, and skin will be infiltrated with the second 30mL syringe.
223920391|NCT02456233|PROCEDURE|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
223920392|NCT02456233|PROCEDURE|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
224090103|NCT04292600|DIAGNOSTIC_TEST|POCKiT diagnostics' algorithm for LVO detection|Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
224090104|NCT04187027|DEVICE|pulsed electromagnetic field therapy device|magnetic field stimulation (MFS) is a novel technique for stimulating the nervous system non-invasively, which can activate deep neural structures via induced electric currents, without pain and discomfort. Also, several clinical trials including placebo-controlled studies have shown that MFS of the pelvic floor and sacral roots is effective for overactive bladder (OAB). MFS induces inhibitory effects on detrusor overactivity in a similar manner to electrical stimulation, with significant clinical advantages. MFS of the sacral nerve roots could be a promising alternative treatment for OAB.
224090105|NCT03040024|DRUG|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
224090106|NCT03040024|DRUG|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
224090107|NCT03040024|DEVICE|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
224090108|NCT04819906|DRUG|Estetrol 20 mg|One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
224090109|NCT04819906|DRUG|Estetrol 100 mg|Five estetrol monohydrate (E4) 20 mg tablets orally once
224090110|NCT04819906|DRUG|Placebo|Five placebo tablets orally once
224090111|NCT04819906|DRUG|Moxifloxacin 400 mg|One moxifloxacin 400 mg tablet orally once (open-label)
224090112|NCT00783627|PROCEDURE|Angiography|Angiography done at the J1 visit
224090113|NCT00134914|DRUG|Buprenorphine|single doses given by sublingual and parenteral routes
224090114|NCT03282032|OTHER|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
224090115|NCT00126971|DRUG|chlorproguanil-dapsone|
224090116|NCT02910427|OTHER|Regular salt|Participants eat a regular salt diet.
224090117|NCT02910427|OTHER|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
224090118|NCT02910427|OTHER|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
224090119|NCT02321969|DIETARY_SUPPLEMENT|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate \[EGCG\]).
224090120|NCT01086787|OTHER|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
224090121|NCT03757039|DEVICE|Multifocal soft contact lenses|Commercially available contact lenses
224090122|NCT03757039|OTHER|Progressive addition lens spectacles|Per subject's habitual prescription
224090123|NCT02278783|DRUG|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
224278985|NCT01142661|DRUG|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m\^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
223920393|NCT06865807|PROCEDURE|PDS 2/0 vs Monomax 2/0|We will include in the study patients who require an emergency midline laparotomy by the General and Digestive Surgery Department of the University Hospital Nuestra Señora de Candelaria. Patients will be randomized based on their medical record number: those with an even number will undergo laparotomy closure using PDS 2/0, and those with an odd number will receive Monomax 2/0.
223717099|NCT01253408|DRUG|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
223717100|NCT01253408|DRUG|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
223717101|NCT02840955|DEVICE|Staphefekt SA.100|
223940684|NCT06593756|DIAGNOSTIC_TEST|Passive Leg Raising|Passive Leg Raising (PLR) is a maneuver that mimics a fluid challenge by shifting about 300 ml of venous blood from the lower body to the heart. Thereby, it can help to predict fluid responsiveness without actual fluid infusion. To start with, the patient is placed in a semi-recumbent position. Then, the bed is adjusted so that the patient's torso is moved to a horizontal position and the lower limbs are raised to an angle of 45°. Hemodynamic effects occur and can be measured within one minute.
223940685|NCT06593756|DIAGNOSTIC_TEST|Vena Cava Ultrasound|Inferior Vena Cava (IVC) Ultrasound has become a popular technique for assessing volume status. IVC diameter is measured in a subcostal long-axis IVC view 1-2 cm from the junction with the right atrium. The magnitude of distensibility during mechanical ventilation cycles or collapsibility during spontaneous breathing has been proposed to correlate with fluid responsiveness
223940686|NCT06593756|DIAGNOSTIC_TEST|End-expiratory /-inspiratory occlusion test|In preload-dependent patients, mechanical ventilation induces periodic changes in cardiac output. Standardized maneuvers of end-expiratory or end-inspiratory interruption over 15 seconds may increase or decrease stroke volume, respectively, which is a valid predictor of fluid responsiveness
223940687|NCT06593756|DRUG|Fluid bolus|To verify fluid responsiveness, 500 ml of balanced crystalloids will be infused over a time of 15-20 min (25-33.33 ml/min) after completion of passive leg raising and restoration of baseline patient positioning
223940688|NCT06593405|COMBINATION_PRODUCT|occupational therapy interventions for low vision care|Occupational therapists utilize many different treatment strategies when caring for the client with low vision. Oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Interventions include task lighting, organizational strategies, smart apps, contrast, enlarged print, typoscopes and electronic magnification devices.
223940689|NCT06246136|PROCEDURE|ELIOS|Following cataract surgery, surgeon will proceed to ELIOS treatment.
223940690|NCT06246136|PROCEDURE|Competitor Device|Following cataract surgery, surgeon will proceed to Competitor treatment.
223940691|NCT02962102|DRUG|Calcifediol|Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
223940692|NCT02962102|DRUG|Calcitriol|Calcitriol 4mcg orally daily x 5
223940693|NCT02962102|DRUG|Placebos|Placebo (medium chain triglyceride oil) orally daily x 5
223940694|NCT05450328|DRUG|Combined Epoprostenol Sodium & Milrinone|"One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
223940695|NCT05450328|DRUG|Normal saline|"The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions."
223940696|NCT06654193|DRUG|Allogeneic HB-adMSCs|Allogeneic HB-adMSCs
223940697|NCT06654193|DRUG|Normal Saline|Sterile Saline Solution
223940698|NCT02901821|GENETIC|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
223940699|NCT03942328|BIOLOGICAL|Atezolizumab|Given IV
223940700|NCT03942328|BIOLOGICAL|Bevacizumab|Given IV
223940701|NCT03942328|RADIATION|External Beam Radiation Therapy|Undergo high-dose EBRT
223940702|NCT03942328|PROCEDURE|Pheresis|Undergo apheresis
223940703|NCT03942328|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
223940704|NCT03942328|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given IT
223940705|NCT03942328|BIOLOGICAL|Tiragolumab|Given IV
223940706|NCT03942328|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
223940707|NCT03942328|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223940708|NCT03942328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223940709|NCT03942328|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223940710|NCT03942328|PROCEDURE|Biopsy Procedure|Undergo biopsy
223940711|NCT03942328|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223940712|NCT02850575|DEVICE|Mpact Double Mobility cup|
223940713|NCT06056427|BIOLOGICAL|HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)|Participants will receive autologous HB-adMSCs through intravenous infusion only, with a treatment duration of 18 weeks, infusion rate 4-5mL/min and total volume of 250 mL Sodium chloride 0.9%. Each participant will receive a total of 6 doses of HB-adMSCs with a dosing regimen of approximately 2 weeks between infusion 1 and infusion 2, and 4 weeks between the remaining infusions.
224090124|NCT00628186|DEVICE|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
224090125|NCT00628186|DEVICE|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
224090126|NCT02976415|OTHER|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
224090127|NCT05462184|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
224090128|NCT05462184|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|
224090129|NCT03501056|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
224090130|NCT03501056|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
224090131|NCT00188084|PROCEDURE|DNA Index|
224090132|NCT00188084|PROCEDURE|S-Phase%|
224090133|NCT00188084|PROCEDURE|CD45 expression|
224090134|NCT00188084|PROCEDURE|P16 metabolic way|
224090135|NCT01126346|BEHAVIORAL|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
224090136|NCT01126346|BEHAVIORAL|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
224090137|NCT01126346|OTHER|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
224090138|NCT00096161|DRUG|Cyclosporine|Given PO
224090139|NCT00096161|DRUG|Mycophenolate Mofetil|Given PO
224090140|NCT00096161|DRUG|Pentostatin|Given IV
224090141|NCT00096161|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
224090142|NCT01133743|DRUG|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
224278986|NCT06030128|BEHAVIORAL|core stabilization exercise|All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
223717102|NCT02840955|OTHER|Placebo|
223717103|NCT02563743|BEHAVIORAL|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
224090143|NCT03904680|DRUG|Methotrexate|Methotrexate 2.5 mg tablet
224090144|NCT03904680|DRUG|Vitamin D|Vitamin D 200,000 IU ampules
224090145|NCT03179917|DRUG|Pembrolizumab|pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles. Pediatric patients will be treated at 2 mg/kg with a maximum dose of 200 mg.
224090146|NCT03179917|RADIATION|Involved Site Radiation Therapy|30 Gy of ISRT
224090147|NCT04636905|OTHER|Questionnaires|Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
224090148|NCT03056443|DEVICE|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
224090149|NCT04722718|DRUG|Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin|Sintilimab:200mg,ivgtt,d1,21days/cycle;Apatinib:250mg po,d1-14days,21days/cycle;Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle;Carboplatin:AUC=1.5,ivgtt,d1,d8, 21days/cycle.Monitoring of blood routine, biochemical and urine routine, electrocardiogram, and record the patient's drug-related adverse reactions every cycle,according to the curative effect of patients, compliance and tolerance, neoadjuvant therapy 6 cycles,every 2 cycles to evaluate curative effect (ultrasonic, breast X-ray CT, bone scan, brain, lungs, assessment and breast MRI imaging).
224090150|NCT05753111|DIETARY_SUPPLEMENT|PEA|PEA supplementation
224090151|NCT05753111|DIETARY_SUPPLEMENT|PLACEBO|Maltodextrin supplementation
224090152|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
224090153|NCT01400737|DRUG|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
224099544|NCT02380131|DRUG|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
224099545|NCT00931164|DRUG|Sodium Oxybate|dosage is by weight
224099546|NCT01288768|PROCEDURE|Knee arthroscopy|Knee arthroscopy within 4 weeks.
224099547|NCT03419793|DEVICE|segmental vibration device|segmental vibration device
224099548|NCT03419793|OTHER|physical therapy exercises|
224099549|NCT02956655|OTHER|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
224278987|NCT00409461|DRUG|ATG-Sirolimus-Tacrolimus|
223920394|NCT06866951|DRUG|Chemo-immunotherapy|"Post-radical surgery for cervical cancer, the first cycle of PD-1 inhibitor combined with chemotherapy will begin 2 to 3 weeks after surgery. Each treatment cycle lasts 21 days, with a total of 6 cycles. A complete imaging efficacy evaluation will be conducted after every 3 treatment cycles. For patients with lymph node metastasis ≥3 or para-aortic lymph node metastasis, 6 cycles of chemotherapy combined with immunotherapy will be administered. Other patients will receive 3 cycles of chemotherapy combined with immunotherapy.~Treatment regimen:~Day 1:~Paclitaxel (albumin-bound) for injection: 260 mg/m², administered intravenously over 30 minutes.~Day 1 to Day 2:~Cisplatin 75-80 mg/m², administered intravenously at a 1 mg/min rate.~Day 3:~PD-1 inhibitor (Camrelizumab for injection, Aikening): 200 mg per dose, infused over 30 to 60 minutes."
223920395|NCT06866951|RADIATION|CCRT|"The overall chemoradiotherapy (including EBRT and brachytherapy) should typically be completed within 6 weeks (with a maximum extension to 10 weeks in case of anticipated delays). External beam radiotherapy (EBRT) should be at least three-dimensional conformal radiotherapy, with image-guided (CT or MR) intensity-modulated conformal radiotherapy techniques recommended, at a 45-50 Gy dose.~Concurrent Chemotherapy:~Cisplatin (40 mg/m²) is preferred on a weekly schedule (administered before the planned EBRT on the same day, once a week \[±1-day window\], for a total of 5-6 infusions). Carboplatin can be used as an alternative if cisplatin toxicity is not tolerated."
223920396|NCT06862765|PROCEDURE|transcatheter tricuspid valve replacement|The LuX-valve was implanted under fluoroscopic and echocardiographic guidance via the transjugular vein approach. Once the delivery system was introduced, it was adjusted within the right heart chamber to be perpendicular to the tricuspid annulus. The anterior leaflet was grasped using two leaflet graspers, and the ventricular portion of the device component was gradually released. After deploying the atrial disc to ensure the elimination of TR, septal anchoring was performed, and the delivery system was subsequently withdrawn.
223920397|NCT06865794|OTHER|Questionnaire and Physical Exam|Rosenberg self-esteem scale pre-operatively, at 3 and 12 months post-op
223920398|NCT06865794|OTHER|Questionnaire and Physical Exam|FACE-Q psychological sub-scale pre-operatively, at 3 and 12 months post-op
223920399|NCT06865794|OTHER|Questionnaire and Physical Exam|BREAST-Q psychological sub-scale pre-operatively, at 3 and 12 months post-op
223920400|NCT06865794|OTHER|Questionnaire and Physical Exam|BSIQ-SF pre-operatively, at 3 and 12 months post-op
223920401|NCT06865794|OTHER|Questionnaire and Physical Exam|FLZ psychological sub-scale pre-operatively, at 3 and 12 months post-op
223920402|NCT06867536|DRUG|Glofitamab + Obinutuzumab|"Obinutuzumab An initial 1000 mg dose of obinutuzumab will be administered as pretreatment 7 days prior to the first glofitamab step-up dose~Glofitamab:~Glofitamab was administered intravenously as step-up doses on day 8 (2.5 mg) and day 15 (10 mg) of cycle 1, followed by a dose of 30 mg on day 1 of cycles 2 through 8, maximum of 12 cycles (Q3W). The efficacy is evaluated after 2 cycles of glofitamab. Those with disease progression will be withdrawn from the study. The remaining patients continue with an additional two cycles of glofitamab (4 cycles in total) and then perform efficacy assessment. If the patients achieve a CR or PR, they will continue to complete the remaining treatment as planned. Patients are recommended to treat for 12 cycles (at least 8 cycles, depending on tumor regression in patients) or until disease progression or unacceptable toxicity, whichever occurs first"
223920403|NCT01960751|OTHER|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
223920404|NCT06673927|DRUG|YZJ-1139|Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg
223920405|NCT06673927|DRUG|YZJ-1139|Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg
224090154|NCT06030011|BEHAVIORAL|NYU Electronic Patient Visit Assessment (ePVA)|The NYU Electronic Patient Visit Assessment (ePVA) for head and neck cancer is a digital patient-reported symptom monitoring system, providing actionable information at point-of-care that enables clinicians to provide real-time interventions. Patients access the ePVA through a web link and complete the survey questions within 10 minutes on digital devices (e.g., smart phones, laptops, or digital devices provided by the clinic).
224278988|NCT05422235|OTHER|Routine Medical Treatment|Subjects will continue their routine medical treatment.
224278989|NCT05422235|OTHER|Aerobic Exercise|Symptom-limited peak heart rates of subjects will be determined using the modified Bruce Protocol. For aerobic training, subject will be carried out on the treadmill according to the results of exercise tests. Initially, 40-60% of the peak heart rate will be trained and progression will be made in subject training programs every 2 weeks. Training will consist of warm-up, main exercise and cool-down periods. Aerobic training will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks. The room temperature will be fixed at 25°C in order to keep the impact of environmental factors at a minimum. In addition, individuals will be asked to come with appropriate shoes and clothes for the training.
224278990|NCT05422235|OTHER|Aerobic Exercise+ Foot-Related Exercise|In addition to walking training specific to the subject in the aerobic exercise group, special exercises will be given to the feet and ankles. These exercises will be aimed at stretching, strengthening, increasing sensory input. Treatment program will be done 3 days a week for 12 weeks. Subjects will be followed for 24 weeks.
224278991|NCT05385471|BIOLOGICAL|Matrix M with R78C and/or RH5.1|50 µg of Matrix-M adjuvant with R78C and/or RH5.1 at different doses and timepoints
223717104|NCT02563743|BEHAVIORAL|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
223920406|NCT06673927|DRUG|Placebo|Placebo administration
223920407|NCT04335682|DRUG|Darolutamide|Patients randomized to darolutamide.
223717105|NCT05239208|OTHER|Oral Nutrition Supplement (ONS) Group|Oral nutritional supplement specifically designed for nutritionally-at risk children and dietary counseling
223717106|NCT05239208|OTHER|Control Group|Dietary counseling
223920408|NCT04335682|DRUG|Enzalutamide|Patients randomized to enzalutamide.
223920409|NCT05257356|BEHAVIORAL|psychophysical tasks|"Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.~Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits."
223920410|NCT06680284|OTHER|Staff Education Program|A staff education and environmental awareness campaign and in-service to highlight strategies to reduce, reuse, and recycle waste, as well as proper waste disposal practice, will be implemented by way of instructional posters, e-learning modules, a grand rounds presentation, journal club discussion, and brainstorming sessions for waste reduction, reuse and recycle and a brief knowledge test at the end.
223920411|NCT06681428|OTHER|Allograft|Placental-based Allografts
223920412|NCT05254314|DRUG|Semaglutide Pen Injector 2.4mg weekly|Once weekly subcutaneous injection
223920413|NCT05254314|OTHER|Placebo|Once weekly subcutaneous injection
224278992|NCT02847208|OTHER|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
223717107|NCT04405414|OTHER|Form|Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD
223717108|NCT05257655|PROCEDURE|MRI after ganglionic local opioid analgesia (GLOA)|MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius
223717109|NCT04456959|DRUG|Inotuzumab Ozogamicin|Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
223717110|NCT03081533|OTHER|Circle Dance Program (CircleCare)|Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
223717111|NCT05026255|PROCEDURE|alveolar recruitment manoeuvre by pressure step|The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
223717112|NCT04505189|DRUG|Psilocybin|Psilocybin assisted psychotherapy
223717113|NCT01430000|BIOLOGICAL|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
223717114|NCT04563351|OTHER|local anaesthetic techniques|The patients were anesthetized with two different local anaesthetic techniques.
223717115|NCT00418457|DRUG|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
223717116|NCT00418457|DRUG|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
223920414|NCT04704700|DEVICE|repair of a cuff tear|Group (Treatment): Arthroscopic Implantation of the System InSpace on a repaired rotator cuff tendon
223920415|NCT04704700|DEVICE|repair of a cuff tear|Group (Control): standard Arthroscopic repair of the cuff rotator
223920416|NCT06865729|BEHAVIORAL|Music therapy|Music therapy will be performed by the researchers for 4 days (average length of stay for inpatients is 4 days), starting from the first day the patients start their inpatient treatment. Music therapy will be performed in the evening hours (between 20:00 and 21:00) and in the patients' own rooms, so as not to disrupt the patients' routine follow-up and treatment. Music therapy will be performed passively using an MP3 music player and headphones provided by the researchers. Therapy time will be limited to 30 minutes. Music therapy will be performed in one session per day for 4 days, and the patients will listen to the same music in each session.
223920417|NCT06870240|DRUG|Neurosteroid enantiomer|A non-natural synthetic neurosteroid enantiomer considered a new chemical entity
224278993|NCT06331767|BEHAVIORAL|mSYNC|mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
224278994|NCT00019734|BIOLOGICAL|aldesleukin|
224278995|NCT00019734|BIOLOGICAL|fowlpox virus vaccine vector|
223920418|NCT03715959|PROCEDURE|Aspiration of Breast|Undergo NAF
224090155|NCT06030011|BEHAVIORAL|Usual Care|Usual care encompasses pre-treatment, on treatment, and post-treatment care. Pre-treatment care includes education of patients on the treatment plan. On-treatment care includes daily monitoring by a nurse in the radiation therapy (RT) department, weekly on-treatment visits with the RT nurse practitioner and radiation oncologist, and weekly visits with medical oncology nurse practitioners and medical oncologists for patients receiving RT plus chemotherapy. Post-treatment care includes follow-up visits with HNC clinicians (i.e., surgeon, medical oncologist, oral maxillofacial surgeons, and radiation oncologist) to assess the patient's cancer status and identify the patient's acute and long-term symptoms. The clinician's decisions on radiologic exams and referrals to appropriate specialist services, including dental care, are based on the patient's cancer status and symptoms.
224090156|NCT04609748|DRUG|Cannabidiol Oil|Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.
224090157|NCT04609748|DRUG|Nimesulide|Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.
224278996|NCT00019734|BIOLOGICAL|vaccinia-tyrosinase vaccine|
224090158|NCT01526148|DRUG|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.
224278997|NCT00664287|DRUG|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
224090159|NCT01526148|DRUG|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
224278998|NCT00664287|DRUG|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
224278999|NCT05050981|DRUG|Hormone replacement therapy|Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
224090160|NCT06167161|DEVICE|Hearing aid|The hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and through a dedicated smartphone application
223717117|NCT00714883|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
223920419|NCT03715959|PROCEDURE|Biospecimen Collection|Undergo NAF
223920420|NCT06870981|OTHER|Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.|
223920421|NCT06867965|DEVICE|BellySense|BellySense is a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
224090161|NCT03308851|PROCEDURE|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
224090162|NCT03308851|PROCEDURE|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
224090163|NCT01173653|OTHER|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
224090164|NCT01173653|OTHER|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
224090165|NCT02107144|DRUG|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
224090166|NCT00227357|DRUG|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
224090167|NCT00227357|DRUG|Off-site - methadone or no agonist|
224279000|NCT05050981|DRUG|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
224279001|NCT02426541|DRUG|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
224279002|NCT02426541|DRUG|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
224090168|NCT06374758|OTHER|The Accelerate model of care|"Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider."
223920422|NCT06868134|BEHAVIORAL|Web-Based Exercise Group|Participants will follow a structured progressive exercise program through the Physitrack web platform, including stretching, strengthening, and aerobic exercises. The program will be assigned to each participant's profile, and they will complete the exercises three times per week with at least one rest day between sessions. Assessments will be conducted at the beginning and at the end of the 8th week.
223920423|NCT06868134|BEHAVIORAL|Supervised Progressive Exercise Program|Participants in this group will receive a supervised progressive exercise program consisting of stretching, strengthening, and aerobic exercises. The intervention will be conducted three times per week with at least one rest day between sessions.
223920424|NCT06868004|BEHAVIORAL|Holistic Nursing|The intervention in this study is based on Holistic Nursing (HN) for patients with Alzheimer's Disease (AD). It involves a comprehensive approach including psychological support, cognitive rehabilitation, memory enhancement, self-care training, and environmental modifications. Psychological interventions focus on personalized communication and emotional support, aiming to reduce negative emotions and improve trust in the healthcare team. Cognitive interventions include activities like painting, card recognition, and storytelling to enhance cognitive function. Memory interventions use personalized memory aids, and self-care interventions aim to improve daily living skills. The ward environment is adjusted to promote safety and comfort. This multi-faceted approach is designed to improve cognitive function, self-care abilities, and emotional well-being in AD patients.
223920425|NCT06867770|BEHAVIORAL|Observe the frequency of clinical or paraclinical complications during the hospitalization of these children.|The goal is to collect data on the files of infants hospitalized at the HFME from 2017 to 2021 for monitoring a isolated skull. The data that will be collected are an integral part of the child's care and pre-exist the study. This data will be anonymized and no interaction with the patient is envisaged.
223920426|NCT06870474|BEHAVIORAL|Psychoeducational intervention|The psychoeducational intervention has the aim of improving quality of life, problem-solving and social skills, leisure time, self-efficacy and social support of caregivers; and decreasing their depressive symptomology, dysfunctional thoughts, burden and stress. Both mediator and outcome variables will be contemplated.
224090169|NCT06374758|DRUG|bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg|Same as above, it is the same intervetion
224090170|NCT00206570|DRUG|Estradiol|
224090171|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
224090172|NCT01053676|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
224090173|NCT03890055|DRUG|Anlotinib Hydrochloride|Best supportive care
224090174|NCT02062931|BIOLOGICAL|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
224090175|NCT06274567|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study uses intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
224090176|NCT06274567|DEVICE|Sham (placebo) TMS|Sham stimulation works by blocking the magnetic field with an internal spacer on the sham side of the TMS coil, allowing the operator to place the coil surface against the scalp. A brief electric pulse calibrated to the stimulator output is delivered to the scalp simultaneous to the TMS pulse to mimic the scalp sensation during the sham condition. 75 Importantly, the electric pulse is calibrated to the stimulator output to ensure a realistic sham condition.
224090177|NCT04696497|DIAGNOSTIC_TEST|Ultrasound|"Ultrasound measurements of muscle thickness, using a linear probe (high frequency) on four muscle groups:~* Shoulder Side muscular compartment~* Anterior Arm muscular compartment~* Anterior thigh muscular compartment~* Antero-lateral leg muscular compartment"
223920427|NCT06870474|BEHAVIORAL|Support group|This intervention is a placebo group. It has the typical structure and characteristics of this type of intervention
223920428|NCT06870474|BEHAVIORAL|Control group|Participants were not subject to any intervention. They received the psychoeducational intervention once the study had ended.
224090178|NCT04696497|DIAGNOSTIC_TEST|Dynamometric muscular assessment|"The principle of electronic dynamometry is to measure an isometric force. To carry out these measurements, the examiner will stand on the side who has to be tested by exerting a pressure diametrically opposite to the patient's movement, thus preventing him/her from carrying out the movement. The patient will perform 3 tests for each movement, the best value will be collected by the examiner.~The reference position is :~Patient elbowed to the body bent at 90°, with trunk inclination at 30° in the resuscitation bed, lower limbs flat."
224090179|NCT04696497|DIAGNOSTIC_TEST|Manual muscular Assessment (MRC-SS)|Following the same positions as for the dynamometer, the examiner will evaluate the 12 motor functions according to the following 60-point rating. With the maximum quote of 5 point representing normal strength and 0 point the total absence of any muscular contraction
224279003|NCT00040690|BIOLOGICAL|filgrastim|
224279004|NCT00040690|DRUG|cyclophosphamide|
224279005|NCT00040690|DRUG|cytarabine|
224279006|NCT00040690|DRUG|doxorubicin hydrochloride|
224279007|NCT00040690|DRUG|etoposide|
223920429|NCT06867211|DIAGNOSTIC_TEST|Use of Ultrasonography for Measuring Achilles Tendon Thickness|Achilles tendon ultrasonography was performed on healthy volunteers included in the study by an emergency physician trained in both basic and advanced ultrasonography techniques. Measurements were conducted using a Butterfly iQ (Butterfly Network, Inc., Guilford, CT) ultrasound device in B-mode with a musculoskeletal preset, using biplane imaging. For Achilles tendon measurement, the image depth was set to 2.0 cm. A linear probe was placed longitudinally and perpendicular to the tendon. The distal portion of the Achilles tendon and the calcaneus were visualized in the long axis, whereas the short axis was used to center the Achilles tendon on the screen for an optimal measurement view. The measurement site was determined as 2 cm proximal to the Achilles tendon insertion at the calcaneus. In biplane imaging, Achilles tendon thickness was measured in the long axis, whereas thickness, width, and cross-sectional area were measured in the short axis. Measurements were performed bilaterally
223920430|NCT06871293|OTHER|Functional and cognitive rehabilitation strategy|"The functional and cognitive rehabilitation strategy is a structured, supervised program, designed to improve physical and cognitive function in patients with Long Covid-19 and chronic diseases. Participants will attend weekly in-person sessions for 8 weeks at study sites.~Each session includes:~* Functional Rehabilitation (60 min): Warm-up, aerobic exercise (elliptical/treadmill), muscle strengthening, and cool-down, all supervised by trained healthcare professionals who monitor effort levels and heart rate.~* Cognitive Rehabilitation (30 min): Memory, attention, and executive function exercises, guided by occupational therapists or speech therapists."
223920431|NCT06871293|OTHER|Evidence-Based Informational Support|"The evidence-based informational support intervention provides structured, research-based health information to patients with Long Covid-19 and chronic diseases. Participants receive weekly digital messages for 8 weeks via email or text, covering key topics such as Covid-19 prevention, treatment, follow-up, and prognosis.~Content is derived from high-quality scientific studies and clinical guidelines.~A total of 24 informational pieces are delivered, ensuring comprehensive coverage of essential health recommendations.~This intervention is remote, accessible, and designed to enhance patient knowledge and self-management, distinguishing it from traditional in-person education programs."
224090180|NCT04364919|BEHAVIORAL|aerobic exercise program|"The program incorporated modified yoga movements suitable for pregnant women. The DVD provides an illustration with the written caption, Please take enough water before exercise, and wear loose and comfortable clothes in a suitable environment. If you feel tired, stop exercising immediately. The DVD's narrator then says, Now you are ready to prepare a comfortable, solid chair with a chair back. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercises were developed as a progressive program in order to achieve the goals of strength-conditioning, moderate-intensity exercise (ACOG, 2015)."
224279008|NCT00040690|DRUG|ifosfamide|
224279009|NCT00040690|DRUG|leucovorin calcium|
224279010|NCT00040690|DRUG|methotrexate|
224279011|NCT00040690|DRUG|vincristine sulfate|
224279012|NCT00040690|RADIATION|radiation therapy|
224279013|NCT02885428|DEVICE|echography|
224279014|NCT06210945|DRUG|10 mg/kg CM-101|10 mg/kg CM-101
224279015|NCT06210945|DRUG|Placebo|Placebo
224279016|NCT05352477|OTHER|Balneotherapy with thermal water|Bath with Acquabios thermal water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
224279017|NCT05352477|OTHER|Balneotherapy with tap water|Bath with tap water at 33°C, 20 minutes daily for a total of 12 days, 6 days a week (from Monday to Saturday, Sundays excluded)
224279018|NCT03523845|OTHER|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
224279019|NCT00235118|DEVICE|Cordis AAA Bilateral Device|
224279020|NCT02951936|DEVICE|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index \< 2.9 +Total Peripheral resistance Index \>3000+Mean arterial pressure \>70mmHG then add vasodilators.~If Heart Rate\<60 consider to reduce beta blockers dose If Cardiac Index\>4.2 and Mean arterial pressure 70-100mmHG and HR \>100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
224279021|NCT02951936|DEVICE|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
224279022|NCT05287399|DRUG|ASC61 200 mg 1|200mg of ASC61 orally once daily for cycles of 28 days
224279023|NCT05287399|DRUG|ASC61 200 mg 2|200 mg of ASC61 orally twice daily for cycles of 28 days
224279024|NCT05287399|DRUG|ASC61 300 mg|300 mg of ASC61 orally twice daily for cycles of 28 days
224279025|NCT05287399|DRUG|ASC61 400 mg|400 mg of ASC61 orally twice daily for cycles of 28 days
224279026|NCT05287399|DRUG|ASC61 600 mg|600 mg of ASC61 orally twice daily for cycles of 28 days
224279027|NCT03998319|DRUG|Tenecteplase (1/3 systemic weight based dose)|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
224279028|NCT03998319|OTHER|Sterile water for injection (WFI)|Placebo comparative arm.
224279029|NCT04422236|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
224279030|NCT06536439|DEVICE|Pre-operative explanation of the procedure (DIPLANN + CT)|Pre-operative study visit explaining the RAPN procedure using the 3D model / DIPLANN-tool (with or without classical CT imaging). Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
223717118|NCT00629707|OTHER|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
223920432|NCT06783712|PROCEDURE|Adductor canal block|Group I: Patients will receive the ultrasound-guided Adductor canal block (ACB) by the supervisors of the research performed just after skin closure. ACB will be performed under complete aseptic conditions. Using a high frequency (6-15MHz) linear probe of an ultrasound machine (Sonosite turbo M, Bothell, Washington, USA) covered with a sterile sheath and 100 mm needle SonoPlex (B-Braun Medical Inc., Bethlehem, PA, USA). ACB block will be performed while the patient is in a supine position at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the sartorius muscle, 100 mm needle SonoPlex will be advanced with the guidance of ultrasound in an in-plane technique and 20 ml bupivacaine (Marcaine) 0.25% will be injected.
224090181|NCT02094144|OTHER|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
224090182|NCT02094144|OTHER|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
224090183|NCT05009758|PROCEDURE|Blood sampling|Blood collection for PBMC isolation, measurement of cytokines in serum, and mass cytometry
223920433|NCT06783712|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block|Group II: The patients will receive ACB by the supervisors of the research just after skin closure as previously described in group I and then an IPACK block will be performed. IPACK block will be performed under complete aseptic precautions using the ultrasound machine with the high-frequency linear probe covered with a sterile sheath and 100 mm needle SonoPlex. IPACK block will be performed while the patient is in a supine position with slight knee flexion, the probe will be applied to the popliteal fossa for identification of the popliteal artery and femur. Then the probe will be distally slided for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappear and the flat metaphysis appear. A needle will be advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reaches the medial edge of the femur,20 ml bupivacaine 0.25% will be injected incrementally
223920434|NCT06885086|OTHER|Control group - 1|Patient data will be collected retrospectively from the records.
223530524|NCT04722822|BEHAVIORAL|(Intervention) Recommending HPV vaccine for patients 9-10 years of age|Practices are randomized to receive training on how to recommend HPV vaccine, including both standardized communication strategies and strategies for switching from 11-12 years to 9-10 years including: challenges with 11-12 strategy, long-term immunity, success of other practices and tips to help standardize to age 9-10. Trainings will be a combination of online and in-person or virtual. Annual trainings will be offered and providers will receive Maintenance of Certification credits (MOC) for participating. Providers will routinely recommend HPV starting at age 9 for all patients -- which is already approved for this vaccine but is not routinely recommended at age 9 years.
223530525|NCT04722822|BEHAVIORAL|(Control) Recommending HPV vaccine for patients 11-12 years of age|Control practices will receive a training on standardized communication for HPV vaccine including: using strong recommendations, using presumptive recommendation, providing specific phrases to use with parents, answering common questions and, HPV vaccine as a cancer prevention. Annual trainings will be offered and providers will receive professional development credit (MOC).
223530526|NCT06364410|DRUG|Azenosertib|Given PO
223530527|NCT06364410|PROCEDURE|Biopsy Procedure|Undergo biopsy
223530528|NCT06364410|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223530529|NCT06364410|PROCEDURE|Computed Tomography|Undergo CT
224090184|NCT05009758|PROCEDURE|Nasosorption|Nasosorptions will be applied for the collection of nasal secretions (Nasosorption FX-I, Hunt Developments (UK) Limited, Midhurst, West Sussex, United Kingdom). Under visualization, the device will be inserted into the nasal cavity and be placed along the lateral wall against the inferior turbinate. The index finger of the patient will be used to press onto the external aspects of the alar and lateral nasal cartilages to hold the device in place. After 1 minute, the devices will be removed.
224090185|NCT05009758|PROCEDURE|Oral sampling|For oral sampling, saliva collection devices (SuperSAL or PureSAL, Oasis Diagnostic Corporation, USA) will be applied followed by elution. Then swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the dorsum of the tongue.
223530530|NCT06364410|PROCEDURE|Echocardiography Test|Undergo ECHO
224090186|NCT05009758|PROCEDURE|Bronchoscopy|The bronchoscopy will be performed in the outpatient clinic of the Department of Pulmonology. Bronchial alveolar lavage (BAL): the bronchoscope is wedged in the segmental or subsegmental bronchus of the middle lobe. Up to 300 ml sterile normal saline is injected stepwise via handheld syringe and then gradually withdrawn back into the syringe. BAL fluid (BALF) will be prepared and further analyzed in the lab. Transbronchial biopsy (TBLB): performed by forceps in the lung periphery under fluoroscopy guidance. Up to 4 biopsies are taken in two different lobes of one lung with a distance of 1-2 cm to the pleura. TBLB is only performed in patients who have got not contraindications.
224279031|NCT06536439|DEVICE|Pre-operative surgical planning (DIPLANN + CT)|Online assessment by surgeon regarding clamping strategy. Assisted by DIPLANN-tool + CT scan.
224279032|NCT06536439|PROCEDURE|RAPN (DIPLANN + CT)|Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by DIPLANN-tool + CT scan.
224279033|NCT06536439|DEVICE|Pre-operative explanation of the procedure (CT only)|Pre-operative study visit explaining the RAPN procedure using CT imaging alone. Included in this visit is a pre-operative physical examination (height, weight, abdominal examination), pre-operative blood examination (Hb, creatinin, eGFR) and patient questionnaires regarding patient knowledge, patient anxiety and patient quality of life.
224279034|NCT06536439|DEVICE|Pre-operative surgical planning (CT only)|Online assessment by surgeon regarding clamping strategy. Assisted by classical CT imaging only.
224279035|NCT06536439|PROCEDURE|RAPN (CT only)|Robot-assisted partial nephrectomy surgical procedure. Peri-operative guidance by CT imaging only.
224279036|NCT06428695|BEHAVIORAL|one-hour dietary self-monitoring tool education session|access the impact of a one-hour dietary self-monitoring tool education session for participants in a calorie-restricted weight management program on their knowledge of the use of the tool to help them adhere to a calorie-restricted weight management program
224279037|NCT03260842|DIAGNOSTIC_TEST|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
224279038|NCT06800755|DEVICE|Dexeryl (RL3020-DP0364)|Product application on body (head excluded)
223530531|NCT06364410|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223530532|NCT06364410|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223920435|NCT06885086|DRUG|Observation group -2|In the literature, multimodal analgesia strategies-as recommended by ERAS guidelines and supported by recent studies-are implemented. In the intraoperative period, patients receive paracetamol, NSAIDs, and local surgical wound infiltration analgesia. In the postoperative period, oral paracetamol and NSAIDs are routinely continued, with opioids administered as needed.
224279039|NCT05672134|DIAGNOSTIC_TEST|Iohexol measurement|Invasive renal hemodynamic measurement of mGFR through the administration of Iohexol.
224279040|NCT05672134|DRUG|Geranylgeranylacetone (GGA)|13 weeks of treatment with GGA/placebo orally, followed by a wash-out period of 6 weeks, then reversal of the treatment arms.
223530533|NCT06364410|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223530534|NCT02266667|DEVICE|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
223530535|NCT02266667|DEVICE|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
223530536|NCT06140017|BEHAVIORAL|Msingi Bora responsive parenting and family wellbeing program|Msingi Bora's structured curriculum of 16 biweekly sessions and monthly boosters thereafter are organized around five key messages: love and respect within the family, responsive talk, responsive play, hygiene, and nutrition.
223530537|NCT06425029|OTHER|Experimental Intervention (Music A)|Participants will be asked to listen to Music A on their personal device daily, at a time most convenient for them.
223530538|NCT06425029|OTHER|Active Comparator Intervention (Music B)|Participants will be asked to listen to music B on their personal device daily, at a time most convenient for them.
223530539|NCT06425029|OTHER|Active Comparator Intervention (Music C)|Participants will be asked to listen to music C on their personal device daily, at a time most convenient for them.
223717119|NCT04317469|DIAGNOSTIC_TEST|VWF measurement|Plasma levels of both vWF and IL.6 were be measured on T=0 i.e. (at start of the study once the patient considered to be risky for A.R.D.S development to obtain their baseline levels), T=48 (after 48 hours), and T=72 (after 72 hours).
223920436|NCT05726929|OTHER|Osteopathic treatment|Osteopathic Manual Treatment
223920437|NCT05726929|OTHER|Capsaicin QUTENZA Patch (TAU)|Capsaicin QUTENZA Patch is the treatment as usual (TAU) delivered in the medical algology service
223920438|NCT05785130|OTHER|white noise|Using sound machine for 3 days at bedtime for 7 hours(11p.m.- 6a.m.) in a decibel of 40-50.
223920439|NCT06607744|DRUG|Pharmacokinetic profiles of Selegiline TDS and EMSAM|Selegiline concentrations will be measured in blood plasma using a validated liquid chromatography tandem mass spectrometry method from Selegiline TDS (test formulation 6mg/24 hours) and EMSAM (6mg/24 hours). The analytical laboratory will be blinded as to samples which are the test and reference products.
223920440|NCT02225301|OTHER|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
223920441|NCT06873022|DEVICE|neuromuscular electrical stimulation|"NMES: Two electrode pads were placed on the anterior, middle, and posterior deltoid boundary lines and at a distance of 1cm distal to the lateral margin of the acromion. The operator palpated the deltoid muscle contraction and asked the subjects to perform arm elevation task with NMES. (frequency of 35 Hz and a duration of 250 microseconds.) A verbal cue was given during both th~A verbal cue was given during both the sEMG biofeedback and NMES interventions: Lengthen your arm as if you want to touch the ground, the scapula keeps in the neutral position, and then elevate your arm. Each intervention consisted of 3 sets of 10 repetitions per set, with a 1-minute rest between sets."
223920442|NCT06873022|DEVICE|biofeedback|sEMG biofeedback: Subjects were instructed to monitor the sEMG signals of the D/UT balances ratio on the screen and maintain the D/UT balances ratio above the threshold during arm elevation and lowering. The threshold was set at 1 standard deviation of the ratio average at baseline (before intervention).
223920443|NCT06871735|PROCEDURE|Acellular matrix|Wound closure is obtained by use of acellular matrix material placed over the exposed barrier membrane. The procedure itself is not part of the research study, nor is the decision to use this procedure, but it is the condition of interest to the research.
223920444|NCT06871735|PROCEDURE|Surgical closure|Wound from the graft is surgically closed, with no use of the acellular matrix. The procedure itself is not part of the research study, nor is the decision to use this procedure, but it is the condition of interest to the research.
223920445|NCT06870786|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|Evaluation of T-PRF membrane structures obtained from the blood of patients before and after vitamin D supplementation.
223920446|NCT06869356|PROCEDURE|D2 gastrectomy|Under the requirement of the guideline for laparoscopic gastrectomy for gastric cancer (2016 edition), laparoscopic radical gastrectomy is performed in patients.
223920447|NCT06661746|DRUG|Multimodal IV analgesia|Multimodal IV analgesia of lidocaine, ketamine and MS
223920448|NCT06661746|DRUG|epidural analgesia|Opioid-based and epidural analgesia
224279041|NCT05672134|DIAGNOSTIC_TEST|Echocardiography|The investigators will perform echocardiography to find changes in cardiac function.
224279042|NCT05672134|DIAGNOSTIC_TEST|6-minute walking distance test|6 minute walking distance test to compare exercise tolerance in participants.
224279043|NCT05672134|DIAGNOSTIC_TEST|EndoPAT|Use of EndoPAT to measure endothelial function.
224279044|NCT05672134|DIAGNOSTIC_TEST|Para-amino Hippuric Acid test|PAH-measurement to measure ERPF.
224279045|NCT05672134|DIAGNOSTIC_TEST|Electrocardiogram|12-lead Electrocardiogram
223717120|NCT02845934|OTHER|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
223717121|NCT03218514|DRUG|Dalteparin|
223717122|NCT00934492|DRUG|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
223717123|NCT00934492|DRUG|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
223920449|NCT06873412|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3).
223920450|NCT06873412|DIETARY_SUPPLEMENT|Placbo|The experimental phase of the study will last for 3 months, and each subject will be followed up 3 times (month 0, Month 1, Month 2, month 3).
224090187|NCT05009758|PROCEDURE|Nasal biopsy|Nasal biopsies will be taken during routine endoscopy performed to score CRSwNP. Patients will receive local anesthesia and decongestants prior to obtaining the biopsy. Samples will either be embedded in OCT or processed for cellular analysis
223717124|NCT01552941|DEVICE|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
223717125|NCT00207350|DEVICE|Interstitial Laser Therapy|Device
223920451|NCT06872346|OTHER|Visit-based IT reminders to patients and practitioners|"To identify patients due for CCSM, simplify test ordering/referral, and track follow-up, PREDICT will include: 1) automated updating of a patient's problem list with the current cervical screening finding, 2) automated updating of cervical cancer health maintenance topics to the appropriate time interval and follow-up test/ procedure through the use of modifiers, 3) SmartSets to standardize ordering of procedures/ specialty referrals."
223920452|NCT06872346|OTHER|Population outreach|"Patients will be sent a reminder letter 90 days prior to the due date via the patient portal or mailed if no portal account (Outreach 1). If needed, four weeks later a phone call from the outreach coordinator reminds patients of the follow-up date if scheduled or helps establish follow-up (Outreach 2). The coordinator could also place an order for a referral and send a reminder to the practitioner to sign it if appropriate. The coordinator will review and document any alternative care plans discussed by the PCP and patient."
223717126|NCT03460730|BIOLOGICAL|Pneumovax|23-valent pneumococcal polysaccharide vaccine
223920453|NCT06861634|PROCEDURE|Nol index|Morphinomimetics will be administered according to NOL Index values or according to the usual criteria.
223920454|NCT06263660|DIETARY_SUPPLEMENT|Keto-like supplement|Participants will consume 9.25g stick packs of the keto-like supplement dissolved in water 3 times per day for 8 weeks.
223920455|NCT06263660|DIETARY_SUPPLEMENT|Placebo|Participants will consume 9.25g stick packs of placebo dissolved in water 3 times per day for 8 weeks.
223920456|NCT06679543|OTHER|Partial sleep deprivation|Participants will be asked to come to the lab for testing after a night of partial sleep deprivation. Participants will be asked to fall asleep at their habitual bedtime but wake up early (\~40% of normal sleep duration).
224090188|NCT05009758|PROCEDURE|Nasal sampling|Swabs optimized for the collection of specimens will be applied (CLASSIQSwabs, Copan Diagnostics Inc. Murietta, CA, USA) to the anterior naris and middle meatus of each nostril
223920457|NCT02422147|PROCEDURE|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
224090189|NCT05009758|PROCEDURE|Nasal mucosa mRNA sampling|Mucosal mRNA sampling will be performed using a 10cm nasal curette (either Rhino-Probe, Arlington Scientific, USA or Cellskim, Hunt Developments, UK). Under direct visualization, the curette will be brought to lie against the mid-inferior portion of the inferior turbinate. The curette will be pressed against the mucosal surface moved outwards 2-3 times. This motion will be repeated 2-3 times to ensure good sample collection. This curette and technique have been shown to cause no significant discomfort to patients and thus it has the advantage of no requirement for local anesthetics.
224090190|NCT05009758|DIAGNOSTIC_TEST|Pregnancy test|In female patients, pregnancy will be excluded with a standard urine pregnancy test at the beginning of the main visit.
224090191|NCT05009758|OTHER|Medical history of patients, demographic data, concomitant medication, questionnaire|Patients will be asked for their medical history including demographic data and concomitant medication. Details will be noted in the source data file. Furthermore, patients will receive a questionnaire including tools to assess QOL impairment by CRS and asthma
224279046|NCT03962868|PROCEDURE|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (\<1.5%)
224279047|NCT03962868|PROCEDURE|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
224279048|NCT01279915|DRUG|ASP0456|oral
224279049|NCT01279915|DRUG|Placebo|oral
224279050|NCT02833428|DEVICE|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
224279051|NCT00225563|DEVICE|Electronic Health Record|e-prescribing methods
224279052|NCT06253338|RADIATION|genomic alterations|Alteration of the genome under radiotherapy
224279053|NCT04703842|BIOLOGICAL|SRD-001|AAV1/SERCA2a
224279054|NCT04703842|DRUG|Placebo|SRD-001 matching placebo
224279055|NCT04412057|DRUG|CERC-002|Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
224279056|NCT04412057|DRUG|Placebo|Administered once subcutaneously
224279057|NCT02558465|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
223920458|NCT05818384|BEHAVIORAL|Wakaya: Rising Up for Choctaw Youth Curriculum|An experiential, outdoor, nature-based program grounded in Choctaw values. It is a multi-level intervention that increases individual motivation and leadership skills to make healthy behavioral choices for behavior and exercise.
223920459|NCT06683196|OTHER|Kinesio Taping|3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
223920460|NCT06683196|OTHER|Rigid Taping|3 types of taping (kinesiotape, rigid tape and placebo tape) applied to all participants.
223920461|NCT06681922|DRUG|Cyclophosphamide, Bortezomib, Abatacept|Drug given for prevention of Graft-versus-Host Disease (GvHD) following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
223920462|NCT06682858|BEHAVIORAL|Group Cognitive Behavioural Therapy|Participants will complete 8 group sessions of a CBT-based intervention designed to help self-regulate sensory difficulties in autistic young people
223920463|NCT01652092|DRUG|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
223920464|NCT01652092|DRUG|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
223920465|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
223920466|NCT01652092|BIOLOGICAL|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10\^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10\^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10\^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be \> 5.0 x 10\^7 nucleated cells/kg."
223920467|NCT01652092|DRUG|Fludarabine phosphate 40 mg|40 mg/m\^2 IV on days -5 through -2 (for children \< 6 months and/or \< 10 kg weight dose at 1.33 mg/kg)
223920468|NCT01652092|DRUG|Melphalan|140 mg/m\^2 IV on day -3
223920469|NCT01652092|DRUG|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
224090192|NCT05009758|DIAGNOSTIC_TEST|UPSIT smell test|University of Pennsylvania Smell Identification Test (UPSIT) smell test will be performed by the patients during the study. It consists of 40 questions in 4 different booklets. The patient needs to scratch a sniff strip with the microencapsulated odorant using a pencil and mark his choice on four-choice multiple-choice questions. The test is then scored by the study team out of the 40 items.
224279058|NCT00490503|PROCEDURE|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
224279059|NCT00490503|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
223717127|NCT06234917|OTHER|EEG-based neurofeedback for brain activity modulation|NFB is a type of biofeedback technique for self-modulating brain activities by means of a learning task performed with ongoing sensory (usually visual) feedback to real-time acquisition of either brain imaging or electroencephalographic (EEG) signal, which serves as a biomarker of brain activity
223717128|NCT04563702|BIOLOGICAL|VXA-CoV2-1|non replicating Ad5 adjuvanted oral tableted vaccine
223920470|NCT01652092|DRUG|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
223920471|NCT01652092|DRUG|Fludarabine phosphate 30 mg|fludarabine 30 mg/m\^2 IV on days -8 through -4
223920472|NCT01652092|DRUG|MESNA|administered as per the standard institutional protocol.
223920473|NCT06682910|DEVICE|Microtech sensor pressure|Microtech sensor implantation
223920474|NCT06682273|OTHER|Thread-embedding acupuncture|Thread-embedding acupuncture is performed every week for 4 weeks, using a single Polydioxaone thread inserted into acupoints on the body through the needle. After the thread is inserted, the needle will be immediately withdrawn.
223920475|NCT06682273|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into therapeutic points on the ear. The patches with the needle will remain in place for one week.
223920476|NCT06682273|OTHER|Sham thread-embedding acupuncture|Sham thread-embedding acupuncture is performed every week for 4 weeks, using the needle without thread inserted into acupoints on the body. After insertion, the needle will be immediately withdrawn, and no thread will be left in the body.
224090193|NCT05009758|PROCEDURE|Spirometry|Lung function will be measured by spirometry in the lung function unit of the Department of Pulmonology. Spirometry will be performed according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines by authorized and properly certified personal.
224279060|NCT06260826|DEVICE|Auto CPAP via nasal mask (JPAP machine)|Auto Continuous Positive Airway Pressure via nasal mask using the JPAP system (Metran, Saitama, Japan) which can provide CPAP with a range of 2-10 cmH2O, the initial CPAP 2 cmH2O, then reach 7.5 cmH2O after a ramping time. CPAP values may vary with each breath until the obstruction is resolved
224279061|NCT06260826|DEVICE|Constant CPAP via facial mask (O2-Max Trio system)|Patients connected to the O2-Max Trio CPAP system (Pulmodyne, Indianapolis, USA) with a facial mask that was adjusted to maintain a CPAP at 7.5 cm H2O and FiO2 30% continuously for the following 1 hour
223920477|NCT06682273|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for 4 weeks using patches, each with a square shape and a side length of 10 mm, along with a sterilized needle measuring 0.25 x 1.3 mm inserted into non-therapeutic points on the ear. The patches with the needle will remain in place for one week.
223920478|NCT06682286|OTHER|NIV mask A|Bridge free face mask
223920479|NCT06682286|OTHER|NIV mask B|Full face mask
223920480|NCT05471947|DRUG|15% Trichloroacetic acid + 3% glycolic acid|Treatment of the hand with an over-the-counter chemical peel containing 15% trichloroacetic acid + 3% glycolic acid
223920481|NCT06685692|DRUG|ADX-629|125 mg twice daily for 28 days
223920482|NCT06685692|DRUG|ADX-629|250 mg twice daily for 28 days
223920483|NCT06683144|BEHAVIORAL|Exposure feedback|"* Determining the actual SHS exposure risk level and providing feedback.~* Determining the urinary cotinine test result and providing feedback.~* Feedback on the consistency or difference between the perceived SHS exposure risk level and the actual SHS exposure risk level."
223920484|NCT06683144|BEHAVIORAL|Interactive education|Slide presentation, video presentation, Q\&A, evaluation of learning and discussion of results
223920485|NCT06683144|BEHAVIORAL|Social media post|Sharing informational materials such as messages, brochures, and videos related to SHS exposure, including ways to protect yourself from SHS exposure and the adverse health effects of SHS exposure.
223920486|NCT05107518|BEHAVIORAL|Children Participation Assessment Scale|Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
224099550|NCT02956655|DRUG|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
224099551|NCT02956655|OTHER|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
224279062|NCT02156154|DRUG|Intravenous Acetaminophen|
224279063|NCT04253353|DRUG|tafamidis|61 mg capsule
224279064|NCT04253353|DRUG|rosuvastatin|10 mg tablet
223920487|NCT05473663|DEVICE|Radiofrequency Ablation|Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
223920488|NCT05473663|DEVICE|Sham|Is performed identically to the active treatment but without the application of the RFA current
223920489|NCT05301881|PROCEDURE|Surgery|resection of the oligometastatic lesion(s)
223920490|NCT05301881|RADIATION|Radiotherapy|radiation of the oligometastatic lesion(s)
223920491|NCT05301881|OTHER|Radiofrequent ablation|radiofrequent ablation of the oligometastatic lesion(s)
223920492|NCT04730518|BEHAVIORAL|Yoga-based group intervention (YoGI)|see above
223920493|NCT06687590|DEVICE|Peripheral balloon angioplasty|Serration balloon angioplasty of iliac, femoral, iliofemoral, popliteal, infrapopliteal and pedal arteries, or dysfunctional native or synthetic arteriovenous dialysis fistula
223920494|NCT06687772|DRUG|Thiotepa|Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.
223920495|NCT06687772|DRUG|Carmustine|Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.
223920496|NCT06687772|PROCEDURE|Autologous Stem Cell Transplant|Infusion of autologous peripheral blood stem cells on Day 0.
223920497|NCT06687772|DRUG|Anthracycline-based induction chemotherapy|Standard of care, not dictated by protocol.
224279065|NCT03002792|PROCEDURE|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
224279066|NCT04512326|PROCEDURE|Total or Subtotal colectomy|Total or subtotal colectomy (emergent or elective) with primary anastomosis (ileorectal or ileosigmoid)
224279067|NCT05773534|DIAGNOSTIC_TEST|MSOT|Similar as the conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via laser light, leading to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same transducer head that releases the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
224279068|NCT01185379|DIETARY_SUPPLEMENT|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
224279069|NCT01185379|DIETARY_SUPPLEMENT|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
223920498|NCT06691191|DRUG|Ticagrelor 90 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
223920499|NCT06691191|DRUG|Prasugrel 10 mg|After providing written informed consent, patients on DAPT meeting study entry criteria will stop aspirin and be randomly assigned in a 1:1 fashion using a computer-based randomization system to either: a) ticagrelor 90 mg bid monotherapy or b) prasugrel 10 mg qd monotherapy. Patients will continue the randomized treatment for 21±7 days.
224090194|NCT05009758|PROCEDURE|FeNO|Airway inflammation will be evaluated using a standardized single-breath FeNO test in accordance with the lung function unit of the Department of Pulmonology. A single exhalation technique recommended by the manufacturer will be followed. The FeNO measurements will not be performed within 2 weeks of a respiratory infection. The FeNO test will be performed prior to spirometry. Subjects should not eat or drink 1 hour prior to having the FeNO test. Subjects should not use their rescue SABA medication (e.g., albuterol/salbutamol) within 6 hours of the measurement. Inhaled bronchodilators (including ICS/LABA) should be withheld for the effect duration specific to the bronchodilator. If not, the assessment should be postponed till after the required time has passed since the meal or drink or bronchodilator inhalation. The NIOX VERO® Airway Inflammation Monitor will be used to measured FeNO in the lung function unit of the Department of Pulmonology.
223530540|NCT05438667|BIOLOGICAL|TCR-T therapy|"1.Preprocessing strategy：~1. Cyclophosphamide: 300-450mg/m², dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 60minutes, and 0.4g Mesna injected at 0hour, 4hours and 8 hours after cyclophosphamide,4days and 5 days before TCR-T cell infusion.~2. Fludarabine: 30mg/m² , dissolved in 100ml 0.9% sodium chloride saline, intravenous drip for 30minutes before 3 to 5days before TCR-T cell infusion.~2.Within 3-5 days after pretreatment, subjects will receive a single TCR-T reinfusion with an infusion dose of about 1 × 10⁹～1 × 10¹⁰.~3.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 (injection unit: 500000 units /m², once every 12 hours, subcutaneous injection) will be injected intravenously for 5 days (10 times in total).~4.After 3 months of treatment, If the subject did not occur tumor progression and did not occur adverse events (AEs) of level 3 or higher, a second TCR-T cell reinfusion can be performed."
223530541|NCT05537584|DRUG|Sertraline|Subjects will receive 8 weeks of sertraline while monitored by the study physician
224090195|NCT05009758|PROCEDURE|Lung X-Ray|After the bronchoscopy, a lung x-ray will be performed and patients will stay overnight in the ward of the Department of Pulmonology.
224090196|NCT05095025|DRUG|Bupivacaine Hydrochloride 20ml injectate|Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
224090197|NCT01647607|BEHAVIORAL|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
224090198|NCT01647607|BEHAVIORAL|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
224090199|NCT05788939|OTHER|Planned Visual Education Based on Health Belief Model|"The students in IG were administered the planned visual education based on Health Belief Model for a period of seven months.~The education materials were a PowerPoint presentation, a skin cancer model, videos titled Dear 16 years old me, Mr. Sun, a brochure, and 3 posters.~."
224090200|NCT05952700|DEVICE|inContAlert|InContAlert is a non-invasive sensor technology to measure the bladder filling level for incontinence patients. The device is fixed about 2cm above the pubic bone using a patch or strap and does not require surgery. The data collected from the patient is analyzed using deep learning algorithms. The bladder filling level determined in this way is then displayed on an app.
224090201|NCT03180775|OTHER|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
224090202|NCT03180775|DIETARY_SUPPLEMENT|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224090203|NCT03180775|DIETARY_SUPPLEMENT|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224099552|NCT02956655|BEHAVIORAL|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
224099553|NCT02956655|DEVICE|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
223530542|NCT05537584|DRUG|Bupropion|Subjects will receive 8 weeks of bupropion while monitored by the study physician
223530543|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 1 - Gluteal|Dose level 1
223530544|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 2 - Gluteal|Dose level 2
224099554|NCT02226666|DRUG|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
224099555|NCT02226666|DRUG|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
224099556|NCT01014884|OTHER|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
224279070|NCT01185379|DIETARY_SUPPLEMENT|Placebo|4 x 500 mg capsules to be taken daily for 6 months
224279071|NCT01961882|DRUG|OCV-501|
224279072|NCT01961882|DRUG|Placebo|
224279073|NCT01191476|DRUG|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
224279074|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
224099557|NCT01014884|OTHER|Multidisciplinary team bimonthly visits either in person or via telephone.|
223920500|NCT03087903|DIETARY_SUPPLEMENT|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
223920501|NCT06686992|BEHAVIORAL|Vaccination|The researcher will fill in the questionnaire and scales 5 minutes before the vaccination. During the procedure, the child will be played with roll-and-draw. The scales will be filled in again 5 minutes after the procedure. It will take an average of 5-10 minutes to fill out the forms.
223920502|NCT06690060|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular 1 to 2 hour educational sessions and lectures, as well as supplemental reading material. In addition, individualized sessions will be offered each week for students who have additional questions and/or need additional time with the material.
223920503|NCT06685913|DIETARY_SUPPLEMENT|Ketone supplement|100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test
223920504|NCT06685913|DIETARY_SUPPLEMENT|Placebo supplement|Placebo with bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test
223920505|NCT06686537|DRUG|Estradiol Patches|Estradiol patched will be worn for 7 days.
223920506|NCT06309238|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication
223920507|NCT06309238|PROCEDURE|Bariatric surgery|Roux-en-Y Gastric Bypass (RYGB) or Sleeve Gastrectomy (SG)
223920508|NCT06691828|DRUG|NX-5948|NX-5948 will be given once by IV and then given once by mouth.
223920509|NCT06690554|OTHER|Education Group|"Women will be given a five-day training in line with the health promotion model.~Information will be provided to women who apply to the hospital. Written consent documents will be obtained from women who agree to participate in the study.~Women assigned to the intervention group will attend classes in groups of 8-10. Women will be given a 60-minute training once a day for five days. The total training duration is five hours. Scales will be applied to women who complete the training at the end of the fifth day.~Women who have completed the training will be contacted by phone at the end of the first and second months, reminded of health promotion behaviors and their questions will be answered and follow-ups will be carried out.~At the end of the third month, women who have received training will be invited to the institution and the Fertility Awareness, Preconceptional Knowledge and Attitude will be filled out face-to-face for the final test."
223920510|NCT06065735|DRUG|Paroxetine|Paroxetine will be administered
223920511|NCT02532621|DEVICE|Venous InterGraft Connector|The device is designed for transcatheter delivery within a vein and connection to an AVG that has been tunneled under the skin in a standard manner. The connection is made via a small skin incision.
223920512|NCT02532621|PROCEDURE|sutured arterial anastomosis of an implanted vascular graft for hemodialysis|The arterial anastomosis of the implanted vascular graft for hemodialysis is formed using standard suturing technique.
223920513|NCT02532621|PROCEDURE|hemodialysis|The implanted vascular graft is intended as a vascular access for performing hemodialysis treatments.
223920514|NCT06628271|DIAGNOSTIC_TEST|Guidelines|Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
223920515|NCT06366633|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 30-45-minute video sessions that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
223920516|NCT00692939|BIOLOGICAL|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
223920517|NCT00692939|DRUG|Alemtuzumab|Transplant conditioning
223920518|NCT00692939|DRUG|ATG|Transplant conditioning
223920519|NCT00692939|DRUG|Melphalan|Transplant conditioning
223920520|NCT00692939|DRUG|Thiotepa|Transplant conditioning
223920521|NCT00692939|DRUG|Rituximab|Transplant conditioning
223920522|NCT00692939|DRUG|Cyclophosphamide|Mobilization
223920523|NCT00692939|DRUG|G-CSF|Mobilization
223920524|NCT00692939|DRUG|Mesna|Mobilization
223920525|NCT06619392|DRUG|HRS-2129|HRS-2129
223920526|NCT06619392|DRUG|HRS-2129 Placebo|HRS-2129 Placebo
223920527|NCT06618651|DRUG|SHR-3821 injection|SHR-3821 injection
223920528|NCT06623006|BEHAVIORAL|mobile health (mhealth)|The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
223920529|NCT06874062|PROCEDURE|Neoputty MTA Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, Neoputty MTA was placed."
223920530|NCT06874062|PROCEDURE|ProRoot MTA Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, ProRoot MTA was placed."
224099558|NCT01014884|OTHER|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
223920531|NCT06874062|PROCEDURE|Theracal PT Pulpotomy Treatment|"All caries were removed before entering the pulp chamber. Once all caries were removed, a carbide bur was used under copious water spray to expose the pulp chamber.Coronal pulp is removed with a round bur on a slow speed handpiece.~Hemostasis was achieved by applying a cotton pellet moistened with sterile saline for no more than 5 minutes. After achieving hemostasis, Theracal PT was placed."
223920532|NCT06874062|PROCEDURE|Stainless Steel Crown Application|After pulpotomy treatment, the pulpotomy material was covered using a capsule-form glass ionomer (EQUIA Forte®, GC, Tokyo, Japan). In the same session, preparation was performed for the placement of a stainless steel crown (SSC), and an appropriately sized SSC (3M ESPE, Seefeld, Germany) was selected based on visual estimation. After trial fitting on the tooth, the crown was cemented using a capsule-form glass ionomer (Riva, SDI Ltd., Victoria, Australia).
223920533|NCT06874465|DEVICE|Transcatheter aortic valve implantation|Compare self expendable and balloon expendable valves
223920534|NCT06875466|DEVICE|Sauna bathing|Finnish sauna bathing, participants will sauna once per week for 8 weeks
223920535|NCT02360371|DRUG|Within-subject test of blinded study medication|Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.
224090204|NCT03180775|DIETARY_SUPPLEMENT|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224090205|NCT03180775|DIETARY_SUPPLEMENT|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224090206|NCT03180775|DIETARY_SUPPLEMENT|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
223920536|NCT04795245|DRUG|afatinib|afatinib
223920537|NCT06875297|DIAGNOSTIC_TEST|FPG500|A cancer genome profiling with FPG500 will be performed on samples available from surgery or biopsy. Specimen are reviewed to assess tumor cell fraction. All H\&E slides are digitized before nucleic acid extraction. Semi-automated process is used for DNA/RNA extraction, DNA fragmentation, quantification, library preparation, and sequencing. Profiling is done with the TruSight Oncology 500 assay, analyzing 523 genes for single nucleotide variants, insertions/deletions, copy number variations, and fusions/splicing variants in 55 genes. It also evaluates genomic signatures like microsatellite instability and tumor mutational burden. Sequencing data are processed using Illumina software and a custom pipeline. Post-sequencing quality control is performed. Variants are classified according to the Human Genome Variation Society and clinical actionability guidelines. Genomic report is reviewed by an institutional Molecular Tumor Board.
224090207|NCT03180775|DIETARY_SUPPLEMENT|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224090208|NCT03180775|DIETARY_SUPPLEMENT|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224279075|NCT01191476|DRUG|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
224279076|NCT00003396|BIOLOGICAL|anti-thymocyte globulin|
224279077|NCT00003396|BIOLOGICAL|graft-versus-tumor induction therapy|
224279078|NCT00003396|DRUG|cyclophosphamide|
224279079|NCT00003396|DRUG|melphalan|
224279080|NCT00003396|PROCEDURE|peripheral blood stem cell transplantation|
224279081|NCT00003396|RADIATION|radiation therapy|
224279082|NCT04063319|OTHER|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
224279083|NCT01270490|DRUG|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
223920538|NCT06875505|OTHER|Dynamic PAPE|In this protocol, the load determined for footballers during knee extension will be applied as 90% of their one repetition maximum (1TM). After a standard warm-up session at the beginning, the protocol will be performed by performing 1 set of 3 repetitions with the previously determined 1TM 90% load without resting between repetitions. Isometric knee extension exercise will be used in the protocol. The movement will be performed sitting, in a position suitable for limb lengths and in a controlled manner using a leg extension machine. At the beginning of the movement, the knees will be flexed 90° and the adjustable lever arm of the machine will be fixed at this angle. Then they will be asked to perform bilateral isometric knee extension until the knees form a 180° angle. They will also be verbally motivated to complete the knee extension exercise.
223717129|NCT01317485|PROCEDURE|Laparoscopic lavage and drainage|"\[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
223717130|NCT01317485|PROCEDURE|Sigmoidectomy with primary anastomosis|\[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
223717131|NCT01317485|PROCEDURE|Sigmoidectomy with end-colostomy|\[OPEN\] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
223717132|NCT04449926|BIOLOGICAL|Bacillus of Calmette and Guerin (BCG)|Prime and boost vaccination
223717133|NCT00002307|DRUG|Stavudine|
223920539|NCT06875505|OTHER|Isometric PAPE|Isometric contraction will be used in the protocol. On the leg extension machine, the protocol will be performed by applying 3 sets of 3 seconds against the lever arm only with 1TM 90% load, 2 minutes rest will be applied between sets. Isometric knee extension exercise will be used in the protocol. The movement will be performed sitting, in a position suitable for limb lengths and in a controlled manner using a leg extension machine. At the beginning of the movement, the knees will be flexed 90° and the adjustable lever arm of the machine will be fixed at this angle. Then they will be asked to perform bilateral isometric knee extension until the knees form a 180° angle. They will also be verbally motivated to complete the knee extension exercise.
223920540|NCT06867978|DEVICE|cCeLL In vivo|Dosage Form: Intravenous injection Dosage: 0.1 - 0.5 mg/kg of Indocyanine Green (ICG) Frequency: Single administration during surgery Duration: Real-time imaging performed immediately after ICG injection and used intraoperatively for tumor margin assessment
223920541|NCT06867978|DRUG|Indocyanine Green|fluorescence dye for staining tissue
223920542|NCT06875869|OTHER|Jones technique|In the Jones technique, pressure will be applied on the tender point and the patient's head will be flexed laterally to the side of the tender point, followed by a shoulder abduction of approximately 90 degrees. This position will be held for 90 s and then patient position will be passively returned to the initial position. This will be repeated three times in each session. Patients will receive two treatment sessions per week for 6 weeks
223920543|NCT06875869|OTHER|Ischemic compression therapy|Patients will receive ischemic compression of the trigger points of the upper trapezius and sternocleidomastoid muscle with hold time varying between 30 seconds to 1 minute repeated 3 to 5 times in each session. Patients will receive two treatment sessions per week for 6 weeks
223920544|NCT06874140|DRUG|Chuanhong Zhongfeng capsule|Basic treatment (refer to China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018) + Chuanhong Zhongfeng capsule
223920545|NCT06875193|DRUG|DW6012(Dasidiem tab. 10/100mg)|Once a day, Oral administration
223920546|NCT03073395|DRUG|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
224279084|NCT06173596|DRUG|ALXN2080|Participants will receive ALXN2080 orally.
224279085|NCT06173596|DRUG|Itraconazole|Participants will receive Itraconazole orally.
224279086|NCT06173596|DRUG|Fluconazole (AxMP)|Participants will receive Fluconazole orally.
224279087|NCT06173596|DRUG|Carbamazepine (AxMP)|Participants will receive Carbamazepine orally.
224279088|NCT05410028|OTHER|No intervention in clinical treatment|No intervention in clinical treatment
224279089|NCT03991442|DRUG|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
224279090|NCT05598879|OTHER|anonymized data collection during programmed surveillance clinical follow up|anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
224279091|NCT06335459|OTHER|epidemiology|Analysis of 2000 AP WB radiographs of Foot in Upper Egypt For Random People and determind cases of Hallux valgus and calculate the prevalence
224279092|NCT01473147|DRUG|Exenatide|Exenatide 5 microgram bid sc.
224279093|NCT01473147|DRUG|Normal saline|Normal saline 2 u bid sc.
224279094|NCT05244018|DRUG|Vitamin D3 tablets|Vitamin D3 tablets 50,000 IU units
223717134|NCT00002307|DRUG|Zidovudine|
223717135|NCT02420171|OTHER|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
223717136|NCT00727493|DRUG|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
223717137|NCT00727493|DRUG|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
223717138|NCT06184932|BEHAVIORAL|HAHE|Participants will self-initiate rehabilitative activities through the HAHE program.
223717139|NCT06184932|BEHAVIORAL|Exergame|Participants will self-initiate rehabilitative activities through the Exergame program.
223717140|NCT00358683|DRUG|Certolizumab pegol|
223717141|NCT03736447|BIOLOGICAL|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
223717142|NCT03736447|BIOLOGICAL|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
223717143|NCT02619175|DEVICE|Stroke Subjects Perturbation-Based Balance Training|
224279095|NCT05244018|DRUG|Vitamin D tablets|Vitamin D tablets 5000 units as daily requirements
224279096|NCT02857556|BIOLOGICAL|Blood sample|
223530545|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Gluteal|Dose level 3
223920547|NCT06624696|DRUG|Penehyclidine hydrochloride|The penehyclidine hydrochloride will be diluted to a total volume of 5 mL with normal saline, added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
223920548|NCT06624696|DRUG|Normal Saline|The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
223920549|NCT04874428|DRUG|Rivaroxaban 10 mg Oral Tablet|Administration of one single dose of rivaroxaban (10 mg) in tablet form.
223920550|NCT04874428|DRUG|Apixaban 2.5 mg Oral Tablet|Administration of one single dose of apixaban (2.5 mg) in tablet form.
223920551|NCT06343688|OTHER|"Assessment of Balance and Lower Extremity Gross Motor Function with and without DAFO"|"Measurements will be conducted with the child's custom-made DAFO (Dynamic Ankle-Foot Orthosis) and barefoot."
223920552|NCT04618406|DEVICE|PICO VAC|PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
223920553|NCT04618406|OTHER|Standard care|Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
223920554|NCT05938127|DEVICE|Inspiratory muscle strength training|High-resistance inspiratory muscle strength training (IMST) is a time-efficient (\~5 minutes/day) form of exercise that employs an affordable, handheld device which impedes inspiratory breathing to train the diaphragm and accessory respiratory muscles
223920555|NCT05938127|DEVICE|Sham Inspiratory muscle strength training|Low-resistance inspiratory muscle strength training
223920556|NCT06361238|DRUG|Liraglutide injection|Subcutaneous injection of liraglutide: 0.6 mg administered the day before surgery, 1.8 mg administered post-anesthesia induction on the day of surgery, followed by 0.6 mg daily for the first three postoperative days.
223920557|NCT06361238|DRUG|Placebo injection|Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
223920558|NCT06408727|DRUG|CNM-Au8|CNM-Au8 (cellular energetic nanocatalyst). Faceted clean-surfaced catalytically-active Au nanocrystals.
223920559|NCT05909046|DIAGNOSTIC_TEST|Immediate inpatient postpartum OGTT|The intervention includes immediate inpatient postpartum 2-hour oral glucose tolerance test (OGTT) prior to delivery discharge
223920560|NCT05909046|DIAGNOSTIC_TEST|Standard of care 4-12 week postpartum OGTT|Standard of care is 4-12 week outpatient postpartum OGTT
223920561|NCT04817969|DEVICE|Zimmer Biomet Persona Ti-Nidium Total Knee System|Primary Knee Total Arthroplasty
223920562|NCT06397716|GENETIC|ALDH2 Genotyping|Cheek swab for PCR testing of ALDH2 genotype.
224279097|NCT02857556|OTHER|Retinal photography:|
224279098|NCT02857556|OTHER|dialyse|
224279099|NCT02762617|DRUG|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
224279100|NCT02762617|DRUG|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
224279101|NCT00379223|PROCEDURE|vitrectomy with radial optic neurotomy|
224279102|NCT04334928|DRUG|Emtricitabine/tenofovir disoproxil|Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.
224279103|NCT04334928|DRUG|Hydroxychloroquine|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.
224279104|NCT04334928|DRUG|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil
224279105|NCT04334928|DRUG|Placebo: Hydroxychloroquine|Placebo: Tablets similar in appearance to Hydroxychloroquine
223530546|NCT06276361|DRUG|Oral risperidone; QUAR F1/2, Dose 3 - Deltoids|Dose level 3
223530547|NCT01863550|DRUG|Bortezomib|Given SC or IV
223530548|NCT01863550|DRUG|Carfilzomib|Given IV
223530549|NCT01863550|DRUG|Dexamethasone|Given PO
223530550|NCT01863550|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223530551|NCT01863550|DRUG|Lenalidomide|Given PO
223530552|NCT01863550|OTHER|Quality-of-Life Assessment|Ancillary studies
223920563|NCT03126292|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
223920564|NCT03126292|OTHER|Child Safety Handout|Handout regarding early child safety
223920565|NCT04722263|RADIATION|Radiotherapy|15 Gy in 3 fractions
223920566|NCT05933772|DEVICE|Lens A (comfilcon A toric lens)|One month wear
223920567|NCT05933772|DEVICE|Lens B (lehfilcon A toric lens)|One month wear
223920568|NCT06875830|PROCEDURE|collagen membrane|augmentation of the buccal plate of bone with xenograft and collagen membrane
223920569|NCT06875830|PROCEDURE|titanium mesh|augmentation of the buccal plate of bone with xenograft and titanium mesh
223920570|NCT06874023|OTHER|Passive heating in hot conditions|Participants performed seated passive heating in 54C conditions
223920571|NCT06874023|OTHER|Active heating + passive heating in hot conditions|Participants performed 30 minutes of biking exercise in 43C + 30 min of passive seated heating in 54C conditions.
223920572|NCT06874023|OTHER|Active heating in hot conditions|Participants performed 60 minutes of biking exercise in 43C.
223920573|NCT06874023|OTHER|Active heating at room temperature|Participants performed active heating through biking exercise for 60 minutes at room temperature.
223920574|NCT06874023|OTHER|Cool vest|Cool vest (18°C) with 500 mL (16 fl oz) ice water consumption
223920575|NCT06874023|OTHER|Damp neck towel combined with arm cool water immersion|Damp neck towel (24°C) combined with arm (i.e. hand, forearm and half of upper arm) cool water immersion (15°C) and 500 mL (16 fl oz) ice water consumption
223920576|NCT06874023|OTHER|Combination of cooling interventions|Combination of cool vest (18°C), damp neck towel (24°C) with arm cool water immersion (15°C), and 500 mL (16 fl oz) ice water consumption
223920577|NCT06874023|OTHER|Control in thermoneutral room without cooling|A control with participant sitting in a thermoneutral room (20°C air temperature) without any additional cooling intervention.
223920578|NCT06867510|PROCEDURE|Block for Anterior Cervical Spine Surgery|The patient will be positioned supine with a slight elevation of the head and the head turned away from the blocked side. After sterilizing the skin, the ultrasound probe will be placed over the middle of the posterior border of the sternocleidomastoid muscle. The needle will be inserted in-plane while keeping the probe in a transverse position. The needle tip will be placed under the sternocleidomastoid muscle and below the superficial fascia, and then, a total volume of 15 ml of 0.25% bupivacaine will be injected bilaterally. The spread of the local anesthetic will be visualized using ultrasound guidance. The same steps will be repeated on the other side
224279106|NCT05840471|DRUG|Tranexamic acid injection|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
224279107|NCT05840471|OTHER|Glucose water 5%|This interventional arm will receive tranexamic acid 1 g(10ml) (2 ampules each of 500 mg, 5ML) of tranexamic acid in 20 ml glucose water 5% intravenously twice daily in the acute stage of bleeding for 48 hours. This will be followed by 500 mg tranexamic acid tablets (Trenaxa; Macleods Pharmaceuticals Pvt. Ltd.) three times daily for five days. Participants will be followed up for recurrence of bleeding during pregnancy. The course of treatment will be repeated again if bleeding recurred. The hospital data safety and monitoring board ensured the continued safety of the Participants.
224279108|NCT00108082|DRUG|carvedilol MR|Study drug
224279109|NCT00108082|DRUG|atenolol|Comparator
224279110|NCT00108082|DRUG|lisinopril|Comparator
224279111|NCT00652756|DEVICE|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
223920579|NCT06867510|DRUG|Saline (NaCl 0,9 %) (placebo)|Total volume of 15 ml of saline 0.9% will be injected subcutaneous bilaterally
224279112|NCT00652756|OTHER|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
223920580|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
223920581|NCT06627088|DRUG|[14C]-LY4100511 (DC-853) Administered oral dose|Administered oral dose
223920582|NCT06627088|DRUG|LY4100511 (DC-853)|Administered oral dose
223920583|NCT06627088|DRUG|[14C]-LY4100511 (DC-853)|Administered IV infusion
224279113|NCT02419924|DEVICE|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
223530553|NCT03123458|BIOLOGICAL|clonal fetal MSCs|clonal fetal MSCs
223530554|NCT06225817|DIETARY_SUPPLEMENT|Open-label placebo pills|The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.
223530555|NCT02616991|PROCEDURE|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
223530556|NCT06285916|DRUG|NORA520 Dose 1|Oral NORA520 tablets Dose 1 for 3 days
223530557|NCT06285916|DRUG|NORA520 Dose 2|Oral NORA520 tablets Dose 2 for 3 days
223530558|NCT06285916|DRUG|Placebo|Oral Placebo tablets for 3 days
223920584|NCT06875284|BEHAVIORAL|Sexual Communication and Consent (SCC)|SCC combines universal classroom instruction with tailored web-based content. Based on sociodemographic characteristics and prior sexual assault experiences, Cadets receive tailored content that addresses either primary victimization prevention, revictimization prevention, or healthy relationships and bystander intervention promotion.
223920585|NCT06875284|BEHAVIORAL|Alcohol eCHECKUP TO GO (eCHECKUP TO GO)|eCHECKUP TO GO is a personalized, online intervention designed to reduce cognitive risk factors for alcohol misuse. eCHECKUP TO GO is brief, self-guided, and provides individualized feedback based on a user's self-reported alcohol use patterns and consequences.
223920586|NCT06875284|BEHAVIORAL|Training as usual (TAU)|TAU involves universal classroom instruction focused on developing knowledge, attitudes, and skills to promote personal resilience, increase potential for success, and develop healthy and rewarding personal relationships.
223920587|NCT06875804|OTHER|baseline physical therapy treatment|Group A focuses on pain relief, muscle relaxation, and strengthening. Hot packs and TENS are applied to the lateral thigh and knee for 20 minutes to reduce pain and muscle tension. Hip strengthening exercises include side-lying hip abduction, clam-shells, prone hip extension, bridging, and lunges. Quadriceps exercises involve straight leg raises, prone terminal knee extension, and mini-squats. Each exercise is done in 2-3 sets of 10-15 repetitions, holding stretches for 5 seconds.
224279114|NCT00295139|BEHAVIORAL|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
224279115|NCT00295139|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
224279116|NCT00295139|BEHAVIORAL|Critical Time Intervention (CTI)|Case management component
224279117|NCT00000486|PROCEDURE|coronary artery bypass|
224279118|NCT04008693|DIETARY_SUPPLEMENT|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
224279119|NCT04008693|OTHER|Placebo|800 mg of maltodextrin (four capsules)
224279120|NCT05192031|BEHAVIORAL|Smoking cessation support|Training healthcare professionals to deliver smoking cessation support as part of hospital-based lung cancer workup.
224279121|NCT00451152|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
224279122|NCT00451152|OTHER|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
224279123|NCT00955552|DRUG|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
224279124|NCT00955552|DRUG|Cosamin DS® (Nutramax)|oral capsule of glucosamine hydrochloride 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
224279125|NCT00784030|OTHER|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
224279126|NCT02607423|DRUG|Cisplatin|Given IV
224279127|NCT02607423|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
224279128|NCT02607423|DRUG|Docetaxel|Given IV
224279129|NCT02607423|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
224279130|NCT02607423|DRUG|Gemcitabine Hydrochloride|Given IV
224279131|NCT02607423|DRUG|Pemetrexed Disodium|Given IV
224279132|NCT02607423|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT
224279133|NCT02940730|DRUG|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
224279134|NCT02940730|DRUG|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
223717144|NCT02619175|DEVICE|Stroke Subjects Weight Shifting and Gait training|
224279135|NCT05947526|PROCEDURE|Oocyte pick-up|With the needle, transvaginally USG-guided oocyte pick-up procedure is going to be performed
224279136|NCT03462836|DRUG|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
224279137|NCT03462836|DRUG|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
224279138|NCT02655055|PROCEDURE|high frequency voluntary apheresis blood donation|
224279139|NCT05724368|DIAGNOSTIC_TEST|Fecal Calprotectin ELISA kit|"* Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions."
224279140|NCT00078481|DRUG|Idebenone|
223717145|NCT00004779|GENETIC|Ad5-CB-CFTR|
223717146|NCT06177730|OTHER|Pre-Hospital ECPR|Implementation of pre-Hospital ECPr in OHCA
223717147|NCT03940222|DEVICE|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
223920588|NCT06875804|OTHER|Compressive myofascial release of vastus lateralis.|The experimental group receives an additional session of Compressive Myofascial Release (CMFR) for the Vastus Lateralis to address lateral patellar tracking in PFPS patients. The patient lies on their side, and the therapist identifies tight areas, applying firm pressure for 20-30 seconds. Deeper pressure is held for 30-60 seconds, followed by 1-2 minutes of cross-fiber friction. The session includes muscle shaking for 30 seconds and stretching the Vastus Lateralis by extending the hip and flexing the knee for 30-60 seconds, repeated 2-3 times. Patient response is documented for progress tracking.
223920589|NCT05766631|BEHAVIORAL|DynamiCare Health|"Participants earn incentives for:~1. CM for opioid and cocaine abstinence. Accomplished via oral fluid (saliva) test kits given to participants.~2. Patients who test negative on opioids and cocaine are also eligible for a bonus if they additionally test negative for non-targeted drugs (except methadone).~3. Patients will receive notices of their medication pickup appointments through the app itself, and monetary rewards will be delivered to the Next Step debit card when the participant's presence at the clinic is verified by clinic records.~4. The app provides 72 self-administered modules based on the principles of cognitive behavioral therapy that are designed to aid in relapse prevention; small incentive rewards ($1) are provided for completion of up to 3 modules per week for the first weeks of treatment."
223920590|NCT05766631|DRUG|Methadone Treatment-As-Usual|Participants will receive treatment-as-usual at the methadone clinic, including daily methadone dosing, individual and group addiction counseling, and OP or IOP behavioral health services, depending on the clinic and the needs of the patient.
223920591|NCT04951856|DRUG|Evolocumab 140 MG/ML|Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.
223920592|NCT04951856|DRUG|Standard of care (SOC)|management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria
223920593|NCT03124303|PROCEDURE|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
223920594|NCT03124303|PROCEDURE|Magnetic Resonance Imaging|MRI scan of brain
223920595|NCT03124303|PROCEDURE|Blood specimen collection|Blood will be collected from participants
223920596|NCT03124303|DIAGNOSTIC_TEST|Pupillometry|A pupillometer is a device that measures the size of the pupils.
223920597|NCT06622538|DEVICE|Orotracheal intubation|Patients who meet the inclusion criteria and sign the informed consent form will be intubated with the ORION or King Vision video laryngoscope according to randomisation.
223530559|NCT05194436|DEVICE|AeviceMD|The AeviceMD will be placed on the patient to detect wheeze and perform auscultation.
224090209|NCT03180775|DIETARY_SUPPLEMENT|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224090210|NCT03180775|DIETARY_SUPPLEMENT|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
223530560|NCT05845749|DRUG|Vosoritide Injection [Voxzogo]|Vosoritide will be given via a once daily subcutaneous injection at a dose of 15 ug/kg/day, at approximately the same time each day when feasible. Vosoritide will be supplied to the subject as 0.4 mg vial, 0.56 mg vial or 1.2 mg vials to be reconstituted with sterile water up to 0.8 mg/mL or 2 mg/mL concentrations for injection. The volume to be administered (injection volume) will be based on the subject's body weight and the concentration of vosoritide. All supplies will be provided to the subject for home based administration after training at the study site.
223530561|NCT05459402|DRUG|Methadone (100% dose)|Methadone for the treatment of opioid use disorder
224090211|NCT03180775|DIETARY_SUPPLEMENT|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
224090212|NCT02452762|DRUG|Vitamin D3|
224090213|NCT02452762|DRUG|Placebo|
224090214|NCT05840939|BEHAVIORAL|Pranayama|"Pranayama, one of the practices of yoga, is a Sanskrit word consisting of a combination of two words, a technique of rhythmic, controlled breathing. So prana means life breath/life energy and ayama means expansion/regulation/control. Pranayama helps to improve lung capacity, heart and respiratory functions, nervous and hormonal systems, as well as mental activity."
223530562|NCT05459402|DRUG|Methadone (50% dose)|Methadone for the treatment of opioid use disorder
223530563|NCT05383482|DRUG|Afuresertib|Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD
223530564|NCT05383482|DRUG|Nab paclitaxel|Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W
223530565|NCT05383482|DRUG|Docetaxel|Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W
223717148|NCT03940222|PROCEDURE|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
223530566|NCT05383482|DRUG|Sintilimab|Sintilimab 200 mg Q3W
223530567|NCT05901636|BIOLOGICAL|INFLUENZA G1 mHA|INFLUENZA G1 mHA will be administered intramuscularly.
223530568|NCT05901636|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly.
223920598|NCT06691867|BEHAVIORAL|I-STRONG|"I-STRONG is an evidence-based protocol from the FIT Teens program. This intervention combines mind-body and cognitive-behavioral approaches with neuromuscular movement training informed by pediatric sports medicine and injury prevention research. It aims to teach mind-body skills applicable during movement training to enhance psychological coping and reduce fear of pain and activity avoidance.~I-STRONG consists of 16 group-based telehealth sessions held twice weekly over 8 weeks. Each group can accommodate up to 6 patients with SCD. Adolescents are expected to attend all sessions, while parents will attend 6 of the 16. Parents will receive education about I-STRONG, guidance on supporting their teen's behavior change, and opportunities for networking with other parents of youth with SCD. Sessions will include brief daily homework (e.g., using phone apps to practice skills) to facilitate proficiency. Participants will self-report their practice of assigned skills."
224090215|NCT05840939|BEHAVIORAL|diaphragm breathing exercise|Diaphragmatic breathing is also known as deep breathing or slow abdominal breathing. This breathing exercise uses the diaphragm muscle. The diaphragm is the muscle under the lungs that supports the lungs in up and down breathing.
224090216|NCT03502850|DRUG|ASK120067|patients take ASK120067 orally once per day at 40,80,160,240,320,480mg
224090217|NCT00408967|DRUG|Tucotuzumab celmoleukin (EMD 273066)|
224279141|NCT01312181|BEHAVIORAL|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
223920599|NCT06691867|OTHER|Enhanced Usual Care (EUC)|The EUC arm is designed to account for potential effects on time and standard medical care outcomes. Patients randomized to EUC will continue with standard care and optimal management of their SCD and chronic pain for approximately 8 months (i.e., time from enrollment through 6-month post-treatment assessment) before starting the intervention program to coincide with the study duration of the ES arm. After completing the 6-month follow-up assessment, patients will have the opportunity to start the I-STRONG for SCD intervention.
223920600|NCT06692920|OTHER|DBS stimulation|"* Standard of care DBS surgery~* stimulation through the DBS lead during their DBS lead surgery, the study team will use 2 sets of stimulation settings on each participant:~  1. Stimulation through the DBS contact whose electrical activity is the MOST similar to the area of the brain that controls movement~ 2. Stimulation through the DBS contact whose electrical activity is the LEAST similar to the area of the brain that controls movement"
223920601|NCT06693830|DEVICE|Phased Variant Enrichment and Detection Sequencing (PhasED-seq)|PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.
223920602|NCT06693830|OTHER|Standard of Care Treatment|Standard of Care Treatment for cycles 1-6
223920603|NCT06693830|OTHER|De-escalated Treatment|Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
223920604|NCT06691880|BEHAVIORAL|MindPod Dolphin VGT|"The MindPod Dolphin, is an interactive video game that allows users to engage in non-task-based tasks to motivate the users to play and relearn motor skills. The MindPod gaming platform uses markerless tracking to sense the patient's affected arm. The paretic limb controls Bandit the dolphin underwater in an effort to eat fish. The patient learns to map his/her movements to Bandit in a 3-Dimensional work space to reach the targets. During gaming, the therapist titrates game difficulty. Bilateral gaming components are used (the participant uses a controller with the participant's less-affected limb to control the timing of Bandit's movement) and in-game difficulty can be adjusted to create an immersive, challenging, and engaging experience. In order to be successful, the patient must coordinate both arms to control the temporal and spatial aspects of the game."
224279142|NCT01312181|BEHAVIORAL|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
224279143|NCT01312181|BEHAVIORAL|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
224279144|NCT00060294|BIOLOGICAL|rituximab|
223530569|NCT05901636|BIOLOGICAL|Al(OH)3|Al(OH)3 will be administered intramuscularly.
224090218|NCT01818297|DEVICE|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
224090219|NCT04506983|BIOLOGICAL|GPC3-CAR-T cells|Patients with hepatocellular carcinoma will be enrolled, and GPC3-CAR-T cells will be intravenously infused with a escalated dose of 1×106 /3×106/10×106GPC3-CAR-T cells.
224090220|NCT04468217|DIAGNOSTIC_TEST|Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples|Each patient will undergo a sample collection where two nasopharyngeal samples will be obtained, one of them with lysis buffer as the transport medium and the other with the AAA-Safe solution as the transport medium. Oropharyngeal, buccal, nasal, and salivary samples will also be obtained using AAA-Safe as the transport medium
224090221|NCT00584870|DRUG|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
224090222|NCT00584870|DRUG|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
224090223|NCT00584870|DRUG|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
224090224|NCT01798576|DRUG|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
224090225|NCT01798576|DRUG|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
224090226|NCT03365193|DIAGNOSTIC_TEST|Transesophageal Echocardiography|Standard transesophageal echocardiography will be performed as clinically indicated by treating physicians.
223920605|NCT06691880|BEHAVIORAL|Bimanual Arm Trainer VGT|"The bimanual arm trainer (BAT) is a device that involves hardware that interfaces with a computer game. The BAT promotes shoulder external rotation and elbow extension in the paretic arm by coupling movements of the paretic arm with the less affected limb as the participant matches his/her arm movements to those of a virtual avatar. The less-affected side and paretic limb are placed in the BAT apparatus and the less affected limb drives the impaired limb through passive, symmetrical movements that simulate rowing down a virtual river. The protocol created by the investigators group, leads the patient through an active-passive training progression similar to paradigms used in neural priming studies. Through these series of movements, the goal is to restore balance between the muscles of the upper back and chest to maximize range of motion in preparation for improved quality of movement."
223920606|NCT04194216|DRUG|"Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg."|Treatment Arm A
224090227|NCT00675597|DRUG|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
224090228|NCT06192173|PROCEDURE|Percutaneous PFO closure|Two kinds of interventional closure methods including DSA-guided and TEE-guided percutaneous intervention were performed on closure group.
224090229|NCT00631137|DRUG|testosterone gel applied to skin|Application of testosterone gel
224090230|NCT00631137|DIETARY_SUPPLEMENT|whey powder protein|
224090231|NCT01805947|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
224090232|NCT03682120|BIOLOGICAL|A/H7N9|"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."
224090233|NCT03682120|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
224090234|NCT03682120|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
224090235|NCT03470181|DIETARY_SUPPLEMENT|Ensure|Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
224090236|NCT04758494|OTHER|Questionnaire|"In the present study a questionnaire was designed by combining three separate questionnaires, which were weighted for use in Greek population and which are often being used to investigate quality of life of young populations diagnosed with stroke or multiple sclerosis, according to international literature. Those were the following questionnaires: Bathrel (Mahoney et al), Patient Health Questionairre (PHQ-9) (Thomson K et al), Health Survey SF-12 (Kontodinopoulos et al 2007). A draft questionnaire was then created with the addition of questions deemed necessary to provide necessary research information. Overall the questionnaire consisted of 42 questions.~Part A The first part of the questionnaire included demographics of participants. Part B. The second part of the questionnaire included an assessment of the functionality and independence, an evaluation of experienced depression and an assessment of the quality of life of the target population."
224090237|NCT06199245|OTHER|emotional freedom technique experimental group|Participants in the experimental group, who had a cesarean delivery on the first postpartum day, filled out the sociodemographic and obstetric information form and the Breastfeeding Self-Efficacy Scale, and then were asked to breastfeed their babies and their breastfeeding was evaluated with the Bristol Breastfeeding Evaluation Scale. The participant was then asked to score her breastfeeding between 0 and 10 to evaluate her Subjective Units of Disturbance Scala (SUD) score. The next evaluation was made 2 hours after the participant received breastfeeding training, the Bristol Breastfeeding Rating Scale score was obtained, and the SUD was scored again after 2 rounds of Emotional Freedom Techniques (EFT) application. Finally, at the end of the day, 2 rounds of EFT application were performed by taking the SUD score before the EFT session, and after the application, the participant's Breastfeeding Self-Efficacy Scale, Bristol Breastfeeding Evaluation Scale and SUD scores were recorded.
224090238|NCT03308188|BEHAVIORAL|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
224090239|NCT04880122|DIAGNOSTIC_TEST|Dried blood spot and venous blood collection|A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
224090240|NCT05398198|DRUG|GSK3923868|GSK3923868 dose and administration as per study intervention.
224090241|NCT05398198|DRUG|Placebo|Placebo matching GSK3923868 will be administered.
224090242|NCT02467998|DEVICE|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
224090243|NCT02382094|DRUG|Bicalutamide|
224090244|NCT02901431|DRUG|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
224090245|NCT02901431|DRUG|RO5285119|Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
224090246|NCT06484894|DEVICE|Pentacam and IOL master|Device used for measurement of central corneal thickness
223920607|NCT04194216|DRUG|"Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days"|Treatment Arm B
223920608|NCT04881110|DRUG|Liraglutide|Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.
223920609|NCT04881110|OTHER|Control|Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
223920610|NCT02213497|RADIATION|18F-FDG (Fluorodeoxyglucose) PET|
223920611|NCT02213497|DRUG|Carboplatin|
223920612|NCT02213497|DRUG|Paclitaxel|
223920613|NCT04893096|DRUG|MOR202|Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
223920614|NCT04926792|DEVICE|Leadless Pacemaker|Leadless pacemaker implantation
223920615|NCT06279975|DIAGNOSTIC_TEST|non-invasive device-supported, automated pupillometry|non-invasive device-supported, automated pupillometry with a precise quantitative measurement of the pupils within the range of micrometers
223920616|NCT05817006|GENETIC|Device|research of the long-COVID-19 in the children
223920617|NCT04157517|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion.
223920618|NCT04157517|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
223920619|NCT06694311|DEVICE|CPAP|"12 cmH2O for 48 hours (at least 10 hours of therapy per day). Nasobucal interface will be the preferred route with complete facial mask being also an acceptable device. If needed, therapy breaks will be delivered with HFNO at 50 L/min.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although CPAP will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
223920620|NCT06694311|DEVICE|HFNO 50 L/min|"HFNO 50 L/min for 48 hours. Therapy breaks with oxygen facemask will be allowed as per clinician decision but the protocol will advise against this practice.~Non-invasive ventilation will not be allowed.~After 48 hours of treatment, clinicians will be able to decide the respiratory support to be provided although HFNO will be recommended to be continued as long as PaO2/FiO2 is less than or equal to 300 and inspired oxygen fraction is 40% or more."
223920621|NCT06694675|DRUG|Sevoflurane (Volatile Anesthetic)|Sevoflurane 1%\~3.5%
223920622|NCT06694675|DRUG|propofol|Propofol 9\~15mg/kg/h
223920623|NCT06695650|OTHER|Mandala Coloring|Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period
223920624|NCT06693934|GENETIC|Risk assessment with biogenetic and clinical test to predict diabetes risk|All participants will undergo genetic test and clinical measurement including body weight, body height, blood pressure, waist circumference and capillary blood glucose to predict diabetes risk with report explanation by doctors (for high risk, IGT and DM) and nurses (low risk). Genetic report will be updated annually for high risk and IGT group using updated clinical factors (e.g. age, BMI, BP).
223920625|NCT06693934|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors|High risk progressors will undergo OGTT and measurement of CKM factors at baseline. In those without IGT or diabetes, they will undergo OGTT and CKM risk factor assessment annually for 2 years. The IGT group will additionally have measurement of beta-cell function (HOMA indexes) and the DM group will additionally have autoimmune marker measurement.
223920626|NCT06693934|DRUG|Medication|Nurse and medical consultations and subsidized medications (metformin, statin, ARB) will be provided to the high risk progressor, IGT and diabetes groups as appropriate for control of glucose and CKM risk factors.
223920627|NCT06693934|DEVICE|Continuous glucose monitoring (CGM) devices and/or weighing scale|All high risk progressors will be given subsidized weighing scale and low-intensity laboratory assessments, nurse and doctor consultation, regular WhatsApp messages and webinars for 2 years. The IGT and DM group will receive additional subsidized CGM devices for empowerment.
223920628|NCT06693934|BEHAVIORAL|Visit to family doctor with nurse education|All participants in high risk, IGT and diabetes groups will have regular follow-up by family doctors and nurses.
223920629|NCT06693934|DIAGNOSTIC_TEST|Joint Asia Diabetes Evaluation (JADE) assessment|Participants found to have diabetes on OGTT will undergo annual JADE assessment which include eye/foot/urine/blood tests with issue of a personalized JADE report. The JADE Program is a quality improvement program to improve self management and inform shared decision making between doctor and patient.
224090247|NCT01400256|DRUG|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
223920630|NCT06693934|BEHAVIORAL|Education webinars, workshops and health messages|All participants would join the webinars. High risk progressors, IGT and DM group will receive regular WhatsApp messages, webinars and workshops.
223920631|NCT06629701|DEVICE|External support for vein grafts|Group A will consist of a group of patients who will be sutured with external support for vein grafts.
224090248|NCT03043144|OTHER|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
224090249|NCT03043144|OTHER|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
224090250|NCT03043144|OTHER|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
224090251|NCT03043144|OTHER|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
224090252|NCT03043144|OTHER|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
224090253|NCT03043144|OTHER|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
224090254|NCT04672083|DRUG|CPT31|CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
224090255|NCT04672083|DRUG|Placebo|matching placebo
223530570|NCT06077994|BEHAVIORAL|digital Remote Patient Monitoring+BEPR+ (dRPM+)|In addition to the BEPR+ program as described, patients will use the Cloud Dx Connect Health System to take daily physiological readings (Blood pressure, heart rate, oximetry, body temperature and body weight). These data will be transmitted to a secured server supported by the provincial health care system. Participants and therapists will interact with these data in their respective dashboards and in conjunction with participants' determined medical action plan, engage in or make changes to participants current self-management regimens.
223530571|NCT06077994|BEHAVIORAL|Enhanced Breathe Easy Pulmonary Rehabilitation Program (BEPR+)|Patients will attend the BEPR+ program 3 days per week for 6 weeks or 2 days per week for 8 weeks (total of 16 sessions). Patients will receive 90 minutes of personalized and supervised exercise training (aerobic and resistance) and 60 minutes of education designed to promote self-management. Patients will also received one-on-one sessions with a therapist to review their medical action plan for exacerbation management, program and lifestyle goals (including physical activity), determine referral needs for other health services (i.e. smoking cessation, weight management, and psychological support). Patients will use an activity monitor for feedback and motivation for physical activity.
223530572|NCT06425120|DRUG|Xuesaitong Soft Capsule|Each participant in the xuesaitong soft capsule treatment group will take a daily dose of 1.32g.
223530573|NCT06425120|DRUG|Placebo|Each participant in the placebo group will take matching placebo.
223920632|NCT06693999|DEVICE|Google-Pixel Watch 3|The participant will wear Google-Pixel Watch 3 for at least 10 hours during the 3-month intervention and will receive goal reminders and motivational and coping messages through those watches. At baseline and after 3-months intervention, demographics (standard questionnaire pertaining to subjects' age, sex, race, education and income), technology literacy (eHealth Literacy Scale pertaining to subjects' ability to perform a number of tasks such as turning on the device, using internet and communication), and wearables affinity (pertains to how the subject currently uses wearable in their daily living tasks) will be measured.
223920633|NCT06693999|BEHAVIORAL|Exercise prompts|The participants will receive goal reminders.
223920634|NCT06694662|DIETARY_SUPPLEMENT|PKU EASY Microtabs Plus|"PKU EASY Microtabs Plus is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in patients from 3 years of age upwards.~PKU EASY Microtabs Plus is a microtablet form, slow-release, phenylalanine-free protein substitute containing a blend of essential and non-essential amino acids, vitamins, minerals and trace elements."
223920635|NCT06630741|OTHER|alternative midwifery units (AMU)|"Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room"
223920636|NCT06689215|DEVICE|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
223920637|NCT06687564|PROCEDURE|Biopsy|A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
223920638|NCT06688968|BEHAVIORAL|neuropsychologist interview|"It will take place either at the hospital or at the participant's home.~This interview will consist of :~* socio-demographic data collection~* neuropsychological tests:~  * MMSE test (Mini Mental State Examination) cognitive function~ * RL-RI-16 test (16-item free recall/indexed recall test)~ * BECS test (Semantic knowledge assessment battery )~ * WCST test (Wisconsin Card Sorting Test )~ * Musical Cognition Test~ * Help from the participant's relative to answer certain questions, in particular the MuseEQ-24 questionnaire"
223920639|NCT06688968|BEHAVIORAL|questionnaire|"The participant answers questionnaires:~* Questionnaire MusEQ-24 self reported (Music Engagement Questionnaire)~* Questionnaire BMRQ (Barcelona Reward Music Questionnaire)~* Questionnaire SHAPS (Snaith-Hamilton Pleasure Scale)~* Questionnaire LARS (Lille's Apathy Rating Scale)~* Questionnaire PHQ-9 (Patient Health Questionnaire 9 items)"
223920640|NCT06685822|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
223530574|NCT06529692|BEHAVIORAL|Placebo Split-Belt Training|Walking on a split-belt treadmill in which the belt under the ACL leg will move at a speed that is minimally slower than the other belt.
224279145|NCT00060294|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
224279146|NCT05992428|DRUG|DA-8010 5mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
224279147|NCT05992428|DRUG|Paroxetine 20mg|\[Part 1\] DA-8010 5mg + Paroxetine 20mg
224279148|NCT05992428|DRUG|Mirabegron 50mg|\[Part 2\] DA-8010 5mg + Mirabegron 50mg
224279149|NCT00668720|DEVICE|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
224279150|NCT00668720|DEVICE|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
223530575|NCT06529692|BEHAVIORAL|Split-Belt Training|Walking on a split-belt treadmill in which the treadmill belt under the ACL leg will move at a speed faster or slower than the belt under the Non-ACL leg.
223530576|NCT06364072|DRUG|CT001|Intranasal
223717149|NCT05152030|DIAGNOSTIC_TEST|'TIB' Olfactory Test|A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
224279151|NCT02470117|DRUG|Alginate-based reflux suppressant|
224279152|NCT02470117|DRUG|magnesium-aluminium antacid gel|
224279153|NCT00347113|DRUG|Albendazole and praziquantel|
224279154|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
224279155|NCT01502124|DRUG|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
223530577|NCT06390579|OTHER|Deep learning algorithm applied on retrospectively collected color fundus photographs|Deep learning algorithm applied on retrospectively collected color fundus photographs
223530578|NCT03032029|DEVICE|Adaptive Servo-Ventilation|Adaptive Bi-Level positive airway pressure with a targeted minute ventilation and auto-adjusting expiratory pressure level.
223530579|NCT06641804|PROCEDURE|Pessary care, change of pessary|Insertion of a new pessary by gynaecologist if not contraindicated, silicon or polyvinyl chloride pessary of same size, blinded to patient
223530580|NCT04385290|DRUG|MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO|"Midostaurin (IMP) induction: 25 mg or 50 mg peroral BID, days 8 to 21 depending on assigned dose level~GO (IMP) induction: 3 mg/m\^2 i.v. max 4.5 mg, on day1, or on days 1, 4, or days 1, 4, 7 depending on assigned dose level~Daunorubicin (DNR, non-IMP) induction: 60 mg/m\^2/day i.v., days 1 to 3~Cytarabine (AraC, non-IMP) induction: 200 mg/m\^2/day cont. infusion, days 1 to 7"
224090256|NCT03266679|OTHER|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
224090257|NCT00987844|DRUG|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
224090258|NCT00130338|DRUG|Rivastigmine|
224090259|NCT05451420|DRUG|PegIFN α- 2b|"Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine~；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）"
224090260|NCT04684654|BIOLOGICAL|BMS-986325|Specified dose on specified days
224090261|NCT04684654|OTHER|Placebo for BMS-986325|Specified dose on specified days
224090262|NCT02048904|DRUG|Sitagliptin|Sitagliptin 100 mg/day for 3 months
224090263|NCT02048904|DRUG|Placebo|Placebo 1 pill/day for 3 months
224090264|NCT01479608|PROCEDURE|Liver transplantation and liver resection|
224090265|NCT04042480|DRUG|SGN-CD228A|SGN-CD228A administered into the vein (IV; intravenously)
224090266|NCT01449890|BEHAVIORAL|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
224090267|NCT04156321|DIETARY_SUPPLEMENT|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
224090268|NCT03541473|DIETARY_SUPPLEMENT|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
224090269|NCT03541473|DIETARY_SUPPLEMENT|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
224090270|NCT02339467|OTHER|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
224099559|NCT03406026|OTHER|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
224099560|NCT03406026|OTHER|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
224099561|NCT01002781|DRUG|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
224099562|NCT04203901|BIOLOGICAL|CMN-001|Autologous Dendritic Cell Therapy
224099563|NCT04203901|BIOLOGICAL|Nivolumab+Ipilimumab|anti-PD-1 and anti-CTLA4 antibodies
224099564|NCT04203901|DRUG|Lenvatinib+Everolimus|TKI+mTOR inhibitors
224099565|NCT05994170|RADIATION|Reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as 5mm margin from GTVp,including pre-induction chemotherapy tumor extension( CTVp1=GTVp+5mm)
223717150|NCT05152030|DIAGNOSTIC_TEST|Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)|The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
223717151|NCT04036890|DRUG|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
224090271|NCT02339467|OTHER|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
224090272|NCT01247311|DIETARY_SUPPLEMENT|Dietary supplement|Placebo given orally 3xweek for six months
224090273|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
224090274|NCT01247311|DIETARY_SUPPLEMENT|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
224090275|NCT05219422|BEHAVIORAL|Project ALERT|14 session drug prevention program for 7th and 8th grade youth.
224090276|NCT05219422|BEHAVIORAL|Getting to Outcomes|The Getting To Outcomes (GTO) implementation support intervention provides technical assistance, training, guides, and tools to improve community-based practitioners capacity to complete tasks associated with implementing an EBP, which in turn leads to improved implementation fidelity.
224090277|NCT05690659|OTHER|device and exercise|cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
224090278|NCT00024232|BIOLOGICAL|monoclonal antibody huJ591|
224090279|NCT05792384|PROCEDURE|transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung cryobiopsy with a 1.1 mm flexible cryoprobe
224090280|NCT05792384|PROCEDURE|transbronchial lung biopsy with biopsy forceps|Obtaining lung biopsy samples of patients after lung transplantation through transbronchial lung biopsy with biopsy forceps
224090281|NCT01446211|DRUG|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
224090282|NCT01446211|DRUG|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
224090283|NCT02102750|DRUG|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
224090284|NCT03114449|DEVICE|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
224090285|NCT03114449|DEVICE|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
224090286|NCT00730743|PROCEDURE|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
224090287|NCT03767569|DRUG|Myo-inositol|Myo-inositol and Folic acid daily
224090288|NCT03767569|DRUG|Folic Acid|Folic Acid daily
224090289|NCT01576211|GENETIC|DNA methylation analysis|
224090290|NCT01576211|GENETIC|RNA analysis|
224090291|NCT01576211|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
224090292|NCT01576211|GENETIC|gene expression analysis|
223530581|NCT04385290|DRUG|MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2 i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
223530582|NCT04385290|DRUG|MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO|"GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg on days 1, 4, 7; 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
223717152|NCT04036890|DRUG|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
223717153|NCT00925093|DRUG|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
223920641|NCT06250933|OTHER|Postpartum Maternal Care and Premature Infant Care Training|"Training and counseling were provided. In this context, training consisting of three sessions of 100 minutes in total was provided and counseling was provided in the following weeks by conducting 3-4 telephone interviews.~The intervention involves the provision of a training and counseling program designed to increase women's breastfeeding and maternal self-efficacy and reduce the risk of postpartum depression.~In the training phase, women will receive training on postpartum maternal care and premature infant care."
223920642|NCT04840394|DRUG|BDB018|BDB018 is an immunotherapy agent.
223920643|NCT04840394|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
223920644|NCT02933489|DIAGNOSTIC_TEST|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
223920645|NCT02933489|DIAGNOSTIC_TEST|Digital Tomosynthesis Mammography|Undergo DBT
224090293|NCT01576211|GENETIC|nucleic acid sequencing|
223717154|NCT00925093|DRUG|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
223717155|NCT00925093|DRUG|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
223920646|NCT02933489|OTHER|Quality-of-Life Assessment|Ancillary studies
223920647|NCT02933489|OTHER|Questionnaire Administration|Ancillary studies
223920648|NCT06868706|BEHAVIORAL|VR-Supported Video Modeling|Participants receive virtual reality (VR) supported video modeling training in addition to traditional swimming training.
223920649|NCT06868706|BEHAVIORAL|Traditional Swimming Training|Participants receive only traditional swimming training. Individuals in this group learn swimming techniques through traditional methods (practising in the water under the supervision of an instructor).
223920650|NCT06872177|OTHER|Measurements|On existing identified chart records: measurements on CBCT and panographic radiographs.
223920651|NCT06697405|OTHER|Prolonged ≥ 120 minutes|No intervention, regular therapy
223920652|NCT03460665|PROCEDURE|Arteriography|knee arteriography
223920653|NCT05650177|BEHAVIORAL|blended Mindfulness-Based Intervention (bMBI)|The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.
223920654|NCT06633029|DEVICE|Prismaflex HF20|CRRT fluid management and reduction of uremic toxins.
224090294|NCT01576211|GENETIC|polymorphism analysis|
223717156|NCT01378637|DEVICE|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
223717157|NCT06193291|PROCEDURE|Feet heating|Feet placed in hot water
223717158|NCT06193291|PROCEDURE|Calf heating|Feet to calves placed in hot water
224090295|NCT01576211|OTHER|laboratory biomarker analysis|
224090296|NCT04752384|DRUG|Buprenorphine|Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
224090297|NCT04752384|DRUG|Tramadol|Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
224090298|NCT04752384|DEVICE|Oral Mucositis (OM) Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
224090299|NCT04190446|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223920655|NCT06633029|DEVICE|Prismaflex M60|CRRT fluid management and reduction of uremic toxins.
223920656|NCT06118099|DRUG|Amlitelimab|Injection solution SC injection
224090300|NCT04190446|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
224090301|NCT04190446|OTHER|Quality-of-Life Assessment|Ancillary studies
223717159|NCT06478485|DIAGNOSTIC_TEST|No Intervention: MCSM|No Intervention: MCSM
223920657|NCT06118099|DRUG|Placebo|Injection solution SC injection
223920658|NCT06365099|DEVICE|Single-pulse TMS|Single-pulse TMS will be applied to the lesioned hemisphere while participants rest quietly with their eyes open
223920659|NCT06173973|DIETARY_SUPPLEMENT|Kenetik; Ketone Concentrate|Ketone Supplement
223920660|NCT06173973|DIETARY_SUPPLEMENT|Isocaloric dextrose placebo|Drink that is taste and visually matched to Ketone supplement
223920661|NCT06870136|DIETARY_SUPPLEMENT|Lion's Mane Study Product|The Lion's Mane Study product contains vegetable cellulose (capsules), Certified organic Lion's Mane (Hericium erinaceus) fruiting body and mycelial biomass cultured on certified whole oats (Avena sativa). Screening assessments, scales and surveys during baseline and during the use of the study product/placebo and end of study experience survey data will be collected.
223920662|NCT05567120|OTHER|PATH-Care|Individuals will receive the 8-session PATH-Care intervention, delivered virtually (via videoconference or phone) to mitigate negative emotions and stress experienced by informal caregivers of individuals with ADRD. The therapist in the first session will also guide the participant in the tablet-based exercises (WELLPath).
223920663|NCT04466241|DRUG|Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet|2 tablets morning and evening from Day 1 to Day 10
223920664|NCT04466241|DRUG|Telmisartan 40Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
223920665|NCT04466241|DRUG|Atorvastatin 20 Mg Oral Tablet|1 tablet daily from Day 1 to Day 10
223920666|NCT06684418|DIAGNOSTIC_TEST|chest enhanced CT|This is an observational study and patients will receive routine clinical treatment according to the corresponding guidelines. We will collect the enrolled patient's chest enhanced CT and clinicopathological parameters.
224090302|NCT04190446|OTHER|Questionnaire Administration|Ancillary studies
224090303|NCT04190446|PROCEDURE|Computed Tomography|Undergo CT scan
223717160|NCT02425020|DIETARY_SUPPLEMENT|Meat Protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
223717161|NCT02425020|DIETARY_SUPPLEMENT|Whey protein|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
223920667|NCT05886452|DEVICE|DT1fA contact lenses|Subjects will be fitted with DT1fA contact lenses
223920668|NCT06695702|OTHER|the effect of work-based learning on the level of knowledge|The benefit of workbased learning on nursing students' knowledge of oncology symptom management
223920669|NCT06695390|OTHER|Nursing students' humanistic care competence|A cross-sectional study with nursing students
223920670|NCT06686745|DRUG|SIM0508 Tablets|Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.
223920671|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Multiple dose levels of SIM0508 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
223920672|NCT06686745|DRUG|SIM0508 in combination with olaparib|Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0508 combination with olaparib established from SIM0508 combination dose escalation.
224090304|NCT04190446|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224090305|NCT04190446|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224090306|NCT05998395|DRUG|Ruxolitinib|Ruxolitinib at 5 mg twice a day (BID) for 1 week and then at 10 mg BID for 13-73 weeks and 1 week of 5 mg BID before stopping ruxolitinib.
224090307|NCT03651947|DRUG|QL1206|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
224090308|NCT03651947|DRUG|Xgeva®|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
224090309|NCT00888511|DRUG|Tarceva|Tarceva 150 mg/day
224090310|NCT00888511|RADIATION|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
224090311|NCT00338507|DRUG|Erdosteine|
224090312|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
224090313|NCT02527356|BEHAVIORAL|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
224090314|NCT02527356|BEHAVIORAL|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. In addition, they will receive training program in a hospital for 2 hours/per session, 2 sessions/per week for a total of 12-week intervention. The participants will also experience the two 30-minute car driving sessions during the whole 2-hour training. The difference between the regular therapy group and the two ROC groups is the experience of car driving is controlled by the therapist, i.e. passive locomotion. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
224090315|NCT04217564|BEHAVIORAL|Nutritional counselling|Nutritional counselling based on the nutritional assessment will be conducted. A booklet that contains the whole instructions and dietary records will be provided to help remembering information and record their application of the plan.
224090316|NCT01132105|DEVICE|Vestibular myogenic evoked potential analyzer|
224090317|NCT00141947|DRUG|bexarotene (Targretin)|
224090318|NCT05448677|DRUG|Ezurpimtrostat|Patients in the experimental arm will be instructed to take their assigned oral dose every day.
223920673|NCT06687785|PROCEDURE|Entire Papilla Preservation Technique|A buccal intrasulcular incision was made in the tooth with the defect and a vertical incision was made extending from the buccal center of the tooth to the mesial papillary crest and crossing the mucogingival line. Then, using a micro periosteal elevator, a full-thickness mucoperiosteal flap was lifted from the incision site to the defect under the papilla. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the vertical incision was sutured with 6/0 polypropylene suture using simple suture technique.
223920674|NCT06687785|PROCEDURE|Conventional Flap Surgery Technique|After buccal and lingual intrasulcular incisions were made to eliminate the teeth and papillae adjacent to the defect, a full-thickness mucoperiosteal flap was raised in the vestibular and lingual direction with a periosteal elevator. After removal of the granulation tissues in the area, bone graft was applied for regenerative purposes and the papillary incisions were sutured with 5/0 polypropylene suture using simple suture technique.
223920675|NCT06875557|BEHAVIORAL|Digital Mental Health Intervention (DMHI)|In the current study, the impact of Digital Mental Health Intervention (DMHI) would be examined through Insight Timer application, focusing on just its one aspect (Reiki healing techniques). Through the usage of DMHIs in the young population, youth would be better able to express their psychological issues with the healthcare professionals instead of the fear of being labelled or stigmatization.
223920676|NCT06875557|BEHAVIORAL|Digital Mental Health Intervention (DMHI)|Digital Mental Health Intervention (DMHI) was provided to the sample of young adults who were experiencing psychological distress. DMHI was being given through Insight Timer application that only focused on reiki healing techniques. Insight Timer is a mobile app that provides guided meditations to calm the mind, alleviate anxiety, manage stress, achieve deep sleep, and enhance well-being and happiness. Additionally, it offers calm and soothing music, educational courses, live events, and workshops in multiple languages. (Insight Network, Inc., n.d.). The app is FREE to download with an email allowing access to their collection of meditation recordings. Insight Timer's free-to-use feature is most suitable for community groups.
224090319|NCT05448677|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle
224090320|NCT05448677|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
224090321|NCT04172285|BEHAVIORAL|Physical activity|Home-based physical activity program
224090322|NCT04172285|DIETARY_SUPPLEMENT|Physical activity and supplementation|Home-based physical activity program and amminoacid supplementation
224090323|NCT04172285|OTHER|Control|No intervention
224090324|NCT03889587|PROCEDURE|Innervation|There will be simultaneous innervation of vascularized iliac or fibular bone flaps through neurorrhaphy between the nerves innervating iliac or fibular bones and recipient site.
224090325|NCT03889587|PROCEDURE|Non-innervation|This will be the traditional method of vascularized iliac or fibular bone flaps, and neurorrhaphy will not be performed.
224090326|NCT05733585|DEVICE|Purabond|hemostatic efficacy of PuraBond
224090327|NCT01979497|PROCEDURE|Suture with Adhesive Stripping|
224090328|NCT01979497|PROCEDURE|Suture without Adhesive Stripping|
224090329|NCT00707798|BIOLOGICAL|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
224090330|NCT00707798|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
224090331|NCT04360967|OTHER|Standard Formula|Standard Formula
224090332|NCT04360967|OTHER|Nutrient-enriched Formula|Nutrient-enriched Formula
224090333|NCT02316834|OTHER|Laboratory Biomarker Analysis|Correlative studies
223530583|NCT04385290|DRUG|MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21, induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles;~GO (IMP): 3 mg/m\^2 i.v. max 4.5 mg, RP2D, 1 induction cycle only~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycles 1-2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
223717162|NCT02425020|DIETARY_SUPPLEMENT|Carbohydrate|Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
223717163|NCT04145557|DEVICE|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
223920677|NCT04873323|DRUG|TS-142|Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
223920678|NCT04873323|DRUG|Moxifloxacin|Single dose of moxifloxacin 400 mg in the morning under fasting in each period
223920679|NCT04873323|DRUG|Placebo|Single dose of TS-142 placebo in the morning under fasting in each period
223920680|NCT05761769|OTHER|no intervention|no intervention
224090334|NCT02316834|DRUG|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
224279156|NCT01611207|DEVICE|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
224279157|NCT01611207|OTHER|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
223717164|NCT04145557|DEVICE|scaling root planing|scaling and root planing
223717165|NCT00873574|BIOLOGICAL|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
223717166|NCT05687383|DEVICE|Safe breastfeeding pillow|A randomized controlled trial
223717167|NCT02657369|DRUG|Lenvatinib 24 mg|
223717168|NCT03054441|OTHER|Actigraph|Actigraphs worn on wrists
223717169|NCT02727361|RADIATION|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
223920681|NCT06700850|DEVICE|Prototype dressing rectangle|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 30x10cm. Topical application. Single use.
223920682|NCT06700850|DEVICE|Marketed dressing rectangle|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 30x10cm. Topical application. Single use
224279158|NCT04631887|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"The Doing What Matters in Times of Stress: An Illustrated Guide is a booklet that is developed by World Health Organization. It is a stress management booklet formed to provide people skills for coping with stress and adversity. The booklet has accompanying audio exercises."
224279159|NCT04203160|DRUG|CPI 613|Given intravenously
224279160|NCT04203160|DRUG|Gemcitabine|Given intravenously
224279161|NCT04203160|DRUG|Cisplatin|Given intravenously
223920683|NCT06700850|DEVICE|Prototype dressing square|Prototype multilayer foam wound dressing with polyurethane, cellulose, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE (Low Density Polyethylene). Size: 7.5x7.5cm. Topical application. Single use.
223920684|NCT06700850|DEVICE|Marketed dressing square|CE marked multilayer foam wound dressing with silicone, polyurethane, viscose, polyester, polyolefins, polyacrylate and superabsorbent acrylate fibres. Size: 7.5x7.5cm. Topical application. Single use.
223920685|NCT06699875|OTHER|Trak exercise prescription protocol at home|Online exercise protocol using the TRAK software. The patient will undergo 4 weeks of an exercise prescription protocol based on shoulder mobility exercises.
223920686|NCT06699875|OTHER|Conventional rehabilitation plan at home|Treatment is based on therapeutic exercise following a conventional rehabilitation plan on paper. The patient will undergo 4 weeks of an exercise prescription protocol based on mobility exercises.
223920687|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific to the device's wavelength.
223920688|NCT06702241|OTHER|Continuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
223717170|NCT02727361|OTHER|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
224090335|NCT05302635|OTHER|Simulated group|"Students will be given training on nasogastic tube insertion and practice will be demonstrated in the laboratory based on the demonstration method and checklists, and will continue until students learn. Forms will be applied to students as a pre-test. A pilot scenario will be applied to two volunteer fourth year students.~Prebriefing: Students will be informed. Students will implement the scenario in the simulation laboratory and will wear uniforms. The student will be given 5 minutes for preparation, the application will be taken one by one and 15 minutes will be given for practice. Researchers will only observe during this time. During the application, the student will be scored according to the checklist. Students will be recorded with video.~Debriefing: Immediately after the end of the scenario, a debriefing session will be held with groups of 5 people. Feedback will be given on students' performance. Each session will last 20-30 minutes. Students will be given a post-test."
224090336|NCT05150548|OTHER|No Intervention|Not applicable, non-interventional study
224099566|NCT05994170|RADIATION|Non-reduction CTVp1|High Risk Primary Tumor Clinical Target Volumes (CTVp1) is defined as whole nasopharynx as well as 5mm margin from GTVp( CTVp1=GTVp+5mm+whole nasopharynx)
223717171|NCT01704378|DRUG|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
223717172|NCT02154178|OTHER|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
223920689|NCT06702241|OTHER|Continuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
223920690|NCT06702241|OTHER|Cycled phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light|The difference in irradiance between the groups will be measured with a radiometer specific for the device's wavelenght
224099567|NCT02186392|DEVICE|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
224099568|NCT05523180|DIETARY_SUPPLEMENT|Probiotic|"Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
224099569|NCT05523180|OTHER|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide"
224099570|NCT01283737|DEVICE|DBX Putty|OCD of the knee will be treated with DBX Putty
224099571|NCT01283737|PROCEDURE|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
224099572|NCT05229965|DRUG|Paracetamol|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
224099573|NCT05229965|DRUG|Paracetamol Codeine|14 pills will be provided with a preconised dose of 1 pill 2 times per day over 7 days period
224099574|NCT05229965|DRUG|Paracetamol caféine|21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
224099575|NCT01640847|DRUG|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
224099576|NCT05485103|DRUG|Polyethylene Glycols|Take asol as total enteral nutrition, and take polyethylene glycols and glycerin enema as bowel preparations
223920691|NCT04177771|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
223920692|NCT04177771|DEVICE|SofPort LI61AO IOL|Control treatment group will receive SofPort LI61AO IOL
223920693|NCT04177771|DEVICE|Tecnis ZCB00 or ZTC150 IOL|Control treatment group will receive Tecnis ZCB00 or ZTC150 IOL
224099577|NCT00613626|DRUG|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
224099578|NCT00613626|DRUG|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
224099579|NCT00613626|DRUG|Placebo|Matched placebo oral daily
224099580|NCT00613626|DRUG|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
224099581|NCT02333227|DIETARY_SUPPLEMENT|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
224099582|NCT01954823|DEVICE|e-diary|"The e-diary can collect data on:~* Medical data: information on diseases, treatments and attending physicians~* Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~* Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~* Reports: textual and graphical reports of the data in the diary can be created"
224099583|NCT04108507|PROCEDURE|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
223920694|NCT03966586|BEHAVIORAL|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
223920695|NCT03966586|BEHAVIORAL|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
223920696|NCT03966586|BEHAVIORAL|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
223920697|NCT03966586|BEHAVIORAL|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
224090337|NCT02500693|BIOLOGICAL|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
224090338|NCT01712347|DRUG|Bevacizumab|Bevacizumab will be administered as per approved label.
224090339|NCT01712347|DRUG|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
224090340|NCT06648590|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
224090341|NCT06648590|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each subject will have 3 follow-up visits(d1、d28、d56).
224090342|NCT02800187|DEVICE|ESWT|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
224090343|NCT00245947|DRUG|ERB-041|
224090344|NCT02796105|DRUG|Progevera|
224090345|NCT02796105|DRUG|Orgalutran|
224090346|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
224090347|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
224090348|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
224090349|NCT00046228|DRUG|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
224090350|NCT00046228|DRUG|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
224090351|NCT00046228|DRUG|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
224090352|NCT01951001|DRUG|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
224090353|NCT02921386|DRUG|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
224090354|NCT01905956|DIETARY_SUPPLEMENT|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
223920698|NCT03966586|BEHAVIORAL|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
223920699|NCT03966586|BEHAVIORAL|Usual clinical care and counseling|Usual clinical care and counseling
224090355|NCT01905956|DIETARY_SUPPLEMENT|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
224090356|NCT03033329|DRUG|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
224090357|NCT03033329|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
224090358|NCT03033329|DRUG|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
224090359|NCT03033329|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
224090360|NCT03033329|DRUG|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
224090361|NCT03137979|BIOLOGICAL|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
224090362|NCT03137979|BIOLOGICAL|Collagen scaffolds|Patients in this group were given collagen scaffolds.
224090363|NCT03137979|PROCEDURE|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
224090364|NCT05323422|PROCEDURE|intravenous Ketamine induction|preoperatively ketamine wll administer in group 1-3
224090365|NCT05998915|OTHER|observe only|observe only
224090366|NCT04007315|DEVICE|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
223530584|NCT04385290|DRUG|MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin|"Midostaurin (IMP):~RP2D peroral, days 8 to 21, induction cycle 1; 50 mg peroral BID, days 8 to 21 induction cycle 2; 50 mg peroral BID, days 8 to 21, 3 consolidation cycles; 50 mg peroral BID, days 1 to 28, 12 maintenance cycles~Daunorubicin (DNR, non-IMP):~60 mg/m\^2/day i.v., days 1 to 3 of induction cycle 1 and 2 in good and moderate responders; 50 mg/m\^2/day i.v., days 1 to 3 of induction cycle 2 in non-responders~Cytarabine (AraC, non-IMP):~200 mg/m\^2/day cont. infusion, days 1 to 7 of induction cycles 1 and 2 in good and moderate responders; 3000/1500 mg/m\^2/day i.v. BID, days 1 to 3 of induction cycle 2 in non-responders; 3000/1500 mg/m\^2 i.v. BID, days 1, 3, 5 of consolidation, 3 cycles"
223530585|NCT00158587|DRUG|primaquine|
224279162|NCT05093465|BEHAVIORAL|Technology Intervention|"Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day."
224279163|NCT05093465|OTHER|Active Control|Participants were provided with sleep hygiene and stimulus control procedures.
224279164|NCT06260020|BEHAVIORAL|Comprehensive module for management of sleep disorders[Behavioral and pharmacological therapy]|"Development of module by Delphi method:components of Module include Behavioural intervention Modifying stimulus by change in location,using bedtime stories. Giving schedules to activities which interfere with sleep before bedtime. Using a bedtime pass to allow child to make a prefixed number of requests for parental attention while in bed.~Giving sleep items like cuddle toys to replace parental presence. Gradually delaying the bedtime so the child feels urge to sleep. Sleep hygiene by providing suitable environment to sleep, proper bedtime routine, sleep wake schedules Providing rewards for following good bedtime routine as positive reinforcement. Pharmacological intervention Sleep disorders due to underlying ENT, pulmonary conditions, to be treated as per standard protocol Usage of melatonin if required for sleep onset difficulty An 80%agreement over an intervention will be included in the module"
224279165|NCT00149526|BEHAVIORAL|Shared Decision-Making|
224279166|NCT05132725|BEHAVIORAL|diet therapy|Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
224279167|NCT03765086|PROCEDURE|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
224279168|NCT03765086|PROCEDURE|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
224279169|NCT05535439|PROCEDURE|EBUS-TBNA using 22 G EBUS-FNB Device OR 19 G EBUS-FNA needle|Both arm will be interventional where mediastinal lymph nodes will be sampled by two typs of needle
224279170|NCT03036839|DRUG|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
224279171|NCT03766217|COMBINATION_PRODUCT|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
224279172|NCT03766217|COMBINATION_PRODUCT|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
224279173|NCT01052324|DRUG|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5\~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
224279174|NCT05685524|DIAGNOSTIC_TEST|DNA methylation test|Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.
224279175|NCT02524184|DRUG|sildenafil|sildenafil 100 mg per day for 7 days.
224279176|NCT02524184|DRUG|placebo|an identical placebo per day for 7 days
223530586|NCT06645223|DRUG|No Interventions|no interventions
223530587|NCT04548999|DRUG|Ocrelizumab|"The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W.~During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total)"
224279177|NCT02299219|BEHAVIORAL|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
223530588|NCT04548999|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg, IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
223530589|NCT04548999|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
223530590|NCT04548999|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
223530591|NCT00432965|DEVICE|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
223530592|NCT00432965|DEVICE|VAC Therapy|VAC Therapy
223530593|NCT00159016|DRUG|Glivec|
223920700|NCT03443791|DIAGNOSTIC_TEST|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
223920701|NCT03443791|DIAGNOSTIC_TEST|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
223920702|NCT06877182|DIAGNOSTIC_TEST|Magnetic Resonance Imaging with Contrast|To evaluate the possibility to improve the neuroradiologic workflow with AI models
223920703|NCT06879691|DRUG|Nimotuzumab|nimotuzumab group nimotuzumab, 200mg/w, for 6 weeks
223920704|NCT06879691|DRUG|cis-platinum|30mg/m2/w, for 6 weeks
223920705|NCT06879691|RADIATION|IMRT combine with cisplatin concurrent chemotherapy|IMRT, 66～70Gy (2Gy/F, 35F), for 6 weeks
223920706|NCT06879691|DRUG|painkiller|three ladders pain analgesic( First step: For mild pain, non-opioid agents (excluding nonsteroidal anti-inflammatory drugs \[NSAIDs\]) combined with adjuvant analgesics are administered; Second step: For moderate pain, weak opioids combined with NSAIDs and adjuvant analgesics are prescribed;Third step: For severe pain, strong opioids combined with NSAIDs and adjuvant analgesics are used.)
223920707|NCT06880289|DRUG|Cisplatin IV on days 1, 22, 43, at a dose of 100 mg/m2|Chemoradiotherapy will be performed from day 1 to day 49 regardless of the arm.
224090367|NCT04007315|BEHAVIORAL|Usual care|6-weeks of usual NHS care
223920708|NCT06877312|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"A light electrical current with zero frequency (tDCS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
224090368|NCT00503256|BEHAVIORAL|Questionnaire|Questionnaires each taking 60 minutes to complete.
224090369|NCT00330707|DRUG|Bacillus Calmette Guerin and interferon alpha|
223530594|NCT02010502|DIETARY_SUPPLEMENT|Beetroot juice|
223530595|NCT02010502|DIETARY_SUPPLEMENT|Beetroot powder|
223920709|NCT06877312|DEVICE|30 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 30 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
223920710|NCT06877312|DEVICE|50 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 50 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
223920711|NCT06877312|DEVICE|70 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 70 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
223920712|NCT06877312|DEVICE|90 Hz Transcranial Alternating Current Stimulation (tACS)|"A light electrical current with 90 Hz frequency (tACS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
224090370|NCT05135286|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
224090371|NCT05135286|DRUG|Carbachol PF|A single drop in each eye at a visit.
224090372|NCT05135286|DRUG|Vehicle|A single drop in each eye at a visit.
223530596|NCT02010502|DIETARY_SUPPLEMENT|Placebo|
224090373|NCT03779178|DRUG|Landiolol|Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
224090374|NCT03779178|DRUG|Placebo|Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
224090375|NCT06385392|DEVICE|Haptic module and insole device|System for use in daily in-community use that detects the occurrence of freezing of gait (FOG) and triggers external cueing stimuli to unfreeze the individual.
224090376|NCT06339138|OTHER|Non-Interventional Study|Non-interventional study
224090377|NCT05177796|DRUG|Carboplatin|Given IV
223530597|NCT05680818|DRUG|Encaleret|Administered as film-coated tablet for oral use
223530598|NCT05680818|DIETARY_SUPPLEMENT|Standard of Care|Calcium supplements and/or active Vitamin D (calcitriol, alfacalcidol, falecalcitriol, etc.)
223530599|NCT01435590|PROCEDURE|Curette v/s endocervical brush|
224090378|NCT05177796|DRUG|Cyclophosphamide|Given IV
224090379|NCT05177796|DRUG|Doxorubicin|Given IV
224090380|NCT05177796|DRUG|Paclitaxel|Given IV
224090381|NCT05177796|BIOLOGICAL|Panitumumab|Given IV
224090382|NCT05177796|BIOLOGICAL|Pembrolizumab|Given IV
224099584|NCT00189826|DRUG|tacrolimus|immunosuppression
223530600|NCT03180268|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223530601|NCT03180268|OTHER|Clinical Observation|Undergo observation
223530602|NCT03180268|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223530603|NCT03180268|OTHER|Laboratory Biomarker Analysis|Correlative studies
223920713|NCT06877312|DEVICE|Transcranial Random Noise Stimulation (tRNS)|"A light electrical current with random noise waveform (tRNS) will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant. They have the option of having their choice of music play in the background while they perform the cognitive exercise.~cognitive exercises Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad and other cognitive games. Participants will be guided by a highly trained research assistant."
223920714|NCT06877481|OTHER|Geriatric Pain Measurement Short Form|Geriatric Pain Measure - Short Form (GPM-SF) is a validated pain assessment tool designed specifically for older adults. It is a 12-item questionnaire that evaluates pain intensity, interference with daily activities, and emotional impact of chronic pain in geriatric patients. The short form provides a quick and reliable assessment of pain-related disability in older populations.
223920715|NCT06877143|DIETARY_SUPPLEMENT|100% of individual calory requirement|Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
224090383|NCT04815096|DRUG|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|\[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
224090384|NCT06763536|OTHER|Carbon Monoxide Measurement|Undergo carbon monoxide measurement
224090385|NCT06763536|OTHER|Nicotine Lozenge|Use nicotine lozenge
224090386|NCT06763536|OTHER|Oral Nicotine Pouch|Use oral nicotine pouch
223530604|NCT03180268|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223530605|NCT03180268|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
223530606|NCT03180268|OTHER|Quality-of-Life Assessment|Ancillary studies
223530607|NCT00537797|OTHER|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
224090387|NCT06763536|OTHER|Nicotine Patch|Use nicotine patch
224090388|NCT06763536|OTHER|Survey Administration|measurements; data gathering
224090389|NCT06763536|OTHER|Check-in Phone Calls|Check-in phone calls to study participants
224090390|NCT05995704|DRUG|Apraglutide|Peptide analogue of GLP-2
224090391|NCT05995704|DRUG|Placebo|Matching placebo to apraglutide
224090392|NCT05995704|DRUG|Acetaminophen|Acetaminophen mixed with a liquid meal
224090393|NCT04837014|OTHER|prescription for regular acetaminophen and naproxen|Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
224090394|NCT04837014|OTHER|prescription for regular acetaminophen , naproxen and dilaudid|prescription for regular acetaminophen , naproxen and dilaudid
224090395|NCT04699188|DRUG|JDQ443|KRAS G12C inhibitor
224090396|NCT04699188|DRUG|TNO155|SHP2 inhibitor
224090397|NCT04699188|BIOLOGICAL|tislelizumab|Anti PD1 antibody
224090398|NCT06501443|DRUG|Usual care|Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines
224090399|NCT06501443|DRUG|KJX839|Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
224090400|NCT05507216|DRUG|ABX464|Administered once daily in the morning with food
224090401|NCT05507216|DRUG|Placebo|Administered once daily in the morning with food
224090402|NCT00002285|DRUG|Zidovudine|
224090403|NCT00313274|DRUG|Clevudine|
224090404|NCT01717248|DRUG|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
224090405|NCT03089788|OTHER|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
224090406|NCT03089788|OTHER|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
224090407|NCT01838135|DEVICE|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
224090408|NCT05163665|PROCEDURE|Closure type|Patients will have their endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) as per standard-of-care. Afterwards, patient will receive one of two intervention options for the closure of the GI defect following polyp removal.
224090409|NCT05742321|GENETIC|Genotyping|Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
224090410|NCT05742321|DIAGNOSTIC_TEST|Histology|Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
224090411|NCT05742321|OTHER|Collection of data|Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
224090412|NCT03688386|BEHAVIORAL|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
224090413|NCT03688386|BEHAVIORAL|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
223530608|NCT06503913|BEHAVIORAL|Cognitive Muscular Therapy|Psychologically informed physiotherapy which integrates training to reduce overactivity of postural muscles which can interfere with the mechanics of breathing.
224090414|NCT03688386|BEHAVIORAL|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
223717173|NCT00705198|DRUG|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
223920716|NCT06877143|DIETARY_SUPPLEMENT|120% of individual calory requirement|Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.
223920717|NCT06880315|BEHAVIORAL|Pre-Generated Personalized LLM Coaching Impact|After the initial 7 days, participants will switch to the other type of prompting for another 7 days. This means that participants who initially received personalized LLM-generated prompts will then receive generic activity prompts, and vice versa. This crossover design allows for each participant to experience both types of interventions, providing a within-subject comparison of the effectiveness of personalized versus generic prompts in increasing physical activity levels.
223920718|NCT06693258|PROCEDURE|thyroidectomy by robotic surgery via axillary approach|thyroidectomy
223920719|NCT06693258|PROCEDURE|thyroidectomy by standard conventional surgery|thyroidectomy by standard conventional surgery
223920720|NCT06876805|DIAGNOSTIC_TEST|CEUS or Contrast enhanced Ultrasound|CEUS performed as normal clinical practice
223920721|NCT05536726|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W ( 6 cycles) +80 mg Q4W during maintenance period
223920722|NCT05536726|DRUG|608 Q4W|608 160 mg Q4W ( 3 cycles) +160 mg Q8W during maintenance period
223920723|NCT05536726|DRUG|Placebo|Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
223920724|NCT06878053|PROCEDURE|ethanol sclerotherapy|The originality of this project consists in evaluating the effectiveness of ethanol sclerotherapy of endometrioma(s) in infertile patients before IVF/ICSI, excluding patients who have previously had an ovarian cystectomy. To date, no prospective randomized comparative study between ethanol sclerotherapy of endometriomas and therapeutic abstention has been carried out.
223920725|NCT06712888|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy|"Drug: Toripalimab 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Other Names:~JS001 PD-1 antibody~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP~Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT"
223920726|NCT06712888|DRUG|GP plus placebo induction therapy|"Drug: Placebo 240mg will be given every 3 weeks for 3 cycles, started on day 1 of induction chemotherapy.~Drug: Gemcitabine 1000mg/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation~Other Names:~DDP Radiation: intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 70 Gy will be given in 33 fractions.~Other Names:~IMRT"
223920727|NCT06881394|DEVICE|Polymer Skin Barrier|A cyanoacrylate polymer will be applied topically once or twice a day to the palmar surface of hands to prevent perspiration
223920728|NCT06882070|OTHER|Vaccine|Trivalent P2-VP8 subunit rotavirus vaccine
223920729|NCT06705426|OTHER|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises|Scapular mobilization with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
224090415|NCT03688386|BEHAVIORAL|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
224090416|NCT03688386|BEHAVIORAL|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
224090417|NCT02732951|DRUG|BI 1026706|
224090418|NCT02732951|DRUG|Placebo|
224090419|NCT03805880|DIAGNOSTIC_TEST|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
224090420|NCT01750918|DRUG|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
224090421|NCT01750918|DRUG|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
224090422|NCT01750918|DRUG|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
224090423|NCT01750918|DEVICE|5-fluorouracil|5-fluorouracil-based chemotherapy
224090424|NCT05426811|DRUG|Regorafenib|Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks
224090425|NCT05426811|DRUG|Raltitrexed|Raltitrexed:3mg/㎡，ivgtt，d1，Every 3 weeks
224090426|NCT01509027|BEHAVIORAL|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
224090427|NCT01509027|BEHAVIORAL|Standard care|standard care
224090428|NCT01509027|BEHAVIORAL|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
224090429|NCT03226093|PROCEDURE|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
224090430|NCT03027167|DRUG|Aspirin|
223530609|NCT06503913|BEHAVIORAL|Breathing visualisation|Breathing visualisation; Data from two 3D camera are combined and used to calculate respiratory volumes. These volumes are then used to drive an animation of breathing so that the patient can understand how their breathing pattern compares to an optimal pattern. Note this is not a medical device as data from this system is only used for education and not for diagnostic or treatment decisions.
223530610|NCT05196776|DEVICE|Portable, handheld point-of-care ultrasound device|The patient will have an ultrasound performed using a handheld, portable device.
223920730|NCT06705426|OTHER|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises|Posterior capsular stretch with addition anterior, posterior ,caudal glenohumeral mobilization, infrared therapy, ultrasound therapy, pendulum exercises
223920731|NCT04750616|DRUG|Niacinamide|Niacinamide 3 grams on the day of surgery and post-surgical days one and two
223920732|NCT04750616|DRUG|Placebo|Matched placebo on the day of surgery and post-surgical days one and two
223920733|NCT04701112|DEVICE|Temporary His bundle pacing|"Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration."
223920734|NCT06707909|DRUG|Menaquinone|the socket will be filled with crushed capsule of vitamin k2 menaquinone in study group
223530611|NCT05196776|DEVICE|Cart-based point-of-care ultrasound device|The patient will have an ultrasound performed using a traditional cart-based model.
223530612|NCT02484274|BIOLOGICAL|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
223530613|NCT03925480|DRUG|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
223530614|NCT03925480|DRUG|Matching Placebo|Matching Placebo
223530615|NCT04565665|OTHER|Best Practice|Receive standard of care
223530616|NCT04565665|BIOLOGICAL|Mesenchymal Stem Cell|Given IV
223717174|NCT00705198|DRUG|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
223717175|NCT00705198|RADIATION|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
223717176|NCT00133497|BIOLOGICAL|MF-59|Microfluoridized adjuvant 59 (MF59).
223717177|NCT00133497|DRUG|Placebo|0.5 mL of saline placebo.
223920735|NCT06720012|DEVICE|Patient specific instrumentation (PSI)|Cutting guides that are manufactured using advanced imaging and modelling techniques to create instruments that align more closely with the unique anatomy of each patient. Custom guides were created based on a preoperative MRI protocol (Zimmer Patient Specific Instrumentation for NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States in collaboration with Materialise NV, Leuven, Belgium) to optimize the placement of the components without the need for intramedullary alignment.
223920736|NCT06720012|DEVICE|Conventional instruments|Instruments specific to the implant that are used to guide bone cutting in reference to the intramedullary canal or using an extramedullary jig.
223920737|NCT06720012|PROCEDURE|Cemented Total Knee Arthroplasty|A cemented TKA (NexGen® Complete Knee Solution, Zimmer Biomet, Warsaw, Indiana, United States) is used in all cases with a cruciate retaining (CR) or posterior stabilized (LPS) prosthesis as determined by the surgeon.
223920738|NCT05359263|DRUG|Dapagliflozin 10 mg|The intervention arm consists of dapagliflozin 10 mg orally once daily
223920739|NCT05359263|DRUG|Placebo|The comparator arm consists of placebo orally once daily
223530617|NCT05662202|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (ALA-PDT, Ameluz®-PDT):~Topical application of up to 3 tubes BF-200 ALA on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
223530618|NCT05662202|COMBINATION_PRODUCT|Vehicle and red light LED lamp|"Up to two PDTs using a RhodoLED lamp (RhodoLED® XL or BF-RhodoLED®) (Vehicle-PDT):~Topical application of up to 3 tubes vehicle on the expanded treatment field (up to 240 cm²), followed by red light illumination with a RhodoLED lamp after 3 h incubation of study medication under occlusive dressing.~PDT-1 will be performed at Visit 2. Clinical clearance will be assessed 12 weeks after PDT-1 (Visit 4). In case of remaining lesions at Visit 4, PDT-2 will be performed at the same visit."
223530619|NCT05949099|DRUG|Nirogacestat|Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
223530620|NCT05949099|PROCEDURE|Cryoablation|Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
223920740|NCT06883773|BEHAVIORAL|Multipurpose Online Tool|The intervention consists of 6 psychoeducational modules, on the Canvas teaching platform. They are automated, requiring no interaction with others (except for communication between participants and the team). Participants go through the psychoeducational modules, then do the corresponding exercise, and then access their rewards (if they belong to the experimental or comparative groups).
223920741|NCT06883773|OTHER|No intervention|The participants will be assessed but without any intervention
223530621|NCT02464748|OTHER|TiM telehealth arm|
223530622|NCT05677347|DRUG|GSK3923868|GSK3923868 will be administered
223717178|NCT00133497|BIOLOGICAL|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
223920742|NCT06884020|BEHAVIORAL|EMOTIONAL REGULATION PROGRAMME|"This programme works on early identification and implementation of strategies to improve self-awareness and facilitate children's emotions.~This intervention is designed to be delivered in the educational setting by the tutor in the form of a learning situation with 8 sessions plus 1 family session.~The topics covered are:~* Embarking on an emotional journey~* Recognising our emotions~* Emotions have a voice~* Identifying different emotions~* How do I make decisions?~* Emotion, action, and consequence~* Learning to self-regulate~* Celebrating our learning"
223920743|NCT06880172|BEHAVIORAL|WeCare|"Individual level: Problem identification, Linking Mental health and minority stress, medication adherence, developing an action plan, complementing the plan, and follow-up.~Group level: Social support and self acceptance in MSM, coping with stigma and minority stress, support for medication adherence"
223920744|NCT06880172|BEHAVIORAL|Standard of Care|Access to services offered at the POP INN Wellness Clinic including psychoeducation for all individuals who enroll in PrEP or ART services, free medication, and enrollment in their standard drop-in. Mpowerment support groups, as well as referrals to mental health services on request
223920745|NCT06883435|PROCEDURE|closed reduction and percutaneous ﬁxation of medial malleolus|No incision is made for fracture reduction, a pointed reduction clamp is applied to reduce the fracture, two 4 mm partially threaded cannulated cancellous screws are inserted over guide wires through stab incisions. Fluoroscopy is used to assess reduction.
224090431|NCT03027167|DEVICE|(Post- discharge) Mechanical Compression Device|
224090432|NCT00460993|DRUG|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
223717179|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
223717180|NCT03873974|DIAGNOSTIC_TEST|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
223920746|NCT06883435|PROCEDURE|open reduction and screw fixation of medial malleolus|An incision is made over the fracture; the MM fracture is reduced under direct vision. fixation is performed with two 4mm cannulated partially threaded cancellous screws. fluoroscopy is used to confirm reduction.
224090433|NCT02610309|BEHAVIORAL|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
224090434|NCT02149641|RADIATION|Intensity modulated radiotherapy with chemotherapy|
224090435|NCT01337349|DRUG|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
224090436|NCT01337349|DRUG|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
224090437|NCT02561897|DRUG|Edoxaban|
224090438|NCT02561897|DRUG|Warfarin|
224090439|NCT03135392|PROCEDURE|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
224090440|NCT03135392|PROCEDURE|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
224090441|NCT03135392|PROCEDURE|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
224090442|NCT00170976|DRUG|valsartan + amlodipine|
224090443|NCT04177836|BEHAVIORAL|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
223530623|NCT05677347|DRUG|Placebo|Placebo will be administered
223717181|NCT03873974|DIAGNOSTIC_TEST|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
224090444|NCT01967043|DRUG|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
223920747|NCT06881914|BEHAVIORAL|Intervention group:|There were 5 sessions for the intervention group. All sessions took place in the participant's home. The first 4th sessions involved participant sharing a particular time of their life event, such as childhood, adolescence, adulthood, and the current stage. Transcripts were prepared and compiled following the completion of the interviews. The participants will proofread their life-story book before sending it for printing. In the 5th session, they were given their life storybooks. A self-report questionnaire was used in every session to collect participants' quality of life, life satisfaction, and depression scores.
223920748|NCT06885021|DRUG|HDM1002 200mg, oral, once daily, 52 weeks|HDM1002 200mg, oral, once daily, 52 weeks
223920749|NCT06885021|DRUG|HDM1002 400mg, oral, once daily, 52 weeks|HDM1002 400mg, oral, once daily, 52 weeks
223920750|NCT06885021|DRUG|HDM1002 placebo, oral, once daily, 52 weeks|HDM1002 placebo, oral, once daily, 52 weeks
223920751|NCT06883942|PROCEDURE|prosthetic group performs the entire protocol with their own prosthesis|"The 1st session is the enrolment and functional evaluation one. The following 2 we test the algorithm functionality verification; one session for both platforms. The last 2 sessions are necessary to acquire prognostic markers for falls; one session for both platforms.~The balance disturbance tests will take place on two platforms:~* The sliding platform consists of a metal supporting structure and a wooden cover, which has a manual release mechanism that allows the activation of the tile responsible for simulating the events that occur during sliding.~* The stumbling platform consists of a metal supporting structure and a wooden cover, which features an electronically activated plastic and foam tripping mechanism that simulates the sequence of events that occur during a stumble."
223920752|NCT06883942|DEVICE|Experimental Group|The fall detection algorithm will be evaluated first. In a second step, the experimentally obtained prognostic markers of fall risk will be studied. The markers thus obtained shall be validated by comparison with markers already established in clinical practice or in the literature.
223920753|NCT04342260|OTHER|Active Monitoring|The participants randomized to active symptom monitoring will have alerts sent to their clinicians when their PRO symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported.
224090445|NCT03041727|OTHER|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
224090446|NCT03041727|OTHER|Standard exercises protocol|Stretching and strengthening exercises
224090447|NCT03898648|OTHER|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
224090448|NCT04840667|DRUG|REPLAGAL|Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
224090449|NCT00622193|DRUG|anamorelin HCl|50 mg tablet
224090450|NCT00622193|DRUG|anamorelin HCl|100 mg tablet
224279178|NCT02299219|BEHAVIORAL|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
223920754|NCT04342260|OTHER|Passive Monitoring|Participants randomized to the passive PRO monitoring arm will complete the same PROs as participants in the active monitoring arm, but will not have alerts sent to their clinician.
223920755|NCT06882590|OTHER|Compassionate-focused therapy|A 9-session therapy intervention targeting negative thinking, feelings of guilt and shame, and cultivating compassion for self and others.
224090451|NCT00622193|DRUG|placebo|placebo tablet
224090452|NCT03332069|DEVICE|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
224090453|NCT03332069|RADIATION|External beam radiation|
224090454|NCT03332069|DRUG|Cisplatin|
224090455|NCT03332069|RADIATION|Brachytherapy|High Dose Rate
224090456|NCT03429218|DRUG|TP-0184|Oral dose once weekly for 4 weeks
224090457|NCT06541847|DRUG|HLX-1502|Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
224090458|NCT00503191|BEHAVIORAL|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
224090459|NCT05780866|OTHER|Video and Activity Tracker|"At enrollment, the participants will complete a baseline survey, PDQ-39 (Parkinson's disease questionnaire), and the Unified Parkinson's Disease Rating Scale (UPDRS) assessment. The researchers will provide the participant with a camera, small tripod, and a set of written directions about how to record the UPDRS motor self-assessment video.~After completing the baseline assessments, the research team will provide the participant with a Fitbit Inspire 3 activity tracker watch. The participant will wear the activity tracker for 24 hours a day for the next 14 days except for if the device needs charging and when bathing.~At 14 days, the research team will send participants a link to complete a web-based exit survey about their experience with the activity tracker during the study."
224279179|NCT01386502|BIOLOGICAL|p53: 264-272 peptide|
224279180|NCT01386502|DRUG|CT-011|
224279181|NCT03015064|OTHER|Myocardial Infarction|Observational study of myocardial Infarction patients
224279182|NCT05379790|DRUG|Irinotecan|3 weekly IP irinotecan (max 6 cycles), dose via dose-escalation design as specified per arm.
224279183|NCT05379790|DRUG|CAPOX|Capecitabine 1000 mg/m2 twice daily day 1-14 (per os), and Oxaliplatin 130 mg/m2 on day 1 IV infusion.
223920756|NCT06882798|BEHAVIORAL|Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)|SCBT-SB is a manualized psychosocial treatment protocol developed specifically with and for L/H youth with suicidal ideation and behaviors. Clinician, adolescents, and caregivers' manuals are available in both Spanish and English. SCBT-SB protocol's main conceptual framework and strategies are informed by Cognitive Behavioral Therapy concepts, psychoeducation, and adolescent parenting strategies. The intervention involves individual, caregivers, and family sessions. SCBT-SB, while maintaining the basic principles of CBT, was further developed to include developmental (e.g., identity), and cultural elements of L/H families (e.g., family communication, language). The protocol has two main phases. Phase 1, the Crisis Module, includes nine standard core sessions, and Phase 2, which proposes a flexible number of sessions, focused on the delivery of interchangeable coping skills modules and the acquisition of skills that reduce STB.
223920757|NCT06882798|BEHAVIORAL|SCBT-SB + CHW|The New Clinical Model consist of one clinician delivering the SCBT-SB and one CHW per each family. The assigned clinician \& CHW will meet at the beginning of treatment to discuss their assigned case and will have follow-up meetings as needed and at a minimum, once monthly. CHWs will support family engagement in treatment. CHWs will assess each family's social needs and concerns about treatment. The CHW intervention will 1) Assess social determinants of mental health; 2) Provide referrals and serve as a bridge to other community resources; 3) Provide psychoeducation on mental health and services to decrease stigma; and 4) Follow-up and provide support on recommended actions.
223920758|NCT06878911|DEVICE|Ultrasound Scans|10 seconds scanning for one block region
223920759|NCT06882551|DRUG|Intravitreal Bevacizumab IVB|Intravitreal bevacizumab alone
224279184|NCT04682509|DRUG|Glecaprevir/pibrentasvir|Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
224279185|NCT03027011|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
224279186|NCT03027011|PROCEDURE|Control|Control group without remote ischemic preconditioning
224279187|NCT03907800|DRUG|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
224279188|NCT03907800|DRUG|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
224279189|NCT03907800|DRUG|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
224279190|NCT01701037|DRUG|dabrafenib|150 mg given PO
224279191|NCT01701037|DRUG|trametinib|2 mg given PO
223530624|NCT04179981|DEVICE|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
223530625|NCT04179981|OTHER|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
224279192|NCT01701037|OTHER|laboratory biomarker analysis|Correlative studies
224279193|NCT00412737|DRUG|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
224279194|NCT00412737|DRUG|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
223530626|NCT05400564|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
224279195|NCT04447937|OTHER|No Interventions|There are no interventions associated with the study.
224279196|NCT02208115|DIETARY_SUPPLEMENT|Meal composition - Low versus high GI.|
224279197|NCT00308360|DRUG|Risperidone, divalproex|
224279198|NCT03519282|DEVICE|comfilcon A multifocal toric lens|contact lens
224279199|NCT03519282|DEVICE|omafilcon A Multifocal Toric Lens|contact lens
224090460|NCT04224363|PROCEDURE|staining from cervical esophagus to esophagogastric junction|This group patients were given Lugol's solution staining from cervical esophagus to esophagogastric junction （downward）during chromemdoscopy.
224090461|NCT04224363|PROCEDURE|staining from esophagogastric junction to cervical esophagus|This group patients were given Lugol's solution staining from esophagogastric junction to cervical esophagus（upward）during chromemdoscopy.
224090462|NCT00654927|DRUG|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
224279200|NCT05054894|OTHER|Therapeutic Plasma Exchange (TPE)|"Following all necessary screening and consenting protocol, patients will be scheduled for the plasmapheresis procedure.~Plasmapheresis~On the days of the scheduled procedure, patients will undergo up to 1.5 hours of plasmapheresis treatment. Patients will be awake and situated in a relaxed position in a reclined chair. The plasmapheresis device to be used is the Fresenius Kabi 'Amicus', which is currently FDA approved for a variety of clinical conditions. In one treatment, roughly 60-70% of a patient's plasma can safely be replaced; by using six consecutive treatments, more of the patient's plasma (approaching 100%) will be replaced in an exponential fashion."
223530627|NCT02390752|DRUG|TURALIO(R)|take oral drug daily for a 28 day cycle
223530628|NCT06326060|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
223920760|NCT06882551|DRUG|intravitreal bevacizumab and suprachoroidal triamcinolone acetonide|Combination of Intravitreal bevacizumab and suprachoroidal triamcinolone acetonide
223920761|NCT06884735|OTHER|exposure to virtual reality|exposure to virtual reality
223920762|NCT06718257|DRUG|Gemcitabine combined with cisplatin or oxaliplatin|Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
223920763|NCT06718257|DRUG|Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors|Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)
223920764|NCT06718933|DRUG|SHR-A1811|ADC
224090463|NCT02807077|DRUG|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
224090464|NCT02276261|PROCEDURE|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
224090465|NCT02276261|PROCEDURE|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
224090466|NCT02830425|OTHER|No intervention|
224090467|NCT03217162|DRUG|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
224090468|NCT03217162|DRUG|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
224090469|NCT05917886|OTHER|Auditory beat stimulation: 8Hz monaural beat stimulation|Auditory beat stimulation is a reversible, non-invasive application of sound to the ears.
224090470|NCT03157544|BEHAVIORAL|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
224090471|NCT04029376|DRUG|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
224090472|NCT03616743|BEHAVIORAL|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
224090473|NCT03616743|BEHAVIORAL|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
224090474|NCT03338556|DRUG|PrEP-001|
223530629|NCT06326060|DRUG|Placebo|Placebo will be administered subcutaneously.
223530630|NCT06326060|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
223530631|NCT06279377|OTHER|Stabilization Exercises|"* Stabilizer Pressure Biofeedback device will be used in deep neck flexors training. Once the starting level is determined, training will be carried out with 2 mmHg pressure increases until the target value is 30 mmHg.~* During the exercises performed with the elastic resistance band, the patient will be asked to move the band with his hands (neck extension, right-left lateral flexion).~* During the exercises with the elastic ball, you will be asked to press your head on the ball at 90 degree angles (in 4 positions).~* Exercises will be performed in 10 repetitions by maintaining muscle contraction for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the color of the elastic resistance band or the level of the exercise will be changed and continued."
223920765|NCT06718933|DRUG|Bevacizumab|bevacizumab biosimilar
223920766|NCT06718933|DRUG|Pyrotinib|anti-HER2 inhibitor
223920767|NCT06716983|DIAGNOSTIC_TEST|fMRI|fMRI in patients with dystonia implanted with deep brain stimulation with neurostimulators capable of recording local field potentials
223920768|NCT06716983|DIAGNOSTIC_TEST|EEG-MEG|EEG-MEG in patients with dystonia implanted with deep brain stimulation with neurostimulators capable of recording local field potentials
223920769|NCT06716983|DIAGNOSTIC_TEST|registration of local field potentials|registration of local field potential in patients with dystonia implanted with deep brain stimulation
223920770|NCT06716983|DIAGNOSTIC_TEST|genetic panel|genetic panel for dystonia
224090475|NCT03338556|OTHER|Placebo|
224279201|NCT01337765|DRUG|BEZ235 + MEK162|
224279202|NCT00935831|DRUG|GSK1278863A|50mg, 150mg
224279203|NCT00935831|DRUG|Placebo|matching placebo
223717182|NCT03873974|DIAGNOSTIC_TEST|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
223717183|NCT03873974|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
223717184|NCT03873974|DIAGNOSTIC_TEST|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
223717185|NCT02271568|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
223920771|NCT06718946|BIOLOGICAL|IDOV-SAFE|Intravenous administration of oncolytic virus every 3 weeks until tumor progression
223920772|NCT06695299|OTHER|selected exercise program|therapeutic ultrasound, Static neck exercise, balance exercises
223920773|NCT06695299|OTHER|Kinesthetic and Visual Motor Imagery Training|Kinesthetic and Visual Motor Imagery Training During kinesthetic imagery, the participants were asked to feel their body parts without any body motion. During visual imagery, the participants were asked to perform a visual presentation of the motion without any body motion.
223920774|NCT06719778|OTHER|Two-stage nutritional therapy concept|"1. Stabilization phase:~   application of a mostly vegetarian Mediterranean wholefood diet and strategies from a comprehensive lifestyle modification concept.~2. Elimination phase:~additional omission diet avoiding the food that was identified by CLE to induce an intestinal barrier defect."
224090476|NCT06031753|BEHAVIORAL|Time restricted eating|Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
224279204|NCT02556892|DRUG|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
224279205|NCT02836301|BEHAVIORAL|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
224279206|NCT02836301|BEHAVIORAL|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots…a missed opportunity.
224279207|NCT02836301|BEHAVIORAL|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
224279208|NCT00750048|DRUG|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
224279209|NCT04057248|DEVICE|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
224279210|NCT04057248|BEHAVIORAL|CDE|Certified Diabetes Educator Sessions
224279211|NCT02792348|OTHER|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
224279212|NCT03130348|DRUG|Bortezomib|Given SC
224279213|NCT03130348|DRUG|Dexamethasone|Given PO
224279214|NCT03130348|DRUG|Ibrutinib|Given PO
224279215|NCT03130348|OTHER|Laboratory Biomarker Analysis|Correlative studies
224279216|NCT06375369|PROCEDURE|Digital health pathway for children with medical complexity requiring tracheostomy (DECIDE-T)|The intervention involves developing a standardized clinical pathway for these children requiring tracheostomy. The pathway comprises of a hospital to home directive, incorporating digital health solutions to support family, caregivers, and healthcare professionals. These digital supports include but are not limited to a Connect Care pathway, resources to aid families to make informed choices during the clinical decision-making process, education modules and high-fidelity simulations to enhance family/caregiver education, an online parental resource center and access to peer support (spanning from hospital to community) and a telehealth post discharge program.
224279217|NCT06004869|BEHAVIORAL|Ecological momentary assessments/interventions with cognitive behavioural therapy for insomnia (EMA/I CBT-I)|an integrated system based on an existing multicomponent cognitive behavioural therapy for insomnia (CBT-I) and EMA app
224279218|NCT06004869|BEHAVIORAL|Self-help cognitive behavioural therapy for insomnia|An mobile app that delivers CBT-I content.
224279219|NCT04788446|BEHAVIORAL|Mini-flipped Game-based Learning|The intervention was 8 weeks, forty minutes adjusted Mediterranean diet learning plan once a week, which includes the 20 minutes for the Mediterranean food table game, and the 20 minutes for the Mediterranean diet nutrition course. The topic of the course includes the relationship between Mediterranean diet and dementia, knowledge of Mediterranean diet, how to integrate local food ingredients into the Mediterranean diet, etc.
224279220|NCT04788446|BEHAVIORAL|Balanced diet|Given a balanced diet nutrition health education manual for the aged.
224279221|NCT02854696|PROCEDURE|Islet graft|Patients will be transplanted with pancreatic islet cells
224279222|NCT02854696|DRUG|best medical care|Patients will continue their insulin treatment
224279223|NCT01575717|DRUG|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
224279224|NCT01575717|DRUG|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
224279225|NCT05518916|OTHER|Nonfarmacology method|Yakson Method and Swaddling
223717186|NCT02271568|OTHER|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
223920775|NCT00556777|PROCEDURE|axillary lymph node dissection|
223920776|NCT00556777|PROCEDURE|conventional surgery|
224090477|NCT02010203|BIOLOGICAL|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
223530632|NCT06279377|OTHER|Standard Exercises|"* Cervical flexion, extension, lateral flexion and rotation movements will be performed within the scope of the warm-up and cool-down program. Cervical movements will be limited to approximately 30 degrees in the early period.~* As posture exercises, you will be asked to do scapular retraction and turning your shoulders forward and backward. In addition to these movements, pectoral stretching, anterior and posterior capsule stretching exercises will be performed.~* Elastic resistance bands will be used during neck exercises. Patients will be asked to perform cervical flexion, extension and right-left lateral flexion movements against the fixed band.~* Patients will be asked to continue each exercise for 10 seconds. Exercises will be performed as 1 set of 10 repetitions or 2 sets of 10 repetitions, depending on the patient's tolerance. When 2 sets are completed successfully, the elastic resistance band color will be changed and the exercise will progress."
223920777|NCT00556777|PROCEDURE|sentinel lymph node biopsy|
223920778|NCT00556777|RADIATION|intraoperative radiation therapy|
223920779|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Hydrogen-rich water|Hydrogen-rich water with 12 mg of hydrogen per serving
223920780|NCT06722326|DIETARY_SUPPLEMENT|Dietary Supplement: Control water|Control water with 0 mg of hydrogen per serving
224090478|NCT02010203|BIOLOGICAL|Placebo|Injection containing sterile solution but no cells
224090479|NCT02010203|BIOLOGICAL|BCG|Vaccine derived from a live bacterium
224090480|NCT01609933|DRUG|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
224090481|NCT01609933|DRUG|ABT-267|ABT-267 (tablets)
224090482|NCT01609933|DRUG|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
224090483|NCT01609933|DRUG|Ribavirin (RBV)|Ribavirin (tablets)
224090484|NCT06464406|BEHAVIORAL|Virtual Reality condition|Participants will watch a video on a virtual reality headset during the completion of the maximal cardiorespiratory exercise test.
224090485|NCT06464406|BEHAVIORAL|Control condition|Participants will complete the maximal cardiorespiratory exercise test under control conditions without video, music, or other distractions.
224090486|NCT00224016|DRUG|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
224090487|NCT00224016|DRUG|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
223530633|NCT00340054|OTHER|questionnaire administration|
223920781|NCT06887738|DRUG|NM8074|NM8074 will be administered as an intravenous infusion at a dose of 20mg/kg
223920782|NCT06724887|BEHAVIORAL|Brain Health Strategy Training and Education|Initial training strategies cover Strategic Memory Advanced Reasoning Tactics (SMART), and subsequent training extends the SMART principles to other life-applications such as stress management, sleep, and lifestyle. Virtual and in-person workshops will expand on topics such as stress management, sleep, resilience, and mental well-being, with an emphasis on how practicing and implementing brain healthy strategies can impact everyday life. For faculty/staff, we will also offer interactive workshops on how to create a brain healthy environment and classroom, including ways to implement and provide brain-healthy strategies and resources in their everyday operations involving students.
223920783|NCT06703658|DRUG|AZD5004(Part A)|Single dose of AZD5004 oral on Day1
223920784|NCT06703658|DRUG|Placebo(Part A)|Single dose of placebo oral on Day1
224090488|NCT01252966|BEHAVIORAL|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
224090489|NCT01252966|BEHAVIORAL|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
224090490|NCT04684030|DEVICE|Continuous glucose monitoring system(CGMS)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in CGMS group will given education on how to use the device and check the result using the smart phone. The data collected from the sensors were computed to generate the respective ambulatory glucose profiles so as to determine the total numbers of scans conducted during the study period.
224279226|NCT02771041|PROCEDURE|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
224279227|NCT00285519|DRUG|Doxazosin (drug)|
223920785|NCT06703658|DRUG|AZD5004(Part B)|AZD5004 will be administered as an oral tablet once daily.
224090491|NCT04684030|DEVICE|Self-monitoring of blood glucose (conventional fingerpricking method)|Patients will randomized 1:1 to either continuous glucose monitoring system(CGMS) or conventional self-monitoring of blood glucose (SMBG) group. After the randomization, patients in SMBG group will check their blood glucose by finger pricking method and record the data in a notebook to share the data in their outpatient clinic visit.
224090492|NCT00197860|BIOLOGICAL|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
224090493|NCT03340350|DRUG|Minocycline|Minocycline capsule
223530634|NCT00340054|PROCEDURE|study of high risk factors|
223530635|NCT06122948|DRUG|The midazolam group|The midazolam group will receive intranasal midazolam (0.1 mg/kg)
223920786|NCT06703658|DRUG|Placebo(Part B)|Placebo will be administered as an oral tablet once daily.
223920787|NCT06882772|DRUG|2 mL SunButyrate-TG|"Participants randomized into the 2 milliliter (mL) SunButyrate-TG will take the supplement once daily for 3 weeks prior to cardiac surgery.~Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated."
223920788|NCT06882772|DRUG|Placebo|Participants randomized into the Placebo arm will take the oil-based placebo once daily for 3 weeks prior to cardiac surgery
223920789|NCT06882772|DRUG|4 mL SunButyrate-TG|"Participants randomized into the 4 mL SunButyrate-TG arm will take the supplement once daily for 3 weeks prior to cardiac surgery.~Note: This is a Dietary Supplement, but the FDA requires an Investigational New Drug (IND) number because inflammation is being treated."
223920790|NCT06887686|BEHAVIORAL|Swaddled Bath Intervention Wipe Bath Intervention|"Swaddled Bath Intervention:~In the swaddled bath group, infants are gently wrapped in a soft towel or blanket to maintain a flexed position. They are then immersed in warm water at an appropriate temperature to regulate body temperature. This intervention is designed to reduce stress and pain, particularly for premature infants, and helps to relax the baby's muscles, stabilize body temperature, and increase overall comfort. It is expected to show a more significant effect on physiological and behavioral stabilization than less invasive methods.~Wipe Bath Intervention:~In the wipe bath group, infants are gently wiped with a cloth soaked in warm water. This method is less invasive than the swaddled bath, aiming to maintain body temperature while providing a milder level of relaxation. The wipe bath is effective for skin cleansing but may not provide the same comfort or stress-reducing effects as the swaddled bath. The expected physiological effects, such as body temperature stabilizatio"
223920791|NCT06886750|DRUG|Botulinum toxin type A injection|Injection of toxin
223920792|NCT06885723|DEVICE|Vibration Anesthesia Device (VAD)|In conclusion, induction of anesthesia with VAD in patients treated with ITS provided pain palliation in a similar way to other local anesthetic techniques. Moreover, the advantage of VAD application over other anesthetic agents was that it eliminated the need to use local anesthetics that may disrupt wound healing. In addition, inducing anesthesia with VAD can be considered as an alternative method in patients allergic to drugs. Our study will shed light on different techniques such as the application of ventilation tube in anesthesia with VAD.
223920793|NCT06885723|DRUG|local anesthetic cream|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
223920794|NCT06885723|DRUG|lidocaine spray|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
223920795|NCT06885723|OTHER|saline drops|Prior to each ITS, all the four methods including local anesthetic cream (EMLA® cream, AstraZeneca PLC), lidocaine spray (Vemcain® Spray), VAD (Blaine®, Blaine Labs, Santa Fe, USA), and saline drops (control) were administered in each patient. The order of administration was determined for each patient using the randomization software (random.org/lists/). For the fifth ITS, however, the method of administration was selected by the patient.
223920796|NCT06887816|DEVICE|silver coated device|Patients who will be implanted with prosthesis with a silver coating to counteract infection relapse
223920797|NCT06887816|DEVICE|not silver coated device|Patients who will be implanted with prosthesis without silver coating
223920798|NCT06887257|OTHER|Telematic cardiac rehabilitation program, that includes exercise, educational and psychological sessions during 3 months|"2 group and telematic exercise sessions/week, 1 educational session/week and 1 psychological session/week, during 3 months.~There are no drugs or devices involved in the intervention."
224090494|NCT03306537|DEVICE|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
224090495|NCT05666154|OTHER|Real diet|Diet excluding either trigger nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger)
224090496|NCT05666154|OTHER|Sham diet|Diet excluding either sham nutrient in a blinded crossover fashion (CLE positive individuals with identified trigger) or wheat and soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
224090497|NCT05666154|OTHER|Wheat exclusion diet|Diet excluding wheat in a blinded crossover fashion (CLE negative individuals without identified trigger)
224090498|NCT05666154|OTHER|Soy exclusion diet|Diet excluding soy in a blinded crossover fashion (CLE negative individuals without identified trigger)
224090499|NCT05734287|DIAGNOSTIC_TEST|clinical, biophysical and biochemical assessment of young females with clinical hyperandrogenism|To assess clinical, biophysical and biochemical criteria of young females with clinical hyperandrogenism as a search for PCOS
224279228|NCT00513617|DRUG|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
224279229|NCT00513617|DRUG|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
224279230|NCT03728023|DRUG|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
223530636|NCT06122948|DRUG|The midazolam ketamine group|the midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)
223920799|NCT06887257|OTHER|Standard recommendations|Standard recommendations about exercise, educational and psychologicla advice
223920800|NCT06716567|BIOLOGICAL|Influenza vaccine|Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.
223920801|NCT06717789|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device|"Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• High Intensity TENS (50-150 Hz)"
223920802|NCT06717789|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device|"Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device, using the following pain management program,~• Low Intensity TENS (5 Hz)"
223920803|NCT06727110|DEVICE|PILP Cement|PILP cement liner.
223920804|NCT06727110|DEVICE|PILP Conditioner|PILP solution.
223920805|NCT06709196|DRUG|Pivmecillinam|Orally administered pivmecillinam 400mg
223920806|NCT06709196|DRUG|Pivmecillinam|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920807|NCT06709196|DRUG|Amoxicillin clavulanic acid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920808|NCT06709196|DRUG|Amoxicillin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920809|NCT06709196|DRUG|Cefuroxime|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920810|NCT06709196|DRUG|Ciprofloxacin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920811|NCT06709196|DRUG|Linezolid|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920812|NCT06709196|DRUG|Nitrofurantoin|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
224090500|NCT01264315|DRUG|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~* absolute neutrophil count \>1x109/L without growth factors~* platelet count \>75x109/L without transfusion support~* calculated/measured creatinine clearance: ≥20mL/minute~* total bilirubin \<2 x the upper limit of normal~* AST (SGOT) and ALT (SGPT) \<2.5 x upper limit of normal~* \<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
224090501|NCT00565955|DRUG|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; \> 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
224090502|NCT00565955|DRUG|Placebo|The patients will receive placebo tablets.
224090503|NCT03835338|DEVICE|Pulmonary Vein Isolation|Pulmonary Vein Isolation by RF Ablation
224090504|NCT03835338|DEVICE|LAA Isolation|LAA Isolation by RF Ablation
224090505|NCT03835338|DEVICE|LAA Occlusion|LAA Occlusion by implantation of the WATCHMAN LAAC Device
223530637|NCT06082453|DIAGNOSTIC_TEST|Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum|A quantitative polymerase chain reaction (qPCR) assay detects and quantifies DNA in a sample, and the qPCR assay used in this study targets the polA gene of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. qPCR data will only be used to determine testing performance and will not be used in clinical management of study participants.
223530638|NCT06082453|DIAGNOSTIC_TEST|Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum|The Aptima transcription-mediated amplification (TMA) assay used in this study will target RNA of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. TMA data will only be used to determine testing performance and will not be used in clinical management of study participants.
223717187|NCT05723978|PROCEDURE|Selective extended dissection of pancreaticoduodenectomy|An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
223717188|NCT02517983|OTHER|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
223920813|NCT06709196|DRUG|Trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920814|NCT06709196|DRUG|Sulfamethoxazole trimethoprim|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920815|NCT06709196|DRUG|Fluconazole|Orally administered targeted antimicrobial prophylaxis based on a urine culture.
223920816|NCT06707389|BIOLOGICAL|autologous blood monocyte vesicles (lower dose)|20 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
223920817|NCT06707389|DRUG|Methylprednisolone|40mg of methylprednisolone was dissolved in 0.2 ml of lidocaine injection and 0.8 ml of sterilized injection water. Intratympanic injection of methylprednisolone was performed three times a week.
224090506|NCT03275870|DRUG|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
224090507|NCT04886765|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
224279231|NCT03728023|DRUG|Placebo|Single dose in SAD and once daily for 14 days
224279232|NCT01091103|DRUG|Enzalutamide|
223717189|NCT03810560|DEVICE|laser device Er,Cr:YSGG laser|laser device with open flap debridement
223530639|NCT06082453|OTHER|Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis|Using the Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines, new born syphilis infection is categorized by clinical providers at birth as follows: confirmed proven/highly probably, possible congenital syphilis (CS), CS less likely, or CS unlikely. These CS categories are determined using neonatal nontreponemal test results, physical exam of the infant, placental pathology, and maternal serologies and treatment history, and comparison of maternal and neonatal nontreponemal tiers. These data will be collected as part of standard clinical care.
223530640|NCT01561469|DRUG|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
223717190|NCT06208683|BIOLOGICAL|Mumps vaccine, Live (MV)|0.5mL per dose,containing ≥3.7 lg CCID50 live mumps virus
224099585|NCT02730806|BEHAVIORAL|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
224099586|NCT03343964|DIAGNOSTIC_TEST|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
224099587|NCT05346302|DRUG|Pneumovax 23|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
224279233|NCT00026871|PROCEDURE|Radiotherapy|
224279234|NCT01270620|DRUG|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
223717191|NCT06208683|BIOLOGICAL|Influenza Vaccine, inactivated, quadrivlent(QIV)|0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.
223717192|NCT01594762|DRUG|Topical pexiganan cream 0.8%|14 days of treatment
223717193|NCT01594762|DRUG|Topical placebo cream|14 days of treatment
223717194|NCT01594762|OTHER|Standard wound care|14 days of treatment
223717195|NCT03547583|DRUG|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
224099588|NCT05346302|DRUG|Typhim VI|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
224099589|NCT05346302|OTHER|Saline|At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
224099590|NCT05004675|BIOLOGICAL|lerodalcibep|300 mg
224099591|NCT05004675|DRUG|Inclisiran|284 mg
224099592|NCT05771922|DIAGNOSTIC_TEST|High-resolution ultrasonography|High-resolution ultrasonography to detect fetal CNS anomalies
224099593|NCT00040157|DRUG|ACH126-443 (Beta-L-Fd4C)|
224099594|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 1|Pilocarpine Ophthalmic Topical Cream, Dose 1
224099595|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 2|Pilocarpine Ophthalmic Topical Cream, Dose 2
224099596|NCT05124275|DRUG|Pilocarpine Ophthalmic Topical Cream, Dose 3|Pilocarpine Ophthalmic Topical Cream, Dose 3
224099597|NCT05124275|DRUG|Placebo Ophthalmic Topical Cream|Placebo Ophthalmic Topical Cream
224099598|NCT01299025|OTHER|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
224099599|NCT01624194|DRUG|Oxytocin nasal spray|24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
224099600|NCT01624194|DRUG|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
224099601|NCT03234114|DRUG|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)
224099602|NCT03234114|DRUG|Dual antithrombotc therapy-1|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)
224099603|NCT03234114|DRUG|Dual antithrombotc therapy-2|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
224099604|NCT00853983|DRUG|[14C] AZD0530|Solution, Oral, once
224099605|NCT05634603|DIETARY_SUPPLEMENT|Lactose-free milk formula (Frisolac LF ®)|Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
224099606|NCT05432570|PROCEDURE|Group A - Muscle Relaxants Used|Induction will be achieved with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol, and 0.6 mg/kg rocuronium stored at 4 degrees. After the induction, laryngoscopy will be performed with a Macintosh laryngoscope after 2 minutes of manual ventilation after muscle relaxant by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
224099607|NCT05432570|PROCEDURE|Group B - No Muscle Relaxants|Induction will be provided with 1 mg/kg lidocaine, 2 μg/kg fentanyl, 2 mg/kg propofol. After ventilation, vocal cords will be seen with a Macintosh laryngoscope, and 2cc of 2% lidocaine will be applied to the vocal cords as a spray with the help of a 5 ml injector. After ventilation, laryngoscopy will be performed with a Macintosh laryngoscope by an anesthesiologist with at least 4 years of experience. It will be intubated with a tube with an inner diameter of 8 mm for men and 7 mm for women. The cuff of the intubation tube will be connected to a manometer and inflated at a pressure of 20-30 mmHg until there is no air leak. Intubation will be confirmed by the appearance of end-tidal CO2.
224099608|NCT05301244|OTHER|laughter yoga for nurses|The experimental group was divided into three groups as 17-17-16 people. For four weeks, laughter yoga sessions were held between 20.00 and 21.00, 2 days a week for each group. Laughter yoga sessions were held for the 1st group between 20.00-21.00 on Mondays and Thursdays, for the 2nd group between 20.00-21.00 on Tuesdays and Fridays, and for the 3rd group between 20.00-21.00 on Wednesdays and Sundays. The first sessions lasted 45 minutes, every other session 40 minutes.
224099609|NCT05301244|OTHER|laughter yoga for nurses-Deep breathing exercises|Deep breathing exercises (5 minutes) Breathing is held for 4-5 seconds after deep inspiration. While the arms are brought to the normal position, exhale slowly and rhythmically. When expressing after deep inspiration, the lips can be pursed as if whistling or exhaled with laughter.
223920818|NCT06707389|BIOLOGICAL|autologous blood monocyte vesicles (higher dose)|50 ml peripheral venous blood was extracted from each patient, anticoagulated with heparin and diluted with PBS. Peripheral blood mononuclear cells were isolated by Ficoll stratified solution. Extracellular vesicles of mononuclear cells were extracted by gradient centrifugation (800g centrifugation at 4 ℃ for 10 minutes, then 2000g centrifugation at centrifuged at 4 ℃ for 10 minutes and then 16000g centrifugation at 4 ℃ for 30 minutes. The precipitate was taken as monocyte vesicle and stored in refrigerator at 4 ℃. For intratympanic injection, precipitate was dissolved in 0.2 ml of lidocaine and 0.8 ml of sterilized injection water. Intratympanic injection of apoVs was performed three times a week.
223920819|NCT06706791|DRUG|Empagliflozin 10 MG|participants will be divided in two groups one group will empagliflozin 10mg once daily along with standard treatment secong group receiving placebo once daily along with standard treatment.
223920820|NCT06719674|PROCEDURE|Professional mechanical plaque removal and Laser|A diode laser will be used as an adjunct to mechanical plaque removal.
223920821|NCT06719674|PROCEDURE|Professional mechanical plaque removal|The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology (13). At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.
223920822|NCT06633146|BEHAVIORAL|Therapies in nature|Therapeutic tasks in nature specifically designed for the study
223920823|NCT05145881|DIETARY_SUPPLEMENT|Low dose probiotics|Taking 1 package of low dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
223920824|NCT05145881|DIETARY_SUPPLEMENT|Normal dose probiotics|Taking 1 package of normal dose probiotic powder (B. breve Bv-889, B. longum subsp. infantis BLI-02, B. bifidum VDD088, B. animalis subsp. lactis CP-9, Lactobacillus plantarum PL-02) twice daily before meals (BIDAC).
223920825|NCT06872606|DRUG|Pucotenlimab|Pucotenlimab (200 mg IV, q3w)
223920826|NCT06872606|DRUG|Bevacizumab|Bevacizumab (7.5 mg/kg IV, q3w)
223920827|NCT06872606|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m² IV, q3w)
223920828|NCT06872606|DRUG|Trifluridine/Tipiracil Hydrochloride|TAS-102 (25 mg/m² orally, days 1-5 and 8-12).
223920829|NCT06872606|RADIATION|Short-course radiotherapy|(25 Gy/5 fractions)
223920830|NCT06872606|RADIATION|intracavitary brachytherapy|brachytherapy (3 Gy/3 fractions).
224279235|NCT01270620|DRUG|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
224279236|NCT03601624|DRUG|Pomalidomide|"1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
224279237|NCT05442203|DEVICE|Zio Patch Monitor|Patch monitor will be applied and worn for a 2-week period at baseline, month 6, and month 12 after assignment to the AF arm.
224279238|NCT05442203|DEVICE|Echocardiogram|Ultrasound study of the heart will be completed upon patient consent after assignment to the SHD arm.
224279239|NCT03008837|DEVICE|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
224279240|NCT03008837|OTHER|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
224279241|NCT01915342|DEVICE|Focal muscular vibration|
224279242|NCT01729988|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
224279243|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
224279244|NCT00906373|BIOLOGICAL|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
224279245|NCT00906373|DRUG|Sorafenib|400 milligrams (mg) twice per day orally
224279246|NCT00192673|DRUG|PEG-asparaginase|
224279247|NCT00890331|BEHAVIORAL|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
224279248|NCT00890331|BEHAVIORAL|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
224279249|NCT04965857|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
224279250|NCT01937819|DEVICE|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
224279251|NCT01597479|DRUG|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
224279252|NCT01713179|DRUG|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
223920831|NCT05576129|DEVICE|TGP-tACS|"38 min and 20s of 4mA peak-to-peak theta-gamma stimulation with 75 Hz-gamma coupled to the peak of 6Hz-theta waves. 3s ramp-up at the beginning of stimulation and 3s ramp-down at the end of stimulation.~Administered using a Starstim® device and 5 gel electrodes with a πcm² area."
224279253|NCT01573533|BIOLOGICAL|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
224279254|NCT05532488|DIETARY_SUPPLEMENT|Inulin 20 mg|Inulin can increase gut Bifidobacterium count. Bifidobacterium has beneficial effects on the metabolic profile and insulin resistance biomarkers.
224279255|NCT05532488|OTHER|Placebo|Placebo
224279256|NCT02291692|PROCEDURE|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
223530641|NCT01561469|DRUG|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
223920832|NCT05576129|DEVICE|Sham-tACS|38 min and 20s of alternation between 10s of 4mA peak-to-peak TGP- tACS and a 6 min 30s stimulation-free interval. Each stimulation consists of 3s ramp-up, 4s TGP stimulation and 3s ramp-down. Administered using a Starstim® device and 5 gel electrodes with a πcm² area.
223920833|NCT06727058|BIOLOGICAL|Pandemic flu H5 mRNA vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intramuscular (IM)"
223920834|NCT06727058|OTHER|Placebo|"Pharmaceutical Form: Liquid solution for injection~Route of Administration: Intramuscular (IM)"
224090508|NCT04092036|DEVICE|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
224090509|NCT04244825|DRUG|BLD-2660|BLD-2660 - 150 mg capsules '00' size (PO) BID
224090510|NCT04244825|DRUG|Control: Placebo|Placebo - 150 mg capsules '00' size (PO) BID
224279257|NCT05037773|BEHAVIORAL|Intervention targeting parental reminiscing style|8-session intervention (i.e., 1 session/week) targeting 3 main aspects of parental reminiscing: the promotion of child participation, the structure of discussions about the past and the content addressed during these discussions. Different learning techniques are used: psychoeducation, modeling and supervised practice.
224279258|NCT03802617|DRUG|MR13A9|Intravenous administration
224090511|NCT01364415|DRUG|Pasireotide LAR|
224090512|NCT05718102|OTHER|Population-health management|Population-health management
224090513|NCT00283829|DRUG|docetaxel|chemotherapy
224279259|NCT03802617|DRUG|Placebo|Intravenous administration
223530642|NCT05002959|DEVICE|Anatomic TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
224090514|NCT00283829|DRUG|IL2|immunotherapy
224090515|NCT03283839|DIAGNOSTIC_TEST|Posturography|Evaluation of postural control and of orientation function
224090516|NCT00919022|DRUG|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
224090517|NCT01133639|DRUG|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
224279260|NCT04923516|OTHER|Dosage of Delta-aminolevulinic acid and Porphobilinogen|Results of dosages of Delta-aminolevulinic acid and Porphobilinogen which are performed in accordance with the current practice will be recorded
224279261|NCT02790541|DEVICE|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
224279262|NCT00591435|OTHER|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
224279263|NCT03764735|DRUG|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
224279264|NCT03764735|DRUG|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
223530643|NCT05002959|DEVICE|Reverse TESS V3|Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
223530644|NCT06151197|BIOLOGICAL|EN3835|Biologic: EN3835 injection
223530645|NCT06151197|OTHER|Placebo|Placebo injection
223530646|NCT06395935|OTHER|Wecare (website)|support feedback of qutionaire \& supply educational contents
223530647|NCT02274675|DEVICE|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
224090518|NCT01133639|DRUG|Placebo|Placebo plus standard of care
224090519|NCT00075517|DRUG|docetaxel|
224090520|NCT00075517|DRUG|gemcitabine hydrochloride|
224099610|NCT05301244|OTHER|laughter yoga for nurses-Warm-up exercises|Warm-up exercises (10 minutes) Rhythm of 1-2, 1-2-3 is added to increase the energy level even more and synchronize the movements of the group. After a few rhythmic clapping movements, another movement is added. Whisking hands left and right. Then an audible rhythm of ho, ho, ha-ha-ha is added to the clapping gesture. Make eye contact with people in the group and smile at them.
224099611|NCT05301244|OTHER|laughter yoga for nurses-Childish games|"Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a Y letter, and saying very good (applause), very good (applause), hey with palms facing the sky."
224279265|NCT03764735|DRUG|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
224279266|NCT06083402|DIETARY_SUPPLEMENT|HyaCera™|1 Ritual HyaCera capsule once daily
223530648|NCT02274675|OTHER|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
224279267|NCT06083402|DIETARY_SUPPLEMENT|Placebo|1 placebo capsule once daily
223920835|NCT06726447|DEVICE|Artificial Intelligence Tool|The intervention in this study consists of the implementation of an artificial intelligence tool for clinical registration during outpatient consultations. This technology facilitates the documentation of interactions in real time, optimizing the workflow of professionals and enabling more patient-centered care.
223920836|NCT06706336|OTHER|radon mitigation system|standard radon mitigation system used to reduce radon in homes
223920837|NCT06706336|OTHER|Sham (No Treatment)|inactive radon mitigation system
223920838|NCT06733701|DEVICE|VR-based intervention (VRReliever Software V0.3.4 fromXRHealth)|The participant will be able to select between four VR environments: beach, lake, forest, or mountain scenery. Each provides an immersive audio and visual environment designed to reduce anxiety and promote relaxation. Each scene is rendered in a high-resolution and life-like fashion which participants can experience in a full 360 degrees. Participants will wear the headset for the duration of the egg retrieval procedure which is approximately 15-20 minutes.
223920839|NCT06733701|DEVICE|VR headset without any scenery|VR headset without any scenery
223920840|NCT06732037|OTHER|Conventional physical therapy program|The conventional physical therapy program will be received for 8 weeks by the two groups. It includes the application of moist heat using a hot pack for ten minutes, followed by continuous ultrasound therapy operated at a frequency of 1 MHz and an intensity of 1.5 W/cm² for five minutes. Transcutaneous Electrical Nerve Stimulation (TENS) will also be utilized, with its development and application based on the Gate Control Theory. TENS will be applied for twenty minutes, with electrodes positioned on either side of the neck at the level of pain, using a pulse rate ranging from 2 to 50 Hz.
223920841|NCT06732037|OTHER|Kinetic control training|The Kinetic Control Retraining Program will be received for 8 weeks by the experimental group. It focuses on addressing uncontrolled movement (UCM) and muscle synergy retraining. UCM retraining starts with patient education on movement deficiencies, their symptoms, and adherence to training. Movement coordination is retrained in test positions, progressing to challenging ones using feedback from mirrors, walls, or hands. Corrections focus on lower cervical flexion, upper cervical extension, mid-cervical translation/extension, side-bending, and rotation, emphasizing controlled dissociation in supported and unsupported postures. Muscle synergy retraining targets global stabilizers (e.g., deep neck flexors and extensors) and mobilizers (e.g., sternocleidomastoid and suboccipital muscles) to enhance coordination, stability, and motor control.
223920842|NCT05293912|DRUG|SG2501|During study treatment, subjects will receive SG2501 treatment via IV infusion once every week at doses of: 0.01, 0.03, 0.1, 0.3, 1, 2, 4 and 6mg/kg.
223920843|NCT06889675|DRUG|YB1-X7 Injection (IT)|Intratumoral injection
223920844|NCT06889675|DRUG|YB1-X7 Injection (IV)|Intravenous infusion
223920845|NCT06884904|DRUG|Low-dose experimental group|2.0\*10\^6/kg
223920846|NCT06884904|DRUG|High-dose experimental group|4.0\*10\^6/kg
223920847|NCT06884904|DRUG|Low-dose placebo control group|Equivalent volume of solvent calculated at 2.0×10\^6/kg
223920848|NCT06884904|DRUG|High-dose placebo control group|Equivalent volume of solvent calculated at 4.0×10\^6/kg
223920849|NCT06886854|DEVICE|Mode of delivery|"Retrieval of delivery data, typically recorded by midwives - retrieval of data per delivery and post-delivery - Consultation of medical data on labor duration, labor onset method, estimated fetal weight, etc.~Data collected for each delivery, identical in both groups."
223920850|NCT04466527|DEVICE|Laser Intervention|Subjects with undergo laser exposure of their active acne vulgaris.
223920851|NCT06733844|DIETARY_SUPPLEMENT|Weekly iron folic acid supplementations|In the intervention arm, adolescent girls will receive weekly iron and folic acid supplements (WIFAS), nutrition education, and group counseling sessions. WIFAS will be delivered quarterly, with each girl consuming one supplement at the facilitation center and the remaining 12 at home, once a week. The supplements contain 60mg of iron and 2.8mg of folic acid. A quarterly cash transfer of PKR 1,000 will be given to the mother, conditional on the girl's WIFAS consumption and attendance at the quarterly education and counseling sessions. The girl will report her supplement intake at each visit and receive 13 more supplements. The intervention will last 18 months.
223920852|NCT06721754|PROCEDURE|Negative Pressure Wound Treatment|Negative Pressure Wound Treatment promotes healing by applying subatmospheric pressure to reduce inflammatory exudate and stimulate granulation tissue.
224090521|NCT04323501|OTHER|Experimental treatment|"Exercises may include UPPER LIMB Passive exercises (stretching), each one greater or equal to 10 minutes; greater or equal once a day: pectoralis; back muscles and triceps; subscapular muscle; elbow flexor; both pronator muscles; flexor of the wrist and fingers; flexor, adductor and opponent muscles of the thumb.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: shoulder abduction, flexion, external rotation; elbow extension and supination; wrist extension; finger extension; thumb extension and abduction.~LOWER LIMB Passive exercises, each one greater or equal to 10 minutes; greater or equal once a day: hamstring; adductor of the hip; gluteus muscles.~Greater or equal to 5 minutes; greater or equal to twice a day: soleus and gastrocnemius.~Active exercises: multiple repetitions possible in 1 minute each one greater or equal to three times a day: hip abduction and flexion; knee flexion; dorsiflexion of ankle; seat-standing"
224090522|NCT04323501|OTHER|Control group|Usual care
224090523|NCT03319628|DRUG|upifitamab rilsodotin|"XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536"
224279268|NCT00833508|OTHER|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
224279269|NCT01727349|OTHER|HbA1c measurement|
224279270|NCT01727349|OTHER|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
224279271|NCT06061406|DEVICE|smart visit app|"Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician."
223717196|NCT03547583|DRUG|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
224090524|NCT04934202|OTHER|Teleconsultation|"Teleconsulting physicians will subject patients to a standardized questionnaire that will look for the following symptoms:~* General signs: Anorexia, fatigue, new hospitalization, weight loss,~* Respiratory signs: recent dyspnoea, chest discomfort, chest pain, new cough, abnormal lung CT scan since discharge~* Neurological signs: headache, paraesthesia, anosmia, limb paralysis~* Digestive signs: abdominal pain, diarrhoea, constipation, nausea, vomiting~Edition 2021~◌ Cognitive signs using the Q3PC questionnaire (10): memory loss, slowness in reasoning, activity planning or problem solving, concentration, attention difficulties"
224279272|NCT05310708|DIAGNOSTIC_TEST|Polysomnography|Measuring and recording multiple physiological parameters from a patient which are used by clinicians to make a decision on the diagnosis of sleep.
223920853|NCT06735703|DRUG|To provide ampicillin sulbactam to pregnant women with premature rupture of membrane|To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation
223920854|NCT06736210|OTHER|Muscle Elastic Properties Measurement|Using the MyotonPro device, the elastic properties, including stiffness, elasticity, and tone, were evaluated for the tibialis anterior, gastrocnemius medialis, gastrocnemius lateralis, and peroneus longus muscles. Measurements were performed in a controlled laboratory setting.
223920855|NCT06736210|OTHER|Muscle Oxygen Saturation (SmO2)|Muscle oxygenation levels were measured before and after a standardized exercise protocol using the MOXY device. The exercise protocol consisted of a light-intensity dynamic task tailored to minimize fatigue and mimic functional activity.
223920856|NCT06736210|OTHER|Plantar Pressure Analysis|Plantar pressure was assessed both statically and dynamically using a pressure-mapping platform. This provided data on pressure distribution, contact times, and high-pressure areas across the foot during various conditions.
224090525|NCT04934202|OTHER|Outpatient clinic|"During a day hospitalization planned during the teleconsultation, patients will benefit from the following multidisciplinary assessment.~* General clinical examination~* Assessment of the state of health~* Respiratory assessment~* Pulmonary CT assessment~* Cognitive evaluation~* Cardiological evaluation~* Renal assessment~* Immunological evaluation"
223920857|NCT06735963|DEVICE|Meta Quest 3 Virtual Reality|Immersive virtual reality Meta Quest 3 device
224090526|NCT00718133|DEVICE|Spirometry (Pony spirometer)|Spirometry at rest
224090527|NCT03910192|BEHAVIORAL|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
224090528|NCT03910192|BEHAVIORAL|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
224090529|NCT06527599|OTHER|Opioid Risk Monitoring (ORM)|A brief battery of self-reported screeners for risk factors associated with opioid misuse (e.g., Current Opioid Misuse Measure; Pain, Enjoyment of life, and General activities scale; Pain Catastrophizing Scale). These measures will be administered within seven days of hospital discharge (i.e., baseline), and again at 2-, 4-, 8-, and 12-weeks following discharge to assess for ongoing risk for opioid misuse. Participants will additionally complete the self-reported Opioid Risk Tool within seven days of hospital discharge.
224090530|NCT06527599|BEHAVIORAL|enhanced Trauma Care Coordination (eTCC)|An enhanced care management model with increased patient contact and embedded interventions based on clinical presentation and collaboration with the patient. eTCC is a telehealth-based care coordinating intervention where a care coordinator assesses the participant, creates a plan of care, collaborates with the eTCC team, follows up with a second virtual visit within a week, and communicates with the participant and care team at least bi-weekly for the 3 month intervention period.
224090531|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Brief (PCST-LITE)|PCST-LITE will consist of a single 55-minute videoconference session, in which participants will receive brief psychoeducation grounded in gate control theory, progressive muscle relaxation (PMR), and therapist-guided imagery. Participants will be asked to practice PMR and imagery daily and will receive four weeks of regular (4-5 times per week) text messaging as a reminder.
224090532|NCT06527599|BEHAVIORAL|Standard Trauma Care Coordination (sTCC)|Standard Trauma Care Coordination (sTCC) will functionally serve as a treatment-as-usual arm, as it will involve no study intervention.
224279273|NCT05993598|OTHER|hippotherapy|Evaluation parameters were applied to 30 children with special needs at the beginning of the session. After the evaluation, each group was given a 30-minute hippotherapy session in the manege area. During the practice, the child simply sat on the horse. The horse was asked to maintain its balance by adapting to the oscillations it creates while walking on the sand. Immediately after the 30-minute application, the initial evaluations were made again. As a result, it was investigated whether hippotherapy applied on different sitting surfaces in children with special needs had an effect on sitting balance and walking speed.
224279274|NCT02507245|DRUG|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
224279275|NCT01537731|PROCEDURE|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
224279276|NCT02168140|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
224279277|NCT02168140|DRUG|bendamustine hydrochloride|Given IV
224279278|NCT03138824|PROCEDURE|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
224279279|NCT03138824|PROCEDURE|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
224279280|NCT02935296|BEHAVIORAL|Integrated Intervention|systems navigation, psychosocial counseling
224279281|NCT00064584|DRUG|CT53518|
224279282|NCT05813379|COMBINATION_PRODUCT|exosime injection|Treatment- exosome injection
224279283|NCT03727737|DEVICE|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
224279284|NCT04317599|OTHER|Non Interventional study|Non Interventional study
223920858|NCT06735963|PROCEDURE|Exercise|Traditional exercise program for knee OA patients
223920859|NCT06735963|DEVICE|Electrotherapy|Electrotherapy including Therapeutic Ultrasound (US) and Transcutaneous Electrical Nerve Stimulation (TENS)
223920860|NCT06505746|OTHER|No intervention|No investigational drug will be administered to participants in this study.
223920861|NCT03587805|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
223920862|NCT06711198|OTHER|virtual reality simulation|The student will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given birth in the delivery room on the delivery table. The student is expected to select the appropriate materials and complete the episiotomy repair of the woman with the correct steps.
223920863|NCT06884878|OTHER|Multi-omic approach to cancer diagnosis.|To assess the impact of intratumoral heterogeneity on the effectiveness of targeted therapies and immunotherapy.
223920864|NCT06739252|COMBINATION_PRODUCT|Gemcitabine Oxaliplatin and 5FU|The perioperative treatment plan includes neoadjuvant therapy and adjuvant therapy. Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), along with additional capecitabine or tegafur as auxiliary maintenance treatment for three cycles. The total treatment duration for the perioperative period is six months. HAIC regimen: gemcitabine (1,000 mg/m2, 2h, d1) + oxaliplatin (35 mg/m2, 2h, d1-2) + 5-FU (0.75g/m2, 22h, d1-2); atezolizumab (PD-L1 inhibitor): 1200 mg, intravenous infusion, administered within 24 hours before HAIC treatment; bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment (bevacizumab use is paused during the third neoadjuvant treatment). Each cycle lasts for three weeks.
223920865|NCT06735391|DRUG|JMT101|JMT101 is a recombinant humanized anti-EGFR monoclonal antibody.
224090533|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Plus (PCST+)|PCST+ will include two videoconferencing sessions, in addition to the first videoconferencing session they previously received. In session 1, participants will be taught an activity/rest cycle to schedule activities, so they are productive while avoiding increasing pain severity due to taking insufficient breaks. Session 2 centers around cognitive restructuring, involving brief psychoeducation and skills development surrounding how participants might recognize the influence that cognitions can have on pain intensity and coping. Participants will receive 3 weekly, 15-minute calls to review skills and problem-solve.
224090534|NCT06527599|BEHAVIORAL|Pain Coping Skills Training - Maintenance (PCST-M)|PCST-M consists of five weekly booster calls from the patient's study therapist to reinforce the techniques covered in the initial PCST-Lite session.
224090535|NCT06183658|DIAGNOSTIC_TEST|Fluids biomarker and neuroimaging of AD diagnosis|Early diagnosis of Alzheimer's disease in South China aging population using fluids biomarker and neuroimaging.
224090536|NCT06472856|PROCEDURE|Acupuncture|Acupuncture will be given using single use sterile stainless steel 34 gauge (Japanese size: 0.20 X 30 mm) filoform needles. Skin will be swabbed with an alcohol prep pad before acupuncture is administered. Needles will be inserted 0.5 to 1.0 centimetres deep into the skin and gently manipulated to create the deqi sensation. No electrical stimulation will be used.
224090537|NCT06657443|OTHER|First Session|Introductions, explanation of the purpose and content of the project, realisation of the pre-test application. Giving the assignment with the theme of 'Nursing and Society' between peer mentors and mentees.
224090538|NCT06657443|OTHER|Second Session|Training of peer mentors on communication techniques, interview methods and empathic approach.
224090539|NCT06657443|OTHER|Third session|Sharing postcasts on communication techniques, interview methods and empathic approach with peer mentors.
224090540|NCT06657443|OTHER|Fourth session|Training of peer mentors on social motivation and leader-member interaction
224090541|NCT06657443|OTHER|Fifth Session|Sharing postcasts with peer mentors on social motivation and leader-member interaction.
223920866|NCT06735391|DRUG|Osimertinib|EGFR TKI
224090542|NCT06657443|OTHER|Sixth Session|Presentation of 'Nursing and Society' themed assignments of peer mentors and mentees as a group (Composition, poem, poster, presentation, role play, etc. are left free among the students) and post-test application.
224090543|NCT03914352|DRUG|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
224090544|NCT03914352|PROCEDURE|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
224090545|NCT05452603|DEVICE|96-hour off IBP wireless pH monitoring capsule|The endoscopic pH measurement capsule will be placed 6cm above the squamocolumnar junction, determined endoscopically, in the sedated patient. Then the plot will be read.
224099612|NCT05301244|OTHER|laughter yoga for nurses-Laughter exercises|Laughter exercises (15 minutes) This section includes a variety of laughter exercises such as greetings, strawberry milk, conductor, bonus, hot soup, lion, aloha, bird, appreciation, laughter lotion, elevator, cream cake, and bursting balloon laughter.
224099613|NCT00708396|DRUG|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
223717197|NCT01645345|DEVICE|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
224279285|NCT03123887|OTHER|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
224279286|NCT04301622|DEVICE|Primary Knee implants|Primary knee arthroplasty
224279287|NCT05630625|BEHAVIORAL|Drinking Dashboard|Day-level feedback on alcohol use and consequences
223530649|NCT02796911|DRUG|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
223530650|NCT02796911|DRUG|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
223530651|NCT01715870|BEHAVIORAL|Life style and food habits questionnaire|
223717198|NCT04933994|DEVICE|computed Tomography|All cases were detected with computed Tomography
223717199|NCT00382252|PROCEDURE|computed tomography|
223717200|NCT00382252|PROCEDURE|positron emission tomography|
223717201|NCT00382252|PROCEDURE|radiofrequency ablation|
224090546|NCT05132166|OTHER|Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.|Will vary depending upon Investigator's choice identified prior to randomization. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT. No cross-over to DSC treatment is planned. The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.
224090547|NCT05132166|BIOLOGICAL|Decidual Stromal Cells|The dose will be 1×106 DSC/kg bodyweight, at least 2 doses at least one week apart. Within the first 28 days, patients meeting criteria of aGvHD disease progression, mixed response or no response, may be given additional weekly doses of DSC until satisfactory response (ie: CR) are reached (max 4 doses in total).
224090548|NCT03884686|OTHER|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
224090549|NCT04677270|BEHAVIORAL|Digital problem solving tool|Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
224099614|NCT02033226|DEVICE|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
224279288|NCT04840784|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
224279289|NCT06245759|OTHER|This was a retrospective study and no patient intervention was performed|This was a retrospective study and no patient intervention was performed
224279290|NCT06614699|OTHER|abdominal fat and muscle area|Abdominal fat and muscle area were calculated based on abdominal CT.
224279291|NCT06279806|OTHER|Mobile health application use|"Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed."
223530652|NCT05825716|OTHER|Ifaa Basic|"* PSNP Systems: (1) Provision of food aid commodities (wheat, oil, and pulse) per the PSNP transfer schedule for 3-6 months; 2) Food System Taskforce (FSTF) capacity building, and 3) private sector engagement~* Health and Nutrition: 1) Government of Ethiopia (GoE) basic health extension program; 2) GoE supportive supervision coaching; 3) GoE-led community social behavior change (SBC) sessions; and 4) Community Management of Acute Malnutrition (CMAM) Programming.~* Water and Sanitation: 1) Water infrastructure development; 2) improved governance via water, sanitation and hygiene (WASH) committees; and 3) water source monitoring.~* Natural Resource Management: 1) Public works projects; 2) community training in planning and sustaining community assets; 3) Implementation of the environment and social management framework; 4) enhance participation of watershed committees"
223920867|NCT06736067|BEHAVIORAL|Exercise|Thirty minutes of exercise on a treadmill, including a 5-minute warm-up followed by increments in speed until reaching optimal moderate to high intensity (60-80% of age-predicted maximal heart rate), which will be maintained for 20 min, followed by a 5-minute cool-down. Age-predicted maximal HR will be defined as 220 beats-per-minute (BPM) minus age in years.
223920868|NCT06734793|DEVICE|Wearable stethoscope|The device is a soft, wearable stethoscope designed for continuous, comfortable monitoring of patients for abnormal breath sounds, such as wheezing, which can indicate asthma exacerbations. It automatically detects and diagnoses abnormal breath frequencies, wirelessly transmitting data for analysis. Preliminary materials have shown biocompatibility, ensuring the device is safe for use in children. A key feature is its machine-learning algorithm, which can classify and differentiate normal from abnormal sounds with an expected accuracy above 80%. Initial in vivo tests will compare the device's findings to those of a commercial-grade stethoscope in healthy subjects and individuals with asthma. Breath sound data will be used to improve the detection of wheezing sounds from these continuous recordings based on frequency and amplitude analysis of the recordings.
223920869|NCT06734793|OTHER|Routine Clinical lung Auscultation|The study PI will auscultate the participant's lungs at enrollment to ensure that wheezing is present before beginning the continuous recording of the participant's lung sounds. The PI will assess the participant's respiratory status daily at the start of each breath sound recording session.
224099615|NCT02033226|DEVICE|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
224099616|NCT00000889|DRUG|Aldesleukin|
224099617|NCT05480514|DEVICE|TEST LENS|etafilcon A with cosmetic pattern
224099618|NCT05480514|DEVICE|CONTROL LENS|Acuvue 1-Day Define Fresh Honey
224099619|NCT03384056|DEVICE|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
224099620|NCT03384056|DEVICE|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
224279292|NCT06279806|OTHER|Information of the breast cancer survivor period booklet|Women in the control group will be given information of the breast cancer survivor period booklet.
224279293|NCT04670406|BEHAVIORAL|acceptance and commitment therapy (ACT) combined with psychoeducation|Participants receive 8 weekly sessions, including 6 ACT sessions and 2 psychoeducation sessions, delivered by trained coaches through Zoom videoconferencing.
224099621|NCT02149992|DIETARY_SUPPLEMENT|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
224099622|NCT02149992|DEVICE|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
223717202|NCT05270343|DRUG|Cholecalciferol (Vit D3) 400Unit Cap|Each subject will take Vit D3 (400Unit Cap) with breakfast for 12 consecutive months, and the initial load will be 140IU/kg qd until the serum 25(OH)D3 is maintained at the upper limit of normal ( 50-80ng/ml\[125-200nmol/L\], ≤100ng/ml\[≤250nmol/L\]), then maintained at 70IU/kg qd, combined with intensive insulin therapy
223920870|NCT06737250|DRUG|R2P -> RP|"Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14"
223920871|NCT06739642|OTHER|Education|caregivers in the intervention group received an individualized educational program intervention. The content of the educational program was developed by the researcher through a review of the literature and interviews with caregivers. The educational program, during three months, was delivered in 6 sessions of 40 minutes each. The topics of the training content were as follows: 1. General Nutrition Information, 2. Changes Affecting Nutrition During Old Age and Nutrition Principles, 3. Anthropometric Measurements and Scans, 4. Nutritional Problems in the Patient with Dementia, Dementiamendations for Increasing Nutritional Intake in Dementia Patients, 6. Alternatives for Severe Feeding Problems. Covering general topics was held as group education; carried out in two separate groups. Another individual session was planned for caregivers who could not attend the group education program, and the missing topics were completed.
223717203|NCT01600638|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223920872|NCT06740227|PROCEDURE|Virtual Reality-Based Balance Training|Virtual reality workout session will be for about 30-40 minutes Warm-up exercise will be for 5 minutes including relaxed breathing For Static Balance, Lotus Focus, Tree pose, Warrior Pose games will be used For Dynamic Balance, Soccer Heading, Ski Jump, Tight Rope Walk, Table Tilt, Ski Slalom games will be used 5 minutes will be given for cool down.
223920873|NCT06740227|PROCEDURE|Conventional Balance Training|one minute of rest for every five minutes of exercise Conventional Balance workout session will be for about 30-40 minutes Warm-up for 5 minutes For Static Balance, Static Balance, Single Leg Standing, Stork Standing will be used For Dynamic Balance, Weight Shifts, Tandem Walk, Single Leg Balance with Arm Movements 5 minutes will be given for cool down
223920874|NCT06891742|DRUG|OriC902|Whole peripheral blood mononuclear cells are extracted from patients (or donors) through leukocyte separation, and then the required T cell subsets are isolated, which will become the basis for the subsequent preparation of CAR T cells
223920875|NCT06735989|OTHER|Lecture on moral reasoning|One and a half-hour long lecture on moral justification and moral reasoning
223920876|NCT06735989|OTHER|Lecture on logical reasoning|One and a half-hour long lecture on logical and argumentative principles
223920877|NCT06734195|DRUG|dexmedetomidine + propofol|Comparison of caudal dexmedetomidine + propofol sevoflurane-related emergence agitation in children undergoing congenital hernia repair.
223920878|NCT06734195|DRUG|Propofol alone|30 patients will receive propofol 1mg/kg before the start of skin closure, administered over 10 minutes and caudal block using 1 ml/kg of bupivacaine 0. 25 % plus 2 ml normal saline.
223920879|NCT06734195|DRUG|Dexmedetomidine|patients will receive caudal dexmedetomidine block using 1 ml/kg of bupivacaine 0. 25 % mixed with dexmedetomidie 1mic/kg diluted in 2 ml normal saline
223920880|NCT06737913|PROCEDURE|HAI Adebrelimab|Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)
223920881|NCT06737913|DRUG|intravenous infusion (IV) of Adebrelimab (ADE)|intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)
223920882|NCT06737913|DRUG|intravenous infusion (IV) of Bevacizumab (Bev.)|intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)
223920883|NCT06737913|PROCEDURE|HAIC with FOLFOX regimen|HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)
223920884|NCT06737913|DRUG|Adebrelimab and bevacizumab maintainance treatment|The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity
223920885|NCT06741852|PROCEDURE|nCLE assisted endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel|Patients received 2.5mL of 10% Fluorescite intravenously during nCLE. The CLE probe was preloaded into a puncture dilation catheter and locked into position with 2mm being exposed beyond the tip. puncture dilation catheter. The lymph node was punctured and the needle positioned at its center. The probe was advanced and locked, and the needle was advanced to the contralateral edge of the lymph node. Image acquisition began at the lymph node capsule, and then the subcapsular region, followed by the cortical sinus. When the image showed granuloma or malignant characteristics, the location will be recorded in EBUS, and retract the CLE probe, leaving the sheath of puncture dilation catheter as a tunnel between airway wall and target lymph node. Then, a 1.1-mm cryoprobe was inserted into the target lymph node through this tunnel under the EBUS guidance. The probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue.
223920886|NCT06741852|PROCEDURE|Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy via a tunnel|First a tunnel between airway wall and mediastinal and/or hilar lesion was made by a puncture dilation catheter (BroncTruTM AK-91-55, Broncus Inc. Hangzhou, China). The 1.1mm cryoprobe (Erbe 20402-401, ERBE, Tübingen, Germany) entered the target lymph node through the tunnel under direct monitoring of EBUS, and the distance between the tip of the cryoprobe and the border of target lymph node was measured using EBUS. After confirming that the distance was \>5 mm, the probe was cooled with liquid carbon dioxide for 5-9 seconds. Then retracted with the bronchoscope and the frozen biopsy tissue. Samples were retrieved by thawing in saline and then fixed in formalin. The same lymph node was operated for 3 times.
223920887|NCT06133231|DIETARY_SUPPLEMENT|Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants|Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
223920888|NCT06743451|OTHER|Health workers training on GMP guideline|One day training will be conducted to health workers on updated GMP guideline for the health workers primarily engaged in Growth monitoring and promotion of the children.
223920889|NCT06743451|OTHER|Female community health volunteers' mobilization for inviting mothers and caretakers|Female community health volunteers will be mobilized for inviting mothers and caretakers for two consecutive months for enhancing GMP practices in the municipality
224090550|NCT05951179|BIOLOGICAL|TARA-002|All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.
224090551|NCT06351631|DRUG|Bomedemstat|10, 15, 20, and 50 mg oral capsules
224090552|NCT05991973|DRUG|Chidamide|In the time window of 30-180 days after transplantation: oral chidamide 10mg twice a week with a total of 96 courses(4 weeks as a course). If the MRD turns positive during treatment, the dose can be increased to a maximum of 20 mg twice a week, and donor lymphocyte infusion (DLI) is also permitted in the case of MRD positivity.
224090553|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.25 mg.kg-1
224090554|NCT04928352|DRUG|Bupivacaine Hydrochloride|Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1
224090555|NCT04928352|OTHER|0.9% saline|Preoperative nebulized same volume of saline placebo
224090556|NCT04546620|DRUG|R-CHOP|Arm A patients will receive R-CHOP alone.
224090557|NCT04546620|DRUG|R-CHOP + acalabrutinib|Arm B patients will receive R-CHOP in combination with acalabrutinib.
224090558|NCT05643144|DEVICE|Continuous Glucose Monitoring|CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
224090559|NCT06364592|DEVICE|Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.30 × 40 mm and 0.30 × 75 mm) and SDZ-V electroacupuncture apparatus will be used. Acupoints of Ciliao (BL32), Shiqizhui (EX-B8), and Sanyinjiao (SP6) will be used for participants.~The needles will be inserted to 60-70mm in BL32 and 25-30mm in EX-B8 and SP6. Needle manipulation will be conducted (except for BL32) to achieve deqi sensation. Then paired electrodes from the electroacupuncture apparatus will be attached transversely to the needle handles at bilateral BL32 and SP6. The electroacupuncture stimulation will last for 30 minutes with a continuous wave of 5Hz and a current intensity of 1 to 5mA. Current intensity was adjusted according to the patients' individual tolerance.Treatment will start within one week before the onset of menstruation and stop before the end of menstruation, three sessions per menstrual cycle in total (ideally every two to three days and at least one session during menstruation period)."
224090560|NCT06364592|DEVICE|Sham Electroacupuncture|"Hwato brand disposable acupuncture needles (size 0.25 × 40 mm and 0.30 × 25 mm) and SDZ-V electroacupuncture apparatus will be used. Sham acupoints of BL32, EX-B8 and SP6 will be used for every participants.~The needles will be inserted to 2-3mm in sham acupoints. Procedures, electrode placements, and other treatment settings were the same as in the electroacupuncture group but with no electricity output or needle manipulation for de qi."
224090561|NCT02863341|OTHER|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
224090562|NCT02162888|DRUG|Test Product (Bendamustine)|
224090563|NCT01382160|BIOLOGICAL|adalimumab|40 mg every two weeks, by subcutaneous way
224090564|NCT01956214|OTHER|FES Exercise|receive FES while exercising
224090565|NCT01956214|OTHER|Mock FES Exercise|participants will receive Mock FES
223717204|NCT03884491|DRUG|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
223717205|NCT03884491|DRUG|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
224090566|NCT01498133|PROCEDURE|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
224090567|NCT04378166|DEVICE|Smart glass|Practitioner wears smart glasses connected to ultrasound machine during central venous catheterization
223717206|NCT03884491|DRUG|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
223920890|NCT06744231|OTHER|Usual Care|Prior to implementation of the Thriving Hearts package of services, people living in participating counties will receive usual care for pregnancy, birth, and postpartum services. The study team will quantify existing services using a study-developed usual care assessment instrument.
224090568|NCT04475341|BIOLOGICAL|BMS + Bone Marrow Aspirate Concentrate|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
224090569|NCT04475341|PROCEDURE|BMS alone|Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
224090570|NCT00412256|DRUG|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
224090571|NCT05774821|PROCEDURE|Tricuspid valve surgery|Surgical repair or valve prosthesis implant to treath the regurgitation of the tricuspid valve
223717207|NCT03884491|DRUG|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
223717208|NCT04959422|OTHER|Active scheduling|Active scheduling, tracking and rescheduling, if necessary.
223717209|NCT04303832|OTHER|eye exercises|Eye exercises for correcting eye deviation
223920891|NCT06744231|BEHAVIORAL|Thriving Hearts|"Thriving Hearts is a collaboration among LHDs in ten North Carolina counties. At the individual level, pregnant individuals will self-screen for HDP risk during prenatal visits, and those at risk will be provided a Mama Hearts Care Kit, including a home blood pressure monitor, low dose aspirin, and culturally tailored educational materials.~At the healthcare provider level, burnout and compassion fatigue will be addressed through skill-building activities, including training in the Community Resilience and Mindfulness-Based Stress Reduction.~At the community level, Loving Connection will provide proactive material and social support through Community Health Workers, text messaging-based communication, a medical legal partnership, and capacity-building support for community-based organizations."
223920892|NCT06740097|DEVICE|Aspirate tissue monitoring|This multicenter controlled clinical trial investigates the clinical performance and outcomes from using an aspirate tissue monitor (ATM, Marginum Ltd HIVEN™) that detects cancerous tissue from the suction waste during the surgical treatment of suspected high-grade gliomas. The ATM provides near real-time audible feedback to the surgeon when tumor-related fluorescence is detected in the aspirated tissues. The trial investigates if the use of ATM to detect 5-ALA induced fluorescence contributes to faster tumor removal, less blood loss, less unintended residual tumor, less morbidity, longer survival and the frequency of local reoperations. The cases are compared with controls (n=50) from applicable local clinical site registers (matched controls). The cases are operated with the help of aspirate tissue monitoring and the controls without. Other preferred adjunct techniques are used in both groups.
223920893|NCT06740097|DEVICE|Fluorescence-guided surgery|Resection utilizing conventional visual fluorescence-guided surgery.
223920894|NCT06736678|DIETARY_SUPPLEMENT|Oral Immunonutrition|Patients receive enteral immunonutrition, Oral Impact® Nestle for 6 weeks from one week before radiotherapy;
224090572|NCT04720703|BEHAVIORAL|Newsletters|Similar to prior empirical pediatric obesity interventions (Elder et al., 2009), the active attention waitlist control group will receive monthly newsletters that focus on physical activity, healthy eating, and screen time. These newsletters will be based on standard materials from the We Can program of the National Heart, Lung, and Blood Institute (NHLBI).
224090573|NCT04720703|BEHAVIORAL|Family-based Telehealth Intervention|All communications related to the intervention will occur through weekly small group video conferencing calls via Zoom and emails or text messages. The intervention will include diverse topics proven effective in prior interventions (Davis et al., 2019; McLean et al., 2003), including reading food labels, eating out, eating at social gatherings, sticker charts, praising/rewarding healthy choices, healthy foods available at home, portion sizes, healthy/easy/low-cost cooking ideas, goal setting, monitoring screen time, exercise opportunities available in neighborhood, family exercise ideas, and healthy sleep. The research team will also send relevant video/audio clips, brochures, reminders (text messages and emails) every week.
224090574|NCT03231514|DIETARY_SUPPLEMENT|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
224090575|NCT03231514|OTHER|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
224090576|NCT03231514|OTHER|Exercise|All groups will participate in a standardized exercise intervention.
224090577|NCT05987761|BEHAVIORAL|PRT for Adolescents|Clinician-led 70-minute PRT sessions targeting social skills once per week at Stanford.
224099623|NCT02149992|DEVICE|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
224099624|NCT03059290|DEVICE|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
224099625|NCT04879940|DEVICE|Merit Medical Embospheres|Prostatic Artery Embolization will performed as an outpatient procedure in Interventional Radiology. Bilateral selective pelvic angiograms will be performed to localize the prostatic arteries. Cone-beam or 3D computed tomography (CT) will be performed prior to embolization, if technically feasible and necessary. Embolization will be performed using Merit Medical Embospheres.
224099626|NCT04879940|RADIATION|Radiation Therapy|Patients will undergo standard of care definitive radiation therapy.
224099627|NCT03991247|BEHAVIORAL|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
224099628|NCT03991247|OTHER|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
224099629|NCT05246410|DEVICE|Spot stent system|Spot stent system designed and produced by Acotec
224099630|NCT05246410|DEVICE|Self-expanding peripheral stent system|Self-expanding peripheral stent system designed and produced by Ev3, Inc
223920895|NCT06739577|DIAGNOSTIC_TEST|Evaluation of walking abilities (manual Timed-Up & Go - TUG and automatic -OpenTUG))|"To evaluate walking abilities, participants performed the Timed-Up \& Go (TUG) f our times (practice trial, normal, slow and fast speed). Patient's performances are videorecorded with an Intel RealSense depth camera D435i to capture their movements, and manual time recording of time taken (in seconds) and number of steps are carried out by the experimenters.~Complementary to manual experimenter recording, a 2D human pose estimation method (OpenTUG) is applied to automatically extract the time and the number of steps taken by the participant during the TUG task."
223530653|NCT05825716|BEHAVIORAL|Ifaa Enhanced|"* PSNP Systems: 1) establishment and training of Community Technical Coordinating Forum; 2) Case management capacity building; and 3) private sector construction of infrastructure~* Health and Nutrition:1) the Care Group Model approach; 2) home garden promotion; 3) the nutrition budget calculator; and 4) labor and time-saving technologies.~* Community-level interventions are 1) adolescent nutrition school clubs; 2) religious leader mobilization and training vulnerable groups; 3) audio toolkit against harmful traditional practice; 4) enhanced SBC tools for health/nutrition promotion; 5) additional health extension programs~* Water and Sanitation: 1) Community Led Total Sanitation and Hygiene; 2) WASH systems assessments and strengthening; 3) Ensuring water quality and safety via routine monitoring; 4) Private sector engagement of WASH-related businesses;"
223530654|NCT05825716|OTHER|Ifaa Enhanced + Livelihoods|"* Additional resources provided to the groups, including 1) Engagement of Private Service Providers to enable access to sustainable credit and larger loans; 2) Financial Education using an expanded 'Smart Skills' curriculum focusing on savings, smart borrowing and effective financial management; and 3) Life Skills Training for Youth.~* Additional supports include: 1) Seven Steps of Marketing Training; 2) Climate Smart Agriculture to reduce water needs and increase soil health and vegetation coverage; 3) Producers Groups and linkages to markets/suppliers/buyers; Selected financial institutions will be provided with a credit guarantee fund and capacity-building support to help facilitate loans. Private sector value chain assessment and financing. Additional private sector engagement and linkage facilitation."
223920896|NCT06739577|DIAGNOSTIC_TEST|Neuropsychological assesment is provide to measure objective and subjective cognition/emotional aspects.|Neuropsychological evaluation assess attention (Test for Attentional Performance -TAP-) and quality-of-life (DHI, HADS, and NVI).
223920897|NCT06739525|COMBINATION_PRODUCT|Blue Light-Blocking Glasses (Intervention Group)|Participants in this arm wore blue light-blocking glasses designed to filter out a portion of short-wavelength blue light. These lenses were intended to reduce eye strain and protect against blue light exposure, especially during prolonged screen time. Participants used blue light-blocking glasses consistently throughout the study period to assess their effect on contrast sensitivity and visual fatigue.
223920898|NCT06739525|DIAGNOSTIC_TEST|Standard Lenses (Control Group)|Participants in this arm wore standard lenses without any blue light-blocking properties. These lenses allow the full spectrum of visible light to pass through and serve as a baseline control to measure against the blue light-blocking glasses. Participants used these lenses under the same conditions to assess contrast sensitivity and visual fatigue without blue light filtration.
223920899|NCT06735326|DRUG|Fluzoparib|Fluzoparib capsule (50mg per capsule) 150mg po BID
223920900|NCT06735326|DRUG|Bevacizumab|Bevacizumab injection (100mg per vial) 7.5mg/kg ivdrip Q3W
223920901|NCT06735326|DRUG|Paclitaxel|Paclitaxel injection 135-175mg/㎡ ivdrip Q3W
223920902|NCT06735326|DRUG|Carboplatin|Carboplatin injection AUC=4-5 ivdrip Q3W
223530655|NCT02065986|DRUG|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
223530656|NCT06535373|OTHER|Blood flow restriction|Both groups will undergo a 6-week training intervention with training 2x a week, after which grip strength and other relevant outcomes will be measured and compared. Exercise sessions will be at least 48 hours apart. Participants will be allowed to continue with their normal exercise routine outside of the study.
223717210|NCT04303832|DEVICE|eye glasses|Eye glasses for correcting eye deviation
223920903|NCT06743360|DEVICE|Insertion|Twenty orthodontic mini-implants (n=20) (AbsoAnchor SH 1312-08, Dentos, Daegu, South Korea) were randomly chosen (every third screw from a sample of 60) numbered consecutively, and embedded in polivynyl siloxane impression material Variotype heavy putty (Kulzer, Hanau, Germany).
223920904|NCT06743360|DEVICE|Scanning|After the planned movement is achieved, the mini-implant will be removed and provided to laboratory analysis. All screws were sputtered (0.6µm CaCO₄) and scanned in blue-light technology, using a 3D optical scanner (Atos III, Triple Scan, GOM, Germany) to the nearest 2 micrometres. Due to regularly performed calibration procedures, recommended by the manufacturer, an error study was superfluous. Subsequently, the scans were superimposed using GOM Inspect Software (GOM, Braunschweig, Germany) in order to verify the shape and size repeatability.
223920905|NCT03982186|DRUG|JNJ-73763989|JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
223920906|NCT03982186|DRUG|Placebo for JNJ-73763989|Placebo for JNJ-73763989 will be administered as subcutaneous injection.
223717211|NCT00484432|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
223717212|NCT00484432|DRUG|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
223920907|NCT03982186|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
223920908|NCT03982186|DRUG|Placebo for JNJ-56136379|Placebo for JNJ-56136379 tablets will be administered orally.
223920909|NCT03982186|DRUG|Nucleos(t)ide Analog (NA)|NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
224099631|NCT05716919|DRUG|Ivaltinostat|Ivaltinostat capsule
224099632|NCT05716919|OTHER|Placebo|Placebo capsule
224099633|NCT00375245|DRUG|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
224099634|NCT00375245|OTHER|Grapefruit Juice|Daily oral doses starting during the second week on study.
224099635|NCT06577818|PROCEDURE|CC+SI (Chest compression during sustained inflation)|CC+SI (Chest compression during sustained inflation)
223530657|NCT06576648|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session, 20-minute, motivational interviewing-based intervention, which will be delivered on the CIAS platform. It will be tailored to participants' responses given during the interaction in the intervention. In the first two sessions, the (virtual) counselor will motivate participants to overcome stigma and utilize HIV prevention services by using tailored motivational interviewing strategies, develop an individualized change goal based on their readiness, and provide cognitive behavioral strategies. In the last two sessions, the counselor will review the change plan, monitor progress, and provide support for sustained behavioral change. The sessions will occur within three months after baseline.
224090578|NCT01903876|BEHAVIORAL|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
223530658|NCT06576648|BEHAVIORAL|Finding Respect and Ending Stigma around HIV (FRESH)|FRESH content includes six 10-15 minute sessions with interactive, culturally sensitive multimedia modules, which will be delivered on the CIAS platform. The content will aim to improve self-efficacy, reduce intersectional stigmas and promote HIV preventative behaviors. The sessions will occur within three months after baseline.
223530659|NCT06576648|BEHAVIORAL|Standard PrEP Counseling|All participants will receive one-on-one, face to face counseling from focusing on sexual and behavioral risk assessment for HIV/STIs, risk reduction, and HIV prevention. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP, and facilitators and barriers to PrEP access. For those on PrEP, the sessions will focus on adherence. The counseling will be provided at baseline, 3 months, and 6 months.
223530660|NCT04031508|COMBINATION_PRODUCT|lipid injectable emulsion with Fish oil|TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
223717213|NCT04741282|OTHER|Pulmonary telerehabilitation|pulmonary telerehabilitation program include breathing exercise,aerobics exercise and upper and lower limbs muscle strengthening exercise
223717214|NCT04741282|OTHER|progressive muscle relaxation training|summarized Jacobson progressive muscle relaxation training method
223920910|NCT06741813|PROCEDURE|ASCT|The chemotherapy-based preconditioning regimen was BeEAM, which consisted of bendamustine (120-180 mg·m-2·day-1，days -8 to -7), etoposide (200 mg·m-2·day-1，days -6 to -3), cytarabine (400 mg·m-2·day-1，days -6 to -3), and melphalan (140 mg·m-2·day-1，days -2).
223920911|NCT06741813|PROCEDURE|Allo-HSCT|"Chemotherapy-based preconditioning regimen consisted of cytarabine 4 g·m-2·day-1 (days -9), busulfan (3.2 mg·kg-1·day-1 administered intravenously on days -8 to -6) (day 0 being the first day of donor cell infusion), cyclophosphamide (1.8 g·m-2·day-1, days -5 to -4), and semustine (250 mg.m-2, day -3). For the patients older than 55 years old or with HCT-CI score of 3 or more, cyclophosphamide can be decreased to 1.0 g·m-2·day-1, days -5 to -4, and added fludarabine (30mg·m-2·day-1, days -6 to -2). Rabbit antithymocyte globulin (thymoglobulin, 1.5 to 2.5 mg/kg, days -5 to -2; Sanofi, France) was administered to the HID and URD groups or MSD HSCT recipients who older than 40 years old (1.5 mg/kg, days -4 to -2).~All MSD, HID, and URD HSCT recipinets received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate (MTX) for GVHD prophylaxis. CsA (2.5 mg/kg, q12h, intravenous \[i.v.\]) was used from day -9, of which the trough concentration was adjusted to 150-250 ng"
224090579|NCT01903876|BEHAVIORAL|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
224279294|NCT02165306|BEHAVIORAL|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
224279295|NCT02165306|BEHAVIORAL|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
224279296|NCT05086198|BEHAVIORAL|Mindfulness-based intervention|An instructor trained in Mindfulness-based Stress Reduction (MBSR; Kabat-Zinn, 1990) will conduct meditations lasting 15 to 30 minutes. The participants will have a mobile application designed ad hoc with the practice of the week so they can do it individually at home.
224090580|NCT00496366|DRUG|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
224279297|NCT05086198|BEHAVIORAL|Physical exercise|An aerobic and fitness trainer will conduct aerobic exercise lasting 15 to 30 minutes. The participants will watch it in a video platform. They will not be able to do anaerobic exercise like weight lifting. The intensity of the chosen exercise will be moderate, maintaining between 120-140 beats per minute.
224279298|NCT03956602|OTHER|Pretzels|To examine postprandial responses of pretzel consumption
224279299|NCT03956602|OTHER|Brazil nuts|To examine postprandial responses of Brazil nut consumption
224279300|NCT03956602|OTHER|Potato chips|To examine postprandial responses of potato chip consumption
223717215|NCT03896386|OTHER|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
223717216|NCT01136603|DEVICE|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
224090581|NCT00496366|DRUG|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
223530661|NCT06149442|OTHER|Dose of five-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (five incisions).
223920912|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
223920913|NCT06737458|DRUG|Bupivacaine + Dexmedetomidine|Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
223920914|NCT06893692|OTHER|Otago exercise program|Experimental group: Group A will perform the Otago Exercise Program. The training protocol consisted of ten repetitions, with a 60-second rest interval between sets. The training protocol consisted of three sessions per week for 12 weeks.
223920915|NCT06893692|OTHER|Balance Training Exercises|Controlled group: Group B will perform Balance Training Exercises for 12 weeks of three sessions per week. BT included exercises such as a single-leg stance with eyes open and closed, standing on heels or toes, tandem and semi-tandem foot stance, tandem walking, walking backward and forward, and weight shifting.
223920916|NCT06747286|OTHER|Virtual Game Simulation|A virtual computer game that enables participation in a clinical scenario to measure competence.
223920917|NCT06048783|BEHAVIORAL|Program of systematic and periodic spiritual accompaniment and care|Systematic and periodic spiritual accompaniment and care
224279301|NCT03956602|OTHER|Mixed nuts|To examine postprandial responses of mixed nut consumption
224279302|NCT03956602|OTHER|White bread|To examine postprandial responses of white bread consumption
224279303|NCT03956602|OTHER|Dried mango|To examine postprandial responses of dried mango consumption
224279304|NCT03956602|OTHER|Mango fruit|To examine postprandial responses of fresh mango consumption
224279305|NCT00809965|DRUG|Rivaroxaban 2.5 mg|One tablet twice daily
224279306|NCT00809965|DRUG|Rivaroxaban 5 mg|One tablet twice daily
223717217|NCT05937542|BEHAVIORAL|Qualitative Investigation of Participant Experiences|There is no intervention. This is a retrospective qualitative study.
223920918|NCT06831318|BEHAVIORAL|Community Health Worker (CHW) Guided Support|"The CHW conducts a family assessment, which identifies caregiving stressors, social support, and needs as related to social determinants of health, dementia education, care navigation, caregiver health and burden. Closer to discharge, dyads receive an individualized dementia caregiving toolkit including the post-discharge care planning checklist, tracking sheets for patient medications, tests, and procedures, and info on local resources. All meetings will be done in person, telephone, or zoom.~Within one week of discharge, the CHW meets the dyad via phone or Zoom to review their goals and to identify any additional needs for coaching, education, or navigation support. In the first month after discharge, the CHW provides weekly or bi-weekly check-ins. For the next two months, the CHW provides about four additional bi-weekly check-in sessions. Each check-in session will last approximately 30-45 minutes. The exact number of meetings will be determined by need and caregiver availability"
223920919|NCT06758557|DRUG|HB0025|HB0025 IV every 3 weeks (q3w)
223920920|NCT06758557|DRUG|Pemetrexed|500 mg/m² iv d1
223920921|NCT06758557|DRUG|Paclitaxel|175 mg/m² iv d1
223920922|NCT06758557|DRUG|Carboplatin|AUC 5 iv d1
224279307|NCT00809965|DRUG|Placebo|One placebo tablet twice daily
224279308|NCT00809965|DRUG|Standard of care|
224279309|NCT01726114|DEVICE|Non-invasive Optical Glucose Monitor™|Test device
224279310|NCT01726114|DEVICE|YSI blood glucose analyzer|Reference device
224279311|NCT05794724|PROCEDURE|Surgical resection|Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
224279312|NCT05653635|RADIATION|Simultaneous-integrated boost with IMRT|Simultaneous-integrated boost guided by FDOPA-PET
224279313|NCT03471208|DEVICE|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
224279314|NCT03471208|PROCEDURE|Freehand Implant Surgery|Dental implant surgery via conventional freehand
224279315|NCT05712642|DRUG|Intravitreal Bevacizumab|Serum systemic level of VEGF was measured before and after 1 week and 4 weeks of intravitreal injection of bevacizumab
224279316|NCT02459041|OTHER|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
224279317|NCT02404519|DIETARY_SUPPLEMENT|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
224279318|NCT02404519|DIETARY_SUPPLEMENT|Placebo|1 tablet without MK-7 taken orally every day during 1 year
223920923|NCT06757101|OTHER|Vojta Therapy|Exercises will be performed in supine, lateral, decubitus and reflex crawling. Exercises will include Stretching's, ROMs Exercises, Stimulation of 10 different zones for locomotion \& gentle pressure applied to stimulation areas. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
223920924|NCT06757101|OTHER|Bobath Therapy|Exercises will be performed in supine, lateral, prone and standing position. Exercises includes stretching Exercises, ROMs, Quadruped imbalance exercise, Imbalance from the kneeling exercise, Cervant Knight exercise, Tandem walk, Kicking a ball, Step climbing, marching at one place with alternate foot Frequency of exercises will be 2 times a week, duration 40 minutes per day.
223920925|NCT06757101|OTHER|Combined Vojta and Bobath Therapy|Combined Vojta and Bobath exercises along with the conventional treatment. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
223920926|NCT06761989|DRUG|Intrathecal morphine injection|A single dose of intrathecal morphine is administered prior to induction of general anesthesia. The patient is placed in the lateral decubitus position on the bed and a 25 guage quincke spinal needle is inserted intrathecally at the L4/5 median or paramedian approach to administer 0.2 mg of morphine.
223920927|NCT06761989|DEVICE|Continuous wound infiltration|Prior to closure of the abdominal wall, a catheter is placed in the preperitoneal space lateral to the surgical incision through the tunneler. The catheter is connected to a prepared infusion pump (275 ml of 0.5% ropivacaine, 4 ml/hr/catheter), and the remaining catheter protruding from the abdomen is secured with a catheterization dressing. The preperitoneal catheter is removed in the afternoon of postoperative day 3.
223920928|NCT05997784|OTHER|Performing lung function tests (spirometry and fraction of exhaled nitric oxide (FeNO))|"Performing lung function tests and FeNO following European Respiratory Society (ERS) standardized guidelines, through the MIR portable spirometer and the NIOX Vero®, respectively.~Spirometry is performed using a portable spirometer. All manoeuvres are performed according to the American Thoracic Society and European Respiratory Society (ATS/ERS) standards.~FeNO test is a quick and non-invasive test that is easy for children to do. To take the test, the child have to blow into a handheld device (NIOX Vero®). More in detail, children are asked to inhale ambient air through a nitrogen oxide scrubber to total lung capacity, and then exhale for 10 seconds. The test results are available right away."
223920929|NCT05997784|OTHER|Filling of standardized questionnaires|"(Baseline, Follow-up, Quality of life and Final) allowing to collect data on sociodemographic characteristics, health outcomes, potential risk factors, lifestyle and living environment.~Health outcomes will consider general health (general status, infections, allergies), respiratory health (asthma symptoms, diagnosis, control, triggers, medications, etc.), perception of health and well-being."
223920930|NCT05997784|OTHER|Using an App on a device|"Children will have to answer a daily questionnaire on cell phone, tablet, computer...), with the help of parents/caregivers.~To encourage children to answer the questions, the questionnaires will be incorporated into a game that will also teach them about environmental challenges and pollutants in Europe.~There will be a general health questionnaire with 3 questions assessed on a Likert scale.~The application will also include 2 questions on respiratory health, with Yes/No answers. If the answer is Yes to one of the questions, the intensity of symptoms will be assessed on a visual analog scale from 0 to 100 (0 almost no symptoms and 100 the most intense symptoms imaginable)."
223920931|NCT05997784|OTHER|Urine sample|On a voluntary basis, a urine sample will be collected, as well.
223920932|NCT05997784|OTHER|Sensors and devices will be used to assess air pollutants in classrooms during the survey|"* Particulate matter (PM) will be assessed with a counter as a well as a remote sensor (Canarin) .~* Volatile Organic Compound (VOCs) with a passive sampler (Radiello).~* Virus and bacteria will be collected with a pump.~The devices will be attached to the classroom wall.~In addition, dust pollution will be assessed by collecting dust with a vacuum cleaner in order to assess phthalates (Dimethyl phthalate, diethyl phthalates, Di(2-ethylhexyl) phthalate)."
223920933|NCT06752200|DEVICE|Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.|Occlusal splints fabricated using a fully digital workflow including the use of a jaw tracking device.
223920934|NCT06752200|DEVICE|Occlusal splints fabricated using a combined digital workflow using a conventional bite technique|upper and lower arches will be scanned intraorally. The bite will be registered at centric by using rubber base bite registration material after patient deprogramming with Lucia jig. Then the bite will be scanned. The splint will be designed and printed in the same workflow as the intervention group.
223920935|NCT05039697|OTHER|oxygen|deliver high flow oxygen (10L/min)
223920936|NCT06814587|DIAGNOSTIC_TEST|Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI)|HP-13C MRI is a metabolic imaging technique that enables real-time assessment of myocardial substrate utilization by tracking the conversion of hyperpolarized \[1-13C\] pyruvate to metabolic intermediates such as bicarbonate and lactate. This imaging modality provides insights into oxidative metabolism and mitochondrial function, facilitating the identification of metabolically active and ischemic myocardial regions in patients with ischemic cardiomyopathy.
224090582|NCT00001087|DRUG|Ritonavir|
224279319|NCT02780167|DRUG|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
224279320|NCT02780167|DRUG|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
224279321|NCT02780167|DRUG|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
224279322|NCT02780167|DRUG|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
224279323|NCT02780167|DRUG|Placebo|Placebo QD for 12 weeks
224279324|NCT05384886|DIAGNOSTIC_TEST|Polymerase chain reaction|Covid-19 genetic material detection from mouth and nose swab
224279325|NCT02336516|DRUG|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
224279326|NCT02336516|DRUG|Placebo (glucose solution 10%)|
224279327|NCT02032355|PROCEDURE|spinal anesthesia|
224279328|NCT05621759|DRUG|Cyclophosphamide|Nitrogen mustard alkylating agent produced by Bristol-Myers Squibb.
223717218|NCT02657915|DRUG|Placebo|Administered as specified in the treatment arm.
223717219|NCT02657915|DRUG|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
223717220|NCT02221791|DIETARY_SUPPLEMENT|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
223920937|NCT06814587|DIAGNOSTIC_TEST|[¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|FDG-PET is a molecular imaging technique used to assess myocardial viability by quantifying glucose uptake in cardiac tissue. This method differentiates viable myocardium, which retains metabolic activity, from non-viable scar tissue. FDG-PET is widely used in ischemic cardiomyopathy for viability assessment to guide revascularization decisions.
223920938|NCT06766773|PROCEDURE|Compound heating strategy|After the surgery begins, a temperature monitoring device (disposable medical temperature sensor provided by the limited company) is inserted into the patient's nasopharynx to record the core temperature, while activating the water blanket and forced air heating system.
223920939|NCT06766773|PROCEDURE|perioperative mandatory warming measures|perioperative mandatory warming measures
224090583|NCT00001087|DRUG|Nelfinavir mesylate|
224279329|NCT05621759|DRUG|Abatacept|Calcineurin-inhibitor produced by Astellas.
224279330|NCT05621759|DRUG|Tacrolimus|Selective T cell co-stimulation modulator produced by Bristol-Myers Squibb.
224279331|NCT01372124|DRUG|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
224090584|NCT00001087|DRUG|Efavirenz|
224090585|NCT00001087|DRUG|Levocarnitine|
224090586|NCT00001087|DRUG|Adefovir dipivoxil|
224090587|NCT00001087|DRUG|Saquinavir|
224090588|NCT00001087|DRUG|Lamivudine|
224090589|NCT00001087|DRUG|Stavudine|
224090590|NCT00001087|DRUG|Zidovudine|
224090591|NCT00001087|DRUG|Zalcitabine|
224090592|NCT00001087|DRUG|Didanosine|
224090593|NCT05135364|DRUG|Camrelizumab|Each infusion is 30 min (not less than 20 min, not more than 60 min), once every 3 weeks
224090594|NCT05135364|DRUG|HAIC|A chemotherapy regimen perfused through the tumor supplying artery, d1-2 administration, perfused every 4 weeks
224090595|NCT05135364|DRUG|TKI|Lenvatinib or Regorafenib
223530662|NCT06149442|OTHER|Dose of ten-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (ten incisions).
223530663|NCT06149442|OTHER|Dose of fifteen-incisions dry needling technique|Once we have assessed the existence of a myofascial trigger point in the levator scapulae muscle, and while the subject is in lateral decubitus on the same side, with a forceps palpation, we apply a rapid in /out dry needling technique (fifteen incisions).
224090596|NCT02427165|DRUG|RPL554|A dual PDE3 and PDE4 inhibitor
224090597|NCT02427165|DRUG|Salbutamol|a beta-2 receptor agonist
224090598|NCT02427165|DRUG|Placebo|RPL554 placebo containing no active ingredients
224090599|NCT01475890|DIETARY_SUPPLEMENT|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
224090600|NCT01475890|DIETARY_SUPPLEMENT|Placebo|Once a day for 12 months.
224090601|NCT06246383|DIETARY_SUPPLEMENT|Q Actin|cucumber extract
224090602|NCT02811744|DRUG|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
224090603|NCT04610099|DEVICE|Banded Sleeve Gastrectomy|banded sleeve gastrectomy
224090604|NCT04610099|DEVICE|Standard SG|Standard SG
224090605|NCT05551130|OTHER|Restoration|Restorations completed with these materials.
224090606|NCT02285829|DRUG|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
224090607|NCT03083717|DIAGNOSTIC_TEST|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
224090608|NCT02072629|OTHER|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
224090609|NCT01975103|PROCEDURE|Topcon Endpoint Management|
224090610|NCT00146692|BEHAVIORAL|Free medical treatment|
224090611|NCT05723887|BEHAVIORAL|Attachment-Based Intervention Program|Attachment-Based Intervention Program
224090612|NCT03780998|DRUG|Life7|Life7 will used on the perianal skin with finger tips
224090613|NCT03661684|DRUG|Prednisone|40 mg po q day of Prednisone for 3 days
224090614|NCT02368470|DRUG|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
224279332|NCT05754424|DRUG|AT278|Concentrated rapid acting insulin aspart
224279333|NCT05754424|DRUG|NovoRapid|Rapid-acting insulin aspart
224279334|NCT05754424|DRUG|Humulin R 500 UNT/ML Injectable Solution|Regular human insulin
223920940|NCT06862687|OTHER|Cooling Spray|"A cooling spray containing propan-butane-pentane was applied 25 cm from the cannulation site until mild whitening/frosting appeared.~The standard AVF cannulation procedure was performed. Pain levels were measured immediately after the procedure using VAS."
223920941|NCT06862687|OTHER|Cold Aloe Vera Gel Application|1 ml of cold aloe vera gel was applied to a 5x5 cm area over the fistula site. The standard AVF cannulation procedure was conducted. Pain levels were assessed post-procedure using VAS.
223920942|NCT06862687|OTHER|Standard Procedure (Control Condition)|"No additional pain-relief intervention was applied. The nurse performed the standard AVF cannulation procedure, including hand hygiene, thrill assessment, and site disinfection.~Pain levels were assessed immediately after cannulation using the Visual Analog Scale (VAS)."
223920943|NCT06742814|DEVICE|stress ball|Stress ball: It is a ball with moderate hardness and softness, about 6 cm, which can be held and pressed by hand.
223920944|NCT06835582|DRUG|Methadone|Comparing methadone point of care test to LC-MS to evalutate methadone and its metabolite levels pre dosing and after dosing using the patient's current methadone prescription.
223920945|NCT06840145|DEVICE|repetitive transcranial magnetic stimulation|Intermittent theta Burst stimulation will be performed as detailed in the Real arm description
223920946|NCT05028387|DRUG|medical abortion|medical abortion
223920947|NCT06836791|PROCEDURE|chemical cautrizating agents to stop epistaxis|All procedures were performed as office-based procedures under the influence of local anesthesia.Patients were treated with chemical cauterization. Prior to cauterization, 2 cotton packs soaked in 10% lignocaine spray were introduced into each nostril for 5-10 minutes. Then, a cotton-tipped applicator dipped in chemical cautrizating agents solution was applied to the bleeding point, and the sample was firmly pressed for 1 minute. In the case of bleeding, a second application of chemical cautrizating agents solution was applied to the area, after which a cotton tip applicator was applied to the area for 30 s with cauterization of all the feeding blood vessels around the bleeding point. This was followed by the prescription of an antiseptic soothing cream topically twice daily for 2 weeks.
223920948|NCT06836791|DRUG|Silver Nitrate|silver nitrate is chemical cautrizing agent ,in the study ,the investigators use it in treatment of anterior epistaxis in children by dissolving silver nitrate crystals in normal saline solution before using.
223920949|NCT06836791|DRUG|Trichloroacetic Acid Topical|trichloroacetic acid is well known peeling agent ,in the study the investigators use it as chemical cautrizing agent to treat anterior epistaxis in children .
223920950|NCT06857084|DEVICE|Arthroscopic rotator cuff repair with REGENETEN Bioinductive Implant augmentation|Arthroscopic rotator cuff repair aims at repairing the rotator cuff following tendon tear. The REGENETEN Bioinductive Implant is a medical device intended for the management and protection of tendon injuries. The REGENETEN Bioinductive Implant is indicated for the management and protection of rotator cuff tendon injuries in which there has been no substantial loss of tendon tissue.
223920951|NCT06822621|OTHER|Control|Dietary intervention with common white wheat bread in mildly hypecholesterolemic subjects following a hypocaloric diet.
223530664|NCT05510908|OTHER|Non-Interventional|Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
223530665|NCT05510908|OTHER|Non-Interventional Follow-up|Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
223530666|NCT06650631|DEVICE|Knee Heatwraps|To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
223920952|NCT06822621|OTHER|Intervention|Dietary intervention with white wheat bread enriched with oat beta-glucans in mildly hypecholesterolemic subjects following a hypocaloric diet.
223920953|NCT06887790|OTHER|Education method (ARCS)|The control group will not be intervened in the study. The experimental group will be given structured training with the ARCS method.
223920954|NCT02129244|OTHER|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~1. Assuring effective, efficient clinical care and self-management support~2. Promoting clinical care consistent with scientific evidence and patient preferences~3. Organizing data to facilitate efficient, effective care~4. Empowering and preparing patients to manage their health and health-care needs~5. Mobilizing community resources to meet the needs of patients"
223920955|NCT05486585|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
223920956|NCT05778591|DRUG|Placebo|Placebo.
223920957|NCT05778591|DRUG|Buprenorphine 0.15 MG [Belbuca]|Buprenorphine
223920958|NCT02620852|OTHER|Complete a health questionnaire|Complete a health history questionnaire.
223920959|NCT02620852|DEVICE|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
223920960|NCT02620852|OTHER|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
223920961|NCT02620852|OTHER|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
223920962|NCT03698669|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
223920963|NCT03698669|BEHAVIORAL|Health Education (HE)|Participants randomized to the control HE condition are offered six telephone sessions led by the Behavioral Health Specialists. The first health session is around nutrition. At the remaining sessions, participants choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
224090615|NCT02368470|DRUG|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
224090616|NCT01771783|DRUG|ACEI-ARB-RI|
224090617|NCT01771783|DRUG|ARB-RI-ACEI|
224090618|NCT01771783|DRUG|RI-ACEI-ARB|
224090619|NCT03509506|BEHAVIORAL|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
224090620|NCT04305392|DRUG|SHR4640|orally SHR4640
224090621|NCT05092607|DIAGNOSTIC_TEST|Venous and Capillary blood sampling|"Venous sample at the bend of the elbow (7mL) taken immediately after the nasopharyngeal sample.~Capillary blood sampling, for patients included in participating centers"
224090622|NCT02612909|BIOLOGICAL|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
224090623|NCT02612909|BIOLOGICAL|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
223920964|NCT01564056|DRUG|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
223920965|NCT01564056|DRUG|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~* Docetaxel 75 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~* Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin \[Myocet®\]+ cyclophosphamide)~* Myocet® 60 mg/m² IV infusion at hospital every 21 days~* Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
224090624|NCT05090956|OTHER|mri|
224090625|NCT02071940|DRUG|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
224090626|NCT01895530|DIETARY_SUPPLEMENT|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
224090627|NCT05773456|OTHER|Sushi and wakame salad|One serving of mixed sushi and wakame salad
224090628|NCT02570451|OTHER|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
224090629|NCT02570451|OTHER|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
224090630|NCT02570451|OTHER|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
224090631|NCT02570451|OTHER|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
224090632|NCT02570451|OTHER|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
224090633|NCT02570451|OTHER|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
224090634|NCT02570451|OTHER|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
224090635|NCT02570451|OTHER|Grip Strength|Measured using the JAMAR dynamometer
224090636|NCT02012010|PROCEDURE|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
224090637|NCT02012010|PROCEDURE|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
223530667|NCT04695080|DRUG|Cladribine (MAVENCLAD®)|"Cladribine (MAVENCLAD®) 3.5mg/kg, administered as weight-adjusted 10mg tablets in two treatment courses (12 months apart) lasting 8- 10 days each.~Cladribine (MAVENCLAD®) 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
223530668|NCT04695080|DRUG|Placebo|"Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets."
223530669|NCT05815134|BIOLOGICAL|blood sample|10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
223920966|NCT04879342|BEHAVIORAL|VIP Program|This intervention will engage the participants with psychoeducational material once a week. This material will include didactic instruction as well as participant engagement in developmentally appropriate activities.
224279335|NCT02582918|BEHAVIORAL|Outreach with patient education and patient navigation services|"* Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
223920967|NCT06087237|DRUG|Pentoxifylline|"Two 400 mg extended-release pentoxifylline oral tablets are administered 2 hours before surgery, then one tablet three times per day after surgery, and continued for four weeks after the surgery.~Standard of care for pain management, including paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours."
223920968|NCT06087237|DRUG|paracetamol +ketorolac|"Patients receive the usual treatment only:~paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours"
223920969|NCT01134172|BEHAVIORAL|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
223920970|NCT01134172|BEHAVIORAL|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. All three follow-up contact methods (email, postcard, call) contain the same question regarding current employment status with minor modifications in formatting. However, the employment question asked in all three follow-up contact methods is shown in the Postcard\_Template document. Due to the recent COVID-19 pandemic study staff will be working from home. Therefore, calls will be made via MSK-approved platforms (e.g. Jabber, etc.). Participants who express concerns or request assistance related to COVID-19 will be referred to publicly available resources as needed (e.g., call 311 for access to health care or food panties, etc.) and will be noted in internal tracking logs. The data collected for these internal tracking logs will be managed through a REDCap database.
223920971|NCT04522544|DRUG|Tremelimumab|300 mg Tremelimumab C1D1
223920972|NCT04522544|DRUG|Durvalumab|1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles)
223920973|NCT04522544|PROCEDURE|Y-90 SIRT|Locoregional therapy will be performed as a standard-of-care procedure
223920974|NCT04522544|PROCEDURE|DEB-TACE|Locoregional therapy will be performed as a standard-of-care procedure
224279336|NCT01685593|DEVICE|abdominal binder|
224279337|NCT01685593|OTHER|no binder|
224279338|NCT02315066|DRUG|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
224279339|NCT02315066|DRUG|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
224279340|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
224279341|NCT02315066|DRUG|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
223920975|NCT06550986|DEVICE|False Lumen Embolization System, IMPEDE-FX RapidFill|Embolization of the false lumen of an aortic dissection
223920976|NCT06208813|DIETARY_SUPPLEMENT|Creatine|Creatine supplementation
223920977|NCT04109365|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
223920978|NCT05020353|DEVICE|OraQuick® HIV Self-Test|OraQuick® HIV Self-Test in oral fluid conducted by observed intended users (non-healthcare professional and inexperienced in HIV self-testing) compared to laboratory 4th generation Ag/Ab enzyme immunoassay (EIA) results performed on venous blood.
223920979|NCT05536414|DRUG|Centanafadine|capsule
223920980|NCT05536414|DRUG|Escitalopram|capsule
223920981|NCT05536414|DRUG|Placebo|capsule
223920982|NCT04945473|PROCEDURE|Endoscopic placement of additional sutures|A new endoscopic suture will be performed in case of a BMI≥30 or total weight loss (TBWL) less than 10%, and relaxation of gastric tubulization during the regular endoscopic follow-up after 6 months from the ESG. The same endoscopic suture technique of the primary ESG will be applied.
223920983|NCT06497010|DRUG|Biological: PD-1|Intravenous (IV) infusion
223920984|NCT06497010|DRUG|Biological: InnoPCV|Intramuscular (IM) injection
223530670|NCT02077621|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
223530671|NCT02077621|DRUG|Placebo|500 mL normal saline
223530672|NCT05713565|DEVICE|A digital care solution for patients with Coronary Artery Disease|A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
223717221|NCT02221791|DIETARY_SUPPLEMENT|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
223717222|NCT02221791|DIETARY_SUPPLEMENT|Placebo|Participants will consume 70g white chocolate + placebo capsules
224279342|NCT04413734|DRUG|Combination therapy|Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin
224279343|NCT04413734|DRUG|Mono-chemotherapy|Gemcitabine plus Cisplatin by intravenous infusion
224279344|NCT06067451|BEHAVIORAL|SMART GOALS Setting Tool/ Protocol|The participants randomized to the study group will receive the SGSP, consisting of the SMART Goal Selection Guide (SGSG) and Weekly Goal Monitoring Tool (WGMT), which will be used in tandem. The participant will first receive the SGSG which will highlight 3 domains of SMART goals (exercise, diet, and behavior). Each domain will have 1 predetermined and unchanging primary goal which will serve as the standard for all participants to strive for.
223530673|NCT05713565|OTHER|Standard of care for patients with Coronary Artery Disease|Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
223530674|NCT03330847|DRUG|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
223530675|NCT03330847|DRUG|Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
223530676|NCT03330847|DRUG|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
223717223|NCT04568733|BEHAVIORAL|Pilates exercise session|The Pilates session will consist of warm-up exercises (e.g. breathing, arm circle, cat and camel spinal rotation etc.) and basic mat exercises (e.g. one leg stretching, double leg stretching, the hundred, saw, rolling like a ball, swimming, pelvic curl etc.). The Pilates session will be presented to the participants via pre-recorded video.
223717224|NCT04568733|BEHAVIORAL|Treadmill walking at 3.2 kph|Participants will walk on a treadmill at 3.2 kph (2 mph) speed for 10 minutes.
224279345|NCT01699529|DEVICE|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
224279346|NCT02848066|PROCEDURE|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
224279347|NCT05009368|DRUG|Drug: Treatment A|CTL0901, single dose, daily, repeated oral administration for 4 days
224279348|NCT05009368|DRUG|Drug: Treatment B|CTL0902, single dose, daily, repeated oral administration for 7 days
224279349|NCT05009368|DRUG|Drug: Treatment C|CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
223530677|NCT00780299|DEVICE|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
223530678|NCT00780299|PROCEDURE|CVVH|hemofiltration intermittent dialysis
223530679|NCT06232044|DRUG|Iberdomide|Receive PO
223717225|NCT04568733|BEHAVIORAL|Treadmill walking at 4.8 kph|Participants will walk on a treadmill at 4.8 kph (2 mph) speed for 10 minutes.
224279350|NCT04549922|DRUG|ISIS 721744|1.2 mL of ISIS 721744 subcutaneous once after randomization
224279351|NCT04549922|DRUG|Normal Saline|1.2 mL subcutaneous
224279352|NCT03180801|BIOLOGICAL|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
224279353|NCT03180801|BIOLOGICAL|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
224279354|NCT03180801|OTHER|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
224279355|NCT02715219|OTHER|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
223530680|NCT06232044|BIOLOGICAL|Belantamab Mafodotin|Receive IV
223530681|NCT06232044|DRUG|Dexamethasone|Receive PO
223717226|NCT01297712|DEVICE|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
223717227|NCT01695902|DRUG|Levosert-20|
223717228|NCT01695902|DRUG|Mirena|
223717229|NCT03384212|DRUG|Cladribine|
223717230|NCT03384212|DRUG|Fludarabine|
223920985|NCT05937854|DRUG|Tadalafil|one or 2 encapsulated tablets of encapsulated tadalafil (20MG) po QD
223717231|NCT03384212|DRUG|Busulfan|
223920986|NCT05937854|DRUG|Placebo|one or two encapsulated tablets of placebo po QD
223530682|NCT06232044|PROCEDURE|Echocardiography|Undergo ECHO
223920987|NCT06206759|DRUG|administration of vitamin C|administration of vitamin C to ICU patients
223920988|NCT06462651|DIETARY_SUPPLEMENT|L. reuteri|Supplementation with drops containing L. reuteri once daily for 21 consecutive days
223920989|NCT06462651|DIETARY_SUPPLEMENT|Placebo|Supplementation with identical drops without L. reuteri once daily for 21 consecutive days
223920990|NCT00640978|DRUG|RAD001|30 mg orally weekly for 4 weeks
223920991|NCT00640978|DRUG|Erlotinib|150 mg by mouth daily for 28 Days
223920992|NCT05543512|DEVICE|Algorithm to diagnose food allergens|An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
223920993|NCT05543512|OTHER|Sham diet|Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
224090638|NCT01947270|OTHER|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~* Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~* Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
223920994|NCT06212583|DRUG|niraparib/abiraterone acetate|Patients on Arm 2 to receive drug for 6 months
224090639|NCT04710108|OTHER|Health Communication|Spoken word poem set to video images performed by author. Comic book was transformed from the video that was equivalent in content to the video.
224090640|NCT01901224|DRUG|Metformin 1000 mg|
224090641|NCT01901224|DRUG|Placebo|
224090642|NCT00241267|DEVICE|Dedicated ultrasonographic probe during bronchoscopy|
224279356|NCT04403217|OTHER|Individualized structured dietary plan based on MD|Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
224279357|NCT06206603|DIAGNOSTIC_TEST|Intestinal biopsies|Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
224279358|NCT06206603|DIAGNOSTIC_TEST|Blood sample|A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
223920995|NCT06212583|RADIATION|Stereotactic ablative radiation therapy (SABR)|Both arms will receive SABR
223920996|NCT06212583|DRUG|Androgen deprivation therapy (ADT)|All ADT is provided as best prescribed for patient per their medical oncologist.
223920997|NCT05968144|BEHAVIORAL|Dietary recommendations|One-on-one meeting with a nutritionist to discuss and personalize dietary recommendations for patients with prostate cancer undergoing ADT.
223530683|NCT06232044|PROCEDURE|Computed Tomography|Undergo CT
223530684|NCT06232044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223530685|NCT06232044|PROCEDURE|Positron Emission Tomography|Undergo PET
223530686|NCT06232044|PROCEDURE|Bone Marrow Biopsy|Undergo Bone Marrow Biopsy
223530687|NCT06232044|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspirate
223530688|NCT06232044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223530689|NCT06646679|OTHER|Ultrasonic imaging|Ultrasonic imaging
223530690|NCT01355627|PROCEDURE|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
223530691|NCT01355627|PROCEDURE|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
223530692|NCT05329831|BEHAVIORAL|Structured training using telehealth|The intervention is based on self-care activities. Self-care states that people have an innate ability to take care of themselves.
223920998|NCT05968144|BEHAVIORAL|Time-restricted eating|12 weeks of time-restricted eating (10-hour window)
223920999|NCT05147597|OTHER|Questionnaire|"Cases diagnosed with Idiopathic pulmonary fibrosis (IPF) in the chest diseases outpatient clinic will be informed about the study, and the informed consent form will be signed by the specialist physician and demographic information will be obtained from the cases who accepted to be included in the study.~The surveys will be contacted by the patient at 1-week intervals and answered by the patient by the responsible researcher and chest diseases physician."
224090643|NCT04967690|DRUG|SI-053|SI-053 will be used as an add-on to SoC for newly diagnosed GBM.In conjunction with surgical resection, SI-053 will be applied intracranially (i.c.) into the cavity that is formed after tumor resection. Post-operative chemoradiotherapy (including concomitant and adjuvant TMZ or following the CeTeG protocol) will be initiated at least 21 and no later than 35 days after SI-053 administration.
224090644|NCT00566306|OTHER|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
224090645|NCT06372925|DRUG|atorvastatin|20mg atorvastatin PO
224090646|NCT06372925|PROCEDURE|IVUS/OCT|performed the IVUS/OCT at baseline and Day 360
223530693|NCT01589640|OTHER|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
223530694|NCT01589640|OTHER|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
223530695|NCT01589640|OTHER|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
224090647|NCT06372925|DRUG|inclisiran|Inclisiran 284mg SC
224090648|NCT05704114|DRUG|Tazarotene 0.045% Lotion|Daily topical use of tazarotene for 16 weeks.
224090649|NCT03902080|DRUG|Vibegron|oral administration
224090650|NCT03902080|DRUG|Placebo|oral administration
223530696|NCT04614714|DRUG|Nicotinamide riboside chloride|Nicotinamide riboside chloride 250 mg capsules, administered once per day (Day 1-7 or Day 11-17)
223530697|NCT04614714|DRUG|Placebo|Maltodextrin placebo, administered once per day (Day 1-7 or Day 11-17)
223530698|NCT03532256|BEHAVIORAL|Observation|Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
223530699|NCT03532256|BEHAVIORAL|Text to online survey|Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
223921000|NCT03998657|DEVICE|Exablate Prostate Treatment|The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
223921001|NCT06288906|OTHER|mechanical thrombectomy of caval and iliofemoral veins|investigate efficacy, safety of mechanical thrombectomy systems used in symptomatic acute and subacute ileofemoral and caval thrombosis
223921002|NCT03357757|DRUG|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
223921003|NCT03357757|BIOLOGICAL|Avelumab|10 mg/kg IV
223921004|NCT06024642|DRUG|V117957|V117957 1 mg - 1 tablet taken orally at bedtime.
224090651|NCT02312570|DEVICE|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
224090652|NCT02312570|OTHER|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
224090653|NCT05571683|OTHER|oxygen support|40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
224090654|NCT04444245|PROCEDURE|lipoaspiration harvest tSVF|Use of disposable, sterile microcannula lipoharvest to acquire tSVF
223530700|NCT03532256|BEHAVIORAL|Bi-directional text script|Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
223530701|NCT02293551|DRUG|Lispro|Administered SC
223530702|NCT05967299|OTHER|Placebo Cohort 1 (1.5 mg/kg/dose) only|30mg/ml Sucrose
223530703|NCT05967299|DRUG|ZMA001 (BC-NKA-20008)|ZMA001 is a fully human, monoclonal antibody (IgG1) that inhibits migration of activated monocytes and macrophages and reduces pulmonary vascular remodeling and pulmonary artery pressure in pre-clinical rodent models of pulmonary arterial hypertension (PAH).
223530704|NCT02748798|DRUG|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
223530705|NCT02748798|DRUG|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
223530706|NCT02748798|DRUG|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
223530707|NCT02748798|DRUG|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
223530708|NCT02748798|DEVICE|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
223530709|NCT02748798|DEVICE|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
223530710|NCT02748798|DEVICE|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
223717232|NCT03384212|DRUG|Cytarabine|
223921005|NCT06024642|DRUG|Placebo|Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
223921006|NCT03785574|OTHER|Follow up|the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
223921007|NCT03785574|DRUG|chemotherapy|First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
223921008|NCT06525363|DRUG|Chitosan|chitosan nanoparticles 1%w/w will be formulated in form of spray for oral application twice daily
223921009|NCT02111538|OTHER|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
223921010|NCT06193083|OTHER|Semi-directed individual interviews|Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)
223940714|NCT06996678|BEHAVIORAL|virtual Reality|Virtual Reality: The virtual reality system consists of a camera, television, Eye Toy Play CD and Play Station 2. It is based on the principle of capturing movements represented in a virtual environment (Gatica and Méndez, 2014). In the Eye Toy system, individuals can see themselves on the screen through the camera. In this way, the person constantly interacts with the movements and challenges brought by video games. We can simply call the Eye Toy system a webcam with a motion sensor and microphone. The individual's position in the game is determined on the screen and can perceive the person according to the movements he/she exhibits. The main skills required by the games are; target-based movement, visuomotor skills, praxis and thinking process skills.
224090655|NCT04444245|PROCEDURE|Platelet Rich Plasma|Standard venipuncture, concentration of PRP in FDA approved device (Emcyte II)
223717233|NCT01703039|DRUG|Riluzole|
223717234|NCT01703039|DRUG|Sertraline|
223717235|NCT01703039|OTHER|placebo|
223717236|NCT02512588|DRUG|BTD-001|
223717237|NCT02512588|DRUG|Placebo|
223717238|NCT02091934|PROCEDURE|Wavefront-guided PRK|Wavefront-guided PRK
223717239|NCT02091934|PROCEDURE|Wavefront-optimized PRK|Wavefront-optimized PRK
224090656|NCT04444245|PROCEDURE|Endovaginal Ultrasound|Endovaginal Ultrasound guidance to intra-ovarian placement, bilaterally
224090657|NCT04444245|DEVICE|Cellular Isolation cSVF|Digestion of tSVF with Liberase, isolation \& concentration of cSVF in Centricyte 1000
224090658|NCT04444245|DRUG|Normal Saline (NS) .9% 10 mL Injection|10 cc Sterile Normal Saline for Injection
224090659|NCT04444245|DEVICE|emulsification tSVF|Harvested tSVF emulsification with sterile, disposable Nanofat screen device
224090660|NCT00286052|DRUG|Low Dose Naloxone|
224090661|NCT03737656|DRUG|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
223530711|NCT02992210|GENETIC|4SCAR-GD2|GD2-specific 4th Generation CART
223921011|NCT06193083|OTHER|The self-administered questionnaires, rPATD and BMQ|"rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.~This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal). Following the analysis of Phase 1 Qualitative of the protocol, three additional questions~BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .~The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.~It comprises 10 items relating to specific beliefs about prescribed treatments:~A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief."
223530712|NCT01933152|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
223717240|NCT04554979|DRUG|Hydroxychloroquine Pill|hydroxychloroquine 400 mg twice daily first day and maintained on 200 mg twice daily for 6 days in mild cases and 10 days in moderate cases. Also they received anticoagulants, vitamin c and zinc. In case of secondary bacterial infection, empiric antibiotics are started
223921012|NCT06193083|OTHER|The self-administered FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale)|"FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )~Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :~Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations"
223921013|NCT05067348|DRUG|Tocilizumab Injectable Product|Participants will receive IV tocilizumab
223921014|NCT06184880|BEHAVIORAL|behavioral|International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,
223921015|NCT06184880|OTHER|Sedentary|Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
223921016|NCT05448014|BEHAVIORAL|Compassion focused group therapy online|Seven sessions of therapist-led online compassion-focused therapy in groups of 4-8 adolescents with mild to moderate symptoms of distress, anxiety, or depression. Trained therapists administer the CFT program in face-to-face meetings.
223921017|NCT05425355|DRUG|Intravenous (IV) acetaminophen + oral placebo|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
223921018|NCT05425355|DRUG|Intravenous (IV) placebo plus oral acetaminophen|Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen
224090662|NCT01583426|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
224090663|NCT01583426|DRUG|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
224279359|NCT04735068|DRUG|Binimetinib Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
224279360|NCT04735068|DRUG|Hydroxychloroquine Pill|Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
223530713|NCT04532749|DRUG|Seltorexant|Participants will receive Seltorexant tablets.
223530714|NCT04532749|DRUG|Placebo|Participants will receive matching placebo tablets.
223530715|NCT01075672|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
223717241|NCT01205711|DRUG|FOLFIRI regimen|
223717242|NCT01205711|DRUG|fluorouracil|
223717243|NCT01205711|DRUG|irinotecan hydrochloride|
223921019|NCT02354547|GENETIC|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
223921020|NCT02354547|DRUG|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
224090664|NCT06053021|DRUG|aspirin, clopidogrel, cilostazol, and dipyridamole|Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
224279361|NCT02772094|BIOLOGICAL|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
224279362|NCT00112294|DRUG|Paclitaxel (Taxane)|IV, 225 mg/m\^2
224279363|NCT00112294|DRUG|Docetaxel (Taxane)|IV, 75 mg/m\^2
224279364|NCT00112294|DRUG|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
224279365|NCT00112294|DRUG|Cetuximab|Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
224279366|NCT05418816|DEVICE|SelfWrap Bioabsorbable Perivascular Wrap|SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
224279367|NCT05883787|OTHER|Exploration of a database|extraction of data
224279368|NCT04202094|DIAGNOSTIC_TEST|Physical examination|A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
223921021|NCT02354547|DRUG|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
223940715|NCT06996678|BEHAVIORAL|occupational therapy|Occupational Therapy: The basis of OT intervention consisted of activities requiring increased attention, behavioral regulation, organizational skills, multiple cognitive skills, and motor skills
223940716|NCT05598931|DEVICE|Transcranial Magnetic Stimulation|Subjects will participate in an on-line neuro-navigation session in which 6 TMS coil positions will be recorded.
223940717|NCT04981119|OTHER|Apheresis|Apheresis procedure performed for collection of PBMCs.
223940718|NCT04981119|DIAGNOSTIC_TEST|Next Generation Sequencing (NGS)|NGS on tumor tissue and a matched normal sample for loss of heterozygosity in tumor tissue and tumor tissue markers.
224279369|NCT04202094|DIAGNOSTIC_TEST|Scrotum ultrasound|A scrotum ultrasound to measure the patients' testicular volume and to investigate potential abnormalities in the testicular parenchyma.
224279370|NCT04202094|DIAGNOSTIC_TEST|Blood sample|A morning blood sample to evaluate the serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone (T), estradiol (E2), inhibin B (INHB), thyroid-stimulating hormone (TSH), free thyroxine (FT4), insulin-like growth factor 1 (IGF1), prolactin (PRL), cortisol and adrenocorticotropic hormone (ACTH). Upon approval by the patient himself, a spare blood sample will be collected and retained for 5 years for subsequent research purposes limited to the context of the present study.
223940719|NCT04981119|DIAGNOSTIC_TEST|Long Range NGS HLA typing|Long range NGS on whole blood to determine germline HLA type.
223940720|NCT07000279|DEVICE|Assistive exoskeleton for activities of daily living (ADLs)|Portable assistive exoskeleton to support upper limb movement during activities of daily living
223940721|NCT07000279|DEVICE|Assistive exoskeleton for box and block|Portable assistive exoskeleton to support box and block test execution
223940722|NCT07000279|DEVICE|Assistive exoskeleton for maximum reaching height|Portable assistive exoskeleton to raise the upper limb at the maximum of its capability to reach objects at different heights
223940723|NCT06527040|OTHER|Opioid Transitions Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR) integrated, provider-facing alert suggesting (a) the patient is transitioning to a new phase of opioid therapy and (b) the provider should review patient pain data and pain management goals as suggested by Center for Disease Control and Prevention (CDC) guidelines.
223940724|NCT05821426|DEVICE|eTrieve PE Kit|Patients will be treated with the eTrieve PE Kit
223940725|NCT05435976|DEVICE|CELLIS Dental (Porcine Acellular Dermal Matrix, PADM)|Biological membranes used in dental surgery
223940726|NCT06697197|DRUG|BMS-986482|Specified dose on specified days
223940727|NCT06697197|DRUG|Nivolumab and rHuPH20|Specified dose on specified days
223940728|NCT06697197|DRUG|Nivolumab/relatlimab/rHuPH20|Specified dose on specified days
223940729|NCT06697197|DRUG|Bevacizumab|Specified dose on specified days
223921022|NCT02047500|DRUG|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
223921023|NCT02047500|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
224090665|NCT05861505|DRUG|Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)|"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"
223530716|NCT03161262|BEHAVIORAL|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
223530717|NCT02430714|DRUG|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
223530718|NCT02769481|DRUG|Bexagliflozin|20 mg, tablet
223530719|NCT02769481|DRUG|Placebo for Bexagliflozin|inactive tablet to match active comparator bexagliflozin
224090666|NCT05861505|OTHER|Repeat local treatment|"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."
224090667|NCT03204630|DIETARY_SUPPLEMENT|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
224279371|NCT04202094|DIAGNOSTIC_TEST|Semen analysis|A semen analysis to evaluate ejaculate volume, sperm concentration, sperm motility, and sperm morphology. If sperm is found in the semen sample, an anti-sperm antibody test and a sperm DNA fragmentation test will be performed. Upon approval by the patient himself, the surplus of the semen sample will be retained for 5 years for subsequent research purposes limited to the context of the present study.
224279372|NCT06050200|PROCEDURE|PVE|The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. Embolization is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). After filling the entire volume of the branch of the portal vein, all catheters, guidewires and the vascular sheaths are removed. A dressing is left over the access site and removed the next day. After treatment the patient is given analgesics and antipyretics if necessary.
224279373|NCT06050200|PROCEDURE|LVD|"The procedure is performed under general anesthesia. Ultrasound-guided percutaneous, transhepatic puncture of the branch of the portal vein is performed and a vascular sheath is inserted on the guidewire. A system of catheters and guidewires is inserted through the sheath. A similar puncture of the hepatic vein or veins is then performed; sometimes with access via the internal jugular vein. Embolization of the portal branch is performed using a homogeneous mixture of Glubran 2 glue and Lipiodol (volume ratio 1:8-1:9). Embolization of the right hepatic vein or veins begins with the insertion of a vascular plug (Amplatzer) approx. 2 cm from the confluence of the vein(s). The remaining part of the hepatic vein(s) is then filled with a homogeneous mixture of histacryl glue and Lipiodol (volume ratio 1:1).~A dressing is left over the access site and removed the next day; patient is given analgesics and antipyretics if necessary."
224279374|NCT06050200|PROCEDURE|ALPPS|"The ALPPS procedure will be performed in the operating theatre, under general anesthesia, preferably using a minimally invasive (laparoscopic) technique.~The procedure consists of surgical ligation or clipping of the branch of the portal vein with a vascular clip and in partial transection of the parenchyma at the plane of the future resection planned in the second stage (partial transection, approx. 75% of the transection plane)."
224279375|NCT04550104|RADIATION|Radiotherapy|Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
224279376|NCT04550104|DRUG|Olaparib Oral Tablet [Lynparza]|Oral tablet
224279377|NCT04550104|DRUG|AZD1390|Oral tablet
224279378|NCT04550104|DRUG|Ceralasertib|Oral Tablet
224279379|NCT04550104|DRUG|AZD5305|Oral Tablet
224279380|NCT04550104|DRUG|Durvalumab|1500mg iv infusion
224279381|NCT05252234|OTHER|Observation of hemodynamic status and post operative pain|No intervention
224279382|NCT01142908|BEHAVIORAL|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
224279383|NCT03803254|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
224279384|NCT03803254|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
224279385|NCT03803254|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224279386|NCT03803254|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
224279387|NCT04899492|BEHAVIORAL|Motivational Interviewing (MI)|1 to 3 Motivational Interviewing (MI) should be performed after randomization by a psychotherapist
224279388|NCT04899492|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|6 Cognitive Behavioural Therapy (CBT) sessions should be performed after motivational interviewing up to 6 months by a psychotherapist
223530720|NCT02769481|DRUG|Glimepiride|2, 4 or 6 mg, capsule
223530721|NCT02769481|DRUG|Placebo for Glimepiride|inactive capsules to match active comparator glimepiride
223530722|NCT02496312|BEHAVIORAL|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
223717244|NCT01205711|DRUG|leucovorin calcium|
223921024|NCT02047500|DRUG|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
223530723|NCT02439463|PROCEDURE|Below-knee amputation|Patients with traumatic below-knee amputation.
223530724|NCT01046994|PROCEDURE|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
223921025|NCT05965414|DRUG|CS6253 Solution for Injection|Solution for intra-venous injection, 50mg CS6253 /mL. Single-use vials containing 100 mg CS6253 (2 mL of 50 mg/mL concentration)
223921026|NCT05965414|DRUG|Placebo|Physiological saline solution for intra-venous injection
223921027|NCT06070051|BIOLOGICAL|VRON-0200-AdC6|VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector
223921028|NCT06070051|BIOLOGICAL|VRON-0200-AdC7|VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector
223921029|NCT06070051|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
223921030|NCT06070051|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
223921031|NCT05782374|DRUG|Ibrutinib|ibrutinib alone or in combination with R-CHOP or R-CHOP like
223921032|NCT03174314|BEHAVIORAL|Standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
223921033|NCT03174314|DEVICE|VIS4ION System|"When in Assistive Mode, participants will navigate campus while receiving navigation assistance (acquiring data and simultaneously providing assistance/audio feedback). When in Passive Mode, participants will navigate campus wearing the backpack without receiving navigation assistant."
224090668|NCT03204630|DIETARY_SUPPLEMENT|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
224090669|NCT03204630|OTHER|Control|Standard infant formula
224090670|NCT03115450|DEVICE|Ultrasound|Type of imaging technology to look at organs and structures inside the body
224090671|NCT03115450|DEVICE|Pupilometer|A device that measures pupil size and how it changes.
224090672|NCT04502615|OTHER|Sand|sand surface
224090673|NCT04502615|OTHER|artificial grass|grass surface
224090674|NCT04502615|OTHER|firm ground|firm surface
224090675|NCT05654402|DIAGNOSTIC_TEST|Non-invasive measurement of carotid-femoral transit time by Doppler velocimetry (Athys Medical©) - WAKIe R3 2TC®) (PWV in cm/s)|"* Measurement of the carotid-femoral transit time (ms) (recorded on Data Warehouse Connect).~* Measurement of the distance between the carotid and femoral points with a tape measure (m).~* Calculation of the propagation speed of the wave PWV (expressed in m/s).~For all patients PWV in (m/s=) will be collected over three distinct periods:~* Before induction (awake without premedication)~* During general anesthesia or loco-regional anesthesia~* Upon awakening from general anesthesia or lifting of the loco-regional anaesthesia"
224090676|NCT06488118|DRUG|R848|Inhaled R848 dose ranging from 0.1 to 100 μg/mL
224090677|NCT06488118|DRUG|Saline|Inhaled Saline control
224090678|NCT00662961|PROCEDURE|Periosteum|Periosteum fixation
224090679|NCT00662961|PROCEDURE|Bone|Bone tunnel fixation
224279389|NCT04899492|BEHAVIORAL|Hypnotherapy|About 3 Hypnotherapy sessions should be performed after motivational interviewing up to 6 months by a hypnotherapist
224279390|NCT04899492|DRUG|Nicotine Replacement Therapy (NRT)|All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
223921034|NCT04314544|DRUG|TILD|one 1 mL injection of study medication
223921035|NCT04314544|DRUG|matching placebo injections|one 1 mL injection of placebo
223921036|NCT06435780|PROCEDURE|DIPRF|Denuded interpositional pedicled rolled flap technique
223921037|NCT05963997|DRUG|Samuraciclib|Samuraciclib capsules by mouth once a day
223921038|NCT05963997|DRUG|Elacestrant Dihydrochloride|Elacestrant tablets by mouth once a day
223530725|NCT01046994|DRUG|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
223530726|NCT01838733|OTHER|Observational study|
223530727|NCT00121966|DRUG|Insulin Aspart|
223530728|NCT00121966|DRUG|Insulin NPH|
224090680|NCT02160067|DRUG|Second generation BTDS patch|
224090681|NCT02160067|DRUG|First generation BuTrans patch|
224090682|NCT01172379|DRUG|E2007|"Experimental 1 Drug: E2007~0.5 mg 1 tablet per day"
224090683|NCT01172379|DRUG|E2007|"Experimental 2 Drug: E2007~1.0 mg 1 tablet per day"
224090684|NCT01172379|DRUG|E2007|"Drug: E2007~2.0 mg 1 tablet per day"
224090685|NCT01172379|OTHER|Placebo Comparator|Placebo 1 tablet per day
224090686|NCT02834130|BEHAVIORAL|Evaluation of psychological and psychopathological|
224090687|NCT01191814|PROCEDURE|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
224090688|NCT01191814|PROCEDURE|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
224090689|NCT06008548|PROCEDURE|TACE|
224090690|NCT03246438|BEHAVIORAL|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
224090691|NCT03246438|BEHAVIORAL|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
223921039|NCT03952520|OTHER|Standard Approach (SA)|The multifaceted implementation strategies for SA sites were identified through centralized Intervention Mapping. Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies was determined through a formal process with investigators, government stakeholders, and clinical representatives.
223921040|NCT03952520|OTHER|Tailored Approach (TA)|The Tailored Approach includes the multifaceted strategy that will be offered to the Standard Approach condition. It will also be tailored to match site-specific barriers to implementation of SNaP at that site. The strategy for TA sites involves a 2-day site-specific training, monthly coaching calls, and an external technical assistance hotline to help organizations to tailor implementation strategies to address their site-specific needs. At the 2-day TA training, the TA sites will be guided on developing site-specific implementation plans, in which they may use additional implementation strategies that they have identified themselves or selected from a list developed by the central team.
223921041|NCT03635567|BIOLOGICAL|Pembrolizumab|IV infusion
223921042|NCT03635567|DRUG|Paclitaxel|IV infusion
223921043|NCT03635567|DRUG|Cisplatin|IV infusion
223921044|NCT03635567|DRUG|Carboplatin|IV infusion
223921045|NCT03635567|BIOLOGICAL|Bevacizumab|IV infusion
223921046|NCT03635567|DRUG|Placebo to pembrolizumab|IV infusion
223921047|NCT06563622|PROCEDURE|Pericapsular Nerves Group Block|USG-guided single-shot PENG in a dose of 0.5 ml/kg of 0.25% bupivacaine per side.
223921048|NCT06563622|PROCEDURE|Caudal Epidural Block|USG-guided single-shot CEB in a dose of 0.5 mL/kg of 0.25% bupivacaine.
223921049|NCT05717842|RADIATION|Nuclear Medicine Scan|Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
223921050|NCT05294172|DRUG|KL-A167|KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.
223921051|NCT05294172|DRUG|Gemcitabine|4-6 cycles for combined therapy
223921052|NCT05294172|DRUG|Cisplatin|4-6 cycles for combined therapy.
223921053|NCT05294172|DRUG|Placebo|4-6 cycles for combined therapy.Placebo maintenance.
224279391|NCT01086930|DEVICE|ReJoyce Workstation|The device has two parts. A muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff and an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. As well as a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association.
224279392|NCT01086930|OTHER|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units.
224279393|NCT05291351|OTHER|Crackers made with whole, coarse, or fine pea and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
224279394|NCT05291351|OTHER|Crackers made with whole, coarse, or fine lentil and/or wheat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
224279395|NCT05291351|OTHER|Porridge made with oat flour|Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
224279396|NCT00035555|DRUG|Belatacept|Solution, intravenous
224279397|NCT00035555|DRUG|Cyclosporine|Oral, capsule
224279398|NCT00035555|DRUG|Mycophenolate mofetil (MMF)|Oral, capsule
224279399|NCT00035555|DRUG|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
224279400|NCT03176524|DRUG|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
224279401|NCT03176524|DRUG|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
223921054|NCT06238882|COMBINATION_PRODUCT|Nitroglycerin|Patients in the intervention group will receive four 8mg-patches (36 mg final dose) of transdermal nitroglycerin with 10 mg release in 24 hours, for 24 hours with 12-hour rest intervals (to avoid receptor saturation) during treatment with radiation therapy (30 Gy in 10 fractions, or 10 days of treatment).
223530729|NCT00121966|DRUG|Metformin|
223530730|NCT00121966|DRUG|Rosiglitazone|
223921055|NCT02662907|PROCEDURE|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
223921056|NCT02662907|BEHAVIORAL|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
223921057|NCT02662907|DEVICE|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
223921058|NCT02662907|DEVICE|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
223921059|NCT02662907|BEHAVIORAL|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
223921060|NCT02662907|DRUG|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
223921061|NCT04889417|BEHAVIORAL|Comprehensive training program|The COPE-iOS program is a pragmatic comprehensive training program that combines computerized cognitive training and progressive supervised video conference physical exercise sessions performed 2-4 weeks prior to surgery and for 3 months after discharge.
223921062|NCT04889417|BEHAVIORAL|Active control|The active attention control will include control computer games and supervised video conference stretching exercises performed 2-4 weeks prior to surgery and for 3 months after discharge.
223921063|NCT05712824|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
223921064|NCT06149624|BEHAVIORAL|upfront advice to walk|Control participants will be given upfront advice to walk and also given the wearable activity monitor (Fitbit) and asked to record the total steps achieved each day in a provided log book.
224279402|NCT03176524|DRUG|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
224279403|NCT04601337|PROCEDURE|Infrared Neural Stimulation|We will stimulate nerves identified for transfer or grafting over a range of simulation parameters (pulse width, spot size, energy per unit area, etc) to determine the stimulation threshold. Only portions of the nerve that are no longer functionally required will be stimulated optically. Successful INS events will be determined by visual muscle contractions. Stimulation thresholds will be determined by fitting the data to a cumulative distribution function. Stimulation sites on the nerve will be harvested and histologically examined for evidence of INS-induced damage.
224279404|NCT04027257|BEHAVIORAL|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
224279405|NCT03510338|DRUG|Sublingual sildenafil|100 mg biphasic sildenafil tablet
224279406|NCT03510338|DRUG|Oral sildenafil|50 mg oral sildenafil (Viagra)
224279407|NCT00611650|DRUG|defined green tea catechin extract|Given orally
224279408|NCT00611650|OTHER|placebo|Given orally
224279409|NCT01650155|DRUG|BI 1005273 s.c.|injection
224279410|NCT01650155|DRUG|BI 105273 i.v. Placebo|infusion
224279411|NCT01650155|DRUG|BI 1005273 s.c. Placebo|injection
224279412|NCT01650155|DRUG|BI 1005273 i.v.|infusion
223530731|NCT06265818|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
223530732|NCT06265818|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
223717245|NCT01205711|DRUG|zibotentan|
223921065|NCT06149624|BEHAVIORAL|Supervised exercise|The onsite physiotherapist will also be trained in appropriate supervision and monitoring of exercise therapy in participants with HIV. This training will include titration of the exercise prescription to ensure safe progress is achieved. Participants will be scheduled to come to Mildmay 2 times per week for eight weeks to perform treadmill walking exercise. Intensity will be regulated using 40-60% of heart rate reserve. Additionally, ratings of perceived exertion via the Adult OMNI Walk/Run Scale will be used to guide the intensity of exercise subjectively at a moderate level. The exercise dose participants complete are standard prescriptions for participants with HIV, according to the American College of Sports Medicine.19 The physiotherapist will document the total steps achieved, including the supervised treadmill sessions and activity completed outside the supervised exercise setting (provided by participants via a log book).
223921066|NCT05044975|BEHAVIORAL|Sleep restriction|Participants will receive sleep restriction intervention
223921067|NCT05044975|BEHAVIORAL|Stimulus control|Participants will receive stimulus control intervention
223921068|NCT05044975|BEHAVIORAL|Systematic light exposure|Participants will receive systematic light exposure intervention
223921069|NCT04963803|DEVICE|Active transcranial direct current stimulation (tDCS)|Active transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 20 minutes/session for 10 sessions.
223921070|NCT04963803|DEVICE|Sham transcranial direct current stimulation (tDCS)|Sham transcranial direct current stimulation will be delivered using a Soterix mini-CT device. Participants receiving this treatment will be administered 2 milliamperes (mA) of current for 1 minute to simulate the experience of tDCS, after which the current will be ramped down to zero for the remaining 19 minutes of the session. Participants in this arm will receive sham stimulation for 10 sessions.
224279413|NCT04409054|OTHER|Cough and Valsalva effort|Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
224279414|NCT02011451|DRUG|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
224279415|NCT02011451|DRUG|Placebo Comparator:|
224279416|NCT01316432|DRUG|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
224279417|NCT01316432|OTHER|Placebo|Placebo will be administered as a 24-hour SQ infusion
224279418|NCT03454737|PROCEDURE|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
224279419|NCT03454737|PROCEDURE|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
224279420|NCT03390244|DEVICE|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
224279421|NCT00000317|DRUG|Risperidone|Risperidone (4mg/day)
223921071|NCT04963803|BEHAVIORAL|Language Specific Attention Treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. All study participants will receive 10 sessions of this treatment.
223530733|NCT06548438|PROCEDURE|Transurethral resection of the bladder performed with PDD tecnique and Hexvix|For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
223530734|NCT01653314|DRUG|Megavec|
223530735|NCT01653314|DRUG|Glivec|
223530736|NCT00642759|DRUG|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
223530737|NCT00642759|DRUG|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
223921072|NCT06960759|BEHAVIORAL|Behavioral cough suppression therapy combined with inactive inhaled drug (BCS+Sham)|Behavioral cough suppression therapy plus inactive inhaled drug. Treatment given twice per week for 12 sessions.
223921073|NCT06960759|COMBINATION_PRODUCT|Behavioral cough suppression therapy combined with capsaicin inhalation (BCS+CAP)|Behavioral cough suppression therapy combined with inhaled capsaicin (cough stimulant). Treatment given twice per week for 12 sessions.
223921074|NCT06960759|DRUG|Inhaled capsaicin (CAP)|Repeated inhalation of diluted capsaicin in increasing concentrations. Treatment given twice per week for 12 sessions.
223921075|NCT06237686|DEVICE|CP363|All subjects will test both Test product A and B, with a minimum of 7 days apart. In total, each subject will be enrolled in the investigation for 8 days +3 days.
223921076|NCT05980884|DIETARY_SUPPLEMENT|L-carnitine|Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days.
223921077|NCT05838066|DRUG|Recombinant Humanized Bispecific antibody against HER2，KN026|IV infusion
223921078|NCT05838066|DRUG|HB1801|IV infusion
223921079|NCT05838066|DRUG|Pertuzumab|840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
223921080|NCT05838066|DRUG|Trastuzumab|8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
223921081|NCT05838066|DRUG|Docetaxel|75 mg/m\^2, D1 Q3W, IV infusion
223921082|NCT01880515|DRUG|Tetracycline|The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
224279422|NCT00000317|DRUG|Placebo|Placebo
224279423|NCT00000317|BEHAVIORAL|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
224279424|NCT03058640|OTHER|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
224279425|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
223530738|NCT00642759|DRUG|Bevacizumab|IV infusion
223530739|NCT04614337|DRUG|LUM-201|Administered orally once daily
223530740|NCT04614337|DRUG|rhGH Norditropin® pen (34 µg/kg)|Administered subcutaneously (s.c., under the skin) once daily.
223717246|NCT01205711|OTHER|laboratory biomarker analysis|
223717247|NCT01205711|OTHER|pharmacogenomic studies|
223717248|NCT05570500|BEHAVIORAL|Oral health education|oral health education sessions that aims to improve both knowledge of primary school children regarding bacteria, caries, number of teeth, plaque formation and attitude of primary school children regarding tooth brushing techniques, number of times per day, dietary instructions to avoid dental caries.
223717249|NCT04527705|PROCEDURE|Non-surgical root canal retreatment|Non-surgical root canal retreatment
223717250|NCT00580021|OTHER|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
223717251|NCT04706091|DRUG|Suvorexant|10-mg or 20-mg suvorexant capsules
223717252|NCT04706091|OTHER|Placebo|Matching placebo capsules
223717253|NCT01419691|DRUG|auranofin|6 mg twice a day for a total of 12 mg total daily dose
223717254|NCT00150202|DRUG|pegaptanib sodium|
223717255|NCT04711044|OTHER|Papain|Papain will be applied using cowhage spicules inactivated by heat
223921083|NCT06352840|BEHAVIORAL|My Pelvic Plan Website|This is a self-directed program which integrates patient education about conditions that frequently contribute to pelvic pain, as well as instruction on cognitive and behavioral restructuring, self-administration of acupressure, engaging in physical activity, and a brief introduction to pelvic floor physical therapy techniques. Participants will have open access to the program over the 6-month intervention period. The intervention will be comprised of an active (12-week) phase and a maintenance (3-month) phase. Participants will receive a weekly text or email prompt directing patients to a specific module. All participants will receive prompts to the same modules for the first four weeks of the study, then during the next 8 weeks, participants will receive prompts to modules that corresponded to the most impactful symptoms on participant's baseline questionnaires. Following 12-week active phase, all participants will enter the maintenance phase.
223921084|NCT06352840|BEHAVIORAL|Control Group website|Patients in the control group will undergo an active control intervention in which participants receive open access to a separate website that contains only the Monitoring Progress symptom tracker subpage over the 6-month study period. Control group participation will also be divided into an active (12-week) phase and a maintenance (3-month) phase. Similar to the intervention group, the control group will receive a weekly text (first 12 weeks) or email prompt directing them to a specific module or portion of the respective website. During the maintenance phase of the study, participants will receive monthly prompts to the Monitoring Progress subpage (without prompting to a specific symptom or activity).
224279426|NCT01201694|DRUG|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
223921085|NCT06542419|DEVICE|Brain Cooling|Brain cooling consists of a 30-minute seated period, in a dimly lit, quiet room, while listening to calming natural sounds, during which they will wear an Arctic Cooling Cap V1.30, set at a temperature of 33.0 degrees Fahrenheit. Participants will be asked to remain awake, refrain from observing a screen, and relax to the best of their ability. This brain cooling treatment will occur on 7 consecutive days.
223530741|NCT03742726|DEVICE|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
223921086|NCT06545279|PROCEDURE|Hall Crown Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation.
223921087|NCT06545279|PROCEDURE|Modified Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation but with interproximal slicing.
223921088|NCT06346860|PROCEDURE|Regional Block Comparison|Comparing postoperative pain and opioid consumption in groups
223921089|NCT06447376|DRUG|Siltuximab|Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.
223921090|NCT06447376|DRUG|Epcoritamab|"Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg"
223921091|NCT06241352|DRUG|statin addition to chemotherapy|Chemotherapy was administered along with 80mg of atorvastatin per day. Atorvastatin was discontinued when CA19-9 levels (with CA19-9 negative patients referenced against CEA or CA-125) rose more than 20% above baseline.
223921092|NCT05201352|DRUG|trifluridine/tipiracil + XB2001|trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
224090692|NCT03246438|BEHAVIORAL|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
224090693|NCT01106261|PROCEDURE|Metastasectomy|Pulmonary Metastasectomy
223921093|NCT05201352|DRUG|trifluridine/tipiracil + placebo|trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
223921094|NCT05970562|DEVICE|Ambulatory Voice Monitoring with Biofeedback (AVM-B)|AVM-B is software on the Voice Health Monitor that uses a neck-placed accelerometer to sense neck skin vibrations during voicing in daily life. The AVM-B consists of cues every time the patient exceeds a subject-specific threshold, \[100% frequency AVM-B\] and/or summary statistics every 2 minutes of voicing \[Summary AVM-B\].
223530742|NCT03510715|DRUG|Alirocumab SAR236553 (REGN727)|"Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)"
223530743|NCT03510715|DRUG|Atorvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
223530744|NCT03510715|DRUG|Simvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
223530745|NCT03510715|DRUG|Fluvastatin|"Pharmaceutical form: capsule,~Route of administration: oral"
223921095|NCT05970562|BEHAVIORAL|Conversation Training Therapy|CTT is a 4-week (1 45-minute session per week) evidence-based voice therapy for patients with VH, developed primarily to maximize the amount and speed of generalization outside the therapy session. It consists of 3 required targets: Decreased overall auditory-perceptual voice severity, improved discrimination between baseline and improved voicing, and adherence to CTT recommendations in daily life. The three optional targets are decreased overall auditory-perceptual severity across an increased pitch range, loudness range, and decreased rate of speech. All voice-related targets are modified through practicing voicing with increased forward resonance and mean airflow in spontaneous speech/conversation.
223921096|NCT00550849|DRUG|RTA 402|5 mg oral capsules
223921097|NCT00550849|DRUG|RTA 402|25 mg oral capsules
223921098|NCT00550849|DRUG|RTA 402|50 mg oral capsules
223921099|NCT02271828|PROCEDURE|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
224090694|NCT01106261|PROCEDURE|Active monitoring|Active monitoring
224090695|NCT00432692|PROCEDURE|Falls Prevention Program|
224090696|NCT01474577|OTHER|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
224090697|NCT00391976|DRUG|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
224090698|NCT05305716|OTHER|Online Pilates Training|The group that received telerehabilitation and telerehabilitation-based pilates training.
223530746|NCT03510715|DRUG|Pravastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
223530747|NCT03510715|DRUG|Lovastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
223530748|NCT03510715|DRUG|Rosuvastatin|"Pharmaceutical form: tablet,~Route of administration: oral"
223530749|NCT03510715|DRUG|Ezetimibe|"Pharmaceutical form: tablet,~Route of administration: oral"
223530750|NCT03510715|DRUG|Cholestyramine|"Pharmaceutical form: oral suspension,~Route of administration: oral"
223921100|NCT06500208|DRUG|Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide|Adebrelimab 1200mg i.v. q3w combined with nab-paclitaxel 100mg/m2 qw\*12w followed by epirubicin 90mg/m2 and cyclophosphamide 600mg/m2 q3w for 4 cycles
223921101|NCT04328740|DRUG|TP-1454 monotherapy|Flat dose once or twice daily, alone
224090699|NCT05305716|OTHER|Control group|The group who received breathing and relaxation exercises with a home program.
223921102|NCT06448208|DIAGNOSTIC_TEST|positron emission tomography (PET) scans|Before and after treatment.
223921103|NCT06208371|PROCEDURE|Surgical resection and/or ablation therapy and/or SBRT|Participants may receive surgical resection and/or ablation therapy and/or stereotactic body radiotherapy
223921104|NCT06208371|DRUG|Palliative Chemotherapy|Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
223921105|NCT06644131|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate
223530751|NCT03510715|DRUG|Nicotinic acid|"Pharmaceutical form: tablet,~Route of administration: oral"
223921106|NCT06644131|DIETARY_SUPPLEMENT|Sugar Pill (Placebo)|Placebo - sugar pill
223921107|NCT04422743|DIETARY_SUPPLEMENT|Citicoline 500 mg plus Homotaurine 50 mg|Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy
223921108|NCT04243759|BEHAVIORAL|Control App Version|"The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition)."
223921109|NCT04243759|BEHAVIORAL|Standard App Version|The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.
223921110|NCT04243759|BEHAVIORAL|Experimental, Feedback App Version|The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
224279427|NCT02255487|DEVICE|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
224279428|NCT02255487|OTHER|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) as surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
224279429|NCT02972515|BEHAVIORAL|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
223921111|NCT05280639|DEVICE|Wooden block|Individuals randomized to this group will be given a wooden block at no cost to them and a simplified version of home, self-guided exercises with instructions on how to do the exercises and how often to do so.
223921112|NCT05280639|OTHER|Formal physical therapy or Home Exercise Program|Individuals randomized to this group will receive the standard formal physical therapy which are sessions run by a physical therapist, usually 2-3 times a week to rehabilitate their ankle OR follow a standardized home exercise program which will be done by yourself with exercise outlined with how they should be performed and how often
224090700|NCT06269523|OTHER|Kinesio taping, Lymphatic drainage|Kinesio tape, is an elastic cotton strip with an acrylic adhesive that is purported to ease pain and disability from athletic injuries and a variety of other physical disorders. The application of Kinesio Tex Tape facilitates the opening of microvalves due to a dynamic pressure variation due to alteration in skin density. This decompression activates lymphatics in the dermis and improves lymphatic flow. The end result is a tissue inflammation and swelling reduction.It has been applied at the end over every session after lymphatic dreinage (see below).
224279430|NCT02972515|DEVICE|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
224279431|NCT00003615|BIOLOGICAL|denileukin diftitox|
223530752|NCT03510715|DRUG|Fenofibrate|"Pharmaceutical form: tablet,~Route of administration: oral"
223530753|NCT03510715|DRUG|Omega-3 fatty acids|"Pharmaceutical form: capsule,~Route of administration: oral"
223530754|NCT02834741|DRUG|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
223530755|NCT01505985|DIETARY_SUPPLEMENT|Oral nutritional Supplement|Specialized nutritional supplement for seniors
223530756|NCT01505985|DIETARY_SUPPLEMENT|Placebo|placebo product with no specific nutrients
223530757|NCT01092650|DRUG|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
224279432|NCT02254109|DRUG|BEA 2180 BR - rising dose|
224279433|NCT02254109|DRUG|Placebo|
223530758|NCT05405608|DRUG|Ondansetron|hemodynamic stability in orthopedic surgeries
223530759|NCT03826472|OTHER|Almond Butter|Natural almond butter
223530760|NCT01613651|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
223530761|NCT01613651|OTHER|questionnaire administration|Ancillary studies
223530762|NCT01613651|OTHER|intraoperative complication management/prevention|Undergo placement of pelvic drain
223717256|NCT04711044|OTHER|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied
223921113|NCT05569759|DRUG|zetomipzomib|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
223921114|NCT05569759|DRUG|placebo|Subcutaneous injection of placebo
223921115|NCT05569759|DRUG|zetomipzomib in open-label extension|Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly
224090701|NCT06269523|OTHER|Lymphatic drainage|Lymphatic drainage is a type of manual manipulation of the skin based on the hypothesis that it will encourage the natural drainage of the lymph, which carries waste products away from the tissues back toward the heart. The lymph system depends on intrinsic contractions of the smooth muscle cells in the walls of lymph vessels (peristalsis) and the movement of skeletal muscles to propel lymph through the vessels to lymph nodes and then to the lymph ducts, which return lymph to the cardiovascular system. Manual lymph drainage uses a specific amount of pressure and rhythmic circular movements to stimulate lymph flow.
223921116|NCT05395819|PROCEDURE|Reverse Total Shoulder Arthroplasty (RTSA)|"Patient will undergo a RTSA as per standard technique. It uses a stemmed metal humeral component attached to the glenoid and the shallow glenoid component attached to the humerus. Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within \< 10 degrees of neutral glenoid version. Standard instruments including a spherical burr and power reamers will be used to achieve this."
223921117|NCT05395819|PROCEDURE|Total Shoulder Arthroplasty (TSA)|Patients will undergo standard glenoid preparation and implantation of a TSA. It uses a stemmed metal humeral component to replace the arthritic head of humerus and a shallow polyethylene glenoid component to replace the arthritic glenoid surface. The degree of anterior- reaming will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
224090702|NCT00679861|BEHAVIORAL|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
224090703|NCT00679861|BEHAVIORAL|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
224090704|NCT00603005|DEVICE|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
224090705|NCT00688038|PROCEDURE|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
224090706|NCT00688038|PROCEDURE|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
224090707|NCT01761734|BEHAVIORAL|text message|
224090708|NCT05548686|OTHER|adapted physical activity|3 sessions of adapted physical activity per week during 12 weeks for each patient
224090709|NCT05759052|BEHAVIORAL|self-administered questionnaire|Patients will answer to a self- administered questionnaire exploring chemotherapy-induced peripheral neuropathy and related comorbidities
224090710|NCT01485874|DRUG|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
224279434|NCT05606328|BEHAVIORAL|Emergency Department Delirium Screening and Detection Program (ED-DDP)|Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses. No adaptations to the ED-DDP will occur between implementation sites and no data will be collected during implementation phases.
223717257|NCT04711044|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
223717258|NCT04711044|OTHER|L-menthol|A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
223717259|NCT03609905|BIOLOGICAL|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10\~7 diluted on 100 mL of normal saline
223717260|NCT03609905|OTHER|Conventional drugs|5-amino-salicylic acid or glucocorticoid
223717261|NCT05465434|DRUG|Zinc Supplement|Zinc sulphate 50 mg
223717262|NCT00953901|DRUG|Fresh Frozen Plasma Transfusion|
223921118|NCT00449748|DRUG|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
223921119|NCT05046600|DEVICE|Products listed in cohort description|Depending on approved indication per product
223921120|NCT06307184|PROCEDURE|Natural proliferative phase frozen embryo transfer|When endometrial thickness is above 7 mm, vaginal micronized progesterone will be administered 400mg 12/12h when the dominant follicle is at least 13 mm, serum estradiol (E2) levels are \>80 pg/ml, and serum progesterone levels are \<1.5ng/ml. Embryo transfer will be performed on the fifth day of progesterone.
223921121|NCT02339168|DRUG|Enzalutamide|Given PO
223921122|NCT02339168|DRUG|Metformin Hydrochloride|Given PO
223921123|NCT05266040|DRUG|Valacyclovir 500 MG|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
224090711|NCT01485874|DRUG|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
224279435|NCT04568577|OTHER|Tape with tension|The elastic bandage will be applied with a voltage increase controlled weekly, for five weeks. Each week, 5% of tension will be added to the application. In the first week the application will be tension-free.
224279436|NCT04568577|OTHER|Tape without tension|Bandaging applications will be weekly, for five weeks, without tensioning the tape.
224279437|NCT01351363|DEVICE|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
223921124|NCT05266040|DRUG|Placebo|Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
223921125|NCT05583422|GENETIC|DPYD or UGT1A1 variants|any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)
223921126|NCT01932125|DRUG|Bevacizumab|Participants will receive five cycles of bevacizumab 15 mg/kg concurrently with six cycles of the standard chemotherapy every three weeks (q3w), followed by extended cycles of bevacizumab 15 mg/kg q3w as a single agent for additional 16 cycles. A total of 21 cycles of bevacizumab will be administered in this study.
223921127|NCT06964880|BEHAVIORAL|Exercise with video on media platform|12-week structured video-guided exercise and peer support program
223921128|NCT06964880|BEHAVIORAL|Printed Educational Handout|12-week printed health education handout program
223921129|NCT06965829|DRUG|Tislelizumab|Neoadjuvant immunotherapy (tislelizumab 200 mg d1, q3w × 2 cycles)
223921130|NCT06965829|DRUG|Carboplatin and Paclitaxel and Radiation Therapy|Neoadjuvant chemotherapy (nad-paclitaxel 260 mg/m2 d1 + carboplatin AUC = 5 d1, q3w × 2 cycles) and node sparing radiotherapy (41.4Gy/23 times: 1.8Gy d1-5, qw × 4-5 cycles)
223921131|NCT06966232|DRUG|Entecavir|anti hepatitis B virus
223921132|NCT03944915|DRUG|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
223921133|NCT03944915|DRUG|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
223921134|NCT03944915|DRUG|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
223921135|NCT03944915|RADIATION|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
223921136|NCT03944915|DRUG|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
224090712|NCT05374486|DEVICE|NeuroExo co-robot neurorehabilitation system|In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
224090713|NCT02724033|PROCEDURE|regional nerve block|regional nerve block
224090714|NCT02724033|DRUG|Antiemetic|Antiemetic
223530763|NCT00385112|PROCEDURE|Echocardiogram|2D echocardiogram with Doppler flow
223921137|NCT03944915|DRUG|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
223921138|NCT03944915|DRUG|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
223921139|NCT03944915|DRUG|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
223921140|NCT06381739|BIOLOGICAL|ChAd-triCoV/Mac|Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.
223921141|NCT06381739|OTHER|Control|A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.
223921142|NCT06020040|DEVICE|Heterograft|Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
223921143|NCT00942734|DRUG|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
223921144|NCT00942734|DRUG|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
223921145|NCT06599086|DRUG|2 cc:(1 cc betamethasone dipropionate+1cc physiological saline)|Each patient will receive 2 cc:(1 cc betamethasone dipropionate+1cc physiological saline) perineural injection into the median nerve under US guidance, for 1 session.
223530764|NCT04632173|OTHER|non interventional study|There is no intervention
223717263|NCT05547685|DIAGNOSTIC_TEST|Methylene blue intradermal injection|Methylene blue intradermal injection
223921146|NCT06842472|DRUG|Ursodeoxycholic Acid (URSO)|UDCA 250 mg twice daily, starting 7 days before radiotherapy and continuing for 1 month after completion.
223921147|NCT06842472|RADIATION|Radiotherapy|Radiotherapy (SBRT) with a dose of 24Gy/3 fractions within 3 weeks after the first immunotherapy dose.
223921148|NCT06842472|DRUG|Adebrelimab (PD-L1 inhibitor)|Adebrelimab (PD-L1 inhibitor) 1200 mg on Day 1, every 3 weeks.
224279438|NCT01351363|DEVICE|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
224279439|NCT01450800|DRUG|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
224279440|NCT01450800|DRUG|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
224279441|NCT00769951|OTHER|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
223530765|NCT03720808|OTHER|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
223921149|NCT06610032|PROCEDURE|Mesotherapy|A total of 3 sessions of mesotherapy will be applied to the shoulder area of the patients, 7 days apart in group 1.
223921150|NCT06610032|PROCEDURE|Intra-articular steroid injection|Single session intra-articular 20 mg triamcinolone hexacetonide injection will be applied for patients in group 2.
223921151|NCT06856681|DIAGNOSTIC_TEST|PrecivityAD2 - Early Testing|Participants in Cohort A will receive PrecivityAD2 testing at Visit 1, with results disclosed shortly after testing.
223530766|NCT03720808|OTHER|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
224279442|NCT00769951|OTHER|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
223921152|NCT06856681|DIAGNOSTIC_TEST|PrecivityAD2 - Delayed Testing|Participants in Cohort B will receive PrecivityAD2 testing at Visit 2, with results disclosed shortly after testing.
223921153|NCT06997874|PROCEDURE|Phacovitrectomy|Participants will undergo phacovitrectomy to remove the lens (phacoemulsification and intraocular lens implantation) and to repair the RRD (vitrectomy). Although a phacovitrectomy is done in the same manner whether the condition to be treated is macular hole or RRD, the calculations required for the surgeon to select which intraocular lens should be implanted are different if there is a RRD with a detached macula. For this reason, a Standard Operating Procedure (SOP) will be prepared for the phacovitrectomy group to guide surgeons on how to best determine the intraocular lens under these circumstances (17). Vitrectomy with any gauge size (e.g.23g, 25g, 27g) will be allowed for the surgery, as per standard care at the participating site. The choice of the tamponade agent will be at the discretion of the treating vitreoretinal surgeon, as per standard care.
224279443|NCT00769951|PROCEDURE|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
224279444|NCT00769951|PROCEDURE|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
224279445|NCT00769951|PROCEDURE|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
224279446|NCT03850613|BEHAVIORAL|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
224279447|NCT01080586|DRUG|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
224279448|NCT03468296|DRUG|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
224279449|NCT02359539|PROCEDURE|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
224279450|NCT04302337|PROCEDURE|Curettage adenoidectomy with transoral endoscopic ablation|Transoral endoscopic examination of nasopharynx at the end of cold curettage adenoidectomy, and, if found, ablation of residual tissue.
224279451|NCT04302337|PROCEDURE|Conventional cold curettage adenoidectomy|Conventional cold curettage adenoidectomy without endoscopic examination for residual tissue.
224279452|NCT03224520|BEHAVIORAL|Recommender CTHC|Enhanced Messaging
224279453|NCT03224520|BEHAVIORAL|Standard CTHC|Standard Messaging
224279454|NCT03224520|OTHER|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
224279455|NCT03224520|OTHER|Standard Online Recruitment|Search Engine and Social Media Advertisements
223530767|NCT03720808|OTHER|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
223530768|NCT03720808|OTHER|Control|No intervention was performed to reduce pain and fear in the control group.
223717264|NCT04007978|GENETIC|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
224279456|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
224279457|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
224279458|NCT01992874|DRUG|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
223530769|NCT00032812|DRUG|Raclopride|
223530770|NCT01931410|DRUG|Misoprostol|
223530771|NCT00726583|DRUG|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
223530772|NCT00238329|BIOLOGICAL|PEG-interferon alfa-2b|
223921154|NCT06997874|PROCEDURE|Vitrectomy|Participants will receive vitrectomy to repair their RRD. The vitrectomy would be done as per standard care. Vitrectomy with any gauge size (e.g.23g, 25g, 27g) will be allowed for the surgery, as per standard care at the participating site. The choice of the tamponade agent will be at the discretion of the treating vitreoretinal surgeon, as per standard care. Then, if a cataract develops, phacoemulsification and intraocular lens implantation will be done as per standard clinical practice.
223921155|NCT05985395|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will complete 150 minutes of moderate-intensity exercise a week with help of a virtual exercise coach.
223921156|NCT06864416|DRUG|dexmedetomidine as adjuvant to bupivacaine|the efficacy of addition of dexmedetomidine as adjuvants to bupivacaine in femorosciatic nerve block
223921157|NCT06864416|DRUG|Fentanyl as adjuvant to bupivacaine|the efficacy of addition of fentanyl as adjuvants to bupivacaine in femorosciatic nerve block
223921158|NCT06864975|DRUG|Advate®|Non-daily dose FVIII 50IU/kg.QoD or 100IU/kg.QoD
224090715|NCT05413681|DIAGNOSTIC_TEST|a supra-maximal exercise test on a cycloergometer.|10 blood samples will be taken: before, during and during recovery from exercise: before the exercise test on the cycloergometer, 2 samples during exercise on the cycloergometer (middle of the threshold and peak of the exercise), 2 samples during recovery from exercise on the cycloergometer (at 2 and 10 minutes), and 1 sample at 24 hours.
224090716|NCT05413681|DIAGNOSTIC_TEST|handgrip muscle activity test.|2 bloods samples : at rest, after the 3 maximum contractions of the forearm, at 5 minute's recovery from the 30-second contraction of the grip test,
224090717|NCT02327650|PROCEDURE|The examinations for bones in joints of OA and RA patients|
224090718|NCT06962696|OTHER|No intervention|no intervention provided
224090719|NCT06961227|OTHER|No investigational intervention|No investigational intervention. Patients will be observed under standard ventilation modes (SIMV and MMV) as part of routine care.
224090720|NCT06838091|OTHER|Observational|"During anesthesia administration:~T0, T1, T2, T3, T4 represent the following periods:~T0: Double lumen ventilation in the supine position immediately after intubation T1: Double lumen ventilation in the lateral position T2: Single lumen ventilation in the lateral position (with the chest wall closed) T3: Single lumen ventilation in the lateral position (with the chest wall open) T4: Just before extubation~1. Airway pressure (P plateau, Ppeak) values from the anesthesia device data,~2. BIS (from routine BIS monitoring)~3. Temperature (Routinely from pharyngeal temperature probe),~4. Oxygen saturation (Routinely from the patient monitor)~5. End-tidal CO₂,~6. Inspiratory O₂ concentration,~7. Inspiratory CO2 concentration,~8. Inspiratory and expiratory desflurane/sevoflurane concentrations,~9. Tidal volume,~10. MAC, routinely from anesthesia device data~11. Blood Gas Analysis (COHgb, Ph, PO 2 , PCO 2 , SaO 2, HCO 3 , Base deficit, glucose, lactate)"
224090721|NCT00057707|DRUG|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
224090722|NCT00057707|PROCEDURE|Functional MRI|
224090723|NCT00057707|PROCEDURE|Neuropsychological Testing|
224090724|NCT05008328|OTHER|Music therapy plus standard care during an SBT|If the participant is randomly assigned to standard care plus music therapy, a music therapist will enter the room five minutes prior to the start of the breathing trial and begin to play quiet music on a guitar. The nurse will reduce medicine to bring the participant to an alert state. The music therapist will introduce themselves and the music intervention, and will continue to play quiet guitar music and sing softly while the respiratory therapist begins the breathing trial. The music therapist will continue playing and singing for 20 minutes into the breathing trial.
224090725|NCT05008328|PROCEDURE|Standard care during an SBT|The patient's nurse will reduce sedatives so the patient is alert and awake. The respiratory therapist will introduce themselves to the patient and inform them of the SBT, stating they will turn off the ventilator machine and allow the patient to breathe independently. The respiratory therapist will switch off the ventilator and leave the room. The respiratory therapist and nurse will both be available throughout the SBT, and the ventilator will automatically turn on if the patient stops breathing. The SBT will last for 30-60 minutes.
224279459|NCT01992874|DRUG|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
223921159|NCT06864975|DRUG|Advate®|Daily dose FVIII 50IU/kg.QD or 100IU/kg.QD
224090726|NCT00220376|DRUG|SPM 907|
224090727|NCT02736747|OTHER|Cryotherapy|
224090728|NCT02736747|OTHER|Placebo|
223921160|NCT06864975|DRUG|Advate®|Low dose FVIII 50IU/kg.QD or 100IU/kg.QoD
223921161|NCT06864975|DRUG|Advate®|Medium and high dose FVIII ≥100IU/kg.QD
224279460|NCT01992874|DRUG|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
224279461|NCT04560426|DEVICE|Intraoperative parathyroid gland auxiliary recognition system|The enrolled patients are grouped according to whether or not to use the intraoperative parathyroid auxiliary recognition system.
224279462|NCT02698930|DRUG|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
223530773|NCT00238329|DRUG|thalidomide|
223530774|NCT01230411|OTHER|saline placebo|250 cc of placebo administered IV
223530775|NCT01230411|DRUG|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
223921162|NCT06864975|DRUG|Advate®|Medium and high dose FVIII ≥100IU/kg.QD with immunosuppressant agent(s)
223921163|NCT06864442|PROCEDURE|Catgut Thread Embedding|Catgut Thread Embedding involved implanting chromic catgut size 4.0 thread, which is attached to a 23G guide needle, into subcutaneous tissue at EX-HN21 acupoint. The guide needle was removed after insertion, while the thread remained and dissolved over 10-15 days to provide continuous stimulation.
224090729|NCT04122287|DRUG|Levofloxacin|levofloxacinn-tetracycline-containing quadruple regimens
224090730|NCT04122287|DRUG|tinidazole|tinidazole-tetracycline-containing quadruple regimens
224090731|NCT05521087|DRUG|JNJ-75276617|JNJ-75276617 will be administered orally.
224090732|NCT05521087|DRUG|Fludarabine|Fludarabine chemotherapy will be administered as intravenous (IV) infusion for participants with AML.
224090733|NCT05521087|DRUG|Cytarabine|Cytarabine chemotherapy will be administered as IV infusion for participants with AML.
223530776|NCT05470686|BIOLOGICAL|blood gas via arterial catheter|Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
224090734|NCT05521087|DRUG|Intrathecal Chemotherapy|Intrathecal chemotherapy will be administered as IV infusion for participants with AML or B-cell ALL.
224090735|NCT05521087|DRUG|Dexamethasone|Dexamethasone chemotherapy will be administered as IV infusion for participants with B-cell ALL.
224090736|NCT05521087|DRUG|Vincristine|Vincristine chemotherapy will be administered as IV infusion for participants with B-cell ALL.
224090737|NCT05521087|DRUG|Pegaspargase|Pegaspargase chemotherapy will be administered as IV infusion for participants with B-cell ALL.
224090738|NCT05910827|DRUG|HMBD-001|HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
224090739|NCT05910827|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
224090740|NCT05910827|DRUG|Cetuximab|Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
223530777|NCT01587560|DEVICE|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
224090741|NCT05935306|DRUG|Ibuprofen|All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.
224090742|NCT05935306|OTHER|Photobiomodulation simulation|The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.
224090743|NCT05935306|DEVICE|Photobiomodulation|. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.
224090744|NCT05935306|OTHER|Ibuprofen simulation|Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)
224090745|NCT06419205|DRUG|ADX-097|Open Label
224090746|NCT06081075|OTHER|Genetic testing|Rapid whole genome sequencing
224090747|NCT05966272|DRUG|HRS9531 injection|single dose
224090748|NCT05966272|DRUG|HRS9531 injection Placebo|single dose
224090749|NCT04130646|DEVICE|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
224090750|NCT04130646|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
224090751|NCT06232512|DEVICE|Haptic Device|Provides sensory substitution by mapping pressure from the insole sensor onto a corresponding vibrating and heating patch to be worn where more sensation is present.
224090752|NCT01701258|DRUG|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
224090753|NCT01701258|DRUG|Placebo|single-dose placebo capsule during the fMRI session only
224090754|NCT04098315|OTHER|REGISTER CREATION|Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.
224090755|NCT01091636|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
223530778|NCT01587560|DEVICE|TITAN, Ascension Orthopedics, Inc.|
223530779|NCT06526234|DEVICE|MRI|MR enterography
223530780|NCT04994613|OTHER|Sensory adaptive environment|A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
223530781|NCT02124408|BEHAVIORAL|Personalized Behavioral Intervention|
223530782|NCT01508767|OTHER|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
223530783|NCT03923335|OTHER|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
223530784|NCT02096107|DRUG|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
223530785|NCT02096107|OTHER|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
224090756|NCT04317755|BEHAVIORAL|AdhaFULL body image comics|The comics were co-created with the expertise of four stakeholders: the investigators, UNICEF, BBC Media Action, and the Dove Self-Esteem Project. There are six different comics, which target issues relating to gender stereotypes and appearance concerns amongst adolescents in rural India. Based on 'Dove Confident Me', each comic tells a story which targets a specific established risk factor for body dissatisfaction. Specifically, they focus on gender prejudice (Comic 1), societal appearance ideals (Comic 2), media literacy (Comic 3), appearance comparisons (Comic 4), appearance-related conversations and teasing (Comic 5), and promoting 'body activism' (Comic 6). In each session, students will read the respective comic as a class. At the end of each comic, the teacher will facilitate one or two activities with the students based on the key learnings from the comics. These activities will encourage students to think critically about what they have read and consolidate their learning.
224090757|NCT03903510|DEVICE|Virtual Reality (VR)|Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
224090758|NCT01072292|BEHAVIORAL|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
224090759|NCT01278576|DRUG|BOTOX-A®|200 units, single treatment only
224090760|NCT03093402|DRUG|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
224090761|NCT03093402|DRUG|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
224279463|NCT02698930|DRUG|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
223921164|NCT06864442|PROCEDURE|Electroacupuncture|Electroacupuncture was administered using four needles (0.3 × 25 mm, diameter × length) inserted at GV-20, EX-HN21, external EX-HN12, and external EX-HN13 acupoints. Electrical stimulation was delivered via the KWD-808I Multipurpose Health Device (Changzhou Yingdi Electronic Medical Device Co., China) with parameters set at 3 Hz frequency and 0.6 ms pulse width, the intensity was adjusted according to the patient's perception. Electroacupuncture was performed daily, except on Saturdays, Sundays, and Vietnamese national holidays, over a treatment course of 30 days.
224090762|NCT05573802|DRUG|Belantamab Mafodotin-Blmf|Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes.
223921165|NCT06863805|DIAGNOSTIC_TEST|4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA|"For each patient enrolled in the present study, 4 EDTA tubes of peripheral blood will be collected to be used to obtain molecular profiling during scheduled laboratory controls as per normal clinical practice according to the following time schedule:~* T0 = basal collection before initiation of systemic treatment;~* T1 = sampling at 1 month after the start of systemic treatment;~* T2 = sampling at 3 months (+/- 1 month) after the start of systemic treatment at the first instrumental re-evaluation of disease;~* T3 = sampling at 6 months (+/- 1 month) from the start of systemic treatment at the time of instrumental disease reassessment;~* T4 = sampling at the time of evidence of instrumental disease progression within 24 months of treatment initiation.~The following analyses will be conducted on the samples thus collected:~* multigenic analysis on ccf-DNA and ccf-RNA at baseline, i.e., before the initiation of systemic treatment;~* isolation, counting and analysis of CTCs at baseline vi"
223717265|NCT02612727|DEVICE|Filtered-sunlight phototherapy|Infants will receive \>= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
223921166|NCT06857669|DIAGNOSTIC_TEST|Diffuse reflectance spectroscopy and Photoacoustic imaging,|The photoacoustic imaging/diffuse reflectance spectroscopy techniques used in this study have a broader wavelength spectrum. The photoacoustic set-up can generate an optical and an ultrasound image simultaneously.
223921167|NCT06860256|OTHER|Basic Body Awareness Therapy|"In TBFT sessions, physiotherapists improve the patient's contact with self by focusing on basic movement principles while performing simple daily movements such as lying, sitting, standing, walking, use of sound and massage. Mental awareness, postural balance and free breathing are considered key elements. The patient is invited to explore and integrate flow, rhythm and intentionality in coordinated movements in relation to time, space and energy. TBFT is practiced 2 days a week, 60 minutes, 5-12 weeks, depending on the patient."
223921168|NCT06860256|OTHER|High Intensity Interval Training|Tabata exercise protocol is an 8 repetition training program with 20 seconds of work and 10 seconds of rest. Warm-up and cool-down exercises of 5 minutes each should be done to prevent injuries and negativities. Although the application varies according to the patient, YŞİA is applied 2 days a week, 15-30 minutes, in processes ranging between 2-12 weeks.
223717266|NCT02612727|DEVICE|Intensive phototherapy|Infants will receive \>= four hours per day of intensive phototherapy for 1 to 10 days.
223921169|NCT06860256|OTHER|Classic Exercise and Lifestyle Tips|Classical Exercise (CE) and Lifestyle Recommendations (LSR), Classical exercises used in PD include abdominal, pelvic floor muscles, hip flexors, whole body stretching. Non-pharmaceutical strategies for pain management in LRS include adopting relaxation (rest, warm-up, massage, music, etc.), antalgic positions, and distraction techniques. Common techniques that facilitate relaxation and thus reduce pain include physical rest, hot showers, various heat applications such as thermal seed bags, electric blankets, and drinking hot herbal teas such as chamomile tea.
223921170|NCT06672315|DIAGNOSTIC_TEST|transesophageal echocardiography|Confirmation of chest compression positioning via transesophageal echocardiography (TEE)
223921171|NCT06864039|DIAGNOSTIC_TEST|SF36 test|Assessment of quality of life by administering the SF36 test
223921172|NCT06864039|DIAGNOSTIC_TEST|WAIS IV test|Assessment of cognitive abilities by administering the WAIS IV test
224090763|NCT05573802|DRUG|Lenalidomide|Lenalidomide will be administered per os.
223921173|NCT06864039|DIAGNOSTIC_TEST|SCL-90 psychopathological screening questionnaire|Assessment of any psychopathological conditions by means of the SCL-90 psychopathological screening questionnaire
223921174|NCT06864039|DIAGNOSTIC_TEST|CBCL questionnaire|For patients up to 18 years of age: CBCL questionnaire to be administered to parents to describe the patient's behavior
224090764|NCT05573802|DRUG|Dexamethasone|Dexamethasone will be administered intravenously or per os.
224090765|NCT05573802|DRUG|Nirogacestat|Nirogacestat will be administrated each day for all subsequent cycles were Blmf is also administrated.
224090766|NCT01276184|BEHAVIORAL|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s).
223530786|NCT03167060|DEVICE|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
224279464|NCT02276625|BIOLOGICAL|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
224279465|NCT02721368|DEVICE|Neuramis® Volume Lidocaine|hyaluronic acid filler
223921175|NCT06864039|DIAGNOSTIC_TEST|bioimpedance analysis|Assessment of body composition by performing bioimpedance analysis
223921176|NCT06864286|BEHAVIORAL|Move for Health|"This multi-domain health promotion intervention utilizes the Community-Based Health Promotion Program for Older Adults - Healthy Exercise Class developed by the Health Promotion Administration (Taiwan). This intervention emphasizes a multi-dimensional health approach, focusing on healthy aging, exercise, and cognitive interventions, supplemented by elements of oral health, nutrition, and social participation. The program aims to promote older adults' health self-management capabilities. This 12-week program meets once weekly for two hours per session. Healthy aging curriculum covers important health issues for older adults, such as fall prevention, healthy eating, oral health, vision care, dementia prevention, medication safety, and knowledge related to healthy lifestyle behaviors including home-based exercise."
223921177|NCT06616597|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg/ day
223921178|NCT06616597|DRUG|Dexamethasone|Dexamethasone 0.5mg/day
223921179|NCT06616597|DRUG|Metronidazole|Metronidazole 1500mg/ per day
223921180|NCT03333915|DRUG|Pamiparib|Pamiparib is provided as oral capsules
223921181|NCT05217680|BIOLOGICAL|Bevacizumab|Administration of monthly intravitreal bevacizumab (4-12 injections)
224090767|NCT00002085|DRUG|Azithromycin|
224279466|NCT02721368|DEVICE|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
224279467|NCT02091310|DRUG|Placebo|
224279468|NCT02091310|DRUG|GFT505|
224279469|NCT02091310|DRUG|Moxifloxacin 400 mg|
224279470|NCT01086969|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
224279471|NCT00139932|DRUG|formoterol fumarate|
224279472|NCT01773239|BEHAVIORAL|TARA computer-based exercises|
223717267|NCT04263220|DEVICE|Industrial passive exoskeleton with a specific value of the torque of the spring for supporting the back|Both exoskeleton types are passive exoskeletons for supporting the back. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions
224090768|NCT03216460|DEVICE|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
224090769|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract|
224090770|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin|
224090771|NCT03205202|DIETARY_SUPPLEMENT|Cocoa extract placebo|
224090772|NCT03205202|DIETARY_SUPPLEMENT|Multivitamin placebo|
224279473|NCT05134116|OTHER|Treatment as usual + cerebral oximetry monitoring the first 72 hours of life|SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants
224279474|NCT00558623|DIETARY_SUPPLEMENT|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
224279475|NCT04253236|DRUG|RVT-1401 680 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
224279476|NCT04253236|DRUG|RVT-1401 340 mg/weekly|Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
224279477|NCT03723837|BIOLOGICAL|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
224279478|NCT01318161|DRUG|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
224279479|NCT01318161|DRUG|Morphine|Morphine via PCA pump
224279480|NCT03667859|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
224279481|NCT01042873|DRUG|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
224279482|NCT06318377|DIETARY_SUPPLEMENT|Peanut group|These are commercially available peanuts that are high in antioxidants and are believed to be beneficial for physiological health
224279483|NCT00432627|DRUG|Deferasirox|one dose of 20 mg/kg/day
223717268|NCT04263220|OTHER|protocol will be performed without exoskeleton|protocol will be performed without exoskeleton
223717269|NCT01095731|DRUG|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
223921182|NCT05217680|BIOLOGICAL|Lucentis®|Administration of monthly intravitreal ranibizumab (4-12 injections)
223921183|NCT04439032|OTHER|NanoBone Bone Graft Substitute|Synthetic, biodegradable bone grafting material that is composed of non-sintered nanocrystalline hydroxyapatite (HA) which is embedded in a silica gel matrix (amorphous SiO2). The ratio of HA/SiO2 has been chosen to optimize the rate of biodegradation for treatment of osseous defects in human bone. NanoBone does not contain any components of animal or human origin, eliminating the possibility of transmission of infection or disease.
223921184|NCT06613217|DRUG|zelenirstat|Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.
223921185|NCT06371261|OTHER|Biological analyses|"A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion.~The micro-organisms will be quantified.~The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021)."
223921186|NCT06673810|OTHER|Ankle Weighted Cuffs Training Along with Routine Physical Therapy Exercises|Group A will have free ankle weighted cuffs while performing routine physical therapy. These weighted cuffs will be above of the child's ankle and child will be encouraged to perform his/her routine physical activities. Ankle weights will correspond to 2% to 3% of the individual's body weight (sandbags) will be attached at 5 cm above the left and right ankle joints
223921187|NCT06673810|OTHER|Routine Physical Therapy Exercises|Group B will perform all the routine physical exercises which include jogging, walk/run interval training, treadmill training and cycling . Intervention period will be of 6 weeks comprising of 3 sessions per week of 30 to 45 minutes per session
223921188|NCT05740007|DRUG|IW-3300 rectal foam|IW-3300 rectal foam administered daily for 12 weeks
223921189|NCT05740007|DRUG|Placebo|Placebo rectal foam administered daily for 12 weeks
223921190|NCT06746207|OTHER|Informed Consent Process Evaluation|This study does not involve a clinical intervention. Instead, it focuses on evaluating the existing process of informed consent in a surgical setting. Patients and caregivers will be surveyed to assess their understanding, satisfaction, and perceptions of the informed consent process. The study examines factors such as clarity of information provided, patient and caregiver involvement, and overall satisfaction with the process, without altering the current practices. The goal is to identify areas for improvement in communication and documentation, ensuring that patient rights and autonomy are respected.
223921191|NCT06660602|PROCEDURE|cardiac surgery|All kinds of cardiac surgeries
223921192|NCT06597942|DEVICE|TMS|rTMS Stimulation Parameters Pulse count: 1600 pulses Frequency: 20Hz Pules per train: 40 pulses Inter-train interval: 28 seconds Intensity: 100% Motor Threshold (depth-corrected from MRI) Target: Precuneus using structural MRI navigation with MNI coordinates
223921193|NCT06597942|DEVICE|Transcranial Magnetic Stimulation Sham|Sham coil placed in same location and set with same parameters as active treatment coil. However, this device will not output active treatment and scalp electrodes will mimic the sensation of rTMS for the participant.
223921194|NCT03601897|DRUG|Rebastinib|Administered orally
223921195|NCT03601897|DRUG|Paclitaxel|Paclitaxel administered by IV infusion at 80 mg/m\^2
223921196|NCT06608108|OTHER|Non-intervention|Non-intervention
224279484|NCT05840276|DEVICE|Cryoneurolysis|The VISUAL-ICE uses a combination of argon and helium, to create a highly localized cold zone with temperatures between -20 and -100°C. A probe will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization to accurately determine the location of the nerve and to account for adjacent neurovascular structures and variations in anatomical structures. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Cryoneurolysis at each target site requires 2 freeze cycles with a duration of 3 mins, and with thaw cycles between 20-40 seconds.
224279485|NCT05840276|OTHER|Sham|A sham needles will be inserted percutaneously at the target AFCN and IBSN guided by ultrasound visualization. The target locations are drawn directly on the patients' skin prior to treatment along which a dose of local anesthetic will be injected subcutaneously before treatment. Sham will simulate cryoneurolysis at each target site for 2 freeze cycles with a duration of 3 mins, and also simulate thaw cycles between 20-40 seconds. No temperature changes will actually occur although the experience and sounds will be similar to cryoneurolysis
224279486|NCT01337882|OTHER|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
224279487|NCT02247076|BEHAVIORAL|Grazing|
224279488|NCT02247076|BEHAVIORAL|Time-restricted feeding (early eating)|
224279489|NCT03847363|PROCEDURE|epidural anesthesia|epidural anesthesia
224279490|NCT03847363|PROCEDURE|nerve block|paravertebral or serratus anterior plane block
224279491|NCT02230111|BEHAVIORAL|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
223921197|NCT03518554|DRUG|JAB-3068|JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
223921198|NCT06856278|DRUG|NKG2D CAR-NK with PD-1 Antibody|Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.
223717270|NCT01095731|DRUG|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
223717271|NCT01423305|DRUG|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
223717272|NCT01423305|DRUG|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
223921199|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion
223921200|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
223921201|NCT06859658|RADIATION|Functional MRI at 3T|At inclusion and at 2 years for CADASIL patients without severe disability (mRS\<4)
223921202|NCT05361980|DEVICE|Pediatric orthopaedic implant|Patient receives a pediatric orthopaedic implant as a part of standard clinical care.
223921203|NCT06860373|BIOLOGICAL|[18F]MK-6240|\[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection.
223921204|NCT06862518|DRUG|Control group|Patients will receive general anesthesia alone
223921205|NCT06862518|DRUG|Serratus Anterior Plane Block (SAPB) group|Patients will receive general anesthesia (GA) with ultrasound guided serratus anterior plane block 0.5 ml/kg 0.25% bupivacaine.
223921206|NCT06862518|DRUG|Erector Spinae Plane Block (ESPB) group|Patients will receive general anesthesia (GA) with ultrasound guided erector spinae plane block 0.5 ml/kg 0.25% bupivacaine
223921207|NCT06862284|DRUG|Upadacitinib (ABT-494)|Upadacitinib 15mg Qd for 52 weeks
223921208|NCT06862284|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine 200mg Bid for 52 weeks
223921209|NCT05869227|DRUG|Capecitabine/Placebo combined with toripalimab|Combined
223921210|NCT05418478|BEHAVIORAL|Intervention transtheoretical model group|"The Transtheoretical Model is a conscious behavior modification model that focuses on individual decision making and planning processes. It is the only model that examines behavior change as a dynamic process rather than an outcome, and considers behavioral strategies that include the individual's cognitive and behavioral processes in this process.~In the model, it is stated that behavior change is a process and develops gradually. It is reported that the change in the behavior of individuals consists of six stages: 1) not thinking, 2) thinking, 3) preparation, 4) taking action, 5) maintaining and 6) terminating. This model consists of four main constructs called change stages (time-related dimension), change processes/behavior modification methods (independent variable dimension), self-efficacy (levels of change) and decision-making balance (perceptions of harm and benefit of change)."
223921211|NCT06677385|RADIATION|diode laser as adjunctive to conventional scaling and debridement|diode laser as adjunctive to conventional scaling and debridement for old age patients
223921212|NCT06677385|PROCEDURE|conventional scaling and debridement|conventional scaling and debridement
223717273|NCT03293290|DRUG|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
223717274|NCT01446289|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
223921213|NCT06676982|BIOLOGICAL|anti-CD19 CAR-T|All subjects were intravenous administrated with CNCT19 CAR-T.
223921214|NCT06524024|BIOLOGICAL|Tumor polypeptide pool induced DC-CTL cell injection|In this study, DC-CTL cells were injected once a day for two consecutive days, 1-2 days after study participants received a conventional antitumor regimen, and subcutaneous injections of DC cells were administered before a second infusion of DC-CTL cells. A total of about 4-6 cycles of cell infusion are required
223921215|NCT06878729|PROCEDURE|CTO PCI using ADR strategy|CTO recanalization using ADR performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).
223921216|NCT06878729|PROCEDURE|CTO PCI using retrograde strategy|CTO recanalization using retrograde approach performed as primary or secondary CTO PCI strategy (i.e. in case of unattempted or failed antegrade wiring, respectively).
223921217|NCT03851640|DRUG|HC-1119|oral
223717275|NCT01446289|BIOLOGICAL|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
223717276|NCT02302807|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
223921218|NCT03851640|DRUG|placebo|oral
223921219|NCT06865001|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
223921220|NCT06865001|OTHER|Graded motor imagery|"Graded motor imagery consists of three stages:~1. limb lateralization task~2. an imaginary limb movement task (motor imagery) and~3. mirror therapy. Each session will consist of 12-15 minutes and 3 sets, with 5 minutes between sessions to rest and relax the limb. The application is planned for 30 minutes."
223921221|NCT06858228|PROCEDURE|Continuous Ablative Radiofrequency|Continuous ablative radiofrequency is a minimally invasive neuroablative procedure that targets the sensory genicular nerves to manage pain in knee osteoarthritis. Under ultrasound guidance, a radiofrequency probe is inserted percutaneously near the target nerves. The procedure delivers continuous thermal energy at 80°C for 120 seconds, creating a controlled lesion that disrupts pain signal transmission. This technique is distinct from pulsed radiofrequency, as it aims for permanent nerve ablation rather than neuromodulation. The expected outcome is prolonged pain relief and improved function in patients with chronic knee osteoarthritis refractory to conservative treatments.
224279492|NCT02230111|BEHAVIORAL|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
223530787|NCT03167060|DEVICE|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
223921222|NCT06858228|DRUG|Chemical Denervation with Absolute Alcohol|Chemical denervation with absolute alcohol is a minimally invasive neurolytic procedure targeting the sensory genicular nerves to manage chronic knee osteoarthritis pain. Under ultrasound guidance, a percutaneous injection of absolute alcohol 66% is administered near the targeted nerves. The neurolytic effect of alcohol induces axonal degeneration and Wallerian degeneration, leading to prolonged disruption of pain signal transmission. This intervention differs from radiofrequency ablation as it achieves chemical neurolysis rather than thermal ablation, with potential for a distinct duration of analgesia and varying nerve regeneration patterns. The expected outcome is long-lasting pain relief and improved function in patients with knee osteoarthritis who have not responded to conservative treatments.
223530788|NCT05023109|DRUG|GP+PD-1+Tight|"Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W"
223530789|NCT03226041|DEVICE|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
223530790|NCT07115667|DRUG|BCMA/CD3 bispecific antibody (CM336)|Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA/CD3 bispecific antibody (CM336)
223921223|NCT06859411|PROCEDURE|visual acuity comparaison|Data collection
223921224|NCT06617299|BEHAVIORAL|Intervention Identifies and Responds|"The treatment of Experimental Group is described, which is made up of eight individual sessions taught over three months. Session one will be in face-to-face format, the content, resources and activities are described in tables 2 and 3. The remaining seven sessions will be follow-up sessions (four sessions by message (WhatsApp®) where motivational messages and reinforcement information will be sent; and 3 sessions by phone call for feedback, see details of time, content, activities and resources in tables 2 and 3.~The design of the intervention is aimed at increasing the practice of Responsive Feeding in mothers with children under 6 months of age, is based on the methodology of Sidani and Braden (2021); on CHW (Bandura, 1986); and behavior change techniques to help people have healthy eating habits (Michie et al., 2011)."
223921225|NCT06616740|OTHER|Cricoid pressure|Cricoid pressure will be applied during LMA ProSeal insertion.
223921226|NCT06616740|OTHER|Paratracheal pressure|Pratracheal pressure will be applied during LMA ProSeal insertion.
223921227|NCT02777593|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
223921228|NCT06672900|DRUG|Carbamazepine|Commercially available supply.
223921229|NCT06672900|DRUG|Itraconazole (Sporanox)|Commercially available supply.
223921230|NCT06672900|DRUG|ALG-000184|Study Investigational Product
223921231|NCT06671379|DRUG|SHR-A2009 monotherapy|SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
223921232|NCT06671379|DRUG|platinum-based dual-agent chemotherapy|Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
223921233|NCT01211964|DRUG|LEO 22811|Oral administration of solution and tablet.
223921234|NCT06094413|BEHAVIORAL|Multicomponent Training Intervention|The intervention was implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session consisted of three phases: warm-up/initiation, conditioning, and cooldown. The intervention was composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects werre informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention was measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which were monitored during the session to measure immediate effect of the intervention. Progressions were guided by individual responsiveness and measured by RPE. Progressions were based on the training principles of specificity, adaptability, and overload.
223921235|NCT06536764|OTHER|Progressive Muscle Relaxation Exercises|Progressive muscle Relaxation exercises will be performed by this group.Advise women to sit in chair. The therapist's voice will then instruct them to contract and release different muscle groups. They will practice tensing a muscle group until they feel the slight contraction and then release it, simultaneously contracting and relaxing all other muscle groups.Practice will progress in the same manner, starting with the muscles in the feet, then the calf, thigh, gluteal muscles, abdomen, chest, hands, forearms, arms, shoulders, neck, face, and finally the forehead muscles .
224279493|NCT03045822|DRUG|Bioimpedance analysis|
223530791|NCT01811420|PROCEDURE|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
223530792|NCT01811420|PROCEDURE|Conventional method|Dental caries removal using rotatory instrument
223921236|NCT06536764|OTHER|Conventional Therapy(Hot pack,TENS,Patient Education)|Conventional therapy including hot pack and TENS will be applied for 10 minutes each. Meanwhile, patients will be given education to ease back pain and improve sleep.
223921237|NCT06334523|DEVICE|Ventilation with Dead Space Washout via Continuous Tracheal Gas Insufflation (CTGI)|"The intervention involves adding a device which allows CTGI (the CTGI-device) to washout the dead space in preterm mechanically ventilated infants. Dead space washout using the CTGI-device is an option added to standard ventilation, to reduce or even cancel anatomical dead space due to respiratory prostheses in intubated preterm infants."
223921238|NCT06054906|DRUG|sintilimab+metronomic PLOF|"Drug: Sintilimab 200mg iv d1 Q3W, 2cycles~Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles~Drug: Oxaliplatin 50 mg/m2, d1, QW, 6cycles~Drug: 5-fluorouracil 425mg/m2 ,d1 ,QW, 6cycles"
223921239|NCT04559685|COMBINATION_PRODUCT|SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 5-7 hours prior to receiving the MRgFUS.
223921240|NCT04559685|DEVICE|MR-Guided Focused Ultrasound device (MRgFUS)|MR-Guided Focused Ultrasound device (MRgFUS) alone
223921241|NCT05520749|DRUG|Luspatercept|Luspatercept treatment in adults with transfusion-dependent anaemia due to MDS
223921242|NCT05178056|DEVICE|Spinal Cord Epidural Stimulation|Spinal Cord Epidural Stimulation (scES) will be administered by a multi-electrode array (5-6-5 SpecifyTM electrode, MEDTRONIC, Minneapolis, MN, USA) previously implanted in the epidural space over the dorsum of the spinal cord.
223921243|NCT05178056|OTHER|Respiratory Training|Standard threshold Positive Expiratory Pressure Device and standard threshold Inspiratory Muscle Trainer (Respironics Inc., Cedar Grove, NJ) assembled together will be used for respiratory training sessions to complete eighty 45-minute sessions during 16 weeks. The participants will be instructed to perform inspiratory and expiratory efforts against a pressure treshold load.
224090773|NCT05760716|OTHER|practicing prone position|Wash your hands. Prepare the materials. Before starting the procedure, inform the patient and explain the procedure. Ensure patient privacy. Raise the guardrail opposite the work area. Take the proper posture. Pay attention to body mechanics. Lay the patient on their back in the middle of the bed. Place a pillow under the patient's head to cover their shoulders. Extend arms to side of body with elbows slightly bent inward (flexion). Place a pillow under your arms. Place roller in palm. Place a thin pillow or a thinly folded towel/sheet under the waist. Place a thin towel under the knees. Support the bottom of the ankles with a pillow. Support the soles of the feet with a foot board. Raise the guardrail on the working side. Inform the patient that they can stay in this position for a maximum of 2 hours.
224090774|NCT05559307|DRUG|Xingnaojing injection|Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
224090775|NCT03496753|DEVICE|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
224090776|NCT04756414|BEHAVIORAL|Exposure based face-to-face Cognitive Behavior Group Therapy|See under detailed description
224090777|NCT05154474|OTHER|Standard|Standard follow-up with clinical exams, functionnal test at baseline, Ct scan MNA, IPAQ, SARC-F and SarQOL questionnaires
224090778|NCT04272593|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device.
224090779|NCT02835170|BIOLOGICAL|Autologous immunoglobulin|Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
224090780|NCT02835170|OTHER|Placebo|"Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)"
224090781|NCT03017209|DIETARY_SUPPLEMENT|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
223717277|NCT02302807|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
224090782|NCT03017209|DIETARY_SUPPLEMENT|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
223530793|NCT03144401|DRUG|Misoprostol|mesotac
223530794|NCT03144401|OTHER|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
223530795|NCT03612570|DEVICE|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
223530796|NCT01415947|DEVICE|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
223921244|NCT06678971|OTHER|FIFA 11+|The FIFA 11+ protocol consists of fifteen exercises organized into three segments, with three levels of difficulty. The first segment includes six running exercises, the second focuses on six exercises to enhance lower body strength, balance, and agility, and the third segment involves three running exercises aimed at activating the cardiovascular system.
223921245|NCT06678971|OTHER|Basket-Up|"The Basket-Up warm-up program is developed by a committee of experts, including the medical staff and the Performance Department of Valencia Basket Club, with detailed information previously published. This protocol is specifically designed to address the physiological, functional, and physical demands of basketball training. Like the FIFA 11+ program, it is structured into three phases with progressively increasing levels of difficulty, lasting a total of 20 minutes.~Phase 1 includes three exercises aimed at improving mobility. Phase 2 features six exercises focused on strength, direction changes, and plyometric activities. Phase 3 consists of six exercises designed to enhance agility and neurocognitive skills."
223530797|NCT01844596|BEHAVIORAL|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
223530798|NCT01844596|BEHAVIORAL|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
223921246|NCT06547346|DIETARY_SUPPLEMENT|Alfamino Junior|To recruit 15 children and evaluate the acceptability (including gastrointestinal tolerance), palatability and compliance of a hypoallergenic amino acid powdered formula (neutral and vanilla flavours) with HMO's for the dietary management of presumed cows' milk allergy, multiple food protein allergies and other conditions where an amino acid formula is recommended in children ≥1 year of age.
223921247|NCT04936620|PROCEDURE|Duroplasty|Expansion Duroplasty
223921248|NCT04936620|PROCEDURE|Spinal surgery|Spinal surgery including laminectomy
223921249|NCT05656742|DIETARY_SUPPLEMENT|Vitamin D|oral vitamin D3
223921250|NCT06866899|PROCEDURE|Surgery for Dupuytren contracture (DC), DeQuervain tenosynovitis (DQS), carpal tunnel syndrome (CTS), or trigger finger (TF)|All of the patients were operated for Dupuytren contracture (DC), DeQuervain tenosynovitis (DQS), carpal tunnel syndrome (CTS), or trigger finger (TF). The study is two center study, one center has the routine of RAAB (regional anesthesia with axillary block) and the other has the routine of WALANT (wide awake local anesthesia no tourniquet) for the mentioned surgeries.
224090783|NCT03017209|OTHER|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
224090784|NCT00278603|BIOLOGICAL|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
224090785|NCT02429856|DEVICE|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
224090786|NCT02271165|DRUG|Immunoglobulin (Hizentra)|
223530799|NCT05391776|DRUG|TST002 Injection|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
223530800|NCT05391776|DRUG|placebo|This single dose study, ascending with phase I dose-escalation principles from 200mg up to 1200mg.
223530801|NCT05748769|BEHAVIORAL|Practice (UL)|Subjects performed RMs toward the units that were activated in the same order as the tested sequence 1-4-3-5-4-2, and with an activation duration and delay of 1 s. The practice included 16 blocks, each consisting of 30 RM with a 30 s pause after each block
223530802|NCT05748769|BEHAVIORAL|Observation (SO)|Subjects observed the illuminating switches while avoiding moving. The subjects observed RMs toward the units that were activated in the same order as the practiced sequence 1-4-3-5-4-2, also with an activation duration and delay of 1 s and 30 s pause after each block.
223530803|NCT05748769|BEHAVIORAL|Nature Observation (NO)|The video-clip consisted of a 16 min nature movie in cycles of one-minute observation and pausing 30 s, equivalent to the timing of RMs performed by groups UL and SO
223530804|NCT05739448|OTHER|nutritional intervention|The nutritional intervention will be based on the following 4 elements: nutritional follow-up by a dietician, fortified meals, tender and juicy meat dishes and fish dishes
223530805|NCT05739448|OTHER|physical activity|The physical activity intervention will be based on the following 2 elements: Follow-up with a trainer for adapted exercise and physical exercise instruction sheets
223530806|NCT05128747|OTHER|DASH diet|it will be face to face about the role of nutritional program to control dyslipidemia
223530807|NCT02225535|OTHER|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
223530808|NCT02225535|OTHER|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
224090787|NCT03471455|DRUG|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
223530809|NCT02225535|OTHER|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
223530810|NCT02645864|DRUG|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
223921251|NCT06866899|PROCEDURE|Regional Anesthesia|Regional anesthesia with axillary block
223921252|NCT06866899|PROCEDURE|Local Anesthesia|Wide awake local anesthesia no tourniquet
223921253|NCT06865937|BEHAVIORAL|Mobile Intervention for Social Recovery in Serious Mental Illness|mSITE is a blended intervention that integrates a brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching. Participants will attend weekly, in-person sessions for 8 weeks and then 15-minute, remote coaching sessions for 10 weeks. The intervention begins with setting a meaningful recovery goal and then the generic cognitive model is introduced and a simple thought challenging skill is trained to specifically address social avoidance behaviors and facilitate work toward recovery goals. Defeatist attitudes, social threat and avoidance behaviors that interfere with working on the goal are then modified using CBT skills and practiced using role-plays.
223921254|NCT06865937|BEHAVIORAL|Supportive Contact|The SC arm will match the mSITE arm on the same amount of individual in-person and coaching, and mobile device contact. Coaching sessions will be semi-structured and consist of setting recovery goals, check-in about symptoms and potential crisis management, flexible discussion involving psychoeducation, instructions for accessing community crisis lines and community resources, and symptom management behaviors that grow out of discussions, with only minimal therapist guidance.
224090788|NCT03471455|DRUG|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
223530811|NCT02645864|DRUG|Irinotecan|150mg/m\^2 i.v. q2w
223530812|NCT02039830|BEHAVIORAL|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
223530813|NCT02039830|BEHAVIORAL|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
223530814|NCT07125742|OTHER|Chewing gum|The chewing gum group was asked to chew sugar-free gum for 15 minutes at each time point.
223530815|NCT07125742|OTHER|Fennel Tea|Fennel Tea: The fennel tea group received 2 g of fennel steeped in 150 ml boiling water for 10 minutes.
223530816|NCT07125742|OTHER|Ginger Tea|Ginger Tea: The ginger tea group received 2 g of fresh ginger steeped in 150 ml boiling water for 10 minutes.
223530817|NCT04756531|DRUG|PF-07321332 Dose 1|PF-07321332 Dose 1 or Placebo
223921255|NCT06865924|OTHER|Use of assembloids as in vitro models to test new pharmacological approaches|Using extracellular vesicles containing the CRISPR/Cas9 genome editing system that by faithfully reproducing the in vivo part will allow a more faithful response than the use of conventional 2D model, organoids or animal model.
223921256|NCT06867016|OTHER|Combined Cognitive & Aerobics Training|The ACT combined training will consist of simultaneous aerobic exercise and cognitive training in a dual-task format, conducted twice a week for 8 weeks. The aerobic training (AT) will consist of twice-weekly sessions that include yoga, brisk walking, pedaling exercises, and step aerobics, alongside cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, 4th week, and 8th week.
224090789|NCT03471455|DRUG|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
224090790|NCT05850078|OTHER|FB101|Intervention will test effects on changes to the vaginal microbiome of FB101 versus diluted FB101 versus placebo
224090791|NCT00978302|DRUG|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
224090792|NCT00978302|DRUG|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
223530818|NCT04756531|DRUG|PF-07321332 Dose 2|PF-07321332 Dose 2 or Placebo
223530819|NCT04756531|DRUG|PF-07321332 Dose 3|PF-07321332 Dose 3 or Placebo
224090793|NCT00978302|DRUG|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
224090794|NCT00978302|DRUG|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
224090795|NCT00978302|DRUG|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
224090796|NCT00978302|DRUG|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
224090797|NCT00978302|DRUG|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
224090798|NCT02159144|OTHER|cold stress|
223530820|NCT04756531|DRUG|PF-07321332 Dose 4|PF-07321332 Dose 4 or Placebo
223530821|NCT04756531|DRUG|PF-07321332 Dose 5|PF-07321332 Dose 5 or Placebo
223530822|NCT04756531|DRUG|PF-07321332 Dose 4 or Placebo (Fed)|PF-07321332 Dose 5 or Placebo with high fat meal
223530823|NCT02375828|DRUG|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
223530824|NCT06854016|DEVICE|Sham Laser therapy|sham laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week, for the first 2 weeks, and then a minimum of 2 sessions per week for the following 2 weeks.
223530825|NCT06854016|DEVICE|Laser therapy|laser therapy for 4 consecutive weeks with a minimum of 3 sessions per week, for the first 2 weeks, and then a minimum of 2 sessions per week for the following 2 weeks.
223717278|NCT02302807|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
223717279|NCT02302807|DRUG|Vinflunine|Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
223717280|NCT01809483|DEVICE|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
224090799|NCT05243849|DEVICE|Optical Coherence Tomography Angiography|Optical coherence tomography angiography (OCTA) is a novel non-invasive, non-dye and high-resolution imaging technique, allowing real-time quantitative evaluation of retinal vasculature and the structure of foveal avascular zone (FAZ).
224090800|NCT05430620|DRUG|Oxygen|Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
224090801|NCT04816240|DRUG|Midodrine|5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90)
224090802|NCT04816240|BIOLOGICAL|Albumin|80grams/week for 2 weeks followed by 40gram/week
224090803|NCT04816240|OTHER|Standard Medical Treatment|Standard Medical Treatment
224090804|NCT04816240|OTHER|Placebo|Placebo
224090805|NCT05057364|OTHER|Heart Smart Virtual Self-Management Group|The Heart Smart Intervention is a 6 week virtual program consisting of one individual technology training session followed by 5 one hour group education sessions.
224090806|NCT03700047|DEVICE|GAL1704|new dermal filler
224090807|NCT03700047|DEVICE|Juvederm Voluma|hyaluronic acid
224090808|NCT03967821|OTHER|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
224090809|NCT00035451|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
224090810|NCT00035451|DRUG|Placebo|tablets, twice daily for 6 months
224279494|NCT05429489|PROCEDURE|Bilevel erector spinae plane block|Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
224279495|NCT05429489|PROCEDURE|Single level erector spinae plane block|Single level erector spinae plane block at 5th thoracic vertebrae
223530826|NCT06854016|OTHER|RICE and physiotherapy/exercise protocol|RICE plus physiotherapy/exercise protocol represents the standard of care (SOC) and the program includes: for the first 2 weeks RICE protocol performed daily at home by the patient, for the following 4 weeks a physiotherapy/exercise protocol will be performed at site with 2 sessions per week.
223717281|NCT01809483|DEVICE|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
223717282|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple|Active juice with added fibre and ginseng
223717283|NCT02396615|DIETARY_SUPPLEMENT|SATIN pineapple control|Control products without active ingredients
223717284|NCT00376727|BIOLOGICAL|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
223717285|NCT00376727|GENETIC|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
223717286|NCT00376727|OTHER|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
223717287|NCT00376727|OTHER|laboratory biomarker analysis|Cetuximab Pharmacodynamics
223717288|NCT00539136|DRUG|GSK561679 tablet or solution|
223717289|NCT02947685|DRUG|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
224090811|NCT00035451|DRUG|Sotalol|160 mg sot twice daily for 6 months
224090812|NCT02537041|PROCEDURE|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
224090813|NCT02537041|PROCEDURE|MRI|
224090814|NCT05588427|DIETARY_SUPPLEMENT|Ketone ester|A total of 240g ketone ester supplementation will be provided in one of the 28h experimental sessions in order to establish intermittent exogenous ketosis. Sucralose (5% w/w) is added to the ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
224090815|NCT05588427|DIETARY_SUPPLEMENT|Placebo|Water, 5% sucralose (w/w), octaacetate (1 mM)
224090816|NCT02952976|DEVICE|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
223717290|NCT02947685|DRUG|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
224090817|NCT02952976|DEVICE|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
224090818|NCT00863551|DRUG|Trospium Chloride|Extended release, 60 mg, oral daily
224090819|NCT01797718|DRUG|Testosterone|1mg/kg every 4 weeks for 6 months
224090820|NCT01797718|DRUG|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
224279496|NCT05429489|DRUG|Intravenous morphine|Intravenous morphine 0.1 mg/kg
224279497|NCT04080596|DRUG|Dorzagliatin|GKA for T2DM currently under clinical development
223921257|NCT06867016|OTHER|Cognitive Training|Cognitive training involving speed processing, memory recall, problem-solving, and visual attention exercises. Each session will last approximately 20 minutes, and assessments will be performed at baseline, the 4th week, and the 8th week.
223921258|NCT06868017|DRUG|Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses|Cohort A will receive initumab at initial load dose of 8mg/kg and maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses. Pyrrotinib 400mg orally once daily; Combined chemotherapy drugs (not limited, according to the actual clinical selection), a total of 4 cycles of administration
223921259|NCT06868017|DRUG|Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 doses|The initial loading dose of initumab was 8mg/kg, and the maintenance dose was 6mg/kg, which was administered intravenously on the first day of every three weeks. Pyrrotinib 400mg orally once daily; Combined chemotherapy drugs (not limited, according to the actual clinical selection), a total of 6 cycles of administration
223921260|NCT06867796|DRUG|TL-001|Intravenously administered
223921261|NCT06867796|DRUG|Placebo|Intravenously administered
223921262|NCT06866496|BEHAVIORAL|Motivational interviews|Three short and structured motivational enhancement interviews to aid alcohol cessation.
223921263|NCT06866496|OTHER|Standard of Care (SOC)|Standard of care including medical treatment of decompensation, nutrition support, medical treatment of alcohol withdrawal symptoms and craving
223921264|NCT06866522|DEVICE|Whole-body Photobiomodulation Therapy|Whole-body Photobiomodulation Therapy applied for approximately 10 minutes, being 5 minutes with the red wavelength and 5 minutes with the infrared wavelength.
224090821|NCT02415790|DRUG|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
224090822|NCT02415790|DRUG|E2027 matching placebo|E2027 matching placebo capsule will be administered.
224090823|NCT03038347|BEHAVIORAL|Training|Six modules containing PDF-files with text-based information, video files, case studies with associated questions and practical exercises. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules and associated exercises once a week. After six weeks the training is completed.
224090824|NCT03038347|BEHAVIORAL|Education only|Six modules containing only PDF-files with text-based information. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules once a week. After six weeks the education is completed.
224279498|NCT01544439|PROCEDURE|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
224279499|NCT01544439|PROCEDURE|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
224279500|NCT02665884|OTHER|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
224279501|NCT00782561|DRUG|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
224279502|NCT04291508|DRUG|Intravenous Acetaminophen (room temperature)|Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
224279503|NCT04291508|DRUG|Intravenous Vitamin C (refrigerated)|Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
224279504|NCT04291508|DRUG|5% Dextrose (room temperature)|Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses)
224279505|NCT04291508|DRUG|5% Dextrose refrigerated|Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses)
224279506|NCT05144464|BIOLOGICAL|Quadrivalent influenza vaccine|Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
224279507|NCT01446224|DRUG|Pazopanib|Patients treated with pazopanib
224279508|NCT01446224|DRUG|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
224279509|NCT00929058|DRUG|Bevacizumab|Intra-arterial infusion during 6 minutes
224279510|NCT02223286|DIAGNOSTIC_TEST|Corus CAD|Age/Sex/Gene Expression Score
224279511|NCT03566238|DRUG|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
223921265|NCT05815043|BEHAVIORAL|Low-sodium intake|Participants will consume less than or equal to 720 milligrams of sodium per day for 3 days.
223921266|NCT05815043|DIETARY_SUPPLEMENT|High-sodium intake|Participants will supplement their existing diets with 10 salt tablets daily for 3 days.
223921267|NCT04130789|OTHER|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
223921268|NCT04130789|OTHER|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
223921269|NCT06085131|DEVICE|Argos|Argos Biometer
223921270|NCT06878274|RADIATION|Post-operative radiotherapy|Mediastinal post-operative radiotherapy to a dose of 40 Gy in 15 fractions
223921271|NCT06675162|OTHER|Pilates Reformer Training|Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.
223921272|NCT06673758|OTHER|tai chi exercises|tai chi exercises of three basic levels will be given with sessions of two weeks five time a day and follow efftects of tai chi exercises by 6minute walk test and time up and go test and check the results before and after exercises
223921273|NCT06673758|OTHER|Art and crafts activity|Art and crafts activity will be given to control group and check cardiorespiratory fitness before and after arts and crafts activity
223921274|NCT03076021|DRUG|Isotretinoin|Drug interaction study
223921275|NCT03076021|DRUG|dextromethorphan|Drug interaction study
223921276|NCT06681233|DEVICE|Comparison of HyperSight CBCT imaging to conventional CBCT imaging.|Participants will receive their daily radiation treatment on a radiation therapy system equipped with HyperSight CBCT imaging. For at least 1 and up to 3 treatment fractions, participants will receive their daily radiation treatment on a system equipped with conventional CBCT imaging.
223921277|NCT06680141|OTHER|Virtual reality glasses|control group
223921278|NCT05451810|DRUG|Epcoritamab|Subcutaneous Injection (SC)
223921279|NCT06679816|DRUG|Hormone replacement therapy|Perioperative Hydrocortisone Reduction Therapy
223921280|NCT06679816|DRUG|Placebo|Perioperative placebo Reduction Therapy
223921281|NCT06483256|DIAGNOSTIC_TEST|radiographic control|Radiographic study with standard projections (AP and LL) is used to assess any signs of anchor loosening and/or presence of heterotopic ossifications (which can restrict movement and is one of the main complications).
223921282|NCT05227352|BEHAVIORAL|Biophilic design experience|Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
223921283|NCT02311959|PROCEDURE|Nipple sparing mastectomy|"Standardized surgical procedure by :~* Nipple sparing mastectomy with nipple core histopathology.~* Immediate breast reconstruction (flap and/or implant).~* +/- lymph node evaluation (sentinel node procedure or axillary dissection)."
223921284|NCT04519814|PROCEDURE|selective laser trabeculoplasty (SLT)|Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
223921285|NCT06412757|DRUG|Silexan|Participants in the Silexan arm will take two over-encapsulated capsules, each containing 80 mg Silexan, daily orally in the morning in addition to their usual medications. No modifications of allocated interventions will be made for any trial participants; if appropriate (i.e following the emergence of adverse events) participants will be withdrawn from the intervention.
223921286|NCT06412757|OTHER|Placebo|Participants in the placebo arm will take two capsules containing an inert placebo daily orally in the morning in addition to their usual medications. The placebo capsules will contain a sub-therapeutic amount of lavender oil to mimic the odor of the experimental drug (Silexan).
223921287|NCT06621732|PROCEDURE|cutanous biopsy and blood sample|cutanous biopsy and blood sample
223921288|NCT06622720|PROCEDURE|surgery|The colorectal surgery of any type conducted in any approach in the timeframe
223921289|NCT06869473|DRUG|Cetuximab/avelumab|"Study Maintenance therapy: AVEC (each cycle every 2 weeks) Cetuximab will be administered at 500 mg/m2 dose (as a 2-hour intravenous infusion) every 2 weeks until disease progression or unacceptable side effects.~Cetuximab will be administered by IV infusion over 120 minutes. The initial dose should be given slowly and speed of infusion must not exceed 5 mg/min.~Avelumab will be administered at 800 mg flat dose (as a 1-hour intravenous fusion) every 2 weeks until disease progression or unacceptable side effects."
223921290|NCT06869694|DEVICE|computerized tomography|mpMRI and Photon-counting Detector CT scan
224090825|NCT04401657|DIAGNOSTIC_TEST|Fractional flow reserve with adenosine stress testing|ECG, FFR, and two-dimensional echocardiographic monitoring will be continued before, during and after adenosine infusion.
224090826|NCT05146557|OTHER|Dental examination|In this cross sectional observational study only Dental examination and a self response survey was applied.
223921291|NCT06868576|DRUG|Dydrogesterone Oral Tablet|Dydrogesterone 20mg tablets daily in PPOS protocol in ovarian stimulation starting from day 2 or 3 of the menstrual cycle until the triggering day
224090827|NCT04471896|DEVICE|Joovv Mini|Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.
224090828|NCT02763956|DEVICE|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
224090829|NCT02763956|OTHER|Placebo|Intradiscal saline injection
224090830|NCT03014960|OTHER|Online Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
224279512|NCT03566238|DRUG|Placebo|Placebo identical in appearance to active drug (A4250).
224279513|NCT00432055|DRUG|Botulinum toxin type A (Botox)|
224279514|NCT00432055|DRUG|placebo (saline)|
224279515|NCT06057506|DEVICE|Paranix® Shampoo|well established medical device for the treatment of head lice infestation (osmolone based)
224279516|NCT06057506|DEVICE|Paranix® Lotion|well established medical device for the treatment of head lice infestation (dimethicone based)
224279517|NCT02151175|DEVICE|LIFUP|
224279518|NCT06189911|PROCEDURE|Open liver resection|The definitions of liver resection and the type of hepatectomy were aligned with the anatomic classification of the Brisbane 2000 Terminology
224279519|NCT05601778|DRUG|HSK31858|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
224279520|NCT05601778|DRUG|placebo|the placebo comparator of study
224279521|NCT01767727|PROCEDURE|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
223921292|NCT06868576|DRUG|Cetrorelix (Cetrotide)|This will be the conventional antagonist in ovarian stimulation given from day 6 of the menstrual cycle until the triggering day
223921293|NCT06869174|DRUG|Pucotenlimab combined with MRG002|Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W
223921294|NCT06869720|DEVICE|Eccentric bike|Received eccentric cycling exercise
223921295|NCT06869720|OTHER|conventional group|Received conventional treatment
223921296|NCT06869291|PROCEDURE|Multi level and multi tunnel puncture treatment|"Multi level and multi tunnel puncture treatment steps~1. Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times;~2. Use a 1ml syringe to extract lidocaine for local anesthesia of the eyelid xanthoma lesion area;~3. Use a 1ml syringe to puncture the area between the epidermis and dermis layers, nipple layer, and reticular layer of the lesion, with the puncture endpoint at the edge of the lesion. Be careful not to penetrate the skin as much as possible, and when withdrawing the syringe, do not let the needle completely leave the puncture hole, leaving only one pinhole as much as possible; Within the same level, the distance between adjacent puncture tunnel ends is 1mm; Arrange the puncture tunnels staggered within adjacent levels;~4. Cover the injection site with gauze and maintain for 6-8 hours."
223921297|NCT06869291|PROCEDURE|Heparin Sodium Injection|"(1) Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times; (2) Prepare heparin sodium and lidocaine in ratios of 1:1, and prepare 0.1ml of liquid per 1cm2 of lesion area; (3) Use a 1ml syringe to insert the needle from the edge of the lesion near the eyebrow, so that it will not cover the field of view with gauze after injection; (4) The injection depth is the gap between the epidermal layer and the dermis layer, forming an orange peel appearance after injection, and completely covering the lesion area; (5) Cover the injection site with gauze and maintain for 6-8 hours."
223921298|NCT06869291|PROCEDURE|Multi Level and Multi Tunnel Puncture Treatment + Heparin Sodium Injection|(1) Disinfect the area within 1cm outside the edge of the eyelid xanthoma and lesion using iodine and cotton swabs three times; (2) Prepare heparin sodium and lidocaine in ratios of 1:1, and prepare 0.1ml of liquid per 1cm2 of lesion area; (3) Use a 1ml syringe to extract lidocaine for local anesthesia of the eyelid xanthoma lesion area; (4) Use a 1ml syringe to puncture the area between the epidermis and dermis layers, nipple layer, and reticular layer of the lesion, with the puncture endpoint at the edge of the lesion. Be careful not to penetrate the skin as much as possible, and when withdrawing the syringe, do not let the needle completely leave the puncture hole, leaving only one pinhole as much as possible; Within the same level, the distance between adjacent puncture tunnel ends is 1mm; Arrange the puncture tunnels staggered within adjacent levels; (5) Cover the injection site with gauze and maintain for 6-8 hours.
223921299|NCT06867874|PROCEDURE|Blood sample|Blood sample
223921300|NCT06869044|DEVICE|omafilcon A lens|Participants will be randomized to wear omafilcon A lens for 15 minutes.
223921301|NCT06869044|DEVICE|Low ADD power somofilcon A lens|Participants will be randomized to wear low ADD power somofilcon A lens for 15 minutes.
223921302|NCT06869044|DEVICE|Medium ADD power somofilcon A lens|Participants will be randomized to wear medium ADD power somofilcon A lens for 15 minutes.
223921303|NCT06869044|DEVICE|High ADD power somofilcon A lens|Participants will be randomized to wear high ADD power somofilcon A lens for 15 minutes.
223921304|NCT06870552|DEVICE|Single-pulse TMS|A single pulse TMS is delivered at different time points when processing words or numbers.
223530827|NCT04788693|OTHER|Physical rehabilitation of gait with motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.
223921305|NCT06869902|BIOLOGICAL|Colostrum|Use of the patient's mother's inhaled colostrum during the frenotomy
223921306|NCT06677138|DRUG|gefurulimab|Participants will receive gefurulimab subcutaneously (SC).
223921307|NCT06625671|DRUG|DB-2304|DB-2304
223921308|NCT06625671|DRUG|Placebo|Placebo
224090831|NCT00680225|DRUG|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
224090832|NCT01569633|DRUG|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
224090833|NCT01569633|DRUG|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
224090834|NCT01569633|DRUG|placebo|The dose of sugar water is 1 ml per 8 hours.
224090835|NCT03837184|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
224090836|NCT00415220|PROCEDURE|Spinal Manipulation, Microdiscectomy|
224090837|NCT06172556|PROCEDURE|Endovascular coiling, Surgical clipping, Mix|Endovascular coiling, Surgical clipping, Mix
224090838|NCT00763009|DRUG|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
224090839|NCT00758784|DRUG|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
224090840|NCT02906553|DRUG|Glyceryl Trinitrate|
224090841|NCT02906553|DRUG|Placebo|
223530828|NCT04788693|OTHER|Physical rehabilitation of gait without motor imagery|Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. Motor imagery exercises are not included in this program.
223717291|NCT02947685|DRUG|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
223921309|NCT06625671|DRUG|Prednisone|Prednisone
223921310|NCT03351998|DRUG|Lipitor 20Mg Tablet|20 mg/day pills.
223717292|NCT02947685|DRUG|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
223717293|NCT02947685|DRUG|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
223921311|NCT03351998|DRUG|Lipitor 80Mg Tablet|80 mg/day pills.
223921312|NCT03351998|DRUG|Placebo Oral Tablet|Matching placebo pill.
223921313|NCT06440447|OTHER|Adult day program use|Day program use patterns will be determined, using Latent Class Analysis. Three continuous variables will be categorized as low, low-moderate, high-moderate, high, using sample distribution quartiles: (1) Time between first RAI-HC assessment and first attendance of a day program, (2) average number of hours of day program attendance (i.e., total number of hours spent in a day program divided by the number of times attended), and (3) total number of days a person attended a day program.
223921314|NCT06440447|OTHER|Other community care (non-attendees)|Any publicly funded continuing care services in the community, other than adult day programming (e.g., home care, in-home respite). Community care participants will be propensity score matched with day program participants, using RAI-HC variables on day program eligibility (to ensure similarity of non-attendees to day program attendees). Matching variables will include: physical functioning, cognition, behavioural symptoms, bladder/bowel continence, availability of a caregiver, and caregiver distress. The investigators will also include variables on health and social characteristics (e.g., age, sex, type/duration of publicly funded community care received before the matching index date, deprivation indices).
223921315|NCT04832412|DIETARY_SUPPLEMENT|BrainPhyt|BrainPhyt low dose supplementation during 6 months
223921316|NCT04832412|DIETARY_SUPPLEMENT|100 % Maltodextrin|100 % Maltodextrin
223921317|NCT06078891|BIOLOGICAL|BCG vaccine|Three intra-dermal vaccinations over a period of one year.
223921318|NCT04814654|BEHAVIORAL|CHALO! 2.0|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) on the following topics: HIV testing, prevention, treatment, linkage-to-care; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
223921319|NCT04814654|BEHAVIORAL|Attention-matched control (AMC)|"The components of the intervention are:~Contents of digital-media (sent twice/week for 12 weeks) only related to general health information; Personalized digital coupon for free testing; Webpage listing testing/ care sites; access to online outreach workers."
223921320|NCT04814654|BEHAVIORAL|Digital coupon only (DCO)|"The components of the intervention are:~Digital coupon for free HIV testing; Webpage listing testing/ care sites; access to online outreach workers."
223921321|NCT04986631|DRUG|Topiramate Tablets|Topiramate intervention
223921322|NCT05376527|BIOLOGICAL|Double Recombinant Vaccinia Virus VV-GMCSF-Lact|"Intratumoral injections:~1\*107 PFU (calculated at minimal ED on mice); 2\*107 PFU; 4\*107 PFU; 6\*107 PFU; 8\*107 PFU; 10\*107 PFU;"
223921323|NCT04703920|DRUG|Talazoparib|Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
223921324|NCT04703920|DRUG|Belinostat|Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
223921325|NCT05265520|PROCEDURE|His-CRT implantation|The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.
223921326|NCT05265520|PROCEDURE|BIV-CRT implantation|Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
223921327|NCT06336291|DRUG|L19TNF|7 μg/kg
223921328|NCT06336291|DRUG|L19TNF|10 μg/kg
224090842|NCT01055509|BEHAVIORAL|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
223921329|NCT06336291|DRUG|L19TNF|13 μg/kg
224090843|NCT01096147|DEVICE|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
224090844|NCT05527951|OTHER|eMBC|The experimental group will implement eMBC with our WeChat Easy to Recover from Depression Mini-Program, which consists of mood tracking and lay-coached self-management.
223921330|NCT06336291|DRUG|Lomustine|90 mg/m2
223921331|NCT06336291|DRUG|Lomustine|110 mg/m2
223921332|NCT06872203|DEVICE|Deep brain stimulation|Deep Brain Stimulation programming
223921333|NCT06873217|OTHER|Acupuncture|Once a patient with Vertigo and Dizziness came to the emergency department, emergency physicians ask if they were willing to accept acupuncture intervention in addition to the routine western medical care.
223921334|NCT06872918|PROCEDURE|Lever positioning manipulation|The patient was placed in the prone position, and the doctor used one-finger Zen pushing, rolling, pressing and kneading, flicking and plucking methods in the patient's lumbar region and the affected side of the lower limb pain repeated massage treatment for 15min; the patient was placed in the prone open-mouth position, and the operator stood on the right side of his/her body, so that the whole body of the patient's muscles were relaxed. According to the type of herniation, the patient with paracentral lumbar disc herniation performed unilateral triggering mode, and the patient with central lumbar disc herniation performed bilateral triggering mode.
223921335|NCT06872918|PROCEDURE|Cluster of pseudo-manipulators|Sham manipulation treatment was given. Recipients take the prone position, the medical practitioner with a finger Zen push method, rolling method, pressing and kneading method, flicking and plucking method in the patient's lumbar region and the affected side of the lower limbs of the pain in the repeated massage treatment for 15min; patients prone position, with traction rope fixed lumbar disc herniation side of the affected limb, so that the affected limb back to the maximum extent of the extension, and then release the traction rope, simulating the backward extension of the force of the lever positioning manipulation, the medical practitioner does not do any manipulation.
223921336|NCT06872918|PROCEDURE|Mechanics and kinematics data acquisition of unilateral wrenching patterns in lever positioning manipulation|During the unilateral trigger mode operation of the lever positioning manipulation, the operator wears a mechanics sensing glove to collect the mechanics parameters of the manipulation, including: hand preload force, hand trigger maximum force, elbow compression preload force, and elbow compression maximum force. At the same time, a motion capture system was used to collect the kinematic parameters of the lever positioning manipulation, including: loading backward extension angle, loading backward extension trigger angle, average trigger time, maximum speed, and maximum acceleration.
223921337|NCT06872918|PROCEDURE|Mechanics and kinematics data acquisition of bilateral wrenching patterns in lever positioning manipulation|During the bilateral triggering mode operation of the lever positioning manipulation, the operator wore a mechanics sensing glove to collect the mechanics parameters of the manipulation, including: hand preload force, hand triggering maximum force, elbow pressing preload force, and elbow pressing maximum force. At the same time, a motion capture system was used to collect the kinematic parameters of the lever positioning manipulation, including: loading backward extension angle, loading backward extension trigger angle, average trigger time, maximum speed, and maximum acceleration.
223921338|NCT06872424|BEHAVIORAL|psychosocial skills-oriented group psychoeducation|A 5-session Psychosocial Skills Focused Group Psychoeducation will be implemented, each session lasting approximately 60-90 minutes. In order to make the training more active and effective, the experimental group will be divided into small groups and divided into 3 groups and each group will be given 5 sessions of Psychosocial Skills Focused Group Psychoeducation once a week.
223921339|NCT06868849|DRUG|JMT203 Injection|"Drug：JMT203 Injection~* Anti-GFRAL monoclonal antibody~* Will be injected subcutaneously once per cycle (3 weeks, on Day 1) for 12 weeks, or will be injected subcutaneously once per cycle (3 weeks, on Day 1)."
223921340|NCT06868615|DEVICE|AVAVA|1550nm Non-Ablative Fractional Laser
223921341|NCT06870461|PROCEDURE|Liver surgery / ablation|Any type of liversurgery or CT-guidede liver ablation
223921342|NCT06870188|OTHER|Composite Restoration|The study included premolar or molar teeth with Class 1 and Class 2 cavity types and a remaining wall thickness of at least 3 mm, which had undergone endodontic treatment from volunteer participants. The teeth randomly assigned were divided into two groups: Group 1: fiber-reinforced composite restoration (FRCR), Group 2: composite restoration (CR). Direct composite restorations with or without fiber reinforced material were applied. The restorations were evaluated at 6 and 12 months using the FDI criteria.
223921343|NCT06870188|OTHER|Clinical evaluation|The restorations were evaluated by two experienced and fully blinded observers according to the functional, esthetic, and biological criteria. The criteria were scored from 1 to 5 (sufficient/acceptable= score 1 to 3, insufficient/inacceptable but repair possible= score 4, and insufficient/inacceptable but repair not possible/reasonable= score 5). Scores of 4 and 5 were considered as failure in the restoration.
223921344|NCT06869083|OTHER|AF application enhancing AF education and drug adhrence|This group will use AF-application. The app will include content related to anticoagulation therapy, such as: medication reminders or intake confirmation for anticoagulants, the importance of anticoagulation therapy in stroke prevention, the role of antiarrhythmic and rate-control medications in symptom management, the necessity of controlling risk factors such as hypertension, diabetes, and hyperlipidemia, and quality of life and cognitive function assessments through questionnaires.
223921345|NCT06869083|OTHER|AF application without enhancing AF education and drug adhrence|This group will use AF-application. However, this application will not contain materials enhancing AF education and adherence.
223921346|NCT06872164|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based psychotherapy for PTSD that provides education and teaches skills to challenge the trauma-related beliefs that maintain PTSD symptoms. In this study, CPT has been adapted to include content on the relationship between substance use and PTSD and a focus on harm reduction.
223921347|NCT06873555|DRUG|DC05F01|DC05F01 capsule
224090845|NCT05527951|OTHER|standard MBC|The control intervention group will implement standard MBC using paper and pencil questionnaires.
224090846|NCT00000312|DRUG|M-CPP|
224090847|NCT00327938|DEVICE|Measuring of skin conductance|
224090848|NCT00327938|PROCEDURE|Tetanic stimuli|
224090849|NCT05773391|DRUG|Take probiotics|Take medication for 21 days (Yihuo 0.2g bid+ Jin Bifid2g tid)
224090850|NCT02734173|DRUG|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
224090851|NCT01840046|DRUG|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
223530829|NCT06588101|OTHER|Written informed consent with infographic|Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.
223530830|NCT06588101|OTHER|Compensation|Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.
223921348|NCT06871995|PROCEDURE|spinal block|All patients will receive spinal anesthesia via midline approach with patients in sitting position established by assistant under complete aseptic conditions. A subcutaneous bleb using Lidocaine 1% through the needle of an insulin syringe followed by minor skin scratch to will help avoiding possible intrathecal dermoid implantation . A lumbar puncture will be performed in L4-L5 or L5- S1 interspace using 25-G 25-mm pencil-point spinal needle . Depth of epidural space is anticipated at 0.1 mm/kg . After getting free flow of cerebrospinal fluid (CSF) hyperbaric bupivacaine (0.5%) in a dose of 0.5 mg/kg (0.1 ml/kg) will be slowly injected in the subarachnoid space . The end of the injection will be taken as time zero for further data recording.
223921349|NCT06872879|OTHER|VEMS Simulation|"Students in the VEMS (Visually Enhanced Mental Simulation) group will receive a structured training programme to improve their PPH management skills. This process consists of three main stages: Theoretical training, skills training and simulation practice.~1.1 hour theoretical training will be given to the students to remind them the basic information about PPH management.~2\. PPH management will be mentally visualised step by step using VEMS materials. Students will be individually involved in the scenario and will apply the steps of PPH management in a mental simulation environment. After the scenario is completed, a 30-minute debriefing session will be organised.~3\. Manikin simulation will be used to evaluate students' PPH management skills. Students' PPH management skills will be evaluated using the Postpartum Haemorrhage Management Observation Form. Attitudes towards the learning process will be measured by applying the Student Satisfaction and Confidence in Learning Scale."
224090852|NCT03978273|DEVICE|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~* They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~* They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
224090853|NCT03978273|OTHER|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
223530831|NCT06654232|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at collecting a complete overview of different aspects of quality of life, including:~* Florida patient acceptance score (FPAS)~* Short Form Health Survey (SF-12)~* Kansas City Cardiomyopathy Questionnaire (KCCQ-12)~* Hospital Anxiety and Depression Scale (HADS)~* Florida Shock Acceptance score (FSAS)~* Steinke Sexual Concerns Inventory~* the Good Death questionnaire"
223530832|NCT06987656|DRUG|Standard Pharmacologic Treatment|Standard pharmacologic management including nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants (e.g., thiocolchicoside), and analgesics (e.g., paracetamol, tramadol) for acute lumbar spasm.
223530833|NCT06987656|OTHER|Physiotherapy Intervention|Physiotherapy interventions included spinal mobilization (Maitland techniques), myofascial release, transcutaneous electrical nerve stimulation (TENS), and personalized exercise programs, as documented in patient medical records.
223717294|NCT02947685|DRUG|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
223717295|NCT02947685|DRUG|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
223717296|NCT05465460|DRUG|Banana Blossom|Banana Blossom 225 mg tablet orally four times per day for 14 days
223717297|NCT05465460|DRUG|Placebo|Placebo tablet orally four times per day for 14 days
223717298|NCT04274413|COMBINATION_PRODUCT|Beta Adrenergic Sweat Test|"In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.~1. Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.~2. Under the first probe, injection atropine will be given in one small area of the skin.~3. Under the second probe, first injection carbachol will be given in one small area of the skin.~4. Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.~5. Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded."
223921350|NCT06872879|OTHER|Hybrit Simulation|"Students in the hybrid simulation group will receive a simulation-based training in which the standard patient and part task trainer are used together. This process consists of three main stages: theoretical training, skills training and simulation practice.~1.1 hour theoretical training to remind basic information about PPH management. 2. Standard patient and part task trainers will be used in the skills training of the students. Students will make patient assessment, check vital signs and plan necessary interventions by contacting the standard patient.After the scenario is completed, a 30-minute debriefing session will be organised.~3\. Manikin simulation will be used to evaluate students' PPH management skills. Students' PPH management skills will be evaluated using the Postpartum Haemorrhage Management Observation Form. Attitudes towards the learning process will be measured by applying the Student Satisfaction and Confidence in Learning Scale."
223717299|NCT00225550|DRUG|ADH -1 (Exherin™)|
223717300|NCT00096798|DRUG|Ethyl-eicosapentanoic acid (ethyl-EPA)|
223921351|NCT04107116|BEHAVIORAL|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
223921352|NCT04107116|OTHER|Usual Care|Usual care as provided by local oncologists
223921353|NCT06685224|DIAGNOSTIC_TEST|Ultrasound Assessment of the aeration of lung tissue and Parasternal Intercostal Muscle Thickness|Examine the predictive value of lung ultrasound in assessing the success of SBTs and tracheal extubation among patients receiving mechanical ventilation in the intensive care unit (ICU)
223921354|NCT06684470|DRUG|Mirtazapine|mirtazapine will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
224090854|NCT03339804|OTHER|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
223921355|NCT06684470|OTHER|Placebo|Placebo will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
223921356|NCT06685289|DRUG|Donafenib|200mg, oral, twice daily, continuous medication for 6 months
223921357|NCT06685289|DRUG|capecitabine|1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)
223921358|NCT05925621|DRUG|Lecanemab|Observational study
224090855|NCT02047006|DRUG|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
224279522|NCT02710591|DRUG|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight \> 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight \> 30kg at Baseline"
224279523|NCT02300168|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
224279524|NCT00597428|DRUG|Lubiprostone|24 mcg capsules twice daily (BID)
224279525|NCT00597428|DRUG|Placebo|0 mcg capsules twice daily (BID)
224279526|NCT04666597|PROCEDURE|Modified CariesCare International management|"Interventions of this single-group study correspond to the 4D, to be implemented by the external DP, when possible with remote care and only with non-AGP:~1. D-DETERMINE risk assessing the protective and risk factors (social/medical/behavioural and clinical), using remote tools. Additionally, the description of tooth brushing behaviours and consumption of free sugars is included.~2. D-DETECT \& ASSESS: Caries staging and activity: ICDAS-merged visual criteria Caries OUT (without using compressed air, and avoiding radiographs). Clinical risk factors are assessed as well.~3. D-DECIDE a personalized care plan: individually designed for caries management home and clinical approaches.~4. D-DO: Appropriate Tooth-preserving \& Patient-level caries: Management plan at the Patient and at the Lesion level and the implementation of the Change Behaviour Tool (CBT) designed for this protocol.~The follow-up data will include a T1, T2 and T3 assessment."
224279527|NCT05404451|DIAGNOSTIC_TEST|Mulligan Mobilization|Using the Technique of Mulligan Mobilization
224279528|NCT05404451|DIAGNOSTIC_TEST|Mckenzie Exercises|Using Mckenzie Exercises
224279529|NCT06492551|OTHER|Trak exercise prescription protocol|Online treatment based on therapeutic exercise using the Trak software. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques to improve secretion management and respiratory mechanics will also be included.
223530835|NCT07004842|OTHER|48 hr Respite Service|Caregivers will be provided with 48 hours of respite service within 6 months. Trained alternative caregivers will provide elderly-sitting service at their home, allowing the caregivers to have their personal time.
223530836|NCT07004400|DEVICE|RefluxStop™ implantation|Standard surgical technique for implantation RefluxStop™, as described in the Instructions for Use
223530837|NCT07004400|PROCEDURE|Nissen fundoplication|Standard surgical technique for Nissen fundoplication
223530838|NCT04810091|DRUG|Placebo Administration|Given PO
223530839|NCT04810091|OTHER|Questionnaire Administration|Ancillary studies
223530840|NCT04810091|DRUG|Telotristat Ethyl|Given PO
223530841|NCT06920238|DEVICE|Therabot-CALM|Therabot is a generative-AI-driven mobile app designed to provide mental health treatment. The feasibility of Therabot-CALM, an adapted Therabot application, is being tested for the future use of treating co-occurring substance use disorders and anxiety and/or depression. The primary purpose of this study is application feasibility.
223530842|NCT06921707|DEVICE|Clinical Decision Support Tool|WounDx is a clinical decision support tool that will help augment the clinicians' judgment regarding the wounds readiness to close.
223530843|NCT06921707|PROCEDURE|Standard of Care (SOC)|The standard of care consists of serial wound irrigation, negative pressure wound therapy, and surgical debridement
223530844|NCT06680583|OTHER|physical indicators such as shock index relatives|shock index relatives indicators used in the prediction of cirrhosis with gastrointestinal bleeding
223530845|NCT07002853|OTHER|Nature-based Intervention|Combination of activities in nature such as walking, exercises (strengthening, mobility, balance), mindfulness, guided meditation, forest bathing or Shinrin-Yoku, interpretation of nature, gardening and pain education.
223530846|NCT06868485|DRUG|WSD0922-FU Tablets, Dose level A|Oral, 21 days in each cycle
223530847|NCT06868485|DRUG|WSD0922-FU Tablets, Dose level B|Oral, 21 days in each cycle
223921359|NCT06407700|PROCEDURE|Brugger's exercise.|Participant was in a high sitting position. An elastic resistance band was be wrapped on each hand of the participant leaving the palm open and instructed to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant were instructed to perform scapular retraction with chin tucked in ,shoulder external rotation, elbow extension, shoulder abduction, and extension. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds, 4 sets 12 times repetitions.
223921360|NCT06407700|PROCEDURE|Kendall Exercise.|Kendall exercises with the frequency 5 sets of consisting of 12 repetitions of postures, each taking 30 seconds,3 times a week for total of 6 weeks.
223921361|NCT04189146|BEHAVIORAL|Inner Engineering Intervention|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
223921362|NCT06243835|DRUG|Kindolor Tosylate|Kindolor Tosylate enteric coated tablets containing the specified amount of drug product
224279530|NCT06492551|OTHER|Conventional rehabilitation plan in the gym|Treatment is based on therapeutic exercise following a conventional rehabilitation plan. The patient will undergo 6 weeks of an exercise prescription protocol based on strength, balance, proprioception, and aerobic exercises. Physical therapy techniques will also be included to improve secretion management and respiratory mechanics.
223719570|NCT03425877|BEHAVIORAL|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, \& Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley \& Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
223921363|NCT06243835|DRUG|Placebo|Placebo enteric coated tablets identically matched to the Kindolor Tosylate tablets with equal amount of Prosolv SMCC replacing the Kindolor Tosylate
223921364|NCT06691282|OTHER|Mindful self-compassion intervention|Participants will receive six weekly sessions of training by a trainer in mindful self-compassion (MSC). Each session lasting around 90 minutes and will be conducted face-to-face at the Hong Kong Metropolitan University. The content of the intervention will include an introduction of mindfulness and self-compassion, practice of body awareness and loving kindness, skills to deal with challenging experiences, and methods for relating to positive aspects of the self.
223921365|NCT03048084|DRUG|Levetiracetam|Antiepileptic drug levetiracetam
223921366|NCT03048084|DRUG|Valproic Acid|Antiepileptic drug valproic acid
223921367|NCT06688162|OTHER|Usual Care|During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
224090856|NCT03649919|OTHER||Patients receive routine diagnostic and treatment medications.
224090857|NCT01560351|DEVICE|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
224090858|NCT00918944|OTHER|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~* A data entry tool for capturing asthma control data~* Standardized documentation templates to facilitate severity classification~* Order sets to facilitate ordering controller medications~* An asthma care plan that can be supplied to families"
224090859|NCT00918944|OTHER|Intervention|"Three alerts and two reminders will be programmed:~* Alert providers to enter asthma severity classification if none is on file~* Alert providers to prescribe controller medications for persistent asthma if none on file~* Alert providers to complete an asthma care plan if none on file~* Remind providers to review the asthma care plan if it is already on file by providing a link to the form~* Remind providers that educational content is available on-line by providing a web link"
224090860|NCT02491385|PROCEDURE|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
224090861|NCT02491385|DRUG|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
224090862|NCT03514914|BEHAVIORAL|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture \& contextually-tailored family planning and gender equity counseling.
224090863|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade the Flexor Hallucis|
224090864|NCT02825121|DEVICE|Monitoring Neuromuscular Blockade adductor of the thumb.|
224090865|NCT00891735|DRUG|Ranibizumab|Sterile solution for intravitreal injection.
224090866|NCT03707457|DRUG|Nivolumab|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
224090867|NCT03707457|DRUG|Anti-GITR Monoclonal Antibody MK-4166|Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
224279531|NCT03744286|DEVICE|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
223530848|NCT06089070|DEVICE|FreeStyle Libre Continuous Glucose Monitor System|Continuous Glucose Monitor System for people with Type 2 Diabetes
223530849|NCT06629064|BEHAVIORAL|Working Memory Training|Computer-administered working memory training program. WMT is a modified working memory capacity task designed to train working memory functioning. WMT is designed to contain high interference across trials and is adaptive to performance. As participants improve working memory, the task becomes more difficult.
223530850|NCT06629064|OTHER|Sham Training|The Sham condition requires participants to complete a similar computer task for the same length of time. The Sham Training is a modified working memory capacity task designed to place less demands on working memory.
223530851|NCT06689072|OTHER|rTMS|To evaluate the role of repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (DLPFC) in reducing pain, decreasing craving, alleviating withdrawal symptoms, lowering relapse rates, reducing impulsivity, and improving cognitive function in patients with Opioid Use Disorder
223530852|NCT06689072|BEHAVIORAL|Psychotherapy|Using psychotherapy in opioid use disorder.
223530853|NCT06870916|OTHER|Multi-cancer Early Detection|Participants will participate in a focus group discussion asking about your knowledge, preferences, and concerns for MCEDs. During the focus group discussion, investigators will specifically talk about what the tests are and how to decide to get the test as well as their risks and benefits.
223717301|NCT04254497|DIAGNOSTIC_TEST|EGFR mutation detection kit|A microsieve membrane filter device to effectively isolate circulating tumor cells from whole blood sample has been developed by the Institute of Bioengineering and Nanotechnology. The device exploits the size difference between cancer cells and blood cells to achieve the cancer cell capture on a microsieve filter with \> 85% recovery rate from 4.5-ml whole blood within 10 min, demonstrated with cancer cells spiked into whole blood samples. The device contains a densely packed pore array (\> 8000 pores/mm\^2) with an optimized pore diameter of 10 µm. Fluid regulation and cell counting are achieved by a simple vacuum pumping and laboratory fluorescence microscope. The captured cells are stained with anti-EpCAM-PE for CTCs, anti-CD45-FITC for white blood cells, and 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei. The CTCs are identified with anti-EpCAM positive, anti-CD45 negative and DAPI positive, characterized using a fluorescence microscope.
223717302|NCT06408610|OTHER|moderate intensity continuous training|exercise and diet
223717303|NCT05001737|DRUG|Emapalumab|Emapalumab iv infusion
223921368|NCT06688162|PROCEDURE|Minimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)|This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
223921369|NCT06691594|RADIATION|neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy|"Eligible participants will receive neoadjuvant treatment consisting of:~SBRT: One session of 10Gy radiation to the primary tumor, followed by a 150mg subcutaneous injection of pembrolizumab (PD-1 inhibitor).~Chemotherapy and Immunotherapy: One week after SBRT, participants will undergo 6 cycles of pembrolizumab (400mg), albumin-bound paclitaxel (250mg/m²), and carboplatin (AUC=5).~Surgery: Surgery will be performed 21 days after the last chemotherapy cycle, with either breast-conserving surgery or modified radical mastectomy. Pathological evaluation will assess the treatment response.~Adjuvant Immunotherapy: Four weeks post-surgery, patients will receive pembrolizumab every 3 weeks for up to 1 year."
224090868|NCT03707457|DRUG|IDO1 inhibitor INCB024360|Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
224090869|NCT03707457|DRUG|Ipilimumab|Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
223717304|NCT04610944|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication.
223717305|NCT03278873|BIOLOGICAL|Prior exposure to AAV-CNGA3 or AAV-CNGB3|Participants previously received AAV-CNGA3 or AAV-CNGB3 in an open-label, Phase 1/2 dose escalation trial for adults and children with achromatopsia owing to defects in CNGA3 or CNGB3, respectively.
223717306|NCT04993742|BEHAVIORAL|MOMS Intervention|Behavioral: Mentors Offering Maternal Support (M-O-M-S) 10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
223717307|NCT01652209|BIOLOGICAL|Hearticellgram-AMI|
224090870|NCT03432728|PROCEDURE|Dental rehabilitation under general anesthesia|Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia
224090871|NCT02850419|DRUG|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
223530854|NCT06874296|DEVICE|Quality Assessment with Normothermic Machine Perfusion (NMP)|"Quality assessment using NMP in the experimental arm is performed according to previously published viability criteria for initially declined liver grafts, which are mandatory for all participating study centers, with minor device-specific modifications. These criteria are based on the Birmingham criteria used in the VITTAL trial for viability assessment of DBD and DCD grafts with the OrganOx Metra device and are comparable to the Groningen criteria previously established with the LiverAssist device, with the exception of biliary viabilit~These criteria are: Lactate clearance \< 2.5 mmol/L, And two or more of the following: Evidence of bile production, maintenance of a perfusate pH \>7.30 (without correction for at least one hour), glucose metabolism (falling perfusate glucose value with consistent downward trend), maintenance of stable arterial and portal venous flows (OrganOx Metra: 150 and 500 mL/min respectively), homogeneous perfusion with soft consistency of the parenchyma."
223921370|NCT06690736|DIAGNOSTIC_TEST|CXCR4 PET/CT Imaging|Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
223530855|NCT06716021|DRUG|Placebo|The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.
223921371|NCT06624215|PROCEDURE|Appendectomy|Robotic-assisted or laparoscopic appendectomy for acute appendicitis.
223921372|NCT06622668|BIOLOGICAL|Biological NTLA-3001|IV administration of AAV and CRISPR/Cas9 gene editing system
223921373|NCT03522298|DRUG|Paxalisib (GDC-0084)|Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
223921374|NCT04752696|DRUG|Onvansertib|Oral capsule
223530856|NCT06716021|DRUG|Etripamil|The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.
223717308|NCT05243641|DRUG|Neratinib|Nertatinib will be supplied as 40 mg tablets, equivalent to 48.31 mg neratinib maleate.
223717309|NCT05243641|DRUG|Capmatinib|Capmatinib will be supplied at 200 mg and 150 mg tablets
223921375|NCT04752696|DRUG|Nanoliposomal irinotecan|Intravenous infusion
223921376|NCT04752696|DRUG|Leucovorin|Intravenous infusion
223921377|NCT04752696|DRUG|Fluorouracil|Intravenous infusion
223921378|NCT06874920|OTHER|No intervention (observational study)|No intervention (observational study)
223921379|NCT06874582|DEVICE|silicone hand or finger prosthesis|To the best of the author's knowledge, no previous studies have evaluated and compared customised finger and partial silicone prostheses in both extremities. This feature distinguishes the present study from other studies.
224090872|NCT02850419|RADIATION|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
224090873|NCT02850419|DEVICE|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
224090874|NCT03226626|DRUG|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) \& Intravenous antibiotic delivery (IVAD).
224090875|NCT03226626|DEVICE|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
224090876|NCT02183714|DRUG|Songha Night ®|
224090877|NCT02183714|DRUG|Placebo|
224090878|NCT05289960|OTHER|lung ultrasound|Lung ultrasound score was done at the end of SBT using curved array ultrasound probe 2-5 MHz, Siemens X300, Korea
223530857|NCT06724159|DRUG|darolutamide|Darolutamide in combination with androgen deprivation therapy and docetaxel. Following the posology and administration details of its marketing authorization and standard clinical practice
223530858|NCT06724159|DRUG|Nivolumab monotherapy|Adjuvant nivolumab following after surgical removal of urothelial carcinoma. Following the posology and administration details of its marketing authorization and standard clinical practice
223530859|NCT06724159|DRUG|enfortumab vedotin|Following the posology and administration details of its marketing authorization and standard clinical practice
223530860|NCT06725706|DIAGNOSTIC_TEST|18F-92/AV45, 11C-PIB|Each subject receive a single intravenous injection of 18F-92/AV45, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
223530861|NCT07040644|DRUG|Sacituzumab Govitecan (SG)|Sacituzumab govitecan will be administered at 10 mg/kg via intravenous infusion on Days 1 and 8 of each 21-day cycle. The treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
223530862|NCT07040644|DRUG|Toripalimab|Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion on Day 1 of each 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
223530863|NCT07040644|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 125 mg/m² via intravenous infusion on Days 1 and 8 of each 21-day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient withdrawal.
223530864|NCT06725095|OTHER|Placebo gel|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of a placebo gel
223717310|NCT05464719|DRUG|Loncastuximab Tesirine|Given by IV
223921380|NCT06874582|DEVICE|silicone foot and foot toe prosthesis|To the best of the author's knowledge, no previous studies have evaluated and compared customised finger and partial silicone prostheses in both extremities. This feature distinguishes the present study from other studies.
224090879|NCT04080011|DEVICE|NP-PWD|Application of NP-PWD device.
224090880|NCT04514263|OTHER|OHIP-14 Administration|All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
224090881|NCT04514263|OTHER|VNS Administration|All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
224090882|NCT02325544|BEHAVIORAL|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.~Standardised medical as described in other intervention."
224090883|NCT02325544|BEHAVIORAL|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
224090884|NCT02506530|PROCEDURE|intensive decongestive treatment|intensive decongestive treatment
224090885|NCT02506530|DEVICE|Cellu M6|Use of Cellu M6
224090886|NCT02814773|OTHER|questionnaires|
223530865|NCT06725095|OTHER|Enamel Matrix Proteins Derivative|Patients were treated with non surgical peri-implant mucositis therapy with non-surgical sub-marginal peri-implant instrumentation plus the use of non-surgical treatment plus Enamel Matrix Proteins Derivative
223921381|NCT06875531|OTHER|Creative Drama trainings|"* The experimental group will be trained with the creative drama method and the control group will be trained with the traditional teaching method in line with the learning objectives on the topics of human dignity, responsibility, taking action, safety, autonomy.~* Creative Drama trainings will be carried out by the creative drama leader and the trainings will be continued in line with the creative drama training steps, starting with the warm-up phase, and continuing with the game, activity, improvisation and evaluation phases. Creative drama methods will be used in accordance with each topic. For each stage of the training, students will be divided into equal groups so that group members will change. Each session of creative drama training; 10 minutes for the warm-up stage, 30 minutes for the game activity stage, 30 minutes for the improvisation stage, 20 minutes for the formation and evaluation stages, and each topic will be carried out for a total of 90 minutes."
223530866|NCT06922851|PROCEDURE|Immunoadsorption|Immunoadsorption (IA) therapy using a protein A column for four consecutive days, plus immunoglobulin supplementation after IA
223530867|NCT06740812|DRUG|Fosaprepitant for Injection|Fosaprepitant 150mg IV administered over 15 minutes
223530868|NCT06740812|DRUG|Metoclopramide Injection|Metoclopramide 10mg IV administered over 15 minutes
223530869|NCT07058298|DRUG|GC012F injection|"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment,the infusion doses will be (CAR-T cell count) 3 × 10\^5/kg.~Note: for subjects weighing ≤70 kg: number of infused CAR-T cells = 3 (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CART cells (fixed doses of GC012F Injection) = 3 (±20%) × 10\^5 × 70 kg."
223717311|NCT04457193|DEVICE|TIF|Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
223717312|NCT04125836|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
223921382|NCT04661280|DRUG|Donepezil|Donepezil 5 mg per day during one month, then 10 mg per day during 5 months.
223530870|NCT03552445|BIOLOGICAL|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
223717313|NCT05326165|DEVICE|Juzo Compression Sleeve and Glove|Elasticized garment sized for arm and hand to create pressure to reduce swelling
223921383|NCT06874166|OTHER|Electroencephalography (EEG)|Recording of resting state EEG will be collected
223921384|NCT06874166|OTHER|Social Cognition Tasks|Comfort-Distance Task: it will be used to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality environment Interoception will be measured through an auditory match task based on participants heart-beat A measure emotion processing will be collected through the emotion priming visual task, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming
223717314|NCT05326165|DEVICE|Compression Sleeve Sensor|Small device embedded within compression sleeve garment collecting usage information
223717315|NCT06666907|DEVICE|Smilefy|AI based DSD
223717316|NCT06666907|DEVICE|EXOCAD|Conventional DSD software
223717317|NCT03847649|DRUG|Durvalumab|1500 mg IV, 60 min, Day 1 every 4 weeks
223717318|NCT03847649|DRUG|Prednisone|0.5mg/kg; PO, Daily cycles 1 \& 2
223921385|NCT06874257|BIOLOGICAL|Laboratory tests and in vitro studies|Cell models, co-culture condition set-up and functional validation, Single-cell RNA sequencing and NGS, Metabolomics analysis, metabolomics validation and intracellular metabolomics analysis, Metabolic ImmunoProfiling and epigenetic profile, CyTOF immune and signaling profiling, Monocyte, macrophages and MSCs in vitro assays.
223921386|NCT06875726|BEHAVIORAL|Sidekick|Sidekick is a just-in-time adaptive intervention that sends behavior change messages based on personalized sleep and physical activity goals.
223921387|NCT06874725|DRUG|Rifapentine and Isoniazid for 3 months|tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)
223921388|NCT06874725|DRUG|Isoniazid (INH) daily for 9 months|tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)
223921389|NCT04151368|PROCEDURE|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
223530871|NCT03552445|BIOLOGICAL|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
223530872|NCT03552445|BIOLOGICAL|Td alone|437 Td recipients: one vaccine injection administered on Day 0
223717319|NCT03847649|DRUG|Prednisone|10mg, PO, Daily cycles 1 \& 2
223717320|NCT03847649|DRUG|Tremelimumab|Patients previously enrolled on a completed CCTG trial to continue treatment with durvalumab (+/- tremelimumab)
223717321|NCT04067752|OTHER|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
223717322|NCT04067752|OTHER|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
223717323|NCT06315595|OTHER|Non-Interventional Study|Non-interventional study
223921390|NCT06874049|DRUG|Vaginal misoprostol|the vaginal misoprostol solution will be prepared by complete crushing of one misoprostol 200 µg tablet into powder then adding the powder into a clean urine specimen cup then adding 20 cc of KY gel measured by a 20 ml syringe then mix the contents together to ensure adequate distribution of the powder , each patient will receive only 2.5cc of the mixture vaginally (inserted into the posterior fornix,) by using medical 3ml syringes equal to 25 mcg misoprostol 4 hourly according to International Federation of Gynecology and Obstetrics (FIGO2023) and remain recumbent for 10-20 minutes
223921391|NCT06874049|DRUG|Oral misoprostol solution (OMS)|the solution will be prepared by dissolving one 200 µg tablet in 200 ml of tap water , each member will receive 25 cc misoprostol solution equal to 25 mcg misoprostol 2 hourly according to International Federation of Gynecology and Obstetrics (FIGO2023)
223921392|NCT06868784|OTHER|Evaluations|Evaluations of executive functions and occupational performance
223921393|NCT06870656|OTHER|Low-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 10 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
223921394|NCT06870656|OTHER|Medium-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 20 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
223921395|NCT06870656|OTHER|High-intensity group|Firstly, they received the same health education as the control group. Subsequently, the elderly individuals with Knee Osteoarthritis (KOA) underwent five interventions per week targeting the quadriceps femoris muscle. For each intervention, the quadriceps performed an isometric contraction and relaxation for 1 second each. The intervention consisted of 30 repetitions per set of Muscle Isometric Contraction (MIC), guided by a rhythmic timer, for a total of 10 sets, with a 30-second rest between sets. The entire intervention lasted for 16 weeks.
223921396|NCT06871202|OTHER|Manual Therapy Protocol|The techniques were divided into three main groups: first, those carried out in cervical, thoracic and upper limbs; second, lumbar, pelvic and lower limbs; and finally, only spine. The techniques are carried out by physiotherapists with more than 15 years of healthcare experience and trained in manual therapy with more than 10 years of experience in this field.
223921397|NCT06871202|OTHER|Sham Protocol|The placebo protocol places the hands on the same areas as the experimental one and for the same application time but without making a manipulative intervention.
223921398|NCT06871202|OTHER|Control-no treatment|Control group without treatment or manual contact
223921399|NCT05755113|DRUG|Tigilanol Tiglate|Tigilanol tiglate is a novel, short-chain diterpene ester in clinical development for intratumoural treatment of a wide range of solid tumours.
223921400|NCT06875401|PROCEDURE|Abdominal cerclage (open or laparoscopic)|Participants who have had either an open transabdominal cerclage or laparoscopic abdominal cerclage procedure performed.
224099636|NCT06577818|PROCEDURE|3:1 C:V (3:1 Compression:Ventilation ratio)|"3:1 C:V Group (Control group - Standard of Care): Newborns randomized to 3:1 C:V will receive a CC rate of 90/min and 30 ventilations/min as per current resuscitation guidelines. The PIP used for the 30 inflations will also be 30cmH2O) as per current resuscitation guidelines. Every 60sec, a HR assessment as per neonatal guidelines will be performed to assess if HR is \<60/min - continue CC or \>60/min - stop CC (current standard of care). 3:1 C:V will be continued until ROSC."
223717324|NCT06469307|OTHER|DIVERSE Review Process|A participant and community-based review system for clinical research protocols that elicits and collects feedback on investigator-initiated protocol reviews.
223921401|NCT06099873|DRUG|ZX-7101A|Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
223921402|NCT06099873|DRUG|Placebo|Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
223921403|NCT06873932|DEVICE|Arm 1: Beveled Attachments|Beveled attachments applied to 20 teeth in each subgroup (horizontal, vertical, and rotational movements).
223921404|NCT06873932|DEVICE|Conventional Rectangular Attachments|Conventional rectangular attachments applied to 20 teeth in each subgroup (horizontal, vertical, and rotational movements).
223921405|NCT06875661|OTHER|Schroth|Patients in the experimental group exercised for 90 minutes a day, three days a week. Schroth exercises were performed in an asymmetrical position to improve the symmetry of the trunk. These exercises include stretching, flexion, spinal lengthening, derotation, strengthening, and rotational breathing exercises. The respondents combined these exercises with everyday life activities. In the control group, subjects were taught Schroth exercises under the supervision of an authorized physiotherapist, and they were asked to practice the exercises as regularly as possible at home.
223921406|NCT06873685|OTHER|Rehabilitation|"After surgery, patients will undergo a personalized rehabilitation program incorporating both conventional and robotic-based approaches. Depending on tumor location, rehabilitation will focus on either the upper or lower limbs.~For lower limb rehabilitation, robotic or technological devices will be utilized for gait training with bodyweight support, as well as for balance and proprioception training. Upper limb rehabilitation will involve robotic or sensor-based devices enabling passive, active, and active-assistive movements of the shoulder, elbow, and hand.~Treatment will be provided in various settings- inpatient, outpatient, or home-based- tailored to each patient's specific needs. Sessions will be conducted daily for 45 minutes, five days per week, over a two-month period."
223921407|NCT01833039|DRUG|Ibrutinib|Ibrutinib
223921408|NCT03412058|PROCEDURE|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
223921409|NCT03412058|PROCEDURE|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
223921410|NCT03412058|PROCEDURE|Biopsy|To be performed at disease progression if medically feasible
223921411|NCT06055686|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test|Electrical stimulation test measures sensory/motor responses
223921412|NCT05323591|DRUG|Filgotinib|Tablets are administered in accordance with the product label
223921413|NCT04298216|DIAGNOSTIC_TEST|Ultrasound Analysis of Inferior Vena Cavae (IVC)|Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
223921414|NCT05191862|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
223921415|NCT05191862|DRUG|PMR 135 mg|Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
223921416|NCT06871384|DIETARY_SUPPLEMENT|Nonalcoholic red wine group (Intervention group)|Mediteranean diet + nonalcoholic red wine (300 mL wine/day, equivalent to a daily dose of 150 mg red wine polyphenols/day, during meals)
224099637|NCT05816954|DIAGNOSTIC_TEST|Chest Computed Tomography Scan per normal clinical practice|Normal Clinical practice
223921417|NCT06871384|DIETARY_SUPPLEMENT|Drinking water group (Control group)|Mediterranean diet + drinking water (300 mL/day, during meals)
223530873|NCT06770634|OTHER|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral thigh, pretibial region and left forearm as remote site and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~Bilateral thigh: Mid-thigh anterior surface Bilateral pretibial region: Anterior proximal 1/3 of the pretibial area Bilateral forearm volar side center as control point"
223530874|NCT06770634|OTHER|Central Sensitization Inventory|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization.
223530875|NCT06770634|OTHER|Numeric Rating Scale|Leg pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
223530876|NCT06770634|OTHER|Lower Extremity Functional Scale|The lower extremity functional scale is a valid patient-rated outcome measure for the measurement of lower extremity function. The scale consist of 4 groups with 20 questions. The questions in these group focus on activities with increasing physical demands like questions from walking between rooms to running on uneven ground. The scoring of this scale varies from 0 (extreme difficulty/unable to perform activity) to 4 (no difficulty). The total score can be obtained by summing the scores of the individual items. The maximum score of 80 indicates no functional limitations and the minimum score of 0 indicates extreme limitations.
223530877|NCT06770634|OTHER|Short form 12|The Short form 12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.The scoring yields two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).Utilize the norm-based scoring system to interpret PCS and MCS scores, with a mean of 50 and a standard deviation of 10 in the general population.Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.
223530878|NCT06770634|OTHER|lower extremity volumetric measurement|It is calculated by converting the circumference measurements taken at 4 cm intervals from the ankle to the proximal thigh into lower extremity volume with Excel.
223530879|NCT06770634|OTHER|lower extremity circumference measurement|bilateral tuberosity tibia, 20 cm proximal tuberosity tibia, tuberosity tibia 10 cm distal and ankle level
223530880|NCT06770634|OTHER|Bioelectrical Impedance Analysis|With Bioelectrical Impedance Analysis, fat, muscle and water ratio and lean mass are calculated in addition to the patient's body weight.
223921418|NCT06692426|DRUG|MyoPAXon|MyoPAXon is a CD54+ allogeneic muscle progenitor cell product derived from the iPSC line LiPSC-ER2.2
223921419|NCT06692426|DRUG|Tacrolimus|Tacrolimus (Prograf) is an immunosuppressant that inhibits calcineurin and T cell activation, and is commonly used to prevent solid organ transplant rejection1 and graft versus host disease (GVHD) as well as allograft rejection in the setting of allogeneic hematopoietic stem cell transplantation.
223921420|NCT06692361|BIOLOGICAL|FMT capsule|The experimental group will maintain escitalopram treatment and take 1.0 g of FMT capsules orally with breakfast every day for 4 weeks.
223921421|NCT06692361|DRUG|Escitalopram (Lexapro)|Both the experimental group and the placebo group were treated with the maximum tolerated dose of escitalopram.
223921422|NCT06692361|BIOLOGICAL|Corn Starch capsules|The placebo group will maintain escitalopram treatment and take corn starch capsules 1.0 g orally with breakfast every day for 4 weeks.
223921423|NCT05155605|DEVICE|Multi-Cancer Early Detection Test|Blood collection and multi-cancer early detection testing with return of results.
223921424|NCT01897441|DRUG|Cyclophosphamide|Given IV
223921425|NCT01897441|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223921426|NCT01897441|DRUG|Doxorubicin Hydrochloride|Given IV
223921427|NCT01897441|OTHER|Laboratory Biomarker Analysis|Correlative studies
223921428|NCT01897441|DRUG|Paclitaxel|Given IV
223921429|NCT01897441|BIOLOGICAL|Trastuzumab|Given IV
223921430|NCT01897441|DRUG|Endocrine therapy|Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
224099638|NCT04798339|DRUG|Canakinumab Injection|Participants will be treated at 1 of 2 dose levels of Canakinumab, beginning at 150 mg and increasing to 300 mg or the Maximum Tolerated Dose
224099639|NCT04798339|DRUG|Darbepoetin Alfa|Participants will receive Darbepoetin alfa subcutaneously at a dose of 300mg on days 1 and 15 of each cycle
224099640|NCT04557527|PROCEDURE|Pars plana vitrectomy, laser or cryo retinopexy and intraocular gas tamponade|Conventional pars plana vitrectomy procedure is used to treat rhegmatogenous retinal detachment- laser or cryo retinopexy intraocular gas tamponade (SF6, C2F6 or C3F8) are chosen according to the number and size of the causative retinal break(s) and surgeons clinical judgement
224099641|NCT04557527|DEVICE|Suprachoroidal viscobuckle with 2.3% Sodium hyaluronate (Healon 5 Ophthalmic viscoelastic device)|After drainage of subretinal fluid, approximately 0.5 ml of Healon 5 is injected in to the suprachoroidal space underlying the retinal break. Laser retinopexy is applied around the break .
224099642|NCT05776160|DRUG|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
224099643|NCT02892305|PROCEDURE|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
224099644|NCT04091217|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
224099645|NCT04091217|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
223921431|NCT06688630|DEVICE|The laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is the application of a Reimers \& Janssen LaserPen, with a power of 150mW and a wavelength of 810nm, alternating between Nogier frequencies A and C. The dosage is 2 joules per point, with a therapy duration of 26 seconds per point, targeting bilateral acupuncture points BL2, TE23, ST2, LI4, and ST36. The LaserPen is applied without pressing the laser probe onto the body surface.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
223921432|NCT06688630|DEVICE|The sham laser acupuncture and artificial tears therapy|"Laser acupuncture therapy is a procedure using the same device but without activating the laser, so no energy is emitted. Performed at the same points as laser acupuncture therapy.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC."
223921433|NCT06690658|DEVICE|incorporating robotic system for upper body physical training of people with lower limb orthopedic condition|A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback (e.g, number of successful repetitions, motivational). At the beginning of the session, the participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. At the end of each exercise, the robot will provide feedback. If the participant successfully performed ten repetitions of the required exercise in the demonstration time allocated, positive feedback will be provided. Resistance (strengthening) exercises for the upper body include lifting weights, working with resistance bands in different directions involving the upper extremity and trunk. Flexibility exercises include upper extremity and trunk stretching.
223921434|NCT06632145|OTHER|Cog Fun Ageing intervention|Cog Fun Ageing is a group-based occupation-centered intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 14 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
223921435|NCT06686329|BEHAVIORAL|Control (CON)|Standardized meal with insulin administered 15 minutes before eating
223921436|NCT06686329|BEHAVIORAL|Missed Dose (MISS)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM
223921437|NCT06686329|BEHAVIORAL|Missed Dose + 15min walk (MISS+EX)|Standardized meal with insulin administered post-prandially when alerted to rapidly rising glucose (increase of 0.2 mmol/L/min) or hyperglycemia (\> 10.0 mmol/L) by CGM with a 15-minute walk performed immediately after insulin administration
223921438|NCT06688266|OTHER|Nerve Gliding Exercises|"This group will receive 25-minute session of nerve gliding exercises per session five days a week for six weeks. It will include: Warm-Up (5 minutes)~Neural Gliding of the upper quadrant:~Median nerve glide (5 minutes) Ulnar nerve glide (5 minutes) Radial nerve glide (5 minutes) Cool Down (5 minutes)"
223921439|NCT06688266|OTHER|Hand Grip Strength Exercises|"This group's participants will also receive a 25 -minute session five days per week (for six weeks). Warm-Up (5 minutes) Conventional Grip Strength Exercises (15 Minutes)~* Tendon gliding sequence of exercises for hand~* Squeezing a rubber ball or stress ball~* Dead Hang Cool Down (5 Minutes)"
223921440|NCT06700330|OTHER|no intervention, observational study|Only data from the patient file.
224090887|NCT02005055|PROCEDURE|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
224090888|NCT06450665|BEHAVIORAL|VR Social Avoidance Intervention|The intervention is based on cognitive-behavioral approach with a virtual coach acting as the therapist. It will be designed in tandem with input from Hong Kong users to ensure the scenario can resonate with them. By testing beliefs that inhibit confidence in a safe and controlled environment, participants will complete tasks with increasing difficulty in three VR scenarios and learn that they can cope in situations that they previously avoid.
224090889|NCT03492593|OTHER|lycopene|A tomato oleoresin containing lycopene
224090890|NCT03492593|OTHER|beta-carotene|13C beta-carotene
224090891|NCT03492593|OTHER|control|emulsified liquid meal alone
224090892|NCT01480739|DRUG|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
224090893|NCT01480739|DRUG|100 mg Placebo|Twice daily for 7 days
224090894|NCT03567655|DRUG|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
224099647|NCT03573024|DRUG|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
224099648|NCT03573024|DRUG|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3 and 600 mg on day 4. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
224099649|NCT05662332|DRUG|Insulin Efsitora Alfa|Administered SC
224099650|NCT05662332|DRUG|Insulin Glargine|Administered SC
223921441|NCT06362382|BEHAVIORAL|tele-rehabilitation training|"During their stay in the hospital, the patients were accompanied by a rehabilitation trainer and a psychotherapist for a complete cycle of (7 days ± 3 days 1 week/times) standardized training.~After discharge from the hospital, patients in the rehabilitation group underwent 3-5 weekly daily （a total of 3 months）training sessions and intensive supervision and management by the online community at least once a week. All patients' routines were monitored by telemetry and data, photographs and video recordings were collected by a specialized agency.~The scheme of rehabilitation is impedance training. A specialized professional team including cardiologists, rehabilitation trainers, psychotherapists and radiologists were involved."
223921442|NCT06362382|BEHAVIORAL|health propaganda and education|"During their stay in the hospital, participants of the control group received health propaganda and education (7 days ± 3 days 1 week/times).~After discharge from the hospital, the control group followed their daily routine."
223921443|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Additive-Manufactured Personalized Titanium Mesh|Preoperative CBCT datas of participants are obtained to design and manufacture personalized titanium meshes.Use additive-manufactured personalized titanium meshes for guided bone regeneration.In the bone grafting surgery, the additive-manufactured personalized titanium mesh is used to secure the bone substitutes, with fixation screws used to secure the titanium mesh.
223921444|NCT06692244|PROCEDURE|Guided Bone Regeneration Surgery Using Prefabricated Titanium Mesh|In bone grafting surgery, prefabricated titanium mesh is used to fix the bone substitutes, and fixation screws are used to secure the titanium mesh.
223921445|NCT06693284|DRUG|mirdametinib and vorinostat|short course of the combination of mirdametinib and vorinostat prior to the most appropriate standard of care treatment for the patient's specific tumor (typically localized radiation followed by surgical resection).
223921446|NCT06693895|BIOLOGICAL|Investigational varicella vaccine|1 dose of investigational varicella vaccine administered subcutaneously.
223921447|NCT06693895|BIOLOGICAL|Marketed varicella vaccine|1 dose of marketed varicella vaccine administered subcutaneously.
223921448|NCT06693895|BIOLOGICAL|Measles, mumps, and rubella vaccine|1 dose of measles, mumps, and rubella vaccine co-administered subcutaneously or intramuscularly.
224090895|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
223921449|NCT06693895|BIOLOGICAL|Hepatitis A vaccine|1 dose of hepatitis A vaccine co-administered intramuscularly.
224090896|NCT03102684|OTHER|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
224090897|NCT02926339|BEHAVIORAL|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
224279532|NCT02515487|OTHER|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
223921450|NCT06693895|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|1 dose of 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223921451|NCT06693895|BIOLOGICAL|PCV 20|1 dose of 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
224090898|NCT05169671|DRUG|ATH-1020|ATH-1020 in oral capsule form
224090899|NCT05169671|DRUG|Placebo|Placebo in oral capsule form
224090900|NCT00326092|DRUG|Brinzolamide/Timolol|
224090901|NCT03280979|DRUG|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
224279533|NCT00337987|DRUG|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
223921452|NCT06693895|BIOLOGICAL|Vaxneuvance|1 dose of 15-valent pneumococcal conjugate (Vaxneuvance) vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223921453|NCT06692270|DRUG|Tislelizumab|Tislelizumab 200mg Q3W, D1 ; 2 cycles
224090902|NCT03280979|DRUG|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
224090903|NCT04582838|DIAGNOSTIC_TEST|Pulse oximeter|"In both groups, pulse oximeters provide continuous monitoring of oxygen saturation (SpO2).~Also, SpO2 curve can be recorded for off-line analysis."
224090904|NCT04582838|DIAGNOSTIC_TEST|ECG|ECG signal is used to monitor respiratory rate (RR).
224090905|NCT06366243|DRUG|Emraclidine|Oral tablet
224090906|NCT06366243|DRUG|Esomeprazole|Oral delayed-release capsule
224090907|NCT00850746|DRUG|YM443|Oral
224090908|NCT00850746|DRUG|Placebo|Oral
223921454|NCT06693362|DRUG|Placebo|The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
223921455|NCT06693362|DRUG|Drug therapy|The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
223921456|NCT06693362|OTHER|Standard Treatment|"Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary."
223921457|NCT06872710|OTHER||There are no interventions. Samples were collected by the Biobank since 2013.
223921458|NCT06872411|OTHER|HealthyDads Digital Intervention|HealthyDads is a prototype bilingual self-guided psychoeducational Digital Intervention with accurate and easily accessible information on topics related to mental health, parenting and health behaviors, along with strategies to optimize each.
223921459|NCT06872528|OTHER|Recording the amount of medication and the number of complications according to observational follow-up|Observational monitoring of patients and recording data for 24 hours
223921460|NCT05153421|DEVICE|All'InCath CBC 035M Balloon Dilatation Catheter|Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.
223921461|NCT04365114|DIAGNOSTIC_TEST|Breast Screening Mammography with single reader|One clinician examined each woman's mammograms for signs of cancer
223921462|NCT04365114|DIAGNOSTIC_TEST|Breast screening mammography with two readers|Two clinicians seperately examined each woman's mammograms for signs of cancer
223921463|NCT04365114|DIAGNOSTIC_TEST|Test threshold|Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
223921464|NCT06673745|OTHER|IASTM|"Group A received IASTM treatment, which will be given by the Edge tool, that is an ergonomically designed stainless steel instrument and offers several different hand holds, eliminating operator fatigue. Prior to the treatment, the IASTM therapeutic effects will be explained. The scanning assessment will be done to identify areas of restrictions directed by the gritty sensations using the Edge tool. Each restriction will be treated with the tool for 30-60 sec and given. This treatment will be given for 30 minutes for 3 days per week for 4 weeks"
224090909|NCT00850746|DRUG|Moxifloxacin|Oral
224090910|NCT00138086|DRUG|Zevalin plus BEAM|
224099651|NCT05071937|DRUG|ZEN003694|ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells.
224099652|NCT05071937|DRUG|Talazoparib|Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers.
224099653|NCT05558566|OTHER|Neurofeedback from the SMA|Feedback is provided regarding activity in the SMA and participant attempts to control SMA activity using the feedback as a training signal
224099654|NCT05558566|OTHER|Neurofeedback from control region|Feedback is provided regarding activity in a control region and participant attempts to control activity in that region using the feedback as a training signal.
224099655|NCT06546319|BEHAVIORAL|Music Therapy|Board-certified music therapists (i.e., MT-BC credential) will provide two music therapy sessions, not to occur on the same day, that include education and disease-specific content (e.g., harmonica exercises for respiratory health \[COPD\] or music-based breathing exercises \[HF\]) prior to patients' discharge and two virtual music therapy sessions that address music-assisted relaxation and imagery, additional techniques for managing psychosocial stressors, and gratitude exercises post-discharge.
224099656|NCT04350333|BEHAVIORAL|CBT-I|Strategies and techniques of Cognitive behavioral therapy for insomnia adapted for pregnant women: stimulus control; sleep hygiene; sleep restriction; cognitive control etc.
224099657|NCT04350333|BEHAVIORAL|Assertive communication training|Intervention based on improving assertive communication and regulating emotions.
224099658|NCT02429999|DRUG|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
224099659|NCT02429999|DRUG|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
224099660|NCT06555068|DRUG|HRS-6209 in Combination with Fulvestrant|HRS-6209 in Combination with Fulvestrant
224099661|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
224099662|NCT06555068|DRUG|HRS-6209 in Combination with Letrozole|HRS-6209 in Combination with Letrozole
224099663|NCT06555068|DRUG|HRS-6209 in Combination with HRS-8080|HRS-6209 in Combination with HRS-8080
224099664|NCT06555068|DRUG|HRS-6209 in Combination with HRS-1358|HRS-6209 in Combination with HRS-1358
223921465|NCT06673745|OTHER|Dynamic cupping therapy|On the contrary, group B the patient will be seated in a chair with the elbow flexed on the plinth to relax the forearm muscles. The area around the elbow joint will be cleaned with alcohol to remove any foreign bodies from the treated area. Dynamic cupping therapy for elbow stiffness will begin with an assessment of the patient\&amp;#39;s condition, where factors such as the extent of stiffness and range of motion in the elbow joint will be evaluated. Following this assessment, lubricant will be applied to the skin surrounding the elbow to facilitate smooth movement of the cups. Cups of suitable size and material will then be strategically placed around the elbow joint, and suction will be created inside each cup to create a vacuum effect. Once thesecurely attached, the practitioner will move them around the elbow area using gentle techniques such as gliding or pumping motions.
223921466|NCT06699810|DEVICE|Continuous Glucose Monitoring|After insulin discontinuation participants continue wearing their CGMs, for a total of 3 months.
223921467|NCT06699810|DRUG|Insulin|Participants will receive standard-of-care insulin treatment. Insulin dosing will be adjusted based on CGM glucose readings.
223921468|NCT06700928|OTHER|External focus training|External focus training
223921469|NCT06700928|OTHER|Internal focus training|internal focus training
223921470|NCT06700928|OTHER|No attentional focus training|no attentional focus training
223921471|NCT02806726|DEVICE|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
223921472|NCT02806726|DEVICE|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
223921473|NCT04429347|DRUG|Gabapentin|Friday night: 1 capsule of 300 mg, Saturday night: 2 capsule of 300 mg (total 600 mg), Sunday night: choice of 1 or 2 capsule of 300 mg (total of 300 or 600 mg)
223921474|NCT04429347|DRUG|Placebo|Friday night: 1 capsule, Saturday night: 2 capsule, Sunday night: choice of 1 or 2 capsules
224090911|NCT04502303|DIAGNOSTIC_TEST|18F-FDG and 68Ga-FAPI PET/CT|Participants will undergo 18F-FDG (0.12-0.15mCi/kg) and 68Ga-FAPI (3-6mCi) PET/CT on two consecutive days. At least 6 hours of fast is required for 18F-FDG PET scan, while no dietary control is necessary for 68Ga-FAPI PET scan. If the patients are on metformin, discontinuation of 48 hours is required before 18F-FDG injection to minimize the bowel uptake. If the patient is planned for surgical resection of one or more stricture (s), the scans have to be completed within a maximum period of 30 days before the surgery.
224090912|NCT02844998|BEHAVIORAL|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
224090913|NCT02844998|DRUG|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
224090914|NCT02519881|PROCEDURE|Microfracture|simple microfracture of ankle
224090915|NCT02519881|DEVICE|CartiFill|add collagen when doing microfracture
224090916|NCT04415398|DEVICE|Automated flying Drone carrying an Automated external defibrillator (AED)|Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
224090917|NCT01494363|DRUG|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
224090918|NCT01494363|DRUG|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
224279534|NCT00337987|DRUG|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
224279535|NCT01570231|DEVICE|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
224279536|NCT01556867|OTHER|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
224279537|NCT01556867|OTHER|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
223921475|NCT04429347|DRUG|Tizanidine|Friday night: 1 capsule of 2 mg, Saturday night: 2 capsule of 2 mg (total 4 mg), Sunday night: choice of 1 or 2 capsules of 2 mg (total of 2 or 4 mg)
224279538|NCT06013111|BIOLOGICAL|Intravenous infusion anti-CEA-CAR-T cell|Anti-CEA-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 0.3×10\^7 CAR-T cells/kg, 1×10\^7 CAR-T cells/kg, and 3×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
224279539|NCT06029582|DEVICE|VR headset|Virtual Reality Headset
224279540|NCT03304431|DRUG|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
224279541|NCT06369506|DIAGNOSTIC_TEST|GTmeasurement|GT was measured from the point corresponding to the base of the gingival sulcus and 1 mm and 2 mm apical to this point. If the GT was ≤1 mm, it was considered a thin phenotype, and if it was \>1 mm, it was considered a thick phenotype.
223921476|NCT06881186|PROCEDURE|Intra-articular injection|Intra-articular injection of a cell-free collagenic gel matrix into the trapeziometacarpal joint
223921477|NCT06881667|DEVICE|Home PSG Assessment|Testing of the Onera STS in the home environment with the current device shipment method and instructions.
223921478|NCT06881576|OTHER|Compare VCI scale|Compare VCI scale
223921479|NCT06880003|OTHER|During delivery, blood samples will be collected from the umbilical cord|During delivery, blood samples will be collected from the umbilical cord of pregnant women who agree to participate in the study.
223921480|NCT06880887|OTHER|nervus vagus stimulation|Vagus stimulation was applied bilaterally through the ear in a transcutaneous manner. transcutaneous auricular VNS (taVNS) was performed using the Vagustim device. The stimulation was applied for 20 minutes with a pulse width of 300 microseconds, a frequency of 10 Hz, and in a biphasic manner. The electrodes were placed on the concha and tragus parts of the ear, and the current was increased until the participant could feel it.
223921481|NCT06881056|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 45 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
223921482|NCT06881056|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 90 mcg, neb.On the 1st, 3rd, and 5th day, take the medication,while providing symptomatic and supportive treatment simultaneously.
223921483|NCT06881056|BEHAVIORAL|symptomatic and supportive treatment|symptomatic and supportive treatment
223921484|NCT06878287|OTHER|Light exposure|30 minutes morning exposure to light (10 000 lux) using a light-box device filtering UV (CE marking)
223921485|NCT06878287|OTHER|Placebo light|30 minutes exposure to the same device using a filter inactivating light intensity (\< 10 lux)
223921486|NCT06881615|DEVICE|MTA PLACEMENT FOR PP|MTA PLACEMENT FOR PP
223921487|NCT06881615|DEVICE|PUTTY PLACEMENT FOR PP|PUTTY PLACEMENT FOR PP
223921488|NCT06879015|PROCEDURE|Tension Band Plate (TBP) Surgery|A guided growth procedure in which a non-locking 8-plate is placed extraperiosteally across the physis (growth plate) with two screws, one in the epiphysis and one in the metaphysis. This allows for gradual correction of coronal angular deformities without causing permanent growth arrest.
224090919|NCT01494363|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
224279542|NCT02452879|DEVICE|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
223921489|NCT06879015|PROCEDURE|Percutaneous Epiphysiodesis by Transphyseal Screw (PETS) Surgery|A minimally invasive procedure in which a partially threaded cannulated screw is inserted across the growth plate (transphyseal) to slow growth on one side of the bone. This technique allows for gradual correction of genu valgum and genu varum.
223921490|NCT06876038|DRUG|5-Amino Levulinic Acid|5-ALA (Gleolan) orally (20 mg/kg BW 5-ALA HCl) 2 to 4 hours prior to undergoing image-guided SITOS-based PDT treatment
223921491|NCT06878950|PROCEDURE|Early Feeding Protocol|The intervention includes removal of Replogle within 24 hours of abdominal closure and the initiation of introductory feeds within 48 hours of abdominal closure.
223921492|NCT06876350|OTHER|Woodcasting Splint|This is the experimental group so we could see the outcomes and preference for patients using surveys and compliance scores
223921493|NCT06876350|OTHER|Control (Standard treatment)|Thermoplastic splints are standard of care treatment for patients after CMC arthroplasty. We will use the data from this group as the comparator to the experimental group.
223921494|NCT06702384|DIAGNOSTIC_TEST|biopsy|Baseline biopsy and biological specimens
223921495|NCT06877936|PROCEDURE|EOS exam|The EOS procedure will consist of taking 3 x-rays per side (6 in total) while the patient is standing (oriented at 35° to the x-ray) with the arm in position 0°, then at 45° and finally at 90° elevation in the frontal plane for 20 seconds per position.
223921496|NCT06877936|OTHER|Questionnaires Constant et ASES|There will be 2 questionnaires : Constant and American Shoulder and Elbow Surgeons to determine their pain level and functional limitations.
224279543|NCT02452879|DEVICE|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
224279544|NCT02452879|DRUG|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R \& D limited company) 5mg / tablet
224279545|NCT01914016|OTHER|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
224279546|NCT04203667|DEVICE|EndoRotor Resection|"The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods.~The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter."
223921497|NCT06879613|DIETARY_SUPPLEMENT|Breastmilk|Breastmilk from the mother of the infant was given for pain
224090920|NCT01494363|DRUG|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
224090921|NCT01903941|BEHAVIORAL|Aerobic Exercise|
224090922|NCT01903941|BEHAVIORAL|Only Counseling|
224090923|NCT02914509|DRUG|Travoprost|
224090924|NCT02914509|OTHER|Placebo Vehicle|
224090925|NCT00140764|DRUG|Metronidazole gel versus placebo gel|
223921498|NCT06879613|PROCEDURE|Massage|The spot that was vaccinated was massaged by the mother/carer of the infant
223921499|NCT05178498|PROCEDURE|Follow-Up|Undergo follow up
223921500|NCT05178498|PROCEDURE|Physical Examination|Complete physical measurements
223921501|NCT05178498|OTHER|Questionnaire Administration|Complete questionnaires
223921502|NCT06881082|PROCEDURE|endoscopic band ligation with cross-section technique|Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the cross-section banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.
223921503|NCT06881082|PROCEDURE|Endoscopic band ligation using stepladder technique|Endoscopic band ligation (EBL) of medium/large-sized esophageal varices using the stepladder banding technique. EBL will be repeated every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3- 6 months to check for variceal recurrence, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment
223921504|NCT06881173|DRUG|Bu Zhong Yi Qi Tang|The experimental group took 15g of Buzhong Yiqi Decoction concentrated powder, 3 times a day, 1 packet each time.
223921505|NCT06881173|DRUG|caramel dyed starch placebo|The control group took 15 grams of caramel dyed starch placebo, 1 pack at a time, 3 times a day.
223921506|NCT06877286|DIAGNOSTIC_TEST|Sirtuin-1 Level Measurement|Measurement of serum Sirtuin-1 levels using ELISA in hemodialysis patients to evaluate the relationship between Sirtuin-1 levels and erythropoietin resistance
223921507|NCT06882694|BEHAVIORAL|Pelvic Floor Imagery Questionairre|This intervention consists of a questionairre
223921508|NCT06880029|OTHER|Morning pembrolizumab infusions|Patients will be randomized 1:1 to receive all three neoadjuvant pembrolizumab cycles in the morning (before noon) or in the afternoon (after noon).
223921509|NCT06879262|BIOLOGICAL|CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）|Administer a single infusion of CAR1922T2 T cells to this group of patients following fludarabine plus cyclophosphamide (F+C) lymphodepletion
223921510|NCT06882499|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy
223921511|NCT06882499|OTHER|Physician's choice of systemic treatment|Physician's choice of systemic therapy does not mandate a change in systemic therapy, however, SABR is not permitted for management in this arm
223921512|NCT06881875|BEHAVIORAL|AI-guided breathing practices|Participant will obtain a wristband with a built-in breathing practices program when assigned to the intervention group. Four kinds of breathing practices are included, which are bee breathing, diaphragmatic breathing, box breathing and 4-7-8 breathing. A specially prompted AI chat bot interviews the participant and designs a personalized daily breathing practice plan according to participant's preference and daily stress. Participant follows the plan in the following 28-day intervention period. Plan is adjusted weekly based on participant's feedback.
223921513|NCT06881875|BEHAVIORAL|Progressive muscle relaxation|Participant practices progressive muscle relaxation for 5 minutes daily.
223921514|NCT06882538|OTHER|awareness-based psychoeducation|The aim of psychoeducation is to create a change in knowledge and behaviour towards healthy lifestyle behaviours (1- Self-actualisation, 2- Health responsibility, 3- Exercise, 4- Nutrition, 5- Interpersonal support, 6- Stress management) by reducing internalised stigma. Therefore, it will be evaluated whether the applied psychoeducation programme creates the intended change in knowledge and behaviour.
223921515|NCT06881550|DRUG|Shenbailing|Adjuvant therapy with Shenbailing granules, starting from 1 day after surgery.
223921516|NCT06881303|OTHER|preoperative stoma identification and education|The guide to good stoma therapy practice recommends that the site of the future stoma should be marked out preoperatively, in the lying, sitting and standing positions, so that the patient can see the stoma. What's more, the psychological impact of the stoma is such that preoperative and regular postoperative education is essential. This identification and initiation of education is carried out by stoma nurses and/or surgeons.
224279547|NCT04659096|DRUG|ION537|ION537 will be administered by IV injection.
223921517|NCT06881355|DIAGNOSTIC_TEST|Bruxism diagnosis|The presence of bruxism was determined based on the participant's self-reported statements and intraoral findings.
224279548|NCT03601845|OTHER|Stimuli|Visual stimulation while using additional sequencing
224279549|NCT03601845|OTHER|No stimuli|Additional sequencing only
224279550|NCT00132457|PROCEDURE|Self-collected vaginal swab for chlamydia testing|
224279551|NCT03062787|DEVICE|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
224279552|NCT03062787|DEVICE|Monovisc® (Sodium hyaluronate)|Intra-articular injection
224279553|NCT05717790|DRUG|Nimotuzumab|"Drug: Nimotuzumab Experimental: Nimotuzumab arm Induction chemotherapy:Nimotuzumab 200mg will be given weekly for 6 cycles, started on day 1 of induction chemotherapy.~Concurrent chemotherapy: Nimotuzumab 200mg/week in concurrent with IMRT. Adjuvant therapy: Nimotuzumab (200mg ) will be given every 3 weeks for 8 cycles.~Active Comparator: Control Nimotuzumab 200mg/week in concurrent with IMRT ."
224279554|NCT05717790|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 2 cycles
224279555|NCT05717790|DRUG|Cisplatin|"Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles.~Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles."
224279556|NCT05717790|RADIATION|Intensity-modulated radiotherapy|Definitive IMRT of 68-78 Gy, 30-33 fractions, 5 fractions/week, 1 fraction/day
224279557|NCT02507063|PROCEDURE|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
224279558|NCT01696305|DEVICE|Hyalobarrier|
224279559|NCT01696305|DEVICE|Guardix-SG|
224279560|NCT00398593|BEHAVIORAL|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
224279561|NCT05549687|OTHER|Questionnaire Administration|Ancillary studies
224279562|NCT05549687|PROCEDURE|Supportive Care|Participate in Pack Health, an electronic support program
224279563|NCT05549687|PROCEDURE|Supportive Care|Access to telephone triage line for support care services
224090926|NCT01857921|DRUG|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization"
224090927|NCT01857921|DRUG|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~1. Test group:~   * Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~2. Control group:~   * Pravastatin 20mg daily for 12 months after randomization"
224090928|NCT03047525|BIOLOGICAL|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
224090929|NCT00242294|DRUG|Roflumilast|
224090930|NCT01656772|DEVICE|Vdrive Lasso navigation|Remote robotic Lasso navigation
223530881|NCT06770634|DIAGNOSTIC_TEST|Ultrasound|Measurement of subcutaneous fat tissue thickness from mid-thigh, pretibial, lateral leg and supramalleolar regions with ultrasound.The average of two measurements taken from the same area will be recorded.According to these measurements; 12-15 mm = mild lipedema or lipohyperplasia, 15-20 mm = moderate lipedema, \>20 mm = significant lipedema, \>30 mm = severe lipedema.
223921518|NCT06881355|DIAGNOSTIC_TEST|Clinical evaluation|The PCRs on the relevant teeth were evaluated according to the revised FDI criteria
223921519|NCT06879600|DEVICE|High-flow nasal cannula therapy application|Patients will undergo HFNC preoxygenation for 3 minutes with a flow rate of 60 L/min of heated and humidified pure oxygen (100% FiO₂, 37°C - Optiflow; Fisher \& Paykel Healthcare, Auckland, New Zealand). To minimize air contamination, large or medium nasal cannulae will be selected based on the patient's nostril size
223921520|NCT06879600|DEVICE|Traditional facemask|Patients will undergo preoxygenation for 3 minutes using a face mask (sized appropriately to fit the patient and ensure an airtight seal) connected to an Aisys CS2 ventilation system (General Electric, GE Healthcare, Oy, Finland). In this group, the ventilation system will be set with a fresh gas flow of 10 L/min, FiO₂ = 100%, without inspiratory support or expiratory positive pressure. The face mask (Economy, Intersurgical, Fontenay-sous-Bois, France) will be removed after induction to enable intubation.
223921521|NCT06881108|OTHER|CHAT Core Functions|CHAT is a virtually delivered patient-level intervention designed to improve health insurance and cost-related literacy
223921522|NCT06881108|OTHER|LIFT Core Functions|LIFT (Lessening the Impact of Financial Toxicity), an intervention developed to coordinate access to existing financial assistance programs.
223921523|NCT06881108|OTHER|Member-Checking Process|Based on the findings from Steps 1 and 2, investigators will develop a document that outlines the points of overlap, harmony, or conflict identified by participants.
223921524|NCT06882707|OTHER|Median Nerve Mobilization|"Passive neuromobilisation of the median nerve and functional self-exercises. The procedure started with the patient in the supine position. The following steps were taken in sequence: shoulder girdle depression; slight abduction of the elbow extension with arm lateral rotation and forearm supination; wrist, finger and thumb extensions were added; and the shoulder was taken into further extension.~To apply maximum stretch opposite cervical side flexion was done, and, in the end, the wrist was repeatedly moved into and out of stretch by performing a few degrees of flexion and extension at the wrist.~This mobilization technique will be performed by an experienced physician/physiotherapist three times a week for 3 weeks, and the patients will be given 3 sets of 15 cycles with a 1-minute rest period in each set."
223921525|NCT06882707|OTHER|Ultrasound therapy|In control group, patients will received only ultrasound therapy. The patient will be in a sitting position with his/her face facing the physiotherapy technician, elbow in 90 degree flexion, forearm in supination, wrist in neutral position and supported by placing a towel under the patient's extremity and will be applied in Us intermittent mode with an intensity of 0.8 W/cm2 in 1 MHZ frequency in 1:4 mode for 10 minutes, moving in a way to draw an infinity sign for 10 seconds. Treatment will be given 5 days a week for 3 weeks and a total of 15 sessions.
223921526|NCT06881771|DIAGNOSTIC_TEST|Clinical phenotyping|"* Visual acuity assessment~* Contrast sensitivity evaluation~* Slit-lamp photography~* Specular microscopy~* Scheimpflug tomography~* Anterior segment optical coherence tomography~* In vivo confocal microscopy~* Spatio-temporal optical coherence tomography"
223921527|NCT06881771|GENETIC|CTG18.1 Expansion Status Genotyping|"Genotyping for trinucleotide repeat in the TCF4 gene (CTG18.1) and other genetic biomarkers using blood or saliva derived genomic DNA. This includes:~* Short tandem repeat - PCR~* Triplet-repeat primed - PCR~* Genome-wide single nucleotide polymorphism genotyping~* Ultra-deep locus-specific next-generation sequencing"
223921528|NCT06882343|OTHER|Beautiful Flow Plus X|Shofu's Beautifil Flow Plus X F03 is an advanced injectable bioactive composite that merges the adaptability of flowable composites with the mechanical properties of hybrid composites
223921529|NCT06882343|OTHER|Dentsply Nanohybrid flowable composite|a conventional nano hybrid flowable composite
224090931|NCT01656772|PROCEDURE|Manual Lasso navigation|Manually maneuver a Lasso catheter
224090932|NCT01415024|PROCEDURE|second LV lead in CRT|second LV lead in CRT
224090933|NCT05774340|DRUG|CM326|CM326 injection
224090934|NCT05774340|OTHER|Placebo|Placebo
224090935|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
224090936|NCT01011348|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
224090937|NCT01011348|DIETARY_SUPPLEMENT|Placebo|Three month period
224090938|NCT02947867|DRUG|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
223530882|NCT05638113|PROCEDURE|Pleural injection of autologous blood|120 ml autologous blood will be drawn from simple venous puncture and immediately injected through the drain into the pleural cavity followed by flushing with 50ml of saline.
223530883|NCT01994876|DEVICE|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
223530884|NCT01994876|DEVICE|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
223921530|NCT06691386|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
223921531|NCT06691386|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
223921532|NCT06691386|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
223921533|NCT06691386|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
223921534|NCT06691386|OTHER|Test Product E|Use of Test Product E in controlled use and ad libitum use sessions
224090939|NCT01651780|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
223530885|NCT04210960|RADIATION|Magentic resonanace imaging|The brain MR imaging examinations were done by using a 3 tesla scanner (Acheiva; Philips Medical Systems, Best, Netherlands). All patients were examined in the supine position using head coil. Routine images (T2, T1, FLAIR) and double inversion recovery sequence (DIR) were done to all patients: repetition time (TR) \_ 9583 sec, echo time (TE) \_ 25 sec, inversion time (TI) \_ 3400 sec, IR delay \_ 325 sec, echo train length (ETL) \_ 17, 50 contiguous axial slices, thickness \_ 3 mm, matrix size 240× 142 mm2, field of view (FOV) 230× 184 mm2.
223530886|NCT04210960|RADIATION|Magentic resonanace spectroscopy|Magnetic Resonance (MR) spectroscopy is a noninvasive diagnostic test for measuring biochemical changes in the brain.While magnetic resonance imaging (MRI) identifies the anatomical location of a lesion, MR spectroscopy compares the chemical composition of normal brain tissue with abnormal brain tissue. This test can also be used to detect tissue changes in stroke and epilepsy.
223921535|NCT06691386|OTHER|Reference Product F: Subjects' OBMST|Use of Reference Product F in controlled use and ad libitum use sessions. The subjects' Own Brand Moist Smokeless Tobacco (OBMST) reference products used in this study were commercially available and had been reported by the subjects as the brands they usually consume.
223921536|NCT06715384|DIAGNOSTIC_TEST|Polyp size measurement using autonomous AI measurement or AI-assisted human measurement with the CAM system|The study of real-time polyp size measurement using the CAM system will be conducted in two phases. Phase I (pilot phase, n=24 polyps, about 27 patients) will be used to assess the feasibility of applying the CAM system in real-time in a clinical video in order to obtain pilot data on the relative accuracy of assessing polyp sizes using autonomous AI measurement and AI-assisted human measurement and to determine the relative accuracy of assessing polyp size in Phase II of the study ( Randomized Controlled Trial) to assess the sample size and reference standards for the CAM system. The sample size for the second phase of the randomized controlled trial (comparing AI-assisted human measurement to non-scaled device) will be based on pilot data in order to compare the relative accuracy of polyp size measurement with AI-assisted human measurement versus non-scaled device in clinical practice.
223921537|NCT06719284|OTHER|HFO&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order|HFO\&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order
223921538|NCT06719284|OTHER|HFOV at the settings applied prior to the study|HFOV at the settings applied prior to the study
223921539|NCT06264245|OTHER|Audiological profile|Video otoscopy Tympanometry High-frequency tonal audiometry
223921540|NCT06264245|OTHER|Hearing self-assessments|Hearing skills questionnaire Subjective assessment of tinnitus using a visual analogue scale Self-questionnaire on the impact of tinnitus Hyperacusis self-questionnaire
224090940|NCT01651780|DRUG|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
224090941|NCT02096094|PROCEDURE|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
224090942|NCT02096094|PROCEDURE|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
224279564|NCT01183884|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in \> or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
224279565|NCT00127166|DRUG|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
224279566|NCT00127166|DRUG|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
224279567|NCT00127166|DRUG|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
224279568|NCT00127166|DRUG|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
224279569|NCT00127166|DRUG|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
224279570|NCT02369549|DRUG|Micro-particle Curcumin|as described in Arm
224279571|NCT02369549|DRUG|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
224279572|NCT04439760|PROCEDURE|Superior Cervical Ganglion Block|Under X-ray guidance, a 23-gauge radiofrequency top-pole needle with an active tip of 5 mm is inserted for test blockade. The needle is directed at the facet joint of the 3rd and 4th cervical vertebrae.The needle is introduced parallel to the radiographic projection and is projected as a dot approximately 1 cm anterior to the spine. The radiographic projection is then changed to lateral, and the needle is slowly advanced until the tip was situated at the anterior border of the third cervical vertebra. On the anteroposterior projection, the tip of the needle is projected over the lateral part of the facetal column. When the tip of the needle is in position, 0.3 mL of Omnipaque is injected. On the transverse projection, the contrast is distinctly anterior to anterior border of the vertebral bodies, and in the anteroposterior projection, the contrast is seen spreading in a space overlying the facetal column in a cranial as well as caudal direction.
224279573|NCT00708682|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|
224279574|NCT03863041|OTHER|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
223717325|NCT04107506|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
223717326|NCT04107506|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
223717327|NCT04109716|BEHAVIORAL|Interpersonal Psychotherapy - Adolescent Skills Training|This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions. IPT-AST will be delivered predominately through telehealth.
223717328|NCT04109716|BEHAVIORAL|Services as usual|Services as usual is expected to be brief periodic sessions (in person or remote) with the school counselor or services in the community.
223921541|NCT06264245|OTHER|Objective and subjective audiological tests|Acoustic Omission Measurement of the stapedial reflex by tympanometry High-frequency tonal audiometry - exposed ear only Speech audiometry in noise Tinnitus and subjective discomfort thresholds Psychoacoustic intensity perception test
224279575|NCT01513395|BEHAVIORAL|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
224279576|NCT05554965|DRUG|Propofol|Remifentanil maintenance analgesic dose was 1.2-9 μg/kg/h. If the CPOT score ≥3 at the time of maintenance administration, dose adjustment can be considered. Propofol was used for sedation at a loading dose of 0.5mg/kg and a maintenance dose of 1.5mg/kg/h.
224279577|NCT05554965|DRUG|Remimazolam besylate|Remifentanil was administered at a maintenance dose of 1.2-9 μg/kg/h for analgesia. If CPOT score ≥3 during maintenance administration, dose adjustment could be considered. For sedation, remazolam besylate was given a load of 0.1-0.2mg/kg and a maintenance dose of 0.1-0.3mg/kg/h.
224279578|NCT04763473|DIETARY_SUPPLEMENT|Avocado extract|Participants will consume 10 grams of freeze dried avocado daily for 12 weeks.
224279579|NCT04763473|DIETARY_SUPPLEMENT|Placebo|Participants will consume 10 grams of corn meal daily for 12 weeks.
224279580|NCT02922582|DRUG|DepoTXA|
224279581|NCT02922582|DRUG|Tranexamic Acid|
224279582|NCT00587249|BIOLOGICAL|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
224279583|NCT00587249|BIOLOGICAL|Alhydrogel|Aluminum hydroxide gel.
224279584|NCT03519490|DEVICE|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
224279585|NCT00840190|DRUG|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
224279586|NCT05430464|DEVICE|1726nm Laser System|Subjects will receive 1726nm laser treatments on one side of the face
224279587|NCT05430464|DEVICE|Sham Laser System|Subjects will receive sham laser treatments on the other side of the face.
224279588|NCT04572204|OTHER|Surgical|Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization
224279589|NCT05548920|OTHER|Ultrasound guided Superior Vena Cava Collapsibility Index|Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured
224279590|NCT05548920|OTHER|Inferior Vena Cava Collapsibility Index|Preoperative Inferior Vena Cava Collapsibility Index will be measured.
224279591|NCT00450567|PROCEDURE|computed tomography|
224279592|NCT00450567|PROCEDURE|positron emission tomography|
224279593|NCT00450567|RADIATION|fludeoxyglucose F 18|
224279594|NCT03437330|DRUG|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
224279595|NCT03437330|DRUG|Insulin Glargine (Lantus®)|"insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)"
224279596|NCT04608682|DRUG|Sugammadex|The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
224279597|NCT04608682|DRUG|Saline|The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
224279598|NCT01304979|PROCEDURE|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
224279599|NCT01304979|PROCEDURE|Control|Indirect therapies that mimic direct therapy intervention
223530887|NCT01346176|OTHER|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
223530888|NCT04194242|DRUG|HEC96719 tablets|0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1
223530889|NCT04194242|DRUG|Placebo tablet|0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
223530890|NCT00536289|DEVICE|Blunt needle|Blunt tipped suture needle
223530891|NCT06564623|DRUG|mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]|Patients will receive treatment on Day 1, 8, 15 and 22 of cycle 1 and on day 1 of remaining cycles (C2-C4) in Prime Phase. In the Boost Phase - every 2 cycles (8 weeks) beginning from C6D1.
223530892|NCT06564623|DRUG|Durvalumab|Patients will receive treatment on Day 1 of each cycle. Durvalumab (1500 mg) will be administered IV every 4 weeks in both the Prime and Boost Phase.
223530893|NCT06564623|DRUG|Tremelimumab|Patients will receive treatment on C1D1. Tremelimumab (300 mg) will be administered IV as a single dose on Day 1 of Cycle 1.
223717329|NCT06420375|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
223717330|NCT06420375|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
223717331|NCT03386500|DRUG|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
223717332|NCT04518306|DRUG|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg|Oral tablets
223717333|NCT04518306|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Oral tablets
223717334|NCT04518306|DRUG|Placebo|Placebo
223717335|NCT06731348|DRUG|restricted opioid prescribing|Participants in the restricted opioid prescribing group will receive restricted opioid prescribing after surgery. They will receive 1 tablet of Oxycodone HCl 5mg.
223717336|NCT06731348|DRUG|standard opioid prescribing|Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.
223530894|NCT06851585|DEVICE|CathIRU Cohort|All adult patients requiring a CVP in an emergency department can participate in the study
223530895|NCT06758869|OTHER|Control|Participants will consume the Base DGA diet with a standardized non-pulse product snack.
223717337|NCT02137161|DRUG|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
223717338|NCT02137161|DRUG|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
223717339|NCT05966792|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
223717340|NCT05966792|DRUG|metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
223717341|NCT00593008|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
223717342|NCT00593008|DRUG|Gemcitabine|Given intravenously every other week of each 28-day cycle.
223717343|NCT06128473|DEVICE|Soft Contact Lens|Vision Correction
223717344|NCT00887653|DRUG|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
223921542|NCT06264245|OTHER|Self-assessment of exposure sound quality|A self-assessment of the sound quality of the manipulated sounds heard during the exhibition will be carried out during the second follow-up visit. The elements on which the participant will be asked to make a qualitative judgement will relate to intelligibility difficulties or not; background noise (these two items in the form of a mark between 0 and 10); the clear, muffled or shrill nature of the sounds, their resonant or saturated side.
223921543|NCT06716242|PROCEDURE|Peripheral blood collection|Maternal peripheral blood will be collected 3 times during pregnancy (1st, 2nd and 3rd trimester) and clinical data will also be compiled.
223921544|NCT06712836|DRUG|MET097|MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
223921545|NCT06712836|DRUG|Placebo|Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
223717345|NCT01848860|PROCEDURE|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
223717346|NCT01848860|BIOLOGICAL|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
223717347|NCT03904043|RADIATION|Radiation therapy|-Monday-Friday treatment is strongly recommended
223717348|NCT03904043|DRUG|FOLFOX regimen|-CAPOX can be given as alternative
224279600|NCT00026416|BIOLOGICAL|recombinant interferon alfa|
223530896|NCT06758869|OTHER|Whole Chickpeas|Participants will consume an adjusted DGA diet with a standardized whole chickpea snack.
223530897|NCT06758869|OTHER|Puréed Chickpeas|Participants will consume an adjusted DGA diet with a standardized puréed chickpea snack.
223530898|NCT06758869|OTHER|100% Chickpea Flour Product|Participants will consume an adjusted DGA diet with a standardized 100% chickpea flour product snack.
223530899|NCT06819306|DEVICE|Hedia Diabetes Assistant|Hedia Diabetes Assistant is an insulin bolus calculator app designed to calculate an insulin bolus dose recommendation for people with type 1 or type 2 diabetes on rapid-acting insulin treatment.
223530900|NCT06898996|OTHER|Fecal immunochemical test|Detects blood in stool
223530901|NCT06903000|DEVICE|a percussion massage gun|Participants in this group will receive percussion-based vibration therapy applied using a percussion massage device (Compex Fix 2.0) with a soft head attachment. Therapy will target trapezius, levator scapula, and cervical paravertebral muscles along their origin-insertion lines for 3 minutes per muscle group.
223530902|NCT06903000|DEVICE|specially designed stainless-steel instruments|Participants will receive instrument-assisted soft tissue mobilization applied using specially designed stainless-steel instruments. Techniques (Sweep, Fan, Brush) will be applied to cervical and upper-back musculature (splenius, suboccipital, upper-middle-lower trapezius) and related fascia between C1-T1 vertebrae, parallel to muscle fibers for approximately 6 minutes per session. Each technique will consist of 8-10 repetitions.
223530903|NCT06903000|OTHER|Conventional Exercise Group (Control)|Participants in this control group will receive conventional physiotherapy treatment alone. The treatment includes heat therapy applied to the cervical region for 20 minutes, TENS application at a frequency of 100 Hz to painful areas, ROM exercises performed in all cervical directions (2 sets of 10 repetitions, 2-second holds at end-range), and isometric strengthening exercises in cervical flexion, extension, and lateral flexion directions (2 sets of 10 repetitions, 6-second holds per repetition). Sessions will take place 4 days per week for 3 weeks.
224279601|NCT00026416|DRUG|thalidomide|
223530904|NCT05019079|OTHER|electroacupuncture|In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
223530905|NCT06924138|OTHER|Exercise|The patients included in the study will be randomly divided into two groups as the study and control groups. Randomization will be provided by a computer-aided program. The patients in the study and control groups will be evaluated at the beginning and after six weeks. Functional Respiratory Muscle Training will be given to the study group with the Powerbreathe Respironics® (UK) device. The initial training intensity will be set at 50% (threshold loading) of the MIP value measured in the patient's first evaluation. The patient will be re-evaluated and the new MIP value will be measured, increasing by 10% every 2 weeks, and the training intensity will be adjusted by calculating the measured MIP value. Patients will be asked to work four days a week until the exercise sets are completed.
223921546|NCT05876780|GENETIC|SRP-9003|Single IV infusion of SRP-9003
224279602|NCT00026416|PROCEDURE|adjuvant therapy|
224279603|NCT02771028|BEHAVIORAL|Emotional Freedom Techniques|
223530906|NCT06924138|OTHER|Standart therapy|In the control group, the same balance exercises will be performed and will not be changed for six weeks.
223717349|NCT03904043|DRUG|CAPOX regimen|Given as an alternative to FOLFOX
223717350|NCT05315609|BEHAVIORAL|VR Meditation|This 4-week VR program will use the Oculus Pro-Quest 2 headsets for the 15-minute seated VR meditation twice per week for a total of 8 sessions over the 4 weeks.
223717351|NCT04340778|DRUG|vaginal dinoprostone|vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion
223921547|NCT06677957|DRUG|Digoxin|Digoxin will be administered together with Rosuvastatin as a drug cocktail as specified for the respective period
223921548|NCT06677957|DRUG|Divarasib|Divarasib will be administered in combination with Digoxin and Rosuvastatin as specified for the respective period
223921549|NCT06677957|DRUG|Rosuvastatin|Rosuvastatin will be administered together with Digoxin as a drug cocktail as specified for the respective period
224279604|NCT05531682|OTHER|Placebo|Subjects will receive several injections of Placebo
224279605|NCT05531682|DRUG|HB0017|Subjects will receive HB0017 in different dosing regimens
224279606|NCT06235268|OTHER|Active systemic or non-systemic treatment (palliative or observation procedure)|The study includes medical visits and clinical-radiological re-evaluations according to clinical practice. The clinician will establish the number of visits necessary for each patient according to the needs encountered and depending on the treatment chosen.
224279607|NCT05434351|OTHER|vaginal dehydroepiandrosterone|the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
224279608|NCT04830241|DRUG|Antidepressant|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
223921550|NCT06373250|BEHAVIORAL|Membrane stripping group|An information form will be filled in for admission to the Primipar participating maternity unit. Membrane stripping will be performed during a vaginal examination at least once during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the visual analogue scale and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
223921551|NCT06373250|OTHER|Control group|You will be asked to fill in an information form to be admitted to the Primipar participating maternity unit. No membrane stripping are applied and no cervical interventions are made during the birth process. A visual analog scale will be completed before and after each vaginal examination. During the vaginal examination, the Bishop scoring form will be filled out. The average of the VAS and Bishop scores obtained during the vaginal examinations will be taken. At four hours postpartum, the pads are weighed and the amount of bleeding is recorded on the form. You will also be asked to complete the short form of the Birth Satisfaction Scale.
223921552|NCT06281327|DRUG|Avatrombopag|"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."
223921553|NCT06704516|DRUG|Menopausal hormone therapy|"Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)"
224090943|NCT02096094|PROCEDURE|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
224090944|NCT01422993|OTHER|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
224090945|NCT04273074|RADIATION|sonographic assessment|preoperative sonographic assessment to airway
224090946|NCT02368548|OTHER|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
224090947|NCT02368548|OTHER|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
224090948|NCT00200265|BEHAVIORAL|diet|diet
224090949|NCT03029832|DRUG|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
224090950|NCT03029832|DRUG|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
224090951|NCT01628926|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
224090952|NCT01628926|DRUG|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
224090953|NCT01628926|DRUG|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
224090954|NCT05207475|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric auto-control device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed twice daily for consecutive 1 years after enrollment.
224090955|NCT00003141|BIOLOGICAL|filgrastim|Given IV
224090956|NCT00003141|DRUG|carboplatin|Given IV
224090957|NCT00003141|DRUG|cisplatin|Given IV
224090958|NCT00003141|DRUG|cyclophosphamide|Given IV
224090959|NCT00003141|DRUG|etoposide|Given IV
224090960|NCT00003141|DRUG|thiotepa|Given IV
224090961|NCT00003141|DRUG|vincristine sulfate|Given IV
224090962|NCT00003141|PROCEDURE|conventional surgery|
224090963|NCT00003141|PROCEDURE|peripheral blood stem cell transplantation|
223921554|NCT04281498|DRUG|Ruxolitinib|Patients who are on ruxolitinib will continue their current dose. Patients who are not on ruxolitinib will receive ruxolitinib dosing based on platelet count
224090964|NCT01412229|DRUG|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
224090965|NCT01412229|DRUG|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
224090966|NCT01412229|DRUG|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
224090967|NCT05548036|DEVICE|OPEP|OPEP (Aerobika (tm)
224090968|NCT03359902|DEVICE|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
224090969|NCT03359902|DEVICE|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
224090970|NCT00323284|DEVICE|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
224090971|NCT00323284|PROCEDURE|Cataract surgery only|Cataract surgery only
224090972|NCT01051089|BEHAVIORAL|Lifestyle modification|Exercise and diet education
224090973|NCT02930174|DEVICE|noninvasive positive pressure ventilation|Application of various levels of positive pressure
224090974|NCT05855161|OTHER|Rebound therapy|Participants will receive exercise-based training on a trampoline
224090975|NCT05855161|OTHER|Exercises on a stable surface|Participants will receive exercise-based training on a stable surface
224090976|NCT02139956|DEVICE|ultrasonography|open
224090977|NCT05388747|DRUG|Cefuroxime|Population pharmacokinetics, effectiveness, and safety of cefuroxime
224090978|NCT01907386|OTHER|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
224090979|NCT00151892|DRUG|SPD476|2.4 g/day Once Daily (QD)
224090980|NCT00151892|DRUG|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
223717352|NCT04340778|DRUG|Lidocaine-prilocaine Cream|Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
223921555|NCT04281498|DRUG|Enasidenib|50mg -100mg daily
223921556|NCT06711510|OTHER|Clinical, behavioral and cognitive evaluation|Questionnaries and tests
223921557|NCT06711510|OTHER|blood sampling|blood sampling (56ml max)
223921558|NCT06711510|OTHER|brain MRI|brain MRI (35 to 70 minutes)
223921559|NCT06711510|OTHER|olfactory swab sampling with nasal brush|olfactory swab sampling with nasal brush
223921560|NCT06711510|OTHER|skin punch biopsy|skin punch biopsy (optional intervention)
223921561|NCT06711510|OTHER|lumbar puncture for CSF sampling|lumbar puncture for CSF sampling (optional intervention)
224090981|NCT03474055|BIOLOGICAL|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
224090982|NCT01889602|DRUG|Lorazepam|Lorazepam: 2mg, po, 1x
224090983|NCT01889602|OTHER|Placebo|Non-active placebo, po, 1x
224090984|NCT01889602|DRUG|Topiramate 100mg|Topiramate: 100 mg, po, 1x
224090985|NCT01889602|DRUG|Topiramate 150mg|Topiramate: 150 mg, po, 1x
224090986|NCT01889602|DRUG|Topiramate 200mg|Topiramate: 200 mg, po, 1x
224090987|NCT03883074|DEVICE|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
224090988|NCT03883074|DEVICE|Placebo|tablets with the same aspect of the active device
224090989|NCT00435734|BEHAVIORAL|obesity intervention|
224090990|NCT00404092|DRUG|caspofungin|i.v.
224090991|NCT01783067|OTHER|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
224090992|NCT01783067|OTHER|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
224090993|NCT04453735|DRUG|Atorvastatin mylan 40 Mg Oral Tablet|Oral tablet on regular prescription
224090994|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
224090995|NCT03303989|DRUG|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
224090996|NCT03303989|DRUG|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
224279609|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
224279610|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
223921562|NCT06381453|DRUG|Belimumab Auto-Injector [Benlysta]|Belimumab 200 MG/ML \[Benlysta\] will be given once a week as single-dose autoinjector
223921563|NCT06720168|DEVICE|Erythritol air polisher|Dental prophylaxis with erythritol air polisher in patients with dental black stain
223921564|NCT06720168|DEVICE|Dental prophylaxis with ultrasonic treatment|Dental prophylaxis with ultrasonic treatment in patients with dental black stain
223921565|NCT06721208|BEHAVIORAL|"use the Move for Knee APP"|"The mobile APP called Move Your Knee allows the collection of data entered by patients, useful for understanding their lifestyle habits and daily physical activity level, and information relating to KOA pathology.~At the end of the questionnaire, the algorithm integrated into the APP's computer code will allow the calculation of the patient's presumed level of physical activity. This will then be followed by the assignment of a specific form which includes the exercises and the related execution parameters (i.e. weekly frequency), and useful advice for safely carrying out the exercises to achieve the specific functional objectives."
223921566|NCT05317819|DRUG|ADI-PEG20|Treatment for hepatocellular carcinoma
224090997|NCT03303989|DRUG|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
223921567|NCT05317819|OTHER|Placebo|Treatment for hepatocellular carcinoma
223921568|NCT06719700|DRUG|Chemotherapy|Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.
223921569|NCT06719700|DRUG|Immunotherapy|Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.
223921570|NCT06719700|DRUG|Angio-immuno kinase inhibitor|Oral surufatinib 200 mg once daily (q.d.), given on days 1-14 of each chemotherapy cycle.
223921571|NCT06719700|RADIATION|radiotherapy|Thoracic radiotherapy will begin no later than the start of the third chemotherapy cycle.
223921572|NCT06719700|RADIATION|Prophylactic Cranial Irradiation|PCI is recommended after the completion of chemoradiotherapy.
223921573|NCT06719700|DRUG|Consolidation Therapy with Toripalimab and Surufatinib|Patients achieving complete response (CR), partial response (PR), or stable disease (SD) following chemoradiotherapy will receive consolidation therapy. Toripalimab: 240 mg intravenously on day 1, every three weeks. Surufatinib: 200 mg orally on days 1-14, every three weeks.
223921574|NCT06719752|OTHER|Placebo|Placebo intervention; the therapy will mimic exceptional mobilization.
223921575|NCT04454203|DRUG|Mepivacaine|An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.
223530907|NCT06900439|OTHER|Dietary Intervention|To carry out a dietary intervention using a standardized test meal where the participant's postprandial glucose to the meal is measured with a continuous glucose monitor and compared to the participant's postprandial glucose from the same standardized test meal 4 months prior.
223530908|NCT05961709|DRUG|Cemiplimab|Given by IV (vein)
223921576|NCT04454203|DRUG|Saline|An infiltration of saline superomedially to the femoral artery via perineural catheter.
223921577|NCT04454203|PROCEDURE|Perifemoral Injection of Local Anesthetic|Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
223921578|NCT04454203|PROCEDURE|Perifemoral Injection of Local Anesthetic|Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.
223921579|NCT06883760|COMBINATION_PRODUCT|Probiotic tablet candy group|40 volunteers were randomly divided into two groups (n=20): Group A (probiotic → washout → placebo) and Group B (placebo → washout → probiotic). Each group took 1g of tablets (0.5g/tablet, 2 tablets) twice daily for 1 week, followed by a 2-week washout, then switched interventions. Fecal samples were collected at baseline, Day 7, and Day 28. Alcohol tests were conducted on Days 7 and 28 after fasting; participants consumed alcohol (1 mL/kg, 40% v/v) with a standard meal. Serum and saliva were collected post-meal. Body weight was measured, and alcohol dosage was adjusted accordingly. Participants maintained their usual diet and avoided alcohol-detoxifying or liver-protecting drugs. Medication during alcohol tests: 2 pills before tolerance test (after lunch), 2 pills before drinking, and 2 pills after waking.
223921580|NCT06884774|PROCEDURE|Hemorrhoidectomy with lateral internal sphincterotomy|Patients undergoing Hemorrhoidectomy with lateral internal sphincterotomy.
224090998|NCT01256216|DEVICE|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
224090999|NCT01278290|DIAGNOSTIC_TEST|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
224091000|NCT01278290|DIAGNOSTIC_TEST|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
223921581|NCT06884774|PROCEDURE|Hemorrhoidectomy|Patients undergoing Hemorrhoidectomy without lateral internal sphincterotomy.
223921582|NCT06884566|DIETARY_SUPPLEMENT|Taurine supplementation|For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.
223921583|NCT06884566|DIETARY_SUPPLEMENT|Placebo|For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.
223921584|NCT06884982|DRUG|QL1706 Plus Lenvatinib|All enrolled subjects will receive QL1706 5 mg/kg intravenously plus lenvatinib 8/12mg on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
223921585|NCT06883682|OTHER|No intervention|No intervention is conducted in this study.
223921586|NCT06552130|OTHER|Spiroergometer test with intranasal insulin spray|Participants will undergo a 60 min bicycle spiroergometer test and intranasal insulin spray. Intranasal insulin will be administered 30 minutes prior to the start of the physical activity.
224091001|NCT02896530|OTHER|No intervention. Description study|
224091002|NCT04799561|BEHAVIORAL|Multimodal Teleprehabilitation|"Exercise Prescription: patients will be instructed on how to perform aerobic exercise (5 times/week: minimum 30-minute/day) and resistance training (3 times/week: 2-3 sets of 6-8 exercises repeated 8-12 times) at home. Exercise counseling will be weekly, using the video-conferencing application (Zoom).~Nutrition: nutritional status and dietary intake will initially be assessed by the nutritionist using zoom. All patients will receive daily whey protein supplements. Special precautions will be considered if patients have specific medical conditions.~Psychosocial intervention: Patients will have access to 1.5 hours of mental relaxation and coping mechanisms session within the first week of enrolment, using Zoom.~Smoking Cessation: Patients with smoking habits will meet with a respiratory specialist using Zoom, who will establish recommendations and contact the physician for the recommended smoking cessation protocol.~More counseling sessions will be provided as needed."
224091003|NCT05812391|PROCEDURE|test|the treatment start with supra-gingival erythritol powerder air polishing followed by sub-gingival erythritol powerder air polishing,supra-gingival debridement and sub-gingival debridement
224091004|NCT05812391|PROCEDURE|conventional|the treatment start with supra-gingival debridement followed by sub-gingival debridement then finished with polishing paste
224091005|NCT01272583|DRUG|Sitagliptin|100 mg once daily for six weeks
224091006|NCT01272583|DRUG|Placebo|placebo, once daily for six weeks
224091007|NCT06088927|DEVICE|Conduction system pacing|Conduction system pacing (His Bundle Pacing or Left Bundle Branch Area Pacing)
224091008|NCT02674945|DEVICE|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
224091009|NCT05666557|OTHER|manual erector spinae myofascial realease|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After physical therapist manual mobilization, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
224091010|NCT05666557|OTHER|self-myofascial release technique|"The subjects first positioned the third, fourth, and fifth lumbar vertebrae in a relaxed lying position, about 2-3 cm away from the left and right sides (depending on the size of the subjects' muscles). And then in six postures (prone, prone with leg raise, sit straight , slouch sitting, stand straight and slouch standing), MyotonPRO was used to test the above-mentioned 8 points in these position.~Subjects will undergo a pre-mobilization assessment to see if MyotonPRO can detect changes in the erector spinae muscle properties, including changes in muscle tone, stiffness, and elasticity, under different test positions. After self mobilization by roller, MyotonPRO's erector spinae muscle biomechanical data was collected again for data analysis to determine MyotonPRO could objectively quantify changes in erector spinae biomechanical characteristics."
224091011|NCT00255073|DRUG|baclofen|
224091012|NCT04223609|DRUG|Oxycodone|5 mg tablet
224091013|NCT04223609|DRUG|Placebo|Oxycodone-matched placebo tablet
224091014|NCT04223609|DEVICE|EyeLink 1000 Plus|Non-invasive video-based eye tracking system
223530909|NCT06777121|OTHER|Shoulder exercises + Thoracic extension exercise|Shoulder exercises and thoracic extension exercises were performed 5 days a week for 3 weeks.
223921587|NCT06552130|OTHER|Spiroergometer test with intranasal placebo spray|Participants will undergo a 30 min bicycle spiroergometer test and intranasal placebo spray. To mimic insulin spill-over from nasal spray into systemic circulation, an i.v. insulin bolus of 3 mU × kg-1. will be administered over 15 minutes 30 minutes prior to the start of the physical activity on the placebo spray day. On the insulin spray day a comparable amount of saline will be infused.
223530910|NCT06777121|OTHER|Shoulder exercises + Thoracic kinesio taping|In addition to shoulder exercises, thoracic kinesio taping was applied. Shoulder exercises were performed 5 days a week for 3 weeks. TKT was applied once a week and remained in place for 5 days.
223530911|NCT06777121|OTHER|Shoulder exercises|Shoulder exercises were performed. They were performed 5 days a week for 3 weeks.
223717353|NCT04340778|DRUG|placebo|inert placebo Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
223717354|NCT06209996|BEHAVIORAL|L4 weight management intervention|he key goals of the intervention are to: (i) teach knowledge of weight loss benefits and health risks of obesity, (ii) offer skill-based dietary and physical activity advice, (iii) develop an achievable weight loss goal and plan, (iv) enhance weight management self-efficacy, (v) provide access to exercise equipment and resources, and (vi) teach strategies for managing cravings. The L4 intervention is a therapist- delivered intervention involving a registered dietitian and a cancer exercise specialist. Participants allocated to the intervention arm will be provided with a schedule to attend the L4 intervention within four weeks post-baseline via phone. They will receive five intervention sessions (120 min each) on a weekly basis, and will be given home-based practices and reading to practice the skills learnt in each session. The intervention sessions will be delivered in a group format with a maximum of 5 individuals per group, which is likely to enhance accountability.
223921588|NCT06882291|OTHER|Intermittent fasting diet|Women in the first experimental group will follow an intermittent fasting diet, where they eat for 8 hours and fast for 16. They can skip breakfast or have an early dinner. Meals will include 500-800 calories of high-fiber and protein-rich foods. Participants can start with 2-3 fasts per week and increase gradually. They must drink 2-3L of water daily and can consume zero-calorie beverages. Weekly assessments will track progress.
223921589|NCT06882291|OTHER|Resistive exercise program|Women in the second experimental group will receive medical treatment and follow an 8-week resistive exercise program (30 min, 5 days/week). Exercises target the upper body, abdomen, and lower limbs, starting with a 10-min warm-up, followed by 30 min of resistance training (biceps curls, triceps exercises, chest press, plank, crunches, squats, lunges, hamstring, and quadriceps curls), and ending with a 10-min cool-down. Repetitions are logged weekly for assessment.
223921590|NCT06882291|DRUG|Medical treatment|Each woman in the three groups will receive medical treatment (metformin tablets) for eight weeks and the dose will prescribed by the gynecologist during the first visit. Patients will be asked to attend the clinic each month for routine monitoring.
223921591|NCT06883786|DEVICE|Virtual reality hypnosis|Virtual reality hypnosis
223921592|NCT06883734|BEHAVIORAL|Illness Management Skills Training|In this study, in addition to routine outpatient clinic check-ups, 12 sessions of Illness Management Skills Training were applied to the intervention group of 25 patients, each in four separate groups of 6+6+6+7 patients (Group 1, Group 2, Group 3, Group 4), once a week, for 60 minutes each. The training consisted of 1) Introduction-Getting Acquainted, 2) Recovery Goals, 3) Understanding Schizophrenia-1, 4) Understanding Schizophrenia-2, 5) Stress Vulnerability Model and Coping with Stress-1, 6) Stress Vulnerability Model and Coping with Stress-2, 7) Learning About Medication, 8) Using Medication Effectively and Monitoring Treatment, 9) Coping with Persistent Symptoms, 10) Recognizing and Monitoring Warning Signs, 11) Warning Signs My Emergency Plan, and 12) Termination sessions.
223921593|NCT06882915|DRUG|Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab|"TAS-102: Use at the recommended dose of 35 mg/m² each time, twice a day on the 1st to 5th day and the 8th to 12th day every 28 days, with meals.~Bevacizumab: Once a day on the 1st and 15th day every 28 days, at the recommended dose of 5 mg/kg each time, with meals.~Putlimumab: At the recommended dose of 200 mg/time, intravenous drip, infusion time is 60 minutes, once every 28 days."
223921594|NCT06884046|OTHER|Personalized support project|"1. Presence of a child nurse at the consultation of the anesthesiologist-resuscitator.~2. Antenatal paramedical consultation conducted by a child nurse composed of a semi-structured interview and an evaluation of Parental Stress by the ISP-4 self-questionnaire.~3. Implementation of the personalized support project~4. Self-assessment of parental stress using the ISP-4 self-questionnaire (child admitted to intensive care or resuscitation unit)~5. Application of the personalised support project~6. Self-assessment of parental stress using the ISP-4 self-questionnaire (child discharged from intensive care)~7. Paramedical follow-up consultation with parents (semi-directive interview, ISP-4 self-questionnaire) and assessment of the child's psychomotor development in the child's 6th month of life"
223921595|NCT06703203|BIOLOGICAL|26-Valent pneumococcal conjugate vaccine|As an experimental group. The active ingredient of 26-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 26 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
223921596|NCT06703203|BIOLOGICAL|23-Valent pneumococcal polysaccharide vaccine|As a control group. The effective ingredients of 23-valent pneumococcal polysaccharide vaccine are 23 serotypes of pneumococcal capsular polysaccharides. Administer one dose of 0.5mL each time.
223921597|NCT06703203|BIOLOGICAL|13-Valent pneumococcal conjugate vaccine|As a control group. The active ingredient of 13-valent pneumococcal conjugate vaccine is the capsular polysaccharide of 13 pneumococcal serotypes conjugated to the tetanus toxoid carrier protein. Administer one dose of 0.5mL each time.
224091015|NCT04223609|DIAGNOSTIC_TEST|Oculo-Cognitive Addition test (OCAT)|Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.
224091016|NCT04223609|DEVICE|VT3mini - Eye Tracking Technology for OEMs|Non-invasive eye-tracking device
224091017|NCT03141944|OTHER|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
223921598|NCT06884345|DRUG|METR-NK cells combined with Solvatinib|"Sorafenib 250mg po qd, 3 weeks as a course, a total of 3 courses, the drug was stopped 3 weeks before cytoreduction of intermediate tumor.~Dilute METR - 200 mL of NK cells in 37 ℃ 1500 mL of 0.9% sodium chloride physiological saline, intraperitoneal infusion, flow rate \> 150 drops/min, each METR - venous back to the throughput of NK cells is lower than 2 x 107 cells/kg, abdominal cavity to throughput of no less than 4 x 107 cells/kg, Three days of continuous infusion was taken as a course of treatment, and four courses of continuous infusion (the first course of infusion did not use METR-NK cells) were given, with an interval of 14 days for each course. The position was switched every 15 min after the completion of each infusion to ensure uniform distribution of cells to the tumor surface."
224091018|NCT03871686|BEHAVIORAL|Brief Internet-based Behavioral Activation Intervention|A brief Internet-based behavioral activation intervention consisting of 4 sessions.
224091019|NCT02154399|DRUG|EF5|Given IV
224091020|NCT02154399|OTHER|Laboratory Biomarker Analysis|Correlative studies
224091021|NCT02154399|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
224091022|NCT02154399|OTHER|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
223717355|NCT06209996|BEHAVIORAL|Active control|A video-based intervention is selected as a low-touch alternative with expected benefits beyond a no treatment control. Participants allocated to the active control arm will receive five educational videos designed to promote a balanced diet and reinforce regular physical activity, weekly through instant messaging, and be encouraged to follow the advice covered in the videos. The materials will be developed based on the existing dietary and physical activity guidelines for cancer survivors. Participants in this arm will be arranged to attend to the L4 intervention upon completion of the study.
223717356|NCT06657716|DEVICE|ANTERION investigational|"Device: ANTERION investigational~Measurements from the investigational device ANTERION with software version 1.5 are to be compared against measurements from the ANTERION with software version 1.2.4 (cleared version)"
223717357|NCT05087459|DRUG|Avatrombopag|On the basis of conventional treatment, Avatrombopag was added, 30×10\^9/L \< platelet count \< 50×10\^9/L patients received Avatrombopag 60mg/d, 50×10\^9/L≤ platelet count \< 75×10\^9/L patients received Avatrombopag 40mg/d for 5 consecutive days, and waited for a period of time after drug withdrawal.Surgery is expected to take place on day 10-13 of the initial dose.
224091023|NCT02222402|BEHAVIORAL|INTRA-DIALYTIC EXERCISE TRAINING|
224091024|NCT06277973|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention is based on EMDR therapy for PTSD treatment. Participants will answer demographic questions, choose a primary distress source and watch a therapist-guided video (male or female, based on participant choice) that will instruct them through the 'Butterfly Hug' method (tapping alternately on both sides of the body) while hearing positive statements from the therapists on the chosen distress source. Before and after each video participants will rate their distress level on a scale between 0 and 10 and they can view up to 8 videos per session. The system will monitor distress levels, and if it detects a sustained deterioration, it will end the intervention. At the end of the intervention, participants will be given information about possible reactions to it and how to deal with them, they will be encouraged to use the technique whenever necessary, and they will be informed of relevant support lines that they can contact if needed.
223717358|NCT02537106|PROCEDURE|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
223717359|NCT02537106|PROCEDURE|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
223717360|NCT01355926|OTHER|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
224091025|NCT02549716|DRUG|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
224091026|NCT02549716|DRUG|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
224091027|NCT02549716|DRUG|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
224091028|NCT02549716|DRUG|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
224091029|NCT04995094|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
224091030|NCT04995094|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein. Pembrolizumab will be administered at 200 mg IV Q3W for 9 weeks.
224099665|NCT06976112|BEHAVIORAL|Pork Diet|The diet will follow the Dietary Guidelines for Americans with 80% of the meat consumption per week being pork. Other animal protein (e.g., turkey, chicken, beef) will be minimized in the dietary plans (≤ 20%) so lean and processed pork are the primary protein source consumed. Within each day, \~80% of the daily pork intake will be fresh, unprocessed lean cuts (e.g., tenderloin, loin chops, sirloin roast, flank, and rump roast) and \~20% will be cured sources (e.g., Canadian bacon, pork sausage).
224099666|NCT06976112|BEHAVIORAL|Plant Diet|The diet will be a Lacto-Ovo Vegetarian Diet following the Dietary Guidelines for Americans with no more than 21 oz per week of animal protein (e.g., eggs, cheese).
223921599|NCT06881238|OTHER|History of IBD course and outcome in HBV patients|"Full history taking including:~* Personal history (name, age, sex, occupation, residence, and marital state).~* Complaint.~* Age at diagnosis of IBD.~* Medication history.~* History of hospital admissions and disease flares.~* Disease extent, location, and behavior. (Montreal classification, Truelove-Witts severity index).~* Surgical history (intestinal resection in CD patients and total proctocolectomy in UC patients).~* Follow up duration and mortality.~* Data of endoscopic examination~* Data of laboratory investigations (complete blood picture, HBV serology, liver and kidney function tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP))."
223921600|NCT06880705|BEHAVIORAL|The TLC Program|Participants randomized to the TLC Program will receive TAU plus the telehealth, peer-delivered group intervention. The TLC Program was adapted from Acceptance and Commitment Therapy (ACT) - an acceptance and mindfulness-based third wave cognitive behavioral therapy. The intervention will be delivered in a group format with peer facilitators via telehealth using videoconferencing. The protocol covers all six ACT core concepts (i.e., contact with the present, acceptance, defusion, self-as-context, values, and committed action) with tailored examples and exercises focused on gender affirmation, internalized stigma, and substance use. Additional sessions are included defining stigma, how stigma affects physical and sexual health and engagement with healthcare, and values-driven self-care goals of substance use reduction and healthcare engagement. Sessions are approximately 1.5 hours each and are delivered over 12 weeks.
223921601|NCT06884150|OTHER|Exercise|Participating in schroth exercises for 45 minutes, 2 days a week after receiving the relevant diagnosis
223921602|NCT05808218|OTHER|Community-Led Total Sanitation|"The community-led total sanitation intervention is implemented across an entire Traditional Authority and includes the following village-level activities:~1. Triggering:~   * Village transect walks and open defecation site mapping~  * Demonstrations of food contamination and medical expense calculations~2. Development of a Community-Action Plan and identification of natural leaders~3. Post-triggering: routine follow-up by selected natural leaders to track and monitor progress against the Community Action Plan~In addition to the activities above, the WASH for Everyone team will:~* Train a cadre of local masons on sanitation construction~* Support the District Health office in the implementation of existing sanitation and hygiene promotion at village markets and other public spaces"
223921603|NCT05808218|OTHER|Care Groups|"* Orientation and training of village-level Care Group members on CLTS, latrine construction, and hygiene promotion~* Routine house-to-house follow-up of Care Group members to provide peer-to-peer counselling and support on sanitation and hygiene behaviours."
223940730|NCT04228666|BIOLOGICAL|HB-adMSCs|Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
223940731|NCT07030712|DRUG|MK-8294|30 µg via intravenous (IV) infusion
223940732|NCT07030712|DRUG|MK-8294|100 µg via intravenous (IV) infusion
224099667|NCT06806137|BIOLOGICAL|Investigational varicella vaccine|Investigational varicella vaccine administered subcutaneously.
223940733|NCT07030712|DRUG|MK-8294|300 µg via intravenous (IV) infusion
223530912|NCT06906926|RADIATION|Certain imaging assessments can be non-Standard of Care|Pre-Implant CT, Chest X-Ray at discharge and any related assessments during the following up visit, can be non-standard of care depending on site's / countries.
223530913|NCT06828406|BEHAVIORAL|TeamBirth|TeamBirth
223940734|NCT07030712|DRUG|MK-8294|1 mg via intravenous (IV) infusion
223940735|NCT07030712|DRUG|MK-8294|3 mg via intravenous (IV) infusion
223940736|NCT07030712|DRUG|MK-8294|10 mg via intravenous (IV) infusion
223940737|NCT07030712|DRUG|MK-8294|30 mg via intravenous (IV) infusion
223940738|NCT07030712|DRUG|MK-8294|70 mg via intravenous (IV) infusion
223940739|NCT07030764|DEVICE|DOCT'UP|In addition to conventional physiotherapy sessions, DOCT'UP® is a mobile application which offers support programmes for patients following ACL reconstruction. This is digital therapy based on homebased physical exercises to be performed by patient.
223940740|NCT07030764|BEHAVIORAL|Physiotherapy|Physiotherapy includes sessions performed at physiotherapist office under physiotherapist overview
223940741|NCT07036627|OTHER|study of microbiota|"* Drug: Esomeprazole, a proton pump inhibitor commonly used in pediatric gastroenterology.~* Administration: Oral, once daily, 30 minutes before meals.~* Dosage: Personalized dosing according to body weight, with an average of approximately 0.6 mg/kg/day.~* Treatment duration: Minimum 45 days, maximum 60 days.~* Comparator: None. This is a within-subject design; each participant serves as their own control with baseline samples (t0) compared to follow-up (t1-t2).~* Monitoring: Adherence to therapy and sample collection timeline will be verified during scheduled clinical follow-up."
223940742|NCT07036159|BIOLOGICAL|RTS,S/AS01E vaccine|RTS,S/AS01E vaccine will be administered intramuscularly.
223940743|NCT07032051|DEVICE|Continuous Passive Motion|Continuous passive motion was applied to the left ankle joint for 30 minutes twice a day using a motorized CPM device.
223940744|NCT06018415|BEHAVIORAL|Early time-restricted eating (eTRE)|The eTRE group is instructed to consume all calories in early 8h eating window,
223940745|NCT06018415|BEHAVIORAL|Late time-restricted eating (lTRE)|The lTRE group is instructed to consume all calories in late 8h eating window.
223921604|NCT04380454|DEVICE|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) is a targeted intervention that provides motor level stimulation-induced cues to improve ankle propulsion. An electrical stimulator will be used to deliver stimulation during walking (Grass S8800 stimulator with SIU8TB stimulus isolation unit; UDel stimulator). A customized, real-time system will be used to control the stimulator and deliver stimulation during appropriate phases of the gait cycle. Stimulation will be delivered to the ankle dorsiflexors when the subject's foot is in the air (swing phase). Stimulation will be delivered to the ankle plantarflexors during the terminal stance phase of gait. 30-Hz variable frequency stimulation trains 170 will be delivered during gait. The intervention comprises 3 training sessions per week for a total of 12 training sessions. FES intensity is determined at the start of every training session as motor-level stimulation that elicits appropriate functional movements.
223921605|NCT04380454|OTHER|Fast treadmill walking|Fast treadmill walking (Fast) is a non-targeted intervention where no specific instructions are provided to target practice to the paretic leg or specific ankle deficits. The intervention comprises 3 training sessions per week for a total of 12 training sessions. Each training session includes six 6-minute walking bouts with 5-minute breaks between bouts.
223921606|NCT06716034|OTHER|Personalized Nutrition Plan and Support|The intervention is a virtually-delivered, personalized nutrition plan and support to improve dietary intake of healthy food (fruit, vegetables and whole grains), based on the principles of a Mediterranean-style diet. Components of the intervention include nutrition counselling, menu planning and the provision of groceries, delivered biweekly, face-to-face, by a registered dietitian over 8 weeks, using a virtual platform. The nutrition counselling structure is grounded in evidence-based behaviour change theory for dietary interventions. Youth and parents will co-develop a personalized menu plan. In addition to biweekly nutrition counselling, participants will receive a food pantry basket, and weekly grocery deliveries to support the menu plan.
223940747|NCT06716931|OTHER|Exercise|"A patient-friendly exercise routine has been designed for patients with myotonic dystrophy type 2. Benefits of this exercise regimen in different settings (at home versus clinic, self-directed versus physical therapist-directed) will be investigated.~In person exercise supervised by physical therapist and then self-directed exercise in Group A"
223940748|NCT06716931|OTHER|Exercise|Exercise virtually supervised by physical therapist and then self-directed for group B
223940749|NCT06716931|OTHER|Exercise|Self-directed and virtually supervised exercise by physical therapist for Group C
223717361|NCT01355926|OTHER|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
223717362|NCT07008352|PROCEDURE|Blood sample collection for amino acid profiling|Blood samples (5 mL) will be collected from participants in both groups. In the bariatric surgery group, samples will be collected at three time points: preoperatively, and at 1 and 3 months postoperatively. For the control group, a single sample will be obtained. Serum will be separated, stored at -80°C, and analyzed for free amino acid profiles using LC-MS/MS.
223940750|NCT07043621|PROCEDURE|Early Scalp Block Group|"Following induction of general anesthesia and prior to head pinning (Mayfield clamp placement), a scalp block was performed under aseptic conditions using 20 mL of 0.25% bupivacaine.~The block targeted six sensory nerves that innervate the scalp: Supraorbital nerve, Supratrochlear nerve, Auriculotemporal nerve ,Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve.~Each nerve was infiltrated subcutaneously at its anatomical location using a 25-gauge needle, with the total volume distributed evenly or proportionally across the injection sites."
223940751|NCT07043621|PROCEDURE|Late Scalp Block Group|"In the pre-emergence group, the scalp block was performed at the end of surgery but before emergence from general anesthesia, while the patient was still under deep anesthesia.~Under strict aseptic conditions, 20 mL of 0.25% bupivacaine was administered to block the following six sensory nerves innervating the scalp: Supraorbital nerve, Supratrochlear nerve, Auriculotemporal nerve, Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve.~The local anesthetic was injected subcutaneously at the anatomical landmarks of each nerve using a 25-gauge needle. The total volume was distributed evenly or proportionally depending on the area. No additional surgical stimulation occurred after the block, and extubation followed routine emergence from anesthesia."
223940752|NCT07043933|BEHAVIORAL|Mobile-Compatible Web-Based Hydration Tracking Program|"Intervention Description:~The SIVI Hydration Application is a mobile-compatible, web-based behavioral intervention designed specifically for older adults. It supports self-monitoring and self-management of daily fluid intake through features such as personalized fluid goals, visual drink-logging with icons, daily reminders, progress graphics, educational videos, and motivational digital badges. The app was developed using gerotechnology and universal design principles to accommodate cognitive and sensory changes common in aging. Its unique focus on hydration behavior, combined with usability features like large fonts, high contrast, and voice-assisted guidance, distinguishes it from general health or diet tracking apps. Participants use the app for 8 weeks as part of a structured intervention with training and weekly follow-up."
223940753|NCT07043205|BEHAVIORAL|Coastal walk|A 40-minute walk with psychophysiological monitoring in Ostend (along the beach)
223940754|NCT07043205|BEHAVIORAL|Urban walk|40' walk in Ghent (urban)
223940755|NCT07043075|DEVICE|TAVR using a guidance software|TAVR procedure with TAVIPILOT augmented reality guidance software operating in parallel on a separate screen in a blind setup, enabling clinicians to assess the analysis and recommendations provided by the software, either immediately after valve deployment or following the completion of the procedure.
223940756|NCT07043049|DRUG|Tramadol|Tramadol 1 mg/kg IV given 5 minutes after spinal anesthesia for prevention of post-anesthesia shivering
223940757|NCT07043049|DRUG|Ketamine|Ketamine 0.5 mg/kg IV administered 5 minutes after spinal anesthesia for prevention of post-anesthesia shivering.
223940758|NCT07042737|BEHAVIORAL|animation-based breast cancer education|The animation-based humorous application consists of four videos, each lasting 40-45 minutes, which separately explain the signs and symptoms of breast cancer, self-breast examination, clinical breast examination, and mammography through animation.
223921607|NCT06715111|DEVICE|Laser acupuncture|A study used a laser acupuncture device to deliver treatment to 27 participants in Group A. The device, was designed for high power, non-thermal treatment. The device had a Class IV- high power, non-thermal laser with a wave length of 808-905 and a 650 nm wavelength. It had an ergonomic handpiece, high efficiency aiming beam, and adjustable emission intensity range. The device also included two laser safety goggles, a touchscreen stylus, and a retractable banner. Participants were instructed to relax and accurately detect acupoints before application. The device was adjusted for safety and both participants and researchers wore laser goggles.
223921608|NCT06715111|OTHER|conventional pelvic floor exercise|The study involved participants from groups A and B who underwent conventional pelvic floor exercises for four weeks. The exercises targeted the pubococcygeus, sphincter ani, and urethral musculatures. Participants underwent a warm-up phase with 3-5 minutes of breathing and circulatory exercises, followed by 10 repetitions, 3-5 sets, a 3-5 minute warm-up, 30 minutes of exercises, and a cool-down in five minutes. The exercise program was repeated three times per week for four weeks. Participants were instructed to ensure bladder emptiness, relax, perform contractions and relaxations, squeeze pelvic floor musculatures around the anus and vagina, and maintain contact with the plinth. The cool-down phase involved supervised training for 3-5 minutes of breathing and circulatory exercises.
223921609|NCT06718907|BEHAVIORAL|Simulated stimuli|Participants will be exposed to a video stimuli in order to assess biophysiological and physiological responses to the stressor and relaxant.
223921610|NCT06718907|BEHAVIORAL|Stress Management|Participants will practice stress management and stress reduction at home, independently.
223921611|NCT06718634|DRUG|BL-M08D1|Administration by intravenous infusion for a cycle of 3 weeks.
223921612|NCT06710223|DRUG|SD-101|Toll-like receptor 9 (TLR9) agonist
223921613|NCT06710223|DEVICE|Cryotherapy|Cryoablation of liver
223530914|NCT07103304|OTHER|Search for activating somatic genetic mutations|"This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of AVMs, and the prevalence of each mutation.~These liquid biopsies will be performed during the embolisation procedure by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to standard care)."
223530915|NCT06914479|GENETIC|Ad-hCMV-Flt3L|Given via injection
223921614|NCT06710223|DRUG|Tremelimumab|Anti-CTLA4
223921615|NCT06710223|DRUG|Durvalumab|Anti-PDL1
223921616|NCT06709898|OTHER|Cognitive job accommodation|Job accommodation focused on the cognitive aspects at work
223921617|NCT07039240|PROCEDURE|Dry needling|The dry needling intervention will follow the fast-in and fast-out technique using disposable stainless-steel needles (0.35 × 40 mm). After insertion with a quick thrust, the needle will be manipulated in multiple directions to elicit at least one local twitch response (LTR). Once the first LTR is obtained, the needle will be moved vertically within a range of 3-5 mm, without rotation, until a total of three LTRs are elicited. The intervention is expected to last approximately 25-30 seconds.
223921618|NCT06723626|DRUG|Metabolic resuscitation agent|Intervention group will receive intravenous hydrocortisone (200mg every 24 hours), vitamin C (1.5g every 6 hours), and thiamine (200 mg every 12 hours).
224091031|NCT02713451|DRUG|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
224091032|NCT01275222|DRUG|RAD001|RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
224091033|NCT01275222|DRUG|Imatinib 600mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
223530916|NCT06914479|GENETIC|Ad-hCMV-TK|Given via injection
224099668|NCT06806137|BIOLOGICAL|Marketed varicella vaccine|Marketed varicella vaccine administered subcutaneously.
224099669|NCT06806137|BIOLOGICAL|MMR vaccine|MMR vaccine co-administered subcutaneously or intramuscularly.
223530917|NCT06914479|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223530918|NCT06914479|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223530919|NCT06914479|OTHER|Survey Administration|Ancillary studies
223530920|NCT06914479|PROCEDURE|Tumor Resection|Undergo standard of care tumor resection
223530921|NCT06914479|DRUG|Valacyclovir|Given PO
223530922|NCT01400412|DRUG|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
223530923|NCT01400412|DRUG|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
223530924|NCT01400412|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
223530925|NCT01400412|DRUG|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
223530926|NCT01400412|DRUG|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
223530927|NCT01400412|DRUG|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
223530928|NCT01400412|DRUG|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
223530929|NCT07149597|RADIATION|Mobile CBCT Three-Dimensional Scanning|Mobile CBCT Three-Dimensional Scanning
223921619|NCT06723626|DRUG|Hydrocortisone|Placebo group will receive intravenous hydrocortisone 200mg every 24 hours.
223921620|NCT06722209|OTHER|polyethylene glycol (Protocol I)|Intestinal preparation protocol with polyethylene glycol (Protocol I)
223921621|NCT06530238|PROCEDURE|Russian Currents|Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.
223717363|NCT06115746|BEHAVIORAL|iDECIDE|iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
223921622|NCT06723340|DEVICE|Scar gel|Scar gel (medical device - topical application)
223921623|NCT06722417|DRUG|Icalcaprant|Oral capsules
223921624|NCT06887712|DRUG|Oral midazolam|The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.3 mg/kg , administered approximately 30 minutes before pediatric dental procedures. Sedation and amnesic effects, behavioral cooperation during treatment, sedation onset time, vital signs, recovery duration, safety, and adverse events are systematically monitored and compared between the two dosing groups.
223921625|NCT06887712|DRUG|Oral midazolam|The intravenous formulation Midazolam Braun 5 mg/ml (B. Braun Melsungen AG, Germany) diluted and mixed with orange juice for oral administration at doses of 0.6 mg/kg, administered approximately 30 minutes before pediatric dental procedures. Sedation and amnesic effects, behavioral cooperation during treatment, sedation onset time, vital signs, recovery duration, safety, and adverse events are systematically monitored and compared between the two dosing groups.
223921626|NCT06885138|DEVICE|active transcranial Direct Current Stimulation|"Patients will undergo repeated sessions of active transcranial Direct Current Stimulation (tDCS) (anodal polarity). The active electrode (35 cm²) will be placed over the left dorsolateral prefrontal cortex (DLPFC), while the reference electrode (35 cm²) will be positioned over the contralateral area, with a stimulation intensity of 2mA.~Patients will undergo a tDCS session on days 1, 2, 3, 4, 5, 12, 19, and 26 of the study. Each session will last 20 minutes."
223921627|NCT06885138|DEVICE|sham transcranial Direct Current Stimulation|"Patients will undergo repeated sessions of sham tDCS. The electrodes will be placed over the left DLPFC and the contralateral area, as in the active stimulation condition. However, the current will be delivered only for the first 5 seconds, preventing the participants from detecting the placebo condition while ensuring that no neuromodulation occurs in the underlying brain areas. Patients will undergo a tDCS session on days 1, 2, 3, 4, 5, 12, 19, and 26 of the study. Each session will last 20 minutes."
223921628|NCT06887556|DIAGNOSTIC_TEST|ELISA|Mpox-specific antibody ELISA
223921629|NCT06887556|DIAGNOSTIC_TEST|Lateral flow assay|Dried blood spot lateral flow assay for Mpox antibody
223921630|NCT06886711|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement: Probiotics. The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
223921631|NCT06886711|DIETARY_SUPPLEMENT|Placebo|Dietary supplement: Placebo. The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
223921632|NCT06883578|DIETARY_SUPPLEMENT|Short-term continuous normal meal replacement|The normal meal replacement intake is calculated at 25kcal/kg body weight per person per day, with the calorie ratio for breakfast, lunch and dinner being 1:2:2. A meal replacement diet is given for 2 consecutive weeks.
223921633|NCT06883578|DIETARY_SUPPLEMENT|Short-term continuous low-valine meal replacements|The low valine meal replacement intake is calculated at 25kcal/kg body weight per person per day, with the calorie ratio for breakfast, lunch and dinner being 1:2:2. A meal replacement diet is given for 2 consecutive weeks.
223921634|NCT06883578|DIETARY_SUPPLEMENT|Long-term intermittent normal meal replacement|The normal meal replacement intake was calculated at 25 kcal/kg body weight per person per day, with the calorie distribution ratio of 1:2:2 for breakfast, lunch and dinner. A meal replacement diet was used for 2 consecutive days per week for 16 consecutive weeks.
223921635|NCT06883578|DIETARY_SUPPLEMENT|Long-term intermittent low valine meal replacement|The low valine meal replacement intake was calculated at 25 kcal/kg body weight per person per day, with the calorie distribution ratio of 1:2:2 for breakfast, lunch and dinner. A meal replacement diet was used for 2 consecutive days per week for 16 consecutive weeks.
223921636|NCT06883552|DRUG|Tislelizumab Injection|During treatment cycles 1-18, Tislelizumab Injection will be administered in combination with Tislelizumab Injection. From cycle 19 onward, treatment will continue with Tislelizumab Injection monotherapy. The specific regimen is as follows: Tislelizumab Injection: 600 mg (initial dose) - 300 mg (subsequent doses), subcutaneously (SC), every 3 weeks (Q3W), for a total of 18 doses (1 year). Tislelizumab: 200 mg, intravenously (IV), every 3 weeks (Q3W).
223921637|NCT06886867|OTHER|Exergaming|Exergaming: Participants will perform different exercises through videogames
223921638|NCT06886867|OTHER|Usual physical therapy care|Usual care: Different exercises will be performed
223921639|NCT06886555|PROCEDURE|Epidural analgesia for labour pain|Patients were divided into two groups according to repertorised cervical dilatation at the start of analgesia: Group A \< 4 centimetres (latent stage according to National Institute for Health and Care Excellence guidelines) and Group B between 4 and 6 centimetres.
223921640|NCT06718010|OTHER|No intervention (observational study)|The study respects the investigator's choice of treatment, without specifying which drugs should be used, the dosage, the administration mode (including monotherapy, combination therapy, or sequential therapy), or the duration of treatment.
223921641|NCT06886685|OTHER|Near Infrared spectroscopy (NIRS)|NIRS is used as a non-invasive light-based optical technology to measure placental oxygenation and metabolism
223921642|NCT06711705|DRUG|Elranatamab|Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.
223921643|NCT06711796|DEVICE|emg measurement in adductor pollucis|EMG measurement from adductor pollucis and dorsal interosseus muscles in supination and pronation using increasing stimulation current
224091034|NCT01275222|DRUG|Imatinib 800mg/day (Glevec is the brand name for imatinib)|Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
224091035|NCT02146339|OTHER|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
224091036|NCT02146339|OTHER|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
224091037|NCT02146339|OTHER|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
224091038|NCT02146339|OTHER|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
224091039|NCT02146339|OTHER|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
224279611|NCT00645151|DRUG|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
223921644|NCT06728631|DRUG|Candonilimab and ATRA|Candonilimab at a dose of 6mg/kg IV Q3W will be administered until a maximum treatment duration of 1 year. All-trans retinoic acid will be administered at a dose of 25mg/m² twice daily on days 1-14, with a treatment cycle of 21 days, until a maximum treatment duration of 6 months, or until the occurrence of oral cancer or other malignancies, death, intolerable toxicity, withdrawal of informed consent, or any other reasons specified in the protocol.
224279612|NCT00480649|DRUG|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
224279613|NCT05116059|DRUG|Amphotericin B colloidal dispersion（ABCD）|The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
223530930|NCT07159399|BEHAVIORAL|Pharmacist-led patient education|Trained pharnacists will provide information on: (1) the indication and the reason of DOAC prescription, (2) the name and the appearance of the DOAC agent, (3) the dose, frequency, time of administration, (4) the mechanism of action, (5) management of missed doses, (6) potential side effects and self-monitoring, and (7) perioperative management. An education leaflet about DOACs will also be provided to improve patients' understanding about the use of DOACs.
223530931|NCT07159399|OTHER|Usual Care|Patients in the usual care group will receive only usual care, without pharmacists providing additional DOAC education materials.
223921645|NCT06728631|OTHER|other treatment or observation|other treatment other than Candonilimab/ATRA or observation
224091040|NCT02146339|OTHER|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
224091041|NCT04152382|DRUG|LY3462817 - IV|Administered IV
223530932|NCT07161609|DEVICE|Particle counter|The collection of air samples will begin with the surgical incision and will continue for 10 minute
223717364|NCT06680713|BEHAVIORAL|Exercise|Progressive exercise testing on a cyclo ergometer
223717365|NCT03557099|DRUG|Hetrombopag Olamine|once daily
223921646|NCT06729112|DIAGNOSTIC_TEST|pan immune inflammation value|Using the ratio of neutrophil, monocyte, and platelet counts to lymphocyte count, NLR, MLR, and PLR were calculated. The pan immune inflammation value (PIV) was calculated by multiplying the neutrophil count by the platelet count and the monocyte count, and then dividing the result by the lymphocyte count.
223921647|NCT04686799|DRUG|Doxycycline Hyclate 20 MG|Subjects will receive doxycycline 20 mg BID
223921648|NCT06880146|OTHER|Blood sample Truculture|"blood sample added to the standard blood test at visit Inclusion and Month 6. This project will use the TruCulture® Whole Blood Stimulation System to assess the Whole Blood Oxylipin Response (WBOR).~WBOR is the ability of patients to produce oxylipins in response to an immune stimulus. One tube is conditioned with LPS stimulant and a control tube is conditioned with no stimulant (Null)."
224091042|NCT04152382|DRUG|LY3462817 - SC|Administered SC
224279614|NCT06326528|DRUG|SGLT2 inhibitor|Dapagliflozin 10 mg or Empagliflozin 25mg
224279615|NCT04718129|BEHAVIORAL|Youth Mindful Awareness Program (YMAP)|The Mindfulness Intervention is an internet-based program that involves a coach. It is 9 weekly sessions and involves practicing the skills between sessions.
224279616|NCT05775120|DIAGNOSTIC_TEST|OLGA and H.pylori culture|Upper endoscopy will be performed by endoscopists using modern endoscopes (Fujinon EG-590WR, Olimpus GIF-H190 and others) while patient is sedated. Using sterile biopsy forceps, biopsy specimens will be taken from five areas of the stomach (two biopsy specimens - greater and lesser curvature of the antrum of the stomach; two biopsy specimens - lesser and greater curvature (or anterior and posterior wall) of the body of the stomach and one from the corner of the stomach) for pathology assessment. Pathology assessment of the gastritis stage and degree will be conducted according to the OLGA system developed by the international group of gastroenterologists and pathologists (Atrophy Club).
224279617|NCT00374166|DRUG|SSR149415|Oral administration (capsules of 50 and 100 mg)
223921649|NCT06883916|BEHAVIORAL|Virtual reality tour|The glasses have a pre-loaded video containing nature images in their memory. The patient feels like they are walking in the natural environment shown in the video.
223921650|NCT06883916|BEHAVIORAL|Massage|A hand massage was applied by the researcher for 5 minutes for each hand. The massage, which was performed using baby oil and a paper towel, lasted 10 minutes in total for both hands.
223921651|NCT06885866|BEHAVIORAL|Emotion regulation treatment|Emotion regulation intervention in two phases. Phase A focus on establishing normalised eating patterns, and in phase B the emotion regulation interventions are added. Participants will get access to treatment modules every third day over a time period of 8.5 weeks, each module consist of psychopedagogical material, excercises and home work.
224091043|NCT04152382|DRUG|Placebo - IV|Administered IV
224091044|NCT04152382|DRUG|Placebo - SC|Administered SC
224091045|NCT04152382|DRUG|LY3509754|Administered orally.
224091046|NCT04152382|DRUG|Placebo|Administered orally.
224279618|NCT00374166|DRUG|Placebo|Oral administration (capsules)
223530933|NCT07161245|OTHER|Multimodal prehabilitation|"The multimodal prehabilitation program will consist of:~1. twice-weekly supervised exercise training at the hospital gym for approximately 8 weeks (induction phase), followed by 16 weeks of telematic, supervised, home-based exercise (maintenance phase);~2. nutritional consultation, including diet optimization and supplementation if needed;~3. individual or group-based psychological support."
223921652|NCT06723301|BEHAVIORAL|Chatbot-base problem-solving skills training(PSST)|The intervention incorporates eight sessions: Session 1 involves rapport building, understanding relevant personal and medical history, and introducing the Chatbot-based program and worksheet; Session 2 focuses on maintaining brightness and optimism when faced with a specific obstacle; Sessions 3-7 involve the continued application of problem-solving skills training(PSST) to identify problems and the promotion of problem-solving strategies and skills in vivo, including (a) identifying the problem, (b) determining the options, (c) evaluating and choosing the best option, (d) acting according to the best option, and (e) seeing if it works; and Session 8 involves a review of PSST principles and termination.
224279619|NCT00374166|DRUG|Paroxetine|Oral administration (capsules)
224279620|NCT06161701|OTHER|no intervention|no intervention
223921653|NCT06888713|OTHER|Telemonitoring of ADL|Telemonitoring of ADL is based on smart environments sensors (non wearables) and gathers information about activity of daily living routines for a better understanding of homecare services needed.
223921654|NCT06889961|DIETARY_SUPPLEMENT|Mixed spices|Mixed spices 4.00 g capsules of spice mixture contain 1.0 g (25%) turmeric, 1.5 g (37.5%) cinnamon, 0.5 g (12.5%) oregano, 0.5 g (12.5%) black pepper, 0.3 g (7.5%) sage and 0.2 (5%) thyme
223921655|NCT06889961|OTHER|Placebo|4.00 g maltodextrin capsules
223940759|NCT07042737|OTHER|Control group (placebo)|No intervention will be applied to the control group.
224279621|NCT03150901|DIAGNOSTIC_TEST|no drug|laboratory tests
224279622|NCT00684801|OTHER|questionnaire administration|Patients complete questionnaires.
224279623|NCT00684801|PROCEDURE|quality-of-life assessment|Patients undergo quality-of-life assessments.
224279624|NCT04319458|BEHAVIORAL|Fotonovela|Secret Feelings/Sentimientos Secretos
224279625|NCT04319458|BEHAVIORAL|Control|NIH Brochure: Depression: What You Need to Know
223530934|NCT07161245|OTHER|standard of care|Participants in the control group will follow the standard of care provided by the hospital and will receive general recommendations on physical activity, nutrition, and stress/anxiety management.
223940760|NCT07041359|DRUG|Compound Danshen Dripping Pills|The experimental group used compound Danshen dripping pills as an intervention on the basis of conventional western medicine treatment.
223940761|NCT07041359|DRUG|Qishen Yiqi Drop Pills|The experimental group used Qishen Yiqi dripping pills as an intervention on the basis of conventional western medicine treatment.
223940762|NCT07041359|DRUG|Placebo|Intervention with placebo on the Basis of optimal medical treatment
223940763|NCT07042373|BEHAVIORAL|Control|In the control condition, participants will purchase tobacco/nicotine products in the ETM. Cigarettes will increase in price across trials.
223940764|NCT07042373|BEHAVIORAL|Product Category Score|In the product category score condition, participants will purchase tobacco/nicotine products in the ETM where the percentage of taxes applied to each product category will be distributed between 0% and 100% proportional to their abuse liability score. Abuse liability scores will be scaled such that the product category with the highest abuse liability will be taxed at 100%.
223940765|NCT07042373|BEHAVIORAL|Product Category Rank|In the product category rank condition, participants will purchase tobacco/nicotine products in the ETM where the tax percentage applied to each product category will be determined by the number of categories and their position in the ranking. The product category with the highest abuse liability will be taxed at 100%; the product with the lowest abuse liability will be taxed at 0%. All other tax rates will be equally spaced across other products based on ranking.
223940766|NCT07042373|BEHAVIORAL|Product Tiers|In the product tiers condition, participants will purchase tobacco/nicotine products in the ETM where tobacco products will be placed in tax tiers to simplify the existing complex tobacco tax system. The investigators will use three tax tiers (i.e., high tax, medium tax, and no tax), as adopted by four states. Products will be placed into tiers depending on their average score (i.e. no tax: \< 0.33, medium tax: 0.33-0.66, and high tax: \>0.66). Products in the high tax tier will be taxed at 100% and products in the medium tax tier will be taxed at 50%.
223940767|NCT06888193|DRUG|Bimekizumab|Bimekizumab under the care of their treating physician.
223940768|NCT06263647|BEHAVIORAL|Houston-HVIP treatment|Participants will be assigned a case manager to provide a brief assessment of , psychological and social needs and a risk assessment and create individualized discharge planning. Participants will be referred to tailored social service programs based on the needs, including assessments of social determinants of health, educational and financial needs, and subsequent referral for programs such as job training, educational support, housing assistance, or financial assistance programs for identified needs. Participants identified at risk for violence perpetration via a risk assessment screener will be referred to the violence interrupter services. Long-term opportunities for engagement with the trauma survivors' network within Memorial Hermann Hospital will be available and encouraged.Participants will receive a structured curriculum that will include regular check-in with an assigned case manager over 6 months to promote successful community-based program integration and completion.
223530935|NCT07159919|DIETARY_SUPPLEMENT|protein supplement|Cricket protein incorporated into a whole-food source (dough balls) to be consumed once after an acute bout of resistance exercise and then consumed daily for 12 weeks alongside regular resistance training.
223530936|NCT07159919|DIETARY_SUPPLEMENT|protein supplement|Whey protein incorporated into a whole-food source (dough balls) to be consumed once after an acute bout of resistance exercise and then consumed daily for 12 weeks alongside regular resistance training.
223921656|NCT06886633|BEHAVIORAL|Breathing exercise|"Patients participating in the breathing exercise group will be trained to apply the breathing exercise at least 1 hour before starting the debridement process. 5 minutes before starting the debridement procedure, the researcher will start breathing exercises in the patient's room. The exercise duration will be approximately 15-20 minutes, and the environment will be quiet, at room temperature and well ventilated during the exercise.~The gel part of the pressurized cold therapy bandage will be removed and kept in the refrigerator for at least 2 hours to make it ready for application. The cold gel pack removed from the freezer section of the refrigerator will be placed inside the pressurized cold therapy bandage before application. Pressurized cold will be applied to the patient 10 minutes before starting the debridement procedure."
223921657|NCT06886633|DEVICE|Experimental: Pressurized Cold Application Group|The gel part of the pressure cold therapy bandage will be removed and kept in the refrigerator for at least 2 hours to make it ready for application, and the cold gel pack taken from the freezer section of the refrigerator before application will be placed inside the pressure cold therapy bandage. Pressure cold will be applied to the patient 10 minutes before starting the debridement procedure. The patient will be assessed and recorded by a nurse independent of the research on the State Anxiety Scale before and after debridement, and the Visual Comparison Scale before, during and after debridement.
223921658|NCT06731608|BEHAVIORAL|OPTIONS|OPTIONS is a multimodal intervention approach that includes providing clinical decision support (CDS) for healthcare providers, patients, and their caregivers focused on exercise, nutrition, and bone-enhancing medications using CDS in SNFs that use the same electronic health record system (PointClickCare).
223921659|NCT06731608|BEHAVIORAL|Enhanced usual care|Enhanced usual care includes access to the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit, a fall prevention program from the CDC.
224091047|NCT04318392|OTHER|Breath Analysis|Breath analysis using the ReCIVA device will take place during each study visit.
223921660|NCT06731023|DRUG|Bismuth|Bismuth 0.6g bid
223921661|NCT06731023|DRUG|Vonoprazan|vonoprazan 20mg bid
223530937|NCT07158736|PROCEDURE|Genicular nerve block with bupivacaine and corticosteroids|genicular nerve block with ideal body-weight dosing of bupivacaine 0.5% with 4 mg dexamethasone
223530938|NCT07158736|OTHER|Standard of Care|This involves standard of care pain relief for patients who do not receive the genicular nerve block for knee pain, such as acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), and opioids.
223921662|NCT06731023|DRUG|Amoxicillin|Amoxicillin 1g bid
223921663|NCT06731023|DRUG|Rifabutin|Rifabutin 0.15g bid
223921664|NCT06731023|DRUG|Metronidazole|Metronidazole 400mg qid
223921665|NCT06731023|DRUG|Other antibiotics|The selection of other antibiotics is based on the results of drug susceptibility testing.
223921666|NCT06731647|PROCEDURE|pleurodesis procedures|All pleurodesis procedures will be conducted with a general anesthesia. The choice of hypnotic, analgesic and neuromuscular drugs will be at the discretion of the physician. Selective orotracheal intubation will be done for all patients with a double lumen tube or a blocker according to centers habits. Regional anesthesia (serratus block, paravertebral block and erector spinae block) will be allowed and chosen at the discretion of the physician. Multimodal pain management will be allowed with the use dexamethasone, ketamine and antinociceptive drugs (nefopam, tramadol, paracetamol at the discretion of the physician. After the surgical procedure, the pleural production of liquid or air will be monitored with a chest tube connected to pleural drainage device according to centers habits. Pain will be monitored with during the hospital stay every 12 h using the pain rate scale graded from 0 to 10. Neuropathic pain will be screened at 48h, 1 months, 6 months and 1 year after the inclusion
224091048|NCT04318392|OTHER|Pulmonary Function Tests|Full Pulmonary Function Tests will be performed at baseline and during each study visit if not performed as part of routine clinical care.
224091049|NCT04318392|OTHER|Blood sampling and storage for genetic analysis|Additional voluntary consent will be sought for blood sampling and storage for genetic analysis at baseline.
224091050|NCT04318392|OTHER|Blood sampling and storage of plasma for metabolomic analysis|Blood sampling and storage of plasma for metabolomic analysis will take place during each study visit.
224099670|NCT06806137|BIOLOGICAL|Hepatitis A vaccine|Hepatitis A vaccine co-administered intramuscularly.
224099671|NCT06806137|BIOLOGICAL|PCV (pneumococcal conjugate vaccine) 13|The 13-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
224099672|NCT06806137|BIOLOGICAL|PCV 20|The 20-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
224091051|NCT04318392|OTHER|Bronchoalveolar lavage|Bronchoalveolar lavage will be performed at baseline on all participants undergoing investigation with bronchoscopy or EBUS as part of routine clinical care for investigation of suspected sarcoidosis.
224279626|NCT02102919|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
224279627|NCT02102919|DEVICE|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
224279628|NCT02102919|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
223921667|NCT06731647|DRUG|KETOPROFEN(RP19583)|one intravenous dose of ketoprofen 100 mg followed by 5 doses every 12 h of ketoprofen LP 100 mg (a total regimen of 6 doses of ketoprofen every 12 h for 72h)
223921668|NCT06731647|DRUG|Placebo|placebo of ketoprofen with the schema of administration consisting in the administration of one intravenous dose of 100 ml of NaCl 0.9% following 6 oral intakes of a placebo pill every 12h (a total regimen of 6 doses of placebo of NSAID every 12 h for 72h)
224279629|NCT02102919|DEVICE|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
224279630|NCT00681473|RADIATION|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
224279631|NCT02440555|OTHER|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
224279632|NCT04084990|DEVICE|S9 VPAP Adapt|Auto-titrated positive airway pressure
224279633|NCT02704195|PROCEDURE|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
224279634|NCT02704195|PROCEDURE|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
224279635|NCT00401154|OTHER|Stationary Cycling|Use of a stationary bicycle for exercise
224279636|NCT02270034|DRUG|Crizotinib|Crizotinib is added to Stupp method
223530939|NCT07160140|OTHER|Participants will receive an 8-week pedal technique training protocol in addition to their regular cycling training.|Pedal Technique Training Protocol This training is designed as a technical training to observe pedaling data, analyze right and left leg power ratios, and determine how they change when pedaling at various intensities and cadences
223921669|NCT06731049|OTHER|Treadmill-based Training Group|The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.
224091052|NCT04318392|OTHER|Sputum Culture|Sputum will be collected during each study visit if the patient can spontaneously expectorate and will be sent for routine microbial analysis as well as metagenomic sequencing.
224091053|NCT04318392|OTHER|Spirometry|Spirometry will be performed on all healthy controls prior to enrolment into the study
224091054|NCT00073840|DRUG|levalbuterol|"* Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID"
224091055|NCT01146925|DRUG|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
224091056|NCT01146925|DRUG|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
224091057|NCT00125047|BIOLOGICAL|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
224279637|NCT05768087|RADIATION|Escalated proton therapy|According to allocated dose level: level 1-8, 69-90 Gy in 30 fractions of 2.3-3.0 Gy, to a subvolume of the radiation target
224279638|NCT05092464|DEVICE|Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
224279639|NCT00096005|DRUG|tanespimycin|Given IV
224279640|NCT00096005|DRUG|bortezomib|Given IV
224279641|NCT00096005|OTHER|laboratory biomarker analysis|Correlative studies
224279642|NCT00052286|DRUG|modafinil|
224279643|NCT00942721|BEHAVIORAL|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
224279644|NCT05263635|OTHER|Music therapy|Music therapy will include music intervention based on recommendations from literature such as slow, flowing rhythm, approximately 60-80 beats/minute and played by string instruments, played with a volume of approximately 45 decibel and will be reviewed by qualified music therapists.
224279645|NCT05263635|OTHER|Standard of Care Enhanced Recovery After Surgery (ERAS)|Patients will receive the standard of care treatment for surgery and post-operative pain management, following the Enhanced Recovery After Surgery (ERAS) protocol
224279646|NCT03252457|DRUG|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
224279647|NCT03252457|DRUG|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
224279648|NCT04087863|OTHER|Not applicable(observational study)|Not applicable(observational study)
223717366|NCT04529434|OTHER|Star Homes|110 identical novel-designed houses, known as Star Homes, include the critical structural components e.g. building orientated to provide optimal shading throughout the day, light-weight \& durable roof, facade and openings screened from insects to reduce insect entry while assuring airflow, an outdoor fly-proof latrine, and solar power providing electric light at night etc.
223921670|NCT06731049|OTHER|Dual-Task Treadmill-based Training Group|In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.
223921671|NCT06710873|DEVICE|TYRX Absorbable Antibacterial Envelope|All enrolled patients will receive the TYRX Absorbable Antibacterial Envelope implanted simultaneously during the CIED surgery.
223921672|NCT05773833|BEHAVIORAL|"Go Healthy program"|Weekly food boxes of fresh fruits and vegetables for 16 weeks; healthy eating and traditional foods curriculum available inside the box; monthly in-person healthy eating and traditional Indigenous foods cooking workshop; Indigenous cooking demonstration video website links to accompany recipes; and a kitchen starter kit with kitchen cooking supplies
223921673|NCT06888518|DIETARY_SUPPLEMENT|OMNi-BiOTiC® FLORA plus+|specially selected probiotic strains for the diatary treatment of Lactobacillus deficiencies in women
223921674|NCT06888518|DRUG|antibiotic|regular antibiotic treatment against bacterial vaginosis
223921675|NCT06882369|PROCEDURE|TAP Block|The transabdominal plane (TAP) block is a regional anesthesia technique used for postoperative pain management in abdominal wall procedures, providing somatic analgesia to the anterior and lateral abdominal walls
223921676|NCT06882369|DRUG|Intrathecal morphine injection|Intrathecal injection of morphine plus 20 mg hyperbaric bupivacaine in spinal anesthesia
223921677|NCT06882369|DRUG|spinal anesthesia|intrathecal injection of bupivacaine
223921678|NCT06881069|BEHAVIORAL|Clinic Level: AAC - SDOH, AAC - Tobacco|Ask-Advise-Connect (AAC) is a health information technology (HIT) implementation strategy that consists of EHR-based point-of-care supports for the assessment of tobacco use and Social Drivers of Health (SDOH).
223921679|NCT06881069|BEHAVIORAL|Non-Bundled|All patient level strategies will address only the content of increasing reach of the Utah Tobacco Quit Services.
223921680|NCT06881069|BEHAVIORAL|Bundled|All patient level strategies will address the content of increasing reach of the Utah Tobacco Quit Services and SDOH.
223921681|NCT06881069|BEHAVIORAL|Dose 1|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 1 opportunity for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
224091058|NCT00125047|BIOLOGICAL|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
224279649|NCT01354301|DRUG|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
223921682|NCT06881069|BEHAVIORAL|Dose 3|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 3 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
223921683|NCT06881069|BEHAVIORAL|Dose 6|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 6 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
223921684|NCT06881069|BEHAVIORAL|Dose 9|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 9 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
223921685|NCT06881069|BEHAVIORAL|Dose 12|The number of proactive outreach opportunities for CA the patient receives. Patient will receive 12 opportunities for CA, over 12 months following a patient's initial clinic visit, that includes a simple one-touch response to directly connect to the Quit Services or the CHW.
223921686|NCT06881069|BEHAVIORAL|RPN|Reactive Patient Navigation Only (RPN): Patient can request to speak to a CHW, over 12 months following a patient's initial clinic visit, at any time.
223921687|NCT06881069|BEHAVIORAL|PPN|Proactive Patient Navigation (PPN): Patient is proactively called, over 12 months following a patient's initial clinic visit, by a CHW up to 4 times.
223921688|NCT06716151|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
224091059|NCT03440944|DEVICE|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
224091060|NCT03440944|DEVICE|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
224091061|NCT00591734|DRUG|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
223921689|NCT06716151|DRUG|HB0034 matching placebo|HB0034 matching Palcebo
223921690|NCT06732258|RADIATION|Low-dose radiotherapy|The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from Day 1 in the first cycle.
224091062|NCT00591734|DRUG|Everolimus|10 mg by mouth daily
224091063|NCT04294485|BEHAVIORAL|Physical therapy|Electrostimulation combined with exercise
224091064|NCT06200350|OTHER|Experimental group|Tailored training based on the profile of each participant.
224091065|NCT06200350|OTHER|Control group|They will continue with the traditional training.
224091066|NCT02407626|DRUG|Propofol|Total intravenous anesthesia is a clinical standard procedure
224091067|NCT02407626|DRUG|Sevoflurane|Volatile anesthesia is a clinical standard procedure
224091068|NCT05888350|DRUG|Beclometasone Dipropionate and Formoterol Inhalation Aerosol|Inhaled Foster (Beclometasone Dipropionate and Formoterol Inhalation Aerosol) , 1puff, BID, 4weeks
224091069|NCT05888350|DRUG|Placebo|Inhaled Placebo, 1puff, BID, 4weeks
224091070|NCT05359107|BEHAVIORAL|"The Free From Pain Exercise Book"|Contains educational information and exercises to improve musculoskeletal pain and reduce sarcopenia.
224091071|NCT05359107|BEHAVIORAL|"The Back Book"|Contains advice and guidance on how to deal with and reduce back pain.
224279650|NCT01354301|DRUG|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
224279651|NCT01354301|DRUG|Basiliximabe|days 0 and 4, according to the package insert instructions.
224279652|NCT01354301|DRUG|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
223921691|NCT06732258|DRUG|Tifcemalimab injection|100 mg or 200 mg q3w until disease progression or intolerable toxicity;
223921692|NCT06732258|DRUG|Toripalimab|240 mg q3w until disease progression or intolerable toxicity;
223921693|NCT06732258|DRUG|Cisplatin|75 mg/m2 q3w for 4-6 cycles;
223921694|NCT06732258|DRUG|Carboplatin|AUC = 5, q3w for 4-6 cycles;
223921695|NCT06732258|DRUG|Etoposide|100 mg/m2, d1, d2, d3, q3w for 4-6 cycles;
223921696|NCT06739772|BEHAVIORAL|HPV Self-Sampling and Behavior Intervention|Participants in the intervention group will receive HPV self sampling and behavioral intervention
224091072|NCT01661790|DRUG|Bevacizumab|Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
224091073|NCT01661790|DRUG|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
224091074|NCT02624648|BEHAVIORAL|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
224091075|NCT02624648|BEHAVIORAL|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
224091076|NCT02624648|BEHAVIORAL|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
224091077|NCT02624648|DRUG|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
224091078|NCT02624648|DRUG|Placebo|They will receive a capsule of Placebo twice a day for 120 days
224091079|NCT00784758|DEVICE|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
224091080|NCT00784758|DEVICE|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
224091081|NCT06057311|OTHER|Hippotherapy|The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
224091082|NCT06057311|OTHER|Equine-Assisted Activities Therapy|The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
224091083|NCT06057311|OTHER|Control|The Control Group (CG) did not receive any training. The assessments were applied twice to CG at baseline and after 6 weeks. The treatments and assessments were performed by the same physiotherapist in the same environment.
224279653|NCT01354301|DRUG|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
224279654|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
224279655|NCT01354301|DRUG|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
223717367|NCT04529434|OTHER|Traditional African houses|A traditional mud house: with wattle and daub walls, a thatched roof, and no electricity or piped water supply.
224091084|NCT02844361|OTHER|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
224091085|NCT02844361|OTHER|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
224091086|NCT00130871|DRUG|levosimendan|
224091087|NCT03877406|DRUG|Empagliflozin 10 MG|addition of empagliflozin 10 MG
224091088|NCT03877406|DRUG|Hypoglycemics Oral|dose escalation of hypoglycemics oral
223717368|NCT07014527|PROCEDURE|Patient specific subperiosteal implants|Patient specific subperiosteal implants
223921697|NCT06739772|BEHAVIORAL|Participants in the intervention group will receive HPV self sampling and behavioral intervention|Received enhance standard care
223921698|NCT06884085|DRUG|Co-administration of AD-227A and AD-227B|Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
223921699|NCT06884085|DRUG|Administration of AD-227|Administration of AD-227 1Tab., Per Oral
223921700|NCT06584292|PROCEDURE|caudal block|Caudal Block (CB) Procedure: The sacral hiatus was identified using an out-of-plane transverse ultrasound view at the level of the sacral cornua. The probe was then rotated longitudinally to visualize the sacrococcygeal ligament and sacral bone. A block needle was inserted through the sacrococcygeal membrane into the sacral canal using the in-plane technique, and 0.125% bupivacaine was administered at a dose of 1 mL/kg, with a maximum limit of 20 mL per side.
223921701|NCT06584292|PROCEDURE|Retrolaminar block|Retrolaminar Block (RL) Procedure: The RL block was performed with the patient in a lateral decubitus position. The ultrasound probe was positioned at the L4 vertebral level in a paramedian sagittal plane. The probe was moved medially until the vertebral laminae were visualized. The needle was inserted using the in-plane technique, advancing from the cephalad to caudal direction until it contacted the L4 lamina. A dose of 0.1 mL/kg of 0.25% bupivacaine was then injected into the retrolaminar space.
223921702|NCT06737055|BEHAVIORAL|Education about behavioral strategies to improve sleep|In collaboration with direct care workers, the investigators are developing an intervention to help home visitors support clients who experience sleep difficulties in the perinatal period. The intervention consists of a series of educational videos about promoting healthy sleep and addressing sleep difficulties during pregnancy and the postpartum period.
223921703|NCT06889402|PROCEDURE|Neoadjuvant therapy with PD-L1 inhibitor|During neoadjuvant treatment, patients may receive neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, or neoadjuvant chemotherapy combined with immunotherapy during the perioperative period.
223921704|NCT06737731|DRUG|SHR-1681|SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.
224091089|NCT06852443|BEHAVIORAL|Selfhelp modules|16 web-based structured selfhelp modules, based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer)
223717369|NCT07015814|OTHER|Golden sugarcane jaggery|Participants will consume a standardized portion of jaggery Type A providing 50 grams of available carbohydrates. Capillary blood glucose will be measured over a 2-hour postprandial period.
223921705|NCT06737692|OTHER|Exercise|"Supervised Aerobic Exercises: Conducted every two weeks, three days a week (on days 11-13 post-systemic treatment). The supervised aerobic exercises will consist of 20 minutes on a treadmill at a heart rate corresponding to 55-75% of the Karvonen formula. Warm-up and cool-down will be performed at 30-40% of the Karvonen heart rate for 5 minutes.~Supervised Resistance Exercises: Conducted every two weeks on consecutive days (days 11 and 13 post-systemic treatment).~Resistance training will involve 12 different exercises targeting major muscle groups, using body weight and resistance bands, at an effort level of 5-7 on the Borg scale, with 8-12 repetitions and 1-3 sets. The intensity will be progressively adjusted based on the individual's perceived exertion.~On weeks without supervised exercises, participants will follow a home exercise program that includes breathing exercises, walking for 20-30 minutes, and resistance exercises."
223921706|NCT06779461|DEVICE|Magnesium Microspheres|Biodegradable Magnesium Embolic Microspheres
223921707|NCT06779461|PROCEDURE|cTACE|cTACE
223921708|NCT01527188|DRUG|100 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
224091090|NCT06852443|BEHAVIORAL|Therapist Chat Service|Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer)
224279656|NCT02196467|BIOLOGICAL|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
224279657|NCT02196467|PROCEDURE|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
224279658|NCT05762653|DIAGNOSTIC_TEST|Endoscopic ultrasound|Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
224279659|NCT02806791|DRUG|FILGRASTIM|
224279660|NCT01978964|BIOLOGICAL|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
224279661|NCT01166464|BEHAVIORAL|text messaging for smoking cessation|A 7-week program of daily text messages
224279662|NCT01166464|BEHAVIORAL|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
224279663|NCT00998595|OTHER|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
223530940|NCT07160296|BEHAVIORAL|20-Week Lifestyle Program|"Nutrition counseling: Weekly group sessions with an oncology dietitian, including individualized calorie and protein goals.~Exercise: Home-based resistance and mobility exercises twice per week using online videos, and daily walking with self-tracking.~Wellness education: Weekly group sessions focused on stress management, sleep, fatigue, and mindset, facilitated by a health and wellness coach. Five of the 20 sessions will include a Speech, Voice, Swallowing, and Airway Care in Head \& Neck Cancer training series led by a speech pathologist."
223530941|NCT07159685|PROCEDURE|Atrial fibrillation ablation|Atrial fibrillation ablation with RF, guided by navigation system
223717370|NCT07015814|OTHER|Dark brown sugarcane jaggery|Participants will consume a standardized portion of jaggery Type B providing 50 grams of available carbohydrates. Capillary blood glucose will be measured over a 2-hour postprandial period.
223921709|NCT01527188|DRUG|300 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
223921710|NCT01527188|DRUG|500 IR house dust mites allergen extract tablet|One sublingual tablet daily during 6 months
223921711|NCT01527188|DRUG|Placebo tablet|One sublingual tablet daily during 6 months
223921712|NCT06743841|DIETARY_SUPPLEMENT|Nutritional supplement|60g of a nutritional supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
224091091|NCT00764556|DRUG|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
224091092|NCT00003454|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224091093|NCT05957705|PROCEDURE|Maxilar Sinus augmentation|The patients will be submitted to bilateral sinus augmentation using two different techniques to provide enough bone tissue for dental implants placement.
224279664|NCT03764657|PROCEDURE|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
224279665|NCT03764657|PROCEDURE|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
223921713|NCT06743841|DIETARY_SUPPLEMENT|Control supplement|60g of a placebo supplement powder, divided into 2 daily intakes, one in the morning and one in the afternoon
223921714|NCT06743607|BEHAVIORAL|Immediate Intervention|Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences immediately after enrollment.
223921715|NCT06743607|BEHAVIORAL|Waitlist control|Participants will engage in a home exercise therapy program in combination with transcutaneous spinal stimulation intended to focus on the upper extremities that commences 12 weeks after enrollment.
223921716|NCT06891092|DEVICE|RayOne EMV|non-diffractive monofocal IOL
223921717|NCT06891092|DEVICE|Vivinex Impress|non-diffractive monofocal IOL
223921718|NCT06891118|PROCEDURE|Stellate gangion blockade %1 5 mL|"SGB is performed under sterile conditions in the operating room, with the patient's intravenous line established, monitored during the procedure, and ultrasound guidance used simultaneously. The patient is positioned supine, with the neck slightly hyperextended and the head slightly turned to the opposite side. After the skin is cleaned with an antiseptic solution and the probe is sterilized, a linear ultrasound probe is placed transversely at the level of the sixth cervical vertebra (C6).~The relevant anatomical landmarks, including the internal carotid artery, internal jugular vein, thyroid tissue, longus colli muscle, prevertebral fascia, C6 transverse process (Chassaignac's tubercle), C6 nerve root, and vertebral artery, are visualized. Avoiding vascular structures and thyroid tissue, a 25-gauge 38 mm sterile needle is advanced with a lateral approach using the in-plane technique, ensuring the needle tip is just below the surface of the longus colli m"
224091094|NCT05957705|PROCEDURE|Dental implant placement using guided surgery|After 4 months of sinus augmentation, patients will be prepared to receive dental implants for oral rehabilitation. Performed by guided surgery the implants will be placed at the best location for the rehabilitation and at the place were the sinus lighting were performed.
224091095|NCT04742335|OTHER|Survey|Survey will be applied to the participants.
224091096|NCT06271525|OTHER|cupping therapy|"All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.~1. -Primary sucking~2. -Scarification 3- Bloodletting 4-Removal~5 -Dressing"
224091097|NCT04141176|DEVICE|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
224091098|NCT04880928|DRUG|Eye injection (Mydrane)|"Mydrane 0.2 mg/ml + 3.1 mg/ml~\+ 10 mg/ml solution for injection tropicamide / phenylephrine hydrochloride / lidocaine hydrochloride"
224091099|NCT04880928|DRUG|eye drops (Phenylephrin)|Phenylephrine 10%
224091100|NCT04880928|DRUG|eye drops (Tropicamid)|Tropicamid 0,5%
224091101|NCT03849339|DRUG|CKD-387|Test drug
224091102|NCT03849339|DRUG|D635|Reference drug
224091103|NCT03633357|DRUG|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
224091104|NCT03633357|DRUG|Placebo|Participants will take two placebo tablets daily, for seven days.
224091105|NCT05136963|DRUG|Iohexol|5 milliliter of iohexol will be administrated.
224091106|NCT05136963|BIOLOGICAL|pharmacokinetics|10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00
224091107|NCT03006614|DRUG|NVB|
224091108|NCT03006614|DRUG|EPI|
224091109|NCT03006614|DRUG|DDP|
224091110|NCT03006614|DRUG|CAP|
224091111|NCT03006614|DRUG|GEM|
224091112|NCT03006614|DRUG|H|
224091113|NCT03006614|DRUG|CTX|
224091114|NCT03006614|DRUG|T|
224091115|NCT03046420|OTHER|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
224091116|NCT00891202|DRUG|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 \[active moiety of ET in plasma\] trough plasma concentration \>=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration \<5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
224091117|NCT00891202|DRUG|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if \>=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
224091118|NCT06376721|DRUG|Linperlisib|Linperlisib: Phase Ib, oral, 80 mg/d, QD; Phase II, oral, RP2D, QD.
224091119|NCT06376721|DRUG|Camrelizumab|Camrelizumab for Injection: 200 mg/d, intravenous drip for 30 min (not less than 20 min and not more than 60 min), administered on day 1 of each cycle, observed for 2 hours after infusion. Every 3 weeks is a dosing cycle. Cycle 2 and subsequent cycles of dosing may be administered up to 5 days before or after the day of the scheduled dosing; more than 3 days after the date of the scheduled dosing will be considered a delayed dosing.
224091120|NCT06376721|DRUG|Pegaspargase|"Pegaspargase: 2500 IU/m2, intramuscular injection, divided into three places, administered on the first day of each cycle, observed 2 hours after injection for the occurrence of anaphylactic reaction, if there is no anaphylactic reaction before giving other test drugs. Every 3 weeks as a dosing cycle.~Camrelizumab for Injection should not be applied on the same day as Dexamethasonee."
224091121|NCT06376721|DRUG|Dexamethasone|Dexamethasone, 20 mg/d, days 1-4. Camrelizumab for Injection should not be applied on the same day as Dexamethasonee.
224091122|NCT06264609|DRUG|Alendronate|Participants in Group 1 low turnover, who have received Teriparatide in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Alendronate for 12 months.
224279666|NCT01275716|BEHAVIORAL|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
224279667|NCT01835548|DRUG|NT0102|NT0102 (methylphenidate polistirex \[MPP\] extended release \[XR\] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
223921719|NCT06741332|DEVICE|Methinks software|Introduction in the stroke code workflow the Methinks AI software capable of detecting LVO on NCCT and CTA, and ICH on NCCT.
223921720|NCT06741332|OTHER|Normal CT scans evaluation|The control group is obtained from a historical cohort at each participating center. We include consecutive suspected acute stroke patients who meet the same inclusion/exclusion criteria defined above, except for Methinks image processing.
224279668|NCT01835548|DRUG|Placebo|Matching ODT placebo was given once daily.
224279669|NCT03121937|BEHAVIORAL|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
224279670|NCT05766124|DRUG|Tissue Plasminogen Activator|Intrapleural administration of tissue plasminogen activator
224279671|NCT03257254|DRUG|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
224279672|NCT02701608|DRUG|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
224279673|NCT02701608|DRUG|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
224279674|NCT02701608|PROCEDURE|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
224279675|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
224279676|NCT00225641|PROCEDURE|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
223921721|NCT06739603|OTHER|pharmaceutical analysis|pharmaceutical analysis
223921722|NCT06740045|BIOLOGICAL|Tezepelumab|10 patients will receive teszpire
223921723|NCT06740266|BEHAVIORAL|Promoting First Relationships in Primary Care (PFR-PC)|"Promoting First Relationships® in Primary Care is based on attachment theory and is strengths-based. The intervention is delivered in 10 home visits, with 2 additional clinic visits. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to their concerns, and establishing a positive, supportive relationship. The provider videotapes playtime between parent and child, and alternates weeks watching the video with the parent, reflecting about the needs of both parent and child (reflective observation). PFR consultation strategies include Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts. These core strategies enhance parents' sense of security and competency. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify their own feelings and needs around parenting."
223921724|NCT04626427|DEVICE|WavelinQ™ EndoAVF System|AVF endovascular creations using the WavelinQ™ EndoAVF System
223921725|NCT06734845|PROCEDURE|Total Knee Arthroplasty|Total Joint (Knee or Hip) Arthroplasty
223921726|NCT06734845|PROCEDURE|Total Joint Arthroplasty|Participants will be patients undergoing first total knee or total hip replacement
223921727|NCT06736054|DRUG|Copper 61-PSMA PET/CT|TEST PRODUCT, DOSE, AND ROUTE OF ADMINISTRATION: Subjects will undergo imaging with 100-300 MBq (2.7-8.1 mCi) of 61Cu-NODAGA-PSMA intravenously (IV), followed by PET/CT imaging 60 (+/- 10) minutes post radiotracer administration.
224091123|NCT06264609|DRUG|Teriparatide|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant did not respond well to therapy; will be assigned to Teriparatide for 12 months.
224091124|NCT06264609|DRUG|Alendronate|Participants in Group 2 low turnover who received Alendronate in the main trial and if it is determined that the participant responded to therapy; will be continue on Alendronate for 12 months.
224091125|NCT02992002|OTHER|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
223921728|NCT06742489|DEVICE|Percutaneous tibial nerve stimulation device|T-PTNS primarily delivers electrical stimulation to the sacral voiding center via the tibial nerve through the S2-S4 sacral plexus via skin-surface electrodes to improve patients' symptoms of urinary frequency, urgency, and urge incontinence.
223921729|NCT06742489|DEVICE|Sham group device|The device in the sham group is manufactured by the same company and has the same appearance, display interface, and operation method as the device in the treatment group. These devices have the output circuit disconnected and no actual current output.
223921730|NCT06744686|DRUG|HT-102|50mg, 150mg, 300mg, 600mg
223921731|NCT06744686|DRUG|HT-102|50mg, 150mg, 300mg
223921732|NCT06744686|DRUG|Placebo|Placebo
223921733|NCT06746636|DEVICE|High velocity nasal insufflation|• HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].
223921734|NCT04270786|PROCEDURE|Early de-escalation|In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.
223921735|NCT04270786|PROCEDURE|Standard|In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.
223921736|NCT06786624|DRUG|NBI-1065845|NBI-1065845 tablets
223921737|NCT06786624|DRUG|Placebo|Matching placebo tablets
223921738|NCT06794320|OTHER|NF Protocol|The daily practice of physicians in evaluating and treating patients with sNF.
223921739|NCT06794320|OTHER|ASTERIC protocol|i. Risk-assessment tools
223921740|NCT06794320|OTHER|ASTERIC protocol|ii. Fast track absolute neutrophil counts turnaround service
223921741|NCT06794320|OTHER|ASTERIC Protocol|iii. A decision tool for patient management and initial antibiotic use
223921742|NCT06794320|OTHER|ASTERIC Protocol|iv. A decision tool for patient management and subsequent antibiotic use
223921743|NCT06794320|OTHER|ASTERIC Protocol|v. An educational package
223921744|NCT06794320|OTHER|ASTERIC Protocol|vi. A decision tool for patient disposal - discharge or emergency department ward observation
223921745|NCT01265537|DRUG|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
223921746|NCT01265537|DRUG|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
224091126|NCT06042673|DIETARY_SUPPLEMENT|Pomegranate seed oil|10 g of pomegranate seed oil+40g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
223921747|NCT05866926|DRUG|FAB122|FAB122 Daily dose 100 mg
223921748|NCT06747013|DEVICE|Point Ablation Catheter|a point ablation catheter using a pulse field energy
223921749|NCT06396949|DIAGNOSTIC_TEST|Fibromyalgia study form|Fibromyalgia study form, consisting of clinical measurement, Fibromyalgia impact questionnaire (FIQ), Beck Anxiety Questionnaire and Beck Depression Questionnaire, Short-Form (SF)-36, who applied to the outpatient clinic with fibromyalgia will be filled in detail.
223921750|NCT06396949|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
224091127|NCT06042673|DIETARY_SUPPLEMENT|Mixed vegetable oil|50g mixed oil (palm oil/ rapeseed oil/ safflower oil (4:0.5:0.5)) will be added to the test meal for breakfast
224091128|NCT04348448|DRUG|Canakinumab 150 MG/ML [Ilaris]|COVID-19
223921751|NCT06396949|DIAGNOSTIC_TEST|Ultrasonographic Diaphragm Thickness Measurement|Diaphragm thickness (millimeter-mm) will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (millimeter-mm), end-inspiratory (Total Lung Capacity) (millimeter-mm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
223921752|NCT05564130|DRUG|Sodium bicarbonate|Sodium bicarbonate 1 mmol/ml
223921753|NCT05564130|DRUG|Sodium chloride|Sodium chloride 9 mg/mL
223921754|NCT06878521|OTHER|Emotional Regulation Skills|"This intervention is inspired by and incorporates elements of Dialectical Behavior Therapy (DBT). It consists of eight weekly group sessions, each lasting approximately 1.5 to 2 hours, held on school premises. Each group includes 8 to 10 adolescents. The sessions are facilitated by two psychologists and/or senior psychology students who have been specifically trained to deliver the intervention.~The sessions focus on developing various emotional regulation skills, which participants are encouraged to practice both during and between sessions. Some of the key skills covered include Mindfulness, Wise Mind, and Problem-Solving, among others."
223921755|NCT06877260|DIAGNOSTIC_TEST|Computer based task with EEG|Participants will undergo EEG recording while performing a computer based neuropsychological task evaluating cognitive control
223921756|NCT06746376|OTHER|Occupational Therapy|"Description:~Participants assigned to the intervention group will undergo a 8-week supervised hand exercise program designed to improve pain, manual dexterity, and functionality."
224091129|NCT03951636|PROCEDURE|Mechanical debridement with curettes|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
224091130|NCT03951636|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
223921757|NCT06754592|DEVICE|Ultrasound|evaluate the effectiveness of dynamic high-resolution ultrasonography in identifying various abnormalities of the shoulder impingement syndrome, especially the subacromial type, and to determine the added value of dynamic ultrasonography compared to static examination of such cases. Furthermore, we will compare these findings to MRI
223921758|NCT06755320|OTHER|mechanical ventilation (MV)|Mechanical ventilation APRV mode ( Airway Pressure Release Ventilation )
223921759|NCT06755320|OTHER|mechanical ventilation (MV)|Mechanical Ventilation in BiPAP mode (Bi-Level Positive Airway Pressure Ventilation )
224091131|NCT03951636|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
223921760|NCT06753539|DEVICE|ILM forceps - membrane grasping|grasping the epiretinal membrane at the starting location, using pinch peeling, is performed with an ILM forceps.
223921761|NCT06870097|OTHER|A2 Milk|Cow's milk that contains only A2 β-Casein
223921762|NCT06870097|OTHER|A1/A2 Milk|Cow's milk that contains both A1 β-Casein and A2 β-Casein
223921763|NCT06739096|DEVICE|Short Wave Diathermy|Shortwave diathermy (SWT) is a form of electromagnetic therapy that causes the movement of ions, the disruption of molecules, and the generation of eddy currents, which ultimately produce heat in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain.
223921764|NCT06739096|OTHER|Exercise|range of motion, strengthening and stretching exercises
223921765|NCT06739096|DEVICE|Sham Short Wave Diathermy|Sham protocol
223921766|NCT06876389|DIETARY_SUPPLEMENT|Probiotic|In group A, children with iron deficiency received standard therapy. This group was given standard therapy in the form of elemental Fe 3 mg/kgBB/day/orally and L Bio as 2 packs per day and Saccharomyces boulardii given 2 capsules per day (dose 2 x 250 mg or 2 x (2.5 x109 cells/cfu)) for ages 1 year - 18 years for 30 days.
223921767|NCT06876389|OTHER|Placebo|In group B, children with iron deficiency received standard therapy with placebo. This group was given standard therapy in the form of elemental Fe 3 mg/kgBB/day/orally and placebo for 30 days.
223921768|NCT06740474|DRUG|ABI-6250|Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
223921769|NCT06740474|DRUG|Placebo|Single dose (SAD) or once or twice daily dosing over 10 days (MAD)
223921770|NCT06764030|OTHER|Educational web-based application|BRIDGES is a patient-directed computerized universal education on RC that is delivered within the FP setting, and that does not require the patient to disclose RC experiences to learn about RC.
223921771|NCT06760260|DRUG|Human Derived anti-CI135 CAR-T Injection|Autologous genetically modified anti-CI135 CAR transduced T cells
223921772|NCT06735339|OTHER|Clinic for Multimorbidity|"The patient is assigned a healthcare coordinator. A review of the patient's medication history and a medication review are conducted. A functional assessment is performed, along with relevant measurements, and the patient consults with a specialist physician. A multidisciplinary team (MDT) conference is held with selected specialists, depending on the patient's needs. This may include a cardiologist, endocrinologist, pulmonologist, gastroenterologist, rheumatologist, nephrologist, geriatrician, clinical pharmacologist, psychiatrist, pain nurse, physiotherapist, occupational therapist, and the patient's GP.~The handover of information to the GP is agreed upon at the time of referral and can be carried out in writing, through virtual MDT participation, or by telephone.~In agreement with the patient, the clinic may initiate follow-up actions, such as counseling on medication or disease management. Additionally, the clinic may facilitate cross-sectoral activities, such as therapy."
223921773|NCT06735170|PROCEDURE|biologic tuberoplasty|a surgical procedure during which an a cellular dermal allograft is attached to the greater tuberosity to prevent bone-to-bone contact between the greater tuberosity and the acromion with the goal of decreasing pain
223921774|NCT06735170|PROCEDURE|subacromial balloon spacer|a biodegradable balloon is inserted into the subacromial space of the shoulder to increase teh distance between the greater tuberosity and the acromion to reduce pain
223921775|NCT06917950|DRUG|Roxadustat|Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Administered orally three times per week. Dosage will be initiated and adjusted according to prescribing guidelines for treating anemia associated with chronic kidney disease in patients on dialysis based on hemoglobin levels.
223921776|NCT06917950|DRUG|Conventional Anemia Management|Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron supplementation. Dosing and specific agents used are per standard clinical practice at the study site and adjusted based on hemoglobin levels and iron status according to prevailing guidelines.
223921777|NCT06729385|DIAGNOSTIC_TEST|The blood Proteome Profiling|Patients who meet the inclusion criteria will undergo fasting blood collection for proteomics analysis upon admission.
223921778|NCT06424249|OTHER|Virtual Reality|A progressive rehabilitation protocol (different levels according to success scores) consisting of several exercises using virtual and augmented reality with mechanical perturbations (pitching of the treadmill), interaction with the virtual environment, interaction with the virtual environment and augmented reality (projection of obstacles on the treadmill), and modification of the gait pattern with visual and/or audio biofeedback
223921779|NCT06424249|OTHER|Standard rehabilitation|A treadmill walking protocol with virtual reality to immerse the patient in a 3 x 5-minute walking session, without visual, mechanical or auditory disturbances, and without prompting the patient to modify their walking pattern.
223921780|NCT05765851|DRUG|DS-1103a|One IV infusion Q3W on Day 1 of each 21-day cycle
223921781|NCT05765851|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
223921782|NCT06032988|DIETARY_SUPPLEMENT|LactoLevure|Participants will receive LactoLevure\^R probiotic dietary supplement or matching placebo once a day.
223921783|NCT05373537|BEHAVIORAL|Cognitive behavioral therapy for Insomnia|Caregiver with insomnia will receive CBT-Insomnia and will be trained to implement CBT-I tailored for their child with Autism Spectrum Disorder and Insomnia
223921784|NCT06098170|BEHAVIORAL|Unguided use of the My SCI Toolkit program|Participants will be asked to use the My SCI Toolkit program for 8 weeks (without a coach), following the prompts and guides built into the program.
223921785|NCT06098170|BEHAVIORAL|Coached My SCI Toolkit|Participants will be asked to use the My SCI Toolkit program for 8 weeks, following the prompts and guides built into the program. Participants will also have weekly phone calls (the first is about 30-45 minutes, and the rest are about 15 minutes) with a study coach. The coach can help answer questions and tailor the skills more to the participant's goals and needs. The coaching sessions will be audio recording for fidelity purposes.
223921786|NCT06207071|DIETARY_SUPPLEMENT|DHA|DHA supplementation
223921787|NCT02076009|DRUG|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
223921788|NCT02076009|DRUG|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
223921789|NCT02076009|DRUG|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
223921790|NCT02390869|DRUG|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
223921791|NCT02390869|DRUG|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
223921792|NCT06415682|DEVICE|SMA+M1 Transcranial Magnetic Stimulation|"The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). For SMA stimulation, a 5s burst of 10Hz rTMS was repeated 20 times (1000 pulse, 20 minutes' duration).~Patients in the Experimental group underwent ten sessions of double-site high frequency rTMS over the bilateral primary motor cortex (M1) of the lower leg and supplementary motor area (SMA)."
223921793|NCT06415682|DEVICE|M1 Transcranial Magnetic Stimulation|The M1 stimulation session consisted 40 trains of 10-Hz rTMS with the protocol of 5s train session and 25s intertrain intervals. There were 4000 pulses per day for M1-LL (unilateral stimulation 2000 pulses). Patients in the Active Comparator group underwent ten sessions of single-site active magnetic stimulation with high frequency rTMS over the bilateral M1 of the lower leg.
223921794|NCT06415682|DEVICE|Sham Transcranial Magnetic Stimulation|Patients in the Sham Comparator group underwent 10 sessions of double sham rTMS on M1 of the lower leg.
223921795|NCT05111093|DEVICE|ARC-IM Investigational System implantation|Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
223921796|NCT06949176|PROCEDURE|Root canal tratment using mecchanical and chemical preparation.|Root canal procedures including access cavity preparation, chemomechanical instrumentation, irrigation with sodium hypoclorite (NaOCl), microbiological sampling and obturation with warm vertical compaction.
223921797|NCT06949176|DRUG|Sodium Hypochlorite.|Sodium Hypoclorite used as the primary irrigant in the root canal treatment at concentrations of 2.5% (Group A) and 5% (Group B).
223921798|NCT06949176|DRUG|Hydrogen peroxide.|Applied to the operating field and tooth as part of initial disinfection prior to cavity access.
223921799|NCT06949176|DRUG|Sodium Sulfate.|Used to inactivate sodium hypoclorite prior to sample collection.
223921800|NCT06949176|DEVICE|Root ZX mini apex locator (Morita).|Used to determine the working length of the root canal.
223921801|NCT06949176|DEVICE|Protaper Gold rotary files (Dentslpy Maillefer).|Used for coronal flaring in root canal instrumentation.
223921802|NCT06949176|DEVICE|Smarttrack and Hyflex totary files.|Used for root canal instrumentation to full working length.
223921803|NCT06949176|DEVICE|Endo-Eze 27G irrigation needle (Ultradent).|Used to deliver irrigant into the root canal.
223921804|NCT04363853|DRUG|Tocilizumab 20 MG/ML|We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.
223940769|NCT06263647|BEHAVIORAL|Standard of Care|Participants will be assigned a case manager to meet with the injured patients to briefly assess (a) psychological and social needs and (b) a risk assessment and create individualized discharge planning. Resources for the patient to connect with social service programs will be provided by the case manager. Long-term opportunities for engagement with the trauma survivors' network within Memorial Hermann Hospital will be available and encouraged. Follow-up contacts and services from an assigned case manager over two weeks following discharge from the hospital to ensure that the patient has contacted the community-level violence outreach organizations.
223940770|NCT07050186|PROCEDURE|Biopsy Procedure|Undergo optional biopsy
223940771|NCT07050186|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223940772|NCT07050186|BIOLOGICAL|Cemiplimab|Given IV
223940773|NCT07050186|PROCEDURE|Computed Tomography|Undergo CT
223940774|NCT07050186|OTHER|Digital Photography|Undergo digital photography
223940775|NCT07050186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223940776|NCT07050186|OTHER|Questionnaire Administration|Ancillary studies
223940777|NCT06733649|OTHER|substance abuse treatment education|Perinatal women and the women's community support will receive a 50 minute education session that provides correct information on opioid agonist medications and neonatal abstinence syndrome.
223940778|NCT06734208|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective cohort.
223940779|NCT03359954|RADIATION|Radiation Therapy|Undergo radiation therapy
223940780|NCT03359954|PROCEDURE|Therapeutic Conventional Surgery|Undergo breast surgery
223940781|NCT07127016|BEHAVIORAL|Mindfulness Sessions|8 sessions of mindfulness prior to completing their physical therapy session. Each mindfulness session will take 5-10 minutes and will be completed once weekly, immediately prior to their physical therapy sessions. Mindfulness prompts will focus on self-reflection, relaxation, body scanning and being present.
223940782|NCT07127016|BEHAVIORAL|No Mindfulness Sessions|Standard of care physical therapy without mindfulness sessions.
223940783|NCT06896188|DRUG|Retifanlimab|(PD-1)-blocking monoclonal antibody
223921805|NCT04626882|PROCEDURE|Staged in-hospital or Immediate complete revascularization|Patients with ST-segment elevation myocardial infarction and multivessel disease will be randomized after primary PCI for IRA. All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-70% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
223921806|NCT04165213|BEHAVIORAL|Care of Older Persons in their Environment (COPE) online module training|An online module version of training for clinicians (OTs and RNs) in the evidence-based dementia caregiving program called Care of Older Persons in their Environment (COPE) is the intervention being tested for non-inferiority against the usual instructor-led COPE training. COPE modules include rich multimedia content, simulated scenarios, interactive assessments to keep the learner engaged The content is packaged into the latest the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions. Each of the ten modules last 45-60 minutes.
223921807|NCT06079840|DEVICE|mindfulness-based stress reduction app|mobile application (app) for caregivers
223921808|NCT03760939|OTHER|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
223921809|NCT02978521|OTHER|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
223921810|NCT06207110|BEHAVIORAL|Regulation of Cues|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to improve satiety responsiveness and decrease food cue responsiveness. This arm will include an experiential component, including hunger monitoring during a meal or snack and participating in exposure exercises.
223921811|NCT06207110|BEHAVIORAL|Family Based Behavioral Treatment|FBT provides nutrition and physical activity education, behavior therapy skills, and parenting skills targeting changes in energy balance.
223921812|NCT06207110|BEHAVIORAL|Regulation of Cues +|ROC+ includes all of the skills provided in ROC but integrates nutrition education and reducing energy intake
223921813|NCT06207110|BEHAVIORAL|Health Education|The HE program provides information about nutrition, physical activity, sedentary behavior, sleep, emotions, and stress.
223921814|NCT06784674|OTHER|No intervention|Observational study
223921815|NCT04933474|BEHAVIORAL|painTRAINER®|PainTRAINER is among the most widely-validated mHealth interventions for pain management.18-25 Originally developed by members of our team at Duke and Northwestern University under NIH funding, the app teaches evidence-based pain coping skills using a self-administered, home-based software program. The system delivers eight sessions via any web-connected platform, including Android or iOS smartphones, tablets, or personal computers. The digital curriculum covers progressive muscle relaxation, activity/rest cycling, pleasant activity scheduling, recognizing negative automatic thoughts, pleasant imagery/distraction, problem solving, and monitoring for maintenance. Patients complete one session per week in a pre-determined order. The program can be completed in a flexible manner to accommodate life and medical events.
223921816|NCT04933474|DEVICE|Skills-Based VR|"Participants will use the Pico G2 4K VR audio and visual head-mounted device, loaded with the EaseVRx+ software. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view. The headset battery requires recharging after approximately 2.5 hours of use.~https://www.pico-interactive.com/us/G2\_4K.html"
224091132|NCT04108429|BEHAVIORAL|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
223921817|NCT03131128|BEHAVIORAL|Mindfulness-based Intervention|"1. Keeping mindful when selecting food.~2. Be aware of hunger and satiety by the body clues.~3. Understanding how stress affect diet and life, and learn how to cope with stress in life.~4. Learning to identify overeating caused by mood, social stress and specific food."
223921818|NCT03131128|BEHAVIORAL|Health Education Intervention|"1. Identifying improper diet patterns and attitudes~2. Understanding the impact of irrational cognition and attitudes on dietary behavior~3. Training coping skills for stresses in real life and preventing the recurrence of bulimia."
223921819|NCT06356584|DRUG|Immunotherapy (Sintilimab)|Sintilimab
223921820|NCT06356584|DRUG|Targeted Therapy Agent (Fruquintinib)|Fruquintinib
223921821|NCT06356584|RADIATION|Radiotherapy (SBRT and LDRT)|SBRT and LDRT
223921822|NCT05451043|BIOLOGICAL|Durvalumab|It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug
224091133|NCT04947644|PROCEDURE|Thoracic epidural analgesia|After negative response, 10 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 5ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
223530942|NCT07158567|DEVICE|intermittent theta burst stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulatory treatment. TMS has been FDA cleared since 2008 for treatment resistant depression. It is now FDA cleared for a few other indications including migraine. Magnetic pulses are delivered through a coil placed on the scalp and when the magnetic field reaches brain cells, it changes to an electric current that can increase or decrease excitability depending on the treatment parameters. Intermittent theta burst stimulation (iTBS) is a type of patterned, excitatory TMS. iTBS only takes 3 minutes to deliver and is theorized to induce a window of neuroplasticity that lasts at least 1 hour. The Magventure with Magoption x100 Stimulator and associated coil the investigators are using can be set to deliver active (real) or sham (fake or inactive) TMS. The sham device is designed to look, sound and feel like real TMS.
223530943|NCT07158567|BEHAVIORAL|LoveYourBrain Yoga Program|This yoga program is evidence-based, standardized and manualized. It is developed by the LoveYourBrain Foundation (www.loveyourbrain.com). Each yoga session includes 10 min of breathing exercises, 45 min of gentle yoga or stretching exercises, 15 min of guided meditation, and 20 min of facilitated discussion with psychoeducation, detailed in a manual to ensure standardization of program content across time and instructors.
223530944|NCT07158762|OTHER|White bread|Two slices of white bread consumption along with 150 ml of pure orange juice and 10 g of butter
223530945|NCT07158762|OTHER|Wholemeal bread|Two slices of wholemeal bread consumption along with 150 ml of pure orange juice and 10 g of butter
223921823|NCT05451043|DRUG|Gemcitabine|Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells
223921824|NCT05451043|DRUG|Nab paclitaxel|Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions
223921825|NCT05451043|BIOLOGICAL|Tremelimumab|Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker.
223921826|NCT05451043|DRUG|Propranolol|Competitively blocks both β1 and β2 adrenergic receptors.
223921827|NCT05451043|DRUG|Cisplatin|cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells.
223921828|NCT06476496|PROCEDURE|Acupuncture|A licensed acupuncturist will insert sterile disposable acupuncture needles in the selected body and ear acupoints aiming to alleviate long COVID related pain symptoms. Needles will be removed after 20 minutes of retention. After all the needles are removed, the acupuncturist will insert Pyonex press tack needles (0.3mm) in the participants' left ears and suggest the participants retain them in their ears for up to 5 days.
223921829|NCT05419856|DRUG|4P-004|single intraarticular administration in the knee joint
223921830|NCT05419856|DRUG|Placebo|single intraarticular administration in the knee joint
223921831|NCT06677879|RADIATION|Proton radiotherapy|"Lumpectomy group: The total dose was 40.05Gy (RBE) , 2.67Gy (RBE) per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy (RBE) , 2.66Gy (RBE) per fraction with 16 fractions. Once a day, five times a week."
223921832|NCT06677879|RADIATION|Photon radiotherapy|"Lumpectomy group: The total dose was 40.05Gy, 2.67Gy per fraction with 15 fractions. Once a day, five times a week. The tumor bed SIB to 48Gy (RBE).~Mastectomy group: The total dose was 42.56Gy, 2.66Gy per fraction with 16 fractions. Once a day, five times a week."
223921833|NCT06687369|DRUG|MB12 (Proposed Pembrolizumab Biosimilar)|200mg IV, every 3 weeks on Day 1
223921834|NCT06687369|DRUG|EU-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
223921835|NCT06687369|DRUG|US-sourced Keytruda®|200mg IV, every 3 weeks on Day 1
223921836|NCT06687369|DRUG|Pemetrexed|500 mg/m2 IV, every 3 weeks on Day 1
223921837|NCT06687369|DRUG|Carboplatin|Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
223921838|NCT06687369|DRUG|Cisplatin|75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
223921839|NCT06635486|BEHAVIORAL|Adapted cognitive-behavioral (CBT) intervention|The intervention is 6-12 sessions, depending on the symptom presentation of the participant. The weekly sessions last 60 minutes and will be delivered remotely and individually via Meet or a similar platform by trained lay providers. Intervention methods include cognitive re-structuring, behavioral activation, exposure to memories and situations, problem solving, and emotional regulation.
223530946|NCT07161596|BEHAVIORAL|oral health educational program|oral health educational program to the hemophilic children guided by the oral and dental care instructions provided by the AAPD and World federation of hemophilia oral care instructions
223530947|NCT07159841|DRUG|Atumelnant|Atumelnant, tablets, once daily by mouth, weight-based dosing
223921840|NCT04867525|OTHER|Physician's choice according to patient's needs.|Routine care as per site standard.
223921841|NCT04793750|DIAGNOSTIC_TEST|Cepheid GeneXpert HIV-1 Qual POC HIV VL test|POC Nucleic acid-based test for HIV RNA.
223921842|NCT04793750|DIAGNOSTIC_TEST|DPP HIV-Syphilis test system|POC Tests for antibodies to HIV 1/2 and Treponema pallidum.
223921843|NCT04793750|DIAGNOSTIC_TEST|OraQuick|POC oral fluid swab test for HIV 1/2 antibodies.
223921844|NCT03358446|OTHER|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
223921845|NCT03358446|OTHER|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
223921846|NCT05900557|DIAGNOSTIC_TEST|ECoG monitoring|Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
223921847|NCT05592093|DRUG|Korean red ginseng capsule (marketed product in Korea)|Korean red ginseng capsule (marketed product in Korea) KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time.
223921848|NCT05592093|DRUG|Korean red ginseng capsule(placebo)|"KRGO group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and KRGO group.~The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the KRGO group and placebo group at a ratio of 1:1. The drug was administered for 12 weeks, 2 times a day, 3 capsules each time."
223921849|NCT06364423|BIOLOGICAL|Autologous HuCD19 ( Anti-CD19)CAR T cells|1.0x10\^6 CAR+T-cells - 12x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
223921850|NCT06364423|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
223921851|NCT06364423|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
224091134|NCT04947644|PROCEDURE|Ultrasound guided continuous erector spinae plane block|After verifying the correct space with hydrodissection by 5mL of saline 0.9%, lifting erector spinae muscle off the bony shadow of the transverse process, a catheter was inserted was inserted 3 cm beyond the needle tip and 20 ml of 0.25% bupivacaine will be injected as a bolus dose in the epidural catheter in 10 ml divided aliquots at 5min intervals, 30 min before the induction of general anesthesia and the patient will be turned to the supine position. Sensory block will be assessed in operated side by loss of pinprick sensation in midclavicular line every 2 min. After 15min, if the sensory block level was still below T5, an additional 5ml bupivacaine was given. Then followed by continuous infusion of bupivacaine 0.125% at a rate of 6 ml/h that will be started before skin incision and the dose was increased in 2 ml/h increments up to 10 ml/h for 24 hours. Rate adjustment according to pain score and side effects
224279677|NCT05194709|BIOLOGICAL|Anti-CAR-NK Cells|The administration of CAR-NK cell will be performed on day 1 and day 3 of each cycle (21 days). The first administration dose in the first cycle is 3.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 4.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 4.0×10\^9 cells.
223921852|NCT06364423|DRUG|Rituximab|500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis
224091135|NCT02257424|DRUG|Trametinib 2 mg daily|
224091136|NCT02257424|DRUG|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
224091137|NCT02257424|DRUG|dabrafenib 150 mg orally twice a day|
224091138|NCT01668368|OTHER|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
224091139|NCT02486861|OTHER|optical coherence tomography|
224279678|NCT05347394|DRUG|VX-708|Solution or suspension for oral administration.
223530948|NCT07159841|DRUG|Placebo|Placebo, tablets, once daily by mouth, weight-based dosing
223530949|NCT07161492|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Individualized dual-target rTMS delivered using MRI-guided neuronavigation (Dolphin Robotics). Stimulation parameters:~* Targets: Left IPL and right dPFC connectivity hotspots~* Protocol: 100 pulse-pairs/session at 0.2Hz~* Intensities: Conditioning stimulus 90% RMT, test stimulus 120% RMT~* Duration: 8.3 min/session, 5 sessions/week × 4 weeks"
224279679|NCT05347394|DRUG|Placebo|Placebo matched to VX-708 for oral administration.
224279680|NCT05531617|PROCEDURE|Intubation|Study groups Intubated with Macintosh or cmac video laryngoscopes
224279681|NCT03201263|PROCEDURE|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
223530950|NCT07161492|BEHAVIORAL|Computerized Cognitive Remediation Therapy|Structured computer-based training targeting cognitive flexibility, consisting of 4-6 exercises per session. Each exercise includes 8-24 progressively challenging tasks. Administered for 45-60 minutes per session, 5 sessions/week over 4 weeks. Delivered via specialized software on desktop computers.
223530951|NCT07161492|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|"Inactive stimulation using identical equipment with:~* Coil tilted at 90° to scalp~* Magnetic shielding insert~* Matched acoustic artifact All other parameters identical to active rTMS arm."
223921853|NCT06463691|DRUG|BGB-11417|Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule
223921854|NCT06463691|DRUG|BGB-3111|Zanubrutinib, orally, 320 mg total daily dose
223921855|NCT06463691|DRUG|CD20|CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.
223921856|NCT05961436|PROCEDURE|PENG block|Using ultrasound-guided technique, a total of 20ml of 0.25 % bupivacaine will be injected after negative aspiration.
223921857|NCT05961436|PROCEDURE|FN block|Using ultrasound-guided technique, after negative aspiration, 20 mL of 0.25 % bupivacaine will be administered.
223921858|NCT05276388|OTHER|biological bank|biological bank of subjects vaccinated against SARS-CoV-2 infection
223921859|NCT06511804|DEVICE|Intracranial Pressure Noninvasive Monitoring|Mespere sensors will be placed on the temporal areas of the head in patients with invasive intracranial pressure monitoring. Blood pressures, intracranial pressure, and Mespere parameters will be recorded.
223921860|NCT06632938|DRUG|ABBV-382|Subcutaneous (SC) Injection
223921861|NCT06632938|DRUG|ABBV-382|Intravenous (IV) Infusion
224091140|NCT06100575|BEHAVIORAL|Website (www.mee-leven.be)|"The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives"
224091141|NCT00793351|PROCEDURE|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~* Enrollment - Pre-RIST treatment - RIST~* 4 cycles of conventional chemotherapy will be given prior to RIST.~* Surgery will be done whenever possible prior to RIST.~* Local radiotherapy will be applied whenever possible prior to RIST.~* topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~* Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
224091142|NCT03275545|OTHER|No intervention|No intervention is being examined in this study
224091143|NCT05238051|OTHER|Gastric residual volume measurement stopped.|GRV is checked during routine enteral nutrition, but we think that GRV prolongs the time to reach target calories and does not reduce complications.
224091144|NCT06654713|OTHER|Commercial AID system|AID system that is commercially available and FDA approved for use
224091145|NCT06654713|OTHER|Open source AID system|AID system that uses unregulated open-source software to customize an insulin delivery algorithm to connect an insulin pump to a continuous glucose monitor
224091146|NCT01629147|DIETARY_SUPPLEMENT|Biogaia|5 drops containing Lactobacillus reuteri Protectis
223530952|NCT07161492|DRUG|Selective Serotonin Reuptake Inhibitors or Serotonin-Norepinephrine Reuptake Inhibitors|"Background antidepressant therapy maintained at stable doses throughout the study. Minimum dose requirements:~* SSRIs: Paroxetine ≥20mg/day, Sertraline ≥50mg/day~* SNRIs: Venlafaxine ≥75mg/day, Duloxetine ≥60mg/day Dosage adjustments prohibited during trial participation."
223921862|NCT06632938|DRUG|Placebo for ABBV-382|IV Infusion
223921863|NCT06632938|DRUG|Placebo for ABBV-382|SC Injection
223921864|NCT05023772|PROCEDURE|Stereotactic Laser Ablation|MR Guided laser ablation therapy
223921865|NCT05023772|RADIATION|Stereotactic Radiosurgery|Precise delivery of radiation to spinal tumor
223921866|NCT05023772|DIAGNOSTIC_TEST|MRI guided laser ablation|Surgery will take place in intraoperative suite to include operating room and MRI scanner
223921867|NCT06956950|DRUG|Bupivacaine + Magnesium sulfate|ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml 10% magnesium sulfate
223530953|NCT07158580|DEVICE|Gait Tracker|Opti Gait is a wearable gait tracker
223921868|NCT06956950|DRUG|Bupivacaine + saline|ultrasound-guided transmuscular quadratus lumborum block using 25 ml of 0.25% bupivacaine + 5 ml normal saline
223921869|NCT02089880|DEVICE|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
223921870|NCT02089880|DEVICE|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
223921871|NCT05444465|DEVICE|Isolated Bioinductive Repair|Isolated Bioinductive repair with REGENETEN™ Bioinductive Implant
223921872|NCT05444465|PROCEDURE|Completion and Repair|Standard surgical repair using the 'Completion and Repair' technique.
223921873|NCT06162091|OTHER|Data collection|"The study will involve at the time of entry into the rehabilitation setting, the collection of data related to demographic and clinical variables assessing:~1. The Level of responsiveness (Coma Recovery Scale -revised (CRS-r);~2. Cognitive functioning (Levels of Cognitive Functioning, LCF);~3. disability (Disability Rating Scale, DRS);~4. level of care needed (Early Rehabilition Barthel Index, ERBI)~The Final outcome measure will be the Glasgow Outcome Scale- Extended (GOSE). It will also collect data on clinical variables and presence of medical devices (e.g. decompressive craniectomy, hydrocephalus, tracheostomy, respiration). For all evaluations, two monthly timepoints will be conducted for a total of 12 timepoints until discharge (0 -6 months). If the patient will be hospitalized for more than 6 months, the assessment will be done monthly up to 12 months."
224091147|NCT01629147|OTHER|Placebo|5 drops
224091148|NCT00508573|BEHAVIORAL|Questionnaire|Follow-up questionnaire done once a year for five years.
224091149|NCT06645886|DRUG|KQB198|Oral KQB198
224279682|NCT03201263|PROCEDURE|Standard of care|Standard of care
224279683|NCT00826345|OTHER|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~\- Active"
224279684|NCT00826345|OTHER|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
224279685|NCT00691041|BEHAVIORAL|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
224279686|NCT00115024|DRUG|Micronized 17B-estradiol|
224279687|NCT00942812|OTHER|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
224279688|NCT00942812|OTHER|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
224279689|NCT03168906|DRUG|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
224279690|NCT03168906|DRUG|Placebo|Saline bag
224279691|NCT05753982|OTHER|Kinesiotape placement|Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
224279692|NCT05065541|DRUG|CC-97489|Specified dose on specified days
223921874|NCT05014971|BEHAVIORAL|Tele-neurohub|Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
224279693|NCT05065541|DRUG|[18F]T-401|Specified dose on specified days
224279694|NCT05065541|DRUG|[11C]MK-3168|Specified dose on specified days
224279695|NCT00972231|OTHER|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
224279696|NCT01321697|PROCEDURE|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
223921875|NCT04276246|DEVICE|dental implants and retentive implant components|retentive components (Group A Test), which are connected to the implants to retain the RPD
223921876|NCT04276246|DEVICE|dental implants and supportive implant components|supportive components (Group B Control), which are connected to the implants to support the RPD
223921877|NCT06964945|BEHAVIORAL|Auricular Acupressure with Vaccaria Seeds|Auricular Acupressure with Vaccaria Seeds Participants in this group receive auricular acupressure using 2 mm Vaccaria seeds adhered to five specific auricular acupoints (TF4, CO15, Extra5, LO4, LO4) with 7 mm × 7 mm adhesive patches. Each session lasts 10-20 minutes, with seeds left in place for 5-7 days. A total of 12 weeks, along with standardized sleep hygiene education.
223921878|NCT06964945|BEHAVIORAL|Sham Auricular Acupressure (No Seeds)|Participants in this group receive sham auricular acupressure using identical adhesive patches without Vaccaria seeds, applied to the same five auricular points. Procedures, duration, frequency, and sleep hygiene education are identical to those in the experimental group to maintain blinding.
223921879|NCT06064812|DRUG|FWD1802|"Subjects will receive FWD1802 tablets orally according to the overall study design; the administration scheme is shown above. Subjects will continue to receive FWD1802 until any of the criteria are met.~Study drugs will be orally administered at the investigational site by site staff at 8 AM on the morning of the dosing days."
223921880|NCT06064812|DRUG|palbocilib|"The palbociclib dose is the fixed approved dose: 125 mg intake daily, for consecutive 21 days then off for 7 days, which composes 28-day treatment cycle, which is consistent with the 28-day treatment cycle of FWD1802.~Every treatment cycle consists of 28 days."
223921881|NCT03796793|PROCEDURE|Wound Edge Debridement|Wound debridement is performed using a sharp, circular disposable curette to remove the slough, non-viable tissue and any fibrous tissue down to the vascular base.
223921882|NCT03796793|OTHER|Standard of Care Treatment|Standard of Care treatment will include foam dressing and 4 layer compression therapy, changed weekly.
223921883|NCT06968091|OTHER|Trendelenburg position|After the loss of consciousness during general anesthesia, the 10° Trendelenburg position is adopted.
223921884|NCT06968091|OTHER|Supine Horizontal Position|After the loss of consciousness during general anesthesia, the Supine Horizontal Position is adopted.
223921885|NCT06967246|COMBINATION_PRODUCT|Kinesio tape|Kinesio tape applied to one surgical site
223921886|NCT06967246|COMBINATION_PRODUCT|non-elastic tape|The non-elastic tape with only adhesive properties was used as the placebo tape on the other side
224279697|NCT02476188|PROCEDURE|Sample of Blood|
224279698|NCT04906941|DEVICE|MRI|"SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment.~\* Sense 2 \* 2: 9min33s"
223921887|NCT06965985|OTHER|Mulligan mobilization therapy|While the mobilization belt is placed around the patient's proximal forearm and looped over the therapist's shoulder, the distal humerus will be stabilized with one hand. A lateral glide will be applied to the forearm through the belt and maintained for approximately 5 to 10 seconds. The patient will perform repeated wrist extensions against the manual resistance provided by the therapist's hand. Once a pain-free wrist extension is achieved, the lateral glide will be released. A total of 6 repetitions will be performed with 15-second rest intervals between repetitions. This protocol will be applied three times per week for two weeks.
223921888|NCT06965985|OTHER|Myofascial release therapy|"The patient will be placed in a supine position with the shoulder internally rotated, the elbow in pronation and approximately 15 degrees of flexion, and the palm resting flat on the table. The therapist will stand beside the table at the level of the patient, facing the patient's ipsilateral arm and shoulder. The treatment will be administered for 10 minutes, three sessions per week for two weeks.~The therapist will begin the treatment from just proximal to the lateral epicondyle, on the humerus, and proceed distally along the path of the common extensor tendon to the extensor retinaculum of the wrist. Using the fingertips, the therapist will engage the periosteum and maintain contact as the technique continues along the common extensor tendon and further distally along the extensor retinaculum of the wrist."
223921889|NCT06965985|OTHER|Exercise Therapy|"All patients will be provided with a home exercise program consisting of eccentric strengthening exercises targeting the wrist extensors, with resistance gradually increased each week. Patients will be instructed in strengthening exercises for the wrist extensors as well as forearm pronation and supination. The home program will consist of 3 sets of 10 repetitions per day.~The exercises will be demonstrated in person by the physician, and each patient will receive a printed handout detailing how to perform the exercises. During weekly treatment sessions and after the treatment period, patients will be contacted by phone to assess adherence to the exercise program and to reinforce the importance of compliance.~Patients with exercise compliance below 75-80% will be excluded from the study."
223921890|NCT06966115|BEHAVIORAL|Multiple Sclerosis Vocational Rehabilitation (MSVR)|"MSVR involves an initial assessment (including vocational goal setting), followed by up to 10 hours of individually tailored support over six months according to need. The support will focus on supporting the person with MS to remain at work by addressing topics such as:~* Understanding MS~* Advice on reasonable adjustments~* Support requesting reasonable adjustments~* Fatigue management~* Managing cognition at work~* Information about legal rights~* Disclosure~* Long-term career planning~* Managing mood difficulties~* Signposting to local and national resources. MSVR addresses the individual needs of the person with MS and offers advice remotely (e.g., via telephone, videoconference, or email). The sessions will be arranged at a time convenient for the person, and the support needed will vary according to the complexity of their workplace difficulties."
223921891|NCT06853327|DRUG|Ketorolac|The experimental condition to be examined by this study is the timing of administration of ketorolac prior to IUD insertion. Ketorolac 20mg PO has proven beneficial at certain timepoints during IUD insertion in prior studies, but pharmacokinetics indicate that it could require more time until peak analgesia.
223921892|NCT06853327|DRUG|Placebo|Placebo will be used to control the timing of administration and be used to compare ketorolac to baseline standard pain control regimens
224091150|NCT06645886|DRUG|Dasatinib|Oral dasatinib
224091151|NCT06813404|BEHAVIORAL|Heavy resistance training|The heavy resistance training intervention will consist of twice weekly exercise sessions of 60 minutes each.
224091152|NCT06813404|BEHAVIORAL|Yoga|Twice weekly yoga sessions of 60 minutes each
224091153|NCT03148210|DRUG|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
224091154|NCT03148210|BEHAVIORAL|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
224091155|NCT03148210|BEHAVIORAL|Participant Education|Standardized education for asthma or COPD disease
224091156|NCT06807606|DRUG|Drugs Cyclophosphamide|Given as standard of care treatment through IV infusion
224091157|NCT06807606|DRUG|Fludarabine|Given as standard of care treatment through IV infusion
224091158|NCT06807606|DRUG|Thiotepa|Given as standard of care treatment through IV infusion
223921893|NCT01746979|DRUG|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
223921894|NCT01746979|DRUG|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m\^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
224091159|NCT06807606|DRUG|Tacrolimus|Given as standard of care treatment through IV infusion
223921895|NCT01746979|DRUG|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
223921896|NCT04215029|BEHAVIORAL|Exercise Intervention|Receive exercise plan
223921897|NCT04215029|OTHER|Informational Intervention|Receive printed exercise materials
223921898|NCT04215029|OTHER|Informational Intervention|Receive physical activity and healthy eating information/materials
223921899|NCT04215029|OTHER|Interview|Participate in interview
223921900|NCT04215029|OTHER|Nutritional Assessment|Complete nutrition counseling sessions
223921901|NCT04215029|OTHER|Questionnaire Administration|Ancillary studies
223921902|NCT04215029|BEHAVIORAL|Telephone-Based Intervention|Receive coaching calls
223921903|NCT06965400|DEVICE|Automatic Cuff Pressure Control|he IntelliCuff® system (Hamilton Medical, Switzerland) continuously monitored and automatically adjusted cuff pressure to keep it within the target range of 15-25 cmH₂O. Manual intervention was only required upon system alert.
223921904|NCT06965335|BIOLOGICAL|BIOLOGICAL STUDY aiming at describing clinicophatological features of EO-CRC vs SO-CRC|Description of clinicophatological features of EO-CRC vs SO-CRC
223921905|NCT03549442|COMBINATION_PRODUCT|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
223921906|NCT03549442|COMBINATION_PRODUCT|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
223921907|NCT03549442|COMBINATION_PRODUCT|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
223921908|NCT03549442|COMBINATION_PRODUCT|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
223921909|NCT05862545|DRUG|BGF (budesonide/glycopyrrolate/formoterol fumarate)|BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.
223921910|NCT04846790|BEHAVIORAL|Nature Only|See above for description.
223921911|NCT04846790|BEHAVIORAL|Nature+Mindfulness|See above for description.
224091160|NCT06807606|DRUG|Mycophenolate mofetil|Given as standard of care treatment through IV infusion
224091161|NCT06814561|DRUG|Marcaine 0.5% Solution for Injection|The study involves the administration of 0.5% Marcaine heavy for spinal anesthesia in patients undergoing vascular surgery. The aim is to assess how this anesthesia affects urine output relative to mean arterial pressure.
224091162|NCT06223698|DRUG|Letrozole|Letrozole 2.5 mg daily
224091163|NCT06223698|DRUG|Anastrozole|Anastrozole 1 mg daily
224091164|NCT06223698|DRUG|Exemestane|Exemestane 25 mg daily
224091165|NCT06223698|DRUG|Tamoxifen|Tamoxifen 20 mg daily
224091166|NCT02631707|OTHER|High protein diet|The intervention diet is higher in protein than the control diet.
223530954|NCT07159152|DIETARY_SUPPLEMENT|Coffee|Participants will consume 3 cups of Arabica coffee (Guatemalan origin), providing a total of 400 mg of caffeine. Each cup is prepared with 6% coffee grounds per 100 mL of water, brewed at 90°C for 6 minutes using an electric drip coffee maker, yielding 100.8 mg caffeine per 100 mL. Immediately following coffee consumption, participants will engage in uninterrupted sitting for 3 hours. Blood pressure, heart rate, and other study questionnaires will be measured at baseline (before coffee), 1 hour after coffee intake, and hourly during the 3-hour sitting period.
223530955|NCT07159152|DIETARY_SUPPLEMENT|Hibiscus drink|Participants will consume 3 servings of hibiscus leaves tea per day, each serving containing 1.25 g of dried hibiscus leaves, totaling 3.75 g per session. The tea will be prepared by steeping the leaves in 240 mL of boiling water (100°C) for 10 minutes. Immediately after consuming the hibiscus tea, participants will engage in uninterrupted sitting for 3 hours. Blood pressure, heart rate, and other study questionnaires will be measured at baseline (before tea), 1 hour after tea intake, and hourly during the 3-hour sitting.
223530956|NCT07160803|OTHER|Intervention Program for Social Network Use Based on Activity Theory|The intervention program is structured around a three - phase framework for migrant elderly's social network use: ① triggering motivation and building basic capabilities; ② reinforcing motivation and enhancing advanced capabilities; ③ sustaining motivation and maintaining usage habits. The process involves assessing baseline status (via scales like ASNSUS, eHEALS), implementing phased interventions (teaching WeChat skills, facilitating social connections), and evaluating effectiveness (process and outcome evaluations). The 12 - week program is executed by a team including researchers, community workers, and elderly volunteers.
223530957|NCT07160803|OTHER|Routine community activities only|After receiving regular community services and management, and understanding the overall situation and needs of the intervention targets, researchers and community managers will conduct a weekly health lecture, an offline social activity involving local elderly people (such as fitness, cultural and entertainment activities, etc.), or a lecture on policies and welfare related to migrant elderly people, etc., and regularly distribute relevant paper materials.
223530958|NCT07160751|OTHER|Self-questionnaire|FACT-Cog, HADS, FA12, EPICES, socio-professional and socio-demographic questionnaire
223530959|NCT07160751|OTHER|Cognitive tests|Hopkins Verbal Learning Test (HVLT). Trail Making Test (TMT). Verbal fluency test. Digit memory WAIS-IV.
223530960|NCT07160751|OTHER|Assessment of the impact of social vulnerability on patient complaints|EPICES at month 12
223921912|NCT02295891|DEVICE|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
223921913|NCT05381766|OTHER|CSA Model|Community-supported agriculture (CSA) involves a community of individuals who support a farm and in return receive distributions of the farm's produce throughout the growing season. Culturally appropriate produce will be provided weekly for 20 weeks to community members in Sunset Park and surrounding neighborhoods. Brooklyn Grange in Sunset Park will grow and provide Chinese specific produce for a fee ranging from $7 to $31 depending on the participant's self-identified situation and Angel Family Farm will grow and provide Mexican specific produce for a fee of up to $15. Participants that receive SNAP benefits can use their EBT card to cover their produce box fees. Education will be offered in the form of nutrition education, cooking tutorials, and farming information provided by staff at Brooklyn Grange.
223940784|NCT06896188|DRUG|Chemotherapy|oxaliplatin - Antineoplastic - Platinum Complexes Chemotherapy agent; leucovorin - a form of Folic acid helps the body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer; irinotecan - anti-cancer medication used to treat colon cancer in combination with other chemotherapeutic agents; 5-FU - 5-fluorouracil is used to treat cancer in combination with other chemotherapeutic agents
223940785|NCT06896188|DRUG|9-ING-41|a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells
224279699|NCT05486299|PROCEDURE|Robotic assisted single-port general surgery|Robot assisted single-port rectal resection, colectomy, partial gastrectomy, appendectomy and cholecystectomy via the single-port configuration
224279700|NCT02277951|DEVICE|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
224279701|NCT02277951|DEVICE|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
223530961|NCT07160426|BIOLOGICAL|Fresh Frozen Plasma (blood product)|Fresh Frozen Plasma
223719571|NCT03425877|BEHAVIORAL|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
224279702|NCT02277951|DEVICE|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
224279703|NCT02277951|DEVICE|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
224279704|NCT04969354|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
224279705|NCT05337202|DEVICE|HeartSDK|The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
224279706|NCT02569307|DRUG|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
224279707|NCT02569307|DRUG|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
224279708|NCT02569307|DRUG|Placebo|Placebo added to TAU
224279709|NCT02569307|DRUG|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
224279710|NCT04489017|DIETARY_SUPPLEMENT|PEA-LUT|PEA-LUT administration at the oral dosage of 700 mg x 2/day
224279711|NCT04489017|DIETARY_SUPPLEMENT|PLACEBO|PLACEBO administration at the oral dosage of 700 mg x 2/day
223530962|NCT07160426|DRUG|MVI and lactated ringers|placebo
223530963|NCT07159451|DRUG|Elacestrant|Patients will receive elacestrant 345 mg/daily administered orally for 4 weeks.
223921914|NCT06490601|DRUG|thalidomide and hydroxyurea|"Thalidomide:~Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor- alpha Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Hydroxyurea:~Hydroxyurea or hydroxycarbamide (HU) lies in the category of antimetabolite. Mechanism of fetal hemoglobin induction includes increase in erythropoietin and nitric oxide production, apoptosis induction and potentiating in granulocyte cycling activity."
223921915|NCT06490601|DRUG|Thalidomide|"Thalidomide glutarimide is derivation of glutamic acid. Potentiating of fetal hemoglobin expression occurs by up regulation of Erythroid transcription factor and Erythroid Krüppel-like factor expression Furthermore few studies also concluded that thalidomide hypomethylate 27th amino acid in Histone H3 in the gamma globin gene. Initiating cause of this process is suppression of Nuclear factor (kappa-light-chain-enhancer of activated B cells) activation by tumor necrosis factor -alpha , Vascular endothelial growth factor , Prostaglandin E2 and inflammatory cytokine.~Investigating the impact of thalidomide on transfusion-dependent beta thalassemia patients is essential for discerning its therapeutic efficacy and safety profile."
223921916|NCT02863107|PROCEDURE|Biospecimen Collection|Undergo collection of blood or saliva samples
223921917|NCT02863107|OTHER|Medical Chart Review|Review of medical charts
223921918|NCT02863107|OTHER|Quality-of-Life Assessment|Ancillary studies
223921919|NCT02863107|OTHER|Questionnaire Administration|Complete questionnaires
223921920|NCT03565913|DRUG|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
223921921|NCT03565913|OTHER|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
223921922|NCT03019263|DIETARY_SUPPLEMENT|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
223921923|NCT03019263|OTHER|Control|Nutritional counseling
223921924|NCT02780024|DRUG|Metformin|Metformin,
223921925|NCT05497024|BEHAVIORAL|Interviews|"Participants will discuss background, such as race, education, and living situation.~Participants will discuss Prostate cancer Participants will discuss feedback on the educational material"
223921926|NCT05497024|BEHAVIORAL|Surveys|Participants may answer questions that are sensitive in nature.
224091167|NCT06605040|OTHER|Dissemination via Social Media|"Participants in the experimental group will follow a scientific Instagram profile where content will be shared. The profile will remain open, allowing permanent access to all posts. To optimize Instagram\&amp;amp;#39;s algorithm, we will use an existing active profile. Any control group participants already following the profile will be removed upon allocation.~For each selected article, we will create three presentations using Instagram features like carousel images and short videos, shared as posts, stories, and reels. This strategy will provide content for 30 weeks of daily posts. Each post will feature visually appealing graphics to convey scientific information and support evidence-based practice (EBP) competencies."
224091168|NCT06605040|OTHER|Dissemination via Email|The participant allocated to the control group will receive a different summary each day, along with a link to the full article. This strategy was chosen to replicate the approach used by scientific journals to disseminate new issues.
224091169|NCT06820242|BEHAVIORAL|HIPS|HIPS is a 6-session (one 30-minute session per week) mind-body intervention delivered in person by a trained physical therapist (PT). Across these six 30-minute sessions, the HIPS intervention aims to teach relaxation and coping skills (e.g., SMART goal-setting, coping thoughts, deep breathing, and progressive muscle relaxation) and provides pain education.
223530964|NCT07159451|DRUG|Leuprorelin|Patients randomized in arm B will recieve Leuprorelin at Day 1 and Day 29
223719572|NCT03425877|BEHAVIORAL|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
223921927|NCT05802602|DEVICE|Porcine Collagen Membrane|Atraumatic tooth extraction with porcine collagen membrane placement
223921928|NCT05802602|DEVICE|Bovine Collagen Dressing|Atraumatic tooth extraction with bovine collagen dressing placement
224091170|NCT01291017|DRUG|PD0332991|PD0332991 125 mg PO days 1 - 21
224099673|NCT06806137|BIOLOGICAL|Vaxneuvance|The Vaxneuvance (15-valent pneumococcal conjugate vaccine co-administered intramuscularly. In some countries PCV will only be administered depending on the availability, country's registration status and national recommendations for pneumococcal vaccination at the time of study conduct.
223921929|NCT05190211|OTHER|Telerehabilitation exercise program|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
223530965|NCT07159334|DRUG|Lignocaine Ointment|Applied to the anal wound three time daily after hemorrhoidectomy.
223530966|NCT07159334|DRUG|Glyceryl Trinitrate Ointment 0.2%|Applied to the anal wound three time daily after hemorrhoidectomy.
223921930|NCT05190211|OTHER|Videobased exercise program|After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
223921931|NCT06972771|DIAGNOSTIC_TEST|TTP-ICG incubation solution|Clinical specimens will be incubated with TTP-ICG with different concentrations and times.
223921932|NCT05988398|BEHAVIORAL|READY To Stand Curriculum|Students will receive the RTS programming over six consecutive school days, spread over two weeks. The program is delivered in mixed-gender groups of 20 to 40 students and includes videos, small and large group discussions, activities, worksheets, and ample opportunities for skill-building. This curriculum is intended to be one piece of comprehensive prevention strategies that has the potential to make immediate and sustained impacts on reducing rates of CSEC perpetration in the lives of youth, including those most vulnerable to this pernicious crime.
223921933|NCT06013241|DRUG|Brensocatib|Film-coated tablet.
223921934|NCT06013241|DRUG|Placebo|Film-coated tablet.
223921935|NCT06013241|DRUG|Mometasone furoate nasal spray (MFNS)|Nasal spray suspension.
223921936|NCT06156774|OTHER|Chimeric Antigen Receptor T-cells (CAR-T) therapy|Patients will be treated with CAR-T cell product as per routine clinical practice.
223921937|NCT06432725|BEHAVIORAL|JUNTOS|HIV test counselor and Latino MSM participants will be given access to the JUNTOS website/app, which shows information about local HIV and ancillary services. HIV test counselor participants will also be given access to a training video explaining how to use the JUNTOS website/app. HIV test counselors are encouraged to use the website/app for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the website/app to locate HIV and ancillary services as needed.
223921938|NCT06432725|BEHAVIORAL|Referral Sheet|HIV test counselor and Latino MSM participants will be given access to referral sheet, which is a list of local HIV and ancillary services. HIV test counselors are encouraged to use the referral sheet for approximately 10 minutes at least once a week when meeting with Latino MSM testing clients. Latino MSM are encouraged to use the referral sheet to locate HIV and ancillary services as needed.
223921939|NCT06805214|OTHER|post tracheostomy fever|incidence of post tracheostomy fever and whether retrospectively the increased temperature indicated development of sepsis or not (no intervention)
224091171|NCT02795455|BEHAVIORAL|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
224091172|NCT02795455|BEHAVIORAL|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
224279712|NCT04202458|DRUG|intra-arterial tenecteplase administration|Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.
223530967|NCT07160465|OTHER|emma application|"1. Emma will allow the patient to spontaneously contact the VigilanS tele-clinician team via a simple and quick access (when the patient presses an ergonomic button with the VigilanS logo). He can also contact the National Service for Suicide Prevention (3114) or the French national emergency medical assistance service 24/7 (Samu).~2. Experts of the field have defined response thresholds for targeted questions on suicide risk and emotional tension. If the patient's answers to these questions reach these thresholds, emma will automatically send a message to the nearest VigilanS center. In this case, a message will appear indicating to the patient that the nearest center will contact him as soon as possible, encourage him to review his strategies and resources available on the app's Home and direct him to the breathing space.~3. Emma offers a Safety Plan module that will allow the patient to help him/her to put into practice what he/she will develop with the VigilanS team on a daily bas"
223530968|NCT07160504|DRUG|Vaginal estradiol tablets|Vaginal estrogen tablets 10 µg at least 3 times a week (on indication, prescribed at the outpatient clinic).
223921940|NCT06525376|DIAGNOSTIC_TEST|smartphone inclinometer application|an instrument for measuring angles of slope (or tilt), elevation, or depression of an object with respect to gravity.
223921941|NCT05441683|PROCEDURE|horizontal extending incision|a papilla preserving incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Then horizontally extending incisions will be added to each side of the initial incision, extending one to two teeth beyond the defected area, before a full-thickness flap is lifted.
223921942|NCT05441683|PROCEDURE|vertical releasing incision|a papilla preserving incision will be made on the labial side of the front teeth with a thin alveolar bone or dehiscence and/or fenestration. Vertical releasing incisions will be made on each side of the initial incision before a full-thickness flap is lifted. The incision formed an oblique trapezoidal flap with a wider base.
224279713|NCT04906837|DIAGNOSTIC_TEST|Trans aortic valve implantation|Measurement of the membranous septum on the pre TAVI scanner and the valve implantation height
224279714|NCT05746052|PROCEDURE|Punch insturment|surgical and dermatological tool used mainly for skin biopsy and therapeutic skin disorders
224279715|NCT00243152|DRUG|Lamotrigine|: 25mg and 50mg tablets
223921943|NCT06501495|OTHER|video polysomnography|video polysomnography during 2 nights
224091173|NCT02795455|DIETARY_SUPPLEMENT|meal replacement shake|
224279716|NCT00243152|DRUG|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
224279717|NCT00476307|BIOLOGICAL|Fluarix™/Influsplit SSW® 2007/2008|
224279718|NCT05306197|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.
223530969|NCT07159724|DEVICE|back up, mollii-suit, compex, tens|"In order to be included in this study, individuals must have undergone at least one session of treatment with a biomedical device.~In the validity and reliability study of the Turkish version of the questionnaire, permission was first obtained from the questionnaire's author via e-mail. The Usefulness, Satisfaction and Ease of Use Questionnaire (USE) was translated from English into Turkish by two independent translators: one was a physiotherapist with a doctoral degree, and the other a faculty member at Hacettepe University School of Foreign Languages. Both translators were native Turkish speakers, fluent in English, and had no personal or professional interaction with each other. They evaluated the original questionnaire in terms of meaning and grammar to produce the Turkish version of the Usefulness, Satisfaction and Ease of Use Questionnaire (USE).~The independently translated Turkish versions of the questionnaire were then reviewed by an expert panel to reach consensus. This exp"
223530970|NCT07158983|OTHER|Registry review|The study is set within a project to evaluate a program for identification of family violence. The study uses mixed methods including registry review of parents to evaluate the effect of the program.
223530971|NCT07158983|OTHER|Interviews|The study is set within a project to evaluate a program for identification of family violence. The study uses mixed methods including interviews with nurses to evaluate the effect of the program.
223530972|NCT07158892|BEHAVIORAL|Diagnostic Advance Care Planning Discussion|The intervention consists of a structured, values-based conversation modeled after Advance Care Planning (ACP) principles, adapted for diagnostic decision-making. Participants will receive a hypothetical clinical vignette involving a musculoskeletal diagnostic test (e.g., MRI, X-ray, CT, or ultrasound), followed by a simulated discussion facilitated by a trained researcher. The conversation is guided by branching scripted prompts designed to elicit the participant's values, goals, expectations, and understanding of the potential benefits and harms of testing. Responses are transcribed using verbal-to-text technology. Unlike standard decision aids or educational materials, this intervention emphasizes patient reflection and shared decision-making by prompting participants to consider what matters most to them before making a decision about the test. The discussion does not involve actual test ordering or clinical decisions but is intended to simulate a real-world ACP discussion process.
223921944|NCT06501495|OTHER|Attention task|Attention task : SART Test (Sustained Attention to Response Task)
223921945|NCT04658693|DEVICE|Implanted Multi contact stimulating electrode and intramuscular electromyography recording electrode|See arm description
223921946|NCT05109871|OTHER|KForce Link|Traction (pull-type) dynamometer
223921947|NCT06853041|DRUG|Esketamine|A single slow intravenous injection of low-dose esketamine (0.15 mg/kg) over 10 minutes using an infusion pump.
223921948|NCT06853041|DRUG|Ketamine|A single slow intravenous injection of low-dose ketamine (0,3 mg/kg) with an infusion pump, during 10 minutes
224091174|NCT06597032|BEHAVIORAL|Resilience Challenge|We previously have tested this online program in people facing health- and work-related stressors (e.g., dementia caregivers, healthcare workers), and in 2020 we enrolled adults in a test of the online program to support coping with the stress of the COVID pandemic. This intervention has been tailored for a widespread, public audience (e.g., we have added a few other safety measures including limits on public forum posting and have clarified wording on some of the intervention content to make it clearer and easier to understand).
224091175|NCT06856252|GENETIC|Liver resection to isolate cells|Isolation and culture of organoids Isolation of hepatic stellate cells Isolation and culture of sinusoidal stellate cells Generation of assembloids
223921949|NCT05525676|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
224091176|NCT05541380|OTHER|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients|A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Advanced Thyroid Cancer Patients
224091177|NCT00462787|BIOLOGICAL|filgrastim|
224091178|NCT00462787|DRUG|clofarabine|
224091179|NCT00462787|DRUG|dexamethasone|
224091180|NCT00462787|DRUG|thiotepa|
224091181|NCT00462787|DRUG|topotecan hydrochloride|
224091182|NCT00462787|DRUG|vinorelbine tartrate|
223921950|NCT05525676|BEHAVIORAL|Co-Located Collaborative Care (CCC)|"The investigators are using the Co-Located Collaborative Care model developed by the VA Center for Integrated Healthcare to deliver at all VAs. Although the CCC model is flexible and can range from 1-6 sessions, in this study the investigators standardize the model to three sessions for a clear comparison with BRC. Session 1 uses the CCC Functional Assessment/Initial Assessment protocol. Sessions 2 \& 3 use the CCC Follow-up protocol.~Session 1 (25-30 min)- Veteran completes a functional assessment of concerns (15 mins) and then develops a personalized action plan (10 minutes) Session 2 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan (20 minutes) Session 3 (25-30 min)- Veteran's progress addressing concerns is assessed (5 mins) and the remainder of the session is spend updating the action plan, including receiving referrals (20 minutes)"
223921951|NCT05912296|DRUG|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
223530973|NCT07158892|BEHAVIORAL|Informational Statement Only|Participants will be presented with a brief, standardized informational statement describing what the test involves, what it may show, and general risks or limitations. No individualized values-based discussion or simulated conversation will occur.
223921952|NCT05912296|DRUG|RBD7022|Subcutaneously Administered RBD7022 in Healthy Subjects.
223921953|NCT05912296|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
223921954|NCT05912296|DRUG|Placebo|Subcutaneously Administered Placebo in Healthys Subject.
224091183|NCT04855773|OTHER|PrEPmate|"PrEPmate is a multi-component mHealth intervention grounded in the information, motivation, behavioral skills (IMB) theory of behavior change and developed through user-centered design. PrEPmate promotes personalized communication between patients and providers through interactive weekly check-in messages asking participants how PrEP is going, allowing navigators to identify patients needing more help in taking PrEP, and customized daily pill-taking reminder messages. Trained PrEP navigators reach out to participants who indicate they need assistance via text or phone call and provide tailored support. Additionally, the platform supports 2-way communication between patients and PrEP navigators, including reminders for upcoming clinic visits. Participants are provided links to key information about PrEP (PrEP Basics), and video testimonials of peers taking PrEP. Messages are available in English and Spanish. PrEPmate is aimed at both patients and PrEP navigators."
224091184|NCT04855773|DEVICE|Dot Diary|Dot Diary is a mobile phone app that integrates an electronic pill-taking and sex diary and delivers real-time feedback on PrEP protection. Using the self-management model to increase self-efficacy and patient empowerment, participants log daily PrEP pill-taking and sexual behaviors in the app, which then provides real-time feedback on the level of protection achieved from PrEP (high, medium, low), and customized instructions on doses of PrEP needed to achieve or maintain high protection. Participants can also view a weekly and monthly calendar, including visualizations of the proportion of sex acts covered by PrEP. Finally, the Dot Diary app incorporates gamification components, including an ability to earn sex-positive badges, to increase engagement. Dot Diary is aimed only at patients.
224091185|NCT02376465|DRUG|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
224091186|NCT02376465|DRUG|PEG based bowel preparation|Oral bowel preparation for colonoscopy
224091187|NCT03204149|DEVICE|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
224091188|NCT03204149|DEVICE|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
224091189|NCT06671626|OTHER|Subcortical Stimulation|Subcortical simulation of the deep brain stimulation surgery target site will be applied by clinically placed deep brain stimulation electrodes at the previously determined therapeutic setting
224091190|NCT04980391|BIOLOGICAL|RSV MAT|Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
224091191|NCT04980391|DRUG|Placebo|Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
224099674|NCT04039230|DRUG|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
224099675|NCT04039230|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
224279719|NCT05306197|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.
224279720|NCT05306197|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose with no operant conditioning.
224279721|NCT00668096|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
224279722|NCT00668096|DRUG|Placebo|Matching Placebo
223530974|NCT07160530|BEHAVIORAL|EAT Family Style|Rural family childcare home providers receive 7 online modules on responsive feeding practices over 16 weeks, plus 7 individual coaching sessions via Zoom with Extension agents. Providers record mealtime videos for personalized feedback, engage in goal-setting and action planning, and receive printed materials and conversation cards.
223530975|NCT07160530|BEHAVIORAL|Better Kid Care|Rural family childcare home providers receive 10 online modules about general childcare topics unrelated to nutrition, including child development, block play, oral health, supervising children, and managing a family childcare home through the Better Kid Care platform.
223921955|NCT06156865|BEHAVIORAL|Intervention to address late talking|this intervention is designed to support both speech and language development in children who are toddlers. Given the age group of children their parents are part of the intervention program. Importantly the frequency of the intervention can range from once to twice per week, with timing also designed to complement the particular agency
223921956|NCT02986087|DEVICE|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of \<25%, LHR \<1, o/e LHR\<30% (moderate), singleton pregnancy, no known other anomalies, gestational age \< 29 weeks 6 days, no maternal disease, maternal age \> 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center.
223921957|NCT06978413|OTHER|Integrated Treatment with Digital Tools|"Patients will undergo a 6-week remote telerehabilitation program. The recommended frequency of treatment is a minimum of 3 sessions per week, but patients may adjust the schedule in agreement with their assigned therapist. If a patient is unable to complete at least 18 sessions due to clinical reasons, they will be considered as a dropout.~Moreover, one session per week will be conducted synchronously, with the therapist remotely supervising the patient's activities in real time, while the remaining sessions will be asynchronous, allowing the patient to complete the exercises independently."
223921958|NCT06978413|OTHER|Home-Based Educational Program|Patients will be monitored over a six-week period through weekly phone calls to assess their progress and overall condition. Additionally, participants are required to maintain an activity diary to document their engagement with the prescribed activities.
223921959|NCT06603870|DRUG|Apixaban|Apixaban is Health Canada approved for routine treatment and secondary prevention of VTE. Upon enrollment and during follow-up, patients will be managed with a prophylactic dose of apixaban (2.5 mg orally twice daily) as long as either a CVC or active cancer is present. Apixaban will be stopped at the time of CVC removal and when cancer is in remission. Patients will be instructed to contact the study team when their CVC is removed (to determine if apixaban should be continued, based on cancer status at the time), or any thrombotic or bleeding concerns were to occur in between visits. The investigators will record loss to follow-up, drop out, or death during the study.
223921960|NCT06815939|DIAGNOSTIC_TEST|HPV Test|The careHPV (QIAGEN, Gaithersburg, MD) test was developed in a public-private partnership specifically for use in low-resource settings. It is a simplified, robust, and affordable HPV test that does not distinguish specific HPV types; rather, it gives a positive result if any of 14 hrHPV types is present in the specimen. Electricity is necessary to run the test, but it does not need running water or air conditioning. In order to be most cost effective, the samples must be run with a full plate of 96 samples. Results take 3-4 hours to complete.
223921961|NCT06815939|DEVICE|EVA System|Digital colposcope
223921962|NCT06815939|PROCEDURE|Visual Inspection with Acetic Acid (VIA)|unaided visual inspection with acetic acid
223921963|NCT06815939|DIAGNOSTIC_TEST|Automated Visual Evaluation (AVE)|Digital diagnostic classification, quality classifier using captured images from EVA System
223921964|NCT06815939|OTHER|Image Capture with Mobile Phone|Compare performance of AVE installed on a mobile phone vs. on the EVA System
223921965|NCT06815939|DIAGNOSTIC_TEST|Pregnancy test|Urine based pregnancy test
223921966|NCT06815939|DIAGNOSTIC_TEST|ScreenFire HPV test|ScreenFire HPV test (Atila BioSystems, Inc, Mountain View, CA) uses isothermal amplification to detect 13 high risk (hr)HPV types directly from clinical samples in approximately one hour. The test can be run on any real-time PCR machine and gives separate results for hrHPV types 16 and 18, as well as a pooled positive result for 13 other hrHPV types. The human cellular gene beta-globin is used as an internal control to measure sample adequacy. ScreenFire can be self-collected and does not require batching. AmpFire® obtained CE-mark in 2017.
223921967|NCT06815939|PROCEDURE|Colposcopy with biopsy|A colposcopic exam with biopsy entails visual magnification of the cervix and the removal of a small piece of cervical tissue. After the application of acetic acid 5% onto the cervix, a device called a colposcope allows the clinician to visually identify changes consistent with HPV. Areas of the cervix where lesions appear (or if not, randomly selected sections) are then biopsied (small piece of sample removed) and an endocervical curettage is performed (removing a small section from the inside of the cervix). Tissue specimens are then sent to the lab for pathology diagnosis.
223921968|NCT06815939|PROCEDURE|Thermal Ablation|Thermal ablation is utilized to treat high-grade cervical precancer. First, a speculum is introduced into the vagina to identify the cervix. Acetic acid 5% is applied to the cervix for one minute and the cervix is observed to look for changes consistent with precancer. If the cervix is able to be fully evaluated and there are no signs of invasive cancer, the tip of the device is heated to 100ºC and applied directly to the cervix for 1-2 minutes, which ablates or destroys the abnormal cells.
224279723|NCT00857818|DRUG|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
223530976|NCT07160790|DRUG|JP-1366 + placebo|taking JP-1366 + placebo
223921969|NCT06815939|PROCEDURE|Loop electrosurgical excision procedure (LEEP)|LEEP is utilized to remove abnormal tissue from the cervix. This may include tissue with precancerous cells (called cervical dysplasia) or cancerous cells. The loop is heated using electricity to remove the tissue. LEEP may also be called a loop excision or large loop excision of the transformation zone (LLETZ).
223921970|NCT04510129|DIAGNOSTIC_TEST|OncoPrism™ assay|OncoPrism™ is a new approach to characterizing the immune component of pre-treatment tumor tissue.
223921971|NCT03902002|DRUG|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
223940786|NCT05463289|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will undergo point-of-care diabetic retinopathy screening using autonomous artificial intelligence software to interpret retinal images taken with a non-mydriatic fundus camera and providing an immediate result.
223530977|NCT07160790|DRUG|Placebo + Placebo|taking placebo + placebo
223530978|NCT07160218|DEVICE|tDCS|A 30-minute tDCS session with the cathode placed over the left dorsolateral prefrontal cortex (DLPFC), delivered in 10 sessions over 2 weeks. This protocol targets cognitive improvement in MS patients
223530979|NCT07160218|DEVICE|Cognitive Rehabilitation|computer-based cognitive rehabilitation exercises. Conducted in 10 sessions over 2 weeks to enhance attention, memory, and neuroplasticity in MS patients.
223921972|NCT06820411|BEHAVIORAL|Young Stroke Clinic Lifestyle Intervention|"The Young Stroke Clinic Lifestyle Intervention is a structured program designed for young adults (18-65 years) recovering from ischemic stroke or high-risk TIA. It includes:~* Personalized risk factor management targeting blood pressure, cholesterol, smoking cessation, and lifestyle habits.~* Intensive lifestyle counseling to improve diet, physical activity, and overall cardiovascular health.~* Wearable device monitoring (Whoop 4.0) to track heart rate variability, sleep patterns, and physical activity.~* Regular follow-up visits at a dedicated stroke clinic with tailored guidance from neurologists."
223921973|NCT06820411|OTHER|Standard Post-Stroke Care|"The Standard Post-Stroke Care group will receive usual medical management based on current clinical guidelines for secondary stroke prevention. This includes:~* Routine follow-up visits with healthcare providers.~* Standard medical treatment for stroke risk factors (e.g., blood pressure, cholesterol, diabetes).~* General lifestyle recommendations on diet, physical activity, and smoking cessation as part of routine clinical care."
223921974|NCT06987526|BEHAVIORAL|Mindfulness-Based Relapse Prevention|Renewed Recovery is a web-based Mindfulness-Based Relapse Prevention (MBRP) continuing care intervention adapted from the original MBRP curriculum by Bowen et al. It consists of 8 weekly modules designed to teach mindfulness and relapse prevention strategies for individuals with alcohol use disorder. The intervention includes educational content, guided meditations, and practical exercises. Modules are delivered asynchronously online, supplemented by two live Zoom sessions for group meditation practice. The purpose of the curriculum is to teach mindfulness and relapse prevention techniques to the participants with the aim of reducing the risk for relapse. The module titles are as follows: (1) Automatic Pilot and Relapse, (2) Awareness of Triggers and Craving, (3) Mindfulness in Daily Life, (4) Mindfulness in High Risk Situations, (5) Acceptance and Skillful Action, (6) Seeing Thoughts as Thoughts, (7) Self-Care and Lifestyle Balance, and (8) Social Support and Continuing Practice.
223921975|NCT06664177|PROCEDURE|Transversalis Fascia Plane Block|In the Transversalis Fascia Block group, the same procedure will be followed as in the Quadratus Lumborum block group, with the ultrasound probe being placed in the same location, and the same in-plane technique will be applied with a 22G 100 mm peripheral block needle. After hydrodissection, 20 mL of 0.5% bupivacaine will be injected slowly in the same manner.
223921976|NCT06664177|PROCEDURE|Quadratus Lumborum Block (QLB)|In the Quadratus Lumborum block group, in the lateral decubitus position, a convex ultrasound probe will be sterilely placed in the subcostal area and above the iliac crest. The quadratus lumborum and psoas major muscles, as well as the L4 vertebra's transverse process, will be visualized. Using the in-plane technique and a 22G 100 mm peripheral block needle, the placement will first be identified through hydrodissection in the subfascial area between the quadratus lumborum and psoas major muscles. After localization, 20 mL of 0.5% bupivacaine will be injected slowly, aspirating every 5 cc, while visualizing the local anesthetic pushing the fascia in the ultrasound image.
223921977|NCT06986070|BIOLOGICAL|Stem cells|The suspension of stem cells will be put in a medical nebulizer machine, commonly used to deliver medicines into the lungs through inhalation. This means that the participants will breathe in the mist containing the SMS cells, produced by the nebulizer machine. This is a Phase I First-in-Human study, which indicates that this treatment is being studied for the first time in humans.
223921978|NCT06098716|BEHAVIORAL|Self Regulation|How to plan for Family PA
223921979|NCT06098716|BEHAVIORAL|PA Support & Family Social Identity|"Exercises that strengthen parents' PA-support identity and a shared active-family identity through values reflection, role-modelling, visualization, and visible active family cues."
223921980|NCT06098716|BEHAVIORAL|Education|Information about healthy living (e.g., PA, sleep hygiene and healthy eating)
223921981|NCT03816397|BIOLOGICAL|Adalimumab|Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8 mL and 40mg/0.8 mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.
223921982|NCT03816397|OTHER|Placebo|The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The volume-matched (0.8mL) placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
223921983|NCT06455358|DRUG|61Cu-NODAGA-LM3|Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.
223921984|NCT06455358|OTHER|Comparator|Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
223921985|NCT06810752|DIETARY_SUPPLEMENT|thyme honey|Topical application on the oral mucosa
223921986|NCT06810752|DRUG|Triamcinolone Acetonide|Topical application on the oral mucosa
223921987|NCT06984276|DRUG|Control|Patients will receive o.5 ug/kg/hr fentanyl infusion all through the whole operation.
223921988|NCT06984276|OTHER|Pectoral nerves (PECS)|This group will receive fentanyl infusion at a dose of (0.5 μg/kg/hr) all through the whole operation, plus ultrasound guided bilateral pectoral nerves (PECS) Block which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
223921989|NCT06984276|OTHER|Transversus thoracic muscle plane block (TTPB)|This group will receive fentanyl infusion at a dose of (0.5 μg/kg/hr) all through the whole operation, plus Ultrasound guided bilateral transversus thoracic muscle plane block (TTPB) which will be done by injecting 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
223921990|NCT05043259|BIOLOGICAL|inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
224279724|NCT00857818|DRUG|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
224279725|NCT00949195|OTHER|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
224279726|NCT00949195|OTHER|Pulmonary pressure response during exercise|Semi-supine echocardiography test
224279727|NCT02413424|DIETARY_SUPPLEMENT|Sucralose|60 ml of 2mM sucralose
224279728|NCT02413424|OTHER|Water|60 ml of water
224279729|NCT02413424|DIETARY_SUPPLEMENT|glucose load|
223921991|NCT05043259|BIOLOGICAL|Low dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.1 ml / dose, contains 1×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
224091192|NCT06666829|OTHER|Multidomain intervention|"treatment plan using combination of more than one technological or robotic devices, choosing from: Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~In this way, the child will be taken care of holistically, considering their needs from a motor, cognitive, and speech therapy perspective. The treatment plan will also include a conventional multi-level rehabilitation program."
224091193|NCT06666829|DEVICE|Single domain intervention|"Treatment plan using only one of these technological or robotic device:~Virtual Reality Rehabilitation System (VRSS), Khymeia TR; HomeKIT Khymeia; VRSS Khymeia EVO; Myro® Tyromotion; Diego Tyromotion; Tyrostation Tyromotion; Pablo® Tyromotion; Amadeo Tyromotion; Lexo® Tyromotion; Humaware MObile RoboT for upper Limb NeurOortho Rehabilitation (MOTORE); Humanware Upper Limb TRAcker(ULTRA+); Gloreha Sinfonia plus; C-Mill Motek; Gait Real Time Analysis Laboratory (GRAIL) Motek Medical; Nirvana BTS; Agilik; Armeo Spring pediatrico Hocoma; Lokomat ® Hocoma; Hand Tutor, Leg Tutor, Arm Tutor (MediTouch); Care Lab; Dessintey IVS3; Rehacom Hasomed; Hunova; GEO System (Kineo).~Technological rehabilitation will focus on the main specific need for the child, it'll be chosen individually. The treatment plan will also include a conventional multi-level rehabilitation program."
224091194|NCT04881565|OTHER|Reactive balance training|During each one-hour session, participants will experience 40-50 perturbations (i.e. approximately one perturbation per training minute) during standing and/or walking activities. The perturbations will be applied in any direction (e.g. forwards, sideways, backwards, etc.) To create a perturbation, the researcher will apply unexpected pushes or pulls to a safety harness at waist level. The perturbation will be sufficient in magnitude to elicit a stepping response from the participant. Throughout the session, participants will complete challenging balance tasks, customized to their ability level. Balance tasks will be organized into five categories: stable, quasi-mobile, mobile, unpredictable and participant-selected.
224091195|NCT03396770|PROCEDURE|Standard clinical routine|Patient management is carried out according to the usual service protocol
224091196|NCT03396770|PROCEDURE|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~* If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~* If the test is negative, patient management is carried out according to the usual protocol.~* A second test is realized 6 hours after the first test whatever the result of it."
224091197|NCT01750892|BEHAVIORAL|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
223530980|NCT07160218|DEVICE|Sham tDCS|Sham stimulation applied over the left DLPFC for 30 minutes, mimicking the sensation of tDCS without delivering active current, over 10 sessions, used as control to blind participants to the intervention
223921992|NCT05043259|BIOLOGICAL|High dose aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.2 ml / dose, contains 2×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, aerosol inhalation.
223921993|NCT03931590|DRUG|[14C]-Omaveloxolone|\[14C\]-Omaveloxolone 50 mg capsules
223921994|NCT06987734|DRUG|Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab|Patients will receive 3-4 cycles of neoadjuvant treatment with preoperative suglizumab in combination with chemotherapy, followed by surgery. After surgery, patients will receive 1-4 cycles of platinum-containing adjuvant chemotherapy，followed by 1 year of adjuvant sugemalimab.
223921995|NCT06859606|OTHER|Lower molar distalization|"Lower Distalization Protocol included extraction of the lower third molars before starting treatment and a 50% sequential lower distalization with two teeth being distalized at a time. The distalization started with the movement of lower second molars, followed by the first molars halfway through the process, and so on. Once the canine reached the right position, the en masse retraction of the four incisors completed the treatment plan. The protocol comprised the use of Class III intermaxillary elastics to support the distalization movement and to control the proclination of lower incisors"
223921996|NCT06859606|OTHER|Class III elastics|Non-Distalization Protocol featured extraction of the lower third molars before starting treatment, transversal dento-alveolar coordination, strategic interproximal reduction (IPR) in the anterior segment of the lower arch, and the addition of Class III elastics
223921997|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM|Experimental subjects will receive the iotaSOFT Insertion System with AIM using robotic controlled stop
223921998|NCT06664710|DEVICE|iotaSOFT Insertion System with AIM Control|iotaSOFT Insertion System with AIM using standard of care insertion techniques
223530981|NCT07161024|DEVICE|Augmented reality|Augmented reality markers of different designs are tested to evaluate how they affect trainee performance.
223530982|NCT07160868|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure - device to be used at night in the treatment of sleep apnoea
223921999|NCT06989203|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
223922000|NCT06989203|BEHAVIORAL|Calorie-restricted balanced diet|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes and APP-connected scale will be used to monitor their weight changes during interventions.
223922001|NCT06989203|DRUG|semaglutide|Participants will receive semaglutide as medically prescribed
223922002|NCT06989203|DIETARY_SUPPLEMENT|Dietary protein supplementation|participants will receive 30 g/day of dietary protein supplementation
223922003|NCT06990815|OTHER|Kinesio Taping|"In the application over the sacrum, one I-strip of kinesio tape will be applied with 25% tension using the fascia correction technique, which requires oscillatory movements between the tape and the skin.~In the application over the suprapubic region, two I-strips will be applied with 25% tension, also using the fascia correction technique, involving oscillations between the tape and the skin."
223922004|NCT06990815|OTHER|Sham|"In the application over the sacrum, one I-strip will be applied without tension.~In the application over the suprapubic region, two I-strips will be placed without tension."
223922005|NCT04643769|DRUG|ORIN1001|Oral tablet - ORIN1001
223922006|NCT04643769|DRUG|Placebo|Oral tablet - placebo
223922007|NCT06996743|OTHER|reformer pilates group|Reformer Pilates exercises were applied to the pilates group twice a week for a total of 8 weeks.
223922008|NCT06996743|OTHER|Mat pilates group|Mat Pilates exercises were applied to the pilates group twice a week for a total of 8 weeks.
223922009|NCT06996743|OTHER|Lifestyle change group|After the doctor's check-up, routine application continued. The patient was informed about physical activity. In addition; a physical activity-based brochure prepared by the Specialist Physiotherapist was distributed to the participants in this group.
224091198|NCT01750892|BEHAVIORAL|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
224091199|NCT01750892|OTHER|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
223530983|NCT07159880|DRUG|Letrozole (aromatase inhibitor)|"Participants will be randomized into two groups:~Extended therapy group: 5 mg/day of letrozole for 10 days (cycle days 2-12). Standard therapy group: 5 mg/day of letrozole for 5 days (cycle days 2-6)."
223530984|NCT07160179|DRUG|ABBV-6628|Intravitreal injection
223530985|NCT07160179|DRUG|SYFOVRE|Intravitreal injection
223530986|NCT05287373|DEVICE|Nalu Neurostimulation System for PNS|The Nalu Neurostimulation System for PNS is a peripheral nerve stimulator
223530987|NCT05287373|OTHER|conventional medical management|Conventional medical management
223719573|NCT03425877|BEHAVIORAL|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
223922010|NCT06993922|OTHER|Scalp block|Patients will receive a scalp block with bupivacaine alone.
223922011|NCT06993922|OTHER|Scalp block + Dexmedetomidine|Patients will receive a scalp block with dexmedetomidine as an adjuvant to bupivacaine.
223922012|NCT06997510|BEHAVIORAL|Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS)|"Personalized lifestyle intervention that integrates artificial intelligence (AI), polygenic risk scores (PRS), and real-time behavioral and environmental data. MyBETTER4U dynamically adapts to individual needs by combining genetic and biological profiling (e.g., PRS, microbiome, metabolomics), behavioral determinants (e.g., eating habits, physical activity, sleep patterns), sociodemographic and environmental context, technology-assisted self-monitoring through wearable devices and digital tools, and AI-driven decision-support systems that generate ongoing, individualized recommendations.~Intervention group participants will receive personalized recommendations via the Better4U Platform, based on the AI model and, when available, their PRS and genetic data. Since genotyping results depend on sample processing timelines, baseline visits should be scheduled when results are available or expected within 1.5 months to ensure inclusion in the next visit."
223922013|NCT06997510|BEHAVIORAL|Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.|"Participants will receive feedback and counselling from the implementers on their weight status and lifestyle behaviours, based on their measurements/responses during the screening assessment. This counselling will be based on the general healthy eating (based on the Mediterranean diet) and healthy lifestyle recommendations for physical activity, sedentary time, and sleep (based on WHO recommendations) and will be considered the standard care. Those recommendations will also be handed in to them in the form of a standard care leaflet to take home. Participants will also be provided with a standard hypocaloric diet based on their needs for weight loss, aiming for a ≥ 5% reduction in body weight at the end of the 6-month intervention period."
223922014|NCT06996912|DRUG|HSK44459|HSK44459 will be administered orally twice daily
223922015|NCT06996912|DRUG|Placebo|Placebo will be administered orally twice daily
223922016|NCT06996379|DEVICE|Experimental J-Tip Needle-Free Injection System|This experimental intervention arm will include use of the J-Tip needle-less device to administer a one-time dose of 1% lidocaine during the superficial (intradermal) numbing step of a bedside abdominal paracentesis for adults with cirrhosis of the liver and ascites requiring bedside paracentesis.
223922017|NCT06996379|DEVICE|Control (Standard treatment)|The control intervention arm will include use of a 25-gauge needle (standard of care) to administer a one-time dose of 1% lidocaine during the superficial (intradermal) numbing step of a bedside abdominal paracentesis for adults with cirrhosis of the liver and ascites requiring bedside paracentesis.
223922018|NCT06996938|DIAGNOSTIC_TEST|Rapid diagnostic orientation tests (TROD) HIV, Hepatitis, syphilis|"The following information will be collected :~* Socio-demographic characteristics~* Lifestyle~* Health status~* Access to care and support in care~* Life events/violence~Knowledge of HIV prevention will be assessed~It will be proposed to screen for potentially serious STIs in the absence of specific management. If one of these infections is detected, the women will be referred and accompanied to a specialized consultation in the medical centers participating in the study~Women's needs in terms of health and access to care will be assessed: infections, gynecology, psychology, management of individual violence, sexual in particular, prophylaxis with regard to HIV"
223922019|NCT06997185|OTHER|Statement communicating uncertainty with a single arm trial|Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.
223922020|NCT06997185|OTHER|Statement communicating uncertainty with limited study duration|Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
224279730|NCT02103582|OTHER|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
224279731|NCT01706718|DIETARY_SUPPLEMENT|Bread|
223719574|NCT00318630|DRUG|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
223719575|NCT00318630|DRUG|Placebo|Subjects will also receive placebo oral tablet.
224279732|NCT04934007|DEVICE|rTMS Treatment|1 Hz rTMS
224279733|NCT03233451|BEHAVIORAL|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
223719576|NCT00285454|PROCEDURE|Retrograde coronary venous delivery of cells.|
223719577|NCT00246155|BIOLOGICAL|Botulinum toxin type A|
223719578|NCT01292616|DRUG|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
223940787|NCT06829368|OTHER|Transcranial Focused Ultrasound Stimulation|Using MRI neuronavigation, the investigators will implement theta-burst tFUS in one of the four targets.
223940788|NCT05223036|PROCEDURE|Biopsy Procedure|Undergo biopsy
223940789|NCT05223036|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223940790|NCT05223036|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
223940791|NCT05223036|BIOLOGICAL|Obeticholic Acid|Given PO
223940792|NCT05223036|DRUG|Placebo Administration|Given PO
223940793|NCT05223036|OTHER|Questionnaire Administration|Ancillary studies
223940794|NCT06854159|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Receive CAR T-cell therapy
223940795|NCT06854159|BIOLOGICAL|Odronextamab|Given IV
223940796|NCT06780150|DRUG|Ocrelizumab|Ocrelizumab will be administered as SC injection as per discretion of the treating physician in accordance with local clinical practice and local labeling.
223940797|NCT07129226|OTHER|Smart Watch|Participants will be asked to wear the smartwatch daily, for at least 12 hours per day during the 12-week study period, with breaks to recharge the watch as needed.
223940798|NCT04900597|OTHER|Elecare Jr|Elecare Jr is a standard pediatric elemental formula
223940799|NCT04900597|OTHER|Nourish|Nourish is a commercially prepared blenderized tube feed that is formulated for pediatric use
223940800|NCT04900597|OTHER|Real Foods Blends|Real Foods Blends is a commercially prepared blenderized tube feed that is formulated for pediatric use
223940801|NCT05340582|DRUG|Acetaminophen Injection|Acetaminophen injection solution 1000 mg/100 mL (10 mg/mL) latex-free plastic bag - dosage for this protocol is 15mg/kg/dose IV four times a day for 3 days
223940802|NCT05340582|DRUG|Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen)|Ibuprofen is not a study drug - standard of care in participating NICUs in the standard clinical dose for neonates (typically, for neonates \< 7 days old - 10 mg/kg/dose on day 1, 5 mg/kg/dose q24h on days 2 and 3; for neonates \> 7 days old - 20 mg/kg/dose on day 1, 10 mg/kg/dose q24h on days 2 and 3)
223940803|NCT05340582|OTHER|Sodium chloride 0.9% injection|Placebo- IV q6h for 3 days
223940804|NCT06675149|DEVICE|Diacutaneus fibrolysis|Material : Stainless steel large angle and small long angle: length 22cm x height 6cm x width 2cm. Weight: 70 grams
223940805|NCT06675149|DEVICE|Transcutaneous electrical nerve stimulation|physical therapy electrical modality
223940806|NCT06675149|PROCEDURE|Massage|manual therapy intervention
223940807|NCT07081243|DEVICE|Symplicity Spyral Renal Denervation System|Symplicity Renal Denervation
223940808|NCT07080762|DEVICE|antimicrobial photodynamic therapy (aPDT) after non-surgical therapy|In the test, a photoactive substance activated with laser light (20 mW, 660 nm) was applied to the post-non-surgical site for 60 seconds to promote disinfection Other Name: antimicrobial photodynamic therapy (aPDT) after non surgical therapy
223922021|NCT06997185|OTHER|Statement communicating uncertainty with a limited study population|Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
223922022|NCT06997185|OTHER|Statement communicating uncertainty with an unvalidated surrogate endpoint|Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
223922023|NCT06997185|OTHER|Statement communicating uncertainty with treatment effect size|It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
223922024|NCT06996093|DRUG|4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy|4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
223922025|NCT06996093|DRUG|aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor|aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
223922026|NCT06997861|OTHER|Medication Review Type III|The MR arm will receive four MR interviews. In the first MR, information about the patient's personal and medical history, along with current health problems, relevant lab exams and medication will be gathered. This will be used to proceed with medication review process and assessment of Drug Related Problems (DRP) that may lead to negative medication results. A personalized care plan will be developed to correct any detected DRP, delivered in writing/e-mail to the patient and carefully explained. Some DRP's may need the physician's intervention to correct. In these cases, a detailed recommendation will be sent to the patient's physician via email. All physicians' recommendations acted upon or not, will be recorded. Subsequent interviews will assess patient compliance with the care plan and if necessary, adjustments will be made accordingly.
223922027|NCT06997861|OTHER|Usual Care|The UC arm will receive an intervention by the investigator at the same time frame defined for the MR arm. The intervention will also consist of interviews, although MR will not be conducted. The investigator will ask questions to the patient about is drug therapy in a similar fashion to what would happen in the community pharmacy. Simple advice and information will be carried out (i.e., reinforcement of adherence, explanation about indication of drugs etc.)
223922028|NCT06091332|DRUG|Sirolimus|Sirolimus is an mTORC1 inhibitor that has received approval from the U.S. Food and Drug Administration (FDA) and has recently been successfully used to treat lymphatic malformations and venous/lymphatic malformations associated with the same PIK3CA GOF mutations.
223922029|NCT06091332|DRUG|Starch flake|The placebo is composed of starch material and is formulated at 0.5 grams per tablet.
223922030|NCT03338387|DRUG|Acipimox|Acipimox
223922031|NCT03338387|DRUG|Placebo|Placebo Other Names: Placebo (for Olbetam)
223922032|NCT06856239|OTHER|Graphene|The study follows an in-vitro experimental design with 76 specimens divided into two groups (conventional PMMA and G-PMMA). These samples will be further divided into two group, the one which undergo thermocycling (simulating oral temperature changes) and the other which don't undergo thermocycling. Flexural strength and modulus will be tested on all these by using a three-point bending test.
223922033|NCT06856993|PROCEDURE|standardized medical care of cardiac arrest|The standardized medical care for cardiac arrest includes early cardiopulmonary resuscitation (CPR), defibrillation, advanced cardiac life support (ACLS), post-resuscitation care, and continuous monitoring of the patient's vital functions.
223922034|NCT06855433|DRUG|Colchicine Pill|Colchicine 0.6mg tab, overencapsulated to match placebo capsule, taken by mouth once daily
223922035|NCT06855433|DRUG|Placebo|Placebo capsule, taken by mouth once daily
223922036|NCT06858098|OTHER|Exercise programme|6 week pre-operative graded prehabilitation programme, delivered by video and performed by participant up to 4 times a week at home or in a gym setting
223922037|NCT06858098|DEVICE|Wearable smart device|Participants will wear a wearable smart device (wrist or ring worn) for a period for 14 weeks; 2 weeks prior to prehabilitation, 6 weeks during pre-operative prehabilitation and 6 weeks post operative monitoring,
223922038|NCT06861985|DEVICE|BOBY|high-frequency multi-band harmonic electromagnetic stimulation device
223922039|NCT06861985|OTHER|Control|placebo group
223922040|NCT06017973|DIAGNOSTIC_TEST|MRI scan including arterial spin labelling of the brain|Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
223922041|NCT06017973|DIAGNOSTIC_TEST|CT perfusion scan of the brain|Siemens Naeotom Alpha with quantum technology (photon-counting)
224091200|NCT06861582|DIAGNOSTIC_TEST|Point-of-care ultrasensitive troponin testing|For patients randomized to the ultrasensitive troponin dosing arm using point-of-care (POC) technology, the Atellica® VTLi Patient-side Immunoassay Analyzer (Siemens Healthineers) will be used. This high-sensitivity troponin I (hs-cTnI) test utilizes Magnotech® Technology with paramagnetic particles and external magnetic fields, providing rapid results (\~8 minutes) using whole capillary blood collected via fingertip puncture, and/or with direct withdrawal from the test tube. Additionally, venous blood samples will be collected for laboratory comparison. The assay measures hs-cTnI within a range of 0-1250 pg/mL, with values \<LoD and \>1250 pg/mL recorded accordingly. Samples will be collected at 0 and 1 hour. Reference values (99th percentile, pg/mL): Women: 18.5, Men: 27.1. This intervention enables bedside testing, reducing turnaround time compared to standard laboratory assays, facilitating early myocardial infarction diagnosis.
223719579|NCT01292434|BEHAVIORAL|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
223719580|NCT00378378|DRUG|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
223719581|NCT00378378|DRUG|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
223719582|NCT05884905|PROCEDURE|short hydration|NSS infusion prior to and following cisplatin administration within 6 hours
223719583|NCT05884905|PROCEDURE|conventional hydration|NSS infusion prior to and following cisplatin administration over 24 hours
223530988|NCT07161128|PROCEDURE|arthroscopic microfracture and biological scaffold implementation for osteochondral defects of talus|"All enrolled patients will undergo a standardized single-stage arthroscopic procedure under spinal or general anesthesia with the patient supine and the ankle placed in appropriated position. Standard anteromedial and anterolateral portals are established. The talar osteochondral defect is inspected, measured, and any unstable cartilage is sharply débrided to create stable vertical walls, exposing healthy subchondral bone. Using a 1.0- to 1.2-mm awl, multiple perforations are made perpendicular to the lesion base, 3-4 mm apart and \~2-4 mm deep, until uniform marrow fat-bleeding is observed-mobilizing mesenchymal stem cells .A sterile, resorbable, type-I/III collagen bilayer scaffold is trimmed to the exact defect footprint using a template fashioned intra-operatively."
223717371|NCT07016048|PROCEDURE|Try-in of one crown test with a digital wax-up (per group)|"In a CAD/CAM software, we will integrate IOS, CBCT, and FS data into the virtual environment, and it will be possible the articulation of virtual models.~The digital wax-up for the preparation of the crown will be designed by the prosthodontist and then adjusted based on the occlusion obtained in each of the groups.~The steps of clinical procedure are:~1. \- In the first appointment, the patients mention their smile concerns, and the dentist evaluate and diagnoses.~2. \- Digital impressions, and a model of the teeth will be done.~3. \- Diagnostic wax-up, where dentist and dental laboratory plan the wax-up on the study models.~4. \- Diagnostic mock-up, where dentist transfers the diagnostic wax-up to the patient's mouth.~We will evaluate the volumetric difference between the diagnostic wax-ups obtained in each group.~After each mock-up, a questionnaire will be delivered to the patients in order to assess patients's aesthetics and comfort self-perception, using a numeric scale."
223922042|NCT06017973|DIAGNOSTIC_TEST|FDG-PET scan of the brain|An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
223922043|NCT03298178|PROCEDURE|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
223922044|NCT03298178|PROCEDURE|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
223922045|NCT06674486|DRUG|Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)|For the Group I, participants will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd). After a washout period, subjects will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France).
223719584|NCT03803397|BIOLOGICAL|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
223922046|NCT06674486|DRUG|Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)|For the Group II, participants will receive a single intravenous injection of the Reference Product (Iron sucrose injection, Venofer®, 100 mg iron/5 mL, held by Vifor France) . After a washout period, subjects will receive a single intravenous injection of the Test Product (Iron sucrose injection, 100 mg iron/5 mL, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd).
223922047|NCT06624657|OTHER|vitamin D supplements fo 16 weks|subjects exercised by HIIT-exercise for 16 weeks
223922048|NCT05029726|DRUG|Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine|Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
223922049|NCT05029726|DRUG|normal saline|normal saline in 30cc syringes administered using ESPB technique
223922050|NCT06442956|OTHER|Rapid Heat Condition|The heat condition is the intervention. Personal protective equipment will be used to create the rapid heat stress condition, resulting in a rapid rise in core temperature. This will be in combination with the physiological heat produced by the treadmill protocol.
223922051|NCT06442956|OTHER|Gradual Heat Condition|The gradual heat condition is the control. Physiological heat will be produced by exercise on a treadmill, and light exercise clothing will help moderate the rise in core temperature.
223922052|NCT06201403|DIAGNOSTIC_TEST|Determination of biomechanical properties of muscles|All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the muscle body. When the red light on the plexiglass frame of the device probe turns green, the pressure application will be stopped and will remain constant until 5 strokes are made. In every 5 beats, the duration of 1 beat is 15 ms and the time between beats is 8 ms. The SENIAM sensor location guide will be considered as a reference for the estimated motor point determination in the MyotonPRO measurement.
223922053|NCT05648110|BIOLOGICAL|AZD5156 (Parent study Sentinel Safety Cohort)|"600 mg AZD5156 consisting of 300 mg AZD1061 at 100 mg/mL and 300 mg AZD3152 at 150 mg/mL~3 mL of AZD1061 2 mL of AZD3152 IM on Visit 1 Day 1"
223922054|NCT05648110|BIOLOGICAL|Placebo (Parent study Sentinel Safety Cohort)|single dose of Placebo (3 mL + 2 mL) IM
223922055|NCT05648110|BIOLOGICAL|EVUSHELD™ (Parent study Main Cohort)|"600 mg EVUSHELD™/AZD7442 consisting of 300 mg AZD1061 and 300 mg AZD8895, both at 100 mg/mL~2 IM injections (thigh) of 3 mL each IM on Visit 1 Day 1 and on Visit 5 Day 181"
223922056|NCT05648110|BIOLOGICAL|AZD3152 (Parent study Main Cohort)|"300 mg AZD3152 at 150 mg/mL~1 IM injection (thigh) of 2 mL of AZD3152 on Visit 1 Day 1 and on Visit 5 Day 181"
223922057|NCT05648110|BIOLOGICAL|Placebo (Parent study Main Cohort)|Single doses of 0.9% sodium chloride 2 mL IM for injection on Visit 1 Day 1 and Visit 5 Day 181
223922058|NCT05648110|BIOLOGICAL|AZD3152 (Sub-study)|Single dose of 1200 mg IV at Visit 1 Day 1
223922059|NCT05648110|BIOLOGICAL|AZD7442 - EVUSHELD™ (Sub-study)|Single dose 300 mg IM administered on Visit 1 Day 1
223922060|NCT05648110|BIOLOGICAL|AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152|Single dose of AZD7442 (EVUSHELD™) 300 mg IM
223922061|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (10ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(10µg)/Matrix-M (50µg)
223922062|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug)|3 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg)
223922063|NCT04271306|BIOLOGICAL|Pfs25-IMX313 (50ug)/Matrix-M (50ug) & Pfs25-IMX313 (10ug)/Matrix-M (50ug)|2 doses of Pfs25-IMX313/Matrix-M at Pfs25-IMX313(50µg)/ Matrix-M (50µg) followed by one at Pfs25-IMX313(10µg)/Matrix-M (50µg)
223717372|NCT07014696|PROCEDURE|PNF application Group|PNF Application; in the application method, the subjects will be in a sitting position. The application will be made to the fingers, wrist and forearm in both D1 and D2 directions in flexion and extension patterns. The techniques will start using rhythmic initiation, then the combination of isotonics, dynamic-opposite, rhythmic stabilization and muscle-relaxation are determined. The movements will be made in 10 repetitions with rest in between (Saklecha et al., 2023).
223922064|NCT06690957|DIAGNOSTIC_TEST|68Ga/18F-TATE/JR11/LM3|Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.
224091201|NCT06861582|DIAGNOSTIC_TEST|Laboratory-based ultrasensitive troponin testing|For patients randomized to the ultrasensitive troponin dosing arm using the local laboratory, the Alinity™ i STAT High Sensitive Troponin-I assay (Abbott) will be used. Samples will be taken at 0 and 1 hour after admission by venipuncture and collected in 5 mL serum tubes with a separator. This chemiluminescence microparticle immunoassay (CMIA) quantifies cardiac troponin I (cTnI) in serum and plasma using the Alinity™ i analyzer, with a measurement range of 10-50,000 pg/mL. Analysis will follow the manufacturer's instructions. Reference values (99th percentile, pg/mL): Women (21-75 years): 15.6, Men (21-73 years): 34.2.
224091202|NCT03454854|DEVICE|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
224091203|NCT01036399|DRUG|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
224091204|NCT04101149|OTHER|No intervention|No intervention.
224091205|NCT06872190|OTHER|ED-Based Clinical Decision Support for Opioid Use Disorder|"The original clinical decision support (CDS) tool, EMergency department initiated BuprenorphinE for opioid use Disorder or EMBED, was designed by researchers at Yale to support emergency department (ED) clinicians with varying levels of experience prescribing buprenorphine for patients with opioid use disorder (OUD). The tool alerts ED providers of a patient who is potentially eligible for MOUD using Epic's storyboard. The provider must then click on the notification to open the OUD evaluation tool, which has multiple components: OUD assessment, OUD diagnosis, withdrawal assessment, and readiness for treatment. These components are then paired with an orderset, ED Opioid Use Disorder Treatment that includes nursing orders, prescriptions for buprenorphine and ancillary medications, and substance use disorder discharge resources."
224091206|NCT06872190|OTHER|Social Care-Enhanced Clinical Decision Support for Opioid Use Disorder|The investigators will use human-centered design to adapt the basic CDS tool to incorporate patient social needs, involving patients, staff, and end-user ED clinicians in the iterative design process. This tool is being actively developed.
223922065|NCT03255434|DRUG|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
224091207|NCT05839535|BEHAVIORAL|BDJ|BDJ is a mind-body intervention
224279734|NCT05307276|OTHER|Heliox|"Participants will then complete 1 FAM (#V3) to Neuromuscular Function Assessment (PRE-POST), Pre- and Post- Exercise Ventilatory Function Assessment, and a Constant Load Ergocycle Test to Tolerance Limit (intensity fixed at 90% of the maximum aerobic power, PMA). The following two experimental visits (#V4 and #V5) will replicate the tests described in #V3. However, during the constant load exercise, participants will breathe either ambient air or heliox (a mixture in which the nitrogen in the air is replaced by the inert gas helium) in a random order. During a final Experiential Visit (#V6), participants will replicate the Medical Gas Administration visit but the exercise will be interrupted when a similar amount of time/work as the ambient air condition is achieved."
224091208|NCT05839535|DEVICE|tDCS|tDCS is a brain stimulation method.
224091209|NCT05839535|DEVICE|sham tDCS|sham tDCS
223530989|NCT07160049|DEVICE|Cold Pressor Task - Upper Limb|"This study uses a three-session cold pressor paradigm to evaluate feasibility of a wearable focused ultrasound (FUS) device for peripheral nerve stimulation.~Session 1 (Baseline): After consent, participants immerse the dominant hand in 0-1 °C water (\~10 cm depth) in an insulated bucket. Time to first pain is recorded, with 5 min rests between immersions (12 total; max single immersion 6 min). Water temperature is digitally monitored, with ice added as needed.~Session 2 (Sham): The median/ulnar/radial nerve in the dominant forearm is located by ultrasound. The FUS device is applied with hydrogel but set to sham (no output). The cold pressor protocol is repeated.~Session 3 (Active FUS): After nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The cold pressor test is repeated to record pain tolerance as an exploratory physiological response during feasibility testing."
223922066|NCT03255434|DRUG|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
223922067|NCT05795231|DEVICE|Macintosh Laryngoscope Vs Video Laryngoscope|Evaluate incidence of first trial success and complications
223922068|NCT05696652|BEHAVIORAL|Acute exercise|40 minute moderate intensity exercise bout on a treadmill. This is similar to a single session of cardiac rehabilitation.
223922069|NCT05696652|BEHAVIORAL|Cardiac rehabilitation|12 week program of standard clinical cardiac rehabilitation for patients with symptomatic heart failure. Patients undergo 3-times weekly sessions of monitored exercise for 12 weeks. This is the same cardiac rehabilitation patients would get as part of clinical care.
224091210|NCT05839535|OTHER|exercise|exercise including stretching and other activities.
224091211|NCT03690869|DRUG|cemiplimab (monotherapy)|To be administered intravenously as monotherapy in Phase 1
223717373|NCT07014696|PROCEDURE|KB application Group|KB Application; In the taping treatment to be applied, taping will be applied starting from the fingers and up to the elbow with kinesiology taping (Huang et al., 2019). Taping will be done 3 days a week and the tape will remain on the patient for 2 days.
223922070|NCT06701305|DRUG|Efinopegdutide|Subcutaneous injectable solution
223922071|NCT06701305|DRUG|Placebo|Subcutaneous injectable solution
223922072|NCT06701305|DRUG|Acetaminophen|Oral solution
223922073|NCT05908084|BIOLOGICAL|Acellular Tissue Engineered Vessel (ATEV)|ATEV implantation
223922074|NCT05908084|OTHER|AVF|AVF creation procedure
223922075|NCT06701890|OTHER|Blood sample collection|16 mL at inclusion 16 mL at 1 month after return from travel
223922076|NCT06701890|OTHER|Fecal sample collection|"1 sample at inclusion~1 sample at day 1, day 7, day 14, day 21, 1 month and 2 month after return from travel"
223922077|NCT06699030|DRUG|Functional fatty acids|Days 1-3: Oral Administration of functional fatty acids Days 4-6: Oral Administration of functional fatty acids
223922078|NCT06699030|OTHER|Placebo|Days 1-3: Placebo Days 4-6: Oral Administration of functional fatty acids
223717374|NCT07014696|PROCEDURE|PNF+KB application Group|PNF+ KB Application; In this application, both PNF and taping will be applied. After each application, conventional treatment will be applied to all three groups at the end of each session. When all treatments are completed, re-evaluations will be made by the blind physiotherapist
223717375|NCT07015008|BEHAVIORAL|Sleep deprivation|Partial (4h) or total (0h) sleep deprivation
223717376|NCT07015008|BEHAVIORAL|Sleep place|8h sleep at home or in the laboratory
223717377|NCT07014605|BEHAVIORAL|Smoking Cessation Self Help Guide|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help guide in this study. Attached to the guide is an information sheet regarding NRT (e.g., patches and lozenges), where to buy them, and how to use them."
223922079|NCT06627244|DRUG|Tebentafusp|Tebentafusp will be administered intravenously to participants at or within 28 days of their first Y-90 TARE procedure. This 28-day period includes the 14- to 28-day Y-90 TARE Recovery Period. For administrative purposes, one cycle of tebentafusp treatment is 28 days in length. Tebentafusp will be administered on a dose escalation schedule for Cycle 1 starting at 20 mcg on Day 1, increasing to 30 mcg on Day 8, and a final dose of 68 mcg on Day 15, which will be administered once per week until unacceptable toxicity develops, disease progression, or withdrawal of consent, whichever occurs first.
223922080|NCT06627244|RADIATION|TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization|Participants will undergo radiographic and 99mTC-labeled macroaggregated albumin (99mTc-MAA) assessment for suitability prior to Y-90 absorbed glass microsphere treatment per institutional procedures. Y-90 trans-arterial radioembolization (TARE) is a standard of care treatment for intrahepatic metastases of uveal melanoma as indicated in the National Comprehensive Cancer Network (NCCN) consensus guidelines (NCCN Guidelines®, 2023). Y-90 absorbed glass microspheres will be administered at least one time prior to initiating Tebentafusp treatment. After the Y90-TARE procedure, participants will have a 14- to 28-day Y-90 TARE Recovery Period.
223922081|NCT06627959|DEVICE|Statseal|This is a vascular closure device which works independently of the clotting cascade to seal access sites
223922082|NCT06627959|DEVICE|Figure of eight suture|The figure of eight suture is commonly used for vascular access closure
223922083|NCT06627192|PROCEDURE|NSPT, clinical and biochemical assesment|Biochemical assessment using ELISA kit for Endcan and TNF alpha GCF sample
223922084|NCT02459717|OTHER|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
223922085|NCT02459717|OTHER|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
223922086|NCT05357222|BEHAVIORAL|Straw phontion|"Pitch Glides: (1 minute) Vocalize through the straw starting from as low as possible to as high as possible. As the participant you will want to get as much as your vocal range as possible. But, don't let the voice get growly at the bottom or press it into a painful range at the top.~2\. Accents: (1 minute) Vocalize progressive little hills or accents. It sounds like a revving engine of the car.~3\. Song: (1 minute) Pick a favorite song and vocalize it through the straw. Examples: National Anthem, Happy Birthday, Mary had a Little Lamb. These are great songs because they have a range of pitches and one can build some accents in, as well.~4\. Reading passage: (1 minute) Vocalize a reading passage through the straw. Be as dramatic as possible, using a lot of inflection."
223940809|NCT06077500|DRUG|BI 764532|BI 764532
223940810|NCT06077500|DRUG|Carboplatin|Carboplatin
223940811|NCT06077500|DRUG|Etoposide|Etoposide
223940812|NCT06077500|DRUG|Atezolizumab|Atezolizumab
224279735|NCT05307276|OTHER|Air|Following the selection visit (#V0) to verify the inclusion and non-inclusion criteria, participants will make 2 visits (#V1 and #V2) including in particular a Respiratory Functional Exploration (EFR) and a triangular VO2 MAX estimation test in Ambient Air or Heliox conditions (depending on randomization).
224279736|NCT05427045|OTHER|home - exercise program|Home exercise program
224279737|NCT06876272|BEHAVIORAL|Healthy eating promoting programme|It is a comprehensive, multi-component intervention tailored specifically for higher education students. Unlike many traditional health programs, this intervention uniquely combines the use of social media campaigns, behavioral nudges in student cafeterias, and interactive boost workshops.
224279738|NCT00003350|DRUG|paclitaxel|Given IV
224279739|NCT00003350|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
224279740|NCT00003350|OTHER|laboratory biomarker analysis|Correlative studies
224279741|NCT00003350|PROCEDURE|quality-of-life assessment|Ancillary studies
224279742|NCT00031707|DIETARY_SUPPLEMENT|eicosapentaenoic acid|
224279743|NCT00031707|DRUG|megestrol acetate|
224279744|NCT00031707|OTHER|placebo|
224279745|NCT02405793|DRUG|Meloxicam Test Capsules|
224279746|NCT02405793|DRUG|Meloxicam Test Capsules|
224279747|NCT02405793|DRUG|Meloxicam Tablets|
224279748|NCT06740500|DIETARY_SUPPLEMENT|Probiotic|probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.
224279749|NCT06740500|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223530990|NCT07160049|DEVICE|Algometry Pain Tests in the Upper Limb|"This session records pressure pain thresholds in the dominant hand with a wearable FUS device and a pressure algometer during feasibility testing.~Session 1 (Baseline): After consent and briefing, the median, ulnar, and radial nerves at three points on the dominant hand (wrist, palm, finger) are located via ultrasound and marked. A pressure algometer is applied to each site, with pressure gradually increased until pain is first reported. Thresholds are recorded, with each location tested three times with short breaks.~Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated.~Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing."
223922087|NCT06048068|BEHAVIORAL|Educational Informational Platform|This intervention contains many informational articles for surrogates about cardiac arrest, the subsequent hospitalization, and the emotional journey following cardiac arrest. All articles are available in both English and Spanish.
223530991|NCT07160049|DEVICE|Algometry Pain Tests in the Lower Limb|"This session records pressure pain thresholds in the dominant foot with a wearable FUS device and a pressure algometer during feasibility testing.~Session 1 (Baseline): After consent and briefing, the tibial, saphenous, and peroneal nerves at three standardized points on the dominant foot are located via ultrasound and marked. A pressure algometer is applied to each site, and pressure is gradually increased until pain is first reported. Thresholds are recorded, with repeated trials and short breaks between tests.~Session 2 (Sham): The same nerve sites are identified and marked. The wearable FUS device is applied with hydrogel but set to sham (no active output). The baseline algometry protocol is repeated.~Session 3 (Active FUS): Following nerve localization, active FUS (650 kHz, 60-100% intensity, 20-30% duty cycle) is delivered for 5 min. The algometry test is then repeated to record pressure pain thresholds as exploratory physiological responses during feasibility testing."
223922088|NCT06054802|DEVICE|eCAP|eCap™ has the look and feel of a regular prescription bottle and records real-time adherence data, tracking each opening with the date and time.
223922089|NCT06242002|PROCEDURE|Set up of sensor|Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
223922090|NCT06186102|DIETARY_SUPPLEMENT|Spermidine|Spermidine capsule of 8 mg x 3 capsules daily.
223922091|NCT06186102|OTHER|Placebo|Placebo capsule. 3 capsules daily.
223922092|NCT04805814|DIAGNOSTIC_TEST|CMR results disclosed|The results of the CMR are disclosed, and used to guide management
223922093|NCT04805814|DIAGNOSTIC_TEST|CMR performed but results not disclosed|The results of the CMR are not disclosed, and management is angiography-guided
223922094|NCT06439342|DRUG|Maribavir|Maribavir tablets
223922095|NCT00077584|DRUG|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
223922096|NCT00077584|DRUG|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
223922097|NCT00077584|DRUG|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
223922098|NCT05068960|DRUG|Liposomal bupivacaine|Addition of liposomal bupivacaine to the interscalene block for extended pain control following total shoulder arthroplasty
223922099|NCT05068960|DRUG|Bupivacaine|Interscalene block with bupivacaine for pain control following total shoulder arthroplasty
223922100|NCT06873750|DEVICE|Transcranial Alternating Current Stimulation|Application of low amplitude alternating electric current across the participant's scalp.
223922101|NCT06871787|DRUG|Indocyanine Green|Indocyanine green (ICG), administered intravenously at a dose of 2.5 mg/ml, will be used during surgery to evaluate bowel anastomosis perfusion through near-infrared fluorescence imaging.
223922102|NCT06871787|DEVICE|Near-Infrared Fluorescence Imaging System|A near-infrared fluorescence imaging device will be used intraoperatively to visualize indocyanine green (ICG) fluorescence, assessing the perfusion of bowel anastomoses during gynecologic oncology surgery.
223940813|NCT06077500|DRUG|Durvalumab|Durvalumab
223940814|NCT06077500|DRUG|Cisplatin|Cisplatin
223940815|NCT06282081|DIAGNOSTIC_TEST|Serum Neurofilament Light|The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.
223940816|NCT06744647|DRUG|ALXN2030|ALXN2030 will be administered subcutaneously (SC).
223940817|NCT06744647|DRUG|Placebo|Placebo will be administered SC.
223940818|NCT07084012|DRUG|hUC-MSCs treatment (high dose)|2.0×10\^8 cells per infusion, single administration on D0. Infusion of cell medium placebo on Day 7 (±2 days), and Day 14 (±2 days).
223940819|NCT07084012|DRUG|hUC-MSCs treatment (low dose)|1.0×10\^8 cells per infusion, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)
223940820|NCT07084012|DRUG|Placebo|Cell medium, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)
223940821|NCT06366750|BIOLOGICAL|barzolvolimab|subcutaneous administration
223940822|NCT06366750|OTHER|Matching Placebo|subcutaneous administration
223922103|NCT06875622|BEHAVIORAL|Automated online weight loss program|Participants receiving this program are given a daily calorie intake goal of 1200-1800 kcal/day based upon their starting weight and a moderate-intensity aerobic exercise (e.g., walking) goal which progresses to 250 min/week. They are instructed to self-monitor body weight, calorie intake, and exercise minutes daily over 12 months, and are provided with a smart scale for electronic transmission of weight data. Computer-generated, personalized feedback is based upon self-monitoring data, and provided weekly during months 1-3, twice per month during months 4-6, and monthly thereafter. Participants are also instructed to view a new multi-media video lesson weekly during months 1-3, 2x/month during months 4-6, and monthly thereafter (24 lessons in total). These videos are 10-15 minutes in duration and are intended to teach behavioral principles for losing weight, healthy eating, and exercise.
223922104|NCT06875622|BEHAVIORAL|Individual coaching|Participants will receive monthly, one-on-one coaching sessions (12 in total) throughout the 12-month intervention period. Coaching sessions will be conducted via videoconference and the initial coaching session will be approximately 30 minutes and all remaining sessions will be approximately 15 minutes. The structure of the coaching sessions will be similar across participants, but the content will be tailored to the individual. Coaches will use goal setting, problem solving, and motivational interviewing to help facilitate adherence and achievement of weight loss program goals.
223922105|NCT06875622|BEHAVIORAL|Group-based, videoconference-delivered weight loss|Participants receiving this program will be instructed to attend interactive group videoconference sessions (60 minutes each) focused on behavioral strategies for changing diet and exercise to promote weight loss. Classes will be weekly during months 1-3, twice per month during months 4-6, and monthly during months 7-12. These classes are designed to allow participants to interact with, support, and learn from one another. Participants are also given a daily calorie intake goal of 1200-1800 kcal/day based upon their starting weight and a moderate-intensity aerobic exercise (e.g., walking) goal which progresses to 250 min/week. They are instructed to self-monitor body weight, calorie intake, and exercise minutes daily over 12 months, and are provided with a smart scale for electronic transmission of weight data. Semi-automated, personalized feedback, based on self-monitoring data, is provided by the group instructor at the same frequency as group sessions are held.
223922106|NCT06874881|OTHER|Aquatic Exercises|The aquatic exercise intervention consists of structured, supervised, water-based exercises designed and delivered by an experienced physiotherapist specifically for individuals with chronic low back pain. Sessions are conducted in a temperature-controlled swimming pool with proper warm-up and cool-down. The intervention follows a progressive intensity approach with easy, medium, and hard approaches.
223922107|NCT06874881|OTHER|Land Exercises|The land-based exercise intervention mirrors the aquatic exercise protocol regarding exercise type, duration, frequency, and progression but is performed on land.
223922108|NCT05485935|DEVICE|Investigational device - intermittent catheter with micro-hole zone|Intermittent male catheter with micro-hole zone for urinary drainage
223922109|NCT05485935|DEVICE|Comparator - standard intermittent catheter|SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
223922110|NCT03865160|DRUG|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
223922111|NCT03865160|DRUG|Atropine eye drops, 0.02%|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
223922112|NCT03865160|DRUG|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned drug will be installed into each eye daily at bedtime.
223922113|NCT06753981|DRUG|Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs|Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
223922114|NCT06781645|OTHER|The system involves a digital table with a tactile and interactive surface, providing several play areas. It simulates a village and offers different types of serious cognitive games: semantic memory|Each patient included will benefit from a series of 6 sessions of cognitive stimulation with the interactive digital table of cognitive games 'Le Village de Verdurable'©, and a series of 6 sessions of 'classic' weekly cognitive stimulation at the rate of one session per week, i.e. without the digital table and using the methods of cognitive stimulation normally used in the department. The weekly session used as a comparator in the usual condition will be a session based on concentration and attention with target finding or error finding. The order in which these 2 series of 6 sessions will be carried out will be defined randomly (by drawing lots) before the start of the trial.
224091212|NCT03690869|DRUG|cemiplimab (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
224091213|NCT03690869|RADIATION|Conventional or hypofractionated|Combined with cemiplimab IV administration
224091214|NCT03690869|RADIATION|Re-irradiation|Combined with cemiplimab IV administration
224091215|NCT02722681|PROCEDURE|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
223922115|NCT05007847|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
223922116|NCT06702293|BEHAVIORAL|Digital psychotherapeutic intervention|Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.
223922117|NCT06702293|BEHAVIORAL|Healthy365|Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.
223922118|NCT06878157|BEHAVIORAL|ontological coaching|Group session: This session will provide an overview of coaching and the following topics will be covered: 1) Experience coaching in teams, 2) The Ideal Life, 3) The Coaching Distinction, 4) Introduction to Body, Emotions, Language (BEL), 5) Deeper understanding of BEL, 6) Applying BEL to clinical scenarios, 7) The coaching perspective in Nursing, 8) Re-visit the Ideal Life, 9) Explore mental/emotional/physical challenges in practicing nursing, 10) Time and stress management, work-life balance; Individual Session: This individualized session will cover the discussions on the topic brought up by novice nurses. The aim of this session is to: 1) Help novice nurses design the steps in their journey towards what they care about, 2) Explore the nurses' world by asking encouraging and evoking questions, 3) Collaborate with nurses in a stimulating and imaginative manner that help them to optimize their potential, 4) Co-create with nurses the professional and personal identity they strive for
223922119|NCT06876181|OTHER|Pharmacokinetics of Intra-Articularly Administered TXA: Postoperative Concentration Dynamics in Periarticular Hematoma|As part of the standard total knee arthroplasty procedure, participants receive a 2 g dose of tranexamic acid into the joint space after suturing the joint capsule. Before closing the joint capsule, a silicone drain is inserted into the joint space, through which periarticular hematoma samples are collected aseptically at 0.5, 1.5, 3, 6, and 9 hours post-application.
224091216|NCT02722681|PROCEDURE|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
224091217|NCT04552145|PROCEDURE|surgery|standard decompression surgery
224091218|NCT04552145|BEHAVIORAL|Physiotherapy|3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
224091219|NCT04892563|PROCEDURE|Erector Spinae Plane Block|Nerve block with local anesthetic in the erector spinae plane
224091220|NCT04892563|DRUG|IV Analgesia|IV analgesia, typically Morphine/Opioid medications
224091221|NCT05850741|DEVICE|Cardiokit|The CardioKit prototype used in the study can monitor cyclical heart-beat motion, cyclical respiratory motion and non-cyclical heart position changes while the patient is lying in supine position.
224091222|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
224091223|NCT01431287|DRUG|tiotropium + olodaterol|fixed dose combination
224091224|NCT01431287|DRUG|tiotropium|low dose or high dose
224091225|NCT01431287|DRUG|tiotropium|low dose or high dose
224091226|NCT01431287|DRUG|olodaterol|one dose only
224091227|NCT01431287|DEVICE|Respimat|Respimat inhaler
224091228|NCT02583984|PROCEDURE|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
224091229|NCT02583984|PROCEDURE|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
224091230|NCT01775748|OTHER|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
224091231|NCT01775748|OTHER|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
224091232|NCT03125603|OTHER|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
224091233|NCT06541444|DRUG|NK520|The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.
224091234|NCT01622426|DIETARY_SUPPLEMENT|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
224091235|NCT01622426|DIETARY_SUPPLEMENT|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
224091236|NCT02569515|DRUG|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
224091237|NCT03900195|OTHER|BottlePEP|Positive expiratory device with a bottle
224091238|NCT00042809|DRUG|paclitaxel|Given IV
224091239|NCT00042809|BIOLOGICAL|trastuzumab|Given IV
224091240|NCT00042809|DRUG|erlotinib hydrochloride|Given orally
224091241|NCT00042809|OTHER|laboratory biomarker analysis|Correlative studies
224091242|NCT00042809|OTHER|pharmacological study|Correlative studies
224091243|NCT04844138|BEHAVIORAL|Overcoming Anxiety in Pregnancy and Postpartum Online Self-Directed Program|The investigators will administer the Overcoming Anxiety in Pregnancy and Postpartum program in an online self-directed format. This program is grounded in Cognitive Behavioural Therapy and will teach participants strategies to manage their anxiety. Participants will complete six modules that will be released to them on a bi-weekly basis.
223922120|NCT06878469|DEVICE|RehaCom|Participants will receive a personalized neuro-cognitive rehabilitation program using the RehaCom software. Sessions will last approximately 30/40 minutes and will be held twice a week for 8 weeks. The rehabilitation will be aimed at enhancing and/or recovering cognitive functions that may have been compromised by the neurosurgical intervention.
223922121|NCT06880471|BIOLOGICAL|TheraCal PT pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, TheraCal PT material will be placed. According to the manufacturer's instructions, the irradiation time is 10 seconds. It is dual-cure. Its content is based on calcium silicate modified with resin.
223922122|NCT06880471|BIOLOGICAL|MTA pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, ProRoot MTA material will be placed. After waiting for 15 minutes for it to set, the restorative treatment will be performed. MTA consists of the main components: tricalcium silicate, dicalcium silicate, tricalcium aluminate, tricalcium oxide, silicate oxide, and calcium sulfate dihydrate.
224091244|NCT03395678|DEVICE|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
224279750|NCT02625974|DRUG|Nifurtimox (Lampit, BAYA2502)|"For pediatric participants with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric participants with body weight \> 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days or 30 days of nifurtimox treatment"
224279751|NCT02625974|DRUG|Placebo|Matching placebo
224279752|NCT01376882|DIETARY_SUPPLEMENT|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
224279753|NCT01376882|DIETARY_SUPPLEMENT|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
224279754|NCT01376882|DIETARY_SUPPLEMENT|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
224279755|NCT01376882|DIETARY_SUPPLEMENT|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
224279756|NCT00157066|DRUG|Ergocalciferol|
224279757|NCT06204770|OTHER|extensive hydrolyzed protein formula|NR Pepti is infant formula for special medical purposes based on extensive hydrolyzed whey protein for infants aged 0-12 months. This milk is intended for cow's milk protein allergy. This product is lactose free with medium chain triglycerides (MCT)
224279758|NCT04469725|DRUG|KN046|KN046 5 milligram per kilogram, every 2 weeks
224279759|NCT02350036|OTHER|ultrasound monitoring|Uterine artery Doppler assessment
224279760|NCT04220736|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
224279761|NCT04651920|GENETIC|Evaluation of homologous recombination deficiency score|Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)
224279762|NCT00833625|PROCEDURE|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
224279763|NCT00833625|OTHER|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
224279764|NCT06738407|DRUG|Doxycycline hyclate delayed released 200 mg|200 mg of doxycycline taken by mouth as soon as possible and within 72 hours after any condomless oral, vaginal, and/or anal sex.
223922123|NCT06880471|BIOLOGICAL|Biodentine pulpotomy|After the coronal pulp tissue is removed using a high-speed sterile diamond bur and bleeding control is achieved, Biodentin material will be placed. After waiting for 12 minutes according to the manufacturer's instructions for it to set, the restorative treatment will be performed. Biodentin is a two-component material. The powder primarily consists of tricalcium silicate.
223922124|NCT06878885|BEHAVIORAL|Acute psychological stress task (Paced Auditory Serial Addition Task)|Volunteers will complete a 4-minute Paced Auditory Serial Addition Task which is a standardized laboratory challenge that is widely used to monitor cardiovascular, neuroendocrine, and inflammatory responses in the laboratory.
224279765|NCT06738407|DRUG|Doxycycline hyclate delayed released 200 mg weekly|200 mg of doxycycline taken by mouth weekly regardless of sexual activity
224279766|NCT01731028|DRUG|Somatropin|Somatropin powder and solvent for solution for injection
224279767|NCT05822375|BEHAVIORAL|Better Together Physician Coaching|Better Together Physician Coaching Program thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies. BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
224279768|NCT00434590|DRUG|Enteric coated mycophenolate sodium (Myfortic®)|
224279769|NCT05462717|DRUG|RMC-6291|Oral tablet once or twice a day
224279770|NCT00548431|DRUG|6-mercaptopurine|Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
224279771|NCT06905002|BEHAVIORAL|Educational program|Unique educational program that educates health care professionals on the unique advantages of the Clinical Trials Navigator program. This program is reserved for those centres entering the study. An interactive component of the study is central.
224279772|NCT06904651|DEVICE|pre-operative positioning of peripherally inserted vascular accesses devices such as midline or minimidline|pre-operative positioning of peripherally inserted vascular accesses devices such as midline or minimidline ultrasound guided by dedicated vascular access team
223922125|NCT06880237|OTHER|Singing|"The programme consists of nin 75-min-long singing sessions spread across 8 weeks (8 sessions are practice sessions and 1 session is a full dress rehearsal), and a final performance. The final rehearsal session and showcase performance will be held at a concert venue, while the 8 practice sessions will be conducted at the nursing home.~Each session will kick off with a Hello song, followed by warm-up activities and vocal exercises. Participants will then sing different songs to explore and rehearse as a group, before concluding with a Goodbye song. All sessions throughout the programme are similarly structured to provide consistency for participants."
223922126|NCT06879288|DRUG|Bupivacaine|Patients received intraperitoneal bupivacaine only at the end of the operations.
223922127|NCT06879288|DRUG|Dexmedetomidine|Patients received intraperitoneal bupivacaine plus dexmedetomidine at the end of the operations.
223922128|NCT06879288|DRUG|Magnesium sulfate|Patients received intraperitoneal bupivacaine plus magnesium sulfate at the end of the operations.
223922129|NCT06876493|OTHER|Aerobic Exercise Programme|The aerobic exercise programme was shown to female students with premenstrual syndrome on the first day by the researcher (D.A.) at the sports centre. Participants were advised to drink water and wear running shoes during exercise. Warm-up exercises were performed for 10 minutes before the exercise. Exercise intensity was determined by the Karvonen formula (HRmax=220-age, HRR=HRmax-HR rest, 60% THR=(0.60xHRR)+HR rest). .According to the pulse rate of the exercise, pulse values are monitored on the treadmill and km/hour speeds are adjusted according to pulse values. The exercise programme started with low aerobic exercise intensity on the treadmill, gradually increased at 5-minute intervals and completed at 40-60% of the heart rate, and finally 5 minutes of light stretching movements were performed to return to the initial state. In the following sessions, the participants performed the exercise programmes individually at the sports centre for 45 minutes (10 min warm-up, 30 min walk,
223922130|NCT06876493|OTHER|Whole Body Vibration Training Programme|The WBV programme used a frequency of 25 Hz and an amplitude of 2 mm (low amplitude). The Power Plate® (pro5TM) machine provided the device's vibration. This device provides a three-plane oscillatory motion. The programme lasted eight weeks and was performed three days a week. There was at least one day's rest between each session. Before and after each vibration, stretching exercises (warm-up and cool-down programme) were performed for 5 minutes, particularly for the quadriceps and trunk extensors
223922131|NCT06876571|DIAGNOSTIC_TEST|IdentiClone Dx TRG Assay|"The IdentiClone Dx TRG Assay (Assay) is an in vitro diagnostic product intended for qualitative capillary electrophoresis based-detection of clonality in T-cell receptor gamma chain (TRG) gene rearrangements in Formalin-Fixed Paraffin-Embedded (FFPE) specimens as an adjunctive method for the diagnosis of T-cell lymphoproliferative disease. This qualitative, non-automated Assay is for use on the ABI 3500xL Dx and ABI 3500xL Genetic Analyzers."
223922132|NCT06880328|DRUG|Ralmitaront|Participants were given a once 150 mg daily dose of Ralmitaront orally during the 14 day treatment period.
223922133|NCT06880328|OTHER|Radiolabeled PET tracer [18F]-DOPA|\[18 F\]-DOPA solution for injection is manufactured by the PET imaging centers according to specifications established for the tracer at the site. The injection will happen prior to the scan being done and will last for approximately 30 seconds.
223922134|NCT06880328|DRUG|Placebo|Participants were given a daily dose of the placebo during the 14 day treatment period.
223922135|NCT06878378|OTHER|Investigation of Factors Influencing Bowel Preparation Quality|Observed parameters include BMI, history of abdominal surgery, history of diabetes, history of diarrhea and constipation, stool characteristics, and specific bowel preparation protocols.
223922136|NCT06880211|OTHER|physical activity recommendations|The participants (bus and tram drivers) in the control group will receive the latest World Health Organization recommendations for physical activity in written form.
223922137|NCT06880211|OTHER|activitysnippets|Participants (bus and tram drivers) in the intervention group will receive the ActivitySnippets toolbox. The toolbox was developed through collaborative workshops with the target group, sports scientists and physiotherapists to create a sustainable, occupation-specific and evidence-based physical activity promotion. The toolbox, which provides simple incentives to integrate physical activity into everyday working life, consists of 30 to 40 activity snippets (exercise cards). The design of the toolbox allows for individualization and variation of the exercise cards. The aim of the exercises is to improve muscle strength, increase physical activity levels at work and reduce stress. All exercises can be performed for between 10 and 60 seconds, allowing for realistic implementation in everyday working life. Participants are encouraged to incorporate the exercises into their daily work routine as often as possible.
224091245|NCT03395678|DEVICE|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
224279773|NCT06904729|BIOLOGICAL|Low-dose CAR-T cells group|This group of patients received low dose novel structure of Chimeric Antigen Receptors T (CAR-T) cells therapy with an infusion dose of approximately 5×100,000 cells/Kg.
224279774|NCT06904729|BIOLOGICAL|High-dose CAR-T cells group|This group of patients received high dose novel structure of Chimeric Antigen Receptors T (CAR-T) cells therapy with an infusion dose of approximately 1×1000,000 cells/Kg.
224279775|NCT06905613|DEVICE|Technical feasibility study of a novel wearable capnograph (MARIE) in an emergency care environment|MARIE will be connected to the patient by attaching the nasal adapter set and connecting the CO2 sensor. ETCO2 and RR values will be logged before and during the transport by writing down the values in the Case Report Form (CRF). On arrival at the hospital ETCO2 and RR will be measured by a reference instrument and logged in to the CRF. There will be trained study personnel responsible for operating the investigational device and populating the CRF, capturing all information which is required according to the study protocol.
223530992|NCT07160114|DEVICE|Electrical Stimulation Glove with Task-Oriented Training|Participants perform structured task-oriented training while wearing an electrical stimulation glove. The glove is embedded with electrodes that deliver low-intensity electrical impulses to the wrist and finger muscles during functional tasks. Training includes warm-up range of motion and stretching, 40 minutes of functional activities such as pegboard tasks, object manipulation, writing, and daily living tasks, followed by cool-down exercises. The intervention is delivered in 60-minute sessions, three times per week, for 8 weeks.
223922138|NCT06880133|DEVICE|Seismocardiography (SCG) and Gyrocardiography (GCG) Screening|"This intervention involves the use of SCG/GCG diagnostic testing, a radiation-free, non-invasive technique for assessing cardiac function. SCG/GCG utilizes high-precision accelerometers and gyroscopes to record and analyze cardiac-induced microvibrations on the chest.~Participants will undergo SCG/GCG testing before their scheduled coronary artery calcium computed tomography (CAC-CT) or coronary computed tomography angiography (CCTA). The study aims to evaluate the diagnostic performance of SCG/GCG in identifying CAD, particularly in hypertensive patients and those with mild CAD.~Data collected from SCG/GCG will be compared with CAC-CT and CCTA findings to determine its predictive value for CAD severity and coronary artery stenosis."
224091246|NCT05751525|DRUG|Sulfonylurea|Glibenlclamide / glyburide
224091247|NCT01150110|DEVICE|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
224091248|NCT02271490|OTHER|Acrosome Reaction induction|
224279776|NCT04808206|DEVICE|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for the creation of anastomoses during laparoscopic bariatric surgery manufactured by Ezisurg Medical.
223922139|NCT06879561|PROCEDURE|Angiography-guided angioplasty|Balloon angioplasty will be performed on the target infrapopliteal artery lesion to achieve an optimal procedural result, as determined by angiography. Optimal results are defined as antegrade blood flow without residual stenosis \>50% or any flow-limiting dissection.
223922140|NCT06879561|PROCEDURE|Pressure wire-guided angioplasty|Balloon angioplasty will be performed on the target infrapopliteal artery lesions to achieve an optimal procedural result, as determined by the pressure gradient across the target lesion. An optimal procedural result is defined as pressure gradient less than 10 mmHg, measured using a Pressure Wire.
224091249|NCT02271490|OTHER|capacitation in incubation medium prior to ICSI|
224091250|NCT03156530|DEVICE|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
224091251|NCT03156530|OTHER|Control|Not receive stimulation.
224091252|NCT04585763|DEVICE|Shockwave Medical M5+ Peripheral Intravascular Lithotripsy (IVL)|The Shockwave Medical M5+ Peripheral IVL System is indicated for lithotripsy-enhanced, low-pressure balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries. This device is not intended for use in coronary, carotid, or cerebrovascular arteries.
224091253|NCT04724525|OTHER|soft contact lens Toric|soft contact lens toric with different axis and power that use in human's eye
224279777|NCT02866591|OTHER|mammography according to an auto-compression procedure|
224279778|NCT02866591|OTHER|mammography according to a standard procedure|
224279779|NCT02866591|OTHER|questionary|
224279780|NCT06904118|DRUG|Nano-reinforced Novel Hydrogen peroxide gel|Group A (Novel Nano-enriched Hydrogen peroxide bleaching gel with Silky Corn hair fiber derived- titania nanoparticles)
223922141|NCT05357105|OTHER|Numerical Pain Scales|Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
224091254|NCT04873687|DEVICE|External Counter Pulsation (ECP) therapy|ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
224091255|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 5mg QD
224091256|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD
224091257|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
224091258|NCT02224664|DRUG|PF-06649751|Oral daily doses titrated up to 25 mg QD
224279781|NCT06904118|DRUG|Conventional Hydrogen peroxide gel without nanoparicles|Drug: Hydrogen peroxide without nanoparicles Group B ( Conventional Hydrogen peroxide gel without nanoparticles)
224279782|NCT06904248|DRUG|Meloxicam Injection|Intravenous meloxicam Injection, 30mg every 24 hours, for a total of 2 doses
224279783|NCT06904248|DRUG|Sodium Chloride Injection|Intravenous Sodium Chloride Injection, 18mg every 24 hours, for a total of 2 doses
223922142|NCT06876961|OTHER|Arm cycling exercise|The study involves a 20-minute arm cycling exercise twice daily for five days, starting with a warming-up and ending with a cooling-down. The workload is gradually increased to 60-70% of maximal heart rate, with patients sitting on a back support chair with 20 degrees backward inclination.
223922143|NCT06876961|OTHER|The traditional physical therapy program|The patient undergoes 10 minutes of deep diaphragmatic breathing exercises, 10 minutes of spirometer training, 3-set ankle pump and heel slide exercises, 10-minute sitting on the bed edge, 5 minutes of walking in the intensive care unit, and 3-set active free range of motion exercises.
223922144|NCT06877754|BEHAVIORAL|Self-Acupressure|Both groups received general health education videos. The experimental group performed SP6 acupressure starting one week before menstruation, 10 minutes per session, twice daily, until the fifth day of menstruation. The control group maintained their usual routines.
223922145|NCT06877351|DRUG|Amoxicillin|Participants randomized to the intervention group will receive oral amoxicillin at a dose of 40-50 mg/kg/day (maximum 1500 mg/day), administered in three doses daily for 14 days for early syphilis and 21 days for late syphilis or syphilis of unknown duration.
223922146|NCT06877351|DRUG|Penicillin G, Benzathine|Participants randomized to the control group will receive intramuscular procaine benzathine penicillin (PGB) at a dose of 50,000 IU/kg (maximum 2,400,000 IU/day), administered as a single dose for early syphilis and as three consecutive weekly doses for late syphilis or syphilis of unknown duration.
223922147|NCT06703060|BEHAVIORAL|Peer Navigation Group|Participants randomized to the intervention will receive behavioral lifestyle education on topics related to biomedical HIV prevention. This will include 4 group sessions and 4 one-on-one sessions with a peer navigator.
223922148|NCT06874907|PROCEDURE|Glucose monitoring|Glucose monitoring
223922149|NCT06874309|DEVICE|home-based tDCS stimulation|stimulation parameters: 20 sessions of tDCS over lDLPFC (anode over F3, based on the 10:20 system, and cathode over the right supraorbital area), 2 mA intensity, 20 min duration (30 s fade in/fade out)
223922150|NCT06874309|DEVICE|home-based tDCS stimulation - sham|20 sessions of tDCS over lDLPFC (anode over F3, based on the 10:20 system, and cathode over the right supraorbital area), the electric current will flow for only 15 s, with similar fade in/fade out, at the beginning and at the end of 20 min, to mimic the subjective sensations that occur during active tDCS.
223922151|NCT06874309|PROCEDURE|Bariatric surgery|The operation itself is not a study-related procedure and thus the indicated patients would undergo the surgery regardless of their participation in this study. The operating surgeons will perform either Roux-en-Y or gastric sleeve resection.
223922152|NCT06877130|OTHER|Aerobic exercise with BFR|"To prescribe BFR training, Systolic blood pressure (SBP) will be measured using an automated oscillometer BP device.~Blood pressure will be measured according to the recommendations of the American Heart Association. A bilateral restriction of 50% of the measured SBP will be applied to each lower limb for the application of BFR of lower limbs using the equipment. A wide cuff (18 cm wide) will be placed in the proximal portion of the thigh (inguinal fold region) and will be inflated until the absence of the tibial artery blood pulse. Thus, a 50% restriction of SBP will be applied in both legs during lower body exercises."
223922153|NCT06877130|OTHER|Aerobic training|"HR max = 206.9 - (0.67 x age).~Moderate intensity aerobic exercise: the rate of heart reaches 64-76 percent of their age predicted peak hearty rate"
224279784|NCT03359941|PROCEDURE|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
224279785|NCT00779441|DRUG|Zolpidem 10mg tablets|
224279786|NCT03849846|OTHER|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
224279787|NCT02175368|DEVICE|Adhese One F Upgrade|
224279788|NCT02518607|DRUG|MGB-BP-3|Treatment of CDI
224279789|NCT02518607|OTHER|Placebo|Placebo
224279790|NCT02875028|DRUG|Vorapaxar|10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
224279791|NCT02875028|DRUG|Placebo|
224279792|NCT02875028|OTHER|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
223922154|NCT06876922|OTHER|Thoracic mobility exercises Group|Thoracic mobility exercises Group: Conventional physiotherapy exercises were given to individuals participating in the control group. Conventional physiotherapy exercises included warm-up, stretching, strengthening, posture and breathing exercises integrated between them. These exercises were performed in 30-40 minute sessions, 3 days a week and for 6 weeks. Thoracic mobility exercises were applied to individuals participating in the study group in addition to conventional physical therapy exercises.
223922155|NCT06876922|OTHER|the Conventional physiotherapy exercises Group|the Conventional physiotherapy exercises Group: Conventional physiotherapy exercises were given to individuals participating in the Conventional physiotherapy exercises group. Conventional physiotherapy exercises included warm-up, stretching, strengthening, posture and breathing exercises integrated between them. These exercises were performed in 30-40 minute sessions, 3 days a week and for 6 weeks. Use this module to add descriptions of each arm in the study and to list the interventions being studied.
223922156|NCT06879158|DRUG|BR3409|One tablet administered alone
223530993|NCT07160114|BEHAVIORAL|Task-Oriented Training Only|Participants receive task-oriented training without the electrical stimulation glove. Training includes warm-up range of motion and stretching, 40 minutes of functional activities such as pegboard placement, grasp-and-release, writing or drawing, and simulated daily living tasks, followed by cool-down exercises. The intervention is delivered in 60-minute sessions, three times per week, for 8 weeks.
223530994|NCT07160738|DRUG|PF-07220060|Tablet given orally
223922157|NCT06879158|DRUG|BR3409-1|One tablet administered alone
223922158|NCT06879158|DRUG|BR3409-2|One tablet administered alone
223922159|NCT06879938|DEVICE|High-concentration vaginal oxygen therapy (Caress Flow) with topical hyaluronic acid|five treatment sessions of high-concentration vaginal oxygen therapy (Caress Flow) with topical hyaluronic acid 2 weeks apart with a duration of approximately 15 minutes
223922160|NCT06879938|DEVICE|hyaluronic acid-based gel (Hydeal-D®)|hyaluronic acid-based gel (Hydeal-D®) applied once every three days for 12 weeks
223922161|NCT06878508|DEVICE|DuoCor Ventricular Assist System|The DuoCor VAS is used to provide hemodynamic support by shareing some or all the workload of the left and right ventricles during the support period.
223922162|NCT06827873|DIETARY_SUPPLEMENT|ARA (Arachidonic Acid) Supplementation|Oral ARA (Arachidonic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsule composition includes: C14:0 (0.15%), C16:0 (6.08%), C16:1 (0.15%), C18:0 (4.57%), C18:1 (19.65%), C18:2 (38.46%), C18:3 (0.87%), C20:0 (0.50%), C20:3 (2.00%), C20:4 (18.66%), C22:0 (1.81%), C24:0 (4.05%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
223922163|NCT06827873|DRUG|TUDCA (Tauroursodeoxycholic Acid) Supplementation|Oral Double Wood brand TUDCA (Tauroursodeoxycholic Acid) dietary supplement capsules, dosage 1000 mg/person/day. Capsules primarily contain TUDCA, with 500 mg per serving (two capsules), other ingredients include gelatin and rice powder. Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue supplementation until Day 24.
223922164|NCT06827873|DIETARY_SUPPLEMENT|Placebo Supplementation|Oral placebo capsules identical in appearance and smell, dosage 1000 mg/person/day. Placebo capsule composition includes: C14:0 (0.09%), C16:0 (6.12%), C16:1 (0.03%), C18:0 (3.50%), C18:1 (28.06%), C18:2 (59.40%), C20:0 (0.27%), C22:0 (0.76%), C24:0 (0.26%). Maintain original lifestyle during intervention, Day 0-Day 2 as adaptation period, receive quadrivalent influenza vaccine on Day 3, continue taking placebo until Day 24.
223922165|NCT06827873|BIOLOGICAL|Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine|Administer Shanghai Biological Quadrivalent Influenza Virus Inactivated Vaccine, produced by Shanghai Biological Products Research Institute Co., Ltd. , specification 0.5ml/dose, containing 15.0 μg hemagglutinin (for each influenza virus strain), suitable for intramuscular injection in individuals 6 months and older. Administer one dose to all study participants on Day 3. Closely observe and record any potential adverse reactions after vaccination.
223922166|NCT06684275|PROCEDURE|Pulsed Radiofrequency (PRF)|Participants will receive pulsed radiofrequency (PRF) treatment targeting the trigeminal nerve to manage pain associated with trigeminal neuralgia. This non-ablative technique uses electrical pulses to modulate nerve function, aiming to provide pain relief without creating a thermal lesion.
223922167|NCT06684275|PROCEDURE|Pulsed and Thermal Radiofrequency (PRF + TRF)|Participants will receive a combination of pulsed radiofrequency (PRF) and thermal radiofrequency (TRF) treatments targeting the trigeminal nerve. This approach combines the non-ablative effects of PRF with the thermal lesioning of TRF to provide long-term pain relief for trigeminal neuralgia.
223922168|NCT00216827|DRUG|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
223922169|NCT06686576|BIOLOGICAL|QL1706|Phase Ib/Ⅲ： QL1706 will be administered
223922170|NCT06686576|DRUG|CAPEOX|Phase Ⅲ：CAPEOX will be administered
223922171|NCT06691087|BEHAVIORAL|Influence of the parameters of the sound timbre on the perception of a sound|"The experiment consists of evaluating the sound level of n complex stimuli, then equalising them in loudness, in order to measure a loudness curve in function of timbre descriptors.~The stimuli will then be listened to again in pairs. The task is there to compare the stimuli using a VAS to indicate how different the two sounds are."
223922172|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test|The experiment consists in identifying the parameters of the sound timbre that most disturb the understanding of complex sound scenes, by asking the participants to identify sounds whose timbre has been modified.
223922173|NCT06691087|BEHAVIORAL|Complex sound scene comprehension test with hearing aids|The experiment will be identical to intervention 2. This time, the modification of the stimulus timbres will focus on the most problematic dimensional modifications, i.e. those where the difference between normal-hearing and hearing-impaired listeners is greatest. We will then modify the signal processing parameters of the hearing aid simulator (for example, the size of the averaging window or the gain balance of the filters), to observe their impact on the salience of certain stimuli.
223922174|NCT05495984|BEHAVIORAL|ERPs with electroencephalography (EEG)|E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.
223530995|NCT07160738|DRUG|Itraconazole|Capsule given orally
223530996|NCT07160738|DRUG|Probenecid|Tablet given orally
223530997|NCT07158606|DRUG|efanesoctacog alpha|Efanesoctacog alpha will be administered at a dose of 50 IU/kg two times weekly during the ITI Treatment Period. The site investigator will determine the dose of efanesoctacog alpha once the subjects reaches the Follow Up Period.
223530998|NCT07158606|DRUG|Emicizumab|Emicizumab will be prescribed as standard of care bleed prevention.
223530999|NCT07161505|DEVICE|TBS-EEG|Theta-burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) synchronized with the ongoing electroencephalographic (EEG) oscillations in the theta (3-7 Hz) range at a suprathreshold pulse intensity (up to 120% rMT).
223922175|NCT05495984|BEHAVIORAL|MIO|A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.
223531000|NCT07161505|DEVICE|TBS-EEG / Spatial Control|Theta-burst stimulation (TBS) over the postcentral gyrus, synchronized with the ongoing electroencephalographic (EEG) oscillations in the theta (3-7 Hz) range at a suprathreshold pulse intensity (up to 120% rMT).
223531001|NCT07161505|DEVICE|TBS / Temporal Control|Theta-burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) at a suprathreshold pulse intensity (up to 120% rMT).
223922176|NCT03527537|DRUG|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be determined by the provider using typical management of gestational diabetes.
223922177|NCT06705465|BEHAVIORAL|video conference|video conference
223922178|NCT06526663|BEHAVIORAL|vignette exposure|"Participants will be randomized to be exposed to one of 16 written vignettes that vary four elements of the primary care experience. The four attributes can take two levels.~In the second round, individuals will be randomized to only 4 different vignettes."
223922179|NCT06706440|OTHER|no intervention, observational study|Only data will be taken of patient's file.
223922180|NCT04731233|BIOLOGICAL|Plasma Rich in Growth Factor (PRGF) Supplementation|After rinsing the joint, the TMJ will be injected with blood plasma rich in growth factors (PRGF). PRGF supplementation which is an autologous platelet-enriched plasma obtained from patient's own blood, which after activation with calcium chloride allows the release of a pool of biologically active proteins that influence and promote a range of biological processes.
223922181|NCT04731233|DRUG|Triamcinolone Acetonide|After rinsing the joint, the TMJ will be injected with 40 mg of triamcinolone acetonide with 5 mg bupivacaine.
223922182|NCT06704945|PROCEDURE|No axillary surgery|BCS only. Ommission of axillary surgery. No axillary surgery after neoadjuvant chemotherapy.
223922183|NCT06704945|PROCEDURE|Axillary surgery|BCS with SLNB(+/-ALND)
223922184|NCT04135300|GENETIC|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
223922185|NCT05259605|OTHER|Observational|The goal is to determine whether the new 2021 WHO classification, based on cIMPACT-NOW recommendations, results in more homogeneous patient groups than the old 2016 classification. Furthermore, it will help derive provisional guidelines on how patients with these newly defined tumour entities are best treated. These recommendations will be based on the experience of EORTC investigators with chosen treatments and their experience as reported in this data collection report.
223922186|NCT03839446|DRUG|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
224279793|NCT06130969|OTHER|Cervical Retraction Exercise|Participants will hold cervical retraction for 10 s up to 10 times. A break of 5 s will be provided per one movement and 30 s per one set. A total of three sets will be conducted. Therefore, the total exercise time will be \<10 mints.
224279794|NCT06130969|OTHER|Diaphragmatic Breathing|The diaphragmatic exercise will be performed in a supine position with 40° trunk flexion while holding 2.5 kg on the abdomen in the first 5 sessions and then 5 kg in the second 5 sessions. Participants will perform 3 sets with 10 repetitions at a ratio of one second of inspiration to two seconds of expiration, three sets of 15 repetitions at a ratio of two seconds of inspiration to four seconds of expiration, and three sets of 20 repetitions at a ratio of three seconds of inspiration to six seconds of expiration. The rest between rests will be 60 s.
223531002|NCT07161505|DEVICE|TBS-EEG / Dose Control|"Theta-burst stimulation (TBS) similar to the TBS-EEG condition but at a subthreshold pulse intensity (up to 80% rMT)."
223531003|NCT07159139|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm description.
223531004|NCT07158866|BEHAVIORAL|Ballroom Dance|"The intervention will involve twice-weekly dance sessions, lasting 45 minutes each, for 6 months. Each session will include:~1. Rhythmic warm-up with music.~2. Combination of aerobic, resistance, and coordination exercises.~3. Technical development and learning of dance routines.~4. Cool down with free-body movements to slow music."
223922187|NCT06708702|DRUG|Copaíba mouthwash|"A 15% aqueous solution of copaíba (Copaifera Officinalis Resin) manufactured by Interativo Farmácia de Manipulação will be used, under the formula of copaíba oil (Copaifera Officinalis Resin) 15%, liquid mint aroma 5%, tween 80 1%, aqueous solution (Distilled water + Nipagin 0.1%) qsp 100%.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use."
223922188|NCT06708702|DRUG|Placebo mouthwash|"Placebo will be used, under the formula of liquid mint flavor 5%, Nipagim 0.1%, and distilled water qsp 60 ml, packed in packaging compatible with that of the product under investigation, maintaining the same physical characteristics to maintain blinding. The product will be stored at room temperature and stored in the INCA pharmacy.~Patients will receive the solution once a week. They will be instructed to shake the bottle before use for homogenization, to use 10mL of the solution for each mouthwash (which should be measured in the 10mL measuring cup that comes with each bottle), 4 times a day, rinsing vigorously for 1 minute and discarding all the solution after use."
223922189|NCT05292027|RADIATION|low-dose radiotherapy|On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
224091259|NCT01322828|PROCEDURE|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
224091260|NCT05109312|DRUG|Bupivacaine Hydrochloride|100 mg
224091261|NCT05109312|DRUG|Bupivacaine Hydrochloride|125 mg
224091262|NCT05109312|DRUG|HTX-011|400 mg
224091263|NCT05109312|DEVICE|Luer lock applicator|Applicator for instillation
224091264|NCT05109312|DRUG|Ibuprofen|400 mg
224091265|NCT05109312|DRUG|Acetaminophen|1 g
223922190|NCT06712069|DEVICE|Multimodal Intraoperative Neurophysiologic Monitoring (MIONM)|"Multimodal Intraoperative Neurophysiologic Monitoring (MIONM) is a real-time, device-based intervention used during neurosurgical procedures to monitor and preserve the integrity of neural pathways. It combines the following modalities:~Somatosensory Evoked Potentials (SSEP): Monitors sensory pathways by stimulating peripheral nerves and recording cortical responses.~Motor Evoked Potentials (MEP): Assesses motor pathways via transcranial stimulation and muscle response evaluation.~Electromyography (EMG): Detects nerve irritation and monitors muscle activity during surgery.~This intervention provides critical real-time feedback to the surgical team, enabling immediate adjustments to prevent neurological damage and enhance surgical outcomes. The Cascade IOMAX system is the primary device used in this study for implementing MIONM."
223922191|NCT06712667|OTHER|Caffeine content|Participants will drink the same volume of water or coffee with different amounts of caffeine.
223922192|NCT06707376|OTHER|Early Kangaroo Mother Care|"* Initiation of KMC within 24 hours of birth.~* Continuous skin-to-skin contact for at least 8 hours per day, with gradual increase based on infant tolerance.~* Support for exclusive breastfeeding or expressed breast milk feeding.~* Ongoing assessment and support from trained neonatal nurses and lactation consultants."
224091266|NCT03050125|DEVICE|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
224279795|NCT06130969|OTHER|Baseline Treatment|"Hot fomentation will be given by applying cervical hot pack over the area in prone lying position for 10 mints and Isometric neck strengthening exercises (10 repetitions, each 5-second hold, 1 set) (20). • Nerve Stimulation (TENS) on the painful regions around the neck for 15 minutes with a TENS device. TENS parameters will be 150 μs square pulses with a frequency of 80 Hz.~The intensity of the current will be adjusted to produce no contraction.~• Posture education to keep upright posture during sitting."
224279796|NCT05758779|BEHAVIORAL|Visualization of coronary Imaging and oral description|The participants is allowed to see their coronary CT scan including oral description. The study will test the effect on smoking habit and changes in LDL-C in one year.
224279797|NCT04436926|BEHAVIORAL|opioid approach bias modification|The investigators will use a training version of the Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different opioid and 20 different non-medication alternative pain managing activities. Training effect is achieved by presenting opioid pictures in push format only and non-opioid pictures in pull format only. Two hundred training trials are presented per session.
224279798|NCT04436926|BEHAVIORAL|sham training|Sham training is identical to opioid approach bias training, except pictures are presented randomly in both formats.
224279799|NCT02677662|OTHER|Diesel Exhaust|Dilute diesel exhaust
224279800|NCT02677662|OTHER|Filtered air|Filtered air
224279801|NCT02966496|BIOLOGICAL|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
224279802|NCT02966496|BIOLOGICAL|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
224279803|NCT05254158|DRUG|NNC0174 0833|Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
224279804|NCT04431635|DRUG|Copanlisib|Copanlisib IV: day 1, 8, 15 every 28 days
224279805|NCT04431635|DRUG|Nivolumab|Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only
224279806|NCT04431635|DRUG|Rituximab|Rituximab IV: Cycle 1 days 1, 8, 15, 22; then day 1 (C2-6); then Q2 cycles (8-12)
224279807|NCT00847743|DIETARY_SUPPLEMENT|Tart Cherry Juice|8 fl.oz. twice per day
224279808|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
224279809|NCT01621906|DEVICE|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
224279810|NCT01150006|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
224279811|NCT02856087|DRUG|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
223922193|NCT06709040|DRUG|Somapacitan|Participants will be treated with commercially available somapacitan according to routine clinical practice at the discretion of the treating physician.
224091267|NCT03050125|DEVICE|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
224091268|NCT03050125|DEVICE|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
224091269|NCT04917783|BEHAVIORAL|Passport Card|"After receiving neurocognitive testing, caregivers in the health-literacy group will be provided with a color-coded passport (a two-sided wallet-sized card) highlighting key findings and recommendations along with their written report. Then, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback passport card and evaluation report."
224279812|NCT02856087|DRUG|Naloxone|naloxone infusion
224279813|NCT02856087|DRUG|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
224279814|NCT02856087|DRUG|Normal Saline|normal saline infusion
224279815|NCT03180528|DRUG|Remetinostat|Applied topically under bandage occlusion
224279816|NCT02447887|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
224279817|NCT02447887|DRUG|Pegylated IFN-alpha 2b|Weekly injection
223922194|NCT06712329|OTHER|extracorporeal shock wave therapy|ESWT (Inceler Medical, Modus Focused ESWT, Turkey) was conducted by a single investigator in accordance with a standardised protocol. The patients were positioned prone on the examination table, with the affected limb placed in a supported position. The focused shockwave was applied in a circular motion along the insertion site of the plantar fascia and over the plantar fascia itself. The participants received 1,800 to 2,000 focused shock waves (0.15-0.25 mJ/mm² session with a frequency of 3-4 Hz). The frequency of the pulses was increased in a gradual manner, in accordance with the maximum tolerable degree of pain for each patient. A minimum dose of 1,000 mJ/mm² was administered. The ESWT was conducted in three sessions, with a two-week interval between each session.
223531005|NCT07158866|BEHAVIORAL|Multicomponent Exercise|"The Multicomponent Exercise intervention will target several physical fitness components simultaneously, including strength, balance, and aerobic fitness. The program will consist of twice-weekly sessions, each lasting 45 minutes, for 6 months. Each session will include:~1. Warm-up with light stretching and joint mobility exercises.~2. Balance exercises~3. Strength training exercises~4. Aerobic exercises~5. Cool down with flexibility and relaxation exercises."
223531006|NCT07160777|DEVICE|cross-linked hyaluronic acid|Semical Dermal Filler Fine Semical Dermal Filler Plus Semical Dermal Filler Ultra
223922195|NCT06712329|OTHER|Prolotherapy|The solution employed for dextrose prolotherapy comprised 1.5 ml of 30% dextrose and 1.5 ml of 0.9% isotonic sodium chloride solution, resulting in a total of 3 ml of 15% dextrose solution. . All procedures were conducted by the same investigator. A dextrose solution was infused into the centre and around the damaged area using a peppering technique. Following the procedure, patients were advised to remain in a supine position with their feet restrained for a period of 15 minutes.. Prolotherapy was repeated on three occasions, with each session occurring at a two-week interval
223922196|NCT06707610|DRUG|ALK202|Administered intravenously, once every 3 weeks
224091270|NCT04917783|BEHAVIORAL|No Passport card|After receiving neurocognitive testing and verbal feedback from the psychologist, approximately 7 - 14 weeks after testing, caregivers will complete a brief questionnaire in person during their follow-up clinic visit or via phone if necessary. The person completing the parent/caregiver/guardian report must have been present for the evaluation and feedback session and must be the parent/caregiver/guardian who received the feedback and evaluation report, but not the passport card.
224091271|NCT01725139|DRUG|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
224091272|NCT01725139|DRUG|Placebo|Matching placebo will be available
224091273|NCT03463330|BEHAVIORAL|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
224091274|NCT03463330|BEHAVIORAL|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
224091275|NCT05928741|BEHAVIORAL|Orange juice with vitamin D3, n-3 fatty acids, and probiotics as preload|Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast consisting of 2 slices of white bread and honey (350 kcal in total) after a 12-hour fast. Two hours later they were offered 347 mL of the enriched orange juice (containing 50 g available carbohydrates), and 3 hours after the preload they were offered an ad libitum lunch (chicken breast with white rice). Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. Fingertip capillary blood glucose samples and visual analog scales (VAS) of 100 mm were collected at baseline and at 60, 120, 135, 150, 180, 210, 240, 270, 300, 330, 360, 390, and 420 minutes after breakfast consumption. Blood pressure was measured at baseline, 120, 300, and 420 minutes.
224091276|NCT03322800|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
224091277|NCT03322800|OTHER|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
224091278|NCT03572088|DRUG|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
224091279|NCT03572088|DRUG|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
223922197|NCT06707220|OTHER|Heart failure medication|Treated with optimal guideline-directed medical therapy
223922198|NCT06709131|DRUG|CAR-T cells（ chimeric antigen receptor T cells）|CAR-T cells（ chimeric antigen receptor T cells）
224091280|NCT00961532|DRUG|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
224091281|NCT00337389|DRUG|5- Fluorouracil (5-FU)|
224091282|NCT00337389|DRUG|bevacizumab (Avastin)|
223531007|NCT07160777|DEVICE|Mesolifter|Stabilized hyaluronic acid with NONASEM Technology. Application with Multi-Aesthetic Point Technique (MAPs)
223531008|NCT07158684|OTHER|Semi-structured interview|A qualitative semi-structured interview of the patient's anxiety before and one month after surgery.
223531009|NCT07159815|OTHER|Digital follow-up|See the arm/group description.
223531010|NCT07159815|OTHER|On-site follow-up|See the arm/group description.
223531011|NCT07159815|BEHAVIORAL|Resistance exercise|See the arm/group description.
223531012|NCT07158918|DRUG|ABL103|IV infusion
223531013|NCT07158918|DRUG|KEYTRUDA® (pembrolizumab)|IV infusion
223922199|NCT06708286|BIOLOGICAL|Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp))|1 dose of Tdcp vaccine (0.5ml) on day 0
224091283|NCT00337389|DRUG|Leucovorin|
223531014|NCT07158918|DRUG|Taxane|IV infusion
224091284|NCT00337389|DRUG|CoFactor (ANX-510)|
224091285|NCT01649492|DIETARY_SUPPLEMENT|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
224091286|NCT05446948|DEVICE|beveled 27G+ vitrectomy system|The device is a novel 27G+ vitrectomy system, whose probe tip is beveled.
224091287|NCT05446948|DEVICE|standard 25G+ vitrectomy system|The device is a traditional instrument, and its probe tip is flat.
224091288|NCT05047523|DRUG|ALXN1840|Administered as an oral tablet.
224091289|NCT05047523|DRUG|Standard of Care|Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
223922200|NCT06708286|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (PPV23)|1 dose of PPV23 vaccine (0.5ml) on day 0
224091290|NCT03414879|DRUG|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
223531015|NCT07160582|BEHAVIORAL|Novel CogXergaming Training|In each session, participants will play 6 games in the same order (Fruit catch, Math, Tracking, Candy match, Letter Number Sequencing - LNS, Stroop), each of which contains 10-20 trials and will last for around 10 minutes (total = 60 minutes. The CXT program employs a progressive method to ensure the intensity of CXT remains challenging without overload. If a participant demonstrates ≥80% accuracy in 3 continuous trials for one game, then the exercises for this game will be progressed to the next level (levels: 1-9 in Table 3). Each session of CXT will last approximately 1 hour. At least one day of rest will be required between weekly training sessions.
224091291|NCT03414879|DRUG|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
224091292|NCT06096519|BEHAVIORAL|Information, motivation, behavioral skills treatment arm|Our intervention will be an updated version of (Guy2Guy) G2G, a 2014 text messaging-based healthy sexuality and HIV prevention program specifically for adolescent males. The treatment arm of G2G was guided by the Information-Motivation-Behavioral Skills (IMB) model and proved to be efficacious at increasing HIV testing in 13-18 year old adolescent males. In this updated version we will continue to utilize the IMB model, but modernize the content to include updated HIV prevention information (e.g., novel methods of HIV testing, PrEP, PEP) and tailor the text-message content to meet the needs of all adolescents.
223531016|NCT07160582|BEHAVIORAL|Exercise and Education Training Program|EEP consists of a conventional exercise program and fall-prevention education. The conventional exercise program comprises 50 minutes of supervised exercises for stretching and strengthening. A fall-prevention education program will also be provided to Group B, for about 10 minutes after each session of the exercise program. Each session of EEP will last approximately 1 hour. At least one day of rest will be required between weekly training sessions.
223922201|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
223922202|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
223922203|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
223922204|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
223922205|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
223922206|NCT06708286|BIOLOGICAL|PPV23|1 dose of PPV23 vaccine (0.5ml) on day 0
223922207|NCT06708286|BIOLOGICAL|Tdcp|1 dose of Tdcp vaccine (0.5ml) on day 0
224091293|NCT06096519|BEHAVIORAL|Information only control arm|This information only control arm will consist of content and text messages focused on health behavior information, including mood, sexual health, substance use, and other health behaviors. It will be identical in length to the intervention arm.
224091294|NCT01804855|BEHAVIORAL|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
224091295|NCT01804855|DEVICE|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
224091296|NCT00811629|OTHER|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
224091297|NCT04363216|DRUG|Ascorbic Acid|Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
224091298|NCT03607344|PROCEDURE|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
224091299|NCT06435507|DRUG|IM-250 (50 mg)|Single dose
224091300|NCT06435507|DRUG|IM-250 (100 mg)|Single dose
224091301|NCT06435507|DRUG|IM-250 (200 mg)|Single dose
224091302|NCT06435507|DRUG|IM-250 (400 mg)|Single dose
224091303|NCT02923271|DEVICE|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
224091304|NCT03047538|DRUG|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
224091305|NCT01014715|OTHER|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
224091306|NCT01434225|DRUG|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
224091307|NCT02708823|OTHER|CogCheck application|The application is administered once to all study participants.
223922208|NCT06708286|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine (DTaP)|1 dose of DTaP vaccine (0.5ml) on day 0
223922209|NCT06710834|DEVICE|Hemoadsorption cartridge|HA 130 cartridge
224091308|NCT02528344|BEHAVIORAL|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
224091309|NCT00489762|PROCEDURE|Installation of an energy efficient heater|
223922210|NCT06710834|DEVICE|Hemodiafiltration|Postdilutional hemodiafiltration
223922211|NCT06708559|OTHER|Breast-fed infants|Immune system characterization via blood and stool samples collection
224091310|NCT04918121|DRUG|Yutiq 0.18 MG Drug Implant|a sustained-release steroid insert (Yutiq)
224091311|NCT01495819|DRUG|Saline|5cc's of saline give at least once.
224091312|NCT01495819|DRUG|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
224091313|NCT03946176|DIETARY_SUPPLEMENT|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
224091314|NCT03946176|DIETARY_SUPPLEMENT|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
224091315|NCT03946176|DEVICE|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
223531017|NCT07158957|OTHER|knowledge|"-knowledge on pain in general and specifically pelvic girdle pain Pregnant women who in addition to usual care get our model WOMENinMOTION on a digital platform with self-directed content areas modules and linked tasks to promote physical activity and function by reducing concerns, pain, and building confidence for physical activity and realistic expectations.~When women consider the digital platform insufficient, they are referred to physiotherapy at clinic for physiotherapeutically individually coached content of WIM"
223531018|NCT07158957|BEHAVIORAL|motivation for behavioral change|motivation to be physically active
223531019|NCT07159932|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug education to the patient before discharge, as well as written drug information
223531020|NCT07159802|PROCEDURE|Papillary reconstruction|"This study will be conducted to compare the effectiveness of three papillary reconstruction techniques: modified Beagle's technique, injection of albumin PRF, and injection of Hyaluronic Acid filler.~Primary outcome: volumetric assessment of papilla regeneration. Secondary outcome: improvement of pink esthetic score."
223531021|NCT07160595|OTHER|Early management of postoperative pain at 3 months detected using sms|During this period, patients with persistent post-operative pain, identified through SMS screening, will receive early treatment starting at 3 months.
223531022|NCT07159906|DRUG|Homoharringtonine|A cephalotaxine alkaloid and protein synthesis inhibitor that downregulates Myeloid Cell Leukemia 1 (MCL-1), administered intravenously in 21-day cycles. Dose escalation in Phase Ib will determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase II dose (RP2D).
223922212|NCT06710028|DEVICE|NORA|NORA app will be downloaded on the patient's mobile device, tablet or computer for clinical monitoring after discharge from the hospital at 3, 6 and 12 months after stroke. At the time of discharge, the patient will be provided with all the information and training necessary for its use. This application has been clinically validated in stroke patients, demonstrating to improve communication between professionals and patients. It improves the adherence of patients to prescribed therapy and their control of cardiovascular risk factors, with the the goal of preventing new episodes. Stroke patients have actively participated in the development of NORA, its use is simple and intuitive, and there are no age restrictions for its use. Through NORA patients will receive questionnaires to evaluate their clinical outcomes after stroke (Patient Reported Outcome Measures- PROMs and Patient Reported Experience Measures- PREMs).
223922213|NCT06707662|DEVICE|Pacemaker and defibrillator|Pacemaker implantation, which can be a regular right ventricle apical lead or a LBBAP lead (LBBP or LVSP dependint on the criteria accomplished).
223922214|NCT06707636|BEHAVIORAL|Experimental: Black Women's Stress and Wellness (B-SWELL) arm|The B-SWELL arm consists of 8-weekly sessions. Sessions last 90 minutes and focus on stress reduction, heart disease, and healthy lifestyle changes. The American Heart Association's Life's Essential 8 metrics are leveraged and culturally tailored in the B-SWELL materials. Participants will also receive personalized health coaching.
223922215|NCT06707636|BEHAVIORAL|Active Comparator: Wellness (WE) arm|This is an attention control group. Participants placed in his arm will receive 8-weekly sessions focused on the Life's Essential 8 metrics.
223922216|NCT06707233|PROCEDURE|SIRT|The patients will receive 1-2 sessions of SIRT.
223922217|NCT06707987|DRUG|Non-immunogenic staphylokinase|Drug: non-immunogenic staphylokinase 10 mg as a single intravenous bolus Other Names: Fortelyzin®
223922218|NCT05172180|DRUG|Reamberin|the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
223922219|NCT05172180|DRUG|Ringer's solution|Ringer's solution at an average daily dose of 8.1 ml/kg/day
224091316|NCT06136858|DEVICE|Cuirass ventilation|We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
224279818|NCT05746130|BEHAVIORAL|Plastic-free diet program|"Applying the plastic-free diet as four meals (three main meals, one snack) in pension kitchen. Promoting of glass water bottle giving and daily use.~Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample."
223531023|NCT07159906|DRUG|BCL-2 inhibitor|An oral selective BCL2 inhibitor administered once daily D1-7. Combined with homoharringtonine, rituximab, and prednisone in 21-day cycles.
223531024|NCT07159906|DRUG|CD20 Antibody|An anti-CD20 monoclonal antibody administered intravenously, used in combination with chemotherapy or targeted regimens for B-cell malignancies.
223531025|NCT07159906|DRUG|Glucocorticoid (GC)|glucocorticoid , given as part of the combination regimen to enhance anti-lymphoma effect.
223531026|NCT07158658|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT (HCT/P 361) is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.
223531027|NCT07160088|OTHER|Observational|This is an observational study without study-related intervention. All the treatments will be depended on the attending doctors and according to the related guidelines.
223531028|NCT06414668|BEHAVIORAL|Cycling Intervention Group|A eight-weeks school-based cycling program. The school-based cycling intervention consists of 2 Bikeability sessions of 60 min at Physical Education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training. In addition, participants will receive encouragement strategies, one for each week of the intervention, for cycling to and from school during eight weeks.
223531029|NCT02203643|DRUG|Carfilzomib|
223531030|NCT02203643|DRUG|Cyclophosphamide|
223531031|NCT02203643|DRUG|Lenalidomide|
223531032|NCT02203643|DRUG|Dexamethasone|
223531033|NCT05341310|BEHAVIORAL|ADHDCoach|ADHDCoach is an individually-tailored intervention to reduce parents' of children diagnosed with ADHD distress.
224091317|NCT04246554|DRUG|Ketorolac|Oral ketorolac for pain control following ACL reconstruction surgery
224091318|NCT04246554|DRUG|Oxycodone-Acetaminophen|Oral oxycodone-acetaminophen for post-operative pain control
224279819|NCT05746130|BEHAVIORAL|Plastic-free diet education program|"Interactive education program: Slogan competition, school board preparation, short film shooting, school canteen visits and plastic-free nutrition day event with the adolescents for four weeks by the researcher.~Peer education will doing by Adolescents with Packaged Product Low Usage Feedback about BPA levels in theirs urinary sample"
224091319|NCT03898570|BEHAVIORAL|Patient reported outcomes|"Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys"
224091320|NCT06066879|DRUG|Ketamine Hydrochloride|Pre-Operative Ketamine infusion
224091321|NCT06793670|DRUG|Landiolol|Intravenous infusion of landiolol
224091322|NCT06793670|DRUG|Placebo|Intravenous infusion of saline solution of NaCl 0.9%
224091323|NCT06106698|OTHER|WMT|Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive one dose of WMT for CDI. During follow-up, those who have non-response or CDI recurrence within 4-week post-WMT will receive rescue WMT.
224091324|NCT03947294|DEVICE|Q-NRG®|Energy expenditure measurements
224279820|NCT05746130|BEHAVIORAL|BPA exposure feedback|Feedback about BPA levels in theirs urinary sample
223531034|NCT05341310|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
223531035|NCT05046626|OTHER|Nutritional counseling|Intervention based on nutritional counseling under Cognitive Behavioral Theory and the used of strategies like self-monitoring, goals, cognitive restructuring and social support.
223531036|NCT06633536|DRUG|Ravulizumab|open-label arm with ravulizumab administrated within the scope of routine clinical practice
223922220|NCT06353269|DRUG|Estring Vaginal Product|estradiol vaginal ring, exchanged every 12 weeks
223922221|NCT06353269|DRUG|Vagifem|vaginal estrogen tablet, used twice per week
223922222|NCT06353269|DRUG|Estrace 0.01% Vaginal Cream|vaginal estrogen cream, used twice per week
223922223|NCT06712121|DRUG|decitabine plus venetoclax|decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days
223922224|NCT06717269|DRUG|NX-5948 capsule|NX-5948 in capsule form
223922225|NCT06717269|DRUG|NX-5948 tablet|NX-5948 in tablet form
223922226|NCT06717269|DRUG|Esomeprazole|Esomeprazole capsule, once daily
223922227|NCT06715904|OTHER|Womens with Morton´s Extension|Morton extension application
224091325|NCT04163198|DEVICE|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
224091326|NCT04163198|DEVICE|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
224279821|NCT06467201|DRUG|KSHN001126 150mg|6 subjects will receive single oral dose of 150mg
223922228|NCT06713304|BEHAVIORAL|A community-based Protective Behavioral Strategies program|"A 5-week group program delivered in a healthcare setting to teach and practice protective behavioral strategies. The objectives of each session are:~Session 1: Setting Safe Drinking Limit: The participants can identify the risk related to their drinking behavior, calculate a standard drink, and set a safe drinking limit.~Session 2: Choosing Nonalcoholic Drinks: The participants can understand the benefits of using nonalcoholic beverages and identify and select nonalcoholic beverages.~Session 3: Planning Ahead: The participants can make a plan to stop using during drinking events and know how to say no to alcohol use.~Session 4: Slowing down drinking: The participants can understand the benefits of slowing down drinking and know how to slow down their drinks.~Session 5: Avoid Risky Drinking Situations: The participants can understand the negative effects of excessive drinking and know how to avoid excessive drinking."
223922229|NCT06713408|OTHER|Experimental (Music)|Audio recordings consisting of pentatonic music and neva makam will be uploaded to the patients' phones by the researcher. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
223922230|NCT06713408|OTHER|Experimental (Affirmation)|Patients in this group will be asked to listen to the audio recording with pentatonic music and neva makam in the background, along with the affirmation sentences provided in the appendix. Patients will be advised to listen to these music during the period they receive chemotherapy, and they will also be asked to listen to these music in at least 15-20 minute sessions per day and for at least 3 days during the week following chemotherapy.
224091327|NCT02272192|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is a comprehensive developmental and behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures based in applied behavioral analysis to deliver this content. The teaching format focuses on trained therapists delivering the intervention 1:1 by engaging reciprocally with children in typical toddler activities involving play or daily routines, adding additional structure for children who need it to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches.
224279822|NCT06467201|DRUG|KSHN001126 300mg|6 subjects will receive single oral dose of 300mg
224279823|NCT06467201|DRUG|KSHN001126 600mg|6 subjects will receive single oral dose of 600mg
224279824|NCT02561234|DRUG|Co-ArgI-PEG|Administered IV
224279825|NCT00571194|DRUG|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
224279826|NCT00752674|OTHER|Neuromuscular balance|
224279827|NCT01174355|DRUG|ND0801|Confidential
224279828|NCT05695755|DIAGNOSTIC_TEST|ECHO, Serum electrolytes|echocardiography, serum electrolytes and cortisol level for all patients
224279829|NCT01323452|DRUG|Entecavir|once daily
224279830|NCT06260579|BEHAVIORAL|Exercise/physical activity|personalized exercise training and physical activity program
224279831|NCT03477955|PROCEDURE|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
223922231|NCT06713577|DEVICE|CEREC Cercon 4D|"One investigational medical device is a new generation of a full contour zirconia restorative material (CEREC Cercon 4D/Dentsply Sirona) for chairside computer assisted design/computer assisted machines (CAD/CAM) restorations. It has an internal core of 4 mol% (4Y) zirconia transitioning to an external layer of 4/5 mol% (4/5 Y) zirconia with a three-dimensional gradient of shade from an inner chromatic layer to an external translucent layer that replicates the natural structure and appearance of a tooth. It is indicated for crowns, bridges, veneers, inlays and onlays and implant crowns Clinical Study of a 3D Shaded Zirconia for Chairside CAD/CAM Restorations The other investigational medical devices are a universal bonding agent (Prime and Bond Active/Dentsply Sirona) and dual-cure, self-adhesive resin cement (Calibra Universal~+/Dentsply Sirona). They are used in combination to deliver ceramic and zirconia restorations."
223922232|NCT06713707|OTHER|Manuel dexterity|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using 9-HPT, and JTHFT.
223922233|NCT06713707|OTHER|Manual Dexterity (only MMDT)|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
223922234|NCT06713005|PROCEDURE|suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve|suprascapular nerve pulsed rf
223922235|NCT06713005|PROCEDURE|suprascapular nerve block and 9 mins Pulsed radiofreuency application to suprascapular nerve|suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
223922236|NCT06698835|DIETARY_SUPPLEMENT|Turnip Consumption|Turnip Consumption and Qigong Exercise with educational Program about loss of weight
223922237|NCT05379855|DRUG|0.01% atropine eye drops|using 0.01% atropine eye drops for both eyes every night
224091328|NCT02272192|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|EIBI is a one-to-one instructional approach based in applied behavior analysis used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Trial by trial data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
224091329|NCT02315521|PROCEDURE|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
224279832|NCT02786719|DRUG|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
224279833|NCT02786719|DRUG|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
224279834|NCT02786719|DRUG|Cisplatin|Cycle 3+5 (given daily x 4 days)
224279835|NCT02786719|DRUG|Etoposide|Cycle 3+5 (given daily for 3 days)
224279836|NCT02786719|DRUG|Vincristine|Cycle 4+6 (given daily for 3 days)
224279837|NCT02786719|DRUG|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
224279838|NCT02786719|DRUG|Doxorubicin|Cycle 4+6 (given daily for 3 days)
224279839|NCT02786719|DRUG|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
224279840|NCT06617767|OTHER|Reiki|The Reiki group received distant Reiki application to their energy centers for 20 minutes, once a day, for 4 consecutive days, by researchers with Reiki Stage II training under the guidance of a researcher with the Usui Reiki Master \& Teacher degree.
224279841|NCT04228978|BEHAVIORAL|Weight loss|Walking exercise combined with weight loss
224279842|NCT04228978|BEHAVIORAL|Exercise|Walking exercise
224279843|NCT00705315|DRUG|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
224279844|NCT00705315|DRUG|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
224279845|NCT00705315|DRUG|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
224279846|NCT04830982|DRUG|IV Diazoxide|500 micromoles added to one liter of cardioplegia
223531037|NCT05456828|BIOLOGICAL|ASKG712|ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
224091330|NCT02240134|BEHAVIORAL|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
224279847|NCT04830982|OTHER|Placebo|Placebo added to one liter of cardioplegia
224279848|NCT00130234|DRUG|Xolair® (Omalizumab)|
224279849|NCT02656316|DEVICE|Active tDCS|In this group subjects will receive 20 min of treatment.
224279850|NCT02656316|DEVICE|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
224279851|NCT01114997|DRUG|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
224279852|NCT01114997|DRUG|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
224279853|NCT01114997|DRUG|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
224279854|NCT00472953|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
224279855|NCT00472953|DRUG|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
224279856|NCT03034161|DEVICE|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
223922238|NCT05379855|DRUG|placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)|using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
223922239|NCT05379855|DRUG|0.05% atropine eye drops|using 0.05% atropine eye drops for both eyes every night
223922240|NCT05129501|BEHAVIORAL|Experimental|The Tiwahe Wicagwicayapi seven-session program is for children ages 10 to 14 who are Native American and/or living in poverty and their caregivers. The program begins with a traditional Lakota meal followed by family time and break-out time for caregivers only and children only. The program includes skill-building activities as well as the integration of Lakota language, history, and culture. The program is facilitated by diverse individuals, predominantly Native Americans in Rapid City and surrounding tribal communities.
223922241|NCT05656586|OTHER|observational-- no intervention|observational
223922242|NCT01543659|DRUG|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
223922243|NCT06885944|DIETARY_SUPPLEMENT|Probiotic mix preparation|Bifidobacterium containing supplement with vitamin D will start after preterm infants reaches full enteral feeding
223922244|NCT06885944|DIETARY_SUPPLEMENT|Bifidobacteria|Rather than early period we will start probiotics after infant receive full enteral feedings
223922245|NCT06887699|OTHER|AI-ECG P4P program|The AI-ECG system will conduct a real-time analysis of the ECG. When the system identifies potential OMI cases, it will immediately send short message service notifications to the on-duty cardiologists. This will enable the cardiologists to promptly review and confirm the diagnosis.
223922246|NCT04000763|DEVICE|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
223922247|NCT06887374|DRUG|Probiotic Bacillus Clausii|Patients were given 2 billion spores of probiotic (Bacillus clausii) every12 hours, contained in a small bottle.
223922248|NCT06709495|DRUG|PEEL-224|Topoisomerase 1 inhibitor, 200mg amber vial, via intravenous (into the vein) infusion per protocol.
223922249|NCT06709495|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsule, taken orally per standard of care.
223922250|NCT06709495|DRUG|Vincristine|Vinca alkaloid, 1 or 2mL vials, via intravenous (into the vein) infusion per institutional policy.
223922251|NCT06709495|BIOLOGICAL|Pegfilgrastim|Myeloid growth factor administered per institutional standards.
223922252|NCT06709495|BIOLOGICAL|Filgrastim|Myeloid growth factor administered per institutional standards.
223922253|NCT06713421|DRUG|Dimethicone+Pronase|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.
223922254|NCT06713421|DRUG|Dimethicone|Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.
223922255|NCT06713421|BEHAVIORAL|with Postural Exercise|After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.
223922256|NCT06713421|BEHAVIORAL|without Postural Exercise.|After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
223922257|NCT06697223|DEVICE|INTERCEPT Blood System for Platelets with LED Illuminator|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) using the LED Illuminator and stored for 5 days at 20 to 24°C with continuous agitation.
224091331|NCT02240134|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
224091332|NCT02240134|DEVICE|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
224091333|NCT05756192|OTHER|Educational video|Intervention is a 10-minute animated video that explains cervical cancer screening and prevention.
224091334|NCT03871907|BEHAVIORAL|Digital technology|Lifestyle-Focused Text Messaging
224091335|NCT05666089|DRUG|N-acetyl cysteine|intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
224091336|NCT05666089|DRUG|Calcium hydroxide|intracanal medication of calcium hydroxide paste (metapaste)
224091337|NCT01517880|DRUG|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
223922258|NCT06713148|BIOLOGICAL|IDOV-SAFETM|Each patient received intratumoral injection on the first day, 14 days as a course of treatment, and the follow-up investigator decided whether to continue the second (D14) and third (D28) course of administration according to the comprehensive evaluation of the subjects' conditions
223922259|NCT05016895|DRUG|Single-dose azithromycin|Bi-annual mass, community-based distribution of single-dose azithromycin to children ages 1 to 11 months.
223922260|NCT06728228|OTHER|Amnioinfusion|A 20- or 22-gauge spinal needle (routinely used obstetrics and gynecology needle) will be used by an expert in fetal procedures with sterile technique to access the amniotic cavity under real-time ultrasound guidance to infuse isotonic fluid (Lactated Ringers with 1g/L of Oxacillin). This fluid will act as replacement amniotic fluid. Regular monitoring of fluid levels may suggest serial infusion, which will be completed as deemed necessary by the study doctor.
223922261|NCT06729021|DEVICE|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
223922262|NCT06729021|DRUG|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
223922263|NCT05416697|DRUG|CBD oil|The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.
223922264|NCT05416697|DRUG|Placebo|The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
223922265|NCT06727812|DRUG|HRS-6208|HRS-6208.
223922266|NCT06728020|OTHER|Active Comparator: Conventional rehabilitation (Group A)|The conventional group will undergo standard rehabilitation treatment according to the rehabilitation plan developed by the rehabilitation team. This group will undergo 3 hours of rehabilitation per day and will carry out face-to-face rehabilitation following an impairment-based approach aimed at the treatment of motor-cognitive functions.
223922267|NCT06728020|DEVICE|ROOMMATE 1st|In addition to Group A, this group will have the bedside multimedia monitor apparatus to access informative, rehabilitation, and entertainment content. Additionally, this group will have a digital and innovation coach to receive support in using the technology.
223922268|NCT06728020|DEVICE|ROOMMATE 2nd|Once the first RCT of the cmRCT is completed, a pilot RCT will be initiated, randomizing 60 cases between Group A and this group. In addition to conventional treatment, this group will have a version of the ROOMMATE system integrated with inertial sensors worn on the hands and fingers to guide the serious games on the platform.
223922269|NCT06727513|PROCEDURE|A single-operator technique for GlideScope intubation.|A single-operator technique where the senior resident will insert the GlideScope and perform the endotracheal intubation using an angulated stylet.
224091338|NCT01517880|DRUG|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
224091339|NCT00206726|DRUG|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
224279857|NCT01560819|DRUG|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
224279858|NCT06307041|DEVICE|Dental floss+Gengigel|0.2% Hyaluronic Acid Gel-Impregnated Dental Flosses
224279859|NCT06307041|DEVICE|Dental Floss|Dental Flosses
223922270|NCT06727513|PROCEDURE|A double-operator technique for GlideScope intubation|A double-operator technique where the senior resident will insert the GlideScope until visualizing an optimal glottic view, then the attending physician will take over the GlideScope keeping it in the same fixed position, while the resident performs the endotracheal intubation using an angulated stylet.
223922271|NCT06879119|PROCEDURE|Localized scalp thread embedding|Volunteers who met the inclusion criteria were enrolled in the trial. All participants underwent treatment intervention in the vertex alopecic area via vertex alopecic area scalp thread embedding. A single thread embedding session was performed upon enrollment, with monthly follow-ups conducted over a total period of 6 months. Operative procedure: After fully exposing and disinfecting the treatment area, threads were inserted into the scalp at an approximately 15-degree oblique angle, with needle tips reaching the subgaleal space at a depth of 2-4 mm. Threads were spaced 1 cm apart. Upon completion, the treated area was disinfected and applied with erythromycin ointment.
223922272|NCT06882239|OTHER|SPINEPASS Physical Therapy|SPINEPASS consists of a core set of three daily exercises integrated into daily activities to improve/restore overall spinal and dural mobility and or stability. It also provides training in the use of specific tools to be used as needed to address symptoms as they occur. Treatment can also include spinal manual therapy and other exercises to enhance the tools, but the emphasis is on self-management.
223922273|NCT06882239|OTHER|Standard Physical Therapy|The cervical therapy for standard Physical Therapy will be based on impairments found but could include cervical and or thoracic manual therapy, exercises to improve segmental range of motion, exercises for cervical and axioscapular neuromotor retraining, and specific cervical related sensorimotor control exercises such as proprioceptive retraining. A home program of exercises tailored for the individual will be provided.
223922274|NCT06882616|OTHER|surgery|All patients will be perform laparoscopic sleeve gastrectomy. Carotid intima-media thickness will be analyzed preoperatively and at the end of the first postoperative year.
223922275|NCT06884839|PROCEDURE|Therapeutic resection|Patients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival.
224091340|NCT00459030|OTHER|educational intervention via internet|additional cancer screening information via password protected internet site
224279860|NCT00864799|DRUG|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
224279861|NCT05538637|DIAGNOSTIC_TEST|Echocardiography|"Mitral velocity time-integral variability measurement before and after passive leg raising.~Mitral velocity time-integral variability measurement after fluid loading in preload-responsiveness patients."
223717378|NCT07014605|BEHAVIORAL|Smartphone-delivered Automated Messaging|The MAP includes text messages, images, and videos with content designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The MAP will begin immediately after enrollment and continue for a 26-week period. The MAP approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
224279862|NCT02674633|DEVICE|AKL-T01|Videogame-like digital therapy
224279863|NCT02674633|DEVICE|AKL-T09|Videogame-like digital therapy
223717379|NCT03481036|DRUG|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
223717380|NCT03481036|DRUG|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
223717381|NCT03481036|DRUG|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
223717382|NCT02342327|OTHER|switch to non-menthol cigarettes prior to cessation attempt|
223717383|NCT02342327|OTHER|continue smoking menthol cigarettes prior to cessation attempt|
223717384|NCT00758212|BIOLOGICAL|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
223717385|NCT05433792|DEVICE|Myolens CN (Central-Near) soft contact lens|Personal fitting of the Myolens-CN/CF.
223717386|NCT05433792|DEVICE|MiSight® soft contact lens|Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
223922276|NCT06883721|BEHAVIORAL|Pilates|Participants in this group performed Pilates exercises twice a week for 8 weeks. The exercises included mat and equipment-based exercises, focusing on core stabilization, breathing control, and postural alignment. Exercise difficulty was progressively increased throughout the intervention period.
223922277|NCT06883721|BEHAVIORAL|Cervical stabilization exercise|Participants in this group performed cervical stabilization exercises at home twice daily for 8 weeks. The exercises included chin tucks, cervical extensions, shoulder elevations, and scapular retractions.
223922278|NCT06886113|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs
223922279|NCT06886113|DEVICE|CorVad|Control group treated with Impella CP for a minimum of 48 hrs
223922280|NCT06879808|OTHER|Color therapy|In the experimental group, color therapy was applied 3 days a week for the first two weeks, while no intervention was performed in the third and fourth weeks. In the fifth and seventh weeks, color therapy was applied for 15 minutes each day, while no intervention was performed in the sixth week.
223922281|NCT06889610|DEVICE|MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer|MTT combined with Pucotenlimab, Sacituzumab Govitecan, Eribulin, and Gemcitabine
223922282|NCT06889610|DEVICE|MTT(Multimodal Tumor Thermal Therapy System)- Melanoma|MTT combined with Pucotenlimab, with other specific drugs determined based on first-line treatment regimen and classification.
223922283|NCT06890104|OTHER|Mouthrinse with Coconut oil pulling|Using mouth rinse with coconut oil for two weeks to treat halitosis
224279864|NCT03417609|DEVICE|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
224279865|NCT03417609|PROCEDURE|Blood sampling|Blood sampling
224279866|NCT03417609|DIAGNOSTIC_TEST|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
224279867|NCT03417609|DIAGNOSTIC_TEST|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
224279868|NCT03417609|DIAGNOSTIC_TEST|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
224279869|NCT03417609|DEVICE|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
224279870|NCT03417609|DIAGNOSTIC_TEST|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
224279871|NCT02625506|DRUG|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
224279872|NCT02625506|DRUG|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
224279873|NCT00460109|BIOLOGICAL|denileukin diftitox|
224279874|NCT00460109|BIOLOGICAL|rituximab|
224279875|NCT05141630|PROCEDURE|sentinel lymph node biopsy or targeted axillary dissection alone|sentinel lymph node biopsy or targeted axillary dissection alone
224279876|NCT03071913|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
224279877|NCT03071913|OTHER|Laboratory Biomarker Analysis|Correlative studies
223717387|NCT03182088|DRUG|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
223717388|NCT03182088|DRUG|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
223922284|NCT06890104|OTHER|Mouthrinse with Chlorhexidine 0.12%|Using mouthrinse with 0.12% chlorhexidine for two weeks to treat halitosis
223922285|NCT06888661|BIOLOGICAL|EXG001-307 injection|non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
224279878|NCT02344745|OTHER|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
223922286|NCT06873321|DRUG|rivaroxaban 2.5 mg bid + aspirin 100 mg|rivaroxaban 2.5 mg bid + aspirin
223922287|NCT06873321|DRUG|clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures|comparator
223922288|NCT06716203|DRUG|Drug: 5 mg BGM0504 Administered SC|Drug: BGM0504 Administered SC
223922289|NCT06716203|DRUG|Drug: : 10 mg BGM0504 Administered SC|Drug: BGM0504 Administered SC
223922290|NCT06716203|DRUG|Drug: Placebo Administered SC|Drug: Placebo Administered SC
223922291|NCT06730360|PROCEDURE|MTA Pulpotomy without photobiomodulation|This intervention involves the application of Mineral Trioxide Aggregate (MTA) to the pulp chamber after the removal of the coronal pulp tissue in first permanent molars with irreversible pulpitis. The procedure is performed without the use of photobiomodulation (low-level laser therapy). The MTA is placed as a seal to preserve the vitality of the remaining radicular pulp.
223922292|NCT06730360|PROCEDURE|MTA Pulpotomy with Photobiomodulation (LLLT)|This intervention combines MTA pulpotomy with photobiomodulation (low-level laser therapy). After performing the MTA pulpotomy, low-level laser therapy is applied to the pulp stumps to reduce inflammation, promote healing, and modulate pain. The laser therapy uses specific wavelengths of light to stimulate cellular activity and enhance the regeneration of pulp tissue.
223922293|NCT06889649|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|Radiation dose of 6-10 Gy per fraction, administered in 5 fractions for peripheral lesions. For lesions near organs at risk, partial-SABR will be used. If neither SABR nor partial-SABR is feasible, moderate hypofractionated radiotherapy (MHFRT) with curative doses will be applied.
223922294|NCT06889649|DRUG|TORIPALIMAB INJECTION(JS001 )|"Toripalimab (intravenous infusion):~Dosage: 240 mg intravenously every 3 weeks. Frequency: Administered every 3 weeks for the duration of the study, until progression or unacceptable toxicity occurs or reach 2 years."
224091341|NCT00459030|OTHER|educational intervention mailed|
224091342|NCT00459030|OTHER|No additional educational intervention|
224091343|NCT06441708|OTHER|No intervention|No intervention on patient
224091344|NCT04507009|DEVICE|Ozone|topical gaseous ozone application
224091345|NCT04507009|OTHER|CGF|concentrated growth factor (CGF) application
224279879|NCT02344745|OTHER|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
224279880|NCT02788513|DRUG|BI 425809 dose 1|
224279881|NCT02788513|DRUG|BI 425809 dose 2|
223922295|NCT06889649|DRUG|Axitinib (VEGF-TKI)|"Axitinib (oral, tablet):~Dosage: 5 mg orally twice daily. Frequency: Daily, for the duration of the study, with continuation during progression or until intolerable side effects occur."
223922296|NCT06883708|BEHAVIORAL|iSupport-Malaysia Web-Based Intervention|"iSupport-Malaysia web-based intervention is a website version of the culturally adapted iSupport for Dementia into the Malaysia context (in local Malay language).~The 23 lessons is arranged under the 5 modules in the same way as the original iSupport manual. Each lesson is delivered in bite-sized knowledge, using engaging videos, interactive quizzes with feedback, and reflection exercises. Each lesson takes an average of 10-20 minutes to complete. At the end of each lesson, a completion batch is given. The lesson plan can be personalised by the caregivers themselves according to individual needs. Caregivers will also have the option to receive a course completion certificate if they completed all 23 lessons in the program. Additionally, in each lesson, participants are encouraged to post comments in response to the prompt questions, and also reply to others' comments."
224091346|NCT04507009|OTHER|Traditional treatment|Alvogyl application
224091347|NCT04790942|DRUG|berberine hydrochloride|the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
224091348|NCT04790942|BEHAVIORAL|lifestyle intervention group|The lifestyle intervention group (CON) mainly includes reducing sodium intake, healthy diet guidance, increasing exercise, quitting smoking and restricting alcohol consumption
224091349|NCT02369783|OTHER|Questionnaire and interview|The aim is to detect social fragility.
224091350|NCT05103150|DIAGNOSTIC_TEST|High-definition white light endoscopy (HD-WLE)|"Evaluation of the duodenal mucosa with HD-WLE (EG-29i10 gastroscope and EPKi7010 video processor). The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) by one endoscopist, randomly assigned via esophagogastroduodenoscopy.~There were used the following standard endoscopic findings were: a) scalloping or dented aspect of the duodenal folds; b) submucosal vascular pattern; c) mosaicism or micronodular look of the mucosa; d) grooves and fissurations of the mucosa."
224091351|NCT05103150|DIAGNOSTIC_TEST|HD-WLE plus I-Scan optical enhancement (OE) virtual chromoendoscopy with High-definition optical magnification (HD-OM)|"Evaluation of the duodenal mucosa through upper endoscopy with the OE System (EPK-i7010 HD Video Processor and MagniView™ EG-2990Zi Video Gastroscope) with intravenous sedation in a standardized manner. This technique involves using a distal black rubber hood (OE-A58; Pentax) at the tip of the endoscope, to fix the distance between the tip of the endoscope and the gastric mucosa at 2 mm. The OE System will be used in mode one and mode two without HD-OM to obtain an overview of the duodenal surface and identify any changes in the mucosa, then HD-OM will be implemented.~There were used OE criteria as previously validated by Cammarota et al: brightness, Ave/peak, blue, red, surface, contrast, and tone enhancement."
224091352|NCT06322758|OTHER|Tidal volume customization in the acute respiratory distress syndrome|During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target
224091353|NCT03006211|OTHER|Nitrogen protoxide|
224091354|NCT03006211|OTHER|Oxygen|
224091355|NCT04023084|DRUG|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
224091356|NCT04490629|DEVICE|Lyoplant Onlay|Lyoplant Onlay is a kind of latest artificial Dura Mater
224091357|NCT04490629|DEVICE|DURAFORM|DURAFORM is a kind of conventional artificial Dura Mater
224091358|NCT04255511|DEVICE|Twin Block|Functional appliance
224279882|NCT02788513|DRUG|BI 425809 dose 3|
224279883|NCT02788513|DRUG|BI 425809 dose 4|
224279884|NCT02788513|DRUG|Placebo|
223922297|NCT06883708|BEHAVIORAL|iSupport-Malaysia eBook|"iSupport-Malaysia eBook is the Malay-translated, culturally adapted version of the iSupport for Dementia manual in PDF format. This eBook is approximately 275 pages long, containing comprehensive text-based details for the 5 modules and 23 lessons. The modules and lessons are similar to the iSupport-Malaysia web-based program. The main lesson content is delivered in text-based format. Each lesson includes at least one case 1 scenario(s) presented in a quiz format. Some lessons offer additional worksheets for caregivers to reflect on their own caregiving experiences and apply the strategies learned to their caregiving journey. A completion batch is given at the end of each lesson. The lesson plan can be personalised by the caregivers themselves according to individual needs."
223922298|NCT06884683|DRUG|Metformin|"Drug: metformin tablet 500 mg, 1 tablet twice a day (total dose 1000 mg daily), administered orally continuously~\+~Biological: Nivolumab 240 mg via IV infusion every 14 days~Other Names:~Opdivo®"
223922299|NCT06889987|DRUG|Intramuscular quadratus lumborum block|Patients will receive bilateral ultrasound-guided intramuscular quadratus lumborum block with an injection of 0.4 ml/kg bupivacaine 0.25% after induction of general anesthesia
223922300|NCT06889987|DRUG|Lateral quadratus lumborum block|Patients will receive bilateral ultrasound-guided lateral quadratus lumborum with an injection of 0.4 ml/kg of bupivacaine 0.25 after induction of general anesthesia.
223922301|NCT06889987|DRUG|General anesthesia|Patients will receive only general anesthesia without any block.
223922302|NCT06885437|OTHER|Pain and sedation assessment with the N-PASS scale by each nurse|After a painful procedure, the infant's N-PASS pain and sedation scores were assessed simultaneously by three observers (two researchers and the patients' head nurses) independently and blinded.
223922303|NCT06883487|OTHER|No intervention|Observational study without intervention
223922304|NCT06887075|BIOLOGICAL|Blood sample|"* Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence~* Serum inflammatory markers : CRP, IL-6, MCP-1, TNF, sTNFR1~* Single Molecule Array for IL1 and LUMINEX for IL18 in patient's sera~* RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells~* Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry"
223922305|NCT06887075|BEHAVIORAL|Geriatric assessment standardized|"* Exhaustion (2 standardized questions)~* Physical activity \<383 kcal/week (men) or \<270 kcal/week (women), measured using a standardized questionnaire (IPAQ)~* 4-meters gait speed, with sex and height-specific cutoffs~* Handgrip strength, measured using a dynamometer, with sex and BMI-sp Comorbidity (CIRS-G score )~* Screening for intrinsic capacity decline (first step of ICOPE program, adapted to the study, )~* Physical performance (SPPB score )~* Cognitive functions (MoCA score ),~* Depression (GDS-15 score ),~* Nutrition (MNA score )~* Sensory functions (Snellen test for vision, HHIES questionnaire for hearing) -- Dependency in activities of daily living (ADL and IADL scores)"
223922306|NCT06885164|OTHER|Continuous monitroing|Continuous monitoring for 30 days with a small combined SCG and 1-lead ECG sensor
223922307|NCT06889363|DRUG|MTA|The indirect pulp capping will be applied using MTA using an MTA carrier, then glass ionomer will be applied, then composite restoration above
223922308|NCT06889363|BIOLOGICAL|PRF|The indirect pulp capping will be applied using PRF on a membrane, then glass ionomer will be applied , then composite restoration above
223922309|NCT06736873|OTHER|Light intervention|Light intervention
224091359|NCT04255511|DEVICE|Fixed orthodontic appliance|Braces
224091360|NCT01871883|PROCEDURE|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
224091361|NCT01871883|PROCEDURE|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
224091362|NCT04486560|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
224091363|NCT04847271|BEHAVIORAL|Physical activity on prescription (PAP)|The intervention in this study will comprise the 3 PAP components. Participants will take part in all components and perform one or several physical activities of their choice in accordance to the written prescription, at the prescribed frequency and duration, for a period of 4 months.
224091364|NCT01719757|DRUG|Oxycodone/Naloxone|Twice daily
224279885|NCT02067702|PROCEDURE|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
224091365|NCT02626338|DRUG|Crenolanib|
224279886|NCT04958252|DRUG|BI 1569912|BI 1569912
224279887|NCT04958252|DRUG|Placebo|Placebo
224279888|NCT02607137|BEHAVIORAL|Health Education|Information on healthy living style in relation to physical activity
224279889|NCT03250455|DIAGNOSTIC_TEST|CTA CTP|CT Angiography myocardial CT Perfusion
224279890|NCT03250455|DIAGNOSTIC_TEST|CTA|CT Angiography
224279891|NCT02555319|DEVICE|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
223922310|NCT06885489|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) based psychoeducation program|This study implements an ACT-based psychological intervention designed to enhance psychological well-being and reduce depression, anxiety, and stress among university students. The intervention consists of structured sessions focusing on psychological flexibility, mindfulness, acceptance, and value-driven actions. Participants engage in experiential exercises, cognitive defusion techniques, and behavioral commitment strategies. The intervention is delivered over 8 weeks, with weekly sessions lasting approximately 40 minutes. The sessions are conducted in groups by trained professionals.
223922311|NCT06739330|DEVICE|Fibroscan|Fibroscan will be used to assess the stages of fibrosis and steatosis using Dimensional ultrasound TE (transient elastography). Dimensional ultrasound TE (transient elastography) will be used for staging liver fibrosis and steatosis by measuring the velocity of a low frequency (50 Hz) elastic shear wave propagating through the liver.
223922312|NCT06881758|BEHAVIORAL|Exercise|The investigators will investigate the differences between high and low intensity training
223922313|NCT06738563|OTHER|Collection breast milk|Collection of a milk sample taken as part of women's donation
223922314|NCT06736236|OTHER|Inspiratory muscle warm-up|This study will use a respiratory muscle warm-up protocol set at 40% of the maximal inspiratory pressure (MIP) using the POWERbreath® device, as this intensity has been shown to optimally stimulate respiratory muscles. The protocol involves two sets of 30 breaths with a 60-second rest between sets, performed with participants sitting and using a nose clip. Participants will be trained in this technique during the familiarization session and monitored throughout the tests to ensure proper execution.
223922315|NCT06736236|OTHER|General warm-up (Control)|The general warm-up (Control) protocol will include exercises such as running and dynamic, active, and passive movements tailored to the diverse sports disciplines in the study. These movements will follow the principles of elevation, activation, and mobilization, focusing on increasing mobility from the arms and shoulders to the lower back and legs. Each session will involve demonstrations emphasizing proper technique and speed, with participants completing a consistent number of repetitions. Researchers will monitor participants closely to ensure correct form and execution throughout the intervention.
223922316|NCT06736236|OTHER|Inspiratory muscle warm-up placebo (IMW %15)|The respiratory muscle warm-up protocol will be conducted at 15% of maximal inspiratory pressure (MIP) using the POWERbreath® device. This placebo protocol will involve two sets of 30 breaths, separated by a 60-second rest, with participants seated and wearing a nose clip. Training for the technique will occur during a familiarization session, and participants will be observed during tests to ensure proper execution. The purpose of this protocol is to serve as a placebo, masking the actual aim of the study to enhance data reliability.
223922317|NCT06735274|DIAGNOSTIC_TEST|Cerebral Autoregulation (CAR)|Cerebral Autoregulation (CAR) is the mechanism capable of maintaining cerebral blood flow constant despite fluctuations in blood pressure. The evaluation of dynamic CAR (dCAR) with spontaneous blood pressure variations allows it to be applied in acute and non-collaborating patients
223922318|NCT06735274|DIAGNOSTIC_TEST|Neurovascular coupling (NVC)|Neurovascular coupling (NVC) is the relationship between neural activity and cerebral blood flow, allowing this activity to be evaluated in spatiotemporal terms .
223922319|NCT06735274|DIAGNOSTIC_TEST|Microembolic signals (MES)|Microembolic signals (MES)
223922320|NCT06735274|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|Montreal Cognitive Assessment (MoCA)
223922321|NCT06735274|DIAGNOSTIC_TEST|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
223922322|NCT06735274|DIAGNOSTIC_TEST|Instrumental Activities of Daily Living Scale (IADL)|Instrumental Activities of Daily Living Scale (IADL)
223922323|NCT06735274|DIAGNOSTIC_TEST|Modified Rankin Scale for Neurologic Disability (mRS)|Modified Rankin Scale for Neurologic Disability (mRS)
223922324|NCT02232386|DRUG|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
223922325|NCT02232386|DRUG|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
223922326|NCT03520114|DEVICE|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
223922327|NCT03520114|DEVICE|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally. The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of Sodium Chloride (NaCl). Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
223922328|NCT03769506|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|Use of ASP-1929 PIT therapy
223717389|NCT03182088|DRUG|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
223922329|NCT03769506|DRUG|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
223922330|NCT06742541|DEVICE|Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively|Planned surgery to receive a spherical Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
224091366|NCT02626338|DRUG|Mitoxantrone|
224091367|NCT02626338|DRUG|Cytarabine|
224091368|NCT02626338|DRUG|Etoposide|
224091369|NCT02626338|DRUG|Fludarabine|
224091370|NCT02626338|DRUG|G-CSF|
224091371|NCT02626338|DRUG|Idarubicin|
224091372|NCT00876031|DRUG|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
223717390|NCT03182088|DRUG|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
224091373|NCT05617170|OTHER|Rehabilitation|"50 case of acute cerebrovascular stroke patients will subject to implanted early rehabilitation programme based on telemedicine if avilable .~50 control patients of acute cerebrovascular stroke patients will subject to ordinary rehabilitation techniques ."
224091374|NCT04101812|DRUG|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
224091375|NCT04101812|DRUG|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
224091376|NCT04676477|DRUG|HER3-DXd|Intravenous infusion at a starting dose of 3.2 mg/kg Q3W
223922331|NCT01220531|BIOLOGICAL|Cultured Thymus Tissue|Potential recipients of cultured thymus tissue are screened for eligibility. The thymus tissue (from an unrelated donor), the donor, and the donor's mother are screened for safety. Cultured thymus tissue is implanted under general anesthesia in the operating room. Cultured thymus tissue is placed into the subject's quadriceps. Two to three months post-implantation, if medically stable, subjects may undergo an allograft biopsy. Subjects undergo laboratory testing for approximately one-year post-implantation. At approximately year 2 post-implantation, subjects are contacted for data collection.
223922332|NCT06890572|DEVICE|HEPA + VOC collecting filter purifier|Subjects operate HEPA + VOC collecting filter purifier
223922333|NCT06890572|DEVICE|fake air purifier|Subjects operate fake air purifiers
223922334|NCT06891638|DEVICE|Schedule of tDCS administration|This study evaluates the combined effects of Phono-Motor Treatment (PMT) and transcranial direct current stimulation (tDCS) for reading rehabilitation in post-stroke aphasia. Unlike standard speech therapy, this intervention integrates non-invasive brain stimulation to enhance language recovery by modulating neural activity in perilesional areas. We hypothesize that active tDCS will enhance PMT efficacy, leading to greater improvements in reading competence and phonological processing compared to sham tDCS. Through systematic testing across the 3 study arms, we expect to identify the most effective stimulation timing.
223922335|NCT06890299|DRUG|BR3006|One tablet administered alone
223922336|NCT06890299|DRUG|BR3006A|One tablet administered alone
223922337|NCT06890299|DRUG|BR3006B|One tablet administered alone
224091377|NCT04676477|DRUG|HER3-DXd|Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
224091378|NCT04676477|DRUG|Osimertinib|Oral administration at 40 mg or 80 mg once daily
224279892|NCT01834898|DRUG|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
224279893|NCT00898820|GENETIC|gene expression analysis|
224279894|NCT00898820|GENETIC|polymorphism analysis|
224279895|NCT00898820|GENETIC|protein expression analysis|
224279896|NCT03380221|OTHER|Watermelon|Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
224279897|NCT03380221|OTHER|Low fat cookies|Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
223922338|NCT06890299|DRUG|BR3006C|One tablet administered alone
223922339|NCT05903859|DRUG|Probenecid 500 Milligrams (mg)|Participants in this group will receive 500 mg of probenecid by mouth twice a day for a total of 90 days.
223922340|NCT05903859|DRUG|probenecid 250 Milligrams (mg)|Participants in this group will receive 250 mg of probenecid by mouth twice a day for a total of 90 days.
223922341|NCT05903859|DRUG|Placebo|Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
223922342|NCT06890806|OTHER|Foot Core Stabilization Exercise Group (FCSEG)|"Exercise Group (Foot Core Stabilization Exercises)~Exercise Group will perform foot core stabilization exercises under the supervision of a physiotherapist, three times a week for five weeks. The exercises will include:~Short foot exercise Towel curl exercise Big toe press exercise Toe splay exercise Calf raise to big toe press exercise Leg swings Backward tandem walking Each exercise will be performed in three sets of 15 repetitions."
223922343|NCT06890806|OTHER|Extracorporeal Shock Wave Therapy Group (ESWTG)|Extracorporeal Shock Wave Therapy Group (ESWTG) One group will receive Extracorporeal Shock Wave Therapy (ESWT) once a week for five weeks. The ESWT sessions will be performed using the Gymna Shockmaster 500 device at a frequency of 15 Hz and a pressure of 3 bar, delivering a total of 1800 pulses per session.
224091379|NCT04676477|DRUG|Osimertinib|Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)
224091380|NCT04676477|DRUG|HER3-DXd|Intravenous infusion 5.6 mg/kg Q3W
224091381|NCT04676477|DRUG|HER3-DXd|Intravenous infusion 4.8 mg/kg Q3W
224091382|NCT04676477|DRUG|Osimertinib|Oral administration at 80 mg once daily
224091383|NCT06478862|DRUG|Promitil|The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent.
224091384|NCT00450580|DRUG|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
224091385|NCT01587066|DRUG|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
224091386|NCT01587066|DRUG|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
224091387|NCT02418130|DRUG|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
224091388|NCT02418130|DRUG|Placebo|
223531038|NCT05243030|BEHAVIORAL|Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP)|MES-PrEP is a two-session computer-delivered intervention based on IMB model. The intervention is tailored based on the person's ratings of perceived importance and confidence of initiating PrEP and sustaining adherence to PrEP. Participants are routed to different intervention content based on their assessment of their importance and confidence. Youth are provided with feedback on scores on the knowledge assessment followed by information about protective effect that can result from improved PrEP adherence. Finally, participants are asked to set a goal: obtain PrEP prescription, optimal adherence, practice steps, or thinking about it more, and they form plans for overcoming barriers. In the second session, branches are based on whether the youth felt they met the goal, partially met the goal, or did not meet the goal. Sessions of MES-PrEP will occur at baseline and month 1.
223531039|NCT05243030|BEHAVIORAL|Motivational Interactive Text Messaging (MTM)|"Participants will receive automated motivational text messages to promote PrEP initiation and adherence. These contents will be customized based on their readiness to change in regards to PrEP. The message content is individualized based on participant response to baseline survey. Those participants who indicate that they are ready to set the goal to take PrEP will receive text messages reminding them to take PrEP. Those who indicate that they are less than ready to take their PrEP can choose from a range of alternatives, such as taking on-demand PrEP or just think about taking PrEP. For those who are not ready to take PrEP, the content will be individualized based on the participant's choice, i.e., a daily message encouraging them to work toward their chosen goal. Participants who are currently not on PrEP will receive daily text messages regarding PrEP effectiveness, HIV risk and where to access PrEP."
223922344|NCT06744179|DIAGNOSTIC_TEST|echocardiography, chest x-ray, full blood count , SGPT, lipid profile, HbA1C, AQ20 questionnaire, mmRC dyspnoea scale, Duke activity status index, COPD assessment test, Age and stage questionnaire|Participants from both exposed and non-exposed groups will be assessed using different standardized questionnaire and a number of investigations to identify any cardiac and pulmonary complications over time. Individuals will be matched for age and sex to ensure comparability. This study aims to evaluate these complications and analyze any significant differences between the groups over the defined follow-up period.
223922345|NCT06744387|DIAGNOSTIC_TEST|clinical assessments and tissue oxygenation monitoring by Near Infrared Spectroscopy|Flap failure will be identified, based upon gold standard monitoring (flaps skin color, temperature, tissue turgor and capillary refill time) along with Doppler technique during a postoperative period of five days. In all patients Near Infrared Spectroscopy (NIRS) by FORE-SIGHT ELITE will be applied to obtain continuous tissue oxygenation measurements. NIRS values and trends from patients with flap failure (case group) will be compared to NIRS values and trends from patients with no flap failure(control group).
223922346|NCT06744738|BEHAVIORAL|Pharmacist led behavioral change technique|"The intervention was developed based on the behavior change technique taxonomy (v1). This intervention was designed to improve adherence to all therapeutic aspects of hemodialysis patients, including the dialysis program, medications, diet, and fluids. Additionally, the effect of the pharmacist intervention on physiological indices (serum potassium, total calcium, phosphate, IDWG, and hemoglobin) was examined.~The program was explicitly created for implementation in an actual setting, ensuring that the time allocation for participants and facilitators (the party responsible for conducting the PL-BCT) remained reasonable in most contexts.~The BCT components were developed after the identification and coding of the BCTs from previous interventional studies that contain behavioral components and result in positive effects on one or more hemodialysis patients' adherence domains toward their therapeutic regimen (dialysis program, medications, diet, and fluid)."
223922347|NCT06743984|OTHER|Polychromatic resin composite|Polychromatic layering resin composite (enamel and dentin shades).
223922348|NCT06743984|OTHER|Monochromatic resin composite|Monochromatic resin composite (opaquer and dentin shades)
223922349|NCT06743464|DRUG|Rifaximin 550 MG|Preoperative Rifaximin supplementation 550 mg twice daily from preoperatively 2 weeks to post op POD 1 to 7
223922350|NCT06743464|OTHER|SOC|SOC means Standard of care which means that the patient will revieve standard post op care followed at our insitute and other hospitals in India.
224279898|NCT05979610|OTHER|Reiki therapy|"Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~* The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~* The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~* During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~* The Reiki therapist may use different techniques, such as hand movements or visualization."
224279899|NCT05747924|DRUG|AOC 1020|AOC 1020 will be administered via intravenous (IV) infusion
224279900|NCT05747924|DRUG|Placebo|Placebo will be administered via intravenous (IV) infusion
224279901|NCT06099301|BEHAVIORAL|Brief advice of a list of mobile apps|The mobile apps in the list should: (1) focus primarily on anxiety/depression/stress, (2) be available for free download; (3) be available in English or Chinese; and (4) have a user star rating in the app store.
224279902|NCT05654493|DEVICE|MicroPulse Transscleral Laser Therapy using revised P3 Delivery Device|The MicroPulse G-Probe was applied to the superior and inferior hemispheres of the eye under varied treatment times and sweep numbers
224279903|NCT02367625|DEVICE|CryoPop|The new CryoPop device will be compared to standard cryotherapy
224279904|NCT02367625|DEVICE|MedGyn MGC 200|Standard cryotherapy
224279905|NCT02118168|OTHER|No intervention|No intervention is foreseen in this Observational Study
224279906|NCT05652270|BEHAVIORAL|Goal Attainment|Development of an attainable goal
224279907|NCT05652270|BEHAVIORAL|Goal Development|"A Systematic process to help patients create SMaRT  goals"
224279908|NCT05652270|BEHAVIORAL|Goal Tracking|Setting milestones to allow patients to track their progress towards their developed goal
223531040|NCT05243030|BEHAVIORAL|Standard PrEP Counseling|All participants will received one-on-one, face to face counseling from lay providers at baseline, months 1, 3 and 6. Standard PrEP counseling includes sexual and behavioral risk assessment for HIV/STIs and risk reduction. For those not on PrEP, the sessions will focus on risk perception, awareness of PrEP/post-exposure prophylaxis (PEP) and facilitators and barriers of accessing PrEP. For those on PrEP, the sessions will focus on adherence. Standard counseling sessions will be nonjudgmental, non-discriminatory and client-centered.
223531041|NCT05395936|OTHER|Myocardial Probe Temperature Screen|The myocardial probe is a needle that measures temperatures. The skin site for introducing the myocardial probe will be small enough that participants will not notice that temperatures have been collected. If participants have multiple operations, temperatures may be collected at each operation.
223531042|NCT05395936|OTHER|Data Collection|Study team members will collect medical history and other information to potentially understand the safety and success of breast surgery better to allow investigators to identify variables, or changes to help understand investigators roles in potential complications in breast surgery.
223531043|NCT05722327|DRUG|MRTX849|Given by PO (mouth)
223531044|NCT05722327|DRUG|Irinotecan|Given by IV (vein)
223531045|NCT05722327|DRUG|Cetuximab|Given by IV (vein)
223531046|NCT03604978|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223531047|NCT03604978|PROCEDURE|Echocardiography Test|Undergo ECHO
223922351|NCT06744309|BEHAVIORAL|Heat Literacy Intervention|The behavioral intervention aims to improve heat literacy among participants through an 8-12 week education and training program. It includes three main modules: enhancing community awareness of hot weather, recognizing and responding to heat-related illnesses, and teaching personal cooling strategies. Participants will use SwitchBot meters to monitor indoor temperature and humidity, access real-time weather information, and learn about heat wave warnings. They will receive educational materials, including infographics, videos, and one-to-one training from field staff. The content of intervention and delivery methods will be refined through co-design workshops with stakeholders and community members to ensure they are practical and culturally appropriate. The goal is to equip participants with the knowledge and skills to protect themselves from extreme heat, resulting in better heat adaptation behaviors and improved health outcomes.
223922352|NCT06744309|OTHER|Structural (Cool Roof) Intervention|The structural intervention in this study involves implementing cool roofs to reduce indoor temperature and mitigate the effects of extreme heat in rural Malaysian communities. Selected households will have their roofs painted with UV-resistant paint, which reflects direct sunlight and reduces thermal absorption. This intervention aims to decrease the amount of solar energy absorbed by the roof, thereby lowering indoor temperature and reducing the physiological heat strain on residents. By maintaining cooler indoor environment, the cool roof intervention seeks to alleviate the health risks associated with prolonged exposure to high temperature.
224279909|NCT05996198|DEVICE|Oculus Rift headset|The Oculus Rift is a commercially-available virtual reality (VR) headset. It is used to present the visual environment in which participants perform the reaching task.
223531048|NCT03604978|BIOLOGICAL|Ipilimumab|Given IV
223922353|NCT06745167|PROCEDURE|Pulsed field ablation|Utilizing pulsed field ablation (PFA), combining pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation.
224091389|NCT03977779|DEVICE|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
223531049|NCT03604978|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
223531050|NCT03604978|BIOLOGICAL|Nivolumab|Given IV
223531051|NCT03604978|RADIATION|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
223531052|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenate|200 µg selenium as selenate
223531053|NCT00271245|DIETARY_SUPPLEMENT|400 µg selenium as selenate|400 µg selenium as selenate
224091390|NCT02268162|PROCEDURE|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
224279910|NCT05996198|DEVICE|Exoskeleton Device|The exoskeleton was designed and constructed to provide either gravity assistance or gravity resistance. It applies a torque to both shoulders. Torque values do not exceed 50% of the torque due to gravity. The device is mounted to a testing chair and attached to the participant using Velcro straps.
224279911|NCT05864365|DRUG|ATH434|ATH434 taken by mouth two times per day
224279912|NCT05877326|DRUG|General anesthesia with propofol or sevoflurane|General anesthesia
224279913|NCT05877326|BEHAVIORAL|CAM-ICU (Confusion Assesment Method ICU) at day 3 post-operative|The presence of mental confusion will be determined by CAM-ICU at J3 post intervention.
224279914|NCT03129230|PROCEDURE|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
223531054|NCT00271245|DIETARY_SUPPLEMENT|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
223531055|NCT00271245|DIETARY_SUPPLEMENT|Placebo|Placebo
223531056|NCT00867607|DRUG|MRX-6|b.i.d treatment for 21 days
223531057|NCT00867607|DRUG|Steroid|b.i.d. 21 days
223531058|NCT06225115|DRUG|KYN-5356|KYN-5356, oral tablet
223531059|NCT06225115|DRUG|placebo|placebo, oral tablet
223531060|NCT01674790|BEHAVIORAL|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
223531061|NCT01674790|BEHAVIORAL|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
223531062|NCT01674790|BEHAVIORAL|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
223531063|NCT01674790|BEHAVIORAL|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
223531064|NCT05481736|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
223531065|NCT00491478|DRUG|sertraline|
224091391|NCT06181955|OTHER|Extracorporeal Shock Wave Therapy|The ESWT was performed by an ESWT instrument (Chattanooga) once a week for four consecutive weeks (a total of four sessions).
223922354|NCT06745167|PROCEDURE|Radiofrequency ablation alone|Using conventional radiofrequency ablation technology, combines pulmonary vein isolation (PVI) with extensive ablation based on anatomical landmarks (including posterior wall box isolation) and electrogram-guided ablation
224091392|NCT06181955|OTHER|conventional physical therapy|Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.
224091393|NCT03732547|DRUG|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
224091394|NCT03732547|DRUG|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
224091395|NCT03061708|DRUG|AZD2014|mTOR inhibitor
224091396|NCT02633449|BEHAVIORAL|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
224091397|NCT02633449|DEVICE|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
224091398|NCT02633449|DEVICE|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
224279915|NCT03917355|BEHAVIORAL|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
224279916|NCT01279655|DEVICE|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
224279917|NCT01279655|BEHAVIORAL|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
224279918|NCT03657238|DRUG|RD01|single S.C. dose of RD01 for subjects in test group
224279919|NCT03657238|DRUG|Placebo|single S.C. dose of placebo for subjects in placebo group
224279920|NCT04024319|PROCEDURE|Genicular Nerve Block|4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
224279921|NCT04138784|OTHER|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
224279922|NCT04138784|OTHER|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
223922355|NCT06743789|RADIATION|Radiation Therapy|"Group 1 (3 participants) - will receive a dose of 20 Gy (Gray, a measurement of radiation) in a single study intervention (one study intervention day)"
223922356|NCT06743789|RADIATION|Radiation Therapy|Group 2 (3 participants) - will receive a dose of 15 Gy in a single study intervention (one study intervention day)
223922357|NCT06743789|RADIATION|Radiation Therapy|Group 3 (3 participants) - will receive a dose of 10 Gy in a single study intervention (one study intervention day)
223922358|NCT06743789|RADIATION|Radiation Therapy|Group 1 (3 participants) - will receive a dose of 12 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 36Gy)
224279923|NCT01675284|BIOLOGICAL|AT-301|Inactivated H5N1 Influenza Virion Vaccine
224279924|NCT04673708|DIAGNOSTIC_TEST|H - Test|Showing different videos for a sexual stimulus and monitor the vitals of each participants to measure any changes can occur with each video.
224091399|NCT05521165|OTHER|therapeutic exercises|strengthening exercises for gluteus medius and APTA guided program for NSCLBP
224091400|NCT03804671|DRUG|BI 730357|Oral dose
224091401|NCT03804671|DRUG|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
224091402|NCT04268134|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
224091403|NCT06256848|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223922359|NCT06743789|RADIATION|Radiation Therapy|Group 2 (3 participants) - will receive a dose of 10 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 30Gy)
223922360|NCT06743789|RADIATION|Radiation Therapy|Group 3 (3 participants) - will receive a dose of 8 Gy given over 3 days (Days 1, 2 and 3). (Total radiation dose = 24Gy)
223922361|NCT06743867|DRUG|Pressurized Intraperitoneal Aerosol Chemotherapy|"The comprehensive therapeutic strategy will be modified based on the integrated 2- or 3-week systemic chemotherapies. In the interim, a total of three PIPAC procedures will be conducted for all qualifying patients.~1. PIPAC combined with 2-week systemic chemotherapies:~   PIPAC therapy will occur every four weeks, while systemic chemotherapies will be administered during the first and third weeks following the initial and second PIPAC procedures respectively.~2. PIPAC combined with 3-week systemic chemotherapies:~(1) Scheme 1: PIPAC therapy will occur every 6 weeks, with systemic chemotherapies administered during the 1st and 4th weeks following the first and second PIPAC procedures, respectively.~(2) Scheme 2: PIPAC therapy will occur every 6 weeks, while systemic chemotherapies will be administered in the 2nd and 5th weeks following the initial and second PIPAC procedures, respectively."
223922362|NCT06744699|OTHER|Infants fed goat milk-based infant formula|Type of infant feeding during the age of 0-12 months
223922363|NCT06745713|OTHER|Turkish- Computer System Usability Questionnaire Short Version|Developed in 1995 by Lewis at IBM, the Computer System Usability Questionnaire (CSUQ) is one of the widely used questionnaires in the field of usability. The scale, which was adapted into Turkish by Erdinç in 2013, consists of 13 items in total. It has 4 sub-dimensions: system usefulness (items 1-6), information quality (items 7-9), interface quality (items 10-12) and general satisfaction (item 13). Each item is scored as 1 (Strongly agree) - 7 (Strongly disagree). The Cronbach α of the scale is \> .70 and the Cronbach α value for each sub-dimension varies between .73 and .92. A minimum score of 13 and a maximum score of 91 can be obtained from the scale. A low score is defined as good usability, and the higher the score, the lower the usability quality of the system (Erdinç \& Lewis, 2013).
223922364|NCT06745713|OTHER|Student Information Form|In the form developed by the researchers in line with the literature, a total of 12 questions were included to determine the socio-demographic characteristics of the students (such as age, gender, academic average, whether they provide care to patients with chest tubes, whether they receive training on chest tube care). All participants in the experimental and control groups were applied once as a pre-test.
223922365|NCT06745713|OTHER|Clinical Reasoning Readiness Scale for Nursing Students|It is a comprehensive assessment tool developed by Huang Huiman (2018) to determine the clinical reasoning readiness levels of nursing students in Taiwan (Ho et al., 2021; H.-M. Huang et al., 2018). 'Clinical Reasoning Readiness Scale for Nursing Students' consists of 4 sub-dimensions. These sub-dimensions are 'awareness of clinical clues' (4 items), 'verification of clinical problems' (4 items), 'action determination and implementation' (4 items) and 'evaluation and reflection' (4 items). Each sub-dimension contains four items to assess students' clinical reasoning readiness levels. The lowest score that can be obtained from the scale is 16 and the highest score is 80. Responses to the scale are evaluated on a 5-point Likert scale (5=strongly agree, 4=agree, 3=decided, 2=disagree, 1=strongly disagree). Cronbach's α ranged from 0.894 for the total and 0.78 to 0.89 for each sub-dimension. The corrected item-total correlation is between 0.627-0.728. Higher scores indicate higher levels
223922366|NCT06745713|OTHER|Self-directed Learning Scale|The original Self-Managed Learning Scale was used as a self-report scale by Lounsbury et. al. (2009). The Turkish adaptation and validity and reliability study of the scale, which shows the extent to which individuals learn autonomously with a one-dimensional structure, was conducted by Demircioğlu, Öge, Fuçular, Çevik, Nazlıgül, and Özçelik in 2018. The scale is 5-point Likert-type and consists of 10 items. For each item, participants are expected to respond according to 1 (Strongly disagree), 2 (Disagree), 3 (No opinion), 4 (Agree) and 5 (Strongly agree). Cronbach's alpha coefficient of the scale is 0.85. In line with the scores obtained from the scale, above average self-directed learning skill means high and below average self-directed learning skill means low (Demircioğlu et al., 2018). Both groups were applied as pre-test and post-test.
224279925|NCT05632692|OTHER|Menthol solution|Menthol application, through oral solutions, stimulates the mandibular and maxillary branches of the trigeminal nerve (which are predominantly responsible for detection of temperature and nociceptive stimuli across the face and within the oral cavity) and has consistently shown to improve thermal comfort and decrease thermal sensation, which are thought to modulate perceived exertion to improve performance in the heat.
224279926|NCT02919111|DRUG|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
223531066|NCT04275804|DEVICE|Low Magnitude High Frequence Vibration Platform|with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)
223531067|NCT04275804|OTHER|Conventional Dressing|Alternate Day Dressing
223531068|NCT01276704|DRUG|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
223531069|NCT01276704|DRUG|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
223922367|NCT06745713|OTHER|Chest Tube Care Management Knowledge Test|It was created by the researchers in line with the evidence in the literature (Abuejheisheh et al., 2021; Basler, 2020; Bertrandt et al., 2019; Charnock \& Evans, 2001; El-Senousy, Mahrous, Abd-Al Salam, \& Zedan, 2020; Ho et al., 2021; Tarhan et al., 2016; Zisis et al., 2015). The 'Chest Tube Care Management Knowledge Test' was initially prepared as a total of 43 multiple-choice questions, including the headings and subheadings in each session (Abuejheisheh et al., 2021; Malone, 2015). Expert opinions were obtained from 5 faculty members with clinical experience and studies on chest tube care. The experts gave suitability scores to the knowledge test questions one by one on a 4-point Likert-type scale (1: The item is not suitable, 2: The item should be seriously revised, 3: Suitable should be slightly revised, 4: Suitable). In line with the suggestions from the experts, the questions were reorganised and 9 questions were removed. For the remaining 34 multiple-choice questions in the kno
223531070|NCT00654108|DRUG|Ciprofloxacin|500 milligrams(mg) will be administered orally twice daily for 5 days.
223531071|NCT00654108|BIOLOGICAL|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10\^7; 1 X 10\^8; 1 X 10\^9; and 1 X 10\^10.
223531072|NCT00654108|OTHER|Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
223922368|NCT06743919|DRUG|Magnesium sulfate 50% - 1g/h|magnesium sulfate group 20 ml bupivacaine 0.25% plus 500 mg magnesium sulfate in 5ml normal saline on both sides.
223922369|NCT06743919|DRUG|dexmedetomidine 0.5 µg/kg IV|dexmedetomidine group 20 ml bupivacaine 0.25% plus o .5 microg per kg dexmedetomidine in 5 ml normal saline on both sides.
224091404|NCT06256848|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
224091405|NCT01996787|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
224091406|NCT01996787|DEVICE|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
224091407|NCT04670705|OTHER|patients' characteristics|There was no intervention.
224091408|NCT02119715|DRUG|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
224091409|NCT02119715|DRUG|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
224091410|NCT02119715|DRUG|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
224279927|NCT04116151|COMBINATION_PRODUCT|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
224279928|NCT04116151|COMBINATION_PRODUCT|Usual treatment|Application on the affected skin of the emollient and moisturizing substance
224279929|NCT00426530|DRUG|everolimus (RAD001)|
224091411|NCT02114190|BEHAVIORAL|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
224279930|NCT01260337|BEHAVIORAL|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
224279931|NCT01260337|OTHER|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
223531073|NCT02411409|BEHAVIORAL|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
223531074|NCT00846157|BIOLOGICAL|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
223531075|NCT00435448|DRUG|Lonidamine|
223531076|NCT02180789|DRUG|Tamsulosin OCAS|oral
223922370|NCT06743919|DRUG|Bupivacaine|20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
223922371|NCT06744218|PROCEDURE|Standard Treatment|Patients who will be assigned to the control group and subjected to standard treatment (usual care at our clinic) will undergo a physiotherapy treatment of 8 in-person sessions for 4 post-operative weeks
224279932|NCT02014441|DRUG|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
224279933|NCT00458419|DRUG|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
224279934|NCT00458419|DRUG|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
223922372|NCT06744218|PROCEDURE|Experimental Treatment|patients who will be assigned to the experimental group and subjected to the experimental treatment will undergo a physiotherapy treatment of 8 sessions in telerehabilitation for 4 post-operative weeks
223922373|NCT06744036|OTHER|Therapeutic Exercise|The therapeutic exercise program includes a warm-up, resistance, neuromuscular, mobility, and balance exercises.
223922374|NCT06744036|DEVICE|Interferential Current|However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The interferential current will be applied for 30 minutes.
223922375|NCT06744036|DEVICE|placebo interferential current|However, the interferential current will be applied at the end of the therapeutic exercises. In this way, the IC will be used through a device (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square), will be positioned around the center of the knee. The parameters used were as follows: carrier current frequency of 4000 Hz; amplitude modulated frequency of 50 Hz; sweep frequency of 50 Hz; oscillation pattern of 1:1 second, and the amplitude of the current will be increased until the research participants report strong but comfortable and non-painful stimulation paresthesia. The device will only be turned on in the first minute
223922376|NCT06890325|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment (CGA)|The intervention will consist of a total of 3 sessions which will take place in different areas of the Faculty of Health and Welfare Sciences (FCSB) at the University of Vic - Central University of Catalonia. In Session 1, a comprehensive geriatric assessment (CGA) will be conducted to the users (by students supervised by health professionals).
223922377|NCT06890325|BEHAVIORAL|Health education|A report with the results of the CGA and health recommendations will be delivered to the users. They will receive health education including specific recommendations and community health resources based on their health status and CGGA.
223922378|NCT06890494|DRUG|BiTE-EV|Thi product organically combines extracellular vesicles with BiTEs, and enables stable expression of the bispecific antibody on the surface of mesenchymal stem cells. By collecting the culture supernatant, the bispecific vesicles BiTE-EV, which express both CD3 and CD19 antibodies on their surface, are enriched and isolated.
224091412|NCT02114190|BEHAVIORAL|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
224279935|NCT00951093|PROCEDURE|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
223922379|NCT06891014|OTHER|Combine Exercise|The participants in the exercise group will be individuals over the age of 65 who applied the same exercise programs 2-3 days a week for 8 weeks under the control of two different physiotherapists independent of the study. The exercise session will be applied for one hour, including a warm-up phase, a combined exercise program including strengthening, stretching, balance and proprioceptive exercises, and a cool-down phase.
223922380|NCT06733207|OTHER|Pupil examination|Pupil assessment : bilateral clinical examination of the patient's pupils, assessed in qualitative data : mydriasis, myosis, pupillary light reflex, anisocoria or isochoria.
223922381|NCT06741124|PROCEDURE|Channel Esophagogastrostomy|Channel Esophagogastrostomy
223922382|NCT06741124|PROCEDURE|Double Tract Reconstruction|Double Tract Reconstruction
223922383|NCT06736717|DRUG|Onvansertib|"20 or30mg flat dose - depending on results from safety lead-in. Administered concurrently with NALIRIFOX.~Once daily on D1-5 of each 14-day cycle."
223922384|NCT06736717|DRUG|NALIRIFOX|"Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle."
223922385|NCT06737042|DRUG|GZR18|GLP-1
223922386|NCT06737042|DRUG|Tirzepatide|Active Comparator
223922387|NCT06737224|OTHER|Fasting + Exercise (FAST+EX): fasting + exercise condition|Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.
223922388|NCT06737224|OTHER|Fasting only (FAST): Non-exercise fasting condition|Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.
224091413|NCT01154101|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
224091414|NCT01154101|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
224091415|NCT05961748|OTHER|Multi-disciplinary assessment|Multi-disciplinary assessment
224091416|NCT00393718|DRUG|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
224091417|NCT00393718|DRUG|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
224091418|NCT00393718|DRUG|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
224279936|NCT01383850|OTHER|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
223531077|NCT01923883|PROCEDURE|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
223531078|NCT01923883|DEVICE|Echoendoscope Olympus GF-UCT240|
223531079|NCT01116284|PROCEDURE|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
223531080|NCT01441960|DRUG|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
223531081|NCT01441960|DRUG|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
223531082|NCT04578626|DEVICE|dry needling|The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
223531083|NCT04841408|OTHER|Vaginal self-sampling|Vaginal self-sampling performed by the patient at the follow-up visit at 3 weeks and remote follow-up at 9 weeks.
223922389|NCT06738758|DRUG|PCSK9 inhibitor|The patient used PCSK9 inhibitor (with or without statins ± Ezetimibe/Hybutimibe) in the early hospitalization, and patients continually prescribed or stopped PCSK9 inhibitors treatment during the follow-up visit, which depend on physician's clinical decision and patient preference. PCSK9 inhibitors include Evolocumab, Alirocumab, Tafolecimab, Recaticimab, and Inclisiran, among others.
223922390|NCT06738758|DRUG|Statin+Ezetimibe/Hybutimibe compound|The patient used statins and Ezetimibe/Hybutimibe in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
223922391|NCT06738758|DRUG|Statin|The patient used statins in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
224091419|NCT00393718|DRUG|placebo|glibenclamide placebo. Given orally once or twice daily.
224091420|NCT05641883|COMBINATION_PRODUCT|CardiaMend with antiarrhythmic|Pericardial patch with antiarrhythmic drug (amiodarone) topically applied
224279937|NCT01383850|OTHER|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
224279938|NCT02295813|BIOLOGICAL|FBF001|
224279939|NCT02295813|DRUG|Placebo|
223531084|NCT04400435|DEVICE|Use of Eko DUO electronic stethoscope|Auscultation of heart sounds using electronic stethoscope
223531085|NCT02986074|DEVICE|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
224091421|NCT03303001|PROCEDURE|Subacromial high volume infiltration|This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
224091422|NCT03303001|PROCEDURE|Subacromial conventional infiltration|This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
223531086|NCT02986074|DEVICE|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
224091423|NCT01015508|OTHER|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
224091424|NCT01015508|OTHER|Weight maintenance|10 months
224091425|NCT06359184|OTHER|yoga|1 hour yoga practice 2 days a week for 8 weeks
224279940|NCT04595032|DEVICE|3DCRT, IMRT, VMAT, SBRT|Radiation treatment
224279941|NCT02283671|BIOLOGICAL|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
224279942|NCT00114231|DRUG|capecitabine|
224279943|NCT00114231|DRUG|oxaliplatin|Given IV
224279944|NCT00114231|PROCEDURE|neoadjuvant therapy|Undergo surgery
224279945|NCT00114231|RADIATION|radiation therapy|Undergo radiotherapy
224279946|NCT03608306|OTHER|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
224279947|NCT03608306|OTHER|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
224279948|NCT05499234|DRUG|Dolantin|If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
224279949|NCT05499234|DRUG|Paracetamol|If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
223531087|NCT03842735|OTHER|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
223531088|NCT03842735|BEHAVIORAL|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
223531089|NCT05511402|OTHER|Exercise training|People with Parkinson's Disease will be received a supervised physiotherapy and rehabilitation program.
223531090|NCT03680807|DIAGNOSTIC_TEST|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
223531091|NCT00360945|DRUG|cisplatin|
223531092|NCT00360945|DRUG|temozolomide|
223531093|NCT00360945|GENETIC|fluorescence in situ hybridization|
223922392|NCT06739889|DIAGNOSTIC_TEST|Elongation longitudinaux articular vertebral and columnar decoaption osteo-articulaire also known as ELDOA|ELDOA targtes cervical and upper thoracic spine. ELDOA exercises involves spicific postural holds that improve forward neck posture.The goal of ELDOA is to help reduce stress and increase space in the vertebral joints so that muscles can move freely. The benefits of these stretches include joint mobility, increased fluid absorption in the discs of the spine, flexibility, improved muscle tone, postural alignment, body-mind connection, and coordination. The tension and release created by these stretches helps normalize the posture.
223922393|NCT06739889|DIAGNOSTIC_TEST|upper thoracic mobilization|Upper thoracic mobilization, often known as joint mobilization, is a common technique in manual therapy. In order to preserve or restore joint mobility, this approach glides and uses distraction on the joint surfaces.
223922394|NCT06739187|DEVICE|Virtual reality platform on head mounted display|Enhance Virtual Reality platform on a Meta Quest head mounted display
223922395|NCT06741098|BIOLOGICAL|NCR100|Subjects will receive multiple intra-articular NCR100 injections.
223922396|NCT06741098|OTHER|0.9% Normal saline|Subjects will receive multiple intra-articular 0.9% Normal saline injections.
223922397|NCT06741176|BEHAVIORAL|Experimental|The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The mothers in the experimental group will be asked to write messages to their babies on the milk bags they bring in the mornings for 3 days. They will be asked to write on the paper attached to the milk bag what they want to tell their baby that the investigators will read the message to them and to return it every morning. The post-test of all surveys will be conducted at the end of the 3rd day.
223922398|NCT06741176|BEHAVIORAL|Control|The research data will be collected with mothers whose babies are in the NICU. Information about the research will be given to mothers who come to leave milk for their babies and the research will be conducted with those who agree to participate. All surveys will be pre-tested on the mothers without randomization and the group they are in will be determined by randomization. The post-tests will be conducted 3 days after the pre-test without any messages being requested from the mothers in the control group.
223922399|NCT06738732|DRUG|CBD: GT4 Transdermal Delivery System|CBD: GT4 Transdermal Delivery System
223922400|NCT06741306|BEHAVIORAL|Group1|Current chemsex users Men who have sex with men, Aged 16-35 years (defined as last chemsex used within 3 months), Able to communicate in Thai fluently.
223922401|NCT06737237|PROCEDURE|cervical plexus block|local anesthetic (10ml of bupivacaine 5mg/ml)
223922402|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|local anesthetic (20ml of bupivacaine 2.5mg/ml)
223922403|NCT06737237|PROCEDURE|cervical plexus block|placebo (10ml of 0.9% sodium chloride)
224279950|NCT02754024|PROCEDURE|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
223531094|NCT00360945|GENETIC|loss of heterozygosity analysis|
223531095|NCT00360945|OTHER|immunohistochemistry staining method|
223531096|NCT00360945|OTHER|laboratory biomarker analysis|
223531097|NCT00360945|RADIATION|radiation therapy|
223531098|NCT00216333|DRUG|combined fixed dose combination|
223922404|NCT06737237|PROCEDURE|Local Infiltration Analgesia (LIA)|placebo (20ml of 0.9% sodium chloride)
223922405|NCT06737848|PROCEDURE|Single catheter adrenal vein sampling|The clinical invasive procedure involves inserting a single catheter into the right and left adrenal veins to collect blood samples from both adrenal veins.
223922406|NCT06737848|PROCEDURE|Double catheters adrenal vein sampling|The clinical invasive procedure involves inserting double catheters into the right and left adrenal veins to collect blood samples from both adrenal veins.
224279951|NCT02754024|PROCEDURE|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
223922407|NCT06735287|PROCEDURE|bladder sparing set|after neoadjuvant chemotherapy combined with immunotherapy, maximal TURBT and a re-TURBT shall be performed then mitomycin C bladder instillation therapy will be administered
223922408|NCT06735287|PROCEDURE|RC|Radical cystectomy performed immediately after three cycles of neoadjuvant therapy.
224279952|NCT02754024|DEVICE|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
224279953|NCT01329224|OTHER|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
224279954|NCT06326034|DRUG|Dapagliflozin|Dapagliflozin 5 mg orally given once daily for four months.
223531099|NCT02481414|BIOLOGICAL|PepCan|50 μg peptide + 0.3 mL Candin® per dose administered intradermally in the extremities
223531100|NCT02481414|BIOLOGICAL|Candin®|0.3 mL Candin® per dose administered intradermally in the extremities
223531101|NCT00071955|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
223531102|NCT00071955|BIOLOGICAL|sargramostim|
223531103|NCT02004626|DRUG|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
223531104|NCT02004626|DRUG|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
223922409|NCT06734403|OTHER|Bladder Augmentation|Bladder Augmentation using bowel loop (ileal or sigmoid loop)
223922410|NCT06735144|DRUG|FH-006|Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
223922411|NCT06735144|DRUG|FH-006|administered once every 3 weeks (Q3W), with a treatment period of 21 days
223922412|NCT06734286|OTHER|CogMed|CogMed which is a computerized working memory training program developed by Karolinska University.
223922413|NCT06742164|DRUG|Ivabradine 5mg Tab|Ivabradine (5 mg twice daily) orally or via nasogastric tube
224091426|NCT06359184|OTHER|control|no intervention for 8 weeks
224091427|NCT05946967|OTHER|Biofeedback with TENS|Constipation patients will be given biofeedback treatment along with transcutaneous electrical stimulation (TENS) of posterior tibial nerve
224091428|NCT05946967|OTHER|Biofeedback only|Constipation patients will be given biofeedback treatment only
224091429|NCT03158402|OTHER|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
224091430|NCT00627666|BIOLOGICAL|anti-thymocyte globulin|
223531105|NCT02457026|DRUG|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
223531106|NCT02457026|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
223531107|NCT02457026|DRUG|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
223531108|NCT01006161|DRUG|SCH 527123|Low dose
223531109|NCT01006161|DRUG|SCH 527123|Medium dose
224091431|NCT00627666|DRUG|busulfan|
224279955|NCT06614608|DRUG|5% ASKC200|5% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
223531110|NCT01006161|DRUG|SCH 527123|High dose
223531111|NCT01006161|DRUG|SCH 527123|Placebo to match SCH 527123
223531112|NCT01444911|DEVICE|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
223531113|NCT01444911|DEVICE|Vaginal Dilator|Still vaginal dilator with lubricant.
223922414|NCT06742164|DRUG|control|Patients didn't receive Ivabradine .
223922415|NCT06739681|OTHER|Routine Intervention|These routine exercises used in archery training will be applied to all participants. Exercise sessions will be planned 2 days a week, every other day, for 8 weeks. It will progress progressively according to the athlete's tolerance.
223922416|NCT06739681|OTHER|Mental Imagery Intervention|Mental Imagination will be done with Recording Audio. An audio recording will last 5 minutes. The audio recording will be listened to 3 times in one session. The total visualization session will last 15 minutes in a dark and quiet room.
223922417|NCT06739681|OTHER|Breathing Exercise Intervention|Participants participating in Pranayama training will practice in a comfortable position in a quiet room at a temperature of 25 ± 2°C. The slow pranayama technique chosen is alternate nasal breathing (Nadishodhana Pranayama).
223922418|NCT06893159|DEVICE|INSTI HIV-1/2 Antibody Test|The INSTI HIV-1/HIV-2 Antibody Test is a single use, rapid, in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1 and/or Type 2 (HIV-1/HIV-2) in human venipuncture whole blood, fingerstick blood, or plasma specimens. The test is intended for use by trained personnel in point of care and laboratory situations to aid in the diagnosis of HIV infections. If multiple rapid HIV tests are available, this test is suitable for use in appropriate multi-test algorithms.
224091432|NCT00627666|DRUG|fludarabine phosphate|
223531114|NCT03581175|PROCEDURE|Colonoscopy|
223531115|NCT03581175|DRUG|Bowel cleansing regimen|
224091433|NCT00627666|DRUG|leucovorin calcium|
224091434|NCT00627666|DRUG|methotrexate|
224091435|NCT00627666|PROCEDURE|allogeneic bone marrow transplantation|
224091436|NCT00627666|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224091437|NCT00627666|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
224091438|NCT02812199|DEVICE|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
224091439|NCT02812199|DRUG|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
224091440|NCT02812199|PROCEDURE|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
224091441|NCT04013126|DIAGNOSTIC_TEST|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
224091442|NCT00460382|DRUG|raltegravir potassium|400 mg twice a day
223922419|NCT06893159|DEVICE|INSTI Multiplex HIV-1/2 Syphilis Antibody Test|The INSTI MULTIPLEX HIV-1/2 Syphilis Ab Test is a single use, rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus Type 1/ Type 2 and Treponema pallidum in human fingerstick blood and serum. The INSTI Multiplex Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and Syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than one minute. Although suitable for near-patient point-of-care (POC) testing, the INSTI Multiplex Test is not suitable for self-testing.
223922420|NCT06893159|DEVICE|Multiplo Complete Syphilis (TP/nTP) Antibody Test|"Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) is a single use, manually performed, visually interpreted, qualitative immunoassay based on Rapid Vertical Flow Technology® for the detection of antibodies to Treponema pallidum (TP), the causative agent of syphilis, and to nontreponemal (nTP; \[RPR titer ≥ 1:8\]) antigens in human serum, plasma, or fingerstick whole blood specimens. Nontreponemal antibodies are called reagins and they are generated after the tissue damage caused by syphilis infection.~Multiplo® TP/nTP is intended for use by healthcare professionals as an aid in the diagnosis of active syphilis infection."
223922421|NCT06741137|PROCEDURE|inhaled nitric oxide combined with prone position ventilation|inhaled nitric oxide combined with prone position ventilation
223922422|NCT06720727|RADIATION|craniospinal irradiation|Delivering radiotherapy to brain, spinal cord and its covering membrane.
223922423|NCT06042153|DRUG|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
223922424|NCT06042153|DRUG|Placebo|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
223922425|NCT06747806|PROCEDURE|Cardiac Surgery and Procedures|To assess blood and tissue biomarkers of patients undergoing cardiac surgery
223922426|NCT06746935|PROCEDURE|Collagen membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with native collagen membrane.
223922427|NCT06746935|PROCEDURE|Polytetrafluoroethylene membrane.|Particulate bone mixture 1:1 autogenous and xenogenic bone covered with polytetrafluoroethylene membrane.
223922428|NCT06742866|DRUG|Amiodarone Injection|Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
223922429|NCT06742866|DRUG|Sodium Chloride Injection 0.9%|Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
223922430|NCT06742242|PROCEDURE|lymphaticovenous anastomosis|supermicrosurgical lymphatic vessel to recipient ven lumen-to-lumen coaptation
223922431|NCT06742515|DRUG|Blinatumomab plus Reduced-dose Chemotherapy|Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.
223922432|NCT06749834|DRUG|Intravenous thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
223922433|NCT06748534|DIAGNOSTIC_TEST|Plus Lens Addition (+0.75 D)|Participants in this group were provided with +0.75 D lenses, designed to assist in alleviating strain caused by accommodative infacility by reducing the demand on the eye's focusing mechanism.
223922434|NCT06748534|COMBINATION_PRODUCT|Vision Therapy Using HART Chart|Intervention Details: Participants in this group underwent vision therapy sessions utilizing the HART chart, aimed at enhancing their accommodative flexibility through repetitive focusing exercises.
223922435|NCT06750614|DEVICE|intermittent theta-burst stimulation (iTBS)|In each visit, the intensity of the iTBS applied to the participant will be set at 70% of their individual resting motor threshold (rMT), with one session specifically targeting the left DLPFC.
223922436|NCT06748508|DRUG|Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib|Patients were randomized in a 1:1:1 ratio to three treatment groups: control group A: pembrolizumab combined with XELOX regimen, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles. Group B: treatment regimen was pembrolizumab combined with Nab-POF regimen, the regimen was repeated every 2 weeks, and tumor efficacy was evaluated every 3 treatment cycles. Group C: treatment regimen was pembrolizumab combined with XELOX regimen and lenvatinib, the regimen was repeated every 3 weeks, and tumor efficacy was evaluated every 2 treatment cycles.
223922437|NCT06750133|BIOLOGICAL|Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)|"Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells(6-10×10\^7 CNK+ cells/kg). The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study."
223922438|NCT05144516|BEHAVIORAL|Behavioral: COPE +|Six sixty minute sessions that teaches participants distress and communication coping skills.
223922439|NCT06784518|OTHER|Clinical scores and functional MRI|Motor evoked potentials between Day 3-Day 7 of the stroke, for a equal distribution of patients into three prognostic groups according to the PREP2 algorithm (good, limited and poor). Longitudinal follow-up with clinical scores and functional MRI at Day 7-Day 10, Day 30, Month 3 and Month 6 of stroke.
223922440|NCT06767475|OTHER|Best Practice|Receive usual care
223922441|NCT06767475|OTHER|Discussion|Attend a focus group
224091443|NCT00460382|DRUG|darunavir/ritonavir|2 pills of 300 mg twice a day
223922442|NCT06767475|OTHER|Health Promotion|Participate in group discussion with exercises and activities
223922443|NCT06767475|OTHER|Interview|Attend a one-on-one interview
223922444|NCT06767475|OTHER|Questionnaire Administration|Ancillary studies
223922445|NCT06787560|BIOLOGICAL|CD7 CAR-T cells injection|Each subject receive CD7 CAR T-cells by intravenous infusion
223922446|NCT06787560|PROCEDURE|Allo-HSCT|allogeneic hematopoietic stem cell transplantation
223531116|NCT02398812|OTHER|Medication assessment and treatment plan based on it|"Intervention~* Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~* Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
223531117|NCT01968343|BEHAVIORAL|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
223922447|NCT06741215|OTHER|Hand Rehabilitation|"Passive mobilization exercises were initiated for these patients in the first postoperative week.~Flexor tendon repair patients were immobilized for 3-4 weeks postoperatively. During this period, passive mobilization exercises were with controlled movement. After removing the splint in the third or fourth week, tendon-gliding exercises were initiated, followed by isolated tendon-gliding exercises in the fifth week. Electrotherapy was started in the sixth week (5 days a week, for 15 sessions).~For extensor tendon repair patients, immobilization lasting 3-6 weeks was applied based on the injury level. During immobilization, passive range of motion (ROM) exercises were performed for adjacent joints while the hand remained in the splint. After splint removal, active and passive ROM exercises, and tendon-gliding exercises with gradually increasing intensity were started according to the injury level. Electrotherapy was started in in the sixth week."
223922448|NCT06790914|BEHAVIORAL|Flurbiprofen axidate combined with noise-cancelling headphones music|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After general anesthesia induction, noise-cancelling headphones (Sony WH-1000XM3) were fully covered with both ears, and MP3 (GoGear, Philips) was connected to play music continuously until the headphones were removed after the operation.
223922449|NCT06790914|BEHAVIORAL|Flurbiprofen axidate combined with noise-cancelling headphones|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline 50ml at 60 drops /min; After induction of general anesthesia, noise-cancelling headphones (Sony WH-1000XM3) were applied to cover both ears completely until the headphones were removed at the end of the procedure.
223922450|NCT06790914|OTHER|Flurbiprofen exate on a drip|30min before induction of general anesthesia, flurbiprofen axidate 50mg+ normal saline at 60 drops /min.
223922451|NCT06793995|DRUG|LY03017|single dose，administered orally for each period
223717391|NCT01655615|BEHAVIORAL|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
223922452|NCT06793995|DRUG|LY03017|single dose，administered orally
224091444|NCT00460382|DRUG|etravirine|2 pills of 100 mg twice a day
224091445|NCT00460382|DRUG|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
224091446|NCT06211855|DIAGNOSTIC_TEST|doppler assesment|In all cases, the measurement, including UA PI and MCA PI, was measured with a 6-4 MHz convex transabdominal probe. All measurements were made by an obstetrician (Ş.D.) with 28 years of experience. Doppler measurements were collected from the proximal third of the MCA and the free-floating segment of the umbilical cord, ensuring that the angle of insonation was as close to zero as feasible and that fetal movements were absent
224091447|NCT04697914|DIAGNOSTIC_TEST|Plantar pressures will be measured in 7 zones using the Footscan® platform following the two-step method. Three plantar pressures measurements were made for each foot.|to protect the metatarsus and prevent the appearance of foot pain.
224091448|NCT02988856|DEVICE|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
224091449|NCT04125680|BEHAVIORAL|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
224091450|NCT02902094|DEVICE|Drug eluting balloons|
224091451|NCT02902094|DEVICE|Non drug eluting balloons|
224091452|NCT01562028|DRUG|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
224091453|NCT01562028|DRUG|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
224279956|NCT06614608|DRUG|1% ASKC200|1% ASKC200 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of1% for this study.
223531118|NCT01968343|OTHER|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
223531119|NCT00078221|DEVICE|Rheopheresis blood filtration|
223717392|NCT02835924|DRUG|Regorafenib|
223717393|NCT03576976|BEHAVIORAL|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
223922453|NCT06791655|DEVICE|Stock Abutment Implant|Participants in this intervention group receive a two-piece dental implant that utilizes a stock abutment. The stock abutment is a prefabricated component that connects the implant to the prosthetic suprastructure. This intervention aims to evaluate the standard outcomes of using stock abutments in the restoration of teeth in esthetic zones after immediate implant placement.
224091454|NCT03850821|BEHAVIORAL|Connect Social Mechanisms Intervention|"The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day."
224091455|NCT06041243|OTHER|Game-Based Exercises|Exercises aimed to improve postural balance with four different games
224091456|NCT04008017|DIAGNOSTIC_TEST|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
224091457|NCT02360098|OTHER|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
224091458|NCT00674011|DRUG|Bevacizumab|Given as part of standard of care or another research protocol
224091459|NCT04321161|DRUG|Bicanorm|"Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)"
224091460|NCT01634373|DRUG|Torrent's Quetiapine Fumarate Tablets|
223922454|NCT06791655|DEVICE|Customized CAD CAM Titanium Milled Abutment Implant|Participants in this intervention group are treated with a two-piece dental implant that includes a customized CAD CAM titanium milled abutment. These abutments are tailor-made using computer-aided design and manufacturing to fit the specific contours and needs of the patient's dental structure. This customized approach is hypothesized to offer superior integration with the soft and hard tissues, leading to better aesthetic outcomes and tissue health around the implant area.
224091461|NCT06063473|DRUG|Trifarotene Cream 0.005%|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
224091462|NCT06063473|DRUG|Placebo|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
224091463|NCT06063473|DRUG|AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)|The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
224091464|NCT01479348|DRUG|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
224279957|NCT01933919|DRUG|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
224279958|NCT01933919|DRUG|Placebo|Placebo tablet matching to fluvoxamine maleate
224279959|NCT03998709|DRUG|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
224279960|NCT03998709|OTHER|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
224279961|NCT03998709|DRUG|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
224279962|NCT03998709|OTHER|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
224279963|NCT04065061|DIETARY_SUPPLEMENT|Erinacine A-enriched Hericium Erinaceus Mycelia|
224279964|NCT04065061|DIETARY_SUPPLEMENT|Placebo|Placebo supplement was given to the participants.
224279965|NCT03965728|DRUG|BAY1830839|Tablet, oral.
224091465|NCT01479348|DRUG|Tetrahydrouridine intravenous (IV)|Total dose of THU = 350 mg/m\^2, IV
224091466|NCT01479348|DRUG|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
224091467|NCT01479348|DIAGNOSTIC_TEST|Positron emission tomography (PET)/Computed tomography (CT)|One prior CT and 3 sequential whole body PET
224091468|NCT00457405|DRUG|dipyridamole|dipyridamole 200mg twice daily
224091469|NCT00522860|PROCEDURE|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
224091470|NCT00522860|PROCEDURE|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
224279966|NCT03965728|DRUG|Placebo|Tablet, oral.
224279967|NCT03965728|DRUG|Midazolam|For all dose steps. Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
224279968|NCT03965728|DRUG|Methotrexate|Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
224279969|NCT02096822|BEHAVIORAL|Facilitated tucking + non-nutritive sucking|
224279970|NCT02096822|OTHER|non-nutritive sucking|
224279971|NCT04159181|OTHER|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
224279972|NCT04159181|OTHER|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
224279973|NCT04159181|OTHER|Placebo (water)|oral administration of Water (200mL).
223922455|NCT06840457|BEHAVIORAL|Mindfulness + Tailored Messages|"Tailored Messages (TM) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Messages will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual messages.~The study will use an app designed to train the user in mindfulness practices."
223922456|NCT06840457|BEHAVIORAL|Mindfulness without Tailored Messages|The study will use an app designed to train the user in mindfulness practices.
223922457|NCT06840457|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) + Tailored Messages|"Tailored Messages (TM) Participants randomized to receive enhanced feedback will receive this feedback from the MyDataHelps study app. This includes varying types of text and visual feedback based on data collected through the app. Messages will be displayed to participants on a dashboard in the app or delivered via pop-up notifications. Participants will receive a combination of text and visual messages.~The study will use an app designed to deliver cognitive behavioral therapy."
223922458|NCT06840457|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) without Tailored Messages|The study will use an app designed to deliver cognitive behavioral therapy.
223922459|NCT06485297|OTHER|questionnary|questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)
223922460|NCT05417165|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|Given IM
223922461|NCT05417165|BIOLOGICAL|Pneumococcal Polyvalent Vaccine|Given IM
224091471|NCT03766425|DRUG|Aflibercept|subconjunctival injection
224091472|NCT03766425|DRUG|Mitomycin|subconjunctival injection
224091473|NCT00507325|PROCEDURE|Blood Sample|Blood samples will be collected.
224279974|NCT02000323|OTHER|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
224279975|NCT02000323|OTHER|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day."
224279976|NCT03070691|DRUG|LDE225B|Cream, 2x daily
224279977|NCT03070691|DRUG|Vehicle|cream, 2x daily
224279978|NCT00928226|RADIATION|Fractionated Stereotactic Radiosurgery (SRS)|Standard of care
224279979|NCT00928226|PROCEDURE|Surgical resection|Standard of care
224279980|NCT01714050|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
224279981|NCT01714050|DEVICE|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
223922462|NCT02325154|DEVICE|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
223922463|NCT05144633|DEVICE|Auscultation|This study will be to determine if the addition of Eko AI-assisted lung auscultation examination to a standard of care Pulmonary POCUS + assists with acute respiratory failure diagnosis.
223922464|NCT02531932|DRUG|Carboplatin|Carboplatin will be administered if ANC \> 1.0 and platelets are \>75k
224091474|NCT00507325|PROCEDURE|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
224091475|NCT02760251|DRUG|romiplostim|
223922465|NCT02531932|DRUG|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
224091476|NCT03448744|DRUG|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
224091477|NCT03448744|DRUG|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
224091478|NCT02220387|OTHER|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
224091479|NCT02220387|OTHER|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
224279982|NCT03942783|OTHER|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
224279983|NCT03942783|OTHER|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
224279984|NCT03297086|PROCEDURE|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
223531120|NCT00069641|BIOLOGICAL|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
223531121|NCT00069641|BIOLOGICAL|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
223531122|NCT00069641|BIOLOGICAL|Placebo|Patients will receive weekly infusions of placebo.
223531123|NCT03461718|DRUG|Ketamine|Experimental arm for sedation.
224091480|NCT05693402|PROCEDURE|opioid anesthesia|opioid-free general anesthesia vs non opioid-free general anesthesia
224091481|NCT00412529|DRUG|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
224091482|NCT00412529|DRUG|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
224091483|NCT02529527|BEHAVIORAL|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
224091484|NCT05781048|DRUG|HRS-6209|HRS-6209
224091485|NCT01769911|DRUG|carmustine|Given IV
224091486|NCT01769911|DRUG|cytarabine|Given IV
224091487|NCT01769911|DRUG|melphalan|Given IV
224091488|NCT01769911|DRUG|etoposide|Given IV
224091489|NCT01769911|DRUG|O6-benzylguanine|Given IV
223922466|NCT06485752|BIOLOGICAL|tNIV 1 and Matrix-M Adjuvant|tNIV will be administered as a single 0.5 mL IM injection Day 0
223922467|NCT06835621|PROCEDURE|Restricted inverse kinematic alignment Total Knee Arthroplasty|Restricted inverse kinematic alignment (restricted iKA) total knee arthroplasty is an alignment technique of total knee replacement surgery, aim to maintain the native coronal alignment within a HKA angle safe zone of 177° to 183°. This technique aims to 'resurface' the femur maintaining the native femoral joint line obliquity, with the flexion and extension gaps balanced by adjusting the tibial resection first. It is considered a more personalized approach because it aims to replicate the knee's pre-arthritic alignment and movement, believing that each patient's knee has a unique alignment.
223922468|NCT06835621|PROCEDURE|Adjusted Mechanical alignment Total Knee Arthroplasty|The adjusted Mechanical Alignment (aMA) technique is an adaptation of the conventional MA technique but with undercorrection of constitutional coronal deformity, within a limit of ± 3°. The femoral resection is adjusted to preserve mild constitutional deformity and/or reduce more severe deformity while leaving the tibial component mechanically aligned. The tibial component was positioned with the aim to be perpendicular (90°) to the mechanical tibial axis.
224279985|NCT06267209|OTHER|Observational group|"After confirming that the patients not meet any of the exclusion criteria, dependent and confounding study variables will be assessed.~Patients will be recruited in 3 regions of Spain (Galicia, Madrid and Malaga), through the respective provincial associations and the Spanish Federation of Hemophilia.~The assessment will take place at the premises of the hemophilia associations included in the study. All the evaluations will be carried out by the same physiotherapist, following the same evaluation protocol.~The primary variable of the study will be the conditioned modulation of pain, being age the dependent variable. Secondary variables, estimated as modifiers or confounders, will be kinesiophobia, catastrophizing, anxiety perception, joint damage, pain intensity, functional capacity and pain threshold to pressure, and type of treatment and development of inhibitors."
224279986|NCT01331577|BEHAVIORAL|Cognitive Behavioural Training|Two day seminar
224279987|NCT01331577|BEHAVIORAL|Integrative Kinesiology Intervention|Two day seminar
224279988|NCT04546152|DEVICE|HYAPROF® SOFT and HYAPROF® BALANCE|Dermal filler injection to different facial areas
224279989|NCT01961752|DRUG|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
224279990|NCT01961752|DRUG|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
223922469|NCT06829290|DIAGNOSTIC_TEST|Ultrasound|Sonographisch measurement of muscles Blood muscle markers
223531124|NCT03461718|DRUG|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
223531125|NCT03461718|DRUG|Fentanyl|Part of standard sedation regimen
223531126|NCT06351618|OTHER|No intervention will be conducted.|No intervention will be conducted.
223531127|NCT05090618|GENETIC|DNA analysis|GWAS
223531128|NCT05101720|PROCEDURE|Ultrasound Guided Axillary Venous Access|Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
223531129|NCT05101720|PROCEDURE|Fluoroscopy-Guided Axillary Venous Access|Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
223531130|NCT05058326|DIAGNOSTIC_TEST|Portable endoanal manometry|Endoanal manometry values will be obtained using de Anopress® device. Fecal incontinence severity questionaries will be filled and collected.
223531131|NCT05058326|DIAGNOSTIC_TEST|Endoanal ultrasound|To assess the integrity of the anal canal.
223531132|NCT05058326|OTHER|Incontinence severity scale questionaires|Wexner and St. Mark's scales.
223531133|NCT00660803|DRUG|Fulvestrant|
223531134|NCT03766061|PROCEDURE|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
223922470|NCT06746272|PROCEDURE|Serratus Anterior Plane Block|Ultrasound guided Serratus anterior block will be performed according to the analgetic standard in our department using an ultrasound guided transducer to inject 2mg/kg of 0.5% ropivacaine with an adjuvant. A sterile plaster will be placed on the puncture site after performing the block. Patients will receive i.v. analgesia according to the analgesic standard of care in our department.
223922471|NCT06746909|OTHER|Multidomain cognitive training and physical training|"The cognitive training programme will be based on 8 cycles composed by 18 sessions of exercises and activities aimed at stimulating multiple cognitive functions. Each cycle will last 3 weeks, after which the same kind of cognitive stimulation sessions will be restarted, with exercises and activities of increased complexity. Each cycle will be structured in sessions aimed at stimulating specific cognitive domains and in sessions focused on multimodal activities (music-therapy, cineforum, etc.).~The physical training will include aerobic exercise on an ergometer cycle, whose duration will be increased gradually from 10 to 20 minutes followed by exercises targeted to improve muscle strength, physical function, neuromuscular control and flexibility."
223922472|NCT00709956|DRUG|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
223922473|NCT00709956|DRUG|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
223922474|NCT01815359|PROCEDURE|Cytoreductive Surgery|Optimal Surgical Debulking
223922475|NCT01815359|DRUG|HIPEC with Mitomycin-C|
223922476|NCT01815359|DRUG|EPIC with FUDR and Leucovorin|
223922477|NCT05719909|BEHAVIORAL|Cognitive Training|8 sessions of web-based cognitive training
223922478|NCT05719909|BEHAVIORAL|Sham Training|8 sessions of web-based sham training
223922479|NCT06578156|DEVICE|Nasal High Flow Cannula|High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
223922480|NCT06578156|DEVICE|Nasal Low Flow Cannula|Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
223922481|NCT06804590|DRUG|9MW0311|9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
223922482|NCT06804590|DRUG|Prolia®|Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
223922483|NCT06877494|DIETARY_SUPPLEMENT|fish oil|Twice a day, with one dose of DHA 300mg: EPA 60mg, for a continuous intervention of 90 days
223922484|NCT06752954|DEVICE|Viabahn endoprosthesis group|Viabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
223922485|NCT06752954|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
223922486|NCT06770803|PROCEDURE|High Pressure Pneumoperitoneum|The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
223922487|NCT06770803|PROCEDURE|Low Pressure Pneumoperitoneum|The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
223922488|NCT06772649|OTHER|Compression sleeve|The Bauerfeind compression sleeve is a fabric sleeve designed to support the ankle during movement. It's made of a compressive knit material that increases sensorimotor feedback, enhances blood circulation, and stimulates metabolism. The design helps reduce ligament strain, activates the foot's stabilizing muscles more quickly, and improves joint coordination.
223922489|NCT04974268|OTHER|Specific supervised exercise and weight loss program|Intervention group that receives supervised exercise and weight loss program based on individual and group intervention with Mediterranean diet and substitute for a daily meal, manual lymphatic drainage and compression garment if there is more than 600 ml of excess volume in the limb affected.
223922490|NCT04604418|OTHER|No intervention. It is observational|No intervention. It is observational
223922491|NCT05589402|DRUG|Lidocaine Cream 5%|Ebanel 5% Lidocaine Topical Numbing Cream Maximum Strength 1.35 Oz, Numb520 Pain Relief Cream Anesthetic Cream Infused with Aloe Vera, Vitamin E, Lecithin, Allantoin, Secured with Child Resistant Cap
224091490|NCT01769911|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
224091491|NCT01769911|PROCEDURE|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
224279991|NCT01961752|DRUG|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
224279992|NCT04679142|DRUG|Baclofen Tablets|Enrolled patients will receive treatment and evaluations for their disease as determined by their physicians in accordance with local standard of care. Visits will be scheduled by their physician according to patient-specific needs and national clinical practice.
224279993|NCT05758909|DEVICE|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
223922492|NCT05589402|OTHER|Rehabilitation Movement Training|reaching tasks, hand exercises (e.g., putty, grip exerciser, resistance bands, etc).
223922493|NCT06581900|OTHER|Vitamin B12|Quantification of Vitamin B12
223922494|NCT06871436|OTHER|Aerobic Exercice and muscular reinforcement|Aerobic exercise and muscle strengthening to increase weekly physical activity at moderate and vigorous intensities
224279994|NCT02371993|DIETARY_SUPPLEMENT|Choline|
224279995|NCT02371993|OTHER|Placebo|
223922495|NCT06746844|DEVICE|ViewMind Atlas™|The intervention involves the use of ViewMind Atlas™, a novel digital tool for cognitive assessment, and traditional cognitive tests. The ViewMind Atlas™ device evaluates cognitive performance through eye-tracking technology and advanced analytics, providing objective measurements of cognitive function. Traditional cognitive tests are used as the standard comparator to validate the device's diagnostic performance
224091492|NCT01769911|OTHER|laboratory biomarker analysis|Correlative studies
224091493|NCT04938648|BEHAVIORAL|Pharmacist-led deprescribing intervention|1\) direct-to-consumer deprescribing educational materials designed to activate the care partner and people living with dementia PLWD; 2) a telehealth visit in which a clinical pharmacist discusses benefits and harms of the patient's medications with the patient and care partner in the context of their goals and preferences; and 3) pharmacist-PCP communication in which the pharmacist provides tailored deprescribing recommendations designed to be useful and actionable for the PCP
223531135|NCT03766061|PROCEDURE|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
224091494|NCT03293654|DRUG|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
224091495|NCT03293654|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
224091496|NCT03293654|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
224091497|NCT01919307|OTHER|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
223922496|NCT06746610|DIAGNOSTIC_TEST|Genetic Screening for Monogenic Diabetes|"This intervention involves genetic testing for monogenic diabetes (MDM) in recruited participants. The testing includes either a panel test specifically targeting genes associated with monogenic diabetes or whole exome sequencing (WES) to comprehensively identify genetic variants linked to MDM.~Precise diagnosis and treatmen：~1. The clinical trial of individualized treatment was carried out for the individuals with diabetes with HNF1A mutation.~2. The research team will closely follow up individuals with GCK mutation diabetes after suspending the current hypoglycemic drugs, and evaluate their clinical glucose metabolism related indicators.~3. Observe the dosage of sulfonylurea drugs used in individuals with different disease course and pancreatic function, and observe the impact of disease course and pancreatic function on the success rate of oral drug replacement."
224091498|NCT05766735|BEHAVIORAL|Routine Care + Glycemic Excursion Minimization (RC+GEM)|In addition to receiving routine care, participants will receive GEM, a structured, self-directed, and personalized program that will allow participants with pre-diabetes to improve their metabolic status by illustrating the effects of their routine food and physical activity choices on their blood glucose levels and variability.
224091499|NCT05766735|OTHER|Routine Care (RC)|RC participants will meet with their primary care provider to determine the best diabetes medication and proper dose. The participant will be allowed to change medications, or use a combination of medications, that is best suited for their care during the duration of the study. The study team will not influence these decisions.
223922497|NCT06757491|DEVICE|repeated transcranial magnetic stimulation treatment|"IBS patients received repetitive transcranial magnetic stimulation at~1 Hz/s for 20 minutes for 2 weeks."
224091500|NCT03742427|DIAGNOSTIC_TEST|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonography on both eyes
223922498|NCT03782116|DEVICE|Transcutaneous electrical stimulation (Elitone)|Transcutaneous perineal area electrical stimulation
224091501|NCT04507815|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
224091502|NCT04507815|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
224279996|NCT04573296|DEVICE|Vitadio|A 6-month digitally administered behavioral change program Vitadio focus on lifestyle change and self-management. The program aims for strengthening patients autonomy with the goal to promote weight loss and improve metabolic health. The program includes personalized education, adaptive daily tasks and weekly goals, automated motivational and educational messaging, monitoring tools, recipes, peer-support group and remote coaching.
224279997|NCT04573296|BEHAVIORAL|Conventional high-intensity lifestyle intervention program|A 6-month high-intensity lifestyle intervention program consisting of 5 face-to-face nutrition/lifestyle education sessions. Participants can use an online diary tool for recording meals with an option to receive remote feedback on their diet from the educator.
224279998|NCT02270424|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
224279999|NCT02270424|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
223922499|NCT06754215|BEHAVIORAL|Focus Group|Participate in focus group
223922500|NCT06754215|OTHER|Interview|Participate in semi-structured interview
223922501|NCT06754215|BEHAVIORAL|Smoking Cessation Intervention|Participate in feasibility study of intervention components
223922502|NCT06754215|OTHER|Survey Administration|Complete survey
223922503|NCT06756126|DRUG|AK120|AK120 subcutaneous injection
224091503|NCT04408456|DRUG|HCQ|Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)
224091504|NCT04408456|OTHER|Standard therapy|Home quarantine for 2 weeks plus social distancing plus personal hygiene
224091505|NCT01346930|DRUG|Macitentan|10 mg, tablet, once daily
224091506|NCT06959745|DRUG|Magnesium-L-Threonate|Magnesium L-threonate, 1740 mg, taken orally, twice a day, for 8 weeks.
224091507|NCT06959745|DRUG|Placebo|Placebo, 1740 mg, taken orally, twice a day, for 8 weeks.
224091508|NCT06961136|DRUG|Fuzheng Yangxin prescription|Fuzheng Yangxin prescription
224091509|NCT06961136|DRUG|placebo|placebo
224091510|NCT06961955|RADIATION|Radiation Therapy|Undergo hypofractionated radiation therapy
224091511|NCT04459845|BEHAVIORAL|Parent Child Interaction Therapy|Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.
224091512|NCT04459845|BEHAVIORAL|Child Parent Psychotherapy|Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
224091513|NCT00925847|DRUG|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
224091514|NCT06110650|DRUG|Surufatinib|Surufatinib 300mg orally, once a day, every 21 days for one cycle, treatment until disease progression or intolerance
224280000|NCT02270424|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
224280001|NCT02270424|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
223922504|NCT06756048|PROCEDURE|Rhomboid Intercostal Nerve Block|"Following standard ASA monitoring, patients were positioned on the surgical table with their backs facing the operator. Skin antisepsis was achieved using povidone. A high-frequency 8-18 MHz linear ultrasound probe was used.~After palpating the rhomboid muscles and intercostal spaces at the T6-T7 levels, the medial border of the scapula and the vertebral column were identified. The ultrasound probe was placed horizontally along the medial border of the scapula. Using ultrasound guidance, the ribs, rhomboid muscles, intercostal muscles, and pleura were visualized. Once these anatomical structures were clearly identified, a 50 mm, 22G regional block needle was advanced in-plane from caudal to cranial under ultrasound guidance until the interfascial plane beneath the rhomboid muscles was reached and total of 20 ml of 0.25% bupivacaine (Marcaine® 0.5%, AstraZeneca PLC, London, UK) was injected."
223922505|NCT06751628|DEVICE|Insides system|The miniaturization of the pump proposed by Insides System enables the patient to perform CR independently and to carry the pump anywhere, thus facilitating outpatient implementation of CR.
223922506|NCT06758375|DRUG|Low-dose teclistamab|NDMM patients will receive VRd 3x cicles followed by low dose teclistamab.
223922507|NCT04084496|DRUG|Folfirinox|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
223922508|NCT06570018|PROCEDURE|Post operative enhanced recovery elements|According to the study group the researchers collaborated with surgeons, nurses, and anesthesiologists to implement post operative enhanced recovery protocol that defined clearly in the following elements Early nutrition, Early mobilization, Non-opioid analgesia. Early removal of abdominal drains and tubes throughout the patients' hospital stay up to their discharge.
223922509|NCT06762262|COMBINATION_PRODUCT|Moderate-Intensity continuous training|refers to a type of aerobic exercise that involves maintaining a steady and moderate level of physical activity for an extended period. The exercise is performed at a consistent and moderate pace without significant fluctuations in intensity. MICT primarily targets the aerobic energy system, enhancing cardiovascular endurance and respiratory efficiency
224091515|NCT00318435|DEVICE|Stent or stent-graft deployment|
224091516|NCT05784389|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
224091517|NCT06637176|DEVICE|Laser speckle contrast imaging|"LSCI measurements will be taken before and after the formation of the anastomosis, with the surgeon blinded to the measurements to prevent any influence on surgical decision-making. The surgery will be performed as standard-of-care, unaffected by the LSCI measurements.~Following the surgery, the LSCI images will be presented to the surgeon, who will complete a questionnaire assessing whether the LSCI images, if presented perioperatively, would have influenced their decision regarding the location of the anastomotic site. Additionally, the surgeon will be asked if they consider LSCI to be a useful intraoperative tool in general. The surgical case and the series of LSCI images will also be presented to an independent surgeon, who will answer the same set of questions.~The LSCI measurements will be correlated with 30-day complication rates, with a specific focus on anastomotic leakage (AL).~Microcirculation is assessed using LSCI at a wavelength of 785 nm (MoorFLPI-2, Moor Instruments"
224091518|NCT05762198|DEVICE|Rezūm|In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
224091519|NCT05762198|DEVICE|TURP|In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
224091520|NCT06346548|OTHER|oral photography|The patient will under go three different color detecting methods. Two photography methodologies and one intra oral digital scanner
224091521|NCT06335082|DEVICE|Pulsed Field Ablation|Ablation using the Boston Scientific Farapulse Pulsed Field Ablation System for the treatment of atrial fibrillation (AF)
224091522|NCT02296060|PROCEDURE|6 minutes walking test|
224091523|NCT00940004|BIOLOGICAL|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
224091524|NCT04000477|DEVICE|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
224091525|NCT04000477|DEVICE|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
224091526|NCT01953952|PROCEDURE|therapeutic conventional surgery|Undergo transoral eHNS
224280002|NCT02270424|DRUG|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
224280003|NCT02270424|DRUG|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
224091527|NCT01953952|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
224091528|NCT01953952|DRUG|cisplatin|Given IV
224091529|NCT01953952|PROCEDURE|quality-of-life assessment|Ancillary studies
224091530|NCT01953952|OTHER|laboratory biomarker analysis|Correlative studies
224091531|NCT00838357|DRUG|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
224091532|NCT02542176|OTHER|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
224091533|NCT02542176|OTHER|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
224280004|NCT02270424|DRUG|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
224280005|NCT00251914|DRUG|Esomeprazole|
224091534|NCT04566484|DRUG|BBV87 Chikungunya vaccine|BBV87 Chikungunya vaccine is a whole virus inactivated vaccine formulated with 0.25 mg aluminum (as aluminum hydroxide) per single human dose.
223922510|NCT06761027|DRUG|Anlotinib combined with Sintilimab|Based on the mFOLFIRINOX chemotherapy regimen, combined with the safe dose of anlotinib determined in phase Ib and sintilimab.
223922511|NCT06753500|PROCEDURE|Autonomic neural blockade|"Autonomic nerve block performed with:~* Bupivacaine: 20 mL of 0.5%.~* Dexamethasone: 8 mg."
223922512|NCT06809673|OTHER|blood sampling|"blood sampling at baseline, 1,3,6 months after surgery and eventually when recurrence is detected.~If adjuvant treatment is planned, blood sampling at baseline, 1 month after surgery, 1,3,6 months after the last fraction of RT and eventually when recurrence is detected."
223922513|NCT06672068|DRUG|TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
223922514|NCT06672068|DRUG|TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin|TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
223922515|NCT06792513|DEVICE|Clear Aligner|In this intervention, clear aligners were digitally designed using three-dimensional models for the upper jaw. Attachments were applied to the patients, specifically placed on the incisors exhibiting a crossbite relationship and on the permanent first molars in the posterior region. The series of clear aligners were replaced every 10 days. The aligners were used full-time, except during meals and tooth brushing.
223922516|NCT06792513|DEVICE|Labiolingual Spring Hawley Appliance|In this intervention, a custom-made labiolingual spring Hawley appliance was designed for the upper jaw. It included two Adams clasps, a vestibular arch, and an active labiolingual spring positioned on the palatal side of the incisor in crossbite. The spring was activated every 10 days. The appliance was used full-time, except during meals and tooth brushing.
223922517|NCT06845176|DEVICE|Tendon vibration (TV)|We use the VIBRAMOOV PHYSIO device which delivers local muscle vibrations at frequencies of 80 Hz and an amplitude of 1 mm.
223922518|NCT06845176|OTHER|Kinesthetic motor imagery (kMI)|kMI is a mental technique in which an individual visualizes performing a movement without physically executing it. This process involves the internal representation of the sensations associated with the movement, engaging neural pathways similar to those activated during actual physical movement. kMI stimulates key motor and sensory areas in the brain, promoting neuroplasticity and enhancing motor performance.
224091535|NCT04566484|DRUG|Normal Saline|Normal saline is the placebo
224091536|NCT00000148|PROCEDURE|Argon Laser Trabeculoplasty|
224091537|NCT00000148|PROCEDURE|Trabeculectomy|
224091538|NCT02542267|DEVICE|Gore VIABAHN Endoprosthesis|
223922519|NCT04997525|DRUG|Estradiol Tablets|Combined with progesterone
223922520|NCT04997525|DRUG|Progesterone|Combined with estradiol
223922521|NCT04997525|DRUG|Follitropin Alfa|Combined with hCG
223922522|NCT04997525|DRUG|Chorionic Gonadotropin, Alpha|In either natural cycle or combined with Follitropin Alfa
223922523|NCT06756672|DEVICE|HPI guidance|patients with HPI guidance
223922524|NCT06756672|DEVICE|No HPI guidance|patients without HPI guidance
223922525|NCT06855784|BEHAVIORAL|Time-Restricted Eating 16h/8h|Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
224280006|NCT00697216|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
223922526|NCT06855784|BEHAVIORAL|Active Control|Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities
223922527|NCT06858020|PROCEDURE|Prophylactic polypropylene onlay mesh|The patients in the mesh group are closed with small bites technique and in addition receiving an onlay polypropylene mesh when closing the fascia in midline laparotomies.
223531136|NCT05086861|DEVICE|Oesophageal pacing after left atrial posterior wall isolation|Following AF ablation with the aim of isolating the left atrial posterior wall oesophageal pacing and sensing is performed to check for left atrial posterior wall. entrance and exit block.
223531137|NCT01332214|DRUG|AZD2820|Subcutaneous Injection in abdomen or Thigh
223531138|NCT01332214|DRUG|Placebo|Subcutaneous Injection in abdomen or Thigh
223922528|NCT06824337|OTHER|mobilization training and targeted mobilization|In the first interview with the patients, the content of the early mobilization training given to the patients, what early mobilization is, why it is important, what benefits it provides, what the mobilization goals determined for the patient within the scope of the research, the benefits of walking and the expected results will be explained. It will be explained how to benefit from the smartphone during the mobilization process. In addition to all the training, the patients in the intervention group will be given detailed information about what they need to record in the mobilization diary (total time they walked, how many steps they took in the pedometer application after each mobilization, positive/negative situations they experienced while standing up and walking) and all the forms that will be used in the data collection phase.
224091539|NCT03720314|OTHER|NA observational study|observational study
224091540|NCT02321592|DRUG|AFM13|
224091541|NCT04082104|DIAGNOSTIC_TEST|Stuttering Severity Instument version 3|Riley's Stuttering Severity Instrument is used for the objective assessment of severity and in other examinations of stuttered speech. Current versions of the instrument measures three parameters: 1) stuttering frequency; 2) duration of selected stutters; 3) observed physical concomitants.
224091542|NCT00386841|DRUG|Escitalopram|Escitalopram 10 mg p.o. per day
224091543|NCT00386841|DRUG|Placebo|Placebo
224091544|NCT00333996|DRUG|Dexamethasone|
224091545|NCT00359892|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
224091546|NCT01636492|DRUG|bitopertin|Single oral dose
224091547|NCT01636492|DRUG|placebo|Single oral dose
224091548|NCT00041314|DRUG|carboplatin|
224091549|NCT00041314|DRUG|exisulind|
224091550|NCT00041314|DRUG|gemcitabine hydrochloride|
224280007|NCT00697216|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
224280008|NCT01695096|OTHER|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
223922529|NCT05155943|DEVICE|KALPA X™|Before and after a transseptal puncture, the right atrium (RA), left atrial appendage (LAA), and left upper superior pulmonary vein (LUSPV) will be mapped using the KALPA™ system (WS Software ver. 1.0.229-0 Source control ID: 65f1dbf7) in combination with a commercially available catheter. Subjects will then undergo LAAC as per routine clinical care. The entire LAAC procedure will be conducted as customary practice using standard and approved off-the-shelf equipment (body surface electrodes, catheters, etc.) the operator will be blinded to the KALPA™ and KALPA X™ system information.
223922530|NCT06754891|DRUG|TQH3906 capsules|TQH3906 is an allosteric inhibitor targeting kinase.
223922531|NCT06866821|OTHER|SMWAM's and PNF C-R Technique|"Treatment provided 3 days every week in 6 total weeks with 1 meeting per day, 3 bunches of 10 times repeat and resting period of one minute among bunches. This group received Mulligan's spinal mobilization with arm movement and proprioceptive neuromuscular facilitatin contract-relax technique. Previous to mobilization, all patients got hot pack (10 minutes) and active range of motion warm up exercises (2 sets of 10 repetitions) and did isometric neck exercise as a home plan of care.~Mobilisation (22) was done depending on the side of involvement, the corresponding spinous process would be mobilised combined with different movements of shoulder (flexion/ abduction/ horizontal abduction/ horizontal adduction).~Proprioceptive neuro-muscular facilitation contract relax technique performed with 3 repetitions in each cervical movement (flexion, extension, lateral flexion and rotation) (27)."
223922532|NCT06866821|OTHER|PNF C-R Technique and PT Protocol|"Treatment provided 3 days every week in 6 weeks with 1 meeting per day, 5 clusters of 3 times repeat and resting period of one minute among clusters. Regime of training involved PNF (proprioceptive neuromuscular facilitation) contract-relax method along with the standard physical therapy protocol which includes passive stretching (3 sets of 10 repetitions) and isometric strengthening exercises (2 sets of 10 repetitions).~Proprioceptive neuro-muscular facilitation contract relax technique performed with 3 repetitions in each cervical movement (flexion, extension, lateral flexion and rotation) (27)."
223922533|NCT06764966|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg Once Daily with previously prescribed Non Selective Beta-Blocker
223922534|NCT06764966|DRUG|Placebo|Placebo Once Daily along with previously prescribed Non Selective Beta Blocker
223717394|NCT06241534|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
223717395|NCT06241534|BEHAVIORAL|Relaxation-therapeutic recordings|"8 sessions of relaxation-therapeutic recordings in the non-sleep deep rest concept.~The content of the recording is based on the 'body scanning technique', which constitutes the core of the therapy. This approach aims to quiet the overactive sympathetic part of the autonomic nervous system. During therapy, the patients take a 'journey' through their own body from feet to head. Following the voice of the narrator, the patient focuses on specific body parts, tries to feel this place and then relaxes tense muscles. Relaxation of individual body parts (muscle groups) is combined with breathing exercises. Conscious and mindful breathing deepens the state of relaxation. Additionally, the recording includes therapeutic suggestions related to making a choice between: overload and relief, holding on and letting go, acting and sensing. Furthermore, suggestions focus the patient on inner wisdom that allows them to make the best decisions."
223922535|NCT06883253|BEHAVIORAL|treadmill walking|all participants walking at increasing speeds on a treadmill
223922536|NCT05578963|OTHER|Schaeffer's Test for palmaris tendon|After demographics, Schaeffer's Test will be used to check the presence or absence of palmaris longus muscle. In this test, students will maintain the forearm at 90 degrees first followed by moving the thumb in opposition towards the little finger with the wrist partially flexed. If the tendon bulges out, it will reflect presence of palmaris longus and vice versa. This finding will be recorded. After that, students will perform Phalen's test. In this test, researcher will ask them to press the backs of their hands and fingers together with their wrists flexed and fingers pointed down. they'll stay that way for a minute or two. If fingers tingle or get numb, it will indicate carpal tunnel syndrome. The reading will be recorded.
223922537|NCT05974904|OTHER|high-sensitivity C-reactive protein to albumin ratio|High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
224280009|NCT01695096|OTHER|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
224280010|NCT04591652|DRUG|99mTc-MIRC208|99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
224280011|NCT02970552|DRUG|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
224280012|NCT02970552|DRUG|Placebo|Indistinguishable placebo vaginal suppository
224280013|NCT02510261|DRUG|Patisiran|Patisiran was administered IV.
224280014|NCT02740920|DRUG|Pembrolizumab|
224280015|NCT02740920|PROCEDURE|CT Scan|
224280016|NCT01064531|DEVICE|MIS Femoral Neck Stem implant|
224280017|NCT00485030|DEVICE|Cypher|sirolimus-eluting stent
224280018|NCT00485030|DEVICE|Xience-V|everolimus-eluting stent
224280019|NCT01357434|BEHAVIORAL|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
224280020|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
224280021|NCT01079819|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
224280022|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
224280023|NCT01079819|DRUG|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
224280024|NCT03172052|DRUG|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is \>100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
224280025|NCT03172052|DRUG|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
223922538|NCT06818123|OTHER|Education Intervention along with the doctor's consultation|This educational intervention will assess the improvement menstrual hygiene knowledge and practices among women at slums who are illiterate and can empower individuals to manage their periods with dignity and comfort.
224091551|NCT05939297|OTHER|Heart Health Self-efficacy and Self-Management Scale|In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
223922539|NCT06818123|OTHER|Control group with doctor's consultation only|Baseline Knowledge will be assessed in this arm about the menstruations hygiene and practices.
223922540|NCT06596772|DRUG|MB04 (proposed biosimilar to etanercept)|MB04 50 mg/week via subcutaneous injection
223922541|NCT06596772|DRUG|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
223922542|NCT04546230|PROCEDURE|Low-Thoracic Epidural Anesthesia|"Under aseptic conditions and local anesthesia, an epidural catheter will be inserted using the Prefix Epidural Anesthesia Tray with an 18 G Tuohy needle \& a 20 G catheter at the T7-8 or T8-9 intervertebral space. The epidural catheter will be threaded leaving 3 cm within the epidural space and tapped in place.~Using a mixed preparation of isobaric Bupivacaine 0.5% with Fentanyl 2 μg per ml volume, a bolus dose of 5-10 ml will then be given via the epidural catheter, followed by 5-10 ml/hr as a continuous infusion to be started 1 hour later \& continued throughout the procedure."
223922543|NCT04546230|PROCEDURE|General Anesthesia|General anaesthesia will be induced with intra-venous administration of Fentanyl (2 μg/kg), Propofol (2 mg/kg), Atracurium (0.5 mg/kg) and Lidocaine (1 mg/kg). After tracheal intubation, balanced anaesthesia will be maintained with isoflurane in oxygen \& infusion of atracurium at a rate of 0.5 mg/kg/hr; and mechanical ventilation will be provided.
223922544|NCT06841744|OTHER|Diaphragmatic Breathing Exercise|Diaphragmatic breathing exercises will be performed twice a day, completing 3 sets of 10 repetitions, 5 days a week for 6 weeks, as instructed by the researcher physiotherapist.
223922545|NCT06841744|OTHER|Information brochure|An information brochure on ergonomic strategies for managing low back pain during pregnancy will be provided.
223922546|NCT03328026|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally at 4 sites.
223922547|NCT03328026|DRUG|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
223922548|NCT03328026|DRUG|Interferon Inoculation|Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
223922549|NCT03328026|DRUG|retifanlimab|retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
223922550|NCT06861569|PROCEDURE|Positive end expiratory pressure|Positive end-expiratory pressure (PEEP) is a value that can be set up in patients receiving invasive or non-invasive mechanical ventilation. 5cmH2O PEEP will be applied to the PEEP group participants.
223922551|NCT06856837|DRUG|Fruquintinib|highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3
223922552|NCT06856837|DRUG|Tislelizumab|humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)
224091552|NCT05939297|OTHER|Self-Care Management Scale in chronic diseases|For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
224280026|NCT03172052|DEVICE|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
224280027|NCT03172052|DEVICE|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
224280028|NCT03449199|DRUG|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
224280029|NCT03449199|DRUG|Placebo|Matching placebo to be taken orally, once daily
224280030|NCT04355299|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
224280031|NCT04355299|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
224280032|NCT04355299|BEHAVIORAL|aerobic exercise|Aerobic exercise is any activity that gets your blood pumping and large muscle groups working. It's also known as cardiovascular activity.
224280033|NCT04355299|BEHAVIORAL|usual care|received usual care
224280034|NCT00003098|OTHER|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
224280035|NCT00003098|OTHER|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
224280036|NCT03497832|OTHER|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
224280037|NCT04797442|DRUG|WST01 strain product|orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)
223922553|NCT06856837|DRUG|Trifluridine/tipiracil|trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor
223922554|NCT06856837|DRUG|Bevacizumab|recombinant humanized anti-VEGF monoclonal antibody composed of human IgG1 framework regions and antigen-binding, complementarity-determining regions from a murine monoclonal antibody (muMAb VEGF A4.6.1)
223922555|NCT06811207|DRUG|Vonoprazan|Vonoprazan (20 mg bid, for 14 days)
223922556|NCT06811207|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg tid, for 14 days)
223922557|NCT06811207|DRUG|Amoxicillin|Amoxicillin (750 mg qid, for 14 days)
223922558|NCT06870890|DIAGNOSTIC_TEST|muscle evaluation|The investigators will evaluate the muscle mass and muscle strenght for all patients included
223922559|NCT06870890|BIOLOGICAL|Dosage|Evaluation of the cinetic of biomarkers during exercise
223922560|NCT06870890|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|CPET
223922561|NCT06870890|COMBINATION_PRODUCT|Questionnaire and Physical Exam|Evaluating dyspnea, anxiety, sleep, physical activity, quality of life
224091553|NCT05939297|OTHER|general self-efficacy scale|For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
224091554|NCT01355289|DRUG|Avatrombopag|
223922562|NCT06693986|BIOLOGICAL|Replicative Adenovirus Vector (RGDCRAdCOX2F)|"RGDCRAdcox2F (RGD) is a local product and is provided through this study."
223922563|NCT06881524|DRUG|First-line licorice and lotus root powder combined with low-dose amoxicillin|For first-line experimental group, patients would receive vonoprazan 20mg twice daily, amoxicillin 0.75g three times daily for 10 days, licorice and lotus root powder 5.0g twice daily for an additional 6 weeks
223922564|NCT06881524|DRUG|First line high-dose amoxicillin|For first-line active comparator group, patients would receive vonoprazan 20mg twice daily, amoxicillin 1 g three times daily for 10 days
223922565|NCT06881524|DRUG|Rescue licorice and lotus root powder combined with low-dose amoxicillin|For rescue experimental group, patients would receive vonoprazan 20mg twice daily, amoxicillin 0.75g three times daily for 10 days, licorice and lotus root powder 5.0g twice daily for an additional 6 weeks
224091555|NCT01355289|DRUG|Placebo|
224091556|NCT01355289|DRUG|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
224091557|NCT01355289|DRUG|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
224091558|NCT01355289|DRUG|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
223922566|NCT06881524|DRUG|Rescue high-dose amoxicillin|For rescue active comparator group, patients would receive vonoprazan 20mg twice daily, amoxicillin 1 g three times daily for 10 days
223922567|NCT06889077|OTHER|QR Code Group|Students will receive support in their clinical practice through QR Code-supported perioperative education materials.
223922568|NCT06750172|DIAGNOSTIC_TEST|The oral sodium loading test|The subjects underwent an oral high-salt diet test with an additional 10g of salt per day for 3 consecutive days, and 24-hour urine measurements of aldosterone, sodium, potassium and creatinine were obtained on days 2 and 3
223922569|NCT06859463|DEVICE|Muscle function|Functional evaluation First, the patients will fill the Fysisk Aktivitet Questionnaire, the o Klinisk Oral Fysiologi (KU) Questionnaire and the Harvard Trauma Questionnaire. Then, the evaluator will applicate the Total Tenderness Score (TTS) for evaluating their tenderness in different spots of the head and neck regions. The next evaluation comprehends the evaluation of the maximal voluntary isometric contraction (MVIC) for the different neck movements and the rate of force development (RFD) of the shoulder elevation. After this, patients will perform the cranio-cervical flexion test (CCFT), and, finally, the Ito test to evaluate the lumbar endurance.
223922570|NCT06876870|DRUG|Anesthesia Maintenance Agent|Difference in renal blood flow (RBF) between Propofol and Sevoflurane groups. Quantified by specific Multiparametric MRI metrics (e.g., (Renal blood flow by phase contrast imaging) (regional perfusion by Arterial Spin labeling (ASL) and global and regional oxygenation by Blood oxygen dependent signal (BOLD))
224091559|NCT01964248|DRUG|Placebo|Placebo cream applied 2 hours before blood sample
224091560|NCT01964248|DRUG|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
224091561|NCT01085682|BEHAVIORAL|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
224091562|NCT01085682|BEHAVIORAL|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
224091563|NCT03906266|DIAGNOSTIC_TEST|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
223922571|NCT06879847|PROCEDURE|Salvage Allogeneic Hematopoietic Stem Cell Transplantation|"1. TBI+BUMEL (IBM) Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally, Day -7; Day -6: Total Body Irradiation (TBI) 4Gy, in two parts, Day -6; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion~2. Donor Stem Cell Infusion (Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg)."
223922572|NCT06879275|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|2 self administered questionnaire for diagnosis of dismorphophobia will be administered
223922573|NCT06878339|BEHAVIORAL|A social robot KaKa-assisted intervention|A social robot KaKa-assisted intervention (SRAI) to provide auditory rehabilitation and physical activity program
223922574|NCT06679803|BEHAVIORAL|Physical Activity Chats after Stroke (PA-ChatS)|"PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety."
223922575|NCT06792292|OTHER|conventional colonoscopy procedure|Study subjects in this interventional arm will undergo conventional colonoscopy.
223922576|NCT06792292|OTHER|artificial intelligence-assisted colonoscopy procedure|Study subjects in this interventional arm will undergo colonoscopy done with a commercially-available module that uses artificial intelligence to highlight suspected polyps on the screen during colonoscopy. This module also attempts to characterize the detected polyp as adenomatous or not. The detection and characterization of polyps is in real time, during the procedure.
223922577|NCT06888401|PROCEDURE|ERCP|
223922578|NCT06738069|OTHER|Participants are not assigned an intervention as a part of the study|Participants are not assigned an intervention as a part of the study
223922579|NCT06750510|BEHAVIORAL|Digitally Delivered Parent Training|The intervention is a universal, digitally delivered parenting program, including 5 themes with recommended length of 1 week each. The total length of the intervention is 8 weeks. The program focuses on positive parenting, encouraging to develop parenting skills that strengthen their relationships and communication with their children.
223922580|NCT06751836|OTHER|Infection and no infection|No intervention apart from the dengue infection
223922581|NCT06753630|BEHAVIORAL|Extensor Muscle Strengthening Exercise|A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
223922582|NCT06753630|PROCEDURE|Extracorporeal Shockwave Therapy|A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.
223922583|NCT06753630|DRUG|Saline injection (Octreotide LAR placebo)|A 3mL injection of saline solution used as a placebo in the study.
223922584|NCT06753630|DRUG|Polydeoxyribonucleotide Injection|A 3mL injection of polydeoxyribonucleotide (5.625mg/3mL) used to enhance the healing process and improve outcomes in lateral epicondylitis treatment.
223922585|NCT06869681|DRUG|Topical Sertaconazole 2%|After cleaning the identified lesions, the patients will topically self-apply the both products/creams using a cotton swab applicator, where the applied amount will be able to make the lesions be covered with a thin layer of medication. Both the creams will be applied topically twice daily for 4 weeks.
223922586|NCT06869681|DRUG|Clotrimazole 1%|Same as above
223922587|NCT06875375|DIETARY_SUPPLEMENT|probiotic LH76|Intervention with LH76 (30 billion CFU/ day, 3g) was administered daily for 8 weeks. Store in a cool, dry place.
223922588|NCT06875375|DIETARY_SUPPLEMENT|Placebo|Every day to give 3 g maltodextrin intervention for 8 weeks. Store in a cool and dry place.
223922589|NCT04750551|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
223922590|NCT04750551|DEVICE|EStim|EStim will applied for 10 to 20 minutes.
223922591|NCT06786702|PROCEDURE|Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Preservation|Group 1 (Round Ligament Preservation): Patients will undergo laparoscopic TAPP surgery with the round ligament preserved. The preservation will be achieved using a longitudinal incision technique in the peritoneum.
223922592|NCT06786702|PROCEDURE|Laparoscopic TAPP (Trans Abdominal Pre-Peritoneal) hernia repair: Round Ligament Cutting|Group 2 (Round Ligament Cutting): Patients will undergo laparoscopic TAPP surgery with the round ligament cut close to the peritoneum using an energy device.
223922593|NCT06872372|DRUG|N-Acetylcysteine (NAC) Treatment|Participants in this group received N-Acetylcysteine (NAC) at a dose of 140 mg/kg orally or via a nasogastric tube every 4 hours for the first 16 hours, followed by the same dose at intervals of 6-8 hours for a total of 3 days, alongside standard supportive care for acute liver failure.
223922594|NCT06872372|OTHER|Standard supportive care|Participants in this group received only standard supportive care for acute liver failure, without N-Acetylcysteine (NAC). Standard supportive care included measures to prevent hypoglycemia, administration of broad-spectrum antimicrobials, proton pump inhibitors, fluid and electrolyte balance maintenance, and supportive treatment for hepatic encephalopathy.
223922595|NCT06922214|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT ( 25 Gy single fractions at isodose 80%) on the area responsible of ventricular tachicardia
224091564|NCT01451645|DRUG|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
223922596|NCT06736002|OTHER|Vitamin D|Vitamin D
224091565|NCT01451645|DRUG|placebo|daily placebo dosing for 16 weeks
224091566|NCT01451645|DRUG|allopurinol|background therapy
224091567|NCT03089307|DEVICE|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
224091568|NCT06140771|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
224091569|NCT06140771|DRUG|1.15% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
223922597|NCT06736002|OTHER|Placebo|Placebo oral solution
223922598|NCT06861309|DEVICE|ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS)|All study participants, regardless of arm, will receive a combine ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS) research exam with the Verasonics Vantage 256 (Verasonics, Inc, Kirkland, WA) every three weeks from their routine growth ultrasound until delivery.
224091570|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
224091571|NCT06140771|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
224280038|NCT04797442|DRUG|placebo powder|orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
224280039|NCT00793117|PROCEDURE|packing|packing in middle meatus for duration of 5 day
224280040|NCT05802199|DIAGNOSTIC_TEST|Hepatic fat fraction and hepatic fibrosis|"All patients underwent measurement of UDFF for hepatic fat fraction and auto-pSWE for hepatic fibrosis.~All patients underwent measurement of MRI-PDFF for hepatic fat fraction and MRE for hepatic fibrosis as reference standard."
224280041|NCT05736380|DEVICE|Cerebellar rTMS|250 pulses at 10 Hertz over the cerebellum
224280042|NCT05736380|DEVICE|Sham cerebellar rTMS|Sham cerebellar rTMS
224280043|NCT05179447|RADIATION|Vaginal brachytherapy|"Internal radiation of the vaginal vault using a vaginal cylinder. For brachytherapy administered alone it is recommended: suggested dose is either 3 fractions of 7 Gy or 5 fractions of 6 Gy.~For brachytherapy administered after completion of External beam radiotherapy (EBRT):~Total dose should aim to be 65 Gy, and suggested dose is 2-3 fractions of 5-6 Gy"
224280044|NCT05179447|RADIATION|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 45-50 Gy in 25-28 out-patients sessions
224280045|NCT05179447|OTHER|Observation|No adjuvant therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
224280046|NCT05179447|COMBINATION_PRODUCT|Chemoradiation therapy|4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )
224280047|NCT06698133|OTHER|Participants in the intervention arm will be invited to join a private social media group|Education content
224280048|NCT06426927|OTHER|Colorectal Cancer Educational Videos in Spanish|Enrolled participants will watch three educational videos on Colorectal Cancer (CRC) in Spanish. Knowledge on CRC symptoms, risk factors, facts, screening and treatment will be assessed before and immediately after the educational video and at 30 +/- 7 days. In addition, the association between increase in CRC knowledge and willingness to participate in Cancer Clinical Trials (CCT) will be explored.
224280049|NCT00633698|DRUG|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
224280050|NCT00633698|DRUG|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
224280051|NCT01601691|DEVICE|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
224280052|NCT00850681|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
224280053|NCT06614751|DRUG|DAT-2645 tablet|The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
223922599|NCT06744452|BEHAVIORAL|harmony|Use of the app-based digital self-help intervention harmony over a 12-week-period. The app was designed for stress management and the preventive promotion of mental health. Harmony provides users with access to a wide range of psychological self-help content, including video episodes, audio sessions, texts, and downloadable materials. Utilizing artificial intelligence, Harmony offers personalized content suggestions tailored to the user's individual situation and preferences, ensuring the content remains relevant and updated. Content is delivered through a combination of psychoeducation, guided exercises, relaxation techniques, meditations, practical tasks, self-reflection activities, and everyday application tasks.
223922600|NCT05738486|DRUG|Donanemab|Administered IV
223922601|NCT05738486|DRUG|Placebo|Administered IV
223922602|NCT05738486|DRUG|Dexamethasone|Administered IV
223922603|NCT05372042|BEHAVIORAL|CBT Text Messages|CBT skills based text messages delivered 3x per week for four weeks
223922604|NCT04947462|DEVICE|Chronically Implanted Neural and Muscular Interface|Participants will be chronically implanted with neural and muscular interfaces to characterize proprioceptive sensations using Functional Electrical Stimulation (FES).
224280054|NCT06614751|DRUG|DAT-2645 tablet|The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
224280055|NCT02618382|DRUG|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
224280056|NCT02445287|RADIATION|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
223922605|NCT00983307|DRUG|Erlotinib|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
223717396|NCT06241534|DEVICE|Virtual reality therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
223717397|NCT06241534|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
224091572|NCT05065112|PROCEDURE|Pulmonary veins isolation + Cartofinder-guided ablation|The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.
224091573|NCT05065112|PROCEDURE|Pulmonary veins isolation|Wide area circumferential pulmonary veins isolation
224091574|NCT03920969|BEHAVIORAL|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
224280057|NCT03235479|DRUG|Rimegepant|75 mg tablet QD
224280058|NCT03235479|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
224280059|NCT01904006|PROCEDURE|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
224280060|NCT01904006|PROCEDURE|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
224280061|NCT00982631|DRUG|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
224280062|NCT06167252|OTHER|Exploration of a database|extraction of data
224280063|NCT03332251|DEVICE|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
223717398|NCT04448288|OTHER|Static stretching|Static stretchings were performed by subjects that involved varied repetitions of 30-s static-stretches and 20-s relax period.
223922606|NCT00983307|RADIATION|Hypofractionated Radiotherapy|Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
223922607|NCT06954480|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.
223922608|NCT06954480|DRUG|Durvalumab|Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.
224280064|NCT00367016|DRUG|Omalizumab|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
224280065|NCT00367016|DRUG|Placebo|Placebo, given by subcutaneous injection.
224280066|NCT06059417|OTHER|2x2 inch piece of 3M microfoam adhesive|"A 2x2 inch piece of 3M microfoam adhesive will be applied to the medial aspect of the subject's upper arm.~The adhesive will remain in place for 48 hours at which time an investigator will remove the adhesive and assess the study area. A numerical value will be assigned based on the Cutaneous Irritancy Scoring System (CISS). The study site will be compared to the contra-lateral upper extremity at the end of the 48 hour period."
224280067|NCT05853809|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement to guide anti-inflammatory asthma treatment
224280068|NCT02419833|PROCEDURE|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
224280069|NCT02419833|PROCEDURE|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
224280070|NCT02419833|DEVICE|Coronary artery stenting|Implantation of coronary stents
224280071|NCT04836351|OTHER|Concentrated rehabilitation for patients with persistent symptoms post COVID-19|3+ 1-2 days concentrated rehabilitation for patients with persistent symptoms post COVID-19 with a mobile application follow-up and physical consultations at 3 months post intervention.
224280072|NCT00258505|PROCEDURE|Procedure: intracranial monitoring up to 9 days after injury|
224280073|NCT03490409|DEVICE|Thigh compression stocking|Thigh compression stocking
224280074|NCT06674694|DRUG|Brexpiprazole long-acting injection|A single injection was administered.
224280075|NCT03270592|OTHER|Service dog|Use of a individualized certified service dog
224280076|NCT03419104|DIAGNOSTIC_TEST|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
223922609|NCT04773834|OTHER|Digital diabetes prevention program (dDPP)|The digital diabetes prevention program is through the Noom app, and the three devices (Fitbit physical activity tracker, Fitbit weight scale, and self-check hemoglobin a1c kit). This is a one year diabetes prevention program where participants will be expected to participate in 5 to 7 interviews over a 18 month period.
223922610|NCT04773834|OTHER|Adapted dDPP-EHR tool|This is a product of Phase 1 and 2 of this study where participants will receive detailed text messaging regarding their engagement levels in Noom app.
223922611|NCT05222984|DRUG|Decitabine|Given IV
223922612|NCT05222984|BIOLOGICAL|Navitoclax|Given PO
223922613|NCT05222984|DRUG|Venetoclax|Given PO
223922614|NCT05896163|DRUG|maplirpacept (PF-07901801)|Intravenous infusion
223922615|NCT05896163|DRUG|Glofitamab|Intravenous infusion
223922616|NCT05896163|DRUG|Obinutuzumab|Intravenous infusion
223922617|NCT01837693|PROCEDURE|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
223922618|NCT05515705|DEVICE|EUS navigation system|Incorporation of the EUS navigation system to the EUS scope
223922619|NCT06166563|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).
224091575|NCT03156036|DRUG|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
224091576|NCT02562547|DEVICE|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
224091577|NCT03749395|PROCEDURE|Erector Spinae Plane Block|The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
224091578|NCT00004029|BIOLOGICAL|recombinant viral vaccine therapy|
224280077|NCT04197128|DEVICE|Resorbable Collagen membrane with bone graft for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision. Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, bovine bone graft will be place with overlying resorbable collagen membrane. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted Vicryl 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)"
223922620|NCT05805436|DRUG|Polyethylene Glycol 3350|Patients in the intervention arm will take polyethylene glycol 3350 for three days before robotic urologic surgery. Patients in the control arm will not.
223922621|NCT04665908|OTHER|Assessment by PT/Orth surgeon|Assessment by orthopaedic surgeon or a PT
223922622|NCT03801616|DEVICE|Virtual Reality|Virtual Reality in controlling pain
223922623|NCT05714384|DEVICE|CeraSeal (Calcium Silicate-based Root Canal Sealer)|A calcium silicate-based root canal sealer will be used in cases requiring root canal retreatment.
223922624|NCT01825226|OTHER|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
223922625|NCT04332744|DRUG|Enzalutamide|Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)
224091579|NCT00004029|BIOLOGICAL|sargramostim|
224091580|NCT05410990|DIAGNOSTIC_TEST|eosinophil and other hematological parameters|
224091581|NCT04948008|BIOLOGICAL|IBI306|IBI306 is a kind of Proprotein convertase subtilisin/kexin 9
224091582|NCT03623919|OTHER|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
224091583|NCT03756090|DRUG|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
223922626|NCT04332744|DRUG|Talazoparib|Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)
223922627|NCT02611687|DRUG|pitolisant|Tablet
223922628|NCT02611687|DRUG|Placebo|Tablet
223922629|NCT03873805|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
223922630|NCT03873805|DRUG|Cyclophosphamide|Given IV
223922631|NCT03873805|DRUG|Fludarabine|Given IV
224091584|NCT03756090|DRUG|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
224091585|NCT03756090|DRUG|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
224091586|NCT03756090|DRUG|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
223922632|NCT03873805|DRUG|Fludarabine Phosphate|Given IV
223922633|NCT06421012|PROCEDURE|Experimental : Patients without additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will not receive additional preoxygenation before any endotracheal suctioning; their FiO2 value will be maintained constant
223922634|NCT06421012|PROCEDURE|Active Comparator : Patients with additional preoxygenation|Throughout the entire period of their mechanical ventilation, patients will receive additional preoxygenation at 100% FiO2 for a systematic 2-minute duration prior to any endotracheal suction. Subsequently, the FiO2 will be reset to the previous default value.
223922635|NCT00447980|DRUG|NT-501|Low Dose
223922636|NCT00447980|DRUG|NT-501|High Dose
223922637|NCT04848974|DRUG|Cladribine|Given IV
223922638|NCT04848974|DRUG|Cytarabine|Given SC
223922639|NCT04848974|DRUG|Uproleselan|Given IV
223922640|NCT01057628|DRUG|ipragliflozin|oral
223922641|NCT01057628|DRUG|placebo|oral
223922642|NCT04745754|OTHER|Embedded primary care in cancer survivorship model|Primacy care physicians will receive comprehensive training in cancer survivorship care for low-risk, early stage breast and colorectal patients. Training will include continuing medical education (CME) modules, webinars, and in-person discussion and clinical shadowing.
223922643|NCT00262717|DIAGNOSTIC_TEST|Blood test: genotype testing|
223922644|NCT06424301|DRUG|Targeting NUDT21 siRNA drugs|It is performed for intravitreal chemotherapy.
223922645|NCT05325424|PROCEDURE|Laparoscopic splenectomy|The laparoscopic splenectomy was performed by the same surgical team.
223922646|NCT05922657|DEVICE|Cerene|Real world use of Cerene.
223922647|NCT06134921|DEVICE|transcranial direct current stimulation (Active)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Active-tDCS group, participants will receive real tDCS with intensity 2.0 mA for 30 minutes, with a 30-second ramp-up and ramp-down."
223922648|NCT06134921|DEVICE|transcranial alternating current stimulation (active)|Electrode placement based on the international 10 - 20 electroencephalography electrode system for the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.
223922649|NCT06134921|DEVICE|transcranial electrical stimulation (sham)|"Electrode placement based on the international 10 - 20 electroencephalography electrode system for applied the cathodal electrode will be applied over the contralesional hemisphere. In contrast, an anodal electrode will be applied over the ipsilesional hemisphere on the primary motor cortex (C3 or C4). Participants will be asked to sit comfortably during stimulation.~In the Sham group, participants will receive sham stimulation with intensity 2.0 mA for 1 minute, with a 30-second ramp-up and ramp-down, and no stimulation until the end of 30 minutes of stimulation. Electrodes will remain for 30 minutes."
223922650|NCT06134921|OTHER|Conventional physical therapy program|A conventional physical therapy program will be provided after 30 minutes of stimulation immediately. The program will be provided for both upper and lower limbs which consist of stretching exercise, active exercise, and functional exercise.
223922651|NCT04765098|DRUG|Tamoxifen|Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
223922652|NCT04765098|DRUG|Etoposide|etoposide 50mg/m2 daily
223922653|NCT05615311|DIETARY_SUPPLEMENT|Vitamin D supplementation|Study participants assigned to the intervention group will receive 800 IU/ day of vitamin D plus 200-300 IU/day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
223922654|NCT05615311|OTHER|No additional vitamin D supplementation|Study participants assigned to the control group will receive 200-300 IU/ day of vitamin D from parenteral and enteral sources during the first 2 weeks after birth.
223922655|NCT04996875|DRUG|bezuclastinib|Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
223922656|NCT05594498|DEVICE|StrataXRT|StrataXRT is a silicone-based film-forming topical gel that may help in reducing radiation dermatitis.
223922657|NCT06953063|DRUG|DA-302168S|A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.
223922658|NCT06953063|DRUG|Placebo of DA-302168S|Matching placebo tablet will be provided
223922659|NCT06800833|OTHER|Low fat cookies|To determine the effects of low fat cookie consumption on physiological indicators of sexual, mental, skin, and gut health
223922660|NCT06800833|OTHER|Mango|To determine the effects of mango consumption on physiological indicators of sexual, mental, skin, and gut health
223922661|NCT04700800|OTHER|Exercise|Acute cycle-ergometer exercise for 45 minutes at 65% of peak oxygen uptake
223922662|NCT04700800|OTHER|Infusion of Amino Acids|Intravenous infusion of mixture of amino acids
223922663|NCT06003153|DRUG|oral semaglutide|Semaglutide is the only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for treatment of type 2 diabetes. Participants will receive 7 mg of oral semaglutide once daily for 14 days in between Visit 1 and Visit 2.
223922664|NCT06003153|OTHER|Mixed Meal Tolerance Test (MMTT)|The MMTT is developed by the Metabolism and Nutrition Metabolic Kitchen at the MGH TCRC. The meal is a high-calorie, high-carbohydrate and moderate-to-high glycemic index challenge composed of commonly consumed breakfast food items. It provides nearly 90 grams of carbohydrates and mimics an oral glucose challenge. The participants will undergo a MMTT at Visit 1 and Visit 2.
223922665|NCT06382844|DIAGNOSTIC_TEST|Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).|Specific, sensitive, and reproducible (blood) detection and quantitation of tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS)
223922666|NCT05583344|DRUG|GSK4532990|GSK4532990 will be administered.
223531139|NCT05251649|DEVICE|tACS combined with 40 Hz sound stimulation|"The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).~Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). Sound stimulation was turned on simultaneously at the beginning of tACS. The duration of sound stimulation was set to 5 min stimulation, 5 min rest, 5 min stimulation, 1 min rest, and continued stimulation until the end of electrical stimulation while sound stimulation was turned off."
223531140|NCT05251649|DEVICE|Transcranial alternating current stimulation|The tACS instrument (model: XPNS208-B). Two electrodes are placed in the dorsolateral prefrontal cortex and the contralateral supraorbital area. and connected to the tACS device via a thin cable. The intervention will be performed using tACS (40 Hz, 1.5 mA) for 15 sessions of 20 min over 3 weeks (21 days).
223531141|NCT05251649|DEVICE|40 Hz sound stimulation|Sound stimulation apparatus: Two sponge earplugs were placed in the ears and the sound stimulator was set to (40Hz, 60dB). The duration of the sound stimulation was set to stimulate for 5 min, rest for 5 min, stimulate for 5 min, rest for 1 min, and last for a total of 20 min. 15 sessions of 20 min were performed over a period of 3 weeks (21 days).
223531142|NCT03187509|DRUG|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
223531143|NCT03187509|OTHER|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
223531144|NCT00006163|BEHAVIORAL|Personalized Self-management|
223531145|NCT00006163|BEHAVIORAL|Community Resources|
223531146|NCT03618537|DRUG|Ixazomib|Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.
223531147|NCT03618537|DRUG|Dexamethasone|Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
223531148|NCT01842659|GENETIC|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
223922667|NCT05583344|DRUG|Placebo|Placebo will be administered.
223922668|NCT06167486|DRUG|SG2918|The SG2918 will be administrated by intravenous infusion every 3 weeks
223531149|NCT01645176|DRUG|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
223531150|NCT03330158|DEVICE|ASTS|Implantation of a motorized spinal distraction rod
223717399|NCT01485237|OTHER|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
223922669|NCT05247801|BEHAVIORAL|Psychoeducational intervention for safe medication use at home + Medication dosing device|"The intervention is yet to be defined. Psychoeducational intervention based on virtual reality, demonstrations, and psychoeducational content using virtual reality. Contents:~Most frequent medication errors at home. Approaches to risk management in the home. Correct use of the most common medications in different patient profiles. Strategies to avoid medication errors. Guidance to alleviate the burden of responsibility suffered by women as a result of the gender bias derived from assuming the caregiver role.~Other."
224091587|NCT03756090|DRUG|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
224091588|NCT01365156|PROCEDURE|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
224280078|NCT04197128|DEVICE|Ribose cross linked collagen matrix for augmentation|"Local anaesthesia Lignocaine and Adrenaline 1:80000 Injection (Lignox® 2% A, Indoco remedies Ltd, Mumbai) will be administered and midcrestal incison will be made and full thickness flap would be raised buccally. To obtain tension free adaptation of flap margins, the buccal flap advancement will be done using periosteal releasing incision.~Implant osteotomies will be performed with sequential drilling and with standardised drills. All the subjects will receive the same implant system. (Norris medical ltd. Hatasia street, Nesher, Israel) For augmentation of deficient ridge, ribose cross linked collagen matrix will be cut and adapted to the buccal wall and ridge around the buccal aspect of healing abutment. Stabilisation would be achieved with internal resorbable horizontal mattress suture.~The tension free flap margins will be adapted around the healing abutment with simple interrupted 4.0, 3/8, reverse cutting resorbable sutures (Ethicon, Hamburg, Germany)."
223717400|NCT04477902|OTHER|none - observational|online survey
223717401|NCT00003746|DRUG|2-chlorodeoxyadenosine (CDA) daily|Daily administration
223717402|NCT00003746|DRUG|2-chlorodeoxyadenosine weekly|Weekly administration
223922670|NCT05247801|DEVICE|Medication dosing device|Use of medication dosing device.
223922671|NCT05227417|BEHAVIORAL|SMS|Weekly text messages that will be sent automatically by a web-based system to participants' cell-phones. Participants will be able to respond and messages will reach the system. The health providers will be in charge to respond (from the web system) to participants who reply asking for support or any other request.
223922672|NCT06580002|DRUG|Riluzole|Given PO
223922673|NCT06580002|DRUG|Placebo|Given PO
224091589|NCT01365156|RADIATION|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
224091590|NCT00924157|DIETARY_SUPPLEMENT|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
224091591|NCT00924157|OTHER|Placebo|Matching placebo capsules
223922674|NCT00730509|DIETARY_SUPPLEMENT|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
223717403|NCT00003325|PROCEDURE|Sentinel lymph node mapping|Sentinel lymph node mapping
224091592|NCT05619458|BEHAVIORAL|Mindfulness Intervention|6-week mindfulness intervention
224280079|NCT01254461|DRUG|AZD1981|100 mg per oral, twice daily for 8 days
224280080|NCT01254461|DRUG|AZD1981|4x100 mg per oral, twice daily for 8 days
224280081|NCT01254461|DRUG|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
224280082|NCT04474093|OTHER|Zirconium-reinforced glass ceramics(ZRGC),Lithium disilicate glass ceramics(LGC), Resin infiltrated glass ceramics(RIGC)|
223717404|NCT05759676|DEVICE|Cre8™/Cre8™ EVO drug-eluting stent|Patient with CAD who undergoing PCI with Cre8™/Cre8™ EVO drug-eluting stent
223717405|NCT01548521|DRUG|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
223717406|NCT03709160|DRUG|Bumetanide 1 MG|all patients will be taking the treatment recommended by heart failure guidelines
223922675|NCT01243814|DEVICE|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
223922676|NCT01243814|DEVICE|placebo injection|joint injection with saline solution for placebo
224280083|NCT00309985|DRUG|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
223922677|NCT01917942|DEVICE|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
224091593|NCT00289822|DRUG|intracoronary infusion of progenitor cells|
224280084|NCT00309985|DRUG|docetaxel|Given IV
223922678|NCT01917942|OTHER|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
223922679|NCT05252468|DEVICE|TaffiX™|Personal nasal powder spray.
223922680|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 266 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg
223922681|NCT05157841|DRUG|Bupivacaine HCl|Sciatic nerve block in the popliteal fossa with Bupivacaine HCl
224091594|NCT04919915|DEVICE|HEPA air cleaner|Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
223922682|NCT05157841|DRUG|Bupivacaine liposome injectable suspension 133 mg|Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg
223922683|NCT06775665|OTHER|No interventions were applied to the patients.|No interventions were applied to the patients.
224091595|NCT03954626|BIOLOGICAL|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
224091596|NCT01523080|DRUG|Acetaminophen|Extended release Gel tabs 650 mg
224091597|NCT03108716|PROCEDURE|hamate hook removal|The patients were assigned to treat with hamate hook removal.
223531151|NCT02102009|DIETARY_SUPPLEMENT|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
223531152|NCT02102009|OTHER|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
223922684|NCT05442580|DRUG|3x10(6) CART-38 cellls|3x10(6) CART-38 cells via intravenous infusion
223922685|NCT05442580|DRUG|7x10(5) CART-38 cells|7x10(5) CART-38 cells via intravenous infusion
223922686|NCT05442580|DRUG|7x10(6) CART-38 cells|7x10(6) CART-38 cells via intravenous infusion
223922687|NCT05442580|DRUG|3x10(7) CART-38 cells|3x10(7) CART-38 cells via intravenous infusion
223531153|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
223922688|NCT05442580|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy administered at physician discretion
223922689|NCT05442580|DRUG|Fludarabine|Lymphodepleting chemotherapy administered at physician discretion
223922690|NCT04520087|PROCEDURE|allograft fixation|Patients with anteroinferior shoulder instability will be clinically treated with a mini-open arthrotomic technique involving the fixation of the corticospongeous bone graft on the glena.
223922691|NCT05755711|DEVICE|Shockwave Medical Coronary IVL System|Coronary Intravascular Lithotripsy (IVL)
223922692|NCT01242228|DRUG|ipragliflozin|oral
223922693|NCT01242228|DRUG|DPP-4 inhibitor|oral
224091598|NCT03108716|PROCEDURE|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
224091599|NCT03108716|OTHER|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
224091600|NCT04727671|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
224091601|NCT04727671|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
224091602|NCT04727671|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
224091603|NCT04727671|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
223717407|NCT02076880|OTHER|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~* usual breakfast of the patient (possibly limited in quantity)~* midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
223717408|NCT02076880|OTHER|No caloric restriction|No change in eating habits to patients in this arm
224091604|NCT03424161|DEVICE|Secret RF|Subjects will receive treatment with the Secret RF device
224280085|NCT06033807|DIAGNOSTIC_TEST|QuantiFERON-TB Gold (QFT) test|Participants will be tested by QuantiFERON-TB Gold (QFT) test to see if they have ever infected by MTB. Those with positive results will proceed to sputum Xpert MTB/RIF, physical examination and chest CT scan, as well as sputum culture if necessary to distinguish latent TB infection (LTBI) from ATB. X-ray scan is conditional on age above 15 years with a positive QuantiFERON-TB Gold (QFT) test result.
224280086|NCT03465072|OTHER|Exercise training|8 weeks, 3 times per week, 30-40 minutes
224091605|NCT06117514|DRUG|Sudapyridine 30mg|Sudapyridine capsule 30mg, orally, single dose
224280087|NCT01148524|BIOLOGICAL|No Vaccine|
224280088|NCT01148524|BIOLOGICAL|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
224280089|NCT00547625|DRUG|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
224280090|NCT00547625|DRUG|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
224280091|NCT01352364|OTHER|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
224280092|NCT01737541|DRUG|Fluoxetine|
224280093|NCT01737541|DRUG|Placebo|
224280094|NCT03110380|DRUG|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
224280095|NCT03110380|DRUG|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
224280096|NCT03110380|DRUG|DTG|50 mg tablet(s) administered orally once daily
224280097|NCT03110380|DRUG|DTG Placebo|Tablet(s) administered orally once daily
224280098|NCT03110380|DRUG|F/TAF Placebo|Tablet(s) administered orally once daily
224280099|NCT03110380|DRUG|B/F/TAF Placebo|Tablet(s) administered orally once daily
224280100|NCT01734694|DRUG|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
224280101|NCT01734694|DRUG|Ceftaroline|"Dose based on package insert labeling~CrCL \> 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL \< 15mL/min: 200 mg q12h;"
223717409|NCT00872534|DRUG|acetylsalicylic acid|325mg once a day for 7 days
224091606|NCT06117514|DRUG|Sudapyridine 100mg SAD|Sudapyridine tablet, 100mg orally, single dose
224091607|NCT06117514|DRUG|Sudapyridine 200mg SAD|Sudapyridine tablet, 200mg orally, single dose
224091608|NCT06117514|DRUG|Sudapyridine 200mg MAD|Sudapyridine tablet, 200mg orally once a day for 14 days
224091609|NCT06117514|DRUG|Sudapyridine 300mg MAD|Sudapyridine tablet, 300mg orally once a day for 14 days
224280102|NCT01734694|DRUG|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL \< 30 mL/min: 6 - 10 mg/kg IV q48h"
224280103|NCT01734694|DRUG|Linezolid|600 mg IV/PO q12h
224280104|NCT05539534|BEHAVIORAL|Training on suicide prevention|Suicide prevention training in Flanders is organised by the Centre for the Prevention of Suicide and the suicide prevention workers of the Centra for Mental Health Care. These trainings are announced via the website zelfmoord1813.be/vormingen or are organized on demand. When a participant registers, they will be invited to participate in the study one week before the training.
224280105|NCT06192641|DRUG|Melatonin 3 MG|patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
224280106|NCT00826137|DIETARY_SUPPLEMENT|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
224280107|NCT00826137|DIETARY_SUPPLEMENT|Placebo|Placebo is base powder of product with no oligosaccharides.
224280108|NCT03355196|DRUG|LRX712|Ascending single dose on Day 1
224280109|NCT03355196|DRUG|Placebo|Ascending single dose on Day 1
224280110|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Knowledge Intervention|Counseling scripts assessing and addressing vaccination-related knowledge gaps
224280111|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Reminders|Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
224280112|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Incentives|Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
224280113|NCT06024317|BEHAVIORAL|Chanjo Kwa Wakati - Service notifications|Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
224280114|NCT01355302|DRUG|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
224280115|NCT01355302|DRUG|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
224280116|NCT01355302|DRUG|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
224280117|NCT00792584|DRUG|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
224280118|NCT00792584|DRUG|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
224280119|NCT04819854|DRUG|EP395|capsule for oral treatment
224280120|NCT04819854|DRUG|Placebo|capsule for oral treatment
224091610|NCT06117514|OTHER|Placebo tablet SAD|Placebo tablet, 100mg orally, single dose
223531154|NCT00402987|DRUG|Celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
223531155|NCT00402987|DRUG|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
224091611|NCT06117514|OTHER|Placebo 200mg SAD|Placebo tablet, 200mg orally, single dose
224091612|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 200mg orally once a day for 14 days
223531156|NCT00402987|DRUG|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
223531157|NCT01668004|BIOLOGICAL|Golimumab|GLM 50 mg subcutaneously once monthly.
224091613|NCT06117514|OTHER|Placebo tablet MAD|Placebo tablet, 300mg orally once a day for 14 days
223531158|NCT03462745|DEVICE|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
223531159|NCT00601341|OTHER|lumbosacral joint manipulation|lumbosacral joint manipulation
223531160|NCT00601341|OTHER|lumbar passive range of motion|lumbar passive range of motion
223531161|NCT00601341|OTHER|No active intervention|Lie on exam table for 3 minutes
224280121|NCT05298592|BIOLOGICAL|BMS-986406|Specified dose on specified days
224280122|NCT05298592|BIOLOGICAL|Nivolumab|Specified dose on specified days
224280123|NCT05298592|DRUG|Carboplatin|Specified dose on specified days
224280124|NCT05298592|DRUG|Pemetrexed|Specified dose on specified days
224280125|NCT05298592|DRUG|Paclitaxel|Specified dose on specified days
224280126|NCT04919759|BEHAVIORAL|R-Basic|Participants in the R-Basic arm received access to a static website that contained educational materials on healthier eating and physical activity and the study questionnaires. The R-Basic intervention was implemented in the University of Sharjah.
224280127|NCT04919759|BEHAVIORAL|R-Enhanced|The R-Enhanced intervention was guided by the Social Cognitive Theory and employed a variety of behavior modification strategies, including self-monitoring, goal setting, self-efficacy, and social support to facilitate changes in diet and physical activity. In addition, participants in the R-Enhanced intervention had online access to a nutritionist. The R-Enhanced intervention was implemented in the United Arab Emirates University.
224280128|NCT03457090|OTHER|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~* To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~* To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~* To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~* To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
224280129|NCT01339377|DEVICE|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
224280130|NCT02082249|DRUG|ABT-SLV187|Dose levels will be individually optimized
224280131|NCT05187741|DEVICE|mobile health (mHealth)|"A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months)."
224280132|NCT01953887|DRUG|EC905|Oral
224280133|NCT01953887|DRUG|solifenacin|oral
224280134|NCT01953887|DRUG|tamsulosin|oral
224280135|NCT05139628|DIAGNOSTIC_TEST|microbiological identification of samples (skin and blood samples)|"Samples will be plated on blood culture plates and will be confirmed biochemically.~Complete Bacteriological diagnosis will be done. The TTP of each BC bottle will be recorded"
224280136|NCT00693225|DRUG|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
224280137|NCT04546048|BEHAVIORAL|Strength Exercise Training|The 8-week exercise-training program consisted of two 30-min sessions a day for 5 days/week and conducted by elastic exercise bands in 2-3 sets, 6-10 repetitions, with 1-2 min rest between sets (M. Deltoideus and M. Quadriceps are trained as major muscle groups). The 8-repetition maximum(8RM) is used to determine training loads with the rated perceived exertion(RPE) lower than 5-7 on the Modified Borg scale(MBS). The program consisted functional exercises by half squat to squat and sit-to-stand chair exercises. Exercise sessions were supervised twice daily during the 1st week, the 2nd week training included one supervised and one unsupervised daily sessions. The remaining 6-week training program conducted at home individually after discharge. Patients instructed for the ongoing 8-week training program and a patient-specific schedule delivered to subjects. Phone calls are provided weekly and training load is assessed while generating 4th week evaluations.
224280138|NCT04091802|PROCEDURE|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
224280139|NCT03330314|BIOLOGICAL|HM12460A|HM12460A is a long-acting insulin
224280140|NCT00538655|DRUG|modafinil|400mg vs. 200mg (PO) daily
224280141|NCT04281732|DEVICE|Virtual Reality Headset based tests|Visual task tests based on Oculus Rift
224280142|NCT03353298|DRUG|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
224280143|NCT03353298|DRUG|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
224280144|NCT06094998|DIAGNOSTIC_TEST|hemogram examination|It will be studied hemogram examination, immunity indicators (cellular components CD3, CD4, CD8, CD16, CD20, CD25, CD95, CD3 HLA DR+, CD# HLA-DR; humoral components - IgM, IgA, IgE, IgG) and laboratory investigations in endocrine system (TSH, free T3 and T4 levels, insulin, insulin-like growth factor-1 (IGF-1), somatotropic hormone (STH); glucose, potassium, sodium) in 120 children born after ART. Researchers will compare 132 children conceived spontaneously to see if ART can influent on the health status in future.
223531162|NCT00499044|OTHER|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
223531163|NCT00499044|OTHER|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
223531164|NCT00182650|BIOLOGICAL|aldesleukin|
223531165|NCT00182650|BIOLOGICAL|rituximab|
223531166|NCT00182650|BIOLOGICAL|therapeutic autologous lymphocytes|
223531167|NCT00182650|DRUG|fludarabine phosphate|
223531168|NCT04473001|OTHER|Continuous vital signs and glucose monitoring|"The patients will have the following parameters and vital signs continuously monitored using wireless equipment:~* Glucose measurements (quasi-continuous, every 5 minutes)~* Heart rate~* Heart rhythm (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Signs of cardiac ischemia (single-lead ECG; quasi-continuous, 10 seconds every minute)~* Respiration rate~* Oxygen saturation of arterial hemoglobin (%SpO2)~* Perfusion index (ratio of the pulsatile blood flow to the non-pulsatile or static blood in peripheral tissue)~* Blood pressure (quasi-continuous; every 30-60 minutes)~* Skin temperature~* Electrodermal activity~* Ambulatory activity (accelerometry)"
223531169|NCT02850588|PROCEDURE|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
223531170|NCT02850588|PROCEDURE|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
223717410|NCT04440202|BEHAVIORAL|Conventional sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 conventional sea bream fillets and will be asked to consume them twice weekly for 1 month. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
223717411|NCT04440202|BEHAVIORAL|Enriched sea bream|Participants initially randomized to this intervention arm will be provided with a total of 8 enriched sea bream fillets and will be asked to consume them twice weekly for 1 month. Enriched sea bream fillets will be produced by a fish farming company from fish bread with a diet enriched with a fraction of bioactive polar lipids extracted from olive oil by-products. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 1-month wash-out period (no fish consumption), participants will cross over to the other intervention arm.
223717412|NCT00540514|DRUG|Albumin-bound paclitaxel|Administered by intravenous infusion.
223717413|NCT00540514|DRUG|Paclitaxel|Administered by intravenous infusion.
223717414|NCT00540514|DRUG|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
223717415|NCT03275662|BEHAVIORAL|Dietary Fiber|
223717416|NCT03275662|BEHAVIORAL|Fermented Foods|
224280145|NCT01456741|PROCEDURE|EBNA with ROSE|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
224280146|NCT01456741|PROCEDURE|standard EBNA|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
223531171|NCT05634486|BEHAVIORAL|Multidisciplinary therapeutic approach (physiotherapy plus cognitive-behavioral therapy)|Patients randomly allocated to this arm of intervention will receive an ambulatory therapy regime of twelve 60-minute physiotherapy sessions plus four 60-minute psychotherapy sessions throughout one month of treatment
224280147|NCT01355848|BEHAVIORAL|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
223717417|NCT02501473|DRUG|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
223717418|NCT02501473|DRUG|Pembrolizumab|PD-1 Inhibitor
223717419|NCT02501473|DRUG|Rituximab|Rituximab (anti-CD20 antibody)
224280148|NCT02531594|BEHAVIORAL|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
224280149|NCT02531594|BEHAVIORAL|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
224280150|NCT00583518|DRUG|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
223717420|NCT00000105|BIOLOGICAL|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
223717421|NCT00000105|BIOLOGICAL|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
223922694|NCT05773690|OTHER|Movement quality|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.
223922695|NCT05773690|OTHER|Conventional Resistance Training|6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
223922696|NCT06836388|PROCEDURE|ultrasound guided bougie insertion|The anesthesiologist will use a high-frequency linear ultrasound probe at the level of the suprasternal notch to identify the tracheal rings. The probe will then be moved cephalad and placed over the cricothyroid membrane to visualize the vocal folds in the transverse view with the patient in the supine position. Using a C-mac laryngoscope, the intubator will assess the difficulty of visualization using the Cormack Lehan score; if the score is three or more, the bougie will be gently inserted with the curved tip anteriorly into the trachea and assess the real-time visualization of the bougie on the ultrasound screen as a linear echogenic structure moving through the hypoechoic lumen of the trachea then the tube will railed on the bougie and connected to the capnograph for endotracheal positioning confirmation when the square waveform will be maintained for five breaths.
223922697|NCT06836388|PROCEDURE|Conventional methods for bougie insertion|The anesthesiologist will perform the bougie insertion using a C-mac laryngoscope, and he will assess the difficulty of visualization using the Cormack Lehan score; if the score is three or more, the bougie will be gently inserted with the curved tip anteriorly into the trachea while feeling the tracheal clicks as a sign of correct its placement, the intubator will advance it gently till feel resistance then withdraw 2-3 centimeters. If the depth of the bougie reaches 30 centimeters from the angle of the mouth without feeling the resistance, the bougie will be removed and reinserted. Then, the tube will be railed on the bougie and connected to the capnograph for endotracheal positioning confirmation when the square waveform is maintained for five breaths.
223922698|NCT06241183|DRUG|Intravenous Famotidine|Patients in this group will receive 20mg IV Famotidine.
223922699|NCT06241183|DRUG|Oral Maalox/ Mylanta|Patients in this group will receive 30 ml Maalox/ Mylanta.
223922700|NCT06099665|BEHAVIORAL|Automated alert|Receiving an automated alert via the EHR to highlight that the patient in question presents for severe aortic stenosis or severe mitral regurgitation according to the AHA guidelines and that they are a good candidate for valve intervention. The alert will not list any specific manufacturer's device.
223922701|NCT06463314|DEVICE|Multiplo TP/HIV Antibody Test|"The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually."
223922702|NCT06419257|DEVICE|VRDS|VRDS is an augmented virtual reality driving simulator.
223922703|NCT02937662|DRUG|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
223922704|NCT02937662|DRUG|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
223922705|NCT02937662|DRUG|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
223922706|NCT02937662|DRUG|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
223922707|NCT03278119|DIAGNOSTIC_TEST|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
223922708|NCT04239157|BIOLOGICAL|Canakinumab|Given SC
223922709|NCT03099681|OTHER|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
223922710|NCT06157996|DRUG|lenvatinib and tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w + Lenvatinib 8mg, qd po regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab + lenvatinib is entered, and the specific dosage is the same as the treatment period.
223922711|NCT06157996|DRUG|tislelizumab plus CapeOX chemotherapy|Tislelizumab 200mg, iv, d1+ oxaliplatin 130mg/m2, iv, d1+ capecitabine 1000mg/m2, bid po, D1-14, q3w regimen are received, respectively (3 weeks as a cycle, a maximum of 8 cycles of treatment). Then the maintenance treatment phase with tislelizumab is entered, and the specific dosage is the same as the treatment period.
223922712|NCT06965179|OTHER|Jenga game|In the Jenga game group, participants will complete the Elderly Information Form and Mini-Mental State Examination (MMSE) before the intervention. As pre-tests, the Life Satisfaction Scale (LSS) and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) will also be administered. Participants will play Jenga in pairs for at least 30 minutes once a week over four weeks. Grouping will consider participant preferences and promote social interaction. After the intervention, the same scales (LSS and WEMWBS) will be re-administered as post-tests to evaluate changes in life satisfaction and mental well-being.
223922713|NCT06965179|OTHER|Bocce game|In the Bocce game group, participants will first complete the Elderly Information Form and Mini-Mental State Examination (MMSE), followed by pre-tests including the SF-36, Life Satisfaction Scale (LSS), and the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). Bocce sessions will take place once a week for four weeks, with each session lasting at least 30 minutes. Games will be played in pairs to enhance social interaction and psychomotor skills. Participants will be randomly assigned to six groups of two, considering individual preferences. Pairings will rotate weekly based on game outcomes to encourage diverse interaction. After the final week, the LSS and WEMWBS will be re-administered as post-tests by the researcher.
223531172|NCT05634486|OTHER|Psychoeducation (Sham intervention)|Patients randomly allocated to this arm of intervention will receive an ambulatory regime of four 60-minute non-organized psychoeducational sessions throughout one month of treatment.
223531173|NCT03573492|OTHER|Education|Type of teaching being assigned to student arms
223531174|NCT02151240|DRUG|Foscarnet Sodium|
223531175|NCT02151240|DRUG|Acyclovir|
223531176|NCT06451588|DRUG|FMT|Active FMT
223531177|NCT06451588|DRUG|Placebo|The placebo treatment will be prepared based on the patients' fecal samples (autologous).
223531178|NCT02196922|DEVICE|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
223531179|NCT02196922|OTHER|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
223531180|NCT05542953|DRUG|[18F]APN-1607|In this study, all patients will receive one injection of \[18F\]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 5-7 mCi IV as a bolus injection. \[18F\]APN-1607 injection will be followed by a 10 ml saline flush.
223531181|NCT04937192|OTHER|No intervention|No intervention
223531182|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) study capsule|The Study mHDx capsule has a mechanism that allows the mHDx to remain resident in the stomach for no more than six (6) hours. After this residency period, the Study mHDx will disassemble and pass safely through the subject's gastrointestinal system.
223717422|NCT00000105|DRUG|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
223922714|NCT02760537|BEHAVIORAL|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
223922715|NCT02760537|BEHAVIORAL|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
223922716|NCT05772533|PROCEDURE|Serratus anterior plane block|The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.
223922717|NCT05772533|PROCEDURE|PENG block|"Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered."
223922718|NCT06973460|DEVICE|Hunova Robotic-Assisted System|Hunova Movendo Robotic System
223922719|NCT06973460|OTHER|Balance and Mobility Exercise|Balance and Mobility Exercise derived from the Otago Exercise Programme
223531183|NCT06240650|DEVICE|modified Health- Dx™ (mHDx) control capsule|The Control mHDX capsule does not have a functional residency mechanism so it will disassemble once safely through the esophagus (within 10 minutes) and will then pass safely through the subject's gastrointestinal system.
224280151|NCT03636386|DEVICE|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
224280152|NCT03636386|DEVICE|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
224280153|NCT01817595|OTHER|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
224280154|NCT01817595|OTHER|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
224280155|NCT03027921|OTHER|elastography|
224280156|NCT03128736|DRUG|Esomeprazole group|Esomeprazole 40mg qd
223531184|NCT02448381|DRUG|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
223531185|NCT02448381|DRUG|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
223531186|NCT06400784|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
223531187|NCT01652313|DRUG|Rasagiline|1 mg/day, tablets for 7 days, orally
223531188|NCT05466305|DEVICE|Gold plated chrome cobalt alloy|Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
223717423|NCT00000105|BIOLOGICAL|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
223717424|NCT03846596|BIOLOGICAL|Additional blood tube|Additional blood tube during care
223717425|NCT03281486|DEVICE|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
224280157|NCT03128736|DRUG|Dexlansoprazole group|Dexlansoprazole 60mg qd
224280158|NCT02227615|DIETARY_SUPPLEMENT|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
224280159|NCT02227615|DIETARY_SUPPLEMENT|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
223717426|NCT03281486|DEVICE|Placebo|Placebo formulation without the active ingredients
223922720|NCT04098276|BEHAVIORAL|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
223922721|NCT02954809|DEVICE|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
223922722|NCT02954809|DEVICE|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
223922723|NCT03242915|DRUG|Pembrolizumab|200mg IV every 3 weeks
223922724|NCT03242915|DRUG|Carboplatin|AUC 5 IV every 3 weeks
223922725|NCT03242915|DRUG|Pemetrexed|500 mg/m\^2 IV every 3 weeks
223922726|NCT05826860|BEHAVIORAL|Mindfulness Practice|Participants follow guided meditations in the Healthy Minds Program (HMP) mobile phone app for at least 15 min per day, for a total of 14 days.
223922727|NCT05826860|BEHAVIORAL|Storytelling Workshop|Participants attend 2 (90 min) workshops, teaching them creative writing tools and giving them opportunities to apply those tools.
223922728|NCT06576271|DRUG|GSK4527363|GSK4527363 will be administered to participants.
223922729|NCT06576271|DRUG|Placebo matching GSK4527363|Placebo matching GSK4527363 will be administered to participants.
223922730|NCT06576271|DRUG|Belimumab|Belimumab will be administered to participants.
223922731|NCT05436652|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
223922732|NCT05436652|DRUG|SPI-62 matched placebo|Inactive tablets identical in appearance to SPI-62 tablets
223922733|NCT05436652|DRUG|Prednisolone 10mg|Standard of care prednisolone
223922734|NCT05436652|DRUG|Additional prednisolone|Over encapsulated prednisolone
223922735|NCT05436652|DRUG|Additional prednisolone matched placebo|Inactive capsules identical in appearance to over encapsulated prednisolone
223922736|NCT03528447|OTHER|Pulmonary Rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band."
223922737|NCT06649266|DRUG|RBD1016|RBD1016, active drug.
223922738|NCT06649266|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
223922739|NCT05456698|DRUG|Inotuzumab ozogamicin|"Patients who achieved CR/CRi had their InO dose at 1.5mg/m2 per cycle (28days/cycle), with 0.5mg/m2 administered on days 1, 8, and 15.~Patients received treatment for up to two cycles in the absence of disease progression or unacceptable toxicity."
223922740|NCT02971046|OTHER|varying protein intakes|"In healthy school-aged children: Four randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are 0.95, 1.3,1.55, and 2.0 grams per kilogram of bodyweight per day.~In healthy young and old adults: Up to six randomly assigned levels of protein intake in a repeated measured design. The levels of protein intake are : 0.66, 0.8, 1, 1.2, and 1.5 grams per kilogram of bodyweight per day."
223922741|NCT06815029|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
223922742|NCT06815029|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given autologous TGF-betaR2KO/IL13R-alpha2-CAR T cells intracranially
223922743|NCT06815029|PROCEDURE|Echocardiography|Undergo echocardiography
223922744|NCT06815029|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET
223531189|NCT03130569|BEHAVIORAL|Web-based Module Group|
223717427|NCT02898337|DEVICE|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
223922745|NCT06815029|PROCEDURE|Intracranial Catheter Placement|Undergo placement of Rickham catheter
223922746|NCT06815029|PROCEDURE|Leukapheresis|Undergo leukapheresis
223922747|NCT06815029|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223922748|NCT06815029|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
223922749|NCT06815029|PROCEDURE|Resection|Undergo surgical resection
223922750|NCT03267498|DRUG|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
223922751|NCT03267498|DRUG|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
223922752|NCT03267498|RADIATION|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
223922753|NCT03614533|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
223922754|NCT03614533|BIOLOGICAL|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
223922755|NCT05511649|DEVICE|continuous electronic monitor|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital, KaiFeng Central Hospital, and the First Affiliated Hospital of Zhengzhou University will receive 24-hour continuous cardiac monitoring until discharge.
223922756|NCT06845631|DEVICE|PNS device, observational study, no intervention during study|PNS device, observational study, no intervention during study
223922757|NCT06985784|OTHER|Interview|Ancillary studies
223922758|NCT06985784|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit
224091614|NCT02446587|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
224091615|NCT01588223|OTHER|Lipid identification|The lipids are identified using Mass Spectrometry
224091616|NCT05569135|DEVICE|Laser ablation|A diode-laser that has been reported to be safe and effective in several treatments including pilonidal disease, anal fistula, hemorrhoids, and vascular ablation was used to obtain shrinkage of pilonidal cyst
224091617|NCT03214835|DEVICE|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
224091618|NCT05675137|DEVICE|mobile-based|Participants who were randomly assigned to the mobile-based intervention group were provided multidomain programs based on scientific evidence of ways to improve brain-health and reduce dementia risk for 10 minutes per day and at least 50 minutes per week.
224091619|NCT05675137|OTHER|paper-based|Participants who were randomly assigned to the paper-based intervention group were provided with the Korean version of the dementia prevention booklet published by the WHO.
224091620|NCT01053312|DRUG|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
224091621|NCT03932526|DRUG|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
224091622|NCT03932526|DRUG|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
224091623|NCT01420133|OTHER|Regimen|regimen normal in salt and sugar
224091624|NCT01420133|OTHER|Standard regimen|with diet low in salt and sugar
223717428|NCT05348070|PROCEDURE|Laparoscopy/Laparotomy|All patients included in the study were operated patients.
223922759|NCT06985784|OTHER|Questionnaire Administration|Ancillary studies
223922760|NCT06985784|OTHER|Virtual Technology Intervention|Receive 3D mindfulness VR headset
223922761|NCT06985784|OTHER|Virtual Technology Intervention|Receive 2D non-immersive VR headset
224091625|NCT05841472|DRUG|Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin|"* 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles."
224091626|NCT01818544|DRUG|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
224091627|NCT01818544|DRUG|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
224091628|NCT05670977|DIETARY_SUPPLEMENT|Study product plus collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
224091629|NCT05670977|DIETARY_SUPPLEMENT|Study product without collagen supplement|The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
224091630|NCT03139292|DEVICE|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
224091631|NCT03139292|DEVICE|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
224091632|NCT01021943|DRUG|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
224091633|NCT01021943|DRUG|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
224091634|NCT02236169|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
224091635|NCT02236169|DRUG|Atrovent CFC inhalation aerosol|
223922762|NCT06980259|RADIATION|Spatially Fractionated Radiotherapy|SFRT builds on CRT, administered at 3.0 Gy per fraction for 15-20 fractions, with the addition of weekly high-dose vertices of 8-15 Gy per fraction for 3-4 fractions. It employs Intensity-Modulated Radiation Therapy (IMRT), Intensity-Modulated Proton Therapy (IMPT), or Volumetric Modulated Arc Therapy (VMAT) to create a grid-like pattern of alternating high- and low-dose regions. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
224091636|NCT02002143|BEHAVIORAL|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
224091637|NCT02002143|BEHAVIORAL|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
224091638|NCT06263088|OTHER|EQUITY GI|"1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."
224091639|NCT05281263|BIOLOGICAL|CPI-RSV-F Vaccine (BLB-201)|see arm/group description
224091640|NCT05105386|DEVICE|SynAir-Child|Monitor the indoor pollutants and their effect on children well being
224091641|NCT00013806|DRUG|131I-MIBG|
224280160|NCT05930405|PROCEDURE|programmed intermittent epidural bolus|Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure
224280161|NCT05930405|PROCEDURE|continuous epidural infusion|continuous epidural infusion
224280162|NCT04909112|OTHER|Evaluation of olfactory function|Evaluation of olfactory function using olfactory detection thresholds
224280163|NCT04909112|OTHER|Evaluation of taste function|Evaluation of taste function using taste detection thresholds
224280164|NCT04909112|OTHER|Evaluation of (intra-nasal and oral) trigeminal functions|Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
224280165|NCT04303624|OTHER|Health sciences survey|Large scale demographic survey evaluating attitudes of population towards organ donation for the self vs. family
224280166|NCT03750695|BEHAVIORAL|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
224280167|NCT03750695|BEHAVIORAL|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
224280168|NCT03750695|BEHAVIORAL|Rest|40 minutes of quiet rest in semi-recumbent position
223531190|NCT01624753|DEVICE|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
223531191|NCT04362735|DRUG|Vedolizumab|Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
223531192|NCT06564883|DEVICE|0.20% sodium hyaluronate gel|Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.
223531193|NCT01841996|DRUG|ME1111 solution|Once a day for 28 days
223531194|NCT01841996|DRUG|Vehicle Solution|Once a day for 28 days
224280169|NCT00365690|BEHAVIORAL|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
223531195|NCT00364169|PROCEDURE|Degree of constipation|
223922763|NCT06980259|RADIATION|Conventional Radiotherapy|CRT is delivered at 3.0 Gy per fraction for a total of 15-20 fractions, utilizing Intensity-Modulated Radiation Therapy (IMRT) or Intensity-Modulated Proton Therapy (IMPT) techniques, ensuring a target volume dose coverage of at least 90%. Target volume delineation includes the gross tumor volume (GTV), clinical target volume (CTV, expanded 0.5-1.0 cm from GTV), and planning target volume (PTV, expanded 1.0 cm from CTV). Prior to each treatment session, cone-beam CT (CBCT) or kilovoltage cone-beam CT (kV-CBCT) is used for Image-Guided Radiation Therapy (IGRT) to verify patient positioning.
223922764|NCT06985277|DIAGNOSTIC_TEST|Urgent endoscopy strategy|Patients will undergo colonoscopy within 24 hours of diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) followed by same-session video capsule endoscopy (VCE) will be performed immediately
223922765|NCT06985277|DIAGNOSTIC_TEST|Standard colonoscopy with standard VCE group|Patients will undergo colonoscopy within 24-48 hours after diagnosed lower gastrointestinal bleeding. If no bleeding source is identified on colonoscopy or presumed diverticular bleeding cases, esophagogastroduodenoscopy (EGD) will be performed immediately. If EGD shows no bleeding source, video capsule endoscopy (VCE) will be performed within 24 hours of the preceding endoscopies
223922766|NCT02347254|DEVICE|Transcranial ExAblate|Transcranial ExAblate MRgFUS
223922767|NCT02765854|DRUG|Dexamethasone|Given PO
223922768|NCT02765854|DRUG|Ixazomib|Given PO
223922769|NCT02765854|DRUG|Lenalidomide|Given PO
223922770|NCT06986603|DRUG|Glucagon for Injection (Fresenius Kabi USA)|We are assessing response to glucose, including incremental glucose values as well as changes in endogenous glucose production, insulin secretion, and glucagon levels.
223922771|NCT06664684|OTHER|Energy-restricted dietary intervention|The diets were planned based on current guidelines, manuals, systematic reviews, and meta-analyses published in recent years on MAFLD \[5-6, 27-28\]. In this diet, carbohydrates constituted 50%-55% of total energy intake, proteins constituted 10%-20%, and fats constituted 25%-35%. The content of the diets was tailored to each patient, considering various factors such as sex, age, and physical activity status.
223922772|NCT06664684|OTHER|Energy + time-restricted dietary intervention|Patients in the energy + time-restricted diet group followed the same dietary intervention and a 16:8 eating pattern where they were instructed to restrict their energy intake to an 8-h time window and not to consume energy-containing foods or drinks during the remaining 16 h. Participants were allowed to consume energy-free beverages such as water, coffee, and tea during fasting. The timing of the eating window during the day varied according to participants' lifestyles and habits. However, considering the importance of nocturnal fasting, the eating window in all patients started at 10:00-12:00 in the day and ended at 18:00-20:00 in the evening. The energy-restricted diet group did not follow any time restriction in the planning of main meals and snacks.
223922773|NCT06664645|PROCEDURE|LHB tendon reinforcement|complete repair with LHB tendon reinforcement
223922774|NCT06664645|PROCEDURE|complete repair without reinforcement|conventional rotator cuff complete repair without reinforcement
223922775|NCT05708443|OTHER|LL group|"The program will include daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 60 minutes on a stationary bike for the lower limbs (2 sessions per day of 30 minutes) at moderate-high intensity;~2. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist."
223922776|NCT05708443|OTHER|L+UL group|"These patients will attend a rehabilitation program with daily sessions of 90 minutes, for a total of 14 sessions, consisting of:~1. 30 minutes on a stationary bike for the lower limbs (1 session of 30 minutes per day) at moderate-high intensity;~2. 30 minutes with arm-ergometer (1 daily session of 30 minutes) at moderate-high intensity;~3. 30 minutes of strengthening exercises for upper limbs (biceps, pectoral, latissimus dorsi) and lower limbs (quadriceps, gluteus and hamstrings) performed free body or with the aid of weights.~All sessions will be supervised by a physiotherapist."
223922777|NCT05800717|BEHAVIORAL|SCI Self-Management for AIS D|An individually administered, self-management intervention for Veterans with AIS D spinal cord injury.
223922778|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose)|Inject 1 dose of low-dose vaccine
223922779|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose)|Inject 1 dose of low-dose placebo
224280170|NCT00365690|BEHAVIORAL|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
224280171|NCT00365690|BEHAVIORAL|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
224280172|NCT06678009|DEVICE|the isokinetic training group with blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
224280173|NCT06678009|DEVICE|the isokinetic training group without blood flow restriction|The isokinetic training protocol for the knee flexor and extensor muscles consisted of 3 sets of 10 repetitions in 60°/sec and 3 sets of 30 repetitions in 180°/sec for 8 weeks, 2 times per week for 16 sessions.
223531196|NCT03942081|DEVICE|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
223531197|NCT03245918|DRUG|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
223717429|NCT04922008|DRUG|capecitabine and trastuzumab|In IRIS-C cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given capecitabine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
224091642|NCT01511484|BEHAVIORAL|Information-only|"Selected pages from the British National Health Service (NHS) information booklets \[5 A Day, Just Eat More (fruit \& veg); pages i, ii, 12-15, 20 \& 21\] and \[5 A Day, Just Eat More (fruit \& veg): What's it all about?; pages i-ii)\] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
224280174|NCT05535192|BEHAVIORAL|THRIVE|"The THRIVE Intervention will involve:~1\) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study"
224280175|NCT05535192|BEHAVIORAL|Health Education Support Program|Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
224280176|NCT05936047|BIOLOGICAL|Vertebral bone marrow clot|vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
223531198|NCT03245918|DRUG|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
223531199|NCT05992272|BIOLOGICAL|fMRI imaging (BOLD)|Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
223922780|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose)|Inject 1 dose of high-dose vaccine
223922781|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (high dose)|Inject 1 dose of high-dose placebo
223922782|NCT06824519|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|Inject 1 dose of positive control vaccine
223922783|NCT06015191|BEHAVIORAL|Remote Cardiac Rehabilitation|Participants will engage in a ramp-up period (weeks 0-2) where participants will attend 1-on-1 live, remote in-home exercise sessions (20-35 min./session, 3-days/wk.) delivered by a health coach via telehealth video conferencing. Participants will be provided a tablet computer and a small set of equipment. Following the ramp-up period, participants will be asked to attend live, in-home, group-based exercise sessions (weeks 3-12, 3-5 participants/group, 45-min, 3-days/wk. minimum). Sessions will be offered 4-days/wk. in the afternoons and early evenings allowing participants to select the most convenient 3 days per week to attend. Sessions will include a variety of dynamic aerobic and anaerobic (resistance) exercises with a target heart rate corresponding to 60-75% of VO2peak. In the group-based exercise sessions, participants will be able to see, hear, and verbally interact with the health coach and the other participants, allowing for supervision and encouraging social support.
223922784|NCT06015191|BEHAVIORAL|Active Control|Participants will receive a handout describing physical activities appropriate for their congenital heart disease diagnosis and providing recommendations consistent with the physical activity recommendations for children and adolescents.
223922785|NCT02343991|DEVICE|Transcranial ExABlate|MR Guided Focused Ultrasound
223922786|NCT06988254|OTHER|Animation-based breathing therapy|The animation-based breathing therapy includes breathing exercises for children, such as lion, crab, and rainbow breathing. The intervention will continue for six weeks (two sessions per day, five days per week).
223922787|NCT06990360|DIAGNOSTIC_TEST|CBCT Scanning|The Styrofoam mandibles were scanned using CBCT, which was performed for each mandible pre-operatively, the raw DICOM data set obtained from the CBCT scanning were imported to a special third-party software\* for secondary reconstruction.
223922788|NCT04242992|BEHAVIORAL|CETA|CETA is a modular, multi-problem, flexible psychotherapy approach that trains a lay provider in nine evidence-based CBT elements so providers can treat a variety of common problems, including violence, substance use, depression, anxiety, risky behaviors (sexual, non-adherence), and other trauma-related symptoms. Patients randomized to CETA will meet weekly with a lay provider or community health worker member of the study staff for about an hour once each week, approximately 6-12 times depending on presentation and symptom level. This treatment arm will include SMS reminders of their HIV care appointments, similar to the active control group.
223922789|NCT04242992|OTHER|Short Message Service (SMS) text reminders|Short Message Service (SMS) text reminders for upcoming appointments will be sent monthly.
223922790|NCT06990919|OTHER|Saliva collection|Pre-operative saliva collected before the full mouth treatment under general anesthesia while, post-operative saliva collected at 1-month follow-up after general anesthesia.
223922791|NCT06989177|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
223922792|NCT06989177|BEHAVIORAL|Energy-restricted nutritional and lifestyle intervention|Participants will receive dietary advice, behavioral guidance and nutritional and lifestyle education by dietitian and physicians. App-connected wearable devices will be utilized to monitor their dietary intakes and App-connected scale will be used to monitor their weight changes during interventions.
223922793|NCT06989177|DIETARY_SUPPLEMENT|Placebo|Participants will receive one bag (2 g; 1 × 10¹² CFU) daily of LC-19.
223922794|NCT06989177|DIETARY_SUPPLEMENT|Probiotic|participants will receive daily one bag of LC-19 (10\^12 cfu/bag).
223922795|NCT06989177|DRUG|semaglutide|Participants will receive prescibed semaglutide therapy
223922796|NCT06021769|OTHER|Observational only|No intervention
223531200|NCT05992272|BIOLOGICAL|sMRI (structure)|Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
223717430|NCT04922008|DRUG|vinorelbine and trastuzumab|In IRIS-4 cohort, patients who met the inclusion criteria(ER and PR\<10%, T≤2cm or ER and/or PR ≥10% 1cm\<T≤2cm) would be given vinorelbine for 4 cycles with standard trastuzumab for 1 year, in which HR+ patients would be given endocrine therapy for 5 years.
223922797|NCT06782035|DEVICE|Ora-Aid-Oral Wound Dressing|Intended as a physical barrier for temporary protection of oral mucosal tissue and to provide pain relief. This product is a non-eugenol protective material applied to intraoral wounds. Ora-Aid is a new concept of pasting intra-oral patch to protect the affected area such as post implant, extraction, orthodontic, and ulcers. This new concept of pasting intra-oral wound dressing is designed to protect the affected area and aid natural healing.
224091643|NCT01511484|BEHAVIORAL|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
223922798|NCT06782035|BIOLOGICAL|Platelet rich fibrin|"It has been reported that the use of Platelet-Rich Fibrin (PRF) to cover palatal wounds accelerates healing and reduces postoperative morbidity. Studies have demonstrated that PRF supports key processes in wound healing, such as immunity, angiogenesis, and cellular proliferation. Its use has garnered significant interest, particularly in non-healing wounds and areas left to heal by secondary intention after surgery. Leukocyte and Platelet-Rich Fibrin (L-PRF) is frequently used in periodontal surgical applications. The platelets and growth factors it contains accelerate the healing process and facilitate tissue repair."
223922799|NCT06782035|DEVICE|Palatal Stent|Palatal stents help prevent complications such as infection or excessive discomfort. These plates are typically customized to fit the patient's palate by taking impressions before the surgery. Once placed, they serve as a barrier, especially during the early stages of healing. Additionally, they may reduce the need for postoperative interventions, such as the use of strong painkillers.
223922800|NCT05374109|BEHAVIORAL|SYV: Sauti ya Vijana (The Voice of Youth intervention)|Mental health is associated with ART adherence and HIV outcomes. SYV was designed to address the specific challenges of young people living (YPLWH) with HIV in Tanzania. SYV includes 10 group sessions (two sessions held jointly with caregivers) lasting approximately 90 minutes and two individual sessions delivered by trained young adult group leaders who use a manualized protocol that is designed to scale in low resource settings. The intervention is applied to the Social Action Theory (SAT), a theoretical framework used to determine factors that influence health behavior. Building off a SAT resilience framework for YPLWH, components of evidence-based treatment models to influence cognitive, self, and social regulation to improve behavioral health outcomes will be strategically used.
223922801|NCT06996041|OTHER|Chocking first aid management program|Power point presentation , Video demonstration, and Practical demonstration of chocking first aid management
224091644|NCT01511484|BEHAVIORAL|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
224091645|NCT05628844|PROCEDURE|Continuous enteral feeding|Enteral nutrition by continuous infusion for 10 hrs at a dose corresponding to 25 kcal/kg body weight/day
224091646|NCT02680782|DRUG|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
224091647|NCT04151108|OTHER|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
224091648|NCT04151108|OTHER|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
224091649|NCT04937023|DRUG|Ursodeoxycholic acid gel|Following scaling and root planing in intrabony defects UDCA gel will be injected
224091650|NCT04530162|PROCEDURE|Ultrasound guided nerve block|nerve block using bupivacaine and dexamethasone.
224091651|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
224091652|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
224091653|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
224091654|NCT02639351|BIOLOGICAL|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
224280177|NCT06146660|DRUG|Mavacamten|According to approved product label
224280178|NCT04411173|DIETARY_SUPPLEMENT|Whey Protein|Each condition (both rice and whey protein) match in color, flavor, and serving size.
224280179|NCT02883439|DRUG|MP29-02|local nasal application
224280180|NCT02883439|DRUG|Fluticasone propionate|local nasal application
224280181|NCT03843125|DRUG|Baricitinib|Administered orally.
224280182|NCT03843125|DRUG|Placebo|Administered orally.
224280183|NCT01586208|DRUG|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
224280184|NCT00409942|DRUG|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
224280185|NCT00409942|DRUG|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
224280186|NCT03173560|DRUG|lenvatinib|lenvatinib capsules.
224280187|NCT03173560|DRUG|everolimus|everolimus tablets.
223922802|NCT06997237|BEHAVIORAL|Music Listening Intervention|Participants listened to a playlist of 5-6 music tracks they personally selected before surgery. The music was played continuously for 30 minutes through Bluetooth headphones during liver transplantation. Volume was kept at 65 decibels.
223922803|NCT06997237|BEHAVIORAL|Silence with Headphones|Participants wore Bluetooth headphones during the surgery, but no audio was played. This intervention was designed to control for the effect of wearing headphones and isolating ambient operating room sounds.
223922804|NCT06996587|PROCEDURE|Robotic-Assisted Flexible Ureteroscopy|Use of the ILY® robotic system to perform flexible ureteroscopy.
223922805|NCT06996587|PROCEDURE|Manual Flexible Ureteroscopy|Conventional flexible ureteroscopy performed manually by the surgeon.
223922806|NCT06996054|BEHAVIORAL|Multifaceted School-Based Mental Health and Suicide Prevention Program|Pupils will receive a four-session psychoeducational programme, delivered weekly by trained psychologists during school hours, covering mental health literacy, emotion regulation, identification of suicide risk, and help-seeking skills. Concurrently, parents and teachers will access a digital co-intervention through a custom-designed platform with four multimedia modules.
224091655|NCT02639351|BIOLOGICAL|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
224091656|NCT02626728|PROCEDURE|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
224091657|NCT01822002|PROCEDURE|Canalith repositioning maneuver|
224091658|NCT02207907|DRUG|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
224091659|NCT02207907|DRUG|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
224091660|NCT06178068|DEVICE|Comparison of bronchodilator effectiveness of nebulizer therapy devices|The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSİM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.
224091661|NCT03024216|DRUG|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
224091662|NCT03024216|DRUG|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
224091663|NCT00158184|DRUG|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
224091664|NCT00158184|DRUG|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
224091665|NCT00158184|DRUG|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
224091666|NCT04856137|DRUG|Rituximab Paclitaxel Ruxolitinib|Rituximab 375mg/m2 on D1 of each cycle Paclitaxel 200mg/m2 on D1 of each cycle Ruxolitinib continuously given (D1-21)
224091667|NCT06011135|OTHER|No intervention|No intervention - qualitative study only using semi-structured interview
224091668|NCT01466842|PROCEDURE|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
224280188|NCT03494933|PROCEDURE|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
224280189|NCT03494933|PROCEDURE|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
223922807|NCT06996405|OTHER|Access to dietary treatment|Dietary treatment using current nutrition guidelines, dialogic communication and Nutrition Care Process repeatedly by weekly access to a dietitian for four month.
223922808|NCT06997653|BIOLOGICAL|TURKOVAC|Inactive COVID-19 Vaccine - TURKOVAC
224091669|NCT04828044|DEVICE|Microwave Ablation/ Coagulation Arm|An 11-gauge microwave probe from MedWaves, Inc., will be placed in the tumor. An ablation lesion will then be generated at the appropriate power (10-35 watts) to maintain up to 130C degrees at the MW applicator tip thermocouple for 10 minutes duration. Palpation and/or ultrasound may be used to place the MWA needle and monitor the progress of the microwave ablation.
224091670|NCT00873002|DRUG|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
224280190|NCT01285505|DRUG|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
224280191|NCT01285505|DRUG|alprazolam test sublingual tablet|0.5 mg tablet, single dose
224091671|NCT00873002|DRUG|sorafenib tosylate|400 mg PO BID
224091672|NCT05340504|DRUG|N-Acetyl cysteine|Group A and Group B will receive N-Acetylcysteine (NAC). Group A will receive NAC as their first 14 day condition and Group B will receive NAC as their second 14 day condition. Participants will take NAC for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
224091673|NCT05340504|DRUG|Placebo|Group A and Group B will receive Placebo. Group A will receive Placebo as their first 14 day condition and Group B will receive Placebo as their second 14 day condition. Participants will take Placebo Oral Capsule for 14 days and then have a MRI exam after completing various assessments (clinical interview, questionnaires, etc).
224091674|NCT00650923|DRUG|ziv-aflibercept|Given IV
224091675|NCT00650923|PROCEDURE|radiation therapy|Undergo RT
224091676|NCT00650923|DRUG|temozolomide|Given PO
224280192|NCT04534140|DIETARY_SUPPLEMENT|HBKB Capsule|The botanical dietary supplement 'Halo Beauty Kiwi Booster' (HBKB) taken daily orally.
223717431|NCT04487730|BEHAVIORAL|"Engage & Connect Psychotherapy"|9-weeks of weekly psychotherapy sessions focused on social reward exposure
223717432|NCT04487730|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
223922809|NCT06997666|PROCEDURE|Prone Position|Patients assigned to the Prone Position Group were placed in the prone position (lying face down) for 30 minutes once daily over two consecutive days while hospitalized in the ICU for COVID-19-induced ARDS. The intervention was performed between 12:30 and 13:00 under nurse supervision. Oxygen saturation, blood gas parameters (SaO₂, PO₂, PCO₂, pH, lactate, sodium), and respiratory rate were measured before and after each prone positioning session. The procedure was standardized across patients and no additional treatments were introduced during the intervention period.
223922810|NCT06996236|DRUG|Treatment with brimonidine eye drops 0.025%|Treatment with brimonidine eye drops 0.025%, instilled once a day at night, with simultaneous occlusion of the lower lacrimal punctum to avoid its systemic absorption, for 2 years.
223922811|NCT06995976|DRUG|68Ga-dPNE|Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.
223922812|NCT06995976|DRUG|18F-FDG|Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.
223922813|NCT06997549|DEVICE|Patients treated with NeuroStar TMS|non-invasive brain stimulation device
224280193|NCT04534140|OTHER|HBKB Supplement Vehicle|Control group participants will take one capsule of the HBKB botanical dietary supplement vehicle orally, once daily
223531201|NCT05992272|BEHAVIORAL|Trier Social Stress Test|Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
223922814|NCT06997549|DRUG|Patients treated with Esketamine|nasal spray for treating depression
223922815|NCT06996509|DEVICE|Non-Invasive Ventilation (NIV)|Bi-Level NIV delivers two preset pressure levels-Inspiratory Positive Airway Pressure (IPAP) and Expiratory Positive Airway Pressure (EPAP)-via a tightly fitting mask interface
224091677|NCT00650923|PROCEDURE|pharmacological study|Correlative studies
224091678|NCT00650923|PROCEDURE|laboratory biomarker analysis|Correlative studies
224091679|NCT00923637|DRUG|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
224280194|NCT01680601|PROCEDURE|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
224280195|NCT01680601|PROCEDURE|Placebo|
224280196|NCT02763631|OTHER|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
223531202|NCT05992272|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
223717433|NCT05592964|DIETARY_SUPPLEMENT|Fasting|Standard fasting
223717434|NCT05592964|DIETARY_SUPPLEMENT|Water|In Group S, water was given 1 hour before the operation.
223717435|NCT05592964|DIETARY_SUPPLEMENT|Carbohydrate fluid|In Group K, carbohydrate fluid was given 1 hour before the operation.
223717436|NCT06060288|DIAGNOSTIC_TEST|Diagnosis by mobile phone imaging|"The photographs will be taken with a smartphone iPhone 14 Pro in a one-year period. Imaging will follow the recommendations regarding intraoral photography in oral mucosal screening set by (Lin et al., 2021).~Personal data and a brief description of the present illness concerning the main complaint will be informed by the patients and recorded in a diagnosis chart of the Oral medicine department Cairo University. Complete intraoral physical examination will be performed by the main investigator under supervision of the main supervisor and the co-supervisor using dental equipment with artificial light."
223717437|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
224280197|NCT02763631|OTHER|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
224280198|NCT02763631|OTHER|Sham Comparator: Stand Care Arm|No change will be made to participants care
224280199|NCT04929730|OTHER|Nephrology care bundle|Nephrology care bundle
224280200|NCT01195220|BEHAVIORAL|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
224280201|NCT01195220|BEHAVIORAL|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
223922816|NCT06996509|DEVICE|High Velocity Nasal Insufflation|High-Velocity Nasal Cannula therapy delivers heated, humidified gas at flow rates exceeding patients' peak inspiratory demands (35-60 L/min), with precise FiO₂ control up to 100 %
223922817|NCT06996223|DRUG|The Group A received PCSK9 inhibitor plus statin therapy|Subjects randomized to the Group A will be treated with a lipid-lowering regimen based on PCSK9 inhibitors (subcutaneous injection, twice a week) + statins (maximum tolerated dose).
224280202|NCT01195220|BEHAVIORAL|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
224280203|NCT00391534|DRUG|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
224280204|NCT00391534|DRUG|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
223531203|NCT05992272|BEHAVIORAL|Counting Stroop task|Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
223531204|NCT05992272|BEHAVIORAL|No-go Simon task|Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
223531205|NCT05992272|DIAGNOSTIC_TEST|Stop Signal Task|"Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped."
223531206|NCT05992272|DIAGNOSTIC_TEST|blood samples|for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
223531207|NCT05992272|DIAGNOSTIC_TEST|questionnaires for chronic stress|"* Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic"
223922818|NCT06997692|DIAGNOSTIC_TEST|Gong's Mobilization with NMES|Gong's Mobilization Technique: The participant will be positioned in a side-lying posture on a height-adjustable bed, with the affected side upward and the head supported by a pillow The therapist will apply an antero-posterior glide to the humeral head while stabilizing the scapula with the other hand. The participant will perform quick, powerful shoulder abduction in the coronal plane without external rotation or elbow flexion while the therapist maintains the mobilization force.
223922819|NCT06997692|COMBINATION_PRODUCT|Comprehensive Conservative Physical Therapy|Thermal Modality Application: Participants will receive either a cold or hot pack (based on individual preference and clinical presentation) applied to the affected shoulder for 10-15 minutes. Cold packs will be wrapped in a thin towel and applied to
223922820|NCT06996106|OTHER|Effect of Platelet Rich Fibrin on Septoplasty|it is a randomized trial of usage of platelet rich fibrin in septoplasty
224280205|NCT00658034|PROCEDURE|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
224280206|NCT00658034|PROCEDURE|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
223922821|NCT06059378|DEVICE|Artificial intelligence-assisted classification (CADx)|CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.
224280207|NCT02864524|OTHER|Manipulative and Massage Therapy|
224280208|NCT02864524|OTHER|Exercise Program|
224280209|NCT05926635|DEVICE|ATLAS 2030|sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
223922822|NCT06747663|PROCEDURE|Needle Depth Measurement Using MRI, Ultrasound, and Fluoroscopy|This intervention involves cervical epidural steroid injection (CESI) for patients with chronic neck and radicular pain. Needle depth is measured pre-procedurally using MRI and ultrasound to predict the ideal needle placement. Fluoroscopy is used during the procedure to confirm and compare these measurements, aiming to evaluate the accuracy of imaging techniques and minimize radiation exposure.
223922823|NCT06996470|OTHER|- Cervical Vestibular-Evoked Myogenic Potential (cVEMP) along the Sternocleidomastoid|Endurance time during gazing
224280210|NCT02525263|BIOLOGICAL|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
223922824|NCT06675240|BEHAVIORAL|MediNF|Over 10-sessions participants will engage in a breath-focused meditative practice with frontal brain connectivity neurofeedback provided to enhance performance.
223922825|NCT05292222|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
223922826|NCT03032588|BIOLOGICAL|sIPV|Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.
223922827|NCT03032588|BIOLOGICAL|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
223922828|NCT05966766|OTHER|Mozart selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections by Mozart of previously studied and shown to reduce anxiety.
224280211|NCT01020617|DIETARY_SUPPLEMENT|Ls-33|10\~10 CFU/day
224280212|NCT00003808|DRUG|theophylline|
224280213|NCT05642533|OTHER|No treatment given|No treatment given
224280214|NCT01222364|PROCEDURE|Standard Cord Clamping|Immediate clamping (\<5 seconds) of the umbilical cord after delivery.
224280215|NCT01222364|PROCEDURE|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
224280216|NCT03853499|OTHER|No intervention (observational study)|No intervention (observational study)
224280217|NCT05580887|DRUG|mFOLFIRINOX|every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1 Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
223922829|NCT05966766|OTHER|Patient-preferred music selections|Music will be played from a speaker connected to a media-playing device for participants to listen to for set durations of time. Music will be selections of patient choice.
223922830|NCT05522517|DRUG|Cosentyx|Cosentyx injection will be administered subcutaneously.
223922831|NCT05522517|DRUG|Candin|Candin will be administered interadermally along with NaCl solution.
223922832|NCT06494878|DRUG|Aspirin|75-100 mg taken once daily by mouth.
223922833|NCT06494878|DRUG|Low-molecular-weight heparin|Low-molecular-weight heparin injections daily as prescribed by the treating physician.
224280218|NCT05580887|DRUG|Doxorubicin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
224280219|NCT05580887|DRUG|Cyclophosphamid|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
224280220|NCT05580887|DRUG|Paclitaxel|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
223922834|NCT06606405|DIAGNOSTIC_TEST|scapular dyskinesis test|Scapular dyskinesia in athletes will be visually evaluated. It will be considered present if, during 3 out of 5 arm elevation attempts, any of the following are observed: prominence of the medial or upper scapular border, lower scapular angle, excessive clavicular elevation, or rapid downward rotation of the scapula. After the tester demonstrates the required movements, the athletes will practice the movement. The test will begin with the arms at the sides of the body, elbows straight, and shoulders in neutral rotation. Two testers will observe from behind and video record the movements. Participants will be instructed to raise their arms as high as possible simultaneously, using the \&amp;#39;thumbs up\&amp;#39; position, and to maintain this position for 3 seconds before lowering their arms for another 3 seconds. Athletes will perform the arm elevation with a dumbbell weight calculated as 1.4% of their body weight (Kamonseki, Haik, Ribeiro, Almeida, \&amp;amp; Camargo, 2023).
223922835|NCT06608615|OTHER|Kinesio Taping|"Facilitation (Functional) Technique for Tibialis Anterior Muscle: The patient sits with his leg extended. The ankle is placed in eversion and dorsi flexion. After one end of the I tape is adhered to the upper part of the Tibia, the other end is adhered to the dorsal surface of the foot with almost 100% tension. During the application, origin and insertion points are considered as the beginning and end. Then, plantar fexion is performed on the ankle and the remaining non-stick part is glued.~Functional Correction Technique: Correction technique is used to ensure full contact of the foot with the ground. The subtalar joint is positioned in eversion and taping is applied starting from under the medial malleolus, without tension until the lateral outer edge of the calceneus, and then with 100% tension, continuing until 10-15 cm below the head of the fibula. No tension is applied in the last 5 cm"
223922836|NCT06608615|OTHER|Rigid Taping|"Talus Stabilization Taping: The affected ankle of the person to be taped was placed on a chair and asked to bring this foot to a neutral position by advancing the tibia over the foot through knee flexion while standing. Starting from the talus of the ankle, maximum tension was applied towards the medial and lateral malleolus.~Inversion Lock: This lock looks like an inverted 6 when viewed from the front and is used to restrict inversion movement. After the underwrap and anchor were applied, the tape was applied starting from the outer malleolus level. It was glued on itself by proceeding diagonally in front of the foot, passing it in front of the inner malleolus, passing under the foot and in front of the outer malleolus and closing the subtalar area, and the taping was completed by making an anchor on the upper side."
223922837|NCT00071708|DRUG|Duloxetine Hydrochloride|
223922838|NCT06997380|DEVICE|Injection of the investigational product via needle|A hyaluronic acid solution (concentration 2.2%) with the addition of lecithin in the form of liposomes (concentration 0.08%) via needle
224091680|NCT04911621|BIOLOGICAL|Dendritic cell vaccination + temozolomide-based chemoradiation|"1. Leukocyte apheresis (before chemoradiation): for dendritic cell (DC) vaccine production.~2. Chemoradiation (1st part standard treatment, initiated as soon as the patient's hematological blood values are adequate after apheresis, but no later than 6 weeks after surgery or confirmed diagnosis): 1.8 Gy once daily 5 days/week for 6 weeks with 90 mg/m² temozolomide daily from the first until the last day of radiotherapy.~3. Induction immunotherapy: intradermal vaccination with autologous Wilms' tumor-1 (WT1) mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 1 week after radiotherapy.~4. Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days +/- 3 days (max. 6 months, 2nd part standart treatment) starting ≥3 days after the third vaccine of the induction immunotherapy + DC vaccination on day 21±3 days of every 28-day cycle."
223922839|NCT06997380|DEVICE|Injection of the investigational product via cannula|A hyaluronic acid solution (concentration 2.2%) with the addition of lecithin in the form of liposomes (concentration 0.08%) via cannula
223922840|NCT06997380|PROCEDURE|Clinical assessment|Clinical assessment of facial skin condition
223922841|NCT06997380|PROCEDURE|Ultrasound measurement|Ultrasound measurement of facial skin thickness
223922842|NCT06997380|PROCEDURE|Multispectral imaging|Multispectral imaging and analysis of facial skin
223922843|NCT03343431|DRUG|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
223922844|NCT06528990|BEHAVIORAL|Telehealth Intervention|This includes the following key components: 1) assignment to a peer ostomate; 2) ostomy self-management skills building delivered through group telehealth sessions and led by trained ostomy nurses and peer ostomates; 3) intervention resource manual.
223922845|NCT06528990|OTHER|Standard of care|standard of care, where patients and family caregivers are managed by the oncology care team. Care may include clinic visits for follow-up, cancer directed treatments, referrals to other medical specialties as needed, and institutional ostomy nurse support before and after surgery as needed.
223922846|NCT06613828|BEHAVIORAL|Mnemonic-Based Educational Training for Stroke Symptom Recognition|"This is a Culturally Adapted Mnemonic-Based Educational Strategies for Rapid Stroke Symptom Recognition in the Spanish-Speaking Population.~It uses five distinct mnemonic strategies (RAPIDO, CORRE, DALE, CAMALEON, ICTUS 911), each specifically tailored for a Spanish-speaking audience.~Aims to improve the recognition of early cerebrovascular disease symptoms, differentiating it from other clinical studies that might focus on different health conditions or target populations.~Emphasizes its focus on rapid action by educating participants about stroke symptoms and the importance of contacting emergency services (911)."
223922847|NCT06526520|DRUG|Exposure to progesterone or HRT medication|to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
224280221|NCT05580887|DRUG|Carboplatin|dose dense doxorubicin and cyclophosphamide (AC) x 4 every 2 weeks followed by 12 weekly PAClitaxel + CARBOplatin every 21 days for 4 cycles
224280222|NCT05009056|DEVICE|Postsurgical computer guided functional appliance|After achieving ideal condylar poison by computer guided surgery. The distal extension of the final occlusal wafer will be cut and the appliance will be fitted to be utilized as a postsurgical functional appliance for condylar adaptation. Patients will be instructed to wear the splints continuously for 3 months, only being allowed to remove them when eating and brushing their teeth.
224280223|NCT02119052|DRUG|octeotride|
224280224|NCT02119052|DRUG|placebo|
224091681|NCT04911621|BIOLOGICAL|Dendritic cell vaccination +- conventional next-line treatment|"1. Leukocyte apheresis (upon recovery of hematological blood values following previous anti-glioma treatments and ≥ 4 weeks after the last dose of any investigational agent): for DC vaccine production.~2. Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly (-1 day, +2 days) for 3 weeks, starting ≥ 4 weeks after apheresis.~3. Booster immunotherapy: 6 DC booster vaccinations administered at regular intervals (+- 4 weeks), starting ≥ 3 weeks after the last induction vaccine.~4. (Optional) Concomitant conventional anti-glioma treatment: The decision to continue or re-initiate conventional anti-glioma treatment, and, if applicable, its dose and scheme, are at the Investigator's discretion and will depend on the patient's previous treatment scheme and condition."
224091682|NCT06013774|DEVICE|IXSI|Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
224091683|NCT03813030|PROCEDURE|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
224091684|NCT03813030|DRUG|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
224091685|NCT03813030|DRUG|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
224091686|NCT03813030|DEVICE|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
224091687|NCT03813030|DEVICE|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
224280225|NCT04254809|BEHAVIORAL|Re-Evaluating Suicidal Thoughts|Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
224280226|NCT04254809|BEHAVIORAL|Healthy Social Living|To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
224280227|NCT04480307|DRUG|temelimab 18 mg/kg|temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
224091688|NCT03813030|PROCEDURE|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
224091689|NCT03813030|PROCEDURE|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
223717438|NCT00907777|BIOLOGICAL|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
223717439|NCT05186064|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing will be performed on tumor material after re-resection per standard of care
224091690|NCT05805514|OTHER|Animal source of food and psychosocial stimulation|209 mother-child pair will receive the animal source of food and psychosocial stimulation for 12 months. Child will be recruited within 6-12 months.
223531208|NCT05992272|DIAGNOSTIC_TEST|hair samples|Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
223531209|NCT05992272|DIAGNOSTIC_TEST|saliva samples|Assessing acute stress effects in AUD.
223531210|NCT05992272|DIAGNOSTIC_TEST|EMA assessment|We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
223531211|NCT05992272|DIAGNOSTIC_TEST|clinical diagnostic|SKID-I Interview neurocognitive and psychopathological testing
223717440|NCT02615366|DRUG|Tranexamic Acid|
223717441|NCT02615366|DRUG|Placebo|
223717442|NCT04221841|OTHER|descriptive|correlation
223922848|NCT05003583|BEHAVIORAL|Speaking after viewing pictures with negative and neutral valence|"Speaking Condition 1: 10 age-appropriate pictures from the International Affective Picture System (IAPS; Lang, Bradley \& Cuthbert, 2005) will be shown to participants. These pictures are classified as high arousal, negative valence stimuli. Participants will be asked to repeat a simple phrase between picture presentations.~Speaking Condition 2: A blank screen will be shown to participants in place of pictures. This condition is classified as low arousal, neutral valence. Participants will be asked to repeat a simple phrase between blank screen picture presentations."
223922849|NCT04908930|BEHAVIORAL|On-field activity group - Aim 3|Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure
223922850|NCT06677320|OTHER|Exercise|Patients with rotator cuff disease will receive exercise treatment for two months.
223922851|NCT06854380|DRUG|Intralesional injection of steroids (betamethasone), (Betafos®) and hyaluronidase (enzyme), (Hynidase®) into benign vocal fold lesions by a naso-fiberscope with a side working channel(Storz 11001UD1)|that this intervention is intralesional injection of glucocorticoid (betamethasone) and enzyme (hyaluronidase) via flexible fiberscope
223922852|NCT04178915|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
223922853|NCT04178915|DIAGNOSTIC_TEST|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
223922854|NCT07007013|OTHER|Humor therapy|The intervention consists of a cycle of 8 group sessions (one per week) led by trained professionals specialized in humor ('clown doctors'). Each session will last approximately 90 to 120 minutes
223922855|NCT06670911|DRUG|Low-dose Pembrolizumab Plus Chemotherapy (Paclitaxel plus Carboplatin or Cisplatin)|Patients will receive pembrolizumab 100mg IV every 3 weeks plus chemotherapy (paclitaxel 175 mg/m² + carboplatin AUC 5 or paclitaxel 175 mg/m² + cisplatin 50 mg/m² for cisplatin-naïve patients).
223922856|NCT06618417|DEVICE|sleep apnea home-evaluation|Participants will receive a home-monitoring device by mail to test for sleep apnea at home
223922857|NCT06863129|PROCEDURE|Internal Fixation|Internal Fixation
223922858|NCT06863129|PROCEDURE|Resection and reconstruction|Resection and reconstruction
223922859|NCT03283137|DRUG|TGR-1202|TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
223922860|NCT03283137|DRUG|Pembrolizumab|Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
223922861|NCT06870565|DRUG|paclitaxel and platinum|After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin \[Area Under Curve (AUC) = 4-5\], Q3W (every 3 weeks is a dosing cycle), administered on the first day of each cycle, for a total of 4 cycles. Adjuvant chemotherapy started 4 weeks after the end of external irradiation therapy, and chemotherapy-related adverse reactions dropped to grade 2 or below before chemotherapy began. If not met, it can be postponed for 2 weeks.
223922862|NCT06870565|DRUG|platinum|During EBRT, cisplatin (40 mg/m2) or carboplatin (AUC = 2) was used for concurrent chemotherapy once a week for a total of 5 times. On the day of cisplatin infusion, radiotherapy should be performed after cisplatin or carboplatin.
223922863|NCT06771284|BEHAVIORAL|Function-based assessment and intervention|This intervention will be implemented by the caregiver. The intervention will consist of teaching the child an alternative, appropriate skill (usually communication) to replace the problem behavior. The caregiver will provide reinforcement for the appropriate skill and no reinforcement (i.e., extinction) following problem behavior. The caregiver will also learn and use general strategies for teaching social-emotional skills (e.g., setting appropriate rules) as part of the intervention.
223922864|NCT06867042|DRUG|Tacrolimus Lipid Suspension for enema|Tacrolimus Lipid Suspension for enema 4 mg/vial
223922865|NCT06867042|DRUG|Identical Tacrolimus-free Lipid Suspension for Enema|Identical Tacrolimus-free Lipid Suspension for Enema
223922866|NCT06685536|OTHER|Safety and efficacy assessments|Safety evaluations,disease-specific assessments,and assessments to monitor for long-term complications of autologous transplant
223922867|NCT05475600|BEHAVIORAL|Classical APA group:|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
223531212|NCT05643404|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is ≥1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
223922868|NCT05475600|BEHAVIORAL|APA with Exergaming device|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
223922869|NCT05475600|BEHAVIORAL|APA associated with biofeedback relaxation|Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
223922870|NCT03861676|RADIATION|Focal brachytherapy with PSMA PET imaging|Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
223922871|NCT03861676|DRUG|(18F)DCFPyL|18F-DCFPyl PET/CT scan
223922872|NCT04494958|DRUG|Combination, Palbociclib + Binimetinib|"Patients will then start treatment with continuous oral binimetinib 45 mg/BID and palbociclib 100 mg daily, 21 days on / 7 days off, until disease progression. Study treatment will continue until disease progression.~If treatment tolerance is good, after a full cycle patients will be allowed to escalate palbociclib to 125 mg, according to the study investigators' decision. Alternatively, patients with non tolerable grade 2 events will resume at 30 mg/BID of binimetinib upon recovery, maintaining palbociclib at 100 mg 21-on/7-off. Depending on the side-effects, in case of clear relationship with palbociclib is established, palbociclib -instead of binimetinib - will be reduced to 75 mg daily."
223922873|NCT05292404|DRUG|alirocumab|In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab,75mg) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months
223922874|NCT05292404|OTHER|conventional treatment|conventional treatment were given according to international uniformguidelines
223922875|NCT05812781|DRUG|VTX2735|Dose A
223922876|NCT05812781|DRUG|VTX2735|Dose B
223531213|NCT05643404|DIAGNOSTIC_TEST|Echocardioghaphy|Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography
223531214|NCT06563518|DRUG|Meridol|toothpaste
223531215|NCT06563518|DRUG|Colgate Cavity Protection|toothpaste
223531216|NCT03685942|DEVICE|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
223531217|NCT03685942|DEVICE|placebo light therapy|placebo portable light visor device
223531218|NCT06198400|DIAGNOSTIC_TEST|Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye|The adequacy of the vascular supply of the post resection pancreatic remnant after pancreatic neck division will be evaluated using ICG detector. Indocyanine green fluorescence product -Verdye™ will be intravenously applied. The application of the substance will be performed according to the current consensus statement and recommendation
223531219|NCT05458739|DEVICE|ClearCoast MR System|The removed specimen is scanned using the ClearCoast MR System.
223922877|NCT05826002|BEHAVIORAL|Digital self-guided psychological intervention for insomnia|A four week digital self-guided intervention for insomnia, with content derived from Cognitive Behavioral Therapy for insomnia, and with a clinical interview before and after the intervention.
223531220|NCT05819359|DRUG|BIA 28-6156 10 mg|BIA 28-6156 10 mg, once daily, oral administration.
223531221|NCT05819359|DRUG|BIA 28-6156 60 mg|BIA 28-6156 60 mg, once daily, oral administration.
223531222|NCT05819359|DRUG|Placebo|Placebo, once daily, oral administration.
223922878|NCT06430177|BEHAVIORAL|Su Jok|Su Jok will be done
223922879|NCT05930860|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
223922880|NCT05145868|BEHAVIORAL|Alcohol Skills and Emotion Regulation Intervention|The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
223922881|NCT05145868|OTHER|Attention Control|Text-messages will be sent that include no intervention content to serve as an attention control
223922882|NCT05035316|DRUG|acetylsalicylic acid|Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day
223922883|NCT05035316|DRUG|Calcium|Oral tablet: calcium, 1 tablet/day
223922884|NCT04254484|BEHAVIORAL|SIESTA Rehab Education|Staff nurses will be trained on how to improve sleep in stroke patients in the acute rehabilitation setting.
224091691|NCT05805514|OTHER|Animal source of food|209 mother-child pair will receive the animal source of food for 12 months. Child will be recruited within 6-12 months.
223922885|NCT04254484|DIAGNOSTIC_TEST|ApneaLink|Stroke patients on the SIESTA Rehab unit will be screened for sleep disordered breathing using ApneaLink monitors. Results will be interpreted by a sleep specialist who will then advise the clinical team at SRALab.
223717443|NCT02252094|DEVICE|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
223717444|NCT02252094|OTHER|Ultra-protective ventilation|Ventilation with \</= 3ml/kg predicted body weight
223922886|NCT06688279|OTHER|Plyometric Exercise|". The session will last for 60 minutes and 3 times per week. 5 minutes warm up with dynamic stretching and 5 minutes cool down period with static stretching and 1-minute rest period is there between each exercise and each repetition and 3-5 minute for each set (total 3 sets).~Following Plyometrics would be performed.~1. Plyo Pushup.~2. Chest Pass.~3. Overhead Throw.~4. Squat jump.~5. Plyo Step-up.~6. Cone jumps.~7. Med Ball drop.~8. Kneeling Squat jump.~9. Lateral jump over hurdle.~10. Overhead throw.~11. Under hand throws.~12. Dynamic Rotational Chest pass.~13. Overhead throw with step. Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
223922887|NCT06688279|OTHER|Standard exercises protocol|"The session will last for 60 minutes and 3 times per week. Following exercises would be performed.~* Push ups.~* Sit ups.~* Lunges~* 500 m running.~* Squats Vertical jump test for lower extremity strength, 3-Hop test for lower extremity power and Star excursion balance test for dynamic balanceis performed at the start of exercise protocol and in the end i.e. Pre and post test."
223922888|NCT06689943|DRUG|Tylenol|Tylenol for children
223922889|NCT05190341|DRUG|Ibuprofen 800 mg oral|1 hour before HSG
223922890|NCT05190341|DRUG|Ketorolac 30mg oral|1 hour before HSG
223922891|NCT04198701|DEVICE|Medtronic PulseSelect Pulsed Field Ablation (PFA) System|Adult subjects with a history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of entrance block and, where assessable, exit block with the PulseSelect PFA System.
223922892|NCT04733183|DRUG|Dacarbazine|Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
223922893|NCT04733183|DRUG|onfekafusp alfa|L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
223922894|NCT07016789|DEVICE|Near-infrared spectroscopy monitoring (NIRS) INVOS 5100C|Continuous bilateral cerebral oxygen saturation monitoring using near-infrared spectroscopy (NIRS) during TAVI. Sensors are placed on the forehead to record rSO₂ values at predefined timepoints. Device used: INVOS 5100C (Medtronic/Covidien).
223922895|NCT06681389|DRUG|NP-201 acetate injection (Part A)|Route of administration- Sub cutaneous. Dosage interval and frequency: MAD1-200mg daily for 5 days; MAD2- 300mg daily for 5 days, MAD3- 400mg daily for 5 days
223922896|NCT06681389|DRUG|Placebo|Matching placebo administered across Part A and Part B
223922897|NCT06681701|PROCEDURE|Combined Manual Therapy and Pulmonary Exercises|"Diaphragmatic breathing exercise:~Segmental breathing exercises (apical, upper lateral, lower lateral and posterior basal), according to site of consolidation:~Active Cycle Breathing Technique (ACBT):~Intensive spirometry: It encourages patients to take deep breaths, which helps to expand the lungs and prevent complications such as pneumonia.~Rib mobilization from sitting:~Rib mobilization from supine:~Central Posterior-Anterior (PA) mobilization of thoracic facet joints:~Unilateral Posterior-Anterior mobilization of costo-vertebral joints:~Diaphragmatic myofascial release (DMR):~Pectoralis minor myofascial release:~Pectoralis major and pectoral fascia myofascial release:~Sternocleidomastoid myofascial release:~Scalene muscle and neck fascia myofascial release:~Mobilize one side of the chest:"
223922898|NCT06681662|DRUG|Ephedrine Hydrochloride 30 mg/ml|0.15 mg/kg during induction.
223717445|NCT02252094|OTHER|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
223922899|NCT06681662|DRUG|Saline (NaCl 0,9 %) (placebo)|1 ml during induction.
223922900|NCT06679829|DRUG|Siltuximab|11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
223922901|NCT06679829|DRUG|Melphalan|"Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2"
223922902|NCT06681246|OTHER|Antibiotic treatment|10 days of either antibiotics- Augmentin (amoxicillin+clauvonate), 875mg, 2 /day
223922903|NCT06681246|OTHER|Placebo|consist of a combination of agarose in normal saline/glycerol
223922904|NCT05797480|OTHER|Real Dry needling|Real dry needling will be applied to the pelvic floor, hip and lower back muscles.
223922905|NCT05797480|OTHER|Non penetrating dry needling|Sham non penetrating dry needling (fixed needle in an introducer tube) will be applied to the pelvic floor, hip and lower back muscles.
223717446|NCT03232957|PROCEDURE|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
223717447|NCT03232957|PROCEDURE|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
223717448|NCT03232957|PROCEDURE|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
223717449|NCT03232957|DRUG|Morphine|intrathecal morphine
223717450|NCT03232957|DRUG|Bupivacaine|0.5 isobaric bupivacaine
223922906|NCT06872216|PROCEDURE|cupping therapy|After the initial vascular occlusion test and a subsequent 10-minute rest period, the plastic therapy cup was placed on the forearm, 5 cm away from the medial and lateral epicondyles by a certified cupping therapist. The size of used cup was determined according to the size of the volunteer's forearm which cover 50% of the area. The cup was vacuumed two times full pumping with a manual hand pump and remained in place for 5 minutes. And then the air was removed by releasing the cups through the release valve.
223531223|NCT03849209|DEVICE|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
223922907|NCT06872216|DIAGNOSTIC_TEST|Vascular occlusion test|A blood pressure cuff was placed on the upper arm. The adult probe of the NIRS device (Covidien INVOS™ 5100C Cerebral/Somatic Oximeter, Dublin) was placed on the thenar region of the ipsilateral hand and the regional oxygen value was recorded during all study term. Baseline arterial pressure and oxygen saturation were monitored (GE Healthcare Oy, Helsinki, Finland) from the side of dominant hand and recorded. After a 3-minute stabilization period, the vascular occlusion protocol was started. The blood pressure cuff was rapidly inflated within 3-4 seconds to 50 mmHg above baseline systolic blood pressure and kept at this pressure during 3 minutes. Following this, the cuff was deflated within 1 second. Five minutes after cupping therapy this protocol had done again.
223531224|NCT03849209|DEVICE|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
223922908|NCT06874972|DEVICE|Music played|Music is played in the study group, and no music is played in the control group.
223922909|NCT06874946|BIOLOGICAL|CD5-targeted CAR-T cells|"Phase I: Eligible patients will receive a single infusion of CD5-targeted CAR-T cells at one of three dose levels (0.5 × 10⁶ cells/kg, 1.0 × 10⁶ cells/kg, or 2.0 × 10⁶ cells/kg) following fludarabine and cyclophosphamide (FC) lymphodepleting chemotherapy. A 3+3 dose-escalation design will be used to determine the recommended Phase II dose (RP2D) based on safety, dose-limiting toxicities (DLTs), and preliminary efficacy.~Phase II: Patients will receive CD5-targeted CAR-T cells at the RP2D following FC lymphodepleting chemotherapy."
223531225|NCT01502735|BIOLOGICAL|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
223531226|NCT01502735|BIOLOGICAL|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
223922910|NCT06874738|DRUG|Liuwei Dihuang pills|Conventional treatment （Hormones, selective 5-hydroxytryptamine reuptake inhibitors, etc.）+ Liu Wei Di Huang Pills
223922911|NCT06875583|DEVICE|Radiation|The use of RAMPART radiation protection device
223922912|NCT06873854|DRUG|LM-108|Q3W, Intravenous Drip
223922913|NCT06873854|DRUG|Toripalimab|Q3W, Intravenous Drip
223531227|NCT01820000|PROCEDURE|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
223531228|NCT01073969|OTHER|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
223531229|NCT01073969|OTHER|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
223531230|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 35mg TID
223531231|NCT00034814|DRUG|Placebo|Enzyme-inducing placebo TID
223922914|NCT05545878|DEVICE|Super enhanced single vision lens 01 for spectacles|This is a spectacle lens designed to have a small amount of positive power towards the bottom of the lens as this is the area that is in line with the eye when downwards for near tasks such as looking at a digital device.
223531232|NCT00034814|DRUG|Talampanel|Enzyme-inducing Talampanel 35 mg TID
223531233|NCT00034814|DRUG|Talampanel|Enzyme-inducing TLP 50mg TID
223531234|NCT00034814|DRUG|Placebo|Non-enzyme-inducing placebo TID
223531235|NCT00034814|DRUG|Talampanel|Non-enzyme-inducing TLP 25mg TID
223531236|NCT02183584|DRUG|Rifampicin|
223531237|NCT02183584|DRUG|Linagliptin|
223531238|NCT01575574|DRUG|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
223922915|NCT01466478|DRUG|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
223922916|NCT01466478|DRUG|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
223922917|NCT01466478|DRUG|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
223922918|NCT01466478|DRUG|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
223922919|NCT01466478|DRUG|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
223922920|NCT01466478|DRUG|Daivonex® ointment|once daily application, 4 weeks
223922921|NCT01466478|DRUG|Diprosone® ointment|once daily application, 4 weeks
223531239|NCT04055974|BEHAVIORAL|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
223922922|NCT06395740|OTHER|Enteral nutrtion|enteral nutrition via nasogastric tube.
223922923|NCT06395740|OTHER|TPN|of NPO strategy except for medications to be given via nasogastric tube till 14 days from day of stroke with fulfilment of nutrition requirement by parenteral route
223922924|NCT06864715|BEHAVIORAL|Tele-delivered Behavioral Activation by lay counselors after Stroke (Tele-BA-S)|The Tele-BA-S intervention will comprise 5 weekly video-conferenced BA sessions delivered by trained lay counselors, homework, and 2 monthly follow-up booster calls.
223922925|NCT06864715|BEHAVIORAL|Treatment as Usual|Participants will receive an educational packet and blood pressure (BP) monitor prior to hospital discharge. They will be contacted by a Licensed Clinical Social Worker (LCSW) at 48-72 hours to determine if they have received their medications and appointments. The stroke practitioner will evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.
223922926|NCT06624878|DRUG|esketamine|0.2 mg/kg esketamine infused intravenously after induction of general anesthesia.
223922927|NCT06624878|DRUG|placebo|a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
223922928|NCT05613426|DRUG|Rosuvastatin 20 mg|Very early use of Rosuvastatin before primary PCI in anterior STEMI
223922929|NCT05613426|DRUG|Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]|Very early use of Evolocumab before primary PCI in anterior STEMI
223922930|NCT05751226|DRUG|BI 1820237|BI 1820237
223922931|NCT05751226|DRUG|semaglutide|semaglutide
223922932|NCT05751226|DRUG|Placebo|Placebo
223922933|NCT05751226|DRUG|BI 456906|BI 456906
223922934|NCT02415933|BEHAVIORAL|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~* Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~* Provision of seed grants to assist in business start-ups through microfinance loans;~* One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~* Trainings on financial planning and household livelihoods."
223922935|NCT02415933|BEHAVIORAL|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
223922936|NCT01992913|BEHAVIORAL|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
223922937|NCT01992913|OTHER|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
223531240|NCT00540631|BIOLOGICAL|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
223531241|NCT05464602|OTHER|Intervention group Lavender|This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
223531242|NCT05464602|OTHER|Intervention group Geranium|This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
223531243|NCT05427292|OTHER|serratus anterior block and PECs II block combination|The pre-surgery block will be applied. Sensorial block will be evaluated at the surgical incision site with the pinpirick test at 30 minutes after the block, and if the block is successful, surgery will begin.
223531244|NCT01170663|BIOLOGICAL|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
223531245|NCT01170663|DRUG|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
223531246|NCT01170663|DRUG|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
223531247|NCT00529295|DRUG|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
223922938|NCT01992913|BEHAVIORAL|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
223922939|NCT04955990|OTHER|PAH Therapies|No Drug will be administered as part of this study. Real world data will be collected in participants who newly initiate PAH therapies in routine clinical setting or have already been receiving macitentan 10 mg for at least 3 months prior to the index date.
223922940|NCT06031025|OTHER|Questionnaire, clinical examination|At each follow up visit, a clinical examination and anthropometric evaluation will be performed. Parents will fill a structured questionnaire to describe the occurrence and characteristics of functional gastrointestinal disorders.
223922941|NCT05718687|DRUG|GBT021601|Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
223922942|NCT03628677|DRUG|Domvanalimab|Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
223922943|NCT03628677|DRUG|Zimberelimab|Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
223922944|NCT06502951|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
224091692|NCT05805514|OTHER|Control|209 mother-child pair will receive the control package for 12 months. Child will be recruited within 6-12 months.
224280228|NCT04480307|DRUG|temelimab 36 mg/kg|temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
224280229|NCT04480307|DRUG|temelimab 54 mg/kg|temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
224280230|NCT04480307|DRUG|Placebo|Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
224280231|NCT00828828|BIOLOGICAL|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
223922945|NCT06502951|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
223922946|NCT01611896|DIETARY_SUPPLEMENT|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
224280232|NCT01132261|OTHER|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
223531248|NCT01394159|PROCEDURE|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
223922947|NCT01611896|OTHER|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
223922948|NCT06700044|DIETARY_SUPPLEMENT|GutMagnific|Participants will take one stick/10\^9 CFU of probiotic dietary supplement GutMagnific per day from gestational week 12 until gestational week 37
223922949|NCT06700044|DIETARY_SUPPLEMENT|Placebo|Participants will take one stick/placebo per day from gestational week 12 until partus.
223922950|NCT06276387|BEHAVIORAL|Mindfulness Program|Participants will receive eight weekly 2.5-hour group sessions and one day-long silent retreat, delivered online. Intervention content will include the MBSR program, which has been extensively studied with many different chronic conditions, and augmentations for individuals with rheumatic diseases. Each MBSR session will include meditation practices (e.g., sitting meditation, body scan, gentle hatha yoga, walking meditation, mindfulness of daily activities, awareness of pleasant and unpleasant events) and review of home practice. Participants will complete daily home practices for about 45 minutes per day and log their practice.
224091693|NCT04934826|DIETARY_SUPPLEMENT|Hydrolyzed Proteins|Patients in experimental arm will receive a test meal based on marked hydrolyzed proteins
224091694|NCT04934826|DIETARY_SUPPLEMENT|Intact proteins|Patients in active comparator arm will receive a meal based on intact marked proteins.
224091695|NCT04568837|DRUG|Prednisone 20 Mg|20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group
224091696|NCT02168595|DRUG|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
224091697|NCT02168595|DRUG|Placebo|
224280233|NCT02494505|DRUG|Mycophenolate Mofetil|2g/day per os
224280234|NCT02494505|DRUG|placebo|
224280235|NCT06551948|DIETARY_SUPPLEMENT|psyllium|15 g psyllium
224280236|NCT06551948|DIETARY_SUPPLEMENT|methylcellulose|15 gm methylcellulose
224280237|NCT06551948|DIETARY_SUPPLEMENT|maltodextrin|15 g maltodextrin
223531249|NCT01394159|PROCEDURE|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
224280238|NCT06551948|DIETARY_SUPPLEMENT|inulin|15g inulin
224280239|NCT04836182|DRUG|IONIS-AGT-LRx|Multiple doses of IONIS-AGT-LRx will be administered by SC injection.
224280240|NCT04836182|DRUG|Placebo|IONIS-AGT-LRx-matching placebo will be administered by SC injection.
224280241|NCT00743860|DRUG|darapladib|experimental drug
224280242|NCT01546727|BEHAVIORAL|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
224280243|NCT01546727|BEHAVIORAL|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
224280244|NCT04480372|DRUG|Gemcitabine|Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).
224280245|NCT04480372|DRUG|Atezolizumab|Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).
224280246|NCT03171324|DRUG|Iron Supplement|2 mg/kg/day elemental iron
224280247|NCT04631133|DEVICE|Lumbar Implant for Stiffness Augmentation (LISA)|The LISA Posterior Dynamic Stabilization System is intended to treat low-back pain that accompanies degenerative lesions of grade II, III and IV (Pfirrmann MRI classification).
223922951|NCT06701422|PROCEDURE|Intraoperative stimulation of the cervical spinal cord|The surgeon will place spinal cord electrodes on the epidural surface, with stimulation sites identified using preoperative MRI. Recruitment curves will be generated by systematically increasing the stimulation intensity across various parameter combinations, including frequency, pulse count, pulse shape, and electrode-specific properties such as size, separation, and arrangement.
223922952|NCT06633562|DRUG|Nezavist SDD|Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.
224091698|NCT02666326|PROCEDURE|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is \<9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is \<14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
224091699|NCT06151652|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.
224091700|NCT06151652|DRUG|Placebo|placebo
223922953|NCT06633562|DRUG|Placebo|Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
223922954|NCT05927142|BIOLOGICAL|Durvalumab|Human anti-PD-L1 antibody
223922955|NCT05927142|DRUG|Rintatolimod|TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)
223922956|NCT06875323|OTHER|ECHO-FostrSpace|Six ECHO-FostrSpace session training for CASA volunteers.
223922957|NCT06875323|OTHER|Informational Session|One ECHO-FostrSpace session training for CASA volunteers.
224280248|NCT00570206|BEHAVIORAL|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
224280249|NCT04592653|BIOLOGICAL|Nemvaleukin alfa|IV infusion over 30 minutes
224280250|NCT04592653|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes
224280251|NCT04911205|OTHER|Preoperative training program|Patients of intervention group (N=44) followed a 6-week supervised high-intensity preoperative training program. They had a session of preoperative resistance training five days per week for a period of 6 weeks before TKA. Each session was supervised by a physiotherapist specifically trained in progressive resistance training. The duration of each session was approximately 60 minutes. If a participant missed a training session, it was attempted to substitute the session on an alternative day.
224280252|NCT02608476|DRUG|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
224280253|NCT02608476|DRUG|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
224280254|NCT02795676|BIOLOGICAL|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
224280255|NCT02795676|BIOLOGICAL|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
224280256|NCT05427994|OTHER|National Eye Institute Visual Function Questionnaire|National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) measures the quality of life related to vision. This questionnaire has been validated for use on low vision patients.
224280257|NCT06074757|DRUG|Fulvestrant injection|phosphate ester of fulvestrant for test arm
224280258|NCT04073134|BIOLOGICAL|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
224280259|NCT04073134|DRUG|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
224280260|NCT01659034|DRUG|Thienopyridine for 3 months|
224280261|NCT06401941|PROCEDURE|Hyperbaric Oxygen Therapy|HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.
224280262|NCT05157035|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA)|This is a mindfulness- and acceptance-based smartphone app. The mindfulness and acceptance exercises embedded in the app are based on the principles of Acceptance and Commitment Therapy. Participants in the intervention group will be using the app for 6 weeks. They are expected to access the meditations and mindfulness exercises within the app on a daily basis.
224280263|NCT04139863|DIAGNOSTIC_TEST|aMMP-8 chairside test|No test
224280264|NCT02995564|BEHAVIORAL|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
224280265|NCT02365909|DRUG|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
224280266|NCT02365909|DRUG|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
223531250|NCT06163339|OTHER|Cultural Formulation Interview|Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence
223531251|NCT02172014|DRUG|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
223531252|NCT02172014|DRUG|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
223531253|NCT06513208|DRUG|Ketorolac Tromethamine|IV Ketorolac 15mg every 6 hours, x 4 doses
223531254|NCT06513208|DRUG|Placebo|IV saline as placebo
223531255|NCT01798602|DRUG|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
223531256|NCT01798602|DRUG|Placebo|Identical placebo for rosuvastatin
224091701|NCT01617538|DRUG|atorvastatin|40mg per day,duration for 24 weeks
224091702|NCT04890873|DRUG|ERX1000|ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension
224091703|NCT04890873|DRUG|Placebo|A suspension containing magnesium hydroxide carbonate in polysorbate
223922958|NCT06875258|DRUG|Sildenafil|Taken daily or on demand. First two weeks dosage of 75mg to manage side effects. If side effects are bearable, dosage will be adjusted to 100mg
223922959|NCT06875258|DEVICE|Erectile vacuum device|5 days a week, generating 5 erections per day
223922960|NCT06875414|BEHAVIORAL|Nursing care model|Describe relation between resilience, quality of life and depression and marital adaptation in the population considered from diagnosis to 24 months later.
223922961|NCT06700278|BEHAVIORAL|auricular acupressure|auricular acupressure was performed three times daily, with each acupoint massaged for three minutes at an optimal pressure level that induced sensations of soreness, numbness, distension, or mild pain. This was conducted five days a week for three weeks, in addition to regular rehabilitation therapy provided five days per week.The selected auricular acupoints include Shenmen (TF4), Subcortex (AT1), Liver (CO12), and Sympathetic (AH6a).
223922962|NCT06700278|BEHAVIORAL|body acupoint massage|The control group will receive acupoint massage three times daily, with each acupoint being massaged for three minutes. The applied pressure will be adjusted to induce sensations of soreness, numbness, fullness, or mild pain. The intervention will be conducted five days per week for a total of three weeks. The selected body acupoints include Quchi (LI11), Hegu (LI4), Sanyinjiao (SP6), and Zusanli (ST36).
223922963|NCT03624790|BIOLOGICAL|rRSV A/Maryland/001/11|10\^5 PFU; delivered intranasally
224091704|NCT03537040|OTHER|Method of Levels|Talking Therapy
224091705|NCT03624816|DEVICE|Restylane Defyne|hyaluronic acid dermal filler gel
224091706|NCT03135366|BEHAVIORAL|Keheala|
224091707|NCT03135366|OTHER|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
224280267|NCT02767947|DRUG|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
224280268|NCT02767947|DRUG|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
224280269|NCT04221594|PROCEDURE|Invasive Cardiac Catheterization (ICA)|Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
224280270|NCT04221594|PROCEDURE|Coronary Computed Tomographic Angiogram (CCTA)|Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
224280271|NCT04221594|PROCEDURE|Dynamic Cardiac Positron Emission Tomography (dPET)|Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
224280272|NCT05624762|DEVICE|Low-Intensity Focused Ultrasound (LIFU)|LIFU device (LCA200; Chongqing Haifu Medical Technology Co., Ltd., Chongqing, China).
224280273|NCT05624762|DEVICE|Sham Low-Intensity Focused Ultrasound|Sham Low-Intensity Focused Ultrasound
224280274|NCT02684396|DRUG|TAK-648|TAK-648 Solution
224280275|NCT02684396|DRUG|TAK-648 Placebo|TAK-648 placebo-matching solution
224280276|NCT02973581|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
224280277|NCT02973581|DRUG|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
224280278|NCT02973581|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
224280279|NCT02973581|DRUG|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
223531257|NCT02466828|DRUG|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
223531258|NCT01471184|DEVICE|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
223531259|NCT01471184|DEVICE|Placebo|Placebo Eye Drops/Nasal Spray
223531260|NCT02767076|PROCEDURE|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
223531261|NCT02767076|DEVICE|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
223531262|NCT05053061|BEHAVIORAL|Application program for pulmonary rehabilitation|Exercise videos for pulmonary rehabilitation
223531263|NCT04076267|OTHER|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
223531264|NCT03185468|GENETIC|4SCAR-PSMA|PSMA-specific 4th Generation CART
223531265|NCT03185468|GENETIC|4SCAR-FRa|FRa-specific 4th Generation CART
223531266|NCT06431347|BEHAVIORAL|Social Determinants of Health Questionnaire|Participants will also complete a questionnaire about financial barriers to care within the past year, including income bracket and difficulty affording cost-of-living or medical expenses.
223531267|NCT05922618|DEVICE|I-One|"I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.~Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier."
223531268|NCT03099122|BIOLOGICAL|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
223531269|NCT03099122|DRUG|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
224280280|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
223531270|NCT03099122|DRUG|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
223922964|NCT06878820|BEHAVIORAL|Function Focused Care|FFCiH is an effective nursing approach and focuses on stimulating nurses to promote patients' self-reliance in daily functioning, encouraging the patients' engagement in daily activities and helping patients to attain and maintain their highest level of function and to increase time spent in physical activity.
223922965|NCT06878794|COMBINATION_PRODUCT|Using medical biological glue for filling And Using the meniscus suture system|Using medical biological glue for filling And Using the meniscus suture system
223531271|NCT03099122|DRUG|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
223531272|NCT03099122|DRUG|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
223531273|NCT03099122|DRUG|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
224280281|NCT01500616|DRUG|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
223531274|NCT04708782|DRUG|Placebo|Placebo administered QID
224280282|NCT00065117|DRUG|ZD6126|
224280283|NCT00065117|DRUG|Placebo|
223531275|NCT04708782|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
223531276|NCT04708782|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
224280284|NCT00065117|DRUG|5-fluorouracil|
223531277|NCT06402838|DRUG|RO7269162|Participants will receive daily doses (one of three dose levels) of RO7269162 for up to 72 weeks.
223531278|NCT06402838|DRUG|Placebo|Participants will receive daily doses of placebo for up to 72 weeks.
223922966|NCT06878794|PROCEDURE|Using the meniscus suture system|Using the meniscus suture system
224280285|NCT00065117|DRUG|leucovorin|
223531279|NCT06459791|PROCEDURE|Biopsy|The recommandation done based on informative tumorogram is up to study investigator
223531280|NCT05141383|OTHER|Urine sampling|A blood sample and a urine sample after prostate massage will be carried out at baseline
223531281|NCT05867953|DEVICE|Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging|Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
223531282|NCT06409065|BEHAVIORAL|Meditation Program|Meditation and discussion sessions will be audio recorded
223531283|NCT01916057|DEVICE|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
223531284|NCT06044740|DRUG|Sevoflurane|After a no-drug control period, subjects will inhale sevoflurane, administered via a breathing circuit and face mask, until a steady-state target end-tidal expired concentration of 0.4% (corresponding to 0.2 Minimum Alveolar Concentration) is reached.
223531285|NCT06044740|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with a fixed number of the experimental cues, in a pattern that appears random to participants.
223922967|NCT06876948|DIAGNOSTIC_TEST|Psychological tests, EEG, Magnetic Resonance|Patients are administered some psychological tests, if they are positive they move on to the next stage, otherwise the patients leave the practice. If they are positive, EEG, MRI and other psychological tests are also administered.
223922968|NCT06877767|OTHER|Graston Technique|"Following the conventional treatment, this technique will be carried out through Graston tool called GT-1 The special Graston Emollient or lubricant will be applied to the hamstrings of the subject then the tool used to find adhesions and break them up for 2.5 minutes per leg. First, the subject will lay prone and bent the knee joint to around 30° to 60°.The Graston instrument will be rubbed on each subject 30 times for 60 seconds from the gluteal line to the popliteal fossa. This treatment technique will be applied twice a week"
223531286|NCT04512235|DRUG|CAEL-101|The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
223922969|NCT06877767|OTHER|Active Release Technique|Following the conventional treatment, subject received single session of ART on each side. There are 3 steps to perform ART. Step 1:Subject lies supine on the plinth and gentle tension was applied to the hamstring muscle along the entire length while stretching the leg in different positions to better work the muscle. Step 2: Gentle tension will be applied at the origin and insertion of the hamstring muscle. Step 3: The therapist will place tension on the bellies of hamstrings longitudinally at a specific tension \& ask the patient to extend his knee as per ART protocol.• This is done for 2.5 minutes on each leg. • This treatment technique will be applied twice a week.
223922970|NCT04569942|DRUG|Vasopressor|Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.
224280286|NCT00065117|DRUG|oxaliplatin|
224280287|NCT04281524|DRUG|CSL312|CSL312 administered as an IV infusion
224280288|NCT04281524|DRUG|Placebo|Solution of 70% 0.9% saline / 30% CSL312 diluent
224280289|NCT04238208|DRUG|Lidocaine 5% patch|5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm
224280290|NCT04238208|DRUG|Capsaicin 8% Patch, Per 10 Square Centimeters|8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)
224280291|NCT03904550|DRUG|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
224280292|NCT03904550|DRUG|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
223531287|NCT04512235|OTHER|Placebo|Commercially available 0.9% Normal Saline will be used as the placebo.
223922971|NCT04569942|OTHER|Fluids|An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.
223922972|NCT06878963|PROCEDURE|PENG Block|The PENG block will be performed on the patient with the injection of local anesthesia under ultrasound guidance in the femoral region, beneath the biceps tendon.
223531288|NCT04512235|DRUG|cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen|According to institutional standard of care.
223922973|NCT06878963|PROCEDURE|SIFICB Block|The SIFIB block will be performed on the patient with the injection of local anesthetic between the iliac fascia and iliac muscle in the femoral region, under ultrasound guidance.
223922974|NCT06876116|DRUG|Fluorometholone 0.1% ophthalmic solution|After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with fluorometholone 0.1% once a day for 8 weeks.
223922975|NCT06876116|DRUG|Cyclosporine 0.05% eye drops|After induction therapy with fluorometholone 0.1% four times a day for 4 weeks, patients continued with cyclosporine 0.05% twice a day for 8 weeks.
223922976|NCT06877741|OTHER|Group A (Heavy Slow Resistance exercises)|Pre - assessment will be taken. Heavy slow resistance exercises will be given to group A and exercises of 4 sets of 10-20 repetitions will be given
223922977|NCT06877741|OTHER|: Group B (Eccentric exercises)|Sessions should be conducted 2 times per week, similar to Group A, in 3 sets of 10-20 repetitions. Exercises focus solely on eccentric loading, such as eccentric squats, eccentric leg presses, and step-down exercises.
223922978|NCT06692517|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
223922979|NCT06692842|DEVICE|CONEMO App|The CONEMO application has three protocol, aimed to improived symptoms of depression, insomnia and anxiety. It is based on cognitive behavioral therapy (CBT) and contextual behavioral therapy (activation behavioral theraphy, mindfulness) and adapted considering broader contexts of mental health care, which involves a low-intensity intervention administered without any or minimal professional guidance and widely accessible. In a brief and structured format, CONEMO involves offering the intervention through texts, audios and videos. Based on the principles of CBT and contextual thrapies, CONEMO is organized into structured sessions that promote psychoeducation and teach basic behavioral skills, often through interactive exercises. Each journey was developed based on scientific evidences. The CONEMO journeys comprise seven weekly modules.
223922980|NCT06720350|DRUG|Romosozumab and Denosumab Combination Therapy|Romosozumab 210mg per month and denosumab 60mg per 6 months will be applied
223922981|NCT06720350|DRUG|Romosozumab Prefilled Syringe [Evenity]|Romosozumab 210mg subcutaneously per month
223922982|NCT06720350|DRUG|Denosumab (Prolia)|Denosumab 60 mg subcutaneously per 6 months
223922983|NCT06719635|PROCEDURE|Laparoscopic Presacral Neurectomy|Laparoscopy will be performed under general anesthesia. Then, nerve plexuses will be identified and freed from their underlying tissue, which contains the left common iliac and middle sacral veins. This will be followed by cauterization and cutting of the nerve plexuses.
223922984|NCT06719635|PROCEDURE|Fluoroscopically guided Superior Hypogastric Plexus Neurolysis|The patients will receive fluoroscopically guided Superior Hypogastric Plexus Neurolysis using 3 mL of 75% ethanol and Radiofrequency of the Sacral nerve Roots 2-4.
223922985|NCT06723665|DRUG|18F-PSMA-1007|18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
223922986|NCT06723665|DRUG|18F-FDG|18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
223922987|NCT06885450|PROCEDURE|Perforator Pedicled Flaps|Perforator Pedicled V-Y Advanced Flaps
223922988|NCT06885567|DRUG|BEY2153|Participants administer once daily, PO, 26 weeks
223922989|NCT06885567|DRUG|Placebo|Participants administer once daily, PO, 26 weeks
223922990|NCT06886243|PROCEDURE|Direct Posterior Composite Restoration|"Description: Composite restorations performed using Clearfil Majesty Posterior (Kuraray, Japan) and Clearfil Universal Bond Quick (Kuraray, Japan) in self-etch mode.~Inferior alveolar nerve block (IANB) administered with articaine hydrochloride with epinephrine (1:100,000) (Maxicaine)."
223922991|NCT06885606|DEVICE|Active tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that involves brief (e.g., 20-min) application of weak electric current (e.g., 2 mA) to the scalp. Active tDCS intervention increases excitability of neurons at the anode with 20-30% of the current going through the brain from anode to cathode so that both cortical and subcortical structures are stimulated. The procedure is very safe, convenient, and fast-acting with well-established parameters. It has the ability to modulate plasticity in specific brain areas and has established efficacy in human laboratory models of addictive motivation and has been shown to decrease craving for cigarettes when the anode is placed over the left dorsolateral prefrontal cortex (DLPFC).
223922992|NCT06885606|DEVICE|Sham tDCS|Sham tDCS applies a 2mA current for the initial 30 seconds, followed by 0 mA for the remaining 19.5 minutes to simulate active tDCS stimulation. The cathode electrode is placed on the right dorsolateral prefrontal cortex (DLPFC), and the anode is positioned on the left DLPFC, aligned with the electrode placement used in active tDCS.
223922993|NCT06886906|BEHAVIORAL|Intermittent light walking|The participant will remain seated throughout the 1 hour experimental period. During this 1-hour period, participants will complete six bouts of 2.5-minutes of light intensity walking. Overall, the bouts will occur on six occasions, providing a total of 15 minutes of light intensity activity.
223922994|NCT06886906|BEHAVIORAL|uninterrupted sitting|The participant will remain seated throughout the experimental period and will be instructed to minimize excessive movement, only rising from the chair to void. This experimental condition is designed to mimic prolonged uninterrupted sedentary behavior.
223922995|NCT06887452|OTHER|Pharmacist-Led|Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
223922996|NCT06886334|OTHER|exercise|Ultrasound (4 minutes), TENS (100 Hz, 20 minutes), heat application (15 minutes), and home exercises will be applied. Treatment will be conducted three times a week for four weeks.
223922997|NCT06886334|OTHER|mobilization|In addition to heat application (15 minutes) and home exercises, the Cox technique will be used. The patient will be placed face down on a specialized table, and traction will be applied to the lumbar spine for 10 minutes.
223922998|NCT06885632|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts 56 days and each patient will have 3 visits (week0, week4, week8).
223922999|NCT06885632|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts 56 days and each patient will have 3 visits (week0, week4, week8).
223923000|NCT06884059|BEHAVIORAL|Time Restricted Eating|Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.
223923001|NCT06885060|DEVICE|BGaze ADHD Diagnostic Test|The BGaze Clinic ADHD diagnostic test will be administered to all participants. This involves a computer-based task, where an eye-tracker will be recording their eye-movements.
223923002|NCT06885060|DEVICE|Oddball/Alerting Computer Task|Oddball/Alerting Computer Task will be completed by all participants while an eye-tracker records their eye movements.
223923003|NCT06885060|DEVICE|Facical Emotion Computer Task|The Facial Emotion Computer Task will also be completed by all participants while their eye movements are recorded using an eye-tracker.
223923004|NCT06886815|PROCEDURE|Popliteal Nerve Block|Popliteal sciatic nerve blocks will be performed with the patient in prone position, with the popliteal fossa of the surgical leg marked and sterilized. A high-frequency 10-12 MHz linear array ultrasound transducer will be positioned transversely at the level of the popliteal crease and moved proximally to identify the bifurcation of the sciatic nerve into the tibial and common peroneal nerves. Under ultrasound guidance, a 22-gauge, 80-mm echogenic needle will be inserted using an in-plane lateral-to-medial approach. 15 mL of 0.5% ropivacaine with 2.5 µg/ml of epinephrine will be deposited between tibial and common peroneal nerves within the paraneural sheath. Adequate spread of local anesthetic will be confirmed by visualization of paraneural spread.
223923005|NCT06886815|PROCEDURE|Sham Block|Sham blocks will be performed using a 25G needle to inject 1 mL of saline subcutaneously in the popliteus of the surgical knee. Sterilization and ultrasound scanning will mirror that of a popliteal nerve block. The ultrasound screen will be blinded from the patient's vision for all patients in the trial to prevent unblinding by patients with knowledge of the technique.
223923006|NCT06726369|DRUG|MK-6204 (SKB535) for Injection|MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
223923007|NCT01499368|DRUG|Lafutidine|Lafutidine 20mg/day
224280293|NCT00948337|BEHAVIORAL|Brochure of Secondary Cancer Screening|One kind of printed educational material
223923008|NCT01499368|DRUG|Famotidine|Famotidine 40mg/day
223923009|NCT01499368|DRUG|Omeprazole|Omeprazole 20mg/day
223923010|NCT06252519|DIETARY_SUPPLEMENT|NAC|1 375 mg capsule containing N-acetyl cysteine
223923011|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC|3 capsules containing a total of 375 mg N-Acetyl L-Cysteine Ethyl Ester
223923012|NCT06252519|DIETARY_SUPPLEMENT|Neuro-NAC XS|3 capsules containing a total of 75 mcg Selenium, 150 mcg Molybdenum, 1800 mg Glycine, and 375 mg N-Acetyl L-Cysteine Ethyl Ester
223923013|NCT07040059|DRUG|AUR103 Calcium|AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
224280294|NCT05922709|DRUG|CS12192 capsule|Participants receive CS12192 orally single or multiple doses
224280295|NCT05922709|DRUG|Placebo capsule|Participants receive placebo matching CS12192 orally single or multiple doses
224280296|NCT01309854|DRUG|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
224280297|NCT01309854|DRUG|pioglitazone|oral tablets, 30mg single dose per period
224280298|NCT01647997|OTHER|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
223923014|NCT07040059|DRUG|Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)|Standard dose of Trastuzumab and CAPOX (Capecitabine + Oxaliplatin) will be administered in the Control Arm of Phase 2.
223923015|NCT06721351|DIAGNOSTIC_TEST|Diabetic Retinopathy screening Point of Care Artificial Intelligence|Random assignment of participants to intervention and control groups minimizes confounding variables. This ensures that any observed differences in outcomes are likely due to the intervention itself and not pre-existing differences between the groups. Participants of the DRES-POCAI study will be randomized into two groups: usual care (receive a retinal screening by an optometrist) or intervention group (receive a retinal screening using a special camera and EyeArt® system, an autonomous AI-based DR screening). The randomization will occur after consenting and completing the surveys, prior to conducting the DR screening process (for those randomized to the intervention group).
223923016|NCT06721897|OTHER|Prehabilitation Program|"A prehabilitation programme supervised by a physiotherapist in a ward is proposed, with a frequency of 3 sessions/week on alternate days lasting 30-45 min/session, in addition to a daily physical exercise programme at home.~The programme will consist of a warm-up, strength exercises with progressive loads, proprioception, balance, cardiovascular training aimed at functional work and a cool-down.~The home programme will be complementary to the supervised programme, which will consist of daily sessions of 20-30 min of flexibility and proprioception exercises.~The same prehabilitation protocol will be proposed for those patients awaiting total hip and knee replacement surgery."
223923017|NCT06721897|OTHER|Non prehabilitation Program|The control group (CG) will carry out a post-operative physiotherapy program in addition to a home exercise program that will be shown by the physiotherapist before hospital discharge.
223923018|NCT06728449|DIETARY_SUPPLEMENT|Cumin tea|The preparation involved boiling 200 ml of water with 2 grams of cumin seeds. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
224280299|NCT05025631|DRUG|Fruquintinib|Fruquintinib was administered for 21 consecutive days of a 28-day treatment cycle. The starting dose of fruquintinib was 3 mg/day, weekly incremental dose escalation occurred up to the maximum of 5 mg/day if no significant drug-related toxicities were observed. The highest tolerated dose from cycle 1 would be administered in cycle 2 and all subsequent cycles.
224280300|NCT06293391|PROCEDURE|cardiac indices in supine and trendelenburg position|Cardiac indices in supine and trendelenburg position in patients undergoing open or laparoscopic major cancer surgery
223531289|NCT02303262|DRUG|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
223531290|NCT02303262|DRUG|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
223531291|NCT00003888|DRUG|cisplatin|
223531292|NCT00003888|DRUG|docetaxel|
223531293|NCT00003888|DRUG|fluorouracil|
223531294|NCT00003888|RADIATION|radiation therapy|
223531295|NCT04758507|BIOLOGICAL|donor FMT|This intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
223923019|NCT06728449|DIETARY_SUPPLEMENT|Ginger Tea|The preparation involved boiling 200 ml of water with 2 grams of ginger. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
223923020|NCT06728449|DIETARY_SUPPLEMENT|Lemon Peel Tea|The preparation involved boiling 200 ml of water with 2 grams of lemon peel. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
224280301|NCT05780996|DEVICE|QMODE +|Atrial fibrillation radiofrequency ablation of the anterior and posterior wall with 90W (vHPSD)
224280302|NCT05780996|DEVICE|QMODE|Atrial fibrillation radiofrequency ablation of the anterior wall with 50W (HPSD). Ablation of the posterior wall with 90 W (vHPSD)
224280303|NCT01909739|DRUG|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
223531296|NCT04758507|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through FMT
223531297|NCT05664373|PROCEDURE|Coronally advanced flap and deepithelized free gingival graft|Free gingival grafts, de-epithelialized intraoraly or extraoraly in combination with coronally advanced flap will be used in the treatment of multiple gingival recessions.
223531298|NCT00047034|DRUG|eribulin mesylate|Given IV
223531299|NCT00047034|OTHER|pharmacological study|Correlative studies
223531300|NCT00047034|OTHER|laboratory biomarker analysis|Correlative studies
223531301|NCT04462471|DIAGNOSTIC_TEST|I-124 PET/CT lesion dosimetry|I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
223923021|NCT06728449|DIETARY_SUPPLEMENT|Functional Tea|The preparation involved boiling 200 ml of water with 2 grams of functional tisane (0.6 g cumin seeds, 0.6 g ginger, and 0.6 g lemon peel) Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
223717451|NCT05695443|BEHAVIORAL|Motivational Interviewing|This study investigates the effects of an intervention based on Motivational Interviewing (MI) on oral hygiene, oral cleaning routines, and attitudes towards own oral health. The first step is for the dental staff to ask open questions to the prisoner about their oral health or oral health behavior. The next step is to confirm to the prisoner what he or she is doing. The third step is called reflection. At this stage, dental staff tries to provide reflections on what the prisoner have said, for example by repeating what the prisoner have said or say the same using synonyms (simple reflection), by extracting the underlying opinion or feeling (complex reflection), or by illuminate both negative and positive sides of the situation (double sided reflection). The final step is to summarize the conversation. In addition, the intervention includes a change plan, in which the prisoner and dental staff agrees on specific behavior that the prisoner should follow based on the MI conversation.
223923022|NCT06728449|DIETARY_SUPPLEMENT|Conventional therapy|A carbohydrate-controlled diet focuses on limiting refined carbohydrates and sugars and total carbohydrate restriction to 50-70gm per major meal.
223923023|NCT06728241|BEHAVIORAL|RecoVRy|A mental health professional (VR therapist) will be together with the patient when VR treatment is provided. The VR therapist will help put on the VR headset, start the program and encourage the patient to apply the learning from RecoVRy to real-world challenges by setting up homework tasks to be carried out between VR sessions. The application will run through Meta Quest 2/3®. RecoVRy is designed as a repeated behavioural procedure in which the main focus is for participants to learn that they are safer than assumed. Participants can proceed at their own pace, allowing for more or less than 8 (+/- 2) sessions of VR treatment. Scenarios and levels may be repeated if necessary
223923024|NCT06728241|BEHAVIORAL|VR Games|Patients randomized to this condition will receive a total of ten sessions of VR games.
223923025|NCT06728436|BEHAVIORAL|CuidaTEXT|CuidaTEXT is a multidomain, bilingual 6-month text message intervention that includes delivery and content features tailored to Latino caregivers. All caregivers receive one core daily automatic message on five domains: ADRD education, social support, self-care, ADRD care management, and behavioral symptoms. Caregivers can access on-demand automatic messages to expand on the five domains via sending keywords and interact with a coach via a live chat for more personalized help.
223923026|NCT06729437|OTHER|tDCS + Therapeutic eccentric exercise|A direct current of 1.5 mA will be applied for 20 minutes to the primary motor cortex (M1) during each session of eccentric exercises.
224280304|NCT01909739|DRUG|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
224280305|NCT06398834|DRUG|Esketamine|In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
224280306|NCT06398834|DRUG|Butorphanol|In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
224280307|NCT03087435|DEVICE|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
224280308|NCT02114112|OTHER|NCPAP cycling|
224280309|NCT02114112|OTHER|NCPAP continuous|
224280310|NCT06679218|OTHER|Activity Coaching Programme|The intervention will consist of individualized physical activity coaching sessions, which will take place twice a week for 8 weeks. These sessions will focus on encouraging progressive and personalized physical activity according to each participant's ability. The sessions will also include relaxation techniques, targeted ventilation and strategies to improve activity management.
224280311|NCT06679218|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
224280312|NCT00002936|DRUG|altretamine|
224280313|NCT00002936|DRUG|etoposide|
224280314|NCT03722108|COMBINATION_PRODUCT|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
224280315|NCT03722108|DRUG|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
224280316|NCT05484609|OTHER|OUD scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
224280317|NCT05484609|OTHER|Diabetes scenario|The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
224280318|NCT05557656|DRUG|Regorafenib 40 MG|participants who received the treatment of Regorafenib
224280319|NCT06679647|BEHAVIORAL|Access to a trained ChatGPT|Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.
224280320|NCT05607433|DEVICE|cook ®Airway Exchanger Catheter|A tube exchanger is a small calibre , flexible tube used to guide endotracheal intubation through a supraglottic device.
224280321|NCT05363982|DEVICE|Transcranial Photobiomodulation (tPBM)|"Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy.~Other Names:~Niraxx G1 Headband"
224280322|NCT05363982|DEVICE|Placebo/ Sham|The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.
223923027|NCT06729437|OTHER|Sham tDCS + Therapeutic eccentric exercise|The current will be interrupted after 30 seconds.
223923028|NCT06818903|DRUG|Misopristol|Foley catheter with Misopristol local application
223923029|NCT06818903|DEVICE|Foley catheter|Foley catheter alone
223923030|NCT06735079|DRUG|REL1017 (esmethadone HCI) (active drug)|REL-1017 is an investigational drug administered as an oral tablet, once daily. The dosing regimen includes a 75 mg dose on Day 1 (three tablets) in the clinic, followed by 25 mg daily (one tablet) at home from Day 2 to Day 28, with regular safety, efficacy, and tolerability assessments REL-1017 (esmethadone HCl) is under investigation as a novel NMDAR antagonist. Unlike racemic methadone, it lacks opioid-like effects such as dependency or respiratory depression. REL-1017 also lacks dissociative effects seen with more potent NMDAR antagonists such as ketamine. Finally, REL-1017 does not appear to have metabolic or neurological side effects.
223923031|NCT06735079|DRUG|Placebo|"The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD)."
223923032|NCT03092674|DRUG|Azacitidine|Given SC or IV
224091708|NCT05965037|DEVICE|FLUYDO NC percutaneous transluminal coronary angioplasty balloon catheter|The FLUYDO NC is a rapid exchange percutaneous transluminal non-compliant coronary angioplasty balloon catheter. It is a single use only medical device, non-implantable, non-pyrogenic and sterilized with ethylene oxide and CO2 mixture. The distal portion has a hydrophilic coating and consists of two lumens: one for balloon inflation and deflation, the other for guidewire advancement and retraction. The product is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion.
224091709|NCT02620020|DRUG|Fasinumab|Participants received fasinumab SC or IV, Q4W or Q8W.
224091710|NCT02620020|DRUG|placebo|Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
224091711|NCT00558935|DIETARY_SUPPLEMENT|Red Wine|20g alcohol daily/red wine for 4 weeks
224280323|NCT01609582|DRUG|TAK-875|TAK-875 tablets
223923033|NCT03092674|DRUG|Cytarabine|Given IV
223923034|NCT03092674|DRUG|Decitabine|Given IV
223923035|NCT03092674|OTHER|Laboratory Biomarker Analysis|Correlative studies
223923036|NCT03092674|DRUG|Midostaurin|Given PO
223923037|NCT03092674|BIOLOGICAL|Nivolumab|Given IV
223923038|NCT06735547|DEVICE|Telerehabilitation|Patients in the Telerehabilitation group will perform an average of three therapy sessions per week, with data collected and monitored by TRAK's physiotherapists. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
223923039|NCT06735547|OTHER|Conventional therapy group|Patients in the conventional group will be assessed by a professional physiotherapist, scheduling appointments according to their own preferences and disponibility. Both groups will have their results measured monthly by the orthopedic surgeons for 12 weeks (3 months) postoperatively.
223923040|NCT06735235|DRUG|0 ppm F|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223923041|NCT06735235|DRUG|250 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223923042|NCT06735235|DRUG|1100 ppm as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
223923043|NCT06735235|DRUG|2800 ppm F as MFP|Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
224091712|NCT05642377|DRUG|HGR4113|Once-daily oral administration
224280324|NCT01609582|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
224280325|NCT05683860|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
223923044|NCT06735352|OTHER|virtual reality intervention|Evaluated the effect of virtual reality use in elderly people with mild cognitive impairment compared to a control group.
223923045|NCT06735508|DRUG|mRNA Neoantigen Vaccine|mRNA Neoantigen Vaccine
223923046|NCT06735508|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody.
223923047|NCT06734455|OTHER|Robot-Assisted Pyeloplasty|Pyeloplasty in Children using robotic surgery
223923048|NCT06404827|OTHER|Horseback riding simulator|Horseback riding simulator (HRS) will be applied in addition to routine Physiotherapy and Rehabilitation.
223923049|NCT06404827|OTHER|Routine Physiotherapy and Rehabilitation|Routine Physiotherapy and Rehabilitation within a spesific programme
224091713|NCT05642377|DRUG|Placebo|Once-daily oral administration
224280326|NCT03934060|OTHER|Exercise|specific strength training
224280327|NCT00206180|DRUG|esomeprazole magnesium (oral medication)|
224091714|NCT05642377|DRUG|HGR4113|Twice-daily oral administration
224091715|NCT05642377|DRUG|Placebo|Twice-daily oral administration
224091716|NCT05318521|DRUG|Placebo|The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
224280328|NCT04161573|BEHAVIORAL|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
224280329|NCT03067740|DRUG|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
224280330|NCT03067740|DRUG|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
223531302|NCT04462471|DRUG|Vemurafenib|Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
223531303|NCT04462471|DRUG|Copanlisib|Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
223531304|NCT00724763|DEVICE|acupuncture|to Liv 3 and PE 9.
223531305|NCT00724763|DEVICE|sham needle treatment|needle not in meridian area
223531306|NCT04921982|DRUG|Propranolol|Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.
223531307|NCT04921982|DRUG|Placebo|Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
223531308|NCT01734525|DRUG|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
223531309|NCT03522402|DRUG|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
223717452|NCT05673278|DIAGNOSTIC_TEST|Bowel Ultrasound Scan|"Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~\+ Image quality"
223717453|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
223717454|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
223717455|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
223717456|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
223923050|NCT06081127|OTHER|MOve-ABC|"The intervention is called Moving On After Breast Cancer (MOve-ABC) and includes:~1. Three in-person visits for clinical measurements~2. Enhanced usual care (EUC)~3. Pre-hab ((Pre-Treatment) PT evaluation and individualized home therapeutic exercise prescription with safe progressions).~4. Teach Back (HEP, post-op movement precautions)~5. Self-management education with reinforcement check-ins via text messaging and phone calls at regular intervals."
223923051|NCT06081127|OTHER|Enhanced Usual Care|"All patients will receive EUC. However, half of our sample will have only EUC consisting of~1. Three in-person visits for clinical measurements~2. Planned oncology treatment (surgery, chemotherapy, radiation)~3. Nursing education on surgical site and drain care, post-operative movement precautions, pain management~4. If needed, laboratory and radiological testing to rule out disorders that interfere with treatment outcomes~5. Monthly monitoring with Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS-PF) surveys beginning at baseline with alerts from scores = or \< 45 (indicating moderate or severe impairment) for physical therapy referral"
224091717|NCT05318521|DRUG|Ibuprofen modified release tablet 800 mg|Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
224091718|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
224091719|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
223531310|NCT01763762|BEHAVIORAL|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
223531311|NCT01763762|BEHAVIORAL|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
223531312|NCT01763762|BEHAVIORAL|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
223531313|NCT05584098|OTHER|qSOFA, MEWS and physiological parameters combination|qSOFA ,MEWS and physiological parameters combination used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
223531314|NCT01276626|DIETARY_SUPPLEMENT|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
223531315|NCT01276626|OTHER|Maltodextrin|Powder containing only maltodextrin
223531316|NCT05666830|DEVICE|Lando® artificial dermal regeneration matrix|Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
223717457|NCT01489488|DRUG|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
223717458|NCT04047498|DEVICE|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
223717459|NCT02301884|BIOLOGICAL|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
223923052|NCT06349889|DRUG|Adebrelimab|"Drug: Adebrelimab Adebrelimab 1200mg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.~Other Names:~PD-L1 antibody~Drug: Gemcitabine Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.~Other Names:~GEM~Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation~Other Names:~DDP~Radiation: Intensity-modulated radiotherapy Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.~Other Names:~IMRT"
223923053|NCT05788666|PROCEDURE|GeriKit Mobile Application|Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
223923054|NCT06216665|OTHER|Continuous Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test
223923055|NCT06216665|OTHER|Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test|Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test
223923056|NCT00766948|OTHER|There is no intervention, this is a biorepository.|There are no interventions in this study.
223923057|NCT06883864|PROCEDURE|Catheter ablation plus medication|All patients will receive atrial fibrillation catheter ablation. They also should receive guideline-directed medical therapy, anticoagulation, and rate control with medications according to the guidelines.
223923058|NCT06883864|DRUG|Medication|Patients will receive guideline-directed medical therapy, anticoagulation, and rate control according to the guidelines for the management of AF and heart failure.
223923059|NCT06883864|PROCEDURE|(ELEVATE-AF X) experimental group|Subsequent ablations may be considered for patients with recurrence，and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
224091720|NCT00844493|BIOLOGICAL|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
224091721|NCT00844493|BIOLOGICAL|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
224091722|NCT02511977|OTHER|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
224091723|NCT00208637|BEHAVIORAL|moderate carbohydrate, high protein diet (MCHP)|
224091724|NCT00208637|BEHAVIORAL|high carbohydrate-high fibre (HCHF) diet|
224280331|NCT02958930|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
223717460|NCT04593225|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL SFCAMINA|Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.
223923060|NCT06883864|PROCEDURE|(ELEVATE-AF X) control group|All patients could receive catheter ablation if the procedure is needed, and the medical therapy for ELEVATE-AF X is identical to that of the ELEVATE-AF trial.
223923061|NCT06884488|DEVICE|repetitive transcranial magnetic stimulation (Magstim Super Rapid stimulator, The Magstim Company Ltd, Whitland, UK)|The paradigm will be applied over the dominant cerebral hemisphere for 10 minutes (600 pulses) over the dominant pharyngeal motor cortex capped at 120% of pharyngeal resting motor threshold.
223923062|NCT06884488|DEVICE|pharyngeal electrical stimulation (Digitimer model DS7; Welwyn-Garden City, Herts, UK)|The PES (0.2-ms pulses, 280 V) was delivered at a set frequency (5 Hz), intensity (75% of maximal tolerated), and duration (10 minutes), which have been reported as the most effective parameters for PES.
223923063|NCT06884488|DEVICE|sham repetitive transcranial magnetic stimulation(Magstim Super Rapid stimulator, The Magstim Company Ltd, Whitland, UK)|Sham rTMS is delivered with the coil tilted to its side at 90 degrees and with the identical stimulation conditions as active 1 Hz rTMS.
223923064|NCT06884488|DEVICE|sham pharyngeal electrical stimulation (Digitimer model DS7; Welwyn-Garden City, Herts, UK)|For sham pharyngeal stimulation, the same method including the insertion of the catherter will be employed without actual electrical stimulation.
223923065|NCT06886984|BEHAVIORAL|Social media motivation|Reminding the oral hygiene instructions using social media tools to keep their oral hygiene stable
224091725|NCT01455974|OTHER|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
224091726|NCT02432547|DRUG|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
224091727|NCT02432547|PROCEDURE|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
223923066|NCT06884280|DRUG|Monofer (iron isomaltoside 1000)|Intravenous iron infusion, administered in this study up to every 3 months. Dosage determined by haemoglobin and weight.
223923067|NCT06884280|DRUG|Ferrous Sulfate|Oral iron tablet taken once daily for duration of study.
223923068|NCT06888739|PROCEDURE|MR4|The study is a clinical retrospective study and does not involve any interventional measures.
223923069|NCT06888063|COMBINATION_PRODUCT|Hepatic Arterial Infusion Pump chemotherapy with floxuridin|Participants in this arm will receive in addition to standard care (surgery) a chemo pump. This pump will provide participants with 4 cycles of treatment with chemotherapy (Floxuridin), each lasting 4 weeks. Total treatment with chemotherapy will last 16 weeks (approx. 4 months)
223923070|NCT06885476|BIOLOGICAL|Infusion of alloreactive NK cells|Infusion of alloreactive NK cells for acute leukemia patients harboring minimal residual disease after conventional chemotherapy and prior to allogeneic stem cell transplantation
223923071|NCT06890182|DRUG|Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed|furmonertinib 80mg/d for 12 weeks and carboplatin AUC5 d1 iv / cisplatin 75mg/m2 d1 iv+ pemetrexed 500mg/m2 d1 iv at 21 day cycles for 4 cycles
223923072|NCT06886789|BEHAVIORAL|Text Messaging|On 3 days/week they receive a text about 1 of the 3 behaviors (weight maintenance or loss, physical activity, and medication adherence) in randomized order with guidance for maintaining or improving these behaviors to reach program-provided goals. The system compares their last week's adherence to the responder criteria. They receive feedback praising adherence and instructions for a theory-driven behavioral strategy (e.g., stimulus control) to increase adherence. Feedback is tailored to the patient's adherence or existence of self-monitoring data.
223923073|NCT06886789|BEHAVIORAL|Fully Automated Online Program|Patients receiving the fully automated online program will select a weight loss or a weight maintenance curriculum based on their goals. Patients will receive 8 weeks of fully automated lessons covering the 3 key behaviors: weight (management or loss), physical activity, and medication adherence. All 3 behaviors are discussed weekly, but the lessons first prioritize PA, then weight management, and then medication adherence to mimic the emphasis in Phase II. Total weekly lesson time is 20-30 minutes. Patients retain access to lessons. They self-monitor calories, weight, moderate-to-vigorous physical activity, and medication adherence. Tracking data are seamlessly integrated into the system. They manually enter their medication adherence data and receive encouraging feedback on each of the behaviors the next week.
223923074|NCT06886789|BEHAVIORAL|Low-Intensity Cardiac Rehabilitation Maintenance Program|Patients are instructed to log in 3 times weekly to view lessons, sync their Fitbit data, and complete a home-based workout video. They track weight, PA, and medication adherence daily. Patients have access to an extensive CR resource library made and curated by the platform provider plus resources on maintaining heart healthy behaviors during Phase III created by the research team. They are reminded to log in if they log in less than twice weekly.
223923075|NCT06886789|BEHAVIORAL|High Intensity Cardiac Rehabilitation Maintenance Program|Patients are instructed to log in 3 times weekly to view lessons, sync their Fitbit data, and complete a home-based workout video. They track weight, PA, and medication adherence daily and attend a once weekly virtual meeting with a CR case manager. Meetings are modeled after Phase II and focus on tailored exercise prescription, addressing cognitive, behavioral, and environmental adherence barriers, and support. Patients have access to an extensive CR resource library made and curated by the platform provider plus resources on maintaining heart healthy behaviors during Phase III created by the research team. They are reminded to log in if they log in less than twice weekly.
223923076|NCT06887673|OTHER|No Interventions|No study treatment other than the standard of care management.
223923077|NCT06887673|DIETARY_SUPPLEMENT|Sports Pro Resolve 4 g|Sports Pro Resolve 4 tabs (2 g) twice daily
223923078|NCT06887673|DIETARY_SUPPLEMENT|Double Wood SPM 4 g|Double Wood SPM 4 tabs (2 g) twice daily
223923079|NCT06887673|DIETARY_SUPPLEMENT|20 California Sweet Almonds|10 California Sweet Almonds twice daily
223923080|NCT06887673|DRUG|Montelukast 10 Mg Oral Tablet|Montelukast 10 Mg Oral Tablet daily
223923081|NCT06887673|COMBINATION_PRODUCT|Montelukast 10 Mg Oral Tablet and SPM 4 g|Montelukast 10 Mg Oral Tablet and SPM 4 g
223923082|NCT06887673|DIETARY_SUPPLEMENT|Cold- Pressed Almond Oil 30 mL|Cold- Pressed Almond Oil 30 mL every morning
224280332|NCT00819767|DRUG|Aliskiren|Aliskiren was supplied in 150 mg tablets.
223531317|NCT00538850|DRUG|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
223923083|NCT06886360|DRUG|norucholic acid|500 mg norucholic acid film-coated tablets; 3 tablets/day
223923084|NCT06889454|DRUG|GLP-1 receptor agonist|30 women will receive lifestyle modification and GLP-1 receptor agonists
223923085|NCT06889454|DRUG|Oral contraceptive|30 women will receive lifestyle modification and oral contraceptive
223531318|NCT00538850|DRUG|Placebo|Matching placebo to fentanyl sublingual spray.
223531319|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
223923086|NCT06889454|DRUG|Metformin|30 women will receive lifestyle modification and metformin
223923087|NCT06889454|OTHER|Lifestyle modification|30 women will receive only lifestyle modification
223923088|NCT06739798|DIAGNOSTIC_TEST|Exp Group|Binocular Spectacle prescription are therapeutic tools used to correct refractive errors in visually impaired patients. They improve Visual acuity as well as other visual functions in Amblyopic and visual impairment patients. They stimulate weaker eye to generate visual impulse and stimulate visual cortex to improve stereopsis and fusion.
224280333|NCT00819767|DRUG|Valsartan|Valsartan was supplied in 160 mg capsules.
224280334|NCT00819767|DRUG|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
224280335|NCT00819767|DRUG|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
224280336|NCT02690935|DRUG|2LALERG|Homeopathic drug
224280337|NCT02690935|DRUG|Placebo|Placebo
224280338|NCT01835535|DEVICE|TIVUS|
224280339|NCT05918341|DRUG|Piracetam|Subtherapeutic dose of piracetam (once-weekly doses of 7.5 mg, 5 mg, 2.5 mg and 1.25 mg)
224280340|NCT02702986|PROCEDURE|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
223923089|NCT06739798|DIAGNOSTIC_TEST|Control Group|Patching therapy is a gold standard tool used world wide to correct visual acuity in amblyopic patients. This tool is used by occluding stronger eye with a patch or bandage or fogging lens and stimulating amblyopic eye to generate visual stimulus to motivate visual cortex.
224280341|NCT02702986|DEVICE|Laser|
224280342|NCT02250924|DIETARY_SUPPLEMENT|Caffeine|caffeinated gum
224280343|NCT02250924|OTHER|Gum|Chewing gum
224280344|NCT02250924|BEHAVIORAL|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
224280345|NCT06422481|OTHER|Fluid administration|Patients will receive fluid administration (500 mL of saline over 30 minutes). The indication of fluid administration will be left to the discretion of the attending physician.
224280346|NCT06422481|OTHER|Norepinephrine administration or increase in norepinephrine dosage|Patients will receive norepinephrine or norepinephrine dosage will be increased if necessary to achieve the appropriate mean arterial pressure level. The indication of norepinephrine administration or increase in norepinephrine dosage will be left to the discretion of the attending physician.
224280347|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added honey|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with honey twice daily for 14 days.
224280348|NCT04187950|DIETARY_SUPPLEMENT|Yogurt with heat-inactivated B. lactis and added cane sugar|The control condition will utilize a commercially available yogurt (Activia) following heat inactivation of the probiotic Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of the heat-inactivated yogurt with added cane sugar twice daily for 14 days.The added cane sugar will be an isocaloric amount to the honey.
224280349|NCT04985838|BEHAVIORAL|HEADS: UP (Helping Ease Anxiety and Depression)|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered online using a video communication platform. An introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course. Course materials include a manual (provided after the introductory session), weekly pre/post-session emails with instructions and information about joining the sessions and engaging in personal practice, including links to audio files to complement class-based sessions.
224280350|NCT03127306|DIAGNOSTIC_TEST|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
224280351|NCT03776578|PROCEDURE|swallow fuction and swallow training|nasogastric tube dependence rate
223531320|NCT04138056|BIOLOGICAL|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
223923090|NCT06737991|OTHER|Range of motion exercises|Range of motion Exercises, soft tissue massage, positioning to prevent pressure sores, stretch pole for 20 minutes
224280352|NCT04944472|BEHAVIORAL|HDKQ questionnaire|Studying the possibilities of perceiving information on the primary prevention of cardiovascular diseases in persons suffering from hypertension through the social network Instagram
224280353|NCT00587431|DRUG|GnRh (Leuprolide)|Leuprolide LUPRON
224280354|NCT00587431|DRUG|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
223531321|NCT04138056|BIOLOGICAL|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
223531322|NCT04138056|BIOLOGICAL|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
223531323|NCT04138056|DRUG|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
223923091|NCT06739018|OTHER|pentacam scheimpflug tomography|"Pentacam tomography is not radiation-based. It uses Scheimpflug imaging, which involves a rotating camera that captures multiple images of the anterior segment of the eye. The system employs light-based technology to measure the front and back surfaces of the cornea, along with the anterior chamber and lens, creating a 3D model of the anterior eye structures.~it uses light instead of ionizing radiation (like X-rays), it is considered safe and non-invasive for routine use in ophthalmology.~* It was used to assess 23 parameters from topographic maps and 15 parameters from Belin-Ambrosio enhanced ectasia (BAD) display maps.~* Parameters included keratometry readings, anterior and posterior sagittal curvature, corneal thickness, anterior chamber volume, and several indices from the BAD display map.~* These parameters were analyzed to discriminate between keratoconus and high myopic astigmatism using Receiver Operating Characteristic (ROC) curves for diagnostic accuracy."
224280355|NCT00587431|DRUG|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
224280356|NCT03890562|OTHER|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
224280357|NCT02124473|OTHER|Homeopathy|
224280358|NCT02124473|OTHER|Placebo|
224280359|NCT02855840|OTHER|completion of the quality of life questionnaire|
224280360|NCT00080431|DRUG|Daclizumab|
224280361|NCT05094596|DRUG|Standart treatment group|Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
224280362|NCT05094596|DRUG|Montelukast sodium 10 mg treatment|Group 2 (n=60) received 10 mg/day oral montelukast in addition to standard treatment
224280363|NCT05094596|DRUG|Montelukast sodium 20 mg treatment|Group 3 (n=60) were given 20 mg/day oral montelukast in addition to standard treatment.
224280364|NCT00032916|DRUG|NS2359|
224280365|NCT04906876|DRUG|Gemcitabine|Gemcitabine as a 90-minute IV infusion
224280366|NCT04906876|DRUG|Docetaxel|Docetaxel as a 60-minute IV infusion
224280367|NCT04906876|DRUG|9-ING-41|9-ING-41 as an IV infusion over 1-4 hours twice weekly
223531324|NCT05229744|DEVICE|sequence MRI 3D FLAIR|"Participation in this research entails the addition of an MRI sequence and an injection of contrast product (Gadovist®):~\- 3D FLAIR MRI sequence dedicated to the exploration of the inner ear, lasting 6min30s, performed 4 hours after the initial injection of contrast product"
223531325|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered during skin closure (end of operation).
223923092|NCT06738706|DEVICE|intermittent hypoxia-hyperoxia treatment|The intermittent hypoxia-hyperoxia training refers to 4 cycles of 10-minute hypoxia inhalation interspersed with 20-minute hyperoxia, which is performed once daily for 14 days within 2 to 3 weeks.
223923093|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (low dose)|Administered intravenously. For phase I: single infusion, 1.0×10\^6 cells/kg. For phase II: 1.0×10\^6 cells /kg once a week for a total of 4 times.
223923094|NCT06740149|DRUG|Solvent of CG-BM1|Administered intravenously, once a week for a total of 4 doses.
223923095|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (medium dose)|Administered intravenously. For phase I: single infusion, 2.0×10\^6 cells /kg. For phase II: 2.0×10\^6 cells /kg once a week for a total of 4 times.
224280368|NCT02762994|DRUG|BCD-085|
224280369|NCT02762994|OTHER|Placebo|
224280370|NCT04231123|PROCEDURE|PENG Block with local anesthetic|After induction of general anesthesia, PENG block with 20 ml of a mixture of 1% Lidocaine with 0,5% Ropivacaine and 1/400.000 Epinephrine will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
224280371|NCT04231123|PROCEDURE|PENG Block with 0,9% saline|After induction of general anesthesia, PENG block with 20 ml of 0,9% saline will be performed as described by Giron-Arongo et al with a high frequency linear probe. A 22G 80 mm needle (SonoPlex, Pajunk ) will be used.
224280372|NCT05021484|DRUG|Felzartamab|Intravenous infusion in regular intervals over 6 months
224280373|NCT05021484|DRUG|Placebo|Intravenous infusion in regular intervals over 6 months
224280374|NCT05860387|DIAGNOSTIC_TEST|Next generation improvement of early invasive aspergillosis|Next generation improvement of early invasive aspergillosis test is intended to determine the suitability of new potential biomarkers of aspergillosis.
224280375|NCT01448148|OTHER|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
224280376|NCT01448148|OTHER|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
224280377|NCT04174573|OTHER|GTO|"1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
224280378|NCT04174573|OTHER|GT-tDCS|"1. Group therapy~   1. Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  2. Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~  3. Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~2. tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
224280379|NCT00134329|PROCEDURE|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
224280380|NCT02636829|OTHER|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
224280381|NCT02636829|OTHER|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL \*.~\* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
224280382|NCT05886257|DRUG|Candonilimab|10mg/kg, iv.drip, every 3 week
224280383|NCT05886257|DRUG|Bevacizumab|15mg/kg, iv.drip, every 3 week
224280384|NCT01334957|DRUG|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
223531326|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered during skin closure (end of operation)
223531327|NCT06479122|DRUG|Acetaminophen|1g acetaminophen is administered 6 hours after the first administration.
223531328|NCT06479122|DRUG|Acetaminophen/Ibuprofen|A mixture of 1g acetaminophen and 300 mg ibuprofen (Maxigesic®IV) is administered 6 hours after the first administration.
223531329|NCT00202579|DRUG|Ivabradine|
224280385|NCT03255044|DRUG|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
224280386|NCT03255044|DRUG|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
224280387|NCT03255044|OTHER|guideline directed therapy|standard heart failure therapy
224280388|NCT06440863|PROCEDURE|Total Knee Arthroplasty|Patients undergoing total knee arthroplasty
224280389|NCT06440863|PROCEDURE|Total Hip arthroplasty|Patients undergoing total hip arthroplasty
223923096|NCT06740149|DRUG|Bone marrow mesenchymal stem cells (high dose)|Administered intravenously. For phase I: single infusion, 4×10\^6 cells /kg.
223923097|NCT06737367|OTHER|CT radiomic analysis|Radiomic features of tumor and peritumor tissue
223923098|NCT06740669|BEHAVIORAL|Virtual reality glasses (VR) application|It will be evaluated at 1 and 6 hours after the Caesarean section and a relaxing video called Relaxation (https://www.youtube.com/watch?v=H1iboKia3AQ, a video containing nature scenes accompanied by nature sounds) will be shown for a maximum of 20 minutes through virtual reality glasses (Toker and Gökduman Keleş, 2024).
223923099|NCT06740669|BEHAVIORAL|Those who are applied expressive touch|Expressive touch does not require any preparation other than warming the hands to the same temperature as the body temperature. During expressive touch practice; the parts of the body that are touched the most are the hands, arms, forehead, hair and shoulders. The hands are massaged during the touch and the arms and shoulders are lightly touched before and after the massage, so that the expressive touch made on the hands is effective (Pinar and Demirel, 2021; Routasalo, 1999) After the evaluation, the researcher will apply expressive touch to one of the mother's hands for an average of 15-20 minutes
223923100|NCT06740669|BEHAVIORAL|Focus|. The researcher mother will be asked to focus on her baby for 10 minutes (Kiliçli Id and Zeyneloglu Id, 2024; Vamour et al., 2019).
223923101|NCT06740851|PROCEDURE|Touch® Trapeziometacarpal Joint Arthroplasty|The intervention involves primary trapeziometacarpal joint (TMJ) arthroplasty using the Touch® prosthesis, a dual-mobility implant designed for the treatment of osteoarthritis in the thumb.
224091728|NCT02704247|DEVICE|CARDIOSPACE System|"* autonomic nervous system test~* tilt test~* ultrasound exploration at rest (heart / vessels)~* laser doppler + iontophoresis test~* sub-maximal exercise test"
223923102|NCT05252312|BEHAVIORAL|Psycho-acoustic tests|"Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry"
223923103|NCT05039411|BIOLOGICAL|PF2020-CELL (UC-MSCs) - Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|All patients will receive a total of 60 million PF2020-CELL (UC-MSCs) cells per treatment visit.
223923104|NCT06713889|BIOLOGICAL|Biocollection|"At each sampling time, 2 dry tubes of 4 ml, 1 EDTA tube of 4 ml, and 1 heparinised tube of 4 ml, i.e. a total of 16 ml per sampling time.~Group A patients will be sampled at inclusion, before, during and after the TAVI procedure, at 1 month follow-up and at 1 year follow-up, for a total of 120 ml. Patients in groups B and C will be sampled at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up, for a total of 80 ml."
223923105|NCT06713889|BEHAVIORAL|Quality of life questionnaires|EQ-5D-5L and HAD questionnaire at inclusion, 1 month follow-up, 1 year follow-up and 2 years follow-up
223923106|NCT05871151|DEVICE|taVNS|Trans-auricular Vagus Nerve Stimulation is a non-invasive method of stimulating the auricular branch of the vagus nerve through the inner ear. Trans-auricular Vagus Nerve Stimulation will be provided using a commercially available device. The investigators will use custom earbuds that will make the experience significantly more comfortable than traditional transauricular Vagus Nerve Stimulation.
224091729|NCT00313924|DRUG|DETRUSITOL|
224091730|NCT01973855|DRUG|Western Medicine|Physical cooling,Hydrocortisone
224091731|NCT01973855|DRUG|TCM and Western Medicine|Third Infectious diseases soup recipe
224091732|NCT02393209|DRUG|Docetaxel|Docetaxel intravenous infusion
223531330|NCT00226005|DRUG|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
223923107|NCT05871151|BEHAVIORAL|Exercise|All participants will be guided through exercises led by a trained exercise specialist, and will include: 1) intensive exercises that focus on increasing the size and amplitude of movements; 2) task-specific practice, which involves practicing functional tasks, such as dressing, bathing, and cooking, in order to transfer the gains made in therapy to real-life situations. The exercise intervention proposed involves the supervision of a licensed PT at all times during the treatment session. Exercise will be provided in a clinical setting, 45 minutes per session, up to 3 sessions/week, for 4-6 weeks total.
223923108|NCT06650995|OTHER|Exercise training|exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
223923109|NCT06734494|DEVICE|Laparoscopic appendectomy Laparoscopic appendectomy with Airseal or with standard insufflation|Airseal is a constant and low-pressure insufflation device. Standard insufflation is a variable pressure insufflation device.
223923110|NCT06734910|BEHAVIORAL|HealthyPregnancy|"A digital care guide comprising of:~1. Information about diet, exercise and mental wellbeing in pregnancy. Presented in text, video and audio material featuring various healthcare professionals.~2. Online exercise. Access to live online structured physical exercise twice a week and to an off line library of exercise videos.~3. Chat function with possibility to chat safely with healthcare professionals.~4. Push-notifications reminding the participants of upcoming antenatal appointments.~In addition an invitation to monthly café sessions focusing on e.g., mental health, parenting skills, breastfeeding and healthy lifestyle."
223923111|NCT04549792|DRUG|Ustekinumab|Each subject will receive ustekinumab at Baseline (Day 0) and Months 1, 3, 5, 7, 9, and 11. During the LTE, subjects will receive injections every 8 weeks for one year: Month 13, Month 15, Month 17, Month 19, Month 21, and Month 23. Subjects will come back in for a follow-up visit at Month 25 for an end of study visit (no drug administration).
223923112|NCT05771467|DIAGNOSTIC_TEST|Comprehensive Ophthalmologic Examination|Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and anterior segment parameters, optical coherence tomography angiography (OCTA)
223923113|NCT06079216|BEHAVIORAL|Volunteer Led Making Connections Thru Music|Volunteer led Group music therapy-based intervention
224091733|NCT02393209|DRUG|TAK-117|TAK-117 Tablets
224280390|NCT00398684|DRUG|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
224280391|NCT00398684|DRUG|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
224280392|NCT00398684|DRUG|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
224280393|NCT01885351|BEHAVIORAL|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
224280394|NCT01885351|BEHAVIORAL|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
223531331|NCT01656161|DRUG|Triptorelin embonate 22.5 mg|
223531332|NCT00002193|DRUG|Amprenavir|
223923114|NCT06079216|BEHAVIORAL|Staff Led Making Connections Thru Music|Staff led Group music therapy-based intervention
224091734|NCT00348166|DRUG|cyclopentolate|
224091735|NCT00755079|DRUG|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
224091736|NCT00755079|DRUG|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
224091737|NCT00630045|DRUG|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
223531333|NCT01215851|DRUG|PA-824|200 mg tablet, once daily for 14 days
223531334|NCT01215851|DRUG|Pyrazinamide|Dosed by Weight
223531335|NCT01215851|DRUG|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
223531336|NCT01215851|DRUG|Rifafour|Rifafour e-275
223531337|NCT01215851|DRUG|Moxifloxacin|moxifloxacin 400 mg
223531338|NCT05672914|BEHAVIORAL|Tablet-based sustained care|A tablet-based motivational-interviewing intervention, tailored specifically to smokers with psychiatric disorders, to motivate the use of evidence-based tobacco treatment and cessation in cigarette smokers upon discharge from an inpatient psychiatric hospitalization. In addition, participants will receive standard hospital tobacco care (see Usual Care Arm).
223531339|NCT05340413|DRUG|Olaparib|300mg twice daily
223923115|NCT06450314|DRUG|Discontinuation of the anti-HER2 maintenance therapy|Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
223923116|NCT06450314|DEVICE|Monitoring with signatera test|"ctDNA test will be performed at 1.5 month after inclusion and every 3 months during 2 years.~Note: For the ctDNA negative patients who become ctDNA positive: ctDNA test will be performed once, 3 months after restarting treatment (+/-1 week)."
223923117|NCT03800017|BIOLOGICAL|Hyperoxia|Participants breathe 60% oxygen during exercise
223923118|NCT06742437|DEVICE|Standard sperm preparation|Sperm samples in the control group will undergo traditional processing
223923119|NCT06742437|DEVICE|HyperSperm|Sperm samples in the experimental group will undergo product-specific processing
223531340|NCT03510273|DEVICE|Liger Medical Thermocoagulator|"Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)"
223531341|NCT00922129|DRUG|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
223531342|NCT00922129|DRUG|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
223923120|NCT06742970|COMBINATION_PRODUCT|Telematic intervention|Telematic intervention will be performed by a specialized company hired by the investigational team. Trained nurses will contact patients assigned to the intervention groups by videocalls at weeks 1,3,5,7,9,11 and 12 after the admission. The specialized nurses will supervise the exercise program sessions (based on an adaptation of he VIVI FRAIL program), correcting potential mistakes and recommending the optimal way for performing the training program. Patients will take a 200 ml dose of hyperproteic, hypercaloric nutrition supplements daily one hour after performing the exercise session. Information about the optimal diet adapted to the clinical profile of patients will be also provided. Additionally, health information about the disease, the importance of adherence to treatments and recommendations and the best measures for controling cardiovascular risk factors, comorbidities and avoiding clinical complications will be also provided
223923121|NCT06741514|DEVICE|Precice IMLL|Parents or legal guardians of children that previously received the Precice IMLL will complete a survey. No additional or new interventions will be administered.
223923122|NCT04629547|DRUG|Suvorexant 20 mg|Suvorexant 20mg will be taken nightly for 24 months.
223923123|NCT04629547|DRUG|Placebo|Placebo will be taken nightly for 24 months.
223923124|NCT06741631|BEHAVIORAL|MyPEEPS Mobile|An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
223923125|NCT06742320|BEHAVIORAL|Asthma education|There are very few studies examining the asthma knowledge level, quality of life and asthma control of children in Turkey.
223923126|NCT06750393|OTHER|Barre exercise along with gym ball exercises|"The Barre exercises will be administer to the participant of Group A for a period of 3 month.~Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. Gym ball exercises program include Knee tucks, leg curls, back extension exercises"
223923127|NCT06750393|OTHER|Barre exercises|"The Barre exercises for a period of 3 month Each exercise will be given for 10 s hold × 12 times/set × 3 sets/day × 3 days/week~× 12. During"
224091738|NCT00630045|PROCEDURE|resection of liver metastasis|surgery with the aim of R0 resection
224091739|NCT04222985|BIOLOGICAL|HSV 2 Formulation 1|Route of administration: Intramuscular
224091740|NCT04222985|BIOLOGICAL|HSV 2 Formulation 2|Route of administration: Intramuscular
223531343|NCT01606150|DRUG|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
223531344|NCT01606150|DRUG|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
223531345|NCT05544318|OTHER|Diatary advices|Advice regarding energy, protein and nutrient intake during cancer treatment
223531346|NCT00196040|DEVICE|PFX Closure System|
223531347|NCT01276106|DRUG|AC-201, 25mg|Capsule, 25mg BID
223531348|NCT01276106|DRUG|AC-201, 50mg|Capsule, 50mg BID
223531349|NCT01276106|DRUG|AC-201, 75mg|Capsule, 75mg BID
223531350|NCT01276106|DRUG|Placebo|Placebo BID
223531351|NCT03078452|DEVICE|Power drill|Undergo bone marrow biopsy using power drill
223531352|NCT03078452|DEVICE|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
223531353|NCT00050804|DRUG|sertraline|
223531354|NCT05799118|GENETIC|GWAS|The study will perform a GWAS experiments for all recruited subjects. The blood sample will be collected during routine clinical visits, only if DNA is not already available in existing biobanks. All individuals will provide consent for participation in the study.
223531355|NCT04502082|BIOLOGICAL|ET140203 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
224091741|NCT04222985|BIOLOGICAL|HSV 2 Formulation 3|Route of administration: Intramuscular
223923128|NCT06892158|OTHER|Massage therapy|Participants in IA will receive a 20-30-minute massage five days per week for 21 days.
223923129|NCT06892158|OTHER|Standard of care|Institutional standard of care treatment
224091742|NCT04222985|BIOLOGICAL|HSV 2 Formulation 4|Route of administration: Intramuscular
224091743|NCT04222985|BIOLOGICAL|HSV 2 Formulation 5|Route of administration: Intramuscular
224091744|NCT04222985|BIOLOGICAL|HSV 2 Formulation 6|Route of administration: Intramuscular
224091745|NCT04222985|BIOLOGICAL|Sodium Chloride 0.9%|Route of administration: Intramuscular
224091746|NCT03366714|DEVICE|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
224091747|NCT03366714|DEVICE|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
224091748|NCT02792140|DRUG|Naltrexone|one week
224091749|NCT02792140|OTHER|Placebo|one week
224091750|NCT00885079|DRUG|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
224091751|NCT00885079|DRUG|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
223940823|NCT06624930|OTHER|Behavioural Counselling|"The PA+BC group will receive a behavioural counselling support session with a QEP every two weeks during the intervention period (12 total). Of the 12 video-conferencing calls, one session will target reflective processes (instrumental/affective attitudes), five sessions will target behavioural regulation (action planning, coping planning, social support, goal setting), and four sessions will target reflexive processing (self-regulation, habit). The remaining two sessions are booster sessions to revisit topics discussed. The importance of sustaining PA for clinical outcomes (e.g., fatigue) and PA logs will be stressed. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up."
224280395|NCT05638607|BEHAVIORAL|Intensified occupational therapy|The intervention is an intensified occupational therapy effort, which does not take time away from other occupational therapy efforts.
224280396|NCT03700827|OTHER|Resistance Training|High-intensity Resistance Training Group
224280397|NCT03700827|OTHER|Aerobic Training|Aerobic Interval Training Group
224280398|NCT03721627|DRUG|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
224280399|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, low dose|infusion
224280400|NCT05445076|BIOLOGICAL|anti-TRBV9 monoclonal antibody, high dose|infusion
224280401|NCT05445076|OTHER|placebo|infusion
224280402|NCT01429831|DRUG|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
224280403|NCT01701973|DRUG|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
224280404|NCT01701973|DRUG|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
224280405|NCT01701973|DRUG|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
224280406|NCT01701973|DRUG|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
224280407|NCT01701973|DRUG|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
224280408|NCT04329715|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
224280409|NCT04329715|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
224280410|NCT04554147|BEHAVIORAL|FAITH! App-enhanced Hypertension Intervention|"FAITH! HTN App: The program promotes HTN self-management through a 10-week education module series on HTN. Participants will follow each module weekly and use a wireless home BP monitor for self-tracking which syncs to the app. The app includes module quizzes, a BP tracking dashboard and a moderated sharing board to foster discussion on HTN management.~Patient-Provider-CHW ICM. The patient-provider-CHW triad works together for personalized, collaborative goal setting. The patient will complete app modules, self-monitor BP, and engage with a sharing board integrating HTN topics. At weekly virtual visits (telephone or video), the CHW will record patient BPs, assist with addressing social determinants of health (SDOH) identified by the patient (eg, local community resources), and review HTN modules. The CHW will upload clinical/SDOH data to the patient electronic medical record (EMR) for FQHC care providers to review. This cycle will be completed weekly over the 10-week intervention."
224280411|NCT01104090|DEVICE|C-MAC direct laryngoscopy|Patients will be intubated using C-MAC with direct laryngoscopy.
224280412|NCT01104090|DEVICE|C-MAC Indirect laryngoscopy|Patients will be intubated using C-MAC with indirect laryngoscopy.
224280413|NCT02084927|BIOLOGICAL|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
224280414|NCT05193773|OTHER|multifactorial interventions|The experimental group underwent multifactorial interventions to reduce physical restraint, including developing routines for physical restraint, promoting institutional policies to reduce the use of physical restraint, developing alternative methods, education, and consultations.
224280415|NCT04305730|BEHAVIORAL|Use of a pedometer following surgery|Subjects in the study group will receive a pedometer with graduated step count goals as discussed in arm description.
224280416|NCT04305730|BEHAVIORAL|Standard of care|Subjects in the control group will be counseled on the importance of ambulation during their pre-operative visit.
224280417|NCT02773433|OTHER|Proportional Assist Ventilation|
224280418|NCT03481517|DRUG|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
224280419|NCT02968719|DRUG|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
224280420|NCT02968719|DRUG|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
224280421|NCT02968719|DRUG|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
224280422|NCT02968719|DRUG|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
223531356|NCT02321501|DRUG|Ceritinib|Given PO
224280423|NCT02968719|DRUG|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
223923130|NCT06891521|PROCEDURE|Electroacupuncture|"Patients received electroacupuncture on the day before and the first day of each ICIs treatment cycle. The electroacupuncture points selected Zusanli (ST36), Quchi (LI11), and Hegu (LI4). Patients will be positioned supine, and the acupuncturist will disinfect the local skin at the acupuncture points using 75% ethanol on cotton balls. A disposable acupuncture needle (0.3mm × 40mm) will be inserted using either a single-hand or double-hand needling technique, with rapid, direct insertion. Once the needle reaches a depth of approximately 0.5 cun, the technique of lifting, thrusting, twirling, and rotating will be applied. After obtaining de qi, the needles will be retained for 30 minutes. Needling will be performed once every 10 minutes, and the needling technique used will be a balanced reinforcing and reducing method. Electroacupuncture will be applied using a dense-wave form, with a frequency of 2 Hz and an intensity not exceeding 10 mA."
223940824|NCT06624930|OTHER|Exercise Counselling|The PA+EC group will receive the same frequency of group-based and 1:1 counseling support sessions via Zoom as PA+BC participants. However, the focus will be on exercise training principles for proper PA technique, how to monitor intensity, and progress PA safely to achieve the PA guidelines.
223940825|NCT06904274|COMBINATION_PRODUCT|BAY865028|Intrauterine delivery system
223531357|NCT02321501|DRUG|Everolimus|Given PO
223531358|NCT02321501|OTHER|Laboratory Biomarker Analysis|Correlative studies
223531359|NCT02321501|OTHER|Pharmacological Study|Correlative studies
223531360|NCT00922857|PROCEDURE|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
223531361|NCT05438147|OTHER|CT-100 DiNaMo|Active Treatment (Study App)
223940826|NCT06904274|DRUG|Medroxyprogesterone acetate|Oral tablet
223940827|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 1|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1
224091752|NCT02953041|DRUG|Glycopyrronium|long-acting muscarinic antagonist
224091753|NCT02953041|DRUG|Indacaterol|ultra long-acting beta agonist
224091754|NCT01709331|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
224091755|NCT01709331|DRUG|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
224091756|NCT03553394|DRUG|Ringer's Acetate|Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
224091757|NCT05791279|OTHER|Heart age|information about their ECG-based Heart-Age and the Heart Age gap, i.e. the difference between chronological and ECG-based Heart Age.
224091758|NCT02630953|BEHAVIORAL|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
224091759|NCT02630953|BEHAVIORAL|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
224091760|NCT03896295|DRUG|M281|M281 injection administered as intravenous infusion
223717461|NCT04593225|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
223531362|NCT05438147|OTHER|Care-as-Usual|Care-As-Usual control
224091761|NCT06375304|DRUG|B/F/TAF|"The intervention consists of prescribing B/F/TAF to eligible ART-experienced migrant patients, free of charge, in four care settings, for 12 months (48 weeks).~B/F/TAF is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements."
223923131|NCT06890949|OTHER|(Group A: Preformed Bioflx Crown)|"Crown Selection \& Tooth Preparation~Measure the mesiodistal width using calipers to select an appropriately sized crown.~If a mesial or distal wall is missing, use the contralateral tooth for size selection.~Choose the crown that closely matches the measured mesiodistal width. Select the smallest crown that preserves proximal contacts using a trial-and-error approach.~if crimping is necessary use Howe's pliers.~Tooth Preparation Perform 1-1.5 mm occlusal reduction using a tapered diamond bur. Reduce proximal areas by approximately 0.5 mm to clear the contact area.~Crown Placement \& Cementation Ensure a snug fit of the selected crown. Apply a thin layer of glass ionomer cement inside the crown. Seat the crown firmly using finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup Remove excess cement with floss or an explorer. Verify the crown's fit, occlusion, and stability."
223940828|NCT06610201|OTHER|Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3|Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2A, Type 2M, Type 2N and Type 3.
223531363|NCT02258490|BIOLOGICAL|G-CSF mobilized CD34+ selected cells for transplantation|After screening and enrollment, donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using standard National Marrow Donor Program guidelines. CD34+ cell selection will be performed according to procedures given in CliniMACS Operating Manual and institutional Standard Operating Procedures. If storage after CD34+ selection is necessary, product will be kept in a monitored refrigerator. During storage, leukocyte concentration should not exceed 2 x 108 cells/ml using platelet poor plasma to adjust cell concentration. If donor's plasma is not available, CliniMACS buffer will be used. Cell processing will be performed by personnel trained by Miltenyi on CliniMACS system prior to initiation of clinical product selection. After tests are performed and product passes release criteria, patient will receive final product. No conditioning regimen will be administered prior to cell infusion.
223531364|NCT02065284|OTHER|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
223531365|NCT05230277|OTHER|the active osteopathic treatment (AOT)|The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. \[8\] which consists in mobilizing the sacrum between the iliac bones.
223531366|NCT05230277|OTHER|the sham osteopathic treatment|For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. \[13\] and proposed by others to perform simulated bone manipulations \[14\], will be applied to the sacrum
223940829|NCT06810466|DIETARY_SUPPLEMENT|Test Product A|Innovative formulation of a dietary supplement for mild hypercholesterolemia. Test Product A will be admistered daily for 8 weeks. After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks.
224091762|NCT05020561|BEHAVIORAL|Group life-coaching|"Group coaching sessions will be focusing on providing material and tools that guide the participants in the transition from cancer treatment to survivorship. All activities of the group session will be following the After Cancer Passport document."
223940830|NCT06810466|DIETARY_SUPPLEMENT|Test Product B|Classic formulation of a dietary supplement for mild hypercholesterolemia. After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks.
223923132|NCT06890949|OTHER|(Group B: Preformed Zirconia crown)|"Crown Selection~Measure the mesiodistal width using calipers to select the appropriate crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection.~Choose the crown that closely matches the measured width. Select the smallest crown that preserves proximal contacts.~Tooth Preparation~Reduce the occlusal surface by 1.5-2 mm using a tapered diamond bur. Reduce interproximal areas by 1-1.5 mm, ensuring a feather-edge finish. Perform a 1-2 mm subgingival preparation using a tapered fissure bur.~Crown Placement \& Passive Fit Check~Place the selected crown and check for passive fit.~Cementation of the Crown~Apply a thin layer of glass ionomer cement inside the crown. Seat the crown with passive finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup~Remove excess cement using floss or an explorer. Verify fit, occlusion, and stability"
223923133|NCT06892249|DIETARY_SUPPLEMENT|Renalive® LP, flavour Vanilla|flavour Vanilla
223531367|NCT03199079|OTHER|Measurement|Measurement of cervix elasticity and length measurements is not an intervention
223531368|NCT03588702|DEVICE|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
223531369|NCT02023437|DEVICE|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
223531370|NCT02023437|DEVICE|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
223923134|NCT06892249|DIETARY_SUPPLEMENT|Renalive® LP, flavour Cappuccino|flavour Cappuccino
224280424|NCT04417751|BEHAVIORAL|Cognitive Stimulation|The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
224280425|NCT03033524|DRUG|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
224280426|NCT01263561|PROCEDURE|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
224280427|NCT01263561|PROCEDURE|trabeculectomy|trabeculectomy filtering surgery
224280428|NCT03256864|DRUG|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
224280429|NCT04552028|OTHER|Non invasive oxygenation|To determine if the SpO2 / FIO2 ratio has a correlation with PaO2 / FIO2 ratio to identify respiratory compromise in acute pancreatitis.
224280430|NCT06615947|DEVICE|Robotic gait training|"RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern."
223531371|NCT06104644|DRUG|Deucravacitinib|Non-interventional observational study of patients receiving treatment with commercially available deucravacitinib 6 mg once daily according to the Summary of Product Characteristics
223531372|NCT03489694|PROCEDURE|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
223531373|NCT01466088|DRUG|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
223531374|NCT01466088|DRUG|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
223923135|NCT05047952|DRUG|Vortioxetine|"Participants aged 18-64 years receiving vortioxetine will be provided 10 mg/day on days 1-14 of the treatment period, and will be titrated to 20 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 20 mg/day, unless adjudicated otherwise by a study clinician.~Per product monograph, participants aged 65+ years receiving vortioxetine will be provided 5 mg/day on days 1-14 of the treatment period, and will be titrated to 10 mg/day at the start of week 3 (day 15) based on study clinician judgment. For the remaining 6 weeks, the dose of vortioxetine will be 10 mg/day, unless adjudicated otherwise by a study clinician."
223923136|NCT05047952|DRUG|Placebo|A placebo pill will be taken once daily.
223923137|NCT06745492|DRUG|Neostigmine + Glycopyrrolate|a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.
223531375|NCT00224549|DRUG|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
223531376|NCT05226494|DRUG|fb-PMT|Daily dosing based on patient weight
223923138|NCT06744764|DEVICE|PEMF (1mT)|1mT of field strength will be given to patients/healthy volunteers for 10 minutes, twice per week for 4 consecutive weeks.
223923139|NCT06744764|DEVICE|PEMF (0mT)|Healthy volunteers will place their legs in the PEMF device, twice per week for 4 consecutive weeks. However, no magnetic stimulation will be given.
223923140|NCT06736327|DRUG|SKB500|The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.
223923141|NCT06743971|BEHAVIORAL|ocean sound concert|intervention group listened to the ocean sound, the control group continued their daily care routines
223923142|NCT06744907|BIOLOGICAL|10% Povidone-Iodine Arm|A second application of surgical antisepsis with a topical povidone-iodine in the subdermal layer after making an incision.
223923143|NCT06744907|PROCEDURE|Saline Arm|An application of saline in the subdermal layer after making an incision.
224091763|NCT05020561|BEHAVIORAL|Individual life-coaching|In the individual coaching sessions, the life-coach will provide guidances that help the participants to put tools into actions. All activities are outlined in the After Cancer Passport. Participants will use their Passport for each individual coaching session to outline their objectives and indicators of success. The life coach will also assign activities, such as self-reflection, for the participants to complete between each session.
224091764|NCT02956811|DRUG|Dapagliflozin|SGLT2 inhibitor
224091765|NCT02956811|DRUG|Placebo|Matching Placebo
224091766|NCT00947648|OTHER|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
223531377|NCT06352346|BEHAVIORAL|Compensatory brain game supporting Goal Management Training intervention|o The investigational treatment is only given during the intervention phase (phase B), and consists of six treatment sessions. In the treatment sessions, patients learn and apply the GMT algorithm. This means that the multiple steps of the GMT as well as the actual performance of the IADL-task goals will be learned under guidance of a therapist. In order to facilitate generalization, patients will learn to use the algorithm during the performance of untrained tasks by playing the treatment supporting Plan Game. Because of this, patients are able to practice the application of the GMT algorithm independently outside the therapy session. Besides, the intervention also includes a Plan Tool. This is a mobile application that can be used as an aid during the performance of (instrumental) activities of daily living (IADL) tasks in order to perform activities more independently. The GMT treatment sessions are given twice a week (max. 60 minutes for each attendance).
223531378|NCT04546789|DRUG|M2951 (BTK inhibitor)|Participants will receive a single oral dose of M2951 (BTK inhibitor).
223717462|NCT02524795|DIETARY_SUPPLEMENT|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
223923144|NCT06743802|DRUG|Coenzyme Q10|Coenzyme Q10 was administered from admission to one month after discharge at a dose of 200 mg per day (200 mg/qd).
224091767|NCT00947648|OTHER|Cooked Foods|Diet containing only cooked foods.
223923145|NCT06743802|OTHER|Placebo|The placebo was administered from hospital admission until one month after discharge.
223923146|NCT06745141|PROCEDURE|Periodontal surgery|"In the intervention group, patients underwent a comprehensive periodontal evaluation conducted by periodontists at a dental clinic. All permanent teeth, except for third molars, were assessed using dental mirrors and periodontal probes. Each tooth was examined at four sites (vestibular, distal, lingual, and mesial) to evaluate visible plaque, probing depth, probing bleeding, and attachment loss.~During the first treatment session, patients were provided with information about periodontal disease, emphasizing the importance of controlling supragingival bacterial biofilms for successful treatment. Plaque-retentive factors (calculus) were removed. Temporary materials were used to restore carious lesions, root remnants were extracted, and maladaptive restorations were adjusted. Supragingival calculus was removed using periodontal scalers, followed by cleaning with a rubber cup, prophylaxis paste, dental floss, and/or interdental brushes. No prophylactic antibiotics were used prior to the"
223923147|NCT06745219|DRUG|herombopag|receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy
223923148|NCT06891430|PROCEDURE|Procedure: Anatomical Single-Bundle ACL Reconstruction|Patients undergo anatomical single-bundle ACL reconstruction with femoral and tibial tunnel drilling.
223923149|NCT06891430|PROCEDURE|Procedure: Central Axial Single-Bundle ACL Reconstruction|Patients undergo central axial single-bundle ACL reconstruction with optimized tunnel positioning.
223923150|NCT06891430|PROCEDURE|Procedure: Double-Bundle ACL Reconstruction|Patients undergo double-bundle ACL reconstruction targeting AMB and PLB footprints.
223923151|NCT06888492|BIOLOGICAL|EXG202|EXG202 is a gene therapy product for the treatment of wet (neovascular) age-related macular degeneration（wAMD） with a single intravitreal injection and administration.
223923152|NCT06890442|DEVICE|CT|"Thickened Medial Pterygoid Plates In bony atresia, excessive thickening of the medial pterygoid plates is common. Narrowing or Fusion of the Posterior Choanae Complete bony or membranous obstruction at the choanal opening. Abnormal Sphenoid Bone Development Hypoplasia or deformity in the sphenoid sinus, affecting adjacent structures. Vomer Deviation or Hypertrophy The vomer bone is often displaced or abnormally thickened, contributing to obstruction.~Abnormal Development of the Hard Palate"
223923153|NCT06732479|BEHAVIORAL|Behavioural Skill Training Programme|"BST was administered in 3 sessions in a week on alternate days, each session lasting for an hour. Training was given in small groups consisting of 4-6 members. Parents were involved as co-therapists, and observed the training given by the researcher and practiced it at home with their children.~The training was carried out through the following steps:~1. Instruction- Involved teaching the location of private parts, difference between appropriate and inappropriate touch, safe and unsafe secrets, sexuality, self-protection skills (saying NO, move from situation, tell trusted person, report the person and situation.~2. Modelling- researcher, modelled, correct responses, and instructed to act in the unsafe situation using role play. Situations were presented using video.~3. Rehearsal-researcher presented situations using video and instructed to rehearse the skills until able to demonstrate the skill independently"
223923154|NCT06738576|DRUG|allogeneic mesenchymal stem cells|"Cell implantation is carried out in the following steps:~1. \- Patient anesthesia~2. \- Identification of the external urinary sphincter and the incompetent area responsible for incontinence through intraurethral cystoscopy.~3. \- Resuspension of the cells by gentle manual shaking of the vials. Once the cells are resuspended, they will be used immediately.~4. \- Injection of the cell suspension with a long, fine needle (those usually used in endoscopic puncture, \<22G) at 2 points of the sphincter that will coincide with the 3 o'clock and 9 o'clock position of the hands of a clock). The injection will be superficial, trying not to go deeper than 2 mm to create a wheal in each injection visible endoscopically.~5. \- Cellular remains, if any, and the vials used will be eliminated following the usual procedures used for the management of hospital surgical waste."
223923155|NCT06738576|DRUG|Placebo|Placebo implantation is carried out in the same way as the drug implantation
223923156|NCT06741800|DRUG|ACARIZAX®️|ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.
223923157|NCT06742138|DRUG|QL2109|QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
223923158|NCT06742138|DRUG|Pomalidomide|Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle
223923159|NCT06742138|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
223923160|NCT06742138|DRUG|DARZALEX FASPRO®|DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
223923161|NCT04403438|OTHER|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.|ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF.
223940831|NCT06810466|DIETARY_SUPPLEMENT|Placebo|"Placebo does not contain functional components and is indistinguishable from Product Test B.~After the fist 8 weeks, this arm will continue with the intake of the Product Test A for other 8 weeks."
223940832|NCT05571553|OTHER|Recommendations and reorientation towards healthcare resources|"Phase 1~* After completing the CARE© questionnaire, participants will be given recommendations.~* After the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments made.~Phase 2~* After completing the CARE© questionnaire, participants will be given recommendations.~* If their health status is judged fragile by the CARE© score, and after the ESOGER© assessment, the participants will be contacted by the Red Cross who will set up the necessary interventions. They will be informed of the results of the assessments.~For both phases, after 3 (6) months, the participants of the Control group will benefit from the recommendations following the CARE© assessment done at M3 (M6), and if necessary from the ESOGER© assessment and the Red Cross intervention. Throughout the study, they will continue to receive their conventional care."
223940833|NCT06766864|DRUG|DR-01|DR-01 is a monoclonal antibody
223940834|NCT06766864|OTHER|Placebo|Placebo
223940835|NCT06742047|BEHAVIORAL|Professional development programme|The professional development programme include dialogue groups facilitated by registered nurses (RN) who are expert and experienced supervisors that received a three day training before conducting the groups. Then including education days with joint lectures and simulations with experts in the field with experience. The programme provides NGNs with regular opportunities for reflection for learning from experiences of care to enhance personal and professional growth.
223717463|NCT01473836|DRUG|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
223940836|NCT07093398|DRUG|D3S-001|"The investigational product dose: 600 mg D3S-001 capsules.~A 600-mg oral dose of D3S-001 will be given to potential participants on Day 1 and Day 4."
223923162|NCT05862636|BEHAVIORAL|Mindfulness Training|"All participants will follow a mindfulness course consisting of group sessions of 2-3h duration that are organized (nearly) weekly and are spread over a period of eight weeks. The specific timeline and organisation of the course may differ between the participating sites but all courses will involve a comparable amount of contact hours with the mindfulness trainer. Each session consists of guided experiential mindfulness exercises (e.g., body scan, breathing space, breath focus, walk meditation), sharing of experiences of these exercises, reflections in small groups, psychoeducation, and review of home practices.~The mindfulness courses are based on one of the two most well-known MBIs, Mindfulness-Based Cognitive Therapy (Segal et al., 2002) and Mindfulness-Based Stress Reduction (Kabat-Zinn, 1990), or a combination thereof. Courses follow a standardised protocol with group sessions and daily homework tasks taught by experienced and certified mindfulness trainers."
223923163|NCT06892873|DEVICE|Comfort-In|Application of Comfort-in Jet Injection Method Comfort-in jet injection method was used for palatal anesthesia of the primary molars. The device was placed 5 mm below the palatal gingival margin, close to the free gingiva, and with a steep angle. 0.2 ml of anesthetic solution was administered by pressing the jet injection system button. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine was used as a local anesthetic agent in the injections. 38 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
223923164|NCT06892873|OTHER|Traditional dental injection|Application of Traditional Dental Injection Method Palatal injection; It was applied 5-10 mm below the palatal gingival margin\*, on the attached gum, and with a 45-degree needle angle. After needle entry, 0.2 mL of anesthetic solution was stored when bone contact was removed. 1 mL Articaine Hydrochloride (Ultracaine D-S forte, Hoechst, Canada) containing 1/100,000 epinephrine and a 27 G dental needle were used as local anesthetic agents for injections. 38 patients were included in this group and the procedure was performed. After waiting for 2 minutes, the anesthetized area was probed with the help of a probe (probing gingiva) to check whether the anesthesia had taken effect. Afterwards, buccal infiltration anesthesia was performed with the help of a traditional dental injector and tooth extraction was performed.
223923165|NCT06736392|PROCEDURE|Ultrasound guided Pericapsular Nerve Group Block|"With the patient in the supine position and the leg slightly abducted, a curvilinear transducer (2.5-7.5 MHz) is prepared with sterile conduction gel and covered with a sterile probe cover. The transducer is placed transversely over the anterior superior iliac spine (ASIS), then aligned with the pubic ramus and rotated approximately 45° parallel to the inguinal crease. The probe is slid medially to identify key landmarks: the anterior inferior iliac spine (AIIS), iliopubic eminence (IPE), iliopsoas tendon, femoral artery, and femoral nerve. Sliding the probe distally or tilting caudally exposes the femoral head.~A 20-22 gauge echogenic needle (100 mm) is inserted in-plane from lateral to medial, targeting the plane between the psoas tendon and the pubic ramus. the anesthetic agent is deposited to lift the psoas tendon while avoiding tendon puncture."
223923166|NCT06736392|DRUG|Isobaric Bupivacaine 0. 25%|group c will receive PENG block with only 20ml isobaric bupivacaine 0.25%
223923167|NCT06736392|DRUG|20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine|group D will receive PENG block with 20 ml isobaric bupivacaine 0.25% and 1.5μg/kg dexmedetomidine
223923168|NCT06736392|DEVICE|the ultrasound machine with curvilinear transducer (high -frequency probe, 2.5Mhz to 7.5Mhz)|the two groups will receive the PENG block under ultrasound guidance
223923169|NCT06736392|DEVICE|a standard echogenic 20-22 gauge 100mm needle|the two groups will receive the PENG block using a standard echogenic 20-22 gauge 100mm needle
223923170|NCT06894004|BEHAVIORAL|Ketogenic Diet|Participants will consume an isocaloric ketogenic diet for 4 weeks with all food provided as packed-out meals.
223923171|NCT06894004|BEHAVIORAL|Control Diet|Participants will consume an isocaloric control diet for 4 weeks with all food provided as packed-out meals.
223923172|NCT06737887|OTHER|Stoma simulation|Patients who will undergo stoma surgery will have an intervention one day before the surgery. The adapter will be cut to an estimated stoma size, heated by rubbing with hands and adapted to the skin by applying stoma paste. The patient will be asked to place their hand on the adapter and apply pressure. Then, the stoma bag filled with tissues and water and the adapter will be combined. The patient will be informed that they should not hesitate to do any activity that they will spend 24 hours with the stoma bag. The patient will be provided with the opportunity to go to the toilet, eat, sleep and experience all their daily activities with the stoma. It allows patients to experience the stoma bag by putting it on 24 hours before the surgery. In this way, patients know that they will not encounter any surprises after the surgery.
223923173|NCT06893991|DIETARY_SUPPLEMENT|SYMBIONIC|"Provision of 100 ml symbiotic beverages daygurt per day for 6 weeks, plus standard dietary advice for dyslipidemia"
223923174|NCT06893991|BEHAVIORAL|Dietary advice|Participants get standard dietary advice for dyslipidemia
223940837|NCT04601428|BIOLOGICAL|IA therapy of HCC with CSR02-Fab-TF|Intra-Arterial Infusion of CSR02-Fab-TF
223940838|NCT07098663|DRUG|MKP10241|Oral liquid suspension of unit dose strength 6.6 mg/mL
223940839|NCT07098663|DRUG|Placebo|Oral liquid suspension matched in appearance to MKP10241 at dosage strengths
223940840|NCT07099482|DEVICE|Sham ultrasound (placebo)|Participants will receive conventional wound care including debridement, cleaning, and dressing. A sham ultrasound device that emits no therapeutic waves will be applied to simulate the intervention procedure.
224091768|NCT02567448|OTHER|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
223717464|NCT01473836|DRUG|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
223717465|NCT01675414|OTHER|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
223531379|NCT06497478|DIAGNOSTIC_TEST|Ultrasonographic examination|"Ultrasonographic examination will be performed using a high-resolution (Epiq Elite Philips Medical Systems, Monza, Italia) and a linear 12-9 MHz transducer.~The patients will be placed in a supine position. Starting with the probe at the base of the neck, the common carotid artery will be explored on the transverse plane and then on the sagittal one, continuing in a cranial sense up to the carotid bifurcation. The medium-intimal thickness will be measured, defined as distance from the first hyperechoic line to the second hyperechoic line.~The femoropopliteal and run-off segments will be continuously scanned from the subinguinal region to the paramalleolar region with axial and sagittal scans. All segments will be examined for the presence of vessel wall calcifications and/or atherosclerotic plaques. In addition, flow velocity measurements will be obtained using spectral Doppler imaging and color Doppler imaging."
223531380|NCT05846776|DEVICE|DigiPrehab system|Using an Artificial Intelligence-Machine Learning (AI-ML) DSS platform, which analyzes a large collection of data (screening and local data) from different sources, the DigiPrehab system will allow to predict the risk of falling in the elderly subjects. Once the screening will be completed, to carry out the prevention of falls, the system will assign to the participants a personalised exercise program that the patient will carry out at home for 12 weeks. The exercises will be chosen from the following: squat at door, squat on chair, squat with knee-lift, squat with heel-raise, stand-no support, toe-raise with support, toe-raise, one leg balance, weight-shift with support, weight-shift without support, lunge with support, lunge, step on book, step over book, step onto box or stair, step forward-sideways, step forward-sideways-backwards, knee to elbow, timed up and go.
223531381|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
223531382|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
223531383|NCT04583618|BIOLOGICAL|Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
223531384|NCT04583618|BIOLOGICAL|Pneumococcal 13 - valent conjugate vaccine-Prevnar 13|Pharmaceutical form:Suspension for injection Route of administration: intramuscular
223531385|NCT04583618|BIOLOGICAL|Pneumococcal Vaccine Polyvalent-Pneumovax 23|Pharmaceutical form:Solution for injection Route of administration: intramuscular
223531386|NCT05968989|BIOLOGICAL|VRC-FLUMOS0116-00-VP( FLUMos-v2)|"The vaccine, FLUMos-v2, is composed of engineered pentamer yeast C. albican lumazine synthase assembled with 20 HA ectodomain trimers from the following 6 influenza strains:~Influenza A:~H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020~Influenza B:~B/Victoria lineage: B/Colorado/06/2017; B/Yamagata lineage: B/Phuket/3073/2013"
223923175|NCT06894966|DEVICE|low intensity transcranial focused ultrasound stimulation (TUS)|Low-intensity transcranial focused ultrasound (TUS) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. TUS is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Low intensities of focused ultrasound (TUS) are used so that tissue damage does not occur, but neural activity can be modulated by mechanical effects.
224091769|NCT00700804|BEHAVIORAL|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
224091770|NCT00700804|BEHAVIORAL|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
224280431|NCT06615947|OTHER|tRHB|"Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions."
223531387|NCT02711202|DRUG|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
223717466|NCT00878774|BIOLOGICAL|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
224091771|NCT02945592|BEHAVIORAL|Cueing|
224280432|NCT02913820|OTHER|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
224091772|NCT00433238|BEHAVIORAL|Participants will be screened for depression and cognitive impairment, then receive screening results.|
224280433|NCT02587806|BIOLOGICAL|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
224280434|NCT02587806|OTHER|Liberation therapy|
224280435|NCT00170703|DEVICE|Cortical Electrical Stimulation|
224280436|NCT00200655|DRUG|Pravastatin|
224280437|NCT00200655|DRUG|Placebo|
224280438|NCT01396421|DRUG|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
224280439|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
223717467|NCT00878774|BIOLOGICAL|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
224091773|NCT02500537|DEVICE|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
224280440|NCT01396421|DRUG|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
224280441|NCT01396421|DRUG|Placebo|Placebo, once daily, for six weeks
224280442|NCT06656598|DRUG|Carboplatin|Neoadjuvant treatment with Carboplatin AUC 5 D1 (3 cycles of 4 weeks).
224280443|NCT06656598|DRUG|Paclitaxel|Neoadjuvant treatment with Paclitaxel 80mg/m² D1 (3 cycles of 4 weeks).
224280444|NCT06656598|DRUG|Cemiplimab|Neoadjuvant treatment with Cemiplimab (Libtayo®) 350 mg D1-D21 (3 cycles of 4 weeks).
223531388|NCT02711202|DRUG|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
223531389|NCT02711202|DRUG|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
223531390|NCT02711202|DRUG|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
223923176|NCT06893276|BEHAVIORAL|ePSMI|Participants will complete an hour of cognitive behavioral stress management program in person or remote each week for ten weeks. The cognitive behavioral therapy (CBT) skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour. After module completion, participants will have access to modules covered during session.
223531391|NCT05844527|DRUG|MRG-001|MRG-001 is a novel fixed-dose drug combination administered subcutaneously to mobilize stem cells and immunomodulatory cells to the wound to accelerate healing.
223531392|NCT05844527|DRUG|Saline|Sterile saline will serve as placebo treatment.
223531393|NCT04331249|PROCEDURE|surgery or catheter based cardiac procedure (catheter ablation)|patients with implanted CIED (pacemaker, ICD or CRT) that undergo any surgery or any catheter based cardiac procedure (e.g. radiofrequency ablation)
223531394|NCT04436731|OTHER|Hypoxia Exposure|Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
223531395|NCT04436731|DRUG|Phenylephrine|Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
223923177|NCT06736119|BEHAVIORAL|Task Oriented Intervention|Intervention group will recieve task oriented interventions.Throwing and catching balls of different sizes and weights will be done. For writing, a task-oriented approach has 4 phases that will involve writing,correcting and fun writing 30-minute per session. Interventions provided 3 days per week for 3 months.
223923178|NCT06892860|DRUG|Avelumab|Avelumab treatment will be given up to a maximum of 2 years from the end of chemotherapy
223923179|NCT06744881|PROCEDURE|CAPA-IVM|On days 2-4 of the menstrual cycle, after patients have consented to CAPA-IVM, they will undergo oocyte aspiration anytime thereafter but no later than day 6 of the cycle. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 or day 5 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transfer
223923180|NCT06744855|DEVICE|Non-invasive circulation gloves|Non-invasive class I medical device, circulation gloves with semiconductors embedded in the fabric.
223923181|NCT06744855|DEVICE|Fabric gloves|These gloves will look and feel identical to the active circulation gloves, but will not have semiconductors embedded in the fabric.
223923182|NCT06736925|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids (EPA plus DHA)|DHA+EPA capsules contain purified deep-sea fish oil, made from 100% wild-caught sardines and anchovies with a 3-year shelf life. The capsule shell is made from bovine limed bone with a size of 20 oblongs. Each soft gel capsule contains 480 mg of DHA, 205 mg of EPA, 145 mg of other omega-3 FA, and 10 mg of vitamin E. Participants in the DHA+EPA group will ingest 5 capsules daily \[a total of 3.4 g/d: DHA (2.4 g), EPA (1.0 g)\].
223940841|NCT07099482|DRUG|Propolis gel (10%)|Participants will receive topical application of 10% propolis gel on the diabetic foot ulcer followed by therapeutic ultrasound (phonophoresis) using 1 MHz frequency, 0.5-1.5 W/cm² intensity, pulsed mode (20%), for 5 minutes per session, 3 sessions/week for 4 weeks.
224280445|NCT06656598|RADIATION|Curative hypofractionated radiotherapy|Curative hypofractionated radiotherapy (55 Gy/20fr) after the end of neoadjuvant treatment.
224280446|NCT06656598|DRUG|Cemiplimab (maintenance)|Maintenance immunotherapy with Cemiplimab 350 mg every 3 weeks after the end of radiotherapy (12 months).
224280447|NCT04006873|DRUG|Tezacaftor/Ivacaftor + Ivacaftor|As per description in arms.
224280448|NCT04006873|DRUG|Placebo oral tablet|As per description in arms
224280449|NCT04881513|DIAGNOSTIC_TEST|Narrow Band Imaging|Testing the taste buds structure (blood vessels morphology- classified to 5 types) and the number of taste buds per 20mm2, by Narrow Band Imaging technique before and after the operation (one and six months)
224280450|NCT04881513|DIAGNOSTIC_TEST|Tongue sensitivity testing|testing the tongue sensitivity change prior to surgery and after (1 and 6 months) the surgery with two point discrimination test in mm.
223531396|NCT04436731|DRUG|Dexmedetomidine|Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
223531397|NCT04436731|DRUG|Phentolamine|Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
223531398|NCT04436731|DRUG|Norepinephrine|Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
223531399|NCT05812170|BEHAVIORAL|Educational online session about PF|The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
223531400|NCT03925246|DRUG|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
223717468|NCT05261360|DRUG|SF-MSC-EX|Intra-articular administration of synovial fluid-derived mesenchymal stem cells-derived exosomes
224091774|NCT05637268|DRUG|Camrelizumab|Camrelizumab 200mg iv q2w
223531401|NCT02381587|OTHER|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
223531402|NCT05804045|DRUG|Pimicotinib(ABSK021)|capsule
223531403|NCT05804045|DRUG|Placebo|capsule
223531404|NCT05168293|OTHER|Detection of HBV-DNA in Peripheral Blood Mononuclear cells|Detection of HBV-DNA level in Peripheral Blood mononuclear cells
223923183|NCT06736925|DIETARY_SUPPLEMENT|Organic soybean oil|We will use organic soybean oil pills ) as a placebo condition for the DHA+EPA group. One capsule contains 485 mg of organic soybean oil, including negligible amounts of DHA (1.1 mg), EPA (1.7 mg), and vitamin E (10 mg). Participants will ingest 5 capsules daily. Soybean oil is one of the most widely used vegetable oils in the world. Soybean oil contains polyunsaturated fats and 18-carbon omega-3 FA (total omega-3 FA of 73.9 mg per capsule), but very low levels of DHA and EPA, which makes it an excellent placebo counterpart when evaluating the effects of DHA/EPA. The placebo capsule's shelf life, composition, shape, size as the DHA+EPA active comparator.
223923184|NCT06736925|OTHER|Soccer Heading Model|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer (G-force tracker) embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 30 mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
223923185|NCT06120608|BEHAVIORAL|Novel dietary approach focused on restricting the intake of highly bioavailable potassium|Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
223923186|NCT06120608|BEHAVIORAL|Traditional approach|Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
224091775|NCT05637268|DRUG|Paclitaxel|150mg/m² iv d1 q2w
224091776|NCT05637268|DRUG|Cisplatin|50 mg/m² iv d2 q2w
224091777|NCT06386458|DEVICE|AThrough radiofrequency transseptal puncture system|Utilizing AThrough radiofrequency transseptal puncture system for left atrial access
224091778|NCT06386458|DEVICE|Traditional mechanical transseptal puncture needle|Utilizing Traditional mechanical transseptal puncture needle for left atrial access
224091779|NCT04418921|BEHAVIORAL|Self-regulation: MRehab - Un colegio emocionante, clinical trial with non-immersive virtual reality|The principles of the programme will be based on the following premises for children with ASD: 1) Strengthening communicative attempts; 2) Choose the most natural contexts possible; 3) Establish structured and predictable routines and environments; 4)Visually support information; 5) Adapting our language to the understanding level of the child. On the difficulty of interpreting and responding to social emotions and cues, games of perspectives are of great interest, where the child and therapist describe the same object from different perspectives, beliefs (guess that may be in this box), games with social stories, which are short stories that use pictograms, to help understand especially situations with social ambiguity: 1) describing what happens; 2) orienting the action, indicating to the child what to do in that situation; 3) anticipating and explaining what can happen and how you can feel; 4) developing a strategy that can be applied in similar situations.
224091780|NCT04418921|BEHAVIORAL|Traditional self-regulation program|The children from control group will follow a program of emotional education of Primary Schools, though group activities in the classroom .The content of the sessions will include 5 sessions of emotional awareness and 5 sessions of emotional and cognitive regulation.Each session will last 50 minutes
223531405|NCT04046237|OTHER|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
223531406|NCT03798210|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
223531407|NCT03798210|DIETARY_SUPPLEMENT|Placebo|Placebo
224280451|NCT04881513|OTHER|Qualitiy of life|Testing the patients quality of life before and after (one and six months) the stapes surgery by SF 36 questionnaire
224280452|NCT04881513|DIAGNOSTIC_TEST|Threshold change|Measuring the intraoperative chorda tympani stimulation threshold change at the beginning and at the end of the procedure- surgery
224280453|NCT04881513|DIAGNOSTIC_TEST|Taste|Taste is measured by applying taste strips (sweet, sour, salty, bitter) in 4 concentrations prior to, 1 and 6 months after surgery.
223531408|NCT04890184|DIETARY_SUPPLEMENT|grape juice|grape juice
223531409|NCT04890184|OTHER|control|no intervention
223531410|NCT03478605|DRUG|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
223531411|NCT03478605|DRUG|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
223531412|NCT03478605|DRUG|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
223531413|NCT03478605|DRUG|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
223531414|NCT06963021|DRUG|NBI-1065845|NBI-1065845 tablets
223531415|NCT06963021|DRUG|Placebo|Matching placebo tablets
223717469|NCT05261360|DRUG|SF-MSC|Intra-articular administration of synovial fluid-derived mesenchymal stem cells
223717470|NCT02206568|DRUG|URAL|
223923187|NCT06201611|DRUG|Nebivolol+ Standard care arm|This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
223923188|NCT06201611|DRUG|Epalrestat + Alpha Lipoic Acid +Standard care|This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
223923189|NCT06201611|DRUG|Standard care alone|Patients in this arm will receive standard care as judged by their treating physicians which is generally pain modifying treatment.
223923190|NCT06117670|COMBINATION_PRODUCT|posterior colporrhaphy using gamma-irradiated amniotic membrane as a graft|Posterior colporrhaphy with application of the gamma-irradiated amniotic membrane graft will be done
223923191|NCT06843395|BEHAVIORAL|ACT-based ecological momentary intervention|The intervention is based on Acceptance and Commitment Therapy (ACT) and includes the six core processes (being present, acceptance, defusion, self-as-content, values, and taking action). It is delivered in the form of an ecological momentary intervention (EMI), lasting for 7 days with two sessions per day. The intervention aims to enhance mental health, well-being, and psychological flexibility.
223923192|NCT06843395|OTHER|Mood monitoring|Participants do not receive any intervention. During the intervention period, they only need to complete ecological momentary assessments twice a day.
223923193|NCT06836193|OTHER|Emotional intervention|Negative emotional intervention
223923194|NCT06836193|OTHER|Emotional intervention|Positive emotional intervention
223923195|NCT04245085|DRUG|Atezolizumab|"Patients in both treatment arms will receive atezolizumab at a fixed dose of 1200 mg i.v. on day one of every 3-week (3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.~Treatment beyond RECIST-defined progression will be allowed if patient is continuing to derive clinical benefit."
223923196|NCT04245085|DRUG|Bevacizumab|Patients in both treatment arms will receive bevacizumab at a dose of 15 mg/kg i.v. on day one of every 3-week (+/- 3 days) cycle, until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
223717471|NCT03291808|BEHAVIORAL|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
223717472|NCT05450341|DEVICE|rTMS over right frontal target|Low frequency (1 Hz) rTMS over right inferior frontal gyrus
223923197|NCT04245085|DRUG|Carboplatin|Patients in treatment Arm A will receive carboplatin, AUC5 every 3 weeks for 4-6 cycles.
223923198|NCT04245085|DRUG|Paclitaxel|Patients in treatment Arm A will receive paclitaxel, 175-200 mg/m2 (at the investigators' discretion), every 3 weeks for 4-6 cycles.
223923199|NCT04245085|DRUG|Pemetrexed|Patients in treatment Arm B will receive Pemetrexed, 500 mg/m2 every 3 weeks until progression of disease determined according to RECIST v1.1 or lack of tolerability, or patient declines further treatment.
223923200|NCT06882109|OTHER|Five-in-two ankle block|"The FIT block is a new approach for regional anesthetic block of the ankle. We use an optimized ultrasound guided approach for the FIT Block, based on optimal nerve anatomical locations. A one puncture proximal approach for the fibular nerves is used, while maintaining the benefit of preserved extrinsic motricity. Another one puncture approaches the sural nerve laterally, after the block of the tibial nerve during the same puncture and then the subcutaneous infiltration of the saphenous nerve. An anatomical proof of concept study has been done before the exploratory clinical study.~These approaches permit a surgical anesthetic block for foot surgery using 2 punctures (instead of 5) with a single patient's body position, compatible with sedation."
223923201|NCT06882135|DRUG|HW071021 Tablets|Administered orally at pre-specified doses once or twice daily.
223923202|NCT06747325|DRUG|Fei Re Qing Granules|Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.)
223531429|NCT04595201|DEVICE|NIPT|Non-invasive pregnancy testing
223531430|NCT06498479|DRUG|HS-20093|HS-20093 will be administered as an IV infusion at dose of 8.0 mg/kg on Day 1 of each 21-day cycle.
223531431|NCT06498479|DRUG|Topotecan|Topotecan will be administered per drug label.
223531432|NCT03255473|DRUG|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
223531433|NCT03255473|DRUG|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
223531434|NCT01732185|GENETIC|Patient|Blood and histological samples will be done at day of the inclusion.
223531435|NCT06057532|DIETARY_SUPPLEMENT|UCAN SuperStarch|Intervention patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the intervention study drink and record information about how they feel before and after consumption.
223923203|NCT06747325|OTHER|Routine standard treatments|Routine standard treatments
223923204|NCT06747325|DRUG|Placebo granules|The placebo granules are prepared using 5% of the active drug, ensuring consistency in appearance, weight, color, and odor with the Fei Re Qing Granules
223923205|NCT06735573|OTHER|the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes|"Primary Objective The primary objective is to measure the relationship between the quantity and source of dietary protein intake, and the prevalence of sarcopenic obesity, and lung function outcomes, in older female participants with clinically diagnosed COPD.~Secondary Objectives The secondary objective is to investigate whether the level of inflammation (plasma CRP) is associated with the intake of total, plant-based and animal-based protein, with the prevalence of sarcopenic obesity, and with lung function outcomes."
223940842|NCT06730386|DRUG|AK138D1|Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
223940843|NCT00310180|DRUG|Anastrozole|Given PO
223940844|NCT00310180|DRUG|Exemestane|Given PO
223940845|NCT00310180|OTHER|Laboratory Biomarker Analysis|Correlative studies
223940846|NCT00310180|DRUG|Letrozole|Given PO
223923206|NCT06728761|BEHAVIORAL|Standardised test meal|"Ingestion of a 1850 Kcal standardised 'Christmas meal' identical for each session. It will consist of the following elements Assortment of Picard Mini-Puff Pastry Aperitifs: 70g = 210 Kcal 1 glass of white wine = 85 Kcal with the aperitif~1 slice of vacuum-packed foie gras = 50 g = 230 Kcal~1 portion of turkey leg 200 g = 250 Kcal 50 g turkey cream = 130 Kcal~1 portion of steamed potatoes = 200 g = 160 Kcal~1 glass of red wine = 85 Kcal to accompany the main course~1 slice of white bread (30 g) = 55 Kcal to eat with the main course Blind test or control drink (trou normand or placebo = water) / 1 scoop of apple sorbet~1 portion 30 g camembert = 90 Kcal + White bread 1 slice (30 g) = 85 Kcal with the cheese~1 portion crumble 100 g = 250 Kcal The different elements will be weighed for each participant."
223531436|NCT06057532|DIETARY_SUPPLEMENT|Gatorade|Active control patients will have a continuous glucose monitor placed on their upper arm by the study team 1 - 5 days prior to surgery. These patients will drink the active control study drink and record information about how they feel before and after consumption.
223531437|NCT06305234|DRUG|Pegvaliase|Must be enrolled in the 165-501 PALace study. Subjects currently receiving or who plan to receive pegvaliase treatment within 30 days after the date of enrollment in the 165-501 study, including subjects who previously received pegvaliase as part of the clinical development program and have completed study participation
223531438|NCT05246566|OTHER|Routine care|"The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge."
223531439|NCT06803030|DRUG|Tamsulosin Hydrochloride 0.4 mg|placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily
223531440|NCT06803030|DRUG|Solifenacin Succinate 5 mg|placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily
223923207|NCT06728761|BEHAVIORAL|Ingestion of test drink|Ingestion of 2,5 cl Calvados 40° at the 70th min of the meal (before cheese and dessert)
223923208|NCT06728761|BEHAVIORAL|Ingestion of Control drink|Ingestion of 2,5 cl water at the 70th min of the meal (before cheese and dessert)
223923209|NCT06728761|DIAGNOSTIC_TEST|Ultrasound measurement of the antral area|Ultrasound measurement of the antral area in the volunteers lying in the 45° semi-recumbent position using an ultrasound machine (Venue Go™, GE Healthcare, Chicago, IL, USA) fitted with an abdominal transducer (probe C1-5, 1.5 to 5 MHz) to obtain a sagittal cross-section of the antrum in a plane including the left lobe of the liver and the aorta. This will be performed during the intake visit, immediately before the test drink ingestion (70th min of the meal) and 15, 45, 60, 90, 120, 150, 180 min after the end of the meal
223923210|NCT06728761|DIAGNOSTIC_TEST|Breathalyser for measurement of the level of exhaled ethanol|Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.
223923211|NCT06728761|BEHAVIORAL|Discomfort|discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
223923212|NCT06728761|BEHAVIORAL|Appetite|Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
223923213|NCT06728761|DIAGNOSTIC_TEST|Pregnancy urine test carried out during the intake visit on the day of the protocol|Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.
223923214|NCT06885411|OTHER|metal-on-metal hip arthroplasty|Cobalt and chromium release from metal-on-metal hip arthroplasties.
223940847|NCT00310180|OTHER|Quality-of-Life Assessment|Ancillary studies
223940848|NCT00310180|RADIATION|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
223940849|NCT00310180|DRUG|Tamoxifen Citrate|Given PO
223940850|NCT02625480|BIOLOGICAL|Brexucabtagene Autoleucel (KTE-X19)|
223940851|NCT02625480|DRUG|Fludarabine|Administered intravenously
223940852|NCT02625480|DRUG|Cyclophosphamide|Administered intravenously
223940853|NCT06776952|DRUG|XNW5004 ; Chidamide placebo|XNW5004 + Chidamide placebo
223940854|NCT06776952|DRUG|XNW5004 placebo; Chidamide|XNW5004 placebo + Chidamide
223940855|NCT06758219|OTHER|There is no intervention in the study.|There is no intervention in the study.
223940856|NCT06779578|PROCEDURE|Bipolar pulsed radiofrequency|Bipolar pulsed radiofrequency ablation: the active comparator
223940857|NCT06779578|PROCEDURE|Mopolar pulsed radiofrequency|Monopolar pulsed radiofrequency ablation: the placebo
223940858|NCT07098312|BEHAVIORAL|creative drama|It is aimed to develop cultural competence in nursing students through creative drama workshops.
223940859|NCT03024866|PROCEDURE|Electronic Brachytherapy|A group receives High-dose-rate electronic brachytherapy (EBT) which provides a non-surgical treatment option and the other group receives Mohs surgery. This matched-pair cohort study compared the outcomes of treatment with EBT to those of Mohs surgery in patients with NMSC.
223923215|NCT06741163|DIETARY_SUPPLEMENT|Pre-activity shot|Water-based shot containing olive leaf extract (100mg Oleuropein), vitamins, and other active ingredients. The product will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the test product before their training session on each intervention day (Day 5, Day 6, and Day 7).
223923216|NCT06741163|DIETARY_SUPPLEMENT|Placebo|Water-based shot with similar appearance and taste but without the active ingredients of the test product. The placebo will be provided in sterilized Nalgene bottles of 60 mL, equivalent to one dose. Participants will consume one dose of the placebo before their training session on each intervention day (Day 5, Day 6, and Day 7).
223923217|NCT06887985|DRUG|JY231 Injection|"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo chimeric antigen receptor T-Cell (CAR-T cell) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."
223923218|NCT06748339|OTHER|no intervention|no intervention
223923219|NCT06893952|DEVICE|TREO Endograft|Post Market collection data in use of TREO modular endografts
223923220|NCT06893354|DRUG|lorlatinib|Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total), and then underwent surgery.
223923221|NCT06893354|DRUG|lorlatinib plus chemotherapy|Subjects will be registered to receive oral lorlatinib 100mg qd for 3 cycles of 4 weeks each (12 weeks total) plus chemotherapy, and then underwent surgery.
223923222|NCT06740643|PROCEDURE|intracanal reinforcement using short composite post|after pupectomy is done flowable composite will be applied 3mm intacanal to make a short compsite post before zircon crown aplicaction
223923223|NCT06740643|PROCEDURE|no intracanal reinforcement|no intracanal reinforcement using resin modified glass ionmer before zircon crown application
223923224|NCT06747975|DRUG|Dexamethasone and Ondansetron|patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline
223923225|NCT06747975|DRUG|Bupivacaine + saline|patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
223531441|NCT06803030|DRUG|Mirabegron 25 mg|placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily
223531442|NCT05462262|DRUG|Intensive lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
223531443|NCT05462262|DRUG|Moderate-intensity lipid-lowering control|The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
223940860|NCT06319872|DRUG|Oral disulfiram|250 mg/day
223940861|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of beef|Beef patty will replace one of the participants protein servings each day for 30 days. Each serving is 114 grams of 90% lean ground sirloin given to participants as an uncooked frozen patty.
223940862|NCT04427852|DIETARY_SUPPLEMENT|30 day Daily consumption of 1 serving of the vegatable protein source|Veggie patty will replace one of the participants protein servings each day for 30 days. No beef will be consumed during this period. The veggie patty is commercially available Morningstar veggie burger and is given to participants in commercial packaging as a frozen precooked patty.
223940863|NCT05487820|DEVICE|IscAlert|Insertion of a CO2- and temperature sensor(s) in the reconstructed flap.
223940864|NCT06618144|OTHER|Texting platform|Participants will be invited to text with a secure, closed artificial intelligence system with clinician oversight to triage patients along predetermined algorithms related to early pregnancy care.
223940865|NCT06869590|OTHER|blood sampling|When blood is drawn as part of the treatment, three additional dry tubes will be taken for the immunology laboratory (see study diagram). These three dry tubes will be used to test for 1/ anti-nuclear autoantibodies and those associated with hepatic autoimmune pathologies 2/ AAHIF and assess their pathogenic potential using techniques already developed. The third dry tube will be sent to the Biogénopole Biological Resource Center (CHU Timone, APHM).
223940866|NCT06869590|OTHER|blood sampling after 3-4 months|In the event of AAHIF positivity, a second sample will be taken between 12 and 16 weeks later to verify the persistence of autoantibodies: Visit 2.
223940867|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
223940868|NCT05434234|DRUG|YL201|Patients will be treated with YL201 intravenous (IV) (A mg/kg or B g/kg infusion once every 3 weeks (Q3W) as a cycle.
223940869|NCT05434234|DRUG|YL201 and atezolizumab|Patients will be treated with YL201 intravenous (IV) infusion (A mg/kg or B mg/kg, up to 200mg) followed by atezolizumab on day 1 of each 21 day cycle
223940870|NCT06515002|GENETIC|BI 3720931|BI 3720931
223940871|NCT06515002|DRUG|Placebo|Placebo
223940872|NCT06515002|DEVICE|Inhaler|Inhaler for application of BI 3720931 and placebo
223940873|NCT04002661|DRUG|Flibanserin|Flibanserin tablet
223940874|NCT04002661|DRUG|Placebo|Oral Tablet
223940875|NCT06474728|OTHER|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus|Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus, with the dose of 100g per week,lasting for 12weeks.
223940876|NCT06827847|PROCEDURE|Traditional polychromatic layering dental composite technique|patient received composite restoration done by layering technique
223940877|NCT06827847|PROCEDURE|Contemporary monochromatic single shade dental composite technique|patient received composite restoration done by single shade composite
223940878|NCT06831747|PROCEDURE|Bilateral salpingo-oophorectomy - S-LPS|In standard laparoscopy (S-LPS), the initial laparoscopic access was performed at the umbilical level using open laparoscopy (Hasson technique). The subsequent accesses were carried out in the right and left iliac fossa. In the S-LPS, these accesses are performed using a 5mm trocars. Finally, a 5mm ancillary trocar was placed in the suprapubic region to use instruments such as bipolar forceps, irrigators, and scissors. The subsequent surgical steps were identical for both techniques.
223923226|NCT06748963|BEHAVIORAL|Fasted Exercise|Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold.
223923227|NCT06748963|BEHAVIORAL|Postprandial Exercise|Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold.
223923228|NCT06741930|DRUG|Ketamine|The Ketamine group received IV ketamine at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
223923229|NCT06741930|DRUG|Midazolam|The Midazolam group received IV midazolam at a titrated dose of 0.15-0.40 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
223923230|NCT06741930|DRUG|Propofol|The Propofol group received IV propofol at a titrated dose of 0.5-1.0 mg/kg with IV fentanyl, administered in small incremental boluses of 25-50 mcg to ensure adequate analgesia.
223923231|NCT06745193|DRUG|chidamide+Camrelizumab+Apatinib|chidamide+Camrelizumab+Apatinib
223923232|NCT06745193|DRUG|Irinotecan or Docetaxel or Paclitaxel|Irinotecan Docetaxel Paclitaxel
223923233|NCT06754865|DRUG|Xiyanping injection+ antibiotic|Xiyanping injection+ antibiotic
224091781|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|"2-4 days SWPBS training for school team and 1-2 days for whole staff training (SW and Classroom Management). Use staff release days for whole staff training.~Schedule up to four meetings with the PBS team~1K/School is to fund part or whole day training meeting with PBS team Schedule whole staff training per school year staff release days Enhanced Intervention Family Support Universal -- parent education and invitation Selective -- Family Check up School Intervention ACT for teachers PBS Calendar Kernel Recipes (Treatment) Reminder Emails Brochures Weekly phone contact (Treatment)"
224091782|NCT04711681|BEHAVIORAL|Positive Behavior Supports in Middle Schools|1 days PBS training for school team and informational presentation to whole staff Attend 2-3 PBS team meetings (coaching) Data-based feedback (limited)
224091783|NCT06153862|DIAGNOSTIC_TEST|Immuno analytical assay|The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
223531444|NCT04653012|DEVICE|Intracranial macro-microelectrode recording|Additionnally to clinical macroelectrodes, Benkhe-Fried depth macro-microelectrodes will be implanted and recorded during the pre-surgical investigation of epileptic patients
223531445|NCT06558578|DIAGNOSTIC_TEST|Helicobacter pylori antigen in stool|"H pylori antigen in stool: for all patients suffering from migraine and control group.~Upper GIT endoscopy: for children with positive H Pylori antigen in stool."
223923234|NCT06754865|DRUG|Antibiotic|Antibiotic
223923235|NCT06752265|BEHAVIORAL|Peran sadar application|The PERAN SADAR application is an android-based SACA prevention application containing material related to SACA prevention which is given in a series for nine days using multimedia video stories and songs, documents, and tiktok in an attractive package, so that it attracts someone's interest in listening to the contents of the message. Social media applications are educational methods that are popular with all ages
223923236|NCT06755905|PROCEDURE|ICGL-guided treatment|Indocyanine green lymphography guided resection combined with sclerotherapy
223923237|NCT06755905|PROCEDURE|Conventional Treatment group|Resection with sclerotherapy
223923238|NCT06755645|OTHER|Lifestyle intervention|A technological smart platform (app) that integrates diets, physical activity programs, sleep habits and other lifestyle interventions
223923239|NCT06753890|DRUG|Changkang granules|7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
223923240|NCT06753890|DRUG|Changkang Granules placebo|7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
223923241|NCT06754449|OTHER|Art therapy group|Application of different applications of art therapy such as painting, drawing, cutting to children
224091784|NCT02954315|OTHER|Almonds|
224091785|NCT02797470|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
224091786|NCT02797470|DRUG|Carmustine|300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
224091787|NCT02797470|DRUG|Cytarabine|100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
223531446|NCT03101748|DRUG|Cyclophosphamide|Given IV
223531447|NCT03101748|DRUG|Doxorubicin|Given IV
223923242|NCT06738095|DEVICE|daily low-level red-light|Daily low-level red-light is a kind of myopia intervention. Red-light typically using 650-nm wave of length. The treatment duration last 3 minutes each time, every day children were anticipated to use two times, at home.
223923243|NCT06755333|BEHAVIORAL|Oral hygiene motivation|the patient underwent a professional oral hygiene session before starting chemotherapy, as part of the routine pre-transplant procedure. Patients then received oral hygiene instructions.
223923244|NCT06738043|DRUG|Dexmedetomidine infusion|A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.
223923245|NCT06738043|DRUG|Ketamine infusion|A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.
223923246|NCT06738043|DRUG|Normal Saline Infusion (Placebo)|A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.
223923247|NCT06766474|DRUG|Bupivacain|to our knowledge, this study is the 1st to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus subcutaneous infiltration for postoperative donor site pain control for patients undergoing STSG procedures.
223923248|NCT06759857|DRUG|FHND9041|FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.
223923249|NCT06759857|DRUG|Afatinib|Afatinib is an approved, second-generation, irreversible EGFR tyrosine kinase inhibitor used as a standard first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, such as L858R and Exon 19 deletions. Participants in this arm will take a 40 mg oral dose once daily. Afatinib serves as the active comparator in this study to evaluate the efficacy and safety of FHND9041.
223923250|NCT06761508|BEHAVIORAL|Intervention study for Arm one using video|A 3 Arm randomized control trial, using video as the first Arm of intervention to assess the behaviour change of the community in hypertension prevention.
223923251|NCT06761508|BEHAVIORAL|intervention 2:using infographics|A 3 Arm randomized control trial,that involves the use of infographics in Arm to assess the behaviour change of the community in hypertension prevention.
223923252|NCT06761508|BEHAVIORAL|intervention 3: use of pamphlet|A 3 Arm randomized control trial,that contains the use of pamphlet for the 3rd Arm which is the control group to assess the behaviour change of the community in hypertension prevention.
223923253|NCT04490057|DRUG|Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler|Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.
223923254|NCT04490057|DRUG|Varenicline or bupropion|Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).
223923255|NCT04490057|BEHAVIORAL|Contingency Management|Participants will be financially rewarded for abstinence to tobacco.
223923256|NCT06761014|OTHER|Instrumental assisted soft tissue mobilization|instrument will be held at 45° angle and the IASTM treatment will be administered for about 20 seconds in a direction parallel to the muscle fibers being treated with deep strokes
223923257|NCT06761014|OTHER|Sustained stretching|The therapist will apply the pressure or ask to maintain the stretch. A total of thirty seconds, divided into three sets of stretches at each intervention, with ten seconds of rest in between
224091788|NCT02797470|DRUG|Etoposide|VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
224091789|NCT02797470|OTHER|Laboratory Biomarker Analysis|Correlative studies
224091790|NCT02797470|BIOLOGICAL|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
224091791|NCT02797470|DRUG|Melphalan|140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
224091792|NCT02797470|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
223531448|NCT03101748|OTHER|Laboratory Biomarker Analysis|Correlative studies
223531449|NCT03101748|DRUG|Neratinib|Given PO
223531450|NCT03101748|DRUG|Paclitaxel|Given IV
223531451|NCT03101748|BIOLOGICAL|Pertuzumab|Given IV
223531452|NCT03101748|BIOLOGICAL|Trastuzumab|Given IV
223531453|NCT06563375|DRUG|NP-101|Given by mouth
223923258|NCT05680298|DRUG|Dupilumab|solution for injection, Subcutaneous injection
224091793|NCT05761301|DRUG|ALN-KHK|ALN-KHK will be administered by subcutaneous (SC) injection.
224091794|NCT05761301|DRUG|Placebo|Placebo will be administered by subcutaneous (SC) injection.
224091795|NCT04529967|OTHER|no interventions|it is a observational study, do not have interventions.
223531454|NCT05580042|DRUG|AC-1101|For each patient, once daily (QD)
223531455|NCT05548283|DRUG|Beta-lactam antibiotic|Intravenous (IV) β-lactam will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
223531456|NCT05548283|DRUG|Aminoglycoside|Intravenous (IV) aminoglycoside will be selected by the treating physician following standard of care. Treatment will last for 14 days (± 2 days).
223531457|NCT01648868|DEVICE|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
223531458|NCT01648868|DEVICE|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
223531459|NCT03615638|OTHER|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
223531460|NCT01292031|DRUG|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
223531461|NCT01292031|DRUG|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
223923259|NCT06761391|DIAGNOSTIC_TEST|Pain Pressure Threshold|A hand-held pressure algometer will be used to record the pressure pain threshold (PPT), defined as the level at which gradually increasing pressure becomes painful. Pressure algometry has shown high intratest reliability in asymptomatic individuals over the suboccipital area and upper trapezius. PPT levels will be measured bilaterally over the neck angle over the middle of the anterior surface of the upper trapezius; and over the rectus capitis posterior major (RCPM) muscle. The physiotherapist will use an increasing pressure of approximately 1 kg/cm²/s. The average of three measurements with a 30-second rest period will be taken for analysis. Two measurements will be taken, before and after.
223923260|NCT06761391|DIAGNOSTIC_TEST|Cervical Range of Motion|The degrees obtained as a result of the Range of Motion (ROM) measurements are made with a universal manual goniometer. Goniometer is still the most commonly used method for ROM measurements. For all ROM measurements to be performed, the necessary measurements can be taken based on the American Academy of Orthopaedic Surgeons (AAOS) guidelines . The flexion, extension, right and left rotation angles of the cervical region will be measured and recorded with the goniometer in the sitting position of the person. The measurement will be made twice, before and after the application.
223923261|NCT06761391|DIAGNOSTIC_TEST|Balance Error Scoring|"Balance performance will be assessed using the Balance Error Scoring System (BESS), known in Turkish as DHPS. Subjects must maintain test positions for 20 seconds under 6 conditions with eyes closed and no support: 2 surfaces (flat and foam) and 3 stance positions (double-foot, single-foot, tandem). A laboratory floor will serve as the flat surface, and an exercise mat will serve as the foam surface. All subjects will perform the conditions in this sequence: double-foot flat, single-foot flat, tandem flat, double-foot foam, single-foot foam, tandem foam, both pre-test and post-test. Each 20-second period will be timed with a stopwatch, and each error within this period will count as 1 point. Each test condition has a maximum error score of 10. Errors include:~1. Lifting hands above the iliac crest,~2. Opening eyes,~3. Taking a step,staggering, falling,~4. Flexing or abducting the hip joint beyond 30°,~5. Lifting the forefoot or heel off the ground,~6. Leaving the test position"
223923262|NCT06761391|DIAGNOSTIC_TEST|Cervical Joint Position Sense|The sense of joint position in the cervical region will be evaluated in four positions: flexion, extension, right rotation, and left rotation, using a goniometer. Participants will sit upright with arms at their sides, looking ahead. The physiotherapist will passively move the participant's head to 65% of the maximum joint range of motion, previously determined, minimizing vestibular function effects. After holding the head in position for three seconds, participants will be asked to remember the position. Subsequently, they will be instructed to return their head to the neutral position and then actively move it to the previously determined point. The degree of error between the target and achieved positions will be measured.
223940879|NCT06831747|PROCEDURE|Bilateral salpingo-oophorectomy - PSS|In the MiniLap® Percutaneous Surgical System (PSS), the initial laparoscopic access was performed at the umbilical level using open laparoscopy (Hasson technique). The subsequent two accesses were carried out in the right and left iliac fossa. These latter accesses are directly performed using MiniLap® with a 2.4mm incision. Finally, a 5mm ancillary trocar was placed in the suprapubic region to use instruments such as bipolar forceps, irrigators, and scissors. The subsequent surgical steps were identical for both techniques.
223940880|NCT06506422|DRUG|Empagliflozin 10 MG|10mg Empagliflozin daily for 12 weeks
223940881|NCT06506422|DRUG|Placebo|10mg Placebo daily for 12 weeks
224091796|NCT06543433|DEVICE|Skincubator 2|"The Skincubator is a small incubator designed to attach to the caregiver's torso without any barrier between the parent's chest and the baby. It creates an environment with the advantages of a standard neonatal incubator, while enabling Skin to Skin contact for extended periods from birth. It has multiple access points, to allow for common nursing procedures. It is anchored safely to the parent's body and secures ventilator and IV tubing. It also includes side ports for the parents to insert their hands to touch their baby.~The investigators will offer the parents in the intervention group the opportunity to perform Skincubator care for as long as they want to each day during the week after enrolment. The investigators will provide the parents with the aids to accomplish this goal: the Skincubator system with a convenient environment, the option for Skincubator surrogates and, where possible, the option for one of the parents to sleep with the baby safely secured in the Skincubator."
224091797|NCT01984515|BEHAVIORAL|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
224091798|NCT01846780|PROCEDURE|PTA & stenting|PTA \& stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
224091799|NCT05280496|DRUG|Metformin|Metformin is used to lower blood sugar in patients with high blood sugar (diabetes).
224091800|NCT05445349|DEVICE|Emptied dry powder inhalers (DPI) used in routine asthma and COPD therapy|The DPI inhaler devices are empty, without any active ingredient or/and carrier substances. Patients are not inhaling drug doses because of the study. They are inhaling only the type and quantity of aerosol drugs that they would inhale because of their treatment. The study does not influences the undergoing treatment by medication in any way.
224091801|NCT02356809|DRUG|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
224091802|NCT02875223|DRUG|CC-90011|Specified dose on specified days
224091803|NCT02875223|DRUG|Rifampicin|Specified dose on specified days
224091804|NCT02875223|DRUG|Itraconazole|Specified dose on specified days
224091805|NCT01608035|PROCEDURE|Sciatic catheter|presurgical sciatic catheter insertion
224091806|NCT01608035|PROCEDURE|Stump catheter|intraoperative placed stump catheter
223717473|NCT05450341|DEVICE|rTMS over right temporal target|Low frequency (1 Hz) rTMS over right posterior superior temporal gyrus
223923263|NCT06761391|OTHER|Suboccipital manual therapy|The procedure will be conducted with the patient lying on their back. The practitioner will be seated on a stool at the top of the examination table, their forearm in contact with the surface. After locating the occipital condyles through palpation, the practitioner will position their fingers in the slightly concave region between the occiput and the second cervical vertebra's spinous process. The patient's head will be gently elevated by the practitioner flexing their metacarpophalangeal joints. With the patient's skull base resting in the practitioner's palm, pressure equivalent to the weight of the patient's head will be applied to the rectus capitis posterior and obliquus capitis superior muscles using the practitioner's second, third, and fourth fingers for a duration of 5 minutes. To prevent eye movements from influencing suboccipital muscle tone, patients will be instructed to keep their eyes closed during the procedure.
223923264|NCT06763874|DEVICE|EMG-based FES device|One session of one hour to execute task-oriented exercises with the upper limb while wearing the EMG-based FES device. Submission of questionnaires related to usability, acceptance and satisfaction of the device.
224280454|NCT04728620|OTHER|Diabetes Care Gaps Patient Portal Intervention|The Diabetes Care Gaps Patient Portal Intervention involves a new feature embedded with the My Health At Vanderbilt (MHAV) native app (on Epic's MyChart platform) for mobile devices that allows patients to: (a) receive notifications when the patient is due for certain types of diabetes monitoring and preventative care and (b) initiate an order for the care. Automated notifications will be sent to patients if, according to the evidence-based guidelines, the patients are due for a hemoglobin A1C blood test, microalbumin urine test, diabetes eye exam, or pneumonia vaccination. Once notified patients can initiate orders for the care within the MHAV app. The patient will receive confirmation when the order has been processed and will be provided instructions to receive the relevant care.
223923265|NCT06771297|OTHER|nursing education|Nursing training will be given before rhinoplasty surgery. As a result, patients' involuntary thoughts and quality of recovery will be questioned.
223923266|NCT06341062|OTHER|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound|Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge
223923267|NCT03008382|DRUG|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
223923268|NCT03008382|DRUG|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
224091807|NCT01233479|DRUG|systemic chemotherapy|
224091808|NCT01233479|OTHER|laboratory biomarker analysis|
223923269|NCT03008382|OTHER|No intervention- observational sub-study|Participants did not receive placebo or metoprolol during the entire duration of the study.
223923270|NCT06833567|BEHAVIORAL|Brief mentalization-based group psychotherapy|"The intervention is an adaptation for anxiety and depression profiles of the introductory group program to Mentalization-Based Treatment for personality disorders.~Sessions program:~* Session 1: Building epistemic trust.~* Session 2: Introduction to mentalization.~* Session 3: Mentalization problems.~* Session 4: Emotions.~* Session 5: Mentalizing emotions.~* Session 6: Attachment relationships.~* Session 7: Attachment and mentalization.~* Session 8: Interpersonal relationships. Mentalizing relationships in the group.~* Session 9: Anxiety, attachment and mentalization.~* Session 10: Depression, attachment and mentalization.~* Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing~* Session 12: Final balance and closing."
223923271|NCT06833567|BEHAVIORAL|Acceptance and Commitment Therapy group intervention|"The intervention includes 12 sessions based on Acceptance and Commitment Therapy. Sessions program:~* Session 1: Presentation.~* Session 2: Cognitive defusion~* Session 3: Uncontrollability of thought, emotions and behavior.~* Session 4: Creative Hopelessness.~* Session 5: Mindfulness and acceptance.~* Session 6: Values.~* Session 7: Values and action.~* Session 8: Vital goals.~* Session 9: Goal achievement plan.~* Session 10: Implementation.~* Session 11: Flexible content depending on pending topics or participants' needs. Preparing for closing~* Session 12: Final balance and closing."
224091809|NCT01233479|PROCEDURE|therapeutic surgical procedure|
224280455|NCT00404625|BEHAVIORAL|Risk factors for infections due to ESBL+ Enterobacteriaceae|
224280456|NCT00404625|BEHAVIORAL|Risk factors for inadequate initial antimicrobial therapy|
224280457|NCT00404625|BEHAVIORAL|Overall and 30-day mortality in bad first antibiotic therapy|
224280458|NCT04590339|PROCEDURE|Guided inferior Alveolar Nerve lateralization|Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
224280459|NCT02376257|DRUG|250 mg DCS|Drug
224280460|NCT02376257|DRUG|100 mg Modafinil|Drug
224091810|NCT01233479|RADIATION|radiation therapy|
224091811|NCT04526184|PROCEDURE|aerobic exercise with blood flow restriction|Patients and healthy individuals will be given 30 minutes of aerobic exercise by cycling, by restricting lower extremity blood flow.
224280461|NCT02376257|DRUG|Placebo|Drug
224280462|NCT04621045|BEHAVIORAL|The Physical Activity for The Heart (PATH) intervention|The web-based Physical Activity for The Heart (PATH) intervention leverages openly accessible platforms, such as YouTube, to proffer workout videos that match the participants preferences. Currently, PATH includes over 90 workout videos vetted by a team of experts and curated on the PATH website in 3 controlled levels of intensity (beginner, intermediate, proficient) to foster gradual progression from low to high intensity PA in accordance with the FITT-VP (frequency, intensity, time, type, volume, progression) principle.
224091812|NCT00000573|PROCEDURE|enteral nutrition|
223923272|NCT06735781|DRUG|Nivolumab|As prescribed by the treating clinician
223923273|NCT06745999|DRUG|Ameluz 10% Topical Gel|Paired with device intervention of red light PDT
223923274|NCT06745999|DEVICE|Red Light PDT|Paired with drug intervention of Ameluz 10% topical gel
224091813|NCT06134297|DEVICE|Cycle ergometer|The Aerobic Exercise Group will perform a cycle ergometer for 15 consecutive minutes with a load adjusted to maintain heart rate (HR) between 65-75% of the maximum HR predicted for age (HRmax = 200-age). Peripheral oxygen saturation will be controlled and, upon a sustained drop (\> 2 minutes after load reduction) below 90%, the session will be interrupted. The subjective feeling of tiredness in the legs and shortness of breath will be constantly monitored and if values equal to or greater than 8 (0-10) occur, the exercise will be stopped.
224091814|NCT06134297|DEVICE|Strength Training - elastic band and shin guards|The Anaerobic Exercise Group will perform muscular strength training using maximum strength, where the contraction time should not exceed 20 seconds. For the upper limbs, the overload used will be through the use of an elastic band, with guidance for the patient to perform the shoulder external rotation exercise, elbow flexion exercises and open row rowing exercise. For the lower limbs, bridge movements, lunges and sit-up exercises will be performed with a maximum of 15 repetitions, and overload with ankle weights or dumbbells can be used in addition to body weight. The muscle contraction should lead the patient to a state of muscular fatigue and if the objective is not achieved, the exercise will be adapted to require greater strength from the patient so that he or she can reach maximum strength.
224280463|NCT04621045|BEHAVIORAL|Be Active Your Way Booklet|Be Active Your Way booklet was developed by the Centers for Disease Control (CDC) to help individuals integrate PA in their daily lives. It simply encourages individuals to increase their PA gradually and gives them examples of things that they can do.
224280464|NCT04011098|DRUG|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
224280465|NCT04011098|DRUG|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
224280466|NCT04326933|DRUG|Tyrosine kinase Inhibitors (Imatinib & Nilotinib)|Administration of tyrosine kinase inhibitors (Imatinib in a dose of 400mg/day \& Nilotinib in adose of 600mg/day)
224280467|NCT04031560|BEHAVIORAL|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
224280468|NCT02248116|DRUG|Talsaclidine|
224280469|NCT04056663|BEHAVIORAL|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
224280470|NCT04631380|OTHER|PRAYER|THE PRAYER GROUP WILL RECEIVE ABSOLUTELY THE SAME CARE AS THE CONTROL GROUP PLUS PRAYERS
224280471|NCT04736394|DRUG|APL-1202|APL-1202 single-agent oral treatment
224280472|NCT04736394|DRUG|Epirubicin Hydrochloride|Epirubicin hydrochloride
224280473|NCT05425368|DRUG|Silver diamine fluoride|First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
223923275|NCT06745999|PROCEDURE|Cryotherapy|Liquid Nitrogen
224280474|NCT05425368|DRUG|Mineral trioxide aggregate|First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
223923276|NCT06757972|COMBINATION_PRODUCT|Tele Rehab|Tele rehabilitation intervention is 6 months standardized program aimed to provide special rehabilitation services to patients with mobility impairments in rural areas without the need for them to travel to healthcare facility in big cities. The program consists of standard exercises addressing key components of mobility impairments.
224280475|NCT00311220|DRUG|tuberculin for skin test|
224280476|NCT06004180|DRUG|Lu AF28996|Hard capsule, orally, per schedule specified in the arm description.
224280477|NCT03693833|DRUG|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
223923277|NCT06757972|DIAGNOSTIC_TEST|Formal Rehab|After formal rehabilitation is completed, some impaired mobility victims re-access services; no attempt will be made to stop the control group from accessing further care, in either a public or private setting. However, physical activity participation will be assured during monthly phone call by a blinded -research assistant. Participants in this group will undergo three assessments at baseline, 6 and 12 months
224280478|NCT03693833|DRUG|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
224280479|NCT05756465|DEVICE|Smartphone-based virtual reality relaxation (SVR)|SVR is virtual relaxation and distraction therapy through a smartphone-based VR device (head-mounted display) that is attached to the head of a cancer patient undergoing chemotherapy, displaying a virtual environment of natural panoramas in 360-degree video and combined with traditional and classic musical instruments. SVR device is paired with smartphone using operating system either Android (minimum generation 11, Android 4.4 KitKat) or OS version 12, minimum screen size of 5.5-inch and maximum of 6.0-inch, screen resolution of at least 1080 x 1920 pixels, can connect to WIFI/ internet and provides a YouTube app to access 360-degree videos. SVR content uses original 360o videos produced by researchers using a video editor software for ± 10 minutes duration.
224280480|NCT04196348|PROCEDURE|Short BPL RYGB|Alimentary limb (AL) with 120 cm and BPL with 100 cm.
224280481|NCT04196348|PROCEDURE|Long BPL RYGB|AL with 120 cm and BPL with 200 cm.
224280482|NCT00957216|DRUG|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
224280483|NCT00957216|DRUG|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
224280484|NCT03559725|OTHER|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
224280485|NCT03559725|OTHER|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
224280486|NCT03559725|DRUG|Nicotine gum (C)|4 mg nicotine gum
223923278|NCT06754527|BEHAVIORAL|ON-TRAC|Online tablet-based intervention that teaches youth emotion regulation skills and integrates substance use prevention content
223531462|NCT03344887|OTHER|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
223717474|NCT03364023|DEVICE|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
223923279|NCT06758180|BEHAVIORAL|verbal basic life support training|"Both groups will be given verbal adult basic life support training simultaneously, on a day and time that will not conflict with the students' class schedules. The Adult Basic Life Support Training presentation published by the Ministry of Health in 2021 will be used in the training and will last approximately 40 minutes.~A week after the verbal training, a basic life support application for adults will be held in the Faculty of Medicine Skills Laboratory."
223923280|NCT06758180|BEHAVIORAL|Interactive game intervention|"The interactive game group will be given reinforcement training before the laboratory application. Here, each student will play the game accompanied by a researcher.~Lifesaver is an educational game developed by the Resuscitation Council (UK), offered in English and completely free of charge. The game can be downloaded to computers, phones or tablets from Google Play or the App Store. Lifesaver includes four different interactive video scenarios to help users develop their lifesaving skills. The Harry scenario to be used in this research is based on a real case. In the scenario, Harry, a high school student who has a sudden heart attack while playing football, is given heart massage, CPR and defibrillation by his friends.~The game offers different options at each stage to improve the players' knowledge and skill levels. If a wrong choice is made, the same section is played again until the correct step is performed. The completion time of the game may vary average 15 minutes."
223923281|NCT06758180|BEHAVIORAL|video training|"One week after all students are given verbal adult basic life support training, a video titled Adult Basic Life Support will be shown to the students in the video training group before the laboratory application. The video will be shown by the researcher using a projector. After the video watching process is completed, each student will apply basic life support on the adult training model in turn and the applications will be evaluated individually. In the video training, the video titled Basic Life Support and AED Use - Adult (TYD), which was published as open access on the 'paramedic online' YouTube channel on May 31, 2023 and prepared in accordance with the 2021 ERC guideline, will be used (Paramedic online, 2023). This video covers the topics of heart massage, artificial respiration and automatic external defibrillator use within the scope of basic life support."
223923282|NCT06759623|DRUG|Different drug type for conduction of general anesthesia|Patients will be randomly divided into two groups: patients for whom general anesthesia will be performed with sevoflurane and patients for whom general anesthesia will be performed with desflurane.
223923283|NCT06760962|BEHAVIORAL|Reflective Mindfulness and Emotional Regulation training|The RMERT program consisted of six weekly 90-minute sessions facilitated by researchers trained in cognitive behavioral therapy (CBT) and transactional analysis (TA). The training employed the ABC model of CBT (Activating events, Beliefs, and Consequences) to address maladaptive cognitive patterns, along with TA techniques such as empathic inquiry and reflection. Relaxation strategies, including diaphragmatic breathing and progressive muscle relaxation, were also integrated. The sessions focused on enabling students to reflect on their mental and emotional states, process their feelings, and apply cognitive reappraisal-a healthy emotional regulation strategy-instead of relying on expressive suppression, which is maladaptive.
223940882|NCT06916637|RADIATION|18F-HER2 Affibody PET scan|HER2 Affibody, labeled with PET radio-nuclide 18F will be used as a molecular imaging tracer for PET scan. All participants will undergo 18F-HER2 Affibody PET scan.
223940883|NCT02492074|DRUG|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
224280487|NCT03689894|DRUG|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events \>Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events \>Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
224280488|NCT03689894|DRUG|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
224280489|NCT05303948|DEVICE|Videolaryngoscopy / Direct Laryngoscopy|First pass success analysis
224280490|NCT01030887|BEHAVIORAL|Exercise programme|Moderate intensity exercise
224280491|NCT00250133|PROCEDURE|Blood draws|
224280492|NCT00005087|BIOLOGICAL|filgrastim|
223531463|NCT03344887|OTHER|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
223531464|NCT06506747|DEVICE|Navigated Photogrammetry|Navigated Photogrammetry shall be performed following implant surgery, rather than standard stereophotogrammetry. The patient will then receive a provisional that was manufactured using the data from FastMap Navigated Photogrammetry.
223531465|NCT06506747|DEVICE|Standard Photogrammetry|The patient will receive the existing patient care protocol that includes anatomy information for the manufacturing of the provisional. Specifically, the patient will receive a preoperative IntraOral Scan (IOS) anatomy scan with IOS-compatible fiducials. Following implant surgery, the patient will receive a scan with a standard stereophotogrammetry device. Additionally, they will receive a post-op alignment IOS with IOS-compatible anatomy fiducials and IOS-compatible implant scan bodies. The patient will then receive a provisional that was manufactured using the data from the standard stereophotogrammetry device.
223531466|NCT04600973|BEHAVIORAL|Technical assistance or team-based coaching|Main comparison in delivering peri-operative preventive strategies against transmission and infection is one on one technical assistance or team-based coaching.
223923284|NCT06773442|OTHER|Rehabilitation Practices Group|"Evidence-Based Training Program:Develop a structured training program for rehabilitation professionals focusing on evidence-based shoulder rehabilitation practices.~Clinical Mentorship and Supervision:Implement a mentorship program where experienced rehabilitation professionals provide guidance and support to junior staff members.~Standardization of Rehabilitation Protocols:Review and standardize rehabilitation protocols for common shoulder conditions based on current evidence and best practices.~Patient-Centered Care Approach:Adopt a patient-centered approach to shoulder rehabilitation, emphasizing shared decision-making and individualized treatment plans Outcome Monitoring and Quality Improvement:Use standardized outcome measures to evaluate improvements in pain, function, range of motion, and patient satisfaction."
223923285|NCT06773442|OTHER|Documentation Protocols Group|"Training and Education Program:Develop and implement a training program for rehabilitation professionals aimed at enhancing their knowledge and skills in shoulder rehabilitation practices and documentation protocols.~Standardization of Protocols:Review and update existing rehabilitation protocols to ensure alignment with current evidence-based guidelines and best practices.~Quality Assurance Measures:Establish a system for ongoing monitoring and evaluation of shoulder rehabilitation practices and documentation protocols.~Patient Education and Engagement:Develop educational materials and resources for patients undergoing shoulder rehabilitation to enhance their understanding of treatment goals, exercises, and self-management strategies.~Outcome Monitoring and Evaluation:Implement a system for monitoring and evaluating patient outcomes, including pain levels, range of motion, functional status, and satisfaction with rehabilitation services."
224280493|NCT00005087|DRUG|cisplatin|
223923286|NCT05699018|DIAGNOSTIC_TEST|eLIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry ≥ 8 kPa and \< 15 kPa)
223923287|NCT06769217|DEVICE|Drug Eluting Coronary Stent|The Drug Eluting Coronary stent is indicated for the treatment of de novo coronary artery lesions in patients with symptomatic ischemic heart disease.
223923288|NCT05002439|OTHER|Multicomponent physical exercise program and a nutritional intervention|The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
223923289|NCT06748586|DEVICE|Hyperbaric Oxygen Therapy|The HBOT protocol is 90 minutes, 5 times/week, for at least 40 sessions, 100% oxygen at 2 ATA with five-minute air breaks every 20 minutes. Investigational product: Multiplace hyperbaric oxygen chamber (Haux Starmed 2700, Germany) located at the Sagol center for hyperbaric medicine and research, Shamir (Assaf-Harofeh) Medical Center, Israel.
223923290|NCT06740292|DEVICE|conventional miniplates|conventional miniplates in double configuration
223923291|NCT06740292|DEVICE|InterFlex plates|InterFlex plates in configuration
223923292|NCT06758271|DRUG|Avacopan|oral administration
223923293|NCT06759870|OTHER|Collection of saliva|An unstimulated saliva sample will be obtained for 1 minute before implant surgery and immediately after implant surgery.
223923294|NCT06759870|OTHER|Collection of gingival samples|Gingival samples will be obtained by punch biopsy 3 months after implant surgery.
223923295|NCT06759870|OTHER|ISQ registration|ISQ value will be record in placement dental implant.
223923296|NCT06782308|OTHER|Survey using a questionnaire.|patients preferences survey
223531467|NCT06281457|OTHER|Stimulus properties: task-defining feature|The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
223940884|NCT02492074|DRUG|Cannabidiol|oral administration of cannabidiol
224280494|NCT00005087|DRUG|paclitaxel|
224280495|NCT00005087|PROCEDURE|conventional surgery|
224280496|NCT00005087|RADIATION|radiation therapy|
224280497|NCT00569777|DEVICE|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
224280498|NCT00569777|DEVICE|Placebo Lens|contact lens without drug
224280499|NCT06811870|DEVICE|hyperbaric oxygen treatment|Patients who meet the inclusion criteria will be enrolled and given hyperbaric oxygen intervention, with a minimum of 5 hyperbaric oxygen treatments per chemotherapy cycle, one per day for 60-90 minutes, for a total of 30-40 hyperbaric oxygen treatments (100% oxygen at a pressure of 2.0 ATA).
224280500|NCT00384124|DRUG|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
224280501|NCT00709306|DEVICE|UV-Detect Photos|UV-Detect Photos
224280502|NCT00709306|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing
224280503|NCT00709306|BEHAVIORAL|Education|Education
224280504|NCT04913519|DRUG|TDM-105795|TDM-105795 topical solution
224280505|NCT04913519|DRUG|Placebo|Placebo for TDM-105795 topical solution
224280506|NCT00866645|DRUG|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
224280507|NCT00866645|DRUG|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
224280508|NCT03170102|OTHER|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
223940885|NCT02492074|DRUG|Placebo|oral administration of placebo
223940886|NCT07118254|DRUG|rhPRG4 450ug/ml|Treatment
223940887|NCT07118254|DRUG|Vehicle Control|PBS Based Vehicle Control
224280509|NCT06663475|BEHAVIORAL|TTM-based health education videos about smoking cessation for expectant fathers|Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
224280510|NCT06663475|BEHAVIORAL|usual care treatment|general health education videos about hazards of smoking for expectant fathers in obstetric clinic
223923297|NCT06751511|OTHER|General warm-up|The General Warm-up (Control) protocol will consist of activities such as running and dynamic, active, and passive movements, adapted to suit the varied sports disciplines included in the study. These exercises will align with the principles of elevation, activation, and mobilization, aiming to enhance mobility across key muscle groups, from the arms and shoulders to the lower back and legs. Each session will include clear demonstrations to ensure proper technique and pacing, with participants performing a standardized number of repetitions. Researchers will supervise participants closely to verify accurate form and consistent execution during the intervention.
223923298|NCT06751511|OTHER|Inspiratory muscle warm-up (Placebo - %15)|The placebo inspiratory muscle warm-up protocol will utilize the POWERbreathe® device at 15% of maximal inspiratory pressure (MIP). This placebo protocol will consist of two sets of 30 breaths, separated by a 60-second rest interval, with participants seated and wearing a nose clip. Proper technique will be taught during a prior familiarization session, and participants will be closely monitored during testing to ensure accurate execution. This protocol is designed to function as a placebo, effectively concealing the study's true objective to improve data validity and reliability.
223923299|NCT06751511|OTHER|Inspiratory muscle warm-up (%40 IMW)|This study will implement a respiratory muscle warm-up protocol at 40% of maximal inspiratory pressure (MIP) using the POWERbreathe® device, as this intensity is considered optimal for effectively stimulating respiratory muscles. The protocol will consist of two sets of 30 breaths, with a 60-second rest period between sets, conducted while participants are seated and wearing a nose clip. Training for proper technique will be provided during the familiarization session, and participants will be closely monitored throughout the tests to ensure correct and consistent execution.
223923300|NCT06769035|DIETARY_SUPPLEMENT|Cocoa, amaranth seed and ginger|Sachet with 20gr of cocoa, 10g of amaranth seed and 1g of ginger, one dose per day for 12 weeks
223923301|NCT06769035|DIETARY_SUPPLEMENT|Amaranth seed|Sachet with 10g of amaranth seed one dose per day for 12 weeks
224091815|NCT06134297|DEVICE|Cycle ergometer, elastic band and shin guards|Mixed Exercise Group will perform the exercises by alternating between aerobic and anaerobic overload, in a 1:1 ratio until the end of the physical rehabilitation program, following exactly the same protocols described previously (alternating one session of the aerobic protocol and in the following session the anaerobic protocol).
224091816|NCT03866200|DRUG|resveratrol|125 mg/day or 5 ml once per day for 90 days
224091817|NCT03866200|DRUG|Placebo|5 ml once per day for 90 days
224091818|NCT05222074|OTHER|Venous congestion|Venous congestion exposures were quantified as area under the curve (AUC) of central venous pressure ≥12, 16 or 20 mmHg
224091819|NCT05222074|OTHER|Introperation hypotension|Introperation hypotension exposures were quantified as area under the curve (AUC) of mean arterial pressure ≤55, 65, 75 mmHg
224091820|NCT05585255|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|After allowing to stand at room temperature for 2h, blood samples are centrifuged at 4 ℃ for 15 min (12000 rpm) to collect the supernatant. Then, the levels of DKK2, IL-6, IL-1β, TNF-α, and IL-10 in the supernatants are tested by ELISA detection.
224091821|NCT01904799|OTHER|Cognitive Assessment test|
224091822|NCT01707992|DRUG|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
224091823|NCT01707992|DRUG|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
224091824|NCT03700099|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
224091825|NCT03700099|DRUG|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
224091826|NCT06244459|OTHER|VR Assessment Tool|Participants diagnosed with stroke will be evaluated with the Box and Block Test, 360 degree rotation test and 5 times squat test. These tests will be presented to the participants first in the real world and then in virtual reality.
224091827|NCT05122130|DRUG|Melatonin|The donor site will be dressed with melatonin loaded gelatin sponge
223923302|NCT06769035|DIETARY_SUPPLEMENT|Cocoa|Sachet with 20gr of cocoa one dose per day for 12 weeks
223923303|NCT06769035|DIETARY_SUPPLEMENT|Placebo|Sachet with coloring and flavoring, one dose per day for 12 weeks one dose per day for 12 weeks
223923304|NCT06812117|OTHER|No Drug|This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on mirogabalin will be enrolled in this study.
223923305|NCT06825013|DRUG|Bronchodilators inhalation|Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)
223923306|NCT06825013|DRUG|Placebo|Nebulized saline
223923307|NCT05758766|DIETARY_SUPPLEMENT|Plant-based omega-3-FA|Plant-based omega 3 Fatty Acids
224091828|NCT05122130|DRUG|Carbopol|The donor site will be dressed with carbopol loaded gelatin sponge (placebo).
224091829|NCT01904981|DRUG|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
224091830|NCT01904981|DRUG|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
224091831|NCT06206889|OTHER|NAS|NAS Turkish language validation will be carried out. NAS and CNSI scores will be recorded during the shifts of nurses serving patients in Level 3 intensive care units by the nurse in charge and another independent evaluator, and the correlation between the two scores will be investigated.
224091832|NCT01041248|DRUG|Tocilizumab|8mg/kg every 2 weeks i.v.
224091833|NCT02654002|DRUG|Cilofexor|Tablets administered orally
224091834|NCT02654002|DRUG|Placebo|Tablets administered orally
224091835|NCT06398873|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|300mg/2 weeks
224091836|NCT01216774|OTHER|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
224091837|NCT00546975|DIETARY_SUPPLEMENT|Resource Support®|
224091838|NCT00546975|DIETARY_SUPPLEMENT|Resource Protein®|
224091839|NCT00546975|DIETARY_SUPPLEMENT|Placebo|
223531468|NCT05311046|DIAGNOSTIC_TEST|Pediatric sepsis screening tool (either algorithmic or manual)|All participating institutions employ either an algorithmic, manual, or combined algorithmic/manual pediatric sepsis screening protocol for patients that present with fever and/or a concern for infection. While the specific parameters tested in screening tools differ, they generally consist of tests for a systemic inflammatory response (e.g. SIRS) and/or organ dysfunction (e.g. SOFA) and/or high susceptibility (e.g. immunocompromised) factors.
223531469|NCT05115630|DRUG|Cyclophosphamide|Given by IV
223531470|NCT05115630|DRUG|Mesna|Given by IV
223531471|NCT05115630|DRUG|Filgrastim|Given by IV
223531472|NCT05115630|DRUG|Melphalan|Given by IV
223531473|NCT05115630|DRUG|Fludarabine phosphate|Given by IV
223923308|NCT06826118|DRUG|Axicabtagene Ciloleucel|"Pre-treatment chemotherapy: Cyclophosphamide 500 mg/m² and Fludarabine 30 mg/m² will be administered intravenously on Days -5, -4, and -3 (with the day of Axicabtagene Ciloleucel Injection infusion being Day 0).~Axicabtagene Ciloleucel Injection infusion: A single dose of autologous T cells transduced with chimeric antigen receptor (CAR) in the form of Axicabtagene Ciloleucel Injection will be administered to the subject intravenously. The target dose is 2.0×10\^6 anti-CD19 CAR-T cells/kg body weight. The minimum dose that can be used is 1.5×10\^6 anti-CD19 CAR-T cells/kg body weight. For subjects with a body weight of ≥100 kg, the maximum total dose is 2.0×10\^8 anti-CD19 CAR-T cells"
223923309|NCT06808438|DEVICE|Esophageal pressure catheter|Esophageal pressure was monitored with an esophageal pressure catheter
223923310|NCT05019495|BEHAVIORAL|PrOMOTE|This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
223923311|NCT06503198|BEHAVIORAL|Virtual care|"Through Cloud DX, intervention group participants will receive:~Remote Automated Monitoring: measurement of: blood pressure, heart rate, respiratory rate, oxygen saturation, temperature and weight.~Frailty-tailored daily symptom survey: The recovery survey consists of questions related to infection, bleeding, pain, appetite, dehydration, appetite, syncope and falls.~The tablet will prompt the participant to complete a Katz Index of Independence in Activities of Daily Living (IADL) survey. The FAM-CAM survey will also be pushed by Cloud DX to be completed.~Virtual RN assessment: a virtual RN assessment will be scheduled at a minimum of every 2 days for the first 7 days. The virtual RN will also perform the 4AT Delirium Assessment.~Medications: the virtual RN will undertake medication review and reconciliation. In addition, they will provide counselling regarding analgesic support and monitor for drug interactions."
223923312|NCT06481995|DRUG|Fibrogammin|Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
223923313|NCT06858657|DRUG|HSK44459|Dose 1 to Dose 5
223923314|NCT06858657|DRUG|placebo|dose 1 to dose 5
224280511|NCT04994405|PROCEDURE|Tourniquet Pressure|"The procedural intervention will be inflation of a pneumatic tourniquet to a lower than standard pressure as determined by the patient's SBP in hand and upper extremity surgery. The control will be inflation of a pneumatic tourniquet at a standard pressure of 250 mmHg in hand and upper extremity surgery.~The tourniquet used will be the standard tourniquet used for hand and upper extremity surgery at our institutions - a tourniquet 18 inches in length and 3 inches in width manufactured by Stryker (Kalamazoo, MI) used in conjunction with a protective sleeve matched to the size of the tourniquet cuff which is provided by the manufacturer. Both pieces are supplied in a sterile packaging. No other tourniquets will be used."
223531474|NCT05115630|DRUG|Tacrolimus|Given by IV
223531475|NCT05115630|DRUG|Mycophenolate mofetil|Given by IV
224280512|NCT00274495|DRUG|Rosiglitazone and Pegasys/Ribavirin|
224280513|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-A) for Adolescents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-A is designed for adolescents to self-evaluate and manage psychological wellbeing/mental health needs, as well as to gain resources and access and connect with adolescent peers.The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
223940888|NCT06753916|PROCEDURE|Corneal Donor Tissue with Cross Linking|Participants are transplanted with corneal donor tissue that has been treated with 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) with UV light treatment.
223940889|NCT06753916|PROCEDURE|Corneal Donor Tissue without Cross Linking|Participants are transplanted with corneal donor tissue that has not been treated with the UV light and the 0.1% riboflavin (Vitamin B2) and 20% dextran (Photrexa® Viscous \& Photrexa®) without UV light treatment, this is the control group.
223940890|NCT05810285|DEVICE|GKS Prime Flex Mobile knee|Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
223531476|NCT05115630|DRUG|Total Body Irradiation One Dose|Given by IV
223531477|NCT02554565|PROCEDURE|Tumor biopsy|Tumor biopsy before treatment
223531478|NCT02554565|PROCEDURE|Blood sampling|Blood sample before, during and after treatment
223531479|NCT02876172|DRUG|MDMA|Two sessions of MDMA-assisted therapy, one with an initial dose of 75 mg midomafetamine HCl (and optional supplemental dose of 37.5 mg) and the second with 75 or 100 mg midomafetamine HCl (with optional supplemental dose of either 37.5 mg or 50 mg respectively) given to the participant with PTSD and their significant other.
223531480|NCT02876172|BEHAVIORAL|CBCT|A three-phase, 15-session, manualized treatment from the CBCT manual
223531481|NCT02876172|BEHAVIORAL|Therapy|Manualized MDMA-assisted therapy
223531482|NCT02035657|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
223531483|NCT00427830|BIOLOGICAL|MVA85A|
223923315|NCT06857149|OTHER|Human milk|"In accordance with the physiology of breastfeeding, mothers will be asked to milk and deliver their milk to the ICU once every 3 hours. The mother will be asked to completely empty her breast with a milking machine. Before milking, the mother will wash her hands, and the parts of the milking machine that come into contact with the milk will also be boiled and disinfected after it is provided to be used. The mother will put the milk she has milked into a milking bag and deliver it to the researcher by writing the date and time on it. Feeding will be initiated by the neonatal specialist with the determination that the newborn is stable. During the period when mothers' babies are in the neonatal intensive care unit, the feeding of the babies in the circadian rhythm group will be carried out taking into account the date and day/night practice.~The milk that the mother expresses at night will be given to her baby at night, and the milk that she expresses during the day will be used for dayt"
223923316|NCT06857149|OTHER|Control Group|"The application in the control group is similar to the application in the cycadian rhythm group (mother's milking technique, collection method, storage and appropriate transportation, etc.) instead of the milk expressed first is given first condition used in routine practice, without taking into account the day and night characteristics of the expressed breast milk. will be brought. The routine practice of the clinic will continue. In line with the practice of the Turkish Neonatology Association (2018) and the clinic, the information of babies given breast milk fortifiers in the expressed breast milk of enterally fed babies will be recorded. In order to ensure that the data is collected safely and to facilitate monitoring, it will be recorded in the Breastfeeding Follow-up Form, as in every feeding intervention group. The monitoring of babies is the same as in the circadian rhythm group. For the first month, the baby's weight and height will be measured and recorded twice a week."
223923317|NCT05706766|BEHAVIORAL|PARE|Aerobic and resistance exercise program via Zoom platform.
223923318|NCT05706766|BEHAVIORAL|Waitlist Control Group|Normal Activities.
223923319|NCT05939336|DIETARY_SUPPLEMENT|Mannooligosaccharides yeast extract|15 g per day of mannooligosaccharide yeast extract.
223923320|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month pre-intervention visit
223923321|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 1-month post-intervention visit
223923322|NCT06607705|DEVICE|Monitoring with contact lens sensor|Monitoring with contact lens sensor at 3-months post-intervention visit
223923323|NCT06866990|DIETARY_SUPPLEMENT|Lactobacillus johnsonii|The investigational product is a probiotic containing Lactobacillus johnsonii. It is recommended to be stored under refrigerated conditions at approximately 4°C. Participants are instructed to take one sachet twice daily, dissolved in warm water, with a total daily oral dose exceeding 1×10¹¹ colony-forming units (CFU).
223923324|NCT06866990|OTHER|Placebo|The placebo product contains the same excipients as the investigational product, except for the absence of Lactobacillus johnsonii. It is identical to the investigational product in appearance, color, weight, and taste. It is recommended to be stored under refrigerated conditions at approximately 4°C. The administration method is the same as that of the experimental group.
223923325|NCT06878183|OTHER|Routine laboratory tests of the patients were examined (such as hemogram, biochemistry, bleeding parameters).|Data obtained from routine examinations, laboratory tests and hospital reports were evaluated.
223923326|NCT05016791|DEVICE|Apple Watch-based heart rhythm monitoring|"For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~1. Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~2. If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~3. If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW."
223940891|NCT06773897|GENETIC|Saliva sample|Saliva sample is sent via prepaid US Mail for DNA extraction
223940892|NCT06773897|OTHER|Health Surveys|Health surveys are filled out online in the study portal.
224091840|NCT02006992|OTHER|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
224091841|NCT02006992|OTHER|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
224091842|NCT01213030|DRUG|[F-18] FMISO|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
224091843|NCT01213030|DRUG|[F-18] HX4|10 mCi \[F18\] HX4 and 10 mCi \[F-18\] FMISO within 7 days of each other regardless of sequence
224091844|NCT06381193|DIETARY_SUPPLEMENT|Probiotic|oral, daily
224091845|NCT06381193|DIETARY_SUPPLEMENT|Prebiotic|oral, daily
224091846|NCT06381193|DIETARY_SUPPLEMENT|Probiotic + Prebiotic|oral, daily
224091847|NCT06381193|DIETARY_SUPPLEMENT|Placebo|oral, daily
223923327|NCT06881134|DEVICE|SCS+EXS|Eligible participants will undergo implantation of the spinal cord stimulation (SCS) system. Intraoperative electrophysiological monitoring will be used to adjust stimulation parameters. SCS will be tested postoperatively to assess the patient's tolerance to stimulation and its therapeutic effects. Parameters designed to improve sensory function and bladder/bowel control will be established. All parameters will be integrated into a sequential stimulation protocol. Additionally, the simultaneous activation of the SCS and the robotic exoskeleton will be tested to ensure smooth integration. Exoskeleton-assisted training will be conducted for no less than 1 hour per day (divided into two 30-minute sessions). Other rehabilitation interventions will be provided for at least 3 hours per day. Follow-ups will be conducted at 1, 2, 3, 6, and 12 months postoperatively.
223923328|NCT06873828|DEVICE|ATP-C135|A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 14 days.
223923329|NCT06873828|DEVICE|ATP-C75|A wearable long-term electrocardiogram monitoring device that monitors electrocardiograms by attaching it for up to 7 days.
223923330|NCT06882486|PROCEDURE|nephrectomy|Nephrectomy scheduled within 3 months of inclusion. Patients may continue their systemic treatment at the usual rate until D-5 prior to surgery. Treatment will not be resumed after surgery. Surgery may consist of partial or enlarged nephrectomy, with or without associated lymph node dissection, depending on technical possibilities and at the surgeon's discretion.
223923331|NCT04912596|DRUG|Albuterol Sulfate inhalation aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
223923332|NCT04912596|DRUG|Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation|equal to albuterol 90 mcg/puff, MDI
223923333|NCT04912596|OTHER|Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo|MDI
223923334|NCT04912596|OTHER|Albuterol Sulfate inhalation Placebo|MDI
223923335|NCT04912596|OTHER|Methacholine|Methacholine 100 mg/vial
224091848|NCT02246972|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
224091849|NCT01654679|DEVICE|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
224091850|NCT01654679|OTHER|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
224091851|NCT01587950|DRUG|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
224091852|NCT01587950|DRUG|Placebo|Sterile Water
224091853|NCT00268645|DRUG|Insulin Glargine|
224091854|NCT04126655|DRUG|Arfolitixorin|Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
223923336|NCT06787976|DRUG|Dolutegravir (DTG)|Dolutegravir + Tenofovir Disoproxil Fumarate / Emtricitabine
223923337|NCT06787976|DRUG|Darunavir/Cobicistat (FDC)|Darunavir Cobicistat + TDF/FTC
223923338|NCT06924281|BEHAVIORAL|Brief motivational interviewing with personalized feedback|The manualized intervention is delivered individually in two phases by an interventionist trained in motivational interviewing. The intervention includes liver health information and explains connections with weight-related behaviors. The enhanced (experimental) group receives personalized feedback, i.e., a summary of self-reported drinking patterns and results of liver imaging with Fibroscan®, i.e., steatosis (liver fat) and fibrosis (liver scaring) scores. The feedback is used to develop discrepancies between a goal of halting or reversing health risks associated with consuming alcohol versus continuing to drink. The sessions are matched in duration and interventionist skill level with the standard (control) group.
223923339|NCT06924281|BEHAVIORAL|Brief motivational interviewing with standard health information|The manualized intervention is delivered individually in two phases by an interventionist trained in motivational interviewing. The intervention includes liver health information and explains connections with weight-related behaviors. The standard (control) group does not receive personalized feedback. The sessions are matched in duration and interventionist skill level with the enhanced (experimental) group.
223923340|NCT06886321|DEVICE|Prostate Irreversible Electroporation|The Prostate Irreversible Electroporation procedure was performed in our institution by a single urologist using an Prostate Irreversible Electroporation device and 18-gauge electrodes (Nanoknife®; Angiodynamics, Queensbury, NY, USA). All patients were positioned in lithotomy position under general anesthesia. A transrectal ultrasound was used to visualize the prostate and a brachytherapy grid was used to place the electrodes. An indwelling catheter was placed to empty the bladder. Four to six electrodes were placed through the perineum via the template grid to surround the targeted lesion. The lesion was defined based on prostate biopsy and MRI images. The active tip varied between 15- and 20-mm exposure. The distances between the electrodes were measured using TRUS and entered into the Nanoknife system. An initial ten pulses were delivered to ensure sufficient current was delivered between the electrodes (20-40 A). If sufficient then the remaining 80 pulses were given.
223923341|NCT06887868|PROCEDURE|Mobilization with movement|Manual application of a sustained translational or rotational glide force, either medial or lateral, on the tibia, while an active partial weight-bearing lunge movement was performed.
223923342|NCT06887868|PROCEDURE|Sham mobilization with movement|The physiotherapist mimicked the pain-reducing glide direction without applying glide force while the participants performed the active lunge movement. To achieve this, the physiotherapist's hands lightly touched the knee skin, with one hand on the tibia and the other on the femur over the joint surfaces.
223923343|NCT06887270|OTHER|Continued DOAC|The continued DOAC group will continue their DOAC peri-procedurally as routine without interruption.
224091855|NCT01274884|PROCEDURE|Tightrope fixation|Arthroscopic repair
224091856|NCT02313831|OTHER|Interval training|Patients of this group will be submitted to an interval training program
224091857|NCT02059083|BEHAVIORAL|Heart rate variability biofeedback|
224091858|NCT02059083|BEHAVIORAL|CBT|
224091859|NCT04870073|PROCEDURE|Retrograde autologous priming|Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.
223923344|NCT06887270|OTHER|Interrupted DOAC|The interrupted DOAC group will take their last DOAC dose on Day -2, unless their DOAC is Dabigatran and their creatinine clearance is \< 50mL/min (Cockcroft-Gault equation), in which their last dose will be on Day -3. The DOAC will be resumed on Day +1.
223923345|NCT06816771|DRUG|pazopanib|Given PO The dosage will be determined according to the participant's body surface area, with body surface area less than 0.75, 1 tablet, and 2 tablets for body surface area greater than 1. 0.75-1,1.5 tablets.
223923346|NCT06816771|DRUG|TGI chemotherapy|TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)
223923347|NCT06816771|DRUG|CIV chemotherapy|CIV chemotherapy (cyclophosphamide +Irinotecan + vinorelbine)
223923348|NCT06726811|DRUG|Droperidol injection|2.5 mg
223923349|NCT06694181|OTHER|AI-PERSONALIZED CLINICAL DECISION SUPPORT|AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
223923350|NCT06442995|DRUG|Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
223923351|NCT06442995|DRUG|Injection of Isotonic saline + 2 mg morphine into the epidural space|When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
223923352|NCT06680635|DIETARY_SUPPLEMENT|Flavonoid-enriched juice and a low-calorie diet|Orange juice enriched in flavonoids (14%: nobiletin, sinensetin, tangeretin) (200 ml/day) and low calorie diet
223923353|NCT06680635|DIETARY_SUPPLEMENT|Food supplement: placebo juice and a low calorie diet|Placebo juice (200 ml/day) and a low calorie diet
223923354|NCT06881316|OTHER|Caffeine|Participants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCAFF (1.2% w/v caffeine solution, Nature's Supreme). An MRI was performed before the LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The caffeine solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
223923355|NCT06881316|OTHER|CHO|Participants' solutions were prepared in separate Falcon Sterile Tubes: LSPTCHO (6% w/ v glucose solution, Protein Ocean, Turkey) An MRI was performed prior to LSPT. The solution was sweetened with non-caloric artificial sweeteners consisting of sucralose. The CHO solution was prepared in an equivalent saccharin base and shaken for 30 seconds in a vortex mixer to ensure distinguishability. Participants swished the solution in their mouth for 10 seconds before LSPT and then emptied it back into the container to be weighed again. To ensure that the solutions were not swallowed, the containers were measured before and after all MRs using a full precision balance (Etekcity, USA) accurate to 1 g/0.04 oz.
223923356|NCT06881316|OTHER|Control|For the control condition, no supplements were taken and only exercise was performed.
224091860|NCT04870073|DRUG|Mannitol|Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.
224091861|NCT04870073|PROCEDURE|Conventional Priming|The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.
224091862|NCT03313050|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
224280514|NCT06403813|BEHAVIORAL|mHealth Toolkit for Screening & Empowering Lives of Youth (mSELY-P) for Parents|mSELY is a preventive intervention tool to be used by adolescents and/or their parents as a self-help support modality. The mSELY-P is designed for parents to self-evaluate their adolescent's development and mental health, gain awareness about their adolescent's mental health status, and learn strategies and resources to support adolescents' mental health. The mSELY integrates 4 key mental health service functions: i) screening for common mental health problems (anxiety, depression, conduct problems) in adolescents and social-cognitive-behavioral-environmental risks in multiple domains; ii) a strength and weakness profile for adolescents' behaviors (to promote self-awareness); iii) tailored mental health literacy and promotion strategies, and iv) tailored referral resources (ii to iv are to be generated from the i screening results).
224091863|NCT03313050|BIOLOGICAL|Tdap|Tetanus, diphtheria, acellular pertussis vaccine
224091864|NCT03313050|BIOLOGICAL|polysaccharide|23-valent pneumococcal polysaccharide vaccine
224091865|NCT00094614|DRUG|Atropine|
224091866|NCT03604666|OTHER|Health care process with Nurse Navigator|"A Nurse Navigator will:~* Be present at the announcement consultation~* Give information on the outpatient circuit~* Offer assistance for patients over 75 years~* Complete onco-geriatric orientation questionnaires~* Take care of patients on the ambulatory circuit"
224280515|NCT06403813|OTHER|Control Tooklit|The toolkit will have the same screening questions, with information, but without any decision support functions.
224280516|NCT03591731|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
224280517|NCT03591731|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
224091867|NCT06599736|DEVICE|RhinAer Stylus|The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG1393, CAT1394), which is a 510(k) cleared (FDA - K221907) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy is also cleared for use in the US (FDA - K162810).
224091868|NCT04211337|DRUG|Selpercatinib|Administered orally
224091869|NCT04211337|DRUG|Cabozantinib|Administered orally
224091870|NCT04211337|DRUG|Vandetanib|Administered orally
224091871|NCT04630379|OTHER|Palliative Therapy|Visit with palliative care team
224091872|NCT04630379|OTHER|Quality-of-Life Assessment|Ancillary studies
224091873|NCT04630379|OTHER|Supportive Care|Visit with neuro-oncologist
223923357|NCT06870292|PROCEDURE|Posterior nasal nerve combined with anterior ethmoid neurotomy|"First, a vertical incision was made in the posterior portion of the middle nasal turbinate. Dissection was performed along the bone to elevate the mucosal flap to expose the thick orbital process of the vertical plate of the palatine bone and the sphenopalatine foramen. The 3-4 mm of mucosal and submucosal neurovascular bundles surrounding the sphenopalatine foramen were subjected to full radiofrequency ablation, directly to the bone. The mucoperiosteal flap is reposited back. The bilateral nasal cavity was packed with Merocel nasal pack and hemostasis was achieved.~The anterior ethmoidal nerves of the lateral nasal branch and septal branch of the nasal cavity were cut off with a plasma treatment needle. Below 30°, the mucous membrane of the posterior lateral wall of the nasal colliculus was cut down to the bone surface using the needle of the nasal endoscope plasma therapy instrument. The contralateral side was then treated in the same way, with an arc cut line and a length of 2cm."
223923358|NCT06870292|DRUG|Drug therapy group|Subjects will be treated with medication according to guideline recommendations when nasal-related symptoms occur. Oral antihistamines or nasal antihistamines are preferred, and nasal hormones (budesonide nasal spray), or a combination of two or three drugs, may be used in severe cases.
224280518|NCT03012893|DEVICE|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
224280519|NCT03012893|DEVICE|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
224280520|NCT03012893|PROCEDURE|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
224280521|NCT02653235|BIOLOGICAL|Salmonella typhi vaccination|
224280522|NCT02653235|BIOLOGICAL|Placebo|
224280523|NCT05548335|PROCEDURE|Ocular Ultrasound|1\. Patients presenting to the emergency department and have a normal head and/or ocular computed tomography scan will be considered for inclusion in this study. Study staff will discuss the study with the patient and obtain consent. At that point, operator will perform ocular ultrasound. Procedure will start with either the linear or microconvex probe. A single-use sterile gel packet will be used to apply gel to one closed eyelid. The probe will be placed with minimal pressure on the eye. A transverse measurement of the ONSD will be taken. In this same view the maximal transverse diameter of the eyeball will also be measured. Images of the eye with ONSD and ETD measurements will be captured. Repeat until three measurements have been obtained resulting in an average ONSD and ETD for that eye. Repeat for other eye. Switch probe and repeat on both eyes.
224280524|NCT06336993|DRUG|herbal compound|patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
224280525|NCT06336993|DRUG|Celecoxib|Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
224280526|NCT02030535|DRUG|olodaterol|free combination with tiotropium
223531484|NCT01146197|DRUG|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
223531485|NCT04863404|OTHER|Face mask with hybrid-hyrax|Face mask with hybrid-hyrax
223531486|NCT04863404|OTHER|Face mask with conventional bonded RME|Face mask with conventional bonded RME
223531487|NCT02893891|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
224091874|NCT04630379|OTHER|Survey Administration|Complete survey
223923359|NCT06815705|PROCEDURE|Vascularized lymphatic transplantation|"Preoperative ultrasonography was performed to check the distribution, quantity and size of axillary lymph nodes. During the operation, methylene blue was injected subcutaneously into the elbow fossa to make the axillary lymph nodes in area B and D chromogenic, and avoid damage to the arm drainage lymph nodes.~Adjusting the flap design according to the size of the defect. The perforating branches of lymphoid tissue in areas A and C of grade I were located about 3-5cm above the perforating branches of the skin, and moved towards the thoracic side to the lymphatic adipose tissue. Finally, the pedicle of the thoracic dorsal artery was separated, and the blood transport of the flap and the lymphatic adipose tissue was examined by fluorescence imaging and other methods. The lymphoid adipose tissue was placed in the neck area I and II, and fixed by suture. The arteriovenous microvessels in the thoracic dorsal were anastomosed to the vessels in the receiving area of neck."
223923360|NCT06814483|BEHAVIORAL|Experimental: A computer-based multimodal mind and body approach (cbMMBA)|cbMMBA will include three modules: BDJ, acupressure, and relaxation techniques including deep breathing, guided imagery, and progressive muscle relaxation.
224280527|NCT02030535|DRUG|tiotropium|free combination with olodaterol
224280528|NCT02030535|DRUG|Placebo|
224280529|NCT02030535|DRUG|tiotropium|fixed dose combination with olodaterol
224280530|NCT02030535|DRUG|olodaterol|fixed dose combination with tiotropium
224280531|NCT01878864|DRUG|Bupivacaine lozenge|
224280532|NCT01878864|DRUG|Lidocaine-adrenalin injection|
224280533|NCT01588548|DRUG|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
224280534|NCT05562648|OTHER|Manual therapy techniques|"Myofascial trigger points are determined and the physiotherapist applies a light and continuous local pressure on them with his/her finger, usually not more than 30 seconds, until the moment of muscle relaxation, and as a result, the pain is expected to decrease to 0 (zero) and he withdraws his finger. He can do 3-5 repetitions until he sees relaxation in the muscle and reduction/disappearance of the pain.~Spinal mobilization is defined as low-speed, non-trust, passive movement within or at the limit of joint range of motion. Mobilization is low-speed, non-trust, passive joint movement.~MUSCLE ENERGY TECHNIQUES The muscle energy technique is a treatment technique that includes alternating periods of resistant muscle contractions and active-assist stretching, mostly used by osteopaths, physiotherapists, and chiropractors."
223531488|NCT02893891|PROCEDURE|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
223531489|NCT02893891|PROCEDURE|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
223531490|NCT02893891|DEVICE|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
223531491|NCT07104513|DEVICE|Red Light|use red light twice per day, both eyes. use red light for one year in The RLRL-1year Group. use red light for two year in The RLRL-2years Group. red light for three years in The RLRL-3years Group.red light for more than three years in The RLRL- more than 3years Group.
223531492|NCT06416475|DIETARY_SUPPLEMENT|Mankai supplementation|The overall dose of the three Mankai duckweed beverages/day contains \~10 grams of dry matter.
223923361|NCT06814483|BEHAVIORAL|A standard cognitive training group|The program uses paper puzzles (Sudoku, crosswords, word-search, etc.) to engage subjects
224280535|NCT05562648|OTHER|Electrophysical agents|"TENS TENS is a low-frequency electrical current applied to the stimulation of sensory nerves, used for the inhibition of pain sensation. Pain inhibition of TENS is based on 3 basic mechanisms. These; gate control mechanism (segmental inhibition), release of endogenous opioids and reduction of excitability with repetitive stimulation (inhibition from pattern).~Ultrasound is an effective electrotherapy modality with a deep heating feature. In addition, it has been suggested that the analgesic effect of ultrasound occurs with the stimulation of sensory afferents and the activation of the gate control mechanism in the posterior horn of the spinal cord."
223531493|NCT06416475|OTHER|Water consumption|Water consumption
223531494|NCT02357303|DRUG|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
223923362|NCT06862947|PROCEDURE|Rectus Sheath Block|Bilateral rectus sheath block performed under ultrasound guidance using 15 ml of 0.4% ropivacaine on each side
223923363|NCT06862947|PROCEDURE|Placebo|Injection of 15 ml of 0.9% saline as a placebo under the same conditions as the experimental group.
224091875|NCT03970343|DEVICE|OPTIMIZER Smart System|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~1. Optimizer Smart or Optimizer Smart Mini~2. Vesta Charger or Guardio Charger~3. Two commercially available intravascular leads"
224091876|NCT05925205|PROCEDURE|Muscle energy technique combined with the physical therapy program.|A manual therapy technique
224091877|NCT05925205|PROCEDURE|Strain counterstrain technique combined with the physical therapy program|A manual therapy technique
224091878|NCT05925205|PROCEDURE|The physical therapy program|Electrotherapy and exercise.
224091879|NCT01189383|BIOLOGICAL|IL15-DC Vaccine|Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10\^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
224091880|NCT05960045|DIETARY_SUPPLEMENT|Direct Milk antigen reintroduction|Direct milk antigen re-introduction milk according to ESPGHAN guidelines
224091881|NCT05960045|DIETARY_SUPPLEMENT|Milk ladder|B: Milk ladder according to the iMAP guideline which are 6 weeks of gradual reintroduction starting with baked milk not direct antigen
224091882|NCT04977037|DEVICE|Active tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
223531495|NCT02357303|DRUG|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
223531496|NCT02357303|OTHER|Placebo|100mL of water
223923364|NCT06887946|OTHER|Medical couching and traditional|"The control group received traditional OHI using the tell-show-do method, which was personalized based on the individual PCR and GBI. The recommendations were tailored to each participant, based on personalized instructions to improve plaque control, decrease of gingival inflammation and facilitate optimal patient compliance, contributing to oral hygiene performance.~The intervention group was actively engaged in an iterative, collaborative process, based on the following steps:~Definition of the goals of oral hygiene and lifestyle styles according to the SMART model (Specific, Measurable, Achievable, Realistic, Timely):"
223923365|NCT06752057|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
223923366|NCT06752057|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
223923367|NCT06752057|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223923368|NCT06749639|GENETIC|PUMCH-E101 Injection（Low dose）|Single intravitreal injection
223923369|NCT06749639|GENETIC|PUMCH-E101 Injection（High dose）|Single intravitreal injection
223923370|NCT06753682|BEHAVIORAL|Healthy Plant Based Diet|Registered Dietician will assist in modifying the patient's diet
224280536|NCT05729854|OTHER|acupressure ( traditional and complementary medicine)|Acupressure will be applied to the shoulders, hands and legs of the women in the experimental group by the researcher.
223923371|NCT03215706|BIOLOGICAL|Ipilimumab|Specified dose on specified day
223923372|NCT03215706|BIOLOGICAL|Nivolumab|Specified dose on specified day
223923373|NCT03215706|DRUG|Carboplatin|Specified dose on specified day
223923374|NCT03215706|DRUG|Paclitaxel|Specified dose on specified day
223923375|NCT03215706|DRUG|Pemetrexed|Specified dose on specified day
223923376|NCT03215706|DRUG|Cisplatin|Specified dose on specified day
223923377|NCT06763965|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a multiple Intratumoral injection. The dose groups to be infusion were 1.0×10\^10 viral particle (VP) ,5.0×10\^10 VP and 2.5×10\^11 VP based on the 3+3 dose escalation principle.
223923378|NCT06760429|PROCEDURE|Pectoral Nerve Block Type II|In the PECS II group,once the needle tip reached the fascial plane between the pectoralis minor and serratus anterior muscles and there was no blood aspiration, 15 mL of 0.375% ropivacaine was injected. Then the needle was withdrawn until the needle tip reached the fascial plane between the pectoralis major and pectoralis minor muscles, and another 15 mL of 0.375% ropivacaine was injected. After the nerve block was implemented, the area of sensory block was marked, and the spread of the local anesthetic was monitored by ultrasound. Alcohol swabs and pinprick tests were used to detect cold and pain sensations.
224091883|NCT04977037|DEVICE|Sham tDCS|Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
224091884|NCT00261235|BEHAVIORAL|Supported Employment|
224280537|NCT02886676|DRUG|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
224280538|NCT03427801|DRUG|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
224280539|NCT00844870|BEHAVIORAL|stabilization training|training of arm function with the trunk stabilized
224280540|NCT00844870|BEHAVIORAL|auditory training group|response to an auditory signal
224091885|NCT00261235|BEHAVIORAL|Using Strengths in Employment System (USES)|
224091886|NCT06767969|DRUG|Acetaminophen|Acetaminophenl 500mg (500mg/50ml) was infused intravenously every 6 hours( a single infusion is completed within 15-30 minutes) from the beginning of endovascular treatment to 48 hours after treatment.
224280541|NCT02248012|DRUG|Everolimus , temozolomide|
224280542|NCT00537017|DRUG|Preladenant|5 mg BID capsules
224280543|NCT00537017|DRUG|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
224280544|NCT00537017|DRUG|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
224280545|NCT02847416|DEVICE|BreatheMAX breathing device|
224280546|NCT00198354|DRUG|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
224280547|NCT00198354|DRUG|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
223923379|NCT06760429|PROCEDURE|Subserratus Plane Block|In the RISS group,the linear ultrasound probe was placed in the sagittal plane at the level of the 5th to 6th thoracic vertebrae (T5-6), just medial to the scapula, to identify the trapezius, rhomboid major, and intercostal muscles. A 21-gauge puncture needle was inserted in a cranial-to-caudal direction into the plane between the rhomboid major and intercostal muscles. When there was no blood aspiration, 20 mL of 0.375% ropivacaine was injected. After that, the ultrasound probe was moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscles for performing the subserratus block at the level of the 8th to 9th thoracic vertebrae (T8-9). The puncture needle was advanced from the previous position, and when there was no blood aspiration again, an additional 20 mL of 0.375% ropivacaine was injected.
223923380|NCT06734221|DEVICE|Paclitaxel Coated Peripheral Angioplasty Balloon Catheter|"Paclitaxel coated peripheral angioplasty balloon catheters are catheters of over the wire (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty."
223923381|NCT03105336|BIOLOGICAL|axicabtagene ciloleucel|A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.
223923382|NCT03105336|DRUG|Cyclophosphamide|Administered intravenously
223923383|NCT03105336|DRUG|Fludarabine|Administered intravenously
223923384|NCT06786793|DEVICE|Computer-aided detection (CADe)|Endo-Aid CADe system is an AI-assisted computer-aided lesion detection application on ENDO-AID hardware. It uses a complex algorithm created via a neural network developed and taught by Olympus. With this new app, the sophisticated machine learning system can alert the endoscopist in real-time when a suspicious lesion appears on the screen. The image from the vision processor is transferred to the CADe device. The computer application recognizes the shape of the polyps and marks their place on the monitor screen.
223923385|NCT06788392|OTHER|reminiscence therapy|Reminiscence Therapy is a supportive care model that has been used in recent years and increases life comfort.
223923386|NCT06760013|BEHAVIORAL|Su Jok Therapy|The researcher, who has a Su-Jok practitioner certificate, applied pressure for 1-2 minutes on the active point on the meridian (the area between the 3rd and 4th fingers pointing to the uterus) that provides energy flow in the palm in 20-minute periods, with the help of a diagnostic probe (diagnostic stick). The point will be determined. Once this point is detected, a massage will be performed on the point. The massage will be applied with a 10-minute rest period between each two periods.
224091887|NCT06661213|DRUG|Tapinarof|A thin layer of tapinarof cream is applied to affected areas once daily.
224280548|NCT04334850|PROCEDURE|Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.
224280549|NCT04334850|OTHER|Usual antibiotic treatment|The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
223923387|NCT04705896|BIOLOGICAL|20-25% Albumin fluid (100 mL)|"Participants will be randomized to receive albumin (20-25%) during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (i.e. for SLED sessions, at 0 and 4 hours; for IHD sessions, at 0 and 2 hours)."
224091888|NCT03042000|OTHER|non-NCRT|without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)
224091889|NCT03042000|OTHER|NCRT|the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)
224091890|NCT03042000|DRUG|capecitabine with oxaliplatin|combined chemotherapy with capecitabine with oxaliplatin
224091891|NCT03042000|DRUG|capecitabine|single-agent chemotherapy with capecitabine
224091892|NCT03042000|PROCEDURE|TEM|transanal endoscopic microsurgery (TEM) excision of the lesion
224091893|NCT03042000|PROCEDURE|radical resection|radical resection of rectal cancer
224091894|NCT00875069|OTHER|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
224091895|NCT02069002|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|
224280550|NCT02821949|BIOLOGICAL|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
224280551|NCT01280227|BEHAVIORAL|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
224280552|NCT00802373|DRUG|Solifenacin succinate|oral
224280553|NCT00802373|DRUG|Tolterodine|Oral
223531502|NCT03666390|DRUG|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
223531503|NCT03666390|DRUG|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
223531504|NCT04273269|GENETIC|LYS-GM101|LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection
223531505|NCT00294749|DRUG|Ciprofloxacine|
223531506|NCT07127250|OTHER|Walking sticks|Walking with walking sticks and pedometer Daily walking activity recorded in a logbook
223531507|NCT03440801|DEVICE|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
223531508|NCT03440801|DEVICE|Xience|Durable-polymer everolimus-eluting stent Xience
223923388|NCT04705896|OTHER|0.9% Normal Saline (100 mL)|"Participants will be randomized to receive normal saline 100 mL boluses during their RRT sessions (either CRRT, SLED or IHD) in ICU. Once randomized the same fluid will be given for all subsequent RRT sessions for up to 14 days in ICU.~RRT sessions will be determined as per the treating physician. Boluses will be given at the start of, and halfway through, RRT sessions (e.g. for 8 hour SLED sessions, at 0 and 4 hours; for 4 hour IHD sessions, at 0 and 2 hours; for CRRT, after starting/randomization then every 12 hours while continuing on CRRT)."
223923389|NCT06819423|DEVICE|AI fundus photography|In the dark room, Canon CR-2AF automatic mydria-free fundus camera was used to collect images of both eyes of the patients, and one fundus photo was taken with macula as the center of each eye
223923390|NCT06817629|OTHER|Effects of ventilation with tidal volume adjusted on driving pressure on ventilation/perfusion ratios and hemodynamics in ARDS|To ventilated patients with ARDS with an objective of driving pressure than a tidal volume set on predicted body weight
223923391|NCT06879444|OTHER|Core Muscle testing and patient reported outcome measures|These are the situation evaluation parameters. It presents the data of the participants at the time of evaluation.
223923392|NCT06870084|OTHER|Ultrasonography|The masseter muscle thickness measurements were performed in B mode of ultrasound, midline between the zygomatic arch and mandibular plane, parallel to the mandibular plane and perpendicular to the mandibular ramus. Prior to the examination being performed in the resting position, the patient was instructed to make minimal contact between the lips without the teeth touching each other.The first USG image was recorded in this position. The patient was then requested to clench their teeth as firmly as possible, after which a second USG image was recorded from the same area. The thickness of the muscles was measured again on second recorded images. To ensure the reliability of the measurements, these procedures were repeated by the same researcher after the patients rested for five minutes.
223923393|NCT06870084|OTHER|Lateral cephalometric radiography|Standard lateral cephalometric radiographs were obtained from the patients.
223923394|NCT06870084|OTHER|Facial photograph|Standard facial photographs were taken from a distance of 1.5 metres.
224280554|NCT02148354|BEHAVIORAL|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
224280555|NCT02813382|DRUG|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
224280556|NCT02813382|DRUG|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
224280557|NCT02813382|DRUG|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
224280558|NCT05228249|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood ASCT
224280559|NCT05228249|DRUG|Carmustine|Given IV
224280560|NCT05228249|DRUG|Cytarabine|Given IV
224280561|NCT05228249|DRUG|Etoposide|Given IV
224280562|NCT05228249|BIOLOGICAL|Loncastuximab Tesirine|Given IV
224280563|NCT05228249|DRUG|Melphalan|Given IV
224280564|NCT01362296|DRUG|GSK1120212|Oral once daily
224280565|NCT01362296|DRUG|docetaxel|IV once every 3 weeks
224280566|NCT03114345|OTHER|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
224280567|NCT03114345|OTHER|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
224280568|NCT02528409|DRUG|Vortioxetine|Medication currently approved for major depression.
224280569|NCT02528409|DRUG|Placebo|
224280570|NCT06262503|DEVICE|Virtual Reality|Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
224280571|NCT06262503|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
223531512|NCT04221529|DRUG|Atezolizumab|1200 mg i.v. on day 1 of each cycle
223531513|NCT02339051|BEHAVIORAL|Jumping on one leg|
223531514|NCT05643495|DRUG|VX-864|Tablets for oral administration.
223531515|NCT00791635|OTHER|Quality-of-Life Assessment|Ancillary studies
223531516|NCT00791635|OTHER|Questionnaire Administration|Complete questionnaires
223531517|NCT02257528|OTHER|Laboratory Biomarker Analysis|Correlative studies
223531518|NCT02257528|BIOLOGICAL|Nivolumab|Given IV
223923395|NCT06870084|OTHER|Weigth and Heigth|The Body Mass Index is calculated by measuring with a standardised scale and height chart.
224280572|NCT06262503|DEVICE|Mirroring Therapy|"Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb."
224280573|NCT06262503|OTHER|Phantom Exercises|The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
224280574|NCT01834027|BEHAVIORAL|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
223531519|NCT04765397|PROCEDURE|Effect of different resectoscope fluids on optic nerve diameter measured by ultrasound|During the operation Blood pressure, pulse minute the number of irrigation solutions used, and intravenous serum amounts, operation time will be saved. If there is an abnormal parameters or increased optic nerve sheath surgical team will be informed.
223531520|NCT03756961|DRUG|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
223531521|NCT03756961|BEHAVIORAL|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge. This will be part of patients in Phase 2
223923396|NCT06870084|OTHER|Electronic caliper|The intermaxillary distance is measured from the cervical level of the palatal surfaces of the first permanent molars to their mesial corners using an electronic caliper.
223923397|NCT06952985|DIETARY_SUPPLEMENT|Sugar free chew gum|Chew gum has a role in ERAS protocol which is significant in early post operative recovery as compared to normal routine care methods
223923398|NCT06952985|OTHER|Nil Per Oral|According to classic protocols patient were kept nil per oral till bowel sounds were audible
223923399|NCT04201184|BEHAVIORAL|Newly created cultural components, adapted Family Spirit lessons, adapted CETA modules|Caregivers will receive 12 lessons, weekly, over a period of 12 weeks. Full curriculum contains: 4 lessons on cultural connection and traditions, 4 lessons on parenting adapted from Family Spirit intervention, and 4 lessons on stress and trauma adapted from CETA. modules
223923400|NCT04201184|BEHAVIORAL|Active nutrition control|The active control condition will receive nutrition information, weekly food boxes and recipes. Recipes will be developed based on seasonal foods and a shopping list for making future meals will be included.
223923401|NCT00945724|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|"Weeks 1-15:~* 6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~* Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~* IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4\&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)"
223923402|NCT06190600|OTHER|High Intensity Interval Training (HIIT)|HIIT training twice a week throughout the chemotherapy: treadmill, elliptical, stationary bicycle and indoor rower. The intensity of physical activity will be increasing during consecutive mesocycles. Each training session will begin with a 10-min. wole-body warm-up session at 50-60% hear rate (HR) max. Mesocycle 1 - one month with 4 sets of 1 min. 45 sec. of exercise at a maximal intensity of 75% HR max. Mesocycle 2 with exercises at 80% to 90% HR max divided into 3 periods: 1/ one month, session of 5 sets 1 min. 30 sec. each; 2/ two months, sessions of 5 sets 1 min. 45 sec. each; 3/ two months, sessions of 5 sets 2 min. each. Moreover patients will be instructed to individually perform- a 45-min. aerobic training session (e.g.: walking, jogging, roller skating, swimming) once a week, in patient's own time.
223923403|NCT06190600|DRUG|neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)|Patients aged 18 to 40 in good physical condition (Eastern Cooperative Oncology Group (ECOG) scale 0-1) who are set to receive neoadjuvant chemotherapy will be selected. Criteria for entry into the study include proper liver, kidney and bone marrow function as well as heart ejection fraction of ≥ 50%. Treatment will be carried out according to 4 x AC regimen (doxorubicin 60 mg/ m2 cyclophosphamide 600 mg/ m2 i.v. every 21 or every 14 days + pegfilgastrim) followed by 12 x paclitaxel 80 mg/ m2 every 7 days and in the case of HER2 positive tumors trastuzumab ± pertuzumab (according to SPC).
223923404|NCT06190600|OTHER|Standard Supportive Care|Patients will be asked to perform 150-300 min. of moderate-intensity aerobic activity or 75-150 min. of vigorous aerobic activity. Each participant will be monitored by an activity watch worn at all times by the patient.
223923405|NCT05598957|DIAGNOSTIC_TEST|Vitamin D Binding protein|Vitamin D-free and bioavailable metabolites were calculated by using Bikle and Vermeulen methods with using albumin, 25-OH vitamin D, vitamin D binding protein (ELİSA kit) levels
223923406|NCT05897047|COMBINATION_PRODUCT|Additional interventional telemedical management|Predefined additional telemedical management including regular telemedicine visits and automatic data transfer (e.g. vital signs, well-being, medication plan laboratory data and chat) between the patient at home and KTC through a certified smartphone application.
223923407|NCT01612351|DRUG|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
223923408|NCT01612351|DRUG|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
223923409|NCT01612351|DRUG|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
224091896|NCT02069002|BEHAVIORAL|Applied relaxation group therapy|
224091897|NCT02069002|BEHAVIORAL|Information session (psychoeducation)|
224280575|NCT01834027|BEHAVIORAL|No music|In this group no music will be played in PACU
223923410|NCT01612351|DRUG|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
223717475|NCT05814978|OTHER|Experimental Scapular Therapeutic Exercise Group|"All subjects will perform a program of scapular therapeutic exercises including: neuromuscular control/strength - scapular therapeutic exercises that leads to, at least, moderate muscular activity levels; and stretching exercises.~The intervention period will be of 8 weeks, considering in-person and/or home sessions."
223923411|NCT01612351|DRUG|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
223923412|NCT01612351|RADIATION|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
223923413|NCT01612351|RADIATION|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
223923414|NCT01612351|PROCEDURE|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
223923415|NCT03512301|DEVICE|CAMCI|CAMCI is a computerized screening tool for the assessment of cognitive status. CAMCI accurately assesses cognitive performance using standard neuropsychological tests of memory, attention, and executive ability modified for computer administration, and an innovative Virtual Environment task, testing domains such as incidental memory, not easily assessed using paper-pencil tests. Computer-administered tasks ensure standard administration and scoring, avoiding inter-site and inter-examiner variability. The CAMCI battery consists of tasks testing multiple aspects of cognitive function, and a series of self-report questions administered via tablet computer. Using touchscreen technology for response input, CAMCI takes approximately 15-20 minutes to complete.
223923416|NCT03512301|DIAGNOSTIC_TEST|MoCA|"The Montreal Cognitive Assessment (MoCA) is a rapid screening tool used to detect mild cognitive impairment (MCI), assessing cognitive domains (visuospatial skills, executive function, memory, attention, language, and orientation). Individual test scores are summed into a total score from 0 (worst) to 30 (best). Individuals may achieve any score within that range. Individual test scores are not reported.~Scores:~26-30 considered Normal; 19-25 may suggest Mild Cognitive Impairment (MCI); 10-18 can suggest moderate impairment; \< 10 may indicate severe impairment"
223923417|NCT03512301|DIAGNOSTIC_TEST|Clinical Adjudication|"Cognitive status assessed by traditional neuropsychological tests measuring visuospatial skills, executive function, memory, attention, language, orientation. Results compared to age-adjusted norms, reviewed by expert neuropsychologists for consensus classification, per Univ of Pittsburgh Alzheimers Disease Research Ctr and Ntl Alzheimers Coordinating Ctr, and Alzheimer's Assoc criteria. Final classification adjusted per clinical judgment.~Impaired: ≥3 scores ≥2SD below norms Indeterminate: ≤2 scores \>1SD below norms Normal: Neither criteria met. Total and domain scores not reported."
223923418|NCT06957730|DEVICE|Phonak Audeo Infinio Hearing Aid|Commercially available receiver-in-canal (RIC) style hearing aid manufactured by Sonova.
223923419|NCT06953791|DIETARY_SUPPLEMENT|aCDED + Modulen|"Unique diet + partial enteral nutrition (PEN): This group will receive as follows:~* Weeks 1-6: 50% of dietary needs from PEN (Modulen, ModuLife phase I) and 50% from a limited whole food diet~* Weeks 7-12: 25% of dietary needs from PEN (Modulen, ModuLife phase II) and 75% from a limited whole food diet~* Weeks 12-48: liberal diet and Modulen as needed"
223923420|NCT06953791|DRUG|Prednisolone|1 mg/kg, tapering scheme
223923421|NCT05968703|DEVICE|Combined STN+NBM DBS|This intervention is a 4-lead deep brain stimulation approach targeting the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM)
223923422|NCT06952634|DRUG|ESK-001|Single oral dose of ESK-001 in participants from all cohorts
223923423|NCT06061939|OTHER|Blood Flow Restriction training with Oclussion Cuff.|A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
223923424|NCT06953895|PROCEDURE|Mulligan's Mobilization With Movement|The Mulligan's MWM group received mobilization with movement in the glenohumeral joint, as described by Mulligan. The participant was seated, and the physiotherapist was placed on the opposite side to the affected shoulder with the thenar eminence of one hand over the anterior aspect of the humeral head, and the other hand over the spine of the scapula posteriorly of the affected shoulder. The hand over the humeral head performed a posterolateral glide, while the other hand stabilized the scapula. This maneuver was sustained while the participant asked to raise the arm in scapular plan (as explained above) without pain. The physiotherapist previously determined the amount of posterolateral pressure which was the best to abolish the pain during shoulder scaption for each participant. The participants performed three sets of 10 trials with a resting time of 30 seconds between each set. After intervention was allowed a resting time of three minutes.
224091898|NCT02963376|DRUG|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
224091899|NCT02963376|DRUG|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
224091900|NCT02963376|DRUG|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
223923425|NCT06953895|PROCEDURE|Active Mobilization|"In the Placebo group, no effective intervention was performed, the participant was asked to raise the affected arm in scapular plane without pain, while the physiotherapist placed their hands-on shoulder, with the same manual contacts described in Mulligan's MWM group, but without performing any pressure.~The participants performed three sets of 10 trials with a resting time of 30 seconds between each set. After intervention was allowed a resting time of three minutes."
224091901|NCT02963376|DRUG|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
224280576|NCT04909645|DIAGNOSTIC_TEST|Clearsight (finger cuff)|Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)\*80/CO.
224280577|NCT04893941|DRUG|CM310|IL-4Rα monoclonal antibody
224280578|NCT04893941|DRUG|Placebo|Placebo
224280579|NCT01939106|DEVICE|One Piece Drainable Pouch|
224280580|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement A|Oral administration of Supplement A
224280581|NCT05336994|DIETARY_SUPPLEMENT|Multivitamin/mineral supplement B|Oral administration of Supplement B
224280582|NCT04734782|DIAGNOSTIC_TEST|Determination of antibodies in maternal serum IgG for respiratory syncytial virus|By venipuncture, a blood sample will be taken and the levels of anti-RSV IgG antibodies will be processed in serum by commercial techniques.
223923426|NCT06953726|DRUG|Apixaban|Study participants will be randomized to twice daily oral administration of apixaban 5mg. Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg/dL.
223923427|NCT06953726|DRUG|Rivaroxaban|Study participants will be randomized to daily oral administration of rivaroxaban 20mg. Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL/min.
223923428|NCT06480994|DIAGNOSTIC_TEST|Routine Assays on fresh plasma|"Routine coagulation tests using STA-R Max analyzer :~Prothrombin Time (PT) activated Partial Thromboplastin Time (aPTT Thrombin Time (TT) Fibrinogen Anti-Xa activity"
223923429|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on fresh plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
224091902|NCT02963376|DRUG|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
224091903|NCT02963376|DRUG|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
224091904|NCT05777733|DRUG|n-acetylcystine|Single daily oral administration of N\_acetylcystein on dose 10mg /kg/day
224091905|NCT02514759|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
224091906|NCT04920032|DRUG|TAS-102|Given PO
224091907|NCT04920032|DRUG|Irinotecan|Given IV
224091908|NCT04920032|COMBINATION_PRODUCT|Standard Treatment|6 cycles for a 2-week regimen (infusional 5FU based) and up to 4 cycles for a 3-week regimen (oral capecitabine based) after randomization
224091909|NCT04920032|DIAGNOSTIC_TEST|Signatera MRD ctDNA Assay|To be performed within 6-8 weeks of Cycle 1 Day 1. A Mid-treatment ctDNA is to be completed within 6 - 8 weeks of starting treatment. ctDNA is to also be completed within four weeks after completion of study treatment (+/- two weeks)
224091910|NCT02847598|DRUG|BIIB059 (litifilimab)|Administered as specified in the treatment arm.
224091911|NCT02847598|DRUG|Placebo|Administered as specified in the treatment arm.
224091912|NCT02848833|DRUG|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
224091913|NCT02848833|DRUG|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
224091914|NCT06351033|DIETARY_SUPPLEMENT|High ozonide (HOO) ozonated oil|ozonated oil with high ozonides (HOO) administered orally (os) in gastro-resistant capsules
224091915|NCT05133102|OTHER|Sample collection|Collection of saliva sample
224091916|NCT06856707|DEVICE|Use of the MIRA Surgical System during surgery|Use of the MIRA Surgical System to perform robotically assisted colorectal surgery.
224091917|NCT00369031|BIOLOGICAL|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
224091918|NCT00369031|BIOLOGICAL|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
224091919|NCT00369031|BIOLOGICAL|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
224091920|NCT06299280|OTHER|dual task training|students will be given additional cognitive tasks while exercising in physical education class
224091921|NCT06299280|OTHER|single task training|students will exercise in physical education class, without additional cognitive tasks
224091922|NCT06682442|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
224091923|NCT06682442|PROCEDURE|Radiographic Imaging|Undergo imaging procedure
224091924|NCT06682442|PROCEDURE|Biospecimen Collection|Blood samples will be collected
224091925|NCT06695663|BEHAVIORAL|Referral and communication skills learning|assigned to receive a brief, live, experiential training on the referral process and communication strategies.
224091926|NCT06695663|BEHAVIORAL|Written guide to the referral process|assigned to receive only written information about the referral process
224091927|NCT06695663|BEHAVIORAL|Empowered Generations (eGen): parent training|eGen is a six-session parent training program provided by therapists via video chat online to parents with a child between the ages of 3-8 years.
223923430|NCT06480994|DIAGNOSTIC_TEST|New Clinical Decision Support on frozen plasma|D-Dimer and fibrin formation assays on STA-R Max analyzer. Calculation of the exclusion score using an algorithm (manual or based on Machine Learning) compared to a Clinical Decision Support cut-off.
223923431|NCT05038150|DRUG|SGN1|The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
223923432|NCT04823247|DRUG|Tildrakizumab|As provided in real world clinical practice.
223923433|NCT06952569|OTHER|IKE System|Age-gate the access and activation of a device to authorized users of legal age
223923434|NCT06952764|OTHER|Seizure risk forecast|Participants are provided with daily risk estimates about upcoming seizure likelihood.
224091928|NCT06695663|BEHAVIORAL|control|The control condition consists of a single scripted session, in which therapists guide the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) vetted parenting advice websites; (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools; and (d) a list of culturally tailored parenting advice websites.
224091929|NCT06629610|BEHAVIORAL|DAiLY|The 2-year intervention includes three components, all supported by social media. Home-Based Workshops will be delivered by community members to increase knowledge and skills related to food choices, and to emphasize the importance of physical activity. Emphasis is placed on the benefits of consuming subsistence foods, as well as healthy store-bought foods. Food store modifications will increase access to healthy foods in local stores by working with store managers to stock and promote affordable healthy foods, and will provide participants with opportunities to implement what they have learned in HBWs. Point of purchase promotions, educational displays, taste tests and cooking demonstrations, will identify and promote these foods to community members. Physical activity promotion will include community-wide traditional activities, such as traditional dance, sports events, and berry festivals. Fitbits will be used as a motivational tool for participants to track their progress.
224280583|NCT03079388|DIETARY_SUPPLEMENT|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
223531522|NCT03756961|DRUG|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
223923435|NCT06952764|OTHER|Control seizure risk forecast|Participant receive uninformative control forecast
223923436|NCT06953518|DIETARY_SUPPLEMENT|Qualia Senolytic|Qualia Senolytic manufactured by Qualia Life Science
223923437|NCT06744777|DRUG|Ribavirin|Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.
223531523|NCT03756961|DRUG|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
223717476|NCT04998461|BIOLOGICAL|urine collection|To isolate urine stem cells, a sample of 30ml minimum an 100ml maximum as a function of the patient, will be collected in a single time in a sterile flask during collection for the nephrologic exams. A transcriptome analysis of USC will be performed.
223717477|NCT04068662|BEHAVIORAL|Pregnant Moms' Empowerment Program|The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.
223923438|NCT06744777|OTHER|Standard Treatment|"The standard treatment for dengue fever includes supportive care measures aimed at managing symptoms and preventing complications. These measures typically involve:~Intravenous (IV) fluid therapy for rehydration and maintaining hemodynamic stability.~Platelet transfusion as needed, based on clinical assessment and platelet counts.~Antipyretics for fever management (excluding non-steroidal anti-inflammatory drugs to prevent bleeding risks).~Continuous monitoring of vital signs and blood parameters, including platelet counts and hematocrit levels.~No antiviral drugs or additional pharmacological interventions are included in the standard treatment protocol."
223923439|NCT05927649|DRUG|Omaveloxolone|Omaveloxolone capsules
223923440|NCT05927649|DRUG|Moxifloxacin|Moxifloxacin capsules
223923441|NCT04224246|DRUG|Gamma Hydroxybutyrate|Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
223923442|NCT03520374|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
224091930|NCT06689410|OTHER|blood or saliva sample|Collection of blood or saliva
224091931|NCT04167345|DRUG|VX-814|Tablet for oral administration.
224091932|NCT04167345|DRUG|Placebo|Placebo matched to VX-814 for oral administration.
224091933|NCT05496855|OTHER|Conventional follow-up|Patients in the conventional/usual care arm will be treated according to current conventional follow-up regimen with PROs, blood tests, and face-to-face visits with an experienced nurse or a rheumatologist every 6 months. They can contact the hospital if they are experience worsening of their disease.
224280584|NCT03079388|DIETARY_SUPPLEMENT|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
224280585|NCT03079388|DRUG|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
224280586|NCT03079388|DRUG|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
223531524|NCT03756961|DEVICE|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
223531525|NCT03756961|DRUG|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
223923443|NCT03496181|BEHAVIORAL|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
223923444|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
223923445|NCT03496181|DIAGNOSTIC_TEST|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms\* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
223923446|NCT04660526|OTHER|Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators|EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch
223923447|NCT04660526|OTHER|Systematic bystander resuscitation instruction by 911 operators|911 operators will be able to describe how to administer CPR over the phone.
223923448|NCT04660526|OTHER|Comprehensive community training of lay people in CPR and AED use.|Training of lay people regarding CPR and AED use.
223923449|NCT04660526|OTHER|Optimized first responder performance including earlier use of AEDs.|First responders will recognize where AEDs are located and use them appropriately
223923450|NCT04050280|DRUG|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)|"Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days."
223923451|NCT06532097|BEHAVIORAL|Physical and behavioral smartwatch-based activation|We used smartwatches to provide an interactive tool for delivering a mixed intervention of physical and behavioral activation, with the former addressing physical activity level and the latter pleasant activities including and beyond physical activity (e.g., social, relaxing activities). Moreover, given the relationship with physical activity level, we additionally incorporated digital insomnia exercises that have also shown large effects in the amelioration of depression.
223923452|NCT06237270|PROCEDURE|Nerve transfer surgery for elbow flexion|A functioning but less important nerve (e.g. spinal accessory nerve, phrenic nerve, fascicle of median nerve, or fascicle of ulnar nerve) was transferred to nerves innervating biceps or brachialis muscle to restore elbow flexion.
223923453|NCT06548009|DIAGNOSTIC_TEST|Metabolomics and other blood samples|Blood samples taken with the objective of identifying a diagnostic test
224091934|NCT05496855|OTHER|Remote monitoring|"The patients in the remote monitoring arm will use a web-app (Youwell) for self-reporting patient reported outcomes (PROs) and CRP/ESR, displaying results for PROs over time, and for synchronous (video) or asynchronous (chat) communication with healthcare providers. The patients will receive a SMS reminder for tasks (e.g., self-reporting PROs or registering results from blood tests) every month.~A study coordinator/nurse will monitor the PROs and blood test (CRP/ESR) results, and respond to chat messages. Based on the algorithm, a triaging functionality in the Youwell platform will aid healthcare providers in highlighting which patients needs attention."
224091935|NCT02507583|DRUG|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
224091936|NCT06695221|DIETARY_SUPPLEMENT|Traditional Kefir|350 mL/day of traditional fermented/prepared kefir
224091937|NCT06695221|DIETARY_SUPPLEMENT|Milk (placebo)|350 mL/day of commercial 2% fat milk
224091938|NCT02229422|DRUG|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~* On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~* On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~* On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~* On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
224091939|NCT00191373|DRUG|Gemcitabine|
224091940|NCT00191373|DRUG|Trastuzumab|
224091941|NCT05067010|OTHER|Detailed ophthalmologic examination|"* Visual acuity~* Eye pressure measurement~* Eye crystalline examination~* Fundus examination~* Optical coherence tomography of the retina~* Retinophotos"
224280587|NCT03079388|OTHER|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
223923454|NCT05134142|OTHER|Electronic Health Record Review|Undergo medical record review
223923455|NCT05134142|OTHER|Physical Performance Testing|Undergo physical performance testing
223923456|NCT05134142|OTHER|Quality-of-Life Assessment|Complete assessments
223923457|NCT05134142|OTHER|Questionnaire Administration|Complete questionnaire
223923458|NCT03512405|BIOLOGICAL|Blinatumomab|Given IV
224280588|NCT03079388|DRUG|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
223923459|NCT03512405|OTHER|Laboratory Biomarker Analysis|Correlative studies
223923460|NCT03512405|BIOLOGICAL|Pembrolizumab|Given IV
223923461|NCT06020261|BEHAVIORAL|Parent Management Training|developing parenting skills and competencies dealing with oppositional and irritable behaviors in the child.
224091942|NCT06724445|BEHAVIORAL|Thabo cartoon|The animated cartoon features Thabo, a Black South African man living with HIV. Through his narrative, viewers follow his daily experiences managing his condition and confronting societal stigma in a South African context. The story explores his interactions with family, friends, and community members, highlighting both challenges and moments of resilience. The animation concludes with Thabo delivering an anti-stigma message directly to viewers.
224091943|NCT06724445|BEHAVIORAL|Steve cartoon|The animated cartoon follows Steve, a White man living with HIV. His narrative parallels Thabo's, showing his daily experiences managing HIV and facing societal stigma. The story depicts his interactions with family, friends, and community members, presenting the same situations and challenges as in Thabo's story. The animation ends with Steve delivering the same anti-stigma message to viewers.
224091944|NCT06926049|OTHER|The Effect of The Mindfulness-Based Psycho-Educational Program Focused on Emotions|The mindfulness based psychoeducation program focusing on emotions that aims to reduce the difficulties in regulating emotions and depressive symptoms in schizophrenia patients and to increase the level of hope.
224091945|NCT06734767|BEHAVIORAL|Mindfulness Based Stress Reduction 8-week course|The Mindfulness Based Stress Reduction (MBSR) 8-week course is an evidence-based curriculum that has been taught for over 40 years and is offered world-wide, teaching mindfulness skills and practices such as meditation.
224091946|NCT06742411|DRUG|XELOX+Sintilimab+HBOT|"Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria."
224280589|NCT03079388|DRUG|Albendazole|Single dose albendazole 400mg given in the second trimester.
224280590|NCT03079388|COMBINATION_PRODUCT|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
224280591|NCT04217538|OTHER|clinical exam|clinical oral examination
224280592|NCT04899076|DEVICE|Stool Processing Kit|The Stool Processing Kit is a centrifuge-free stool processing solution that allows preparation of stool samples for testing with the Xpert Ultra MTB/RIF assay
224280593|NCT06878222|DRUG|Neoadjuvant Chemotherapy|paclitaxel, 135-175mg/m2, q3w, 3 cycles
224280594|NCT06878222|DRUG|Neoadjuvant Chemotherapy|cisplatin, 75-80mg/m2, q3w, 3 cycles
224091947|NCT06889766|BIOLOGICAL|NY-ESO-1 TCR redirected autologous T cell product|Ex vivo expanded autologous CD4+/CD8+ cells expressing the transgenic TCR I53F recognizing NY-ESO-1 peptides presented on tumor cells in the context of HLA-A\*02. The LauT-1-ACT infusion contains a minimum of 3x10\^8 transduced cells (i.e. CD3+vβ13.1+) and a maximum of 1x10\^10 total cells.
224280595|NCT06878222|DRUG|Immunotherapy|Iparomlimab and Tuvonralimab, 5mg/kg, q3w, 3cycles
224280596|NCT06878222|PROCEDURE|Radical surgery|After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo radical hysterectomy plus lymphadenectomy
224280597|NCT06878222|PROCEDURE|Fertility-preserving surgery|After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo Fertility-preserving surgery. For stage IB1/IB2 patients, conization or simple trachelectomy plus lymphadenectomy will be performed. For stage IIA1/IIA2 patients, radical trachelectomy plus lymphadenectomy will be performed.
224280598|NCT06715475|DIETARY_SUPPLEMENT|Food containing plasmalogen|Take five capsules per day in the morning.
224280599|NCT06715475|DIETARY_SUPPLEMENT|Food not containing plasmalogen|Take five capsules per day in the morning.
224280600|NCT06732830|DEVICE|DayDrop Advanced ophthalmic drop|The patient will administer 1 or 2 drops of DayDrop Advanced in each eye 3 times a day for 3 months.
224280601|NCT02582307|DRUG|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
223923462|NCT04274881|PROCEDURE|Catheterization of internal jugular vein|"The right internal jugular vein will be cannulated under transesophageal echocardiographic (TEE) guidance in order to place the catheter tip in the mid-SVC.~The length of the catheter required to place the tip at the mid-SVC as guided by TEE will be regressed on the C-length or on the distance from the entry point to the surface point corresponding to the mid-SVC on the chest wall in order to obtain a predictive equation.~The accuracy of either equation will be assessed by estimation of the standard error of the estimate (SEest)."
224280602|NCT02582307|DRUG|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
223923463|NCT06435260|DRUG|Camrelizumab+chemotherapy|"Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles."
223923464|NCT06435260|RADIATION|hypofractionated radiotherapy|Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),
223923465|NCT04425018|DRUG|Paclitaxel|Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.
223923466|NCT04425018|DRUG|Pertuzumab|Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
223923467|NCT04425018|DRUG|Margetuximab|Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.
223923468|NCT04425018|DRUG|Trastuzumab|Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.
223923469|NCT03554902|PROCEDURE|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
223923470|NCT03983382|DIAGNOSTIC_TEST|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
223923471|NCT01161732|PROCEDURE|Early surgery|Early surgery is performed within 2 months of randomization.
223923472|NCT05239169|DRUG|Durvalumab|Durvalumab at a fixed dose of 1500 mg as an IV infusion over 1 hour, on day 1 together with the Tremelimumab infusion. Durvalumab only infusion to be repeated every 4 weeks for a maximum of 12 months on day 1 of each cycle.
224091948|NCT06889766|RADIATION|Low-dose irradiation|1Gy will be administered using tomotherapy (Accuray) to all irradiable lesions.
224091949|NCT06889766|DRUG|Non-myeloablative lymphodepleting chemotherapy|Fludarabine (30 mg/m2 x 4 days, from D-6 to D-3) and cyclophosphamide (2400 mg/ m2 x 2 days, on days -6 and -5) are administered as an IV infusion. The cyclophosphamide dose may be reduced to 1800mg/m2 on days -6 and -5, if the patient has previously been exposed to significant cumulative doses of chemotherapy)
224091950|NCT06895525|DIETARY_SUPPLEMENT|HellenCare|2 g, twice daily, to be taken on an empty stomach.
223717478|NCT04068662|BEHAVIORAL|Nondirective Support Group|Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
223717479|NCT00056524|DRUG|AVP-923|
223717480|NCT02924779|OTHER|No intervention|Retrospective observational study
223717481|NCT02837094|DRUG|C19-A3 GNP|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
223717482|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
223923473|NCT05239169|DRUG|Tremelimumab|Tremelimumab at a fixed dose of 300 mg as an IV infusion over 1 hour on day 1 of cycle 1.
223923474|NCT05239169|DRUG|Capecitabine|Capecitabine at 1250 mg/m² p.o. twice a day on days 1 to 14 of a 3-weekly cycle (eight cycles).
223923475|NCT04174170|DRUG|Brexpiprazole|3 mg pill
223923476|NCT04174170|DRUG|Sertraline|150 mg pill
223923477|NCT04174170|OTHER|Placebo|Pill
223923478|NCT04174170|DRUG|Brexpiprazole|2 mg pill
223923479|NCT06217276|OTHER|Respiratory muscle fatigue protocol|It will be performed using a powerbreath device at 60% of the maximum inspiratory pressure (MIP) amount obtained by measuring mouth pressure. The protocol includes 7 sets consisting of 2 minutes of inspiratory effort and 1 minute of rest. To further confirm the occurrence of fatigue, the patient will score fatigue using the modified Borg scale, and the score will be 5 or above11. During the application, heart rate, blood pressure and peripheral oxygen saturation will be monitored. The measurement will be performed once for each case.
223923480|NCT06798155|OTHER|Standardized Music Listening Therapy|"Type of Intervention: Pre- and postoperative listening to standardized music sequences designed specifically for relaxation and pain management.~Delivery Method: Sessions are conducted via the Music Care® application, using a tablet and headphones provided during hospitalization. Participants select their preferred music style, tempo, and tracks to tailor the experience to their preferences.~Duration and Schedule:~Pre-surgery: One 20-minute session in a dedicated room before entering the operating theater.~Post-surgery: Daily 20-minute sessions at home for 28 days post-surgery using participants' own devices (smartphone, tablet, or computer).~Purpose: To evaluate the effect of music on reducing postoperative pain, minimizing analgesic use, and improving the quality of life.~Distinctiveness: This intervention uniquely integrates patient-controlled music preferences with a structured listening regimen before and after surgery, offering a personalized approach to enhancing recovery outcom"
223923481|NCT05556967|DRUG|Immulina|Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
224091951|NCT06895525|DIETARY_SUPPLEMENT|Placebo|2 g, twice daily, to be taken on an empty stomach.
224091952|NCT06842524|DRUG|Dihydroartemisinin|Dihydroartemisinin tablets 40mg tid po for 90 days
224091953|NCT06842524|DRUG|Placebo|Identical placebo tid for 90 days
224280603|NCT03478007|DEVICE|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
224280604|NCT03478007|DEVICE|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
223531526|NCT03756961|DRUG|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
223531527|NCT03756961|DRUG|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
223531528|NCT03756961|DRUG|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
223531529|NCT06655181|DEVICE|Respiratory Muscle Training|Expiratory muscle training will be performed with POWERbreathe EX1 Medic (POWERbreathe®) device and inspiratory muscle training will be performed with POWERbreathe Medic Classic device.
223531530|NCT06813261|OTHER|GLYLO|"commercially available combination of glycation-lowering compounds that are GRAS (generally recognized as safe) by the FDA.~GLYLO Ingredients Benfotiamine (fat-soluble Vitamin B1 derivative)-100mg Vitamin B6 (Pyridoxine Hydrochloride)-50mg Nicotinamide-200mg Alpha Lipoic Acid-150mg Piperine-10mg~For the first week, one GLYLO capsule daily, 5 minutes after the first meal. From week 2 onwards, two capsules of GLYLO daily, one capsule after the first meal and a second capsule after the last meal."
223923482|NCT00324415|BIOLOGICAL|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
223923483|NCT00324415|DRUG|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
223923484|NCT00324415|DRUG|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
223923485|NCT00324415|RADIATION|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy \[5 weeks if given on schedule and without interruption\], maximum 54.0 Gy \[6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
223923486|NCT06207253|DRUG|Diclofenac Sodium|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
223923487|NCT06207253|DRUG|Calcium hydroxide|placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
223923488|NCT04611880|DRUG|Crizanlizumab|Drug: crizanlizumab is a humanized monoclonal anti-P-selectin antibody that prevents leukocyte adhesion to the vascular endothelium, thereby limiting risk of microvascular occlusion. It is administered intravenously.
223923489|NCT05621954|PROCEDURE|Telehealth Monitoring|Connected devices and smartphone apps to measure symptoms and observations at home, with centralisation of results to a staffed hub
224091954|NCT06796608|BEHAVIORAL|Behavioral Activation|Behavioral activation is an evidence-based intervention based on the idea that depression leads to withdrawal from rewarding activities, which sustains or exacerbates depression, and breaks this cycle by increasing the frequency with which people engage in rewarding activities regardless of their motivation. Like those with depression, people living with advanced cancer may reduce or stop participation in meaningful life activities resulting in decreased positive emotion and worse quality of life. The goal of this intervention is to adapt and test a fully remote technology-supported behavioral activation intervention aimed at supporting patients with advanced cancer to optimize the quality of their remaining years of life.
224280605|NCT06897072|BEHAVIORAL|Yoga|In the experimental group, yoga exercises were performed for 50 minutes with physical yoga movements (Vrksasana (tree pose), janusirsasana (head-knee pose), modifiedmarichyasana (great sage pose), baddhakonasana (connected angle pose), malasana (garland pose), sukhasana (meditation pose), ardhapadmasana (lotus sitting pose), gomukhasana (cow face pose), supta matyendrasana (spinal rotation pose on the back), bharmanasana (table pose), chakravasana (cat/cow pose), dandayamanabharmasana (balancing yoga pose), vajrasana (diamond pose), viraphadrasana 1-2 (warrior 1-2 pose). The class will include 15 minutes of meditation (deep relaxation with a focus on breath and self-awareness), breathing exercises in between and 10 minutes of relaxation.
223531531|NCT06813261|OTHER|Placebo|"Visually matched capsule with microcrystalline cellulose as an inert ingredient.~For the first week, one placebo capsule daily, 5 minutes after the first meal. From week 2 onwards, two capsules of the placebo daily, one capsule after the first meal and a second capsule after the last meal."
223531532|NCT06272383|DRUG|0.15 mg/kg dexamethasone|25% less than the standard practice of dexamethasone at 0.6mg/kg
223531533|NCT06589999|DIAGNOSTIC_TEST|MP2RAGE sequence|Addition of MRI sequence MP2RAGE
223531534|NCT05994248|DEVICE|Enform Mesh|Use of absorbable mesh in umbilical hernia repair
223531535|NCT05994248|DEVICE|Marlex|Use of non-absorbable mesh in umbilical hernia repair
223531536|NCT02831634|PROCEDURE|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
223531537|NCT06667427|PROCEDURE|Nerve transfer techniques|Participants will undergo facial nerve reconstruction using nerve transfer techniques
223717483|NCT02300584|BEHAVIORAL|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
223531538|NCT06656442|DRUG|Trimetazidine|an anti-ischemic medication.
223531539|NCT06204484|OTHER|CAPEOX adjuvant therapy|In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.
223717484|NCT02300584|OTHER|iPad|a tablet computer with an internet connection
223923490|NCT04601051|BIOLOGICAL|NTLA-2001|A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration
223923491|NCT06807697|RADIATION|Curative radiotherapy for Head and Neck Cancers|Radiotherapy is a localized, non-invasive, painless therapy, mostly performed on an outpatient basis, capable of causing necrosis or the death of tumor cells through the use of high-energy radiation called ionizing radiation.
223531540|NCT06204484|OTHER|deferred CAPEOX adjuvant therapy|In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.
223531541|NCT06204484|OTHER|mFOLFOXIRI intensive adjuvant therapy|In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
223531542|NCT04885530|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
223531543|NCT04885530|DRUG|Fluvoxamine|"Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days."
223717485|NCT01892293|DRUG|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
223717486|NCT00005045|DRUG|carboxyamidotriazole|
223923492|NCT06333938|OTHER|Nonpharmacologic Treatment|At least one three nonpharmacologic treatments (Music Medicine, Aromatherapy, Battlefield Acupuncture) will be delivered. Music Medicine is the delivery of personal music players to listen to patient-preferred music before, during, or after surgical or non-surgical procedures. Aromatherapy is the delivery of personally-preferred AromaTabs before, during, or after surgical or non-surgical procedures. Battlefield Acupuncture is the delivery of Auricular Acutherapy by trained providers using acupuncture needles or acupressure beads before, during, or after surgical or non-surgical procedures.
223923493|NCT06333938|OTHER|Standard Care|Patients will receive standard clinical care without the addition of Music Medicine, Aromatherapy, or Battlefield Acupuncture
223923494|NCT05931848|OTHER|Warm-up and Cool-down Program|"Each exercise in the warm-up and cool-down protocols consisting of active movements and static stretching exercises will be performed as 1 set and 10 repetitions. Active movements will be performed for 10 seconds. The detailed protocol is shown below.~Neck flexion/extension/lateral flexion Circles made with the head chin-tuck Backward bilateral shoulder circumduction Shoulder external rotation with hands clasped at neck Circles with wrists clasped clockwise and counterclockwise Reciprocal upper extremity flexion-extension cat-camel Trunk lateral flexion with hands clasped overhead Trunk rotation in both directions Ankle dorsi/plantar flexion with knee extension Static Stretching Exercises Neck lateral flexor stretch Posterior capsule stretching Hands clasped trunk flexion lateral Trunk lateral flexion with hands clasped Trunk rotation in both directions Knee extensor and ankle plantar flexor stretching by reaching for toes"
223923495|NCT05931848|OTHER|Strengthening Exercises|"The progression of the strengthening program will be achieved by gradually changing the number of repetitions, sets, resistance and the number of exercises.~1-6 Weeks Upper extremity strengthening in unilateral PNF D2 pattern, Scapulothoracic strengthening with shoulder extension in elbow extension, Scapulothoracic strengthening with shoulder extension in elbow flexion, hip flexor strengthening, Hip abductor strengthening in knee flexion, when sit on the chair fingertip ups and downs 7-12 Weeks Added exercises Scapular adductor strengthening with shoulders in horizontal abduction position, Shoulder adductor strengthening in elbow extension with trunk lateral flexion in arms overhead position, hip abductor strengthening 13-16 Weeks Added exercises Shoulder abductor/flexor strengthening in the scapular plane, Elbow flexor strengthening, Upper extremity strengthening in unilateral PNF D2 pattern with trunk rotation, Taking a lateral step in a mini-squat position"
224091955|NCT06896929|DRUG|Permethrin Cream, 5%|Permethrin 5% cream will be given as a single application
224091956|NCT06896929|DRUG|Permethrin Cream, 5%|Permethrin Cream will be given as twice application
224091957|NCT06896929|DRUG|Ivermectin 200 µg/kg|Group C will be given Tab Ivermectin
224091958|NCT06771037|DEVICE|Transcutaneous Auricular Neurostimulation (tAN)|Transcutaneous Auricular stimulation will be delivered using the Spark Biomedical Sparrow Link pulse generator with Sparrow Ascent earpieces. The Sparrow Link generator is based on FDA-cleared predicate Sparrow Ascent.
224091959|NCT03820817|DRUG|Rifaximin|Given PO
224091960|NCT06907511|BIOLOGICAL|Pandemic flu H5 HA mRNA SD2 vaccine|"Pharmaceutical Form:~Suspension in a vial~Route of Administration:~Intramuscular injection"
224091961|NCT06907511|OTHER|Placebo|"Pharmaceutical Form:~Liquid solution in a vial~Route of Administration:~Intramuscular injection"
224091962|NCT04572009|OTHER|Bio-mathematical model|bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
224091963|NCT04572009|OTHER|Without bio-mathematical model|No bio-mathematical model to help the physician identify the parameters of flexible insulin therapy (basal rate, insulin sensitivity, carbohydrate ratios)
224280606|NCT06746233|DEVICE|Drug (paclitaxel) coated balloon (DCB)|In the experimental arm, a drug-coated balloon (DCB) with a concentration of 3 μg of Paclitaxel per 1 mm² will be used in patients with STEMI following successful lesion preparation (defined as residual stenosis ≤30%, TIMI flow grade 2-3, and absence of flow-limiting dissection). If the result after DCB treatment is unsatisfactory, a bailout drug-eluting stent (DES) will be implanted.
224280607|NCT06746233|DEVICE|Second-generation Drug Eluting Stent (DES)|If the patient is randomized to the DES treatment arm, a second-generation drug-eluting stent (DES) will be implanted using standard techniques.
224280608|NCT06905574|OTHER|surgeon guided serratus block|Surgeon guided Serratus Block will be applied before closing dermoglandular flaps
224280609|NCT06055673|GENETIC|DNA extraction AND Real- time polymerase chain reaction analysis to POLYMORPHISM OF in in-stent restenosis (ISR) in CAD|Real- time polymerase chain reaction a gene polymorphism in in-stent restenosis (ISR) in CAD.
224280610|NCT06904417|OTHER|The Feldenkrais-based intervention|The Feldenkrais-based intervention consisted of guided awareness exercises aimed at improving movement patterns, proprioception, and postural control. Sessions were conducted twice weekly for 12 weeks, with each session lasting approximately 45 minutes
223923496|NCT05931848|OTHER|Balance Exercises|"Balance exercises will be applied following the strengthening exercises. The exercises will be gradually made more difficult. Participants will be encouraged to complete the balance exercises by standing next to the grab bar and with as little support as possible.~1-6. Week Rising and falling on the heels Hands at waist trunk extension hip abduction 6-9. Week Hip abduction and extension without lowering the foot to the ground, respectively 5 sec stop on tiptoe 5 seconds standing on one leg 10-12. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~5 sec stop on tiptoe 10 sec stop on tiptoe 5 seconds standing on one leg 10 seconds standing on one leg 13-16. Week Abduction, extension, and flexion of the hips without lowering the foot to the ground, respectively.~10 sec stop on tiptoe 15 sec stop on tiptoe 10 seconds standing on one leg 15 seconds standing on one leg"
224091964|NCT06910787|DEVICE|VR-directed BGBT|VR-directed BGBT using the Oculus Meta Quest 3 VR headset will be delivered using the Synergi application. The program includes 4-weeks of daily self-led activities using 5 virtual modules: (1) education (2) two interactive games (3) breathing exercises (4) gut-directed meditation and (5) gastroenterology-specific Cognitive behavioral therapy (CBT). Participants will also receive standard care. On day 1, intervention arm participants will undergo a brief in-person or virtual (i.e., zoom or Microsoft teams) training with study staff to learn how to use the VR headset and access intervention modules. On day 1 participants will be asked to explore each of the program modules to achieve initial familiarity. Participants will be encouraged to use the VR-BGBT program for at least 15 minutes daily, but at minimum 3-4 days each week. Additionally, study assessments will be completed at baseline, 2-weeks, 4-weeks, and 8-weeks, with an interview within 1-2 weeks of completing the program.
224091965|NCT06910787|OTHER|E-TAU|Participants will receive standard of care, as directed by the participant's gastroenterologist. Participants will also receive an educational video and fact sheet on pain in IBD. This will be 4-weeks with study assessments at baseline, 2-weeks, and 4-weeks, 8-weeks.
224091966|NCT05832918|OTHER|exercise therapy|Exercise therapy is one of the rehabilitation methods that is defined as a regimen or plan of physical activities designed and prescribed to facilitate the patient's recovery from diseases and any conditions which disturb their movement and activity of daily life or maintain a state of well-being through neuro re-education, gait training, and therapeutic exercises.
224091967|NCT03598244|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224091968|NCT03598244|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
224091969|NCT03598244|DRUG|Savolitinib|Given PO
224091970|NCT03598244|PROCEDURE|X-Ray Imaging|Undergo X-ray imaging
224091971|NCT06481137|DIAGNOSTIC_TEST|Electrophysiological study (EP study)|Electrophysiological study: A second EP study 30-45 days after TAVI will be performed in the group of patients with positive EP study 3-7 days after TAVI.
224091972|NCT06481137|DIAGNOSTIC_TEST|ePatch (extended Holter Monitoring)|Continuous cardiac rhythm monitoring using the ePatch (Philips) will be performed during 4 weeks after TAVI
224091973|NCT04577040|DRUG|Tadalafil 5mg|Drugs
224091974|NCT03270215|PROCEDURE|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
224091975|NCT06915129|DIETARY_SUPPLEMENT|Prebiotic galactooligosaccharides (GOS)|Galactooligosaccharides (GOSs) are a group of nondigestible oligosaccharides consisting of galactose units linked via glycosidic bonds to galactose, terminal glucose, or sucrose. The linkages are not digested by human and animal pancreatic or intestinal enzymes. Some recent papers reported that daily supplementation with prebiotic GOS to lactose-intolerant individuals altered the gut microbiome and decreased lactose intolerance (LI) symptoms.
224091976|NCT06915337|DEVICE|Gastric-Jejunal Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: gastric-jejunal anastomosis creation in subjects undergoing surgical procedures. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically and/or endoscopically into portions of the stomach and the jejunum that are intended to be anastomosed. An OTOLoc device will be deployed into the gastric wall of the stomach to provide access for the deployment of a Flexagon SFM into the stomach. The process is repeated at an intended section of jejunum. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two lumens until the anastomosis is fully formed.
224091977|NCT06915974|DIAGNOSTIC_TEST|Interleukin 6|Interleukin 6 and procalcitonin will be sampled for all patients on days 1, 3, 7, and 10
224091978|NCT06858709|PROCEDURE|True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment|"Participants will receive a total of 8 treatments over 6 weeks, with twice a week treatments for the first and the forth weeks and weekly treatment for the remaining weeks.The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. In the meantime, participants will receive the same standard anti-CIPN treatments."
224091979|NCT06858709|PROCEDURE|Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group. Care was taken to avoid de qi sensation. In the meantime, participants will receive the same standard anti-CIPN treatments."
224280611|NCT06904417|OTHER|conventional balance training program|a conventional balance training program consisting of static and dynamic balance exercises, gait training, and strength-building activities, matched for session frequency and duration
223717487|NCT03506178|DRUG|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
224091980|NCT03596073|DRUG|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
223531544|NCT04885530|DRUG|Fluticasone|Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
223531545|NCT04885530|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
224091981|NCT03596073|OTHER|Topical Vaseline|Placebo
224091982|NCT03510325|DRUG|Phase 1: Olanzapine|Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
224091983|NCT03510325|DRUG|Phase 1: Risperidone|Initial dosage: 1-2 mg; recommended dosage: 2-6 mg/d; dosage form: po. duration: 8 weeks
224091984|NCT03510325|DRUG|Phase 1: Amisulpride|Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
224091985|NCT03510325|DRUG|Phase 1: Aripiprazole|Initial dosage: 5-10 mg; recommended dosage: 10-30 mg/d; dosage form: po. duration: 8 weeks
224091986|NCT03510325|DRUG|Phase 1: Perphenazine|Initial dosage: 2-4 mg; recommended dosage: 6-36 mg/d; dosage form: po. duration: 8 weeks
224091987|NCT03510325|DRUG|Phase 2: Olanzapine|Initial dosage: 5-10 mg; recommended dosage: 5-20 mg/d; dosage form: po. duration: 8 weeks
224280612|NCT06905821|BEHAVIORAL|Transformational Learning-Based Antenatal Education Program|The Transformational Learning-Based Antenatal Education Program helps pregnant women reduce birth-related anxiety and fear by utilizing transformational learning theory. Unlike traditional antenatal education, it emphasizes psychological preparedness, focusing on emotional well-being and coping strategies. The program includes interactive learning, group discussions, and self-reflection to engage participants actively. This approach aims to boost women's confidence and reduce stress as they approach labor and delivery.
224280613|NCT06905730|DIAGNOSTIC_TEST|sensory integration deficits in balance|By assessing sensory integration deficits in balance recovery, the study will help establish meaningful thresholds for rehabilitation outcomes, guiding clinicians in tailoring therapy for improved post-stroke balance and functional independence
224280614|NCT00291473|DRUG|CHP-HER2, CHP-NY-ESO-1|
224280615|NCT03667846|DRUG|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
224280616|NCT03667846|OTHER|Placebo|Placebo tablets will be encapsulated in identical capsules.
224280617|NCT06903949|PROCEDURE|Lumbar Dorsal Root Ganglia Pulsed Radiofrequency|It is an interventional pain management technique used to treat chronic radicular pain, often associated with conditions like lumbar disc herniation or degenerative disc disease. It involves the application of pulsed radiofrequency energy to the dorsal root ganglia (DRG), which are clusters of nerve cell bodies located just outside the spinal cord. DRG is involved in transmitting sensory signals from the periphery (e.g., the limbs) to the central nervous system.
224280618|NCT04149535|DEVICE|Sentinel® Cerebral Protection System|cerebral embolic protection system
224280619|NCT05540171|OTHER|Oral health education and instructions/training for self-oral care|Education intervention
224280620|NCT06212869|DEVICE|Transcranial direct current stimulation|tDCS group will give active tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
224091988|NCT03510325|DRUG|Phase 2: Amisulpride|Initial dosage: 200-400 mg; recommended dosage: 400-1200 mg/d; dosage form: po. duration: 8 weeks
224091989|NCT03510325|DRUG|Phase 2: Clozapine|Initial dosage: 25-50 mg; recommended dosage: 200-400 mg/d; dosage form: po. duration: 8 weeks
224091990|NCT03510325|OTHER|Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapy|"Clozapine extended treatment:~dosage: 200-600 mg/d; dosage form: po.~Combined clozapine-MECT therapy:~Dosage of clozapine: 200-600 mg/d; The modified electroconvulsive therapy (MECT) will be administered three times per week for the first 2 weeks, then twice a week for the next 2 weeks. The total treatment duration is about one month."
224091991|NCT03510325|DRUG|Phase 3B: Clozapine or another SGAs|"Clozapine:~Initial dosage: 25-50 mg; recommended dosage: 200-600 mg/d; duration: 8 weeks~Another Second generation antipsychotics (SGAs) (not previously used in phase 1 and 2): Olanzapine, risperidone, amisulpride, or aripiprazole The dosage of each drug is the same as that of phase 1 and phase 2."
224091992|NCT06935565|OTHER|Trifocal IOL implantation|Patients were implanted bilaterally with Asqelio Trifocal IOL 270±90 days before study visit
224091993|NCT06936735|DRUG|HS-20108 Monotherapy|Intravenous (IV) Infusion
224280621|NCT06212869|DEVICE|Sham transcranial direct current stimulation|Sham tDCS group will give sham tDCS with the prescribed medications for 20 minute. The intervention will conduct 3 consecutive days in a week.
224280622|NCT06212869|DEVICE|Green light|Green light group will give green light exposure with the prescribed medications for 1-2 hour. The intervention will conduct 5 days in a week.
224280623|NCT02727725|OTHER|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
224280624|NCT06524817|OTHER|transcranial magnetic stimulation|Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
224280625|NCT06245382|DIETARY_SUPPLEMENT|Goode Health Beverage|This is a commercially available beverage powder that is high is healthy ingredients that are believed to be beneficial for physiological health.
223923497|NCT05931848|OTHER|Otago Home Exercise Program|"The exercises included in the Otago Home Exercise Program will be taught to the participants after the group exercise session held at the Social Life Center. At the same time, home exercise training will be supported by brochures and videos. In addition to the exercises in the program, participants will be asked to do 30 minutes of moderate-intensity walking 2 days a week. Participants will be asked to record the exercises they did during the week in the exercise diary given to them.~Balance Exercises~1. Knee bend (half squat)~2. Walking backwards~3. Walk and turn around~4. Sideways walking~5. Tandem stance~6. Tandem walking~7. Standing on one leg~8. Walking on the heel~9. Toe walking~10. Tandem walking backwards~11. Sit down~12. Going up and down stairs Strengthening Exercises~1\. Knee extension 2. Knee flexion 3. Hip abduction 4. Ankle plantar flexion 5. Ankle dorsiflexion"
223531546|NCT04885530|DRUG|Montelukast|Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
223923498|NCT04340882|DRUG|Docetaxel|Given IV
224091994|NCT06935539|DEVICE|Cryoneurolysis|"The iovera° system consists of a reusable, portable Handpiece, along with single-patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The STT21180STIM Smart Tip will be used in this study."
224091995|NCT06935539|DEVICE|Radiofrequency ablation|Radiofrequency ablation is a minimally invasive procedure that uses heat at the lumbosacral spine to destroy the target spinal nerves.
224091996|NCT06935318|OTHER|Exercise|The exercise group performed an 11-week high-functional resistance program in a group training format. They trained 3-4 days a week following nationally assigned workouts
224091997|NCT06935318|OTHER|Control|Did not participate in exercise related activities for the duration of the study period.
224091998|NCT06936865|BEHAVIORAL|VIVIFIL App Program|A digitally supported multicomponent exercise program delivered through the VIVIFIL mobile application. Participants followed a daily home-based routine including strength, balance, flexibility, and aerobic exercises, adapted to their functional reserve. The app provided video instructions, progression tracking, and a chat for remote communication with healthcare professionals.
224091999|NCT06936865|BEHAVIORAL|Hospital-Based Multicomponent Exercise|A supervised multicomponent exercise program delivered at a geriatric day hospital by trained professionals. Sessions lasted 45-60 minutes, 2-4 times per week for 8 weeks. Exercises included strength training, balance, flexibility, and aerobic components, adjusted to the participant's functional status.
224092000|NCT06935773|OTHER|High-Fidelity Simulated Emergency Training|A high-fidelity simulation-based in-service training program focusing on emergency scenarios. The training includes simulated resuscitation cases, teamwork drills, and post-simulation debriefings conducted at Chang Bing Show Chwan Memorial Hospital.
223531547|NCT04885530|DRUG|Metformin|Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
223531548|NCT01573117|DEVICE|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
223531549|NCT01573117|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
223531550|NCT06981975|DEVICE|single plastic stent|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of a single plastic stent. Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
223531551|NCT06981975|DEVICE|Multiple plastic stents|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of multiple plastic stents. Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
223531552|NCT06981975|DEVICE|Fully covered self-expanding metal stents|Endoscopic biliary stenting was performed using standard techniques. The maximum bile duct diameter and length of stricture were measured after visualization on x-ray films by retrograde cholangiography. If necessary, sphincterotomy or dilation of the stricture was performed before insertion of the stent. Endoscopic stenting comprised the placement of fully covered self-expanding metal stents (fcSEMS) . Stents were exchanged at regular intervals or when signs of stent dysfunction were present. If imaging evaluation demonstrated spontaneous passage of the stent with resolution of the stricture, ERCP for stent retrieval was no longer necessary.
223531553|NCT00253422|DRUG|Anastrozole|This may be Anastrazole OR a placebo
223531554|NCT00253422|DRUG|Exemestane|
223531555|NCT00253422|DRUG|Fulvestrant|
223923499|NCT04340882|BIOLOGICAL|Pembrolizumab|Given IV
223923500|NCT04340882|BIOLOGICAL|Ramucirumab|Given IV
223923501|NCT02131584|OTHER|Questionnaire Administration|Ancillary studies
223923502|NCT02131584|DRUG|Ruxolitinib Phosphate|Given PO
224092001|NCT06935773|OTHER|No intervention (observational study)|Participants in this arm will not receive any training or simulation intervention during the study period.
224280626|NCT06245382|DIETARY_SUPPLEMENT|Vanilla Base Beverage Blend|This is a commercially available beverage powder.
224092002|NCT06935929|BIOLOGICAL|Ustekinumab - Standard Dosage|Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
224092003|NCT06937021|OTHER|Art and philosophy intervention (APBI)|8 session intervention delivered during school time. Each session involves an art activity with a corresponding philosophical discussion.
224092004|NCT06937021|OTHER|Art based intervention (ABI)|A 8 session intervention delivered during school time. Each session involve a creative arts activity.
224092005|NCT06935279|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
223717488|NCT03506178|DRUG|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
223923503|NCT03593811|DIAGNOSTIC_TEST|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
223923504|NCT03593811|DIAGNOSTIC_TEST|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
223923505|NCT03593811|DIAGNOSTIC_TEST|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
223923506|NCT03593811|DIAGNOSTIC_TEST|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
223923507|NCT03593811|DIAGNOSTIC_TEST|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
223923508|NCT03593811|DRUG|Ondansetron|Patients will be administered 4mg or 8 mg ondansetron dependent upon age in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
223923509|NCT03593811|DRUG|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 4mg twice a day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
223923510|NCT04726410|BIOLOGICAL|Cold Stored Platelets|early infusion of urgent release CSP
223923511|NCT04726410|BIOLOGICAL|Standard Care|standard care including room temperature platelets
224092006|NCT06936332|DEVICE|Omnilux Clear Light Emitting Diode Treatment|Omnilux Clear is a medical-grade, home light emitting diode (LED) treatment for acne-prone skin, using the most clinically effective LED's available, optimized for superior results. The blue light (415nm) targets and kills P. acnes bacteria living on the skin's surface. Red light (633nm) penetrates the dermis, triggering the body's own natural healing response, including the production of new collagen, the downregulation of excess oils, and the reduction of inflammation and redness.
224092007|NCT06935864|DIAGNOSTIC_TEST|KLF factor (4 and 7)|Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.
224092008|NCT06935552|DRUG|Ketamine infusion|group A will receive ketamine intravenous infusion
224092009|NCT06935552|DRUG|Lidocaine Intravenous Infusion|group B will receive lidocaine intravenous infusion
224092010|NCT06935552|DRUG|Dextrose 5% in water|group C will only receive Dextrose 5% in water
224280627|NCT03939949|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
224280628|NCT03939949|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
224280629|NCT03939949|BEHAVIORAL|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
223923512|NCT00076310|DRUG|Docetaxel|60 mg/m\^2 IV repeated every 21 days.
223923513|NCT00076310|DRUG|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
223923514|NCT00076310|DRUG|Cisplatin|75 mg/m\^2 IV every 21 days.
223923515|NCT04957849|PROCEDURE|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery|The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery
223923516|NCT04957849|PROCEDURE|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach|Endoscopic Evacuation of Acute Hypertensive Intracerebral Hemorrhage via Trans-frontal keyhole approach
223923517|NCT05037305|OTHER|Educational video|The brief educational video provides information about pharmacogenetic testing, the results of pharmacogenetic testing, and how to find these results in the patient portal.
223923518|NCT05325437|PROCEDURE|Laparoscopic splenectomy and azygoportal disconnection|The laparoscopic splenectomy and azygoportal disconnection was performed by the same surgical team.
223923519|NCT06036407|DIAGNOSTIC_TEST|Hearing test|Participants visit a local hearing aid shop to assess their hearing function
223923520|NCT04684524|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
223531556|NCT06662760|DRUG|TQB3002 Tablets|TQB3002 is a fourth-generation small molecule Epidermal growth factor receptor (EGFR) inhibitor, which inhibits relevant tyrosine kinase activity and intracellular phosphorylation process by competitively binding to Adenosine triphosphate (ATP) site of intracellular tyrosine kinase binding domain, thereby inhibiting EGFR downstream signaling, ultimately achieving the purpose of inhibiting tumor growth.
223531557|NCT02900404|OTHER|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
223923521|NCT04684524|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
223923522|NCT06070376|DEVICE|Fully Covered Esophageal Prosthesis (FC-SEMS)|The placement of the Fully Covered Esophageal Prosthesis (FC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
223923523|NCT06070376|DEVICE|Partially Covered Esophageal Prosthesis (PC-SEMS)|The placement of the Partially Covered Esophageal Prosthesis (PC-SEMS) will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the Cancer Institute of the State of São Paulo (ICESP). The tests will be performed under radioscopic control. The tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.
223923524|NCT06195150|OTHER|Blood collection|15ml of blood are harvested before surgery
223923525|NCT06179485|DRUG|Ketamine|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.
224092011|NCT06936397|BEHAVIORAL|Cognitive Remediation Therapy|CRT is a structured behavioral intervention consisting of weekly 60-minute sessions for 12 weeks. The therapy includes tasks to enhance cognitive skills such as attention, memory, executive function, and emotional regulation using computer-based training and therapist-guided exercises.
224092012|NCT06936098|PROCEDURE|CRLM surgery|Surgical resection of colorectal cancer liver metastasis (CRLM) involves the removal of metastatic lesions from the liver. This procedure is aimed at improving survival rates and reducing tumor burden in patients diagnosed with CRLM. The resection is performed to treat liver metastasis, and clinical outcomes, such as progression-free survival (PFS) and overall survival (OS), are assessed post-surgery to determine treatment efficacy.
224092013|NCT06936228|DIETARY_SUPPLEMENT|Propolis spray|The product obtained from 30% pure Anatolian propolis was applied once daily.
224092014|NCT06936358|OTHER|Control|Control group received bone graft alone after extraction
224092015|NCT06936358|OTHER|A-PRF|30 mL of whole venous blood will be withdrawn from the antecubital vein via scalp vein catheter centrifuged at 1500 rpm for 14 minutes.
224280630|NCT02839798|DEVICE|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
224280631|NCT02999451|DEVICE|snare-assisted POEM|"POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips."
224092016|NCT06936358|OTHER|I-PRF|30 mL of whole venous blood will be withdrawn from the antecubital vein via scalp vein catheter centrifuged at 700 rpm for 3 minutes
224092017|NCT06935617|PROCEDURE|nissein|nissein surgery
224092018|NCT06936644|DRUG|IBI351+AK112|The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in first-line treatment
224092019|NCT06936267|OTHER|rehabilitation : eyes closed|proprioceptive exercise with eyes closed
224092020|NCT06936267|OTHER|rehabilitation : eyes open|proprioceptive exercise with eyes open
224092021|NCT06935955|DIAGNOSTIC_TEST|upper endoscopy|"All subjects will be asked to complete a medical history questionnaire, followed by physical examination (height, body weight, waist circumference and blood pressure), and laboratory investigations (fasting blood glucose, liver function test, total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol( The endoscopy will be carried out by the same specialist, with assessment of chronic and acute gastritis, atrophic gastritis and metaplasia. The endoscopist will obtain five biopsies samples, two from the antrum, two from the corpus and one from incisura.~All biopsies will be processed at the Pathology Department laboratory and embedded in paraffin blocks. For histological examination, two sets of tissue sections will be stained: one with hematoxylin and eosin (H\&E) and the other with Giemsa stain. Each sample will undergo a double-blind review by two independent pathologists according to the USS (HP, neutrophils, mononuclear cells, atro"
224092022|NCT06936137|DRUG|lactobacillus LS|Probiotic supplementation (Lacteol fort 10 billion) which contains culture medium and lactobacillus LS as active ingredients
224092023|NCT06936514|PROCEDURE|Bilateral Cervical Deep Lymphatic Trunk Decompression Combined with Mid-Cervical Deep Lymph Node-External Jugular Vein Anastomosis for Alzheimer's Disease|This intervention involves a surgical approach that combines bilateral cervical deep lymphatic trunk decompression with mid-cervical deep lymph node-external jugular vein anastomosis (LVA) to enhance lymphatic drainage in Alzheimer's Disease (AD) patients. The aim is to reduce the accumulation of neurotoxic substances in the brain, potentially improving cognitive function by facilitating waste clearance via the lymphatic system. The procedure is intended to restore normal lymphatic flow, potentially slowing disease progression in AD patients who have moderate to severe cognitive impairment.
223531558|NCT02900404|OTHER|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
223923526|NCT06179485|DRUG|Etomidate|The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
223923527|NCT06128356|DRUG|Dexmedetomidine Sublingual|Dexmedetomidine 120 mcg on two thin dissolvable films for sublingual administration
223923528|NCT05255926|DRUG|68Ga-pentixafor|All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
223923529|NCT05255926|DEVICE|PET/CT|PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
223923530|NCT06426004|OTHER|patients will receive NPH education|Patients will benefit from the Hydrocephalus Association's (HA) educational strategy for idiopathic normal pressure hydrocephalus (iNPH) emphasizes patient collaboration in the development of educational materials specifically for this condition. HA has a library of assets that include PowerPoint presentations, videos, and online and print educational materials. There will be also in-person outreach resulting recruitment, website (the study website and HA website), webform (with a symptom of gait, dementia, and bladder symptoms), YouTube videos. The investigators will also go to the communities like senior centers, health fair, and churches, then we will give a talk about iNPH. These resources will be carefully adjusted to suit low-income demographics, guided by feedback from Baltimore audiences and HA's iNPH volunteers.
223923531|NCT06426004|OTHER|primary care physicians (PCPs) will receive professional NPH education|A comprehensive professional development program for PCPs and CHWs, featuring presentations, educational videos, webinars, and tools on iNPH diagnosis, treatment, and care management. Provider Continuing Medical Education (CME) credits will be offered for in-person lectures, aiming to equip PCPs with the skills needed to address iNPH in low-income settings effectively
223923532|NCT06426004|OTHER|A community health worker will assist PCP|A community health worker will assist PCP to identify barriers and help overcome these barriers in order for patient to access iNPH care.
223923533|NCT05377411|DEVICE|tDCS|During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue
223923534|NCT05377411|BEHAVIORAL|cognitive training|Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
223923535|NCT05643196|DEVICE|PLIFUS|The Sonicator-1000 system will non-invasively deliver ultrasound sonications transcranially that selectively target specific areas of the brain using a neuronavigation system and the participant's MRI brain scan. The sonication parameters follow FDA and Electrotechnical Technical Commission regulation standards for diagnostic and therapeutic ultrasound.
223923536|NCT05643196|DEVICE|Sham PLIFUS|Sham PLIFUS treatment delivers noise and patient experience that is identical to PLIFUS with Sonicator-1000 system.
223923537|NCT05643196|DEVICE|MRI|A total of 5 MRIs will be performed using a Siemens 3T Prisma; one prior to the intervention visit, and one preceding and one immediately after each of the two sonication/sham visits.
223923538|NCT04772534|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
224092024|NCT06936371|DEVICE|Open Bite Activator with Skeletal Anchorage-Supported Vertical Elastics|Participants received a removable open bite activator constructed with the mandible opened beyond the freeway space and combined with vertical intermaxillary elastics applying 150g of force, supported by mini-screws placed between the lateral and canine teeth in both the maxilla and mandible. The appliance was worn 20-22 hours daily for 12 months. This approach aimed to treat skeletal open bite without using extraoral appliances by promoting anterior mandibular rotation and inhibiting posterior vertical dentoalveolar development.
224092025|NCT06295705|BEHAVIORAL|Hip-Hop Dance|"I. Week 1 - Session 1~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Hip-Hop~4. Cool-Down: Deep Breathing~5. Debrief Check-In~II. Week 2 - Session 2~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Locking~4. Cool-Down: Instructed Yoga~5. Debrief Check-In~III. Week 3 - Session 3~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Breaking~4. Cool-Down: Sensory Time~5. Debrief Check-In~IV. Week 4 - Session 4~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Style - Popping~4. Cool-Down: Animal Deep Breathing~5. Debrief Check-In~V. Week 5 - Session 5~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Learn Showcase Routine~4. Cool-Down: Animal Instructed Yoga~5. Debrief Check-In~VI. Week 6 - Session 6~1. Daily Check-In~2. Warm-Up: Mobility/Grooves~3. Lesson: Review Showcase Routine~4. Cool-Down: Sensory Time~5. Debrief Check-In~VII. Week 7 - Dance Showcase"
224092026|NCT06935682|DRUG|Y-4 tables|Each subject will receive a single dose and multiple doses. During the single dose phase (Day1-Day4), the subjects will be administered with single dose of Y-4 tablets on fasting state in the morning of Day D1. During the multiple dosing phase (Day5-Day13), the subjects will be required to administer with Y-4 tablets continuously for 6 days, BID of Day5-Day9 (once in the morning and once in the evening, Q12h) and QD of Day10, for a total of 11 doses.
224280632|NCT02999451|DEVICE|knife-assisted POEM|"POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips."
223531559|NCT06446518|DEVICE|Virtual reality exposure|Assessing immersive virtual reality as a distraction tool in anxiolysis and pain modulation.
223531560|NCT02918942|DEVICE|Tympanoseal|All subjects will receive the Tympanoseal device that will be placed during a surgical procedure.
223531561|NCT04504071|DRUG|Dacomitinib|Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
223923539|NCT05267496|DEVICE|oscillating positive expiratory pressure device|Patients randomized to the experimental arm of the study will receive an AEROBIKA oscillating positive expiratory pressure device in addition to the standard pulmonary rehabilitation program. The patient will receive instructions pertaining to the use of the device during the first evaluation visit to the rehabilitation service and this information will be reinforced at each follow-up visit. The patient will receive a log book in order to record date and time of use to assess treatment compliance and an instructions and maintenance booklet will be handed out to ensure adequate use of the device.
223923540|NCT05267496|PROCEDURE|Pulmonary rehabilitation|"Educational ventilatory techniques will be explained in order to re-educate respiratory muscles and increase patient awareness regarding the importance of complying with the exercise schedule to improve muscular strength. Including:~Pre-surgical rehabilitation~* Directed ventilation~* Physical conditioning Post-surgical rehabilitation~* Diaphragmatic mobilization~* Thoracic expansion through incentive flow spirometry"
223923541|NCT05435547|DRUG|Dexamethasone|Will take Dexamethasone pre-operatively
223923542|NCT05435547|DRUG|Placebo|Will take Placebo pre-operatively
223923543|NCT05520515|OTHER|Aquatic Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention is performed at the thermal pool sector of Clube Brilhante in Pelotas city. The pool water temperature is maintained between 30-32°C, with participants immersed in the depth level between the xiphoid process and shoulders. The aquatic training group performs the following water aerobics exercises: stationary running, frontal kick, cross-country skiing, and butt kick during the stimulus and jumping jacks during the active recovery. The training session is collective, with 3 to 6 participants, supervised by two experienced instructors, one outside and one inside the pool. The group also receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
223923544|NCT05520515|OTHER|Land Training Plus Health Education|Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.
224280633|NCT04455971|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a form of meditation that increases bodily awareness during structured, partnered female genital stimulation over a 15-minute period.
224280634|NCT02092883|DRUG|ACTH|PK PET scan before and after ACTH treatment
224280635|NCT03441139|OTHER|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
224280636|NCT03441139|DRUG|Medical Analgesics|Best analgesic therapy at investigator's discretion
224280637|NCT04703855|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
224280638|NCT01556152|DRUG|GRC 17536 (Medium Dose)|1 BD for 28 days
224280639|NCT01556152|DRUG|GRC 17536 (Low Dose)|1 BD for 28 Days
224280640|NCT01556152|DRUG|Placebo|Matching Placebo for 28 Days
224280641|NCT04808349|OTHER|no intervention|no intervention
224280642|NCT01297816|DRUG|placebo|100mg,BD, fo three month
224280643|NCT01297816|DRUG|Minocycline|100mg
224280644|NCT04992793|COMBINATION_PRODUCT|Congenital heart surgery|Paediatric congenital heart surgery
224280645|NCT06196593|DEVICE|AcrySof™ IQ Vivity™ Toric intraocular lens|Uneventful phacoemulsification and implantation of IOL
224280646|NCT03323411|BEHAVIORAL|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
224280647|NCT02013752|DEVICE|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
224280648|NCT00820508|DRUG|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
224280649|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 100 mg
224280650|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 50 mg
224280651|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
224280652|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Titration 25 mg
224280653|NCT00401245|DRUG|Placebo|Tapering placebo
224280654|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
224280655|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
224280656|NCT00401245|DRUG|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
224280657|NCT04867811|OTHER|conventional therapy|conventional therapy
224280658|NCT04867811|OTHER|cupping therapy|cupping therapy
224280659|NCT04867811|DEVICE|TENS|transcutaneous electrical nerve stimulation
224280660|NCT04867811|OTHER|TENS and cupping therapy|TENS and cupping therapy
224280661|NCT01989676|BIOLOGICAL|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
223531562|NCT06985147|DRUG|DISC-3405|DISC-3405 is administered subcutaneously.
223923545|NCT05520515|OTHER|Health Education|The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
223923546|NCT01287871|OTHER|supportive care|
223923547|NCT04194450|DIETARY_SUPPLEMENT|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
223923548|NCT04194450|DIETARY_SUPPLEMENT|Placebo|Acute ingestion of taste-matched placebo prior to assessment of outcomes.
223923549|NCT02828150|DIETARY_SUPPLEMENT|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure \[Harris-Benedict\] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI \>30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
223923550|NCT05142371|OTHER|Best Practice|Continue current activities of daily living
223923551|NCT05142371|OTHER|Exercise Intervention|Participate in exercise intervention
223923552|NCT05142371|OTHER|Quality-of-Life Assessment|Ancillary studies
223923553|NCT05142371|OTHER|Questionnaire Administration|Complete questionnaires
223923554|NCT02252380|DEVICE|Transcranial ExAblate System|MR Guided Focused Ultrasound
223923555|NCT05890716|DIAGNOSTIC_TEST|AI-powered ECG analysis to detect cardiac arrhythmic episodes|ECG recording and processing by AI platform
224092027|NCT06935682|DRUG|Y-4 placebos|Each subject will receive a single dose and multiple doses. During the single dose phase (Day1-Day4), the subjects will be administered with single dose of Y-4 placebos on fasting state in the morning of Day D1. During the multiple dosing phase (Day5-Day13), the subjects will be required to administer with Y-4 placebos continuously for 6 days, BID of Day5-Day9 (once in the morning and once in the evening, Q12h) and QD of Day10, for a total of 11 doses.
224092028|NCT06936969|PROCEDURE|Autologous blood patch pleurodesis|The intervention in this study is distinguished by the fact that patients are randomized, the dose of both glucose and ABPP is 120 ml, the patient remains in a supine position for 2 hours after administration, the procedure can be repeated at 48-hour intervals, a maximum of 3 times.
223531563|NCT06037811|DRUG|Adalimumab|Participants will be randomized 1:1 (non-blinded) to receive either adalimumab (40 mg subcutaneous every 2 weeks for 12 weeks) and prednisone vs prednisone alone. Addition of methotrexate (MTX) and/or hydroxychloroquine (HCQ) is permitted, as needed, at the discretion of the treating rheumatologist. No additional conventional synthetic, targeted synthetic or biologic DMARDs are permitted during the trial.
223531564|NCT06037811|DRUG|Prednisone|Prednisone as per standard of care.
223531565|NCT06601335|DRUG|AK117 in combination with AK112|Following a predefined dose and date.
223531566|NCT06601335|DRUG|Placebo in combination with Pembrolizumab|Following a predefined dose and date.
223923556|NCT05781438|BEHAVIORAL|In-home standing and walking intervention|"Parents/legal guardians will be educated on and provided an activity booklet on intensive standing and walking play activities for their infant in a 9 by 9 foot body-weight support system (BWS). Activities include: squatting play at a couch or table, cruising along and between furniture, walking with a push toy or with one or two hands held, walking without support, and kicking and throwing a soft ball.~For 16 weeks, parents/legal guardians will be encouraged to implement the parent-led, intensive standing and walking intervention using BWS for at least 5 days/week for 30-60 min/day, with weekly telehealth calls and monthly home visits to coach parents in identifying key activities and progressing the program."
223923557|NCT05816343|DRUG|Orlistat|Orlistat is an inhibitor of gastric and pancreatic lipases and can reduce dietary fat absorption by 30%. Orlistat at a dose of 2 capsules (each containing 60 mg of active drug) three times a day with each meal (a total dose of 360 mg daily).
223923558|NCT05816343|DRUG|Placebo|Placebo at a dose of 2 capsules (each containing 60 mg placebo) three times a day with each meal (a total dose of 360 mg daily).
223923559|NCT03857490|BEHAVIORAL|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
223923560|NCT03130244|DEVICE|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
223923561|NCT03130244|DRUG|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
223923562|NCT05858905|DEVICE|Intravascular Lithotripsy|The Shockwave Medical IVL System is intended for lithotripsy-enhanced treatment of lesions, including calcified lesions, to increase luminal diameter, allowing for further treatment (e.g. post-dilatation) in the peripheral arterial vasculature. Not for use in the coronary or cerebral vasculature.
223531567|NCT06590116|OTHER|Physical therapy|Patients with low back pain will receive a combination of education, spinal manipulative therapy, and exercise as prescribed by their physical therapist
223531568|NCT06590116|OTHER|Physical therapist provider|Physical therapists will provide a combination of education, spinal manipulative therapy, and exercise to their patients with low back pain participating in the study
223531569|NCT06987487|BEHAVIORAL|Job Rotation Program|Nurses assigned to the intervention group will participate in a structured job rotation program across multiple cardiovascular units (e.g., intensive care, medical, surgical, rehabilitation) every two months for a period of 12 months. Each rotation cycle involves temporary reassignment to a different unit, followed by a return to the original unit. Each nurse will undergo orientation and receive support from a dedicated tutor in the host unit.
223531570|NCT06987487|BEHAVIORAL|No Job Rotation (Standard Care)|Nurses in the control group will continue their usual duties in their respective units without participating in the job rotation program. They will be exposed to the same data collection tools as the intervention group, but without any planned rotation or inter-unit movement.
223531571|NCT06668896|DRUG|Progesterone|Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period.
223923563|NCT05379725|OTHER|Mediterranean Dietary Pattern|The Mediterranean dietary pattern includes whole or minimally processed foods with a high intake of vegetables, fruits, whole grains, fish, and olive oil.
223923564|NCT05379725|OTHER|High Fermented Food Dietary Pattern|Fermented foods such as yogurt, kefir, fermented cottage cheese, fermented vegetables, vegetable brine drinks, kombucha, other fermented non-alcoholic drinks, and other foods will be recommended.
223923565|NCT04983511|DIAGNOSTIC_TEST|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
223923566|NCT04263038|DRUG|Rivaroxaban|Anticoagulation
223923567|NCT04263038|DRUG|Placebo|Study drug without active agent
223923568|NCT06250673|DIETARY_SUPPLEMENT|Diet experiment|For the isotretinoin users
223923569|NCT06148077|OTHER|Manual Therapy|3 times a week, for 6 weeks.
223923570|NCT06148077|OTHER|Motor control exercises|3 times a week, for 6 weeks.
223923571|NCT05453084|BEHAVIORAL|Exercise Program|The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
223923572|NCT04991129|DRUG|WJ01024|5mg QD: WJ01024, Q4W, once per day
223923573|NCT04991129|DRUG|WJ01024|5mg BID: WJ01024, Q4W, twice per day
223923574|NCT04991129|DRUG|WJ01024|10mg BID: WJ01024, Q4W, twice per day
223923575|NCT04991129|DRUG|WJ01024|40mg BIW: WJ01024, Q4W, twice per week
223923576|NCT04991129|DRUG|WJ01024|60mg BIW: WJ01024, Q4W, twice per week
224280662|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
224280663|NCT01989676|BIOLOGICAL|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
224280664|NCT01989676|DRUG|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m\^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m\^2 and then 60 mg/m\^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
224280665|NCT03941834|DRUG|Rimegepant|BHV3000 (rimegepant) 75mg tablet
223923577|NCT04991129|DRUG|WJ01024|80mg BIW: WJ01024, Q4W, twice per week
223923578|NCT04991129|DRUG|WJ01024|60mg QW: WJ01024, Q4W, once per week
223923579|NCT04991129|DRUG|WJ01024|80mg QW: WJ01024, Q4W, once per week
223923580|NCT04991129|DRUG|WJ01024|50mg QW: WJ01024, Q4W, once per week
223923581|NCT04991129|DRUG|WJ01024|40mg QW: WJ01024, Q4W, once per week
223923582|NCT06248125|BEHAVIORAL|Singing intervention|The goal of this intervention is to improve the frequency and quality of active parent-infant interaction via infant-directed singing.
223923583|NCT06248125|BEHAVIORAL|Music listening intervention|This intervention follows the same structure as the singing intervention but focuses on the use of passive music listening rather than live singing.
223923584|NCT06248125|BEHAVIORAL|Book reading intervention|This intervention follows the same structure as the singing intervention, but without the musical elements, while emphasizing enriched parent- infant interaction in non-musical (or less-musical) contexts.
223923585|NCT03718130|COMBINATION_PRODUCT|Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
224280666|NCT03941834|DRUG|Placebo|Placebo
224280667|NCT03911596|DEVICE|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
223923586|NCT03718130|COMBINATION_PRODUCT|Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
223923587|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
223923588|NCT03718130|COMBINATION_PRODUCT|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
223923589|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
223923590|NCT03718130|COMBINATION_PRODUCT|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroporation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
223923591|NCT03021330|DRUG|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
223923592|NCT03021330|DRUG|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
223923593|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous quadriceps tendon graft|Surgical reconstruction of anterior cruciate ligament with autologous quadriceps tendon graft
223923594|NCT06189573|PROCEDURE|Anterior cruciate ligament Reconstruction with autologous bone patellar tendon bone graft|Surgical reconstruction of anterior cruciate ligament with autologous bone patellar tendon bone graft
223923595|NCT04282109|DRUG|Nivolumab + Paclitaxel|"Combination treatment: Nivolumab 240 mg will be administered via IV infusion every 2 weeks. Paclitaxel 80mg/m2 will be administered via IV infusion weekly. After 12 weeks from the start of the combined treatment paclitaxel will be stopped.~Maintenance treatment with nivolumab 480 mg every 4 weeks will start two weeks after the last administration of nivolumab 240 mg. Once nivolumab is administered at 480 mg, paclitaxel can no longer be administered.~Nivolumab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
223923596|NCT04282109|DRUG|Cetuximab + Paclitaxel|"Combination treatment: Cetuximab 250 mg/m2 (first dose of 400 mg/m2) administered via IV infusion weekly plus weekly paclitaxel (80 mg/m2) administered via IV infusion.~After 12 weeks from the start of the combined treatment paclitaxel will be stopped and weekly cetuximab will be continued alone until disease progression, unacceptable toxicity or withdrawal of consent up to a maximum of 24 months."
223923597|NCT03529019|DRUG|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
223923598|NCT03529019|DRUG|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
223923599|NCT01783587|DRUG|Afatinib|Taken orally once per day
223923600|NCT01783587|DRUG|Docetaxel|15 mg/m2, given intravenously once per week
223923601|NCT01783587|RADIATION|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
223923602|NCT06442579|OTHER|Walking on a treadmill|Participants have to walk without holding handrails and without bodyweight support for at least 200 gait cycles. They are asked to walk at comfortable walking speed while watching forward to a screen without virtual reality projection. Arm should be next to the body to allow arm swing if possible.
223923603|NCT04554121|BEHAVIORAL|Brain Basics|"Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life."
223923604|NCT04554121|BEHAVIORAL|Brain Training|Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
224092029|NCT06936969|PROCEDURE|40% glucose solution pleurodesis|"After obtaining informed consent, the patient will lie supine in their room. 30 minutes before the procedure, the patient's capillary blood glucose level will be measured. The patient does not have to fast before the procedure. The nurse will be asked to collect 120 ml of peripheral venous blood from the patient. Then the doctor, assisted by the nurse, will first administer 20 ml of 1% Lignocaine through the pleural drain, and then after about 5-10 minutes, the patient's previously collected venous blood. At the moment of blood administration, the drainage system will be disconnected. Then, the drain will be injected with 20 ml of air to avoid clogging the drain. The patient will remain supine for two hours post-procedure, maintaining fasting status. After 30 minutes from the administration of the patient's own blood, the capillary blood glucose level will be measured again. After two hours, the patient, with nursing assistance, may resume normal activities."
224099676|NCT06074887|BEHAVIORAL|transtheoretical model-based intervention|"Pretest data are collected for patients in the intervention group in a face-to-face interview in the hospital setting.~The training prepared according to the behavior change phase will be conducted one week later in the patients' home environment and the required data will be collected.~In the fourth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the eighth week of the research, the patient is visited at home, the training prepared according to the behavior change phase is performed at the patient's home, and the required data will be collected.~In the twelfth week of the study, post-tests will be collected in the hospital."
223923605|NCT04688333|OTHER|Internet-Based Intervention - Complete iConquerFear program|Online adaptation of a highly effective face-to-face treatment for fear of recurrence.
223923606|NCT04688333|OTHER|Quality-of-Life Assessment|Ancillary studies
223923607|NCT04688333|OTHER|Questionnaire Administration|Complete questionnaires
223923608|NCT06649435|PROCEDURE|PPG measurement|"PPG signal will be measured on CE certified medical devices. Two measurements will be performed - standing and in the recumbent position using reflectance and transmitance method on finger and in ear canal. The each measurement will be 120s long.~Detailed analysis of PPG signal and pathophysiological phenomena associated with HF - peripheral volume changes detectable in PPG signal - will help to understand better and clarify the pathophysiological mechanisms of peripheral volume changes in a failing heart."
223923609|NCT06474754|DIAGNOSTIC_TEST|High-sensitivity troponin, serum|A serum derived measure of myocardial injury. Threshold value of 14ng/L.
223923610|NCT06474754|DIAGNOSTIC_TEST|Submaximal Cardiopulmonary Exercise Testing|FDA-approved device uses breath by breath sampling during calibration and exercise challenge. Analysis is performed using a differential pressure pneumotach method for volume calibration and measurement, an infrared sensor for CO2 and a paramagnetic sensor for O2 measurements. Automated calibration using a calibration gas mixture (15.6% O2/5% CO2) is performed at regular intervals. The Shape II calculations used to differentiate causes of exertional dyspnea are Artificial Intelligence (AI) based algorithms and measurements have been previously validated to conventional cardiopulmonary exercise testing methods. Brief smCPET is comprised of a 2-minute calibration phase, 3 minutes of graded exercise using a stair-step and a 1 minute recovery phase for a total of 6 minutes. An instant report is then generated.
223923611|NCT06474754|DIAGNOSTIC_TEST|Duke Activity Status Index|A validated measure of preoperative functional capacity which will be utilized to cross-validate smCPET peak VO2. Low DASI score has been found to estimate peak oxygen uptake (VO2), predict MINS, myocardial infarction, and inducible myocardial ischemia on myocardial perfusion scintigraphy.
223923612|NCT03678350|DEVICE|Light Dosimetry for Intranoperative Therapy|Undergo IO-PDT
223923613|NCT03678350|PROCEDURE|Photodynamic Therapy|Undergo IO-PDT
223923614|NCT03678350|DRUG|Porfimer Sodium|Given IV
224099677|NCT06561438|DRUG|Vortioxetine 20Mg Tab|20 mg oral vortioxetine tablet 2 hours before the procedure
224099678|NCT04543331|DRUG|brolucizumab|There is no treatment allocation. Patients administered Brolucizumab by prescription that have started before inclusion of the patient into the study will be enrolled.
223923615|NCT04033822|PROCEDURE|cholecystectomy|If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
223923616|NCT05696704|OTHER|Behavioral: Mindfulness Based Cognitive Therapy|Individual tele-therapy 12 to 16 weeks
224280668|NCT05315245|OTHER|AGI|no intervention, only observation
224280669|NCT05247333|OTHER|Minor ailment service|The service had several components: agreed standard operational procedures between community pharmacists and primary care physicians for 31 minor ailments, IT based consultation protocol and training before and during the study for the pharmacists. Practice change facilitators were used to confirm the fidelity of the intervention.
224280670|NCT00441233|DEVICE|Silicone hydrogel contact lens|
224280671|NCT04869371|DRUG|Docetaxel injection|75 mg/m2 body surface area every 3 weeks for 6 cycles before robot assisted radical prostatectomy
224280672|NCT04869371|DRUG|Triptorelin Pamoate for Injectable Suspension|15mg every 12 weeks
224280673|NCT04869371|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone, once daily
224280674|NCT03201978|DRUG|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
224280675|NCT03201978|DRUG|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
224280676|NCT00088387|DRUG|Divalproex|
224280677|NCT00088387|DRUG|Lithium|
224280678|NCT00978887|OTHER|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
224280679|NCT00978887|OTHER|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
224280680|NCT03721302|OTHER|Main study clinical sepsis|No intervention-Observational study
224280681|NCT03721302|OTHER|Microbiology sub study|Analysis of Bacterial isolates
224280682|NCT06457620|BEHAVIORAL|Conventional Physiotherapy|Each participant received conventional physiotherapy at the clinic as a part of their management plan. Group A exercise was five times a week for thirty minutes, beginning on the third day after total knee arthroplasty (TKA). The program aimed to improve leg strength, core stability, balance, and overall performance through exercise instructions. The baseline evaluation was completed one day before the TKA, and the posttest was completed four weeks after the TKA.
224280683|NCT06457620|OTHER|Traditional Physical Preatment|Each participant got traditional physical treatment during a video conference as part of telerehabilitation. The physiotherapy assistant contacted Group B to arrange a virtual follow-up clinic appointment via Zoom or WhatsApp, along with a 4-week program. We inquired about the patient's level of satisfaction with their TKR procedure. The patient was informed that clinical photos were taken, and the video call was to be recorded. Before the virtual clinic, each patient's verbal agreement was acquired. With workout instructions, the program pursued to enhance leg strength, core stability, balance, and overall performance. The posttest was conducted four weeks after the TKA, and the baseline assessment was finished one day before the procedure.
224280684|NCT00368316|BIOLOGICAL|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
224280685|NCT00991510|DRUG|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
223923617|NCT05696704|OTHER|Behavioral: Behavior Activation|Individual therapy 12 to 16 weeks
223923618|NCT03786926|DRUG|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
223923619|NCT03957252|DIAGNOSTIC_TEST|Blood test: ClarityDX Prostate|PSA on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
223531572|NCT05782855|OTHER|Active Robot assisted physical training during acute hospitalisation|"Active training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the exercise movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform extension of hip and knee. The patient must use their muscular power to stretch the leg while ROBERT® provides resistance.~Training is defined as a minimum of three sessions before discharge."
223717489|NCT03506178|DRUG|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
223923620|NCT04899479|DRUG|SGLT2 inhibitor|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
223923621|NCT04899479|OTHER|Control|In patients with AMI and high risk of heart failure, 1:1 randomization will be performed to either SGLT2 inhibitor or control group.
223923622|NCT06054295|OTHER|Biospecimen collection|Collection of both blood and saliva samples from participants at the time of study enrollment
223923623|NCT06054295|OTHER|Questionnaire Administration|The brief questionnaire will assess health history, demographics, environmental exposures, family history of cancer, and birth characteristics.
223923624|NCT05123261|BEHAVIORAL|the mindfulness-based elder care (MBEC) therapy|According to the mindfulness-based elder care (MBEC) therapy developed by McBee (2008), the experimental group was offered eight 50-minute courses once a week.
223923625|NCT02591433|OTHER|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
223923626|NCT02591433|OTHER|Support Group Therapy|Undergo JeffQuit group therapy
223923627|NCT02591433|OTHER|Quality-of-Life Assessment|Ancillary studies
223923628|NCT06367192|BEHAVIORAL|The adapted Kids in Transition to School Intervention|An intensive, school readiness intervention designed to improve preschoolers' social skills, early literacy, numeracy, and self-regulation skills at high risk for academic difficulties. The intervention is delivered virtually over 8 weeks with caregivers and intentionally occurs over the summer when there is a gap in preschool services.
223923629|NCT06367192|BEHAVIORAL|Standard school resources|Information about local preschool programs and age appropriate books for children will be provided.
224092030|NCT06937008|OTHER|Whole body vibration|"All women in group (A) received whole body vibration and balance board training, three times per week for three months.~Parameters: The WBV was performed by using whole body vibration which is a side-alternating vibration device working as a teeterboard with amplitude of 0 to 5.3 mm (medial to distal) and a variable frequency of 5 to 30 Hz. The amplitude was controlled by adjusting the foot position from 1 to 3, with the larger the position, the greater the amplitude. Before the treatment, procedures of using the Galileo 900 were instructed by the research assistant and its safety issues explained.~Patient's position: The patient was asked to stand on WBV device by Hold hand support for those elderly women. the vibrating platform in a 100 to 110° squat position, the oscillating platform operating at 20Hz in bare feet at the second foot position for 15 minutes a day for 3 days a week for 3 months. All unusual or uncomfortable complaints from subjects during the WBV treatment were docu"
224092031|NCT06937008|OTHER|Balance training|Balance training exercises treatment: All women in both group (A, B) received balance training exercises on balance ball, half ball and balance board exercises three times per week for 3 months
223923630|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with hydroxyethylamide|The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
223923631|NCT06077981|PROCEDURE|Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)|The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
224092032|NCT03690154|DRUG|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
224092033|NCT02908399|DEVICE|FLIR ONE|
224092034|NCT06416501|OTHER|Mode of detection|Mode of detection
224092035|NCT02536287|PROCEDURE|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
223923632|NCT05486793|BEHAVIORAL|Written Exposure Therapy (WET)|5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.
223923633|NCT05486793|BEHAVIORAL|Emotion Focused Supportive Therapy (EFST)|5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
223923634|NCT04876339|DEVICE|"Gait rehabilitation with sonification"|The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).
223531573|NCT05782855|OTHER|Passive Robot assisted physical training during acute hospitalisation|"Passive training is delivered by an innovative training robot (ROBERT®). The robot is handled by staff who attaches the robot to the patient's leg. The staff programs the movement, whereby the robot remembers the movement. The robot holds the patient's leg and perform passive extension of hip and knee. ROBERT® moves the leg independently without the patient using any muscle power.~Training is defined as a minimum of three sessions before discharge."
223923635|NCT04876339|OTHER|Standard gait rehabilitation (without sonification)|"The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed."
223923636|NCT04791943|DRUG|Melatonin 10 MG|3 melatonin 10mg capsules will be given to the treatment arm
223923637|NCT04791943|DRUG|Lactose pill|3 lactose pills will be provided to the control arm
224092036|NCT02536287|PROCEDURE|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1\*1 \*1 mm,and placed into the subcutaneous of the forearm.
224092037|NCT06955728|DRUG|Vaccine|The active ingredients in RSVpreF are 2 stabilized RSV prefusion F antigens, in equal amounts from virus subgroups A and B, in a lyophilized dosage form for reconstitution.
224092038|NCT06955728|OTHER|Placebo|Placebo matched to vaccine but not containing any active ingredients
224092039|NCT04068103|DRUG|Capecitabine|Given PO
224092040|NCT04068103|DRUG|Fluorouracil|Given IV
224092041|NCT04068103|DRUG|Leucovorin|Given IV
224092042|NCT04068103|DRUG|Leucovorin Calcium|Given IV
224092043|NCT04068103|DRUG|Oxaliplatin|Give IV
224092044|NCT04068103|OTHER|Patient Observation|Undergo active surveillance
224092045|NCT06119191|DEVICE|Control Lenses (comfilcon A with current process)|Daily wear lenses for 30±2 days
224092046|NCT06119191|DEVICE|Test Lenses (comfilcon A with novel process)|Daily wear lenses for 30±2 days
223531574|NCT06991140|OTHER|Thorocal Mobilization Exercises|Thoracic mobilisation exercises were performed 3 days a week for a total of 6 weeks under the supervision of a physiotherapist. Thoracic mobilisation programme consisted of active self-mobilisation techniques, mobilisation exercises with foam rollers, stretching exercises including thoracic rotation and extension movements and dynamic postural exercises. Especially 'thread the needle' exercise in sitting or quadruped position, 'thoracic extension press-up' in prone position and 'extension on foam rollers' were preferred to increase the mobility of thoracic vertebral segments. The exercises were gradually made more difficult according to the tolerance of the individuals. Each exercise was performed as 10-15 repetitions and 2-3 sets. Exercise safety was ensured by informing the patients about the correct posture and movement patterns before all applications.
223923638|NCT06103201|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
223923639|NCT06463951|OTHER|Psychotherapy - Gestalt psychotherapy|Gestalt psychotherapy is an aesthetic-phenomenological approach that aims to improve self-awareness and integration by promoting emotional and relational well-being through what is happening in the present moment in the relationship with the therapist. The patient's current experiences are explored to better understand problems and behaviors and by promoting relational self-regulation
223923640|NCT06251050|DRUG|lithium-containing mouthwash|The main ingredients of lithium-containing mouthwash are lithium carbonate and citric acid. A total of 5 concentration gradients of lithium-containing mouthwash are set, including 0.03, 0.06, 0.10, 0.15 and 0.30 mol/L. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
223923641|NCT06251050|DRUG|Plcacebo mouthwash|Placebo Mouthwash is mainly composed of citric acid and sodium hydroxide, transparent colorless liquid. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
224092047|NCT04788992|OTHER|Intervention group|Dementia care training consists of dementia care e-books, dementia virtual reality activity and peer support program.
224092048|NCT04788992|OTHER|Control group|Dementia care training consists of dementia care e-books and peer support program without dementia virtual reality activity
224092049|NCT05948176|OTHER|The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition|It is a standardized measure of fine and gross motor skills in children and youth aged 4-21 years
224092050|NCT06398301|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
224092051|NCT05436379|DEVICE|Theta Burst Stimulation|TBS, a next-gen form of transcranial magnetic stimulation (TMS), requires shorter duration and frequency of stimulation and provides comparable clinical efficacy to traditional repetitive TMS for depression. Thus it is an appropriate technique for use with young adults with depression. TBS can be delivered safely and effectively on an accelerated schedule with two sessions/day. Based on an earlier (ongoing) study of TBS to dorsomedial prefrontal cortex, investigators will administer TBS to dmPFC over 2 weeks in young adults with depression. Addressing the behavioral aspects of anhedonia and reward processing, a subset of participants will also receive positive affect training. Magnetic resonance imaging will guide the personalized location of TBS and will be used to examine change in frontostriatal circuitry with TBS. This study has the potential to influence development of new treatments for depression and anhedonia, with possible mechanisms in frontostriatal brain function.
224092052|NCT05979493|DRUG|Bupivacain|30cc IM injection in each quadratus lumborum muscle (60cc total).
224092053|NCT05979493|DRUG|Saline|30cc IM injection in each quadratus lumborum muscle (60cc total).
224280686|NCT00991510|DRUG|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
224280687|NCT05472155|DEVICE|Bulb syringe|Suctioning with a bulb syringe
224280688|NCT05472155|DEVICE|Suction catheter|Suctioned with a suction catheter
224280689|NCT05831735|BEHAVIORAL|Physical activity|"The 6-month APA program is supervised via the videoconference platform and/or carried out independently based on a personalized written program that is updated weekly. The program is based on structured sessions alternating 3 types of PA: aerobic sessions, stretching sessions and muscle strengthening sessions (to be practiced following the teacher's oral or written instructions).~The sessions last from 20 minutes to 1 hour and are of low to moderate intensity depending on the initial level of fitness. The sessions are structured, adapted and progressive. During the sessions, the exercises are adapted according to the means and materials available to the patients at home or in their immediate environment.~The patients will be progressively led to practice in an autonomous way (i.e., without supervision) but following an adapted, personalized and structured program. These PA sessions can be declared afterwards to the PA teacher,(duration and the exercises actually performed)."
223923642|NCT06251050|DRUG|lithium-containing mouthwash|Effective lithium salt concentrations screened in the Phase I trial is used as active interventions in this group of interventions. Mouthwash is used to gargle and left in the mouth for 5 min to be spat out three times a day from the first day of radiotherapy up to the end of treatment.
223531575|NCT06991140|OTHER|Core Stabilization Exercises|Core stabilization exercises were structured to target activation of deep muscle groups supporting cervical and thoracic spine stability. The exercise programme was performed 3 days a week for a total of 6 weeks under the supervision of a physiotherapist. The programme included exercises to improve head and neck control (chin tuck, head lift in supine position), exercises to improve scapular stability (scapular retraction, wall slide, serratus anterior activation) and exercises to improve trunk control in neutral spine position (arm and leg extension in four-point position, plank variations). The exercises were gradually made more difficult according to the tolerance of the individuals and each session lasted approximately 40-45 minutes. By ensuring that the exercises were performed in the correct form and in a controlled manner, overloading of the musculoskeletal system was prevented.
223923643|NCT01167010|DRUG|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
223923644|NCT01167010|DRUG|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
223923645|NCT01167010|DRUG|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
224092054|NCT06448988|OTHER|Park Bench position|To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
224092055|NCT05798923|DRUG|LAM-001|LAM-001 administered via dry powder inhalation
224092056|NCT06161077|DIAGNOSTIC_TEST|Voice Biomarker Screening Too|The investigators will develop a screening tool using voice that can predict disease severity in idiopathic subglottic stenosis
224092057|NCT05764330|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224092058|NCT05764330|OTHER|Dietary Intervention|Undergo CER intervention
224092059|NCT05764330|OTHER|Dietary Intervention|Undergo IF intervention
224092060|NCT05764330|BEHAVIORAL|Fasting|Undergo fasting
224280690|NCT05831735|BEHAVIORAL|Physical activity and education|"In addition to the intervention in physical activity, the people participating in this program will benefit from 6 months of educational activity (EA). The EA program includes 6 sessions scheduled according to the patients' availability in groups and by videoconference.~Following their entry into the study and their allocation to the programs (1 month maximum), the patients will be invited to a first individual EA session, in order to establish an educational diagnosis (1 hour). This session will allow for an assessment of their needs and the presentation of the workshops. Then, between the second and the sixth month following randomization, patients will benefit from 5 collective EA sessions per group of 6 patients maximum (1h30 to 2h). These sessions will be about PA, nutrition, pain management. An individual session will be held at the end of the intervention and will allow for an educational assessment."
224280691|NCT01124695|DRUG|tamoxifen|PO
224280692|NCT00891423|DRUG|Meropenem short infusion|
224280693|NCT00891423|DRUG|Meropenem extended infusion|
224280694|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
224280695|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
224280696|NCT00805155|DRUG|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
224280697|NCT02495181|DRUG|Intravitreal Aflibercept|
224280698|NCT01269450|DRUG|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
224280699|NCT01269450|DRUG|placebo|placebo 200mg vaginal tablets
224280700|NCT05389709|DRUG|Iberogast (STW5-II, BAY98-7410)|Survey without any intervention assigned in the study.
224280701|NCT01922219|BEHAVIORAL|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
224280702|NCT01795079|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
224280703|NCT01607177|BEHAVIORAL|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
223923646|NCT06573424|COMBINATION_PRODUCT|Tislelizumab+anlotinib|Patients who have been treated with anlotinib + tislelizumabline
223923647|NCT06573424|DRUG|anlotinib|Patients who have been treated with anlotinib monotherapy
224092061|NCT05954910|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
224092062|NCT03317964|OTHER|Saliva sample|Extract sample of saliva only once
224092063|NCT02237235|DRUG|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
224092064|NCT02237235|DRUG|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
224280704|NCT02948790|DEVICE|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
223923648|NCT04430309|BEHAVIORAL|Baduanjin exercise program|The sessions includes 10-minute warm-up, 40-minute Baduanjin exercise and 10-minute cool down.
223923649|NCT04430309|BEHAVIORAL|Brisk walking program|The sessions includes 10-minute warm-up, 40-minute brisk walking and 10-minute cool down.
223923650|NCT03740867|OTHER|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
223923651|NCT06099548|DEVICE|The Elevate™ System|The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
223923652|NCT03984318|PROCEDURE|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
223923653|NCT05492201|DRUG|LY3873862|Administered orally.
223923654|NCT05492201|DRUG|Placebo|Administered orally.
223923655|NCT05133076|BIOLOGICAL|Lactobacillus gasseri BGP345A|Active and placebo capsules for oral use
223923656|NCT05133076|BIOLOGICAL|Placebo|Placebo
223923657|NCT04315571|DEVICE|Gore® Viatorr® Endoprosthesis with controlled expansion|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
223923658|NCT04315571|PROCEDURE|Large Volume Paracentesis with albumin infusion|For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
223923659|NCT05641207|DEVICE|RheOx™ with the RheOx™ Catheter treated in the trial|"Eligible patients be assigned two sessions of RheOx bronchial rheoplasty procedures~* Treatment 1 is for the treatment of right lung~* Treatment 2 is scheduled one month apart for left lung"
223923660|NCT03340428|BEHAVIORAL|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
223923661|NCT06265506|BEHAVIORAL|Contingency Management|Contingency Management (CM) is an intervention that uses positive reinforcement (e.g. gift cards) to reinforce a desired behavior (e.g. negative alcohol biomarker tests) on a frequent (e.g. weekly), escalating (e.g. $5/week) schedule (e.g. 26 weeks) in order to increase the occurrence of that behavior (e.g. long term alcohol abstinence or reduction in drinking).
224092065|NCT05286879|BEHAVIORAL|Patient Navigator|Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period
224092066|NCT05286879|BEHAVIORAL|Mobile Health Unit|Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
224092067|NCT05053659|DRUG|Loncastuximab tesirine|Loncastuximab tesirine 50 - 150 μg/kg will be administered as a 30 minutes IV infusion on Day 1 of each cycle for 6 cycles. On doses over 100 μg/kg, subsequent dosing (i.e. beyond 100 μg/kg) will be done at 50% of the dose that is administered on the first 2 cycles.
224092068|NCT05053659|DRUG|Venetoclax|"Participants will receive venetoclax at target doses of 400 - 800mg orally on days 1 - 5 of each (21 day) cycle.~On cycle 1, venetoclax dose will be escalated to reach the target dose over the course of 5 days for target dose 400mg, 6 days for target dose 600mg and 7 days for target dose 800mg~Venetoclax should preferably be given after a meal and on cycle 1 should be preceded by prophylaxis for tumor lysis syndrome (TLS)."
224092069|NCT00873275|BIOLOGICAL|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
224092070|NCT00873275|DRUG|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
224092071|NCT00873275|DRUG|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
224092072|NCT00873275|DRUG|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
224092073|NCT00873275|DRUG|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
224092074|NCT00873275|DRUG|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
224092075|NCT00873275|GENETIC|RNA analysis|Analysis on discard tissues
224092076|NCT00873275|GENETIC|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
224092077|NCT00873275|GENETIC|polymerase chain reaction|Analysis on discard tissues
224092078|NCT00873275|GENETIC|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
224092079|NCT00873275|OTHER|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
224092080|NCT00873275|OTHER|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
224092081|NCT00873275|OTHER|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
224092082|NCT00873275|PROCEDURE|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
224280705|NCT02948790|DEVICE|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
224280706|NCT00978913|BIOLOGICAL|DC vaccine|DC vaccination, one vaccine biweekly
224280707|NCT02287324|PROCEDURE|Manipulation|
224280708|NCT02287324|PROCEDURE|Manual Contact|
224280709|NCT02443324|DRUG|Ramucirumab|Administered IV
223531576|NCT01983345|PROCEDURE|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
223531577|NCT05593380|DEVICE|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
223531578|NCT05593380|OTHER|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
223531579|NCT06616155|PROCEDURE|Biopsy|Undergo tissue biopsy
224280710|NCT02443324|DRUG|Pembrolizumab|Administered IV
223923662|NCT06265506|BEHAVIORAL|Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)|CBT4CBT is an evidence-based online intervention that teaches CBT principles and skills to help people with alcohol use disorder reduce their drinking. CBT4CBT teaches CBT principles through video, graphics, audio instruction, and interactive exercises. Modules include video-based examples to emphasize learning of behavioral, cognitive, and affective strategies, with an emphasis on learning from examples of individuals using skills in a range of situations. Skills taught include functional analysis, coping with craving and emotions, problem solving, decision making, challenging thoughts, and assertive alcohol refusal. Interactive exercises and homework are used to encourage skills learning and practice.
223923663|NCT05763251|OTHER|therapy duration|the standard-course arm will receive 14 days total of antifungal therapy and the short-course arm will only receive 7 days of therapy
223923664|NCT04696523|DRUG|Xenon|Xenon arm will be treated with xenon inhalation with endtidal concentration of 50 % in air/oxygen and with standard of care
223923665|NCT04696523|DRUG|air/oxygen|Control group will be treated with air/oxygen
223923666|NCT06853275|BEHAVIORAL|Experimental: External Focus|Participants will perform a short, standardized warm-up (1 set of 10 repetitions of 20% of the participant's estimated 1-repetition maximum). Following the warm-up, participants will perform 30 repetitions using 50% of their estimated 1-repetition maximum on a leg press machine. Participants will receive visual feedback from a linear position transducer for each repetition, indicating the speed of the last repetition/movement.
224092083|NCT06094010|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as an oral suspension per body weight (≥80 kilograms (kg): 80 milligrams (mg); ≥20 kg to \< 80 kg: 40 mg; \<20 kg: 2 mg/kg).
224092084|NCT06360822|BEHAVIORAL|ED-LCS|This is a lung cancer educational intervention for patients in the emergency department.
223531580|NCT06616155|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223531581|NCT06616155|PROCEDURE|Bone Scan|Undergo bone scan
223531582|NCT06616155|PROCEDURE|Computed Tomography|Undergo CT
223531583|NCT06616155|DRUG|Enzalutamide|Given PO
224092085|NCT05372172|OTHER|none, observational study|none, observational study
224092086|NCT05604807|OTHER|Dementia course with virtual reality|dementia virtual reality activity, intergenerational learning, world café teaching method and community practice
224092087|NCT05604807|OTHER|Dementia course with no virtual reality|dementia course, intergenerational learning, world café teaching method and community practice
224092088|NCT03896581|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
224092089|NCT03896581|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
224092090|NCT04304820|DRUG|Eltrombopag|Between 12 and 17yo (adult dose of 150mg) Between 6 and 11yo (75 mg) Between 3 and 5 yo (2.5 mg/kg)
224092091|NCT04304820|DRUG|Cyclosporine|Day 1 to start of h-ATG: 2mg/kg/day by mouth (All subjects) Start of h-ATG to Month 6: 3 mg/kg/dose by mouth administered every 12 hours (12yo and above) 6 mg/kg/dose by mouth administered every 12 hours (less than 12yo) Month 6 to Month 24: Dosing to be adjusted based on response
224092092|NCT04304820|DRUG|Horse-Anti-thymocyte-Globulin|h-ATG at a dose of 40 mg/kg/day for 4 days (intravenously for approximately 4 hours daily) Note: Omitted in patients who have achieved a complete response at the initial NIH visit after initiating oral treatment remotely
224092093|NCT06357221|DRUG|Cetaphil|Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
224092094|NCT06954220|OTHER|Baduanjin exercises|Baduanjin has 8 movement forms, which are relatively less demanding. Assistive equipment is also not necessary during Baduanjin. These advantages make Baduanjin a suitable form of exercise training for post thyroidectomy patients. The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully. In 8 movement forms of Baduanjin all include shoulder joint function exercises, thus making Baduanjin a potentially useful method for improving activity level and arm strength.
224092095|NCT06951906|DIAGNOSTIC_TEST|fMRI|Baseline imaging will utilize advanced diffusion MRI metrics to determine which brain areas are structurally connected to the stimulation target and their structural integrity. Post-operative assessments will include behavioral measures of FOG response and imaging measures of neural response to stimulation. Pre- and post-operative data will be used to evaluate the association between structural integrity, connectivity and behavioral response.
224092096|NCT05394402|DRUG|SHR0410 Injection|SHR0410 Injection
224092097|NCT05394402|DRUG|Placebo for SHR0410 Injection|SHR0410 Injection blank preparation
224092098|NCT06521489|DEVICE|Asymmetrical High Flow Nasal Cannula Oxygenation|Asymmetrical High Flow Nasal Cannula Oxygenation will be implemented in this study group. (1st study group, 60l/min airflow, 60% fiO2)
224092099|NCT06521489|DEVICE|Conventional High Flow Nasal Cannula Oxygenation|Conventional High Flow Nasal Cannula Oxygenation will be implemented in this study group. (2nd study group, 60l/min airflow, 60% fiO2)
224092100|NCT06054737|PROCEDURE|SPA THERAPY|"Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks~The balneotherapy sessions included:~* 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression);~* 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues);~* Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes"
224092101|NCT05622747|OTHER|Passive heating|1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C)
224092102|NCT06222268|DRUG|Cannabidiol (CBD) only|Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.
223923667|NCT06853275|BEHAVIORAL|Other: Internal Focus|Arm Description: Participants will perform a short, standardized warm-up (1 set of 10 repetitions of 20% of the participant's estimated 1RM). Following the warm-up, participants will perform 30 repetitions using 50% of their estimated 1-repetition maximum on a leg press machine. Participants will NOT receive visual feedback for each repetition. This is the control condition.
224092103|NCT06222268|DRUG|Placebo only|Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD
223923668|NCT06379490|DRUG|Ropivacaine 0.2% Injectable Solution|30 ml of Ropivacaine 0.2% = 60 mg ropivacaine
223923669|NCT06379490|DRUG|Lidocaine epinephrine|30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
223923670|NCT06379490|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
223923671|NCT05875701|BIOLOGICAL|NVX-CoV2373|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
224092104|NCT06222268|DRUG|Delta-9-tetrahydrocannabinol (THC) only|Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.
224092105|NCT06222268|DRUG|THC:CBD 1:1|Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.
224092106|NCT06222268|DRUG|THC:CBD 1:10|Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.
224092107|NCT04155749|DRUG|anitocabtagene-autoleucel|Chimeric Antigen Receptor T cells
224092108|NCT04913766|BEHAVIORAL|Problem Management Plus|Five session psychological intervention focusing on problem management skills.
224092109|NCT04913766|BEHAVIORAL|Services as Usual|Mental health services provided by a mental health specialists according to their standard practices of care
224092110|NCT05554939|BIOLOGICAL|Allogenic CD19 CAR-γδT cell|Phase 1 dose escalation (3+3) : dose 1 (6 × 10\^6 cells/kg) , dose 2 (1.2 × 10\^7 cells/kg), dose 3 (1.8 × 10\^7 cells/kg); Phase 2 : dose of RP2D.
224092111|NCT05554939|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
224092112|NCT05554939|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
224092113|NCT05091346|DRUG|E7386|E7386 tablet.
223923672|NCT05875701|BIOLOGICAL|SARS-CoV-2 rS antigen/Matrix-M Adjuvant|1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
223923673|NCT04548830|PROCEDURE|Transbronchial cryobiopsy|After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
223923674|NCT04799119|BEHAVIORAL|Do As I Do (DAID) dog training|Children and their family dog will participate in this dog training program.
223923675|NCT05667610|OTHER|Immune-supportive diet|The intervention includes a immune-supportive diet over a period of 4 months
223923676|NCT05667610|OTHER|Standard care|Standard care: Peanut or nut free diet
223531584|NCT06616155|DRUG|Ruxolitinib|Given PO
223531585|NCT05828030|PROCEDURE|high flow nasal cannula|the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
224092114|NCT05091346|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
224092115|NCT05091346|DRUG|Lenvatinib|Lenvatinib capsule.
224092116|NCT06087835|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
224092117|NCT06087835|DRUG|Dapagliflozin|Participants will receive dapagliflozin as per the arms they are randomized to
224092118|NCT03496506|DRUG|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
224092119|NCT03496506|DRUG|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
224092120|NCT05121415|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
224092121|NCT05564767|DIETARY_SUPPLEMENT|B. adolescentis Bif-038|B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day
224092122|NCT05564767|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®|Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day
224092123|NCT05564767|DIETARY_SUPPLEMENT|Placebo|Placebo capsule delivered orally once daily
224092124|NCT04850183|BEHAVIORAL|Education on disease management on the quality of life, and anxiety and depression about Rheumatoid Arthritis|The patients in the intervention group participated in a one-to-one training program consisting of a 30-min onset session.
224092125|NCT03751332|DRUG|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
224092126|NCT05590572|DRUG|Sulfatinib|(1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
224092127|NCT05590572|DRUG|Etoposide|(1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
223923677|NCT06557980|OTHER|toothpaste|group of patients with hypersensitive areas will use the calcium silicate toothpaste twice per day (morning and bedtime) the toothpaste will be applied uniformly using medium toothbrush to the hypersensitive surfaces for 30seconds. After that, the patient will rinse their mouth with plain water. the other group of patients will use the sodium fluoride toothpaste twice per day (morning and bedtime). The toothpaste will be applied uniformly using a medium toothbrush to the hypersensitive areas for 30 seconds after that the patients will rinse their mouth with plain water
223923678|NCT06037889|DRUG|Tirofiban|Tirofiban, a GPIIb/IIIa receptor inhibitor. Intravenous administration.
223923679|NCT06037889|DRUG|Aspirin tablet|Aspirin. Oral administration.
223923680|NCT06037889|DRUG|Clopidogrel tablet|Clopidogrel. Oral administration.
223923681|NCT06130826|PROCEDURE|Biopsy|Undergo tissue biopsy
223923682|NCT06130826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223923683|NCT06130826|PROCEDURE|Bone Scan|Undergo bone scan
223923684|NCT06130826|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224092128|NCT05590572|DRUG|Isophosphamide|(1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
224092129|NCT05105243|DRUG|CVN766|highly selective orexin-1 receptor (Ox1R) antagonist
223923685|NCT06130826|DRUG|Immunotherapy|Receive M5A-IL2 ICK SC
223923686|NCT06130826|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224092130|NCT06369779|DEVICE|TM Fill in combination with TM Flow|The newly developed resin composites (TM Flow in combination with TM Fill) will be used for the restoration of class I and II cavities (3 seconds light-curing mode, 3000 milliwatt per square centimeter).
224092131|NCT00960076|DRUG|Saxagliptin|5mg oral tablet once daily
224092132|NCT00960076|DRUG|Metformin XR|500mg oral tablet once daily
224092133|NCT00960076|DRUG|Metformin XR|750mg, 2 tablets once daily
224092134|NCT00500266|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
224092135|NCT00136864|PROCEDURE|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
224092136|NCT01365221|DRUG|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
224092137|NCT01365221|DRUG|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
223923687|NCT06130826|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223923688|NCT06130826|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223923689|NCT06449482|DRUG|Selinexor|three dosage groups were set up, selinexor 60mg QW, 40mg BIW, or 60mg BIW
223923690|NCT06449482|DRUG|Venetoclax|cycle 1 100mg d1 200mg d2 400mg d3-28 cycle 2-4 400mg d1-d28
223923691|NCT06449482|DRUG|Azacitidine|75mg/m2 d1-d7 28d/cycle 4 cycles
223923692|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~1 hour, 3 times a week for six weeks."
223923693|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (six weeks)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~1 hour, 3 times a week for six weeks."
224092138|NCT05809934|DRUG|AZD2693|AZD2693 solution SC once per month
224092139|NCT05809934|OTHER|Placebo|Sodium chloride 0.9% solution SC once per month
224092140|NCT00968266|BEHAVIORAL|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
224092141|NCT04537611|DIAGNOSTIC_TEST|dHb contrast and gadolinium contrast imaging|see arm description
224092142|NCT04285528|DRUG|General anesthetia Fentanyl and Propofol|Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
224092143|NCT04285528|COMBINATION_PRODUCT|PFK|A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
224092144|NCT01149200|DRUG|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
224092145|NCT01149200|DRUG|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
224092146|NCT00000264|DRUG|30% Nitrous oxide|
224092147|NCT00000264|OTHER|0.35 g/Kg ethanol|
224092148|NCT00000264|OTHER|0.7 g/Kg ethanol|
224092149|NCT00000264|OTHER|0 g/Kg ethanol|
224092150|NCT00393562|DRUG|modafinil|
224092151|NCT00393562|DRUG|methylphenidate|
224092152|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT with post procedure curettage
223923694|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
224092153|NCT00215618|DEVICE|Uterine Balloon Therapy|UBT without post procedure curettage
224092154|NCT03757598|OTHER|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
224092155|NCT00659295|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
224092156|NCT03263806|DIAGNOSTIC_TEST|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
223531586|NCT05828030|PROCEDURE|Oxygen mask|All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
223531587|NCT00955578|PROCEDURE|Punch Biopsy|5-6 punch biopsies of affected areas
223531588|NCT04866719|DEVICE|IOL implantation experimental|Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
223923695|NCT05799690|BEHAVIORAL|Gait and balance training with dual-task (twelve weeks: 6 +6)|"Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution.~The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14)~1 hour, 3 times a week for twelve weeks (6+6)."
224280711|NCT06256835|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224280712|NCT06256835|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
224280713|NCT03543709|DIAGNOSTIC_TEST|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
223531589|NCT06659692|DRUG|Gonadotropins Subcutaneous|Gonadotropins s.c. multiple dose
223923696|NCT06965868|DRUG|Metformin|The Metformin intervention will be self-administred capsules, taken during a 12-week period: Four weeks of dose increase; first and second week 500 mg once daily, third and fourth week 500mg twice daily. Full-dose administration (850 mg twice daily) for eight weeks.
224280714|NCT03543709|OTHER|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
224280715|NCT04953078|BIOLOGICAL|Baiya SARS-CoV-2 Vax 1|Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 1 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
224280716|NCT05915793|OTHER|Diaphragm strengthening and accessory muscles stretchings|Diaphragm strengthening and accessory muscles stretchings
224280717|NCT05915793|OTHER|Diaphragm strengthening|Diaphragm strengthening
223531590|NCT06990880|DRUG|GSK5458514|GSK5458514 will be administered.
223531591|NCT06861413|DRUG|VX-828|Tablets for Oral Administration.
223531592|NCT06861413|DRUG|VX-828|Suspension for Oral Administration.
223531593|NCT06592872|BEHAVIORAL|Bullying prevention|The intervention utilizes a serious (educational) videogame and teacher-led, interactive class sessions. Students exposed to the intervention will learn to respond to in-person and online bullying from the perspectives of perpetrator, victim, and bystander. The intervention enhances personal self-management skills, social skills, refusal skills, and other life skills needed to successfully navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
223923697|NCT06965868|DRUG|Placebo|This intervention will be self-administered placebo capsules
223923698|NCT04160494|DRUG|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
223923699|NCT04160494|DRUG|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
223923700|NCT04160494|DRUG|D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)|dual-specific mAB
223923701|NCT06966206|DRUG|Multiprofen-CC™ plus standard treatment|Standard care pain medications and topical Multiprofen-CC™ (1g TID) for 2 weeks
223923702|NCT06966206|OTHER|Placebo plus standard treatment|Standard care pain medications and visually identical topical placebo (1g TID) for 2 weeks
223923703|NCT06964919|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
223923704|NCT06964919|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8， week 12)
223923705|NCT06966362|DRUG|Motivation-Phase Varenicline|Varenicline reduction dosing will start when participants initiate Motivation-phase treatment: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the duration of the 12-week reduction regimen.
223923706|NCT06966362|DRUG|Motivation-Phase Nicotine Mini-Lozenge|NRT mini-lozenge reduction dosing will start when participants initiate Motivation-phase treatment: 2-mg mini-lozenges in place of cigarettes (5-15/day).
223923707|NCT06966362|DRUG|Cessation-Phase Combination Nicotine Replacement Therapy (NRT)|Combination NRT (nicotine patch + nicotine mini-lozenge) cessation dosing will begin on the target quit day: if smoking \>10 cigarettes/day = 8 weeks of 21-mg, 2 weeks of 14-mg, and 2 weeks of 7-mg nicotine patches; if smoking 10 cigarettes/day = 10 weeks of 14-mg and 2 weeks of 7-mg nicotine patches. All participants will receive 2 or 4 mg mini-lozenge for the 12-week cessation period (9/day, 1 piece every 1-2/hours).
223923708|NCT06966362|DRUG|Cessation-Phase Varenicline|Varenicline cessation dosing will start one week prior to their TQD: 0.5mg once daily for 3 days, increasing to 0.5mg twice daily for days 4 to 7, and then to the maintenance dose of 1mg twice daily for the remainder of the 12-week cessation regimen.
224280718|NCT05567939|OTHER|Natural course of disease|Sample and questionnaire collection
223531594|NCT06207422|OTHER|Moderate intensity training program|A 10-week intervention program performed at 60-70% of the heart rate reserve. Heart rate reserve will be calculated using the Karvonen formula (target heart rate = \[(predicted maximum heart rate (= 220 - age) - resting heart rate) x %intensity\] + resting heart rate). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
223923709|NCT06966362|BEHAVIORAL|Motivation-Phase Counseling|All participants receive motivation-phase counseling. Motivation-phase counseling involves 5, 10-15-minute counseling calls. The counselor will work with participants on smoking control skills selected by the participant, such as avoidance of smoking cues, reducing smoking heaviness/contexts, developing urge coping skills, or finding support from friends and family. Counseling will emphasize setting realistic and achievable smoking control goals. Counseling will also emphasize competence and self-efficacy, which will be linked to success in smoking control.
223923710|NCT06966362|BEHAVIORAL|Cessation-Phase Counseling|All participants who enter cessation treatment will be offered 4, 10-15-minute counseling calls. The first counseling session involves pre-quit preparation, and can occur any time before the target quit day. The other 3 counseling calls will be scheduled for 1 day, 1 week, and 4 weeks after the target quit date. Cessation counseling will be based on treatment guidelines and will review instructions for when to start cessation medication, the timing of the quit day (relative to medication start), and medication adherence. Counseling will involve problem solving and skill development.
223923711|NCT06966245|DRUG|mastalgia-oil|External mastalgia-oil 1 ml/d per breast for 3 consecutive menstrual cycles
223923712|NCT06966245|DRUG|Mastalgia-oil placebo|External mastalgia-oil placebo 1 ml/d per breast for 3 consecutive menstrual cycles
223923713|NCT06014385|DRUG|Scopolamine|TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
223923714|NCT06014385|RADIATION|[11C]EMO ([11C]LSN3172176)|A radiotracer specific for imaging M1 receptors. For each PET scan, up to 20 mCi of \[11C\]EMO i.v. will be administered twice, at baseline and post dosing with scopolamine.
223923715|NCT06685432|BEHAVIORAL|Diet|"The effect of motivational interviewing techniques was examined in addition to diet treatment. The effect of motivational interviewing techniques on anthropometric measurements before and after the study was evaluated. The participants' indecisiveness was investigated and a self-directed change conversation was presented. Behavior change strategies including determining positive and negative aspects, using importance and confidence scales, and setting the agenda were applied by the researcher.~In the interviews that included motivational interviewing techniques:~1. A participant-centered interview was conducted by collaborating with the participant.~2. The researcher was impartial and did not assume the role of an expert.~3. At the beginning of the interview, an evaluation of what was discussed in the previous week was made.~4. First of all, an attempt was made to determine the agenda according to the topic the participant wanted to discuss.~5. The importance scale was used (1-10)."
224280719|NCT02860819|DRUG|Veliparib|Veliparib 250mg BID, continuously
224280720|NCT02860819|DRUG|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
224280721|NCT02860819|DRUG|Carboplatin|Carboplatin AUC = 4, day 1
224280722|NCT05171764|DEVICE|Additional Gemstone Spectral Imaging (GSI) cardiac scan|After the subject undergoes the clinically prescribed cardiac Computed Tomography (CT) scan for their diagnostic purposes, the investigational Gemstone Spectral Imaging (GSI) scan will be conducted following the diagnostic CT scan utilizing the same contrast administration.
224280723|NCT01059721|PROCEDURE|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
224280724|NCT04310306|DEVICE|Thrombectomy using EmboTrap II|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, using a stent retriever, contact aspiration EmboTrap II. The number of thrombectomy attempts is at the operator's discretion. Combination of balloon guide catheter or intermediate catheter is recommended.
224280725|NCT03965637|DRUG|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
224280726|NCT03001999|BEHAVIORAL|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
224280727|NCT05184699|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with psoriatic disease will be randomized to receive food supplement Endocalyx for 4 months.
223531595|NCT06207422|OTHER|High intensity training program|A 10-week intervention program performed at ≥80% of the predicted maximum heart rate (target heart rate = predicted maximum heart rate (= 220 - age) x %intensity). The intervention program will consist of three exercise sessions per week, of which one guided group session at Ghent University Hospital and two sessions to be carried out at home.
223531596|NCT07004062|OTHER|Structured Risk Assessment-Based Targeted Nursing Intervention|"Comprehensive Risk Assessment: Evaluation of lifestyle factors (diet, exercise, sleep), psychosocial stressors, medical history, and endocrine-specific biomarkers~Personalized Care Plan: Tailored interventions addressing identified risk factors~Psychological Component: Cognitive-behavioral techniques and stress management~Lifestyle Modification: Guided nutrition (low-glycemic, high-fiber diet) and physical activity plans~Reproductive Health Support: Menstrual cycle monitoring and fertility-related counseling"
223923716|NCT05010369|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
223923717|NCT05010369|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
223531597|NCT07003022|DRUG|cadonilimab combined with an anti-angiogenic agent, which is selected by the investigator from bevacizumab, regorafenib, or fruquintinib.|Cadonilimab: 10mg/kg Q3W; Bevacizumab: 7.5mg/kg Q3W; Regorafenib: 80mg QD; Fruquintinib: 3mg QD.
223531598|NCT07003347|DEVICE|oral spray of MgCl2|Magnesium Salt Oral Spray Device
223531599|NCT07003347|DEVICE|Saline|oral saline aerosol
223531600|NCT07004491|OTHER|Conventional therapy|Ultrasound, Transcutaneous Electrical Nerve Stimulation (TENS) and hot pack application
223923718|NCT05010369|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
223923719|NCT04120805|DEVICE|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
223923720|NCT04120805|OTHER|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
223923721|NCT06690333|DEVICE|Pacemaker|Transvenous pacemaker with left bundle area pacing
223923722|NCT06690333|DEVICE|Pacemaker|Transcatheter pacemaker with MICRA AV
223923723|NCT05989763|DEVICE|Transcutaneous Electrical Acustimulation (TEA)|TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
223923724|NCT05989763|DEVICE|Sham-TEA|Sham TEA will then be administrated for 1 hour twice daily for a period of 4 weeks
223923725|NCT04011839|DRUG|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
223923726|NCT05567003|PROCEDURE|Percutaneous transhepatic cholangioscopic (PTCS) laser incision|Infrared percutaneous transhepatic cholangioscopic guided holmium laser incision for treatment of benign biliary strictures.
223923727|NCT06965205|DIETARY_SUPPLEMENT|MCT feeding|"MCT feeds will be initiated using Nutrison Peptisorb 1kcal/ml. Peptisorb has lower fat content, with a higher proportion of MCTs. The feeding protocol for both formulae will be the same, with equivalent rates of enteral feeding:~* Day 1: if no clinical contra-indication, commence feeding either with standard or MCT feeds at 20ml/hr for 24 hours. Feeds to commence at 8am.~* Day 2: if tolerating feeds continue feeds at 20ml/hr for 12 hours, then increase to 40ml/hr for 12 hours~* Day 3: if tolerating feeds increase feeds to 60ml/hr and await dietician review regarding target rate and duration.~By POD6, if there is no chyle leak, all patients will be given standard feeds for discharge home.~For oral feeding, if patients are progressing clinically, they will have restricted fluids on POD3, with introduction of diet in each group from day 4 onwards. This allows a direct comparison of chyle leak rates for 72h of regular vs MCT enteral feeding."
223923728|NCT06965205|DIETARY_SUPPLEMENT|Standard feeds|Nutrison Protein Plus 1.25kcal/ml.
223923729|NCT06964984|OTHER|Music intervention|The patient will be asked to choose their favorite music. The playlist will include ten songs from each music group (pop, Turkish classical music, local folk songs and religious music), a total of 50 songs. The options will be shown to the patient via the phone (Apple/ MU783TU/A) and the music they want will be added to the playlist. The selected music will be listened to for 15 minutes before the surgery.
224280728|NCT05184699|DIETARY_SUPPLEMENT|Placebo|Patients with psoriatic disease will be randomized to receive placebo for 4 months.
224280729|NCT01188265|DRUG|Valproate|
224280730|NCT01188265|DRUG|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
224280731|NCT01188265|DRUG|Placebo|VPA plus placebo
224280732|NCT01188265|DRUG|Dextromethorphan 30 mg|VPA \& Dextromethorphan 30 mg per day
224280733|NCT03235609|DRUG|Fentanyl|fentanyl used with propofol for sedation
224280734|NCT03235609|DRUG|Ketamine|ketamine used with propofol for sedation
224280735|NCT03264820|DEVICE|Laser Doppler|\- Laser measurements at the level of each finger at 47 °C and at ambient temperature
224280736|NCT03264820|DEVICE|Laser speckle|\- Laser measurements at the forearm
224280737|NCT03264820|BEHAVIORAL|pain evaluation|Visual scale assesment pain
224280738|NCT03264820|OTHER|Blood pressure and heart rate|Measurement of blood pressure and heart rate
224280739|NCT02039752|OTHER|Treatment|
224280740|NCT02292511|BEHAVIORAL|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
224280741|NCT06200428|OTHER|sleep support pillow|A sleep support pillow will be used in this study.
224280742|NCT06436352|PROCEDURE|Capsulotomy and fixation|"Firstly, Guide wire insertion passing anterior to the GT and the neck is done. then passing a pointed Schanze 5 or 6 ± scalpel, under X-ray in AP-lateral views until reaching the capsule (intra trochanteric line). Aspiration of hematoma with suction was done.~Then we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
224280743|NCT06436352|PROCEDURE|Fixation only|"we fix the fracture by proceeding with drilling over the wires using a 3.6 mm cannulated drill bit. Then, we place three 7.0 mm or 7.3 mm cannulated cancellous screws over the wires. In younger patients with thick cancellous bone, a cannulated tap may be required to precut the thread. A washer may be used to prevent the screw head from penetrating the thin cortex."
224280744|NCT02384291|DEVICE|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
224280745|NCT02384291|DEVICE|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
224280746|NCT00298740|DEVICE|Aventis U-400 Insulin|
224280747|NCT03684031|BEHAVIORAL|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
224280748|NCT03684031|BEHAVIORAL|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
224280749|NCT04270006|BIOLOGICAL|adipose derived stem cells exosomes|they are small extracellular vesicles
223531601|NCT07004491|OTHER|Conventional therapy+ Mulligan mobilization|Conventional therapy+ Mulligan mobilization
223923730|NCT06964984|OTHER|stres ball|Stress balls will be given to the patient in both palms, they will be asked to count from one to five and squeeze twice. The patient will be shown and made to use the stress balls for 15 minutes before the surgery. When the 15 minutes are up, the patient will be informed by the nurse and the patient will be asked to release the balls.
223923731|NCT06964984|OTHER|Virtual Reality Glasses|The patient will be shown a video of a nature walk by the nurse providing nursing care to the patient. The patients will be shown a video with virtual reality glasses for 15 minutes before the surgery.
223923732|NCT06966830|DRUG|Lacosamide (LCM)|Intravenous lacosamide is given for the treatment of seizure termination in patients with status epilepticus
223923733|NCT06536049|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223923734|NCT06536049|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223923735|NCT06536049|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223923736|NCT06536049|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
223923737|NCT06536049|BIOLOGICAL|Epcoritamab|Given SC
223923738|NCT06536049|DRUG|Ibrutinib|Given PO
223923739|NCT06536049|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223923740|NCT05258357|DEVICE|Ultrasound-assisted bone marrow biopsy|"After the usual landmark technique is performed and the potential site has been marked, the ultrasound machine fine tunes the drill site location. The probe is placed over the marked site in the transverse orientation. In this view, the location where the sacrum articulates near the ilium is visualized. The physician then searches for the location of the PSIS at its most superficial location, then the PSIS is centered. The probe is then rocked back and forth to determine the optimal drill angle.The skin is marked at the probe indicators on both long sides. In the sagittal orientation the PSIS is visualized and centered. The skin is then marked at the probe indicators on both long sides. The marker is then used to connect the marks, creating an X that marks the desired skin entry point"
224092157|NCT03263806|DIAGNOSTIC_TEST|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
224092158|NCT04360304|DEVICE|Echocardiographic exam|"An echocardiographic exam is realised after inclusion, measuring especially :~* LVOT VTI~* Respiratory variation of inferior veina cava diameter For theses two measurements, the manual method is first recorded, and then the automated one is done.~For patients that need fluid resuscitation of at least 250mL in less than 10minutes (indication at the discretion of the physician in charge of the patient), a second echocardiography is done according to the same protocol described before."
224092159|NCT02249715|DEVICE|Brainsway Multiway deep TMS device (two channels)|
224092160|NCT00371267|BEHAVIORAL|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
224092161|NCT00371267|OTHER|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
224092162|NCT05973409|DEVICE|scleral lens|scleral lens with and without hydra-peg coating
224092163|NCT02509325|DEVICE|Parkinson's Kinetigraph|
223923741|NCT05258357|PROCEDURE|Landmark palpation bone marrow biopsy|The lateral, superior iliac crest is palpated and an attempt is made to follow the course of the posterior iliac crest until the posterior superior iliac spine (PSIS) is palpated. Additionally, the gluteal cleft is visualized indicating the patient midline. The area over the sacrum at midline is then palpated, proceeding laterally until the PSIS can be felt. The skin is marked with a marker at the estimated PSIS and point of entry.
224092164|NCT02714530|DRUG|Erlotinib|Tarceva daily during radiotherapy course
224092165|NCT02714530|RADIATION|Radiation|Radiotherapy
224092166|NCT05811195|DEVICE|Diode Semiconductor, Duo|Intraoral photobiomodulation therapy (660nm, 3s/point, 10J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
224092167|NCT05811195|DEVICE|Gemini laser|Extraoral photobiomodulation therapy (810 + 980 nm, 20s/point, 4.07J/cm²) for the management for the oral mucositis in pediatric patients. Mainly in the decrease of oral mucositis rates severity, healing of the ulcers of OM. The results obtained will be compared with the other group.
224092168|NCT01834495|DEVICE|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
224092169|NCT01834495|DEVICE|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of \> 15mmHg, residual stenosis of \>30% and flow limiting dissection
224092170|NCT04673994|BEHAVIORAL|Single, acute bout of high intensity interval exercise|Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
224092171|NCT00469937|DRUG|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
224092172|NCT00469937|PROCEDURE|cognitive assessment|cognitive assessment
224092173|NCT00469937|PROCEDURE|quality-of-life assessment|quality-of-life assessment
224280750|NCT01465282|DRUG|CT327 0.05%|0.05% CT327 (w/w) ointment
223531602|NCT07004491|OTHER|Conventional therapy+ Graston|Conventional therapy+ Graston application
223531603|NCT07002801|COMBINATION_PRODUCT|remimazolam-remifentanil|For elderly patients scheduled for elective painless gastro-intestinal endoscopy, remimazolam 0.2mg/kg and remifentanil 0.2ug/kg are used for anesthesia induction. During the operation, the doses are adjusted according to the depth of sedation of the patients.
223531604|NCT07002801|COMBINATION_PRODUCT|remimazolam-esketamine|For elderly patients scheduled for painless gastroenterological endoscopy, remimazolam 0.2mg/kg and esketamine 0.15mg/kg are used for anesthesia induction. During the operation, the dosage is adjusted according to the patient's level of sedation.
224092174|NCT00469937|RADIATION|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
224092175|NCT05856864|DRUG|Cadonilimab Injection|Cadonilimab Injection, 10mg/kg, intravenous drip ,q2w,
224092176|NCT05856864|DRUG|Ramucirumab Injection|Ramucirumab Injection，8mg/kg, intravenous drip ,q2w,
224092177|NCT01724281|OTHER|No intervention, only follow up|
224092178|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
224092179|NCT01991561|BIOLOGICAL|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
223923742|NCT05259306|DEVICE|Insightec Exablate Neuro MR-guided focused ultrasound transducer|This study will be utilizing the Insightec Exablate Neuro MR-guided focused ultrasound transducer to deliver low-intensity ultrasonic energy precisely and safely to the target region of the brain. MRgFUS has been FDA approved at high-intensity to treat essential tremor and Parkinson's disease associated tremor. Device premarket approval number (PMA) is P150038, and FDA approval notice was July 11, 2016. This study will be using this device not to make any lesions in the brain (as it is currently FDA approved), but instead to use the precision and non-invasive nature of the device to target the MD thalamus region of the brain at intensities currently approved by the FDA for transcranial ultrasound.
223923743|NCT05151731|DRUG|Vamikibart|Vamikibart will be administered by IVT injection as specified in each treatment arm.
223923744|NCT05151731|DRUG|Ranibizumab|Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
223923745|NCT05151731|OTHER|Sham Procedure|Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
224092180|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
224092181|NCT01991561|BIOLOGICAL|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
224092182|NCT01991561|BIOLOGICAL|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
224092183|NCT01991561|BIOLOGICAL|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
224092184|NCT00896961|DRUG|EF5|
224092185|NCT00896961|OTHER|diagnostic laboratory biomarker analysis|
223531605|NCT07004413|DRUG|FOLFIRI+cetuximab|Cetuximab 500 mg/m², 90 min IV infusion on d1; Irinotecan: 180 mg/m², 90-120 min IV infusion on d1; Folinic acid: 400mg/m², 1-2h IV Infusion on d1; 5-FU: 2400 mg/m², 46 h IV infusion on d1. Cycles are repeated on day 15.
223531606|NCT07004413|DIAGNOSTIC_TEST|Guardant360 ctDNA assay|Determination of circulating tumor DNA (ctDNA) in the peripheral blood, part 1: retrospective threshold determination to predict radiological disease progression in Arm 2; part 2: prospective validation of the in part 1 identified ctDNA threshold to guide the scheduled treatment breaks and treatment in Arm 2
223531607|NCT07004621|OTHER|measurment of intubation time in seconds|determine whether modern technologies such as videolaryngoscopy shorten intubation time.
223923746|NCT03492762|DRUG|Cu-DOTA-ECL1i|Radiolabeled probe called Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
223923747|NCT05770908|OTHER|Therapeutic exercise program|"Therapeutic exercise program based on increasing resistance with elastic bands or weights. The programmes are composed of combinations of the following exercises:~* Scaption with elastic band.~* External rotation at 0º of abduction with elastic band.~* Internal rotation at 0º of abduction with elastic band.~* Shoulder protraction in supine position with weights.~* Low row with elastic band.~* Horizontal adduction stretching."
224092186|NCT00896961|OTHER|pharmacological study|
224092187|NCT03397836|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
224092188|NCT03397836|OTHER|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
224092189|NCT06006975|RADIATION|Computed Tomography (CT) and Computed Tomography Angiography (CTA)|CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.
223531608|NCT07003802|BEHAVIORAL|Resistance exercise|An acute bout of a 3 minute resistance exercise will be performed using a lumbar extension exercise machine
223923748|NCT05770908|OTHER|Multimedia animation information|Multimedia animation videos (including audio) showing the performance of the prescribed exercises.
223923749|NCT05770908|OTHER|Paper-based information|Paper-based information showing the performance of the prescribed exercises, based on figures and a brief description of the exercise performance.
224092190|NCT06006975|DIAGNOSTIC_TEST|Multimodal physiological monitoring|"Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor."
224092191|NCT05806242|OTHER|Italian Validation of the Italian Elderly Mobility Scale (EMS-I)|Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
223717490|NCT03506178|DEVICE|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
223717491|NCT03660267|OTHER|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
223923750|NCT04965454|COMBINATION_PRODUCT|Fluorine-18 fluorocholine|18F-fluorocholine is a radiopharmaceutical imaging agent intended for use only with positron emission tomography (PET) imaging. PET with in-line computed tomography imaging of the torso will be performed following intravenous administration of a single unit dose of this investigational new drug.
223923751|NCT06238297|DIAGNOSTIC_TEST|MRSA nasal swab based de-escalation|Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.
223923752|NCT06965283|BEHAVIORAL|Providing training and Mentoring|The intervention packages are providing postpartum family planning training at each MCH units, Using WHO PPFP counseling toolkit, mentoring health care provider to fill knowledge and skill gap, contraceptive logistic availability, and regular supportive supervision
223923753|NCT03049189|DRUG|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
223923754|NCT03049189|DRUG|Everolimus|Everolimus will be administered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
223923755|NCT03049189|OTHER|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
223923756|NCT06964958|DRUG|177Lu-PSMA-617|A radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.
223923757|NCT06966466|DEVICE|HuGgy Compression vest|This intervention involves the use of a HUGgy compression vest, a wearable device that provides deep touch pressure (DTP) to pediatric patients undergoing tonsillectomy and adenoidectomy under general anesthesia. The vest is worn by patients immediately after surgery, and pressure is applied to provide calming sensory input. The pressure level is adjusted based on the manufacturer's guidelines, providing a gentle, even compression to reduce emergence agitation (EA) during the recovery period.
223923758|NCT06965959|BEHAVIORAL|Exergaming Intervention Group|A behavioral intervention involving the use of motion-based digital games such as table tennis, boxing, skiing, and bowling. Participants performed exergaming sessions twice per week for eight weeks. Each session lasted approximately 15 minutes and was conducted in pairs under supervision. The intervention aimed to promote physical activity, cognitive engagement, and social interaction among older adults in a nursing home setting.
223923759|NCT06965959|BEHAVIORAL|Autogenic Relaxation|A behavioral mind-body intervention in which participants practiced standardized verbal relaxation techniques focused on passive concentration and bodily awareness. Sessions were conducted in quiet rooms in small groups, twice per week for eight weeks, each lasting approximately 15 minutes. The goal was to enhance psychological well-being and reduce emotional tension in institutionalized older adults.
223923760|NCT06970483|DRUG|Tranexamic acid|Transamine1 gram was administered intravenously during the lower segment incision.
223923761|NCT06970483|DRUG|Misoprostol 200mcg Tab|Cytotec 400 micrograms were administered sublingually immediately after delivery of the baby and clamping of the umbilical cord.
223923762|NCT06972927|OTHER|Smoothie containing iron biofortified microgreens|30g of iron biofortified microgreens consumed within a smoothie for 28 days
223923763|NCT02340117|GENETIC|SGT-53|The dose of SGT-53 will be 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 2.4 mg, 1.2 mg or 0.6 mg DNA per infusion in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
223923764|NCT02340117|DRUG|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 100 or 75 mg/m² when appropriate.
223923765|NCT02340117|DRUG|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 800 or 600 mg/m² when appropriate.
223923766|NCT04408755|DRUG|AVP-786|oral capsules
223923767|NCT04408755|DRUG|Placebo|oral capsules
223923768|NCT05778617|DRUG|Ambroxol Hydrochloride (420mg)|Oral tablet
223923769|NCT05778617|DRUG|Placebo|Oral tablet
223923770|NCT02570347|DRUG|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
223923771|NCT02570347|BIOLOGICAL|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
223923772|NCT00308997|DEVICE|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
224092192|NCT00390832|DRUG|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
224092193|NCT00390832|OTHER|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
224280751|NCT01465282|DRUG|CT327 0.1%|0.1% CT327 (w/w) ointment
224280752|NCT01465282|DRUG|CT327 0.5%|0.5% CT327 (w/w) ointment
224280753|NCT01465282|DRUG|Placebo|Placebo
223923773|NCT00308997|DEVICE|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
223923774|NCT04490356|BEHAVIORAL|Legacy Intervention|The Legacy intervention is a nutrition and exercise protocol delivered using video conference technology. The Legacy protocol incorporates behavioral strategies along with nutrition and exercise to maintain and extend functional benefits of obesity treatment.
223923775|NCT03299426|BIOLOGICAL|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
223923776|NCT03299426|BIOLOGICAL|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
223923777|NCT06997562|OTHER|Greater occipital nerve blockade|Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.
223531609|NCT07003815|DRUG|Envafolimab + Gemcitabine + Cisplatin + Simvastatin|"Envafolimab (generic name):~Dose: 300 mg, intravenous (IV) infusion. Schedule: Day 1 of each 21-day cycle (induction phase); every 28 days (maintenance phase).~Role: PD-L1 inhibitor immunotherapy.~Gemcitabine (generic name):~Dose: 1,000 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only).~Cisplatin (generic name):~Dose: 25 mg/m², IV infusion. Schedule: Days 1 and 8 of each 21-day cycle (induction phase only).~Simvastatin (generic name):~Dose: 40 mg, oral tablet. Schedule: Daily (continuously through induction and maintenance phases). Investigational Role: Potential immunomodulator and chemosensitizer in biliary tract cancer.~Treatment Phases:~Induction Phase (Cycles 1-8, 21-day cycles): All four drugs administered. Maintenance Phase (Post-Cycle 8): Envafolimab + Simvastatin only (28-day cycles)."
223923778|NCT06997562|OTHER|Sphenopalatine ganglion blockade|Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.
224092194|NCT03503123|DEVICE|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
224092195|NCT01737775|PROCEDURE|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
224092196|NCT02773797|DRUG|IN-DEX 1.0 mcg/kg, intranasal saline|
224280754|NCT05261789|OTHER|Turkish Get Up exercise|"Before the exercise, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes. 7 different steps (1. Starting position, 2. Supine kettlebell lift, 3. Elbow-supported kettlebell lift, 4. Hand-supported kettlebell lift, 5. High bridge, 6. Half-kneeling and lunge position, 7. Standing up) and the return of these different steps, a total of 2 stages exercise program was applied.~The exercise was started with 3 repetitions for each side and 3 sets with a 30-second rest period between repetitions, and 2 minutes of rest between sets. At the beginning of the 3rd week, the exercise was applied as 3 sets of 4 repetitions, and at the beginning of the 5th week, 3 sets of 5 repetitions were applied. At the end of the exercise, cool-down exercises (low intensity jogging and static stretching) were applied for 5 minutes."
224280755|NCT05261789|OTHER|Core Stability exercise|"After the individuals were taught how to activate their core muscles before the exercise, they were asked to do bridge, prone and lateral bridge exercises by contracting their core muscles. Before the exercises, warm-up exercises (low intensity aerobic activity, short-term stretches) were applied for 5 minutes.~Bridge exercise, prone bridge exercise, lateral bridge exercise were applied"
224280756|NCT05261789|OTHER|Control Group|No exercise will be applied to the individuals in the control group. At the end of the 6-week period, all parameters will be evaluated again.
223531610|NCT07002788|DRUG|Bupivacaine|Used for regional anesthesia during VATS procedure (e.g., paravertebral or serratus anterior plane block)
223531611|NCT07002788|DRUG|Morphine|Used for postoperative pain control via PCA device.
223531612|NCT07002788|DRUG|Paracetamol|Used as part of postoperative multimodal analgesia
223531613|NCT07002788|DRUG|Diklofenak Sodyum|Administered for postoperative pain management
223531614|NCT07003178|DRUG|STR-P004|An in vivo CART drug administered intravenously
223531615|NCT06616610|BEHAVIORAL|Intervention with the Mobility Platform|The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.
223531616|NCT06616610|BEHAVIORAL|Intervention with Traditional Therapy|The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
223531617|NCT04840186|PROCEDURE|Liver-resection or ablation|Liver-resection of colorectal liver metastasis. Ablation can be used as adjunct to surgery.
223531618|NCT04840186|DRUG|2nd line chemotherapy|2nd line chemotherapy. Type of chemotherapy is determined by treating oncologist
223531619|NCT06866145|PROCEDURE|functional endoscopic sinus surgery|sinus surgery
223531620|NCT06866145|DRUG|Dexmedetomidine|precedex
223531621|NCT07003269|DRUG|Hetrombopag|In allogeneic hematopoietic stem cell transplantation, hetrombopag is initiated at 3 µg/kg subcutaneously on day +6 post-transplant. The dose is increased by 2 µg/kg weekly up to a maximum of 10 µg/kg. Treatment is discontinued when platelet counts rise to 100×10⁹/L. If platelet counts remain ≤20×10⁹/L on day +20, hetrombopag is combined with eltrombopag 25 mg orally once daily. Fresh apheresis platelet suspensions (1 therapeutic dose, containing \>2.5×10¹¹ platelets) are administered when platelet counts are ≤20×10⁹/L or when counts are between 21-50×10⁹/L with active bleeding. If engraftment has not occurred by day +28 post-transplant, re-transplantation is required, and hetrombopag is considered ineffective.
223531622|NCT02229630|RADIATION|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
224092197|NCT02773797|DRUG|IN-DEX 1.5 mcg/kg, intranasal saline|
224092198|NCT02773797|DRUG|Placebo - Saline|
223531623|NCT07004075|DRUG|Luvometinib|Luvometinib oral tablet
223531624|NCT07004075|BIOLOGICAL|Chemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide|Investigator's choice of chemotherapy administered IV or orally
223923779|NCT06996067|BEHAVIORAL|Essential Coaching Postpartum|Essential Coaching Postpartum consists of one-way, standardized text messages sent to parents from birth to 6-weeks postpartum to provide evidence-based information on newborn care and mental health. Messages are sent twice a day for the first three weeks (10am and 5pm) and then once a day for the following three weeks (10am), starting the second day after birth.
223923780|NCT06996262|OTHER|observational study|The questionnaire consisted of structured questions covering sociodemographic information, health status, dietary habits, and physical activity levels.
223923781|NCT06996262|OTHER|observational study|Anthropometric measurements was taken.
223923782|NCT06996262|OTHER|observational study|Biochemical analyses were measured was measured using routine methods.
224092199|NCT03415230|OTHER|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
224092200|NCT03415230|OTHER|Sham massage|Sham massage involves only light touch massage in a non systematic way
224092201|NCT02490852|OTHER|Investigational infant formula|fed ad libitum
224092202|NCT02490852|OTHER|Active Comparator: Commercially available Infant formula|fed ad libitum
224092203|NCT02490852|OTHER|Active Comparator: Human milk|fed ad libitum
224092204|NCT03829761|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
223531625|NCT07003360|PROCEDURE|application of beautiful blukfill II shofu composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, beautiful bluk fill II composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
223923783|NCT06996262|OTHER|observational study|Blood pressure were measured was measured using routine methods.
223923784|NCT06997172|PROCEDURE|TCTR (thread carpal tunnel release)|Percutaneous sonography guided release of carpal tunnel release
223923785|NCT06997172|PROCEDURE|Standard-of-care|Open or endoscopic carpal tunnel release based on patients' and physicians' preferences
223923786|NCT04809363|OTHER|CDPATH™|Crohn's disease risk prediction tool.
223923787|NCT04809363|OTHER|Blood Draw|Three blood samples will be drawn.
223923788|NCT06692153|DEVICE|An AID System.|The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
223923789|NCT06692153|OTHER|Standard of Care (SC)|Participants will continue to use their current therapy for T2D.
223923790|NCT06875063|DRUG|GB5005 CART|Included patients will receive GB5005 chimeric antigen receptor T-cell injection: A sterile syringe will be used to draw the assigned dose volume (calculated based on the patient's weight and converted to volume). The cells will be slowly infused intravenously at a rate of about 10 mL/min.
223923791|NCT06686433|OTHER|Novel infant formula|Infants are fed with the novel infant formula from the date of enrollment to the age of 6 months.
224092205|NCT03829761|DEVICE|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
224092206|NCT03645187|DRUG|FOLFERI|FOLFERI regimen
224092207|NCT03645187|DRUG|Folferi and celecoxib|Folferi regimen and celecoxib
224092208|NCT03959436|DRUG|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
224092209|NCT01300104|BEHAVIORAL|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
224092210|NCT01300104|BEHAVIORAL|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
224092211|NCT01300104|BEHAVIORAL|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
224092212|NCT01858103|DRUG|BMN 110|
224092213|NCT01888094|OTHER|Ultrasound-guided cannulation and examination|
224092214|NCT01902108|DRUG|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
224092215|NCT01902108|DRUG|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
224092216|NCT04287530|DIETARY_SUPPLEMENT|Poly-unsaturated fatty acids supplementation|Daily supplementation with 6 daily PUFA (Omega-3 and Omega-6) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
224092217|NCT04287530|BEHAVIORAL|Neuropsychological intervention|"Rehabilitation protocol adopted at IRCCS E. Medea (remote intervention delivered through the Tachidino platform), delivered during four weeks, starting two months after the pre-testing session."
223923792|NCT06686433|OTHER|Standard infant formula|Infants are fed with the standard infant formula from the date of enrollment to the age of 6 months.
223923793|NCT06872021|OTHER|Early IABP use|Patients receive IABP for left ventricular unloading within 6 hours after VA-ECMO initiation.
223923794|NCT06872021|OTHER|Conventional approach|Patients do not receive mechanical unloading within 6 hours after VA-ECMO initiation.
223923795|NCT06871423|BEHAVIORAL|distraction|"distraction via virtual reality game named Waltz of the Wizards aka magic bowl."
223923796|NCT06697158|OTHER|Physiotherapy and rehabilitation|"Complex Decongestive Physiotherapy (CDP) Complex Decongestive Physiotherapy (CDP) consists of Manual Lymphatic Drainage (MLD), skin care, compression bandaging, and exercise, which are routinely used in clinical practice (9). CDP sessions will last approximately one hour each and will be administered for 4 weeks, with 5 sessions per week, totaling 20 sessions.~Manual Lymphatic Drainage (MLD) is a massage technique involving rhythmic, gentle pressure movements aimed at reducing the accumulation of lymphatic fluid in conditions such as lymphedema. This therapy facilitates the drainage of lymphatic fluid into the body's primary lymphatic pathways, thereby reducing edema, pain, and tightness, while enhancing range of motion and overall quality of life. MLD typically focuses on areas with a high concentration of lymph nodes, promoting the smooth circulation of lymph fluid. Treatment sessions usually last between 30 minutes to one hour."
223923797|NCT06697015|OTHER|Pendulum Exercises|In this group, 18 participants will perform pendulum exercises, which involve leaning forward and allowing the affected arm to hang down, swinging it gently in small circular or side-to-side motions. This exercise is designed to enhance shoulder mobility and promote relaxation of the rotator cuff muscles without straining the shoulder joint. The pendulum movement helps improve circulation and relieve tension in the shoulder area, making it a suitable intervention for individuals experiencing rotator cuff pain.
223923798|NCT06697015|OTHER|Serratus Punch Exercises|In this group, 18 participants will engage in serratus punch exercises, focusing on strengthening the serratus anterior muscle. Participants will perform a punching motion by extending the arm forward while maintaining shoulder stability. This exercise activates the shoulder muscles to enhance scapular control, supporting the rotator cuff and improving overall shoulder function. The goal is to build strength in the stabilizing muscles, which can help alleviate pain and enhance mobility in participants suffering from rotator cuff issues.
223923799|NCT06699303|OTHER|Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care|In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
223923800|NCT04212234|DEVICE|ultrasound propagation velocities, ultrasound fetal quality|"Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al."
223923801|NCT07030985|RADIATION|CTP scan|Patients with diagnosed aSAH and no evidence of early radiologic vasospasm will receive a CTP scan within 48 hours of aSAH symptom onset.
223531626|NCT07003360|PROCEDURE|application of Ivoclar vivadent bulkfill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Ivoclar vivadent bulkfill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
223923802|NCT07030985|DIAGNOSTIC_TEST|Neurological and neuropsychological testing|All enrolled patients will receive neurological and neuropsychological assessment at 12 months after aSAH.
223923803|NCT06876844|DRUG|combination of Surufatinib and Envolizumab|envolizumab: 300 mg subcutaneously every 3 weeks (Q3W); Surufatinib : 200 mg orally within 1 hour after breakfast, once daily continuously every 3 weeks as a treatment cycle until intolerable toxicity or disease progression. If any ≥ Grade 2 treatment-related adverse event occurs during treatment, the dose may be adjusted to 100 mg according to the investigator 's clinical assessment.
223923804|NCT06877689|DRUG|Apitegromab|Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
223923805|NCT07028008|BIOLOGICAL|tumor-infiltrating lymphocyte (TIL)|tumor-infiltrating lymphocyte (TIL): CT-SP 1\~100 x10 9 cells
223923806|NCT06879743|OTHER|Suboccipital release|"The ptients in this group recieve suboccipital release. The patient is positioned in a supine (lying on their back) position, allowing full relaxation of the cervical spine.~The therapist places their fingertips or hands under the patient's occiput, making contact with the suboccipital muscles.~Using gentle, sustained pressure, the therapist allows the weight of the head to create a release, often holding for 1-5 minutes.~Subtle adjustments may be made, such as slight traction or rocking, to facilitate myofascial release and relaxation."
223923807|NCT06880185|OTHER|Connective Tissue Graft|Implant treatment was performed in 20 patients with a single tooth deficiency and soft tissue deficiency in the horizontal direction in the edentulous site. All patients received bone-level titanium implants. Soft tissue augmentation was performed simultaneously with implant treatment. The group were divided into CTG , and 10 patients were randomly assigned to group.
223923808|NCT06880185|OTHER|Ribose Cross-Linked Thick Collagen Membrane|Implant treatment was performed in 20 patients with a single tooth deficiency and soft tissue deficiency in the horizontal direction in the edentulous site. All patients received bone-level titanium implants. Soft tissue augmentation was performed simultaneously with implant treatment. The groups were divided into RCCM, and 10 patients were randomly assigned to group.
223923809|NCT06879509|DIAGNOSTIC_TEST|Thromboelastography|All participants will receive this intervention. Thromboelastography (TEG) is a blood test that provides a detailed assessment of the clotting process, measuring how blood clots form, strengthen, and dissolve. It offers real-time insights into a patient's coagulation status, helping to identify clotting disorders and guide treatment decisions.
223923810|NCT06877871|OTHER|WBV utilizes mechanical vibrations to excite muscle, nerves. Abdominal binders are to help patients who have suffered abdominal trauma to stabilize core muscles, reduce pain, and improve mobility|(WBV) is a therapeutic modality that utilizes mechanical vibrations to excite muscle, nerve and tissue structures in the body. WBV was developed initially for fitness and physical rehabilitation and has been moving into other areas of healthcare such as pain management and neurological recovery and improving circulation.However, this activation can help to elevate intestinal motility, reduce bloating and help overall digestion.
224092218|NCT04287530|DIETARY_SUPPLEMENT|Placebo|Daily supplementation with 6 daily Placebo (triglycerides) chewable capsules from the beginning (immediately after the pre-testing session) to the end (immediately before the post-testing session) of the observation period, for a total of three months.
224092219|NCT02451956|DRUG|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
224092220|NCT02451956|DRUG|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
224092221|NCT04039139|BEHAVIORAL|Mind Body Intervention 1: Mind-Body-Syndrome-Therapy (MBST)|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
224092222|NCT04039139|BEHAVIORAL|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
224092223|NCT00110305|DRUG|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
224092224|NCT00110305|DRUG|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
224092225|NCT00110305|DRUG|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
223923811|NCT06757868|DRUG|Amobarbital|Amobarbital 1mg/kg is given prior to cardiopulmonary bypass
223923812|NCT06757868|DRUG|Midazolam|midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
223923813|NCT06877039|OTHER|Observational studies did not involve any interventions|
223923814|NCT06880614|DIAGNOSTIC_TEST|Oral Glucose Tolerance test (75g 2-hour)|The participants are required to drink a glucose solution containing 75 g of glucose dissolved in 250 mL of water
224092226|NCT00110305|DRUG|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
224092227|NCT00110305|DRUG|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
224280757|NCT04610060|BEHAVIORAL|Power walking|"Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~* Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~* Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~* Week 3 70-75 % of the target heart rate (THR) \>=10,000 steps/day~* Week 4 75-80 % of the target heart rate (THR) \>12,500 steps per day"
224280758|NCT04610060|BEHAVIORAL|Standardised outpatient cardiac rehabilitation|Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
224092228|NCT00142506|DRUG|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
224099679|NCT05163704|DRUG|Dexmedetomidine|Dexmedetomidine is a beneficial sedative for children. It provides a sedation equivalent to a natural deep sleep with negligible respiratory effects. Administration via the nose provides better absorption and faster impact effect. The drug does not taste and does not sting when administered.
224099680|NCT00195130|BEHAVIORAL|There are no interventions in this study|
223923815|NCT06880614|DIETARY_SUPPLEMENT|Whey|Supplemented with whey protein isolate masked with a chicken-flavored soup
223923816|NCT06880614|DIETARY_SUPPLEMENT|House cricket|Supplemented with house cricket powder masked with chicken-flavored soup
223923817|NCT06880614|DIETARY_SUPPLEMENT|Placebo|Placebo consists of chicken-flavored soup without any supplement inside
223923818|NCT06880484|DEVICE|Far-Infrared Radiation (FIR) Socks|Participants in the experimental group will receive two pairs of Far-Infrared Radiation (FIR) emitting socks, designed to be worn for at least 8 hours per day over a 3-month period. These socks utilize FIR technology, which is hypothesized to improve circulation, reduce neuropathic pain, and enhance quality of life in patients with diabetic peripheral neuropathy (DPN). Participants will be educated on the proper use of the socks, provided with a usage protocol, and monitored for adherence via three follow-up phone calls assessing compliance and comfort using the Visual Analog Scale (VAS). At the end of the study, participants will undergo a follow-up Electroneuromyography (ENMG) evaluation, and pain and quality of life will be reassessed using the LANSS Scale and NePIQoL forms.
223923819|NCT06880484|DEVICE|Placebo Socks|Participants in the placebo group will receive two pairs of non-FIR socks, which are visually identical to the FIR socks but lack FIR-emitting properties. They will follow the same 8-hour daily usage protocol for 3 months and receive the same education on sock usage. Compliance and comfort will be monitored through three follow-up phone calls, and assessments will be conducted using the VAS, LANSS Scale, and NePIQoL forms. At the end of the study, participants will undergo a final ENMG evaluation.This study aims to determine the effect of FIR socks on neuropathic pain, nerve conduction, and quality of life, using both subjective (pain scales) and objective (ENMG) measures.
223923820|NCT06880432|OTHER|Collection of fluid samples|\- Blood sampling, urine sampling and tissue sampling
223923821|NCT06877832|OTHER|Static Stretching (SS)|For the SS, participants will be instructed to stand and place their dominant foot on a wedge with a 35° incline, stretching the plantar flexor muscles.
224092229|NCT00142506|DRUG|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
224092230|NCT04652362|BEHAVIORAL|Growth Mindset Online Single-Session Intervention|During the self-administered single session intervention participants are provided with basic information about the brain and are introduced to the concept of neuroplasticity. The concept of neuroplasticity is applied to personal traits, such as shyness, anxiety and sadness, and young people are taught that these traits are the result of thoughts and feelings in our brain and are amenable to change. Participants are presented with scientific information and research evidence to support the idea that people have the potential to change and are given vignettes from older children detailing how they have used a growth mindset to overcome difficulties. The intervention takes approximately 20-30 minutes to complete.
224092231|NCT04652362|BEHAVIORAL|Supportive Therapy Online Single-Session Intervention (Control)|The single session supportive therapy intervention was designed to be structurally comparable to the growth mindset intervention, including the same number of reading and writing activities. Participants were provided with information about emotions and the benefits of expressing emotions. Vignettes from older children described times they had shared their emotions with friends and family members.
224092232|NCT05290467|BEHAVIORAL|Online antenatal care|ANC will be provided by obstetricians, and health education will be provided online by midwives. Obstetricians will schedule appointments for the succeeding contacts/visits of the participants. CSOG-recommended prenatal care services will be provided to both the experimental and control groups, using different delivery strategies. Participants in the control group will be scheduled for 12 routine ANC visits, and those in the experimental group will be scheduled for 9 outpatient visits and additional 3 times of services through an online medical service platform. The obstetricians/midwives will train pregnant women how to monitor and record their weight, heart rate, blood pressure, urinary protein, blood glucose, and fetal movement at home. Messages, audio and video chats will be used at online ANC contacts to ensure service quality and accuracy of monitoring the results.
224092233|NCT00033735|DRUG|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
224280759|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, augmented with collagen membrane|Wrapping graft (tendon of the long fibular muscle) with collagen membrane before implantation
223717492|NCT03660267|OTHER|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
224280760|NCT06331741|PROCEDURE|Anterior cruciate ligament reconstruction, using graft, not augmented with collagen membrane (control group)|Implantation of the native graft (tendon of the long fibular muscle) without any augmentation method
224280761|NCT06331741|PROCEDURE|Resection arthroplasty of the first metatarsophalangeal joint with the introduction of a collagen membrane into the joint cavity|Arthroplasty with consequent collagen membrane implantation
223717493|NCT03660267|OTHER|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
223717494|NCT03490097|DRUG|Simvastatin 10mg|tablets
223717495|NCT03490097|DRUG|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
223923822|NCT06877832|OTHER|Foam Rolling (FR)|For the FR, participants will be instructed to position the muscle belly of the PF on the roller. Thirty rolls (15 proximal and 15 distal) will be performed on the muscle belly while maintaining compression on the muscle.
223923823|NCT06877832|OTHER|Foam rolling with dynamic movement (FR-DM)|The FR-DM will involve positioning the muscle belly of the PF on the roller and, without moving the roller, performing 15 plantar flexions and 15 dorsiflexions of the ankle for a period of 30 seconds while compressing the dominant leg with the contralateral leg.
223923824|NCT06879132|DRUG|BR3409|One tablet administered alone
223923825|NCT06879132|DRUG|BR3409-1|One tablet administered alone
223923826|NCT06879132|DRUG|BR3409-2|One tablet administered alone
223923827|NCT06880497|PROCEDURE|total knee arthroplasty|Replacement of knee articulating surface for patients with end-stage osteoarthritis.
223923828|NCT06185595|OTHER|Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.|9.3 oz (273 ml) aliquot of one of the study beverages every 15 min for a total of 28 oz (828 ml) over a 45-min period, followed by 15 min of rest. Flavored water matched for sweetness, color. flavor, but cannot be matched for saltiness. All sodium-containing drinks will include a base blend of other electrolytes (potassium 15 mmol/L, magnesium 8 mmol/L, and calcium 5 mmol/L).
223923829|NCT07033520|BEHAVIORAL|Online Mindfulness-Based Cognitive Therapy|The intervention consists of an 8-week Online Mindfulness-Based Cognitive Therapy (MBCT) program for adults with chronic migraine and adverse childhood experiences. Participants attend one 90-minute virtual group session per week via video conferencing, led by a trained therapist. Daily home practice is encouraged, including 20-30 minutes of guided mindfulness exercises provided as audio files. The program includes cognitive restructuring, body scans, breathing awareness, and acceptance-based techniques. The intervention is fully remote and requires no in-person contact.
223923830|NCT06705153|OTHER|laughter yoga|Patients who come to the outpatient clinic will be met, informed about the study and written informed consent will be obtained from patients who agree to participate in the study. Patient information form will be applied, baseline measurements will be made (IBS-SSS, DAS-42, PSQI and IBS-QOL) and IBS type will be determined according to Bristol stool scale. Type 1-2 constipation, Type 6-7 diarrhea, Type 1 or Type 2 at the same time with Type 6 or Type 7 will be considered as mixed type IBS and those who do not fit any of the scales will be considered as unclassifiable IBS. A total of 8 sessions will be held with the patients in the intervention group in the form of meetings via zoom with the help of a smart cell phone/computer (2 weekly sessions). The meetings will be in 3 groups.
223923831|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to healthy controls|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 100 healthy subjects to determined reference metabolite maps of the whole brain
223923832|NCT06705010|DEVICE|Application of new pulse sequence package SIGNATURES2023 to 4 groups of patients (pilot)|One or more novel or further optimized non CE-marked pulse MRSI sequence is/are applied to 4 time 10 patients with AD, MCI, DM and HGCS to determine metabolite maps of the whole brain.
223923833|NCT06705140|BIOLOGICAL|Low Dose (LD) RSVt vaccine|"Pharmaceutical form:~Liquid for nasal spray~Route of administration: Intranasal"
223923834|NCT06705140|BIOLOGICAL|Standard Dose (SD) RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
223923835|NCT06705140|BIOLOGICAL|High Dose (HD) RSVt vaccine|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
223923836|NCT06705140|BIOLOGICAL|Placebo|Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
223923837|NCT06000254|DEVICE|High energy density pulse electromagnetic field|The treatment coil is positioned over the area of the shoulder that experiences the most pain, and it remains in place for a duration of 9 minutes. The patient is subjected to a high-energy high-PEMF with a frequency of 3 pulses per second during the session.
223923838|NCT06000254|OTHER|physiotherapy|Physiotherapy includes a range of activities such as passive and active-assisted shoulder range of motion (ROM) exercises, Pendulum exercises, Codman's exercises, and Cross-body reach exercises. These exercises are conducted under the supervision of a physiotherapist and each training session lasts approximately 30 minutes.
223923839|NCT06000254|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is positioned over the area of the shoulder where maximum pain is experienced, and it remains in place for a duration of 9 minutes. The parameters are consistent with those used in the experimental group. The key distinction lies in the fact that the energy output is not delivered to the patient.
223923840|NCT06453421|OTHER|Pulmonary rehabilitation|Enrolled patients are subjected to a personalized respiratory rehabilitation treatment aimed both at weaning from the tracheostomy tube and at functional recovery
223923841|NCT06707623|OTHER|Respiratory Physiotherapy|Physiotherapy will include: Progressive breathing retraining, neurosensory training, nose breathing training, activity modification, inhalation-exhalation ratio training, dynamic respiratory control training and instructions for continuing all of the above training at home. Total 5 sessions in 9 weeks time.
223923842|NCT06707623|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation will be completed in 16 sessions (2 times a week for 8 weeks). It will combine exercise with breathing retraining guided by CPET findings regarding erratic breathing pattern and/or hyperventilation.
223923843|NCT06704217|DIAGNOSTIC_TEST|Six Spot Step Test|The Six-Spot Step Test (SSST), which evaluates balance and functional ambulation, will be performed in an area 5 meters long and 1 meter wide. Five wooden cylinders will be arranged in a zig-zag pattern within this space, with the last cylinder positioned at the centerline. The participant will be asked to strike the wooden cylinders with the medial or lateral side of the same foot and push them outward. The test will be repeated twice with the dominant foot and twice with the non-dominant foot. A trial will be conducted before the test to familiarize participants with the procedure. A two-minute rest period between the test and trials will be provided to minimize fatigue effects. The test's inter-rater reliability will be assessed by two physiotherapists with more than 5 years of clinical experience, who will administer the test twice at 5-minute intervals.
223923844|NCT06704217|DIAGNOSTIC_TEST|Oxford Hip Score|The Oxford Hip Score will be used for functional level assessment.
223717496|NCT03602482|BEHAVIORAL|Standing|Participants will stand and complete cognitive tests.
223717497|NCT03602482|BEHAVIORAL|Supine|Participants will complete cognitive tests while supine.
223717498|NCT01445262|DRUG|Levocetirizine|
223923845|NCT06704217|DIAGNOSTIC_TEST|Berg Balance Scale|The Berg Balance Scale (BBS) will be used to assess dynamic balance, which is reliable and commonly used within the orthopedic setting.
223923846|NCT06708260|DRUG|ENN0403, low dose|ENN0403 capsules will be orally administered once a day for 12 weeks.
223923847|NCT06708260|DRUG|ENN0403, high dose|ENN0403 capsules will be orally administered once a day for 12 weeks.
223923848|NCT06708026|BEHAVIORAL|Action Observation and Motor Imagery (AOMI) training|Participants will watch home-based exercise videos and simultaneously imagine themselves performing these exercises in their minds by following verbal instructions in the videos, without actual execution.
223923849|NCT06708026|BEHAVIORAL|Basic wheelchair exercises|A set of low-intensity warm-up wheelchair exercises developed specifically for survivors with spinal cord injury
223923850|NCT06708026|BEHAVIORAL|Watch landscape videos|A set of landscape videos
223923851|NCT06303037|DRUG|Remimazolam besylate and low-dose Esketamine|Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg
223923852|NCT06303037|DRUG|Remimazolam besylate and Medium dose Esketamine|Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
223923853|NCT06708156|DRUG|Atropine sulfate eye drops 0.01%|Drug: 0.01% atropine sulfate eye drops Dosage form and strength: 0.01% (0.4 mL: 0.04 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
223923854|NCT06708156|DRUG|Atropine sulfate eye drops 0.02%|Drug: 0.02% atropine sulfate eye drops Dosage form and strength: 0.02% (0.4 mL: 0.08 mg) eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
223923855|NCT06708156|DRUG|Placebo eye drops|Drug: placebo eye drops Dosage form and strength: 0.4 mL eye drops Usage: both eyes, 1 drop in each eye, once a day, every night before sleep, gently press the dacryocyst on both sides for about 1 minute.
223923856|NCT06707805|OTHER|Traditional Physical therapy|Conventional treatment protocol including moist Heating pad for low back pain for 15 minutes. TENS for pain for 10 minutes. Stretchings of tight muscles would be 1 set of 5-7 reps with 5 sec. hold 3 times a week. Strengthing of weak muscles would be 2-3 times a weak with 10-15 reps.Stretching protocol will be followed for Iliopsoas and erector spinae muscles. Strengthening protocol will be followed for weak abdominals and Gluteus maximus muscles
223923857|NCT06707805|OTHER|lumber SNAGS|": Lumber mobilizations with conventional treatment protocol.~* Lumber Mulligan(SNAGs) technique~* Technique applied at L4-L5, L5-S1 level.~* Techniques applied for flexion ,extension, side bending and rotation 6 to 8 cycles per session"
223923858|NCT06707753|DRUG|AL-001|Administered via suprachoroidal space injection.
223923859|NCT06753864|DRUG|Test (T)|Abaloparatide injection, specification :3120 μg/1.56 ml(2000 μg/ml), drug information subject to actual supply, Qilu Pharmaceutical Co., LTD. The test preparations for the subjects are all from the same batch number.
223923860|NCT06753864|DRUG|Reference (R)|Abaloparatide injection (Tymlos®), specification :3120 μg/1.56 ml(2000 μg/ml), drug information is subject to actual supply, provided by Qilu Pharmaceutical Co., LTD. The reference preparations for the subjects were all from the same batch number.
223923861|NCT06706739|OTHER|Online art game intervention group|The researchers conducted a prospective randomized controlled trial in which elderly patients with mild cognitive impairment combined with subthreshold depression who met the inclusion exclusion criteria were randomized into an online art game intervention group and a health education control group, with each group receiving an individualized intervention for 12 weeks. Participants in the experimental group created comic strips through an art game platform developed by the researchers' research team.
223923862|NCT06708000|DIAGNOSTIC_TEST|Clinical Likelihood (CL) Model-Based Diagnostic Strategy|The Clinical Likelihood (CL) model-based diagnostic strategy utilizes two models: the RF-CL model and the CACS-CL model. These models assess the pre-test probability of obstructive coronary artery disease (CAD) based on patient factors such as age, sex, symptoms, and traditional cardiovascular risk factors like smoking, diabetes, and hypertension. The CACS-CL model incorporates coronary artery calcium scoring to further refine the risk assessment. Patients identified with a low likelihood of CAD may avoid unnecessary diagnostic testing, such as cardiac CT, while maintaining diagnostic accuracy and safety. This approach aims to optimize resource use, reduce patient burden, and focus on other potential causes of symptoms when CAD is unlikely.
223923863|NCT06708000|DIAGNOSTIC_TEST|Standard of care treatment|Patients will follow the standard diagnostic pathway, which includes the use of cardiac CT and other advanced diagnostic procedures based on clinical guidelines. This approach is the current standard of care for patients with suspected obstructive coronary artery disease (CAD). The control group allows for comparison of outcomes with those in the intervention arm, particularly in terms of resource utilization, patient safety, and diagnostic accuracy.
223923864|NCT04717102|DRUG|0.5 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.
223923865|NCT04717102|DRUG|0.75 MAC desflurane|Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.
223923866|NCT04717102|DRUG|1.0 MAC desflurane|On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
223923867|NCT06697782|DRUG|Ondansetron 8mg|Patients in the ondansetron group received 8 mg of ondansetron orally 1 hour before anesthesia and twice at 8-hour intervals thereafter
223923868|NCT06697782|DRUG|Aprepitant 125 mg|Patients in the aprepitant group received 125 mg of aprepitant orally 1 hour before anesthesia and 80 mg orally once daily in the morning of postoperative days 2 and 3 (the day of the surgery was day 1)
223923869|NCT06713226|DEVICE|Hativ P30 and 12-lead ECG comparator device|"The purpose of this study is to compare the clinical equivalence and diagnostic ability of the Hativ P30 against the 12-lead ECG comparator device.~Electrocardiograms of all participants will be obtained using both the Hativ P30 and a 12-lead ECG comparator. That is, all participants will get the same intervention."
223923870|NCT06876675|DRUG|Lorlatinib|To study hyperlipidemia frequency, levels, impact on cardiovascular events after use of Lorlatinib in NSCLC patients.
223923871|NCT06882148|DRUG|target therapies (biological drug, small molecules)|describe the drug sruvival rate of the different approved drugs
224092234|NCT00033735|DRUG|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
223531627|NCT07003360|PROCEDURE|application of Predicta bulk fill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Predicta bulk fill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed
223717499|NCT02720471|DRUG|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
223923872|NCT06882473|OTHER|Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day|Brachytherapy and CT-guided online adaptive external beam pelvic radiotherapy are delivered on the same day.
223923873|NCT06880926|DRUG|Krill oil|Antarctic krill oil was used for intervention in the experimental group.
223923874|NCT06880926|DIETARY_SUPPLEMENT|Olive Oil|Olive oil was used for intervention in the placebo group.
223923875|NCT06881680|DEVICE|virtual reality (VR) head mounted display|This group of subjects received immersive and interactive VR training, which combined rich immersive VR scenes with specific interactive tasks, including two VR scenes. Task selection was based on the subjects' upper limb functional performance, and experienced therapists provided guidance and monitoring, and adjusted the tasks when necessary.
223923876|NCT06882200|OTHER|A combined mindfulness and therapeutic scuba-diving protocol|The Bathysmed program is a unique scuba diving program that combines scuba immersion with techniques from mindfulness meditation, psychology and sports mental preparation. The program includes 30 different exercises over ten scuba-diving sessions with mindfulness training, twice a week for five weeks.
223923877|NCT06882200|OTHER|Control group regular follow up in primary care|Standard care includes regular appointments and health education with their general practitioner and monthly appointments with the dietician and psychotherapist at the primary care centre in Montpellier, France throughout the study. This care includes monthly sessions on diet, exercise and general stress management with a registered dietician.
223923878|NCT06694714|DRUG|0.5 ml lidocaine + epinephrine 1:100,000|0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
223923879|NCT06694714|DRUG|1.0 ml lidocaine + epinephrine 1:100,000|1.0 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb
223923880|NCT06718621|DRUG|BL-M08D1|Administration by intravenous infusion for a cycle of 3 weeks.
223923881|NCT06706960|DIAGNOSTIC_TEST|measurement of IJV-height|"Protocol 1: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is smaller than CCA throughout the whole respiratory cycle.~Protocol 2: IJV tapering portion is portrayed in a transverse view. With a skin marker, the IJV height is marked and measured as soon as IJV is completely collapsed throughout the whole respiratory cycle.~Protocol 3: IJV tapering portion is portrayed in a longitudinal view. With a skin marker, the IJV height at the end of expiration is marked and measured at the following two positions:~1. Measurement 1: at the very end of the tapering portion (collapsing point / top of pulsation).~2. Measurement 2: at the beginning of the tapering portion (taper point)."
223923882|NCT06714708|RADIATION|Experimental|Radiation: 30Gy/15F Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
223923883|NCT06714708|DRUG|Active comparator|Drug: Sintilimab, 200mg IV D1 Q3W Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W
223923884|NCT06719427|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation that uses magnetic fields to stimulate specific areas of the brain. It is commonly used for the treatment of neurological and psychiatric disorders, such as major depressive disorder (MDD), anxiety, and sometimes ALS.
223717500|NCT02720471|DRUG|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
223717501|NCT04344509|OTHER|Bacterial species isolated|in the respiratory specimen
223923885|NCT06704477|OTHER|Survey|Eight questions about protein intake
224092235|NCT00581503|DEVICE|diagnostic|oct imaging
224092236|NCT06131645|DIAGNOSTIC_TEST|IASLC grading system|A cohort of 2160 patients with invasive nonmucinous EGFR-mutant LADCs were retrospectively collected and classified according to the IASLC grading system. The role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy was investigated.
224280762|NCT00684567|RADIATION|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
224280763|NCT00684567|DRUG|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
224280764|NCT01311401|OTHER|NONE intervention|NONE intervention
224280765|NCT01083017|DRUG|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
224280766|NCT01083017|BEHAVIORAL|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
224280767|NCT01083017|DRUG|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
223717502|NCT00192556|BEHAVIORAL|food|
223923886|NCT06706908|OTHER|Health questionnaires|Participants are expected to complete a series of health questionnaires (i.e. numerical rating scale, Oswestry Disability Index) relevant to their treatment using a SI-BONE implant.
223923887|NCT06705218|BEHAVIORAL|MINDSET|2.5-hour mHealth intervention consisting of three modules containing brief films and corresponding interactive reflection activities aimed to improves whole patient health (physical, social, emotional, and functional quality of life as measured by the FACT-G) in patients undergoing systemic treatment for cancer with curative intent. Films feature interviews with people living with cancer describing their experience with diagnosis, treatment, and recovery, and the importance of their mindsets during their experience. The films also feature Stanford faculty with expertise in oncology, psychiatry, and psychology who offer a scientific framework for the importance of mindsets during cancer treatment and provide examples from their clinical practices. The reflection exercises that follow the films are designed to help patients craft a personalized strategy (a) for changing maladaptive mindsets and maintaining adaptive ones and (b) for translating ideas from the film into actionable behavior
223923888|NCT06705218|BEHAVIORAL|Digital Information Series for Cancer|This behavioral intervention provides educational information on coping strategies for individuals undergoing cancer treatment through a hybrid of videos and corresponding questions.
223923889|NCT06733753|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radio frequency ablation, laser ablation
224092237|NCT04128098|OTHER|Evaluation|"* Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~* 3D analysis of locomotion and posture~* Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
224092238|NCT04128098|OTHER|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
224280768|NCT05386095|PROCEDURE|0.25%Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
224280769|NCT05386095|PROCEDURE|0.19% Bupivacaine Axillary brachial plexus block|Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
224280770|NCT00607295|DRUG|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
224280771|NCT02451150|DRUG|Azilsartan|Azilsartan tablets
224280772|NCT04100824|PROCEDURE|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
223717503|NCT00164775|DRUG|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
223717504|NCT00164775|DRUG|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
223923890|NCT06721143|BIOLOGICAL|AION-301|AION-301 Infusion
223923891|NCT06721143|DRUG|Placebo|Placebo Infusion
224092239|NCT04128098|OTHER|Rehabilitation care program|"* Personalized global exercises (aerobics) on ergometers~* Muscle strengthening with resistance~* Balneotherapy~* Learning health skills related to their condition (therapeutic education)~* Personal and group motivational interviews~* Nutritional advice~* Relaxation session"
224092240|NCT05617885|DRUG|Darolutamide|Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.
224092241|NCT05617885|DRUG|Abemaciclib|"Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing."
224092242|NCT05617885|DRUG|GNRH-A Leuprolide Acetate|Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.
224092243|NCT05617885|DRUG|GNRH-A Goserelin|Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.
223531628|NCT07003360|PROCEDURE|application of Stela self-cure bulk fill composite|Operative procedures were performed under local anesthesia and rubber dam isolation. Cavities were prepared using round diamond points (for enamel) and straight fissure and round carbide burs (for cutting in dentin) in a high-speed handpiece. Remaining infected carious dentin was excavated using a hand excavator. Cavities were finished using fine grit yellow-coded tapered diamond stones. 37% phosphoric acid gel was applied for 15 seconds on enamel margins, rinsed with water for 15 seconds and cavities were air-dried with Teflon protection on dentin. Self-etching universal adhesive was actively rubbed on cavity surfaces. Light curing was performed for 20 seconds. In cavities without a liner, Stela self-cure bulk fill composite were placed in bulk (maximum 4mm thickness layer) and cured for 40 seconds, Occlusal adjustments were performed.
223531629|NCT07002983|OTHER|motor control retraining exercises|"The motor control retraining package was targeted at correcting movement impairments of the scapula by re-educating muscle recruitment. There were two components to the package:~1. Motor control exercises to correct alignment and coordination, which involve a) learning optimal scapular orientation at rest and then controlling optimal orientation during active arm movements; b) muscle specific exercises for trapezius and serratus anterior~2. Manual therapy techniques commonly used in clinical practice to manage symptoms, as trigger point therapy and pectoralis minor supine manual stretch will be performed as necessary."
223923892|NCT06721611|DEVICE|Optical Blood Pressure Monitoring Device (Aktiia G1)|"Non-hypertensive Nucor employees that accept to wear an optical blood pressure monitoring device (Aktiia 24/7 device) to screen for and identify potential undiagnosed hypertension.~100 participants. Each participant will wear the device continuously for 28 days."
223531630|NCT07002983|OTHER|traditional physical therapy for shoulder dysfunction|shoulder joint mobilization, posterior capsule stretching and shoulder range of motion exercise (ROM) (Codman's pendulum exercises)
223923893|NCT06882967|DEVICE|Thoracic Endovascular Aortic Repair|Placement of a covered stent (a metal mesh tube with a layer of fabric) into the weakened area of the artery.
224092244|NCT05617885|DRUG|Degarelix|Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.
224092245|NCT04776850|DRUG|Bortezomib|Given IV
224092246|NCT04776850|DRUG|Busulfan|Given IV
224092247|NCT04776850|DRUG|Cyclophosphamide|Given IV
224092248|NCT04776850|DRUG|Dexamethasone|Given IV
224092249|NCT04776850|DRUG|Fludarabine Phosphate|Given IV
224092250|NCT04776850|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
224092251|NCT04776850|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
224092252|NCT04776850|DRUG|Mycophenolate Mofetil|Given IV or PO
224092253|NCT04776850|PROCEDURE|Plasmapheresis|Undergo plasmapheresis
224092254|NCT04776850|BIOLOGICAL|Rituximab|Given IV
224092255|NCT04776850|DRUG|Tacrolimus|Given IV or PO
224092256|NCT01673048|PROCEDURE|3-Nail-ESIN in femoral shaft fractures|
224092257|NCT04385498|BEHAVIORAL|BREATHE Intervention|5 session program focusing on breathing retraining, psychoeducation, and positive coping.
224092258|NCT04385498|BEHAVIORAL|Waitlist Treatment as Usual|Typical primary care treatment which will include medication management and follow-up at the health facilities, at at least the same frequency as treatment arm. At the end of the trial Participants will be able to receive the BREATHE Ethiopia treatment.
224092259|NCT04239417|OTHER|Graduated abdominal strengthening exercises|"1. Exercise mat and inflatable Swiss ball~2. Wall bar, wedges, elastic tubing"
224092260|NCT04239417|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
224280773|NCT04100824|DRUG|Nimodipine|Nimodipine 60mg every 4h
224280774|NCT05419349|PROCEDURE|esophagogastric junction cancer surgery|esophagogastric junction cancer surgery
224280775|NCT02419235|OTHER|20% ethanol|Unmedicated 20% ethanol.
224280776|NCT02419235|OTHER|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
224280777|NCT00746902|DEVICE|nCPAP|Active nCPAP
224280778|NCT04199884|BEHAVIORAL|Active IU-focused Psychoeducation Intervention|This paradigm was an IU-focused psychoeducation intervention wherein participants were provided psychoeducation about the nature of IU and anxiety, given strategies to cope with fear of uncertainty, and provided examples and information as to how they can expose themselves to uncertainty.
224280779|NCT04199884|BEHAVIORAL|Health-focused Psychoeducation Intervention|This intervention is a health-focused psychoeducation intervention wherein participants learn ways to engage in healthy behaviors, such as getting adequate sleep, eating healthier, and exercising regularly.
223923894|NCT06879379|DRUG|KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation|After post-transplant randomization, patients will receive either KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation then maintenance or no consolidation and maintenance.
223923895|NCT06703632|DIAGNOSTIC_TEST|blood sampling|PreveCol test based on blood sampling
223923896|NCT06703632|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
223923897|NCT06703632|OTHER|Survey using a questionnaire.|PREMs for colorectal cancer screening programme
223923898|NCT06880094|GENETIC|blood withdrawal|blood withdrawal for genetic testing
223923899|NCT06884709|OTHER|Mirror Therapy|"During mirror therapy, participants will sit in an arm chair with a mirror placed in their mid-sagittal plane so that their non-paretic lower limb is reflected and their paretic lower limb is hidden. They will be asked to complete activity-based exercises with their non-paretic limb whilst watching the reflection in the mirror and imagining the reflection is their paretic limb.~The activity-based exercises consist of rocker board dorsi/plantarflexion, rocker board in/eversion, step ups, wiping floor (or ball rolling) in/external hip rotation, wiping floor ab/adduction, ball kicking, and picking up marbles with the toes. Participants will do these exercises for 15 minutes, three days per week for four weeks.~Participants will also receive 45 to 60 minutes of usual personalized conventional physiotherapy such as neurodevelopmental facilitation, sensory motor re-education, active/active-assisted exercises, and balance/gait training, five days per week."
223923900|NCT06724523|BEHAVIORAL|Business-as-usual instruction|Deaf children are receiving business-as-usual instruction in sign language in deaf education programs.
223923901|NCT06887309|DIAGNOSTIC_TEST|MRI|MRI : anatomical (3DT1, 3D-FLAIR), functional (task-based and resting-state) and tractographic (multiband diffusion imaging) at three time points: one week, three months and twelve months after the spinal cord injury (SCI)
223923902|NCT06887309|BEHAVIORAL|Neuropsychological tests|The following tests will be performed: the Montreal Cognitive Assessment (MOCA), the Montgomery-Åsberg depression rating scale (MADRS), the Medical Outcome Study Short Form 36 (SF-36)
223923903|NCT06878482|DRUG|Botulinum toxin A|subcutaneous injection of Botulinum toxin A
223923904|NCT06882252|OTHER|Low glycemic index diet|Replacement of typical meal/snack with lean pork containing meal/snack
223923905|NCT06882681|DIETARY_SUPPLEMENT|LipoMicel Milk Thistle|A maximum single dose of approx. 140 mg silymarin (in soft gel capsule)
223923906|NCT06882681|DIETARY_SUPPLEMENT|Unformulated Milk Thistle Extract|A maximum single dose of approx. 130 mg silymarin (in hard gel capsules)
223923907|NCT06885242|DEVICE|Microdrop instillation of cyclopentolate 1%|1 drop administered through the Nanodropper device adapted to the commercially available multi-dose dropper bottle
223923908|NCT06885242|DEVICE|Standard drop instillation of cyclopentolate 1%|1 drop administered directly through the commercially available multi-dose dropper bottle
223923909|NCT06427447|COMBINATION_PRODUCT|Adjuvant chemoradiotherapy|Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
223923910|NCT06427447|DRUG|Adjuvant chemotherapy|Chemotherapy (gemcitabine plus capecitabine)
223923911|NCT06726889|BEHAVIORAL|Standard care|Patient will not receive any additional interventions
224092261|NCT04239417|COMBINATION_PRODUCT|Graduated abdominal strengthening exercises and the Russian current stimulation|Combination between The Russian current and abdominal exercises
224092262|NCT00006122|DRUG|cytarabine|
224092263|NCT00006122|DRUG|etoposide|
224092264|NCT00006122|DRUG|gemtuzumab ozogamicin|
224092265|NCT00006122|DRUG|idarubicin|
224092266|NCT00006122|DRUG|mitoxantrone hydrochloride|
224092267|NCT00044447|DRUG|Glimepiride|
223923912|NCT06726889|BEHAVIORAL|Decision Support System (DSS)|DSS will be used to deliver educational material through a web-page (in Italian language) accessible through a link
223923913|NCT06726889|BEHAVIORAL|Reminders|Personalized reminders will be delivered to patients through a common messaging application (WhatsApp)
223923914|NCT06726889|BEHAVIORAL|Feedback|Feedback message will be delivered by physician to patients, through WhatsApp, after medication diary revision
223923915|NCT06705712|BEHAVIORAL|Use of activity trackers and motivational conversations to enhance focus on physical activity among women trying to conceive.|"All participants will receive a wrist-worn activity tracker (Garmin VívoSmart 5) which will be connected with an application, Fitrockr. Data from the devices will be linked to data from the Snartforældre-questionnaires. The participants are asked to wear the tracker 24/7 during preconception and during the first trimester of their pregnancy if they conceive within 12 months.~Participants will receive information material and be asked to set goals for their PA level. To follow-up on the goal setting, they will receive two phone calls, where the conversations will be inspired by motivational interviewing."
223923916|NCT06883968|BEHAVIORAL|Therapeutic exercise during hemodialysis session|"Participants in the intervention group will receive a therapeutic exercise program during hemodialysis sessions at the hospital. The physiotherapist, after assessing the participant, will plan a program with the sets and number of repetitions for the prescribed exercises based on the participant's condition.~In this exercise program, the lower and upper extremities will be worked on with the aim of improving strength, balance, as well as contributing to the improvement of the participant's quality of life and mood."
224092268|NCT05802810|DRUG|[14C]JT001|Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.
224092269|NCT05289089|BEHAVIORAL|Positive Psychology Intervention|Participants will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Participants will independently complete PP exercises between phone sessions and review them with their study trainer during phone sessions. A total of 9 sessions will be completed over the course of the program.
224092270|NCT06313944|DIAGNOSTIC_TEST|Registry|Clinical data collection of patients scheduled for on-label treatment
224092271|NCT03360929|DRUG|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
224092272|NCT04285918|PROCEDURE|Percutaneous device closure|If there is no relevant AF detected for 6 months during intermittent follow-up or ICM, device closure of PFO is recommended for high-risk PFOs but is decided ultimately at the discretion of the attending physician. If there is any relevant AF identified from ICM or other modalities during follow-up, adequate secondary prevention with anticoagulants should be carried out. All this process and decision making should be a part of routine clinical practice.
223717505|NCT02222974|DRUG|BIIR 561 CL|
223717506|NCT02222974|DRUG|Placebo|
223923917|NCT06880952|OTHER|Chlorhexidine Digluconate Mouthwash without Alcohol|In the rinsing group, the patients received a bottle of 0,2% chlorhexidine
224092273|NCT04080206|DRUG|188-0551 Spray|Applied topically twice daily for two weeks
224092274|NCT04080206|DRUG|RLD|Applied topically twice daily for two weeks
224092275|NCT03481647|PROCEDURE|Oral care programme|Professional oral care (dental hygienist), intensified oral care measures by the patient
224092276|NCT06460350|DEVICE|NEUROCUPLE™ Patch|nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year.
223923918|NCT06879821|OTHER|high intensity functional training|The pillar of rehabilitation will be based on high intensity functional training. 45-minute sessions divided into 5 minutes of warm-up, 35 minutes of functional exercises, and 5 minutes of going back to bed and cooling down. The 35 minutes of exercises were divided into 3 categories: lower extremity exercises, upper extremity exercises, and static and dynamic coordination and balance exercises. Each category will consist of 3 exercises per session, performing 2-3 series with a maximum of repetitions of 10-RM. The progression of the load will be progressively increased in weeks 3, 5 and 8 between 40-60% of the 1-RM.
223923919|NCT06884475|PROCEDURE|Implantoplasty|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a operator. After, anesthesia, surgical access will be performed for debridement and implantoplasty of the affected dental implant.
223923920|NCT06884475|PROCEDURE|Surgical access|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a operator. After, anesthesia, only surgical access will be performed for debridement without implantoplasty of the affected dental implant.
223923921|NCT06881407|DEVICE|Robot|This robot will serve as a cheerleader and coach to provide encouragement and feedback.
223923922|NCT06881407|DEVICE|Virtual Reality|Our developed Super Pop VR system will be used to provide virtual reality intervention.
223923923|NCT06887127|DRUG|TLL-018|TLL-018 20 mg BID for 78 weeks
223923924|NCT01654133|DEVICE|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
223923925|NCT01654133|DEVICE|Endovascular repair of ascending/arch aortic aneurysm using branched stent graft|Repair of ascending/arch aortic aneurysms
224092277|NCT06460350|DEVICE|Placebo Patch|The placebo patch is identical to the active patch but with no active agents.
224092278|NCT04962373|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
224092279|NCT03818269|PROCEDURE|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1 and D2
224092280|NCT06508619|DEVICE|Corsano CardioWatch 287-2 non-invasive blood pressure (NIBP) monitoring|Patients receive Corsano CardioWatch 287-2 for continous NIBP monitoring and perform several spot-checks using an automated BP cuff as a reference during the start or uptitration of BP lowering medication
224092281|NCT05010148|DRUG|Lidocaine IV|Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery
224092282|NCT05010148|DRUG|Placebo|D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
224092283|NCT04676802|DRUG|NSAID capsules|1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
224092284|NCT04676802|DRUG|Opioid capsule|1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
224092285|NCT05113940|DRUG|PF-07258669|PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
224280780|NCT05604079|DEVICE|Electrolarynx|The device transmits electronic sound source vibrations through soft tissue, either the neck at the level of the glottis, or less commonly the check. Speech is created through movements of articulators including the lips, tongue and jaw.
224280781|NCT03136406|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
224280782|NCT03136406|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
224280783|NCT03136406|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
224280784|NCT03136406|DRUG|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
224280785|NCT03136406|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
224280786|NCT03136406|DRUG|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
223923926|NCT06889376|DRUG|Intranasal midazolam administration via the DART™ intranasal atomization device along with routine comfort care.|"Intervention: Intranasal midazolam (0.2 mg/kg) administered 10 minutes before ROP screening via the DART™ intranasal atomization device.~Comfort Measures:~* 1 ml of 20% glucose solution orally with a pacifier, 5 min before screening.~* Swaddling and placement under the radiant warmer.~Monitoring:~* Vital Signs (heart rate, respiratory rate, blood pressure, oxygen saturation monitoring before drug administration until 2 hours after).~* Pain assessment (PIPP scale) conducted before, during, and 10 and 30 min post-procedure.~* Modified N-PASS to assess the level of sedation conducted before, during, 10, 30 minutes 1 hour and 2 hours post-procedure~Observations for signs of:~* Respiratory Distress (apnoea, desaturation, increased work of breathing)~* Cardiovascular Instability (Bradycardia, tachycardia, hypotension)~* Neurological Symptoms (Lethargy, seizures, abnormal tone)~* Gastrointestinal Issues (Feeding intolerance, NEC-like symptoms)"
223923927|NCT06725433|PROCEDURE|Nissen fundoplication|Hiatal hernia repair and Nissen fundoplication
223923928|NCT06725433|PROCEDURE|Dor fundoplication|Hiatal hernia repair and Dor fundoplication
223923929|NCT06704763|DRUG|Orforglipron|Administered orally
223923930|NCT06704763|DRUG|Midazolam|Administered orally
223923931|NCT06704763|DRUG|Quinidine|Administered orally
224092286|NCT05113940|DRUG|Placebo|Placebo will be administered as tablets; Q8H or Q12H over 14 days
224092287|NCT05113940|DRUG|Midazolam|Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
224092288|NCT05826353|DRUG|Ripasudil|K-321 ophthalmic solution
224092289|NCT05826353|DRUG|Placebo|Placebo ophthalmic solution
224280787|NCT03136406|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
224280788|NCT03136406|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
224280789|NCT03136406|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
224280790|NCT03136406|BIOLOGICAL|aNK for Infusion|NK-92 cells
224280791|NCT03136406|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223531631|NCT07003776|OTHER|Biological: Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against Pan- cytokeratin by immunohistochemical procedures.
223923932|NCT06705387|BIOLOGICAL|Dupilumab|Subcutaneous injection of 300mg per week for 16 weeks.
223923933|NCT06705387|DRUG|Fluticasone|Metered dose swallowed topical corticosteroid, given 1760mcg per day for 16 weeks.
223923934|NCT06732674|DIAGNOSTIC_TEST|A home monitoring strategy with event driven management|Bi-weekly home monitoring with forced vital capacity (FVC), patient reported outcome measures (PROMs), at-home measures of blood oxygen levels (SpO2) during 1-minute-sit-to-stand test (1MSTS) and temperature with algorithm based risk evaluation of deterioration and infection and consecutive event driven management
223923935|NCT06059443|BEHAVIORAL|mLab App Plus|Participants will use the mLab Plus app to test for Syphilis and HIV using the DPP HIV/Syphilis Test
223923936|NCT06726577|DRUG|TP04HN106|During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106.
223923937|NCT06726577|DRUG|Saline|The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.
223923938|NCT06704906|DEVICE|Use of Viper Prime/Expedium system with Fibergraft BG Putty|Patients who require spine surgery under standard of care and meet the inclusion and exclusion criteria identified, will be recruited from clinic. Consent for participation in study will be signed at the same time as consent for surgery. All PROMs and scans will be done as standard of care and data will be obtained through chart review for this study.
223923939|NCT05288361|DIAGNOSTIC_TEST|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|"Patients presenting with symptomatic ischemic heart disease (including chronic stable angina or unstable angina) without evidence of myocardial infarction who require elective or urgent cardiac catheterization, and who meet all eligibility criteria will be enrolled.~Participants will undergo routine coronary angiography as well as comprehensive physiologic assessment with intracoronary acetylcholine provocation for diagnosis of vasospastic angina (VSA), coronary thermodilution to evaluate for coronary microvascular dysfunction (CMD), and intracoronary imaging with optical coherence tomography (OCT) or intravascular ultrasound (IVUS) to evaluate for the presence of atheroma, plaque burden, and myocardial bridging."
223923940|NCT03535142|PROCEDURE|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
224280792|NCT03136406|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
224280793|NCT04778306|PROCEDURE|Transoral Laser Surgery|Remove of the laryngeal tumour via diode laser
223923941|NCT06734481|DRUG|Sodium bicarbonate pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of 2.5% sodium bicarbonate in 7 days. For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage.Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days.
223923942|NCT06734481|DRUG|Saline pleural lavage|All participants will receive a standardized antimicrobial therapy regimen, with antibiotics selected based on susceptibility testing. Within 2 days of initiating treatment, all patients will undergo catheter placement for continuous drainage of pleural effusion. Participants will receive a daily intrapleural injection of 200 mL of saline in 7days For patients with ultrasound evidence of pleural effusion loculations or drainage tube obstruction, intrapleural administration of urokinase may be performed at the discretion of the treating physician to ensure effective drainage. Following each daily injection, the catheter will be clamped for 2 hours before resuming continuous drainage, a process that will continue for 7 days..
223923943|NCT06734013|DIAGNOSTIC_TEST|Molecular diagnostic|RNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
224280794|NCT03670732|OTHER|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
224280795|NCT03670732|OTHER|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
223923944|NCT06492213|OTHER|No interventions|It is a observational study to investigate the efficacy and safety of PRP combined PRF on IONa compared to PRF alone.
224280796|NCT04859387|OTHER|set of pragmatic shoulder technique|Group A received pragmatic intervention which includes Pectoralis major and minor stretch, AC joint mobilization, rotator cuff facilitation for subscapularis and infraspinatus, serratus anterior stretch, thoracic manipulation and posterior capsular stretch.
224280797|NCT04859387|OTHER|traditional physical therapy|Group B received traditional interventions which includes modalities such as TENS and hot pack, soft tissue mobilization, joint mobilization, stretching and strengthening etc. other than pragmatic intervention
223923945|NCT06741384|OTHER|Diaphragmatic breathing exercises|Participants will be directed to position their hands on the rectus abdominis muscle located under the anterior chest wall while resting in a hook position. They will be instructed to inhale slowly and deeply via the nostrils, expanding their abdomen without raising their upper chest, and resting their shoulders. Following the cessation of respiration, the woman will slowly exhale by pursing her lips. A respiratory cycle will consist of a three-second inhalation, a three-second pause, and a six-second exhalation. The diaphragmatic training regimen will consist of doing 3-5 sets of 5-10 deep breaths, with 2-minute intervals of rest in between sets.
223923946|NCT06741384|OTHER|Aerobic training|The women will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
223923947|NCT06638645|PROCEDURE|VATS/RATS anatomical lung resection|Perioperative care according to the ERAS protocol for lung surgery
223923948|NCT06890858|DRUG|Fasudil Hydrochloride|Exploring whether the study of using Exploring whether the study of using Fasudil Hydrochloride for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors
223923949|NCT06745271|DRUG|[14C]-tebapivat|Oral Capsule
223923950|NCT06745271|DRUG|[13C2,15N3]-tebapivat|Intravenous Solution
223923951|NCT06890910|OTHER|evidence based intervention|"sleep hygiene education. This education focused on four main aspects as follows:~* Personal habits: Women were educated on establishing a regular bedtime routine, engaging in regular exercise, maintaining a healthy diet, avoiding caffeine and nicotine before bedtime, consuming adequate calcium and magnesium, drinking warm milk before sleep, and avoiding gas-producing foods or excessive fluid intake before bed.~* Sleep environment: Women were advised to associate the bedroom only with sleep and intimacy, remove electronic devices, maintain a dark, quiet, and cool environment, ensure mattress and pillows were comfortable, and eliminate noise disturbances such as television.~* Stimulus control: Participants were instructed to use the bed only for sleeping, avoid staying in bed if unable to sleep, and engage in minimally stimulating activities instead of worrying about insomnia.~* Progressive muscle relaxation: Women in the study group received an educational session on the Jacobson's met"
223923952|NCT06890819|BEHAVIORAL|Assigned Interventions|Behavioral: Structured Feedback, Clinical Decision-Making, Anxiety, Self-Confidence,
223923953|NCT06892470|OTHER|No intervention|No intervention
223923954|NCT06733116|OTHER|Delphi method survey|This intervention involves a Delphi method study, where a panel of experts in isokinetic testing will collaborate to reach a consensus on best practices for standardizing the reporting of isokinetic test data. Unlike other clinical studies, this intervention focuses on gathering expert opinions iteratively to establish a unified framework for data reporting, without direct clinical or experimental treatment. The process includes multiple rounds of feedback, refining key elements related to testing protocols, measurement parameters, and result presentation, ensuring broad expertise from various fields such as medicine, rehabilitation, and biomechanics.
223923955|NCT06738940|DEVICE|CPAP|Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 48 weeks
223923956|NCT06738979|DRUG|TQF3510 (Semaglutide Injection)|Semaglutide injection is a long-acting Glucagon-like peptide-1 (GLP-1) receptor agonist.
223923957|NCT06738979|DRUG|Wegovy®|Active Comparator
223923958|NCT06739265|DRUG|Golidocitinib plus CHOP|Phase 1: dose escalation phase. Drug Golidocitinib: 2 dose level of 150 mg qod and 150 mg qd; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle. Phase 2: dose expansion phase. Drug Golidocitinib: RP2D established in the phase I study; CHOP regimen: cyclophosphamide (750 mg/m2 intravenously on day 1), epirubicin (70 mg/m2 intravenously on day 1), vindesine (4 mg intravenously on day 1), and prednisone (60 mg/m2 orally on days 1-5) in a 3-week cycle.
223923959|NCT06739213|DRUG|SYHA1813|The starting dose of SYHA1813 is 20mg QD
223923960|NCT06739213|DRUG|Investigator's Choice Treatment|Investigator's Choice Treatment
223923961|NCT06740916|DRUG|81-mg aspirin once daily|81-mg aspirin once daily
223923962|NCT06740916|DRUG|81-mg aspirin twice daily|81-mg aspirin twice daily
223923963|NCT06740448|DIETARY_SUPPLEMENT|Green Tea|200 mL Green Tea
223923964|NCT06740448|DIETARY_SUPPLEMENT|Control (Hot Water)|200 mL hot water
223923965|NCT06741358|OTHER|Glialia|Participants in the PPPD-Glialia group will receive the Glialia supplement, which contains 700 mg of Palmitoylethanolamide (umPEA) along with 70 mg of additional supportive ingredients. Each participant will be instructed to take two soluble sachets daily for a total duration of 60 days. This group aims to evaluate the effects of Glialia on PPPD, with outcomes assessed for neuroinflammation, mental clarity, quality of life, balance, and gait quality.
223923966|NCT06741358|OTHER|Placebo|Participants assigned to the PPPD-Placebo group will receive a placebo that is designed to be indistinguishable from the Glialia supplement in terms of appearance and packaging. They will also take two soluble sachets daily for 60 days. The purpose of this group is to serve as a control to evaluate the effects of the Glialia supplement by comparing the outcomes with those of the PPPD-Glialia group. The same assessments for neuroinflammation, mental clarity, quality of life, balance, and gait quality will be performed.
223923967|NCT06741358|OTHER|Control|Individuals in the Control Group will receive the same Glialia supplement as the PPPD-Glialia group, containing 700 mg of Palmitoylethanolamide (umPEA) and 70 mg of supportive ingredients. They will also take two soluble sachets daily for 60 days. The primary goal for this group is to assess how the Glialia supplement affects neuroinflammation and related outcomes in individuals who have recovered from COVID-19 but do not have PPPD. This comparison will help clarify the potential effects of Glialia in the context of both PPPD and recovery from COVID-19.
224092290|NCT06018207|DRUG|Midazolam oral solution|"The ED50 dose of midazolam oral solution for hypnosis is studied using an up-and-down sequential allocation while waiting for surgery and general anesthesia in preoperative room.~The starting dose is 6 mg and the step size is 1 mg. The interval sequential dose is varied by 1 mg based on the hypnosis response of the previous patient after one hour.~Definition of successful hypnosis by taking midazolam oral solution:~The polysomnograph (PSG) not only shows stage N2 within 30 minutes, but also shows stage N3 within an hour; or else, definition of unsuccessful hypnosis.~The procedure is as follows: (1) The first subject is given 6mg of midazolam oral solution; (2) If succeed, the second subject takes 5mg; (3) If not succeed, the second subject takes 7mg; (4) Until seven sequence reversal inflection points."
224092291|NCT05475002|OTHER|care empowerment program|dementia care e-books, dementia virtual reality activity and family support group
224280798|NCT01082887|OTHER|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
224280799|NCT04778618|DRUG|Antithymocyte Globulin|Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 6 mg/kg to 10mg/kg). Antithymocyte globulin (ATG) was added to conditioning regimens for 4 days (days -5 and -2). Prophylaxis against graft-versus-host disease (GVHD) was performed with cyclosporine A (CsA), mycophenolate mofetil (MMF) and short-term methotrexate
224280800|NCT03576287|DRUG|Apremilast Oral Product|Apremilast
224280801|NCT05209828|DEVICE|pfmmedical implantable vascular access ports|Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
224280802|NCT00588328|DEVICE|PET/CT scan|PET/CT scans
223531632|NCT07003711|OTHER|aerobic exercise and relaxation trainig|Aerobic exercise and progressive muscle relaxation training will be given to the exercise group.
223531633|NCT07003711|OTHER|aerobic exercise|Aerobic exercise will be applied to the control group.
223531634|NCT07003438|DRUG|Fecal microbiota transplantation (FMT)|FMT was slowly administered to the patient's small intestine with fecal suspension under anesthesia and patients received a second transplant through oral administration freeze-dried capsules containing the fecal matter.
223531635|NCT07005011|OTHER|oral irrigator|oral irrigator
224092292|NCT05475002|OTHER|dementia education|dementia education manual and family support group
224092293|NCT06513884|DRUG|HB-202/HB-201 alternating 2-vector therapy|Intravenous administration of HB-202 alternating with HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
224280803|NCT01705431|BEHAVIORAL|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
224280804|NCT00001662|DRUG|CX516 (Ampalex)|
224280805|NCT03056768|BEHAVIORAL|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
224280806|NCT03056768|BEHAVIORAL|Active control|Health promotion activities provided by local health bureau.
224280807|NCT03404401|DRUG|BLI4700|Oral bowel preparation
223717507|NCT01180946|DIETARY_SUPPLEMENT|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
223717508|NCT01180946|OTHER|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
223717509|NCT02601469|DRUG|DSXS|twice daily for 28 days
223531636|NCT06673901|DEVICE|Measurments|Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.
223531637|NCT06679881|DRUG|Deucrictibant|Deucrictibant extended-release tablet for once daily oral use
223531638|NCT06875141|BIOLOGICAL|DM199|DM199 is a synthetic form of rhKLK1
223923968|NCT06736665|DEVICE|Orbital atherectomy|The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
223923969|NCT06736665|DEVICE|Intravascular lithotripsy|The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
223923970|NCT06736665|DEVICE|Optical Coherence Tomography (OCT)|"Optical Coherence Tomography (OCT) is an intravascular imaging modality that uses near-infrared light to provide high-definition, cross-sectional and three-dimensional images of the vessel microstructure.~These images provide additional information on the degree and characteristics of coronary artery disease compared to angiography which doesn't delineate the composition of the coronary artery. With automated, highly accurate measurements, OCT can guide stent selection, placement, and deployment."
223923971|NCT06736665|DEVICE|Percutaneous coronary intervention with stent implantation|All patients will undergo percutaneous coronary intervention with drug-eluting stent implantation after plaque modification using the technique assigned by randomization.
223923972|NCT06737757|DEVICE|Artificial polymer heart valves|The experimental group will use polymer material surgical aortic valves(PoliaValve, Hearthill Medical) for aortic valve replacement
223923973|NCT06737757|DEVICE|Bovine pericardial aortic valve|The control group will undergo aortic valve replacement using bovine pericardial aortic valve
223923974|NCT06739694|BEHAVIORAL|PNE|A manual therapy(Mulligan´s Mobilization with Movement) and 4 sessions of strenght exercises program was administered for both groups. In addition, a pain neuroscience education protocol was administered for the experimental group for a whole period of 4 weeks (1 session/week, 75mins per session).
223923975|NCT06739694|PROCEDURE|Manual therapy|5 sessions of Mulligan´s Mobilization with Movement and 4 sessions of strenght exercises
224092294|NCT06513884|DRUG|Placebo|Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
224092295|NCT06513884|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
223531639|NCT07039058|BEHAVIORAL|Brief Dialectical Behavior Therapy-Skills Training|"The intervention is administered in a single session, lasting approximately 60 minutes and conducted in person. It is important to note that there are no ongoing sessions.~In the intervention, participants are provided with 5 basic skills of Dialectical Behavior Therapy: 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing body chemistry. These strategies are grouped under 3 categories: 1) Mindfulness, 2) Emotion regulation (mindfulness of current emotions, opposite-to-emotion action), 3) Tolerating distress (distraction, changing body chemistry). These skills are not designed to treat or solve the crisis. The main aim is to provide effective coping mechanisms that can be implemented quickly before the crisis escelates, to help overcome the intense emotional pain and keep the person alive."
224092296|NCT06021080|PROCEDURE|CVVH|CVVH therapy
224092297|NCT06021080|PROCEDURE|CVVHD|CVVHD therapy
224092298|NCT06584110|OTHER|Buddy-Up Dyadic Physical Activity (BUDPA) program|"BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support."
223923976|NCT06738238|OTHER|ELDOA|"In this, each position will be maintained for 1 minute Level: C0/C1/C2 The patient is side lying with bottom arm folded under the head and maintain the neck in a horizontal position with the spine. the bottom leg is bent to stabilize the torso in a vertical position.~Level: C4/C5 Patient lying in supine position and raise both hand arm towards the roof of the room with extended wrist. Bilateral knee to chest with planter flexion at ankle joint.~Level: C5/C6 Same position as for c4/c5 with the arms will be elevated 120 degree Level C6/C7 Supine position with one arm abducted 90 degree and wrist joint at extension and the other hand abducted 30degrees with wrist joint at extension and one leg knee to chest and one leg raise with knee extension and planter flexion at ankle joint.~Level: T4/T5 Quadruped position with one arm abducted 90degrees with wrist at extension Level: T6/T7. Conventional TX is Hot Pack, Tens for 10min. Patient is assessed through baseline, week 1, week 2 and week 4."
223923977|NCT06738238|OTHER|CORRECTIVE EXERCISES|All position will be held for 10 seconds. Initial phase Duration of this phase is 2 weeks. Exercise 1: lying supine on a foam roll with different abduction angles Exercise 2: side lying with external rotation Exercise 3: side lying with forward flexion Exercise 4: standing diagonal flexion Exercise 5: military press Improvement phase. Duration of this phase is 1 week we only add thera- band and dumbbells to the previously mentioned exercises Exercise 1: side lying external rotation with dumbbell Exercise 2: side lying forward flexion with dumbbell Exercise 3: standing diagonal flexion with thera-band Exercise 4: standing external rotation with thera band. Exercise 5: abduction in sitting on training ball. Exercise 6: lying prone on foam ball with different abduction angles Maintenance phase. Duration of this phase is 1 week. Conventional treatment Hot Pack, Tens for 10 minutes Patient is assessed through baseline, week 1, week 2 and week 4.
224092299|NCT06584110|OTHER|Usual care with waiting list|Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
224092300|NCT04122196|DRUG|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
224092301|NCT04122196|DRUG|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
224092302|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Monococcum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Monococcum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
224092303|NCT06191432|DIETARY_SUPPLEMENT|Administration of Triticum Aestivum flour|"Patients will be administered a daily dose of 80g of flour of Triticum Aestivum (equivalent to 10g of gluten), which will be dissolved and cooked by the patients themselves. During the challenge, the severity of the symptoms will be recorded using a 10-points visual analog scale (VAS). The challenges will be stopped when clinical reactions will occur for at least 2 consecutive days (increase \>3 in VAS) for either GI or extraintestinal symptoms.~Challenges will be considered positive if symptoms, which had been initially present, reappear after their disappearance on elimination diet, and if the GI and/or extraintestinal symptom's scores will be \>30% compared to any eventual increase determined during the administration of the other wheat variety."
224092304|NCT05074264|PROCEDURE|Biopsy|Undergo biopsy
224092305|NCT05074264|PROCEDURE|Biospecimen Collection - Anal|Undergo collection of anal swabs
224092306|NCT05074264|PROCEDURE|Biospecimen Collection - Cervical|Undergo collection of cervical swabs
224092307|NCT05074264|PROCEDURE|Colposcopy|Undergo colposcopy
224092308|NCT05074264|PROCEDURE|High Resolution Anoscopy|Undergo high-resolution anoscopy
224092309|NCT05074264|PROCEDURE|Imaging Technique|Undergo cervical imaging
224092310|NCT00808743|DRUG|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
224092311|NCT00808743|DRUG|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
224280808|NCT03404401|DRUG|Polyethylene glycol bowel preparation|Oral bowel preparation
224280809|NCT00204022|DRUG|Mycophenolate mofetil|Mycophenolate mofetil
224280810|NCT00204022|DRUG|Azathioprine|Azathioprine
224280811|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil|Ready to Use Therapeutic Food
224280812|NCT01593969|DIETARY_SUPPLEMENT|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
224280813|NCT01593969|DIETARY_SUPPLEMENT|Standard RUTF|Standard formulation RUTF given according to National Guidelines
224280814|NCT00988208|DRUG|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
224280815|NCT00988208|DRUG|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
224280816|NCT00988208|DRUG|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
224280817|NCT00988208|DRUG|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
224280818|NCT00271739|DEVICE|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
223923978|NCT06736730|BEHAVIORAL|Hospital-Linked Violence Intervention Program|Activation of Operation Good, our community partner with a history of direct violence interruption in the streets and longitudinal health and wellness services to firearm injured patient (i.e. linking and aiding those who have suffered from violent injury to mental healthcare, job services, educational services)
223923979|NCT06736730|BEHAVIORAL|Mobile Community Event Support|A menu of services provided to the community in an activated cluster where funding will be provided to assist that community in holding events that support overall health and wellness (community clean-up, legal advisory services, pop-up clinic for blood pressure checks).
223923980|NCT06736730|BEHAVIORAL|Unrestricted Cash Assistance|A participant in an activated cluster after firearm injury will receive two disbursements of 500$. One at the time of initial hospital evaluation and a second disbursement \~1 month later to offset the financial burden associated with firearm injury on the individual.
223923981|NCT06737523|DRUG|CVA|Chiglitazar Sodium in combination with Venetoclax and Azacitidine
223923982|NCT06869304|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Preoperative and postoperative MoCA test scores
223923983|NCT06251245|PROCEDURE|Oral Injector|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* • Experimental Group (Giving the medicine orally to the child with an Oral Injector)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
223923984|NCT06251245|PROCEDURE|Spoon|"* Admission of a child with fever to the pediatric inpatient ward~* Obtaining parental consent~* Completing the patient identification data collection form~* Obtaining the child's consent~* Applying the Child Fear Scale to the child~* Measuring the child's pulse and SpO2~* Applying the Child Fear Scale to the parent~* Explaining the procedure using the educational therapeutic play method before oral medication administration~* Administering the Child Fear Scale to the child and parent before oral medication administration~* Measurement of the child's pulse and SpO2~* Control Group (Giving the medicine orally to the child with an oral medication spoon)~* Application of the Child Fear Scale to the child and parent after oral medication administration~* Measurement of the child's pulse and SpO2"
223923985|NCT06736197|PROCEDURE|Group TVB|Patients who could not reach ETO2 value 90 with tidal volume breathing for 3 min were included in Group TVB tidal volume breathing was continued for 2 min.
223923986|NCT06736197|PROCEDURE|Group PSV|Preoxygenation was continued by providing 6cmH2O pressure support to the patients included in this group.
223923987|NCT06736197|PROCEDURE|Group PSV+PEEP|At the 4th minute, preoxygenation was continued by adding 4 cmH2O positive end-expiratory pressure to the same 6 cmH2O pressure support for 1 min in patients whose end-tidal O2 value still reached 90% and who were included in this group.
223923988|NCT06734598|DRUG|Echo-guided Botox injection|Echo-guided Botox injection to the masticatory muscles
223923989|NCT06734598|PROCEDURE|echo-guided normal saline injection|echo-guided normal saline injection
223923990|NCT06735495|DRUG|CD19&CD22 bispecific CAR-T cells|Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
223923991|NCT06734715|OTHER|Conservative oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
223923992|NCT06734715|OTHER|Liberal oxygenation|Patients that were previously randomised to receive conservative oxygenation while in paediatric intensive care
224092312|NCT00808743|DRUG|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
223531640|NCT07039058|BEHAVIORAL|Relaxation|The control group will be subjected to a relaxation exercise, with the objective of managing participant expectations, researcher attention/interest, and time spent, as well as providing a coping strategy for stress.
223531641|NCT04187404|BIOLOGICAL|EO2401|Multiple dose of EO2401
223531642|NCT04187404|BIOLOGICAL|Nivolumab|Multiple dose of nivolumab
223531643|NCT07039084|DEVICE|Speech-generating device|The device is an iPad loaded with a grid-based and speech-generating communication application - a suitable application for the participant is determined at the beginning of the trial. This device is used in all 12 therapy sessions and implemented by a qualified speech pathologist in a natural, play-based setting.
224092313|NCT03135145|DEVICE|Lite Run Gait Trainer|"Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient."
224092314|NCT03135145|OTHER|Usual Treatments|The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
224092315|NCT03619213|DRUG|Dapagliflozin|10 mg tablets given once daily, per oral use.
224092316|NCT03619213|DRUG|Placebo|Placebo matching dapagliflozin 10 mg
224092317|NCT01002508|BIOLOGICAL|Influenza vaccine|One dose of influenza vaccine
224092318|NCT06033586|DRUG|Open-label rusfertide|subcutaneous rusfertide
224092319|NCT04384237|PROCEDURE|Er,Cr:YSGG laser-aided CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a 9 x 0.5 mm laser tip into the gingival sulcus with an angle of 10-15º to the radicular surface
224092320|NCT04384237|PROCEDURE|Conventional CSF|After injection 2% lidocaine with 1:80.000 epinephrine concentration in labial and lingual vestibule the fiberotomy is carried out by inserting a surgical blade (#11)into the gingival sulcus at an angle of 10-15º to the radicular surface
224280819|NCT00271739|OTHER|usual care|usual diabetes care, as provided by primary care providers
224280820|NCT00037687|DRUG|rPAF-AH|
224280821|NCT05498493|BEHAVIORAL|Cognitive Rehabilitation|The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
223923993|NCT06735586|PROCEDURE|neuromuscular control exercise|All of the 17 participants participating in the study will be included in the 6-week exercise program investigators created after the initial evaluations. Exercises will be done 3 times a week, 10 sets of each exercise. And the participants will be given a rest period of 3 minutes between each set.1st and 2nd (5 times) week exercise program: Non-weight bearing exercises will be given in the first week; lateral hip abduction, clam shell exercises, and bridging exercises. 3rd and 4th week (5 times) exercises: This week investigators will give controlled weight lifting exercises:pelvic drop exercise, single leg squat exercise,step down exercise,single leg raise exercise. 4th and 5 th week exercise: lateral band walks, side lunges, forward lunges, and back lunges. 5 th and 6 th week exercise: Plyometric exercises: jump exercise, BOSU single knee scales exercise,resistive single leg squats,resisting vertical bridge.
223923994|NCT06735586|PROCEDURE|neuromuscular control exercise and taping|Exercises and taping will be done 3 times a week, 10 sets of each exercise. Mulligan Knee Taping Application: The application was made with Protape 38mm x 10 m rigid tape. The application will be performed in the participant's foot, with the hip and knee in internal rotation, and the knee in 20º flexion. The tape will be applied starting from the head of the fibula, passing over the tibia anteriorly, passing under the medial joint line of the knee and ending at the back of the knee, bringing the tibia to internal rotation.
223923995|NCT06735794|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-c (active comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-c, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
223923996|NCT06735794|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-s (experimental study intervention), which will be delivered unilaterally to the left motor cortex. Following iTBS-s, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
224092321|NCT00378326|DRUG|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
224092322|NCT01256541|DRUG|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
224092323|NCT03881709|BEHAVIORAL|Using an E-Book|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
224280822|NCT05498493|BEHAVIORAL|Brain Health Education Program|The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
224280823|NCT05524311|DRUG|Baricitinib|Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
224280824|NCT05524311|BIOLOGICAL|pharmacokinetics study|additionnal blood sampling at week 4, 8, 12, and 24
224092324|NCT04375306|PROCEDURE|RFR guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the experimental arm the decision to revascularize will be based on RFR.
224092325|NCT04375306|PROCEDURE|Angio guided CABG|All patients will undergo RFR and FFR measurement before CABG. RFR and FFR values will be blinded to the patients. In the control arm the RFR values will be blinded to the cardiothoracic surgeon.
224092326|NCT05397236|DRUG|Bupivacaine- Magnesium|Patients received QL block with 20 ml of 0.25% bupivacaine (2, 4)plus 5 ml of 10% MgSO4.
224092327|NCT05397236|DRUG|Bupivacaine dexamethasone|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 2 ml of 8 mg dexamethasone plus 3 ml of 0.9% NS.
224092328|NCT05397236|DRUG|Bupivacaine saline|Patients received QL block with 20 ml of 0.25% bupivacaine (2,4)plus 5 ml of 0.9% NS.
224280825|NCT05524311|BIOLOGICAL|dosage of cytokines|additionnal blood sampling at weeks 0, 4 and 24
224280826|NCT05524311|BIOLOGICAL|transcriptomic analysis|additionnal blood sampling at weeks 0, 4 and 24
224280827|NCT05524311|BEHAVIORAL|Parent version of the Child Health Questionnaire (CHQ)|Evaluate by parents at each visits
223923997|NCT06735794|DEVICE|Sham iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left motor cortex to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity.~During the intervention, the study team will conduct two pre-iTBS TMS measurements (Pre-30 and Pre-15). Participants will then complete iTBS-sh (sham comparator), which will be delivered unilaterally to the left motor cortex. Following iTBS-sh, five post-iTBS TMS measurements (Post-0, 15, 30, 45, and 60) will be obtained. Motor evoked potentials (MEPs) will be recorded from the right APB, ADM, and FDI muscles to assess the effects of the stimulation.~The MCF-B65, MCF-P-B65, and/or Cool-B65 A/P TMS coils will be used, alongside the MagPro R30 or the MagPro X100 TMS stimulators to deliver the intervention."
224092329|NCT01350089|DRUG|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
224092330|NCT01350089|DRUG|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
224092331|NCT01350089|DRUG|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
224092332|NCT01350089|DRUG|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
224092333|NCT02073487|DRUG|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
224092334|NCT02073487|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
224092335|NCT02073487|DRUG|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
224092336|NCT02073487|DRUG|Abraxane|albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
224092337|NCT02073487|DRUG|Paclitaxel|chemotherapy - microtubule inhibitor
224092338|NCT02073487|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
224092339|NCT05789992|DRUG|Propofol|Propofol (Random:3-5ug/ml)
224092340|NCT05789992|DRUG|Low Remifentanil|Remifentanil (Random:0-3ug/ml)
224092341|NCT05789992|DRUG|Heigh Remifentanil|Remifentanil (Random:3-5ug/ml)
224092342|NCT05789992|PROCEDURE|Intubation|Endotracheal intubation before surgery
224092343|NCT05789992|PROCEDURE|tetanic electrical stimulation|tetanic electrical stimulation before surgery
224092344|NCT04488237|DRUG|Vitamin D|oral administration of Vitamin D in patients with acute leukemia treated with methotrexate
224092345|NCT02886702|DRUG|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
224092346|NCT02886702|DRUG|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
224092347|NCT02886702|DRUG|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
224092348|NCT01627418|BEHAVIORAL|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
224092349|NCT01627418|BEHAVIORAL|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
224092350|NCT01206569|DRUG|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
224092351|NCT00550160|DRUG|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
224092352|NCT05533567|DRUG|Remimazolam|The experimental group was sedated with remimazolam.
224092353|NCT05533567|DRUG|Propofol|The control group was sedated with propofol.
224092354|NCT03437421|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|"* Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~* Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~* Patients with : 25-OH-D3 \<10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
224280828|NCT05524311|BEHAVIORAL|Childhood Health Assessment Questionnaire|Evaluate by parents at each visits
224280829|NCT05524311|BIOLOGICAL|Pregnancy test|Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
224280830|NCT05073250|DRUG|IBI376|IBI376 is administered orally once daily at a dose of 20 mg for 8 weeks, followed by an oral dose of 2.5 mg once daily. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of IBI376 at an oral dose of 2.5 mg once daily.
224280831|NCT05073250|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m\^2 intravenously in the first 4 weeks, once a week. Subsequently, rituximab will be dosed once every 4 weeks. Patients assessed as PR after 6 cycles of induction therapy will receive another 6 cycles of rituximab at a dose of 375 mg/m\^2 intravenously once every 4 weeks.
223923998|NCT06735521|DIAGNOSTIC_TEST|Cardiac magnetic resonance stress-perfusion|"Included patients will be examined at the Karolinska University Hospital in a 1.5T Siemens Sola magnetic resonance camera at rest and during adenosine stress with specific CMR sequences (adenosine stress-perfusion, myocardial velocities, and tissue characterization) for non-invasive determination of macro- and microvascular dysfunction, global myocardial function, pulmonary artery pressure and scarring of the myocardium.~Adenosine or Regadenoson will be used as stress medication which is according to clinical routine. Adenosine will be infused over approximately 5 minutes (110-140 μg / kg/min), Regadenoson (5 ml) will be a 10-second injection (400 μg single dosage). Intravenous gadolinium-based contrast agents will be administered, Gadovist (1 mmol/ml, gadobuterol), 0.15 mmol/kg during stress and rest."
224092355|NCT01323907|DRUG|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
224092356|NCT05736263|BEHAVIORAL|Moderate intensity exercise|moderate intensity aerobic exercise trial
224092357|NCT05736263|BEHAVIORAL|High intensity interval exercise|High intensity interval exercise trial
224092358|NCT05736263|BEHAVIORAL|Combined exercise|Combined aerobic and resistance exercise trial
224092359|NCT05736263|BEHAVIORAL|Resistance exercise|Resistance exercise trial
224092360|NCT01624584|BEHAVIORAL|Experimental treatment|six sessions of child anxiety treatment
224092361|NCT01624584|BEHAVIORAL|Traditional Treatment|six sessions of treatment consistent with current practice
224092362|NCT00054847|PROCEDURE|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
224280832|NCT03907514|BEHAVIORAL|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
224280833|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
224280834|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
224280835|NCT00645424|DRUG|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
224280836|NCT04211519|DIAGNOSTIC_TEST|sampling|sampling from endodontically infected primary and permanent teeth by using paper point method
224280837|NCT03868046|DRUG|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
224280838|NCT03868046|DIAGNOSTIC_TEST|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
224280839|NCT06462144|DRUG|IMPT-514 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
224280840|NCT06616805|DEVICE|treadmill|Treadmill JAGUAR treadmill:( T900, China) motorized treadmill model (T900) motor power (6.OHP) input voltage (AC220-240 V, 50Hz) speed range (1-20KM/H), inclination range (1-15%) was used for exercise treatment
224280841|NCT04927325|OTHER|Set of Photos|A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
224280842|NCT04504006|PROCEDURE|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)|Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
224280843|NCT04628481|DRUG|Ladarixin|Oral ladarixin twice a day for 13 cycles
224280844|NCT04628481|DRUG|Placebo|Oral placebo twice a day for 13 cycles
224280845|NCT00502658|BEHAVIORAL|Dietary supplement containing vitamins, minerals, and herbs|
224280846|NCT00502658|BEHAVIORAL|Shakes with nutrients and herbs|
224280847|NCT00502658|BEHAVIORAL|Control dietary supplement|
224280848|NCT00502658|BEHAVIORAL|Isocaloric, isonitrogenous control shakes without herbs|
224280849|NCT00502658|BEHAVIORAL|Personal energy tracking tool|
224280850|NCT05878041|DIAGNOSTIC_TEST|Molecular and genetic screening|Molecular and genetic screening
224280851|NCT05181800|OTHER|Degarelix Cohort|Non-interventional
224280852|NCT01315028|OTHER|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley \& Schwannauer, 2006).
224280853|NCT01315028|OTHER|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
224280854|NCT06493890|OTHER|Validation PEQ-DLV|Validation of the Dutch Language version of the Prosthesis Evaluation Questionnaire
224280855|NCT01063959|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
224280856|NCT01063959|PROCEDURE|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
224280857|NCT04126486|OTHER|Zio®XT Monitor|A Zio® XT monitor will be affixed to the participant's chest
224280858|NCT04435002|OTHER|Acupressure|Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
223531644|NCT07039084|OTHER|Control|Participants will continue their current model of care. This means that if participants are receiving speech therapy locally, they may continue to do so given that no speech-generating device is introduced or used during this time. Participants will check in with the researching clinician at least once a week via telehealth or phone call - the aim is to stay in contact with families and reduce loss to follow-up. The clinician will also monitor treatment integrity and document any differences that may be present during this phase.
223531645|NCT06884670|DRUG|Interleukin-2|Tislelizumab 200mg ivd D1+Interleukin 2 100IU HD, d1-d14+ CapeOX (Capecitabine: 825mg/m2 bid po, d1-d14；Oxaliplatin 200 mg/m² ivd, d1)
223531646|NCT06884670|RADIATION|Radiotherapy|Radiotherapy 1.8Gy per time\*28
223923999|NCT06734117|DIAGNOSTIC_TEST|Elecsys® Troponin T hs Gen 6|It is an immunoassay for the in vitro quantitative determination of cardiac troponin T (cTnT) in human serum and plasma using cobas e platforms. This investigational immunoassay is intended to aid in the diagnosis of myocardial infarction.
223924000|NCT06734117|PROCEDURE|Blood sample collection|Blood will be collected from each recruited individual by a healthcare practitioner at five time points after emergency department presentation.
223924001|NCT06734572|DRUG|18F-FAPIBiotin|The dose will be 148-296 MBq given intravenously.
223924002|NCT06734650|OTHER|peripheral waveform collection|The peripheral venous pressure waveform is collected by connecting a pressure transducer that is currently in use to the placed central venous line. In addition, the pulse pressure variation or stroke volume variation value that can be obtained from the arterial catheter. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithm' study (B-2202-738-401).
223924003|NCT06742099|PROCEDURE|Intercostal chest tube|the use of chest tubes to drain malignant pleural effusion
224092363|NCT00054847|PROCEDURE|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
224092364|NCT00245271|DRUG|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
224092365|NCT00245271|DRUG|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
224092366|NCT05213247|DEVICE|electronic apparatus (visocor OM50).|Measurement of blood pressure and heart rate
224092367|NCT00281814|PROCEDURE|psychosocial assessment and care|psychosocial assessment and care
224092368|NCT04271267|OTHER|No Intervention|
223924004|NCT06742099|COMBINATION_PRODUCT|Pleurodesis|the injection of Talc in pleural space to induce inflammation reaction and produce pleurodesis
224092369|NCT04864587|DIAGNOSTIC_TEST|Artificial intelligence used for image recognition in pouchoscopy|The aim of this study is to develop an image recognition algorithm that reliably detects the different graduations of pouch inflammation and neoplasms in the pouch
224092370|NCT01262898|DRUG|GSK962040 (5 mg tablet)|5 mg tablet
223531647|NCT06884670|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
223531648|NCT06884670|DRUG|Oxaliplatin|Oxaliplatin 200 mg/m² ivd, d1
223531649|NCT06884670|DRUG|Capecitabine|Capecitabine: 825mg/m2 bid po, d1-d14
223924005|NCT06741696|PROCEDURE|Surgical extraction|saline irrigation at different temperatures
223924006|NCT06741696|PROCEDURE|saline irrigations|saline irrigation done after 3rd molar surgery
223924007|NCT06742892|DRUG|HLX43 DOSE 1|Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924008|NCT06742892|DRUG|HLX43 DOSE 2|Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924009|NCT06742892|DRUG|HLX43 DOSE 3|Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924010|NCT06727396|DRUG|CKD-508 Tablet|Investigational drug
223924011|NCT06727396|DRUG|Placebo Tablet|Placebo
223924012|NCT06743763|BEHAVIORAL|fNIRS-based neurofeedback|fNIRS-based neurofeedback is provided during a simulated classroom scenario where the child participants are asked to learn to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
223924013|NCT06743763|BEHAVIORAL|Virtual Reality Simulated Classroom|A simulated classroom scenario is integrated in VR setting and children are asked to complete academic tasks in the simulated classroom.
223924014|NCT06738992|DRUG|Aspirin|Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
224092371|NCT01262898|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
224092372|NCT01262898|DRUG|GSK962040 (125 mg tablet)|125 mg tablet
224092373|NCT01262898|DRUG|Placebo|matching placebo tablet
224092374|NCT02731742|BIOLOGICAL|MK-1966|MK-1966 administered as an intravenous (IV) infusion
224092375|NCT02731742|DRUG|SD-101|SD-101 administered as an intratumoral (IT) injection
223531650|NCT06732999|BEHAVIORAL|Gaze-Contingent Music Reward Therapy (GC-MRT|Gaze-Contingent Music Reward Therapy (GC-MRT) is a treatment method for adults with social anxiety disorder found to be effective in reducing social anxiety in various RCTs. This method includes a computerized cognitive training to redirect threat-related attention patterns.
223531651|NCT06926595|DRUG|Cyclophosphamide (primary intervention for GVHD prophylaxis)|This study evaluates the use of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) following allogeneic stem cell transplantation. The intervention involves administering PTCy on days +3 and +4 post-transplant, in combination with tacrolimus and mycophenolate mofetil (MMF) for GVHD prevention. The goal is to assess the safety and efficacy of this regimen in patients undergoing reduced-intensity or non-myeloablative conditioning using peripheral blood stem cells from matched sibling, matched unrelated, and haploidentical donors
224092376|NCT01305447|BEHAVIORAL|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
224092377|NCT01305447|BEHAVIORAL|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
223924015|NCT06738992|DRUG|Warfarin|Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
223924016|NCT06740604|DEVICE|BSD-10CH|The BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
223924017|NCT06740604|DEVICE|Sham BSD-10CH|The Sham BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
223924018|NCT06739629|OTHER|Insect porridge|Yellow mealworm porridge
223924019|NCT06739629|OTHER|Maize Porridge|Maize porridge
223924020|NCT06737068|PROCEDURE|Low pressure pneumoperitoneum (8-10mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with low pressure pneumoperitoneum (8-10mmHg) with AirSeal device
223924021|NCT06737068|PROCEDURE|Standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device|Elective robot assisted hiatal hernia repair with standard pressure pneumoperitoneum (13- 15 mmHg) with AirSeal device
224280859|NCT02607020|OTHER|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1\. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
223531652|NCT06689475|OTHER|Psychoacoustic approach|The psychoacoustic approach group will listen to normal heart sounds (S1, S2), abnormal heart sounds (S3, S4) and murmur sounds from the audio file uploaded to their mobile phones in the laboratory environment through headphones for 500 repetitions each.
223531653|NCT06689475|OTHER|Simulation|The simulation group will practice auscultation of heart sounds in a one-to-one and repetitive manner, working with a high reality simulator. Trainers will act as facilitators during the cardiac auscultation practice of the students in the intervention groups.
223717510|NCT04356950|OTHER|Thrombin generation test assay|lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: \[ETP (%)(TM+) / ETP (%)(TM-)\].
223924022|NCT06740201|DRUG|Cipepofol|Adjust plasma target-controlled concentration
223924023|NCT06736145|OTHER|Traditional Physical Therapy|"Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
223924024|NCT06736145|OTHER|Mulligan Glides|"Natural Apophyseal Glides of Cervical spine are given 3 repetitions x 3-6 sets, 3 days/week.~Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week~Total of 9 sessions were given each consisting of 40 mins."
223924025|NCT06735313|DIAGNOSTIC_TEST|Periodontal examination and saliva collection|Before the periodontal examination, saliva samples are collected from each patient participating in the study and periodontal measurements are made.
224092378|NCT01305447|BEHAVIORAL|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
224092379|NCT00055640|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
224092380|NCT00055640|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
224092381|NCT00055640|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
224092382|NCT00055640|DRUG|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
223531654|NCT06888726|DEVICE|High-intensity transcranial alternating current stimulation (Hi-tACS)|The equipment used is the transcranial microcurrent stimulator (Nexalin ADI), operated by trained therapists following standardized instructions. Three Nexalin conductive electrodes are placed on the patient's head. A 4.45×9.53 cm electrode is placed on the forehead, corresponding to the Fpz region of the 10/20 international standard electrode placement system. Two 3.18×3.81 cm electrodes are placed on the bilateral dorsolateral prefrontal cortex, corresponding to the F3 and F4 regions of the international standard electrode placement system. The stimulation frequency is 77.5 Hz, and the current intensity is 15 mA.
223531655|NCT06888726|DEVICE|Sham High-intensity transcranial alternating current stimulation (Sham-Hi-tACS)|A sham device looks exactly the same as Nexalin ADI is used.
223531656|NCT06739291|DRUG|SIGX1094R|Single drug treatment by SIGX1094R, orally administered once daily.
223717511|NCT04356950|OTHER|Fibrin generation markers assays|D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)
223717512|NCT02292277|DRUG|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
223531657|NCT06659705|DRUG|68Ga-FAPI-46 for PET / CT scan and 177Lu-EB-FAPI for therapy|Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.
223924026|NCT06735157|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (intermittent theta burst stimulation) will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby iTBS will be delivered three times during the same study session. Each iTBS session will deliver 600 pulses in 50 Hz bursts of 3 pulses for a total of 1800 pulses delivered each day. iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
223924027|NCT06735157|BEHAVIORAL|Augmented reality vestibular rehabilitation therapy|Participants will complete the vestibular training through Nreal Air AR Glasses (Nreal, China). The vestibular training task was custom-made in Unity V2021.3.14fI software using C+ script language. Participants will be standing upright for the AR training, with a safety bar positioned directly in front of them should they need to hold onto something. A large cross-shaped target will be positioned approximately 3 feet in front of the participant's head with its vertical center aligned with the participant's midline. This will act as a visual starting point. The training is adapted from clinical vestibular rehabilitation training methods used in PCD. The vestibular training task consists of locating and tracking a series of moving 3-dimensional balls presented at random within the participant's field of view.
224092383|NCT00055640|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
224280860|NCT02607020|OTHER|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
224280861|NCT01077817|DRUG|Alendronate|
224280862|NCT01077817|DRUG|Etidronate|
224280863|NCT01077817|DRUG|Ibandronate|
224280864|NCT01077817|DRUG|Risedronate|
224280865|NCT01077817|DRUG|Raloxifene|
224280866|NCT03282539|DEVICE|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
224280867|NCT03282539|DEVICE|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
224280868|NCT02670785|DRUG|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
224280869|NCT02670785|DRUG|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
224280870|NCT00448227|DRUG|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
224280871|NCT00280930|DRUG|Letrozole|
224280872|NCT05960422|PROCEDURE|Popliteal Sciatic Nerve Block|Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
224280873|NCT05960422|PROCEDURE|Adductor canal block|Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
224280874|NCT06039774|DRUG|α-Mangostin Hydrogel Film With Chitosan Alginate Base|Patients will apply α-Mangostin Hydrogel Film With Chitosan Alginate Base once a day for 7 days
224280875|NCT06039774|DRUG|Placebo|Placebo
223531658|NCT07056712|DIETARY_SUPPLEMENT|Fenugreek seed|Fenugreek seed: 1500 mg per day for 12 weeks
223531659|NCT07056712|OTHER|Placebo|Placebo: Calcined magnesia 1500 mg per day for 12 weeks
223531660|NCT06748989|DIETARY_SUPPLEMENT|Cortexium food supplement|Cortexium (a specially formulated dietary supplement with pyrroloquinoline quinone, γ-aminobutyric acid and B vitamins).
223531661|NCT06748989|DIETARY_SUPPLEMENT|Placebo food supplement|Placebo food supplement is completely identical weight and outlook capsule to Cortexium, with 50% microcrystalline cellulose and 50% starch.
223531662|NCT06747611|DRUG|Vancomycin, Neomycin and MTT capsules|patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
223531663|NCT06747611|DRUG|Placebo capsules|patients will take 2 capsules per day for 14 days. These patients will then be clinically followed for a period of 24 weeks.
223531664|NCT06738017|DRUG|BMN 349|250mg oral tablet
223531665|NCT06738017|DRUG|Placebo|250mg oral tablet
223531666|NCT07060820|PROCEDURE|Radial Artery Puncture at 0-20 mm|Radial artery puncture performed 0-20 mm proximal to the radial styloid process during transradial coronary angiography to evaluate its impact on the incidence of radial artery spasm (RAS).
223531667|NCT07060820|PROCEDURE|Radial Artery Puncture at >21 mm|Radial artery puncture performed at a distance greater than 21 mm proximal to the radial styloid process during transradial coronary angiography to evaluate its impact on the incidence of radial artery spasm (RAS).
223717513|NCT03129698|DRUG|Apatinib|Apatinib 250mg daily
223924028|NCT06735157|DEVICE|SHAM repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be delivered using a Magstim Rapid 2 sham stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of sham stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby sham iTBS will be delivered three times during the same study session. Each sham iTBS session will sound and feel identical to real iTBS delivery, but will not deliver a stimulating current. Sham iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Sham stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of sham iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.
223924029|NCT06734663|PROCEDURE|Clinical outcomes of sutured versus sutureless conjunctival autograft in primary pterygium excision|Studies have concluded that pterygium surgical excision is the main treatment for pterygium. Pterygium excision with superior graft is the procedure followed most commonly at present. This is achieved by many methods, with the result differing from one method to another. The most important difference is the incidence of recurrence(4)But Varioustechniques such as Bare Sclera, Rotational Conjunctival Flap, Limbal Conjunctival Autograft, Amniotic Membrane Graft, and Free Conjunctival Autograft are also used for the removal of pterygium(3 ,4)Of the various possible alternative approaches, conjunctival autograft is usually preferred. Diverse methods for grafting with sutures, glue or autologous serum from the recipient bed are in use (5,6). Many adjunctive therapies like mitomycin C, corticosteroids, thiotepa, interferon-alpha- 2b, beta irradiation, 5-FU are being used to decrease the risk of recurrence after surgical removal of pterygium.
223924030|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft suturing|pterygium is surgically removed, and a conjuctival graft is placed on bare sclera using sutures to surrounding conjuctiva.
223717514|NCT02646072|DRUG|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
224092384|NCT00055640|GENETIC|microarray analysis|genetic testing
224092385|NCT04073550|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
224280876|NCT00564096|DEVICE|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
224280877|NCT00564096|DEVICE|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
224280878|NCT01353716|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
224280879|NCT04832334|OTHER|Kinesthetic and Visual Imagery Questionnaire, Box and Block Test, Hand Lateralization Test.|Imagery ability was determined.
224280880|NCT04832334|OTHER|Berg Balance Scale, Functional Reach Test|Balance level was determined.
224280881|NCT04832334|OTHER|Timed Up and Go Test, Functional Independence Scale|Functionality was evaluated.
224280882|NCT05453708|OTHER|Survey|One 15-20-minute survey
224280883|NCT00725764|DRUG|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
224280884|NCT03953664|OTHER|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
224280885|NCT03460899|OTHER|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
224280886|NCT03460899|OTHER|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
224280887|NCT01360437|DRUG|Prasugrel|Prasugrel 10mg/day
224280888|NCT01360437|DRUG|Ticagrelor|Ticagrelor 90mg twice a day
224280889|NCT01928615|DRUG|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
224280890|NCT01928615|DRUG|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
224280891|NCT01928615|DRUG|Chemotherapy|Standard chemotherapy for early breast cancer.
224280892|NCT02625337|DRUG|Pembrolizumab|
224280893|NCT02625337|DRUG|Dabrafenib|
224280894|NCT02625337|DRUG|Trametinib|
224280895|NCT02625337|PROCEDURE|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
224280896|NCT02625337|PROCEDURE|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
224280897|NCT02627274|DRUG|RO6874281|RO6874281 will be administered as per the schedule specified under arm description.
224280898|NCT02627274|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified under arm description.
224280899|NCT02627274|DRUG|Cetuximab|Cetuximab will be administered as per the schedule specified under arm description.
224280900|NCT04692857|PROCEDURE|supra inguinal fascia iliaca block|injection of 30,40 or 50 ml of 0.2 ropivacaine .
224280901|NCT00178724|OTHER|No Treatment Given|Intervention is not given.
224280902|NCT03837158|PROCEDURE|early loading|two TiZr implants on SLA surface
224280903|NCT03837158|PROCEDURE|immediate loading|four TiZr implants on SLA surface
224280904|NCT02190786|DRUG|KUX-1151|
224280905|NCT01723917|DIETARY_SUPPLEMENT|PhytoSERM tablet|
224280906|NCT01723917|DIETARY_SUPPLEMENT|placebo|
224280907|NCT05188417|DRUG|Tirofiban 0.05 MG/ML|intravenous injection of the drug according to different body weights and arms
224280908|NCT05188417|DRUG|0.9% sodium chloride solution|intravenous injection of the drug according to different body weights and arms
223717515|NCT03797599|BEHAVIORAL|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
223717516|NCT03797599|BEHAVIORAL|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
223924031|NCT06734663|PROCEDURE|pterygium excision and conjuctival graft placement by autologous blood|pterygium is surgically removed and a conjuctival graft is placed on bare sclera on which the patient's blood remains. the graft is left without sutures, adhering only by autologous blood.
223924032|NCT06306534|OTHER|Auditory Nerve Acute (ANA) Electrode Array|To measure eABRs when stimulating the human auditory nerve
223924033|NCT06741527|DEVICE|Integrity Implant System|Integrity Implant System used for Rotator Cuff Repair
223924034|NCT06743438|DRUG|Tenofovir Amibufenamide（TMF）|Once-daily oral dose of 25 mg TMF were maintained in all participants
223924035|NCT06743139|DIAGNOSTIC_TEST|Echography|Simultaneous performance of an echocardiogram (part of the follow-up assessment for sickle cell heart disease) at rest and then during the cardiorespiratory stress test, and an ear capillary lactatemia analysis (already routinely performed to ensure the safety of the cardiorespiratory stress test) during the cardiorespiratory stress test routinely performed at Mondor University Hospital prior to cardiovascular rehabilitation programs.
223924036|NCT06743113|DEVICE|Hemanext ONE System|Hypoxic red blood cells
223924037|NCT06743113|DEVICE|Conventional RBCs|Conventional red blood cells
223924038|NCT06353334|DRUG|Butylphthalide and Sodium Chloride Injection|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
223924039|NCT06353334|DRUG|Saline Solution|All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
223924040|NCT06893744|DEVICE|occlusal splint|
223924041|NCT06744946|PROCEDURE|thoracoscope|bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage
223924042|NCT06743737|DEVICE|Digital skin test reading device|The device to be studied measures optically the size of the wheals from skin tests (SPT) performed for the diagnosis of allergen sensitization.
223924043|NCT06743646|DRUG|ZVS101e|subretinal injection of ZVS101e
223924044|NCT06892626|PROCEDURE|RIRS|RIRS performed in lithotomy position for which guide wire pass to the kidney, then passing ureteral dilators up to 14F and ureteral access sheath. Dusting stones by RIRS and holmium laser Fiber 200 mm, at the end of operation DJ was fixed.
224280909|NCT03023137|BEHAVIORAL|Walking & dietary modification|"1. Daily walking at a moderate pace (4 km/h) \> 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding \>12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~2. At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
224280910|NCT01913054|DRUG|Fentanyl Injection|
224280911|NCT01913054|DRUG|Etomidate Fat Emulsion Injection|
224280912|NCT01913054|DRUG|Propofol Injection|
224280913|NCT04785911|DRUG|Antiemetic Combinations|Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score
224280914|NCT00344045|DRUG|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
224280915|NCT00344045|DRUG|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
224280916|NCT04012216|DEVICE|Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)|A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
223717517|NCT03797599|OTHER|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
223717518|NCT03797599|OTHER|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
223717519|NCT03797599|OTHER|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
223924045|NCT06892626|PROCEDURE|PNL|PNL performed in prone position, after passing guide wire and ureteric catheter in lithotomy position. Puncture to the kidney, passing 2 wires, then using renal dilators and access sheath to enter kidney by nephroscopy, fragment stones by pneumatic and remove stones, then place nelaton 28F at end of operation
224092386|NCT04073550|DRUG|Placebos|Anlotinib blank analog capsule.
224092387|NCT04073550|DRUG|Topotecan|A topoisomerase I inhibitor.
224092388|NCT04035876|DRUG|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
224092389|NCT03846245|OTHER|No intervention|No intervention
224092390|NCT04436302|DEVICE|Exergame device|motor-cognitive training
224092391|NCT00000402|DRUG|Calcium|
224280917|NCT04012216|DEVICE|Gold standard: polysomnography|Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
224280918|NCT02811341|DRUG|Scopolamine Hydrobromide|
224280919|NCT02811341|DRUG|normal saline|
223924046|NCT06892730|DEVICE|Hybrid TEVAR combined with long bare-metal stent intervention|"\- Primary TEVAR: Primary TEVAR: Employ Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm endograft deployed with ≥2cm proximal landing zone coverage.~Concurrent bare-stenting: Post-TEVAR femoral access deployment of Fabulous® (45-150mm) long bare-metal stent with:~Proximal overlap ≥3cm with TEVAR graft. Distal extension 2-6cm below renal artery plane. Maximum distal limit: above iliac bifurcation.~\- Intraprocedural angiography with spinal reference mapping guides precise stent positioning relative to visceral arteries and infrarenal aorta."
223717520|NCT01236599|OTHER|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
223717521|NCT04980040|DRUG|Alogliptin Benzoate|Alogliptin benzoate tablets
223717522|NCT04249674|DIAGNOSTIC_TEST|Dextrometorphan|Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
223717523|NCT04249674|GENETIC|Genotyping by single nulcetoide polymorphism.|Single nucleotide polymorphism determination
223924047|NCT06893926|DIAGNOSTIC_TEST|Prenatal ultrasound examination with blood flow analysis|"For all patients who provide informed consent to participate in the study, an ultrasound examination is performed within 48 hours prior to delivery. This assessment includes:~1. Measurement of fetal anthropometric parameters and estimation of fetal weight.~2. Evaluation of blood flow using the pulsatility index (PI) in the UA, UtA, DV, and MCA."
223924048|NCT06893926|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis|A 0.5 mL blood sample is collected from the clamped section of the umbilical cord and immediately sent to the laboratory for cord blood gas analysis, including the determination of pH, base excess (BE), and lactate levels.
223924049|NCT06893926|DIAGNOSTIC_TEST|Umbilical cord blood S100B protein level|A 1 mL sample of cord blood is collected in a labeled tube, which includes the mother's name, the child's gender, date of birth, and date of collection. The sample is then sent to the laboratory for centrifugation. The resulting serum samples are frozen, and once approximately 80 samples have been collected, they will be thawed and analyzed for S100B protein concentration. Any remaining material after laboratory processing will be properly disposed of.
223924050|NCT06893926|DIAGNOSTIC_TEST|Neonatal transfontanelle ultrasound assessment|A transfontanelle ultrasound examination is performed to assess for any abnormalities in the newborn.
223924051|NCT06893172|OTHER|Warm acupuncture and Gabapentin|This group used gabapentin 300mg per tablet, twice a day, for a treatment period of 4 weeks, combined with warm acupuncture at the Ashi point, EX-B2, LI4, TE6, PC5 and SP6, five times a week for 4 weeks.
223924052|NCT06893172|DRUG|Gabapentin|This group used gabapentin 300mg per tablet, twice a day, for a treatment period of 4 weeks
223924053|NCT06894030|BEHAVIORAL|Gait Training Video|Personalized gait training videos featuring cued and non-cued gait for participants
223924054|NCT06894030|BEHAVIORAL|Cognitive Cue|A verbal cue to be mentally rehearsed by each participant
223924055|NCT06892808|PROCEDURE|Non-Surgical Periodontal Therapy|"Under local anesthesia, full-mouth debridement (supragingival and subgingival scaling and root planing, FM-SRP) was performed by an experienced periodontist, initiated within 48 hours post-atrial fibrillation ablation and completed in two sessions within 48 hours. Polishing was performed using a rubber cup with prophylaxis paste. The procedure utilized Gracey curettes and piezoelectric ultrasonic tips combined with a force-controlled system.~Postoperative Care Immediate Care: Local Adjunctive Therapy: 2% minocycline gel was injected into deep periodontal pockets (PD ≥5mm). Antimicrobial Rinse: 0.12% chlorhexidine solution (15 mL, 30-second rinse twice daily) for 14 days.~Follow-Up Intervention At the 6-month follow-up, additional oral debridement was performed in the intervention group if indicated by the presence of bleeding points and/or increased probing pocket depth (PPD)."
223924056|NCT06892808|PROCEDURE|Background Periodontal Care|All study participants received oral hygiene instruction using the modified Bass technique. At baseline, supragingival deposits (dental plaque and calculus) were removed with an ultrasonic scaler or rubber cup with prophylaxis paste. To maintain blinding, simulated subgingival instrumentation sounds were played during the procedure for control group participants.
223717524|NCT01308554|DRUG|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
223717525|NCT01308554|DRUG|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
223924057|NCT06894238|DIAGNOSTIC_TEST|Sub-hairline EEG Monitoring|Participants will receive standard postoperative care as per institutional protocols, including neuromonitoring, delirium screening, and ICU management. The study will not alter or assign any treatments but will analyze the association between sub-hairline EEG parameters and postoperative delirium (POD) outcomes
223924058|NCT06894186|OTHER|Gaenial universal injectable|GC Gaenial universal injectable advanced injectable composite with nano sized filler that merge the adaptation of flowable composite and mechanical properties of hybird composite
223924059|NCT06893835|DRUG|Colistimethate Sodium|compare the clinical outcomes and safety between colistin and tigecycline for multi-drug-resistant gram-negative bacteria.
223924060|NCT06893835|DRUG|Tigecycline|compare the clinical outcomes and safety between colistin and tigecycline for multi-drug-resistant gram-negative bacteria.
223924061|NCT06893718|OTHER|Compressions Stocking Group|"* Incline: Initially 5% incline and after 4 weeks an incline of 10% will be observed~* Speed: Constant speed of 3.4 mph.~* Warm up: Calf stretch 10 reps/ 2 sets."
223924062|NCT06893718|OTHER|Treadmill Training Group|"* Incline: Initially 5% incline and after 4 weeks an incline of 10% will be observed~* Speed: Constant speed of 3.4 mph.~* Warm up: Calf stretch 10 reps/ 2 sets."
223924063|NCT06893575|BEHAVIORAL|TTM-Guided Digital Sleep Health Program|This intervention is a TTM-based sleep health improvement program designed for HF patients. It includes three components: (1) Sleep health education sessions (Weeks 1-4) delivered face-to-face and via telehealth, (2) WhatsApp-based sleep hygiene support (Weeks 5-12) with daily reminders, educational messages, and video content, and (3) Follow-up monitoring (Weeks 13-24) with periodic motivational messages. Patients will track their sleep using smartwatches and share data via WhatsApp. The intervention guides behavior change through TTM stages, promoting sustainable sleep hygiene practices.
223531668|NCT07060898|DIETARY_SUPPLEMENT|Active Product|Novel Nutritional Product targeting Cognition
223717526|NCT00869674|PROCEDURE|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
223717527|NCT03202498|DEVICE|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
223924064|NCT06892678|DRUG|DFMO|DFMO dose will be calculated based on the BSA measured within 14 days prior to the beginning of each cycle. Tablets may be swallowed whole, chewed, or crushed and mixed with soft food or liquid.
223924065|NCT06893861|OTHER|Metabolomic profiling|Blood samples will be collected from these subjects, and following metabolomic profiling, the data will provide the foundation for training machine learning models capable of recognizing the metabolomic profiles of subjects with endometrial carcinoma and differentiating them from subjects with other conditions.
223924066|NCT06736886|OTHER|Light application|Light application
223924067|NCT06738186|OTHER|Video-based exercise program|"The video-based exercise program - Bliib fit -mach mit! focuses on mobilization, muscle strengthening (focus on lower and upper extremities), coordination, balance, and relaxation. Each participant requires the use of a chair for support and to perform exercises in a seated position, if required. The group sessions are supervised by a care professional or registered activation specialist of the residential care facility."
223924068|NCT06738186|OTHER|Caregiver-led activation program|The caregiver-led activation program (DESKK- Demenzspezifisches Kurzzeitpflegekonzept) is instructed and carried out by care professionals (e.g., nursing staff) as optimized standard care conducted individually or in groups.
224092392|NCT03792048|PROCEDURE|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
224092393|NCT05947240|OTHER|aerobic exercises|The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist.
223531669|NCT07060898|DIETARY_SUPPLEMENT|Placebo Product|Identical placebo product
223531670|NCT05605093|DRUG|Shionogi Protease Inhibitor (S-217622)|S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
223531671|NCT05605093|DRUG|placebo|Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
223531672|NCT02220985|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
223531673|NCT02220985|DRUG|Cyclophosphamide|Given IV
223531674|NCT02220985|DRUG|Fludarabine Phosphate|Given IV
223531675|NCT02220985|OTHER|Laboratory Biomarker Analysis|Correlative studies
223531676|NCT02220985|DRUG|Methotrexate|Given IV
223531677|NCT02220985|DRUG|Mycophenolate Mofetil|Given IV and PO
224092394|NCT05947240|OTHER|active alternating movements for the upper limbs|The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute. Intervention will be for 3 times a week or 6 weeks.
223924069|NCT06737835|DEVICE|18 FDG|18 flurodeoxy glucose PET/CT
223924070|NCT06736639|PROCEDURE|Anchor Suture with Titanium Cable Cerclage|This intervention involves the use of \*\*anchor suture fixation combined with titanium cable cerclage\*\* for the treatment of inferior pole patellar fractures (IPPF). The anchor suture provides stable fixation of fracture fragments by anchoring directly into the bone, while the titanium cable cerclage offers additional reinforcement around the patella to enhance stability and minimize fragment displacement. This method is specifically designed to address the limitations of traditional Kirschner-wire tension band techniques, such as hardware irritation and infection, by using biocompatible and low-profile materials.
223924071|NCT06736639|PROCEDURE|Kirschner wire tension band + cerclage cable|This intervention uses \*\*Kirschner wire tension band combined with cerclage cable\*\* to treat inferior pole patellar fractures (IPPF). The Kirschner wires are positioned across the fracture site to form a tension band, which transforms tensile forces into compressive forces, promoting fracture stability. The cerclage cable is added to reinforce the fixation by encircling the patella, providing additional stability to comminuted or complex fractures.
224092395|NCT00046722|DRUG|Smoked Marijuana|
224092396|NCT00921869|DRUG|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
224092397|NCT00559091|DRUG|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
224092398|NCT01576640|DRUG|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
224280920|NCT01107327|PROCEDURE|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
223924072|NCT06738875|DEVICE|manometre|Increases in peak and mean airway pressures of ETT cuff pressures will be monitored in patients undergoing laparoscopic bariatric surgery
223924073|NCT06737211|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|2000 mL of peripheral parenteral nutrition with electrolytes (20 mL 7.45% KCl, 10 mL 20% MgSO4 and 20 mL 8.7% Na3PO4) will be administered via a peripheral venous catheter with a rhythm of 80cc/h from the time they will leave the operation room and will be transferred to the ward or the critical care unit (CCU) until the 5th postoperative day
223924074|NCT06739564|PROCEDURE|ICE PACKING|ICE PACKING ON LOWER LIMB AFTER AN EXHAUSTION EFFORT.
223924075|NCT06739564|PROCEDURE|DRY NEEDLING|DRY NEEDLING ON LOWER LIMB AFTER AN EXHAUSTION TRIAL
223924076|NCT06889064|DRUG|BR1400-1|One tablet administered alone
223924077|NCT06889064|DRUG|BR1400-2|One tablet administered alone
223924078|NCT06889064|DRUG|BR1400-3|One tablet administered alone
224092399|NCT01576640|DRUG|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
223924079|NCT06888622|DRUG|Eculizumab administration|Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks
223924080|NCT06889948|DRUG|Daratumumab|All patients will receive either fixed-dose daratumumab as a single agent therapy or fixed-dose daratumumab combined with stem cell transplantation.
224092400|NCT01576640|OTHER|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
224092401|NCT04857021|DIETARY_SUPPLEMENT|GABA|oral administration of GABA capsule once daily before sleep
224092402|NCT04857021|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo capsule once daily before sleep
224092403|NCT01412853|OTHER|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
224280921|NCT01638273|DRUG|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
224280922|NCT01638273|DRUG|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
224280923|NCT04850027|PROCEDURE|TME+Lateral lymph node dissection.|TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.
223924081|NCT06894472|OTHER|Electromyography biofeedback|Participants in the experimental group will receive surface electromyography (SEMG) feedback training, targeting the Masseter muscle, for 40 minutes per session according to the Evidence-Based practice since longer practice may become counterproductive due to fatigue and loss of focus. The frequency of the sessions will be 3 sessions/week for 4 weeks.
224280924|NCT00000680|DRUG|Zidovudine|
224280925|NCT00000680|DRUG|Aldesleukin|
224280926|NCT05862844|BEHAVIORAL|Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )|The Intervention Arm involves a 90-minute educational session tailored to Muslim women. They will learn about HPV infection risks, cervical cancer risks, and benefits of early screening and HPV vaccination. Discussions cover transmission, consequences, risk factors (behaviors, infections, family history), and importance of early detection. The session provides information on screening methods, check-ups, and HPV vaccine safety. Participants actively engage in discussions, ask questions, and share thoughts. The session empowers women with knowledge to make informed decisions about their health, promoting cervical cancer prevention.
224280927|NCT01843257|OTHER|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
224280928|NCT01843257|OTHER|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
224280929|NCT05856058|DRUG|SHR0302|SHR0302 oral solution 1 time, SHR0302 tablets 1 time
224280930|NCT02909517|OTHER|cSLO imaging|
224280931|NCT03114358|OTHER|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
224280932|NCT05522634|DRUG|TJAOA101|Once enrolled, participants will be administrated TJAOA101
223531678|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
223531679|NCT02220985|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
223531680|NCT02220985|DRUG|Tacrolimus|Given IV or PO
223924082|NCT06894472|DRUG|Pharmacotherapy|Pharmacotherapy will be received by all participants in the two groups in the form of multi relaxant (cyclobenzaprine) 10 MG twice daily for 4 weeks \& anti inflammatory (non steroidal anti-inflammatory drugs).
223924083|NCT06894901|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
223924084|NCT06888362|DRUG|GZ21T|GZ21T cream is intended to be studied as a potential treatment for patients with actinic keratoses and other dermatologic conditions which may be amendable to the study treatment.
223924085|NCT06668077|DEVICE|iTBS of the left DLPFC|Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the DLPFC of the left hemisphere while not performing any other task
223924086|NCT06668077|DEVICE|iTBS of the vertex|Participants will receive a 3 minutes active theta burst transcranial magnetic stimulation (iTBS) of the vertex while not performing any other task
223924087|NCT06668077|BEHAVIORAL|Inhibitory control training|Computerized cognitive training. Participants will perform the task of the FoodT app for 10 minutes during two weeks (taking advantage of time of maximum brain potentiation after the iTBS, Rossi et al., 2009). Images of food and non-food appear on the left, right or centre of the smart phone screen and participants must touch it (or not, depending on the cue) with their index finger as quickly as possible. Participants earn points for correct tap responses and lose points for incorrect tap responses. If the image has a green border around it, participants must tap the image and win 1 point. But if the image has a red border around it, participants must inhibit the tapping response, otherwise 1 point will be lost. Participants must respond as quickly and accurately as possible. Pictures of healthy and unhealthy foods are always paired with the Go and the No-Go signal, respectively. Non-food images are paired 50% of the time with the Go and the No-Go signal
223924088|NCT03032627|PROCEDURE|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
223924089|NCT05166616|PROCEDURE|Biopsy|Correlative studies
223924090|NCT05166616|DRUG|Osimertinib|Given PO
223924091|NCT05166616|DRUG|Triptolide Analog|Given PO
223924092|NCT01553149|DRUG|Lenalidomide|Given PO
223924093|NCT01553149|OTHER|Pharmacological Study|Correlative studies
223924094|NCT04386746|DRUG|Gemcitabine|1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
223924095|NCT04386746|DRUG|Docetaxel|37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
224280933|NCT01203917|DRUG|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
223531681|NCT02220985|DRUG|Thiotepa|Given IV
223531682|NCT02220985|RADIATION|Total-Body Irradiation|Undergo TBI
224280934|NCT00361686|DRUG|tramadol|
224280935|NCT00361686|DRUG|remifentanyl|
224280936|NCT00361686|DEVICE|patient contolled analgesia|
224280937|NCT02449616|DRUG|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
224280938|NCT00239824|BEHAVIORAL|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
224280939|NCT00239824|BEHAVIORAL|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
224280940|NCT01691586|DEVICE|Remote patient monitoring|Remote monitoring of ICD and heart failure data
224280941|NCT01691586|OTHER|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
223924096|NCT06886178|DEVICE|STIL Orthosis|STIL Orthosis, a brace for the arm equipped with passive dampening designed to suppress high-frequency movements.
223924097|NCT06886178|DEVICE|Sham|A version of the STIL Orthosis that is visually indistinguishable from original, but which does not have the passive dampening mechanism.
224092404|NCT00649454|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
224092405|NCT00649454|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
224092406|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
224280942|NCT00680524|OTHER|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
224280943|NCT04659486|BEHAVIORAL|Home-based exercise training|Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
224280944|NCT05696041|OTHER|Static strength training program or/and Dynamic strength training program of the hand|Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
224280945|NCT02673086|OTHER|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
224280946|NCT02673086|OTHER|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
224280947|NCT00218335|BEHAVIORAL|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
223924098|NCT06746922|DEVICE|Intermittent theta-burst stimulation|"Neuro-MS/D (Neurosoft) rTMS device will be used for stimulation with an angulated figure-of-eight coil. Neuronavigation system will be used to determine the application site. Before each session, active motor threshold (aMT) will be determined by obtaining a motor evoked potential with an amplitude of \>200μV in the EMG recording of the first dorsal interosseous muscle (FDI), which is slightly contracted (10-20% of maximum contraction) in at least five out of 10 stimuli delivered to the primary motor cortex. The handle will be held at a 45° angle to the sagittal plane, pointing backwards and laterally to create posterior-anterior current flow in the brain. The stimulation parameters are as follows:~Parameters:~Stimulation type:Burst Stimulus amplitude (% MT): 80 Burst frequency in sequence (Hz):5 Pulse frequency within burst (Hz):50 Number of bursts in the sequence: 10 Number of series:20 Interval between sequences: 8 sec Total time: 3min 47sec Total number of pulses: 600"
223924099|NCT06746922|DEVICE|Sham Intermittent theta-burst stimulation|In the sham application, the probe of the transcranial magnetic stimulation device will be placed in the vertical position and held perpendicular to the vertex and applied at an ineffective dose so that the patient hears the same sound. In order for the device to produce the same sound and warning sounds as the active application, it will be operated at the lowest operating power of 1 power. In the device operating at this power, there is no possibility of any warning due to the upright position of the probe.
224092407|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
224092408|NCT03390140|BEHAVIORAL|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
224092409|NCT02505256|OTHER|No intervention|
224092410|NCT04900402|OTHER|Survey|International Physical Activity Questionnaire Short Form (IPAQ) and Quality of Life Scale for Children (PedsQL)
224092411|NCT02303925|DEVICE|NESTER COILS|
224092412|NCT03044392|OTHER|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
224092413|NCT01340183|DRUG|AZD5099|IV Dose
223531683|NCT06857487|DRUG|Qingre Huatan Formula|Qingre Huatan Formula, granules, 1 bag each time, twice a day, orally, continue for 10 days.
224092414|NCT01340183|DRUG|Placebo|IV Dose
224092415|NCT02899169|DRUG|Realgar-Indigo naturalis formula|
224092416|NCT02899169|DRUG|all-trans retinoic acid|
224092417|NCT02899169|DRUG|Arsenic trioxide|
224092418|NCT02899169|DRUG|Hydroxyurea|
224092419|NCT04480151|OTHER|standard of care|retrospective study: standard of care
224092420|NCT00502840|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
223717528|NCT03202498|OTHER|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
223717529|NCT03202498|DEVICE|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
223717530|NCT03202498|OTHER|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
223924100|NCT06746818|BEHAVIORAL|Heart Math interventions|". The key components of Heart Math interventions include:~1. Heart Rate Variability (HRV) Training: This involves biofeedback techniques to help individuals learn how to control their heart rate and promote emotional balance.~2. Quick Coherence Technique: Participants are guided through a series of steps to shift their emotional state from stress to calmness, facilitating a sense of peace and emotional clarity.~3. Focus on Positive Emotions: Encouraging individuals to cultivate feelings like gratitude and compassion can enhance resilience and overall mental well-being.~4. Mindfulness Practices: Incorporating mindfulness helps individuals become more aware of their thoughts and feelings, allowing them to respond to stressors more effectively."
223717531|NCT00542854|DEVICE|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
223717532|NCT01108302|OTHER|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
223717533|NCT02139228|BIOLOGICAL|Hib-CRM197|No vaccine administered in V37\_07E2 study
223717534|NCT02139228|BIOLOGICAL|Hib-TT|No vaccine administered in V37\_07E2 study
223924101|NCT06747026|DRUG|initial Sequential iRT|"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days."
223924102|NCT06747026|DRUG|initial Concurrent iRT|"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT."
223924103|NCT06747026|DRUG|RT with maintenance of ICI|For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
223924104|NCT06747026|DRUG|RT after discontinuation of ICI|For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
224099681|NCT03706586|PROCEDURE|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
224280948|NCT00218335|BEHAVIORAL|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
224280949|NCT01764750|DRUG|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
224280950|NCT01764750|DRUG|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
224280951|NCT05741502|DRUG|Clozapine|We will assess inflammatory/immune marker labs
224280952|NCT05741502|DRUG|Antipsychotics,Other (non-Clozapine)|We will assess monitor inflammatory/immune marker lab
224280953|NCT00108550|DRUG|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
224280954|NCT00108550|DRUG|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
224280955|NCT03028155|DRUG|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
224280956|NCT03028155|DRUG|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
224280957|NCT05126212|OTHER|User experience|User experience is assessed by validated scale
224280958|NCT01863355|DRUG|B0 group: bolus 0.6mcg/kg without background infusion|
224280959|NCT01863355|DRUG|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
224280960|NCT01863355|DRUG|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
224280961|NCT03604549|DRUG|Lipiodol UF|Up to 10cc of Lipiodol Ultra Fluid will be infused via intrauterine catheter
224280962|NCT03604549|DRUG|Saline|Up to 10cc of saline will be infused via intrauterine catheter
224280963|NCT01867190|BIOLOGICAL|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
224280964|NCT04379284|OTHER|Biospecimen collection|"Maternal blood, vaginal swab, and anorectal swab will be obtained at the time of enrollment prior to delivery. A sample of breastmilk before hospital discharge and again at six weeks postpartum will be obtained if the mother is lactating.~Neonatal specimens collected following delivery will include placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab."
224280965|NCT03022890|BEHAVIORAL|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
223717535|NCT02301052|DRUG|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
223924105|NCT06746987|OTHER|Meditation|After the appropriate sample group for the research is created, study and control groups will be determined. Firstly, randomization of the study and control groups in the research will be done by an independent researcher on the randomizer.org website. Secondly, the Pitsburg Sleep Quality Scale and PERMA test will be applied to the study and control groups as a pre- test. Thirdly, theta healing meditation will be applied to the study group for 4 weeks, 2 days a week, 15- 30 minutes a day. After the 4 week meditation practice is completed with the study group, a final test will be given to the study and control groupsthe Pitsburg Sleep Quality Scale and PERMA test will be applied as the final test.
223924106|NCT06747754|OTHER|Establishment of a Database of HIV Patients|Establishment of a database that allows for systematic and continuous collection of data relating to clinical, laboratory and treatment characteristics of patients with HIV-1 for research purposes.
223924107|NCT06741787|DRUG|Patients desensitized by sublingual spray|Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
224092421|NCT04278794|OTHER|Transitional Care Stroke Intervention (TCSI)|"Core components:~1. Comprehensive Hospital Discharge Plan. The Care Coordinator will meet with staff in the in-patient unit along with patients and their caregivers to develop and implement a comprehensive discharge plan.~2. Structured home visits and telephone support. As part of the structured home visits and telephone support, a member of the IP team will provide up to 6 home visits over 6 months. The team will provide: screening and assessment; medication review and reconciliation; self-management support; education; and caregiver assessment.~3. Monthly IP case conferences. 6 monthly IP team case conferences will be held to discuss goals identified by the patient, collectively develop a plan of care, and identify needs.~4. Linkages to services. Facilitate timely follow-up with the primary care provider and build relationships with local health and social service providers. These referrals and links will provide the foundation for continued use post-intervention."
224092422|NCT01962220|BEHAVIORAL|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~* Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~* Providing tailored individualized health education during home visits.~Additional intervention components include:~* Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~* Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
224092423|NCT01974323|DRUG|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
224092424|NCT01974323|DRUG|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
224280966|NCT03022890|BEHAVIORAL|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
224280967|NCT00512538|DEVICE|Bi-layered cell therapy (Apligraf)|
224280968|NCT05885386|DRUG|Temozolomide|TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
224280969|NCT04072003|DEVICE|intravascular ultrasound (IVUS)|use IVUS in the procedure
224280970|NCT04072003|OTHER|coronary angiography|Coronary angiography is required for all PCI procedure.
224280971|NCT03039036|PROCEDURE|Amniotomy|Artificially rupturing membranes
224280972|NCT03039036|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
224280973|NCT03039036|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
224280974|NCT01745887|DRUG|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
224280975|NCT06403137|BEHAVIORAL|Resistance exercise|4 single-leg exercise sessions
224280976|NCT06403137|BEHAVIORAL|Standardized diet|Fully standardized provided energy-balanced diet providing recommended daily allowance for protein.
224280977|NCT06403137|DIETARY_SUPPLEMENT|Plant protein supplement|Dissolved in water with breakfast and prior to sleep.
224280978|NCT06403137|DIETARY_SUPPLEMENT|Maltodextrin supplement|Dissolved in water with breakfast and prior to sleep.
224280979|NCT06403137|DIETARY_SUPPLEMENT|Milk protein supplement|Dissolved in water with breakfast and prior to sleep.
224280980|NCT02111109|DEVICE|Side Stream Dark Field Microscopy|
223717536|NCT02301052|DRUG|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
223717537|NCT02301052|DRUG|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
224092425|NCT04076826|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
223531684|NCT06857487|DRUG|Qingre Huatan Formula placebo|Qingre Huatan Formula placebo, granules, 1 bag each time, twice a day, orally, continue for 10 days.
223531685|NCT06857487|OTHER|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
223531686|NCT06866236|DRUG|QRX-3|capsule
223717538|NCT03185767|OTHER|blood sampling|blood sampling
223717539|NCT04670848|DEVICE|Sleepiz One+ vs. polysomnography|Simultaneous sleep recording with polysomnography and Sleepiz One+ device
223924108|NCT06742177|PROCEDURE|Group Bi-level ESPB|The block procedure is performed immediately before surgery begins after general anesthesia induction, with the patient in the lateral decubitus position. For the block, sterile conditions are provided with USG, and the erector spinae muscle and vertebral process are visualized, and the in plane technique is used. The target vertebral level for bi-level ESPB is two levels, T5 and T7. The block needle is advanced in the caudo-cranial direction, and the potential area between the erector spinae muscle and the transverse process of the relevant vertebra is targeted. The block location is confirmed by injecting 2 ml of saline between the transverse process and the muscle. After the block location is confirmed, a total of 40 ml of 0.25% bupivacaine is applied, using 20 ml of 0.25% bupivacaine for a single level.
223924109|NCT06742177|PROCEDURE|Group M-TAPA block|The procedure is performed in the supine position immediately before surgery after general anesthesia induction and the in plane technique is used. The transversus abdominis, internal oblique and external oblique muscles are identified at the costochondral angle in the sagittal plane under ultrasound guidance at the 10th costal margin. The block needle is advanced in the caudo-cranial direction and a deep angle is given with the probe in the sagittal direction to the costochondral angle at the edge of the 10th rib to visualize the lower surface of the costal cartilage in the midline. The block location is confirmed by injecting 2 ml of saline onto the transverse abdominis muscle under the 10th costal cartilage. After the block location is confirmed, 20 ml of 0.25% bupivacaine is used. This procedure is repeated for the opposite side and a total of 40 ml of 0.25% bupivacaine is used.
223924110|NCT06741371|PROCEDURE|Monocryl|Closure of the uterine scar by monofilament suture material
223924111|NCT06741943|DEVICE|insulin pump (model: AR-B200A)|USE insulin pump (model: AR-B200A) and continuous glucose monitoring (FreeStyle Libre)
223924112|NCT06743087|DIAGNOSTIC_TEST|Jamar handheld dynamometer|Jamar handheld dynamometer
223924113|NCT01607853|DRUG|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
223924114|NCT01607853|DRUG|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
223924115|NCT01607853|DRUG|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
224280981|NCT03585309|PROCEDURE|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
224280982|NCT02729207|DRUG|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
223531687|NCT02796716|DEVICE|Testing on new technology called Accelerate ID/AST system|
223531688|NCT07131644|DRUG|Sirolimus|Comparison of different sirolimus discontinuation strategies.
223531691|NCT05627674|BEHAVIORAL|Usual Care|Usual care incorporates guideline awareness and brief advice.
223531692|NCT05627674|BEHAVIORAL|RiskProfile-Clin|RiskProfile-Clin incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors.
223531693|NCT05627674|BEHAVIORAL|RiskProfile-Gen|RiskProfile-Gen incorporates standard brief advice and guideline awareness plus specific patient risk feedback using clinical factors and genetic factors.
223531694|NCT07085117|DRUG|Teprotumumab|Participants received teprotumumab as an intravenous (IV) infusion.
223717540|NCT02471430|DRUG|Panobinostat|Panobinostat will be administered orally.
223717541|NCT02471430|DRUG|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
223717542|NCT03555201|OTHER|Manual therapy|protocol of soft tissues techniques
223717543|NCT03555201|OTHER|Regular treatment control.|Regular treatment control.
223717544|NCT00618072|DRUG|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
223924116|NCT01607853|DRUG|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
223924117|NCT02322905|BEHAVIORAL|Emotion Regulation Therapy|8 sessions of ERT
223924118|NCT06741150|BIOLOGICAL|NWRD09 administered by intramuscular injection|Intramuscular injection administration was carried out according to the protocol design.
223924119|NCT06750003|PROCEDURE|3D versus 4K laparoscopic bilateral salpingo-oophorectomy|3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents
223924120|NCT06749002|PROCEDURE|Turning based specific training along with functional Muscle training|"Experimental group will receive Turning based specific training protocol for 6 weeks along with functional muscle training, training will be done on alternate days.~Functional muscle training:~Details: Week 1-6: 3 days a week on alternate days.~Hip Abductors:~Side lying leg raises Single leg squatting Standing leg wall press Progressing to Adding resistance bands~Hip adductors:~Side lying adduction Standing Adduction Progress to adding resistance bands~Hip Flexors:~Standing leg lift Straight leg raises Progress to adding resistance bands~Hip Extensors:~Prone lying raises Standing single leg extension Progress to adding resistance bands~Plantarflexors/ DorsiFlexors:~Plantarflexors:~Plantarflexion against resistance Toe raises~Dorsiflexors:~Dorsiflexion against resistance Heel raises~Hip external rotators:~Sitting-externally rotate hip 0-30° Add resistance bands~Hip Internal rotators:~Sitting-internally rotate the hip 0-30° Add resistance bands."
224280983|NCT04660032|BEHAVIORAL|Nudge|An electronic prompt (nudge) will be sent to the participant's obstetric care provider. The provider will receive a staff message in Epic (Penn Chart) that his/her patient has an upcoming postpartum visit. The message will be sent 1 week before the scheduled visit. The message will have patient-specific information including hypertensive diagnosis, blood pressure medication(s), gestational diabetes diagnosis, and primary care provider as listed in the Epic banner. The message will also have dot phrases for recommended counseling and contact information for UPHS primary care and cardiology providers. There will be example text recommending follow-up with primary care or cardiology; counseling on risk of future CVD; and recommending aspirin in a future pregnancy.
224280984|NCT01845753|OTHER|Observation|Observation
224280985|NCT00090753|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
224280986|NCT00090753|DRUG|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
224280987|NCT00090753|DRUG|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
224280988|NCT00090753|DRUG|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
224280989|NCT00535353|DRUG|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
224280990|NCT00535353|DRUG|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
224280991|NCT03895151|DIETARY_SUPPLEMENT|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
224280992|NCT03895151|OTHER|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
224280993|NCT04666753|DIETARY_SUPPLEMENT|ImmunoFormulation|The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).
224280994|NCT04415047|DEVICE|JenaValve Trilogy Heart Valve System|TAVR with JenaValve Trilogy Heart Valve System
224280995|NCT04437277|DIAGNOSTIC_TEST|Hepatitis C, serology|Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
224280996|NCT01712451|DRUG|salmeterol xinafoate, fluticasone propionate|LIPO-102
224280997|NCT01712451|DRUG|Placebo|Placebo
224280998|NCT01712451|DRUG|salmeterol xinafoate|Salmeterol
224280999|NCT01358253|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
224281000|NCT01358253|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
224281001|NCT01358253|DRUG|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
224281002|NCT01358253|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
224281003|NCT01358253|DRUG|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
224281004|NCT01358253|DRUG|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
224281005|NCT01358253|DRUG|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
224281006|NCT01358253|DRUG|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
224281007|NCT01358253|DRUG|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
223717545|NCT01264497|DRUG|TH9507|1 and 2 mg, sc daily for 12 weeks
223924121|NCT06749002|PROCEDURE|turning based specific training.|"Week 1:~90 Degrees turns on the spot~Visual cues to follow~Week 2-3:~90 degrees turns on the spot~Figure of 8 walking~Visual cues to follow~Week 4-5:~90 Degrees turns on the spot~Figure of 8 walking~Step across body~Braiding~Week 6:~90 degree turns on the spot~Figure of 8 walking~Step across body~Braiding~Visual cues to follow~Obstacle avoidance"
223924122|NCT06748833|BEHAVIORAL|SMILE Intervention App|The SMILE app, an iOS and Android compatible smartphone app, is based on effective CBT-based treatment features to help patients manage anxiety symptomology. Access requires a unique login. The SMILE app utilizes three relaxation features: calm breathing, mindfulness meditation, and deep muscle relaxation; one cognitive feature, thought journaling and the challenging of thoughts; one self-monitoring technique; a positive imagery game; and a feature aimed to reduce avoidance behaviour through exposure. The app will be self-guided, with no additional human involvement needed. Participants will be instructed to actively engage with at least one of the app's major functions for a minimum of 3 minutes per day.
223924123|NCT06787794|BEHAVIORAL|Virtual Reality-assisted hypnosis|"The VRH intervention consists of 6 interventional sessions. Every session, first, participants receive hypnotic induction and go through a deepening phase using a hypnotic script and a VR environment designed based on input from individuals suffering from chronic itch. To this end, participants are instructed to close their eyes while they will continue to listen to the recorded hypnotic script developed based on general hypnotic principles as amongst others described by Yapko (2013). Direct antipruritic suggestions are used such as your skin will feel so soft, relaxed and cool, it is fully at ease. After these standardized suggestions, the participants will be alerted again. Home exercises (ca 5 min/day) include guided self-hypnosis records with direct antipruritic suggestions comparable to the ones they listen to during the intervention at location."
224092426|NCT04076826|DRUG|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
224092427|NCT04076826|DIAGNOSTIC_TEST|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
224092428|NCT00331760|DRUG|cisplatin|
224092429|NCT00331760|RADIATION|intensity-modulated radiation therapy|
224092430|NCT05211167|DRUG|Human Erythropoiesis Injection (CHO cell)|Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
224281008|NCT01358253|DRUG|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
224281009|NCT03363698|OTHER|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
224092431|NCT05211167|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
224092432|NCT04515355|BEHAVIORAL|Ready for MS|Receive 'ready for MS' programme in addition to standard care.
224281010|NCT01160445|DRUG|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
224281011|NCT01160445|DRUG|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
224281012|NCT04145245|DRUG|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
224281013|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
224281014|NCT00605176|DRUG|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
224092433|NCT04738955|DRUG|Micafungin Sodium|micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
224092434|NCT01597947|DRUG|ACHN-975|Intravenous single dose
224092435|NCT01597947|DRUG|placebo|Intravenous single dose
224092436|NCT04574726|OTHER|static balance|30-second right and left unipodal static balance test
224092437|NCT04574726|OTHER|dynamic balance|"for the unipodal dynamic balance test, 4 movements will be done by the volunteers in this order :~* 180° elevation of the arms~* lowering of the arms on the side of the single-legged support to the horizontal position~* 180° horizontal translation of the arms~* return from the horizontal to the starting point"
224092438|NCT02339948|RADIATION|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
224092439|NCT00347815|DRUG|Buprenorphine|
224092440|NCT02514044|DRUG|Dexedrine|10 mg immediate release of Dexedrine
224281015|NCT00605176|DRUG|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
224281016|NCT00776568|PROCEDURE|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
224281017|NCT00776568|DRUG|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
224281018|NCT04337229|OTHER|Artifical intelligent|it is planned to create a technology that determines the comfort level of the newborn quickly and simply, easy to use, time-saving and can be used by the mobile device.
224281019|NCT01256060|DRUG|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
224092441|NCT02514044|DEVICE|Active tDCS|1.5 mA tDCS anodal tDCS
224092442|NCT02514044|BEHAVIORAL|Speech Therapy|60 min of speech therapy
224092443|NCT02514044|DRUG|Placebo|
224092444|NCT02514044|DEVICE|Sham tDCS|
223924124|NCT06807801|BEHAVIORAL|Baby swimming|Participants in the treatment group will be contacted by a researcher and invited to an introductory meeting at the swimming facility, where they will receive information about the baby swimming course from the instructor. The course will take place twice a week for five weeks, totaling 10 sessions of 30 minutes each. During the sessions, mothers will be encouraged to engage in physical contact, maintain eye contact, and respond to their baby's signals. The course will also include water safety exercises.
223924125|NCT06747793|OTHER|Virtual Reality|The intervention will consist of relaxing virtual reality stimulation, which will be started after obtaining informed consent. Immersive 360-degree videos (nature environments) will be played inside a head-mounted display, with the video sound played inside headphones. Each virtual reality video will last 30 minutes. The stimulation will be provided two times per day, morning and evening, every day until the patient ICU discharge, or the maximum of 7 days will be reached. The intervention group will also receive standard intensive care unit care, same as in the control group.
223924126|NCT01105091|DRUG|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
223924127|NCT01105091|DRUG|Flolan®|Per Prescribing Information
223924128|NCT06346379|BEHAVIORAL|Baduanjin exercise|Baduanjin has 8 movement forms, which are easy to learn without special equipment.These advantages make Baduanjin a suitable exercise for dialysis patients.The movements involved in Baduanjin require the individual to reach beyond the base of support, change the base of support between bilateral and unilateral stance, and perform movements in a sustained squatting posture. These maneuvers challenge balance and require muscle strength to be executed successfully.During the exercise of Baduanjin, the knees are half bent and the body center of gravity is stable between the feet, which can effectively develop the strength and endurance of skeletal muscle groups, improving the physical fitness and Bone mineral density.
223924129|NCT06860789|DRUG|AK135|IV infusion, specified dose with specified treatment frequency
223924130|NCT06866158|BIOLOGICAL|Dendritic cell immunotherapy|DCL (Dendritic Cells+Lymphocytes) previously matured with S-Protein of SARS-CoV-2. The number of cells given depends on individual yields.
223924131|NCT06887361|BEHAVIORAL|MOON Program|The MOON Program aims to contribute to the primary prevention of sexual violence among young university students. The program aims to achieve this goal by promoting bystander attitudes and behaviors through psychoeducation and skills training that enable participants to be active agents in this process. During the sessions, beliefs that legitimize violence will be deconstructed and skills such as communication about consent and empathy will be promoted. The MOON program consists of five online sessions, which are intended to be completed autonomously on a weekly basis. Throughout the sessions, participants will learn on the following topics: SV and consent, gender stereotypes, SV myths and bystander attitudes and behaviors.
223924132|NCT06741774|DEVICE|Trabecular Meshwork Microstent Drainage System|The device is implanted on the functional trabecular meshwork with head in schlemm canal and tail in anterior chamber. There is a hollow tube connecting schlemm canal and anterior chamber. The device can promote external drainage of aqueous humor to reduce intraocular pressure.
223924133|NCT06741774|PROCEDURE|phacoemulsification|Eyes with OAG and cataracts randomly divided into control group that were planned for phacoemulsification alone.
223924134|NCT06739954|COMBINATION_PRODUCT|Mulligan's Two Leg Rotation technique|The participants will undergo Mulligan's Two Leg Rotation technique, performing 10 repetitions with a 30-second hold for each repeat. There will be a 1-minute rest period between each stretch. The therapist positions themselves on the affected side of the supine patient lying on the treatment table and holds onto the side of the table with their hand on the opposite side. Both legs will be bent so that the feet are raised from the plinth. Maintaining the subject's shoulders on the bed, he gradually moves the subject's legs to the side, considering the restricted flexibility of the hamstring muscles. Once the patient reaches their maximum, the therapist applies extra pressure to sustain the posture for 30 seconds. Then, the legs are lowered to the plinth. A 1-minute interval was provided between each stretch, and the stretches were performed for a total of 10 repetitions. The identical technique is performed on the opposite side to address insufficient flexibility in the hamstrings.
224092445|NCT01856101|DRUG|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
224092446|NCT03093155|DRUG|Ixabepilone|"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
224281020|NCT01115062|DRUG|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
224281021|NCT01115062|DRUG|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
224281022|NCT01115062|DRUG|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
224281023|NCT04396444|COMBINATION_PRODUCT|Aromastick|Vascular surgery patients will be randomized to either the intervention group and receive a lavender infused aromastick to use as an adjunct to their inpatient pain management plan, or to the control group, given a blank aromastick. Subjects will be blinded to their group.
224281024|NCT01467362|DRUG|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
224281025|NCT01467362|DRUG|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
224281026|NCT01467362|DRUG|desonide 0.1% cream|cream, once a day (in the evening) during flares
224281027|NCT01467362|OTHER|Foaming gel|for the washing and cleaning
224281028|NCT01540344|PROCEDURE|CRS|complete macroscopic cytoreduction (CC-0/1)
223924135|NCT06739954|DIAGNOSTIC_TEST|Dry Needling|The DN technique, based on previous research, involved slowly inserting and removing the needle in the muscle or tendon to elicit a specific response. This response could be a local twitch, a dull ache, a feeling of heaviness or distension, or the reproduction of the participant's symptoms. The needle is manipulated in and out of the targeted tissue five times every five minutes for a total of fifteen minutes. After the treatment, sterile gauze is applied and pressed on the DN site, and sterile non-stick pads are used to cover the treated areas. The number of needles used varied depending on the participant's condition. The knee muscles that will be included in the dry needling intervention are the Quadriceps and Hamstrings .
223924136|NCT06891872|BIOLOGICAL|Vaicella Vaccine+DTaP on Day 0, MMR on Day 30|"Varicella vaccine: lyophilized powder, subcutaneous injection~DTaP: intramuscular injection~MMR: lyophilized powder, subcutaneous injection"
223924137|NCT06891872|BIOLOGICAL|Varicella vaccine+MMR on Day 0，DTaP on Day 30|"Varicella vaccine: lyophilized powder, subcutaneous injection~MMR: lyophilized powder, subcutaneous injection~DTaP: intramuscular injection"
223531695|NCT07083154|DRUG|Mazdutide|Mazdutide injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.
223924138|NCT06891872|BIOLOGICAL|Varicella Vaccine|lyophilized powder, subcutaneous injection
223924139|NCT06747598|DIAGNOSTIC_TEST|pregnancy test|POC pregnancy testing using peripheral serum
223924140|NCT06746571|DIAGNOSTIC_TEST|complete blood count|measure cbc and blood ratios to compare their values with respone of patients to treatment
224281029|NCT01540344|DRUG|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
224281030|NCT05513469|DRUG|Lutathera|regulair PRRT of 4 cycles with 7.4GBq
224281031|NCT05577494|OTHER|Questionnaire online|"Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual."
224281032|NCT00579631|BEHAVIORAL|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
224281033|NCT01347320|OTHER|Preoperative MRI|Preoperative staging
224281034|NCT06678282|DRUG|JY231 Injection|The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.
224281035|NCT00786630|BEHAVIORAL|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
224281036|NCT00786630|BEHAVIORAL|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
224281037|NCT02126657|DRUG|70% glycolic acid|
224281038|NCT06024967|DRUG|PEG-somatropin|PEG-somatropin
224281039|NCT00214812|DRUG|HEC placebo gel|
224281040|NCT02324231|OTHER|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
224281041|NCT02324231|OTHER|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
224281042|NCT00925873|DRUG|Active comparator (no fludarabine)|"1. Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~2. The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~3. Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
224281043|NCT00925873|DRUG|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~1. Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~2. Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~3. Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
224281044|NCT04946786|DIAGNOSTIC_TEST|Laboratory investigations, pelvi-abdominal US, fibroscan, and in body analysis|"1. Complete history taking.~2. Thorough clinical examination :Assessing for buffalo hump, double chin, acanthosis nigricans, skin tags or acrochordon and xanthelasma and anthropometric measurements as measuring height m, weight Kg, waist circumference (WC) Cm, hip circumference (HC) Cm.~3\. Pelvi-abdominal ultrasound. 4. Fibroscan examination will be done for all subjects to assess steatosis by measuring the CAP score.~5\. Body composition analysis: to detect water, muscle and fat percentage in the body.~6\. Laboratory investigations:All samples wil be analyzed for fasting blood glucose (FBG), and post-prandial (2hrs after meals) blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein (VLDL-C), alkaline phosphatase (ALK), aspartate transaminase (AST),alanine transaminase (ALT).~• Fasting insulin levels will be measured using ELISA kits"
223924141|NCT06768281|DIAGNOSTIC_TEST|Headache Impact Test-6 (HIT-6)|Patients who had injections were asked to mark their headache severities with a survey includes six questions about their past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
223924142|NCT06768281|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Patients who had injections were asked to reply some questions about their sleeping habits for past 4 weeks. The test applied preoperatively, postoperatively 1st and 3rd months.
223924143|NCT06768281|DIAGNOSTIC_TEST|Visual Analogue Score (VAS)|Patients who had injections are asked to state their pain with a 10 cm visual analogue scale preoperatively and postoperatively 1st,2nd weeks and 1st and 3rd months.
223924144|NCT06768281|OTHER|Masseter muscle injection|1 ml of insulin needle with a 27-gauge ½ inch 13 mm needle tip will be injected into up to 4 trigger points in the taut bands that cause the most pain in the masseter muscle. Injections were done at most 3 times. As the control group, the first group was injected with isotonic saline; the second group was injected with 2% lidocaine without vasoconstrictor; the third group with ozone gas; and the fourth group with ozonated isotonic saline.
223924145|NCT06768073|DEVICE|Sham (No Treatment)|The Sham device is identified to the Active device with the exception that it has a black connector component, part number 10531-02, to block the vacuum from reaching the vaginal tissue with vacuum pump activation. In this manner, the control procedure has been designed to mimic the active therapy to the extent practicable allowing for subject blinding.
223924146|NCT06759675|OTHER|group based exercise with Cognitive functional therapy|"1. Cognitive functional therapy CFT A cognitive functional therapy is the behavioral approach which is used to treat low back pain. This approach has 3 components Making sense of pain Exposure with control Lifestyle changes~2. Group exercises Group exercises will be the exercises that perform on all individuals. It is performed in a group session having 3 components Pain education Exercises Relaxation"
223924147|NCT06759675|OTHER|Group based exercise|Group exercises Group exercises will be the exercises that perform on all individuals. It is performed in a group session having 3 components Pain education Exercises Relaxation
223924148|NCT06772766|DRUG|9MW3011|Ascending IV doses administered per protocol
223924149|NCT06772766|DRUG|9MW3011 placebo|Ascending IV doses administered per protocol
223924150|NCT06773260|DIAGNOSTIC_TEST|Liver and Spleen stiffness measurement.|The use of spleen stiffness measurement to reduce unnecessary upper digestive endoscopies has never been evaluated in this patient setting.
223924151|NCT05062057|DEVICE|Adhesive ambulatory ECG recording patches|All women in both groups will undergo sequential placement of two 14-day adhesive ambulatory ECG recording patches for a total of 28 days of ECG recording
223924152|NCT06492057|DEVICE|Electromyostimulation (EMS)|EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs
223924153|NCT06492057|DEVICE|Myoton|The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
223924154|NCT06492057|DIAGNOSTIC_TEST|Electromyography (EMG)|As a standard method, surface EMG collects data from nerve impulse-triggered active muscle contractions, pre/postflight only
223924155|NCT06492057|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI is a clinically standard (non-radiation) imaging method to study structural changes of the human body (organs, muscle, bones, tendons) at the macroscopic level, pre/postflight only
223924156|NCT06492057|DIAGNOSTIC_TEST|Dynamometry|Dynamometry is a standard functional and diagnostic method to test muscle strength in sports and rehabilitation. pre/postflight only
223924157|NCT06596733|DEVICE|Vit-A-Vision|Participants will apply Vit-A-Vision ointment on a daily basis, up to 3 times daily per eye, for at least 30 days.
224092447|NCT03093155|DRUG|Bevacizumab|"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
224281045|NCT05934539|DRUG|ALG.APV-527|ALG.APV-527 is a human bispecific antibody in the ADAPTIR™ format with a silenced immunoglobulin 1 (IgG1) Fc domain targeting the co-stimulatory receptor 4-1BB, expressed on immune cells such as CD8+ T cells and natural killer (NK) cells, and the tumor associated antigen 5T4. ALG.APV-527 is being co-developed by Alligator Bioscience AB (Lund, Sweden) and Aptevo Therapeutics Inc. (Seattle, WA, USA) as a cancer immunotherapy.
223924158|NCT06752785|DRUG|CAR-T Therapy|CD19/CD22 CAR-T cell therapy
223924159|NCT06754111|BEHAVIORAL|ideal birth environment|"ideal birth room While designing a single room without unnecessary medical equipment, your own bed linen, bed linen, It will be a pillow case, a photo frame, he will be able to listen to the music he wants, he will be able to make a photo of his own choice.~There will be a companion, a birthing ball and chair, and the room will allow freedom of movement.~It will be designed to allow"
223924160|NCT06758349|OTHER|General questionnaire|Demographic, medical history, and musical activity data will be collected using a specifically designed questionnaire
223924161|NCT06758349|OTHER|Pain Questionnaire|"Questionnaire that evaluate pain and functional limitation during last week, last six months e during the carrier.~The impact of painful symptoms on professional and non-professional activities , during the last week, will be assessed using the QuickDASH scale for the upper limb, the Modified Oswestry Low Back Disability Index for low back pain, and the Neck Disability Index questionnaire for cervico-dorsalgia"
224092448|NCT05631132|PROCEDURE|BAL + PAP|May noninvasive mechanical ventilation (NIV) and/or continuous positive airway pressure (CPAP) increase the bronchoalveolar lavage (BAL) salvage in patients with pulmonary diseases?
224092449|NCT02999087|DRUG|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
223924162|NCT06758349|OTHER|Postural assessment without musical instrument in sitting position|Postural assessment without the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
224092450|NCT02999087|DRUG|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
224092451|NCT02999087|DRUG|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
224092452|NCT02999087|RADIATION|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
224092453|NCT00000769|DRUG|Interleukin-4|
224092454|NCT04456829|DIETARY_SUPPLEMENT|Resveratrol drink|Subjects will consume a bottle of resveratrol drink for two months.
224092455|NCT04456829|DIETARY_SUPPLEMENT|Placebo drink|Subjects will consume a bottle of placebo drink for two months.
224092456|NCT06220695|BEHAVIORAL|Dietary intervention|The dietary intervention is a personalized counselling programme implemented in form of a moderate caloric restriction (≈500 kcal/day) to allow for a moderate weight loss (≈5% BW). Each participant will be invited for consultation visits to a study dietitian, lasting up to 30 minutes. During the sessions, participants will be provided with written information material that explains the principles of diet in concern. Dietary interventions for both groups will be standardized in terms of education and one-on-one counseling. Education and dietary prescription will be individualized by the study dietitians within the diet-specific recommendations, to allow for personal food preferences. All subjects will receive equivalent intensity of care in terms of opportunities for contact and availability of individual dietary counseling. Motivational interviewing techniques and behavior change techniques will be adopted by study dietitians to ensure long-term maintenance of dietary modification.
224281046|NCT01921335|DRUG|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
224281047|NCT01921335|DRUG|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
224281048|NCT01921335|DRUG|Trastuzumab|6 mg/kg IV every 3 weeks
224281049|NCT03394716|RADIATION|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
224092457|NCT05896007|DRUG|Zanubrutinib|160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
224092458|NCT05896007|DRUG|Rituximab|375 mg/m\^2 ivgtt, D0 of each 28-day cycle
224281050|NCT04983602|OTHER|Comprehensive Geriatric Assessment arm|The intervention will involve a comprehensive geriatric assessment which will be provided by a geriatric doctor, physiotherapist, occupational therapist, social worker, pharmacist and specialist nurse.,
224281051|NCT04983602|OTHER|EDPLUS|EDPLUS involves a 6 week physiotherapy led community based intervention involving 3 home visits and weekly telephone support.
224092459|NCT05896007|DRUG|Methotrexate|3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
224092460|NCT05896007|DRUG|Temozolomide|150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
224092461|NCT00188578|PROCEDURE|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
224092462|NCT06033729|DRUG|Remifentanil TCI|REMI-TCI administration begun 5 minutes before the procedure, starting from an initial target at the effect site of 1 ng/ml and gradually increasing by 0.5 ng/ml until reaching an adequate level of sedation (Ramsey score between 2-3).
224092463|NCT06033729|DRUG|Midazolam injection|Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
224092464|NCT06033729|DRUG|Fentanyl|Bolus adminitration of fentanyl (50-100 mcg) until a Ramsey score 2-3 was reached
224092465|NCT06033729|DRUG|Propofol|Bolus adminitration of propofol until a Ramsey score 2-3 was reached
224281052|NCT04738838|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
224281053|NCT04738838|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
223924163|NCT06758349|OTHER|Postural assessment with the instrument in sitting position.|Postural assessment with the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
223924164|NCT06758089|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
223924165|NCT06758089|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
223924166|NCT06760078|DRUG|intravenous tranexamic acid (TXA) infusion|Intravenous tranexamic acid will be administered as an initial dose of 1 g (10mL: 1g, diluted in 90 mL normal saline) over 10 minutes, followed by a maintenance dose of 1 g over 8 hours (10mL: 1g, diluted in 240 mL normal saline). Intensive blood pressure lowering will be maintained throughout the treatment period until 24 hours after onset.
224092466|NCT01800188|PROCEDURE|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
224092467|NCT01800188|PROCEDURE|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
224092468|NCT01800188|PROCEDURE|Meal test|A 3 hour standardized liquid meal test without dialysis
224281054|NCT02626208|DEVICE|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
224281055|NCT02292550|DRUG|Ribociclib|CDK 4/6 inhibitor
224281056|NCT02292550|DRUG|Ceritinib|ALK inhibitor
223531696|NCT07083154|DRUG|Placebo|Placebo injection (pre-filled auto-injector pen) is administered subcutaneously at the same time each week. The starting dose is 2.0 mg administered once weekly (QW). Based on individual patient tolerance, the dose should be gradually increased to the target therapeutic dose of 4.0 mg QW over a period of 4 to 12 weeks. The protocol permits adaptive dose escalation up to 6.0 mg weekly when clinically indicated. For participants unable to tolerate dose increases, treatment continue at their maximum tolerated dose. The total intervention duration is 76 weeks.
223717546|NCT03292588|BIOLOGICAL|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
223924167|NCT06760078|DRUG|Placebo|An intravenous placebo (10mL NS, diluted in 90mL NS) matching the specification and appearance of TXA will be administered as an initial bolus over 10 minutes, followed by a continuous infusion of placebo (10mL NS, diluted in 240mL NS) over 8 hours, with intensive blood pressure lowering maintained throughout the treatment period and continued until 24 hours after symptoms onset.
223924168|NCT06759987|BEHAVIORAL|self-care behavior intervention|The intervention group received the self-care behavior intervention program based on the interaction model of health behavior
223924169|NCT06749275|DEVICE|5,000 ppm fluoride toothpaste|In group 1, toothbrushing with toothpaste of 5,000 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
223924170|NCT06749275|DEVICE|22,600 ppm fluoride varnish|The application protocol of 5% fluoride varnish will be used together with the 1,450 ppm paste with the same protocol of the group 1: toothbrushing with toothpaste of 1.450 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
223924171|NCT06749275|DEVICE|38% SDF|The application protocol of 38% SDF annually will be used together with the 1,450 ppm paste with the same protocol of the group 2: toothbrushing with toothpaste of 1.450 ppm of fluoride twice per day for two minutes, after breakfast and before bedtime. Participants will be also instructed not to rinse with water after brushing and to only eliminate the excess of the dentifrice by spitting out. The amount of toothpaste to be used had to be about the size of a pea.
224092469|NCT05932719|OTHER|COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.|"The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM"
223531697|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days
223531698|NCT05858853|DRUG|Recombinant Human Serum Albumin|The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
224092470|NCT02906800|DRUG|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
224092471|NCT00619229|DRUG|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
224092472|NCT00619229|OTHER|Placebo|Placebo/d i.v. for 15 days
224092473|NCT01700829|DRUG|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
224092474|NCT01700829|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
224281057|NCT01839838|RADIATION|Proton Therapy|
224281058|NCT05857917|DEVICE|Virtual Reality|Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
224281059|NCT03417206|DRUG|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
223924172|NCT06795854|OTHER|Aerobic training|Sessions will be conducted 3 times per week. Each 40-minute session will include a 5-minute warm-up involving fast walking, slow running, and stretching, followed by an active phase of continuous running. The running period will start at 15 minutes and increase by 2 minutes every two sessions until reaching 30 minutes. The session will conclude with a 5-minute cool-down of slow running and stretching. Exercise intensity will be maintained at 13-15 on the Borg Rate of Perceived Exertion, with continuous walking performed on a treadmill.
223924173|NCT06795854|OTHER|Relaxation techniques|Relaxation techniques will include slow deep breathing and mindfulness meditation exercises. The breathing exercise will involve six cycles per minute, with a 4-second inhalation and a 6-second exhalation, repeated for 30 minutes, three sessions per week. Mindfulness meditation will include a stress and pain management program with sessions starting at 10-15 minutes and gradually increasing to 20-30 minutes, three times per week. Sessions will be conducted in a quiet, comfortable space, focusing on breath awareness, body scanning, thought observation, and optional loving-kindness meditation, concluding with a reflection period.
223924174|NCT06795854|OTHER|Low fodmap diet|All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.
223924175|NCT04506255|DEVICE|Silicone tape|Medical grade tape with silicone adhesive
223924176|NCT06763497|OTHER|Systematic Oral Feeding Education Program|The experimental group will receive 11 intervention sessions during the study period. The first intervention will occur immediately after the pretest and will involve a systematic oral feeding education program, including guided feeding techniques and practical feeding demonstrations. During the feeding session, caregivers' practices will be recorded on video. These recordings will then be reviewed with the caregiver to identify areas for improvement.The remaining 10 intervention sessions will take place daily on days 2-4, 6-9, and 11-13, during which the researcher will observe the primary caregiver's feeding practices, provide assistance, and offer tailored suggestions. On the 14th day, the experimental group will complete the same posttest assessments as the control group.
223924177|NCT02030964|DRUG|DFMO|
223924178|NCT02030964|DRUG|Celecoxib|
223924179|NCT02030964|DRUG|Cyclophosphamide|
223924180|NCT02030964|DRUG|Topotecan|
223924181|NCT06769503|OTHER|aromatherapy|Lavender oil dropped on gauze will be smelled for approximately 3-5 minutes.
223924182|NCT06777953|OTHER|Erector Spinae (ESP) Block with Lidocaine/Bupivacaine|This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
223924183|NCT06777953|OTHER|Popliteal Sciatic Nerve Block|This study is to retrospectively compare the analgesic efficacy and impact on postoperative recovery of popliteal sciatic nerve blocks and Lumbar-Sacral Erector Spinae Plane blocks administered for postoperative pain management in tibial fractures.
223924184|NCT06377124|BEHAVIORAL|3S intervention|"The 3S intervention includes information and support related to self-management of lung cancer, including~1. an individual 3S session at baseline,~2. 24-week messaging, telephone coaching and hotline services."
223924185|NCT06377124|BEHAVIORAL|GH information|"The GH information includes information related to general health, including~1. an individual GH session at baseline,~2. 24-week messaging, telephone coaching and hotline services."
223924186|NCT05298904|DIAGNOSTIC_TEST|Genetic Health Screen Panel|This panel covers cardiomyopathy genes, and cancer genes. The results of this panel are reported as Positive (pathogenic or likely pathogenic mutation identified in one or more genes) or Negative (no pathogenic/likely pathogenic mutations identified).
223924187|NCT06862583|PROCEDURE|surgery|Open heart surgery
223924188|NCT06862583|PROCEDURE|endovascular intervention|Aortic endovascular intervention
223924189|NCT06892236|GENETIC|iPSC generation|Base editing
223924190|NCT06411522|DEVICE|Mouthwash containing 0.12% CHX (Chlorhexidine)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.2% CHX mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
223924191|NCT06411522|DEVICE|Mouthwash containing 0.05% CHX (Chlorhexidine) and 0.05% CPC (Cetylpyridinium Chloride)|Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.05% CHX + 0.05% CPC mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
223924192|NCT05457725|BEHAVIORAL|Contingent rtfMRI neurofeedback training|Contingent rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about real-time brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
223924193|NCT05457725|BEHAVIORAL|Non-contingent/sham rtfMRI neurofeedback training|Non-contingent/sham rtfMRI neurofeedback training will follow an alternating up-regulation/rest block design with screen-color cues. Visual feedback about non-contingent/sham brain activity in the ROI will be provided (e.g., via a thermometer bar). During resting blocks, the thermometer bar remains static.
223924194|NCT06089551|DRUG|SmofKabiven|Participants will receive supplementary parenteral nutrition based on their calorie intake. The dosage will be adjusted on a daily basis depending on intake.
224281060|NCT03417206|DEVICE|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity \> 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity \<5%
223924195|NCT06782815|DEVICE|Acupuncture|acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.
224281061|NCT01466036|DRUG|Cabozantinib|60 mg QD orally in cycles of 28 days
224281062|NCT01744964|DRUG|Apomorphine|1.5 mg Apomorphine
223924196|NCT06782815|DEVICE|Acupuncture|（1）Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; （2）Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.
223924197|NCT06749860|DRUG|Disitamab Vedotin + tislelizumab + bevacizumab|"Disitamab Vedotin, dosing regimen: 2.0 mg/kg, intravenous infusion, infusion should be about 30-90 minutes (usually about 60 minutes), every 21 days a cycle, the first day of administration, continuous use.~Tislelizumab, dosing regimen: 200 mg administered by intravenous infusion every 21 days in a cycle on the first day, continuous.~Bevacizumab, dosing regimen; 7.5 mg/kg administered by intravenous infusion every 21 days in a cycle on the first day of continuous use."
223924198|NCT06889337|OTHER|head elevated laryngoscopy position by Oxford pillow|ramped position, also known as head elevated laryngoscopy position,
223924199|NCT06881017|DRUG|Trastuzumab|iv，d1
223924200|NCT06881017|DRUG|Adebrelimab|iv，d1，q3w
223924201|NCT06881017|DRUG|Apatinib|po，qd，d1-21，q3w
223924202|NCT06881017|DRUG|S-1|po，bid，d1-14，q3w
223924203|NCT06881017|DRUG|Capecitabine|po，bid，d1-14
223924204|NCT06881017|DRUG|Oxaliplatin|iv，d1，q3w
223924205|NCT06881017|DRUG|zolbetuximab|iv，d1
223924206|NCT06881017|DRUG|SHR-A1811|iv，d1 ，q3w
223924207|NCT06881017|DRUG|SHR-A1904|iv，d1 ，q3w
223924208|NCT06881017|DRUG|SHR-1701|iv，d1 ，q3w
223924209|NCT06750068|OTHER|3D printed space maintainer|Digitally fabricated #d printed space maintainer
223924210|NCT06750068|OTHER|Conventional space maintainer|Stainless steel space maintains
223924211|NCT06757166|PROCEDURE|endotracheal intubation|endotracheal intubation for invasive mechanical ventilation
223924212|NCT06954376|OTHER|Hyperbaric oxygen therapy|Patients received hyperbaric oxygen therapy (HBOT) using a monochamber hyperbaric chamber in addition to conventional rehabilitation.
223924213|NCT06954376|OTHER|Conventional rehabilitation|Patients received conventional rehabilitation alone.
223924214|NCT06953622|DRUG|Conservative treatment|Receive no antipaletet drug treatment and surgery
223924215|NCT06953622|DRUG|Antipaletet drug|Use of antipaletet drugs.
223924216|NCT06953622|PROCEDURE|Patent Foramen Ovale Closure|Receive the surgery of Patent Foramen Ovale
223924217|NCT06952673|BEHAVIORAL|Multiple speed increments from 3km/h to 8km/h on a treadmill|Healthy participants will undergo a fixed experimental protocol of multi-stage treadmill speed walking/running wearing microsensors and a respiratory/metabolic testing mask.
223924218|NCT06390059|DEVICE|Tumor Treating Fields|"The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit."
223924219|NCT06390059|DRUG|Atezolizumab|"Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
223924220|NCT06390059|DRUG|Gemcitabine|"Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
223924221|NCT06390059|DRUG|nab-paclitaxel|"Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit."
223924222|NCT06784843|DRUG|Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block|Dexmedetomidine as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
223924223|NCT06784843|DRUG|Midazolam as an adjuvant to local anesthesia for peribulbar block|Midazolam as an adjuvant to a local anesthetic mixture (bupivacaine, lidocaine, and hyaluronidase) for peribulbar block during cataract surgery
223924224|NCT03934931|OTHER|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
223924225|NCT03934931|OTHER|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
223924226|NCT03934931|OTHER|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
223924227|NCT03934931|OTHER|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
223924228|NCT03934931|OTHER|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
223924229|NCT03934931|OTHER|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
223924230|NCT02020694|DRUG|Vitamin D|
223924231|NCT02020694|DRUG|Placebo (for vitamin D)|
223924232|NCT06037252|DRUG|Tirzepatide|Administered SC
223924233|NCT06037252|DRUG|Placebo|Administered SC
223924234|NCT06460441|DIAGNOSTIC_TEST|SUNRISE© device|"The device under study is the Sunrise© sensor, a single-use Class IIa medical device with CE marking and ISO 13485 certification.~The system combines a mandibular movement sensor with an artificial intelligence program to collect and interpret data. It consists of a three-gram device that is placed on the chin using an adhesive. The sensor is linked to a (free) mobile app, enabling data to be sent to the Sunrise© company's secured platform at the end of the night, and results to be transmitted to the prescribing physician."
224092475|NCT05012748|OTHER|Ketogenic diet|The ketogenic diet will consist of 75% fat, 20% protein and 5% carbohydrates. The diet will be standardised and matched to the energy consumption of each participant. The diet does not dictate time of consumptions. The food regime will be strictly followed every day for 3 weeks, where the investigator will contact the participants every day to secure adherence.
223717547|NCT03292588|DRUG|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~* 100 mg for participants ≥12 years of age and~* 40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
223924235|NCT05362006|DEVICE|Exopulse Mollii Suit|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate 40 groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more."
224092476|NCT04402047|OTHER|Electroacupuncture|We will apply Ashi points, Ex-UE9, SI3, and TE5. Sterile needles (0.3mm× 40mm) and SDZ-V EA apparatus will be utilized. Acupuncturists will insert needles perpendicularly into Ashi points for approximately 2-3mm until they pierce into the bone surface; acupuncturists will insert needles horizontally into Baxie points towards the wrist with a depth of 5-10mm; and acupuncturists will insert needles perpendicularly into SI3 and TE5 for approximately 5-10mm. All needles except Ashi points will be manually manipulated to achieve De qi. The needles at Baxie 1 and Baxie 4 will be connected using alligator clips from the EA apparatus. The electrical stimulation will last for 30 minutes with a continuous wave of 10 Hz and a fixed current intensity of 0.5 to 2 mA. All the needles will be retained for 30 minutes. Participants will undergo EA treatment three times per week for a total of 12 sessions in four consecutive weeks. If bilateral hands were affected, both sides will be treated.
224092477|NCT04402047|DRUG|Topical diclofenac sodium gel|The gel will be gently rubbed over the affected joints without excessive joint movement four times per day for 4 weeks and will be asked not to wash hands for one hour after application. Each hand treatment will be used in identical dispensing doses of gel (4 cm strip, approximately 2g, which was judged sufficient for approximately half the surface of each hand (200 cm2)). Dosing times should be distributed evenly over waking hours.If bilateral hands were affected, both sides will be treated.
224092478|NCT06399783|DRUG|Simvastatin|Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
224281063|NCT04747184|OTHER|DNA extraction and 16S rRNA sequencing|DNA extraction using QIAamp® DNA mini kit (QIAGEN) was done under aseptic techniques in the sterile room for all samples according to the manufacturer instructions. The DNA extracts for the 54 samples collected (27 from asthmatic patients and 27 from healthy subjects) were stored at -80° C in a sterile Eppendorf tubes until they were sent to the Molecular Research (MR DNA) Lab (Molecular Research LP, Shallowater, TX, USA) for sequencing.
223717548|NCT02395380|OTHER|C-reactive protein dosage|
223717549|NCT04479423|PROCEDURE|Soda-water instead of pure water to observe gastric filling|All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (\>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
223717550|NCT00062374|DRUG|Cisplatin|Given IV
223717551|NCT00062374|PROCEDURE|Computed Tomography|Undergo FDG and FLT PET/CT
223717552|NCT00062374|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
223717553|NCT00062374|OTHER|Fluorothymidine F-18|Undergo FLT-PET/CT
223717554|NCT00062374|DRUG|Irinotecan Hydrochloride|Given IV
224092479|NCT06399783|DRUG|Mometasone Furoate|Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of Mometasone Furoate.
224092480|NCT06399783|PROCEDURE|Fractional CO2 laser|Fractional CO2 laser will be used for assisted drug delivery for both topical simvastatin and mometasone Furoate.
224092481|NCT04845217|DRUG|Peppermint oil|Enteric coated peppermint oil taken by mouth three times daily for 8 weeks.
224092482|NCT04845217|DRUG|Coconut Oil|Enteric coated coconut oil taken by mouth three times daily for 8 weeks
224092483|NCT02548065|OTHER|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
223717555|NCT00062374|PROCEDURE|Positron Emission Tomography|Undergo FDG and FLT PET/CT
224281064|NCT04167384|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
224281065|NCT04167384|OTHER|Product B|Nicorette® Mint 4 mg nicotine lozenge
224281066|NCT04167384|OTHER|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
224281067|NCT04167384|OTHER|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
224281068|NCT04167384|OTHER|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
224281069|NCT04167384|OTHER|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
224281070|NCT04167384|OTHER|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
224281071|NCT04167384|OTHER|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
224281072|NCT02845011|DEVICE|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
224281073|NCT02845011|OTHER|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
223924236|NCT05362006|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
223924237|NCT05542082|DEVICE|CHILLS Procedure|Cryotherapy
223924238|NCT05368467|COMBINATION_PRODUCT|The clinical course and disease management|The clinical course and disease management of pulmonary hypertension patients
223924239|NCT06448091|DIAGNOSTIC_TEST|Panel-based pharmacogenetic genotyping|After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card
223924240|NCT06323512|DEVICE|Pulmonary artery denervation (PADN)|Combining invasive angiography with pulmonary artery CTA is frequently employed to determine the final size of the PADN catheter, aiming for an expected ratio of distal ring/vessel diameter between 1.1 and 1.2. The PADN system comprises a radiofrequency generator, connecting tubing and control handle, and the PADN catheter. The main interface of the radiofrequency generator offers multiple language options and displays parameters such as temperature, impedance, energy, and ablation time. The generator features three control modes: temperature control, power control, and a combination of both.
223924241|NCT05260047|BEHAVIORAL|IMANI|For the intervention, the study will introduce and offer Medication Assisted Treatment. Those participants wishing to receive MAT will be randomized to one of two intervention IMANI + church-based telehealth MAT or IMANI + Traditional MAT + Referral and Linkage. Those who do not wish to partake of MAT services will remain in the IMANI alone.
223924242|NCT05260047|BEHAVIORAL|Telehealth MAT|Describe what is the Telehealth MAT briefly
223924243|NCT05260047|BEHAVIORAL|Traditional MAT plus Referral and Linkage|Describe what he traditional MAT plus referral and linkage briefly
223924244|NCT04242589|RADIATION|Radiotherapy|External beam radiation therapy is a type of radiation therapy used for cancer treatment. A machine is used to aim high-energy rays from outside the body into tumor
223924245|NCT04242589|PROCEDURE|Vertebropladty|Vertebroplasty is a procedure for stabilizing compression fractures in the spine. Bone cement is injected into vertebrae that have cracked or broken. The cement hardens, stabilizing the fractures and supporting your spine.
223924246|NCT06337474|DRUG|anti-CD19 CAR NK cells (KN5501)|Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
223924247|NCT06620952|PROCEDURE|O-ring technique|"O-ring technique. consists on a different arrangement of fibrin-glue on a polymethilmetacrylate cranioplasty, with the aim to create a gasket to prevent CSF leakage"
223924248|NCT05078879|DRUG|Empagliflozin|This is an open-label pilot study to evaluate the efficacy, safety, and tolerability of empagliflozin as a treatment for severe congenital neutropenia (SCN) in patients with glucose-6-phosphatase 3 (G6PC3) deficiency. Participants will be on a 12-month daily regimen of empagliflozin at a starting dose of 10 mg (phase A), which may be increased after 2 months to 25 mg (phase B). Evaluate the safety and efficacy of the biomarker response (the change in absolute neutrophil count \[ANC\] after one year of empagliflozin treatment relative to baseline ANC prior to drug treatment) in patients with G6PC3 deficiency.
223924249|NCT05281744|BEHAVIORAL|Dementia Care Consultation program|The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
223924250|NCT01248624|BEHAVIORAL|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
223924251|NCT06507371|RADIATION|node-sparing modified short-course radiotherapy|radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx
223924252|NCT06507371|DRUG|PD-1 antibody|PD-1 antibody (Tislelizumab): 200mg d1 q3w
223924253|NCT06507371|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
223924254|NCT06507371|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223924255|NCT06507371|RADIATION|standard short-course radiotherapy|radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx
223924256|NCT04323488|BEHAVIORAL|Lindamood-Bell Seeing Stars|Seeing Stars in a curriculum developed by Lindamood-Bell. It is published and openly available. It involves systematic training in the building blocks of skilled reading.
224281074|NCT03293771|OTHER|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
224281075|NCT03293771|DIAGNOSTIC_TEST|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
224281076|NCT03225352|DRUG|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
223924257|NCT04909697|DRUG|Sivelestat sodium|4.8mg/kg sivelestat sodium was given in 50ml normal saline, and was continuously pumped in the dark for 24h, equivalent to 0.2mg/kg/h.Applied for 5 consecutive days
224092484|NCT02548065|OTHER|Placebo|Bath with Thermal tap water
224092485|NCT01284881|DEVICE|MRA|daily wear overnight
224281077|NCT03225352|DRUG|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
224281078|NCT03225352|DRUG|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
224281079|NCT03225352|DRUG|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
224281081|NCT05757037|DEVICE|laser acupuncture|a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5Hz, B2: 1199Hz, B3: 2398Hz, B4: 4776Hz, B5: 9552 Hz, B6: 19,104Hz, and B7: 38,208Hz\].
223531699|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 10 g/ day for 14 days
223531700|NCT05858853|DRUG|Human serum albumin|Control drug (human blood albumin injection) 20 g/ day for 7 days
223531701|NCT07086703|OTHER|Induced hypothermia at 33°C|"Cooling and maintenance phase :~The aim is to achieve the target temperature of 33±0.5°C within 60 minutes after randomization. The target temperature of 33±0.5°C and device setting of 33°C will be maintained until 28 hours after randomization.~\- Rewarming: Normothermia will be restored by gradual rewarming at a rate of 0.2°C/h.~\- After rewarming: After 40 hours, in those participants who are still comatose or sedated, normothermia (36.5-37.7°C) will be maintained until 72 hours after randomization, and active warming will be avoided."
223924258|NCT04909697|DRUG|Saline|50ml normal saline was continuously pumped in the dark for 24h. Applied for 5 consecutive days
223924259|NCT01242202|DRUG|ipragliflozin|oral
223924260|NCT01242202|DRUG|alpha glucosidase inhibitor|oral
223717556|NCT00062374|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
223717557|NCT04083053|PROCEDURE|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
223924261|NCT05810025|BEHAVIORAL|RealRisks|RealRisks is a web-based patient-centered decision aid (DA) designed to improve: 1) accuracy of breast cancer risk perceptions; 2) chemoprevention knowledge, and 3) informed choice. The DA includes audio and modules about breast cancer risk (including interactive games on risk communication) and chemoprevention. Through RealRisks, the investigators will collect information on breast cancer risk factors to calculate a patient's BCSC breast cancer risk score and also factors that influenced decision-making about chemoprevention through the preference elicitation game. RealRisks generates an action plan for patients summarizing their personalized breast cancer risk profile and preference elicitation for chemoprevention. Of note, the tool is designed for patients with varying levels of health literacy and numeracy and is available in English and Spanish.
223924262|NCT04599010|OTHER|Dietary intervention|energy-restricted diet appropriate for resting metabolic rate using FFM as proxy
223924263|NCT03603730|DEVICE|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
223924264|NCT05384873|DIETARY_SUPPLEMENT|Immunonutrition|In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Oral Impact®). The intervention will start approximately two weeks before anticancer treatment initiation and will continue up to first disease re-assessment (12-14 weeks) and prolonged according to patient's needs
223924265|NCT05384873|OTHER|Control dietary intervention|Patients will receive nutritional counseling as standard of care. Nutritional counseling may comprise the use of oral nutritional supplements (ONS), which are usually prescribed when patients are unable to maintain satisfactory spontaneous food intake (less than 50% of the requirement for more than one week or only 50-75% of the requirement for more than two weeks). Therefore, in this arm the use of isonitrogenous standard blend ONS will be considered according to the regular assessment of food intake.
223924266|NCT05524844|OTHER|Sample Collection|Saliva, gastric aspirate, and esophageal brushings and biopsies.
223924267|NCT05524844|OTHER|Endoscopy results|Results from standard of care endoscopy (scheduled separate of study)
223924268|NCT05524844|OTHER|Dietary questionnaire|Diet History Questionnaire (II)
223924269|NCT05769634|BEHAVIORAL|Stereoelectroencephalography|Computer-based tasks designed to evoke changes in interoceptive attention, arousal and anticipation will be completed. The first asks patients to attend to their heartbeat to manipulate interoceptive attention. The second asks patients to judge affective pictures to manipulate states of arousals. The third engages patients in a probabilistic reward-learning task, or gambling task, and anticipate the outcomes of risky decision-making. A final task guides patients to slow their breathing to 6 breaths per minute.
223924270|NCT04811027|DRUG|eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
223924271|NCT04811027|DRUG|pembrolizumab (KEYTRUDA®)|anti-PD-1 antibody
223924272|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.
223924273|NCT04614103|BIOLOGICAL|LN-145|A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.
223924274|NCT06649747|DRUG|AFA-281|A small molecule, orally available
223924275|NCT05677230|PROCEDURE|Balloon occluded/plug assisted retrograde transvenous obliteration.|Balloon occluded/plug assisted retrograde transvenous obliteration will be done one time only.
223924276|NCT05677230|PROCEDURE|Endoscopic Variceal Obturation|Endoscopic Variceal Glue Therapy will be done till obturation every 3 weekly.
223924277|NCT04728230|DRUG|Carboplatin|Given IV
223924278|NCT04728230|BIOLOGICAL|Durvalumab|Given IV
223924279|NCT04728230|DRUG|Etoposide|Given IV
223924280|NCT04728230|DRUG|Olaparib|Given PO
223924281|NCT04728230|RADIATION|Radiation Therapy|Undergo consolidative thoracic radiation therapy
223924282|NCT04821765|DRUG|PD-1 antibody|200mg, d1, q3W
223924283|NCT04821765|RADIATION|Chemoradiation|50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week
223924284|NCT04821765|DRUG|Albumin-Bound Paclitaxel|150mg/m2, d1, q3W
223924285|NCT04821765|DRUG|Cisplatin|75mg/m2, d1, q3W
223924286|NCT04002505|OTHER|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
224092486|NCT00061386|BEHAVIORAL|Nutrition and physical activity program|
224092487|NCT05357794|DRUG|Brentuximab vedotin|Given by Vein (IV)
224092488|NCT03182764|OTHER|No intervention|No intervention
224092489|NCT04819321|DEVICE|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
224092490|NCT01907620|OTHER|blood sample|
223717558|NCT04083053|PROCEDURE|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
223924287|NCT06214793|DRUG|Taletrectinib|Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
223924288|NCT06500910|OTHER|Physical Exercise|10 weeks of child-friendly physical exercise program
224281082|NCT03267654|DRUG|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
223924289|NCT05699525|BEHAVIORAL|Personalized MAYA Mobile App|All new material in the personalized condition will be introduced within the first four weeks and will contain modules targeting participant's personal symptom profiles. The remaining two weeks in the personalized condition will consist of practicing previously learned skills.
223924290|NCT05699525|BEHAVIORAL|General MAYA Mobile App|New material will be introduced to participants over all the six weeks of the intervention and will include all application modules.
223924291|NCT01937039|PROCEDURE|Sample collection|Blood, tissue, urine, and other samples may be collected
223924292|NCT02295072|BEHAVIORAL|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
223924293|NCT06294691|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
223924294|NCT06776471|OTHER|Resin-based flowable filling material|Preventive restoration
223924295|NCT04008186|DRUG|Omaveloxolone|50 mg capsules
223924296|NCT04008186|DRUG|Midazolam oral solution|2 mg/mL oral solution
223924297|NCT04008186|DRUG|Repaglinide 1 MG|1 mg tablet
223924298|NCT04008186|DRUG|MetFORMIN 500 Mg Oral Tablet|500 mg tablet
223924299|NCT04008186|DRUG|Rosuvastatin|10 mg tablet
223924300|NCT04008186|DRUG|Digoxin tablet|0.25 mg tablet
223924301|NCT04008186|DRUG|Gemfibrozil Tablets|600 mg tablet
223924302|NCT04008186|DRUG|Itraconazole capsule|100 mg capsule
223924303|NCT04008186|DRUG|Verapamil Pill|120 mg tablet
223924304|NCT03918252|DRUG|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
223924305|NCT03918252|DRUG|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
223924306|NCT03990233|DRUG|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
223924307|NCT03990233|DRUG|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
223924308|NCT03733626|COMBINATION_PRODUCT|ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system|ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion.
223924309|NCT03733626|COMBINATION_PRODUCT|Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system|Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion.
223924310|NCT05283330|DRUG|²¹²Pb-DOTAM-GRPR1|²¹²Pb-DOTAM-GRPR1 is a radioimmunoconjugate comprised of ²¹²Pb, the metal chelator DOTAM (1,4,7,10-Tetrakis(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane) and a GRPR-targeted antagonist.
223924311|NCT03031249|DRUG|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
223924312|NCT03031249|DRUG|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
223924313|NCT03031249|DRUG|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
223924314|NCT05804461|BEHAVIORAL|Motivational Interviewing|Upon refinement from Formative Research (Aim 1), a three-session, individual-level intervention to increase Pre-Exposure Prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Puerto Rico will be implemented. The facilitator will use Motivational Interviewing techniques to guide the sessions. The intervention's design and content will be the same for each study group; the only difference will be the modality of implementation; one group of participants will receive a face-to-face intervention, while another group will receive an online intervention.A total of 170 participants will be randomized in a 1:1 ratio into each of the two intervention modalities (n=85 face-to-face and n=85 online) while a control group will be recruited following a 3:1 ratio of intervention vs. control. In addition to baseline assessment, participants will be asked to complete a post test at the end of the third session (60 days) and a follow-up post-test at the 150-day mark, separately.
223924315|NCT06828822|OTHER|Neurodevelopmental assessment|This assessment will be conducted using the ASQ-3 test. (ASQ-3 stands for Ages and Stages Questionnaires, Third Edition, which is a common screening tool for evaluating developmental progress in young children.)
224092491|NCT06381583|DIAGNOSTIC_TEST|EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)|A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.
224092492|NCT01734343|DEVICE|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
224281083|NCT03267654|DRUG|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
224281084|NCT03267654|DRUG|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
223924316|NCT06828822|OTHER|Meeting with the parents|This meeting will evaluate the parents' acceptance of the lesion and their quality of life using the MARKS test (Measure of Acceptance of Skin Marks). The results will provide insights into how the parents perceive the lesion and how it impacts their daily lives.
223924317|NCT06828822|OTHER|Patient quality of life assessment|Collection of patient quality of life data
223924318|NCT06978257|BEHAVIORAL|Digital positive affect intervention (PAI)|"The Positive Affect Intervention (PAI) is a fully digital, self-guided program uniquely designed to deliver weekly 30-minute online sessions focused on cultivating positive emotions, meaning, and engagement, alongside daily ecological momentary prompts delivered thrice daily over six weeks. Distinctively, the intervention seamlessly integrates multimedia content (e.g., brief weekly videos introducing each session's core principles), practical exercises, and in-the-moment reflection, aiming to reinforce positive affect skills in real time. Its structure not only emphasizes proactive skill application through digital reminders but also systematically assesses user engagement and perceived helpfulness via ecological momentary assessments and post-session feedback questionnaires.~Unlike conventional digital interventions that primarily focus on symptom reduction through passive content consumption, this PAI leverages continuous ecological momentary engagement via a dedicated mobile app, e"
224092493|NCT01734343|DEVICE|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
224092494|NCT02484027|DRUG|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
224092495|NCT02086227|DRUG|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
223717559|NCT05512845|PROCEDURE|Double Factor technique|"The double factor computer assisted surgery technique, involves the combination of the static and dynamic computer assisted surgery protocols to place dental implants in the same surgery."
223924319|NCT06978257|BEHAVIORAL|Self-monitoring intervention|The self-monitoring intervention serves as an active comparator designed to isolate the effects of mood self-awareness without introducing therapeutic content. Participants in this arm receive daily prompts via the Qualtrics mEMA mobile app, three times per day over a six-week period, instructing them to track their mood and emotional states through brief ecological momentary assessments (EMAs). Unlike the digital positive affect intervention, this arm does not include psychoeducational material, skills training, or active enhancement strategies; instead, it focuses solely on routine self-monitoring to control for digital engagement and expectancy effects. This minimalist structure allows for a clean contrast between passive self-observation and active therapeutic engagement, enabling robust evaluation of the added value of the Positive Affect Intervention beyond self-monitoring alone
223924320|NCT06977815|BEHAVIORAL|VR-Enhanced Cognitive Rehabilitation|A program consisting of 45-minute computer-based cognitive rehabilitation exercises, enhanced with 15-20 minutes of immersive virtual reality (VR) content per session. The VR component targets memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks.
223924321|NCT06977815|BEHAVIORAL|Standard Cognitive Rehabilitation|A program consisting of 45-minute computer-based cognitive rehabilitation exercises targeting memory, attention, and executive function. Sessions are delivered twice per week over 12 weeks. No VR content is included.
224281085|NCT01618487|PROCEDURE|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
224281086|NCT01618487|PROCEDURE|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
224281087|NCT01618487|PROCEDURE|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
224281088|NCT01874977|BEHAVIORAL|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
224281089|NCT01874977|BEHAVIORAL|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
224281090|NCT01874977|BEHAVIORAL|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
224281091|NCT01747577|DRUG|Solifenacin Succinate|Oral
224281092|NCT01747577|DRUG|Placebo|Oral
224281093|NCT00348153|DRUG|Adalimumab|
223531702|NCT07086703|OTHER|Control normothermia|"Participants whose initial temperature is below 33°C may be actively rewarmed to 36.5°-37.7°C, at which point active rewarming will be stopped and passive rewarming performed according to the latest guidelines. Participants whose initial temperature is above 33°C will not be actively rewarmed to normothermia. The goal will be to maintain temperature no higher than 37.8°C.~After 40 hours, in those participants who are still comatose or sedated, normothermia (36.5-37.7°C) will be maintained until 72 hours after randomization, and active warming will be avoided."
223531703|NCT06904027|DRUG|Glycerol phenylbutyrate Oral Liquid|"Administration and dosage: The recommended total daily dose of glycerol phenylbutyrate is calculated based on the patient's body surface area, ranging from 4.5 mL/m2/d to 11.2 mL/m2/d:~1. Recommended initial dose in phenylbutyrate-naïve patients~   * Patients with body surface area (BSA) \< 1.3 m2: 8.5 mL/m2/day~  * Patients with body surface area (BSA) ≥ 1.3 m2: 7 mL/m2/day~2. Initial dose for patients switching from sodium phenylbutyrate to glycerol phenylbutyrate: Total daily dose of glycerol phenylbutyrate (ml) = total daily dose of sodium phenylbutyrate granules (g) ×0.81 Medication Schedule: The daily total dose should be divided into equal amounts and administered with each meal or feeding (such as three to six times daily)."
223531704|NCT04163757|DIETARY_SUPPLEMENT|crocin|2 tablets crocin per day
223531705|NCT04163757|DIETARY_SUPPLEMENT|placebo|2 tablets placebo per day
223531706|NCT05472675|PROCEDURE|Botulinum toxin and bupivacain|Botulinum toxin A AND bupivacain( local anesthetic)
224092496|NCT02086227|DRUG|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
224281094|NCT00981227|DRUG|Eslicarbazepine acetate|Scored tablets
224281095|NCT00981227|DRUG|Placebo|oral route
224281096|NCT00985231|DEVICE|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
224281097|NCT00985231|DEVICE|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
224281098|NCT03869294|DRUG|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
224281099|NCT05704673|DRUG|nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.|investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
224281100|NCT05622994|DRUG|Rimonabant|Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
224281101|NCT05014880|BEHAVIORAL|ICR (Intensive Cardiac Rehabilitation)|Participants in this arm will not have to adopt a 10-hour eating window while taking part in UCSD's 9-week ICR program.
224281102|NCT05014880|BEHAVIORAL|ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)|Participants in this arm will adhere to a daily, consistent 10-hour eating window while undergoing UCSD's 9-week ICR program to see if there is an improvement on cardiometabolic parameters.
224281103|NCT04491695|DRUG|Tirofiban Hydrochloride|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.
224281104|NCT04491695|DRUG|Oral antiplatelet|Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
224281105|NCT06149091|DRUG|Tranexamic Acid；|Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.
224092497|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
223924322|NCT06737471|OTHER|Intensive rehabilitation treatment|"A 3-hour daily rehabilitation treatment will be delivered to each patient 5 days a week for 5 weeks (45 hours) in the care units of the Hospital.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
224092498|NCT02786901|DRUG|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
224092499|NCT02786901|DRUG|Vehicle Gel|Gel
223924323|NCT06737471|OTHER|Extensive rehabilitation treatment|"A 3-hour weekly rehabilitation treatment will be delivered to each patient for 15 weeks (45 hours) in an outpatient setting.~Rehabilitation will address the following macro goals: gross motor, manipulative, visual and visual-cognitive."
223924324|NCT06644690|BEHAVIORAL|CO-OP with Creative Dance|The CO-OP with Creative Dance intervention integrates the Cognitive Orientation to daily Occupational Performance (CO-OP) approach with structured creative dance sessions. The CO-OP approach focuses on improving cognitive and functional performance through goal-setting, problem-solving, and the use of metacognitive strategies. Creative dance sessions involve simple, rhythmic movements aimed at enhancing motor coordination, memory, and attention. This intervention is administered three times per week for 60 minutes over 8 weeks. The sessions alternate between CO-OP activities and creative dance exercises.
223924325|NCT06644690|BEHAVIORAL|CO-OP Only|The CO-OP Only intervention involves the Cognitive Orientation to daily Occupational Performance (CO-OP) approach, which is designed to improve cognitive and functional performance through structured goal-setting, problem-solving, and metacognitive strategies. Participants engage in activities focused on improving their ability to perform daily tasks by using cognitive tools to develop and execute solutions. The intervention is administered three times per week for 60 minutes over an 8-week period. No additional physical or dance activities are included in this arm.
224092500|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Ruby-O|Subject will receive a single 1000 mg oral dose of EPA + DHA Ruby-O capsule
224092501|NCT05438173|DIETARY_SUPPLEMENT|EPA + DHA Krill Oil|Subject will receive a single 1000 mg oral dose of EPA + DHA krill oil capsule
224281106|NCT06149091|DRUG|Adrenalin|In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.
224281107|NCT06149091|DRUG|Hemagglutinase|Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
224281108|NCT02462434|BEHAVIORAL|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
224281109|NCT06106334|DRUG|S309309|Administered as oral capsules
224281110|NCT06106334|DRUG|Itraconazole|Administered as oral capsules
224281111|NCT05607563|DRUG|PM1009 injection|Participants receive PM1009 intravenously, every 2 weeks
224092502|NCT02476487|PROCEDURE|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2\. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
224281112|NCT01283646|DRUG|Apevitin BC|3.5 to 5 ml 3 times a daily
224281113|NCT01283646|DRUG|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
224092503|NCT04626713|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro-/ bio-feedback-based game interface that is driven by an EEG algorithm.
224092504|NCT03367871|DRUG|Pembrolizumab|IV
224092505|NCT03367871|DRUG|Paclitaxel|Administered intravenously (IV) on day 1
224092506|NCT03367871|DRUG|Cisplatin|Administered intravenously (IV) on day 1
224092507|NCT03367871|DRUG|Carboplatin|Administered intravenously (IV) on day 1
224092508|NCT03367871|DRUG|Bevacizumab|Administered intravenously (IV) on day 1
224092509|NCT01843010|DRUG|Parecoxib|Parecoxib 40mg will be intravenously infused.
224281114|NCT04385095|DRUG|SNG001|SNG001 via inhalation
224281115|NCT04385095|DRUG|Placebo|Placebo via inhalation
224281116|NCT00838981|DRUG|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
224281117|NCT00838981|DRUG|Sugar Pill|placebo, sugar pill will mirror active drug
224281118|NCT00838981|BEHAVIORAL|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
223924326|NCT06852560|BEHAVIORAL|Gratitude, exercise, and mindfulness program|"Participants will be enrolled in an 8-week GEM (Gratitude, Exercise, and Mindfulness) program conducted entirely in person at Blossoming Butterfly in Gainesville, Florida. Participants will attend weekly group sessions combining gratitude journaling, mindfulness-based stress reduction/emotional freedom technique, and physical activity goal-setting. Participants will also be provided with a toolkit to support at-home practices, including gratitude journaling, physical activity tracking, and mindfulness meditation.~Blood, saliva and urine will be collected from each participant at baseline and post-intervention to measure the following allostatic load biomarkers: fasting glucose or hemoglobin A1c; lipid panel (total cholesterol, LDL, HDL); C-reactive protein; dehydroepiandrosterone sulfate; cortisol; glomerular filtration rate; and albumin-to-creatinine ratio."
223924327|NCT05570149|DRUG|Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution|migraine prophylaxis
223924328|NCT06538779|DIAGNOSTIC_TEST|elastography,usg|Patients' general pain will be assessed with Visual Analog Scale (Global Pain), symptom severity and functional status will be assessed with Boston Carpal Tunnel Questionnaire, hand grip strength will be measured with dynamometer. Patient hand diagram will be marked according to patient's sensory symptoms. Median nerve cross-sectional area measurement at pisiform level with ultrasound, distal motor latency and sensory nerve conduction velocity with emg will be performed and recorded. Median nerve stiffness will be assessed with real-time elastography.
223924329|NCT06985745|OTHER|Standard Cleanser, Investigational emulsion, Standard moisturizer, Standard Sunscreen|"Products Application and Usage Instruction:~Wash out: T-2W \~ T0~Frequency:~AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: All the products should be applied to full face. No any other skincare or facial make up products are used except provide products.~b. Mode of application : 4-week Treatment T0 \~ T4W~Frequency:~AM: Standard cleanser + test emulsion (FLA#2039180 68) + standard sunscreen PM: Standard cleanser + test emulsion (FLA#2039180 68) Caution: All the products should be applied to full face. No other skincare or facial make up products are used except provide products.~c. Mode of application : 2-week relapse T4W \~ T6W AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer~Usage Instruction： Test emulsion (FLA#2039180 68): Self-application 0.6 ml for full face by hand every day (2x/day)."
224281119|NCT00838981|DRUG|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
223924330|NCT06655688|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
224092510|NCT01843010|DRUG|Placebo|Normal saline 5ml will be intravenously infused.
223924331|NCT06651580|PROCEDURE|Biospecimen Collection|Undergo collection of blood, saliva, urine or stool samples
223924332|NCT06651580|OTHER|Quality-of-Life Assessment|Complete QoL assessment
223924333|NCT06651580|OTHER|Questionnaire Administration|Complete questionnaire
223924334|NCT06651515|BIOLOGICAL|Allogeneic Pancreatic Endocrine Cell Clusters|Allogeneic Pancreatic Endocrine Cell Clusters
223924335|NCT05088356|DRUG|Purified regulatory T-cells (Treg) plus CD34+ HSPC|"Purified regulatory T-cells (Treg) plus CD34+ hematopoietic progenitor cells (CD34+ HSPC), followed by conventional T-cells (Tcon) Manufactured at SCTT Laboratory, dose 1x10\^6 cells/ kg to 3x10\^6 cells/kg"
223924336|NCT05088356|DRUG|Fludarabine|Fludarabine (160 mg/m2)
223924337|NCT05088356|DRUG|Melphalan|Melphalan (50 mg/m2)
223924338|NCT05088356|DEVICE|CliniMACS CD34 Reagent System|The CliniMACS® CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations is manufactured by Miltenyi Biotec
223924339|NCT05088356|DRUG|Tacrolimus|4-6ng/mL
224092511|NCT02983604|DRUG|GS-5829|Tablet(s) administered orally once daily
224281120|NCT00838981|BEHAVIORAL|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
224281121|NCT00838981|BEHAVIORAL|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
224281122|NCT04928664|DRUG|Liposomal bupivacaine|Single shot injection of 10ml 1.33% LB; Due to the milky colour of LB, syringe containing the LB will be covered; Followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml NS; The default fixed rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
223531710|NCT04106505|BEHAVIORAL|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
223924340|NCT05088356|DRUG|Cyclophosphamide|40mg/kg
223924341|NCT05088356|DRUG|Plerixafor|Dose 0.24 mg/kg, manufactured by Genzyme
223924342|NCT05088356|DRUG|Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent|Single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL
223924343|NCT05088356|DRUG|Thiotepa|Thiotepa 10 mg/kg
223924344|NCT05088356|DRUG|Mycophenolate Mofetil (MMF)|MMF 1000 mg BID
223924345|NCT05088356|DRUG|Ruxolitinib|Ruxolitinib 5 mg BID
224092512|NCT02983604|DRUG|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
224092513|NCT02983604|DRUG|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
224092514|NCT04761796|OTHER|Sleeping condition self-questionnaire|Professional flight members will answer a self questionnaire related to their sleeping conditions
223924346|NCT06589674|DIAGNOSTIC_TEST|Pulse variability index measurement|Peripheral perfusion index (PI) is an easy-to-implement and low-cost monitoring procedure obtained by interpreting non-invasive data obtained from pulse oximetry via plethysmography. It is a tool that allows interpretation of fluid status through changes in pulse oximetry waves caused by respiration. High perfusion indices are interpreted as low arterial tone. Changes in perfusion index are interpreted as indicators of vascular tone or fluid deficit problems in patients. The ratio of the highest and lowest PI values gives the Pleth Variability Index (PVI) (3,4). Hypotension can be predicted during anesthesia induction with PVI
224281123|NCT04928664|DRUG|Standard bupivacaine|Single shot injection of 10 ml 0.25% SB in ISB; In order to have blinding to the drug injected, syringe containing SB will be covered; followed by placement of indwelling catheter in ISB; Catheter will be connected to a fixed-rate portable elastometric pump ( Easy pump, ®) upon arrival in the recovery room by the nurse; The pump will be filled with 300ml 0.2% SB; The default fixed-rate of infusion will be 5ml/hr; Both the pump and the clamp will be covered by an aluminium foil; Catheter and pump will be removed on post-operative day 2
223924347|NCT06589674|OTHER|Diastolic shock index|The Diastolic Shock Index (DSI) is a hemodynamic parameter calculated by dividing the heart rate (HR) by the diastolic blood pressure (DBP). It reflects the balance between cardiac output and systemic vascular resistance, particularly in critically ill patients. A higher DSI can indicate impaired vascular resistance and may be useful for predicting the need for vasopressor support, especially in conditions like septic shock. However, its application in predicting hypotension during anesthesia induction is still under investigation.
223924348|NCT06599788|BEHAVIORAL|Standard work pace|Participants will work at a standard pace of one box per minute during the box carrying protocol
223924349|NCT06599788|BEHAVIORAL|Reduced-pace work|Participants will work at a slower pace than the standard work pace of the box carrying protocol
223924350|NCT06599788|BEHAVIORAL|Increased-pace work|Participants will work at a faster pace than the standard work pace of the box carrying protocol
223924351|NCT06599788|BEHAVIORAL|Additional rest breaks|Participants will work at the standard work pace during the box carrying protocol and have superimposed 5 minutes of rest every 30 minutes.
223924352|NCT06984380|OTHER|Telerehabilitation|Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. BTS TELEREHAB is a platform that allows the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device, that measures movements in real-time, allowing the clinician to remotely monitor the correct execution of the exercises. In addition to the proposed therapeutic exercises, functional assessment tests are also included for patient follow-up. The presence of the inertial sensor supports the clinician in verifying the correct execution of the motor task and in the precise quantification of joint mobility.
223924353|NCT06984380|OTHER|Usual care|Participants will receive a booklet containing information and activities on well- being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
223924354|NCT06653244|DRUG|Injection|dexmedimidine infusion
223924355|NCT06665568|DRUG|Intranasal ketamine hydrochloride|Flexible-dose intranasal ketamine hydrochloride (5 - 50 mg)
224092515|NCT03573713|OTHER|Care Groups|The Care Groups model has strong evidence of improvement of maternal and child health and maternal hygiene/nutrition behaviors.Through Care Groups, women will learn about proper water, sanitation, and hygiene behaviors; Infant and Young Child Feeding practices; management of childhood illnesses; home management, referral and care seeking for sick children; family planning; and use of preventive services available at health facilities (e.g., growth monitoring, deworming, vitamin A supplementation). All children under five years of age will also be screened for acute malnutrition by the Care Group Volunteers, and receive deworming medication and vitamin A supplementation twice a year through the Ministry of Health and Community Health Workers as part of national campaigns.
224092516|NCT03573713|BEHAVIORAL|IPT-G|"IPT-G is an effective, low-cost, short-duration community-based method for decreasing depression has been established that was first rigorously tested in Uganda. Several Private Voluntary Organizations in Africa have used this low-cost, short-duration, community-based group psychosocial approach and found it to be a culturally-sensitive, acceptable, and feasible approach to address depression.~IPT-G treatment spans 12 weeks of treatment, consisting of 3 phases (early, middle, and termination). Within this treatment, participants are also assessed for symptoms of depression every week."
224092517|NCT01111604|BIOLOGICAL|Ramucirumab|8 mg/kg IV Q2W
224092518|NCT01111604|BIOLOGICAL|Icrucumab|15 mg/kg IV Q2W
224092519|NCT01111604|DRUG|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
224281124|NCT02994290|DRUG|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
223531711|NCT04106505|BEHAVIORAL|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
224281125|NCT02994290|BEHAVIORAL|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
223531714|NCT06764121|OTHER|Haskap Berry Powder|The participants will consume four packets (16g) of haskap berry powder. The powder can be consumed with other food products.
223924356|NCT05446662|OTHER|music therapy|Patients participating in the study will be informed about the application of music therapy in the preoperative period. The patients who will take part in the music group are given 30 minutes the day before the surgery, and 30 minutes a day on the 1st and 2nd days after the surgery. Music that is selected by the researcher and grouped as relaxing music, classical music, sufi music and Turkish folk music will be played. The patients will be listened to the music with headphones that cover the whole ear, and the music will be adjusted to make them feel comfortable.
223531715|NCT06764121|OTHER|Placebo Powder|The participants will consume four packets (24g) of placebo powder. The powder can be consumed with other food products.
223924357|NCT05446662|OTHER|aromatherapy|Patients participating in the study will be informed about the application of aromatherapy in the preoperative period. During this period, patients undergo elbow test (1 drop of lavender oil will be dripped onto the inside of the patient's elbow, after 20 minutes, it will be evaluated whether an allergic reaction has developed). Lavender oil as aromatic oil will be administered to the patients in the aromatherapy group in the form of inhalation. Lavender oil inhalation (1 drop of 0.1 cc) It will be applied by inhalation with gauze on which 3-4 drops of lavender oil are poured. 30 minutes before surgery. Aromatherapy will be applied four times with an interval of 30 seconds on the 1st and 2nd days before and after the surgery.
223924358|NCT05446662|OTHER|Progressive Relaxation Exercises|Patients participating in the study will be informed about relaxation exercises in the preoperative period. Progressive relaxation training will be applied to the patients for 30 minutes once a day, on the day before the operation and on the 1st and 2nd days after the operation.
223924359|NCT05446662|OTHER|Hand massage|Patients participating in the study will be informed about the application of massage therapy in the preoperative period. 10-15 minutes once in the preoperative period. And in the postoperative period, the 1st and 2nd days are 10-15 minutes. application will be carried out. Lavender oil (Lavandula Angustifolia) will be used in hand massage, sweet almond oil (Prunus Amygladus Sativa) will be used as essential oil.
223924360|NCT06858527|OTHER|TAU+integrated group CBT|"TAU+integrated group CBT : participants receive a group psychotherapeutic intervention of Integrated CBT lasting eight weekly two-hour sessions, in parallel with their usual individual care. The sessions are led by a psychologist trained and certified in the practice of CBT and a psychiatrist specialized in addiction medicine. The psychotherapeutic intervention follows a fixed structure and is inspired by the CBT manual for the management of ADHD associated with SUDs published by Matthys et al. (2018). This intervention includes modules on planning and organization, time and distraction management, emotional regulation, work on impulsive behaviors and social skills, cognitive work, as well as substance use management and relapse prevention.~The sessions will be punctuated by regular breaks to ensure participants' comfort and the integration of the skills worked on during the sessions.~TAU : participants receive their usual care, in exception of group psychotherapeutic interventions."
223924361|NCT06988228|BIOLOGICAL|15% Dextrose Injection|15% dextrose solution will be administered by injection in three sessions at two-week intervals. It will be applied in combination with conventional exercise therapy.
223924362|NCT06988228|OTHER|izotonic saline injection|Participants will receive isotonic saline solution injections in three sessions at two-week intervals, as a placebo comparator to the 15% dextrose injections. All participants will also receive conventional exercise therapy.
223924363|NCT06988943|DEVICE|Low-dose CT screening|Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination
223924364|NCT06988943|DEVICE|AI full-lung model interpretation system|Using artificial intelligence technology to assist in the interpretation of CT images
223924365|NCT06988943|DEVICE|Digital Health Platform|"Community health centers and streets in Guangzhou use a program called Fei Anxin to manage residents' information in a unified way"
223924366|NCT06996847|BEHAVIORAL|psychoeducational programme to promote a critical attitude towards the symbolic consumption of yoghurt in primary school children|The promotion of critical consumption in children is to be developed in primary school classrooms. Students will spend a total of 7 hours: (2 sessions of 1 hour per week) for 3 consecutive weeks, plus a feedback session (1 hour per week); and there will be another session with parents (1 hour per week). The psychologist tutor will receive a set of six activities related to discriminating between symbolic and critical yoghurt consumption in children, understanding the persuasive intent of yoghurt advertising, awareness of social pressure and critical attitude. Psychological tutors will be trained and provided with support materials and equipment
223924367|NCT06997757|BEHAVIORAL|Mobile health|Instructions for brushing twice daily and using interdental cleaning aids via regular mobile phone messages will be sent atleast twice a week.
223924368|NCT06997757|PROCEDURE|Phase I Therapy|Instructions for brushing twice daily and using interdental cleaning aids during appointment only.
224092520|NCT04531267|DIETARY_SUPPLEMENT|Individualized dosage of calcium and magnesium|Participants' diet will be assessed by food frequency questionnaire to obtain calcium and magnesium intake. Individualized dosage of dietary supplements will be provided to maintain a calcium/magnesium ratio as 2.3. Participants will stay with the original medication plan.
224092521|NCT00431392|DRUG|Phenylephrine|
224092522|NCT00431392|DRUG|NG-Monomethyl-L-Arginine|
223531716|NCT05743075|DRUG|Ensifentrine|A dual PDE3/PDE 4 inhibitor
223531717|NCT05743075|DRUG|Placebo|Placebo solution
223531718|NCT07089511|OTHER|CB3P-ED + 0.1% cyclosporine eye drops|Combination of CB3P-ED + 0.1% cyclosporine eye drops
223531719|NCT07089511|OTHER|0.15% hyaluronic acid + 0.1% cyclosporine eye drops|Combination of 0.15% hyaluronic acid + 0.1% cyclosporine eye drops
223531720|NCT06872359|DEVICE|KIO017-1|Subcutaneous and/or supraperiostal injections in chin and/or mid-face and/or jawline. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
223717560|NCT05868200|DRUG|Capitano zenzero toothpaste|"Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months ."
223924369|NCT06997289|DRUG|Group that is receiving treatment.|"Incorporate the following regimen into your daily routine for optimal health benefits:~Chinese Medicine: Take a combination of Modified Xiaoyao Powder (2g), Tianwang Buxin Dan (1.5g), Wendan Decoction (0.5g), Night Jiaoteng (0.5g), and Fushen (0.5g) twice a day for a duration of 1 month. This regimen comes from Keda GMP Pharmaceutical Factory.~Auricular Point Stimulation: Apply small 0.2cm ear magnetic beads on the Shenmen, heart, and brainstem points on both sides of the ear.~Consistency is key to achieving positive results, so make sure to follow this routine diligently.~Two treatment methods are carried out simultaneously"
223924370|NCT05727163|DRUG|Dexamethasone|25mg via HAI (Pre-chemotherapy)
223924371|NCT05727163|DRUG|Anisodamine|10 mg via HAI (Pre-chemotherapy)
223924372|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 via HAI over 3 hours
223924373|NCT05727163|DRUG|Leucovorin|200 mg/m2 via HAI
223924374|NCT05727163|DRUG|Fluorouracil|400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
223924375|NCT05727163|DRUG|Irinotecan|150 mg/m2 intravenously
223924376|NCT05727163|DRUG|Bevacizumab|5 mg/kg intravenously
224092523|NCT00431392|DRUG|Propanolol|
224092524|NCT00431392|DRUG|Atropine|
224092525|NCT03607721|DEVICE|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
224092526|NCT01687790|DEVICE|molecular breast imaging (Discovery)|
223531721|NCT06872359|DEVICE|KIO017-2|Subcutaneous injections in temples and/or nasolabial folds and/or marionette lines and/or mid-face. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
223924377|NCT05727163|DRUG|Oxaliplatin|85 mg/m2 intravenously over 3 hours
223924378|NCT05727163|DRUG|Leucovorin|200 mg/m2 intravenously
223924379|NCT05727163|DRUG|Fluorouracil|400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
223924380|NCT06996860|DEVICE|foam roller|fascial therapy for performance effect
223924381|NCT06996860|DEVICE|theragun|fascial therapy for performance effect
223924382|NCT06996860|OTHER|general warm up|fascial therapy for performance effect
223924383|NCT06997367|BIOLOGICAL|MTBVAC|MTBVAC (BBV169) vaccine is a freeze-dried powder containing live attenuated Mycobacterium tuberculosis (M. tb), which is presented as a lyophilized product in a 10- dose vial. After reconstitution with 1.0 mL sterile water for injection, one dose (0.1mL) of vaccine contains 5 x10\^5 CFU live attenuated M. tb. One dose (0.1mL) of the MTBVAC (BBV169) vaccine is to be administered in the right deltoid region via the intradermal route.
223924384|NCT06997367|BIOLOGICAL|BCG Sii|Comparator vaccine: BCG Vaccine (TUBERVAC- Moscow strain), manufactured by Serum Institute of India, is a freeze-dried powder containing an attenuated strain of Bacillus Calmette-Guerin Mycobacterium bovis as a lyophilized product in a 10-dose vial. After reconstitution with 1.0 mL diluent (Sodium chloride) for injection, one dose (0.1mL) of BCG vaccine will be administered in the right deltoid region via the intradermal route.
223924385|NCT06997458|DIAGNOSTIC_TEST|xF Tempus assay|"The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs.~The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021).~The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021)."
223924386|NCT06997796|DRUG|Tranexamic Acid|Tranexamic acid powder intranasally
223924387|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
223924388|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
223924389|NCT06996535|DIAGNOSTIC_TEST|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
223924390|NCT06996652|DRUG|Adalimumab|40 mg self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
224092527|NCT01136395|DRUG|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
224092528|NCT01136395|PROCEDURE|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
224092529|NCT01136395|PROCEDURE|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
224092530|NCT04996719|DRUG|Rapamune|We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).
224092531|NCT05871203|OTHER|Gene sequencing|Participants were taken blood samples for gene sequencing at three time periods: before, after, and 24 hours after the end of the surgery
223924391|NCT06996652|DRUG|Placebo|40 mg matching placebo self-administered subcutaneously using a pre-filled syringe (PFS) every 2 weeks for up to 2 years
223924392|NCT06996028|OTHER|Strengthening domain, Balance domain, Coordination domain, Gait domain|The experimental group will engage in a structured exercise program targeting strength, balance, gait, and coordination. Strength exercises include sit-to-stand, step-ups, vertical jumping, and stair climbing. Balance training involves tandem walking, one-leg standing, and balancing on unstable surfaces. Gait exercises include bridging, clamshells, and heel rises, while coordination activities involve ball kicking, hopping through squares, and galloping/skipping. The program runs for 2 hours per day, 5 days a week, over 6 weeks, with sessions optionally split into shorter segments.
223924393|NCT06996028|OTHER|Lower extremity strengthening, Cardiorespiratory endurance|Group B will follow the PEDALS program, involving stationary cycling three times a week for 30 minutes per session. Each session includes lower-limb strengthening with gradual resistance progression and cardiorespiratory endurance training aimed at increasing cycling duration to 15-30 minutes. Proper bike setup and participant support are ensured, and each session ends with a cool-down period of pedaling without resistance until heart rate returns near baseline.
223924394|NCT06997315|OTHER|Time of exercise|The intervention is 1 hour of exercise at 50% between lactate threshold 1 and 2 either in the morning or the evening at the start of the 24 hour sampling period.
223924395|NCT06997315|OTHER|No exercise|The participants will rest for the full 24 hour sampling period.
224092532|NCT06548841|OTHER|Nanobiotechnology platforms|"The analyses will be carried out using the novel devices, which are of two types:~1. The first type of nanobiotechnological platform encompasses the hybridization of pathogen nucleic acids - that may be present in the clinical specimen - by employing specific molecular probes.~2. The second type of nanobiotechnological platform encompasses the use of capture bacteriophages or bait Phages to specifically detect bacterial or protozoan cell surface antigens (in the case of P. aeruginosa or L. infantum respectively) or viral particles (in the case of SARS-CoV2) and the use of reporter bacteriophages (transducer Phages) for the transduction of the electrochemiluminescent signal."
224092533|NCT03744455|BIOLOGICAL|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
224092534|NCT00316264|BIOLOGICAL|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
224092535|NCT00316264|BIOLOGICAL|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
224092536|NCT00316264|BIOLOGICAL|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
224092537|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
224092538|NCT00607048|DRUG|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m\^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
224092539|NCT01287663|DRUG|Permethrin impregnated|
224092540|NCT01287663|DRUG|no Permethrin impregnated|
224092541|NCT04118803|DEVICE|ICD replacement or upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
224092542|NCT04587115|DRUG|Risperidone|Risperidone 1mg to be used in combination with other drugs
224092543|NCT04587115|DRUG|Ziprasidone|Ziprasidone 80mg to be used in combination with other study drugs
224092544|NCT04587115|DRUG|Oxycodone|Oxycodone alone in a capsule will be considered the control. Oxycodone 15 mg will also be used in combination with other study drugs
224092545|NCT04345419|DRUG|Remdesivir|Remdesivir as antiviral drug
224092546|NCT04345419|OTHER|Standard of care treatment|Standard of care treatment
224092547|NCT01743430|OTHER|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
224092548|NCT05155098|OTHER|secukinumab|Prospective observational study. There is no treatment allocation. Patients who are receiving or intend to receive secukinumab are eligible to enroll into this study.
224092549|NCT00064922|BEHAVIORAL|Behavior Therapy|
224092550|NCT03926143|DRUG|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
224092551|NCT05733455|DRUG|Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg)|Participants will ingest two overencapsulated tablets of alpelisib at 23:00, along with a saltine cracker.
224092552|NCT05733455|DRUG|Placebo (microcrystalline cellulose), 2 capsules|Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
224092553|NCT05733455|DEVICE|FreeStyle Libre Pro|Continuous glucose monitoring for 24 hours (double blinded)
224092554|NCT05733455|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT) with Trutol glucose beverage|Participants will drink Trutol glucose beverage (D-glucose 75 g in 10 fl oz) and blood will be sampled at baseline and at 15, 30, 60, 90, 120, 150, and 180 minutes.
224092555|NCT05733455|DIETARY_SUPPLEMENT|BOOST Plus nutritional beverage|Participants will consume a quantity of BOOST Plus calculated to match their daily caloric needs, divided over three liquid meals.
223531722|NCT06872359|DEVICE|KIO017-3|Injections in or around labial mucosa for lip volume and contour and/or intradermal injections in perioral lines. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
223531723|NCT06761196|OTHER|Questionnaire|The quality of life measured with different scales (BREAST-Q, EORTC QLQ C30 and BR42)
223531724|NCT07095361|DRUG|Fibrinolytic once daily|tissue plasminogen activator (tPA) 10mg will be administered once a day as part of intrapleural enzyme therapy (IET) for 3 consecutive days.
223531725|NCT07095361|DRUG|Fibrinolytic twice daily|tissue plasminogen activator (tPA) 10mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.
223717561|NCT05868200|DRUG|Colgate total toothpaste|Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
223924396|NCT06995911|DEVICE|Virtual Far-sight Reading Device|The Virtual Far-sight Reading Device utilizes a birdbath optical configuration and freeform surface technology to extend the working distance from 30 cm to over 6 meters, thereby simulating distance viewing conditions and maintaining ciliary muscle relaxation. Study participants were required to engage in reading and writing tasks using the device for a cumulative daily duration of at least 1 hour.
223924397|NCT06997471|BIOLOGICAL|Investigational cellular therapy consisting on a HSCT using a graft enriched in CD34+, depleted of naïve T-lymphocytes and supplemented with memory lymphocytes|"Infusion Schedule~1. Primary Infusion: the enriched graft, containing the CD34+ progenitors and depleted naïve T cells, will be infused after the patient has undergone conditioning therapy.~2. In the case of haploidentical donors, an additional NK cell infusion will be administered whenever possible around day 7 post-transplant from a non-mobilized apheresis collection, aiming to enhance graft tolerance and prevente HHV6 disease.~3. Post-Transplant Memory T cell Infusions: beginning on days 15 and 30, and then administered monthly up to a maximum of one year or until the supply is depleted, memory T cells will be infused.~Conditioning Regimen~Prior to HSCT, all patients will undergo a low-intensity conditioning regimen designed to allow engraftment of the donor cells while minimizing toxicity:~1. Total Lymphoid Irradiation (TLI): 8 Gy of total lymphoid irradiation will be administered.~2. Fludarabine: a total dose of 120 mg/m², spread over 4 days (-6 to -3 before transplant), will serv"
223924398|NCT06996600|DEVICE|wireless thermal anisotropy measurement device|Wireless wearable thermal anisotropy measurement device designed for use at home
223924399|NCT06995989|OTHER|energy conservation techniques with pursed lip breathing|"Group A will receive energy conservation techniques with pursed lip breathing with~1 session a day for total 5 days in a week. 1 session will consist of 3 cycles of pursed lip breathing for duration of 10 minutes with a break of 20 minutes in between. ECTs will be trained for 2 weeks. A detailed manual will be developed to ensure the consistency of the training for all subjects. Examples of interventions are training to use ergonomic principles along with pursed lip breathing. The subjects were trained to place their equipment at chest height; they were trained to work at paced speed and in some cases instructed to use technical aids."
223924400|NCT06995989|OTHER|pursed lip breathing|pursed lip breathing
223924401|NCT06879483|PROCEDURE|Thoraco-laparoscopic partial esophagogastrectomy|"1. Laparoscopic Phase:~   * The stomach is mobilized, and a part of it is resected to include the lower esophageal segment.~  * Left gastric nodes, the splenic and common hepatic nodes are dissected.~  * A gastric tube is created using endoscopic staplers for esophageal reconstruction and fixed to the proximal gastrectomy specimen using sutures~2. Thoracoscopic Phase:~   * The patient is positioned in prone position~  * Three small incisions are made in the thorax~  * Further esophageal mobilization through a right thoracoscopy is performed in left lateral decubitus. Periesophageal nodes are retrieved en bloc. Left and right paratracheal and subcarinal lymph nodes are resected separately. The esophagus is transected at the tumor's proximal margin.~3. Reconstruction:~   * An anastomosis (esophagogastric connection) is performed to restore continuity, typically using a circular stapler or hand-sewn technique."
223924402|NCT06865209|DEVICE|Monolithic Zirconia Posterior Single Screw Retained Implant Crowns|Posterior single edentulous sites will be rehabilitated with monolithic zirconia single posterior implant crowns following two different full digital workflows
223924403|NCT06864728|BEHAVIORAL|Video Diabetes Education|Participants will receive a link to a short video explaining their findings. They can use the link as often as they'd like. They will get the results for the CGM and the laboratory findings. They will be linked to their 2 week diet diary
223924404|NCT06864728|BEHAVIORAL|In person or virtual diabetes education|Participants will meet with a nurse to discuss their CGM results and their lab results and get appropriate education.
223924405|NCT06860945|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223924406|NCT06997159|DRUG|LXE408|LXE408 film-coated tablets.
224092556|NCT05100537|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of emotions, awareness of thoughts, awareness of sensations. It involves full awareness of daily activities, using the breath as an anchor for attention.In addition to mindfulness practices and experiential work, psychoeducation and participants' sharing will clarify the issues of stress, stress management and how mindfulness is applied in daily situations and interpersonal communication.
223531726|NCT07095361|DRUG|DNA degradation once daily|Deoxyribonuclease (DNase) 5mg will be administered once a day as intrapleural enzyme therapy (IET) for 3 consecutive days.
223531727|NCT07095361|DRUG|DNA degradation twice daily|Deoxyribonuclease (DNase) 5mg will be administered twice a day as intrapleural enzyme therapy for 3 consecutive days.
223531728|NCT06909162|DRUG|INCB123667|single dose administered orally
223531729|NCT07098988|BIOLOGICAL|Visugromab|Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
223717562|NCT05339568|OTHER|Patients' whole process follow-up and management platform|Patients' whole process follow-up and management platform is a software for the patients and investigators. This platform will use to collect patients' information when they are out of patients and will provide the patients' education materials.
224281126|NCT02285933|OTHER|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
224281127|NCT02285933|OTHER|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
224281128|NCT04283370|OTHER|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
223924407|NCT06997159|DRUG|Miltefosine 50 MG Oral Capsule [Impavido]|Each capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. Capsules are supplied in packs of 56 capsules sealed in 8 aluminum blister stripes, each containing 7 capsules.
223924408|NCT06997159|DRUG|Placebo to LXE408|Film-coated tablets.
223924409|NCT03907982|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
223924410|NCT03907982|PROCEDURE|Pulmonary vein isolation|The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
223924411|NCT03907982|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
223924412|NCT06677112|PROCEDURE|Selective surgical staging|Intraoperative Consultation, performed by pathologist and surgeon jointly. The uterus is inspected for extra-corpus spread (cervix, parametria, adnexa, distant). The surgical pathologist will evaluate the uterus according to the IOC Worksheet and promptly notify the surgeon of the results. The IOC will include evaluation for extra-corpus disease, lesion measurement, frozen section (to confirm measured lesion is malignant, cell type, and re-grading of tumor). Non-sentinel nodes will be handled according to institutional standard-of-care practice.
223924413|NCT06677112|PROCEDURE|REFLEX|The surgeon will perform a side-specific lymphadenectomy when there is no mapping on a hemipelvis (no tracer uptake in nodes). If neither side has successful Sentinel Node mapping, the surgeon performs a complete pelvic lymphadenectomy. Surgeons will remove the para-aortic lymph nodes at their discretion.
223924414|NCT06676345|PROCEDURE|Surgical treatment|Surgical repair of post-infarction mechanical complications (e.g. sutureless or sutured repair for LVFWR, David or Daggett technique for VSR, mitral valve repair or replacement for PMR)
224092557|NCT05100537|OTHER|continuing a routine life|No intervention will be made in the control group.
224092558|NCT00750984|PROCEDURE|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
224092559|NCT00750984|PROCEDURE|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
224092560|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
224092561|NCT00750984|DEVICE|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
224092562|NCT02573116|PROCEDURE|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
224092563|NCT03862027|DEVICE|Esophageal Balloon catheter|"Pressures \[Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)\] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
224092564|NCT02749214|OTHER|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
223531730|NCT07098988|DRUG|Matching placebo for visugromab|Participants receive Matching Placebo intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
223924415|NCT06676345|PROCEDURE|Percutaneous treatment|Percutaneous approach for the management of post-infarction mechanical complications (e.g. percutaneous closure with device for VSR, Mitraclip for PMR, PIFIT for LVFWR)
223924416|NCT06997484|DRUG|HL-400|Part 1:Experimental: Single oral dose of HL-400, Single ascending doses, sequential assignment group design; Part 2: Experimental: Multiple oral doses of HL-400, Multiple ascending doses, QD for 14 days, sequential assignment group design; Part 3: Experimental: Multiple oral doses of HL-400, QD for 5 days.
223924417|NCT06997484|DRUG|Placebo|Part 1: Placebo comparator: Single oral dose of placebo, single doses, matching placebo; Part 2: Placebo comparator: Multiple oral doses of placebo, multiple ascending doses, QD for 14 days, matching placebo.
223924418|NCT05590663|OTHER|Physiotherapy|routine referral-based physiotherapy treatment for patients with knee osteoarthritis
223924419|NCT07002671|PROCEDURE|Appendectomy|Appendectomy (Laparoscopic or conventional open surgery)
224092565|NCT02749214|OTHER|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
224092566|NCT05294029|OTHER|standard of care for patients with neuromotor disability|clinical examination, radiological, biological and physiological examinations.
224092567|NCT03711383|DIETARY_SUPPLEMENT|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
224092568|NCT03711383|DIETARY_SUPPLEMENT|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
224092569|NCT03711383|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before test day
224092570|NCT02938182|DRUG|clopidogrel|clopidogrel troche 75 mg daily for three months
224092571|NCT02794337|RADIATION|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
224092572|NCT02794337|PROCEDURE|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
224092573|NCT02794337|DRUG|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
224092574|NCT05627466|DRUG|Magrolimab|Administered intravenously
224092575|NCT00728546|DRUG|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
224092576|NCT05904444|PROCEDURE|microperimetric biofeedback training|Microperimetry biofeedback training is a noninvasive stragegy to develop a new trained retinal locus or strength the spontaneous preferred retinal locus to get better visual performances.The rationale of MBFT consists in reeducating visual system to a new visual condition, promoting retina-brain transmission, and further enhancing synaptic plasticity and neural capacity by acoustic biofeedback or structured light stimulus biofeedback.
224092577|NCT03545282|BEHAVIORAL|Amigas Latinas Motivando el Alma (ALMA)|"In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.~Due to COVID-19 pandemic, the intervention was changed to online synchronous delivery via Zoom over 6 weekly sessions."
224092578|NCT03494283|BEHAVIORAL|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
224092579|NCT03216993|OTHER|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
223531731|NCT07098988|BIOLOGICAL|Pembrolizumab 200 mg Q3W|Participants receive Pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments after visugromab infusion.
223531732|NCT07098988|DRUG|Pemetrexed 500 mg/m^2|Participants receive Pemetrexed 500 mg/m\^2 IV on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
223924420|NCT07002671|DIAGNOSTIC_TEST|blood sampling|Blood samples, in the preoperative period, routinely collected from the patients of acute appendicitis cases
223924421|NCT05954091|DRUG|OH2 Injection|OH2 injection will be given intratumorally, and Q2W.
223924422|NCT06867653|OTHER|Retraining|Each retraining session begins with a 15-minute comprehensive review, followed by hands-on practice
223924423|NCT04586244|DRUG|retifanlimab|retifanlimab will be administered via IV over 30 minutes (+ 15 min) on Day 1 of each 28-day cycle, up to 3 cycles,
223924424|NCT04586244|DRUG|epacadostat|epacadostat will be administered daily twice daily orally up to and including day of surgery.
223924425|NCT04586244|DRUG|INCAGN02385|INCAGN02385 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
223924426|NCT04586244|DRUG|INCAGN02390|INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
224092580|NCT03216993|OTHER|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
224092581|NCT00212329|PROCEDURE|T Cell Proliferation and Autoreactivity Assays|
224092582|NCT00212329|PROCEDURE|Cellular Immunoblot Assays|
224092583|NCT00212329|PROCEDURE|Tetramer Studies|
224092584|NCT00212329|PROCEDURE|Cytokine ELISPOT|
224092585|NCT03545139|BIOLOGICAL|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
224092586|NCT03545139|BIOLOGICAL|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
223531733|NCT07098988|DRUG|Carboplatin AUC 5|Participants receive Carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) on Day 1 of each 21-day cycle for four cycles.
223924427|NCT06886945|OTHER|Audio-Visual Perceptual Tasks|"Around 75 participants will be recruited for this study (25 per each group), and asked to perform two distinct audiovisual tasks (run via Matlab-based automated routines, and presented using a CRT monitor and a pair of loudspeakers) :~1. TOJ task, in which a white flashing dot, and a basic auditory stimulus, will be presented in close temporal proximity at several stimulus onset asynchronies (SOAs, from 30 to 540 ms in steps of 30 ms), with participants asked to report ( after each trial), which stimulus occurred first (task duration estimate: 25 minutes, 30 trials per each SOA)~2. A modified version of the SIFI (mSIFI), in which the presentation of paired (and temporally close) auditory stimuli will be coupled with the occurrence of either 1 or 2 flashing dots, at several different SOAs (from 30 to 250 ms in steps of 10 ms), with participants asked to report (after each trial), whether they saw 1 vs 2 flashes (task duration estimate: 25 minutes, 30 trials per each SOA)"
223924428|NCT06868953|DRUG|combination of sumatriptan 85 mg and naproxen 500 mg|combination of sumatriptan 85 mg and naproxen 500 mg
223924429|NCT06868693|DRUG|Neoadjuvant Chemotherapy (NAT) Group|This cohort includes elderly patients (≥70 years) with resectable or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) who underwent neoadjuvant chemotherapy (NAT). The NAT regimens include 5-FluoroUracil, Irinotecan, Oxaliplatin (FOLFIRINOX), gemcitabine/nab-paclitaxel (GnP), and other standard chemotherapy protocols. The study aims to evaluate the impact of NAT on overall survival (OS), progression-free survival (PFS), R0 resection rates, and postoperative outcomes, as well as the toxicity profile of different NAT regimens.
223924430|NCT04983199|DEVICE|Hexoskin Medical System|Hexoskin is a smart shirt that can detect heart rates, lung function and physical activity of patients before and after radiotherapy.
223924431|NCT06875713|BEHAVIORAL|Parenting for Lifelong Health Program (DAYEM)|This intervention consists of the Parenting for Lifelong Health (PLH) program, delivered through eight in-person sessions, supplemented by a digital parenting program (ParentApp). The intervention aims to enhance positive parenting behaviors and reduce child maltreatment.
223924432|NCT06875713|BEHAVIORAL|Adult nutrition|The control group will receive education on adult nutrition over the same period.
223924433|NCT06870032|OTHER|standard medical care|standard medical care
223924434|NCT06870032|OTHER|structured pulmonary rehabilitation|"structured pulmonary rehabilitation program including:~* Physical Therapy: Breathing exercises, airway clearance techniques, inspiratory muscle training.~* Pediatrics \& Chest Medicine: Medical supervision, optimization of pharmacological treatment.~* Physiology: Monitoring pulmonary function and physiological responses to exercise.~* Public Health: Evaluating program feasibility and its impact on healthcare utilization."
223924435|NCT04276779|OTHER|Alcohol administration|Participants in the alcoholic beverage group will be provided a dose of 95% alcohol (0.99g/kg for males and 0.90 g/kg for females body weight) distributed in two equally spaced beverages (mixed with orange juice 1:5 ratio). This dose will produce a breath alcohol content ranging between .08-.10.
223924436|NCT04276779|OTHER|Placebo administration|Individuals in the placebo condition will receive orange juice with 4 ml of alcohol layered on top of the juice. Ethanol will be sprayed on the rims of the glasses.
223924437|NCT04276779|BEHAVIORAL|Positive mood induction|Participants will be randomized to either positive mood induction procedure. Both conditions involve listening to music that reliably induces positive mood, while simultaneously reading self-referent statements that also induce either positive mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
223531734|NCT07101835|PROCEDURE|Bilateral ultrasound guided external oblique intercostal block (EOIB)|Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Patients scheduled for LSG will receive a Bilateral ultrasound guided external oblique intercostal block (EOIB) preoperatively, and sensory block status will be evaluated after 30 minutes.
223531735|NCT07101835|DRUG|ıv morphine PCA|ıV PCA of 0,5mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount).
223531736|NCT07102966|GENETIC|Rapid whole genome sequencing|All consented patients will receive a virtual genetic evaluation and rapid whole genome sequencing
223531737|NCT06147089|BEHAVIORAL|Sleep Intervention|Participants in the sleep intervention receive advice on: sleep hygiene/environment, sleep timing, naps, and exposure to light. These advices will be tailored to the personal situation of the participant, as measured during the run-in period.
223531738|NCT06147089|BEHAVIORAL|Nutritional intervention|Participants in the nutritional intervention receive personalised advice on the distribution of calories and nutrients over 24 hrs, and on specific food products based on the outcomes of the continuous glucose measurements (CGM) during the run-in period. The guidelines will include room for personal dietary preferences.
223924438|NCT04276779|BEHAVIORAL|Negative mood induction|Participants will be randomized to either negative mood induction procedure. Both conditions involve listening to music that reliably induces sad mood, while simultaneously reading self-referent statements that also induce either sad mood. This procedure lasts about 10 minutes and produces a transient mood state that passes by the end of the study.
223924439|NCT04037007|PROCEDURE|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
223924440|NCT04037007|PROCEDURE|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
223924441|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
223924442|NCT04037007|PROCEDURE|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
223924443|NCT06303297|OTHER|REFLEXOLOGY|will receive foot and hand reflexology and stretching. The researcher will administer foot and hand reflexology to the participant for a period of 3 weeks this last for a duration of 10 min on each hand and foot with total duration of 40 minutes. Foot reflexology include general foot massage, including the foot rotation, Achilles stretching, and the foot extension and stretching, will be performed for a minute on each foot. In the right foot, the bottom of the heel will be kept with the left hand, and the metatarsal arch of the same foot will be held with the other hand. Then, the foot will be rotated clockwise and counter clockwise three times each direction. The same technique will be performed on the left foot. On hand lubricated with moisturizer to the dorsal and plantar surface and apply pressure on for 10 minutes. Noninvasive and safe complementary therapy that involves a direct pressure on specific body points connecting specific organs.
223924444|NCT06303297|OTHER|GENERALIZED STRETCHING|will receive Stretching of upper and lower limbs. The stretching program lasts for 3 weeks with 60 min of stretching session 3 times a week. Extension of body include shoulder extension, torso rotation, hip extension, calf stretching (ankle pumps). ten stretches of 30 s each, with 15 s of rest between each stretch
223924445|NCT05574036|DRUG|Febuxostat 80 MG Oral Tablet|Febuxostat used as 80 mg oral tablet once daily for 6 months
224281129|NCT04283370|OTHER|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
224281130|NCT05321875|DRUG|Candesartan|3 years treatment with candesartan target dose: 32 mg or maximum tolerated dose after dose escalation from 16 mg
224281131|NCT02861833|OTHER|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
224281132|NCT03227133|OTHER|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
224281133|NCT03227133|OTHER|Psychiatric interview|
224281134|NCT03227133|OTHER|Cardiovascular risk assessment|
224281135|NCT01325506|OTHER|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
224281136|NCT05849688|OTHER|Designed Physical Therapy Program|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied.
223924446|NCT05574036|DRUG|vit E|Vitamin E used as 400 mg soft gelatin capsules twice daily for 6 months
223924447|NCT02333162|DRUG|Fludarabine Phosphate|Given IV
223924448|NCT02333162|DRUG|Melphalan|Given IV
223924449|NCT02333162|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMTMI
224281137|NCT05849688|OTHER|Bicycle Ergometry Training|The designed physical therapy program include gentle stretching exercises for biceps brachii, hamstrings and calf muscles bilaterally (5 times for every muscle) and isometric muscle contraction for quadriceps, hamstrings, anterior tibial group, calf muscles, biceps and triceps muscles (5 times for every muscle). Also, diaphragmatic breathing exercises will be applied + bicycle ergometry training
224281138|NCT00754871|DRUG|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
224281139|NCT00754871|DRUG|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
224281140|NCT00754871|DRUG|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
224281141|NCT00754871|DRUG|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
224281142|NCT02425384|BEHAVIORAL|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
224281143|NCT02425384|BEHAVIORAL|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
224281144|NCT02425384|OTHER|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
224281145|NCT00808509|BIOLOGICAL|adalimumab|40 mg every other week via subcutaneous injection
223924450|NCT02333162|RADIATION|Total Marrow Irradiation|Undergo IMTMI
224092587|NCT03146286|DIETARY_SUPPLEMENT|Saturated fat|Palm stearin
224092588|NCT03146286|DIETARY_SUPPLEMENT|Placebo|Water
224092589|NCT03146286|DIETARY_SUPPLEMENT|Fish Oil|Fish Oil, Omega 3 PUFA
223924451|NCT02333162|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
223924452|NCT02333162|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
224281146|NCT00808509|DRUG|methotrexate|At least 10 mg/week administered orally or subcutaneously
223924453|NCT02333162|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
224281147|NCT04248517|OTHER|mHealth Intervention|Participants will download the app onto their smartphone and complete ecological momentary assessements
224281148|NCT00436917|DRUG|zoledronic acid|zoledronic acid
224281149|NCT00436917|PROCEDURE|Letrozole as adjuvant therapy|standard care
224281150|NCT03466827|DRUG|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
224281151|NCT00196820|DRUG|Capecitabine|
224281152|NCT04570176|PROCEDURE|adrenalectomy for adrenal adenoma|adrenalectomy， cystectomy and nephrectomy
224281153|NCT01679431|DIAGNOSTIC_TEST|Doppler-echocardiography|
224281154|NCT01679431|RADIATION|Computed tomography|
224281155|NCT01679431|OTHER|Magnetic resonance imaging|
224281156|NCT01679431|BIOLOGICAL|Fasting blood sample|
223924454|NCT02333162|DRUG|Tacrolimus|Given IV or PO
223924455|NCT02333162|DRUG|Mycophenolate Mofetil|Given IV or PO
223924456|NCT02333162|OTHER|Laboratory Biomarker Analysis|Correlative studies
223924457|NCT03661255|BEHAVIORAL|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
223924458|NCT04174560|BIOLOGICAL|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
223924459|NCT06626958|BEHAVIORAL|Stress Ball|Stress Ball app
223924460|NCT06627426|OTHER|VR-based patient informed consent|"The intervention group will be the on receiving VR-based patient informed consent. One surgeon from the study team will be guiding the patient through their VR model first with demonstration of the technology and the model, afterwards the patient will be enabled to use the VR system by themselves. During the whole process the patient will be able to ask questions. Depending on the planned surgery, the surgical approach as well important anatomical structures will be explained."
223924461|NCT06627920|DEVICE|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.|Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.
223924462|NCT06870903|PROCEDURE|Extraperitoneal(transvaginal paracervical sentinel lymphadenectomy) group lymphadenectomy|The procedure begins with a vaginal incision in the lateral vaginal fornices (on both sides), which is then extended to allow placement of the V-NOTES apparatus. By identifying an appropriate cleavage plane, the obturator fossa is accessed to excise the obturator lymph nodes. Following this, an anterior colpotomy is performed to access the vesicocervical space, and a posterior colpotomy is made to open the rectouterine pouch. The V-NOTES apparatus is then placed to continue with the hysterectomy and bilateral salpingo-oophorectomy (BSO).
223924463|NCT06870903|PROCEDURE|Transperitoneal lymphadenectomy|In this arm, patients will undergo transperitoneal lymphadenectomy with V-NOTES. The procedure begins with anterior and posterior colpotomies, followed by placement of the V-NOTES apparatus. Hysterectomy is performed first, followed by peritoneal dissection and lymph node excision.
223924464|NCT06872008|BEHAVIORAL|Hand Massage|"Hand massage to elderly people Hand massage application consists of five basic classical massages including efflorage, petrissage, friction, tapotman and vibration.~It is a massage that includes manipulation and is performed with western technique.~The researcher will collaborate with the institution's physiotherapist throughout the application. Hand massage in the literature Although there is no standard duration for how long the massage should be applied, studies have shown that the massage is applied for an average of 5-10 times, and in this study the massage application time was It was determined as 10 minutes in total, 5 minutes for each hand. Hand massage with baby oil will be performed 3 times a week for 4 weeks, for a total of 12 sessions."
223924465|NCT06868602|OTHER|psychoeducation|Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study,Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.
224281157|NCT04855591|DRUG|SHR-1703|SHR-1703 will be administered subcutaneously
224281158|NCT04855591|DRUG|Placebo|Placebo of SHR-1703 will be administered subcutaneously
224281159|NCT00535080|DRUG|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
224281160|NCT02169791|DRUG|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
223717563|NCT04688853|BIOLOGICAL|TEG002|TEG002 cells are autologous T cells transduced with a specific γδTCR
223717564|NCT02870582|DRUG|Donafenib|treatment drug
223717565|NCT02870582|DRUG|Placebo|Best support treatment
224092590|NCT05014854|DEVICE|Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.|Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
224092591|NCT01933087|BEHAVIORAL|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
224281161|NCT05308368|DEVICE|Ultrasound Imaging|We will collect ultrasound images during the grasping motion for both groups
224281162|NCT05308368|DEVICE|Electromyography|We will collect electromyography (EMG) signals of both the flexor and extensor muscles of the wrist during the grasping motion for both groups
224281163|NCT05308368|DEVICE|Inertial Measurement Units (IMU)|We will use data from the ultrasound images and EMG to develop a tremor model. The model will be validated in comparison to joint angle measurements from an Inertial Measurement Unit (IMU) collected during the grasping motion
224281164|NCT05308368|DEVICE|Functional Electrical Stimulation (FES)|We will use the develop closed-loop control methods for tremor suppression using information from the ultrasound-image based tremor models. FES will be used to provide stimulation that will help with tremor suppression
223924466|NCT06868602|OTHER|Exercise|Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study, Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.
223924467|NCT06875050|OTHER|Mediterranean diet|Tailored dietary plan following Mediterranean diet to cover macronutrients needs according to recommended daily allowance (RDA) for age
223924468|NCT06875050|DIETARY_SUPPLEMENT|Fat soluble vitamins supplementation|Fat soluble vitamins supplementation (150 μg vitamin A, 2000 IU vitamin D, 100 mg vitamin E and 1000 μg vitamin K).
223924469|NCT06875050|DIETARY_SUPPLEMENT|Antioxidant Supplement|Antioxidant supplements in specific doses in oral liquid form (200 mg vitamin E, 300 mg vitamin C, 90 μg Se, 500 μg vitamin A, 30 mg zinc, 3 mg copper and 2000 IU vitamin D).
224092592|NCT04506112|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention (TranS-C), adapted for cardiac rehabilitation|Participants will complete the TranS-C intervention as adapted for cardiac rehabilitation. TranS-C is a behavioral intervention that is rooted in basic sleep and circadian science and draws from empirically-supported treatments including Cognitive Behavioral Therapy for Insomnia (CBT-I), Interpersonal and Social Rhythm Therapy (IPSRT), chronotherapy, and light therapy. It was designed to promote sleep health across a range of sleep problems. Participants in this group will also continue to receive care as usual, cardiac/sleep-related or otherwise.
224092593|NCT02582671|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
224092594|NCT02582671|DRUG|Dasabuvir|Tablet
224092595|NCT02582671|DRUG|Ribavirin|Tablet
224092596|NCT05043584|DEVICE|Fluobeam LX, Fluoptics, Grenoble, France|See arm description
224092597|NCT03578679|DRUG|Ivermectin Oral Product|treatment of pediculosis (head lice)
224281165|NCT03601494|OTHER|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
224281166|NCT03601494|DRUG|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
223717566|NCT01211327|DRUG|Cyclosporine A|Cyclosporine 2% eye drops
223717567|NCT01211327|DRUG|Dexamethasone|Dexamethasone 0,1% eye drops
224092598|NCT01287104|BIOLOGICAL|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
224092599|NCT01287104|BIOLOGICAL|Stem Cell Infusion|Transplant Day 0: \>4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) \>5000/microliters x2
224092600|NCT01293617|OTHER|Blackberries|300 g blackberries daily for 5 days
224092601|NCT01293617|OTHER|Gelatin|300 g gelatin per day for 5 days
224092602|NCT01755169|DRUG|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
224092603|NCT01755169|DRUG|Placebo|
224281167|NCT03019562|DRUG|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
224281168|NCT03019562|DRUG|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
224281169|NCT03454282|OTHER|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
224281170|NCT05556226|DRUG|ABBV-154 Dose Formulation A|Subcutaneous Injection
224281171|NCT05556226|DRUG|ABBV-154 Dose Formulation B|Subcutaneous Injection
224281172|NCT02913131|DRUG|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
224281173|NCT02913131|DEVICE|MRI|MRI scan following the pyruvate (13c) injection
224281174|NCT02438540|DRUG|metformin|metformin tablet 500 mg
223924470|NCT06874543|OTHER|visceral osteopathic manual therapy|In the study, relaxation techniques, hepato-gastric ligamentum mobilization, pyloric valve mobilization, sphincter odi mobilization, sphincter ilio-jejunum mobilization, cecal valve mobilization, iliopsoas and iliacus mobilization, peritoneal mobilization, intestine, kidney, bladder, stomach, liver and bladder organ mobilizations will be applied to the experimental group patients as VOMT program. Until the next session, bladder mobilization will be taught as a home program and they will be asked to do it every day. After VOMT is applied by the physiotherapist once a week, a total of 4 times, the evaluation scales will be applied again. In order to see the long-term effect, the patients will be evaluated again in the first month and the third month after the end of the treatment. The forms will be filed as pre-treatment, post-treatment, first month and third month data and will be entered into the computer and recorded
223924471|NCT06874608|DIETARY_SUPPLEMENT|complete, polymeric formula, fiber, lactose and gluten free|The dietary intervention attempts to induce remission in the first 4-week treatment without any change in the pharmaceutical therapy. In case of worsening or not reaching the outcomes, the patient will be defined as a failure and start rescue therapy with the standard of care.
223924472|NCT06875349|OTHER|foot reflexology|Foot reflexology is a complementary therapy that involves applying pressure to specific points on the feet, which are believed to correspond to different organs and systems in the body. This technique aims to promote healing by improving blood circulation, reducing stress, and supporting overall well-being. Reflexology is often used to help with issues such as constipation, stress, sleep disorders, and pain management.
223924473|NCT06875349|OTHER|abdominal massage|Abdominal massage is a therapeutic technique that involves applying gentle pressure and circular motions to the abdominal area to stimulate digestion, improve bowel movements, and relieve discomfort. It is commonly used to help with issues such as constipation, bloating, and digestive disorders by promoting intestinal motility and blood circulation. This technique can be performed manually or with the help of tools and is often incorporated into holistic and nursing care practices.
223924474|NCT06693076|PROCEDURE|Laparoscopic cholecystectomy|The intervention in this study is urgent, not elective. The conditions for the surgery are therefore different: any time of day, the surgeon on shift, the state of the patients.
223924475|NCT06693570|OTHER|Intact Fish Skin Graft (IFSG) + Standard of Care|Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223924476|NCT06693570|OTHER|Standard of Care|Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
223924477|NCT06263686|OTHER|Pasteurised yoghurt|Pasteurised (heat treated) natural yoghurt containing \<15 CFU/g of Lactobacillus delbrueckii bulgacirus and \<15 CFU/g of Streptococcus thermophilus.
223924478|NCT06263686|OTHER|Fresh yoghurt|containing ≥ 108 CFU/g of Lactobacillus delbrueckii bulgacirus and ≥ 108 CFU/g of Streptococcus thermophilus
223924479|NCT06263686|OTHER|Sterilised yoghurt|Not containing viable bacteria
223924480|NCT02823327|GENETIC|Laboratory Biomarker Analysis|Correlative studies
223924481|NCT02823327|OTHER|Medical Chart Review|Medical chart review is performed
223924482|NCT06630169|COMBINATION_PRODUCT|Cryopreserved AURN001|Corneal Endothelial Cells and Y27632
223924483|NCT06631729|BEHAVIORAL|HRV-bio|participants will complete a HRV biofeedback task via the Elite HRV app. In this intervention, participants will learn how to use their HRV data that they will see in real-time via the Elite HRV app to improve their HRV by engaging in an app-guided diaphragmatic breathing exercise. They will complete this exercise twice daily (morning, night).
223924484|NCT06631729|BEHAVIORAL|ED-JITAI|"participants will be prompted to complete focused, guided body scan tasks that will be sent to them via the MindLogger app. These guided tasks will be sent to them in the form of 1 of 3 brief (3-5 minute) videos via the MindLogger app. The body scans will be designed to promote participants' connection with, vs.~distancing/distraction from, feared ED sensations (e.g., hunger, satiety, bloating).~Participants will receive prompts to complete the body scans at times when they report via EMA that they are experiencing worse interoception than usual. Worse interoception than usual will be defined as participants' EMA-reported interoception scores during the intervention period that fall 1 SD or more above their baseline EMA-reported interoception levels."
223924485|NCT06694766|PROCEDURE|Blood sample collection|A blood sample collection of 18.5 mL will be required for the immunogenicity component.
223924486|NCT06687408|PROCEDURE|RATS Group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in robotic-assisted thoracic surgery (RATS) approach, which has been already applied to these patients in minimally invasive surgical techniques as part of their regular medical care recently.
223924487|NCT06687408|PROCEDURE|VATS group|The participants with centrally located lung cancer in this group were performed sleeve lobectomy in video-assisted thoracic surgery (VATS) approach.
223924488|NCT06689995|OTHER|Bio-immune Capsule|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
223924489|NCT06689995|OTHER|Placebo|Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days
223924490|NCT06686875|OTHER|Questionnaire|Patients will receive a link to a web-based questionnaire on the prevalence and characteristics of pain symptoms including the PainDETECT questionnaire.
223924491|NCT06631898|OTHER|SaaTwae Bio-Natural Moisturizing Cream|A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
223924492|NCT06632028|OTHER|artificial intelligence assisted spinal rehabilitation|In artificial intelligence-based rehabilitation, it is more advantageous compared to other treatment methods in terms of the fact that technology applications can be designed according to the level and abilities of the individual and that the parameters such as duration, intensity, difficulty and speed of the treatment can be flexibly configured for the therapist and the patient.
223924493|NCT06632028|OTHER|conventional therapy|In cervical disc herniation, non-invasive physical therapy applications such as laser treatment, hot-cold treatment methods, Transcutaneous Electrical Nerve Stimulation (TENS), interferential currents, manual therapy applications, kinesiological taping and exercise therapy, as well as painkillers and nonsteroidal anti-inflammatory drugs and antidepressive drugs are among the most preferred methods in treatment.(6)
223924494|NCT06687343|DIETARY_SUPPLEMENT|EAA Supplement|Dissolved in water and ingested 4 times a day
223924495|NCT06687343|DIETARY_SUPPLEMENT|NEAA Supplement|Dissolved in water and ingested 4 times a day
223924496|NCT06687343|DIETARY_SUPPLEMENT|Maltodextrin Supplement|Dissolved in water and ingested 4 times a day
223924497|NCT06691256|DEVICE|HiDO-ALZ|HiDO-ALZ platform, an AI-driven medication dispensing and observation system designed to improve adherence in individuals with dementia and diabetes.
223924498|NCT05386173|PROCEDURE|Fetal aortic balloon dilatation|Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
223924499|NCT06871527|DRUG|fruquintinib + tislelizumab + FOLFOX|"phase Ib: fruquintinib (3+3 dose escalation design): L1: 3 mg/d, L2: 4 mg/d, L3: 5 mg/d, qd po, D1-14, Q3W; tislelizumab: 200mg, I.V., D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W; leucovorin : 400mg/m2, I.V., D1, Q2W; Oxaliplatin: 85mg/m2, ivgtt 2h, D1, Q2W.~phase II: fruquintinib: RP2D; tislelizumab: 200mg, I.V., D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours,Q2W; leucovorin: 400mg/m2, I.V., D1, Q2W; Oxaliplatin: 85mg/m2, ivgtt 2h, D1, Q2W."
223924500|NCT06873477|DIAGNOSTIC_TEST|Gross Motor Function Classification System|Clinical assessment of the outcome of patients with traumatic and hypoxic-ischemic brain injury at least 2 years post-event.
223924501|NCT06872242|DIAGNOSTIC_TEST|Polysomnography|Polysomnography after enrollment for suspected obstructive sleep apnea
223924502|NCT06873737|OTHER|Blood samples for inflammatory markers|Blood sampling in the first, second, trimester of pregnancy
223924503|NCT06875115|DEVICE|laser acupuncture|laser acupuncture on acupoints
223924504|NCT06296394|OTHER|Parenthood|The intervention group will consist of participants who became first time parents to children under 5 years of age.
223924505|NCT01487928|DIETARY_SUPPLEMENT|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
223924506|NCT05454241|DRUG|Anti-CD7 CAR-T|Universal CAR-T cells targeting CD7
223924507|NCT05424718|BEHAVIORAL|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk young men that have sex with men (YMSM).
224092604|NCT00728429|BEHAVIORAL|exercise intervention|24 week program of exercise
224092605|NCT05495347|OTHER|patients diagnosed with OSA|All patients diagnosed with OSA since March 2020 with an indication for treatment with PAP have been telemonitored permanently since the start of therapy and continue to be telemonitored at the present time. Data are sent remotely daily to the telemonitoring platform.
224092606|NCT02210156|DIETARY_SUPPLEMENT|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
224092607|NCT02210156|OTHER|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
224092608|NCT03068715|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
224281175|NCT02438540|OTHER|acupuncture|Electro body acupuncture and auricular acupuncture
223531739|NCT06912646|DEVICE|Erchonia® EVRL™|The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device. The diodes are positioned approximately 3 to 6 inches from the top of the foot. The treatments will be self-administered by the subject at his or her's place of residence, two times per day for 21 days. Each procedure administration lasts 5 minutes per foot, for a total of 10 minutes.
223924508|NCT04889989|DEVICE|Microwave Ablation|Percutaneous microwave ablation using the NeuWave Microwave Ablation System for non-small cell lung cancer or oligometastatic lung tumors
223924509|NCT06697587|BEHAVIORAL|Enhanced Cognitive Reappraisal and Emotion Awareness Training (eCREAT)|"eCREAT features psychoeducational content on anger management, practical exercises, and homework assignments, all supported by an online therapist who provides text-based feedback. The protocol builds on a previously evaluated protocol for maladaptive anger (ClinicalTrials.gov; ID: NCT03858296) with added focus on anger inhibition.~eCREAT is based on the two-stage model of maladaptive anger inhibition (Burns et al., 2008), which posits that suppressed anger may rebound and return as angry fantasies and ruminations. To address these core mechanisms, the treatment includes training on adaptive anger processing and expression and strategies for disrupting anger ruminations. These added treatment components are based on established protocols for depressive rumination, and assertive expression of emotion, adapted for an anger context. Additionally, the treatment also focuses on how to flexibly shift between different emotion regulation strategies depending on contextual demands."
224281176|NCT02221440|DEVICE|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
223924510|NCT06696521|BEHAVIORAL|Intervention A- Telephone|For intervention A: Once a patient is randomized to telephone (Intervention A), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
223924511|NCT06696521|BEHAVIORAL|Intervention B- Televideo|For intervention B: Once a patient is randomized to televideo (Intervention B), s/he will be scheduled for the series of follow up encounters via the assigned modality. The first interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months to assess for adherence and toxicity. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS), fill history will be obtained prior to each interaction to verify medication possession ratio (MPR) and proportion of days covered (PDC). Each patient in the study will participate for a duration of up to 4 months.
223924512|NCT06696573|DRUG|Prophylactic NSAID Administration|Participants in this arm will receive a prophylactic dose of a non-steroidal anti-inflammatory drug (NSAID) prior to the onset of pain during medical abortion procedures for pregnancies between 13 and 22 weeks. The intervention aims to reduce pain intensity throughout the process. The NSAID administration involves a specific dosage and schedule, adhering to safety guidelines and monitored for potential side effects.
224092609|NCT03068715|DEVICE|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
224092610|NCT03068715|DEVICE|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device."
224281177|NCT02221440|DEVICE|Low flow room air|Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
224281178|NCT01350596|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
224281179|NCT01350596|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
224281180|NCT00091286|BIOLOGICAL|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
224281181|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 day before ablation|24 hours Holter EKG - 1 day before ablation
224281182|NCT06276296|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation using radiofrequency ablation
224281183|NCT06276296|PROCEDURE|Pulsed field ablation|Pulmonary vein isolation using pulsed field ablation
224281184|NCT06276296|DIAGNOSTIC_TEST|Holter EKG - 1 month after ablation|24 hours Holter EKG 1 month after ablation
224281185|NCT01642563|PROCEDURE|Platelet transfusion|One dose of pathogen reduced platelets
224281186|NCT01642563|PROCEDURE|Platelet transfusion|One dose of standard platelets
224281187|NCT02851719|OTHER|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
224281188|NCT02851719|OTHER|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
224281189|NCT00732524|DRUG|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
224281190|NCT00732524|DRUG|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
224281191|NCT01118234|DRUG|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
224281192|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
224281193|NCT02122614|BEHAVIORAL|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
224281194|NCT03066895|DEVICE|BabyGentleStick|Experimental device.
224281195|NCT03066895|DEVICE|Standard Lancing Device|HMC standard of care.
224281196|NCT06353412|PROCEDURE|Lumbar puncture|Medical treatment Lumbar puncture Theco peritoneal shunt
224281197|NCT03184012|DEVICE|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
224281198|NCT03184012|DEVICE|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
224281199|NCT03028623|PROCEDURE|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
224281200|NCT03028623|PROCEDURE|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
224281201|NCT03692091|PROCEDURE|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
224281202|NCT01287455|DRUG|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
224281203|NCT01287455|OTHER|placebo|drops, 70 placebo drops, once weekly for 6 weeks
224281204|NCT02993419|DRUG|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
223531740|NCT07107412|OTHER|Translating the Questionnaire into Turkish and Related Processes|"The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the index and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.~Other: Validity The scale will be applied"
223924513|NCT06696573|DRUG|On-Demand NSAID Administration|Participants in this group will receive a non-steroidal anti-inflammatory drug (NSAID), such as Ibuprofen, in oral tablet form at a dose of 400 mg. The drug will be administered as needed when participants report experiencing pain during the medical abortion process for pregnancies between 13 and 22 weeks. The goal of this intervention is to provide pain relief in response to individual needs, with administration and dosage adjusted as clinically indicated. Monitoring will occur to assess the efficacy, safety, and patient response to the on-demand approach.
223924514|NCT05198765|BEHAVIORAL|BMI-CDS|The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
223924515|NCT06501924|DIETARY_SUPPLEMENT|DA-005|Oral Botanical Supplement HIF-1a inhibitor
223924516|NCT06501924|DRUG|Topical minoxidil 5%|Topical minoxidil 5%
223924517|NCT06501924|DRUG|DA-002|Topical Alpha 1 Agonist (GRAS)
223924518|NCT06501924|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Placebo Oral Tablet
223924519|NCT06501924|OTHER|Placebo Topical Solution|Placebo Topical Solution
223924520|NCT04046549|DRUG|Belatacept|Protocol versions 1 through 4: Belatacept 10 mg/kg by intravenous (IV) infusion on post-op Day 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), and at the end of Weeks 2, 4, 8 and 12; then 5 mg/kg IV every 4 weeks from Week 16 to Week 48.
223924521|NCT04046549|DRUG|VIB4920|"Protocol versions 1 and 2: VIB4920 1500 mg by IV infusion on post-op Days 1 and 14, and at the end of Weeks 4, 6, 8 and 10; then 1500 mg every 4 weeks from Week 12 to Week 48.~Protocol versions 3 and 4: VIB4920 1500 mg by IV infusion on post-op Days 1, repeated on post-op Day 3 or 4 (timing is at investigator's discretion), Week 2, and at the end of Weeks 4, 6, 8, and 10; then 1500 mg every 4 weeks from Week 12 to Week 48."
223924522|NCT04046549|DRUG|Thymoglobulin|"Protocol versions 1 and 2: Thymoglobulin 3.0 mg/kg by intravenous (IV) infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0) (1 dose).~Protocol versions 3 and 4: Thymoglobulin 1.5 mg/kg by intravenous infusion prior to reperfusion of the allograft on the day of transplantation surgery (Day 0), prior to VIB4920+belatacept infusion on post-op Day 1, on post-op Day 2, and prior to VIB4920+belatacept infusion on post-op Day 3 or 4."
223924523|NCT04046549|DRUG|Methylprednisolone|"Protocol versions 1 and 2: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6.~Protocol versions 3 and 4: Methylprednisolone by IV infusion (500, 250, 125 and 60 mg on Days 0, 1, 2 and 3, respectively) followed by oral administration of prednisone 30 mg per day on Days 4, 5, 6 and 7. Participants may be tapered to at least 20 mg per day on Day 8, to at least 10 mg per day on Day 15, and to at least 5 mg per day on Day 22. Discontinuation of prednisone following the post-op Day 28 visit."
223924524|NCT06700187|OTHER|Interrupting sitting with walking breaks|Participants will engage in 27 minutes walking in different frequencies, including short breaks (walk 1 minute every 10 minutes), moderate breaks (walk 3 minutes every 30 minutes), and long breaks (walk 27 minutes in one time during the intervention).
223924525|NCT06872229|BEHAVIORAL|Autism Spectum Conditions - intervention|"Initially, participants will participate in a familiarization session in which they will see and hear all pairs of pictures and sounds without any associated task, thus ensuring adequate understanding of the stimuli. Next, each child will be tested for each predicted condition, receiving clear instructions on the task: they will have to indicate whether the picture and sound are related. The main task consists of presenting 40 pairs of image-sound stimuli. For each pair, participants must answer the question, Does what you saw match what you heard? using a keypad with a green key for Yes and a red key for No. Each condition includes 10 trials, distributed randomly, with short breaks between them to keep participants focused."
223924526|NCT06872229|BEHAVIORAL|Typical Development - intervention|"Initially, participants will participate in a familiarization session in which they will see and hear all pairs of pictures and sounds without any associated task, thus ensuring adequate understanding of the stimuli. Next, each child will be tested for each predicted condition, receiving clear instructions on the task: they will have to indicate whether the picture and sound are related. The main task consists of presenting 40 pairs of image-sound stimuli. For each pair, participants must answer the question, Does what you saw match what you heard? using a keypad with a green key for Yes and a red key for No. Each condition includes 10 trials, distributed randomly, with short breaks between them to keep participants focused."
223924527|NCT03501836|DEVICE|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
223924528|NCT03965234|DRUG|Cisplatin|Given via infusion
223924529|NCT03965234|PROCEDURE|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
223924530|NCT03965234|PROCEDURE|Metastasectomy|Undergo metastasectomy
223924531|NCT07029945|DRUG|BRX011|Subjects will ingest BRX011 orally, as capsules.
223924532|NCT07029945|DRUG|Placebo|Subjects will ingest Placebo orally, as capsules.
223924533|NCT06694337|DIETARY_SUPPLEMENT|300 mg Palmitoylethanolamide (PEA) Phytosome®|Oral supplement intake
223924534|NCT06694337|DIETARY_SUPPLEMENT|450 mg Palmitoylethanolamide (PEA) Phytosome®|Oral supplement intake
223924535|NCT06694337|OTHER|Control group|Placebo
223924536|NCT06694935|DRUG|QX1206|QX1206 will be administered orally before bedtime
223924537|NCT06874400|OTHER|Dairy|The dairy products that participants will be required to consume include: 1) Trial 1: 2% cow's milk; 2) Trial 2: dairy yogurt; 3) Trial 3: 2% cottage cheese; 4) Trial 4: 2% cow's milk; and 5) Trial 5: isolated whey protein beverage. Participants will only be enrolled in 1 of the 5 trials; as such, they will only consume the 1 dairy product in that trial.
223924538|NCT06874400|OTHER|Plant-based alternative|The plant-based products that participants will be required to consume include: 1) Trial 1: soy beverage; 2) Trial 2: plant-based yogurt; 3) Trial 3: tofu; 4) Trial 4: 2% simulated milk; and 5) Trial 5: isolated soy protein beverage. Participants will only be enrolled in 1 of the 5 trials; as such, they will only consume the 1 plant-based alternative product in that trial.
223924539|NCT06289153|DEVICE|Arthrex Internal Brace|The Arthrex Internal Brace method for ACL reconstruction consists of suture tape used to reinforce the ACL during surgery. This suture tape is secured in place with bioabsorbable anchors that gradually degrade within the body over time.
223924540|NCT06289153|PROCEDURE|ACL Reconstruction|All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
223531741|NCT06162572|DRUG|S095018|Via IV infusion on Day 1 of each 21-day cycle
223924541|NCT07030049|DEVICE|Postero-stabilized total knee replacement for knee osteoarthritis|Total knee arthroplasty in which the osteoarthritic knee is replaced with a postero-stabilized total knee replacement. The postero-stabilized TKA consists of a femoral component with a build-in cam mechanism and a tibial component with a post-mechanism.
223924542|NCT07030049|DEVICE|Cruciate-retaining total knee replacement for knee osteoarthritis|Total knee arthroplasty in which the osteoarthritic knee is replaced with a cruciate-retaining total knee replacement. The cruciate-retaining TKA consists of a femoral component and a tibial component that leaves the posterior cruciate ligament intact.
223924543|NCT05220553|DEVICE|PROLIMB Prosthesis|Participants will be given the PROLIMB prosthesis to test in the lab and to use in their daily lives
224281205|NCT02993419|OTHER|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
223924544|NCT07031726|BEHAVIORAL|Worksite Nutrition and Wellness Program|A structured behavioral intervention combining personalized physical activity and structured physical activity (Zumba classes), personalized nutrition counseling, and mobile app-based self-monitoring.
223924545|NCT07031726|BEHAVIORAL|Standard education|General educational materials on healthy eating and physical activity based on the Ministry of Health guidelines. No tailored or active intervention provided.
223924546|NCT06879834|DEVICE|taking fundus photos using non-mydriatic fundus camera|using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.
223924547|NCT06876818|OTHER|Evaluation of transcriptomic and cardio-metabolic profiles|The parameters and variables collected in 2006-2007 (T0) will be re-evaluated at the follow-up visit (T1), including demographic, anthropometric, lifestyle data (smoking habit, physical activity, sleep quality) blood pressure, standard biochemical analysis and inflammatory profile. To assess the evolution of glucose tolerance and vascular damage, metabolic (OGTT) and cardiovascular (carotid ecodoppler) profile analyses will be repeated. For gene expression analyses, in addition to messenger RNA from PBMCs (as at T0), RNA from PBMC-derived monocytes will also be extracted and sequenced at T1.
224092611|NCT05431244|DRUG|Antiviral treatment in combination with low-dose gemcitabine|-maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
224092612|NCT05671276|DRUG|aspirin and clopidogrel|DAPT (until 6 months) + ASA
224092613|NCT05671276|DRUG|Rivaroxaban|half-dose NOAC
224092614|NCT00078130|DRUG|Buprenorphine/naloxone|
224092615|NCT01849757|OTHER|prime crystalloid|used for priming the CPB circuit
224281206|NCT05108506|BEHAVIORAL|No Strict need to void following surgery|Certain patient will be randomized without a strict need to void prior to discharge following surgery.
224281207|NCT05108506|BEHAVIORAL|Strict need to void following surgery|Certain patient will be randomized with a strict need to void prior to discharge following surgery.
224281208|NCT04181164|OTHER|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
224281209|NCT04181164|OTHER|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
224281210|NCT04181164|BIOLOGICAL|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
224281211|NCT06678802|OTHER|Blood sampling|blood sampling from peripheral vein
224281214|NCT02715232|DRUG|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
224281215|NCT02715232|DRUG|Lynestrenol|2-3 tablets/day, if menstruation still occurs
224281216|NCT02715232|DRUG|Cyproterone Acetate|25mg daily
224281217|NCT02715232|DRUG|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
224281218|NCT02715232|DRUG|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
224281219|NCT05730452|BEHAVIORAL|Risk-stratified discharge and post-discharge care|"Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)"
224281220|NCT02466334|DRUG|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
224092616|NCT01849757|OTHER|Human Albumin|Used as a constituent for priming the CPB circuit
224092617|NCT01849757|OTHER|Voluven|Used as a constituent for priming the CPB circuit
224281221|NCT02466334|DRUG|Placebo|40 ml of normal saline over 20 mins
224281222|NCT06127745|DEVICE|Discure System|All subjects enrolled into the study will be implanted with the Discure System in a minimally invasive procedure.
224281223|NCT01017094|DRUG|silversulfadiazine|apply once a day
224281224|NCT03046082|DRUG|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
223531742|NCT06162572|DRUG|S095024|Via IV infusion on Day 1 of each 21-day cycle
223531743|NCT06162572|DRUG|S095029|Via IV infusion on Day 1 of each 21-day cycle
223717568|NCT05593393|DEVICE|Endoscopic ultrasound|The EUS follow-up will be conducted at baseline and every 12 months thereafter. For patients with new WF or HRS in the evaluation, the follow-up physician and the patient can jointly decide whether to perform EUS evaluation in the 6 or 3 month intensive follow-up.
223717569|NCT04817865|DIAGNOSTIC_TEST|Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST)|M-PCR/P-AST is a dual assessment test that detects pathogenic DNA commonly associated with urinary tract infections and identifies their genotypic and phenotypic antibiotic resistance.
223924548|NCT06875856|OTHER|Kendall exercises|"1. Positioning supine with the chin tucked in and lifting the head for 2 to 8 sec to strengthen deep cervical flexors.~2. Maintaining a sitting posture, with hands on the occipital region, and flexed spine while moving head downwards to stretch cervical extensors, maintaining an upright posture.~3. Keep the resistance band circling with strong support and stretching it with the upper limbs of both sides so that there is full retraction of the scapula to strengthen retractors of the shoulder.~4. Stretching the pectoralis major and minor while keeping the patient's hands-on the occipital region and standing behind the patient and pulling both elbows backward to target the bilateral pectoralis muscles"
223924549|NCT06875856|OTHER|Cailliet exercises|The intervention of group B will include baseline treatment, followed by maneuvers, including: Neck Cailliet exercise using isometric contractions against the prisoner to the maximum that ends with relaxation and continued with stretching. Each posture was maintained for 30 s and 3 sets of 10 repetitions were performed with 3 sessions per week on alternate days for 4 weeks.
223924550|NCT06878196|DRUG|cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab|Patients with persistent, recurrent, or advanced metastatic cervical cancer who have not received systemic treatment are treated with cadonilimab combined with cisplatin-based chemotherapy ± bevacizumab (treatment dosage: cadonilimab 10 mg/kg, paclitaxel 175 mg/m\^2, cisplatin 50 mg/m\^2, cisplatin AUC 4-5, bevacizumab 7.5-15 mg/kg), once every 3 weeks, for a total of 6 cycles (if the patient continues to benefit, chemotherapy is allowed beyond 6 cycles), followed by maintenance treatment with cadonilab ± bevacizumab.
223924551|NCT06877728|OTHER|Neck isometric exercises: 3 times weekly for 6 consecutive weeks (18 sessions)|Neck isometric exercises: 3 times weekly for 6 consecutive weeks (18 sessions) Duration: 10 to 15 repetitions with 3 sets, and 6 sec hold in flexion, extension and side flexion on both right and left.
223924552|NCT07032714|DRUG|Talquetamab|Talquetamab is injected under the skin (subcutaneously injected) by trained medical staff. During first cycle of talquetamab, the dose of talquetamab will increase until the goal dose (treatment dose) is reached (pre-determined dose escalation).
223924553|NCT07032714|DRUG|Mezigdomide|Administered orally once per day (days 1-21 of applicable 28-day cycles; Days 1-7 of the 7-day Cohort B pre-phase cycle).
223924554|NCT07032714|DRUG|Dexamethasone|Administered orally once per day, at the schedule outlined in the Arm Descriptions.
223924555|NCT06696326|DIAGNOSTIC_TEST|standard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.
223924556|NCT06876519|PROCEDURE|Translateral Maxillary Sinus Floor Elevation|Translateral maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region.
223924557|NCT06876519|PROCEDURE|Hydraulic Transcrestal Maxillary Sinus Floor Elevation|Hydraulic transcrestal maxillary sinus floor elevation with simultaneous implantation in the maxillary molar region.
223924558|NCT06882226|OTHER|Maslach burnout inventory|Assessing the emotional burden on nursing staff
223924559|NCT06882382|OTHER|conventional physiotherapy|normal joint movements, chest physiotherapy, and mobilization for 40 min
223924560|NCT06882382|OTHER|Virtual reality|normal joint movements, chest physiotherapy, and mobilization for 40 min and 20 min virtual reality
223924561|NCT06877780|DEVICE|RMR with SME|The RMR will be used in conjunction with slow maxillary expansion
223924562|NCT06877780|DEVICE|BAIMT with RME|The bone-anchored intermaxillary traction will be used with rapid maxillary expansion
223924563|NCT07037823|OTHER|Modified Yishen Daluo Yin formula|The specific application of the modified Yishen Daluo Yin formula, including the starting point, dosage, and duration of treatment, should be determined based on medical advice, the patient's condition, and their individual preferences.
223924564|NCT07038330|DRUG|Sucrosomial Iron|Sideral Forte, Italian market formulation of Sucrosomila Iron 30mg per cp
223531744|NCT06162572|DRUG|S095018 Recommended Dose Expansion (RDE)|Via IV infusion on Day 1 of each 21-day cycle
223531745|NCT06162572|DRUG|S095024 RDE|Via IV infusion on Day 1 of each 21-day cycle
223531746|NCT06162572|DRUG|S095029 RDE|Via IV infusion on Day 1 of each 21-day cycle
223924565|NCT06719180|DRUG|Bupivacain|Injection into the vaginal cuff will occur before vaginal cuff closure with stratafix suture. There will be four points of injection 1cm from the edges of the vaginal cuff with a sterilized needle to a depth of 3-4cm. 5cc of bupivacaine with epinephrine or 5cc of normal saline will be injected into each area
223924566|NCT06719180|OTHER|Saline (NaCl 0,9 %) (placebo)|A saline placebo
223924567|NCT06874348|DIAGNOSTIC_TEST|structural and functional MRI|structural and functional MRI
223924568|NCT06875245|DRUG|Faricimab Injection|Intravitreal Injection
223924569|NCT05975736|BEHAVIORAL|Search only for masses|Participants search the simulated mammogram for simulated masses.
223531747|NCT06162572|DRUG|Cemiplimab|350 mg via IV infusion on Day 1 of each 21-day cycle
223531748|NCT06829550|DIAGNOSTIC_TEST|indirect- 3D digital scanning|examination for dental caries, erosive tooth wear and dental fluorosis using direct assessment (visual) and indirect assessment (digital scanning)
223717570|NCT04817865|DIAGNOSTIC_TEST|Urine Culture|A traditional clinical UTI evaluation consisting of non-molecular standard urine culture (SUC) and sensitivity testing methods.
223717571|NCT03710538|DIETARY_SUPPLEMENT|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
223717572|NCT03710538|BEHAVIORAL|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
223717573|NCT05887726|DRUG|Zanubrutinib|Zanubrutinib 160mg bid p.o d0-d20(21-day cycles)
223717574|NCT05887726|DRUG|Rituximab|Rituximab 375 mg/m2 i.v d0(21-day cycles)
223531749|NCT05871814|DEVICE|Colon preparation guided by an artificial intelligence device|Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing
223531750|NCT05385978|DRUG|APHD-012|Distal jejunal-release dextrose beads (Aphaia technology, AT)
223531751|NCT05385978|DRUG|APHD-012P|Distal jejunal-release placebo beads
223717575|NCT05887726|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
223924570|NCT05975736|BEHAVIORAL|Search only for calcifications|Participants search the simulated mammogram for simulated calcifications.
223924571|NCT05975736|BEHAVIORAL|Search for both together|Search the simulated mammogram for both simulated masses and simulated calcifications at the same time.
223924572|NCT05975736|BEHAVIORAL|Search for one after the other|Search the simulated mammogram for first for simulated masses and then for simulated calcifications sequentially (or vice versa).
223924573|NCT06884124|BEHAVIORAL|Experimental|Micro teaching method will be applied for ventrogluteal injection training. Students will be trained with short learning units, multimedia content and feedback sessions.
223924574|NCT06884124|BEHAVIORAL|Control|Routine lectures and practice will be done on the model
223924575|NCT06884163|GENETIC|comprhensive spatial transcriptomic profile on lesional skin biopsies|Spatial transcriptomics (Visium, 10X Genomics) will be used to analyze gene expression of chronic eczema derived from lesional skin biopsies
223924576|NCT06883890|DRUG|Recombinant LH (Luveris)|In the treatment group patients will receive the pretreatment with rLH, a daily dose of 187.5 IU (75 U in the morning and 112.5U in the evening) rLH treatment for 60 days will be administered.
223924577|NCT06883890|DRUG|No Treatment Added|In the control group, women will not receive any therapy and will be followed up with the same schedule as women in the treatment group
223924578|NCT06717243|DRUG|Carboplatin/Cisplatin -Etoposide - Atezolizumab|"This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis."
223924579|NCT06718686|DRUG|Rifaximin SSD 40 mg IR tablet|Drug therapy vs placebo
224099682|NCT03706586|PROCEDURE|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
224099683|NCT06504667|DEVICE|Point Mini|The Point Mini finger prosthetic system consists of 1-4 ratcheting mechanical digits and mounting brackets
224281225|NCT02775539|DRUG|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
224281226|NCT02775539|DRUG|Placebo|
224281227|NCT00220727|DRUG|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
223717576|NCT05887726|DRUG|Epirubicin|Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)
223717577|NCT05887726|DRUG|Vincristine|Vincristine 1.4 mg/m2 i.v d1 (2 mg max) (21-day cycles)
223717578|NCT05887726|DRUG|Prednisone|Prednisone 100 mg p.o d1-d5 (21-day cycles)
223924580|NCT06718686|DRUG|Placebo|Placebo drug
223924581|NCT06719076|BEHAVIORAL|Diabetes Healthcare Program (DHCP)|"Training for Type-II Diabetics~The program includes 6 structured training sessions, each session will delivered biweekly and lasting for 1 hour and 20 minutes , covering topics such as:~Week 1: Diabetes Education and Goal Setting Week 3: Nutrition and Meal Planning Week 5: Physical Activity and Exercise Week 7: Medication Management Week 9: Stress Management and Emotional Well-being Week 11: Review and Future Plans Time, Venue, and Interactive Activities Sessions will be held at the Federal General Hospital Basement, on Fridays, from 10:00 am to 11:20 am. Each session includes interactive elements, such as group discussions, practical exercises, and hands-on activities, to ensure participants are fully engaged and equipped to manage their T2DM diabetes."
223924582|NCT07038720|DRUG|UA026|UA026 will be administered as tablet
223924583|NCT07038720|DRUG|Placebo|Matching placebo will be administered as tablet
223924584|NCT07038174|OTHER|Fertility preservation decision aid intervention group|Visited the website containing the web-based decision aid regarding fertility preservation at least once before cancer treatment initiation to independently use the tool in a private setting
223924585|NCT07039760|DRUG|Asciminib|Commercially available stock
223924586|NCT07039760|DRUG|Sildenafil|Commercially available stock
224281228|NCT04079582|OTHER|Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
224281229|NCT04079582|OTHER|Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).|(Dialysate magnesium concentration currently used in Canada and the United States)
224281230|NCT02825576|DRUG|Sugammadex|Sugammadex 2mg/kg given for reversal agent
224281231|NCT02825576|DRUG|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
224281232|NCT00761176|DEVICE|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
223924587|NCT07039760|PROCEDURE|Surgical resection or biopsy|Standard of care
223924588|NCT07039162|DRUG|Tislelizumab|"1. ICRT phase -Tislelizumab and CRT regimen Tislelizumab 200 mg IV, C1D1 and C4D1~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Tislelizumab 200 mg IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles. )~3. Adjuvant phase-Tislelizumab Tislelizumab 200 mg IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of one year or 17 cycles.)"
223924589|NCT07039162|DRUG|Paclitaxel|"1. ICRT phase -Tislelizumab and CRT regimen Paclitaxel 50 mg/m2 IV, D1, weekly (\* 4-6 cycles judged by investigators.)~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Paclitaxel 135 mg/m2 IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles.)"
223924590|NCT07039162|DRUG|Cisplatin|"1. ICRT phase -Tislelizumab and CRT regimen Cisplatin 25 mg/m2 IV, D1, weekly ( 4-6 cycles judged by investigators.)~2. Consolidation phase: Tislelizumab-Paclitaxel-Cisplatin regimen Cisplatin 75 mg/m2 IV, D1, every 3 weeks (\*The regimen is repeated until unacceptable toxicity or disease progression, up to maximum of 2 cycles. )"
223924591|NCT07039162|RADIATION|Radiation Therapy|1\. ICRT phase -Tislelizumab and CRT regimen Radiotherapy treatment: IMRT 41-50.4Gy, a dose of 1.8 to 2Gy per day, 5 days per week for 5 weeks during the RT phase.
223924592|NCT07030751|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a specific order (stress, sleep, physical activity). Each module will be composed of 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
223924593|NCT07039825|OTHER|Computed tomography angiography|The results of computed tomography angiography on abdominal aortic aneurysm are collected.
223924594|NCT03142009|OTHER|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
223924595|NCT07038564|OTHER|Immune-Nutritional Scoring and Postoperative Sleep Assessment|Routine preoperative laboratory data (hemoglobin, albumin, lymphocyte, platelet) will be used to calculate immune-nutritional scores (HALP, PNI). Postoperative sleep quality will be assessed with the Richards-Campbell Sleep Questionnaire (RCSQ).
223924596|NCT06886425|OTHER|genetic study|"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"
224281233|NCT05312476|DRUG|Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets|"1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg.~2. Dose extension study:3 cases (1 dose group)."
223924597|NCT06886425|OTHER|Pharmacokinetic study|"Cure 1: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 3: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase.~Cure 6: after completion of subcutaneous administration of azacytidine A total of 5 samples in the induction phase."
224281234|NCT01139294|DRUG|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
224281235|NCT04035382|PROCEDURE|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
224281236|NCT05103657|DRUG|BI 1358894|BI 1358894
224281237|NCT05103657|DRUG|Placebo|Placebo
224281238|NCT04347330|DRUG|Intensive BP Control|Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.
224281239|NCT04347330|DRUG|Standard BP Control|Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
224281240|NCT06151067|DIAGNOSTIC_TEST|High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testing|High-Resolution Manometry Upper-GI endoscopy pH-Impedance testing
224281241|NCT03097939|DRUG|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
224281242|NCT03097939|DRUG|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
224281243|NCT04366596|DEVICE|Angioplasty with paclitaxel eluting balloon|The patients will be treated with renal artery angioplasty using paclitaxel eluting balloon
224281244|NCT04366596|DEVICE|Angioplasty with plain old balloon|Angioplasty with plain old balloon
224281245|NCT00075686|BIOLOGICAL|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 \& days 1,8,15,22 of all subsequent cycles
223531752|NCT06920160|DEVICE|software Caaring (remote monitoring app)|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/ questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to Heart Faillure.
223924598|NCT06886425|OTHER|Study of phenotypic activity of cytidine deaminase|"Blood sampling :~Cure 1 before starting treatment Cure 3 before starting treatment Cure 6 after completion of treatment"
223924599|NCT06887725|OTHER|Exercise|The Cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) is an innovative exercise approach developed based on the biopsychosocial model. The parameters that form the basis of BETY are function-oriented core stabilization exercises, information management in pain, information management in mood, and information management in sexuality. BETY was shaped by the feedback of individuals with rheumatism who participated in regular exercise sessions for years and was introduced to the literature as a treatment method aiming to create changes in the cognitive structures of patients through exercise.
223924600|NCT06885840|DRUG|MCLA-129|MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
223924601|NCT06703255|DRUG|HX301+/Temozolomide|"Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each."
223924602|NCT06885112|DEVICE|FoLix treatment for improving the scalp hair appearance|The study patients will receive 4 FoLix treatment in 4 weeks intervals. the scalp hair improvement will be evaluated by 3 blinded assessors who shall review before and after images, as well as hair count data
223924603|NCT06885788|PROCEDURE|To remove the uterine uterine ligament|Both groups underwent laparoscopic inguinal hernia repair. The preservation group retained the uterine round ligament, while the resection group had it removed.
223924604|NCT06885593|DIAGNOSTIC_TEST|Supine Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in supine and left lateral tilt (LLT) positions. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
223924605|NCT06885593|DIAGNOSTIC_TEST|Supine Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in supine position. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
223924606|NCT06885593|DIAGNOSTIC_TEST|Left Lateral Tilt Position|All ultrasonography (USG) procedures will be performed by the same anesthesiologist using a Ultrasound device before the start of spinal anesthesia (SA) and after baseline blood pressure and heart rate have been measured. Patients will be placed in left lateral tilt (LLT) position. After at least 3 minutes in each position, ultrasound of the inferior vena cava (IVC) and femoral vein (FV) will be performed. The oblique probe will be placed below the xiphoid. Anteroposterior diameters and peak velocities of the IVC will be measured 2-3 cm below the IVC-right atrium For standardization purposes, measurements of the right femoral vein will be used in the study. The FV will be visualized with B-mode ultrasound 2-5 cm below the level of the inguinal ligament where the femoral artery is best palpated, without applying any pressure that may affect the FV diameter.
223924607|NCT06886607|BEHAVIORAL|the Mindfulness and Web-Based Physical Activity Program|"The Mindfulness and Web-Based Physical Activity Program consists of two phases: the Mindfulness Skill Development Program and the Mindful Physical Activity Program. In the first phase of the Program, the Mindfulness Skill Development Program was implemented for two weeks, five days a week, from October 23 to November 3, 2023. The program includes activities for individuals to develop mindfulness skills through videos uploaded on the YouTube channel. In the second phase of the Program, The 12-week Mindful Physical Activity Program, implemented between November 2023 and January 2024, consisted of Mindful Walking and Mindful Physical Activity Day sessions held twice a week (Tuesday and Thursday) and three days a week for 50 minutes. Each session began with a 10-minute warm-up exercise, followed by 40 minutes of endurance and strength training sessions, and ended with 10 minutes of cool-down exercises."
223924608|NCT06884371|OTHER|physical therapy|ultrasound and TENS for the back
223924609|NCT06882395|DEVICE|Group 1: FLX aligners for 10 days|FLX aligners worn for 10 days
223924610|NCT06882395|DEVICE|Group 3: FLX aligners for 7 days, followed by new FLX aligners for 3 days.|Group 3: FLX aligners worn for 7 days, followed by new FLX aligners for 3 days.
223924611|NCT06882395|DEVICE|Group 2: FLX aligners worn for 7 days, followed by FLX35 aligners for 3 days.|Group 2: FLX aligners for 7 days, followed by FLX35 aligners for 3 days.
223531753|NCT06919939|DRUG|Epcoritamab|"Epcoritamab will be administered via subcutaneous injection at the following dose levels and schedule over a total of twelve cycles:~* Cycle 1 Day 1: Step-up dose of 0.16 mg~* Cycle 1 Day 8: Step-up dose of 0.80 mg~* Cycle 1 Day 15: First full dose of 48 mg.~* Cycles 2 through 4 Days 1, 8 and 15: 48 mg~* Cycles 5 through 12 Days 1 and 15: 48 mg"
223531754|NCT06919939|DRUG|Loncastuximab Tesirine|"Loncastuximab will be administered intravenously (IV) at the following dose level and schedule over a total of four cycles:~* Cycles 1 and 2 Day 1: 120 mcg/kg~* Cycles 3 and 4 Day 1: 75 mcg/kg~* Cycle 4 Day 22: 75 mcg/kg"
223531755|NCT05732961|DRUG|Luspatercept|Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
223531756|NCT05405595|DRUG|ADG126|ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
223924612|NCT06882044|DEVICE|mHealth|The mobile application contains medication and personalised reminders, the screen where blood pressure and pulse are entered, the lifestyle change recommendations information, and the section that allows users to communicate with the researcher. Also, there is a control panel that allows the application to be controlled remotely, patient information to be viewed, data to be monitored, lifestyle information to be uploaded and viewed in the mHealth, personalised reminders to be sent to patients, and communication with patients.
223924613|NCT06881732|BIOLOGICAL|NF54/iGP3|Mosquito-generated sporozoites of the genetically modified, inducible gametocyte-producing parasite line NF54/iGP3, created via CRISPR/Cas9 genetic engineering of the parental wildtype strain Plasmodium falciparum (Pf) NF54 to contain a trimethoprim (TMP)-inducible copy of the Pf gdv1 gene in the dispensable Pf cg6 locus.
223531757|NCT05405595|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab (KEYTRUDA®) is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
223531758|NCT05405595|DRUG|Standard of Care (Trifluridine/Tipiracil-Bevacizumab)|The standard of care therapies will include Trifluridine/Tipiracil-Bevacizumab, approved for treating metastatic colorectal cancer (CRC)and various solid tumors.
223531759|NCT05405595|DRUG|Standard of care (Fruquintinib)|The standard of care therapy, Fruquintinib, is approved for treating metastatic colorectal cancer (CRC) and various solid tumors.
223531760|NCT07116486|DIAGNOSTIC_TEST|Radiopharmaceutical 18F-FSPG|Given by injection
223531761|NCT06921148|DEVICE|Sylk Wound Dressing|Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.
223717579|NCT01613404|OTHER|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
223924614|NCT06882213|OTHER|transcranial direct current stimulation|transcranial direct current stimulation
223924615|NCT06882213|OTHER|core stability exercise.|core stability exercise.
223924616|NCT06886035|DRUG|liposomal curcumin|The study group began a regimen of 100 mg oral liposomal curcumin (administered as 50 mg twice daily) one day prior to the procedure. Following surgery, oral liposomal curcumin (50 mg twice daily) was restarted 8 hours postoperatively and maintained for an additional two days. ( A total dose 300 mg)
223924617|NCT06717230|OTHER|EverX Posterior|Restoration
223924618|NCT06885255|OTHER|Alternate day fasting|Participants are instructed to alternate between consuming 100% of their usual energy intake on one day and only 25% on the following day.
223924619|NCT06885255|OTHER|Time restricted eating|Subjects are instructed to limit their energy intake to 8 hours a day and to fast for the remaining 16 hours.
223924620|NCT06885255|OTHER|High-intensity interval training|Patients participate in high-intensity interval training.
223924621|NCT06725121|BIOLOGICAL|Atezolizumab & Bevacizumab|Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
223924622|NCT06725121|DRUG|Yttrium-90 (Y-90)|Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
223924623|NCT06725121|RADIATION|Stereotactic body radiotherapy (SBRT)|Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
223924624|NCT06727409|DRUG|Finerenone|Finerenone 10mg or 20 mg as tolerated on top of maximal tolerated RASi and stable SGLT2i therapy
223924625|NCT06725693|DIAGNOSTIC_TEST|18F/68Ga-Exendin 4|Each subject receive a single intravenous injection of 68Ga/18F-Exendin 4, and undergo PET/CT imaging within the specificed time.
223924626|NCT06704620|DRUG|Diphenhydramine|Diphenhydramine intramuscular injection 20mg qd d0-2 Q3W
223924627|NCT06704620|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d1
223531762|NCT06921148|DEVICE|Dermabond/Prineo Dressing|Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.
223531763|NCT07118215|DRUG|KarXT|Specified dose on specified days
223531764|NCT07118215|DRUG|Midazolam|Specified dose on specified days
223531765|NCT07118215|DRUG|Fexofenadine|Specified dose on specified days
223531766|NCT07118215|DRUG|Digoxin|Specified dose on specified days
223531767|NCT02661672|DEVICE|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
223531768|NCT02661672|DEVICE|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
223531769|NCT02581930|DRUG|Ibrutinib|Given PO
223531770|NCT02581930|OTHER|Laboratory Biomarker Analysis|Correlative studies
223531771|NCT02581930|OTHER|Pharmacogenomic Study|Correlative studies
223531772|NCT02581930|OTHER|Pharmacological Study|Correlative studies
223924628|NCT06704620|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
223924629|NCT06704620|DRUG|Albumin paclitaxel|Albumin paclitaxel intravenous infusion 260mg/m2 d1
223924630|NCT06704620|DRUG|Carboplatin|Carboplatin intravenous infusion AUC5 d1
223924631|NCT06704620|DRUG|Cisplatin|Cisplatin intravenous infusion 75mg/m2 d1
223924632|NCT07038109|OTHER|Progressive relaxation exercise|The intervention was based on Jacobson's Progressive Muscle Relaxation (PMR) technique. Participants in the experimental group practiced PMR three times per week for four weeks. Each session lasted approximately 45 minutes and was conducted in a quiet environment. In the first session, the researcher provided face-to-face instruction. Subsequent sessions were guided by standardized audio recordings, and the participants were followed through scheduled online video calls. The intervention aimed to reduce depression, anxiety, and stress symptoms and to promote biopsychosocial well-being in nursing students.
223924633|NCT06729723|DEVICE|SAT-001|SAT-001 Treatment Group Participants in this group will use the SAT-001 device for 30 minutes. Before and after using the device, choroidal thickness will be measured using Optical Coherence Tomography (OCT) to assess changes in choroidal thickness.
223924634|NCT06729723|DEVICE|modified SAT-001|"mSAT-001 Treatment Group Participants in this group will use the modified SAT-001 (mSAT-001) device for 15 minutes. Similar to the SAT-001 group, choroidal thickness will be measured using Optical Coherence Tomography (OCT) before and after device usage.~This protocol will help evaluate the effect of the SAT-001 and modified device on choroidal thickness, with measurements taken before and after each usage."
223924635|NCT06883812|DEVICE|CGM|The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously but levels are not shown on the participant's phone app in phase A.
223924636|NCT06883812|DEVICE|CGM|The CGM sensor is worn on the back of the arm and glucose levels are recorded continuously with levels shown on the participant's phone app in phase B.
223924637|NCT06883422|DIETARY_SUPPLEMENT|Preoperative oral immunonutrition formula|Intervention arm will daily receive, for 7 days, a preoperative oral formula with immunonutrients: 500 kcal of energy, 41 g of protein, 60 g of carbohydrates, 11 g of lipids, 5.7 g of glutamine, 7 g of arginine, 3.6 g of leucine, 2.7 g of isoleucine, 3.7 g of valine, and 0.35 g of omega 3
223924638|NCT06883422|DIETARY_SUPPLEMENT|Preoperative oral Isocaloric and isoproteic polymeric formula|Control arm will daily receive, for 7 days, an isocaloric and isoproteic preoperative oral formula: 500 kcal of energy, 41 g of protein, 60 g of carbohydrates, and 11 g of lipids
223924639|NCT06886074|DRUG|Short course of blinatumomab|"Patients will receive 175 mcg of blinatumomab trough out seven days in a 24-hours infusion.~Blinatumomab therapy will be assigned 17.5 mcg per day for the first 2 days. Then blinatumomab 28 mcg per day for 5 days (completing 7 days). A single intravenous 20 mg dose of dexamethasone will be applied one hour before starting dose."
223924640|NCT06872567|DEVICE|genicular artery embolization|genicular artery embolization
223924641|NCT06872567|DRUG|Corticosteroid Injection|Corticosteroid Injection
223924642|NCT06885541|DIAGNOSTIC_TEST|Detection of objective internal tremors|head-mounted motion sensors
223924643|NCT06883136|DRUG|Sintilimab+Cis-platinum/Carboplatin with Pemetrexed or Gemcitabine|"1. Sintilimab, 200mg, intravenous infusion on day 1 of each cycle, every 3 weeks as a cycle (Q3W), until disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new anti-tumor therapy, or termination of treatment for other reasons specified in the protocol; The longest treatment time of sintilimab was 24 months.~2. Chemotherapy regimen:~1\) Pemetrexed combined with platinum regimen (non-squamous cell carcinoma) : pemetrexed 500mg/m2, intravenous infusion on day 1 of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W) for a total of 4-6 cycles.~2\) Gemcitabine plus platinum regimen (squamous cell carcinoma) : gemcitabine 1000mg/m2 intravenously on days 1 and 8 of each cycle, cisplatin 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W) for 4-6 cycles."
223924644|NCT06886724|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
224092618|NCT05174091|OTHER|Functional Movement Screen, Spinal Mouse, Core Endurance, Funcitonal Capacity|Due to the difficulties in the diagnosis and treatment of NSLBP, it has been causing many problems such as limitation of activation, socioeconomic burden, and biopsychosocial factors for years. It is thought that the effectiveness of treatment will increase if the needs and problems of individuals with NSLBP are clearly revealed beforehand. Although there are studies on core endurance and physical capacities in individuals with NSLBP in the literature, the number of studies examining functional movement analysis and spinal mobility in individuals with NSLBP is very few. Therefore, aim of this research is to compare functional movement analysis, physical capacity, core endurance, and spinal mobility in individuals with and without NSLBP. With the results we will reveal, we aim to contribute to the evaluation and treatment of patients with NSLBP. Thus, the negative effects of this pathology, which causes serious labor and financial losses, can be minimized.
224092619|NCT03244657|DRUG|conbercept ophthalmic injection （0.5mg）|"The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment"
224092620|NCT03244657|DRUG|conbercept ophthalmic injection （0.5mg）|"In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given."
224092621|NCT00643383|DRUG|Combination drug (Acetaminophen + Tramadol)|
224092622|NCT00643383|DRUG|Placebo|
223924645|NCT06886724|DIETARY_SUPPLEMENT|Placebo|The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
223924646|NCT06888934|DEVICE|Intervention with Lync device.|Treatment of arthritis and/or correction of bone alignement default in the toes (mallet toes, claw toes, hammer toes) with Lync device.
223924647|NCT06888440|PROCEDURE|scaling and zinc stents|this group will receive scaling and zinc containing stents
223924648|NCT06888440|PROCEDURE|scaling and placebo stents|this group will receive scaling and placebo stents
224092623|NCT03787069|DRUG|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
224092624|NCT03462251|COMBINATION_PRODUCT|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
223924649|NCT06890169|BEHAVIORAL|OneSTOP program|The OneSTOP program will incorporate at least 50% (4 out of 8 sessions) of the doctor and dietician consults over the 26-week study as teleconsults, which may be scheduled as joint or asynchronous consults. The exercise prescription and calorie restriction will be tailored to each subject's individual needs as in the F2F structured weight management program in the control group. In addition, participants will be taught to use the EMPOWER app will be used to enable them to upload their weight, blood pressure and glucose, food and exercise duration records. The app also has the capability to co-ordinate visits and investigations, deliver intelligent health nudges and reminders on adherence to treatment which can be individualized to their progress, and provide information on their conditions curated by their doctors and dieticians.
223924650|NCT06890169|BEHAVIORAL|Standard of care weight management program|The standard face-to-face weight management program consists of 4 doctor and 4 dietician consults over 26 weeks, at 2-4 weekly intervals in the first 3 months, and 6-8 weeks in the next 3 months. At the baseline visit, participants are provided with an aerobic and resistance exercise prescription individualized to each subject's fitness and comorbidities to target at least 180 minutes/week of moderate-intensity physical activity (with exercise on at least 3 days/week), and dietary advice based on a calorie-deficit diet (400-600 kilocalories less than the calculated daily caloric requirement, based on the Mifflin-St Jeor equation) which emphasizes reduction in sugar-sweetened beverages, refined carbohydrates and saturated fats. Subjects will be provided with a list of fitness resources such as gyms and fitness corners with advice on use of the equipment, and specific guidance on increasing intensity and duration of exercise and monitoring for injury.
223924651|NCT06889636|OTHER|Pharmaceutical care in solving drug-related problems in subjects using psychotropic medicines based on standardized protocol..|Pharmacists' interventions were based on Medication Review and Medication Therapy Management evaluations of a subjects' pharmacotherapy to optimize medicine use, improve treatment outcomes and quality of life. The intervention involved the identification of drug-related problems and addressing these issues through pharmacist interventions. The intervention was based on information gathered from the subjects and a list of medicines in use.
223924652|NCT06889636|OTHER|Common pharmacists' practice in Croatia.|Group B participants received pharmaceutical care based on common pharmacists' practice in Croatia during the dispensing of psychotropic drugs.
223924653|NCT06723808|OTHER|Leisure-Time Physical Activity and Occupational Physical Activity|This study does not involve a specific intervention but explores the relationship between leisure-time physical activity (LTPA) and occupational physical activity (OPA) in university staff, with a focus on work ability, musculoskeletal disorders, and quality of life.
223924654|NCT06888037|DRUG|Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）|"CAPOX/SOX (each cycle is 21 days): Oxaliplatin 130mg/m2, ivgtt, D1; Capecitabine 1000 mg/m2, po, bid, D1-14 or S-1: 40-60mg according to BSA, bid, D1-14.~FOLFOX (each cycle is 14 days): Oxaliplatin 85mg/m2, ivgtt, D1, Q2W; 5-Fluorouracil: 400mg/m2, D1, followed by 2400 mg/m2 as a continuous IV infusion over 46 hours; Leucovorin: 400mg/m2, iv, D1.~PD-1 monoclonal antibody:~Nivolumab 360mg/3 weeks or 240mg /2 weeks, iv, D1; If weight ≥60 kg, Sintilimab 200mg/3 weeks; if weight \< 60 kg, Sintilimab 3mg/kg/3 weeks, iv, D1; Tislelizumab 200mg/3 weeks, iv, D1; Pembrolizumab 200mg/3 weeks, iv, D1;"
223924655|NCT06888037|DRUG|Maintenance treatment (after 3 months): fruquintinib+PD-1|"After 3 months (12 weeks) of initial treatment with oxaliplatin-based chemotherapy combined with PD-1 monoclonal antibody, those with complete response (CR), partial response (PR) or stable disease (SD) assessed by imaging evaluation continued to receive maintenance treatment with furoquininib and PD-1 monoclonal antibody.~Fruquintinib 3 mg/d, qd po, D1-21, Q4W; PD-1 monoclonal antibody is repeated as initial treatment until the disease progresses or unacceptable toxicity."
223924656|NCT06888752|BIOLOGICAL|Cell injection|LCAR-M61SQ cells intravenous infusion; Prior to infusion of the LCAR-M61SQ cell, Subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
223924657|NCT06889051|PROCEDURE|Flexible & Navigable Suction Ureteral Access Sheath (FANS)|The Flexible \& Navigable Suction Ureteral Access Sheath (FANS) is used during retrograde flexible ureteroscopy (FURS) for renal stones (1.5-2 cm). It allows continuous active suctioning, improving stone fragment evacuation, reducing operative time, lowering intrarenal pressure, and optimizing stone-free rates (SFR). The procedure involves inserting the Navigator 10F, 55 cm YIGAOMED FANS over a guidewire, followed by flexible ureteroscopy with PUSEN® 9.2 Fr ureteroscope and laser lithotripsy using Holmium Laser (JenaSurgical® MultiPulse HoPLUS™ 150W).
223924658|NCT06889051|PROCEDURE|Antegrade Suction via Percutaneous Nephrostomy|This technique involves antegrade suction from the kidney during flexible ureteroscopy (FURS) without the use of a ureteral access sheath. A percutaneous nephrostomy (PCN) tract is created using an 18G needle, and a 6F renal dilator is placed and fixed to the skin, allowing for direct suctioning from the collecting system. Following this, retrograde flexible ureteroscopy (FURS) is performed using the PUSEN® 9.2 Fr ureteroscope and Holmium Laser (JenaSurgical® MultiPulse HoPLUS™ 150W) for stone fragmentation. This technique aims to improve stone clearance while minimizing ureteral trauma associated with access sheaths.
223924659|NCT06731166|BEHAVIORAL|self-care|Videomonitoring provide by cardiovascular nurses
223924660|NCT06730399|DEVICE|Computed-assisted-cryotherapy|cryotherapy device
223924661|NCT06731036|BIOLOGICAL|CD34+ cell enriched stem cell graft|Patients will receive a peripheral blood stem cell graft that has been CD34+ cell enriched using the Miltenyi CliniMACS Prodigy® system.
223924662|NCT06730906|DEVICE|PACTAID App|The PACTAID app will provide real time decision support during exercise for patients with type 1 diabetes.
224092625|NCT03462251|COMBINATION_PRODUCT|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
224092626|NCT02598830|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
224092627|NCT02598830|DIETARY_SUPPLEMENT|Placebo|Olive oil, encapsuled
224092628|NCT05015309|DRUG|SH3765 tablet|Starting dose 2.5mg, oral administered once daily. If tolerated subsequent cohorts will test increasing doses (5mg, 10mg, 15mg, 20mg, 25mg, 30mg) of SH3765.
224092629|NCT01276288|DRUG|BI 10773|multiple oral doses
224092630|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
224092631|NCT01276288|DRUG|torasemide|multiple oral doses
224092632|NCT01276288|DRUG|BI 10773|multiple oral doses
224092633|NCT01276288|DRUG|torasemide|multiple oral doses
224092634|NCT01276288|DRUG|BI 10773|multiple oral doses
224092635|NCT01276288|DRUG|hydrochlorothiazide|multiple oral doses
223924663|NCT06731556|DRUG|Intravenous paracetamol|Paracetamol was administered intravenously at a dose of 20 mg/kg/day, twice daily.
223924664|NCT06731556|DRUG|Intranasal Paracetamol|Paracetamol at a concentration of 1.25 mg/mL was administered intranasally.
223924665|NCT06731556|DRUG|Intranasal Diclofenac Sodium|Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
223924666|NCT06731556|DRUG|Intranasal Ibuprofen|Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
223924667|NCT07038252|DIETARY_SUPPLEMENT|Oral SPM-enriched marine oil (LIPINOVA)|LIPINOVA is an oral dietary supplement provided by Solutex, consisting of marine oil enriched in specialized pro-resolving mediator (SPM) precursors. Each daily dose (3 g/day) includes 1500 mg of omega-3 free fatty acids and a minimum of 520 mcg of SPM precursors (17-HDHA, 18-HEPE, 14-HDHA). The supplement is administered orally in 6 softgel capsules per day (3 after breakfast, 3 after dinner) over 12 weeks. It is used to investigate its effect on vascular function and inflammation in patients with obesity-related hypertension. The product is over-the-counter and commonly available in the EU, including France.
223924668|NCT07038252|DIETARY_SUPPLEMENT|Placebo|Placebo capsules provided by Solutex, identical in appearance to LIPINOVA, contain refined olive oil with no active omega-3 fatty acids or SPM precursors. The placebo is administered orally in 6 softgel capsules per day (3 after breakfast, 3 after dinner) for 12 weeks, following a randomized, double-blind, crossover design. It serves as a control to evaluate the effects of SPM-enriched marine oil on vascular and inflammatory parameters in patients with obesity-related hypertension.
224092636|NCT03759158|DRUG|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
224092637|NCT03759158|DRUG|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
224092638|NCT03429868|DEVICE|integrated PET/MRI|"The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan."
224092639|NCT03652922|DRUG|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
224092640|NCT06003062|DRUG|Narcissus Tazetta Bulb Extract and Novel Hemp Extract|Topical nightly application of phytonutraceutical
224092641|NCT04125537|BEHAVIORAL|IHI Breakthrough Collaborative Model|Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
224092642|NCT01484964|DRUG|ASP015K|oral
224092643|NCT03168867|BEHAVIORAL|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
224092644|NCT04209231|OTHER|1.25(OH)2D3|
223531773|NCT04547075|OTHER|Turkish validity and reliability|"1. Contact with developers and formation of steering committee~2. Translation from English to Turkish~3. Back translation from Turkish to English~4. Comparison of translation~5. Review of translated versions.~6. Reaching consensus and development of pilot version~7. Testing in clinical setting~8. Revision of pilot version~9. Testing of final version"
223924669|NCT06716216|DRUG|Drug: 5 mg BGM0504 Administered SC|Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
223924670|NCT06716216|DRUG|Drug:10 mg BGM0504 Administered SC|Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
223924671|NCT06716216|DRUG|Drug: Semaglutide Administered SC|"Active Comparator: 1 mg Semaglutide~1 mg semaglutide administered SC once a week"
223924672|NCT06715488|DIAGNOSTIC_TEST|AI assisted smartphone diagnosis|Patients will examination and clinical photographs for convolutional networks to diagnose inflammatory arthritis
223924673|NCT06726954|DEVICE|High-frequency real-time rTMS DLPF cortex protocol|It was planned to apply the dorsolateral prefrontal cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
223924674|NCT06726954|DEVICE|High-frequency real-time rTMS M1 motor cortex protocol|It was planned to apply the M1 motor cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
223924675|NCT06726954|DEVICE|Sham rTMS Protocol|It was planned to apply the daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
224092645|NCT04209231|OTHER|25(OH)D|
224092646|NCT05288712|OTHER|Training protocol with the device cervical for treatment (CDAT)|Training protocol with the cervical device for treatment (CDAT)
224092647|NCT05288712|OTHER|Conventional training protocol|Conventional training protocol
224092648|NCT04964258|DRUG|TAK-105-a|TAK-105-a subcutaneous solution.
224092649|NCT04964258|DRUG|TAK-105-a Placebo|TAK-105-a placebo-matching solution.
224092650|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
224092651|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
224092652|NCT00971308|DRUG|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
224092653|NCT00971308|DRUG|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
223924676|NCT06727045|OTHER|Mandala Coloring|"A literature review was conducted to determine the frequency and number of mandalas to be applied to the patients in the intervention group, and the average of the number of mandala sessions applied to different patient groups was obtained, and mandala application was performed during a total of eight hemodialysis sessions, every other day. Mandala painting was performed approximately 30 minutes after the start of HD treatment, considering the art therapist's recommendation and the symptoms that may develop during HD. Each mandala painting was performed with a structured and different mandala pattern. Since it was stated that the use of round patterns instead of square patterns was effective in increasing the comfort level, the booklet called Mandala Booklet, consisting of 8 structured mandala patterns with round shapes and containing general information about mandala, was used in the study. The group was informed about the content of the booklet face to face. Dry pencils were prefer"
223924677|NCT06726395|DRUG|Penicillin G_1200mg|benzylpenicillin preferred dosing 1gx4
223924678|NCT06726395|DRUG|cloxacillin|cloxacillin 2gx4
223924679|NCT06725732|DRUG|Tranexamic Acid (TXA)|To see if nebulised TXA is better to control blood loss in functional Endoscopic sinus surgery
223924680|NCT06725732|DRUG|Tranexamic Acid|To see if intravenous TXA is better to control blood loss in functional Endoscopic sinus surgery
223924681|NCT06725719|DIAGNOSTIC_TEST|18F-DPA714/FDPA|Each subject receive a single intravenous injection of 18F-DPA714/FDPA, and undergo PET/CT or MRI imaging within the specificed time.
223924682|NCT06725459|DEVICE|Prophylactic ciNPWT|The prophylactic closed incision negative pressure wound therapy (ciNPWT) will be applied to one breast for up to 7 days postoperatively to promote wound healing and prevent complications.
223924683|NCT06725459|OTHER|Standard Adhesive Dressing|The standard adhesive strip dressing will be applied to one breast immediately after surgery. It provides a protective covering for the wound during the initial healing phase and is the standard of care for incision management.
224092654|NCT00971308|DRUG|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
224092655|NCT04552470|DRUG|Placebo|3 matching placebo tablets taken twice a day (BID)
224092656|NCT04552470|DRUG|PF-06882961|Participants will be randomized to one of 3 active doses (40, 80, or 120 mg), taking 3 tablets twice daily for 8 weeks.
223531774|NCT07139301|DRUG|Early anticoagulation|Early initiation of direct oral anticoagulants will be started within four days after symptom onset.
223531775|NCT07139301|DRUG|Delayed anticoagulation|Delayed initiation of direct oral anticoagulants will be started between 5-14 days after symptom onset.
223531776|NCT07140237|DRUG|Oxytocin lower does (24IU)|Oxytocin (24IU) will be administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue)
223531777|NCT07140237|DRUG|Oxytocin higher does (48IU)|Oxytocin (48IU) will be administered as a lingual spray (6, 0.1ml sprays (8IU per puff) on and under the tongue)
223924684|NCT06705595|DRUG|Tracheo-Spray|Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.
223924685|NCT06705595|DRUG|Lidocaine Spray on DLT|Before intubation, participants will receive 10% lidocaine spray applied to the distal surface and cuffs of the double-lumen tube (DLT).
223924686|NCT06705595|DRUG|Saline (Placebo)|Before intubation, participants will receive 1 ml of 0.9% saline applied to the distal surface and cuffs of the double-lumen tube (DLT).
223924687|NCT06705881|OTHER|Eccentric exercise program (EEP)|All participants will perform a 6-week single-leg eccentric squat exercise. It will be performed on an incline board with a 25° incline. It will consist of a single-leg squat, with the downward component (eccentric phase) of the EEP performed using the symptomatic leg and the upward component (concentric phase) using the contralateral leg primarily. If pain occurs during the exercises, athletes will be asked to continue the exercise if they score ≤5 out of 10 on the Visual Acuity Scale (VAS). The exercises will be attempted in the first session of each week, and if no or very little pain is felt, the weight will be increased by 2.5% to increase the intensity of the exercise. Three sets of 15 repetitions per session will be performed twice a day. It will be performed 5 days a week. Participants will be asked to fill out an exercise diary (sets, repetitions, and daily frequency) and return it to the researchers at each follow-up session.
223924688|NCT06705881|OTHER|ESWT (Extracorporeal Shock Wave Therapy)|ESWT is a therapy method routinely used in private and public hospitals. Tendinopathy therapy parameters approved by the International Society for Medical Shock Wave Therapy (ISMST) for focused ESWT treatment are: 0.10-0.25 mJ/mm (dosing appropriate to pain), up to a maximum of 5 Hz, 1500-2500 pulses per session, 1-2 weeks apart. Accordingly, in our study, the focused ESWT dosage of the ESWT group will be applied as; 0.10-0.25 mJ/mm (dosing appropriate to pain), 4 Hz, 2000 pulses, 1 session per week for 3 weeks. No exercise will be done on the day of ESWT.
223924689|NCT03872466|DEVICE|GRASP HEP|The GRASP system comprises a sensor package and therapy game software that works with a commercial glove orthosis to enable virtual world-based practice of activities of daily living (ADLs) involving the hand.
224092657|NCT03931018|OTHER|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
224092658|NCT05943730|DEVICE|Seismofit|The Seismofit device uses seismocardiography to estimate peak oxygen consumption from a resting measurement. This study will assess its validity against the gold standard measure of peak oxygen consumption, cardiopulmonary exercise test, conducted as part of standard care.
224092659|NCT00902629|PROCEDURE|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
224092660|NCT00058461|DRUG|ifosfamide|Given IV
224092661|NCT00058461|DRUG|etoposide|Given IV
224092662|NCT00058461|BIOLOGICAL|rituximab|Given IV
224092663|NCT00058461|DRUG|carboplatin|Given IV
224092664|NCT00058461|BIOLOGICAL|filgrastim|Given SC
224092665|NCT00058461|DRUG|methotrexate|Given IT
224092666|NCT00058461|DRUG|cytarabine|Given IT
224092667|NCT00058461|OTHER|laboratory biomarker analysis|Correlative studies
224092668|NCT00620061|DRUG|Lubiprostone 24|24 mcg capsules for oral administration
224092669|NCT01717534|DIETARY_SUPPLEMENT|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
224281246|NCT00075686|DRUG|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
224092670|NCT01133964|DIETARY_SUPPLEMENT|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
224092671|NCT03778489|OTHER|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
224092672|NCT06278623|DEVICE|Focal Muscle Vibratory Energy (EVM) Treatment|"The patients involved in the study will undergo muscle vibratory stimulation in association with conventional rehabilitation treatment three times a week, for three weeks for a total duration of 9 sessions in association with conventional treatment.~The vibration will be applied at a frequency of 100 Hz and an amplitude of 0.2 cm for 30 minutes (three sessions of 10 min each with 1 min break in between) three times a week for three weeks at the level of the quadriceps femoris and triceps surae bilaterally for balance improvement and stimulation of proprioception and in the trapezius and trunk extensor muscles bilaterally for pain relief."
224092673|NCT00024687|DRUG|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
224092674|NCT04288245|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper extremity rehabilitation. VNS stimulation as described in the current study consists of 0.5 s trains of 0.8 mA 100 µs biphasic pulses delivered at 30 Hz. Stimulation trains are delivered only during rehabilitation.
223924690|NCT03872466|BEHAVIORAL|Usual Care Treatment (UCT)|Participants in the control group will continue to receive any previously prescribed therapy services. These patients will not receive any treatment services through the study as UCT group participants.
223924691|NCT06710249|DIETARY_SUPPLEMENT|Salovum/SPC flakes|Egg yolk powder and specially processed cereals
223924692|NCT06707259|BIOLOGICAL|anti-CD19 IL10 CAR-NK|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19-IL10 CAR
223924693|NCT06733350|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsy
223924694|NCT06733350|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223924695|NCT06733350|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223924696|NCT06733350|OTHER|Patient Observation|Undergo standard AS
224092675|NCT04288245|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
224092676|NCT04911387|DEVICE|Intraocular pressure measurments|Intraocular pressure measurements with iCare Home by participants (patients, volunteers) and healthcare staff as well as intraocular pressure measurements with GAT by participants different healthcare staff.
224092677|NCT01274221|DRUG|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
224092678|NCT01274221|OTHER|Placebo|1 capsule per day for one week of the double-blind crossover phase
224092679|NCT00534534|BEHAVIORAL|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
224092680|NCT03026738|PROCEDURE|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
224092681|NCT03026738|PROCEDURE|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
224092682|NCT03026738|DEVICE|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
224092683|NCT04401059|DRUG|Elemene plus first or third generation EGFR-TKIs|"Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label."
224092684|NCT04401059|DRUG|First or third generation EGFR-TKIs|refer to the drug label.
223924697|NCT06733350|OTHER|Questionnaire Administration|Ancillary studies
223924698|NCT06733350|DRUG|Therapeutic Testosterone|Given via injection, gel, lotion, or transdermal patch
223924699|NCT06732687|OTHER|Calisthenics|"Calisthenics~Arm Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks."
223924700|NCT06732687|OTHER|Plyometrics|Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
223924701|NCT06732687|OTHER|Combined( Calisthenics+ Plyometrics)|Description: Both exercises would be performed. First Calisthenics will be performed and then plyometrics will be performed.
223924702|NCT06723262|OTHER|Tonotopic cochlear implant fitting FS4T|Comparison of FS4T and FS4noT
223924703|NCT06723717|DRUG|Daily infusion of dornase alfa|Daily infusion of dornase alfa at a dose of 125 microg/kg as an intravenous bolus until day 14 after SAH
223924704|NCT06733077|DEVICE|gait with cueing wearable device and neuro-ocular performance|"Participants will be invited to participate in the following sequential phases. Participants can participate in Phases as selected. Control participants will not be invited to Phase 4.~Phase 1. Lab testing \[2 hours\] Validation study of digital technology measures MachineMD and gaitQ to criterion metric of UPDRS.~Phase 2. home/community testing \[2 weeks daily\] Determine feasibility of daily measuring in the home of gaitQ to determine usability, acceptability, and day to day variability of measurement metrics and to determine concurrent validation of home metric to lab metrics to determine, reliability, concurrent validity of change, minimal detectable change and criterion validation to lab-based measures.~Phase 3. Lab retesting \[2 hours\] see Phase 1~Phase 4. Home/community intervention \[2 weeks\] Determine the potential for effect of the gaitQ vibration intervention from a 2-week exposure in the home."
223924705|NCT06733051|DRUG|Golidocitinib|150 mg, administered once daily from Day 1 to Day 21 (D1-D21)
223924706|NCT06733051|DRUG|Benmelstobart|1200 mg, administered on Day 1 (D1) of every cycle
223924707|NCT01778686|DRUG|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
223924708|NCT01778686|OTHER|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
223924709|NCT01778686|DIETARY_SUPPLEMENT|Acute tryptophan depletion|
223924710|NCT06720675|PROCEDURE|Hypothermic Oxygented Perfusion|HOPE start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid (cold Belzer MPS solution) during back-table preparation. Hepatic perfusion was performed through the vein leads to a pressure of 3-5 mmHg. Organ were treated with continuous HOPE until transplant and the perfusion was continuously monitored and data downloaded in a USB memory.
223924711|NCT06720675|PROCEDURE|Static Cold Storage|Liver grafts are stored in sterile organ bags with cold Belzer or Celsior solution and kept in ice at 4°C.
223924712|NCT06720909|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The standard 8-week MBSR program will be led by certified MBSR instructors from the UCSD Center for Mindfulness. The program content will consist of a variety of mindfulness and meditative techniques, such as sitting meditation, body scans, and mindful yoga. Participants will engage in weekly sessions via Zoom, participation in group discussions, and honing their other mindfulness skills. Throughout the program, participants will be instructed to commit to a daily mindfulness meditation practice lasting approximately 45 minutes, at least 6 days a week.
223924713|NCT06720909|OTHER|Open-Label Placebo (OLP)|The placebo pills will be size #1 capsules filled with (1) microcrystalline cellulose, a common inert excipient for pharmaceuticals, and (2) 25 mg riboflavin tracer. Participants will be informed that the placebo pills are inactive substances, like sugar pills, and contain no active medication. Then, they will watch a brief introduction video which will cover four main discussion points: (1) the placebo effect can be powerful and can have beneficial effects for diverse symptoms, (2) the body can respond to taking placebo pills automatically despite the knowledge that it is placebo (e.g., Pavlov's dogs), (3) a positive attitude or expectation can be beneficial but is not necessary, and (4) taking the pills faithfully throughout the intervention period is critical.
223924714|NCT06720909|OTHER|MBSR+OLP|This condition involves a combination of interventions, where participants will receive both MBSR and OLP treatments.
223924715|NCT06721520|BIOLOGICAL|Botulinum Toxin A (Botox )|Patients randomized for intrapyloric Botox injection will undergo the following standard procedure: 100 units of Botox are dissolved in 10 mL normal saline. After identifying the pylorus, the 10 mL of Botox solution is injected intramuscularly at the anterior pyloric ring in 2 separate areas and in 1 area on each side of the pyloric ring.
223924716|NCT06721520|PROCEDURE|Pyloromyotomy|Patients randomized for pyloromyotomy will undergo standard pyloromyotomy as follows: after identifying the pylorus, a 2-cm longitudinal incision is made with Metzenbaum or Mayo scissors on the anterior pylorus, centered on the pyloric ring. The incision extends through the serosa and muscular layers to expose the submucosa and mucosa, which is left intact. The cut muscle is spread apart until the submucosa bulges up to the level of the cut serosa. Care is taken to avoid perforation, and the surgeon confirms no mucosal perforation at the end of the procedure. If a perforation is encountered, it will be repaired primarily.
223924717|NCT06720389|RADIATION|peri implant bone loss was assessed by CBCT|using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)
223924718|NCT06720389|OTHER|posterior ridge resorption was assessed by CBCT|posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.
223924719|NCT06729801|DEVICE|IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS)|The IRP-Monitoring Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a novel device designed to enable real-time monitoring of intrarenal pressure (IRP) during retrograde intrarenal surgery (RIRS). It incorporates a pressure-sensing port connected to a gas conduit embedded in the sheath, which allows the surgeon to adjust irrigation flow and suction pressure based on real-time IRP readings, thereby optimizing stone retrieval efficiency while ensuring safety by maintaining a safe IRP range. The device improves surgical outcomes, particularly in complex cases involving larger renal stones, by reducing operative time and minimizing the risk of complications.
224092685|NCT03519048|PROCEDURE|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
224092686|NCT03519048|OTHER|Low Dose Chest CTscan|every year in patients with tobacco consumption history of \> 20 pack-year
224092687|NCT03519048|OTHER|injected CT-scan|the first performed 12 months after inclusion
224092688|NCT03519048|OTHER|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
224092689|NCT03519048|PROCEDURE|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
224092690|NCT03519048|PROCEDURE|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
223924720|NCT06729801|DEVICE|Conventional FANS|The Conventional Flexible and Navigable Suction Ureteral Access Sheath (FANS) is a standard device used in retrograde intrarenal surgery (RIRS) for stone retrieval. Unlike the IRP-monitoring version, this device does not provide real-time monitoring of intrarenal pressure (IRP). Irrigation flow and suction pressure are pre-set and adjusted based on clinical protocols. It facilitates the removal of renal stones through a flexible and navigable design, but without the added capability of monitoring and adjusting IRP during the procedure.
223924721|NCT06729645|OTHER|radiotherapy|External beam radiotherapy and endorectal brachytherapy
223924722|NCT06727864|DRUG|4-month regimen (2HERZ/2HRE)|4-month (2HERZ/2HRE)
223924723|NCT06727864|DRUG|6-month (2HERZ/4HRE)|2 months of HREZ followed by 4 months of HR/HRE
223924724|NCT06728592|DEVICE|Portable Magnetic Resonance Imaging|0.23T Low-field Magnetic Resonance Imaging
223924725|NCT06727734|DRUG|Levonorgestrel|Levonorgestrel 1.5 mg
223924726|NCT06727734|DRUG|Piroxicam|Piroxicam 40 mg
223924727|NCT06727734|DRUG|Ulipristal Acetate|Ulipristal 30 mg
223924728|NCT06727734|DRUG|Placebo - LNG|Placebo of levonorgestrel
223924729|NCT06727734|DRUG|Placebo - Piroxicam|Placebo of piroxicam
224092691|NCT00682656|DRUG|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
224092692|NCT00682656|DRUG|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
224092693|NCT01495026|DRUG|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
224092694|NCT01495026|DRUG|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
224092695|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
223924730|NCT06727734|DRUG|Placebo - UPA|Placebo of ulipristal acetate
224092696|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
224092697|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
224092698|NCT01495026|DRUG|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
224092699|NCT01495026|DRUG|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
224092700|NCT01495026|DRUG|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
224092701|NCT01495026|DRUG|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
223924731|NCT06731192|BIOLOGICAL|hUC-MSC|"This group of patients received a total of 2 peripheral intravenous Human umbilical cord mesenchymal stem cells (hUC-MSC) infusions during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days, and the single infusion dose was approximately 2×1000,000 cells/Kg.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
223924732|NCT06731192|DRUG|Placebo control drug|"This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs."
223924733|NCT06730763|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (TDCS) is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain.
223924734|NCT06730763|OTHER|Exercise|selected traditional physical therapy program for improve balance and decrease risk of falling
223924735|NCT06888336|BEHAVIORAL|Yoga nidra (full)|"The intervention consists of remotely delivered audio recordings (\~30 minute length) of iRest yoga nidra meditation instructions that participants will be asked to listen to daily for 8 weeks, for a total listening time of about 3.5 hours each week. The yoga nidra practices will be in the tradition of iRest. They will include the following sections: intention setting, articulating a heartfelt desire, inner resource, body sensing, breath sensing, emotion and cognition sensing and opposites, welcoming joy, witnessing awareness, and integration. Each week includes an additional brief (\~2-5 minute) introduction to one of the iRest yoga nidra sections. Participants will be asked to lie on a lightly cushioned surface when listening to the practices.~Participants are informed that they may opt to listen to the recordings more often but are instructed to listen to the recordings at least once per day."
224092702|NCT05134909|DEVICE|Customized contact lens|The customized lenses are designed to correct the eye's optical aberrations.
223924736|NCT06888336|BEHAVIORAL|Yoga nidra (brief)|"The intervention will consist of remotely delivered audio recordings of yoga nidra meditation instructions. Participants will be asked to listen to one \~30-minute practice and six \~10-minute practices per week (total listening time of \~1.5 hours each week) for 8 weeks. The yoga nidra practices will be in the tradition of iRest. They will include the following sections: intention setting, articulating a heartfelt desire, inner resource, body sensing, breath sensing, emotion and cognition sensing and opposites, welcoming joy, witnessing awareness, and integration. Each week includes an additional brief (2-5 minute) introduction to one of the iRest yoga nidra sections. Participants will be asked to lie on a lightly cushioned surface when listening to the practices.~Participants are informed that they may opt to listen to the recordings more than once a day but are instructed to listen to the 30-minute recording once per week and the 10-minute meditations the other 6 days of the week."
223531778|NCT07140237|DRUG|Atosiban|150ug atosiban administered by lingual sprays (6, 0.1ml sprays on and under the tongue)
223531779|NCT07140237|DRUG|Placebo|Placebo administered as a lingual spray (6, 0.1puffs (4IU per puff) of spray on and under the tongue). Placebo has the same composition of 0.9% saline and glycerol as for oxytocin and the atosiban interventions.
223531780|NCT06821542|DRUG|INCA034176|IV infusion
223531781|NCT06821542|DRUG|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
223924737|NCT06888349|PROCEDURE|spinal anesthesia|spinal anesthesia using 15 mg 0.5% hyperbaric bupivacaine in the sitting position at L3-4 or L4-5 intervertebral space.
223924738|NCT06888349|PROCEDURE|Adductor Canal Block|local anesthetic spread around the saphenous nerve in the adductor canal ultrasound guided using 22 Gag spinal needle with injection of 15ml 0.25% bupivacaine with addition of 2mg dexamethasone and 2.5mcg /ml epinephrine as an adjuvant to prolong its action.
223924739|NCT06888349|PROCEDURE|interspace between Popliteal artery and capsule of knee (IPACK) block|ultrasound guided Local anesthetic infiltration over the posterior aspect of the femur underneath the popliteal artery targeting the genicular nerves which are the articular branches of tibial and common peroneal nerves, posterior branches of the obturator nerve, and medial genicular nerve using 22Gag spinal needle injecting 20ml 0.25%bupivacaine with addition of 2mg dexamethasone and 2.5mcg /ml epinephrine as an adjuvant to prolong its action.
223924740|NCT06888310|PROCEDURE|extra blood sampling|search for biomarkers for the prevention of liver disease
223924741|NCT06888167|OTHER|Study setting|"The subjects in the study will undergo two days of visits, in random order.~1. Following a fasting period of at least 4 hours, the study participants will undergo a PET-CT examination with Ga-exadin-4. Fasting will reduce the endogenous secretion of GLP-1 by the small intestine, which can otherwise compete with exendin-4 for binding to GLP-1R. Blood glucose will be measured before the injection of the tracer and monitored at each time point.~2. On a fasting basis, the anthropometric data of the enrolled subjects will be collected and they will undergo a short interview on their lifestyle. Subsequently, at time 0, the subjects will ingest a standard mixed meal consisting of 2 commercially available ABC Parmareggio snacks. Venous blood samples will be taken at specific time intervals (from -20 to 300 minutes) to measure glucose, C-peptide, insulin, glucagon, GLP-1 and glucose-dependent insulinotropic (GIP) curves. An additional blood sample will be taken at time -10 in order to isolate"
223924742|NCT06886100|DEVICE|Diode laser|Diode Laser is a semiconductor device similar to a light-emitting diode in which a diode pumped directly with electrical current can create lasing conditions at the diode's junction. It is used in periodontal surgery as melanin depigmentation
223924743|NCT06886100|DEVICE|Scalpel No 15|The No.15 blade has a small curved cutting edge and is the most popular blade shape ideal for making short and precise incisions.
223924744|NCT06883955|COMBINATION_PRODUCT|Disease education, pharmacological treatment, Non-pharmacological treatment|"Disease education: Provide patients with education on knowledge related to primary headache, including the causes, pathogenesis, symptoms, treatment methods, and preventive measures of headache, etc., to help patients better understand their own diseases and improve their self-management ability.~Non-pharmacological treatment: Although specific non-pharmacological treatment methods are not elaborated in detail in the research protocol, they may include psychotherapy, physical therapy, etc. For example, biofeedback therapy, relaxation training, transcranial magnetic stimulation, etc. These can all be recorded as possible intervention measures.~Pharmacological treatment: Record the medications used for the treatment of acute episodes and preventive treatment by patients during the research process, including the types of medications, dosages, frequency of use, etc. For instance, non-steroidal anti-inflammatory drugs and triptan drugs used during acute episodes, and β-blockers."
223924745|NCT06889285|PROCEDURE|Continuos epidural infusion|"This group of parturient will be inserted epidural catheter at L3/L4 or L4/L5 depending on anaesthetist-in-charge justification, epidural catheter will be kept 4-5 cm in epidural space and anchored with adhesive tape. Similarly, a test dose of LA Lignocaine 2% 2ml will be given after epidural insertion. Infusion tubing will be primed in advance. Epidural catheter will be connected to epidural cocktail (Bupivacaine 0.1% + Fentanyl 2mcg/ml in 50ml mixture) with the protocol as below: (directly extracted from Malaysia Pain management in Obstetrics and Gynaecology Procedure Guideline 2023)~* Loading dose 10 ml~* Continuous infusion: 10ml/hour"
223924746|NCT06889285|PROCEDURE|Programmed intermittent epidural bolus|"This group patient will be inserted epidural catheter at L3/L4 or L4/L5 depending on anaesthetist-in-charge justification, epidural catheter will be kept 4-5 cm in epidural space and anchored with adhesive tape. A test dose of LA Lignocaine 2% 2ml will be given after epidural insertion. CADD-Solis infusion tubing will be primed in advance. Epidural catheter will be connected to epidural cocktail (Ropivacaine 0.05% + Fentanyl 2mcg/ml in 100ml mixture) with the protocol as below:~* Loading dose: 10ml~* Intermittent bolus: 10ml, bolus interval 1 hour, next bolus 1 hour~* PCEA dose: 10ml, lockout interval 10 minutes"
223924747|NCT06888232|DRUG|Thalidomide|Thalidomide was administered at a dose of 1.5 mg/kg/day, and all patients continued standard iron chelation therapy and other supportive treatments as per institutional protocols.
223924748|NCT06889623|PROCEDURE|Immediate postoperative chemotherapy|Systemic chemotherapy with cisplatin/gemcitabine intravenous infusion within 24 hours after TURBT
224092703|NCT05657262|OTHER|Pre-post test|Personal Information Form, Vas Scale, Undesirable Symptoms Form and General Comfort Scale Questions will be asked to immunotherapy patients with this research.
223924749|NCT06882941|DIETARY_SUPPLEMENT|Fermented Black Soybean and Adlay Supplement|The preparation of the fermented black soybean and adlay supplement involves autoclaved black soybean and dehulled adlay, which are inoculated with Bacillus subtilis natto (1.3 × 10⁶ CFU/g) and incubated for 43 hours at 28°C. Participants assigned to the experimental group will take the Fermented Black Soybean and Adlay Supplement daily for 12 weeks.
223924750|NCT06882941|DIETARY_SUPPLEMENT|non-fermented black soybean and adlay supplement|The placebo product was prepared using uninoculated autoclaved black soybean and dehulled adlay. The samples were provided as frozen food and required microwaving for 30 seconds before serving. Participants assigned to the placebo group will take the non-fermented black soybean and adlay supplement daily for 12 weeks.
223924751|NCT06375941|OTHER|Observational|Observational
223924752|NCT06733896|OTHER|trigger point pressure|The midpoint of the sternocleidomastoid muscle with abundant nerve distribution and the onset and endpoint of the sternocleidomastoid muscle were used as acupoints, which can relieve localised muscle spasms and promote nerve nutrition.
223924753|NCT06733896|OTHER|neck exercises|Manual Cervical Traction Technique and others
223924754|NCT06886880|DEVICE|endoscope|findings in upper GIT Endoscopy
223924755|NCT06885528|DIAGNOSTIC_TEST|Complete Blood Count with differential|First CBC w/diff test ordered within 12 hours of presentation to ED as part of standard medical care. The MDW result will be used as diagnostic marker to predict the risk of developing sepsis.
223924756|NCT06887400|OTHER|Point of care ultrasound (POCUS)|In this study, POCUS was performed by the same emergency medicine physician who had basic and advanced USG training and at least two years of POCUS experience, in accordance with ACEP imaging protocols. A portable USG device with B-Mode, M-Mode, Color Doppler, Power Doppler, Pulsed Wave Doppler modes, and which can be used in all clinical modes with a single probe was used during the protocol application (Butterfly iQ+™, Burlington, United States). Eight abdominal points (epigastric region, right upper quadrant, right side, right lower quadrant, suprapubic region, left lower quadrant, left side and upper quadrant, umbilical region) were scanned with POCUS, the findings were recorded on the previously prepared form, the triage categories of the patients (cl) were updated and the patients were directed to the area where they would be examined with the form.
223924757|NCT06738784|BEHAVIORAL|Perceive, Recall, Plan and Perform (PRPP) evaluation|Passing the PRPP for 2 activities
223924758|NCT06883396|PROCEDURE|Medial Patellofemoral Ligament (MPFL) Reconstruction|For the purposes of this study, isolated MPFL reconstruction is defined as MPFL reconstruction with a tendon graft, with or without additional soft tissue procedure(s) including lateral retinacular lengthening or release, patellofemoral chondroplasty and/or cartilage restoration. No patient in the study will receive a bony realignment procedure to treat patellar instability.
223924759|NCT06885008|OTHER|Active video game|The participants played the video game using an Xbox 360 Kinect console connected to a 55-inch Full HD television. The video games were planned with the assistance of a physiotherapist, 3 days per week, with 8 repetitions during the first 4 weeks and 12 repetitions during the final 4 weeks. The warm-up and cool-down periods were designed and applicated.
223924760|NCT06885008|OTHER|Aerobic exercise|Aerobic exercise training was performed on a stationary bike, 3 days per week, for 20 minutes per session. The intensity of the aerobic exercise was determined using the Karvonen method. For the first 4 weeks, the intensity was set at 30-50% of the maximum heart rate (MHR), corresponding to light intensity, and was then increased to 50-70% (moderate intensity) for the following 4 weeks. A pulse oximeter (ChoiceMMed, China) was used to monitor the target heart rate. During both the warm-up and cool-down phases of the aerobic exercise, participants performed hip abduction and adduction, hip-knee flexion, heel raises, and mini squats while standing for 3-5 minutes.
223924761|NCT06885008|OTHER|Conventional treatment|Convetional treatment included Hotpack, Transcutaneous Electrical Nerve Stimulation (TENS), and Ultrasound (US) modalities, were applied to the symptomatic knee(s) for a total duration of 30 minutes. Following this, the exercise program outlined below was performed with 3 sets of 10 repetitions each. The session lasted approximately 45 minutes.
223924762|NCT06886503|OTHER|Inspiratory Warm-Up - 60% MIP|Inspiratory Muscle Warm-up Protocols In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the IW60 arm, inspiratory muscle warm-up was performed at 60% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
223924763|NCT06886503|OTHER|Inspiratory Warm-up - 40% MIP|Inspiratory Muscle Warm-up Protocols In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the IW40 arm, inspiratory muscle warm-up was performed at 40% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
224281247|NCT05332886|BEHAVIORAL|MetaHealth Group|Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.
224281248|NCT05332886|BEHAVIORAL|MobileHealth Group|The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
224281249|NCT05681416|DIAGNOSTIC_TEST|Panel sequencing, whole exome sequencing, whole genome sequencing|Besides the mutation positive men (group 2), all will receive multigene panel analysis in a patient care setting and if negative, whole exome sequencing (WES), whole genome sequencing and transcriptome analyses. In PCA-affected men (group 3), additional mutational analysis will be performed on formalin-fixed paraffin embedded (FFPE) - and fresh frozen (FF) tumor tissue from biobanked radical prostatectomy specimens using FFPE panel analysis (like TruSightOncology 500) or WES if FF samples are available.
223924764|NCT06886503|OTHER|Sham|In addition to athletic warm-up an athletic warm-up protocol, participants performed inspiratory muscle warm-up (IMW) using the POWERbreathe® Plus Blue Medium Resistance (POWERbreathe International Ltd., Warwickshire, England UK). In the sham arm, inspiratory muscle warm-up was performed at 15% of maximal inspiratory pressure (MIP). Each protocol consisted of two sets of 30 repetitions (Marostegan et al., 2022; Demirkan et al., 2025).
223924765|NCT06884228|DEVICE|Vibrating mesh nebulisation|Vibrating mesh nebulisation (VMN) uses a mesh membrane that oscillates at high frequency (typically 128kHz) to produce a stream of drug-carrying droplets of pre-determined size to be inhaled
224092704|NCT05657262|BEHAVIORAL|experimental group|The experiment group will be applied with the Z technique.
224092705|NCT06294600|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
224092706|NCT06294600|DRUG|Tablets|Oral tablets of similar appearance to active study drug
223924766|NCT06884228|DEVICE|Jet nebuliser|Jet nebulisers use the flow of a gas (air or oxygen) to draw medication up through a capillary tube to generate small particles to be inhaled.
223924767|NCT06738745|DRUG|HRS-2189|HRS-2189
223924768|NCT06738745|DRUG|HRS-5041|HRS-5041
223924769|NCT06738108|DRUG|ECOS|The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE
223924770|NCT06738108|DRUG|Control group|Alteplase IV infusion
223924771|NCT06739382|COMBINATION_PRODUCT|extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin in group (A) of patients.
223924772|NCT06739382|COMBINATION_PRODUCT|two β-lactam antibiotics plus a single non-β-lactam antibiotic|In the case of XDR or PDR Pseudomonas spp. or Acinetobacter spp. isolation from the patient's specimen, treatment was adjusted to include two β-lactam antibiotics plus a single non-β-lactam antibiotic, or a combination of double β-lactam antibiotics, with the aim of avoiding aggressive and toxic antibiotics in group (B) of patients
223924773|NCT06739382|OTHER|Control group received standard therapy|Treatment was adjusted to the second-line empirical antibiotic according to the hospital's local policy.
223924774|NCT06740331|BEHAVIORAL|Analysis of social cognition, memory functioning, and executive functioning processes|Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
223924775|NCT06737185|OTHER|EAFS4T: modification with evolutionary algorithm of tonotopic-based fitting|Comparison of FS4T and EAFS4T
223924776|NCT06778200|OTHER|client interview|using a data collection form clients voluntarily described services provided by practitioner
224281250|NCT05091216|OTHER|Traditional Chinese Medicine mouthwash|The mouthwash used in this test is based on the records of past traditional Chinese medicine classics and the existing antibacterial experimental evidence. The selected medicinal materials are honeysuckle, scutellaria, peppermint, licorice, and rhizome.
223924777|NCT06778200|OTHER|practitioner responses|completed reflections after each module completion
223924778|NCT06093438|DRUG|Toripalimab|Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).
224092707|NCT00794287|OTHER|Taking blood samples|No intervention is done. Only blood samples are taken.
224281251|NCT05091216|OTHER|Dilute 50 times of Traditional Chinese Medicine mouthwash|Dilute 50 times of traditional Chinese medicine mouthwash.
223924779|NCT06737133|PROCEDURE|Surgery|Rhinoplasty
224092708|NCT01307423|DRUG|Apremilast 20mg|Apremilast 20mg twice daily, orally
224092709|NCT01307423|DRUG|Apremilast 30mg|Apremilast 30mg twice daily, orally
224092710|NCT01307423|DRUG|Placebo|Placebo
224092711|NCT01482702|BEHAVIORAL|weight loss intervention|Behavioral weight loss intervention
224092712|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
224092713|NCT01482702|BEHAVIORAL|Weight Loss|Behavioral weight loss intervention
224092714|NCT00572884|OTHER|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
224092715|NCT06337396|DIAGNOSTIC_TEST|WGS and transcriptome analysis|In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways
224281252|NCT06429514|DIETARY_SUPPLEMENT|Ganoderma lucidum spore powder|One bag at a time, 2 times a day, 2g / bag
224281253|NCT06429514|OTHER|placebo|One bag at a time, 2 times a day, 2g / bag
224281254|NCT01216410|DRUG|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
224281255|NCT01216410|DRUG|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
224281256|NCT01216410|DRUG|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
224281257|NCT05600023|DRUG|Nitrofurantoin|Nitrofurantoin has been found to successfully eradicate gram-negative bacteria such as Enterococcus faecalis that one of the most important bacteria in endodontic lesions
224281258|NCT05600023|DRUG|Double Antibiotic|DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole
223924780|NCT06739733|DIAGNOSTIC_TEST|SRG|Soft robotic gloves stimulation 30-minute sessions, 5 times per week upto 8 week Soft robotic gloves are assistive devices designed to enhance hand function for individuals with disabilities or injuries. These gloves use flexible materials, such as silicone or fabric, combined with pneumatic or cable-driven mechanisms to mimic natural hand movements. They provide assistance for gripping, holding, or manipulating objects, often controlled by sensors or user inputs. Soft robotic gloves are lightweight, adaptable, and offer rehabilitation potential, helping restore motor function in conditions like stroke or spinal cord injury. They are increasingly used in clinical and home-based therapy settings.
223924781|NCT06739733|DIAGNOSTIC_TEST|EMS|"Electrical muscle stimulation 30-minute sessions, 5 times per week upto 8 weeks.~Electrical Muscle Stimulation (EMS) is a technique that uses electrical impulses to contract muscles, often used for rehabilitation, strength training, or pain management. Electrodes placed on the skin deliver controlled currents to target specific muscle groups, mimicking natural nerve signals. EMS is commonly used in physiotherapy to prevent muscle atrophy, improve circulation, and enhance recovery after injury. It is also utilized in fitness and sports for performance enhancement. Safe and non-invasive, EMS can be adjusted for therapeutic or functional goals."
223924782|NCT06162052|OTHER|Tele-Rehabilitation|Technology will be used to enhance rehabilitation.
223924783|NCT06303544|BEHAVIORAL|Wedge 1|Wedge1 will receive intervention consisting of culturally based physical activity module, built environment, community healthy lifestyle promotion
223924784|NCT05591794|OTHER|Aerobic and resistance exercises|Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.
223924785|NCT05591794|DIETARY_SUPPLEMENT|Diet program|Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.
223924786|NCT05591794|OTHER|Regular walking program|Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
223924787|NCT06737666|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang granules were taken 2 bags at a time, 2 times per day at 1h after meal for 4 weeks.
223924788|NCT06880068|DIAGNOSTIC_TEST|Dual Task Impact on Daily-living Activities Questionnaire|This questionnaire makes us assess dual-task performance while performing daily-living activities.
223924789|NCT06747767|PROCEDURE|Arthroscopy|Arthroscopy
224092716|NCT06112587|BEHAVIORAL|strength training|A targeted 8-week strength-training course was offered as an intervention in combination with ergonomics and posture corrections and recommendations
223924790|NCT06747767|PROCEDURE|Open reduction|Open reduction
223924791|NCT06746480|DRUG|Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))|Intratumoral injection only. The dosing date is Days 1 through 3.
223924792|NCT06736756|OTHER|Stretch Exercise|To stretch Tensor fascia lata muscle,each participant starts with side lying position with the tested limb upmost. The lower limb (non-tested) is kept in hip and knee flexion to ensure stability. The tested limb is then taken into hip extension and adduction with knee extended. The exercise is held for 60 seconds and repeated 5 times with 10 seconds break intervals.
223924793|NCT06788808|OTHER|Comparison between groups|Ultrasound images acquired during routine ultrasound scans performed in healthy fetuses and in fetuses found to have CNS malformations will be reviewed. Ultrasound images acquired from January 2000 to May 2021 will be analyzed until a sample size of approximately 80 patients is reached, who will be divided into 2 groups: group A (patients whose fetus has CNS malformations) and group B (healthy patients whose fetus has no anatomical CNS abnormalities).
223924794|NCT06793514|DRUG|Probiotic|The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles) alongside with fructooligosaccharide (FOS), which is prepared in the concentration of 109 cfu by Bisot Khimr and is in the form of an edible sachet that can be dissolved in cold water, which is consumed once a day for one month. Sachets should be stored at a temperature of 2 to 8 degrees Celsius (in the refrigerator), which increases the useful life of probiotic bacteria and makes them more effective.
223924795|NCT06793514|DRUG|Placebo Drug|The placebo is also prepared in the form of probiotic supplement in the form of sachets with similar packaging by the bio-fermenting pharmaceutical company.
223924796|NCT06829186|DIETARY_SUPPLEMENT|Curcumin (Longvida™)|patients will be suplemented during 3 months with longvida, 2 cap /8 hours
223924797|NCT06829186|DRUG|Placebo|one capsules every 8 hours during 12 weeks
224092717|NCT03248921|PROCEDURE|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
224092718|NCT04970329|DRUG|Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,|Drugs will be given to two group and third group will kept on placebo.
224092719|NCT03295825|DIAGNOSTIC_TEST|Biomarker|Measument of heparin-binding protein in the serum of patients
224092720|NCT05192343|DEVICE|Virtual Reality and nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before and during the HSG shooting, the virtual reality and nature sounds application group watched a video with a nature view with virtual reality glasses and listening nature sounds.~Glasses were introduced before the procedure. Before the procedure started, glasses were put on and training was given to continue watching the video by wearing glasses during the procedure.~The women include in the virtual reality and nature sounds application group will make to watch a video with a nature view with nature sounds for 15 minutes before and during the HSG procedure.~Each woman was shown the same video."
223924798|NCT06837064|DEVICE|Chatbot supporting system|"The intervention tool is the automated chatbot supporting system, which contains:~A) educational information (therapeutic education and psychoeducation); B) symptom monitoring (stool quality and frequency, assessment of mood, sleep quality, physical activity, and dietary adherence on a scale of 0 to 10); C) behavioral distraction techniques, and body tension reduction techniques."
223924799|NCT06789016|DRUG|Dexmedetomidine|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
223924800|NCT06789016|DRUG|0.9%NaCl|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
223924801|NCT06795542|PROCEDURE|lumbosacral transforaminal epidural injection at the level of L4-5, L5-S1, or S1 neural foramina|The most widely used injection therapy is epidural injection of steroids, by either the interlaminar route or the caudal route. More contentious are transforaminal injections of steroids. These involve the injection of steroids directly and accurately onto the affected spinal nerve, under radiologic guidance. Meanwhile, transforaminal injection of steroids has been shown to be more effective than interlaminar injection of steroids
224092721|NCT05192343|OTHER|nature sounds|"After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale for pain were applied to both groups by face to face interview during the day giving appointment for HSG. Before the procedure started, glasses will put on and training was given to continue. After the groups were formed, a nature-based sound was played to the women in the nature sounds group before and during the HSG shooting.~Listening to nature-based sound will perform for a total of 15 minutes half an hour before the HSG procedure, and for 15 minutes during the procedure, for a total of 30 minutes."
224281259|NCT05530941|BEHAVIORAL|Online suicide prevention campaign|The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
224281260|NCT01418950|OTHER|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
224281261|NCT01836614|DRUG|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
224281262|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
223531782|NCT05185583|DRUG|Methylphenidate Hydrochloride|Participants will receive twice daily doses of Methylphenidate Hydrochloride four hours apart. There will be three dosage schedules, determined based on three weight ranges (20-30kg; 30-40kg; ≥40kg). For children weighing 20-30kg, the maximum daily dose will be 20mg. For children weighing 30-40kg, the maximum daily dose will be 30mg. For children weighing ≥40kg, the maximum daily dose will be 40mg.
223531783|NCT05185583|DRUG|Placebo|Participants will receive twice daily doses of placebo capsules. Gelatine placebo capsules will contain hypromellose, an inert substance.
223531784|NCT05891158|DRUG|Fazirsiran|Fazirsiran SC injection
223531785|NCT05438940|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
223531786|NCT05438940|BEHAVIORAL|Nutrition Counseling|Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth
223924802|NCT02951052|DRUG|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
223531787|NCT05438940|BEHAVIORAL|Survey|Participants will take a survey at baseline and weeks 4,8,12 \& 16. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
223531788|NCT07139626|OTHER|This is an observational Study.|This is an observational study with no study-assigned interventions.Only observational measurements (blood collection for biomarker analysis) will be performed without modifying existing treatments.
223531789|NCT06929533|DIAGNOSTIC_TEST|Pharmacogenetic Testing|Participants will donate a 1ml (one-fifth of a teaspoon) sample of saliva. DNA extracted from the saliva sample will be used for genotyping. Genotyping results will be translated into an interpretative clinical report using evidence-based software (Sequence2Script) and delivered to the treating physician for use in their clinical decision-making. The report will contain genotyping results, predicted phenotype, and evidence-based drug selection and dosing recommendations relevant to the patient's current and future care.
224281263|NCT00980408|DRUG|Sugar pill|250 mg, one dose, 60 min prior
224281264|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
224281265|NCT00980408|DRUG|Sugar pill|20 mg, one dose, 8 hours prior
223924803|NCT02951052|DRUG|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
223924804|NCT02951052|DRUG|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
223924805|NCT02951052|DRUG|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
223924806|NCT02951052|DRUG|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~* INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~* NNRTI (either the initial or second cART regimen)~* Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)"
223924807|NCT04227600|DRUG|JR-171 (lepunafusp alfa)|IV infusion
223924808|NCT06831266|OTHER|High Intensity Interval Training (HIIT)|"1 minute interval, 1 minute active recovery~5 minutes warm-up - 3 minutes cool-down will be done at 60% of peak heart rate.~Weeks 1-2: Loading at an intensity of 85% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 4x1~Weeks 2-7: Loading at an intensity of 90% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 6x1~Weeks 8-12: Loading at an intensity of 90% of peak heart rate, active recovery at an intensity of 60% of peak heart rate 8x1"
223924809|NCT06831266|OTHER|Moderate Intensity Continuous Training (MICT)|"5 minutes warm-up - 3 minutes cool-down will be done at 60% of peak heart rate.~Weeks 1-2: Loading at 65% of peak heart rate intensity (22 minute)~Weeks 2-7: Loading at 75% of peak heart rate intensity (30 minute)~Weeks 8-12: Loading at 75% of peak heart rate intensity (38 minute)"
223924810|NCT06844201|DRUG|Ephedrine|Received ephedrine the same day of surgery.
223924811|NCT06844201|DRUG|Norepinephrine|Received norepinephrine the same day of surgery.
224092722|NCT05779891|OTHER|Mulligan Traction Straight Leg Raise Technique|The individuals in the Group A will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Mulligan straight leg raise technique . Three repetitions of Mulligan's Traction Straight Leg Raise will be done with 7 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes.
224092723|NCT05779891|OTHER|Slump Stretching|The individuals in the Group B will be receive hot pack at lower back for 10 minutes followed by ultrasound at 1.5w/cm2 for 10 minutes. The treatment will be preceded by Slump Stretching technique. Five repetitions of Slump stretching technique will be done with 30 seconds hold and 5 seconds relax time. The total treatment protocol will be 30 minutes
224092724|NCT03989830|DRUG|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
224092725|NCT03989830|DRUG|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
223924812|NCT06860555|DEVICE|Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)|Imaging with the MHRC and optical coherence tomography (OCT).
223924813|NCT06866301|BEHAVIORAL|Progressive Resistance Exercise|The exercise program will have a duration of 10 weeks. It will be divided in two phases: conditioning phase and training phase. During the conditioning phase (2-3 weeks), participants will learn exercise techniques, work on their interoceptive awareness and perform same exercises at a lower intensity to prepare the muscles for the next phase. In the training phase, the intensity will be moderate starting at approximately 60% of capacity, with a frequency of three days per week and continuous adjustment (progression) based on the participant's improvements. Each session will include a warm-up and cool-down of approximately 10 minutes. The central part of the session will be in the form of a circuit and will include 6 large muscle group exercises using a combination of machine exercises following the PPL (push, pull and legs) model and 3 core strengthening exercises.
223924814|NCT06734520|DRUG|super-transplantation in 3 severe β -thalassemia pediatric patients.|Haplo-identical donors are mobilized with G-CSF and PBMCs that contain CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators. Then the patients will be infused with the PBMC
223924815|NCT06883448|COMBINATION_PRODUCT|Home monitoring care|Patients in the home monitoring group will receive a home spirometer, pulse oximetry meter, and access to a smartphone or tablet app, where they can perform home based measurements weekly and complete PROMs. Furthermore, this app includes disease specific information and allows for direct communication with the hospital via eConsultation. In the home monitoring group, half of the outpatient clinic visits will alternately be replaced by remote visits via video consultation.
223924816|NCT06889922|DEVICE|Transcranial Magnetic Stimulation|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Coil
224092726|NCT06162455|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
224092727|NCT06162455|DRUG|200- ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
224092728|NCT00056706|PROCEDURE|Transient deafferentation|
223531790|NCT07141134|DEVICE|TAPAM|Device: Turn-Assist Alternating Pressure Air Mattress (TAPAM) Automated lateral turning with pressure redistribution.
223924817|NCT06889922|DEVICE|Transcranial Magnetic Stimulation Sham|Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland Dyfed, UK), 70 mm Figure-of-eight Sham Coil
223924818|NCT06748430|OTHER|Grape variety control|Reference grape variety
223924819|NCT06748430|OTHER|Grape variety 1|First grape variety to evaluate
223924820|NCT06748430|OTHER|Grape variety 2|Second grape variety to evaluate
223924821|NCT06046898|DEVICE|non-invasive ventilation with or without resistance|non-invasive ventilation with or without resistance.
223924822|NCT06742645|BEHAVIORAL|Brief Motivational Interviewing|"Brief Motivational Interviewing (BMI), the object of the training and of the present research study, is an interview methodology that includes the intervention on the motivation to change of subjects with risky behaviors for their health, in order to obtain changes in their lifestyle and maintain correct behaviors for health over time (1). The BMI is mainly based on the Transtheoretical Model of Change by Di Clemente CC. and Prochaska JO (2).~In particular, the BMI has been defined by its creators, Miller and Rollnick, as a collaborative style of conversation aimed at strengthening motivation and commitment to change (3), both through defined attitudes, strategies and techniques, and through the exploration of ambivalence or internal fracture, which together with availability and a sense of self-efficacy (4) provides a framework of personal motivation."
223924823|NCT06742645|BEHAVIORAL|Standard of Care (SOC)|Standard of Care (SOC) - The health workers of the Navile Community House carry out the outpatient visit and after having identified the health problems they propose a possible treatment. The users belonging to the control arm will complete the SF-36 questionnaire
223924824|NCT06749938|OTHER|Holistic Intervention|"* Aerobic Exercise Prescription. Each participant will be given instruction on an exercise program to progress to perform a total of 150 minutes/wk of moderate-vigorous aerobic activity (including any yoga practice they choose to do) with two days of strengthening exercises using exercise bands.~* Yoga Protocol and Meditation Exercise. Participants will be asked to practice three 75-min session days per week. The program will focus on developing breath and body awareness/control (pranayama), focused concentration, meditation, muscular strength, muscular endurance, and mobility (flexibility) training that involves the mind body spirit connection.~* Diet Intervention. Coaching for diet modification will be incorporated into the psychosocial support messaging.~* Psychosocial Support. Motivational strategies to enhance exercise compliance comprise of electronic messaging using the BlueJay Mobile-Health, (Livermore, CA). This tele-health HIPPA compliant allows private communication."
223924825|NCT06752044|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
223924826|NCT06752044|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
223924827|NCT06752044|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223924828|NCT06752408|DRUG|Aumolertinib|Aumolertinib will be administered orally at a dose of 110 mg per time, Q.D.
223924829|NCT06752408|DRUG|Osimertinib|Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
223531791|NCT07141134|DEVICE|HSFM|Device: High-Specification Foam Mattress (HSFM) Standard ICU care support surface.
223531792|NCT07141134|OTHER|Manual Turning (with pillows, per protocol)|Nurse-performed scheduled manual turning (target every 2 hours, with pillows).
223531793|NCT07141134|OTHER|Positioning Pillows|Supplemental pillows used to support and maintain patient position.
223924830|NCT06749756|DRUG|vitamin B6+ Vitamin B12 +vitamin C|In addition to the basic treatment of sepsis, intravenous injection of vitamin B6 300mg qd Vitamin B12 0.5mg q6h, vitamin C 50mg/kg q6h for 4 days.
223924831|NCT06749756|DRUG|vitamin B6+ Vitamin B12|In addition to the basic treatment of sepsis, vitamin B6 300mg qd and vitamin B12 0.5mg q6h were given intravenously for 4 days.
223924832|NCT06749756|DRUG|vitamin C|On the basis of the basic treatment of sepsis, intravenous vitamin C 50mg/kg q6h was given for 4 days.
223924833|NCT06749756|DRUG|0.9%Nacl|The same dose of placebo (0.9% sodium chloride solution) was administered on top of the sepsis base treatment for 4 days.
223924834|NCT06752343|DRUG|Photodynamic Therapy|Procedure: Photodynamic Therapy the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power de
223924835|NCT06752343|DRUG|Clobetasol|"The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.025 CLO for 8 days~Other Names:~topical steroid administration"
223924836|NCT06753565|DRUG|Carnitine|"It is a nutritional supplement with trade name  Carnitol® in Egypt."
223531794|NCT04697823|OTHER|use of hyaluronan-enriched transfer medium|In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
223924837|NCT06753565|DRUG|Disease-modifying anti-rheumatic drugs|They are immunosuppressive drugs used to improve disease activity in Rheumatoid Arthritis patients . Conventional DMARDs include methotrexate (Imutrexate®) , leflunomide(Arthfree®) , hydroxychloroquine (plaquenil®) and sulfasalazine(colosalazine®) .
223531795|NCT05760404|PROCEDURE|Surgery for colorectal cancer|Patients undergoing upfront surgery or surgery after neoadjuvant therapy for colorectal cancer with curative intention
223531796|NCT05760404|OTHER|in vitro study|on tissues from colorectal resections
223531797|NCT07119281|PROCEDURE|Group A: Cordless paste with astringent (EXP): Expasyl (Acteon PVT LTD)|Chemical gingival retraction method
223531798|NCT07119281|PROCEDURE|Group B: Cordless paste without astringent (MF): Magic FoamCord (Coltene Whaledent AG)|Chemical gingival retraction method
223531799|NCT07119281|PROCEDURE|Group C: Laser troughing (LT): Diode laser (iLase; Biolase Inc.)|Gingival retraction will be performed by using only laser. Cord will not be used.
223924838|NCT06756061|DRUG|Prednisone + Jakavi(ruxolitinib)|"The experimental group will receive ruxolitinib 10 mg orally twice daily (BID) and prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease. (However, after the 48-week mark, participants in the ruxolitinib treatment group may continue to receive ruxolitinib for an additional maximum of 2 years, based on the investigator's judgment regarding the need for ongoing treatment. The total duration of ruxolitinib administration will not exceed 3 years.)"
224281266|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
223924839|NCT06756061|DRUG|Prednisone|"The control group will receive prednisone (or equivalent) at a dosage of 1 mg/kg/day.~Subjects are orally administered with an investigational medicinal product (IMP) according to their designated treatment group for 48 weeks, and the investigator may adjust the dosage of IMPs based on symptoms of the target disease."
223924840|NCT06754605|BIOLOGICAL|SCTV02|Participants will receive a singe dose of SCTV02 on Day 0.
224281267|NCT00980408|DRUG|Glutamic Acid|250 mg, one dose, 60 minutes prior
224281268|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
224281269|NCT00980408|DRUG|Memantine|20 mg, one dose, 8 hours prior
224281270|NCT04234464|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol single dose
224281271|NCT04234464|COMBINATION_PRODUCT|Placebo metered-dose inhaler|Placebo inhalation aerosol single dose
224281272|NCT01614184|DRUG|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
224281273|NCT03635983|BIOLOGICAL|NKTR-214|Specified dose on specified days
224281274|NCT03635983|BIOLOGICAL|Nivolumab|Specified dose on specified days
224281275|NCT04763278|DEVICE|Point Digit|The Point Digit partial hand prosthetic system consists of 1-4 ratcheting mechanical digits and a mounting bracket
224281276|NCT03430011|BIOLOGICAL|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
224281277|NCT03430011|BIOLOGICAL|JCARH125 + anakinra|Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
224281278|NCT03799848|DRUG|Vadadustat|Oral tablet
224281279|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot A|
224281280|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot B|
224281281|NCT00489099|BIOLOGICAL|V232 Modified Process Hepatitis B Vaccine: Lot C|
224281282|NCT00489099|BIOLOGICAL|V232 Current Process Hepatitis B Vaccine|
224281283|NCT01228227|DRUG|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
224281284|NCT01228227|DRUG|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
224281285|NCT03330860|OTHER|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
224281286|NCT03330860|OTHER|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
224281287|NCT06678750|DEVICE|TKA using computer navigation|TKA using Exactech GPS Newton Knee protocol
223924841|NCT06754605|BIOLOGICAL|Placebo|Participants will receive a singe dose of Placebo on Day 0.
223924842|NCT06752447|DRUG|LNF2007|"LNF2007，9 dose groups:0.2μg/kg、1μg/kg、5μg/kg、20μg/kg、60μg/kg、120μg/kg、240μg/kg、360μg/kg、540μg/kg（0.2\~5μg/kg for accelerated titration, and i3+3 ramp-up starting from 20μg/kg dose group），IV, infusion time 60min±10min, Q4W, until disease progression 、intolerable toxicity or other reasons to stop treatment, the longest administration to 2 years, whichever occurs first."
223924843|NCT06753643|OTHER|The IMPACTFrail programme|The IMPACTFrail programme
224281288|NCT06678750|PROCEDURE|TKA|TKA using manual instrumentation
224281289|NCT05647616|OTHER|Strengthening exercises|Participants in group A will be required to complete 12 sessions in 4 to 6 weeks. Resistance-Bands will be used to do ankle plantar flexion and eversion (3 sets of 10 repetitions). Participants will have to be seated on the floor with the knee extended and instructed to perform the movement at the ankle joint without allowing extraneous movement at hip and knee. The resistance band will be doubled and securely attached to the base of a table. The training resistance will be determined by calculating 70% of the resting length of the resistance band and adding this distance to the resting length of the resistance band. Using this calculated distance, the examiner will place a mark to which the resistance band will be stretched during exercise performance on the floor. Each week a study investigator will track each participant's completion. Participants will be instructed to move through their entire range of motion for the direction of each exercise.
224281290|NCT01358084|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
224281291|NCT01358084|DRUG|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
224281292|NCT01358084|OTHER|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
224281293|NCT04126343|DRUG|Padsevonil|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
223717580|NCT00869349|BEHAVIORAL|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
223717581|NCT00869349|OTHER|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
223717582|NCT02266121|DEVICE|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
223717583|NCT04072302|DRUG|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
223924844|NCT06755346|DRUG|Cannabis plant (THC 20mg)|Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
224281294|NCT04126343|DRUG|Moxifloxacin|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period"
224281295|NCT04126343|DRUG|Placebo|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
224281296|NCT02389699|RADIATION|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
224281297|NCT02389699|RADIATION|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
223717584|NCT04072302|DRUG|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
223717585|NCT03633695|DEVICE|IC-8 IOL Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye for use over the lifetime of the patient. The IC-8 IOL implanted in the second eye for use over the lifetime of the patient.
223924845|NCT06755346|DRUG|Cannabis (0%/ THC / 0% CBD)|THC (0%) / CBD (0%) - Placebo marijuana
223924846|NCT06755346|DRUG|Cannabis plant (THC 40mg)|Cannabis flower - very High THC (\>10%) / Low CBD (\<1%)
224092729|NCT05278390|RADIATION|Thoracic CT scan|Automated quantitative analysis of altered pulmonary volume
224281298|NCT00084799|BIOLOGICAL|monoclonal antibody hu3S193|
224281299|NCT01235442|DRUG|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
224281300|NCT01235442|DRUG|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
224281301|NCT01672047|DRUG|Vitamin D2|25（OH）D level \<12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month， \>116.75nmol/L stopped.
224281302|NCT00736398|PROCEDURE|Spinal fusion|Spinal fusion
224281303|NCT02890225|PROCEDURE|3 days after|in 3 days after RIRS.
224281304|NCT02890225|PROCEDURE|10days after|in10 days after RIRS.
223924847|NCT06753929|DEVICE|wireless wearable thermal anisotropy measurement device|non-invasive device used for assessing CSF shunt flow via thermal anisotropy measurements in a routine outpatient clinic setting
223924848|NCT06755385|OTHER|Pleuropulmonary ultrasound|pleuropulmonary ultrasounds performed at D0, between D2 and D5 during hospitalization and at D-1 on discharge
223924849|NCT06768112|DEVICE|Non-Invasive Vagus Nerve Stimulation|Using non-invasive vagus nerve stimulation at the ear to stimulate the adrenergic and serum hormone pathways, activating the frontal lobe system, sensory-motor nervous system, and cerebellum, to investigate the effects and neural mechanisms of dynamic posture training and learning.
223924850|NCT06768112|BEHAVIORAL|balance training|Participants will be asked to stand on a soft-platform and hit on blaze-pod LED within 60 seconds.
223924851|NCT06768112|BEHAVIORAL|Mini-Mental State Examination|The mini-mental state examination (MMSE) or Folstein test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.
224092730|NCT04268030|OTHER|collection of LFPs|collection of local field potentials (LFPs) at rest and during hand opening and closing
224281305|NCT02890225|PROCEDURE|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
224281306|NCT05352282|PROCEDURE|Serratus Anterior Plane Block|SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.
224281307|NCT05352282|PROCEDURE|Lumbar Intrathecal Fentanyl Injection|Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
224281308|NCT06525857|OTHER|LTOT|Patients with newly prescribed LTOT will be monitored for physiological changes
224281309|NCT03617120|DEVICE|Ergonomic Brace vs hard brace|"Visit 1:~1. Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~2. Pressure measurement of participant wearing their hard brace~Visit 2:~1. Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~2. 3D body scanning (before wearing the Ergonomic Brace)~3. Fitting of the Ergonomic Brace~4. Pressure measurement of participant wearing the Ergonomic Brace (instant)~5. Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~6. 3D body scanning (after wearing the Ergonomic Brace for 2 hours)~7. Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~1. Standing in-brace radiograph of the Ergonomic Brace~2. Doctor consultation"
224281310|NCT03712124|DRUG|CNSA-001|CNSA-001 Powder for Suspension
224281311|NCT03712124|DRUG|Placebo|Placebo Suspension
224281312|NCT01332721|DRUG|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
224281313|NCT04323462|DRUG|Insulin Glargine|Three times bolus insulin with regular or Shorter acting insulin
224281314|NCT04323462|DRUG|Diabetic DM|Previously receiving OADs and/or basal insulin
224281315|NCT04258280|BEHAVIORAL|Education and counseling|Education includes a workbook, counseling includes peer support.
224281316|NCT04258280|BEHAVIORAL|Education|Education includes a workbook.
224092731|NCT00444015|DRUG|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
224092732|NCT02262403|OTHER|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
224092733|NCT02916277|BIOLOGICAL|endocan|to look series Endocan level for 5 days in intubated patients
224092734|NCT00219908|DRUG|Mitoxantrone|
224092735|NCT02610985|DEVICE|3-D laparoscopy|3-D laparoscopy
224092736|NCT02610985|DEVICE|2-D laparoscopy|2-D laparoscopy
224092737|NCT00454233|DRUG|YM543|Oral
224092738|NCT00454233|DRUG|Metformin|Oral
224092739|NCT00454233|DRUG|Placebo|oral
224281317|NCT02941523|DRUG|NOX66|NOX66 administration
224281318|NCT02941523|DRUG|Carboplatin|Carboplatin administration
224281319|NCT03791294|DRUG|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
224281320|NCT00419224|BIOLOGICAL|inactivated split-virus influenza vaccine|
224281321|NCT02118025|PROCEDURE|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
224281322|NCT02118025|PROCEDURE|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
224281323|NCT04499482|OTHER|Food|Soy-fiber containing food
224281324|NCT04618939|BIOLOGICAL|BR-TD-1001|0.5 mL, IM
224281325|NCT04618939|BIOLOGICAL|Td-pur inj|0.5 mL, IM
224281326|NCT00006009|BIOLOGICAL|visilizumab|
224281327|NCT02335957|RADIATION|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
224281328|NCT03110016|DEVICE|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
224281329|NCT03754530|DRUG|Icotinib|orally three times per day
224281330|NCT03754530|RADIATION|WBRT or SRS|\>3 with WBRT;\<=3 with SRS
224281331|NCT00873834|DRUG|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
223531800|NCT07119281|PROCEDURE|Group D: Retraction cord with astringent (RCA; Control group): Knitted cord impregnated with aluminum chloride (Ultrapak + Viscostat Clear; Ultradent Inc.)|Mechanical and chemical gingival retraction method will be used.
224281332|NCT00873834|DRUG|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
223531801|NCT07119762|OTHER|Pilates sections|This intervention combines Pilates with dual-task training over 20 weeks, featuring twice-weekly 60-minute sessions at moderate to vigorous intensity. It is uniquely grounded in methods from the Polestar and PhysicalMind schools and adapted for older adults (≥65 years), utilizing chairs, elastic bands, and minimal equipment. Unlike typical exercise programs, this protocol integrates cognitive tasks within Pilates exercises to simultaneously challenge physical and executive functions. Exercise intensity is individualized using heart rate monitors and the Borg scale. Assessments include trunk strength (Biodex System 4), balance (Biodex SD), and cognitive function (MoCA, Stroop, WAIS-III, TMT), making it one of the few trials to rigorously evaluate physical, cognitive, and dual-task performance outcomes in older adults. This approach is low-cost, scalable, and focused on fall prevention and autonomy maintenance.
223531802|NCT06940141|COMBINATION_PRODUCT|Rademikibart in prefilled syringe|Participants receive 600 mg (4mL) of rademikibart administered subcutaneously.
223531803|NCT06940141|DRUG|Matching placebo in prefilled syringe|Participants receive 4mL of placebo matched to rademikibart administered subcutaneously.
223531804|NCT07143396|BEHAVIORAL|Mind-body mobile application and guided movement|Self-directed: The study team recommends daily use of the mobile app for 6 weeks, with a minimum of 4 times per week, and engagement with the somatic education program at least 3 times per week for 6 weeks. Frequency of app usage and somatic education engagement will be monitored via weekly surveys.
223531805|NCT06942689|DRUG|Perform adductor canal block with liposomal bupivacaine.|"Patient Positioning: Supine with the surgical limb slightly flexed and externally rotated.~Operator Setup: The operator stands on the surgical side, with the ultrasound machine positioned contralaterally. The anterior thigh is sterilized and draped.~Ultrasound Technique: A high-frequency (5-12 MHz) linear ultrasound probe (Sonosite M-Turbo), protected by a 3M Tegaderm dressing, is placed perpendicular to the skin at the midpoint between the femoral trochanter and the superior patellar margin. The probe is maneuvered to visualize the adductor canal structures.~Needle Insertion: After local anesthesia at the insertion site, a 22G 80 mm needle is advanced using an in-plane technique until the tip reaches the triangular hypoechoic area lateral to the femoral artery. Following negative aspiration for blood, 1.33% liposomal bupivacaine is injected around the target site."
224281333|NCT06312423|DRUG|Oligonucleotides, Phosphorothioate|Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
224281334|NCT01526135|DRUG|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
224281335|NCT01526135|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
224281336|NCT01899326|DRUG|Desipramine Hydrochloride|Given PO
223531806|NCT07146243|BEHAVIORAL|Swedish Shoulder Control Programme|An evidence-based warm-up and strengthening routine developed for handball players to reduce the risk of shoulder injuries. The physiotherapy component includes exercises for scapular control, rotator cuff strength, and shoulder mobility. The throwing block is excluded in this trial, as it is designed for the off-season and the programme is implemented during the competitive season. Exercises are performed twice per week before training sessions, last about 15 minutes, and are supervised by two physiotherapists.
223531807|NCT07146243|BEHAVIORAL|Norwegian OSTRC Shoulder Injury Prevention Programme|An evidence-based warm-up and strengthening routine developed for handball players to reduce the risk of shoulder injuries. The programme focuses on exercises for scapular control, rotator cuff strength, and functional shoulder stability. Exercises are performed twice per week before training sessions, last about 15 minutes, and are supervised by two physiotherapists.
223531808|NCT07138586|RADIATION|low level laser therapy group|patients received low level laser therapy using diode laser 980 nm with a low power
223531809|NCT07138586|DRUG|Lidocaine gel group|patients was instructed to use Lidocaine gel (Oracure gel) 4 times daily.
223717586|NCT03633695|DEVICE|Control Group|A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted for lifetime use of the patient.
224281337|NCT01899326|BIOLOGICAL|Filgrastim|Given PO
224281338|NCT01899326|OTHER|Laboratory Biomarker Analysis|Correlative studies
224281339|NCT05595122|DEVICE|EUS-CDS|EUS-CDS with FCSEMS through LAMS
223531810|NCT07138586|DRUG|Chlorhexidine mouthwash group (positive control group).|patients was instructed to use Chlorhexidine mouthwash (Orovex) 4 times daily (control group).
223531811|NCT07146308|OTHER|Lifestyle Management|Participants will undergo dietary and exercise interventions. The dietary intervention includes breakfast, lunch, and dinner, while the exercise intervention consists of both aerobic and resistance training.
224281340|NCT00055718|DIETARY_SUPPLEMENT|silymarin|
224281341|NCT02390310|DEVICE|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
224281342|NCT02390310|DRUG|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
224281343|NCT02390310|DRUG|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
224281344|NCT00332943|PROCEDURE|MR colonography with fecal tagging|
224281345|NCT00373425|DRUG|Erlotinib|150 mg tablet
224281346|NCT00373425|DRUG|Placebo|Placebo tablet
223717587|NCT06446700|OTHER|neck disability index and visual functional questionnaire|participants complete the 2 questionnaire by an online form and paper
223717588|NCT00487773|DRUG|budesonide|budesonide
223924852|NCT06763354|RADIATION|Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection|On the examination bed, the patient was placed in the lying truncated position, the perineum was disinfected with a towel, and a double-lumen urinary catheter was inserted via the perineum.Inject 50ml saline to clean the bladder once, open the drainage bag to drain.1mci SGC8 was dissolved in 50ml physiological saline. The drainage bag was clamped shut and 50ml of developer was injected into the bladder through the catheter, followed by 10ml of gas or saline (all developer in the ureter was injected into the bladder. The catheter was closed for 1 hour, during which time the patient was placed in the flat position, left lateral position, right lateral position, and supine position changing positions every 15 minutes.After 1 hour, the drainage bag was opened, the bladder was emptied with radioactive fluid, and the urine bag was replaced.
223924853|NCT06762145|DRUG|Methylprednisolone (Corticosteroid)|Intravenous Methylprednisolone 1mg/kg/d for 3 days started from the day on TAVR
223924854|NCT06762145|DRUG|Placebo|Placebo for 3 days started from the day on TAVR
223924855|NCT03875001|DRUG|Placebo|For each dose group a placebo group was given matching placebo tablets, participants were randomized within each dose group in a 3:1 ratio (active drug:placebo), tablets taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
223924856|NCT03875001|DRUG|Dose group 1 - 50 mg BI 1358894|2 film-coated tablets of 25 milligram (mg) BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
223924857|NCT03875001|DRUG|Dose group 2 - 100 mg BI 1358894|1 film-coated tablet of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
223924858|NCT03875001|DRUG|Dose group 3 - 200 mg BI 1358894|2 film-coated tablets of 100 milligram BI 1358894 taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
223717589|NCT00487773|DRUG|D3 vitamin|D3 vitamin
223924859|NCT06761287|PROCEDURE|Endoscopic resection|Eligible patients will undergo endoscopic submucosal dissection (ESD) or endoscopic intermuscular dissection (EID) after two to eight weeks of nCRT completion, depending on the used neo-adjuvant regimen. Procedures will be performed using the GIF EZ-1500 endoscope (Olympus America, Center Valley, PA, USA) and an electrosurgical unit (VIO 300 D; Erbe, Germany) to power the electrosurgical knife (1.5-mm DualKnife J, Olympus America). For mucosal incision, Endocut or Drycut mode will be used, while Precise, Swift or Spray Coagulation modes will support submucosal dissection and hemostasis. An initial submucosal lift will be created by Glycéol Gel injection. The ERBE Flushing Pump (Erbe, Germany) will supply further submucosal lift during dissection through foot pedal-controlled, pressurized injections of methylene blue and saline solution delivered via the DualKnife J's ceramic-tipped tubing.
223924860|NCT06761287|BEHAVIORAL|Short interval restaging|"Close follow-up and endoscopic re-evaluation four to eight weeks after the initial evaluation\*.~\*Defined as the first endoscopic evaluation after completion of the neoadjuvant treatment"
224281347|NCT06428513|BEHAVIORAL|HCTP|10 weekly 1-on-1 30-minute tele-sessions via Zoom, delivered by a certified health coach. At baseline assessment including full medical history, medications, lifestyle practices, self-reported health status, psychosocial status, and other relevant information will be taken. At the first session, participants identify their health vision and 3-month health goals. At subsequent meetings, participants review their progress towards reaching the prior week's goals and identify goals for the next week. An individualized action plan will be formulated to help each participant achieve their goals. The action plan will focus on important lifestyle practices (physical activity/exercise training, correct nutrition, weight management, tobacco cessation, and stress management. Patients can request further health care advice felt necessary for their progress, and will be referred to health care professionals in the rehabilitation hospital that provide care for lung transplantation candidates.
224281348|NCT05848401|DEVICE|Biosound Therapy System|Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
224281349|NCT02409940|BIOLOGICAL|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
224281350|NCT04629274|PROCEDURE|Blood sampling|The patients will be asked to provide at least 2 peripheral blood samples of approximately 100 milliliters each time, with a minimum of 14 days interval between these 2 samples.If the results obtained with the 2 initial samples would be of interest to the Sponsor, the patient will be asked to come back for additional samplings with a maximum of 6 additional blood draws
224281351|NCT03073811|DIETARY_SUPPLEMENT|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
223924861|NCT06761287|PROCEDURE|Total mesorectal excision|This technique consists of the surgical complete removal of the rectum, together with the surrounding mesorectum lymphovascular fatty tissue (mesorectum).
223924862|NCT06765694|DRUG|Botulinum toxin injection|first injection was done under ultrasound control in the extensor carpi radialis brevis (ECRB). The second one if necessary was subordinated to clinical examination and focused in one or more of the following: ECRB, extensor digitorum communis, supinator.
223924863|NCT06773143|DRUG|Esketamine at low dose|After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg/kg/h) until the end of the operation.
223924864|NCT06773143|OTHER|Normal Saline (0.9% NaCl)|After the patient's general anesthesia induction is completed, normal saline will be continuously infused until the end of the operation, and the infusion volume is the same as that of the esketamine group.
224281352|NCT03073811|OTHER|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
224281353|NCT02387567|DRUG|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
223717590|NCT00487773|DRUG|montelukast sodium|montelukast sodium
223717591|NCT00487773|DRUG|salbutamol|salbutamol
224281354|NCT02387567|DRUG|Sham Lidocaine|Sham injection, without lidocaine.
223924865|NCT06018701|DEVICE|"A dental device made of zirconia. This is a new invention and does not exist generically. The given generic name of the invention (dental device) is Dantya Nikhan."|Dental device is surgically placed and cemented with PMMA bone cement on edentulous region.
223924866|NCT06746649|PROCEDURE|Combined training|12-week long time specific combined training 2 times a week
223924867|NCT06749587|DEVICE|TEOSYAL RHA® 1|"Product injection in infraorbital hollows~TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin"
223924868|NCT06755593|PROCEDURE|Electroacupuncture|We use acupuncture needles of size 0.30 \* 25 mm and electroacupuncture machine KWD808-1 manufactured by Gujin Greatwall (Frequency 100Hz)
223924869|NCT06755593|DEVICE|Intravenous laser|We use intravenous laser with the iBIO-ILIB He-Ne laser device Mini-630 with 635 nm wavelength manufactured by Vietnam Laser Technology Center.
223924870|NCT05495945|DEVICE|Low-intensity focused ultrasound pulsation (LIFUP)|LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents.
223924871|NCT05495945|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) using Propofol|Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations
223924872|NCT06019728|DRUG|AGALSIDASE BETA (GZ419828)|Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
223924873|NCT06019728|DRUG|Acetaminophen|Tablet or solution; Oral
223924874|NCT06019728|DRUG|Diphenhydramine|Tablet or solution; Oral
223924875|NCT06019728|DRUG|Dexamethasone|Tablet or solution; Oral
223924876|NCT06019728|DRUG|Montelukast|Tablet or chewable tablet or oral granules; Oral
223924877|NCT06019728|DRUG|Loratadine|Tablet or chewable tablet; Oral
224281355|NCT02387567|OTHER|Standard treatment|Standard treatment only, without lidocaine or sham injection.
223531812|NCT06051357|DRUG|HRS-5965 tablets|HRS-5965 tablets for 12 weeks
223531813|NCT02586194|DRUG|ASP015K|Oral
223531814|NCT06952010|BIOLOGICAL|XB628|Intravenous infusion(s)
223924878|NCT06019728|DRUG|Cetirizine|Tablet or oral solution; Oral
223924879|NCT06019728|DRUG|Fexofenadine|Tablet or oral suspension; Oral
223924880|NCT05477589|DRUG|busulfan, cyclophosphamide and melphalan, BuCyMel|a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
223924881|NCT05477589|DRUG|clofarabine, fludarabine and busulfan, CloFluBu|combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
223924882|NCT05309577|BEHAVIORAL|Behavioral Self-Monitoring + Motivational Interviewing|Participants (n=20) will wear a iWatch to continuously measure their objective sleep-wake activity. The iWatch data sync to the new myRhythmWatch app, where participants will monitor their behavioral rhythm. Participants will also interact with a 'health coach' about their recorded behaviors weekly. This health coach will use motivational interviewing to enhance older adult caregivers' confidence and intrinsic motivation to engage in regular self-care.
223924883|NCT06769113|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924884|NCT06769113|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924885|NCT06769113|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924886|NCT06759454|DRUG|Glutaraldehyde-Based Desensetizing Agent|A glutaraldehyde-based desensitizing agent applied to the cervical area of affected teeth using a micro-brush, left undisturbed for 30 seconds, and air-dried. Both interventions aim to reduce pain associated with dentinal hypersensitivity by either occluding dentinal tubules or reducing nerve excitability
223924887|NCT06759454|DEVICE|Low Level Laser Therapy|Low-level laser therapy (LLLT) using a diode laser set to a low power level (e.g., 100 mW, continuous wave mode). Each affected tooth will be treated for three minutes, targeting apical, cervical, and middle points
223924888|NCT06769724|PROCEDURE|Anterior cruciate ligament reconstruction surgery|Anterior cruciate ligament reconstruction surgery with semitendinosus tendon autograft
223924889|NCT06769724|PROCEDURE|Anterior cruciate ligament reconstruction surgery|Anterior cruciate ligament reconstruction surgery with peroneus longus autograft
223924890|NCT06892613|BEHAVIORAL|Emotion-Focused Couples Therapy (EFCT)|EFCT is a structured approach to couples therapy that focuses on helping partners understand and express their emotions, address attachment insecurities, and strengthen their emotional connection.
223924891|NCT06892613|BEHAVIORAL|Behavioral Couples Therapy (BCT)|BCT is a form of therapy that aims to improve relationship satisfaction through behavioral change, communication training, and problem-solving techniques.
223924892|NCT06736912|DRUG|IN-114199 2.5mg or placebo|IN-114199 2.5mg or placebo (1 Tablet, QD)
223924893|NCT06736912|DRUG|IN-114199 10mg or placebo|IN-114199 10mg or placebo (1 Tablet, QD)
223924894|NCT06736912|DRUG|IN-114199 20mg or placebo|IN-114199 10mg or placebo (2 Tablets, QD)
223924895|NCT06736912|DRUG|IN-114199 40mg or placebo|IN-114199 10mg or placebo (4 Tablets, QD)
223924896|NCT06736912|DRUG|IN-114199 5mg or placebo|IN-114199 2.5mg or placebo (2 Tablets, QD)
223924897|NCT06739473|BEHAVIORAL|Movies|Participants will watch eight short movie clips, and the changes different emotions evoked by the clips will be studied using H2\[15O\]O PET/CT.
223924898|NCT06739473|BEHAVIORAL|Cold|Participants will be studied with H2\[15O\]O PET/CT while one of their legs will be exposed to cold to study the effects of cold stimulus on whole-body blood flow.
223924899|NCT06739473|DRUG|Hyperinsulinemic euglycemic clamp|Participants will be administered intravenous fast acting insulin (NovoRapid, Novo Nordisk, 1 mU/m2 body surface area/min) together with 20 % glucose to maintain normal glucose values (5.0 mmol/L) to study the effects of insulin on whole body blood flow with H2\[15O\]O PET/CT, and to assess tissue insulin-stimulated glucose uptake with \[18F\]FDG PET/CT.
223924900|NCT06739473|RADIATION|H2[15O]O PET/CT|H2\[15O\]O PET/CT, with a dose of 25-700 MB/bolus repeated 2-8 times per scan.
224281356|NCT00004344|DRUG|leuprolide|
223924901|NCT06739473|RADIATION|[18F]FDG PET/CT|Whole-body \[18F\]FDG PET/CT scan to study tissue glucose uptake, dose 100 MBq
223924902|NCT06739473|DRUG|CEUS or Contrast enhanced Ultrasound|Contrast-enhanced ultrasound of left forearm muscles is performed during fasting and after 30-40 minutes of hyperinsulinemia
223924903|NCT06739538|DIAGNOSTIC_TEST|Bobath exercises|Bobath concept, are therapeutic techniques designed to improve motor control and function in individuals with neurological conditions, particularly those with cerebral palsy. These exercises focus on facilitating normal movement patterns, enhancing postural stability, and reducing muscle spasticity. The approach emphasizes individualized treatment, utilizing hands-on techniques to promote movement awareness and encourage the development of functional skills. By reinforcing weak movements and inhibiting overactive ones, Bobath exercises aim to enhance overall motor abilities and improve the quality of life for affected individuals.
224092740|NCT01334073|DRUG|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
224092741|NCT00012610|PROCEDURE|Telepsychiatry|
224092742|NCT01415388|DIETARY_SUPPLEMENT|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
224092743|NCT03547141|DRUG|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
224092744|NCT03547141|DRUG|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
224092745|NCT05811065|DEVICE|OPTIVF dosage|Opt-IVF dosage
224092746|NCT05811065|DEVICE|traditional drug treament|Traditional drug treatment
224092747|NCT00762346|DRUG|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
224092748|NCT01956981|DRUG|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
224092749|NCT01956981|DRUG|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
224281357|NCT00004344|DRUG|testosterone|
224281358|NCT00551616|DRUG|CDB-2914|Single dose
224281359|NCT00551616|DRUG|Levonorgestrel|Single dose
224281360|NCT02270216|PROCEDURE|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
224281361|NCT02270216|PROCEDURE|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7\*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
224281362|NCT04005963|DIAGNOSTIC_TEST|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
224281363|NCT04282655|OTHER|Treatment Guardian Milk Warmer (Medela TM)|Infants were randomized to receive prepared syringes of breast milk via the continuous milk warmer (treatment arm)
224281364|NCT04282655|OTHER|Control|Standard warming procedure of breast milk in syringe prior to feeding.
224281365|NCT04825002|DIAGNOSTIC_TEST|Urinary multimarker sensor|We will develop a urinary multimarker sensor, able to measure trace amounts of biomarkers from naturally voided urine.
224281366|NCT01944384|DRUG|aldactone|aldactone 25 mg for 6 months
224281367|NCT00578838|OTHER|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
224281368|NCT00578838|OTHER|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
224281369|NCT03993327|BIOLOGICAL|Iodine I 124 Monoclonal Antibody M5A|Given IV
224281370|NCT03993327|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224281371|NCT02630290|DRUG|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
224281372|NCT02630290|DRUG|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
224281373|NCT05220891|OTHER|Paracentesis|Paracentesis from ascitic patient
224281374|NCT00037531|DRUG|Sirolimus (RAPAMUNE)|
224281375|NCT03134430|OTHER|Normal saline|Injection of Normal saline around peripheral nerve
224281376|NCT03134430|OTHER|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
223924904|NCT06739538|COMBINATION_PRODUCT|Gasotransmitters|such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H₂S), are small gaseous signaling molecules that play key roles in various physiological functions, including the regulation of muscle tone and neuroinflammation. In the context of spastic diplegic cerebral palsy (CP), gasotransmitters may help reduce spasticity and pain. Gasotransmitters help reduce spasticity and pain in children with spastic diplegic cerebral palsy through multiple mechanisms: Muscle relaxation and improved blood flow reduce muscle tightness, Anti-inflammatory and neuroprotective properties help minimize the damage that exacerbates spasticity.They also modulate pain pathways, both centrally and peripherally, reducing pain perception.
223924905|NCT06739850|COMBINATION_PRODUCT|Identification of Risk Phenotypes of Sarcopenia|Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.
223924906|NCT06892535|DRUG|Albumin infusion, 2g/L of ascitic fluid aspiration.|Albumin infusion lower than the standard dose, either 2g/L or 4g/L of ascitic fluid aspiration is termed as low dose.
223924907|NCT06891963|OTHER|Acupuncture-like TENS|"The first experimental group will receive 20-minute sessions of TENS, where participants adjust the amplitude to achieve strong muscle twitching beneath the electrodes at an intensity below the pain threshold. Acupuncture-like TENS uses high-frequency pulsed currents at two trains per second with an internal pulse frequency of 100 pps. The pulse pattern is set to burst, with an asymmetrical biphasic waveform and a pulse duration of 200 µs. Minor fluctuations in pulse rate between 100 and 104 pps were noted using a cathode ray oscilloscope before the experiment."
223924908|NCT06891963|OTHER|Dry needling|The second experimental group will receive 20-minute sessions of dry needling. Patients will be positioned in a prone, relaxed position, and the overlying skin will be cleaned with alcohol. The muscle will be palpated to locate the trigger point (MTrP), with the muscle grasped between the thumb, index, and middle fingers. A solid filiform needle within a guide tube will be inserted into the MTrP using a tapping motion at an oblique angle. The upper trapezius muscle will be palpated for trigger points, with needle insertion depths ranging from 10-15mm. After obtaining a local twitch response, the needle will be moved vertically 3-5mm until no more twitch responses occur. This group will also receive 20 minutes of conventional physical therapy.
224092750|NCT04610255|OTHER|Assigned Interventions|"* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
223924909|NCT06891963|OTHER|Conventional treatment|All participants in the three groups will receive conventional treatment in the form of hot pack treatment followed by active range of movement (AROM) exercises. A hot pack will be placed on the patients cervical, paraspinal, and upper thoracic areas (including the upper trapezius muscle with aMTrP) for 20 minutes. This will be followed by AROM exercise for cervical spine joints. Participants were asked to actively flex the neck so that the head dropped toward the contralateral trapezius muscles. Patients then rotated the head toward ipsilateral side. This exercise will be repeated five times.
223924910|NCT06759909|DRUG|Dapagliflozin (DAPA)|"We will record all baseline characteristics (Age, sex, BMI, HR and BP), AF type, EHRA class, previous use of ADD (B blockers, Class I, III AAD), previous CV, prior cerebrovascular stroke and Co-morbidities (HTN, DM, IHD, HF, Renal impairment, peripheral arterial disease, OSAS). CHADS2Vasc score and HAS-BLEED score will be calculated. Trans-thoracic echocardiograms will be performed within 4 weeks before the rhythm control attempts to determine LA diameter and volumes and left ventricular hypertrophy and functions (EF and E/'e).~After enrollment, the patients will be treated with dapagliflozin (10 mg/d) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period."
224092751|NCT04610255|OTHER|Dynamic myofascial release|"DMFR involves a manual application of low amplitude, long duration stretch to the fascia and muscle. Participants were instructed to relax as much as possible, and the therapist proceeded to smoothly move the joints in a diagonal or horizontal direction at a slow rate within the ROM. The therapist repeatedly pushed, pulled, or shook the joint area about three to five times for about 3 seconds with slight motion at the end of ROM.~Conventional therapy will includes~* Hot pack for 10 minutes~* TENS for 10 minutes~* Trigger point release if any found.~* Myofascial release~* Home plan for stretching exercises will be prescribed to the patient. Receive two weeks intervention plan, three sessions per week."
224092752|NCT04624425|OTHER|Segmental breathing exercises|Segmental breathing exercises along with the Conventional Treatment of buteyko breathing exercises for two weeks of duration. Segmental breathing exercises include 18-20 breaths in one session (6 breaths/min) with rest interval after every 6 breaths.
224092753|NCT04624425|OTHER|Buteyko breathing exercises|Buteyko exercises for two weeks of duration. Treatment session will be last for 10-15minutes.
224092754|NCT03237468|OTHER|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
224092755|NCT01507376|DRUG|recombinant hCG|recombinant hCG(250 µg Ovitrell)
224281377|NCT02434263|DEVICE|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
224281378|NCT02589886|OTHER|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
224281379|NCT06595004|DRUG|HCP1004|Test Drug
224281380|NCT06595004|DRUG|RLD2401|Reference drug
224092756|NCT01507376|DRUG|recombinant hCG|recombinant hCG(500 µg Ovitrell)
224092757|NCT01507376|DRUG|urinary hCG|10,000 IU urinary hCG
224281381|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 1 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
224281382|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 2 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
223924911|NCT06761950|DEVICE|Low Level laser therapy|The patient received low-level laser therapy three times per week for four weeks, with immobilization maintained. The Mustang 2000 Laser device was used with an infrared laser probe to accelerate tendon healing. The device's specifications include peak power output of 15W, power density of 15W/cm2, wave length of 890nm, pulse frequency of 100Hz, spherical size of 0.002cm2, pulse duration of 130 ns, exposure duration of 60 sec, and energy density of 5.85J/cm2.
223924912|NCT06761950|DEVICE|Placebo low level laser therapy|Same as in the study group except turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect 3 sessions per week for 4 weeks.
224092758|NCT04409938|OTHER|Progressive Muscle Relaxation|PMR participants rested for ten minutes between the sessions and then practiced PMR for 15 minutes. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
224092759|NCT04409938|OTHER|Nature Sounds|PMR+NS participants practiced PMR accompanied by nature sounds. PMR consisted of taking a deep breath five times and then clenching fists, raising the shoulders, bringing the forearms towards the body, stretching the triceps muscle, and tensing and relaxing the forehead, eye, chin, neck, chest, abdomen, back, hips, thigh, and feet muscles. The investigators made a video of exercises in a certain order and uploaded it to the television in the lab prior to the intervention. The investigators turned on the video during the intervention and asked the participants to follow the instructions for PMR exercises.
224092760|NCT00889044|DRUG|clopidogrel by chewing|600 mg clopidogrel by chewing
224092761|NCT00889044|DRUG|Placebo|Placebo p.o
223924913|NCT06761950|OTHER|medical treatment|the patients received their drugs from their treating physicians
224092762|NCT00766805|DRUG|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
224092763|NCT00766805|OTHER|EVL alone|
224092764|NCT05295537|PROCEDURE|PERCUTANEOUS LIVER BIOPSY (PLB)|Percutaneous liver biopsy using a 16 gauge (G) Trucut needle.
224092765|NCT05295537|PROCEDURE|ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS-LB)|EUS-guided liver biopsy using a 19 gauge (G) Franseen core EUS needle
224281383|NCT05410821|DRUG|177Lu-DOTA-EB-FAPI 3 radionuclide therapy|radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
223531815|NCT07148336|OTHER|Symptom-based scoring system|The patients will be asked to complete the self-evaluation of symptoms and signs of neuropathy using a Neuropathy Tracker that questions symptoms quality, severity and distribution and guide the user through a systematic evaluation of pin-prick from a needle and vibration from the mobile on successive levels from the toes to the knee on both legs. Finally, the extension force or both great toes will be self-assessed by the participant. The self-examination is based on the structure of the Utah Early Neuropathy Score.
223924914|NCT06761950|OTHER|physical therapy program|patients received the traditional program after flexor tendon repair involving isometric exercise, stretching and mobilizations
223924915|NCT06761274|OTHER|peripheral blood sampling|"It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:~* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).~* newly diagnosed (stage II b, III or IV, Ann Arbor Classification)."
223924916|NCT06765265|DRUG|Rosuvastatin 20 mg/day|Rosuvastatin 20 mg / Day for 24 weeks
223924917|NCT06765265|DRUG|Atorvastatin 40 mg|Atorvastatin 40mg / Day for 24 weeks
224092766|NCT00481065|BIOLOGICAL|MF59-eH5N1|
224092767|NCT00481065|BIOLOGICAL|eTIV_a|
224092768|NCT00481065|BIOLOGICAL|MF59-eH5N1 + eTIV_a|
224092769|NCT02058901|DRUG|Sunitinib|
224092770|NCT00312455|DRUG|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
224092771|NCT00312455|DRUG|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
224092772|NCT00312455|DRUG|Placebo|5 capsules/day
224092773|NCT00372918|PROCEDURE|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
224092774|NCT05786950|DRUG|compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)|inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
224092775|NCT00243997|BEHAVIORAL|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
224092776|NCT03633500|OTHER|Sterile water|Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
224281384|NCT04199416|DEVICE|mRehab app|The mRehab app will be an interactive system with a user-friendly graphical user interface to provide multiple motivational functions that engage individuals in their prescribed home exercises. The app will contain video-based lower limb strengthening and aerobic exercise materials, health information, and motivational functions to increase their access to rehabilitation and care resources to augment their self-management ability.
224281385|NCT04199416|DEVICE|Sham app|The sham app will only contain educational components and text-based exercise recommendations.
224281386|NCT02079233|DRUG|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
223531816|NCT06947291|DRUG|Glumetinib Tablets|glumetinib once daily once daily under fasting conditions in each 21-day treatment cycle.
223924918|NCT06766682|BEHAVIORAL|The Skill Development Program for Emotion Regulation|The Skill Development Program for Emotion Regulation to be carried out with the intervention group was planned as 6 sessions. The aim of this study was to investigate The Skill Development Program for Emotion Regulation Program on oncology nurses' emotion regulation difficulties, emotion regulation skills, experiential avoidance, and compassion fatigue.
223924919|NCT06769737|DRUG|Interventional group#1|"The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) + 3 mcg of Dexmedetomidine HCL, Demexa®, 4mcg/ml (0.75 ml) total volume = 3.55 ml.~The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision. The Bromage score is a clinical scale used to determine motor block during regional anesthesia by evaluating lower limb movement: Grade 0: Full movement of hips, knees, and ankles (no block). Grade 1: Unable to lift the leg but can move knees and ankles (partial block). Grade 2: Unable to bend the knee but can move ankles (near-complete block). Grade 3: No movement in hips, knees, or ankles (complete block). Dermatomal coverage will be assessed simultaneously till it reaches the L1-L2 level. Also, The Ramsay Sedation Scale (RSS) will be used to evaluate the sedation depth, if any."
224092777|NCT03633500|BIOLOGICAL|Breastmilk|Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
224092778|NCT01639326|DRUG|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 \* 1 / \* 1 and 260 mg / m² in patients UGT1A1 \* 1 / \* 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
224092779|NCT01639326|DRUG|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
224092780|NCT01926626|DRUG|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
224092781|NCT01926626|DRUG|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
224281387|NCT00151255|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
223717592|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
224281388|NCT00151255|DRUG|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
224281389|NCT00151255|DRUG|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
224281390|NCT00151255|DRUG|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
224281391|NCT00151255|DRUG|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
224281392|NCT01932190|PROCEDURE|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
224281393|NCT01932190|PROCEDURE|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
224281394|NCT02129517|OTHER|IMPACT intervention|Tailored, web-based educational short video clips
224281395|NCT02129517|OTHER|Online education materials|Online NCI-based educational materials
224281396|NCT02129517|OTHER|survey administration|Ancillary studies
224281397|NCT02510950|BIOLOGICAL|Personalized peptide vaccine|
224281398|NCT02510950|DRUG|Poly-ICLC|
224281399|NCT02510950|DRUG|Temozolomide|
224281400|NCT00876720|DEVICE|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
224281401|NCT00876720|DEVICE|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
224281402|NCT01482117|DRUG|Clopidogrel|single oral administration of 300mg of clopidogrel
224281403|NCT01482117|DRUG|Cilostazol|single oral administration of 100mg cilostazol
224281404|NCT01482117|DRUG|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
224281405|NCT05852873|DRUG|Nirmatrelvir/ritonavir|Participants in the intervention arm will receive a standard 5-day treatment course Paxlovid (nirmatrelvir plus ritonavir) in addition to standard of care.
224281406|NCT05852873|DRUG|Placebo|Participants in the control arm will receive a 5-day course of placebo tablets, with the same appearance and quantity, in addition to standard of care.
224281407|NCT05736796|OTHER|Lumber strengthening exercises|Complex Training program to Achieve the normal postural. Lumber Extension Excersie will be done to prevent the lumber straighten.
224281408|NCT05736796|OTHER|General cervical Exercise|Students of this group will perform general exercises of the cervical region to strengthen the Muscles.
224281409|NCT02687958|DRUG|Everolimus|Maintenance therapy
224281410|NCT05842720|PROCEDURE|un-sedated colonoscopies|un-sedated colonoscopies in high risk patients with ASA\>=3
224281411|NCT03942211|DRUG|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
223924920|NCT06769737|DRUG|Interventional group#2|"The intrathecal mixture of spinal anesthesia: 12 mg of isobaric Bupivacaine 0.5%, Bucaine®, (2.4 ml) + 20 mcg of Fentanyl, Martindale pharma Fentanyl®, 50mcg/ml (0.4ml) total volume = 2.8 ml.~The intravascular mixture consists of 0.5 mcg/kg of Dexmedetomidine HCL, Demexa®, and a maximum of 30 mcg diluted to 4 mcg/ml. According to body weight, the total volume is 7.5 ml or less and given using a syringe pump over 30 minutes. The anesthesiologist will start the infusion once the patient is positioned supine post-spinal anesthesia and has stable hemodynamics. The Bromage score will be assessed by the anesthesiologist every 5 minutes after positioning the patient supine until the first incision reaches grade 3: No movement in hips, knees, or ankles (complete block). The anesthesiologist will assess dermatomal coverage until it reaches the L1-L2 and calculate the Ramsay Sedation Scale (RSS) of the depth of sedation aiming for level 2: Patient is cooperative, oriented, and calm"
223924921|NCT06767371|PROCEDURE|Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.|Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.
224092782|NCT05203250|RADIATION|Heavy-ion therapy (hadrontherapy)|Only data available from routine clinical practice at the National Center for Oncological Hadrontherapy (CNAO), based Pavia, will be collected. Intervention is not assigned.
224092783|NCT03809897|DRUG|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
224092784|NCT03809897|DRUG|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
224092785|NCT06385704|PROCEDURE|DMR Procedure|Endoscopic procedure
224092786|NCT03146364|DEVICE|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
224092787|NCT04923594|DRUG|mazindol extended release|Dosed orally, once daily for up to 3 weeks
224092788|NCT04923594|DRUG|Placebo|Dosed orally, once daily for up to 4 weeks.
224092789|NCT04743050|DRUG|Fatty Acids, Unsaturated|All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
224092790|NCT04743050|DIAGNOSTIC_TEST|Diagnostic Tests|All participants will have laboratory tests marking: CRP, fasting glucose, lipid profile, total blood count, and additional tests, which will include blood pressure measurements and measurements of body mass and composition on a specialized body composition analyzer (InBody 270). All the mentioned tests will be performed at the time of joining the research program, after 3 months (in the middle of the research program) and after 6 months (at the end of the research program).
224092791|NCT01393093|PROCEDURE|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
224092792|NCT00448292|DRUG|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
224092793|NCT00448292|DRUG|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
224092794|NCT06295445|PROCEDURE|care cardio-pulmonary ultrasound|Evaluation of the heart and lung conditions in shocked patients using focused cardio-pulmonary ultrasound for treatment guidance and their implication on the patient's outcome
224092795|NCT06295445|OTHER|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management|treatment without any use of point of care cardio-pulmonary ultrasound scans for guidance of the management
224092796|NCT02254343|DEVICE|proximal robot-assisted therapy|
224092797|NCT02254343|DEVICE|distal robot-assisted therapy|
224092798|NCT02254343|BEHAVIORAL|individualized intensive therapy|
224092799|NCT00434200|PROCEDURE|long-term intensive exercise|
224092800|NCT01500837|DRUG|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
224092801|NCT01500837|DRUG|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
224092802|NCT00216567|DRUG|topamax|
224092803|NCT05335538|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
224092804|NCT00004486|DRUG|fluoxetine|
224092805|NCT04969055|OTHER|Not|Not
224092806|NCT02803333|OTHER|No Intervention|No intervention
224281412|NCT03942211|DRUG|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
224281413|NCT03977441|DRUG|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
224092807|NCT01348737|DRUG|AZD3839|Single Oral Dose
224092808|NCT01348737|DRUG|AZD3839 Placebo|Single Oral Dose
224092809|NCT02382133|DEVICE|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
224092810|NCT00655928|DRUG|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
224092811|NCT00655928|DRUG|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
224092812|NCT01572090|BEHAVIORAL|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian."
224281414|NCT01673841|PROCEDURE|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
224281415|NCT05389241|OTHER|Method A|The subjects will perform tasks on the liver phantom (identification of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method A means that the trainings set up is performed first with Method A an after that with Method B.
223924922|NCT06767371|PROCEDURE|Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.|Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.
223924923|NCT06767371|PROCEDURE|Teeth with irreversible pulpitis|Teeth with irreversible pulpitis to be treated with conventional root canal treatment
224092813|NCT01572090|OTHER|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
224092814|NCT01572090|PROCEDURE|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
224092815|NCT01572090|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
224092816|NCT02125214|DEVICE|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
224092817|NCT04906707|DEVICE|EaseVRx|EaseVRx is a commercially available pain management program. It is a multi-modal, skills-based, 8-week, VR, mind-body approach to daily management of chronic pain that is designed for home use to be worn over the eyes. The program contains five types of modules that are as follows: Interoception, Education, 360-degree relaxation videos, Games, and Dynamic breathing. All program content is mapped to a therapeutically designed curriculum with weekly themes. The following core themes are infused into the curriculum: Acceptance, Attention shifting, Awareness, Rehabilitation, Self-compassion, Healthy Movement, Deep relaxation, Visualization, Knowledge of pain, Distraction, and Immersive enjoyment.
224092818|NCT04906707|BEHAVIORAL|Audio-only version of EaseVRx|Participants in the control group will be asked to use the audio-only version of EaseVRx, which excludes references to visual content, to complete 7 sessions weekly. They will receive an electronic link to the recordings on SoundCloud (a music streaming platform) where they can choose to stream or download the audio recordings on their smartphone, laptop, or desktop computer.
224092819|NCT00841451|DRUG|Lovaza (Fish Oils)|Double blinded placebo controlled
224092820|NCT05834738|DRUG|Atrasentan|Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo
224092821|NCT05834738|DRUG|Atrasentan|Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet
223924924|NCT06769321|DEVICE|Automatic Thermo-mechanical Massage Bed|The MASTER V6 (Master series, CGM MB-1701, CERAGEM Co. Ltd., Cheonan, Korea) used in this study is a commercially available automated thermo-mechanical therapy device that combines mechanical spinal stimulation with far-infrared (FIR) heat treatment.
223924925|NCT06768788|BEHAVIORAL|Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 1|Intervention: need support, two-month face-to-face and web-based need-supportive intervention program for PE teachers.
223924926|NCT06768788|BEHAVIORAL|Face-to-face and web-based need-supportive intervention program based on the main tenets of SDT in the field of PE 2|Intervention: autonomy or competence or relatedness support, one-month face-to-face and web-based need-supportive intervention program for PE teachers.
224092822|NCT05834738|DRUG|Placebo|Placebo
224092823|NCT05019937|BEHAVIORAL|Educational meeting|The investigators will hold a full-day educational meeting. The meeting will include educating 4-5 representatives of each school, and school-district representatives about the guideline and the advantages of adhering to the guideline.
223531817|NCT06947291|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous injection in each 21-day treatment cycle.
223924927|NCT06831981|OTHER|Hyperthermia|Additional hyperthermia to radiochemotherapy regime in Arm 1 and radiochemotherapy without additional hyperthermia in Arm 2.
223924928|NCT06831981|RADIATION|Radiotherapy|Radiotherapy of the pelvis
224092824|NCT05019937|BEHAVIORAL|Implementation team|The school-principal forms an implementation team that is responsible for implementing the guideline within their school. The team members (n=4-5) reflect on the implementation progress, make, and refine plans according to Plan-Do-Study-Act, share lessons learned and support each other.
224281416|NCT05389241|OTHER|Method B|The subjects will perform tasks on the liver phantom (identifikation of target lesions). They will perform the tasks with Method A (2D-CT) or Method B (2D-CT + 3D augmented reality model). the intervention type Method B means that the trainings set up is performed first with Method B an after that with Method A.
223924929|NCT06831981|DRUG|Chemotherapy with 5-fluorouracil|Chemotherapy with 5-flurouracil is given in parallel to radiotherapy
223924930|NCT06831981|DRUG|Consolidation chemotherapy with FOLFOX|Consolidation chemotherapy with 5-fluorouracil and oxaliplatin
223924931|NCT06758115|PROCEDURE|Tuina (Massage) Therapy|"Operation Method:~Correct abnormal joint alignment - Manipulatively realign the vertebral segments and pelvis affected by scoliosis.~Correct abnormal muscle function - After realigning the vertebral bodies to their normal position, stretch the corresponding tight and shortened muscles while strengthening the muscles that need to be lengthened.~Restore joint stability - After adjusting the vertebrae and muscles, instruct the patient to hold the corrected posture for at least 10 seconds, then relax for 10 seconds. Repeat this cycle 3-5 times.~Restore sensorimotor control - Provide appropriate movement disturbances to patients maintaining the corrected posture to enhance proprioception and motor memory in the corresponding muscles.~The total duration of the manipulation is 20-25 minutes. Treatment is performed twice a week for a total of 12 weeks."
223924932|NCT06757556|OTHER|Non-starchy vegetables will be provided to the participants as an intervention.|Intervention will consist of provision of vegetables (based on WHO criteria of 2-3 servings) to overweight and obese adults fo weight loss purpose.
224281417|NCT05772286|BIOLOGICAL|763SIP8/MPLA-5 vaccine|763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48.
224281418|NCT05093686|BEHAVIORAL|RUBIES|RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).
223924933|NCT06756711|DIETARY_SUPPLEMENT|A combination of apitherapy and plant extracts|This combination contains the active comparator
223924934|NCT06756711|COMBINATION_PRODUCT|Placebo Combination|A combination containing inert substances - placebo
223924935|NCT06758193|OTHER|No intervention was applied in this study.|No intervention was applied in this study.
223924936|NCT06755749|BEHAVIORAL|Family Planning Education|"Stage 1 (Day 1, 10-15 min): The education content for Session 1 in the FP Education Booklet prepared by the researchers was provided to the participants using the face-to-face interview method. After making an appointment for Stage 2 (Day 3) to be carried out at the FHC, the first stage of the data collection process was complete.~Stage 2 (Day 3, 10-15 min): The education content for Session 2 in the FP Education Booklet was provided to the participants who arrived at the FHC on their predetermined appointment days using the face-to-face interview method. After making an appointment for Stage 3 (Day 7) to be carried out at the FHC, the second stage of the data collection process was complete.~Stage 3 (Day 7, 1-5 min): The data collection forms were administered again to the participants who arrived at the FHC on their appointment days assigned at Stage 2, and the data collection process was complete."
223924937|NCT06761040|OTHER|Intrinsic foot muscle training|"Technique In intrinsic foot muscle training, there are following exercises:~1. Toe spread out~2. First toe extension~3. Second to fifth toe extension The exercise would be performed in following positions 1. Sitting position for the first 2 weeks (3sec hold; 4 sets ×15 reps) 2. Standing position on the 3rd and 4th weeks (8sec hold; 4 sets × 8 reps) 3. One-leg standing position during the 5th and 6th week (20 sec hold;4 sets ×3 reps)"
224092825|NCT05019937|BEHAVIORAL|Workshops|"The investigators will hold 5 workshops. Workshops will include providing in-depth knowledge and skills on the guideline recommendations. During each workshop one of the guideline recommendations will be presented and discussed.~Moreover, the concept of Plan-Do-Study-Act will be introduced and how it can be used to implement the guideline recommendation(s). During each workshop, the implementation team will share with the group their developed PLAN and barriers and facilitators that have influenced the execution of the PLAN."
224092826|NCT05019937|BEHAVIORAL|Plan-Do-Study-Act improvement cycles|The implementation team will implement the guideline in a cyclical manner by using Plan-Do-Study-Act. First a Plan is specified during the workshop by using SMART-goals, next the change is carried out between workshops (Do), the implementation team analyses whether it went well and what needs to be improved (Study), changes are made (Act) and finally the next cycle is planned.
224281419|NCT05093686|BEHAVIORAL|Usual Care Training|Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
224281420|NCT01886534|OTHER|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
223924938|NCT06761040|OTHER|hip abductor muscle training with intrinsic foot muscle training|"Hip abductor muscle training consists of the following two exercise~1. Resisted hip abduction 90° (2 sec hold; 3 sets × 10 reps)~2. Resisted hip abduction 45° (2 sec hold; 3 sets × 10 reps)~Standard treatment~* Shoe insoles (eight hours a day, medial longitudinal arch support,raised for by about 1.8 cm)~* Stretching of Hamstrings and Calf muscles (3 times for 30 seconds hold) Number of Sessions Per Week : 3 times Per week for 6 weeks"
223924939|NCT06758531|DIETARY_SUPPLEMENT|Instant coffee given as a drink|Commercially available instant coffee (3.6 g) will be provided in the form of a drink prepared with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
223924940|NCT06758531|DIETARY_SUPPLEMENT|Coffee given in a tablet form|Commercially available instant coffee (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
223924941|NCT06758531|DIETARY_SUPPLEMENT|Control (placebo)|A caffeine and coffee free control (3.6 g) will be provided as 4 tablets given with 400 ml of water. A standard breakfast consisting of cereal with milk will be provided at 60 mins after the intervention. A standard lunch (cheese sandwiches, potato crisps and shortbread biscuits) will be given at 300 after coffee intake.
223924942|NCT06771856|BEHAVIORAL|Standard Care CBTi|Standard Care CBTi will take 10 weeks, during which the participant will receive 5 online les-sons and 3 online face-to-face talks with the therapist. The construction of the online intervention was based on self-help materials, research of the literature, and patient interviews. It consists of 5 online les-sons and incorporates elements commonly used in face-to-face CBTi. The 5 online lessons, one introduced every second week, cover the following topics: Education, stimulus control, sleep restriction, relaxation, cognitions. The intervention is supported by online coaching, with feedback aimed at reviewing exercis-es, clarifying information, and motivating patients to continue the course and make necessary behavioral changes.
223924943|NCT06771856|BEHAVIORAL|Stepped Care CBTi|"The stepped care approach in CBTi entails a two-step approach. Participants in this group all receive an initial entry level session of 1 hour delivered by a trained physiotherapist. Step 1: The entry level in this stepped care approach will imply a single, 1-hour long session, administered by a physiotherapist. This single session will cover: 1) education on sleep, sleep pressure, circadian rhythms; 2) introducing entry-level CBT-i principles (e.g., optimizing sleep environment, pre-bedtime food and beverage consumption) 3) pinpointing 2 to 3 of the most relevant strategies for the participant; and 4) creating an action plan for consistent implementation of these strategies over the next month. One month after 'Step 1' the participants' score on the Insomnia Severity Index (T1) will guide further decision making. Those with ISI scores \<12 will enter the follow-up phase immediately. Those with ISI scores ≥12 after step 1 will be referred to standard care CBTi."
223924944|NCT06775041|DRUG|Progerinin|Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.
223924945|NCT06775041|DRUG|Lonafarnib|Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
223924946|NCT06770088|DRUG|vnacicizumab|Vunakizumab 120 mg subcutaneous injection at baseline and week2, week4, then every other 4 weeks.
223924947|NCT06773078|OTHER|High intake group|Intake of a breakfast containing the foods of interest avocado (80gr), corn tortilla (60 gr), nopal (200 gr), guava (108 gr), mango (100 gr), amaranth (14 gr).
223924948|NCT06773078|OTHER|Average intake group|Intake of a breakfast containing the foods of interest avocado (40gr), corn tortilla (30 gr), nopal (100 gr), guava (54 gr), mango (50 gr), amaranth (7 gr).
223924949|NCT06770881|DRUG|JSKN033|JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
224092827|NCT05019937|BEHAVIORAL|Internal facilitator|Each municipality assigns one or more internal facilitators, for example HR-strategist. The internal facilitator will meet their local implementation teams during the educational meeting and workshops. Further meeting can be scheduled based on the needs of each implementation team. The internal facilitator will create a supportive environment within which knowledge is exchanged, barriers to implementation identified, and processes or solutions to overcome those barriers developed, applied, and refined. Moreover, the internal facilitator will establish ongoing audit and feedback processes.
224092828|NCT00002310|DRUG|Crofelemer|
224092829|NCT04409847|DIAGNOSTIC_TEST|ABPM|24 hour ambulatory blood pressure monitoring
224092830|NCT04409847|DIAGNOSTIC_TEST|ECG|Electrocardiogram
224092831|NCT04409847|DIAGNOSTIC_TEST|FMD|Flow mediated dilatation
224092832|NCT04409847|DIAGNOSTIC_TEST|PWV|Pulse wave velocity
224092833|NCT04409847|DIAGNOSTIC_TEST|Rarefaction|nailbed capillaroscopy
224092834|NCT05330026|COMBINATION_PRODUCT|Diaphragm´s study during yoga breathing|Study and compare the activation of the diaphragm during different breaths: rest, ujjayi and pursed lips
224281421|NCT01886534|BEHAVIORAL|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
224281422|NCT01886534|OTHER|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
223924950|NCT06770816|OTHER|Echocardiography|HR, MAP, SBP and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Changes in LV systolic function will be assessed with three parameters: fractional shortening (FS), ejection fraction (EF) using the Simpson method and S' wave of tissue Doppler imaging (TDI) of the mitral annulus (average of values at the medial and lateral annulus). LV diastolic function will be assessed with three parameters and interpreted according to the European Association of Cardiovascular Imaging guidelines. Pulsed wave (PW) Doppler of trans-mitral flow will be used to obtain the ratio between early (e) and late (atrial, a) waves. A PW Doppler between the LV outflow tract and the mitral valve will be performed to estimate the iso-volumetric relaxation time IVRT. TDI will be used to investigate myocardial relaxation at the mitral annular level (ear
223924951|NCT06770946|OTHER|Amniotic Membrane Application|"Amniotic Membrane Application:~This intervention involves the application of an amniotic membrane harvested intraoperatively from the fetal side of the placenta during cesarean delivery. The membrane is placed directly on the incision site before surgical closure to promote wound healing and reduce complications such as infection, dehiscence, and scarring. The membrane is removed 24 hours postoperatively, and standard wound care is continued thereafter."
223924952|NCT06771258|OTHER|Red Light (PDT)|Red LED light
223924953|NCT06770426|DRUG|carbogen with or without phenyleprhine|Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
223924954|NCT06770426|DRUG|phenylephrine|All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
223924955|NCT06772337|BEHAVIORAL|digital cardiac rehabilitation|Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
223924956|NCT06772337|BEHAVIORAL|Regular Treatment|Intra-hospital cardiac rehabilitation: For patients after PCI, reasonable dietary intervention, conventional drug treatment and conventional rehabilitation are given, without lower extremity power bike and respiratory training.Out-of-hospital cardiac rehabilitation: Receiving conventional treatment and secondary prevention drugs recommended by current guidelines, nutritional diet and lifestyle guidance, and establishing a WeChat group as a postoperative follow-up contact method.Outside-hospital cardiac rehabilitation: The experimental group received conventional treatment and secondary prevention drugs recommended by the current guidelines, and carried out supervised digital cardiac rehabilitation on this basis.Doctors prescribe progressive aerobic exercise (walking) through mobile phone apps or computer terminals. Patients will train with wearable devices that can monitor physiological parameters in real time through the mobile phone FREE Rehabilitation APP.
223924957|NCT06759610|DRUG|Tetracyclin|to evaluate the effect of tetracycline socked pack on acceleration of healing during marsupialization as a primary treatment for locally invasive lesions.
223924958|NCT06776991|BEHAVIORAL|Positive Affect Treatment - Behavioral (PAT-B)|8 therapy sessions conducted individually with a therapist. Focuses on improving reward processing to increase positive emotional experience. Specific techniques include psychoeducation on mood cycle and positive emotions, mood monitoring, behavioral activation, and imaginal recounting and savoring of behavioral activation events. Intervention includes between-session practice.
223924959|NCT06776991|BEHAVIORAL|Relaxation Treatment|8 therapy sessions conducted individually with a therapist. Focuses on mindfulness and relaxation skills. Specific techniques include mindfulness approaches from dialectical behavior therapy, diaphragmatic breathing, and progressive muscle relaxation. Intervention includes between-session practice.
224092835|NCT01512940|PROCEDURE|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.~Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
224092836|NCT06331091|OTHER|Home exercise|Home exercise are done at home without the supervision of a specialist.
224092837|NCT06331091|OTHER|Manual therapy|Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.
224092838|NCT06331091|DEVICE|Neuromuscular electrical stimulation|"Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist."
224092839|NCT06331091|OTHER|Supervised exercise|Supervised exercise is done under the supervision of a physiotherapist.
224092840|NCT01976806|DRUG|Aspirin|
224092841|NCT01976806|DRUG|Docosahexaenoic acid|
224092842|NCT01976806|DRUG|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
224092843|NCT04188730|DRUG|Lofexidine (granules for reconstitution)|All subjects will be administered one 0.36 mg dose of lofexidine granules for reconstitution.
224092844|NCT04188730|DRUG|LUCEMYRA (lofexidine) tablets|All subjects will be administered one 0.36 mg dose of LUCEMYRA (lofexidine) tablets.
224092845|NCT03582358|OTHER|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
224092846|NCT02484469|DEVICE|The Virtual Human Project|Virtual Human educational videos about leprosy
224092847|NCT01453504|DRUG|DHAP|Dexamethasone, Cytarabine, Cisplatin
224092848|NCT01453504|DRUG|Everolimus|
224281423|NCT01886534|OTHER|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
224281424|NCT01886534|OTHER|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
224281425|NCT04333134|DRUG|SHR3162|Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
224281426|NCT01878773|OTHER|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~\--------------------------------------------------------------------------------"
224281427|NCT02076516|DEVICE|Drug-eluting stent: CORACTO®|
224281428|NCT02219308|PROCEDURE|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
224281429|NCT02219308|PROCEDURE|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
224281430|NCT01900457|OTHER|electromyography|
224281431|NCT01900457|OTHER|electroencephalography|
224281432|NCT01900457|OTHER|approaches from psychophysics|
224281433|NCT00588783|DEVICE|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
224281434|NCT00588783|DEVICE|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
224281435|NCT00890279|DRUG|Cilnidipine|Cilnidipine up to 20 mg
224281436|NCT00890279|DRUG|Imidapril|Imidapril up to 10 mg per day
224281437|NCT03247699|OTHER|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
224281438|NCT03247699|OTHER|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
224281439|NCT06898736|DEVICE|3d miniplate|3d miniplate was used for mandibular fracture fixation
224281440|NCT06905496|DRUG|High-Dose|Caffeine
224281441|NCT06905496|DRUG|Low Dose|Caffeine citrate is a combination of caffeine and citric acid, commonly used as a central nervous system stimulant. It is primarily used to treat apnea of prematurity in neonates.
224281442|NCT06905028|OTHER|Fasting and Plant-Based Diet|The participants will undergo an initial 7-day fasting regime according to Buchinger (max. 350 kcal per day as liquids), followed by a dietary intervention that encompasses a plant-based diet (PBD) and time restricted eating (TRE) for 11 weeks.
224281443|NCT06513377|OTHER|Performance test|The participant will be asked to execute a protocol in the movement lab that induces progressive feelings of fatigue. This protocol includes a sequence of relevant functional activities, such as stair walking, slope walking, crouching, walking different path shapes. During this execution the Ratings of Perceived Exertion will be questioned, and simultaneously physiological and movement data will be collected.
224281444|NCT06905015|DEVICE|High stroke volume variation group|Anesthesiologists will perform methods to achieve and maintain SVV at 13-20% during liver parenchymal transection (fluid restrictive phase). Central venous pressure monitoring will be concealed with drapes, and the room anesthesiologist will use SVV for guiding fluid management only during parenchymal transection phase. If SVV exceeds 20%, a balanced salt crystalloid will be administered in the minimal amount necessary to reduce the SVV to below 20%.
224281445|NCT06904859|BIOLOGICAL|TCR-T Cells Injection|The TCR sequences of AML patients were analyzed by next generation sequencing to find the specific TCR clone against leukemia，then TCR gene-modified T cells were infused back into the patients
224281446|NCT02562287|DRUG|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
224281447|NCT02562287|DRUG|Risperidone|Risperidone, in a flexible dosage
224281448|NCT02562287|DRUG|Olanzapine|Olanzapine, flexible dosage
224281449|NCT02562287|DRUG|Quetiapine|Quetiapine, flexible dosage
224281450|NCT00375791|DRUG|perifosine|100 - 150 mg daily
224281451|NCT00375791|DRUG|dexamethasone|20 mg twice weekly
224281452|NCT00735930|DRUG|Alvocidib Hydrochloride|Given IV
224092849|NCT04144621|PROCEDURE|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
224092850|NCT04551014|DEVICE|Use of EverLift|Use of EverLift for submucosal injection prior to polypectomy
224092851|NCT04551014|DEVICE|Without use of EverLift|Without use of EverLift for submucosal injection prior to polypectomy
224092852|NCT02221492|DRUG|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
224092853|NCT02221492|DRUG|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
224092854|NCT06253416|OTHER|Exercise|a home exercise program consist of stretching and strengthening exercises , 5 repetitions of each exercise three days a week for 12 weeks
224281453|NCT00735930|DRUG|Lenalidomide|Given PO
224281454|NCT00735930|OTHER|Pharmacological Study|Correlative studies
224281455|NCT00735930|OTHER|Laboratory Biomarker Analysis|Correlative studies
223924960|NCT06776991|BEHAVIORAL|Exposure Therapy|8 therapy sessions conducted individually with a therapist using the inhibitory retrieval model of exposure therapy. Sessions are designed to include four exposures each (32 exposures total). Each exposure is a public speech delivered to an audience. Goal of this treatment is to reduce public speaking anxiety. Principles of exposure therapy that will be incorporated are maximizing prediction error, maintaining attention to the situation/stimuli that are perceived predictors of the feared outcome (e.g., social rejection), removing safety signals, variability, engaging in post-exposure rehearsal/consolidation, deepened extinction, and positive occasion setter extinction. Intervention does not include between-session practice.
223924961|NCT06775314|DRUG|Cleanser|Cleanser consist of Triethyl citrate and Pyruvic acid, will be given to subjects to be applied every morning, evening and night in group 2
223924962|NCT06775314|DRUG|Combination cream|combination cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic acid will be given to subjects to be applied every morning, evening and night in group 2
223924963|NCT06775314|DRUG|spot cream|spot cream consist of Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol, will be given to subjects to be applied every morning and evening in group 2
223924964|NCT06775314|DRUG|Adapalene 0,1% cream|adapalene 0.1% cream will be given to subjects to be applied every night in group 1 and 2
223924965|NCT06775314|DRUG|placebo cleanser|placebo cleanser will be given to subjects to be applied every morning, evening and night in group 1
223924966|NCT06775314|DRUG|placebo cream combination|placebo cream combination will be given to subjects to be applied every morning, evening and night in group 1
223924967|NCT06775314|DRUG|placebo spot cream|placebo spot cream will be given to subjects to be applied every morning and evening in group 1
223924968|NCT06777225|OTHER|breathing exercises|"This study is to examine the effects of breathing exercises on nausea, vomiting and anxiety levels in patients with gynecological cancer.~1 Exercise:~* Find a quiet, calm and comfortable place for yourself.~* Lie on your back in a comfortable place (flat surface, bed or couch) and bend your knees or sit in a comfortable place (chair or armchair).~* Close your eyes.~* Place your left hand on your belly and your right hand on your chest.~* Take a deep breath through your nose for 4 seconds.~* Feel your hand on your belly rise and your belly swell as you breathe in.~* Make sure your chest is not swollen.~* Hold your breath for 4 seconds. Breathe out in 4 seconds.~* Do this 10 times every day, morning and evening, 3 times."
223924969|NCT06777225|OTHER|scale|The patient received standard nursing care and the scale was applied after the intervention. The 21-question inventory developed by Dr. Aaron T. Beck was used. The reliability and validity of the Beck Depression Inventory (BDI), which is used to measure the severity of depression, was performed in our country by N. Hisli in 1989. (Cronbach's alpha value was calculated as 0.85). Each question takes a value between 0-3 points. When evaluating the results; 0-10 points are normal; 11-16 points are mild mood disorder; 17-20 points are borderline clinical depression; 21-30 points are moderate depression; 31-40 points are severe depression and over 40 points are very severe depression (Çiçekçe et al, 2023).
223531818|NCT06952790|BEHAVIORAL|EveryDose Mobile Application|Participants will use this application every day for up to 10 minutes, for up to 12 weeks. The purpose of the application is to improve medication adherence. Participants will receive an alert to the mobile device while at home to ensure medication was taken, and to serve as a medication log.
224092855|NCT06253416|OTHER|Control|exercise freely and without supervision with their daily routine
224281456|NCT01302509|DIETARY_SUPPLEMENT|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
223531819|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
224092856|NCT05863611|OTHER|arms|During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
224092857|NCT02607215|DRUG|Vinorelbine|25 mg/m2, D1, D8
224092858|NCT02607215|DRUG|DDP|75 mg/m2, D1
224092859|NCT00998738|DRUG|Calcium Gluconate|Given IV
224092860|NCT00998738|DRUG|Magnesium Sulfate|Given IV
224092861|NCT00998738|OTHER|Placebo|Given IV
224092862|NCT00998738|OTHER|Quality-of-Life Assessment|Ancillary studies
223531820|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
223531821|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
223531822|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
223531823|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
223531824|NCT03125577|BIOLOGICAL|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
223531825|NCT06948292|DRUG|QRX-3|phase 2B CKD study
223531826|NCT06954740|DRUG|Amimestrocel|Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15.
224092863|NCT00998738|OTHER|Questionnaire Administration|Ancillary studies
224092864|NCT00998738|DRUG|Ixabepilone|Given IV
224092865|NCT04391140|OTHER|Prone position|HFNC set to a SpO2 of 90-95% combined with prone position. At least 2 sessions of 30 minutes or more will be performed daily.
224092866|NCT06960330|OTHER|Wearable Biofeedback + Virtual Physiotherapy|Participants will use wearable devices designed to monitor physiological parameters and provide real-time feedback during exercises. The intervention includes remote guidance from physiotherapists via virtual consultations.
224092867|NCT06960330|OTHER|Standard Physiotherapy Exercises|Participants will be given printed or video instructions for standard physiotherapy exercises commonly used for arthritis and fibromyalgia management, without any digital monitoring or remote guidance.
224092868|NCT01914952|DIETARY_SUPPLEMENT|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
223924970|NCT06777225|OTHER|scala|The scale was developed by Rhodes and McDaniel (1999), and its Turkish validity and reliability were carried out by Fatma Genç and Mehtap Tan. The scale, which evaluates the number and severity of nausea-vomiting-retching episodes in the last 24 hours, consists of eight items. The scale has three sub-dimensions: Symptom Experience, Symptom Formation, and Symptom Distress. The responses to the items on the five-point Likert-type scale are scored as 0 = minimum 22 distress level, 4 = maximum distress level. When evaluating the scores, items 1, 3, 6, and 7 are reversed. The highest score that can be obtained from the scale is 32, and higher scores mean that nausea-vomiting symptoms have increased in patients (Odabaşı et al, 2021).
223924971|NCT06770205|OTHER|traditional physical therapy|hot pack and TENS for 10 minutes and massage that will as 3 sessions per week for 4 weeks.
223924972|NCT06770205|OTHER|kendall Exercise Group A|"The group B will receive Proprioceptive Neuromuscular Facilitation technique for stretching and rhythmic stabilization technique for strengthening. Proprioceptive Neuromuscular Facilitation (PNF) is a stretching technique utilized to improve muscle elasticity and has been shown to have a positive effect on active and passive range of motions. The PNF group performed the intervention for 30 minutes a day, six times a week, a total of 24 times. (13) In this group, two types of PNF techniques were given:~1. first is strengthening technique included rhythmic stabilization that is characterized by alternating isometric contractions against resistance, no motion intended to apply for the weak muscles of upper cross syndrome included deep neck flexors specifically lower trapezius and serratus anterior.~2. Second is stretching technique included contract relax that is resisted isotonic contractions of the restricting muscles (antagonists) followed by relaxation and movement"
223924973|NCT05073510|DEVICE|BVE|Participants will undergo BVE evaluation for assessing Peripheral Arterial Disease (PAD)
223924974|NCT06761807|PROCEDURE|Electrophysiology study of heart|"The procedure will be done comparatively for each patient; before the device placement and immediately after the procedure.~This will be done approaching the same sheath that is placed for ASD device closure (the right femoral vein).~Only one quadripolar EP catheter will be used, it will be placed in high right atrium then at His bundle.~The EP study will include:~Assessment of SAN function using cSNRT (through HRA pacing) Assessment of AH and HV intervals (through His bundle EGM) Assessment of antegrade AVN RP (refractory period) and AVN WP (Wenckebach point) through extra-stimuli and incremental atrial pacing.~Any inducible arrhythmia will be reported"
223924975|NCT06768970|DIETARY_SUPPLEMENT|CARDIO® salmon oil|CARDIO® is a natural salmon oil manufactured from the enzymatic hydrolysis of Norwegian Atlantic salmon. Salmon capsules contain a full spectrum omega- and non-omega marine fatty acids with naturally occurring astaxanthin.
223924976|NCT06769152|DRUG|HLX43 DOSE 1|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924977|NCT06769152|DRUG|HLX43 DOSE 2|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924978|NCT06769152|DRUG|HLX43 DOSE 3|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223924979|NCT06781463|OTHER|Registry (N/A)|This study is a registry, thus no research intervention is being directly tested.
223924980|NCT06782022|DRUG|5-Fluoro-Uracil|"Patients without common DPYD variant will be used for this study as a control group. Patients will receive the first 5-FU-dose based on their body surface area. 5-FU plasma concentrations will be measured during cycle 1. If patients experience CTC grade 3-4 toxicity, DPYD sequencing will be performed. Dose reduction or discontinuation of 5-FU therapy will be considered according to the physician's discretion.~Patients with a DPYD variant will receive the first dose based on their body surface area and gene activity score according to Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline or according to the physician's descretion. Patients' blood sample will be collected and the 5-FU dose for the next cycle will be calculated according to a modified algorithm of Goirand or according to the pharmacist's discretion. 5-FU plasma concentrations will be monitored until a steady state AUC of 20-30 mg.h/L is reached."
223924981|NCT04924491|BIOLOGICAL|Autologous thyTreg|Treg lymphocytic cells, differentiated, autologous, of thymic tissue, expanded and stimulated with Interleukin (IL-) 2 (thyTreg)
223924982|NCT06839326|BIOLOGICAL|Autologous Conditioned Serum, Genesis Biyomedikal, Sanakin®-Acrs produce|Arthrocentesis and 1ml ACS injection will be performed twice in total, two weeks apart.
224092869|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
224092870|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid mixed in water|0.8 g HMB free acid in water
224092871|NCT01914952|DIETARY_SUPPLEMENT|CaHMB in water|1.0 g CaHMB powder mixed in water
224092872|NCT01914952|DIETARY_SUPPLEMENT|HMB free acid|0.8 g HMB free acid
224092873|NCT04774939|PROCEDURE|Endovenous laser ablation|The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment
224092874|NCT05124223|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
224092875|NCT02158559|DRUG|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
224092876|NCT02158559|DRUG|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
223531827|NCT07161531|DIAGNOSTIC_TEST|Surface Electromyography|The primary lower limb muscles to be monitored include the gluteus medius, rectus femoris, vastus lateralis (quadriceps ), biceps femoris (hamstrings), tibialis anterior, and gastrocnemius medialis (calves). This setup fully utilizes a 16-channel sEMG system by monitoring each muscle group bilaterally to capture comprehensive data on muscle activity and fatigue.
223531828|NCT07158931|OTHER|nordic walking|Before the NW program, participants completed a one-week familiarization phase to practice pole use. Training was held three times: 15 minutes on days 1 and 2, and 20 minutes on day 3, at 40-60% heart rate reserve (measured with a pulse oximeter). Warm-up included a 1-minute slow walk, toe raises, seated dorsiflexion, mini squats, scapular adduction, and shoulder/wrist stretches. Each session ended with a cool-down of a 2-minute slow walk and 20-second stretches for major muscle groups (quadriceps, hamstrings, lumbar extensors, gastrocnemius, shoulders, wrists).The walking poles used in this study were the Evolite Ultralite Titanium Antishock Trekking Pole, which has a titanium alloy body and a three-piece telescopic structure, adjustable to the desired length between 68 and 135 cm.
223924983|NCT06839326|BIOLOGICAL|Platelet Rich Plasma|Arthrocentesis and 1ml PRP injection will be performed twice in total, two weeks apart.
223924984|NCT06839326|OTHER|Control Group/ Only Arthrocentesis|Arthrocentesis will be performed twice in total, two weeks apart.
223924985|NCT06810414|BEHAVIORAL|Food and alcohol disturbance expectancy challenge|The intervention will focus on strengthening negative FAD expectancies and weakening positive FAD expectancies.
223924986|NCT06815900|OTHER|one group .observational study|observational study of this group
223924987|NCT06772727|DRUG|Lidocaine|After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)
223924988|NCT06772727|DRUG|Fentanyl|After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).
223924989|NCT06772727|DRUG|Propofol|After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously
223924990|NCT06772727|DRUG|Succinyl choline|After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.
224092877|NCT01722513|DRUG|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
224092878|NCT01422005|OTHER|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
223924991|NCT06891989|OTHER|Mindfulness meditation (MM) Intervention|"Participants will be asked to download the Mindfulness Coach app that provides simple instructions and brief meditation exercises.This is a a gradual training program of 14 levels which will be completed in the first 2-3 weeks. Each level provides short readings about mindfulness and one or two guided meditations (a silent seated practice for increasing lengths of time plus typically an additional 8-13-minute meditation). As participants progress through the levels, they earn badges displayed in the app, and an image of a tree on the home screen grows as each successive level is completed.For the remaining weeks of the intervention, participants will select at least one (and ideally two) guided meditation per day from the complete list of available meditations.Participants will track their progress through weekly logs."
223924992|NCT06891989|OTHER|Health Education Active Control Intervention|Participants will be asked to download and use the free TED Talk app, which will have 50 TED talk videos related to health that range from 3-20 minutes. Participants will be asked to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week and complete weekly logs of the TED Talk app use.
223924993|NCT06844825|OTHER|Tele rehabilitation|The experimental group will receive the treatment remotely by ZOOM platform and phone call
223924994|NCT06844825|OTHER|usual care only|in-person usual care provided by the physical therapist
223924995|NCT06754657|PROCEDURE|Continuous perineural infusion|infusion rate 4 ml/h, with 5 ml boluses (30-minute lockout). The PCA button disabled
223924996|NCT06754657|PROCEDURE|Single injection|infusion rate 0 ml/h, with 5 ml boluses (30-minute lockout). The PCA button will be enabled for rescue bolus administration
223924997|NCT06875037|DEVICE|Electric stimulation removable appliance|The device will be used with the fixed appliance to accelerate orthodontic tooth movement (i.e., canine retraction).
223924998|NCT06875037|PROCEDURE|Traditional orthodontic fixed appliance without accleration|The traditional method of canine retraction will be employed using fixed appliances. No additional appliances will be used to activate orthodontic tooth movement.
223924999|NCT06782698|BEHAVIORAL|Home-based exercise program|"The home-based program follows the National recommendations on Physical Exercise for Cancer Patients \[Bruno RC, 2023\]. It is logbook-guided and technology-enabled.~It consists of:~* Two initial supervised explanatory sessions, in the Physic and Rehabilitation Medicine Gym of our institution.~* Followed by 2 muscular training sessions + 3 additional periods of aerobic exercise per week in their home environment until the end of neoadjuvant treatment. Patients are given a logbook with instructions and a sports bracelet for heart rate monitoring.~The training sessions will be monitored by smartwatch heart rate measurements and self-notion of effort according to Borg Categorization \[Borg GA, 1982\] and recorded by the participants in the Mi Fitness application or an Exercise Diary.\[Nilsen TS, 2018\]"
224092879|NCT01422005|OTHER|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
224092880|NCT06587100|DEVICE|Fitbit|Participants will wear Fitbit device
224092881|NCT06587100|DEVICE|Apple HealthKit-based devices|Participants will wear personal device and share data with study team.
224092882|NCT06819488|DRUG|[14C]HRS-7535|\[14C\]HRS-7535.
224092883|NCT02093702|BEHAVIORAL|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
224092884|NCT02093702|BEHAVIORAL|Unstructured Physical Activity and Exercise Education|
224092885|NCT05351476|BEHAVIORAL|Resistance Exercise|300 Kcal worth of weight lifting, 3 times/week for 12 weeks
224092886|NCT05351476|BEHAVIORAL|Endurance Exercise|300 Kcal worth of treadmill walking, 3 times/week for 12 weeks
224092887|NCT05651516|DRUG|18F-PI-2620 PET/CT|PET/CT imaging will be used to evaluate the uptake of tau in the brain using the investigational radiotracer \[18F\]PI-2620. Each subject will have one \[18F\]PI-2620 positron emission tomography/computed tomography (PET/CT) scan performed.
224281457|NCT06051409|DRUG|Olverembatinib|Orally, once every other day (QOD).
224281458|NCT06051409|DRUG|Imatinib|Orally, once daily (QD).
224281459|NCT03209349|PROCEDURE|Water Exchange Sigmoidoscopy|See arm description.
224281460|NCT03209349|PROCEDURE|Air Insufflation Sigmoidoscopy|See arm description.
224281461|NCT06165263|BEHAVIORAL|Mobile earthquake education|The mobile earthquake education application was developed to increase high school students\&#39; knowledge about earthquakes through videos, activities or games. In the mobile earthquake education application, there are 4 modules that provide general information about the earthquake and what to do before, during and after the earthquake.
224281462|NCT01471925|DRUG|Nexium®|"The medication, esomeprazole magnesium trihydrate (40 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days."
223925000|NCT06782698|BEHAVIORAL|Promotion of Healthy Physical Activity|"The short counseling consists of at least one opportunistic talk for promotion of physical activity, taking up to 5 minutes, during the Medical Oncology appointment or during Physical Assessments at T0. It should follow the instructions of the Portuguese Directorate-General of Health, Short Counselling for the Promotion of Physical Activity, including the delivery of a Physical Activity Guide plus a Auxiliar of Decision or a Plan of Action or Maintenance.\[Mendes R, 2020\] All patients will receive a Guide about Nutrition for Cancer Patients \[Capela AM, 2023\] and may be offered Nutritional, Psychological or other additional consultations according to clinical judgement of the Medical Oncologist."
223925001|NCT06848452|OTHER|no-intervention|no-intervention
223925002|NCT06765447|PROCEDURE|hemostasis with 3% NaOCl in direct pulp capping|after pulp exposure bleeding was control by placing a cotton pellet soaked with 3%NaOCl over the pulpal wound upto 1 minutes.If hemostasis was not achieve with in 1mins we again use soaked cotton pellet of 3% NaOCL for another 1 mint until the hemostasis acheived. Tooth with excessive uncontrollable bleeding even after 5 mins was excluded from the study; however, definite treatment was provided to the patient.The time used to control bleeding was recorded for each tooth by using stop watch.Once hemostasis is achieved, exposed pulp was capped with biodentine.
223925003|NCT06765447|PROCEDURE|hemostasis with diode laser in direct pulp capping|Hemostasis was achieved by exposure to Primo dental diode laser by medency (980 nm), at 0.5 W(medency Primo laser) .During laser application patients, operator and assistant were asked to wear protective eye shields.The laser energy of wavelength 980 nm introduced to the exposure site through a 400 µm optical fiber in a non contact mode for 2-3 seconds at exposure site for three times at 10s time interval to achieve complete hemostasis.For disinfection same diode laser of wavelength 980nm with energy set at 1W used in non contact mode in circular motion in the cavity .Biodentine was used as pulp capping agent.
223925004|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,0.25mg, s.c.,day 1 single dose .
223925005|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,0.5mg, s.c.,day 1 single dose .
223925006|NCT06893796|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim Injection,1mg, s.c.,day 1 single dose .
223925007|NCT06761417|DRUG|Mitoxantrone liposome|Mitoxantrone liposome: 16 mg/m\^2, d1; Each 21-day cycle was used for a total of 4-6 cycles.
223925008|NCT06761417|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.
223925009|NCT06761417|DRUG|Anlotinib|Anlotinib: according to patient weight: 8mg/ day in patients \<35kg; 10mg/ day for patients with 35kg≤ patient weight ≤50kg; 12mg/ day for patients \> 50kg; d1-14; Each 21-day cycle was used for a total of 4-6 cycles.
223717593|NCT00628784|PROCEDURE|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
223925010|NCT06760871|OTHER|nebulised distilled water|After the surgery, the patients will be admitted to the ward and taken to the bed, and their care and treatment will be applied by the nurse. Afterwards, the researcher will apply cold vapour as an inhaler for 15 minutes. For this application, the stand to which the ultrasonic nebuliser device is connected will be positioned close to the patient's bed. 200 ml of distilled water will be placed in the liquid reservoir of the device. The patient will be given a comfortable position and the device will be adjusted so that the steam hose covers the patient's mouth and nose and the patient will be allowed to inhale the steam through the mouth and nose. After the electrical connection of the device is provided, the device will be started and cold steam application will begin. In the 1st hour, inhaler cold water vapour application will be performed for 15 minutes.
223925011|NCT06737679|BEHAVIORAL|Body Scan|"Body scan is a guided meditation technique that allows people to detect signs and signals from their body (for instance, heart rate).~The intervention will last 20 minutes and will be performed 21 consecutives days. The first and last days it will be performed in presence, while the other ones online."
223925012|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)|Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)
223925013|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)|Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)
224281463|NCT01471925|DRUG|Esomeprazol (40mg) + Sodium Bicarbonate (721mg)|"The medication, Esomeprazol (40 mg) + Sdium Bicarbonate (721 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally) with liquid (water at room temperature - 200 to 250 ml.~The study treatment will last a total of 28 days."
223925014|NCT06772051|PROCEDURE|Resin composite restoration bonded using universal adhesive in self-etch mode|Resin composite restoration bonded using universal adhesive in self-etch mode
223925015|NCT06770153|PROCEDURE|Tensor|balancing will be carried out using the TEMIS DePuy tensioner and carrying out any releases according to the gap-balancing technique
223925016|NCT06770153|PROCEDURE|standard|primary TKA implantation with ligament balancing without use of the tensioner
223925017|NCT06901167|OTHER|Residential In-Reach Program|All enrolled residential aged care homes will be able to access the residential-in-reach (RIR) program intervention. The RIR program provides a consultation service from a central hospital to an aged care facility in the Grampians region in the state of Victoria, Australia. Aged care staff will make a telehealth referral to central hub, where a nurse practitioner will triage the patient and make recommendations (for example, monitor resident condition, more examples: comprehensive assessment for unwell residents, liaison with the General Practitioners for diagnosis and treatment plan, provide education and support to staff) or further referrals (for example, refer to geriatrician or call an ambulance).
224281464|NCT05805813|COMBINATION_PRODUCT|peritoneal rest|Change continuous ambulatory peritoneal dialysis to intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month. In this way, give a chance of peritoneum rest.
224281465|NCT04628936|DRUG|KZR-616|Subcutaneous 30 mg for 1 week, then 45 mg weekly
224281466|NCT00403949|DRUG|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
224281467|NCT00403949|DRUG|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
223717594|NCT00436683|DRUG|Fermagate|Film coated tablet 500mg
223925018|NCT06853158|BEHAVIORAL|Music therapy|Participants in the 2 experimental MT conditions (In person MT (InMT) or hybrid (inperson.virtual (HybMT) will receive 6 MT sessions over 6 weeks. Each MT session will last no longer than one hour. This 6-week treatment period may be extended to up to 8 weeks if a scheduling conflict prevents a participant from receiving the 6 MT sessions over 6 consecutive weeks.
223925019|NCT06853158|OTHER|Health education|The content for the HybHE control was adapted from Project PEEP: Patients Empowered and Educated Providers. The Sickle Cell Community Consortium developed Project PEEP with a grant from Global Blood Therapeutics. Project PEEP addresses unmet needs directly identified and prioritized by a collective of patients with SCD, caregivers, and community-based organizations. The objective is to provide the tools and resources to improve communication and increase positive patient-provider interactions to receive quality, timely care. For the proposed study, we will use modules from the curriculum developed for patients living with SCD.
223925020|NCT06867679|OTHER|Recreational Soccer Training (Boys Group)|This group will have 3 training sessions per week, with each session lasting 60 minutes (13). The session will include: Warm-up (10 minutes): Light jogging, Dynamic stretching (Arm circles, Leg swings, Hip circles), Mobility exercises (Ankle roll, Trunk rotations),Technical Skills Training (20 minutes):Dribbling, passing, and shooting drills, Small-Sided Games (20 minutes): 3v3 or 4v4 games emphasizing teamwork, passing, and movement off the ball.Cool Down (10 minutes):Light jogging, Static stretching, Breathing exercises. Training Progression: Weeks 1-2: Basic skills and small-sided games, Weeks 3-5: Increased drill complexity, Weeks 6-8: Enhanced tactical awareness and structured gameplay.
223925021|NCT06867679|OTHER|Recreational Soccer Training (Girls Group)|This group will have 3 training sessions per week, with each session lasting 60 minutes (13). The session will include: Warm-up (10 minutes): Light jogging, Dynamic stretching (Arm circles, Leg swings, Hip circles), Mobility exercises (Ankle roll, Trunk rotations),Technical Skills Training (20 minutes):Dribbling, passing, and shooting drills, Small-Sided Games (20 minutes): 3v3 or 4v4 games emphasizing teamwork, passing, and movement off the ball.Cool Down (10 minutes):Light jogging, Static stretching, Breathing exercises. Training Progression: Weeks 1-2: Basic skills and small-sided games, Weeks 3-5: Increased drill complexity, Weeks 6-8: Enhanced tactical awareness and structured gameplay.
223925022|NCT06857565|DIETARY_SUPPLEMENT|Lactobacillus crispatus M247|CRISPACT® (Lactobacillus crispatus M247), Pharmextracta, S.p.A
223925023|NCT06857565|DIETARY_SUPPLEMENT|iNatal-duo® (containing Bifidobacterium animalis subsp. lactis BB-12 and Enterococcus faecium L3)|iNatal-duo®, PharmExtracta S.p.A
223925024|NCT06627790|DRUG|Mouthwash preparation|Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
224092888|NCT03337256|DIAGNOSTIC_TEST|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~* 75 2.5 Haemoglobin(g/L)~* 10.0 0 \<9.9 2 Systolic blood pressure (mmHg)~* 110 0 90-109 1.5 \<90 2.5 Pulse (beats per min) \<100 0~* 100 1.5 Creatinine (mmol/L) \<200 0~* 200 3.5 Number of blood transfusion 0 0~  1 1.5~* 2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
224092889|NCT06900556|PROCEDURE|Dry cupping with suction|Dry cupping with suction applied to the biceps
224092890|NCT06900556|PROCEDURE|Dry cupping without suction|Dry cupping without suction applied to the biceps
224092891|NCT06823973|BEHAVIORAL|CBT-based transdiagnostic approach to sexual distress|"It is constituted by 8 modules:~1. Psychoeducation about sexual function~2. Difficulties in emotional regulation~3. Non-judgmental emotional awareness~4. Cognitive flexibility~5. Worry and rumination~6. Perfectionism~7. Communication~8. Summary"
224092892|NCT06823973|BEHAVIORAL|Waiting list condition|The participants in the waiting list condition will receive the intervention after the participants in the intervention condition.
224092893|NCT06932016|BEHAVIORAL|Grammar Treatment|Behavioral intervention that focuses on improving passive sentence structure knowledge.
224092894|NCT06918509|DEVICE|OdonAssistTM|Innovative medical device for operative vaginal delivery as an alternative to vacuum or forceps
224092895|NCT06935292|DRUG|Dexmedetomidine|Nebulized Dexmedetomidine (1μg/kg)
224092896|NCT06935292|DRUG|Melatonin|Oral Melatonin tablet (5mg)
224092898|NCT03019549|DRUG|Lanabecestat|Administered orally
224092899|NCT03019549|DRUG|Rosuvastatin|Administered orally
223531829|NCT07158931|OTHER|General walking|The program was performed on concrete or compacted soil surfaces, under the same physiotherapist's supervision. Walking speed was adjusted to remain below 60% of maximal heart rate and to allow participants to converse comfortably during exercise.
223717595|NCT00436683|DRUG|Sevelamer HCl|tablet 800mg
223717596|NCT01882491|DRUG|Placebo|Solution for subcutaneous injection
223717597|NCT01882491|DRUG|gevokizumab|Solution for subcutaneous injection
223717598|NCT02728050|DRUG|Cladribine|Given IV
223925025|NCT06868979|OTHER|Clinical assessment|Clinical examination including Medical history, developmental trajectory, epilepsy history, ASD symptoms, clinical examination at the inclusion visit by a neuropediatrist
223925026|NCT06868979|OTHER|Parental questionnaires|Parental questionnaires including Vineland-2, ABC, CBCL, PPD-MRS, SRS-2 and BRIEF completed at the inclusion visit
224092900|NCT02189265|OTHER|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
224092901|NCT01412879|BIOLOGICAL|rituximab|Given IV
224092902|NCT01412879|DRUG|bendamustine hydrochloride|Given IV
224092903|NCT01412879|DRUG|cyclophosphamide|Given IV
224092904|NCT01412879|DRUG|cytarabine|Given IV
224092905|NCT01412879|DRUG|dexamethasone|Given PO or IV
224092906|NCT01412879|DRUG|doxorubicin hydrochloride|Given IV
224092907|NCT01412879|DRUG|leucovorin calcium|Given PO or IV
224092908|NCT01412879|DRUG|methotrexate|Given IV
224092909|NCT01412879|DRUG|vincristine sulfate|Given IV
223925027|NCT06868979|OTHER|Cognitive assessment|Cognitive assessment including Leiter-3, PPVT 5, EVT 3 completed at the inclusion visit
223925028|NCT06868979|OTHER|Reasoning assessment|Simple reasoning tasks on tablets performed at the inclusion visit.
223925029|NCT06868979|DEVICE|fNIRS assessement|Imaging session using fNIRS (NIRSport 8x8, NIRx Medical Technologies LLC, Berlin, Germany) performed at the inclusion visit.
223925030|NCT06756295|BIOLOGICAL|individualized tumor FAST vaccine combination (including adjuvant)|Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.
223925031|NCT04653740|PROCEDURE|specimen sample collection|"Before and during treatment, and at progression, collection of :~* Blood~* Exhaled air~* Saliva~* Sweat~* Tears~* Urine"
223925032|NCT06761248|DEVICE|Fluorescent Starch Nanoparticles Caries Detection Rinse|The fluorescent starch nanoparticles caries detection rinse is an innovative diagnostic tool designed to enhance the early detection of active dental caries. It contains proprietary fluorescent starch nanoparticles that infiltrate the porous enamel of active caries lesions. Upon illumination with a standard dental curing light, the nanoparticles fluoresce, allowing clinicians to differentiate active caries from inactive lesions and other enamel conditions. This rinse is evaluated as a non-invasive, highly sensitive, and specific diagnostic device.
223925033|NCT06930443|OTHER|Oxygen consumption measurement|After arrival to the ICU, prior to cessation of iv anaesthetics and extubation, indirect calorimetry will be performed by connecting a metabolic monitor to the ventilator during a minimum of 20 minutes.
223925034|NCT06878573|DRUG|Intravitreal Aflibercept Injection|After instillation of topical anesthesia (0.4% oxybuprocaine hydrochloride and lidocain; own production), sterilization of the eyelid (Betaisodona solution 11% povidone-iodine, Mundipharma, Limburg, Germany), and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) will be injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions.
223925035|NCT06878573|DEVICE|Laser speckle flowgraphy|"The RetFlow consists of a fundus camera equipped with a diode laser at a wavelength of 830 nm and a digital charge-coupled device camera (750 x 360 pixels). A total of 118 images are acquired at a rate of 30 frames per second over a 4-second measurement period. The main output parameter of LSFG, mean blur rate (MBR), is calculated from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. MBR was calculated for the total ONH area, defined by a ellipsoid region of interest (ROI). By using the on-board software, the MBR will be calculated in the large vessels within the ONH (ONH-MV, mean MBR of vascular area) and the tissue area containing the microvasculature (ONH-MT, mean MBR of tissue area)"
224092910|NCT04942548|OTHER|Ketogenic Diet|Ketogenic diet intervention that is high in fat and low in carbohydrates, causing the body to induce a state of metabolic ketosis, whereby fat is broken down into ketones to provide an energy source for the body.
224092911|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in capillary blood|After a finger prick, patients will be taken a drop of capillary drop. This drop will be used to perform the MagIA IBC test.
224092912|NCT06082336|DIAGNOSTIC_TEST|MagIA IBC test in other matrices|Blood samples will be taken and used to perform the MagIA IBC in veinous blood, serum and plasma.
224092913|NCT01676038|PROCEDURE|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
224092914|NCT01676038|PROCEDURE|Conventional Total Knee Arthroplasty|Conventional technique.
224092915|NCT02109029|DRUG|Insulin Peglispro|Administered IV
224092916|NCT02109029|DRUG|Human Insulin|Administered IV
224092917|NCT02693964|OTHER|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
224092918|NCT04544566|DEVICE|Test product A|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
224092919|NCT04544566|DEVICE|Test product B|one new adhesive material which is applied to the baseplate and the subjects peristomal skin
224092920|NCT04544566|DEVICE|Comparator|Already CE- marked product as a comparator which is applied to the baseplate and the subjects peristomal skin
224092921|NCT02704962|DRUG|full-dose olanzapine|trifluoperazine 5mg/d
224092922|NCT01445171|DEVICE|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
224092923|NCT00787111|DRUG|Fluoxetine (prozac)|Formulation: ODT
224092924|NCT06117189|OTHER|Questionnaire|Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
224092925|NCT03195894|DEVICE|TripleA|
224092926|NCT00957541|DEVICE|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
224092927|NCT01575912|OTHER|experimental pain tests|
223717599|NCT02728050|DRUG|Cytarabine|Given IV
223717600|NCT02728050|BIOLOGICAL|Filgrastim|Given SC
223717601|NCT02728050|OTHER|Laboratory Biomarker Analysis|Correlative studies
223717602|NCT02728050|OTHER|Quality-of-Life Assessment|Ancillary studies
224092928|NCT05995444|DRUG|Epetraborole and matching placebo|Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
224092929|NCT05995444|DRUG|Epetraborole|Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
224092930|NCT05995444|DRUG|Placebo|Treatment C (Placebo control): Epetraborole matching-placebo (8 tablets)
224092931|NCT05995444|DRUG|Moxifloxacin|Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
224281468|NCT03040752|DRUG|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
224281469|NCT03040752|DRUG|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
224281470|NCT03973788|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
224281471|NCT04266652|PROCEDURE|tooth block|tooth root blocks were used to increase the bone width
224281472|NCT04266652|PROCEDURE|autogenous bone block|autogenous bone block were used to increase the bone width
224281473|NCT03358095|DEVICE|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
223925036|NCT06876545|DIAGNOSTIC_TEST|systematical screening of at risk patients based on predefined hemorrhagic criteria|"Patients selected if condition present:~Hematuria (blood in urine)~Macroscopic hematuria (visible blood in urine) Hematuria detected by urine dipstick or microscopic analysis Ecchymoses (bruising)~Epistaxis (nosebleeds)~Petechiae (small pinpoint hemorrhages on the skin)~Gastrointestinal bleeding~Upper GI bleeding: Hematemesis (vomiting blood) Lower GI bleeding: Melena (black tarry stools) Positive fecal occult blood test (FOBT) Cerebral hemorrhage (brain bleeding)"
223925037|NCT06504966|DRUG|MAB-22|Single subcutaneous dose of 60 mg
223925038|NCT06504966|DRUG|Prolia®|Single subcutaneous dose of 60 mg
223925039|NCT06869421|OTHER|Questionnaire|group of questions about the predictors (age, type of diabetes, level of education) and about the outcomes: knowledge and awareness of the link between diabetes and oral health, and attitude towards maintaining their oral health as diabetics
223925040|NCT06225648|OTHER|threonine|There are 7 different threonine test levels ranging from 5 to 45 mg of threonine per kilogram body weight per day.
223925041|NCT06738472|OTHER|home based exercises|given exercises to the participants
223925042|NCT05860452|OTHER|ropivacaine|single shot bilateral TAP block
223925043|NCT05860452|OTHER|normal saline|single shot bilateral TAP block
223925044|NCT06759116|PROCEDURE|Control group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ml saline)
223925045|NCT06759116|PROCEDURE|Fentanyl group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 50 mcg fentanyl)
223717603|NCT02728050|DRUG|Mitoxantrone|Given IV
223717604|NCT02728050|DRUG|Sorafenib|Given PO
223717605|NCT00798499|OTHER|Laboratory variables|1 visit
223717606|NCT01167894|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
223925046|NCT06759116|PROCEDURE|Dexmedetomidine group|The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ug/kg dexmedetomidine not exceeding 100 ug (to be completed to 1mL with normal saline if needed). )
223925047|NCT06114069|PROCEDURE|implant supported maxillary fixed prosthesis|Maxillary fixed prosthesis according to all on four or all on six concept
223925048|NCT03109873|RADIATION|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
223925049|NCT03109873|DRUG|Metformin Hydrochloride|Given orally
223925050|NCT03109873|OTHER|Placebo|Given orally
223925051|NCT06243575|DRUG|Multimodal Intraosseous Femoral Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
223925052|NCT06243575|DRUG|Multimodal Intraosseous Tibial Injection|Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
223925053|NCT06791564|DEVICE|AVELI|Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.
223925054|NCT05220501|DIAGNOSTIC_TEST|Micro-US Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
223925055|NCT05220501|DIAGNOSTIC_TEST|MRI Targeted Biopsy|All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
223925056|NCT06294678|PROCEDURE|Time of stem cell infusion|Randomization of patients according to the time of stem cell infusion
223925057|NCT00994643|BIOLOGICAL|Rituximab|Given IV
223925058|NCT00994643|BIOLOGICAL|Interleukin-2|Given SC
223925059|NCT05443555|DRUG|Gabapentin|Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.
223925060|NCT05443555|DRUG|Placebo|Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.
223925061|NCT05994508|OTHER|Pickleball program|The intervention will be a 6-week pickleball program, at a frequency of two times a week. Each session will be one hour which will consist of dynamic warm-up drills, pickleball-related skill practice and game play, and a cool-down period.
223925062|NCT01761968|DRUG|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
223925063|NCT05990790|DRUG|Desflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
223925064|NCT05990790|DRUG|Sevoflurane|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
223925065|NCT05990790|DRUG|Propofol|After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
223925066|NCT06048978|OTHER|Commercial native starch without processing|A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
223925067|NCT06048978|OTHER|Modified starch with extrusion processing|A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
223925068|NCT06046820|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
223925069|NCT06046820|DRUG|Control Arm (Conventional Therapy)|Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.
223925070|NCT06953648|BEHAVIORAL|High Intensity Interval Training|The intervention will consist of three 30-minute training sessions/week, each starting with a five-minute warm-up, followed by 20 minutes of interval training, and ending with a five-minute cool-down. The interval training will consist of 10 alternating high- and low-intensity intervals, with a 1:1 work-to-rest ratio (one minute of high intensity followed by one minute of low-moderate intensity). As participants' fitness improves, the interval intensity will increase accordingly.
223925071|NCT06104670|DIETARY_SUPPLEMENT|Synaquell(TM)|7.9 grams (1 scoop) of Synaquell powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams).
223925072|NCT06104670|DIETARY_SUPPLEMENT|Placebo|7.9 grams (1 scoop) of placebo powder mixed with 12 ounces of water two times per day for the duration of the sport season. The daily amount taken by each participant is (15.8 grams). The placebo looks, smells, and tastes like Synaquell but does not contain active ingredient.
224281474|NCT04261569|DEVICE|Ev-NIRT|Endoventricular near infra red treatment : Intraventricular pulsed, chronic, cyclic, near-infrared illumination of the Central Nervous System (CNS) at 150 Hz, 15 mW, 1 minute ON and 5 minutes OFF
224281475|NCT00959322|DEVICE|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
224281476|NCT02394639|OTHER|video-EEG monitoring|
223925073|NCT06952933|BEHAVIORAL|Other|Surveys will be distributed for data collection. A subset of patients will participate in diagnostic clinician interviews. No interventions will be tested.
223925074|NCT06670404|DEVICE|Vertebroplasty|Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement
223925075|NCT06281795|DEVICE|tVNS|tVNS will be performed daily after workouts for 60 minutes over a period of 8 weeks.
223925076|NCT04864145|DEVICE|Transcatheter Aortic Valve Implantation|The VitaFlow™ system (MicroPort®, Shanghai, China) was a novel TAVR system, which incorporates high-radial force and a double layer polyethylene terephthalate (PET) skirt to optimize frame geometry and minimize the risks of paravalvular leak (PVL). The VitaFlow™ transcatheter aortic valve is made of a self-expanding nitinol frame and tri-leaflet bovine pericardial valve.
223925077|NCT04864145|DRUG|Medical therapy|Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
223925078|NCT05025774|OTHER|Physical activity|Participant Reported Physical Activity and Outcomes (completed via REDCap or on paper)
223925079|NCT06378619|DIAGNOSTIC_TEST|Tapping Test|For the administration of the tapping test, a computer application installed on a Tablet will be used. The test will be administered up to 3 times, with a 15-minute interval between each administration. Each tapping test trial will last 15 seconds. At the beginning of the session, the patient will perform 2 practice attempts.
224092932|NCT05377632|PROCEDURE|Robotic-assisted laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN)|laparoscopic partial nephrectomy (LPN) or laparoscopic nephrectomy (LN) include bilateral tumors or tumors in a solitary kidney. Relative indications include familial renal cancer syndromes such as Von Hippel-Lindau, hereditary leiomyomatosis, or hereditary papillary renal cell carcinoma. Patients with chronic kidney disease are generally offered nephron sparing surgery for hope of future renal function preservation. This reasoning also applies to those patients with preexisting diseases that may threaten a solitary kidney such as uncontrolled diabetes and hypertension.
224092933|NCT00162773|DRUG|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
224092934|NCT00162773|OTHER|Placebo|150-375 milligrams depending on body weight and serum IgE.
224092935|NCT01715844|DIETARY_SUPPLEMENT|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
224092936|NCT05415579|OTHER|Traditional Chinese medicine (TCM)|TCM treatment includes Chinese herbal medicine, acupuncture, moxibustion, massage, taiji, and qigong.
224092937|NCT02493179|DRUG|Serodase 5 mg|Serodase 5mg two tablets three times per day
224092938|NCT02493179|DRUG|Placebo|Placebo two tablets three times per day
224092939|NCT00784407|DEVICE|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
224092940|NCT01745003|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes-anode and cathode. We will be using this device to investigate fibromyalgia.
224092941|NCT04412304|DRUG|Dose of Tinzaparin or Dalteparin|The patients will be categorised into three groups depending on initial regime of anticoagulants after arrival in the ICU.
224092942|NCT01812525|DRUG|NaCl 3%|NaCl 3%: 4ml QID
224092943|NCT01812525|OTHER|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
224092944|NCT06487377|BIOLOGICAL|IX001 TCR-T cells|IX001 TCR-T cell injection will be administered intravenously after lymphodepletion.
224281477|NCT02837133|BEHAVIORAL|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
224281478|NCT01241682|BIOLOGICAL|DC + CTX|3x 50x10e6 DC + cyclophosphamide
224281479|NCT05965791|DIAGNOSTIC_TEST|Phalen's wrist flexion test|The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
224281480|NCT04489186|DEVICE|Wearable device|Multimodal electrocardiography (ECG), bioimpedance (bioZ) and tri-axial accelerometry (ACC) monitoring with a single wearable device (Byteflies Sensor Dot) to derive heart rate, respiratory rate and actigraphy.
224281481|NCT05007184|BEHAVIORAL|Chilean Warning Labels|These labels were implemented in Chile in 2016. They are shown on those less-healthy food and beverage products that do not fall within thresholds that are defined for the following nutrients: sugar, sodium, calories and saturated fats. The original labels are in Spanish but the ones that we displayed were in Arabic.
224281482|NCT05007184|BEHAVIORAL|Nutri-Score Labels|These labels were implemented by the French government in 2017. They are shown on all food and beverage products and range from A to E with the corresponding colours moving from Green to Red (symbolizing best to worst). The scores and grades are calculated based on 7 different nutrients grouped into 2 categories i.e. nutrients to consume (such as fibre) and nutrients to avoid (such as sugar). We modified the labels by adding % sugar per serving on the right side of the labels.
224281483|NCT05533099|OTHER|Observational study|Observational study of a device implanted in a previous clinical study
223925080|NCT06378619|DIAGNOSTIC_TEST|Archimedes Spiral|For the administration of the Archimedean spiral, a computer application installed on a Tablet will be used. The Tablet screen will display a drawing of the spiral, serving as a reference for the participant. The test will be administered up to 3 times, with a 15-minute interval between each administration. At the beginning of the session, the patient will perform 2 practice attempts.
223925081|NCT02905357|DEVICE|OCT|Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
223925082|NCT02905357|OTHER|CMR|Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
223925083|NCT06202560|DRUG|Tofacitinib 5 MG|Participants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
223925084|NCT05550571|DEVICE|Nautilus Intrasaccular Bridging System|Patients will be treated with the Nautilus, then followed-up for 12 months
223925085|NCT05207033|OTHER|Regulated ad condition|This intervention will determine if restriction of appealing features in e-cigarette ads deter young adults from trying the product.
223925086|NCT05207033|OTHER|Unregulated ad condition|This intervention will determine if unrestricted appealing features in e-cigarette ads deter young adults from trying the product.
223925087|NCT04875754|GENETIC|ICM-203|Intra-articular injection
223925088|NCT04875754|DRUG|Placebo|Intra-articular injection
223925089|NCT06182423|BEHAVIORAL|STEPS-CI (Support, Training, and Education for Pain Self-management- Cognitively Inclusive version)|This intervention is a community health worker (CHW)-led chronic pain self-management program designed for older adults with chronic pain and mild to moderate cognitive impairment. It is a 7-week intervention that includes two primary components: a website that includes brief instructional videos on pain management skills as well as testimonials from individuals living with the two target health conditions; and weekly telephone sessions with a CHW to support and motivate participants in setting goals related to pain management. Reminder strategies and content addressing pain management challenges related to cognitive impairment are incorporated throughout. Participants may choose to work with a care partner during intervention activities.
223925090|NCT06286670|PROCEDURE|Single Implant Fixation|Single implant fixation with either a precontoured lateral locking plate or an intramedullary nail.
223925091|NCT06286670|PROCEDURE|Dual Implant Fixation|Dual implant fixation with either a lateral locking plate plus an intramedullary nail or a lateral locking plate plus a supplemental medial plate.
223925092|NCT06493461|BIOLOGICAL|HS135|HS135 is dosed subcutaneously
223925093|NCT05412004|DRUG|Tirzepatide|Administered SC
223925094|NCT05412004|DRUG|Placebo|Administered SC
223925095|NCT04644029|DRUG|Islatravir|Oral 60 mg tablet administered once monthly during Part 1.
223925096|NCT04644029|DRUG|Placebo to FTC/TDF|0 mg tablet administered once daily during Part 1.
223925097|NCT04644029|DRUG|FTC/TDF|Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
223925098|NCT04644029|DRUG|Placebo to ISL|0 mg tablet administered orally once monthly in Part 1.
224281484|NCT01976728|DRUG|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
224281485|NCT01976728|DRUG|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
224281486|NCT01976728|DRUG|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
224281487|NCT01976728|DRUG|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
224281488|NCT02356211|OTHER|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
224281489|NCT05975177|DEVICE|Sterify Gel|A mucoadhesive polymeric hydrogel in a prefilled syringe for nonsurgical treatment of periodontal and peri-implant pockets, composed of polyvinyl polymers, hydroxytyrosol, nisin, and magnesium ascorbyl phosphate
223925099|NCT05448833|DEVICE|V-LAP™ SYSTEM|Delivery of the V-LAP™ implant by right heart catheterization. A catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
223925100|NCT05783934|DIAGNOSTIC_TEST|18F-florbetaben PET/CT|"The PET/CT study will be performed using a dual time acquisition protocol consisting of an early acquisition and a late acquisition.~Early acquisition Early acquisition starts with the patient already positioned on the PET/CT bed and venous access available.~A low-dose CT scan is performed for attenuation correction, the PET acquisition is started in list mode and a couple of seconds after the start, 300 MBq of 18F-Florbetaben is administered followed by washing with 10 ml of saline.~Early acquisition will last 30 minutes. Late acquisition A low-dose CT scan is performed to correct for attenuation and anatomical localisation, followed by a 20-minute list mode PET acquisition so that images are acquired after 90 minutes (tolerance: +10 minutes) of radiopharmaceutical uptake."
224092945|NCT05700461|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."
224281490|NCT05975177|PROCEDURE|Scaling and root planing|The non-surgical procedure involved SRP under local anesthesia with EMS scalers and Gracey curettes.
223531830|NCT07161466|BEHAVIORAL|lung recruitment maneuvre; PEEP|"After the patient enters the operating room, routine monitoring of ECG, non-invasive blood pressure, and SpO₂ is performed. Local anesthesia is used for radial artery puncture and catheterization to monitor invasive blood pressure.~After 3 minutes of pre-oxygenation, tracheal intubation is performed with the following ventilation parameters: VT 6-8 ml/kg, FiO₂ 60%, RR 15 breaths/min, I/E 1:2, and PEEP 4 cmH₂O. Ten minutes after the establishment of pneumoperitoneum during surgery, baseline levels of respiratory mechanical parameters and hemodynamic variables are recorded. Subsequently, alveolar recruitment is performed at a pressure of 30 cmH₂O for 30 seconds. Immediately after recruitment, the PEEP level is adjusted according to the group. The changes in respiratory mechanics parameters and hemodynamic variables after recruitment are recorded. After the outcome indicators recover to the new baseline level, the PEEP is readjusted to 4 cmH₂O."
223531831|NCT07158827|DRUG|Tavapadon|Oral: Tablet
223531832|NCT07158840|DRUG|AK112|AK112 Monotherapy
223531833|NCT07158671|OTHER|Intervention Group|"Participants in the intervention group will:~Use the survivorship programme through mHealth every day for 3 months; Be called by the healthcare provider every 2 weeks for consultation"
223531834|NCT07160946|OTHER|AI folow-up system|In AI follow-up group, patients will be followed up by an AI system.
223531835|NCT07159217|DRUG|Disitamab Vedotin|2.0 mg/kg administered intravenously every three weeks
223531836|NCT07159217|DRUG|Lenvatinib|≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily
223925101|NCT06797050|DEVICE|Training in reordering figurative stories with a social robot through the Learning by Teaching approach|A test session of the 'picture sequencing' task with the social robot is planned. The selected children will undergo an initial neuropsychological, motor and school learning assessment and will be divided into Group 1 and Group 2: Group 1 (Experimental) will be offered training with the social robot, while Group 2 (Control) will continue standard care. Both groups will be re-evaluated after approximately about 4 months. After which Group 2 will be able to start treatment. After about 4 months, the children in both groups will again undergo the planned assessments. During the training, the child will be asked to help the social robot to reorder sequences of pictures from figurative stories in order to create a story that respects temporal or causal links, or motor actions of increasing complexity, according to the Learning by Teaching paradigm.
223925102|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle Slow-pull capillary sampling|The slow-pull capillary technique was performed as follows: after identification and measurement of the target lymph node, a needle was used to puncture the lymph node with the stylet in place.At the same time, the stylet was slowly and continuously pulled to create weak negative pressure.
223925103|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration|The operation steps are the same as above, but the negative pressure device of 10ml syringe is connected behind the puncture needle.
223925104|NCT05628454|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle capillary sampling|The operation steps are the same as above, but there is no negative pressure device behind the puncture needle
224092946|NCT02473796|OTHER|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight \<2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term \& weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
224092947|NCT06151925|DEVICE|Laminaria|mechanical method for induction of labor
224092948|NCT06151925|DRUG|Vaginal prostaglandin|Vaginal prostaglandin for ripening
223531837|NCT07159217|DRUG|Pembrolizumab|200 mg intravenously every three weeks
223531838|NCT07159217|DRUG|Toripalimab|240 mg intravenously every three weeks
223531839|NCT07159217|DRUG|Camrelizumab|200 mg intravenously every three weeks
223531840|NCT07159464|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
223531841|NCT07160920|OTHER|Collect clinical data of pregnant women|Collect clinical data of pregnant women
223531842|NCT07158853|DEVICE|Transcranial Direct Current Stimulation (tDCS)|We will deliver 2-mA tDCS current intensity during a 30 minute stimulation period (including a 30-second ramp-up and 30-second ramp-down period) to the dorsolateral prefrontal cortex. Electrodes will be fixed on marked locations based on the 10-20 EEG system. Anodal stimulating electrode will be over the left DLPFC (F3) and cathodal electrode over the right DLPFC (F4).
223531843|NCT07158853|DEVICE|Sham Stimulation|electrodes will have the same montage as active tDCS (F3/F4), but current will be ramped down after the initial 30 seconds ramp-up period. Thus, participants will feel the initial sensation associated with tDCS but will receive no active current for the rest of the stimulation period.
223531844|NCT07159633|BEHAVIORAL|Online Couple Intervention|The OurRelationship program is approximately 8-10 hours of online content and will delivered over the course of 5-8 weeks. For the current study, we have tailored the general OurRelationship content for couples in recovery from substance misuse. For example, all users receive informational material on the nature of addition and recovery. All of the videos in the adapted program depict couples struggling with recovery-related issues. Additionally, the assessments and feedback content has been tailored. In addition to the online content, couples receive up to 100 minutes of scheduled coach Zoom calls (up to five 20-minute calls).
223531845|NCT07160907|BEHAVIORAL|Ageing Simulation Experience Program|Ageing Simulation Experience Program is a structured training that includes a multimedia lecture, a hands-on aging simulation using the PengZu Suit, and a peer discussion. It aims to enhance care workers' aging knowledge, empathy, attitudes, and communication skills through experiential learning.
224092949|NCT01980446|PROCEDURE|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
224092950|NCT03916068|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
224092951|NCT03916068|DRUG|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
223925105|NCT05040841|BEHAVIORAL|M1/OTR: Immediate outreach to subject due to unsuppressed viral load test result|"Standard of care viral loads are drawn at month 4, month 12 and annually thereafter. Those with a raised viral load are often not immediately recalled, but identified at their next visit (1-2 months later) and asked to attend the Risk of Treatment Failure (ROTF) clinic for adherence support when they next attend. For subjects assigned to M1 we will add a call or other outreach (e.g., text, Whatsapp, in accordance with the outreach methods subjects indicate are appropriate for them at the Enrollment visit); to the subject as soon as a raised viral load result is received (±3-5 days), thus expediting entry to existing adherence support. There are two chances to be identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M1."
223925106|NCT05040841|BEHAVIORAL|M2/PRM: Immediate outreach to subject after a missed pharmacy refill|The subject will be contacted if he/she fails to collect medication from the pharmacy. A subject who is ≥7 days late for a monthly medication pick-up or 14 days late for a 2-monthly pick-up will be notified, again expediting entry to existing adherence support. There are 8-10 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
223925107|NCT05040841|BEHAVIORAL|M3/EAM: Immediate outreach to subject after EAM-identified missed doses|The subject will be contacted if he/she misses ≥4 doses or any three consecutive doses in a 14-day period, reviewed weekly, as identified by the EAM (electronic adherence monitor). There are 52 chances of being identified as nonadherent and linked immediately to existing adherence support in the first 12 months of care with M2.
223925108|NCT05040841|BEHAVIORAL|S1/Text: Weekly check-in texts|"Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent."
223925109|NCT05040841|BEHAVIORAL|S2/Peer: Enhanced peer group support|"Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks."
224092952|NCT03916068|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
224092953|NCT03793478|DRUG|Quizartinib|"Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28"
224092954|NCT03793478|DRUG|Fludarabine|30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)
224092955|NCT03793478|DRUG|Cytarabine|"2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18"
224092956|NCT03793478|DRUG|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site
224092957|NCT03793478|DRUG|Etoposide|"Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5"
224092963|NCT02243878|RADIATION|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
224092964|NCT02243878|DRUG|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
224092965|NCT04759898|DEVICE|transcranial direct current stimulation (noninvasive recording)|Subjects will enter the EEG lab and be seated in a chair. The 26-electrode EEG array will be placed using a conductive paste. The electrodes will be connected to a clinical grade EEG machine used in standard of care routine EEG monitoring. Next, a soft cloth cap will be placed over the subject's head with the tDCS electrodes pre-positioned in place. The cap will be positioned so that the tDCS electrodes cover the scalp without disturbing the underlying EEG electrodes. Conducting gel will be applied in direct contact with the scalp to facilitate stimulation. In addition, lidocaine jelly will be added topically to provide local anesthesia. The tDCS electrodes will be connected to a low-current generator. Participants receive 2.0 milliamps in electrical stimulation from the tDCS machine for 20 minutes. The device will be manually controlled by study personnel assisting with the experiment. A virtual reality environment will be utilized to collect kinematic data during the study.
224092966|NCT04759898|DEVICE|sham transcranial direct current stimulation (noninvasive recording)|Subjects receiving sham undergo the same setup as the stimulation group with the exception that sham subjects experience stimulation for one minute only (30 second ramp-up to 2 milliamps immediately followed by 30 second ramp-down to 0 milliamps for the remaining 19 minutes). This provides similar sensory feedback to sham subjects that treatment subjects experience. The same electrode array, soft cloth cap, conducting gel application, and lidocaine are applied as in a stimulation subject. The tDCS electrodes will be connected to a low-current generator. A virtual reality environment will be utilized to collect kinematic data during the study.
223925110|NCT00968149|DRUG|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
223925111|NCT00968149|DRUG|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
223925112|NCT06490783|OTHER|Noninvasive wearable devices (smartwatch and heart rate monitor band)|"Each enrolled subject will be equipped with noninvasive wearable devices (smartwatch and heart rate monitor band) to monitor physiological parameters and emotional states related to anxiety and stress. Each subject will be required to wear the smartwatch on his or her wrist for the duration of the study, about 3-6 months; while the heart rate monitor band will be worn for about 10 minutes a day. At the same time, a mobile application, RESILIENT, will be developed and implemented to serve as the main interface for self-assessment data entry and for feedback and recommendations.~The psycho-physical condition of each subject will be monitored by the app through customized and contextualized mental exercises based on daily activities. This approach will test the effectiveness of the proposed architecture in reducing unhealthy habits and promoting health and wellness recommendations"
223925113|NCT05266417|DRUG|INS-GSH|Intranasal INS-GSH Twice Daily
223925114|NCT05266417|DRUG|Matched Placebos|Intranasal Matched Placebos Twice Daily
223925115|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
224092967|NCT04759898|DEVICE|transcranial direct current stimulation (invasive recording)|Subjects are brought into the operating room. The scalp is prepped with a sterilizing solution. Following infiltration with local anesthetic and incision, a 6-contact electrocorticography strip is inserted into the burr hole covering primary motor cortex. Electrocorticography strip terminals are connected to an amplifier for signal recording. Gas-sterilized transcranial direct current stimulation electrodes are placed on the scalp directly overlying primary motor cortex. tDCS electrodes are connected to a low-current generator. During electrocorticographic recording, stimulation is turned on while subjects are asked to flex each arm. At the conclusion of the experiment, the electrocorticography strip and tDCS electrodes are removed and the surgery proceeds as planned.
224092968|NCT03667820|DRUG|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
224092969|NCT03667820|RADIATION|SABR|Stereotactic Ablative Radiation (SABR)
224281491|NCT05393128|PROCEDURE|Control group (Supine Position)|"In this group the patients will be given supine position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be given supine position.~3. The arms and the hands will be elevated and supported, the legs will be elevated and supported.~4. The patient will be covered.~5. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
223925116|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase)
223925117|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 1 (Crossover Phase)
223925118|NCT05383352|DRUG|Irinotecan liposome injection|Onivyde 70 mg/m2 intravenously over 90 minutes on Cycle 1 Day 15 (Crossover Phase) and from cycle 2 onwards on Day 1 and Day 15 of every 28-day cycle (Extension Phase)
224092970|NCT01393587|PROCEDURE|Taking blood samples|
224092971|NCT02091440|DEVICE|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
223925119|NCT05383352|DRUG|Folinic Acid|LV 400 mg/m2 intravenously over 30 minutes, on Day 1 and Day 15 of every 28-day cycle
224092972|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
223925120|NCT05383352|DRUG|5-Fluorouracil|5-FU 2,400 mg/m2 intravenously over 46 hours, on Day 1 and Day 15 every 28-day cycle
223925121|NCT06283147|BEHAVIORAL|Risk assessment and Management Programme - Knee Osteoarthritis|"(i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis What Do People With Knee or Hip Osteoarthritis Need to Know~(ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings.~(iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2.~(iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment.~(v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management."
223925122|NCT05901727|OTHER|No intervention|Observational data collection only.
223925123|NCT01688765|OTHER|Observational|
223925124|NCT05180838|DEVICE|BioSticker|The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring
223925125|NCT03771001|OTHER|Motivational Interviewing coaching and habit-building app|Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
223925126|NCT05354323|BIOLOGICAL|NECVAX-NEO1|Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes
223925127|NCT05468827|PROCEDURE|lymphatic mapping with indocyanine green|subserosal injection of indocyanine green near the primary tumour with subsequent assessment of the dye spread along lymphatics
223925128|NCT03217461|PROCEDURE|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera and cornea by sutured femtosecond laser-assisted limbal autograft.
223925129|NCT03217461|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
223925130|NCT06158152|DIETARY_SUPPLEMENT|AM3 + Probiotic|Two capsules daily in the morning during 12 weeks. The capsule contains the mixture of AM3 Technology and probiotic SynBalance Metsyn.
223925131|NCT06158152|DIETARY_SUPPLEMENT|Placebo|Two capsules daily in the morning during 12 weeks. The capsule contains starch.
223925132|NCT06158152|DIETARY_SUPPLEMENT|AM3|Two capsules daily in the morning during 12 weeks. The capsule contains AM3 Technology.
224092973|NCT02144649|DIETARY_SUPPLEMENT|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
224092974|NCT02144649|OTHER|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
224092975|NCT02144649|OTHER|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
224092976|NCT05381402|OTHER|Questionnaire|Questionnaire to assess the impact of COVID 19 on psoriasis patients
223925133|NCT06368310|DEVICE|INBRAIN Graphene Cortical Interface|Study device to be evaluated intra-operatively alongside standard of care neurophysiological monitoring.
223925134|NCT04232085|DRUG|Alemtuzumab|Preparative regimen
223925135|NCT04232085|DRUG|Fludarabine|Preparative regimen
223925136|NCT04232085|DRUG|Melphalan|Preparative regimen
223925137|NCT04232085|RADIATION|Low Dose Total Body Irradiation|Preparative regimen
223925138|NCT04232085|DRUG|Cyclophosphamide|GVHD prophylaxis
223925139|NCT04232085|DRUG|Tacrolimus|GVHD prophylaxis
223925140|NCT04232085|DRUG|Mycophenolate Mofetil|GVHD prophylaxis
224092977|NCT06325449|BEHAVIORAL|STREAM program|The STREAM program is a 24-week weight-loss program which includes meal replacement, dietician coaching/teaching and weekly visits with a physician.
224092978|NCT00768222|DEVICE|silk suture|skin closure
224092979|NCT00768222|DEVICE|VICRYL* Plus suture|skin closure
224092980|NCT02602509|DRUG|Celecoxib|
224092981|NCT02602509|DRUG|Rifampicin|
224092982|NCT02602509|DRUG|Pyrazinamide|
223925141|NCT03713554|PROCEDURE|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
223925142|NCT00495677|DRUG|PF-00232798|Solution, 20 mg. once daily, 10 days
223925143|NCT00495677|DRUG|PF-00232798|Solution, 150 mg. once daily, 10 days
223925144|NCT00495677|DRUG|PF-00232798|Solution, 5 mg. once daily, 10 days
224092983|NCT03389243|DRUG|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
224092984|NCT03389243|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
223925145|NCT00495677|DRUG|PF-00232798|Solution, 40 mg. once daily, 10 days
223925146|NCT00495677|DRUG|PF-00232798|Solution, 300 mg. once daily, 10 days
223925147|NCT00495677|DRUG|PF-00232798|Solution, 400 mg. once daily, 10 days
223925148|NCT01969916|DRUG|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
223925149|NCT05779839|BEHAVIORAL|Algorithm|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be matched using an algorithm. They can then choose make a connection and maintain a connection for the duration of the study.
223925150|NCT05779839|BEHAVIORAL|Random Match|For purpose of finding peer-to-peer support, current and/or former caregivers of persons with dementia will be randomly matched. They can then choose make a connection and maintain a connection for the duration of the study.
223925151|NCT04319549|OTHER|Ketorolac Tromethamine irrigant|Ketorolac tromethamine, a potent NSAID available in both oral and injectable forms, is over 400 times more potent as a selective inhibitor of COX-1 over COX-2 than many other drugs. When ketorolac tromethamine was used as an intracanal medicament in teeth with irreversible pulpitis undergoing root canal treatment, it contributed to significant post operative pain relief.
223925152|NCT04319549|OTHER|sodium hypochlorite irrigant|NaOCl is the gold standard and the most commonly used root canal irrigant. NaOCl is able to dissolve the organic tissues inside root canal due to its alkalinity (pH11), which causes amino acid degradation and hydrolysis through the production of chloramine molecules. In addition, it possesses highly antibacterial effect and its low cost makes it the most frequently used root canal irrigant. Dual rinse is considered an effective time saving root canal irrigant with a better antibacterial property in comparison to NaOCl alone. In addition to its effectiveness on smear layer removal and reduction in the debris accumulation during root canal instrumentation.
223925153|NCT02932761|DRUG|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
223925154|NCT02932761|PROCEDURE|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
223925155|NCT05438992|DRUG|Bupivacaine 0.25% Preservative-Free Injectable Solution|local anesthetic drug injection for postoperative pain
223925156|NCT06510608|DIAGNOSTIC_TEST|Biochemical analysis of saliva sample|It is the examination of saliva samples taken with biochemical methods. In this way, the substances in its content and the concentration of cytokines are analyzed.
223925157|NCT01476241|PROCEDURE|PEG tube placement|Percutaneous endoscopic gastrostomy
223925158|NCT05980559|DRUG|Xeomin|50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
223925159|NCT05036837|DRUG|OZOPROMAF_SEQ1|"OZOPROMAF protocol consists of: local superficial anesthesia by EMLA® cream, intra-tissue injection of a 15 ml OxigenOzone (mixture by 26Gx 1⁄2 - 0.45x13mm needle into the mucosal margin surrounding the bone exposure or around the situs already evidenced by CT scan. It is applied on 7-15 days, depending on the patient compliance, until the formation of sequestrum and clinical healing (T1).~Pain intensity is assessed by means of a questionnaire for pain and/or other symptoms evaluation before and after the protocol, based on numerical rating scale (NRS).~After resolution (T1), follow-up visits are scheduled to confirm the healing of MRONJ at 1 (T2), 3, 6 (T3), 12 (T4), 18- 24 months (T5).~Radiographic evaluations of bone healing are scheduled at T3 and T4.~Positive outcomes for the OZOPROMAF protocol are evaluated at T1 as no clinical signs of acute phlogosis and no symptoms compatible with MRONJ; at T5 as clinical healing and no radiological signs of MRONJ."
223925160|NCT02559349|OTHER|Stool Collection|
223925161|NCT04914403|BIOLOGICAL|UMC119-06-05|Cohort 1: Low does of UMC119-06-05 Cohort 2: High does of UMC119-06-05
223925162|NCT00448552|DRUG|capecitabine|
223925163|NCT00448552|DRUG|oxaliplatin|
223925164|NCT05220943|BEHAVIORAL|Video|This 5-minute video presents clips with voiceover narration summarizing and highlighting the key safety points in the Center for Surgical Innovation (CSI) location.
224092985|NCT03389243|DRUG|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
224092986|NCT04153630|BIOLOGICAL|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
224092987|NCT05152186|DRUG|Topical Solution|Topical administration
224092988|NCT05152186|DRUG|Topical Foam|Topical administration
224092989|NCT05152186|OTHER|Topical|Topical administration
223717607|NCT04657120|PROCEDURE|YEARS algorithm|Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.
223925165|NCT02056236|DRUG|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
223717608|NCT04657120|PROCEDURE|CTPA|Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
223717609|NCT03902821|OTHER|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
224092990|NCT00779129|DRUG|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
223531851|NCT07159555|OTHER|Blood sampling for neurofilament analysis|An additional blood sample (maximum 1 mL) is collected during routine clinically indicated blood draws in late preterm infants (34-37 weeks of gestation). Samples are obtained at birth, day 2, and weekly until 37 weeks of gestation if blood draws are already planned. No separate venipuncture is performed. Samples are processed and stored for subsequent neurofilament concentration analysis.
223531852|NCT07160335|DRUG|HLX17|Subjects will receive HLX17 (200 mg) on Day 1 of each 3-week cycle
223531853|NCT07160335|DRUG|US-sourced Keytruda®|Subjects will receive US-sourced Keytruda® (200 mg) on Day 1 of each 3-week cycle
223531854|NCT07159750|DRUG|CGRP antibody or gepant|Patients will start anti-CGRP or its receptor antibody or gepants
223531856|NCT07161206|BEHAVIORAL|Digital Mindfulness Nudge Intervention|Participants will be guided through 28 Days of Mindfulness Exercises via a Telegram Channel (In a digital and nudge-based format)
224092991|NCT00779129|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
224092992|NCT02505048|DRUG|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
224092993|NCT03576144|DRUG|BI 1265162|Multiple rising inhaled doses
224092994|NCT03576144|DRUG|Placebo|Multiple rising inhaled doses
224092995|NCT00278629|BIOLOGICAL|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
224092996|NCT02461017|OTHER|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
224092997|NCT02461017|OTHER|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
223531857|NCT07160569|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGS), Sequence Type Analysis (ST)|Whole Genome Sequencing (WGS), Sequence Type Analysis (ST), resistome, viruloma, and phenotypic resistance of CRE
223531858|NCT07160647|DRUG|Ipalolimab and Tovorilimab|1.Active Ingredients: Ipalolimab and Tovorilimab (a dual-functional combination antibody consisting of Ipalolimab, a recombinant humanized monoclonal antibody targeting programmed death receptor-1 \[PD-1\], and Tovorilimab, a recombinant humanized monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein-4 \[CTLA-4\]). 2.Specification: 50 mg (2 mL) per vial. 3.Dosage and Administration: Administer via intravenous infusion at a recommended dose of 5 mg/kg every 3 weeks.
223531859|NCT07161050|BEHAVIORAL|Nicotine Content|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
223531860|NCT07161050|BEHAVIORAL|Illegal cigarette price|At each level of nicotine content, we will manipulate the price of illegal cigarettes (1xMP, 1.5x MP, 2x MP). MP is market price.
223531861|NCT07161050|BEHAVIORAL|E-cigarette price|At each level of nicotine content and illegal cigarette price, we will manipulate the price of e-cigarettes (1xMP, 1.5x MP, 2x MP). MP is the market price.
223531862|NCT07160959|BEHAVIORAL|Exercise|Patients will undergo a home-based low-intensity interval multi component exercise program including aerobic and strengthening exercise
223531863|NCT07160959|OTHER|Control (Standard treatment)|Patients will be treated with standard therapy based on their CKD stage
223531864|NCT07159035|PROCEDURE|Flexible ureteroscopy with FANS|The FANS with negative-pressure suction, enhancing intrarenal pressure control and fragment evacuation during flexible ureteroscopy.
223925166|NCT02056236|OTHER|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
223925167|NCT04632394|DIAGNOSTIC_TEST|Generation of computational model from cardiac MRI.|Routine cardiac MRI scan results will be sent to Johns Hopkins University where a computer-generated model of the heart will be made, which will demonstrate predicted areas critical to VT generation and maintenance. This data will be sent back to St George's, and integrated with the standard VT ablation mapping software to allow comparison of its accuracy with standard mapping techniques.
223531865|NCT07159035|PROCEDURE|Mini-percutaneous nephrolithotomy (mini-PCNL)|Mini-PCNL is performed under general anesthesia with less than 20 Fr access tract, using rigid nephroscopy and stone fragmentation under direct visualization. Postoperative drainage is provided via nephrostomy or ureteral stent as per protocol.
223531866|NCT07161284|OTHER|Exposition to trained peer-support registrars for a year|Exposition to trained peer-support registrars for a year
223531867|NCT07159594|OTHER|Energy restriction|Diet with LED and energy restricted diet with gradually inclusion of meals
223925168|NCT04632394|PROCEDURE|VT ablation|Routine VT ablation as described elsewhere in the literature. However, a brief period of extra time (\~30 minutes) will be spent analysing the areas of the heart which the MRI scan predicted as being important for generation of VT. We will study the effect of ablation of these areas (if indicated) on distant parts of the heart.
223925169|NCT03554889|BIOLOGICAL|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
223925170|NCT03554889|DRUG|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
223925171|NCT02438059|BEHAVIORAL|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
223925172|NCT00995631|PROCEDURE|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
223925173|NCT02297919|BEHAVIORAL|Effectiveness of Internet Based Obesity Control Programme|
223925174|NCT05353894|DRUG|GNS561 oral tablets and capsules|Two formulations and Two dosage will be compared
223925175|NCT05934383|DEVICE|Paradise® ultrasound renal denervation system.|Bilateral renal sympathetic denervation of the native kidneys using the Paradise® ultrasound renal denervation system.
224092998|NCT01906749|DRUG|Colchicine|0.5mg once daily orally
224092999|NCT01906749|DRUG|Placebo|
223925176|NCT05566067|OTHER|Survey|There will be no interventions for study participants. Participants will be asked to complete a survey.
223925177|NCT06030648|BIOLOGICAL|Mesenchymal stem cells (IV-MSC)|Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.
223717610|NCT01837615|DEVICE|Photopill treatment|
223717611|NCT00004814|DRUG|copolymer 1|
223925178|NCT05002738|DRUG|Desogestrel and Ethinyl Estradiol Tablets|Combined oral contraceptive pill
223925179|NCT04129164|DRUG|VIB4920|Intravenous Dose 1.
223925180|NCT04129164|DRUG|Placebo|Intravenous dose matched to VIB4920.
224093000|NCT03323749|COMBINATION_PRODUCT|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
224093001|NCT03323749|COMBINATION_PRODUCT|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
224093002|NCT03323749|COMBINATION_PRODUCT|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
224093003|NCT01444716|BIOLOGICAL|Ofatumumab|Given IV
224093004|NCT04250584|DEVICE|iSlpr™|mandibular advancement device
224093005|NCT04250584|DEVICE|SomnoDent® Classic|mandibular advancement device
223925181|NCT03868930|BEHAVIORAL|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
223925182|NCT03868930|BEHAVIORAL|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
223925183|NCT05441449|DEVICE|Cooling Vest|"A self-regulating cooling vest for persons with SCI that can utilize both conductive and evaporative methods to dissipate body heat as a proof-of-concept to prevent an excessive rise in Tcore and thermal discomfort during a controlled exposure to a warm environment. The vest is an article of clothing, is made of commercially-available wicking material, which once saturated with water, uses evaporation to dissipate heat. Channels embedded in the vest supply cooled water to keep the wet vest cool. The cooling capacity of the vest is regulated by a microprocessor which continuously receives feedback from the user's skin and core temperature. The vest is non-invasive and supplies no energy to the user."
223925184|NCT06960018|DEVICE|Ennovate® Cervical, open surgical technique|"Patients with need of posterior monosegmental and multisegmenta stabilization of the cervical and upper thoracic spine, because of~* Fractures~* Degenerative instability~* Post-trauma instability~* Tumors~* Degenerative cervical myelopathy due to multilevel subaxial spinal canal stenosis will be treated with Ennovate® Cervical system using an open surgical technique"
224093006|NCT03420976|DIETARY_SUPPLEMENT|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
224093007|NCT00507715|DRUG|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
224093008|NCT00507715|OTHER|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
224093009|NCT00312013|DRUG|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
224093010|NCT03263091|DRUG|Roxadustat|Oral tablets
224093011|NCT03263091|DRUG|Placebo|Oral tablets
224281492|NCT05393128|PROCEDURE|Experimental Group (Right Lateral position)|"In this group the patients will be given right lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the right side of the patient and the patient will be turned with 60-90 degrees right lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital signs, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
224281493|NCT05393128|PROCEDURE|Experimental Group (Left Lateral position)|"In this group the patients will be given left lateral position.~1. Body temperature, heart rate, respiration rate, blood pressure, oxygen saturation and CVP will be recorded before the process.~2. The patient will be positioned supine and the bed will be straightened.~3. Lines, probes will be taken to the left side of the patient and the patient will be turned with 60-90 degrees left lateral and the back will be supported with a pillow along the neck and sacrum.~4. Between the legs will be supported with pillows.~5. The patient's head will be elevated with 45-60 degrees.~6. The patient will be covered :~7. The patient's vital findings, SpO2 levels will be registered right before giving position, on the 1st minute, on the 1st hour and on the 2nd hour from right after giving position."
224281494|NCT00777933|DRUG|tacrolimus|
224281495|NCT00777933|DRUG|cyclosporine|
224281496|NCT06617533|OTHER|PCF model|PCF practices practices receive (1) a per-beneficiary-per-month prospective payment that depends on the average health of their attributed Medicare beneficiaries; (2) a Flat Visit Fee for primary care visits, subject to a geographic adjustment factor, and (3) a Performance-based Adjustment (PBA). The PBAs depend on practices' performance on several quality measures in addition to their performance in reducing beneficiaries' use of inpatient care or total cost of care, relative to national and regional benchmarks. Practices must meet a limited set of care delivery requirements and can use the PCF Model's flexible use of payments to invest in strategies that best suit their practices' unique patient population and resources. In return, practices take on limited financial risk in exchange for performance-based payments that reward participants that meet certain performance and quality benchmarks for selected outcomes.
224281497|NCT04344132|PROCEDURE|Scalp Block|standard practice of controll the pain after surgery. Block of the nerve emergences.
224281498|NCT03527680|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
224281499|NCT03527680|DRUG|Placebo - Cap|daily one capsule of placebo
224281500|NCT00643734|DRUG|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
224281501|NCT00643734|OTHER|placebo|placebo
224281502|NCT00643734|DRUG|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
224281503|NCT00643734|OTHER|placebo|placebo
224281504|NCT04703517|DIAGNOSTIC_TEST|Point of care ultrasound|Patients will receive a point of care ultrasound at the bedside in the Emergency Department and compare the impression to the x ray result
224281505|NCT05108116|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS 3D recontruction of the lower limb and pelvis will be performed.
224281506|NCT03765996|OTHER|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
223925185|NCT06960018|DEVICE|Ennovate® Cervical, minimal invasive surgical technique|"Patients with need of posterior monosegmental and multisegmenta stabilization of the cervical and upper thoracic spine, because of~* Fractures~* Degenerative instability~* Post-trauma instability~* Tumors~* Degenerative cervical myelopathy due to multilevel subaxial spinal canal stenosis will be treated with Ennovate® Cervical system using a minimally invasive technique."
223531868|NCT07161401|OTHER|Observational assessment|Evaluation of sleep quality using the Children's Sleep Habits Questionnaire (CSHQ) and cephalometric analysis of mandibular position (SNB), vertical dimensions (SNGoGn, FMA), and upper airway measurements. No active intervention was performed.
223925186|NCT06562218|PROCEDURE|isokinetic strengthening exercise|"Participants' isokinetic strength measurements will be assessed using the Cybex II Humac Norm isokinetic dynamometer. A strengthening programme will be performed for a total of 12 sessions, 3 days a week for 4 weeks, at 20 degrees of flexion, 20 degrees of extension, 60-90 and 180 degrees/s speed.~At the beginning and end of the 12th session, isokinetic and isometric muscle performance tests will be performed on the healthy wrist, and isometric wrist flexor and extensor strength measurements will be performed in neutral position 1 week after removal of the cast on the fractured wrist."
223925187|NCT06562218|PROCEDURE|conventional exercise programm|The immobilised limb was given finger grip exercises.
223925188|NCT01401231|BEHAVIORAL|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
223925189|NCT01401231|OTHER|Usual care|Continued usual care (could include referral for medication or psychotherapy)
223925190|NCT03466476|DEVICE|Consensus TracPatch|Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
223925191|NCT04772911|DEVICE|Optical Coherence Tomography (OCT)|OCT will be performed at baseline and prior to each standard of care laser treatment to characterize the mean diameter and depth of blood vessels.
223925192|NCT02231749|BIOLOGICAL|Nivolumab|
223925193|NCT02231749|BIOLOGICAL|Ipilimumab|
223925194|NCT02231749|DRUG|Sunitinib|
224281507|NCT03765996|OTHER|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
224281508|NCT02512614|OTHER|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
223925195|NCT04838301|DRUG|Allopregnanolone|Allopregnanolone 4mg IV via 30-minute infusion, once per week.
223717612|NCT01512277|BIOLOGICAL|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
223925196|NCT04838301|OTHER|Placebo|Normal saline solution IV via 30-minute infusion, once per week
223925197|NCT05249842|DIAGNOSTIC_TEST|Spirometric evaluation|Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75
223925198|NCT05249842|DIAGNOSTIC_TEST|Physical component summary|Evaluation of the physical component summary of SF-36 quality of life
223925199|NCT05249842|DIAGNOSTIC_TEST|6MWT|6 minute walk test
223925200|NCT03582592|BEHAVIORAL|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
223925201|NCT05080413|DEVICE|Laser shoes|Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
223925202|NCT05080413|DEVICE|Metronome|The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
223925203|NCT05541926|BEHAVIORAL|e-Connect|Implementation of the e-Connect system
223925204|NCT06498258|OTHER|Pozitif Psikoterapi Denge Modeli Temelli Psikoeğitim|In this study, it can be said that adopting a loving, connected and balanced state of mind in the face of the difficulties experienced and responsibilities undertaken by caregivers will increase the joy, meaning and self-sufficiency in life and as a result, it can positively contribute to their level of well-being. All these results are important for caregivers to be able to recognise their own resources, to maintain their life balance, to develop a positive perspective towards themselves, to make subjective evaluations and to recognise their strengths.
223925205|NCT06550232|DRUG|Papaverine|Within 30-minutes prior to catheter insertion, women in the intervention group will receive IV-papaverine 80 mg in 100 ml 0.9% saline
224093012|NCT04470895|DIAGNOSTIC_TEST|Failure Track patients analysis|"The nurse coordinator of the Fracture Track first comes to give the patient a written information note. She answers the patient's questions and obtains his or her non-opposition. The patient must be given sufficient time for reflection to make his decision in order to participate in the study. His non opposition will be traced in the computerized medical record. Each enrolling patient in the study can simultaneously participate in another research. There is no exclusion period in the protocol.~Once the patient is included, a semi-directed interview is conducted. The name of the patient's usual pharmacy will be collected. Data from the computerised medical record concerning the patient's stay are also analysed.~The patient's usual pharmacy or the nurse in charge of the patient will then be questioned in order to carry out a drug reconciliation interview."
224093013|NCT02468193|DRUG|Osilodrostat|Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
224093014|NCT00659672|DIETARY_SUPPLEMENT|Whey Protein|40 grams per day Whey Protein
223925206|NCT06550232|OTHER|placebo|I.V Sallne
223925207|NCT03678441|BEHAVIORAL|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
224093015|NCT00659672|DIETARY_SUPPLEMENT|Soy Protein|40 grams per day soy protein
224093016|NCT00659672|DIETARY_SUPPLEMENT|Control (carbohydrate)|40 grams per day maltodextrin
224093017|NCT04996056|DRUG|TNX-1300|TNX 1300 200 mg Intravenous injection
224093018|NCT04996056|OTHER|Usual Care|Usual Care per the Emergency Department protocol for Cocaine Intoxication
224093019|NCT06456177|DEVICE|Assessment of nociception in obstetric patients during epidural analgesia|Comparing nociception in obstetric patients during epidural analgesia, subjectively, by Visual analog scale and objectively by monitoring Nociception level Index
224093020|NCT01306981|DRUG|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
224093021|NCT01306981|DRUG|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
224093022|NCT06475404|BIOLOGICAL|verenafusp alfa 6 mg/kg|Single intravenous administration of 6 mg/kg of verenafusp alfa
223925208|NCT03678441|PROCEDURE|Cognitive Assessment|Receive pen and paper cognitive assessment
223925209|NCT02263274|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
224093023|NCT06475404|BIOLOGICAL|verenafusp alfa 9 mg/kg|Single intravenous administration of 9 mg/kg of verenafusp alfa
223925210|NCT01380743|DRUG|duvoglustat|Single oral dose
223925211|NCT01380743|DRUG|rhGAA|Single intravenous infusion
224093024|NCT06475404|BIOLOGICAL|verenafusp alfa 12 mg/kg|Single intravenous administration of 12 mg/kg of verenafusp alfa
223925212|NCT06292767|OTHER|mechanical power calculation|Mechanical Power= 0.098×Minute ventilation× (peak pressure - 0.5 (plato pressure-PEEP)). These parameters are monitored on the monitor while the patient is mechanically ventilated and placed into the equation
223925213|NCT06494605|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model (ESDM) is an early naturalistic and behavioural intervention for children with initial signs of neurodivergence or on the autism spectrum between the ages of 12-48 months. This early intervention aims to increase the rates of development in several domains and to decrease the characteristics of autism conditions that hinder children's ability to learn from everyday experiences and interactions.
223925214|NCT05876078|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in ADHF patients
224093025|NCT00762151|OTHER|Negative Control (Regular Toothpaste)|Regular Toothpaste
224093026|NCT00762151|OTHER|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
224093027|NCT00762151|DRUG|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
224093028|NCT00728338|DIETARY_SUPPLEMENT|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
224093029|NCT00728338|DIETARY_SUPPLEMENT|Olive oil|7.5 g olive oil/day
224093030|NCT04674943|OTHER|Breathing exercises|Breathing exercises as well as Buteyko technique and Papworth relaxation method was performed as relaxation technique. All exercises were performed 15rep 3 sets for 15 min.
224093031|NCT03714893|DEVICE|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
224093032|NCT01979107|BEHAVIORAL|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
223925215|NCT02224729|DRUG|Bendamustine hydrochloride|Given IV
223925216|NCT02224729|DRUG|Bortezomib|Given SC
223925217|NCT02224729|DRUG|Dexamethasone|Given PO
223925218|NCT06966154|DRUG|tislezumab|Tislelizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks (Q3W).
223925219|NCT06966154|DRUG|golidocitinib|"Golidocitinib: Dose-escalating oral regimens:~Dose level A: 150 mg every other day (QOD). Dose level B: 150 mg once daily (QD)."
224093033|NCT00826748|DRUG|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
224093034|NCT05951582|OTHER|Plyometric Exercises|"The group will receive plyometric exercises in a controlled environment. Following Plyometrics were performed.~1. Horizontal jumps over hurdle.~2. Standing long jump~3. Front cone hops~4. Forward-backward run~5. Double leg horizontal jump~6. Lateral jump over hurdle~7. Side to side sprint~8. Jumps over low hurdles~9. Split squat jump~10. Cone hops with change of sprint direction~11. Lateral jump over hurdle~12. Side to side slide and hops.~13. Lateral and horizontal jump~14. Cone hops with 180o turn~15. Vertical, Lateral, and horizontal jump~16. Lateral cone jump~17. Single leg lateral jump~18. Diagonal Jumps.~19. Standing long jump with diagonal sprint.~20. Single leg vertical jump~21. Cone hop with 1800 turn~22. Skipping over cone"
224281509|NCT02430415|DEVICE|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
224281510|NCT02430415|DEVICE|traditional lightwand intubation|traditional lightwand intubation
224281511|NCT01185028|DRUG|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
224281512|NCT00922259|BIOLOGICAL|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
224281513|NCT03063424|DIAGNOSTIC_TEST|Eucapnic voluntary hyperventilation|
224281514|NCT03063424|DIAGNOSTIC_TEST|Exercise challenge on a cycle ergometer|
224281515|NCT01569347|OTHER|Interviews|Interviews
224281516|NCT01569347|OTHER|Blood sample|Blood sample
224281517|NCT01569347|OTHER|Hair sample|Hair sample
224281518|NCT03389256|DRUG|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
224281519|NCT03389256|DRUG|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
224281520|NCT01563237|DEVICE|MIDI Arrow|Implantation of MIDI Arrow
224281521|NCT01904422|PROCEDURE|conventional periodontal treatment|
224281522|NCT01835704|OTHER|Radio-frequency dennervation of facet joint|
224281523|NCT01835704|OTHER|Diagnostic nerve-blocks performed under direct x-ray vision|
224281524|NCT02246868|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
224281525|NCT02033135|PROCEDURE|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
224281526|NCT02033135|OTHER|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
224281527|NCT02033135|DEVICE|Zilver PTX|
224281528|NCT01938235|DRUG|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
223925220|NCT06966154|DRUG|Selinexor|Selinexor: Dose-escalating oral regimens: Dose A: 40 mg once weekly (QW) . Dose B: 60 mg QW for 2 consecutive weeks, followed by 1 week off.
224281529|NCT01938235|DRUG|Placebo|Intravenous bolus and 24-hour infusion of placebo
224281530|NCT03347357|DRUG|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
224281531|NCT05303935|DRUG|Quetiapine 50 MG|A single dose of 50mg of quetiapine taken at bedtime for one night.
224281532|NCT05303935|DRUG|Placebo|A placebo sugar pill that looks like the quetiapine tablet taken at bedtime for one night.
224281533|NCT06678646|PROCEDURE|Elbow ultrasound-guided surgery|Percutaneous Ultrasound-Guided Release of the Lacertus Fibrosus for Median Nerve Entrapment at the Elbow
224281534|NCT04910828|OTHER|Common foods of varying glycemic indices|Examples of foods of varying glycemic index to be tested include bread, rice, breakfast cereals, starchy vegetables, legumes, fruit and dairy products.
224281535|NCT00191464|DRUG|premeal insulin lispro mixtures|
224281536|NCT00191464|DRUG|insulin glargine|
224281537|NCT00191464|DRUG|metformin|
224281538|NCT03176355|PROCEDURE|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
224281539|NCT04445064|BIOLOGICAL|IO102|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
224281540|NCT04445064|BIOLOGICAL|IO103|100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
224281541|NCT00966381|OTHER|Exercise and weight loss intervention|randomized control trial, stratified by parity
223531869|NCT07161076|DEVICE|3d Printed space maintainer|using Next dent permanent crown resin, a digitally designed space maintainer will be 3d printed to maintain space after extraction
223531870|NCT07161076|DEVICE|stainless steel band and loop|lab fabricated metal band and loop
223925221|NCT06966414|BEHAVIORAL|Morning exercise|Participants performed bodyweight exercise in the morning between 08:00 to 11:00 AM.
223925222|NCT06966414|BEHAVIORAL|Evening exercise|Participants performed bodyweight exercise in the morning between 18:00 to 21:00 PM.
224281542|NCT03782480|DRUG|Intrarosa|Prasterone intravaginal inserts
224281543|NCT03782480|DRUG|Placebos|Placebo intravaginal inserts
224281544|NCT04421092|PROCEDURE|Superior laryngeal nerve block|Injection of either the steroid-lidocaine mixture or placebo through the skin around where the superior laryngeal nerve is located on the neck. The procedure lasts 5 minutes and is done in the clinic.
224281545|NCT04421092|PROCEDURE|Injection of placebo (saline)|Superior laryngeal nerve block using 1mL of saline as the injection.
224281546|NCT04421092|PROCEDURE|Injection of steroid-lidocaine mixture|Superior laryngeal nerve block using 1mg 1:1 triamcinolone 40mg: 1% lidocaine with 1:200000 epinephrine as the injection.
223925223|NCT06965543|PROCEDURE|Immediate G-POEM|Gastric POEM (G-POEM) performed under general anesthesia. A submucosal tunnel will be created along the greater curvature of the stomach to access the pyloric muscle under endoscopic vision. The pylorus will be incised at two locations with a dual myotomy between the 5 and 8 o'clock positions on the clock face
223925224|NCT06965543|PROCEDURE|Delayed G-POEM|Participants will receive standard medical treatment, including prokinetic agents, antiemetics (ondansetron 8 mg twice daily), nutritional support, and dietary counseling. Laxative treatments will be prescribed as needed. After three months, participants will undergo G-POEM as described above
223925225|NCT06834425|DRUG|Peritendinous NSAID injection|Peritendinous NSAID (parecoxib) injection
223925226|NCT06834425|DRUG|Control group (placebo)|Normal saline mixed with local anesthetics injection
223925227|NCT02989662|DRUG|Mifepristone|Participants receive 6 doses.
223925228|NCT02989662|DRUG|Placebo - Cap|Participants receive 6 doses
223925229|NCT06280235|DRUG|BI 1569912|BI 1569912
223925230|NCT06280235|DRUG|Placebo|Placebo matching BI 1569912
223925231|NCT06541522|DEVICE|EIT|Two PEEP titrations monitored by EIT will be performed, each with the electrode belt positioned at a different chest height (2nd intercostal space or 5th intercostal space). The order will be drawn at random.
223925232|NCT03819101|DRUG|Acetylsalicylic acid|100mg
223925233|NCT03819101|DRUG|Atorvastatin|80 mg
223925234|NCT04527094|DIAGNOSTIC_TEST|Prediction of postoperative respiratory failure using a machine learning|The performance of a machine learning model to predict postoperative respiratory failure after general anesthesia within postoperative day 7 was tested prospectively.
223925235|NCT01181154|DRUG|rituximab (Mabthera®)|1000 mg at day 1 and day 15
224093035|NCT05951582|OTHER|Conventional Exercises|"The group will receive conventional exercises in a controlled environment. Following conventional exercises were performed.~1. Single Leg Squat/ Lunges~2. Modified Box Step Ups~3. Press Ups~4. Box Jumps~5. Shoulder Press~6. Standing Band Row~7. Band Butterfly Pills"
224093036|NCT02261623|DEVICE|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
224093037|NCT02261623|DEVICE|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
224093038|NCT02261623|DEVICE|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
224093039|NCT04214080|OTHER|Neurodevelopmental treatment (NDT)|NDT is a holistic and interdisciplinary clinical practice model informed by current and evolving research that emphasizes individualized therapeutic handling based on movement analysis for habilitation and rehabilitation of individuals with neurological pathophysiology.
224093040|NCT04214080|OTHER|Feeding and oral-motor intervention strategies|Feeding and oral-motor intervention strategies have been developed to address difficulties with sucking, chewing, swallowing, and improve oral-motor skills.
224093041|NCT04214080|OTHER|Neck and trunk stabilization exercises|Trunk control affects head control. After gaining head control, it causes jaw stability and oral motor control (tongue control and lip closure). All of these affect communication and quality of life.
224093042|NCT03707561|DIAGNOSTIC_TEST|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
224093043|NCT04807361|BEHAVIORAL|Auditory biofeedback traing|Subjects who wear MFCLs for myopia control will receive one episode of auditory biofeedback training, and their accommodative responses to various demands (0, 2.5, 3, and 4 D) before and after the training were measured using a power refractor.
224093044|NCT04064710|PROCEDURE|Vertebral Body Augmentation|Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
224281547|NCT01119807|DEVICE|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
223925236|NCT01181154|DRUG|Placebo|equivalent volume total
223925237|NCT06752993|DEVICE|Expiratory Muscle Strength Training (EMST-150)|Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) used to exhale against a same-pressure load every exhalation for strengthening primarily the core muscles. The device pressure is adjusted according to PEmax and reliability/reproducibility has been demonstrated.
223925238|NCT06752993|DEVICE|Sham Training|Training is going to perform by using a pressure treshold-loading device (EMST-150, Aspire Products, LLC, Gainesville, FL) without physiological load. The sham device closely resembled the EMST device, with the only difference being that the pressure release valve was rendered nonfunctional by removing the spring. As a result, it exerted minimal to no physiological load on the targeted muscles.
223925239|NCT05515978|DRUG|Metformin|Metformin is a medication used to treat type 2 diabetes, gestational diabetes, and prediabetes. In this study, patients on the Metformin arm will be started on 850 mg daily for 2 weeks, then escalated to a final dose of 850 mg twice daily, which is lower than the maximum recommended dose of 2550 mg total daily.
223925240|NCT05515978|BEHAVIORAL|Lifestyle Modification|"Patients randomized to this arm will receive standard lifestyle modification recommendations. This will include the general recommendation to increase exercise level mildly, after discussing with the medical provider. There is a potential low-level risk in increasing one's exercise levels.~Here are some examples of the educational material from the American Diabetes Association website, and topics will be rotated on quarterly basis:~Healthy eating: https://www.diabetes.org/nutrition/healthy-food-choices-made-easy Prediabetes: https://www.diabetes.org/diabetes-risk/prediabetes Fitness: https://www.diabetes.org/fitness/get-and-stay-fit Weight loss: https://www.diabetes.org/fitness/weight-loss"
223925241|NCT01054092|DRUG|ipragliflozin|oral
224093045|NCT04064710|DEVICE|Manual Surgical Instruments|Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.
224093046|NCT03312218|BEHAVIORAL|Spaced educational intervention|A spaced educational intervention will be provided to participants
224093047|NCT00000790|DRUG|Thalidomide|
224281548|NCT01119807|DEVICE|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
223925242|NCT06965790|DRUG|contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume|Calculation of the standardized contrast agent (Imeron 350, active ingredient Iomeprol) quantity (0.35 g iodine/kg) and calculation of the specific blood volume using the established Nadler formula for male and female. Adjustment of the contrast agent according to the ratio of the blood volumes. The amount of saved contrast agent is replaced 1:1 by NaCl.
223925243|NCT04868656|OTHER|Implementation Strategy: Foundational Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We propose that low intensity implementation support that promotes adapting STRIDE for context and provides tools for ongoing STRIDE evaluation (defined as foundational support), will be sufficient for some but not all hospitals to successfully incorporate STRIDE into routine practice.
223925244|NCT04868656|OTHER|Implementation Strategy: Enhanced Support|The goal is to test implementation intensification approaches for STRIDE hospitals that have not met implementation program benchmarks, specifically Foundational Support vs. Enhanced Support. We posit that monitoring hospitals' progress and adding, for hospitals with low adoption, higher intensity strategies (defined as Enhanced Support) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
223925245|NCT04715139|DEVICE|Products listed in Group/Cohort Description|Depending on approved indication per product
224093048|NCT01836861|DRUG|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
224093049|NCT02046330|DEVICE|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
224093050|NCT03802721|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
224093051|NCT03802721|DRUG|Brussels sprouts before 50 ng dose|Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
224093052|NCT03802721|DRUG|DIM supplement before 50 ng dose|DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
224093053|NCT00537719|DRUG|GSK716155|albiglutide subcutaneous injection
224093054|NCT00537719|DRUG|Placebo|placebo injection
224093055|NCT05055908|DRUG|Pemetrexed plus Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc. Pemetrexed, 500mg/m2, ivgtt, every 21 days
224093056|NCT05055908|DRUG|Pembrolizumab|Atezolizumab(1200mg) ivgtt, every 21 days, or pembrolizumab, 200mg ivgtt, every 21 days etc.
224281549|NCT01119807|DEVICE|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
224281550|NCT04130178|DRUG|Nerve block|block of the digital nerves in rheumatoid arthritis patient
224281551|NCT04130178|DRUG|Saline injection|subcutaneous saline injection
224281552|NCT04115709|DEVICE|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
224281553|NCT04115709|DEVICE|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
224281554|NCT00097786|DRUG|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
224281555|NCT00097786|DRUG|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
224093057|NCT05055908|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt, every 21 days etc.
224093058|NCT02169076|DEVICE|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
224093059|NCT01662089|DRUG|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
224093060|NCT01662089|DRUG|Placebo drug supplement|Placebo drug instead of Zinc supplement
224093061|NCT00714142|DRUG|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
224093062|NCT00714142|DRUG|15O-water|10-20 mCi, IV
224093063|NCT00714142|PROCEDURE|Positron Emission Tomography|PET Scan
224093064|NCT01760434|OTHER|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
223531871|NCT07160283|DRUG|Bile duct cancer cohort|"Trilaciclib: 240 mg/m², administered via intravenous infusion over 30 minutes, completed within 4 hours prior to chemotherapy on the same day.~Chemotherapy Agents: Investigators will select chemotherapy regimens based on individual patient status. Regimens must be single-day protocols (including but not limited to gemcitabine, nab-paclitaxel, etc.), with dosing and administration per prescribing information.~Subjects receiving concomitant immunotherapy or targeted therapy in addition to chemotherapy are eligible for enrollment."
223531872|NCT07160283|DRUG|Pancreatic cancer cohort|"rilaciclib: 240 mg/m², administered via intravenous infusion over 30 minutes, completed within 4 hours prior to chemotherapy on the same day.~Chemotherapy Agents: Investigators will select chemotherapy regimens based on individual patient status. Regimens must be single-day protocols (including but not limited to gemcitabine, nab-paclitaxel, etc.), with dosing and administration per prescribing information.~Subjects receiving concomitant immunotherapy or targeted therapy in addition to chemotherapy are eligible for enrollment."
223531873|NCT02619565|OTHER|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
223531874|NCT04817189|DRUG|NEPA (300mg netupitant/0.5mg palonosetron)|Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
223531875|NCT04817189|DRUG|Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)|Standard of care will be administered on Day 1 of each cycle.
223531876|NCT04817189|DRUG|Dexamethasone, 8 mg (oral) or equivalent IV dose|Dexamethasone (8 mg) will be administered on Day 1 of each cycle.
223531877|NCT02979574|PROCEDURE|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
223531878|NCT02979574|PROCEDURE|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
223925246|NCT04282304|BEHAVIORAL|Preoperative usual care|"Usual care during the preoperative preparation for bariatric surgery consists of:~* Endocrinologist work-up and follow-up, with at least 2 consultations;~* Dietary advice, provided during the endocrine consultation or dietician consultation~* Psychological counselling with the patient's usual psychiatrist (at least 2 consultations~* Physical activity and nutrition are encouraged, but entrusted to the patient's freedom of choice. Weight loss, or at least, weight stabilization, is recommended before the surgery, without initiating a specific behavioural procedure."
223925247|NCT04282304|BEHAVIORAL|Preoperative intensive behavioral lifestyle intervention|"The intensive behavioral lifestyle intervention program takes place over 4 weeks of 5 days. It includes:~* Rehabilitation to physical exercise every morning~* Therapeutic cooking sessions; during these sessions, the patients prepare the day's meals under the supervision of a nutritionist~* Psychological counselling~* One swimming session per week~* One relaxation session~* Regular physical activity (aerobics, work-up)~* Individual entertainment with the physiotherapist physician and discussion groups~* Weight, BMI and waist circumference control at the end of each week."
223925248|NCT06776393|OTHER|ultrasound|"Dynamic translaryngeal Ultrasound Motion mode ultrasound of the laryngeal region during phonation Acoustic recordings VHI questionnaires "
224093065|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
224093066|NCT01880346|DIETARY_SUPPLEMENT|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
224281556|NCT00097786|DRUG|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
223531879|NCT02979574|DEVICE|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
223531880|NCT04696146|DRUG|Berinert|Intrarenal dose of 500 U of Berinert
223531881|NCT04696146|DRUG|Placebo|Normal Saline placebo
224281557|NCT00097786|DRUG|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
224281558|NCT04632524|DRUG|MgSO4|Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
223531882|NCT06270407|DRUG|Tranexamic Acid 100 MG/ML|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
223531883|NCT06270407|DRUG|0.9%sodium chloride|If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
223531884|NCT06275516|DEVICE|multi-sensory stimulation immersive VR+ treadmill training|Treadmill training with multi-sensory stimulation immersive VR in VR+treadmill training group
223531885|NCT06275516|DEVICE|treadmill training|Only treadmill training in treadmill training group
223531886|NCT05849597|DRUG|Dexmedetomidine|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous dexmedetomidine infusion in doses 0.2-0.7 mcg/kg/h.
223531887|NCT05849597|DRUG|Propofol|Upon arrival to the intensive care unit after open heart surgery, the patients will be sedated with continuous propofol infusion in doses 1-2 mg/kg/h.
223531888|NCT04119037|PROCEDURE|Cordotomy|Undergo cordotomy
223531889|NCT04119037|DRUG|Morphine|Given via injection
223531890|NCT04119037|OTHER|Questionnaire Administration|Ancillary studies
223531891|NCT04119037|PROCEDURE|Sham Intervention|Undergo fake cordotomy
223531892|NCT04376593|DRUG|18F-αvβ6-BP|Subjects will be injected once per imaging session (a maximum of 3 imaging sessions) with up to 10 mCi (±20%) of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 secs).
223531893|NCT05763563|BEHAVIORAL|Resistance Training|Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
223531894|NCT05763563|BEHAVIORAL|Aerobic Exercise|Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
223531895|NCT05763563|BEHAVIORAL|Optional Aerobic Exercise Procedure|"Participants will be encouraged to complete 3 tele-supervised aerobic training sessions per week, each lasting 30 minutes. Participants will be encouraged to achieve moderate exercise intensity based on heart rate visualized on PM5 monitors. Participants will report their heart rates every 3-5 minutes during an exercise session and be encouraged to adjust pedaling cadence or flywheel resistance accordingly to achieve moderate intensity.~Exercise trainers will access logged heart rate ranges (64-76% of age-predicted maximum heart rate) to provide individualized and appropriate guidance during sessions.~Participants who are untrained or otherwise uncomfortable maintaining moderate aerobic intensity for 30 minutes will be encouraged to gradually increase the duration and intensity of their sessions until they are meeting these guidelines."
223531896|NCT05763563|RADIATION|Optional In-Person Exercise Sessions|Participants who prefer to complete RT and/or aerobic exercise sessions in-person will be allowed to do so. These sessions will be conducted in the Moffitt Promotes Resilience in Oncology Via Exercise (MPROVE) Laboratory using the same equipment participants would use for Zoom sessions, with guidance and supervision from certified exercise trainers.
223925249|NCT05923255|PROCEDURE|LISH （Laparoscopic Ileocecal-Sparing Right Hemicolectomy）|Preserve the ileocolic blood vessels, and perform dissection of lymph node groups 203, 202, and 201d along the root of ICV(Ileocolic artery)/ICA(Ileocolic vein). Group 201d lymph nodes are defined as the distal lymph nodes of the ileocolic vessels (colonic branch). Use an intracavitary cutting and sealing device to transect the proximal colon along the predetermined margin, and transect the transverse colon at 10cm distal to the tumor. Perform ileocecal-transverse colonic anastomosis.
223925250|NCT05923255|PROCEDURE|TRH（Traditional Laparoscopic Right Hemicolectomy）|Transect the root of the ileocolic vessels and perform dissection of lymph node groups 203, 202, and 201; sever the roots of the right colic and middle colic vessels, and clear the surrounding lymphoadipose tissue (lymph node groups 211/212/213 and 221/222/223). Transect the transverse colon 10cm distal to the tumor and cut the terminal ileum 10cm from the ileocecal junction. Perform ileum-to-transverse colon anastomosis.
224281559|NCT05403619|DIAGNOSTIC_TEST|Diagnostic test|Cardiac Ultrasound in order to explore the causes of shortness of breath
223531897|NCT00561990|DRUG|Nimotuzumab|
223531898|NCT06224023|DIAGNOSTIC_TEST|Determination of presepsin levels in ascites|A diagnostic paracentesis will be performed and presepsin level will be determined in ascites.
223531899|NCT06117930|OTHER|Non-Interventional Study|Non-interventional study
223531900|NCT02172794|DRUG|Tiotropium|
223531901|NCT02172794|DRUG|Placebo to tiotropium|
223531902|NCT02172794|DRUG|Salmeterol|
223531903|NCT02172794|DRUG|Placebo to salmeterol|
223531904|NCT00285779|DRUG|Etanercept|etanercept 50 mg twice weekly for 12 weeks
223531905|NCT00285779|DRUG|Placebo|
223531906|NCT03561311|DEVICE|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
223531907|NCT03561311|DEVICE|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
223531908|NCT06035042|PROCEDURE|Scheduled surgery|All subjects will be exposed to surgery
223531909|NCT04164277|BEHAVIORAL|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face or virtual caregiver meetings: Meeting 1: Study orientation and healthy cooking education will be offered, and each family will receive a small bag of groceries to facilitate preparation of a recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: Study interveners will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: Study interveners will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource booklet.
223531910|NCT04164277|BEHAVIORAL|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger on two weekdays. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
223717613|NCT03629132|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
223925251|NCT06297967|DRUG|Acetic Acid|The intervention treatment will consist of cleaning with water and soap, application of a compress soaked in 2% dilution of glacial acetic acid (CAS 64-19-7) for 15 minutes, irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the ulcer bed. Depending on the amount of exudate, more or less alginate will be added as a secondary dressing. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
223925252|NCT06297967|DRUG|Prontosan|The treatment includes ulcer cleansing with water and soap, application of ProntosanⓇ compress for 15 minutes, subsequent irrigation with distilled water, application of peri-ulcer barrier cream or spray, and the application of ActicoatⓇ on the wound bed. More or less alginate will be applied depending on the amount of exudate. A tertiary dressing of polyurethane foam or bandage will be applied according to the area and the nurse's discretion.
223925253|NCT06315166|DEVICE|triLift/Legend Pro+ Fractional RF System|The triLift/Legend Pro+ Fractional investigational device is intended for the treatment of acne vulgaris when using Fractional RF energy.
223925254|NCT06467019|OTHER|Informative Session|The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.
223925255|NCT03218306|DEVICE|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
223925256|NCT03218306|OTHER|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
223925257|NCT02726386|DRUG|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
223925258|NCT00704769|DRUG|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
223925259|NCT04955431|BEHAVIORAL|Sleep Restriction|Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.
223925260|NCT04955431|BEHAVIORAL|Normal Sleep|Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
223925261|NCT05855954|COMBINATION_PRODUCT|controlled low central venous pressure technique (CLCVP)|20min after the end of cardiopulmonary bypass, on the basis of ensuring that the mean arterial pressure (MAP) ≥ 60mmHg, we maintain the patient's central venous pressure below 10 mmHg by adjusting the posture and pumping nitroglycerin.
223717614|NCT03629132|PROCEDURE|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
223925262|NCT06982274|DRUG|Realgar-Indigo Naturalis Formulation|Oral Arsenic (Realgar-Indigo Naturalis Formulation) plus ATRA for low-intermediate risk APL pts, combined with daunorubicin for high-risk during induction
223925263|NCT06841406|DRUG|budesonide|During an 8-week treatment period, patients will receive 9 mg of Budesonide daily, administered orally in enteric-coated capsules. Following this period, participants will undergo a gradual dose reduction to minimize the risk of adrenal insufficiency: 6 mg daily for 2 weeks, followed by 3 mg daily for another 2 weeks before discontinuing treatment.
223925264|NCT06841406|DRUG|Mannitol|During an 8-week treatment period, patients will receive 9 mg of Mannitol daily, administered orally in enteric-coated capsules as placebo control. Following this period, participants will undergo a gradual dose reduction as is the case in the experimental group: 6 mg daily for 2 weeks, followed by 3 mg daily for another 2 weeks before discontinuing treatment.
223925265|NCT06827249|DRUG|Peginterferon α-2b injection|Peginterferon α-2b injection, 90 mcg, on the basis of conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, nebulized inhalation using air compression or oxygen-driven methods is administered on days 1, 3, and 5, once a day.
223925266|NCT06827249|DRUG|Recombinant Human Interferon α2b|Recombinant Human Interferon alpha 2b, at a dose of 100,000 IU/kg, based on the conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, will be administered via nebulized inhalation using air compression or oxygen-driven methods from day 1 to day 5, twice daily.
223925267|NCT06988020|DEVICE|MRI|Whole body MRI including ZTE sequences
223925268|NCT06836453|DEVICE|Sweat stimulation and secretion quantification|"First session (50 minutes): a. Left arm: Iontophoresis using the Macroduct for the cholinergic and β-adrenergic stimulation (2 iontophoresis), then bubble test. b. right arm: Iontophoresis using the Macroduct for the cholinergic and β-adrenergic stimulation (2 iontophoresis), then evaporimetry.~Second session (50 minutes): a. Left arm: Iontophoresis using the Macroduct for the cholinergic and intradermal injection for the β-adrenergic stimulation, then bubble test. b. Right arm: Iontophoresis using the Macroduct for the cholinergic and intradermal injection for the β-adrenergic stimulation, then evaporimetry."
223925269|NCT05811078|BEHAVIORAL|training sessions with peer interactive group|"Data were collected with data collection forms consisting of  Diabetes Adolescent Diagnosis Form, Diabetes Information Evaluation Form, Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes and Child's Attitude towards Own Disease Scale ."
224093067|NCT02063529|DRUG|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
224093068|NCT02063529|DRUG|FOLFOXIRI|Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
223925270|NCT06611293|DIAGNOSTIC_TEST|Breath test|"Participants will perform breath testing in Primary care followed by Secondary care on Day 1. At each location, participants will be asked to perform three breath tests (15 minutes apart). The environmental air will also be sampled.~This entire process will be repeated in the reverse order (i.e. breath testing in Secondary care followed by Primary care on Day 2).~Participants will be asked to maintain a clear fluid diet for a minimum of six hours prior to breath collection on both Day 1 and Day 2 of sampling."
224281560|NCT02668822|DRUG|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
223717615|NCT03096210|OTHER|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
224281561|NCT02668822|DRUG|Placebo vaginal ring|Placebo vaginal ring
224281562|NCT02668822|DRUG|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
224281563|NCT01284855|DRUG|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
224281564|NCT04600024|DIAGNOSTIC_TEST|Ultrasound guided diagnostic injection|4 cc lidocaine %2 injection into the piriformis muscle was performed for the diagnosis of piriformis syndrome. It was performed by the ultrasound-guidance to increase the accuracy of the injection.
224281565|NCT05707455|OTHER|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.|evaluating blood levels of hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin concentration, serum transferrin and serum ferritin.
224281566|NCT01358539|BEHAVIORAL|Pain education|Patients receiving pain education
223717616|NCT03096210|OTHER|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
223717617|NCT02052284|OTHER|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
224281567|NCT05633914|DRUG|Tucidinostat|20mg, po., biw, q3w
224281568|NCT05633914|DRUG|nab-paclitaxel|125mg/m2, d1, iv.drip, q7d
223925271|NCT06781905|OTHER|Assessments of neuropsychiatric, neurocognitive and psychosocial alterations|Assessments will be conducted over two consecutive days. The first day will focus on the evaluation of neuropsychiatric and neurocognitive alterations. A comprehensive assessment involving various tools (clinical examination, individual interview, psychometric tests, standardized scales) will be carried out by a psychiatrist, a neuropsychologist, and a neurologist. The second day will be dedicated to psychosocial assessments by a team of social psychologists using a comprehensive qualitative and quantitative approach to quality of life. Quality of life will be understood as a subjective appreciation of the individual's place in their existence and three main dimensions will be explored: daily life management, social relationships, and self-image and self-esteem. The collected data will be subjected to a reflexive thematic analysis. The qualitative exploration of quality of life will be complemented by a quantitative assessment using a standardized tool (EORTC QLQ LC13).
223925272|NCT06788405|OTHER|hand hygiene theoretical training with a hand hygiene virtual reality simulation application|After giving 360 hours of hand hygiene theoretical training to the participants in the experimental group, a hand hygiene virtual reality simulation application will be performed.
223925273|NCT06788405|OTHER|hand hygiene theoretical training|Participants in the control group will receive only 360 hours of hand hygiene theoretical training. Participants in this group will not be given hand hygiene virtual reality simulation application.
223925274|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
223925275|NCT02051257|BIOLOGICAL|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
223925276|NCT02051257|OTHER|Laboratory Biomarker Analysis|Correlative studies
223925277|NCT06990386|BEHAVIORAL|self-management program|Self-management booklet based on the self-management framework consisting of 4 categories: a) self-monitoring, which consisted of self-observation and self-recording of DU and RP; b) performing special tasks to manage the disease, including keeping warm, maintaining moisture, and taking traumatic wound precautions; c) information seeking; and d) self-adjustment based on disease activity and treatment.
223717618|NCT05025761|OTHER|Personal protection package|The personal protection package will be distributed to mobile and migrant peoples in each village according to the stepped wedge design.
223925278|NCT06990386|BEHAVIORAL|Video guide and usual education|Video guide was the hand and joint exercise video guide that included a 3.27-minute educational video on 6 basic daily hand exercises including: a) stretching wrist flexion and extension, b) range of motion (ROM) ulnar and radial deviation, c) ROM finger abduction and adduction, d) finger pincer, e) finger flexion and extension, and f) finger grab.
223925279|NCT06990386|BEHAVIORAL|Telephone notification, video guide and usual education|Telephone notifications consisted of weekly calls for further continuity and engagement with hand exercises. Each call lasted about 10 minutes, providing problem-solving support, knowledge reinforcement, and motivation to encourage adherence to the program.
223925280|NCT06988579|OTHER|AI|An integrated AI-human collaborative workflow for lung cancer screening interpretation
223925281|NCT03124277|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
223925282|NCT03124277|OTHER|Control Group|Best local diet
223925283|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
224281569|NCT00970255|PROCEDURE|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
224281570|NCT00970255|PROCEDURE|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
223925284|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide|Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
223925285|NCT06991712|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide|Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
223925286|NCT06991712|DIETARY_SUPPLEMENT|Nicotinic Acid|Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
223925287|NCT06991712|OTHER|Placebo (Corn Starch)|Oral supplementation of 300mg Placebo daily for 2 weeks
223925288|NCT06991712|OTHER|Placebo (Corn Starch)|Oral supplementation of 300mg Placebo daily for 2 weeks
223925289|NCT06997432|PROCEDURE|Double-blind placebo-controlled oral challenge test (DBPCFC)|Group 1. To evaluate MTD, DBPCFC will be done with peach with skin and/or peach juice as described. The patient will remain under observation for at least 2 hours.
223925290|NCT06997432|OTHER|Dietary intervention|Group 2. Patients will take for one year, MTD of fresh peach or peach juice with a frequency of 3 times/week.
224281571|NCT04987255|OTHER|Free visit|The persons with sedentary (healthy) in this group will have to visit the museum freely (without a guide) for a period of 75 minutes.
224281572|NCT04987255|OTHER|Guided visit|The persons with sedentary (healthy) in this group will have to visit the museum with a guide for a period of 75 minutes.
224281573|NCT04987255|OTHER|Guided visit (stroke)|The persons with motor disability after stroke in this group will have to visit the museum with a guide for a period of 75 minutes.
224281574|NCT01477814|BEHAVIORAL|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
224281575|NCT01477814|BEHAVIORAL|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
224281576|NCT01477814|BEHAVIORAL|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
223717619|NCT04522362|OTHER|Control task and Trier Social Stress Task|Same as Arm
223717620|NCT00692081|BEHAVIORAL|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
223717621|NCT00692081|BEHAVIORAL|Special vocational training|as provided in German special centres for vocational training
223925291|NCT06997211|BEHAVIORAL|EFT|The EFT session will be conducted mutually with the practitioner. The average duration of the session is planned to be 40-45 minutes.
223925292|NCT06996457|DEVICE|VR|The use of a virtual reality (VR) headset to present videos with nature imagery and natural sounds (music)
223925293|NCT06996522|PROCEDURE|underwater endoscopic mucosal resection|The Pedunculated colorectal polyps less than 10mm in size in this group will be treated by UEMR
223531911|NCT04164277|BEHAVIORAL|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU student educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat \& Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
223717622|NCT00617773|BIOLOGICAL|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
223717623|NCT00189254|DRUG|Imiquimod|No defined treatments were given during this study.
223925294|NCT06996522|PROCEDURE|Hot snare polypectomy|The Pedunculated colorectal polyps less than 10mm in size in this group will be treated by HSP
223925295|NCT06996340|OTHER|White noise group|The woman who was taken to the gynecological table for invirto fertilization will be made to listen to white noise (rain and waterfall sound) with a Bluetooth headset at a range of 75-85 decibels during the procedure. Because, it covers all sound ranges that people can hear within the range of 75-85 decibels (Cho and Hwang, 2021; Lin et al, 2018).
223925296|NCT06996340|OTHER|routine care|routine care
223925297|NCT06996704|DRUG|AK0610 Injection solution|Active Substance: AK0610 Pharmaceutical Form: Injection solution Route of Administration: Intramuscular injection or intravenous injection.
223925298|NCT06996704|DRUG|Placebo|Active Substance: Placebo Pharmaceutical Form: Injection Route of Administration: Intramuscular injection or intravenous injection
223925299|NCT06996834|DEVICE|Non-Invasive ventilation (NIV)|Participants in this arm will receive noninvasive ventilation using bilevel positive airway pressure (BiPAP) delivered via a full-face mask to support ventilation in patients with acute hypoxemic respiratory failure due to CAP.
223925300|NCT06996834|DEVICE|High Velocity Nasal Insufflation|Participants in this arm will receive high-velocity nasal insufflation therapy, a type of high-flow nasal cannula (HFNC) therapy that delivers heated and humidified oxygen at high flow rates to support patients with acute hypoxemic respiratory failure resulting from community-acquired pneumonia (CAP).
223925301|NCT06996171|DRUG|Magnesium glycinate|Tab Magnesium glycinate 500mg will be given to one group for treatment of primary insomnia
223925302|NCT06996171|DRUG|Melatonin|Tab Melatonin 10mg will be given to the other group for treatment of primary insomnia
223925303|NCT06996613|PROCEDURE|Upper endoscopy|It's a diagnostic endoscope to show the cause of upper Git bleeding
223925304|NCT06997822|BEHAVIORAL|LINE Bot-Based Remote Care Combined with In-Person Post-ICU Clinic|"Participants in this group will receive the I-CARE intervention, which includes two components: (1) a LINE Bot-based remote care system providing scheduled health education, functional assessments, and reminders tailored to ICU survivors, and (2) structured in-person visits to a post-ICU recovery clinic, where multidisciplinary professionals provide follow-up assessments and individualized rehabilitation guidance. The LINE Bot also features an interactive module (Thanks to Nurses) that allows patients to send messages, images, or audio clips to their ICU care team, with optional reciprocal feedback. The intervention will be delivered for up to 6 months following hospital discharge."
224281577|NCT01522950|DRUG|Nebivolol|5 mg daily or 10 mg daily
224281578|NCT01522950|DRUG|atenolol|25 mg daily or 50 mg daily
224281579|NCT01522950|DRUG|placebo|one tablet daily
224281580|NCT03109119|DRUG|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
224281581|NCT03109119|DRUG|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
224281582|NCT02484313|OTHER|dietary treatments|commercially available food products
224281583|NCT03214302|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
224281584|NCT05616078|OTHER|laser treatment|a maximum of 4 sessions, with an interval of 3 to 4 weeks
224281585|NCT05616078|OTHER|cryotherapy|a maximum of 4 sessions, with an interval of 3 to 4 weeks
224281586|NCT01378741|DRUG|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
224281587|NCT01378741|DRUG|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
224281588|NCT06424717|DRUG|Avelumab|Participants will be administered Avelumab intravenously (IV).
224281589|NCT06424717|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
224281590|NCT00908921|DRUG|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
224281591|NCT00506506|DRUG|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
224281592|NCT00506506|DRUG|Placebo|
224281593|NCT03244475|DEVICE|TES|"The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes."
224281594|NCT04377906|BEHAVIORAL|Modification Lifesyle|high protein-fiber and exercise
224281595|NCT03282006|DRUG|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
223925305|NCT06997809|OTHER|pathway care|"Group for whom the test results will be used to determine the management strategy. If one of the tests performed before randomization is positive an algological consultation before surgery will be performed with an adapted treatment. Then surgical treatment as planned.~If all tests are negative, surgical treatment is performed. The dedicated algology consultation must be done with an experienced practitioner different from the one who will perform the surgery. A rapid algological treatment circuit must be put in place to maintain the surgery date set.~Group without using the results of test for associated pain components. Standard surgical treatment as planned through dedicated staff on endometriosis treatment."
224281596|NCT02177006|BEHAVIORAL|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
223925306|NCT06997731|PROCEDURE|Non -surgical treatment and oral hygiene instruction|Scaling and root planing which involves mechanical removal of sup-gingival calculus and necrotic cementum. Tis will be associated with oral hygiene instruction in the form of twice daily brushing for 2 minutes.
224281597|NCT00333476|DRUG|MSI-1256F (Squalamine Lactate)|
224281598|NCT03323060|DEVICE|Transanal endoscopic surgical procedure|Resection of tumors or lesions
224281599|NCT04341272|DEVICE|Intermittent Pneumatic Compression Device (FDA approved)|Compression Device placed on either upper or lower extremity for DVT prophylaxis following surgery
223925307|NCT06997731|DRUG|Application of minocycline and hyaluronic acid gel.|application of minocycline and Gengigel® topical gel twice weekly for 3-week 1cc for each.
223925308|NCT06997731|DRUG|local application of placebo gel|The placebo gel will be applied in the periodontal pocket twice weekly for 3-week 1cc for each.
223925309|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）|The 4-hour group treatment session lasts 4 hours (±15 minutes). In the HBAL mode of the combined bioartificial liver device QH-1A, blood is initially filtered to separate the plasma, which is then pumped into a bioreactor. In this study, this bioreactor is uniquely filled with immortalized mesenchymal stem cells (PT-MSCs) optimized for blood purification. These cells are cultured to adhere to the outer surface of hollow fibers within the bioreactor, creating a stable and efficient living interface that continuously secretes bioactive factors such as exosomes.After passing through the bioreactor, the plasma is re-filtered and then returned to the patient's circulation via a dedicated pump.
223925310|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）|After the three subjects in the 4-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 6-hour group.The 6-hour group treatment session lasts 6 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
223925311|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours）|After the three subjects in the 6-hour group completed their 4-week follow-up, the Safety Evaluation Committee convened a meeting to review the safety data and determine whether to proceed with the recruitment for the 8-hour group. The 8-hour group treatment session lasts 8 hours (±15 minutes).The treatment procedure is identical to that of the 4-hour group.
223925312|NCT06996392|COMBINATION_PRODUCT|Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（Multiple-treatment）|Subjects in the multiple-treatment group will receive 2-3 sessions of bioartificial liver treatment; the number of sessions will be determined by the investigators based on the subjects' clinical needs. The treatment duration for each session will be set as the maximum tolerable period, as confirmed by the Safety Evaluation Committee based on 28-day safety observations from the 4-hour, 6-hour, and 8-hour groups. Each treatment session is administered following the procedure applied to patients in the group with the optimal tolerability duration.
223925313|NCT06997302|OTHER|Nutritional Supplement|Dietary nutrition guidance.
224093069|NCT05367531|DEVICE|Autoinjector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
223925314|NCT06997575|DRUG|Magnesium Sulphate infusion|Infusion of 20% MgSO4 solution
223717624|NCT02283697|BEHAVIORAL|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
223925315|NCT06997575|DRUG|Magnesium sulphate intramuscular|Intramuscular injections will be instituted in gluteal region.
223925316|NCT06322433|DIAGNOSTIC_TEST|no drugs used for this study|tomographic, angiographic and clinical follow up
223925317|NCT06860685|DIETARY_SUPPLEMENT|gum chewing|Participants allocated to chewing gum will be instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily from the first postoperative morning until oral dietary intake. They were instructed to chew the piece of gum for at least 10 minutes.
223925318|NCT03201939|DRUG|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
223925319|NCT03201939|OTHER|Placebo Oral Tablet|Comparator placebo (control arm)
223925320|NCT06617364|PROCEDURE|gastrointestinal transit time measurement using MSOT and ICG contrast agent|The subject arrives at the clinic in the morning, fasting according to the preparation instructions from the Childrens Hospital Erlangen for the H2 breath test. Before taking the liquid containing lactose and ICG, the first measurement is performed using MSOT, followed by the H2 breath test. After the liquid to be detected is fully consumed, the second H2 breath test measurement, which only takes a few minutes, is conducted. According to the official guidelines of the Childrens Hospital Erlangen, the hydrogen concentration in the breath is measured at 30-minute intervals. During the 30-minute breaks, further MSOT measurements are carried out, also at 30-minute intervals. Each of these only takes about 10 minutes, they do not interfere with the H2 breath test measurement routine. After the ninth and final H2 breath test measurement a final MSOT examination is conducted. Afterwards participants are offered an optional MRI examination, which can be used to measure intestinal motility.
223925321|NCT06996119|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223925322|NCT06996119|DRUG|Busulfan|Given IV
223925323|NCT06996119|PROCEDURE|Computed Tomography|Undergo chest CT
223925324|NCT06996119|DRUG|Cyclophosphamide|Given IV
223925325|NCT06996119|PROCEDURE|Echocardiography Test|Undergo ECHO
223925326|NCT06996119|BIOLOGICAL|Emapalumab|Given IV
223925327|NCT06996119|DRUG|Fludarabine|Given IV
223925328|NCT06996119|PROCEDURE|Hematopoietic Cell Transplantation|Given infusion
223925329|NCT06996119|DRUG|Melphalan|Given IV
223925330|NCT06996119|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223925331|NCT06996119|DRUG|Mycophenolate Mofetil|Given IV or PO
223925332|NCT06996119|OTHER|Questionnaire Administration|Ancillary studies
223925333|NCT06996119|DRUG|Tacrolimus|Given IV or PO
223925334|NCT06996899|OTHER|Health Improvement Profile (HIP)|"The Health Improvement Profile (HIP) is a comprehensive physical assessment conducted by a trained clinician which aims to link evidence based interventions for flagged abnormal health parameters. There are 27 health parameters assessed such as weight, Body Mass Index (BMI), blood pressure, blood glucose, cholesterol levels, and waist circumference, alongside questions on lifestyle factors like smoking, diet, and physical activity, as well as medication use and its side effects.~Client participant will collaborate with their clinician in developing an individualised Health Improvement Profile which identifies suitable health behaviours interventions to improve physical health.~Health behaviours may be associated with diet, exercise, sleep, hygiene (including oral care) and mindfulness."
223925335|NCT06996899|OTHER|Clinician Health Improvement Profile user training|Clinician/staff participants will receive Health Improvement Profile user training on how to conduct the comprehensive physical assessments for 27 health parameters and how to link the evidence based actions to develop an individualised Health Improvement Profile for clients admitted to inpatient service. Training includes online videos simulating assessments and completing the Health Improvement Profile and face to face workshops.
223925336|NCT06997406|DIETARY_SUPPLEMENT|Inner ear support|"FB-1603 (150 mg): A cold water extract of Arthrospira maxima (a species of blue-green algae), rich in the antioxidant pigment C-phycocyanin (C-PC).~GABA (126 mg): A natural calming neurotransmitter that can help reduce nerve-related overactivity.~γ-Oryzanol (12 mg): A component from rice bran oil, known for its antioxidant properties.~Sesamin (12 mg): A compound from sesame seeds, with potential neuroprotective and anti-inflammatory benefits."
223925337|NCT06017115|DEVICE|Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)|Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
223925338|NCT06865092|BIOLOGICAL|injectable platelet-rich fibrin|Blood samples were collected in two 10 ml plastic tubes without anticoagulant. The tubes were centrifuged for 3 min at 2500 rpm in a centrifuge device and i-prf was obtained.
223925339|NCT06865092|BIOLOGICAL|titanium-prepared platelet-rich fibrin|The blood was drawn into a 20 ml syringe and immediately divided into two sterile grade IV titanium tubes containing 10 ml of blood. The tubes were placed opposite each other and centrifuged at 2700 rpm for 12 minutes at room temperature and t-prf was obtained.
223925340|NCT06865092|DRUG|Hyaluronic Acid (HA)|0.8% hyaluronic acid (HA) gel (Gengigel) was applied to the wound sites.
223925341|NCT06865092|OTHER|control group|Nothing has applied.
223925342|NCT06619847|DRUG|VX-993|Tablets for oral administration.
223925343|NCT06619847|DRUG|HB/APAP|Capsules for oral administration.
223925344|NCT06619847|DRUG|Placebo (matched to VX-993)|Placebo matched to VX-993 for oral administration.
223925345|NCT06619847|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
223925346|NCT06619483|DRUG|BAY3018250 Dose 1|Single dose
223925347|NCT06619483|DRUG|Placebo|Matching placebo to BAY3018250
223925348|NCT06619483|DRUG|BAY3018250 Dose 2|Single dose
223925349|NCT06869512|BEHAVIORAL|SUCCESS|6 group-based sessions with 25 minutes of didactic content, 25 minutes of facilitated support group, and 10 minutes of group physical activity
223925350|NCT06866093|OTHER|Lifestyle|Participants are asked to answer online survey questions about their anthropomethry, clinical conditions, socio-economical status, dietary habits, physical activity levels, quality of life, sleep quality and pshycological distress.
223925351|NCT01089101|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223925352|NCT01089101|DRUG|Selumetinib|Given PO
224093070|NCT05367531|DEVICE|Standard Injector|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
224093071|NCT05367531|DEVICE|Prefilled|"For each scenario the appropriate medication administration type will have to be selected amongst groups of options: 1) autoinjectors equivalents (ie medication, needle and syringe attached) 2) prefilled syringes where a needle is attached prior to administration; and 3) standard protocol (i.e. drawing medication from the vial and injecting via syringe/22 gauge needle). Medications options will include 1) Naloxone (opioid overdose) 2) Epinephrine (anaphylaxis) 3) Tranexamic acid (bleeding).~The order of administration for each scenario and injection type will be randomized to exclude any bias. To minimize risk to participants, active drug products and live/loaded autoinjectors will not be used. The target injection will be placed in an inanimate object (e.g. orange) or phantom simulator (i.e. inanimate object such as a gel or organic material such as jello or fruit to simulate an injection experience)."
224093072|NCT02306278|DRUG|gabapentin|gabapentin capsules 0.3g
224093073|NCT02306278|DRUG|vitamin capsules|vitamin B
224093074|NCT01887912|BIOLOGICAL|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
224093075|NCT01887912|BIOLOGICAL|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
224093076|NCT06423885|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
224093077|NCT06423885|DRUG|PD-1 monoclonal antibody|Administration by intravenous infusion for a cycle of 3 weeks.
224093078|NCT04612075|DIAGNOSTIC_TEST|FDG-PET/MRI|Performed at baseline, interim and at 12-16 weeks post radiotherapy.
224093079|NCT04611217|OTHER|Dietary fiber: 10-25g|10-25 g/day of fiber
224093080|NCT04611217|OTHER|Dietary fiber: 5g|5 g/day of fiber
224093081|NCT02924896|DIETARY_SUPPLEMENT|Palm olein|60g of palm olein will be given in a milkshake at breakfast
224093082|NCT02924896|DIETARY_SUPPLEMENT|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
224093083|NCT02924896|DIETARY_SUPPLEMENT|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
223925353|NCT06832332|BEHAVIORAL|alternative birthing positions|In this stage, students will be given a simulated breech birth with alternative birth positions as opposed to the traditional position in the second stage of labor.
223925354|NCT06775028|OTHER|iABC platform use|The novel platform (iABC) that will be used in AFFIRMO will consist of an educational program, a healthy or functional diet/physical activity, guideline-adherent drug treatments, periodic (re)assessment.
223925355|NCT07015749|DRUG|Placebo|Participants with asthma will receive Placebo at the corresponding dose and dosing interval.
223925356|NCT07015749|DRUG|IBI3002|Participants with asthma will receive IBI3002 at the corresponding dose and dosing interval.
223925357|NCT06756321|BIOLOGICAL|anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells|"Each subject will be infused with single dose. A classic 3+3 dose escalation will be employed.~anti-CD19-CAR T-cells~Dose level 1：1x10\^5 CAR T cells/kg, Dose level 2：3x10\^5 CAR T cells/kg, Dose level 3：1x10\^6 CAR T cells/kg~anti-CD30-CAR T-cells~Dose level 1：3x10\^6 CAR T cells/kg, Dose level 2：6x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg~anti-CD20/CD30-CAR T-cells~Dose level 1：1x10\^6 CAR T cells/kg, Dose level 2：3x10\^6 CAR T cells/kg, Dose level 3：1x10\^7 CAR T cells/kg"
223925358|NCT06756321|DRUG|Fludarabine|Fludarabine will be given at a dose of 25 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
223925359|NCT06756321|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 250 mg/m\^2/day intravenously (IV) for 3 days prior to the infusion of CAR T-cells.
223925360|NCT04894864|DRUG|Opioid-Based Anesthesia-Analgesia Strategy|A perioperative Opioid-Based multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Based arm of the study.
223531912|NCT02286609|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
223531913|NCT02485015|BIOLOGICAL|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
223925361|NCT04894864|DRUG|Opioid-free Anesthesia-Analgesia Strategy|A perioperative Opioid-Free multimodal Anesthesia-Analgesia strategy will be implemented as described in the Opioid-Free arm of the study.
223925362|NCT05836675|OTHER|Intradialytic exercise|The exercise program will be carried out during dialysis time. Participants will be asked to carry out cycling for 15-20 minutes, resistance exercises, and Kegel exercises during the first 2 hours of their regular routine hemodialysis session. Exercise can be done with rest periods as necessary.
223925363|NCT07013929|DEVICE|Renal nerve stimulation|Renal nerve stimulation will be performed prior to and post renal denervation.
223925364|NCT05588505|BEHAVIORAL|Cognitive-Behavioral Therapy Targeting Executive Dysfunction in College Students with ADHD|The intervention is 12 weeks long, made up of one 2- hour session each week. These sessions are designed to help the participants develop strategies to improve their executive functioning skills including self- care, time management and organizational skills. These skills will also be applied to specific academic tasks such as note-taking during reading and lectures, organizing and conducting research, and writing papers.
223925365|NCT05707351|BIOLOGICAL|Adynovate|Adynovate was injected intravenously using an appropriately sized syringe as a bolus infusion over a period of less than or equal to (\<=) 5 minutes (maximum infusion rate, 10 milliliters per minute \[mL/min\]).
223925366|NCT01996436|DRUG|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
223925367|NCT01996436|DRUG|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
223925368|NCT01996436|DRUG|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
223925369|NCT06186414|DRUG|SIM0237|Several dose levels of SIM0237 will be administered as a single agent for evaluation
223925370|NCT06186414|DRUG|SIM0237 and BCG|Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
223925371|NCT06186414|DRUG|SIM0237|RD level of SIM0237 will be administered as a single agent for evaluation
223925372|NCT06186414|DRUG|SIM0237 and BCG|RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
223925373|NCT02831283|DRUG|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
223925374|NCT02831283|DRUG|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
223925375|NCT02831283|PROCEDURE|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
223925376|NCT06866600|BIOLOGICAL|low dose CABG+iPSC-CMs|CABG+0.5×10\^8 iPSC-CMs
223925377|NCT06866600|BIOLOGICAL|High dose CABG/LVAD+iPSC-CMs|CABG+1.5×10\^8 iPSC-CMs or LVAD+1.5×10\^8 iPSC-CMs
223925378|NCT06866600|OTHER|CABG/LVAD+Saline|CABG/LVAD+Saline
223925379|NCT06867900|DIETARY_SUPPLEMENT|Bifidobacterium Longum ES1|Oral administration of Bifidobacterium Longum ES1 for three months.
223925380|NCT06870123|DEVICE|TT cup and ST-C cup|Patients are allocated in 2 different group (one with ST-C Cup and another one with TT Cup)
223925381|NCT06874179|DIAGNOSTIC_TEST|Optic nerve sheath diameter measurement 0|optic nerve sheath diameter (ONSD) measured via ultrasonography before intubation
223925382|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 1|optic nerve sheath diameter measurement 1 via ultrasonography after intubation 1st minute
223925383|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 2|optic nerve sheath diameter measurement via ultrasonography after intubation 5th minute
223925384|NCT06874179|DIAGNOSTIC_TEST|optic nerve sheath diameter measurement 3|optic nerve sheath diameter measurement via ultrasonography after intubation 10th minute
223925385|NCT06874179|PROCEDURE|Pre-intubation oropharyngeal topical %10 lidocaine|Pre-intubation oropharyngeal topical %10 lidocaine
223925386|NCT06874179|PROCEDURE|Pre-intubation intravenous %2 lidocaine|Pre-intubation intravenous %2 lidocaine
224093084|NCT04529265|DRUG|Methylene Blue|Intraoperative infusion of 2mg/kg MB after induction of anesthesia for 1 h and 1mg/kg MB with 30 min before the end of surgery
224281600|NCT06051604|DEVICE|Mi-Helper|The Mi-Helper device is a non-invasive, drug-free, novel therapy that uses a patented process of dry air flow across the nasal turbinates to induce a phase change (evaporation) that extracts energy (thermodynamics) causing local cooling which modulates nerves associated with pain and other symptoms of migraine. The device delivers a controlled pressure and flow of dry room temperature air along with a nebulized saline mist for added comfort and evaporative efficiency.
224281601|NCT01129739|OTHER|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
224281602|NCT01129739|OTHER|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
224281603|NCT04651322|DEVICE|upper robot Robot assisted upper arm training(RAT)|"The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy"
224281604|NCT04651322|BEHAVIORAL|Conventional therapy|The control group received the usual conventional therapy \*Only Conventional occupational therapy
224281605|NCT01178164|GENETIC|Blood sampling for biological and genetic analysis|"* Clinical examination~* Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
224281606|NCT00846859|DRUG|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
224281607|NCT00846859|DRUG|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
224281608|NCT06286059|DRUG|Phentolamine|In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
224093085|NCT04529265|DRUG|Placebo|Equal volume of normal saline after induction of anesthesia for 1 h and Equal volume of normal saline within 30 min before the end of surgery
223717625|NCT02283697|OTHER|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
223717626|NCT03519425|OTHER|Optimised HIV screening and linkage to care|As described in group descriptions
223717627|NCT03519425|OTHER|Optimised tuberculosis screening and linkage to care|As described in group descriptions
224093086|NCT03844087|DEVICE|Multiplanar neuromuscular training|See arm description
223925387|NCT06873984|OTHER|compression products|"Compression Group (CG):~Participants received individually fitted, round-knit compression stockings with a pressure of 23-32 mmHg (Class 2, RAL-GZG standard).~Compression garments were selected based on circumference measurements taken in the morning to ensure proper fit.~Participants were instructed to wear the stockings for approximately 9 hours per day.~The compression garments were provided by the same manufacturer (Medi GmbH \& Co., Bayreuth, Germany).~Additionally, participants were advised to engage in daily physical activity (walking for at least 20 minutes per day) while wearing compression.~Comprehensive education was provided on skin care, self-manual lymph drainage (simple lymph drainage, SLD), and lymphedema prevention."
223717628|NCT05371743|DIAGNOSTIC_TEST|Plasma RNA isolation, qPCR analysis of micro RNA|qPCR will be performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Total RNAs going to be used to make cDNAs using TaqMan microRNA RT Kit. Diluted cDNAs were mixed with TaqMan Universal PCR Master Mix (No AmpErase UNG). Taqman miRNA assay will run in the 7500 Real-Time PCR System (Applied Biosystems). miR-39 also will be used as an exogenous control. All assays will be done in triplicates. The expression levels will be evaluated using the comparative cycle threshold (∆∆\_Ct) method
223717629|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL2|"2ml of patient serum will be used to measure IL 2 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
223925388|NCT06347809|OTHER|Non-Interventional Study|Non-Interventional Study
223925389|NCT06693648|DRUG|AMZ001 Diclofenac gel|Diclofenac gel applied once daily
223925390|NCT06693648|DRUG|Placebo gel|Matching placebo gel applied once daily
223925391|NCT06692621|DRUG|Oxytocin|Medicines were administered in appropriate doses
223925392|NCT06692621|DRUG|Carbetocin|Medicines were administered in appropriate doses
223925393|NCT06044571|OTHER|Prescriptive|Prescriptive A diet and exercise prescription individually tailored to each participant's multiple chronic health conditions will provide concrete advice with less autonomy, and will minimize risks of physiologic changes due to weight loss (hypoglycemia, hypotension, muscle loss). Licensed, trained professionals, Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs), will introduce clinical reasoning, knowledge, and experience, assess biological adaptations to weight loss, modify prescriptions based on changing medical needs, and provide real-time and asynchronous guidance. Registered Dietician Nutritionists (RDNs) and Physical Therapists (PTs)will deliver group and individual, live sessions to the home by telemedicine. Sessions will last 60-min (Registered Dietician Nutritionist: 20 min; Physical Therapist: 40 min).
223925394|NCT06044571|BEHAVIORAL|Behavioral|Behavioral Health coaches have a bachelor's degree and take a 6-8-week certification program. Behavioral Health coaches will use a structured manual involving evidence-based behavior change techniques (problem-solving, self-regulation, motivation). Group and individual sessions will be via telemedicine.
223925395|NCT06418997|BEHAVIORAL|CBI|CBI sessions follow a detailed manual to teach a group of peers cognitive and behavioral strategies that they may utilize in their daily lives, often based around the cognitive-behavioral model as a teaching tool. CBI aims to develop cognitive-behaviorally-based skills and habits in participants, such as behavioral activation, mood tracking, the identification and reframing of automatic thoughts, and assertion training.
223925396|NCT03740191|OTHER|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
223925397|NCT03740191|RADIATION|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
223925398|NCT03740191|RADIATION|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
223925399|NCT06828653|DEVICE|Part A First Wear Period: Traditional AFO(s)|Participants are randomized to wear traditionally produced AFOs during Weeks 1 through 3.
224093087|NCT06311773|DEVICE|Boomerang Catheter|The study device used for this procedure makes an anastomosis between a tibial vein and a tibial artery to direct blood flow around blocked arteries.
224093088|NCT04053387|DRUG|tapinarof cream, 1%|Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score
224093089|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.
224281609|NCT03767699|BEHAVIORAL|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never \< 1,500 kcal).
224281610|NCT05357859|DIETARY_SUPPLEMENT|solubilized vitamin D3|solubilized vitamin D3
224281611|NCT05357859|DIETARY_SUPPLEMENT|medium chain triglyceride|MCT with same amount
223717630|NCT05371743|DIAGNOSTIC_TEST|estimation of serum level of IL17|"2ml of patient serum will be used to measure IL17 in patients with different groups by ELISA technique.~The techniques will be done in the central research laboratory in Sohag university hospital"
223717631|NCT03732235|DEVICE|TACE+ systemic Bevacizumab|PEG embolics
223717632|NCT03732235|DRUG|FOLFIRI+Bevacizumab|antiangiogenic factor
223717633|NCT03732235|DEVICE|TACE|PEG embolics
223717634|NCT02554669|BEHAVIORAL|postprandial and postabsorptive physical activity on treadmill|
223925400|NCT06828653|DEVICE|Part A First Wear Period: Digital AFO(s)|Participants are randomized to wear digitally produced AFOs during Weeks 1 through 3.
223925401|NCT06828653|DEVICE|Part A Second Wear Period: Traditional AFO(s)|Participants wear traditionally produced AFOs during Weeks 4 through 6.
223925402|NCT06828653|DEVICE|Part A Second Wear Period: Digital AFO(s)|Participants wear digitally produced AFOs during Weeks 4 through 6.
223925403|NCT06828653|DEVICE|Part B Long-term Evaluation Period: Traditional AFO(s)|Participants are randomized to wear traditionally produced AFO(s) during Weeks 7 through 14.
223925404|NCT06828653|DEVICE|Part B Long-term Evaluation Period: Digital AFO(s)|Participants are randomized to wear digitally produced AFO(s) during Weeks 7 through 14.
223925405|NCT06062160|OTHER|Therapeutic Touch|Experimental group received deep Therapeutic Touch two time at 10th and 40nd hours after cesarean section.
223925406|NCT04712903|DRUG|Durvalumab|Durvalumab 1500 mg via IV infusion over 60 minutes on Day 1 of each cycle.
223925407|NCT04712903|DRUG|Cisplatin|Cisplatin as an IV infusion per local standards (usually over 60 to 120 minutes on Day 1) of each cycle.
223925408|NCT04712903|DRUG|Etoposide|Etoposide sequentially administered per local standards (usually over 30 to 60 minutes IV infusion) on Days 1, 2, and 3 of each cycle.
223925409|NCT04712903|DRUG|Carboplatin|Carboplatin as an IV infusion per local standards (usually over 30 to 60 minutes on Day 1) of each cycle.
223925410|NCT05244317|DEVICE|cast|the cast of the upper limb from just below elbow joint to the knuckle of fingers
223925411|NCT05244317|DEVICE|splint|Removable splint
224093090|NCT04181424|BEHAVIORAL|Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
224093091|NCT04181424|BEHAVIORAL|Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
224093092|NCT04181424|BEHAVIORAL|Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
224093093|NCT03217188|RADIATION|conventionally fractionated full dose re-irradiation|re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions
224093094|NCT03217188|RADIATION|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles)."
224093095|NCT04709549|BEHAVIORAL|Diabetes Prevention Program + Job and Legal Services|"Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.~Job readiness services will be provided by YMCA SF service connectors, trained staff with expertise in employment services who are bi-lingual in English/Spanish and/or Cantonese/English to serve the needs of the community. Service Connectors will assist with providing employment services (e.g job search, potential placement and retention services, relationship development with partners and employers) and job readiness instruction/training."
223531914|NCT02485015|DRUG|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
223717635|NCT02799511|BIOLOGICAL|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
223925412|NCT06687603|DEVICE|EsoCheck|FDA-approved, non-endoscopic, encapsulated swallowable balloon. EsoCheck will produce a sample which will subsequently be tested with EsoGuard assay. The EsoCheck is performed and completed in approximately 5 minutes.
223925413|NCT06687603|DIAGNOSTIC_TEST|EsoGuard|Approved laboratory, methylated DNA panel that detects esophageal neoplasia. The EsoGuard assay tests the EsoCheck samples to detect BE in GERD participants.
223925414|NCT06688786|DRUG|neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy|Preoperative treatment with 4-6 cycles of mFOLFOX6 regimen combined with serplulimab
223925415|NCT06871319|DIAGNOSTIC_TEST|periapical x-ray, orthopantomography|Radiographic exams such as periapical x-rays and orthopantomography are necessary to evaluate the root canal system of teeth.
223925416|NCT06873919|OTHER|Geriatric assessment|The tertiary hospital's geriatrics department is implementing a one-year mobile team composed of a geriatrician and a nurse to conduct geriatric assessments (Anamnesis and heteroanamnesis - Clinical examination - Medication review - Proposed management plan provided to the general practionner, who independently decides which recommendations to implement) in three nursing homes. This non-randomized pilot project aims to establish a new standard of care for residents selected by their primary care physician. The project is accompanied by a clinical study designed to assess the feasibility, effectiveness, and acceptability of this intervention. Prospectively collected data will also help define key indicators for a future large-scale study focusing on cost-effectiveness.
223925417|NCT04732416|DRUG|HM15136|Low dose of HM15136/ High dose of HM15136, SC injection, weekly
223925418|NCT04552119|DEVICE|HEALICOIL Knotless PEEK|HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping
223925419|NCT04552119|DEVICE|HEALICOIL Knotless REGENESORB|HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
223925420|NCT06226948|DEVICE|CGM|Participants will wear CGM monitors for 10 days.
223925421|NCT06226948|DIAGNOSTIC_TEST|Visualization|Enriched visualization of SCORE2 CVD risk.
223925422|NCT06632379|DRUG|Atorvastatin 10 mg|Participants will be assigned to 10 mg Atorvastatin
223925423|NCT06632379|DRUG|Placebo|Participants will be assigned to identical appearing placebo
223925424|NCT00638898|DRUG|busulfan|Given IV
223925425|NCT00638898|DRUG|melphalan|Given IV
223925426|NCT00638898|DRUG|topotecan hydrochloride|Given IV
223925427|NCT00638898|OTHER|laboratory biomarker analysis|Correlative studies
223925428|NCT00638898|BIOLOGICAL|filgrastim|Given IV or subcutaneously
223925429|NCT00638898|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo transplantation
223925430|NCT00638898|OTHER|pharmacological study|Correlative studies
223925431|NCT00638898|PROCEDURE|autologous bone marrow transplantation|Undergo transplantation
224093096|NCT04709549|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
223925432|NCT06875570|OTHER|Pliometric Training|The full intervention program will cover 12 weeks in the season. Prior to training, players will be instructed to warm-up for ten minutes with general running exercises and dynamic stretching. The plyometric training intervention will consist of 5 exercises performed in the following order: Leap forward and backward on the line, leap sideways on the line, double leg knee to chest, split squat jump, and squat jump (Bavli, 2012). A volleyball coach will monitor the whole training.
223925433|NCT06875570|OTHER|Jump Rope Training|The entire intervention program will last for 12 weeks during the season. Before training, players will be instructed to warm up with general running exercises and dynamic stretching for ten minutes. The jump rope intervention will consist of 5 exercises performed in the following order: basic jump step, double leg double jump, double leg jump left and right, double leg jump forward and backward, and scissor steps (Trecroci et al., 2015). Each exercise will be performed by all participants using a jump rope with the same characteristics in terms of weight (e.g. 230g), length (e.g. shoulder size) and material (e.g. PVC, Polyvinyl Chloride). A metronome speed of 120 beats per minute will be used to ensure equal exercise intensity in both exercise programs Furthermore, a volleyball coach will monitor the entire workout.
223925434|NCT06875570|OTHER|Small Sided Games|More complex, skill-based conditioning exercises for volleyball are small-sided games (2v2, 3v3) and competition drills (6v6). Although the duration of each rally in these drills is not controlled by the coach, the total duration of the drill will be recorded to aid in-session and inter-session planning. Total repetitions will be easily measured by adding up the total points played in the rally and then multiplying by the number of rallies per point. The coach will create an emotionally intense environment by applying a scoring system (e.g. team winning 2 out of 3 rallies gets 1 big point, 5 seconds rest) and encouraging the players (Trajkovic et al., 2012).
223925435|NCT06873061|OTHER|telenursing|This study aims to examine the impact of telemedicine training on nursing students. The training content is designed specifically for nursing students and includes various techniques such as simulations.
223925436|NCT06689488|DEVICE|Ablation|Bronchoscopy and microwave ablation prior to surgical resection.
223925437|NCT04149210|DRUG|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
223925438|NCT04149210|DRUG|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
223925439|NCT07030426|DRUG|Vaginal Estrogen - Twice Weekly|Twice weekly for six weeks following pelvic organ prolapse repair surgery. 0.5 grams of cream per vagina at bedtime .
223925440|NCT07030426|DRUG|Vaginal Estrogen - Daily|Daily for six weeks following pelvic organ prolapse repair surgery. 0.5 grams of cream per vagina at bedtime.
223925441|NCT07031349|DEVICE|MARPE|Adult patients with maxillary constriction underwent maxillary expansion using a miniscrew-assisted rapid palatal expander (MARPE).
223925442|NCT06879587|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants could take BC99 daily and record any adverse reactions. Participants filled out questionnaires and collected stool and serum samples, which were used to detect and analyze the improvement of participants' constipation function.
223925443|NCT06879587|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants could take maltodextrin daily and record any adverse reactions. Participants filled out questionnaires and collected stool and serum samples, which were used to detect and analyze the improvement of participants' constipation function.
223925444|NCT06715163|DIETARY_SUPPLEMENT|Dose 1 (42mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Lowest dose of DAO administered in this study
224093097|NCT05067127|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
224093098|NCT05067127|OTHER|Placebo|Sterile solution of equal volume to active arm
224093099|NCT03180450|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
224093100|NCT03180450|DRUG|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
224281612|NCT01358799|DEVICE|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
224281613|NCT00641199|OTHER|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
223717636|NCT03582540|PROCEDURE|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
223925445|NCT06715163|DIETARY_SUPPLEMENT|Placebo|Contains the same excipients as the DAO tablets but without the diamino oxidase content
223925446|NCT06715163|DIETARY_SUPPLEMENT|Dose 2 (84mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Medium dose of DAO administered in this study
223925447|NCT06715163|DIETARY_SUPPLEMENT|Dose 3 (210mg) of DAO|DAO extract is obtained from pea sprout dehydrated powder. Highest dose of DAO administered in this study
224093101|NCT06306417|OTHER|lifestyle intervention|lifestyle intervention
224093102|NCT06306417|DEVICE|acupuncture|acupuncture
224093103|NCT06306417|DEVICE|Sham acupuncture|Sham acupuncture
224093104|NCT04462536|DRUG|Placebo|Vehicle only
224093105|NCT04462536|DRUG|Nerinetide|Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
224093106|NCT06640114|DEVICE|Efferon CT|"Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.~The duration of hemoperfusion is from 2 to 6 hours through peripheral venous access, followed by follow-up for 4 hours. The rate of hemoperfusion is from 60 to 80 ml/min. Anticoagulation is systemic (heparin)."
224281614|NCT03115606|DEVICE|C-Mac D Blade|Videolaryngoscope
224281615|NCT03115606|DEVICE|Fastrach LMA|Laryngeal mask airway
224281616|NCT03803111|BEHAVIORAL|Initial exercise training|Initial exercise training program
224281617|NCT03803111|DRUG|Initial FCM|Initial intravenous iron supplementation (FCM)
224281618|NCT03803111|DRUG|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
223925448|NCT06878352|OTHER|Educational intervention BUNDLE, prepared in accordance with the recommendations of the Global Initiative for Asthma- GINA (2024)).|"The educational intervention bundle was designed in accordance with the recommendations of GINA (2024), and will cover topics on the etiopathogenesis and pathophysiology of asthma, inhaler treatment, precipitating factors for crises, self-management skills, environmental control, as well as the importance of drawing up a written therapeutic plan and regular medical follow-up.~The educational intervention will be offered as a group activity and will be conducted in a single meeting, lasting approximately sixty minutes. Users will attend a standardized dialogical lecture using audiovisual resources, where they will have the opportunity to discuss and answer any questions related to the topics covered. At the end of the intervention, participants will receive a booklet containing all the points covered in the intervention, as well as a diary to record the amount of medication used, visits to the emergency room and asthma-related hospitalizations."
223925449|NCT07039890|DRUG|Empagliflozin + Linagliptin filmcoated tablets|Empagliflozin + Linagliptin 10 mg/5 mg filmcoated tablets
224093107|NCT04980898|DEVICE|WoundEL medical device|"The WoundEl system is composed by: a class IIa device , a class IIb dressing electrode and a class I disperser electrode.~Applied to the leg ulcer, WoundEL® reproduces the endogenous electrical current to stimulate all the factors contributing to healing. Electrical current is evenly spread over the Dressing Electrode which also maintains a moist wound healing environment."
223925450|NCT07039890|DRUG|Glyxambi film-coated tablets|Glyxambi 10 mg/5 mg film-coated tablets
224093108|NCT04980898|OTHER|Standard cares|Cleaning and monitoring
224093109|NCT02325674|DRUG|Metreleptin|
224093110|NCT06046482|DRUG|Pembrolizumab|Given by IV (vein)
223717637|NCT06476561|OTHER|- Sociodemographic Assessment - Psychological Assessment - Quality of Life Assessment - D|"The study involves several assessments to evaluate the impact of various factors on dual-task performance in elderly individuals:~1. Sociodemographic Assessment: Collection of data on age, gender, education, income, marital status, and other relevant factors.~2. Psychological Assessment: Use of the Depression Anxiety Stress Scales-21 (DASS-21) to measure levels of depression, anxiety, and stress.~3. Quality of Life Assessment: Utilization of the World Health Organization Quality of Life Brief Form (WHOQOL-BREF) to assess physical health, psychological health, social relationships, and environment.~4. Dual-Task Performance Evaluation: Measurement of the ability to perform a cognitive task (counting backward by threes) simultaneously with a motor task (Nine-Hole Peg Test). The dual-task cost (DTC) is calculated to quantify the impact of cognitive load on motor performance."
223717638|NCT01751867|DRUG|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
223925451|NCT07038811|DEVICE|Tät®II|"The Tät®II app offers a treatment program for women with urge or mixed urinary incontinence. The program includes information on the pelvic floor, urinary incontinence, and factors affecting incontinence; a bladder training program; a pelvic floor muscle training program; and incontinence-related psychoeducation. The app also contains helpful functions, the ability to create reminders, visualization of each training level, a statistics function regarding the number of exercises performed, and feedback on changes in the level of bother due to urinary incontinence during treatment.~The Tät®II app is available for download on Google Play and the App Store. Users need a one-time code to access the app, which is provided by the research team after they are included in the study. The app is self-instructive and can be used anywhere; no formal education is necessary. There is no option to communicate through the app."
223925452|NCT07038954|OTHER|Stone Composition Analysis|This intervention involves the compositional analysis of kidney stone fragments retrieved during surgical procedures. The stone samples are analyzed using X-ray diffraction (XRD) and infrared spectroscopy (IR) to determine their crystal composition. This is a non-invasive, laboratory-based diagnostic procedure. No drug, device, or therapeutic intervention was administered to participants as part of this observational study.
223925453|NCT07040020|PROCEDURE|Underwater ESD (U-ESD)|Underwater ESD (U-ESD): after filling the lumen with saline and sucking all the air, initial submucosal injection of saline and methylene blue is performed; subsequent mucosal incision with ESD knife all around the lesion and submucosal dissection deep in the submucosal layer leading to an en bloc resection is carried out
223925454|NCT07040020|OTHER|Conventional ESD (C-ESD)|Conventional ESD (C-ESD): under CO2 insufflation, initial submucosal injection of saline and methylene blue is performed; subsequent mucosal incision with ESD knife all around the lesion and submucosal dissection deep in the submucosal layer leading to an en bloc resection is carried out.
223925455|NCT06299514|DEVICE|Pace and Ablate|Conduction System Pacing (CSP) followed by AtrioVentricular Node Ablation (AVNA)
223925456|NCT06299514|DRUG|Medication|Optimization of heart failure therapies includes maximum tolerated doses of beta-blockers, aldosterone antagonists, ACE inhibitors, ARB, diuretics, ARNis
224093111|NCT06046482|DRUG|Magrolimab|Given by IV (vein)
224093112|NCT06046482|DRUG|cetuximab|Given by IV (vein)
223717639|NCT01751867|DRUG|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
224093113|NCT06046482|DRUG|Docetaxel|Given by IV (vein)
224093114|NCT06385886|BEHAVIORAL|Linkage Coordinator|The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
224281619|NCT03803111|BEHAVIORAL|Subsequent exercise training|Subsequent exercise training program after 2 months
224281620|NCT05062915|DIAGNOSTIC_TEST|HINTS|HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
224281621|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
224281622|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
224281623|NCT01844531|DRUG|metformin (Glucophage®)|single tablet metformin
224281624|NCT01844531|DRUG|empagliflozin|single tablet empagliflozin
224281625|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
224281626|NCT01844531|DRUG|empagliflozin and metformin|FDC tablet empagliflozin and metformin
224281627|NCT01657084|DEVICE|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
224281628|NCT01657084|DEVICE|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
224281629|NCT04894084|DEVICE|CP321|The primary objective is to evaluate the system performance of the test product. This is done by asking subjects to answer questions throughout the study
223925457|NCT06883994|OTHER|Fermented vegetable intervention|"Participants will be provided with reduced-sodium fermented vegetables developed by Dr. Ilenys Pérez-Díaz at the USDA-ARS Food Science and Market Quality and Handling Research Unit. The fermented, refrigerated vegetables have been shown to have Lactiplantibacillus spp. content \>10\^7 CFU/mL at 21 days shelf-life.~Products are prepared in a Good Manufacturing Practices Facility at North Carolina State University, Department of Food, Bioprocessing, and Nutrition Sciences.~The fermented vegetables will be shipped in coolers on cold packs with temperature indicators to the WHNRC. Participants will be asked to consume two pre-packaged 50g servings of fermented vegetables a day, for a total daily serving of 100g, not to heat the fermented vegetables prior to consumption, to log their consumption and to rate the acceptability of the fermented vegetables. They will be advised to avoid other fermented foods and to otherwise maintain their habitual diet."
223925458|NCT06715085|DRUG|Plasma Rich in Growth Factors (PRGF)|The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
223925459|NCT06715085|DRUG|Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.|The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.
223925460|NCT07038057|DIETARY_SUPPLEMENT|Short peptide enteral nutrition|Short peptide formula enteral nutrition was initiated within 48 hours after admission to the ICU. For patients with poor swallowing function or no consciousness, nasogastric tubes were placed. Starting from low-calorie or nourishing feeding, 70% of the target energy should be achieved within 7 days, and the protein should be 1.2-1.5 g/kg/d. Due to the large individual differences in energy expenditure among patients with sepsis, the indirect calorimetry (IC) method was used to determine energy expenditure. If the IC method is not feasible, the calculation formula based on body weight: 20-25 kcal/kg/d should be applied for calculation. If the patient is not transferred out of the ICU after 7 days, continue to gradually increase to the target energy and protein requirements under tolerable conditions, and gradually transition to whole protein nutrition after 7 days.
223925461|NCT07038057|DIETARY_SUPPLEMENT|Whole protein enteral nutrition|The whole protein formula enteral nutrition was initiated within 48 hours of admission to the ICU, and the rest were same.
223925462|NCT07037979|OTHER|Not applicable- observational study|non-applicable
223925463|NCT06881810|DRUG|Oxytocin nasal spray|Syntocinon® nasal spray is applied according to description in arms section
223925464|NCT06881810|OTHER|Placebo|Placebo nasal spray is applied according to description in arms section
223925465|NCT07038005|DRUG|SPGL008|Biological product
223925466|NCT06725953|BEHAVIORAL|Social Cognitive Theory-based, Technology-delivered Physical Activity Program|Participants will engage in a 12-week program of aerobic and muscle-strengthening physical activity. This program will be delivered remotely via two smartphone applications--one for providing health education, goal setting, and journaling features and the other for delivery of the physical activity program in a highly-personalized and HIPAA-compliant manner. Participants will receive a Fitbit to track their activity and resistance bands to use during their resistance training physical activity. All program components will be based in the Social Cognitive Theory and will target improving participants' physiological and psychological health outcomes.
223925467|NCT06726057|BEHAVIORAL|Imlementation strategies in conjunction with multicomponent hypertension intervention|In this study, the researchers will develop and test strategies for the implementation and scale-up of a proven multicomponent hypertension intervention (MCHI) programme in Pakistan. Implementation strategies will be devised through an engagement process and will involve the use of implementation frameworks including the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of MCHI\&amp;amp; Expert Recommendations for Implementation Change (ERIC) to identify a set of implementation strategies addressing each barrier. Input for the development of strategies will be sought from the community, public health sector managers, general practitioners and community health workers. The implementation strategies will be used to randomise study clusters while MCHI will be implemented in both intervention and control arms.
223925468|NCT06726057|BEHAVIORAL|Multicomponent hypertension intervention|"The multicomponent hypertension intervention has four components as follows:~1. Training of community health workers (CHWs) in conducting health education sessions regarding hypertension, its risk factors, prevention, and health-seeking~2. Blood pressure (BP) monitoring and referral of hypertensive individuals by CHWs to general practitioners in primary care facilities~3. Training of general practitioners in primary care settings in BP monitoring and management of hypertension~4. Hypertension care coordination in primary care facilities for the care of referred patients."
223925469|NCT06720610|DRUG|Vonoprazan 20 mg|Vonoprazan PO, 20mg, once a day, 14 days.
223925470|NCT06720610|DRUG|Esomeprazole|Esomeprazole PO, 40mg, once a day, 14 days
223925471|NCT06728267|OTHER|Core stabilization training|Exercise training will be given for 6 weeks, 3 days a week, 2 sets of 10 repetitions for the first two weeks, 2 sets of 15 repetitions for the second two weeks, and 3 sets of 12 repetitions for the third two weeks.
223925472|NCT06728267|OTHER|Training|Routine training sessions conducted by coaches specific to the sport of underwater rugby.
223925473|NCT04207931|DRUG|Topical steroid class I-II|applied once daily - 18 month duration of the study
223925474|NCT04207931|DRUG|Triamcinolone Acetonide|Intralesional Steroid Injection, 7.5mg/cc. max dose of 3 cc. Scalp injections will be administered every 6-8 weeks, for a total of 8 injections.
223925475|NCT04207931|DRUG|Doxycyline|oral antibiotic twice daily for 6 months
223925476|NCT04207931|DRUG|Minoxidil|5% solution or foam started after month 8
223925477|NCT06296082|DRUG|Botulinum toxin type A|Botulinum toxin type A injections are a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a chimical disruption of dysfunctional endplates.
223925478|NCT06296082|OTHER|Dry Needling|Dry Needling is a treatment technique to treat the spastic muscles in patients with stroke that targets on the neuromuscular endplate zone provoking a mechanical disruption of dysfunctional endplates.
223925479|NCT05355441|DRUG|Paracetamol|Routine clinical practice treatments recommended by the medical team involved
223925480|NCT05355441|DRUG|Ibuprofen 600 mg|Routine clinical practice treatments recommended by the medical team involved
223925481|NCT05355441|DRUG|Tramadol|Routine clinical practice treatments recommended by the medical team involved
223925482|NCT05355441|DRUG|Morphine|Routine clinical practice treatments recommended by the medical team involved
223925483|NCT06722560|OTHER|GLP-1 hormone|s.c. continuous infusion for 72 hours using an insulin pump
223925484|NCT06722560|OTHER|Placebo|s.c. continuous infusion for 72 hours using an insulin pump
223925485|NCT06724796|OTHER|Y4BI|"The yoga classes will follow the Iyengar method, one of the most widely practiced traditional yoga styles, aimed at promoting body alignment and precision in executing poses (asanas) through the use of props such as blankets, straps, cushions, chairs, and blocks, making the poses accessible to all individuals.~The classes will be conducted once a week, in groups, with each session lasting 1 hour. They will be led by a qualified instructor with over 10 years of teaching experience in yoga. The classes will be adapted for beginners who do not practice yoga regularly."
223925486|NCT06724796|OTHER|ACTIVE|The total body classes will take place once a week, with each session lasting one hour. They will be led by a kinesiology specialist in preventive and adapted physical activities.
223925487|NCT06723418|OTHER|Malnutriton Screening Tool (PYMS)|In a pilot implementation study, PYMS will be used on children with IBD attending the outpatient and inpatient hospital clinics
223925488|NCT06731699|DRUG|FD-001|"The initial dose was 0.4mg, and subsequent doses of 0.8mg, 1.6mg, 2.4mg, 3.2mg, and 4.0mg were proposed to be administered in a progressive manner using the rapid titration method combined with the traditional 3+3 experimental design. The trial process consists of three periods: screening period, treatment period, and follow-up period. The screening period lasted from D-28 to D-1 for treatment (DLT observation period): during this time frame, there was a single administration period (C0D1-C0D4) where oral administration occurred on day one followed by safety observations on days two to four; as well as multiple administration period one (C1D1-C1D28) where oral administration took place on days one to two and seven to nine with rest periods in between. The drug is available in capsule form."
223925489|NCT06884644|DIAGNOSTIC_TEST|Death by Airsquat|Increasing number of squats have to be completed every minute (EMOM principle).
223925490|NCT06886594|OTHER|breast cancer education program training|"The first researcher conducted the breast cancer education program for the experimental group, and the researcher completed her doctorate in Obstetrics, Gynecology and Diseases Nursing. The content of the education given to the experimental group was prepared in accordance with the Breast Cancer Prevention, Screening, Diagnosis, Treatment and Follow-up Clinical Guide 2020 (Version 1.0) of the Ministry of Health of the Republic of Turkey. Each woman in the experimental group was given face-to-face individual education in accordance with the education material prepared by the first researcher, and their questions were answered at the end of the education. After the theoretical education was completed, each woman in the experimental group was given BSE practical education using the Wearable Breast Examination Simulator by the first researcher using the demonstration method in accordance with the steps in the Breast Self-Examination brochure by the Cancer Early Diagnosis, Screening"
223925491|NCT06707194|BIOLOGICAL|Etanercept|Prefilled syringe, 25mg of hypodermic injection, twice a week
223925492|NCT06707194|DRUG|Benzathine Penicillin|Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, 1.2 million units of intramuscular injection, once every two weeks
223925493|NCT06707194|OTHER|Placebo|Preparation of suspension with appropriate amount of sterilized water (4-5ml) for injection, intramuscular injection, once every two weeks
223925494|NCT06733480|DEVICE|Band Connect|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
223925495|NCT06732115|PROCEDURE|One-step polishing system with nanohybrid resin composite restorations.|one-step polishing system using OneGloss by Shofu
223925496|NCT06732115|PROCEDURE|Multistep system polishing system Super-Snap X-treme (Shofu) with nanohybrid resin composite restorations.|A multi-step polishing system
223925497|NCT06733389|OTHER|peripheral waveform collection|The peripheral venous pressure is collected by connecting a pressure transducer that is currently in use to the central venous line. In addition, pulse pressure variation and stroke volume variation that can be obtained from the arterial catheter. In addition, the pleth variability index is collected through the oxygen saturation monitoring. This extracts the medical records and bio-signal information of the subjects registered through the previously approved 'Establishment of a Bio-signal and Clinical Information Registry for the Development of Patient Monitoring Algorithms' (B-2202-738-401).
223925498|NCT07039201|BIOLOGICAL|CG-102-12C|Chimeric Antigen Receptor Autologous T-cell
223925499|NCT05146297|BEHAVIORAL|Clinical trial match-list|Creation and dissemination educational materials designed to inform and empower patients' participation in their cancer treatment including the consideration of clinical trial participation and provide clinical trials' patient navigators (CTPN) to further aid with education about clinical trials.
223925500|NCT05146297|BEHAVIORAL|Match-list intervention|Providers by intervening at the clinical and systems levels to provide them with tools and processes and informational and practical support to facilitate CT consideration, discussion, and offer to aid with education about clinical trials and facilitate CT consideration at a treatment decision node.
223925501|NCT06727526|OTHER|Acupressure|The literature found that acupressure positively affects child health, but no study was found to determine the effect of acupressure on pain and physiological parameters in children undergoing cardiac catheterization. Therefore, this study was designed to determine the effect of acupressure applied before and after cardiac catheterization on infants' pain levels and physiological parameters.
223531915|NCT05157061|DIETARY_SUPPLEMENT|Galacto-oligosaccharides (GOS)|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
223717640|NCT01659775|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
223531916|NCT05157061|DIETARY_SUPPLEMENT|Maltodextrine|An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
223531917|NCT04681144|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|Decision to initiate treatment with Radium-223 made as per investigator's routine treatment practice
223531918|NCT06715748|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-4 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
224093117|NCT06295146|OTHER|Intervention A: 1-on-1 wheelchair skills training by a peer coach|"Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback."
224093118|NCT06295146|OTHER|Intervention B: Training via educational videos|Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
223717641|NCT01659775|DRUG|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
223925502|NCT06727526|OTHER|Placebo acupressure|In health sciences, placebo refers to an inactive intervention used to relax the patient and assess treatment efficacy. It may involve inert substances (e.g., sugar tablets, saline) or non-therapeutic interventions (e.g., artificial electrical stimulation or conversations). Expectancy theory often explains The placebo effect, which suggests that treatment expectations can induce physiological changes. Factors like age, cognitive development, and previous pain experiences influence children's responses to placebo. Parental belief in an intervention's efficacy can reduce a child's pain expectations and positively influence their perception of pain. Although the sample included young children, our study incorporated the placebo group to account for this effect, especially since the parents evaluated pain scores.
223925503|NCT05786131|PROCEDURE|Culprit-lesion revascularization|Percutaneous coronary intervention of culprit-lesion
223925504|NCT05786131|PROCEDURE|Non-culprit-lesion revascularization|Complete percutaneous coronary intervention of all angiographically significant non-culprit lesions
223925505|NCT06779565|DEVICE|Hyflex EDM system|A rotary file system
223925506|NCT06779565|DEVICE|Reciproc VDW system|A reciprocating file system
223925507|NCT06735690|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHSCT
223925508|NCT06735690|BIOLOGICAL|Anti-CD19-CAR CMV-specific T-lymphocytes|Given IV
223925509|NCT06735690|PROCEDURE|Biospecimen Collection|Undergo blood and optional CSF sample collection
223925510|NCT06735690|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
223925511|NCT06735690|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
223925512|NCT06735690|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223925513|NCT06735690|PROCEDURE|Echocardiography|Undergo ECHO
223925514|NCT06735690|PROCEDURE|Leukapheresis|Undergo leukapheresis
223925515|NCT06735690|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223925516|NCT06735690|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224093119|NCT03624738|PROCEDURE|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
224093120|NCT03312192|DEVICE|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
223925517|NCT06735690|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223925518|NCT06735690|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224093121|NCT03312192|DEVICE|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
224093122|NCT01499173|BEHAVIORAL|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
224093123|NCT02861170|BEHAVIORAL|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
224281630|NCT04452279|DEVICE|iStent or iStent inject implantation with concomitant cataract surgery|Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
224281631|NCT04913207|PROCEDURE|method of device size selection|device size selection based on 3D-CTA
224281632|NCT02480426|DEVICE|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
224281633|NCT02480426|DRUG|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
223717642|NCT04932096|DRUG|melatonin|melatonin supplementation
223717643|NCT04932096|OTHER|placebo|microcrystalline cellulose filled capsule
223925519|NCT06735690|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223925520|NCT06735690|OTHER|Transplant Conditioning|Given HSCT conditioning regimen
223925521|NCT06735690|PROCEDURE|X-Ray Imaging|Undergo chest x-ray
223925522|NCT06734390|OTHER|Bladder Neck Surgery|Bladder Neck Surgery regroups many surgical procedures to cure urinary incontinence.
223925523|NCT06734312|DEVICE|Gastric Fundal Mucosal Ablation (GFMA)|Endoscopic Gastric Fundal Mucosal Ablation (GFMA) after discontinuation of GLP-1 therapy
223925524|NCT06736015|DIETARY_SUPPLEMENT|Myo-Inositol 600 mg + Selenium 83 mcg|Myo-Inositol 600 mg + Selenium 83 mcg: 1 tablet once a day for 6 months
223925525|NCT06736496|DRUG|Nalbuphine|patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.
223925526|NCT06736496|DRUG|Dexmedetomidine|patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
223925527|NCT05693363|DEVICE|AURA10 Specimen Imager|High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
223925528|NCT05188079|DIETARY_SUPPLEMENT|Beetroot juice|high nitrate supplement
223925529|NCT05188079|DIETARY_SUPPLEMENT|Placebo drink|placebo
223925530|NCT06734533|OTHER|Anlotinib+eribulin/nab-paclitaxel/etoposide/capecitabine/pembrolizumab/ sintilimab/ fulvestrant, etc|Anlotinib (8/10/12 mg daily, Day 1-14 of each cycle) was administered orally to fasting patients, with dose reductions to 10 mg or 8 mg in cases of intolerable toxicity. Combination agents included eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant, among others.
223925531|NCT06734832|BIOLOGICAL|bivalent enterovirus vaccine (Vero cell), inactivated|Two doses are administered with a one-month interval between each dose.
223925532|NCT06734832|BIOLOGICAL|Enterovirus Type 71 Vaccine (Vero Cell), Inactivated|Two doses are administered with a one-month interval between each dose.
223925533|NCT06883617|DEVICE|Neuro stimulator Implant|Neuro Stimulator for treating sleep disordered breathing
223925534|NCT06740240|DRUG|68Ga-FAPI-Biotin|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
223925535|NCT06740240|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
223925536|NCT06885502|DEVICE|RGS|The standardized intervention schedule consists of 20-30-minute daily training sessions (including weekends) for 6 weeks, in addition to the prescribed conventional therapy (Standard of Care, SoC). Each session includes 4 to 6 exercises, each lasting approximately 5 minutes. To promote variability and engagement, at least one exercise will be replaced every week based on the participant's progress. Participants are encouraged to train more than the prescribed duration if desired. The RGSapp training will take place at home, and patients will use a smartphone. An optional wearable device (smartwatch) will be used to remotely monitor the use of the paretic upper arm for the duration of the trial. Regular check-ins by clinicians will monitor adherence, adjust the intervention if needed, and ensure the participants' safety.
223717644|NCT03004456|OTHER|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
223717645|NCT02442518|PROCEDURE|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
223925537|NCT06737445|PROCEDURE|Radiofrequency ablation alone|RTL was performed as a single session using the radiofrequency ablation device (NeuroTherm JK4A; NeuroTherm Ltd, Croydon, London, England).
223925538|NCT06737445|PROCEDURE|Cortisone Injection|An injection of 1 ml of betamethasone 40 mg/ml and 2 ml of bupivacaine 5 mg/ml was performed.
223925539|NCT06737445|OTHER|Extracorporeal shock wave therapy|Patients underwent 3 ESWT sessions applied to the plantar heel area, once a week with the same ESWT dose (15 Hz, 2000 pulse, 4.0 bar energy density) using a BTL-5000 SWT device (BTL Industries, USA).
223925540|NCT06739031|DEVICE|PEF Treatment|PEF Energy ablation of lung tumors
223925541|NCT06740175|DEVICE|Multispectral optoacoustic tomography|If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
223925542|NCT06741033|DIAGNOSTIC_TEST|Conventional physiotherapy|Conventional physiotherapy of medial knee osteoarthritis patients: Isometric exercises, strengthening exercises, stretching exercises and electrotherapy.
224281634|NCT03663790|OTHER|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
224281635|NCT03663790|OTHER|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
224281636|NCT02000531|DRUG|Erlotinib|150 mg oral dose of erlotinib given once daily
224281637|NCT02000531|DRUG|Chemotherapy|Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1 and gemcitabine (1250 mg/m\^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
224281638|NCT02591563|OTHER|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
224281639|NCT04065568|DEVICE|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
224281640|NCT03631368|DRUG|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
224281641|NCT02956616|DRUG|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
224281642|NCT02956616|OTHER|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
224281643|NCT02956616|PROCEDURE|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
223925543|NCT06741033|COMBINATION_PRODUCT|Toe-in gait modification|A specific alteration in walking pattern where the toes are directed inward during walking. This modification should be clearly defined, including the degree of inward rotation of the foot and how it is taught and monitored in participants. Toe-in gait modification basically includes decrease foot progression angle from baseline through internal foot rotation. Participants are instructed to increase the Toe-in angle of their study limb by 5 degree and walk at least 5-10 minutes (progressed to 15-20 min after 4 week) with this progression angle.
223925544|NCT06739343|PROCEDURE|PHACO-Trabeculectomy|Phaco-Trabeculectomy is a combined surgical procedure that integrates phacoemulsification, a modern cataract extraction technique using ultrasound, with trabeculectomy, a glaucoma filtration surgery. This intervention is distinguished by its precision, minimal incision size, and suitability for patients with coexisting cataract and glaucoma. Phacoemulsification efficiently emulsifies and aspirates the cataract through a small incision, while trabeculectomy creates a filtration bleb to lower intraocular pressure (IOP). This combination allows for simultaneous management of both conditions, particularly in cases where phacoemulsification is preferred for cataract extraction.
223531919|NCT06715748|DIETARY_SUPPLEMENT|Placebo|Participants will perform a randomized, double-blind ZWIFT event, once with ketone ester intake and once with placebo, separated by an interval of 1-3 weeks. Ketones and placebo will be orally administered according to a fixed schedule.
223925545|NCT06739343|PROCEDURE|MSICS-Trabeculectomy|Manual Small Incision Cataract Surgery (MSICS) with Trabeculectomy is a cost-effective, combined surgical approach involving a manual technique for cataract removal alongside glaucoma filtration surgery. MSICS utilizes a larger incision than phacoemulsification, allowing for the manual extraction of the cataract nucleus. This procedure is particularly advantageous in resource-limited settings where phacoemulsification equipment may not be available. The trabeculectomy component is the same as in the PHACO-Trabeculectomy intervention, providing effective IOP reduction through the creation of a filtration bleb.
223925546|NCT06738680|DIAGNOSTIC_TEST|LAFOV system (an innovative, latest-generation system) scan|To collect data from the LAFOV system (an innovative, latest-generation system) during the PET scan planned as part of your treatment.
223925547|NCT06736782|BEHAVIORAL|Self-Empowerment Care Intervention Group|"The intervention emphasizes four key principles: hydration, exercise, dietary support, and defecation care. Each component is designed to address fundamental needs and promote independence in activities of daily living (ADLs).~Individualized care plans will be developed in collaboration with healthcare professionals and caregivers to ensure alignment with participants' functional capabilities and personal goals."
223925548|NCT06736782|BEHAVIORAL|Control Group|"Standard caregiving practices without emphasis on structured hydration, exercise, or dietary programs.~General assistance with ADLs as per existing care routines in the respective facilities."
223925549|NCT06549933|OTHER|Criostymulation|"Method: Cryosauna. Temperature: -160°C. Duration: 5 days. Session Timing: 9:00 a.m.~Session Length: 3 minutes per day"
223925550|NCT05317364|DRUG|Estradiol 0.01% Vag Cream|1g estradiol vaginal cream 0.01% or placebo will be administered nightly for 2 weeks then twice weekly to complete 6 months therapy
223925551|NCT05317364|DRUG|Placebo vaginal cream|Placebo cream
224281644|NCT01768819|BEHAVIORAL|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
223531920|NCT00307957|DEVICE|Pillar Palatal Implants|
223531921|NCT00529633|DRUG|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
224281645|NCT01345318|BIOLOGICAL|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
224281646|NCT01345318|BIOLOGICAL|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
224281647|NCT02063308|DIETARY_SUPPLEMENT|Oxaloacetate (OAA)|
223531922|NCT00529633|OTHER|Sugar pill|Placebo by mouth at night for a total of 24 weeks
223531923|NCT00414375|PROCEDURE|Operation on Admission|Laparoscopic appendectomy on admission
223531924|NCT00414375|PROCEDURE|Drainage and Interval Appendectomy|drainage with interval appendectomy
223531925|NCT04572334|OTHER|Auto and Subjective Refraction|All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
223531926|NCT06032611|DIAGNOSTIC_TEST|COGNUM_ALZVR|"Participants will complete a battery of tests/quizzes:~* cognitive tests~* medical questionnaire~* lifestyle/fragility questionnaire~* digital clock test~* fine motor skills tests They will also wear a connected watch for 7 days."
223717646|NCT04294576|DRUG|BJ-001|BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
223925552|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 14 day
223925553|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + low dose amoxicillin|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 2 times/day, oral, for 14 day
223925554|NCT06734260|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin（H-KA-10d）|Keverprazan Hydrochloride tablets 20 mg/time, 2 times/day, oral Amoxicillin 1000mg/ time, 3 times/day, oral, for 10 day
223925555|NCT06735378|OTHER|Intradialytic Cycling|The impact of interdialytic exercise on cardio protection during HD has never been studied. This approach may enhance cardiovascular benefits and overall physical fitness, thereby contributing to better health outcomes in individuals undergoing HD.
224093124|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Group (EBCM-G)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol.~Additionally, participants in the Group Intervention will be able to communicate with and respond to one another through the group chat rooms within the app."
224093125|NCT04948996|BEHAVIORAL|El Buen Consejo Móvil- Individual (EBCM-I)|"1. Psycho-education and Information using a CBT toolbox approach.~2. Self-Assessment to track, label and describe moods by daily prompts to state or text level of mood on the mood tracker (termómetro de animo).~3. Symptom Identification and Management: after identifying a label for type of thinking from a pull-down list, a corresponding short 1-3-minute recorded strategy such as Thought Stopping, Increasing Pleasurable Activity, Mindfulness or Priming will be provided.~4. Monitoring of treatment engagement and response to treatment: Reminders to engage will include text messages and phone calls from the facilitator to encourage use of the app according to a scripted protocol."
224093126|NCT05662644|PROCEDURE|Minimally Invasive Surgery for Esophageal Cancer|Assessment of minimally Invasive Surgery for Esophageal Cancer
224093127|NCT03819075|DEVICE|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
224093128|NCT03819075|OTHER|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
224093129|NCT05057390|DIETARY_SUPPLEMENT|New Human Milk Fortifier (NHMF)|"The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use."
224093130|NCT01046812|DRUG|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
224281648|NCT00528684|BIOLOGICAL|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
223925556|NCT06734143|DIAGNOSTIC_TEST|Neuropad|Neuropad examination was performed in all patients, after 10 minutes of rest without socks in a well-temperatured room. The result was considered normal if there was a complete color change and abnormal if there was no or incomplete color change.
223925557|NCT06736106|OTHER|screening|Comprehensive screening of bone metabolic status and bone fragility in the largest cohort to date of patients with degenerative spinal diseases
223925558|NCT06091540|BEHAVIORAL|Feasibility and Efficacy of Individual SH+ Intervention|The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
223925559|NCT06048263|BEHAVIORAL|interpersonal psychotherapy (IPT)|The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.
223925560|NCT06048263|DRUG|Ketamine|During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
223925561|NCT06173102|DEVICE|Cranial Orthosis|Early versus usual reception of orthosis.
223925562|NCT06307002|OTHER|Playing a contraception education videogame|"The WMM game is divided into three parts- a reproductive anatomy quiz (Parts), an interactive tool for education about each individual birth control method (Methods), and a section in which players help avatar couples choose the most effective method for them."
224093131|NCT04453150|OTHER|Standard hypocaloric die|Standard hypocaloric diet
224281649|NCT01247779|PROCEDURE|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
224281650|NCT01247779|PROCEDURE|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
224281651|NCT01022684|OTHER|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
223531927|NCT04796584|OTHER|Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus|mRNA vaccination for SARS-CoV-2 is not provided by the study
223925563|NCT06742983|OTHER|Isobutyl cyanoacrylate|Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution
223531928|NCT01270529|OTHER|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
223531929|NCT00736983|DRUG|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
223531930|NCT00736983|DRUG|ciprofloxacin|12 weeks; daily 2 x 500mg
223925564|NCT06742983|OTHER|Chlorhexidine (0.2%)|Chlorhexidine Digluconate 0.2%
223531931|NCT05615402|OTHER|Bone-specific strength training|Muscular strength and rate of force development (RFD) will be assessed in the key exercises of the intervention protocol
223925565|NCT06742983|OTHER|Normal Saline (0.9% NaCl)|Sodium chloride 0.9%
223925566|NCT03696433|DIETARY_SUPPLEMENT|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
223925567|NCT03696433|DIETARY_SUPPLEMENT|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
223925568|NCT06742554|DRUG|Buprenorphine transdermal patch|"Buprenorphine Transdermal Patch (10 mg): Applied once before surgery for continuous pain control.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
223925569|NCT06742554|DRUG|Tramadol|"Tramadol: Administered orally or intravenously at a standard dose of 100 mg every 8 hours, based on patient-reported pain levels.~Interscalene Brachial Plexus Block: Administered intraoperatively using 25 mL of 0.5% bupivacaine."
223925570|NCT06742827|OTHER|educational intervention based on information and communication technologies.|will be carried out through a mobile application, which will be installed on each person's device, as well as short text messages will be sent and counseling will be available 24/7. The contents of the application will be educational and will be elaborated framed in the following components: understanding of the disease and the consequences of not adhering (comprehensibility) to the treatment, maintaining a balance between the psychosocial resources that the patient has and the demands that the disease places on them (manageability), and the involvement of the person in decision making and the sense of continuing to adhere to hemodialysis treatment (meaningfulness).
223925571|NCT01242215|DEVICE|ipragliflozin|oral
223925572|NCT01242215|DRUG|Placebo|oral
223925573|NCT01242215|DRUG|Sulfonylurea|oral
223925574|NCT03950076|DRUG|Edoxaban|Edoxaban 60mg (or 30mg as determined by clinical criteria)
224093132|NCT04453150|OTHER|Intermittent fasting 16/8 (early fasting)|Intermittent fasting 16/8 (early fasting)
224093133|NCT04453150|OTHER|Intermittent fasting 16/8 (late fasting)|Intermittent fasting 16/8 (late fasting)
224093134|NCT04453150|OTHER|Alternate-day fasting|Alternate-day fasting
223925575|NCT03950076|OTHER|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
223925576|NCT06891274|DEVICE|USN before SVN|The group that received ultrasonic rock salt aerosol inhalation therapy followed by small-volume nebulized inhalation therapy.
223925577|NCT06891274|DEVICE|SVN before USN|The group that received small-volume nebulized inhalation therapy followed by ultrasonic rock salt aerosol inhalation therapy.
223925578|NCT06888973|BIOLOGICAL|Mesenchymal Stem Cells|allogeneic bone marrow-derived mesenchymal stem cells therapy
223531932|NCT05615402|DIETARY_SUPPLEMENT|Nutrition optimalisation|Dietary supplement of protein, vitamin D and Calcium 3x/w Dietary counselling based on individual dietary records
223717647|NCT04294576|DRUG|Pembrolizumab|"BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks."
223925579|NCT06888973|OTHER|Placebo|0.9% Saline as placebo
223925580|NCT06891573|BEHAVIORAL|Lifestyle Management|For 16 weeks, participants will receive exercise, cognitive training, nutrition education, and disease education through a smartphone app, and the content and intensity of the intervention will be adjusted every four weeks through an assessment of frailty symptoms through the app.
223925581|NCT06891326|DEVICE|sham transcranial Alternating Current Stimulation|we use fade-in, short-stimulation, fade-out (FSF) stimulation pattern, with 60s-long fade-in/out periods, 2.0mA peak current at the beginning and the end of stimulation session
223925582|NCT06891326|DEVICE|active tACS|The active tACS protocol lasted for 40 min of continuous sine-wave stimulation with the frequency of 10Hz and an amplitude ranging from 1.5mA to 2.0mA, adjusted according to the tolerability among individuals.
224093135|NCT04453150|OTHER|Ketogenic diet|Ketogenic diet
224093136|NCT03222661|DIAGNOSTIC_TEST|Refraction|Refractive error measurement
224093137|NCT04466124|RADIATION|Liver Cancer Patients Treated With Proton Beam Therapy|Proton Beam Therapy
224093138|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #1|Ad26.ZEBOV - Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
224093139|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #2|Ad26.ZEBOV - Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
224093140|NCT02543268|BIOLOGICAL|Ad26.ZEBOV-Batch #3|Ad26.ZEBOV - Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
224093141|NCT02543268|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- live replication incompetent vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57.
224093142|NCT02543268|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
224093143|NCT04504318|DRUG|Apixaban 2.5 MG Oral Tablet|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
223717648|NCT02170298|DRUG|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
223925583|NCT06890663|OTHER|Nonspecific Hypnotherapy for Relaxation|A therapeutic technique that uses hypnosis for relaxation.
223925584|NCT06890663|OTHER|Gut-Directed Hypnotherapy (GDH)|A therapeutic technique that uses hypnosis and relaxation to help with gastrointestinal (GI) disorders.
223925585|NCT06890663|OTHER|3-month Follow-Up|A 3-month follow is completed after both intervention phases (general hypnotherapy and Gut Directed Hypnotherapy) are completed for each participant.
223925586|NCT06890546|DIETARY_SUPPLEMENT|Nigella Sativa Oil capsule|8 weeks 2 x 900 mg Nigella Sativa oil capsule daily
223925587|NCT06890546|BEHAVIORAL|Diet|Low calorie diet intervention
223925588|NCT04096066|DRUG|Carfilzomib|"* 20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~* 56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~* 56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
223925589|NCT04096066|DRUG|Lenalidomide|\- 25 mg orally on days 1-21 of each cycle.
223925590|NCT04096066|DRUG|Dexamethasone|"\- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients \>75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
223925591|NCT06744803|BEHAVIORAL|Gamified Neuropathy Management Application on Cancer Behavior|"The study will be conducted in three phases:~Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature.~Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks.~Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data."
224281652|NCT00317642|DRUG|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m\^2 / day up to 3 cycles
224281653|NCT00317642|DRUG|placebo|placebo (sodium Chloride) 1-hour IV infusion
224281654|NCT00317642|DRUG|cytarabine|cytarabine IV infusion 1g/m\^2/day for up to 3 cycles
223925592|NCT06744790|DEVICE|Linshom Continuous Predictive Respiratory Monitoring|Observational study. Monitoring of Linshom, pulse oximetry and capnography data with comparison to current standard of care.
223925593|NCT05578651|DEVICE|SternaLock XP|Plating system with cable cerclage bands that is used in the stabilization and fixation of fractures of the anterior chest wall, including sternal fixation following sternotomy
223925594|NCT06891391|OTHER|Dynamic Neuromuscular Stabilization exercises|DNS is a method used to enhance muscle stability. It is a manual and rehabilitative approach based on developmental kinesiology to optimize the movement system. These exercises optimize internal muscle forces on each spinal segment.
223925595|NCT06891391|OTHER|Deep Cervical Muscle exercises|Deep cervical muscle exercises are isometric exercises that strengthen weak muscles without causing discomfort to pain-sensitive structures like ligaments, tendons, or neck joints. This involves contracting specific muscles without changing muscle length or impeding joint movement.
223925596|NCT06892392|PROCEDURE|ICG administration|"For the administration of ICG, it is necessary to perform a gastroscopy by the Digestive Service of each center, with sedation 24 h before surgery. For this, the lesion is located by gastroscopy, after which it is injected in 4 quadrants in the submucosa, with a total volume of 2 ml.~To prepare the ICG, 0.5 ml (containing 0.625 mg of ICG) is dissolved in 1.25 mg/dl of sterile water"
223925597|NCT06891196|OTHER|Long-term Follow-up Surveys|Patients will be given surveys, including validated PRO measures such as the Hip Disability and Osteoarthritis Outcomes Score (HOOS), Short-Form 12 (SF-12), Visual Analog Scale (VAS) for pain, and Marx activity scores.
223925598|NCT06737965|OTHER|Medical abortion|"Medical abortion performed according to standard practice with cord blood sample (1 to 10ml) collected on EDTA tube before injection of foeto toxic agent.~EDTA tube transfered to laboratory on ambient temperature. Blood sample will be centrifuged to isolate the extracellular vesicles once in the laboratory."
223925599|NCT06737965|OTHER|Foetopathology exam|"Foetopathology exam is performed according to standard practice on the day after abortion (H12 to H48 from foetus death).~Investigator will recover 2 horizontal slices (in line with the heart) between 3 and 5 mm thick, including the right and left ventricles put them in a cold physiological saline solution, and transfer them rapidly to the laboratory.~Investigator will also recover segments of the descending aorta (approximately 2cm, between the ductus arteriosus and the celiac trunk) and the left renal artery. The isolated segments will be separated from the fat and connective tissue by the foetopathology team and put in a cold physiological saline solution."
224281655|NCT00450983|BIOLOGICAL|muromonab-CD3|
224281656|NCT00450983|BIOLOGICAL|natural killer cell therapy|
224281657|NCT00450983|DRUG|fludarabine phosphate|
224281658|NCT00450983|DRUG|methotrexate|
224281659|NCT00450983|DRUG|thiotepa|
224281660|NCT00450983|GENETIC|gene expression analysis|
224281661|NCT00450983|OTHER|flow cytometry|
224281662|NCT00450983|OTHER|immunologic technique|
224281663|NCT00450983|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224281664|NCT00450983|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224281665|NCT00450983|RADIATION|total-body irradiation|
224281666|NCT00031928|DRUG|mafosfamide|
223925600|NCT06737965|OTHER|Outcomes mesurement|"* From the myocardial samples, 10 µm thick sections will be prepared and slides will be incubated with antibodies directed against proteins of interest (adrenergic receptors, protein kinase A, ryanodine receptor, PDE3, troponin). After washing, fluorescent secondary antibodies will be used and slides will be observed under a fluorescence microscope. Rest of the cardiac tissue will be frozen in liquid nitrogen in order to perform Western blots.~* Vessel samples will be put in a myograph to study contractile function. Concentration-response curves will be constructed by cumulative application of noradrenaline or U46619. For the study of endothelial function, arteries with and without functional endothelium will be pre-contracted to 80% of maximal contraction with U46619. When contraction reaches a plate, cumulative addition of different vasodilating agents will be performed. The vessels will also be cannulated on an arteriograph to assess dilation in response to flow and myogenic tone."
223925601|NCT06737900|OTHER|traditional physical therapy|"* Heating pad for 10 minutes~* Core stability exercises for 20 minutes with 10 seconds of rest intervals~* Patients were advised to stretch for 5 minutes then perform lumber stability exercises.~* These stability exercises included side bridges, supine extension bridge, straight leg raise in prone lying, alternate arm and leg raise from quadruped position and prone bridges.~Both groups took sessions thrice a week for a total of 4 weeks."
224093144|NCT04504318|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
224093145|NCT06656819|DEVICE|Magstim Rapid2|"AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females"
224093146|NCT01082276|DRUG|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
223531933|NCT02951637|DRUG|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
223531934|NCT02951637|DRUG|Gefitinib|Gefitinib (250mg daily)
224093147|NCT01702116|PROCEDURE|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
224093148|NCT01702116|PROCEDURE|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
224093149|NCT02747784|BEHAVIORAL|Cognitive training program RehaCom®|Cognitive training program RehaCom®
224093150|NCT03849729|DRUG|Phentermine|This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
224093151|NCT03849729|OTHER|Placebo|his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI \>35 kg/m2 with comorbidities or BMI \> 40 kg/m2).
224093152|NCT06190483|DRUG|Diazepam 5 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
224093153|NCT06190483|DRUG|Ascorbic Acid 50 Mg Oral Tablet|Single dose given orally (opaque capsule) 60 minutes prior to MRI scan
224093154|NCT05347823|DIAGNOSTIC_TEST|Hair analysis for drug concentration|Sample collection for the determination of treatment adherence
223531935|NCT04240340|OTHER|semi-structured interview|Semi-structured, face-to-face interviews will be carried out with participants.
223531936|NCT01131897|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
223925602|NCT06737900|OTHER|jandas approach|"* Stretching exercise for erector spinae and back extensors muscles~* Stretching exercises for iliopsoas muscle and rectus femoris muscle~* Strengthening exercise for abdominal muscle and gluteal maximus muscle Stretching exercise was performed actively for 3 repetitions x 1 set and 4 days a week Strengthening exercise was performed for 10 second hold and 10 repetitions. All Exercises was performed 3 times per week for total of 4 weeks"
223925603|NCT06736314|DEVICE|a removable titanium clip|The removable titanium clip is a new type of titanium clip that offers advantages such as easy operation and convenient disassembly.
223531937|NCT03521700|DRUG|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
223925604|NCT06742255|DRUG|Stellate Ganglion Block|Stellate ganglion block is an injection of local anesthetic at the level of the neck to target the stellate ganglion, a sympathetic ganglion to interrupt abnormal autonomically-mediated pain in patients resistant to medical treatment
223925605|NCT06743048|PROCEDURE|Tissue Sparing Laser Implantation|A penile implant will be implanted using the cavernosal sparing technique and assisted by a laser fibre optic
223925606|NCT06744205|BIOLOGICAL|Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
223925607|NCT06744205|BIOLOGICAL|TIV mRNA-neuraminidase (NA)|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
223925608|NCT06744205|BIOLOGICAL|TIV mRNA-HA Vaccine 2|"* Pharmaceutical form: solution for injection in a vial~* Route of administration: Intramuscular injection"
223925609|NCT06744205|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|"* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection"
223925610|NCT06744205|BIOLOGICAL|Quadrivalent Influenza Vaccine High Dose|"* Pharmaceutical form: Liquid suspension for injection in pre-filled syringe~* Route of administration: Intramuscular injection"
223925611|NCT05722561|BEHAVIORAL|Telehealth Motivational Counseling|At baseline, after randomization, participants will receive their first telehealth session (20\~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15\~20 minutes each.
223925612|NCT05722561|DRUG|Nicotine Replacement Product|Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
223925613|NCT05722561|DEVICE|National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).|Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.
223925614|NCT06749379|OTHER|Presence and stages of lipedema were diagnosed with examination.|Lipedema stage characteristics: stage 1: Smooth skin with a uniform increase in subcutaneous tissue; stage 2: Irregular skin surface with indentations and nodular alterations in the subcutaneous tissue; stage 3: Significant increase in circumference accompanied by loose skin/tissue ('dewlap').
223925615|NCT06739408|DIETARY_SUPPLEMENT|Lean red meat|30g of protein from lean beef.
223717649|NCT03508479|BIOLOGICAL|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
223925616|NCT06739408|DIETARY_SUPPLEMENT|Whey protein|Whey protein to provide 30g protein
223925617|NCT06739408|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin, to provide 0g protein but matched isocalorically
223925618|NCT06751121|DRUG|DWP14012 40mg|DWP14012 40 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
223925619|NCT06751121|DRUG|DWC202301 30mg|DWC202301 30 mg, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
223925620|NCT06751121|DRUG|Amoxicillin 1000mg|Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).
223531938|NCT05916300|OTHER|Diagnostic ultrasonography-guided physiotherapy group|"All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination."
223531939|NCT01576783|DRUG|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
223531940|NCT01576783|DIETARY_SUPPLEMENT|Placebo|400 mg corn oil per day for 6 months
223717650|NCT01976338|DRUG|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
223717651|NCT01976338|OTHER|Sham injection|Sham intravitreal injection
223717652|NCT00040573|DRUG|131I-TM-601|
223925621|NCT06751121|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
223925622|NCT06751121|DRUG|DWC202301 30mg placebo|DWC202301 30 mg placebo, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
223925623|NCT06751121|DRUG|DWP14012 40mg placebo|DWP14012 40 mg placebo, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
223925624|NCT06749795|DRUG|LIV001|Orally administered for 8 weeks
223925625|NCT06749795|DRUG|Placebo|Orally administered for 8 weeks
223531941|NCT01082848|DRUG|aripiprazole|10 mg QD during 26 weeks
223925626|NCT06750250|OTHER|Patient education|"The group A will be Education and Self-Management. Patient Education: Providing information on the benefits of physical activity, proper exercise techniques, and self-care strategies.~Self-Management Programs: Empowering women to take an active role in managing their health and fitness. Frequency: 3 session/ month, Intensity: Mild to moderate, Type: Walking Time: 30 to 45mints /sessions"
223925627|NCT06750250|OTHER|Aerobics|Treadmill: A manual Treadmill intervention involves moderate-intensity aerobic exercise on a treadmill for 15 minute with the heart rate gradually reaching 75-85% of the maximum. Training frequency was not specified. It significantly reduced menstrual pain intensity 3 session per month. Stationary Bicycling: Start with gentle, low-intensity cycling and gradually increase as comfort allow the duration of exercise 10 mints per month. Running : The running is a low intensity effort of short to moderate duration 10 to 15 mints per mile
223925628|NCT06748755|RADIATION|Group 1|To determine the sensitivity of ultrasound in detecting HCC
223925629|NCT06751095|OTHER|Maitland's Mobilization in End range|End-range mobilization will be performed individually in flexion and extension end range of the tibiofemoral joint .(0-135 degree)
223925630|NCT06751095|OTHER|Maitland's mobilization in Mid range|Mid range Maitland's mobilization will be performed in (approx. 50-70° knee flexion) of the tibiofemoral joint
223925631|NCT06749808|DIETARY_SUPPLEMENT|Carotenoid Nutritional Supplement|Carotenoid Nutritional Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 10 mg Lutein, 2 mg Zeaxanthin, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
223925632|NCT06749808|DIETARY_SUPPLEMENT|Placebo|Placebo Supplement: capsules with 500 mg Vitamin C, 200 IU Vitamin E, 25 mg Zinc, 2 mg Copper, 70 mcg Selenium, 3mg boron, 255mg calcium, 100mcg chromium, 0.9mg copper, 150mcg iodide, 180mg magnesium, 75mcg molybdenum, 2.3mg manganese, 140mcg selenium, 20mcg vanadium, 15mg zinc
223925633|NCT06750523|DIAGNOSTIC_TEST|Cord blood sampling|A cord blood sample will be taken at birth for analysis of oxidative stress markers, endocrine disruptors, and microRNAs.
223925634|NCT06750523|DIAGNOSTIC_TEST|urine sampling|At one month of age, urine samples will be collected from newborns to analyze oxidative stress markers and endocrine disruptors.
223925635|NCT06750523|BEHAVIORAL|Life style questionnaire|At the time of enrollment, mothers will complete a specialized questionnaire designed to assess potential exposure to endocrine disruptors (EDCs) through diet, clothing, and the use of cosmetics and detergents.
223925636|NCT06750081|OTHER|Physical Therapy|Exercises to improve locomotor abilities of children with CP
223925637|NCT06750081|OTHER|Designed rehabilitation program|Program of exercises to enhance abilities
223925638|NCT06780826|DRUG|Atezolizumab|Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
223925639|NCT06780826|DRUG|Etoposide|Etoposide,intravenous infusion, 100mg/m,21 days per cycle
223925640|NCT06780826|DRUG|Carboplatin|carboplatin,intravenous infusion, AUC=5, 21 days per cycle.
224281667|NCT02130167|DRUG|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
224281668|NCT00213057|DRUG|Carraguard (PC-515)|
224281669|NCT01800435|DRUG|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
224281670|NCT01800435|DRUG|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
223925641|NCT06781606|PROCEDURE|Penile transplantation|The penile transplantation will take place at the Edouard Herriot hospital, part of the Hospices Civils de Lyon. It will be carried out on the same day or the day after the harvesting depending on the timing of the harvesting.
224281671|NCT01978899|BEHAVIORAL|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
224281672|NCT01978899|BEHAVIORAL|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
224281673|NCT00098228|DRUG|QAB149|
224281674|NCT00556491|DRUG|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
224281675|NCT00556491|DRUG|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
224281676|NCT02921503|OTHER|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
224281677|NCT04305379|PROCEDURE|Augmented Bladder Neck Reconstruction|Augmented Bladder Neck Reconstruction including a Medial Umbilical Ligament Sling plus Intussusception
224281678|NCT04305379|PROCEDURE|Standard Bladder Neck Reconstruction|Standard Bladder Neck Reconstruction with Intussusception Only
224281679|NCT03269799|DRUG|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
224281680|NCT03269799|OTHER|placebo|non surgical periodontal treatment+placebo for 2 months
224281681|NCT02639728|OTHER|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
224281682|NCT02639728|OTHER|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
223531942|NCT01082848|DRUG|placebo|QD during 26 weeks
223531943|NCT02228538|DEVICE|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system \& off-the-shelf standard knee implant system from various manufacturers
223531944|NCT01897493|DRUG|Evacetrapib|Administered orally
223531945|NCT01897493|DRUG|Digoxin|Administered orally
223531946|NCT06786572|OTHER|Mindfulness training|Brief mindfulness training focused on management of unwanted internal sensations
224281683|NCT02639728|OTHER|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
224281684|NCT01602471|DRUG|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
224281685|NCT06366945|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 1, 3, and 6
224281686|NCT06366945|DRUG|Tislelizumab|Tislelizumab 200 mg on weeks 3, 6, and 9;if adjuvant immunotherapy is omitted, Tislelizumab will be administered on weeks 1, 3, 6, 9, 12, 15 after surgery
224281687|NCT06366945|DRUG|Polymeric Micellar Paclitaxel|Polymeric Micellar Paclitaxel 300mg/mg/m2 on weeks 1, 3 and 6
223531947|NCT06786572|BEHAVIORAL|Interoceptive exposure|Cognitive behavioral therapy focused in interoceptive exposure to unwanted internal sensations
223531948|NCT02298725|OTHER|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
223531949|NCT02298725|OTHER|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
223531950|NCT04015258|DIETARY_SUPPLEMENT|Blueberries|fresh spanish blueberries
223531951|NCT04015258|DIETARY_SUPPLEMENT|Blueberry powder|freeze-dried blueberry powder
223531952|NCT04015258|DIETARY_SUPPLEMENT|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
223531953|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
223531954|NCT01354093|DRUG|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
223531955|NCT01067430|DRUG|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
223925642|NCT05066503|DIETARY_SUPPLEMENT|260279 active study product|The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.
223925643|NCT06745089|DEVICE|Intense pulsed light|Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.
223925644|NCT06745089|DEVICE|thermal pulsation therapy|Thermal pulsation therapy utilizes local heating and massage on the eyelids.
224281688|NCT06366945|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
224281689|NCT06366945|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic assesment following induction systemic therapy and surgery is ypT(pCR 或 MPR) and ypN(pCR) or ypT（ pCR 或 MPR）and ypN（ MPR）without the presence of Serious Adverse Event, adjuvant radiation will not be administered. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
223531956|NCT01067430|DRUG|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
223531957|NCT02107885|DRUG|DS-1971|6 subjects in each group will receive DS-1971.
223531958|NCT02107885|DRUG|placebo|2 subjects in each group will receive placebo.
223531959|NCT05489328|OTHER|Candidate-1|Biological
223531960|NCT05489328|OTHER|Candidate-2|Biological
223531961|NCT05489328|OTHER|Candidate-3|Biological
223531962|NCT05489328|OTHER|Candidate-4|Biological
223531963|NCT05489328|OTHER|Candidate-5|Biological
224281690|NCT03648619|DIAGNOSTIC_TEST|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
224281691|NCT00519974|OTHER|counseling intervention|
223531964|NCT05489328|OTHER|Candidate-6|Biological
223531965|NCT05489328|OTHER|Candidate Control|Biological
223531966|NCT05489328|BIOLOGICAL|13vPnC|13-valent pneumococcal conjugate vaccine
223531967|NCT05489328|BIOLOGICAL|PCV15|15-valent pneumococcal conjugate vaccine
223531968|NCT06101173|BIOLOGICAL|Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
223531969|NCT06101173|BIOLOGICAL|Inactivated poliomyelitis vaccine (IPOL)|1 dose of IPOL vaccine (0.5ml) on Visit 1
223531970|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
223531971|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
223531972|NCT06101173|BIOLOGICAL|VLP-Polio|1 dose of VLP-Polio vaccine (0.5ml) on Visit 1
223531973|NCT06101173|BIOLOGICAL|IPOL|1 dose of IPOL vaccine (0.5ml) on Visit 1
223531974|NCT04326452|DEVICE|bidirectional oxygenation mouthpiece|Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
223531975|NCT01083602|DRUG|panobinostat|PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
223531976|NCT01083602|DRUG|bortezomib|
223531977|NCT01083602|DRUG|dexamethasone|
223717653|NCT00987675|OTHER|pharmacological study|
223717654|NCT00987675|OTHER|questionnaire administration|
223717655|NCT00987675|PROCEDURE|assessment of therapy complications|
223717656|NCT00987675|PROCEDURE|high-intensity focused ultrasound ablation|
223717657|NCT00987675|PROCEDURE|quality-of-life assessment|
223717658|NCT03530878|PROCEDURE|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
223717659|NCT01655914|DRUG|Flumazenil|
223717660|NCT00404846|PROCEDURE|Hyperbaric Oxygenation Therapy|
223925645|NCT06745089|DRUG|Ocular lubricant|Ocular lubricants moisturize the ocular surface.
223925646|NCT06744725|DEVICE|Pleural biopsy using dual-function semirigid thoracoscopy|Patients will receive pleural biopsy using dual-function semirigid thoracoscopy.
223925647|NCT06744725|DEVICE|Pleural biopsy using semirigid thoracoscopy|Patients received pleural biopsy using semirigid thoracoscopy
223925648|NCT05951452|OTHER|Blood samples for testosterone and SHBG measurements|"Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
223925649|NCT05951452|OTHER|Saliva samples for oxytocin measurements|"Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video"
223925650|NCT02722512|BIOLOGICAL|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
224281692|NCT00519974|OTHER|study of socioeconomic and demographic variables|
224281693|NCT00519974|PROCEDURE|management of therapy complications|
223925651|NCT02722512|PROCEDURE|Tumor Resection|Clinically-indicated removal of the tumor
224281694|NCT00519974|PROCEDURE|psychosocial assessment and care|
224281695|NCT01239472|DRUG|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
224281696|NCT03138902|DIETARY_SUPPLEMENT|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
224281697|NCT01579760|DRUG|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
224281698|NCT01579760|DRUG|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
224281699|NCT02334241|DEVICE|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
223531978|NCT05745155|DEVICE|Senti Wear device system with Senti-AI subsystem|"This device is a smart garment, with a similar form to a T-Shirt, jacket or tabard, embedded with ten sensor modules (nine acoustic sensors, one kinetic sensor - all able to detect signals from the chest wall and underlying structures, including the lungs) encased in silicone; the device is charged via a charging port in the garment. The device has two modes of operation: recording mode and charging mode. The device is internally (battery) powered during recording mode and mains-powered during charging mode. The device is accompanied by cloud-based software to listen to both contemporaneous and historically recorded breath sounds, for each Senti patient. To use the device, the user puts the garment on (overhead, like a T-Shirt, before joining the back piece to the front like a tabard).~Additionally, Senti-AI adds an anomaly burden score and an alert flag for review against each acoustic record for each patient."
223717661|NCT00777608|DRUG|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
223717662|NCT00777608|DRUG|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
223717663|NCT00777608|DRUG|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
223925652|NCT02722512|RADIATION|Radiation|Focal Radiation Therapy
223925653|NCT04258189|DRUG|JNJ-64417184|Single dose of JNJ-64417184 solution (with or without preservatives) will be administered orally.
223925654|NCT05682235|OTHER|Therapeutic exercise AND pain neurophysiology education|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group and talks on healthy habits to the placebo group participants.
223925655|NCT05682235|OTHER|Sham|Talk about healthy habits
223925656|NCT06792578|PROCEDURE|Surgical Start Time|This intervention focuses on the retrospective analysis of the association between surgical start times (morning, afternoon, and nighttime) and postoperative outcomes in non-cardiac surgeries. The study evaluates how the timing of surgery impacts mortality, complications, transfusion rates, and ICU admissions in a tertiary hospital setting
223925657|NCT06740565|PROCEDURE|thoracic endovascular aortic repair|stent-graft implanted to seal the proximal entry tear of type B aortic dissection
223925658|NCT06740162|BEHAVIORAL|PACE Program|The PACE program is a 16-week inclusive exercise program taught and adapted by certified Inclusive Fitness Specialists. Study participants, called athletes, will engage in the fitness class with non-study participants with and without disabilities. Athlete participants will also meet weekly with their coaches (also study participants) to discuss goal setting and interact with the web-based dashboard.
223925659|NCT06792253|DRUG|Ifupinostat Hydrochloride for Injection|Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.
223925660|NCT06792253|DRUG|Rituximab Injection|Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.
223925661|NCT06792253|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
223925662|NCT06792253|DRUG|Oxaliplatin Injection|Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
223925663|NCT06792253|DRUG|Etoposide Injection|Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.
224281700|NCT02334241|DEVICE|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
224281701|NCT04781114|DRUG|JS002|JS002: 150mg(1mL) Q2W; Placebo 1mL Q2W.
224281702|NCT04781114|DRUG|Placebo|JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
224281703|NCT02201979|PROCEDURE|Vertical breast lift with implants|
224281704|NCT01163084|DRUG|Goserelin Acetate|Given SC
224281705|NCT01163084|OTHER|Laboratory Biomarker Analysis|Correlative studies
224281706|NCT01163084|DRUG|Leuprolide Acetate|Given IM
224281707|NCT01163084|DRUG|Vismodegib|Given PO
223531979|NCT02543775|PROCEDURE|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
223531980|NCT01227785|DEVICE|INCEPTA ICD or CRT-D|
223925664|NCT06792253|DRUG|Ifosfamide for Injection|Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
223925665|NCT06792253|DRUG|Carboplatin Injection|Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
223925666|NCT06740825|DRUG|Quizartinib|Single oral dose of 60 mg
223925667|NCT06740825|DRUG|Rufinamide|Twice daily (BID) dose of 400 mg on Days 1 through 32
224093155|NCT02637687|DRUG|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
224093156|NCT04439266|DRUG|Crizotinib|Given PO
224093157|NCT01649700|BIOLOGICAL|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
224093158|NCT02354833|DRUG|Phenylephrine|
224093159|NCT02354833|DRUG|Norepinephrine|
224093160|NCT06640907|BEHAVIORAL|e-Perinatal personalized mHealth intervention integrated into routine maternal care|The e-Perinatal intervention combines a personalized mobile health (mHealth) app with targeted training for healthcare professionals to support perinatal mental health within routine maternal care. Participants allocated to the intervention arm will use the app for a period of two months. The app offers psychoeducational content, video-guided physical activities, mindfulness exercises, mood-tracking tools, personalized recommendations through a rule-based algorithm, and social-community features. Healthcare professionals assigned to the intervention arm receive specialized training to integrate the app into their daily practice, enhancing their ability to promote and support mental health during the perinatal period.
224093161|NCT06640907|OTHER|Standard routine maternal care with general perinatal health information|Standard maternal care as routinely provided by the Andalusian public healthcare system (Spain). This includes scheduled visits with midwives, nurses, and pediatrician for maternal and infant health monitoring, as well as access to childbirth education programmes. Participants also receive monthly psychoeducational emails (two months) containing general information on perinatal mental health, pregnancy, and infant development. Healthcare professionals in this arm do not receive specialized training in perinatal mental health or in the use of digital interventions, and participants do not have access to the e-Perinatal app.
224093162|NCT05485480|DRUG|conventional opioid-based group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
224281708|NCT05025579|OTHER|Aerobic Exercise|"Since up in 2 min 10 repetitions active joint movement (while seated knee flexion and extension the ankle plantar and dorsal flexion , standing the hip flexion , extension the , abduction and adduction ) , treadmill for 3 minutes, 0.5 m / sec speed walk with and to adapt both warming bike 5 minutes, RPE ( Rating of Perceived exertion discoverable by exertion rate) will be 2/10 in a way was built.~As aerobic exercise, the first week will be RPE 4/10 for 10 minutes, the second week with RPE 4/10 12 minutes, the third week with RPE 4/10 14 minutes, the fourth week with RPE 4/10, 16 minutes, the fifth week with RPE 5/ 2 0 will be as 18 minutes sixth week RPA 10.6 will form was done 20 minutes of exercise .~Cooling period in the RPE 2.10 will be the 5 minute turning cycling, 5 min active range of motion exercises and stretching was done."
224281709|NCT05752188|OTHER|Multimarker approach in acute coronary syndrome|The main objective of the study is to evaluate the prognostic role of the biochemical marker sST2 in patients attending the Emergency Department of our hospital with acute chest pain with suspected acute coronary syndrome.
224281710|NCT01145924|PROCEDURE|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
224281711|NCT01470196|DRUG|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
224281712|NCT01470196|DRUG|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
224281713|NCT01470196|DRUG|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
224281714|NCT04815252|BEHAVIORAL|CHIME|CHIME is a professional development program to provide knowledge and skills for nurturing early childhood educator mindfulness, compassion and socio-emotional learning. CHIME is a manualized curriculum delivered by a trained facilitator. The intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Sessions can be delivered online or in-person.
224281715|NCT03018093|BIOLOGICAL|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
224281716|NCT00002787|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
224281717|NCT00002787|BIOLOGICAL|sargramostim|Given SC
224281718|NCT00002787|BIOLOGICAL|aldesleukin|Given SC
224281719|NCT00002787|OTHER|laboratory biomarker analysis|Correlative studies
224281720|NCT05840094|DRUG|18F-FDG|18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
224281721|NCT05840094|DEVICE|MR STIR|The overall scanning time of MR is about 13min.
224281722|NCT05840094|PROCEDURE|EBUS-TBNA|Puncture about 20 times, 3 stitches in each group of enlarged lymph nodes, 1 stitch in the anterior, middle and posterior parts respectively
224281723|NCT03974165|OTHER|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
224281724|NCT03974165|OTHER|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
224281725|NCT03974165|OTHER|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
223925668|NCT05795881|OTHER|Cyclic daytime enteral nutrition|The allocated feeding schedule is followed from the start of enteral nutrition after ICU admission until discharge from the ICU.
223925669|NCT06737926|BEHAVIORAL|Sensorimotor Training Exercise|Participants will perform sensorimotor training exercises designed to improve balance, reduce pain intensity, and enhance functional exercise capacity. The program will include progressive exercises focusing on proprioception, neuromuscular coordination, and functional mobility. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
223925670|NCT06737926|BEHAVIORAL|Conventional Exercise Therapy|Participants will undergo conventional exercise therapy, including stretching, strengthening, and aerobic exercises, based on standard physiotherapy protocols. The therapy aims to maintain joint mobility, reduce stiffness, and improve general physical fitness. Sessions will be conducted thrice weekly over 12 weeks, supervised by a physiotherapist.
223925671|NCT06799793|DEVICE|GI Genius|GI Genius software component is an artificial intelligence-based medical device that has been trained to process colonoscopy images containing regions consistent with colorectal lesions such as polyps, including those with flat morphology (nonpolyp).
223925672|NCT06799793|OTHER|Colonscope Olympus|Colonoscopy with one of the Olympus colonoscopes supplied to the IRCCS AOUBO Gastroenterology Unit without the aid of the CAD system
223925673|NCT06740955|RADIATION|hypofractionated postoperative radiotherapy|hypofractionated radiotherapy with a total dose of 52.5Gy, 3.5 Gy/ fraction, 15 fractions, 5 fractions per week,
223925674|NCT06740955|RADIATION|Conventionally fractionated postoperative radiotherapy|Conventionally fractionated radiotherapy with a total dose of 60 Gy, 2 Gy/ fraction, 30 fractions, 5 fractions per week,
223925675|NCT06839820|OTHER|Infusion rate of infliximab|Infusion reactions of infliximab is compared between 30 and 60 minutes infliximab infusion-rates.
223925676|NCT06840626|OTHER|Series of breathing exercises|During the intervention, participants perform respiratory exercises, including deep breathing, belly breathing, exhalation with vocalization, and forced exhalation. Each exercise is repeated five times, three times per day: twice in the morning and once in the afternoon. The exercises are conducted in a seated, corrected position, guided by rehabilitation specialists or special needs teachers who provide instructions and demonstrations. Teachers are provided with the exact protocol for the breathing exercises series. Each breathing exercise focuses on maintaining a specific rhythm, with inhalation lasting approximately 3-4 seconds, holding for 1-2 seconds, and exhalation for 5-6 seconds. Forced exhalation is facilitated using playful motivational tools such as windmills and balloon blowing. The protocol includes instructions for the breathing exercises in first-person singular. The entire session lasts approximately 5 minutes, resulting in a total of 15 minutes of training per day.
223925677|NCT05739435|DRUG|ESK-001|Oral tablet
223925678|NCT04277637|DRUG|Sonrotoclax|Film-coated tablets administered once daily at a dose as specified in the treatment arm
223925679|NCT04277637|DRUG|Zanubrutinib|320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
223925680|NCT04277637|DRUG|Obinutuzumab|Given as an intravenous infusion administered per label.
223925681|NCT06747559|DRUG|Vitamin D|Vitamin D oral supplementation
223925682|NCT06646549|OTHER|No intervention|No intervention
223925683|NCT06747741|PROCEDURE|PNF stretching(Contract relax with agonist contraction)|1.Passively dorsiflex the patient's foot then ask to perform active planterflexion against resistance and hold for 7-10 sec then ask patient to perform dorsiflexion to the maximum available range.
223925684|NCT06747741|PROCEDURE|Conventional physical therapy|"Static Stretching:(Seated Calf Stretch With a Resistance Band)~1. Sit on the floor with your legs extended.~2. Loop a resistance band around one foot, holding both sides of it with your hands.~3. Gently pull your toes toward your shin until you feel the stretch in your calf.Repeat on the other side.~Isometric Calf Raise:~1. Stand with feet shoulder-width apart and arms at sides.~2. Engage your abs for stability and roll up onto the balls of your feet, lifting both heels off the floor.~3. Hold for 5 seconds, then return to the starting position. Frequency : 5 reps with 5-7Sec hold,3 days per week for 4 weeks (alternatively)"
223925686|NCT06742021|DIAGNOSTIC_TEST|Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer|Chest MRI scans outside of the standard treatment protocol
223925687|NCT06741878|BEHAVIORAL|Exercise|Involves participants engaging in physical training group sessions in light-to-moderate intensity.
223925688|NCT06741878|BEHAVIORAL|Psychosocial|Involves participants engaging in selected board and card games which require cognitive and socialization skills to play in a group setting of 2-4 people.
223925689|NCT06741878|BEHAVIORAL|Nutritional|Involves participants attending dietary classes taught by a certified dietitian, including individualized consultation.
223925690|NCT06735092|OTHER|Exercise-Only Group (Control Group)|Participants in this group will only undergo a standardized exercise protocol. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
224281726|NCT03974165|OTHER|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
224093163|NCT05485480|DRUG|opioid-sparing group|In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
224281727|NCT04683757|OTHER|Establishment of a Survival Prediction Model|a nomogram to predict the survival of patients with ER positive / HER-2 negative advanced breast cancer
224281728|NCT02839486|OTHER|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
224281729|NCT02839486|OTHER|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
224281730|NCT06296524|OTHER|Footcore exercises and conventional therapy|30 minutes exercises protocol will be provided
224093164|NCT05196269|DEVICE|Artificial Intelligence and Digital Health Arm|A previous large database repository of images having thousands of pre and postoperative photographs of breast cancer patients proposed for locoregional treatment with clinical and biometric data will be matched using artificial intelligence within the CANKADO platform. Patients proposed for breast cancer locoregional treatment will have access to the software installed, and they will have access to all the information about the type of treatment they will receive. All the questions and questionnaires will be filled out online, and they can visualise the expected outcome from excellent to poor.
224093165|NCT06565741|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
223925691|NCT06735092|OTHER|Exercise + Forearm Counterforce Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a counterforce forearm brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
224281731|NCT06296524|OTHER|conventional therapy|conventional therapy will be provided.
223925692|NCT06735092|OTHER|Exercise + Wrist Brace Group|Participants in this group will undergo a standardized exercise protocol and will be provided with a wrist brace in addition to exercise therapy. The exercises will be part of a program lasting 6 weeks, conducted 2 days per week. A combined evidence-based exercise program consisting of wrist isometric, concentric, and eccentric exercises will be applied to the individuals in the group. For free-weight exercises, participants will start with weights of 0.5-1 kg, tailored to the individual. Progression will be achieved with 0.5-1 kg increments. For exercises using resistance bands, the increase in resistance will be provided by selecting the next level band color. Participants will be assessed before treatment, at the end of the 6th week, and at the end of the 12th week.
224093166|NCT06565741|PROCEDURE|ThuFLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or ThuFLEP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50 cases) and possessing experience with both laser types, will perform the surgical procedure.
224093167|NCT05528146|DIETARY_SUPPLEMENT|Psyllium huks|psyllium in 250ml of water
224093168|NCT06140927|DRUG|Ketamine|Patients will be administered ketamine at increasing doses followed by measurements of motor-evoked potentials.
224093169|NCT06654726|DRUG|aldafermin|aldafermin
224093170|NCT06654726|DRUG|Placebo|placebo
224093171|NCT06161012|DEVICE|Senofilcon A contact lenses (TEST)|Rotationally stabilized astigmatic soft contact lenses in senofilcon A containing a chromophore to filter High-Energy Visible Light (HEVL)
224093172|NCT06161012|DEVICE|Delefilcon A contact lenses (CONTROL)|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
224093173|NCT02601950|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
224093174|NCT05723055|DRUG|Axatilimab|Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
224093175|NCT05723055|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
224093176|NCT06617039|DRUG|Remifentanil and ciprofol|R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
224093177|NCT06617039|DRUG|esketamine 0.3mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
224281732|NCT03119493|BEHAVIORAL|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
224281733|NCT03024931|OTHER|observational study|No intervention
224281734|NCT01120769|DRUG|Acetaminophen|single dose
224281735|NCT01120769|DRUG|Placebo|single dose
224281736|NCT02323165|OTHER|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
224281737|NCT03022669|BEHAVIORAL|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
224281738|NCT03022669|BEHAVIORAL|Mobile Application|
224281739|NCT03022669|OTHER|Website|American Heart Association patient education website
223717664|NCT00777608|DRUG|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
223925693|NCT06891768|DIAGNOSTIC_TEST|Blood culture|Blood culture for bacteriological profile and antibiotic sensitivity
224093178|NCT06617039|DRUG|esketamine 0.5mg/kg and ciprofol|Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
224093179|NCT06617039|DRUG|Ciprofol|Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
223531981|NCT06520397|DRUG|Ustekinumab and Upadacitinib|Participants in this group will maintain the original Ustekinumab regimen, receiving 90 mg administered subcutaneously every 8 weeks. In addition, they will receive Upadacitinib administered orally at a dosage of 45 mg daily for 12 weeks. After the 12-week period, the dosage of Upadacitinib will be adjusted based on patient condition and clinical judgment, continuing until the evaluation at week 16. Clinical efficacy of the dual-target therapy will be evaluated at week 16.
223531982|NCT06520397|DRUG|Ustekinumab|Participants will receive an additional induction dose of Ustekinumab administered intravenously at 6 mg/kg at baseline. This will be followed by subcutaneous maintenance therapy of 90 mg every 4 weeks. Clinical efficacy will be evaluated at week 16.
223925694|NCT06892964|GENETIC|Genetic profiling of all eligible patients|Performed genetic profiling in DNA extracted from fresh tissue or FFPE in all patients affected by lymphatic malformation recruited
223925695|NCT06750692|OTHER|Procedure: Mirror therapy|The first group of participants will receive a total of 20 sessions of upper extremity mirror therapy program, 5 sessions per week for 4 weeks.
224093180|NCT06405425|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
224093181|NCT06405425|DRUG|PD-1|Administration by intravenous infusion for a cycle of 3 weeks.
224093182|NCT06771492|DRUG|Amoxicillin|Antibiotic treatment (amoxicillin) with a dosage of 1000 mg (3 times a day) for a period of 100 days
224093183|NCT06771492|OTHER|Placebo|Placebo with a dose of 1000 mg (3 times a day) for a period of 100 days
224093184|NCT04642287|DRUG|Calcipotriol Only Product in Cutaneous Dose Form|Calcipotriene is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.
224093185|NCT04642287|DRUG|Vaseline|Placebo
224093186|NCT04642287|DRUG|Topical 5FU|5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
223531983|NCT00569933|BEHAVIORAL|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
223531984|NCT02147821|PROCEDURE|No Pleural Chest Tube|
224093187|NCT03829579|DRUG|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
224093188|NCT06417515|DRUG|Xiao-Yao-San|Patients who received Xiao-Yao-San 9 g/day (Kaiser Pharmaceutical Co. Ltd.) were selected for the Xiao-Yao-San group by traditional Chinese doctor with 8 years of experience.
223531985|NCT05949879|OTHER|Pecan LOW|Participants are provided with a quantity of pecans that delivers 6% of the participant's estimated energy needs for 28 days.
223531986|NCT05949879|OTHER|Pecan MID|Participants are provided with a quantity of pecans that delivers 13% of the participant's estimated energy needs for 28 days.
223531987|NCT05949879|OTHER|Pecan HIGH|Participants are provided with a quantity of pecans that delivers 20% of the participant's estimated energy needs for 28 days.
223531988|NCT05949879|OTHER|CONTROL|Participants are asked to maintain their current habitual diet and to avoid any tree nut/peanut consumption for the entire 28-day intervention period.
223531989|NCT01051245|BEHAVIORAL|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
223531990|NCT01051245|OTHER|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
223531991|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
223925696|NCT06750692|DEVICE|Device: Low Frequency rTMS Protocol|Repetitive Transcranial Magnetic Stimulation (rTMS) will be applied at an intensity of 100-110% of the resting motor threshold and low frequency (1 Hz) to the contralateral M1 upper extremity motor cortex region for a total of 20 sessions, 5 sessions per week for 4 weeks. rTMS application is planned to provide magnetic stimulation with the stimulator of the Magventure MagPro R30 device.
223925697|NCT06750692|DEVICE|Robotic-assisted hand therapy|In the Robot Assisted Therapy group, a total of 20 sessions will be applied 5 days a week for 4 weeks using continuous passive range of motion, active assistive exercise and play therapy programs for hemiplegic upper extremities with AMADEO (Tyromotion Austria).
224093189|NCT06417515|OTHER|Weight loss class(WLC) group|Participants who attended the WLCs in our hospital and were willing to participate in our study were included in the WLC group (control group). Our WLCs consisted of 8 sessions of 2-hour dietary advice/exercise guidance and 1 session of weight-loss consultation in 3 months. The participants assessed their weights at the beginning, at 1.5 months, and after every class. They underwent pre-PSG tests in the beginning and post-PSG tests after 3 months of lectures.
224093190|NCT02148029|OTHER|Exercise|Upper and Lower extremity exercise
224093191|NCT02148029|OTHER|Standard Care|anticoagulation, compression, and ad-lib ambulation
224093192|NCT05762926|OTHER|Transcranial pulse stimulation (TPS)|Clinical treatment consists in ten sessions of neuronavigation system guided halocranial application of 6000 focused sound wave pulses, with energy flux density of 0.25 mJ/mm2, depth of focus of 5 cm and useful energy between 4 to 6 cm, frequency of 4 Hz, total energy applied will be 50 Joules, for it will be used the Storz Neurolith™ equipment.
224093193|NCT04901572|DIAGNOSTIC_TEST|QISI device|QISI device will simulate its use in ICSI procedures and evaluate sperm cells according to WHO guidelines.
224093194|NCT03288298|DRUG|luteolin|flavonoid natural extract
224093195|NCT03288298|DRUG|nano-luteolin|nanoparticles of luteolin
224093196|NCT00000257|DRUG|0% N2O and 10% N2O|
224093197|NCT00000257|DRUG|0% N2O and 20% N2O|
224093198|NCT00000257|DRUG|0% N2O and 30% N2O|
223531992|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
223531993|NCT03698279|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
223531994|NCT03698279|BIOLOGICAL|Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
223925698|NCT03795311|DRUG|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
223925699|NCT06748079|DRUG|TQC3721 inhalation powder|TQC3721 is a target inhibitor.
223925700|NCT06748079|DRUG|Placebo for TQC3721 inhalation powder|Placebo without drug substance.
223925701|NCT06741488|OTHER|no intervention|Exercise Adaptation Rating Scale
223925702|NCT06752395|DIAGNOSTIC_TEST|Transbronchial lung biopsy with radial probe endobronchial ultrasound (Cryobiopsy centered)|When the lung nodule is visualized by bronchoscope using RP-EBUS, cryobiopsy is performed, followed by forceps biopsy.
223925703|NCT06752395|DIAGNOSTIC_TEST|Transbronchial lung biopsy with radial probe endobronchial ultrasound (Forceps biopsy centered)|When the lung nodule is visualized by bronchoscope using RP-EBUS, forceps biopsy is performed, followed by cryobiopsy.
223925704|NCT06755138|OTHER|Observational Assessment|This study includes the use of surface electromyography (sEMG), video analysis, and questionnaires to assess trunk compensation patterns and their relationship with scoliosis, functional, quality-of-life, and pain parameters
223925705|NCT06738810|DIAGNOSTIC_TEST|Fibrotest-actitest/NASHtest|A blood sample will be collected from the patient in order to do Fibrotest-actitest/NASHtest and to calculate the NAFLD fibrosis score
223925706|NCT06771154|DRUG|Adebelimab Combined with Apatinib|"Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Apatinib, 250 mg, once daily (qd), orally (po). Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation."
223925707|NCT06771154|DRUG|Adebelimab|"Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation."
223925708|NCT06827431|DRUG|Ammoxetine|Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Ammoxetine and Sertraline.
223925709|NCT06827431|DRUG|Ammoxetine|Drug: Ammoxetine Ammoxetine hydrochloride enteric-coated tablets Drug: Placebo placebo to Sertraline.
223925710|NCT06827431|DRUG|Placebo|Drug: Placebo placebo to Ammoxetine hydrochlorid and Sertraline.
223925711|NCT06827431|DRUG|Sertraline|Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.
223925712|NCT06754735|DEVICE|Topical Wound Oxygen Therapy|The active intervention is the application of the Topical Wound Oxygen device that supplies cyclical oxygen pressure directly to the wound site within a sealed environment.
223531995|NCT03698279|BIOLOGICAL|FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)|Pharmaceutical form: Solution for injection Route of administration: IM
223925713|NCT06754735|DEVICE|Sham Control Topical Wound Oxygen|The sham control intervention is the application of Topical Wound Oxygen device that supplies topical room air to the wound site within a sealed environment.
223925714|NCT06754332|DRUG|human chorionic gonadotropin|The POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.
223531996|NCT06632626|OTHER|Task oriented training exercises|Task oriented training is a type of exercises in form of tasks using papers, pens, scissors, clips, coins, screws and clay
223531997|NCT06632626|OTHER|Traditional physical therapy|Traditional physical therapy inform of mobilization, strengthening exercises of hand and streching exercises.
223925715|NCT06754371|DRUG|tranexamic acid|intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection
223925716|NCT06754371|DRUG|normal saline|intravenous infusion of normal saline 20ml 10min before skin dissection
223925717|NCT06754761|DRUG|[14C] AZD6738|radiolabeled AZD6738 / ceralasertib
223925718|NCT06754761|DRUG|AZD6738 / ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR
223925719|NCT04198194|DIAGNOSTIC_TEST|Predictors of events|Apple Heart \& Movement Study in Apple Research app
223925720|NCT05977023|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of bipolar depression
223531998|NCT04972253|DRUG|Infigratinib|Oral, dosage per protocol
223531999|NCT02180828|DRUG|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
223532000|NCT02180828|DRUG|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
223532001|NCT00871026|PROCEDURE|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
223532002|NCT00871026|PROCEDURE|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
223717665|NCT00158990|DRUG|triiodothyronine|
223925721|NCT05977023|DRUG|Placebo Cap|Use of placebo as a comparator.
223925722|NCT00866021|DRUG|Lopinavir/ritonavir|NRTI sparing-regimen
223925723|NCT00866021|DRUG|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
223925724|NCT06757673|DEVICE|Robot-Assisted Therapy using Kebbi Air|Participants in this group will engage with the Kebbi Air smart robot, which is programmed with interactive scripts designed to enhance social-emotional regulation skills. The intervention includes weekly 30-minute sessions over a 12-week period, where the robot simulates real-life social scenarios and provides verbal and visual responses to guide participants in developing emotional and social skills. Occupational therapists will supervise these sessions to ensure the appropriateness of interactions and provide additional support as needed.
223925725|NCT06757673|BEHAVIORAL|Sensory Integration Therapy|Participants in this group will receive traditional sensory integration therapy guided by occupational therapists. The therapy focuses on improving sensory processing and emotional regulation through structured activities targeting visual, auditory, and tactile stimuli. Each session is conducted weekly, lasting 30 minutes, for a total of 12 weeks. The therapy aims to help children adapt to sensory inputs and enhance their ability to engage in social interactions and manage emotions effectively.
223925726|NCT06757907|DRUG|Acyclovir 400 MG|Acyclovir is used to treat infections caused by certain types of viruses.
223925727|NCT06757907|DRUG|Ganciclovir (GCV)|Ganciclovir is an anti-viral drug
223925728|NCT06757452|DIETARY_SUPPLEMENT|Supplement with curcuminoids|Cal LX is a food-grade dietary supplement based on turmeric, it has been designed to improve physical resistance during exercise, accelerate post-exercise recovery, and reduce the feeling of muscle soreness. Cal LX was determined as not cytotoxic or genotoxic. The supplement or placebo dosage was one (1) 250 mg capsule 45 minutes before exercising.
223925729|NCT06757452|OTHER|Physical excercise|Participants performed 45 minutes of physical activity twice a week. The intervention program included a five-minute warm-up, composed of two series of joint mobility and three series of eight seconds of lower limbs stretching. Then, a routine of intermittent training composed of four six-minute rounds was directed. Each routine included running for 10 seconds and a pause between them. The first round had a 20 s pause, the second round 15 s, and the third and fourth rounds 10 s. Between the rounds was a two-minute passive pause. Finally, three series of twenty seconds of elongation of the lower extremities were required as colling down.
224093199|NCT00000257|DRUG|0% N2O and 40% N2O|
223925730|NCT02817958|DRUG|Chemotherapy TIP|Paclitaxel, ifosfamide, and cisplatin
224093200|NCT03049449|BIOLOGICAL|Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
224093201|NCT03049449|DRUG|Cyclophosphamide|300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
224093202|NCT03049449|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
224093203|NCT00472693|DRUG|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
224093204|NCT04089956|OTHER|No interventation|A retrospective cohort Observational study with no intervention
224093205|NCT02281890|OTHER|Proven sepsis|Exposure is proven sepsis
224093206|NCT00442598|DRUG|Glufosfamide|
223925731|NCT06760468|OTHER|Control|Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the control group. Participants in the control group will undergo an 8-week placebo supplementation intervention. The placebo has a similar appearance and taste to the probiotic powder but does not contain active probiotic ingredients. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the placebo once a day at the same time to ensure the consistency and standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise capacity tests and blood sample collections will be conducted again. Comparing exercise performance and biochemical markers before and after t
224093207|NCT02075801|OTHER|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
223925732|NCT06760468|DIETARY_SUPPLEMENT|Experimental Group|"Experimental:~Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the experimental group. Participants in the experimental group will undergo an 8-week probiotic powder supplementation intervention. The dosage of the probiotic powder is set at 1x10\^9 CFU/kg·bw·d, which means ingesting 10 billion CFU (Colony-Forming Units) of probiotics per kilogram of body weight per day. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the probiotic powder once a day at the same time to ensure the consistency of the dosage and the standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise ca"
223925733|NCT06759246|PROCEDURE|implant placement|Placement of short implants for the rehabilitation of single-tooth edentulism in atrophic maxillae near the maxillary sinus.
223925734|NCT06760195|PROCEDURE|Intra-arterial hypothermic magnesium sulfate infusion|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 330 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 30 ml MgSO4 solution will be infused into the ischemic territory at 15 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.
223925735|NCT06760195|PROCEDURE|Endovascular thrombectomy|All patients that are eligible for endovascular thrombectomy will receive this surgery in aim to remove thrombus and restore reperfusion.
223925736|NCT06760195|DRUG|Intravenous thrombolysis|All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
223925737|NCT06759779|DEVICE|inspiratory muscle training|Inspiratory muscle training will be performed
223925738|NCT06759779|DEVICE|expiratory muscle training|Expiratory muscle training will be performed
223925739|NCT06758843|OTHER|measure the axial length, visual acuity, and refraction at follow-up of 6- and 12-month|the intervention is follow-up with parameters to measure and data to record
223925740|NCT06760234|DIAGNOSTIC_TEST|No Interventions|The high-throughput extraction of quantitative image features from medical images
223925741|NCT06760234|DIAGNOSTIC_TEST|No Interventions|Immunohistochemical analysis
223925742|NCT06759090|DRUG|Metronomic capecitabine|Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;
223925743|NCT06759090|DRUG|Camrelizumab|Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;
223925744|NCT06759090|DRUG|Apatinib Mesylate Tablets|Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.
223925745|NCT06759688|BEHAVIORAL|Carbohydrates restriction|"Patients followed a low carbohydrate dietary approach (LCDs). It means lower than 130 grams carbohydrates per day with special restriction restrictions on:~* Artificial sugars (e.g., sweets, baked goods, pasta, bread).~* Also, rice, butter made from vegetable oils and all types of oils except olive oil.~They were allowed:~* All types of fresh fruits and vegetable.~* Boiled potatoes."
223925746|NCT05934227|DRUG|Amoxicillin 500 milligrams capsules plus metronidazole 400 milligrams|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of amoxicillin (500 milligrams) + metronidazole (400 milligrams) three times a day for 7 days after SRP
223925747|NCT05934227|OTHER|placebo|supra and subgingival scaling and root planing (SRP) using manual and ultrasonic instruments in all residual pockets under anesthesia, performed within 2 consecutive days; systemic use of placebo containing corn starch capsules three times a day for 7 days after SRP
223925748|NCT06761573|DEVICE|Bilateral Bispetral Index Monitor will be applied on forehead of our patients, before surgery begins|In patients undergoing surgery and general anesthesia, the investigators want to examine -using bilateral BIS monitor- synthetic electroencephalographic differences between the two cerebral hemispheres (ASYM) to evaluate any correlation with the development of POD and POCD in the post-operative period.
223925749|NCT06788847|PROCEDURE|Ultrasound guided needle knife dissection|"This procedure involves a minimally invasive dissection of the fibrous cords in Dupuytren's Contracture using a needle knife guided by ultrasound imaging. Local anesthesia using 3-5 ml of 1% Lidocaine and 0.25% bupivacaine is administered for patient comfort. The technique aims to improve precision, minimize complications and reduce recurrence.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure."
223925750|NCT06789354|OTHER|Questionnaire and Physical Exam|All assessments were carried out face-to-face with the same physiotherapist.
223925751|NCT06752837|DEVICE|Tornado rotary system|In arm one, stainless steel tornado files works by high-speed rotation that influences the fluid dynamics within the canal and improves irrigation efficiency. Canals are finished with a file having a 4% taper and an apical diameter of 0.25 mm.
223925752|NCT06752837|DEVICE|WaveOne rotary system|In arm two, WaveOne system is a single reciprocating file system with a heat-treated NiTi Memory Wire (M Wire).It has a taper of 0.08 in apical 3 mm, with a tip diameter of 0.25 mm. in a torque control endodontic handpiece (X smart plus with reciprocation mode)
223925753|NCT06752837|DEVICE|OneShape rotary system|In arm three, OneShape system utilizes a conventional, continuous rotational motion. It has asymmetric cross-sectional geometry, and traveling waves of motion that are produced along the file's active region. It has a single constant taper of 0.06 and a tip size of 25 with distinct cross-sectional designs along the whole length of the working parts
223925754|NCT06752837|DEVICE|Cone beam computed tomography|A post-operative CBCT image was obtained and compared to the pre-operative one to assess the impact of canal preparation of each file on the periapical lesion.
223717666|NCT00158990|DRUG|sertraline|
223925755|NCT06751732|OTHER|Craniocervical Flexion Training (CCFT)|CCFT is a targeted intervention aimed at improving neuromuscular control in the cervicoscapular and craniocervical regions through low-load endurance exercises. A pressure biofeedback unit placed behind the neck sets a baseline at 20 mmHg, ensuring relaxed neck muscles. Participants open the mouth 20 mm to activate deep cervical flexors and minimize superficial muscle use, maintaining head contact with the surface while gazing 45 degrees below the horizontal. Pressure is increased in 5 mmHg steps (20 to 40 mmHg), with each level held for 10 seconds, followed by a 10-second rest. CCFT can also be performed seated, reducing sternocleidomastoid activity and promoting longus colli thickness for functional training.
223925756|NCT06751732|OTHER|Diaphragm Respiratory Training|Patients will undergo a 15-minute diaphragmatic respiratory training session, focusing on smooth diaphragmatic breathing with gentle expirations.
223925757|NCT06751732|OTHER|Cervical Mobilization and Traction|A physiotherapist will perform a low-velocity, passive cervical joint mobilization technique (Oscillation technique) based on the regimen described by Maitland.(17) This will be followed by cervical spine traction while patients continue diaphragmatic breathing.
223925758|NCT06751732|OTHER|Digital Compression on Muscle Trigger Points|Digital compression will be applied for 90 seconds on identified trigger points in the craniocervical muscles, not exceeding eight trigger points in each session.
223925759|NCT06751732|OTHER|Passive Stretching of Neck Muscles|Passive stretching will be performed three times for neck flexion and rotation associated with ipsilateral flexion directions, using moderate force within the patient's pain limits, and maintained for 30 seconds.
223925760|NCT06751732|OTHER|Instruction on Postural Correction|Physiotherapists will provide instructions on postural correction, addressing craniocervical extension, cervicothoracic flexion, protraction of shoulders, increased thoracic kyphosis, and flattened lumbar lordosis. Patients will be guided on correcting these postural abnormalities through craniocervical flexion, cervicothoracic extension, shoulder retraction, thoracic spine extension, and normalization of lumbar lordosis.
223925761|NCT06754228|DIETARY_SUPPLEMENT|Probiotic Agent|Bacillus coagulans JBI-YZ6.3 (BC4U)
223925762|NCT06754228|DIETARY_SUPPLEMENT|Probiotic Agent|An escalating dose cross-over design: Participants are fed 0 mg, 100 mg, 200 mg, and 400 mg on different clinic visits.
223925763|NCT06842719|PROCEDURE|on-site housing counseling|on-site housing counseling by a certified housing counseling expert
224093208|NCT02075801|OTHER|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
224093209|NCT05046756|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
224093210|NCT02069691|DEVICE|virtual reality-cycling training system|
224281740|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions|"The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive."
223925764|NCT06765785|DIAGNOSTIC_TEST|CTCA|Screening CTCA will be performed in the experimental arm after 1:1 randomisation using sealed envelope technique
223925765|NCT06840353|OTHER|Experimental group (Pecha Kucha training)|Ventrogluteal injection training given to students using the Pecha Kucha training method
223925766|NCT06766123|PROCEDURE|CABG|All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
224093211|NCT04106388|BEHAVIORAL|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
224093212|NCT01073579|DRUG|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
224093213|NCT03160014|DRUG|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
224093214|NCT02113202|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
224093215|NCT02113202|DEVICE|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
224093216|NCT04337437|DRUG|Genakumab|150 mg/1ml/bottle, single subcutaneous injection.
224093217|NCT04337437|DRUG|Placebo for this trial|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection, 150 mg/1ml/bottle, single subcutaneous injection.
223532003|NCT01617473|PROCEDURE|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
223925767|NCT06768996|BEHAVIORAL|Synchronous Rhythm Production|The treatment group will take part in a dyad-based musical rhythm production activity facilitated by a trained musician. This activity will involve two rhythm conditions. The first condition requires tapping along to one pre-recorded audio track composed of an ensemble of Brazilian percussion instruments. The second condition requires tapping along with prerecorded audio tracks of rhythms progressively increasing in difficulty. Participants who indicate proficiency in learning to tap along in both conditions will be able to progress to more complex rhythms. All tapping data will be gathered through a Roland digital hand percussion controller.
223925768|NCT06768996|BEHAVIORAL|Solo Rhythm Production|Participants randomized to the control condition will complete the same rhythm conditions to the same recorded audio tracks described in the experimental condition. However, they will not interchange their tapping with their caregiver. They will participate in the rhythm task as a solo producer.
223925769|NCT06768385|PROCEDURE|Transversus abdominis plane (TAP) block|: It was performed under USG guidance using 30 ml of 0.25% bupivacaine with an 80 mm insulated peripheral block needle. Local anaesthetic was applied between the upper fascia of the transversus abdominus muscle and the fascia of the internal oblique muscle at the midpoint of the distance between the costal margin and the iliac crest in the midaxillary line under USG imaging guidance.
224093218|NCT02358811|DEVICE|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~* Before any examination, the manipulator will check the absence of contraindication to MRI.~* During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~* Throughout the examination, a physician will always be present."
224093219|NCT02358811|BEHAVIORAL|Cognitive assessment|"This cognitive assessment will include the following executive tests :~* test of Stroop~* left Trail Making Test A and B~* verbal fluence test~* test of memory of figures direct and inverse in order~* completion of matrices~* Paced Auditory Serial Addition Test (PASAT)"
224093220|NCT02336477|DRUG|Mexiletine|"* Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~* Patients will receive gradual dose of the treatment as it would be done in clinical practice.~* Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~* The duration of each treatment period is 18 days minimum (maximum 22 days)."
224093221|NCT02336477|DRUG|placebo|
224093222|NCT05029050|DRUG|Dexmedetomidine|Continous intravenous infusion
224093223|NCT05029050|DRUG|Clonidine|Continous intravenous infusion
224093224|NCT05029050|DRUG|Natriumchlorid|Continous intravenous infusion NaCl
223532004|NCT05662657|DIAGNOSTIC_TEST|Diagnostic Test: PCL-S Questionnaire|PCL-S and HADS questionnaires
223532005|NCT02276040|DRUG|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
223532006|NCT02196350|BEHAVIORAL|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
223532007|NCT02196350|BEHAVIORAL|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
223717667|NCT03148132|DRUG|Bevacizumab Injection|0.5mg/0.02 mL
223717668|NCT03148132|DRUG|Ranibizumab Ophthalmic|0.25mg/0.025 mL
223925770|NCT06768385|PROCEDURE|thoracoabdominal nerve blockage with perichondrial approach (TAPA) block|Under USG guidance, 20 ml of 0.25% bupivacaine was administered between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue at the level of the 9th and 10th ribs (arcus costarum) in the midclavicular line with an 80 mm insulated peripheral block needle. Then, 10 ml of 0.25% bupivacaine was injected into the upper fascia of the costochondral tissue and the lower fascia of the external oblique muscle. The block was performed by following the needle path in the ultrasound image.
223925771|NCT06768593|PROCEDURE|RIFP Block|After aseptic conditions are ensured, with high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Pajunk Sonoplex Nanoline Stim Cannula, Germany) bilateral block will be applied to Group R. As the patient is in supine position, the USG probe is placed in transverse plane on the sternum and will be directed downwards and laterally and rotated to determine the xiphoid and just below the rectus abdominis muscles. Costal cartilage and rectus abdominis muscle sonographically will be shown. This region corresponds to the 3-4 cm lateral and 3-4 cm caudal region of the xiphoid. Using the in-plane technique, the block needle will be advanced in the caudal-cephalic direction, and 5 ml saline will be injected into the area between the rectus muscle and costal cartilage to verify the block location. 30 ml of 0.25% bupivacaine (Buvacaine, Polifarma ®) will be injected to each side, which corresponds to 60 ml total local anesthetic-saline mixture in Group R.
223925772|NCT06768593|OTHER|Postoperative pain management|"Ibuprofen 400 mg (Ibuprofen, Polifarma ®) and tramadol 100 mg (Contramal, Abdi İbrahim ®) IV single bolus dose will be given 20 minutes before the end of the surgical procedure for postoperative analgesia.~NRS scores at rest and while moving will be evaluated and recorded and if the NRS score is ≥ 4, meperidine 0,5 mg/kg (Aldolan®) IV will be administered as a rescue analgesic."
223925773|NCT06769607|DEVICE|Investigational algorithm|Investigational algorithm developed for the treatment of Obstructive Sleep Apnea.
223925774|NCT06769607|DEVICE|Control algorithm|Released algorithm intended for the treament of Obstructive Sleep Apnea
223925775|NCT06757699|OTHER|Walking|"Participants will perform 30 minutes of walking and cycling exercises. During the cycling and walking exercises, heart rate will be calculated using the Karvonen formula based on heart rate reserve.~HRmax (maximum heart rate)=220-age HRR (%)(heart rate reserve)= (HR-HRrest)/(HRmax-HRrest)\*100~Blood samples will be collected from participants before starting the exercise, at the end of the 30-minute exercise session, and twice more at 30-minute intervals. The same participants will perform the cycling exercise half an hour later, and the same procedures will be applied."
223925776|NCT06757699|OTHER|Cycling|Cycling
223925777|NCT06751017|DRUG|S-892216|S-892216 will be administered orally as a tablet.
223925778|NCT06751017|DRUG|Carbamazepine|Carbamazepine will be administered orally as a tablet.
223925779|NCT06750211|OTHER|METs|"* Hot pack for 10 minutes.~* Neck isometrics with 10 second hold.~* Each series of neck isometrics strengthening exercises had three movements including cervical flexion, cervical extension and cervical side flexion.~* Muscle energy technique protocol: The individual was in a position of supine. The therapist was at the edge of bed, near the participants head. the therapist positioned the joint at the point of beginning range of motion resistance when performing a given movement. When the therapist felt restriction, positioned the cervical spine in that region and apply the resistive force. Patient was instructed to contract isometrically for five seconds without exceeding the therapist force. thereafter, therapist counterforce gradually reduced and patient was asked to relaxed. Therapist move the joint into new point of barrier and same protocol repeated three times.~Patient came thrice per week for a total of 4 weeks."
224093225|NCT04653519|DEVICE|Virtually guided minimally invasive preparation|Intraoral virtually guided minimally invasive design with an occlusal reduction of 1.5mm, axial reduction will be performed with 6 degrees axial taper and a circumferential chamfer margin of 0.5mm in width and 0.5mm coronal to the gingival margin. A milled guiding occlusal resin template of the teeth will be checked for fitting then fixed using spot etching and will be used to guide the amount of axial reductions and taper degree.
224093226|NCT05946343|DIAGNOSTIC_TEST|Surface Electromyography (sEMG) Assessment|Surface electromyography (sEMG) will be used to assess the activation patterns of scapular and rotator cuff muscles during functional tasks, such as shoulder flexion, abduction, and external rotation. The sEMG assessment will be conducted using a wireless sEMG system with a sampling rate of 2000 Hz and a bandwidth of 20-500 Hz. Pre-gelled, disposable, self-adhesive Ag/AgCl electrodes will be placed on the muscle belly according to SENIAM guidelines, with an inter-electrode distance of 20 mm.
224093227|NCT01147497|DRUG|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
224093228|NCT01147497|DRUG|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
224093229|NCT00211614|DRUG|Lansoprazole|
224093230|NCT00972699|BEHAVIORAL|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
224093231|NCT04134650|COMBINATION_PRODUCT|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
224093232|NCT04134650|DRUG|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
224093233|NCT03691714|DRUG|Durvalumab|Two hour infusion
224093234|NCT03691714|DRUG|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
223717669|NCT01754701|DIETARY_SUPPLEMENT|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
223532008|NCT02196350|BEHAVIORAL|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
224281741|NCT05852795|OTHER|Virtual Reality-mediated Mindfulness-Based Interventions without audio guided experience|"The Control will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a monosensorial experience with video guided stimulation of naturalistic scenarios."
223532009|NCT06327438|OTHER|Complex decongestive therapy|"1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care."
223532010|NCT06327438|DEVICE|Cryotherapy|It is a mature and safe-to-use system that cools the air to -32°C. Steps of application included: 1) Apply oil or cream to moisture the skin before cryotherapy application; 2) Initialize the mini cryo-air equipment at level 6.
223532011|NCT06327438|OTHER|Kinesio taping|It is a new choice in the field of physical therapy. The material used for the KT and the original concept of the taping technique were introduced by Dr Kenso Kase in 1973.
223532012|NCT05160389|DRUG|PBI-200|Single dose of PBI-200
223532013|NCT01015521|DRUG|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
224281742|NCT01049412|DRUG|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
224281743|NCT01049412|DRUG|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
224281744|NCT02264535|DRUG|0.1mg/ml Ginkgolides Meglumine Injection|
224281745|NCT02264535|DRUG|1mg/ml Ginkgolides Meglumine Injection|
224281746|NCT02264535|DRUG|5mg/ml Ginkgolides Meglumine Injection|
224281747|NCT03703024|DIETARY_SUPPLEMENT|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
224281748|NCT03703024|DIETARY_SUPPLEMENT|Placebo|Delivered in a capsule
224281749|NCT05517161|BEHAVIORAL|INSIGHT|See Keegan et al., 2020
224281750|NCT02255188|PROCEDURE|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
223532014|NCT02995590|DRUG|Hyperpolarized He3|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
223532015|NCT05213806|OTHER|Withholding feeds around transfusion|Withholding enteral feeds for preterm infants (\<30 weeks) around the time of blood transfusions to determine if any impact on the development and/or severity of Necrotizing Enterocolitis.
223532016|NCT05213806|OTHER|Continued feeds around transfusion|Continued enteral feeds
224281751|NCT04236583|OTHER|Telehealth|Post-discharge virtual visit
224281752|NCT01944787|OTHER|Routine|IV Hydration at 125 cc hour
224281753|NCT01944787|OTHER|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
224281754|NCT06044194|DRUG|L-arginine and liposomal vitamin C|Once the diagnosis of heart failure is established, patients will be randomized into a double-blind treatment to receive with a 1:1 ratio an oral supplement of 1.66 g L-arginine and 500 mg of liposomal vitamin C once a day (Bioarginine. C , Pharmaceutical Damor) for 3 months (treatment group) or an oral supplement of Placebo once a day for 3 months (control group)
224281755|NCT01283815|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
224281756|NCT01283815|PROCEDURE|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
223532017|NCT02121093|PROCEDURE|vibration|
223532018|NCT01434004|BEHAVIORAL|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
223532019|NCT00224393|DRUG|Enbrel|
223532020|NCT03719807|OTHER|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
223532021|NCT03719807|OTHER|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
223532022|NCT00097630|PROCEDURE|SAT: Spontaneous Awakening Trial|
223532023|NCT00097630|PROCEDURE|SBT: Spontaneous Breathing Trial|
223532024|NCT06372795|OTHER|pure effortful swallowing|"The investigator instructed the patient to swallow forcefully while squeezing the tongue upward and backward in the direction of the soft palate based on the sounds of an electronic timer."
223532025|NCT06372795|OTHER|progressive resistance swallowing training|Patients in the test group, resistance swallowing exercise was performed by providing external resistance through Iowa Oral Performance Instrument (IOPI), and all other protocols were performed the same as those in the control group.
223532026|NCT03801525|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody~* administered as an IV infusion"
223532027|NCT03801525|DRUG|Umbralisib|"* inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e)~* Tablet form"
223532028|NCT03801525|DRUG|Venetoclax|"* B-cell lymphoma 2 (BCL-2) inhibitor~* Tablet form"
223532029|NCT04573855|BIOLOGICAL|Anti-SARS-CoV-2 immunoglobulin|Treatment with Anti-SARS-CoV-2 immunoglobulin
223532030|NCT00022178|DRUG|cisplatin|
223532031|NCT00022178|DRUG|cyclophosphamide|
223532032|NCT00022178|DRUG|doxorubicin hydrochloride|
223532033|NCT00022178|DRUG|epirubicin hydrochloride|
223925780|NCT06750211|OTHER|MCTE along with METs|"▪ Hot pack for 10 minutes.~* Neck isometrics with 10 second hold.~* Each series of neck isometrics strengthening exercises had three movements including cervical flexion, cervical extension and cervical side flexion.~* After it was treated with motor control therapeutic exercises together with muscle energy technique. Motor control therapeutic exercises included cranio-cervical flexor exercises, cranio-cervical extensor exercises, co contraction of flexor and extensor and synergy exercise for strengthening deep neck flexor. Exercises were performed in three sets with 10 repetitions with an approximate duration of 10 to 20 minutes. They were advised to perform at home once in a day, five times in a week for a duration of 4 weeks.~All exercises were performed three times per week for total of 4 weeks."
223925781|NCT06757088|DEVICE|M1 Stimulation Group|For M1, the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
223925782|NCT06757088|DEVICE|Cerebellar Stimulation Group (CbSG)|For the Cerebellar Stimulation Group, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below the inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle
223925783|NCT06757088|COMBINATION_PRODUCT|M1 + Cerebellar Stimulation Group|In M1, the anodal electrode will be placed over the M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region whereas simultaneously for the CbSG, active anodal electrode will be placed over the cerebellum bilaterally about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode will be placed on right buccinator muscle.
223925784|NCT06757088|DEVICE|Sham Stimulation Group|In Sham stimulation, Electrodes will be placed according to M1 Stimulation i.e., the anodal electrode will be placed over M1 region while the cathodal electrode will be placed over the right contralateral supraorbital region.
223925785|NCT06771375|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|EMDR is a psychotherapeutic approach originally designed for individuals suffering from trauma and post-traumatic stress disorder (PTSD). It facilitates the processing of memories through a structured eight-phase treatment, involving the patient's focused attention on traumatic images, thoughts, and sensations while simultaneously engaging in bilateral stimulation, typically through guided eye movements. This process aims to reduce the emotional distress associated with aversive memories, promoting adaptive coping mechanisms and psychological healing. Recently, the indications for the method have been extended so that EMDR is also used for chronic pain and depressive disorders.
223925786|NCT06762418|DEVICE|RMR+SME|Patients will be asked to wear this removable appliance for 16 hours daily. The expansion screw is activated twice a week.
223925787|NCT06762418|DEVICE|BAIMT+RME|The elastics are worn 18 hours per day to achieve the sagittal correction. The RME appliance on the upper jaw is activated twice daily until the required expansion is achieved.
223925788|NCT06768879|RADIATION|Ultrasound|To evaluate the different location of uterine fibroids in patient with disturbed menstrual cycle on ultrasound
223925789|NCT06773676|DEVICE|B-Cure laser pro|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
223925790|NCT06773676|DEVICE|Sham|The sham device is externally identical to active, emits the same guiding light and sound but does not emit the therapeutic near infrared invisible rays
223925791|NCT06778421|PROCEDURE|Intramuscular injection|Injection performed using method for aesthetic facial rejuvenation procedure with neuromuscular chemodenervation agents
223925792|NCT06778421|DRUG|OnabotulinumtoxinA (Botox®) Injections|"Injection of 64 units of active drug at a ratio of 4 units to 0.1 mL of sterile, preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only~\- Abbvie/Allergan drug."
223925793|NCT06778421|OTHER|Sodium Chloride|Placebo injection of the same volume of preservative-free 0.9% Sodium Chloride Injection, United States Pharmacopeia (USP) Only.
223925794|NCT06111885|DRUG|Indapamide 2.5 MG|1 indapamide 2.5 mg capsule per day for 28 days
223925795|NCT06111885|DRUG|Hydrochlorothiazide 50Mg|1 hydrochlorothiazide 50 mg capsule per day for 28 days
223925796|NCT06111885|DRUG|Chlorthalidone 25mg|1 chlorthalidone 25 mg capsule per day for 28 days
223925797|NCT06876025|OTHER|questionnaires|Application of the questionnaires Measure of Participation and Environment - Children and Youth, (PEM-CY), or Measure of Participation and the environment - young children (YC-PEM), and the Pediatric Disability Assessment Inventory (PEDI).
224093235|NCT02818699|DIETARY_SUPPLEMENT|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
224093236|NCT02818699|DIETARY_SUPPLEMENT|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
223532034|NCT00022178|DRUG|fluorouracil|
223532035|NCT00022178|DRUG|vincristine sulfate|
224093237|NCT01994083|DRUG|Placebo|Administered orally
224093238|NCT01994083|DRUG|IX-01|Administered orally
224093239|NCT00753389|OTHER|None (anesthesia)|anesthesia
224093240|NCT03495492|DEVICE|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
224093241|NCT03495492|DIETARY_SUPPLEMENT|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
224093242|NCT02991599|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
224093243|NCT02991599|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
224093244|NCT04698876|PROCEDURE|Self-tonometry by means of ICareHOME|Outpatient measurement of intraocular pressure at home
224093245|NCT04698876|PROCEDURE|Intraocular measurement by means of rebound tonometry or Goldmann applanation tonometry|Stationary measurement of intraocular pressure in a clinic
224093246|NCT04698876|PROCEDURE|Blood pressure|Blood pressure measurement for 24 h
224093247|NCT04528485|OTHER|Sea swimming|8 sessions of swimming activities in the sea
224093248|NCT00316823|GENETIC|gene expression analysis|
224093249|NCT00316823|GENETIC|polymerase chain reaction|
224093250|NCT00316823|GENETIC|reverse transcriptase-polymerase chain reaction|
224093251|NCT00316823|OTHER|diagnostic laboratory biomarker analysis|
224093252|NCT00316823|OTHER|immunohistochemistry staining method|
223532036|NCT05586373|DRUG|medication 1|Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
223925798|NCT06858644|DIAGNOSTIC_TEST|BUB1-Integrated Deep Learning Model for Gastric Cancer Metastasis and Cachexia Prediction|This intervention utilizes a deep learning model that integrates BUB1 gene expression, radiopathomics (quantitative imaging features), and histopathological data to predict peritoneal metastasis and cachexia in gastric cancer (GC) patients. Unlike traditional approaches, this model combines genomic, imaging, and pathological data to enhance early detection and improve prognostic accuracy. The model aims to identify key patterns in multi-modal data to offer personalized predictions for GC progression. By leveraging artificial intelligence, it seeks to support clinicians in decision-making, improving patient outcomes through earlier interventions and tailored treatments. This approach offers a novel, comprehensive method for predicting GC metastasis and cachexia, providing a unique tool compared to existing interventions.
223925799|NCT06860074|BEHAVIORAL|Sustainable Environmental Health Programs|"* Sustainable Future: Environment, Ecological Balance and Health,~* Ecological Balance and Pollution: Protecting Environmental Health~* Ecological Balance and Environmental Health~* A New Life for Waste: A Sustainable Future with Recycling~* Environmental Behaviors~* Recycling for Street Animals: A Shed Construction Project"
223925800|NCT06872983|PROCEDURE|cyanoacrylate tissue adhesive beside sutures|"A supracervical hysterectomy will be performed in the standard manner. Uterine amputation above the cervix will be performed with a monopolar needle or scissors. Concomitant adnexal surgery will be performed according to the presence of adnexa and the patient's request or medical indication.~In this study group, the implant is secured to the vaginal wall with cyanoacrylate tissue adhesive. Fixation of the implant to the cervix and promontory will be identical to the control group."
223925801|NCT06872983|PROCEDURE|Suture|A supracervical hysterectomy will be performed in the standard manner. Uterine amputation above the cervix will be performed with a monopolar needle or scissors. Concomitant adnexal surgery will be performed according to the presence of adnexa and the patient's request or medical indication. In this control group, the mesh will be fixed to the cervix with four non-absorbable sutures. In addition, the implant will be fixed to the anterior vaginal wall with four absorbable sutures and to the posterior vaginal wall with four absorbable sutures. The implant will be secured to the promontory with one non-absorbable suture.
223925802|NCT06890195|PROCEDURE|dialysate cooling|patients will be subjected to individualized cool dialysate (dialysate temperature 0.5 °C lower than core body temperature)
223925803|NCT06890195|PROCEDURE|standard dialysate temperature|patients will be subjected to standard dialysate temperature (dialysate temperature of 37 °C).
223925804|NCT06833749|DRUG|KBP-336|KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
223925805|NCT06833749|DRUG|Placebo|Placebo to match KBP-336
223925806|NCT06849154|BEHAVIORAL|REAL™ SEL Intervention Group|A structured intervention using virtual reality (VR) components to improve emotional regulation in early adolescents
223925807|NCT06851494|DEVICE|PMMA|Safety and efficacy evaluation of PMMA LinneaSafe 30% use for gluteal augmentation. Linnea Safe is a water-based gel containing Polymethylmethacrylate (PMMA) in concentrations of 2%, 10% or 30%. LInnea Safe is indicated for facial and body volumetric correction in cases of lipodystrophy due to the use of antiretrovirals in HIV-positive patients. It is also indicated for facial volumetric correction, and can be used in nasolabial folds, glabellar lines, corners of the mouth, upper lip lines, chin lines/chin lines, in the malar region, in acne scars, on the nose, to increase lips and facial contour.
224093253|NCT00316823|PROCEDURE|needle biopsy|
224093254|NCT00618150|BEHAVIORAL|Patient education|An educational program: Three lessons spaced over 2 weeks.
224093255|NCT00355264|DRUG|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
224093256|NCT00928330|DRUG|GDC-0941|Oral repeating dose
224093257|NCT00928330|DRUG|Trastuzumab|Intravenous repeating dose
224093258|NCT00928330|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
224093259|NCT02492945|DRUG|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
224093260|NCT02492945|DRUG|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
224093261|NCT00446303|DRUG|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
224093262|NCT02185391|PROCEDURE|Audience Response System|patients use during oral presentations an audience response system
224093263|NCT02185391|BEHAVIORAL|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
224281757|NCT00002262|DRUG|Tumor Necrosis Factor|
224281758|NCT02372591|DRUG|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
224281759|NCT02372591|DRUG|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
224281760|NCT02372591|DRUG|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
223532037|NCT05586373|DRUG|medication 2|Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
223717670|NCT01754701|DIETARY_SUPPLEMENT|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
223925808|NCT06769243|DEVICE|TMS|"Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat OCD, particularly in patients who have not responded well to traditional treatments such as medications or psychotherapy. The most common target is the supplementary motor area (SMA), which has an indirect connection with the Cortico-Striato-Thalamo-Cortical (CSTC) pathway, known to be hyperactive in OCD.~Another option to target the CSTC pathway is deep TMS, although it is not available in most advanced centers. The magnetic pulses from TMS stimulate or inhibit brain activity in the targeted area, which is believed to help reset or correct neural activity patterns associated with OCD and other psychiatric disorders.~TMS represents an alternative treatment for those struggling with OCD, offering a non-invasive approach with relatively few side effects and significant potential benefits."
223925809|NCT06832995|DRUG|IV morphine administered during the PACU stay|IV morphine administered during the PACU stay
223925810|NCT06795984|OTHER|Establishing the correlation between KIR AA and KIR non-AA and CD56 endometrial cells and IVF succes|The analysis aimed to compare CD56 levels between patients with the KIR AA genotype and those without. A multiple linear regression model was used to determine the predictive value of CD56+ levels, KIR genotype, and age on the number of blastocysts.
223925811|NCT06769555|DRUG|CM-336 BCMA/CD3 bispecific antibody|Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1. For patients achieve hematological PR or better after 2 cycles, and hematological VGPR or better after 4 cycles, the treatment regimen will change to 160mg once every 2 weeks (Q2W).
223925812|NCT06844123|PROCEDURE|Robot-assisted keratoplasty|Feasibility pilot interventional study. Monocentric, one arm. Microsurgical robot will be used to perform penetrating keratoplasty. During the procedure, the corneal sutures will be performed using symani surgical system, that is a microsurgical robot controlled by a surgeon
223925813|NCT06523556|BIOLOGICAL|Axatilimab|Given IV
223925814|NCT06523556|DRUG|Azacitidine|Given IV or SC
223925815|NCT06523556|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223925816|NCT06523556|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
223925817|NCT06523556|OTHER|Survey Administration|Ancillary study
223925818|NCT06930092|PROCEDURE|Physiology-and imaging-guided PCI|"The criteria for performing revascularization are as follows~1. Lesions with ≥50% diameter stenosis and FFR ≤ 0.80, or lesions with severe stenosis (\>90%)~2. In vessels meeting the above criteria, IVUS findings consistent with either:~   * Minimum lumen area (MLA) ≤ 3 mm²~  * 3 mm² \< MLA ≤ 4 mm² and plaque burden \>70%~For all target vessels and lesions identified for intervention, optimal revascularization should be pursued. The criteria for optimal revascularization are as follows, and operators are encouraged to achieve them:~1. Post-PCI FFR \> 0.86 in all treated vessels is recommended, with a minimum threshold of post-PCI FFR \> 0.80 to achieve functional complete revascularization.~2. Post-PCI ΔFFR (defined as \[FFR at stent distal edge\] - \[FFR at stent proximal edge\]) \< 0.05 is recommended.~3. On IVUS, achieving a minimum stent area (MSA) \> 5.5 mm² and MSA/average reference lumen \> 80% is recommended."
223925819|NCT06930092|DRUG|Optimal medical treatment|All study participants will receive guideline-directed medical therapy. Even for patients assigned to the optimal medical therapy group, revascularization may be performed during follow-up if clinically indicated. If such a decision is made prior to the primary endpoint assessment, a gadolinium-enhanced cardiac MRI will be performed at the time of consideration to reassess myocardial viability.
223925820|NCT06373653|DRUG|Manzanilla Sophia®|Matricaria recutita 0.025%, Ophthalmic solution.
223925821|NCT06373653|DRUG|Meticel Ofteno®|Hypromellose 0.5%, Ophthalmic solution.
223925822|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 175mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
223925823|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 225mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
223925824|NCT05470075|DRUG|HR18042 tablets|Drug: HR 18042 tablets 275mg and placebos match to Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
223925825|NCT05470075|DRUG|Tramadol hydrochloride SR Tablets|Drug: Tramadol hydrochloride SR Tablets 100mg and placebos match to HR18042 tablets Dosing frequency: single dose; Route of administration: oral
223925826|NCT05470075|DRUG|Placebos|Drug: Placebos match to HR18042 tablets and Tramadol hydrochloride SR Tablets Dosing frequency: single dose; Route of administration: oral
224093264|NCT01157117|BIOLOGICAL|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
224093265|NCT01157117|BIOLOGICAL|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
224093266|NCT01157117|DRUG|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
224093267|NCT04290182|BIOLOGICAL|MSC-KI-PL-204|Autologous MSC product
224281761|NCT03367325|DEVICE|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in \> 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
224281762|NCT02668848|DIETARY_SUPPLEMENT|water|If USG\>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
224093268|NCT02867696|OTHER|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
223532038|NCT02673944|DEVICE|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
223532039|NCT00352300|PROCEDURE|Adjuvant Therapy|
223532040|NCT00352300|DRUG|Carboplatin|Given IV
223925827|NCT06912477|DIAGNOSTIC_TEST|Hyperspectral imaging|"Hyperspectral imaging will be performed at study inclusion and will be repeated longitudinally every 1-2 days until delivery and on the first and second day after delivery. After a baseline measurement, a blood pressure cuff is inflated on the upper arm to 50 mmHg above the systolic blood pressure for 5 minutes, and then the hyperspectral imaging measurement is repeated.~Blood samples are collected at study inclusion and on the first and second day after delivery and are processed within the Department of Gynecology and Obstetrics of the Heidelberg University Hospital."
223532041|NCT00352300|DRUG|Paclitaxel|Given IV
223532042|NCT00352300|BIOLOGICAL|Pegfilgrastim|Given IV
223532043|NCT04388826|DRUG|Veru-111|Respiratory Distress Syndrome, Adult
223532044|NCT00098800|DRUG|fenretinide|
223532045|NCT05832892|DRUG|surufatinib|"In phase Ib, surufatinib will be orally administrated 200 mg once a day (QD) or 250 mg QD per cohort escalation assignment on a 21-day cycle.~In phase II, surufatinib will be orally administrated at RP2D as determined in phase Ib."
223532046|NCT05832892|DRUG|KN046|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
223532047|NCT05832892|DRUG|gemcitabine|Gemcitabine will be administrated at 1000 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
224281763|NCT03418857|DRUG|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
223925828|NCT06912477|DIAGNOSTIC_TEST|Further markers of endothelial dysfunction|"At study inclusion: 1. blood samples will be collected for the measurement of EASIX and cardiac/endothelial markers; 2. sublingual in vivo microscopy will be performed (requires about 20 minutes and can be compared to a sublingual temperature measurement); 3. Doppler ultrasound will be performed to evaluate uterine and ophthalmic arteries.~Blood samples will also be collected at the first and second day after delivery."
223925829|NCT06892366|BEHAVIORAL|Home-Based Aerobic Exercise Program|Aerobic Exercise (AE) Group This intervention consists of a home-based aerobic exercise program emphasizing moderate-intensity walking, tailored to 40-60% of peak VO2 or Borg Scale 4-6 for those on beta blockers. Distinctive features include real-time session supervision via video conferencing and heart rate monitoring with a smart wristband. This approach ensures remote guidance, personalized intensity, and participant safety throughout the 8-week program.
223925830|NCT06892366|BEHAVIORAL|Home-Based Aerobic and Resistance Exercise (ARE) Group|Participants engaged in a combined home-based aerobic and resistance exercise program. Aerobic sessions followed the same protocol as the AE group (3 days/week). Resistance training was performed 2 additional days per week using elastic resistance bands set at 40-50% of one-repetition maximum (1RM). Resistance exercises targeted major muscle groups, with each session consisting of 3 sets of 10 repetitions, and 1-3 minutes of rest between sets. All sessions were monitored and supervised remotely.
223925831|NCT05838924|OTHER|PHYSICAL ACTIVITY + VIRTUAL REALITY|"The VR therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 VR exercises of Back School by manipulating visual proprioceptive information during all lumbar movements. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
224281764|NCT03418857|DRUG|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
224281765|NCT00206830|DEVICE|Triage Profiler S.O.B. Panel|
224281766|NCT00362830|DRUG|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
224281767|NCT01842126|BIOLOGICAL|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
224281768|NCT01842126|BIOLOGICAL|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
224281769|NCT01842126|DRUG|Placebo IV|Ascending Doses intravenous (IV) of Placebo
224281770|NCT01842126|DRUG|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
224281771|NCT01655524|DRUG|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
224281772|NCT02642796|DEVICE|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
224281773|NCT01638858|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
223532048|NCT05832892|DRUG|Nab paclitaxel|Nab-paclitaxel will be administrated at 125 mg/m2 intravenously on day 1 and 8 of each 21-day cycle.
223532049|NCT05393700|BEHAVIORAL|Action Observation Therapy|Action Observation Therapy implies the observation of video-clips representing motor tasks alone or followed by imagination and/or imitation of observed tasks.
223532050|NCT00025415|DRUG|imatinib mesylate|Given orally
223532051|NCT00025415|OTHER|pharmacological study|Correlative studies
223532052|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
223532053|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
224093269|NCT02867696|BEHAVIORAL|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
223532054|NCT00329420|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
223532055|NCT02862574|DRUG|Andecaliximab|Administered via subcutaneous injection once weekly
223532056|NCT02862574|DRUG|Placebo|Administered via subcutaneous injection once weekly
223532057|NCT02862574|DRUG|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
223532058|NCT02862574|DRUG|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
223532059|NCT03985202|OTHER|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
223532060|NCT02150161|DRUG|Lidocaine/ ketamine|
223925832|NCT05838924|OTHER|PHYSICAL ACTIVITY|"The 8 therapeutic exercise program will be implemented for 6 weeks at a frequency of 2 sessions per week with the aim of improving pain and disability, kinesiophobia, range of motion (ROM), catastrophizing, quality of life, and physical fitness. This group will perform the 8 exercises of Back School without VR. They will be performed in 2 sets whose intensity and repetitions will be configured and individualized by a self-reported rating of perceived exertion (RPE) through the Borg 6-20 scale. The appropriate training intensity is established with an RPE score between 13 and 17; for this reason, the first 2 weeks will work at an RPE of 14, the 3rd and 4th weeks at an RPE of 15; and finally, the last 2 weeks will work at an RPE of 16. The first 3 weeks will work without additional load, and the last 3 weeks will work with weights, increasing their weekly load individually."
224281774|NCT03585907|DIETARY_SUPPLEMENT|MAD|A high fat, low carbohydrate diet
224093270|NCT00002586|DRUG|13-cis retinoic acid|
224093271|NCT00002586|DIETARY_SUPPLEMENT|Tocopherol|
224093272|NCT04203914|DRUG|Empagliflozin Tablets|Add-on 25mg once daily
224281775|NCT03585907|DIETARY_SUPPLEMENT|MIND|A combination of the Mediterranean and DASH diets
224281776|NCT00742599|DRUG|NPO-11|20 ml NPO-11
224281777|NCT00742599|DRUG|Placebo|20 ml NPO-11(Placebo)
224281778|NCT03574311|DRUG|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
224281779|NCT03574311|OTHER|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
224281780|NCT02594371|DRUG|Oraxol|
224281781|NCT02594371|DRUG|IV paclitaxel|
224281782|NCT04914624|BEHAVIORAL|ACBT training|Performed 5 days before surgery and one month after surgery, twice a day.
224281783|NCT04914624|DEVICE|acpella®PEP|Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.
224281784|NCT04914624|DEVICE|EDP-type II external diaphragm pacemaker|Use external diaphragm pacemaker to stimulate patients' diaphragms.
224281785|NCT00845234|BEHAVIORAL|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
224281786|NCT01280617|DRUG|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
223532061|NCT02150161|DRUG|Fentanyl|
223532062|NCT03276182|DEVICE|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
223532063|NCT03271866|DRUG|metformin|metformin 1500mg per day
223532064|NCT03386773|BEHAVIORAL|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
223717671|NCT01482000|OTHER|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
223717672|NCT01482000|OTHER|usual care|The control group will get the usual care with some additional tests for the study.
224093273|NCT02676258|DEVICE|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
224281787|NCT01280617|DRUG|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
224281788|NCT06308835|OTHER|questionnaires|BREF(Batterie d'efficience Frontale), SDMT (Symbol Digit Modalities Test), TMT (Trail making test), Empans verbaux et BNT (Boston naming Test)
224281789|NCT05335213|DIAGNOSTIC_TEST|16S rRNA gene sequencing|"DNA extraction and 16S rRNA gene sequencing DNA extraction, 16S rRNA gene amplification, and deep sequencing of the 16S rRNA amplicon performe.~The V4-V5 region of the 16S rRNA gene amplify with barcodes for multiplexing."
224281790|NCT05966090|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).
224281791|NCT05966090|BIOLOGICAL|HZ/su vaccine|Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.
224281792|NCT00692224|DRUG|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
224281793|NCT00692224|DRUG|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
223925833|NCT04794114|DEVICE|experimental ankle foot orthosis|On the basis of an accurate kinetic and kinematic analysis, a customized orthosis in thermoplastic material with carbon inserts will be created that will make the brace more elastic and facilitate the child's motor activities.
223925834|NCT04794114|DEVICE|traditional ankle foot orthosis|The normal afos in thermoplastic material, while guaranteeing an ankle joint stability, make the joint more rigid and reduce the elasticity of movement especially during running, jumping and sprinting.
223532065|NCT03386773|BEHAVIORAL|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
223925835|NCT00349830|PROCEDURE|blood draw|
223925836|NCT05756660|DRUG|Sodium Thiosulfate|This goal of this study is to evaluate the efficacy of the proposed regimens in patients with relapsed/refractory platinum pre-treated patients with Hepatoblastoma, Wilms tumor, Germ Cell Tumor (GCT), and Neuroblastoma. The patients' initial cisplatin response (hepatoblastoma) and diagnosis will determine their treatment regimen on this study.
223925837|NCT05315427|OTHER|one music therapy session|Edmonton Symptom Assessment System (ESAS) scale (before and after music therapy session), Numerical pain scale (before and after music therapy session)
223925838|NCT06035276|OTHER|Exposure to clean air|"Subjects will be exposed to filtered indoor air (clean air) for 4 hours in the Fraunhofer Environmental Exposure Chamber. The chamber can accommodate up to 18 subjects, is ventilated by HEPA-filtered and conditioned air, ensuring a constant humidity (40 ± 10%), temperature (22 ± 2°C), and airflow (1500 ± 100 m3/hr). During exposure they will perform an intermittent bicycle ergometer activity at 50 W for 10 minutes alternating with 20 minutes rest."
223925839|NCT06035276|OTHER|Exposure to urban air|"Subjects will be brought to a traffic dense urban region (urban air) with high traffic density and increased levels of particulate matter and vehicle emissions. Subjects will stay in this area for 4 hours. During exposure, all subjects will walk together with study staff. Rest periods are only allowed outside. Intervals of activity and rest will be similar to the clean air regimen."
223925840|NCT06737016|DRUG|Tamsulosin|Children will be maintained on an oral dose of Tamsulosin 0.1 mg once daily (in children aged less than 2 years old) and 0.2 mg once daily (≥2 years old).
223925841|NCT06737016|DRUG|Oxybutynin|Children will be maintained on an oral dose of Oxybutynin 0.2 mg/kg 2 times daily.
223925842|NCT06737016|DRUG|Trimethoprim/sulfamethoxazole (TMP/SMZ)|Children will be maintained on an oral prophylactic dose of Trimethoprim/sulfamethoxazole 2 mg/kg single dose at night.
223925843|NCT06762782|DRUG|Postoperative adjuvant lenvatinib|Follow the instructions and take lenvatinib 8 mg (body weight ≤ 60Kg) or 12 mg (body weight ≥ 60Kg) orally once a day.
223925844|NCT06762782|OTHER|Supportive care measures|Adjuvant treatments such as antiviral, TACE, HAIC, radiotherapy, and systemic antitumor therapy can be used
224093274|NCT02676258|DEVICE|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
224093275|NCT03217851|DIAGNOSTIC_TEST|Blood Collection|blood smear and/or rapid diagnostic
224093276|NCT03217851|DIAGNOSTIC_TEST|Dried Blood Spot|Dried Blood Spot on filter paper
223532066|NCT03274778|DRUG|Ruxolitinib 20 MG|tablets
223532067|NCT03639610|DRUG|Melflufen|Melflufen was distributed in the European Union (EU) as a powder for concentrate for solution for infusion; in the US, it was distributed as a powder for injection. Melflufen was administered as a 30-minute intravenous infusion on Day 1 of every 28-day cycle via a central catheter.
223925845|NCT06756893|PROCEDURE|Dorsal Root Ganglion Pulsed Radiofrequency|"Using C-arm fluoroscopy, a 22G, 10 cm RF needle with a 5 mm active tip will be directed from lateral to medial towards the vertebral foramen. Once the needle reaches the lateral edge of the pedicle shadow, the C-arm will be adjusted to a lateral view to confirm that the needle is located at the craniodorsal portion of the intervertebral foramen. Sensory stimulation will be delivered through the RF generator at 50 Hz, and paresthesia will be sought in the corresponding dermatome at values between 0.4-0.8 mA.~After achieving paresthesia, motor stimulation at 2 Hz will be applied, and the location near the DRG will be confirmed if motor stimulation is not elicited at values less than 1.5 times the sensory threshold. Pulsed RF will then be applied for 4 minutes at a setting of 45 V, 20 ms pulse width, and 2 Hz frequency. Following the application, needle will be directed slightly anterior and after appropriate contrast flow, dexamethasone will be injected."
223925846|NCT07040046|DRUG|HS-10542|"1. SAD：HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1.~2. Food Effect \[FE\] study：HS-10542 capsule (in one predefined dose cohort ) will be administered orally once on Day 15."
223925847|NCT07040046|DRUG|HS-10542 Placebo|SAD：HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1
223925848|NCT07040046|DRUG|HS-10542|MAD：HS-10542 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.
224093277|NCT00093236|PROCEDURE|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
224093278|NCT00093236|PROCEDURE|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
224093279|NCT01976949|BEHAVIORAL|online social-networking intervention|
224093280|NCT00826514|DRUG|Tanezumab|Intravenous, 20 mg, single dose.
224093281|NCT00826514|DRUG|Placebo|Intravenous placebo, single dose
224281794|NCT00512837|BEHAVIORAL|Mobile phone technology|
224281795|NCT06685159|PROCEDURE|Laparoscopic Surgery|Laparoscopic surgery (with controlled pneumoperitoneum) in the Trendelenburg position
223532068|NCT03639610|DRUG|Dexamethasone|Tablets. Administered orally on Days 1, 8, 15, and 22 of each 28-day cycle. Dose of 40 mg for patients aged \<75 years. Dose of 20 mg for patients aged ≥75 years.
223532069|NCT04328389|BEHAVIORAL|electric toothbrush|Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
223925849|NCT07040046|DRUG|HS-10542 Placebo|MAD：HS-10542 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 10.
223532070|NCT04328389|PROCEDURE|Professional oral hygiene|Professional oral hygiene using ultrosound scaling and root planing
223532071|NCT03136055|DRUG|Pembrolizumab|Given Intravenously (IV)
223532072|NCT03136055|DRUG|Irinotecan|Given IV
223532073|NCT03136055|DRUG|Paclitaxel|Given IV
223532074|NCT01115504|DRUG|Thiamine|300 mg daily for 30 days
223532075|NCT04115462|DRUG|Morphine|A 20 mg tablet of morphine
223532076|NCT04115462|DRUG|Placebo oral tablet|Matching tablet of placebo
223925850|NCT06736080|DRUG|MUNC-CD34|"* Dosage: ≥ 2 x10e6 CD34/kg after thawing, dose limit: 20x10e6 CD34+ cells/kg~* Route of administration: intravenous, on D0"
223532077|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
223925851|NCT06736080|DRUG|MUNC-T3|"* Dosage: \[1.10e4; 5.10e6\] T-CD3+/kg after thawing,~* Route of administration: intravenous, on D14 post-GT +/- D28 In case of persistent circulating T-cell after the HLH remission at inclusion, the MUNC-CD34 will be completed by MUNC-T3 infusion"
223925852|NCT06673290|DRUG|Sirolimus (RAPAMUNE)|Use of different doses of the same drug
223925853|NCT06922669|DRUG|Methylprednisolone|Initially, an intravenous dose of 1 mg/kg/day of methylprednisolone will be administered for one week, with the possibility of extending treatment to two weeks if necessary. Following this, participants will receive oral methylprednisolone tablets, starting at a dose of 40 mg/day. The oral dosage will be gradually tapered based on the participants' condition over a period of 1 to 3 months.
223925854|NCT06922669|DRUG|Magnesium isoglycyrrhizinate|It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 0.15g to 0.2g
223925855|NCT06922669|DRUG|Glutathione|It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 1.2g to 1.8g
223925856|NCT06922669|DRUG|Silymarin|It is suitable for patients with hepatocellular or mixed DILI. The dosage is 140 mg, taken 2 to 3 times per day.
223925857|NCT06922669|DRUG|Polyene Phosphatidylcholine|It is suitable for patients with hepatocellular or mixed DILI. The dosage is 228mg-456mg, taken 3 times per day.
223925858|NCT06922669|DRUG|Ursodeoxycholic acid capsules|It is suitable for patients with cholestatic or mixed DILI. A daily dose of 10mg-15mg/kg/day.
223925859|NCT06922669|DRUG|Ademetionine 1,4-Butanedisulfonate|It is suitable for patients with cholestatic or mixed DILI. A daily dose of 0.5g to 1g.
223925860|NCT06922669|PROCEDURE|Plaslna exchange|It is suitable for patients whose condition continues to worsen or even develop to liver failure.
223925861|NCT06922669|PROCEDURE|Liver transplantation|It is suitable for patients whose condition continues to worsen or even develop to liver failure.
223925862|NCT06922812|DEVICE|Intermittent White Light Stimulation (IWLS)|A wearable device developed by SyntropicMedical (Austria) delivers intermittent white light at 60 Hz using LED strips embedded in safety goggles. The light is diffused (approximately 700 lux) and projected tangentially to the participant's eyes. Participants will undergo 10 daily sessions (30 minutes each) over a two-week period. The intervention aims to evaluate the safety, tolerability, and potential antidepressant effects of 60 Hz visual stimulation in individuals with moderate to severe Major Depressive Disorder.
223925863|NCT06855927|OTHER|Guided Imagery|Guided imagery is a potential healing technique that aims to help individuals mentally visualize positive physical and psychological states.
223925864|NCT06939088|DRUG|Tirzepatide|Once weekly injections s.c. with tirzepatide (Mounjaro(R))
223925865|NCT06939088|DRUG|Placebo|Once weekly injections s.c. with placebo (BD Posiflush)
223925866|NCT06946654|PROCEDURE|Geriatric Assessment|This is a study held in all patients undergoing allogenic hematopoietic stem cell transplantation. Pre-transplant assessment: (1)Patients-related assessment: (a) Age; (b) Functional status (BADL score; IADL score; KPS score; ECOG PS score); (c) Comorbidities (HCT-CI score); (d) Nutritional Status (Body weight; BMI; NRS-2002; MNA-SF; MUST); (e) Psychological Status (SF36-MCS; GDS; PHQ-9; GAD-7); (f) Cognitive Function (MMSE; BMOC); (g) Social Support Level (MOS-SSS; MSPSS); (h) Total Number of Medications Used. (2) Disease-Related Factors Assessment: Primary Disease Diagnosis; ELN Risk Stratification (assessed only for AML patients); Disease Status. (3) Donor-Related Factors Assessment: Donor Age; Donor Sex; Donor-Recipient Blood Type Compatibility; Donor Type; DSA. (4) Treatment-Related Factors Assessment: Conditioning Regimen; GVHD Prophylaxis Regimen; Graft Type.
224281796|NCT05640336|PROCEDURE|Single Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint. The polyethylene (plastic) insert, which acts as the articulating surface (modular component) of the prosthesis, will be removed and the exposed surfaces scrubbed, sterilized, and soaked. A new modular component will be placed with additional irrigation and antiseptic soak. Tissue cultures will be sent to the lab for further evaluation and antibiotic guidance. After the operation subjects will continue six weeks of IV antibiotics followed by oral antibiotic suppression for the life of the implant or at least two years after operation.
223925867|NCT02911064|BEHAVIORAL|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
223925868|NCT06562673|DRUG|intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)|After insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under local anesthesia, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
223925869|NCT05006989|OTHER|Blueberry Powder|Administered one packet per day (10 grams/packet) and participants consume up to 10 grams per day.
223925870|NCT05006989|OTHER|Placebo Powder|Administered one packet per day (10 grams/packet) and participants consume up to 10 grams per day.
223925871|NCT05576207|DIETARY_SUPPLEMENT|Balanced energy and protein supplement for pregnant women|A fortified balanced energy and protein supplement providing both macro and micronutrients recommended for use during pregnancy in undernourished contexts.
223925872|NCT05576207|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement for pregnant women|"Prenatal supplements containing vitamins and minerals - also called multiple micronutrient supplements will be used in the control group."
223925873|NCT03779984|DEVICE|Red Rubber Catheter|Experimental group will be intubated with red rubber catheter guidance
223925874|NCT03779984|DEVICE|Standard nasal tracheal Intubation|Control group will be intubated with standard nasal tracheal tube without guidance
223925875|NCT06791577|DRUG|Carboxytherapy|Application of the intervention (CO2 Lift) in the area according to the protocol schedule
223925876|NCT06791577|OTHER|Placebo|Application of the placebo (Vaseline) in the area according to the protocol schedule
223925877|NCT06797180|DEVICE|Virtual Reality Education for Dementia Caregivers|This group will receive 100 minutes of BPSD foundational education followed by 100 minutes of VR-based training focused on managing BPSD.
223925878|NCT04300127|DRUG|Pioglitazone 30 mg|Patients will received 30 mg of Pioglitazone once a day for 8 weeks
223925879|NCT02932618|BIOLOGICAL|Vonicog alfa|Lyophilized powder and solvent to prepare solution for injection.
223925880|NCT02932618|BIOLOGICAL|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
223925881|NCT06224439|PROCEDURE|hypobaric spinal anaesthesia|0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
223925882|NCT06224439|PROCEDURE|lumbar plexus block|ultrasound and nerve stimulator will be used for lumbar plexus block
223925883|NCT06224439|PROCEDURE|hyperbaric spinal anesthesia|0.5% hyperbaric Bupivacain hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.
223925884|NCT05880004|BEHAVIORAL|Support Application for Food PAntrieS (SAFPAS) - A mobile app that helps food pantries recruit, train and schedule volunteers, offer choice safely, and provides multilevel communications|The primary intervention is a mobile application (app) which supports food pantries to recruit, train and schedule volunteers; provide a safe, remote form of client choice; and provides a means of sharing real-time status information with clients, pantries, food banks, and emergency operation centers. Following formative work, user centered design, and usability testing, the SAFPAS app will be implemented in three stages, where each stage introduces new features. Pantry clients will be encouraged to download the app and learn its key features at the end of baseline data collection. During the first weeks of each stage, training of participating food pantry directors/staff and Maryland Food Bank (MFB) staff will take place - focusing on use of any new features. Initial training will be follow up by proficiency testing.
223925885|NCT03705793|DRUG|Mometasone Furoate Nasal Irrigation|Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.
223925886|NCT03705793|DRUG|Mometasone Nasal Spray|Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
223532078|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
223532079|NCT04115462|DRUG|isotonic saline|A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
223925887|NCT02719574|DRUG|FT-2102 (olutasidenib)|FT-2102 (olutasidenib) will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
223925888|NCT02719574|DRUG|Azacitidine|azacitidine will be administered per site's standard of care
223925889|NCT02719574|DRUG|Cytarabine|low-dose cytarabine will be administered per site's standard of care
223925890|NCT01443260|BIOLOGICAL|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
223925891|NCT03027128|BIOLOGICAL|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
223925892|NCT06465420|BIOLOGICAL|Haemophilus influenzae type a (Hia) glycoconjugate vaccine|0.5 mL intramuscular injection, given on days 0 and 28
223925893|NCT02720068|BIOLOGICAL|Favezelimab|IV infusion
223925894|NCT02720068|BIOLOGICAL|Pembrolizumab|IV infusion
223532080|NCT04115462|DRUG|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the mandibular area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
223925895|NCT02720068|DRUG|Oxaliplatin|IV infusion
223925896|NCT02720068|DRUG|Irinotecan|IV infusion
223925897|NCT02720068|DRUG|Leucovorin (Calcium Folinate)|IV infusion
223925898|NCT02720068|DRUG|Fluorouracil [5-FU]|IV infusion
223925899|NCT02720068|BIOLOGICAL|Favezelimab/Pembrolizumab|IV infusion
224281797|NCT05640336|PROCEDURE|Planned Double Debridement, Antibiotics and Implant Retention|Surgical debridement and wash out of infected joint with an additional irrigation and debridement scheduled for approximately 5 days after the initial DAIR. During the first washout, antibiotic cement beads will be placed in the joint and these will remain in the interim until they are removed during the second washout. During the second DAIR, the antibiotic beads are removed, and the modular components are once again removed and replaced with new components. Exposed surfaces are again irrigated and debrided following a standardized protocol. A six-week course of IV antibiotics will follow the DAIR with additional oral antibiotics for the life of the component (standard of care) or at least a minimum of two years.
224281798|NCT00111462|DRUG|Darbepoetin alfa|
224281799|NCT04232657|DRUG|Romosozumab|39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.
223925900|NCT02720068|DRUG|Lenvatinib|Oral
223925901|NCT06284876|DRUG|Ilaprazole|Ilaprazole 10 mg
223925902|NCT06284876|DRUG|Lansoprazole|Lansoprazole 15 mg
223925903|NCT06284876|DRUG|Ilaprazole Placebo|Placebo of Ilaprazole 10 mg
223925904|NCT06284876|DRUG|Lansoprazole Placebo|Placebo of Lansoprazole 15 mg
223925905|NCT06165380|DRUG|Cardenilimab Combined With Chemotherapy|Cardenilimab Combined With Chemotherapy
223925906|NCT04801797|DRUG|Cytarabine|Intravenous infusion
223925907|NCT04801797|DRUG|Idarubicin|Intravenous infusion
223925908|NCT04801797|DRUG|Daunorubicin|Intravenous infusion
223925909|NCT04801797|DRUG|Liposomal daunorubicin and cytarabine|Intravenous infusion
223925910|NCT04801797|DRUG|Venetoclax|Orally by mouth
223925911|NCT04801797|DRUG|Azacitidine|Intravenous infusion
223925912|NCT05282043|OTHER|Evaluation of Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults|Participants' upper extremity and lower extremity muscle strength, 6-minute walking distance, O2 saturation, posture evaluation, spirometric evaluation, pain threshold, pain intensity, dyspnea, and leg fatigue measurements will be recorded. In addition to these measurements, general fatigue, quality of life, depression, physical activity level, sleep quality parameters will be evaluated and the data obtained will be analyzed with appropriate statistical methods.
223925913|NCT04115007|RADIATION|Stereotactic Body Radiotherapy (SBRT) + Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used."
223925914|NCT04115007|DRUG|Standard of care|"Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel)."
223532081|NCT04115462|DRUG|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
223925915|NCT03094052|DRUG|Neratinib|Given orally (PO)
223925916|NCT03094052|BIOLOGICAL|Trastuzumab|Given Intravenously (IV)
223925917|NCT03094052|DRUG|Loperamide|Given PO
223925918|NCT03094052|DRUG|Crofelemer|Given PO
223925919|NCT03094052|DRUG|Diphenoxylate/Atropine|Allowed for participants experiencing refractory diarrhea
223925920|NCT05567068|DRUG|Atorvastatin 80mg|Atrovastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement and immunomodulation independent of its basic lipid-lowering properties
223925921|NCT05567068|DRUG|Mesalamine|Mesalamine
223925922|NCT05441280|DRUG|pimavanserin|pimavanserin 34mg PO at bedtime
223925923|NCT05441280|OTHER|Placebo|The placebo is a pill that looks like a study medication but has no medication in it
223925924|NCT05734495|DRUG|Pirtobrutinib|Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
223925925|NCT05734495|DRUG|Venetoclax|Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
223925926|NCT04864652|DEVICE|CHILLS Procedure|CHILLS Cryotherapy procedure
223925927|NCT00113360|DRUG|RAD001|Starting dose of 5 or 10 mg by mouth daily.
223925928|NCT00113360|DRUG|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
223925929|NCT03831178|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
223925930|NCT03831178|DRUG|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
223925931|NCT03844152|DIETARY_SUPPLEMENT|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
223925932|NCT02454283|DRUG|Vanoxerine HCl|
223925933|NCT02454283|DRUG|Placebo|
223925934|NCT04221503|DRUG|Niraparib|Niraparib (\[3S\]-3-\[4-{7-(aminocarbonyl)-2H-indazol-2-yl} phenyl\] piperidine \[tosylate monohydrate salt\]) is an orally available, potent, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) -1 and -2 inhibitor. The niraparib drug product is provided as 100-mg capsules filled with a dry blend of niraparib tosylate monohydrate, lactose monohydrate, and magnesium stearate in a hard gelatin capsule.
224093282|NCT06327230|PROCEDURE|Thoracic Epidural Analgesia|Thoracic epidural analgesia is performed by a standardized anesthesia team. Patients are positioned in the lateral decubitus position, and routine disinfection is performed. The puncture site is selected at the T7-T9 level. When encountering sudden disappearance of resistance and appearance of negative pressure during needle advancement, it is determined that the needle has entered the epidural space. After confirming needle tip placement in the epidural space with a test dose, an epidural catheter is inserted approximately 3-5cm cephalad and securely fixed in place. The test dose consists of 3 mL of 1% lidocaine injection solution, administered to observe the level of anesthesia, confirming the effectiveness and safety of the epidural anesthesia. Subsequently, a maintenance regimen of 0.15% ropivacaine 250mL with 2.5mg of hydroma.
224093283|NCT03245879|BEHAVIORAL|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for \>48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
224281800|NCT04232657|DRUG|Denosumab|Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
223925935|NCT04221503|DEVICE|Optune|"Optune, which is manufactured by Novocure, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells."
223925936|NCT04221503|PROCEDURE|Planned surgical resection|Surgery of supratentorial glioblastoma (GBM).
224093284|NCT03245879|BEHAVIORAL|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
223925937|NCT04310449|PROCEDURE|Connective tissue graft and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Connective tissue grafts from the hard palate will be placed at the implant sites in a supraperiosteal partial dissection prepared at the buccal aspect. Sutures will be used to stabilize the graft, followed by customized healing abutment. Flowable composite will be injected at the gingival margin level to adapt to the sandblasted abutment, taking the shape of the socket at the marginal gingiva. Buccal groove will be made after the polymerization of this material for easier application. The abutments will be removed for final configurations of the apical part mimicking the emergence profile of the extracted tooth and finishing with laboratory discs and burs. The custom healing screw will be screwed to the implant.
223925938|NCT04310449|PROCEDURE|Dual zone concept and customized healing abutment|Immediate implant placement without flap raising using standard implant system protocol preparation will take place. Followed by bone grafting following dual zone concept and customized healing abutment.
223925939|NCT00124735|DRUG|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
223925940|NCT00124735|DRUG|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
223925941|NCT04910438|OTHER|STIs screening and care|"* Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).~* Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM."
223925942|NCT00630487|DRUG|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
224093285|NCT03245879|BEHAVIORAL|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
224093286|NCT00673595|DRUG|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
224093287|NCT00673595|DRUG|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
224093288|NCT02318056|OTHER|Aquacel® Ag Burn Glove|burn dressing
224093289|NCT02318056|OTHER|Mepilex® Transfer Ag|burn dressing
224093290|NCT02318056|DRUG|antibiotic|antibiotic burn dressing
224093291|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
224093292|NCT01527721|PROCEDURE|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
224093293|NCT00135980|BEHAVIORAL|professional audit and feedback|
224093294|NCT00135980|BEHAVIORAL|integrated care programmes|
224093295|NCT03262376|DIETARY_SUPPLEMENT|Minerals + Vitamins|A mineral and vitamin tablet
224093296|NCT03262376|DIETARY_SUPPLEMENT|Botanical A|Botanical extract administered in capsule form
224093297|NCT03262376|DIETARY_SUPPLEMENT|Botanical B|Botanical extract administered in capsule form
224093298|NCT03262376|OTHER|Placebo|Cellulose crystalline tablet
224093299|NCT03663166|RADIATION|Thoracic Radiotherapy|2 Gy in 30 fractions directed at all sites of suspected disease
224093300|NCT03663166|DRUG|Platinum Based Chemotherapy|Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).
224093301|NCT03663166|DRUG|ipilimumab|ipilimumab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy
224281801|NCT04232657|DRUG|Placebo|Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
224281802|NCT06676449|DRUG|Immunotherapy|PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.
224281803|NCT06676449|DRUG|chemotherapy: Paclitaxel/Cisplatin|Paclitaxel 135mg/m2 d1, cisplatin 25mg/m2 d1-3, once every 3 weeks for 4 cycles.
223925943|NCT00630487|DRUG|Somatropin|Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
223925944|NCT03958019|OTHER|RESTORE II Program|Detailed in arm description
223925945|NCT04967118|BEHAVIORAL|Skin-to-skin contact|Diaper clad baby will be placed ventral position on bare chest of mother 30 minute prior to the heel lance
223925946|NCT04967118|BEHAVIORAL|Mother's heartbeats as sound and vibration|The mother's heartbeat will be recorded and the heartbeat sounds will be saved to the platform. The platform will be placed under the infant's mattress and the heartbeat will be started 30 minute prior to the heel lance.
223925947|NCT04967118|DRUG|30% oral glucose|The infant will be given 30% oral glucose solution 2 minutes before the injection
223925948|NCT04861558|DRUG|5Fluorouracil|Injection of 250-850 mg/m2.
223925949|NCT04861558|DRUG|Irinotecan|Injection of 360 mg/m2
223925950|NCT04861558|DRUG|Oxaliplatin|Injection of 460 mg/m2
223925951|NCT01308684|DRUG|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
223925952|NCT01308684|DRUG|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
223925953|NCT02467270|DRUG|Ponatinib|Tablet, taken orally once daily.
223925954|NCT06752109|OTHER|Antipronation Taping|Before applying the tape, its length was measured by passing it over the areas on the foot where it would be applied. The tape was first attached to the medial side of the big toe, with tension in the direction of flexion and abduction of the toe. The ankle was then positioned in full plantar flexion. The tape was applied from the medial side of the foot towards the heel, wrapping around it, and then directed towards the sole. While the foot was in an inversion position at the navicular level, the tape was applied with maximum tension from medial to lateral and brought back to the sole. The remainder of the tape, with maximum tension, was applied from the sole to the dorsal side of the ankle, ending without tension at the proximal and lateral side of the leg. A second strip of tape, with maximum tension, was applied to support the medial longitudinal arch. The ends of the tape were placed over the malleoli without tension, aiming to reduce excessive pronation.
223925955|NCT06752109|OTHER|Sham|In the sham taping application, the length of the tape was measured by passing it over the areas where it would be applied. The tape was applied to the medial side of the big toe, but without tension, simply placed. Then, the tape was directed towards the sole of the foot, passing over the heel. At the navicular level, the tape was applied from medial to lateral, returning to the sole without tension. A second strip of tape was applied to the sole without tension. The ends of the tape were placed over the malleoli without stretching. Since no tension was applied, this application was only placed and has a limited effect on reducing excessive pronation.
224093302|NCT03663166|DRUG|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
224093303|NCT05957887|DRUG|Dapagliflozin|Assess the efficacy of Dapagliflozin on cardiac function and LV remodeling in acute ST elevation anterior myocardial infarction patients
224093304|NCT00643240|RADIATION|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
224093305|NCT00643240|RADIATION|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
224093306|NCT01666223|DRUG|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
224093307|NCT01666223|DRUG|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
224093308|NCT01666223|OTHER|saline|100 ml saline
224281804|NCT06676449|RADIATION|TDLN-sparing RT|TDLN-sparing radiotherapy 50.4Gy/28Fx.
224093309|NCT01666223|DRUG|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
224093310|NCT02148367|DRUG|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
224093311|NCT03859284|OTHER|flowable resin composite|gold standard
224093312|NCT03859284|OTHER|self adhering flowable|moist bonding self adhering flowable composite
224093313|NCT03859284|OTHER|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
224281805|NCT05872334|DEVICE|Monofix|a new absorbable barbed suture device
224281806|NCT04473716|DRUG|Toripalimab|Neoadjuvant therapy with Toripalimab of 240mg, iv, qd, on day 1, 22
224281807|NCT04473716|DRUG|Paclitaxcel|Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22
224281808|NCT04473716|DRUG|Cisplatin|Neoadjuvant therapy with Cisplatin of 75mg/m2, iv, qd, on day 1, 22
224281809|NCT04473716|PROCEDURE|Radical surgery|Radical surgery will be performed on the 43th-48th after initiation of inductive therapy.
224281810|NCT04473716|RADIATION|Post-operative radiotherapy/chemoradiotherapy|Post-operative radiotherapy/chemoradiotherapy will be performed within 1.5 months after radical surgery, depending on the post-operative pathological diagnosis.
223925956|NCT06441487|BEHAVIORAL|Mobile Health Decision Support|Subjects randomized to this arm receive a link to a mobile health decision support tool (mPATH™- Cloud). Within mPATH™-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who select FIT, as well as subjects who do not click on the link or select a screening test receive a FIT mailed to their home address.
223925957|NCT06441487|BEHAVIORAL|Usual care|The study team will send subjects a prompt to visit the mobile health decision support tool (mPATH™-Cloud). Subjects with a mobile phone (as determined by their electronic health record) will receive a link to mPATH-Cloud by text. Subjects with a mailing address, but no mobile phone number in the EHR, will receive a letter inviting them to access mPATH-Cloud via URL code. Within mPATH-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who do not click on the link or select a screening test receive a FIT.
223925958|NCT01086163|DRUG|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
223925959|NCT00327561|PROCEDURE|Intensive periodontal therapy|
223925960|NCT00327561|PROCEDURE|Community based periodontal therapy|
223925961|NCT00739908|DRUG|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
223925962|NCT00739908|DRUG|Placebo|Six capsules administered three times a day for six weeks.
223925963|NCT02261506|OTHER|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
223925964|NCT02261506|OTHER|14 days of adequate antibiotic treatment durations|
223925965|NCT01440933|DRUG|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
223925966|NCT01440933|DRUG|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
223925967|NCT01334489|DEVICE|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
223925968|NCT05088421|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days."
223925969|NCT05088421|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
223925970|NCT02972788|DRUG|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
223925971|NCT02972788|OTHER|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
223925972|NCT04921488|DEVICE|screening colonoscopy|The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
223925973|NCT03311516|OTHER|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
223925974|NCT03311516|OTHER|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
223925975|NCT03890848|BEHAVIORAL|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
223532082|NCT02410772|DRUG|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
223925976|NCT03890848|BEHAVIORAL|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
224093314|NCT06156527|DRUG|Lazertinib|Lazertinib 240mg, QD, daily
224093315|NCT06156527|DRUG|Bevacizumab Injectable Product|Bevacizumab: 15mg/kg IV every 3 weeks
224093316|NCT01916278|DEVICE|Emervel Lips Lidocaine|
224093317|NCT01916278|DEVICE|Juvéderma Volbella with Lidocaine|
224281811|NCT02079675|DRUG|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
224281812|NCT02079675|DRUG|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
223532083|NCT02410772|DRUG|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
223532084|NCT02410772|DRUG|control|standard six-month treatment
223925977|NCT06403995|BEHAVIORAL|Self-referred, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
223925978|NCT06403995|BEHAVIORAL|Recommended, undirected Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
223925979|NCT06403995|BEHAVIORAL|Recommended, directed Internet-based cognitive behavioral therapy for social anxiety|The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
223925980|NCT06539715|DIAGNOSTIC_TEST|Visual field assessment|Automated perimetry
223925981|NCT00047190|DRUG|tipifarnib|Given PO
223925982|NCT00047190|OTHER|laboratory biomarker analysis|Correlative studies
223925983|NCT06274775|OTHER|Educational Video|Educational video about the nail biopsy procedure
223925984|NCT03426800|OTHER|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
223925985|NCT04852315|DIETARY_SUPPLEMENT|Caffeine|Gelatine capsule with caffeine (3 mg/kg body mass of caffeine) (Bulk Powders, London, United Kingdom). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
223925986|NCT04852315|DIETARY_SUPPLEMENT|Placebo|Gelatine capsule with placebo (Cellulose; Guinama, Valencia, Spain). The capsule containing the treatment was ingested with 150 mL of water 60 minutes before the onset of the experiment to allow substance absorption.
223925987|NCT01894074|BEHAVIORAL|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
223925988|NCT01894074|BEHAVIORAL|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
223925989|NCT03479411|DRUG|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
223925990|NCT03479411|DRUG|Itraconazole 200 mg|Sporanox® Oral Solution
223925991|NCT02988193|DEVICE|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
223925992|NCT02299349|DRUG|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
223925993|NCT02299349|DRUG|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
223925994|NCT00787969|BIOLOGICAL|rituximab|Give IV
224093318|NCT04485455|DEVICE|iTBS Device/Motor Threshold Coil|Motor Threshold determination, done prior to starting treatments, determines the location and the intensity for the iTBS treatments. A magnetic field is applied with increasing intensity stimulating the motor region of the brain until there is thumb movement; this indicates the intensity of the treatments; the location for treatment is in the sensory area parallel to this location.
224093319|NCT04485455|DEVICE|iTBS Device/Treatment Coil|iTBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz very quickly). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatments lasts approximately 3 minutes, and sessions are provided 20 times (Monday-Friday for 4 consecutive weeks).
223532085|NCT05067335|DRUG|Romosozumab|Subjects will receive romosozumab in a specified sequence during the treatment Period.
223532086|NCT05067335|DRUG|Placebo|Subjects will receive Placebo in a specified sequence during the treatment Period.
223925995|NCT00787969|DRUG|cladribine|Give IV
223925996|NCT00787969|DRUG|temsirolimus|Give IV
223925997|NCT00787969|BIOLOGICAL|Filgrastim|Give SC
223925998|NCT00787969|BIOLOGICAL|Pegfilgrastim|
224093320|NCT03244358|DRUG|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
224093321|NCT01110187|DRUG|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
223717673|NCT02688205|OTHER|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
223925999|NCT04304768|BIOLOGICAL|Fluzone Quadrivalent|0.5 ml prefilled syringe administrated intramuscularly
223926000|NCT06199635|DEVICE|Self-Forming Magnetic Anastomosis Device and Delivery System|Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis
223926001|NCT04416412|OTHER|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
223926002|NCT04755439|PROCEDURE|DHCA|DHCA THE USE OF SEREBRAL PROTECTİON TECHNİQUE
223926003|NCT05494762|DRUG|BGB-B167|Intravenous administration
223926004|NCT05494762|DRUG|Tislelizumab|Intravenous administration
223926005|NCT03443999|DEVICE|Supraflex Family Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex Family sirolimus-eluting stent as a part of planned clinical care
223926006|NCT01864538|DRUG|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
223926007|NCT05184088|DRUG|[18F]florbetaben|All enrolled patients will undergo \[18F\]florbetaben PET imaging.
223926008|NCT04227899|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
223926009|NCT04227899|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
223926010|NCT05038215|BEHAVIORAL|adherence promotion techniques|The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.
223926011|NCT05038215|PROCEDURE|Routine Care|The control group will receive routine care
223926012|NCT06837805|OTHER|Iowa Produce Prescription Program (I-PPP)|The I-PPP intervention offers a produce prescription in the form of $30.00 per family member in a household every month to spend on fruit and vegetables. The dollars can be used at local retail partners, which are specific to each community. A mobile app has been developed for the I-PPP intervention participants. At the beginning of each month for six months, the app asks participants to complete a nutrition education module and a corresponding short quiz. After the participant completes the module, $30.00 per family member in the house will be loaded into the app for participants to use over the next month at local retail partners to buy fresh fruits and vegetables. Participants will have 30 days from the date of distribution to spend the funds before they expire.
223926013|NCT06837805|BEHAVIORAL|Produce Your Path Behavioral Nutrition Intervention (PYP)|The PYP Intervention is a six-month virtual behavioral intervention grounded in Self Determination Theory. The intervention aims to improve participants' competence, autonomy, and sense of relatedness through educational videos, recipes, and supplemental resources. Each monthly module contains several short videos, totaling around 15 minutes in length. The module topics include goal-setting, planning meals, preparing fruits and vegetables, reading nutrition labels, budgeting for healthier eating, and making healthier food swaps. The videos are tailored to represent a variety of cultures, ethnicities, and backgrounds, with diverse actors and recipes. Upon completion of each monthly module, a short quiz is administered to participants to measure self-efficacy related to the topic and prompt goal-setting. To further increase social support, an optional Facebook Group component allows participants to post questions, share goals and recipes, and answer prompts from the research team.
223926014|NCT06065501|BEHAVIORAL|PACE intervention|"The PACE intervention involves using Line (technological devices) to establish a collaborative group with patients. The researchers will regularly provide reminders to chronic kidney disease patients regarding the importance of nutrition and exercise. They will also provide information on how to adhere to nutritional and exercise regimens, offering praise for consistent performance."
223926015|NCT06065501|BEHAVIORAL|Usual care|Nurses provide routine education and consultation
223926016|NCT04740541|OTHER|Dietary Intakes (Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies)|Reference protein drinks (Scandishake, Solcarb, Beneprotein) and cookies to meet nutritional requirements, 5 levels of threonine intakes
223926017|NCT05889793|DRUG|Emetine Hydrochloride|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
223926018|NCT05889793|DRUG|Placebo|Participant takes a placebo for 10 consecutive days.
223926019|NCT05504135|DIAGNOSTIC_TEST|Pharmacogenomics Testing|To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.
223926020|NCT04697784|DEVICE|TREO Abdominal Stent-Graft System|The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.
223926021|NCT02885714|PROCEDURE|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
224093322|NCT01110187|DRUG|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
224093323|NCT04424563|DEVICE|ventilators|all patients in both groups will be ventilated if shocked and no recordable blood pressure
223926022|NCT02885714|PROCEDURE|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
223532087|NCT05871931|OTHER|Tidal Model-based psychiatric nursing approach|"The intervention group will receive an eight-session Tidal Model-based psychiatric nursing approach. The sessions will take place once a week over an 8-week period. All sessions will be conducted face-to-face.~The content of the interview plan, consisting of a total of 8 interviews, is as follows:~The first interview was 'Meeting and Pretesting', the second interview was 'Creating a Personal Safety Plan, Making a Holistic Assessment', the third interview was 'Recognizing Emotions, Emotion Management and Communication Skills', the fourth interview was 'Coping Skills', and the fifth interview was 'Self Perception', The sixth interview consisted of 'Strengthening Socialisation', the seventh interview consisted of 'Planning for the Future' and the eighth interview consisted of 'Defining the achievements that will accompany him/her in the next voyages of exploration, ending the relationship between the captain and the lifeguard and making a process evaluation'."
223717674|NCT02688205|DEVICE|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
223926023|NCT04430075|DEVICE|Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System|Transcatheter Valve Repair with Edwards PASCAL and PASCAL Precision System
223926024|NCT01046825|DRUG|COPAD|"Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
223926025|NCT01046825|DRUG|COP, COPD M3, CYM|"GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
223926026|NCT01046825|DRUG|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications.~In the event the patient cannot receive G-CSF, Pegfilgrastim can be substituted."
223717675|NCT04592601|PROCEDURE|S.L.I.M.M.S. Procedure|Combined Gastric Bypass with Vertical Sleeve Gastrectomy
223926027|NCT04299113|DRUG|Vinorelbine|Given IV
223926028|NCT04299113|DRUG|Mocetinostat|Given PO
223926029|NCT04353492|BIOLOGICAL|Ofatumumab|Subjects will receive ofatumumab injections in an autoinjector (AI) for subcutaneous administration containing 20 mg ofatumumab (50 mg/ml, 0.4 ml content)
223926030|NCT04617587|BEHAVIORAL|Early Intervention|The early intervention (EI) is delivered during the NICU stay. It is a multisensory intervention which consists in three parts: parental training, massage therapy and visual interaction. The EI is first focused on parental training, according to PremieStart Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior through the identification of infant's behavioral states; adopt principles of graded stimulation; sustain infant's attention and respond to infant's cues; optimize interactions and avoid overwhelming infants through facilitation strategies. The program is held in eight main sessions and one additional post-discharge session. In addition, parents are trained and invited to daily promote preterm baby massage therapy and visual interaction (visual fixation/tracking and visual attention).
223926031|NCT01198431|BEHAVIORAL|Sleep duration|Duration of sleep per night
223926032|NCT03694262|DRUG|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
223926033|NCT03694262|DRUG|Bevacizumab|15mg/kg IV on day 1 of every cycle
223926034|NCT03694262|DRUG|Atezolizumab|1,200mg IV on day 1 of every cycle
223926035|NCT06799052|DEVICE|Transcervical single-balloon catheter|A single-balloon (Foley) catheter will be placed through the cervix and filled to 30cc of water or saline. The balloon will remain in the participant until their procedure, usually 3-4 hours, or earlier if it falls out on its own.
223926036|NCT06799052|DEVICE|Synthetic osmotic dilators|Dilators will be maintained in the cervix between 3-4 hours, during which each dilator rod will swell several times its initial dried diameter.
223926037|NCT00167765|DRUG|Abciximab|
224281813|NCT02079675|DRUG|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
223926038|NCT02574611|DRUG|Neostigmine|
223926039|NCT02574611|DRUG|Glycopyrrolate|
223926040|NCT02574611|OTHER|Saline (Placebo)|
223926041|NCT02574611|DEVICE|High Resolution Colonic Manometry|
224093324|NCT04424563|DRUG|aminocaproic acid|4 gram slowly intravenous infusion over 1 hour and continues slowly intravenous infusion 1 gram/ hour for 8 hours.
224281814|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
224281815|NCT00337428|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
223926042|NCT01773993|DRUG|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
223926043|NCT06136260|OTHER|CommunityRx-Bereavement|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For CRx-B, a Grief Navigator from Missing Pieces will text and/or call the parent after receiving the referral; share information about grief and support resources; learn what resources the parent needs for themselves and their family; send the parent a personalized list of grief and social support community resources called a HealtheRx via text, email, or mail; and plan future text message communications with bidirectional functionality and, if requested, subsequent calls or texts from the Grief Navigator to occur at least 3, 6, and 12 months after the child's death."
223926044|NCT06136260|OTHER|General Bereavement Support Information|"The medical examiner or coroner will refer parents to an organization called Missing Pieces. Missing Pieces does not deliver healthcare services to grieving families; rather, Missing Pieces helps families find grief services in their community.~For GBSI, Missing Pieces sends parents a unidirectional text message providing a link to a webpage with a general list of grief resources (e.g., support groups) and information about grief and bereavement within two weeks of the child's death and again 3, 6, and 12 months after the child's death."
223926045|NCT02332850|BIOLOGICAL|Isatuximab|Given IV
223926046|NCT02332850|DRUG|Carfilzomib|Given IV
223926047|NCT02332850|DRUG|Dexamethasone|Given IV or PO
223926048|NCT02994667|DEVICE|Permanent Pacemaker Placement|
223926049|NCT05010746|DEVICE|Innovalve TMVR system|Innovalve TMVR system
223926050|NCT04664881|DEVICE|SmartHeart Device|A body-worn device that allows an individual to immediately transmit a 12-lead ECG from anywhere and anytime, using a smartphone application to a physician's office, hospital or monitoring center where designated on-call staff interpret the ECG and make recommendations.
223926051|NCT04153994|PROCEDURE|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
223926052|NCT04493476|DRUG|Chinese herbal formula|Chinese herbal formula
223926053|NCT06386419|DRUG|inclisiran|Inclisiran sodium 300 mg SC. Three single doses of inclisiran sodium will be administered to the participants on Day 1, Day 90, and Day 270, respectively
223926054|NCT06102421|DEVICE|BTL-6000 FSWT|Low-energy focused extracorporeal shockwave therapy will be applied 4 times with an interval of 7 days from the BTL-6000 FSWT device with piezoelectric generator. The energy can vary between 0.12-0.20 mJ/mm2 based on the pain toleration, frequency 5 Hz, total number of shocks 2x2000. The application of the first set of shocks will be semi-static at the location of the largest USG defined pathology in the patellar tendon and the second set of shocks will be performed dynamically to the proximal tendon. These parameters were selected in accordance to ISMST guidelines.
223926055|NCT04400071|BEHAVIORAL|Active Music Engagement|Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
223926056|NCT04400071|BEHAVIORAL|Audio Storybooks|Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment. Children with standard risk ALL will receive 4 sessions over 4 weeks. Children with high risk ALL will receive 8 sessions over 8 weeks. Sessions are delivered in a private setting during regularly scheduled clinic appointments. Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
223926057|NCT06014528|DRUG|IN10018|100mg QD orally (PO)
223926058|NCT06014528|DRUG|Placebo of IN10018|100mg QD orally (PO)
223926059|NCT06014528|DRUG|Pegylated Liposomal Doxorubicin|40 mg/m2 once every 4 weeks (Q4W) intravenously (IV)
223926060|NCT06414434|DRUG|BTX-A51|Multi-kinase inhibitor, 1.0 mg, 2.0 mg, and 7.0 mg immediate-release capsules, taken orally per protocol.
223926061|NCT06100939|COMBINATION_PRODUCT|Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment|"Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source"
223926062|NCT06100939|COMBINATION_PRODUCT|Placebo and sham treatment|"Drug: placebo ophthalmic solution~Device: UV-3000 light source"
223926063|NCT05727332|BEHAVIORAL|Single-Sprint Training|A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks
223926064|NCT06647303|BEHAVIORAL|Training on communication framework|Surgeons will receive training on the Better Conversations framework
223926065|NCT06647303|OTHER|Focus Group|Participants will attend a focus group to discuss the survey instruments used in this study which will help with future study design
223926066|NCT06647303|OTHER|Surveys|Participants will complete surveys regarding the surgeon's communication skills
223926067|NCT06495099|OTHER|Russian electrical stimulation|Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)
223926068|NCT06346249|OTHER|Electrical Stimulation Therapy|Ten Electrical Stimulation Therapy sessions lasting 30 minutes were carried out. Analgesic currents of the TENS type, placed in the cervical region.
223926069|NCT06346249|OTHER|Manual Therapy|Manual Therapy consistin of soft tissue mobilization and release techniques over the neck and craniocervical regions. Ten sessions.
223926070|NCT06346249|OTHER|Exercise Therapeutic|The exercise therapeutic program consisting of neck movement control and stretching exercise. Ten sessions.
223926071|NCT04732962|DEVICE|AposHealth|"AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately."
223926072|NCT04732962|PROCEDURE|Total Knee Replacement (TKR)|A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
223926073|NCT02055534|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
223926074|NCT02055534|OTHER|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
223926075|NCT05352022|BEHAVIORAL|Monthly Unconditional Financial Incentive|No requirements will be placed on how or where funds will be spent.
223926076|NCT05352022|BEHAVIORAL|Weekly Food Purchasing Financial Incentive|Incentive for healthy food purchases
223926077|NCT05352022|BEHAVIORAL|Glycemic Control Financial Incentive|Incentive for absolute drop in HbA1c
223926078|NCT05352022|BEHAVIORAL|Diabetes Education|mailed education information
223926079|NCT05110261|DRUG|Nirsevimab|Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.
223926080|NCT05110261|DRUG|Placebo|Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)
223926081|NCT05708534|DRUG|Belatacept|Switching from anticalcineurins to belatacept in a cohort of kidney transplant recipients seropositive for CMV
223926082|NCT04757753|DEVICE|ready-to-use root canal sealer: PA1704|The participant will be treated with the ready-to-use root canal sealer (PA1704) in combination with gutta percha.
223926083|NCT04757753|DEVICE|root canal sealer: BioRoot™ RCS|The participant will be treated with BioRoot™ RCS sealer in combination with gutta percha.
223926084|NCT06965647|BEHAVIORAL|Partner-Conducted Fetal Heart Sound Measurement|Expectant fathers in the intervention group were trained in basic Leopold maneuvers and fetal heart sound measurement using a Doppler device. Under the supervision of a midwife, fathers located the fetus's back, applied gel, and measured the heart sound during prenatal visits at 28-32 and 33-38 weeks of gestation.
223926085|NCT06965270|BEHAVIORAL|Standardized clinical intervention|"This manualized intervention consists of 8 sessions of evidence-based treatments for substance abuse and mental health problems.~Session 1: Introduction, Psychoeducation, Assessment and Safety: Introduces what the patient's clinical assessment suggests about strengths and needs.~Session 2: Relaxation, Mindfulness and cognitive distortions in CBT. Session 3: Getting started in Cognitive Restructuring (CR): thought challenge and action plan.~Session 4: Craving management practice: includes challenging and replacing thoughts that lead to drug and alcohol use.~Session 5: CR practice exercises and motivation: introduction to risk behaviors and triggers for drug and alcohol use. Relapse prevention.~Session 6: Assertiveness and refusal techniques. Session 7: Problem solving, practice and reinforcement: CR skills, relaxation and relapse prevention applied in current circumstances.~Session 8: Care plan and end of program."
224281816|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
223926086|NCT06965270|BEHAVIORAL|Internet/App intervention|"Using an already developed Internet/App platform (MeMind), patients will have access to the same therapeutic components as in the standardized intervention arm, arranged in sessions by modules.~Components will be released weekly and reminded via push notifications. Patients will also receive two counseling calls at weeks 1 and 8 to help with technical issues and review problems with the program modules."
223926087|NCT06965270|BEHAVIORAL|Treatment as usual|Patient will recieve the usual intervention provided by the Health system
223926088|NCT04457843|OTHER|usual medical care|Prospective monitoring of clinical Outcomes and digital collected outcomes via the mobile COPD staus test app.
223926089|NCT00328783|DEVICE|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
223926090|NCT00328783|RADIATION|Radiation Therapy|
223926091|NCT04678752|OTHER|Weight management care path|"* Documentation and data capture built in the Electronic Health Record~* Clinical data support that suggests weight loss approach(es)~* Tracking of weight loss progress and weight loss maintenance during patient visits to guide the patient-clinician conversation~* Diagnosis and billing in EHR automatically adds the diagnosis of overweight or obesity and links the most common weight-related co-morbidities to ensure adequate provider reimbursement~* Evidence-based online training on weight management for clinicians~* Practice quality improvement and training for use of PATHWEIGH for weight-prioritized visits through practice coaches/facilitators~* Consultation support by practice facilitators with implementing PATHWEIGH and by obesity providers for clinicians with creating patient treatment plans"
223926092|NCT04678752|OTHER|Control|"Within primary care the option to select Obesity brief HPI, this is a brief historical intake of a patient's weight - when either they or their clinician decides to have a weight-prioritized visit. It is intended to initiate a discussion regarding potential strategies for weight loss (often eat less, exercise more). The provider has the discretion to augment or add support as they see fit."
223926093|NCT00357682|DRUG|Esomeprazole|20mg per day
223926094|NCT00357682|DRUG|Esomeprazole|80mg per day
223926095|NCT00357682|DRUG|Aspirin|300mg per day
224093325|NCT04424563|DRUG|Novo Seven|200 microgram/kg. If patient still oozing, vital data not stable and/or could not achieve and keep the target Hb (\>10 gm%) another 2 doses of aFVII received
224281817|NCT00337428|BIOLOGICAL|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
223717676|NCT00682162|DEVICE|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, \[22\]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
223926096|NCT04899739|DIAGNOSTIC_TEST|Echoendoscopy|Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
223926097|NCT02514915|RADIATION|Stereotactic Radiosurgery|Radiation therapy
223926098|NCT06966349|DRUG|Systane Complete Preservative-Free|"One drop of Systane Complete Preservative Free will be instilled in each eye.~Higher order aberrations assessed before and after instillation."
223926099|NCT06966349|DEVICE|Senofilcon A|"Daily disposable silicone hydrogel contact lenses indicated for myopia or hyperopia.~Higher order aberrations assessed before and after instillation."
223926100|NCT06966349|DEVICE|Somofilcon A|"Daily disposable silicone hydrogel contact lenses indicated for myopia or hyperopia.~Higher order aberrations assessed before and after instillation."
223926101|NCT06966102|DRUG|Lidocaine group|25ml of lidocaine hydrochloride 2% will be added to 25 ml of standard saline 0.9% solution in a 50ml syringe to be infused via a syringe pump. The resultant concentration will be 10mg/ml. According to the calculated study drug dose, each patient will receive 0.2ml/kg/h
223926102|NCT06966102|DRUG|Magnesium group|a 50ml syringe will be filled with magnesium sulfate solution (100mg/ml) to be infused via a syringe pump. According to the calculated study drug dose, each patient will receive 0.2ml/kg/h
223926103|NCT06966102|DRUG|Control group|a 50ml syringe will be filled with a standard saline 0.9% solution to be infused via a syringe pump. Each patient will receive 0.2ml/kg/h
223926104|NCT03228719|BEHAVIORAL|Standardize PT after TKR with a Physical Activity Intervention|Standardized PT and a physical activity intervention. Participants will be provided a FitbitTM Zip within one week after enrolling in the study. Participants will self-track their steps/day using their FitbitTM Zip. Participants ≤ 3 weeks' post-operative TKR are expected to maintain and not increase steps/day. Beyond 3 weeks after surgery, step goals will be initiated and evaluated on a weekly basis. Progression of weekly steps/day goal will be a joint decision between the participant and physical therapist. As a guide, a 10-20% increase in steps/day until at least 6,000 steps/day is achieved. Each week the physical therapist will review the participant's steps/day goal and if at least 4 of the 7 previous days per week were at or above the prior week's steps/day goal, then next week's steps/day goal will increase. The physical therapist will discuss current steps/day with the participant using the Fitbit TM Zip and set a personalized steps/day goal each week during PT.
224093326|NCT00291720|DRUG|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
224093327|NCT00291720|DRUG|Placebo|matching placebo
224281818|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
224281819|NCT03756883|DRUG|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
224281820|NCT03756883|DRUG|Placebo Inhalation Powder|No active content
224281821|NCT03536182|RADIATION|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
224281822|NCT03536182|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
224281823|NCT06617078|PROCEDURE|long-term oxygen therapy (LTOT)|Usual care with LTOT for 2 weeks
224281824|NCT06617078|PROCEDURE|High Flow Nasal Therapy (HFNT)|High Flow Nasal delivered by myAirvo3 (4 hours minimum and during th 3-minute chair rise test, 30L/min, 34°C, identical O2 flow rate as LTOT) for 2 weeks
224281825|NCT06251895|OTHER|DKA protocol|IV fluids and IV insulin as per guidelines. reference 1-2
224281826|NCT03643367|DRUG|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
224281827|NCT03643367|DRUG|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
224281828|NCT03052114|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
224281829|NCT05894148|DRUG|Genakumab injection|Group 1: 120mg Q4W，group 2: 200mg Q4W
224281830|NCT05894148|DRUG|placebo|The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.
224281831|NCT01889472|DEVICE|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
223926105|NCT03228719|OTHER|Standardized PT after TKR|Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.
223926106|NCT05563649|BEHAVIORAL|Online Guided Self-Help-Family-based Treatment|GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.
223926107|NCT05563649|BEHAVIORAL|FBT via Videoconferencing|15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
223717677|NCT00682162|DEVICE|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
223926108|NCT06461078|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
223926109|NCT04091126|DRUG|Belantamab mafodotin|Selected doses of belantamab mafodotin will be administered as intravenous infusion.
223926110|NCT04091126|DRUG|Bortezomib|Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
223926111|NCT04091126|DRUG|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
224281832|NCT03460158|DRUG|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
224281833|NCT03460158|DRUG|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
224281834|NCT03460158|DRUG|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
224281835|NCT03989011|DIAGNOSTIC_TEST|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celsius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
224281836|NCT03989011|DIAGNOSTIC_TEST|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~* Peripheral pressure parameters~* Central and abdominal aneurysm pressure parameters (derived using a transfer function)~* Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
224281837|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 24 or 48 weeks
224281838|NCT00869661|DRUG|Copegus|1000/1200mg po daily for 48 weeks
224281839|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
224281840|NCT00869661|DRUG|Pegasys|180 micrograms sc weekly for 48 weeks
224281841|NCT00869661|DRUG|RO5024048|1000mg bid for 24 weeks
223926112|NCT04091126|DRUG|Dexamethasone|Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
223926113|NCT01187199|DRUG|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
224281842|NCT00869661|DRUG|RO5024048|500mg bid for 12 weeks
224281843|NCT00869661|DRUG|RO5024048|1000mg bid for 8 weeks
224281844|NCT00869661|DRUG|RO5024048|1000mg bid for 12 weeks
224281845|NCT00529217|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (\~2Tesla) generated briefly (\~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
224281846|NCT00640458|DRUG|Sildenafil 100 mg|
224281847|NCT00640458|DRUG|Placebo|
224281848|NCT05509959|BEHAVIORAL|Women SHINE|Minimum of nine weekly one-on-one peer navigation sessions and 7 weekly psychoeducation support group sessions.
224281849|NCT05509959|BEHAVIORAL|Control|Single group session and access to website
223532088|NCT01071460|DEVICE|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~* Contralateral retrograde common femoral cross-over access or antegrade access~* Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~* Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~* Deployment of an appropriately sized FlexStent® to cover target lesion~* Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~* Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
223532089|NCT05948553|DRUG|Intervention A Fluoxetine Hydrochloride (HCl)|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
223532090|NCT05948553|DRUG|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
223532091|NCT03308357|DIAGNOSTIC_TEST|Drug assays to measure infliximab|See protocol
223532092|NCT05472493|BIOLOGICAL|[18-F]CETO|PET/CT will be performed; Non-contrast CT images will be acquired over the adrenals (slice width, \~3 mm). CETO (\~2.5 MBq/kg; up to 365 MBq +/- 20%) will be administered as a single dose intravenously and dynamic PET images will be acquired from \~0-90 minutes.
223532093|NCT00022438|BIOLOGICAL|aldesleukin|
223532094|NCT00022438|BIOLOGICAL|incomplete Freund's adjuvant|
223532095|NCT00022438|BIOLOGICAL|recombinant tyrosinase-related protein-2|
223532096|NCT00830050|DRUG|Naproxen|500 mg BID 7 days
223532097|NCT00830050|DRUG|Placebo|BID 7 days
223532098|NCT02234362|DRUG|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
224281850|NCT01999894|DRUG|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
224281851|NCT03928535|DEVICE|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
224281852|NCT03928535|DEVICE|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation \[SaO2\] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
224281853|NCT01546519|DRUG|Vismodegib|oral repeating dose of 150 mg once daily
224281854|NCT05236842|DRUG|Sulthiame|oral
224281855|NCT06080659|DIAGNOSTIC_TEST|fMRI|functional MRI
224281856|NCT06080659|DIAGNOSTIC_TEST|CONFMEM|The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
224281857|NCT01140737|DRUG|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
224281858|NCT00779402|OTHER|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
224281859|NCT00779402|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
223926114|NCT01187199|DRUG|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
223926115|NCT01187199|DRUG|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
224281860|NCT04143282|DRUG|Metformin plus chemotherapy|determine the effect of metformin along with standard chemotherapy
224281861|NCT04143282|DRUG|Chemotherapy|standard chemotherapy
224281862|NCT03356106|DEVICE|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
224281863|NCT01281787|DRUG|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
224281864|NCT01281787|DRUG|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
224281865|NCT02741154|DRUG|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
224281866|NCT02741154|DRUG|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
224281867|NCT02741154|DRUG|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
224281868|NCT02741154|DRUG|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
224281869|NCT01226537|DRUG|Taurine|500 mg taurine capsules twice per day for 6 months
224281870|NCT04513860|DRUG|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
223926116|NCT01187199|DRUG|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
223926117|NCT01187199|DRUG|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
223532099|NCT03981276|OTHER|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
223532100|NCT03981276|DIAGNOSTIC_TEST|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
223532101|NCT03913351|BEHAVIORAL|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
223532102|NCT05338138|DEVICE|ultrasound guided central venous catheter insertion|Prospective comparative randomized controlled clinical study.
223532103|NCT03126487|PROCEDURE|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
223532104|NCT00560417|DRUG|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
223532105|NCT00560417|DRUG|Insulin Glargine|Administered subcutaneously once a day at bedtime
223532106|NCT03807089|DEVICE|Conventional Pediatric Colonoscope|
223532107|NCT03807089|DEVICE|Short-Turn Radius Colonoscope|
223532108|NCT02164864|DRUG|Dabigatran Etexilate 110mg|Active treatment
223532109|NCT02164864|DRUG|Warfarin 3mg|Active comparator
223532110|NCT02164864|DRUG|Aspirin|Active comparator
223532111|NCT02164864|DRUG|Dabigatran Etexilate 150mg|Active treatment
223532112|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
223532113|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
223532114|NCT02164864|DRUG|Warfarin 5mg|Active comparator
223532115|NCT02164864|DRUG|Clopidogrel or Ticagrelor|Active comparator
223532116|NCT02164864|DRUG|Warfarin 1mg|Active comparator
224281871|NCT03704974|BEHAVIORAL|Video-Based Parent Training Program|An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
224281872|NCT02559076|BEHAVIORAL|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
224281873|NCT03811132|OTHER|Observation|There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
224281874|NCT01303068|DEVICE|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
224281875|NCT02409186|DRUG|Nimotuzumab|400mg/w，d1, week 1-7
224281876|NCT02409186|RADIATION|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
224281877|NCT02409186|DRUG|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
224281878|NCT02409186|DRUG|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
224281879|NCT02409186|OTHER|placebo|400mg/w，d1, week 1-7
224281880|NCT06227702|OTHER|Fluid management according to Venous Excess Ultrasound (VExUS) Score|Management of furosemide intravenous infusion according to VeXus results
224281881|NCT03920683|OTHER|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
224281882|NCT05290779|PROCEDURE|selective lumbar nerve root injection|selective lumbar nerve root steroid injection for treatment of radicular pain.
224281883|NCT02274948|DRUG|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
224281884|NCT02274948|DRUG|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
224281885|NCT04886557|PROCEDURE|L4-L5 decompression and dynamic instrumentation|All surgeries were performed by a senior surgeon using a traditional midline approach. Stability-preserving lumbar decompression with facet joint undercutting was performed to preserve the facet joints as much as possible. In cases of severe stenosis, a bilateral partial facetectomy (\< 25%) was performed for adequate decompression. Posterior tension of the supra- and inter-spinous ligaments was preserved at the most cranial level. Patients were encouraged to ambulate after drain removal and wear a soft lumbar orthosis for at least 3 months after the operation.
224281886|NCT04611984|PROCEDURE|Piezocision|Piezocisions were performed on the mesial and distal sides of the right maxillary canines. Then canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
224281887|NCT04611984|PROCEDURE|Control|The mesial and distal sides of the left maxillary canines served as controls and canine distalization was performed via closed-coil springs applying 150 g of force by using mini-screws as anchorage.
224281888|NCT00707434|DEVICE|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
224281889|NCT05376618|OTHER|no intervention|no intervention
224281890|NCT05440019|DEVICE|IMAGE CAPTURE SESSION|"The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis."
223532117|NCT03257891|DRUG|Cabazitaxel|Cabazitaxel will be administered every 21 days
223532118|NCT04668833|PROCEDURE|Autologous lymphocyte infusion (ALI)|On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
223532119|NCT06427096|BEHAVIORAL|Multifaceted intervention|"The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by family health instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes education for a healthy lifestyle, free provision of sodium substitute, weight management, physical exercise, BP monitoring, and appropriate antihypertensive treatment for individuals with hypertension."
223532120|NCT02569853|DRUG|DFN-11|
223532121|NCT02569853|OTHER|Placebo|
223926118|NCT03910218|BEHAVIORAL|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
223926119|NCT03910218|BEHAVIORAL|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
223926120|NCT06047132|DIAGNOSTIC_TEST|Salivaru biomarkers|C-reactive protein (CRP), triggering receptor expressed on myeloid cells-1 (TREM-1), interleukin (IL)-1beta, metalloproteinase (MMP)-8, IL-10, IL-6, monocyte chemoattractant protein-1 (MCP-1), Macrophage Inflammatory Protein-1 Alpha (MIP-1), interferon-gamma (IFN-gamma), osteoprotegerine (OPG), Receptor activator of nuclear factor kappa B ligand (RANKL), Tumor Necrosis Factor-Alpha (TNF-alpha)
223926121|NCT06439693|DRUG|Nab-Paclitaxel|Anti-microtubule agent, via intravenous (into the vein) infusion per institutional guidelines.
223926122|NCT06439693|DRUG|Paclitaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
223926123|NCT06439693|DRUG|Docetaxel|Anti-microtubule agent, via intravenous infusion per institutional guidelines.
223926124|NCT06439693|DRUG|Phesgo|Pertuzumab plus trastuzumab plus hyaluronidase-zzxf, 10 or 15mL single-dose vial, via subcutaneous (under the skin) injection per protocol.
223926125|NCT06439693|DRUG|T-DM1|HER2-targeted antibody-drug conjugate, 16 or 100 mg single-use vials, via intravenous infusion per institutional guidelines.
223926126|NCT06439693|DRUG|Pertuzumab|Recombinant humanized monoclonal antibody, 20mL single-use vial, via intravenous infusion per institutional guidelines.
223926127|NCT06439693|DRUG|Trastuzumab Deruxtecan|HER2-directed antibody drug conjugate, 100mg vial, via intravenous infusion per institutional guidelines.
223926128|NCT06439693|DRUG|Trastuzumab Subcutaneous Subcutaneous|Humanized IgG1 kappa monoclonal antibody, 6mL vial, via subcutaneous injection per institutional guidelines.
223926129|NCT06439693|DRUG|Tucatinib|Tyrosine Kinase HER2 Inhibitor, 50 or 150mg tablet taken orally per institutional guidelines.
223926130|NCT06439693|DRUG|Trastuzumab|Humanized IgG1 kappa monoclonal antibody, 150 mg single-dose vial, via intravenous infusion per institutional guidelines.
224093328|NCT04579549|DEVICE|Saliva Assay|saliva assay test for high concentrations of SARS-CoV-2
224093329|NCT01591980|DRUG|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
224093330|NCT01591980|DRUG|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
224093331|NCT01591980|DRUG|placebo|Identical placebo capsules will be administered in the same way.
224281891|NCT04676880|DEVICE|Left atrial appendage occlusion (Watchman FLX or Amplatzer Amulet)|Currently, there are two devices available on the Dutch market, Watchman and Amulet. After randomization to the intervention arm, additional randomization for type of device will follow. If the amount of procedures is too small to implant two devices, the centre will implant a device of choice.
224281892|NCT05021913|DEVICE|DKL crosslinked sodium hyaluronate 23|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 23 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
224281893|NCT05021913|DEVICE|Juvéderm Volift™ with lidocaine (Allergan, Inc)|is injected into the NLF on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Volift™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
224281894|NCT01765517|DIETARY_SUPPLEMENT|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
224281895|NCT01765517|DIETARY_SUPPLEMENT|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
223532122|NCT00261833|BIOLOGICAL|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
223532123|NCT00261833|OTHER|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
223532124|NCT01135472|DRUG|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
223926131|NCT04875871|RADIATION|Particle radiotherapy|Partial radiotherapy targeting the hypoxic tumor segment
223926132|NCT04875871|DIAGNOSTIC_TEST|Magnetic resonance imaging|For treatment planning as well as for follow-up radiological tumor assessment.
223926133|NCT04875871|DIAGNOSTIC_TEST|Computertomography|For treatment planning as well as for follow-up radiological tumor assessment.
223926134|NCT04875871|DIAGNOSTIC_TEST|Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)|For the definition of the hypoxic tumor segment in treatment planning.
223926135|NCT04875871|DIAGNOSTIC_TEST|18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)|For follow-up radiological tumor assessment.
223926136|NCT04875871|DIAGNOSTIC_TEST|Blood sampling|Evaluation before treatment-start, during treatment and follow-up period.
223926137|NCT06112847|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223926138|NCT06112847|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223926139|NCT06112847|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224281896|NCT04344457|DRUG|Hydroxychloroquine|200 mg PO BID 7 days
224281897|NCT04344457|DRUG|Indomethacin|50 mg PO TID 14 Days
223926140|NCT06112847|OTHER|Electronic Health Record Review|Ancillary studies
223926141|NCT06112847|BIOLOGICAL|Epcoritamab|Given SC
223926142|NCT06112847|DRUG|Lenalidomide|Given PO
223926143|NCT06112847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223926144|NCT06112847|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223926145|NCT03560908|DRUG|Dasatinib|Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
224093332|NCT05137938|DRUG|Intranasal Ketamine (IN)|A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
224093333|NCT05576220|DEVICE|IDION iTempShield|Subject is being treated for a cancer diagnosis with a plan for outpatient transplant or CAR-T therapy
224093334|NCT02349126|DRUG|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
224093335|NCT00691665|DRUG|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
224093336|NCT00691665|DRUG|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
224093337|NCT01865292|DRUG|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
224093338|NCT01865292|DRUG|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
224093339|NCT00006120|DRUG|docetaxel|
224093340|NCT00006120|DRUG|paclitaxel|
224093341|NCT03048630|BEHAVIORAL|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
224093342|NCT03456115|DEVICE|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
224093343|NCT04917926|BEHAVIORAL|Financial and social incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target. Regarding social incentives, participants will be placed in teams of six, receiving feedback of their physical activity performance, rankings within their groups, and positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
224093344|NCT04917926|BEHAVIORAL|Financial incentives|Participants will be credited with HK$1,000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, they will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.
224093345|NCT00476099|DRUG|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
224093346|NCT00476099|DRUG|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
224093347|NCT00476099|DRUG|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
224093348|NCT00152633|DRUG|Losartan|
223926146|NCT06273579|BEHAVIORAL|Expert instruction using AI tutor script|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. They will also be provided with a list of commands that the ICEMS uses. When the system detects an error in a student's performance for a given metric, the instructor must deliver this command using the exact wording provided by the ICEMS.
223926147|NCT06273579|BEHAVIORAL|AI-augmented personalized expert instruction|Expert instructor assigned to tutor this group will receive error detection data from the ICEMS. When the system detects an error in a student's performance for a given metric, the instructor will have the freedom to personalize and contextualize feedback without restriction to ICEMS wording.
223926148|NCT03111537|OTHER|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
223926149|NCT03111537|OTHER|E-Cigarette|Use of E-cigarette: multiple flavors offered.
223926150|NCT03111537|OTHER|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
224093349|NCT00152633|DRUG|Metoprolol|
224093350|NCT00152633|DRUG|Losartan|Treatment with Losartan
224093351|NCT05567523|DRUG|Dexmedetomidine|In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.
224093352|NCT05567523|DRUG|Normal saline|normal saline
224093353|NCT05567523|DRUG|Midazolam|midazolam
224093354|NCT04453111|BIOLOGICAL|Placenta-derived MMSCs|Cryopreserved placenta-derived multipotent mesenchymal stem / stromal cells
224093355|NCT04453111|BIOLOGICAL|Bone marrow-derived MMSCs|Cryopreserved bone marrow-derived multipotent mesenchymal stem / stromal cells
224093356|NCT04453111|DRUG|Hyalgan 20 mg in 2 ML Prefilled Syringe|Hyaluronic Acid 20 mg
224093357|NCT02209506|DRUG|MLN3126|MLN3126 tablets
223532125|NCT00622726|DRUG|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
223926151|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Once the intra-cuff pressure is measured and recorded, the cuff will be deflated by drawing the air 0.5ml per step with each step lasting 3 breaths until a leak, in which a 10% reduction in expiratory volume over the inspiratory tidal volume, is detected.Cuff will then be reinflated until the expiratory tidal volume reaches the inspiratory tidal volume and the discrepancy between the inspiratory and expiratory tidal volume is less than 10 percent. If the intra-cuff pressure applied by the anesthesia care team is inadequate and the discrepancy between the inspiratory and expiratory tidal volume is 10% or greater, the cuff will be further inflated with air 0.5ml per step with each step lasting 3 breaths until it reaches Pcr. This Pcr will be maintained during the entire anesthesia time until extubation.During the course of surgery, if any leak is detected, the cuff will be re-inflated by 0.5ml of air until the leak is not detectable.
223926152|NCT04302142|DEVICE|ventilation with critical intracuff pressure (Pcr)|Pcr is obtained just as it is done in the intervention group. The cuff will then be reinsufflated to the actual cuff pressure the care team initially chose. The care team will be blinded to the measured critical cuff pressures and hence will maintain the usual level of intracuff pressure in the control group during the entire anesthesia time.
223926153|NCT06647277|COMBINATION_PRODUCT|Fecal Microbiota Transplant|Fecal Microbiota Transplant
223926154|NCT01135433|DRUG|ipragliflozin|oral
223926155|NCT01135433|DRUG|Placebo|oral
223926156|NCT01135433|DRUG|metformin|oral
223926157|NCT05071105|RADIATION|Stereotactic Body Radiation Therapy|In every group, the dose is prescribed at the edge of the PTV. To be approved, 95% of the PTV will be conformally covered by the prescription isodose surface and 99% of PTV will receive a minimum of 90% of the prescription dose.
223926158|NCT06651554|BEHAVIORAL|Digital Platform Intervention|Key features of the digital platform include mental health self-help tools, a customizable safety plan, links to online counseling services, and gamification elements. Youth will be able to access the digital platform as often as they like during their assigned 3-month intervention period.
223926159|NCT06469190|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
223926160|NCT06011629|DEVICE|Aquacel dressing|Patients will be recruited into the study after completing a standard questionnaire for pre-operative enrollment. After meeting inclusion criteria and passing the screening process, the patient will be enrolled into the study. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.
223926161|NCT02752685|DRUG|Pembrolizumab|
223926162|NCT02752685|DRUG|Nab-Paclitaxel|
223926163|NCT06825195|OTHER|isokinetic muscle strength measurement|Wrist isokinetic eccentric flexor and extensor peak Torque and fatigue will be measured at the angular velocity of 180°/s
223926164|NCT06825195|OTHER|Minimum pinch force measurement|the minimum fingertip pinch force required to hold a constant weight will be measured
224093358|NCT02209506|DRUG|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
224281898|NCT04344457|DRUG|Zithromax Oral Product|500 mg PO QD 3 Days
224281899|NCT03191110|OTHER|No intervention: observational study|
223532126|NCT00622726|PROCEDURE|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
223926165|NCT04265872|DRUG|Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis|injection into a vein
223926166|NCT06772662|PROCEDURE|Tubing Direction|We are studying the procedure of placing the Cryotherapy Tubing in two different directions: up vs down
223926167|NCT06997328|OTHER|Implementation of the '5 Rs to Rescue'|Quality improvement intervention increases surveillance for patients at risk of 'failure to rescue' after surgery
223926168|NCT06997055|DRUG|Ustekinumab 45 mg|biosimilar
223926169|NCT06997055|DRUG|Ustekinumab 90 mg|biosimilar
223926170|NCT06996717|DRUG|ESA|anemia management algorithm will successfully increase the number of patients in the target hemoglobin range
223926171|NCT01459107|PROCEDURE|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
223926172|NCT01459107|DRUG|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
223926173|NCT06995807|OTHER|EL-SHIN THERAPY|"Participants will be randomly assigned to Group A and Group B. Group A : Attend a talk on Malaysia Tourism + current coping strategies.~Group B : EL-SHIN® Therapy + current coping strategies. Duration of therapies: 2 weeks Assessments using (i) DASS-21 (ii) MHQoL (iii) SLEEP QUALITY SCALE (SQS) at baseline, after 1st week \& 2nd weeks for both groups. Assessment will be done on end of 3rd week to see effect when EL-SHIN Therapy Stopped.~Group B participants: Attend a workshop on administration of EL-SHIN® Therapy. Will reinitiate EL-SHIN Therapy on the 4th week and assess on the 8th day to see the effect."
224093359|NCT05886361|OTHER|No intervention involved|No intervention involved
224093360|NCT02100384|PROCEDURE|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
224093361|NCT00098787|BIOLOGICAL|bevacizumab|Given IV
224093362|NCT00098787|DRUG|fluorouracil|Given IV
223926174|NCT06997679|DIAGNOSTIC_TEST|Patients receiving CPM|Group A was treated with Continuous Passive Motion for 30-45 minutes for 2 sessions per day for 8 weeks. CPM can be initiated in the immediate post-operative period, typically within 24-48 hours after surgery. Range of motion will be 0-90 degrees of flexion, with a gradual increase in range over time. Speed is 1-2 cycles per minute. Therapist will Monitor patients for pain and discomfort during CPM, and adjust the protocol as needed. Therapist will Monitor patients range of motion and adjust the CPM protocol to ensure optimal progress. Therapist will monitor patients' knee functions and adjusts the CMP protocol to ensure optimal progress
223926175|NCT06997679|COMBINATION_PRODUCT|Patients receiving intermittent compression|Group B was treated with Intermittent Compression Therapy for 30-45 minutes for 2 sessions (morning and evening) per day for 8 weeks. Therapist stand beside the patient .IC therapy initiated in the immediate post-operative period, typically within 24-48 hours after surgery .Pressure of device between 30-40 mmHg and Cycle time is 10-30 seconds inflation, 10-30 seconds deflation. Therapist will Monitor patients for pain and discomfort during IC therapy, and adjust the protocol as needed. Therapist will Monitor patients' swelling and edema, and adjust the IC therapy protocol to ensure optimal progress. Therapist will Monitor patients' knees functions and adjust the IC therapy protocol to ensure optimal progress.
223926176|NCT06499506|PROCEDURE|Below knee amputation|trans tibial amputation one hand breadth below tibial tuberosity
223926177|NCT05393531|DEVICE|Mandibular advancement device (MAD)|Active therapy
223926178|NCT05393531|DEVICE|Continuous positive airway pressure (CPAP)|Active therapy
223926179|NCT06995846|DIAGNOSTIC_TEST|Bacterial DNA Levels in Ascites|The bactDNA was detected by droplet digital polymerase chain reaction (ddPCR).
223926180|NCT06858995|OTHER|to measure the residual activity on the Totally Implantable Venous Access Port|VOI (volume of interest)TIVAP at 4 ml were drawn manually on the chamber of the TIVAP on each tomography. Blood background was determined by an VOI (volume of intesrest of Right Auricle on the right atrium. The VOIRA was automatically delineated on the CT by XXX. Standardized Uptake Value (SUV)max, SUVpeak, SUVmean were extracted from the VOIs and unilateral comparisons of superiority were performed using Wilcoxon tests. A qualitative analysis along the (TIVAP) catheter was performed: positive if an uptake was superior to the blood background and negative if any.
223926181|NCT06670274|DRUG|HC002 SAD|"Part 1 will enroll 32 participants across 4 cohorts.~Route of administration: Oral Dose interval and frequency: Single oral dose range across 4 cohorts."
223926182|NCT06670274|DRUG|HC002 MAD|"Part 2 will enroll 24 participants across 3 cohorts.~Route of administration: Oral Dose interval and frequency: Once daily for 7 days"
224093363|NCT00098787|DRUG|irinotecan hydrochloride|Given IV
223926183|NCT06670274|DRUG|Placebo|Matching placebo will be administered across SAD and MAD
224281900|NCT06407076|OTHER|Interviews|Following the design of the questionnaire, using open-ended questions based on the availability, accessibility, acceptability and quality (AAAQ) framework, qualitative semi-structured personal interviews were used to collect the data. In this way it was possible to collect information in a more detailed way. The subjects included in the study had to answer the questions posed by the main researcher, responding with open or closed answers, through a questionnaire created for this purpose.
224281901|NCT03540758|DRUG|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
223926184|NCT03598998|BIOLOGICAL|Pembrolizumab|Given IV
223926185|NCT03598998|DRUG|Pralatrexate|Given IV
224281902|NCT03540758|DRUG|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
224281903|NCT03540758|DRUG|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study."
224281904|NCT01165749|BEHAVIORAL|stop exercising|
224281905|NCT02572791|DRUG|Chlorhexidine|
224281906|NCT02572791|DRUG|Mupirocin|
223926186|NCT05585346|DEVICE|MLS laser|Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
224093364|NCT00098787|DRUG|leucovorin calcium|Given IV
224093365|NCT00098787|DRUG|Oxaliplatin|Given IV
224093366|NCT01422330|DRUG|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
224093367|NCT00003688|BIOLOGICAL|dactinomycin|
224093368|NCT04421326|OTHER|Analysis of the clot|Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
224093369|NCT03827161|DIETARY_SUPPLEMENT|Glucosamine|Given PO
224093370|NCT03827161|OTHER|Placebo|Given PO
224093371|NCT03501862|BEHAVIORAL|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
224281907|NCT02572791|BEHAVIORAL|Household cleaning|
224281908|NCT02643927|BEHAVIORAL|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
224281909|NCT02643927|BEHAVIORAL|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
223926187|NCT05585346|DRUG|Oral vitamin B1|Oral vitamin B1 10mg, times/day
223926188|NCT06997705|BEHAVIORAL|Optimized VMS|Building on the Systematic Medical Visits (VMS) the Optimized VMS, optimizes these services for in-school and out-of-school adolescents by expanding availability of VMS services through community and facility platforms and building capacity of health workers to provide integrated services. Also the intervention will involve demand generation activities such as community sensitization.
223926189|NCT05794932|DIAGNOSTIC_TEST|Stress test|"Diagnostic Test:~* Maximum effort test (CPET) on a cycloergometer~* Leg muscle strength assessment~* Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~* Spirometry, arterial blood gaz, NO/CO transfer"
223926190|NCT06810453|OTHER|A 5 cc venous blood sample was obtained|A 5 cc venous blood sample was obtained just before anesthesia induction and at the end of surgery.
223926191|NCT06810453|PROCEDURE|low-flow anesthesia|Low-flow anesthesia, also known as inhalational anesthesia method, is a type of anesthesia that is performed using a semi-closed, rebreathing system containing at least 50% fresh gas. Generally, low-flow anesthesia is used in anesthesia practices because it reduces costs, prevents environmental pollution, increases the humidity of gases, and reduces heat loss. Another important benefit of low-flow is that it requires closer monitoring of patients, which allows for early detection of complications during general anesthesia, thus improving patient safety. Concerns about low-flow anesthesia being used infrequently in the past have been addressed by the introduction of modern anesthesia workstations with sophisticated monitoring and safety features, which have made low-flow anesthesia widely used in most centers.
223926192|NCT02701283|DEVICE|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
223926193|NCT02701283|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
223926194|NCT06479174|BEHAVIORAL|CHAMPS-TR|Persons with stroke ( n=20) and at least 1 targeted family member (TFM) (n=20) will engage with the CHAMPS-TR protocol which involves 10 virtual intervention sessions (bi-weekly for 5 weeks) with key elements including metacognitive problem-solving training (i.e., goal setting, guided discovery, strategy development) and vascular risk reduction coaching building on existing American Heart Association (AHA) LE8 content. Probands that are eligible for RS-tDCS (n=10) will receive 5x weekly (weeks 2-5) RS-tDCS applied to the left dorsolateral prefrontal cortex (DLPFC).
224093372|NCT03501862|BEHAVIORAL|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
224093373|NCT01834404|DRUG|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
224093374|NCT01834404|DRUG|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
224093375|NCT01520246|GENETIC|gene expression analysis|
224093376|NCT01520246|OTHER|laboratory biomarker analysis|
224093377|NCT00116025|DRUG|Human acylated ghrelin|
224093378|NCT01360996|DRUG|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
224093379|NCT02229734|RADIATION|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
224281910|NCT05484791|OTHER|The Lumbar Rotational Spinal Mobilization Technique|Patients included in the study underwent the lumbar rotational spinal mobilization(LRSM) technique during two sessions per week. The LRSM technique is applied while patients are lying on their side. The uppermost hip and knee are placed in 90 degree flexion, this is to assist rotational stress, and the lower leg is placed in extension. The lower shoulder is strongly pulled; thus, the upper shoulder is positioned toward the posterior and the pelvis moves anteriorly. The clinician stands in front of the patient. They stabilize the upper shoulder with one hand, and place the palm of the other hand behind the hard part of the ilium wing, with forearm horizontal and fingers turned toward the clinician. A rotational force is applied with pressure in the horizontal direction by pulling the hand on the ilium toward the clinician. In this position, 30 slow repeated movements are performed. The same practice is performed on both sides
224093380|NCT02229734|DRUG|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
224281911|NCT04915222|OTHER|Natural apophyseal glides|Patients received conventional therapy and NAGS with 2-3 hertz (less than 6 repetitions) in 3 sets for 3 weeks. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
224281912|NCT04915222|OTHER|Cervical manual traction|Patients received cervical manual traction (CMT) along with traditional therapy. Treatment frequency was 3 sessions per week for total three weeks duration. CMT applied was intermittent type traction.8 to 10 kg force was applied at an angle of 20 to 25 degree from horizontal. 5sets of cervical traction are performed. In every set traction is given for 1 minute with rest period of 20 seconds. The total time of traction session was 10 minute. The conventional therapy included hot pack, Neck range of motion exercises, neck strengthening and stabilization exercises. The hot pack is a form of thermo therapywas applied for 10 to 15 minutes and was applied at each visit during 3 sessions per week for total 3 weeks. The strengthening and stabilization exercises are form of therapeutics exercise are prescribed at 15 to 20 times per session for total 3 weeks. Intensity of exercise may rise gradually according to patient tolerance and muscular strength.
224281913|NCT00153257|DEVICE|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
224281914|NCT01386125|DRUG|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
224281915|NCT01386125|DRUG|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
224281916|NCT04085744|DRUG|Lidocaine 10% Spray|lidocaine will be apply on the cuff
224281917|NCT04085744|DRUG|Mometasone nasal spray|mometasone spray will be applied on the cuff
224281918|NCT01866644|DRUG|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
223532127|NCT04142489|OTHER|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
223926195|NCT07022769|BEHAVIORAL|LLM-facilitated cognitive debiasing aid|"As part of the intervention, patients first respond to a series of questions about their beliefs regarding their symptoms (e.g., What's usually behind these symptoms?), with responses transcribed verbatim via tablet. These responses are input into a Large Language Model (LLM), which generates a brief, supportive summary of the patient's beliefs, shared back with the patient to encourage self-awareness and reflection. Patients are then invited to consider prompts such as, What emotions or circumstances might be influencing your thinking? with their reflections again transcribed. The LLM analyzes these reflections to identify potential signs of emotional distress or maladaptive beliefs, and this output is again provided to the patient. The LLM summary of identified maladaptive beliefs is then also shown to the clinician ahead of the consultation to support more tailored, empathetic communication."
223926196|NCT03741140|DIAGNOSTIC_TEST|Motivation tests|Motivation tests will characterize elementary deficits of motivation
223926197|NCT06631131|DEVICE|Distalization with clear aligners supported by Class II elastics|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. ). In group 1, with the beginning of the movement of the upper first molars, Class II intermaxillary elastics were used from precision cuts of the upper canines to the buttons on the lower first molars for supporting distalization movement.
223926198|NCT06631131|DEVICE|Distalization with clear aligners supported by miniscrew|Sequential distalization (50%) with clear aligners was planned in the maxillary arch for each patient. In group 2, IZC miniscrews were inserted in the IZC region between the upper molars in both sides before first molar movement started. The same intramaxillary elastics were used from precision cuts of the upper canines to the IZC miniscrew for supporting distalization movement.
224093381|NCT02537678|BEHAVIORAL|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
223926199|NCT06870513|PROCEDURE|Antegrade Cerebral Perfusion via Axillary Artery|In antegrade cerebral perfusion (ACP), patients underwent cannulation of the right axillary artery using an interposition Dacron graft (7 mm) connected to a cardiopulmonary bypass (CPB) circuit. During surgery, ACP delivered oxygenated blood flow directly into the brain arteries to maintain cerebral protection during the period of deep hypothermic circulatory arrest (DHCA), enabling the surgical team to perform the distal aortic anastomosis safely.
223926200|NCT06870513|PROCEDURE|Retrograde Cerebral Perfusion via Superior Vena Cava|In retrograde cerebral perfusion (RCP), cannulation of the superior vena cava (SVC) was performed to deliver blood flow in reverse direction during deep hypothermic circulatory arrest (DHCA). This method aimed to provide cerebral protection by supporting cerebral metabolism during the surgical repair of acute Type A aortic dissection.
223926201|NCT07022782|OTHER|A nutritional intervention based on the principles of Mediterranean diet|The patients will consume meals three times (i.e., breakfast, lunch and dinner) per day for 90 days (i.e., three months) that are based on the principles of Mediterranean diet.
223926202|NCT06698003|DRUG|Mogamulizumab|Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
223926203|NCT02739711|DRUG|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
223926204|NCT07026994|DRUG|Colchicine 0.5mg|Oral colchicine 0.5mg once per day combined with standard treatment
223926205|NCT07026994|DRUG|Matching placebo|Oral matching placebo once per day combined with standard treatment
223926206|NCT06710106|DIETARY_SUPPLEMENT|Prebiotic + hypocaloric diet|Study participants will add prebiotic formula in a natural yogurt every day to be consumed within a hypocaloric diet.
223926207|NCT06710106|DIETARY_SUPPLEMENT|Placebo + hypocaloric diet|Study participants will add placebo formula in a natural yogurt every day to be consumed within a hypocaloric diet.
223926208|NCT06713538|OTHER|Equine assisted therapy|The intervention will last for 12 sessions, with two 1.5-hour sessions per week. The program is offered to patients in addition to their usual daily schedule. These 12 sessions will be organized as follows:
224093382|NCT02537678|BEHAVIORAL|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
223926209|NCT06713538|OTHER|Physical activity|The subjects will independently carry out 12 sessions (2 sessions of 90 minutes per week for 6 weeks) of moderate-intensity physical activity. The endurance activity should be performed according to the patient's capabilities and fatigue levels.
223926210|NCT06713928|OTHER|Oral hygiene with dog therapy|The DAT session is divided into two phases: a pre-sitting phase in which the patient could interact with the dog, touching, caressing and playing with him, under the supervision of the dog-trainer. This phase lasted about 15 minutes. The second phase was a during-sitting phase in which the dog was in the chair, next to the patient, during the entire oral hygiene procedure, under the supervision of the dog-trainer.
224093383|NCT02633176|DRUG|Cetuximab|400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.
224281919|NCT01866644|DRUG|Saline|Bath saline transplanted liver
223532128|NCT03243461|DRUG|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
223532129|NCT04358406|DRUG|Recombinant human plasma gelsolin (Rhu-pGSN)|Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses
223926211|NCT06881030|PROCEDURE|Noninvasive transcranial magnetic stimulation was administered six times daily|The motor threshold of 100% intensity, a TBS stimulus train for 2 seconds, including 10 times of 3 intrapascicular stimulation at 50 Hz and interapascicular stimulation at 5HZ, intervals of 10s, 60 repetitions, that is, a total of 1800 pulses per treatment, 6 treatments per day, 50 min apart, a total of 10800 pulses/day, continuous stimulation for 5 days.
223926212|NCT06881030|PROCEDURE|Noninvasive transcranial magnetic stimulation was administered 10 times daily|The motor threshold of 100% intensity, a TBS stimulus train stimulation for 2 seconds, including 10 times of 3 intrapascicular stimulation at 50 Hz and interapascicular stimulation at 5HZ, intervals of 10s, 60 repetitions, that is, a total of 1800 pulses per treatment, 10 treatments per day, intervals of 50 min, a total of 18000 pulses/day, continuous stimulation for 5 days.
223926213|NCT06881030|PROCEDURE|Sham|The appearance of the sham stimulation coil was consistent with that of the real stimulation coil, which could simulate the touch and sound of the scalp caused by the real stimulation. The treatment frequency, location, intensity and time of the sham stimulation group were the same as those of the real stimulation group.
223926214|NCT06881225|OTHER|Using DCE-MRI, fMRI, and DSI, establish a longitudinal brain functional and structural imaging database for three groups of nasopharyngeal carcinoma patients before and 18 months after radiotherapy.|"1. Resting-state fMRI:~   Use the Gradient Echo Echo Planar Imaging (GRE-EPI) sequence with the following parameters: repetition time (TR) = 2000 ms, echo time (TE) = 30 ms, flip angle (FA) = 90°, slice thickness = 3.0 mm, slice spacing = 0.8 mm, field of view (FOV) = 240 mm × 240 mm, matrix = 128 × 128, in-plane resolution = 64 × 64, 39 axial slices scanned, 240 dynamic scans.~2. DSI:~   Use diffusion-sensitive imaging (DSI) with 64 diffusion directions, b-values of 0 and 1000 s/mm², TR = 3000 ms, TE = 64 ms, number of excitations (NEX) = 1, matrix = 112 × 112, FOV = 224 mm × 224 mm, slice thickness = 2 mm, no spacing between slices, full brain coverage, and 75 slices scanned.~3. Three-dimensional brain structural MRI:~Sagittal data acquisition is performed with the following parameters: TR = 8.16 ms, TE = 3.18 ms, inversion time (TI) = 800 ms, flip angle (FA) = 8°, matrix = 256 × 256, FOV = 256 mm × 256 mm, voxel size = 1 mm × 1 mm × 1 mm, and 176 slices scanned."
223926215|NCT06684327|DRUG|Albumin-paclitaxel Injection|Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.
223926216|NCT07039435|OTHER|Alternative Frequency Mapping|Patients will have their speech processors programmed with four maps, three of which use a higher low-frequency cutoff than the default map (313 Hz, 438 Hz, 563 Hz, compared to the default map that has a low-frequency cutoff of 188 Hz).
223926217|NCT07037810|DEVICE|iBolus|MDI+ FreeStyle Libre 2 +iBolus
223926218|NCT07037810|OTHER|Carb counting|MDI+FreeStyle Libre 2+ Carbcounting
223926219|NCT06688071|DIAGNOSTIC_TEST|Single Group Assignment|68Ga-DOTA/NOTA-FAPI-04 Each subject receive a single intravenous injection of 68Ga/18F-FAPI, and undergo PET/CT imaging within the specificed time.
223926220|NCT07038681|OTHER|Mediterranean Diet Intervention Group|In the same way as the control group, the intervention group receives standard nutritional care from the hospital nutritionist, since all the pregnant women have at least one of the following risk factors: obesity, diabetes or hypertension, nutritional - standard-care procedure in the Portuguese National Health System.
223926221|NCT07038681|OTHER|Control Group (Standard Hospital Dietary Care)|The control group will receive standard care from the nutritionist in the hospital.
223926222|NCT07039812|DEVICE|Virtual Reality Headset|During the dressing change, nature-themed videos will be shown through a virtual reality headset that immerses the user in a 360-degree, three-dimensional virtual environment.
223926223|NCT07039812|DEVICE|Eye Mask|A soft, adjustable, 3D-structured eye mask (Poblex brand) will be applied during the dressing procedure.
223926224|NCT07039695|PROCEDURE|Volar buttress plate|Patients will be treated by a volar buttress plate.
224093384|NCT02633176|DRUG|Cisplatin|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
224093385|NCT02633176|DRUG|Docetaxel|75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
224093386|NCT02633176|DRUG|Capecitabine|1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
224093387|NCT02633176|RADIATION|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
224093388|NCT01766648|DEVICE|Far Cortical locking screw fixation|Standard screw fixation
224281920|NCT04260035|DRUG|Vasoactive Intestinal Polypeptide (VIP)|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
224281921|NCT04260035|DRUG|Sterile saline|20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
223926225|NCT07039695|PROCEDURE|Herbert screw|Patients will be treated by Herbert screw.
224093389|NCT01766648|DEVICE|Standard screw fixation|
224093390|NCT00646893|PROCEDURE|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
224093391|NCT00825604|PROCEDURE|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
224093392|NCT00242918|DRUG|docetaxel|
224093393|NCT00242918|DRUG|ZD1839|
224281922|NCT01307943|OTHER|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
224281923|NCT01307943|OTHER|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
224281924|NCT01100905|OTHER|Iron-containing food product|
223532130|NCT04358406|OTHER|Placebo|Normal saline in matched volume to treatment arm. Undistinguishable in syringe.
223532131|NCT04607343|DEVICE|Rehabilitation device based on electrical stimulation|Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
223926226|NCT07040072|COMBINATION_PRODUCT|Stapokibart and Finotonlimab|"Receive the combination of Stapokibart and Finotonlimab in cycles 1-3, and maintain treatment with Finotonlimab in subsequent cycles.~Stapokibart, 600mg for the first cycle, 300mg for the second and third cycles, administered subcutaneously every 3 weeks, for a total of 3 doses of Stapokibart; Finotonlimab 200mg, administered intravenously every 3 weeks until confirmed disease progression occurs according to the RECIST 1.1 imaging criteria (if the researcher determines that the subject can benefit from continuing PD-1 drug treatment, and the subject can tolerate the study treatment and agree, PD-1 drug can be continued and recorded in the study records), unacceptable toxic side effects, initiation of new anti-tumor treatment, withdrawal from the study or death (whichever occurs first), or reaching a maximum treatment period of 2 years."
223926227|NCT07038941|DRUG|CG2001|combination of minoxidil and finasteride
223926228|NCT07038941|DRUG|Placebo foam|Placebo foam
224281925|NCT06291454|DIAGNOSTIC_TEST|Routine periodontal examination|In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness \& Löe, 1964), Löe-Sillness's gingival index (GI)(Löe \& Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo \& Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
224281926|NCT00002727|RADIATION|radiation therapy|
223926229|NCT07038213|GENETIC|glycation genes|glycation genes
223926230|NCT07038213|DIAGNOSTIC_TEST|beta 2 microglobulin|b2m
223926231|NCT07038850|OTHER|Multimodal nurse training about nurse driven sedation-analgesia protocol|"The training program for nursing staff in the use of the sedation-analgesia protocol includes 3 stages:~1. Initial training: e-learning module to be validated~2. Feedback session: sessions in small groups of 5 to 6 participants, led by a nurse trainer, allowing interprofessional transmission (questions/answers and critical analyzes of sedation collection sheets).~3. Bedside rehearsal: individual practice of the sedation-analgesia protocol at the patient's bedside under the supervision of a doctor or nurse trainer."
224281927|NCT01745081|DRUG|20% mannitol bolus administration|
224281928|NCT01745081|DRUG|Hypertonic saline 3% bolus administration|
223717678|NCT01145443|OTHER|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
223926232|NCT06717867|DIETARY_SUPPLEMENT|Palmitoylethanolamide (PEA)|Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.
223926233|NCT06717867|OTHER|Placebo|Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.
223926234|NCT06875076|DRUG|Ivonescimab Combined With Chemotherapy|ivonescimab 20mg/kg combined with pemetrexed 500mg/m²/gemcitabine 1000mg/m²/vinorelbine 25mg/m² every 21 days for 4 cycles followed by a maintenance phase (ivonescimab monotherapy 20mg/kg every 21 days until disease progression, intolerance, or up to 2 years)
223926235|NCT06874127|DRUG|Nucleos(t)ide Analogs (NA)|all patients received NAs
223926236|NCT07039019|DRUG|Corticosteroid|Patients take 40 mg of prednisone daily for 4 weeks to help reduce inflammation.
223926237|NCT07039019|OTHER|No Corticosteroid|Patients do not take corticosteroid.
223926238|NCT06884865|BIOLOGICAL|Enekinragene Inzadenovec (PCRX-201)|Enekinragene Inzadenovec (PCRX-201) injection
223926239|NCT06884865|BIOLOGICAL|Placebo|Placebo injection
223926240|NCT06882863|BEHAVIORAL|Motivational interviewing|"This intervention consists of a single nurse-led motivational interview aimed at reducing sedentary behavior in patients with severe COPD. The session, conducted in the patient's home, lasts approximately 60 minutes and focuses on identifying personal barriers, exploring motivation, and setting small, realistic goals to reduce sedentary time.~Unlike traditional pulmonary rehabilitation, this intervention does not involve structured exercise but instead uses motivational interviewing (MI) techniques to encourage gradual behavior change in daily routines. Before the intervention, patients wear an accelerometer for seven days to objectively measure baseline sedentary time. The study assesses feasibility, patient engagement, and adherence to determine whether the approach is suitable for a larger randomized controlled trial (RCT)."
223926241|NCT06703710|DRUG|JW2286|a single administration of JW2286 per dose
223926242|NCT06703710|DRUG|Placebo of JW2286|a single administration of Placebo of JW2286 per dose
224281929|NCT06453837|OTHER|Mentha Suaveolens extract incorporated into a food supplement|Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.
224281930|NCT06453837|OTHER|Placebo product|Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
224281931|NCT00002633|DRUG|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
223926243|NCT06719063|OTHER|Multisensory Virtual Reality|"The VirtySens® multisensory travel capsule is an immersive virtual reality technique. This total immersion occurs through the simultaneous stimulation of four of the five senses.~Session duration: 45 minutes, with 15 minutes dedicated to the protocol administration. The remaining 30 minutes will be used to welcome the patient, explain the content of the session, and review the session's outcome, particularly to assess tolerance (Simulator Sickness Questionnaire (SSQ) completed at the start of each week after the first VirtySens® session). The sessions will take place in the morning to prevent the session from being disrupted by fatigue related to the rehabilitation day."
223926244|NCT07040098|DRUG|Sintilimab|PD-1 inhibitor
223926245|NCT07040098|RADIATION|Short-course radiotherapy|Pelvic radiation, SCRT, 5 Gy x 5 alone
223926246|NCT07040098|RADIATION|Long-course concurrent chemoradiotherapy|Pelvic radiation, 50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine (825 mg/m2, twice a day).
223926247|NCT07040098|COMBINATION_PRODUCT|CAPOX|chemotherapy regimen, Oxaliplatin 130 mg/m2 IV day 1，Capecitabine 1000 mg/m2 twice daily PO for 14 days(3 weeks per cycle)
223926248|NCT06886776|BEHAVIORAL|Implementation package (training and facilitation)|"Training includes an initial presentation on S.A.F.E. Firearm, S.A.F.E. Firearm informational guides and other resources to support delivery, and recommendations for additional, optional self-guided learning resources.~Facilitation will last twelve months at each site. It may involve 1) a pre-implementation readiness assessment for each clinic to identify potential implementation barriers and develop relationships with constituents; 2) kick-off meetings at the launch of the trial, at which clinic staff will identify how and where S.A.F.E. Firearm will be implemented within the clinic; 3) goal-setting within the first few months of the program; 4) trouble-shooting to address barriers identified during the pre-implementation readiness assessment and emergent challenges; and 5) designing a sustainment plan to maintain S.A.F.E. Firearm for future years."
223926249|NCT06706544|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
223926250|NCT06706544|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
224093394|NCT04348851|BEHAVIORAL|Caregiver problem-solving|Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
224093395|NCT04348851|BEHAVIORAL|Attention Control|The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
224093396|NCT05054855|BEHAVIORAL|: Cognitive Support Technology (CST)|"Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012)."
224093397|NCT02965378|DRUG|Docetaxel|Given IV
224093398|NCT02965378|DRUG|FGFR Inhibitor AZD4547|Given PO
224093399|NCT02965378|OTHER|Laboratory Biomarker Analysis|Correlative studies
224093400|NCT01361256|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
224093401|NCT01361256|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
224093402|NCT05837754|OTHER|C8-C12|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
224093403|NCT05837754|OTHER|Placebo|5-15mL (one teaspoon to one tablespoon) once or twice a day. The participants will be dispensed a 5 ml pipette for consuming the IP.
224093404|NCT01311778|DRUG|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
224093405|NCT01311778|DRUG|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
224093406|NCT02536586|DRUG|LY3023414|LY3023414 administered orally.
224093407|NCT02867631|BEHAVIORAL|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
224093408|NCT00895063|BEHAVIORAL|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
224093409|NCT00817271|DRUG|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
224093410|NCT00817271|DRUG|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
224093411|NCT00073190|BEHAVIORAL|Osteoporosis Education|
223926251|NCT07038590|OTHER|exergame program with virtual reality|Participants who attend a patient association will add to their usual therapies or virtual exercise program to be developed 2 days a week for 3 months.
223926252|NCT07038590|OTHER|usual treatment patient association|Common therapies in patient associations: memory workshops, relaxation, and occupational therapy
223926253|NCT03734809|DRUG|Pembrolizumab|200mg every 3 weeks infusion
223926254|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H1coil|Participants will receive dTMS treatment with H1 coil
223926255|NCT06728280|DEVICE|deep transcranial magnetic stimulation with H7 coil|Participants will receive dTMS treatment with H7 coil
223926256|NCT06877195|PROCEDURE|CABG|Aortocoronary bypass procedures with venous grafts on right coronary territory
223926257|NCT06880458|OTHER|Oral health education|The participants will receive oral health education from multiple different sources, including the Know Your OQ website (https://www.knowyouroq.com/).
223926258|NCT06883825|OTHER|Myofunctional Therapy|Participants will only receive myofunctional rehabilitation therapy. This treatment includes massage and exercises to improve the function of the jaw muscles.
223926259|NCT06883825|OTHER|Myofunctional Therapy + Respiratory Exercises|Participants will receive breathing exercises as well as myofunctional therapy. This treatment includes exercises to improve jaw function and support the respiratory system.
223926260|NCT06883825|OTHER|Myofunctional Therapy + Thoracic Region Exercises|Participants will receive myofunctional therapy as well as exercises for the thoracic region. This treatment includes exercises to improve jaw function and increase the flexibility of the chest area.
223926261|NCT06886919|BIOLOGICAL|Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells|"About 6 subjects will be included in the study, and a 3+3 dose escalation method will be used. The dosage will be gradually increased in two dose groups: 1 × 10 \^ 8 CAR-T cells/dose and 2 × 10 \^ 8 CAR-T cells/dose. Three subjects are enrolled in each dose group first, and within the same dose group, the cell transfusion interval between the first two subjects should not be less than 14 days. If no dose limiting toxicity (DLT) is observed in a certain dose group, the dose will be increased to the next dose; If one case of DLT occurs, this dose group needs to be divided into three additional subjects (a total of six subjects). If no new DLT occurs, the dosage will be increased to the next dose; If more than 1/6 of the 6 subjects develop DLT, the dose escalation will be terminated, and the Safety Review Committee (SRC) will discuss whether to reduce the dose and continue the monotherapy study."
223926262|NCT06888219|OTHER|Acupuncture and Auricolotherapy|"Based on the patient's condition and the physiology of traditional Chinese medicine, sterile disposable acupuncture needles will be placed on selected points:~Auricular:~* Esophagus point~* Shen Men point~* Palate area/ Throat point~* II and III Trigeminal branches~Somatic:~* 17 Triple heater (if bruxisme)~* 22 Conception Vessel~* 23 Conception Vessel~* 3 Small Intestine~* Yin Tang (if apathy)~* 3 Large Intestine (if xerostomy)~* 36 and 44 Stomach"
223926263|NCT06888219|OTHER|Conventional logopedic rehabilitation|"Patients assigned to the control arm will undergo a total of 3 hours of speech and physiotherapy rehabilitation per day from Monday to Friday, and 1 hour on Saturday.~Regarding speech therapy treatment, both restorative and compensatory interventions will be applied, based on the patient's clinical condition.~Compensatory approaches include postural techniques (such as adopting a flexed head posture) and swallowing techniques (e.g., supraglottic swallowing, forced swallowing, the Mendelsohn maneuver), as well as modifying the consistency of liquids and food.~Restorative methods involve swallowing exercises aimed at enhancing muscular strength, resistance training, and motor training of the oral structures involved in swallowing."
223926264|NCT06888999|OTHER|In vitro exposure to workplace by VR plus CAU|During the VR-session, guided by the psychotherapist, participants are virtually exposed to their workplace using VR glasses. Based on the experience of the participants during the vitual visit to their workplace, the psychotherapist can adjust the therapy. In addition Care As Usual is provided (see description active comparator).
223926265|NCT06888999|OTHER|CAU: Psychotherapy focused on return to work|Psychotherapy focused on return to work, provided by a psychotherapist specialized in counseling cabin crew.
223926266|NCT06890078|OTHER|Biological sampling|Mouthwash, nasopharyngeal swab, blood sampling
223926267|NCT06887933|DRUG|Niraparib|Niraparib will be administered.
223926268|NCT06731530|DEVICE|Pentacam-AXL|Pentacam-AXL (Oculus, Wetzlar, Germany)
223926269|NCT06731530|DEVICE|HD Analyzer|HD Analyzer (Visiometrics, Terassa, Spain, Keeler)
223926270|NCT06731530|DEVICE|Corvis ST|Corvis ST (Oculus, Germany)
223717679|NCT04786015|OTHER|Active Surveillance Reporting System|A system to actively record change in symptoms older adult patients experience following a chiropractic visit.
223717680|NCT03910023|OTHER|Usual care comporting a home-exercise program (UCHE)|"The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program."
223926271|NCT06731530|DEVICE|OCT-A Angiovue|OCT-A Angiovue (Optovue, Inc., Fremont, California, USA)
223926272|NCT06731530|DEVICE|IOLMaster V.5.4|IOLMaster V.5.4 (Carl Zeiss., Meditec)
223926273|NCT06731530|DEVICE|Topcon SP-1P|Topcon SP-1P (Topcon Medical Inc., Tokyo, Japan)
224093412|NCT05747989|PROCEDURE|two-component skin adhesive, Glubran Tiss 2|After subcutaneous stitches a two-component skin adhesive, Glubran Tiss 2®, will be applied. G Each subject will receive 0.35 mL of Glubran Tiss® in the open wound, and before bandaging, subjects rested for 20 minutes for a polymerization process.
223926274|NCT06731530|OTHER|BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus examination|BCVA (ETDRS), Slit lamp examination, Goldmann Applanation Tonometry, Fundus Examination
224093413|NCT05747989|PROCEDURE|skin is stitched with transcutaneous nylon sutures|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
224093414|NCT00211406|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
224281932|NCT00002633|DRUG|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
223532132|NCT05482061|OTHER|visual analog scale (VAS).|The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
223532133|NCT06157021|PROCEDURE|Rotary pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using (Fanta AF baby\* rotary files and Endo Radar\* rotary device).
223532134|NCT06157021|PROCEDURE|Manual pulpectomy|Pulpectomy procedures by making cleaning and shaping of root canals of necrotic primary molars using Manual H files, Mani\*)
223926275|NCT06730321|OTHER|Observations on clinicopathological factors influencing the assessment score of surgery|Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data
223926276|NCT06730074|DEVICE|Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)|This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
223532135|NCT05447403|OTHER|Chewing gum combined with WeChat enhanced instructions|Patients in the chewing gum and WeChat group are advised to chew one piece of sugarless gum for 20 minutes after drinking each 1 liter PEG. They also receive enhanced instructions via WeChat before two days and one day of colonoscopy to further inform how to chew gum and highlight the importance of adequate bowel preparation.
223532136|NCT04475666|OTHER|Replenish protein group|For patients with Body mass index(BMI) \<30, use pre-ICU actual body weight(BW) for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
223926277|NCT07040085|DRUG|Y-6|each tablet of Y-6 contained 6 mg of dexborneol and 25 mg of cilostazol; Both groups took one tablet q12h for 28 days.
223926278|NCT07040085|DRUG|Y-6 placebo|each tablet of Y-6 placebo contained 0.06 mg of dexborneol and 0 mg of cilostazol. Both groups took one tablet q12h for 28 days.
224093415|NCT03182530|DEVICE|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
224093416|NCT03182530|DEVICE|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
223926279|NCT07039552|PROCEDURE|risk-reducing salpingo-oophorectomy (RRSO)|The proportion of BRCA1/2 germline mutation carriers in the high-risk population of ovarian cancer who undergo risk-reducing salpingo-oophorectomy (RRSO). RRSO refers to the preventive surgical removal of both fallopian tubes and ovaries to reduce the risk of ovarian cancer, fallopian tube cancer, and peritoneal cancer.
223926280|NCT04878445|PROCEDURE|Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.|Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
224093417|NCT03182530|DEVICE|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
224093418|NCT04077333|PROCEDURE|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
224093419|NCT03634982|DRUG|RMC-4630|RMC-4630 for oral administration
224093420|NCT01504503|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
224093421|NCT01504503|DRUG|Aricept|Aricept 10 mg Tablets
224093422|NCT00629083|DEVICE|Bulkamid|Bulking injection with Bulkamid injection device
224093423|NCT00629083|DEVICE|Contigen|Transurethral bulking injection
224281933|NCT00002633|DRUG|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
223926281|NCT04012567|DEVICE|Investigational device: Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
224093424|NCT00003176|DRUG|carmustine|
224093425|NCT00003176|DRUG|temozolomide|
224093426|NCT05465135|DRUG|Dihydroartemisinin|Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
223926282|NCT04012567|DEVICE|Control device: BIOSURE HA Interference Screw|BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
223926283|NCT06731868|DRUG|LPM3770164 sustained release tablet 5 mg|LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
223717681|NCT03910023|OTHER|Spa therapy|the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
223926284|NCT06731868|DRUG|LPM3770164 sustained release tablet 10 mg|LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
223926285|NCT06731868|DRUG|LPM3770164 sustained release tablet 20 mg|LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
223926286|NCT06731868|DRUG|LPM3770164 sustained release tablet simulant|LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
223926287|NCT06715553|BEHAVIORAL|BALANCE Program (Body, Art, Learning, Activities, Nutrition, Creativity, and Education)|"Six types of intervention will be done on the patients as follows:~* Psychoeducational intervention program~* Art therapy program~* Bibliotherapy program~* Nutrition program~* Sport activity~* Ping Pong activity"
223926288|NCT06736353|DRUG|Beta Blocker Therapy or No Therapy (Control)|Beta blocker therapy or no Beta blocker therapy initiated after type 2 myocardial infarction
223717682|NCT03766581|DRUG|BMS-986177|Oral administration
223926289|NCT06736353|DRUG|RAAS blocker Therapy or No therapy (Control)|RAAS blocker therapy or no RAAS blocker therapy initiated after type 2 myocardial infarction
223926290|NCT06736353|DRUG|Statin Therapy or No Therapy (Control)|Statin therapy or no Statin therapy initiated after type 2 myocardial infarction
223926291|NCT06736353|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or no antiplatelet therapy initiated after type 2 myocardial infarction
223926292|NCT06736353|DRUG|Dual Antiplatelet Therapy or No Therapy (Control)|Dual Antiplatelet Therapy or no Dual Antiplatelet Therapy initiated after type 2 myocardial infarction
223717683|NCT03766581|OTHER|Placebo|Oral Administration
223926293|NCT06735677|BEHAVIORAL|sexual health education|These sessions covered reproductive health, sexual activity during pregnancy and the postpartum period, personal and sexual hygiene, domestic violence during pregnancy, and misconceptions about pregnancy.
223926294|NCT06328114|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will experience two accelerated transcranial magnetic stimulation (TMS) sessions, with 12 week (three-months) gap between each session.
223926295|NCT04319887|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
224281934|NCT00002633|DRUG|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
223926296|NCT06541054|OTHER|WARM SOCKS|One hour before the operation,warm socks will be put on the experimental group,body temperature,heart rate,blood pressure,SPO2 will be measured and recorded every fifteen minutes.During the surgery,body temperature,heart rate,blood pressure,SPO2 value, drainage amount will be measured and recorded every fifteen minutes.The patient will be transferred to the postoperative care unit with warm socks and will stay on his feet in the postoperative care unit.Body temperature, heart rate,blood pressure,SPO2 values will be recorded every fifteen minutes.He will be transferred from the postoperative care unit to the clinic with socks.will stay. After transferring to the bed,body temperature,heart rate, arterial blood pressure, SPO2 will be recorded every fifteen minutes for a total of 180minutes.Chills,chills and the total drainage amount for 24hours will be recorded in the same section.
223532137|NCT04475666|OTHER|Standard protein group|For patients with BMI \<30, use pre-ICU actual BW for the calculation; if unavailable, use weight on ICU admission. For patients with BMI \>=30, use adjusted body weight
223532138|NCT00633685|DRUG|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
223532139|NCT00633685|DRUG|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
223926297|NCT06733298|DRUG|[ 14C]-labeled RO7269162|Participants will receive one oral dose of \[14C\]-labeled RO7269162.
223926298|NCT06883643|BEHAVIORAL|Differentiated service delivery approach (DSD) in TB treatment and prevention.|Although DSD models have been widely adopted in HIV programs, DSD is a relatively new approach for TB programs because of an historical reliance on directly observed therapy (DOT) (6). DSD provides opportunities to improve health outcomes and reduce the burden of seeking care for people diagnosed with TB.
223926299|NCT06887894|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy, plaque histological analysis and miRNA expression
223926300|NCT06737289|PROCEDURE|Surgical Guide|Placing extralarge implats for rahabilitation atrophic maxilla
223532140|NCT05504122|PROCEDURE|inguinal hernia repair|Patients who will undergo inguinal hernia repair will be divided into two groups(TEP versus Lichtenstein) according to the technique to be applied
223717684|NCT03766581|DRUG|Clopidogrel|Oral administration
223717685|NCT03766581|DRUG|Aspirin|Oral administration
223717686|NCT03501316|DEVICE|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
223717687|NCT03501316|DEVICE|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
223926301|NCT06739876|BEHAVIORAL|Wearable device-based intervention (with motivational support via social media)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity. Motivational support will be provided via an online community created using LINE platform. The platform serve for the following purposes: a) providing psychoeduation prior to the intervention; b) providing a place for participants to motivate and encourage each other; c) provide health knowledge to participants weekly, to motivate behavioral change; d) encouraging participants to upload their daily step count to the community page to motivate each other's progress; e) based on participant's performance, research assistants will provide tailored support using Line stickers designed for the present intervention; f) research assistants will monitor participants' step counts and provide prizes (vouchers) for those who had the most step counts and made the most improvements.
223926302|NCT06739876|BEHAVIORAL|Wearable device-based intervention (without support)|The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity.
223926303|NCT06741241|BEHAVIORAL|eHealth Promotora|Intervention participants attend an eHealth promotora-delivered educational session. Activities include an icebreaker, the completion of a baseline survey, an introduction to cervical cancer using a video and slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore possible barriers and solutions to health care access. Main topics included in the slide presentation are: female anatomy; cervical cancer etiology and disease progression by stage; cancer prevention including diet, exercise, safe sex, cancer screening; human papillomavirus (HPV) vaccine recommendations; Pap test preparations, procedure, screening interval; and information about where to receive a Pap test and seek more information about cervical cancer.
223926304|NCT06741241|BEHAVIORAL|eHealth Healthy Nutrition|Control group participants attend an eHealth educational session on healthy nutrition. Activities include an icebreaker, the completion of a baseline survey, an introduction to healthy eating using a video and a slide presentation, a cervical cancer knowledge pretest/posttest, and a dialogue activity to explore benefits and challenges to healthy eating.
223926305|NCT06040359|OTHER|The Thriving Mamas programme|Enhanced antenatal course plus usual perinatal care
223926306|NCT06040359|OTHER|Usual care|Usual perinatal care
223926307|NCT05321784|OTHER|Dermoscopy|Take digital dermoscopy images (DDI)
223926308|NCT05321784|OTHER|Digital Photography|Take smartphone clinical images (SCI)
223926309|NCT05321784|PROCEDURE|Self-Skin Examination|Perform self-skin exam (SSE)
223926310|NCT05321784|DEVICE|Skin Examination with Sklip|Apply Sklip System
223926311|NCT05321784|PROCEDURE|Skin Examination|Undergo in-person full body skin examination (FBSE)
223926312|NCT05321784|OTHER|Survey Administration|Ancillary studies
223926313|NCT06887140|DIAGNOSTIC_TEST|Echocardiography|"* First echocardiography: within 24 hours after study enrollment,~* Second echocardiography: 48-72 hours after the initial echocardiography.~* The recorded echocardiographic parameters include:~  * Morphological and Functional Parameters~ * Mitral Valve Flow Parameters~ * Tissue Doppler Echocardiography Parameters~ * STE Parameters for Left Ventricle Assessment~ * STE Parameters for Right Ventricle Assessment"
223926314|NCT06735443|DRUG|Bupivacaine with Dexmetedomidine|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with dexmedetomidine 0.5μg/kg. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
223926315|NCT06735443|DRUG|Bupivacaine with Tramadol|children will be anesthetized generally using Propofol 2.5mg/kg bodyweight, Atracurium 0.5mg/kg body weight and appropriately sized endotracheal tube (ETT) according to the age. Patients will be given 0.25% bupivacaine 1 mL/kg with 1 mg/kg of tramadol. Neostigmine 0.05mg/kg plus Glycopyrrolate 0.2mg/1mg of neostigmine will be used as reversal agents. After surgery, children will be shifted in post-surgical wards and will be followed-up there for 24 hours. After 24hours, children will be assessed for postoperative pain score.
223926316|NCT06736184|DRUG|Sodium Zirconium Cyclosilicate (SZC)|5g/meal\*3meals/day
223926317|NCT06735118|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy
223926318|NCT07039851|OTHER|Experimental|"Each session in the experimental group includes four phases:~1. Warm-up (10 min): Students engage in ice-breakers and movement activities to relax and prepare mentally and physically.~2. Games \& Activities (30 min): Drama and game-based tasks related to nature and recycling promote experiential learning and teamwork.~3. Improvisation (30 min): Students take part in role-plays and skits (e.g., acting as a tree or a recycled item) to build empathy and deepen their connection to environmental themes.~4. Evaluation (20 min): Students reflect on their learning, share feelings, and receive feedback. Facilitators summarize key points and reinforce the session's goals."
223926319|NCT06808061|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus plantarum KABP-51
223926320|NCT06808061|DIETARY_SUPPLEMENT|Placebo|maltodextrin
223926321|NCT06892431|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome Injection 20mg/m2, or 16mg/m2, intravenous drip, Q4W.
223926322|NCT06892431|DRUG|JMT101 injection|JMT101 Injection 6 mg/kg, intravenous drip,
223926323|NCT06892431|DRUG|Capecitabine|The dosage of capecitabine is 1000 mg/m2, taken orally twice daily, administered on D1-14 (Days 1-14) of each cycle, with every 3 weeks as one cycle (Q3W);
223926324|NCT06892431|DRUG|Docetaxel injection|The dosage of docetaxel is 75 mg/m2, administered via intravenous drip on D1 of each cycle, Q3W.
223926325|NCT06892431|DRUG|Gemcitabine hydrochloride for injection|The dosage of gemcitabine is 1000 mg/m2, administered via intravenous drip on D1 and D8 (Day 1 and Day 8) of each cycle, Q3W;
223926326|NCT06891404|OTHER|Nurse-Led Health Belief Model-Based Education|"Topic of the Training:~Importance of Genital Hygiene Behaviors Definition of Urinary Tract Infection (UTI) Complications that may arise if left untreated Effects on daily life Proper toilet hygiene Selection and cleaning of underwear Menstrual hygiene Importance of sexual hygiene Common Misconceptions About Genital Hygiene Behaviors"
223926327|NCT06890429|BIOLOGICAL|RSV/Flu-01E|Participants will receive single intranasal injection of RSV/Flu-01E vaccine in 0.5 ml, containing 8.4 lg EID50 of A/H1N1pdm09 recombinant attenuated influenza vector with modified NS gene, encoding for the F antigen of respiratory syncytial virus
223926328|NCT06890429|OTHER|Placebo|Participants will receive single intranasal injection of physiological buffer solution in 0.5 ml
223926329|NCT06739863|OTHER|healthcare waste management|"To evaluate and compare the healthcare waste management practices in primary and secondary hospital Mianwali.~Focuses on assessing the current methods of waste disposal, segregation, treatment, and overall management in healthcare settings at two different levels of care: primary and secondary hospitals."
224093427|NCT05144425|PROCEDURE|total knee arthroplasty with and without using pneumatic tourniquet|The randomization will be performed by a research fellow who will not be involved in patient care. All of the operations will be performed through the medial parapatellar approach by experienced knee surgeons. Drainage system will be used for 48 hours postoperative. In the tourniquet group, the tourniquet will be inflated to a pressure of systolic blood pressure plus 100 mm Hg and will be released after the joint capsule has been closed. hemostasis and then will be wrapped with elastic bandages. In the non-tourniquet group, the tourniquet will be wrapped around the thigh but will not be inflated during the surgery. The criterion for a blood transfusion will set as a hemoglobin (Hb) level of\<8 g/dL or patient with symptomatic anemia.
223532141|NCT02332811|DRUG|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
223926330|NCT06893874|OTHER|Preventive migraine treatment|Participants will be observed while receiving treatment-as-usual for their migraine by their treating physician
223926331|NCT06888648|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
224093428|NCT00223340|BEHAVIORAL|Patient Activation and Diabetes Registry|
223926332|NCT06888648|DRUG|mFOLFIRINOX Treatment Regimen|continuous intravenous infusion of fluorouracil 2400mg / m², for 46 hours, leucovorin 400mg / m², irinotecan 135mg / m², and oxaliplatin 68mg / m², every 2 weeks
224093429|NCT02909153|DRUG|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
223926333|NCT06888648|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks
223532142|NCT02332811|DRUG|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
223532143|NCT03190122|PROCEDURE|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. \[NCT ID not yet assigned\]
223532144|NCT03156829|OTHER|Splint|Custom made splint
223532145|NCT03156829|DRUG|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
223532146|NCT03156829|COMBINATION_PRODUCT|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
224281935|NCT00002633|DRUG|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
223926334|NCT06742268|OTHER|Single vision spectacles|Other interventions for myopia treatment, except for glasses, will not be provided.
224093430|NCT05213871|OTHER|Instrument-assisted soft tissue mobilization|For IASTM, the subject will be seated in a comfortable position. The subject's forehead will be rested on his/her forearm on a table in front of him/her. A lubricant (Vaseline) will be applied to the skin around the neck area prior to treatment and the M2T blade will be cleaned with an alcohol pad. The M2T blade will be used, at an angle of 45 without causing discomfort or pain, from the muscle origin to its insertion (sweeping technique), for approximately 3 min. Subjects will be instructed to put an ice pack on the area if they feel any burning sensations after the session. This procedure will be repeated twice a week for four weeks.
224093431|NCT05213871|OTHER|Myofascial release therapy|Firstly, the subject will lay supine with no pillow under his/ her head then the subject will rotate his/her head and neck away from the side which will be treated. Therapist will sit or stand at the corner, edge or top of the treatment table and therapist will place one hand proximal to the shoulder with skin on skin and therapist's fingers pointing towards the subject's elbow on the same side. Other hand of the therapist will be placed inferior to the subject's jaw (body of the mandible), using it as a handle, with fingers pointing towards the top of the subject's head. Then therapist will lean into the subject to the tissue depth barrier, wait and follow each subtle release three-dimensionally. Therapist should avoid forcing the tissue or slipping or gliding over the skin. The technique should be applied for at least five minutes for optimal results. This procedure will be repeated twice a week for four weeks.
224093432|NCT05213871|OTHER|Postural correction exercises (PCE)|Postural correction exercises will be applied for patients in groups A and B. This program will be conducted according to the protocols of exercise will be performed as 3 sets of 10 repetitions each for 2 times/ week for 4 weeks. The patients will be instructed to continue the exercises as a daily home program to influence the self-correction kinesthetic awareness. Exercises will be performed while the patients in a neutral sitting posture
223926335|NCT06741839|PROCEDURE|Confocal laser endomicroscopy guided pleural biopsy using medical thoracoscopy|After the completion of the routine thoracoscopic examination, the biopsy location was determined based on the results of chest CT/ ultrasound. The benign and malignant states of pleural lesions were explored by nCLE and image records were collected. Then, the biopsy tissues were collected under the guidance of nCLE.
223926336|NCT06741839|PROCEDURE|Plerual biopsy using medical thoracoscopy|After the completion of the routine thoracoscopic examination, the biopsy location was determined according to the results of chest CT/ ultrasound, and random pathological biopsy was performed, and biopsy tissues were collected by biopsy forceps.
223926337|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy followed by Exercise Training|6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
223926338|NCT05543083|BEHAVIORAL|Exercise Training followed by Cognitive-Behavioral Therapy|6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
223926339|NCT05543083|BEHAVIORAL|Cognitive-Behavioral Therapy Only|6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
224093433|NCT02515513|PROCEDURE|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
224093434|NCT05003115|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
224281936|NCT00002633|DRUG|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
224281937|NCT00002633|PROCEDURE|orchiectomy|Optional orchiectomy
224281938|NCT00002633|RADIATION|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
223926340|NCT05543083|BEHAVIORAL|Exercise Training Only|6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
223926341|NCT05217927|DRUG|Rimegepant 75mg daily dosing|Daily
224281939|NCT02275754|BEHAVIORAL|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
224281940|NCT02275754|BEHAVIORAL|PN Only|Participants will be navigated by PN on request
224281941|NCT03549897|DRUG|Placebo|Placebo Product
224281942|NCT03549897|DRUG|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
224281943|NCT03549897|DRUG|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE \[TEVA RESPIRATORY, LLC\]
224281944|NCT03549897|DRUG|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA \[AMNEAL IRELAND LIMITED\]
224281945|NCT02907073|DRUG|BF4|Single IV dose of 9-11 millicurie (mCi) sodium \[Fluorine-18\] radiolabeled B4\^F
224281946|NCT00732160|DRUG|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
224281947|NCT00732160|DRUG|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
224281948|NCT00732160|OTHER|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
224281949|NCT00732160|OTHER|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
223926342|NCT05217927|DRUG|Rimegepant 75mg every other day dosing|Every other day
223926343|NCT05217927|DRUG|Placebo comparator dosing|Placebo comparator
223926344|NCT06768645|BEHAVIORAL|Diabetic foot care education delivered using the Pecha Kucha method|"The study commenced after obtaining ethical approval and written consent from the relevant institution. The Pecha Kucha presentation was prepared by the researcher, adhering to established literature and the specific requirements of the technique. The education covered six key topics: 1) Diabetes and Foot Problems, 2) Daily Foot Care, 3) Appropriate Socks, 4) Appropriate Footwear, 5) Nail Care, and 6) Daily Life Precautions. Expert opinions were sought from four academics (S.Ö; K.L; Z.Z; G.F) with expertise in the field to establish content validity for the final version of the Pecha Kucha diabetic foot care presentation. Following expert approval, a pilot study was conducted with 10 diabetic patients who met the sample group criteria. Feedback from these patients regarding system functionality, clarity, and flow was incorporated to finalize the presentation. Afterward, the finalized Pecha Kucha Information training was delivered to the experimental group. The presentations were cond"
223926345|NCT06768645|BEHAVIORAL|traditional diabetic foot care education|traditional diabetic foot care education
223926346|NCT06788093|BEHAVIORAL|ED Clinical Decision Support (CDS-ED)|The ED-CDS intervention is designed as a discrete decision support aid to influence initial antibiotic decision-making in the ED. This intervention will feature a clinician-facing LRTI dashboard for end-users that assimilates relevant clinical data (e.g., vital signs, select diagnostic tests, links to reference information) and offers tailored suggestions for antibiotic initiation, related diagnostic testing, and in those receiving antibiotics, preferred options and alternatives for antibiotic choice, route, dose, and duration.
223926347|NCT06788093|BEHAVIORAL|Transitions Clinical Decision Support (CDS-Tr)|The CDS-Tr intervention is designed as a longitudinal decision support aid to influence initial and ongoing (i.e., continuation, discontinuation, escalation, or de-escalation) antibiotic decision-making in the hospital setting. This intervention will also feature the LRTI dashboard along with additional tailored suggestions and recommendations for antibiotic decision-making upon hospital admission, and for those receiving antibiotics, at the time of discharge. Additionally, CDS-Tr will be active at the time of any service transition (i.e., hospital to intensive care or vice versa) and at pre-specified time points (e.g., approximately 48 hours and 120 hours following ED triage for encounters remaining in the hospital).
223926348|NCT06765798|OTHER|Group A : receive neural mobilization for radial nerve , mulligan mobilization with movement and conventional Therapy|Group A :Neural Mobilization for radial nerve, Mulligan Mobilization with Movement and Conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for
223926349|NCT06765798|OTHER|Group B receive neural mobilization for radial nerve and conventional|Group B receive neural mobilization for radial nerve and conventional neural mobilization for radial nerve: The physiotherapist holds the patient's arm and wrist while the patient reclined on his side then depress the shoulder, extend the elbow and then internally rotated the patient's arm. The patient's wrist, thumb, and fingers were all flexed, and the patient's ulnar was brought to deviation. While the patient's position was maintained, and the arm was abducted and then contralateral cervical side bending conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors
223926350|NCT06765798|OTHER|Group C receive Mulligan mobilization with movement and conventional|"Group C receive Mulligan mobilization with movement and conventional~Mulligan mobilization with movement manual lateral glide MWM with gripping: Patient: Supine with upper limb fully supported on a treatment table. Treated body part: Relaxed extension of the elbow, shoulder internal rotation, with pronation of the forearm. Hands loosely around the grip dynamometer handles. Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session, conventional ; Ultrasound therapy , stretching and strengthening for wrist flexors and extensors"
223926351|NCT06765798|OTHER|Group D receive conventional|"Group D receive conventional :~Ultrasound therapy , stretching and strengthening for wrist flexors and extensors"
223926352|NCT06764797|DEVICE|Transcranial Direct Current Stimulation|tDCS will be used during the sessions. The anodal tDCS (2 mA) will be applied for 20 minutes. Continuous, direct currents. The anodal electrode will be positioned over the ipsilesional primary motor cortex (M1) (C3 or C4, international 10-20 system) of the affected hemisphere and the cathodal electrode over the contralateral orbit.
223926353|NCT06764797|DEVICE|Virtual reality|The VRMT group will receive VRMT game-based training using their non-affected upper limb. using a semi-immersive motion-tracking device.
223926354|NCT06764797|DEVICE|Transcranial Direct Current Stimulation compined with virtual reality based mirror therapy|20 minutes of tDCS during 45 minutes of VRMT games.
223926355|NCT06764797|OTHER|Conventional physical therapy|45 minutes of conventional physical therapy with sham tDCS
224093435|NCT04352920|OTHER|Experimental group|PHYSIUM System® provides standardized negative pressure massage for 15 minutes with the analgesic program and 15 minutes with the trigger points program at 80 millibars with eight adjustable arms both in the entire muscle and in muscle fibrosis.
224093436|NCT01147809|DRUG|Eltrombopag olamine|thrombopoietin receptor agonist
224093437|NCT01147809|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
224093438|NCT01993472|DRUG|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
224093439|NCT01993472|DRUG|Capecitabine|
224093440|NCT03112811|DEVICE|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
224093441|NCT03112811|DEVICE|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
223532147|NCT05367947|BEHAVIORAL|In-phase Bilateral Exercises of the upper limbs|"The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session."
223532148|NCT06217263|DEVICE|Vibration device|Vibracool vibration device from Pain Care Labs will be used.
223532149|NCT06217263|OTHER|Vibration device&Cold application pack|Pain Care Labs' Vibracool vibration device and cold gel pack will be used.
223532150|NCT04600284|DRUG|AD-2101|AD-2101 16/5mg
223926356|NCT05974553|BEHAVIORAL|Dialectical Behavior Therapy for Justice-Involved Veterans|16 weeks of Dialectical Behavior Therapy for Justice-Involved Veterans, including weekly 60-minute group therapy and biweekly 30-minute individual case management
223926357|NCT05974553|BEHAVIORAL|Supportive Group Psychotherapy for Justice-Involved Veterans|16 weeks of clinician-facilitated supportive group psychotherapy for justice-involved Veterans, including weekly 75-minute group psychotherapy (20 hours total intervention). All interventions delivered via telehealth.
223926358|NCT06786260|OTHER|Interventional Diet|Low salt, limited caffeine, high potassium, low phosphate, and limited protein and carbohydrate intake along with adequate water intake diet
223926359|NCT06791460|DRUG|Pegylated liposomal doxorubicin plus adebrelimab with mirabegron|Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.
223926360|NCT06791460|DRUG|Pegylated liposomal doxorubicin plus adebrelimab|Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.
223926361|NCT06798428|DEVICE|group A will receive ultrasound phonophoresis (Glucosamine, Chondroitin and Some Herbs Extract )|Group (A)will have GL, CH and natural herbs phonophoresis .Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm).
223926362|NCT06798428|DEVICE|Group B will receive ultrasound with topical gel , same parameter as group A|Ultrasound parameters are 1 W/cm for intensity, 1 MHz for frequency and 5 min continuous mode then 5 min pulsed mode. The device that will be used is medserve, England (the head of the device is 5cm). Topical gel with no drugs
223926363|NCT06798428|DEVICE|Group C sham ultrasound for massage - 5 minutes|sham ultrasound for massage - 5 minutes
223926364|NCT05120505|DRUG|Metformin|The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
223926365|NCT05120505|DRUG|Placebo|The patients in this group will be obtain starch tablets (which had same appearance and size comparing to Metformin) starting from 50mg everyday to 1-2g per day according to weights of patients for 6 months.
223926366|NCT06172283|OTHER|Intermittent Fasting|Dietary intervention
223926367|NCT06846827|OTHER|Oyster mushroom|Sachet containing the equivalent of 1 serving (9.39g) of dried ergothioneine-rich Pleurotus oyster mushrooms
223926368|NCT06846827|OTHER|Maltodextrin|Sachet containing 6.67g of maltodextrin
223926369|NCT06830941|DRUG|Iron isomaltoside|Intravenous infusion of 1000mg iron isomaltoside as a single dose for over 15min. Iron isomaltoside 1000mg was diluted in 100ml of 0.9% saline.
223926370|NCT06830941|DRUG|Ferrous succinate|Patients received ferrous succinate treatment orally given as 200mg twice a day for 8 weeks.
223926371|NCT01839747|PROCEDURE|PET-MRI|Imaging
223926372|NCT01839747|PROCEDURE|PET-CT|Imaging
223926373|NCT06786377|GENETIC|saliva sampling|saliva sampling
223926374|NCT06747780|BEHAVIORAL|Text messaging|A digital booklet, text messages for two weeks, and two family-based activity boosters
223926375|NCT06747780|BEHAVIORAL|Control (Usual care)|Control only
223532151|NCT04600284|DRUG|AD-2102|AD-2102 25mg
223532152|NCT04600284|DRUG|AD-2101 + AD-2102|AD-2101 16/5mg + AD-2102 25mg
223532153|NCT04745091|PROCEDURE|total mesorectal excision|excision of the rectum with complete excision of the mesorectum
223926376|NCT06746545|DRUG|Fruquintinib+S-1|Fruquintinib: 5 mg, oral, once daily，2w/1w；Q3W S-1：40-60 mg (dosed according to body surface area), oral，2w/1w；Q3W
223926377|NCT06702657|DEVICE|balloon dilatation and/or stenting|balloon dilatation and/or stenting immediately after randomization
223926378|NCT06702657|DRUG|medication|medication after randomisation, mechanical thrombectomy again if necessary, avoiding balloon dilatation and/or stenting.
223926379|NCT05650320|DRUG|0.3% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
223926380|NCT05650320|DRUG|1% OPA-15406 Ointment|Twice-daily administration for 4 weeks.
223926381|NCT05650320|OTHER|0% OPA-15406 vehicle|Twice-daily administration for 4 weeks.
223926382|NCT04079517|DRUG|Tamoxifen|A registered SERM drug, Tamoxifen.
223926383|NCT04952129|DRUG|Selenomethionine|Seleno-amino acid
223926384|NCT04952129|DRUG|Methylselenocysteine|Seleno-amino acid
223926385|NCT01028963|DRUG|Placebo|Placebo capsules once daily
223926386|NCT01028963|DRUG|pioglitazone|pioglitazone 30 mg tablet once daily
223926387|NCT01028963|DRUG|CCX140-B|CCX140-B capsules once daily (Group C)
223926388|NCT01028963|DRUG|CCX140-B|CCX140-B capsules once daily (Group D)
223926389|NCT06821594|DRUG|Furosemide|Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks
223926390|NCT05025826|OTHER|Phycocare|Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)
223926391|NCT05025826|OTHER|Placebo|Placebo every day during 9 months (except days of chemotherapy = no Placebo)
223926392|NCT02446405|DRUG|Enzalutamide|
223926393|NCT02446405|DRUG|NSAA|
223926394|NCT02446405|DRUG|LHRHA or Surgical Castration|
223926395|NCT06852105|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes
223926396|NCT06852105|DRUG|0.1% hyaluronic acid|0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
223926397|NCT05328401|DEVICE|Verum laser acupuncture|Applied verum laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
223926398|NCT05328401|DEVICE|Sham laser acupuncture|Applied sham laser acupuncture on specific acupoints in patient with post stroke shoulder pain.
224281950|NCT00676494|DEVICE|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
223926399|NCT06837038|DEVICE|rhythmic auditory stimulation|The intervention group was treated with a gait rhythm device under the supervision of the researchers. The complete gait training was conducted once a day for 15 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.
224281951|NCT03826394|BEHAVIORAL|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
223926400|NCT06837038|DEVICE|No rhythm stimulation|The control group received gait training without rhythmic auditory stimulation under the supervision of the researchers. The complete gait training was conducted once a day for 15 to 20 minutes for 7 consecutive days. Each patient wore inertial sensors at both ankles during gait training to collect gait information during walking.
223926401|NCT06750718|DEVICE|Virtual Reality (VR)|Oculus Quest 2 (OQ2) advanced 256 GB all-in-one virtual reality headset, Wi-Fi will be used.
224093442|NCT05934214|DRUG|Immune checkpoint inhibitor|"Reports associated with an an Immune checkpoint inhibitor with a status of Suspect or Interacting~ICI will include the following list of FDA-apporved ICIs:~nivolumab, pembrolizumab, cemiplimab, dostarlimab, durvalumab, atezolizumab, avelumab, ipilimumab, tremelimumab, relatlimab"
224281952|NCT03826394|BEHAVIORAL|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
224281953|NCT00020839|DRUG|temozolomide|
224281954|NCT00020839|RADIATION|radiation therapy|
224281955|NCT04859140|OTHER|Psychometric ratings (Likert-scale)|Self-report of perceived anxiety and physical sensations (muscle pain, relaxation and warmth)
224281956|NCT04859140|BEHAVIORAL|Range of motion measures|Sit-and-reach and toe touch tests
223926402|NCT06750718|OTHER|Comprehensive Sensorimotor Training|An exercise program consisting of Cervical JPSM, Cervical movement sense, and Oculomotor control exercises.
223926403|NCT06748313|OTHER|Mango Pickle (Water-Based)|The ingredients used in Mango Pickle (Water-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Mashed garlic, Mustard oil, Vinegar, and Water. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.
223926404|NCT06748313|OTHER|Mango Pickle (Oil Based)|The ingredients used in Mango Pickle (Oil-based) are Raw mangoes, Carrots, Lemon, Green chili, Gum Berry (Lasora), Grewia asiatica (Phalsa), Sea salt, Fenugreek seeds whole, Fenugreek mashed, Fennel seeds, Chili flakes, Coriander seeds, Turmeric powder, Cumin, Black seeds, Bay leaves, Vinegar, Mashed garlic, and Mustard oil. The pickle's fermentation process will be completed in 6-7 days, and it will be ready to use.
223926405|NCT06748313|OTHER|Carrot Pickle (Water-Based)|The ingredients used in Carrot Pickle (Water-Based) are Carrots, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
223926406|NCT06748313|OTHER|Radish Pickle (Water-Based)|The ingredients used in Radish Pickle (Water-Based) are Radish, Spring garlic, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
223926407|NCT06748313|OTHER|Onion Pickle (Water-Based)|The ingredients used in Onion Pickle (Water-Based) are Onion, Vinegar, Turmeric, water, mashed mustard seeds, chili powder, salt, and Mustard oil. The pickle's fermentation process will be completed in 3-4 days, and it will be ready to use.
223926408|NCT06748313|OTHER|Lemon & Chili Pickle (Water-Based)|The ingredients used in Lemon \& Chili Pickle (Water-Based) are Lemon, Green Chili, Turmeric, Vinegar, water, and salt. The pickle's fermentation process will be completed in 2-3 days, and it will be ready to use.
223926409|NCT06750796|BEHAVIORAL|The Half Swaddling Application|Half swaddling application in term babies
223926410|NCT06749418|DRUG|Eplerenone|Local heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
223926411|NCT06647342|DRUG|Bleomycin|In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.
224093443|NCT01956006|DRUG|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
224281957|NCT04859140|BEHAVIORAL|Mental calculation task|Iterated substractions (for 2 minutes)
224281958|NCT04859140|DEVICE|Resting-state electroencephalography|Alpha and beta oscillation power (4 minutes recordings)
223532154|NCT04966325|DRUG|LC350189 200mg|Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
223532155|NCT04966325|DRUG|Placebo|Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
223926412|NCT06069570|BIOLOGICAL|KB-GDT-01|KB-GDT-01 is an allogeneic, gamma delta T-cell suspension product manufactured from the isolation of healthy donor peripheral blood mononuclear cells (PBMC). The KB-GDT-01 cells are cryopreserved in vapor phase liquid nitrogen (LN2) in 50 mL CryoMACS® cryobags for a total of 200 × 106 viable cells/bag. The KB-GDT-01 cryopreserved product is thawed and administered intravenously (IV) until the entire bag is infused by gravity. Low dose radiotherapy (LDRT) will be administered to selected tumor sites (maximum of 5 isocenters) at 1.0 Gy/fraction on Days 1 and 2, followed by the KB-GDT-01 IV infusion on Day 3. LDRT will be repeated on Days 8 and 9, and the 2nd KB-GDT-01 IV infusion on Day 10.
223926413|NCT06805279|PROCEDURE|Axillary Vein Cannulation|"This study aims to evaluate the potential advantages of using the hockey stick ultrasonography probe for axillary vein cannulation and determine whether this probe enhances axillary vein imaging, accelerates the central vein cannulation procedure and reduces the rate of complications compared to the linear probe"
223532156|NCT04966325|DRUG|Moxifloxacin 400mg|Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
223926414|NCT06841926|DRUG|ZX-7101A dry suspension|Test formulation (T) : ZX-7101A dry suspension Specification: 10 mg/ bag Dosage：40 mg (4 bags)、 once
223926415|NCT06841926|OTHER|ZX-7101A tablet|Reference formulation (R): ZX-7101A tablet Specification: 40 mg/ tablet Dosage：40 mg (1 tablet)、 once
223926416|NCT06816173|DRUG|Propofol group|"Induction phase: Administer fentanyl at a dose of 2-3 mcg/kg, and after 3 minutes, administer propofol intravenously at a dose of 2.0 mg/kg.~Maintenance phase: Infuse propofol (4-12 mg/kg/h) and maintain a constant infusion of remifentanil at a rate of 0.05-0.4 μg/kg/min. Subsequently, perform regional block (0.25% ropivacaine 0.5 ml/kg) or caudal block (lower limbs or perineal area: 0.25% ropivacaine 0.5 ml/kg; lower abdomen/inguinal area: 0.25% ropivacaine 0.75 ml/kg). After the local anesthetic has taken full effect, stop the infusion of remifentanil."
223926417|NCT06816173|DRUG|Remimazolam group|"Induction phase: Administer fentanyl at a dose of 2-3 mcg/kg, and after 3 minutes, administer remimazolam intravenously at a dose of 0.45-0.55 mg/kg.~Maintenance phase: Infuse remimazolam (1-3 mg/kg/h) and maintain a constant infusion of remifentanil at a rate of 0.05-0.4 μg/kg/min. Subsequently, perform regional block (0.25% ropivacaine 0.5 ml/kg) or caudal block (lower limbs or perineal area: 0.25% ropivacaine 0.5 ml/kg; lower abdomen/inguinal area: 0.25% ropivacaine 0.75 ml/kg). After the local anesthetic has taken full effect, stop the infusion of remifentanil."
223926418|NCT06820320|DRUG|oral iohexol|Upon diagnosing chylous ascites, patients received oral iohexol treatment, a critical intervention in our therapeutic armamentarium. The initial oral dose was standardized to ensure a balance between efficacy and patient safety. In the event of a less than optimal response or significant drainage within the first 24 hours, a second identical dose of Iohexol was considered to maintain therapeutic concentration levels in the body.
224093444|NCT04318574|OTHER|Balance, Agility, Strengthening Exercise (BASE) Class|The BASE class will be conducted twice weekly for 1.5 hours each session over a 6-week period and will include a 10-minute warm-up, 30 minutes of static and dynamic balance exercises, 20 minutes of lower extremity strengthening exercises, and a 10-minute cool-down. There will be weekly falls prevention and mobility enhancement education provided during the class.
224093445|NCT02227576|DRUG|Romiplostim|
224093446|NCT06027801|OTHER|Iron-fortified cookies|Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.
224093447|NCT06027801|BIOLOGICAL|Japanese encephalitis (JE) vaccine|All participants will be administered the live attenuated JE vaccine
224093448|NCT06027801|BIOLOGICAL|Typhoid Vi polysaccharide (Vi-PS) vaccine|All participants will be administered the typhoid Vi-PS vaccine
224093449|NCT06027801|OTHER|non-fortified cookies|Study cookies containing no iron
224093450|NCT01901887|DRUG|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
223532157|NCT04966325|DRUG|LC350189 600mg|Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)
224093451|NCT01901887|DRUG|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
224093452|NCT02687269|DRUG|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
224093453|NCT02687269|DRUG|Placebo|Patients receive Placebo twice daily in the three days before surgery
224093454|NCT04101110|OTHER|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
224093455|NCT00550498|BIOLOGICAL|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
224093456|NCT01499290|DRUG|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
224093457|NCT01499290|DRUG|Metronidazole|500 mg of Metronidazole
224093458|NCT01499290|DRUG|Meropenem|1 gram of Meropenem
224093459|NCT03885921|DRUG|Ezetimibe|oral tablet
224093460|NCT03885921|DRUG|Atorvastatin|oral tablet
224093461|NCT03885921|DRUG|Simvastatin|oral tablet
224093462|NCT00495027|BEHAVIORAL|Internet-delivered Stress Innoculation Training|
224093463|NCT03561727|PROCEDURE|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
223532158|NCT02434081|DRUG|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
223926419|NCT06820320|PROCEDURE|Lymphangiography and Embolization|"When conservative methods fall short in resolving chylous ascites, our protocol advances to precise interventional treatments. The escalation begins with ultrasound-guided lymphangiography. Through unilateral or bilateral inguinal lymph node access, iodized oil contrast is infused via a 9 ml/hour micro-pump, meticulously monitored by fluoroscopic imaging at 3-5 minutes intervals.~Following precise localization of the leakage site, embolization is performed with a sequence of carefully calibrated steps. The process entails cone-beam CT scanning and 3D reconstruction for a clear depiction of the leak, followed by direct needle access to the lymphatic rupture under DSA guidance. A fine guidewire is inserted above the rupture, which facilitates the delivery of an embolizing mixture of iodized oil and NBCA glue. This is done with the utmost precision to prevent any spillage, ensuring the embolization's success and marking the conclusion of the procedure."
223926420|NCT06819527|OTHER|Medication reconciliation service|Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.
223926421|NCT05054257|DRUG|Autologous CAR19 T lymphocytes|First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
223926422|NCT06673342|BEHAVIORAL|Nutritional Counseling|Nutritional counseling based on Stephan's Curve. The Stephan's curve is a diagram that shows how the acidity of the oral cavity changes with consumption of food, specifically with added sugar. A laminated Stephan's curve will be used to show the drop of pH (acidity) based on the subject's reported daily consumption of food and snacks. Recommendations will be provided on a balanced diet according to the American Dental Association guidelines and recommendations on reducing the frequency of snacking.
223926423|NCT04285957|OTHER|Questionnaire administration pre test|"Pre-test:~Two expert physicians/physical therapist shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI);"
223926424|NCT04285957|OTHER|Questionnaire administration - validation|Validation Two expert physicians shall be involved in the questionnaire administration (A/B). The questionnaires shall be randomly administered to the patients by one operator at T0 the same test shall be readministered after 1-2 weeks by another operator (T1), blind to the first assessment; the second operator shall also administer the additional measures (SIP and RMI); In case the patient is unable to be interviewed due to aphasia cognitive or sensorial problems, a proxy would be interviewed both at T0 and at T1 (the same proxy would be interviewed both times)
223926425|NCT06752083|DIETARY_SUPPLEMENT|AHCC® (Active Hexose Correlated Compound)|3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.
223532159|NCT05738226|DEVICE|EpiCare@Home, wearable multimodal seizure monitoring system|"Two wearable devices (Byteflies Sensor Dots) will be used. One Sensor Dot will be placed in the neck with a skin adhesive and will be connected to EEG electrodes placed behind each ear. The second Sensor Dot will be placed on the chest with an adhesive ECG electrode (i.e., a cardiac patch)."
223926426|NCT06752083|BIOLOGICAL|Gardasil 9®|Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
223926427|NCT06757179|DIETARY_SUPPLEMENT|Elysium Naso Gola|"Elysium Naso Gola Supplement is a dietary supplement designed to soothe the upper respiratory tract, providing a range of benefits thanks to the properties of its natural ingredients. Its anti-inflammatory, antibacterial, antifungal, antiviral, antioxidant, and prebiotic activities suggest a comprehensive product for supporting respiratory health.~Mullein promotes the functionality of the respiratory mucous membranes. Thyme supports nasal and throat well-being, aids in the fluidity of bronchial secretions, and has antioxidant properties."
224281959|NCT04859140|DEVICE|Resting-state galvanic skin resistance measures|Skin conductance during the resting state period
224281960|NCT04245358|DEVICE|Ainara|1g of gel per administration
224281961|NCT01264835|DEVICE|Slotted Anoscope|SA411
223532160|NCT00419744|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|
223532161|NCT00419744|DRUG|Formoterol Turbuhaler|
223926428|NCT06757179|OTHER|Placebo|Placebo
224281962|NCT04939558|DEVICE|N-Tidal C handset|Participants are to use the 'N-Tidal C' handset every day for 14 days. This will ideally be two times a day (once in the morning and once in the evening, before using any regular inhalers). Each breath record requires the participant to breathe through the mouthpiece for 75 seconds in a relaxed manner.
224281963|NCT02833636|PROCEDURE|ACEF score|
223926429|NCT04962139|DRUG|ON101 Cream|Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
223926430|NCT04962139|OTHER|Vehicle Cream|ON101 Cream Placebo
223926431|NCT05460520|BEHAVIORAL|VOR Readaptation|"The stimulus will be a combination of horizontal visual motion and a head maneuver. The subject will sit in a stationary chair, and a treatment provider will stand behind the subject. While the subject views the slow horizontal motion up to 10°/s of vertical stripes, the provider will gently hold the head of the subject above the ears and tilt the head in the roll (side-to-side) or pitch (up-down) plane by approximately ±20° at the frequency of 0.2 to 0.05 Hz for up to 10 min. The treatment will be repeated with breaks of approximately 5 min. A treatment session will last no longer 120 min including the breaks.~In Groups 1, 3, and 4, subjects will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius, and full-field visual motion will be generated with light projected on the wall of this chamber. In Group 2, visual motion will be presented on the screen of a VR headset. Unlike groups 3 and 4, groups 1 and 2 do not receive any complementary treatment."
223926432|NCT05460520|BEHAVIORAL|VOR Habituation|The subject will sit in a chair placed in the center of a cylindrical enclosure of a 95 cm radius. Physical motion will be generated by rotating the chair sinusoidally to the left and right, and full-field visual motion will be generated with light projected on the wall of this chamber. Velocity storage will be weakened by inducing a conflict between physical and visual motions. Subjects will be first treated with a stimulus with a peak speed of 5°/s. The stimulus speed will be gradually increased from 5°/s on Day 1 to 40°/s on Day 5. In total, the subjects are expected to undergo 200-280 min of treatment over the five days, broken up into several 10-20 min sessions per day with a 10-min break in between. If signs or symptoms of motion sickness are reported by the subject (nausea, sweating), the session will be immediately paused. Treatment may be continued after a short rest if the discomfort is alleviated or on the following day.
223926433|NCT05460520|BEHAVIORAL|Visual Motion Desensitization|The subject will be situated in darkness and view the movement of a visual pattern presented on a disk, sized 1 m in diameter and placed 1 m away from the subject with its center at the eye level. The disk will be rotated clockwise and counter-clockwise for up to 10 min at a fixed maximal speed within a treatment session but varying across sessions between 5 to 60°/s. Within a single session, the visual stimulus will be first presented with the subject sitting upright in a chair, and then the treatment will be repeated with the subject standing. The disk will be mounted on a vertical sled, so the center of rotation can be kept at the eye level when sitting and standing. A treatment session will be repeated or conducted with an increased visual motion speed up to 60°/s according to the subject's readiness. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions per day with a 10-min break in between
223926434|NCT05460520|BEHAVIORAL|Opposing visual motion stimulus|"The investigators characterize gravitational pull as a misaligned sense of upright in the velocity storage mechanism, and hypothesize that that this misalignment can be corrected with an opposing visual motion stimulus, e.g., backward pulling will be corrected with upward visual motion.~Patients in Group 5 will undergo view visual motion in a physical setting, and those in Group 6 under a VR setting. In total, the subjects are expected to undergo up to 300 min of treatment over the five days, broken up into several sessions of 1-10 min per day with an approximately 5-min break in between."
223926435|NCT06717295|DIAGNOSTIC_TEST|DiNanoQ: A multi-cancer early detection (MCED) blood test|"Procedure: Participants will undergo a single blood draw at baseline.~Sample Analysis:~Platelet Isolation: Platelets will be extracted from the collected blood samples.~RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer."
223926436|NCT06717295|OTHER|DiNanoTrack: Therapeutic Response Monitoring Blood Test|"Procedures:~Blood Sample Collection: Participants will have blood samples drawn at three time points:~Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes.~Sample Analysis:~Platelet and Immune Cell Isolation:~Platelets: Extracted from each blood sample to continue monitoring RNA profiles.~Immune Cells: Separated from the blood samples to analyse immune response to therapy.~RNA Analysis:~Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools.~Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses.~Data Correlation:~Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance."
224093464|NCT03561727|PROCEDURE|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
224093465|NCT04052139|DRUG|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
224281964|NCT04423445|OTHER|Laser acupuncture combined with acupressure|Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
223926437|NCT06746727|BEHAVIORAL|Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE)|This single-arm intervention will pilot a new, manualized intervention adapted from existing interventions using Acceptance and Commitment Therapy (ACT) to address alcohol use, PTSD, social functioning, and IPV use. ACT for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) aims to assist Veterans in developing skills central to psychological flexibility (e.g., acceptance, mindfulness, commitment to values-based action) to improve their relationship functioning and decrease IPV use in the presence of PTSD symptoms (e.g., anger, irritability, detachment from others) and alcohol use issues (e.g., cravings, triggers, disconnection from valued roles).
223926438|NCT06747494|PROCEDURE|General Anesthesia|Participants will receive a one-time general anesthesia dose during the total joint arthroplasty procedure as per standard of care.
223926439|NCT06747494|PROCEDURE|Spinal Anesthesia|Participants will receive a one-time spinal anesthesia dose during the total joint arthroplasty procedure as per standard of care.
223926440|NCT06746454|OTHER|Video Instructed Training Group|"Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included a landing error scoring system, knee position error sense, and frontal plane projection angle. After the pre-test measurements, 2 training packages with special instructions were performed for the video instructed training (VIT) group. The special instruction for the VIT group included a previously prepared video of a successful vertical jump landing task. This video was shown to the VIT group. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases."
223926441|NCT06746454|OTHER|Verbal Combined Focus Instructed Training Group|"Pre-test measurements were taken to determine the baseline values of the athletes before the training packages specific to their group. The pre-test measurements included landing error scoring system, knee position error sense, and frontal plane projection angle. After the pretest measurements, 2 training packages with specific instructions were performed for the CSE group. The special instruction given to the CSE group consisted of the following sentence, which included the both internal and external focus of attention; focus on how hard you push yourself off the ground and how fast you straighten your knees during this push-off. Immediately after the training packages, post-test measurements were taken. The post-test measurements included the same tests as the pre-test measurements. A follow-up test was taken 7 days after the measurements. The follow-up test included the same measurements as in the pre-test and post-test phases."
223926442|NCT06745973|DRUG|EPI-003|Intravenous (IV) infusion.
223926443|NCT06746389|DIETARY_SUPPLEMENT|3000 IU per Day Spray|Effects of vitamin D supplementation vs placebo on MPS in response to exercise and feeding
223926444|NCT05848791|OTHER|Exercise exposure|Participants are exposed to three different air quality environments in central London, chosen to maximise differences in nontailpipe air pollution. Participants will cycle at 60% of estimated maximum vo2 on static bikes for six 15 minute bouts with 15 minutes rest between bouts.
223926445|NCT06735040|OTHER|Photobiomodulation Therapy|Before each treatment session, the borders of the thyroid gland were marked with ultrasound by an endocrinology specialist. Eight target points (superior, mediolateral, inferior borders of the right and left thyroid lobes, right and left side of the isthmus) were demarked with a surgical pen. PMBT was applied to the marked areas on the thyroid gland, which were approximately 1 cm apart from each other.
223926446|NCT06735040|OTHER|Sham|In the sham PMBT group, the probe was placed similarly to the treatment group. The screen of the laser device was active; however, the energy was set to 0 J and the power to 0 Mw, and the same procedures were also performed.
224093466|NCT04052139|DRUG|Gabapentin|Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
223532162|NCT05528770|DEVICE|FCL+BPS|The automated insulin delivery system includes the Bolus Priming System, a software automatically analyzing past continuous glucose monitoring values to trigger priming insulin bolus delivery isn the suspected presence of meal like glycemic disturbances
223926447|NCT06743061|BEHAVIORAL|Post-Op Follow Up|Post Arthroscopic Biceps Tenotomy and Subacromial Decompression in Chronic Massive Rotator Cuff Tears.
223926448|NCT06738654|PROCEDURE|robot-surgery|Breast-conserving surgery for breast cancer using single-port robotic surgery.
223926449|NCT06738654|PROCEDURE|traditional open surgry|Breast-conserving surgery for breast cancer using traditional open surgery.
223926450|NCT06739239|DEVICE|Extra-Vascular Implantable Cardioverter Defibrillator|The pulse generator is implanted along the patient's left midaxillary line, and the lead is positioned substernally.
223926451|NCT05466799|DRUG|FOLFIRINOX chemotherapy|Standard Of Care Chemotherapy regimen for treatment of Locally Advanced Pancreatic cancer
223926452|NCT05466799|DEVICE|OncoSil™|Implantation of OncoSil 32P microparticles into the Pancreatic Tumour under EUS guidance
223926453|NCT06738342|OTHER|CHX 0.09% + Citrox + HA|The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
223926454|NCT06738342|DRUG|CHX 0.12%|The patient will use the assigned mouthwash starting 24 hours after the surgical procedures and continuing twice a day for 14 days.
223926455|NCT06748183|OTHER|Functional Power Training|Group A will participate in Functional Power Training (FPT) alongside routine physical therapy The exercise protocol aims to enhance strength, mobility, and endurance through resistance training across various functional activities. It includes exercises such as running, walking, chair pushing, stair climbing, propelling a stable scooter, and sideways walking, all performed at 50-70% of the participant's maximum speed. Resistance is added using methods like dragging a loaded box with a belt during running and walking, pushing a chair with a loaded box underneath, wearing a loaded vest while climbing stairs, and attaching a loaded box to a scooter for propulsion exercises. Each exercise involves 6 to 8 repetitions lasting 25 seconds, followed by 30 to 50 seconds of rest. This structured regimen focuses on controlled movement and endurance, providing a comprehensive approach to improving physical performance.
223926456|NCT06748183|OTHER|Routine physical therapy|Routine physical therapy for a child with Cerebral Palsy involves hot pack for muscle relaxation and isometric exercises to enhance motor skills, muscle strength, and coordination. Passive stretching will be given as a treatment plan. Therapists employ sit to stand exercise to improve gait, posture, and overall functional abilities. Regular progress evaluations are conducted to adjust interventions, ensuring ongoing improvements.
223926457|NCT06894953|DEVICE|Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)|AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Personalised AMPER is personalised to preferences and age of the participant.
223926458|NCT06894953|DEVICE|Non-Personalised Agent-based Memory Prosthesis to Encourage Reminiscing (AMPER)|AMPER has an embodied agent (CGI character) who will ask questions about various memory cues such as pictures, audio files and videos from a BBC reminiscence archive (https://remarc.bbcrewind.co.uk/) to bring to the surface memories residing in the still viable regions of the brain. Non-personliased AMPER is not personalised to preferences or age of the participant.
224093467|NCT04052139|DRUG|Placebo|In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
224093468|NCT03603743|BEHAVIORAL|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
224093469|NCT00743795|DRUG|placebo|oral BID
224093470|NCT00743795|DRUG|GS-9190|40 mg oral BID
224093471|NCT00743795|DRUG|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
223926459|NCT06894147|PROCEDURE|Genicular nerve pulse radiofrequency|After performing a diagnostic block with 1 mL of 1% lidocaine on the superior medial, lateral, and inferior medial genicular nerve branches, patients who experience more than 50% benefit from the procedure will undergo pulsed radiofrequency aplication.
223926460|NCT06892301|DRUG|YOLT-203|The IP is administered intravenously at the predetermined dose.
223926461|NCT06895356|DRUG|Tavapadon|Oral: Tablet
223926462|NCT02817659|DRUG|Glucagon|Glucagon infusion
223926463|NCT06760091|OTHER|baseline data collection and follow-up|At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
223926464|NCT06758830|RADIATION|Radiation Therapy|Radiation therapy (RT) is administered at a dose of 2 Gy per day for a total dose of 50 Gy delivered to the pelvis. This is done throughout 5 to 6 weeks.
223926465|NCT06758830|DRUG|Chemoradiotherapy|"Capecitabine: 825 mg/m² twice daily, prescribed 1-5 days per week, for 5 weeks during RT.~Or Bolus 5-FU regimen: 5-fluorouracil (5-FU) 400 mg/m2/day intravenously, administered on days 1-4 and 33-35. Calcium folinate (folinic acid) 20 mg/m2/day intravenously on days 1-4 and 33-35."
224093472|NCT00743795|DRUG|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
224093473|NCT03406962|DRUG|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
224093474|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
224093475|NCT00681551|DRUG|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
224093476|NCT00190775|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
224093477|NCT00190775|DRUG|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
224093478|NCT02568436|RADIATION|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
224093479|NCT03943329|PROCEDURE|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
223926466|NCT06758830|DRUG|Consolidation Chemotherapy|"XELOX: Oxaliplatin 130 mg/m² (day 1) + capecitabine 1000 mg/m² (days 1-14), every 3 weeks for 4 cycles.~Or FOLFOX: Oxaliplatin - 85 mg/m2 intravenously (2-hour infusion), drip for 1 day. Calcium folinate (folinic acid) - 400 mg/m2/d. intravenously (2-hour infusion), started on day 1. F(5-fluorouracil) - 400 mg/m2/d. intravenously (bolus), started on day 1. Repeat every 2 weeks for 6 times."
223926467|NCT06758830|PROCEDURE|Surgery|Transabdominal Resection: Abdominoperineal resection, low anterior resection, or coloanal anastomosis using total mesorectal excision.
223926468|NCT06758830|OTHER|Part two|Standard treatment protocols and follow-up procedures are implemented in clinical practice.
223926469|NCT06758830|OTHER|Adjuvant treatment|If indicated, adjuvant therapy will be administered as usual in clinical practice.
223926470|NCT06439160|OTHER|Participants will be asked to complete a series of questionnaires at t0, t1 and t2|"Individuals will be people who voluntarily will take part in a residential three to six weeks multidisciplinary inpatient intensive rehabilitation treatment targeting the improvement of psychological well-being, body image, and psychopathology for anorexia nervosa.~Therefore, at T0 (at the beginning of the treatment) and T1 (at the end of the rehabilitation programme), participants will fill out some self-report questionnaires to evaluate the effect of the multidisciplinary inpatient intensive rehabilitation treatment on different outcomes (i.e. psychological well-being, eating pathology, body image, and comorbidities), among which their social components/skills. Moreover, we will ask participants to complete 3 months after discharge the questionnaires related to the social components/skills only. Participants will be contacted by email, within the email participants will find a link to click on for the completion of the questionnaires."
223926471|NCT06754969|PROCEDURE|Peripheral Nerve Regenerative Interface (RPNI) and Nerve/Muscle Biopsy|RPNI is a surgical technique which wraps denervated muscle targets around severed nerve ends.
223926472|NCT06754969|PROCEDURE|Biopsy Alone|Sural nerve and muscle biopsy performed in the standard fashion.
223926473|NCT06841120|DEVICE|Actual laser application|At approximately 45 minutes into the treatment session, subjects in the laser group received irradiation from a 4 W power, 810 nm diode laser (Fox; ARC Laser, GmbH, Nürnberg, Germany). The laser was operated in continuous mode, delivering 12-second shots per point using a therapy head with a point size of 0.38 cm². Each point received 6.3 J/cm² of laser energy, resulting in a total energy density of 37.8 J/cm² across 6 points.
223926474|NCT06841120|DEVICE|Sham laser application|Sham laser was applied symbolically as a diffused closed laser (targeted beam) at the same distance and simultaneously. Evaluations after laser irradiation were conducted by a responsible specialist physician who was not involved in performing the treatment procedures.
223926475|NCT05197309|DIETARY_SUPPLEMENT|Metabolic Diet|Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
223926476|NCT06865963|GENETIC|vulvar biopsy and blood semples|Collection of different types of specimen from VBD patients and healthy controls: mRNA, protein, cells, blood
223926477|NCT06881537|DRUG|Capecitabine|Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 4 cycles
223926478|NCT06881537|DRUG|Oxaliplatin|Oxaliplatin is given by intravenous infusion at 130mg / m² on Day 1 every 3 weeks for 4 cycles
223926479|NCT06881537|DRUG|Bevacizumab|Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 4 cycles
224093480|NCT03943329|PROCEDURE|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
224093481|NCT00519077|DRUG|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
224093482|NCT01967225|DRUG|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
224093483|NCT01967225|DRUG|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
224093484|NCT06006078|DEVICE|Endoscopic Patient Facemask|A commonly used endoscopic patient facemask that is normally used for oxygen delivery during endoscopy will be tested in this trial as a potential intervention for decreasing particle aerosolization
223926480|NCT06881537|DRUG|Tislelizumab|Tislelizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles
223926481|NCT06886568|PROCEDURE|Ultrasound-guided ganglion impar block|The procedure will be performed under sterile conditions and continuous monitoring. Using an ultrasound device with a 10-12 MHz linear probe, a 22G spinal needle will be advanced into the sacrococcygeal joint space using the out-of-plane technique. After confirming loss of resistance with a syringe containing normal saline as the needle exits the capsule anterior to the joint, approximately 1 mL of contrast medium will be injected. Anteroposterior (AP) and lateral fluoroscopic images will be obtained to verify the spread of the contrast agent. Once adequate contrast distribution is confirmed anterior to the coccyx on the lateral view, a mixture of dexamethasone and bupivacaine will be injected to complete the block. Procedures that cannot be completed or successfully visualized under ultrasound guidance will be finalized under fluoroscopic guidance.
223926482|NCT06884111|DRUG|EE001，70-105ml per day by IV|EE001 is a brand-new testing agent for human studies, it is the first time in human being
223926483|NCT06883656|DRUG|SAL067|Fasting oral test drug 12mg
223926484|NCT06765512|OTHER|use of deep learning and automated machine learning to diagnose and classify adenomyosis|Vertex AI Vision V1 software will be used as an automated machine learning tool and Pytorch 2.5 as deep learning framework. The complete set of reviewed, formatted and labelled images will be uploaded and split manually into two different datasets in 9:1 ratio; 90% of the selected images will be used as training dataset (training + validation) and 10% as test dataset.
223717688|NCT06436365|PROCEDURE|Locking expert intramedullary nail fixation|"the fracture was reduced to enable the insertion of the guide wire to restore the rotation, length, and angulation. Poller screws were used as control deformity by narrowing the medullary canal and were inserted on the deformity concave side between the nail and bone cortex. A ball-ended guidewire was placed through the entry point to the tibial canal and then to the tibial fracture site under the guidance of fluoroscopy. The guide wire should be inserted centrally within the distal segment on both lateral and anteroposterior views and be far about 1 to 0.5 centimeters from the ankle joint. Reamers with deep fluted and small diameters were used slowly to increase the diameter to reach 0.5 mm till the cortical chatter.~The nail was inserted by attachment of insertion device and locking of the proximal screw to the nail by directing its apex posteriorly. The nail insertion was done by flexing the knee to prevent any patellar impingement."
223926485|NCT06766812|DEVICE|epidural set|The epidural space will be identified at either the L3-L4 or L4-L5 interspace using the loss of resistance technique with an 18 Gauge Epidural needle.A test dose of 3 mL of 2% lidocaine with epinephrine will be administered to each participant to rule out intravascular or intrathecal placement of the catheter. This ensures the proper placement of the catheter before the full dose of analgesia is administered.Following the test dose, an initial bolus of 8 mL of 0.25% bupivacaine combined with 2 μg/mL fentanyl will be administered to provide effective labor analgesia. Subsequently, maintenance Dose 0.125% 2 ml/0.5 hr
223926486|NCT06765772|PROCEDURE|Erector spinae plane block|the patient will recieve ultrasound guided erector spinae plane blockbe. A 20-gauge needle will be placed between the erector spinae muscle and the thoracic transverse processes at the level of T10 using an 'in plane' technique, 20 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
223926487|NCT06765772|PROCEDURE|Rectus sheath block|the patient will recieve ultrasound guided rectus sheath block. An 18-gauge needle will be introduced- in plane- just below the costal margin at an angle of approximately 45 degrees to the skin between the rectus abdominis muscle and posterior rectus sheath. 10 ml of (0.25% bupivacaine and 1% xylocaine) will be injected on each side.
223926488|NCT06763601|PROCEDURE|SSMP, Isometric exercise, eccentric exercise, heavy slow resistance , functional program|In this group the patients will be given symptom modification procedure in the first phase followed by isometric exercises in second phase, eccentrics and HSR in third phase and functional program in fourth phase
223926489|NCT06763601|PROCEDURE|MWM,Isometric exercise, eccentric exercise, heavy slow resistance , functional program|in this mobilization with movement in first phase will be given followed by isometrics, eccentrics and heavy slow resistance exercise and finally the functional program
223926490|NCT06763601|PROCEDURE|sham mobilization|Sham mobilization followed by isometrics, eccentric training and heavy resistance training and finally the functional program .
223926491|NCT06885463|PROCEDURE|platelets rich plasma combined with PDO threads|"1. Injections of platelets-rich plasma in the Anterior Vaginal Wall.~2. PDO thread placement in the paraurethral, lateral urethrovaginal, and suburethral areas"
223926492|NCT05545280|DRUG|Neostigmine with glycopyrrolate|Administration by intravenous infusion
223926493|NCT05545280|DRUG|Sugammadex|Administration by intravenous infusion
223926494|NCT06295952|DRUG|Pasireotide|Pasireotide will be initiated at 40 mg IM one time dose and if tolerated dose will be increased to 60 mg IM every 4 weeks +/-7 days.
223926495|NCT06295952|OTHER|SF-36 and HADS|Baseline assessment will be conducted within 30 days of starting treatment, week 12, 24 and week 28.
223926496|NCT06760988|DIETARY_SUPPLEMENT|CL22205|Experimental Dose: 200 mg, Mode: Oral, once daily after breakfast Duration: 135 days
224093485|NCT01443013|OTHER|Renal Transplant|urinary sample at month 3, 6 and 12
224093486|NCT03955367|RADIATION|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
224093487|NCT03955367|RADIATION|Pelvic irradiation|CTV covers pelvis.
224093488|NCT03955367|RADIATION|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
224093489|NCT03955367|DRUG|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
224093490|NCT03747952|PROCEDURE|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
224093491|NCT03747952|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
223926497|NCT06760988|OTHER|Placebo|Mode: Oral, once daily after breakfast Duration: 135 days
223926498|NCT06715501|DRUG|Cadonilimab|Cadonilimab is a PD-1/CTLA-4 bispecific antibody. The drug is administered at a fixed dose of 10mg/kg, intravenously (i.v.), on day 1, every 3 weeks (q3w), until disease progression or intolerable toxicity occurs, with a maximum treatment duration of 1 year.
223926499|NCT06715501|RADIATION|radiotherapy|GTV is defined as visible lesions (GTVp: primary lesion; GTVn: metastatic lymph nodes), CTVp is defined as 3cm above and below the primary lesion, with 0.5cm outward expansion around the periphery, and CTVn is defined as 0.5cm outward expansion of GTVn; PTVp is an outward expansion of 0.5cm for CTVp, and PTVn is an outward expansion of 0.5cm for CTVn. Radiotherapy dose: DT50.4Gy/28f, once daily, 5 times a week
223926500|NCT06715501|DRUG|carboplatin, paclitaxel|Induction chemotherapy: carboplatin 5AUC，q3w; Paclitaxel 135mg/m2,q3w. Simultaneous chemotherapy: 2AUC/W，total 5w; Paclitaxel 50mg/m2/w，total 5w
224093492|NCT04261244|RADIATION|preoperative radiotherapy|preoperative radiotherapy instead of postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
223926501|NCT06745687|DRUG|CM336|Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1 and cycle2. Then patients will be given 160mg every 2 weeks from cycle 3 to cycle 6. The dosing interval is adjusted according to the evaluation of efficacy every 6 cycles from cycle 7 to cycle 24.
223926502|NCT06748885|DEVICE|Mpact 3D Metal Monolith|THA with Mpact 3D Metal Monolith
223926503|NCT06758453|OTHER|Dietary Challenge|Ingestion of a high-fat, high-glucose meal to induce postprandial variations in bile acids and other metabolic markers.
223926504|NCT06759337|BEHAVIORAL|Stress Ball Group|Participants are given a colored silicone stress ball (5-7 cm diameter) 5 minutes before the procedure. During the procedure, they are instructed to squeeze the ball twice after counting to 10 and repeat this until the procedure is complete.
223926505|NCT06759337|BEHAVIORAL|Hand-Holding Group|The researcher holds one of the participant's hands during catheter insertion and removal. The researcher's fingers are closed but not interlocked and placed gently on the participant's hand without additional movements or gloves.
224093493|NCT04261244|RADIATION|postoperative radiotherapy|postoperative radiotherapy in breast cancer after neoadjuvant chemotherapy
224093494|NCT06007612|BEHAVIORAL|Context Sensitivity in Emotion Regulation|Context Sensitivity of affective intensities and its association to Emotion Regulation Flexibility Selection
224093495|NCT04381234|DEVICE|dialyzer|Asymmetric triacetate dialyzer
224093496|NCT04381234|COMBINATION_PRODUCT|hemodialysis with citrate-containing dialysate|acetate-free dialysate
224093497|NCT04381234|OTHER|predilution hemodiafiltration|predilution hemodiafiltration
224093498|NCT02134600|DIETARY_SUPPLEMENT|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
224093499|NCT04960891|DRUG|Tebentafusp|Concentrate solution for intravenous infusion
224281965|NCT01889550|BEHAVIORAL|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
223926506|NCT06744361|DRUG|esketamine hydrochloride|Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
223926507|NCT06744361|DRUG|propofol|Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol
223926508|NCT06749743|DIAGNOSTIC_TEST|FASTER RCNN|train artificial intelligence models ( FASTER RCNN, YOLOY ) to detect dental caries , then test their accuracy
223926509|NCT06761001|DEVICE|I-PRF|After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution. I-PRF is given to patients in the experimental group.
223926510|NCT06761001|OTHER|Control|After local anesthesia is injected, alveolar curettage is performed and the socket is irrigated with saline solution.
223926511|NCT06763900|DEVICE|Skeletal anchorage and intermaxillary elastic assisted maxillary protraction|maxillary protraction with corticotomy-assisted different miniplate and intermaxillary elastic applications after growth spurt in patients with skeletal Class III malocclusion
223926512|NCT06764914|OTHER|integrative and complementary medicine|Treatment with integrative and complementary methods for both, inpatients and outpatients, includes conventional therapy, integrative methods and ordinal therapy/MBM, which are individually designed for each patient. Similar to a shedule, with therapy units from the following areas: hydrotherapy/thermotherapy, exercise therapy, physiotherapy, nutritional therapy and bodywork therapy, supplemented as required by phytotherapeutic and other therapies, such as acupuncture, neural therapy and cupping. After inpatient treatment, patients can receive up to 10 additional outpatient treatments at our TCM outpatient clinic. There is also a 10-week programme for day patients. This focuses on ordinal therapy to achieve sustainable, balanced lifestyle changes. This includes classic acupuncture and drainage techniques such as Gua Sha (connective tissue massage in TCM) or cupping, as well as neural therapy, electro-acupuncture and others. Daily medical visits and self-care advice are also included.
223926513|NCT06773221|DRUG|Chiglitazar 64mg|Chiglitazar 64mg, oral, qd, for 72 weeks
223926514|NCT06773221|DRUG|Placebo|Placebo, oral, qd, for 72 weeks
224093500|NCT04884828|DEVICE|external gas during NIV|The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
224093501|NCT00257036|DRUG|levofloxacin|
224093502|NCT02646904|DRUG|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
224093503|NCT02646904|DRUG|CERCHIO 10 mg/ml OS|For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
224281966|NCT01889550|BEHAVIORAL|Access to the website www.ouh.dk|Access to the usual information from the hospital website
224281967|NCT00959569|DRUG|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
224281968|NCT00959569|DRUG|Placebo|normosaline (same ml of the study drug)
224281969|NCT00671567|DRUG|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
224281970|NCT00671567|DRUG|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
224281971|NCT00671567|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
223926515|NCT05198297|DEVICE|Hydrus Microstent|Minimally invasive glaucoma surgery device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
223926516|NCT05198297|PROCEDURE|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
223926517|NCT06779253|DRUG|pimicotinib capsules|the effect of multiple oral doses of pimicotinib (50 mg QD) on the pharmacokinetics of fexofenadine (P-gp sensitive substrate), rosuvastatin (BCRP sensitive substrate) and metformin (MATE1 sensitive substrate). Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration
223926518|NCT06779903|OTHER|the psychoeducation intervention program booklet|Psychoeducation Program was composed of nine basic topics (postpartum period and care, adaptation to the role of motherhood and mother-infant bonding, postpartum psychological changes, frequency, causes, symptoms of PPD, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support and suggestions for coping, breast milk and breastfeeding, breast care and practices, nutrition and baby care).
223926519|NCT06779903|OTHER|routine care|routine care
223926520|NCT06779955|BEHAVIORAL|foot massage application|The characteristics of Massage Manipulations are an important feature in planning. Since the purpose of the massage is to rest, calm and relax, Effleurage (Stroke), Petrisage (Kneading) and Friction (Circular Rubbing) techniques that support circulation and have a loosening effect on the tissues have been chosen.A massage will be given to both feet for a total of 16 minutes, 8 minutes for each foot.The person receiving the massage will be lying down comfortably in a supine position, supported by pillows under the head and lower legs.Foot massage will be applied once to patients in the supine position at the first hour after their admission to the coronary intensive care unit following transfemoral angiography.
223926521|NCT06768775|DIETARY_SUPPLEMENT|Pastured Livestock Diet|Participants will consume a diet consisting of animal-source foods (chicken, beef, pork, and eggs) from regenerative/pastured farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
223926522|NCT06768775|DIETARY_SUPPLEMENT|Conventional Livestock Diet|Participants will consume a diet consisting of animal-source foods (chicken, ground, pork, and eggs) from conventional farming practices. Foods will be provided weekly in specific quantities for a 16-week intervention. Adherence will be monitored through dietary logs and ASA24 dietary assessments.
223926523|NCT06765174|DEVICE|Suction Drain placement (Example: Q-vac)|After thyroid surgery we pust drain at bed of surgery to monitor post operative bleeding.
223926524|NCT06766110|OTHER|Assessment|31 volunteer participants who were followed up at the Department of Chest Diseases, Istanbul University, Istanbul Faculty of Medicine and met the inclusion criteria were included in the study. Participants' body composition, upper extremity functional exercise capacity, grip strength, and activities of daily living were evaluated.
223926525|NCT06768021|BEHAVIORAL|Guided visualization and standardized pre-sedation instructions|One arm will receive standardized pre-sedation instructions, as well as one-minute guided visualization.
223926526|NCT06768021|BEHAVIORAL|Standardized pre-sedation instructions only|One arm will receive standardized pre-sedation instructions only.
223926527|NCT06307704|PROCEDURE|Lung Ultrasound - guided Stepwise PEEP|After endo-tracheal intubation; A PEEP of 4 cmH2O will be initially used till 5 min after pneumoperitoneum. Then The PEEP will be adjusted in a stepwise approach after performing bedside lung ultrasound. The PEEP will be increased by 2 cmH2O until no lung collapse is detected. Lung ultrasound will be repeated 5 min after every change in the PEEP with a maximal PEEP of 12 cmH2O.
223926528|NCT06307704|PROCEDURE|Standard Ventilation Protocol|Volume-controlled ventilation (VCV) mode; with a tidal volume of 6 mL/kg of ideal weight, inspiratory : expiratory ratio 1: 2, PEEP 4 cmH2O, respiratory rate adjusted to keep end-tidal carbon dioxide tension (EtCO2) between 35 and 40 mm Hg, and inspired oxygen fraction of 50%.
223926529|NCT06824389|OTHER|Consultation Model of large language model in Ophthalmology Clinics|Large language model completes the medical history collection and recommends examinations.
223926530|NCT06758336|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
223926531|NCT06756594|DRUG|Dexmedetomidine-Propofol|efficacy of sedation with Dexmedetomidine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
224093504|NCT04782622|DRUG|Apatinib+Camrelizumab|Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
224093505|NCT03376828|DEVICE|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
224093506|NCT03376828|DEVICE|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
224093507|NCT05681728|DRUG|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
224093508|NCT05681728|DRUG|Paclitaxel|On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
223532163|NCT05528770|DEVICE|FCL|The automated insulin delivery system does not include the Bolus Priming System, and therefore does not automatically command priming boluses.
224093509|NCT05681728|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
224093510|NCT05681728|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion
223532164|NCT05543317|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-RGD PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-RGD, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
223532165|NCT01101126|OTHER|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
223532166|NCT01101126|OTHER|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
224093511|NCT03229577|BEHAVIORAL|Sudarshan Kriya Yoga|Yoga-based breathing program.
223717689|NCT06436365|PROCEDURE|Distal locked plate|Cobb dissector was used in creation extra-periosteal subcutaneous tunnel for gentle introduction of a proper plate which was determined by choosing appropriate size and level guided by imaging which helped in prevention of any periosteal damage. Manual closed reduction was performed using the percutaneous clamps. Distal screws were positioned as the following, one was inserted above the medial malleolus, another one was inserted right and below the fracture, and the other screws were inserted to help in anatomical plate positioning. By reduction preservation, proximal screws were inserted by small incisions which was followed by insertion of the remained distal screws.
223717690|NCT02648776|DRUG|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
223717691|NCT00520936|DRUG|pemetrexed|1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
223717692|NCT00783003|DRUG|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
223717693|NCT00783003|DRUG|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
223717694|NCT00783003|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
223717695|NCT00783003|DRUG|Placebo|Matching placebo.
223717696|NCT05818397|BEHAVIORAL|Self-Compassion for Children and Caregivers (SCCC)|A standardized, manualized adaptation of the mindful self-compassion curriculum for adults, designed for online delivery. Dyads join a group video conference call along with other caregiver-child dyads and and up to two experienced SCCC facilitators. Sessions occur 1-hour per week for 6 weeks at a time convenient for the group.
223717697|NCT05062382|BEHAVIORAL|Complementary feeding intervention|"The study promoted eggs.~GAIN provided training to egg farmers to increase their egg production and marketing, helped increase mother's access to eggs by making them more available in local kiosks and getting retailers to display promotional messages around eggs, conducted sensitization workshops with retailers to increase egg purchases, and employed a demand creation campaign."
223717698|NCT02759328|BEHAVIORAL|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
223717699|NCT02759328|BEHAVIORAL|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
223717700|NCT03369405|OTHER|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
223717701|NCT04561193|OTHER|Observational|Observational
223717702|NCT02454400|OTHER|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active"
223717703|NCT02454400|OTHER|Waiting-list|"Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active"
223717704|NCT03888456|OTHER|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
223717705|NCT03888456|OTHER|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
223926532|NCT06756594|DRUG|Ketamine-Propofol|efficacy of sedation with Ketamine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
223926533|NCT05652673|DRUG|nivolumab|Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
223926534|NCT06762028|DEVICE|SIMBA capsule|The small intestine microbiome aspiration (SIMBA) system is a single-use, ingestible passive capsule that allows for the non-invasive sampling of small intestinal contents. It is designed to open and adsorb intestinal content after having passed the acid stomach environment and to close mechanically before passing into the large bowel. It has distinct markers built in to allow radiographic tracking of its passage throughout the GI system.
223926535|NCT06830902|DEVICE|Regular Double J stent|Regular Double J stent
223926536|NCT06830902|DEVICE|Comfi J stent|Comfi J stent
223926537|NCT06828211|DIETARY_SUPPLEMENT|Trans-resveratrol extract from Polygonum Cuspidatum|Trans-resveratrol extract from Polygonum Cuspidatum
223926538|NCT06828211|OTHER|Placebo|Placebo
223532167|NCT04281667|DRUG|Oral Antibiotics|Oral antibiotics (neomycin 1g and metronidazole 1g at 3pm and 11pm the day before surgery)
223532168|NCT04281667|DRUG|Placebo|Oral placebos (placebo 1 and placebo 2 at 3pm and 11pm the day before surgery)
223532169|NCT04281667|DRUG|Mechanical Bowel Preparation|Mechanical Bowel Preparation using 2L polyethylene glycol (Moviprep)
223532170|NCT03931551|DRUG|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
223532171|NCT04838652|DRUG|Pembrolizumab plus Chemotherapy (ICE or DHAP)|Pembrolizumab (200mg) alone or in combination with ICE (or DHAP in case of PET positive findings after P-ICE) will be admistered. 6 additional courses of pembrolizumab will be administered after the completion P-ICE or P-DHAP
223532172|NCT01117779|DEVICE|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
223532173|NCT00444314|DRUG|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
223532174|NCT00444314|DRUG|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
224281972|NCT04712916|BEHAVIORAL|Health education|Individualized education intervention on medication use, appropriate diet and physical activity was explained to participants. Participants were guided on achieving recommended metabolic equivalent per week (MET) physical activity considering their health status and daily activities. Furthermore, participants were guided on appropriate dietary recommendation and resolving non-adherence behaviour to medication(s), diet and physical activity.
224281973|NCT04912986|BEHAVIORAL|Early Lung Rehabilitation Training|It is implemented in accordance with the Early Lung Rehabilitation Training Program for Adult Double Lung Transplant Patients. Establish multidisciplinary collaboration teams, including competent doctors, nurses, rehabilitation physicians, and psychologists.
224281974|NCT04912986|BEHAVIORAL|Routine treatment|Provide rehabilitation training as usual, without standard program
223532175|NCT04902612|DEVICE|HM242-Solution|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
223532176|NCT04902612|DEVICE|Saline|HM242-Solution compared to Saline compared in patients with a venous leg ulcer
223532177|NCT05941286|DEVICE|CGM system with both glucose predictive alerts and threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with both glucose predictive alerts and threshold alerts on
223926539|NCT06776978|DEVICE|Active treatment|Participants receive anodic tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). A constant current of 2 mA is applied for 20 minutes per session. The stimulation targets the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
223926540|NCT06776978|DEVICE|Sham Stimulation|Participants receive sham tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). No therapeutic current is applied during the 20-minute session. The electrode placement mimics the active condition, targeting the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. Sham tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
223926541|NCT06776588|PROCEDURE|Microwave ablation combined with biopsy|CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.
223926542|NCT06776237|DIAGNOSTIC_TEST|PoCUS|Participants after getting recruited will be asked for an ultrasonography of the neck. It will take around 30 minutes. At home, participants will be asked to wear a portable sleep study device overnight, to perform home sleep study. Although these devices are noninvasive and safe, they are not routinely used as a standard of care in the pregnant patient population.
223926543|NCT06776276|BEHAVIORAL|Tai Chi exercises|Tai-chi (TC) is a kind of CAM Qigong exercises, is a type of classic Chinese martial arts. It entails deliberate, slow-motion physical movements that are done alongside inward concentration, awareness of breathing, and the inherent power or energy in the body. It promotes general purposes of health and spirituality. It is generally accessible and offered to older people in public places.
223926544|NCT06775353|DRUG|Dexamethasone eyedrop|Infants who developed stages of pretreatment-requiring severe ROP were usually given one eyedrop of dexamethasone daily until the ROP changes regressed.
223926545|NCT06776835|DIAGNOSTIC_TEST|Analysis of relative quantitative of small non-coding RNAs|Each participant was enrolled to assess the of relative quantitative of small non-coding RNAs
223926546|NCT06777186|OTHER|10 meter walk test|"The dual task skills of the individuals will be evaluated by adding motor and cognitive tasks to the 10-meter walk test. Tasks given to individuals~Single motor task (comfortable walking): The individual is asked to walk at normal speed, the time is recorded Motor-motor dual task: Both hands carry a half-full water bottle, time is recorded Motor-cognitive dual task (mental) : counts backwards from 10 by 1, time is recorded Motor - cognitive dual task (memory) : The individual is asked to say 3 words that were previously spoken. The time is recorded."
223926547|NCT06777186|OTHER|Functional Balance|It will be assessed with the TUG test. The TUG measures the time it takes for an individual to get up from a chair, walk a distance of 3 meters, turn around, walk back to the chair and sit down again after a ready, go signal.
224093512|NCT03229577|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness program.
224093513|NCT03229577|BEHAVIORAL|Emotional Intelligence|Emotional Intelligence program.
224281975|NCT02414763|BEHAVIORAL|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
224281976|NCT01903564|DEVICE|magnetocardiography|recording of magnetic heart activity
224281977|NCT01903564|DEVICE|postnatal ECG|postnatal ECG
224281978|NCT01903564|DEVICE|fetal echocardiography|fetal echocardiography
224281979|NCT02227550|DRUG|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
224281980|NCT02227550|DRUG|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.
223532178|NCT05941286|DEVICE|CGM system with only glucose threshold alerts on|the cloud-based real-time continuous glucose monitoring and management system with only glucose threshold alerts on
223532179|NCT05941286|DEVICE|CGM system with glucose alerts off|the cloud-based real-time continuous glucose monitoring and management system with glucose predictive/threshold alerts off
223926548|NCT06777186|OTHER|Social Adaptation Assessment|Adaptive behavior will be assessed with the Vineland Adaptive Behavior Scales. It is a parent interview designed to assess functioning in daily life. \[35\]Specifically, adaptive behavior is assessed in four domains: Communication, Daily Living, Socialization and Motor skills. Vineland has reliability and current validity. It has been reported to be sensitive to the difficulties experienced by children with ASD
224281981|NCT00128817|RADIATION|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
224281982|NCT00128817|PROCEDURE|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
224281983|NCT04694703|DRUG|Covid-19 group|Routine COVID-19 treatment
224281984|NCT02257437|DIETARY_SUPPLEMENT|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
224281985|NCT02257437|DIETARY_SUPPLEMENT|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
224281986|NCT02257437|DIETARY_SUPPLEMENT|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
224281987|NCT02257437|DIETARY_SUPPLEMENT|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
224281988|NCT05152615|DIETARY_SUPPLEMENT|Short Chain Fatty Acids (SCFA) Dietary Supplement|Butryate 1000 mg three times daily will be used in this study.
223926549|NCT06777186|OTHER|Motor skills and proficiency|The Bruininks-Oseretsky Motor Proficiency Test (BOT-2) assesses fine motor, hand coordination, body coordination, strength and agility between the ages of 4-21 years.There are 53 items in the BOT-2. In BOT-2, there are four motor domains including fine motor control, hand coordination, body coordination, strength and agility and a total of eight subtests related to these domains.
223926550|NCT06767410|OTHER|Multidomain Intervention|The intervention is distinguished by its multidomain approach combining cognitive, social, and musical activities through choir participation, targeting holistic cognitive and emotional benefits, unlike active controls (general activities) and passive controls (no activities).
223926551|NCT06767410|OTHER|General activities|Participants will carry out a series of physical, manual and/or intellectual activities (e.g., horticulture, physical activities, theatre, learning programs etc.) but not musical activities
223926552|NCT06769139|OTHER|Red blood cell exchange|Red blood cell exchange manual exchange and automatized exchange
223926553|NCT06768853|PROCEDURE|Lymph node dissection based on the guidelines|During surgery, mediastinal lymph nodes will be dissected based on the NCCN guidelines (2023) .
223926554|NCT06768853|PROCEDURE|Lymph node dissection based on the model|During surgery, lymph nodes will be dissected based on the predicted lymph node status by the model.
223926555|NCT06768190|BEHAVIORAL|WhatsApp as usual|Pregnant women and their partners are instructed to use WhatsApp as normal for six weeks.
223926556|NCT06768190|BEHAVIORAL|WhatsApp-based psycho-socio-educational intervention (WeLove)|The intervention comprises six sessions, including psychoeducation, communication training, sleep hygiene, stimulus control, cognitive restructuring, and behavioural activation. Each session has two short videos, quizzes, forums, and homework. The content is presented through a virtual midwife using storytelling of real-life scenarios, animation, and case vignettes about psychological and sleep problems during pregnancy. A virtual midwife acts as an educator to explain the prevalence, causes, and factors of psychological and sleep problems. Every session will concentrate on certain courses and offer specialised advice to expectant mothers and their partners. Using the security links on the WhatsApp platform, each session takes 15 to 20 minutes to finish.
223926557|NCT06766669|OTHER|Shaping method activities combined with mirror therapy|This intervention involves the application of exercises consisting of shaping method activities accompanied by a mirror device. It is basically an intervention consisting of exercises that require manual dexterity.
223926558|NCT06778746|OTHER|no interventions|No interventions, this is an observational study
223926559|NCT06778681|OTHER|Cheer|"During voluntary muscle contraction subjects will be cheered with verbal encouragement (push, push, push) and clapping."
223926560|NCT06778902|DRUG|azacytidine|Azacytidine: 75mg/m2, d1-d5
223926561|NCT06778902|DRUG|R-GemOx|Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
223926562|NCT06778720|BEHAVIORAL|Music Therapy with over-the ear headphones|Eligible patients undergoing VATS procedure can have music therapy as an intervention to reduce pain levels after surgery and improve outcomes.
223926563|NCT06779539|DRUG|Ensartinib|Ensartinib 225 mg oral once daily 12 weeks
223926564|NCT06779422|BEHAVIORAL|Pai.ACT|The Pai.ACT mobile app is an innovative therapeutic tool that utilizes Acceptance and Commitment Therapy (ACT). It integrates a sophisticated algorithm to analyze self-reported data and conversation texts when the user interacts with the AI chatbot and identifies what psychological inflexibility processes are required to be the most essential to be addressed for process-matched ACT interventions. These interventions, including self-help modules and experiential exercises, are enhanced with dynamic animations and audio metaphors (see NCT06086951). The contents of Pai.ACT is underpinned by: (i) the core principles of Focused ACT, (ii) our validated Focused ACT protocol used in our ongoing Focused ACT trial (see NCT05803252), and (iii) our validated ACT protocols, established since 2019, that address psychological challenges specific to the Chinese parenting context (e.g., affiliate stigma, internalisation of external criticism, self-blame) through a 4-to-6 week of ACT.
224093514|NCT02290210|DRUG|URC102 0.25mg|
224093515|NCT02290210|DRUG|URC102 0.5mg|
224093516|NCT02290210|DRUG|URC102 1.0mg|
223926565|NCT06779422|OTHER|Positive parenting advice|Positive parenting advice is recommended by the Child Assessment Services under the Department of Health, and videoconferencing session(s) led by another experienced counsellor for content revision. No access to AI chatbot/ACT modules will be granted.
223926566|NCT04468178|DEVICE|Total joint arthroplasty of the glenohumeral joint|The arthroplasty of the glenohumeral joint will be performed as an anatomical reconstruction after primary or post-traumatic osteoarthritis.
224093517|NCT02290210|DRUG|URC102 2.0mg|
224093518|NCT02290210|DRUG|placebo|
223926567|NCT06760702|DRUG|AUR109 200mg|AUR109 200mg (once daily)
223926568|NCT06760702|DRUG|AUR109 300mg|AUR109 300mg once daily
224093519|NCT06143410|DRUG|Lidocaine 2% Injectable Solution|administration of a bolus of lidocaine 1.5 mg/kg
224093520|NCT06143410|DRUG|Saline administration as placebo|administration of a bolus of saline solution as a placebo
224093521|NCT06143410|DRUG|Propofol injection|Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)
224093522|NCT06143410|PROCEDURE|gastroscopy|esogastroduodenoscopy
224093523|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
224093524|NCT00327444|DRUG|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
224093525|NCT00327444|DRUG|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
224093526|NCT04941326|OTHER|Diaphragmatic stimulation treatment with PNF techniques|Thumbs and palms are placed along the cartilage edges of the lower ribs. At the end of the expiration, pressure and stretching are given as far into the chest and upwards as possible and a deep inspiration is requested immediately after the pressure. Both sides can be stimulated by repeated contraction technique. Hand holding positions may differ according to the patient's preference. If the patient's physical condition is not suitable, the application can be done with the thumbs, the thumb of the left hand for the right rib, and the thumb of the right hand for the left rib in the same lying position. The patient will be asked to do the application 2 times in a day with 10 repetitions for 4 weeks.
224093527|NCT04941326|OTHER|Costal mobilization|In the supine position, the individual will place both hands around the 10-12th ribs and alternately apply an oblique push from the right and left sides to the opposite side. The exercise will be taught to the patient as training, and he will be asked to apply it 2 times a day with 20 repetitions for 4 weeks.
223926569|NCT06760702|DRUG|AUR109 400mg|AUR109 400mg once daily
223926570|NCT06762678|DIAGNOSTIC_TEST|RNA sequencing and whole genome sequencing in a trio way|Patient is not required to be blinded
224093528|NCT04941326|OTHER|Breathing exercises|It is done to increase the diaphragm activity of the individual and to suppress chest breathing. While lying in the supine position, the legs are placed in a hooked position, with one hand on the abdomen and the other on the chest, and the deep breath that is taken from the nose in 2 seconds is asked to exhale through the mouth in 4 seconds, while revealing as little movement in the chest as possible, the main movement is requested to be around the abdomen. The application will be given to the patient as a home program and he will be asked to do it 2 times a day with 5 repetitions for 4 weeks.
223926571|NCT06772688|PROCEDURE|orthognathic surgery|Maxillary repositioning and fixation with custom made plate
223926572|NCT06847347|BEHAVIORAL|More Than Words®|More Than Words® (MTW) is a 13-week parent-implemented program designed to enhance communication, play development, and parent-child interaction for children under 4 years of age who have autism or social communication challenges. MTW is delivered by speech-language pathologists (SLPs) certified by The Hanen Centre, a global not-for-profit organization based in Toronto. MTW is delivered virtually in this trial. The program an orientation session, an individual pre-program consultation appointment, 8 x 2½ hour group training sessions (with 6-8 parents per group), and 3 individual video feedback sessions. During video feedback, the parent demonstrates use of communication facilitation strategies with their child, while the SLP records the interactions. The parent and SLP then review the videos together, analyze use of the strategies and how the child responded, and formulate plans to foster development of new skills.
223926573|NCT06761703|DEVICE|TAP® Micro Select Device (Touch Activated Phlebotomy)|The TAP Micro Select device will be used in an investigational capacity by participants for self-collection of whole capillary blood.
223926574|NCT06640543|OTHER|Kinesiotape|Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks
224093529|NCT04941326|OTHER|Spinal mobilization|T12 vertebrae will be found by following the 12th rib in the prone position of the individual and spinous of L1 and L2 vertebrae will be determined with this reference. Then, small amplitude rotational movements in the vertebrae will be revealed by pushing in the anterior direction over the transverse processes. This application will be applied once a week for an average of 10 minutes for 4 weeks.
224093530|NCT04941326|OTHER|Sham mobilization|Sham pressures will be applied to the lumbar region of the patient, away from the vertebrae. This application will be applied once a week for an average of 10 minutes for 4 weeks.
224093531|NCT02516930|BEHAVIORAL|crowdsourced video|video promoting condom use
224093532|NCT02516930|BEHAVIORAL|social marketing video|
224093533|NCT06016543|PROCEDURE|osteopathic manipulative treatment (OMT)|Osteopathic manipulative treatment provided at the discretion of the treating physician and based on the patient's response to previous treatments.
224093534|NCT05861583|OTHER|fat tissue|fat tissue sample collected while cosmetical liposuction
224093535|NCT05861583|OTHER|lipoedema tissue (stage 1)|lipoedema tissue sample (stage 1) collected while medical liposuction
224093536|NCT05861583|OTHER|lipoedema tissue (stage 2)|lipoedema tissue sample (stage 2) collected while medical liposuction
224093537|NCT05861583|OTHER|lipoedema tissue (stage 3)|lipoedema tissue sample (stage 3) collected while medical liposuction
224093538|NCT02678806|RADIATION|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
223926575|NCT06640543|OTHER|Myofascial release|Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
223926576|NCT06891248|PROCEDURE|Osteopathic Manipulative Treatment|See treatment arm
223926577|NCT06762158|RADIATION|Neoadjuvant Chemoradiotherapy|"Neoadjuvant chemoradiotherapy:~1. Radiation dose: 1.8Gy/Fx, DT41.4Gy/23Fx.~2. Concurrent chemotherapy: Albumin-bound paclitaxel 60mg/m² + Cisplatin 25mg/m² on D1, D8, D15, D22, D29."
223926578|NCT06762158|DRUG|neoadjuvant immunotherapy|Begins on the second day after the completion of concurrent chemoradiotherapy, and no later than one week. Toripalimab 240mg Q3W, for a total of two cycles.
223926579|NCT06762158|PROCEDURE|Surgery|Preoperative assessment is conducted 3 weeks after the last neoadjuvant immunotherapy, and surgery is performed within 4-6 weeks. All patients undergo minimally invasive radical esophagectomy, either McKeown or Ivor-Lewis, with extended two-field or three-field lymph node dissection.
223926580|NCT06762158|DRUG|adjuvant immunotherapy|Whether to undergo postoperative adjuvant immunotherapy is determined based on the pathological response. Patients with pCR are only observed without receiving adjuvant treatment, while those not reaching pCR receive one year of adjuvant Toripalimab.
223926581|NCT06748300|BEHAVIORAL|web- based education|breastfeeding education
223926582|NCT06737081|DRUG|SAL-0951 tablets 4mg|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
224093539|NCT02678806|DRUG|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
224093540|NCT00049387|DRUG|tipifarnib|Given PO
224093541|NCT00049387|DRUG|temozolomide|Given PO
224281989|NCT03079427|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
224281990|NCT03079427|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
224281991|NCT04232527|DIAGNOSTIC_TEST|Y Balance Test|The footballer will place one foot on the stationary platform of the test set during the test so that the top of the sneaker does not exceed the starting line. The second foot, or the tip of the foot, will push the movable part of the platform down the measuring tube, which is marked by half-inch intervals. Any lifting of the standing leg on the heel, on the toes or loss of balance will be considered a mistake and the attempt will be repeated. Mobility will be tested through 3 trial and 3 valid measurements of the lower limbs in the anterior, posteromedial, and posterolateral directions. The arms should rest on the hips.
223532180|NCT00398814|DRUG|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
223532181|NCT00398814|DRUG|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
223532182|NCT06793397|DRUG|CYB003|CYB003 is a deuterated psilocin analog.
223926583|NCT06737081|DRUG|SAL-0951 tablets 5mg|initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
223926584|NCT06739395|DRUG|Olaparib tablet|Usage and dosage: The recommended dosage is 200mg, twice a day, equivalent to a total daily dose of 400mg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided(from the I-PREDICT study).
223926585|NCT06739395|DRUG|Temozolomide capsule|Administration method and dosage: 75mg/m2, orally administered for 7 consecutive days, with a treatment cycle of every 21 days.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
224093542|NCT00049387|RADIATION|radiation therapy|Undergo partial brain radiation therapy
224093543|NCT03899701|PROCEDURE|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
224093544|NCT03609580|DRUG|Tamsulosin - 1 week|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
224093545|NCT03609580|DRUG|Tamsulosin - 3 days|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 3 days), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
224093546|NCT03155646|DRUG|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
224093547|NCT03155646|DRUG|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
224093548|NCT03155646|DRUG|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
224093549|NCT05023031|DRUG|NVP-2102|Tablet formulation for oral administration, single dose of NVP-2102 at Day 1
223532183|NCT06793397|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitator.
223926586|NCT06739395|DRUG|Anlotinib|Usage, dosage, and administration method: Take orally once a day before breakfast. Take the medication continuously for 2 weeks and stop taking it for 1 week, that is, 3 weeks (21 days) is one course of treatment. Until disease progression or intolerable toxic side effects occur.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926587|NCT06739395|DRUG|Trametinib tablet|Usage, dosage, and administration method: The recommended dose is 2 mg, taken orally once a day with an interval of approximately 24 hours. The dose should be taken at least 1 hour before meals or 2 hours after meals. Do not take any missed doses of trametinib within 12 hours of taking the next dose.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926588|NCT06739395|DRUG|Dabrafenib|Usage and dosage: Take 150mg orally twice a day, with an interval of about 12 hours.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided. When this product is used in combination with trametinib, it should be taken once a day at the same time, along with this product administered in the morning or evening.The dosage for combined use will be adaptively adjusted by the researcher.
223926589|NCT06739395|DRUG|Vebreltinib Enteric Capsules|Usage and dosage: The recommended starting dose is 200 mg/time, taken orally twice a day (once in the morning and once in the evening), until disease progression or intolerable toxicity occurs.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926590|NCT06739395|DRUG|Alpelisib Pill|Usage and dosage: The recommended dosage is 300mg (two 150mg film tablets), taken once a day with food; Continue treatment until the disease worsens or unacceptable toxicity occurs.Administration method: Patients should take aspirin at approximately the same time every day and swallow the entire aspirin tablet (the tablet should not be chewed, crushed, or separated before swallowing).The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926591|NCT06739395|DRUG|Sacituzumab Govitecan-Hziy 180 MG|Usage and dosage: The recommended dosage is 10 mg/kg, administered intravenously every 21 days as a treatment cycle on the 1st and 8th days, and continued until disease progression or unacceptable toxicity occurs. The dosage of this product should not exceed 10 mg/kg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926592|NCT06739395|DRUG|Lenvatinib Capsules|Usage and dosage: For patients weighing less than 60kg, the recommended daily dose of lenvatinib is 8mg once a day; For patients weighing ≥ 60kg, the recommended daily dose of lenvatinib is 12mg once daily. Lunvatinib should be taken at a fixed time every day, on an empty stomach or with food.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926593|NCT06739395|DRUG|Pazopanib Pill|"Usage and dosage: In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.The dosage for combined use will be adaptively adjusted by the researcher.~Administration method: Oral treatment once a day, with a cycle of 28 days.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided."
224093550|NCT05023031|DRUG|NVP-2102-R|Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
224093551|NCT03787589|BEHAVIORAL|Exercise Prescription|"Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription and monitor adherence."
224093552|NCT04439344|DRUG|Binimetinib|Given PO
224093553|NCT05284201|DEVICE|LIFT System|The LIFT System delivers the Functional task practice and ARC Therapy to improve upper extremity function in individuals with tetraplegia.
224093554|NCT03464669|OTHER|Prenatal education|Observational study : natural distribution of participants between groups
223717706|NCT00587054|DRUG|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
223717707|NCT03701347|DEVICE|Reeve's model|Reeves, K. O., Young, A. E., \& Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
223717708|NCT03701347|DEVICE|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., \& Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
223717709|NCT03701347|DEVICE|Ida's model|Reusable, portable and modular 3D printed simulator
223717710|NCT06960421|BEHAVIORAL|XFIT|XFIT is an 8-week telehealth-delivered, home-based exercise/behavior modification intervention. It integrates theoretical frameworks of behavior change to engage frail lung transplant candidates in program of pre-habilitation.
223717711|NCT05194358|DRUG|Stabilized Isoamyl Nitrite (SIAN)|"SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs."
223717712|NCT02153619|BEHAVIORAL|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
223717713|NCT02153619|BEHAVIORAL|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSK Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
223717714|NCT02153619|BEHAVIORAL|questionnaires assessments|
223717715|NCT06279234|DRUG|Placebo|Oral tablet
223926594|NCT06739395|DRUG|Palbociclib Pill|Usage, dosage, and administration method: 100mg, orally administered once daily for 21 consecutive days, followed by a 7-day discontinuation; Every 28 days is a treatment cycle.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926595|NCT06739395|DRUG|Chidamide|Usage and dosage: It is recommended to take 30mg (6 tablets) each time, twice a week, with an interval of no less than 3 days between each dose (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.). It should be taken 30 minutes after breakfast.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
224093555|NCT03607773|BEHAVIORAL|Mindfulness Behavioural Intervention (MBI) group|While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
224093556|NCT01587742|DRUG|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
224093557|NCT00552110|DRUG|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
224093558|NCT00552110|DRUG|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
223717716|NCT06279234|DRUG|Rosuvastatin|Oral tablet
223717717|NCT06279234|DRUG|Midazolam|Oral suspension
223717718|NCT06279234|DRUG|Omeprazole|Oral tablet
223717719|NCT06279234|DRUG|PF-06954522|Oral tablet
223717720|NCT01433705|OTHER|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
223717721|NCT01433705|OTHER|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
223926596|NCT06739395|DRUG|PD-1/PD-L1/PD-1&CTLA4 inhibitor|Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
224093559|NCT00552110|DRUG|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
224093560|NCT00552110|DRUG|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
224093561|NCT00552110|DRUG|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
224093562|NCT01743573|OTHER|yoga|
224281992|NCT04232527|DIAGNOSTIC_TEST|Sit and Reach Test|This test involves sitting on the floor with your legs stretched straight forward. Shoes should be removed. The feet themselves are set straight against the box. Both knees must be stretched. With the palms facing down and the palms side-by-side or side-by-side, the subject approaches the measurement line as far as possible. It is important to keep your hands in the same position level, not that one reaches further than the other. Once the subject has reached the maximum distance, hold this position for one to two seconds and record the distance.
224281993|NCT04232527|DIAGNOSTIC_TEST|"Maximum Legs Abduction Test"|Seated legs abduction is a test to assess the flexibility of the groin region. Respondent without the shoe sits with its back and head resting against the wall. As a sign, the subject extends the legs (stretches) to the maximum extent. During the test, the legs should not be bent at the knee joint.
223535273|NCT04175184|OTHER|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
223926597|NCT06739395|DRUG|Target Gene|Granting CFDA or FDA approved drugs(off-label approved drugs) based on specific molecular characteristics.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
223926598|NCT07039188|DEVICE|Use device in home environment|Patients will use the device in their home environment for four weeks.
223926599|NCT06777823|BEHAVIORAL|Social Rejection Task|All participants will receive this
223926600|NCT04150965|DRUG|Elotuzumab, pomalidomide, dexamethasone|Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.
223926601|NCT04150965|DRUG|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
223926602|NCT04150965|DRUG|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.
223926603|NCT04150965|DRUG|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~Each cycle is 28 days."
224281994|NCT04232527|DIAGNOSTIC_TEST|"S_RAG (reactive agility) Test"|The test consist of fast-moving forward, and a change of direction conditioned by visual stimuli.
224281995|NCT04232527|DIAGNOSTIC_TEST|S_CODS (change of direction speed) Test|S\_CODS (change of direction speed) is a test that allows athletes to outperform their opponents in situations where they can pre-define a movement pattern.
224281996|NCT04226586|DIETARY_SUPPLEMENT|Essential Amino Acid (EAA) group|Eligible children will be supplemented with Essential Amino Acids (EAA) for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
224281997|NCT04226586|DIETARY_SUPPLEMENT|Placebo|Eligible children will be supplemented with a placebo for 6 months twice a day. Caution will be exercised to match the groups for age and sex.
223926604|NCT04150965|DRUG|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..
223926605|NCT06832566|DRUG|Fludrocortisone 0.1 Milligrams (mg)|Treatment of hypotension with fludrocortisone 0.05mg/day in patients with secondary adrenal insufficiency before Ramadan fasting. Outcomes (number of fasted days and complications during fasting) will be compared between Ramadan fasting 2025 (with fludrocortisone) and Ramadan 2023 (without fludrocortisone).
223926606|NCT06825598|BEHAVIORAL|Constraint-induced movement therapy|Constraint-induced movement therapy is a therapy for post-stroke patients to improve their motor functions
223926607|NCT06825598|DIAGNOSTIC_TEST|Magnetic resonance imaging|Magnetic resonance imaging is performed to monitor the changes in the brain of post-stroke patients along the course of intervention
224093563|NCT03624647|DEVICE|Power toothbrush|Experimental power toothbrush
224093564|NCT03624647|DEVICE|Manual toothbrush|Marketed manual toothbrush
224093565|NCT00834015|OTHER|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
224093566|NCT06300801|DIAGNOSTIC_TEST|Is the preoperative c-reactive protein/albumin ratio successful in predicting postoperative pancreatic fistula in patients undergoing pancreatoduodenectomy?|In this study, predicting pancreatic fistula before surgery will reduce postoperative complications and mortality.
224093567|NCT00938730|DRUG|YM150|oral
224093568|NCT00938730|DRUG|Warfarin|oral
223926608|NCT06776562|OTHER|Exercise|Education on activities of daily living will be provided. In addition, a program including muscle strengthening, neuromuscular control and flexibility exercises for lower extremity and trunk muscles will be performed. Exercise Program will be performed for 8 weeks, 2 sessions per week.
223926609|NCT06776562|OTHER|Control|Education will be provided for activities of daily living. Individuals with dynamic knee valgus in the control group will not receive any intervention. Exercise program will be implemented after the end of the study.
223926610|NCT06775717|OTHER|Motor Imagery with conventional Treatment|This treatment will be given 5 sessions a week in 4 consecutive weeks.
223926611|NCT06775717|OTHER|Mirror therapy with conventional Treatment.|This treatment will be given 5 sessions a week in 4 consecutive weeks.
223926612|NCT06774157|OTHER|A session combining motor imagery and listening to low frequency sounds|Prospective study of the efficacy of the Allyane procedure after knee sprain
223926613|NCT06774157|OTHER|Standard management - Control group|Active extension (e.g. by lateral raising of the quadriceps, strengthening of the quadriceps) quadriceps)
223926614|NCT06774157|OTHER|Standard management - Control group|Flexor inhibition (e.g. massage, hamstring stretching)
223926615|NCT06774157|OTHER|Standard management - Control group|Active flexion (e.g. strengthening the flexors)
223926616|NCT05154669|OTHER|Financial counseling|The goals of the financial counseling will be to: (1) screen and refer participants to financial benefits and empowerment programs; (2) help participants create and maintain a household budget to meet short- and long-term goals; and (3) help participants link smoking cessation to their budgeting goals.
223926617|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Patches|24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin. Nicotine patches are available in 3 dosages: 21 mg, 14mg, and 7mg. Patches will be adjusted based on withdrawal symptoms, urges, and comfort. After 4-6 weeks of abstinence, taper ever 2-4 weeks in 7-14 mg steps as tolerated.
223926618|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Lozenges|"General Info 24 hour dosing system that provides regular, measured nicotine to the bloodstream through the skin.~Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch, the idea is to taper the amount of lozenges used until you no longer need it. Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Comes in 4mg or 2mg. Initial dosing is 1-2 lozenges every 1-2 hours (minimum of 9/day). Taper as tolerated"
223926619|NCT05154669|DRUG|Nicotine Replacement Therapy Agent - Gum|Provides regular, measured, amount of nicotine to the bloodstream through the mucous membranes of the mouth. As with the patch and lozenge, the idea is to taper the amount of gum chewed until you no longer need it. Initial dosing is 1-2 pieces every 1-2 hours (10-12 pieces/day). Taper as tolerated
223926620|NCT06742151|PROCEDURE|implant can be placed or not|the possibility of receiving dental implants
224093569|NCT06044896|PROCEDURE|Supine Positioning|The participant will be guided to the Multicare bed and will be positioned supine with the headboard not tilted. At this point, the participant will already have the EIT electrode belt and head, trunk and lower limb cushions around it, providing stability. After the participant has been correctly positioned, ventilatory monitoring will begin using the EIT. The environment must be fully controlled, that is, with adequate lighting, all collection members in silence, as well as the devices in the place, air-conditioned environment, without exposing the participant to heat or cold. Before starting the collection, the volunteer will be asked to try not to sleep or talk, making it clear that any discomfort can be reported at any time. To keep the volunteer awake, visual and sound stimuli can be performed. Furthermore, if you cough or sigh, the collection will restart. The intervention will last 5 minutes and will be repeated twice, with intervals between body lateralization.
224093570|NCT06044896|PROCEDURE|Body Lateral Positioning|The participant will start from the bench press to the 30-degree lateral position. The cushions placed at the beginning of the collection will provide stability so that the inclination does not compromise the correct positioning of the participant, preventing them from sliding on the bed. Furthermore, it is also a safety measure for the participant. The environment will be controlled throughout the intervention and visual and sound effects will also be performed in lateral positioning. The volunteer will remain in this position for five minutes and shortly after will be placed in the supine position again. To start the protocol for the second and final time, the participant will have a washout time of thirty minutes.
224093571|NCT01672957|DRUG|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
224281998|NCT02816424|BEHAVIORAL|Teens Exploring and Managing Prevention Options (TEMPO)|
224093572|NCT01672957|DRUG|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
224281999|NCT01401335|BEHAVIORAL|Questionnaires|questionnaires at entry, month 4, 8 and 12
223535274|NCT04175184|OTHER|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
224282000|NCT02351635|OTHER|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
224282001|NCT04366284|OTHER|No Facilitation Support|Clinicians will have full use of the NOCTEM platform. They will not have scheduled and/or structured contacts with the facilitation teams, however can reach out to the NOCTEM team or their local point of contact and coordinator with questions or technical issues that may arise.
224282002|NCT04366284|OTHER|External Facilitation Support|Clinicians will have full use of the NOCTEM platform and the NOCTEM team will provide external facilitation via bi-weekly consult or supervision teleconference, or via telephone. The NOCTEM team will also be available by email and text messaging on an as needed basis.
224093573|NCT04466033|DEVICE|Magneto Microcatheter|All patients will be treated with Magneto Microcatheter
223926621|NCT06855849|DRUG|Amivantamab + FOLFIRI|"The dosage of amivantamab will be based on the participant's body weight during screening. Participants will receive 1,050 mg if BW is \<80 kg or 1,400 mg if BW is ≥80 kg.~* Cycle 1: once weekly (with the first dose split over Day -2 \[350 mg, IVF for 4-6hrs\] and Day -1 \[remainder of the dose, IVF for 6-8hrs\]; subsequent dose \[planned dose IVF over 2 hrs\]).~* Cycles 2+: Days 1 and 15 of each cycle (planned dose IVF over 2 hrs) On days when both amivantamab and chemotherapy are administered, amivantamab should be administered before chemotherapy. In general, leucovorin 400 mg/m2 IV over 2 hours and irinotecan 180 mg/m2 IV over 90 min, then 5-FU 400 mg/m2 IV bolus followed by 5-FU continuous infusion 2,400 mg/m2 over approximately 46-48 hours or 1,200 mg/m2/day for two days. Irinotecan and leucovorin may be administered concurrently (via separate infusion lines) or sequentially according to the institutional standard."
223926622|NCT06702046|DEVICE|transcutaneous pulsed radiofrequency acupuncture|For the TCPRF acupuncture group, the investigators choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. Electrical stimulation is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
223926623|NCT06702046|DEVICE|Sham Comparison|same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
223926624|NCT06703281|PROCEDURE|Interscalene Nerve Block|Patients assigned to the Interscalene Nerve Block would have spirometry and ultrasound-guided diaphragm excursion measurements both pre and post-blok 30 minutes.
223926625|NCT06703281|PROCEDURE|Superior trunk block|Patients assigned to the Superior Trunk Nerve Block would have spirometry and ultrasound-guided diaphragm excursion measurements both pre and post-blok 30 minutes.
223926626|NCT06890832|DRUG|50 mg cabazitaxel|50 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6
224093574|NCT02210663|DRUG|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
224093575|NCT01658267|OTHER|nutritional supplement|2 servings per day
224093576|NCT05220267|DRUG|Anlotinib plus Sintilimab|Anlotinib was taken orally (10mg mg qd, d1-14, 21 days per cycle).Sintilimab was administered intravenously (200mg once every 3weeks).
224093577|NCT04901156|DEVICE|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
224093578|NCT04901156|BEHAVIORAL|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
224093579|NCT04901156|DEVICE|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
224282003|NCT04366284|OTHER|External and Internal Facilitation Support|Clinicians will have full use of the NOCTEM platform and external facilitation support. In addition to external facilitation by the NOCTEM team a local point of contact and coordinator will serve as a more proximal facilitator.
224282004|NCT05609695|DRUG|Immune checkpoint inhibitor|After signing the written informed consent form, patients begin to receive single or combined therapy with immune checkpoint inhibitor. The use of immune checkpoint inhibitors takes 3 weeks as a cycle, and the treatment dose for each cycle is carried out in accordance with the latest international authoritative guidelines.
224282005|NCT04611594|BEHAVIORAL|Fluid restriction|Ingestion of approximately 20 ml / kg of ideal weight,
224282006|NCT03002480|OTHER|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
223535275|NCT06305390|DIAGNOSTIC_TEST|PET/MRI|18F-PSMA PET/MRI
223535276|NCT05985239|PROCEDURE|VI|Laparoscopic or robotic surgery with virtual ileostomy
223535277|NCT05985239|PROCEDURE|DI|Laparoscopic or robotic surgery with virtual ileostomy
223717722|NCT01433705|OTHER|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
224093580|NCT04207476|DEVICE|EMF|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
224093581|NCT04207476|DEVICE|Placebo|No magnetic field exposure will be given while patients are assigned to this arm for a duration of 1 hour.
224093582|NCT02375867|DRUG|prednisolone|Oral administration of 1 mg/Kg/day
224093583|NCT02375867|DRUG|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
224093584|NCT00542711|DRUG|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
223926627|NCT06890832|DRUG|100 mg cabazitaxel|100 mg cabazitaxel to be taken every week for 6 cycles (3 doses per cycle), 10 mg prednisone to be taken daily till end of cycle 6
223926628|NCT06890832|DRUG|200 mg cabazitaxel|200 mg cabazitaxel to be taken every 3-week for 6 cycles (1 dose per cycle), 10 mg prednisone to be taken daily till end of cycle 6
223926629|NCT06741501|PROCEDURE|"C Single Flap Plasty Reconstruction"|"1\. C-shaped flap creation: A 3.0 cm wide by 3.5 cm high C-shaped flap is marked on the anterior gastric wall, 1.5-2.5 cm distal to the stomach transection line. The flap is created by carefully separating the submucosa from the muscular propria using an electric scalpel, forming a left-opening flap. This flap will later be used to cover the anastomotic site. 2. Esophagogastric anastomosis: The esophagus and stomach are anastomosed intracorporeally. After continuous suturing of the posterior esophageal wall to the remnant stomach, the common opening between the esophagus and the stomach is closed. 3. Flap coverage: After anastomosis, the C-shaped flap is sutured over the anastomotic site, reinforcing it by covering both the esophageal stump and the gastric window, which helps prevent complications like leakage or reflux."
223926630|NCT06741501|PROCEDURE|Normal Reconstruction|1\. Preparation of the Remnant Stomach and Esophagus: After the resection of the proximal stomach, the remaining stomach is prepared for direct anastomosis with the esophagus. The esophageal stump and gastric stump are aligned, typically without additional modifications to the gastric wall. 2. End-to-End or End-to-Side Anastomosis: The esophagus is directly connected to the remnant stomach, either in an end-to-end or end-to-side fashion, using a stapler or manual suturing techniques.
223926631|NCT06888791|PROCEDURE|US-guided Hydro Dissection|All procedures are performed under sterile conditions. The patient is seated in a sitting position with the physician behind the patient, the shoulder joint and the surrounding area is cleaned extensively with 10% povidone iodine. The probe is placed in the posterior lateral region of the shoulder, below the level of the scapular spine. The posterior labrum is observed as a triangular hyperechoic structure extending from the glenoid to the humeral head. A 22 G spinal needle is inserted approximately 1 cm medial to the probe along the axis of the spina scapula and 8 mg (2 mL) dexamethasone, 80 mg (4 mL) 2% lidocaine, 14 mL 0.9% saline is slowly injected into the joint in a total of 20 mL into the glenohumeral region. For suprascapular nerve block, 2 ml 0.5% bupivacaine + 2 ml 0.9% saline is administered. Patients are followed up in the recovery unit for 30 minutes after the procedure.
223926632|NCT06888791|PROCEDURE|Fluoroscopy-guided Hydro Dissection|The patient is placed on the scope table in supine position and the shoulder joint is cleaned with 10% povidone iodine. The acromioclavicular joint and the glenohumeral joint are visualized using C-arm fluoroscopy with anteroposterior view. The acromioclavicular joint is marked as the entry point to the shoulder joint. After the skin and subcutaneous tissue is anesthetized with 1 cc 2% lidocaine with a 27 G needle, a 22 G spinal needle is inserted through the acromioclavicular joint and the needle is directed towards the glenohumeral joint. With 1 ml of contrast medium, the localization of the needle is confirmed. After appropriate spread of contrast agent, 8 mg (2 mL) dexamethasone, 80 mg (4 mL) 2% lidocaine, 14 mL 0.9% saline are administered into the joint in a total of 20 mL. For US-guided suprascapular nerve block, 2 ml 0.5% bupivacaine + 2 ml 0.9% saline is administered. Patients are followed up in the recovery unit for 30 minutes after the procedure.
223926633|NCT06887114|OTHER|Experimental Group (Mulligan Mobilization + Conventional Therapy)|Mulligan Sustained Natural Apophyseal Glides (SNAGs) applied to the lumbar spine, combined with conventional rehabilitation exercises (neuromuscular training, stretching, strengthening, and balance exercises).
223926634|NCT06887114|OTHER|(Conventional Therapy Only)|Neuromuscular training, stretching, strengthening, balance exercises, and gait training performed without Mulligan mobilization.
223926635|NCT06744634|OTHER|Romania group|The questionnaire which was prepared by researchers will be performed by older adults from Romania. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
224282007|NCT04418531|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria .
224282008|NCT01808248|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
224282009|NCT01808248|DRUG|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
224282010|NCT01808248|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
224282011|NCT05377125|BEHAVIORAL|Computerized cognitive training|This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
223535278|NCT05498584|BEHAVIORAL|exercise based cardiac rehabilitation|The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
224282012|NCT05377125|BEHAVIORAL|Computerized placebo training|This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
224282013|NCT04190927|BIOLOGICAL|Compounded topical estradiol and compounded topical progesterone in a carrier cream|Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
223535279|NCT01819272|DRUG|Met DR|metformin delayed-release tablets
223535280|NCT01819272|DRUG|Met XR|metformin extended-release tablets
223926636|NCT06744634|OTHER|Turkey Group|The questionnaire which was prepared by researchers will be performed by older adults from Turkey The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
223926637|NCT06744634|OTHER|Croatia Group|The questionnaire which was prepared by researchers will be performed by older adults from Croatia. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
223926638|NCT06738199|DIETARY_SUPPLEMENT|dietary iron supplementation|This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).
223926639|NCT06740994|PROCEDURE|conventional landmark paramedian technique|"a blind landmark scanning will be done and skin marking of the best palpable spinous process will be made.~the site of injection will be determined by palpation. continuous spinal anesthesia will be performed via paramedian approach."
224093585|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
224093586|NCT01511445|DEVICE|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
224282014|NCT05939804|DEVICE|TENS|TENS will be applied to the experimental group on the 0th and 1st days after the surgery, and the pain assessment at the time of movement/rest before and after the procedure will be made by the researcher.
223926640|NCT06740994|PROCEDURE|preprocedural ultrasound guided midline technique|"a preprocedural ultrasound scanning will be done, and skin marking of the best quality space will be made.~the site of injection and the insertion angle of the needle will be determined by ultrasound.~continuous spinal anesthesia will be performed via midline approach."
224282015|NCT06677944|RADIATION|Preoperative PBI|Preoperative PBI: 21 Gy \* 1 fraction Preoperative PBI is administered within 6 weeks of the patient's initial registration, and surgery is scheduled within 8 to 12 weeks after PBI.
224282016|NCT00560326|DRUG|Tacrolimus Ointment 0.03%|Once or twice daily topical application
224282017|NCT00002244|DRUG|WF10|
224282018|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
224282019|NCT04087317|DRUG|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
223926641|NCT06888089|OTHER|AI-assisted MatchMiner Platform|A medical record data analysis tool that uses conjunction machine learning and natural language processing models to predict changes in treatment and prognosis and ascertain progression of disease and metastatic sites using retrospective imaging reports. MatchMiner is an established clinical operations tool at Dana-Farber Cancer Institute that links OncoPanel next-generation sequencing data to basic clinical information and clinical trial eligibility criteria to suggest biomarker-selected therapeutic trials for participants.
223926642|NCT06809153|BEHAVIORAL|Putting Children First|An online parenting intervention for families experiencing high inter-parental conflict during divorce or separation. Children in these families are at greater risk of adverse health outcomes such as mental illness, substance use, and social adjustment problems. Putting Children First will include evidence-based parent training and employ motivational interviewing to increase engagement, will promote parallel parenting to help parents minimize conflict, thereby mitigating negative health outcomes in their children.
223926643|NCT06809647|DEVICE|Glaucoma surgery|This is an implant-free, minimally invasive glaucoma surgery
223926644|NCT06884813|DRUG|Conventional nanohybrid multishade composite and hydrogen peroxide 40% in-Office Tooth Whitening System|Teeth restored with conventional multi shade nanohybrid Resin Based Composite (RBC) Filtek Z350Xt (3M ESPE, San Paul, MN, USA) subjected to bleaching using Opalescence Boost 40% In-Office Tooth Whitening System (Ultradent, Utah, USA)
223926645|NCT06884813|DRUG|Single shade nanohybrid composite and hydrogen peroxide 40% in-Office Tooth Whitening System|Teeth restored with One-shade Resin Based Composite (Omnichroma, Tokuyama Dental, Tokio, Japan) subjected to bleaching using Opalescence Boost 40% In-Office Tooth Whitening System (Ultradent, Utah, USA)
223926646|NCT06881836|DRUG|ONO-2020|ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.
223926647|NCT06881836|DRUG|Placebo|Placebo group: Two ONO-2020 placebo tablets will be orally administered once daily.
223926648|NCT06842160|DEVICE|intervention group|A smart electrocardiogram watch based on the PPG algorithm for monitoring atrial fibrillation load after catheter ablation.
223926649|NCT06841549|OTHER|FAPI|FAPI is a new method to find the myocardial fibrosis under some conditions, like myocardial infarction or cardiac myopathy.
223926650|NCT06818513|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
223926651|NCT06818513|DIETARY_SUPPLEMENT|Gastrostomy|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
223926652|NCT06818513|DIETARY_SUPPLEMENT|Oral tube feeding|During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223926653|NCT06779877|PROCEDURE|Percutaneous dilatational tracheostomy|Percutaneous dilatational tracheostomy
223926654|NCT06779877|DIAGNOSTIC_TEST|The optic nerve sheath diameter measurement method by ultrasonography|The optic nerve sheath diameter measurement method by ultrasonography-Determine intracranial pressure.
223926655|NCT06844708|BIOLOGICAL|CMTS0929|China Microbiota Transplantation System 0929 (CMTS0929) is defined as suspension from washed microbiota.
223926656|NCT06746038|DEVICE|Extended Wear Hearing Aid|Extended wear hearing aid means that the device is worn 24 hours per day, 7 days a week for months at a time. However, this study will only fit devices on participants for one testing session lasting 2 hours.
223926657|NCT05990062|DEVICE|K-Socket-Harness|"A transradial socket and harness design that offers a hybrid polymer and textile-based design derived from advanced athletic shoe technology. The KSH integrated socket, frame, and wrist, the variable compliance prosthetic socket with breathable matrix, creates a dynamic and secure attachment with a combination of two lacing systems. The lacing systems lengthen and shorten six flexible hinges at the elbow, maintaining a secure attachment throughout the range of motion and accounting for volume changes in the soft tissue of the elbow that would otherwise restrict range of motion or cause the socket to separate from the residual limb."
224093587|NCT06154629|DIETARY_SUPPLEMENT|Botanical ingredient|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
224093588|NCT06154629|DIETARY_SUPPLEMENT|Control group|Consumption for 90 days. Subjects should consume one capsule one hour before going to sleep
223532184|NCT05638074|PROCEDURE|Interlaminar Epidural Steroid Injection|"The patient will be placed in the prone position and cutaneous anesthesia is performed with 3 mL of 2% prilocaine using the sterile technique. After imaging the C7-T1 space with fluoroscopy, it will be entered from the right/left paramedian part of the C7-T1 space with an 18G Touhy needle, and the C-arm will be set in the contralateral oblique position for depth determination.~Under intermittent fluoroscopic imaging, the needle will be advanced, and access to the epidural space wiil be confirmed by the loss of resistance technique. Afterwards, the epidural spread will be controlled with a contrast agent, and a mixture of 10 mg dexamethasone, 1 mL 2% lidocaine hydrochloride, and 1 mL 0.9% saline will be applied to the epidural space. The patient will be discharged with recommendations after being kept under observation for 2 hours post-procedure. All injections will be performed by the same pain medicine specialist who has at least 5 years of experience."
223532185|NCT02037529|DRUG|Eribulin Mesylate|Given IV
223532186|NCT02037529|OTHER|Laboratory Biomarker Analysis|Correlative studies
224093589|NCT00269009|BEHAVIORAL|CHERL|
224093590|NCT02413203|DRUG|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
224093591|NCT02413203|DRUG|Placebo|Blood and urine collections before and 3 hours after placebo administration.
224093592|NCT01061489|OTHER|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
223926658|NCT06773832|DIAGNOSTIC_TEST|Real-time Artificial Intelligence Model for Diagnosing Colorectal Polyp Pathology and Endoscopic Classification|"During the AI model development phase, the aim is to include as many samples as possible. Given the focus on the diagnostic accuracy of serrated lesions, we retrospectively collected approximately 400 cases serrated lesions with pathological diagnosis by the department of pathology at Peking Union Medical College Hospital to date. Additionally, we matched with 400 cases each of hyperplastic polyps, conventional adenomas, and early-stage colorectal cancer, totaling approximately 1600 cases.~The model employs mainstream AI classification algorithms to construct the model and compare the predictive performance of different models. Utilizing the dataset established in the first phase, which contains static images of polyp lesions along with their corresponding pathological diagnosis and endoscopic classifications, we developed and optimized the AI model. Then the model will be be compared with endoscopists in a prospective cohort to investigate the efficacy."
223926659|NCT06225297|COMBINATION_PRODUCT|Intervention package|Intervention package will include vector control through meganets (multiple insecticide-treated mosquito nets sewn together), seasonal malaria chemoprevention (SMC) extended to all ages using DHA-PQ, and behavior change communication.
223926660|NCT06762574|OTHER|Low Level Laser Therapy|Low Level Laser Therapy sometimes known as Low Level Light Therapy or Photobiomodulation (PBM) is a low intensity light therapy. The effect is photochemical not thermal. The light triggers biochemical changes within cells and can be compared to the process of photosynthesis in plants, where the photons are absorbed by cellular photoreceptors and triggers chemical changes.
223926661|NCT06762574|OTHER|Placebo Low Level Laser Therapy|Placebo Low Level Laser Therapy:turning on the device with covering probe by aluminum foil and ask patient to wear sun glasses to obtain the placebo effect.
223926662|NCT04446442|DEVICE|tDCS|A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
223926663|NCT06873542|DRUG|DC05F01|DC05F01 capsule
223926664|NCT06751966|COMBINATION_PRODUCT|Combination Product: Conventional third-line therapy|Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
223926665|NCT06751966|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223926666|NCT06752122|DRUG|Placebo (in SAD)|Inhalation once daily in the SAD part
223926667|NCT06752122|DRUG|RCS-21 (in SAD)|Inhalation once daily in the SAD part
223926668|NCT06752122|DRUG|Placebo (MAD)|Inhalation once daily for seven days in the MAD part
223926669|NCT06752122|DRUG|RCS-21 (in MAD)|Inhalation once daily for seven days in the MAD part
223926670|NCT06762990|RADIATION|Plain radiographs|Plain radiographs, including the lumbar spine, pelvis, and the upper half of both femora, will be obtained using the lowest radiation dose possible. The radiographs will be obtained in five positions representing the Muslim Prayers positions, namely 1-standing, 2-Sitting in 90 degrees (both 1 and 2 are the standard positions obtained in all previous studies), 3-bowing (Ruku), 4-prostration (sujud), and 5-sitting with knees bent (Tashahud).
223926671|NCT06766643|PROCEDURE|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic radiosurgery for liver lesions: with a total dose of 40\~50Gy/3\~5fraction;
223926672|NCT06766643|PROCEDURE|Radiofrequency ablation therapy|Radiofrequency ablation therapy:1 complete radiofrequency ablation of liver lesions for liver lesions
223926673|NCT06771609|DRUG|Adebry single antibody + VEX metronomic chemotherapy + radiotherapy|1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
223926674|NCT06771609|DRUG|debry single antibody + VEX metronomic chemotherapy|1、Adebry antibody: 1200mg on day 1, every 3 weeks； 2、VEX Metronomic Chemotherapy: Vinorelbine 20mg orally, once every other day, Q3W Cyclophosphamide 50mg orally, once daily, Q3W Capecitabine 500mg orally, three times daily, Q3W
223926675|NCT06891157|DRUG|Chidamide plus R-CHOP|Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)
223926676|NCT06794762|OTHER|Conventional exercises|"Aerobic exercise and stretching exercises will be applied in the conventional exercise program.~A 20-30 minute walking will be done as aerobic exercise. Stretching exercises will be done for major muscle groups in 3 sets and 10 repetitions."
224093593|NCT01061489|OTHER|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
224093594|NCT01656642|DRUG|Atezolizumab|Atezolizumab will be administered q3w or q2w.
224282020|NCT04087317|DRUG|Paracetamol 1000 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
224282021|NCT04087317|DRUG|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
224282022|NCT04087317|DRUG|MIR|At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
224282023|NCT00165516|DRUG|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
224282024|NCT00165516|DRUG|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
224282025|NCT05703841|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
224282026|NCT04754555|OTHER|Arm Activity Measure (ArmA) in french|The Arm Activity Measure (ArmA) provides a standardized assessment of upper limb passive and active perceived performance
224282027|NCT05854706|DEVICE|Theta Burst Stimulation|Theta Burst Stimulation
224282028|NCT00153205|BEHAVIORAL|computerized physician order entry|
224282029|NCT03025776|BEHAVIORAL|Reaching|sitting reaching under various task conditions (size, speed, location)
224282030|NCT03025776|BEHAVIORAL|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many \& which hand to use, kinematic data collected
223532187|NCT02037529|DRUG|Paclitaxel|Given IV
223926677|NCT06794762|OTHER|Core stabilization exercises in addition to conventional exercises|In addition to the conventional exercise program, core stabilization exercises will be applied. During the exercises, participants will be trained on neutralizing the spine and working the transverse abdominis and multifidus muscles, correct postural control, and performing the exercises with diaphragmatic breathing.
223926678|NCT05517902|BIOLOGICAL|StrataGraft|StrataGraft® Construct
223926679|NCT06833060|DEVICE|Selective Laser Trabeculoplasty|Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty
223926680|NCT06826716|DIETARY_SUPPLEMENT|Fenugreek (Trigonella foenum graecum)|"Dose: 600 mg/day Regimen:~One capsule (300 mg) to be taken twice a day 30 minutes post breakfast and dinner Route of administration: Oral"
223926681|NCT06826716|DIETARY_SUPPLEMENT|Placebo (Maltodextrin)|"Dose: 600 mg/day Regimen:~One capsule (300 mg) to be taken twice a day 30 minutes post breakfast and dinner Route of administration: Oral"
223926682|NCT01513122|DRUG|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
223926683|NCT01513122|DRUG|2-3N(t)RTI|
223926684|NCT01513122|DRUG|raltegravir|raltegravir 400mg 1 tablet twice daily.
223926685|NCT05604963|PROCEDURE|Total Thyroidectomy|Total Thyroidectomy - surgical removal of entire thyroid gland
223926686|NCT05604963|PROCEDURE|Hemithyroidectomy|Hemithyroidectomy - surgical removal of partial thyroid gland
223926687|NCT04978129|BEHAVIORAL|Online and Text Messaging Intervention|The online and TM intervention, and its delivery, will be designed and adapted based on the results of the formative focus groups and cognitive interviews and is meant to be non-confrontational in tone, seeks to increase motivation to increase the quality use of PBS and decrease motivations for non-use of PBS.
223926688|NCT03133988|BIOLOGICAL|Margetuximab|anti-HER2 monoclonal antibody
223940893|NCT07162012|DRUG|EBV TCR-T|"After signing the informed consent form and completing screening according to the inclusion/exclusion criteria, eligible subjects will be sequentially assigned to the following dose cohorts of TCR-T cells (single administration): 1×10⁶ TCR-T cells/kg, 2.5×10⁶ TCR-T cells/kg, 5×10⁶ TCR-T cells/kg, and 10×10⁶ TCR-T cells/kg.~The first dose cohort (1×10⁶ TCR-T cells/kg) will use a rapid titration approach. If no significant safety issues occur within 28 days after infusion-defined as ≥Grade 3 non-hematologic toxicity, Grade 4 hematologic toxicity lasting more than 28 days (excluding disease- or chemotherapy-related causes), ≥Grade 2 neurotoxicity, or ≥Grade 3 cytokine release syndrome (CRS)-the next dose cohort will be initiated. If a dose-limiting toxicity (DLT) occurs, evaluation will be performed after 6 subjects have been treated.~The subsequent three dose cohorts will follow a 3+3 dose-escalation design, with 3-6 subjects per cohort receiving a single infusion. For subjects in th"
223717723|NCT01433705|DRUG|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
223940894|NCT03935750|PROCEDURE|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
223940895|NCT03935750|PROCEDURE|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
223940896|NCT06216249|PROCEDURE|Computed Tomography|Undergo PSMA PET/CT, SPECT/CT, PET/CT and CT
223940897|NCT06216249|OTHER|Gallium Ga 68 Gozetotide|Given IV
223940898|NCT06216249|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
223940899|NCT06216249|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223940900|NCT06216249|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
224282031|NCT00197080|DRUG|Ropinirole Extended Release (XR)|
223532188|NCT02037529|OTHER|Quality-of-Life Assessment|Ancillary studies
223940901|NCT06216249|OTHER|Questionnaire Administration|Ancillary studies
224282032|NCT04936594|DEVICE|iTBS|1800 pulses of iTBS
224282033|NCT04936594|DEVICE|TMS|MagVenture MagPro x100 device. This will be used as the comparator.
224282034|NCT06677931|PROCEDURE|Placebo Comparator:1565 non-ablative fractional laser combined with normal Saline|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply normal Saline.
223940902|NCT06216249|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223940903|NCT07175155|DEVICE|COMBO Endoscopy Oropharyngeal Airway with High-Flow Nasal Cannula Oxygenation|Using the COMBO endoscopy oropharyngeal airway with High-Flow Nasal Cannula Oxygenation in sedated gastrointestinal endoscopy for morbidly obese patients
223940904|NCT07175155|DEVICE|High-Flow Nasal Cannula Oxygenation|In this group, patients use high-flow nasal cannula oxygenation
223940905|NCT07189572|DRUG|Triamcinolone Acetonide|Triamcinolone acetonide is a medium-potency synthetic corticosteroid. This intervention is administered via a commercially available, metered-dose nasal spray that delivers 55 μg of the active drug per spray. It exerts potent local anti-inflammatory and immunomodulatory effects in the nasal mucosa and Eustachian tube orifice. In this study, it is investigated for the prevention of radiotherapy-induced otitis media with effusion in patients with nasopharyngeal carcinoma.
223940906|NCT07189572|DRUG|Placebo|The placebo nasal spray is specifically formulated to be indistinguishable from the active triamcinolone acetonide nasal spray. It is identical in all physical properties including appearance, scent, taste, packaging, and administration procedure. It contains the same inactive excipients (e.g., preservatives, suspending agents) but does not contain any triamcinolone acetonide or other active pharmaceutical ingredient.
223940907|NCT07195708|DEVICE|Treatment group|The treatment group was the group with the placement of Orbera 365 plus lifestyle management
224093595|NCT01656642|DRUG|Cobimetinib|Oral repeating dose
223532189|NCT05523908|RADIATION|High-dose hypofraction Arm|Patients in this arm would receive high-dose fractionated radiotherapy with 60Gy/15f
223532190|NCT05523908|RADIATION|Low-dose hypofraction Arm (Standard BED)|Patients in this arm would receive low-dose fractionated radiotherapy with 48Gy/12f
223535281|NCT01819272|DRUG|Placebo|placebo delayed-release tablets
224093596|NCT01656642|DRUG|Vemurafenib|Oral repeating dose, depending on arm/cohort
223926689|NCT06191848|DRUG|Tirzepatide|Participants will receive tirzepatide subcutaneously
223926690|NCT06191848|DRUG|Placebo|Participants will receive placebo subcutaneously
223926691|NCT01675440|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
224093597|NCT03006653|BEHAVIORAL|Assessment only|Mobile ecological assessment only.
224093598|NCT00291304|PROCEDURE|MRI|pre-surgery
224093599|NCT05868369|DEVICE|iVR Group|"On the day of surgery, the iVR group will receive a 30-minute sessions or dose of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay. The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes."
224093600|NCT05868369|DRUG|Standard pain management regimen|In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).
224093601|NCT00157547|DRUG|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
224093602|NCT04325477|DEVICE|Nolix Device|The Nolix device is a single use, dynamic, and soft flexible intra-vaginal device for temporary management of SUI
224093603|NCT00351364|DRUG|Montelukast Sodium|100 mg P.O. One time only
224282035|NCT06677931|PROCEDURE|1565 non-ablative fractional laser combined with umbilical cord mesenchymal stem cell-derived exosomes.|Based on the patient's age, skin color, location of skin lesions, and Fitzpatrick skin type, adjust treatment parameters accordingly. The operator holds the treatment head, vertically applies parallel sweeps closely to the lesion area until the endpoint of slight skin redness is reached. After completion, apply exosomes.
224282036|NCT04374422|BEHAVIORAL|fsfi survey|sexual behavior Questionaire
223926692|NCT05062291|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target Lesion Primary Patency (TLPP)
223926693|NCT05795153|DRUG|LOU064|One film-coated tablet (25 mg) was to be taken in the morning and evening, respectively, with a 12-hour interval at approximately the same time everyday.
223926694|NCT01614405|DRUG|TDF/FTC/LPV/r|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
223926695|NCT01614405|DRUG|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada.
223926696|NCT05237466|BEHAVIORAL|RECLAIM: Reducing Clutter and Increasing Meaning|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
223926697|NCT05237466|BEHAVIORAL|Sorting Practice|Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
223926699|NCT00207480|BEHAVIORAL|Brief, motivational interviewing intervention|
223926700|NCT05180539|BEHAVIORAL|SPLASH Intervention Condition|Two-session in person group discussions focusing on behaviors in drinking contexts
223926701|NCT05180539|BEHAVIORAL|Control Condition|Two-session in person group discussions focusing on college health behaviors
223926702|NCT02566889|DRUG|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
223926703|NCT06952166|BEHAVIORAL|Qigong (Baduanjin)|Participants will receive 24 sessions of Baduanjin training over 12 weeks (2 sessions per week). Each session will last for 60 minutes. Baduanjin consists of eight forms of gentle movements, and it takes about 10 to 15 minutes to complete a full cycle. Participants will learn to practice each form gradually over the first 12 sessions. In the remaining 12 sessions, the participants will go through all the movements 2-3 times, with guided practice on rhythmic breathing and mind regulation (attention to body and breathing) to be performed in coordination with the movements. The training will be delivered by an instructor after training by the project team.
223926704|NCT06952166|BEHAVIORAL|Mindfulness-based intervention|Participants will receive mindfulness-based intervention with the same duration and frequency as qigong group. The intervention incorporates psychoeducation on mindfulness and stress management and group-based mindfulness practice about breathing, awareness of body sensations, thoughts, stretching, and walking. All the mindfulness practices are based on publicly accessible audio recordings. The training will be delivered by an instructor after training by the project team.
223926705|NCT06952166|BEHAVIORAL|Physical exercise|Participants of the physical exercise group will receive training of a series of low-to-moderate intensity physical activities for the same duration and frequency as qigong group. The physical activities include stretching, flexibility exercise, balance exercise, and aerobic exercise. The training will be delivered by an instructor after training by the project team.
223926706|NCT05247164|PROCEDURE|EUS-guided Portal Vein sampling|"Transgastric and Transhepatic Fine Needle Aspiration of a branch of the Portal Vein under EUS guidance.~A paired peripheral sample will be acquired."
223717724|NCT05184985|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
223717725|NCT05184985|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
223717726|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
223717727|NCT01529502|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
223717728|NCT01529502|DRUG|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
223717729|NCT03397537|DRUG|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
223717730|NCT03397537|DRUG|GnRH analogue|3.75 mg triptorelin im. q28d
223717731|NCT05598541|PROCEDURE|Surgical or non-surgical treatment|Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
223926707|NCT06500572|OTHER|Landmark Guided Intercostobrachial Nerve Block|In addition to the supraclavicular plexus block, the intercostobrachial nerve block block will be performed without ultrasound guidance and based on the traditional method using superficial anatomy and nerve pathway by subcutaneous injection of 20 mL of bupivacaine 0.25% at the site of the pulse.
223926708|NCT06500572|OTHER|Ultrasound Guided Intercostobrachial Nerve Block|The patient's head will be turned to the opposite side while the patient is in the supine position and the shoulder to be treated will be elevated 5- 10 cm. The high-frequency linear ultrasound probe (12-4 MHz) and the region to be treated will be prepared in sterile conditions and placed transversely across the external jugular vein at 3-4 cm above the clavicle. Between the anterior and middle scalene muscles, the imaging of the brachial plexus showed three to five hypoechoic circles. The entry will be in-plane technique using an 80-mm block needle from lateral to medial. After confirming the needle insertion site with 2 mL saline solution, a 20 mL bupivacaine 0.25% will be administered.
223926709|NCT06500572|OTHER|Serratus Plane Block|The patient will be placed in the lateral decubitus position with the area to be treated on the upper side. The high-frequency linear ultrasound probe and the region to be treated will be sterilized. The ultrasound probe will be placed on the anterior line at the level of fourth and fifth ribs. Images of the muscle's latissimus dorsi and serratus anterior, the ribs, and the pleura will be obtained. Subsequently, with the in-plane technique, an 80-mm block needle will be advanced between the latissimus dorsi and the serratus muscles planes in a caudal to the cranial direction. There is no blood or air in aspiration. After confirming the location of the needle with 2 mL of saline solution, (20 mL of bupivacaine 0.25%) will be administered between the two muscles.
223926710|NCT06297551|DIAGNOSTIC_TEST|Quantification of blood cells positive for CLL1 and CD45RA surface markers by flow cytometry|During induction therapy for AML, researchers will measure the relative percentage of hematopoietic stem cells (defined by markers CD34+/CD38-) that test positive for CLL1 and CD45RA surface markers in the blood of participants on day 3, 5 and 7 days of systemic therapy. The variation of blood cells positivity for these markers, will be correlated with treatment outcome (complete response, partial response, no response), as determined by a bone marrow biopsy done approximately 4 weeks after induction chemotherapy.
223926711|NCT05858879|OTHER|Notification of patients and clinicians|"Notification Patients randomized to notification will receive a message sent by either the electronic health record (EHR) patient portal or US mail that will inform them of the CAC identified on their previous chest CT scan and a recommendation that they discuss this finding and initiation of lipid-lowering therapy with their clinician. The clinicians will be notified of these findings by an earlier EHR message that will be sent 2 weeks before the patient notification.~Usual Care The usual care arm will not receive any additional notification beyond this standard of care."
223926712|NCT04518943|BEHAVIORAL|Walking|Inactive Veterans will be encouraged to increase their step count to 7,000 steps per day by the end of the 12-week intervention period. Weekly the step goal will increase 15% if they were successful in reaching their goal the previous week.
223926713|NCT02734069|DRUG|Carboplatin|Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
224093604|NCT05588388|DRUG|Bevacizumab|Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM
224093605|NCT02901314|OTHER|on-demand audio messages of heart failure education themes|
223717732|NCT02019693|DRUG|INC280|Supplied by Novartis as film-coated tablet for oral use.
223717733|NCT02611219|OTHER|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"* 38 question questionnaire~* Answers range from 1=all of the time to 5=none of the time"
223717734|NCT02611219|OTHER|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"* 38 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
223717735|NCT02611219|OTHER|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
223717736|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"* 38 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
223717737|NCT02611219|OTHER|General Health Module-Baseline Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
223717738|NCT02611219|OTHER|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"* 34 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1-all of the time to 5=none of the time"
223717739|NCT02611219|OTHER|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
223717740|NCT02611219|OTHER|SCT Daily Activity Log|"* Uses Fitbit Flex~* Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
224093606|NCT03529747|OTHER|Online self-help|As detailed in experimental arm description.
224093607|NCT06330909|RADIATION|Radiotherapy (RT) Arm A - IMRT/IGRT/SBRT|"technique: IMRT/IGRT/SBRT~The HypoFocal-SBRT study combines ultra-hypofractionated RT / stereotactic body RT (reduction of treatment time) with a focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts."
223926714|NCT01496651|PROCEDURE|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
223926715|NCT01496651|PROCEDURE|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
223926716|NCT05774704|DRUG|Low curcumin group|One curcumin capsule (250 mg curcumin) after each meal, 3 times a day for 2 weeks.
223926717|NCT05774704|DRUG|High curcumin group|One curcumin capsule (500 mg curcumin) after each meal, 3 times a day for 2 weeks.
223926718|NCT03928041|DEVICE|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
223926719|NCT06173466|DRUG|Liposomal bupivacaine|Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
224093608|NCT06330909|RADIATION|Radiotherapy (RT) Arm B - IMRT/IGRT|"technique: IMRT/IGRT~Moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide."
224093609|NCT05928286|DRUG|Remaxol|The perioperative infusion of Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid)
223926720|NCT06173466|DRUG|Bupivacaine Hydrochloride combined with dexamethasone|Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
223926721|NCT06579807|BEHAVIORAL|Exercise training|The multimodal supervised exercise program will include aerobic, resistance, and flexibility exercises. The training program will last 12 weeks, performed in 3 weekly sessions lasting 60 minutes each. Aerobic exercise, lasting between 20-30 minutes, will be conducted on a treadmill or stationary bike at an intensity ranging from 75-85% of the maximal heart rate (HR), based on the cardiopulmonary exercise testing. Resistance training, lasting 30 minutes, will include 8 to 10 exercises performed in 3 sets of 10 to 12 maximum repetitions with 1-minute intervals, targeting major muscle groups of the upper and lower limbs, with loads corresponding to 80-90% of the 10-repetitions maximum (RM).
223926722|NCT01805219|OTHER|GPS and accelerometer recording (s) during exercises|
223926723|NCT02324790|DEVICE|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
224093610|NCT05945264|BEHAVIORAL|Music Intervention (MI)|The intervention will involve listening, playing and/or singing melodies or songs, that are meaningful to the participant, with interpretation/reflection on their relevance/capacity to alter stress.
223926724|NCT05661955|DRUG|BGB-A445|administered intravenously
223926725|NCT05661955|DRUG|Tislelizumab|administered intravenously
224093611|NCT05945264|OTHER|Sham Control (SC)|The intervention will be to support a woman to talk about anything she wants that is important to her.
224093612|NCT06486012|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device home-use with a marker substance
223535282|NCT02868424|DRUG|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
223926726|NCT03699163|DIAGNOSTIC_TEST|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
223926727|NCT06446492|OTHER|ViDEO explaining study|The research team will introduce themselves and ask the parents to watch an informational video explaining the ViDES study on an iPad while they stay in the room with the parents. After viewing the video, the team will answer any questions and provide written consent and enough time to decide whether to participate in the study. The research team will also provide a QR code that grants parents/guardians access to the video on their own device at any time. This allows them to pause, rewind, and revisit the information.
223926728|NCT06446492|OTHER|Usual Care|The research team will present a detailed explanation of the ViDES study, answer questions, provide written consent, and provide enough time to decide on participation or not in the study.
223926729|NCT06570616|DEVICE|CPAP (fixed mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
223926730|NCT06570616|DEVICE|APAP (automatic mode)|Patients will undergo strategies to control excessive leakage while using autoCPAP vs. progressively decreasing fixed nasal CPAP. Before randomization, subjects will undergo an autoCPAP titration for 3 days. Subjects will then be randomized to start the protocol with autoCPAP or fixed CPAP and then will switch to the alternative arm.
223926731|NCT04090541|OTHER|Rigid Tape|Non-Elastic Tape
223926732|NCT04090541|OTHER|Kinesiology Tape|Tape can be elongate only one direction
223926733|NCT04090541|OTHER|Biomechanical Tape|Tape can be elongate only two direction
223926734|NCT06137976|PROCEDURE|Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)|Placement of tube through the nose or mouth into the stomach for gastric decompression
223926735|NCT06261814|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
223926736|NCT06261814|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
223926737|NCT06261814|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
223926738|NCT06261814|OTHER|Medical Chart Review|Ancillary studies
223926739|NCT06336967|BEHAVIORAL|GUIDE|The GUIDE App is a wellbeing app designed for first responders and veterans that uses small group support, a learning management system, drivers of behavior change, and an anonymous member experience safeguarded by a leader in identity and login privacy, Okta (okta.com). It includes three main features: 1) Community, 2) Wisdom, and 3) Daily Practice. The Community feature connects app users with an online community of like folks, allowing for human support, encouragement, accountability and coaching. Online communities are moderated by GUIDE employees. The Wisdom feature includes tools and interactive media for personal growth. The Daily Practice feature includes simple, daily routines to maintain mental and emotional wellness.
224093613|NCT06486012|OTHER|Standard oral hygiene|Standard oral hygiene performed at home
223926740|NCT06547931|OTHER|Data collection and analysis|Retrospective collection of clinical and laboratory data relating to the definition of the nature of neutropenia
223926741|NCT06513507|DIETARY_SUPPLEMENT|Cannabigerol (CBG)|The daily dose will consist of 50 mg of CBG. Blood tests will be conducted at Baseline, Week 2, Week 4, Week 6, and Week 8 to monitor inflammatory markers and immune response. Self-reported questionnaires will be completed at Baseline, Week 4, and Week 8 to assess symptoms and quality of life.
223926742|NCT04173442|DRUG|dupilumab|Dupilumab cohort
223926743|NCT05639309|DEVICE|near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)|regional oxygen saturation measurement
223926744|NCT05384847|DRUG|Thyroid hormone T3|Participants will be admitted to the General Clinical Research Center (GCRC) for up to 5 days and will receive study medication twice a day. Participants will receive oral T3 under the supervision of the Principal Investigator or qualified co-investigators at the GCRC. The study drug will be given within 30 days after enrollment.
223926745|NCT05384847|OTHER|Control Group|The control group will have testing and study procedures as per protocol but will not be admitted to the General Clinical Research Center (GCRC) and will not receive the study medication. After completion of phase I, participants will be permitted to enroll in Phase II.
223926746|NCT01461759|DRUG|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
224093614|NCT04109729|DRUG|Nivolumab|Nivolumab 480mg IV every 4 weeks for up to 2 years
224093615|NCT04109729|DRUG|Radium-223|Radium-223 55 kilobecquerel (kBq)/kg IV q4 weeks for 6 cycles total
224093616|NCT05662826|BEHAVIORAL|Avatar-based Social Physical Activity|Exercise, group discussions, role-playing skits, and group painting done in a virtual setting.
224093617|NCT02619851|BIOLOGICAL|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
224093618|NCT02619851|DEVICE|Conventional Therapy|Typical therapy conducted for burn injury patients
224093619|NCT00490542|DRUG|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
224093620|NCT00490542|DRUG|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
224093621|NCT04696861|BEHAVIORAL|IDEAS for Hope|Participants will receive three counseling sessions at two week intervals, delivered by telehealth by a trained psychiatric nurse, focused on managing suicidal ideation and enhancing HIV care engagement.
223926747|NCT01461759|DRUG|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
223926748|NCT01646450|DRUG|Icotinib|Icotinib: 125mg, oral administration, three times per day.
223926749|NCT04347733|DRUG|Triamcinolone Acetonide 40mg/mL|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
223926750|NCT04347733|DRUG|Hyaluronidase Injection|We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
223926751|NCT01921075|OTHER|normal dietary behavior|normal dietary behavior during examination days
223926752|NCT01921075|OTHER|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
223926753|NCT02996136|DEVICE|Flu Symptoms|Flu Symptoms
223926754|NCT02254720|DRUG|BEA 2180 BR solution for infusion|
223926755|NCT02254720|DRUG|Placebo|Intravenous infusion
223926756|NCT02254720|DRUG|BEA 2180 BR solution for inhalation|
224093622|NCT04696861|BEHAVIORAL|Enhanced Standard of Care (Safety Planning)|Participants will receive a brief, 10-15 minute counseling session, delivered by telehealth by a trained psychiatric nurse, focused on safety planning.
224093623|NCT06573853|PROCEDURE|Focal Pulsed Field Ablation (PFA)|Patients in the PFA group underwent ablation procedures utilizing a force-sensing PFA catheter for the treatment of PSVT.
224093624|NCT06573853|PROCEDURE|Focal Radiofrequecy Ablation (RFA)|Patients in the PFA group underwent ablation procedures utilizing force-sensing RFA catheters for the treatment of PSVT.
224093625|NCT06267560|DRUG|TQJ230|TQJ230 80mg QM s.c.
223532191|NCT02131766|DEVICE|DiAs|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
223532192|NCT02131766|OTHER|Sensor Augmented Pump Therapy|Insulin pump plus CGM.
223532193|NCT02474121|DEVICE|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
223532194|NCT00718315|DRUG|erlotinib [Tarceva]|150mg po daily
223532195|NCT00718315|DRUG|fusidic acid [Verutex]|topical, daily for 30 days.
223532196|NCT00718315|DRUG|erythromycin [Eritex]|topical, daily for 30 days.
223532197|NCT00718315|DRUG|Fisiogel|topical, daily for 30 days
223532198|NCT03152448|BEHAVIORAL|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
223926757|NCT02254720|DEVICE|Respimat®|
223926758|NCT00367653|DRUG|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
223926759|NCT00367653|DRUG|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
223926760|NCT05222646|DRUG|Metoclopramide|Will receive single dose of 10mg of Metoclopramide intramuscularly
223926761|NCT01534546|DRUG|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1\~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
223926762|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，po, d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
223926763|NCT01534546|DRUG|Oxaliplatin S-1|S-1: 40\~60mg bid，d1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
223926764|NCT03875313|DRUG|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
223926765|NCT03875313|DRUG|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
223926766|NCT05521386|DRUG|Caffeine|Single pill in an acute dose of 5 mg per kg of body mass
223926767|NCT05521386|DRUG|Placebo|Single pill in an acute dose of 5 mg per kg of body mass
223926768|NCT05825066|DRUG|Nab paclitaxel|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
223926769|NCT05825066|DRUG|Gemcitabine|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
223926770|NCT05825066|OTHER|Radiological Assessments|CT imaging of chest abdomen and pelvis will be performed every 8 weeks. MRI may be used.
224093626|NCT06267560|DRUG|Placebo|matching placebo
224093627|NCT05795699|DRUG|Ripasudil|K-321 ophthalmic solution
224093628|NCT05795699|DRUG|Placebo|Placebo ophthalmic solution
224093629|NCT02823158|PROCEDURE|Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|"Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS."
223926771|NCT05825066|DRUG|mFOLFIRINOX|"The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician."
223926772|NCT06295341|DRUG|Recombinant human growth hormone (only for children with growth hormone deficiency)|6 months of therapy with recombinant DNA GH (at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
223926773|NCT05816265|DRUG|IV Iron Infusion Group|Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
223926774|NCT05290714|BEHAVIORAL|Mentalization-Based Treatment for Children (MBT-C)|MBT-C will involve 12 paralel individual sessions with the parents and children separately conducted by two different therapists.
223926775|NCT05290714|BEHAVIORAL|Parenting and Social Skills Group|Parenting/social skills groups will be co-led by two therapists and involve 12 group therapy sessions with the parents and their children separately (10 parents and children per group).
223926776|NCT04963088|DRUG|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason
224282037|NCT02166801|BEHAVIORAL|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand \& Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
223926777|NCT04963088|DRUG|Anlotinib|oral administration daily d1-d14, q3w;
223926778|NCT04963088|DRUG|Oxaliplatin|30 mg/m² IV on Day 1 during each 21-day cycle. during each 21-day cycle
223926779|NCT04963088|DRUG|Capecitabine|1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
223940908|NCT07196189|OTHER|Patients|A clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the patients eligibility criteria to be verified. If the patient is included, the self-questionnaire will be completed on site and stool collection will be carried out.
223940909|NCT07196189|OTHER|healthy volunteer|A clinical examination (weight, height, Body Mass Index calculation) and ED screening using the SCOFF questionnaire will then be carried out, allowing the volunteer's eligibility criteria to be verified. If the volunteer is included, the self-questionnaire will be completed on site and stool collection will be carried out.
223940910|NCT07196696|DEVICE|GMA-Tulip|Under general anesthesia, GMA-Tulip laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
223940911|NCT07196696|DEVICE|I-gel|Under general anesthesia, I-gel laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
223717741|NCT02611219|OTHER|The Functional Independence Measure for Children|"* 18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~* Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
223717742|NCT02611219|OTHER|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
223717743|NCT02611219|OTHER|3-Minute Step Test|"* Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~* Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
223717744|NCT02611219|OTHER|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"* 7 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
223717745|NCT02611219|OTHER|HSCT Module-Follow Child-Self Report (5-12 years)|"* 10 question questionnaire about child~* Answers range from 1=all of the time to 5=none of the time"
223717746|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
223717747|NCT02611219|OTHER|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"* 7 question questionnaire about child~* 49 question questionnaire about parent~* Answers range from 1=all of the time to 5=none of the time"
223717748|NCT04876924|DRUG|BBP-711|BBP-711, oral suspension
223717749|NCT04876924|DRUG|Placebo|Placebo matching BBP-711
223717750|NCT06798233|DIAGNOSTIC_TEST|Non-Ambulatory Hip Pain questionnaire|a new questionnaire for care givers to identify hip pain in pediatric patients with quadriplegia
224282038|NCT02166801|BEHAVIORAL|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
224282039|NCT01304186|BEHAVIORAL|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
224282040|NCT02010996|PROCEDURE|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
224282041|NCT02010996|PROCEDURE|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
224282042|NCT01503463|PROCEDURE|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
224282043|NCT01710124|OTHER|Financial incentives|
224282044|NCT03285919|DEVICE|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
223717751|NCT06491940|DRUG|Losartan|Patients will receives Losartan (LS) 50 mg per day.
223717752|NCT06491940|DRUG|Losartan + Hydrochlorothiazide|Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
223940912|NCT07196696|DEVICE|LMA-Supreme insertion|Under general anesthesia, LMA Supreme laryngeal mask is inserted following standardized protocols. CT scanning and fiberoptic laryngoscopy are performed to assess insertion depth, anatomical alignment, and tissue compression.
223940913|NCT07196423|DEVICE|Transcranial direct current stimulation (tDCS)|2mA anodal stimulation to be delivered for 20 minutes using a Neuroconn DC stimulator PLUS which will be repeated once after a 20-minute break.
223940914|NCT07196423|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Using a 7T Philips scanner with total scanning session lasting no more than 1 hour.
223940915|NCT03147287|DRUG|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
223940916|NCT03147287|DRUG|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
223926780|NCT06418217|PROCEDURE|Exercise and Patient Education|"Patients will undergo a 12-week physiotherapist-led exercise program consisting of 8 supervised sessions and home-based training in between.~Patients will keep training diaries, where each session is tracked in regards of completed repetitions and pain before and after the sessions. Each session will consist of four exercises."
223926781|NCT05870254|OTHER|ExeRVIEM Program|Virtual exercise based program
223926782|NCT05870254|OTHER|Usual center program|Usual center cares
223926783|NCT05442489|DEVICE|GORE Excluder Thoracoabdominal Branch Endoprosthesis|TEVAR
223926784|NCT05785754|DRUG|DCSZ11|A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
223926785|NCT05785754|DRUG|Pembrolizumab|Pembrolizumab injection
223926786|NCT05785754|DRUG|Doxorubicin|1b SOC Cohort 1: Doxorubicin combination in soft tissue sarcoma
224282045|NCT04316195|DIAGNOSTIC_TEST|Assessment of the bulbocavernosus reflex|"According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA."
224282046|NCT00347906|PROCEDURE|laser treatment|
224282047|NCT01406249|DRUG|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
224282048|NCT01406249|DRUG|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
224282049|NCT00456482|DRUG|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
224282050|NCT00456482|DRUG|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
224282051|NCT04037982|PROCEDURE|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
224282052|NCT04037982|PROCEDURE|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
223926787|NCT05785754|DRUG|Tebentafusp|1b SOC Cohort 2: Tebentafusp combination in uveal melanoma
223926788|NCT05526664|OTHER|Genetic testing and Omics analysis|Blood sample for genetic analysis and for Omics analysis as metabolomics and transcriptomics
223926789|NCT04838717|DRUG|BPG|intramuscular injection of 2.4 million units
223926790|NCT04838717|DRUG|Doxycycline|Oral: at a dose of 100 mg bid for 14 days
223926791|NCT06467136|BEHAVIORAL|Sound production treatment|Evidence based treatment for apraxia of speech, developed by Julie Wambaugh.
223926792|NCT06467136|BEHAVIORAL|Motor Imagery Practice|Practice of target items using motor imagery during home practice
223926793|NCT06416085|DRUG|Psilocybin|Single high-dose (25mg) capsule of psilocybin taken orally in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy
223926794|NCT01606488|DRUG|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
223926795|NCT01606488|OTHER|no intervention|
223926796|NCT05975554|DRUG|Interleukin-2 [IL-2]|5 sequential days of treatment (1.5MIU/day subcutaneously)
223926797|NCT05975554|PROCEDURE|Standard care - Carotid Endarterectomy|Standard care for patients with carotid stenosis undergoing carotid endarterectomy
223926798|NCT06203990|BEHAVIORAL|Barre exercise|Group barre exercise class
223926799|NCT06289504|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously once weekly.
223926800|NCT06289504|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
223926801|NCT06289504|DRUG|Atorvastatin|Atorvastatin will be administered as a single dose orally 2 times during the study.
223926802|NCT06289504|DRUG|Warfarin|Warfarin will be administered as a single dose orally 2 times during the study.
223926803|NCT02632305|DRUG|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
223926804|NCT03286114|DRUG|Pembrolizumab|200mg IV every 21 days
223926805|NCT06418178|DRUG|Midomafetamine|One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)
223926806|NCT06418178|BEHAVIORAL|Psychotherapy|Standardized psychotherapy performed by therapy team
223940917|NCT03147287|DRUG|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
223940918|NCT04152408|DEVICE|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
223940919|NCT07196371|BEHAVIORAL|Aerobic Training with Blood Flow Restriction|"Participants will undergo a 6-week aerobic training intervention with blood flow restriction applied to the lower limbs.~Blood flow restriction will be applied using a blood pressure cuff set between 60-80% of limb arterial occlusion pressure.~Training will consist of treadmill walking at 40-50% of heart rate reserve (HRR) for 32 minutes per session, 3 times per week for a total of 96 minutes per week."
223940920|NCT07196371|BEHAVIORAL|Standard Aerobic Training|"Participants will follow the same aerobic training protocol as the AT+BFR group but without blood flow restriction.~Training will consist of treadmill walking at 40-50% of HRR for 32 minutes per session, 3 times per week for a total of 96 minutes per week."
223940921|NCT07197567|DRUG|Sevoflurane + Remifentanil|Combination of an inhalational anesthetic (sevoflurane) and an intravenous opioid analgesic (remifentanil), both routinely used in clinical practice for maintenance of general anesthesia. These agents are administered according to standard of care, not as experimental interventions.
223940922|NCT07197567|DRUG|Propofol + Remifentanil|Combination of an intravenous anesthetic (propofol) and an intravenous opioid analgesic (remifentanil), both routinely used in clinical practice for induction and maintenance of general anesthesia. These agents are administered according to standard of care, not as experimental interventions.
223940923|NCT07197567|DRUG|Sevoflurane + Propofol + Remifentanil|Combination of an inhalational anesthetic (sevoflurane), an intravenous anesthetic (propofol), and an intravenous opioid analgesic (remifentanil). These agents are routinely used together in clinical practice for combined intravenous-inhalational anesthesia (CIVIA). All drugs are administered according to standard of care, not as experimental interventions.
223717753|NCT03923712|BEHAVIORAL|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
223717754|NCT00404261|DRUG|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
223717755|NCT02591069|DEVICE|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
223717756|NCT02936830|DRUG|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
223717757|NCT02936830|DRUG|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
223717758|NCT02936830|DRUG|Glycerol|Glycerol with water in a 1: 1 ratio
223717759|NCT02523248|PROCEDURE|tonsillectomy|Tonsillectomy with cold steel
223717760|NCT02523248|PROCEDURE|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
223717761|NCT02370745|DRUG|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
223717762|NCT02370745|DRUG|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
223926807|NCT06953128|PROCEDURE|Spinal Anesthesia|Participants will receive subarachnoid (spinal) anesthesia with 15-20 mg of isobaric bupivacaine 0.5% and 100 μg of intrathecal morphine. Clonidine (1 μg/kg) may be added at the discretion of the anesthesiologist. Sedation will be achieved with intravenous midazolam (up to 5 mg), fentanyl (up to 100 μg), and/or target-controlled infusion of propofol. Patients will remain spontaneously breathing throughout the procedure and receive supplemental oxygen via nasal cannula.
223926808|NCT06953128|PROCEDURE|General Anesthesia|Participants will undergo general anesthesia induced with intravenous propofol (1.5-2.5 mg/kg) or etomidate (0.2-0.3 mg/kg), remifentanil (0.2-0.4 μg/kg/min), and rocuronium (0.6 mg/kg), followed by endotracheal intubation and controlled mechanical ventilation. Maintenance will include continuous remifentanil infusion and inhaled sevoflurane. Ventilation parameters will follow a protective strategy (tidal volume 6-8 mL/kg predicted body weight and PEEP of 5 cmH₂O).
224093630|NCT02823158|PROCEDURE|Best medical treatment|Patients will receive optimized medical treatment according to published evidence based guidelines.
223717763|NCT02370745|DIETARY_SUPPLEMENT|Oral amino acids|Oral amino acids containing 15 g of amino acids
223717764|NCT02370745|DRUG|GIP|This will be co infused with GLP-1 and intravenous amino acids
223717765|NCT02370745|DRUG|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
223717766|NCT04468854|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
223717767|NCT04468854|OTHER|Placebo|mannitol formulated for oral administration (capsules)
223717768|NCT02777801|DRUG|Entecavir|anti-HBV
223717769|NCT00524862|DRUG|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
224093631|NCT02399033|DRUG|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
224093632|NCT00818259|DRUG|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
224093633|NCT00818259|DRUG|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
224093634|NCT00818259|DRUG|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
223926813|NCT04947475|BEHAVIORAL|SBIRT|First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.
223926814|NCT05895552|DRUG|RTA 901|Administered as specified in the treatment arm.
223926815|NCT05895552|DRUG|RTA 901-Matching Placebo|Administered as specified in the treatment arm.
223926816|NCT06951438|DIAGNOSTIC_TEST|Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas|Self-swab collection PCR test for chlamydia, gonorrhea, trichomonas
223926817|NCT02629497|DIETARY_SUPPLEMENT|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
223926818|NCT02629497|DIETARY_SUPPLEMENT|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
223926819|NCT04285671|BIOLOGICAL|Necitumumab|Given IV
223926820|NCT04285671|DRUG|Osimertinib|Given PO
223926821|NCT04285671|OTHER|Quality-of-Life Assessment|Ancillary studies
223926822|NCT04285671|OTHER|Questionnaire Administration|Ancillary studies
223926823|NCT04285671|BIOLOGICAL|Trastuzumab|Given IV
223926824|NCT05869149|BEHAVIORAL|Multilevel restaurant intervention to improve the food environment|FRESH is a restaurant-based intervention in low-income neighborhoods in Baltimore, MD and the Washington, District of Columbia metro area that aims to improve the healthy prepared-food environment for consumers, informed by community members and other stakeholders. FRESH intervention components include food preparation, food access and procurement, and consumer nutrition environment. Activities will take place over 16 months, and include training restaurant chefs to use healthier cooking methods, partnering with restaurant suppliers to offer healthier ingredients, and offering point-of-purchase promotions to educate customers on the healthier promoted food options. Intervention staff will form strong relationships with restaurant owners and chefs via in-person visits at least twice a month. Data from the intervention trial will inform the development of a system dynamics simulation model that will allow stakeholders to test new policy ideas prior to implementation.
223926825|NCT05743387|OTHER|T2D care package|T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
224093635|NCT00818259|DRUG|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
223717770|NCT00524862|DEVICE|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
223926826|NCT05743387|OTHER|Referral to the responsible health facility|CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
223926827|NCT05864612|BEHAVIORAL|Screening Questionnaires|Standard care screening questionnaires on anxiety and depression
223926828|NCT05598151|DRUG|HM97662|To evaluate the safety, tolerability, preliminary anti-tumor efficacy, PK and PD of HM97662 in solid tumors
223926829|NCT03304418|DRUG|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
224093636|NCT00818259|DRUG|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
224093637|NCT06230354|DRUG|Tezepelumab|Tezepelumab subcutaneous injection
224093638|NCT06230354|DRUG|Placebo|Placebo subcutaneous injection
224093639|NCT00421330|PROCEDURE|Open Aneurysm Repair|
224093640|NCT00421330|PROCEDURE|Endovascular Aneurysm Repair|
224093641|NCT02129673|DRUG|VS101 Insert Dose A|Sustained release of latanoprost into the eye
224093642|NCT02129673|DRUG|VS101 Insert Dose B|Sustained release of latanoprost into the eye
224093643|NCT02129673|DRUG|VS101 Insert Dose C|Sustained release of latanoprost into the eye
224093644|NCT02129673|DRUG|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
224093645|NCT03223571|OTHER|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
224093646|NCT06190457|OTHER|intrathecal rituximab|All children were treated with a modified NHL-BFM95 regimen for children NHL with the addition of rituximab, both intravenous and intrathecal, and rituximab intrathecal infusion is scheduled to be used simultaneously with rituximab intravenous drip. rituximab intrathecal doses are 10 mg, 15 mg, and 20 mg in increments every 3 weeks. rituximab intrathecal injection does not use methotrexate or/and cytarabine intrathecaline chemotherapy.
224093647|NCT00120003|DRUG|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
224093648|NCT00120003|DRUG|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
224093649|NCT00457574|DRUG|GMX1777|
223717771|NCT00000430|DRUG|Alendronate|
223717772|NCT00000430|DRUG|Estrogen/progestin therapy|
223717773|NCT02746146|OTHER|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
223717774|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
223926830|NCT03304418|RADIATION|Radiation|"All external beam radiations oligometastatic sites will commence after cycle 1 of Radium-223 but prior to cycle 2 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~* Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~* Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~* Five fractions: 30 Gy total at 6Gy per fraction (SBRT).When using five fractions, can reduce to 25 Gy total at 5 Gy per fraction (SBRT) or to a minimum of 20 Gy total at 4 Gy per fraction (SBRT), per treating investigator.~* Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
223926831|NCT06066242|OTHER|Different induction chemotherapy regimens|azacitidine combined with venetoclax or chemotherapy with or without venetoclax
223926832|NCT06191198|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
223926833|NCT06191198|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
223926834|NCT06638372|DIETARY_SUPPLEMENT|caffeine|The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
223926835|NCT05933551|OTHER|Z Technique Training|Training on Z technique will be given on the planned day, time and place. The education is planned to be given at Tarsus University. The training content will be presented to the participants as a powerpoint presentation (30 min), laboratory practice (15 min) and question-answer (15 min).
223926836|NCT05154201|DRUG|ORIN1001|Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
223926837|NCT05512910|DRUG|Minocycline|200 mg minocycline orally or via feeding tube, followed by 100 mg every 12 hours times for a total of 5 days. If vomiting occurs within half an hour of the first dose, the clinician should assess the necessary of re-administering 100mg based on the severity of vomiting. Considering the risk of difficulty in feeding tube before EVT, minocycline administered within one hours after EVT is acceptable.
223926838|NCT05993689|OTHER|BUNDLE|An integrated model of community-based doulas and clinical obstetric providers
223926839|NCT05993689|OTHER|Usual Care|Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
224093650|NCT05042726|DEVICE|cTBS First|Continuous θ-burst stimulation (cTBS) is characterized by plexus stimulation. The stimulation intensity was 80% resting motor threshold (RMT) at 50Hz of intra plexus pulse while the frequency of inter plexus pulse is 5Hz, the duration was 33.2s, and the number of stimulation pulses was 600. Two groups of stimulation were repeated in each cerebellar dentate nucleus with an interval of 5 min in each group.
224093651|NCT05042726|DEVICE|Pseudo-stimulation First|The transcranial magnetic stimulator operating system has a built-in control group option, in which the stimulation parameters are set consistent with the research group, which can realize the operation of only sound without stimulation.
223717775|NCT01773811|BEHAVIORAL|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
224282053|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|A multi-detector row CT scanner with minimum section collimation of ≤1 mm and minimum number of data acquisition channels ≥ 16will be employed.
224282054|NCT05762731|DIAGNOSTIC_TEST|Low dose CT thorax|Control subjects will also proceed to CT thorax, and outcome measures be compared to subjects
224282055|NCT00000425|DRUG|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
224282056|NCT00000425|DRUG|Acetaminophen|
224282057|NCT02868996|DRUG|Recombinant human tissue kallikrein|Intravenous DM199
223717776|NCT00096070|RADIATION|radiation therapy|Undergo radiation therapy
223717777|NCT00096070|DRUG|oxaliplatin|Given IV
223717778|NCT00096070|DRUG|fluorouracil|Given IV
223717779|NCT00096070|DRUG|gemcitabine hydrochloride|Given IV
223926840|NCT01957332|PROCEDURE|Molecular imaging|On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
223926841|NCT01957332|PROCEDURE|Molecular imaging|All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
223926842|NCT03913117|BIOLOGICAL|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
223926843|NCT03913117|BIOLOGICAL|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
223926844|NCT06643715|DEVICE|PANDA PLUS|Using the PANDA PLUS model to assist in image interpretation, radiologists are provided with the model's output classification-non-PDAC, PDAC, or normal-alongside the initial CT image assessment. The radiologists then integrate the information from both the PANDA PLUS output and the original image interpretation to formulate the final report.
223926845|NCT06644183|DRUG|Roginolisib|Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.
224282058|NCT00049296|DRUG|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
224282059|NCT00049296|DRUG|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
224282060|NCT03507686|DRUG|BIIB111|Administered as specified in the treatment arm.
224282061|NCT02508116|GENETIC|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
224282062|NCT02630316|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
224282063|NCT02630316|DRUG|Placebo|Placebo administered four times daily
224282064|NCT03935841|DIETARY_SUPPLEMENT|3-OHB salt (NaCl)|36 gram 3-OHB salt diluted in 500 ml sterile water
223926846|NCT06644183|DRUG|Venetoclax|B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.
224093652|NCT01943656|DEVICE|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
224093653|NCT01053429|DRUG|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
224093654|NCT00825370|DRUG|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
224093655|NCT00825370|DRUG|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
224282065|NCT03398590|BEHAVIORAL|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
223926847|NCT06644183|DRUG|Rituximab|Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
223926848|NCT06643208|DRUG|TACE-HAIC, Envafolimab and Lenvatinib|TACE-HAIC (GEMOX regimen) combined with Envafolimab and Lenvatinib
223926849|NCT06643117|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
223926850|NCT06643117|BIOLOGICAL|FYB206|Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)
223926851|NCT06643117|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)
223926852|NCT00050063|BIOLOGICAL|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
223926853|NCT02075554|DEVICE|CALIBER|Expandable interbody spacer
223926854|NCT06091267|DRUG|IV Decitabine|The subjects will receive decitabine 20 mg/m\^2 IV daily × 5 days in 28-day cycles.
223926855|NCT06091267|DRUG|Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles.
224093656|NCT01841892|BEHAVIORAL|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
224282066|NCT03549455|BEHAVIORAL|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 \& 4 will have Exposure therapy with Self-Distancing; Weeks 5 \& 6 will have Exposure therapy only; Weeks 7 \& 8 will have Exposure therapy with Self-Distancing;
223926856|NCT06091267|DRUG|only Decitabine and cedazuridine|subjects will receive treatment with ASTX727, 1 tablet/day for 5 consecutive days, in 28-day cycles, until disease progression, unacceptable toxicity, or the subject/investigator decides that the subject should discontinue treatment or withdraw from the trial.
223926857|NCT02320370|DEVICE|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
223926858|NCT03124017|OTHER|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
223926859|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h
223926860|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h
223926861|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h
223926862|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
223926863|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
223926864|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
223926865|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
223926866|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
223926867|NCT00624442|DRUG|Placebo|IV infusion for 2 hours
223926868|NCT00624442|DRUG|Placebo|IV infusion for 24 hours
223926869|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
223926870|NCT00624442|DRUG|Placebo|IV infusion for 72 hours
223926871|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
223926872|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
223717780|NCT05732688|DIAGNOSTIC_TEST|Image-based ex-vivo drug screening platform (pharmacoscopy)|"Leukemic cells from a patient at relapse can be screened for sensitivity to single compounds. A drug score is calculated for each compound (defined as 1 - (% target cells in drug treated conditions / % target cells under control condition)). If a drug kills all target cells specifically, the best possible score is 1. If the drug is killing all non-target cells, the score goes to negative infinite. If a drug kills both target and non-target cell populations equally, or does nothing, the score is 0."
223926873|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
223926874|NCT00624442|DRUG|CK-1827452|IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
223926875|NCT03462485|OTHER|Golf|Eight weeks of twice-daily golf training
223926876|NCT04263610|DRUG|Dimethyl fumarate (DMF) standard scheme|Participants will receive DMF gastro-resistant tablet orally from baseline to Week 16, at a dose of 30 milligrams (mg) once daily, twice daily, thrice daily in Week 1, Week 2, Week 3 respectively, 120 mg only once in Week 4. Participants will increase DMF dose by 120 mg tablet per week for the subsequent 5 weeks. Participants achieving Psoriasis area and severity Index (PASI) 50-75 (partial responder) or 75 (responder) will continue the DMF treatment until Week 40. The maximum daily dose taken by a participant will be 720 mg.
223926877|NCT04263610|DRUG|Dimethyl fumarate (DMF) simplified scheme|Participants will receive DMF gastro-resistant tablet orally at a dose of 60, 120, 180, 240, 360 mg daily in Week 1, Week 2, Week 3, Week 4, Week 5 respectively, and 480 mg daily from Week 6 to Week 8. If a PASI is greater than or equal to (\>=) 30% at Week 8, no dose increase will be done and if PASI is less than (\<) 30% at Week 8, participants will receive 600 mg daily in Week 9 and 720 mg from the Week 10 onwards.
223926878|NCT04263610|DRUG|Tildrakizumab|Participants who achieve PASI less than (\<) 50 (non-responders) at Week 16 will receive Tildrakizumab subcutaneous injection at a dose of either 100 or 200 mg \[(as per the Summary of Product Characteristics (SmPC)\] at Weeks 16, 20 and 32 up to Week 40.
223926879|NCT00127387|DRUG|Enbrel|
223926880|NCT03618758|DRUG|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
224093657|NCT04708587|DRUG|dual anti-platelet therapy at least 6 months|Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
224093658|NCT04708587|DRUG|dual anti-platelet therapy 3months or less|Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
224093659|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
224093660|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
224093661|NCT00752986|DRUG|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
223717781|NCT04085276|DRUG|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
223926881|NCT03618758|DRUG|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
223926882|NCT03568409|DEVICE|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
223926883|NCT03568409|OTHER|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
223926884|NCT02757898|DRUG|Biotin-Labeled Red Blood Cells (RBCs)|"500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
223926885|NCT06632158|BEHAVIORAL|MindBoba|MindBoba is a smartphone app that uses strategies based on Problem-Solving Therapy to help decrease stress and anxiety, and teach new skills.
223926886|NCT06632158|BEHAVIORAL|Mindshift CBT|MindShift® CBT uses strategies based on Cognitive Behavioural Therapy (CBT) to help participants learn to relax and be mindful, develop more effective ways of thinking, and use active steps to take charge of their anxiety.
223926887|NCT01316107|DRUG|ipragliflozin|oral
224093662|NCT00752986|DRUG|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
223717782|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
223717783|NCT04085276|DRUG|Placebo|Placebo, i.v., q3w;
223717784|NCT04085276|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
223717785|NCT05759728|BIOLOGICAL|CNA3103: 5 x 10^7 cells|CNA3103: 5 x 10\^7 cells - intravenous infusion
223717786|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^8 cells|CNA3103: 1.5 x 10\^8 cells - intravenous infusion
223926888|NCT01316107|DRUG|nateglinide|oral
223926889|NCT02401711|BEHAVIORAL|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
223717787|NCT05759728|BIOLOGICAL|CNA3103: 4.5 x 10^8 cells|CNA3103: 4.5 x 10\^8 cells - intravenous infusion
223926890|NCT02401711|BEHAVIORAL|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
223926891|NCT02401711|BEHAVIORAL|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
223926892|NCT05175794|DIAGNOSTIC_TEST|Xpert® MTB/XDR|The Xpert MTB/XDR Assay, performed on the GeneXpert Instrument Systems, is a nested real-time polymerase chain reaction(PCR) in vitro diagnostic test for the detection of extensively drug resistant (XDR) Mycobacterium tuberculosis (MTB) complex DNA in unprocessed sputum samples or concentrated sediments prepared from sputum. In specimens where MTB is detected, the Xpert MTB/XDR Assay can also detect isoniazid (INH) resistance associated mutations in the katG and fabG1 genes, oxyRahpC intergenic region and inhA promoter; ethionamide (ETH) resistance associated with inhA promoter mutations only; fluoroquinolone (FLQ) resistance associated mutations in the gyrA and gyrB quinolone resistance determining regions (QRDR); and second line injectable drug (SLID) associated mutations in the rrs gene and the eis promoter region.
223926893|NCT04993677|DRUG|SEA-CD40|Given into the vein (IV; intravenously); schedule is cohort-specific
223926894|NCT04993677|DRUG|pembrolizumab (KEYTRUDA®)|Given by IV; schedule is cohort-specific.
223926895|NCT04993677|DRUG|pemetrexed|Given by IV on Day 1 of each 21-day cycle.
223717788|NCT05759728|BIOLOGICAL|CNA3103: 1.5 x 10^9 cells|CNA3103: 1.5 x 10\^9 cells - intravenous infusion
223717789|NCT05759728|BIOLOGICAL|CNA3103: 2.5 x 10^7 cells|CNA3103: 2.5 x 10\^7 cells - intravenous infusion
223926896|NCT04993677|DRUG|carboplatin|Given by IV on Day 1 of Cycles 1-4. Each cycle will be 21 days long.
223926897|NCT05817370|BEHAVIORAL|Enhanced Training on screening and treatment of HSIL (e-STH)|Tailored training developed to overcome key barriers and promote facilitators unique to implementing HSIL screening and treatment. The development will be driven by the implementation science committee over 3 iterations every 4 months for up to a year to refine the adoption of strategies with the greatest breadth to facilitate implementation.
223926898|NCT03462147|DEVICE|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
223926899|NCT04899778|DRUG|Oral Contraceptive Pill, norethindrn a-e estradiol-iron|tablet
223926900|NCT05799053|DRUG|Small intestinal release peppermint oil|Tempocol®, a gastric acid resistant (enteric-coated) capsule containing 182mg of Menthae Piperitae Aetheroleum (peppermint oil), is currently registered as an over the counter prescription drug on the Dutch market for treatment of abdominal pain, discomfort or flatulence.
223926901|NCT05799053|DRUG|Peppermint sweets|Wilhelmina® peppermints contain 9.2 mg of Menthae Piperitae Aetheroleum (peppermint oil), and 18.4 Kcal per mint and are to be taken orally.
223926902|NCT05799053|DRUG|Placebo|Capsule containing microcrystalline cellulose
223926903|NCT06798467|OTHER|Endodontic sealer|endodontic sealer is a material used in root canal therapy to fill the microscopic spaces between the root canal filling material (typically gutta-percha) and the walls of the root canal. Its primary function is to create a tight seal that prevents the ingress of bacteria and fluids into the root canal system, helping to prevent reinfection and promoting the healing of periapical tissues. Endodontic sealers also help to ensure that the root canal filling reaches all parts of the canal, especially in complex or irregularly shaped anatomies.
223926904|NCT06798467|OTHER|post obturation pain|Unpleasant sensation of any degree of pain after root canal treatment.
223717790|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) as usual|Parents as Teachers parent-education program as designed. Delivered in the home to parents of children under 5. Parents begin with the foundational curriculum (mostly taught within the first six sessions) focused on healthy child development, parenting behaviors including parent-child interactions and communication, and creating a safe home environment in terms of avoiding accidents and injuries. After the foundational curriculum, additional sessions are delivered based on the continued needs of the family until the child ages out or the parent discontinues services. PAT uses development-centered parenting, family well-being, and community connections to reinforce this foundational curriculum.
223926905|NCT02446444|DRUG|Enzalutamide|
223926906|NCT02446444|DRUG|Conventional NSAA|
223926907|NCT02446444|DRUG|LHRHA|
224093663|NCT00752986|DRUG|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
224093664|NCT06202248|DEVICE|Experimental: DaRT seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
224093665|NCT03481270|BEHAVIORAL|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
224093666|NCT00792779|DRUG|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
224093667|NCT00924703|DRUG|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
224093668|NCT00666562|DIETARY_SUPPLEMENT|Defined Green Tea Catechin Extract|Given orally
224093669|NCT00666562|OTHER|Laboratory Biomarker Analysis|Correlative studies
224093670|NCT00666562|OTHER|Pharmacological Study|Correlative studies
224093671|NCT00666562|DRUG|Placebo|Given orally
224093672|NCT00666562|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223926908|NCT02446444|RADIATION|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
223926909|NCT06324981|BEHAVIORAL|Generic text messages|The same unidirectional text message will be sent each week for 9 weeks.
223926910|NCT06324981|BEHAVIORAL|Interactive AI chatbot text messaging|Each week for 9 weeks, patients will be sent four messages that are specific to the LE8 topic for that week and with each message, they will be invited to engage with the chatbot to ask more questions about that topic. The first message of the week will be informational about the topic consistent with how the AHA provides information: 1) to understand readings and levels, 2) to encourage people to track levels, and 3) to offer specific skills building strategies. The fourth message will ask them to report out on short term (i.e., things they can do that week) plans for self-management for that topic and again invite their engagement with the chatbot to reinforce support for their plans.
223926911|NCT06324981|BEHAVIORAL|Proactive pharmacist support|Pharmacists that will proactively facilitate effective engagement with patients.
223926912|NCT00149591|PROCEDURE|coronary balloon-angioplasty with stenting|
224093673|NCT06290440|OTHER|Telepharmacy-led counselling|The counselling process will be delivered as follows: (1) researchers assist patients in signing up and using the telepharmacy application; (2) researchers send the counselling information from the telepharmacy application to the patient's account (the information will be provided as leaflets and 3-5-minute videos to improve the accessibility); (3) the integrated chatbot system forwards any additional questions or concerns of the patients to the counselling pharmacists; and (4) the pharmacists directly address the patient's questions or concerns through phone calls within the shortest possible timeframe.
224093674|NCT06290440|OTHER|Pharmacist-led counselling|Pharmacists will counsel the patients on how to use their OAC. Each counselling section will take approximately 7-15 minutes, depending on the patient's questions or concerns. The counselling contents have already been compiled and validated by NDGD Hospital to ensure rationale and simplicity for every patient. Counselling pharmacists have received specialised training in drug information and patient communication so intervention delivery will be consistent across different pharmacists.
224093675|NCT05491759|DRUG|Product 1 - AquaCelle Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.4g AquaCelle.
224093676|NCT05491759|DRUG|Product 2 - AquaCelle Fish Oil Ethyl Ester|1 dose of 2 capsules equivalent to 1.6g Fish Oil Ethyl Ester (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)) and 0.28g AquaCelle
223926913|NCT06242366|BEHAVIORAL|Intervention group|"Intervention 2 phases Phases 1) In-hospital period (4 times and 30-60 mins/times) intervention includes Stroke education, Rehabilitation, environmental management, and complication prevention. Intervention participants will receive a booklet (choose between hard copy or electronic copy) self-care for stroke patients, Rehabilitation clip, and Self-care record form.~Phases 2) after hospital discharge 5 times (first times within 24 hours after hospital discharge) and (second-fifth time: 1 time/weekly)15-30 mins/times by Line Application for repeat and following education, rehabilitation complication prevention and finding limit to self-care management."
223926914|NCT04900675|OTHER|Bright light intervention|Exposure with 5,000 lux at eye level for one hour and a Correlated Color Temperature of 5,300 Kelvin every morning for three weeks.
223926915|NCT04900675|OTHER|Reddish placebo light|Exposure with 50 lux at eye level for one hour and a Correlated Color Temperature of 2,200 Kelvin every morning for three weeks.
223926916|NCT01318694|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
223926917|NCT01318694|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
223926918|NCT01318694|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
223926919|NCT01318694|DRUG|ALV Placebo|ALV placebo soft gel capsules administered orally
223926920|NCT05513742|DRUG|CTX-009|IV infusion administered on day 1 and 15 of every 28-day cycle
223926921|NCT00003222|BIOLOGICAL|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
224093677|NCT05491759|DRUG|Product 3 - Standard Fish Oil Triglyceride|1 dose of 2 capsules equivalent to 1.6g Fish Oil Triglyceride (standardised to contain 1120 mg of eicosapentaenoic acid and docosahexaenoic acid (EPA+DHA)).
224093678|NCT06055166|DRUG|Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))|Arm A: untreated surgically resectable rectal cancer. Patients accept preoperative long-range synchronous chemoradiotherapy → fluzoparib combined with capecitabine (Q3W, 4 treatment cycles) → surgery → observation and follow-up Arm B, C and D: include untreated locally advanced unresectable non-small cell lung cancer, esophageal squamous cell carcinoma and cervical carcinoma. Patients accept radical synchronous chemoradiotherapy following → fluzoparib combined with camrelizumab or fluzoparib monotherapy maintenance treatment for 17 cycles
224093679|NCT01106040|DRUG|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
224093680|NCT05792202|PROCEDURE|microfracture procedure|double raw repair combined with microfracture procedure which promotes tendon healing by releasing growth factors
224093681|NCT05792202|PROCEDURE|only double raw repair|the double raw repair was used to repair the tendon tear
223532199|NCT05931731|OTHER|Mechanical interference|The patients will receive mechanical interference treatment in the form of five techniques, including wrist distraction (3 sets for 3 minutes), rhythmic and gentle stretching of the transverse carpal ligaments, the release of palmar hand fascia, gliding of the finger flexor tendons (using the oscillatory flexion-extension movement of the metacarpophalangeal joint) and release of the upper forearm muscle and fascia were applied. Manual techniques were performed total of 15 minutes in each session each technique included 3 sets for 3 minutes and conventional treatment
224093682|NCT04695873|DEVICE|Corn Foam Cushion|An anatomically shaped foam pad with a central hole. The upper layer is made from a honeycomb of interconnecting cells, the external facing surface is smooth, the underside is coated with adhesive.
223532200|NCT05931731|OTHER|Neural mobilization|the patients will receive neurodynamic mobilizations, including sliding techniques and tensioning techniques which are thought to enhance ulnar nerve gliding and restore neural tissue mobility and conventional treatment
223926922|NCT00003222|BIOLOGICAL|gp100 antigen|
223926923|NCT00003222|BIOLOGICAL|incomplete Freund's adjuvant|
223926924|NCT00003222|BIOLOGICAL|sargramostim|
223926925|NCT00003222|BIOLOGICAL|tetanus peptide melanoma vaccine|
223926926|NCT00003222|BIOLOGICAL|tyrosinase peptide|
223926927|NCT03898596|DIAGNOSTIC_TEST|ECG|An ECG collects superficial readings of heart activity
223926928|NCT04736485|DRUG|perioperative treatment|FLOT + Spartalizumab
223926929|NCT04625023|OTHER|Observational|Retrospective cohorts and Prospective observation of standard clinical practice
223926930|NCT03011671|DRUG|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
223926931|NCT03011671|DRUG|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
223926932|NCT06564909|DRUG|L-Carnitine|L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)
223926933|NCT06564909|DRUG|The standard care for the management of myocardial infarction post PCI|include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
223926934|NCT05572970|DRUG|Balstilimab|An anti-programmed death 1 (PD-1) monoclonal antibody.
223926935|NCT05572970|DRUG|Zalifrelimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
223926936|NCT06561009|DRUG|Anti-BAFFR CART|Anti-BAFFR CART
224093683|NCT02238535|DRUG|Ventavis|
224093684|NCT02238535|DRUG|Warfarin|
224093685|NCT06381830|OTHER|Apheresis|Participants will undergo two separate apheresis procedures, including: G-CSF primed hematopoietic stem cell collection and peripheral blood mononuclear cell apheresis for CAR-T cell manufacturing.
224093686|NCT06381830|OTHER|Autologous Stem Cell Transplantation|Participants are designed to receive myeloablative conditioning regimen prior to infusion of a minimum 2 x 10\^6 CD34+ stem cells/kilogram.
224093687|NCT06381830|DRUG|CAR-T Cell Therapy|CAR-T cells will be infused within 7 days after autologous hematopoietic stem cell infusion (2-10×10\^6 CAR-T/kg，ivgtt).
223926937|NCT05072093|BEHAVIORAL|PrEP discontinuation intervention|Men taking daily oral PrEP (Truvada) will receive a monthly screener through the mobile app. If answers to screener questions indicate a participant is at risk for PrEP discontinuation, then a peer navigator will deliver a motivational interviewing intervention and a clinician will consult with the participant. These efforts are intended to avert PrEP discontinuation.
223926938|NCT05072093|DRUG|Offering of on-demand oral PrEP|For men who are not interested in daily oral PrEP or plan to discontinue daily oral PrEP, the investigators will offer on-demand oral PrEP (Truvada) which will allow them to take it immediately before/after a sexual encounter. It is hoped that this will serve as an alternative to daily oral PrEP use that is desirable for some people.
223926939|NCT05072093|DRUG|Offering of STI PEP|All men in the cohort will be offered STI PEP (doxycycline) to use after condomless sex with the goal of averting STI diagnoses. At a dosage of 200 mg to be taken in a single dose ideally within 24 hours of possible exposure (e.g. condomless anal sex) and no later than 72 hours after exposure. Participants will be dispensed enough pills to allow for up to 3 weekly doses of 200mg doxycycline (i.e. 6 pills/week) for 3 months (the interval between STI testing visits).
223926940|NCT05072093|DRUG|Injectable PrEP|For men who are interested in injectable PrEP, they will be referred to local providers to access Apretude (Cabotegravir injection) every two months. In the study, their use of the medication will be monitored through monthly surveys during which they have the option to indicate interest in switching to oral PrEP.
223926941|NCT05904054|BIOLOGICAL|SARS-CoV-2 DNA Vaccine (ICCOV)|The SARS-CoV-2 DNA Vaccine (ICCOV) was developed by Immuno Cure Holding (HK) Limited.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The unit dose strength is 1 mg/0.5 mL and the dose volume is 1.0 mL/dose.
223926942|NCT05708495|OTHER|posterior ilium mobilization|the therapist will mobilize the innominate on the affected side posteriorly
223926943|NCT05708495|OTHER|strengthening and stretching exercises|the participants will receive strengthening exercises on the hip and knee joint beside that they will receive stretching exercises
223926944|NCT06466330|DEVICE|microparticles|inert microparticles
223926945|NCT06466330|PROCEDURE|embolization|Injection of inert microparticles in neovessels using a microcatheter
223926946|NCT06466330|PROCEDURE|sham embolization|injection of saline solution
223926947|NCT05877898|BEHAVIORAL|CHW Education|Participants will be invited to meet with the CHW to learn about eating healthier to reduce blood pressure and enhance quantity and quality of life.
223926948|NCT05877898|BEHAVIORAL|CHW Education and Navigation|Participants will be invited to complete all the CHW education arm material and be offered a menu of optional services for personalization including: (1) transportation to the grocery store (weekly for 4 weeks), (2) culturally adapted hypertension-tailored cooking recipes, (3) a virtual cooking class with food delivered to their door led by community partner, (4) access to UF IFAS's online library of healthy food cooking videos, and (5) in-store education on food labels, grocery shopping, and food resource management skills through the Cooking Matters at the Store curricula.
223926949|NCT06160102|OTHER|Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities|"Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation."
223926950|NCT06552091|OTHER|self-hypnosis sessions|3 self-hypnosis sessions over 3 weeks, one session per week to be practiced daily
223926951|NCT03767335|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle
223926952|NCT03767335|DRUG|Trastuzumab|Trastuzumab solution for infusion administered weekly via IV
224093688|NCT00003721|DRUG|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
223532201|NCT05931731|OTHER|conventional treatment|the patients will receive therapeutic ultrasound (frequency of 1 MHz, intensity of 1 W/cm2, for 5 minutes), transcutaneous electrical nerve stimulation (TENS) (frequency of 80 Hz, pulse duration of 60 μs, at the level of comfortable tingling sensation, for 20 minutes) and therapeutic exercises.
223532202|NCT00365950|DRUG|Duration of anticoagulation|
224093689|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 1-12
224093690|NCT01587989|DRUG|methotrexate|15-25 mg orally weekly, Weeks 13-24
224093691|NCT01587989|DRUG|placebo|methotrexate placebo orally weekly, Weeks 13-24
223532203|NCT00365950|DRUG|Warfarin duration|
223532204|NCT00003561|BIOLOGICAL|recombinant interferon alfa|
223532205|NCT00003561|BIOLOGICAL|sargramostim|
223532206|NCT05406973|DEVICE|SBK microkeratome versus femtosecond laser in flap creation|prospective comparative non randomized interventional clinical study
223532207|NCT00208130|DRUG|Topiramate|
224093692|NCT01587989|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
224093693|NCT02570672|DRUG|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
223532208|NCT00427037|DRUG|Cholecalciferol|50,000 IU weekly by mouth
223532209|NCT00427037|DRUG|Placebo|identical placebo pill orally by mouth
223532210|NCT02006927|DEVICE|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
223532211|NCT03229538|DRUG|Methylprednisolone|IV Steroid pre-operative and intra-operative
224093694|NCT02570672|DRUG|Placebo|Subjects will randomized to placebo will receive placebo
223532212|NCT03229538|DRUG|Isotonic saline|Isotonic saline pre-operative and intra-operative
223532213|NCT02621892|DRUG|Tenapanor|
223532214|NCT02621892|DRUG|Placebo|
223532215|NCT01358162|OTHER|Placebo|Placebo given orally, daily for 14 consecutive days
223926953|NCT03767335|DRUG|Fulvestrant|Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
223926954|NCT06648135|PROCEDURE|Immediate implants with bone grafts|Immediate implants with bone grafts
223926955|NCT06648135|PROCEDURE|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap|Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
223926956|NCT05327270|DRUG|Nivolumab|Given by IT
223926957|NCT04832100|DRUG|Pregabalin 150mg, imipramine 25mg|Conventional treatment for fibromyalgia was given to patients. Clinical follow-ups with questionnaires and interview were arranged then.
223926958|NCT05345561|OTHER|Clinical data collection|Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
223926959|NCT03510104|DRUG|MRX-2843|MRX-2843 capsules
223926960|NCT06106191|BEHAVIORAL|Mindfulness meditation|Ordinary activities like breathing, eating, and walking are turned into a meditation by creating greater awareness of the moment-to-moment sensations, emotions, thoughts and behaviors that arise during these activities.
223926961|NCT06106191|OTHER|Perspectives on pain|Understanding pain from a mind-body perspective and viewing pain as a stressor on physical sensations, thoughts, emotions, and behavior.
223926962|NCT06106191|OTHER|Discussion|Discussion on patients' use of mindfulness to work with pain and pain-themed meditations.
223926963|NCT05116462|DRUG|Pemetrexed|500 mg/m2 D1 IV Q3W
223926964|NCT05116462|DRUG|Carboplatin|AUC 5 or 6 mg/ml/min D1 IV Q3W
223926965|NCT05116462|DRUG|Paclitaxel|175 or 200 mg/m2 D1 IV Q3W
223926966|NCT05116462|DRUG|Sintilimab|200 mg D1 IV Q3W
223926967|NCT05116462|DRUG|Cisplatin|75 mg/m2 D1 IV Q3W
223926968|NCT05116462|DRUG|Nab paclitaxel|100 mg/m2 D1, 8, 15 IV Q3W
223926969|NCT05116462|DRUG|Placebo|20 ml D1 IV Q3W
223926970|NCT06549296|DRUG|RD06-04 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
223926971|NCT03725670|GENETIC|Intrathecal and intravenous LV gene therapy|Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 transduction units/ml which carry a normal ARSA gene
223926972|NCT05988957|OTHER|Semi-structured interviews using an IRB-approved interview guide|A single, semi-structured interview will be conducted using an IRB-approved interview guide. The interviews will be approximately 30 minutes total.
223926973|NCT04495621|DRUG|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
224093695|NCT02053688|DEVICE|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
224093696|NCT02053688|DEVICE|Toric Soft Contact Lenses|astigmatism correction using toric optics
224093697|NCT02503605|DRUG|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
224093698|NCT02503605|DRUG|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
224093699|NCT04312087|PROCEDURE|Lateral neck sentinel lymph node biopsy|Lateral neck sentinel lymph node biopsy is performed in all patients in Arm B.
224093700|NCT04312087|PROCEDURE|Modified lateral neck lymph node dissection|Modified lateral neck dissection (compartment II-V) is performed in all patients in Arm A, and some of the patients in Arm B (according to sentinel lymph node biopsy results).
224093701|NCT04312087|PROCEDURE|Super selective lateral neck lymph node dissection|Super selective lateral neck lymph node dissection is performed in some of the patients in Arm B (according to sentinel lymph node biopsy results).
224093702|NCT02300649|DRUG|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
223926974|NCT04495621|DRUG|Cetuximab|Cetuximab solution for infusion administered weekly via intravenous infusion.
223926975|NCT06199986|BEHAVIORAL|ADT Order Check Attestation (Or)|Clinical reminder order check in electronic health record
223926976|NCT06199986|BEHAVIORAL|Provider Script (Sc)|Provider script added to progress note in electronic health record
223926977|NCT04932525|PROCEDURE|Biopsy|Blood and tumor samples for Genetic Profiling research
223926978|NCT04967131|OTHER|PNF exercises|PNF exercises were applied in 3 sets of 15 repetitions based on movement in the diagonal plane, using head, neck and chin patterns. Contractions were sustained for at least 10 seconds.
223926979|NCT03553810|DRUG|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
224093703|NCT02300649|DRUG|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
223926980|NCT03553810|DRUG|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
223926981|NCT02834884|GENETIC|RP-1828 IMMUcan|WES, lcWGS and RNAseq, multiplex IF and IMC
223926982|NCT02834884|GENETIC|RP-1759 AYA/TYA|WES, RNAseq and EPIC array
223926983|NCT02834884|GENETIC|RP-1843 Arcagen|NGS panel
223926984|NCT02834884|GENETIC|RP-1920 BioRadon|NGS panel
223926985|NCT06295354|OTHER|No intervention, we just study 'aging'|No intervention, we just study 'aging'
223926986|NCT05089084|DRUG|Plozasiran|ARO-APOC3 injection
223926987|NCT05089084|DRUG|Placebo|sterile normal saline (0.9% NaCl)
223926988|NCT03766126|BIOLOGICAL|CART123 cells; cyclophosphamide; fludarabine|"CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10\^6 CART123 cells/kg for Cohort 1a, 5x10\^6 CART123 cells/kg for Cohort 1b, or 2x10\^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10\^5 CART123 cells/kg."
223926989|NCT06559462|OTHER|Focus Group|Open-ended group discussion of potential nudges to elicit constructive feedback on nudge development.
223926990|NCT06559462|OTHER|Discrete Choice|Survey involving choice between two potential nudges to elicit feedback on which nudge version is considered superior.
223926991|NCT06315933|PROCEDURE|General anesthesia|General anesthesia including inhaled and intravenous
223926992|NCT05150145|RADIATION|Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.|Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .
223926993|NCT06839001|PROCEDURE|cryoablation|"Two devices can be used to perform cryoablation: Cryocare® and ProSense IceCure®:~* Cryocare® - This procedure utilizes two types of gases: argon gas for freezing and helium gas for thawing.~* ProSense IceCure® - This procedure uses extremely low temperatures generated by liquid nitrogen (LN2) to freeze and destroy the target tissue, without the need for an additional gas."
224093704|NCT03637049|DRUG|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
224093705|NCT03445286|DEVICE|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
224093706|NCT03445286|OTHER|Normal Saline|Normal Saline for the control group
224093707|NCT04915196|DIETARY_SUPPLEMENT|Liposomally-bound Iron|Ferric pyrophosphate microencapsulated in liposomal form is an over the counter natural health product approved by Health Canada and commonly used for iron replacement. If this product is prescribed as part of usual management of iron deficiency and patients consent to participation they will be contacted by telephone survey of gastrointestinal tolerability.
224093708|NCT06960525|OTHER|Cervical joint mobilization|Passive cervical joint mobilization following Maitland's approach for 3 sets of 1 minute on the most painful segment with one minute rest between sets.
224093709|NCT06960525|OTHER|cervical strengthening exercises|concentric and eccentric training of the craniocervical, cervical flexors, extensors, muscles involved in cervical spine rotation and axioscapular muscles.
224093710|NCT03128957|DEVICE|IVOS cerebral oximeter|Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
224093711|NCT03128957|DEVICE|Licox cerebral oxygenation monitor|Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
224093712|NCT03128957|OTHER|Cerebral oxygenation|Measuring cerebral oxygenation with varying ventilation strategy
224093713|NCT00684177|DRUG|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
224093714|NCT00684177|DRUG|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
223532216|NCT01358162|DRUG|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
224093715|NCT04590001|DEVICE|MobiusHD|The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.
223532217|NCT02009566|RADIATION|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
223532218|NCT02746809|DEVICE|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~1. Evolut 34R Transcatheter Aortic Valve (TAV)~2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~3. EnVeo R Loading System (LS)"
223926994|NCT06839001|PROCEDURE|Breast Surgery (Lumpectomy or Mastectomy)|Surgery can be performed as lumpectomy or mastectomy and axillary surgery, preferably sentinel lymph node biopsy.
223926995|NCT05579626|DRUG|high-intensity statin arm|•high-intensity statin strategy (standard arm): rosuvastatin 20 mg PO qd, once daily
223532219|NCT01071161|DRUG|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
223926996|NCT05579626|DRUG|low-intensity statin plus ezetimibe|•low-intensity statin plus ezetimibe strategy (experimental arm): rosuvastatin 5mg /ezetimibe 10mg PO qd), once daily
223926997|NCT02944487|DRUG|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
224093716|NCT04188366|BEHAVIORAL|FAMES|Participants will receive three distinct and revolving components - early, continuous, and motivational contact - that incorporate motivational techniques and the Diagnostic and Statistical Manual of Mental Disorders 5TH Edition (DSM-5) Cultural Formulation Interview (CFI).
224093717|NCT04188366|BEHAVIORAL|Treatment-as-Usual|Participants will receive usual services and family-based treatment offered
224093718|NCT05783700|DIAGNOSTIC_TEST|BIOIMPEDANCEMETRY|The impedance of cellular tissue can be modeled as a resistor (representing the extracellular path) in parallel with a resistor and capacitor in series (representing the intracellular path, the resistance that of intracellular fluid and the capacitor the cell membrane). This results in a change in impedance versus the frequency used in the measurement. Whole body impedance measurement is generally measured from the wrist to the ipsilateral ankle and uses either two (rarely) or four (overwhelmingly) electrodes. In the 2-elctrode (bipolar) configuration a small current on the order of 1-10 μA is passed between two electrodes, and the voltage is measured between the same whereas in the tetrapolar arrangement resistance is measured between as separate pair of proximally located electrodes. The tetrapolar arrangement is preferred since measurement is not confounded by the impedance of the skin-electrode interface
224093719|NCT04394442|DRUG|Hydroxychloroquine|400mg BD first day then 200 mg BD for 5 days
224093720|NCT00933036|DEVICE|Crosstrees Pod system for PVA|Minimally invasive spine surgery
223532220|NCT01071161|DRUG|placebo|placebo
223532221|NCT00673920|DRUG|Methotrexate|Oral or parenteral repeating dose
223532222|NCT00673920|DRUG|Ocrelizumab|"Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate."
223717791|NCT05976867|BEHAVIORAL|Parents as Teachers (PAT) + Smart Parents|"Added session to PAT following foundational visit 6. Smart Parents is comprised of 3 CSA specific prevention components: (1) healthy child sexual development, (2) communication about sexual concepts and sexual behaviors, and (3) safety strategies (including online safety.~Delivered in one session (\~60 min). Parents return to PAT as usual following this session."
223717792|NCT06132386|OTHER|biopsy|colorectal biopsy for tissue acquisition
223717793|NCT04213729|BEHAVIORAL|Diet Counseling|Standard of care diet counseling provided at clinic visit 1.
223717794|NCT04213729|OTHER|CD LFD|Daily breakfast, lunch, dinner and snacks LFD catered meals. Meals will have approximately 20% calories from fat, a goal ratio close to 1:1 omega-6/omega-3 fatty acids, and approximately 25-35 grams of fiber per day.
223717795|NCT04213729|BEHAVIORAL|Dyadic Psychological Support (DPS)|The dyadic psychosocial support (DPS) intervention will be provided for a total of 12 weeks. The 12-week DPS intervention consists of eight sessions (main sessions) and two booster sessions. The intervention will incorporate psychoeducational components that combine didactic and behavioral regulatory procedures to promote healthy diet behavior for self-determined reasons.
223717796|NCT02099708|DRUG|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
223717797|NCT04802291|BEHAVIORAL|HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood|Comparison of 2 educational interventions
223926998|NCT02944487|DRUG|Placebo|Matching placebo capsules
223926999|NCT05118919|BIOLOGICAL|BGP-014|Oral capsule containing lyophilised Lactobacillus reuteri
223927000|NCT05118919|BIOLOGICAL|Placebo|Oral capsule
223532223|NCT00673920|DRUG|Placebo|Intravenous repeating dose
223532224|NCT05217173|OTHER|telerehabilitation|It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
223532225|NCT04931381|OTHER|Chemotherapy guided by organoid drug sensitivity test|Chemotherapy guided by organoid will be given to advanced pancreatic cancer patients.
223532226|NCT05149820|OTHER|Electronic Point of Care Randomisation tool|Two designs of electronic point of care randomisation tool will be evaluated.
223532227|NCT05149820|DRUG|Magnesium|Liberal Strategy: magnesium supplementation at serum level \< 0.75 mmol/L Restrictive Strategy: magnesium supplementation at serum level \< 1.0 mmol/L
223532228|NCT02055508|BEHAVIORAL|Exercise Intervention|
223532229|NCT02055508|OTHER|Care-Management-Phone-Calls|
223532230|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
223532231|NCT01195454|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
223532232|NCT04764526|OTHER|Protein-enriched ice cream|Offering two protein-enriched ice creams
223532233|NCT00281970|DRUG|cisplatin|
223532234|NCT00281970|DRUG|docetaxel|
223532235|NCT00281970|PROCEDURE|adjuvant therapy|
223532236|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
223927001|NCT06965218|DIAGNOSTIC_TEST|Trans thoracic echo doppler|Aortic valve sclerosis severity study be transthoracic echo doppler
223532237|NCT01650402|OTHER|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
223532238|NCT02230345|DIETARY_SUPPLEMENT|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
223532239|NCT02230345|DIETARY_SUPPLEMENT|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
223532240|NCT00205127|PROCEDURE|Cardiac PET imaging- rest and pharmacological stress|
223532241|NCT02279927|DEVICE|Ureteroscopy|Ureteroscopy with laser stone fragmentation
223532242|NCT05740514|BEHAVIORAL|Exercise|Exercise training.
223532243|NCT05740514|BEHAVIORAL|De-training|Exercise de-training via unilateral knee immobilization.
223532244|NCT01924780|DEVICE|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
223717798|NCT01184391|DRUG|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
223717799|NCT01184391|DRUG|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
223717800|NCT03655509|PROCEDURE|Dynamic test ACTH stimulation|
223717801|NCT03282682|PROCEDURE|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
223717802|NCT01284829|OTHER|FDG-PET scan|
223717803|NCT02723214|PROCEDURE|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
223927002|NCT06964906|PROCEDURE|HIFU|HIFU therapy is administered to the targeted breast lesion site.
223927003|NCT06964906|DRUG|Toripalimab|240 mg, IV infusion, Q3W
223927004|NCT06964906|DRUG|nab-Paclitaxel (nab-P)|125 mg/m2, IV infusion, QW
223927005|NCT06964906|DRUG|Epirubicin (E)|90 mg/m2, IV infusion, Q3W
223927006|NCT06964906|DRUG|Cyclophosphamide (C)|600 mg/m2, IV infusion, Q3W
223927007|NCT06964971|DRUG|Luspatercept|The recommended starting dose of luspatercept is 1.5 mg/kg administered subcutaneously (SC) once every 3 weeks. Treatment response should be evaluated and dosage adjusted after at least 3 treatment cycles (9 weeks).
223927008|NCT06964971|DRUG|Luspatercept combine with Deferasirox|"The recommended starting dose of luspatercept is 1.5 mg/kg administered subcutaneously (SC) once every 3 weeks. Treatment response should be evaluated and dosage adjusted after at least 3 treatment cycles (9 weeks).~For patient with platelet counts \< 50×10⁹/L:~Deferasirox dosage: 8-10 mg/kg/day, orally.~For platelet counts ≥ 50×10⁹/L:~Deferasirox dosage: 20 mg/kg/day, orally. Discontinue deferasirox if serum ferritin drops below 500 μg/L."
223927009|NCT06965062|PROCEDURE|Deep cervical lymph node to venous bypass (DCLNV-BP)|Participants will under bilateral deep cervical lymph node to venous bypass procedure under general anaesthesia.
223927010|NCT06965127|DEVICE|NNP-LE|Networked NeuroProsthesis - Lower Extremity Configuration (NNP-LE) measuring physiologic command signals and delivering neural stimulation to intramuscular and nerve cuff electrodes for trunk and leg muscle assistance.
223927011|NCT06965673|BEHAVIORAL|Visual exploration training|Visual exploration of natural scenes guided by closed-loop auditory biofeedback through eye-tracking
223927012|NCT06965673|BEHAVIORAL|Standard neuropsychological rehabilitation|Standard rehabilitation delivered at the IRCCS San Camillo hospital
223927013|NCT06965491|DIETARY_SUPPLEMENT|Placebo Supplement|"Placebo supplement:~Oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water"
223927014|NCT06965491|DIETARY_SUPPLEMENT|Ketone ester supplement|Ketone ester supplement Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
224093721|NCT06382090|OTHER|Laughter yoga|This practice, which includes deep breathing exercises and laughter exercises, takes approximately 45 minutes. The sessions will be conducted by the principal investigator.
224093722|NCT03542994|OTHER|EDP1066|EDP1066 is an orally administered monoclonal microbial
224093723|NCT03542994|DRUG|Placebo oral capsule|placebo
223927015|NCT06966310|OTHER|Prone position|depending on tolerance, the objective is to spend as much time as possible, up to 16h and beyond, in prone position per period of 24 hours. For each session the patients will be encouraged to stay as long as possible in the prone position (i.e. ideally 4-8 hours each session).
223927016|NCT06965517|PROCEDURE|Maxillary implant supported overdenture , Digital jaw relation group|implant supported maxillary overdenture constructed using electronic facebow to record maxillo-mandibular relation.
223927017|NCT06965517|PROCEDURE|Maxillary implant supported overdenture , Static jaw relation group|implant supported maxillary overdenture constructed using the conventional jaw relation method.
223927018|NCT06965075|BEHAVIORAL|Diabetes Prevention Program|Diabetes Prevention Program (DPP) is a one-year lifestyle modification program that helps adults at risk for developing type 2 diabetes gain tools for healthy living.
224093724|NCT06507904|DRUG|Osivelotor|A medicine to treat sickle cell disease.
224282067|NCT00109850|BIOLOGICAL|cetuximab|400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
223927019|NCT01313559|DRUG|Pasireotide|Given IM
223927020|NCT01313559|DRUG|Everolimus|Given PO
223927021|NCT01313559|OTHER|Laboratory biomarker analysis|Correlative studies
223927022|NCT06455475|OTHER|Derm-Maxx|Derm-Maxx™ Dermal Matrix is an acellular human dermis graft sterilized using the Tutoplast® Tissue Sterilization Process.
224093725|NCT06507904|OTHER|Famotidine|Famotidine is a marketed medicine which decreases the amount of acid made in the stomach and is used to prevent and treat heartburn.
224093726|NCT06930209|DEVICE|CelluJuve®|CelluJuve® injected into upper brachium
224093727|NCT06907732|PROCEDURE|Fetoscopic robotic open spina bifida closure|"Three 9 mm laparoscopic trocars will be inserted into the uterus after the uterus is exteriorized through a maternal laparotomy. Partial amniotic carbon dioxide insufflation will be done with heated humidified gas. Using a surgical robot, multilayer closure of the lesion will be performed, similar to our current protocol in open fetal spina bifida closure (durapatch, myofascial flap, skin closure).~Pre- and postoperative management will be similar to our current open fetal surgery protocol. Delivery will be by cesarean section, either when spontaneous labor occurs or at 39 weeks, whichever presents first."
224282068|NCT00109850|DRUG|cisplatin|30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.
224282069|NCT00109850|DRUG|irinotecan hydrochloride|65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.
223532245|NCT01924780|DEVICE|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
223532246|NCT01924780|DEVICE|NEMOS Device sham stimulation 10 minutes|
223940924|NCT07195838|BEHAVIORAL|Hybrid Mindfulness-Based Group Sessions|Eight 60-min hybrid group sessions, combining mindfulness-based pulmonary rehabilitation and lifestyle modification. The sessions cover topics such as the eight yoga's ethical guidelines (yamas and niyamas) for positive lifestyle behaviors, breathing mechanisms, dysfunctional breathing styles, voluntary control of breathing (pranayama), relaxation and sense withdrawal (pratyahara), concentration (dharana), meditation (dhyana), and enlightenment (samadhi). Subsequent sessions will be delivered via videoconferencing using Zoom and will include guided breathing-focused practices.
224093728|NCT06936800|DRUG|Pinaverium bromide|Preoperative, intraoperative, and postoperative oral administration of 100mg povidonium bromide in P-ESWL
224093729|NCT06936800|DRUG|Placebo for control group|Preoperative, intraoperative, and postoperative oral placebo 100mg for P-ESWL
224093730|NCT06935175|DRUG|SHR-1826|SHR-1826 will be administrated per dose level in which the patients are assigned.
224282070|NCT00109850|RADIATION|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
224282071|NCT00983528|BIOLOGICAL|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
224282072|NCT00983528|DRUG|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
223532247|NCT00734552|DIETARY_SUPPLEMENT|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
223532248|NCT00734552|DIETARY_SUPPLEMENT|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
223940925|NCT07195838|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Personalised mindfulness-based lifestyle counselling through instant messages with chat-based support throughout the 8-week intervention period. The intervention protocol will cover message content library, regular message delivery and personalised chat-based support.
223940926|NCT07195838|BEHAVIORAL|Single General Education on Pulmonary Rehabilitation and Lifestyle Modification Group|The control group participants will receive a single in-person 60-min group session on general education on pulmonary rehabilitation and lifestyle modification based on the GOLD 2024 teaching set and HEARTS technical package for NCD prevention as recommended by the WHO.
224093731|NCT06935175|DRUG|SHR-1826 and immunotherapy combination therapy|SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned.
224093732|NCT06936072|PROCEDURE|Titanium Ring Inlay Eminence Augmentation|"* Preauricular approach with subperiosteal dissection~* Dual osteotomy (transverse mid-eminence + vertical parallel to skull base)~* Titanium ring inlay placement with anatomical contouring~* Intraoperative functional assessment"
224093733|NCT05372809|BIOLOGICAL|SkinTE|SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.
224093734|NCT05372809|OTHER|Control|"Standard care is defined in this protocol to include the following:~* Debridement~* Collagen-alginate primary wound dressing~* Local offloading with felt pad for wounds on weight bearing surfaces~* Foam~* Multi-layer compression dressing~* Off-loading device such as a full-length boot or total contact cast (if full-length boot cannot accommodate the patient) or surgical shoe for ulcers in non-weight bearing locations"
224282073|NCT00476593|DRUG|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
224282074|NCT00476593|DRUG|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
223532249|NCT01255280|BEHAVIORAL|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
223532250|NCT01255280|BEHAVIORAL|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
223532251|NCT04518137|DRUG|ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle|48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
223532252|NCT06164158|OTHER|Procedural Videos|A randomized controlled trial was conducted at Pakistan Institute of Medical Sciences (PIMS) Islamabad between September 1, 2023 to November 30, 2023 under ethical approval from the Institutional ethical review board.
224282075|NCT01942447|BIOLOGICAL|FMT|
224282076|NCT01942447|DRUG|Vancomycin|
224282077|NCT00004188|BIOLOGICAL|filgrastim|Given IV
224282078|NCT00004188|DRUG|carboplatin|Given IV
224282079|NCT00004188|DRUG|cisplatin|Given IV
224282080|NCT00004188|DRUG|cyclophosphamide|Given IV
224282081|NCT00004188|DRUG|doxorubicin hydrochloride|Given IV
224282082|NCT00004188|DRUG|etoposide|Given IV
224282083|NCT00004188|DRUG|isotretinoin|Given IV
224282084|NCT00004188|DRUG|melphalan|Given IV
224282085|NCT00004188|DRUG|topotecan hydrochloride|Given IV
224282086|NCT00004188|DRUG|vincristine sulfate|Given IV
224282087|NCT00004188|PROCEDURE|autologous bone marrow transplantation|
224282088|NCT00004188|PROCEDURE|bone marrow ablation with stem cell support|
224282089|NCT00004188|PROCEDURE|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
224282090|NCT00004188|PROCEDURE|peripheral blood stem cell transplantation|
224282091|NCT00004188|RADIATION|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
223532253|NCT06164158|OTHER|No procedural videos|No procedural videos
223940927|NCT07195838|DEVICE|Activity Monitoring|All participants will wear a wristband activity tracker to monitor their physical activity in daily life.
224282092|NCT05541640|DRUG|normal saline group|normal saline infusion at the start of surgery
224282093|NCT05541640|DRUG|lidocaine group|lidocaine infusion at the start of surgery
224282094|NCT00575380|DRUG|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
224282095|NCT00575380|DRUG|Vigamox Eye Drops|One drop three times a day for seven days
224282096|NCT02546024|DRUG|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
224282097|NCT03424655|PROCEDURE|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
224282098|NCT03424655|PROCEDURE|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
223927023|NCT06965088|BIOLOGICAL|Combined Intra-operative platelet-rich plasma with corticosteroid injection|Combined Intra-operative platelet-rich plasma with corticosteroid injection was administered around the surgical wound. Each patient had 10 ml of blood collected into a RegenKit A-PRP tube. The blood-filled tube was then placed into a RegenLab PRP centrifuge and spun for approximately 5 minutes to obtain platelet-rich plasma (PRP), yielding around 5 ml of injectable PRP. Once prepared, the PRP was stored in the collection tube and used within 4 hours from the time of blood draw to the time of injection. After the keloid excision and wound closure were completed, the PRP was aseptically aspirated from the tube using a sterile needle and injected into the intradermal layer along the wound edges using a 30G needle. The injection was performed in a sterile manner, with a dosage of 0.5 ml of PRP per 1 centimeter of wound length. For corticosteroid administration, triamcinolone acetonide (40 mg/ml) was used. The medication was injected into the intradermal layer using a 30G needle along the
224093735|NCT06277648|PROCEDURE|PENG block|PENG block was performed by the primary investigator (B.C) following proper skin disinfection with the patient in the supine position. Under the guidance of a low-frequency curvilinear ultrasound probe, the iliopubic eminence and the psoas tendon were identified, and local anaesthetic as 30 mL 0.375% bupivacaine was injected between the periosteum and psoas tendon following negative aspiration.
223927024|NCT06965088|DRUG|Intra-operative corticosteroid injection|Intra-operative corticosteroid injection alone was administered around the surgical wound using triamcinolone acetonide (40 mg/ml). The injection was performed into the intradermal layer using a 30G needle, immediately after keloid excision and wound closure. The medication was injected along the wound edges following the suture line, at a dosage of 0.1 ml per 1 centimeter of wound length.
223927025|NCT06505889|OTHER|Local anesthesia methods|Local pain control method before arterial blood sampling procedure
224093736|NCT06277648|PROCEDURE|SIFIB|The high-frequency linear probe was placed medial to the anterosuperior iliac spine in a parasagittal orientation to visualize the bow tie appearance formed by the sartorius's internal oblique and iliacus muscles. The needle tip was placed under fascia iliaca through an in-plane approach, and local anaesthetic as 30 mL 0.375% bupivacaine was injected from the caudad to the cephalic direction.
224093737|NCT00787293|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
224093738|NCT06950476|PROCEDURE|Oocyte Retrieval|Oocyte retrieval is performed at the end of ovarian stimulation (OS) to collect oocytes for use in IVF or ICSI cycles.
224093739|NCT04963413|BIOLOGICAL|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF|Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF
224093740|NCT05812716|BEHAVIORAL|resiLIR Healthcare Professionals|"Weeks 1 and 2: Theoretical part on stress, resilience, self-care, and self-compassion~Weeks 3 to 6: Training phase of a weekly introduced practical exercise (reflection on living with ease, self-compassionate body scan, planning of positive activities, self-compassionate letter). This phase additionally includes smartphone reminders to apply the exercises in everyday life."
224093741|NCT02906514|DRUG|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
223927026|NCT01102673|DRUG|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
224093742|NCT02906514|DRUG|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
224093743|NCT06399406|COMBINATION_PRODUCT|Medi-TBS|The multimodal intervention involves combining FDA-approved repetitive transcranial magnetic stimulation (rTMS) with digital mindfulness exercises.
224093744|NCT05053646|PROCEDURE|Meniscal repair|The meniscus is trimmed with an arthroscopic punch followed by an electric shaver to expose the margins of the tear and remove damaged tissue. Vertical sutures are made using TRUESPAN™ Meniscal Repair System (DePuy Synthes) to approximate both the femoral and tibial surfaces of the torn meniscus.
224093745|NCT05053646|PROCEDURE|Marrow venting procedure|After meniscal repair, a bone marrow venting procedure will be performed: a 45° micro-fracture awl is repeatedly penetrated through the bone of the intercondylar notch at the PCL origin until marrow elements are seen to enter the joint.
224282099|NCT03424655|PROCEDURE|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
224282100|NCT03424655|PROCEDURE|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
223532254|NCT05453214|DRUG|Fludrocortisone Acetate 0.1 MG|Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.
224093746|NCT05340309|BIOLOGICAL|Atezolizumab and Recombinant Human Hyaluronidase|Given SC
223532255|NCT01164007|DRUG|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
223532256|NCT01164007|DRUG|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
223532257|NCT01416025|DRUG|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
223927027|NCT01102673|DRUG|Placebo|Placebo to match PF-04991532 will be provided
224282101|NCT01632384|BEHAVIORAL|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
224282102|NCT04006938|BEHAVIORAL|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
224282103|NCT04006938|BEHAVIORAL|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
223927028|NCT05324683|OTHER|No intervention planned|No intervention planned; study is observational
223532258|NCT00894387|DRUG|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
223532259|NCT00894387|DRUG|Placebo|Placebo
223532260|NCT01352884|DRUG|AMP-224|Escalating doses of AMP-224
223927029|NCT06755411|OTHER|OHFCP2|The proposed intervention consists of a two-phase approach for implementing guidelines and evidence-based recommendations: educating healthcare professionals and enhancing clinical activity.
224093747|NCT05340309|OTHER|Survey Administration|Ancillary studies
224093748|NCT04857359|DRUG|Dipraglurant|Oral 50mg and 100mg tablet
224282104|NCT00559364|DRUG|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
223927030|NCT04661423|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch.
224282105|NCT00559364|DRUG|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
224282106|NCT00559364|DRUG|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
223927031|NCT04878094|DIAGNOSTIC_TEST|Intravenous Indocyanine Green/ICG injection|Intravenous Indocyanine Green/ICG injection will be administered for visualization
223927032|NCT04878094|DIAGNOSTIC_TEST|PINPOINT endoscopic fluorescence imaging system|After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.
223927033|NCT04878094|DIAGNOSTIC_TEST|Endoscopy|Standard technique and assessment of anastomosis without the use of NIR angiography
223927034|NCT06823661|DEVICE|transcutaneous electrical nerve stimulation (TENS)|"A TENS 3000-unit, which is FDA and health Canada approved (Licence No.: 95655) and operated by a small 9V block battery will be used. Potential participants will receive a detailed written explanation of the TES protocol and a brief demonstration of how it works, including the feeling produced by the skin stimulator. Patient-specific TES thresholds will be determined after informed written consent for study participation is obtained. Surface electrode pads will be placed on the ventral surface of the forearm, and 1-Hz pulses will be gradually administered with an increase in current. Patients will be asked to report when they first feel the stimulation and when it becomes annoying. The milliamp current associated with these two levels of stimulation will be recorded on the participant's baseline data collection form. The annoying thresholds for all study participants will be used to deliver stimuli in response to respiratory depression in the PACU."
223927035|NCT05719883|DEVICE|Maurora® Sirolimus Eluting Stent System|The Maurora® for intracranial PTA treatment comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
223927036|NCT05719883|DEVICE|APOLLO™ Intracranial Stent System|The Apollo stent system comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
224093749|NCT04857359|DRUG|Placebo|Oral matching placebo tablet
224282107|NCT00559364|DRUG|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
224282108|NCT04458558|DRUG|Mifepristone|Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
224282109|NCT03604432|DEVICE|propylactic maze|Prophylactic limited left sided maze procedure for subjects in the treatment arm
224282110|NCT02979691|RADIATION|SIB-IMRT|
224282111|NCT02979691|DRUG|S-1|
223927037|NCT02656706|DRUG|Ipilumumab|
223927038|NCT02656706|DRUG|Nivolumab|
224093750|NCT03949764|DRUG|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
224093751|NCT06787651|PROCEDURE|RIMA-SVG|Saphenous vein grafts (SVGs) are connected to the right internal mammary artery (RIMA)
224093752|NCT06787651|PROCEDURE|Ao-SVG|The ascending aorta is clamped, and SVGs are anastomosed to the aorta.
224093753|NCT06033404|PROCEDURE|Normal Clinical practice|Normal Clinical practice
224282112|NCT00801294|DRUG|BIBF 1120 and BIBW 2992|
224282113|NCT00330460|DRUG|Alendronate|ALN; 70 mg; oral; once weekly
224282114|NCT00330460|DRUG|Denosumab|60 mg; SC; every 6 months
224282115|NCT05683782|DRUG|Split thickness Apically positioned flap with Chitosan based Erythropoietin Gel application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva .1 mL of EPO-loaded with chitosan 5% and β-glycerophosphate disodium salt (GP) 20% gel will be used by the patient two times daily for 14 days.
224282116|NCT05683782|DRUG|Split thickness Apically positioned flap without Erythropoietin application|Split thickness Apically positioned flap will be performed to increase width of attached gingiva.The patient will use a Chitosan gel without being loaded with erythropoietin two times daily for 14 days
224282117|NCT06360029|BEHAVIORAL|LvL UP|"The LvL UP app includes four lifestyle intervention components centred around three core pillars, Move More (physical activity), Eat Well (healthy nutrition), and Stress Less (mental well-being), as follows: (i) conversational agent-delivered health literacy coaching sessions, (ii) daily Life Hacks (healthy habit suggestions), (iii) therapeutic Tools including step-based activity tracker, food diary, and journal and (iv) gamified slow-paced breathing training (Breeze). These components are delivered using an innovative engagement approach that combines storytelling, MI, feedback on progress, just-in-time adaptive notifications and gamification.~As part of the LvL UP app onboarding, participants are asked to nominate a 'LvL UP Buddy' (e.g., a friend, family member, or spouse) to provide additional support. Buddies are expected to complete different tasks, such as sending messages of encouragement or engaging in intervention-related activities together with the participant."
223927039|NCT05237908|DEVICE|Transforaminal Lumbar Interbody Fusion|Interbody Fusion means the operative immobilization or ankylosis of two or more vertebrae by fusion of the vertebral bodies with a short bone graft or often with diskectomy or laminectomy. (From Blauvelt and Nelson, A Manual of Orthopaedic Terminology, 5th ed, p236; Dorland, 28th ed
223927040|NCT05546567|DIETARY_SUPPLEMENT|Nicotinamide Riboside|1200mg x1 Nicotinamide Riboside
223927041|NCT05192057|DEVICE|Hypertonic Saline inhalation|Hypertonic Saline inhalation is thought to increase mucociliary clearance of the airways
223927042|NCT06462027|DRUG|Packed Red Blood Cells (1 unit)|500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
223927043|NCT06462027|DRUG|Packed Red Blood Cells (2 units)|1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.
223927044|NCT06462027|OTHER|Saline|Control subjects will receive 500mL of normal saline intravenously.
223927045|NCT03725332|BEHAVIORAL|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with substance use counselor or perinatal nurse facilitator. Consultations will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months postpartum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
223927046|NCT03725332|BEHAVIORAL|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator or substance use counselor, with a peer support specialist. Small group care meetings will occur twice a month until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1) Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
223927047|NCT04783441|DEVICE|Dexcom G6|access to continuous glucose monitoring in the Dexcom G6 arm 24/7
223927048|NCT04783441|DEVICE|Dexcom G6 blinded sensor|retrospective access to continuous glucose profile after 10 days of wear
223927049|NCT06277960|DEVICE|percutaneous intramyocardial septal radiofrequency ablation system|The device is introduced into the right ventricle and performs ablation treatment on the hypertrophic interventricular septum.
224093754|NCT01610921|OTHER|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
224282118|NCT06360029|BEHAVIORAL|LvL UP + MI|"After 4 weeks, participants categorized as non-responders from the LvL UP group will be re-randomized into second-stage conditions: (i) continuing with the initial intervention (LvL UP) or (ii) additional human-delivered motivational interviewing (MI) support sessions (LvL UP + MI). The MI-informed sessions for non-responders will consist of four sessions delivered via WhatsApp, lasting between 30 and 40 minutes. The content of support will include various MI-based strategies such as use of ask-offer-ask framework and strategic use of communication skills (open-ended questions, reflections, affirmations and summaries) as per four MI processes:~* Engaging (foster collaboration and trust the research staff-user relationship)~* Focusing (conversation to focus on lifestyle changes)~* Evoking (elicit and strengthen participants' motivation towards lifestyle changes), and~* Planning (when the participant is ready, commitment to a change plan aimed at adopting a healthy lifestyle)."
223532261|NCT01352884|DRUG|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
223532262|NCT03830580|OTHER|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
223532263|NCT02950337|RADIATION|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
223532264|NCT02950337|RADIATION|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
223927050|NCT05035108|BIOLOGICAL|hiHep bioartificial liver therapy|HiHep cell bioartificial liver treatment was performed 48-72 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 4-6h.
223927051|NCT05086393|DRUG|Duloxetine|Patients will be randomized to receive Duloxetine or a placebo.
223927052|NCT05086393|DRUG|Placebos|Patients will be randomized to receive Duloxetine or a placebo.
223927053|NCT06559774|BEHAVIORAL|Hastiin Bidziil|Common Elements Treatment Approach (CETA) modified for cultural and gendered specific delivery for maximum community impact
223927054|NCT06559774|OTHER|Control condition - vehicle maintenance|Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance such as changing tire, checking fluid levels, and winterizing vehicles.
223927055|NCT06965244|DRUG|Lenalidomide|Lenalidomide with oral dose of 5 mg/day during 16 weeks associated with low-dose aspirin of 100 mg/day except for patients already receiving anticoagulant therapy
223927056|NCT06965244|DRUG|Methotrexate (MTX)|Methotrexate oral dose of 15 mg per week for individuals \< 80 kg, and a dose of 20mg per week for those over 80 kg, along with an equal dose of folic acid supplementation given 48 hours after each dose
223927057|NCT04665921|DRUG|SGN-STNV|Given into the vein (IV; intravenously)
223927058|NCT05902572|OTHER|No intervention|Observational data collection only.
223927059|NCT05377528|DRUG|AGEN1571|A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously.
224282119|NCT06360029|BEHAVIORAL|Comparison|Participants randomised to the comparison condition will receive a study pack including physical activity, diet and mental well-being content extracted from existing Health Promotion Board (HPB) resources. Established in 2001, the HPB (https://hpb.gov.sg/) is a government organisation under the Ministry of Health committed to promoting healthy living in Singapore. HPB's organises health promotion and disease prevention programmes covering various health domains. HPB-developed resources were selected as the comparator because they are the 'go-to', nation-wide health resources in Singapore which cover LvL UP's domains.
224282120|NCT04039048|DEVICE|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
224282121|NCT04039048|DEVICE|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
224282122|NCT04039048|OTHER|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
223927060|NCT05377528|DRUG|Balstilimab|A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously.
223927061|NCT05377528|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
223927062|NCT04207086|DRUG|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223927063|NCT04207086|DRUG|Lenvatinib|Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
223927064|NCT02879656|PROCEDURE|non-operative treatment|conservative treatment with 5 weeks cast immobilization
223927065|NCT02879656|PROCEDURE|operative treatment|surgery with volar locking plate with modified Henry's volar approach
223927066|NCT06149156|BEHAVIORAL|Healthy Minds Program App|The four-week intervention comprises two introductory lessons and guided meditations followed by one week of content for each pillar of well-being. Each week includes two brief lessons (5-7 minutes) with education on the scientific research behind the practices, as well as examples of how to strengthen the skills of each pillar in daily life, along with three guided meditations for which the participant can select the practice length (5-30 minutes).
223927067|NCT06149156|BEHAVIORAL|Well-being Resources|List of well-being resources that comprises of online video links and books
224282123|NCT01571726|DRUG|Fluciclatide|7mCi
223717804|NCT03008603|DEVICE|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
223927068|NCT04262206|DRUG|Atorvastatin 40 Mg Oral Tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
223927069|NCT04262206|DRUG|Placebo oral tablet|To generate knowledge about the role of statins in older adults in whom risk/benefit for primary prevention is understudied,
223927070|NCT03567876|DRUG|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
223927071|NCT06367933|PROCEDURE|mini-invasive spine surgery|spine deformity correction using a mini-invasive technique
223927072|NCT04221035|DRUG|Vincristine|1.5 mg/m2 (max dose 2 mg)
224282124|NCT00533806|BEHAVIORAL|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
224282125|NCT00533806|BEHAVIORAL|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
223717805|NCT03064997|DIETARY_SUPPLEMENT|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
223927073|NCT04221035|DRUG|Carboplatin|750 mg/m2
223927074|NCT04221035|DRUG|Etoposide|175 mg/m2
223927075|NCT04221035|DRUG|Vindesine|3 mg/m2/day (max dose 6 mg)
223927076|NCT04221035|DRUG|Dacarbazine|200 mg/m2/day
223927077|NCT04221035|DRUG|Ifosfamide|1500 mg/m2/day
223927078|NCT04221035|DRUG|Doxorubicin|30 mg/m2/dose
223927079|NCT04221035|DRUG|Busulfan|\< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses
223927080|NCT04221035|DRUG|Melphalan|140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose
223927081|NCT04221035|DRUG|Thiotepa|300 mg/m2/day over 2 hours
223927082|NCT04221035|RADIATION|Radiotherapy|21.6 Gy 21.6 Gy + boost de 14.4 Gy
223927083|NCT04221035|DRUG|Dinutuximab Beta|Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day
223927084|NCT04221035|DRUG|Cisplatin|80 mg/m2/24h
223927085|NCT04221035|DRUG|Temozolomide 100 MG|100 mg/m²/Day
223927086|NCT04221035|DRUG|Irinotecan|50 mg/m²/jour de J0 à J4
223927087|NCT04221035|DRUG|Cyclophosphamid|Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
223927088|NCT06436625|OTHER|outpatient pulmonary rehabilitation|Patients undergo six weeks of an outpatient rehabilitation program in one of the rehabilitation centers (Therme Wien Med, Klinik Pirawarth in Wien).
223927089|NCT06186869|BEHAVIORAL|Aerobic Exercise and diet intervention|subjects randomized and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform moderate-intensity aerobic exercises
223927090|NCT06186869|BEHAVIORAL|Hiit and diet intervention|subjects randomised and assigned to one intervention group, will follow the low glycaemic index Mediterranean diet and simultaneously perform high-intensity interval exercises in the gym
223927091|NCT06186869|BEHAVIORAL|Diet|subjects randomised and assigned to this intervention group will follow the low-glycaemic index Mediterranean diet
223927092|NCT05617638|BEHAVIORAL|Intervention|Participants will watch nature images in virtual reality from the e-Natureza VR Database for 20 minutes for 2 consecutive days.
224093755|NCT06123988|BEHAVIORAL|Prolonged Overnight Fasting|"Participants will undergo a 12-week program of prolonged overnight fasting (POF) during which they will abstain from consuming food or drink after 8pm, and wait 12 to 14 hours before resuming eating the next day. Participants will fast overnight for six nights each week, with one night off, and log their fasting start and stop times and timing of food intake daily via text messaging, or via study-provided app accessible by web browser or smart phone, or via paper journal returned by mail at the end of each month.~Participants will also complete one weekly session with a health coach to review their fasting log and any barriers to and/or facilitators of meeting the POF goals. Sessions may be delivered in-person, by telephone, or by video call based on participant preference. Sessions will last 15 to 30 minutes each, for a total of 12 sessions.~Participants will be provided with a notebook with information and support to encourage meeting the POF goals."
224282126|NCT02412722|DRUG|Sapanisertib|Sapanisertib capsules
223532265|NCT02950337|RADIATION|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
223532266|NCT03448328|DIETARY_SUPPLEMENT|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
223532267|NCT03448328|DIETARY_SUPPLEMENT|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
223532268|NCT03448328|DIETARY_SUPPLEMENT|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
223927093|NCT04599296|DEVICE|Hip brace|Hip brace
223927094|NCT06177769|DEVICE|LMA classic|Airway is secured with LMA clasic
223927095|NCT06177769|DEVICE|LMA Proseal|Airway is secured with LMA proseal
223927096|NCT06177769|DEVICE|I-gel|Airway is secured with I-gel
223927097|NCT06131437|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
223927098|NCT06131437|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
223927099|NCT06131437|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
223927100|NCT04370509|DRUG|Axitinib (VEGF-TKI)|Given PO
223927101|NCT04370509|PROCEDURE|Cytoreductive Nephrectomy (CN)|Undergo CN
223927102|NCT04370509|PROCEDURE|Metastasectomy (MET)|Undergo MET
224282127|NCT02412722|DRUG|Paclitaxel|Paclitaxel injection
223532269|NCT00133627|DRUG|Ketotifen|
223532270|NCT01656577|DRUG|Pexacerfont|
223532271|NCT04856527|BEHAVIORAL|Physical therapist support|Participants will receive physical therapist support to reduce postural sway variability while completing an upper limb precision aiming task in virtual reality.
223532272|NCT00005852|BIOLOGICAL|anti-thymocyte globulin|
223532273|NCT00005852|BIOLOGICAL|filgrastim|
223532274|NCT00005852|BIOLOGICAL|muromonab-CD3|
223927103|NCT04370509|BIOLOGICAL|Pembrolizumab|Given IV
223927104|NCT05356169|DRUG|with or without venetoclax|Bcl-2 inhibitor
223532275|NCT00005852|DRUG|cyclophosphamide|
223532276|NCT00005852|DRUG|cyclosporine|
223532277|NCT00005852|DRUG|methylprednisolone|
223927105|NCT06144073|BEHAVIORAL|Intervention (Mandala art therapy) group|Personal Information Form, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied to the students in both groups before mandala art therapy. The students in the experimental group will be given mandala activity by the researcher two days a week for 12 weeks/total 24 times. Three months after the first interview, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be administered as a post-test. One month after the end of the study, Premenstrual Syndrome Scale, Coping with Premenstrual Change Scale, Perceived Stress Scale, Beck Depression Inventory will be applied again as follow-up evaluation.
223927106|NCT06130722|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
223927107|NCT06648278|BEHAVIORAL|Patient Navigation Program|Online health tool
223927108|NCT06648278|OTHER|Quality-of-Life (QOL) Assessment|Online surveys to assess QOL
223532278|NCT00005852|PROCEDURE|allogeneic bone marrow transplantation|
223532279|NCT01816295|DRUG|Testosterone Solution|Administered topically to axillae.
223927109|NCT06648278|OTHER|Survey Administration|Ancillary studies
223927110|NCT05513586|DRUG|TAK-771|Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
223927111|NCT02612454|DRUG|Dupilumab|Weight-tiered dosing administered subcutaneous (SC)
223927112|NCT06476717|PROCEDURE|Biopsy|Kidney allograft biopsy
223927113|NCT06476717|DIAGNOSTIC_TEST|Blood Biomarkers - cfDNA|dd-cfDNA
223927114|NCT06476717|DRUG|Antirejection therapy|Patients will receive standard antirejection therapy according to center protocol.
223927115|NCT04503265|DRUG|AMXI-5001:Dose Escalation Phase I|Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
223927116|NCT04503265|DRUG|AMXI-5001:Dose Expansion Phase II|Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
223927117|NCT05247424|DRUG|Unfractionated heparin|Unfractionated heparin at dose of 100 IU /kg body weight
223927118|NCT04906096|DRUG|PAXALISIB|Each study treatment cycle lasts 28 days, up to 24 months. Oral, daily, dosage per protocol
224093756|NCT06123988|BEHAVIORAL|Moderate-Intensity Exercise|"Participants will undergo a 12-week program consisting of three weekly sessions of moderate-to-vigorous aerobic and resistance exercises, under the supervision of a health coach. Sessions may be delivered either in-person or virtually via telehealth. Sessions will be tailored to the individual participant based on fitness level and symptoms at study entry, and limited to daylight hours as much as possible. Each session will last 30 to 50 minutes, as tolerated by the participant, for a total of 36 sessions.~Participants will receive a Fitbit device to track their activity, and to provide heart rate monitoring during each session. Participants without access to wi-fi will be loaned cellular-enabled tablets to allow them to participate in telehealth sessions. Participants will also receive a notebook with information and support to encourage exercise."
224093757|NCT06123988|BEHAVIORAL|General Health Education Sessions|Participants will receive a general health education resource manual at study entry, followed by six bi-weekly sessions with a health coach to review the information. Six topics, one topic for each session, will be selected based on topics of potential interest to a population living with advanced breast cancer, focusing on general nutrition, healthy lifestyle, and quality of life, with no discussion of prolonged overnight fasting or exercise. Each session, administered via telephone or video call, will last about 15 to 30 minutes, and have a specific topic and call script for the health coach to follow to minimize any intervention drift and/or contamination. Participants will receive a Fitbit activity monitoring device and additional study materials at the end of their participation in the study.
223927119|NCT02887950|OTHER|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
223927120|NCT02887950|DIETARY_SUPPLEMENT|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
223717806|NCT03064997|DIETARY_SUPPLEMENT|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
223927121|NCT02887950|DIETARY_SUPPLEMENT|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
223927122|NCT06732505|DRUG|[225Ac]Ac-DOTATATE|"The dose escalation phase will be divided into two cohorts: patients who had previously received 177Lu-PRRT will be enrolled in cohort 1, and patients who had not received 177Lu-PRRT will be enrolled in cohort 2. Dose escalation was performed independently in the two cohorts. DL1 will be administered as a dose of 90kBq/kg per cycle, and DL2 will be administered as a single dose of 120kBq/kg per cycle.Every patient will receive one \[225Ac\]Ac-DOTATATE infusion every 8 weeks for up to 4 cycles.~The dose expansion phase will be divided into 3 cohorts based on Ki-67 index."
223927123|NCT06662357|BEHAVIORAL|Behavioral Treatment|"Family Connections Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning."
223717807|NCT01609374|DEVICE|M6-C Artificial Cervical Disc|Total disc replacement
223717808|NCT01609374|DEVICE|Anterior plate system with corticocancellous allograft bone|Cervical fusion
223532280|NCT01816295|DRUG|Placebo Solution|Administered topically to axillae.
223532281|NCT06078852|OTHER|Diaphragmatic ultrasound|Ultrasound evaluation of diaphragm thickness, contractility, and excursion in semi-supine and sitting positions.
223532282|NCT06078852|OTHER|Pulmonary function test|Routine spirometry, body plethysmography (FRC, TLC), maximal inspiratory/expiratory pressures (MIP, MEP), and nocturnal oximetry.
223532283|NCT02055846|PROCEDURE|Realisation of blood sample, urinary sample and tumor biopsy|
223532284|NCT04165824|DRUG|MT-1186|"* An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
223532285|NCT00808392|BIOLOGICAL|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
223532286|NCT00808392|BIOLOGICAL|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
223532287|NCT02976181|DEVICE|IPG|Patient might require IPG device to be implanted under standard of care
223927124|NCT06587568|BEHAVIORAL|Mobile chat messaging|A trained counsellor will interact with a participant individually and provide personalised alcohol reduction information and advice via a mobile instant messaging app in real time for 3 months from randomisation.
223927125|NCT06587568|BEHAVIORAL|Screening, brief intervention and referral to treatment|Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet
223927126|NCT06771791|OTHER|oral provocation test|Progressively increasing doses of peeled fresh Golden apple or placebo will be consumed by the patient (4g, 12g, 40g, 120g) with a time interval of 20 minutes between each dose.
223927127|NCT06996691|PROCEDURE|Erector Spinae Plane Block (ESPB) group|30ml of 0.25% levobupivacaine for erector spinae block at level of T5
223927128|NCT06996691|PROCEDURE|Serratus Anterior Plane Block (SAPB) group|30 mL of 0.25% levobupivacaine injected anteriorly to the rib and deep to the serratus anterior at level of 5 th rib
223927129|NCT06995755|BEHAVIORAL|atlas|A theoretically-grounded, highly individualized text messaging intervention that 1) provided information on current climate-related and environmental risks (e.g., high temperatures, air quality alerts, asthma triggers etc.) that might adversely affect a user's current health conditions; 2) linked users to local zip-code matched resources to mitigate their specific risk (e.g., cooling centers, hurricane shelters); 3) implemented a full range of best practices in tailored health behavior change communications to personalize ongoing communications regarding the link between human actions and extreme weather based on the user's level of concern about and belief in climate change; and 4) provided customized actionable tips for addressing climate change to promote climate efficacy at the individual, community, and policy/advocacy level based on the user's level of motivation.
223927130|NCT06997783|OTHER|warm up|"1. Standard Warm-Up (SWU):~   This condition will involve a typical judo-specific warm-up protocol lasting approximately 25 minutes.~2. Moderate-Load PAPE Warm-Up (80% of 6RM):~   This experimental warm-up condition will consist of the same initial exercises as the SWU, followed by the addition of a moderate-load squat-based PAPE protocol.~3. Maximal-Load PAPE Warm-Up (100% of 1RM):~This condition will also begin with the same general and judo-specific exercises as the SWU, followed by a high-intensity PAPE protocol: 1-2 sets of a single repetition of back squats at 100% of the participant's 1-repetition maximum (1RM)."
224093758|NCT06834880|DEVICE|No intervention; Observational study|Sample bank with Health Questionnaire
224282128|NCT03837171|BIOLOGICAL|Liberal Red blood cell transfusion|"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"
224282129|NCT03837171|BIOLOGICAL|Restrictive Red blood cell transfusion|Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
224282130|NCT04449341|DEVICE|Oculus Go headset with Ocean Rift application|Information already included in arm description
223940928|NCT07196241|OTHER|Survey using a questionnaire.|Questionnaires regarding cancer treatment and follow-up care, fertility preservation, clinical trial participation, general information (education on health- related topics, gender, and sexual orientation, perceived needs for resources, support areas, programs and activities.), emotional health and interpersonal relationships, financial burden and mental health status.
223940929|NCT07196540|COMBINATION_PRODUCT|Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab|radiotherapy + rmhTNF-NC + tislelizumab
223940930|NCT07197138|DEVICE|Intermittent theta-burst stimulation (iTBS) using PowerMAG 100 ppTMS|iTBS at 90% resting motor threshold; bursts of 3 pulses at 50 Hz repeated at 5 Hz; \~3 minutes per session; applied to left dorsolateral prefrontal cortex; 30 total sessions; schedule per arm as specified.
224282131|NCT01057173|PROCEDURE|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
223532288|NCT04713085|DEVICE|Invasive Sacral Neuromodulation|Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
223532289|NCT04713085|DEVICE|Non-invasive Sacral Neuromodulation|External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
223532290|NCT05849766|DRUG|Dapagliflozin Farxiga®|Dapagliflozin 10 mg once daily
223532291|NCT05849766|DRUG|Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®|Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
223532292|NCT02923154|DRUG|MT-3995|
223532293|NCT02923154|DRUG|Placebo|
223532294|NCT06463184|DRUG|Xevinapant|Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
223940931|NCT07196605|DRUG|Sodium Sivelestat|For enrolled patients, administer intravenous sodium sivelestat as soon as possible (recommended within 2 hours). The daily dosage is 4.8 mg/kg, delivered via continuous infusion with a microinfusion pump or intravenous drip, for a total duration of 5 days
223940932|NCT07196501|DRUG|NBI-1065845|Oral tablet
223940933|NCT07196501|DRUG|Placebo|Oral tablet
223940934|NCT07197216|BEHAVIORAL|Tap Trust|Home-based intervention includes tap water testing kits (instructions provided with videos or phone/Zoom), filtration devices if water quality concerns are identified, reusable water bottles and educational materials (handouts and videos), and phone/Zoom sessions with the research team using motivational interviewing.
223940935|NCT07197307|DRUG|Loncastuximab Tesirine and Epcoritamab|Combination therapy of loncastuximab tesirine and epcoritamab
223940936|NCT05192434|BEHAVIORAL|Expressive Writing|Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.
223940937|NCT05192434|BEHAVIORAL|Contingency Management|Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
223927131|NCT05663723|DEVICE|Intervention group with the IV and V LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
223927132|NCT05663723|DEVICE|Intervention group with the IV, V and Violet LED board|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
223927133|NCT05663723|DEVICE|Control group with LED board without emitting light|Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
223927134|NCT06997224|OTHER|triflow application|After we have exhaled, we will try to hold the balls up as long as possible by pulling them inward with all our strength. After repeating this five times, we will turn them over.
224093759|NCT06834035|BIOLOGICAL|Immunoglobulin G|Purified IgG from human serum, delivered via IV
224093760|NCT06833463|DRUG|LCP Tacro (tacrolimus)|Treatment with LCP Tacro will begin on the day of the kidney transplant. If a patient is switching from another form of tacrolimus to LCP Tacro, the transition will be completed no later than day 8, following the standard procedures of the medical institution.
224093761|NCT04375761|PROCEDURE|Collection of Biological Samples|Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.
224093762|NCT04375761|PROCEDURE|Symptom and Exposure Surveys|Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
224093763|NCT03797001|DRUG|Anakinra|100 mg subcutaneous injection, daily for 24 weeks
224093764|NCT03797001|DRUG|Placebo|subcutaneous injection, daily for 24 weeks
224282132|NCT01057173|PROCEDURE|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
224282133|NCT02266940|DRUG|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
224093765|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening with tension.|A Foley balloon will be placed for cervical ripening with tension.
224093766|NCT05404776|OTHER|Placement of Foley balloon for cervical ripening without tension.|A Foley balloon will be placed for cervical ripening without tension.
224282134|NCT02266940|DRUG|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
223532295|NCT04773665|BIOLOGICAL|VBI-2902a|VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
223532296|NCT04773665|BIOLOGICAL|Placebo|0.9% sodium chloride
223532297|NCT04773665|BIOLOGICAL|VBI-2905a|VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
223532298|NCT02192567|DRUG|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
223532299|NCT04946695|OTHER|Telefisio India|Implement telephysiotherapy programmes in low-resource areas.
223532300|NCT05476991|DRUG|Colchicine 0.5 MG|Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
223532301|NCT05476991|DRUG|Ticagrelor 90mg|Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
223532302|NCT05476991|DRUG|Aspirin 75-300mg|Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
223532303|NCT03215043|DIETARY_SUPPLEMENT|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
223927135|NCT06746168|PROCEDURE|Locoregional anesthesia|The FTB + iPACK group will receive 12 ml 0,5% ropivacaine for the FTB and 20 ml of ropivacaine 0.5% for the iPACK block under US guidance after spinal anesthesia
223927136|NCT06746168|PROCEDURE|Local Anesthetic Ropivacaine|The control group (LIA) will receive 120 ml 0.25% ropivacaine for surgical LIA placement.
223927137|NCT06757062|DEVICE|Kinesiology Tape|The kinesiology tape (KT) is applied with the dorsal application for the treatment of carpal tunnel syndrome (CTS). This method is utilized and explained in Krause et al. (2020). This study will assess the efficacy of the application method as well as the varying effects of the color of the KT. Red KT will be compared to skin tone KT. The skin tone KT will be color-matched as closely as possible to each participant's skin tone to reduce the effect of the KT color. In this way, the study's second purpose is to understand the potential effect of color on psychological function and performance in the context of aggressive first-person shooter esports games.
223927138|NCT06918431|DRUG|Asparaginase Erwinia chrysanthemi|Given IM
223927139|NCT06918431|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223927140|NCT06918431|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and/or biopsy
223927141|NCT06918431|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and/or biopsy
223927142|NCT06918431|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223927143|NCT06918431|DRUG|Cyclophosphamide|Given IV
224093767|NCT05630846|BIOLOGICAL|Investigational MMRV(H)NS vaccine|1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
224093768|NCT05630846|BIOLOGICAL|Investigational MM(H)RVNS vaccine|1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
223532304|NCT03215043|OTHER|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
223532305|NCT06559709|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223532306|NCT06559709|OTHER|Dietary Intervention|Receive 3 meals per day and snacks
223532307|NCT06559709|OTHER|Dietary Intervention|Meet with dietitian
223532308|NCT06559709|OTHER|Medical Chart Review|Ancillary studies
223927144|NCT06918431|DRUG|Cytarabine|Given IT
223927145|NCT06918431|DRUG|Cytarabine|Given IV or SC
223927146|NCT06918431|DRUG|Daunorubicin Hydrochloride|Given IV
223927147|NCT06918431|DRUG|Dexamethasone|Given PO
223927148|NCT06918431|PROCEDURE|Echocardiography|Undergo echocardiography
223927149|NCT06918431|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223927150|NCT06918431|DRUG|Mercaptopurine|Given PO
224093769|NCT05630846|BIOLOGICAL|Investigational M(L)M(L)R(L)V(L)NS vaccine|1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
224093770|NCT05630846|BIOLOGICAL|Marketed MMRV_Lot 1 and Lot 2 vaccine|1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
224093771|NCT05690048|DRUG|Fecal microbiota transfer|FMT via capsule (50 g of fecal matter) on day 0 and day 21.
224093772|NCT05690048|DRUG|Vancomycin Oral Capsule|Vancomycin orally (250 mg 4xd, day -3 to 0).
223532309|NCT06559709|OTHER|Questionnaire Administration|Ancillary studies
223927151|NCT06918431|DRUG|Methotrexate|Given IT
224093773|NCT05690048|DRUG|Atezolizumab + Bevacizumab|Atezolizumab 1200mg i.v. \& Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
223532310|NCT03574961|BEHAVIORAL|e-Support group|Online (remote), web-based support group via private video link.
223532311|NCT03574961|BEHAVIORAL|e-Journaling placebo|Online journaling activity.
223927152|NCT06918431|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223927153|NCT06918431|BIOLOGICAL|Rituximab|Given IV
223927154|NCT06918431|DRUG|Vincristine Sulfate|Given IV
223927155|NCT03236428|DRUG|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
223927156|NCT06680297|DIETARY_SUPPLEMENT|Carbohydrates loading|Patient who is randomised in the intervention group will receive Nestle drink 2hours before the operation and a night before operation. They will receive 10mls/kg a night before operation and 5mls/kg 2 hour before operation of the carbohydrate drink.
223927157|NCT06680297|DIETARY_SUPPLEMENT|Control group|Patient assigned to this group will receive standard surgical fasting treatment which include 6hrs of fasting and 2 hrs of clear fluid prior operation
223927158|NCT06870058|DRUG|NH280105- SAD|Dose formulation: Capsule Route of administration: oral
223927159|NCT06870058|DRUG|NH280105- MAD|Dose formulation: Capsule Route of administration: oral
223927160|NCT06870058|DRUG|Placebo|Matching placebo comparator
223927161|NCT05418101|DRUG|VIS171|Participants will receive VIS171 via SC route of administration.
223927162|NCT05418101|DRUG|Placebo|Participants will receive Placebo via SC route of administration
223927163|NCT06874244|DRUG|Local Anesthesia (lidocaine hydrochloride)|Injection of lidocaine as local anesthesia
223532312|NCT05884125|DEVICE|Checkpoint BEST System|Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair
223532313|NCT03976297|OTHER|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
223532314|NCT05884333|DRUG|Conditioning Chemotherapy|Conditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
223532315|NCT05884333|BIOLOGICAL|Cord blood graft|The double-unit CB graft will be infused on day 0 per standard practice.
223927164|NCT06874244|DRUG|Iontophoresis of Tetracaine and oxymetazoline|Injecting Tetracaine Hydrochloride 4% with 0.5% Oxymetazoline to the oral tissue using iontophoresis technique
223927165|NCT06625970|DRUG|Darolutamide|Pharmaceutical form: 300 mg tablets Administration route: oral (PO) Posology: 600 mg twice daily (BID)
223940938|NCT07197229|BEHAVIORAL|Pulmonary Rehabilitation|A tailored pulmonary rehabilitation program combining hospital-based and home-based components over 12 weeksParticipants undergo a 12-week structured PR program including both hospital-based sessions (education, structured exercise, nutrition counseling, smoking cessation) and home-based exercises (daily walking, strength training progression
224093774|NCT05690048|DRUG|Placebo Vancomycin Oral Capsule|Placebo Vancomycin orally (4xd, day -3 to 0).
224093775|NCT05690048|DRUG|Placebo Fecal microbiota transfer|Placebo Fecal microbiota transfer (FMT) via capsule on day 0 and day 21.
224282135|NCT04409587|DRUG|Aspart|"A population of well controlled patients with type 1 diabetes who are experienced in the use of both Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitor (CGM) was chosen in order to assess the effect of the change in glycemic profile using two different methods of basal insulin delivery. Allowing the subjects to use their insulin pumps for bolus insulin delivery, as they are accustomed, will minimize the chances of skipping meal boluses and correction doses.~Replacing basal insulin delivery by CSII with a single daily injection of degludec will add minimal, if any, treatment burden which will be offset by potential therapeutic benefits. These benefits include the potential for reduced glycemic variability and the elimination of the risk of hyperglycemia and DKA with basal insulin interruption which can occur with infusion set occlusion or disgorging inherent to Continuous Subcutaneous Insulin Infusion."
224282136|NCT04952467|DRUG|14C-XEN1101|Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101
223940939|NCT07197866|DRUG|TEV-56286|administered orally
223940940|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
224282137|NCT06388031|DRUG|Immune checkpoint inhibitor|"Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg."
224282138|NCT04314843|DRUG|Cyclophosphamide|Administered according to package insert
224282139|NCT04314843|DRUG|Fludarabine|Administered according to package insert
224282140|NCT04314843|BIOLOGICAL|Lenzilumab|Administered as an IV infusion
224282141|NCT04314843|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously.
224282142|NCT00471991|DRUG|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
224282143|NCT00471991|DRUG|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
223532316|NCT06510036|OTHER|The post-processing generated after scanning is converted into energy spectrum image data (SBI)|It will not open special sequences for patients, will not increase the cost of diagnosis and treatment, will not increase radiation exposure during enhanced CT scanning, and will not affect the normal diagnosis and treatment process of patients throughout the process.
223940941|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
223927166|NCT06625970|RADIATION|Stereotactic Body RadioTherapy (SBRT)|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~At study entry, each investigational site will be asked to choose one regimen (normo-fractionation or moderate hypo-fractionation) which will be applied for all patients included by the investigational site in the study.~SBRT, experimental treatment, will be used as a boost in Arms C \& D. The placement of 3 to 4 fiducial markers for stereotactic boost is mandatory.~SBRT will be applied only on Prostate: 2 times 10 Gy delivered to the prostate with a gap of one week between each SBRT fraction."
223927167|NCT06625970|DRUG|ADT (Standard of Care)|"Androgen Deprivation Therapy (ADT)~The ADT treatment will be chosen at the investigator's discretion, and will be administered according to local standard procedures for up to 2 years.~Patients who may have received ADT prior joining the study should have started the ADT treatment within a maximum of 6 weeks before randomization. Otherwise ADT will be started on Day 1 (or 14 days at the latest after the randomization)."
223927168|NCT06625970|RADIATION|radiotherapy|"Following randomization, patients will receive dose escalated intensity modulated radiotherapy (IMRT) using normo-fractionation or moderate hypo-fractionation including whole pelvic nodal radiotherapy (WPRT).~Arm A and Arm B:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46-54 Gy and prostate 78 Gy (39 fractions over 8 weeks).~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions; prostate 60 Gy delivered concomitantly in 20 fractions over 4 weeks.~Arm C and Arm D:~If Normo-fractionated radiotherapy: Pelvic nodes 46 Gy, seminal vesicles 46 Gy in 23 fractions over 4.5 weeks.~If Hypo-fractionated radiotherapy: Pelvic nodes and seminal vesicles 44 Gy in 20 fractions over 4 weeks."
223927169|NCT06336681|DEVICE|PrO2Fit Device|The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.
223927170|NCT04591080|DEVICE|GUMMETAL Orthodontic Wire|Orthodontic archwire made of TiNbTaZr alloy.
223927171|NCT04591080|DEVICE|Stainless Steel (CrNi)|"Stainless steel (18% Chromium and 8% Nickel) used as the control, and linked anteriorly to the GUMMETAL counterpart. Size of archwire is 0.016 x 0.022"
223927172|NCT06881589|DIAGNOSTIC_TEST|Ultrasound mesurements|Compare various clinical test with ultrasound parameters to predict difficult videolaryngoscopy intubation.
223927173|NCT07038837|OTHER|"Synchronised arm (intervention)"|Vaccines received together with CPS
223927174|NCT07039409|BEHAVIORAL|Acupressure|Patients will receive three 1-hour sessions of training at home within 3 days by Community Psychiatric Nurse (CPN), who was trained by an experienced TCM practitioner. They will learn acupressure. After the training, they will be assessed by the CPN to ensure that they are able to identify the acupoint based on reports of a sensation of obtaining 'Qi' when using the Point Locator device. They will then apply constant pressure for approximately 1 minute on each acupoint using the Acupen, as indicated by a marking in red by themselves. To ensure treatment compliance, the participants will apply this intervention once per day for 10 days. During the 10-day intervention period, and the patient should sign in on WhatsApp every day. If the patient is unable to use WhatsApp, the print edition of diary will be provided and supervision will be performed by short message and home visit during the 1st day, 5th day and 10th day of the intervention period.
223927175|NCT06883513|OTHER|Osteopathic Manipulative Therapy Long-COVID protocol|"1. Rib Raising~2. Suboccipital Release~3. Thoracic Inlet Release~4. Miller Pump~5. Pedal Pump~6. Suboccipital Release~7. Cranial Sequence of Sinus Effleurage followed by indirect force within vault hold"
223927176|NCT06883513|OTHER|Osteopathic Manipulative Therapy NOT Long-COVID treatment protocol|"1. Bilateral Trapezius Direct Myofascial Release~2. Still's technique of the First rib Bilaterally:~3. Hamstring Muscle Energy"
223927177|NCT06808009|DRUG|Lactulose|Syp lactulose
223927178|NCT06808009|DRUG|Rifaximin|Rifaximin
223927179|NCT06808009|OTHER|Standard Medical treatment|Standard Medical treatment
223927180|NCT07039747|DRUG|treatment with DIELEN® Protect|treatment with DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
223927181|NCT07039747|DRUG|treatment with placebo of DIELEN® Protect|treatment with placebo of DIELEN® Protect for 8 weeks at a dose of 5 grams, 3x a day
223927182|NCT06888596|BEHAVIORAL|Exercise|Exercise using cycle ergometer
224282144|NCT05996692|OTHER|Evaluation of adherence to walking prescriptions|Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.
223927183|NCT06725784|DEVICE|ReHandyBot|"The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.~The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions."
224282145|NCT00261417|DRUG|Tesaglitazar|
224282146|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
224282147|NCT01363063|DRUG|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
223532317|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice|Maintaining Independence and Sobriety through Systems Integration Outreach and Networking- Criminal Justice version (MISSION-CJ) programming targets co-occurring substance use and mental health disorders and other related health outcomes faced by justice-involved homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based services. Patients will receive 2 hours of MISSION-CJ services per week during and after their stay in the mental health residential rehabilitation program (total of 6-months). Services are delivered using a Critical Time Intervention stepdown approach.
223532318|NCT04523337|BEHAVIORAL|Maintaining Maintaining Independence and Sobriety through Systems Integration Outreach and Networking Peer Support|The MISSION Peer Support Curriculum is rolling entry, and includes 24, one-hour exercises focused on co-occurring substance use and mental health disorders, recovery, and community integration.
223532319|NCT06402162|OTHER|exercise|The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
223532320|NCT06492928|OTHER|Psychomotor Vigilance Task|T0 - at the start of the shift: completion of the 1st PVT / socio-demographic and workstation questionnaire T1 - at the end of the shift: completion of the second PVT and questionnaire on the course of the shift that has just taken place T2 - 1 week after the end of the shift: additional questionnaire sent with scales to assess work-related fatigue (MBI), anxiety (PSS), sleep quality (PSQI) and chronotype (MEQ).
223927184|NCT06779383|OTHER|pilates mat exercises|The Pilates exercises were performed on mats. The functional performance on one-leg stance (OLS), five-times-sit-to-stand (STS) and 6-min walk (6 MW) tests was evaluated before and after the 12-week Pilates training or control follow-up period.
223927185|NCT06778928|PROCEDURE|laparoscopic cholecystectomy|Posterior wall sparing of laparoscopic cholecystectomy in cirrhotic patients
223927186|NCT06741267|DEVICE|RBS|physicians control RBS
223927187|NCT06741267|DEVICE|AB|physician control automatic bronchoscopy
223927188|NCT06741267|DEVICE|ENB|physicians control electromagnetic bronchoscopy
223927189|NCT06886191|DEVICE|RenalGuard Therapy|Fluid management system, which weighs urine and controls intravenous administration of crystalloid solution.
223927190|NCT05229341|PROCEDURE|Diagnostic Procedure|Analysis via DDMS-2
223927191|NCT05229341|OTHER|Electronic Health Record Review|Review of medical records
223927192|NCT05229341|PROCEDURE|Needle Biopsy|Undergo needle biopsy
223927193|NCT00391443|DRUG|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)
223927194|NCT00391443|DRUG|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
224093776|NCT05868616|DEVICE|Cardiac Resynchronization Therapy (CRT)|Cardiac resynchronization therapy (CRT) is a modality of cardiac pacing used in patients with left ventricular (LV) systolic dysfunction and dyssynchronous ventricular activation that provides simultaneous or nearly simultaneous electrical activation of the LV and right ventricle (RV) via stimulation of the LV and RV (biventricular pacing) or LV alone.
224093777|NCT06258993|BEHAVIORAL|Core Exercise Promotion Program|Core intervention content will be delivered during the Visit 1 and 1-Month-Check-in meetings. Definitions of exercise will be provided, participants will be asked to discuss their past experiences with exercise, guidelines for being safe during exercise will be reviewed, and strategies for overcoming potential barriers to exercise will be discussed. All participants will be given an exercise plan organized according to the FIIT Principle (Frequency, Intensity, Time, and Type). The intensity component of the exercise plan will differ by study arm, all other elements will be delivered the same across both conditions. All participants will be given the goal of increasing weekly time spent exercising to ≥150 minutes, consistent with recommended guidelines. All participants will be given a smartwatch to support self-monitoring of exercise and activity levels throughout the 12-week study period.
224093778|NCT06258993|BEHAVIORAL|Affect-based exercise prescription|"Participants assigned to Affect-Rx will receive instructions to select a pace of exercise that makes you feel as good as possible. The exercise intensity prescription section of their exercise plan will include the Feeling Scale as an attachment and participants will be given the instruction to stay in the green zone on the Feeling Scale."
224093779|NCT06258993|BEHAVIORAL|Effort-based exercise prescription|"Participants assigned to RPE-Rx will receive instructions to select a pace that would make it challenging for you to carry on more than a short conversation. The exercise intensity prescription section of their exercise plan will include the Rating of Perceived Exertion (RPE) scale as an attachment and participants will be given the instruction to stay in the green zone on the RPE Scale."
224093780|NCT05556616|DRUG|Modakafusp alfa|Modakafusp alfa intravenous infusion.
224093781|NCT05556616|DRUG|Lenalidomide|Lenalidomide capsules orally.
224093782|NCT05556616|DRUG|Bortezomib|Bortezomib injection subcutaneously.
224093783|NCT05556616|DRUG|Carfilzomib|Carfilzomib intravenous infusion.
223927195|NCT06750835|PROCEDURE|SPSIP block|Serratus posterior superior intercostal plane block
223927196|NCT06750835|PROCEDURE|SAP block|Serratus anterior plane block
223927197|NCT06750835|PROCEDURE|Paravertebral block|"* The block will be administered under ultrasound guidance at the T2-T5 levels.~* A total of 15 mL of 0.25% bupivacaine will be injected into the paravertebral space on the side of the surgery."
223927198|NCT06671600|PROCEDURE|Osteopathic Manipulative Treatment|"Osteopathic manipulative treatment(OMT) protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMT procedures performed on the treatment group will consist of~1. suboccipital decompression/release~2. base spread~3. occipitoatlantal (OA) decompression~4. venous sinus drainage~5. compression of the fourth ventricle~6. cervical myofascial (unilateral perpendicular stretch)~7. thoracic inlet release (direct or indirect)~8. Bilateral rib raising~9. thoracoabdominal diaphragm doming (direct technique)~10. pedal pump (Dalrymple lymphatic pump)"
223927199|NCT06671600|PROCEDURE|Sham (No Treatment)|The sham group will serve as the control group and will receive a light touch-control procedure based on prior study utilizing light touch.
223927200|NCT06751459|DEVICE|MEMO Patch 2 - 14-day Monitoring|A wearable ECG monitoring device used for continuous 14-day monitoring to detect atrial arrhythmias during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to assess early recurrence of atrial arrhythmias.
223927201|NCT06751459|DEVICE|MEMO Patch 2 - 1-day Monitoring|A wearable ECG monitoring device used for 1-day monitoring during the second monitoring phase (at 3 months post-ablation). MEMO Patch 2 collects ECG data for remote analysis to detect early recurrence of atrial arrhythmias.
223927202|NCT06751459|DEVICE|MEMO Link|A supplementary ECG monitoring device used alongside MEMO Patch 2 during the 1st monitoring session.
223927203|NCT04908514|DRUG|ADX-629|ADX-629 administered orally twice daily (BID) for approximately 12 weeks.
223927204|NCT06759883|COMBINATION_PRODUCT|local dishes using the my plate concept|The intervention in this study consists of replacing the ready-to-use therapeutic foods prescribed in phase 2 of the management of acute severe malnutrition with balanced local dishes.
223927205|NCT06759311|OTHER|ART|The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin
223927206|NCT06759311|OTHER|Brix 3000|Brix 3000 gel will be applied to the caries lesion using a spoon excavator\*\* leaving gel according to the manufacturer's instructions. After 2 minutes, the gel will turn from translucent green colour to cloudy after the gel removal.
223927207|NCT06759311|OTHER|Carie Move|Carie-Move gel will be applied to the caries lesion according to the manufacturer's instructions at second visit in the same child. After 30 second the gel will be removed.
223927208|NCT06759311|OTHER|Smart Bur|Removal of carious dentin will be carried out employing smart bur II mounted on a low-speed handpiece without water spray. Caries removal will be proceeded until the smart bur II becomes dull after repeated contact with healthy dentin (21) (figure 3)
223927209|NCT06750224|OTHER|Alexander technique|24 sessions for 8 weeks, per week 3 sessions will be given
223927210|NCT06750224|OTHER|Feldenkrais method|The method is divided into eight lessons according to 'Awareness Through Movement'. Each lesson will be given three times for one week.
223927211|NCT06794294|BIOLOGICAL|Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell|"Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 1x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator"
223927212|NCT06761209|OTHER|blood sampling|For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
223927213|NCT06762106|RADIATION|shockwave therapy|solid unite made with metal frame and case
223927214|NCT06762106|RADIATION|hot back|thermal hot back
223927215|NCT06762353|PROCEDURE|3-month supportive peri-implant care (SPIC)|SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 3-month frequency after surgical treatment of peri-implantitis.
224093784|NCT05556616|DRUG|Daratumumab|Daratumumab injection subcutaneously.
224093785|NCT05556616|DRUG|Pomalidomide|Pomalidomide capsules orally.
224093786|NCT03408132|DRUG|FE203799|FE203799 5 mg subcutaneous once weekly
224093787|NCT05507203|DRUG|ABX464|Administered once daily in the morning with food
224093788|NCT05507203|DRUG|Placebo|Administered once daily in the morning with food
224093789|NCT03704766|DIAGNOSTIC_TEST|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
224093790|NCT03704766|DIAGNOSTIC_TEST|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
224093791|NCT03704766|DIAGNOSTIC_TEST|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
224093792|NCT03704766|DIAGNOSTIC_TEST|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
224093793|NCT03704766|DIAGNOSTIC_TEST|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
223532321|NCT06100276|DRUG|AMT-162|AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
223927216|NCT06762353|PROCEDURE|6-month supportive peri-implant care (SPIC)|SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD \>4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 6-month frequency after surgical treatment of peri-implantitis.
223927217|NCT06761378|PROCEDURE|Renal stent|Renal stent before flexible uretroscopy
223927218|NCT06761378|DEVICE|Flexible uretroscopy|Renal stent for 2 weeks prior flexible uretroscopy
223927219|NCT06826261|DEVICE|transcranial alternating current stimulation|The intervention employs transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique designed to modulate neural oscillations in targeted brain regions. tACS operates by applying low-intensity, alternating electrical currents through electrodes placed on the scalp, synchronizing with the brain's natural frequency patterns. In this arm, a frequency of 40 Hz (gamma frequency) is used to enhance oscillatory activity related to cognitive functions often impaired in Alzheimer's disease (AD). The Neuroelectrics Starstim-home device will be used. This compact, portable device allows for easy use within the home setting, reducing the need for daily clinic visits. Designated caregivers will administer the one-hour tACS sessions under remote supervision via a digital monitoring portal, which tracks adherence, technical performance, and safety data in real time.
223927220|NCT06826261|DEVICE|sham transcranial alternating current stimulation|The intervention employs transcranial alternating current stimulation (tACS), a non-invasive brain stimulation technique designed to modulate neural oscillations in targeted brain regions. tACS operates by applying low-intensity, alternating electrical currents through electrodes placed on the scalp, synchronizing with the brain's natural frequency patterns. In this arm, the stimulation will be delivered in 'sham' mode which is characterized by 30 seconds of tACS stimulation at the beginning and end of the protocol to help with blinding. During the rest of the stimulation period (1h) no stimulation will be delivered. The Neuroelectrics Starstim-home device will be used. This compact, portable device allows for easy use within the home setting, reducing the need for daily clinic visits. Designated caregivers will administer the sham tACS sessions under remote supervision via a digital monitoring portal, which tracks adherence, technical performance, and safety data in real time.
223927221|NCT04939272|DRUG|Copanlisib Hydrochloride|"Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8, and 15 for each cycle.~Copanlisib will be given at 30mg, 45mg, or 60 mg depending on the assigned dose level."
224093794|NCT03704766|DIAGNOSTIC_TEST|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
224093795|NCT03704766|DIAGNOSTIC_TEST|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
224093796|NCT03704766|DIAGNOSTIC_TEST|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
224093797|NCT03704766|DIAGNOSTIC_TEST|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
224093798|NCT03704766|DIAGNOSTIC_TEST|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
224093799|NCT03704766|DIAGNOSTIC_TEST|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
224093800|NCT03704766|DIAGNOSTIC_TEST|Synovial PCR for Kingella kingae|In participants \< 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
224093801|NCT03704766|DIAGNOSTIC_TEST|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
223532322|NCT06963190|OTHER|Constant Resistance (CR)|Will perform inspiratory muscle training at 30% of MIP. Two daily sessions of 30 breaths or 10 minutes.
224093802|NCT03704766|DIAGNOSTIC_TEST|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
224093803|NCT03704766|DIAGNOSTIC_TEST|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
223532323|NCT06963190|OTHER|Intermittent Variable Resistance (IVR)|Will perform inspiratory muscle training at 30% of MIP. This will consist of two daily sessions of 30 breaths or 10 minutes. Additionally, the participant will complete 8 sets of 3 repetitions at 60% of the MIP, distributed throughout the day, with a one-minute rest between each repetition.
223532324|NCT05200845|OTHER|Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose|Participants will consume flavored beverage solutions containing 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
224093804|NCT03704766|DIAGNOSTIC_TEST|Serum D-dimer|A blood test performed at the hospital.
224093805|NCT03704766|DIAGNOSTIC_TEST|Serum Procalcitonin|A blood test performed at the hospital.
224093806|NCT03704766|DIAGNOSTIC_TEST|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
224093807|NCT03704766|DIAGNOSTIC_TEST|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
223927222|NCT04939272|DRUG|Venetoclax|Patients receive venetoclax PO QD on days 1-28 for each cycle. Venetoclax will have a weekly dose ramp up in cycle one from 20mg, 50mg, 100mg, 200mg, and then 400mg daily thereafter starting from cycle 2.
223927223|NCT06816056|OTHER|Manual Therapy|The patients included in the experimental group will receive a 50-minute physiotherapy intervention involving global passive mobilisation, calcaneocuboid mobilisation, talus-navicular mobilisation, talar manipulation, tibial displacement manipulation, tibiotarsal decompression, plantar fascia induction, tibiotarsal unwinding and triceps surae induction techniques
223927224|NCT06816056|OTHER|Placebo|The patients included in the control group will receive a 50-minute physiotherapy intervention in which the physiotherapist's hands and the times per technique will be the same as in the experimental group, but without applying any sliding, mobilisation or manipulation
223927225|NCT06855940|OTHER|Bleaching Agents|whitening agent containing fluoride and 40% hydrogen peroxide
223927226|NCT06855940|OTHER|Bleaching Agents|whitening agent containing calcium and 35% hydrogen peroxide
223927227|NCT06855940|OTHER|Bleaching Agents|whitening agent containing hydroxyapatite and 18% hydrogen peroxide
223927228|NCT06588231|BEHAVIORAL|Individual rehabilitation exercise training|Under the guidance of a specialist, medium-and high-intensity interval training was conducted for 16 weeks, 3 times a week, 30-40 minutes each time, including the beginning of 5 minutes of warm-up and the last 5 minutes of cooling-off period, during which the exercise included 4 intervals, with the 85-95% pre intensity of HR reserve for 15-18 minutes, and then with the 50-70% pre intensity of HR reserve for 12-14 minutes, exercise for 3 minutes, and so on for 4 times. Warm-up and cooling-off periods can be done through stretching exercises, flexibility exercises (that is, neck, shoulders, upper back, buttocks and ankles) and low and medium intensity (50-70% heart rate reserve)
223927229|NCT06588231|DRUG|optimal medical therapy ：aspirin, clopidogrel, statins.|those in the control group were treated with routine antiplatelet drugs and lipid-lowering drugs after operation. Professional salesmen, according to the specific physical conditions of the patients, formulate corresponding recipes to ensure that the patients have a light diet, low salt, low fat and high nutritional value, and prohibit tobacco and alcohol.
223927230|NCT06825585|DEVICE|Orthokeratology with 5.0mm back optical zone diameter|The orthokeratology lenses used in this study were Double Reservoir Lenses (DRL) manufactured by Precilens (Creteil, France). The lenses feature a dual reverse-curve design with a back optic zone diameter (BOZD) of 5.0 mm.
223927231|NCT06825585|DEVICE|Orthokeratology with a 6.2 mm back optical zone diameter|The orthokeratology lenses used were Euclid lenses manufactured by Euclid Systems (Herndon, VA, USA). These lenses feature a four-zone, five-curve design with a back optic zone diameter (BOZD) of 6.2 mm.
223927232|NCT06883604|RADIATION|Proton therapy.|Pencil beam scanning proton therapy to a dose of 20 or 29.75 Gy (RBE) after standard chemotherapy (2-4 ABVD).
223927233|NCT06892717|OTHER||
223940942|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
223940943|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
223940944|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
223940945|NCT07195799|DRUG|Linperlisib combined with CPT regimen|Linperlisib: 80mg QD during the cycle 1-2，80mg QD for the first 7 days of cycle 3-6 (each cycle is 28 days) Cyclophosphamide: 50mg QD during the cycle 1-6 (each cycle is 28 days) Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days) Thalidomide: 50mg QD during the cycle 1-6 (each cycle is 28 days) After six cycles, patients with CR or PR continue to receive linperlisib at a dose of 80mg for the first 7 days every cycle (each cycle is 28 days) until disease progression, intolerable toxicity, investigator judgment that treatment should be discontinued, or subject withdrawal of consent, whichever occurred first.
223940946|NCT07197723|GENETIC|cheek (buccal) swab|swab sample in person or at home with a mailed test kit and will fill out a survey
223940947|NCT07197723|OTHER|Assessments|about 1 week, 6 months, and 12 months after getting the updated cancer risk assessment to complete additional surveys.
223940948|NCT07197723|OTHER|optional collection of blood|for research testing
224282148|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
224282149|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
223940949|NCT07196969|DEVICE|Electric toothbrush|Two minutes; twice a day; 3-months.
223717809|NCT03182478|BEHAVIORAL|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
223717810|NCT03182478|BEHAVIORAL|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
223717811|NCT05129215|OTHER|Questionnaire|The LARS score is used for assessment of bowel dysfunction after rectal cancer resection.
223717812|NCT02052531|DRUG|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
223717813|NCT02052531|OTHER|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
223717814|NCT05517915|OTHER|Inspiratory muscle training.|Interval inspiratory muscle training was performed using the inspiratory muscle trainer.
223717815|NCT05517915|OTHER|Sham inspiratory muscle training.|Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
223717816|NCT05466682|BEHAVIORAL|Smartphone-Based Progressive Muscle Relaxation Therapy (PMR)|Relaxation technique delivered via RELAXaHEAD app.
223717817|NCT05466682|BEHAVIORAL|Monitored Usual Care (MUC)|Standard of care plus daily symptom reporting using the RELAXaHEAD app electronic diary.
223717818|NCT01697566|DRUG|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
223717819|NCT01697566|OTHER|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
223717820|NCT01697566|PROCEDURE|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
223717821|NCT01697566|BEHAVIORAL|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
223717822|NCT01697566|BEHAVIORAL|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
223717823|NCT05468931|DEVICE|Prostate stimulator|Prostate stimulation device for sexual dysfunction
223717824|NCT00003331|DRUG|fluorouracil|
223717825|NCT00003331|DRUG|leucovorin calcium|
223717826|NCT00003331|DRUG|topotecan hydrochloride|
223717827|NCT05409326|DRUG|TQH2722 injection|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
223717828|NCT05409326|DRUG|Placebo to match TQH2722|TQH2722 is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α subunit (IL-4Rα) of IL-4 heterodimeric type I and type II receptors that mediate IL-4/IL-13 signaling through this pathway. Blockade of these receptors broadly suppresses type 2 inflammation associated with atopic/allergic diseases.
223717829|NCT05092646|BIOLOGICAL|Axolotl Ambient|Axolotl Ambient is an allogeneic amniotic intra-articular injection therapy consisting of a growth factor and cytokine-rich fluid derived from human amnion cells.
223717830|NCT05092646|DRUG|"Drug/Placebo: 0.9% Normal Saline"|"Drug/Placebo: 0.9% Normal Saline"
223717831|NCT02334358|DEVICE|YVOIRE Classic s|
223717832|NCT06376149|BEHAVIORAL|M3 Intervention group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
223717833|NCT06376149|BEHAVIORAL|M3 Waitlist Group|The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.
223717834|NCT02178735|PROCEDURE|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
223717835|NCT02178735|PROCEDURE|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
223717836|NCT05073211|PROCEDURE|PDT|A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
223717837|NCT03953820|DRUG|Diazepam Buccal Film|Diazepam Buccal Film administered on inner aspect of the cheek at the recommended dose regimen (10 mg to 17.5 mg according to body weight) following ingestion of a moderate fat meal and following ingestion of a high-fat meal.
223717838|NCT03953820|DRUG|Diastat® Rectal Gel (Valeant Pharmaceuticals USA)|Diastat Rectal Gel administered rectally according to product label administration and dosing instructions (10 mg to 20 mg according to body weight) following ingestion of a moderate-fat meal.
223717839|NCT01847378|PROCEDURE|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
224282150|NCT00625924|BEHAVIORAL|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
224282151|NCT02586363|DRUG|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
224282152|NCT02586363|DRUG|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
224282153|NCT02586363|DRUG|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
223532325|NCT05200845|OTHER|Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose|Participants will consume flavored beverage solutions sweetened with sucralose to match the sweetness of 75 calories of sucrose in 6 exposure sessions within 1 week. One exposure session will include pre- and post-consumption blood draws over a 2-hour period, and one exposure session will include indirect calorimetry measurement pre- and post-consumption. The other 4 exposure sessions will occur at specified times outside the laboratory sessions. Subjective ratings of internal state (i.e., hunger, fullness, and thirst) will be collected throughout each exposure. Subjective ratings of liking and wanting of each beverage will also be assessed.
223532326|NCT05200845|OTHER|High-Fat Test Meal Inside a Metabolic Chamber|A high-fat test meal (60% fat, 20% carbohydrate) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
223532327|NCT05200845|OTHER|High-Carbohydrate Test Meal Inside a Metabolic Chamber|A high-carbohydrate test meal (60% carbohydrate, 20% fat) will be provided after a 1-hour baseline measurement of substrate oxidation during a 6-hour metabolic chamber stay. Postprandial substrate oxidation will be measured for 5 hours.
223532328|NCT05200845|OTHER|fMRI Scan|A subset of participants with BMI \> 25 will be invited to complete an functional magnetic resonance imaging (fMRI) scan as a feasibility measure. fMRI scans will be performed while beverages (without calories) used during the intervention are delivered through a custom manifold fitted to a head coil and connected to a pump system that allows precisely timed and measured delivery of liquids. Because this is feasibility-based measure, the outcome is a count of participants who completed this task.
223532329|NCT06058091|DRUG|RY_SW01 cell injection|Administer basic treatment with an injection of RY\_SW01 cell solution
223532330|NCT06058091|DRUG|Basic treatment|Basic treatment for SSc
223717840|NCT00969696|DRUG|Placebo|8Mg a day of a sugar pill
223717841|NCT00969696|DRUG|Galantamine|8mg of Galantamine
223940950|NCT07196969|DEVICE|Manual toothbrush|Two minutes; twice a day; 3-months.
223940951|NCT07197684|DRUG|Ketamine|"Before skin incision, a bolus 0.35 mg/kg ketamine will be given followed by a continuous infusion 0.25 mg/kg/hr.~Ketamine infusion will be stopped 30 minutes before the end of the surgery"
224282154|NCT00426179|DRUG|Imatinib|
224282155|NCT03605823|DEVICE|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
224282156|NCT00151216|BIOLOGICAL|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
224282157|NCT02588196|DRUG|Dexamethasone acetate|
224282158|NCT05375890|OTHER|no intervention|Narcolepsy patients in Russia gathered according to criteria.
224282159|NCT00280969|DRUG|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
224282160|NCT00280969|DRUG|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
224282161|NCT00521482|DRUG|Temozolomide|
224282162|NCT00521482|DRUG|Temozolomide plus Thalidomide|
224282163|NCT00003348|DRUG|O6-benzylguanine|
224282164|NCT00003348|DRUG|carmustine|
224282165|NCT01644149|DEVICE|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
223940952|NCT07197684|PROCEDURE|Pecs block|Pecs block will be performed before surgical incision with the help of an ultrasound (US) by experienced anesthesiologist. The drug used for the pecs block will be two syringes of 10ml and 20 ml containing bupivacaine 0.25% (total 30 ml).
223940953|NCT07197684|DRUG|Nalbuphine|Intravenous Nalbuphine 0.1 mg/kg
223940954|NCT07197684|DRUG|Paracetamol|Intravenous Paracetamol 1g or 15mg/kg (if weight is \< 50kg).
223940955|NCT05157581|DEVICE|Extracorporeal photopheresis (ECP)|Extracorporeal photopheresis is a process that exposes a collection of white blood cells and plasma to a light sensitizing agent, methoxsalen, and returns that compartment to the body.
224282166|NCT01644149|DEVICE|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
224282167|NCT01644149|BIOLOGICAL|2011-2012 Fluzone trivalent inactivated influenza vaccine|
224282168|NCT06427187|DEVICE|an array of devices are used in thrombectomy. These include guide catheters, stent-retrievers, microcatheters, aspiration catheters, and aspiration pump systems|each patient with distal vessel occlusion subjected to mechanical thrombectomy using aspiration technique or stent retriever
224282169|NCT05555927|DEVICE|transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is an non-invasive brain stimulation that is proposed as a possible interventional tool for major depressive disorder. tDCS device that this study used is from Neuroelectrics, Starstim 8, USA.
224282170|NCT02697539|OTHER|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
224282171|NCT02697539|OTHER|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
224282172|NCT05162729|BEHAVIORAL|Game-like online working memory training|Participants in the WM group will be receiving two types of WM training tasks (two mini-games) in each session. Half of the training time will be spent on playing a game that requires visual-spatial WM, and the other half of the training time will be spent on playing a game that demands verbal WM. In both the games, the participant is asked to remember the pictures or audios (numbers) presented, and then recall them and select them on the screen.
223927234|NCT06893913|BEHAVIORAL|pyramidal training plus intermittent fasting|"twenty obese patients with dryness of eye, obesity, (prediabetes), and psoriasis will receive intermittent fasting consisted of eating ad libitum for 5 days and then will restrict calories ('fasting') for two days weekly, for 12 weeks. On the fasting days, participants will restrict calories to a maximum of 600 kcal/day for females and 650 kcal/day for males.~The dietary intervention will be based on the 5:2 fasting diet. Subjects will be asked to consume a total of allowed calories in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per week on 2 non-consecutive days.~also this group will receive a pyramidal training nearly 60 minutes (nearly two rounds of 21 minutes of running on treadmill will be separated with 10 min of rest between the two rounds. Also, warming (4 min before start of pyrimidal trianing) and cooling (4 minu after pyramidal training) will be done through gentle stretching. the exercise will be applied 3 times weekly for 12 weeks"
223927235|NCT06893913|BEHAVIORAL|intermittent fasting|"twenty obese patients with dryness of eye, obesity, (prediabetes), and psoriasis will receive intermittent fasting consisted of eating ad libitum for 5 days and then will restrict calories ('fasting') for two days weekly, for 12 weeks. On the fasting days, participants will restrict calories to a maximum of 600 kcal/day for females and 650 kcal/day for males.~The dietary intervention will be based on the 5:2 fasting diet. Subjects will be asked to consume a total of allowed calories in a window of 6 hours or less from 8:00 am till 2:00 pm, twice per week on 2 non-consecutive days."
223927236|NCT06744049|DEVICE|Transfer Direct System (TDS)|Class IIA medical device (according to rule 5 of Annex VIII of Regulation (EU) 2017/745 for medical devices). A semi-automated medical equipment designed to inject an embryo into the maternal uterine endometrium through the lumen of the female reproductive system.
223927237|NCT06748794|DIAGNOSTIC_TEST|group 1|A comparative analysis was conducted to assess sensory and motor block characteristics, postoperative analgesia duration, maternal hemodynamic stability, and neonatal outcomes. Results demonstrated that intrathecal midazolam significantly prolonged postoperative analgesia and reduced analgesic requirements while maintaining hemodynamic stability and maternal-neonatal safety. This combination provides a potential enhancement to spinal anesthesia techniques, improving maternal comfort and overall perioperative outcomes in obstetric patients.
223927238|NCT06754254|DIAGNOSTIC_TEST|blood biomarkers from the internal jugular vein|blood biomarkers (Aβ42/40, p-tau217, p-tau181, NFL, GFAP, etc.) from the internal jugular vein
223927239|NCT06754384|BIOLOGICAL|Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)|Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ）
223927240|NCT06754384|BIOLOGICAL|Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)|Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
223927241|NCT06754384|BIOLOGICAL|High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )|High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )
223927242|NCT06754384|BIOLOGICAL|EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）|EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）
223927243|NCT06754384|BIOLOGICAL|placebo (for ages 6-12 years)|placebo (for ages 6-12 years)
223927244|NCT06757153|DRUG|NRG-103|NRG-103 is an oncolytic virus, which can kill GBM cells via three manners.
223927245|NCT06762210|OTHER|AI Molar Mind|a baseline oral health assessment using AI Molar Mind, which analyzes intraoral images and self-reported oral health data.
224093808|NCT04840836|BEHAVIORAL|Telehealth-supported LARC provision|"Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents)."
224093809|NCT06799195|DRUG|Attenuated-dose Cyclophosphamide|Cyclophosphamide administered at an attenuated dose of 25 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
224282173|NCT05162729|BEHAVIORAL|Game-like online social emotional training|"Participants in the SE group will be also receiving two types of SE training tasks in each session, to match with the ones in the WM training. There are two mini-games for training.~To match with the spatial-visual WM training, participants in the SE group will be asked to first look at a picture that depicts a daily social scenario (i.e., a child who fell down and hurt himself), and then to choose an emotion that the child in the picture may feel from four options of facial emotions displayed on the screen. The other mini-game, with the aim to match with the auditory WM training, will first tell a short story of a social scenario (i.e. David accidentally fell down and got hurt), and then will ask the child to choose the emotion that the character in the story may feel from the four options displayed on the screen. Each mini game lasts for about 7 minutes in each training session."
224282174|NCT02241135|BIOLOGICAL|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
223532331|NCT05892341|DEVICE|AQUACEL® Ag+ Extra™|Wound treatment with AQUACEL® Ag+ Extra™ dressing
224282175|NCT06608355|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen of brain.
224282176|NCT05766787|DEVICE|Serafilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
224093810|NCT06799195|DRUG|High-dose Cyclophosphamide|Cyclophosphamide administered at the standard high dose of 50 mg/kg on days +3 and +4 post-transplant for GVHD prophylaxis.
224282177|NCT05766787|DEVICE|Senofilcon A contact lenses|Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
224282178|NCT05766787|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
224282179|NCT02912767|BEHAVIORAL|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
223532332|NCT05892341|DEVICE|Cutimed® Sorbact®|Wound treatment with Cutimed® Sorbact® dressing
223532333|NCT05130073|PROCEDURE|Computed Tomography|Undergo PET/CT
223532334|NCT05130073|OTHER|Electronic Health Record Review|Review of medical records
223532335|NCT05130073|PROCEDURE|Follow-Up|Undergo follow-up
224282180|NCT05578469|PROCEDURE|surgical treatment of Marfan Syndrome with subluxation lens|different surgical treatment of Marfan Syndrome with subluxation lens
223927246|NCT06762301|BEHAVIORAL|sexual education and counseling|After the initial evaluation, pregnant women who will be included in the study group will be given an appointment for 1 week later, they will be asked to come with their partners and couples will be given sexual education and counseling in line with the PLISSIT model. After the initial evaluation, couples will be interviewed in the 1st, 2nd and 3rd trimesters, their sexuality since the previous evaluation according to the PLISSIT model, their problems, if any, will be discussed and short counseling will be given if necessary. In the first 4 weeks after delivery, couples in the study group will receive sexual education and counseling for the postpartum period in line with the PLISSIT model. They will be interviewed at the 3rd and 6th month after delivery and their postpartum sexuality and problems, if any, will be discussed and the sexual functions of the couples for the last 4 weeks will be evaluated.
223927247|NCT06762301|OTHER|Routine clinical care|Control Group
223927248|NCT06764732|BIOLOGICAL|bioactive glass|supplied as resorbable form, (400-800um) particle siz
223927249|NCT06764732|RADIATION|bioactive glass graft and PBM irradiation|The used laser parameters were set as: wavelength, 980 nm; power, 0.55 W; energy, 36 J; power density, 0.76 W cm2
224093811|NCT06799195|DRUG|Sirolimus|Sirolimus is started on day +5 with a loading dose of 6 mg, followed by a maintenance dose of 2 mg daily, adjusted to target trough levels of 8-12 ng/mL. Sirolimus taper is recommended to start at day +90 and to be completed by day +180, provided there is no evidence of acute GVHD.
224093812|NCT06799195|DRUG|Mycophenolate Mofetil (MMF)|MMF is started on day +5 at a dose of 15 mg/kg per dose (maximum 1 g per dose) three times daily. MMF is generally discontinued by day +35 in the absence of GVHD.
223532336|NCT05130073|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223717842|NCT02974283|OTHER|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
223927250|NCT06764732|BIOLOGICAL|Platelet rich fibrin|10 ml of blood was withdrawn from the patient and immediately centrifuged for 10 minutes at 3000 revolutions/min and the layer of fibrin clot was obtained
223927251|NCT06763614|BEHAVIORAL|Dog assisted therapy - animal interventions|Animal Assisted Therapy is when animals are used in goal directed treatment sessions. These goals are working emotionalaspects pf childres and adolescents with SAF
223532337|NCT04505488|BEHAVIORAL|ASD Screening Parent ENgagement Intervention Program (ASPEN)|The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
223940956|NCT05157581|DRUG|Methoxsalen Injection|Methoxsalen is a light-sensitizing sterile compound added to the collected white blood cells and plasma during ECP.
223940957|NCT06148506|OTHER|Ribociclib|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with ribociclib+ET by prescription within the study enrollment timeline will be recruited.
224093813|NCT06111755|OTHER|SmokefreeTXT|National Cancer Institute's SmokefreeTXT is a text message quit smoking program available nationally. Users sign up and choose a target quit date that is within 2 weeks of their signup date. Users receive 3-5 text messages per day for up to 2 weeks pre-quit and 6 weeks post-quit. The quit date can be reset as often as needed by the user.
224093814|NCT06111755|DEVICE|Smartband|A smartband that will track smoking in real-time and ask the individual to confirm/deny smoking. Participants will be asked to wear the smartband during their waking hours and to charge it overnight.
224093815|NCT03697564|DRUG|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 Q4W
223940958|NCT06148506|OTHER|Combination chemotherapy|There is no treatment allocation. Participants with HR+HER2- aBC that initiated treatment with CT by prescription within the study enrollment timeline will be recruited.
224093816|NCT03697564|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV on Day 1 Q4W
224282181|NCT04759534|BIOLOGICAL|protein convertase subtilisin/kexin type 9 inhibitor|IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
224282182|NCT05147974|BEHAVIORAL|DOZE app|"Complete DOZE app: Delivering Online ZZZ's with Empirical support (DOZE) app plus a Consensus Sleep Diary (CSD).~The DOZE app, is a web-based app optimized for desktop, smartphone, or tablet use. It is a self-management program for adolescents and young adults with sleep problems. The intervention will be delivered on restricted password-protected applications that will allow tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log onto the sleep dairy (via automated alerts) once a day over a 10-week period to complete sleep diary entries, develop and track their goals, and receive sleep health education/tailored sleep health interventions.~1-week pre- and post- intervention, participants will complete a battery of baseline study questionnaires and have the option of using a Geneactiv actigraphy device along with a CSD."
224282183|NCT00002869|BIOLOGICAL|recombinant interferon alfa|
224282184|NCT00002869|DRUG|cytarabine|
224282185|NCT00002869|DRUG|hydroxyurea|
223532338|NCT05746988|OTHER|Mouthwash gargling|15 - 20 ml of mouthwash to be gargled vigorously for 30 to 60 seconds daily (morning and night) as an adjunct to regular toothbrushing, and before and/or immediately after sexual activities.
223532339|NCT01486888|DRUG|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
223532340|NCT02065219|DRUG|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
223717843|NCT01344785|PROCEDURE|Intramedullary nailing|All patients will be treated with Intramedullary nailing
224093817|NCT03697564|DRUG|Cabiralizumab|4mg/kg IV on day 1 and 15 Q4W
224093818|NCT03055026|DRUG|Rivaroxaban|Tablets
224093819|NCT03055026|DRUG|Placebo|Tablets
224093820|NCT05726370|DRUG|Pembrolizumab|Immunoglobulin G4 monoclonal antibody, via IV infusion
224093821|NCT05726370|DRUG|CISPLATIN|Platinum agent, via IV infusion
224093822|NCT05726370|DRUG|Carboplatin|Platinum agent, via IV infusion
223532341|NCT02065219|DRUG|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
223717844|NCT03047057|DRUG|Lidocaine|IV Lidocaine infusion
223717845|NCT03047057|DRUG|IV normal saline|IV normal saline infusion
223927252|NCT06763237|DEVICE|abdominal transcutaneous electrical acupoint stimulation (abdominal TEAS)|"The TEAS intervention is delivered using an electroacupuncture device (SDZ-V, Hwato, Soochow Medical Instruments Co., Ltd., China). Self-adhesive electrodes are placed at acupoints Zhongwan (RN12), bilateral Tianshu (ST25), Qihai (RN6), and Guanyuan (RN4). Stimulation is applied using dense-sparse wave alternating frequencies (3 Hz for 2 s cycles) at an intensity of 3-10 mA, adjusted to the participant's tolerance. Each session lasts 30 minutes, conducts once daily, five days per week, for a total of 40 sessions.~The ABA therapy focuses on enhancing skills in areas such as social interaction, communication, academics, motor function, and self-care. ABA is delivered in a variety of settings, including school, home, clinic, and other community settings. The goal of treatment is to help children function as independently and successfully as possible. Each session lasts 30 minutes, conducts once daily, five days per week, for a total of 40 sessions."
223927253|NCT06828003|BEHAVIORAL|Resistance Training|The resistance training intervention will consist of two remotely-delivered exercise sessions per week for eight weeks (16 sessions total). One session will be a live, remotely delivered 1:1 class led by a qualified exercise professional (\~one hour). The second session will be unsupervised, completed by watching a pre-recorded workout video that will vary bi-weekly to elicit progressive overload. Pre-recorded workout videos will be emailed and feature the qualified exercise professional who will provide instruction to mimic live sessions. Both sessions will involve a dynamic warm-up (\~10 minutes), 8 resistance-band exercises (\~30-45 minutes), followed by a cool-down (\~10 minutes).
223927254|NCT06761911|DRUG|Brentuximab Vedotin (Bv)|1.2mg/kg/2w or 1.8mg/kg/3w
223927255|NCT06761911|DRUG|Sintilimab|200mg/3w
223927256|NCT06761911|DRUG|Tislelizumab|200mg/3w
223927257|NCT06761911|DRUG|Bendamustine|90mg/m2/3w
223927258|NCT06759077|DRUG|Dapagliflozin (DAPA)|adult patients with advanced CKD who will take SGL2I(DAPAGLIFLOZINE at a dose (10 mg/day) orally for 6months
223927259|NCT06770244|BEHAVIORAL|positive psychology-based intervention package|The postpartum depression intervention program will be developed in accordance with the principles of positive psychology, incorporating online psychological interventions as the primary mode of delivery. Specifically, psychological courses and training based on positive psychology will be conducted in addition to the usual community-based primary health care. Interventions use formats that include online videos and supplemental materials. The aim of the intervention is to help pregnant and postpartum women understand mental health, enhance positive emotions, improve negative emotions, maintain interpersonal relationships, and explore life meaning. Additionally, one-on-one online consultations based on positive psychology will be offered to high-risk women.
223927260|NCT06773429|DRUG|E2 Valerate|To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).
223927261|NCT06773429|DRUG|Placebo|Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
223927262|NCT06774443|OTHER|Neuropsychological assessment|Neuropsychological assessment consisting of tests measuring social cognition and memory
223927263|NCT06772610|DRUG|Ensartinib group|Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.
223927264|NCT06772389|OTHER|Peer Tutoring|"Peer tutoring is defined as individuals who are in a similar social group and are not professional teachers helping each other to learn and teach. For peer tutoring, the subject of EFM was grouped under 6 headings. The students in the Peer tutoring group were divided into groups of 6. The researcher explained a heading of the EFM subject to each of these 6 groups. Then, new groups were formed by taking one student from each group. In these new groups, each student explained his/her own subject to his/her peers."
223927265|NCT06749080|BEHAVIORAL|Assist Reablement (including education and mentoring)|Reablement on-line education will be standard and mandatory for both intervention groups. Mentoring will be formed according to the pre-requisites at the site.
223927266|NCT06760910|PROCEDURE|tDCS Stimulation|Anode tDCS or sham stimulation for amblyopia of Adolescents
223532342|NCT01749488|OTHER|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
223532343|NCT05957627|PROCEDURE|Saleem's protocol|It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
223927267|NCT06760910|DEVICE|Anodal tDCS|Anodal tDCS
223927268|NCT06760910|DEVICE|Sham tDCS|Sham tDCS
224282186|NCT06682637|DRUG|Melflufen|Pepaxti 20 mg powder for concentrate for solution for infusion
224282187|NCT06682637|DRUG|Dexamethasone|SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution
223717846|NCT03965039|DEVICE|Dipotassium oxalate toothpaste|Experimental dipotassium oxalate (3%) toothpaste
223940959|NCT03614299|OTHER|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
223940960|NCT03614299|DIAGNOSTIC_TEST|Interferometry|Evaluation of the mebomian function using the LipiView methodology
224282188|NCT02157363|PROCEDURE|Repositioning|
224282189|NCT02157363|PROCEDURE|Single positioning|
224282190|NCT03528096|DEVICE|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
224282191|NCT03528096|OTHER|Sound|Sound of the moving bed was recorded and played back during the baseline night.
224282192|NCT01547507|DEVICE|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
224282193|NCT02751892|BEHAVIORAL|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
224282194|NCT01435928|DRUG|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
223927269|NCT06775288|OTHER|Hypoglycemia prevention and awareness program (HypoPAP)|Online hypoglycemia prevention and awareness training Supporting the prevention of hypoglycemia with the use of evidence-based diabetes-friendly plates Encouraging physical activity and supporting glycemic control with a pedometer Filling in a weekly problem-solving notebook Conducting weekly online problem-solving meetings Online counseling service when needed
223927270|NCT06776432|DRUG|Sivopixant|Administered as specified in the treatment arm
224093823|NCT05726370|DRUG|Docetaxel|Antineoplastic agent, via IV infusion.
224093824|NCT01848314|PROCEDURE|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
224093825|NCT01377493|DIETARY_SUPPLEMENT|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
224093826|NCT04746521|DIAGNOSTIC_TEST|Multitest 6 color TBNK and BD Lyotubes|The Multitest 6 color TBNK allows us to count the population-specific B, T, NK cells
224093827|NCT04746521|BIOLOGICAL|genomicDNA extraction|Peripheral blood biospecimens (about 10-15 mL) will be collected through venipuncture in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) will be isolated using Ficoll® Paque Plus (Sigma-Aldrich) centrifugation gradient and genomic DNA will be extracted from fresh PBMCs using DNeasy Blood \& Tissue kit (QIAGEN), according to manufacturer protocols
224093828|NCT06443086|PROCEDURE|Radical operation and perioperative therapy|Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
224093829|NCT00075881|DRUG|bortezomib|Given IV
224093830|NCT00075881|OTHER|laboratory biomarker analysis|Optional correlative studies
224282195|NCT01435928|DRUG|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
223927271|NCT06776432|DRUG|Placebo|Administered as specified in the treatment arm.
224093831|NCT02031679|DRUG|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
224093832|NCT02031679|DRUG|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
224093833|NCT00520026|DRUG|lithium|
224093834|NCT00520026|DRUG|placebo|
224093835|NCT05139524|OTHER|Evidence of past or recent RVF exposure|Detection of RVF exposure.
224093836|NCT06959550|DRUG|Ivonescimab|Given by IV
223927272|NCT06776432|DRUG|Acetazolamide|Administered as specified in the treatment arm
223927273|NCT06776432|DRUG|SASS-001|Administered as specified in the treatment arm
223927274|NCT06776185|PROCEDURE|Liver Surgery|Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
223927275|NCT06776107|OTHER|Risk factor present|Demographic, and severity.
223927276|NCT06777472|OTHER|lung-benefiting moxibustion|A kind of external treatment，the treatment theory is to treat winter diseases in summer.
224093837|NCT04030195|GENETIC|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
224093838|NCT04030195|DRUG|Fludarabine|Fludarabine is used for lymphodepletion (30 mg/m\^2/day, Days -5 to -3).
224093839|NCT04030195|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion (500 mg/m\^2/day, Days -5 to -3).
224282196|NCT06221124|DEVICE|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Sleep stage (bSTAGES) and respiratory event index (bAHI) are estimated.
224282197|NCT04158427|PROCEDURE|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
224282198|NCT04158427|PROCEDURE|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
224282199|NCT04795869|DRUG|Brentuximab Vedotin|Given IV
224282200|NCT04795869|BIOLOGICAL|Pembrolizumab|Given IV
223927277|NCT06777472|DRUG|"The specific drug comes from GINA (2024)"|"Refer to GINA (2024)."
224093840|NCT01228773|BEHAVIORAL|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
224093841|NCT03025412|PROCEDURE|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
224093842|NCT03025412|BEHAVIORAL|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
223927278|NCT06775652|DRUG|Neoadjuvant Chemoradiotherapy|Patients assigned to the NCRT group received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles. Concurrently, they received intensity-modulated radiotherapy (IMRT) with a total of 20 sessions (CTV 40 Gy, GTV 44 Gy) five days per week. All radiotherapy plans were reviewed by designated radiation oncologists before treatment to ensure quality control. Patients were assessed 4 to 6 weeks after completing NCRT following RECIST 1.1 criteria.
223927279|NCT06775652|PROCEDURE|Adjuvant therapy|Patients in the AT group received surgery as soon as possible after randomization, followed by adjuvant therapy, postoperative adjuvant therapy based on pathological staging, as recommended by the NCCN Clinical Practice Guidelines for Esophageal and Esophagogastric Junction Cancers (2017 V4), starting one month post-surgery with either adjuvant chemotherapy or chemoradiotherapy. The adjuvant chemotherapy regimen was the same as the neoadjuvant chemotherapy regimen, and the adjuvant radiotherapy regimen and dose were administered according to guideline recommendations.
224093843|NCT04057170|OTHER|accelerated protocol and mulligan method|manual therapy technic
224093844|NCT05136391|DRUG|XTR003|Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
224093845|NCT03890679|DIAGNOSTIC_TEST|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
224093846|NCT05011396|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
224093847|NCT05011396|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
224093848|NCT02251743|DEVICE|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~1. The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~2. Average voltage of theta waves~3. Average voltage of beta~4. Average ratio of theta to beta power (TBR)"
224093849|NCT00215150|DRUG|Ziprasidone|Sertraline augmentation with ziprasidone
224282201|NCT02966158|OTHER|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
224282202|NCT02452528|DRUG|ARC-520|
224282203|NCT02452528|DRUG|Placebo|
224282204|NCT02452528|DRUG|Entecavir|0.5 or 1.0 mg/day orally
224282205|NCT02452528|DRUG|Tenofovir|300 mg/day orally
224282206|NCT02452528|DRUG|diphenhydramine|50 mg orally as pretreatment antihistamine
223717847|NCT03965039|DRUG|Stannous fluoride toothpaste|Marketed stannous fluoride (0.454%) toothpaste
223927280|NCT06775652|PROCEDURE|Surgery|Surgery
224093850|NCT00215150|DRUG|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
224093851|NCT05983432|DRUG|BL-B01D1|BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen
224093852|NCT04724590|RADIATION|IMRT(IMAGE GUIDED INTENSITY-MODULATED RADIATION THERAPY )|Evaluation the optic neuropathy in nasopharynx cancer patients treated in our clinic.
224282207|NCT03530241|DIAGNOSTIC_TEST|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
223717848|NCT03965039|DRUG|Potassium nitrate toothpaste|Marketed potassium nitrate (5%) toothpaste
224093853|NCT00077454|DRUG|erlotinib hydrochloride|Given orally (PO)
224093854|NCT00077454|DRUG|temozolomide|Given PO
224093855|NCT00077454|OTHER|pharmacological study|Correlative studies
224093856|NCT00077454|OTHER|laboratory biomarker analysis|Correlative studies
224093857|NCT01810887|DRUG|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
224093858|NCT01810887|DRUG|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
224093859|NCT00716521|DRUG|placebo|single oral dose placebo
224282208|NCT03530241|DIAGNOSTIC_TEST|Non-presence of bile duct stones|MRCP without bile duct stones
224282209|NCT01396694|OTHER|Questionnaire|Questionnaire
224282210|NCT00568711|DRUG|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
224093860|NCT00716521|DRUG|zolpidem|single oral dose, 5 mg zolpidem
223717849|NCT03965039|DRUG|Sodium monofluorophosphate toothpaste|Marketed sodium monofluorophosphate (0.76%) toothpaste
224093861|NCT00716521|DRUG|zolpidem|single oral dose, 10 mg zolpidem
224282211|NCT00568711|DRUG|rifampin|a 5-day course of daily 600-mg doses of rifampin
224282212|NCT04015531|RADIATION|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
224282213|NCT04015531|RADIATION|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
224282214|NCT03261024|DEVICE|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
224282215|NCT03261024|DEVICE|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
223927281|NCT06777407|BEHAVIORAL|Brief Mindfulness-Based Intervention to Reduce Psychological Distress|The brief mindfulness-based intervention is an eight-week training program designed for groups of 15 to 20 participants. The weekly sessions will last 90 minutes for the first session and 60 minutes for the following seven sessions. The program will be led by a certified mindfulness trainer, who is not part of the research team and will be solely responsible for training-related activities.
223927282|NCT06777407|OTHER|Psychoeducational brochure|Information on self-care and managing psychological distress will be provided. Once the study is completed and the data has been collected, participants in the control group will receive the intervention.
223927283|NCT06776328|OTHER|Tools|In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of children and adolescents with suicidal thoughts/behavior.
223927284|NCT06775509|DEVICE|Ortho-K|Utilization of Ortho-K Contact Lenses for The Treatment of Myopia
223927285|NCT06775561|GENETIC|PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.|Samples are collected by UO1/UO2/UO3. DNA/RNA samples are sent to UO3 for genome and transcriptome sequencing. In vitro systems or patient-derived cell models are used for in vitro experimental validation (UO2) or development of therapeutical approaches (UO2/UO4). Samples of cases still undiagnosed after the combined sequencing and validation approaches undergo long-read sequencing by an outsourcing facility. Sequencing data are transferred to UO1 for bioinformatic analysis and may be deposited into RDconnect for still inconclusive cases. Variants of interest from bioinformatic analyses and in vitro validations are collectively discussed by UO1/UO2/UO3 to evaluate their clinico-molecular significance and to be selected for testing therapeutic approaches by UO2/UO4. Blue arrows and shapes denote samples and personal data, while green data that make no identifiable person.
223927286|NCT06776822|OTHER|Dynamic neuromuscular stabilisation|"The nervous system establishes programs that control human posture, movement and gait. This 'motor control' is largely established during the first critical years of life. Therefore, the Prague School emphasizes neurodevelopmental aspects of motor control in order to assess and restore dysfunction of the locomotor system and associated syndromes."
223927287|NCT06775548|OTHER|Aerobic Exercises + Vitamin E|"For aerobic exercise, patient will perform cycling. The patient will perform stationary bike with an intensity of 60-85% of MHR by using Karvonean formula for duration of 30 minutes for 4 days/ week. Participants will be advised by the physical therapist to sit on a cycle ergometer with back supported, hands holding the handle bar and feet firmly placed on the pedals.~The imprint of FITT protcol by ACSM for aerobic exercise will be as follows, Frequency: 4 days/week Intensity: 60-85% of MHR Time: 30 minutes Type: Stationary bike"
223927288|NCT06775548|OTHER|Resistance Exercises + Vitamin E|The strength training protocol will focus on 10 major muscles of the body. The sessions will be performed for 4 days per week, lasting approximately 30 minutes. The training will be divided in a systematical manner, on first- and third-day participant will perform strength training of upper limb and abdominal muscles that include: Biceps, Triceps, Pectoralis Major, Deltoid, and abdominal muscles. On second and fourth day, participant will perform strength training of lower back and lower limb muscles that include: Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight bearing exercises will be calculated using 1 Repetition Maximum (RM) method. The protocol will be divided as follows: 2 days the participant will perform exercises for upper limb and 2 days, patient will perform exercises for lower limb.
223927289|NCT06775548|OTHER|Aerobic Exercises + Vitamin D|For aerobic exercise, patient will perform cycling. The patient will perform stationary bike with an intensity of 60-85% of MHR by using Karvonean formula for duration of 30 minutes for 4 days/ week. Participants will be advised by the physical therapist to sit on a cycle ergometer with back supported, hands holding the handle bar and feet firmly placed on the pedals. The imprint of FITT protcol by ACSM for aerobic exercise will be as follows, Frequency: 4 days/week Intensity: 60-85% of MHR Time: 30 minutes Type: Stationary bike
223927290|NCT06775548|OTHER|Resistance Exercises + Vitamin D|The strength training protocol will focus on 10 major muscles of the body. The sessions will be performed for 4 days per week, lasting approximately 30 minutes. The training will be divided in a systematical manner, on first- and third-day participant will perform strength training of upper limb and abdominal muscles that include: Biceps, Triceps, Pectoralis Major, Deltoid, and abdominal muscles. On second and fourth day, participant will perform strength training of lower back and lower limb muscles that include: Latissimus Dorsi, Abdominals, Back Extensors, Hamstrings, Quadriceps and Calf. The intensity of the weight bearing exercises will be calculated using 1 Repetition Maximum (RM) method. The protocol will be divided as follows: 2 days the participant will perform exercises for upper limb and 2 days, patient will perform exercises for lower limb.
223927291|NCT05504278|DRUG|IBI351|recommended dose, po
223927292|NCT05504278|DRUG|Cetuximab|500mg/m\^2, Q2W, day1, i.v.
223927293|NCT05504278|DRUG|pemetrexed|500mg/m\^2, Q3W, day1, i.v.
223927294|NCT05504278|DRUG|Carboplatin|AUC=5, Q3W, day1, i.v.
223927295|NCT05504278|DRUG|Sintilimab|200mg, Q3W, day1, i.v.
223927296|NCT05504278|DRUG|cis-platinum|75mg/m\^2, Q3W, day1, i.v.
223927297|NCT06775899|DEVICE|PC-Based Ultrasound Training Tool|An interactive, PowerPoint-based PC tool designed to simulate pathology recognition and ultrasound image optimization for medical students. It provides real ultrasound videos and images, allowing students to practice diagnostic interpretation and image acquisition in a structured training format.
223927298|NCT06775899|DEVICE|Traditional Ultrasound Simulator (VausSim)|A medium-cost ultrasound simulator used for hands-on training in thoracic and abdominal ultrasound. It allows medical students to practice probe handling, image acquisition, and pathology recognition in a controlled simulation environment.
223717850|NCT00457925|DRUG|GSK221149A|
223717851|NCT01481597|DRUG|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
223927299|NCT06777212|BEHAVIORAL|Mindfulness Training Program|The Mindfulness Training Program is a 30-day behavioral intervention designed to help children with body-focused repetitive behaviors (BFRBs) such as nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program includes daily audio-guided exercises focused on mindfulness techniques such as deep breathing, body scans, and emotional awareness. Children will be encouraged to practice mindfulness for 10-15 minutes each day, with the goal of improving emotional regulation, reducing impulsive behavior, and enhancing self-awareness. Family support is involved, with parents helping children track their progress and offering reinforcement.
223927300|NCT06777212|BEHAVIORAL|Psychosocial Education Program|The Psychosocial Education Program is a 30-day behavioral intervention designed for children with body-focused repetitive behaviors (BFRBs), including nail-biting, skin-picking, and hair-pulling. Delivered through JD Health, the program provides daily educational content in the form of articles and coping strategies. The intervention focuses on improving emotional regulation, promoting family support, and developing positive behavioral strategies. Parents play an active role by reviewing the content with their children and helping them apply the strategies in daily life. Behavioral and psychological assessments are conducted at baseline, one month, and three months to evaluate the program's impact.
224093862|NCT03052153|OTHER|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
224093863|NCT00205192|PROCEDURE|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
224093864|NCT04154488|DRUG|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
224093865|NCT03581942|DRUG|Ibrutinib|(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
224093866|NCT03581942|DRUG|Copanlisib|(MTD) Copanlisib 60 mg weekly (3w on/1w off)
224093867|NCT03215966|COMBINATION_PRODUCT|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
224093868|NCT03215966|DRUG|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
224093869|NCT03215966|DRUG|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
224093870|NCT06144515|PROCEDURE|Blood test|"Blood is collected in order to perform in vitro research:~1. If a routine blood test is performed for clinical tests, the sponsor will receive the results of the Complete blood count (CBC) and an additional blood sample from the same puncture of 20ml to maximum 40ml will be collected for this study.~2. If no routine blood test is performed for clinical tests, a CBC will be performed for the study and an additional blood sample of 20ml to maximum 40ml will be collected.~Additional Bone marrow (BM) material will be obtained from the same puncture performed for routine clinical tests:"
224093871|NCT05464355|PROCEDURE|Intraoperative electroencephalography recording|Intraoperative electroencephalography measurements, a non-invasive routine monitoring device used during anaesthesia to measure the brain's electrical activity
224093872|NCT05464355|PROCEDURE|Neurofilament light chain measurement|Measurement of the level of neurofilament light chain in a blood sample
224093873|NCT05464355|PROCEDURE|Tau protein measurement|Measurement of the level of tau protein in a blood sample
224093874|NCT03021577|DEVICE|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
224093875|NCT03021577|DEVICE|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
224093876|NCT03021577|PROCEDURE|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
224093877|NCT06369246|DEVICE|Stereotactic Body Radiation Therapy|Undergo Radiation Therapy
224093878|NCT02231775|DRUG|Dabrafenib|Given PO
224093879|NCT02231775|OTHER|Laboratory Biomarker Analysis|Correlative studies
224093880|NCT02231775|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224093881|NCT02231775|DRUG|Trametinib|Given PO
224093882|NCT04057105|DEVICE|Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)|Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
224093883|NCT04057105|DEVICE|MusicGlove|Both groups will undergo MusicGlove video-game based hand exercises.
224282216|NCT04459130|BEHAVIORAL|Child Obesity Program|"The program consists of 10 sessions, each lasting 40 minutes. An EOP booklet containing session programs will be distributed to children.~The topics of the sessions are as follows:~Session 1: Healthy lifestyles~* Session 2: Self-esteem and positive thinking, Setting goals Session 3: Stress and Coping, Coping with Emotions in Healthy Ways Session 4: Personality and effective communication~* Session 5: Activity: Time for action Session 6: Nutrition basics Session 7: Reading tags Session 8: Portion size, nutrition and healthy food choices in schools Session 9: Snacks can also be healthy: Healthy choices~* Session 10: Together for a healthy life (Melnyk et al., 2006; 2007; 2009). Detailed information about the sessions is given in annex -3."
223717852|NCT01481597|DRUG|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
223717853|NCT01481597|DRUG|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
223717854|NCT01481597|DRUG|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
223717855|NCT01481597|DRUG|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
223532344|NCT05707260|BEHAVIORAL|CKD SMS|The intervention begins with a face-to-face or digitally assisted session, entry into improving the knowledge and self-management of CKD through, using the four sources of manipulation of self-efficacy (achievement of performance, indirect experience, verbal persuasion, and self-evaluation). In this session, participants will be asked to identify their problems related to CKD and establish, based on these two goals, that they are real and achievable according to their priorities. These goals will be recorded in the monitoring format and will be monitored in the telephone or WhatsApp follow-ups. This using the performance achievement manipulation source, said session lasts 60 minutes, as does the final session at week 16.
223927301|NCT06776081|OTHER|Weight loss without pharmacotherapy|Adults with obesity participating in the 12-week hypocaloric diet-induced weight loss intervention will be individually counseled by the Clinical and Translational Research Center (CTRC) bionutritionist to consume a hypocaloric diet consistent with current dietary recommendations for weight loss until a 6-10% weight loss is achieved.
223927302|NCT06775522|DRUG|YHP2205|Test drug: YHP2205 Comparator: YHR2401
223927303|NCT06775522|DRUG|YHR2401|Test drug: YHP2205 Comparator: YHR2401
223927304|NCT06776757|DRUG|Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)|Sintilimab (100mg,150mg, 200mg; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
223927305|NCT06776757|DRUG|Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)|Sintilimab (Based on Phase 1b recommended dose; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
223927306|NCT06776523|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders."
223927307|NCT06768242|RADIATION|Cone beam CT|Each patient will undergo three cone beam CTs per session, and a total of three sessions.
223927308|NCT06775171|BEHAVIORAL|video training group|"Creation of the Education Booklet While creating the education booklet that includes the definition of BY, the areas where it frequently develops, risk factors, classification, prevention and situations where it requires professional support, it will be created by the researcher by scanning the current literature and taking the opinions of the Faculty Members from the Nursing Fundamentals field in terms of scope, comprehensibility and scientific content.~Creation of Videos The videos will be prepared in five separate videos that will include the definition of BY, the areas where it frequently develops, risk factors, classification, prevention and situations where it requires professional support in line with the education booklet. QR codes of the prepared videos will be created. Each video will be planned to be 5-10 minutes. The videos will be checked by the Advisor Faculty Member and corrections will be made in line with his/her suggestions."
223927309|NCT05130983|BIOLOGICAL|ExoFlo|Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
223927310|NCT06771804|DIETARY_SUPPLEMENT|Cricket Protein|Participants are provided with muffins containing either whey or cricket protein.
223927311|NCT06774651|PROCEDURE|Procedure: Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure using FEMTO LDV Z8 laser system for correction of Myopia.
223927312|NCT06774651|PROCEDURE|Procedure: Small Incision Lenticule Extraction (SMILE)|Routinely conducted procedure using VisuMax laser system for correction of Myopia.
223927313|NCT06772454|DRUG|Antitumor therapy|"All patients received suglizumab + paclitaxel + carboplatin:~Suglizumab 1200 mg IV Q3W Paclitaxel (albumin-bound) 100 mg/m2 IV, D1, 8, 15, Q3W Carboplatin AUC=5 mg/mL/min IV Q3W A total of 4 administration cycles were given, and Suglizumab 1200 mg IV Q3W was maintained after 4 administration cycles"
223927314|NCT06772454|DRUG|Inhaled preparation for COPD|"60 patients were randomly assigned to the following two groups in a 1:1 ratio, with about 30 patients in each group.~Group A: Receiving a long-acting beta-2 agonist (LABA) + a long-acting anticholinergic (LAMA) combination: Glonium bromide formoterol inhalation aerosol (7.2ug/5ug, trade name: Biwapin, Astrazeneca), 2 inhalations twice a day.~Group B: Received inhaled glucocorticoid (ICS) +LABA+LAMA as a three-drug combination: budesonide/glononium bromide/formoterol :160ug/7.2ug/4.8ug, Astrazeneca), 2 inhalations twice daily."
223927315|NCT06779721|OTHER|Sestrin-2|Sestrin-2 levels were studied in three different groups
223927316|NCT06779240|OTHER|Quality of life questionnaires|The clinical protocols at our institute involve the regular and continuous evaluation of the quality of life in patients undergoing treatment and monitoring for scoliosis and other vertebral deformities. To this end, the SRS-22 (Scoliosis Research Society) questionnaire and the ODI (Oswestry Disability Index) questionnaire are employed, along with other measures such as the COMI (Core Outcome Measure Index) and ISYQoL (Italian Spine Youth Quality of Life) and administrated to every patients
223927317|NCT06778733|DRUG|Clomiphane citrate|Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))
224282217|NCT06492408|DRUG|ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks, total 3-4 times.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks, total 3-4 times.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks, total 3-4 times."
224282218|NCT04083443|OTHER|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
223532345|NCT00272181|DRUG|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
224282219|NCT00099957|DRUG|vildagliptin|
223927318|NCT06778733|DRUG|recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)|"All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)"
223927319|NCT06843460|BIOLOGICAL|Sotatercept|Single subcutaneous injection
223927320|NCT06843460|OTHER|Placebo|Single subcutaneous injection
223927321|NCT06765525|OTHER|Junior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
223927322|NCT06765525|OTHER|Senior sonographer measurement of DDH|Participants will not receive visual cues from the DeepDDH system.
223927323|NCT06765525|OTHER|Automated annotation of the DDH measurement through deep learning|Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
223927324|NCT06765525|OTHER|AI-assisted junior sonographer meaturement of DDH|Participants will receive visual cues from the DeepDDH system.
224093884|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Therapeutic|"Photobiomodulation (PBM) is a non-invasive treatment option that uses nonionizing light sources such as laser diodes and light-emitting diodes in the visible and near-infrared spectrum.~Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'therapeutic setting' of 35mW/cm2 = 42J/cm2"
224093885|NCT05855694|DEVICE|THOR LED Photobiomodulation Helmet - Control|"Each participant will be required to sit with the helmet device over their head for the length of their study session. Participants and study staff will wear protective goggles throughout each session. These goggles help to block out any red LED light emitted from the helmet device. Participants may experience a pleasant warmth upon their head during both the therapeutic and control settings.~Helmet will be in 'non-therapeutic setting' of 0mW/cm2 = 0J/cm2"
224093886|NCT02407535|DEVICE|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
224093887|NCT04489654|BIOLOGICAL|deproteinized bovine bone mineral (DBBM) by OneXeno Graft. ( OneGraft, Germany)|deproteinized bovine bone mineral (DBBM) put in the gap between implant and labial shield
224093888|NCT02935972|DRUG|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
224093889|NCT02935972|DRUG|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
224282220|NCT06409858|OTHER|Pilates|Twice-weekly mat Pilates class for 8 weeks, either in person or online (depending on participant availability)
223532346|NCT02814656|DRUG|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
223927325|NCT06763783|DRUG|Shingrix|all participants vaccinates with two doses of Shingrix vaccine
224093890|NCT02935972|DRUG|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
224093891|NCT04194060|COMBINATION_PRODUCT|Enhanced Recovery after Surgery group|"* Tracheal intubation and with General anesthesia~* Short acting anesthetic agents,avoid opioid agents~* Omental patch repair with placement of sub hepatic drain~* Bilateral Transverse abdominis plane block/ Rectus sheath block immediately after surgery.~* Post operative nausea and vomiting prophylaxis.~* Encourage to mobilize out of bed after effect of general anesthesia has weaned off.~* Initiation of feeding-Oral sips on day 1, step up day 2 onward~* Removal of nasogastric tube-immediately after surgery after aspirating the gastric content through nasogastric tube.~* Removal of urinary catheter-after weaning from the effect of general anesthesia.~* Sub hepatic drain removal -anytime within 24 hours;drain will not be removed if fluid is bilious or pus.~* Avoid opiod analgesics."
224282221|NCT01543867|DRUG|somatropin|Prescribed at the discretion of the treating physician according to product labelling
224282222|NCT02725164|DRUG|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
224282223|NCT02725164|DRUG|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
224282224|NCT02725164|DRUG|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
223532347|NCT02814656|DRUG|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
223927326|NCT06763783|DRUG|vaccination with 2 doses of Shingrix vaccine|all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
223927327|NCT06769971|DRUG|Ivonescimab|20mg/kg，IV infusion，Day1，Q3W
223927328|NCT06769971|DRUG|Cadonilimab|10mg/kg，IV infusion，Day8，Q6W
223927329|NCT06769971|DRUG|Etoposide|100mg/kg，IV infusion，Day1-3，Q3W
223927330|NCT06769971|DRUG|Carboplatin|AUC 5，IV infusion，Day1，Q3W
224282225|NCT02725164|DRUG|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
224282226|NCT00655317|OTHER|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
224282227|NCT00655317|OTHER|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
223927331|NCT06763419|DEVICE|External low level laser therapy|Patients received 8 sessions of external diode laser (635 nm).
223927332|NCT06763419|DEVICE|Internal low level laser therapy|Patients received 8 diode laser (635 nm) sessions applied internally
224282228|NCT00442546|DRUG|pregabalin|150 milligram (mg)/ day (double blind)
224282229|NCT00442546|DRUG|pregabalin|300 mg/day (double blind)
224282230|NCT00442546|DRUG|Placebo|Placebo
224282231|NCT01557582|DEVICE|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
224282232|NCT02378441|DRUG|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
223532348|NCT05616442|DRUG|Ketotifen|Mast cell stabilizer
223532349|NCT05616442|DRUG|Vitamin E|Dietary supplement
223532350|NCT00153660|DRUG|Celecoxib(drug)|Celecoxib 100 mg bd
223927333|NCT06768359|PROCEDURE|Manual acupuncture and standard therapy|"Manual acupuncture is acupuncture needle insertion was done perpendicularly to the acupuncture points GV20, EXHN3, HT7, and PC6 using Huanqiu needle measuring 0.25 x 25mm with mild stimulation rotation technique at a speed of 60x/minute and needle retention for 30 minutes. Therapy was performed every day for 6 days.~Standard therapy is anxiolytic drugs and supportive psychotherapy given to patients according to the decision of the psychiatrist treating the patient."
223927334|NCT06768359|PROCEDURE|Sham acupuncture and standard therapy|"Sham acupuncture is when acupuncture needles are inserted into acupuncture points, but do not actually penetrate the skin, only attached to the plaster. Therapy was performed every day for 6 days.~Standard therapy is anxiolytic drugs and supportive psychotherapy given to patients according to the decision of the psychiatrist treating the patient."
223927335|NCT06768801|BEHAVIORAL|WPAPP-Latina|The WPAPP Latina intervention provides 1) educational information via modules and online resources and 2) coaching via an online forum with a chat function. The educational modules include 11 modules on physical activity promotion and 7 modules on depressive symptoms. The women are also invited to share their experiences with culturally matched interventionists (e.g., Spanish speaking graduate research assistant with expertise in depressive symptoms and physical activity) and with peer participants using a de-identified name in the online chat forum. Participants will be directed to information about physical activity with age-appropriate guidelines from the Centers for Disease Control and Prevention.
223927336|NCT06781021|PROCEDURE|Tourniquet|In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
223927337|NCT06781021|PROCEDURE|TXA|In all cases the application of a pneumatic torniquet will be applied to the proximal thigh after induction of anesthesia but will not be inflated for the group receiving TXA.
223532351|NCT00153660|DRUG|Naproxen(drug)|Naproxen 500 mg bd
223532352|NCT02052973|OTHER|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
223532353|NCT05018364|DIAGNOSTIC_TEST|Serum erythropoietin level|Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
223532354|NCT03255616|OTHER|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
223532355|NCT03255616|OTHER|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
223532356|NCT03377660|OTHER|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
223927338|NCT06774911|OTHER|YUIT|Product with protein source from pea and rice.
223927339|NCT06774911|OTHER|P_PS|Product with protein source from soy protein.
223927340|NCT06781125|DRUG|JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion|"JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability .~Anti-PD-1 antibody:Dosage and administration according to the instructions."
223940961|NCT05986773|DRUG|Furosemide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
223940962|NCT05986773|DRUG|Metolazone|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
223940963|NCT05986773|DRUG|Acetazolamide|Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
223940964|NCT04069754|BEHAVIORAL|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
223940965|NCT04908358|OTHER|Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Stimulation of vagus nerve in the outer ear
223940966|NCT04908358|OTHER|Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions|Sham stimulation of vagus nerve in the outer ear
223940967|NCT05507151|PROCEDURE|Endoscopic Sleeve Gastroplasty|endoscopic suturing of the stomach
223940968|NCT06006117|DRUG|Mosunetuzumab + Lenalidomide|"* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)"
223927341|NCT06781684|PROCEDURE|ulna shaft fracture fixation in children by intramedullary k wire|"* In the 1st group The Antegrade intramedullary k wire with appropriate diameter according to the child ulna diameter is introduced from the olecranon of the fractured ulna,cross the fracture site after good reduction under C arm in the anterioposterior and lateral views and the wire continues until reaching before the distal ulna .~* In the 2nd group The Retrograde intramedullary k wire with appropriate diameter is introduced from the diatal end of the ulna and cross the fracture site after good reduction under C arm and continues until reaching before the olecranon."
223927342|NCT06781866|OTHER|Massage|A relaxation type of massage will be used as the main massage intervention in this study. This technique is designed to promote deep relaxation, reduce stress, and enhance overall well-being. It is characterized by the use of five primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage (long, gliding strokes), petrissage (kneading and squeezing), tapotement (rhythmic tapping), friction (deep, circular rubbing), and vibration or shaking movements (Table 1). In addition to these, the technique also incorporates rhythmic movements and deep light pressure to enhance relaxation and alleviate tension. It is designed to promote relaxation, increase blood circulation, relieve muscle tension, improve flexibility and promote relaxation and reduce pain. The total duration of the Relaxation massage is 45 minutes.
223927343|NCT06781866|OTHER|Sham (No Treatment)|The Sham massage (PLA) will be used as a control session, without applying the deeper techniques that characterize the Relaxation massage in order to eliminate the influence of the human touch sensation on the participant's skin. This massage consisted only of superficial oil application movements over the entire body, without any added pressure or deep muscle manipulation. Oil was used to facilitate smooth gliding, mimicking the sensation of a full massage, but without the intensity or techniques aimed at muscle tissue relaxation. The total duration of the sham massage is 45 minutes.
223927344|NCT06780540|OTHER|Operation Alert: Support prgram|"Substudy 1:~Testing of a newly developed psycho-education tool will occur across four partner hospitals and participating nonprofit organizations (NGOs). Victims of violence seeking care at these sites will receive immediate support, with the pilot study integrated into standard care practices. The psycho-education toolkit enhances the foundational care already provided. The tool supports healthcare providers in offering psycho-education about e.g. violence and (the effects) of trauma, ...~Substudy 2:~This pilot study evaluates the Operation Alert guidelines within the geriatrics departments of four hospitals. A geriatric assessment is standard care during admission to these departments. The pilot will be embedded into this existing practice to ensure alignment with routine care. Additional questions will be embedded in a geriatric assessment/intake focusing on older adults' well-being, relationships and social network, and potential life events (e.g. experiences of violence)."
223927345|NCT06780982|BEHAVIORAL|Balloon-Blowing exercise program|"he program begins with a one-on-one session on the first day of the research project and continues with home-based care through the LINE application on a smartphone for 5 weeks. The program consists of four steps:~1. Decision-Making in Self-Care~2. Setting Goals and Planning Self-Care~3. Self-Care Implementation: practicing the balloon-blowing exercise daily for 3 sets of 3 balloons per set (a total of 9 balloons/day), with a 1-minute rest between sets, over a period of 5 weeks.~4. Maintaining Self-Care Behaviors"
223927346|NCT06780982|BEHAVIORAL|Standard nursing care|The actions of nurses towards school-age children with obstructive sleep apnea at the hospital involve screening patient records and distributing educational materials in the form of brochures to individual pediatric patients and their parents. The knowledge provided in the brochures includes instructions on how to administer inhaled medication, avoiding allergens, performing facial and neck muscle exercises, and attending follow-up appointments as scheduled.
223927347|NCT06780072|OTHER|Activation Massage therapy|"Massage Sessions~Activation (Sports) massage The activation (sports) type of massage will be used as one of the massage interventions. This technique will be performed on a full body with more attention given to specific leg muscle groups such as the feet, the gastrocnemius, the femoral biceps and quadriceps and in upper body muscle groups such as the triceps, the rhomboid, the deltoid, the trapezius and head areas. Briefly, this type of massage involves a wide range of techniques that include effleurage, palmar sliding, pounding and hacking. The total duration of the activation message will be 30 minutes."
223927348|NCT06780072|OTHER|Relaxation Massage Therapy|Relaxation massage The Relaxation type of massage will be used as the second type of intervention in this study. This technique is designed to promote deep relaxation, reduce stress and enhance overall well-being. It is characterized by the use of four primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage
223940969|NCT06006117|DRUG|- Rituximab + Lenalidomide (28-days cycles|"* Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12"
224282233|NCT02378441|DRUG|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
224282234|NCT06020482|OTHER|Molecular markes of fibrosis of single types of endometriosis and their use in predicting disease severity|The aim of the study is to analyze molecular markers of fibrosis in female patients with endometriosis vs. without endometriosis. These features will be compared for their clinical status and progression of the disease before and after treatment. Identification and validation of these features appears to be a crucial step in predicting progression of the disease. Moreover, we would be able to modify follow-up and treatment management in high-risk patients for endometriosis.
224282235|NCT03840382|BEHAVIORAL|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
224282236|NCT02843659|DRUG|BMS-931699|Specified dose on specified days
224282237|NCT02843659|DRUG|BMS-986142|Specified dose on specified days
224282238|NCT02843659|DRUG|Placebo|Specified dose on specified days
224282239|NCT02413294|DEVICE|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
224282240|NCT04854213|DEVICE|Stereotactic Body Radiation Therapy (SBRT)|Radiation treatment
223927349|NCT06782412|DIAGNOSTIC_TEST|[18F]AlF-FAPI-74 PET/CT|A \[18F\]AlF-FAPI-74 PET/CT will be performed at the same site of the screening visit (UZ Leuven, UZ Gent or UZ Antwerpen). Subjects are required to be sober four hours before the scan. The patient will get an IV line, through which the \[18F\]AlF-FAPI-74 will be injected in one bolus (3,5 MBq/kg). After 60 minutes, the acquisition on the PET/CT scan will take place. The CT will be a low dose CT with oral contrast. After the scan, participants will be observed at the department in case of adverse events. During this time, the participant can fill in the PRO. The estimated duration of this visit is three hours. If the patient receives neo-adjuvant therapy, a second \[18F\]AlF-FAPI-74 PET/CT will be performed maximum one month before surgery. If the planned surgery gets postponed after the second \[18F\]AlF-FAPI-74 PET/CT has been performed, we will have the possibility to perform one additional (i.e. third) \[18F\]AlF-FAPI-74 PET/CT, before the final surgery.
223927350|NCT06770010|BEHAVIORAL|Cogmed+|"Cogmed is a home-based, digital working memory training program compatible with tablet devices. The program, designed for children ages 7 and older, consists of engaging cognitive exercises that target skills involving visuospatial and verbal working memory. An essential component of Cogmed training involves assignment of an intervention coach who has access to detailed data on the user's training data. Families will have videoconference meetings once per week with an intervention coach to review progress, provide feedback and answer any questions that arise during treatment. In addition, participants' coaching calls will be supplemented with direct instruction on the use of memory strategies. Social support interventions will also be provided involving three primary approaches: (1) multi-family Cogmed Kickoff social events; (2) social incentives; and (3) peer navigator support."
223927351|NCT06771531|DEVICE|transcranial direct current stimulation|tDCS can safely and selectively modulate cortical excitability (specifically neuronal firing likelihood) by transferring weak electrical currents between scalp electrodes. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA in this study.
223927352|NCT06771531|DEVICE|active sham stimulation|sham stimulation will implement the same protocol of the tDCS intervention; however, only very low-level currents (no more than 0.5 mA) are transferred between the same electrodes used for the tDCS throughout the 20-minute session. This strategy effectively mimics the cutaneous sensations and skin redness induced by creating only micro cortical electric fields.
223927353|NCT02355639|DRUG|Clobetasol propionate 0.05 % ointment|
223927354|NCT02355639|DRUG|Betamethasone dipropionate 0.064 % ointment|
223927355|NCT02355639|DRUG|Petrolatum ointment|
223927356|NCT06777134|OTHER|Assessment of pelvic floor dysfunction|Pelvic floor dysfunctions in patients with multiple sclerosis will be assessed using the Pelvic Floor Distress Inventory-20 (PFDI-20). The scale is designed to assess all symptoms related to pelvic floor disorders and the severity of the distress they cause. The PFDI-20 consists of 3 subscales and 20 items, with each item rated on a scale from 0 (none) to 4 (quite a bit). To determine the scale scores, the average of the responses for each item in the subscales is multiplied by 25, resulting in a subscale score ranging from 0 to 100, and a total score ranging from 0 to 300. The Turkish validity and reliability of the scale were conducted by Çelenay et al.
223927357|NCT06777134|OTHER|The Quality of Life Assessment|The quality of life of the patients will be assessed using the Multiple Sclerosis International Quality of Life Questionnaire. The questionnaire consists of 31 questions and 9 subscales. The lowest score that can be obtained from the scale is 0, the highest score is 124, and a high score indicates a low quality of life. The subscales of the questionnaire include daily living activities, psychological well-being, relationships with friends, symptoms, relationships with family, relationships with the healthcare system, emotional and sexual life, coping, and rejection. The Turkish validation of the questionnaire has been conducted.
223927358|NCT06777134|OTHER|Core endurance assessment|"Core endurance in patients will be assessed using McGill's core endurance tests Trunk Flexor Test: Patients sit at a 60° trunk angle with knees bent, arms crossed, and feet stabilized. Time holding the position is recorded.~Trunk Extensor Test: Patients lie prone with the pelvis stabilized, lift the upper body above table level, and hold. Time is recorded until the body drops.~Lateral Trunk Test: In a modified side plank (knees bent, elbow support), patients lift hips off the mat. Time is recorded until hips lower or extra support is needed."
223940970|NCT06006117|DRUG|- Rituximab + Bendamustine (28-days cycles)|"* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6."
223532357|NCT01259011|BEHAVIORAL|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
223532358|NCT01911260|DIETARY_SUPPLEMENT|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
223532359|NCT01911260|OTHER|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
223532360|NCT06561139|BEHAVIORAL|Mindfulness|Weekly group sessions of mindfulness, for eight weeks
223532361|NCT02157428|DRUG|Flumazenil|
223532362|NCT02157428|DRUG|saline|
223927359|NCT06777134|OTHER|Hip strength assessment|The assessment of hip strength will specifically focus on the hip adductor and hip external rotator muscle strength. Both muscle groups are considered to be associated with the pelvic floor. Among the hip external rotators, the piriformis muscle functions as an internal stabilizer for the hip joint, while the obturator internus muscle shares fascial connections with the pelvic floor, playing a significant role in pelvic floor function. MR and EMG studies have demonstrated that the levator ani and gluteus maximus muscles are morphologically and functionally connected, and that the contraction of hip adductor and gluteal muscles facilitates the synergistic contraction of pelvic floor muscles. Based on this information, a handheld dynamometer will be used to measure the strength of the two muscle groups planned for evaluation. Measurements will be performed three times, and the average value will be recorded.
223927360|NCT06777134|OTHER|Tibialis posterior muscle activation|"The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the posterior tibialis muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned at the exact midpoint between the tibial tuberosity and the medial malleolus (32,33); the passive electrode will be placed 4 cm distal; and the reference electrode will be placed on the lateral malleolus.~The patient will be asked to perform isometric plantar flexion + inversion movement of the ankle against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage."
223927361|NCT06777134|OTHER|Tibialis anterior muscle activation|"The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the tibialis anterior muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned on the muscle body of the tibialis anterior, the passive electrode will be placed 4 cm distal, and the reference electrode will be placed on the lateral malleolus (34,35).~The patient will be asked to perform isometric ankle dorsiflexion against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage."
223927362|NCT06787391|PROCEDURE|Neurotization of Spinal Accessory Nerve To Supra-Scapular in children with OBPP with deficiency of Shoulder External Rotation|Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve in children with OBPP presented with deficiency of Shoulder External Rotation.
223927363|NCT06787391|PROCEDURE|Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve|Just to assess clinical outcomes after Neurotization of spinal accessory nerve to Supra-Scapular Nerve in patients with deficiency of Shoulder External Rotation
223927364|NCT06774976|OTHER|8-week Evidence-Based Neck Resistance Training Program|See arm/group description.
223927365|NCT06860893|DRUG|Spinal Anesthesia with Bupivacaine|After obtaining return of cerebrospinal fluid, hyperbaric bupivacaine 5 mg/mL 1,5 mL (7,5 mg) and morphine 200 µg/mL, 0.5 mL (100 µg) was injected intrathecally.
223927366|NCT06860893|DRUG|Placebo|Local skin infiltration with lidocaine
223927367|NCT06861387|DEVICE|Cryotherapy|AtriCure's cryoICE cryoSPHERE probe will be inserted through one of the incisions used for VATS/RATS. Cryo-analgesia will be performed unilaterally on the intercostal nerve at the level Th3-Th7. Thus, cryo-analgesia will be applied on 5 intercostal levels. The probe will be placed at the inferior aspect of the ribs, posterior to the mid-axillary line, directly on the neurovascular bundle. One freezing cycle takes approximately 2 minutes and a temperature of between minus 50 and 70 degrees Celsius will be applied.
223927368|NCT06861387|DRUG|PAiN - multimodal analgesia|Our standard postoperative pain management plan consists of intercostal nerve block, patient controlled analgesia and acetaminophen
223532363|NCT06172140|DRUG|Ciprofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
223927369|NCT06862336|PROCEDURE|intra-dialytic exercise program associated with medical treatment|"* Stretch for pectorals and calf muscles: Two sets - 3 times/ set.~* Breathing exercises associated with upper limb movement.~* Resistive exercise for hip abductors, hip flexors, and calf muscles by using theraband.~* Sit to stand strengthening exercises: -"
223927370|NCT06862336|PROCEDURE|inter-dialytic combined exercise program with their medications|receive the inter-dialytic combined exercise program with their medications. Like the study group except for diaphragmatic breathing instead of breathing with upper limb exercise.
223927371|NCT06887166|PROCEDURE|Platelet Rich Plasma|injection of PRP IN PERIANAL WOUNDS AFTER FISTULOTOMY OPERATIONS
223927372|NCT06886763|OTHER|Liver innervation markers|Liver innervation markers will be quantified immediately after resection by transparisation technique.
223927373|NCT06884098|DRUG|AD-228B|AD-228B, 1Tab., Per Oral
223927374|NCT06884098|DRUG|AD-2284|AD-2284, 1Tab., Per Oral
223927375|NCT06740552|DRUG|Evolocumab|Evolocumab 140mg every two weeks
223927376|NCT06740552|DRUG|Lipid Lowering Medication|Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
223927377|NCT06737497|PROCEDURE|retrograde Intrarenal Surgery ( RIRS ) under local anesthesia|retrograde Intrarenal Surgery ( RIRS ) under local anesthesia
223927378|NCT06892054|DRUG|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|A minimum of 6 and a maximum of 15 patients will be enrolled to receive first-line chemotherapy (gem/nab-P or mFOLFIRINOX) in combination with sotorasib 960 mg daily (QD). The treatment with gem/nab-P and mFOLFIRINOX should be managed as per clinical practice.
223927379|NCT06746220|OTHER|Microbiota sample|Microbiota sample: one sample at inclusion and one sample at the end of the study
223927380|NCT06746220|OTHER|Salivary sample|Salivary sample: one sample at inclusion and one sample at the end of the study. In the morning, on an empty stomach.
223927381|NCT06746220|OTHER|Quality of life questionnaires|Quality of life questionnaires: 5 auto-questionnaires to be filled at inclusion and at the end of the study
223927382|NCT06746220|OTHER|Nutritional evaluation|Nutritional evaluation: food diary completed by participants for 3 consecutive days at inclusion and at the end of the study
223927383|NCT06746220|OTHER|Assessment of physical health|Assessment of physical health : 3 tests to assess strength and endurance. These tests will be performed at inclusion and at the end of the study.
223927384|NCT06746220|OTHER|Physical activity|Physical activity: 2 sessions per week for 6 weeks. For each session, 45 minutes of physical activity consisting of muscle strengthening and endurance exercises.
223927385|NCT06746220|OTHER|Treatment with placebo or probiotic|Treatment with placebo or probiotic: 1 capsule per day during 42 consecutive days. In the morning, on an empty stomach with a large glass of water 20 minutes before the meal
223927386|NCT06747429|OTHER|High fat diet|Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).
224282241|NCT02495532|OTHER|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
224282242|NCT02495532|OTHER|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
224282243|NCT01039454|DRUG|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
224282244|NCT01039454|DRUG|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
224282245|NCT01598545|DRUG|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
224282246|NCT06893562|BEHAVIORAL|Safe Hands and Safe Bladder intervention|Evaluating changes in urinary tract infections and bladder distension nine-year after implementing preventive measures
223927387|NCT06747429|OTHER|Standard diet|Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.
223927388|NCT06888141|BEHAVIORAL|Virtual Sequential Emotional Processing Task|A 20-minute interactive session delivered 3 times over a one week period.
223927389|NCT06888141|BEHAVIORAL|Virtual Control Task|A time-matched (ie., 20 minute) interactive session delivered 3 times over a one week period.
223927390|NCT04121676|DRUG|AGEN2373|An Anti-CD137 Monoclonal Antibody
223927391|NCT04121676|DRUG|Botensilimab|Anti-CTLA-4 Monoclonal Antibody
224282247|NCT01947686|DEVICE|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
224282248|NCT00475917|DRUG|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
224282249|NCT00475917|DRUG|Gemcitabine|once-weekly 30-minute IV infusion
223927392|NCT06755502|COMBINATION_PRODUCT|Garlic oil|garlic oil mixed with zinc oxid powder, as root canal filling material
223927393|NCT06755502|DRUG|Calcium Hydroxide, Iodoform, paste|Metapex as root canal filling materials
223927394|NCT06762327|DRUG|Ensartinib|ensartinib 225mg ,PO,QD,until disease progression or intolerable toxicity
223927395|NCT06755073|RADIATION|Pulmonary artery Doppler ultrasound|Doppler ultrasound of fetal pulmonary artery
223927396|NCT06840249|PROCEDURE|surgery|surgery by graft or repair or thrombectomy and completion angiography
223927397|NCT06875232|PROCEDURE|Living liver donors|Adults who are screened for living liver donation.
223940971|NCT06006117|DRUG|- Rituximab + CHOP (21-days cycles)|"* CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)"
223940972|NCT06448624|DRUG|Ampicillin sulbactam 3 days|Ampicillin sulbactam 1.5 gram IV BID for 3 days after CIED implantation
223927398|NCT06832748|OTHER|VR neck training|VR intervention 8 weeks. A VR headset is used for assessment and training of sensorimotor functions of the neck. The VR headset has a built-in sensor which can measure movements and give objective test and training results. The results serve as a guide for tailored home-based training programs, also performed with the VR headset in the experimental group. The participant performs the training at home, 15-20 minutes/day 5 days/week, initiallay divided into 3 sessions of 5 minutes each, while progression may lead to longer but fewer sessions. The program is individually tailored to target specific sensorimotor disturbances, and progressed during the intervention to increase the challenge. Participants will have video consultations with their physiotherapist once a week for the first 4 weeks, and every second week for the final 4 weeks. This can be adjusted to fit the participants needs. The VR is a novel technology, and this particular VR based training is not yet evaluated in research.
223927399|NCT06832748|OTHER|Endurance neck training|An 8-week traditional endurance neck training intervention. The training program consists of neck and shoulder exercises performed with body weight, rubber bands, and free weights. The training is carried out at home, 15-20 minutes per day, 5 days a week. The training is individualized and progressed during the intervention. Participants will have video consultations with their physiotherapist once a week for the first 4 weeks, and then every second week for the final 4 weeks. This can be adjusted to fit the participants needs. This intervention is often used in the clinic and has been evaluated in several research studies with good results to reduce neck pain. However, its effects on sensorimotor functions have been less evaluated. Also, its effects compared to novel VR-training still needs to be evaluated.
223927400|NCT06798103|PROCEDURE|Erector Spinae Plane Block|Erector spinae plane block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved to a parasagittal plane to visualize skin and subcutaneous tissue layers, trapezius muscle, and lastly the erector spinae muscle just superficial to the transverse processes. The in-plane technique will be used, and the tip of the needle will be inserted in the fascial plane deep to the erector spinae muscle. After 2-3 mL of normal saline injection for hydro dissection to verify the correct needle tip placement, 30 mL of 0.25% bupivacaine will be injected deep to the erector spinae muscle. The same technique will be repeated on the contralateral side.
223927401|NCT06798103|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block will be performed using an ultrasound machine with a high frequency linear probe. The patients will be in sitting position to perform the block, the skin is sterilized and the transducer will be placed across the T7 spinous process then move laterally to identify transverse process of T7. Thereafter, the probe will be moved 3-5 cm laterally to identify the paravertebral space as the target injection site. After probe being rotated into transverse orientation, the needle will be inserted using the out-plane technique. Once the needle threads the internal intercostal membrane and arrives in the paravertebral space, 3 ml of normal saline will be injected firstly. If displacement sign of the pleura occurs, 25 ml of 0.25% bupivacaine will be then injected into the confirmed paravertebral space. The same technique will be repeated on the contralateral side.
223927402|NCT05035563|BEHAVIORAL|Intervention. Early and integral communication strategy (EICS)|"This intervention will be implemented in patients since they are hospitalized in the ICU where is expected:~* Facilitate contact and communication between patients, families and the health team.~* Respond to the communication needs of family members.~* Reduce equipment overload and facilitate communication with families and patients, providing tools and timely support.~* Build a positive and trusting relationship of relatives and patients with health teams.~The intervention considers the following actions:~1. \- Training in communication to the health team~2. \- Written material~3. \- Family website~4. \- Standardized and daily telephone information~5. \- Health Team Support Strategy~6. \- Weekly multidisciplinary virtual meeting with the family~7. \- ICU diaries for family members"
223927403|NCT04233853|BEHAVIORAL|CoLiPri intervention|General practitioners and their screened patients have access to the consultation-liaison services for a total duration of 12 months, including standard screening, expert consultations, on demand patient referral for structured mental health diagnostics, psychoeducation and treatment planning, as well as brief psychotherapeutic intervention and triage.
223927404|NCT04233853|OTHER|Usual primary care enhanced|Usual primary care practice as offered in routine care. Enhanced means that practitioners receive a basic training which consists of guideline-based structured screening procedures for depression and anxiety mental disorders in primary care.
223927405|NCT05407038|OTHER|Exercise Counseling|Receive call from health coach
223927406|NCT05407038|OTHER|Exercise Intervention|Undergo routine exercise
223927407|NCT05407038|OTHER|Internet-Based Intervention|Receive Android tablet
223927408|NCT05407038|OTHER|Interview|Complete a qualitative interview
223927409|NCT05407038|OTHER|Medical Device Usage and Evaluation|Wear Garmin Vivofit and Nonin 3150 WristOx2 pulse oximeter
223927410|NCT05407038|OTHER|Questionnaire Administration|Ancillary studies
223927411|NCT02544529|DRUG|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
224282250|NCT06760273|OTHER|No Intervention: Observational Cohort|Observational study, no additional intervention
224282251|NCT06768099|OTHER|Linear Cognitive Aid|"Key features of this tool include:~* Minimal input: Teams input the patient's age and clinical scenario (e.g. arrest, childbirth, or trauma).~* Linear logic: Based on initial simple input, the tool provides straightforward guidance without requiring multiple Y/N input or advanced decision-making.~* Guidance based on individual characteristics: The tool tailors AHA guidance for the specific emergency scenario to the individual patient's size (estimated by age), emphasizing key interventions for the individual scenario and giving appropriate size-based guidance regarding choice of equipment, medication dosage, and resuscitation technique (e.g., chest compression depth).~* Time-based and on-demand guidance: Based on the time elapsed from the start of the resuscitation, the app will provide audio guidance regarding the next key steps."
224282252|NCT01077505|BIOLOGICAL|albiglutide|albiglutide 50mg weekly subcutaneous injection
224282253|NCT01077505|DRUG|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
224282254|NCT01195116|DRUG|Dexmedetomidine|1 mcg/kg/hour
224282255|NCT01195116|DRUG|Normal Saline|1mcg/kg/hr
224282256|NCT02040961|DEVICE|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
224282257|NCT00406016|DRUG|ATI355|
223532364|NCT06172140|DRUG|Propofol group|All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of propofol, followed by intravenous injection of propofol (2 mg/kg) for 30 seconds. When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
223532365|NCT05010473|BEHAVIORAL|Speech and non-speech sound stimulation|Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
223532366|NCT02464982|PROCEDURE|Tattoo|tattoo device with EC standards, and sterile single-use only needle
223532367|NCT01923922|RADIATION|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
223532368|NCT02807701|PROCEDURE|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~1. dissection~2. reconstruction"
223532369|NCT02807701|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
223532370|NCT06033534|DEVICE|STIMULAN|"Procedures:~Surgical repair of the open fracture, as per standard-of-care guidelines. Insertion of the STIMULAN device at the site of the fracture. Standard post-operative care, including monitoring of inflammatory markers and clinical signs of infection."
223532371|NCT00002217|DRUG|Lamivudine/Zidovudine|
223927412|NCT02544529|DRUG|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
223532372|NCT00002217|DRUG|Abacavir sulfate|
223532373|NCT00002217|DRUG|Amprenavir|
223532374|NCT02740465|BEHAVIORAL|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
223532375|NCT02740465|BEHAVIORAL|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
223532376|NCT04395547|DIETARY_SUPPLEMENT|JointAlive™|Combination herbal extract
223717856|NCT03958851|DIAGNOSTIC_TEST|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
223927413|NCT06780228|BEHAVIORAL|chatbot-assisted clinical learning|The participants will recevie a self-developed web-based chatbot platform which is accessible via smartphones. It provides real-time dialogue with the chatbot through texts, visual aids, and audio files. The intervention will be available throughout the 12-week study. the chatbot is characterized by a gender-neutral persona, assumes the role of a friendly and empathetic clinical mentor. Its communication style can be described as calm, tolerant, supportive, and appreciative. Participants will receive weekly SMS notifications to remind them to consult with the chatbot.
223927414|NCT05849727|DRUG|TQH3821 tablets 200 mg|TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
223927415|NCT05849727|DRUG|TQH3821 tablets matching placebo|TQH3821 tablets matching placebo without active substance.
223927416|NCT06821490|PROCEDURE|Targeted axillary dissection and subsequently a lymphadenectomy|Selective sentinel lymph node biopsy is performed, along with biopsy of the node marked at diagnosis. Subsequently, a lymphadenectomy is performed, with the three samples separated for pathological study during the same surgical procedure
223940973|NCT06448624|DRUG|Placebo 3 days|Placebo for 3 days after CIED implantation
224282258|NCT03765190|COMBINATION_PRODUCT|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
224282259|NCT00067132|PROCEDURE|Juven (nutritional), HMB (nutritional)|
224282260|NCT06899438|DRUG|Botulinum Toxin A Injection|
224282261|NCT06899438|DRUG|Prilocaine HCl % 2 injectable solution|
224282262|NCT06903962|BEHAVIORAL|Mind-Body Intervention|The mind-body intervention will include regular approximate 2 hour educational sessions and didactics learning mind body techniques. The sessions will be twice per week for the first 4 weeks and then subsequently once per week for a total of 13 weeks.
224282263|NCT01322334|BEHAVIORAL|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
223940974|NCT04986930|RADIATION|SBRT+mFOLFIRINOX|Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
223532377|NCT04395547|DIETARY_SUPPLEMENT|Placebo|Combination placebo product
223927417|NCT05754983|DRUG|Solid tumor patients receiving immunotherapy for the first time were included in the study|Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
223927418|NCT05081102|DRUG|FDC of oxycodone 5 mg/ibuprofen 400 mg|receive one (1) experimental drug tablet (FCD of oxycodone 5mg/ibuprofen 400mg) + one (1) Tylex® placebo.
223927419|NCT05081102|DRUG|Tylex|receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
223927420|NCT06891105|DIETARY_SUPPLEMENT|Lactogemikan (Probiotic Supplement)|This intervention involves daily supplementation of Lactogemikan from Pescado Company, which contains Lactobacillus plantarum, a well-known probiotic strain. The probiotic is intended to improve gut microbiota balance, which may lead to improved nutritional status and health outcomes in hemodialysis patients. The dosage is one tablet daily for a duration of six months.
223927421|NCT06891105|DIETARY_SUPPLEMENT|Lactogemikan + Prebiotic Fiber (Synbiotic Supplement)|This intervention involves daily supplementation of Lactogemikan (containing Lactobacillus plantarum) combined with prebiotic fibers from oat (3g per day). The synbiotic is designed to provide the benefits of both probiotics (to balance gut microbiota) and prebiotics (to support the growth of beneficial bacteria). This intervention is intended to improve the nutritional status of hemodialysis patients over a 6-month period. The dosage is one tablet daily, combined with 3g of oat fiber.
223927422|NCT06752369|BEHAVIORAL|T1D-specific depression SSI|The T1D-specific depression SSI will include 1) psychoeducation about depression, including how behavior shapes feelings and thoughts, 2) a values assessment, where youth will identify key areas (i.e., family relationships, friendships, school, or hobbies) from which they draw (or once drew) enjoyment and meaning, and 3) the creation of an activity action plan, wherein youth identify (from pre-generated lists) and personalize (in guided exercises) three activities to target for change.
223927423|NCT06752369|BEHAVIORAL|T1D Educational|T1D Educational Material
223927424|NCT06799988|BEHAVIORAL|Digitally Delivered Lifestyle Performance Medicine intervention|Participating is realized by downloading the application to their phone with the privacy statement for participation in the study must be read and accepted before use can begin. Application can be removed at any stage. Intervention protocol and implementation responsibility is in the University of Helsinki and digital coaching tools is provided by the Metabite Ltd. Digital tool in the intervention is Metabite (https://www.metabite.com/) with specified version designed with the Finnish Defense Force. All content within the application is based on scientific evidence and has been reviewed for relevance and applicability to the Finnish context by local healthcare professionals
223927425|NCT06796842|OTHER|Ballistic Exercises|Ballistic training program was set for 6 weeks. Each week consisting of 5 exercises with sets of 3 and repetitions of 10,15 and 20 times, recovery time and training intensity differed each week.
223927426|NCT06796842|OTHER|Plyometric exercises|Plyometric training program was set for 6 weeks. With four exercises in 1st week. Five in 2nd and 3rd weeks, six exercises in 4th and seven exercises in last two weeks. Each exercise consisted of 3 sets with 10, 15 and 20 repetitions in each. Recovery time and training intensity differed each week.
224282264|NCT06904131|DRUG|Cell therapy with bispecific antibodies|"The dose-escalation phase is designed with three predefined dose levels, following a 3+3 design and progressing from low to high doses. The 3+3 dose-escalation scheme is as follows: if no dose-limiting toxicity (DLT) occurs in the three subjects at a given dose level during the observation period, the dose will be escalated to the next higher level. If one subject out of the initial three experiences DLT at a dose level, an additional three subjects will be enrolled at that dose level for further DLT observation. The dose level at which no more than one subject out of the final six subjects experiences DLT will be defined as the maximum tolerated dose (MTD)."
224282265|NCT06905678|OTHER|Questionnaires|The participants will fin in questionnaires about the financial and emotional burden they experience.
224282266|NCT06905678|OTHER|Semi-structured interviews|After the participants have filled in the questionnaires they will get the chance to participate in an interview to talk about their perceptions and experiences.
224282267|NCT06904911|DRUG|intra-arterial tenecteplase administration|Patients will receive a single dose of tenecteplase, administered intra-arterially after successful large vessel recanalization. The treatment will be administered via intra-arterial catheter in the distal M1 segment of the middle cerebral artery (distal to lenticulostriates).
224282268|NCT06903689|DRUG|Pentoxifylline 400 MG Oral Tablet|Oral tablet, 400 mg, administered twice daily with food for 6 months. To be taken in addition to conventional medications for chronic kidney disease.
224282269|NCT06903689|OTHER|Conventional Medications for Chronic Kidney Disease|This arm receives conventional medical management for chronic kidney disease (CKD). This includes medications and treatments as deemed necessary and appropriate by the participant's treating physician, according to established clinical guidelines for CKD. These may include, but are not limited to, medications for blood pressure control, management of diabetes, anemia treatment, mineral and bone disorder management, and fluid and electrolyte balance management. The specific medications and treatments are individualized and not dictated by the study protocol, but follow standard clinical practice for CKD.
223532378|NCT06005402|BIOLOGICAL|CSX-1004|Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs
223532379|NCT06005402|BIOLOGICAL|Placebo|Sterile saline for injection
223532380|NCT05583955|DRUG|NOE-105|Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
223532381|NCT05583955|DRUG|Placebo|Escalating dose levels of matching Placebo will be given
223532382|NCT01960491|DEVICE|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
223532383|NCT01772940|DRUG|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
223532384|NCT01772940|DRUG|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
223532385|NCT01772940|DRUG|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
223927427|NCT06883929|DEVICE|virtual reality glasses|"Animation video application with virtual glasses by the researcher himself was applied. The application was performed in a quiet environment in the patient's room, in a sitting area where the child was comfortable.~position and wearing virtual goggles over his eyes."
223927428|NCT06883929|DEVICE|virtual reality goggles|vr 360 degree screen viewing
223927429|NCT06118034|DRUG|Colchicine 0.5 MG|Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
223927430|NCT06118034|DRUG|Placebo|Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
224282270|NCT06904690|OTHER|Educational training|"The educational training is divided into the following five modules:~Module 1: Raising Awareness of eHealth and Health Literacy (Introduction to the aims and context of JACARDI and diabetes);~Module 2: Acquiring New Knowledge (Health Literacy and Self-Management of Diabetes);~Module 3: Acquiring New Knowledge (Technological and Non-Technological Strategies to Support the Self-Management of Diabetes);~Module 4: Practicing New Skills (Usability with Practice Sessions);~Module 5: Self-Evaluation and Sustainability of Improvement (Final Questionnaire).~The training will be conducted over 10 weeks (one session every other week), with each session lasting an average of 90 minutes."
223532386|NCT01772940|DRUG|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
224282271|NCT06904703|DRUG|General anesthesia|Patients will receive general anesthesia.
223532387|NCT01951391|OTHER|Control Hand Soap|Commercially available soap will be used to wash the subject's forearms
223532388|NCT01951391|OTHER|Benzalkonium Chloride Soap|Commercially available soap containing benzalkonium chloride will be used to wash the subject's forearms
223532389|NCT01951391|OTHER|Triclocarban Soap|Commercially available soap containing triclocarban will be used to wash the subject's forearms
223532390|NCT02643485|PROCEDURE|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
223532391|NCT05181488|RADIATION|intraoperative radiotherapy, IORT|A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
223532392|NCT03849261|DRUG|CKD-387|Test drug
223532393|NCT03849261|DRUG|D635|Reference drug
223532394|NCT05895994|DRUG|RD13-02 cell infusion|CAR-T cells
223532395|NCT00305396|DRUG|Sirolimus|
223532396|NCT00048984|OTHER|laboratory biomarker analysis|Correlative studies
223927431|NCT06760442|PROCEDURE|Subcrestal implant placement|Delayed implant placement 2 mm subcrestally in missing mandibular posterior site.
223927432|NCT06760442|PROCEDURE|Crestal implant placement|Delayed implant placement equicrestally in missing mandibular posterior site.
223927433|NCT06777173|DRUG|Peg interferon alfa-2b|NA combined with Peg interferon alfa-2b
223927434|NCT06843278|OTHER|maternal breast milk|Very preterm infants receiving maternal breast milk
223927435|NCT06843278|OTHER|Donor breast milk|Very preterm infants receiving donor breast milk
223927436|NCT06844344|DIAGNOSTIC_TEST|forceps biopsies|5 forceps biopsies
223927437|NCT06844344|DIAGNOSTIC_TEST|Cryo biosies|5 cryo biopsies
224282272|NCT06904703|DRUG|Bupivacaine 0.5%|Patients will receive general anesthesia and erector spinae plane block.
223927438|NCT06779019|DIAGNOSTIC_TEST|LSCI|LSCI evaluates at 2 timings:immediately after the mastectomy (prior to immediate reconstruction) and again following reconstruction (after the skin was sutured). The perfusion score was calculated by normalizing these values against the perfusion value of a control.
223927439|NCT06779019|DIAGNOSTIC_TEST|ICG (Indocyanine Green)|Performed immediately after the mastectomy (prior to immediate reconstruction) .Perfusion scores were determined by comparing the fluorescence intensity of the target area to that of the non-surgical region on the contralateral chest wall.
223717857|NCT03958851|DIAGNOSTIC_TEST|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
223717858|NCT03958851|DIAGNOSTIC_TEST|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
223927440|NCT06745726|DRUG|Zestril|N/A, this is an observational study.
223927441|NCT06852196|PROCEDURE|orthognathic surgery ,lefort 1,bsso ,DO|Le Fort I osteotomy is often used in the correction of dental occlusion and maxillary hypoplasia in cleft patients. In addition, the osteotomy may also improve patients' facial appearance and self-esteem
223927442|NCT06852196|PROCEDURE|distraction osteogenesis|Distraction osteogenesis is a surgical technique that uses body's own repairing mechanisms for optimal reconstruction of the tissues.
223927443|NCT06810869|DRUG|human induced pluripotent stem cell derived exosomes （GD-iExo-003）|human induced pluripotent stem cell derived exosomes （GD-iExo-003）
223927444|NCT06810869|DRUG|a placebo of exosomes derived from human induced pluripotent stem cell for injection|a placebo of exosomes derived from human induced pluripotent stem cell for injection
223927445|NCT06820151|OTHER|Sample collection|Sample collection: EVT sponges, tissue brushings and pinch biopsies
223927446|NCT06790407|DIETARY_SUPPLEMENT|Mimio Study Product|Active ingredients in the Mimio study product include Nicotinamide 250mg, Ultra-Micronized Palmitoylethanolamide 600mg, Oleoylethanolamide 400mg, Spermidine 8mg; Other Ingredients: Hydroxypropyl-Methylcellulose (capsule), Silicon Dioxide, Magnesium Stearate.
223927447|NCT06790407|DIETARY_SUPPLEMENT|Placebo|Non-active study ingredients in the placebo include Micro Crystalline Cellulose 250mg, Hypromellose, Titanium Dioxide.
223927448|NCT06795932|DEVICE|Tendon Vibration|"Vibration can create kinesthetic illusions when applied at some modalities. The vibration will be put at 80 Hz and 1 mm of amplitude for 10 seconds to create 1 illusion/minute, during 20 minutes.~Two interventions per week, for three weeks. Total : 6 interventions"
223927449|NCT06795932|OTHER|Exercices|Standardized exercise protocol, performed daily for 3 weeks, with a diary.
223927450|NCT06795932|DEVICE|Tendon vibration|"Tendon vibration will not induce kinesthetic illusions, since it will be applied 40 Hz and 1 mm of amplitude for 10 seconds.~Two interventions per week, for three weeks. Total : 6 interventions"
223927451|NCT01643954|PROCEDURE|robotic radical prostatectomy|robotic assisted surgery
223927452|NCT06776653|OTHER|Tovertafel Pixie|The Tovertafel Pixie® projector has a distracting effect, which can help divert the patient's attention while waiting for or undergoing treatment.
223927453|NCT05725876|DRUG|Ustekinumab|Patients not on therapy and patients on therapy will undergo fluorescence molecular imaging.
223927454|NCT01225081|DRUG|ipragliflozin|oral
224282273|NCT06904703|DRUG|Bupivacaine 0.5%|Patients will receive general anesthesia and erector spinae plane block with pericapsular nerve block.
224282274|NCT06293326|DRUG|bi-layer calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
224282275|NCT06293326|DRUG|Immediate release calcium carbonate tablet (BAY1180654)|Singal dose; two tablets; administered 1-2 hours post standardized meal depending on day or night dosing.
224282276|NCT02910024|DEVICE|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
223927455|NCT01225081|DRUG|Placebo|oral
223927456|NCT01225081|DRUG|Pioglitazone|oral
223927457|NCT04990479|BIOLOGICAL|GAd-PEV|Priming phase including 1 GAd-PEV administration with Standard of Care pembrolizumab (cycle 4).
223927458|NCT04990479|BIOLOGICAL|MVA-PEV|Boosting phase including 3 boosting administrations of MVA-PEV with Standard of Care pembrolizumab (cycles 5, 6 and 7).
223927459|NCT06754514|DEVICE|liver retraction|A different way to lift the liver during bariatric surgery
223927460|NCT05789615|DRUG|Letermovir|Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
223927461|NCT06755242|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
223927462|NCT06768255|DRUG|Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT|Abiraterone Acetate（II）
223927463|NCT06768255|DRUG|Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT|Abiraterone acetate 1000 mg
223927464|NCT04478279|DRUG|ST101|ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm
223927465|NCT04478279|DRUG|Temozolomide|Temozolomide
223927466|NCT04478279|RADIATION|Radiation|Radiation
224282277|NCT02910024|DEVICE|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
224282278|NCT06271902|OTHER|Singapore Youth Shoulder Overuse Injury Prevention Program|A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
223927467|NCT06886399|DRUG|"AS-Probionorm"|"Phase II of the clinical trial of the medicine included 210 study subjects with identified clinical and/or microbiological signs of dysbiosis. 3 groups of 70 research subjects will be formed.~Group 1 - study subjects with an identified decrease in intestinal microflora activity; Group 2 - study subjects with an identified fungal (candidiasis) infection; Group 3 - study subjects with active pathogenic microflora.~Dosage regimen for first group - 1 sachet (1 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days. Dosage regimen for the second and third groups - 2 sachet (2 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days."
223927468|NCT06892782|OTHER|Hot Water Pack Application|A hot water pack heated to 40-42°C will be applied to the lumbar region of the patient for 20 minutes at three intervals per day during the first 48 hours post-surgery.
223927469|NCT06796751|GENETIC|DNA/RNA sequencing and bioinformatic data analysis|"DNA will be extracted from peripheral blood or from somatic tissues. In some cases a skin biopsy will be performed to obtain fibroblasts for further analysis (DNA/RNA extraction and preparation of cell culture for high-throughput genomic and epigenomic technique (Hi-C).~LRS will be performed on extracted DNA using Oxford Nanopore Technology by two different approaches:~* Target, in samples with monoallelic alterations in genes related to autosomal recessive disease;~* Genomic in other cases.~Sequencing data will be analyzed through a dedicated bioinformatics pipeline, to reconstruct the tridimensional structure of chromatin and the regions"
223927470|NCT06844097|BEHAVIORAL|Cervical Cancer Trans Inclusive Education (CC-TRAINED) Module|An online course designed to increase cervical cancer prevention clinical skills among medical students when working with Latinx transmasculine populations.
223927471|NCT06844097|BEHAVIORAL|Disaster Preparedness Course|An online course designed to improve professionals' skills and competencies for engaging in disaster preparedness.
223927472|NCT06845098|PROCEDURE|Total thyroidectomy|Total thyroidectomy
223927473|NCT06845098|PROCEDURE|Total thyroidectomy + RAIT|Total thyroidectomy + RAIT
223927474|NCT06845098|PROCEDURE|Thyroid one-sided lobe + isthmus resection|Thyroid one-sided lobe + isthmus resection
223927475|NCT05672017|BEHAVIORAL|Dietary Instructions|Dietary Instructions
223927476|NCT05362474|DRUG|Montelukast|10mg orally once a day
224282279|NCT06271902|OTHER|Lower body stretching program|A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
224282280|NCT00110695|DRUG|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. \[or if given with trastuzumab 75 mg/m2 IV over 15 min.\]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
224282281|NCT05054322|DRUG|Fluticasone Propionate|Fluticasone propionate added to usual care, total dose 1000 mcg per day for 14 days
223927477|NCT05921266|DIETARY_SUPPLEMENT|Urolithin A|Participants in the intervention group will receive 500 mg of urolithin A twice daily for 4 weeks (1,000 mg daily in total). The supplement will be administered in the form of softgels (4 softgels daily).
223927478|NCT05921266|OTHER|Placebo|Participants in the control group will receive 0 mg of urolithin A twice daily for 4 weeks. The placebo will be administered in the form of inactive capsules (4 capsules daily).
223927479|NCT06741423|OTHER|Radiomics Algortihm|A radiomics algorithm designed to distinguish retroperitoneal fibrosis from other retroperitoneal tumors and provide recommendations for clinical treatment decisions.
223940975|NCT04986930|DRUG|mFOLFIRINOX|mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
223940976|NCT04823624|DRUG|MBG453|intravenous infusion
223940977|NCT05395351|DRUG|rt-PA|Intravenous recombinant tissue plasminogen activator (IV rt-PA)
223940978|NCT05696821|DIAGNOSTIC_TEST|Educational intervention|The educational intervention includes a 3-months training program in the use of point-of-care ultrasound tailored to meet the educational needs of general practitioners. The training programs consists of three teaching seminars over a three month time period, a curriculum of 10 POCUS applications, and an online learning platform providing educational support before, during and after the teaching sessions.
223940979|NCT05295108|OTHER|Caring Connections|peer-based letter writing social connectedness intervention to improve social health outcomes
223940980|NCT05295108|OTHER|Attention control|informational materials provided to educate on life domains that are important to social health
223940981|NCT04931225|DRUG|Landiolol|Intravenous Landiolol injection (from 0.5 to 10 µg/kg/min during 12 hours) up to a 15% decrease in HR on microcirculatory vascular reactivity.
223940982|NCT05567016|OTHER|Active case detection using molecular testing (ACDm)|In the ACDm arm, children will receive ACD using RDT and qPCR 3x yearly with treatment using artemether-lumefantrine (AL) if RDT or qPCR positive. With fevers, participants will receive standard PCD using RDT.
223940983|NCT05567016|OTHER|Passive case detection using molecular testing (PCDm)|With fevers, participants will receive PCDm, in which qPCR will be done in RDT negatives with treatment using AL if positive.
223940984|NCT05567016|OTHER|Control (standard of care)|With fevers, participants will receive standard PCD using RDT with treatment using AL if positive.
223940985|NCT05707013|DEVICE|HP Arize 3D-Printed Orthotics|Custom 3D-printed orthotics manufactured by HP.
223940986|NCT05707013|DEVICE|Traditional Orthotics|Traditionally fabricated custom orthotics manufactured by a local supplier.
223940987|NCT06335511|PROCEDURE|microsurgical decompression|decompression of neurological structures
223940988|NCT06335511|PROCEDURE|decompression and instrumented fusion|decompression of neurological structures and spine stabilization
223940989|NCT05465941|PROCEDURE|Biopsy|Undergo biopsy
223940990|NCT05465941|DRUG|Pegylated SN-38 Conjugate PLX038|Given IV
223940991|NCT05465941|PROCEDURE|Computed Tomography|Undergo CT
223940992|NCT05465941|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
223927480|NCT06742450|OTHER|Constant current (CC) subthalamic nucleus deep brain stimulation|For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant current (CC) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant current (CC) mode will be maintained.
223927481|NCT06742450|OTHER|Constant voltage (CV) subthalamic nucleus deep brain stimulation|For subjects who have decided to undergo STN-DBS surgery and meet the inclusion criteria, the constant voltage (CV) mode is selected as the original electronic modality one week after surgery. Regardless of any changes in programming parameters over the following year, the constant voltage (CV) mode will be maintained.
223927482|NCT04678427|OTHER|6 Minute Walk Functional Test|Complete 6-minute walk test
224093892|NCT04194060|COMBINATION_PRODUCT|Conventional|"Tracheal intubation~* Short acting anesthetic agents, avoid opiod anesthesia agents.~* Omental patch repair along with sub hepatic drain placement.~* Post operative nausea and vomiting prophylaxis.~* Ambulation-as per patients' own request.~* Initiation of oral feed- after passage of 1st flatus.~* Nasogastric tube removal-output \<300ml/day with resolution of ileus.~* Removal of urinary catheter- when patient sits on bed side/ambulate.~* Removal of sub hepatic drain-when patient tolerates unrestricted amount of liquid diet and drain output is less than 200 ml /day.~* Patient will receive opiod analgesics."
224093893|NCT05332860|PROCEDURE|Congenital Cardiovascular Surgery|Relationship between perioperative and postoperative hemodynamics, laboratory, oxygenation parameters and demographic data with extubation times in pediatric cardiac surgery cases taken in our hospital.
224093894|NCT02768376|DRUG|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
224093895|NCT02768376|DRUG|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
224093896|NCT02947919|BEHAVIORAL|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
224093897|NCT02850302|OTHER|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
224093898|NCT02850302|OTHER|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
224093899|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
224093900|NCT01978704|OTHER|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
224282282|NCT04529876|DRUG|Tofacitinib|Tofacitinib claim is used as the reference group.
224093901|NCT01871506|BEHAVIORAL|Standard Care (SC)|"1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
224093902|NCT01871506|BEHAVIORAL|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
224093903|NCT01973257|PROCEDURE|imaging diagnostics|
224093904|NCT04627740|DRUG|Retroviral vector-transduced autologous T cells to express anti-ALPP CARs|Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
224093905|NCT00626873|DRUG|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
224282283|NCT04529876|DRUG|Abatacept|Abatacept claim is used as the exposure group.
224282284|NCT01877694|DRUG|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
224282285|NCT01877694|DRUG|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
224282286|NCT05829850|DEVICE|SYNOLIS VA 40/80|Three 2mL injections of SYNOLIS VA 40/80, one week apart
224282287|NCT01806610|DRUG|BPS804|Single dose BPS804 administration.
224282288|NCT01806610|DRUG|Placebo|Single dose placebo administration.
224282289|NCT03458143|DRUG|Ketamine 150 ng/ml|conscious sedation in TCI-mode
223927483|NCT04678427|BEHAVIORAL|Behavioral Intervention|Participate in walking and other activities
223927484|NCT04678427|OTHER|Survey Administration|Complete survey
223927485|NCT04678427|BEHAVIORAL|Timed Get Up and Go Test|Complete timed get up and go test
223927486|NCT06627855|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
223927487|NCT06627855|PROCEDURE|Sham treatment|The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
223927488|NCT05061719|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily
223927489|NCT06894303|DEVICE|Target CI v1.5 remote programming|Use of the remote programming function of Target CI v1.5 and the AB remote support application
224093906|NCT00626873|OTHER|medical chart review|
224093907|NCT06147024|OTHER|historical control|Received a conventional preoperative assessment
224093908|NCT06147024|OTHER|3D printed lesion model|Received 3D printed lesion models for preoperative planning
224282290|NCT03458143|DRUG|Remifentanil|conscious sedation in TCI-mode
224282291|NCT03458143|PROCEDURE|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
224282292|NCT03458143|DRUG|Ketamine 200 ng/ml|conscious sedation in TCI-mode
224282293|NCT04372719|DRUG|H3N2|
224282294|NCT00000302|DRUG|Buprenorphine|
224282295|NCT04755621|OTHER|Core stability training|Core stability exercises
224282296|NCT04755621|OTHER|Rocabado Exercises|Exercises for Temporomandibular Disorders
224282297|NCT05756738|DIAGNOSTIC_TEST|Dried blood spot testing|To evaluate the efficacy defined as the rate of diagnostic tests against hepatitis C virus (HCV) performed with a dried blood spot test
224282298|NCT02121041|DRUG|Amlodipine|Amlodipine 5 mg or 10 mg
224282299|NCT02121041|DRUG|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
224282300|NCT02121041|DRUG|Losartan|Losartan 50 mg or 100 mg
224282301|NCT02857387|BIOLOGICAL|blood sample withdrawn|
224282302|NCT05565261|DEVICE|complete denture|Bite force was measured with a bite force measuring device. Quality of life and patient satisfaction were evaluated with questionnaires.
224282303|NCT03477383|DIAGNOSTIC_TEST|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
223927490|NCT06781515|OTHER|Peripheral and BM blood sample|Peripheral and BM blood samples will be analyzed with the ddPCR method
224282304|NCT03868111|DRUG|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
223532397|NCT01938729|PROCEDURE|Liver resection and placement of hepatic artery infusion pump|
223927491|NCT06757855|DRUG|Olverembatinib|"induction therapy：40mg,QOD；~consolidation maintenance therapy: If patients with CMR are reduced to 30mg."
223927492|NCT06757855|DRUG|Venetoclax|"induction therapy：leverl 0: 100mg d-2; 200mg d-1; 400mg d1-14~leverl -1: 100mg d-2; 200mg d-1; 400mg d1-7~leverl 1: 100mg d-2; 200mg d-1; 400mg d1-21~consolidation maintenance therapy: 400mg d1-7"
223927493|NCT06757855|DRUG|Azacitidine|"induction therapy：75mg/m2/d, d1-7~consolidation maintenance therapy: 75mg/m2/d, d1-7"
224282305|NCT03868111|DRUG|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
224282306|NCT05672745|DEVICE|WB-LIFE|WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
224282307|NCT00813345|OTHER|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
224282308|NCT00813345|OTHER|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
224282309|NCT00865449|DRUG|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
224282310|NCT00865449|DRUG|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
224282311|NCT02939261|BEHAVIORAL|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
224282312|NCT02939261|BEHAVIORAL|Control|monthly emails with general health information
224282313|NCT04500132|DRUG|EC-18|EC-18 QD
224282314|NCT04500132|DRUG|Placebo EC-18|Placebo EC-18 QD
224282315|NCT06462365|BIOLOGICAL|TRX103|TRX103 infusion via central line.
224282316|NCT06291090|BEHAVIORAL|OUD treatment intervention|Participants received education on the diagnosis and management of OUD, have access to protocols to walk them through assessment of OUD using Diagnostic and Statistical Manual, fifth Edition (DSM)-5, COWS score to calculate severity of opioid withdrawal, buprenorphine or methadone initiation with pre-populated orders, and clickable links for OUD treatment referral post discharge.
224093909|NCT04339868|DRUG|Terlipressin|Terlipressin (20-100 mcg/hr) plus norepinephrine and/or epinephrine
224093910|NCT04339868|DRUG|Placebo|0.9% NaCl plus norepinephrine and/or epinephrine
224093911|NCT06368726|DEVICE|tDCS or Transcranial Direct Current Stimulation|We use weak currents applied over the child's scalp over 30 minutes twice a week during 100 days
224093912|NCT06368726|DRUG|Risperidone|Risperidone Risperidone according to child's weighs
224282317|NCT05933473|PROCEDURE|Percutaneous coronary intervention|percutaneous intervention to oseal LAD with or without LM stenting
224282318|NCT00088049|DRUG|Olanzapine|
224282319|NCT00088049|DRUG|Aripiprazole|
224282320|NCT02617641|BEHAVIORAL|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
223717859|NCT03958851|DIAGNOSTIC_TEST|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
223927494|NCT04959812|DRUG|Sufentanil|Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
223927495|NCT04959812|OTHER|Placebo|Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
223927496|NCT02650622|PROCEDURE|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
223927497|NCT05121051|PROCEDURE|Biospecimen Collection|Undergo collection of blood, buccal cell, and nasal epithelial cell samples
223927498|NCT05121051|DIETARY_SUPPLEMENT|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
223927499|NCT05121051|DRUG|Placebo Administration|Given PO
223927500|NCT05121051|OTHER|Questionnaire Administration|Ancillary studies
224093913|NCT01028352|DRUG|Duloxetine|"Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
224282321|NCT02617641|BEHAVIORAL|Publicly available websites|"* Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
224282322|NCT02915237|DIETARY_SUPPLEMENT|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
224282323|NCT02915237|DIETARY_SUPPLEMENT|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
223927501|NCT04720625|BEHAVIORAL|Adapt2Quit|Motivational text messages and quitline facilitation text messages will be sent to participants; these participants will receive Adapt2Quit (experimental) messages as well as quitline facilitation messages.
223927502|NCT04720625|BEHAVIORAL|Control|Quitline facilitation text messages will be sent to participants; these participants will receive quitline facilitation-only messages.
223927503|NCT03188835|DIETARY_SUPPLEMENT|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
223927504|NCT03188835|OTHER|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
223927505|NCT03188835|RADIATION|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
223927506|NCT03188835|RADIATION|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
223927507|NCT03188835|RADIATION|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of \[3-3H\]-glucose
224282324|NCT04904055|OTHER|Value-based Formulary|Prescription drug formulary tiers informed by estimated value
224282325|NCT02238132|DRUG|ATROVENT® inhalets|
224282326|NCT02192294|DRUG|Oral Bosutinib|a single dose of 500 mg oral bosutinib
224282327|NCT02192294|DRUG|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
224282328|NCT03561922|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
224282329|NCT02981316|BIOLOGICAL|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
224282330|NCT00137657|DRUG|Cotrimoxazole (trimethoprim sulfamethoxazole)|
224282331|NCT05195177|DRUG|Anti-histamine cream 1 hour|At the start of session 1, one area of the middle forearms of the participant will be located (4x4cm). On the area, anti-histamine cream will be applied for approximately 1 hour.
223717860|NCT03958851|DIAGNOSTIC_TEST|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
223927508|NCT03188835|OTHER|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of \[U-13C\]-palmitate
223927509|NCT03188835|OTHER|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
223927510|NCT03188835|DEVICE|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
223927511|NCT03188835|DEVICE|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
223927512|NCT03188835|DEVICE|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
223927513|NCT03188835|DEVICE|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
223940993|NCT06358755|DEVICE|Defocus Incorporated Multiple Segments lenses|Defocus Incorporated Multiple Segments lenses that provide optical defocus for myopia control will be given to this group of participants.
223940994|NCT06358755|DEVICE|single vision spectacle lenses|Single vision spectacle lenses will be given to this group of participants.
223940995|NCT06358755|DRUG|Low dose atropine|0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
223940996|NCT03945773|DRUG|Cabozantinib|Oral tablets of 60mg, 40mg and 20 mg.
224282332|NCT05195177|DRUG|Local anesthetic cream 1 hour|At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will be applied for approximately 1 hour.
224282333|NCT01118026|DRUG|ABVD|doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV
224282334|NCT01118026|DRUG|BEACOPP|bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
224282335|NCT01118026|RADIATION|radiation therapy|
224282336|NCT02809820|DRUG|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
223532398|NCT01938729|DRUG|FLOXURIDINE|
223532399|NCT01938729|DRUG|DEXAMETHASONE|
223532400|NCT01938729|DRUG|GEMCITABINE|
223532401|NCT02481557|DEVICE|Oxalate Salt Solution|Applied by dentist
223532402|NCT06490692|OTHER|Blood Flow Restriction Training|The affected limb will have a cuff placed proximally and inflated to occlude the blood flow by 40% attested using a golden standard vascular doppler after which the individuals will perform the strengthening program set forth by the physical therapist. This is preceded by other tennis elbow interventions such as ultrasound, stretching, and deep friction massage at the extensor origin.
223532403|NCT06490692|OTHER|Conventional Strength Training|The individuals in this group will undergo the same conventional physical therapy program as the other group including ultrasound, stretching, and deep friction massage. In addition, they will undergo the same strengthening program set forth by the physical therapist however with no blood flow restriction of any kind.
223532404|NCT00220662|BEHAVIORAL|Readiness and Motivation Therapy|
223532405|NCT05267782|DEVICE|Masimo's O3 Regional Oximetry|Correlation between new O3 regional oximetry monitoring, electroencephalography and somatosensory evoked potential in carotid endarterectomy and data collection during different stages of anaesthesia and correlation with new O3 regional oximetry
223532406|NCT02135484|DRUG|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
223532407|NCT03416894|DEVICE|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
223532408|NCT01239550|DRUG|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
223532409|NCT04271293|DRUG|Edoxaban|Edoxaban will be administered via PEG in patients who are eligible for the anticoagulant treatment according to the current guidelines.
223532410|NCT04462575|PROCEDURE|Onlay bone block covered using collagen membrane|The ratio is 40% of xenogenic bone particles (low resorption rate) to 60% of autogenous bone particles (contains viable cells) to be placed in recipient decorticated site and covered by onlay bone block..
223532411|NCT04462575|PROCEDURE|Onlay bone block without collagen membrane|Onlay bone block without collagen membrane
223532412|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
223532413|NCT01138514|DRUG|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
223532414|NCT01138514|DRUG|Placebo|Placebo
223532415|NCT05288192|DRUG|Suprachoroidal triamcinolone acetonide (SCTA) injection|Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.
223532416|NCT00458549|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
223532417|NCT00458549|PROCEDURE|biopsy|
223532418|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg twice daily
223532419|NCT01242514|DRUG|Fostamatinib|Fostamatinib 150mg once daily
223532420|NCT01242514|DRUG|Fostamatinib|Fostamatinib 100mg once daily
223532421|NCT01777477|DRUG|Chloroquine|Addition of Chloroquine to Gemcitabine
223532422|NCT01777477|DRUG|Gemcitabine|
223532423|NCT02351089|DIETARY_SUPPLEMENT|Capsules placebo|Capsules
223532424|NCT02351089|DIETARY_SUPPLEMENT|Capsules probiotic powder and corn starch|
223532425|NCT03746210|DIAGNOSTIC_TEST|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
223532426|NCT02985723|DEVICE|AT LISA tri toric 939MP|
223532427|NCT03861338|DRUG|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
223532428|NCT03112902|DEVICE|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
223532429|NCT02274571|DRUG|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
223532430|NCT02274571|OTHER|Placebo|non active
223532431|NCT03829111|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
223532432|NCT03829111|BIOLOGICAL|Ipilimumab|Given IV
223532433|NCT03829111|BIOLOGICAL|Nivolumab|Given IV
223532434|NCT04079738|DRUG|TAK-659|TAK-659
223532435|NCT04079738|DRUG|Ixazomib|Ixazomib
223532436|NCT02647671|DRUG|Aquamin®|90 days of Aquamin
223532437|NCT02647671|DRUG|Calcium Carbonate|90 days of Calcium Carbonate
223927514|NCT06762912|OTHER|Passive application of BFR cuff|The first experimental session will start by conducting the one repetition maximum (1-RM) test of unilateral knee extension of the dominant leg, in which the dominant side was identified by asking the participants which side they will use to kick a ball. Before conducting the 1-RM test, 5 minutes warm-up on the cycle ergometer at 75W will be done. Calibration of the dynamometer will be done before operating the machine with each participant, then the participant will be positioned on the dynamometer seat comfortably with ensuring the back is supported and the knee is aligned with the axis of rotation. The participant will be asked to complete one successful repetition of knee extension through full range of motion (ROM), with increasing load until the participant can no longer complete full knee extension ROM, 3 minutes of rest will be allowed between attempts until the 1-RM is identified.
223532438|NCT02647671|DRUG|Placebo|90 days of placebo
223532439|NCT04416958|DEVICE|cardiac implantable electronic device (CIED) implantation|CIED Implantation according to the Guidelines aiming to avoid pacing induced dyssynchrony
223927515|NCT06762912|OTHER|Resistance exercise with BFR|"For both experimental sessions 2 and 3, the order of exercise condition will be randomly selected, either to be (1) the application of BFR cuff with resistance exercise, or (2) resistance exercise without the application of BFR cuff to decrease the incidence of learning effect. Cuff pressure during the application of BFR will be standardized to 50% of AOP.~The resistance exercise for both experimental sessions 2 and 3 will be exactly similar and will involve four sets of isometric knee extensions at an intensity of 20% of 1-RM with repetitions of 30, 15, 15, and 15 by using the isokinetic dynamometer machine, which has a good to excellent test-retest reliability for knee extension movement with ICC value of 0.95-0.99. To minimize cognitive and neuromuscular fatigue, the experimental sessions will be separated by a minimum of three days (72 hours)."
223927516|NCT06762912|OTHER|Resistance exercise without BFR|"For both experimental sessions 2 and 3, the order of exercise condition will be randomly selected, either to be (1) the application of BFR cuff with resistance exercise, or (2) resistance exercise without the application of BFR cuff to decrease the incidence of learning effect. Cuff pressure during the application of BFR will be standardized to 50% of AOP.~The resistance exercise for both experimental sessions 2 and 3 will be exactly similar and will involve four sets of isometric knee extensions at an intensity of 20% of 1-RM with repetitions of 30, 15, 15, and 15 by using the isokinetic dynamometer machine, which has a good to excellent test-retest reliability for knee extension movement with ICC value of 0.95-0.99. To minimize cognitive and neuromuscular fatigue, the experimental sessions will be separated by a minimum of three days (72 hours)."
223927517|NCT06774456|DEVICE|instrumented 3D serious game (BE API 3.0)|It is composed of bimanual tasks integrated into a game scenario. The child is first equipped with markers on the upper limb (UL) and trunk (3D motion analysis and electromyography), and he/she can then play the game. There are several tasks ('piloting missions') to evaluate specific UL movements. The UL movements are recorded when the child is playing. The instruments of the set-up (wheel, turbo, etc.) are connected to the game to play and can also be used as measurements (grip strength, etc.). The markers are then removed. The total duration of the game is about 30-45 minutes, including placing/removing markers and the game.
223927518|NCT06885684|BEHAVIORAL|Cognitive Control Training + Metacognition Coaching|Computer training is delivered in person by a coach. Training consists of four games; each requires multiple aspects of cognitive control. Training levels progress in difficulty by increasing the number of items or simultaneous dimensions, decreasing the available response time, requiring greater accuracy, or adjusting the proportion of distractors or their complexity. Parameters that influence the difficulty of each level and passing criteria are fixed, but children progress from level to level at their own pace. Training is accompanied by manualized metacognition coaching to provide strategies to meaningfully engage with the tasks, simplify the tasks, support sustained effort, emphasize key cognitive control skills needed, provide coping strategies to reduce frustration associated with challenging aspects of the games, and use guided conversations to highlight metacognition.
223927519|NCT06893445|PROCEDURE|Deep Tissue Massage|Administered as a soft tissue mobilization performed by the therapist with fingertips, knuckles, elbows and/or fists on the tissues that manifest symptoms of fascial restrictions. The techniques were performed with individually adjusted force until the change (eg. increased mobility) in the tissue being treated was stated by the therapist.
224282337|NCT02809820|DRUG|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
224282338|NCT04467099|OTHER|Foot Exam Follow-Up|All participants will have a clinical assessment of their surgery foot by the study doctor.
224282339|NCT04467099|RADIATION|X-ray|Standard x-ray of the foot.
224282340|NCT04467099|OTHER|Questionnaire|All participants will complete a questionnaire.
224282341|NCT01566279|DRUG|Everolimus|All patients will receive everolimus 10mg q.d.
224282342|NCT00831233|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
224282343|NCT00831233|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
223532440|NCT06212817|OTHER|Dietary intervention|Increase dietary fiber intake
223532441|NCT04493671|DRUG|TBAJ-876 suspension|TBAJ-876 oral suspension, orally administered
223532442|NCT04493671|DRUG|Placebo suspension|Placebo for TBAJ-876 oral Suspension; orally administered
223532443|NCT04493671|DRUG|TBAJ-876 100 mg tablet|TBAJ-876 100 mg tablets, orally administered
223532444|NCT04493671|DRUG|TBAJ-876 25 mg tablet|TBAJ-876 25 mg tablets, orally administered
223927520|NCT06893445|PROCEDURE|Classic massage|The subject was lying supine on the table, with a roller placed under the knee joints, the upper limbs along the body. The following sequence of techniques was used in the longitudinal and transverse strands and in the intercostal spaces (excluding the breast in women): effleurage, friction, petrissage, pressures, tapotement and vibrations.
223927521|NCT06747936|DRUG|AD-2281|PO, Once daily, 8weeks
223927522|NCT06747936|DRUG|AD-2282|PO, Once daily, 8weeks
223927523|NCT06747936|DRUG|Placebo of AD-2282|PO, Once daily, 8weeks
223927524|NCT02379351|DEVICE|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
223927525|NCT06909175|DEVICE|Transesophageal echocardiography|Portal vein velocities were measured using TEE and intraoperative doppler in patients undergoing living donor liver transplantation
223927526|NCT06423391|OTHER|NeuOst|As above
223927527|NCT06423391|OTHER|Control Intervention|As above
223927528|NCT06423391|OTHER|Usual Care|As above
223927529|NCT06881940|OTHER|Rehabilitation Program|"Three of the five weekly sessions will take place at the gym in the Functional Unit of Breast Tumors at INCAN, under the supervision of Physical and Sports Medicine specialists and three physical therapists. These sessions allow for personalized feedback, enabling participants to confidently perform prescribed aerobic exercises at home on the remaining two days.~Each session starts with a 10- to 15-minute warm-up focused on joint mobility. Aerobic training is conducted at moderate intensity (40-59% VO2max or heart rate reserve), monitored with a Polar® FT1 device. Intensity is periodically adjusted based on the Borg Rating of Perceived Exertion and the talk test. Over 4-6 weeks, session duration will gradually increase to 90 minutes per week, remaining consistent thereafter.~Following aerobic training, resistance exercises targeting major muscle groups are performed using gym machines and dumbbells. The program includes seven exercises, progressively increasing load over 3-4 weeks."
224282344|NCT00831233|DRUG|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
223927530|NCT06881940|OTHER|No Rehabilitation Program|The control group will continue standard oncological treatment in addition to general recommendations regarding diet and physical activity, but without a structured exercise protocol.
223927531|NCT06942858|DEVICE|Deep transcranial magnetic stimulation|M-100 Ultimate pulsed magnetic field stimulator is used for dTMS treatment. The coil is positioned 4 cm anterior to the scalp point and the foot motor cortex, corresponding to the ACC. A naturally cold HF001A coil is used to obtain a greater depth of stimulation, up to about 6 cm subcortical. The coil is an integrated coil for true and false stimulation loops. The intervention protocol is as follows: 30 treatments are given 5 times per week (Monday to Friday) for 6 consecutive weeks. Intervention mode: stimulation frequency 20Hz, stimulation intensity 100% RMT, number of serial pulses 50, sequence interval 20s, a total of 40 trials, 2000 pulses, stimulating the left and right ACC respectively.
223927532|NCT06942858|BEHAVIORAL|cognitive behavior therapy|Each patient receives 12 individual sessions of 50 minutes twice a week for 6 weeks.The CBT therapists are nationally registered psychotherapists with systematic professional training and uniform training in CBT for anorexia nervosa to ensure consistency. They are also supervised by a CBT supervisor at the end of each session.
223927533|NCT06942858|DEVICE|Sham deep transcranial magnetic stimulation|M-100 Ultimate pulsed magnetic field stimulator is used for dTMS treatment. The coil is positioned 4 cm anterior to the scalp point and the foot motor cortex, corresponding to the ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field). A naturally cold HF001A coil is used to obtain a greater depth of stimulation, up to about 6 cm subcortical. The intervention protocol is as follows: 30 treatments are given 5 times per week (Monday to Friday) for 6 consecutive weeks. Intervention mode: stimulation frequency 20Hz, stimulation intensity 100% RMT, number of serial pulses 50, sequence interval 20s, a total of 40 trials, 2000 pulses, stimulating the left and right ACC respectively.
223927534|NCT06942858|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
223927535|NCT06953778|DEVICE|Zio XT® Patch|For participants randomized to be systematically screened, ambulatory ECG monitoring of up to 14 days will be performed using the Zio XT® Patch (iRhythm Inc, San Francisco, CA). The Zio XT® patch is a small, cutaneous ambulatory ECG recording device that provides cardiac rhythm monitoring for up to 14 consecutive days (significantly longer than the 48 hours of monitoring provided by a typical Holter Monitor). The device is approved by the Food and Drug Administration and is in routine clinical use, including in the VA system.
224282345|NCT01960868|OTHER|standard physiotherapy|
224282346|NCT01960868|OTHER|experimental physical therapy|
224282347|NCT06068777|DRUG|Rosmary|inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar
224282348|NCT06068777|DRUG|Lemongrass Oil|inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
224282349|NCT01956487|DRUG|Propafenone|Comparison of drug from 2 manufacturing sites
224282350|NCT06677853|DRUG|Timolol Maleate Gel+Placebo|Subjects were applied with the 0.5% timolol maleate gel at the affected area twice a day, and with the placebo once a day for 24 weeks.
224282351|NCT06677853|DRUG|Timolol Maleate Gel|Subjects were applied with the 0.5% timolol maleate gel at the affected area 3 times a day for 24 weeks.
224282352|NCT06677853|DRUG|Placebo|Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
223927536|NCT06796257|OTHER|radiotherapy planning|In this study, CT localization images from 32 patients were retrospectively used for radiotherapy treatment planning. Three radiotherapy plans were designed based on different K-value intervals of the Monaco-Serial biological function constraint for the heart. The dose-volume parameters of the organs at risk were compared.
223927537|NCT05933057|DRUG|Givinostat|Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
223927538|NCT05933057|DRUG|Placebo|Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
223927539|NCT05720299|DRUG|Akkermansia muciniphila|one tablet of AKK
223927540|NCT05720299|DRUG|Berberine|one tablet of Berberine
223927541|NCT05720299|DRUG|AKK Placebo|one tablet of AKK placebo
224282353|NCT01338714|OTHER|Compound Herbal Formula (RHD-1)|100 ml/per day
224282354|NCT01338714|OTHER|dilute RHD-1|100 ml/per day
224282355|NCT05149924|DRUG|QL1012|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
224282356|NCT05149924|DRUG|Gonal-f ®|Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
224282357|NCT00622115|DRUG|Enoxaparin|
224282358|NCT00640263|DRUG|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
224282359|NCT00640263|DRUG|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
224282360|NCT03064087|DEVICE|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
224282361|NCT03064087|DEVICE|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH \& Co. KG, Wiesbaden, Germany).
224282362|NCT03064087|DEVICE|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
223927542|NCT05720299|DRUG|Berberine Placebo|one tablet of Berberine placebo
223927543|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 25mg|Given PO
223927544|NCT04047706|DRUG|Nivolumab|Given IV
223927545|NCT04047706|RADIATION|Radiation Therapy|Undergo radiation therapy
223927546|NCT04047706|DRUG|Temozolomide|Given PO
223927547|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 50 mg|Given PO
223927548|NCT04047706|DRUG|IDO1 Inhibitor BMS-986205 100 mg|Given PO
223927549|NCT02118870|DRUG|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
223927550|NCT02118870|DRUG|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
223927551|NCT02134171|OTHER|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
223927552|NCT00002866|BIOLOGICAL|filgrastim|
223927553|NCT00002866|DRUG|docetaxel|
223927554|NCT00002866|DRUG|epirubicin hydrochloride|
223927555|NCT00070486|DRUG|carboplatin|given IV
223927556|NCT00070486|DRUG|celecoxib|given PO
223927557|NCT00070486|DRUG|gemcitabine hydrochloride|given IV
223927558|NCT00070486|DRUG|zileuton|given PO
223927559|NCT03676088|PROCEDURE|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
224282363|NCT03064087|DEVICE|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
224282364|NCT03064087|DIAGNOSTIC_TEST|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH \& Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
224282365|NCT02978352|OTHER|learning|
224282366|NCT06317948|OTHER|treatment plan comparison|In order to assess inter-Institute variability of DVH prediction of the various models, for the different situations and the different OARs, DVH and dose statistics (min, mean, median, max and SD of the dose received by each OAR) predicted on the patients owning to the different centers by the different models will be compared
224282367|NCT02171767|DRUG|BIBW 2992 MA2 - single rising dose|
224282368|NCT04823507|DEVICE|BIOFLEX DUO+|"* Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment.~* Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine.~* Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test.~* Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared."
224282369|NCT02211014|DRUG|acalabrutinib|
223927560|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
223927561|NCT02777541|DIETARY_SUPPLEMENT|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
223927562|NCT02894554|DRUG|Telbivudine|
223927563|NCT02894554|DRUG|Lamivudine|
223927564|NCT03986840|OTHER|Exercise training|A multicomponent exercise program
223927565|NCT04047784|DEVICE|Endobronchial ultrasound (EBUS)|"An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn."
223927566|NCT04975217|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
223927567|NCT04975217|DRUG|Fecal Microbiota Transplantation Capsule|Given PO
223927568|NCT04975217|OTHER|Questionnaire Administration|Ancillary studies
223927569|NCT04975217|PROCEDURE|Resection|Undergo standard of care resection
223927570|NCT04975217|PROCEDURE|Therapeutic Colonoscopy|Undergo colonoscopy
223927571|NCT02260973|DIETARY_SUPPLEMENT|Omega-3 (Triglyceride form)|
223927572|NCT03373916|BEHAVIORAL|Peer mentorship|The PREVAIL intervention will be delivered by a Certified Peer Support Specialist (CPSS) or Peer Recovery Coach. Participants will select a Peer to work with based on brief personal descriptions. Sessions may occur in-person (public place, the participant's home, or a research clinic space) or remotely (phone or video call). The first meeting will occur while the participant is hospitalized, and subsequent sessions will be scheduled per the participant's preferences, with a suggested frequency of twice weekly for weeks 1-2, weekly for weeks 3-8, and every other week for the last month. Sessions will last 1 hour on average and will consist of semi-structured conversations focused on protective factors such as hope, safety planning, and coping skills. Session structure and content are intentionally flexible to allow for general supportive listening, validation, sharing, and genuineness in the relationship, thereby increasing acceptability and implicit belongingness.
223927573|NCT03373916|BEHAVIORAL|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
224282370|NCT00003330|BIOLOGICAL|recombinant interleukin-12|
224282371|NCT00519922|OTHER|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion \& agility, dynamic proprioception,functional strength \& endurance.~Kinesthesia \& Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability \& confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia \& balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
223532445|NCT06320197|OTHER|In situ simulation assessment|Unannounced in situ simulation assessment during working hours
223532446|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
223532447|NCT01019941|DRUG|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
223532448|NCT00811837|DRUG|Midazolam|Intravenous infusion
223927574|NCT06078813|RADIATION|Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB)|Treatment will consist of image guided dose escalated SABR using a simultaneous integrated boost (SIB) delivered in two fractions adhering to organ at risk dose-volume histogram constraints. There will be three dose levels delivered to the Planning Target Volume\_1 (PTV\_1) in each treatment arm as follows: 28 Gy (14 Gy per fraction), 30 Gy (15 Gy per fraction) and 32 Gy (16 Gy per fraction). A lower dose of 20 Gy (10 Gy per fraction) will be delivered to the PTV\_2 which will be defined according to international consensus guidelines (Cox et al., 2012). The dose to PTV\_2 will remain the same through all dose levels. All doses are prescribed to the target volume.
223927575|NCT04959669|OTHER|DeSSBack|The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
223927576|NCT00004361|DRUG|calcium gluconate|
223927577|NCT00004361|DRUG|sodium citrate|
223927578|NCT03820544|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
223927579|NCT03820544|OTHER|Standard of care|Undergo standard of care surgical resection
223927580|NCT05682144|BIOLOGICAL|Autologous Plasmablasts (B cells)|Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
223927581|NCT05630508|BEHAVIORAL|interactive Mhealth Lifestyle behavior intervention|Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
223927582|NCT05630508|OTHER|Sham|Receiving standard care, LIVEN educational material and access to the application
223927583|NCT06152809|BIOLOGICAL|Cytokine-Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
223927584|NCT06152809|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous (under the skin) injection per protocol.
223532449|NCT00811837|DRUG|Remifentanil|Intravenous infusion
223927585|NCT06152809|DRUG|Venetoclax|Selective inhibitor of BCL-2 protein, 10, 50, or 100 mg tablets, via orally per standard-of-care.
223927586|NCT06189807|BEHAVIORAL|Decision aid|Enrolled participants will be sent the novel educational decision aid about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment, study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
223927587|NCT06189807|OTHER|Standard handout|Enrolled participants will be sent the standard information about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment, the participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
224093914|NCT02670876|BEHAVIORAL|Anti-bullying intervention|"The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem"
224093915|NCT02718820|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
224093916|NCT02718820|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
224093917|NCT05738915|DIAGNOSTIC_TEST|CRP/Albumin ratio in IBD|Role of C-Reactive Protein /Albumin Ratio in evaluation of Disease Activity in Patients with Inflammatory Bowel Disease.
224093918|NCT01816503|DRUG|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
224093919|NCT05388851|OTHER|Educational Intervention|Complete educational training module
224093920|NCT05388851|OTHER|Questionnaire Administration|Complete questionnaire
224093921|NCT01083108|OTHER|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
223927588|NCT04782830|DEVICE|Accelerometer|A uniaxial accelerometer-based activity monitor (ActivpalTM) will be worn by participants on one of the thighs during the 7 days of the placebo and treatment periods.
224093922|NCT01083108|OTHER|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
223927589|NCT04782830|DRUG|placebo pill|Placebo pill will be taken for 7 days at the same frequency as their regular treatment with either midodrine or atomoxetine.
223927590|NCT04782830|DRUG|Midodrine or atomoxetine pill|Either midodrine or atomoxetine at their regular dose.
223927591|NCT06435845|DRUG|Anti-(integrin beta-3) human monoclonal antibody|human monoclonal anti-human platelet antigen (HPA)-1a immunoglobulin G antibody
223532450|NCT06767956|DRUG|GOLCADOMIDE|Golcadomide (GOLCA, CC-99282) is an oral cereblon E3 ligase modulator (CELMoD®) agent with immunomodulatory and tumor cell-autonomous activities. It is a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities.
223532451|NCT06767956|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeted therapy drug that blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system, boosting the immune system's response.
223532452|NCT02850341|DEVICE|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
223532453|NCT02107612|DEVICE|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
223532454|NCT02107612|OTHER|Denture|
223532455|NCT06149585|OTHER|Microbial Sampling|Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
223532456|NCT02996929|DEVICE|LC System|Subjects will undergo CIED lead extraction with the LC system
223532457|NCT02327377|BEHAVIORAL|Online Cognitive Behavior Therapy|
223532458|NCT02327377|BEHAVIORAL|Online Education|
223927592|NCT03248492|DRUG|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
223927593|NCT05740241|OTHER|Elderly|A group of participants with physical activity (protocolized)
223927594|NCT03705390|DRUG|ILB®|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
223927595|NCT06269432|DRUG|Precision Antiplatelet Therapy Trial Group|Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
224093923|NCT00975091|DRUG|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
223532459|NCT05857748|DRUG|lifitegrast|patient newly started on medication will be followed for 6 months
223532460|NCT05876754|DRUG|Ivosidenib Oral Tablet|Ivosidenib 500 mg
223927596|NCT06269432|DRUG|Traditional Antiplatelet Therapy Control Group|No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
223927597|NCT06213493|DIAGNOSTIC_TEST|measurement of RNAs|RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
223927598|NCT06730893|OTHER|SDM protocol|Card news and Videos related to general knowledge and treatment of low-risk thyroid cancer
223927599|NCT05386615|DEVICE|Body System - Functional|MR-Guided Focused Ultrasound
223927600|NCT06696092|DEVICE|Hemostatic Agent|WoundClot Surgical may be used in a single target bleeding site of each subject.
223927601|NCT06697678|OTHER|No Intervention: Observational Cohort|No intervention
223927602|NCT06828510|DEVICE|With device|"Medical Device Installation Visit (V2, Day 0 + 21 ± 10 days): This visit, lasting approximately 1.5 hours, takes place in a consultation room at the center. A representative from ORTHOPUS adapts and installs the Partner on the patient's wheelchair, and an initial training session on the use of the medical device is provided.~Use of the Medical Device in Ecological Conditions (between V2 and V3): Between Day 21 and Day 42, the patient is invited to use the MD without restrictions in real-life conditions.~Final Evaluation Visit (V3, three weeks after V2, up to four weeks if necessary): The assessment session for the primary outcome-functional goal achievement using the GAS method-is conducted following the SCED (Single-Case Experimental Design) procedure, with multiple introduction-withdrawal phases and randomized phase sequencing and repeated measures :"
224093924|NCT00975091|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
224093925|NCT00755820|BEHAVIORAL|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
224093926|NCT00755820|BEHAVIORAL|Exposure Therapy + Placebo|Exposure therapy with placebo medication
224093927|NCT00755820|BEHAVIORAL|Supportive Psychotherapy|Supportive psychotherapy
223532461|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
223532462|NCT03151564|DIAGNOSTIC_TEST|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
223532463|NCT03151564|DIAGNOSTIC_TEST|Deep Learning Image Reconstruction (DLIR)|Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
223532464|NCT05464823|OTHER|Molecular Functional Portrait|Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
223532465|NCT00055185|DRUG|CD4-IgG2 (PRO 542)|
223927603|NCT07031063|DRUG|DTG/3TC|Dual therapy of 2 drugs co-formulated in 1 tablet: Dolutegravir 50 mg/ lamivudine 300 mg, it is the experimental group
223927604|NCT07031063|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|It is a triple-drug antiretroviral drug co-formulated in a single tablet. It contains bictegravir 50 mg, tenofovir alafenamide 25 mg, and emtricitabine 200 mg. It is the standard therapy.
223927605|NCT07034053|DRUG|Clofarabine|Patients receive i.v. clofarabine in a dose-escalation regimen
223927606|NCT06713720|DEVICE|Remote Ischemic Conditioning Device|Participants in this group will use a remote ischemic conditioning device that applies five cycles of 5-minute inflation at 200 mmHg followed by 5-minute deflation on both arms, twice daily, for at least five days per week over one year. The device is designed to enhance retinal oxygenation and reduce hypoxia-related damage.
223927607|NCT06713720|DEVICE|Sham Remote Ischemic Conditioning Device|Participants in this group will use the same remote ischemic conditioning device set to an inflation pressure of 60 mmHg to simulate the treatment. This placebo intervention follows the same timing and cycle frequency as the active intervention group.
224093928|NCT03904927|OTHER|Radiation, Surgery or Radiofrequency ablation|Patients with no more than 4 metastases located in less than 3 organs/ lymphatic drainage regions treated with combined systemic therapy and radiation, surgery or radiofrequency.
224093929|NCT03904927|DRUG|Systemic therapy|"1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy."
224093930|NCT00260208|DRUG|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
224093931|NCT00260208|DRUG|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
224093932|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
223927608|NCT07035626|DRUG|Spermidine|As a member of the polyamine family, spermidine is a trivalent cationic compound found in eukaryotic cells. It interacts with polyanions such as nucleic acids, proteins, and ATP through electrostatic binding, thereby maintaining genomic DNA stability, regulating gene transcription and translation, and modulating autophagy, apoptosis, oxidative stress, angiogenesis, and intercellular communication. Spermidine is indispensable for cell division and proliferation.
223927609|NCT07035626|DRUG|Spermidine simulants|Patients in control group were treated with Spermidine simulants, and its use method and use time are the same as intervention group.
223927610|NCT07032285|DRUG|Cirtuvivint|Cirtuvivint (SM08502) will be administered orally at 80 mg/day, 5 days on/2 days off. Cirtuvivint is supplied as tablets containing 10 mg or 50 mg of the active pharmaceutical ingredient (API). Cirtuvivint is taken with water once a day (on dosing days) at the same time every day. Doses will be taken without food (foo restriciton 1 hour before treatment and 2 hours afterdosing). Doses delayed by 12 hours will be considered missed and should not be taken. If vomiting occurs,the dose must not be retaken. Cirtuvivint is dosed in 28-day continuous cycles (28 days of treatment will beconsidered as one cycle) Treatment will continue until disease progression, unacceptable toxicity or investigator/patient decision
223927611|NCT06880757|OTHER|Radionuclide treatment with Lu-177 FAPI|Systemic radionuclide treatment with Lu-177 FAPI
224093933|NCT01121289|DRUG|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
224093934|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
224093935|NCT01121289|DRUG|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
224093936|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
224093937|NCT01121289|DRUG|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
224093938|NCT06144008|BEHAVIORAL|Answering questionnaire|A questionnaires for each group has been developped and will be distributed for voluntary and anonymous completion.
224093939|NCT02979314|DEVICE|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
224093940|NCT01929252|DRUG|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
224093941|NCT01929252|DRUG|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
224093942|NCT00919659|DIETARY_SUPPLEMENT|parenteral nutrition|25kcal/kg bw with parenteral nutrition
224093943|NCT02357992|RADIATION|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
224093944|NCT05144165|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
224093945|NCT01284192|DRUG|ASP3026|Tablet
224093946|NCT05723146|BEHAVIORAL|Spatial cognition assessment|The intervention will be composed of tasks assessing spatial cognition in a real environment (cancellation task, line bisection and baking tray task) and in a virtual environment (cancellation task, line bisection, baking tray task and localization tasks).The Catherine Bergego Scale (questionnaire) will also be used.
224093947|NCT01671904|DRUG|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
224093948|NCT01671904|DRUG|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
224093949|NCT01671904|DRUG|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.
224093950|NCT01671904|DRUG|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
223532466|NCT06586619|BEHAVIORAL|Tai chi/qigong intervention group|The intervention is a tai chi/qigong intervention for older people living with HIV. This behavioral group-based intervention will be delivered through Zoom twice a week for 12 weeks. Each class lasts 45-60 minutes. Tai chi/qigong is a slow low impact meditative movement.
223927612|NCT06880822|BEHAVIORAL|Closed-Loop and Neuroplasticity-Based Mindfulness Program|The intervention includes three weekly 90-minute face-to-face mindfulness training sessions and daily guided self-practice using a closed-loop, neuroplasticity-based mobile app over 8 weeks. Training integrates mindfulness practices (e.g., mindful eating, body scanning) to help caregivers apply mindfulness in daily life. During self-practice, participants listen to a lesson, monitor distractions, and refocus on their breathing. Initial trials start at 20 seconds, adjusting by 10% if focused or decreasing by 20% if distracted, helping participants regulate attention. Progress is stored to continue in later sessions, with instant feedback during trials and delayed feedback on overall progress. Facilitators provide weekly follow-ups via the app to monitor caregivers' progress.
223927613|NCT06880822|BEHAVIORAL|Traditional Mindfulness Program (Without the Closed-Loop Approach)|Family caregivers in the traditional mindfulness group will participate in general mindfulness practices (e.g., mindful eating, body scanning, and mindful walking) without the closed-loop approach. These practices aim to help caregivers learn mindfulness skills and integrate them into their everyday life. Sessions will be delivered through a mobile approach with the same group size, duration, and frequency as the intervention groups.
223927614|NCT06880822|BEHAVIORAL|Psychoeducation|Family caregivers in the control group will receive self-directed e-learning on dementia care with support from a registered nurse experienced in dementia care or elderly care. This group will serve as a control for socialization and interaction aspects with peers and the interventionist (nurse). The self-directed learning will be delivered through a mobile approach, maintaining the same group size, duration, and frequency as the intervention groups. Educational content will include brief sessions on dementia care, caregiving skills, and group sharing of caregiving tasks.
224093951|NCT02863263|DEVICE|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
224093952|NCT02863263|DEVICE|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
224093953|NCT03026803|DRUG|Oxaliplatin|Given IV
224093954|NCT03026803|DRUG|Capecitabine|Given PO
224093955|NCT02139189|DEVICE|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
223532467|NCT06586619|BEHAVIORAL|Health Education group|Participants will be assigned to a health and wellness education group for older people living with HIV. This group will be delivered through Zoom twice a week for 12 weeks, and each class will last 45-60 minutes. Each group will learn about and discuss a health and wellness topic.
223532468|NCT06978439|DRUG|Rivaroxaban (Xarelto)|Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model-informed dose optimization study
223532469|NCT00789555|DRUG|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
224093956|NCT00998101|DRUG|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
224093957|NCT00998101|DRUG|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
224093958|NCT00998101|DRUG|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
224093959|NCT01586728|OTHER|Air - oxygen|"1. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~2. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
224093960|NCT01586728|OTHER|Oxygen - Air|"1. nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 \> 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~2. his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 \<= 90%."
224093961|NCT00368173|DRUG|rhIGF-I/rhIGFBP-3|
224093962|NCT02555800|DRUG|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
224282372|NCT00519922|OTHER|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal \& external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
224282373|NCT02577224|OTHER|Patient-initiated treatment|Please see Intervention Arm
223532470|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
223532471|NCT00789555|OTHER|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
224282374|NCT01741467|BEHAVIORAL|RT-CGM|Dexcom Seven+
223532472|NCT00404248|DRUG|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
223532473|NCT00404248|OTHER|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
223532474|NCT04649645|OTHER|TOBACCO CIGARETTES|Participants in Arm A will continue smoking their own cigarette brand as usual.
223532475|NCT04649645|OTHER|COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)|Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
223532476|NCT04649645|OTHER|NOT SMOKING|Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
223940997|NCT05176756|BEHAVIORAL|Gamification and Social Support|Participants will be entered into a points and levels-based game designed to help them meet their step count goals. At the start of each week, the participant will receive a set amount of points. Each day their step goal is not met, they lose points. If the participant meets a certain point value at the end of the week, they will either advance one level (of five total levels); if they do not, they will drop one level. Each participant will also select a family member or friend or the study coordinator to serve as a support partner. At the beginning of the intervention, the participant and support partner will identify at least 3 ways in which they can help the participant meet their step goals. This partner will receive a weekly email reminding them of these approaches and updating them on the participant's progress.
224093963|NCT02555800|DRUG|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
224093964|NCT02555800|OTHER|Placebo|Saline solution
224093965|NCT02318004|OTHER|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
224093966|NCT06265545|DRUG|Ivosidenib,Venetoclax,gilteritinib,Selinexor|if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)
224282375|NCT05382156|DRUG|Osilodrostat|oral administration of Osilodrostat tablets at different doses according to patient's need
224282376|NCT05547334|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach (IBA) (as described by Visser et al., 2015 and adapted for use in adolescents by L. Webers)is a focused form of psychotherapy consists of twenty 45-minutes sessions, delivered weekly and carried out as specified in a Dutch session-by-session IBA protocol, containing standardized forms for exercises and homework assignments. Each session has a standard format, starting with agenda setting and evaluating homework assignments, followed by determining and executing a new exercise and determining new homework. The IBA model is based on the assumption that adolescents with OCD and poor inside misjudge the actual state of affairs. It is assumed that certain reasoning processes lead to these erroneous conclusions and distract the childs attention from observable reality.
224282377|NCT06615882|DEVICE|stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)|"I. Procedure \& Intervention~1. Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.~2. Solitaire-X stent types are selected~3. During the stent-angioplasty, IA nimodipine was also infused.~4. Retrieve Solitaire-X after maintaining deployment for 3 minutes.~5. Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography."
224282378|NCT04822376|DRUG|ansuvimab|Human monoclonal antibody to Zaire strain GP (EBOV GP)
223940998|NCT05176756|BEHAVIORAL|Attention control|Participants will receive a daily text message with their step count from the day prior.
224282379|NCT04822376|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
224282380|NCT05664282|DEVICE|Damon self-ligating brackets|
224282381|NCT05664282|DEVICE|Victory self-ligating brackets|
224282382|NCT05403957|OTHER|TID video|"Main intervention: A video introducing the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 6 screenshots from the video and 6 true or false questions."
224282383|NCT05403957|OTHER|TID worksheet|"Main intervention: A worksheet using pictures and texts to introduce the tobacco industry's marketing tactics to attract children and adolescents to smoke and their manipulation of tobacco control policy formation.~Booster intervention: 8 pictures from the TID worksheet in the main intervention and 6 true or false questions."
223532477|NCT06857513|DIAGNOSTIC_TEST|Questionnaire and Physical Exam|Patients will be interviewed about the current suffering of post-intensive care symptoms
223532478|NCT06857513|DIAGNOSTIC_TEST|EuroQol 5-Dimension 3-Level|to assess health-related quality of life, focusing on the assessment of five key dimensions: mobility, self-care, daily activities, pain/discomfort and anxiety/depression.
223532479|NCT06857513|DIAGNOSTIC_TEST|EuroQol Visual Analogue Scale (EQ-VAS)|"records the patient's self-rated health on a vertical visual analogue scale where endpoints are labelled: 0 best imaginable health - 100 worst imaginable health"
224093967|NCT04349930|DRUG|Cannabidiol vaginal suppository|Cannabidiol vaginal suppository
224093968|NCT04349930|DRUG|Placebo vaginal suppository|Placebo vaginal suppository
224093969|NCT05394298|DRUG|Short-treatment of any active antibiotic regimen 7 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity from a pre-stablished list of antibiotics included
224093970|NCT05394298|DRUG|Long-treatment of any active antibiotic regimen 14 days of any active antibiotic treatment for uncomplicated enterococcal bacteremia.|Any active antibiotic with treatment with proven in vitro activity a pre-stablished list of antibiotics included
224093971|NCT06434168|BEHAVIORAL|Yoga intervention|Patients in the yoga group will receive a 60-minute session, twice per week over 12 weeks for a total of 24 sessions. Each yoga session consists of a warm-up, yoga postures standing or seated depending on the capability of the patient, and relaxation.
223927615|NCT07039604|DEVICE|Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China|PADN: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA. The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 # for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA. For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician.
223927616|NCT07038187|BEHAVIORAL|Music Listening (Binaural Beats via Gnaural)|Modern 'relaxation' music regularly includes binaural beats. Binaural beats can be defined as a sensation produced by the arrival of sine tones of different frequencies in each ear. This sensation is created by the difference in frequency between the two tones reaching the ear. Music with binaural beats has been associated with reduced anxiety and increased relaxation by activating theta and delta wavelengths in the electroencephalography (EEG). The authors used Gnaural (GPL-2.0), a freely programmable sound generator, for the binaural beats. Two pieces of instrumental 7 Hz binaural beats were used, a piano and an instrumental. The music volume was between 50-60 decibels and was at a level where the participant could hear the healthcare professional performing the procedure.
223927617|NCT07039487|OTHER|Blood sampling collection|"CBC performed on the background of an EDTA tube, collected routinely allowing neutrophil fluorescence measurements.~This tube will then be passed over on the automaton for a CBC measurement with leukocyte differentiation."
223927618|NCT07038577|OTHER|Fenugreek Seed Powder|Participants in the intervention group received 10 grams of ground Fenugreek seed powder, administered twice daily (before breakfast and dinner), for a total of 3 months. The Fenugreek powder was consumed mixed with water, in addition to the participants' regular antidiabetic medications and a standardized meal plan. The supplement was provided in a non-encapsulated, natural powdered form, and was not combined with any other herbal or pharmaceutical products.
223927619|NCT07038525|OTHER|Suturing training|This intervention involves basic suturing skills training delivered either in-person or online. In the in-person group, participants receive live instruction and hands-on supervision. In the online group, participants watch a standardized video tutorial and receive remote feedback via Zoom. All participants use identical suturing kits and are evaluated using the same OSATS checklist by a blinded assessor. The content and learning objectives are standardized across both formats.
223927620|NCT07038603|OTHER|BAPP-VR|A carefully considered adaptation of a BA protocol enhanced with the use of VR
223927621|NCT07038096|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
224093972|NCT06434168|BEHAVIORAL|Control condition|Patients in the control group will receive care-as-usual from their healthcare providers and will be asked to avoid engaging in yoga during their 3 months in the study.
224093973|NCT03739619|DRUG|Bendamustine|Given IV
224093974|NCT03739619|DRUG|Gemcitabine|Given IV
224093975|NCT03739619|BIOLOGICAL|Nivolumab|Given IV
224093976|NCT03095703|DRUG|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
224093977|NCT04778839|DRUG|Paclitaxel Micelles for Injection|Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
224093978|NCT04778839|DRUG|Paclitaxel injection|Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
224093979|NCT06556108|BIOLOGICAL|ALPP CAR-T cells|T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells
224093980|NCT06556108|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
223717861|NCT01268969|PROCEDURE|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
223717862|NCT01268969|PROCEDURE|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
223717863|NCT03209661|DRUG|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
223717864|NCT03209661|DRUG|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
223717865|NCT03209661|DRUG|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
223717866|NCT03962842|OTHER|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
223717867|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
223717868|NCT02056496|DIETARY_SUPPLEMENT|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
223717869|NCT03322631|DRUG|Tirzepatide|Administered SC.
223927622|NCT07038096|DRUG|ZG005|ZG005 will be administered as an intravenous (IV) infusion.
224282384|NCT05403957|OTHER|SSB worksheet|"Main intervention: A worksheet using pictures and texts to introduce the beverage industry's marketing tactics to attract children and adolescents to drink SSBs and the health risks of SSBs.~Booster intervention: 8 pictures from the SSB worksheet in the main intervention and 6 true or false questions."
224282385|NCT01123096|PROCEDURE|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
224282386|NCT01123096|OTHER|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
224282387|NCT03898102|DRUG|Regorafenib|regorafenib plus zinc gluconate
223532480|NCT06857461|BEHAVIORAL|Uriclarity Program|"The Uriclarity Program is a behavioral lactation support intervention designed to reduce the perception of insufficient milk supply (PIM) in postpartum women. The program consists of a two-hour hands-on training session delivered within the first 24-48 hours postpartum and a WhatsApp-based follow-up support system.~During the in-person training, participants learn essential breastfeeding techniques, how to recognize normal lactation patterns, and how to use the Uriescala Ashiyama, a self-monitoring tool that evaluates neonatal urine color to assess milk transfer. Right after hospital discharge, participants receive virtual support including educational videos.~This intervention differs from standard lactation counseling by integrating self-monitoring strategies, community-based digital support, and a non-technology-dependent educational approach, making it a scalable and sustainable strategy for breastfeeding promotion."
223532481|NCT04646005|DRUG|Cemiplimab|Administered intravenously (IV) every three weeks (Q3W)
224282388|NCT03898102|DIETARY_SUPPLEMENT|Zinc gluconate supplement|Zinc gluconate supplement
224282389|NCT05019482|BEHAVIORAL|University-based intervention to promote PA and reduce ST|"This intervention was realized with all college student and involved:~1. Design-based innovative workshops during the first week;~2. 8-weeks program of Physical Activity constructed by users~3. Information session focusing on the promotion of active behaviors~4. Feedback provided to the users with an individualized report"
223532482|NCT04646005|BIOLOGICAL|ISA101b|Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
223532483|NCT04410900|BIOLOGICAL|Wistar Rabies Virus Strain PM-1503-3M Vaccine|Given IM
223532484|NCT04410900|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223532485|NCT06313619|COMBINATION_PRODUCT|SmartAMR|"SmartAMR is a digital system including a mobile app that helps keeping record of medicine sales, sending auto-generated messages to the consumers to remind them about medicine taking time and completing doses. It also poses a symptom checker driven by artificial intelligence and a telemedicine service."
223532486|NCT06524414|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine
223717870|NCT03322631|DRUG|Placebo|Administered SC.
223717871|NCT02378961|DRUG|VOX|100 mg tablet(s) administered orally once daily with food
223927623|NCT07038434|DIAGNOSTIC_TEST|Multimodal AI-Based Pain Assessment|A non-invasive, multimodal diagnostic procedure combining self-reported pain scales (NRS, DN-4, BPI), wearable biosignal acquisition (EDA, EMG, HRV, EEG), facial thermography (HIRA system), video-based facial expression analysis, linguistic interview, and the Stroop Test. Data are used to train and validate machine learning models for automatic pain assessment in chronic pain patients.
223927624|NCT07038226|BIOLOGICAL|Placebo|a visually identical capsule containing skim milk powder
223927625|NCT07038226|BIOLOGICAL|Oral capsule-delivered FMT|Oral capsules of lysophilized fecal microbiota
224093981|NCT06556108|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224282390|NCT01344616|BEHAVIORAL|lifestyle support|computer-based lifestyle improvement support and clinician support
224282391|NCT04694612|DRUG|Favipiravir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
223532487|NCT06524414|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine
223532488|NCT06524414|BIOLOGICAL|15-valent pneumococcal conjugate vaccine (PCV15)|15-valent pneumococcal conjugate vaccine
223717872|NCT02378961|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
223927626|NCT07037836|DRUG|Inhaled Treprostinil (Tyvaso Nebulizer)|Participants will receive inhaled Treprostinil (Tyvaso nebulizer), 6 µg per breath, administered four times daily for 4 weeks. The starting dose will be 3 breaths per session. The dose will increase by 1 breath per session each week, as tolerated, to a target of 6 breaths per session by week 4. If adverse effects occur, participants will remain at the highest tolerated dose. The drug will be administered using the Tyvaso inhalation system provided by United Therapeutics. No changes to baseline COPD maintenance medications are allowed during the treatment period. Participants will be monitored for safety throughout the study.
223927627|NCT07037849|DEVICE|Robot-assisted overground gait training|Post-stroke patients were required to complete a session of robot-assisted training, which involved nine repetitions of 5-meter overground walking (three trials for each of the three controllers).
223927628|NCT06708455|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
223927629|NCT06708455|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Carboplatin + Paclitaxel Regimen (CP Regimen)
223927630|NCT06874829|OTHER|Electrical Muscle Stimulation|EMS will be applied bilaterally to the wrist flexor and elbow extensor muscles using a portable EMS stimulator (Compex Rehab 400, Medicompex SA, Ecublens, Switzerland). Four 2 mm thick, self-adhesive electrodes (5x5 cm) will be placed on the superficial aspect of each muscle group. The athletes will simultaneously receive EMS intervention with a pulse frequency of 75 Hz and a duration of 400 μs (19 seconds rest between pulses) during bench press and triceps pushdown exercises. Bench press and triceps push down exercises will be performed with 30% 1TM, 30-15-15-15 repetitions and thirty seconds rest between sets.
223927631|NCT06874829|OTHER|Blood Flow Restriction|The arterial occlusion pressures (AOP) of the athletes randomized to the experimental group will be obtained automatically with the digital LED display CAC device BFR Unit (Fit Cuffs BFR Unit, Denmark). The AOP pressure device BFR Unit (Fit Cuffs BFR Unit, Denmark) will be used to apply 50% occlusion pressure during exercise. Bench press and triceps push down exercises will be performed with 30% 1TM, 30-15-15-15 repetitions and thirty seconds rest between sets.
223927632|NCT06874829|OTHER|Low-Load Resistance Exercise|Bench press and triceps pushdown exercises will be performed with 30% 1RM, 30-15-15-15 repetitions and 30 seconds rest between sets.
223927633|NCT06719791|DRUG|Sirolimus|Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².
223927634|NCT07040007|BEHAVIORAL|Strengthening Exercises|"In the strengthening exercises, the amount of weight was determined based on 40 to 60 percent of the one-repetition maximum. Each exercise was performed in two sets of six to eight repetitions. The exercise sessions lasted approximately 40 minutes and included a 10-minute warm-up, 20 minutes of strengthening exercises, and a 10-minute cool-down period. To perform the strengthening exercises, resistance bands (Theraband), dumbbells, weighted balls, sandbags, and a resistance bicycle were used. The exercises were performed for both the upper and lower extremities.~For the upper extremities, shoulder abduction, elbow extension, and shoulder extension exercises were performed using a theraband; elbow flexion, shoulder flexion, and elbow extension exercises were performed using dumbbells; and shoulder abduction exercises were performed using a weighted ball. For the lower extremities, knee extension, hip extension, and hip abduction exercises were performed using a resistance bicycle."
224093982|NCT06487780|BEHAVIORAL|Lifestyle-focused Occupational Therapy Intervention|The proposed intervention, led by trained occupational therapists, will focus on establishing sustainable self-care routines. It will consist of approximately 12 biweekly sessions, each lasting about an hour on average. Therapists will customize session timing and duration based on participant needs.
224093983|NCT06487780|OTHER|Education|Participants in the education group will receive standardized education materials on diabetic foot ulcers (DFUs), foot care, and offloading treatment to prevent foot ulcer recurrence.
224093984|NCT06272643|DIAGNOSTIC_TEST|IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography)|OCT and IVUS in Patients with LMCA lesion (25-60%)
224093985|NCT05787613|DRUG|HLX26|Anti-LAG-3 monoclonal Antibody Injection
224093986|NCT05787613|DRUG|Serplulimab|anti-PD-1 humanized monoclonal antibody injection
224093987|NCT05787613|DRUG|Chemotherapy drug|non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.
224093988|NCT05787613|DRUG|Placebo|placebo
224093989|NCT05265208|DRUG|Capecitabine|Capecitabine will given at 1250mg/m², 2 times a day with an interval of about 12 hours between two intakes, 2 weeks on, 1 week off, for 4 pre-surgery cycles.
224093990|NCT05265208|DEVICE|Selective Internal Radiotherapy (SIRT)|During the first week of cycle 2 of capecitabine, patients will receive SIRT using Yttrium-90 glass microspheres. Treatment with Yttrium-90 glass microspheres requires two steps, one or two weeks apart. Both stages are performed under local anesthesia after a short hospitalization : the treatment simulation and therapeutic angiography.
224093991|NCT05265208|PROCEDURE|Surgery|Surgery will be performed according to local practice.
224093992|NCT04846309|RADIATION|Radiation|Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic. Subjects with tumors identified by imaging as hypoxic will be treated with a higher dose of radiation therapy. Tumors will be defined as being hypoxic if FMISO accumulation occurs as demonstrated by standardized uptake value (SUV) uptake in the tumor.
223717873|NCT06447740|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
223717874|NCT06447740|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
224093993|NCT04846309|DRUG|FMISO PET CT|Prior to the start of study therapy, eligible subjects will receive a FMISO-PET scan. If there is uptake visualized on the scan, the tumor will be considered as hypoxic. If there is no uptake seen on the FMISO-PET scan, tumors will be labeled not hypoxic.
224282392|NCT04694612|DRUG|Placebo|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to placebo in the patients with mild COVID-19
223717875|NCT06447740|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
223927635|NCT07040007|BEHAVIORAL|Balance Exercises|"Each session was carried out over approximately 40 minutes, consisting of a 10-minute warm-up, 20 minutes of balance exercises, and a 10-minute cool-down period. The exercises were individually planned based on the participant's performance. To perform the balance exercises, supportive equipment such as balance discs and Pilates balls, as well as environments such as soft surfaces and stairs, were used.~The balance exercises applied during the intervention included standing on a balance disc with weight shifting, walking on a soft surface, tandem walking, walking while stepping over obstacles, and cross-step walking. Additionally, seated balance activities, standing trunk rotations using a Pilates ball, sit-to-stand exercises from a chair, and stair climbing exercises were also performed as part of the program."
223927636|NCT07038707|OTHER|Extract the serum and feces of the patients for standard screening of early biomarkers|In this study, blood and fecal samples from patients with herpes and herpes neuralgia were collected for genomic sequencing of the gut microbiota and metabolome analysis, etc. Based on the principle of diffusion tensor imaging, by measuring the anisotropic diffusion of white matter around the corpus callosum at the horizontal level of the lateral ventricle body, the lymphatic system clearance function is quantified
223927637|NCT07038707|OTHER|Meningeal lymphatic vessel imaging|The functional changes of the cerebral lymphatic system in patients with PHN were detected by meningeal lymphatic vessel imaging
223927638|NCT07039318|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells
223927639|NCT07039318|DRUG|Normal Saline (Placebo)|Normal Saline (Placebo)
223927640|NCT07038512|DEVICE|Floora Pelvic Rehabilitation Vaginal Dilator|The Floora Pelvic Rehabilitation Vaginal Dilator, created by Hyivy Health Inc, is a multi-therapy hand held ergonomic intravaginal wand device that is designed to be used in the comfort of the user's home. The Floora has two main therapeutic functions, controllable dilation and thermal therapy. It is the first vaginal dilator that performs auto-dilation using one or two air chambers inflated from the device surface by an internal pump, eliminating the need for reinsertion. The device is equipped with biosensors that measure the pressure from the vaginal canal which allows this device to provide a gradual and gentle stretch to the pelvic floor muscles. The thermal therapy is achieved through an electrical circuit, changing the temperature of the device in small increments. Users are able to force-stop and change the temperature and dilation settings during a session.
223927641|NCT07039682|DEVICE|Digital HIV Education and Self-Screening (EKSTRIM Model)|Participants in this arm will receive access to the EKSTRIM platform, a web-based digital tool designed for adolescents. The platform includes interactive educational content on HIV prevention, a self-assessment screening tool to evaluate individual HIV risk, and online peer educator support. The intervention will be implemented over a 6-week period. Participants will be encouraged to use the platform independently, with monitoring of access logs and engagement levels.
223927642|NCT07038824|DRUG|ENTR-601-45|intravenous infusion
223927643|NCT07038824|DRUG|ENTR-601-45 - matching placebo|intravenous infusion
224093994|NCT06331884|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
223927644|NCT07038291|OTHER|Not applicable- observational study|Observational study without intervention
223717876|NCT01217801|DRUG|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
223717877|NCT01217801|DRUG|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
223927645|NCT07039448|BEHAVIORAL|Acupressure|The acupressure intervention including the five acupoints. The acupressure will be performed once a day for 10 days in a group setting with same sex, supervised by a trained psychiatric nurse and preferably at least 2 hours after a meal.
223927646|NCT07039448|BEHAVIORAL|Sham Comparator|The sham group will be trained to perform acupressure in a similar way to the intervention group, except that they will use five sham acupoints. After completion of the project, patients in the sham group will receive the same interventions as the intervention group.
223927647|NCT06754020|DEVICE|Heart Rate Variability,HRV - ANSWatch|Please have the participant lie down and rest for 10 minutes, and remove any metallic items from their body. Next, put on the wrist-worn monitor, and avoid moving during the monitoring process. The device will emit a sound when the monitoring session is complete.
223927648|NCT06754020|DEVICE|Traditional Chinese Medicine Tongue Imaging|Use a camera to capture images of the tongue, and then have a Traditional Chinese Medicine (TCM) practitioner perform the diagnosis based on these images.
223927649|NCT06702618|DRUG|TQB3616 capsule+Fulvestrant Injection|TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
223927650|NCT06884800|PROCEDURE|Laparoscopic toupet fundoplication|Patients will undergo laparoscopic toupet fundoplication.
223927651|NCT07039643|OTHER|Pilates exercise|This study investigates a novel Pilates-based rehabilitation program for Achilles tendinopathy (AT). While eccentric loading is the standard treatment, many patients experience persistent symptoms or poor adherence. Pilates emphasizes core stability, neuromuscular control, and functional movement, offering a holistic approach that addresses kinetic chain dysfunction and movement impairments often overlooked in standard protocols. This trial will assess the feasibility and effectiveness of Pilates in improving pain, function, and movement quality in adults with AT. To our knowledge, this is the first clinical trial to evaluate Pilates as a targeted intervention for AT.
223927652|NCT07039643|OTHER|Alfredson protocol|At our knowledge this is the first study that will compare the most popular protocol in Achilles Tendinopathy to an alternative exercise method
223927653|NCT07030855|COMBINATION_PRODUCT|Elixirium thymi compositum (FoNo VIII.)|During the study, the dosage is for children and adolescents as follows: 6 ml three times a day for 6-9 years, 8 ml three times a day for 9-15 years, and 10 ml three times a day for 15-17 years.
223927654|NCT07030855|COMBINATION_PRODUCT|Elixirium thymi compositum (FoNo VIII.) placebo|During the study, the dosage is for children and adolescents as follows: 6 ml three times a day for 6-9 years, 8 ml three times a day for 9-15 years, and 10 ml three times a day for 15-17 years.
223927655|NCT07032532|DRUG|Golidocitinib|Golidocitinib 150mg orally once daily in a 21-day cycle
224093995|NCT06331884|DRUG|Placebo|Application of placebo
224282393|NCT04694612|DRUG|Remdesivir|Comparison of clinical improvement and clinical deterioration between those receiving Favipiravir compared to Remdesivir Injection in the patients with moderate COVID-19
224282394|NCT01706861|DEVICE|Celotres|Celotres following surgical removal of earlobe keloid.
223927656|NCT07032532|DRUG|Golidocitinib plus CHOP|Golidocitinib 150mg orally every other day with CHOP (Cyclophosphamide: 750mg/m2, IV, d1 ; Doxorubicin: 50mg/m2, IV, d1; Vincristine: 1.4mg/m2, IV, d1 ; Prednison: 100mg, po, d1-5) in a 21-day cycle for 6 cycles.
223927657|NCT06886646|OTHER|Allogeneic Mesenchymal Stromal Cell Therapy|Patients in this arm will receive 4 injections of allogeneic mesenchymal stromal cells (CSM) derived from human umbilical cord. The doses will be 1.106 cells/kg administered intravenously at days 0, 7, 14, and 21. The injections are given after thawing, washing, resuspension, and adjusting the dose. The CSM treatment aims to control chronic active antibody-mediated rejection (cABMR), improve renal function, reduce proteinuria, and increase graft survival without changing the immunosuppressive regimen.
223927658|NCT06886646|OTHER|Placebo (NaCl 0.9%) Treatment|Patients in this arm will receive placebo treatments, which will consist of 150 mL of saline (NaCl 0.9%) administered intravenously at the same intervals as the CSM group (days 0, 7, 14, and 21). The placebo will be administered under the same conditions as the treatment, and the participants and investigators will remain blinded to the group allocation. Like the CSM group, no changes will be made to the patients' immunosuppressive regimen.
223927659|NCT07038395|DEVICE|workflow|Placement of the surgical device and its effect on workflow
223927660|NCT06882525|PROCEDURE|Lidocaine (drug)|Lidocain subcuteous infiltratyion will be done to rush area.
223927661|NCT03803787|DRUG|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
224093996|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
224093997|NCT03934645|OTHER|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
224282395|NCT02760264|DRUG|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
224282396|NCT02760264|DRUG|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
223532489|NCT06816433|DRUG|Intervention D SLS-002|SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
223532490|NCT06816433|DRUG|Intervention D Placebo|A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
223927662|NCT06728462|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|The usual dose for oral use is 5 ACC tablets (equal to 1000 mg calcium element) daily given after meals.
223927663|NCT06656975|BEHAVIORAL|Brief Cognitive Therapy|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
224282397|NCT02760264|DRUG|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
224282398|NCT02760264|DRUG|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
224282399|NCT02480218|OTHER|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
224282400|NCT00013494|PROCEDURE|Stroke Rehabilitation|
224282401|NCT00773942|BEHAVIORAL|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
224282402|NCT00773942|BEHAVIORAL|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
224282403|NCT03360175|OTHER|No intervention - observational study|No intervention - observational study
224282404|NCT01796964|DRUG|ESBA1008 solution|For intravitreal (IVT) injection
224282405|NCT01796964|DRUG|Aflibercept|For intravitreal (IVT) injection
224282406|NCT04025684|OTHER|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
224282407|NCT04025684|OTHER|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
223532491|NCT06594770|PROCEDURE|Atraumatic Restorative Treatment|"A sharp excavator will be used to remove soft demineralized carious tissue from the patient\&#39;s primary molar 2-The molar will then be restored with capsulated Glass Ionomer in accordance to ART procedure.~3-Each capsule will be mixed for ten seconds and used for restoring teeth isolated by cotton rolls.~4-After the cement is cured, excess material will be removed with an excavator and a carver.~5-The occlusion will be tested for interferences with carbon paper. A layer of varnish coat will be applied to the surface and light-cured for 20 seconds ."
223717878|NCT00827333|OTHER|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
223717879|NCT00827333|OTHER|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
223927664|NCT06656975|BEHAVIORAL|Social Prescribing|"This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes."
223927665|NCT06656975|OTHER|Enhanced Usual Care|Participants will receive an informational booklet on improving loneliness. Participants may initiate or continue Collaborative Care for other conditions on a not research basis.
223927666|NCT06723145|DRUG|Aspirin|perioperative aspirin continuation
223927667|NCT06723145|DRUG|Aspirin interruption|Aspirin interruption 5-7 days before surgery
223927668|NCT06722547|OTHER|Standard PR|PLB, ACBT, Aerobic exercise, Education
223927669|NCT06722547|OTHER|Standard PR plus Respiratory Muscle Stretching|Standard PR plus Respiratory Muscle Stretching (RMS)
223927670|NCT06541834|DEVICE|Retinal imaging|Data of retinal imaging were acquired using Spectralis (Heidelberg, Germany) and California (Optos, UK).
223927671|NCT06607276|DRUG|Adebrelimab and capecitabine|Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
223927672|NCT06607276|DRUG|capecitabine|capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
223927673|NCT05856266|PROCEDURE|Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)|Ultrasound examination
224093998|NCT03934645|OTHER|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
224093999|NCT03352401|OTHER|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
224094000|NCT01977287|DEVICE|Functional Electrical Stimulation|
224282408|NCT04025684|OTHER|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
224282409|NCT04025684|OTHER|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
223927674|NCT05856266|OTHER|Haemophilia Joint Health Score (HJHS)|Functional joint examination
224282410|NCT04458961|PROCEDURE|One-stage|A one-stage revision operation involves one operation to remove the joint, thoroughly cleaning the infected area and then implanting a new joint immediately.
224282411|NCT04458961|PROCEDURE|Two-stage|A two-stage revision operation involves two operations: the joint is removed in one operation, a temporary spacer device is inserted, then the infection is treated with antibiotics, and then a new joint is implanted in a second operation.
224282412|NCT00003293|DRUG|leflunomide|
224282413|NCT00003293|DRUG|procarbazine hydrochloride|
224282414|NCT04577885|DRUG|SHR2554 and Rifampin|Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules
224282415|NCT02070757|DRUG|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
224282416|NCT02070757|DRUG|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
224282417|NCT01546922|DRUG|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
224282418|NCT05281926|DRUG|Poly ICLC|IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
224282419|NCT04171557|BEHAVIORAL|Bicycling|Total bicycling is reported in categories of: (0 - reference), (\>0 to \<60), (≤60 to \>150), (≤150 to \< 300) and (≥300) minutes/week
223927675|NCT06733220|PROCEDURE|Surgery for strabismus|Patients will undergo surgery to correct strabismus, congenital or acquired
223927676|NCT06738667|OTHER|Acupuncture|Patients in the acupuncture group will receive treatment at specified acupoints, performed by acupuncturists with at least five years of experience. The acupoints include bilateral Hegu (LI4), Yanglingquan (GB34), and affected-side Jiache (ST6), Xiaguan (ST7), and Tinggong (SI19). Participants will lie supine, and the skin will be sterilized. Sterile stainless-steel needles (0.25 mm diameter, 40 mm length) will be inserted using a guide device and a self-adhesive pad. Needles will be manipulated for at least 10 seconds to induce Deqi. Participants will receive 30 minutes of acupuncture for twelve sessions (3 per week for 4 weeks).
224094001|NCT01977287|DEVICE|Ankle Foot Orthosis|
224094002|NCT00318292|DRUG|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
224094003|NCT00318292|DRUG|Placebo|20 ml normal saline injection.
224094004|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
224094005|NCT01062477|BIOLOGICAL|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
224094006|NCT01062477|BIOLOGICAL|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
224094007|NCT03975192|DEVICE|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
224094008|NCT06261788|DEVICE|Temporary pacing|Transvenous temporary cardiac pacing - right internal jugular insertion
224094009|NCT03332888|DRUG|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
224282420|NCT03918941|DEVICE|Carey|mobile application
224282421|NCT03918941|OTHER|conventional information|leaflet, internet link and oral information
224282422|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
223927677|NCT06738667|OTHER|Sham treatment|The Park Sham device will be used for the sham acupuncture group. To maintain blinding, the acupuncture ritual will be identical in both groups, with the following exceptions: patients in the sham group will receive noninvasive acupuncture at the same acupoints as the acupuncture group. Sham needles, which resemble real needles but are blunt and slide within their handles, will be applied using the Park Sham device, secured to the skin with a self-adhesive pad. The procedure of manipulation is the same as for acupuncture, but without Deqi.
223927678|NCT06737744|OTHER|Active Games for Change (AG4C)|This intervention was carried out in Turkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The programme included a series of innovative, face-to-face active games with a non-formal approach that prioritised physical activity, specifically designed to support the development of social and emotional competencies identified for the first time in the field in a probation directorate serving young adult offenders.
223927679|NCT06737744|BEHAVIORAL|Active Games for Change Group Working|The Active Games for Change intervention program was implemented in Izmir, Türkiye within the Erasmus+ Key Action 3 project titled Active Games for Change (AG4C). The AG4C intervention program included a series of innovative, face-to-face active games with a non-formal approach that prioritised support for developing social and emotional competencies of young adults with substance use problems, for the first time in the field.
223927680|NCT06737549|DRUG|Nerver growth factor (NGF) injection|The 20ug mouse nerve growth factor (NO. S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd., Wuhan, China. mNGF will be dissolved in 2 ml of sterile water for injection and then injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
223927681|NCT06737549|DRUG|Placebo injection|Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
224094010|NCT01490593|BEHAVIORAL|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
224282423|NCT03122587|DEVICE|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
224282424|NCT03122587|DEVICE|Active sham transcranial alternating current stimulation|Active sham (placebo)
223532492|NCT06594770|PROCEDURE|Hall technique|"The procedure involves assessing the occlusion, contact points, and tooth shape. If contact points are present, orthodontic separators will be placed between the primary molars to create space for crown fitting, with the child seated upright to maintain airway safety. After 3 to 5 days, the separators will be removed, and loose plaque and debris will be cleared.~The correct crown size will be selected, ensuring it doesn't impinge on adjacent teeth, and will be filled with glass ionomer cement. The child will be instructed to bite down for two minutes to ensure proper seating. Excess cement will be removed, and contacts will be flossed. Any initial occlusal discrepancies are expected to resolve within weeks."
223532493|NCT06600971|OTHER|acupressure application|The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
223532494|NCT03011528|DRUG|VDC-IE x2|"Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
223532495|NCT03011528|DRUG|VDC-IE|"Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d"
223532496|NCT03011528|DRUG|TEMIRI|"Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d"
223532497|NCT03011528|DRUG|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~\- PBSC infusion, D0, at least 3.10\^6 CD34/kg"
223532498|NCT03011528|DRUG|Maintenance|"\* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously"
223532499|NCT03011528|PROCEDURE|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
224094011|NCT02241486|DRUG|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
224282425|NCT02940678|OTHER|No intervention|
224282426|NCT03170388|DRUG|IDP-126 Gel|Gel
224282427|NCT03170388|DRUG|IDP-126 Component A|Component A
223717880|NCT00827333|PROCEDURE|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
223717881|NCT00827333|PROCEDURE|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
223717882|NCT00827333|PROCEDURE|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
223717883|NCT01844128|DIETARY_SUPPLEMENT|weight loss|
223717884|NCT02285842|DEVICE|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
223717885|NCT04282642|BEHAVIORAL|Cognitive Training|Participants (n=20) provided game console with cognitive training games and activities.
223717886|NCT04282642|BEHAVIORAL|WLC (Waitlist Control)|Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
223717887|NCT02137265|DRUG|Clomiphene|Clomiphene citrate 50 mg orally daily
223717888|NCT02137265|DRUG|Placebo|One pill every other day
224094012|NCT02770521|DRUG|Treprostinil|Administered SC.
224282428|NCT03170388|DRUG|IDP-126 Component B|Component B
224282429|NCT03170388|DRUG|IDP-126 Component C|Component C
224282430|NCT03170388|DRUG|IDP-126 Vehicle Gel|Vehicle Gel
224282431|NCT00627471|DRUG|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
223927682|NCT06737549|DEVICE|EA intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are stimulated by using an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) with a frequency of 2/100 Hz and an intensity of patient can tolerate, targeting a current strength of 3.0mA, for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
223927683|NCT06737549|DEVICE|Acupuncture intervention|"Patients take supine position. After skin disinfection with 75% ethanol routine disinfection, the stainless needle (size 0.25mm×40mm, Hwato brand, Suzhou Medical Supplies Company Ltd in Jiangsu, China) will be inserted in GV20（Baihui) and the stainless needle(size 0.25mm×25mm, described above) will be inserted in GV26 (Shuigou), acupoints will be stimulated manually until patients feel soreness, distension or heaviness (the reaction of De Qi). Then, the needles are connected to an acupuncture point nerve stimulator (HANS-200, Nanjing Jisheng, Ltd., China) without closed circuit, with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off), three times a week for 6 weeks."
223927684|NCT05197400|DIAGNOSTIC_TEST|preoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
223927685|NCT05197400|DIAGNOSTIC_TEST|postoperative airway ultrasonography|"Tongue thickness Median sagittal tongue cross-sectional area Tongue width~Tongue volume:~Lateral parapharyngeal wall thickness"
223927686|NCT05480098|DRUG|Brimonidine Topical|Topical brimonidine intraoperatively for hemostasis
223927687|NCT06863285|OTHER|Educational|"intervention included the usual counselling by pharmacist e.g. Patients Education regarding Medications~* Pharmacist counseling patients regarding their disease and severity~* Pharmacist counseling (5- to 10-minute sessions) on the proper and safe use of medication.~* Pharmacist counseling patients regarding the importance of their therapy (treatment), non-pharmacological treatment like diet and exercises.~pharmacist counselling regarding the preventive measures that prevent patient from triggers that can initiate asthmatic attacks."
223927688|NCT06793176|DIAGNOSTIC_TEST|Video capture|A 20-second video capture of head-neck movements at high frame rates is conducted for all participants to obtain high-resolution images. The captured videos are analyzed using an algorithm based on Vibraimage technology to infer whether the participants have depression.
223927689|NCT06756412|PROCEDURE|Temporomandibular Joint Arthrocentesis|The symptomatic temporomandibular joint (TMJ), either right or left, will be anesthetized using an auriculotemporal nerve block and intracapsular anesthesia. The arthrocentesis procedure will be performed using the double-puncture technique. A 21-gauge needle will be inserted into the posterior region of the joint capsule, targeting the upper joint compartment at a point located 10 mm anterior to the tragus. A second 21-gauge needle will be introduced into the anterior region of the joint capsule, also targeting the upper compartment, at a point located 20 mm anterior to the tragus. The upper joint compartment will then be irrigated with a minimum of 200 mL of saline solution through one of the needles.
223927690|NCT06756412|PROCEDURE|Self Exercise Following Arthrocentesis|Following the arthrocentesis procedure described for the other study group, patients will undergo a standardized exercise regimen based on established literature. The regimen includes two sets of movements. The first set involves freely opening the jaw, shifting it right, left, and forward, and repeating these movements while applying finger resistance-closing the mouth against the pressure or forcing the jaw open with the fingers. Each movement will last 10 seconds and be performed 10 times daily. The second set aims to improve the mandibular condyle-articular disc relationship. Patients will open their mouth as wide as possible, advance their lower jaw fully, and close their teeth in an edge-to-edge position. These movements will be performed three times daily for 5 minutes after meals.
223927691|NCT06735430|DRUG|Ciprofol|Ciprofol for anesthesia induction (0.5mg / kg) and anesthesia maintenance (1-2.5mg/ (kg·h))
224094013|NCT02770521|DRUG|Placebo|Administered SC.
224094014|NCT02770521|DRUG|LY900014|Administered SC.
224094015|NCT02770521|DRUG|Insulin Lispro|Administered SC.
224094016|NCT00220363|DRUG|SPM 907|
224094017|NCT00321516|DRUG|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
224094018|NCT06318208|DIAGNOSTIC_TEST|lung function testing|lung function testing including LCI, FEV1, FVC, DLCO
224094019|NCT02665689|DRUG|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
223717889|NCT00687960|DIETARY_SUPPLEMENT|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
223717890|NCT00687960|DIETARY_SUPPLEMENT|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
223717891|NCT00687960|DIETARY_SUPPLEMENT|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
223717892|NCT00687960|DIETARY_SUPPLEMENT|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
223717893|NCT04977193|BIOLOGICAL|LY011|CAR-T
223717894|NCT02051686|DRUG|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
223927692|NCT06735430|DRUG|Propofol|Propofol for anesthesia induction (2mg / kg) and maintenance of anesthesia (4-10 mg / (kg·h))
223927693|NCT06735365|OTHER|CRRT|Hemodiafiltration
223927694|NCT06747312|DRUG|Belimumab+SOC|10mg/kg once a month for 18 months
223927695|NCT06747312|DRUG|SOC|SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
223927696|NCT06729983|PROCEDURE|Prophylactic Conjoint Tendon Lengthening|During a standard reverse shoulder arthroplasty procedure, the conjoint tendon will be incised and lengthened prophylactically
223927697|NCT06729983|PROCEDURE|Standard Reverse Shoulder Arthroplasty|A standard reverse shoulder arthroplasty procedure will be performed
224094020|NCT00824564|DRUG|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
224094021|NCT00824564|PROCEDURE|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
224094022|NCT04927273|OTHER|Survey|Surveyed neurological and orthopedic surgeons
224094023|NCT04404335|DIAGNOSTIC_TEST|Crevicular fluid analysis by using ELISA testing.|Samples of crevicular fluid (fluid existing in the space between the gums and the roots of the teeth) will be obtained from healthy and periodontal patients. In periodontal patients, samples will be taken before and after receiving a routine course of periodontal treatment (root scale and polish) to assess the levels of a peptide called LL-37 and inflammatory cytokines (IL-4, IL-6, IL-10): Samples will then be analysed using laboratory procedures (ELISA)
224094024|NCT04825548|OTHER|No intervention|Examination of patients with previous DVT
224094025|NCT02109081|DRUG|Dexamethasone|
224094026|NCT02109081|DRUG|Placebo|
223717895|NCT02051686|DRUG|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
223717896|NCT04967443|DRUG|Prazosin HCl 2mg|Prazosin HCL 1 X 2 mg capsule.
223717897|NCT04967443|DRUG|Prazosin HCl 1 mg|Prazosin HCl 2 X 1 mg capsule.
223717898|NCT04967443|DRUG|Prazosin HCl 5 mg|Prazosin HCL 1 X 5 mg capsule.
223717899|NCT00335478|DRUG|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is \>500 cells/mm\^3.
223927698|NCT05821283|PROCEDURE|exercise program consisting of supervised exercise and physical activity|The Physical Activity Group (PAG) included in an exercise program consisting of supervised exercise and physical activity (30 minutes of moderate-intensity walking). Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions.The physical activity program was applied as moderate intensity (maximum heart rate 50-70%) walking exercise. The patients were recommended to walk for 30 minutes, 3 days a week (total of 90 minutes) for the first 3 weeks, and 30 minutes 5 days a week (total of 150 minutes) for the 2nd 3 weeks
223927699|NCT05821283|PROCEDURE|exercise program consisting of only supervised exercises.|The Control Group (CG) included in the program consisting of only supervised exercises. Patients received 6 week (2-3 times a week) rehabilitation program composed of 15 physical therapy sessions
223927700|NCT06797414|OTHER|Pilate Exercises|"PILATES EXERCISE METHODS:~1. The cranium, triceps, back, and shoulder blades against the mat, then breath while maintaining muscle contraction .~2. Arm circles (both directions) on the mat, then use strong ribcage breathing to connect into scapula.~3. Diamond press: lie prone on a mat, using the lower part of the trapezius and serratusanterior muscles to slide shoulder blades out and down. Move into slight back extension maintaining this position.~4. Diamond press: repeat above but add lateral arm movement to back extension .~5. Arm slides 90°: lies supine on mat with arms bent at 90° and thumbs on floor. Slide elbows on floor toward waistline while contracting serratus anterior muscle.Repeat on the floor with other fingers. Always maintain proper neck alignment .~6. Arm circles on a tiny barrel while lying on back with the head and neck supported by the barrel. Opened chest, then link the scapula to the barrel. Hold this position while performing arm circles."
223927701|NCT06797414|OTHER|Whole-body vibration|Subjects were placed in a modified push-up position , put their hands in the middle of the platform, shoulder width apart, elbows slightly flexed, and their lower extremities were supported by kneeling on the floor . Vibration protocol included 5 sets of 60 s duration, at 5 mm amplitude and 30 Hz frequency, with a rest period of 60 s between sets . The subjects were reminded kneeling but upright and detached from the platform between sets.
224094027|NCT00486902|DRUG|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
224094028|NCT00486902|DRUG|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
224094029|NCT03485989|OTHER|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
224094030|NCT00277537|DRUG|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
224094031|NCT00277537|DRUG|placebo|BD for 12 weeks
224094032|NCT03396289|OTHER|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
224094033|NCT03396289|OTHER|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
224094034|NCT03198221|DRUG|Golytely|bowel preparation
224094035|NCT03198221|DRUG|Clenpiq|bowel preparation
224094036|NCT03892421|DRUG|Rituximab|Rituximab 375 mg/m²
224094037|NCT03892421|DRUG|Carboplatin|Carboplatin AUC5
224094038|NCT03892421|DRUG|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
224094039|NCT03892421|DRUG|Dexamethasone|Dexamethasone 40 mg
223927702|NCT06797414|DEVICE|Hot Pack|for 10 to 15 minutes
223927703|NCT03876951|DIAGNOSTIC_TEST|Vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
223927704|NCT05759923|DRUG|OATD-02|Boin Design Scheme will be applied for dose escalation. Dose will start with 2.5mg o.d., the desicion about dose escalations will be made based on the occurence of DLT
223927705|NCT06281054|PROCEDURE|Revascularization|Performing PCI or CABG
223927706|NCT01830595|DRUG|Recombinant Lactoferrin|
223927707|NCT01830595|DRUG|Placebo|
223927708|NCT06754566|BEHAVIORAL|Caregiver-Assisted Rehabilitation with Strategy Training|CAR-ST is a home-based rehabilitation that guides both stroke survivors and their caregivers to implement strategy training for addressing daily activity limitations after stroke. The caregiver, as an active partner, not only supervises the participant but also co-participates in the practice. Caregivers are instructed on when and how to provide assistance during task practice, using physical, verbal, or visual guidance. As the participant's performance improves, the caregiver is empowered to motivate them to exert greater efforts, encouraging higher repetitions, longer durations of the same task, and an increased level of difficulty.
223927709|NCT06754566|BEHAVIORAL|Strategy Training|Compared to CAR-ST, ST is a home-based rehabilitation that guides stroke survivors only to implement strategy training for addressing daily activity limitations after stroke.
223927710|NCT06754566|BEHAVIORAL|Education|Stroke-related information and knowledge that includes stroke subtypes and their etiology, risk factors of primary and secondary stroke, healthy lifestyles, common sequala, and adaptive skills for impaired functions are provided.
223927711|NCT05188664|DRUG|LM-302|LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
224094040|NCT03892421|DRUG|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
224094041|NCT03234335|OTHER|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
224282432|NCT00627471|DRUG|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG\<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
224094042|NCT02521129|DEVICE|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
223927712|NCT05188664|DRUG|Toripalimab|Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
223927713|NCT05301335|DEVICE|SCONE|The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
223927714|NCT06847425|PROCEDURE|Sphenopalatine Ganglion Block trans oral approach saline injection|The sphenopalatine block will be done by the end of the operation using a trans-oral approach at the greater palatine foramen with the help of a Macintosh blade number 3 for good visualization of the hard and soft palate using a 25 Gauge 1.5 inch needle curved at 45 degrees 25 mm from the tip and filled with 1.5 ml of normal saline. The greater palatine foramen is located posteromedial to the third maxillary molar and anteromedial to the pterygoid hamulus and maxillary tuberosity. The foramen will be identified by digital palpation, and the needle will be inserted until reaching the bone then redirected slightly until the foramen is localized and the needle easily gets in the greater palatine canal. aspiration will be done to ensure that no blood vessels are punctured, and the solution will be injected.
224094043|NCT00003060|BIOLOGICAL|filgrastim|
224094044|NCT00003060|DRUG|busulfan|
224094045|NCT00003060|DRUG|cyclophosphamide|
224094046|NCT00003060|DRUG|cyclosporine|
224094047|NCT00003060|DRUG|methotrexate|
224094048|NCT00003060|PROCEDURE|allogeneic bone marrow transplantation|
224094049|NCT02363829|DRUG|Nelfinavir|
224094050|NCT02363829|BIOLOGICAL|Cisplatin|
224094051|NCT05250856|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
224282433|NCT03113526|PROCEDURE|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
224282434|NCT02285634|DRUG|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
224282435|NCT02285634|DRUG|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
223717900|NCT03801460|OTHER|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
223717901|NCT02405780|DRUG|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
223927715|NCT06847425|PROCEDURE|Sphenopalatine ganglion block trans oral approach bupivacaine injection|The sphenopalatine block will be done by the end of the operation using a trans-oral approach at the greater palatine foramen with the help of a Macintosh blade number 3 for good visualization of the hard and soft palate using a 25 Gauge 1.5 inch needle curved at 45 degrees 25 mm from the tip and filled with 1.5 ml of bupivacaine. The greater palatine foramen is located posteromedial to the third maxillary molar and anteromedial to the pterygoid hamulus and maxillary tuberosity. The foramen will be identified by digital palpation, and the needle will be inserted until reaching the bone then redirected slightly until the foramen is localized and the needle easily gets in the greater palatine canal. aspiration will be done to ensure that no blood vessels are punctured, and the solution will be injected.
223927716|NCT05510921|OTHER|Minimalist music group|Participants in this group will listen individually a live session of minimalist music piano piece, in a break room in the oncology sector, lasting between 10 and 15 minutes.
223927717|NCT05510921|OTHER|Minimalist music + birdsongs group|Participants in this group will listen individually a live session of minimalist music piano piece with the superposition of bird song sounds, in a break room in the oncology sector, lasting between 10 and 15 minutes.
223927718|NCT06836037|DRUG|Efinopegdutide|Subcutaneous injection
223927719|NCT06836037|DRUG|Placebo|placebo matching efinopegdutide
223927720|NCT03487185|DEVICE|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
223927721|NCT03487185|OTHER|Sleep Advice Control|Initial sleep advice counseling alone
223927722|NCT04338152|BEHAVIORAL|Family Focused Therapy for Clinical High Risk Youth (FFT-CHR)|Family-Focused Therapy (FFT) has been tested in randomized trials involving persons with bipolar disorder, depression, and clinical high-risk syndromes. FFT-CHR provides families with psychoeducation (sessions 1-6) about prodromal symptoms and the role of the family in helping maintain stability. Clients are supported in building coping skills and monitoring thoughts, perceptions, and mood. The family formulates a prevention action plan to prevent prodromal symptoms from escalating into full episodes. Communication training (sessions 7-13) teaches families to express positive and negative feelings, listen actively, make positive requests for change, and communicate clearly through role-playing and between-session practice. In problem solving (sessions 14-18) participants learn to break down problems into smaller ones, evaluate pros/cons, and choose solutions to implement.
223927723|NCT04338152|BEHAVIORAL|Enhanced Care (EC)|Enhanced care (EC) has been tested as a family educational treatment in CHR and bipolar youth. The first 3 sessions of EC involve the CHR person and family (parents, siblings) and cover the same content as the psychoeducational module of FFT in abridged form. The objective of these sessions is to develop a prevention action plan. Then, the CHR person is offered monthly individual sessions with the same clinician over the next 5 months, for a total of 8 sessions over 6 months. The individual sessions focus on applying the prevention action plan when symptoms emerge, and supportive, nondirective problem-solving regarding areas of conflict with family, with peers or in the educational or occupational arena. The clinician also serves as case manager.
223927724|NCT06747988|DEVICE|Traction Device|After circumferential incision and trimming the submucosa at the incision's edge, dissection is initiated until approximately 20 to 30% of the anal side (for colonic lesions) or oral side (for gastric lesions) of lesion has been dissected leaving a flap of at least 1 cm in length. Once the mucosal flap is created the X-tack device is introduced through the endoscope channel. The first tack is placed on the opposite wall of the lesion, the 2nd and 3rd tack will then be placed next to each other on the mucosal flap portion of the lesion. The 4th tack does not have to be placed but can be used to generate further traction at any time. Clips can be placed along the suture and clipped to the wall at any point to change angulation of traction. The sutures can then be cut and released from the tissue
223927725|NCT02728336|PROCEDURE|Cardiac MRI|
224094052|NCT05250856|DRUG|Placebo|Placebo, (0.9% Sodium Chloride for IV infusion)
223717902|NCT02405780|DRUG|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
223717903|NCT01654536|DRUG|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
224094053|NCT05629702|DRUG|Nabiximols|Oromucosal spray
224094054|NCT05629702|DRUG|Temozolomide|Oral capsule
224094055|NCT05629702|DRUG|Nabiximols-matched placebo|Nabiximols-matched placebo oromucosal spray
224094056|NCT04545307|BIOLOGICAL|Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis|The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
223717904|NCT01654536|DRUG|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
223717905|NCT05047835|DIAGNOSTIC_TEST|electrocardiogram|Prone position electrocardiogram
223717906|NCT06409715|OTHER|Enhanced Care with PMRT and Acupressure|Progressive Muscle Relaxation Training (PMRT) is a structured strategy created to reduce psychological and physiological stress by alternating muscle contraction and relaxation.Rooted in traditional Chinese medicine's meridian theory, acupressure employs manipulative techniques on distinct acupoints to induce therapeutic effects 18. Targeting enhanced circulation, pain relief, muscle relaxation, and systemic regulation, acupressure's efficacy as both a preventive and therapeutic modality in complementary and alternative medicine is well-established
223717907|NCT06409715|OTHER|standard care|vital sign monitoring, positional support, dietary management, pain control, psychological support, functional training, and educational initiatives on health matters.
223717908|NCT03464071|DEVICE|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
223927726|NCT05406349|BEHAVIORAL|Self-navigation task|Participants will perform a self-navigation task with two experimental conditions: Either they will be asked to walk towards a visible wall-mounted sign, or they will be asked to find and learn a hidden target location within the experimental room.
223927727|NCT05406349|BEHAVIORAL|Observation task|Participants will sit on a chair in a corner of the room (RNS participants) or watch a video that was recorded from the corner of the room (EMU participants). They will be asked to keep track of another person's location who is walking around the room, and to press a button whenever the other person crosses a previously-learned target location.
223940999|NCT02815917|DRUG|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
224282436|NCT02285634|DRUG|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
224282437|NCT02285634|DRUG|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
223717909|NCT03464071|DEVICE|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
223717910|NCT00726869|DRUG|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
223717911|NCT01837108|DRUG|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
223941000|NCT03432000|OTHER|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
223941001|NCT06305884|PROCEDURE|Bioelectric Impedance Analysis|Undergo BI
223717912|NCT01837108|DRUG|Placebo|
223941002|NCT06305884|OTHER|Exercise|Pedal an exercise bike
223941003|NCT06305884|PROCEDURE|Photoplethysmography|Undergo PPG
223941004|NCT06305884|BEHAVIORAL|Questionnaire Administration|Ancillary studies
223941005|NCT02562937|BEHAVIORAL|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
223941006|NCT02714777|DEVICE|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
223941007|NCT06522165|OTHER|Analysis|analysis and review of imaging and clinical data
223941008|NCT06840496|DRUG|Bionetide|Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
223941009|NCT06840496|DRUG|Placebo|"Placebo~• Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks"
223941010|NCT05905926|DRUG|Tenapanor|Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study. Doses can be titrated to either 50 mg BID or 25 mg BID
223941011|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.1mg/kg|Remimazolam Tosilate for Injection 0.1mg/kg at induction
223941012|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.15mg/kg|Remimazolam Tosilate for Injection 0.15mg/kg at induction
223941013|NCT04908553|DRUG|Remimazolam Tosilate for Injection 0.2mg/kg|Remimazolam Tosilate for Injection 0.2mg/kg at induction
223941014|NCT02407808|DRUG|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
223941015|NCT02407808|DRUG|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
223941016|NCT05944094|DEVICE|Clorhexidine|Antiseptic treatment aimed at reducing potential bacterial overgrowth consisted of 10 days (1 box) of vaginal ovules of CLX (CumLaude CLX ® , CLX digluconate 0.2%) always starting between 10+0 and 16+0 weeks.
223941017|NCT01970878|DRUG|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
223941018|NCT01970878|DRUG|GP MDI (PT001)|GP MDI administered as two puffs BID
223941019|NCT01970878|DRUG|FF MDI (PT005)|FF MDI administered as two puffs BID
223941020|NCT01970878|DRUG|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
223941021|NCT06317610|OTHER|growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI|biopsy or puncture: Patients received biopsy or puncture to obtain tumor tissues or Malignant effusion for organoids establishment
223941022|NCT02412540|BEHAVIORAL|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
223941023|NCT01840085|DRUG|0.03% DSC127 topical gel|
223941024|NCT03050931|DEVICE|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
223941025|NCT06505382|DIAGNOSTIC_TEST|Ultrasound-guided percutaneous neuromodulation|Percutaneous ultrasound-guided neuromodulation of the saphenous nerve in subjects with patellofemoral pain to assess its positive effects on pain and functionality.
223941026|NCT04407247|BIOLOGICAL|Infliximab|Given IV
223941027|NCT04407247|BIOLOGICAL|Vedolizumab|Given IV
223532500|NCT03011528|RADIATION|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
223532501|NCT04726592|DRUG|Clorazepate Dipotassium|Clorazepate Dipotassium : 20 mg intravenous injection
223532502|NCT04726592|DRUG|Placebo|Placebo IV
223927728|NCT05993650|OTHER|Inspiratuar Muscle Training Group|Inspiratory muscle training will be done for 15 minutes/session, 2 times/day, or 30 minutes/day if tolerated, 5-7 days/week (one under supervision and others at home), for a total of 6 weeks. Applications made at home will be followed with a diary. Inspiratory muscle training will be performed using an inspiratory muscle training device (PowerBreathe®) working with the threshold loading principle.In the first week of the training, 30-50% of the maximal inspiratory pressure (MIP) measured in the initial evaluation of the individual will be adjusted according to the patient's tolerance, and inspiratory muscle training will be performed. Respiratory muscle strength measurement will be repeated every week in the individuals in the training group. 30-50% of the new MIP value obtained will be calculated and adjusted by calculating the new training workload for the application of inspiratory muscle training in the following weeks
223927729|NCT05993650|OTHER|Thoracic Expansion Exercise Group|"Individuals in this group will be given thoracic expansion exercises and patient education. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of inhale a deep breathing + holding the deep breath for 3 seconds + slowly exhale all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
224094057|NCT06404489|BEHAVIORAL|Multimodal prehabilitation Program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals."
224282438|NCT03297372|DEVICE|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
223532503|NCT04726592|DRUG|Ketoprofen|Ketoprofen 100 mg IV
223532504|NCT04726592|DRUG|Metoclopramide|Metoclopramide 10 mg IV
223532505|NCT06858735|DRUG|Durvalumab|Given by IV
223532506|NCT06858735|DRUG|Gemcitabine|Given by IV
223532507|NCT06858735|DRUG|Cisplatin|Given by IV
223532508|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 1|Pharmaceutical form:liquid Route of administration: intramuscular
223532509|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 2|Pharmaceutical form:liquid Route of administration: intramuscular
223532510|NCT04398706|BIOLOGICAL|Pneumococcal Conjugate Vaccine formulation 3|Pharmaceutical form:liquid Route of administration: intramuscular
223532511|NCT04398706|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
223717913|NCT06341751|BEHAVIORAL|Psychological treatment for persistent fatigue|The treatment consists of three main phases: 1) goal-setting; stabilizing sleep-wake patterns and even distribution of activities over the day (pacing). Attention-shifting and cognitive reappraisal 2. Gradual increase in physical activity followed by gradual increase in mental and social activity 3. Individual work to reach treatment goals.
223927730|NCT04809584|DRUG|F18-DCFPyL|Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL
223927731|NCT04809584|DRUG|Gadolinium|Contrast agent
223927732|NCT04809584|PROCEDURE|Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan|Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)
223927733|NCT06573385|OTHER|Questionnaire|Questionnaire application
223927734|NCT06812871|DRUG|furmonertinib|furmonertinib (160mg, once a day, continuous administration); bevacizumab (7.5 mg/kg body weight, once every 3 weeks); Pemetrexed (50 mg intrathecal injection chemotherapy, once every 3 weeks, up to 9 cycles).
223532512|NCT04398706|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form:liquid Route of administration: subcutaneous
223532513|NCT04398706|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Pharmaceutical form:liquid Route of administration: intramuscular
223532514|NCT04398706|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)|Pharmaceutical form:liquid Route of administration: intramuscular
223717914|NCT02140086|BEHAVIORAL|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
223717915|NCT06361160|DEVICE|Active Transcranial Magnetic Stimulation (TMS)|Active rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) at the onset of the Auditory Verbal Hallucinations (AVH).
223927735|NCT06820580|OTHER|Salutogenic Approach Based Interview|Salutogenic Approach Based Interviewing Program consists of 8 sessions. The interview will be conducted for four weeks and on two specific days of the week. Interviews will be conducted in groups of 6-8 people. The interview will last 30-40 minutes on average.
223927736|NCT04751331|BIOLOGICAL|LPS|Lipopolysaccharide (LPS) (0.8ng/kg of body weight; E. coli group O:113)
223927737|NCT04751331|BIOLOGICAL|Saline|0.9% saline administered as an intravenous bolus
223927738|NCT06739551|DRUG|Methotrexate (drug)|oral methotrexate 10 mg per week for 12 weeks
223927739|NCT06739551|DRUG|Acitretin|oral acitretin 50 mg once daily for 12 weeks
223927740|NCT04940624|DRUG|Soticlestat|Soticlestat mini-tablets or tablets.
223927741|NCT04940624|DRUG|Placebo|Soticlestat placebo-matching mini-tablets or tablets.
223927742|NCT06862232|PROCEDURE|"Modified Winograd Bird Flap Technique"|"In the first group (n=36), the modified Winograd Bird Flap technique will be performed for medially ingrown toenails. Local anesthesia with 1% lidocaine will be administered at the base of the first toe, and a temporary tourniquet will be applied using a sterile glove to minimize bleeding.~This technique modifies the Winograd method, optimizing functional and cosmetic outcomes while reducing recurrence rates. A sparrow-shaped incision will be made, encompassing the lateral nail bed, proximal germinal matrix, and underlying bone tissue, improving surgical access while preserving the healthy nail structure.~Granulated and infected tissue will be excised completely down to the periosteum to prevent recurrence. The wound will be sutured using 3/0 prolene sutures, ensuring optimal healing and minimal scarring. This method aims to reduce pain, shorten recovery time, and improve patient satisfaction compared to traditional approaches."
224094058|NCT05292469|BEHAVIORAL|Comprehensive approach to hypertension management|Trained health workers will review blood pressure (BP) logs and provide treatment. The patients will receive a BP lowering informational package, BP monitoring device and log book and pill-box and medication table. The participants will receive monthly home visits (6 visits) to discuss hypertension and ways to manage it. They will be encouraged to identify problems and developing an action plan to solve them. The participants will be encouraged to set behavioral goals. The follow up visits will review the progress made in implementing action plan and goals set and updating them. Review BP logs and facilitate tailored discussion on topics based on problems faced by participants on barriers to medication adherence, physical activity, weight management or diet. The family members will be involved and be accountable in supporting the patients in achieving the action plans.
224094059|NCT05842954|DRUG|KLU156|Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
224094060|NCT05842954|DRUG|Coartem|Oral use. Dosing will be selected based on patient's body weight as per product's label.
224094061|NCT06649357|PROCEDURE|MoLEP|Patients with an indication for surgery for BPH via EEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
224094062|NCT06649357|PROCEDURE|BiTURP|Patients with an indication for surgery for BPH viaEEAP with a prostate volume exceeding 80cc will be included in the study on a prospective basis. Surgery will be randomly assigned using MoLEP or BiTURP. A qualified surgeon, having completed their learning curve for endoscopic enucleation (more than 50cases) and possessing experience with both laser types, will perform the surgical procedure.
223532515|NCT04398706|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:liquid Route of administration: oral
224094063|NCT04726085|DRUG|Indomethacin 150mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
224094064|NCT04726085|DRUG|Ibuprofen 2400mg|Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
224094065|NCT06657339|PROCEDURE|Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)|"The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach."
224094066|NCT06334835|DIAGNOSTIC_TEST|lncRNA signature analyses|Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.
223532516|NCT04398706|BIOLOGICAL|Hepatitis B Vaccine* [Recombinant] *as applicable|Pharmaceutical form:liquid Route of administration: intramuscular
223532517|NCT04792216|OTHER|Wild Salmon|Wild salmon fillets
223532518|NCT04792216|OTHER|Farmed Salmon|Farm salmon fillets
223532519|NCT07000669|OTHER|Bilateral peribulbar block|Patients undergoing bilateral peribulbar anesthesia for cataract surgery.
223532520|NCT07003191|DRUG|Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)|First-time treatment with Metformin Hydrochloride and Empagliflozin Tablets (metformin 500mg and empagliflozin 5mg per table) for at least 6 months
223532521|NCT07004348|OTHER|Animation group will receive 4 sessions of animation as education media as intervention.|Wait list group will receive the conventional session of education
223532522|NCT07003204|PROCEDURE|medical thoracoscopy|pleural fluid aspiration and cellular analysis
223532523|NCT07003854|DEVICE|Mandibular advancement device|Custom made titrable bi-bloc MADs worn during sleep to stabilize airway and treat obstructive sleep apnea
223927743|NCT06862232|PROCEDURE|Classic Winograd Technique|"The classic Winograd technique, a widely used traditional surgical approach, will be performed. Local anesthesia with 1% lidocaine will be administered, and a temporary tourniquet will be applied. A linear incision will be made to separate the nail bed from the soft tissue, followed by the excision of the lateral nail bed and germinal matrix in a linear fashion to ensure complete removal of the affected nail portion. The wound will then be sutured using 3/0 prolene sutures.~This method is a standard approach for ingrown toenail surgery, offering high recurrence prevention rates but carrying a risk of cosmetic and structural nail alterations."
223532524|NCT07004829|BEHAVIORAL|Exercise counselling via instant messaging|The 12 weeks of messages will be sent by a trained counsellor. At baseline, participants will select their desired IM application (WhatsApp/WeChat), timing of messages (morning/noon/afternoon), message format (audio/text), and language style (spoken/written). The message library, established in the HMRF-funded study, consists of messages in text and pre-recorded voice message formats, images, videos, and stickers. Each week starts with messages on factual information and ends with a question to initiate conversations to clear any queries; counsellor will provide real-time replies. The 12-week messages are structured based on the M-PAC framework.
223532525|NCT07003659|OTHER|Tele-Yoga|This program consisted of diaphragmatic breathing, pranayama techniques consisting of nadi sodhana and ujjai, yoga poses consisting of sukhasana, bharadvajasana, marjaryasana - bitilasana, bhujaganasana, salabhasana, kapotasana, hasta uttanasana, virabhadrasana, adho mukha svanasana, bhujangasana. The exercises were carried out in a way that they would be followed up with an exercise diary in which they would take notes on continuing these exercises throughout the tele-yoga practice period, and reminder messages for the exercises were sent by the researchers to the WhatsApp group opened with the participants who participated in the study and were included in the exercise group.
223532526|NCT06543862|OTHER|CADx (AI) system|The CADx system will be used to predict the histopathology of the polyp detected.
223532527|NCT07003945|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation|With the real-time guidance of TTE, a radiofrequency electrode needle was percutaneously inserted via the transapical intramyocardial approach into the hypertrophied septum for thermal ablation. Intraoperative TTE and 12-lead electrocardiographic monitoring were employed to assess the ablation extent and prevent vascular and cardiac conduction bundle injury. The success of ablation was confirmed by evaluating contrast medium perfusion defects in the ablated areas and comparing them with the preprocedural hypertrophied septum.
223532528|NCT07003633|PROCEDURE|PENG block with 0.25% bupivacaine guided by ultrasound.|PENG (Pericapsular nerve block) is a peripheral nerve block which is performed for patients with hip fractures aimed to prevent preoperative and postoperative pain. It is performed under sterile conditions under ultrasound guideance.
223532529|NCT06151483|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223532530|NCT06151483|OTHER|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223532531|NCT07005050|DEVICE|RPD|Renal Pelvic Denervation
223927744|NCT06862232|PROCEDURE|Modified Noel Technique|"Local anesthesia with 1% lidocaine will be administered, and a temporary tourniquet will be applied. A 4-6 mm semi-elliptical incision will be made adjacent to the lateral borders of the nail bed to access the granulated tissue.~Unlike the Bird Flap technique, this method preserves both the nail bed and proximal germinal matrix, ensuring that only the inflamed soft tissue and granulated tissue are excised. The remaining tissue will be sutured subungually using 3/0 prolene sutures, promoting proper healing and maintaining the nail's structural integrity. This technique is designed to be less invasive while effectively treating infected and inflamed tissue."
223927745|NCT06862700|OTHER|Vasopressor Exposure Levels|This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.
223927746|NCT06860087|DIETARY_SUPPLEMENT|Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (200 µg/d)|50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 200 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.
224094067|NCT03396549|DEVICE|new sham tDCS|1 ch TCT transcranial stimulator
224094068|NCT03396549|DEVICE|real tDCS|1 ch TCT transcranial stimulator
224094069|NCT04915508|DRUG|Hormone Therapy|Receive hormonal therapy
224094070|NCT04915508|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223532532|NCT07005050|DRUG|Active hypertension medical therapy|Prespecified two medication regimen for control of hypertension
223532533|NCT07002879|PROCEDURE|dry needle|"An 18-gauge needle was first used to fenestrate the common extensor tendon and lateral periosteum. Once adequate anesthesia was confirmed, an 18-gauge needle was inserted along the tendon's longitudinal axis (without exiting the skin) and advanced in a peppering motion 40 to 50 passes from superficial to deep layers over approximately two minutes"
224094071|NCT06960239|DEVICE|IRE System|Irreversible Electroporation (IRE) System for the Treatment of Upper Airway Obstruction due to Adenotonsillar Hypertrophy in Children
224094072|NCT06960395|DRUG|VIR-5525|Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion
224094073|NCT06960395|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for Infusion Route of Administration: Intravenous (IV) infusion
224094074|NCT02214979|DRUG|Telmisartan/Ramipril|fixed dose combination tablet
224094075|NCT02214979|DRUG|Telmisartan|
224094076|NCT02214979|DRUG|Ramipril capsule|
223927747|NCT06860087|DIETARY_SUPPLEMENT|Dietary Supplement: Oral chromium supplementation during gestational diabetes mellitus through the administration of chromium picolinate tablets (400 µg/d)|50 Pregnant women with gestational diabetes mellitus will receive an oral supplementation of 400 µg of chromium picolinate (Nutraxin, B'IOTA Laboratories, Istanbul, Turquie) per day for 06 weeks, starting from their 28th week of pregnancy. 02 fasting blood samples will be taken: one just before the supplementation begins and the other upon its completion, to assess biomarkers of glucose and lipid metabolism, oxidative stress, and inflammation.
223927748|NCT06778889|BEHAVIORAL|Undergraduate Medical Students|This is an observational study without any intervention. Data will be collected using standardized questionnaires to assess physical activity, mental health, and stress levels in the participants.
224094077|NCT02214979|DRUG|Ramipril tablet|
224094078|NCT02935738|DRUG|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
224094079|NCT04072770|DIETARY_SUPPLEMENT|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
224094080|NCT04072770|DIETARY_SUPPLEMENT|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
223717916|NCT06361160|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|"Sham rTMS (continuous theta burst, cTBS) applied to the temporo-parietal junction (TPJ) during the onset of the Auditory Verbal Hallucinations (AVH).~An electrical stimulator is synchronised with the magnetic stimulation to recreate the tactile sensation and the coils emits the same noise during sham stimulation as in the active configuration, making it impossible to distinguish between active and placebo magnetic stimulation."
223717917|NCT04843020|DRUG|ION 682884|Subcutaneous injection every month
224094081|NCT06960135|PROCEDURE|open partial nephrectomy|open partial nephrectomy
223717918|NCT05209425|DIETARY_SUPPLEMENT|Vitamin D3|Participants are randomly divided into 4 groups. The first group receives regular Vitamin D3 (1000IU), the second receives microencapsulated D3 (1000IU), the third group receives regular Vitamin D3 (2500IU), the fourth receives microencapsulated D3 (2500 IU). Plasma concentrations of Vitamin D (D3, 25(OH)D3 and D2) are measured at baseline-before treatment start (day 0), during treatment (day 14) and at end of treatment (day 30). After the end of supplementation, blood vitamin D concentrations are checked again at day 45 and day 60.
223717919|NCT00602797|DRUG|Paclitaxel|Given IV
224094082|NCT06960135|PROCEDURE|laparoscopic partial nephrectomy|laparoscopic partial nephrectomy
224094083|NCT00469508|DRUG|Modafinil|400mg pills taken orally daily for 12 wks.
223717920|NCT00602797|OTHER|Quality-of-Life Assessment|Ancillary studies
223717921|NCT00602797|OTHER|Questionnaire Administration|Ancillary studies
223717922|NCT00602797|DRUG|Vinorelbine Tartrate|Given IV
223717923|NCT03473977|BIOLOGICAL|Benralizumab|Benralizumab (anti-IL5Ra) will be injected every 4 weeks in doses of 30 mg (total of 3 injections) in subjects with active Eosinophilic Gastritis.
223717924|NCT03473977|BIOLOGICAL|Placebo|Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
223717925|NCT01560793|BIOLOGICAL|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
224094084|NCT00469508|DRUG|Placebo|400mg pills taken orally daily for 12 wks
224094085|NCT06960447|DEVICE|Nd:YAG Laser|Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
224094086|NCT06960447|DEVICE|Alexandrite Laser|Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
224094087|NCT04721873|DRUG|Phentermine-Topiramate|Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --\> 7.5-46mg x 1 week --\> 11.25-69mg x 1 week --\> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
223927749|NCT06858033|DEVICE|Clear aligner|The effects of treatment on periodontal parameters (plaque index, gingival index, bleeding index on probing), salivary parameters (stimulated/unstimulated flow rate, stimulated/unstimulated pH, buffering capacity) and oral microorganism counts (S. mitis, S. salivarius, S. mutans, C. albicans) of children treated with labiolingual spring hawley and clear aligners were investigated.
223927750|NCT06858033|DEVICE|Labiolingual spring hawley|The effects of treatment on periodontal parameters (plaque index, gingival index, bleeding index on probing), salivary parameters (stimulated/unstimulated flow rate, stimulated/unstimulated pH, buffering capacity) and oral microorganism counts (S. mitis, S. salivarius, S. mutans, C. albicans) of children treated with labiolingual spring hawley and clear aligners were investigated.
223927751|NCT06876376|PROCEDURE|intraoperative ultrasound for the assessment of bowel deep infiltrating endometriosis|Women with posterior compartment deep infiltrating endometriosis with or without bowel involvement scheduled for surgical treatment at the Department of Obstetrics, Gynecology, and Reproductive Medicine of Dexeus University Hospital.
223927752|NCT06877442|DIAGNOSTIC_TEST|serum level of neurofilament light chain|labarotory investigation to evaluate serum level of neurofilament light chain
223532534|NCT07002879|PROCEDURE|Platelet Rich Plasma|A 15 mL peripheral blood sample was drawn and centrifuged at 3 000 rpm for 3 minutes. Approximately 2 mL of PRP was aspirated directly from the buffy coat and injected into the epicondylar region under ultrasound guidance.
223532535|NCT06873724|DRUG|SPY003-207|Experimental
223927753|NCT06885554|DEVICE|SANA|SANA is an audio-visual stimulation device found to reduce symptoms commonly found in AjDs. SANA is an eye mask that delivers coordinated pulses of light and sound that facilitate relaxation in the wearer. The device's mechanism of action is neuromodulation through audiovisual stimulation (AVS). When the brain receives a stimulus through the eyes or ears, it emits a responsive electrical charge, called a Cortical Evoked Response (CER). The brain responds by synchronizing to it, a process known as Frequency Following Response (FFR). FFR can be used to trigger each electrical pattern to facilitate a state of relaxation. The Sana device utilizes AVS to induce FFR.
223532536|NCT06873724|OTHER|Placebo|Placebo
223532537|NCT05666609|PROCEDURE|placement of non-cutting seton (silicone)|Treatment of Fistula in ano is conducted according to the institution's treatment guidelines. Silicon seton placement is conducted under general anesthesia. Identification of the FIA is secured by the insertion of a bulb-headed lacrimal probe, on which a silicon vessel loop is attached and pulled through the entire fistulous tract. In case of a perianal abscess, drainage and sphincter-sparing debridement is performed followed by secondary wound healing. The loop is ligated loosely outside the anus without any additional tension to the skin. Duration of placed seton is depending on group assignment and is set to either 4 or 12 weeks.
223532538|NCT06879210|DEVICE|Mobile device.(phone)|Develop a mobile device \[Disease Assistance Consultation\] to help patients promptly understand their disease and how to care for it. After a 4-week trial period, conduct interviews with participants to determine whether using the mobile device can increase participants' knowledge and improve the quality of healthcare.
223532539|NCT07033195|DEVICE|Skills-based Virtual Reality Therapy|"1. A 34-minute education video session on the science behind chronic pain and the scientific principles of the therapy.~2. VR skills-based therapy: a virtual reality therapy consisting of different psychological training exercises"
223532540|NCT07033195|DEVICE|Distraction-based Virtual Reality Therapy|1\. A 7-minute education video session on the science behind pain-focused attention and distraction. 2. VR distraction-based therapy: a virtual reality therapy that encourages passive attention and minimizes external cognitive demands.
223532541|NCT07135869|DIAGNOSTIC_TEST|One minute sit-to-stand test|The one minute sit-to-stand test will be used as acute fatigue protocol to generate fatigue.
223717926|NCT01893164|PROCEDURE|simple decompression|decompression of the ulnar nerve
223717927|NCT01893164|PROCEDURE|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
223717928|NCT01893164|PROCEDURE|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
223927754|NCT06716086|OTHER|shape memory alloy-based orthosis|The home program with the shape memory alloy-based orthosis contains warm-up part and correction part. The SMA-based orthosis is an improvement over traditional dynamic splint. This corrective device uses shape memory alloy as an elastic component specifically designed to address finger joint stiffness. It provides continuous force for stiff joint in order to address stiffness.
223927755|NCT06716086|OTHER|conventional stretching program|The home program for the stretching group includes active joint range of motion exercises and passive stretching exercises. Participants will follow instructions to perform various joint movements, with a focus on their restricted fingers.
223927756|NCT06747065|PROCEDURE|Radiotherapy|Radiotherapy post-mastectomy prepectoral implant-based breast reconstruction (IBBR)
223927757|NCT06742749|PROCEDURE|Proximal level|For the proximal level of psoas tenotomy at the pelvic brim, the hip was slightly flexed to relax the iliopsoas muscle; the iliacus muscle fibers were retracted anteriorly until the deeply seated posteromedially psoas tendon was isolated and transected
224094088|NCT04721873|DRUG|Placebo|Matching placebo, titrated as active intervention
224094089|NCT06836830|PROCEDURE|PEEP 5 mbar|Positiv-End-Expiratory Pressure
224094090|NCT06836830|PROCEDURE|ZEEP 0 mbar|Zero-End-Expiratory Pressure
223927758|NCT06742749|PROCEDURE|Distal level|For the distal level of iliopsoas tenotomy just above the lesser trochanter, the thigh was put in the position of FABER (flexion, abduction, and external rotation). A curved right-angle hemostatic clamp was used to retract and bring the iliopsoas tendon into the field. Then, the tendinous fibers were transected.
223927759|NCT06741462|DEVICE|Digital health assistant ADELE A0004|The digital health assistant ADELE A0004 (ADELE for short) improves the daily lives of patients with care level and enables them to deal better and more independently with the everyday burdens resulting from the need for care. Participants in the intervention group were provided with ADELE to use during the study period for e.g., tracking of daily reminders, voice-based recording, interpretation and classification of their vital signs and body conditions.
223927760|NCT06742216|DRUG|Monosialoganglioside|Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
223927761|NCT06742216|DRUG|Placebo|Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
223927762|NCT06732167|PROCEDURE|GBR Lyoplant|GBR surgical procedure with simultaneous implant placement including membrane placement
223927763|NCT06732167|PROCEDURE|GBR Bio-Gide|GBR surgical procedure with simultaneous implant placement including membrane placement
223927764|NCT06739837|DIAGNOSTIC_TEST|traditional physiotherapy|Participants in this arm will undergo traditional physiotherapy exercises for managing tennis elbow.
223927765|NCT06739837|COMBINATION_PRODUCT|Non-immersive VR therapy|Participants undergo a VR-based rehabilitation program targeting tennis elbow symptoms. Sessions last 30 minutes, conducted 3 times per week for 6 weeks. Exercises focus on improving grip strength, wrist flexibility, and functional movement through interactive VR environments that visually engage the affected arm, promoting adherence and motivation without full immersion. The VR setup includes headsets or screens that enable visual interaction, enhancing the rehabilitation experience. The goal is to alleviate pain, increase range of motion, and restore muscle strength.
223927766|NCT06741254|OTHER|Stress Ball|During the NST procedure (average 20-30 minutes), the pregnant woman will lie on her left side. A stress ball will be placed in the right hand of the pregnant woman. The pregnant woman will be instructed to squeeze the stress ball for 2-3 seconds and then relax the hand and arm. This process will be repeated throughout the NST.
223927767|NCT06886022|PROCEDURE|Colorectal cancer procedures|Procedures
223927768|NCT06885814|DRUG|Adebrelimab: 20mg/kg day1, Q3W, 3 times|Concurrent Chemoradiotherapy combined with Immunotherapy，including： Radiotherapy: intensity modulated radiotherapy, PGTV 50-50.4Gy/25-28F, 1.8-2Gy/F, 5 times a week; Chemotherapy: paclitaxel 50mg/ m2 + cisplatin 25mg/ m2, intravenous infusion of day1, once a week, a total of 5 times; Adebrelimab: 20mg/kg day1, Q3W, 3 times.
223927769|NCT06886308|DEVICE|Repetitive trans-spinal magnetic stimulation|For repetitive trans-spinal magnetic stimulation - rTsMS (high-frequency or sham), volunteers will be positioned comfortably in a lateral decubitus position. High-frequency rTsMS will be applied with an eight-shaped coil over the tenth thoracic vertebra (10 Hz; 100 pulses per train, 20-second interval between trains; 100% resting motor threshold). For sham rTsMS, two coils will be used: (i) a coil connected to the stimulator will be placed behind the patient (away from the spine) to generate the characteristic sound, and (ii) another coil, disconnected from the stimulator, will be placed on the tenth thoracic vertebra. Both real and sham stimulation will last 20 minutes. Gait training with body weight support will be performed on a Biodex Rehabilitation treadmill for 20 minutes. Researchers will assist the patient in foot placement, knee extension, and pelvis/trunk alignment. Body weight support and treadmill speed will be adjusted based on the patient's performance.
223927770|NCT06749730|DRUG|Adebrelimab|adepelizumab ,1200mg, q3w
223927771|NCT06749730|DRUG|Apatinib|apatinib，250mg，QD
223927772|NCT06749730|DRUG|gemcitabine and cisplatin|cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w
223717929|NCT04502693|COMBINATION_PRODUCT|rMenB+OMV NZ vaccine|rMenB+OMV NZ vaccine was administered intramuscularly.
223927773|NCT06894550|BEHAVIORAL|Participants will be escorted to high altitude and undergo a series of test|"Participants will be escorted to high altitude and undergo the following examination both at 540 and 3545m above sea level:~* 12-lead electrocardiogram~* Transthoracic echocardiography with measurement of left and right ventricular dimension and function, global longitudinal strain and transvalvular gradient~* Symptom-limited cardiopulmonary stress exercise test with a ramp protocol with a focused echocardiography for the assessment of cardiac output and transvalvular gradient and blood gas analysis~* 24 hours wearable rhythm monitoring~* Blood Work: cardiac biomarkers (Troponin T, CK, CK-MB, NT-pro-BNP), blood gas analysis, Hemoglobin, Hematocrit, Leucocytes, Thrombocytes, Creatinin, eGFR, Sodium, Potassium, ASAT, ALAT, Bilirubin)"
223927774|NCT05098847|DRUG|Sintilimab|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
223927775|NCT05098847|DRUG|Lenvatinib|Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223927776|NCT05098847|DRUG|Cryoablation|Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
223927777|NCT06742567|DRUG|Apixaban 2.5 MG PO BID|Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.
223927778|NCT06742567|DRUG|Control (Standard treatment)|DAPT plus guideline directed medical therapy
223927779|NCT06742229|DEVICE|Research Ultrasound scan|Both the study groups will be asked to undergo a research scan performed by an FDA approved ultrasound device
223927780|NCT06821711|OTHER|Intensive LDL-C control|"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin + PCSK9i; for LDL-C level ≥ 3.0 mmol/L, statin + ezetimibe + PCSK9i"
223927781|NCT06821711|OTHER|Conventional LDL-C control|"By Statin, Ezetimibe, or PCSK9i, prescribed according to LDL-C level at baseline and follow-up;~For patients with baseline LDL-C level \< 3.0 mmol/L, it is recommended to start lipid control by statin alone or statin + ezetimibe; for LDL-C level ≥ 3.0 mmol/L, statin + PCSK9i"
223927782|NCT06768060|BEHAVIORAL|Short mindfulness-based intervention|The intervention includes a short mindfulness-based intervention with a duration of 5 minutes. It involves a sitting mediation focused on breath adapted from the existing protocols of the Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT). The intervention is audio-guided and will be delivered via headphones.
223927783|NCT06758726|DRUG|Mitoxantrone Hydrochloride Liposome combined with BU/Cy|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day -9, iv Busulfan (3.2mg/kg/d) on day -7\~-5, iv Cyclophosphamide (60 mg/kg/d) on day -3\~-2, iv
224094091|NCT03446677|OTHER|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
224094092|NCT04728633|DRUG|Carmustine|Given via infusion
224094093|NCT04728633|DRUG|Ethiodized Oil|Given via infusion
224094094|NCT04728633|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
224282439|NCT04567758|OTHER|Telerehabilitation|"The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises~A web-based telerehabilitation platform (Fizyoweb) will be used to deliver the exercise program. Using the Fizyoweb web application, exercises will be presented to the patients in the form of audio-video and detailed instructions with explanations. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. The exercise protocol will be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each."
224094095|NCT04728633|OTHER|Medical Device Usage and Evaluation|Given gelatin sponge via injection
224094096|NCT03211182|BEHAVIORAL|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI\>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
224094097|NCT01552057|DRUG|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
224094098|NCT01552057|DRUG|Placebo|Placebo taken orally once every day for 15 weeks
224094099|NCT05303454|BEHAVIORAL|Cartoons|cartoons were found to be effective in reducing children's pain and fear levels.
224094100|NCT05303454|BEHAVIORAL|musical-moving toys|musical-moving toys were found to be effective in reducing children's pain and fear levels.
223927784|NCT06760897|DIETARY_SUPPLEMENT|Gastrogenic Microbiota|Take 1 sachet of gastric-origin probiotic powder (containing 5 x 1011 CFU per sachet) twice daily for 8 weeks.
223532542|NCT06712927|DRUG|Ipilimumab|1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
223927785|NCT06760897|OTHER|Placebo|similar powder administered twice daily
223927786|NCT06772883|BEHAVIORAL|sexual education and counseling|The women included in the Working Group were contacted by phone and invited to the hospital. Sexual education and counseling were provided in accordance with the PLISSIT model. A total of 5 interviews were conducted with the women, the first face-to-face interview and the subsequent ones by telephone. FSFI assessments in the study FSFI assessments were performed 5 times (initial, 1st, 3rd, 6th months and 1 year later). According to the PLISSIT model, their sexuality and any problems since the previous assessment were discussed and a short counseling was given if necessary.
223927787|NCT06772883|OTHER|control group|routine clinical care
223927788|NCT06764251|DRUG|Tislelizumab + SOX|tislelizumab combined with SOX
223927789|NCT06764173|OTHER|Oat drink|6 dl of oat drink daily
223927790|NCT06764173|OTHER|Cow's milk|6 dl of cow's milk daily
223927791|NCT06773728|DEVICE|Record occlusal contacts|Register using a digital device (t-scan) the occlusal contacts
224094101|NCT05387356|OTHER|prone position|thirty-one patients who had a positive test result for SARS-CoV-2 RNA through nasopharyngeal swab and underwent three subsequent prone positions for 16 hours will be enrolled the study. Medical datas of the patients will be obtained from patients' files which are strictly filled during pandemic. Prone position indication of intensive care unit (ICU) is in case of severe ARDS with PaO2/FiO2 \<150 despite a PEEP \>10 cmH2O.
224094102|NCT00864760|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
224094103|NCT00864760|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
223532543|NCT06712927|DRUG|Nivolumab + Relatlimab FDC|Relatlimab 160mg + Nivo 480mg will be administered via IV every 4 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
223532544|NCT05198557|DRUG|Inebilizumab|Participants will receive IV inebilizumab.
223927792|NCT06773728|DEVICE|Tracking of jaw movement|An optical jaw tracking system (Modjaw, Modjaw) is going to be implemented
223927793|NCT06773728|DEVICE|Tracking of jaw movement|Jaw tracking will be performed using an optical jaw tracking system (Zebris, Zebris medical)
223927794|NCT06771518|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy using 4D technique by irradiating the initial sites of disease (primary tumor and involved hilo-mediastinal lymph nodes). The treatments must be provided with the modulated intensity technique (IMRT or VMAT), treatments with conformal technique (3DCRT) are not permitted, where necessary, the Simultaneous Integrated Boost (SIB) technique can be used.
223927795|NCT06771518|DRUG|Atezolizumab 1200 mg e.v. q21|Radiotherapy treatment associated with Atezolizumab 1200 mg i.v. q21 administered according to clinical practice
223927796|NCT06771362|PROCEDURE|ART with Bulk-Fill composite|Restoration using Bulk-fill flowable self-cured composite
223927797|NCT06771362|PROCEDURE|ART with Glass Ionomer|Restoration Using High-Viscosity Glass Ionomer Cement
223927798|NCT06831331|OTHER|REK-diet|Personalized diet- the participants will get individual advice how to adapt their habitual diet to the Nordic Nutrition Recommendations 2023
223927799|NCT06831331|OTHER|RICH-diet|Diet rich in nutrients and with high quality protein
223927800|NCT05346718|OTHER|Ragweed pollen, birch pollen, clean air (placebo)|Participants are exposed for 4 hours in the Fraunhofer Allergen Challenge Chamber with varying pollen concentrations of ragweed or birch pollen and once with clean air, serving as a placebo exposure.
223927801|NCT06822166|DRUG|rifampicin|rifampicin capsule，600 mg
223927802|NCT06822166|DRUG|Fluconazole|Fluconazole capsules: 400 mg for the first dose and 200 mg for the remaining doses
223927803|NCT06822166|DRUG|Omeprazole|Omeprazole enteric-coated capsules: 20 mg
223927804|NCT06822166|DRUG|midazolam|midazolam injection 0.05 mg/kg was administered intravenously
223927805|NCT06822166|DRUG|ET-26|the dose is 0.8 mg/kg, single dose, Infusion time was 60seconds ± 5seconds
224094104|NCT00476086|DRUG|Gemcitabine|
224094105|NCT00476086|DRUG|Oxaliplatin|
224094106|NCT00476086|RADIATION|Radiation|
224094107|NCT04727515|DRUG|fentanyl 2µg/kg intravenously and maintained with isoflurane|Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.
224094108|NCT04727515|PROCEDURE|Axillary nerve Block|Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
224094109|NCT03173469|OTHER|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
223532545|NCT05198557|DRUG|Placebo|Participants will receive IV placebo matched to inebilizumab.
223927806|NCT06734936|OTHER|Playing videos with sgg|Playing videos with sgg
223927807|NCT06746532|BIOLOGICAL|Intranasal breast milk|"Own-mother's fresh breast milk (within 4 hours of having been expressed), is administered intranasally to neonates with hypoxic-ischemic encephalopathy receiving therapeutic hypothermia, starting from the first day of life and continuing for 28 days.~Dose: 2 times daily, 0.4 ml in each nostril."
223927808|NCT06746103|PROCEDURE|Surgery|Surgery may be instrumented stabilization surgery alone, instrumented stabilization and decompression, or decompression surgery alone.
223927809|NCT05453851|PROCEDURE|Pancreatectomy|Undergo pancreatectomy
223927810|NCT05453851|OTHER|Quality-of-Life Assessment|Ancillary studies
223532546|NCT06878144|BEHAVIORAL|Mucormycosis|Tell the study team about any symptoms or side effects you have, follow study directions, and come to all study appointments (or contact the study team to reschedule).
223532547|NCT06721884|DIETARY_SUPPLEMENT|Artemisia Annua Leaf|"The intervention is Artecinua™ which is an organic Artemisia annua dried leaf powder in a vegan / kosher/ halal capsule. Artemisia annua L is classified as a 'generally regarded as safe' (GRAS) herb. Participants will be instructed to wean up to a full 5g dose by the following schedule.~1. gram (3 caps) 1st day,~2. grams (6 caps) 3/am, 3/pm, for the 3rd day,~3. grams (9 caps) 3/am 3/noon 3/pm for the 5th day,~4. grams (12 caps) 4/am, 4/noon, 4/pm for the 7th day,~5. grams (15 caps) 5/am, 5/noon, 5/pm for rest of intervention period (4 weeks)~Containers of ArtecinuaTM will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.~The justification of the 5g a day dosing is based on empiric experience and is in line with recommended dosages by the pharmacopeia of the People's Republic of China and has been previously used in clinical trials"
223532548|NCT06721884|OTHER|placebo|We have chosen dried-leaf alfalfa of equal weight and dosing to the interventional product (5 grams, 15 caps, 5/am, 5/noon, 5/pm for the 4 weeks of the intervention period plus an additional 1 week dose escalation period to match the dosing of the Artemisia product). We have chosen this as a comparator in consultation with SIBO and herbal medicine content experts as alfalfa matches the texture and color of Artemisia annua and, in the doses used, will provide no meaningful amounts of FODMAPs or antimicrobial phytochemicals. The alfalfa will be sourced from Bulk Apotherapy, LCC, and encapsulated at the same facility as the Artemisia capsules. Containers of placebo capsules will be kept in a secured cabinet before being administered, under climate-controlled conditions, and checked weekly to ensure consistent ambient temperature.
223532549|NCT06894160|DEVICE|Adults EXPLORER|Two sessions with the robotic gait device in patients with neuromuscular diseases.
223532550|NCT06893783|DRUG|Tarlatamab|1 mg step dose on cycle 1 day 1 10 mg target dose starting cycle 1 day 8, cycle 1 day 15, and every 2weeks thereafter
223532551|NCT06240260|DEVICE|TENS (transcutaneous electrical nerve stimulation) unit|"Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of a mild electrical current.~A TENS machine is a small, battery-operated device that has leads connected to sticky pads called electrodes."
223532552|NCT06240260|OTHER|Standard care|Paracervical block only or participant declines analgesia for IUD insertion
223927811|NCT05453851|OTHER|Treatment Planning|Undergo IV autologous islet cell transplant
223927812|NCT06757465|OTHER|Counseling education based on Watson's Theory of Human Caring|In this study, a total of 75 interviews were conducted with 25 participants in the intervention group in three sessions. During the interviews, counseling training based on Watson IBK developed by the researchers was applied. Each session lasted between 30-45 minutes per participant. The first session was conducted face-to-face, and the second and third sessions were conducted using online platforms (Zoom, Microsoft Teams, WhatsApp video call) within the scope of telehealth applications. Sessions were structured according to the individual needs of the participants and the durations were arranged flexibly when necessary. Telehealth applications provided easy access to the participants during the counseling process and supported the continuity of individual counseling services.
223927813|NCT06757127|OTHER|ERAS Protocol Adaptation for Emergency Laparotomy|The intervention incorporated a comprehensive quality improvement approach, including a presentation, live demonstrations, and an instructional video to support the implementation of ERAS protocols. These methods emphasized the key components outlined by the ERAS ® Society guidelines for emergency laparotomy, ensuring that participants understood the importance of each protocol step and its application in clinical practice. As part of the quality improvement initiative, efforts were made to engage key stakeholders, including local governance and healthcare authorities, to align the intervention with policy frameworks. Training materials, including videos and manuals, were reviewed by a consultant surgeon to ensure accuracy and relevance. Additionally, a consultant surgeon conducted individual demonstrations in the operating room and ward, supplemented by weekly morning meetings with nurses, anesthesiologists, residents, and doctors for one month.
223927814|NCT06760065|DRUG|Keverprazan Hydrochloride tablets + high dose amoxicillin|Keverprazan Hydrochloride, a potassium-competitive acid blocker (P-CAB), is administered at a dose of 20 mg twice daily in combination with Amoxicillin 0.75 g four times daily for 14 days. This dual therapy is designed to provide rapid and sustained gastric acid suppression and evaluate its efficacy in eradicating Helicobacter pylori.
223927815|NCT06760065|DRUG|Susceptibility-Guided Quadruple Therapy|Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
224094110|NCT06260787|PROCEDURE|In Vitro Fertilisation|Assisted reproductive technology in the form of in vitro fertilisation
224094111|NCT04705454|BIOLOGICAL|Loncastuximab Tesirine|
224094112|NCT02427061|BEHAVIORAL|Intervention Program (Manhood 2.0)|
223717930|NCT04502693|BIOLOGICAL|Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)|MenACWY vaccine was administered intramuscularly.
223532553|NCT06893419|OTHER|Geriatric telemanagement|The geriatrician will coordinate, through a telemedicine consultation, a team consisting of the general practitioner and the nursing home staff. The geriatrician will review the diagnoses, treatments, and results of the comprehensive geriatric assessment performed by the nursing home staff. Subsequently, the entire team will conduct a multidisciplinary conference.
223532554|NCT04577404|DRUG|MT-1186|Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.
223532555|NCT06885957|DRUG|Mab Therapy|Whether receive mab therapy or not.
223532556|NCT03995472|DRUG|SHR-1501|Administered subcutaneously
223532557|NCT03995472|DRUG|SHR-1316|Administered intravenously
223532558|NCT06839261|DIAGNOSTIC_TEST|Intubation Difficulty Scale|The Intubation Difficulty Scale (IDS) is an objective way to classify easy and difficult intubation. A score ≤ 5 indicates an easy or mildly difficult intubation, while IDS \> 5 suggests difficult intubation, requiring additional techniques or attempts.
223532559|NCT06839261|OTHER|Artificial Intelligence|The program made with Python 3 programming language using open source libraries. It will be developed to predict difficult intubation with 6 different photo data of patients, this process will be taught with a learning process and then tested.
223927816|NCT06759051|DEVICE|tDCS|The stimulation pattern for the true intervention was that the current level ramped up from 0 to 2 mA for the first 10 seconds of stimulation, then maintained at 2 mA for 19 minutes and 40 seconds, and then ramped down from 2 mA to 0 mA for the last 10 seconds, all over a 20-minute period.
223927817|NCT06759051|DEVICE|Sham (No Treatment)|In contrast to the active intervention, the sham intervention consisted of a current ramp from 0mA to 2mA for the first 20 seconds of stimulus onset, followed by a ramp down to 0mA. the current was maintained at 0mA for 19 minutes and 20 seconds, and then the current was ramped from 0mA to 2mA for the last 20 seconds, followed by a ramp down to 0mA. The entire procedure lasted the same as the active intervention, which lasted for 20 minutes.
223927818|NCT06761560|DIAGNOSTIC_TEST|Pharmacokinetic based dosage change|This study will compare 2 groups of sickle cell patients that are receiving hydroxyurea. Group A will have an increase in their dosage based on the pharmacokinetic result over a period of 12 months and Group B will have an increase in their dosage based on the standard of care follow-up over a period of 12 months. The aim is to evaluate if the group A can reach MTD faster than than the Group B
223927819|NCT06761560|DIAGNOSTIC_TEST|Pharmacokinetic dosing|Patient with sickle cell disease will undergo one pharmacokinetic test after taking 12 months of hydroxyurea to evaluate HU-AUC at that timepoint
223927820|NCT06794593|DRUG|Camostat Mesylate|Oral Camostat Mesylate 200 mg x 3 daily for 4 days.
224094113|NCT02427061|BEHAVIORAL|Control Program (Job Skills Training)|
224094114|NCT02900092|DRUG|Ganaxolone|Participants received ganaxolone
224094115|NCT02811705|OTHER|Quality of life|Quality of life
224094116|NCT06139770|BEHAVIORAL|Family based therapy- Metacognitive therapy|Family based therapy and Metacognitive therapy
224094117|NCT02411123|GENETIC|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
224094118|NCT06499636|OTHER|other|other
224094119|NCT06962111|BEHAVIORAL|Psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss who live alone. In addition, during this intervention, participants will have access to general and personalized virtual resources with materials for use during and after the intervention.
224094120|NCT03193866|DRUG|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
224094121|NCT03765645|DRUG|Piperacillin + Tazobactam|Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
224094122|NCT01762579|DIETARY_SUPPLEMENT|wheat flour|wheat flour is administered three times per day for 15 days
223532560|NCT04667962|OTHER|Online questionnaire|Participants will have to complete 3 online self-questionnaires: the first one at enrollment, the second one 1 month after enrollment (M1) and the third one 3 months after enrollment (M3). Each questionnaire will take an estimated 20 minutes to complete.
223532561|NCT05690841|DRUG|Focal Mass Drug Administration (fMDA)|"Administration of focal mass drug administration for high-risk individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household). Intervention to be administered two times, two months apart each cycle, for 3 cycles spaced apart by regular intervals.~Each year will include 2 rounds of fMDA.~Round 1) Chloroquine (CQ)+ Tafenoquine (TQ) for \>= 16y (CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg CQ, TQ 300 mg on Day 1); CQ+ Primaquine (PQ) for \<16y (CQ: age-based dosing, PQ age-based dosing); CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, Day 2 600 mg, Day 3 300 mg, PQ age-based dosing).~Round 2) single dose CQ+TQ for \>= 16y (CQ: Day1 600 mg, TQ 300 mg on Day 1); single dose CQ+PQ for \<16y (CQ: age-based dosing, PQ age-based dosing); single dose CQ+PQ for G6PD intermediate individuals \>=6mo and \<16y ((CQ: Day1 600 mg, PQ age-based dosing)."
223532562|NCT07065968|DRUG|Teriflunomide|Teriflunomide 14 mg orally once daily for 24 weeks.
223532563|NCT07065968|DRUG|Dexamethasone|Dexamethasone 40 mg orally once daily for four consecutive days.
223532564|NCT06566079|DRUG|ISM6331|"Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment."
224094123|NCT01762579|DIETARY_SUPPLEMENT|Xylose|Xylose will be administered three times per day for 15 days
224094124|NCT06136546|DRUG|Infliximab|Intravenous infusion of infliximab
224094125|NCT06136546|OTHER|Placebo|Intravenous infusion of saline solution (matching in color and consistency in infliximab)
223532565|NCT06654323|BEHAVIORAL|Intensive Behavioral Lifestyle Modification|Participants in all arms will receive visits with their child's primary care provider (4 visits, 1 hour total), on-demand web-based learning modules that focus on building skills and knowledge in health behaviors (7 hours), and community resource counseling sessions delivered by a social worker or similar healthcare professional (4 sessions, 2 hours total). The difference between arms will be in the frequency and duration of personalized nutrition counseling delivered by a registered dietitian or similar healthcare professional: 16 sessions (60 minutes per session), 12 sessions (60 minutes per session), 9 sessions (60 minutes per session), 8 sessions (45 minutes per session), or 6 sessions (30 minutes per session).
223532566|NCT01613885|OTHER|No Intervention|This study does not involve any intervention other than obtaining blood, nasal/cheek/throat/skin swabs, saliva, sputum, urine, and stool samples, breathing and skin tests.
223532567|NCT03370315|OTHER|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
223927821|NCT06797154|BEHAVIORAL|StrokeWear Motor and Behavioral Intervention|The intervention will consist of 1) the use of StrokeWear for goal directed movements (GDM) feedback and goal setting, 2) use of daily activity action planning (DAAP) to foster planned hemiparetic UE use during daily activities in the home and community, and 3) patient empowerment. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to manage their GDM and DAAP.
223927822|NCT06797154|OTHER|Usual Care + Sham|The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.
223927823|NCT06837714|OTHER|PİLATES GROUP|A total of 16 sessions were applied for 8 weeks, 2 sessions per week.
223927824|NCT06837714|OTHER|Behavioral: lifestyle changes|presentation including lifestyle changes was prepared and training was provided.
223927825|NCT06515223|DEVICE|Epidural Spinal Cord Stimulation|Epidural Spinal Cord Stimulation Mapping and Pelvic Floor Muscle Training
223927826|NCT06830135|DEVICE|Continues glucose monitoring with remote glucose monitoring for 90 days|CGM + RPM
223927827|NCT01871766|DRUG|Vincristine|"Dosage and route of administration:~* \< 1 year of age=0.025 mg/kg intravenously (IV)~* \> 1 year and \< 3 years= 0.05 mg/kg IV~* ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants."
223532568|NCT03370315|OTHER|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
223532569|NCT04237584|DRUG|Enzalutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
223927828|NCT01871766|DRUG|Dactinomycin|"Dosage and route of administration:~* \< 1 year=0.025 mg/kg IV push~* ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
223927829|NCT01871766|DRUG|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~* \< 3 years of age = 40 mg/kg IV~* ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~* oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)"
223927830|NCT01871766|PROCEDURE|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
223927831|NCT01871766|PROCEDURE|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
223927832|NCT01871766|DRUG|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
223927833|NCT01871766|DRUG|Sorafenib|Dosage and route of administration: 90 mg/m\^2/dose twice daily.
223927834|NCT01871766|DRUG|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
223927835|NCT01871766|PROCEDURE|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
223927836|NCT01871766|DRUG|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.
223927837|NCT01871766|DRUG|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.
223927838|NCT01871766|DRUG|Etoposide|"Dosage and Route of Administration:~Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis"
224094126|NCT06617429|DRUG|GTX-102|antisense oligonucleotide
224094127|NCT06617429|PROCEDURE|Sham-LP|Small needle prick on the lower back at the location where the LP injection is normally made
224094128|NCT05571969|DRUG|2X-121 and dovitinib|"The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;"
223927839|NCT01871766|DRUG|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.
223927840|NCT01871766|DRUG|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
223927841|NCT01871766|DRUG|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
224094129|NCT03878147|BEHAVIORAL|Cognitive Games Training|Brain Powered Games (BPG) uses games for neurocognitive assessment and training, using images and sounds more familiar to African children. As a computerized cognitive rehabilitation training (CCRT) program designed for Sub-Saharan African school-age children, it can help children infected affected directly or indirectly by HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records game play data for research purposes. Village Builder (VB) is a pro-social reasoning/planning world building strategy type game intended to evaluate frontal lobe executive functions in a culture-friendly and enjoyable game manner. It consists of many of the village artistic components as used in BPG but orchestrated into a village setting where children must gather resources and protect them in order to expand the capacity of the village.
223927842|NCT01871766|DRUG|^1^1C-methionine|Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
223927843|NCT03944941|DRUG|Avelumab|Given IV
223927844|NCT03944941|DRUG|Cetuximab|Given IV
223927845|NCT06349707|OTHER|other: Observational|For 18 ICU patients, retrospective collection of routine bioclinical database (ICCA db)
223927846|NCT06772012|OTHER|Low-Level Laser Therapy (LLLT)|"* Frequency: LLLT was administered 3 times per week.~* Duration: Each session lasted approximately 15-20 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.(50)"
223927847|NCT06772012|OTHER|Orofacial Physical Therapy|"* Frequency: Orofacial physical therapy sessions were conducted 3 times per week.~* Duration: Each session lasted around 30-40 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.~* Components:~  * Manual Therapy: Included techniques such as joint mobilization, soft tissue manipulation, and muscle stretching.~ * Therapeutic Exercises: Focused on strengthening, coordination, and improving mobility of the masticatory muscles.~ * Postural Training: Addressed poor posture and cervical muscle spasm.(50)"
223927848|NCT05699226|DEVICE|Soterix Medical Incorporated 4x1 adapter|Device permits individualized amplitudes
223927849|NCT05699226|DEVICE|Traditional ECT device|FDA approved ECT device with fixed amplitude.
223927850|NCT06793072|DIAGNOSTIC_TEST|Leptin concentration in blood serum|Fasting plasma leptin concentration measurement with results expressed in pg/ml and comparison across all study arms
223927851|NCT06793072|DIAGNOSTIC_TEST|Resistin concentration in blood serum|Fasting plasma resistin concentration measurement with results expressed in pg/ml and comparison across all study arms
223927852|NCT06793072|DIAGNOSTIC_TEST|Omentin-1 concentration in blood serum|Fasting plasma omentin-1 concentration measurement with results expressed in pg/ml and comparison across all study arms
223927853|NCT06751745|BEHAVIORAL|Online Emotional Intelligence Training|The intervention is a 4-week online Emotional Intelligence (EI) training program for Bangladeshi youth. It includes weekly one-hour sessions focusing on self-awareness, self-regulation, social awareness, and relationship management. Led by experts, the program uses interactive activities and practical exercises to enhance emotional skills. Pre- and post-training assessments with the Bengali Emotional Intelligence Scale measure outcomes.
223927854|NCT06841523|DEVICE|Intelligent Pressure and Temperature-Controlled Ureteroscope System|RIRS procedure for upper ureteral or renal stone lithotripsy with Intelligent Pressure and Temperature-Controlled Ureteroscope System
223927855|NCT06841523|DEVICE|Conventional Ureteroscope|RIRS procedure for upper ureteral or renal stone lithotripsy with conventional ureteroscope
223927856|NCT06862453|OTHER|Normal Saline (Placebo)|The blinded control group (n = 6) of the main cohort will receive normal saline as placebo, also by DVI.
223927857|NCT06862453|BIOLOGICAL|PfSPZ-LARC2 Vaccine|Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).
223927858|NCT06862453|BIOLOGICAL|PfSPZ Challenge (NF54)|Main cohort participants will undergo homologous CHMI using DVI of 3.2x10\^3 PfSPZ of PfSPZ Challenge (NF54), which are infectious cryopreserved Pf sporozoites.
223927859|NCT06870500|DRUG|Methotrexate|"1. Assess the response of psoriasis and psoriatic arthritis to Methotrexate.~2. Assess the relation between Card14 gene(rs 34367357 ) Polymorphism in psoriatic and psoriatic arthritis patients and their clinical response to methotrexate"
223927860|NCT06870500|DRUG|Placebo|Placebo
223532570|NCT04237584|DRUG|Lead-in Enzalutamide followed by Radium-223/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
223532571|NCT04237584|DRUG|Lead-in Enzalutamide followed by Placebo/Enzalutamide|After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
223532572|NCT04237584|DRUG|Darolutamide during Lead-in Period|Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
223927861|NCT06617780|RADIATION|X-ray (wrist)after 3 months and CT (wrist) the day after closed reduction|One addition x-ray and on addition CT scan of the wrist
223927862|NCT06767007|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will begin SBRT treatment within 2 weeks after the first round of chemotherapy. Intensity-modulated radiation therapy (IMRT) technology will be used, with a target gross tumor volume (GTV) of 5-8Gy/5 sessions, a total dose of 25-40Gy equivalent to a biological effective dose (BED) of 37.5-72Gy, administered from Monday to Friday. For patients who have previously received pelvic radiotherapy, the re-irradiation dose will be 3-5Gy/5 sessions, a total dose of 15-25Gy equivalent to a BED of 19.5-37.5Gy, administered from Monday to Friday.
223927863|NCT06767007|DRUG|PD1|The PD-1 monoclonal antibody used is Sintilimab 200mg every 3 weeks
223927864|NCT06767007|DRUG|Chemotherapy|First-line chemotherapy regimen of rectal cancer, using a second-line regimen primarily based on fluorouracil, such as a tri-weekly CAPOX or a bi-weekly mFOLFOX6/FOLFIRI/FOLFOXIRI + targeted therapy
223927865|NCT06763809|DIETARY_SUPPLEMENT|PMS Capsule|Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
223927866|NCT06763809|DIETARY_SUPPLEMENT|Capsule Placebo|Participants will take 2 capsules, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
223927867|NCT06763809|DIETARY_SUPPLEMENT|PMS Gummy|Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
223927868|NCT06763809|DIETARY_SUPPLEMENT|Gummy Placebo|Participants will take 2 gummies, 4 times daily, starting at the onset of PMS symptoms and continuing until symptoms subside.
223927869|NCT06745115|DIAGNOSTIC_TEST|Blood fluorescence metabolite analyzer|This study does not involve Intervention. The fluorescence intensity quantified by the blood fluorescence metabolite analyzer does not affect or interfere with clinical diagnosis and treatment. In both the early and late stages of sepsis, a significant increase in inflammatory free radicals changes the optical properties of the patient's blood, distinguishing it from that of healthy individuals. To explore this phenomenon, 10 cc of fasting blood is drawn from patients who pass our screening criteria. This sample is then centrifuged in accordance with our detailed standard operating procedures to ready it for analysis. Subsequently, the fluorescence intensity of the blood is measured quantitatively using a precisely calibrated blood fluorometer, which is specifically designed to detect subtle variations indicative of both early and late sepsis. This entire process is executed under stringent quality control protocols to ensure the reliability and accuracy of the results.
223927870|NCT06744556|DRUG|daunorubicin|Used in combination with cytarabine and venetoclax for induction therapy in DAV.
223927871|NCT06744556|DRUG|Venetoclax|Used in combination with cytarabine and daunorubicin for induction therapy in DAV.
223927872|NCT06744556|DRUG|cytarabine|Used in combination with venetoclax and daunorubicin for induction therapy in DAV or used by intermediate does for consolidation therapy.
223927873|NCT06744556|DRUG|azacitidine|Used in combination with venetoclax for maintenance therapy.
223927874|NCT06744556|DRUG|Homoharringtonine|Used in combination with cytarabine and venetoclax for induction therapy in HAV.
223927875|NCT06744556|DRUG|Idarubicin|Used in combination with cytarabine and venetoclax for induction therapy in IAV.
223717931|NCT04502693|COMBINATION_PRODUCT|Placebo|Placebo was administered intramuscularly.
223927876|NCT06763380|DIAGNOSTIC_TEST|Ultrasound|Detection of uterine abnormalities in patients who are infertile buy using Ultrasound
223927877|NCT06763380|DIAGNOSTIC_TEST|ultrasound then hysterosalpingography|If uterine abnormality could not diagnosed with ultrasound then hysterosalpingography would be performed
223927878|NCT06763029|DRUG|Irinotecan liposomes combined with cetuximab + vermofenib|Vermofenil 960mg orally twice daily; Irinotecan liposomes, 70mg/m2, d1, 90 min intravenously, Q2W; Cetuximab 500mg/m2, d1, Q2W;
223927879|NCT06763692|DEVICE|LIFU Neuromodulation|Subjects will undergo a single LIFU of the target brain region
223927880|NCT06740682|BEHAVIORAL|Podcast olumlu doğum hikayeler|"ositive birth stories were listened to by women who gave birth in the hospital included in the study and created with their permission. The podcast recording was done in a single session. These positive birth stories were expertly reviewed by 3 obstetricians and 3 academics. Each podcast content is 10 to 20 minutes (Cai et al., 2023). A WhatsApp reminder msg will be sent so that the stories are not forgotten.~In addition, the pregnant woman will be contacted by phone and trained to listen (Cai et al., 2023).~Participants will be allowed to listen to the podcasts as much as they want (Cai et al., 2023). After listening to each story, their feedback will be received and the participants' doubts will be clarified. (Cai et al., 2023; Çankaya and Şimşek, 2021; Mousavi et al., 2022).~Based on multimedia principles, podcast positive birth experiences will be prepared (Clark and Mayer, 2023). Week 24, Week 30-32, Week 36-38 First story"
223927881|NCT06735196|DEVICE|sampling capsule endoscopy|Healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas. When SCEs excreted, the fluids inside SCEs would be collected for microbiome and metabolome analysis.
223927882|NCT06742632|BEHAVIORAL|Symptoms checklist-90|The Symptom Checklist-90 (SCL90) is a 90-item questionnaire used to assess psychological problems. The Symptom Checklist-90-Revised (SCL90R) is the revised version of the questionnaire.
223927883|NCT06764147|DRUG|ET-26HCl|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
223927884|NCT06763393|RADIATION|Ultrasound|To determine the correlation between adnexal masses and endometrial thickness measured with ultrasound in adults women.
224094130|NCT04774354|DIAGNOSTIC_TEST|POSSUM|These scales will be calculated and compared to the outcomes obtained in our center.
223717932|NCT04502693|COMBINATION_PRODUCT|MenABCWY-1|Lot 1 of the MenABCWY vaccine was administered intramuscularly.
223717933|NCT04502693|COMBINATION_PRODUCT|MenABCWY-2|Lot 2 of the MenABCWY vaccine was administered intramuscularly.
223717934|NCT04502693|COMBINATION_PRODUCT|MenABCWY-3|Lot 3 of the MenABCWY vaccine was administered intramuscularly.
223927885|NCT06764628|DRUG|SHR-4375|SHR-4375 injection
224094131|NCT01875497|DIETARY_SUPPLEMENT|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
224094132|NCT05085561|DRUG|REC-994|REC-994 200 mg tablets
224094133|NCT05085561|DRUG|Placebo|Placebo Tablets
224094134|NCT05760898|BEHAVIORAL|Blood pressure intervention arm|The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
223927886|NCT06835764|BEHAVIORAL|NOVELA|The family caregivers that consent to participate will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the telenovela video (one of four episodes, each 3-6 mins) twice per week over the course of 4 hospice telehealth visits (one episode per visit). All four visits will use telehealth via video-conferencing. The number of visits is based on the number of videos which content is prioritized based on previous work. The interventionist will introduce the purpose and topic of the video, facilitate video viewing and then elicit clarifying questions and reinforce main message.
223927887|NCT04261790|DRUG|Ocrelizumab|Patients will be treated with two courses of ocrelizumab (Ocrevus) 600mg/course, for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience the return of the disease activity can go back on the medication.
223927888|NCT04366310|DEVICE|capillary refill index|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
223927889|NCT04366310|PROCEDURE|rewarming|warming fingertip skin temperature using an instant hot pack
223927890|NCT06263166|BEHAVIORAL|Stress ball intervention|Women should squeeze and loosen the stress ball given to them during the vaginal examination and continue this process until the examination is completed.
223927891|NCT06765083|DIAGNOSTIC_TEST|POCUS of the hip|POCUS of the hip (proximal femur) by the (resident) emergency physician, prior to radiograph imaging.
223927892|NCT06762756|BEHAVIORAL|Messages on tobacco packaging labels|The intervention was messages of the benefits of smoking cessation formatted as tobacco packaging labels with three conditions. Participants viewed the messages online. There were four messages in each condition. The intervention was informed by relevant patient and public groups.
223927893|NCT06766084|PROCEDURE|CABG|All patients underwent isolated CABG and retrospectively followed to asses clinical outcomes of the two different revascularization techniques
223927894|NCT06766188|OTHER|Online Video training for Teachers based on Reading for all|"Reading intervention over a year for students with intellectual disabilities who use AAC. This study included teachers from 14 different schools and 8 municipalities and their students. It is two arms in the intervention, with approximately 7 schools and their teachers in video training for teachers and in person mentoring for teachers. The schools are randomized into these two groups, but in both groups, they will carry out the same intervention.~The students in both groups will work explicitly and systematically with the reading material Reading for all, which is based on the research of, among others, Janice Light and David McNaughton, and their reading program Accessible Literacy Learning (ALL)."
223927895|NCT06811740|PROCEDURE|Individualized cluster management|Individualized cluster management for treatable traits
223927896|NCT06811740|PROCEDURE|Routine asthma treatment|Routine asthma treatment according to current guidelines
224094135|NCT03754049|DRUG|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
224094136|NCT03754049|DRUG|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
223927897|NCT06765915|DRUG|Avapritinib|After allo-HSCT, CBF-AML patients who have kit mutation would receive avapritinib for maintenance therapy.
223927898|NCT05841420|DRUG|Gemcitabine|Gemcitabine monotherapy, 1000 mg/m2 weekly on days 1, 8, and 15 every 4 weeks or gemcitabine: 800 mg/m2 on day 1, 8 and 15 every 4 weeks
223927899|NCT05841420|DRUG|Nab paclitaxel|Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks
223927900|NCT06786728|DRUG|frusemide|in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group
223927901|NCT02586974|DEVICE|Humigard|warmed and humidified CO2 insufflation
224094137|NCT05817045|DEVICE|RD-X19|Investigational device that uses safe electromagnetic energy to target the oropharynx.
223532573|NCT04237584|DRUG|Lead-in Darolutamide followed by Radium-223/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
223532574|NCT04237584|DRUG|Lead-in Darolutamide followed by Placebo/Darolutamide|After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
223532575|NCT01092221|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, BID
223532576|NCT01092221|DRUG|Placebo|Placebo 1 capsule, 300 mg, BID
223532577|NCT03586973|DRUG|Cabozantinib|Cabozantinib tablet
223532578|NCT06672822|DRUG|Sodium Thiosulfate (STS)|Depending on the size of the calcinosis lesion, 1-5ml of STS (250mg/ml) will be used for injection under ultrasound guidance.
223927902|NCT06769308|DEVICE|Sedation titration according to qEEG|Sedation will be titrated according to the EEG derived indexes (qCON/qNOX)
223927903|NCT06769308|PROCEDURE|Sedation titration according to standard of care|Sedation will be provided according to the standard of care of the unit (clinical scales)
223927904|NCT06792071|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|The intervention is a psychological treatment using Radically Open Dialectical Behavior Therapy (RO-DBT), consisting of individual therapy and skills training in group for approximately 22 weeks. Additionally, a parent group consisting of four sessions will be included as an adaptation to the adolescent group.
223927905|NCT06768047|OTHER|Microporous tape|Microporous tape is a dressing tape that was discovered to have scar modulating effects. It is made up of a conformable, inextensible, nonwoven fabric manufactured from 100% viscose and coated with a layer of acrylic adhesive. It is cheap, cost-effective, readily available, and relatively affordable for post surgical patients.
224094138|NCT05817045|DEVICE|Sham|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
223717935|NCT01954719|PROCEDURE|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
223717936|NCT01954719|PROCEDURE|control group|surgeon not dilated cervix after surgery
223927906|NCT06768047|OTHER|Tradition physical therapy|"Tradition physical therapy as stretching exercises and deep friction massage, Stretching is a form of physical exercise in which a specific muscle or tendon (or muscle group) is deliberately expanded and flexed in order to improve the muscle's felt elasticity and achieve comfortable muscle tone. The result is a feeling of increased muscle control, flexibility, and range of motion.~Deep friction massage also known as cross friction massage, is a specific connective tissue massage which maintain the mobility within the soft tissue structures of ligament, tendon, and muscle, and prevent adherent scars from forming."
223927907|NCT06792682|BIOLOGICAL|Dose escalation|"Three dose groups are preset. The doses are 2.0×10\^6/kg/time, 3.5×10\^6/kg/time and 5.0×10\^6/kg/ time respectively, in accordance with the 3+3 dose escalation principle, and proceed in turn.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."
223927908|NCT06792682|BIOLOGICAL|Dose extension|"According to the safety data of dose escalation stage, one dose group is selected for extension.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."
223927909|NCT04095572|DRUG|intravesical instillation with HA-CS|intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
223927910|NCT04095572|DRUG|intravesical instillation of sterile purified water|intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
223927911|NCT05784883|DIAGNOSTIC_TEST|Echocardiography|A comprehensive 2- and 3-dimensional transthoracic echocardiography (TTE) assessment of the tricuspid valve and right side of the heart at baseline.
223927912|NCT06746870|DRUG|IMM2510|"Cohort1:~Phase I #: 10 mg/kg or 20 mg/kg, Q3W, intravenous infusion Phase II \&: 20 mg/kg, Q3W, intravenous infusion~Cohort2:~Phase I #: 10 mg/kg or 20 mg/kg, Q2W, intravenous infusion Phase II \&: 20 mg/kg, Q2W, intravenous infusion"
223927913|NCT06746870|DRUG|Chemotherapy (pemetrexed + cisplatin/carboplatin)|Non-squamous non-small cell lung cancer (NQ-NSCLC): Pemetrexed 500 mg/m2 in combination with carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles, followed by maintenance treatment with pemetrexed
223717937|NCT04312880|DRUG|Tranexamic Acid|IV and topical form of TXA will be administered to patients in the respective groups.
223717938|NCT06086470|DEVICE|Qidni/D Hemodialysis System|Qidni/D is a hemodialysis device for patients with end-stage renal disease.
223927914|NCT06746870|DRUG|Chemotherapy (paclitaxel + cisplatin/carboplatin)|Squamous non-small cell lung cancer (SQ-NSCLC): Paclitaxel 175 mg/m2 + carboplatin (AUC 5-6) or cisplatin (75 mg/m2), intravenous infusion, Q3W, for 4 cycles.
223927915|NCT06746870|DRUG|Chemotherapy(Nab-paclitaxel)|Nab-paclitaxel, 100 mg/m2, 4 weeks as a cycle, administered on D1, 8, and 15 of each cycle.
223927916|NCT06747676|DEVICE|Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)|Active high-definition transcranial direct current stimulation (HD-tDCS) will be delivered by a low-intensity direct current stimulator (Soterix Medical) using a 3x1 ring configuration with a central cathode over the contralesional temporo-parietal junction. During the stimulation, participants will perform tasks to stimulate correct visual verticality perception. Six active HD-tDCS sessions of 2mA for 20 minutes HD-tDCS, 3 times daily for 2 days with session intervals greater than 3 hours.
223927917|NCT06747676|DEVICE|Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)|Six sessions (3 times daily for 2 days) of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20min. Direct current (DC) will be generated by a low-intensity direct current stimulator (Soterix Medical) and then split into the 3 high-density Ag/AgCl sintered ring electrodes. The sham stimulation condition will consist of the same positioning of the electrodes as the active condition, with a ramp-up to 2mA over 30 seconds and a subsequent ramp-down of 30 seconds.
223927918|NCT06756828|DRUG|Melatonin|3months melatonin
224282440|NCT04567758|OTHER|Conventional Rehabilitation|"The home exercise program, which will be given with conventional rehabilitation, will be educated to the patient in the clinic on the first day. Exercise information form including explanation and picture of the exercises will be given to the patients. The exercise program to be given will be prescribed specifically with slight changes according to the patient's condition. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.~The home exercise program includes the following exercises:~1. Lumbar region and lower extremity stretching exercises;~2. Exercises to strengthen the abdominal muscles;~3. Exercises to strengthen the lumbar muscles;~4. Bridging, spine mobility exercise, McKenzie extension, and Williams flexion exercises"
224282441|NCT03301818|DEVICE|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
224282442|NCT00792623|BIOLOGICAL|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
223717939|NCT01450995|DRUG|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
223717940|NCT01450995|DRUG|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
223717941|NCT00834171|DRUG|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
223717942|NCT00834171|DRUG|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
223717943|NCT05729646|DRUG|Toripalimab|Perioperative Toripalimab, 240 mg IV infusion
223717944|NCT05729646|DRUG|Oxaliplatin|Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
223717945|NCT05729646|DRUG|S1|S-1 orally intake as perioperative chemotherapy
223927919|NCT06756828|BEHAVIORAL|Cognitive behavioral therapy group for insomnia|15minutes of sleep hygiene education on the first day of visiting the hospital
223927920|NCT05116774|DRUG|Eculizumab|Administered by intravenous infusion per current dose regimen
223927921|NCT05116774|DRUG|Ravulizumab|Administered by intravenous infusion per current dose regimen
223927922|NCT05116774|DRUG|BCX9930|Administered orally twice daily
223927923|NCT06756815|OTHER|Cross bracing and conservative treatment|Week Exercise Training Frequency (sets x reps) Week 1-2 1. Cross Bracing (Isometric Holds) 2. Quad Sets 3. Straight Leg Raise 4. Ankle Pumps 5. Heel and Toe Raises 6. Glute Bridge 2 sets x 10 reps Week 3-4 1. Cross Bracing (Isometric Holds) 2. Hamstring Curls 3. Step-ups 4. Mini Squats (with support) 5. Leg Press 6. Lateral Leg Raises 3 sets x 12 reps Week 5-6 1. Cross Bracing (Isometric Holds) 2. Single-leg Balance (with support) 3. Lunges (with proper technique) 4. Squats (bodyweight) 5. Box Jumps 6. Lateral Step-ups 3 sets x 15 reps
223927924|NCT06756815|OTHER|Cross bracing and DNS with conservative treatment|"Week Exercise Training Frequency (sets x reps) Week 1-2~1. Cross Bracing (Isometric Holds)~2. DNS Core Activation (supine, prone positions)~3. Quad Sets~4. Straight Leg Raise~5. Ankle Pumps~6. Heel and Toe Raises~7. Glute Bridge 2 sets x 10 reps Week 3-4~1\. Cross Bracing (Isometric Holds) 2. DNS Core Stabilization (advanced activation) 3. Hamstring Curls 4. Step-ups 5. Mini Squats 6. Leg Press 7. Lateral Leg Raises 8. Pelvic Tilts 3 sets x 12 reps Week 5-6~1. Cross Bracing (Isometric Holds)~2. DNS Dynamic Stabilization (with resistance)~3. Single-leg Balance (with and without support)~4. Lunges (with added resistance)~5. Squats (bodyweight or weighted)~6. Box Jumps~7. Lateral Step-ups~8. Running Drills (if tolerated) 3 sets x 15 reps"
223717946|NCT04490850|PROCEDURE|Blood sample|Blood sample
223927925|NCT03392467|BIOLOGICAL|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
223927926|NCT03392467|OTHER|Placebo|normal saline
223927927|NCT03150862|DRUG|Pamiparib|Administered as specified in the treatment arm
223927928|NCT03150862|DRUG|TMZ|Administered as specified in the treatment arm
224094139|NCT05936619|DEVICE|Mind Extender (MindEx)|NeuroPort Multi-Port Arrays allow for the local recording of cerebral cortex. The Mind Extender (MindEx) system is primarily composed of two NeuroPort Multi-Port Arrays. Each Multi-Port device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D), and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array. The four arrays of the two Multi-Port device will be implanted into prefrontal cortex, premotor cortex, primary motor cortex, and posterior parietal cortex.
223717947|NCT00749645|DRUG|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
224282443|NCT06132152|PROCEDURE|Open hemorrhoidectomy with 'cold' scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. 'Cold' scalpel will be used for cutting the perianal skin and anal mucose. To stop and prevent bleeding the monopolar coagulation may be used but on low energy level and with no touching the skin and mucose.
224282444|NCT06132152|PROCEDURE|Open hemorrhoidectomy with electrosurgical scalpel|Open hemorrhoidectomy will be performed in traditional way, including radial skin-mucosal excision of enlarged hemorrhoids with ligation of the vascular pedicle. Electrosurgical scalpel will be used during all steps including cutting the perianal skin and anal mucose and to stop and prevent bleeding.
223717948|NCT00749645|DRUG|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
223717949|NCT02416921|BEHAVIORAL|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
223717950|NCT02416921|BEHAVIORAL|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
223927929|NCT03150862|RADIATION|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
223927930|NCT06757244|DRUG|Dostarlimab|Intra-venous (i.v) dostarlimab: day1 - d21: 500mg IV q3Weeks (cycle 1 to cycle 4) then 1000 mg IV q6Weeks (from cycle 5 onwards)
223927931|NCT06757244|DRUG|Vitamin D3 (Cholecalciferol)|Oral vitamin D3 8000 IU/d for 14 days, then 4000IU/d
223927932|NCT06757244|DRUG|mFOLFIRINOX Treatment Regimen|mFOLFIRINOX d1, d15, d29 cycle 1 to cycle 4 is administered as follow: oxaliplatin 85 mg/m2 on day1, IV infusion over 2 h, immediately followed by folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion, with the addition of irinotecan 180 mg/m2 as per dose-level given as a 90-min intravenous infusion through a Y-connector immediately followed by 5- fluorouracil 2400 mg/m2 over 46 h continuous infusion.
223927933|NCT06757244|DRUG|LV5FU2|folinic acid 400 mg/m2 Or calcium levofolinate 200 mg/m2 2-h IV infusion 5- fluoro-uracil 2400 mg/m2 Over 46 h continuous infusion. From cycle 5 onwards, D1=D43
223927934|NCT06759948|DRUG|GC012F injection|"Subjects will be infused with GC012F Injection within 48-72 hours after lymphodepletion pretreatment, the infusion dose (CAR-T cells) and groups are as follows:~1. Dose group 1: 1 × 10\^5/kg;~2. Dose group 2: 2 × 10\^5/kg;~3. Dose group 3: 3 × 10\^5/kg; Note: For subjects weighing ≤70 kg: number of infused CAR-T cells = (1, 2 or 3) (±20%) × 10\^5 × body weight(kg); for subjects weighing \>70 kg: number of infused CAR-T cells (fixed doses of GC012F Injection) = (1, 2 or 3) (±20%) × 10\^5 × 70 kg."
223927935|NCT06758908|DEVICE|Antibiotic|SALI
223927936|NCT06755580|PROCEDURE|spinopelvic fixation|open and minimally invasive spinopelvic fixation for unstable or dislocated high-energy sacral fractures
223927937|NCT06768619|DRUG|Group 1: single-dose of test formulation+single-dose of reference formulation|Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
223927938|NCT06768619|DRUG|Group 2: single-dose of reference formulation+single-dose of test formulation|Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
223927939|NCT06760247|PROCEDURE|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|endotracheal intubation by using direct laryngoscopy
223927940|NCT06041256|COMBINATION_PRODUCT|AURN001|Corneal Endothelial Cells and Y27632
224282445|NCT02975037|DRUG|Sildenafil|sildenafil 25 mg PO
224282446|NCT02975037|DRUG|Clarithromycin|clarithromycin 250 mg PO
223927941|NCT06768749|OTHER|Melatonin lotion|3 g lotion applied one hour before bedtime
223717951|NCT03159221|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
223927942|NCT06768749|OTHER|Placebo lotion|3 g of placebo lotion (scent-matched control) applied one hour before bedtime
223927945|NCT06758921|DEVICE|Oscar Peripheral Multifunctional Catheter|"Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon.~Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU)."
223927946|NCT06418061|DRUG|IBI3005|Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
223927947|NCT06398860|PROCEDURE|SIOHPS|The intervention is comprised of several core components such as targeted education, daily team reflections and support for systematic management. First, a two hour education will be conducted for management, HCW involved in patient safety work, safety representatives and intervention facilitators. The second core component is a short daily team reflection conducted by HCW at the unit in connection to the end of work shifts. These are standardized to support identification of situations at work related to both Safety I and II perspective for both occupational health and patient safety as well as learning. The third component includes risk assessment, planning and implementation of appropriate measures, follow up and evaluation, based in information identified in the second component. The steps in this component targets the management and should be conducted in close collaboration with HCW involved in patient safety work and the safety representatives.
223927948|NCT06398860|PROCEDURE|Wait-list|No intervention
223927949|NCT06755957|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Posture exercise, stretching exercise, breathing exercise, back strengthening exercise, self-mobilization exercise, cat camel exercise and postural correction exercise will be applied.
223927950|NCT06755957|OTHER|CONTROL|Posture exercise, stretching exercise, breathing exercise, back strengthening exercise, self-mobilization exercise, cat camel exercise will be applied.
223927951|NCT06511843|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
223927952|NCT06511843|BEHAVIORAL|Lyrical Music|"A 4-minute audio recording of Leonard Cohen's song Hallelujah sung by Rufus Wainwright with choral accompaniment."
223927953|NCT06511843|BEHAVIORAL|Instrumental Music|A 4-minute audio recording of instrumental, theta wave music.
223927954|NCT06769958|BEHAVIORAL|Reflexology|Reflexology application
223927955|NCT06736366|DIETARY_SUPPLEMENT|Dietary supplement - Active comparator|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone); 2 capsules - 100 mg total coenzyme Q10
223927956|NCT06736366|DIETARY_SUPPLEMENT|Dietary supplement - Experimental product|Single dose intervention with Experimental product; BMT® coenzyme Q10; 2 capsules - 100 mg total coenzyme Q10
223927957|NCT06734559|DIAGNOSTIC_TEST|Patients who have not antibiotic treatment for acute apical periodontitis in the last month and have not taken any anti-inflammatory medication in the past 24 hours.|Patients with acute apical periodontitis will first have masseter muscle measurements in the relevant area and then the decayed tooth will be treated with calcium hydroxide for 14 days. Then the dressing will be applied with calcium hydroxide again. At the end of 28 days, the patient will be measured again by ultrasonography and the initial and final data will be compared.
223927958|NCT06734559|OTHER|patients who have not acute apical periodontitis|Masseter measurements will be made from day 1 to day 28 in healthy subjects without acute apical periodontitis.
223927959|NCT06891690|OTHER|tDSC stimulation|tDCA stimulation not exceeding 2 mA
223927960|NCT06750549|DEVICE|ENGAGE-HF Mobile Application|"The mobile app aids ambulatory heart failure monitoring and patient engagement through several features:~Physiologic Monitoring: Daily tracking of blood pressure, weight, and heart rate using Bluetooth devices. Data is shown in graphical and tabular formats.~Health Status Assessment: Biweekly KCCQ-12 surveys and dizziness questions provide scores (0-100), helping visualize therapy benefits and medication adherence, and reducing clinician inertia.~Medication Checklist: Lists current medications and target doses for common heart failure therapies, encouraging adherence and optimization, with alerts for potential improvements.~Education: Animated videos from heart failure experts and societies explain medications, monitoring rationale, app features, and interpretation of data.~The app enhances heart failure management via consistent monitoring, assessment, medication adherence, and educational content."
223927961|NCT06749015|OTHER|Non interventional study|Non interventional study
223927962|NCT06748742|DRUG|In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by the device|In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by using the fluorescence imaging equipment that comes with the device. Guided by real-time fluorescence imaging, the urethra is precisely dissected and severed in front of the bladder neck. Through this improved operation, the bladder neck is protected, the neck injury that is common in conventional surgical operations is reduced, and the reconstructive surgical operations necessary after loss are reduced, and the surgical efficiency is improved. By protecting the bladder neck, the sphincter is better preserved, postoperative urinary incontinence is reduced, and the surgical outcome is improved.
223927963|NCT06738823|PROCEDURE|INTERVENTION GROUP : TRAINING WITH WIIFIT|RCT (RANDOMIZED CONTROL TRIAL) GROUP 1 : Wii FIT TRAINING TIGHT ROPE TENSION, SKI SLALOM, PENGUIN SLIDE, TABLE TILT GROUP 2 : VESTIBULAR REHABILITATION TRAINING WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
223927964|NCT06738823|PROCEDURE|VESTIBULAR REHABILITATION TRAINING|WEIGHT SHIFTING, NECK ROTATIONS, SIT TO STAND EXERCISES ON PADDED MAT AND HEAD MOVEMENTS WITH EYES CLOSED.
224282447|NCT02975037|DRUG|Itraconazole|itraconazole 100 mg PO
223717952|NCT00502047|DRUG|Plantago ovata husk|
223927965|NCT06739980|DRUG|INZ-701|Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
223927966|NCT06757374|DIAGNOSTIC_TEST|Resistin|Considering the HG effect on endocrinologic and metabolic complications, resistin levels in maternal serum may change in the presence of HG severity
223927967|NCT06757569|DEVICE|PET|Feasibility assessment of using the Radialis PET Imager for the detection of amyloid plaque burden using PET amyloid tracer.
223927968|NCT06891183|RADIATION|Percutaneous thermal ablation of lung tumors|Percutaneous radiofrequency ablation
223927969|NCT06759298|DRUG|methylphenidate|patient group will recieve methylphenidate
223927970|NCT06759298|DRUG|matched placebo tablet|placebo gtoup will recieve matched placebo tablet
223927971|NCT06751381|DEVICE|IVIM Imaging MRF Imaging|"IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of nasopharyngeal carcinoma patients undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage.~MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI."
223927972|NCT06751108|DRUG|Corticosteroids (CS)|Concomitant use of immune checkpoint inhibitors and corticosteroids
223927973|NCT06751108|DRUG|Immune Checkpoint Inhibitors|Non-concomitant use of corticosteroids
223927974|NCT06746493|OTHER|Rehabilitation|People after a stroke participated in a standard rehabilitation process carried out at the neurological rehabilitation department.
223532579|NCT07073781|DIETARY_SUPPLEMENT|Lab4p Probiotic Consortium|"The investigational product in this study is Lab4P, a patented multi-strain probiotic consortium formulated as a food supplement and supplied in capsule form. Each daily dose contains a total of 5 × 10¹⁰ CFU of live bacteria, comprising five strains: Lactobacillus acidophilus CUL60 and CUL21, Lactobacillus plantarum CUL66, Bifidobacterium bifidum CUL20, and Bifidobacterium animalis subsp. lactis CUL34. In addition to probiotics, each capsule also contains three micronutrients at 100-200% of the recommended daily intake: Vitamin D (10 µg; 200%), Vitamin C (80 mg; 100%), and Zinc (10 mg; 100%).~Lab4P is a marketed, human-approved product manufactured by Cultech Ltd. (Port Talbot, UK) and is classified as a food supplement, available for purchase without prescription. Both the active product and placebo will be identically packaged to maintain blinding."
223532580|NCT07073781|OTHER|Placebo|Placebo capsules are composed of microcrystalline cellulose, and are identical in appearance to the test product.
223927975|NCT06748638|DRUG|Lactulose|At 20:00 the night before the examination, pour 2 boxes of lactilose into a cup, add 1000ml of water and drink it; 4 to 6 hours before the examination, dissolve the third box of lactulose into 1000ml water, and drink it; Until pale yellow or clear dung water is drawn.
223927976|NCT06748638|DRUG|Lactulose+ linaclotide|1 capsule of linalotide (290ug) taken orally half an hour before meal at 12:00 noon on the previous day， and two doses were taken after 20:00 according to the above Lactulose-taking method.
223927977|NCT06748638|DRUG|polyethylene glycol (PEG)|a bag of PEG was dissolved into 1L at 20:00 1d before the examination, and was drunk at a constant rate within 2h; 4 to 6 hours before the inspection, dissolve the second bag of PEG into 2L water and drink it.
223927978|NCT06897410|OTHER|Interdisciplinary Program for Post-Hospitalization / Hospital at home Management and Long-Term Outcomes in Older Adults with Chronic Cardiorespiratory Condition|"Intervention Phase 1: Feasibility Assessment Duration: January 7, 2025 - January 11, 2025 Participants: 10-15 patients~Description:~All involved services will be available to address and resolve potential issues.~The objective is to assess the feasibility of the program, ensuring that the intervention can be implemented as planned and identifying any practical or logistical challenges.~Phases 2 \& 3: Comprehensive Intervention Duration: January 12, 2025 - June 30, 2025 Participants: 200 patients~Description:~Full-scale implementation of the intervention. Includes interdisciplinary care, home follow-ups, therapeutic optimization, functional rehabilitation, health education, and psychosocial support.~Phase 4: Long-Term Follow-Up Duration: April 7, 2025 - June 30, 2026 Participants: 200 patients~Description:~Follow-up assessments at 3, 6, 9, and 12 months post-intervention. Evaluates hospital readmissi"
223927979|NCT06742424|DRUG|PD-L1 antibody|1200mg intravenously every 3 weeks
223927980|NCT06742424|DRUG|Bevacizumab|15mg/kg intravenously every 3 weeks
224094140|NCT03584022|DEVICE|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
224094141|NCT03584022|PROCEDURE|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
224094142|NCT04889209|BIOLOGICAL|Ad26.COV2.S|Formulated to contain 5x10\^10 virus particles of the Ad26 vector encoding the S glycoprotein of SARS-CoV-2. Each dose of the Ad26.COV2.S vaccine also includes sodium chloride, citric acid monohydrate, trisodium citrate dihydrate, polysorbate-80, 2-hydroxypropyl-ß-cyclodextrin, and ethanol. Ad26.COV2.S will be used undiluted to obtain the specified vp content in 0.5 mL doses. Each dose is 0.5 mL.
224094143|NCT04889209|BIOLOGICAL|BNT162b2|A nucleoside-modified messenger RNA (modRNA) encoding the viral spike glycoprotein (S) of SARS-CoV-2. Each vial contains up to six doses. BNT162b2 (250 mcg/0.5 mL) will be administered in diluted 0.3 mL doses (30 mcg/0.3 mL).
224094144|NCT04889209|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike (S) protein of the 2019 novel coronavirus (2019-nCoV). Doses are either 0.25 mL or 0.5 mL.
224094145|NCT04889209|BIOLOGICAL|mRNA-1273.211|Lipid nanoparticle (LNP) dispersion containing 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the B.1.351 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273. mRNA-1273.211 (0.2 mg/mL) will be administered in 0.5 mL doses (100 mcg/0.5 mL).
223927981|NCT06742424|PROCEDURE|HAIC-FOLFOX|Oxaliplatin 130 mg/m² via hepatic arterial infusion over 3 hours Leucovorin 400 mg/m² via hepatic arterial infusion over 2 hours Fluorouracil 400 mg/m² bolus via hepatic arterial infusion at hour 5, followed by 2400 mg/m² continuous hepatic arterial infusion over 46 hours HAIC treatment repeats every 3 weeks for up to 6 cycles
223927982|NCT06739759|DRUG|Antagonist protocol for IVF|antagonist protocol with triggering by Decapeptyl
223927983|NCT06739759|DRUG|Modified Agonist protocol for IVF with additive treatments as HCQ|giving additive drugs to agonist protocolas HCQ
223927984|NCT06745245|DIETARY_SUPPLEMENT|Nutritional counseling and supplementation with a gelatin with prebiotic fiber and probiotic microorganisms|One serving (15 g) of symbiotic gelatin
223927985|NCT06745609|OTHER|Prehabilitation|"Pre-KiT prehabilitation consists of~1. A geriatric guided assessment with relevant interventions. The assessment will include cognitive evaluation, screening for depression, functional assessment, as well as evaluation of nutritional risk, assessment of past and current diseases, and a thorough review of the patient's medication list focusing on drug interactions. It will also include social history and standard laboratory results,~2. Physical activity. A four week home exercise program, adjusted to the participants physical abilities.~3. Assisted smoking cessation"
223927986|NCT06739720|DRUG|LingZhi capsule|Lingzhi-containg capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm CO LTD containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black sesame extract
223927987|NCT06755151|DRUG|Fenofibrate|Fenofibrate 200mg
223927988|NCT06753474|BIOLOGICAL|Influenza Virus influenza A H3N2 strain|"Live Influenza Virus RG-A/Texas/71/2017 (H3N2). It is a cell-grown, reverse genetics-derived influenza A virus manufactured to conduct clinical trials that involve controlled human infection with influenza A virus. This influenza human challenge virus was produced for the National Institute of Allergy and Infectious Diseases (NIAID).~The final Drug Product Live Influenza Virus RG-A/Texas/71/2017 (H3N2) (Lot #1507-232149) vial contains 1.86 X 106 median tissue culture infectious doses (TCID50)/mL formulated in 1X sucrose-phosphate-glutamate (SPG; 7.4% sucrose, 3.8 mM KH2PO4, 7.2 mM K2HPO4, 5.4 mM L-glutamic acid) in Ex-Cellä 293 serum-free medium (Sigma-Aldrich). It is susceptible to the FDA-approved neuraminidase (NA) inhibitors (NAI) oseltamivir phosphate, zanamivir, and peramivir, and the polymerase acidic (PA) inhibitor (PAI) baloxavir marboxil.x"
223927989|NCT06761846|BIOLOGICAL|Sintilimab plus Chemotherapy|chemotherapy includes SOX and XELOX
223927990|NCT06760767|BEHAVIORAL|sexual therapy|In sexual therapy sessions, sexual education, cognitive restructuring, body awareness exercises, systematic desensitization, relaxation training, individual and partner home exercise training and dilator treatment were applied with the supervision of a physiotherapist. All techniques and stages were not applied in the same session and were used with a certain progression
223927991|NCT06760767|BEHAVIORAL|Pelvic floor physiotherapy combined with sexual therapy|Pelvic floor physiotherapy combined with sexual therapy was applied in the experimental group. Sexual therapy techniques were added appropriately before, during and after the pelvic floor physiotherapy session. In the pelvic floor physiotherapy sessions, pelvic floor muscle training, biofeedback, electrotherapy, manual therapy applications, breathing exercises, stretching and relaxation exercises were applied with the physiotherapist. Pelvic floor physiotherapy techniques and stages were applied in the same session and followed a certain progression.
223927992|NCT06764550|OTHER|This is an observational study, participants are not assigned an intervention as part of the study.|This is an observational study, participants are not assigned an intervention as part of the study.
223927993|NCT06447532|PROCEDURE|Surgery (Mastectomy or quadrantectomy)|Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy
223927994|NCT06773403|DRUG|Upadacitinib|All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
223927995|NCT06323837|DRUG|Mirtazapine|This is a Phase 2, randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of mirtazapine (MZP) to increase methamphetamine (MA) abstinence among treatment-seeking medication for opioid use disorder (MOUD) adults.
223927996|NCT06323837|DRUG|Placebo|Placebo to match.
223927997|NCT04529616|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Eligible eyes will receive Light adjustable lens with Light delivery Device treatments
223927998|NCT06779045|DRUG|AK-1286|Cohort 1: 1 mg/d QD AK-1286 PO,DLT observation period: 21 days. Cohort 2: 2 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 3: 4 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 4: 5 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 5: 16 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 6: 24 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 7: 36 mg/d BID AK-1286 PO,DLT observation period: 21 days. Cohort 8: 50 mg/d BID AK-1286 PO,DLT observation period: 21 days.
223927999|NCT06781138|DEVICE|Conventional stabilization splint|conventional versus 3D designed and printed stabilization splints
223928000|NCT06781138|DEVICE|3D designed and printed stabilization splints|Conventional versus 3D designed and printed stabilization splints
223928001|NCT06754358|PROCEDURE|LenSx|Participants undergo FLACS using LenSx femtosecond laser system
223928002|NCT06754358|PROCEDURE|Z8|Participants undergo FLACS using Z8 femtosecond laser system
223928003|NCT06752434|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
223928004|NCT06768554|OTHER|Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)|Level of blood sugar control (e.g., hemoglobin A1C), severity of infection, blood supply status, and other complications (e.g., peripheral neuropathy)
223928005|NCT06769516|DEVICE|Auricular Vagus Nerve Stimulation (aVNS)|"This intervention involves transcutaneous auricular vagus nerve stimulation (taVNS) using the VagusStim device. The device consists of earphones tailored to fit the individual's ear size (S, M, L) and is connected to a TENS unit. The stimulation is applied to the tragus and concha of the ear for 30 minutes, three times a week, over a 4-week period. The device operates with a pulse duration of less than 500 microseconds, a frequency of 10 Hz, and in a modulated TENS mode. The current intensity is individually adjusted to the participant's sensory threshold. This method targets the vagus nerve to potentially regulate autonomic activity and improve symptoms of Irritable Bowel Syndrome (IBS).~The study combines this intervention with a low FODMAP diet for all participants, distinguishing it from studies focused solely on vagus nerve stimulation or dietary changes."
224094146|NCT04889209|BIOLOGICAL|mRNA-1273.222|Formulated in the same way as the mRNA-1273 vaccine but contains 1:1 mix of mRNAs that encodes for the prefusion stabilized S protein of the Omicron BA.4/BA.5 variant SARS-CoV-2 strain and the prefusion stabilized S protein of the Wuhan-Hu-1 strain used in mRNA-1273.
224282448|NCT03179449|DIAGNOSTIC_TEST|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
224282449|NCT03179449|PROCEDURE|Surgery|Undergo surgical resection
223717953|NCT03943147|DRUG|BMS-986165|Specified dose on specified days
223928006|NCT06769516|BEHAVIORAL|Aerobic Exercise Therapy|"This intervention involves a structured aerobic exercise program designed to improve physical activity levels and modulate symptoms of Irritable Bowel Syndrome (IBS). Participants engage in walking exercises at a moderate intensity, maintaining 50-70% of their maximum heart rate, ensuring the ability to converse comfortably during the activity. The exercise sessions last for at least 30 minutes, three days a week, on alternate days, over a 4-week period.~Participants are individually trained and monitored to ensure proper technique and adherence to the exercise protocol. The intervention is combined with a low FODMAP diet, providing a multimodal approach to IBS symptom management. This distinguishes it from other interventions by emphasizing physical activity's role in enhancing gastrointestinal and overall health."
223532581|NCT06752551|BEHAVIORAL|Apprehension-based training|"This intervention is comprised of the 3 phases:~Static phase - Isometric (static) exercises performed in progressively greater shoulder apprehension (instability) provoking conditions Dynamic phase: Isotonic (dynamic) exercises using shoulder apprehension-provoking movement patterns at a gradually increasing pace of movement.~Neurocognitive phase: Dynamic phase exercises are continued at a high pace with the addition of cognitive tasks (distractions).~The intervention is guided by a physical therapist and includes up to 8 individual (one on one) sessions. In each session the physical therapist assesses exercise performance quality and when appropriate progresses exercise intensity and/or phase. Patients are expected to perform home exercises according to their phase of the program on a daily basis in between physical therapy sessions."
223928007|NCT06769516|BEHAVIORAL|Low FODMAP Diet Intervention|"This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications."
223928008|NCT06756945|DRUG|aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily|STEMI patients receive aspirin 50 mg once daily (one 50 mg aspirin tablet plus one matching placebo tablet) plus ticagrelor 90 mg twice daily
223928009|NCT06756945|DRUG|aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily|STEMI patients receive aspirin 100 mg once daily (two 50 mg aspirin tablets) plus ticagrelor 90 mg twice daily
223928010|NCT06756347|PROCEDURE|Patients receiving landmark-based brachial plexus blocks|The operator will visualize anatomical structures in real time, identify the brachial plexus (supraclavicular approach), and guide the needle to the injection site under direct ultrasound visualization
223928011|NCT06756347|PROCEDURE|Landmark-Based Brachial Plexus Block|The operator will identify anatomical landmarks (e.g., interscalene groove, supraclavicular fossa) using palpation and surface anatomy. The needle will be inserted based on these landmarks, with no direct visualization of internal structures.
223928012|NCT06756347|DRUG|Bupivacaine|injected in both group as local anesthetic agent ( at a standardized concentration and volume) to ensure comparability.
223717954|NCT03943147|DRUG|Placebo|Specified dose on specified days
223928013|NCT06755047|RADIATION|3D Ultrasound|3D placental volume and vascular indices
223928014|NCT06755047|RADIATION|2D ultrasound|2D placental criteria of invasion and color Doppler
224282450|NCT03179449|DRUG|Ferumoxytol|Given IV
224282451|NCT03179449|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
223717955|NCT03943147|DRUG|Mycophenolate Mofetil|Specified dose on specified days
223717956|NCT00171392|DRUG|Enteric-coated mycophenolate sodium|
223717957|NCT02758990|DIETARY_SUPPLEMENT|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
224282452|NCT05234320|DRUG|CG-SpikeDown, intranasal formulation|The CG-SpikeDown peptide produces a dose-dependent increase in binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein and a dose-dependent inhibition of SARS-CoV-2 protein binding to ACE2, the key cellular target. A similar inhibition of binding to ACE2 in human alveolar basal epithelial cells has been demonstrated.
224282453|NCT05234320|DRUG|Vehicle (Placebo)|patients will receive active drug or placebo in addition to standard of care
224282454|NCT05234320|DRUG|Standard of core (type of therapy is depend of decide of the site)|patients will receive active drug or placebo in addition to standard of care
224282455|NCT00894114|BIOLOGICAL|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
224282456|NCT00894114|BIOLOGICAL|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
224282457|NCT06503107|DRUG|Nanobody-based biepitope BCMA-targeting CAR-T cells|Each patient will receive nanobody-based biepitope BCMA-targeting CAR-T cell by intravenous infusion on day 0.
224282458|NCT00377078|DRUG|recombinant human lactoferrin|
224282459|NCT05260723|BEHAVIORAL|Behavioral: Sit Less|The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
224282460|NCT06363630|DRUG|Itraconazole|Specified dose on specified days.
224282461|NCT06363630|DRUG|Rifampin|Specified dose on specified days
224282462|NCT06363630|DRUG|Golcadomide|Specified dose on specified days
224282463|NCT03239236|PROCEDURE|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
224282464|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
224282465|NCT03239236|PROCEDURE|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
224282466|NCT03239236|PROCEDURE|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
223717958|NCT02758990|DIETARY_SUPPLEMENT|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
223928015|NCT06753877|BEHAVIORAL|holistic rehabilitation|Holistic rehabilitation service All participants in the study were cared for in the inpatient unit. The same physician and nurses followed the participants for 1 month. The participants were regularly taking their medication and had no co-morbidities. All participants stayed in double rooms and all stayed with their caregivers. The assessments were carried out within the first 3 days of admission to the inpatient unit. The second assessments were repeated by the same professional. Rehabilitation interventions were provided by different therapists. Participants were given standard physiotherapy services (electrotherapy, exercise, gait training, hydrotherapy, respiratory therapy) and standard occupational therapy services. Occupational therapy interventions were provided by the researchers. Physiotherapy services were provided by physiotherapists working full-time in the hospital. Physiotherapy was provided 5 days a week and occupational therapy was provided 3 days a week.
223928016|NCT06749821|OTHER|Kinesio Tape|Kinesio tape (KT) is an elastic therapeutic tape used to treat sports injuries and various other disorders. It was first used by Dr. Kenzo Kase in 1979 to relieve pain and promote healing in soft tissues and is a method that is constantly being updated. The KT method is a therapeutic taping technique that relieves pain and facilitates lymphatic drainage by microscopically lifting the skin.
223928017|NCT06749821|OTHER|Placebo Tape (Arm 1)|In this application, taping was applied in the same way but with a plaster tape.
223928018|NCT06749821|OTHER|Control (no last irrigation)|No application was made.
223928019|NCT06750848|DRUG|Chidamide，Fulvestrant，angiogenesis inhibitors|chidamide，30mg，po. biw fulvestrant ，500mg， im., d1(c1d15), q4w angiogenesis inhibitors , according to the doctor's advice
223928020|NCT06752616|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs
223928021|NCT06752616|DRUG|Buccal midazolam|Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs
223928022|NCT06752616|DRUG|Oral lorazepam|Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
223928023|NCT06752863|DRUG|Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions|The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries
223928024|NCT06752967|OTHER|High protein liquid test meal|High protein liquid test meal consisting of whey protein, water and sugar-free coadial mix for flavour.
223928025|NCT06752967|OTHER|High carbohydrate liquid test meal|High carbohydrate liquid test meal consisting of sucrose, water and sugar-free coadial mix for flavour.
223928026|NCT06755463|OTHER|Self-acupressure education|Participants will undergo acupressure therapy for 8 weeks, with twice-weekly sessions between 8:00 AM and 10:00 AM. A certified practitioner will train participants on target points, pressure techniques, frequency, and duration. Practical demonstrations will ensure correct application. Groups of up to 10 participants will be trained in a comfortable setting and practice techniques under supervision until proficient. The treatment protocol, based on literature, focuses on beta-endorphin and hypocretin levels, cognition, and patient-reported outcomes (pain, fatigue, depression, and quality of life). Participants will apply 3-5 kg pressure for 2 minutes per point at 12 symmetrical points (LI4, SP6, GV20, HT7, EX-HN3, LV3) using rhythmic movements, totaling 24 minutes. They will receive a diary to track home practices and a visual guide explaining each point's location and steps for application.
223928027|NCT03849131|BIOLOGICAL|Biological collection|"Blood samples will be collected only once at enrollment, before initiation of a checkpoint inhibitor.~It will include:~* DNA samples collection~* RNA samples collection~* Blood sample collection"
223928028|NCT06749678|BEHAVIORAL|Prehabilitation|In addition to routine nursing measures, the prehabilitation group underwent prehabilitation measures during the conversion therapy period. It includes the following strategies: (1) Exercise: Exercise should be carried out when the patient's condition allows, and the exercise programme should be dynamically adjusted according to the patient's tolerance, and it is advisable to maintain the Borg score between 11\~13 points (i.e., subjectively feel relaxed or a little strained). (2) Nutritional support: ensure that the patient's daily energy intake is 20\~25kcal/kg (the target energy reaches 30\~35kcal/kg), and the protein intake is 1.2\~1.5g/(kg·d). (3) Psychological intervention: for patients with mild to moderate anxiety or depression, health education, music therapy and other psychological interventions are carried out. For patients with severe anxiety or depression, psychologists will conduct psychological consultation for patients and provide professional psychological therapy.
223941028|NCT06572189|GENETIC|Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)|Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
224094147|NCT04889209|BIOLOGICAL|SARS-CoV-2 rS/M1|SARS-CoV-2 rS Drug Substance containing the prototype Wuhan is formulated with saponin-based Matrix-M adjuvant in a buffer of 25 mM sodium phosphate (pH 7.2), 300 mM sodium chloride, and 0.01% (weight per volume \[w/v\]) polysorbate 80. NVX-Co-V2373 will be administered in 0.5 mL dose (5 mcg Prototype SARS-CoV-2 rS with 50 mcg Matrix-M adjuvant)
224094148|NCT05424081|BEHAVIORAL|EMBER|Self-help tool to increase weight management engagement
224094149|NCT05424081|BEHAVIORAL|Control|List of weight management programs
224094150|NCT05862272|DRUG|Relugolix Combination Tablet|A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
223717959|NCT02758990|DIETARY_SUPPLEMENT|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
223717960|NCT02758990|DIETARY_SUPPLEMENT|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
223717961|NCT02758990|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
223717962|NCT02758990|DIETARY_SUPPLEMENT|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
223717963|NCT02758990|OTHER|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.
223928029|NCT06749678|BEHAVIORAL|Routine nursing measures|Routine nursing measures including: (1) general education: for different patients, cards and manuals were used to focus on the diagnosis and treatment matters such as examination, treatment, surgery and perioperative treatment, so as to alleviate the anxiety and fear of patients and better cooperate with hospital management. (2) Medical optimization: including smoking cessation, alcohol restriction, chronic disease control, etc. (3) Nutritional support: Routine dietary guidance and nutritional support are given, and intravenous or oral nutrition therapy is given to patients who are emaciated and have lost more than 3kg in the past one month. (4) Rehabilitation training: Carry out rehabilitation training education and guidance, including fist exercises, chest expansion exercises, deep breathing, sputum discharge, abdominal muscle strengthening training, etc.
223717964|NCT02758990|OTHER|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.
223928030|NCT06756854|BIOLOGICAL|Biologic Agent: injectable platelet rich fibrin.|injection of I-PRF to thin gingival phenotype 3 times with 7 days interval between sessions.
223928031|NCT06756854|OTHER|injecable platelet rich fibrin, and low level laser therapy radiation.|injection of I-PRF+ exposure to LLLT to thin gingival phenotype 3 times with 7 days interval between sessions.
223928032|NCT06760975|OTHER|Vestibular Habituation Exercises|The vestibular habituation exercise group follows a structured progression over six weeks. in week 1 participants perform large amplitude, rapid cervical rotations seated, completing 3 sets of five cycles each. By week 2, the exercises increase in complexity , incorporates standing pivots or seated trunk flexion extension. in week 3 the cervical rotations are continued with seated or standing posture. week 4 introduces a busy visual background during the exercise to challenge visual-vestibular integration. In week 5 the exercises are performed standing with the addition complex visual target against a busy background. finally week 6 includes most advance movement including standing pivots 180 degrees and brand-daroff exercises with further visual challenges of near and far targets in busy background. Each exercise session last for 2 minutes and is aimed at progressively enhancing vestibular processing and adaptability.
223928033|NCT06760975|OTHER|Ocular Reflex Excercises|The Ocular reflex exercises focuses on enhancing visual tracking and reflexes through targeted viewing exercises. In week 1, participants perform horizontal and vertical X1 viewing exercises with a near target, holding each position for 1 minute while seated. In week 2 the duration of the X1 exercises is extended to 2 minutes with the near target still in seated position. Week 3 shift to a far target for the X1 exercises and the participants performs them while standing increasing the challenge. By week 4 the exercise incorporate both near and far target in front of a busy background. extending the duration to 2 minutes while standing. In week 5 horizontal and vertical X2 viewing exercises are added with a plain background, while still using near and far targets in front of a busy background . finally week 6 continues the X1 and X2 exercises with near and far targets in a busy background, performed for 2 minutes while standing. This aims to improve visual tracking.
223928034|NCT06762652|OTHER|Wash-in period|The goal of the wash-in period between the control and intervention period is to intensively educate and train physicians to use the algorithm as intended during daily postoperative care. The coordinating investigator along with the local principal investigator will be responsible for this training. Training will be performed in a standardized approach in order to guarantee uniformity across centres.
223928035|NCT06762652|DIAGNOSTIC_TEST|Algorithm-based care|During the intervention period, (participating) patients will receive algorithm-based care. The RESCUE algorithm is a consensus-based clinical care algorithm developed to standardize postoperative care. The algorithm includes the same modalities as applied in usual care, and does not include novel/experimental modalities, but rather offers a novel, standardized approach to guide the use of common modalities during postoperative care. The daily objective evaluation of patients' condition, vital signs and biochemical parameters is thought to aid early diagnosis of complications after esophagectomy which enables treatment before systemic symptoms become apparent and prevent development of sepsis. Physicians are always allowed to deviate from the RESCUE, but reasons for deviating will be recorded.
223928036|NCT06898385|BIOLOGICAL|IX001 TCR-T injection|IX001 TCR-T injection will be administered intravenously after lymphodepletion.
223928037|NCT06898385|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223928038|NCT06898385|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223928039|NCT06515275|OTHER|Education via video (QR code links)|Video education on self-administered medications for women undergoing IVF treatment
223928040|NCT06761183|GENETIC|intracerebral stereotactic injection of NXL-001|intracerebral stereotactic injection of NXL-001: with 3 subjects in each group to receive a single stereo-tactically intracerebral injection of NXL-001 at escalating doses.
223928041|NCT04789044|DRUG|NTX-001|• PEG fusion is the application of a polyethylene glycol (PEG) using a combination of sequenced reagents to a freshly performed nerve coaptation, or neurorrhaphy, to allow the axonal membranes of the proximal and distal axonal stumps to fuse back together and re-establish full axonal continuity.
223928042|NCT06753058|DIETARY_SUPPLEMENT|25 gram of maltodextrin in 330 mL , Nutricia Fantomalt 4 Gram, Nutri Gıda Ürünleri San. ve Tic. A.Ş., Istanbul, Türkiye, 2 h prior to surgery.|Although 45 g of different carbohydrate solutions either Gatorade 54 g carbohydrate or clear apple juice 56 g carbohydrate in non-diabetic women have been recommended by SOAP, we preferred 25 g of carbohydrate, fantomalt, nutricia, diluted in the 330 mL in both diabetic and non-diabetic pregnant women.
223928043|NCT06753058|BEHAVIORAL|Mother baby bonding|In the ERAS implemented group, mother-baby contact to promote early bonding was established, and both mother and baby were encouraged for breastfeeding. In the control group, only mother-baby contact was facilitated without proactive breastfeeding encouragement.
224282467|NCT03239236|PROCEDURE|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
223717965|NCT02758990|DIETARY_SUPPLEMENT|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
223717966|NCT02758990|OTHER|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
223717967|NCT02758990|DEVICE|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
223717968|NCT02758990|OTHER|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
223717969|NCT00991718|DRUG|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
223928044|NCT06753799|BEHAVIORAL|The intervention group received training based on Social Cognitive Learning Theory.|One of the theories that provides a conceptual framework for the learning and behavior change process is Social Cognitive Learning Theory. Verbal information is commonly provided in the education of individuals with diabetic foot ulcers. The difference of this study from other studies is that an educational booklet, an educational video and a demonstration method with a diabetic foot model are used during the education within the scope of theory-based education.
223928045|NCT06752629|DRUG|Bupivacaine and Dexmedetomidine|Adult patients will take 10 ml Bupivacaine 0.5% plus 2ml solution of Dexmedetomidine 1mic/kg in the bilateral T5\&6 preoperatively
224094151|NCT06517121|DEVICE|Personalized Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity over personalized brain regions based on the particular neural correlates of socio-affective processing.
224094152|NCT06517121|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants assigned to the sham control group will only receive 30 seconds of active stimulation.
224094153|NCT06517121|DEVICE|Conventional Experimental Transcranial Direct Current Stimulation (tDCS)|This study will deliver tDCS sessions for ten sessions completed within two weeks. Participants will receive 20 minutes of active stimulation with a 2mA intensity with anode placed over F3.
224094154|NCT03905928|OTHER|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
224282468|NCT03239236|DRUG|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
224282469|NCT03239236|DIAGNOSTIC_TEST|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
224282470|NCT03239236|DIAGNOSTIC_TEST|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
224282471|NCT03239236|DIAGNOSTIC_TEST|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
224282472|NCT00002702|BIOLOGICAL|aldesleukin|
224282473|NCT00002702|PROCEDURE|adjuvant therapy|
224282474|NCT00002702|PROCEDURE|conventional surgery|
223928046|NCT06752629|DRUG|Bupivacaine and Fentanyl|Adult patients will take 10 ml Bupivacaine 0.5% plus 2ml solution of Fentanyl 20 microgram with the bilateral T5\&6 preoperatively
224282475|NCT00002702|PROCEDURE|neoadjuvant therapy|
224282476|NCT00002702|RADIATION|radiation therapy|
223928047|NCT06766461|DRUG|Double dosing of beta-lactam antibiotic|This arm will receive double dosing of beta-lactam antibiotics for the first 48 hours after inclusion.
223928048|NCT06765005|DRUG|MG-K10|Subcutaneous injection, once every 4 weeks
223928049|NCT06764004|GENETIC|Stem Cell Product|Human umbilical cord stem cells and exosomes will be used.
224094155|NCT03905928|OTHER|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
224094156|NCT03905928|OTHER|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
224094157|NCT03905928|OTHER|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
224282477|NCT01705860|BIOLOGICAL|Santyl|
224282478|NCT04154826|DRUG|Recombinant human interleukin-7|weekly intra-muscular (IM) administration
224282479|NCT01854086|OTHER|Questionnaires about compliance and persistence with bisphosphonates treatment|
224282480|NCT05002686|DRUG|Sintilimab|200 mg Q3W on Day 1 by IV infusion
224282481|NCT05002686|DRUG|Albumin-Paclitaxel|200 mg/m\^2 Q3W on Day 1 by IV infusion
224282482|NCT05002686|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
224282483|NCT05002686|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
224282484|NCT05002686|RADIATION|Radiation|Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.
224282485|NCT05002686|PROCEDURE|Radical gastric cancer surgery|Radical gastric cancer surgery with D2 lymph node dissection
224282486|NCT05424614|OTHER|Functional outcome follow-up of patients|Patients were followed up by telephone after discharge, every 4 weeks, until the end of the 3-month follow-up. Their functional status was determined based on the MRS score (modified Rankin Scale). Those with less than 3 points were defined as having a good prognosis, and those with more than 3 points were defined as having a poor prognosis
224282487|NCT02823314|DEVICE|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
223532582|NCT06752551|BEHAVIORAL|Standard physical therapy|Standard physical will be provided based on the assessment and judgment of the physical therapist. Intervention may include active exercises for increased shoulder mobility, muscle strength and neuromuscular control. Intervention may also include manual therapies such as massage, soft-tissue and joint mobilizations, dry needling, and electrophysiological modalities. No more than 8 individual sessions with a physical therapist will be provided over the course of treatment with some form of a home exercise program in between.
224282488|NCT02823314|DEVICE|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
223532583|NCT00152438|DRUG|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
223532584|NCT00152438|OTHER|Placebo|3 identical placebo pills daily, no active ingredient.
223532585|NCT06792799|BIOLOGICAL|anti-CD19/BCMA CAR NK cells (KN5601)|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5601) will infused in each group using the 3 + 3 dose-escalation strategy."
223532586|NCT05475366|OTHER|Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC|Formalin-Fixed Paraffin-Embedded (FFPE) samples will be centralized in which nucleic acids extraction (DNA+RNA) and FFPE-compatible RNA-sequencing will be performed in real-time (≤28 days). RNAseq reads will be processed and all 5 transcriptomic signatures will be applied for prediction of response to 5FU, oxaliplatin, irinotecan, gemcitabine and taxane. In addition, biomarkers status will be obtained for all patients as part of good clinical practice.
223928050|NCT06764004|BIOLOGICAL|Bleeding and clots|Exosomes obtained from human umbilical cord stem cells will be used
223928051|NCT06769893|DIAGNOSTIC_TEST|68Ga-NOTA-RCCB6 PET/CT Scan|"The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations.~Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL."
223928052|NCT06763068|OTHER|Skeletal muscle mass and frailty|Measurement correlation variable
224282489|NCT03687879|OTHER|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
224282490|NCT00021489|DRUG|Abacavir sulfate|
224282491|NCT00021489|DRUG|Mycophenolate mofetil|
224282492|NCT06022367|DIAGNOSTIC_TEST|Head Turn Activation Technique|Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
223532587|NCT05475366|OTHER|Biomarkers of tumor signatures (translational studies)|Blood (serum and plasma) will be drawn at baseline, week 8, and tumor progression in order to look for surrogate biomarkers of tumor signatures in liquid biopsy
223532588|NCT04630769|DRUG|IP FT516|FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
223532589|NCT04630769|DRUG|Enoblituzumab|Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
223532590|NCT04630769|DRUG|IL-2|IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
223532591|NCT05714072|DRUG|Ruxolitinib|10mg BID or 15mg BID
223532592|NCT05714072|DRUG|Abemaciclib|50, 100 and 150 mg
223717970|NCT00991718|DRUG|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
223717971|NCT00991718|DRUG|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
223717972|NCT03674671|DRUG|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
223717973|NCT03674671|PROCEDURE|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
223717974|NCT02527005|DRUG|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
223717975|NCT02527005|DRUG|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
223717976|NCT01446978|BIOLOGICAL|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
223928053|NCT06768125|RADIATION|Hypofractionated Radiation Therapy|95% PGTVp: 33 Gy in 3.3 Gy per session for 10 sessions, and 95% PTV1: 25 Gy in 1.5 Gy per session for 10 sessions, with an interval of 1-2 weeks, for a total of 2 cycles.
223928054|NCT06757660|PROCEDURE|Furcation Repair|to evaluate the clinical and radiographic effects of chitosan and Naocl as an irrigation protocols applied during repair of furcation perforation.
223928055|NCT06761521|DIAGNOSTIC_TEST|Peri-Implantitis and Peri-implant mucositis|peri-implant mucositis, peri-implantitis
223928056|NCT06762236|OTHER|Pillatate Training|.The session will repeated three times per week for 6 weeks with 40-minute sessions In Pilates we include 5 Pilate exercise, The Hundred (Rhythmic Breathing), Single Leg Stretch (Rhythmic Breathing), side kick, Toe Taps (Set Breathing Pattern) ,leg pull front for 6 weeks.
223928057|NCT06761547|DRUG|magnsium sulfate|patients will take magnsium sulfate 15 mg/kg IV
223928058|NCT06761547|DRUG|Lidocaine (drug)|patients will take lidocaine2% 1 mg/kg
223928059|NCT06761547|DRUG|Saline|50 ml saline IV
223928060|NCT06776861|DRUG|PD-1 / PD-L1 monoclonal antibody|Patients with advanced breast cancer who have already received and continue to use immunotherapy, or are planned to receive immunotherapy, and have been recommended for radiotherapy after evaluation by a multidisciplinary team (MDT) in the early stage and have completed radiotherapy, are registered and followed up in this study.
223928061|NCT06767657|PROCEDURE|CEA (carotid endarterectomy)|Intervention (CEA) is associated to both arms (group A and B)
223928062|NCT06761300|OTHER|Psychological assessment|Psychological assessment evaluation at different time points and its correlation with pain outcomes and satisfaction with the SCS intervention.
223928063|NCT06761599|DIAGNOSTIC_TEST|group 1|To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.
224094158|NCT05432999|DEVICE|Extracorporeal Shockwave Therapy|Shockwaves are high pressure sound waves that interact with tissues to elicit a biological response. The shockwave probe will be placed on the skin with ultrasound gel and the muscle will be stimulated for a few minutes.
224094159|NCT01491087|BIOLOGICAL|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
224282493|NCT06022367|DIAGNOSTIC_TEST|Head Raise Activation Technique|Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
224282494|NCT02303886|DRUG|Methylene blue|In NaCL0.9% 100 ml
224282495|NCT02303886|DRUG|Methylene blue|in NaCl 0.9% 100 ml
223928064|NCT06826443|DRUG|Mosapride Citrate Tablets|Prokinetic Drug
223928065|NCT06826443|DRUG|Metoclopramide 10mg|Prokinetic Drug
223928066|NCT06828068|DEVICE|Ultrasound (Scolioscan system), and EOS radiography system|"Scolioscan ultrasound system was reported to be reliable and valid for spinal deformity assessment. The system composes of an ultrasound scanner with a linear probe of 10 cm width and frequency range of 4-10MHz, a frame structure and a spatial sensor attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using phantom to assure accuracy of spine image formation and subsequent angle measurement. Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process. The probe will be steered from L5 to C7 spinous process for scanning. SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral. Coronal Cobb angle measurement on EOS radiographs will be used as gold standard."
223928067|NCT06826417|DRUG|Xanax|double-blind randomized controlled clinical trial: in a double-blind manner, to receive Xanax
224094160|NCT05505422|DEVICE|Routine ECMO|Routine ECMO during lung tansplant
224094161|NCT05505422|DEVICE|On demand ECMO|"Selective, indication-based intraoperative cardiopulmonary support. In this group, the transplant will be planned without cardiopulmonary support. intraoperative ECMO will be used selectively based on hemodynamic and/or gas exchange abnormalities :~1. Inability to maintain adequate hemodynamics and stable perfusion or oxygenation during surgery~2. Prolonged high dose pressor required to maintain adequate perfusion~3. A sustained drop in cerebral saturation \> 25% of baseline despite initial attempts at optimization~4. Inability to tolerate pulmonary artery clamping~5. Inadequate gas exchange despite attempts at the optimization of ventilator parameters and treatments related to respiratory mechanics and ventilation/perfusion matching~6. Inadequate exposure to the surgical field"
224094162|NCT06159478|DRUG|Binimetinib 15 MG|Binimetinib 45mg is orally administered twice daily.
224094163|NCT01725165|OTHER|Clinical Observation|Undergo clinical observation
224094164|NCT01725165|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224094165|NCT01725165|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224094166|NCT01725165|OTHER|Quality-of-Life Assessment|Ancillary studies
224282496|NCT02916693|DRUG|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
224282497|NCT03433365|OTHER|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
224282498|NCT05491239|PROCEDURE|Thoracic epidural analgesia|After correct placement of the epidural catheter, a local anaesthetic (ropivacaine, levobupivacaine or bupivacaine) will be started and, according to in house protocols, an opioid will be added to the epidural solution. A provisional stop of the administration of the epidural infusion is planned after 48 hours (on the second postoperative day).
223928068|NCT06826417|OTHER|placebo tablets|double-blind randomized controlled clinical trial: in a double-blind manner, to receive a placebo (identical in appearance to Xanax but without any active effects)
224094167|NCT01725165|PROCEDURE|Standard Follow-Up Care|Undergo standard maintenance therapy
224094168|NCT01725165|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224094169|NCT02896582|DRUG|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
224094170|NCT02896582|DRUG|Dexamethasone|40 mg D1 to D4 in GA-DHAP
224094171|NCT02896582|DRUG|Aracytine|2g/m² D1 \& D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
224094172|NCT02896582|DRUG|Cisplatinum|100 mg/m² D1 in GA-DHAP
224094173|NCT02896582|DRUG|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
223532593|NCT03423979|DEVICE|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
223532594|NCT03423979|DRUG|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
223532595|NCT06908577|DRUG|Tozorakimab|Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.
223532596|NCT06908577|DEVICE|Autoinjector (AI) Device|AI device will be used to administer single SC dose of tozorakimab on Day 1.
223532597|NCT06908577|DEVICE|Accessorised Prefilled Syringe (APFS) Device|APFS device will be used to administer single SC dose of tozorakimab on Day 1.
223928069|NCT06774079|DRUG|Tirzepatide|Patients in this arm will receive tirzepatide starting at 2.5 mg subcutaneous (SC) weekly for 4 weeks, then increase to 5 mg SC weekly for 4 weeks and then 7.5 mg SC weekly for the last 4 weeks of the intervention period. Place of injection includes abdomen, thigh, or upper arm.
223532599|NCT02760342|DRUG|peficitinib|Oral
223532600|NCT02760342|DRUG|Metformin|Oral
223532601|NCT07088796|DEVICE|Toric IOL implantation|All surgeries were performed by the same surgeon (J.Y.) using a standardized surgical technique (phacoemulsification for cataract extraction+ IOL implantation + anterior vitrectomy) under general anesthesia. Scleral tunnel incision was created firstly. Thereafter, 5.0-5.2mm anterior capsule capsulorrhexis, and cataract aspiration were performed. A single-piece hydrophobic acrylic IOL (SN6AT3-T9) was implanted into the capsular bag. After the corneal incision was closed with 10-0 sutures, a posterior capsulectomy of 3-4 mm and anterior vitrectomy were performed through the pars plana using 25-gauge instrumentation with high cutting frequency (3,000 to 4,000 cuts per minute) and low aspiration pressure (300 to 350 mm Hg) in all eyes. A 3.5-4.0 mm posterior capsule capsulorrhexis and anterior vitrectomy were performed in patients.
223532602|NCT07088796|DEVICE|Non-toric IOL implantation|All surgeries were performed by the same surgeon (J.Y.) using a standardized surgical technique (phacoemulsification for cataract extraction+ IOL implantation + anterior vitrectomy) under general anesthesia. Scleral tunnel incision was created firstly. Thereafter, 5.0-5.2mm anterior capsule capsulorrhexis, and cataract aspiration were performed. A single-piece hydrophobic acrylic IOL (SN60WF) was implanted into the capsular bag. After the corneal incision was closed with 10-0 sutures, a posterior capsulectomy of 3-4 mm and anterior vitrectomy were performed through the pars plana using 25-gauge instrumentation with high cutting frequency (3,000 to 4,000 cuts per minute) and low aspiration pressure (300 to 350 mm Hg) in all eyes. A 3.5-4.0 mm posterior capsule capsulorrhexis and anterior vitrectomy were performed in patients.
223532603|NCT07099352|DEVICE|Acupuncture Laser Therapy|Participants will receive low-level laser therapy sessions during dialysis , applied three times per week for 4 weeks to selected treatment areas.
223532604|NCT06889701|DRUG|TNP-2092 for injection|TNP-2092 for injection, 100 mg/vial, Intra-articular administration (IA), 10ml (50 mg) once daily for 14 days. TNP-2092 dose volume, dose, frequency, and duration can be adjusted according to the sentinel group synovial fluid TNP-2092 concentration, PK characteristics, and safety results at the EA visit.
223532605|NCT06889701|DRUG|Vancomycin Hydrochloride for Injection (IA)|Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intra-articular administration, 10 mL (0.5 g) once daily for 14 days.
223532606|NCT06889701|DRUG|Vancomycin Hydrochloride for Injection (IV)|Vancomycin Hydrochloride for Injection, 0.5 g/vial, Intravenous infusion, 250 mL (1 g) q12h ± 1h per day, for 14 days.
223532607|NCT06889701|DRUG|Oral antibiotics|"Rifampicin capsules: 0.15 g/capsule. 0.45 g (3 capsules) orally once daily within 1 h before breakfast for 8 weeks (56 days).~Levofloxacin Tablets: 0.5 g/tablet. 0.5 g (1 tablet) orally once daily within 1 hour before breakfast for 8 weeks (56 days).~If susceptibility testing results show resistance to rifampicin and/or levofloxacin, or intolerance by the patient 's participant, treatment with oral minocycline hydrochloride capsules will be substituted as follows:Minocycline hydrochloride capsules: 100 mg/capsule. Administered orally q12h ± 1h daily, doubling the first dose, 200 mg (2 capsules) orally, then 100 mg (1 capsule) each time for 8 weeks (56 days).~The total duration of oral treatment during the oral administration period was 8 weeks (56 days) regardless of whether oral medication will be changed (eg, intolerance)."
223532608|NCT06889701|DRUG|Background Treatment|Background treatment will be determined by the investigator.
223532609|NCT07097909|OTHER|LLM-based CBT|An intelligent mobile application that delivers CBT for tinnitus, powered by a LLM. The app provides daily interactive sessions (≥20 minutes per day) over 4 weeks, incorporating cognitive restructuring, relaxation training, attention-shifting, and sleep hygiene guidance. The content dynamically adapts to user input to enhance engagement and personalization.
223532610|NCT07099846|DEVICE|regeneration of post extraction socket with biomaterials|after tooth extraction, in the test group we will place a demineralised bovine bone graft mixed with a gel containing hyaluronic acid and polynucleotide and we will cover the entrance of the socket with a collagen matrix
223532611|NCT06522386|DRUG|Pirtobrutinib|Given by mouth
223532612|NCT06522386|DRUG|Rituximab|Given by vein (IV)
223532613|NCT06522386|DRUG|Venetoclax|Given by mouth
223532614|NCT06857903|BEHAVIORAL|Recruitment nudges|Participants who in the intervention condition will receive recruitment materials that contain behavioral nudges
223532615|NCT06827262|DEVICE|Intracept™ Intraosseous Nerve Ablation|Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain
223532616|NCT05239221|DRUG|AZP-3601|Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection
223532617|NCT05239221|DRUG|Placebo|Saline solution visually matching active medication
223532618|NCT06474013|DEVICE|ExAblate 4000 Type 2.1|The ExAblate BBB disruption procedure will be performed with ExAblate 4000 type 2.1 system, and this will be performed 3 times every 2 months.
223532619|NCT07114341|OTHER|Cranberry Intervention|30 grams of lyophilized cranberry containing 1187 mg/100 g anthocyanins were given for 7 days.
224094174|NCT02896582|DRUG|Melphalan|140 mg/m² D-2 in GA-BEAM
224094175|NCT02896582|DRUG|Carmustine|300 mg/m² D-7 in GA-BEAM
224094176|NCT05039086|DRUG|PDE5 inhibitor|PDE5 inhibitors (sildenafil, tadalafil) claim is used as the exposure group.
223928070|NCT06774079|BEHAVIORAL|Mediterranean diet|The diet is comprised of a content of 25-30 grams of fiber per day (from fruits, vegetables, whole grains) that is low in animal protein and minimally processing of foods The diet arm will receive dietary guidance from our dietician on weekly 30-minute guided sessions. Participants will be encouraged to adhere to the diet for up to three meals per day for the duration of the study.
223928071|NCT03732703|DRUG|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
223928072|NCT03732703|DRUG|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
223928073|NCT03732703|DRUG|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
223928074|NCT03732703|DRUG|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
223928075|NCT03732703|DRUG|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
223928076|NCT03732703|DRUG|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
223928077|NCT03732703|DRUG|Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
223928078|NCT03732703|DRUG|Selinexor, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
223928079|NCT06773338|BEHAVIORAL|Tetris|Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
223928080|NCT06773338|OTHER|No intervention|Participants do not receive any intervention.
223928081|NCT06772493|DEVICE|ViewFlex X ICE System|Subjects to undergo cardiac ablation procedure utilizing the ViewFlex X ICE System
224094177|NCT05039086|DRUG|Endothelin Receptor Antagonists|Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) claim is used as the reference group.
224094178|NCT04193371|OTHER|Active acupuncture|The rationale of the active acupuncture protocol is based on Western Medical Acupuncture theories and follows CONSORT and STRICTA protocols. All patients received acupuncture treatment for 30 minutes three times a week, with a maximum of 48 acupuncture treatments.
223928082|NCT06770608|PROCEDURE|micro-needling with topical human actrapid insulin|Micro-needling with topical application of 2ml of human actrapid insulin once monthly for 4 months
223928083|NCT06770608|PROCEDURE|Micro-needling with topical Platelet rich plasma|Micro-needling with topical application of 2ml Platelet rich plasma once monthly for 4 months
223928084|NCT06774222|DRUG|Fruquintinib|Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks
223928085|NCT06773559|DIAGNOSTIC_TEST|plantar pressure, gait and static balance analysis|Plantar pressure, gait and static balance analysis performed using Ultium Insole SmartLead insoles.
223928086|NCT06773559|DIAGNOSTIC_TEST|trunk posture analysis|Trunk posture analysis was performed using Diers Formetric 4D.
223928087|NCT06760000|DEVICE|Five seasons Sleep Tracking Mat|Non-contact mat monitoring sleep data through pulse wave detection
223928088|NCT06758687|OTHER|Kinesiotape Application|"Before the appropriate taping is applied to the waist area, a small piece of kinesio tape will be attached to the participant's thigh area and an allergy test will be performed. If the participant does not have any complaints within 5-10 minutes, the participant will be taped. The tape to be used in this study will be waterproof, porous, breathable, 5 cm wide and 0.5 mm thick.~After the initial evaluation is completed, kinesio taping will be applied to the paravertebral muscles. First, the participant will be asked to perform trunk flexion while standing with their forearms supported by a table. While the participant is in this position, two I shaped tapes will be attached to the right and left sides of the spine (in the cranial direction) along the paravertebral muscle line without applying tension. Then, the field correction technique will be applied. While the participant is standing with their forearms supported on the table, four I tapes overlapping in"
223928089|NCT06759571|PROCEDURE|low level laser treatment|to evaluate the effect of low-level laser therapy (LLLT) bone healing when used prior and following enucleation of intra-body maxillary cystic lesions
223928090|NCT06758778|DIETARY_SUPPLEMENT|CreNeuroS CNS Fish Oil Plus Softgel [380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals]|Test product
224094179|NCT04193371|OTHER|Sham acupuncture|In the sham acupuncture protocol, 2 needles were inserted superficially to a depth of less than 5 mm, 1 in each shoulder and 1 in each upper arm at nonacupuncture and non-meridian points, and then, 4 needles were attached to electrodes and the stimulator was turned on to mimic the active acupuncture but with zero intensity, no electrical stimulation. They also received the treatment for 30 minutes three times a week and a maximum of 48 treatments.
223928091|NCT06758778|DIETARY_SUPPLEMENT|Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules|Reference product
223928092|NCT06759324|DIETARY_SUPPLEMENT|Live kombucha (non filtered/ non pasteurized)|Participants receive a daily amount of 33 cl of live kombucha (non-pasteurized/ non-filtered) for 4 weeks (28 days).
223717977|NCT01446978|BIOLOGICAL|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
223928093|NCT06759324|DIETARY_SUPPLEMENT|Pasteurized kombucha (non filtered)|Participants receive a daily amount of 33 cl of kombucha (pasteurized drink) for 4 weeks (28 days).
223928094|NCT06759324|OTHER|Control (sparkling water)|Participants receive a daily amount of 33 cl of sparkling water for 4 weeks.
223717978|NCT01318993|DRUG|GSK1605786A|500 milligrams twice daily
223928095|NCT06759467|DIAGNOSTIC_TEST|AI-Driven Virtual Biopsy for Diagnosis of Peritoneal Exfoliative Cytology-Positive Gastric Cance|"The intervention involves the use of an artificial intelligence (AI)-driven virtual biopsy technology for the non-invasive diagnosis of gastric cancer with positive peritoneal exfoliative cytology (PEC). Unlike traditional biopsy methods, which require invasive procedures to obtain tissue samples, this intervention utilizes AI algorithms to analyze non-invasive biomarkers derived from patient samples such as blood, urine, or peritoneal lavage fluid.~The AI model is designed to integrate various data types, including transcriptomic profiling, imaging data, and other biomarkers, to predict the presence of PEC-positive gastric cancer. This technology employs advanced machine learning techniques to identify molecular and cellular features indicative of peritoneal metastasis, providing a diagnostic tool that is potentially more sensitive and less invasive than conventional methods.~The intervention is unique in its ability to combine multi-omics data (such as gene expression and imaging."
223928096|NCT05755919|PROCEDURE|Epilepsy surgery|Epilepsy surgery will be performed as a part of the clinical management of patients with drug-resistant epilepsy.
223928097|NCT06774300|BEHAVIORAL|BASICS|The intervention is the BASICS protocol outlined in the BASICS manual. It includes an online self-administered assessment and then delivery of a feedback session either in-person or over Zoom.
223928098|NCT06774300|BEHAVIORAL|Online alcohol programming|This is a control intervention that is used as the first-line sanction for students at the two universities. It is an online program, informed by BASICS content, but contains no facilitator and is self-directed.
223928099|NCT06748248|OTHER|suspension Therapy|suspension therapy for individuals with Down syndrome is an approach that focuses on improving mobility and balance through different activities that will be conducted through universal exercise unit. This method involves organizing individuals with Down syndrome into two groups. Group A will perform Suspension Therapy in addition to routine physical therapy. These routine exercises will consist of stretching exercises (arm raises, chest stretch, leg swings, hamstring stretch, cat-cow poses, starfish stretch), strength and endurance training (like stepping, carrying light weights) and balance training (playing hopscotch and kicking a ball). The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. Suspension Therapy will consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. Repeated corrective movements will be performed.
223928100|NCT06748248|OTHER|Routine Treatment|"Group B will perform routine physical therapy (RPT) alone. These routine exercises will consist of stretching exercises (particularly upper and lower body stretches and full body stretches). Stretches will be gentle and avoid bouncing. Hold for each stretch will be 15-30 seconds. Balance and coordination exercises (Walking on balance beams, obstacle courses) will be performed as RPT. The exercise program will gradually increase in intensity in accordance with each participant's functional improvement. These exercises will be carried out 5 days in a week for one hour daily.~Data will be assessed by assessor at baseline and at the end of 5th session of treatment (Pre and post)."
223928101|NCT06760845|DIAGNOSTIC_TEST|Imaging Time|Raman spectroscopy images of blood and urine
223928102|NCT06775184|DEVICE|a native video image system|The visualization of the glottic structures through the SaCoVLM™ imaging system is graded as follows: Grade1: Visibility of the lateral portion of the right epiglottic fold and part of the laryngeal inlet. Grade 2: Visibility of both epiglottic folds and part of the laryngeal inlet. Grade 3: Visibility of the laryngeal inlet and part of the vocal cords. Grade 4: Visibility of the entire vocal cords.
223928103|NCT06775184|DEVICE|Fiberoptic bronchoscope|The position of the i-Gel is checked using a fiberoptic endoscope
223928104|NCT06771752|OTHER|Questionnaire|The questionnaire will be made comprised of the questions taken from the Whole Day Matters Toolkit (WDMT) 24-hour movement questionnaire (The Canadian Society for Exercise Physiology, 2021), which is based on the official 24-hour movement guidelines (Ross et al., 2020) (see appendix). For diet quality, Mini-EAT, a short dietary screening tool will be used (Lara-Breitinger et al., 2023) (see appendix). The questionnaire will be open for two months during the football mid-season time period (January 15th to March 15th). The principal investigator will distribute the questionnaire digitally via Google Forms. It will be sent directly to sports staff professionals, individually and to football clubs and to universities to distribute to their cohort. Only people with the link will be able to access the questionnaire. Participants will answer the questionnaire, which will take roughly 10 minutes, completing the intervention.
224094180|NCT04193371|OTHER|Lifestyle management|"All women will receive lifestyle management before randomization after baseline measurements. The lifestyle management assisted by a PCOS lifestyle management system (Invention patent, ZL 2015 1 0500978.9).~All participants will get a step-counter for daily use and physical exercise diary for daily reporting of exercise: number of steps, type of activity, intensity and time (minutes). Once a week each participant receive a SMS in which they report the activity during the week."
224094181|NCT05207826|DIAGNOSTIC_TEST|Cystometrogram|Serial cystometrogram every 3 days for acute traumatic spinal cord injured patients
223717979|NCT02337660|PROCEDURE|Liver biopsy|One ultrasound guided liver biopsy
223717980|NCT02337660|OTHER|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
223717981|NCT00864331|RADIATION|radiation|39 Gy in 13 daily fractions of 3 Gy
224094182|NCT05095142|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
224094183|NCT04298762|OTHER|No peer comparison email|The comparison group received no email communication on their cancer stage documentation activity.
223532620|NCT07124923|OTHER|Continuity-of-Care intervention|"The intervention is a structured, multidisciplinary training and feedback program led by the Endocrinology Service at HTVC in collaboration with primary care centers in Terres de l'Ebre.~Four endocrinologists and four nurses (three educators and one diabetic foot referent) will provide onsite training to primary care physicians and nurses. Training includes six modules with theoretical and practical components, covering T2DM management, cardiovascular risk reduction, and diabetic foot care. Sessions will be held biweekly and delivered by doctor-nurse teams rotating through the participating primary care centers from July 2025 to July 2026, with each center receiving a total of 15 sessions per year.~The program also includes regular feedback to professionals on clinical performance and patient outcomes, adapting content to each center's needs. A qualitative component, involving focus groups before and after the intervention, will gather feedback and inform future implementation."
223717982|NCT00864331|OTHER|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
223928105|NCT06776809|OTHER|Music listening|Selection of Sufi music will be played to the patients during the course of the operation.
223928106|NCT06775444|BEHAVIORAL|Breastfeeding Education Program Based on Planned Behavior Theory|"In addition to routine breastfeeding training at the hospital where the study is conducted, the intervention group will be given a 2-session Breastfeeding Training Program Based on Planned Behavior Theory.~Education Content:~The importance of breast milk, the benefits of breastfeeding, the dangers of artificial feeding, putting the baby to the breast, signs of hunger in the baby, the harms of bottle and pacifier, breastfeeding positions, breast-related problems, information sources about breastfeeding, birth and breastfeeding leave for working mothers, breastfeeding in the community, the importance of environmental and professional support during breastfeeding. Insufficient milk anxiety, increasing milk intake and production, situations where milk should be expressed, milk expression methods, storage conditions of breast milk, alternative feeding methods with expressed milk, methods to be applied to increase breast milk, differences between breast milk and formula milk."
223928107|NCT06775444|BEHAVIORAL|Routine Breastfeeding Training|The control group will receive routine breastfeeding education at the hospital where the study is conducted. Routine breastfeeding education includes the importance of breast milk and breastfeeding (benefits of breast milk and breastfeeding, correct breastfeeding technique and breastfeeding positions, time for the first feeding of the newborn, feeding method, expressing and storing breast milk, techniques for giving expressed breast milk as close as possible to breastfeeding, harms of bottle use, breast problems and coping methods). Pregnant women who give birth at the hospital where the study is conducted receive routine breastfeeding education from the breastfeeding nurse in the ward before being discharged.
223928108|NCT06768307|DRUG|First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC|"Cohort 1:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Concurrent Radiotherapy Phase: the fourth cycle will incorporate concurrent radiotherapy along with atezolizumab and chemotherapy.~Maintenance Phase: Atezolizumab monotherapy will be administered until disease progression or intolerance by the patient, with atezolizumab being administered for a maximum duration of 2 years.~Cohort 2:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Sequential Radiotherapy Phase: the fourth cycle will receive sequential radiotherapy in combination with atezolizumab.Final，Atezolizumab monotherapy will be continued until disease progression."
223928109|NCT06768632|DRUG|Group 1: single-dose of test formulation+single-dose of reference formulation|Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
223928110|NCT06768632|DRUG|Group 2: single-dose of reference formulation+single-dose of test formulation|Eltrombopag Tablets is a small molecule non peptide thrombopoietin receptor agonist.
223717983|NCT00864331|DRUG|Chemotherapy|Chemotherapy given alone
223928111|NCT05168124|BEHAVIORAL|Acceptance Commitment Therapy for chronic fatigue|ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
224094184|NCT04298762|OTHER|Peer comparison email|The intervention group received three separate emails with individualized data on their cancer stage documentation activity in the previous 1-3 months. The email described the number and percent of attributed patients for whom cancer stage was documented, and included a figure showing their staging documentation rate compared to their peers.
223717984|NCT00864331|OTHER|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
223717985|NCT00004983|BEHAVIORAL|diabetes self-management education|
223717986|NCT05122832|DIAGNOSTIC_TEST|Blood test|Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
223928112|NCT05168124|BEHAVIORAL|Micro breaks in everyday life for chronic fatigue|"In terms of break design in the work context, research in recent years has increasingly focused on so-called micro breaks (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being."
223928113|NCT06771245|DRUG|SYH9056|PO once daily, 1 tablet each time, each tablet contains 2.5mg levamlodipine and 80mg valsartan
223928114|NCT06771245|DRUG|Levamlodipine|2.5mg PO once daily
223928115|NCT06771245|DRUG|Valsartan|80mg PO once daily
223928116|NCT06771245|DRUG|SYH9056 placebo|PO once daily
223928117|NCT06771245|DRUG|Levamlodipine placebo|PO once daily
223928118|NCT06771245|DRUG|valsartan placebo|PO once daily
223928119|NCT06772805|DRUG|Nemtabrutinib|Oral Tablet
223928120|NCT06772428|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.
223928121|NCT06772428|RADIATION|standard treatment|radiotherapy ± chemotherapy
224094185|NCT06121726|OTHER|Ilioinguinal-Iliohypogastric nerve block|local anesthetic will be administered near ilioinguinal-iliohypogastric nerves under ultrasound guidance. Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
224282499|NCT05491239|PROCEDURE|Continuous regional paravertebral block|"The PVB catheter is placed under general anaesthesia at the beginning of the VATS procedure under direct thoracoscopic vision. The level of the PVB catheter placement is chosen at the intercostal space of the largest incision (mostly thoracic level 4 or 5). Under direct thoracoscopic vision, the surgeon inserts a Touhy needle. The tip of the needle is observed beneath the pleural surface thoracoscopically. Injection of about 2 mL ropivacaine 7.5mg/mL will create subpleural hydrodissection to reach the adequate paravertebral plane for placement of the catheter. The PVB catheter is subsequently placed under direct thoracoscopic vision and left next to the sympathetic chain in the paravertebral space. Next, a bolus of ropivacaine (total amount 20 mL including the given amount for hydrodissection) is given through the catheter.~Postoperatively, a ropivacaine 2 mg/mL pump for continuous infusion is given with an infusion rate of 8-14 ml/hour."
223717987|NCT05122832|DIAGNOSTIC_TEST|STEPwise Approach to NCD Risk Factor Surveillance (STEPS)|The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
223717988|NCT05122832|DIAGNOSTIC_TEST|Spirometry|Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
223928122|NCT04505722|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered at a single dose of 5\*10\^10 virus particles (vp) on Day 1 (or Month 6 for placebo recipients) and as a single booster dose at Year 1.
223928123|NCT04505722|OTHER|Placebo|Participants will receive Placebo.
223928124|NCT05505799|OTHER|Intubation Checklist|A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
223928125|NCT05505799|OTHER|Standard Care|Clinicians will intubate as per their usual practice
223928126|NCT06744842|OTHER|genicular nerve block|genicular nerve block
223928127|NCT06744842|OTHER|Exercise|isometric exercise
223928128|NCT06745375|DEVICE|contact lens wear|participants wear two different powered contact lenses (one with actual power, and one +/- 2.00Ds) contact lenses. No 2nd arm
223928129|NCT06766929|DRUG|VSA012|subcutaneous injection
223928130|NCT06766929|DRUG|Placebo|subcutaneous injection
223928131|NCT04755595|DRUG|Botox Cosmetic Injectable Product|Acetylcholine release inhibitor and a neuromuscular blocking agent
223928132|NCT04755595|DEVICE|Juvéderm Voluma XC|Gel implants consisting of cross-linked hyaluronic acid
223928133|NCT04755595|DEVICE|Juvéderm Volbella XC|Gel implants consisting of cross-linked hyaluronic acid
223941029|NCT06296940|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings.
223941030|NCT06296940|BEHAVIORAL|Treatment as Usual|Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
223941031|NCT05472532|PROCEDURE|Patient sampling.|"One or several bio-specimens will be sampled depending on the cohort :~* Blood (40 ml)~* Pleural Fluid (40 ml)~* Peritoneal liquid (40 ml)~* Solid tumors"
223941032|NCT05512819|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
223941033|NCT05512819|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
223941034|NCT05971979|OTHER|No intervention|No intervention
223928134|NCT06840158|DRUG|Miotox (Botulinum toxin type A is a hemagglutinin complex)|"During the study, patients were injected with the investigational drug Miotox® .~For the treatment of spasticity and equine varus deformity of the foot in children with cerebral palsy, drugs were injected into two points of each head of the calf muscle (medial and lateral). In case of damage to one limb, the total dose was 4 units / kg of body weight per affected limb. In diplegia, the total dose was 6 units / kg of body weight for both affected limbs. The total total dose should not exceed 200 units.~This course of treatment is based on the current instructions for the medical use of Botox®."
223928135|NCT06840158|DRUG|BOTOX®|"During the study, patients were injected with the investigational comparison drug Botox®.~For the treatment of spasticity and equine varus deformity of the foot in children with cerebral palsy, drugs were injected into two points of each head of the calf muscle (medial and lateral). In case of damage to one limb, the total dose was 4 units / kg of body weight per affected limb. In diplegia, the total dose was 6 units / kg of body weight for both affected limbs. The total total dose should not exceed 200 units.~This course of treatment is based on the current instructions for the medical use of Botox®."
223928136|NCT06750679|OTHER|Compression bandage|A multicomponent inelastic compression bandage will be applied to the patient. Skin care and simple exercises will be added to intervention
223928137|NCT06750679|OTHER|Manual lymphatic drainage added to compression|Manual lymphatic drainage will be added to multicomponent inelastik compression bandage, skin care and simple exercises
223928138|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).
223928139|NCT02895815|COMBINATION_PRODUCT|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
223928140|NCT06809439|PROCEDURE|Non-Surgical Intervention|Oral hygiene instructions including tooth brushing, flossing, and interdental brushing were given to all patient groups before non-surgical periodontal treatment. In both periodontitis groups, scaling, and root surface smoothing were performed using ultrasonic instruments (Woodpecker Medicals Ins. Co., USA) and Gracey Curettes (Hu-Friedy, Chicago, IL, USA) under local anesthesia once a week for 4 weeks.
223928141|NCT06809439|DIAGNOSTIC_TEST|Saliva Collection (Baseline)|Unstimulated saliva samples were collected from all participants between 9:00 and 11:00 am. Clinical periodontal measurements were performed after saliva collection to prevent contamination (bleeding, etc.). Participants refrained from brushing their teeth the morning before sampling and from eating, drinking, or smoking for at least 2 hours before sampling. Patients were asked to rinse their mouths with distilled water 5 minutes before saliva collection. A saliva sample was then collected by spitting directly into a sterile tube. Sample collection was continued for 5 minutes.
223928142|NCT06809439|OTHER|Probing|Clinical and radiographic evaluations were performed by trained and calibrated examiners at Ankara University (SY) and Ataturk University (OT). Clinical parameters of probing depth (PPD), clinical attachment level CAL, plaque index PI, and bleeding on probing (BOP) were recorded from six tooth regions (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, middle lingual, and disto-lingual) using periodontal probe. Bone loss was assessed using panoramic radiographs, confirming the diagnosis of periodontitis.
223928143|NCT06809439|DIAGNOSTIC_TEST|Saliva Collection (After treatment)|Unstimulated saliva samples were collected from all participants between 9:00 and 11:00 am. Clinical periodontal measurements were performed after saliva collection to prevent contamination (bleeding, etc.). Participants refrained from brushing their teeth the morning before sampling and from eating, drinking, or smoking for at least 2 hours before sampling. Patients were asked to rinse their mouths with distilled water 5 minutes before saliva collection. A saliva sample was then collected by spitting directly into a sterile tube. Sample collection was continued for 5 minutes.
223928144|NCT06654167|OTHER|Low temperature (15℃) group|The exposure group will be exposed to low temperature (15℃) in a chamber for about 2 hours, resting during the whole period.
224282500|NCT05491239|PROCEDURE|Single shot intercostal nerve block|At the end of the surgery a single shot ICNB will be placed at 9 levels (thoracic level 2 to 10) with 2-3mL local anaesthetics per intercostal space under direct thoracoscopic vision. The injection site will be chosen just lateral from the sympathetic trunk. This group will have no analgesic catheters for continuous analgesia. No mobility restrictions are instructed in this group.
224282501|NCT06616948|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
224282502|NCT06616948|BEHAVIORAL|coaching calls|individuals will receive a phone call every 14 days to discuss ongoing exercise maintenance efforts.
224282503|NCT06616948|BEHAVIORAL|No coaching calls|Following completion of the 6-month cycling sessions, no maintenance calls will be placed.
224282504|NCT06616012|DEVICE|Neosense umbilical catheter|The Neosense umbilical catheter is used instead of a standard umbilical catheter
224282505|NCT02667821|OTHER|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
224282506|NCT01996384|PROCEDURE|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
223928145|NCT06654167|OTHER|Moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
223928146|NCT06656104|DEVICE|Reference strategy|Routine strategy based on the usual catheters and infusion systems used during the reference period
223928147|NCT06656104|DEVICE|Experimental strategy|EDELVAISS multi-infusion strategy as routine strategy during the experimental period
223928148|NCT06655753|OTHER|Reliability and Validity|Reliability and validity of Craniocervical Dysfunction Index in Turkish Patients With Temporomandibular Joint Disorders
223928149|NCT00319696|DRUG|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
223928150|NCT00319696|DRUG|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
223928151|NCT02923011|DEVICE|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
223717989|NCT02548780|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
223928152|NCT02923011|DEVICE|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
223928153|NCT06877455|PROCEDURE|Fractional CO2 laser assisted PDT|"One side of the body will receive fractional CO2 laser combined with methotrexate 1% gel , while the other side will receive topical methotrexate alone (or vice versa, randomized to avoid bias) for 3 months.~Laser therapy will be performed as 4 sessions of 3 weeks interval using fractional ablative CO2 10,600 nm laser device (Daeshin Enterprise Co., Ltd. Model: Multixel, Seoul, Korea). A single pass will be performed at the following parameters: pulse energy 42-45 mJ, density of 100 spots/cm2 depth level of 1-2 covering an area of 1 cm2 MTX gel will be prepared in the Department of Pharmaceutics at Assiut University Patients will be followed up for total 6 months (e.g., baseline, weeks 3, 6,9,12,15 and post-treatment at months 4 and 6)."
224282507|NCT01996384|PROCEDURE|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
224282508|NCT01996384|DRUG|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
224282509|NCT03384706|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week."
223928154|NCT06891716|OTHER|[18F]ACI-19626|\[18F\]ACI-19626 is an intravenously administered radioactive imaging agent being studied as a potential positron emitting radiopharmaceutical for in vivo imaging of TDP-43 deposits.
223928155|NCT06756009|DIAGNOSTIC_TEST|Ophthalmic examination|Various ophthalmic examination modalities, including slit lamp photography, fundus photography, optical coherence tomography imaging and optical coherence tomography angiography, etc.
223928156|NCT06756009|DIAGNOSTIC_TEST|General Condition Examination|Various general condition examination, including blood pressure measurement, blood glucose testing, blood routine examination, coagulation function test, liver function test, etc.
223928157|NCT06762496|OTHER|Healthcare professionals|healthcare professionals (HCPs) targeted, including team members: we will involve 30 physicians (who are involved in the process of care towards patients with early breast cancer (10 oncologists, 10 breast surgeon, and 10 breast radiologists specifically) for the semi-structured interviews
223928158|NCT06762496|OTHER|Patients PDA group|Participants will receive via mail the final version of the PDA and a Qualtrics link with a battery of questionnaires
223928159|NCT06762496|OTHER|Patients control group|Participants will receive only the online link with the battery of questionnaires
223928160|NCT05501548|DRUG|Olaparib|Olaparib 300mg by mouth twice daily
223928161|NCT05501548|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid 1g/kg administered intravenously twice weekly
223928162|NCT06885736|BEHAVIORAL|Resistance exercise|Participants assigned to the resistance exercise group will be asked to perform exercises 3 times a week for the intervention period. The first 3 sessions of the exercise will be performed under the supervision of a qualified exercise specialist to ensure that the participants are happy with the exercises and are performing them appropriately. These will also be group sessions to encourage participants to build social connections to support them during the intervention. A similar group social session will take place at week 4 and then every 4 weeks of the study to overcome any issues with the exercises and to ensure progression to an appropriate intensity.
223928163|NCT06885736|DIETARY_SUPPLEMENT|Protein Intake|The aim of this arm of the intervention is to ensure a protein intake of 1.6g/kg/day, as this was the intake level identified as the level after which no further effect was found on muscle mass in the meta-regression from (Morton et al., 2018). For the initial 2 weeks of the study, we will ask participants to consume 2 protein drinks, containing 25g protein (3g leucine), per day - one in the morning and one in the evening. At this stage, we won't know the magnitude of reduction of protein intake following initiation of semaglutide/tirzepatide treatment. After 2 weeks, when the first assessment of dietary intake after beginning semaglutide/tirzepatide treatment occurs, the additional protein will be based on the amount required to ensure 1.6g/kg/day with an aim to spread protein evenly across the day and aim for at least 25g protein (3g leucine) per meal or snack.
223928164|NCT06885736|COMBINATION_PRODUCT|Resistance exercise + protein intake|Participants in this arm will follow the above resistance exercise and protein intake interventions
223928165|NCT06816394|DRUG|Tarlatamab|All subjects will receive a step dose (1 mg tarlatamab) on cycle 1 day 1 administered as a 60-minute intravenous (IV) infusion then 10 mg tarlatamab IV administered on cycle 1 day 8, cycle 1 day 15, and every 2 weeks (Q2W) thereafter.
223928166|NCT06855459|DEVICE|Biophoton Generators|Users will be receiving biophotons emitted from the 4 devices during sleep and other time.
223928167|NCT06894316|DEVICE|Inspiratory muscle warm-up training|The Powerbreathe brand device was used to perform inspiratory muscle pre-activation. Two sets of 30 breaths were carried out at 40% of each participant's maximal inspiratory mouth pressure (MIP), with a one-minute rest in between. MIP was measured once at the first session, and that value determined 40% and 5% for IMpa and IMPpa, respectively, in later visits. Participants were seated, wearing a nose clip, instructed to exhale forcefully, then inhale forcefully against a closed airway for one to three seconds. Measurements were repeated until values within 5 cmH₂O of each other were obtained, recording the best result in cmH₂O.
223928168|NCT06894316|OTHER|General Warm-up Protocol|The participants engaged in a 10-minute jogging activity, which was followed by a 10-minute stretching exercise. Subsequently, the general warm-up protocol was completed with shooting drills tailored to the specific requirements of basketball, without inducing fatigue.
223928169|NCT06894316|DEVICE|Placebo inspiratory muscle warm-up training|The Powerbreathe brand inspiratory muscle warm-up device was employed to facilitate an exercise regimen comprising two sets of 30 breaths, performed at an intensity of 5% of the participants' maximal inspiratory mouth pressure (MIP), with a one-minute interval between sets. This minimal load was intended as a placebo-like condition for inspiratory muscle usage.
223928170|NCT06842849|OTHER|Exercise program|Multimodal and multicompetent exercise program 2 days a week for 60 minutes and 1 day of walking exercise for 60 minutes.
223928171|NCT06175936|OTHER|Laugther Yoga|Laughter yoga will be applied to the intervention group in 6 sessions (45 minutes each session).
223928172|NCT06601257|DRUG|Vancomycin (IV)|Vancomycin weight-based or kidney function-based dosing
223928173|NCT06762886|DEVICE|Cycle ergometer|The case was lying back in a comfortable position on the stationary bike ergometer when the exercise test was conducted. The exercise test began with a 3-minute warm-up session of unloaded cycling on a cycle ergometer, and then progressed at a rate of 10 W per minute up to the subject's threshold. After cycling for 30 W to warm up, the intensity was raised by 15 W every 60 seconds until fatigue, after which the individuals cycled for 30 W to cool down. This treatment protocol was administered to each patient 3 times/week for a total of 15 minutes of treatment, broken into intervals of two to three minutes each.
223928174|NCT06762886|DEVICE|Low-level laser therapy|The laser probe was administered using the contact approach on the dorsal midline, in the depression below the spinous process of C7 at Governor Vessel, with the patient seated in a chair with back support (GV - 14 Dazhui). The primary power switch was activated. The following settings were used for applying laser puncture: 5 mW, the maximum average power. Type of laser: gallium arsenide (Ga-As), 904 nm wavelength, 5 kHz maximum repetition rate - Program: Maintaining programs for people who had their neck lymph nodes removed and have a low leukocyte count, up to 30 J/cm2 of energy, a 2 J/cm2 energy density, and protective glasses were required to prevent irreversible eye injury from either direct or indirect laser exposure. The treatment took place for 15 minutes.
223928175|NCT06891365|DRUG|NNC0581-0001|NNC0581-0001 will be administered subcutaneously.
223928176|NCT06891365|DRUG|Placebo (NNC0581-0001)|Placebo matched to NNC0581-0001 will be administered subcutaneously.
223928177|NCT06781112|DRUG|albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).|"Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined."
223928178|NCT06796192|OTHER|Visible Light Exposure - Treated zones|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.
223928179|NCT06796192|OTHER|Visible Light Exposure - Untreated zone|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
223928180|NCT06634680|PROCEDURE|Procedure: Selection of parent(mother or father) according to children preference|Children will choose the parent who will accompany them.
223928181|NCT06634680|PROCEDURE|Procedure: Both parents will accompany the children.|Both parents will accompany the children.
223941035|NCT06292689|DRUG|Cardunolizumab|"1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment."
224094186|NCT06121726|DRUG|Local anesthetic|Given the observational nature of the study dose and drugs will be decided by the attending anesthesiologist
223928182|NCT06846814|DIAGNOSTIC_TEST|CEM protocol|"The intervention consists of Second-Look Ultrasound (SLUS) performed following Contrast-Enhanced Mammography (CEM) to further evaluate additional lesions detected during routine breast imaging.~When CEM identifies additional or suspicious lesions not clearly characterized by mammography alone, targeted ultrasound is conducted to assess lesion morphology, vascularity, and acoustic characteristics. Radiologists with expertise in both CEM and ultrasound interpretation will perform SLUS to determine whether the lesions require biopsy, short-term follow-up, or no further action. Findings will be correlated with histopathological results (if biopsy is performed) or follow-up imaging to assess diagnostic accuracy."
223928183|NCT03971669|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
223928184|NCT02469662|DEVICE|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
223928185|NCT04603898|DIETARY_SUPPLEMENT|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
223928186|NCT04603898|DIETARY_SUPPLEMENT|Carbon-13 Ascorbic Acid Oral Load|Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
223928187|NCT04219709|OTHER|Very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein."
223928188|NCT04219709|OTHER|Standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
223928189|NCT03891758|BIOLOGICAL|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
224094187|NCT03389945|PROCEDURE|25G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
224094188|NCT03389945|PROCEDURE|27G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
224094189|NCT05891665|PROCEDURE|Corticotomy|A corticotomy procedure will be applied with some osteoperforations during the surgical exposure of the impacted canine. Then this will be followed after 8 weeks with another surgical stimulation using piezosurgery.
224094190|NCT05891665|PROCEDURE|Traditional traction of the impacted canine without corticotomy|In this group of patients, the traction of the impacted canine will be performed traditionally without the involvement of additional surgical intervention.
224094191|NCT00092508|DRUG|OPC-6535|
224094192|NCT00092508|DRUG|Asacol®|
224094193|NCT05881382|DRUG|Dutogliptin + Filgrastim|dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.
224094194|NCT05881382|DRUG|Placebo|Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
224282510|NCT03384706|BEHAVIORAL|Accelerated Resolution Therapy (ART)|"ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week."
224282511|NCT06364878|DIAGNOSTIC_TEST|In vivo confocal microscopy|The patients cornea will be examined non-invasively by IVCM
224282512|NCT06364878|DIAGNOSTIC_TEST|Tear film sampling|Patients tear film will be collected and stored at -80 degrees for analysis
224282513|NCT03173170|DRUG|TAK-954|TAK-954 Infusion
224282514|NCT03173170|DRUG|Itraconazole|Itraconazole Capsule
224282515|NCT01066117|OTHER|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
224282516|NCT00548379|DRUG|vitamin D|vitamin D 100,000 units once in 3 months
223928190|NCT03891758|BIOLOGICAL|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
223928191|NCT03891758|BIOLOGICAL|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
223928192|NCT06766409|BEHAVIORAL|A community group-based demonstration counseling method|At the community level, a perinatal woman in the intervention arm will get individual family planning counseling along with group-based counseling that includes a planned demonstration of all possible techniques.
223928193|NCT06766409|BEHAVIORAL|An individual family planning counseling|The control group's pregnant and postpartum women will simply get standard individual FP counseling in accordance with Ethiopian national recommendations.
224094195|NCT00660894|DRUG|folinate calcium|
224094196|NCT00660894|DRUG|tegafur-uracil|
224094197|NCT00660894|DRUG|tegafur-gimeracil-oteracil potassium|
224094198|NCT02688647|DRUG|Belumosudil|
224094199|NCT02688647|OTHER|BSC|Treatment/drug as determined by each subject's prescribing physician
224094200|NCT04481022|OTHER|proximal control exercises|"study investigates the effectiveness of proximal control exercises for patients with PFPS in improving pain and function. The findings of this systematic review are consistent with previous evidence reporting effectiveness of exercise for PFPS. In particular, there is consistent moderate to high quality evidence (three RCT, one CCT, three cohort studies, and one case series) that proximal interventions provide relief of pain and improved function in the short term, whereas the knee programs have variable effectiveness. Physical therapists should consider using proximal interventions for early stage treatment for PFPS (Peters et al., 2013).~After 4 weeks of a combined knee and hip strengthening exercise program, sedentary females with PFPS had a greater reduction in pain during stair descent compared to the group who performed knee strengthening exercises only. Both groups also showed significant improvement in function and pain during stair ascent (Fakuda et al., 2010)."
223928194|NCT06758635|BEHAVIORAL|VRET-O Group|Arm Description: the participants of this group will get 3 hours lasting online single session VR therapy
223928195|NCT06758635|BEHAVIORAL|Flash-O Group|Arm Description: the participants of this group will get 3 hours lasting online single session EMDR Flash therapy
223928196|NCT06758635|BEHAVIORAL|PYSCHOEDU-O Group|Arm Description: the participants of this group will get 1 hour lasting online psychotherapy
223928197|NCT06762041|DRUG|Metformin treatment|Interested subjects with autism are treated with metformin with a standard dosage
223928198|NCT06766448|OTHER|robotic training|continuous passive mobilization and robotic therapy on armeo sping
223928199|NCT06766448|OTHER|conventionnal rehabilitation|rehabilitation sessions with a physiotherapist
223928200|NCT06768216|OTHER|Indianized version of Mediterranean Diet|Indo Mediterranean diet will have Carbohydrates 40-45%, fats 30-35% and proteins 15-20%. Mediterranean diet, it will be specified to use Mustard oil, use of specific fruits like orange, apple, mosambi (avoid high glycemic fruits), use more of green leafy vegetables, Use of multigrain atta (Home made- 10 kg of multigrain atta will have - 8 kg of wheat + 500g each of Ragi+Bajra+ Jowar + Chana dal flour).
223928201|NCT06768216|OTHER|Low Fat Diet|Low fat diet will have 50-60% carbohydrate, 20-30% fat (with \<10% saturated fat), and 20% protein. In the Low Fat Diet group, there will be only be restriction of total fat content to less than \<30%. They can use whichever household oil, consume any fruit or vegetables, any atta and no restriction on diary or non-vegetarian diet. Along with this, both groups will be given a list of do's and dont's. In the list of Do's , it will be mentioned to Eat plenty of vegetables, Fruits, Nuts, Whole grains, Screen time of less \<2 hrs /day (According to American academy of pediatrics) and Average hours of sleep in a day for age 8-18 = 8-9 hrs (According to American academy of sleep medicine). In the dont's list, it will be mentioned to avoid Sugar, Soda, Beverages, cold drinks, processed juices, processed food, junk foods, Maida, Ice cream, Creamy Desserts, Biscuit, chips and cake.
223928202|NCT06768216|OTHER|Physical Activity|At least 45- 60 mins of exercise (peer group activity - cycling, football, brisk walking),
223928203|NCT06770062|DIAGNOSTIC_TEST|Cardiac MRI|Each subject will receive two cardiac MRI scans (with and without contrast), one preoperative and another 6-12 months after. The duration of each MRI is approximately 45-60 minutes
223928204|NCT06758882|DRUG|Apalutamide|administration of non steroid androgenic receptor inhibitors plus androgen deprivation therapy
223928205|NCT06758882|DRUG|Androgen receptor (AR) inhibitor|administration of androgen deprivation therapy
223928206|NCT05691972|DEVICE|Restylane Contour|a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)
223928207|NCT05527691|BEHAVIORAL|SupportGroove|"An app-delivered program consisting of positive psychology-based activities, such as expressing gratitude, finding meaning, savoring, and fostering connections. Participants complete daily quests suggested through the app, some of which are completed on their own, and some with their partner."
223928208|NCT06769867|RADIATION|PS-3D-DSA|undergo a PS-3D-DSA scan
223928209|NCT06769867|RADIATION|classic 3D-DSA|undergo a classic 3D-DSA scan
223928210|NCT06755268|OTHER|listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music|Listening to nature sounds (the sound of birds, water flowing in a river, wind or walking in the forest) based music during the angiography procedure.
223928211|NCT06751849|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-loaded DC vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
223928212|NCT06751849|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
223928213|NCT06751849|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223928214|NCT06753292|PROCEDURE|active gas aspiration|surgeon will be instructed to actively aspirate the intraperitoneal CO2 gas
223928215|NCT06753292|PROCEDURE|pulmonary recruitment maneuver|patients will receive the PRM which consisted of five manual pulmonary inflations, where each positive pressure inflation will be done for 5 s at a maximum pressure of 30 cm H2O, manually by using the APL valve in the anesthesia machine. The patient will be in a Trendelenburg position (30°). The fifth positive pressure inflation lasted for approximately 5 s. During that time, the patient will be closely monitored, while the anesthesiologist performed PRM
223928216|NCT06764017|DRUG|CHiR-DEL|Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large B-cell lymphoma (DLBCL) who are intolerant to chemotherapy.
223928217|NCT06755021|DIETARY_SUPPLEMENT|Whey Protein Milk-Derived Exosomes|WPMDE2 (Whey Protein Milk-Derived Exosomes 2) is an advanced nutritional supplement developed from natural milk components.
223928218|NCT03860792|BEHAVIORAL|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
223928219|NCT03860792|BEHAVIORAL|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
223928220|NCT06780787|BIOLOGICAL|Balstilimab|Given IV
223928221|NCT06780787|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224094201|NCT03091504|DEVICE|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
224094202|NCT03091504|DRUG|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
224282517|NCT00548379|DRUG|placebo|olive oil 1ml
224282518|NCT04880720|OTHER|Blood sampling|Blood sampling - 10mL
224282519|NCT01969474|DRUG|Cannabis|Cannabis capsules given once daily for a month
224094203|NCT06500663|OTHER|haemodialysis|haemodialysis effect on thyroid function
223532621|NCT07126977|BEHAVIORAL|Urotherapy training|Standard urotherapy consists of five main components aimed at regulating lower urinary tract (LUT) function in children: education about LUT function and dysfunction, establishing healthy voiding habits and behavioral modifications, lifestyle recommendations such as balanced fluid intake and nutrition, monitoring of symptoms and voiding habits, and consistent caregiver support. In contrast, specific urotherapy focuses on treating particular LUT dysfunctions and includes interventions such as alarm therapy, pelvic floor training, biofeedback, neuromodulation, and clean intermittent catheterization. All children and their caregivers participating in our study will receive urotherapy training prior to the pelvic floor rehabilitation interventions. Each urotherapy session will last approximately 60 minutes.
223928222|NCT06780787|BIOLOGICAL|Botensilimab|Given IV
223928223|NCT06780787|DRUG|Capecitabine|Given PO
223928224|NCT06780787|PROCEDURE|Computed Tomography|Undergo CT
223928225|NCT06780787|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
223928226|NCT06780787|PROCEDURE|Endoscopic Biopsy|Undergo biopsy with endoscopic exam
223717990|NCT02548780|OTHER|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
223928227|NCT06780787|DRUG|Fluorouracil|Given IV
223928228|NCT06780787|DRUG|Leucovorin Calcium|Given IV
223928229|NCT06780787|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223928230|NCT06780787|DRUG|Oxaliplatin|Given IV
223928231|NCT06780787|RADIATION|Radiation Therapy|Undergo radiation therapy
223928232|NCT06780787|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
223928233|NCT06774885|DRUG|Folic Acid 1 Mg Oral Tablet|1 mg oral folic acid tablet
223928234|NCT06774885|DRUG|Folic Acid 5 Mg Oral Tablet|5 mg oral folic acid tablet
223928235|NCT06863376|DRUG|Carbocysteine 375 MG|Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders
224094204|NCT00382967|PROCEDURE|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
224094205|NCT03499431|DEVICE|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
224094206|NCT06546033|OTHER|application of different types of diet|application of different types of diet
224282520|NCT01969474|DRUG|Placebo|Placebo
224282521|NCT04968860|OTHER|This study is observational|"* Clinical evaluation of the oral health condition~* Microbiota evaluation by analyzing the collected saliva~* Application of questionnaires of quality of life"
223717991|NCT00439478|DRUG|Radioiodine|
223717992|NCT03668860|DRUG|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
223717993|NCT03668860|DRUG|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
223717994|NCT03668860|DRUG|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
223717995|NCT03668860|DRUG|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
223928236|NCT06863376|OTHER|Physical activity, walking, and calorie restriction|• The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients
223928237|NCT05720065|DRUG|Botulinum toxin type A|Randomized double-blind administration
223928238|NCT05720065|DRUG|Isotonic saline 0,9%|Randomized double-blind administration
223928239|NCT06755567|DIAGNOSTIC_TEST|MRI-based radiomics-clinical model|Response to NACI was predicted using MRI-based radiomics-clinical model.
223928240|NCT06095960|BEHAVIORAL|Telehealth MOM|Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.
223928241|NCT06095960|OTHER|Enhanced Standard of Care|Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
223928242|NCT06750120|DIETARY_SUPPLEMENT|Family food ration|Monthly household food rations providing 5 daily food groups and a mean of 165 kcal/per capita/day
223928243|NCT06750120|BEHAVIORAL|Optimal weight counseling|Counseling on health gestational weight gain and post partum weight loss
223928244|NCT06750120|OTHER|Enhanced Usual Care|"Enhanced usual care includes~1. Usual care: free standard pregnancy, postnatal, and infant care through Ministry of Health services.~2. Enhancements to usual care: Participants in both arms will be enrolled in Maya Health Alliance's free care navigation program. In this program, navigators accompany patients to clinical visits at national hospitals, provide interpretation, and cover emergency transportation cost."
223928245|NCT05479006|DEVICE|Transcranial direct current stimulation (high- definition)|20 minutes, 2 mA stimulation.
223928246|NCT06471127|BEHAVIORAL|Pseudoword learning paradigm task|Pseudoword learning is an experimental learning task by which participants view two novel objects (a target and a foil) and simultaneously hear an audio recording of the pseudoword name of one of the two objects. Participants must choose (via mouse click) which object corresponds to the word presented, immediately after which feedback is provided.
223928247|NCT03976960|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
223928248|NCT06410547|OTHER|LLM|A LLM-based comparison between treatment and guideline.
224094207|NCT00906438|DIETARY_SUPPLEMENT|2006-RD-05|300 mg daily, once a day for 28 consecutive days
224094208|NCT00906438|DIETARY_SUPPLEMENT|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
224094209|NCT00474240|DRUG|Atorvastatin 20 mg|
224282522|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
223928249|NCT05018611|BEHAVIORAL|LifeSkills Mobile|A mobile app designed to facilitate the broad reach and impact of the LifeSkills intervention to reduce sexual risk behavior which drives HIV infection. The LifeSkills intervention addresses the specific structural, developmental, and interpersonal challenges to HIV prevention among YTW ages 16-29, with prior evidence of the efficacy to reduce sexual risk.
223928250|NCT05747599|BEHAVIORAL|Intervention with contingent incentives and text-based support|Contingent incentives on abstinence from alcohol, tobacco, and cannabis; Text-based support based on educational components
223928251|NCT06618703|RADIATION|Blood sample, urine sample, osteodensitometry|Blood sample, urine sample, osteodensitometry
223928252|NCT05395663|BEHAVIORAL|Community health worker|A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
223928253|NCT06888947|PROCEDURE|use immediate implant in socket with collagen cone|use immediate implant in socket with collagen cone
223928254|NCT06749704|DIETARY_SUPPLEMENT|High protein diet|High protein diet
223928255|NCT06749704|DIETARY_SUPPLEMENT|Normal Protein diet|Normal protein diet
223928256|NCT06750367|OTHER|Klapp method exercises|The researcher will administer Klapp method exercises to the participant for a period of 1 month (twice in a week for 50 min .The researcher will perform stretching of upper limb, neck and thoracic region to the participants as a baseline treatment. Klapps exercises program include four point walk followed by two point walk and back walk, breathing exercise from kneeling position, breathing exercise from quadrapedal position, simple bounce glide with simulanteos breathing, bunny hop greeting. Each exercise will be performed with 10 repetitions
223928257|NCT06750367|OTHER|At-Home exercise program|theywill begiven printed information on an at-home exercise program, such corrective exercises (Chin tuck, stretchingof neck extensormuscles andpectoral musclegroups instandingandsupinepositions) (16) ,posturecorrection exercises(Thisexerciseprogramconsistedof2strengthening(of thedeep cervical flexorsandshoulderretractors)(26) ,andbreathingexercises(Deep breathing is an exercise that can regulate breathing patterns and improve posture. The deep breathing that is done repeatedly can overcome stiffness in the thoracic cage and straighten the curve of thoracic kyphosis)(27).Theywillbeaskedtoperformtheperiodof1month twiceinaweekfor50minwith10repetitionsofeachexercise.
223928258|NCT05019027|DRUG|Beta blocker|"The intervention is a single-arm crossover withdrawal/reversal design (On vs Off) with 2 total periods, each period lasting between up to 6 weeks. During the On period, subjects will be on their beta blocker. During the Off period, their beta blockers will be down-titrated by 50% each week and until subsequently discontinued (or the lowest dose the subject can safely tolerate).~Other Names:~* acebutolol~* atenolol~* betaxolol~* bisoprolol~* carvedilol~* labetalol~* metoprolol succinate~* metoprolol tartrate~* nadolol~* nebivolol~* penbutolol~* pindolol~* propranolol"
223928259|NCT04270045|DEVICE|Non-invasive forced airway oscillometry|This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
223928260|NCT06569992|OTHER|VIS, TIES|The vasopressor and inotropic drug dosages administered during the follow-up of these patients will be recorded, and the Vasoactive-Inotropic Score (VIS) and Total Inotrope Exposure Score (TIES) will be calculated.
224094210|NCT00474240|DRUG|AEGR-733 5 mg|
223532622|NCT07126977|OTHER|Diaphragmatic Breathing Exercise|The exercise will be performed under the supervision of a physiotherapist, twice a week for 8 weeks. After the correct position is established, participants will be instructed to slowly inhale through their nose and focus on feeling the breath move from top to bottom (cranial to caudal). They will be asked to hold their breath for a few seconds, then exhale slowly through pursed lips. Additionally, they will be reminded not to push only their abdomen upward while inhaling, but to feel the intra-abdominal pressure expanding evenly in all directions (360 degrees). This exercise will be performed in 3 sets of 10 repetitions.
223717996|NCT03668860|DRUG|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
223717997|NCT00317512|PROCEDURE|Percutaneous Coronary Revascularization|
224094211|NCT00474240|DRUG|AEGR-733 10 mg|
224094212|NCT00474240|DRUG|Placebo|
224094213|NCT00474240|DRUG|AEGR-733 5 mg + atorvastatin 20 mg|
223717998|NCT00317512|DRUG|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
223717999|NCT00317512|DRUG|Voluven|
223718000|NCT04597723|DRUG|oxygen|Patients will be given different concentrations of oxygen.
223718001|NCT06265246|OTHER|Habitual Diet + Milk|1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)
224094214|NCT00474240|DRUG|AEGR-733 10 mg + atorvastatin 20 mg|
224094215|NCT01808560|DEVICE|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
224094216|NCT01808560|DEVICE|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
224094217|NCT02493647|BEHAVIORAL|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
223928261|NCT06890871|RADIATION|Intensity-modulated radiotherapy|Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
224094218|NCT03330327|BIOLOGICAL|HM12470|HM12470 is a long-acting insulin analogue
224094219|NCT00435422|PROCEDURE|Stroke volume optimization|Stroke volume optimization
223928262|NCT06890871|DRUG|Immunotherapy Therapy|Radiotherapy With Immunotherapy and Anti-Angiogenic Therapy
223928263|NCT06762171|PROCEDURE|open wedge high tibial osteotomy|All procedures will be performed based on the technique recommended by the AO international knee expert group. Biplanar osteotomy, which comprises osteotomies in the axial and frontal planes, will be performed in all cases. Ascending frontal osteotomy, leaving the tibial tuberosity on the distal fragment, will be also performed. All osteotomies will be performed without the use of additional bone grafts, and the opening of the osteotomy was maintained with a Tomofix plate (Orthomed-E Co., Egypt). Wound closure will be performed in layers.
223928264|NCT06762171|PROCEDURE|Arthroscopic partial lateral patellar facetectomy|Diagnostic arthroscopy will be performed in all cases to assess Patellofemoral articular cartilage degeneration , assess the lateral compartment and exclude any other pathology. The knee is taken throughout a range of motion to directly visualize the impingement of the lateral patellar facet against the trochlea. Next, a radiofrequency probe is used to outline the area to be resected along the lateral patellar facet While maintaining the knee at 20 degrees of flexion, a 5.5-mm burr is introduced, and under arthroscopic visualization, the overhanging portion of the lateral patellar facet is carefully resected. Once the bony resection is complete, the knee is dynamically re-evaluated (through flexion and extension) for residual impingement and to assess for improvements in patellar mobility. Patellar tracking is assessed to verify that there is no catching in flexion and that patellar mobility is improved.
223928265|NCT06841874|DRUG|Taletrectinib|Oral capsule
223928266|NCT06818435|DEVICE|Myval THV series|Transcatheter Aortic Valve Implantation
223928267|NCT06816199|OTHER|Hyperbaric oxygen exposure|Between 1 week and 3 months after the traumatic brain injury, participants will receive hyperbaric oxygen therapy on a 2.0 ATA protocol for 60 minutes once a day, five times a week.
223928268|NCT06865430|DRUG|Tamsulosin Hydrochloride|Alpha blockers will be started and symptoms will be questioned.
223928269|NCT06865430|OTHER|Sham|Patients who were not started on alpha blockers will constitute this group.
223928270|NCT06751212|PROCEDURE|Radiofrequency ablation alone|Endoscopic radiofrequency ablation (RFA) consists of delivering a 465 KHz energy waveform to the diseased tissue through an array of bipolar electrodes. The electrodes are mounted externally to the balloon, on an articulating platform attached to the distal end of the endoscope, or on a flexible catheter that penetrates the scope. The principle of radiofrequency ablation is that the action of high-frequency alternating current (HFAC) induces the movement of charged particles within the tissue to generate heat, which results in evaporation of water inside and outside the cell, drying, and solidifying and shedding to the point of aseptic necrosis.RFA has been demonstrated to safely, effectively, and durably eradicate early stage tumors of Barrett's esophagus as well as gastric low-grade endoepithelial neoplasia, and is said by a consensus of experts to be capable of treating moderately severe atrophic enterocolitis that has not yet progressed to gastric low-grade intraepithelial neoplasi
223928271|NCT06780761|OTHER|simulation training|The author further demonstrated taking body temperature, heart rate and its characteristics, respiratory rate and saturation, blood pressure and pain assessment in line with previously created cases on the NOELLE® Maternal Birthing Simulator with Advanced Resuscitation Neonatal M-W45111 to the students deployed in the intervention group. Furthermore the students were allowed to work individually on the infant simulator, their questions were answered and feedback was given to them. Students were also offered free time to work on the infant simulator. One week after the training, before proceeding with the clinical practice, the students were individually assessed on measuring the vital signs by 2 different observers and were administered the post-tests.
223928272|NCT06780761|OTHER|Classical training|Before proceeding with the clinical practice, the students deployed in the control group were trained on how to measure the five vital signs, which tools to use and why, and normal and abnormal vital sign values by demonstration and explaining on a pediatric nursing manikin. Then, volunteering students were given the opportunity to develop their vital sign measurement skills on a pediatric nursing manikin and feedback was provided to them. One week after the training, all students were individually assessed on measuring the vital signs by 2 different independent observers on the simulator neonatal used in the intervention group and they were administered the post-tests.
223941036|NCT04636138|OTHER|Exercise|Patients will exercise on a treadmill three times weekly at approximately 60% VO2max for 30 minutes (week one) followed by 45 minutes (week two and thereafter) for a total of 6 seeks.
223718002|NCT06265246|OTHER|Habitual Diet + Yogurt|2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
223718003|NCT04836572|OTHER|3M 1529 Adhesive Tape|5-12 hour adhesive wear
223718004|NCT06515743|OTHER|Delayed surgical obturator|Prosthetic rehabilitation after surgical treatment of mucormycosis is essential for the early restoration of oral function and facial esthetics which is performed by using the surgical obturator.
223718005|NCT03989271|DRUG|Quercetin|Placebo
223718006|NCT05663190|OTHER|mental foramen location|location of mental foramen in relation to primary molars
223718007|NCT06376396|DRUG|albendazole and praziquantel|Combination of albendazole plus praziquantel
223718008|NCT06376396|DRUG|Albendazole|Albendazole alone
224094220|NCT03985176|DEVICE|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
224094221|NCT03985176|PROCEDURE|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
224094222|NCT03985176|PROCEDURE|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
224094223|NCT04801407|PROCEDURE|percutaneous radiofrequency trigeminal rhizotomy|percutaneous radiofrequency trigeminal rhizotomy is a perctaneous procedure that ablate the sensory part of the nerve and
224094224|NCT04801407|PROCEDURE|Microvascular decompression of the trigeminal nerve|Microvascular decompression is a procedure that decompress the nerve from vascular conflict
224094225|NCT06056947|DRUG|EVEGYN A|EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
224094226|NCT06056947|DRUG|EVEGYN B|EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
224094227|NCT06056947|DRUG|Gynomax® XL Vaginal Ovule|200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
224094228|NCT05595538|BIOLOGICAL|Multiple doses of anti-SARS-CoV-2 Convalescent Plasma|SARS-CoV-2 Convalescent Plasma(1-2 units; \~300-600 mL with the presence of IgG anti-SARS-CoV-2.
223718009|NCT04014816|OTHER|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
223718010|NCT04014816|OTHER|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
223718011|NCT01749397|DRUG|Floxuridine|Given IP
223718012|NCT01749397|OTHER|Laboratory Biomarker Analysis|Correlative studies
223718013|NCT01749397|OTHER|Pharmacological Study|Correlative studies
223718014|NCT01749397|DRUG|Veliparib|Given IV
223718015|NCT06297161|DRUG|Bosulif|chronic myelogenous leukemia patients
223718016|NCT03600571|PROCEDURE|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
223718017|NCT03600571|PROCEDURE|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
223718018|NCT00118677|PROCEDURE|Treatment interruption|
223718019|NCT02381145|DIETARY_SUPPLEMENT|EGCG+RSV-supplementation|Teavigo (\~300mg/d) Resveratrol (\~80mg/d)
223718020|NCT02381145|DIETARY_SUPPLEMENT|Placebo|
223718021|NCT03434093|DEVICE|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
223718022|NCT03434093|BEHAVIORAL|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
224094229|NCT00575861|DRUG|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
224094230|NCT05838326|DEVICE|Symmetrical high flow nasal cannula (HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'conventional HFNO' or 'DUET HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%."
224094231|NCT05838326|DEVICE|Asymmetrical high flow nasal cannula (DUET HFNO)|"After a 'baseline' trial using Venturi Mask, within the first 120 minutes after extubation, and assessing a PaO2/FiO2 ratio \< 300, patients will be randomly assigned to a first 1h-phase of 'DUET HFNO' vs 'conventional HFNO'. At the end of each session several clinical parameters (i.e. DUS, EIT, ABGs, comfort, VAS) will be collected.~Specifically, Gas-flow rate will be set at a maximum of 60 L/min, temperature at a maximum of 37°C, while FiO2 will be adjusted to maintain SpO2 between 92 and 98%.~A 5-10min 'washout' phase using VM, between different interfaces, will be allowed."
223928273|NCT06769230|OTHER|Core strengthening exercise|The participants will perform warm-up exercises including Cat and Camel, spinal movement (spinal flexion and extension cycles), and stretching exercises for the calf, hamstrings, quadriceps and lower back for about 5 minutes. After that, the women will be asked to perform core stability exercises including abdominal hollowing, bilateral knee raise, supine extension Bridge, straight leg rise from prone and alternate arm and leg raise from quadruped. Each exercise will be repeated for 10 times with 7-8 seconds hold and will be increased by four repetitions each week throughout the interventions. During each repetition for every exercise, the patient will be asked to contract her abdominal muscles and maintain this contraction while maintaining her normal breathing pattern.
223928274|NCT06769230|OTHER|sensory motor training|The participants will perform warm-up exercises including neck rotations, arm circles, ankle rotations, trunk rotations, trunk bending and extending for 5-10 mins. After warm up the women performs Bosu ball exercises including Bosu ball one Leg Bridge, Bosu Crunch, Bosu Sit ups, Bosu compressions, Bosu side crunch and Bosu bodyweight squat . Each exercise will be repeated for 6 repetitions in each set. At least 3 sets of each exercise are performed per session. Each exercise will be increased by five repetitions each week throughout the interventions.The total duration of each session is 45 minutes.
223928275|NCT06413576|DIAGNOSTIC_TEST|homocysteine measurement|measuring the serum level of homocysteine
223718023|NCT03334539|BIOLOGICAL|HL036 ophthalmic solution|HL036 ophthalmic solution
223718024|NCT03334539|OTHER|Placebo vehicle solution|Placebo vehicle solution
223718025|NCT00194571|BEHAVIORAL|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
223718026|NCT00967057|DRUG|asparaginase|Given intramuscularly
223718027|NCT00967057|DRUG|dexamethasone|Given orally
223718028|NCT00967057|DRUG|idarubicin|Given IV
223718029|NCT00967057|DRUG|methotrexate|Given intrathecally
223718030|NCT00967057|DRUG|mitoxantrone hydrochloride|Given IV
223718031|NCT00967057|DRUG|pegaspargase|Given intramuscularly
223928276|NCT06724016|DRUG|HM16390|HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
223928277|NCT06749574|DIAGNOSTIC_TEST|stability ball exercises|articipants in the first group performed stability ball exercises designed to enhance balance, core stability, they were introduced to the stability ball with instructions on maintaining proper posture, alignment, and safety to prevent injuries. The program included exercises such as the Stability ball bridging, stability ball bird dog and stability ball pelvic tilts were included to activate the lower abdominal muscles and glutes through gentle, controlled movements
223928278|NCT06749574|DIAGNOSTIC_TEST|dead bug exercise|The second group focused on dead bug exercises, Participants performed exercises such as extending one arm and the opposite leg while lying on their backs, ensuring their spine remained neutral and their lower back stayed pressed into the floor. Variations included alternating opposite arm and leg movements and holding the extended position to increase the challenge and enhance core stability. These exercises were performed slowly to maintain control and improve movement precision over the eight-week period
223941037|NCT04589624|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223718032|NCT00967057|DRUG|vincristine sulfate|Given IV
223718033|NCT00968201|DRUG|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
223718034|NCT00968201|DRUG|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
223718035|NCT00363883|DRUG|vorinostat|Given orally
223718036|NCT00363883|OTHER|laboratory biomarker analysis|Correlative studies
223718037|NCT06393829|BEHAVIORAL|Applying the Early Mobilization Program|A mobilization intervention based on the level of function (LOF) ( i.e. patients should be assessed for mobilization status within 24 hours of admission; mobilization should occur at least three times a day, and mobility should be progressive and scaled, tailored to the patient's abilities); The frequency of patient mobilization (primary outcome) will be assessed 20 weeks before implementation, during the 20 weeks of implementation and 20 weeks after the end of implementation (60 weeks in total).
223718038|NCT00230204|PROCEDURE|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
223718039|NCT04399317|DEVICE|Flow controlled ventilation (Evone-ventilator)|The new ventilation technique will be applied
223718040|NCT06147804|PROCEDURE|Surgical managment of Urinary bladder trauma after gynaecological and obstetric operation|How to manage Urinary bladder trauma after gynaecological and obstetric operations by the best method to prevent the occurrnce of vesicouterine fistula
223718041|NCT06310317|BEHAVIORAL|Applied Behavior Analysis protocol|"The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. The use of Applied Behavior Analysis procedures, with the help of technological tools such as a tablet or robot can facilitate the increase of new knowledge and skills.~The criterion is acquired if the subject emits 8 out of 10 independent correct responses (90%) for 3 consecutive sessions.~The objective is to test whether the technological tool used (tablet or robot) can make the proposed learning procedure more effective. The experimental group carries out the procedure by means of stimuli presented on tablets or robots."
223928279|NCT06749574|COMBINATION_PRODUCT|Combined Groupo|The third group combined stability ball and dead bug exercises for a comprehensive training approach targeting both core stability and balance. Participants alternated between dead bug exercises, which required controlled arm and leg extensions while lying on their backs, and stability ball exercises such as the ball with bridging and bird dog. Throughout the eight weeks, participants were encouraged to maintain proper posture, alignment, and a neutral spine during all activities to ensure safety and effectiveness
223928280|NCT06770075|OTHER|Observational|Participants will not receive any study intervention. During the six month study period, participants will complete four active assessments at Months 0, 1, 3 and 6, and data from the study-provided wearable (Fitbit Charge 6) and sensors from the participant's smartphone (through the Brightline app) will be collected passively throughout.
223928281|NCT05039021|DEVICE|HARMONIC 1100 Shears|HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
223928282|NCT04566250|COMBINATION_PRODUCT|Non-Opioid Prescription and Infographic|"The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control."
223928283|NCT04977583|BEHAVIORAL|Unmet Need Screening|"Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization."
223928284|NCT04977583|BEHAVIORAL|Unmet Need Referral - Resource Sheet|Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.
223928285|NCT04977583|BEHAVIORAL|Unmet Need Referral Assistance|Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
223928286|NCT02422615|DRUG|Ribociclib|Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.
223928287|NCT02422615|DRUG|Fulvestrant|Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
223928288|NCT02422615|DRUG|Placebo|Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
223928289|NCT02034292|DRUG|Clopidogrel|
223928290|NCT02034292|DRUG|Aspirin|
223928291|NCT02034292|DRUG|APD791|
223928292|NCT02034292|DRUG|Placebo|
223928293|NCT00998413|BEHAVIORAL|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
223928294|NCT00800579|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
223928295|NCT00800579|DRUG|Placebo|Inhaled volume-matched placebo in sterile saline
223928296|NCT01345422|OTHER|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
223928297|NCT03575624|BEHAVIORAL|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
223928298|NCT03002259|DRUG|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
223928299|NCT01267370|DIETARY_SUPPLEMENT|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and \> 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
223941038|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223718042|NCT06310317|BEHAVIORAL|Traditional intervention|The main objective of the experimental protocol is to promote the development of cognitive skills, facilitate the acquisition of new skills and promote the adoption of functional and adaptive behaviors. In this group the materials are traditional, such as image printed. The criterion is acquired if the subject emits 9 out of 10 independent correct responses (90%) for 3 consecutive sessions. The control group performs the procedure with images printed on A4 laminated sheets.
223928300|NCT00995592|BEHAVIORAL|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
223928301|NCT01639131|DRUG|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
223928302|NCT01639131|DRUG|Docetaxel|intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle
223928303|NCT01639131|DRUG|Filgrastim or Pegfilgrastim|filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle
223928304|NCT03778541|DRUG|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
223928305|NCT03778541|RADIATION|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
223928306|NCT00991549|BEHAVIORAL|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
223928307|NCT00166322|PROCEDURE|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
223928308|NCT01645566|BEHAVIORAL|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
223928309|NCT05049421|DIAGNOSTIC_TEST|Echocardiography|Full 2D and 3D echocardiography with special focus on right ventricular function
223928310|NCT04157894|OTHER|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
223718043|NCT06492317|DRUG|Disitamab Vedotin|Disitamab Vedotin: 2.5mg/kg, d1, ivdrip, Q2W (every 2 weeks)
223718044|NCT06492317|DRUG|Cadonilimab|Cadonilimab: 6mg/kg, d1, ivdrip, Q2W (every 2 weeks)
223928311|NCT04157894|OTHER|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
223928312|NCT04157894|OTHER|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
223941039|NCT04589624|PROCEDURE|Magnetic Resonance Imaging|Undergo hpMRI
223941040|NCT04606264|DRUG|Neuraxial Analgesia|This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
223941041|NCT04606264|DRUG|Regional Block 1: Paravertebral|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
223941042|NCT04606264|DRUG|Perphenazine|This randomized group will receive 8 mg of perphenazine orally preoperatively.
223941043|NCT04606264|DRUG|Aprepitant|This randomized group will receive 40 mg of aprepitant orally preoperatively.
223941044|NCT04606264|DRUG|Dimenhydrinate|This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
223941045|NCT04606264|DRUG|Ondansetron 4 MG|This randomized group will receive 4 mg of ondansetron orally.
223941046|NCT04606264|DRUG|Dexamethasone|This randomized group will receive 4-5 mg of dexamethasone intravenously.
223941047|NCT04606264|DRUG|Regional Block 2: QL1|This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
223941048|NCT05255172|OTHER|Supervised Exercise|12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
223941049|NCT05091255|PROCEDURE|Cryotherapy|The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.
223941050|NCT04926857|OTHER|Non-Interventional|Non-Interventional
223941051|NCT05923684|BEHAVIORAL|NLP-based Feedback|Audio recordings will be made using either digital recorders or telehealth platform-generated transcripts. Patient reports will include only the extracted sentences related to content areas. Physician reports will note the extracted statements across each content area, the quality scores for individual statements based on the pre-specified hierarchy, the statements that achieved the highest score across each content area, and feedback on what could be improved. For patients, decisional conflict and risk perception will be assessed before and after receiving the NLP-based feedback. For physicians, the investigators will assess baseline quality of risk communication by pre-specified hierarchy, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas.
223941052|NCT06358625|OTHER|Pre-treatment biopsy|"A breast biopsy is performed just before the clip is placed in the tumour and additional blood samples are performed."
223941053|NCT06578949|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
223941054|NCT06362200|DEVICE|40 Hz tACS intervention|The central electrode is placed in the CP6 and the other four electrodes are placed around the CP6. 40 Hz tACS group participants will receive alternating current stimulation (40Hz, 2.0mA, 20min/time, three times a day, 21 times in total) for 1 week. Subjects in the placebo comparator group will receive sham tACS for 1 week, which mimics the tACS intervention in terms of electrode placement and session frequency. However, the device will deliver a 0mA current, ensuring no actual stimulation occurs.
223941055|NCT05893966|RADIATION|Whole breast irradiation +/- tumor bed boost|Postoperative whole breast irradiation (3D-conformal radiation therapy or IMRT) with or without tumor bed boost (sequential or simultaneous integrated boost)
223941056|NCT04456413|BIOLOGICAL|Convalescent Plasma|Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
223941057|NCT04456413|OTHER|Best Supportive Care|Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
223928313|NCT01681654|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
223928314|NCT01681654|BEHAVIORAL|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
223928315|NCT05004207|DIAGNOSTIC_TEST|99mTc Scintigraphy|"After fasting for at least 8 to 12 hours, standardized meal mixed with 99mTc-sulfur colloid radiolabeled test will be administered as quickly as possible, optimally within 10 min. Imaging will be obtained with Siemens SYMBIA E dual head (SPECT) scanner in a format of at least 128 x 128 pixels. Anterior and posterior planar images (or a single left anterior oblique image) with the distal esophagus, stomach, and proximal small bowel in the field of view will be obtained for 1 min immediately after ingestion of the test meal and repeated images will be obtained in the same projections with 2 min static images at hourly intervals up to 6 h and at 24 hours as was used for the initial images.~Next day LHBT will be performed after at least 12 hours of fasting. Following administration of test substrate (Lactulose 10 grams) with one cup of water, breath samples will be analyzed for hydrogen every 15 minutes for 1 hour followed by every half hour for next 2 hour with LACTOFEN 2 device."
223928316|NCT03172871|DRUG|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
223928317|NCT03172871|DRUG|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
223928318|NCT02925988|DEVICE|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
224094232|NCT02363179|BEHAVIORAL|Live preferential music|Live preferential music will be performed for patients in the emergency department.
224094233|NCT01617044|DIETARY_SUPPLEMENT|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
224094234|NCT01617044|DIETARY_SUPPLEMENT|Placebo|Placebo
224094235|NCT01316042|DRUG|sugar pill|2 pills per day for 12 months
224094236|NCT01316042|DRUG|Metformin, glucophage|2 212.5mg pills/day for 12 months
224094237|NCT04026568|DRUG|4-Aminopyridine|Single drug test for nerve continuity
224094238|NCT04026568|DRUG|Placebo oral tablet|Placebo arm
224094239|NCT02197377|DEVICE|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
224094240|NCT02197377|DEVICE|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
224094241|NCT01380054|BEHAVIORAL|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
224094242|NCT01969266|DRUG|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
224094243|NCT01969266|DRUG|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
224094244|NCT02786069|DRUG|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
223928319|NCT03789071|DIAGNOSTIC_TEST|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
223928320|NCT00084435|DRUG|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
223928321|NCT00084435|DRUG|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
224094245|NCT01350869|DEVICE|Xience|Patients with Xience
224094246|NCT00468234|DRUG|nicotine polacrilex|
224094247|NCT00468234|DRUG|nicotine transdermal system|
224094248|NCT00468234|DRUG|nicotine inhaler|
224094249|NCT02357511|DEVICE|Study Monitor used|
224094250|NCT04177303|DRUG|Metformin|Participants will be randomized to metformin 2000 mg
224094251|NCT04177303|DRUG|Placebo|Participants will be randomized to placebo
224282523|NCT01014962|DRUG|Placebo|Placebo oral once daily for 5 days
224282524|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
224282525|NCT01014962|DRUG|Placebo|Placebo oral every 12 hours for 5 days
224282526|NCT01014962|DRUG|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
224282527|NCT01014962|DRUG|Placebo|Placebo oral every 8 hours for 5 days
224282528|NCT01610609|BEHAVIORAL|Population Health Management Intervention|"This intervention includes:~* Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~* Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
224282529|NCT03675334|PROCEDURE|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
224282530|NCT03675334|PROCEDURE|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
224282531|NCT03675334|OTHER|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
224282532|NCT03452124|DEVICE|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
224282533|NCT03452124|OTHER|Conventional cigarette|Conventional cigarette smoking continuation
224282534|NCT05266079|DRUG|Intervention Group|Gan Mai Bai He Di Hung Tang, Tian Wang Bu Xin Dan,Shugan Granules,Liu Wei Di Huang Pill and Er Zhi Pill , You Gui pill and Li Zhong pill addition and subtraction
224282535|NCT05266079|DRUG|Control Group|Er-Xian decoction
223928322|NCT00084435|RADIATION|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
223928323|NCT02956109|DRUG|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
223928324|NCT02956109|DRUG|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
223928325|NCT02956109|DRUG|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
223941058|NCT05980507|DRUG|ICI201|ICI201 CAR-T cell injection
223941059|NCT02021396|PROCEDURE|Embolization|this arm of the study was interventional (splenic artery embolization)
223941060|NCT00418652|DEVICE|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
223941061|NCT00418652|DEVICE|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
223941062|NCT00418652|DEVICE|TMS over the vertex|10Hz TMS for over vertex.
223941063|NCT01742494|PROCEDURE|Water-jet POEM|Water-jet assisted POEM procedure was performed
223941064|NCT01742494|PROCEDURE|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
223941065|NCT03115099|DRUG|LY3325656|Administered orally
223941066|NCT03115099|DRUG|Placebo|Administered orally
223941067|NCT03115099|DRUG|Liraglutide|Administered subcutaneously
223941068|NCT03115099|DRUG|Sitagliptin|Administered orally
223941069|NCT00000388|BEHAVIORAL|Psychosocial treatment|
223941070|NCT00000388|DRUG|Anti-ADHD medication|
223941071|NCT00000388|BEHAVIORAL|Assessment-and-Referral|
223941072|NCT00089609|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
223941073|NCT00089609|DRUG|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
223941074|NCT00089609|DRUG|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
223941075|NCT00089609|BIOLOGICAL|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
223941076|NCT00089609|GENETIC|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
223941077|NCT00089609|OTHER|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
223941078|NCT00089609|OTHER|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
223941079|NCT00089609|OTHER|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
223941080|NCT03706261|DRUG|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
223941081|NCT03706261|DRUG|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
223941082|NCT05650125|OTHER|Biosampling|Biosampling of blood/tumour/adjacent normal tissue
223941083|NCT00004807|DRUG|dextromethorphan|
223941084|NCT00004807|DRUG|topiramate|
223941085|NCT00004807|DRUG|Donepezil|
224094252|NCT01629303|PROCEDURE|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
223928326|NCT03194516|OTHER|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
223928327|NCT04541797|DRUG|Empagliflozin 10 MG|Intervention group: Patients will be prescribed empagliflozin 10mg once a day and optimised medical therapy for 6 months and standard follow-up like the control group.
224094253|NCT00645086|DRUG|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
224094254|NCT00645086|DRUG|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
224282536|NCT03452072|DRUG|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
224282537|NCT03452072|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
224282538|NCT04247984|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered on day 1 of a 2-week cycle.
223928328|NCT04541797|DRUG|Placebo|Control group: Patients will have placebo and optimised medical therapy and will continue to have protocol driven therapy and follow-up appointments (currently 1 appointment every 3 months).
223928329|NCT04541797|DIAGNOSTIC_TEST|Stress Cardiac Magnetic Resonance|Imaging: All patients will have stress CMR examinations at recruitment.
224282539|NCT04247984|DRUG|Capecitabine|2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.
224282540|NCT04247984|DRUG|Irinotecan|180 mg/m2 intravenously administered on day 1 of a 2-week cycle.
224282541|NCT04247984|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.
224282542|NCT04247984|DRUG|CF|300 mg/m2 intravenously administered on day 1 of a 2-week cycle.
224282543|NCT04247984|DRUG|Irinotecan|150 mg/m2 intravenously administered on day 1 of a 2-week cycle.
223928330|NCT06307743|PROCEDURE|rapid local ischemic postconditioning|Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
223928331|NCT02524769|DRUG|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
223928332|NCT05437952|DIETARY_SUPPLEMENT|Taurine and Exercise (Tau+Ex)|"Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks"
223928333|NCT05437952|OTHER|Placebo and Exercise (PL+Ex)|"Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.~Pshysical exercise~Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks."
223928334|NCT05437952|DIETARY_SUPPLEMENT|Taurine (Tau)|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
223928335|NCT05437952|OTHER|Placebo (PL)|Participants will receive 3g of placebo to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
224094255|NCT02833025|DEVICE|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
224094256|NCT05146167|BEHAVIORAL|Bodhi AIM (intervention group)|"Bodhi AIM (Action In Mindfulness) is a smartphone-based app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations (e.g., attending a party)."
224094257|NCT05146167|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone-based app that is matched to Bodhi AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in Bodhi AIM. Like Bodhi AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
224094258|NCT02331576|DRUG|rocaine|
224094259|NCT02331576|DRUG|Fentanyl|
224094260|NCT01773473|DRUG|Insulin Lispro Mix25|Administered SC
224282544|NCT03744078|DEVICE|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
224282545|NCT02084368|PROCEDURE|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
224282546|NCT02084368|PROCEDURE|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8\~10mg at L2-3 or L3-4.
224282547|NCT02084368|DRUG|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
224282548|NCT02084368|DRUG|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8\~10mg.
224094261|NCT01773473|DRUG|Insulin Lispro Mix50|Administered SC
223718045|NCT05536050|OTHER|Migraine diary and Questionnaires|Patients who already have a prescription for low-dose naltrexone will be administered questionnaires twice during the trial. Additionally, patients will maintain migraine diary for the duration of the trial.
223718046|NCT02223832|DRUG|ACT-128800|
223928336|NCT00355888|DRUG|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
223928337|NCT03202992|DRUG|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
223928338|NCT01606813|OTHER|Usual Care|Standard care
223928339|NCT01606813|BEHAVIORAL|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
224094262|NCT06401356|DRUG|Pelabresib|Small molecule inhibitor of bromodomain and extraterminal (BET) protein
224094263|NCT05179616|PROCEDURE|Transcatheter edge-to-edge tricuspid valve repair|Percutaneous edge to edge repair of tricuspid valve using the TriClip system
224094264|NCT02739087|PROCEDURE|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
224094265|NCT02739087|DEVICE|Magnetic resonance imaging|
224094266|NCT03251885|OTHER|swabs|Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
224094267|NCT05244772|OTHER|Remote monitoring|Remote monitoring with a smartphone application of pain and nausea after day care surgery
224094268|NCT05628922|DRUG|Toripalimab|"Early Responders: They receive the second and third cycle of induction chemotherapy (GP regimen), followed by cisplatin-based concurrent chemoradiation.~Intermediate Responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation.~Late responders: they received the second and third cycle of induction chemotherapy (GP regimen) with combination of toripalimap (240mg d1, q3w \* 2 cycles), followed by cisplatin-based concurrent chemoradiation. At 4-6 weeks post-chemoradiation, they received adjuvant capecitabine and toripalimab for 6 months."
224094269|NCT05628922|OTHER|Induction chemotherapy and concurrent chemoradiation|"Induction chemotherapy (GP regimen) and cisplatin-based concurrent chemoradiation.~GP regimen: Gemcitabine 1.0 g d1,d8, cisplatin 25mg/m2 d1-3 q3w Cisplatin based chemotherapy: cisplatin 80mg/m2 given in three consecutive days, q3w \* 2 cycles."
224094270|NCT00058864|DEVICE|Energy absorbing and distributing trochanteric pad|
224094271|NCT02561156|DRUG|TAK-653 Placebo|TAK-653 placebo-matching tablets.
224094272|NCT02561156|DRUG|TAK-653|TAK-653 tablets.
224094273|NCT05247411|OTHER|Educational intervention|"During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life."
224094274|NCT00596544|BEHAVIORAL|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
224094275|NCT00596544|BEHAVIORAL|questionnaires|Those women who have a FSFI score \> 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
224094276|NCT01330901|DRUG|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
224094277|NCT03898635|DRUG|Linezolid|To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
224094278|NCT00358813|DRUG|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
224094279|NCT02351362|BEHAVIORAL|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
224094280|NCT04902235|DRUG|Experimental: CRH administration|CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
223718047|NCT04974697|DEVICE|JJVC Investigational Multifocal Toric Contact Lens|TEST
223718048|NCT03085381|BIOLOGICAL|HPV vaccine|
223718049|NCT03085381|BIOLOGICAL|Placebo|
223718050|NCT00515346|DEVICE|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
223718051|NCT01016197|PROCEDURE|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
223718052|NCT01016197|PROCEDURE|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
224094281|NCT04902235|DRUG|Control: Placebo administration|Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)
224094282|NCT05859087|BEHAVIORAL|Counseling|Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
223928340|NCT01606813|BEHAVIORAL|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
223928341|NCT01606813|BEHAVIORAL|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
223928342|NCT05973240|OTHER|Participation in an web-based survey|Patients who agree to participate will access a web-based survey (SurveyMonkey) via social media, mobile messages, or emails. The invitation will provide study details, eligibility criteria, and tasks. Patients will confirm inclusion/exclusion criteria upon access, and those ineligible will opt out. Data collection will take approximately 10 minutes per patient. Collected data will be sent to an electronic data collector and saved as an eCRF file in REDCap. The study will conduct two cross-sectional data collection rounds using web surveys to ensure anonymity. Convenience sampling will target anticoagulated patient associations' webpages and social media (e.g., Feder-AIPA, AICCA). In the second round, participants will be informed not to resubmit if they have already completed the survey to avoid overlapping responses.
223928343|NCT04098575|DRUG|Empagliflozin|drug
223928344|NCT03367338|OTHER|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
223928345|NCT04121546|BEHAVIORAL|Telecare Intervention|Patients will meet with a care coordinator to discuss current opioid use pattern and potential reduction strategies. Participants will fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete outcome measures.
223928346|NCT04540003|OTHER|Access to School Based Health Centre|The SBHC will be staffed by a family physician, two pediatricians and a developmental pediatrician, each with at least one half-day of clinic time per week from September through June. The SBHC is also staffed by a clinic coordinator who is responsible for booking appointments on a first-referral, first-serve basis.
224094283|NCT05859087|BEHAVIORAL|Flyer|Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
224094284|NCT01130506|DRUG|Cytarabine|Given IV
223928347|NCT03568175|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
223928348|NCT00418795|DRUG|recombinant human porphobilinogen deaminase (Porphozym)|
223928349|NCT03653364|DRUG|Baloxavir Marboxil|Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age. Participants aged ≥ 3 months to \<12 months old received baloxavir marboxil, 2 milligrams per kilograms (mg/kg). Participants from birth to \< 4 weeks old and ≥ 4 weeks to \< 3 months old received baloxavir marboxil, 1 mg/kg.
223928350|NCT00299572|DRUG|alendronate (Fosamax)|
223928351|NCT02282709|DRUG|Daclatasvir|60 mg once daily
223928352|NCT02282709|DRUG|asunaprevir|100 mg BID
223928353|NCT03998098|DIAGNOSTIC_TEST|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
223928354|NCT03998098|DIAGNOSTIC_TEST|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
223928355|NCT03998098|DIAGNOSTIC_TEST|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
223928356|NCT03998098|DIAGNOSTIC_TEST|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
223928357|NCT00686595|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg IV infusion.
223928358|NCT00488566|DRUG|GSK drug|GSK drug
224094285|NCT01130506|DRUG|Decitabine|Given IV
223928359|NCT00488566|OTHER|Placebo|Placebo
223928360|NCT00488566|OTHER|Lamictal|Positive control
224094286|NCT01130506|OTHER|Laboratory Biomarker Analysis|Correlative studies
224094287|NCT01130506|OTHER|Pharmacological Study|Correlative studies
224094288|NCT01130506|DRUG|Vorinostat|Given PO
224094289|NCT01071070|DRUG|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
224282549|NCT02228109|DEVICE|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
224282550|NCT02228109|DEVICE|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
223928361|NCT00405990|BEHAVIORAL|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
223928362|NCT00405990|BEHAVIORAL|VCT|HIV VCT for PMTCT
223928363|NCT01752699|DRUG|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
223928364|NCT01752699|DRUG|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
223928365|NCT01825850|DRUG|Gemigliptin|
223928366|NCT01825850|DRUG|Irbesartan|
223928367|NCT06003075|COMBINATION_PRODUCT|Nivolumab and Chemotherapy|3 cycles of the proposed nivolumab + platinum doublet (either pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous; or gemcitabine + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for squamous) will be administered then CT and biopsy, followed by surgery with option for post-op NIVO-XRT, then 12 cycles NIVO at 480 mg IV every 4 weeks for 12 weeks
223928368|NCT06003075|DRUG|Nivolumab|Participants will receive NIVO at 480 mg IV every 4 weeks for 12 cycles after either surgery or treated with concurrent chemotherapy-nivolumab-radiation
223928369|NCT06003075|PROCEDURE|Post Induction Surgery|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by surgery in patients whose tumors were unresectable stage IIIA-C at baseline on the basis of lymphadenopathy and are determined to be resectable after responding to induction chemotherapy-nivolumab. The participants have an option for post op XRT, then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles
223928370|NCT06003075|RADIATION|Post Induction XRT|Induction Chemo-NIVO x 3 cycles then CT and biopsy, followed by concurrent Chemo and Nivo XRT (60Gy). Participants will receive concurrent thoracic radiation therapy using a standardized 3DCRT or IMRT technique on a linear accelerator operating at 2:6 MV beam energy. The target total dose of thoracic radiation therapy will be 60 Gy in 30 daily fractions of 2 Gy prescribed to the PTV. The participants then will receive NIVO at 480 mg IV every 4 weeks for 12 cycles.
223928371|NCT06951750|OTHER|Reflexology|The participants will receive two minutes of specific reflexology on each point of the uterus, pituitary, and solar plexus in the form of rotational pressures. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
223928372|NCT06951750|OTHER|placebo reflexology|The participants will receive rotational pressures on a neutral point on the lateral side of the heel (placebo point) for six minutes. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
223928373|NCT06951750|OTHER|general foot massage|The participants will receive a general massage on each foot for four minutes. This will be performed in the first hour post-partum and will be repeated in the second hour post-partum
223928374|NCT02956642|DEVICE|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
224094290|NCT03651843|OTHER|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
224094291|NCT00021294|DRUG|eflornithine|
223928375|NCT02956642|DEVICE|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
223928376|NCT05288348|DRUG|Sufentanil 30 MCG Sublingual Tablet|30 microgram sublingual tablet administered using sublingual applicator
223928377|NCT05288348|DRUG|standard care pain treatment|standard care pain treatment given in Emergency Department
223928378|NCT05182229|OTHER|Home-based (a hybrid model) CDT|Participants will be provided therapist-administered, in person complete decongestive therapy (CDT) two times per week for two weeks (4 sessions), followed by real-time, virtual CDT consultations two times per week for three weeks (7 sessions) and one in person follow-up visit.
224094292|NCT00021294|DRUG|triamcinolone|
224094293|NCT00745108|DRUG|tibolone|oral 1.25 mg tablet, once daily, for 2 years
224094294|NCT00745108|DRUG|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
223928379|NCT05182229|OTHER|Clinic-based CDT|Participants will be provided therapist administered, in-person CDT two times per week for six weeks (12 sessions).
223928380|NCT06643169|BEHAVIORAL|home-based fall prevention program with multifactorial|"* Health Education~* Otago Exercises~* Assessing and Organizing the Safe Home Environment"
223928381|NCT03053960|DEVICE|Computed Tomography|Undergo helical CT scan
223928382|NCT03053960|DEVICE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
223928383|NCT03053960|DEVICE|Cone-Beam Computed Tomography|Undergo CBCT scan
223928384|NCT03053960|DEVICE|Magnetic Resonance Imaging|Undergo MRI scan
223928385|NCT03053960|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection of tumor
223928386|NCT03053960|PROCEDURE|Histopathologic Examination|Correlative studies
223928387|NCT06156046|DIAGNOSTIC_TEST|skin prick test|Skin prick test for bee venom
223928388|NCT06156046|DIAGNOSTIC_TEST|Blood tests|IgE/G and T cell tolerance studies
224094295|NCT00745108|DRUG|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
224094296|NCT05503953|DRUG|AGSAVI|Uptitation
224094297|NCT05503953|DRUG|AGLS|Uptitration
224094298|NCT02760628|BEHAVIORAL|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
224094299|NCT02760628|BEHAVIORAL|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
224094300|NCT04894799|OTHER|Vestibular stimulation|In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
224282551|NCT02228109|DEVICE|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
224282552|NCT02037282|DRUG|Anti-influenza IVIG|
224282553|NCT06125756|DRUG|Low dose KL001|Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
223928389|NCT06274086|PROCEDURE|Two-session catheter-directed sclerotherapy|"After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook)."
223928390|NCT03042039|OTHER|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
223928391|NCT03380013|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
223928392|NCT02696161|OTHER|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
223928393|NCT02696161|OTHER|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
223928394|NCT01866215|OTHER|exercise|cycling at 100W during 60 min
223928395|NCT01866215|DIETARY_SUPPLEMENT|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
223928396|NCT01866215|DIETARY_SUPPLEMENT|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
224094301|NCT04894799|OTHER|Neck Control facilitation exercises|all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
224094302|NCT03469076|OTHER|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
224094303|NCT03152292|OTHER|Real-world, non-interventional|N/A - non-interventional
224094304|NCT05329116|DRUG|Lidocaine 2% Injectable Solution|"Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection"
223718053|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 4mg/kg|IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
223928397|NCT02023346|BEHAVIORAL|surveys and cognitive tests|
223928398|NCT01302600|DRUG|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
223928399|NCT01302600|DRUG|Placebo|0.1ml/kg once a day with food at dinner.
224094305|NCT05329116|BIOLOGICAL|Platelet-rich plasma|8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
223928400|NCT06157645|DEVICE|Prolene mesh|Application of mesh onlay post stoma closure
223928401|NCT00940069|DRUG|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
223928402|NCT01616537|OTHER|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
224094306|NCT04714112|DRUG|dexamethasone|Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
224094307|NCT01549990|DRUG|Sevoflurane|maintenance of general anesthesia with sevoflurane
224094308|NCT01549990|DRUG|desflurane|maintenance of general anesthesia with desflurane
224282554|NCT06125756|DRUG|Middle dose KL001|Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
224282555|NCT06125756|DRUG|High dose KL001|Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
223718054|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 6mg/kg|IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
223718055|NCT05232396|BIOLOGICAL|IL-6R Monoclonal Antibody Injection 8mg/kg|IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
223928403|NCT00410423|DRUG|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
224094309|NCT01948492|DIETARY_SUPPLEMENT|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
224094310|NCT00267735|BEHAVIORAL|Use of Computerized Decision Aid on Childbirth|
224282556|NCT02044250|DRUG|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
224282557|NCT02044250|DRUG|Aspirin|Aspirin 100\~200mg 1\~2tab P.O. daily
224282558|NCT02721706|OTHER|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
223928404|NCT00410423|DRUG|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
223928405|NCT00410423|DRUG|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
223928406|NCT05789329|BEHAVIORAL|Trauma Informed Guilt Reduction Therapy|behavioral intervention aimed to reduce trauma-related guilt and shame
223928407|NCT05789329|BEHAVIORAL|Cognitive Processing Therapy|behavioral intervention aimed at reducing PTSD symptoms
223928408|NCT04503395|DEVICE|ESAR treatment: Endograft + Heli-FX Endoanchor|ESAR treatment: Endurant II or Endurant IIs endograft + Heli-FX Endoanchor
223928409|NCT04503395|DEVICE|FEVAR treatment : Fenestrated endograft|Cook Zenith Fenestrated Graft or the Terumo Fenestrated Anaconda Graft
223928410|NCT06288854|OTHER|weight gain each group|weight gain after 12 Weeks
223928411|NCT05563766|DRUG|Itraconazole|Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
223928412|NCT04991831|DEVICE|Unilateral thalamotomy|Unilateral thalamotomy using focused ultrasound for the treatment of medication-refractory tremor dominant idiopathic Parkinson's Disease.
223928413|NCT04767009|DRUG|PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)|Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
223928414|NCT04767009|RADIATION|SBRT|Patients with oligo-residual NSCLC after effective treatment with PD-1/PD-L1 inhibitors will be treated with curative-intent SBRT of residual lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. PD-1/PD-L1 inhibitors will be withheld one day before the treatment and resumed within 2 weeks after completion of SBRT.
223928415|NCT05581498|BEHAVIORAL|Exercise, Bike exercise and muscle strength exercise.|"Study participants will perform 12 weeks of home-based exercise training with a health bike and muscle strength exercise with a resistance belt under the supervision of a certified exercise trainer.~The exercise will be delivered 3 days a week for 75 minutes for 12 weeks."
223928416|NCT06764342|RADIATION|Full-mouth scaling combined with antimicrobial photodynamic therapy|After full-mouth scaling procedures antimicrobial photodynamic therapy was carried out using a laser-activated disinfection device with a red laser emission (wavelength: 630 nm, irradiance: 2000-4000 mW/cm², spot size at the probe tip: 8 mm diameter) and high-viscosity methylene blue gel (0.1 mg/mL) which was applied at six spots on the tongue dorsum. Antimicrobial photodynamic therapy was also applied iIn sites with altered periodontal pocket depth (≥ 4mm). The dye remained in the pockets for 10 minutes to ensure full absorption and its excess was rinsed with sterile saline after laser exposure.
223928417|NCT06764342|PROCEDURE|full-mouth scaling|Full-mouth scaling within 24 hours, divided into two sessions of ultrasonic instrumentation followed by manual supra- and subgingival scaling and root planing. Tongue cleaning was performed with a tongue scraper.
223928418|NCT06755476|OTHER|Psychological Counseling Program|"The Psychological Counseling Program consists of 8 sessions for caregivers of individuals diagnosed with Alzheimer's.~Aims of the sessions:~Session 1: Introduction, Collection of pretest data Session 2: It is aimed to inform Alzheimer's caregivers about the disease and its symptoms.~Session 3: It is aimed to strengthen caregivers' coping skills. Session 4: It is aimed to inform Alzheimer's patients about daily care practices.~Session 5: It is aimed to provide information to Alzheimer's caregivers about coping with stress.~Session 6: It is aimed to provide information about medical and financial support that individuals diagnosed with Alzheimer's and their relatives can receive in the region they live.~Session 7: It is aimed to conduct Q\&A sessions on the problems that caregivers bring.~Session 8: Collection of posttest data Sessions will be completed in 8 weeks, one day a week. Each session is planned to last approximately 60 minutes."
223928419|NCT06866249|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children. The test is designed to identify de"
223718056|NCT05232396|BIOLOGICAL|Tocilizumab Injection 8mg/kg|Tocilizumab Injection 8mg/kg i.v., single use
223718057|NCT04790890|DEVICE|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive imaging test which uses light waves to take cross-section pictures of the retina.
223718058|NCT02010775|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
223928420|NCT06866249|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|Test Of Sensory Functions In Infants (TSFI) provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old.
223928421|NCT06866249|BEHAVIORAL|Brief Infant Sleep Questionnaire|"Infant sleep problems are among the most common problems presented to pediatricians. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood."
224282559|NCT00468793|PROCEDURE|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
224282560|NCT04415684|DEVICE|Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
224282561|NCT04415684|DEVICE|No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)|For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
224282562|NCT06240364|DIETARY_SUPPLEMENT|Saffron extract (Crocus sativus)|Daily intake of one tablet for 84 days.
224282563|NCT06240364|DIETARY_SUPPLEMENT|Placebo|Daily intake of one tablet for 84 days.
223718059|NCT02010775|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
223718060|NCT02389361|DRUG|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
223718061|NCT02389361|DRUG|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
223718062|NCT02030041|DRUG|Vitamin D|Vitamin D will be given to achieve normal serum levels
223928422|NCT06867406|DRUG|KPC000154 10mg Tablet Intervention|KPC000154 10mg Tablet administered orally in the morning once daily for 1 day
223928423|NCT06867406|DRUG|KPC000154 30mg Tablet Intervention|KPC000154 30mg Tablet administered orally in the morning once daily for 1 day
223928424|NCT06867406|DRUG|KPC000154 60mg Tablet Intervention|KPC000154 60mg Tablet administered orally in the morning once daily for 1 day
223928425|NCT06867406|DRUG|KPC000154 120mg Tablet Intervention|KPC000154 120mg Tablet administered orally in the morning once daily for 1 day
223928426|NCT06867406|DRUG|KPC000154 200mg Tablet Intervention|KPC000154 200mg Tablet administered orally in the morning once daily for 1 day
223928427|NCT06867406|DRUG|KPC000154 300mg Tablet Intervention|KPC000154 300mg Tablet administered orally in the morning once daily for 1 day
223928428|NCT06867406|DRUG|KPC000154 400mg Tablet Intervention|KPC000154 400mg Tablet administered orally in the morning once daily for 1 day
223928429|NCT06867406|DRUG|KPC000154 80mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 80mg tablet administered orally in the morning for 14 days
223928430|NCT06867406|DRUG|KPC000154 120mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 80mg tablet administered orally in the morning for 14 days
223928431|NCT06867406|DRUG|KPC000154 40mg multiple-dose Tablet Intervention（To Be Determined）|KPC000154 120mg tablet administered orally in the morning for 14 days
223928432|NCT06867406|DRUG|Placebo-controlled（SAD）|A placebo used in a single-dose study where participants receive either the experimental drug or the placebo.
223928433|NCT06867406|DRUG|Placebo-controlled（MAD）|A placebo used in a multiple-dose study where participants receive either the experimental drug or the placebo.
223928434|NCT06862037|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication (LNF) is the most commonly performed anti-reflux surgery. LNF is performed in patients with GERD refractory to medication or those expected to require long-term medical treatment. During LNF, the fundus of the stomach is mobilized and wrapped 360 degrees around the lower esophagus to reinforce the lower esophageal sphincter (LES), preventing the reflux of gastric contents into the esophagus.
224282564|NCT03074864|DRUG|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
224282565|NCT04186559|DRUG|Topical Pentoxifylline Gel (Vehicle +PTX)|Patients will be given 1 tube containing 20 ml of topical PTX gel (containing 1,000mg of PTX) to be applied no fewer than four times per day with complete consumption of the entire tube each day.
224282566|NCT04186559|DRUG|Topical Placebo Gel (Vehicle)|Patients will be given 1 tube containing 20 ml of topical placebo gel to be applied no fewer than four times per day with complete consumption of the entire tube each day.
224282567|NCT01189526|DRUG|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
224282568|NCT01189526|PROCEDURE|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
224282569|NCT06090682|DEVICE|Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)|We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
224282570|NCT02358551|DEVICE|Placement of electrode lead through axillary vein puncture|
224282571|NCT02358551|DEVICE|Placement of electrode lead through subclavian vein puncture|
224282572|NCT04147962|DEVICE|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
224282573|NCT01162278|RADIATION|SBRT|Single fraction SBRT
224282574|NCT06420609|OTHER|Go-TAD|The participants will receive a medical visit that will include the 4 open-ended questions comprising the Go-TAD intervention
224282575|NCT05045469|DRUG|dian dao san|dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
224282576|NCT04744428|BEHAVIORAL|Autism Parent Navigators|The Autism Parent Navigator program consists of six sessions delivered to parents in the home, supporting adjustment to ASD, accessing services, and coparenting support.
224282577|NCT04744428|BEHAVIORAL|Peer mentoring|Six in-home or telephone sessions, depending on family uptake, providing non-manualized general support as usual from parent peer mentors regarding adjustment to ASD.
224282578|NCT04751045|PROCEDURE|EUS liver biopsy|Endoscopic ultrasound guided liver biopsy
224282579|NCT04044560|BIOLOGICAL|blinatumomab|Continuous intravenous infusion
224282580|NCT04082806|DRUG|GHB|50 mg/kg GHB at one experimental night
224282581|NCT04082806|DRUG|Trazodone|1.5 mg/kg trazodone at one experimental night
224282582|NCT04082806|DRUG|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
224282583|NCT02001051|PROCEDURE|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
224282584|NCT02001051|OTHER|Observation|Observation for 6 months prior to surgery
224282585|NCT03856606|BEHAVIORAL|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
224282586|NCT03856606|BEHAVIORAL|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
224282587|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
224282588|NCT03777904|DIAGNOSTIC_TEST|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
223718063|NCT02030041|DRUG|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
223718064|NCT02030041|DRUG|Placebo|Placebo will be provided to the study participants
223718065|NCT01916720|DRUG|SB-480848 40 mg|Study Drug
223928435|NCT06865547|BEHAVIORAL|The 4A ProActive Management Model|This model focuses on four key areas - Active Education, Active Prevention Strategies, Active Management, and Active Follow-up. Active Education involves providing patients with detailed information on treatment regimens, potential AEs, and self-care through verbal education, reminder cards, and direct counseling. Active Prevention Strategies aims to directly reduce risks through nursing care bundles that incorporate supportive medications, fall risk assessments, and dietary guidance. Active Management establishes robust protocols for early AE reporting, rapid treatment, and standardized order sets. Active Follow-up comprises additional outpatient visits, patient surveys, medication refill coordination, and pharmacist/nurse follow-up calls to closely monitor patient adherence and symptoms.
223928436|NCT02016924|DRUG|ATV|Capsules administered once daily according to dosing recommendations per product monograph
224282589|NCT03777904|DIAGNOSTIC_TEST|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
224282590|NCT03777904|DIAGNOSTIC_TEST|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
223718066|NCT01916720|DRUG|SB-480848 80 mg|Study Drug
223718067|NCT01916720|DRUG|Placebo|Study Drug
223928437|NCT02016924|DRUG|DRV|Tablets administered once daily according to dosing recommendations per product monograph
224282591|NCT03841890|DEVICE|the Clarus Video System as a video stylet|video-guided intubation
223928438|NCT02016924|DRUG|Cobicistat|Tablets administered orally once daily with food
223928439|NCT02016924|DRUG|BR|Background Regimen (BR) include Food and Drug Administration (FDA)-approved nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), and emtricitabine (FTC).
223928440|NCT02016924|DRUG|F/TAF|Tablets administered orally once daily
223928441|NCT02016924|DRUG|LPV/r|Solution administered orally
223928442|NCT02016924|DRUG|Third Unboosted Drug|ATV (administered orally), DRV (administered orally), and LPV/r (administered orally) would be general list but unspecified for sites.
223928443|NCT02016924|DRUG|Cobicistat TOS|Tablets for oral suspension
223928444|NCT02016924|DRUG|F/TAF TOS|Tablets for oral suspension
223928445|NCT00673842|DEVICE|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)
223928446|NCT00673842|OTHER|Usual care|Usual post-MI care
223928447|NCT05699408|DRUG|INS068 injection|INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
223928448|NCT05699408|DRUG|Insulin Glargine|Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
223928449|NCT06811610|DIAGNOSTIC_TEST|Participants were tested for hearing using a new type of hearing detection device|Participants' hearing was tested using a portable audiometry device (E200) based on active noise-cancelling headphones, manufactured by Wuhan Doulisten Technology Co., LTD
224282592|NCT03841890|DEVICE|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
224282593|NCT03841890|DEVICE|direct laryngoscope|Macintosh laryngoscope size 3
224282594|NCT04090879|OTHER|Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)|1\) Altering the nicotine content of the tobacco research cigarette
224282595|NCT04090879|OTHER|E-Cigarettes|1\) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
223718068|NCT03621397|DEVICE|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
223718069|NCT05907512|DRUG|Endostar|The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
223718070|NCT05907512|DRUG|Toripalimab|3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
223928450|NCT06811610|DIAGNOSTIC_TEST|Participants' hearing was tested using a new portable pure tone audiometry device|Participants' hearing was tested using a portable audiometry device (E200) based on active noise-cancelling headphones, manufactured by Wuhan Doulisten Technology Co., LTD
223928451|NCT05270525|DRUG|Ensifentrine|Ensifentrine twice daily administered with jet nebulizer for 8 weeks
223928452|NCT05270525|DRUG|Placebo|Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
223928453|NCT05613894|DRUG|Cabozantinib|(177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.
224094311|NCT03058484|BEHAVIORAL|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
224094312|NCT06124989|DIAGNOSTIC_TEST|MINERVA Machine Learning model|The MINERVA score for the prediction of the risk of relapse of acute pancreatitis in patients who did not undergo early cholecystectomy after the first episode of acute biliary pancreatitis will be grounded upon a Machine Learning model that takes into account patients' demographic, clinical, and laboratory variables that can be easily collected and recorded at index patient admission.
224282596|NCT06327737|DIAGNOSTIC_TEST|Capnography|This is non-invasive follow-up method to the management of DKA and the reduction of the frequency of invasive procedures was investigated in patients diagnosed with diabetic ketoacidosis (DKA) in the pediatric emergency department and followed up with capnography.
224282597|NCT00232479|DRUG|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
224282598|NCT06392542|BEHAVIORAL|Whole Selves|Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
223718071|NCT02788812|PROCEDURE|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
223928454|NCT04908020|OTHER|Follow-up patients|The intervention consists in the assessment of some psychological aspects (post traumatic stress symptoms and coping) of cancer patients in follow-up care, through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
223928455|NCT06642545|DRUG|Disitamab Vedotin|Disitamab Vedotin 2.0mg/kg,intravenous infusion, every 2 weeks
223928456|NCT06642545|DRUG|RC148|20mg/kg, intravenous infusion, once every 2 weeks
223928457|NCT06642545|DRUG|Albumin-bound Paclitaxone|125 mg/m2,intravenous infusion, D1-8, every 3 weeks
224094313|NCT03415165|DRUG|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
224282599|NCT04119024|PROCEDURE|Biopsy|Undergo biopsy
224282600|NCT04119024|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224282601|NCT04119024|PROCEDURE|Computed Tomography|Undergo CT scan
224282602|NCT04119024|DRUG|Cyclophosphamide|Given IV
224282603|NCT04119024|DRUG|Fludarabine Phosphate|Given IV
224282604|NCT04119024|OTHER|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
223718072|NCT02788812|PROCEDURE|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
223718073|NCT05512572|DEVICE|IPL|intense pulsed light
223928458|NCT06642545|DRUG|Toripalimab|240mg,intravenous infusion, once every 3 weeks
223928459|NCT06748235|OTHER|Intensive Strength Training|Comprehensive Hand Repetitive Intensive Strength Training and Routine Physical Therapy 60 minutes per session, three sessions a week, at a total of 30 sessions per ten weeks. Comprehensive hand repetitive intensive strength training included treadmill training for the upper limb with body weight supporting the using upper limb. The posture of an arm swing was to maintain the joints of the elbows and wrist as much as possible, and the shoulder joint was allowed to be flexed by 160 degrees .The posture of the arm stance supported the weight using metacarpal heads, hands, and elbows, and the shoulder joints were allowed to be flexed by 90 degrees.
224094314|NCT03415165|DRUG|Corticosteroids Topical|kenacort in orabase 4 times aday
224094315|NCT02594501|DEVICE|COBRA PzF|
224094316|NCT02594501|DEVICE|Drug Eluting Stent|
224094317|NCT00426348|DRUG|Valsartan|Valsartan (80-160mg/day)
224094318|NCT00426348|DRUG|Probucol|Probucol (750mg/day)
224094319|NCT00426348|DRUG|Placebo|Placebo
224094320|NCT02351102|DRUG|Valacyclovir|
224094321|NCT02351102|DRUG|Placebo|
224094322|NCT03128463|DRUG|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
224094323|NCT03205579|OTHER|Video group|Using video for educate cancer pain patients
224094324|NCT03205579|OTHER|conventional group|Face to face cancer pain education by trained nurse
224094325|NCT03733652|DRUG|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
223532623|NCT07126977|OTHER|Biofeedback-Assisted Pelvic Floor Muscle Exercises|"No invasive procedures will be performed. The physiotherapist will begin with external palpation of the perineal area to teach correct pelvic floor contractions without using accessory muscles. Once the patient masters this, animation-supported biofeedback exercises will start. If relaxation is insufficient, biofeedback will first target muscle relaxation.~Using the NeuroTrac Myoplus Pro4 device, surface electrodes will be placed at 2 and 7 o'clock on the perineum, and the reference electrode on the right thigh. Exercises will start in a lying position and progress to sitting and standing as control improves. Each session will last about 20 min, with 2-5 s contractions followed by 5-10 s relaxations."
223928460|NCT06748235|OTHER|Routine Physical Therapy|Received 60 minutes per a session, three sessions a week, at a total of 30 sessions per 10 weeks by creating a home program, which consisted of a total of 8 exercises that enhanced the muscular strength of the upper limb including the triceps brachii and extensor carpi radialis, and conveyed an effect of reaching the muscles out. flexion and extension muscle strengthening with towel, hand grip and wrist extension muscle strengthening This exercise consisted of shoulder extension muscle, elbow flexion muscle, shoulder abduction muscle, and elbow extension muscle strengthening with a thera band, as well as hand grip, forearm with a velcro board, wrist extension muscle strengthening with sandbag and shoulder abduction-extension muscle strengthening with a thera band.
223928461|NCT06763653|DEVICE|ULF therapy|ultra low frequency spinal cord stimulation
223928462|NCT06763653|OTHER|CMM|conventional medical management
223928463|NCT04739696|BEHAVIORAL|PEPRR|Briefly presented in the following order, sessions will include: 1) Overview and Introduction to Stress Management 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with work and caregiver stress, 5) Strategies for maintaining energy and stamina with caregiver and work demands, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs to employers and your loved ones, and 8) Getting the support they need including work accommodations and/or legal protections (e.g., Family Medical Leave Act, Americans with Disabilities Act)
223928464|NCT04739696|BEHAVIORAL|Pep-Pal|Pep-Pal program consisted of 11 sessions: 1) Introduction to stress management, 2) Stress and the mind body connection, 3) How thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty, 7) Managing changing relationships and communicating needs, 8) Getting the support they need; 9) Employment related challenges and resources for working caregivers; 10) Employment session one; 11) Employment session two
223718074|NCT05512572|PROCEDURE|Conservative treatment or excision with curettage|conservative treatment or excision with curettage but without IPL-MGX treatment as a control
224094326|NCT03723447|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
223928465|NCT06692309|PROCEDURE|cardiovascular surgery|Heart bypass surgery; Heart valve replacement surgery
223928466|NCT07022704|DRUG|Doxapram|Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT
224094327|NCT03723447|DRUG|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
224094328|NCT02862769|DRUG|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
224094329|NCT02862769|DRUG|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
224094330|NCT02000609|DRUG|CHF 1535 NEXThaler 800/48|
224094331|NCT02000609|DRUG|CHF 1535 NEXThaler 200/12|
224094332|NCT02000609|DRUG|CHF 1535 NEXThaler PLACEBO|
224094333|NCT02000609|DRUG|CHF 1535 pMDI 200/12|
224094334|NCT02000609|DRUG|CHF1535 pMDI 800/48|
224094335|NCT00864240|DRUG|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
224282605|NCT04119024|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
224282606|NCT04119024|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224282607|NCT04119024|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224282608|NCT01040273|DRUG|Bupivacaine|
224282609|NCT01040273|DRUG|Placebo|
224282610|NCT04763096|DRUG|Advagraf|"Researchers must check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~10ng/ml of study treatment. Duration of treatment The investigational product will be administered for 24 weeks. (The lowest blood levels shall be adjusted at the discretion of the researchers, taking a blood sample is carried out in the morning before administrated of Investigational Product)~Tacrolimus blood level is 3-10 ng/ml for 6 months prior to screening and during the maintenance therapy.~( ① -1day to enrollment : swich to the day before ADVAGRAF®, ② 0day to enrollment : the day swich to ADVAGRAF® )~Duration of treatment the investigational product will be administered for 24 weeks."
224282611|NCT00020358|BIOLOGICAL|aldesleukin|
224282612|NCT00020358|BIOLOGICAL|gp100 antigen|
224282613|NCT00020358|BIOLOGICAL|incomplete Freund's adjuvant|
224282614|NCT00020358|BIOLOGICAL|tyrosinase peptide|
223718075|NCT02277145|BIOLOGICAL|clinical grade umbilical cord mesenchymal stem cells|10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
223718076|NCT01197560|DRUG|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
223718077|NCT01197560|DRUG|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
223928467|NCT07023510|DIAGNOSTIC_TEST|AI-ECG driven echocardiography|The intervention utilizes a previously validated deep learning model based on 12-lead electrocardiogram (ECG) data to screen for moderate-to-severe valvular heart diseases (VHD). The model processes raw ECG signals and integrates age and sex to enhance prediction. (doi: 10.18632/aging.205835.) Participants identified as high-risk for any moderate-to-severe VHD by the algorithm of artificial intelligence-powered electrocardiogram (AI-ECG) in this intervention arm will receive transthoracic echocardiography to confirm diagnosis and guide further management.
223928468|NCT06696404|PROCEDURE|Combined Lumbar Plexus and Sacral Plexus Block|This intervention of Combined Lumbar Plexus and Sacral Plexus Block is assigned to Nerve block anesthesia group (NA group): A combined Lumbar Plexus Block (0.33% Ropivacaine 30ml) and Sacral Plexus Block (0.33% Ropivacaine 20ml) administered as a single injection.
223928469|NCT06696404|PROCEDURE|iliac fascial block|iliac fascial block administered as a single injection below the iliac fascial with 0.33% ropivacaine 30ml.
224094336|NCT02815215|PROCEDURE|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
224094337|NCT02815215|PROCEDURE|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
224094338|NCT00533962|DRUG|Anterior Juxtascleral Depot of Anecortave Acetate|
224094339|NCT05750940|DIAGNOSTIC_TEST|31Phosphor Magnetic Resonance Spectroscopy|Measurement of skeletal oxidative metabolism with 31phosphor magnetic resonance spectroscopy
224094340|NCT01492010|DIETARY_SUPPLEMENT|whey protein|25 g whey protein
224094341|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
224094342|NCT01492010|DIETARY_SUPPLEMENT|whey protein supplemented with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
224094343|NCT03505268|BEHAVIORAL|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
224094344|NCT05468970|OTHER|NO Intervention|NO Intervention
224094345|NCT04239209|BEHAVIORAL|Indirect - other patients|Video depicting an indirect response focusing on a comparison to other patients.
224282615|NCT00160888|DRUG|sodium nitroprusside, bradykinin, acetylcholine|
224282616|NCT03562949|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
224282617|NCT03562949|DRUG|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
224282618|NCT03562949|DRUG|Placebo|Placebo Product
223928470|NCT06696404|PROCEDURE|spinal anesthesia|Spinal anesthesia was performed as a standard care of spinal anesthetic. The spinal puncture site is at L2-3 or L3-4. After the puncture needle reaches the subarachnoid space, 1% ropivacaine 0.8-2 ml, totaling 8-20mg, is injected. Depending on the center's practice, it may be replaced with an equivalent dose of bupivacaine .
224094346|NCT04239209|BEHAVIORAL|Indirect - physiology|Video of an indirect response focusing on the physiology of the patient.
224094347|NCT04239209|BEHAVIORAL|Redirection|Video of a redirection towards discussing the patient's values and possible future decisions.
223928471|NCT03687710|BEHAVIORAL|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
223928472|NCT06699498|DRUG|Benmelstobart|1200mg, D1, IV,q3w
224094348|NCT04239209|BEHAVIORAL|Direct communication|Video of a direct response.
224282619|NCT04623528|DIAGNOSTIC_TEST|T1 and T2 relaxometry of the liver parenchyma|Evaluate T1 and T2 relaxomatry of the liver parenchyma to depict liver congestion in the different patient groups
224282620|NCT04205162|DEVICE|Verafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
224282621|NCT04205162|DEVICE|Etafilcon A|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
224282622|NCT04245293|DEVICE|Ainara|Each administration kit (subject kit) for patients of Ainara® will contain a box with 1 tube with 30 g gel, 1 cannula and 1 plunger. The gel quantity is enough for one subject over the course of the study (1 g at each administration).
224094349|NCT05595525|DEVICE|1064NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
224094350|NCT05595525|DEVICE|755NM pico Laser|There have been small studies demonstrating the use of picosecond lasers for treatment of wrinkles and skin laxity; however, there have been no studies investigating the use of picosecond lasers for the overall improvement in skin quality.
224094351|NCT05555004|OTHER|TEST1|Toddler milk with preconditioned L. reuteri and containing GOS
224094352|NCT05555004|OTHER|TEST 2|Toddler milk with standard/non-preconditioned L. reuteri and not containing GOS.
224094353|NCT04586491|COMBINATION_PRODUCT|Oral care protocol|Oral care protocol
224282623|NCT04245293|DEVICE|HyaloGin|"Active Comparator: HyaloGin Each administration kit (subject kit) for patients allocated to HyaloGyn® group will contain a box with: 1 tube with 30g gel and 10 single-use applicators consisting of a piston and one opaque plastic plunger.~The gel quantity is enough for one subject (3g application every three days over the course of the study)."
224282624|NCT03649945|DRUG|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
224282625|NCT03649945|DRUG|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
224282626|NCT03649945|DRUG|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
223928473|NCT06699498|DRUG|Anlotinib|10mg，D1-14，po，q3w
223928474|NCT06699498|DRUG|Cisplatin|60mg/m2， D1， IV，q3w
223928475|NCT06699498|DRUG|Paclitaxel for Injection （Albumin Bound）|260mg/m2，IVgtt ，D1，q3w
223928476|NCT04629599|BEHAVIORAL|Interpersonal psychotherapy for major depression following perinatal loss|Participants in the IPT condition will receive 12 group sessions and 2 individual (pre-group and 1-month booster) sessions as outlined in the manual The individual sessions prepare patients to use the group effectively, to keep group members focused on their treatment goals, and to maintain treatment gains. In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. These sessions are important because relationship distress is common following perinatal loss. Our IPT intervention allows new women to enter the group every 4 weeks of the 12-week group. Group sessions are semi-structured, and each woman will cover the four group topics three times, approaching each topic from a different stage in the mourning process.
223928477|NCT04629599|BEHAVIORAL|Coping with Depression|The Coping with Depression (CWD) course is a structured, manualized psycho-educational group treatment for MDD. The CWD course is based on social learning theory which posits that depression is associated with a decrease in pleasant and an increase in unpleasant person-environment interactions. The problems shown by depressed individuals are viewed as behavioral, with cognitive patterns that can be unlearned or relearned. Its effectiveness is comparable to other forms of psychotherapy in depression. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. As in the pilot trial, CWD will consist of an individual pregroup session, 12 group therapy sessions (allowing new women to enter every 4th session) and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
224094354|NCT05379751|PROCEDURE|Fixation free Spigelian hernia repair with tentacle mesh|Spigelian hernias are repaired through the fixation free placement of a tentacle mesh in preperitoneal sublay thanks the friction exerted by the tentacle straps delivered by a proprietary needle passer crossing trouh the abdominal wall from the preperitoneal space until the subutaneous layer. This procedural approach should also grant a broad overlap of the implant over the hernial defect
224094355|NCT04417257|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
224094356|NCT04417257|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.
224094357|NCT03314285|OTHER|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
224094358|NCT05963503|OTHER|Assessments|Health literacy Anxiety and depression Physical activity Adherence to airway clearance techniques
224094359|NCT04427254|DRUG|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies|Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
224282627|NCT03816449|OTHER|exercises|"Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks."
224282628|NCT06532968|DEVICE|Sham|Sham
224282629|NCT06532968|DEVICE|ORION spinal lamina cover|an artificial lamina coverage of the ORION spinal system
224282630|NCT02136238|DEVICE|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
224282631|NCT02136238|DEVICE|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
224282632|NCT01660477|DRUG|Isavuconazole|oral
224282633|NCT01660477|DRUG|Lopinavir/ritonavir|oral
224282634|NCT04010734|PROCEDURE|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
224282635|NCT04013698|OTHER|PEEP level 5 cmH2O|PEEP level set for 45 minutes
224282636|NCT04013698|OTHER|PEEP level 15 cmH2O|PEEP level set for 45 minutes
224282637|NCT04888533|OTHER|EHSSA- An Efficient and Holistic/Heuristic Semi-structured Suicide Assessment Tool|EHSSA will be used to evaluate every patient for suicide risk.
224282638|NCT02078011|DEVICE|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
224282639|NCT03776617|PROCEDURE|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
223718078|NCT01197560|DRUG|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
224282640|NCT01899196|BIOLOGICAL|blood sampling,|
223718079|NCT01197560|DRUG|Rituximab|Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
223928478|NCT06073431|PROCEDURE|Biospecimen Collection|Undergo collection of blood and archived tumor samples
223928479|NCT06073431|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224094360|NCT02203149|DRUG|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
223928480|NCT06073431|OTHER|Electronic Medical Record|Review of medical record
223928481|NCT06073431|OTHER|Medical Device Usage and Evaluation|Wear actigraph
223928482|NCT06073431|OTHER|Physical Performance Testing|Undergo physical function tests
223928483|NCT06073431|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223928484|NCT06073431|OTHER|Survey Administration|Complete surveys
223928485|NCT00087685|DRUG|RAD001|10 mg by mouth Daily
224094361|NCT02203149|DRUG|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
224094362|NCT02203149|DRUG|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
224094363|NCT02203149|DRUG|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
224094364|NCT02617914|PROCEDURE|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
224094365|NCT01892488|DRUG|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
224094366|NCT01892488|DRUG|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
224094367|NCT03496701|DEVICE|Test lens|contact lens
224094368|NCT03496701|DEVICE|control lens|contact lens
224094369|NCT02635230|DRUG|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
223718080|NCT01197560|DRUG|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles"
223928486|NCT06711042|DIAGNOSTIC_TEST|functional tests and radiographic analysis|In this observational study, no active interventions or treatments will be administered to the participants. Both groups (Control Group and Experimental Group) will undergo clinical evaluations, including functional tests (WOMAC, Harris Hip Score, Oxford Hip Score, SF-12, TUG) and radiographic analysis (angular measurements). The participants' outcomes will be compared based on their implant placement (within or outside the Functional Safe Zone).
223928487|NCT05233267|OTHER|Blood sample|Dosage of neopterin
223718081|NCT05201703|DRUG|Fycompa|Fycompa 4 mg daily
223718082|NCT05201703|DRUG|Fycompa with a boost|Fycompa 4 mg daily with a boost to 6 mg daily a week before the start of your menstruation cycle until Day 4 of your cycle.
223928488|NCT06878300|DEVICE|Over the counter hearing aid (Lexie)|The study will compare user perceptions of two over-the-counter (OTC) hearing aids, with the Lexie B3 Pro serving as the reference device. Participants will be fitted with each device for a predetermined period in a randomized order to ensure balanced exposure.
223928489|NCT06878300|DEVICE|Comparator over the counter hearing aid|The comparator OTC hearing aid will undergo the same evaluation process as the Lexie B3 Pro, ensuring an equivalent and unbiased comparison. Participants will be provided with the comparator device along with its standard user instructions, including any mobile applications or self-fitting guidance designed for independent setup.
223928490|NCT07038304|RADIATION|Metastasis directed radiotherapy|According to guidelines, in the case of oligoprogression next line systemic treatment is recommended. This study investigates the potential delay of NEST and rPFS by MDRT.
224094370|NCT04210479|PROCEDURE|Filled-bladder|Urinary bladder filling with 300 ml diluted methylene blue
224094371|NCT04210479|PROCEDURE|non filled-bladder|Pull up the empty (non-filled) urinary bladder using Allis forceps
224094372|NCT02604004|DRUG|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
224094373|NCT02604004|DRUG|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
224094374|NCT02747485|DEVICE|Cardiac MRI|
224094375|NCT02747485|BIOLOGICAL|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
224094376|NCT02747485|PROCEDURE|myocardial biopsy|
224094377|NCT02747485|GENETIC|blood samples|extract DNA to look for genomic mutations associated with the disease.
224094378|NCT01454076|DRUG|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
224094379|NCT01454076|DRUG|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
224094380|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
224094381|NCT01454076|DRUG|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
224094382|NCT01454076|DRUG|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
223928491|NCT07039097|PROCEDURE|Transcervical resection of septum|Transcervical resection of septum (TCRS) is divided into two categories: one is plasma hysteroscopic electrosurgical resection (actually TCIS), which uniformly uses a 7mm external diameter hysteroscopic electrosurgical resectoscope to reduce the difficulty of cervical dilation; the other is micro (5 or 7Fr) hysteroscopic cold knife incision, equipped with a 5Fr bipolar electrocoagulation stick for electrocoagulation and hemostasis.
223928492|NCT07038408|PROCEDURE|Angioplasty with DCB (bail-out BRS)|"Angioplasty starts with lesion preparation in both arms with a PTCA balloon catheter.~The lesion is treated with the Mozec SEB through femoral or brachial artery. The DCB should be delivered to the target lesion within 120 seconds of insertion into the guide catheter. Under fluoroscopic visualization, the DCB is inflated at least 30 seconds (single inflation). If the results are insufficient, multiple inflation is permitted. If despite appropriate delivery and inflation of the DCB, the results remain insufficient bail-out BRS should be performed.~Bail-out BRS is performed through femoral or brachial artery. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, Optical Coherence Tomography (OCT) is performed, if available."
224282641|NCT03112148|DRUG|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
223928493|NCT07038408|PROCEDURE|Angioplasty with BRS|Bail-out BRS is performed through femoral or brachial artery. BRS implantation is guided by OCT, if available. After correct positioning, the BRS is deployed slowly, i.e. 10 seconds/atm up to 4 atm, then 5 seconds/atm up to nominal pressure or higher until desired expansion is obtained. After desired expansion obtained, pressure is maintained for 30 seconds before balloon deflation. After BRS implantation, OCT is performed, if available.
223928494|NCT07039357|DEVICE|Near-infrared (spectroscopy) for non-invasive assessment of glycated keratin of nail|both interventions will be applied in both participant groups
224094383|NCT01454076|DRUG|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
224094384|NCT01454076|DRUG|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
224094385|NCT05658757|OTHER|Regular sweetened commercial foods|"This is your usual habits period. Consume the chosen, sweetened commercial products of your choice in the breakfast cereal/cereal-granola bar category (at least 1 daily serving) and sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat the regular sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as your usual habits if more often.~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume these regular sweetened beverages as you usually do."
224094386|NCT05658757|OTHER|Allulose sweetened commercial foods|"This period emphasizes minimizing added sugar, aligning intake levels with recommendations from the AHA and Dietary guidelines by consuming allulose sweetened products.~Participants will eat at least 1 daily serving of the chosen, provided allulose sweetened breakfast/cereal-granola bar, and at least 1 daily serving of allulose sweetened baked goods/candy/desserts in place of the usual sweetened products from these food categories.~* If they eat peanuts or nuts, and willingly consume chocolate covered peanuts or nuts, eat allulose sweetened chocolate covered nuts/peanuts at least 3 days a week (1 serving/day), or as frequently as usual habits if more often.~* If they consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume allulose sweetened beverages in place of their artificial or regular sweetened beverages (provided commercial and/or syrups), and sweeten coffee or tea with the provided allulose sweetener. Do this according to usual habits."
224094387|NCT05658757|OTHER|Whole and minimally processed and sweetened foods|"Consume at least 1 daily serving of the chosen, minimal to no sweetened breakfast product in place of your usual sweetened breakfast cereal/cereal-granola bar and consume a whole piece of fruit (or serving of fruit) in place of a sweetened baked goods/candy/desserts (at least 1 daily serving).~* If you eat peanuts or nuts, consume plain or dry-roasted (no to low sodium) nuts/peanuts at least 3 days a week (1 serving), or as frequently as your usual habits if more often~* If you consume sweetened beverages (artificial or regular) or sweetened coffee or tea, consume unsweetened coffee or tea and consume plain water in place of the sweetened beverages at the same frequency/amount that you usually do.~This period emphasizes incorporating minimally processed (e.g., intact whole grains) foods with minimal to no added sugar, aligning added sugar intake levels with recommendations from the American Heart Association and Dietary guidelines."
224094388|NCT02836561|OTHER|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
224094389|NCT02769598|DEVICE|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
224282642|NCT01098110|DRUG|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
224282643|NCT01098110|DRUG|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
224282644|NCT01098110|DRUG|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
223928495|NCT07038044|DIETARY_SUPPLEMENT|Arginine-restricted diet|"Targeted Arginine Metabolism: The intervention zeroes in on arginine metabolism. As solid tumors often have arginine synthesis flaws and rely on external arginine, dietary restriction of arginine is a novel approach.~Dietary Intervention: The -Arg liquid diet in this study is precisely defined. Dosage is determined by patient weight, following 30 kcal/kg/day for energy and 1.5 g/kg/day for protein. A low - arginine food list is provided.~Study Design and Endpoints: It's a Phase I single - arm study. Its main goal is to evaluate the safety and tolerance of the combined treatment. Secondary and exploratory endpoints cover efficacy, nutritional state, and immune status."
223928496|NCT07039773|DIETARY_SUPPLEMENT|Vital wheat gluten|Gluten-containing shake vs gluten-containing cookie
223928497|NCT07039773|DIETARY_SUPPLEMENT|Vital wheat gluten|Half of participants will receive gluten-containing shake first, then gluten-containing cookie next, and vice versa
223928498|NCT07038863|DIAGNOSTIC_TEST|Community screening for hepatitis B, C and delta in the Mongolian population living in France|"Screening will be organised in 11 centres in France, with 1 to 3 screening sessions per centre: patients will be informed of these screening sessions by the Mongolian Embassy in France, social networks and communities.~During this screening visit, Rapid Diagnostic Orientation Test (RDOT) will be carried out to screen for HBV and HCV. If the RDOT is negative for both viruses, an information on transmission and prevention of viral infection will be given.~If the RDOT is positive, confirmation of these tests by blood sampling will be organized and complementary biology (ASAT, ALAT, GGT, PAL, bilirubin total, bilirubin conjugated). If HBV RDOT positive, additional tubes will be collected for centralized analysis at the end of the study (VHD DNA, VHD genotyping, fibrotest and LCR1/2 test).~Once these confirmatory tests have been carried out, the patient will be referred to a hepatology consultation."
223928499|NCT07039903|BEHAVIORAL|Cognitive behavioral therapy (CBT) + Functional Remediation (FR)|VECTOR will provide a newly designed intervention, based on the adaptation of two existing evidence-based and effective interventions (CBT for ADHD and FR for BD)(Corrales et al., 2024; Torrent et al., 2013).
223928500|NCT07038018|DIAGNOSTIC_TEST|AI-ECG Algorithm|AI-ECG Algorithm to detect LVEF\<=40%
223928501|NCT07038317|OTHER|Intervention|Intervention involves e-cigarette education messages tailored to participants' vaping status that will be sent out in SMS via text messaging three times per week over the course of 6 months.
223928502|NCT07038317|OTHER|Control|Participants will receive non-tobacco messages (messages about sun safety) three times per week over the course of 6 months.
223928503|NCT07039513|OTHER|Blood sampling collection|Collection of an additional of 2.7mL citrate tube of blood for a D-dimer dosage.
223928504|NCT07038993|OTHER|Venous Pressure Monitoring|Measurement of venous pressure will be taken at dialysis machine pump speed set at 200ml/min, fistula needle gauge 16.
223928505|NCT07038993|OTHER|Color Doppler Ultrasound|Arteriovenous fistula (AVF) Access flow (QA) will be obtained using color Doppler ultrasound using the Mindray-M5 ultrasound system. AVF feeding arterial flow will be measured immediately proximal to the fistula. The QA volume will be obtained using the algorithm available on the system, which is based on the mean flow of two measurements.
223928506|NCT07038265|BEHAVIORAL|Personalised treatment|Patients going through a personalized intervention program
223928507|NCT07038265|OTHER|Usual Care|Usual cardiac rehabilitation program
223928508|NCT06716957|OTHER|Schroth exercise|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
223928509|NCT06716957|OTHER|Dynamic Stabilization exercises|The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 12 weeks
224094390|NCT02190734|OTHER|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
223928510|NCT07039370|DEVICE|TMS|"Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique approved for the treatment of major depressive disorder (MDD), particularly in individuals with treatment-resistant depression (TRD). TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region often underactive in depression, and modulates neural activity through magnetic pulses.~This study aims to evaluate the effects of TMS on plasma proteomic and metabolomic profiles in patients with TRD. Participants will undergo 20 sessions of intermittent theta burst stimulation (iTBS) over four weeks. Blood samples will be collected before and after treatment to identify molecular changes associated with clinical response. Healthy controls will provide single-time-point blood samples for baseline comparison. Findings may support the development of biomarker-based strategies for personalized treatment in psychiatry."
223928511|NCT07038070|DRUG|Vaginal estrogen tablet|The dosage of the vaginal estrogen will be one 10mcg tablet administered vaginally nightly for 2 weeks, then administered vaginally twice weekly for 14 weeks.
223928512|NCT07038070|DEVICE|Via Solv Wellness (Hyaluronic Acid Therapy)|The dosage of Via will be a pea-sized amount applied vaginally along the vaginal and vulvar walls nightly for 16 weeks.
224094391|NCT02190734|OTHER|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
224094392|NCT02190734|OTHER|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
224094393|NCT06488677|BEHAVIORAL|Lifestyle changes (diet and physical activity)|Nurse-led telephone personalized dietary and PA advice
224094394|NCT02235818|DEVICE|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
224094395|NCT02235818|DEVICE|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
223928513|NCT05023382|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
224094396|NCT06351202|OTHER|Abdominal massage|An abdominal massage for premature babies lasts 10 minutes. Our abdominal massage techniques is described in our protocole and will be adapted according to the term of the child.
224094397|NCT01478958|DIETARY_SUPPLEMENT|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
224094398|NCT01478958|DIETARY_SUPPLEMENT|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
224094399|NCT01478958|DIETARY_SUPPLEMENT|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
224094400|NCT04003129|OTHER|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
224094401|NCT03416231|DRUG|Apatinib|apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
224094402|NCT03416231|DRUG|Docetaxel|Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
223532624|NCT07126977|OTHER|Video Game-Based Balance Exercise Training|"In our study, in addition to the standard protocol, virtual reality-supported video game-based balance exercises will be performed twice a week for 8 weeks. Each session will include a 5-minute warm-up, 20 minutes of balance exercises, and a 5-minute cool-down period. All sessions will follow the same protocol, with identical game order and duration. Each game will be played for approximately 5 minutes, and the number of repetitions for each game will vary depending on the participant's performance level.~As a therapeutic tool, the Wii console, Wii Fit Plus game disc, and Wii Balance Board will be used. The selected exercise games will include Hula Hoop Plus, Penguin Slide, Soccer Heading, Table Tilt, Tightrope Walk, Ski Jump, and Step Up."
223532625|NCT07126977|OTHER|Functional Exercise Training|Our study will include exercises aimed at improving core stabilization, dynamic neuromuscular control, and pelvic mobility. Exercise selection will be tailored to individual needs, and the number of repetitions and duration will be adjusted based on the participant's progress. Preferred exercises will include movements such as bridge, dead bug, bilateral arm and leg lift, bear position, cat-camel, and pelvic clock.
223532626|NCT06934473|OTHER|GIP(3-30)NH2 / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
223532627|NCT06934473|OTHER|Saline (NaCl 0,9 %) (placebo)|Placebo (NaCl 0,9%)
223928514|NCT07037888|DRUG|Ketorolac|IV ketorolac intraoperative loading dose Ketorolac 10mg 1 tablet q6hrs to start on POD0
223928515|NCT07037888|DRUG|Control (Standard treatment)|hydrocodone-acetaminophen 5mg/325mg 1 tablet q6hrs PRN to start on POD0 30 tablets
223928516|NCT07037888|DRUG|Control (Standard treatment)|indomethacin 75mg 1 tablet QD to start on POD0 10 tablets
223928517|NCT07037888|DRUG|Control (Standard treatment)|diazepam 5mg 1-2 tablets q8hrs PRN to start on POD0 15 tablets
223928518|NCT07037888|DRUG|Omeprazole|20 mg qd
223928519|NCT07038629|DRUG|S1|PO, 40\~60mg，BID（d1-14，d22-35，two cycles)
224094403|NCT00427856|DRUG|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
224094404|NCT00427856|DRUG|Rituximab|Rituximab
224094405|NCT05173584|DRUG|Levalbuterol|Levalbuterol nebulizer solution 1.25mg/3ml with a total dose of 5 mg (12ml) for each patient.
224094406|NCT05173584|DRUG|Albuterol|Albuterol nebulizer solution 2.5 mg/3ml with a total dose of 0 mg (12ml) for each patient.
224094407|NCT03185546|OTHER|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
224282645|NCT02759549|BEHAVIORAL|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
224282646|NCT02759549|OTHER|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
224282647|NCT02759549|BEHAVIORAL|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
224282648|NCT05402787|OTHER|Virtual visit|A virtual visit will be made to mothers whose babies are hospitalized in the neonatal intensive care unit
223532628|NCT06934473|OTHER|GIP(1-42)|Agonist of the GIPR, GIP(1-42)
223928520|NCT07038629|DRUG|Iparomlimab|IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)
223928521|NCT07038629|RADIATION|Radiation|Concurrent Radiation, 1.8Gy/f, 28f;
223928522|NCT07038889|DEVICE|C-Mill VR+ by Motek|Participants perform treadmill-assisted walking while interacting with non-immersive, game-like environments displayed on screens attached to the treadmill.
223928523|NCT07038889|DEVICE|Walk-over-Ground|This intervention utilizes the HTC VIVE Pro 2 system for a realistic, fully immersive VR-assisted overground gait therapy. The immersive VR environment is designed to mimic real-world scenarios and challenges, enhancing the rehabilitation process by engaging patients in naturalistic gait activities.
224094408|NCT03185546|OTHER|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
224094409|NCT03185546|OTHER|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
224094410|NCT03185546|OTHER|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
224094411|NCT03185546|OTHER|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
223532629|NCT06941480|DIAGNOSTIC_TEST|PET/CT|Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT
223532630|NCT06941480|BIOLOGICAL|177Lu-DTPA-SC16.56|177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT
223532631|NCT07143695|DEVICE|Parasternal intercostal thickening fraction|Parasternal intercostal thickening fraction less than 6.5%
223532632|NCT07143695|DEVICE|Sham parasternal intercostal thickening|Ultrasound assessment only for purpose of blinding
223718083|NCT02077920|DRUG|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
223928524|NCT07038148|PROCEDURE|Stapled reversal of gastric bypass to sleeve gastrectomy utilising stapling technique.|This research entails a single-stage laparoscopic conversion of gastric bypass to sleeve gastrectomy. The procedure entails the closure of the gastrojejunostomy with an endo-stapler and the reconstruction of the stomach by resecting along the greater curvature to create a sleeve gastrectomy. An intraoperative leak test will be conducted using methylene blue. Patients are monitored postoperatively for at least 24 hours, with subsequent assessments of nutritional status, weight, gastroesophageal reflux disease (GERD) symptoms, and quality of life at 3 and 6 months.
223928525|NCT06751472|DIAGNOSTIC_TEST|VPS (Verbal Pain Score)|İt is a pain intensity determination system based on the system where there person tells a point between 0=(no pain) 10=( unbearable pain) and to describe their pain
223928526|NCT06751472|DIAGNOSTIC_TEST|WOMAC (Western Ontario and McMaster Universities Arthritis Index) scale|It includes 24 questions under three sub-headings as pain, stiffness and physical function
223928527|NCT06881147|BEHAVIORAL|Multimodal physiotherapy program|"Multimodal physiotherapy program of 6 weeks (3 times a week for 45 minutes), each session will include:~* Soft tissue mobilization of inoculated muscles;~* Stretching exercises of the inoculated muscles;~* Strengthening of antagonist muscles;~* Motor learning exercises (attentive strategies, feedback-based cervical active exercises).~Exercises will be progressively difficult (increase of active ROM) according to clinical improvements."
223718084|NCT02077920|DRUG|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
223928528|NCT06690788|BEHAVIORAL|Individual intervention condition (PreventT2)|PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.
224094412|NCT03185546|OTHER|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
224094413|NCT02237690|DRUG|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
224282649|NCT02147587|DRUG|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
224282650|NCT02147587|DRUG|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
224282651|NCT06617000|BIOLOGICAL|SCG101|Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
224282652|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
224282653|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
224282654|NCT02865941|DIETARY_SUPPLEMENT|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
224282655|NCT00660088|OTHER|Ketasyn|10g for 7 days, 20g for 7 or 14 days
224282656|NCT02184741|DRUG|GB-0998|Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.
224282657|NCT02184741|DRUG|Placebo|Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
224282658|NCT02246088|PROCEDURE|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
224282659|NCT02246088|PROCEDURE|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
224282660|NCT05785806|BEHAVIORAL|Skin to skin contact and co-parenting theory course|On the day before delivery, pregnant women and their husbands attend a course on the theory of skin contact and co-parenting to explain the role and importance of skin contact ; to understand the knowledge of co-parenting and parenting care ; to learn the communication method and future parenting plan based on the theory of co-parenting, and to learn the operation of skin contact with newborns after delivery.
224282661|NCT05785806|BEHAVIORAL|Skin to skin contact instruction manual and co-parenting theory brochure|According to reading and analyzing the literature on skin contact, summarize the content of skin contact operation guidance ; read and analyze the relevant literature of co-parenting theory, and summarize the theoretical knowledge and practical operation methods of co-parenting. Pregnant women and their spouses can check in time.
223718085|NCT02077920|DEVICE|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
223718086|NCT02077920|DEVICE|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
223928529|NCT06690788|BEHAVIORAL|Couple-based intervention condition (PreventT2 Together; couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP)|PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
223928530|NCT06717425|DRUG|PF-07976016|Taken once daily
223928531|NCT06717425|DRUG|Placebo|Taken once daily
223928532|NCT07039968|RADIATION|Spine Stereotactic Radiosurgery (SSRS)|A non-invasive procedure that uses highly focused, high-energy radiation beams to precisely target metastatic tumors in the spine. The procedure is delivered using advanced techniques like Intensity Modulated Radiotherapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT/RapidArc), which allow the radiation dose to conform tightly to the shape of the tumor. This approach maximizes the dose to the cancer while carefully sparing surrounding healthy tissues, especially the critical spinal cord. The entire course of treatment is delivered in a single session, guided by on-board imaging to ensure sub-millimeter accuracy.
223928533|NCT07037797|DIAGNOSTIC_TEST|Order of the FAST echography|Randomisation of the order in which probes are used
224094414|NCT03692416|DRUG|Ibuprofen|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
224094415|NCT03692416|DRUG|Prednisone|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
224094416|NCT03692416|DRUG|Methotrexate|"Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique."
224094417|NCT00815958|PROCEDURE|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
224282662|NCT05785806|BEHAVIORAL|Daily face-to-face skin to skin contact guidance during hospitalization|After delivery, face-to-face skin-to-skin contact guidance and co-parenting communication and practice were given to the parturient and her husband on a daily basis during hospitalization. Establish a daily fixed skin contact duration target, and the specific operation is freely allocated by both parents.
224282663|NCT05785806|BEHAVIORAL|Online punching skin to skin contact|Share common parenting related knowledge, daily skin contact reminders, emphasize mutual recognition and mutual support of parents, and conduct WeChat follow-up every two weeks to understand the physical and mental status of both parties and the growth of infants.
224282664|NCT05785806|BEHAVIORAL|Routine obstetric care|Routine prenatal training and postpartum education, including basic breastfeeding guidelines, touching, etc.
224282665|NCT00615849|PROCEDURE|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
224282666|NCT00263887|DRUG|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
224282667|NCT00263887|DRUG|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
224282668|NCT03862573|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
224282669|NCT03776734|OTHER|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
224282670|NCT05398835|BEHAVIORAL|Online interventions promoting HIV self-testing|1\) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
224282671|NCT00022841|DRUG|Pamidronate|
224282672|NCT03904901|DIETARY_SUPPLEMENT|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
224282673|NCT03904901|DIETARY_SUPPLEMENT|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
224282674|NCT03041207|BEHAVIORAL|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
224282675|NCT00277407|PROCEDURE|NAET with acupressure and/or chiropractic procedures|
224282676|NCT00003707|DRUG|gemcitabine hydrochloride|
224282677|NCT00003707|DRUG|tipifarnib|
224282678|NCT03691688|DRUG|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician's discretion
223718087|NCT04736030|BEHAVIORAL|Intervention|Twelve weekly sessions will be led by Ms. Schneider and Ms. Montañez supported by Drs. Arredondo and Ayala and student research assistants. Mothers and daughters will participate in weekly virtual 1.5-hour sessions that include didactic teaching, skill building (including PA parenting and communication skills training), interactive discussions, PA, and homework review (homework examples: 30-min walks, practicing communication strategies). Mothers and daughters will attend sessions together, with 10-12 mother-daughter dyads participating in each series. Sessions 2-12 will include at least 30 min PA. Sessions will discuss strategies to engage in PA outside the sessions (goal of 60-min MVPA daily).
223928534|NCT05812027|DIAGNOSTIC_TEST|Tumor and HLA Profiling|HLA genotyping and tumor tissue profiling for certain tumor-associated antigens and HLA LOH.
223928535|NCT06715397|OTHER|No intervention|No intervention
223928536|NCT07038460|DRUG|Limertinib+sintilimab+chemotherapy|Experimental group patients receive Limertinib for 6 weeks. Within 7 days thereafter, imaging assessment will be performed. If no progression is observed, experimental group patients discontinue therapy for 1 week, then receive Sintilimab + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.
223928537|NCT07038460|DRUG|Limertinib+chemotherapy|Control group group patients receive Limertinib for 6 weeks. Within 7 days thereafter, imaging assessment will be performed. If no progression is observed, control group patients receive Lilotinib for next 9 weeks + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.
223928538|NCT07038460|PROCEDURE|surgery|The surgical procedure may involve minimally invasive surgery (video-assisted thoracoscopic surgery, robot-assisted surgery) or open thoracotomy. The surgical methods include lobectomy, combined lobectomy, pneumonectomy, sleeve resection, and ipsilateral systematic mediastinal lymph node dissection (for left-sided tumors, stations 4L, 5, 6, 7, and 9 should be included; for right-sided tumors, at least stations 2R, 3A, 4R, 7, and 9 should be included).
223928539|NCT07038460|DRUG|Osimertinib|Adjuvant treatment with Osimertinib for 2 years
223928540|NCT07039994|OTHER|Standard intervention|"Routine intervention in the service:~* Good control: In-person visit every 4 weeks.~* Poor control: Nurse calls at 1 week to assess and decide on treatment changes, visits, or referral. In-person visit by need or after 1 month."
223928541|NCT07039994|OTHER|E-health intervention|"Combined system using ICT and in-person care. It includes spontaneous use (symptom tracking, messages, reminders via app) and scheduled use:~* Good symptom control: Basic Telematic Evaluation (BTE) at 1 month. If stable, videoconference at 2 months, BTE at 3 months, and in-person visit at 4 months.~* Poor symptom control: BTE at 1 week. If warning signs appear, a nurse evaluates by phone and may adjust treatment, schedule a visit (in-person or video), or refer to emergency care. In-person visit by need or after 1 month."
223928542|NCT06729190|DEVICE|biofeedback|biofeedback therapy and FES at anti spastic muscles(shoulders flexors, elbow and wrist extensors) while doing specific exercises (including basic reaching, grasping, carrying, release
223928543|NCT06729190|PROCEDURE|Physical therapy program|Flexibility exercises for shorted muscles and spastic muscles, Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles, Postural control exercise in different positions and different surfaces, General endurance training, Exercises to facilitate hand function, Exercises included, grasping a cube, transferring cube, removing and placing pegs, releasing cube and placing cubes. Strengthening exercises of the intrinsic muscles of the hand
223928544|NCT06884969|BEHAVIORAL|Test of Sensory Function in Infants|It was planned to use the Test of Sensory Function in Infants to evaluate the sensory development of infants. Test of sensory function in infants is frequently used to evaluate the sensory processing functions of infants aged 4-18 months.
223928545|NCT06884969|BEHAVIORAL|Peabody Motor Development Scale-2|Peabody Motor Development Scale-2 was planned to be used to assess motor development. Peabody Motor Development Scale-2 was designed to determine developmental delays in children between 0-72 months.
223928546|NCT06882603|OTHER|hydrodissection|5 ml of 0.9% isotonic sodium chloride solution will be applied to the intracarpal area median nerve area once with the USG probe.
223928547|NCT06882603|OTHER|Steroid injection|1 ml of 3mg/ml betamethasone sodium phosphate or 3mg/ml betamethasone acetate solution will be applied with the USG probe.
224094418|NCT00815958|PROCEDURE|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
223718088|NCT03472183|OTHER|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
223718089|NCT05013684|OTHER|Particle Repositioning Maneuver|treatment with Particle Repositioning Maneuver
223718090|NCT02006719|BIOLOGICAL|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
223718091|NCT02006719|OTHER|Placebo|Placebo injection
223718092|NCT01132430|BEHAVIORAL|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
223718093|NCT01132430|BEHAVIORAL|Usual care|Standard medical care within 4-6 week period
223718094|NCT04497831|DRUG|Morphine hydrochloride|5 mg milligram(s) per day per two days of dosage
223718095|NCT04497831|DRUG|Placebo|Inhalation use
223718096|NCT00541710|DIETARY_SUPPLEMENT|genistein|pills of 27 mg, twice per day for 12 months
223718097|NCT00541710|DIETARY_SUPPLEMENT|placebo|sugar pills twice per day for 12 months
223718098|NCT04841460|DIETARY_SUPPLEMENT|Low-fat ground beef|5% fat ground beef
223718099|NCT04841460|DIETARY_SUPPLEMENT|High-fat ground beef|25% fat ground beef
223718100|NCT00565045|DEVICE|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
223928548|NCT06882603|OTHER|Exercise|Performed with 6 different consecutive positions of the hand and wrist. 1- Wrist in neutral position, fingers and thumb in flexion 2- Wrist in neutral position, fingers and thumb in extension 3- Wrist and fingers in extension, thumb in neutral position 4- Wrist, fingers and thumb in extension 5- Forearm in supination, wrist and fingers in extension 6- Forearm in supination, wrist and fingers in extension, gentle stretching is applied to the thumb with the hand. Tendon gliding exercises: Performed to ensure isolated mobility of the flexor digitorum superficialis and profundus muscles in the canal. Tendon gliding exercises are performed in 5 different consecutive positions, respectively. 1- Fingers straight 2- Fingers in hook position 3- Fingers in fist position 4- Fingers in table shape position 5- Fingers in straight fist. The exercises will be asked to be done 10 times, once a day, every day for 3 weeks.
223928549|NCT06722534|DRUG|Celecoxib 400mg|Participants in the interventional group receive 200 mg celecoxib twice daily for 6 months
223928550|NCT06722534|DRUG|Placebo|Participants in the control group receive identically appearing placebo twice daily for 6 months
223928551|NCT06722807|PROCEDURE|sutureless, clampless partial nephrectomy|All subjects will undergo a clampless, sutureless robotic partial nephrectomy.
223928552|NCT06889311|PROCEDURE|Subperiosteal hyaluronic acid injection overlay technique|using subperiosteal hyaluronic acid injection overlay technique showed promising results in treating lost interdental papilla which needs further assessment to its clinical effectiveness
223928553|NCT06889311|PROCEDURE|Tunneling with connective tissue graft.|Connective tissue graft base techniques have been for years the most predictable approach for treatment of interdental papillary defects. CTG can as a biological filler which enhances flap stability and wound strength. CTG also can promote coagulation cascade and protects the maturating fibrin clot (Tavelli et al. 2019). Moreover, CTG results in significant increase in gingival tissue thickness which positively improve tissue fill and soft tissue volume creeping which influence esthetic outcomes following periodontal regeneration
223928554|NCT06888674|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Neoantigen Therapeutics Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
223928555|NCT06888674|DRUG|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m², administered intravenously over 30 minutes on Day 1 and Day 8; Capecitabine: 1650-2000 mg/(m²·day), divided into two daily oral doses from Day 1 to Day 14.~Treatment cycles repeat every 3 weeks for 8 cycles, with the actual number of cycles determined by the investigator based on comprehensive evaluation of the patient's physical status, disease progression, and adverse reactions."
223928556|NCT06888674|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion, every 3 weeks
224282679|NCT03691688|DRUG|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician's discretion
224282680|NCT05631535|OTHER|Intensive lifestyle change program with a very-low-energy diet|The intervention will consist of two phases. In the first phase, the participants receive weekly visits for two months. During these visits, a nutritionist will take the participants' weight and abdominal circumference measurements, and each one will receive a meal plan with a very low-energy diet (800 kcal/d). The second phase will implement in the third and fourth months, and nutritional counseling will continue to be provided every week in the third and biweekly in the fourth month. In this second phase, a gradual reintroduction to low-energy dietary meal plans (1200-1800 kcal/d) will perform. In addition, a specially adapted Diabetes Prevention Program for a very low-energy diet will implement.
224282681|NCT05631535|OTHER|Intensive lifestyle change program with a low-energy diet|The structure (frequency of nutritional counseling, number of sessions, time of sessions, etc.) in this group will be the same as that of the intervention group, and a modified Diabetes Prevention Program will also provide. From the beginning of the study will recommend meal plans with a low-energy diet (1200-1800 kcal).
224282682|NCT04088747|DIAGNOSTIC_TEST|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
224282683|NCT00055484|DRUG|zonisamide|
224282684|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously
223718101|NCT04575116|DRUG|Tafamidis free acid tablet|12.2 mg tafamidis free acid tablet
223928557|NCT06723899|OTHER|CanWork|CanWork is an online, occupational therapy intervention to develop knowledge and skills to manage cancer-related symptoms that interfere with return to work. It consists of five, 90-minute group-based modules and an individual meeting between the occupational therapist facilitator and each participant. Each of the five-week group-based modules consists of two components: (i) education and peer-led discussion of cancer-related symptom management and supports available to manage difficulties in work and (ii) goal setting to facilitate application of knowledge and skills to work-related activities. Weekly topics include managing fatigue in work, understanding cancer-related cognitive impairments, strategies for managing physical and mental health in work and effective communication with employers and colleagues. The individual meeting between each participant and the occupational therapist is focused on designing a tailored return to work plan for each participant.
223928558|NCT06724692|OTHER|Ultra-processed breakfast|With this intervention, participants will consume ultra-processed foods
223928559|NCT06724692|OTHER|Low-processed breakfast|With this intervention, participants will consume low-processed foods
223928560|NCT06395415|BEHAVIORAL|EQUIP|The intervention is delivered directly to participants' mobile phones using the Insight® platform, which allows for the implementation of assessments and interventions. Insight has been used in prior mHealth studies and allows for the delivery of tailored content based on parameters, such as intervention stage. The intervention has two stages: 1) Motivational enhancement (weeks 1-2) and 2) Skills and information (weeks 3-6). The first stage of messages will utilize personalized feedback and motivational interviewing prompts, while the second stage will provide health information on ENDS and skills, such as deep breathing. Content is tailored to motivation level (low/medium or high) and dual use status.
223928561|NCT06395415|BEHAVIORAL|Standard Care|Those in the standard advice group will be given offered a sample of NRT, instruction on its use, and will be encouraged to use in conjunction with standard web-based resources on ENDS and cessation over the course of a ten minute walk-through with study staff.
223928562|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (400mg of nitrate per serving)|Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
223928563|NCT04299945|DIETARY_SUPPLEMENT|concentrated beetroot juice (trace amounts of nitrate per serving)|Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
223928564|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (Zepbound) placebo"
223928565|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound NA-931 Placebo (oral, daily)"
223928566|NCT06732245|DRUG|Tirzepatide|"Tirzepatide (s.c. weekly), a Glucagon-like peptide-1 (GLP-1) receptor agonist~• Other Names:~* Mounjaro~* Zepbound~NA-931 Placebo (oral, daily)"
223928567|NCT06732245|DRUG|NA-931|"NA-931, an oral, daily~• A quadruple receptor agonist"
223928568|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
223928569|NCT06732245|DRUG|NA-931|"NA-931 (oral daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
223928570|NCT06732245|DRUG|NA-931 150 mg + no Tirzepatide|NA-931 150 mg + no Tirzepatide
223928571|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
223928572|NCT06732245|DRUG|NA-931|"NA-931 (oral, daily), a quadruple receptor agonist~Tirzepatide (s.c. weekly)~* Glucagon-like peptide-1 (GLP-1) receptor agonist~* Other Names:~  * Mounjaro~ * Zepbound"
223928573|NCT06733597|PROCEDURE|Cement|The cemented approach includes inserting cement into the femur and tibia prior to setting the prosthetic.
223928574|NCT06733597|OTHER|Cementless|The non-cement approach uses a different type of prosthetic that is placed tight against the bone and requires no other fixation material.
223928575|NCT06733597|PROCEDURE|Manual Surgery|The manual approach is the surgeon determining prosthetic placement using techniques developed during training.
223928576|NCT06733597|PROCEDURE|Robotic Surgery|The haptic robotic assisted approach uses a computer and robot to determine specific placement of the prosthetic.
223928577|NCT06737328|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK) tip followed by copious irrigation with sterile saline
223928578|NCT06734182|DRUG|Envafolimab injections+intravenous Disitamab Vedotin+carboplatin|Biological: Envafolimab 300 mg by subcutaneous injections every 3 weeks (Q3W), given on cycle day 1; Biological: Disitamab Vedotin 2.5mg/kg by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;
223928579|NCT06896110|DRUG|Nivolumab|Intrathecal nivolumab will be given at a flat dose of 40 mg
223928580|NCT06896110|DRUG|Azacitidine (AZA)|Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design.
223928581|NCT06896110|PROCEDURE|lumbar puncture|Lumbar puncture for intrathecal delivery and collection of CSF
223928582|NCT06896110|DIAGNOSTIC_TEST|MRI Contrast|MRI Brain and full Spine (with and without contrast) will be performed prior to enrollment. During trial therapy, MRI Brain (with and without contrast) will be performed after cycle 1 and after that every 8 weeks (e.g. after cycle 3, cycle 5, etc…)
223928583|NCT03213457|DRUG|Estradiol/Norethindrone Acetate|Tablets
223928584|NCT03213457|DRUG|Placebo for Elagolix|Tablet
223928585|NCT03213457|DRUG|Elagolix|Tablet
223928586|NCT03213457|DRUG|Placebo for E2/NETA|Tablets
223928587|NCT06740539|PROCEDURE|Catheter ablation of atrial fibrillation|Catheter ablation of atrial fibrillation
223928588|NCT06745076|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223928589|NCT06745076|PROCEDURE|Computed Tomography|Undergo CT scan
223928590|NCT06745076|DRUG|Dacarbazine|Given IV
223928591|NCT06745076|DRUG|Doxorubicin|Given IV
223928592|NCT06745076|PROCEDURE|Echocardiography Test|Undergo echocardiography
224282685|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously
223718102|NCT04575116|DRUG|Tafamidis meglumine capsule|20 mg tafamidis meglumine soft gelatin capsule
223928593|NCT06745076|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223928594|NCT06745076|BIOLOGICAL|Nivolumab|Given IV
223928595|NCT06745076|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223928596|NCT06745076|DRUG|Vinblastine|Given IV
223928597|NCT06745076|OTHER|Questionnaire|Complete questionnaire
223928598|NCT06843057|OTHER|Kinesio taping|Kinesio taping is a therapeutic technique that involves applying a special elastic tape to the skin to support and stabilize muscles and joints without restricting their range of motion.
223928599|NCT06843057|OTHER|Mulligan's mobilization with movement techniques|Mulligan's mobilization with movement (MWM) techniques involve the application of a sustained manual force or glide to a joint while the patient actively performs a movement that is typically painful or restricted.
223928600|NCT06843057|OTHER|Conventional physiotherapy|Mulligan Mobilization with Movement, Ultrasound Therapy, Active assisted ROM exercises for shoulder, Capsular Stretching exercises
223928601|NCT06820073|BEHAVIORAL|Global Postural Reeducation (RPG) using the K-Stretch hammock|The intervention involves Global Postural Reeducation (RPG) using the K-Stretch hammock. This therapeutic approach focuses on sustained stretching of muscle chains to improve posture, reduce cervical and lumbar musculoskeletal discomfort, and enhance flexibility. Participants complete 12 sessions over six weeks, with two 30-minute sessions per week. Each session includes guided exercises that target muscle imbalances, improve alignment, and alleviate tension caused by prolonged sedentary behavior. The K-Stretch hammock provides support for optimized stretching and alignment during the exercises.
223928602|NCT06817473|BEHAVIORAL|CAST|CAST is a transdiagnostic cognitive behavioral therapy (CBT)-based protocol designed to address elevated AS, particularly the amplification of cognitive stress symptoms including perceived confusion and memory problems. CAST is a fully computerized, 1-hour intervention. CAST contains video animation and audio narration throughout, as well as interactive features (e.g., brief quizzes to promote comprehension). Procedures draw heavily on standard CBT techniques; AS, a core vulnerability for anxiety and depression is targeted using these procedures. In this study, participants complete CAST as a group alongside other participants.
223928603|NCT06817473|BEHAVIORAL|HET|The HET protocol covers standard healthy lifestyle behaviors as well as broad coping strategies to address stress. HET is a fully computerized 1-hour control condition focused on increasing healthy behaviors and decreasing unhealthy behaviors. Content includes healthy eating, hydration, sleep and rest, stress management as well as other healthy lifestyle tips. HET was administered in a group format for this study.
223928604|NCT06596356|DRUG|[14C] TS-172|Subjects will receive single dose of about 30 mg of TS-172 containing 1 MBq \[14C\]TS-172 as an oral solution
223928605|NCT06879860|PROCEDURE|3D Mesh Single-Suture Fixation|3D mesh fixation in 1 points
223928606|NCT06879860|PROCEDURE|3D mesh Non-FIxation|3D mesh fixation with non-flxation
223928607|NCT06882161|BIOLOGICAL|Acetal resin|Effect of acetal resin versus Polyether ether ketone (PEEK) partial dentures on abutment teeth supporting structures in Kennedy class I mandibular partial denture cases
223928608|NCT06746467|DEVICE|pentacam|evaluate corneal changes by pentacam
223928609|NCT06744894|DRUG|Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy|Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.
223928610|NCT06746077|OTHER|No intervention|No intervention
223928611|NCT06753656|PROCEDURE|Open Surgery|Open surgery technique: A longitudinal incision is made over the lateral malleolus, followed by sharp dissection down to the bone. The fracture is reduced under direct visualization and fixed with a plate and screws.
223928612|NCT06753656|PROCEDURE|Minimally Invasive Surgery|Closed surgery technique: A 2-3 cm longitudinal incision is made distal to the lateral malleolus to allow for plate placement. A periosteal elevator is used to create a pathway for the plate. The fracture is reduced in a closed manner using reduction clamps, and the plate position is confirmed fluoroscopically. A second longitudinal incision is made proximal to the fracture, and the plate is temporarily fixed with Kirschner wires. The plate is then used as an external guide, with screws placed through mini-incisions. The fracture is fixed with the plate-screw system in a minimally invasive manner.
223928613|NCT06769620|DRUG|ORT247|ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.
223928614|NCT06769620|DRUG|Placebo|Placebo consists of normal saline
223928615|NCT06768931|OTHER|Biolosion (oral probiotic compound preparation)|Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.
224282686|NCT04934852|DRUG|Ephedrine|When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
223928616|NCT06775145|DEVICE|HD-R_cDC+cTBS & sham-L_aDC+iTBS|HD-tES inhibitory waveform (cDC+cTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
223928617|NCT06775145|DEVICE|sham-R_cDC+cTBS & HD-L_aDC+iTBS|Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
223928618|NCT06775145|DEVICE|HD-R_cDC+cTBS & HD-L_aDC+iTBS|HD-tES inhibitory waveform (cDC+cTBS) applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
224282687|NCT03068949|BIOLOGICAL|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
224282688|NCT03068949|BIOLOGICAL|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
224282689|NCT03068949|BIOLOGICAL|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
224282690|NCT03068949|BIOLOGICAL|Fluzone HD|Fluzone HD Trivalent High Dose Influenza Vaccine .5 mL given intramuscularly
224282691|NCT01519947|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
223928619|NCT06775145|DEVICE|sham-R_cDC+cTBS & sham-L_aDC+iTBS|Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
224282692|NCT02427087|BEHAVIORAL|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
224282693|NCT02427087|BEHAVIORAL|Healthy Diet|Diet group (21) Recommendation for healthy diet.
224094419|NCT03084133|BEHAVIORAL|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
224282694|NCT03633552|DRUG|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
223928620|NCT06772545|PROCEDURE|Epidural Analgesia|Patients in the EA group underwent epidural anesthesia after admission to the operating room. Following successful epidural puncture, 3 ml of 2% lidocaine was administered. Once the block level was confirmed, the epidural analgesia pump was activated, delivering 8 ml/h of 0.1% ropivacaine.
223928621|NCT06772545|DEVICE|Paravertebral Block|Using an in-plane technique, the puncture needle was advanced from lateral to medial under real-time ultrasound guidance to the target paravertebral space, passing through the intercostal fascia, avoiding the parietal pleura, and positioning the needle tip superior to the costotransverse ligament. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was slowly injected in divided doses, observing for the spread of the local anesthetic to ensure adequate distribution within the PVS for effective block.
223928622|NCT06772545|DEVICE|Transversus Abdominis Plane Block|The plane of blockade and whether to perform a single or double injection technique were determined based on the incision location. Under real-time ultrasound guidance, the puncture needle was advanced to the target transversus abdominis plane. After confirming needle tip placement, 10 mL of 0.5% ropivacaine was injected slowly in a fractionated manner while observing the local anesthetic spread to ensure effective blockade.
223928623|NCT06772545|DEVICE|patient-controlled intravenous analgesia (PCA)|The patient-controlled analgesia (PCA) device was programmed to deliver bolus doses of 15 μg fentanyl, with a 10-minute lockout period and no background infusion. The PCA solution consisted of 1 mg fentanyl and 8 mg of tropisetron mixed in 100 mL of normal saline.
223928624|NCT06056141|DRUG|Misoprostol 200mcg Tab|Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
223928625|NCT06056141|DEVICE|Foley Catheter|Transcervical Foley catheter (silicone, size 20F with 30ml balloon)
224094420|NCT02704598|DRUG|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
224282695|NCT01736787|DIETARY_SUPPLEMENT|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
224282696|NCT01736787|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
224282697|NCT00618033|PROCEDURE|Hemodialysis|varying concentration of glucose in dialysate
224282698|NCT03795584|PROCEDURE|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
224282699|NCT01028911|DRUG|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
224282700|NCT01028911|DRUG|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
224282701|NCT01992016|DRUG|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
224282702|NCT04624152|BEHAVIORAL|Soccer heading|A standardized and reliable soccer heading protocol will be used to induce subconcussive impacts for the experiment. A triaxial accelerometer (Triax Technologies, Norwalk, CT) embedded in a head-band pocket and positioned back of the head to monitor linear and rotational head accelerations. A JUGS soccer machine (JUGS Sports, Tualatin, OR) will be used to simulate a soccer throw-in with a standardized ball speed of 25 mph across all groups. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practices and games. Participants will stand approximately 40ft away from the machine to perform the heading. Participants will perform a total of 10 headers at a rate of 1 header per minute and will be instructed to direct the ball back towards the JUGS machine. Previous uses of this soccer heading model have reported an average peak linear acceleration per header of 14.5 to 33.5 g.
224282703|NCT01704937|DRUG|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
224282704|NCT05669807|DRUG|Camrelizumab|200mg d1, the first day, every 14 days as a cycle
224282705|NCT05669807|DRUG|Albumin-Bound Paclitaxel|100 mg/m2, the 1st, 8th and 15th days, every 28 days as a cycle
224282706|NCT05669807|DRUG|Irinotecan|180 mg/m2, the first day, every 14 days as a cycle
224282707|NCT00530348|BIOLOGICAL|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
224282708|NCT00530348|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
224282709|NCT03292263|DRUG|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
223928626|NCT06758258|DEVICE|Negative Pressure Wound Therapy|"Preparations for NPWT:~1. Impressions \& Model:~   Lower jaw impressions were taken with alginate and modified trays for optimal tissue recording.~   Dental plaster models were created.~2. Splint Fabrication \& Connection:~2mm hard splints were thermoformed and modified for vacuum. Intraoral splint fit was assessed, and soft acrylic ensured an airtight seal. The irrigation hose was connected to the splint via cyanoacrylate adhesive. 3. NPWT Application: The physiodispenser pump was operated in reverse at reduced power (10-20%). Three 1-hour NPWT sessions were performed."
223928627|NCT06758258|DEVICE|Sham Therapy|The same preparations will be conducted for the sham application arm, except that the peristaltic pump of the physiodispenser will remain inactive during application.
223928628|NCT06757998|PROCEDURE|Mesh|Compare between On-lay versus pre-peritoneal hernioplasty in incisional lumbar herni
223928629|NCT06756867|OTHER|hand massage with violet oil|In this study, individuals receiving hemodialysis treatment will be massaged with 2% violet oil for 5-7 minutes on the hand on the non-fistula arm during the dialysis session, 3 times a week for six weeks.
223928630|NCT06756867|OTHER|hand massage with jojoba oil|Hand massage with jojoba oil for hemodialysis patients 3 times a week for 6 weeks
223928631|NCT06757829|BEHAVIORAL|inspiratory muscle training and acupucnture like transcutanoeus electrical nerve stimulation|sickle cell disease patients whose number will be 20 patients will be trained with IMT (threshold inspiratory muscle training) and treated with AC-tens. The number of sessions per week will be three sessions for IMT or AC-tens for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles. Also the session of AC-tens will be 45 minute on bilateral Ex-B1 acupoint. the parameters of AC-tens will be four hertz and 200 microsecond pulse duration.
223928632|NCT06757829|BEHAVIORAL|inspiratory muscle training|sickle cell disease patients whose number will be 20 patients who will trained with IMT (threshold inspiratory muscle training). The number of sessions per week will be three sessions for IMT for 12 weeks. the IMT will be performed for six sets of respiratory training cycles and the set will contain 10 respiratory cycles.
223928633|NCT06757816|PROCEDURE|accessory rod and iliac fixation for distal augmentation for S1 fixation.|patients who were admitted to the spine unit and needed extension of fixation for L5 S1 fusion due to failed previous surgery, instability, or degenerative changes ,infection, tumors and pseudoarthrosis.
223928634|NCT06749665|DRUG|polidacanol 3%|Aethoxysklerol 3%,60mg/ ml ampoule, kreussler pharma, Germany
223928635|NCT06749665|BIOLOGICAL|candida antigen|delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart
223928636|NCT06749613|DIETARY_SUPPLEMENT|digestive enzymes|A jar or single-dose sachets containing the digestive enzymes in the form of powder will be provided to each patient at the study entry. Patients will be instructed to use the powder formulation according to manufacturer instructions and according to the meals that they consume per day, for 1 month. Participants will be asked to return the jar or the single dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned. To reduce the placebo effect, patients will be misinformed that half will take a placebo formulation, randomly. Participants will be asked to return the jar or the single-dose sachets with the remaining product to assess compliance either by weighting the jar or by counting the number of single-dose sachets returned.
223928637|NCT06749535|RADIATION|group 1|The aim of my study, we should diagnose diabetes on time. If diabetes mellitus untreated or uncontrolled for a long they directly affect all over the body, mostly they caused chronic disease due to hyperglycemia that damages the blood vessels. Rapture or damages the blood vessels of the lung causes COPD.
223928638|NCT06750471|BIOLOGICAL|Dupilumab|Dupilumab is an anti-IL 4-13 biologic therapy that has been recently approved for use in recurrent chronic rhinosinusitis with nasal polyposis.
223928639|NCT06748105|DRUG|Dapagliflozin (DAPA)|"Participants will receive 10mg/day of dapagliflozin orally. The administration will occur within a synchronous range, meaning that the time difference between dapagliflozin administration and glucocorticoid administration should not exceed 12 hours."
223928640|NCT06749561|DIAGNOSTIC_TEST|Group 1|To Compare the safety and effectiveness of boyh types
223928641|NCT06756269|BIOLOGICAL|Medium dose for 15-HPV vaccine|Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
224094421|NCT02704598|DRUG|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
224094422|NCT01422954|DRUG|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
224094423|NCT01422954|DRUG|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
224282710|NCT03292263|DRUG|Nivolumab|iv infusion 100 mg on day -3, +17
224282711|NCT03292263|PROCEDURE|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
224282712|NCT04364763|DRUG|RBT-9 (90 mg)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
224282713|NCT04364763|DRUG|0.9% sodium chloride (normal saline)|Subjects will receive a single dose and study duration will be approximately 60 days per subject.
224282714|NCT04192929|DEVICE|Narrow band imaging|Blue light is used during withdrawal phase instead of the regular white light to highlight surface changes
224282715|NCT04192929|OTHER|Chromoendoscopy|Indigo carmine will be sprayed during withdrawal phase of colonoscopy
224282716|NCT04192929|OTHER|High definition white light endoscopy|High definition equipment will be used to perform colonoscopy
224282717|NCT05489796|DRUG|Fentanyl selector|Selector (1 ml; Lock out 10 min): Fentanyl 200 mcg + N/S 16 ml = total 20 ml
224282718|NCT05489796|DRUG|Fentanyl continuous|Continuous (2 ml/hr): fentanyl 700 mcg + N/S 86 ml = total 100 ml
224282719|NCT05489796|DRUG|Ketorolac continuous|Continuous (2 ml/hr): Ketorolac 180 mg + N/S 94 ml = total 100 ml
224282720|NCT05971524|DIETARY_SUPPLEMENT|6-BT|2,4 or 8mg of 6-BT once daily for 4 weeks
223928642|NCT06756269|BIOLOGICAL|High dose for 15-HPV vaccine|Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
223928643|NCT06756269|BIOLOGICAL|Placebo|Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
223928644|NCT06756269|BIOLOGICAL|9-HPV vaccine|Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
223928645|NCT06755515|DRUG|Rulonilimab|"Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles."
223928646|NCT06755515|DRUG|Placebo|"Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles."
223928647|NCT06755515|DRUG|cisplatin/carboplatin + paclitaxel ± bevacizumab|cisplatin/carboplatin + paclitaxel ± bevacizumab
223928648|NCT06754800|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
223928649|NCT06751524|DRUG|Botensilimab|Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL).
223928650|NCT06751524|DRUG|Balstililmab|Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL).
223928651|NCT06751953|COMBINATION_PRODUCT|Conventional third-line therapy|Conventional third-line therapy includes oral chemotherapy drugs and/or targeted cancer drugs. The medication, dosage and treatment cycle of oral chemotherapy drugs and/or targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances.
223928652|NCT06751953|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223928653|NCT05178472|OTHER|Immunotherapy|Receive SOC immunotherapy
223928654|NCT05178472|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223928655|NCT05178472|PROCEDURE|Vertebroplasty|Undergo vertebroplasty
223928656|NCT06757257|DRUG|fostamatinib|oral administration
223928657|NCT06756789|PROCEDURE|Laparoscopic Roux-en Y Gastric bypass (RYGB)- Conventional approach|The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, standard limb lengths of 75cms BP limb and 125cms Alimentary limb were measured and performed, irrespective of the total bowel length
223928658|NCT06756789|PROCEDURE|Laparoscopic Roux-en Y Gastric bypass (RYGB)- Tailored approach|The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, limb lengths are tailored according to the total small bowel length, 1/3rd of the total bowel length is measured and in that 3/8th and 5/8th were kept as BP limb and alimentary limb respectively.
223928659|NCT06757985|PROCEDURE|a clinically guided resuscitation protocol,|a clinically guided resuscitation protocol, derived from EGDT and modified to match with the latest survival sepsis campaign guidelines
223928660|NCT06757985|PROCEDURE|a transthoracic bedside focused echocardiographic assessment|a transthoracic bedside focused echocardiographic assessment of the patient will be done, as a baseline ECHO in a three-step approach to monitor hemodynamics using Logiq P7, S5-1 ECHO probe;
224094424|NCT01422954|BIOLOGICAL|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
224094425|NCT01422954|BIOLOGICAL|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
224094426|NCT01422954|DRUG|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
224094427|NCT04373460|BIOLOGICAL|SARS-CoV-2 convalescent plasma|SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
224094428|NCT04373460|BIOLOGICAL|Plasma from a volunteer donor|Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.
224094429|NCT03103893|DRUG|Rapamycin|topical formulation
224094430|NCT05320575|DRUG|Zanubrutinib|The dosage of zanubrutinib is 160mg twice a day (80mg twice a day for patients over 75 years old) for 2 months. The remission rate is evaluated after treatment. If it is above PR, continue the dose maintenance treatment.
224282721|NCT05971524|DIETARY_SUPPLEMENT|Placebo|A placebo capsule once daily for 4 weeks
224282722|NCT02359864|RADIATION|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
224282723|NCT02359864|RADIATION|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
224282724|NCT04937738|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
224282725|NCT04937738|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
224282726|NCT04937738|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
223532633|NCT07139483|DEVICE|Trans Direct-Cranial Stimulation (tDCS)|The tDCS electrodes will be inserted into 5×7 cm (35 cm2) sponges soaked with saline (0.9 M) and placed as follows: anode over the M1 contralateral to the amputated limb (adjusted based on lower/upper amputation), and cathode over the forehead, contralateral to the anode (ipsilateral to amputated limb). Total stimulation duration will be 20 min, with a rise and decline time of 30 sec and stimulus intensity of 1.5 mA for the real tDCS real. The intensity of 1.5 mA is in the midrange of recommended intensities (1-2 mA) and supports successful blinding. The sham tDCS will be identical to the real tDCS, except no current will be applied. However, as recommended, during the first and last 30 sec, the current will be ramped up to 1.5 mA and immediately back to 0 to induce scalp sensations similar to those in real tDCS, further supporting blinding. The Mini-CT tDCS Stimulator device has been developed for home use and allows double-blind administration.
223928661|NCT06758284|OTHER|Laughter Yoga|The first component of the intervention is laughter therapy, which is a combination of warm-up exercises, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy via WhatsApp video call. Laughter yoga will be a single session and will last approximately 30 minutes.
223928662|NCT06757387|DRUG|chidamide and golidocitinib|Enrolled patients will receive combination therapy with golidocitinib (150 mg QD or 150 mg QOD) and chidamide (20 mg BIW or 25 mg BIW)； If the MTD is determined at Dose Level 1 (chidamide 20 mg BIW / golidocitinib 150 mg QD), Dose Level 0 (chidamide 20 mg BIW / golidocitinib 150 mg QOD) will be further investigated. If the MTD is not established after escalating to Dose Level 2 (chidamide 25 mg BIW / golidocitinib 150 mg QD), the recommended Phase 2 dose (RP2D) will be determined through investigator consensus.
223928663|NCT06756698|OTHER|conventional treatment plus music intervention|Each music therapy session will include 5 stages. In stage 1, an emotional assessment is conducted to observe the patient's current emotional experience and feelings (provide a VAD score), which lasts about 1 minute. In stage 2, relaxation exercises (breathing relaxation, progressive muscle relaxation, and imaginary relaxation) are conducted under the guidance of the therapist to the music corresponding to the relaxation target VAD, which lasts about 8 minutes. In stage 3, the patient independently selects the music and discusses it with the therapist, which lasts about 10 minutes. In stage 4, the patient listens to resource and positive-oriented music and discusses specific topics with the therapist, which lasts about 10 minutes. Finally, in stage 5, the therapist again conducts an emotional assessment of the patient and observes the patient's current emotional experience and feelings, which lasts about 1 minute.
223928664|NCT06756698|OTHER|conventional treatment|The conventional treatment group received DBT group therapy 5 times a week, each session lasting 1 hour, and also received individual personalized therapy twice a week.
223928665|NCT06756633|OTHER|Respiratory Function Test|A spirometer (microQuark, COSMED) will be used to assess respiratory functions. During a forced expiratory maneuver after a deep, full inspiration, airway and lung volumes are measured. During the measurement, a deep inspiration followed by a strong, fast, and continuous expiration until unable to exhale anymore should be performed. The expiration time should be at least 6 seconds, and if necessary, extended up to 15 seconds. More than eight repetitions at one time are not recommended.
223928666|NCT06756633|OTHER|Structured light plethysmography|Participants' thoracoabdominal movements will be assessed using the PneumoCare device that measures with the SLP technique. The evaluation begins with positioning participants wearing a white tank top, t-shirt, or with a bare chest. In our study, measurements will be taken with participants seated, supported by their backs, and their chest area exposed. The participant's age, height, and weight information are entered into the system. After the participant is positioned, the lights of the SLP measuring device are set up 90-100 cm away to encompass the chest area. The light field, which is in a checkerboard pattern, rectangular or square, should align its upper edge with the participant's clavicles and its lower edge with the anterior-superior iliac spine. During this measurement, the participant is asked to look straight ahead and breathe normally for five minutes. At the end of the measurement, the three-dimensional movements of the chest and respiratory parameters are recorded.
223928667|NCT06756633|OTHER|6 Minute Walking Test|"For Ambulatory Participants:~Exercise capacity will be assessed using the Six-Minute Walk Test (6MWT). The test will be performed according to ATS/ERS guidelines . The test involves walking for six minutes at a submaximal level in a 20-meter corridor. Blood pressure, heart rate, respiratory rate, oxygen saturation, and dyspnea, general fatigue, and leg fatigue according to the Modified BORG Scale (MBS) will be assessed before and after the test. Participants can stop and rest during the test. In such cases, the test duration is paused, and the rest time is recorded, then the test resumes from where it was left off. The distance walked in meters at the end of the test is recorded."
223928668|NCT06756633|OTHER|6-Minute Peg Board Ring Test|"For Non-Ambulatory Participants:~The 6-Minute Pegboard Ring Test will be used to assess upper extremity exercise capacity . Pre- and post-test evaluations of heart rate, blood pressure, respiratory rate, and MBS for dyspnea and fatigue will be made. The board used for the test has a total of 6 holes spaced 10 cm apart horizontally and another set of 6 holes 20 cm below aligned with the top row. There are four 20 cm long iron rods suitable for the holes. A total of 20 rings suitable for the iron rods will be used. The iron rods will be placed in the designated holes according to the patients' shoulder width. An adjustable chair will be used to suit the patients' heights, and the distance between the chair and the board will be adjusted according to arm length. Patients will be asked to place the rings from top to bottom and bottom to top with both hands simultaneously. The total number of rings placed in six minutes will be recorded in units."
223928669|NCT06756633|OTHER|Hand Grip Strength|Hand grip strength will be measured using a digital hand dynamometer (CAMRY Digital Hand Dynamometer) . The device handle will be adjusted according to the participants' hand size. The test is conducted while seated, with the dominant upper extremity in 90 degrees of elbow flexion. Participants are asked to squeeze the dynamometer as strongly as possible. The value displayed on the dynamometer is recorded. The measurement is repeated three times, and the average of the three measurements is taken to determine the participant's hand grip strength. The measurement takes five minutes and does not need to be repeated.
224282727|NCT04937738|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
224282728|NCT04937738|DRUG|Capecitabine|1000 mg/m² two times per day (BID), d1-14
224282729|NCT04937738|DRUG|Oxaliplatin|130 mg/m² d1 i.v. every 3 weeks
224282730|NCT01788709|OTHER|preparation cleaning solution|
224282731|NCT04496037|DRUG|Rituximab|See NCT03994783
224282732|NCT05040737|DEVICE|PS membrane versus PMMA membrane,|Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
224282733|NCT01223209|DRUG|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
224282734|NCT04924751|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine needle biopsy|Under endoscopic ultrasound guidance, fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions.
223928670|NCT06759272|GENETIC|CYP2C19 genotype-guided antiplatelet therapy|A panel of genes including CYP2C19\*2 (rs4244285) and CYP2C19\*3 (rs4986893) will be genotyped using the real-time PCR and the expected turnover time will be 48 hours. Patients who are identified to have reduced function CYP2C19 allele will receive 90 mg ticagrelor and patients with wild-type CYP2C19 allele will receive clopidogrel 75 mg in the next scheduled dose. The switching done from clopidogrel to ticagrelor is supported by Antiplatelet Therapy Switching Clinician Guideline, whereby in the maintenance or low risk phase, there is generally no need to administer a loading dose of ticagrelor; one can switch directly to ticagrelor maintenance dose 24 hours after the last dose of clopidogrel
223928671|NCT06759545|OTHER|Dietary MOH recommendations and daily addition of 42 ml (three tablespoon) at each morning of EVOOEH|Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) with addition of three tablespoon (42 ml) EVOOEH (up to 0.8% free acidity) per day at each morning for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)
223928672|NCT06759545|OTHER|Dietary MOH recommendations|Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)
224282735|NCT01239498|PROCEDURE|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
223928673|NCT06748625|BEHAVIORAL|Luci Coach-Assisted Intervention|The Luci intervention is a personalized behaviour change program delivered via an interactive web platform with the online support of a coach. It targets 3 lifestyle domains: physical activity, healthy diet and cognitive engagement. Participants will be encouraged to adopt a healthy lifestyle, as a means for cognitive decline/dementia risk reduction. This will be achieved by providing educational materials, practical tips and strategies, and by assisting participants outlining SMART goals to progressively adopt and maintain a healthier lifestyle. Coaching sessions will be held on a weekly basis from week 1 to 12, and every 2 weeks from week 13 to 24.
223928674|NCT06761092|DRUG|Nebulized Dexmedetomidine for Post-Anesthesia Delirium in Preschool Children|"Nebulization with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, administered before the induction of anesthesia in the reception area.~After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room"
223928675|NCT06761092|PROCEDURE|Nebulized 0.9% Normal Saline|Nebulization with normal saline 0.9% 3 ml, administered before the induction of anesthesia in the reception area. After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
223928676|NCT02382003|BEHAVIORAL|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
224094431|NCT05726214|OTHER|Exercise|"The face-to-face multicomponent program entailed:~* Strength training of upper and lower limbs. Familiarization phase included 2-3 exercises of 1-2 series and 8-12 repetitions per session. During the acquisition phase, 2-3 exercises of 2-3 series and 8-12 repetitions at a higher velocity. The resting time between sets lasted 1-3 minutes.~* Balance exercises included proprioception, agility and weight transfer exercises. Difficulty progressively increased by reducing the base of support, by including multidirectional displacements, walking on tiptoe or heels, body-weight transfer, dynamic exercises modifying the centre of gravity, and stressing postural muscles and by sensorial reductions.~* Flexibility exercises: Static stretching maintained during 20-30s carried out at the end of each session.~The Vivifrail exercise wheel corresponding to each participant was given according to their functional level type."
224094432|NCT05726214|OTHER|Recommendations for active lifestyle|After the baseline assessments, all participants received individualized counseling for following physically active lifestyle and reducing sedentary behaviors. Participants were encouraged to increase the physical activity time and intensity, and to hourly break the sedentary time while at home. The recommendations were transmitted verbally and through written material.
224094433|NCT02345798|PROCEDURE|Standard Follow-Up Care|Undergo usual care
224094434|NCT02345798|OTHER|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
224282736|NCT01239498|PROCEDURE|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
224282737|NCT01424098|BEHAVIORAL|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
223532634|NCT07139483|BEHAVIORAL|Mirror therapy|Participants will be seated with a portable mirror between their limbs so that the unaffected limb is reflected in the mirror. The participants will focus their attention on the reflection in the mirror and perform the following movements: plantarflexion and dorsiflexion and inversion and eversion of the foot, flexion and extension of the wrist and ulnar and radial deviation, for lower and upper limp amputates, respectively. The participants will continue performing the 2 sets of movements for 20 minutes (with short intermissions if needed)
224282738|NCT05567627|BIOLOGICAL|Genetic: GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
223532635|NCT07145333|DRUG|Topotecan - usual|Topotecan Capsule
223928677|NCT02382003|BEHAVIORAL|50/50 Cognitive Bias Modification - Interpretation|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.
223928678|NCT02382003|BEHAVIORAL|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
223928679|NCT02382003|BEHAVIORAL|Neutral Imagery Prime|At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
223928680|NCT03612258|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
223928681|NCT05684705|DRUG|BV100|Intravenous infusion
223928682|NCT02606526|BIOLOGICAL|BCG at birth|See previous description
223928683|NCT02606526|BIOLOGICAL|Control arm: Delayed BCG|See previous description
223928684|NCT06754293|BEHAVIORAL|rehabilitation exercise|"The intervention group will participate in a home-based exercise program alongside standard rehabilitation guidance. Patients will receive exercise materials developed by the intervention team, along with a detailed explanation of the program, including its components, specific exercises, and expected benefits.~The exercise program focuses on aerobic warm-ups and functional training, targeting key areas such as the hands, arms, shoulders, hips, legs, and back. It is designed to meet the rehabilitation needs of breast cancer patients undergoing endocrine therapy after surgery, addressing their unique challenges and enhancing recovery.~The intervention team, composed of specialists in breast cancer treatment, rehabilitation therapists, nursing experts, and methodologists, has created a professional exercise guidance manual. This manual provides detailed descriptions of exercise types, specific methods, and safety precautions. To ensure effective implementation, instructional videos have"
223928685|NCT06753032|DIAGNOSTIC_TEST|Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Myopic Participants|"Intervention Description: This group will be exposed to positive defocus induced by +2.00 D spectacle lenses. The lenses are designed to create optical blur to evaluate the effects on contrast sensitivity and visual fatigue. Measurements will be conducted at baseline, 2 weeks, and 4 weeks after exposure to assess changes in visual function."
223928686|NCT06753032|DIAGNOSTIC_TEST|Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Myopic Participants|"Intervention Description: This group will be exposed to negative defocus induced by -2.00 D spectacle lenses. The induced defocus will allow for the evaluation of its impact on contrast sensitivity and visual fatigue. Assessments will be carried out at baseline, 2 weeks, and 4 weeks."
223928687|NCT06753032|COMBINATION_PRODUCT|Positive Lens-Induced Defocus Using Spectacle Lenses (+2.00 D) for Non-Myopic Participants|"ntervention Description: This group will undergo positive defocus using +2.00 D spectacle lenses. The intervention aims to examine the effect of induced defocus on contrast sensitivity and visual fatigue in non-myopic participants. Data will be collected at baseline, 2 weeks, and 4 weeks."
223928688|NCT06753032|COMBINATION_PRODUCT|Negative Lens-Induced Defocus Using Spectacle Lenses (-2.00 D) for Non-Myopic Participants|Intervention Description: This group will experience negative defocus induced by -2.00 D spectacle lenses. The purpose is to evaluate how negative lens-induced defocus affects contrast sensitivity and visual fatigue in non-myopic participants. Measurements will be taken at baseline, 2 weeks, and 4 weeks.
223928689|NCT06800482|BEHAVIORAL|online outpatient follow-up|The investigators use Huayitong APP for the post-operating follow-up of participants with papillary thyroid cancer
223928690|NCT06752135|PROCEDURE|cervical biopsies/conization,|Diagnostic laparoscopy was used in selected cases to evaluate potential peritoneal spread.
223928691|NCT06752135|DIAGNOSTIC_TEST|imaging tests (TCTB, TC-PET, MRI)|The staging procedures included imaging such as chest CT, abdomino-pelvic MRI, and PET-CT to assess tumor spread and lymph node involvement.
224094435|NCT02345798|OTHER|Educational Intervention|Undergo video-assisted intervention
224094436|NCT02345798|OTHER|Quality-of-Life Assessment|Undergo quality of life assessment
224094437|NCT02345798|OTHER|Questionnaire Administration|Undergo questionnaire administration
224094438|NCT06154902|DRUG|Idecabtagene vicleucel|According to approved product label in France
224094439|NCT06154902|OTHER|Not treated|Eligible for idecabtagene vicleucel treatment but not treated
224094440|NCT03012581|DRUG|Nivolumab|Treatment
223532636|NCT07145333|DRUG|Topotecan - study|China Import Topotecan Capsule
223532637|NCT02556047|DEVICE|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N\&S
224094441|NCT00714779|DRUG|Fluoxetine|20-40 mg / day orally
224094442|NCT00714779|BEHAVIORAL|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
224094443|NCT01800942|DRUG|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
224094444|NCT00642642|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
224282739|NCT02396927|DEVICE|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
224282740|NCT02396927|DEVICE|2D HD laparoscopy|Placebo
223928692|NCT06752135|DRUG|neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel)|Patients received three cycles of platinum-based neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel), followed by imaging to assess treatment response.
223928693|NCT06752135|PROCEDURE|hysterectomy, salpingo-oophorectomy, and lymphadenectomy|Eligible patients underwent radical surgery, including hysterectomy, salpingo-oophorectomy, and lymphadenectomy, with adjuvant therapy administered as needed based on surgical findings. Follow-up included regular clinical exams, imaging, and tests to monitor for recurrence.
223928694|NCT06752135|RADIATION|brachytherapy|alternative to cCRT-B.
223928695|NCT06807333|BEHAVIORAL|Pharmacist led Education|Pharmacist-led education for diabetic patients focuses on enhancing their understanding of the disease, improving self-management skills, and promoting better health outcomes. The education covers key aspects of diabetes, such as the importance of blood sugar control, the role of diet and exercise, and how to monitor blood glucose levels. Patients are also taught effective self-management strategies, including how to make healthy food choices, incorporate physical activity into daily routines, and manage potential complications. By providing tailored education, pharmacists aim to empower patients to take an active role in their care, which can lead to improved disease management, better glycemic control, and reduced risk of complications.
223928696|NCT06737770|PROCEDURE|osseointegrated surgery for transfemoral amputation|osseointegrated surgery for transfemoral amputation
223928697|NCT06813547|BEHAVIORAL|emotional freedom techniques|emotional freedom techniques
223928698|NCT06813547|BEHAVIORAL|emotional freedom techniques and virtual reality|emotional freedom techniques and virtual reality
224094445|NCT00642642|BIOLOGICAL|Placebo|"1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart."
224094446|NCT01459978|OTHER|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
224094447|NCT04214652|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
224094448|NCT04214652|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
224094449|NCT02423096|DRUG|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
224094450|NCT01237860|DEVICE|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
223532638|NCT07146776|PROCEDURE|open flap debridement with I-prf and xenogeneic graft|During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be completely removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. Subsequently, a xenogeneic bone graft mixed with injectable platelet-rich fibrin (i-PRF) will be applied. The flap will then be sutured using 4-0 polypropylene sutures.
224094451|NCT02179840|PROCEDURE|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
224094452|NCT04351412|OTHER|Gluma|Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
224282741|NCT04491734|DIETARY_SUPPLEMENT|maltosyl-isomalto-oligosaccharides (MIMO)|Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
224282742|NCT04371263|OTHER|Emotional Change of Nursing Manpower in Emergency and Critical Unit After Keen Election And What's The Influence of Emotional Change|use the emotion regulation questionnaire (ERQ) to realize the influence in duty work
223928699|NCT06813547|BEHAVIORAL|control group/ none intervention|None intervention
223928700|NCT06814353|PROCEDURE|Intraoperative assessment of the site of origin and growth pattern|The assessment of the epicenter and extension and therefore the assumed origin of tumor growth is conducted by an experienced pediatric neurosurgeon blinded to group allocation based on the intraoperative impression. The anatomical features and site of origin are systematically documented on the surgical form in all cases of this study.
223928701|NCT06841458|OTHER|Oral Supplement|Participants in the Active Comparator group will receive a dietary supplement designed to manage androgenetic alopecia (AGA). The intervention consists of one oral capsule per day for six months, containing active ingredients such as Saw Palmetto, Pumpkin Seed Oil, Pygeum africanum, L-Cystine, Oleanolic Acid, and Horsetail Extract.
223928702|NCT06841666|DRUG|Atomoxetine|Atomoxetine, 0.5-1.2 mg/kg/day, administered in the evening for six months.
223928703|NCT06841666|DRUG|Placebo|Placebo identical in form and dosing schedule for six months.
223928704|NCT06842758|OTHER|Rehabilitation Treatment|Group A patients came to our department to perform rehabilitation treatment. They underwent rehabilitation treatment for a total of 20 rehabilitation sessions, performed on a daily basis lasting 60 minutes, on a 1:1 basis with a physical therapist, . They performed postural re-education and posterior kinetic chain strengthening exercises.
223928705|NCT06842758|OTHER|None Treatment|Group B patients did not undergo rehabilitation treatment. They underwent subcutaneous Teriparatide drug treatment on a daily basis for the treatment of osteoporosis
223532639|NCT07146776|PROCEDURE|open flap debridement with saline and xenogenic graft|During the surgical phase of treatment, patients will undergo open flap debridement surgery. Infiltrative local anesthesia will first be administered to the involved teeth. The gingiva will be incised within the gingival sulcus using a scalpel, and a full-thickness flap will be carefully elevated with a periosteal elevator. Granulation tissue and dental calculus will be thoroughly removed using Gracey curettes (American Eagle, USA) and an ultrasonic scaler. A xenogeneic bone graft mixed with physiological saline will then be applied. Finally, the flap will be sutured using 4-0 polypropylene sutures.
223928706|NCT06812039|DRUG|HAIC combined with sintilimab and donafenib|"HAIC: Two cycles, Q3W. The chemotherapy regimen consists of oxaliplatin 85 mg/m² over 2 hours and raltitrexed 2 mg/m² over 1 hour.~Donafenib: Treatment should begin the day after the completion of the first HAIC, with an initial dose of 0.1g bid p.o.. The investigator may increase the dose to 0.2g bid depending on the patient's condition.~Sintilimab: Administration may begin after the first HAIC, 200 mg iv Q3W. After surgery, continued sintilimab and donafenib for 6 cycles."
223928707|NCT06812039|DRUG|Sintilimab and Donafenib|Donafenib: an initial dose of 0.1g bid p.o. The investigator may increase the dose to 0.2g bid depending on the patient's condition. Sintilimab: 200 mg iv Q3W. After surgery, continued sintilimab and donafenib for 6 cycles.
223928708|NCT06812039|PROCEDURE|Surgery|After surgery, received sintilimab and donafenib for 6 cycles.
223928709|NCT01801709|GENETIC|intracerebral administration of AAVrh.10cuARSA|
223928710|NCT06842108|OTHER|Exercise tolerance test|"• The ETT will be performed using Bruce protocol. The Bruce protocol is a standardized treadmill exercise test used in Exercise Tolerance Testing (ETT) to evaluate cardiovascular fitness and diagnose heart conditions. This protocol is divided into seven stages, each stage duration is 3 minutes and date will be recorded at the end of the each stage. The recorded data will include heart Rate, Rate pressure product (∆RPP), HRR1 and Blood Pressure.~STEP 1:~Patient Preparation~STEP 2:~Consent and history:~STEP 3:~Start of ETT:~• Graded Exercise~STEP 4:~Parameters Recorded During ETT:~* Heart Rate: Monitoring heart rate response to exercise stress.~* Exercise induced changes in heart rate (∆HR) along with change in rate pressure product (∆RPP) due to excercise intensity.~STEP 5:~Cardiopulmonary Fitness Assessment VO2 Max"
224094453|NCT04351412|OTHER|fluoride varnish|fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
224094454|NCT04351412|OTHER|Tetric N-Bond self-etch adhesive|Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
224094455|NCT00712101|DRUG|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
224094456|NCT00712101|DRUG|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
224094457|NCT00370344|PROCEDURE|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
224094458|NCT00370344|PROCEDURE|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
224094459|NCT04523740|DRUG|Placebo|Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
224282743|NCT01710670|DRUG|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
223928711|NCT06842368|PROCEDURE|Hyaluronic Acid (HA)|"Hyaluronic acid is one of the essential components of extracellular matrix, which plays a predominant role in tissue morphogenesis, cell migration, differentiation, and adhesion. It has been recently reported that hyaluronic acid increases osteoblastic bone formation in vitro through increased mesenchymal cell differentiation and migration.~It has demonstrated that Hyaluronic acid not only acted as a carrier of growth factors and cell but also stimulated bone formation through chemotaxis, proliferation and differentiation of mesenchymal cells into osteoblasts.~Although Hyaluronic acid shares bone induction properties with growth factors as bone morphogenic protein 2 and osteopontin"
224094460|NCT04523740|DRUG|Paracetamol|Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
224094461|NCT06095830|DIAGNOSTIC_TEST|Complete blood count|Complete blood count done on admission and on discharge for patients, from which the blood indices of systemic inflammation will be calculated and correlated with outcome
224094462|NCT04976452|OTHER|Multi-component teaching content|The students assigned to Group 1 will undergo interactive module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines. Following completion of the module, students will be presented with a powerpoint lecture by the Primary Investigator on Blood Pressure. Students will then undergo a competency examination that assesses their ability to measure blood pressure following the guidelines of the American Heart Association.
224094463|NCT00705237|PROCEDURE|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
224094464|NCT03817918|PROCEDURE|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
223928712|NCT06842368|PROCEDURE|Vitamin D|"It was shown that locally applied vitamin D3 in combination with bovine bone mineral matrix improved the bone formation and strengthened the site of the fracture in ovariectomized rats.~Local application of vitamin D3 also proved to be promising in promoting osteo- genesis and mineralization for restoration of bone defects. Grounding on this incites, it has been suggested that vitamin D3 might exert a positive local effect on alveolar bone regeneration"
223928713|NCT06861777|OTHER|Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy|"Neoadjuvant treatment:~adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 followed by chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), surgical resection 4-8 weeks later neoadjuvant treatment."
223928714|NCT06861777|OTHER|chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin|"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel /nab-paclitaxel + cisplatin + 41.4Gy/23f), followed by adebrelimab 1200 mg/m2 d1+ paclitaxel d1/nab-paclitaxel d1,8, + cisplatin d1, Q2W×2 surgical resection 4-8 weeks later neoadjuvant treatment."
223928715|NCT06861777|OTHER|TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]|"Neoadjuvant treatment:~TNT treatment \[TNT group one (phase 2) or TNT group two (phase 2)\] followed by surgical resection 4-8 weeks later adjuvant treatment: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year"
223928716|NCT06861777|OTHER|Chemoradiotherapy|"Neoadjuvant treatment:~chemoradiotherapy (paclitaxel 50 mg/m2/nab-paclitaxel 60 mg/m2 d1, 8, 15, 22,29 + cisplatin 25 mg/m2 d1, 8, 15, 22,29 + 41.4Gy/23f), followed by surgical resection 4-8 weeks later. adjuvant treatment: non-pCR: adebrelimab 1200 mg/m2 d1, W3Q, adjuvant treatment for one year pCR: observation"
224094465|NCT04233125|PROCEDURE|Core Decompression|Core Decompression
224094466|NCT04233125|PROCEDURE|PMMA augmentation|Polymethylmethacrylate (PMMA) augmentation
224094467|NCT01503216|DIETARY_SUPPLEMENT|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
224094468|NCT01503216|DIETARY_SUPPLEMENT|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
224094469|NCT01503216|DIETARY_SUPPLEMENT|Placebo|Placebo
224094470|NCT04574843|PROCEDURE|Embolization of MMA|embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
224094471|NCT05674448|BIOLOGICAL|HH-003 20mg/kg|HH-003 20mg/kg Q2W intravenously for 24 weeks
224094472|NCT05674448|BIOLOGICAL|HH-003 3mg/kg|HH-003 3mg/kg Q2W intravenously for 24 weeks
224094473|NCT02337387|BIOLOGICAL|Blosozumab|Administered SC
224094474|NCT02337387|OTHER|Placebo|Administered SC
224094475|NCT01856114|DRUG|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
224094476|NCT01856114|OTHER|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
224094477|NCT01856114|BEHAVIORAL|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
224094478|NCT03731663|BEHAVIORAL|Exposure to pictures of appetizing food (known as Foodporn)|\- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
224094479|NCT03731663|BEHAVIORAL|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
224094480|NCT03372525|DEVICE|HFOV|Infants were randomized to HFOV
224094481|NCT03372525|DEVICE|CMV|Infants were randomized to CMV
224094482|NCT04947293|OTHER|Physical activity|Both groups will practice a physical activity adapted to their motor skills. They will have two group sessions (maximum 5 people per group) in a face-to-face setting, and one independent session at home supported by a video, each week. These programs last 12 weeks, and will be supervised by the same person, a physiotherapist.
223532640|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
223928717|NCT06860451|DEVICE|TMS|The single-pulse TMS
224094483|NCT00790517|BEHAVIORAL|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
224094484|NCT00707356|DRUG|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
224094485|NCT06152887|DEVICE|Sooma Oy (tDCS), Helsinki, Finland|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1)
224094486|NCT06152887|DEVICE|Sooma Oy (Sham), Helsinki, Finland|For the sham treatment, an electrical current will also be increased from 0 mA to 2 mA over the first 30 seconds, however, the current will be ramped back down to 0 mA after the initial ramp-up phase and no stimulation is delivered for the rest of the treatment.
224094487|NCT05021809|DRUG|Calcium hydroxide intracanal medication application|The patient will be anaesthized with Articaine hydrochloride 40 mg/ml + 1/100000 Epinephrine bitartrate solution . Then the rubber dam isolation will be conducted, the access will be opened and then cleaning and shaping will be done by using Protaper Next rotary file system and irrigation by sodium hypochlorite 2.5% by side vented needle, EDTA 17%, sodium hypochlorite and the final rinse by saline where the canal will be dried by absorbent paper point. The application of calcium hydroxide intracanal medication will be done according to the manufacturer instructions then temporization by glass ionomer will be applied .
223928718|NCT06764056|DRUG|semaglutide|Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.
223928719|NCT06764056|OTHER|Diet|Participants receiving this intervention will be seeing a registered dietician at each visit. The individualized approach will be based on recent literature (mostly hypocaloric) by using different methods.
223928720|NCT06886061|DIETARY_SUPPLEMENT|The capsules contain Ergothioneine.|Take one 30 mg Ergothioneine capsule orally every day for a period of eight weeks.
223928721|NCT06886061|DIETARY_SUPPLEMENT|The capsules do not contain Ergothioneine.|Take one capsule devoid of Ergothioneine orally every day for a period of eight weeks.
223928722|NCT06891807|DEVICE|Robotics Assisted TKA|Skywalker Robotics Assisted TKA using Evolution Medial Pivot Knee
223928723|NCT06891807|DEVICE|Augmented Reality assisted TKA|Pixee Knee+ assisted TKA using Evolution Medial Pivot Knee
223928724|NCT06764069|DEVICE|Sensor Lead|The Glucotrack Sensor Lead will be inserted into the subclavian vein, using a Seldinger technique, where it will continuously measure blood glucose levels.
223928725|NCT06764368|DRUG|Adebrelimab + Apatinib|"Induction Phase:~Subjects will receive Adebrelimab (1200 mg, Day 1) + Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator) + Apatinib (250 mg, orally, once daily) in 3-week cycles (Q3W) for 4 to 6 cycles.~Maintenance Phase:~Adebrelimab (1200 mg, Day 1) + Apatinib (250 mg, orally, once daily) will be administered for 1 year or until one of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent by the subject, voluntary withdrawal from the study, or other protocol-specified reasons."
223928726|NCT06892132|OTHER|Supervised feeding intervention|Participants will be fed a peanut product during a supervised feeding visit and observed for an allergic reaction.
223928727|NCT06892132|OTHER|Handout|Participants will receive a handout on how to introduce peanut products.
224094488|NCT05052489|OTHER|registy|Children with diarrhea were registered in the hospital. Baseline information of the children was recorded and followed up to observe the distribution of disease types, clinical manifestations, treatment plans and clinical outcomes
224094489|NCT02160457|OTHER|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~1. Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~2. Impairment-Focused Interpretation~3. Recommendation for interdisciplinary interventions~4. Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
224094490|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
224094491|NCT02539706|DRUG|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
224094492|NCT02968355|OTHER|Observational study|Observational study
224094493|NCT03394638|OTHER|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
224094494|NCT03394638|OTHER|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
224094495|NCT03394638|PROCEDURE|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
224094496|NCT01364987|DRUG|ASP015K|oral
224094497|NCT01364987|DRUG|Mycophenolate Mofetil|oral
224094498|NCT00716716|DRUG|rFIXFc|As specified in the treatment arm
224094499|NCT02581709|BEHAVIORAL|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
224094500|NCT02272790|DRUG|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
224282744|NCT01710670|OTHER|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
223532641|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
223928728|NCT06763302|DRUG|Blinatumomab|The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
223928729|NCT06763861|OTHER|Biopsy|Biopsies from EAS
223928730|NCT06762951|OTHER|Pilates mat exercices|Pilates mat exercise which consists of (single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions.
223928731|NCT06762951|OTHER|Segmental control exercises|Segmental control exercise which consists of (Segmental control over primary stabilizers, Exercises in closed chain, and Exercises in open chain)
223928732|NCT06762951|OTHER|Traditional physical therapy|Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)
223928733|NCT06762847|DEVICE|Use of Conventional Silicone Prosthetic Liner|At this stage participant who will be fitted with a standard silicone liner typically used for transtibial prosthetics. Over a set duration, we will assess the liner's performance, particularly in terms of durability, comfort, skin health, and fit stability. Acting as the control group, this cohort will provide essential baseline data for comparison with the innovative prosthetic liner.
223928734|NCT06764394|OTHER|Exercise|home based exercise 5 days/week
223928735|NCT06764394|OTHER|Exercise|home based exercise plus myofacial release exercise Myofascial release exercises will continue for 6 weeks, 2 sessions per week and each session will continue for 30 minutes.All evaluations will be performed at the beginning of radiotherapy treatment and at the end of the 6th week.
223928736|NCT06766994|OTHER|intrathecal morphine|Preoperatively, patients will be injected with 200 μg morphine intrathecally with a 27G pencil point spinal needle at the L4-L5 or L3-L4 intervertebral space in a sitting position.
223928737|NCT06766994|OTHER|Erector Spinae Plane Block|Preoperatively, patients will be placed in the prone position before the operation and an ESPB block will be applied bilaterally at the T9 vertebra level with the help of USG. 0.25% bupivacaine 20 ml will be used bilaterally as the blocking fluid.
223928738|NCT06790927|DRUG|Usual Care|The doctor prescribes medication for patients and follow-up every 3 months
223928739|NCT06790927|DRUG|Standard Medical Therapy|The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.
224094501|NCT02272790|DRUG|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
224094502|NCT02272790|DRUG|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
224282745|NCT01710670|OTHER|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
224094503|NCT02272790|DRUG|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
224094504|NCT02272790|DRUG|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
224094505|NCT01869335|DEVICE|radiography|
224094506|NCT01869335|DEVICE|MRI (magnetic resonance imaging)|
224094507|NCT03036878|OTHER|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
224282746|NCT01710670|OTHER|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
224282747|NCT03733587|DRUG|GX-I7|GX-I7 25mg/ml/vial
224282748|NCT03733587|DRUG|Cyclophosphamide|Cyclophosphamide 500mg/vial
224282749|NCT04973800|DRUG|Simvastatin 20mg|Simvastatin 20mg ON PO for 28-30 days
224282750|NCT04973800|DRUG|Placebo|Sucrose placebo ON PO for 28-30 days
224282751|NCT06251960|PROCEDURE|socket preservation with completely demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
224282752|NCT06251960|PROCEDURE|socket preservation with partially demineralized dentin graft|socket preservation with completely demineralized dentin graft followed by delayed implant placement after 4 months
223532642|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
224094508|NCT01206907|DRUG|oxymorphone IR|oxymorphone IR liquid
224094509|NCT02193789|PROCEDURE|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
224094510|NCT02193789|DEVICE|Covered Self-expandable Metallic Stents|
224094511|NCT05975229|OTHER|Knitting and education (pamphlet)|Pamphlet and knitting program (-8-week duration). The knitting program has two components: bi-weekly 20-minute group knitting sessions and 20-minute home daily knitting on the 5 remaining weekdays.
224094512|NCT05975229|OTHER|Education (pamphlet)|Receive only the pamphlet, not the knitting program.
224282753|NCT00669435|DRUG|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
224282754|NCT00669435|DRUG|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
224282755|NCT02045524|OTHER|Deep muscle injection|
224282756|NCT02045524|OTHER|Sub-Q Injection|
224282757|NCT00952224|OTHER|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
224282758|NCT02990078|DRUG|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
223928740|NCT06726941|OTHER|Physiotherapy and Rehabilitation Practices|It was planned to give the participants a routine stroke rehabilitation program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, balance exercises, walking training and 20 minutes of bicycle ergometry, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. It was planned to give passive bicycle ergometry to patients without voluntary muscle movement and muscle strength, and active bicycle ergometry to participants with voluntary muscle movement and muscle strength, with the bicycle rehabilitation. It was planned to apply the exercise program to the patients for 5 days a week and for a total of 30 sessions. It will be recommended that they continue the medical treatment they are using during the treatment program. Routine evaluations will be made by the physiatrist before the rehabilitation program starts and 2 tubes of venous blood will be taken from the patients by an experienced nurse
223928741|NCT05934292|DRUG|Enlicitide Decanoate|Oral dose
223928742|NCT06565780|DEVICE|Device under test evaluation against references|"Subjects will be asked to stay seated while blood pressure and pulse rate measurements are taken at different timepoints with the device under test and references.~Device under Test: Aktiia.product-G0 References: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate."
223928743|NCT06542666|OTHER|Cognitive Functional Therapy|"The intervention focuses on addressing the maladaptive cognitive, physical, and lifestyle behaviors related to the disorder.~Cognitive functional therapy will focus on factors considered to contribute to the pain disorder, addressing the following topics:~1. The multidimensional nature of persistent pain, beliefs, emotions, and behaviors (movement and lifestyle) that can reinforce a vicious cycle of pain sensitization and disability.~2. Specific functional training designed to normalize maladaptive and provocative postural and movement behaviors as directed by the individual's presentation.~3. Targeted functional integration into daily activities that are avoided and/or provocative for the patient.~4. Counseling on physical activity and lifestyle, which will include promoting a gradual increase in physical activity based on the individual's preference and availability, advice on sleep hygiene, stress management strategies, and social re-engagement"
223928744|NCT06542666|OTHER|Exercises|"Individuals allocated to this group will perform stretching and strengthening exercises. The self-stretching exercises will target the upper trapezius and posterior shoulder region. Each stretching exercise will be performed for 3 repetitions of 30 seconds, with an interval of 10 seconds between repetitions.~The strengthening exercises will be performed using resistance elastic bands. Three sets of 10 repetitions will be performed for each strengthening exercise, with 1 minute of rest between sets. The strengthening exercises will target the lower and middle trapezius, anterior serratus, and the external and internal rotators of the shoulder."
223928745|NCT06361329|DRUG|Homoharringtonine|Intravenous infusion
223928746|NCT06361329|DRUG|venetoclax|Orally by mouth
223928747|NCT06361329|DRUG|Cytarabine|subcutaneous injection or Intravenous infusion
223928748|NCT06361329|DRUG|G-CSF|subcutaneous injection
223928749|NCT06361329|DRUG|Vindesine|Intravenous infusion
223928750|NCT06361329|DRUG|Daunorubicin|Intravenous infusion
223928751|NCT06361329|DRUG|cyclophosphamide|Intravenous infusion
223928752|NCT06361329|DRUG|Dexamethasone|Intravenous infusion or orally
223928753|NCT06361329|DRUG|L-ASP|subcutaneous injection
223928754|NCT06745544|OTHER|Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)|The Rhythm- and Multitask-Based Activity (RYMA) program is a unique cognitive-motor exercise intervention designed for older adults with diabetes. It incorporates rhythm-based multitasking exercises, performed to improvised piano music, combined with Activities of Daily Living (ADL)-focused exercises. The intervention targets physical (strength, balance, and coordination) and cognitive (executive function, reaction time) components to reduce fall risk, improve bone health, and optimize cardiovascular outcomes. Delivered over 26 weeks, the program emphasizes social interaction to enhance adherence and long-term engagement.
223928755|NCT06744257|OTHER|Online Education tool|An online education tool that contains 4 modules
224094513|NCT01882361|DRUG|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
223718103|NCT04561830|PROCEDURE|laparoscopic-assited excision of mesorectum with pelvic lymph nodes excision|"We performed laparoscopic dissection of the lateral pelvic lymph node for thirty patients while we performed open lateral pelvic lymph node dissection for the remaining thirty patients.~Performed surgical approaches were abdominoperineal resection, internal sphincter resection, and low anterior resection. All performed surgical procedures included lateral pelvic lymphadenectomy in addition to performing total mesorectal excision.~Choosing whether to perform unilateral or bilateral lymphadenectomy depends on lymph nodes invasion by cancer was on one side or both sides."
223718104|NCT03645798|BEHAVIORAL|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
223928756|NCT04479787|DEVICE|Spinal Cord Stimulation|Utilization of BURSTDR stimulation
223928757|NCT04479787|OTHER|Conventional Medical Management|Assessing type of CMM, location and frequency.
223928758|NCT06790667|DEVICE|Low Level Laser Therapy|Participants in this arm will receive Low-Level Laser Therapy (LLLT) using a Gallium Aluminum Arsenide (GaAlAs) semiconductor diode laser. The treatment involves a wavelength range of 650-808 nm with a power output of 775 mW. The therapy is administered by exposing tender points around the temporomandibular joint (TMJ) to the laser for 2 minutes per session. Each participant will receive treatment on alternate days (three sessions per week) over the course of three weeks. The goal is to assess the effectiveness of LLLT in reducing pain and improving mouth opening in patients with myofascial pain associated with Temporomandibular Disorders (TMD).
224094514|NCT01882361|DRUG|placebo comparator|this placebo has no specific pharmacological activity
224094515|NCT00332202|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
224094516|NCT00332202|DRUG|placebo|oral, daily
224094517|NCT01929070|DRUG|HCP1007|
223928759|NCT06790667|DEVICE|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Participants in this arm will undergo Transcutaneous Electrical Nerve Stimulation (TENS), utilizing a four-electrode unit. The device will be set to deliver electrical impulses at a frequency of 150 Hz with a pulse width of 200 µs. Electrodes will be placed over the cutaneous region between the TMJ and coronoid process to stimulate the trigeminal and facial nerves. Each treatment session will last 15 minutes and occur on alternate days, three times a week for three weeks. This therapy aims to provide pain relief and improve jaw function for patients suffering from myofascial pain associated with TMD.
224094518|NCT01929070|DRUG|Omarco and Crestor|
224094519|NCT05079438|DRUG|Dendrobium Huoshanense Suppository|1.7g rectal administration per day for 5 weeks
224094520|NCT04439890|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
224094521|NCT04439890|DRUG|Carboplatin injection|Carboplatin injection AUC 5mg/mL/min, intravenous drip, on Day 1 in 21-day cycle.
223928760|NCT06744140|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|To Evaluate the breast Magnetic Resonance Imaging (MRI) in detecting Ductal Carcinoma In Situ (DCIS) lesions among high-risk breast cancer patients while keeping the histopathology as a GOLD standard
223928761|NCT06832267|DRUG|Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)|Rituximab: 375 mg/m2 intravenously on day 3,7; Methotrexate: 1.5-3.5 g/m2 intravenously on day 1,14(≤65 ,3.5g/m2；\>65,1.5g/m2); Temozolomide 150 mg/m2 on days 3-7； Thiotepa:40 mg/m2 intravenously on day 17。 Treatment will be given for 4 cycles（28 days for each cycle）, and patients who achieve a CR or better can choose to undergo ASCT or WBRT(23.4Gy).
223928762|NCT06787339|DRUG|Capecitabine|Capecitabine 650mg/m2, bid, p.o for 1 year
223928763|NCT06766045|DIAGNOSTIC_TEST|Diaphragmatic Ultrasound|"Diaphragmatic ultrasound was performed bedside in the ICU with supine position. Diaphragmatic thickness was measured by placing the ultrasound on 8th-10th intercostal space between anterior and mid-axillary line with marker at 12 o'clock. B-mode ultrasound was used to measure the distance between thoracic and abdominal diaphragm which resulted in the diaphragmatic thickness at inspiration (DTi) and diaphragmatic thickness at expiration (DTe).~The ultrasound was then placed on the subcostal area between anterior and mid-axillary line with marker at 12 o'clock to observe the diaphragmatic motion on each side. Measurement of diaphragmatic excursion as well as recording and evaluation of diaphragmatic sliding and motion were performed during both inspiration and expiration using M-mode."
224094522|NCT04439890|DRUG|Pemetrexed disodium f Injection|Pemetrexed disodium f Injection 500mg / m2, intravenous drip, on Day 1 in 21-day cycle.
224094523|NCT04439890|DRUG|Placebo|Placebo
224094524|NCT00036114|DRUG|aripiprazole|
224094525|NCT00836940|DRUG|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
224094526|NCT01068561|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
224094527|NCT02901171|BEHAVIORAL|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
224094528|NCT02901171|BEHAVIORAL|ACT group treatment|
224094529|NCT02901171|BEHAVIORAL|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
224094530|NCT03034941|DRUG|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
224094531|NCT03034941|DRUG|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
224094532|NCT05006053|OTHER|Interviews/Focus groups|Qualitative study (no intervention delivered)
224094533|NCT04812561|DIETARY_SUPPLEMENT|Bronch™|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
224094534|NCT04812561|DIETARY_SUPPLEMENT|placebo|2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
224094535|NCT00378118|OTHER|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
224094536|NCT00378118|OTHER|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
224094537|NCT00373074|OTHER|Epidural Blood Patch|Use 15 cc of blood
224094538|NCT00373074|OTHER|Epidural Blood Patch|Inject 20 cc of blood into epidural space
224094539|NCT00373074|OTHER|Epidural Blood Patch|Inject 30 cc of autologous blood
224094540|NCT00518349|DEVICE|Passive bending function|Colonoscope with a passive bending function
224094541|NCT00518349|DEVICE|No passive bending function|Examination using standard colonoscope without passive bending function
224094542|NCT00005630|BIOLOGICAL|ras peptide cancer vaccine|
224094543|NCT00005630|BIOLOGICAL|sargramostim|
224094544|NCT06551623|DRUG|Midazolam|Midazolam Oral Solution 2 mg
224094545|NCT06551623|DRUG|Clarithromycin|Clarithromycin tablets 0.5 g
224094546|NCT06551623|DRUG|TNP-2198|TNP-2198 Capsules 400 mg
223928764|NCT06766045|DIAGNOSTIC_TEST|Fluoroscopy|Fluoroscopy test was conducted in cathlab with supine position and anteroposterior (AP) projection for at least 5 breathing cycles. The fluoroscopy recording was then expertised and interpreted by the pediatric cardiologist in charge.
223928765|NCT06791226|DIAGNOSTIC_TEST|18F-AlF-FAPI PET/CT, 18F-FDG PET/CT|Subjects with orbital neoplasms underwent contemporaneous 18F-AlF-FAPI and 18F-FDG PET/CT for diagnosis and staging.
223928766|NCT06769074|BIOLOGICAL|Platelet Rich Plasma|PRP injection into the midurethra and its instillation into urinary bladder
223928767|NCT06792422|DRUG|Oral semaglutide|"Participants will receive oral semaglutide once daily.~1. Starting dose 3 mg/day for one month (day 1-28)~2. Intermediate dose 7 mg/day for one month (day 29-56)~3. Maintenance dose 14 mg/day (day 57-182)"
223928768|NCT06792422|DRUG|Placebo|"Participants will receive an oral placebo once daily.~1. Placebo tablets received on visit 1 (baseline) for one month (day 1-28)~2. Placebo tablets received on visit 2 (month 1) for one month (day 29-56)~3. Placebo tablets received on visit 3 (month 2) for four months (day 57-182)"
223928769|NCT06785766|BEHAVIORAL|Yoga-Based Exercise Program|This intervention is an 8-week yoga-based exercise program conducted with 60-minute sessions twice a week. The program aims to improve flexibility, mobility, and overall well-being. Each session consists of 5 minutes of warm-up, 5 minutes of breathing exercises, 40 minutes of yoga postures, 5 minutes of deep relaxation, and 5 minutes of meditation. The intervention adapts yoga postures based on participants' individual needs, offering a flexible approach. The difficulty of the yoga flows gradually increases over the 8 weeks. When necessary, postures are adapted using props like blocks, straps, blankets, and chairs. A physiotherapist guides participants, demonstrating correct techniques and providing verbal instructions. This program combines yoga, breathing exercises, and meditation to enhance physical and mental well-being, promoting long-term health benefits.
223928770|NCT06767397|DIAGNOSTIC_TEST|general anesthesia|To evaluate the factors that affect the hemodynamic stability in patients undergoing spinal anesthesia and general anesthesia during pelvic surgery.
224094547|NCT06386406|DEVICE|TAP insole|"The patients will have to wear the TAP insole when walking during the everyday life activities.~This plantar insole is not a custom-made insole but a pre-confectioned one because designed according to two parameters: shoe size and gender."
224094548|NCT06186375|OTHER|Patients with planned biotherapy|Single additional volume of blood (10 ml) to be collected using the PAXgene system at the same time as the routine blood test before starting biotherapy.
224094549|NCT05391438|OTHER|Meal-timing|We propose a cross-over, proof-of-concept study to measure glycemic and metabolic responses to a test meal (controlled for macronutrient profile and caloric amount) administered at various times of the day (early vs. afternoon vs. late) in thirty Latino adolescents (ages 13-19 years), with obesity, without diabetes, to determine how timing of eating impacts glycemic response to the test meal after a 16-h fasting period. All participants will consume three standard test meals administered in random order at different times of day over two-weeks: (1) Early: test meal consumed at 8 AM; (2) Afternoon: test meal consumed at 12 PM; (3) Late: test meal consumed at 4 PM. A continuous glucose monitor (CGM) will be placed on the participant for the duration of the 2-week period. Baseline and post-meal samples will be assayed for glucose, insulin, c-peptide, GLP-1, GIP, PP at times -10, -5, 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minutes after glucose.
224094550|NCT05941104|OTHER|frailty|Frailty is a group of common clinical syndromes in the elderly, characterized by systematic, dynamic and reversible, the core of which is the decline of physiological reserves and the destruction of self-balance.
224282759|NCT02990078|DEVICE|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
224282760|NCT02990078|OTHER|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
223928771|NCT06834529|GENETIC|CAR2219-T cells|"Genetic: CAR2219-T cells Each subject will be infused with single dose of CD2219-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 5×10\^5 /kg, the medium dose is 1×10\^6 /kg, and the high dose is 2×10\^6 /kg.~Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells.~Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD2219-CAR-T cells."
223928772|NCT06765421|BEHAVIORAL|Intervention Group|"Intervention group activity involves three components:~1. Intervention group GPs will be provided with a long COVID 'toolkit'. The toolkit will be prepared by the study team in collaboration with expert clinicians and public and patient representatives as a resource for GPs to use in patient care.~2. GPs will attend an expert clinician / patient led long COVID educational session grounded in the findings of the toolkit.~3. Applying learnings to date, each GP will conduct case reviews of eight patients with long COVID attending their practice and provide patient care as appropriate."
223928773|NCT06765252|DRUG|Capecitabine-based chemotherapy|Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
223928774|NCT05351593|DRUG|Tafasitamab|Given IV
223928775|NCT05351593|DRUG|Lenalidomide|Given Orally
223928776|NCT06832917|DRUG|AK104 plus|SCRT followed by 6 cycles of cadonilimab (AK104) plus mFOLFOX6 as neoadjuvant therapy for patients
223928777|NCT06832917|DRUG|Chemo only|Short-course radiation (SCRT) followed by 6 cycles of mFOLFOX6 as neoadjuvant therapy for patients
224094551|NCT05754775|BEHAVIORAL|Calorie restriction via total food replacement|Restricted foods designed by a clinical nutritionist that delivers to home for diabetic patients.
224094552|NCT03629548|PROCEDURE|early amniotomy|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
223532643|NCT06950645|BIOLOGICAL|Placebo|Placebo of experimental vaccine for infants three doses administered orally
223532644|NCT06950645|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
223928778|NCT06768502|OTHER|Community Based Approach (CBA)|The community-based approach on IPV and sexual violence is conceived as a dynamic process where community members willing to recover from life wounds induced by IPV and sexual violence agree to share their lived experiences in order to work on them accordingly and to support each other in this healing journey.
223928779|NCT06768723|OTHER|Warm-up (specifically, Post-Activation Performance Enhancement)|Assess which intervention delivered the best acute performance enhancements.
223928780|NCT06768203|OTHER|umbilical vein catheterization|In our NICU, UVC placement is a sterile bedside procedure carried out by pediatric residents, neonatology fellows, and neonatology specialists, using polyurethane, single-lumen catheters sized according to the infant's weight: 3.5 Fr for those under 1500 g and 5 Fr for those over 1500 g. Catheter placement is performed using the Modified Shukla-Ferrara Formula
223928781|NCT06768203|OTHER|Control|No umbilical vein catheter was inserted in these infants.
223928782|NCT03621813|BEHAVIORAL|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
223928783|NCT03621813|OTHER|Control|Participants are instructed to maintain current activity level and are monitored for changes.
223928784|NCT06785571|DRUG|Nalbuphine hydrochloride injection|a loading dose of Nalbuphine hydrochloride injection administered in 30 ±10 seconds, followed by a maintenance dose of 2.0mg/h (a recommended maintenance dose range of 1.0\~5.0mg/h)
223928785|NCT06785571|DRUG|Hydromorphone hydrochloride injection|A maintenance dose of 0.5mg/h (a recommended maintenance dose range of 0.5\~3.0mg/h)
223928786|NCT06788288|OTHER|Massage Chair session|The intervention is composed of a full-body relaxation massage offered by an automatic electric massage chair. The intervention will last for 3 months while the participant will change between massage and washout periods.
223928787|NCT06788288|OTHER|Washout period|During this phase, participants will spend on month without any intervention (massage) accounting for a washout period.
223928788|NCT06791278|BEHAVIORAL|Exercise|After-school childcare educators will participate in a professional development course on delivering pedagogical and child-friendly exercise sessions. The children will receive 1-2 weekly sessions of 45-60 minutes of child-friendly exercise during after-school childcare programs. Duration: 1 year.
223928789|NCT06786078|DEVICE|Lily Device|Participants will wear the Lily Device at each chemotherapy session for the prescribed duration, where the device must be used during infusion and for at least two (2) hours and up to four (4) hours post infusion.
224094553|NCT03629548|DEVICE|foley catheter balloon placement|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix
224094554|NCT02863198|DEVICE|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
224094555|NCT01483677|OTHER|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
224094556|NCT01483677|OTHER|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
224094557|NCT06206096|DRUG|oxaliplatin+capecitabine+bevacizumab+PD-1 antibody|oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
224094558|NCT05466643|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
223532645|NCT06950645|BIOLOGICAL|Placebo|Placebo of experimental vaccine for infants three doses administered orally
223532646|NCT07159763|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
223532647|NCT07159763|COMBINATION_PRODUCT|Placebo|Placebo to match
223532648|NCT07159529|PROCEDURE|flapless technique|taking a punch of tissue to place dental implant through surgical guide
223928790|NCT06768606|BEHAVIORAL|EMPOWER Social-emotional learning curriculum|EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context. The STEM Academy program will implement a shortened version of the social-emotional learning curriculum to meet their timelines.
223532649|NCT07159529|PROCEDURE|flap technique|conventional flap elevation and drilling to place dental implant
223532650|NCT07159529|PROCEDURE|tissue punching|just a punch of tissue taken to place dental implant
223718105|NCT03645798|BEHAVIORAL|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
223718106|NCT04729868|DRUG|Levobupivacaine(chirocaine) plus dexmedetomidine(precedex)|evaluate the efficacy of levo-bupivacaine alone and with dexmedetomidine in Ultrasound guided infraclavicular brachial plexus block for hand and forearm surgeries
223928791|NCT06768736|COMBINATION_PRODUCT|Personalised early warning system|Early warning system personalised forecasting messages
223928792|NCT06769542|BEHAVIORAL|Experimental (micro teaching)|The experimental group was taught using the micro-teaching method for 8 weeks. Psychomotor skills for drug administration were performed on models. Video recordings were taken while the students were performing the skills. These videos were evaluated by the instructor and the students and the students were given the opportunity to see their own mistakes. During 8 weeks, each student was given the opportunity to perform the applications and evaluate themselves. In addition, activities for drug applications were carried out with students within the scope of small group work. Micro teaching with 4 groups of 8 students was applied for 8 weeks.
224094559|NCT05466643|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
224282761|NCT00277160|DRUG|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
223928793|NCT06737120|PROCEDURE|Mod-fgg|"Following an intrasulcular incision, 2 mm long horizontal incisions will be made on each side at the level of the gum line. From these incisions, divergent vertical release incisions will be made extending towards the alveolar mucosa. To prepare the recipient area, a thin partial thickness flap will be lifted and then removed. A foil template will be obtained by measuring the dimensions of the resulting area.~A horizontal incision will be made apical to the exposed root area of the target teeth at a distance corresponding to the height of the exposed root surface. Starting from the endpoints of this incision, two more slightly divergent incisions will be made in the coronal direction. Thus, a connective tissue pedicle flap will be formed and carefully separated from the periosteum. The pedicle graft will be turned over the exposed root surface and fixed with bioabsorbable sutures. The palatal graft will be sutured to cover the connective tissue."
223928794|NCT06737120|PROCEDURE|Fgg|The surgical procedures to be performed in this group will be the same as in the modified free gingival graft group, but no connective tissue pedicle flap will be performed.
223928795|NCT06737939|OTHER|intravenous ibuprofen|A systemic analgesic (NSAID) administered intravenously for pain management during prostate biopsy, without the need for additional invasive interventions.
223928796|NCT06737939|OTHER|periprostatic nerve block|A local anesthetic injection targeting the periprostatic nerves to provide direct pain relief during the biopsy procedure, considered the gold standard for pain management in prostate biopsies.
223928797|NCT06793657|DIAGNOSTIC_TEST|computed tomography and poppy seed|comparison of both interventions
223928798|NCT06838884|OTHER|6 minutes step test and bicycle ergometer|Evaluation
223928799|NCT06796465|OTHER|McKenzie with Progressive Postural Control Exercises|"The McKenzie Exercises focus on progressive spinal extension to alleviate back pain. Key steps include Extension in Standing, where patients lean backward and return to a neutral stance; Extension in Lying (Partial Range), involving partial pushups in a prone position; and Extension in Lying (Full Range), where patients fully extend their arms to achieve maximum spinal extension. Each movement is held for 1-2 seconds.~The PPCE program enhances core strength and stability through three stages. In the First Stage (2 weeks), core muscles are trained against gravity using movements like pelvic retroversion, crunches, and glute bridges. The Second Stage (3 weeks) incorporates a Swiss ball to challenge trunk muscles with instability. In the Third Stage (3 weeks), a Swiss ball, stretch bands, and a 5 kg sandbag are used to increase complexity on unstable surfaces. Each stage includes six movements, lasting 5 minutes each, for a total session duration of 30 minutes."
223718107|NCT06131567|PROCEDURE|Implantoplasty|Implantoplasty as surface decontamination method
223718108|NCT04992676|DIAGNOSTIC_TEST|Polysomnograpy|Home polysomnography will be conducted using the scalable, modular Embletta system. Trained staff will instrument the participants in the evening and perform biocalibration to ensure optimal data quality
223928800|NCT06796465|OTHER|McKenzie without Progressive Postural Control Exercises|"Subject were treated with McKenzie exercises without the addition of Progressive Postural Control Exercises (PPCE).The exercises included the following:~Standing Extension Exercises: Patients leaned backward from a balanced standing position, arching their back before returning to a neutral stance.~Extension in Lying (Partial Range): Performed in a prone position with hands placed under the shoulders, patients lifted their upper torso in a motion similar to a push-up.~Extension in Lying (Full Range): Similar to the partial range extension, but with fully extended arms, aiming for the maximum tolerated extension. Each movement was sustained for 1-2 seconds."
224094560|NCT06544239|BEHAVIORAL|Virtual reality basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
224094561|NCT06544239|BEHAVIORAL|Traditional basketball asymmetric training|This study established two experimental groups, namely the experimental group and the control group. The experimental group received virtual reality device assisted training, while the control group received traditional training
224094562|NCT01526421|OTHER|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
224094563|NCT06115109|OTHER|Non intervention, Observational study|Non intervention, Observational study
224094564|NCT03679325|DIETARY_SUPPLEMENT|vitamine D|a dose once a week
224094565|NCT03679325|OTHER|whole body vibration (WBV)|03 months of WBV training three times per week
224094566|NCT05943080|DRUG|PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.
224282762|NCT03244982|DRUG|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
223928801|NCT06796465|DEVICE|Hot Pack|for 10 to 15 minutes
223928802|NCT06788626|DRUG|Semaglutide 0.5 mg|0.5mg semaglutide injection before and 1 week after endovascular treatment.
223928803|NCT06788626|OTHER|Standard medical treatment|Standard medical management
223928804|NCT06797011|BIOLOGICAL|High volume Plasma Exchange|High volume Plasma Exchange with minimum 3 sessions on alternate days
223928805|NCT06797011|OTHER|Standard Medical Treatment|Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
223928806|NCT06797193|OTHER|Electronic Health Record Review|Ancillary studies
223928807|NCT06797193|PROCEDURE|Liver Biopsy|Undergo liver biopsy
224094567|NCT05943080|DRUG|IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)|It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.
224094568|NCT05943080|DRUG|ACB ( 0.25% marcaine + %0.9 saline)|It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.
224094569|NCT01832740|DEVICE|brain stimulation|oscillating direct current brain stimulation
224094570|NCT01832740|DEVICE|SHAM|no stimulation
224094571|NCT02380755|DRUG|Clomiphene Citrate|50 mg orally daily during 12 weeks
224282763|NCT03244982|DRUG|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
224282764|NCT01123291|PROCEDURE|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
224282765|NCT01123291|PROCEDURE|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
223928808|NCT06797193|OTHER|Medical Device Usage and Evaluation|Undergo ultrasound with SHAPE technique
223928809|NCT06797193|DRUG|Perflutren Lipid Microspheres|Given IV
223928810|NCT06797193|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
223928811|NCT05453136|DRUG|TS-142 5 mg|Participants received repeated doses of 5 mg of TS-142 (oral tablet)
223928812|NCT05453136|DRUG|TS-142 10 mg|Participants received repeated doses of 10 mg of TS-142 (oral tablet)
223928813|NCT05453136|DRUG|Placebo to TS-142|Participants received repeated doses of placebo to TS-142 (oral tablet)
223928814|NCT05903352|OTHER|Stop antibiotic|Stop the antibiotic treatment on day S (stability criteria reached for 24 h or within 48 hours after the start of antibiotic treatment).
223928815|NCT05903352|DRUG|Continue the antimicrobial treatment|Continue the antimicrobial treatment for a duration predetermined by the investigator (usual practice, at least 5 days of treatment in total).
223928816|NCT06325046|PROCEDURE|Computed Tomography|Undergo CT
223928817|NCT06325046|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
223928818|NCT06325046|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo near margin-less ART
223928819|NCT06325046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223928820|NCT06325046|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo standard SABR
223928821|NCT06325046|OTHER|Survey Administration|Ancillary studies
223928822|NCT06793813|DRUG|cadonilimab，bevacizumab，docetaxel|Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
223928823|NCT06794918|DIAGNOSTIC_TEST|progressive relaxation exercise|Researchers will teach individuals pge exercises to help them relax
223928824|NCT06796088|OTHER|Treated zones exposed to Visible Light source|The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application.
223928825|NCT06796088|OTHER|Untreated zone exposed to Visible Light source|The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
223928826|NCT06794788|DEVICE|VR-The iWear|The immersive virtual reality device was used for this study from(Vuzix®, Rochester, New York, USA). The iWear consists of a lightweight high-end pair of video headphones that contain pair of VR goggles
224094572|NCT02380755|DRUG|Placebo|1 pill orally daily during 12 weeks
224094573|NCT04762030|DRUG|Durvalumab Anlotinib Carboplatin Nab-paclitaxel|"Neoadjuvant treatment (durvalumab+carboplatin+nab-paclitaxel + anlotinib) will start within 1-3 days from enrollment. 2 cycles will be administered at 21-day (+/- 3 days) intervals (QW3). Then, two cycles of combined durvalumab and anlotinib (QW3) will be administered prior to surgery. Before surgery, a tumor assessment will be done. Patients with stable disease or partial response may be considered for surgery.~Surgery: Surgery must be done within the 5rd-7th week from day 1 cycle 4 of neoadjuvant treatment (day 35-49 after day 1 of cycle 4). Adjuvant treatment: Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 2rd to 8th week from surgery. Twelve cycles of durvalumab adjuvant treatment (Q4W) will be administered."
224282766|NCT01397266|PROCEDURE|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
223928827|NCT06840236|BEHAVIORAL|Adapted Flu nudge messages|Adapted Flu nudge messages - digital health intervention aimed at improving influenza vaccination rates among adults with diabetes at Dario digital platform approach.
223928828|NCT06840236|BEHAVIORAL|Previously studied based on RCT|Previously studied flu nudge messages in RCT
223928829|NCT05714059|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
223928830|NCT06840054|DRUG|Sodium Pentaborate Pentahydrate|will receive 1000 mg of sodium pentaborate pentahydrate daily along with donepezil.
223928831|NCT06840054|DRUG|Placebo|will receive a placebo along with donepezil
223928832|NCT06838559|DRUG|Short-Duration Oral Prednisolone with Extended Tapering|In treatment arm A, oral prednisolone will be administered in tablet form (5 mg strength) as follows: an initial phase of 10 mg four times daily (total 40 mg/day) for 7 days, followed by a 15-day tapering phase-10 mg three times daily for 5 days, 10 mg twice daily for 5 days, and 10 mg once daily for 5 days. After tapering, a prolonged low-dose maintenance phase will be implemented, where 10 mg is given once daily twice a week for an additional 10 weeks. This regimen is designed to test whether a shorter high-dose course, combined with extended low-dose maintenance, can provide equivalent control of infantile epileptic spasms syndrome while reducing the adverse effects associated with longer high-dose therapy, compared to the standard 14-day high-dose regimen (treatment arm B).
223928833|NCT06838559|DRUG|Standard Oral Prednisolone Regimen with Tapering|Prednisone oral tablets, 10 mg, administered four times daily (40 mg/day) for 14 days, followed by a tapering phase over 15 days: 10 mg three times daily for 5 days, 10 mg twice daily for 5 days, and 10 mg once daily for 5 days. No further tapering will be implemented after the initial 14-day treatment period. This regimen represents the standard therapy for Infantile Spasms in Sri Lanka.
224094574|NCT06545227|DEVICE|continuous blood glucose monitoring in a subset of women (n=25) in the early monitoring group.|To continuously monitor blood glucose from baseline to 28 weeks to determine if if there is hyperglycaemia in a subset of women (n=25)
224094575|NCT06545227|OTHER|Collection of urine, maternal blood at baseline and 28 weeks in a subset of women (n=25)|To study maternal metabolome
224282767|NCT01397266|PROCEDURE|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
223928834|NCT06793007|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic resonance imaging cholangiopancreatography
223928835|NCT04418778|BEHAVIORAL|BEAR|Building Empowerment and Resilience Therapy group
223928836|NCT06370052|PROCEDURE|excision|excision of the affected area
223928837|NCT04878029|DRUG|Cabozantinib S-malate|Given PO
223928838|NCT04878029|DRUG|Enfortumab Vedotin|Given IV
223928839|NCT04878029|OTHER|Quality-of-Life Assessment|Ancillary studies
223928840|NCT04878029|OTHER|Questionnaire Administration|Ancillary studies
224094576|NCT06545227|OTHER|Collection of umbilical cord blood, placental samples and cord tissue in a subset of women (n=25)|To study mesenchymal stem cell differentiation, change in fetal epigenetic and placental signalling pathways.
223928841|NCT06114212|DEVICE|dTMS stimulation via the H4 coil|Deep repetitive transcranial magnetic stimulation (dTMS) uses transient electromagnetic fields to stimulate the brain and is approved by Health Canada and the FDA for the treatment of depression, anxious depression, obsessive-compulsive disorder, and tobacco use disorder. Compared to the traditional TMS, dTMS is able to target brain depths ranging from 2 to 6 cm. With the use of various H-coils, dTMS has been used to target specific neural networks with the aim of producing desired clinical effects in psychiatric populations. The intervention in this study is the H4 dTMS coil which stimulates the lateral prefrontal cortex and the insula in the brain.
223928842|NCT06837909|PROCEDURE|Transversus abdominis plane (TAP) block|A regional anesthesia technique in which a local anesthetic is injected into the transversus abdominis plane under ultrasound guidance to provide postoperative analgesia.
223928843|NCT06837909|PROCEDURE|Wound infiltration|A local anesthetic technique where bupivacaine with epinephrine is injected directly into the surgical wound sites to provide postoperative analgesia.
223928844|NCT06474533|DRUG|Fluorethyltyrosine (18-F)|Given intravenously (IV)
223928845|NCT06474533|PROCEDURE|Positron Emission Tomography (PET)|Undergo Imaging Procedure
223928846|NCT03685461|OTHER|Electrocochleography|Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.
223928847|NCT04899674|DRUG|Elontril|Tablet
223928848|NCT04899674|DRUG|BI 1358894|Film coated tablet
223928849|NCT05976945|BEHAVIORAL|Imagery Rescripting|In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
223928850|NCT03774472|DRUG|Hydroxychloroquine|Given PO
223928851|NCT03774472|DRUG|Letrozole|Given PO
223928852|NCT03774472|DRUG|Palbociclib|Given PO
224094577|NCT06545227|OTHER|Maternal and neonatal outcome data collection for all women in the study|Data for maternal and neonatal outcomes will be collected
224094578|NCT06217679|OTHER|Control Oral Glucose Tolerance Test|control oral glucose tolerance test
224282768|NCT06503003|DEVICE|Leonardo® Diode laser|The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
224094579|NCT06217679|OTHER|Mixed Exercise|exercise performed in randomized order
223718109|NCT04992676|DIAGNOSTIC_TEST|actigraphy|A water resistant accelerometer with light sensor and event marker will be worn on the nondominant wrist for approximately 7 days. Activity counts from the device will be analyzed by proprietary software algorithms for determination of the following: sleep onset, sleep offset, total sleep time, total wake time, and sleep efficiency.16 Daytime sleep periods will be also scored to determine frequency and duration of naps. Daily data will be averaged across the 7-day period, as well as separately for weekdays and weekend, to compute measures of habitual sleep patterns.
223928853|NCT06837818|DRUG|Dexmedetomidine|The first patient was started on dexmedetomidine Cp 0.4 ng/ml, 2 minutes before the procedure, and the up and down method was used, with the Cp of dexmedetomidine adjusted to 0.05 ng/ml each time. The analgesia nociception index (ANI) during skull pin fixation is lower than (\<) 30 and the heart rate (HR) and arterial blood pressure (ABP) exceed (\>) 20% of the baseline (or the HR is \>100 bpm and the ABP is \>180/100 mmHg), indicating insufficient analgesia or hemodynamics (failure). If the patient is failure for the procedure, increase the Cp by 0.05 ng/ml for the next patient; the ANI is higher than or equal to (≥30) and the HR and ABP do not exceed 20% of the baseline or the HR is ≤100 bpm and the ABP is ≤180 /100 mmHg) indicates that the analgesia and hemodynamic stability are acceptable (success), and the next patient will be adjusted downward by 0.05 ng/ml.
223928854|NCT06847490|OTHER|No intervention (observational study)|This is an observational study aimed at developing and validating a predictive model for perioperative blood transfusion. The study utilizes retrospective clinical data from surgical patients to identify key risk factors associated with transfusion requirements. No experimental intervention will be applied to participants, as the study solely focuses on data analysis and model development.
223928855|NCT06847308|BEHAVIORAL|visual biofeedback through trans-perineal ultrasound|Trans-perineal ultrasound will be used to provide visual biofeedback during the active 2nd stage of labour, this for ten consecutive uterine contractions / pushing efforts
223928856|NCT01202708|DEVICE|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
223928857|NCT01202708|DEVICE|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
224094580|NCT01237951|DRUG|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
224094581|NCT01237951|DRUG|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
224094582|NCT01237951|DRUG|Gemcitabine|1875 mg/m\^2 IV (75 mg/ m2 bolus followed by 1800 mg/m\^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
224094583|NCT01237951|DRUG|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
223928858|NCT06796348|PROCEDURE|Radiofrequency ablation alone|RFA of a cancer in the thyroid gland.
223928859|NCT06796348|PROCEDURE|Surgery|Hemithyroidectomy of the thyroid lobe with cancer
223928860|NCT06483789|DRUG|HB-1|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
223928861|NCT06483789|DRUG|Telmisartan Only Product in Oral Dose Form|Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
223928862|NCT06483789|DRUG|Verapamil Only Product in Oral Dose Form|Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
223928863|NCT06483789|DRUG|Placebo|Matched Placebo will be supplied as a tablet.
223928864|NCT06571240|PROCEDURE|Anterior cruciate ligament reconstruction|Patients with anterior cruciate ligament rupture will undergo anterior cruciate ligament reconstruction surgery.
223928865|NCT05109689|BEHAVIORAL|ACT-P|ACT-P consists of five modules. The Big Picture sessions are interwoven throughout the 24 sessions to introduce the main concepts of the curriculum, such as values identification and awareness of criminal behaviors. The Emotion Regulation and Cognitive Skills modules focus on awareness of internal experiences; learning new ways to respond to internal experiences; identifying and stepping back from problematic/criminal thoughts and beliefs; awareness of behaviors in service of values versus behaviors in service of control/avoidance; and identifying steps for behavior change. The Behavioral Skills module focuses on practicing prosocial behaviors, such as speaking and listening effectively and conflict resolution. Finally, the Barriers to Change module addresses environmental or life circumstances that can hinder successful behavior change (e.g., toxic masculinity, substance use, and parenting difficulties).
223928866|NCT05109689|BEHAVIORAL|T4C|T4C is an integrated cognitive behavioral change program authored by Drs. Jack Bush, Barry Glick, and Juliana Taymans under a cooperative agreement with the National Institute of Corrections (NIC). The program is based on the principle that thinking controls how people act, and that to change the way people act, they have to control their thinking. T4C systematically presents the concept that thoughts cause one's behavior, and offenders learn to identify their own thought patterns that lead to risky behavior, and then to replace those maladaptive thoughts with new ones. T4C incorporates research from cognitive restructuring theory, social skills development, and the learning and use of problem solving skills.
223928867|NCT06793826|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T combined vaccine|prefilled syringe injection intramuscular
223928868|NCT05975593|OTHER|Tumor collection via biopsy|"Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence."
223928869|NCT05975593|OTHER|Blood collection|"Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence"
223928870|NCT05975593|DEVICE|Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)|"Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.~Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.~The imaging will be performed when possible."
223928871|NCT06637774|DEVICE|Aspirometer|a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively
223928872|NCT06637774|DEVICE|Videofluoroscopic X-ray|MBS is a fluoroscopic diagnostic test to evaluate swallowing physiology. Its images are judged by humans trained to do so.
223928873|NCT06287671|PROCEDURE|Colorectal resection or stoma closure|Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
223928874|NCT06315816|BEHAVIORAL|virtual reality glasses used during tooth extraction and extirpation treatment|The effect of virtual reality glasses used during tooth extraction and extirpation treatment under local anesthesia on anxiety and fear in 7-10 years old children
223928875|NCT06832904|DRUG|pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy|Receive four neoadjuvant cycles of oral pyrotinib (400 mg) once daily, plus intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) , nab-paclitaxel (260 mg/m2) and carboplatin（AUC=5）every 3 weeks.
223928876|NCT05026125|DRUG|Remifentanil Injection|Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
223928877|NCT05026125|DRUG|Remifentanil Injection plus 30%|Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
223928878|NCT06735053|OTHER|Virtual Reality group|Virtual reality group will perform online reality-based device following a therapeutic protocol supervised by a physiotherapist in which the level of demand will be adjusted to the patient's evolution. This programme provides a gamified and challenging online environment to enhance motor learning and induce sensorimotor adaptations. Additionally, they will receive conventional physiotherapy approach, oriented to the specific objectives of each patient, aiming to normalize tone, activate weakened muscles, facilitate movement, recover sensitivity, and compensate for functional deficits. Additionally, global kinesitherapy, motor coordination exercises, pedalier, vibration therapy (vibrosphere®), and analgesic electrotherapy will be performed if necessary.
223928879|NCT06735053|OTHER|Placebo virtual reality group|The control group will undergo a conventional physiotherapy program based on the normalization of tone, activation of weakened muscles and facilitation of normal movement, recovery of alterations in sensitivity, and compensation of lost functional deficits. In addition, global kinesitherapy exercises will be performed on a stretcher, motor coordination exercises, pedalier, vibration therapy (vibrosphere ®) and analgesic electrotherapy if necessary. Finally, in order to minimize the differences between the control and intervention groups, the participants of the control group will watch a 15-minute generic 2D video freely accessible on the Youtube platform from the VR glasses, without specific software.
223928880|NCT06837506|DRUG|Rectus sheath block|Patients will receive rectus sheath block (20 ml bilaterally, bupivacaine 0.25%) after induction of general anesthesia.
223928881|NCT06837506|DRUG|Intrathecal morphine|Patients will receive 150 µg intrathecal morphine after induction of general anesthesia.
223928882|NCT04059406|DRUG|sapablursen|sapablursen administered subcutaneously
223928883|NCT06734377|DEVICE|Delta TMS|TMS will be administered at the frequency of delta oscillation (2.2Hz)
223928884|NCT06734377|DEVICE|Theta TMS|TMS will be administered at the frequency of theta oscillation (6.5Hz)
224094584|NCT01237951|DRUG|Melphalan|60 mg/m\^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
224094585|NCT01237951|PROCEDURE|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
223928885|NCT06734377|DEVICE|Arrhythmic TMS|TMS will be administered arrhythmically. In this intervention, the inter-pulse intervals are randomized between delta and theta durations for each trial, ensuring the same total number of pulses but without rhythmic consistency
223928886|NCT05155306|DRUG|BI 1358894, intended Commercial Formulation (iCF) (T)|A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning
223928887|NCT05155306|DRUG|BI 1358894, Trial Formulation 2 (TFII) (R)|A single dose of 100 mg (milligram) BI 1358894 given orally as a film-coated tablet in the morning.
223928888|NCT06746090|BEHAVIORAL|Reminders|"Group A(Intervention): Patients who will be reminded daily via whatsapp text message.~Group B(Intervention): Patients who will be asked through a weekly phone call about elastic wear and then motivated."
223928889|NCT06747533|OTHER|Standard Patient Education|"If participants are found to be eligible to take part in this study, participants will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups: the Standard Patient Education group or the Breathe Radiation Protocol Coaching group. This is done because no one knows if one study group is better, the same, or worse than the other group.~If participants are in the Standard Participants Education group, participants will receive standard of care participants education."
223928890|NCT06747533|OTHER|Breathe Radiation Protocol Coaching group|If participants are in the Breathe Radiation Protocol Coaching group, participants will have access to a video that helps guide participants through a relaxed breath hold for the radiation treatment and also access to a coach for questions about the breathing process during radiation. This coaching will take place in the week before participants undergo radiation planning.
223928891|NCT06823388|DEVICE|acupuncture|acupuncture
223928892|NCT06823388|DEVICE|pseudo-acupuncture|The pseudo-acupuncture device can simulate the sensation of acupuncture stimulation.
223928893|NCT06779357|OTHER|Artwork|d. A 3-arm randomized control trial will be used: one arm with Zentangle workshops, the other arm with Pastel Nagomi Art, while the control group will receive usual care. Data collection from each participant will be conducted at 3-time points, at baseline (T0) before the 4-week weekly Pastel Nagomi Art or Zentangle Art program, right after the program (T1), and one month after the program (T2).
223928894|NCT04095260|OTHER|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
223928895|NCT05812859|DEVICE|Vaginal Orthosis (COSM Medical)|A vaginal orthosis will be 3-D printed by COSM Medical and provided for patients to use from week 2 through week 12 post-operatively. Device will be placed in morning and removed before bed daily.
223928896|NCT06758492|DEVICE|Video laryngoscopy used to insert thin endotracheal catheter|Video laryngoscopy used to insert thin endotracheal catheter
223928897|NCT06758492|DEVICE|Direct laryngoscopy used to insert thin endotracheal catheter|Direct laryngoscopy used to insert thin endotracheal catheter
224094586|NCT01237951|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
223718110|NCT00858130|DEVICE|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
223718111|NCT04848597|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody injection|200mg , once every 3 weeks
224282769|NCT02527330|OTHER|MR T2* imaging|Cardiac magnetic resonance imaging with T2\* imaging
223532651|NCT07159776|DEVICE|monitoring of wearable data, shopping data, biomarkers and patient reported outcomes|"1. All participants will receive a wearable device type Corsano Health Cardio watch 287-2 which is provided by the sponsor via Inovigate. Participants will be encouraged to wear the device 24h per day and need to wear the wearable device at least 12 hours per day, preferential during daytime.~2. All participants will receive a loyalty card (Xtra card Colruyt group) which is provided by the sponsor via Inovigate for food data capturing. The patient is requested to execute all grocery shopping at one of the Colruyt Group stores. He/she will always need to offer the loyalty card to the cashier prior to payment. The purchase receipt will then be automatically sent to the central food data repository at the sponsor set up for this study. Non-food or non-food related data will neither be captured nor stored during the trial.~3. biomarkers in blood and feaces will be monitored according to standard of care~4. patient reported outcomes will be monitored according to standard of care"
223928898|NCT06757790|OTHER|A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section|A comparison between primary ceaseran section women and primary vaginally delivery women to determine predictors of primary ceaseran section
223928899|NCT06759480|PROCEDURE|Laparoscopic radical hysterectomy based on space anatomy|This is a modified laparoscopic radical hysterectomy based on space anatomy. By identifying the vesicouterine ligament and four associated special spaces, the ureter can be completely liberated from the external aspect of the uterus. This skill not only reduces rate of surgical complications but also facilitates optimal tumor resection.
223928900|NCT06759480|PROCEDURE|Abdominal radical hysterectomy|This producre is a classic and traditional radical hysterectomy.
224094587|NCT05337618|DIAGNOSTIC_TEST|Full-band Electrocorticography|Diagnosis of spreading depolarizations in continuous electrocorticography
224094588|NCT05337618|COMBINATION_PRODUCT|Treatment Algorithm|Protocol for escalation and de-escalation of physiologic-targeted and pharmacologic therapies to treat and prevent spreading depolarizations
224094589|NCT01560065|DIETARY_SUPPLEMENT|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
224094590|NCT01560065|DIETARY_SUPPLEMENT|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
224094591|NCT06100783|DEVICE|Depot-medroxy Progesterone Acetate Injectable Contraceptives|Depot-medroxy progesterone acetate injectable contraceptives
224282770|NCT02758548|PROCEDURE|Blood sample|Fingerprick and venous
224282771|NCT02758548|DEVICE|POCT device|Investigational device
223928901|NCT06810219|DEVICE|Cognixion ONE|A wearable augmented reality brain computer interface with self contained computer and software to enable communication using the device input and output capabilities.
223928902|NCT06809803|DRUG|Extended-release sodium oxybate|Participants will take Extended-release sodium Oxybate (Lumryz) 4.5-9 g oral suspension in approximately ⅓ cup of water orally once a day before bedtime. Dosage of Lumryz will be the same as the equivalent total dose of the Non-Extended-release Oxybate (Xywav or Xyrem) that participants use before starting the study
223928903|NCT06809803|DRUG|Non-extended-release oxybates|Participants will take Non-Extended-release Oxybates (Xyrem oral solution or Xywav oral solution) 4.5-9 g orally per night (divided into two doses, once before bedtime and another dose 2-4 hours later) at the same dose of Xyrem or Xywav that participants use before starting the study will be continued to compare with Extended-release sodium Oxybate (Lumryz)
223928904|NCT06750380|OTHER|Tailored mat exercise program|The Group A will receive TENS plus moist hot pack and follow the Tailored mat exercise program for 10 weeks, two times per week, in 45-min sessions under supervision of trained physical therapist. The choice of exercises will be made based on the suggested exercises of Wood for the treatment of back pain, while the easiest versions of each exercise would be selected in order for the program to be adapted to older adults. Patient's outcomes will be measured at baseline and after 10 weeks.
223928905|NCT06750380|OTHER|McKenzie exercises|The Group B will receive McKenzie exercises plus moist hot pack and TENS in the region of lumbar spine for 10 minutes and Mckenzie exercises of seven to ten repetitions for 45 min/session two times per week for ten weeks. Patient's outcomes will be measured at baseline and after 10 weeks.
223928906|NCT06751264|PROCEDURE|Peritoneal combined with intrauterine water isolation|On the basis of the conventional peritoneal water isolation group, the improved technology group added additional intrauterine water isolation, and continued to inject ice saline to separate the endometrium on both sides.
223928907|NCT06751264|PROCEDURE|Peritoneal water isolation|Transabdominal injection of saline into the abdominal cavity to achieve complete separation of the uterus from the surrounding organs and structures
223928908|NCT03987282|OTHER|Enhanced usual care (EUC)|Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
223928909|NCT03987282|BEHAVIORAL|Peer-based counseling|Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
223928910|NCT06824805|BEHAVIORAL|Exercise|aerobic exercise for 30 minutes at 40-60% HRres
223928911|NCT03872284|OTHER|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
223928912|NCT04445025|DRUG|Elagolix 200 MG|Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
223928913|NCT04445025|DRUG|Leuprolide Acetate 3.75 MG/ML|Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
223928914|NCT04445025|DIAGNOSTIC_TEST|Lab work|Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
223928915|NCT05375903|DRUG|UGN-301|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
223928916|NCT05375903|DRUG|UGN-201|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
223928917|NCT05375903|DRUG|Gemcitabine|"Induction Period: Intravesical administration once weekly for 6 weeks.~Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment)."
223928918|NCT06751979|DIETARY_SUPPLEMENT|Probiotic treatment|Daily intake of a lozenge containing the probiotic strain S. salivarius M18.
223928919|NCT06751979|DIETARY_SUPPLEMENT|Placebo|Placebo
223928920|NCT04222062|DRUG|Carmustine 7.7Mg Wafer|GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
223928921|NCT06884553|DEVICE|Robotic therapy (Gloreha Sinfonia system)|"Group A will receive rehabilitative treatment using the Gloreha Sinfonia system . The treatment regimen spans five weeks and encompasses a progressive series of exercises. Gloreha features an adaptable mechanical design developed for hand rehabilitation. Its activities involve grasping and releasing, facilitated through a lightweight and flexible orthosis. The device, comprising a robotic glove and mechanical arm, enables both finger mobility and upper limb support, facilitating semi-autonomous execution of motor tasks. Gloreha's versatility allows for exercises involving the entire upper limb, including motor-cognitive serious games utilizing virtual reality and interaction with real objects. Real-time feedback enhances patient self-assessment. Moreover, the robot incorporates an automated component interfacing with flexion sensors, gauging the patient's autonomous engagement in Occupational Therapy tasks and serious games."
223928922|NCT06884553|OTHER|Occupational therapy|"Occupational Therapy is also recommended in Stroke Rehabilitation Clinical Guidelines. However, its implementation in rehabilitation services in Italy is still limited, presumably due to regulatory factors. For stroke patients, the goal of occupational therapy is to enhance the ability to perform activities of daily living, often focusing on the use of the hand and upper limb in purposeful tasks. Strategies employed by occupational therapists include assessment, treatment, compensation strategies, assistive technologies, and environmental adaptations.~Occupational therapy appears to enhance performance in activities of daily living and reduce the likelihood of impairment in these abilities, although the evidence is of low quality. There is also limited and moderately quality evidence in the area of occupational therapy for addressing depressive and anxiety symptoms in hospital-based rehabilitation for physical disabilities."
223928923|NCT06884553|BEHAVIORAL|Control|Participants will be provided guidance by a skilled physiotherapist to follow a customized exercise regimen independently within the comfort of their homes. This program will specifically target the upper limb and will be tailored according to the evaluation performed at the initial assessment.
223928924|NCT06743178|BEHAVIORAL|Photo of a person injecting drugs|Exposed to a photo of a person injecting drugs
224094592|NCT02226965|DRUG|PNT2258|
223928925|NCT06743178|BEHAVIORAL|Photo of EMS responding to an overdose (White)|Exposed to a photo of EMS responding to an overdose (White)
223928926|NCT06743178|BEHAVIORAL|Photo of EMS responding to an overdose (Black)|Exposed to a photo of EMS responding to an overdose (Black)
223928927|NCT06743178|BEHAVIORAL|Photo of a person receiving treatment (Jail)|Exposed to a photo of a person receiving treatment (Jail)
223928928|NCT06743178|BEHAVIORAL|Photo of a person receiving treatment (Community)|Exposed to a photo of a person receiving treatment (Community)
223928929|NCT06743178|BEHAVIORAL|Photo of a person in recovery (White)|Exposed to a photo of a person in recovery (White)
223928930|NCT06743178|BEHAVIORAL|Photo of a person in recovery (Black)|Exposed to a photo of a person in recovery (Black)
223928931|NCT06743178|BEHAVIORAL|Photo of a family member of an overdose decedent|Exposed to a photo of a family member of an overdose decedent
223928932|NCT06890975|BEHAVIORAL|Lifestyle Coaching|"The schedule for the individual and group coaching sessions is summarized below:~* Individual Coaching: Six one-on-one online sessions with a trained dietician, starting with an initial 30-minute session at baseline, followed by sessions at one month and then every other month.~* Group Coaching: 60-minute group online sessions with up to 15 participants per group. Group sessions schedule: there will be a total of 13 group sessions. They will meet once a week for the first 4 weeks, twice monthly for the next 8 weeks of follow-up, and then monthly for the remaining follow-up until the 13th session."
223928933|NCT06892028|DEVICE|EEG-based personalized TMS|Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
223928934|NCT06892028|DEVICE|Sham Comparator|Sham Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG). No stimulation is provided.
223928935|NCT06890715|DRUG|Test product (T): Ramelteon Modified-Release Tablets|Oral, take 1 tablet at a time, once a day.
223928936|NCT06890715|DRUG|Reference product (R): Ramelteon Tablets|Oral, take 1 tablet at a time, once a day.
223928937|NCT06749886|DRUG|Denosumab|Denosumab, 120 mg subcutaneous injection, every 21-28 days a cycle, given on the first day, a loading dose is given on d8 of the first cycle, and continued use
223928938|NCT06749886|DRUG|tislelizumab|Tislelizumab, 200 mg intravenous infusion, every 21 days a cycle, given on the first day, and continued use
224094593|NCT05394259|DRUG|Piflufolastat F18|Given by vein (IV)
224094594|NCT02662790|OTHER|Doppler|
224094595|NCT02029742|BEHAVIORAL|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
224094596|NCT02029742|BEHAVIORAL|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
223928939|NCT06749886|DRUG|Docetaxel|Docetaxel, 60 mg/m2 intravenous infusion, every 21 days a cycle, given on the first day, and continued use.
223928940|NCT06894641|BEHAVIORAL|Cognitive Behavior Therapy for Older Adults (CBT-OA)|CBT-OA integrates modifications to standard CBT to consider age-related physical, cognitive and psychological changes. CBT-OA also integrates positive psychiatry principles for older adults to promote behavioural change and health attitude change.
223928941|NCT06750900|OTHER|NORMAL CONDITION|They perform 3 lumbar extensions until the onset of pain without virtual reality
223928942|NCT06750900|OTHER|UNDERSTATED CONDITION|They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10%less than they are really moving.
223928943|NCT06750900|OTHER|OVERSTATED CONDITION|They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10% more than they are really moving.
223928944|NCT06892223|DRUG|Monalizumab (anti-NKG2A monoclonal antibody)|Monalizumab (humZ270 mAb, IPH2201) is a humanized IgG4 monoclonal antibody targeting the NKG2A receptor on NK cells. Administered intravenously at a dose of 1 mg/kg on days +30 and +44 after haploidentical stem cell transplantation with post-transplant cyclophosphamide (PT-Cy) as GVHD prophylaxis, Monalizumab aims to enhance NK cell activity by blocking NKG2A. This intervention is unique in its timing, as it is given during a period when CD94/NKG2A+ NK cells are abundant, and its two-dose regimen is designed to optimize NK cell reconstitution. It targets patients with hematologic malignancies, such as AML and MDS, to improve GVHD-free and progression-free survival by enhancing NK cell-mediated immunity. This approach differs from other therapies by focusing on NK cell alloreactivity in the post-transplant setting. Cyclophosphamide is used as part of the pre-transplant conditioning regimen and is part of the inclusion criteria, but it is not part of the protocol-specific intervention.
223928945|NCT06891209|OTHER|Non-Interventional Study|Non-interventional study
224094597|NCT00275561|DRUG|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
224094598|NCT00275561|DRUG|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
224094599|NCT06158243|OTHER|Sono-anatomical Study|The arm is abducted (90°), externally rotated, with the forearm flexed over the arm (90°). A linear ultrasound probe (8-15 MHz) is placed in front of the humeral head, in a sagittal plane. Location begins at axillary level, vessels, nerves and humerus are identified, and the probe is moved medially to reach and identify the humeral head.
224094600|NCT01530243|DRUG|Placebo|same as tolterodine and terazosin dose
223532652|NCT07160543|BEHAVIORAL|Imagination Exposure|Participants were guided to close their eyes and imagine discarding their personal object. The experimenter provided standardized verbal instructions to help participants visualize moving the item from their own space into a trash bin.
223718112|NCT05728905|OTHER|Therapeutic exercise|Intervention with therapeutic exercise: coordination, relaxation and disc recapture exercises.
224094601|NCT01530243|DRUG|Terazosine|2 mg BID
224094602|NCT01530243|DRUG|Tolterodine|2 mg daily
224094603|NCT01530243|DRUG|Tolterodine + Terazosin|2mg daily and 2mg BID
224094604|NCT00407355|DRUG|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
223928946|NCT06756568|DIAGNOSTIC_TEST|Reduced Morbidity|Early and accurate diagnosis using ultrasound minimizes delays in treatment initiation, thereby preventing complications such as chronic pain and abscess formation. By reducing the severity and duration of the disease, ultrasound contributes to improved patient well-being and a quicker recovery trajectory.
223928947|NCT06759155|RADIATION|de-intensified radiation|Adjuvant radiation will be administered on a de-intensified schedule.
223928948|NCT06760377|DIETARY_SUPPLEMENT|Dietary supplement Group|Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.
223928949|NCT06758947|DRUG|Upadacitinib 15 MG|oral tablet upadacitinib
223928950|NCT06758947|DEVICE|Cellcept Oral Product|active control group 2000mg MMF daily
223928951|NCT06748781|PROCEDURE|Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant.|2.5% Calcium Hypochlorite used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
224094605|NCT00407355|DRUG|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
224094606|NCT05852756|BEHAVIORAL|pecha kucha|pecha kucha training
224094607|NCT06873308|DEVICE|UCP-LF CAA assay|dry LF-CAA, or CAA
224094608|NCT06936761|DRUG|Propofol|This is an observational study about routines of anesthesia induction and extubation
224094609|NCT06936761|DRUG|Sevoflurane|This is a retrospective evolution of anesthesia drugs used routinely in an anesthesia clinic.
224094610|NCT02058121|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
224094611|NCT02058121|BEHAVIORAL|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
224094612|NCT02593929|DRUG|ruxolitinib|
224282772|NCT04810169|DEVICE|Smart inhaler|"* Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~* Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given"
223928952|NCT06748781|PROCEDURE|Pulpectomy using Saline as root canal irrigant|Saline used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
223928953|NCT06748118|OTHER|Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.|This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.
223928954|NCT06753318|DIAGNOSTIC_TEST|The assistance of the Joint-AI model|Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis
223928955|NCT06753318|DIAGNOSTIC_TEST|The assistance of the interpretable Joint-AI model|Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis
223928956|NCT06761859|OTHER|Aromatherapy Inhalation in Psychiatric Nurses|Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The lavender essential oil to be used in the study will be dropped 3 drops onto a cotton handkerchief cut into a disc shape and fixed to the clothes of the psychiatric nurses, 20 cm away from their noses, and they will be asked to inhale it for 30 minutes.
224094613|NCT03232112|DRUG|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
224094614|NCT03232112|DRUG|BD PosiFlush (saline)|Subcutaneous injection once-weekly
224094615|NCT00608465|DRUG|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
224094616|NCT00608465|DRUG|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
224094617|NCT01912885|DEVICE|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
224094618|NCT01912885|DEVICE|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
224094619|NCT01912885|DEVICE|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
224094620|NCT01912885|DEVICE|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
224094621|NCT01912885|DEVICE|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
224094622|NCT02393092|BEHAVIORAL|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
224094623|NCT02393092|BEHAVIORAL|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
224094624|NCT02393092|BEHAVIORAL|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
224094625|NCT02477098|DRUG|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
223718113|NCT05728905|OTHER|Orthopedic manual therapy|Intervention with orthopedic manual therapy: traction, ventral sliding and massage.
224094626|NCT02477098|DRUG|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
224094627|NCT02395315|DEVICE|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
223928957|NCT06754631|DRUG|Continuous Nebulization of Salbutamol|Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).
223928958|NCT06754631|DRUG|Intermittent Nebulization of Salbutamol|were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
223928959|NCT06755918|BEHAVIORAL|Control|Children will be monitored when fowler is in position during the use of nebulizers. In the Fowler position, the drug will be drained into the nebulizer chamber. Mask and nebulizer connections will be completed. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. Routine nursing care is applied during the use of nebulizer. During the use of a control group nebulizer, routine nebulizer will be used without video game and mask painting. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
223928960|NCT06755918|BEHAVIORAL|Video game|Children will be monitoring while the fowler position during the use of nebulizers. While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, the Water-Sorting Game will be introduced while the use of nebul will be introduced and you will be asked to play. After the receipt of the receipt, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
223928961|NCT06755918|BEHAVIORAL|Mask painting|While the Fowler position is in the position of the drug, the drug will be drained into the nebulizer reservoir. The nebul mask will be attached to cover the mouth and nose. The patient will be told to breathe slowly and deeply. It will be examined whether sufficient steam is formed from the nebulizer device. The continuation of the application steps will be ensured until the nebulizer drug application is finished. At the same time, mask painting process will be introduced while the use of nebul continues. For mask painting, six color paint will be given and the shapes and colors will be completely left to the child by leaving it to him. After the mask painting and receipt is finished, the child's anxiety scale-status scale will be requested to be filled by the child's parent and child. The treatment questionnaire developed by the researchers will be filled by the researcher. After 24 hours a day after the first nebulizer treatment of hospitalization, measurements will be made again.
223928962|NCT06760026|PROCEDURE|2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision|2-octyl cyanoacrylate tissue adhesive applied continuously over the Pfannenstiel-type cesarean incision
223928963|NCT06760026|PROCEDURE|subdermal suture|wound closure with subdermal sutures using 2-0 nylon thread, under the same evaluation scheme
223928964|NCT06761768|DRUG|Corticosteroids Triamcinolone Acetonide|ultrasound-guided sacroiliac joint corticosteroid injections (1 ml SHINCORT INJ 10 MG/ML + 1 ml 2% Xylocaine)
223928965|NCT06761768|DEVICE|extracorporeal shockwave|a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: low to moderate, adjusted based on patient tolerance; frequency: 5 Hz; 2000 shocks per session)
223928966|NCT06761768|DEVICE|extracorporeal shockwave(minimum intensity)|a three-week course of weekly extracorporeal shockwave therapy sessions (intensity: minimum setting on the device; frequency: 5 Hz; 2000 shocks per session)
224094628|NCT02395315|DEVICE|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
224094629|NCT00928980|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
224094630|NCT00928980|DRUG|Optimal Medical Care|Therapeutic dose of antidepressant medication
224094631|NCT01987544|OTHER|Ergometer Training|
224094632|NCT01987544|OTHER|Motivation|
224094633|NCT05692349|DEVICE|MRI|MRI will be employed to assess muscle composition, evidence of degeneration or replacement by fat
224094634|NCT04215094|DIAGNOSTIC_TEST|postoperative fever, serum procalcitonin, C-reactive protein and white blood cell coun|All patients in Intracranial Infection group were cured with antibiotic treatment
224094635|NCT02511522|OTHER|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
224094636|NCT02511522|RADIATION|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
224094637|NCT00267254|DRUG|torcetrapib/atorvastatin|
224094638|NCT00267254|DRUG|simvastatin|
224094639|NCT06111326|DRUG|BC3402 injection|Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
224094640|NCT06111326|DRUG|Durvalumab injection|Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
223532653|NCT07160543|DEVICE|Non-immersive Virtual Reality Exposure|Participants used a desktop computer to interact with a virtual household environment. Their personal object, photographed beforehand, was digitally embedded in the scene. Using keyboard and mouse, participants navigated to the virtual garage and dragged the object into a virtual trash bin. The experimenter remained present to provide support.
224094641|NCT05992779|OTHER|Measuring the vocal audiometry of patients.|Measuring vocal audiometry at 6 months, 1 year and annually until the last date of follow-up
224094642|NCT05992779|OTHER|Measuring data loging|Measuring data loging at 6 months, 1 year and then annually until last date of follow-up
224094643|NCT01596205|BEHAVIORAL|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
223928967|NCT06760325|BEHAVIORAL|Tidal Model Intervention|"The model emphasizes long-term developmental care, extending support from hospital to home after discharge. This approach equips individuals with skills to understand and address challenges, emphasizing therapeutic interventions and sustained support through professionals or community groups. By focusing on the chaos and tide concepts of the Tidal Model, psychosocial interventions aim to enhance independence, manage symptoms, and improve quality of life.~In this arm, Tidal Model-based approaches will be applied during home visits to COPD patients. Within the scope of the intervention, psychosocial needs of patients will be assessed, individualized care plans will be created and symptom management and independence will be promoted by focusing on the chaos and tide concepts of the Tidal Model."
223928968|NCT03857646|DRUG|Intralipid, 20% Intravenous Emulsion|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
223928969|NCT03857646|DRUG|Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
223928970|NCT06771427|OTHER|acupuncture GB20 or GB20 plus BL2|acupuncture at acupoint GB20 or GB20 plus BL2 twice a week 8 weeks for efficacy evaluation.
223928971|NCT06771427|DRUG|Chinese herbal tea TBDESJS|Chinese herbal tea TBDESJS 8 weeks on Nourishing Yin and Moistening Dryness the ocular dryness evaluation.
223928972|NCT06772116|PROCEDURE|Focal Therapy|"Primary focal treatment (targeted or partial gland ablation) of PCa lesion(s) detected on mpMRI, where a PCa ISUP 2 or 3 has been identified (PCa ISUP 1 outside the treatment areas is acceptable, regardless of volume).~Focal treatment will be performed using one of the following energy-based techniques: high-intensity focused ultrasound (HIFU), cryotherapy (CRYO), brachytherapy (BT), irreversible electroporation (IRE), focal laser ablation (FLA), vascular-targeted photodynamic therapy (VTP), or radiofrequency ablation (RFA). The specific technique will depend on the rules, approvals, and regulations of the country where the treatment is performed."
223928973|NCT06771726|DEVICE|RedScar App|use of the RedScar© app on patients' smartphones. Patients will complete a brief health questionnaire and upload a wound photograph to the app, which will provide recommendations based on the risk of infection detected. Simultaneously, an in-person wound assessment will be conducted by the investigator to compare results.
223928974|NCT06759844|BEHAVIORAL|Educational Booklet|A printed booklet containing general information on chronic disease management provided to participants for reference without interactive or digital features
224094644|NCT01596205|BEHAVIORAL|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
224094645|NCT00036218|DRUG|sumanirole|
224094646|NCT00036218|DRUG|ropinirole|
224282773|NCT03690167|OTHER|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
224282774|NCT03690167|OTHER|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
224282775|NCT03690167|OTHER|Control|Nothing applied after extraction
224282776|NCT00110734|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
224282777|NCT03038763|OTHER|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
224282778|NCT03038763|DIAGNOSTIC_TEST|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
224282779|NCT01416116|DRUG|QUTENZA|topical
224282780|NCT01416116|DRUG|Lidocaine|topical
224282781|NCT01416116|DRUG|Tramadol|oral
224282782|NCT05507320|BEHAVIORAL|Mechanisms of action perception and execution|Study the mechanisms of action perception and execution
224282783|NCT05193422|DIAGNOSTIC_TEST|Spirometry - baseline|"Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF.~Baseline spirometry will be performed before CPET in both study arms"
224282784|NCT05193422|DIAGNOSTIC_TEST|Spirometry - post CPET|Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms
223532654|NCT07158710|DRUG|HSK42360|Oral administration, QD/BID
223928975|NCT06759844|BEHAVIORAL|Mobile Health Application|A mobile health application that facilitates self-management of chronic conditions through daily education, personalized goal setting, and lifestyle monitoring. The intervention aims to improve participants' health behaviors and clinical outcomes by promoting active engagement with their health.
223928976|NCT06777719|DRUG|Eight Treg|"The experimental drug Eight Treg is given to patients with a peripheral IV infusion the day before the graft (cf section 5.1.5. Infusion of the experimental drug of this protocol) in addition to the maintenance protocol combining corticosteroids, tacrolimus and MPA which are classically pre-scribed in kidney graft patients from a living donor at the Nantes CHU."
223928977|NCT06778590|PROCEDURE|Piezoelectric technique in third molar germectomy|Application of piezoelectric technique in third molar germectomy procedures
223928978|NCT06778590|PROCEDURE|Traditional technique in third molar germectomy|Application of traditional technique in third molar germectomy procedures
223928979|NCT06777602|DRUG|[14C] MK-5475|\[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1.
223928980|NCT06777810|OTHER|The infected wound of the patient's foot ulcer was collected|The infected wound of the patient's foot ulcer was collected
223928981|NCT06778304|DRUG|Gonal F|The reference formulation is the recombinant human follicle-stimulating hormone injection (Gonal-f®) originally developed and produced by Merck Serono
223928982|NCT06778304|DRUG|jzb30|The test formulation is the recombinant human follicle-stimulating hormone injection (code: JZB30) produced by Shanghai Jingze Biotechnology Co., Ltd./Chengdu Jingze Biopharmaceutical Co., Ltd.
223928983|NCT06777940|OTHER|Kegel exercises|It consists of 25 patients who will receive Kegel exercises with Myokinetic active release of trigger points in quadratus lumborum, rectus abdominis and gluteus medius. Patient will be in lying position with empty bladder. Ask patient to tight pelvic floor muscle group and hold tight from 3-5 seconds Then relax muscle group from 3-5 seconds with Myokinetic therapy targeted at releasing muscle of quadratus lumborum, rectus abdominis and gluteus medius release was applied passively by sustained pressure for 8-10 seconds. This protocol consisted of three sets with 2 minutes of rest..Participants will be asked to perform exercise 30 times each session following hold and relax of muscle group for 3-5 seconds
223928984|NCT06779110|PROCEDURE|Percutaneous Coronary Intervention|Using OCT to guide PCI in ISR
223928985|NCT06778668|PROCEDURE|TAP block with bupivacaine only|Patients undergoing laparoscopic cholecystectomy will receive TAP block with bupivacaine only after induction and before the surgical procedure begins.
223928986|NCT06778668|PROCEDURE|TAP block with bupivacaine and fentanyl|Patients undergoing laparoscopic cholecystectomy will receive a TAP block with bupivacaine and fentanyl after induction and before the surgical procedure begins
223928987|NCT06778044|OTHER|ReDirection 1.0|A free, anonymous, online, self-guided cognitive behavioral therapy (CBT) intervention. Consists of 6 modules.
223928988|NCT06778044|OTHER|ReDirection 2.0|A free, anonymous, online, self-guided, cognitive behavioural therapy (CBT) intervention. Consists of 5 modules and the option for asynchronous messaging with a ReDirection specialist.
223928989|NCT06778044|OTHER|Waitlist|Participants in the waitlist control will wait six weeks before starting active treatment. While on the waitlist, participants will respond to questions about ongoing sexual urges and behaviour.
223928990|NCT06779084|OTHER|contemporary fasting principle|(clear fluids for up to 2 hours before anesthesia)
223928991|NCT06779084|OTHER|conventional fasting time|(≥ 8 hours)
223928992|NCT06779279|DEVICE|Water flosser and super flosser|Participant will use in one area superfloss and the other area waterfloss
223928993|NCT06779279|DEVICE|Orthodontic brush|Participant will use orthodontic brush to brush in the upper/lower quadrant
223928994|NCT06760689|DEVICE|virtual reality glasses|One of the videos chosen by the patient will be opened in the virtual reality glasses and will be played for 20 minutes.
223928995|NCT06760689|OTHER|scale|The patient received standard nursing care. Scales were filled in after the course.
223928996|NCT02158507|DRUG|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
223928997|NCT06775743|DRUG|ORIENT-31 regimen|Sintilimab plus bevacizumab plus platinum-doublet chemotherapy
224094647|NCT06098885|OTHER|extraction orthodontic treatment|bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
224094648|NCT02660580|DRUG|MSB11022|Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
224094649|NCT02660580|DRUG|Humira®|Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
224094650|NCT05794165|DRUG|Thrombate infusion|Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
224094651|NCT05794165|DRUG|Placebo|Normal Saline will be given as one time IV before the 3rd dose of Enoxaparin. The dose will be based on patient weight.
224094652|NCT05723185|OTHER|Outpatient visit|Patients will be seen and treated at the outpatient clinic like in the usual care
224094653|NCT05823558|DIAGNOSTIC_TEST|Lomber Muscle Thickness Measurement|Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
224094654|NCT04632199|DRUG|111In-IPN01087 Low dose|Administered once via slow intravenous injection.
224094655|NCT04632199|DRUG|111In-IPN01087 High dose|Administered once via slow intravenous injection.
224094656|NCT00377962|DRUG|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
224094657|NCT00377962|DRUG|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
223928998|NCT06775743|RADIATION|SBRT|"Based on the results of the response evaluation, personalized SBRT will be arranged after cycle 4:~A. Complete response, CR: continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression, intolerable toxic side effects, or up to two years.~B. Stable disease, SD/partial response, PR: if the residual lesions do not exceed three organs and five lesions, and if the investigator deems SBRT feasible, curative-dose stereotactic radiotherapy covering all residual lesions will be administered, with dosing based on the NRG-BR001 study.~C. If the residual lesions exceed three organs or five lesions, SBRT (24 Gy/3 Fx) targeting 1-3 selected tumor lesions will be performed, and then continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression.~D. Progressive disease, PD: subsequent treatment is conducted according to the standard guidelines."
224282785|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - baseline|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured before CPET in both study arms"
224282786|NCT05193422|DIAGNOSTIC_TEST|Nasal peak inspiratory flow - post CPET|"Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask.~nPIF will be measured after CPET in both study arms"
224094658|NCT00377962|DRUG|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
224094659|NCT00377962|DRUG|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
224094660|NCT05751408|PROCEDURE|gait analysis using 3D (Vicon) and IMU (Movella)|Subjects are measured using Vicon 3D analysis, combined with IMU-sensors
224282787|NCT05193422|DIAGNOSTIC_TEST|Oxygen saturation|Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms
224282788|NCT05193422|DIAGNOSTIC_TEST|Heart Rate|Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms
224282789|NCT05193422|DIAGNOSTIC_TEST|End-tidal CO2|Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms
224282790|NCT05193422|DIAGNOSTIC_TEST|Respiratory rate|Continuous monitoring of RR using a Microstream capnograph, in both study arms
224282791|NCT05193422|DIAGNOSTIC_TEST|Temperature|Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm
224282792|NCT05193422|DIAGNOSTIC_TEST|Humidity|Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm
224282793|NCT05193422|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|"CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg.~CPET will be performed in both study arms"
224282794|NCT05193422|DIAGNOSTIC_TEST|Discomfort level|"Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020).~Both study arms, after CPET."
224282795|NCT06427044|DRUG|Anterior serratus block group|Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
224282796|NCT00418067|DEVICE|Endeavor|Zotarolimus-eluting stent
224282797|NCT00418067|DEVICE|Cypher|Sirolimus-eluting stent
224094661|NCT00186602|BEHAVIORAL|Peer counseling|
224282798|NCT00418067|DEVICE|Taxus Liberte|Paclitaxel-eluting stent
224282799|NCT02020967|OTHER|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
224282800|NCT04944316|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet
224282801|NCT04944316|BEHAVIORAL|Dietary intervention|Portion-controlled diet (compliant with ADA guidelines)
223532655|NCT07159191|DRUG|Envafolimab Injection, Axitinib Tablets|"Envafolimab + Axitinib~* Envafolimab 400 mg, subcutaneous injection, day 1, every 3 weeks;~* Axitinib 5 mg, orally, twice daily"
224282802|NCT03722862|DIETARY_SUPPLEMENT|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
224282803|NCT03722862|DIETARY_SUPPLEMENT|Placebo|Participants will receive the placebo/dextrose.
224282804|NCT03722862|DIETARY_SUPPLEMENT|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
224282805|NCT00973089|OTHER|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
224282806|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
224282807|NCT03110796|DEVICE|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
224282808|NCT03110796|DEVICE|Dressing without LU3103209|Dressing without LU3103209
223532656|NCT07158996|DRUG|Biological: cizutamig|Cizutamig will be dosed according to the protocol.
223532657|NCT07160699|DRUG|Botulinum Neurotoxin Type A|The effectiveness of the combination of BoNT with treatment goal specific non-pharmacological interventions will be evaluated.
223532658|NCT07160699|OTHER|Non-pharmacological therapies|Depending on the treatment goal different non-pharmacological therapies as a standard of care will be provided
223532659|NCT07160348|OTHER|Questionnaire and Physical Exam|Translation and validation of the existing HPES-Symptom and HPES-Impact Questionnaires in the Greek population
223532660|NCT07159620|DRUG|VEN (Venetoclax)|Orally
223532661|NCT07159620|DRUG|Azacitidine (AZA)|Subcutaneous injection
223532662|NCT07159620|DRUG|Chidamide|Orally
224282809|NCT00384306|DRUG|prednisolone|
224282810|NCT02578745|DEVICE|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (\~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
224282811|NCT02578745|OTHER|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
223532663|NCT07159620|DRUG|vindesine|intravenous infusion
223532664|NCT07159620|DRUG|Dexamethasone|intravenous infusion or orally
223928999|NCT06777264|BIOLOGICAL|Biological: single dose of Inaticabtagene autoleucel|Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.
223929000|NCT06776302|DIAGNOSTIC_TEST|Raise of blood flow through the brain|At each patient two test are preformed. The first test is based on increasing blood flow through the brain through a controlled gradual infusion of norepinephrine (noradrenalin). The patient will receive such an infusion immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission. The second test is based on passive elevation of the lower extremities. The second test will also be performed on the patient immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission.
223929001|NCT06767501|OTHER|E-GRAFT ™|E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
223929002|NCT06767501|DEVICE|FIBRACOL™|510K FDA cleared Collagen alginate dressing
223929003|NCT06767046|DRUG|KRAS-specific Autologous TCR-T cell injection|Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
224094662|NCT05671900|DRUG|Gemcitabine 1000 mg, Docetaxel 37.5g|6 weekly instillations of gemcitabine (1 gram of gemcitabine in 50 ml of sterile water) followed immediately by docetaxel (37.5 mg of docetaxel in 50 mL of saline) and subsequent monthly maintenance installations for those with no evidence of disease.
224094663|NCT04511299|OTHER|SMOFlipid 20%|Fish oil-enriched intravenous lipid emulsion
224094664|NCT04511299|OTHER|Lipofundin 20%|MCT/LCT standard intravenous lipid emulsion
224094665|NCT02856737|OTHER|eye masks and earplugs|Materials similar to those offered on long commercial flights
224094666|NCT02202603|DRUG|Teriparatide|single oral tablet
224094667|NCT02202603|DRUG|Teriparatide|subcutaneous standard injection
224094668|NCT02202603|DRUG|placebo|Oral placebo
224282812|NCT06591182|OTHER|Survey using a questionnaire.|Observational study, participants are not assigned an intervention as part of the study (Survey using a questionnaire).
224282813|NCT00136760|DRUG|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
224282814|NCT00136760|DRUG|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
224282815|NCT00136760|DRUG|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
224282816|NCT00136760|DRUG|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
224282817|NCT04540692|DRUG|Docetaxel or Paclitaxel|Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks
224282818|NCT04540692|DRUG|Cyclophosphamide + Doxorrubicin|Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
224282819|NCT02663882|BEHAVIORAL|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
224282820|NCT02663882|BEHAVIORAL|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
224282821|NCT04139031|DEVICE|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
224282822|NCT04458467|DEVICE|Continuous Infusion|A continuous infusion of ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room.
224282823|NCT04458467|DEVICE|Automated Intermittent Boluses|Administration of automated intermittent boluses of ropivacaine 0.2% (8 mL every 2 hr with 4 mL patient controlled bolus with 30-minute lockout) will be initiated in the recovery room, but with a 5-hour delay for the first bolus (can be overridden by patients if they would like to initiate their perineural infusion earlier than 5 hours).
224094669|NCT02786641|DRUG|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
224282824|NCT03754504|DIETARY_SUPPLEMENT|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
224282825|NCT03754504|DIETARY_SUPPLEMENT|Placebo|3 capsules/day of a placebo comparator
223532665|NCT07161583|DEVICE|Advanta VXT Vascular Graft|The Advanta VXT graft is a two (2)-layer graft employing a single layer ePTFE graft, which is then wrapped with an additional layer of ePTFE for increased support. Some Advanta VXT configurations include Helix, which is a monofilament bead wrapped circumferentially around a portion or the entire length of the graft (such a graft is also called a Ringed Graft). The helix rings are bonded to the exterior surface of the graft. Advanta VXT Tapers are formed by changing the graft diameter, expanding from a small Inner Diameter (ID) to a larger ID (with the result that one end is larger).
223532666|NCT07161583|DEVICE|Flixene Vascular Graft|The Flixene vascular graft is a three (3)-layered graft comprised of ePTFE. The Flixene graft was designed with an additional layer of ePTFE. As a result of its design, ring support is not necessary
224282826|NCT04766216|OTHER|Patient self-management|Patient makes independent decisions regarding warfarin therapy changes using warfarin dosing tools
224282827|NCT04766216|OTHER|Usual care provided by anticoagulation providers|Normal care provided by anticoagulation providers
223718114|NCT05006196|DIAGNOSTIC_TEST|Outpatient MRI|"Participation in the study includes up to a maximum of 2 study visits. The visits will include clinical measurements (height, weight, blood pressure), blood tests, MRI scan and patient symptoms and experience questionnaires.~There will be no medical interventions as part of the study. All participants will receive standard-of-care by their healthcare provider/s. With the participant's consent, the participant's primary care physician will be made aware of their participation in the study. Furthermore, participants will be informed of any structural abnormalities found in the MRI scan (e.g. abnormal vessels, haemangioma, tumour, cyst, among others) and abnormal blood test results as these may have clinical implications. These will be managed by the routine clinical care team as part of standard care."
223718115|NCT02639143|DRUG|ticagrelor|
223718116|NCT02639143|DRUG|Clopidogrel|
223929004|NCT06750627|PROCEDURE|Continuous Erector Spinae Plane Block|Catheter are placed between the erector spinae muscle and the transversus processus with ultrasound guidance, blocking the dorsal and ventral ramus from the thorax and abdominal spinal nerves, at the level of T5. Local anesthesia is injected. Drugs used are Bupivacaine 0.25% with volume of 25 ml.
223929005|NCT06750627|DRUG|Multimodal Intravenous Analgesia|"Multimodal intravenous analgesia refers to the use of multiple intravenous (IV) agents with different mechanisms of action to provide effective pain relief. The goal is to achieve synergistic effects that improve analgesia while minimizing the doses of individual drugs, thereby reducing side effects. This approach is often used in perioperative and acute pain management.~Patient will receive combinations of opioid through Patient Controlled Analgesia (PCA) device, NSAIDs, and Paracetamol (Acetaminophen)"
223929006|NCT06780722|OTHER|blood sampling|"* The first sample is taken at the start of the therapeutic stop.~* The second sample is taken when the mean arterial pressure drops to 45mmHg.~* The third sample is taken when circulatory arrest occurs.~* The fourth sample is taken at the start of extracorporeal circulation. These four samples will be destroyed at the end of the study."
224282828|NCT06535555|DEVICE|Investigational Safety and Feasibility|"Technical feasibility will be assessed based on a five-point rating scale assessing the ease-of-use, ureteral visibility, and time required to identify the ureter using ActivSight™. All images and video of the ureter will be recorded, but surgeon feedback will be used to assess technical success based on a five point scale, rather than these (subsequently de-identified) recordings.~Safety will be confirmed through clinical assessments and evaluation of adverse events intraoperatively and through a 28-day follow-up period using the criteria listed below. All adverse events will be adjudicated by the site's Principal Investigator (PI) to judge the relatedness of the adverse event to either the administration of riboflavin or the use of the prototype ActivSight™ device (or whether the adverse event was unrelated to either)"
223718117|NCT03119584|DRUG|linaclotide or placebo|
223718118|NCT04284410|BEHAVIORAL|CLASP-PE arm|Participants will complete 8-16 weekly or twice weekly individual therapy sessions (with total session number determined by clinical need, as is typical in clinical trials of PE for PTSD), 1 therapy session (session 3) with a supportive significant other (SO), consistent with the CLASP protocol, and 11 brief (30 minute) phone calls as possible, with calls occurring every week in between therapy sessions and on a less frequent basis following treatment termination up to 3 months after the final in-person therapy session. In addition, the supportive SOs will complete 11 brief (30 minute) phone calls with the therapist at the same frequency as participants. Participants will sign a release of information prior to involving the supportive significant other in treatment.
223718119|NCT01149226|DRUG|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
223718120|NCT02021240|DRUG|Ketamine|
223718121|NCT02021240|DRUG|Dexamethasone|
223718122|NCT02021240|DRUG|Normal Saline|
223718123|NCT05953311|OTHER|Blood analysis|Blood analysis for neurological biomarkers measurements
224282829|NCT03743090|DIAGNOSTIC_TEST|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
224282830|NCT04904484|DEVICE|iZephyr hood|Assessment of an aerosol containment device
224282831|NCT04068987|DIAGNOSTIC_TEST|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2\* mapping, ECV mapping) to determine the MR signal characteristics of the body
224282832|NCT04602793|DIAGNOSTIC_TEST|ultrasonography|All ultrasonographic examinations were performed by a single physiatrist experienced in musculoskeletal sonography. The full course of the sciatic nerve (SN), tibial nerve (TN), and common peroneal nerve (CPN) was assessed in a craniocaudal direction starting from the subgluteal fold to the popliteal fossa. The probe was placed axially on the nerves (perpendicular to the nerve) and the cross-sectional area (CSA) was measured at the same level proximal to the bifurcation for the SN , and at a point distal to the bifurcation of the SN for the TN and CPN (Figure 2). The values from the normal sides were accepted as controls.
224282833|NCT06014879|BEHAVIORAL|Type 1 Doing Well (T1DW) Program|"Parent and youth will each have access to a version of the app. The study app activities include parents and youth:~* noticing what the youth does well for diabetes;~* setting and tracking a family diabetes goal in the app; and~* having a weekly meeting to review what the youth is doing well with diabetes and progress on the family diabetes goal.~Parents and youth will also have access to age-appropriate libraries of videos with diabetes-specific content.~Parents and youth will also have a conversation with the youth's diabetes care provider at a regularly scheduled diabetes appointment at participating hospital sites."
223718124|NCT05953311|OTHER|Cognitive tests|Questionnaires assessing cognitive function
223718125|NCT02166905|BIOLOGICAL|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
223718126|NCT02166905|DRUG|Epacadostat|Given PO
223718127|NCT02166905|OTHER|Laboratory Biomarker Analysis|Correlative studies
223718128|NCT02166905|OTHER|Pharmacological Study|Correlative studies
223718129|NCT02166905|DRUG|Poly ICLC|Given SC
223929007|NCT06769932|DIAGNOSTIC_TEST|preoperative computed tomography|subject's muscle mass from preoperative computed tomography (CT) images.
224094670|NCT02786641|DRUG|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
224094671|NCT02786641|DRUG|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
224094672|NCT02786641|RADIATION|IMRT|IMRT for all patients
223929008|NCT06842771|OTHER|Normal Saline (0.9% NaCl)|"Women will undergo planned, laparoscopic gynecologic surgery with an intraperitoneal wash of 20 mL of saline (standard) at the end of the operation, prior to insufflation, release, and skin closure.~The wash will be instilled into the peritoneal cavity and the surgical area (over the vaginal cuff and along the bilateral pelvic sidewalls to the paracolic gutters).~All participants will rate their pain using a Visual Analogue Scale (VAS). The VAS is a numerical rating system where the scores range from zero (0) to ten (10), with zero indicating 'no pain at all' and ten indicating 'the worst possible pain'.~Participants will be asked to rate their current level of pain and also report their current dosage of pain medication at the following intervals: pre-operatively, 2 hours post-operatively, and 24 hours post-operatively."
223929009|NCT06842771|DRUG|Marcaine hydrochloride without epinephrine 0.5%|Women will undergo planned, laparoscopic gynecologic surgery with an intraperitoneal wash of 20 mL Marcaine hydrochloride (bupivacaine) without epinephrine 0.5% (the comparator) at the end of the operation, prior to insufflation, release, and skin closure. The wash will be instilled into the peritoneal cavity and the surgical area (over the vaginal cuff and along the bilateral pelvic sidewalls to the paracolic gutters). All participants will rate their pain using a Visual Analogue Scale (VAS). The VAS is a numerical rating system where the scores range from zero (0) to ten (10), with zero indicating 'no pain at all' and ten indicating 'the worst possible pain'. Participants will be asked to rate their current level of pain and also report their current dosage of pain medication at the following intervals: pre-operatively, 2 hours post-operatively, and 24 hours post-operatively.
223929010|NCT06738537|OTHER|Focus Groups/Quantitative Survey for Patients|5 quantitative focus groups will be conducted with 5-10 patients each to elicit the range of outcomes patients consider important when selecting treatment options. 100 quantitative surveys to characterize how patients with severe MR prioritize outcomes when making treatment decisions.
223929011|NCT06738537|OTHER|Focus Group/Quantitative Survey for HCPs|5 quantitative focus groups will be conducted with 5-10 providers to elicit the range of outcomes providers consider important when recommending treatment options to patients. 100 quantitative surveys to characterize how providers prioritize outcomes for patients with severe MR when making treatment recommendations.
223929012|NCT06738537|OTHER|Qualitative Focus Group|Qualitative focus groups will be conducted to determine barriers and facilitators to implementing shared decision making in multidisciplinary mitral valve heart team clinics.
223929013|NCT06791694|OTHER|Resins, Composite|Graduate students; healthy maxillary central teeth and color measurements will be performed with 4 different methods in at least 32 patients aged between 18-40 years. Firstly, students will be asked to make color measurements using the traditional method with two different color scales (Vita classical and Vita 3D master). As the third method; the enamel color of the teeth will be determined on digital photographs using the buton technique. Finally, tooth color will be measured on the buccal surface of the central teeth using a spectrophotometer.
223929014|NCT06775431|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection|Pethidine will be administered intravenously in group A 0.5 mg/kg as premedication
223929015|NCT06775431|DRUG|Pethidine Hydrochloride 50 Mg/mL Solution for Injection administered intrathecally|0.2 mg/kg pethidine in trathecally will be administered with bupivacaine 0.5% in group B
223929016|NCT06782737|OTHER|Dietetic interventión with mediterranean diet|Personalized dietary Mediterranean diet
223929017|NCT04307615|COMBINATION_PRODUCT|Oxygen + continuous positive airway pressure (CPAP)|Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment
223929018|NCT04307615|DRUG|Oxygen|Oxygen: 20 min treatment followed by 10 min rest and assessment
223929019|NCT05619783|DRUG|AMX0035|Combination of 3 g phenylbutyrate and 1 g taurursodiol
223929020|NCT06823531|OTHER|Not applicable (Observational Study)|Not applicable (Observational Study)
223929021|NCT03869892|DRUG|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
223929022|NCT03869892|DRUG|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
223929023|NCT03869892|BIOLOGICAL|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
224094673|NCT02786641|DRUG|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
224094674|NCT04972383|COMBINATION_PRODUCT|Platelet Rich Plasma|In the Platelet Rich Plasma group, 4mL Platelet Rich Plasma was given.
224094675|NCT04972383|COMBINATION_PRODUCT|Hyaluronic Acid|In the Hyaluronic group, 3mLHYAJOINT Plus was given.
224282834|NCT06014879|OTHER|Diabetes-Related Information and Resources Program|Parent and youth will receive diabetes-related information and resources in the form of electronic handouts. They will receive one handout per month by email during the 6-month intervention period. These handouts include a variety of diabetes-related topics curated by the study team. Handouts will not include any specific information about the youth's health.
224282835|NCT02839993|DEVICE|tDCS|
224282836|NCT02839993|BEHAVIORAL|training|
224282837|NCT04674709|DRUG|Oleander 4X - single|Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.
224282838|NCT04674709|DRUG|Oleander 4X - double|Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.
224282839|NCT04674709|DRUG|Oleander 4X - quadruple|Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.
223929024|NCT03869892|BIOLOGICAL|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
224094676|NCT05741021|DRUG|F520|F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).
224094677|NCT05741021|DRUG|Pemetrexed|A chemotherapy medication used to treat a number of types of cancer.
224094678|NCT05741021|DRUG|Carboplatin|A chemotherapy medication used to treat a number of types of cancer.
224094679|NCT05741021|DRUG|Paclitaxel|A chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer (NSCLC).
223929025|NCT05139979|BEHAVIORAL|Breathing and Wellness Webinar|"Simha Kriya : a 3-minute energizing breathing practice to expand lung capacity and improve immunity, to be practiced twice daily.~Nadi Shuddhi - a gentle 4-minute breathing practice for creating mental balance and relaxation, to be practiced for a minimum of 4 minutes daily.~Isha Kriya - a 15-minute guided meditation that incorporates the breath and the awareness to create mental clarity and health, to be practiced at least once (ideally twice) daily."
223929026|NCT05139979|OTHER|Routine Daily Activity|Participants in the control group are asked to perform routine daily activities until enrolled into the intervention arm.
223929027|NCT06843083|DIAGNOSTIC_TEST|CEM protocol|CEM combines low-energy mammography with high-energy contrast-enhanced imaging to highlight areas of neo-angiogenesis, which are indicative of malignancy. This intervention will be used to evaluate the diagnostic performance of CEM in detecting and characterizing breast lesions, especially in patients with dense breast tissue or inconclusive findings from routine mammography.
224094680|NCT02997124|PROCEDURE|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
224094681|NCT02997124|PROCEDURE|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
224094682|NCT03206658|DRUG|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
224094683|NCT03206658|DRUG|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
224094684|NCT02042066|DEVICE|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
224094685|NCT00367809|BEHAVIORAL|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
224094686|NCT00367809|BEHAVIORAL|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
224094687|NCT00367809|BEHAVIORAL|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
224094688|NCT06109545|PROCEDURE|Laparoscopy|Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed
224094689|NCT02154646|DRUG|LY2157299|Administered orally
224094690|NCT02154646|DRUG|Gemcitabine|Administered IV
224094691|NCT06390670|DIETARY_SUPPLEMENT|Colostrum Bovinum supplementation|In the experimental procedure each athlete was supplemented with a chronic dose of 25 g/day of COL. Supplement was particularly prepared for the study from a first post-delivery milking and had a high content of IgG (60%; certified Colostrum Bovinum; Agrapak, Poland). The COL was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the COL supplement in 250 mL of plain water.
224094692|NCT06390670|OTHER|Placebo treatment|In the control procedure each athlete was supplemented with a chronic dose of 25 g/day of placebo (PLA). PLA was particularly prepared for the study, and was an isoenergetic/isomacronutrient product (high quality protein) prepared for the trial (Agrapak, Poland). The PLA was provided in the powder form and were taken twice a day (12.5 g in the morning and 12.5 g in the afternoon). Participants were instructed to dissolved each portion of the PLA preparation in 250 mL of plain water.
224094693|NCT01716819|OTHER|Urine sample|dosages on one spot and 24h collection
224094694|NCT01716819|OTHER|Blood sample|dosages
224094695|NCT01716819|OTHER|Assessment of sleep apnea syndrome|
224094696|NCT01716819|OTHER|Electrocardiogram|
224094697|NCT01716819|OTHER|Glucose tolerance test|
224094698|NCT01716819|OTHER|Echocardiography|
223929028|NCT06843083|DIAGNOSTIC_TEST|breast MRI|"MRI (Magnetic Resonance Imaging):~MRI will be used as an alternative imaging modality for breast lesion detection and characterization. MRI provides detailed soft tissue imaging and is widely used in the evaluation of high-risk patients or those with dense breast tissue. The results from MRI will be compared to CEM findings to determine which modality offers superior diagnostic accuracy and clinical impact."
223929029|NCT03991156|DEVICE|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|Audio Visual System
223929030|NCT03991156|OTHER|Quality of Life Survey, PedsQL3.0|Quality of life survey using the PedsQL 3.0 Cancer Module
223929031|NCT03991156|OTHER|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).\[24\] is a survey to measure anxiety
223929032|NCT03956680|DRUG|BMS-986301|Specified dose on specified days
223929033|NCT03956680|BIOLOGICAL|Nivolumab|Specified dose on specified days
223929034|NCT03956680|BIOLOGICAL|Ipilimumab|Specified dose on specified days
224094699|NCT01716819|OTHER|cardiac and abdominal magnetic resonance imaging|
224094700|NCT01716819|OTHER|Ambulatory blood pressure monitoring|
224094701|NCT01716819|OTHER|Echotracking|
224094702|NCT01716819|OTHER|Pulse wave velocity|
224094703|NCT01716819|OTHER|Composition of body mass by Dual x-ray absorptiometry|
224094704|NCT06124703|DRUG|Prednisone tablet|Prednisone acetate tablet (5 mg prednisone acetate per tablet) was provided
223532667|NCT07159984|BEHAVIORAL|Education on Changes During Pregnancy|In the first session of the researcher-prepared training presentation, women will be informed about the structure and functions of their internal and external reproductive organs, as well as changes in physical, hormonal, social, and lifestyle activities. After the first session, there will be a 15-minute break before the second session, which will include evidence-based training on the effects of pregnancy-related changes on stress, couple harmony, and quality of life. Methods for coping with stress and pregnancy-related complaints, process management that positively impacts couple harmony, and healthy lifestyle behaviors that enhance quality of life will be discussed.
223718130|NCT01686529|PROCEDURE|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
223718131|NCT01686529|DRUG|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
223718132|NCT05041205|DIETARY_SUPPLEMENT|Beauty drink powder|Beauty drink powder is designed as a oral beauty product to provide benefits to skin
223929035|NCT05591859|DEVICE|Restoration Anatomic Acetabular Shell|Multi-hole acetabular shell intended for cementless fixation into a prepared acetabulum and is a modular component design that is assembled intra-operatively.
223929036|NCT06640010|OTHER|Non-Interventional Study|Non-interventional study
223929037|NCT06732531|DRUG|BH011|BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.
223929038|NCT06751199|DRUG|human umbilical cord mesenchymal stem cells|Portal vein infusion human umbilical cord mesenchymal stem cells
223929039|NCT06751199|DRUG|allogeneic islet|Portal vein infusion of allogeneic islet
223929040|NCT06752733|PROCEDURE|electrical cardioversion|synchronized electrical shocks to restore normal sinus rhythm in patients with atrial fibrillation, performed under sedation
223929041|NCT06756087|RADIATION|Radiofrequency Ablation (RFA)/Vertebroplasty+Stereotactic Radiotherapy|"All patients received OsteoCool™ radiofrequency ablation + vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital.~Standard Control Group: Patients received SBRT (Stereotactic Body Radiation Therapy) from the Department of Radiation Oncology 2-3 weeks post-surgery. This included pre-radiation positioning, mold preparation, and radiation therapy. After radiation therapy, patients rested for 2 weeks before resuming their original anti-tumor treatment and starting follow-up.SBRT therapy was administered according to the recommendations, using one of the following dose and fractionation schemes: 4 sessions of 24 Gy, 5 sessions of 30 Gy, 6 sessions of 36 Gy, or 7 sessions of 42 Gy."
223929042|NCT06756087|PROCEDURE|Experimental|patients received OsteoCool™ radiofrequency ablation+vertebroplasty for spinal metastatic tumors at the Department of Bone Oncology, Shanghai First People's Hospital. patients continued their original anti-tumor treatment within 1-2 weeks based on their recovery. No further local intervention was performed at the surgical site, and normal follow-up was started.
223929043|NCT06749470|DRUG|Jieyu Chufan Capsules|4 capsules, tid; 8 weeks
224094705|NCT06124703|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract (EGb) is a compound drug derived from Ginkgo biloba trees native to China.
223532668|NCT07159204|DRUG|Paclitaxel polymer micelle immunocombination|Paclitaxel polymer micelle immunocombination
223718133|NCT05041205|DEVICE|Cosmetic apparatus|This device is designed to let participants to experience brighter, softer, smoother skin and an energizing facial massage. A synergestic effect when combine with beauty drink powder is expected.
223929044|NCT06749470|DRUG|Jieyu Chufan Capsules simulant|4 capsules, tid; 8 weeks
223929045|NCT06760676|RADIATION|Pulsed low dose rate radiotherapy (PLDR)|Radiation 5 times per week, 2Gy each time which divided into 10 pulse doses, each pulse interval was 3 minutes, the dose rate was 0.067 Gy/min, and each treatment time was 30 minutes.
224094706|NCT04294888|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
224094707|NCT00742781|DIETARY_SUPPLEMENT|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
224094708|NCT02691273|BEHAVIORAL|cellular application treating diabetes using breathing technique|
224094709|NCT03951987|DRUG|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
223718134|NCT02617628|DRUG|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
224094710|NCT03951987|DRUG|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
224094711|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|The dose groups of ZG005 for dose escalations are set as 0.3 mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, and 20mg/kg, intravenous infusion, once every 3 weeks.
224094712|NCT06233292|BIOLOGICAL|ZG005 Powder for Injection|Recommended Phase 2 Dose (RP2D) of ZG005 monotherapy, intravenous infusion, once every 3 weeks.
224282840|NCT04674709|DRUG|Placebo|The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
224282841|NCT01290237|DRUG|vancomycin hydrocloride|see description of study arms
224282842|NCT00249015|BEHAVIORAL|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
224282843|NCT03070015|BEHAVIORAL|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI \> 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables \& no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch \& 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (\~50% kcal from carbohydrate,\~25% from protein,\~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
223929046|NCT06760676|DRUG|Alpaloritovorelli antibodies|PLDR external irradiation therapy was administered simultaneously with 5mg/kg Alpaloritovorelli antibodies for a 3-week regimen, the following maintenance treatment was 2 years.
223929047|NCT06748261|DIAGNOSTIC_TEST|CCTAI model|Using a derivative sub-cohort, the investigators aim to first develop an CCTA-based AI-assisted (CCTAI) screening model to distinguish patients with cardiac abnormalities from those normal controls. Second, the investigators target at developing a CCTAI diagnostic model with multi-classification output of cardiomyopathy diagnosis. Both models will be tested in internal validation cohort and external validation cohort.
224094713|NCT05442385|OTHER|Evidence based management|clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
224094714|NCT04905797|DIAGNOSTIC_TEST|Emotional Stop Signal Task|Emotional Stop Signal Task (modified version from CANTAB). Outcome Measure is commission and omission errors - higher score (percentage) indicate worse performance.
224094715|NCT04905797|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging (fMRI) Diffusion Tensor Imaging (DTI) Volumetry
224094716|NCT04905797|OTHER|World Health Organizations Disability Assessment Schedule (WHODAS 2.0)|Self-reported data on World Health Organizations Disability Assessment Schedule - 36 items self-administered (WHODAS 2.0). Assessing six domains of functional disability in daily life. Each item is rated on a Likert scale ranging from 0-4. Total range 0 - 144. High scores scores indicate more severe disability.
224094717|NCT04905797|DIAGNOSTIC_TEST|Personality Inventory for DSM-5 (PID-5)|Self-rated personality traits through Personality Inventory for DSM-5 (PID-5). Self-reported scores on domains of personality traits. Higher scores in one domain indicate more pronounced traits in this domain.
224094718|NCT04905797|DIAGNOSTIC_TEST|Stop Signal Task (CANTAB)|The estimate of time where an individual can successfully inhibit their responses 50% of the time.
224094719|NCT04905797|DIAGNOSTIC_TEST|Intra-Extra Dimensional Set Shift (CANTAB)|"1. The number of trials for which the outcome was an incorrect response (subject pressed the incorrect button within the response window), calculated across all assessed trials.~2. The total number of times that the subject chose a wrong stimulus - i.e. one incompatible with the current rule, adjustment for every stage that was not reached."
224282844|NCT03070015|BEHAVIORAL|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts \& sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day \& men ate 1500 kcal/day. Subjects with BMI \>40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
223532669|NCT07159100|DEVICE|Active tDCS + elbow flexion exercise|"Participants will receive anodal tDCS targeting motor-related cortical areas using either traditional sponge-based or high-definition (HD)-tDCS configurations. The intervention is delivered at 1.5-2.0 mA for 20-30 minutes, either before or during a sustained submaximal isometric contraction task designed to induce fatigue.~tDCS will be administered in a counterbalanced crossover design, where each participant completes both active stimulation and sham stimulation conditions in separate sessions spaced at least one week apart. Sham stimulation mimics the sensory effects of active tDCS (30-second ramp-up and down) without delivering sustained current.~The intervention is unique as the target population is cancer survivors with persistent fatigue \>6 months post-treatment. Also, the tDCS is combined with neurophysiological assessments, including EMG, TMS, EEG, and MRI, to provide neurophysiological evidence of acute effects."
223532670|NCT07159100|DRUG|Sham tDCS + elbow flexion exercise|"Participants will receive anodal tDCS targeting motor-related cortical areas using either traditional sponge-based or high-definition (HD)-tDCS configurations. The intervention is delivered at 1.5-2.0 mA for 30 seconds to mimic the sensation of active tDCS (20 minutes long), either before or during a sustained submaximal isometric contraction task designed to induce fatigue.~tDCS will be administered in a counterbalanced crossover design, where each participant completes both active stimulation and sham stimulation conditions in separate sessions spaced at least one week apart. Sham stimulation mimics the sensory effects of active tDCS (30-second ramp-up and down) without delivering sustained current."
223532671|NCT07160309|DEVICE|Densah Bur|Implant site preparation will be performed using the Densah bur system to achieve osseodensification in narrow alveolar ridges prior to implant placement.
223532672|NCT07160309|DEVICE|Magnetic Mallet|Implant site preparation will be performed using the Magnetic Mallet device to achieve osseodensification in narrow alveolar ridges prior to implant placement.
223718135|NCT02065375|DRUG|Omaveloxolone Ophthalmic Suspension 1.0%|
223718136|NCT02065375|DRUG|Omaveloxolone Opthalmic Suspension 0.5%|
223929048|NCT06669676|OTHER|acupuncture|patients will be given acupuncture in addition to standard medical treatment to prevent ponv
224282845|NCT00388037|DRUG|sunitinib malate|Given PO
224282846|NCT00388037|OTHER|laboratory biomarker analysis|Correlative studies
224282847|NCT00602537|DRUG|Venlafaxine|75 to 375 mg
224282848|NCT00602537|DRUG|Lithium Carbonate|300 to 2400 mg
224282849|NCT04451928|DIAGNOSTIC_TEST|Serum sample analysis|Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels
224282850|NCT00329628|DRUG|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
224282851|NCT00329628|DRUG|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
223929049|NCT06669676|OTHER|No acupuncture|patients will be given standard medical treatment to prevent ponv
223532673|NCT07158723|OTHER|Higher protein dietary pattern|Follow energy-restricted (10% calorie reduction), higher protein dietary pattern (1.6 g protein/kg body weight)
223532674|NCT07158723|OTHER|Calorie restriction|Follow energy-restricted (10% calorie reduction) dietary pattern for 16 weeks. No restrictions on macronutrient content.
223532675|NCT07159126|DRUG|DS3610a|Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.
223532676|NCT07159477|BEHAVIORAL|Skin to Skin contact|Fathers are briefed on skin-to-skin: what it is/isn't, why it matters, how to do it, and benefits for father, mother, and baby. Keep the room quiet; close windows to avoid drafts. Do not perform if the father is sleeping. Smokers must not perform while smoking and should do it before smoking when possible. After mother-infant skin-to-skin and breastfeeding, start father-infant contact within four hours of birth. If clothing is unsuitable, provide a surgical gown. Place the diapered infant upright on the father's bare chest. The father supports shoulders and back, maintains eye contact, speaks softly, and touches the baby. Cover both with a blanket; only mother, father, and infant remain, with the researcher silent. Continue at least 15 minutes; end if the father requests care or the infant needs care (diapering, dressing, breastfeeding). Repeat once for the early-contact group and at least daily until discharge for the frequent-contact group; on discharge, remind daily home practice.
223718137|NCT02065375|DRUG|Placebo|
223929050|NCT06761690|OTHER|hybrid simulated wound training|hybrid simulated wound training
223929051|NCT06761443|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
223929052|NCT06761443|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 8 weeks and each patient will make 3 visits (week 0, week 4, week 8).
223929053|NCT05962489|OTHER|Clinically optimized deep brain stimulation|Participants will have DBS implanted as standard-of-care. We will be examining the effects of their regular clinical stimulation settings versus no stimulation.
223929054|NCT06782750|OTHER|Physiotherapy|Traditional physiotherapy treatment was applied 5 days in a week, 1 hour in a day for 6 weeks.
223929055|NCT06784050|PROCEDURE|Bilateral Balanced Occlusion|Dentures designed under this scheme feature a fully bilateral balanced articulation, ensuring bilateral, simultaneous contact of the anterior and posterior denture teeth in both centric and eccentric positions. This occlusal scheme is aimed at promoting stability and functionality of the dentures during various mandibular movements.
223929056|NCT06784050|PROCEDURE|Monoplane Occlusion|This scheme utilizes zero-degree teeth to create a flat occlusal plane, which is designed to simplify the occlusal contacts and minimize the transmission of lateral forces during mastication. The aim is to improve masticatory efficiency by reducing the complexity of tooth contact
223929057|NCT05147636|PROCEDURE|Extubation with PEEP|No aspiration within the 3 minutes before extubation and extubation with 10cmH2O PEEP
223929058|NCT05147636|PROCEDURE|Endotracheal Aspiration|Aspiration during cuff deflation
223929059|NCT04056910|DRUG|ivosidenib and nivolumab|Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events. Nivolumab will be administered at 480 mg IV every 28 days.
223929060|NCT06784128|OTHER|Therapeutic Exercise Program|All patients were administered a therapeutic exercise program that included passive, active-assisted, and active range of motion exercises, stretching, strengthening, and mobilization exercises based on their level of movement restriction and pain intensity for 5 sessions per week for 2 weeks under the supervision of an experienced physiotherapist.
224282852|NCT01310361|DRUG|Amoxicillin|
224282853|NCT01310361|DRUG|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
224282854|NCT02537509|DRUG|Cholecalciferol|
224282855|NCT02537509|DRUG|Placebo of cholecalciferol|
224282856|NCT05181267|DIETARY_SUPPLEMENT|Intermittent fasting|Subjects fast from after dinner and throughout the next day, i.e., 36 hours of fasting, after which they are allowed to eat as usual until dinner the same day. Then they fast again for 36 hours, and this regimen will continue for three entire weeks.
224282857|NCT04272489|DEVICE|EMG-Pattern Recognition Controller|Using an electromyographic (EMG)-based pattern recognition controller to move an upper limb prosthetic device in a home trial.
224282858|NCT05070390|DRUG|Enlicitide Chloride|10 mg capsule administered orally
224282859|NCT03124290|OTHER|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
224282860|NCT06393764|OTHER|Collection of biological samples|Collecte of blood and urine samples
224282861|NCT00703976|DRUG|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
224282862|NCT00703976|DRUG|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
223532677|NCT07161154|DEVICE|Transcutaneous bone conduction hearing system|The Sentio system is an active transcutaneous bone conduction hearing system (single armed study)
223532678|NCT07159568|OTHER|Pet dog visit|Pet dog visit will take place during dedicated time slots, following prior verification of the dog's hygiene criteria. The dog may stay in the patient's room for a maximum of 15 minutes. After the visit, an evaluation questionnaire will be completed by the healthcare staff and by the relative who accompanied the dog. The patient's evaluation questionnaire will be completed at ICU discharge if patient is able to respond, or at most 28 days after inclusion if the patient remains in the ICU.
223929061|NCT06784128|OTHER|Hot Pack|As part of the treatment protocol, a hot pack was applied to the affected shoulder area for 30 minutes prior to any other therapeutic interventions. This initial application of heat was intended to promote muscle relaxation, increase local blood circulation, and reduce joint stiffness, effectively preparing the shoulder for the subsequent treatments, including therapeutic exercise, TENS and TECAR therapy. The hot pack was maintained at a temperature between 40-45°C, which is considered optimal for achieving therapeutic heat without causing discomfort or skin irritation.
224282863|NCT00703976|DRUG|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
224282864|NCT00703976|RADIATION|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
224282865|NCT02119962|BEHAVIORAL|Working memory training|
224282866|NCT02119962|BEHAVIORAL|Placebo training|
224282867|NCT05778240|BEHAVIORAL|Phone call|"Participants were given the vaccination appointment card and participants received a telephone call every month two days before their appointment. Participants were reminded that they have a set appointment and were asked to plan the day of their appointment as detailed below. The standard script used in the telephone call in every hospital was as follows:Hello, we are calling you because you are enrolled in the palivizumab prophylaxis research program. As you know, you have a vaccination appointment on \[enter date\] at \[enter time\]. To help you plan your day of appointment, we have a few short questions.~1. At your appointment day, will you be coming to the hospital from home, or will you need to get permission from your workplace?~2. What kind of transportation do you plan to take to come to the hospital at your appointment day?~3. At what time do you plan to leave home or work to come to the hospital?"
224282868|NCT05778240|BEHAVIORAL|Text message|Participants were given the vaccination appointment card and participants were included in a messaging group (on Whatsapp or SMS, depending on the participant's preference) where, twice a month they received a message informing them on RSV, on the additional risks caused by RSV infection in children with congenital heart diseases and on the benefits of adherence to the prophylaxis program. These messages also involved statements about the high number of patient families that kept their appointments in the previous month.
224282869|NCT05778240|BEHAVIORAL|Control|Participants were given the vaccination appointment card.
224282870|NCT04067154|DIAGNOSTIC_TEST|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
224282871|NCT05543694|DRUG|Bupivacaine Hydrochloride|Subjects will receive a dose of bupivacaine as described in the arm section of this trial
224282872|NCT00932594|PROCEDURE|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
224282873|NCT00932594|OTHER|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
224282874|NCT00647894|DRUG|Alprazolam Extended-Release Tablets 1 mg|
224282875|NCT00647894|DRUG|Xanax XR Tablets 1 mg|
224282876|NCT01199120|DIETARY_SUPPLEMENT|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
224282877|NCT06384794|DEVICE|Sperm capacitation through the ZyMōt®Sperm Separation Device®|This chip based on microfluidic properties will help us to separate and recover the semen sample with improved sperm quality. It is composed of two microwells, one initial and one final, and a porous membrane through which the sample will be filtered and the capacitated spermatozoa with better motility will be selected. Syringe 850µL of the initial seminal sample into the first well and 750µL of seminal wash medium into the second well. The device is incubated at 37°C for up to 30 minutes. During this incubation, the sample will travel by microfluidic properties from the first well through the porous membrane to the second well. This membrane will filter those spermatozoa with a higher motility. Thus, at the end of the established incubation time, the medium with the selected spermatozoa from the second well (final well) will be collected with a syringe. After this, the sample will be processed and ready for the following procedures.
224282878|NCT06384794|PROCEDURE|Swim-up|The swim-up is a sperm capacitation technique in which the motile spermatozoa of the seminal sample, after centrifugation and incubation, move to the upper part of the medium. In this way, spermatozoa with good progressive motility will remain in the supernatant.
224282879|NCT00760526|DEVICE|Continuous glucose monitor|Daily use of a continuous glucose monitor
224282880|NCT00760526|DEVICE|Home blood glucose monitor|Home monitoring 3 or more times a day
224282881|NCT01472926|DRUG|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
224282882|NCT01472926|DRUG|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
224282883|NCT02191566|DRUG|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
224282884|NCT02191566|DRUG|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
224282885|NCT00027417|DRUG|Liothyronine sodium/triiodothyronine|
224282886|NCT00027417|PROCEDURE|Cardiopulmonary bypass and cardiac surgery|
224282887|NCT00898768|PROCEDURE|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
224282888|NCT03098693|BEHAVIORAL|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
224282889|NCT03098693|BEHAVIORAL|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
224282890|NCT03098693|BEHAVIORAL|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
224282891|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with devices|Devices
224282892|NCT04201028|BEHAVIORAL|Video Conferencing Health Coaching with no devices|No Devices
224282893|NCT00288925|DRUG|Z-360|
224282894|NCT02539368|DRUG|CT-P13|biosimilar infliximab
224282895|NCT02539368|DRUG|Remicade|infliximab
224282896|NCT03230123|DIETARY_SUPPLEMENT|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
224282897|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 1|Laparoscopic Hypo gastric Neural Plexus Block
224282898|NCT05345782|DRUG|MARCAINE AND BETAMETHAZONE 2|Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
223929062|NCT06784128|DEVICE|TECAR Therapy|TECAR therapy was administered using the BTL-6000 TR-Therapy PRO device which emitted energy at a frequency of approximately 500 kHz and used three types of electrodes: active, neutral, and static application electrodes. Each patient was seated in a comfortable position with the affected shoulder exposed, ensuring adequate support and stability throughout the treatment session. The affected shoulder was prepared with a conductive gel to enhance energy transfer. During the session, the capacitive electrode was initially applied, targeting the superficial muscles and tendons around the shoulder joint using circular or linear movements for 5 min. Following this, the resistive electrode was employed to target deeper structures, focusing on the joint capsule and rotator cuff muscles for 10 min. The output power was adjusted based on the patient's tolerance, ensuring a comfortable warm sensation without causing discomfort or burning feeling or pain.
224094720|NCT04905797|DIAGNOSTIC_TEST|Spatial Working Memory Test (CANTAB)|"1. The number of times the subject incorrectly revisits a box in which a token has previously been found. Calculated across all assessed four, six and eight token trials.~2. The number of times a subject begins a new search pattem from the same box they started with previously. If they always begin a search from the same starting point, we infer that the subject is employing a planned strategy for finding the tokens. Therefore, a low score indicates high strategy use (1 = they always begin the search from the same box), a high score indicates that they are beginning their searches from many different boxes. Calculated across assessed trials with 6 tokens or more."
224094721|NCT04905797|DIAGNOSTIC_TEST|Multitasking Test (CANTAB)|"1. The number of trials for which the outcome was an incorrect response.~2. The median latency of response (from stimulus appearance to button press). Calculated across all correct, assessed trials.~3. The difference between the median latency of response on the trials that were congruent versus the trials that were incongruent. A positive score indicates that the subject is faster on congruent trials and a negative score indicates that the subject is faster on incongruent trials. A higher incongruency cost indicates that the subjects take longer to process conflicting information.~4. The difference between the median latency of response during assessed blocks in which both rules are used versus assessed blocks in which only a single rule is used. A positive score indicates that the subject responds more slowly during multitasking blocks and indicates a higher cost of managing multiple sources of information."
224094722|NCT04905797|DIAGNOSTIC_TEST|Cambridge Gambling Task Test|"1. The proportion (0 - 1) of all trials where the subject chose the majority box color. Calculated over all assessed trials from both the ascending and descending conditions in which the number of boxes of each color differed.~2. Risk adjustment is a measure of sensitivity to risk, based on the ability to modify choices in the light of information about the probability of different outcomes and to track the optimal outcome on eaeh trial. The measure is calculated from the average proportion of points that the subject ehose to bet with, taking into aeeount the number of colored boxes in the majority.~3. Allows for the dissociation between risk taking and impulsivity by determining whether subjects simply just place a bet at the first opportunity. Calculated as CGT Risk Taking for all trials from the descending condition minus CGT Risk Taking for all trials from the ascending condition."
224094723|NCT06583083|DRUG|Sintilimab with P-GEMOX Regimen|Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
224094724|NCT06583083|DRUG|P-GEMOX Regimen|Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
224094725|NCT06081387|OTHER|Resistance training|Sarcoplasm stimulating training system. This program will run for a total of 16 weeks and three sessions a week. This exercise plan is designed in three 5-week periods plus a familiarization session.
224094726|NCT05166057|OTHER|Synchronized online telerehabilitation exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient by videoconference.
224094727|NCT05166057|OTHER|Videobased telerehabilitation exercise program|A video containing breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be given to the patient and will be asked to exercise regularly.
224094728|NCT05166057|OTHER|Hospital based outpatient exercise program|Breathing exercises, inspiratory muscle training, peripheral muscle strengthening training and gait training will be applied to the patient in the hospital..
224094729|NCT05054985|DEVICE|Multi-Branched Thoracoabdominal Stent Graft System|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with multi-branched thoracoabdominal stent graft system .
224094730|NCT06226597|DEVICE|Fitbit device|Daily use of a fitbit wearable activity tracker device.
224094731|NCT02750358|DRUG|Enzalutamide|
224094732|NCT02750358|BEHAVIORAL|assessment|
224282899|NCT00931996|DRUG|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
224094733|NCT03539432|DRUG|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
224094734|NCT03539432|DRUG|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
224094735|NCT04440267|DRUG|vincristine|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094736|NCT04440267|DRUG|daunorubicin|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094737|NCT04440267|DRUG|cyclophosphamide|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094738|NCT04440267|DRUG|L-Asparaginase|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094739|NCT04440267|DRUG|prednisone|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094740|NCT04440267|DRUG|mercaptopurine|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094741|NCT04440267|DRUG|methotrexate|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094742|NCT04440267|DRUG|dexamethasone|acute lymphoblastic leukemia (ALL) -based chemotherapy
224282900|NCT00267163|DRUG|donepezil|
224094743|NCT04440267|DRUG|Tyrosine kinase inhibitor|acute lymphoblastic leukemia (ALL) -based chemotherapy
224094744|NCT03427437|DRUG|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
224282901|NCT00267163|DRUG|Placebo|
224282902|NCT02095886|DRUG|BMS-955176|BMS-955176
224282903|NCT05186779|DRUG|Progestagen|Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
223929063|NCT06784128|DEVICE|TENS|TENS was employed as a non-invasive pain management technique in this study, utilizing the Intellect Advanced device manufactured by Chattanooga Group. Electrodes were strategically placed over the affected shoulder, ensuring coverage of the most painful areas as well as relevant nerve pathways to maximize the analgesic effect. A symmetric biphasic waveform was selected, with a frequency of 100 Hz and a pulse duration of 100 microseconds. The intensity of the stimulation was adjusted according to the patient's tolerance, typically aiming for a strong, yet comfortable tingling sensation.
223929064|NCT05029414|PROCEDURE|Endovascular Therapy|Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
223929065|NCT06847568|DRUG|Adrenaline|Intracoronary 10 mcg adrenaline will be given via the guiding catheter in study group after restoration of epicardial coronary flow of the culprit vessel and achievement of TIMI I flow either after wiring and/or passage of a deflated balloon and/or PTCA with a small balloon, and/or use of thrombus aspiration and before stenting.
223929066|NCT06869343|OTHER|Physical Therapy|Subjects will begin physical therapy at either 2 or 6 weeks s/p a rTSA.
223929067|NCT06878768|DEVICE|Additional free breathing MR acquisitions|
223929068|NCT06830967|OTHER|Prehabilitation|Prehabilitation will consist of exercise therapy, smoking cessation, nutritional counselling, psychological intervention and patient education.
223929069|NCT06830967|BEHAVIORAL|Exercise therapy|Exercise therapy will consist of tailored 6-week prescribed exercise program consisting of 150-minutes of moderate-vigorous exercise weekly based on patient-to-patient resource availability (eg. neighborhood walk, body-weight exercises). It will target moderate intensity (11-13 on the Borg Rating of perceived exertion scale) and will be adjusted throughout the program as required. It will target aerobic, strength and inspiratory muscle training (IMT). Participants will receive a logbook where the exercise specialist will prescribe the intensity, type, time, and frequency of aerobic, strength and IMT exercises. Each time the participant performs the prescribed home-based exercises they will register their activity in the logbook provided. Exercise specialist will review the logbook every week and will adjust the home-based exercise plan accordingly to ensure both safety and exercise progression.
223929070|NCT06830967|BEHAVIORAL|Smoking cessation counselling|Smoking cessation will be provided through motivational interviewing with a counselor who will assess participant's smoking status, willingness and readiness to quit and provide prescriptions for nicotine replacement therapy in combination with non-nicotinic pharmacotherapy (Varenicline, Buprorprion) as appropriate
223929071|NCT06830967|BEHAVIORAL|Nutritional counselling|Nutritional counseling will be provided through consultation with a registered dietician. Participants will be educated on correct portion sizes, building a balanced plate, learning sources and importance of protein, importance of timing and spacing of meals, along with practicing mindful eating. Promotion and encouragement of dietary changes to ensure balanced intake with adequate protein, weight management, and the regulation of blood glucose will be discussed. Possible barriers to attain the proposed dietary changes and ways to overcome them will also be discussed along with the importance of perioperative nutrition. Based on estimated habitual protein intake, participants will receive a tailored dietary advice aiming a total protein intake of 1,2-1,5g /kg daily, unless contraindicated. Also, participants will be recommended to evenly 'spread' their protein intake over 3 meals with a minimum of 25-30 gram of protein/ meal.
223929072|NCT06830967|BEHAVIORAL|Psychological intervention|"Participants will receive one hourly session of psychological intervention called surgical stress tolerance training with a trained counselor. In this session the psychosocial specialist will address the patient's anxieties, coping strategies, and post-operative expectations, with the goal of optimizing psychological well-being and ways of coping with surgery. The importance of the patient's active participation in the preparation for surgery and healing process will also be discussed. All participants will be given instructions on relaxation and deep breathing techniques."
223929073|NCT06830967|BEHAVIORAL|Patient Education|Patient education will be provided through virtual consultations with a vascular surgery nurse practitioner. These consultations will describe to the patient their journey pre and post-operatively, what to expect and what they are likely to experience, both physically and emotionally. These consultations will also ensure participants have a support person at home available for supervision during prehabilitation and available during their recovery. Additionally, they will ensure that their home is organized for their discharge from hospital and if required, an occupational therapy home consultation may be organized.
223929074|NCT04943172|DEVICE|Hancock-Jaffe bioprosthetic venous valve (VenoValve®)|Surgical implantation of the VenoValve device
223929075|NCT06776198|DRUG|Chemotherapy|Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue
223929076|NCT06778655|DIETARY_SUPPLEMENT|5% propolis gel|5% propolis gel (prepared according to Joshy et al. 2018) Joshy A, Doggalli N, Patil K, Kulkarni PK. To Evaluate the Efficacy of Topical Propolis in the Management of Symptomatic Oral Lichen Planus: A Randomized Controlled Trial. Contemp Clin Dent. 2018 Jan-Mar;9(1):65-71.
223929077|NCT06778655|OTHER|Placebo gel|placebo mucoadhesive gel having the same flavor, consistency, and color as the propolis.
224094745|NCT03427437|DRUG|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
224094746|NCT03427437|DEVICE|Ultrasound|caudal block was performed by ultrasound method
224094747|NCT03530449|DEVICE|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
224094748|NCT03530449|DEVICE|Color Fundus Photography|Non-contact white light photography
224282904|NCT03573817|DRUG|Revefenacin|Revefenacin is administered via a nebulizer.
224282905|NCT03573817|DRUG|Placebo|Placebo version of Revefenacin is administered via a nebulizer.
224282906|NCT03573817|DRUG|Formoterol|Administered sequentially in both revefenacin and placebo arms using a nebulizer.
224282907|NCT01275157|DRUG|LY2452473|Administered orally as a liquid suspension
224282908|NCT05827640|OTHER|data recording using conventional ventilation strategies (PCV and VCV)|no intervention
223929078|NCT06308029|BEHAVIORAL|eHealth self-management support program|This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.
223929079|NCT06308029|BEHAVIORAL|Face-to-face rehabilitation program|The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
223929080|NCT06890156|BEHAVIORAL|ENREACH child-parent-teacher triad|"Prior to enrolling study participants, we will conduct sensitization meetings with each selected government primary school. These meetings will be oriented toward community leaders, caregivers of children with or without disabilities, and school management committees to introduce them to the program, ensure the inclusion of all children, and address concerns related to gender, poverty, and disability.~A disability-inclusive module will be delivered to preschoolers in their regular pre-primary classrooms by trained pre-primary teachers. This module will cover foundational skills, the importance of play, communication, socio-emotional learning, and strategies for adapting the curriculum to accommodate children with disabilities.~ENREACH parent group school readiness intervention package will be provided to parents during monthly parent-teacher meetings, facilitated by trained preschool teachers."
223929081|NCT06769672|OTHER|active tDCS with dual-task training|participants receive three 20-minute active tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
223929082|NCT06769672|OTHER|sham tDCS with dual-task training|participants receive three 20-minute sham tDCS treatment and three 60-minute COGMOTION dual-task exercise sessions per week for four consecutive weeks.
223929083|NCT06746974|DEVICE|Shockwave|In the Shockwave group, will be applied focused shockwaves therapy of 1500 impulses at 0.01 mJ/mm2 over the painful area or the pathologic flexor tendon to each participant under the supervision of a physiatrist. The ESWT will be conducted once weekly for 4 weeks with a sham splint (DIP joint blocking splints) for at least 8 hours per day for 6 weeks.
223929084|NCT06746974|DEVICE|Splint|In the splinting group, will be provided a PIP blocking splint at least 8 hours per day for 6 weeks with the sham shockwave (the patients close their eyes, extend their hand through a partition, apply shockwave device head with gel on the patient's finger, and play a mobile phone sound that mimics the sound of a real shockwave machine) once a week for 4 weeks.
223929085|NCT06829758|BEHAVIORAL|Compartiendo Salud|The intervention proposed (Compartiendo Salud) is a multicomponent intervention based on prevention and on promoting the health of older adults that live alone. The community-based intervention consists in five workshops that are carried out during a week (one day for each workshop). The sessions (which last 2.5 hours each) are designed in an expository and participatory way, using gaming dynamics that foster learning and social interaction. The content of the workshops is the same for all BHDs. Each workshop addresses risk factors that predispose the population to experiencing more unwanted loneliness and social isolation. The concepts corresponding to each of the five sessions that comprise the intervention are: Sleep hygiene, Healthy and sustainable eating habits, Physical activity and exercise, Memory and music therapy, Digital literacy
224094749|NCT03530449|DEVICE|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
224094750|NCT00686556|DRUG|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
224094751|NCT00686556|DRUG|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
224094752|NCT00686556|DRUG|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
224094753|NCT00686556|DRUG|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients \>40 kg.
224094754|NCT00686556|RADIATION|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
224094755|NCT00686556|PROCEDURE|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
224282909|NCT02323802|BEHAVIORAL|educational group intervention|
224094756|NCT00686556|BIOLOGICAL|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.
224094757|NCT00686556|BIOLOGICAL|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
224094758|NCT03543969|DRUG|Encorafenib|450 mg encorafenib daily by mouth
224094759|NCT03543969|DRUG|Binimetinib|45 mg binimetinib daily by mouth
224094760|NCT03543969|DRUG|Nivolumab|240 mg Nivolumab IV every 2 weeks
224094761|NCT06538155|DEVICE|Wearable device|Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked
224094762|NCT06538155|OTHER|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation
224282910|NCT02323802|BEHAVIORAL|prescriptive diet|
223929086|NCT06386692|BEHAVIORAL|FCHVs-led community based educational physical activity intervention|This intervention will be designed to promote physical activity among adults
223929087|NCT00650078|DRUG|MR prednisone|1 x 5 mg daily
223929088|NCT00650078|DRUG|Placebo|1x daily
223929089|NCT06837051|DEVICE|Conventional olfactory training device|"Four odorants are used: phenyl ethyl alcohol (PEA): rose, menthol: mint, citronellal: lemon, and eugenol: cloves. Training patients will receive four glass vials. Each contains one odorant (5 mL, soaked in cotton pads to prevent spilling) and is labeled with the name of the odorant.~Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects."
223929090|NCT06837051|DEVICE|Modified olfactory training device|"The modified olfactory training device is based on the nasal bidirectional drug delivery system. The device uses breathing pressure to create positive pressure, significantly increasing the deposition rate of odors in the olfactory cleft area.~Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects."
223929091|NCT06837051|DRUG|Budesonide irrigation|Budesonide irrigation can effectively target the olfactory cleft area to provide anti-inflammatory effects.
223929092|NCT06418633|OTHER|60-minute walking test|Treadmill walking test in the morning, 2 hours after breakfast, following a clinical examination, resting 12-lead electrocardiogram and blood pressure measurement. After a 3-minute warm-up and walking of speed 2.5 km per hour, no incline, the speed and incline are gradually increased to reach a target heart rate close to the theoretical ventilatory threshold, around 70% of the theoretical maximum value (evaluated by Astrand's formula: 220-age), i.e. aerobic conditions of moderate intensity so that prolonged effort can be maintained. Test performed in presence of a physician trained in stress testing. Emergency cart and defibrillator available in the department. Intra-hospital vital emergency protocol in place, with resuscitation teams on standby. The cardiology department, in the same building, can be contacted in the event of a cardiological abnormality during the test or recovery. The test takes 60 minutes, including a 3-minute initial warm-up.
223929093|NCT06418633|DIAGNOSTIC_TEST|Static blood test|33.3 ml of blood will be taken from each participant whilst at rest, before undergoing the 60-minute walking test
223929094|NCT06418633|DIAGNOSTIC_TEST|Post-effort blood test|33.3 ml of blood will be taken from each participant immediately after undergoing the 60-minute walking test.
223929095|NCT06418633|OTHER|Electrocardiogram|An electrocardiogram will be carried out throughout the exercise period and during the first 30 minutes of recovery.
223929096|NCT06418633|OTHER|Blood pressure monitoring|Blood pressure will be monitored out throughout the exercise period and during the first 30 minutes of recovery.
223929097|NCT06795802|BEHAVIORAL|Evaluative conditioning|The evaluative conditioning procedure is a learning technique performed on a monitor. It consists of being exposed to the repeated association of an object (conditioned stimulus, in our case, Physical Activity or fruit and vegetables) to stimuli with a positive or negative valence (unconditioned stimulus, US). The total duration of the CE is approximately 15 minutes.
224094763|NCT06538155|OTHER|CT scan, TEE exam, or chest X ray|Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray
223929098|NCT02542683|OTHER|structured physical activity program|a structured modest physical activity program
223929099|NCT06909279|BEHAVIORAL|The Hanen Centre's More Than Words® program|The Hanen Centre's More Than Words® program is a globally used, parent coaching intervention delivered by speech-language pathologists (SLPs) to parents of children who have social communication challenges, which includes children with a confirmed or suspected diagnosis of autism. The training program is designed to provide parents with the tools, strategies, and support they need to help their children reach their full communication and social interaction potential.
223929100|NCT06901635|OTHER|Dual Task|In our study, manual dexterity and cognitive task performance during a dual task will be evaluated. Box and Block Test was used to assess dexterity and 4 different cognitive functions were used as cognitive tasks. Previous studies used one or two cognitive tasks when examining the relationship between cognitive task and dexterity performance during a dual task. This study will examine the effect of different cognitive tasks such as attention, memory, executive functions and working memory on the motor task requiring dexterity during a dual task.
223929101|NCT05568030|BEHAVIORAL|Mindfulness|One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
223929102|NCT05568030|BEHAVIORAL|Psycho-education|One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
223929103|NCT02107573|PROCEDURE|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
223929104|NCT02107573|PROCEDURE|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
223929105|NCT06905405|DIAGNOSTIC_TEST|Advanced imaging|Cardiac MRI scan Transthoracic ECHO
223929106|NCT06905405|DRUG|SGLT-2 inhibitor|SGLT-2 inhibitor
223929107|NCT06865287|OTHER|STR Group|"Both TPCT and STR groups will follow identical underwater rugby training sessions. Structure: Warm-up (15%): Land-based mobility (5 min) + in-water rondos (10 min). Small-Sided Games (30%): Tactical principles via modified scenarios. Full-Team Games (45%): 6v6, 5-min games with 3-min recovery. Cool-down (10%).~Training includes 20 sessions: 8 defensive (Containment, Recovery) and 12 offensive (Penetration, Offensive Coverage, Space).~SSGs focus on tactical principles:~Containment (4v4, restricted defensive movement) → Defensive positioning, communication.~Recovery (5v6, interception-based) → Quick transitions, passing accuracy. Penetration (4v2, lane-based) → Offensive coordination, defensive pressure. Offensive Coverage (6v6, restricted movement) → Off-the-ball play, passing options.~Space (3v4, defenders in pairs) → Forward movement, spatial awareness."
224094764|NCT02443402|DRUG|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
224094765|NCT02443402|DRUG|Placebo|One pill daily until discharge
224282911|NCT04224194|COMBINATION_PRODUCT|Adalimumab|Combined product as Drug is delivered through an autoinjector pen on which real-life patient handling experience is assessed.
224282912|NCT05680792|DRUG|Nitazoxanide|1000 mg nitazoxanide tablets twice daily. The drug will be administered after meal for 5 days
224094766|NCT02443402|DRUG|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
223929108|NCT06865287|OTHER|TPCT Group|"Both TPCT and STR groups followed identical underwater rugby training: Warm-up (15%), SSGs (30%), Full-Team Games (45%), Cool-down (10%). Training included 20 sessions: 8 defensive (Containment, Recovery) and 12 offensive (Penetration, Offensive Coverage, Space).~SSGs focused on tactical principles:~Containment (4v4) → Defensive positioning, communication. Recovery (5v6) → Quick transitions, passing accuracy. Penetration (4v2) → Offensive coordination, defensive pressure. Offensive Coverage (6v6) → Off-the-ball play, passing options. Space (3v4) → Forward movement, spatial awareness. The TPCT group engaged in 10-min reflective discussions post-warm-up, SSGs, and games. Prompts included: What key moments defined the activity? How effective were our decisions? How well did we contain attackers? What hindered or helped recovery? How could we improve movement and space usage? Players progressively led discussions, enhancing tactical awareness."
224094767|NCT02443402|DRUG|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate \>2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~* If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~* If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~* If fasting and pre-dinner BG is \> 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~* If fasting and pre-dinner BG is \< 100 mg/dL in the absence of hypoglycemia: stop glargine"
224094768|NCT02443402|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG \> 400 mg/dL; 7-9 units of insulin lispro"
224094769|NCT02443402|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG \>240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG \> 400 mg/dL; 7-9 units of insulin aspart"
223929109|NCT06081426|OTHER|Non-ketogenic Diet|Consuming a non-ketogenic diet
224094770|NCT05075642|OTHER|Initial management of the urinary disorder/s identified during the screening phase|Intervention can be defined as the initial management of the LUTS identified during the screening phase; management lasts at least three months. As observation of routine clinical practice, no specific intervention is included, but any counseling/drug/rehabilitation included as first line management.
224094771|NCT05272514|OTHER|Hypoxia|Individuals will be exposed to varying levels of hypoxia according to the protocol detailed above.
224094772|NCT00003417|DRUG|carmustine|
224094773|NCT00003417|RADIATION|radiation therapy|
224094774|NCT01035151|BEHAVIORAL|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
224094775|NCT01035151|BEHAVIORAL|Control|Written Cessation Materials
224094776|NCT06489288|OTHER|ERAS protocol|The ERAS process mainly includes removing the urethral catheter before the recovery of anesthesia, removing the abdominal drainage tube within 3 days after surgery, removing the nasogastric feeding tu
224094777|NCT05203939|DRUG|OCU400 Low Dose|subretinal injection of up to 1.66×10E10 vg/mL
224094778|NCT05203939|DRUG|OCU400 Med Dose|subretinal injection of up to 3.33×10E10 vg/mL
224094779|NCT05203939|DRUG|OCU400 High Dose|subretinal injection of up to 1.66×10E11 vg/mL
224094780|NCT05203939|DRUG|OCU400 Second Eye Dosing|subretinal injection of 1.0x10E11vg/mL in 250 μl
224094781|NCT04964869|PROCEDURE|epinephrine solution injection|epinephrine solution injection at least 1 ml to the post- sphincterotomy wound
224094782|NCT05947149|OTHER|questionnaires administration|"Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS.~Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS.~Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43."
224094783|NCT03771625|RADIATION|radiotherapy|whole brain with/without spinal cord
224094784|NCT05283733|PROCEDURE|reverse conversion technique|converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
224094785|NCT06474663|DRUG|Cladribine|Given by IV
224094786|NCT06474663|DRUG|Cytarabine|Given by SC
224094787|NCT06474663|DRUG|Sorafenib|Given by PO
224094788|NCT06474663|DRUG|Decitabine|Given by IV
223929110|NCT06081426|OTHER|Ketogenic Diet|Consuming a ketogenic diet
223929111|NCT06081426|OTHER|No diet|Participants without Bipolar Disorder will not participate in the diet phases of the study
223929112|NCT06761664|OTHER|Platysma Exercise Group|The participants in this group will perform a platysma exercise for 7 days following third molar extraction surgery.
223929113|NCT06761664|OTHER|Control (Standard treatment)|Participants in this group will receive routine treatment following third molar extraction.
223929114|NCT06783114|BIOLOGICAL|Recombinant Botulinum Toxin Type A for injection (YY001)|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort)/ 300 U (medium dose cohort)/ 400 U (high dose cohort).
224094789|NCT05192603|DIETARY_SUPPLEMENT|low FODMAP or SSRD|The participants are given oral and written information about each diet. No food is delivered from the investigator to the participant
224094790|NCT04253132|DRUG|Tolfenamic Acid|Tolfenamic acid is an NSAID closely resembling mefenamic and flufenamic acid.
224094791|NCT04253132|DRUG|Placebos|oral placebo
223929115|NCT06783114|BIOLOGICAL|BOTOX®|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort).
223929116|NCT06783114|BIOLOGICAL|Placebo|Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection.
223929117|NCT04710316|DIAGNOSTIC_TEST|SARS-CoV-2 screening by molecular biology|SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome
223929118|NCT04710316|DIAGNOSTIC_TEST|Serological screening|Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
223929119|NCT06871059|BEHAVIORAL|Adapted Diabetes Prevention Program|Participants assigned to this group will participate in a group-based behavioural change program to improve diet and increase physical activity levels during 12 months.
223929120|NCT06871059|BEHAVIORAL|Usual Care|Participants assigned to this groups will receive usual care according to national guidelines
224282913|NCT05680792|DRUG|Atazanavir/ritonavir|300/100 mg atazanavir/ritonavir tablets in the evening once daily, to be administered after meal for 5 days.
224282914|NCT02800031|DEVICE|Transvaginal ultrasonography|
224282915|NCT05022563|DRUG|Parenteral anticoagulant|Parenteral anticoagulant only
224282916|NCT05022563|DRUG|Warfarin|Warfarin-based
224282917|NCT05022563|DRUG|Apixaban|Apixaban
224282918|NCT05022563|DRUG|Rivaroxaban|Rivaroxaban
224282919|NCT05022563|DRUG|Dabigatran|Dabigatran
224282920|NCT05022563|DRUG|Edoxaban|Edoxaban
224282921|NCT06357923|DIAGNOSTIC_TEST|dosage|Presence of mutation on the gene panel and Frequency of allele variation
224282922|NCT02252523|DRUG|Dexmedetomidine|
224282923|NCT05618145|OTHER|Clinical information|The investigators will recruit PSC patients and collect important clinical information and laboratory investigation, together with biological samples.
223929121|NCT06520371|DEVICE|Percutaneous radiofrequency|For the percutaneous radiofrequency treatment, a medium electrode size will be placed on either side of the knee: one skin electrode on the inside and one on the outside of the knee for 15 minutes.
224282924|NCT05390125|OTHER|A team, proficiency based progression, simulation training programme|The training programme will consist of two components (i) a short online training course including video examples of high performing teams and also poor practice (ii) a ward-based team huddle simulation training and assessment programme. The design and shape of the training and assessment will be based on the development of robust metrics. The design of the metrics and programme will centre around use in the acute hospital setting but will be readily adaptable to the obstetric, paediatric setting. The process of validating the metrics and building the online and simulation course involves the review of videotapes of safety huddle performance.
224282925|NCT05434130|BEHAVIORAL|High Dose Exercise|The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
224282926|NCT02692482|DEVICE|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
223929122|NCT06520371|DEVICE|Conventional radiofrequency|For the conventional radiofrequency treatment, a 50 Hz sensory stimulation will be performed with a 10 cm, 22 gauge, 10 mm active tip radiofrequency cannula. After receiving the appropriate sensory and motor stimuli, a radiofrequency of 90°C will be applied for 90 s.
223929123|NCT05364762|DRUG|Cyclophosphamide|Given IV
223929124|NCT05364762|DRUG|Itacitinib|Given PO
223929125|NCT05364762|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell infusion
224282927|NCT02692482|PROCEDURE|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score \<18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
223929126|NCT05364762|OTHER|Quality-of-Life Assessment|Ancillary studies
223929127|NCT05364762|DRUG|Tacrolimus|Given IV or PO
223929128|NCT06336655|DEVICE|IABP|LV unloading via intra-aortic balloon pump (IABP)
223929129|NCT06737315|PROCEDURE|Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning|The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
223929130|NCT06890286|DRUG|BR3006|One tablet administered alone
223929131|NCT06890286|DRUG|BR3006A|One tablet administered alone
223929132|NCT06890286|DRUG|BR3006B|One tablet administered alone
223929133|NCT06890286|DRUG|BR3006C|One tablet administered alone
223929134|NCT06777238|DRUG|GZR18|Administered SC
223929135|NCT06777238|DRUG|Placebo|Administered SC
223929136|NCT06404320|BEHAVIORAL|PA program - MoveU.HappyU|"Participants will meet with their program trainer once a week virtually for 4 weeks to engage in 30 minutes of behavioral change coaching and 30 minutes of a structured PA program that is tailored to their needs and goals. The intensity of the PA sessions will be self-selected. PA sessions will involve a warmup, a conditioning component consisting of individualized aerobic or resistance exercises, and a cool down/stretch.~Participants will also be instructed to independently engage in PA (outside of their session with the trainer) for 120 minutes at 50-65% of their maximum work capacity. This can be done by engaging in PA between 3-5 times per week."
223929137|NCT06952413|DRUG|Rituximab(Genetical Recombination)|Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.
223929138|NCT06952413|DRUG|Placebo|Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods.
223929139|NCT06231472|PROCEDURE|preoperative inferior vena cava measurement|preoperative inferior vena cava measurement
223929140|NCT01596972|DEVICE|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
223929141|NCT01623908|DRUG|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
223929142|NCT00263549|BIOLOGICAL|House dust mite Novo Helisen Depot|
223929143|NCT02745249|BEHAVIORAL|Maternal Nutrition Behavior change|
224282928|NCT03376620|DRUG|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
224282929|NCT03376620|DRUG|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
224282930|NCT02588547|DRUG|Granisetron|IV granisetron 1 mg before spinal anethesia
224282931|NCT02588547|DRUG|Granisetron|IV granisetron 0.7 mg before spinal anethesia
224282932|NCT02588547|DRUG|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
224282933|NCT04978844|BEHAVIORAL|IWOTCH|Arm 1
224282934|NCT04978844|BEHAVIORAL|Dyadic therapy|Arm 2
224282935|NCT00747292|PROCEDURE|epidural|Patients in this limb receive epidural analgesia
224282936|NCT00747292|PROCEDURE|PCA|Patients in this limb receive a PCA for their pain control
224282937|NCT00747292|PROCEDURE|Spinal|Patients in limb will receive spinal analgesia
224282938|NCT05470829|DRUG|ZM-H1505R|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
224282939|NCT05470829|OTHER|ZM-H1505R Placebo|"Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28"
224282940|NCT05896969|DRUG|SNK-396 - SAD cohort|A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
224282941|NCT05896969|DRUG|SNK-396 - MAD Cohort|Multiple doses of SNK-396 within the dose range of from 25 to 800 mg, or matching placebo.
224282942|NCT06139055|DRUG|GSBR-1290 (Capsule/Tablet)|Participants will receive GSBR-1290 oral capsules or tablets.
224282943|NCT06139055|DRUG|GSBR-1290|Participants will receive GSBR-1290 oral tablets.
224282944|NCT06139055|DRUG|Placebo|Participants will receive matching-placebo oral tablets.
224282945|NCT06139055|DRUG|Placebo (Capsule/Tablet)|Participants will receive matching-placebo oral capsules or tablets.
224282946|NCT00613730|DRUG|Gemcitabine|Intravenous administration
224282947|NCT00613730|DRUG|panitumumab|Intravenous administration
224282948|NCT00479388|DRUG|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
224282949|NCT00479388|DRUG|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
224282950|NCT00479388|DRUG|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
224282951|NCT06595147|BEHAVIORAL|Structured Exercise Training|Participants will complete 12-weeks of supervised, structured moderate-to-high intensity aerobic and resistance training three times per week.
224282952|NCT06595147|BEHAVIORAL|Group-based Yoga and Stretching|Participants will complete 12-weeks of supervised group-based yoga and stretching once per week.
224282953|NCT03737916|OTHER|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
224282954|NCT03737916|OTHER|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
224282955|NCT05467826|DRUG|Sofosbuvir/Velpatasvir + Ribavirin|Sofosbuvir 400mg/velpatasvir 100mg + ribavirin 1000mg/1200mg for 12 weeks
223929144|NCT05792956|BEHAVIORAL|Using mobile app|Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
224282956|NCT05467826|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir|Sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg for 12 weeks
224282957|NCT05367765|DRUG|Flumatinib|Flumatinib 600mg orally daily
224282958|NCT05367765|DRUG|Imatinib|Imatinib 400mg orally daily (Reference drug instructions)
224282959|NCT03548662|BIOLOGICAL|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
224282960|NCT03548662|DRUG|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
224282961|NCT03548662|OTHER|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
224282962|NCT00133679|DRUG|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
224282963|NCT00133679|DRUG|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
224282964|NCT01451320|DRUG|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
224282965|NCT01451320|DRUG|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
223929145|NCT04946682|DIAGNOSTIC_TEST|Types of etiological diagnostic methods|In Group of mNGS, all patients will be tested by meta next generation sequncing on admission, while patients in Group of PCR will be tested by polymerase chain reaction in accordance with the method in the guidelines.
223929146|NCT03656211|OTHER|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
223532679|NCT07159438|OTHER|AI-Generated Video Radiology Report Explanation|Participants receive a personalized video explanation of their own radiology imaging results, generated using artificial intelligence technology. The AI converts the participant's existing written radiology report into an easy-to-understand video format featuring an avatar narrator. Each video is approximately 1-5 minutes long and explains the participant's specific imaging findings in plain language. All AI-generated videos are reviewed by qualified medical personnel before delivery to ensure accuracy and prevent misleading information. Participants watch their personalized video and then complete survey to evaluate how well the video helped them understand their radiology results compared to the original written report.
223532680|NCT07160894|OTHER|Saliva and Serum sampling|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 5 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
223929147|NCT02029469|DEVICE|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
224282966|NCT01451320|DRUG|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
224282967|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
224282968|NCT01451320|DRUG|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
223532681|NCT07160894|OTHER|Saliva and Serum sampling|ELISA method will be used to measure IL-10 and IL-6 values in collected saliva and serum samples. For ELISA analysis, a commercial kit (Sunred Bio, Shanghai, China) pre-coated with human selected antibodies will be used.
223532682|NCT07158905|BIOLOGICAL|AV-1980R 20 µg|MultiTEP-based investigational tau vaccine formulated with the adjuvant. The vaccine is designed to elicit anti-tau antibodies in participants with preclinical Alzheimer's disease.
223532683|NCT07158905|BIOLOGICAL|AV-1980R 60 µg|MultiTEP-based tau vaccine formulated with the adjuvant, 60 µg per dose; intramuscular injections at Weeks 0, 4, 12, and 36; secondary-prevention immunotherapy in preclinical AD.
223929148|NCT03580551|BEHAVIORAL|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
223929149|NCT03580551|BEHAVIORAL|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
224094792|NCT04704180|BEHAVIORAL|Facilitation Tuchking Position|The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
224094793|NCT00743886|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
224094794|NCT00743886|DRUG|saline|injection of 6 cc of saline into injured area
224094795|NCT04178590|DRUG|SRP + Injectable Platelet-Rich Fibrin|Injectable Platelet-Rich Fibrin application as adjunct to scaling and root planing
224094796|NCT04178590|DRUG|SRP + placebo|Saline application during scaling and root planing
224094797|NCT01001585|DRUG|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
224094798|NCT06786767|DRUG|BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg|As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.
224094799|NCT05067088|OTHER|CPAP (all patients receive CPAP as part of routine clinical care)|Continuous positive airway pressure
223929150|NCT00777894|RADIATION|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
224282969|NCT06534931|PROCEDURE|High velocity low amplitude thoracic spine manipulation|Participants were supine on a treatment table. The chiropractor determined levels of apparent spinal dysfunction by means of static palpation. Participants were then asked to curl forward and bring their knees to their chest as the chiropractor placed a fist just inferior to the targeted level, anywhere between the T4 - T10 vertebrae. The participant was instructed to inhale and then exhale, at which point the chiropractor lowered the participant's torso back to the table and delivered a thrust using his body into his fist.
224282970|NCT06534931|PROCEDURE|Sham|A previously validated physiologically inert manual procedure to the thoracic spine
223532684|NCT07158905|BIOLOGICAL|AV-1980R 180 µg|MultiTEP-based tau vaccine formulated with the adjuvant, 180 µg per dose; intramuscular injections at Weeks 0, 4, 12, and 36; secondary-prevention immunotherapy in preclinical AD.
223532685|NCT07158905|OTHER|Placebo|10 mM phosphate buffer formulated with the adjuvant; intramuscular injections at Weeks 0, 4, 12, and 36; no active antigen.
223532686|NCT07159854|DEVICE|RICORDO-DTx system|Participants with will undergo a cognitive enhancement program using the Astir RICORDO-DTx system (http://www.ricordo-dtx.com), which allows for the personalization of rehabilitative content based on the needs of the target population and can be delivered remotely.
223929151|NCT00777894|RADIATION|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
223929152|NCT00777894|RADIATION|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
223929153|NCT04433637|DIETARY_SUPPLEMENT|Cake + fruit juice|Cake+fruit juice experiment group, pregnant were allowed to consume fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST.
223929154|NCT04433637|OTHER|Video group|Music with motivational video experimental group, pregnant women were provided with fruit juice and cake, and it was expected that half an hour would pass after feeding to get NST. During this waiting period, the researchers were informed about the development and changes in the body and the fetus specific to the gestational week and NST. Later, NST was applied, and during the procedure, the pregnant women were watched with music that provides relaxation with the video regarding the fetal development appropriate for the gestational week and changes in the mother.
224094800|NCT05899348|BEHAVIORAL|iTEST|iTEST is a computerized training intervention delivered on a mobile device that is coupled with individual contacts with a therapist/coach. The mobile components train in improving participant's ability to form accurate judgments about their performance and their rate of functional activities. The intervention involves coaching coupled with automated training that is delivered on a mobile device. The automated training involves daily cognitive tests in which the goal for treatment is to improve judgments of accuracy of self-assessment, and coaching is aimed at applying improving metacognitive awareness to every day activities.
224094801|NCT02381158|DRUG|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
224094802|NCT06161116|BIOLOGICAL|MK-6194|SC Injection
224094803|NCT06161116|BIOLOGICAL|Placebo|SC Injection
224094804|NCT01389245|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
224094805|NCT04666207|DIAGNOSTIC_TEST|PCR|RT-PCR for SARS-CoV-2
224094806|NCT02292849|BEHAVIORAL|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
224094807|NCT02292849|OTHER|Standard Mental Health Referral|Standard mental health referral to a community agency
224094808|NCT02623179|OTHER|culture versus Molecular diagnostics|Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
224094809|NCT05844917|DEVICE|ultrasound|Ultrasound detection of subclinical arthritis among Patients With SLE
224094810|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
224094811|NCT03737825|DEVICE|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
224094812|NCT04274296|DEVICE|Activation of Advisory|Advisory is activated which will show if driving pressure is greater or equal 15
224094813|NCT02479347|DRUG|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
224094814|NCT02479347|DRUG|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
223929155|NCT00195403|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
223929156|NCT05761626|OTHER|MP/Crs assessment < = 0.48 J/min/ml/cmH2O|Assessment of the ventilatory variables according to the MP/Crs value (\<= or \> 0.48 J/min/ml/cmH2O)
223929157|NCT06951308|DIETARY_SUPPLEMENT|Carbohydrate loading before surgery|Carbohydrate loading 2 hours before the surgery (400 ml of 12.5 maltodextrin and 400 ml of over-the-counter fruit-based lemonade)
224282971|NCT01955044|DIETARY_SUPPLEMENT|LCPUFA supplement|
224282972|NCT01955044|DIETARY_SUPPLEMENT|placebo|
224282973|NCT01876368|DRUG|LCZ696|
224282974|NCT01876368|DRUG|Olmesartan|
224282975|NCT01876368|DRUG|Placebo of LCZ696|
224282976|NCT01876368|DRUG|Placebo of Olmesartan|
224282977|NCT02962089|DIETARY_SUPPLEMENT|Branched chain amino acids (BCAA)|
224282978|NCT02962089|DIETARY_SUPPLEMENT|Placebo|
224282979|NCT01755117|OTHER|Sciatic, femoral, obturator nerve blocks|
224282980|NCT01755117|OTHER|Sciatic nerve block, posterior lumbar plexus block|
224282981|NCT06275178|PROCEDURE|Medical thoracoscopy|The included particpants are the patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy.
224282982|NCT00679250|DRUG|levocetirizine|5 mg once nightly before visit
224282983|NCT00679250|DRUG|placebo to levocetirizine|1 tablet once nightly before visit
224282984|NCT02285348|PROCEDURE|Lumbar puncture|Lumbar puncture is done according to general practice
224282985|NCT04889391|DRUG|[14C]-Danicopan|Liquid-filled capsules.
224282986|NCT03513536|OTHER|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
224282987|NCT03513536|OTHER|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
224282988|NCT03513536|OTHER|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
224282989|NCT03513536|OTHER|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
224282990|NCT06109701|PROCEDURE|Debridement with ultrasonic device and scaling with plastic curettes|Supragingival and subgingival debridement
224282991|NCT06109701|PROCEDURE|Debridement with erythritol based air-polishing powde|Supragingival and subgingival debridement
224282992|NCT00265772|DRUG|MODULEN IBD (R) (specific Enteral Nutrition)|
224282993|NCT00265772|DRUG|prednisolon|
224282994|NCT06657872|PROCEDURE|water vapor therapy under general anesthesia|Water vapor procedure will be performe under conscious intravenous sedation with anesthesia team
223929158|NCT01158417|DRUG|Placebo|oral
223929159|NCT01158417|DRUG|Resveratrol 40 mg oral three times a day|Drug
223929160|NCT01158417|DRUG|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
223929161|NCT05609734|OTHER|no intervention, only observational retrospective study|no intervention, only observational retrospective study
223929162|NCT02094560|DRUG|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
223929163|NCT00412646|DRUG|TMC125|
223929164|NCT05427305|DRUG|TAB008|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
223929165|NCT05427305|DRUG|Bevacizumab|15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
223929166|NCT03502369|PROCEDURE|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
224282995|NCT06657872|PROCEDURE|water vapor therapy under local anesthesia|Water vapor procedure will be performe under local anethesia administrated with Schelin® catheter via the trans-urethral route : injection of 20cc of lidocaine 2% intra-prostatically via the schelin catheter at 4 injection points (3cc at 1h, 3cc at 11h, 7cc at 4h, and 7cc at 8h).
224282996|NCT03024268|DEVICE|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
224282997|NCT06070974|DIAGNOSTIC_TEST|CMR and blood collection|All patients enrolled will undergo 2 CMR examination (within 3-5 days post PCI and after six months), and blood collection at third day after PCI (T0). Patients recruited at Centro Cardiologico Monzino will be subjected to a blood withdrawal also at different time points: 1- 3- 6 months after STEMI (T1, T2, and T3 respectively).
224282998|NCT06309914|DIETARY_SUPPLEMENT|Placebo|Subjects will consume one capsule of the Placebo twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
224094815|NCT01849926|DRUG|Ibuprofen|
224094816|NCT01849926|DRUG|Mecillinam|
224094817|NCT02883699|BEHAVIORAL|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
224094818|NCT02883699|BEHAVIORAL|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
224094819|NCT02883699|BEHAVIORAL|Standard resistance training|Machine based hypertrophy training 2 x per week
224282999|NCT06309914|DIETARY_SUPPLEMENT|Enovita Grape Seed Extract|Subjects will consume one capsule of Enovita twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
224094820|NCT02883699|BEHAVIORAL|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
224094821|NCT04957888|OTHER|none intervention|none intervention.
224094822|NCT04561505|PROCEDURE|Holmium laser enucleation of prostate|surgical management of BPH by Holmium laser enucleation using 0.9% saline fluid for irrigation
224094823|NCT04561505|PROCEDURE|monopolar transurethral resection of prostate|surgical management of BPH by monopolar TURP using distilled water for irrigation
224094824|NCT05731960|DRUG|Dexamethasone|10 mg IV dexamethasone provided immediately after spinal anesthesia
224094825|NCT05731960|DRUG|Metoclopramide|10 mg IV metoclopramide provided immediately after spinal anesthesia
224094826|NCT00003029|DRUG|cisplatin|
224094827|NCT00003029|DRUG|fluorouracil|
224094828|NCT04407715|PROCEDURE|The Effect Of Minimal and High Flow Anesthesia on Optic Nerve Sheath Diamater|The patients were randomly allocated to one of the two groups of fresh gas flows using the closed-envelope technique: 2 L/min high flow and 0.5 L/min minimal flow.
224094829|NCT01689558|DRUG|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
224094830|NCT00364793|DRUG|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
224094831|NCT00002025|DRUG|Ganciclovir|
224094832|NCT05090241|DIAGNOSTIC_TEST|Instrumental measurement of balance and gait|The balance measurement was performed on a force platform. The walk test was carried out using sensors to analyze and retrieve data from the participant's walk (gait speed, step length, duration of the double support phase).
224094833|NCT02397252|DEVICE|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
224094834|NCT02397252|DEVICE|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
224094835|NCT02397252|PROCEDURE|Physician-collected sampling|Routine colposcopy sample collected by a physician.
224094836|NCT03423355|DRUG|Dapagliflozin (Forxiga®)|10mg p.o. daily
224094837|NCT03423355|DRUG|Hydrochlorothiazide 25 mg|25mg p.o. daily
224094838|NCT03423355|DRUG|Placebo matching Dapagliflozin|Placebo matching Dapagliflozin p.o. daily
224094839|NCT05393154|DEVICE|Biopsy Adequacy Evaluation by Aquyre Biopsy Scanner|Microscopic viewing and imaging of Bronchoscopic Biopsy Specimens using Full Field Optical Coherence Tomography and Dynamic Cell Imaging
224094840|NCT03037294|DIETARY_SUPPLEMENT|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
224094841|NCT05127486|DRUG|Galcanezumab|Administered SC.
224094842|NCT05127486|DRUG|Rimegepant|Administered orally.
224094843|NCT05127486|DRUG|Placebo|Administered orally.
224094844|NCT05127486|DRUG|Placebo|Administered SC.
224094845|NCT00972608|OTHER|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
224094846|NCT05902585|BEHAVIORAL|Virtual reality|In the virtual reality group, patients will view a video with the virtual reality glasses from the beginning to the end of the venipuncture.
224094847|NCT06076044|DEVICE|toDCS 2mA 1Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 1Hz.
224094848|NCT06076044|DEVICE|toDCS 2mA 10Hz|The subgroup treated by transcranial oscillatory direct current stimulation of 2mA and 10Hz.
224094849|NCT06076044|DEVICE|tDCS 1mA|The subgroup treated by transcranial direct current stimulation of 1mA.
224094850|NCT06076044|DEVICE|sham|The subgroup treated by sham stimulation.
224094851|NCT04740957|OTHER|Distal limb reintroduction of ileostomy effluent|"Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma."
223929167|NCT01231438|DRUG|Renvela|800mg t.i.d. over 2 weeks
223929168|NCT01231438|DRUG|Etalpha|0.25ug o.d. for 2 weeks
223929169|NCT01260896|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
223929170|NCT01260896|DRUG|Effexor® XR|150 mg Extended-Release Capsule
223929171|NCT01189149|PROCEDURE|IV fluids|Infants will be allocated to IV fluids
223929172|NCT01189149|PROCEDURE|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
223929173|NCT01746706|DEVICE|PET amyloid tracer (Florbetapir F18 AV45 F18|
223929174|NCT00144287|DRUG|Tipranavir/Ritonavir|
223929175|NCT03809416|DEVICE|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
223929176|NCT03809416|OTHER|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
224094852|NCT05041738|PROCEDURE|Intraoral Cryotherapy|small ice packs wrapped in sterile gauze placed in the mouth on the vestibular surface of the treated tooth
224094853|NCT05041738|PROCEDURE|Intracanal Cryotherapy|Intracanal cryotherapy technique using 2.5°C cold saline irrigation as final irrigant
224094854|NCT00310310|BEHAVIORAL|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
224283000|NCT06309914|DIETARY_SUPPLEMENT|Mirtoselect Bilberry Extract|Subjects will consume one capsule of Mirtoselect twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
224283001|NCT06309914|DIETARY_SUPPLEMENT|Virtiva Plus Ginko Biloba Extract|Subjects will consume one capsule of Virtiva Plus twice daily for 28 days. At Day 0, they will perform the full cognitive assessment (\~45 minutes) and complete the abbreviated POMS questionnaire in a fasted state. Immediately after, subjects will consume two capsules of their randomly assigned study product. At 60 minutes post-consumption, subjects will repeat the computerized cognitive assessment. At 180 minutes post-consumption, subjects will repeat the computerized cognitive assessment and abbreviated POMS questionnaire. Subjects will then be instructed to continue to take their respective study product twice daily, one capsule with the first meal of the day and one capsule with the evening meal, for the duration of the supplementation period (28 days). After 28 days of supplementation, subjects will be reassessed on the computerized cognitive assessment and abbreviated POMS.
224283002|NCT01867606|BIOLOGICAL|serum-derived bovine immunoglobulin protein isolate|Given PO
224283003|NCT01867606|OTHER|placebo|Given PO
224283004|NCT01867606|OTHER|laboratory biomarker analysis|Correlative studies
224283005|NCT01867606|OTHER|quality-of-life assessment|Ancillary studies
224283006|NCT01867606|OTHER|questionnaire administration|Ancillary studies
224283007|NCT01378962|DRUG|erlotinib|150 mg orally once a day for 12 months
223929177|NCT03809416|COMBINATION_PRODUCT|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
223929178|NCT03853161|OTHER|Vapotherm|A form of non invasive ventilation used in newborns
223929179|NCT03853161|OTHER|NIPPV|A form of non invasive ventilation used in newborns
223929180|NCT04255212|OTHER|Soft tissue treatment|Participants will be asked to sit in front of a medical table with their forearms supinated and relaxed. 5 minutes of deep tissue manual flossing on the proximal and medial aspect of the forearm of each side will be administered by keeping the hands contact on the skin of the participants for all the treatment duration. Direction of the gentle repeated manual compressions and shifts will be proximal to distal or vicerversa depending on the symptom reduction reported by the participants. Stimuli frequencies will be about 0,2-03 Hz. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
224094855|NCT00310310|BEHAVIORAL|Usual care|Usual sleep apnea and cpap care
224094856|NCT03615092|PROCEDURE|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
224283008|NCT04612530|DEVICE|Irreversible Electroporation (IRE)|Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
224283009|NCT04612530|DRUG|Nivolumab|Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
224283010|NCT04612530|DRUG|Toll-Like Receptor 9|Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
224283011|NCT00352196|DRUG|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
224283012|NCT00352196|OTHER|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
224283013|NCT05663372|DRUG|Efez 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
223929181|NCT04255212|OTHER|Mechaninsms explanation|Participants will be instructed with a 10 minutes lesson on mechanisms hypothesized to generate Delayed Onset Muscle Soreness. To trigger the most the bottom down pain modulation given by the placebo effect lesson will be concluded stressing the fact that DOMS have a good prognosis and that in a short amount of time they will be pain free and also that no drugs are effective to reduce pain intensity in DOMS condition suggesting them to stay physically active.
223929182|NCT04255212|OTHER|Control Group|Participants will be asked to wait 10 minutes and to relax until the tests will be performed again.
223929183|NCT04255212|OTHER|Neurodynamic treatment|Participants will be asked to lay supine on a medical table and keep their arms relaxed. 30 repetitions of gentle upper limb nerves mobilization, performed through a combination of neck and arm physiological movements, will be administered with cycles of tensions and relaxation of 1/5 seconds for 3 minutes in total for each arm. Subjects will be instructed to report immediately if the manual treatment starts to induce an increase in symptoms
223929184|NCT06225336|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
223929185|NCT05028933|DRUG|EPCAM CAR-T|Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion
223929186|NCT05980247|DEVICE|Thimble Application|Use of of thimble application to practice mindfulness before needle procedure.
223532687|NCT07159854|DEVICE|HOMING system|Participants will also undergo motor rehabilitation sessions focused on improving balance, gait, and muscular endurance using the HOMING system (https://www.tecnobody.com/homing).
223929187|NCT06431737|DRUG|Amoxicillin|Tegoprazan 50 mg bid, amoxicillin 1000 mg bid or 500 mg qid, clarithromycin 500 mg bid for 14 days
223929188|NCT06673511|PROCEDURE|Lymph node visualization|Resect the developing lymph nodes and the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
223929189|NCT06673511|PROCEDURE|No visualization of lymph nodes|Resect the systematic lymph nodes. Conduct postoperative follow-up and pay attention to the relevant indicators of the patient after surgery.
223929190|NCT06997640|DIAGNOSTIC_TEST|Dynamic Stretching Protocol|Participants assigned to Group A will undergo a structured dynamic stretching protocol, designed to enhance lumbar flexibility, core muscle activation, and postural alignment, specifically targeting the pelvic inclination associated with radicular low back pain (RLBP). The intervention will be administered three times per week under the direct supervision of a qualified physiotherapist. Each session will last for 30 minutes, beginning with a 5-minute warm-up involving light aerobic activity such as marching or gentle trunk rotations to prepare the body for movement. This will be followed by 20 minutes of dynamic stretching exercises, focusing on the major muscle groups that influence pelvic and lumbar mobility.
223929191|NCT06997640|COMBINATION_PRODUCT|Neural Mobilization Technique Protoco|Participants in Group B will receive a standardized neural mobilization intervention, targeting the sciatic nerve and lumbar plexus, known to contribute to pain and restricted mobility in radicular low back pain (RLBP). The treatment will be conducted three times per week, with each session lasting 30 minutes under the guidance of an experienced physiotherapist trained in neurodynamic techniques. The session will begin with a 5-minute preparatory phase to position the participant comfortably and explain the sequence of movements. This will be followed by 20 minutes of gentle neural mobilization techniques, including nerve sliders and tensioners, performed through movements such as the Straight Leg Raise (SLR) sliders and the Seated Slump mobilization technique.
224094857|NCT01065935|DRUG|ALN-RSV01|Administered by nebulization once daily for 5 days
224094858|NCT01065935|DRUG|Normal Saline|Administered by nebulization once daily for 5 days
224094859|NCT05527925|DEVICE|MRI|Brain testing of patients using MRI
224283014|NCT05663372|DRUG|INSPRA® 50 mg eplerenone film-coated tablets|Oral, mineralocorticoid receptor antagonist, a blocker of aldosterone
224283015|NCT02885441|DRUG|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
223532688|NCT07159854|DEVICE|Home-based training program|Subjects will view videos on Tablet. The treatment will be provided via a digital medicine platform on a mobile device (tablet).
224283016|NCT05500768|PROCEDURE|hypothermic compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants, a frozen prosthesis is added
224283017|NCT05500768|PROCEDURE|Conventional compression bandage|a compressive bandage is applied for 8 hours to the surgical wound of the cardiac device implants
224283018|NCT05793632|DRUG|Quetiapine|The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
224283019|NCT02482558|OTHER|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
224283020|NCT02176057|DRUG|Azithromycin|
223532689|NCT07159230|DIAGNOSTIC_TEST|point-of-care multiplex PCR test|community health care center in intervention group were provided with point-of-care multiplex PCR test (POCT) plus routine test. POCT testing was recommended for all enrolled patients presenting with acute respiratory infections who meet the predefined inclusion criteria. The therapeutic interventions were determined by health-care workers on the basis of POCT result, clinical assessment and guideline.
223532690|NCT07159893|DRUG|Inebilizumab + Rapid Steroid Tapering group|"Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ；Day 20 (Week 2): Second dose ；Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-19: 60 mg daily；Day 20: 60 mg every other day (EOD)~；Day 34: 30 mg EOD → Day 48: 15 mg EOD → Day 62: 10 mg EOD → Day 76: 5 mg EOD → Day 90: Discontinue Route: Oral"
224283021|NCT00924963|DEVICE|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
224283022|NCT00924963|DEVICE|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
224283023|NCT00924963|DRUG|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
224283024|NCT05747560|DIETARY_SUPPLEMENT|Buckwheat|Take buckwheat at a dose of 500 mg twice a day for 6 months.
223929192|NCT06996288|DEVICE|Transpulmonary pressure-guided individualized PEEP|Transpulmonary pressure-guided individualized PEEP group was an intraoperative ventilation strategy based on esophageal pressure (Pes) monitoring of transpulmonary pressure-guided ventilation, using a small tidal volume (6-8 ml/kg of ideal body weight), maintaining the transpulmonary pressure in the safe range of 5-15 cmH2O PEEP for Pes+1 cm H2O level.
223929193|NCT06867731|PROCEDURE|Endosonographic Elastography|The patient will undergo a standard-of-care endoscopic ultrasound with liver biopsy. At the time, elastography of the liver and spleen will be performed while using the echoendoscope. Different degrees of pressure will be applied while performing elastography of the left and right lobes of the liver as well as the spleen. The E values and VsN values will be recorded and then compared to liver histology.
223929194|NCT06867731|DIAGNOSTIC_TEST|Endosonographic shear wave elastography|The patient will undergo an upper endoscopic ultrasound procedure. During this procedure, the patient will be put to sleep and a trained endosonographer physician will insert an echo-endoscope through the mouth and guide it down to the stomach and the duodenum. This endoscope is equipped with technology that uses sound waves to assess the stiffness of the liver and spleen. For research purposes, the doctor will also press on these organs in order to take the additional measurements.
223929195|NCT06613490|BIOLOGICAL|anti CD19 CAR NK cells|This study is a single-arm, open-label and single-center exploratory clinical study to evaluate the safety and effectiveness of anti CD19 CAR NK cells in patients with refractory antisynthetase antibody syndrome (ASyS) and rheumatoid arthritis (RA). All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by Anti-CD19 CAR NK cells infusion.
223929196|NCT03786237|DRUG|Rigosertib Oral Capsules / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
223929197|NCT07007117|BIOLOGICAL|PHOX2B PC-CAR T Cells|The PHOX2B PC-CAR T cell investigational product is comprised of autologous human T cells that have been genetically modified to express a a PHOX2B-targeting chimeric antigen receptor (CAR) transgene.
223929198|NCT03971500|DRUG|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
223929199|NCT03971500|PROCEDURE|Percutaneous coronary intervention|PCI with DES implantation
224094860|NCT00427414|DRUG|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
224283025|NCT05747560|DIETARY_SUPPLEMENT|Astragalus extract|Take astragalus extract at a dose of 450 mg twice a day for 6 months.
224283026|NCT05747560|DIETARY_SUPPLEMENT|Wolfiporia extract|Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.
224283027|NCT06875791|COMBINATION_PRODUCT|Green Tea Extract with Morphine|TV5M01 is a novel oral rinse combining 5% green tea extract with 0.1% morphine in a gel formulation specifically designed for the treatment of radiation-induced oral mucositis. This unique combination leverages the antioxidant and anti-inflammatory properties of green tea polyphenols (particularly EGCG) with the analgesic effects of morphine delivered directly to the oral mucosa. Unlike other interventions, this formulation is administered as a 10 mL rinse three times daily with subsequent ingestion, targeting both local tissue healing and pain relief through a dual-action mechanism.
224283028|NCT06875791|COMBINATION_PRODUCT|Active Comparator: Triple Mixture Oral Rinse for Radiation-Induced Mucositis|This arm will receive a Triple Mixture oral rinse (combination of 0.19% w/w Lidocaine, 0.29% w/w Nystatin, and 5.50% w/v Hydroxides). Participants will use 10 mL of the preparation three times daily at 8-hour intervals (±2 hours) from the diagnosis of grade 1 or higher mucositis until mucositis resolves. The medication should be administered at consistent times daily without fasting requirements. Doses vomited while in clinic may be replaced; however, participants should not take replacement doses for self-administered doses vomited at home. Missed doses should be skipped rather than doubled at the next scheduled time
224283029|NCT03846063|OTHER|Home-based rehabilitation program|The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
224283030|NCT03922139|DRUG|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
224283031|NCT05963841|DEVICE|treatment program|the study aims to set up an artificial intelligence diagnostic assistance program
224283032|NCT01932905|DEVICE|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
224283033|NCT03814122|BEHAVIORAL|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
224283034|NCT03814122|OTHER|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
223929200|NCT05322629|BEHAVIORAL|PrEP adherence biofeedback|Services for women in the intervention arm includes bio-feedback adherence counseling based on urine lateral flow assays of tenofovir to measure adherence with rapid PrEP delivery .
223929201|NCT05322629|BEHAVIORAL|Standard of care counseling|Adherence counseling based on self report and following national guidelines
223929202|NCT06809387|OTHER|Brain stimulation|Participants will be included in the real and sham rTMS. Participants will perform speech and reading tasks before and after stimulation.
223929203|NCT06811168|OTHER|web based gamification|Kahoot gamificiation
223929204|NCT06122103|DEVICE|Clareon Monofocal|Clareon Monofocal Intraocular Lens (toric and non-toric)
223929205|NCT06122103|DEVICE|Light-Adjustable Lens|Light-Adjustable Lens (Intraocular Lens)
223929206|NCT03803969|DEVICE|ConfirmRx (Insertable Cardiac Monitor)|This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
223929207|NCT06651736|BEHAVIORAL|Low Vision Rehabilitation (LVR)|"The initial session will be with an LVR specialist that will recommend vision-enhancing devices and techniques to improve participant's vision and mobility functionality depending on needs. The devices will be given at no cost and include, but are not limited to: magnifiers that participants can hold or wear, glasses attachments that help filter out light to see better, or items that help with glare or seeing color. This session will be followed by at least one session with an occupational therapist, that will train participants to use the devices (take home and use) and recommend/teach ways to achieve functional goals.~Most participants will be asked to attend 2-4 visits, but additional visits may be needed depending on needs and progress toward functional goals. Additional visits if orientation and mobility training is also recommended. Participants will be asked to share experiences approximately 1-week after all visits."
223929208|NCT06651736|BEHAVIORAL|Emotion Regulation Therapy (ERT)|There will be ten 1-hour weekly sessions of specialized psychotherapy with an ERT-trained therapist. These are typically done virtually but may be able to provide in-person sessions to those where this is needed. At the beginning of each session, the therapist will give participant's several questionnaires to learn about participant's experience with ERT. Questionnaires will also be completed after all sessions are completed.
223929209|NCT06773195|DRUG|Ulixertinib|There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)
223929210|NCT06773195|DRUG|Ruxolitinib|Ruxolitinib for 28 day cycles.
223929211|NCT06825143|PROCEDURE|Ischemic preconditioning|The objective of this Intervention is to show that ischemic preconditioning (IPC) protects against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm, followed by 3 × 5-minute cycles of IPC in the opposite arm. IPC will be induced using a blood pressure cuff placed on the opposite upper arm and inflated to 220 mmHg for 5 min, followed by 5 min of deflation. This procedure will be repeated two additional times taking about 30 minutest to complete. Following a 10-minute rest phase, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
224283035|NCT04086160|DEVICE|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
224283036|NCT00292227|DRUG|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
224283037|NCT00292227|OTHER|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
224283038|NCT00292227|DRUG|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
224283039|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
224283040|NCT00292227|OTHER|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
224283041|NCT05148533|DRUG|TJ1133 Injection|TJ011133 (30 mg/kg, 45 mg/kg,QW) in combination with toripalimab injection (240 mg, Q3W)
224283042|NCT00163709|PROCEDURE|BNP test|
224283043|NCT04615494|PROCEDURE|Position|Pneumoperitoneum with Steep Trendelenburg position
224283044|NCT04038606|OTHER|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
224283045|NCT05440695|DEVICE|Continuous non-invasive arterial pressure (Infinity® CNAPTM, Dräger)|The basic working principle of CNAP is to keep the blood volume of the finger arteries constant by applying an exterior pressure to the vessel wall, that is done by an electronic system controlling the pressure inside a cuff around the finger. The pressure in the cuff, which is needed to keep the volume constant during arterial pulsation, corresponds to the AP.
224283046|NCT02682134|DRUG|xylocaine|First group were given xylocaine
224283047|NCT02682134|DRUG|Dexamethasone|Second group were given Dexamethasone
224283048|NCT02682134|DRUG|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
224283049|NCT02093923|DRUG|DX-2930|Participants will receive SC injection of DX-2930 (a recombinant, Chinese hamster ovary \[CHO\] cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody) once and followed by the second dose after 2 week into the upper arm.
224283050|NCT02093923|DRUG|Placebo|Participants will receive matching placebo subcutaneously.
223929212|NCT06825143|DRUG|Intravenous lactate infusion|The objective of this Intervention is to show that an intravenous infusion of lactate protects against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous intravenous infusion of lactate will be delivered in the contralateral arm. After systemic lactate reaches \~3 mmol/L, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
223929213|NCT06825143|PROCEDURE|No ischemic preconditioning (control)|The objective of this Intervention is to show that a control experiment without ischemic preconditioning does not provide protection against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm, followed by 3 × 5-minute cycles of no upper arm occlusion in the opposite arm. To avoid upper arm occlusion, a blood pressure cuff will be placed on the upper arm and inflated to a low pressure of 20 mmHg pressure to not influence blood flow through the arm. This control procedure will be repeated two additional times taking about 30 minutes to complete. Following a 10-minute rest phase, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
223929214|NCT06825143|DRUG|Normal Saline Infusion (Placebo)|The objective of this Intervention is to show that a placebo intravenous infusion does not protect against endothelial ischemia/reperfusion injury. Baseline endothelium-dependent vasodilation to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous infusion of normal saline that does not contain lactate will be delivered in the contralateral arm. After 20 minutes of the placebo infusion, endothelial injury will be induced using a blood pressure cuff that will be inflated to stop blood flow through the nondominant arm for 20 minutes, followed by 15 minutes of cuff deflation. Endothelium-dependent vasodilation measurements will be repeated immediately after the 15-minute cuff deflation phase.
224094861|NCT03175523|DEVICE|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
224094862|NCT03175523|DEVICE|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
224094863|NCT04945655|OTHER|Adolescents and parents' education and motivation at school (component 1)|"The component 1 includes first an information group session (duration: 1h30) on HPV infection and vaccination for parents. This session starts with a webconference delivered by two medical experts on HPV, using a standardized presentation. Then, a discussion is open for parents' questions and/or comments.~Second, adolescents participate during the school time to two educational group sessions on HPV infections and vaccination, using a pedagogy based on active learning. These sessions (duration: 2h each) are delivered by the school staff (e.g., nurse, teacher in life sciences) using an educational package comprising: a guide that describes activities that should be implemented during each session; one video and a fact sheet developed by health students; a serious video game that promotes HPV vaccination and accessible on an internet website. Before the sessions, the school staff is encouraged to attend an e-learning training course (duration: 1 hour)."
224094864|NCT04945655|OTHER|General practitioners' training (component 2)|The component 2 consists of an individual e-learning training session for general practitioners (GPs) that is accessible on computer and smartphone. Lasting 3 hours, GPs are able to access to the training whenever they want and then to progress at their own pace. The training includes three main parts: up-dated information on HPV infection and vaccination; an introduction to the use of motivational interviewing techniques in the field of vaccination; and a presentation of the decision aid tool developed as part of the intervention and explanation of how to use it during consultations. GPs may ask questions to the consortium team by using a dedicated chat.
224094865|NCT04945655|OTHER|Access to vaccination at school (component 3)|The component 3 aims at enhancing access to HPV vaccination for adolescents by offering them the first free-of-charge injection at school, without any medical prescription. For each concerned school, we organise a vaccination day inside the school premises where health professionals (one physician and one nurse) from the local vaccination centre initiate HPV vaccination with Gardasil-9® (in accordance with the French recommendations) for all eligible adolescents.
224094866|NCT03020511|OTHER|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
224094867|NCT06962332|DRUG|Zanzalintinib|Administered as specified in the treatment arm.
224094868|NCT03566212|DEVICE|Conventional Syringe|local anesthesia was administered in first group using Conventional syringe
224094869|NCT03566212|DEVICE|Camouflage Syringe|local anesthesia was administered in second group using Camouflage syringe
224094870|NCT01287754|DRUG|erlotinib [Tarceva]|150 mg daily orally
224094871|NCT06960954|DIAGNOSTIC_TEST|Prothrombin induced by vitamin K absence II (PIVKA-II)|Serum PIVKA-II level will be measured in HCC patients with and without PVTT.
224094872|NCT03392233|RADIATION|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
224094873|NCT06526026|BEHAVIORAL|Virtual crisis stabilization support with a multi-disciplinary team|Daily 1:1 sessions with multidisciplinary team via a range of virtual modalities (videoconferencing, phone, text, email), group programming, self-management resources, remote home monitoring app, referrals and linkages to community programs.
223532691|NCT07159893|DRUG|Inebilizumab + Standard Steroid Tapering group|Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ；Day 20 (Week 2): Second dose ；Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-34: 60 mg daily;Day 34: 60 mg EOD → Day 62: 30 mg EOD → Day 90: 15 mg EOD → Day 118: 10 mg EOD → Day 146: 5 mg EOD → Day 174:Discontinue; Route: Oral
224094874|NCT04442607|DEVICE|artificial intelligence image processing|Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
224094875|NCT04600570|OTHER|ultrasound|ultrasound measurement for optic nerve outer diameter
224094876|NCT06642974|OTHER|Education module on learning disabilities|Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m
224094877|NCT06642974|OTHER|pamphlet on learning disability|Education pamphlets will be provided to total of 67 samples
224283051|NCT04038645|OTHER|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
224094878|NCT06176521|PROCEDURE|Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Performed Without Mesh|Comparison of pre and postoperative POP-Q values of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy SurgeriesWithout Using Mesh Comparison of pre and postoperative PISQ-12 scores of the patients undergone Laparoscopic Sacrohysteropexy and Sacrocolpopexy Surgeries Without Using Mesh
224094879|NCT06642753|BIOLOGICAL|immediate implant with buccal plate augmentation using sticky bone|"* Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the pouch ."
224094880|NCT06642753|BIOLOGICAL|immediate implant with sticky bone as a filling material in the jumping gap|"Venous blood will be withdrawn and transferred into sterile tubes which will be devoid of anticoagulants. I- PRF preparation will be done using the protocol developed by Mourãoet al.~* Plastic PET tubes to create Liquid-PRF, while glass tubes will be used to obtain Solid-PRF.~* Blood will be centrifuged at a speed of 3000 rpm for 10 minutes to obtain autologous PRF plug.~* Blood will be centrifuged at a speed of 700 rpm for 3 minutes. An orange- colored fluid will be formed as the upper layer in the test tubes i.e., I- PRF. Approximately 1 ml of I-PRF will be collected in a syringe.~* Solid-PRF + Liquid-PRF mixed DBBM: Solid-PRF membranes will be mixed thoroughly with 0.25 g of DBBM particles. Then 1 mL Liquid PRF from the buffy coat layers will be added drop by drop to the DBBM.~* Following polymerization by 15-20 minutes, sticky bone will be ready to be grafted in the jumping gap."
224283052|NCT04038645|OTHER|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
224283053|NCT01571817|BIOLOGICAL|Isolated Human Pancreatic Islets|
224283054|NCT04938986|DIAGNOSTIC_TEST|IMMUNOSCORE®|recommendation for patient care according to the result of the IMMUNOSCORE®
224283055|NCT02282202|DEVICE|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
224283056|NCT00006399|DRUG|Donepezil|
224283057|NCT00006399|DRUG|Estrogen|
224283058|NCT00006399|DRUG|Progesterone|
224283059|NCT04509999|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily
224283060|NCT04509999|DRUG|Placebo|Placebo as formulated by mouth daily
224283061|NCT00248170|DRUG|Letrozole|2.5 mg tablets
224283062|NCT00248170|DRUG|Anastrozole|1 mg tablets
223532692|NCT07159997|DIAGNOSTIC_TEST|Accuracy of rail sign by ultrasound st diagnosis placent previa|Accuracy of rail sign by ultrasound at derection of PAS
223532693|NCT07161414|DRUG|IV Rilvegostomig|Rilvegostomig administered IV.
223532694|NCT07161414|DRUG|Recombinant Human Hyaluronidase (rHu)|rHu administered subcutaneously.
223532695|NCT07161414|DRUG|SC Rilvegostomig|Rilvegostomig administered subcutaneously.
223532696|NCT07161414|DRUG|SC rilvegostomig + rHu|SC rilvegostomig + rHu administered subcutaneously.
223532697|NCT07159074|DRUG|Tc 99m tilmanocept|150 mcg containing 10 mCi of Tc 99m tilmanocept will be administered through an IV route of injection. SPECT-CT imaging will then be performed.
223532698|NCT07159243|DRUG|HL-1186|HL-1186 tablet for oral administration.
223929215|NCT06825143|COMBINATION_PRODUCT|Ischemic preconditioning and intravenous lactate|The objective of this Intervention is to show that combining ischemic preconditioning (IPC) with an intravenous infusion of lactate provides the best protection against endothelial injury. First, baseline endothelial function to reactive hyperemia will be performed on the nondominant arm. Thereafter, a continuous intravenous infusion of lactate will be delivered in the contralateral arm. After that investigators will administer IPC using a blood pressure cuff placed on the same upper arm and inflated to 220 mmHg for 5 min, followed by 5 min of deflation. This procedure will be repeated two more times taking about 30 minutes to complete. The intravenous lactate infusion will be maintained. After a 10-minute rest phase and while lactate is still being infused, endothelial injury will be induced using a blood pressure cuff inflated to stop blood flow through the opposite arm (nondominant arm) for 20 minutes, followed by 15 minutes of cuff deflation. Endothelial function will be repeated.
223929216|NCT06724432|DRUG|oral melatonin|Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
223929217|NCT06724432|DRUG|Placebo|Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
223929218|NCT05720468|OTHER|Exercise|Combined endurance and resistance exercise training
223929219|NCT05720468|OTHER|No Exercise|Continue usual level of physical activity; option to participate in exercise training program after 26-week intervention period
223929220|NCT06741956|BEHAVIORAL|Weapom Lifestyle Intervention to measure bone impacts using a Fitbit Versa wearable device and the Weapom App.|A. Program to increase physical activity and impacts For the intervention, a biosensor -wearable device- (Fitbit Versa) will be used. The device is linked to an App (Weapom) that will allow users to quantify the number of steps (including the rate of steps per minute), the impacts and their intensity. Users will be given feedback from the application on the level of achievement of the objectives proposed in the impact program (EV). It will be proposed to achieve 50 vertical and multidirectional jumps per day (milestone 1. The number of jumps\> 3.9 G per day will be recorded 28, divided between 3-5 sets of 10-20 repetitions with a minimum 1-2 minute rest between sets. A frequency between 4-7 days per week will be used. In the same way, it will be recommended to reach 10,000 steps per day (milestone 2. The number of daily steps will be recorded) and, as far as possible, at a rapid pace (milestone 3. The number of daily minutes walking at a pace over 110 steps/minute will be r
223929221|NCT06741605|OTHER||
224094881|NCT06638099|BEHAVIORAL|CGM Toolkit Prescriber Training|A CGM prescription toolkit was created for prescribing clinicians and staff that includes written guidance on CGM eligibility criteria, instructions for screening patients for eligibility using EHR records and during healthcare visits, recommended provider documentation templates to address all required eligibility criteria for insurance coverage of CGM device and supplies (e.g., Medicare, Medicaid), sample scripts for communicating with patients about the purpose and use of CGM, and patient-level frequently asked questions (FAQs), including free resources available to learn more about CGM benefits, where/how to acquire CGM, and determining out-of-pocket costs. The toolkit will be introduced during a 20 minute initial training session and reinforced during a 10 minute booster training approximately one month after initial training
224094882|NCT04971226|DRUG|Imatinib|Comes in 100 mg and 400 mg tablets and taken orally
224094883|NCT04971226|DRUG|Nilotinib|Comes in 150 mg and 200 mg capsules and taken orally
224094884|NCT04971226|DRUG|Bosutinib|Comes in 100 mg and 400 mg tablets and taken orally
224283063|NCT02346682|DRUG|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
224094885|NCT04971226|DRUG|Dasatinib|Comes in 20 mg, 50 mg, 70 mg and 100 mg tablets and taken orally
224283064|NCT01463150|DRUG|Clopidogrel|Clopidogrel 150mg per day for 15 days
224283065|NCT01463150|DRUG|Prasugrel|Prasugrel 5mg per day for 15 days
223532699|NCT07159243|DRUG|HL-1186|HL-1186 tablet for oral administration.
223532700|NCT07159243|DRUG|HL-1186 placebo|HL-1186 placebo tablet for oral administration.
223532701|NCT07159360|DEVICE|CLINICAL EXPLORER|8 sessions of use of the device in the rehabilitation center
223532702|NCT07159373|DRUG|MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole|"Mass drug administration with moxidectin co-administered with DEC and albendazole (MoxDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged ≥ 2 years but \< 4 years - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
223532703|NCT07159373|DRUG|IDA - Ivermectin + DEC + albendazole|"Mass drug administration with ivermectin co-administered with DEC and albendazole (IDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged \< 2 years or weight \< 15 kg - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"
223718138|NCT02035098|OTHER|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
223929222|NCT06741917|DRUG|Levofloxacin|single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery
223929223|NCT06741917|DRUG|Cefmetazole (drug)|single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
223929224|NCT06742918|OTHER|Placebo|Placebo was given to the Group IV which was 2 grams of glucose.
223929225|NCT06743230|OTHER|Neuro athletic training|The neuroathletic training includes exercises that stimulate the visual, vestibular, and proprioceptive systems. The neuroathletic training includes 3 days per week for 8 weeks.
223929226|NCT06743230|OTHER|Conventional training|Conventional training includes flexibility exercises, strengthening exercises, running, balance and sport-specific technique work 5 days per week.
223929227|NCT06896474|BEHAVIORAL|Shared Decision-Making Training and Decision Aid|The intervention includes training surgeons in shared decision making techniques and providing eligible participants with a tailored breast cancer treatment decision aid prior to the initial surgical consultation.
223929228|NCT06748521|DRUG|R-CHOP + X|Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
223929229|NCT06783075|OTHER|MILK|Drink containing amino acids in the composition of milk protein
223929230|NCT06783075|OTHER|WHEAT|Drink containing amino acids in the composition of wheat protein
223929231|NCT06737146|DRUG|MT027 cells suspension|MT027: CRISPR/Cas9 edited B7H3-specific allogeneic CAR-T cells
223929232|NCT06794060|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
223929233|NCT06794060|DIETARY_SUPPLEMENT|Vitamin C (Ascorbic Acid)|Participants swallow naturral vitamin C tablets 500mg with water, twice a day.
223929234|NCT06794060|OTHER|Placebo|Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
223929235|NCT06844682|OTHER|intervention group|Following the removal of the mattresses, the patient was placed in the semi-fawler position.
223929236|NCT06794632|OTHER|HANDY occupational therapy intervention|The HANDY occupational therapy intervention is occupation-centred and follows the Occupational Therapy Intervention Process Model (OTIPM), specifying the steps of a problem-solving process focused on enabling performance of tasks in everyday life. The HANDY occupational therapy intervention consists of six mandatory sessions of 120 minutes representing a combination of individual and group sessions. Each group includes a maximum of eight participants with hand osteoarthritis, facilitated by two OTs.
223929237|NCT04966702|DRUG|Albendazole Pill|Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
223929238|NCT04966702|DRUG|Ivermectin Pill|Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
223929239|NCT04966702|DRUG|Ivermectin Injectable Product|Veterinary ivermectin injectable will be given to livestock in the relevant cluster
223929240|NCT05966636|PROCEDURE|Fractional CO2 Laser Ablative Resurfacing|Fractional lasers stimulate scar improvement through production of microscopic patterns of dermal injury, vaporizing scar tissue and inducing neocollagenesis, subsequently improving scar tissue texture and range of motion, and decreasing symptoms such as pain and pruritis. Current clinical consensus is supportive that fractionated lasers are the most effective option for the treatment of scars. Other laser wavelengths and modalities used for vascular deformities and hair removal for instance, have an adjunctive role in improving scars and may be used in the same laser session. Case reports provide evidence of substantial improvement in sensory symptoms and physical mobility within days to weeks after each treatment.
223929241|NCT04233099|PROCEDURE|Raman analysis of saliva with data collection and analysis|Saliva collection and processing to all the enrolled subjects and consecutive Raman analysis of the biological fluid. Statistical processing of the collected data.
223929242|NCT00897702|OTHER|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
223929243|NCT00897702|OTHER|immunoenzyme technique|
223929244|NCT00897702|PROCEDURE|biopsy|
223929245|NCT00897702|PROCEDURE|histopathologic examination|
223929246|NCT06716840|DRUG|Remimazolam|participants in the remimazolam group received remimazolam besylate intravenously at an initial infusion rate of 0.2mg/kg/h and adjusted (maximum of 2 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale(RASS) score between - 2 and 0.If the maximum dose of remimazolam was insufficient to sedate, add rescue dexmedetomidine.
224094886|NCT04971226|DRUG|Asciminib|Comes in 40 mg tablets and taken orally
224094887|NCT02516657|DRUG|Liraglutide|Liraglutide 0.6 mg
224094888|NCT06261385|BEHAVIORAL|typology-based intervention|"The typology-based intervention includes:~1. typology-based counselling,~2. personalized E-message based on the counselling content discussed~3. a booklet introducing the typology of quit identity.~All interventions and materials are delivered by smoking counselling."
223929247|NCT06716840|DRUG|Propofol|participants in the propofol group received propofol intravenously at an initial infusion rate of 1 mg/kg/h and adjusted (maximum of 4 mg/kg/h) to maintain a Richmond Agitation-Sedation Scale (RASS) score between - 2 and 0.If the maximum dose of propofol was insufficient to sedate, add rescue dexmedetomidine.
223929248|NCT06749769|BEHAVIORAL|simulation-based education|Patients will learn how to care for their stomata on a stoma simulator
223929249|NCT06751316|PROCEDURE|Conventional Pulpectomy|Removal of radicular pulp tissue, placing Zinc Oxide/Eugenol and covered by stainless steel crown
223929250|NCT06751316|PROCEDURE|MTA Pulpotomy|Removal of coronal pulp tissue, placing MTA and covered by stainless steel crown
224094889|NCT06261385|BEHAVIORAL|Routine Treatment|"The routine smoking cessation intervention includes:~1. Routine counselling generic advice on preventing smoking relapse~2. Brief e-messages that consist of general quit advice for 4 weeks.~Counsellors implement both routine practices."
224283066|NCT00858013|DRUG|Nateglinide|Nateglinide 90\~120mg three times a day
224094890|NCT05548634|DRUG|TAVO412|Biologic
224283067|NCT00858013|DRUG|Glimepiride|Glimepiride 1\~2mg once a day
224283068|NCT04762459|DRUG|Almonertinib|Almonertinib 110mg PO once daily
223718139|NCT05775458|DIAGNOSTIC_TEST|Blood, CSF and tumor samples|Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
223929251|NCT06748937|DRUG|Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD|Cohort 1 Arm 1
223929252|NCT06748937|DRUG|Alpibectir 45 mg OD plus Ethionamide 250 mg OD|Cohort 1 Arm 2
223929253|NCT06748937|DRUG|Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based|Active Comparator
223929254|NCT06748937|DRUG|Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD|Cohort 2 Arm 4
223929255|NCT06571422|DRUG|WJ47156|Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
223929256|NCT06571422|DRUG|JS001+Bevacizumab|Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.
223929257|NCT06571422|DRUG|JS207|Participants in Cohort2 of combination therapy phase will receive WJ47156 plus JS207. JS207 is administered intravenously.
223929258|NCT06804863|BEHAVIORAL|Postoperative Regret Reduction through Immediate Quality of Life Intervention|Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.
223929259|NCT06805435|DEVICE|Continuous non-invasive blood pressure monitoring|A continuous non-invasive blood pressure monitoring cuff will be placed on the volunteers index finger (as intended) and 2nd toe (primary outcome).
223929260|NCT06805006|DEVICE|SSLF|Bilateral sacrospinous ligament fixation with i-Stitch device
223929261|NCT06576752|OTHER|Digital follow-up and uptitration of medications at home after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
223929262|NCT06576752|OTHER|Follow-up and uptitration of medications at the hospital outpatient-clinic after hospital discharge for heart failure|Both arms will treat the patients according to the STRONG-HF intensive care strategy, as recommended by current guidelines. That is up-titration to at least half of maximum tolerated doses of HF medications at discharge, followed by up-titration to maximum tolerated doses after 2 weeks. Safety visits will be performed after 1, 3 and 6 weeks.
223929263|NCT06577415|DRUG|RAY1225|Administered SC
224283069|NCT04762459|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) Pemetrexed
224283070|NCT04762459|DRUG|Cisplatin|75mg/m² Cisplatin taken intravenously (IV) once every 3 weeks concurrently
223929264|NCT05413733|BEHAVIORAL|Digital care pathway|"Sessions of the digital neuropsychological program:~1. Subjective functional ability and goals~2. Fatigue after ABI~3. Attention and concentration~4. Memory~5. Memory strategies~6. Working memory and executive functions~7. Emotional reactions~8. Summary and future goals"
224283071|NCT05507528|DEVICE|reborn treatment|Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure
224283072|NCT06427369|OTHER|Radioconjugate|1241-hJAA-F11 IV administration
224283073|NCT06427369|PROCEDURE|Positron Emission Tomography|PET/CT Imaging
224283074|NCT06427369|PROCEDURE|Computed Tomography|PET/CT Imaging
224283075|NCT06427369|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT Imaging
224283076|NCT06427369|PROCEDURE|Biospecimen Collection|Blood sample collection imaging
223929265|NCT05413733|BEHAVIORAL|Care as usual|The standard care of patients with ABI including all necessary outpatient rehabilitation visits. Neuropsychological visits may include a short period of psychoeducation with a clinical neuropsychologist.
223929266|NCT06811571|BEHAVIORAL|the mobile-based early intervention|The theoretical framework of the intervention was based on Cognitive Behavior Therapy (CBT). We designed three modules, which were the Gaming behavior management, the Gaming cognition establishment and the Early intervention on risk and protective factors. The interventions included self-monitoring questionnaires, scientific popular articles, and online lectures.
223929267|NCT06808971|DRUG|Adebrelimab, Nab-paclitaxel, Oxaliplatin, Tegafur Gimeracil Oteracil Potassium Capsule|Adebrelimab combined with Nab-paclitaxel, Oxaliplatin andTegafur Gimeracil Oteracil Potassium Capsule
223929268|NCT06671574|OTHER|Emotional intelligence and Relaxation techniques|In each session, participants will engage in exercises aimed at recognizing, understanding, and regulating their emotions. These interactive activities will foster personal reflection and group discussion, helping individuals identify emotions in various situations and their impact on behavior. This approach will enhance emotional awareness and equip participants with practical tools for managing stress and anxiety. Various relaxation techniques will also be introduced. Deep breathing exercises will teach participants to calm their minds and bodies, reducing tension. Guided meditation will help them focus inward, promoting mental peace and deep relaxation. Additionally, visualization exercises will encourage imagining calming scenarios, alleviating anxiety and improving overall well-being.
224283077|NCT04351347|DRUG|Ivermectin|ivermectin
224283078|NCT02521181|DRUG|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
224283079|NCT02521181|DRUG|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
224283080|NCT02521181|DRUG|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
224283081|NCT06357156|RADIATION|CBCT|The data collection will be obtained from the data base available at the department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University. CBCT images will be obtained from Egyptian patients who were referred to the CBCT unit in oral and maxillofacial radiology department for different purposes.
224283082|NCT01304381|OTHER|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
224283083|NCT01304381|OTHER|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
223718140|NCT06573359|OTHER|questionnaire|Turkish translation of the scale will be made by a native English speaker and the back translation will be made into English, and the consistency of the original and Turkish translation will be evaluated by a three-person expert committee. The psychometric properties of the scale will be investigated according to the methods used for the validity of the original scale. The validity of the scale was validated by analyzing the correlations between the rcs-e-tr score obtained at admission (both for each partial item and the total score) and other suitability indicators used in Turkey (FIM Motor and Barthel) using Spearman's rank correlation coefficient r (rho). will be evaluated. Additionally, to check the ability of rcs-e-tr to capture case complexity, it will be correlated with other scores usually recorded in our rehabilitation services on admission, using Spearman's rank correlation coefficient r(rho).
223718141|NCT02801331|DEVICE|Stochastic Vibrotactile Stimulation (SVS)|Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle, stochastic vibration during mattress stimulations.
223929269|NCT06661395|DEVICE|Wingate Anaerobic Test with Virtual Reality|"Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown."
223929270|NCT05999721|PROCEDURE|superficial parasternal intercostal plane block|Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1
223929271|NCT05999721|OTHER|Standard care|"Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered."
223929272|NCT06864091|OTHER|Rapid Manufacturing|The first intervention (I1) involves direct printing of the final prosthesis (rapid manufacturing, RM). The final prosthesis will be printed using a biocompatible rubber-like printable soft resin (Biomed Flex 80A resin, Formlabs, USA), and then will be colored and characterized to match the surrounding anatomy.
223929273|NCT06864091|OTHER|Direct Mould Making|In the second intervention (I2), the negative mold will be achieved directly, will be virtually designed based on an inverted STL file of prosthesis prototype/ pattern (direct mold making, DMM).
223929274|NCT06864091|OTHER|Indirect Mould Making|"the negative mold will be fabricated indirectly by printing the prosthesis prototype from resin for subsequent mold fabrication (indirect mold making, IMM). The printed prototype will be tried on the patient and adjusted in terms of shape, size and marginal fit.~After the try-in stage the prototype will be duplicated into wax by using silicone rubber molding and a conventional stone mold will be fabricated."
223929275|NCT06861946|DIAGNOSTIC_TEST|Corvis ST|"Corvis ST is used to assess corneal biomechanical changes following vitrectomy with silicone oil tamponade, specifically:~Corneal stiffness and elasticity using the Stress-Strain Index (SSI) Corneal deformation response via Deformation Amplitude (DA)"
223929276|NCT06861946|DIAGNOSTIC_TEST|Conrneal endothelial cell density|"The study evaluates the impact of silicone oil tamponade on corneal endothelial cell density (ECD) in patients undergoing vitrectomy for retinal detachment. The intervention involves:~Preoperative and Postoperative Assessments at 1, 3, and 6 months to monitor changes in ECD.~Specular Microscopy to measure ECD (cells/mm²), coefficient of variation (CV) in cell size, and hexagonality (% of hexagonal cells)."
224099684|NCT06127602|BEHAVIORAL|Reactive balance training with Neuromuscular Electrical Stimulation|REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
223929277|NCT05101096|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously (IV)
223929278|NCT06866067|DEVICE|PEEK clip|The overdentures were attached with PEEK clip . The retention of overdenture was assessed
223929279|NCT06866067|DEVICE|Nylon clip|The overdentures were attached with Nylon clip . The retention of overdenture was assessed
223929280|NCT06865716|DEVICE|Active noninvasive vagus nerve stimulation|The stimulation parameters include a 200µs stimulation width, at an intensity level of 10-50ma (adjusted for patient-comfort), at a frequency of 20Hz during 60min .
223929281|NCT06865716|OTHER|Chum electrode attached to patient's lower ear lobe|The clip stimulator is attached to the patient's lower ear lobe without stimulation.
223929282|NCT06867458|DEVICE|Antimicrobial photodynamic therapy (aPDT) nasal decolonization device|aPDT is a technique that employs a specific wavelength of light to activate a photosensitizer substance. Once activated, this photosensitizer reacts with surrounding molecules to produce radicals and reactive oxygen species. When activated in the presence of microorganisms, these molecules serve to disrupt membrane structure and protein cross-linking, leading to their death.
223929283|NCT03443492|DRUG|S-1|Intervention is administered to patients in this Arm.
223929284|NCT03443492|DRUG|Leucovorin(oral )|Intervention is administered to patients in this Arm.
223929285|NCT03443492|DRUG|Gemcitabine|Intervention is administered to patients in this Arm.
223929286|NCT03443492|DRUG|Oxaliplatin|Intervention is administered to patients in this Arm.
223929287|NCT03443492|DRUG|Irinotecan|Intervention is administered to patients in this Arm.
223929288|NCT03443492|DRUG|5-FU|Intervention is administered to patients in this Arm.
223929289|NCT03443492|DRUG|Leucovorin(IV)|Intervention is administered to patients in this Arm.
223929290|NCT06625957|DRUG|NTCB02-1|3 Days infusion
223929291|NCT06625957|DRUG|NTCB-C|3 Days infusion
224094891|NCT06498895|RADIATION|lung ultrasound|"Lung ultrasound score will be done within one hour of admission,12 hours post admission then 24 hours in intensive care unit,follow up of patients will continue for 72 hours .~a complete lung ultrasound evaluation will be performed using low frequency curved probe (2MHz-5MHz) according to the lung ultrasound score . The external lung fields will be examined by longitudinal and transverse plane scans, dividing the surface of the thorax into 12 zones: 6 on the right (anterior: upper R1 and lower R2; lateral; upper R3 and lower R4; posterior: upper R5 and lower R6) and 6 on the left side (front: upper L1 and lower L2; lateral: upper L3 and lower L4; rear: upper L5 and lower L6). LUS assigns 0 points to A lines or \< 2 separate B lines plus regular sliding; 1 point with lines B ≥ 3 or spaced focal points plus regular sliding; 2 points with coalescing B lines, and 3 points to pulmonary consolidations for each zone with a score ranging from 0 (normal lungs) to 36 (worst case scenario)"
224094892|NCT03398161|OTHER|Quality-of-Life Assessment|Ancillary studies
224094893|NCT03398161|OTHER|Questionnaire Administration|Ancillary studies
224283084|NCT06722755|DEVICE|CPAP device|Eligible participants with OSA will be started on automatically-adjusting CPAP.
223532704|NCT03094143|PROCEDURE|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
223718142|NCT06505447|OTHER|Daytime light exposure|Participants will be exposed to a 10,000 lux light source within 3 feet of their face/eyes to promote the natural circadian rhythm for 2-3 hours from 10am to 12/1pm depending on their nap time at home
223718143|NCT06505447|OTHER|Daytime restricted feeding|Participant's nutrition, parenteral or enteral, will be restricted to the hours when they are normally awake at home.
223718144|NCT05212428|PROCEDURE|Biospecimen Collection|Undergo collection of saliva, blood, urine and stool samples
223929292|NCT06876129|DEVICE|TMS|Subjects will either receive iTBS using a Magventure TMS device or 18-Hz H1 TMS using a dTMS Brainsway device plus placebo.
223929293|NCT06876129|COMBINATION_PRODUCT|D-serine + TMS|"D-serine, 80 mg/kg, oral administration, will be advised to be taken 1-hour prior rTMS treatment day (Mon-Fri) for 6 weeks. Dosing is based on maximal plasticity at 80 mg/kg, and clinical dose-finding studies demonstrating that doses between 60 - 120 mg/kg were superior in clinical effectiveness to 30 mg/kg and were safe.~Subjects will not be randomized into their TMS group and will either receive iTBS using a Magventure TMS device or 18-Hz H1 TMS using a dTMS Brainsway device. Subjects will have their TMS protocol/treatment determined at the time of consultation according to clinical appropriateness as is the standard of care at the TMS clinic at McLean Hospital."
223929294|NCT06876467|OTHER|Evaluation of cellular response|detection of HBsAg-specific T lymphocytes by spectral cytometry
223929295|NCT06879470|DRUG|JY231 Injection|"This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell leukemia.~Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 15 years to determine if the disease is under control."
223929296|NCT06885372|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
224094894|NCT03398161|RADIATION|Radiation Therapy|Undergo ultra low dose radiation therapy
224094895|NCT04203147|BEHAVIORAL|Supportive Therapy (Control)|Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
224283085|NCT06722755|BEHAVIORAL|CPAP technical support|Trained personnel will conduct mask selection and fitting, provide continual troubleshooting, and train participants on CPAP.
223532705|NCT05691647|BEHAVIORAL|Chronotherapy|Chronotherapy involves three different interventions. Sleep deprivation/wake therapy will be conducted for 34 hours. To assist wake and to ensure that the participants adhere to the sleep deprivation, outpatients will be admitted to a one-night stay at the inpatient ward that is connected to the outpatient clinic at Nidaros DPS. Patients already admitted to inpatient treatment will be temporary transferred to the ward selected to oversee the sleep deprivation. Upon discharge, participants are encouraged to adhere to the sleep schedule which presents the sleep-wake phase advancement and later stabilization of the sleep-wake phase. Light therapy is provided for half an hour every day from day four in the study. In addition to the chronotherapeutic interventions, the participants will receive treatment as usual (TAU) with their assigned therapist.
223718145|NCT05212428|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223929297|NCT06885372|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
223929298|NCT06747416|DRUG|KN057|KN057 will be administered subcutaneously once a week.
223929299|NCT06418269|OTHER|Therapeutic Play|"Children will be asked to fill in the Child Patient Identification Form, State Anxiety Scale in Children and Child Fear Scale 30 minutes before insulin treatment. Before the insulin treatment, the children in the experimental group will have their blood glucose measured and insulin administered on a doll using the therapeutic play method. The child will be told that the doll is hospitalized with a diagnosis of Type 1 diabetes and will be expected to assume the role of a nurse to administer insulin to the doll. Then, the steps of blood glucose measurement and insulin treatment (subcutaneous) will be explained to the child and the child will be asked to administer insulin to the baby. Within 10 minutes after subcutaneous insulin treatment, the child will be asked to fill out the State Anxiety Scale in Children and Child Fear Scale."
223929300|NCT06892067|COMBINATION_PRODUCT|Cosmetic Products|To evaluate and analyze the safety of commonly used ingredients in over-the-counter personal care and cosmetic products.
223929301|NCT06742775|OTHER|physiological signal acquisitions|"Subjects will be fitted with non-intrusive devices. In a semi-recumbent position, they will be asked to perform~* 10 minutes of resting breathing~* 10 cycles consisting of a 20-second apnea, to be performed at the end of inspiration, and 1 minute 40 of breathing (100 seconds).~This single participation session will last a total of one hour for the volunteer (equipment, recording, de-equipping), including 30 minutes of acquisition."
223929302|NCT06741826|PROCEDURE|Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.|Navigation bronchoscopy combined with radial endobronchial ultrasound guided pulmonary nodule biopsy under needle-based confocal laser endomicroscopy.
223929303|NCT06740032|OTHER|Transcutaneous vagus nerve stimulation|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
223929304|NCT06740032|OTHER|Deep breath exercise|Investigation of the effects of vagus nerve stimulation on the autonomic and somatic systems together
223929305|NCT06763822|BEHAVIORAL|close eyes|ask participants to close their eyes for rest
223929306|NCT06763822|BEHAVIORAL|cold compress|cold compress on participants' eyes for rest
223929307|NCT06405295|OTHER|no intervention|Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
223929308|NCT06865755|DEVICE|integrated medication monitoring (MM) system|We have created a new integrated medication monitoring (MM) system consisting of baseline, 3-month, and 6-month surveys, smartphone-based ecological momentary assessment via an application installed on a smartphone (Digital Trails based on the UVA Sensus app), a wireless medication event monitoring system device (MEMS; Wisepill), and a wearable sensor (Fitbit), and data collected passively from smartphone sensors using the Digital Trails app. These sources of information will be used to understand predictors of medication taking behaviors and, after two months of monitoring, to deploy appropriate interventions which will be delivered via the Digital Trails app platform.
223929309|NCT06745453|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block
223929310|NCT06745453|PROCEDURE|Sham Procedure|Sham Procedure
223929311|NCT06846099|DRUG|RP903|Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle； Ib: RP903,RP2D,po qd for each 28-day cycle
224094896|NCT04203147|BEHAVIORAL|Home DM-BAT|Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
223929312|NCT04831125|OTHER|Data collection|Data collection on the use of pacemaker, implantable cardioverter-defibrillator (ICD), and cardiac resynchronization therapy (CRT) devices and leads that are approved for clinical use.
224094897|NCT00001337|DRUG|Etoposide|"Etoposide 50mg/m\^2/day were delivered as continuous intravenous (CIV) infusions over 96 hours starting on day 1 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
224094898|NCT00001337|BIOLOGICAL|Rituximab|"Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
224094899|NCT00001337|DRUG|Prednisone|"Prednisone 100mg by mouth (PO) twice a day (bid) on days 1 through 5 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
224094900|NCT00001337|DRUG|Cyclophosphamide|"Cyclophosphamide 750mg/m\^2 on day 5 every 21 days.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
224283086|NCT06722755|BEHAVIORAL|Phone follow-up for adherence feedback and self-management skills|The research coordinator will call participants approximately monthly to provide any needed support.
223718146|NCT05212428|OTHER|Genetic Counseling|Receive genetic counseling
223929313|NCT06734052|BEHAVIORAL|CAPPA|See CAPPA arm description.
223929314|NCT06734052|BEHAVIORAL|Health education|See health education arm description
223929315|NCT06767150|DRUG|a second infusion of ZOL when crosslaps levels reach 300 pg/mL|a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
223929316|NCT06767150|DRUG|a rescue second infusion at month-12 (standard traitment)|a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
224094901|NCT00001337|DRUG|Vincristine|"Vincristine 0.4mg/m\^2/day.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
224094902|NCT00001337|DRUG|Doxorubicin|"Doxorubicin 10mg/m\^2/day.~Combination chemotherapy given with Rituximab, Etoposide, VP-16; Prednisone, Cyclophosphamide, Vincristine, and Doxorubicin (EPOCH-R) intravenous (IV) every 3 weeks for 6 cycles."
224094903|NCT00001337|DIAGNOSTIC_TEST|MRI|Baseline and/or on completion of therapy.
223532706|NCT05691647|BEHAVIORAL|Treatment as usual|Participants allocated to receive TAU alone, will receive standard treatment for a depressive episode in the outpatient or the inpatient clinic. This study will not give restrictions or guidelines on how this treatment should be performed. The TAU-group will receive the treatment the responsible therapist considers and evaluate best fitting in the situation. Typical interventions administered in therapy for a depressive episode includes medication, cognitive behavioral therapy, and other psychotherapies.
223929317|NCT06765837|DEVICE|biolase laser|after secondary cleft lip surgery to improve wound healing and prevent scar formation laser was used with group I and Gel was applied to Group II
223929318|NCT06765837|DRUG|blue m gel|active oxygen releasing gel was used after the secondary cleft lip repair surgery
223929319|NCT06773702|OTHER|gastroenterology and otolaryngological evaluation|"* Gastroenterology evaluation: presence and intensity of esophageal symptoms of gastro esophageal reflux disease, high-resolution esophageal manometry, and 24-hour pH-impedancometry in the absence of PPI therapy.~* otolaryngological evaluation: presence and intensity of laryngopharyngeal reflux symptoms, laryngoscopy."
223929320|NCT06757400|OTHER|Mobilization|Mobilization will be conducted on an examination table with the subject in prone position. Therapist will place his hypothenar to the most hypomobile lumbar spine segment after assessment.It will be a posteroanterior (PA) direction tecnique, Maitland's GRADE 4, 3 sets of 60 seconds duration for each set.
223929321|NCT06757400|OTHER|manipulation|Manipulation will be conducted on an examination table with the subject in right lateral decubitus. It will be a rotary manipulation to the most hypomobile lumbar spine segment after assessment.
223929322|NCT06756022|DRUG|Dolasetron mesylate injection|"1.8 mg/kg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg/kg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy.~Other antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice."
223929323|NCT06762509|DRUG|Botulinum toxin type A|Local injection of botulinum toxin type A was given at the time of enrollment
223929324|NCT06761729|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
223929325|NCT05601882|DRUG|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection.
223929326|NCT05601882|DRUG|Upadacitinib|Extended-release tablet
223929327|NCT06458322|OTHER|Home dialysis or In-Center dialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)
223929328|NCT04704219|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
223929329|NCT04704219|DRUG|Lenvatinib|Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
223929330|NCT06757608|OTHER|Assessment of postprandial metabolism after intake of different meat|30 healthy adults (15 male and 15 female) consumed sardines (Opisthonema oglinum, marine fish), tambaqui (Colossoma macropomum, freshwater culture), and beef (Bos taurus). The meal consisted only of meat, with 7g per BMI unit. The postprandial response was observed for 5 hours, after an overnight fast.
223929331|NCT03741790|PROCEDURE|Ventilation|The difficult mask ventilation is defined as A) It is not possible for unassisted anesthesiologist to maintain the SpO2 \> 90% using 100% oxygen and positive pressure mask ventilation in a patient whose SpO2 \> 90% before anesthetic intervention; and/or B) It is not possible for unassisted anesthesiologist to prevent or reverse signs of inadequate ventilation during positive mask ventilation.
224094904|NCT00001337|DIAGNOSTIC_TEST|CT|Baseline and/or on completion of therapy.
224094905|NCT00001337|PROCEDURE|Biopsy|Baseline and/or on completion of therapy.
223929332|NCT03741790|PROCEDURE|Intubation|"The difficult endotracheal intubation is defined as  It is not possible to visualize any portion of the vocal cords with conventional laryngoscopy or when proper insertion of the endotracheal tube with conventional laryngoscopy requires more than three attempts or more than ten minutes."
223929333|NCT05943041|DRUG|GB104(Level 1)|One capsule QD oral administration for 28 days
224094906|NCT00001337|DIAGNOSTIC_TEST|PET scan|As clinically indicated.
224094907|NCT00001337|PROCEDURE|Laparotomy|As clinically indicated.
224094908|NCT00001337|OTHER|Ondansetron|Nausea and/or vomiting.
224094909|NCT00001337|OTHER|Prochlorperazine|Nausea and/or vomiting.
224094910|NCT00001337|OTHER|Omeprazole|Gastroesophageal reflux disease (GERD).
224094911|NCT00001337|OTHER|Docusate Sodium + Sennosides|Constipation.
224094912|NCT00001337|OTHER|Lactulose|Constipation
224094913|NCT04506892|BEHAVIORAL|Meditation|meditation
224094914|NCT04609904|DRUG|BGF MDI 320/28.8/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
224094915|NCT04609904|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler
224094916|NCT04609904|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler
224094917|NCT04609904|DRUG|BFF pMDI 320/9 μg|Budesonide/formoterol fumarate pressurized metered dose inhaler
224094918|NCT04006808|BIOLOGICAL|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
223532707|NCT05986929|OTHER|focus group|Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).
223532708|NCT05986929|OTHER|electronic survey|An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
223532709|NCT04861584|DRUG|Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin|4 cycle neoadjuvant therapy and radical cystectomy
223718147|NCT05212428|OTHER|Questionnaire Administration|Complete family history
223929334|NCT05943041|DRUG|GB104(Level 2)|Three capsules QD oral administration for 28 days
223929335|NCT05943041|DRUG|GB104(Level 3)|Five capsules QD oral administration for 28 days
223929336|NCT06773182|OTHER|Intermittent Fasting Intervention|A 14:10 intermittent fasting regimen, where participants fast for 14 hours and consume all meals within a 10-hour eating window daily.
223929337|NCT06773182|OTHER|Mediterranean Diet Intervention|A diet emphasizing whole grains, fruits, vegetables, olive oil, lean proteins, and minimizing processed foods.
223929338|NCT06773182|OTHER|Low FODMAP Diet Intervention|A diet limiting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols to manage gastrointestinal symptoms.
223532710|NCT05639881|BEHAVIORAL|Enhancing Your Immune Health|In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.
223532711|NCT05823896|DRUG|Nirmatrelvir/ritonavir|300/100 mg tablet twice daily (q12h) administered orally for 15 days
223929339|NCT05411640|OTHER|Aerobic exercise with Blood flow restriction|Experimental group will be given aerobic exercises with blood flow restriction training. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. . Arterial occlusion of 60% will be achieved by Blood Flow Restriction apparatus. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
223929340|NCT05411640|OTHER|Aerobic exercise without Blood flow restriction|Active Comparator group will be given aerobic exercises. For first four weeks, aerobic exercise will be performed for 25 min with 60-65 % of the maximum heart rate reserve (MHRR). During second four weeks, time of exercise will be 30 min with intensity 60-65% of the MHRR, and for third four weeks, time will be increased to 35 min and intensity will be raised up to 70-75% of the MHRR. Total intervention protocol for this group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
223929341|NCT05411640|OTHER|Patient Education and dietary modification|Participants will individually instruct to reduce total energy intake and increase physical activity, aiming at a 5% reduction in body weight. The participants will be given pamphlets providing general information on pre diabetes and dietary modifications. Total intervention protocol for the group will be given for 12 weeks of duration 4 sessions per week with total 48 sessions.
223532712|NCT05823896|DRUG|Placebo/ritonavir|100mg tablet twice daily (q12h) administered orally for 15 days
223532713|NCT02842593|BEHAVIORAL|Lower-repetition, heavier-load|8-12 reps/set at \~80% 1 repetition maximum
224094919|NCT04516252|BEHAVIORAL|BodyWorks Intervention|BodyWorks (BW), a Comprehensive Behavioral Family Lifestyle Interventions (CBFLI), a national, empirically validated, curriculum-based 7-week program will be implemented (Borden et al., 2012; DHHS, 2013)
223532714|NCT02842593|BEHAVIORAL|Higher-repetition, lighter-load|20-25 reps/set at \~30% 1 repetition maximum
223929342|NCT06835140|DRUG|Donor-derived CD123-CD16 bispecific antibody-modified NK cells|Patients enrolled sequentially received varying doses of NK cell infusions. The first three patients received 1×10⁷ cells/kg, the next three received 2×10⁷ cells/kg, and the final three received 4×10⁷ cells/kg.
223929343|NCT06772792|DRUG|Alendronate|Oral administration
224094920|NCT04516252|BEHAVIORAL|Canine Curriculum|Using our team's expertise in veterinary medicine, human-animal interaction, and animal behavior modification, develop an empirically-based, 7-week module on canine health and behavior.
224094921|NCT04516252|BEHAVIORAL|Ecological Momentary Assessment|Ecological Momentary Assessments (EMA) of physical activity will be conducted using mobile phones for 7 weeks of the BW program, prospectively collecting data on 4 days per week (Saturday to Tuesday) (Dunton et al., 2011; Liao et al., 2016).
223929344|NCT06772792|DRUG|Enlicitide Decanoate|Oral administration
224283087|NCT06722755|BEHAVIORAL|myAir|Study personnel will assist participants in registering for and using the myAir (ResMed) self-tracking app. This app also provides a library of how-to videos and provides email updates to participants.
224283088|NCT06722755|BEHAVIORAL|Tailored messages|Tailored text messages will be sent to participants. Two-way texting messaging will also be available between the study team and participants.
224283089|NCT06722755|BEHAVIORAL|Written Materials|A binder of written educational materials will be provided to participants.
224283090|NCT06722755|BEHAVIORAL|Motivational Enhancement Therapy (MET)|A trained sleep coach will conduct up to 5 MET sessions with participants and 2 sessions with a CPAP partner during the study time period.
224283091|NCT01631682|DRUG|Propranolol|40mg single pill
224283092|NCT01631682|BEHAVIORAL|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
224283093|NCT01631682|DRUG|Mifepristone|1800mg, 9 tablets
224283094|NCT01631682|DRUG|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
224283095|NCT05522218|DEVICE|Eluvia drug eluting stent|Eluvia drug eluting stent for peripheral arterial disease
224283096|NCT02408445|DRUG|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
224283097|NCT01253317|DRUG|rhIGF-1|1\) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
224283098|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
224283099|NCT00503113|DRUG|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
224283100|NCT00503113|DRUG|Alendronate|70mg per oral (po) weekly
224283101|NCT01962649|BIOLOGICAL|ICG|
223532715|NCT05981326|PROCEDURE|Biopsy|biopsy will be performed for multi-omicanalysis at inclusion before initiation of treatment
223532716|NCT05981326|PROCEDURE|Blood samples|Centralized blood samples will be performed at inclusion + evaluation visits
223718148|NCT05212428|OTHER|Questionnaire Administration|Ancillary studies
223718149|NCT05240534|BEHAVIORAL|ET-Text (Laptop)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Text arm will access ET on Laptop."
223718150|NCT05240534|BEHAVIORAL|ET-Voice (Smart System)|"ElderTree (ET) is based on the extensively tested Comprehensive Health Enhancement Support System (CHESS). ET is a walled garden free of ads, with design features based on older users' feedback as well as best-practice principles such as uncluttered screens and large type. Like all CHESS systems, ET uses computers to deliver key elements of successful interventions: long duration, ongoing outreach, prompts, monitoring, cognitive reframing, action planning, problem solving, self-tailoring, and peer support. ET-Voice arm will access ET on a smart speaker. Voice-activated devices can potentially be easy to use, even by those with limited dexterity or computer experience."
223929345|NCT04484636|DIAGNOSTIC_TEST|FoundationOne®CDx and FoundationOne®Liquid|FoundationOne CDx is a FDA-approved broad companion diagnostic (CDx) that is clinically and analytically validated for solid tumors. The test is designed to provide physicians with clinically actionable information - both to consider appropriate therapies for patients and understand results with evidence of resistance - based on the individual genomic profile of each patient's cancer. Every test result includes microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions. FoundationOne®Liquid is a liquid biopsy test for solid tumors that analyzes circulating tumor DNA (ctDNA) in blood.
223929346|NCT06852508|BEHAVIORAL|TwySHE|Interpersonal support from trained peers to access and use PrEP and contraception.
223929347|NCT06094881|DRUG|Obinutuzumab Injection [Gazyva]|"intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment."
223929348|NCT04158141|DRUG|Carboplatin|Intravenously
223929349|NCT04158141|DRUG|Cisplatin|Intravenously
223929350|NCT04158141|PROCEDURE|Decortication|Undergo decortication
223929351|NCT04158141|RADIATION|Intensity-Modulated Radiation Therapy|Daily fractions
223929352|NCT04158141|DRUG|Pemetrexed|Intravenously
223929353|NCT04158141|DRUG|Pemetrexed Disodium|Intravenously
223929354|NCT04158141|RADIATION|Pencil beam scanning proton therapy|Daily fractions
223929355|NCT04158141|PROCEDURE|Pleurectomy|Undergo pleurectomy
223929356|NCT06808035|OTHER|Activity-Based Recovery Training|ABRT uses task-specific training to improve neuromuscular capacity. ABRT will be tailored to participant presentation. Activity-Based Locomotor Training consists of stepping, standing, and sitting activities on a body weight support (BWS) treadmill using a harness and while overground. Therapists and trainers provide hands-on assistance for safety and kinematics. BWS is varied during sessions with a goal of optimal kinematics at the lowest BWS. Activities performed standing will focus on alignment incorporating static, active, and dynamic tasks. Activities performed during overground are based on neuromuscular capacity and appropriate developmental and functional levels. Principles of ABRT will be shared with parents/caregivers to foster activity in the home and community. Activity-Based Upper Extremity Training uses task-specific training of the trunk and upper extremities administered in sitting or standing via manual facilitation or support in a stander for best posture.
223929357|NCT06808035|DEVICE|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation (scTs) is a non-invasive stimulation administered over the skin using a modulated biphasic or monophasic waveform at 15-90Hz and a carrier frequency of 5-10kHz. Bouts of scTs at the cervical, thoracic, lumbar, and/or coccygeal level will be administered midline or just lateral to the spinous processes during activity-based recovery training.
223929358|NCT06276686|OTHER|Supervised Vigorous intensity aerobic interval exercise|11-weeks course of aerobic and resistance exercise, delivered 2 weeks before long course NACRT, 5-weeks during NACRT and 4 weeks post NACRT. Alongside twice weekly unsupervised resistance exercise training.
224283102|NCT01962649|DEVICE|Optical molecular imaging|
223532717|NCT05981326|BEHAVIORAL|Questionnaires|Food inquiry + food-frequency questionnaire + physical activity questionnaire will be performed at inclusion
223532718|NCT04460781|BIOLOGICAL|Flublok Quadrivalent influenza vaccine RIV4|Route of administration: Intramuscular
223532719|NCT04460781|BIOLOGICAL|Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4|Route of administration: Intramuscular
223532720|NCT02025998|DRUG|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
223532721|NCT02025998|OTHER|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
223532722|NCT04096417|DRUG|Pemigatinib|Given PO
223532723|NCT04096417|OTHER|Quality-of-Life Assessment|Ancillary studies
223532724|NCT04161534|DEVICE|KT Tape|in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
223532725|NCT04161534|DEVICE|Arm Sling|An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
223532726|NCT05420948|DRUG|Pembrolizumab|A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.
223532727|NCT05420948|DRUG|Carboplatin|A chemotherapy drug used to treat cancer.
223532728|NCT05420948|DRUG|Paclitaxel|A chemotherapy drug used to treat cancer.
223532729|NCT00054522|DIETARY_SUPPLEMENT|calcitriol|
223532730|NCT00054522|DRUG|dexamethasone|
223532731|NCT03697850|DRUG|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
223718151|NCT01352546|BIOLOGICAL|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
223718152|NCT00946478|DRUG|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
223929359|NCT06653530|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed using polyglycolic acido thread. Needles have a gauge size of 23G, a shaft length of 60mm, and a thread length of 50mm, folded in half, and are applied to fourteen acupoints, including Zhongwan (CV12), Qihai (CV6), bilateral Tianshu (ST 25), bilateral Wailing (ST 26), bilateral Daheng (SP 15), bilateral Zusanli (ST 36), bilateral Pishu (BL 20), and bilateral Weishu (BL 21). After the thread is inserted into the body, the needle will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
223929360|NCT06653530|OTHER|Sham thread embedding acupuncture|The protocol includes the same duration and frequency of sessions as for thread embedding acupuncture, but the treatment will be delivered superficially at non-acupuncture points 10mm from the lateral of the corresponding acupuncture and not above a meridian line. Needles without threads have a gauge size of 23G, and a shaft length of 60mm will be used. After the needle is inserted into the body, it will be withdrawn immediately. During the treatment period, health counseling will be provided by qualified staff at every visit, including diet and physical activity, but there will be no strict restrictions.
223929361|NCT06816615|PROCEDURE|Percutaneous cholangioscopic-assisted treatment|The intervention administered is a percutaneous colangioscopic assisted technique that uses endoscopic Spyglass system. The endoscopic Spyglass system is designed to provide direct viewing and to guide both optical devices and accessories for lithotripsy in case of litiasic pathology and is equipped with a suitable bioptic clamp in case of biopsy collection. The use of the digital Spyglass catheter involves the preliminary percutaneous puncture of the bile ducts with a right, left or combined approach, and the subsequent execution of a cholangiographic study. Additional treatment sessions may be performed every 15-20 days in case of residual lithiasis. At the end of each session, an internal-external transeptic percutaneous drainage (ptbd) of adequate caliber (8-14 fr) is left in place to monitor any complications and maintain a route of access for sequential treatments.
223929362|NCT06816732|BEHAVIORAL|Nurse-led Modular Training|The intervention group participants filled out all the data collection tools in the first interview and three months later. They received modular training by phone 2 weeks, 4 weeks, 8 weeks, and 12 weeks after the first interview.The modular training addressed (1) defining hypertension, (2) systemic effects of hypertension, (3) general effects of antihypertension drugs, (4) regular medication and blood pressure monitoring, and (5) eating a healthy diet and being active (what to do for a better heart health and a more stable blood pressure)
223929363|NCT06817915|BEHAVIORAL|AI assisted assessment of SD-OCT scans|AI 2nd opinion report on nAMD treatment planning
223929364|NCT06857266|OTHER|Live Video-delivered Feedback|Feedback is delivered to students through a live video call.
223929365|NCT06857266|OTHER|In-Person Feedback|In-Person Feedback
224094922|NCT04516252|BEHAVIORAL|Physical Activity Trackers|Three types of consumer-grade wireless personal activity trackers (PATs): FitBit Inspire® designed for children 8 years of age and older; FitBit Inspire® for adults (Diaz et al., 2015; Espinoza et al., 2017); and FitBark®, wireless, global positioning systems (GPS)-based personal activity trackers for dogs (Patel et al., 2017). This approach will allow us to evaluate quantity (number of steps) and intensity of physical activity in the adolescents, their parents, and their dogs, as well as to synchronize Fitbit Ace and FitBark to establish the amount of shared physical activity of adolescents and their dogs.
224094923|NCT06099288|BEHAVIORAL|Home-Based Video and Motivational Interviewing Intervention|The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.
224283103|NCT01083862|BEHAVIORAL|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
224283104|NCT01083862|BEHAVIORAL|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
224283105|NCT04836520|DRUG|SHR6390+anatrozole|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
223532732|NCT06549153|OTHER|Education Content|Participants will be offered group based education sessions expected to last 90 minutes
223718153|NCT00946478|OTHER|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
223532733|NCT06549153|OTHER|Focus Group|Participants will attend via Zoom
224283106|NCT06749925|BIOLOGICAL|Dendritic Cell Vaccine|This intervention distinguishes itself from others by utilizing allogeneic dendritic cells derived from healthy donors fused with autologous tumor cells from patients, which is a novel approach compared to the commonly used autologous DC-based vaccines (DCVax).
224283107|NCT06749925|COMBINATION_PRODUCT|Pembrolizumab|Recent findings have shown that the anti-PD1 monoclonal antibody, a checkpoint inhibitor, can sustainably enhance the anti-tumor immune response. In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
224283108|NCT06749925|OTHER|Placebo|In this study, all patients in the intervention group (vaccine) who reach the fifth dose will be randomized to receive either pembrolizumab or a placebo as an addition to the experimental treatment regimen.
223929366|NCT06857266|OTHER|Recorded Video-delivered feedback|Feedback is delivered via a personalized recorded video made by the instructor specific to the student's performance.
223929367|NCT04310644|OTHER|No intervention planned, but all patients get our standart treatment|Patients are selected from clinical Routine and get our standart Treatment based on their disease
223929368|NCT06771882|OTHER|BMOS technique|"The researcher obtained 5cc soaked in a 2cm×2 cm piece of sterilized gauze for every intervention administration.~* The preterm neonates were positioned in the supine position and the head turned to one side~* The gauze was placed near the head, 2cm away from the nose for 2 minutes before feeding to stimulate an olfactory sense of preterm neonates 3 times per day (11 am, 2 pm, and 5 pm)."
223929369|NCT06586021|DEVICE|Aortoseal Endostapling System|Aortoseal Endostapling System
223929370|NCT06863025|BEHAVIORAL|Neurofeedback training|Neurofeedback (NF) or electroencephalographic feedback (EEG) training refers to a type of computerized cognitive training that changes EEG patterns through operant conditioning. NF is a computerized rehabilitation technique but also a non-invasive neuromodulation approach, as it alters brain activity by delivering a stimulus. It is well-established for the treatment of conditions such as anxiety and ADHD. During NF rehabilitative training, the subject is provided with real-time EEG feedback, usually with a visual or auditory stimulus, with the aim of normalizing brain oscillations. Rehabilitation through NF training generally targets EEG frequencies that are affected and underlie the observed behavioral deficit (e.g., attentional dysfunctions).
223929371|NCT06863025|BEHAVIORAL|Standard cognitive therapy|This is the control intervention and it involves standard practice cognitive therapy in neurorehabilitation. Neuropsychologists and other clinicians test and train the patients' cognitive specific aspect (in this case, attention) with some validated tools and/or games
223929372|NCT06883877|OTHER|Multi-Modal Program (MMP)|MMP includes three modules: addressing psychological problems such as FCR; addressing problems related to breast cancer symptoms; and addressing tangible problems such as social support. Each module is divided into the chemotherapy period (hospitalization) and the chemotherapy interval (post-discharge). Each phase involves face-to-face, digital, and remote tools, with the intervention lasting 8 weeks. Each module has a different goal, and depending on the goal setting, the topic of the intervention is different. The goal of the information education stage is to improve patients' overall understanding of the disease and pay attention to the psychological problems of FCR. The goal of coping skills is that through the practice of coping skills, patients can learn to change thoughts, problem emotions, and behaviors. The objective of social support group interaction is to strengthen their social support networks.
223929373|NCT06883877|OTHER|Routine care|The control group will receive routine care.
223929374|NCT06744530|PROCEDURE|stereotactic radiotherapy ablation|Single dose of 25 Gy up to 32.5 Gy on the myocardium in patients with therapy-refractory ventricular tachycardia
223929375|NCT06744608|OTHER|Structured Myofascial Release|haftada 2 seans 8 hafta boyunca toplam 16 seans uygulama yapıldı
223929376|NCT06744608|DEVICE|tens (transcutaneous electrical nerve stimulation)|A total of 16 sessions of application were applied to the groups, 2 sessions per week for 8 weeks.
223929377|NCT06744608|BEHAVIORAL|lifestyle changes|A presentation including lifestyle changes was prepared and training was provided.
223929378|NCT06750406|OTHER|mind body exercises|intervention might consist of a structured program of mind-body exercises designed specifically for pregnant women. This could involve a combination of yoga sessions, mindfulness meditation practices, deep breathing exercises, and progressive muscle relaxation techniques. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
223929379|NCT06750406|OTHER|relaxation exercises|It involves relaxation exercises including deep breathing, relaxing postures etc. The duration of these sessions will be 45 to 60 minutes each, with a recommended frequency of 2-3 times per week for 8 weeks
224283109|NCT06895382|PROCEDURE|Caudal Epidural Block|A caudal epidural block was performed after the induction of general anesthesia. Using a 35-mm 22G or 30-mm 25G block needle, the sacral hiatus was identified, and the needle was inserted through the sacrococcygeal ligament into the epidural space under aseptic conditions. After confirming negative aspiration for cerebrospinal fluid or blood, 1 mL/kg of 0.25% bupivacaine was administered.
224283110|NCT06895382|PROCEDURE|Transversus Abdominis Plane (TAP) Block|A transversus abdominis plane (TAP) block was performed after the induction of general anesthesia. Using a 22G, 50-mm insulated block needle, the injection was administered under ultrasound guidance using a linear probe and in-plane technique. The needle was advanced into the fascial plane between the internal oblique and transversus abdominis muscles. After confirming placement with a 0.5-1 mL test dose of 0.9% NaCl and negative aspiration for blood, 0.3 mL/kg of 0.25% bupivacaine was administered.
224283111|NCT06895382|DRUG|Bupivacaine 0.25%|"0.25% bupivacaine was administered in both intervention arms as part of the regional anesthesia procedure In the Caudal Block group, 1 mL/kg of 0.25% bupivacaine was administered into the caudal epidural space.~In the TAP Block group, 0.3 mL/kg of 0.25% bupivacaine was administered into the transversus abdominis plane under ultrasound guidance"
223929380|NCT06812689|DIETARY_SUPPLEMENT|Flavanol|Natural cocoa powder containing 710 mg of flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
223929381|NCT06812689|DIETARY_SUPPLEMENT|Placebo|Alkalized cocoa powder containing no flavanols was dissolved in 250 mL of hot water and sweetened with 6 g of sugar.
223929382|NCT06812689|OTHER|Sugar water|250 mL of hot water with 6 g of sugar
223929383|NCT06762431|DRUG|Lenalidomide|Dose Level 1
223929384|NCT06762431|DRUG|Lenalidomide|Dose Level 2
223929385|NCT06786299|BIOLOGICAL|RD-IIT-001|Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
223929386|NCT06786299|DRUG|CD84-CART|Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
223929387|NCT06321536|DRUG|Allogeneic Microbiota in Glycerol (9%) (AMG)|Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or 30mL instillation via an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.
223929388|NCT06795607|DIETARY_SUPPLEMENT|Probiotic|The experimental product is a dietary supplement manufactured by Cerbios-Pharma S.A, Each stick contains probiotic live cultures of Enterococcus lactis SF68® at a concentration of 10\^9 CFU, phytosterols, 6S-5MeTHF, maltose and silicon dioxide. Study participants will be given N°3 packs each containing 30 stick packs of 1.7 g each, in granulated form in sufficient quantity for the entire duration of the study (12 weeks). Subjects will be required to consume N°1 stick pack of the supplement daily after dinner for 12 continuous weeks. The product should be placed directly on the tongue and should be taken without water. After taking the product, the subject should drink half a glass of water to promote solubilization and transit. The supplement should be stored in a cool, dry place, away from light, moisture and direct heat sources to ensure the viability of the probiotic strain until the expiration date.
223929389|NCT06795607|DIETARY_SUPPLEMENT|Placebo|N°1 stick/day of placebo food supplement (i.e., stick without added probiotics), with the same intake modalities as probiotic.
223929390|NCT06797843|OTHER|"SPRG-based Resin Composite : (BEAUTIFIL II, Shofu Inc. Kyoto, Japan)."|A fluoride releasing, highly aesthetic dental material that is S-PRG (Surface Pre-reacted Glass Ionomer) based , has the ability to recharge fluoride and appropriate for patients with a high caries index.
223929391|NCT06797843|OTHER|Alkasite based restoration : Cention N|Cention N offers tooth-coloured esthetics together with high flexural strength. The new filling material belongs to the materials group of Alkasites. The patented alkaline filler increases the release of hydroxide ions to regulate the pH value during acid attacks. As a result, demineralization can be prevented. Moreover, the release of large numbers of fluoride and calcium ions forms a sound basis for the remineralization of dental enamel. The initiator system enables good chemical self-curing.
223929392|NCT06797843|OTHER|provisional Resin modified glass ionomer followed by Nanohybrid composite|"GC Fuji IX GP® EXTRA is the fastest setting glass ionomer on the market.The faster final set saves valuable chair time which provides improved stability against water, an important feature in challenging oral environments. This product contains a next generation glass filler which elicits higher translucency, fluoride release, reactivity and a faster setting time.~Then followed by Conventional Nano hybrid composite restoration(Neo Spectra® ST LV, Dentsply Sirona) which is nano-ceramic, light-cured, radiopaque, universal composite with novel SphereTEC filler technology."
223929393|NCT06793878|BEHAVIORAL|Living in Families With Emotions|This is an 8-week group-based psychosocial intervention teaching adolescents how to recognize their feelings, manage them, and talk about emotions through group discussions, live exercises, and games. The adolescents' caregivers are also provided with the same information, through two live sessions.
223929394|NCT06795295|PROCEDURE|Implant retained mandibular overdenture|Participants received dental implants to retain mandibular overdentures.
223929395|NCT04121741|OTHER|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
224094924|NCT06099288|BEHAVIORAL|Read Educate and Develop Youth (READY) Comparison|The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
224094925|NCT06182293|OTHER|Subgingival dental plaque sampling for whole metagenome sequencing of the periodontal microbiota|Subgingival plaque will be collected at 6 sites using sterile curettes after removal of supragingival biofilm by brushing. After microbial DNA extraction, whole metagenome will be sequenced.
224094926|NCT02623972|DRUG|Eribulin|administered IV for 4 cycles
224283112|NCT06897085|DEVICE|viscoelastic gel containing polynucleotides and hyaluronic acid|"Defects randomized to test treatment will receive a viscoelastic gel containing polynucleotides and hyaluronic acid (PN-HA gel) immediately at the completion of intra-surgical instrumentation. PN-HA gel will be also applied on the surgical wound at the completion of the suturing phase."
224283113|NCT06897085|OTHER|No intervention|"Defects randomized to control group will be accessed with the SFA and no PN-HA gel will be applied."
224283114|NCT05924867|OTHER|plasma activated saline|The plasma activated normal saline used in the intervention was prepared by a self-made machine, and the safety of the plasma activated water produced by the machine has passed the national quality inspection.
224094927|NCT02623972|DRUG|Adriamycin|administered IV with cyclophosphamide for 4 cycles
224094928|NCT02623972|DRUG|Cyclophosphamide|administered IV with adriamycin for 4 cycles
224094929|NCT06043817|DRUG|STX-721 (Escalated)|STX-721 dose will be escalated per cBLRM-design.
223718154|NCT05510531|BEHAVIORAL|Diabetes Survival Skills Training|During the course of the DSS sessions, participants receive blood glucose logs, glucose meters; lancets, testing strips and demonstration insulin pens with injecting pillow will only be used in class. In summary, the DSS is focused on increasing knowledge, motivation, and self-efficacy and decreasing diabetes related distress, IMB components relevant to incarcerated persons and proximal to behavior change, through engagement, return demonstrations, skill practice, and positive reinforcement.
223718155|NCT02214407|DRUG|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts \> 30 G/L, and mandatory if WBC \> 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
223718156|NCT02214407|DRUG|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
223718157|NCT02043275|OTHER|Leg training|Lower body resistance training twice per week for one hour each time.
223718158|NCT02043275|OTHER|Arm training|Upper body resistance training twice per week for one hour each time.
223718159|NCT05438888|DRUG|Warfarin|This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.
223718160|NCT05438888|DRUG|Apixaban|This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.
223718161|NCT04180358|BEHAVIORAL|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
223718162|NCT04180358|BEHAVIORAL|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
223718163|NCT03246893|DEVICE|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
223718164|NCT03246893|DEVICE|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
223718165|NCT04698187|DRUG|CMP-001|Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
223718166|NCT04698187|DRUG|Nivolumab|Nivolumab 360 mg IV is administered Q3W.
223718167|NCT03179696|BEHAVIORAL|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
223718168|NCT06046365|DIAGNOSTIC_TEST|lymphoscintigraphy|lymphoscintigraphy
223718169|NCT06046365|DIAGNOSTIC_TEST|circumference measurement|circumference measurement
223718170|NCT06046365|DIAGNOSTIC_TEST|sonography|B-mode sono and elastography
223718171|NCT06046365|DIAGNOSTIC_TEST|DXA body composition analysis|DXA body composition analysis
223929396|NCT04121741|OTHER|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
223929397|NCT04121741|OTHER|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
223941086|NCT03983642|DEVICE|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
224094930|NCT06043817|DRUG|STX-721 (3 dose levels)|Participants will receive STX-721 at one of two dose levels.
224094931|NCT06043817|DRUG|STX-721 (RP2D)|Participants will receive the RP2D of STX-721.
224094932|NCT04754529|OTHER|Quality-of-Life Assessment|Ancillary studies
224094933|NCT04754529|OTHER|Survey Administration|Ancillary studies
224094934|NCT04754529|OTHER|Yoga|Receive yoga intervention
224094935|NCT05543681|DRUG|IGC-AD1-Active|A non-sterile solution for oral administration.
224094936|NCT05543681|DRUG|IGC-AD1-Placebo|A non-sterile solution for oral administration similar in color and texture to the Active.
224094937|NCT05116813|DRUG|Dipraglurant|Oral 50 mg and 100 mg tablet
224094938|NCT05590377|DRUG|Modakafusp Alfa|Modakafusp alfa intravenous infusion
224094939|NCT05590377|DRUG|Daratumumab|Daratumumab SC injection
224094940|NCT06500754|OTHER|Ultra-strict gluten-free diet|ultra-strict gluten-free diet (avoiding traces and contamination) under dietitian supervision
224094941|NCT03227263|DRUG|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
224094942|NCT03227263|DRUG|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
223718172|NCT02633605|DEVICE|First Sense Medical®|
223718173|NCT06997601|OTHER|Serratus posterior superior intercostal plane block|Patients will receive a serratus posterior superior intercostal plane block.
223718174|NCT06997601|OTHER|Suprascapular nerve block + Axillary nerve block|Patients will receive suprascapular nerve block + axillary nerve block.
223929398|NCT06801080|OTHER|HealthySteps (https://www.zerotothree.org/our-work/healthysteps/)|Within the DoD, most elements of the civilian HS model copyrighted by ZeroToThree.org were implemented. However, there were some modifications to accommodate the unique environment of the military community. The pilot utilized the pre-existing Military Family Life Counseling Program (MFLC) staff to serve as HS Specialists at participating clinics. MFLCs were hired and trained in the HS model through the HS Institute provided by ZeroToThree.org. Although the DoD pilot offered all 3 tiers of targeted care standard for the HS model, note that the DoD pilot did not offer a 24-hour parent support line at tier 1. Also, the DoD pilot required participating pilot clinics to utilize a modified version of the Tufts Survey of Well-Being of Young Children (SWYC; https://www.tuftsmedicine.org/medical-professionals-trainees/academic-departments/department-pediatrics/survey-well-being-young-children) to provide augmented screenings for infants at all tiers of pilot service provision.
223941087|NCT06642584|DRUG|Semaglutide B|Semaglutide B will be administered subcutaneously.
223941088|NCT06642584|DRUG|Semaglutide J|Semaglutide J will be administered as oral tablets.
224094943|NCT06334367|DRUG|CD25 treatment|CD25 prophylaxis
224094944|NCT06334367|DRUG|low-dose ATG|HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
223718175|NCT03814317|DRUG|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
223718176|NCT04329533|OTHER|"Calm is a mindfulness meditation mobile app"|"Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
223718177|NCT01504620|OTHER|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
223718178|NCT01504620|DRUG|insulin infusion|i.v. infusion of insulin
223718179|NCT07132463|RADIATION|Long-course chemoradiotherapy|45-50.4 Gy in 25-28 fractions to the pelvis on Days 1-5 each week. Capecitabine at a dose of 825 mg/m², taken orally twice daily (bid), 5 days per week during radiotherapy.
223941089|NCT06642584|DRUG|Semaglutide L|Semaglutide L will be administered as oral tablets.
223941090|NCT06642584|DRUG|Semaglutide M|Semaglutide M will be administered as oral tablets.
223941091|NCT06642584|DRUG|Semaglutide N|Semaglutide N will be administered as oral tablets.
223941092|NCT06417008|DRUG|HS-20117|Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)
223941093|NCT06417008|DRUG|Aumolertinib|110 mg orally once daily.
223941094|NCT03028389|PROCEDURE|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
223941095|NCT00981552|RADIATION|IMRT planning|
223941096|NCT00981552|RADIATION|4-Field Radiation Planning|
223941097|NCT01270282|DRUG|AM-101 0.81 mg/mL|
223941098|NCT01270282|DRUG|Placebo|
223941099|NCT04388865|BEHAVIORAL|Control|Subjects will engage with their providers as is standard of care.
223941100|NCT04388865|BEHAVIORAL|Text-based Clinical Hovering|Subjects will receive remote monitoring via text messaging of clinical symptoms and medication adherence reminders with feedback to social support.
223941101|NCT00747006|DRUG|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
224094945|NCT02292823|DEVICE|MGuard™ Prime Embolic Protection Stent System|
224094946|NCT00274391|DRUG|7% NaCl|
223941102|NCT00747006|DRUG|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
223941103|NCT01724905|DIETARY_SUPPLEMENT|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
223941104|NCT01724905|DIETARY_SUPPLEMENT|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
223941105|NCT01053650|DRUG|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
223941106|NCT03926026|DRUG|Fluticasone Propionate|NCX 4251 Ophthalmic Suspension, 0.1%
223941107|NCT03926026|DRUG|Placebo|NCX 4251 Ophthalmic Suspension, 0%
223941108|NCT02577939|BEHAVIORAL|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
223941109|NCT05917236|PROCEDURE|hepato-portoentostomy|the retro-colic Roux-en-Y limb of the jejunum, and finally hepato-portoentostomy (Kasai operation)
223941110|NCT06159959|DRUG|Carbetocin|To assess the effectiveness of single IV bolus dose of carbetocin in the prevention of primary PPH in obese versus non obese women undergoing elective cesarean section.
223941111|NCT03106259|DRUG|FURESTEM-RA Inj.|Non-interventional observational study
223941112|NCT01372085|DRUG|LY2584702 Reference Formulation|Administered orally
223941113|NCT01372085|DRUG|LY2584702 Test Formulation|Administered orally
223941114|NCT01372085|DRUG|Placebo|Administered orally
223532734|NCT06261255|PROCEDURE|ATT + EMD|All surgical treatments will be performed by the same experienced periodontist (IP) after the administration of local anesthesia. Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the remaining fragments will be extracted as minimally invasively as possible. A tooth-supported surgical guide will be used to prepare the recipient site following the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the CARP model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if osteotomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, EMD will be applied to the root surface of the donor tooth
223532735|NCT03381599|DRUG|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
224283115|NCT05924867|OTHER|Routine nursing|For postoperative incision infection group and infected ulcer group, conventional dressing change treatment was given, namely chlorhexidine disinfectant washing, drainage and bandaging; For the fat liquefaction group, conventional treatment was given, namely negative pressure suction.
224283116|NCT00383058|DRUG|the extract of green tea|
224283117|NCT06897969|DRUG|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|Monthly intralesional injection
223718180|NCT07132463|DRUG|Tislelizumab combined with the CAPOX regimen|"Tislelizumab 200 mg IV on Day 1 of each 21-day cycle. Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle.~Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle."
224283118|NCT06897969|DRUG|Verapamil Injection|2.5 mg of intralesional Verapamil injection monthly
224283119|NCT06891924|COMBINATION_PRODUCT|14-day daily pre-operative application of the formulations containing MLYAAT-1002® before Fotona4D treatment|All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations containing MLYAAT-1002® of the active comparator to randomly assigned split-face (the treatment side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.
224283120|NCT06891924|COMBINATION_PRODUCT|14-day daily pre-operative application of the formulations without MLYAAT-1002® before Fotona4D treatment|All enrolled subjects will complete a 14-day washout period followed by a 14-day run-in phase prior to Fotona 4D® laser treatment. During the initial washout phase, participants will exclusively use basic skincare products: sunscreen, cleansing foam, and moisturizing emulsion. Then the subjects will apply the formulations without MLYAAT-1002® of the placebo comparator to randomly assigned split-face (the control side) for the subsequent 14-day period. Following completion of the product application regimen, all participants will undergo a single session of Fotona 4D laser therapy.
224283121|NCT06900335|DRUG|GH treatment (Somatropin)|Treatment with Somatropin (recombinant GH), with doses starting from 0.2 mg/day and adjusted as necessary.
224283122|NCT06900335|BEHAVIORAL|Eating|Allowing patients to break fasting.
224283123|NCT06898528|BEHAVIORAL|The group-based mat exercise training on experimental group.|The training program is divided into two phases: the first phase focuses on fundamental movements, whereas the second phase introduces more advanced exercises. With progress, additional exercise equipment is incorporated, along with increased sets, duration, movement variations, and training intensity. Training sessions (10-week duration) can be conducted in a simple, progressive manner or a game-competitive format.The control group maintained their usual daily activities.
224283124|NCT06898528|BEHAVIORAL|The control group|The control group maintained their usual daily activities.
224283125|NCT03888612|DRUG|ARV-110|"Part A: Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment~Part B: Daily oral dosage and schedule at a recommended Phase 2 dose based on data from Part A"
223532736|NCT02724202|DRUG|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
223532737|NCT02724202|DRUG|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
223532738|NCT03292237|DIETARY_SUPPLEMENT|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
223532739|NCT05918848|DEVICE|Filme Gyno-V® Vaginal Ovules|Administration of tocopherol (Filme Gyno-V® Vaginal Ovules) for 14 days
223718181|NCT07132463|DRUG|CAPOX regimen|"Capecitabine: 1000 mg/m² orally twice daily (bid) on Days 1-14 of each 21-day cycle.~Oxaliplatin: 130 mg/m² IV on Day 1 of each 21-day cycle."
223718182|NCT03352349|DRUG|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
223532740|NCT01295489|OTHER|Laboratory Biomarker Analysis|Correlative studies
223718183|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (real stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
223532741|NCT04368208|OTHER|Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery|The Edinburgh questionnaire is a self questionnaire validated for postnatal depression between 4 and 6 weeks postnatal
223532742|NCT01068184|DRUG|AZD6553|Single or multiple oral dose
224094947|NCT00274391|DRUG|Amiloride HCl|
224283126|NCT05941611|DEVICE|Powered toothbrush|Oral-B powered toothbrush
224283127|NCT06442410|DEVICE|DTM™ spinal cord stimulation therapy delivered via Intellis™ neurostimulator system|Along with the appropriate Conventional Medical Management treatment made by the Investigator, the subject will be trialed and implanted with an Intellis™ neurostimulator system using DTM™ SCS programming parameters.
223929399|NCT06801080|OTHER|Treatment as Usual (TAU)|The comparison clinics included in this intervention were selected to represent pediatric care within military treatment facilities throughout the DHA medical system located at Army, Navy, Marine Corps, and Air Force facilities. There is variability in pediatric practice across military service branches. However, all clinics follow the American Academy of Pediatrics Bright Futures guidelines.
223929400|NCT04100135|DEVICE|Actual device PFO closure|Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
224094948|NCT06528600|DEVICE|Hymovis ONE|Single injection of Hymovis ONE®, a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
224094949|NCT06528600|DEVICE|Monovisc|Single injection of Monovisc™ a sodium hyaluronate formulation, for the treatment of pain from osteoarthritis (OA) of the knee in patients who have not responded to non-pharmacological therapies or analgesic regimens
224094950|NCT00828464|DRUG|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
224094951|NCT06340919|DEVICE|Sudden Sound Reduction Setting|Each participant will listen to recordings of sentences processed by a hearing aid with settings for treating sudden sounds set to Low, High, or Maximum. Recordings with the different settings will be randomized from trial to trial.
224094952|NCT02744976|DRUG|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
224094953|NCT02744976|BEHAVIORAL|Lifestyle recommendations|Standard lifestyle recommendations
224094954|NCT06483646|OTHER|Gaseous sampling:|the subject is asked to aspirate the gaseous contents of his oral cavity using a 1ml plastic syringe.
224094955|NCT03821857|DRUG|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
224094956|NCT00375544|DEVICE|Low level light therapy|
224094957|NCT01486420|PROCEDURE|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
224094958|NCT01486420|PROCEDURE|Open surgery|Open A1-pulley release
224094959|NCT01203657|BEHAVIORAL|Tai Chi|Tai Chi classes, 60 minutes, 2x week
224094960|NCT02599402|DRUG|Nivolumab|
224094961|NCT02599402|DRUG|Ipilimumab|
224094962|NCT04285060|DEVICE|Samsung GEMS-H|Subjects will participate in 18 sessions of training in the outpatient clinic with a licensed physical therapist. Therapy sessions will include 30 minutes of task specific training and another 15 minutes of the session can be used to focus on patient specific goal areas related to functional mobility and balance. Training sessions will occur 2-3 times a week for 6-8 weeks to complete the training protocol.
224094963|NCT05443022|RADIATION|Photobiomodulation|Participants will receive an application of low intensity light directly in the region of the three pairs of salivary glands. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
223532743|NCT01068184|DRUG|Placebo|single or multiple oral dose
224094964|NCT05443022|RADIATION|Simulation of Photobiomodulation|The placebo group will have a simulation of the application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
224094965|NCT05664620|DIAGNOSTIC_TEST|Risk Stratification Tool|Patients will be allocated to three groups (Low,medium and high risk) by using the Risk Stratification Tool, and High risk patients will receive multidisciplinary treatment assigned to them by a physician
224094966|NCT01851967|OTHER|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
223532744|NCT00805389|BIOLOGICAL|Engerix-B™|2 doses intramuscular injections
223532745|NCT00805389|BIOLOGICAL|Fendrix™|2 doses intramuscular injections
223532746|NCT00805389|BIOLOGICAL|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
223532747|NCT00805389|BIOLOGICAL|HBsAg (Booster injection)|Single dose intramuscular injection
223929401|NCT04100135|DRUG|Thienopyridine (clopidogrel or prasugrel)|Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
223929402|NCT04100135|DEVICE|Sham device PFO closure|Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
223929403|NCT03473223|BIOLOGICAL|Apolipoprotein A-I [human] (apoA-I)|Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration
223929404|NCT03473223|OTHER|Placebo|25% albumin solution diluted to 4.4%
223929405|NCT06838949|DRUG|herombopag olamine tablets|The patient received herombopag 5mg/d at the beginning of the day, was orally taken on an empty stomach in the morning, and could eat 2 hours after taking the drug, once a day for 24 weeks. Investigators will adjust the dosage of herombopag once a week according to the platelet count, with a maximum dosage of 7.5 mg per day. Efficacy and safety were evaluated once a week.
224094967|NCT03375385|DRUG|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
224094968|NCT03007264|DEVICE|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
224094969|NCT03488199|DEVICE|Stent Acculink ™|Carotid Artery Revascularization using Stents
224283128|NCT06442410|OTHER|Conventional Medical Management (CMM)|The CMM treatment can be modified at any moment by the investigators based on their clinical evaluation and local standard of care. They may also consists of one or more of the following treatments: medications, combined physical and psychological management, physical therapy, back rehabilitation program, spinal manipulation and spinal mobilization, traction, acupuncture, cognitive behavioral therapy, biofeedback, nerve blocks, radio frequency ablation, epidural steroid injections, transcutaneous electrical nerve stimulation, intradiscal electrothermal therapy, nucleoplasty, also called plasma disc decompression (PDD) or similar
224283129|NCT04163588|DRUG|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
223532748|NCT03893526|DRUG|Entresto|Single dose administration of entresto
223532749|NCT03893526|DRUG|Sitagliptin|Single dose administration of sitagliptin
223929406|NCT06212453|PROCEDURE|Targeted Microwave Ablation|3D ultrasound-guided focal thermal ablation of the prostate transition zone
223929407|NCT06811350|PROCEDURE|post-implementation cohort|Patients recieved a structured early mobilization pathway was introduced. The pathway included standardized assessments for patient stability and phased rehabilitation, progressing from passive to active mobilization.
223929408|NCT06810908|PROCEDURE|Internal fixation or bracing|Adult patients with humeral shaft fractures have been treated either with internal fixation or functional bracing according to the discretion of the treating surgeon.
223929409|NCT06745570|BEHAVIORAL|Lifestyle Modification and Sleep Intervention|This study is being performed to develop, refine, and test the effects of a group lifestyle modification intervention augmented with a sleep intervention on weight loss, eating behaviors, and sleep outcomes. Results from this study will inform future studies to test the efficacy of this intervention. This intervention is being offered as part of a research study within Drexel University's WELL Center. Participants will receive remote, group-based, weekly weight loss and sleep coaching (90 minutes per coaching session) for 16 weeks.
223929410|NCT06791083|DRUG|Envafolimab|150mg/m2 , IH， d1；Q3W
223929411|NCT06791083|DRUG|Fruquintinib|5 mg ，po，QD，d1-d14；Q3W
223929412|NCT06798051|DRUG|Roxithromycin tablets 150mg|Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug
224094970|NCT03488199|DEVICE|CGuardTM™|Carotid Artery Revascularization using Stents
224094971|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
224283130|NCT04163588|DRUG|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
224283131|NCT06903767|DEVICE|Automated Impaction (HAMMR)|For cases that are randomized to the automated impaction HAMMR group, the surgeon will utilize an automated impactor device for impaction of the implant during total hip arthroplasty.
224283132|NCT06903767|DEVICE|Manual Malleting|For cases that are randomized to the manual malleting group, the surgeon will utilize a mallet for impaction of the implant during total hip arthroplasty.
224283133|NCT06905379|OTHER|Moringa Oleifera|Moring Oleifera Varnish application Using a disposable bond brush, the varnish will be painted on the diagnosed surfaces, then the patient will be instructed to avoid brushing or flossing and to avoid hard and sticky food or any products that may contain alcohol (oral rinses, beverages, etc.) for the next 4 hours after application.
224283134|NCT06905379|OTHER|Varnish|"MI Varnish application~The varnish will be applied on the clean surfaces according to manufacturer instructions as follows:~1. The foil cover of the MI Varnish unit dosage bottle will be peeled-off and MI Varnish will be stirred with the disposable brush before application.~2. The surfaces will be covered with a thin uniform layer using a disposable bond brush to avoid clumping.~3. The area will be allowed to become wet to ensure the setting of the varnish."
223532750|NCT03893526|DRUG|Valsartan|single doses administration of valsartan
223532751|NCT03893526|DRUG|Placebo|placebo day
223532752|NCT02036346|DIETARY_SUPPLEMENT|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
223532753|NCT02036346|OTHER|Advise on calculated oral fluid requirements|
223532754|NCT02036346|OTHER|No nutritional advice will be given|
223532755|NCT05962944|DEVICE|Olympus Cellsens software|Olympus cellsens software will be used to visualise the cells and MS teams screen share will be used to send the live images in real time.
223532756|NCT02550145|DRUG|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
223532757|NCT02550145|OTHER|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
223532758|NCT04209556|DRUG|PF-06826647 100 mg QD|Investigational Product
223532759|NCT04209556|DRUG|PF-06826647 300 mg QD|Investigational Product
223532760|NCT04209556|DRUG|PF-06826647 600 mg QD|Investigational Product
223532761|NCT04209556|DRUG|Placebo|Matched Placebo
223532762|NCT04209556|DRUG|PF-6826647 400 mg QD|Investigational Product
223929413|NCT05417867|PROCEDURE|Biospecimen Collection|Undergo collection of stool and blood samples
223929414|NCT05417867|OTHER|Questionnaire Administration|Complete questionnaires
223929415|NCT02848625|OTHER|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
223929416|NCT05991908|DRUG|Fludarabine, busulfan and melphalan|FLudarabine 150mg/m2 + Busulfan 6.4mg.kg + Mel 140mg/m2
223929417|NCT05991908|DRUG|Fludarabine and Busulfan|FLudarabine 150mg/m2 + Busulfan 12.8mg.kg
223929418|NCT06785753|DRUG|Irrigation Solution|normal saline will be used as irrigation solution
224094972|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
224094973|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
224094974|NCT00809133|DRUG|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
224094975|NCT00809133|DRUG|BIBW2992|MTD dose of part A
224094976|NCT00809133|DRUG|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
224094977|NCT00809133|DRUG|Carboplatin|AUC6 given on day 1 of 21 day cycle
223929419|NCT06045351|DRUG|Vitamin D|"Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day"
223929420|NCT06045351|OTHER|Active Comparator|"Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued"
223929421|NCT03817229|BEHAVIORAL|Education microlearning sessions|mHealth education microlearning sessions
223929422|NCT03817229|BEHAVIORAL|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
223929423|NCT03817229|BEHAVIORAL|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
223929424|NCT03817229|BEHAVIORAL|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
223929425|NCT06339788|DRUG|HD-P023|Single dose administration of HD-P023
223929426|NCT06339788|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
223929427|NCT06339788|DRUG|Empagliflozin|Single does administration of Teneligliptin and Empagliflozin High
223929428|NCT06813066|BEHAVIORAL|High Levels of Common Therapeutic Factors|The therapist large language model (LLM) is designed to show high levels of empathy, warmth, and genuineness. This setup aims to create a supportive and trusting therapeutic environment to improve patient engagement. High levels of these positive factors are linked to better psychotherapy outcomes and a stronger therapist-patient relationship.
223929429|NCT06813066|BEHAVIORAL|Low Levels of Common Therapeutic Factors|The therapist LLM for this group is designed to show low levels of empathy, warmth, and genuineness. This setup aims to examine how a less supportive and empathetic therapist affects psychotherapy sessions. Lower levels of these positive behaviors can lead to reduced patient engagement and a weaker therapist-patient relationship, potentially hindering therapy outcomes.
223929430|NCT06813066|BEHAVIORAL|Standard motivational interviewing|Motivational interviewing techniques as applied during the sessions on which the transcripts are based.
223929431|NCT06853756|DEVICE|Ambu Auragain|Ambu Auragain was inserted after induction.
223929432|NCT06853756|DEVICE|I-gel|The I-gel device was inserted after induction.
223929433|NCT06854588|DIAGNOSTIC_TEST|Point-of-care ultrasound|POCUS screening will be conducted to measure the maximum diameters at end diastole of the aortic root, ascending aorta, aortic arch, and descending thoracic aorta.
223929434|NCT06820489|PROCEDURE|Conventional connective tissue graft after immediate implant placement|A pouch is made in the buccal mucosa extending 3 mm below the buccal bone crest. Thereupon, a free gingival graft is harvested from the palatal mucosa and de-epithelialized. The CTG is brought into the pouch and fixed with two single sutures onto the buccal mucosa. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Sutures are removed 1 week after the surgery.
223929435|NCT06820489|PROCEDURE|Scarf connective tissue graft after immediate implant placement|No pouch is made in the recipient site. A free gingival graft is harvested from the palatal mucosa and de-epithelialized. The small CTG is fixed at the transmucosal aspect onto the buccal mucosa. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Sutures are removed 1 week after the surgery.
223929436|NCT06820489|PROCEDURE|Dual zone concept after immediate implant placement|DBBM is applied and condensed up to the level of the buccal soft tissue margin. A healing abutment is installed, which is replaced by a provisional implant crown 2 days later. Usually, sutures are not needed in this group, unless minimal papilla opening was required to extract the tooth. In that case, sutures will be removed after 1 week.
223929437|NCT06818058|DRUG|Brimonidine tartrate Gel|Once daily applications for 7 days
224283135|NCT06904209|DEVICE|AI|"Each photo will be uploaded and analyzed by AI to predict the adequacy of their bowel preparation with immediate results of pass or not pass, indicating if their bowel preparation is adequate or inadequate. If the result is pass, patients will stop consuming the remaining PEG solution. If the result is not pass, patients will be advised to gently rub their lower abdomen in a clockwise direction or walk around and continue consuming the remaining PEG until the AI evaluation gives a pass result or until the full dose of 3 L PEG have been consumed. If the patient's rectal effluent deems IBP after consumption of the full dose of 3 L of PEG, an additional 1 L or more of PEG will be administered as a remedial dose at the discretion of the physician-in-charge."
223929438|NCT06818058|DRUG|Placebo gel (no Brimonidine tartrate)|Once daily applications for 7 days
223929439|NCT06766149|BEHAVIORAL|CogniFit Computerized Cognitive Training|In the CogniFit Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory, attention, and inhibitory control, with automatic level advancement after each exercise.
223929440|NCT06766149|BEHAVIORAL|Cogmed Computerized Cognitive Training|In the Cogmed Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory and attentional control, with automatic level advancement after each exercise.
223929441|NCT06768905|DRUG|Iomab-B|single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion.
223929442|NCT06768905|DRUG|CAR-T cell|CAR-T cell therapy
223929443|NCT06769100|DIETARY_SUPPLEMENT|Ketone Monoester (KET)|\- Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight). The ketone brand name: delta G Oxford Ketone Ester
223929444|NCT06769100|DIETARY_SUPPLEMENT|Ketone Monoester + Whey Protein (KET+PRO)|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
223929445|NCT06769100|DIETARY_SUPPLEMENT|Whey Protein (PRO)|"* 25g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
223532763|NCT03054714|DEVICE|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
223532764|NCT02182518|DRUG|Epinastine|
223532765|NCT02182518|DRUG|Pseudoephedrine|
223532766|NCT02182518|DRUG|Placebo|Placebo during run-in period
223532767|NCT01409096|DRUG|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
223929446|NCT06769100|DIETARY_SUPPLEMENT|Flavour matched placebo (CON)|\- Flavoured water (non-caloric bitter + citrus flavours)
223929447|NCT06769100|OTHER|Resistance exercise|\- 8 sets of 10 reps at 90% of 10- repetition maximum (10-RM) of unilateral leg extension with 90 seconds rest in between sets.
223929448|NCT06735417|BEHAVIORAL|Indashyikirwa program|"Indashyikirwa training curriculum is delivered to heterosexual married couples in Syrian communities in Al-Hasakah governorate. The curriculum includes between 21 and 22 sessions, delivered to groups of up to 30 couples. Each week, participants will attend one session, lasting at least 3 hours.~Topics covered include: gender, power imbalance, triggers for GBV, conflict management, building healthy relationships, and coping mechanisms for managing GBV-related triggers.~The curriculum is designed to address both the wife and her husband and includes interactive exercises, take-home assignments, and reflections.~The sessions are delivered by trained facilitators."
223929449|NCT06734884|DRUG|Benralizumab 30 MG/ML [Fasenra]|Subcutaneous injection 30 mg at day 2, week 4 and week 8.
223929450|NCT06734884|DRUG|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Subcutaneous injection at day 2, week 4 and week 8
223929451|NCT06892405|DEVICE|SonoSite™ S Series ultrasound|"US measurements will be performed in the pre-operating room a~, patients are placed in supine position with the head in a sniffing position on a surgical pillow and using the 15 MHz linear array transducer of the SonoSite™ S Series ultrasound in transverse position. A scan is made from the skin surface of the floor of the mouth to the trachea exerting the minimum possible pressure to identify the structures correctly."
223929452|NCT06893003|OTHER|Baby Bridge|The Baby Bridge program is an evidence-based implementation strategy aimed at enhancing early and continuous therapy services following NICU discharge for infants with alterations in neurodevelopment. The Baby Bridge program utilizes an occupational or physical therapist to see the infant and family in the NICU prior to discharge, complete a comprehensive neurodevelopmental and feeding assessment to inform targeted interventions, and provide early therapy services in the home environment within one week of discharge and weekly thereafter, until other community-based services commence. While most of the program occurs after NICU discharge, a hallmark of the Baby Bridge program is that families establish rapport with the therapist while the infant is still in the NICU. The therapist also educates the family on ways to support their infant's development between sessions and offers support and assistance during the transition from hospital to home.
223929453|NCT06760858|DRUG|Tislelizumab|Tislelizumab: 200mg IV, day 1, Q3W, for a total of 3 cycles.
223929454|NCT06760858|DRUG|SOX|SOX: S-1 dosage based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 3 cycles.
223929455|NCT06760858|DEVICE|HIPEC|HIPEC: Docetaxel: 120mg, day 1, day 3.
223929456|NCT06774105|OTHER|Static Stretching|The protocol consisted in 2 sessions per week, each comprising 8 exercises of static stretching targeting all major muscle groups: 1) Hamstrings, 2) Knee Extensors, 3) Dorsal muscles, 4) Pectoralis muscles, 5) Elbow Flexors (biceps), 6) Elbow Extensors (triceps), 7) Adductors, and one day 8a) Spine Extensors while the second 8b) Spine Flexors. Each exercise involved 4 sets of 30 seconds of SS and 30 seconds of rest.
223929457|NCT06807710|OTHER|DNS Group|Dynamic neuromuscular stabilization exercises, on the other hand, are designed to achieve sagittal stabilization by utilizing the stabilizing function of the thoracic diaphragm muscle.
223929458|NCT06807710|OTHER|Pilates Group|Reformer pilates exercises, focusing on core stability, flexibility, postural alignment, and breath control using a Reformer Pilates machine under the supervision of a physiotherapist.
223718184|NCT05806736|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham stimulation)|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the left earlobe. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs, twice a day, 30 minutes each time.
223718185|NCT06680349|DRUG|Anti-CD20 antibodies|comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
223929459|NCT06765928|DRUG|selinexor in combination with venetoclax|After allo-HSCT, intermediate-high risk MDS/AML patients are maintenanced with selinexor given in combination with venetoclax for 2 years
223929460|NCT06749873|OTHER|Background of different SP information|Sp was asked with the following baseline information: 1. 50 years of age and gender; 2. positive urea breath test; 3. asymptomatic; 4. family history of gastric cancer; 5. gastroscopy: atrophic gastritis; 6. untreated; and 7. no history of drug allergies.
223929461|NCT06750770|DIAGNOSTIC_TEST|KDIGO CRITERIA|2012 KDIGO DIAGNOSTIC CRITERIA
224094978|NCT00809133|DRUG|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
224094979|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
224283136|NCT04947150|BEHAVIORAL|Location-triggered notification|"If participants are randomized to have this component ON, the app will send the notification when the participant's smartphone is within a 50-meter geofence around designated grocery stores. No more than one notification will be sent per week. Mindfulness of program goals in the moment of decision making is expected to facilitate program-consistent food purchasing behaviors. Participants assigned to have location-triggered message delivery OFF will receive their weekly recommendations and reminders messages at standard times throughout the week. The content of the messages will not differ according to whether this component is ON vs. OFF."
223532768|NCT01409096|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
223532769|NCT01887405|DRUG|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
223532770|NCT05050903|OTHER|Rhinovirus infection|Inoculation with rhinovirus-16
223532771|NCT04726995|OTHER|CHOP and BFM regiments|used CHOP and BFM regiments
223718186|NCT06681753|OTHER|Experimental|No training will be planned for the Control Group, and their undergraduate education will be included in the study. After the study data is collected and the study is concluded, the control group will be given breastfeeding support training from the intervention group.
223718187|NCT06861101|DRUG|JT002 Nasal spray|200 μg BID, 400 μg BID, 400 μg QD, 800 μg QD, 64 patients per cohort, total 256 patients for treatment 14 days
223718188|NCT06861101|DRUG|Placebo|Total 64 patients for treatment 14 days
223718189|NCT06869278|BIOLOGICAL|LCAR-AIO T cells|Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
223718190|NCT07015801|BIOLOGICAL|CMV-VST|30-40 x 10\^3 viable CD3+ cells/kg
223718191|NCT07016373|DEVICE|Palatal Plate without Manuka Honey|A Palatal plate without Manuka Honey will be inserted by a blinded investigator on the donor site for post-operative procedures.
223718192|NCT07016373|DEVICE|Palatal plate with Manuka Honey|A Palatal plate with Manuka Honey will be inserted by a blinded researcher on the donor site.
223929462|NCT06748573|DEVICE|SafeGuard FocusTM compression bandage|"If randomized to the study group, The study device was applied immediately after pocket closure using following steps:~* Preparation: cleaning wound and surrounding area.~* Placement: application of isobetadine gauze and transparent bandage. Study device placement at the level of the pocket.~* Applying compression: inflation of 60ml of air. If oozing persisted 5ml increments were added (maximum of 120ml) until oozing stopped.~The study device was gradually deflated by removal of 20ml of air every 2 hours. When oozing occurred 5ml increments were added until oozing stopped. When all air was deflated the study device was left in deflated mode and changed by conventional bandage at discharge."
223929463|NCT06748573|DEVICE|Conventional bandage|If randomized to the control group, compressive bandage was applied immediately after pocket closure. The bandage was removed after 6 hours and changed by conventional bandage.
223929464|NCT06764238|DRUG|Blinatumomab (Group A)|For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
223929465|NCT06764238|DRUG|Venetoclax (nonRand Group)|For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy
223929466|NCT06764238|DRUG|Blinatumomab (Group B)|For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
223929467|NCT06777849|BEHAVIORAL|Right to Play-Plus (RTP-Plus)|"The comprehensive curriculum comprises of themes: Social and Emotional Development and Sexual and Reproductive Health will be delivered by school teachers who will receive training from Right to Play and Aahung. There will be 60 sessions for two years."
223929468|NCT06777849|OTHER|Control|There will be no intervention given to control arm during two years of cluster randomised control trial (cRCT). However, a delayed intervention having teachers' training, will be provided to the control arm after the completion of endline for the duration of 3-4 months.
224283137|NCT04947150|BEHAVIORAL|Reflections on benefits of change|Participants will reflect on anticipated benefits of purchasing healthy foods, consistent with motivational interviewing and self-determination theory. Message content will be personalized as follows: During the initial workshop, all participants will complete an exercise identifying benefits of healthy eating that are important to them. Message content will then be programmed to be personalized according to anticipated rewards important to that participant. Participants assigned to have this intervention component OFF will not have content about anticipated benefits of change added to any messages.
224283138|NCT04947150|BEHAVIORAL|Coach monitoring|Coaches will monitor participant food purchases via a dashboard for viewing purchase data, and send messages designed to provide feedback and enhance supportive accountability for program goals. The messages will provide reinforcement for purchases consistent with program goals and express concern for areas in which adherence is low. Participants assigned to have this component OFF will not receive these extra messages or phone calls, and their food purchases will only be viewed by research staff for research outcome assessment purposes.
224283139|NCT04947150|BEHAVIORAL|Household support|If participants are assigned to have household support ON, one adult in the household will receive weekly text messages designed to elicit support for changing food purchases. In addition, the index participant and household member will be invited to participate in one extra workshop session and three brief coaching calls focused on household support. If participants are assigned to have this OFF, household members will have no program involvement.
224283140|NCT02315547|DRUG|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
223532772|NCT04232852|DIETARY_SUPPLEMENT|Probiotic mix|The probiotic mix will contain strains of Streptococcus thermophilus, Saccharomyces cerevisiae, Lactobacillus acidophilus, L. rhamnosus L. helveticus, L. gasseri, L. plantarum, Bifidobacterium bifidum, Enterococcus faecium at a daily dose of 7 × 1010 CFU in the form of a capsule.
223532773|NCT04232852|DIETARY_SUPPLEMENT|Placebo|Patients in the placebo group will receive an identical capsule of maltodextrin.
223532774|NCT00099255|DRUG|SGN-30|
223532775|NCT01180283|DRUG|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
223532776|NCT05061030|BIOLOGICAL|the ATMP Protrans|Protrans consists of Wharton's jelly derived mesenchymal stromal cells
223532777|NCT06026150|OTHER|Ultrasound scanning of inguinal area for femoral nerve and artery|ultrasound scanning of inguinal region is done in femoral fracture patient to identify femoral artery and nerve
223929469|NCT06779006|BEHAVIORAL|Self-help acceptance and commitment therapy with behavioral activation|Internet-based self-help acceptance and commitment therapy with behavioral activation
223929470|NCT06769815|OTHER|Blood sample|For febrile children at the time of inclusion : 6.25 ml to 8.25 ml of blood ; For non febrile children at the time of inclusion : 4 ml of blood ; For pregnant women at the time of inclusion : 5 ml of peripheral blood, 5 ml of placental blood, 20 to 40 ml of umbilical cord blood ; For new borns : drop of blood on child's heel each month and 5 ml of blood the 12th and last month.
223929471|NCT06769815|OTHER|Urine sample|For febrile children : 10 ml of urine
223929472|NCT06769815|OTHER|oropharyngeal sample|For febrile children : oropharyngeal swab sampling
223929473|NCT06769815|OTHER|Optionnal : stool sample|For febrile children (only as part of the care of the child) : 5g stool
223929474|NCT06769815|OTHER|Optionnal : cerebrospinal fluid|For febrile children (only as part of the care of the child in case of suspected meningitis) : 4 additional drops of cerebrospinal fluid
223929475|NCT06769815|OTHER|placental biopsy|For pregnant women : placental biopsy the size of 2 rice grains
223929476|NCT06775392|DRUG|bromelain-quercetin gel|bromelain-quercetin gel is prepared from capsules in laboratory
223929477|NCT06775392|DRUG|chlorhexidine gel|chlorhexidine gel is prepared in laboratory
224283141|NCT06021470|BEHAVIORAL|Cognitive rehabilitation intervention|The intervention comprises a five-week group-based cognitive rehabilitation intervention delivered by a clinical neuropsychologist, with home activities tailored to each stroke survivor's identified goals. Sessions involve four patients and are delivered once per week lasting 2.5 hours with breaks.
224283142|NCT02506205|BEHAVIORAL|Lee Silverman Voice Treatment (SVLT) LOUD|
224283143|NCT05571033|BEHAVIORAL|Spinal reflex conditioning|Each participant will serve as their own control. The intervention is 30 sessions. The first 6 sessions are baseline measures of reflexes. The remaining sessions will engage participants in learning how to decrease their reflex activity in their calf muscle on the more-affected leg. Each intervention visit will involve 20 trials in which participants do not get visual feedback about their performance, then 225 trials with visual feedback.
224283144|NCT00237419|DRUG|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
224283145|NCT06676293|DRUG|Anti-PD1|Pembrolizumab 100mg in normal saline 100ml infusion over 30 minutes for every two month
224283146|NCT06676293|DRUG|asparaginase|The patients will receive asparaginase 10000IU/vail IM QD for three or five days.
224283147|NCT02824185|DEVICE|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
224283148|NCT03245307|DRUG|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
224283149|NCT03245307|DRUG|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
223532778|NCT02282228|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
223532779|NCT02270658|DEVICE|CPAP|
223532780|NCT04003298|DEVICE|Electric toothbrush|Electric toothbrush and power interdental device
223532781|NCT04003298|DEVICE|Control|Oscillating-rotating
223532782|NCT04375436|DRUG|NTRX-07-SDD|NTRX-07-SDD for oral administration
223929478|NCT06775392|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
224283150|NCT03245307|DRUG|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
224283151|NCT02464488|OTHER|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
224283152|NCT04100096|DRUG|Brexpiprazole|Tablet
224283153|NCT04100096|OTHER|Placebo|Tablet
224283154|NCT06331234|OTHER|Vena cava inferior diameter|he VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
223532783|NCT06316726|COMBINATION_PRODUCT|full bed silicone mattress plus other measures|full bed silicone mattress plus put silicone pads on the head and shoulders, cotton rolls wraps bony prominence (elbows and heels), petrissage every two hours on shoulders to fingers and lower legs to heels, change location of ankle pads, use round gel full of air sit pad, a pillow on the knees
223532784|NCT00498992|DIETARY_SUPPLEMENT|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
223718193|NCT07014566|OTHER|Digital Combined Decongestive Therapy|The intervention consisted of a digitally delivered combined decongestive therapy (CDT) program for patients with unilateral or bilateral lower extremity lymphedema. Patients attended a single face-to-face session where a physiotherapist provided training on skin care, self-bandaging, self-manual lymphatic drainage, and therapeutic exercises (breathing, gluteal sets, knee sets, and toe movements). Caregivers recorded the demonstrations for home use. Following this session, a 4-week remote physiotherapy program was implemented using telecommunication technologies. Patients continued self-management with guidance via digital platforms. Compression stockings replaced self-bandaging during the 12-week follow-up phase.
224094980|NCT00809133|DRUG|BIBW 2992|Escalating dose cohorts
223532785|NCT03680885|DRUG|Lidocaine gel|Lidocaine gel 5%, PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
223532786|NCT03680885|DRUG|Placebo|PEG with FD\&C Blue No.1 (Brilliant Blue FCF)
223532787|NCT03680885|DRUG|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
223532788|NCT03578250|OTHER|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
223718194|NCT07016126|COMBINATION_PRODUCT|D-BACE in combination with chemotherapy and karelizumab|3 cycles of D-BACE (DCB-loaded microspheres loaded with epirubicin 50 mg) in combination with chemotherapy and karelizumab (the specific regimen of chemotherapy is determined by the investigator, and platinum-containing two-agent chemotherapy is generally used).
224094981|NCT04814264|BIOLOGICAL|Red blood cells|All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
224094982|NCT06286501|DEVICE|Lumoral Treatment|Home-use photodynamic antibacterial dual-light oral health care device with a marker substance
224094983|NCT06286501|OTHER|Standard, personalized oral health care|Home-based oral health care instructed by a professional, with emphasis on personal needs according to oral condition and previous oral health care habits.
224094984|NCT03420534|DRUG|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
224094985|NCT03420534|DRUG|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
223929479|NCT05972876|BEHAVIORAL|Blood flow restriction training|BFR will be achieved using an automatic personalized tourniquet system (MAD-UP, Angers, France) designed to automatically calculate limb occlusion pressure
223929480|NCT05972876|BEHAVIORAL|Resistance training|Resistance training will be performed without any blood flow restriction
223929481|NCT06757725|DIAGNOSTIC_TEST|colour doppler of the renal artery and measurement of resistive index|using colour doppler to asses vascular resistance and resistive index
223929482|NCT03556592|DRUG|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
223929483|NCT03556592|DRUG|Caffeine|1x 100 mg tablet
223929484|NCT03556592|DRUG|Warfarin|2x 5 mg tablets
223929485|NCT03556592|DRUG|Omeprazole|1x 20 mg capsule
223929486|NCT03556592|DRUG|Metoprolol|1x 100 mg tablet
223929487|NCT03556592|DRUG|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
223929488|NCT06069765|OTHER|TUPEX|"This program contains exercises with their own body weight or with Thera-bands for gaining strength in their shoulder and trunk muscles. It contains some progression exercise if needed.~Each session can last between 20 and 30 minutes. Children have to do each session three times a week during 8 weeks."
223929489|NCT06247124|BEHAVIORAL|multi-channel communication campaign to promote HPV vaccination|High school students will develop, implement, and evaluate a multi-channel communication campaign to promote HPV vaccination.
224094986|NCT03420534|DIETARY_SUPPLEMENT|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
224094987|NCT03420534|DIETARY_SUPPLEMENT|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
224094988|NCT01321047|DRUG|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age \> 70 or ASA class III-IV)
224094989|NCT01321047|DRUG|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
224094990|NCT06334679|OTHER|Cold Gel Packet Application|Cold gel packs will be placed on the burn areas of the patients in the maturation phase and applied for 20 minutes.
224283155|NCT04047953|DRUG|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg，bid, d1-14( BSA\<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA\>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.
223718195|NCT07015034|OTHER|focus on vision impairment in older patients in general practice|GP or GP nurse carry out the three vision tests. All patients visit optician shop collaborating with the project. An ophthalmologist review data from optometrists and provide an epicrisis to general practice. In case of acute conditions, the ophthalmologist is responsible for expedient treatment. If the patient needs further control by ophthalmologist within 12 month waiting time, general practice are responsible for referring the patient.
223929490|NCT06846047|DEVICE|electrical vestibular stimulation (EVS)|EVS involves electrically activating the vestibular nerves by passing small electrical currents through electrodes placed on the mastoid processes (behind the ears) via battery powered, constant current isolated stimulators.
223929491|NCT06846047|DEVICE|Sham Comparator|No current is applied during EVS treatment
223929492|NCT06817876|DEVICE|Care Buddy|Care Buddy mobile intervention will be a one-stop solution for caregivers of dementia patients and help them in their care-giving journey by providing them solutions to manage behavioural problems, physical conditions of their loved one. The app will be multi-component and will provide tools for the caregiver to manage their stress and burden. It will provide information on dementia, list of service providers, information on grief, financial support. This app will provide a platform for all enrolled caregivers to chat with each other and provide social support.
224283156|NCT02137382|DRUG|Creon®|active comparator
224283157|NCT02137382|DRUG|Creon N|experimental drug
224283158|NCT05562453|DEVICE|FlowOx 2.0|Subjects randomized to tretament with the investigational device will receive treatment with -40 mmHg intermittent negative pressure for 60 minutes per day.
223929493|NCT06741722|DRUG|Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF|"The specific administration times and dosages for the DCMG chemotherapy regimen are as follows:~M: Mitoxantrone Hydrochloride Liposome Injection: 15 mg/m², IV, on Day 1, every 4 weeks (q4w); D: Decitabine: 20 mg/m², IV, Days 1-5, q4w; (or Azacitidine: 75 mg/m², IV, Days 1-7, q4w); C: Cytarabine: 100 mg, IV, every 12 hours on Days 1-5, q4w; For patients with hypoplastic bone marrow, the dose of cytarabine injection is 10 mg, every 12 hours, q4w; G: G-CSF: 5 μg/kg, subcutaneous injection, from Day 0 until the white blood cell count exceeds 10.0×10\^9/L, at which point chemotherapy is stopped; or Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0.~One cycle lasts for 4 weeks, with a planned administration of 1 or 2 cycles."
223929494|NCT06736301|DEVICE|a fully covered stent|a double pig-tail stent for cross fixation of a fully covered stent
223929495|NCT06796270|RADIATION|Hypofractionated radiotherapy|The patients with nasopharyngeal carcinoma were given the dose of large segmentation radiotherapy, 2.64Gy/ time, 5 times/week, a total of 25 times, a total of 66Gy/5 weeks.
223929496|NCT06741748|OTHER|Direct Warming Method|This intervention involves thawing vitrified blastocysts using a simplified, one-step direct warming method. The blastocyst is placed in a pre-warmed embryo culture medium for approximately one minute, then transferred directly into the embryo culture medium within a time-lapse system until ready for uterine transfer. The total thawing process takes approximately three minutes, reducing the duration and complexity of the procedure compared to conventional methods.
223929497|NCT06741748|OTHER|Conventional Multi-step Thawing Method|This intervention involves thawing vitrified blastocysts using a standard, multi-step process. The procedure includes sequential exposure of the blastocyst to different thawing solutions containing varying concentrations of cryoprotectants, followed by its transfer into an embryo culture medium in a time-lapse system. The overall process takes approximately 10-30 minutes.
223929498|NCT06888700|DEVICE|Transcranial direct current stimulation|The participant cohort recruited for this study consists of individuals with substance use disorder (SUD), specifically those addicted to drugs. During the intervention phase, this group will adhere to a strict non-pharmacological intervention protocol, meaning they will not receive any form of pharmacotherapy, neurosurgical intervention, or other neuromodulation-based cognitive interventions, including but not limited to techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). This design aims to ensure the internal validity of the study results and to exclude potential confounding effects of other interventions on neuroplasticity and cognitive function.
223929499|NCT06744023|OTHER|To examine the effect of the improved environment according to Watsons Human Care Theory on sleep quality, anxiety, and depression in patients undergoing open heart surgery.|"The patients who underwent open heart surgery and who were in the experimental group were admitted to the ward from the postoperative intensive care unit and the environment was improved for three days based on the improved environment of Watson's HCT, and on the morning of the fourth day in the clinic, the patients were interviewed face to face and the Personal Information Form, RSCQ and HAD Scale were completed. The following improvements were implemented within the scope of environmental improvement:~* Considering the seasonal conditions, the patient room was ensured to have appropriate temperature (18-26 °C) and humidity values (30-60%), and the temperature and humidity were gradually reduced and maintained in the appropriate range by monitoring at 21:00, 22:00, and 23:00 (Days 1, 2, and 3)~* In line with the environmental arrangements, the brightness of the light in the patient room was gradually reduced at 21:00, 22:00, and 23:00 using the Light Meter LM-3000 (Days 1, 2, and 3)"
223929500|NCT06760416|OTHER|Nursing Education|5 modules of online foot care training, motivational messages and informative videos for the patient who was given a foot care kit
223929501|NCT06844565|PROCEDURE|Immunohistochemistry procedure|"Briefly, all slides will be rehydrated, and antigen retrieval will be performed using sodium citrate (pH = 6.0) in a pressure cooker (EDTA buffer, pH = 8.4).~All slides will be blocked with endogenous peroxidase with 3% hydrogen peroxide and blocked non-specific protein with 2.5% bovine serum albumin in phosphate-buffered saline.~If the result shows non-specific ileitis, immunohistochemical staining for IL-12 and IL-23 will be performed using sandwich enzyme-linked immunosorbent assays (ELISA)."
223929502|NCT06846931|OTHER|Extracorporeal Shock Wave Therapy|By the same physiotherapist with more than 5 years of clinical experience, radial ESWT treatment with 2500 pulses, 10 Hz frequency, 2.5-3 bar pressure, is applied to the most painful point of the heel and surrounding soft tissues, plantar aponeurosis and Achilles tendon insertion area on the dorsum of the heel, once a week for a total of 3 sessions.
223929503|NCT06846931|OTHER|Low Intensity Laser|A total of 28j (5.6jx5 points) are applied to the plantar fascia at 5 points on the heel by the same physiotherapist for 3 weeks, a total of 9 sessions (every other day) with the patient lying face down.
223929504|NCT06846931|OTHER|EXERCİSE|Exercise therapy is carried out by the patient for 3 weeks. Plantar fascia stretching exercises (exercises to stretch the membrane on the sole of the foot), gastrocsoleus stretching exercises (exercises to stretch the calf muscles), foot intrinsic muscle strengthening exercises (exercises to strengthen the muscles on the sole of the foot) are taught to the patients by the doctor and they are asked to perform them 2 times a day 10 times for a total of 3 weeks.
223929505|NCT05651594|PROCEDURE|Biopsy|Undergo tissue collection
223929506|NCT05651594|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223929507|NCT05651594|PROCEDURE|Computed Tomography|Undergo CT scans
223929508|NCT05651594|DRUG|Fluorouracil|Given IV
223929509|NCT05651594|DRUG|Leucovorin|Given IV
223929510|NCT05651594|DRUG|Oxaliplatin|Given IV
223929511|NCT05651594|BIOLOGICAL|Pembrolizumab|Given IV
223929512|NCT05651594|DRUG|Propranolol Hydrochloride|Given PO
223929513|NCT05651594|OTHER|Questionnaire Administration|Perceived Stress Scale
223718196|NCT07014813|PROCEDURE|Sub pectoral fixation|Subpectoral biceps tenodesis via mini-open incision. Biceps tendon prepared with Krackow sutures, press-fit into bony tunnel using harvested bone plug. Stability checked post-fixation.
223718197|NCT07016087|OTHER|Cosmetic formulation experimental|Cosmetic formulation containing emollients and a butyrate releaser: the postbiotic N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA)
223718198|NCT07016087|OTHER|Cosmetic formulation usual|Cosmetic formulation containing emollients
223929514|NCT06850844|DEVICE|electrical impedance tomography|The individualized high PEEP with RMs group commences with a PEEP of 5 cm H2O and undergo an RM followed by a decremental PEEP trial. Pressure-controlled ventilation mode is set with a respiratory rate of 16 breaths per minute and ΔP=15 (ΔP is calculated by subtracting PEEP from the plateau pressure (Pplat). In intervals of 5 breaths, PEEP is incrementally increased by 5 cm H2O, starting at 5 cm H2O and reaching up to 20 cm H2O. The decremental PEEP trial is immediately performed following the first RM, beginning at a PEEP of 20 cm H2O with a respiratory rate of 15 breaths per minute. Every 30 seconds, PEEP is decreased by increments of 2 cm H2O until it reaches a minimum of 6 cm H2O. This decremental PEEP trial is succeeded by a second RM, after which the individualized PEEP level will be established as determined by the decremental PEEP trial and sustained until the completion of ventilation.
223929515|NCT06850844|DEVICE|Conventional Ventilation|Ventilation is set in volume-controlled mode with a tidal volume of 7 ml/kg predicted body weight (PBW), the respiratory rate is adjusted to target normocapnia (end-tidal carbon dioxide partial pressure between 35 and 45 mmH), an inspiratory to expiratory ratio of 1:2, and a PEEP of 5 cmH2O.
223929516|NCT06772558|DRUG|Desflurane Inhalation|Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
223929517|NCT06772558|DEVICE|mechanical ventilation (MV)|Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.
223929518|NCT06496724|BIOLOGICAL|Albumin paclitaxel/neutrophil drug|Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
223718199|NCT07014956|PROCEDURE|Labour epidural analgesia|Prenatal exposure to labour epidural analgesia during delivery
224283159|NCT05562453|DEVICE|FlowOx2.0 (Sham)|Subjects randomized to treatment with the comparator will receive treatment with -10 mmHg intermittent negative pressure for 60 minutes per day.
224283160|NCT03397953|DRUG|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
224283161|NCT00256529|PROCEDURE|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
224283162|NCT06616116|DEVICE|Biosignal feedback|"1. Real-time neurofeedback guided mindfulness~   : Unlike standard mindfulness therapies, this intervention integrates real-time monitoring of brainwave activity (EEG). Participants in the experimental group receive immediate auditory feedback during their mindfulness sessions, which helps guide their practice and enhance engagement.~2. Tailored progress report In addition to real-time feedback, participants in the Mindfulness with biosignal feedback group receive detailed reports of their biosignal data (EEG and HRV) before, during, and after each session. These reports allow for deeper self-reflection and personalized adjustments to their mindfulness practice, which is not commonly provided in other mindfulness programs."
224283163|NCT06616116|DEVICE|Sham Comparator|Biosignal Monitoring (EEG and HRV) during Mindfulness without real-time feedback
224283164|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-I)|0,05ml intravitreal injection
224283165|NCT02985619|DRUG|Triamcinolone Acetonide 10mg/mL (IVT-II)|0,03ml intravitreal injection
224283166|NCT02985619|DRUG|Bevacizumab Injection [Avastin] (IVB-III)|0,05ml intravitreal injection
224283167|NCT02380313|DRUG|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
224283168|NCT02380313|DRUG|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
224283169|NCT02380313|DRUG|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
224283170|NCT02380313|DRUG|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
224283171|NCT06615856|OTHER|Questionnaire|"Two questionnaires will be provided to participants to complete before their routine tests (which they would already be having regardless of the study and are not affected by their participation in the study).~The questionnaires include: A Gastro-Oesophageal Reflux Symptom Questionnaire; and the ROME-IV Diagnostic IBS Module Questionnaire"
224283172|NCT04787952|OTHER|cold expossure|subjects were exposed for the cold, to activate and diagnose potential brown tissue activity
224283173|NCT03664050|DRUG|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
224283174|NCT03664050|PROCEDURE|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
224283175|NCT02265341|OTHER|Laboratory Biomarker Analysis|Correlative studies
224283176|NCT02265341|DRUG|Ponatinib Hydrochloride|Given PO
224283177|NCT02265341|OTHER|Quality-of-Life Assessment|Ancillary studies
224283178|NCT04617392|PROCEDURE|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.
223929519|NCT06640868|BEHAVIORAL|MyChart nurse message|Receipt of a MyChart nurse message around 34 weeks encouraging RSV vaccination
224283179|NCT04617392|OTHER|Strength endurance training|Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
224283180|NCT05815082|PROCEDURE|Colorectal cancer resection combined with liver metastasis resection.|The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
224283181|NCT05815082|DRUG|FOLFOX chemotherapy regimen|Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
224283182|NCT04531787|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season: 2004-2005, 2005-2006, 2006-2007, 2007-2008 for season specific A/H1N1, A/H3N2, and B antigens
224283183|NCT05896215|DRUG|KNP2002|Dairy topical administration for 12 weeks
224283184|NCT05896215|DRUG|Placebo of KNP2002|Dairy topical administration for 12 weeks
224283185|NCT01613378|OTHER|No intervention|No intervention administered in this study
224283186|NCT01754818|DRUG|Bendavia 10mg|
224283187|NCT01754818|DRUG|Bendavia 50mg|
223929520|NCT06640868|BEHAVIORAL|SMFM video|Receipt of SMFM video around 34 weeks encouraging RSV vaccination
224283188|NCT01754818|DRUG|Bendavia 100mg|
224283189|NCT01754818|DRUG|Placebo|
224283190|NCT04265690|BEHAVIORAL|Cooking classes|Participants will receive 2 cooking classes (each 1-hour long) during their Centering group-care visit at the BMC teaching kitchen, taught by a Registered Dietitian. The recipes taught during the cooking classes will follow the Special Supplemental Nutrition Program for Women, Infants, and Children, the 2015-2020 Dietary Guidelines for Americans, and recommendations from The American College of Obstetricians and Gynecologists.
224283191|NCT04265690|BEHAVIORAL|Text messages|Participants will receive text messages, through a password secured phone, based on their content and frequency preferences.
224283192|NCT05281978|BEHAVIORAL|Decrease Sedentary Time + Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise; personalized step count goals to increase daily volume of physical activity and displacement of sedentary time
224094991|NCT04912167|DRUG|Sacubitril-Valsartan|After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
224283193|NCT05281978|BEHAVIORAL|Increase MVPA group|12 week home-based exercise program to promote engagement of 150 min/week of moderate-vigorous intensity exercise
223929521|NCT06640868|BEHAVIORAL|Visual aid|Receipt of a visual aide encouraging RSV vaccination at 28-30 wks
223929522|NCT06853873|BEHAVIORAL|The Counselling for Alcohol Problems in Pregnancy (CAP-Pre) intervention|"Five structured 60-minute counseling sessions (weekly, CHW-delivered).~Key components:~Motivational interviewing (MI) to enhance behavior change. Cognitive-behavioral strategies (CBT) for managing alcohol cravings. Goal-setting and self-monitoring for tracking progress. Problem-solving techniques and social support enhancement."
223929523|NCT06858670|PROCEDURE|Auxiliary Segmental Lingual Appliances|This intervention involves the use of auxiliary segmental lingual appliances specifically designed to level the Curve of Wilson at the second molars in patients undergoing labial fixed orthodontic treatment. The primary goal is to adjust the lingual inclination of the mandibular second molar, thereby achieving a more balanced and functional occlusal plane.
223929524|NCT06744348|PROCEDURE|ENTİRE PAPİLLA PRESERVATİON|"The EPP technique is a tunnel-like approach of the defect-associated inter-dental papilla. Surgical loupes (3.3× magnification) with LED light illumination were used to increase visibility of the surgical site. Following a buccal intra-crevicular incision, a bevelled vertical releasing incision was performed in the buccal gingiva of the neighbouring inter-dental space and extended just beyond the mucogingival line to provide appropriate mechanical access to the intrabony defect."
223929525|NCT06892145|BIOLOGICAL|MC-1-50|A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
223929526|NCT06755723|OTHER|Rib fractures manangement|This is an observational study, so participants are not assigned interventions. However, the study investigates the outcomes of patients undergoing rib stabilization surgery as part of their routine clinical care. The exposure of interest includes surgical rib stabilization and its timing, combined with any related clinical and care procedures. The outcomes and clinical data collected reflect routine care practices.
223929527|NCT04643574|BIOLOGICAL|NeoTIL|Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
223929528|NCT04643574|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223929529|NCT04643574|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223929530|NCT04643574|DRUG|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.
223929531|NCT04643574|RADIATION|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
223929532|NCT06761326|PROCEDURE|Ultrasound guided right infraclavicular approach of subclavian vein cannulation|All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
223929533|NCT06761326|PROCEDURE|Ultrasound guided left infraclavicular approach of subclavian vein cannulation|All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
223929534|NCT06752148|COMBINATION_PRODUCT|neurofeedback intervention training game|"1. Issuance of training equipment and training in its use: For subjects randomly assigned to the intervention group, a volunteer who has received adequate training in the use of the equipment will issue the EEG monitoring electrodes (model: HXD-1) and paired PADs, and will provide an activated account for the use of the subject only and training in its use. Subjects will be provided with a short tutorial on how to use the APP, which is very user-friendly and suitable for elderly novices. An initial training session will consist of 3 training components and will be completed with a volunteer.~2. Training programme and supervision: The closed-loop neurofeedback training will consist of 3 parts, namely Digital Meditation, Brain Training and Sleep Induction. The brain training will consist of three games: Idea Chase, Idea Magic Ball and Focused Archery. The control subjects lived a normal life before the surgery, and all subjects underwent the surgery as planned."
223929535|NCT06812208|BEHAVIORAL|Teleultrasound with Philips Lumify ultrasound probes and Reacts software|"Clinicians at hospitals randomized to Arm 1 will be provided with Reacts licenses and trained to use Reacts with Philips Lumify devices immediately following the baseline training. Each hospital will be assigned to 2-3 radiologist supervisors (typically 1 Rwandan, 1 U.S.-based), with at least one available on each designated U/S clinic day to provide real-time teleultrasound mentorship. Clinician trainees scan the breast, document their independent findings and management plan in the study REDCap database, and then call the supervisor using Reacts. Reacts permits supervisor and trainee to see each other virtually; the supervisor can also view live U/S images and the trainee's probe and hand position to provide real-time feedback."
223929536|NCT06812208|BEHAVIORAL|Asynchronous virtual feedback|Clinicians at Arm 2 hospitals will save static images, with or without video at clinicians' discretion, onto the Philips Lumify tablets. These will be uploaded to a secure internet-based folder with case descriptions, and assigned U.S.- and Rwanda-based experts will be notified that images are available. Experts will review images within 24 hours and email feedback to trainees on imaging quality/ technique and management; trainees can also email questions.
223929537|NCT06842043|OTHER|AI-assisted model|physicians will be authorized to access the AI model's predictions during patient care as an additional decision-making reference. These predictions will be generated in seconds and can help identify issues such as tube misplacement (e.g., nasogastric tube, endotracheal tube) and pneumothorax through AI analysis of CXRs, which will alert the physician to review the images.
223929538|NCT06812390|DRUG|Albumin infusion (25% albumin)|Albumin 25 gram infusion
223929539|NCT06812390|DRUG|Normal Saline (0.9% NaCl)|100 cc of normal saline
223929540|NCT06842641|OTHER|Cool roof|Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy
223929541|NCT06753812|OTHER|constraint induced movement therapy|Children in this group will receive constraint induced movement therapy for 10 sessions over 2 weeks, each session lasting 90 minutes, in addition to the treatment they receive 2 days a week at the special education and rehabilitation centers they attend.
223929542|NCT06753812|OTHER|Control (Standard treatment)|Children in this group will continue to receive their treatment at the special education and rehabilitation center they attend, two days a week for 40 minutes.
223929543|NCT06811051|BIOLOGICAL|Menthol lozenge|Patients in the menthol group will fill out the Patient introduction form, patient follow-up form, and numerical pain scale just before the first application. After 60 minutes after extubation, they will be asked to take the lozenge into their mouth without chewing or swallowing it and suck it, and the patient will be monitored until the lozenge is completely dissolved. After the first lozenge is finished, the patient follow-up form and numerical pain scale will be filled out. The second lozenge will be sucked 90 minutes after extubation. The third lozenge will be sucked 120 minutes after extubation and the patient follow-up form and numerical pain scale will be filled out.
223929544|NCT06811051|BIOLOGICAL|Clove lozenge|Patients in the clove group will fill out the Patient introduction form, patient follow-up form, and numerical pain scale just before the first application. After 60 minutes after extubation, they will be asked to take the lozenge into their mouth without chewing or swallowing it and suck it, and the patient will be monitored until the lozenge is completely dissolved. After the first lozenge is finished, the patient follow-up form and numerical pain scale will be filled out. The second lozenge will be sucked 90 minutes after extubation. The third lozenge will be sucked 120 minutes after extubation and the patient follow-up form and numerical pain scale will be filled out.
223929545|NCT06811051|OTHER|None-placebo|Before routine clinical procedures after surgery, the patients in the control group will fill out the Patient introduction form, Patient follow-up form, and Numerical pain scale. After 60 minutes after extubation; clinical procedures do not include any procedures or interventions and the patient follow-up form and Numerical pain scale will be evaluated. After 120 minutes after extubation; the patient follow-up form and numerical pain scale will be evaluated.
223929546|NCT06843200|BEHAVIORAL|Parent Group Discussion|A 2-hour interactive parent group delivered to 5-10 parents via zoom; discuss weight bias and discrimination; brainstorm ways to respond in parent-child interactions involving health and appearance; and identify action steps.
223929547|NCT06812351|DRUG|Osteon III collagen|Hydroxyapatite and tricalcium phosphate particles embeded in bovine collagen
223929548|NCT06812351|BIOLOGICAL|Blood clot|Induction of bleeding from apical papilla
223929549|NCT04855370|DEVICE|Non-invasive hemodynamic measurements|A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds every 15 minutes for 12 to 24 hours. If two finger probes are available, measurements will alternate between fingers.
223929550|NCT06809738|PROCEDURE|reconstructive technique|"1. Analysis and limitation of the tissue injury. Bilateral testicular and spermatic cord dissection.~2. Formation of cutaneous flaps and bilateral inguinal neocavity.~3. Perineal-scrotal reconstruction with fascial facing and cutaneous flaps"
224094992|NCT04912167|DRUG|Enalapril|After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
224094993|NCT04912167|DRUG|Valsartan|For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
224094994|NCT00833092|DIETARY_SUPPLEMENT|Sugar Pill|Sugar pill supplementation for 9 weeks
224094995|NCT00833092|DIETARY_SUPPLEMENT|magnesium|300 milligrams daily for 8 weeks
224094996|NCT03510793|DRUG|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
224094997|NCT03510793|DRUG|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
224094998|NCT06165588|OTHER|Tour de France|Participating in the Tour de France as cyclist
224094999|NCT01103739|DRUG|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
224095000|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
223532789|NCT01188941|BEHAVIORAL|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
223929551|NCT06595329|PROCEDURE|Epidural analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned puncture. The epidural space will be identified at the level of the tenth thoracic intervertebral space using the loss of resistance technique and an 18G Tuohy epidural needle. After placing the epidural catheter, 4 ml of local anesthetic Levobupivacaine 0.25% will be administered into the epidural space. After inducing general anesthesia, an additional 4 ml of Levobupivacaine 0.25% will be administered before the surgical incision. Subjects in the control group will receive an infusion of 0.125% Levobupivacaine for 24 hours after the procedure.
223929552|NCT06595329|PROCEDURE|Intrathecal opioid analgesia|After establishing standard non-invasive monitoring of vital functions (electrocardiogram, blood pressure, peripheral oxygen saturation) and securing intravenous access, the patient will be seated. After sterile field preparation, a local anesthetic (2% lidocaine) will be administered at the site of the planned intrathecal puncture. Subsequently, at the selected site, the dura will be punctured using a spinal needle (25G Quincke spinal needle), and 0.3 mg of morphine will be administered to the patient. Following the intervention, the patient will be induced into general anesthesia.
223532790|NCT02863393|OTHER|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
223532791|NCT01798888|PROCEDURE|Implantation of Deep Brain Stimulation|
224095001|NCT01103739|DRUG|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
223532792|NCT04128709|DEVICE|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
223929553|NCT06819800|OTHER|Transparent Waterproof Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Ulcer Risk Assessment Scale' were applied to the patients in the transparent waterproof flaster group, one of the experimental groups. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, a transparent waterproof flaster was applied. The transparent waterproof flaster was prepared using the nasal preparation by pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
223941115|NCT00387075|PROCEDURE|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, \[123I\]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
224283194|NCT06177847|DEVICE|BIS|In the group with BIS where the anesthesia protocol is opened, namely the use of anesthetic gas, the anesthetic drug will be adjusted to the BIS value range of 40-60 or BIS-guided
224283195|NCT02744755|BIOLOGICAL|Adalimumab - GP2017|Adalimumab - GP2017
224283196|NCT02744755|BIOLOGICAL|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
224283197|NCT03618329|OTHER|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
224283198|NCT04344626|DEVICE|Intra-operative brain tonometry|Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
224283199|NCT03033719|PROCEDURE|Laparotomy|Open surgery
224283200|NCT03033719|PROCEDURE|Laparoscopy|Minimally invasive surgery
224283201|NCT03988452|DRUG|Darunavir|Antiretroviral therapy
224283202|NCT03988452|DRUG|Ritonavir|Antiretroviral therapy
224283203|NCT03988452|DRUG|Dolutegravir|Antiretroviral therapy
224283204|NCT03988452|DRUG|Zidovudine|Antiretroviral therapy
224283205|NCT03988452|DRUG|Tenofovir|Antiretroviral therapy
224283206|NCT03988452|DRUG|Lamivudine|Antiretroviral therapy
224283207|NCT01343069|PROCEDURE|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
224283208|NCT03669575|DIETARY_SUPPLEMENT|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
224283209|NCT03669575|DIETARY_SUPPLEMENT|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
224283210|NCT00880087|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
224283211|NCT00880087|PROCEDURE|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
224283212|NCT02184559|DRUG|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
224283213|NCT02184559|DEVICE|The infiltration continues catheter|
224283214|NCT03159286|BEHAVIORAL|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
224283215|NCT03159286|BEHAVIORAL|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
224283216|NCT03159286|BEHAVIORAL|Control|Participants view social networking site profiles with no alcohol content.
224283217|NCT02396173|OTHER|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
224283218|NCT00752284|PROCEDURE|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
224283219|NCT00752284|PROCEDURE|Total Excision|Total excision of lower third molar
224283220|NCT02358967|DIETARY_SUPPLEMENT|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
224283221|NCT02358967|DIETARY_SUPPLEMENT|Placebo|2 x 150 mg capsules
224283222|NCT05135819|BEHAVIORAL|Cyber School for Grandparents|Educational program for secondary school students to become cyber tutors for their grandparents or for senior citizens, who are interested to learn new digital use and skills.
223941116|NCT00387075|DRUG|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
223941117|NCT04707170|DEVICE|MRI with gadolinium injection|"Patients presenting for imaging for whom an MRI examination with gadolinium injection has been prescribed and who meet the inclusion and non-inclusion criteria will be offered to participate in the study.~The patients included, hospitalized at the A. de Rothschild Foundation Hospital for at least 24 hours, may be included in the ancillary study to meet secondary objective number 5."
223941118|NCT02824198|BIOLOGICAL|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
224095002|NCT01103739|DRUG|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
224095003|NCT03714126|DEVICE|Cordio Medical|Recording to an app, no interference to the regular care
224095004|NCT00005104|DRUG|clomiphene citrate|
224095005|NCT00005104|DRUG|metformin|
224283223|NCT00757549|BIOLOGICAL|cetuximab|
224283224|NCT00757549|DRUG|cisplatin|
224283225|NCT00757549|GENETIC|TdT-mediated dUTP nick end labeling assay|
224283226|NCT00757549|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
224283227|NCT00757549|OTHER|immunohistochemistry staining method|
224283228|NCT00757549|OTHER|laboratory biomarker analysis|
224283229|NCT00757549|RADIATION|fludeoxyglucose F 18|
224283230|NCT00757549|RADIATION|radiation therapy|
224283231|NCT00035321|DRUG|Olanzapine|
224283232|NCT00035321|DRUG|Fluoxetine|
224283233|NCT04397289|DRUG|Heparin and Rivaroxaban|Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
224283234|NCT04863157|BEHAVIORAL|Survivor-SHIP|Parent/guardian education about healthy sleep practices to improve their child's sleep health.
224283235|NCT04239482|DIETARY_SUPPLEMENT|L-arginine + Nitrate / Nitrite|Longer-term supplementation (8 weeks)
224283236|NCT04239482|DIETARY_SUPPLEMENT|Placebo|Longer-term supplementation (8 weeks)
224283237|NCT04423159|BIOLOGICAL|OCV Vaccine|2 doses of OCV were administered to all enrolled participants 1st dose administered at baseline and second dose administered 28 days post 1st dose.
224283238|NCT00975962|DRUG|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
224283239|NCT00975962|PROCEDURE|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
224283240|NCT01011556|DRUG|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
224283241|NCT01011556|DRUG|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
224283242|NCT03952988|DIETARY_SUPPLEMENT|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (\>10(exp7)/g) every day for 4 weeks
224283243|NCT03952988|DIETARY_SUPPLEMENT|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
224283244|NCT01845116|DRUG|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
224283245|NCT00004424|DRUG|fentanyl|
224095006|NCT06438328|DIAGNOSTIC_TEST|Left/ Right affected arm|Therapeutic exercises: eccentric and concentric exercises and wrist isometrics 10 repetitions of 3 sets with 10 seconds interval
224095007|NCT06438328|OTHER|Grip strength|assessed by using modified sphygmomanometer in which it first inflated to 100 mmHg with closed valve. The pressure was reduced to 20mmHg and the resisted wrist extension performed at baseline and at the 4th week.
224095008|NCT05366829|DRUG|Tislelizumab|Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
224095009|NCT00699192|DRUG|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
224283246|NCT00004424|DRUG|Midazolam|
224283247|NCT00004424|DRUG|propofol|
224283248|NCT00030641|BIOLOGICAL|oblimersen sodium|
224283249|NCT00030641|DRUG|docetaxel|
224283250|NCT01625117|BEHAVIORAL|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
224283251|NCT01841541|BEHAVIORAL|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
224283252|NCT01712815|OTHER|laboratory biomarker analysis|Correlative studies
224283253|NCT01712815|OTHER|pharmacological study|Correlative studies
224283254|NCT01712815|OTHER|questionnaire administration|Ancillary studies
224283255|NCT01712815|RADIATION|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
224283256|NCT01712815|PROCEDURE|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
224283257|NCT02270749|DRUG|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
223532793|NCT06090344|OTHER|Traditional video format|6 x 3 minute videos designed in the same format as traditionally found on the internet
223532794|NCT06090344|OTHER|Evidence-informed video format|6 x 3 minute videos designed in the format recommended by advice in the literature
223532795|NCT06389058|OTHER|Recommendation for the diagnoses and treatment of Severe Asthma|No intervention planned in this phase for the patients. Recommendations to be developed for healthcare and condition.
223532796|NCT06068504|OTHER|Arm-cranking exercise|Arm-cranking exercise
223532797|NCT06068504|OTHER|Heating|Immersion of the foot in warm water
223532798|NCT02549066|PROCEDURE|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
223929554|NCT06819800|OTHER|Medical Silk Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Wound Risk Assessment Scale' were applied to the patients in the medical silk flaster group, one of the experimental groups. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, a medical silk flaster was applied. The medical silk flaster was prepared using the nasal preparation by pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
223929555|NCT06819800|OTHER|Elastic Flaster|"Patients determined by randomization method were divided into three groups. Patient Information Form, 'Patient Follow-up Form', 'Glasgow Coma Scale' and 'Braden Pressure Wound Risk Assessment Scale' were administered to the patients in the control group, which was in the elastic flaster group. Nasogastric tube care was applied at 24-hour intervals. The dorsum of the nose was first cleaned with saline and then disinfected with a skin antiseptic containing alcohol and chlorhexidine gluconate. Afterwards, an elastic flaster was applied. The elastic flaster was prepared using the preparation of the nose by the pants tape method technique. Afterwards, the Patient Follow-up Form, Glasgow Coma Scale and Braden Pressure Injury Risk Diagnostic Scale were re-administered by the investigator at 72 hours and at discharge. If pressure injury developed, the Nasogastric Tube-Related Pressure Injury Staging Form was completed."
223929556|NCT06818110|OTHER|Exercise|The supervised exercise-training sessions will last \<1 hour, and exercise-training intensities will be individually tailored to each participant using the results from their CPET. Participants will be screened prior to each session to ensure that it is safe to perform exercise. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high-intensity (50%∆) for a predetermined amount of time. Five minutes of freewheel cycling will be performed at the start and end of the protocol for a warm-up and cool-down. Exercise sessions can be terminated by the participant at any time. Participants will have continuous ECG and SpO2 monitoring throughout the training session. Vital signs will be taken before (some during) and after each training session.
223929557|NCT06819046|DRUG|Rocklatan|netarsudil and latanoprost ophthalmic solution 0.02%/0.005%
223929558|NCT06819046|DRUG|Systane Ultra|artificial tears
224095010|NCT00699192|DRUG|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
224095011|NCT00699192|DRUG|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
224095012|NCT00699192|DRUG|Placebo|1 capsule placebo to match valsartan orally once daily
224095013|NCT03409549|RADIATION|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
224095014|NCT02588378|PROCEDURE|multi-modal cSLO imaging|
224283258|NCT02270749|DRUG|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
224283259|NCT00194792|DRUG|exemestane|Given PO
224283260|NCT00194792|DRUG|triptorelin pamoate|Given IM
224283261|NCT00194792|DRUG|capecitabine|Given PO
224283262|NCT00194792|DRUG|methotrexate|Given IV
224283263|NCT00194792|DRUG|vinorelbine tartrate|Given IV
224283264|NCT00194792|DRUG|paclitaxel|Given IV
224283265|NCT00194792|PROCEDURE|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
224283266|NCT00194792|RADIATION|radiation therapy|Undergo radiation therapy
224283267|NCT00194792|OTHER|laboratory biomarker analysis|Correlative studies
224283268|NCT05871333|DRUG|Losartan 50mg Tab|Losartan 50 mg oral tablets
224283269|NCT01714739|DRUG|Lirilumab|Specified dose on specified days.
224283270|NCT01714739|DRUG|Nivolumab|Specified dose on specified days.
224283271|NCT01714739|DRUG|Ipilimumab|Specified dose on specified days.
224283272|NCT01853241|PROCEDURE|Single Balloon|All patients in this group will undergo single balloon enteroscopy
224283273|NCT01853241|PROCEDURE|Spirus|All patients in this group will undergo Spirus Enteroscopy
224283274|NCT04468906|PROCEDURE|Biceps Tenodesis|Biceps tenodesis describes the surgical procedure that will be performed to treat LHBT lesions.
224283275|NCT04468906|PROCEDURE|"Self-locking T Tenotomy"|"Self-locking T Tenotomy describes the surgical procedure that will be performed to treat LHBT lesions."
224283276|NCT03086876|BEHAVIORAL|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
224283277|NCT04891692|DEVICE|StimaWell 120MTRS system|Medium-frequency electrotherapy device that delivers current via up to 12 channels. The device also provides heat therapy up to 40°C.
224283278|NCT03585959|DEVICE|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
224283279|NCT04158817|DRUG|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
224283280|NCT04158817|DRUG|Non-labeled PSMA|Patient will be injected with microdose (\<100 ug) of THP-PSMA
223929559|NCT06824714|DRUG|glucocorticoid, immunosuppressants, targeted therapy|Drug intervention protocol will be determined by clinicians
223929560|NCT06878625|COMBINATION_PRODUCT|Sacituzumab Govitecan combined with Toripalimab|Sacituzumab Govitecan combined with Toripalimab
223929561|NCT06878625|COMBINATION_PRODUCT|Sacituzumab govitecan combined with anti-angiogenesis|Sacituzumab govitecan combined with anti-angiogenesis( Bevacizumab or Anlotinib Hydrochloride)
223929562|NCT06780644|DRUG|Triple combination cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle."
223929563|NCT06780644|DRUG|Triple combination cream|"1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream containing mometasone furoate 0.1%, hydroquinone 4%, tretinoin 0.05% at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle"
223929564|NCT04028973|OTHER|Single then dual task situation|Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
223929565|NCT04028973|OTHER|Dual then single task situation|Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
223929566|NCT06782555|DRUG|Evofosfamide|Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.
224095015|NCT02490657|DRUG|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
224095016|NCT02490657|DRUG|normal saline (Saline 0.9%)|
224095017|NCT05900141|DRUG|Pelacarsen|Pelacarsen 80mg s.c. monthly
224095018|NCT03190343|PROCEDURE|cholangio-pancreatoscopy|
224095019|NCT00422279|DEVICE|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
224095020|NCT04007614|OTHER|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
224095021|NCT05766592|BEHAVIORAL|LGBTQ-affirmative CBT|16-session LGBTQ-affirmative psychotherapy using cognitive behavioral techniques
224095022|NCT05766592|BEHAVIORAL|ABFT-SGM|16-session attachment-based family therapy for sexual and gender minority young adults and their nonaccepting parents
224095023|NCT03431012|OTHER|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
224095024|NCT03431012|OTHER|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
224095025|NCT05595876|PROCEDURE|stent retriever thrombectomy|The technique used should be in accordance with the device IFU (instructions for use). A large bore access guide catheter possible is mandatory. A suitable delivery microcatheter is navigated over a microwire across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent is left in place according to the internal practice of each participating center before the withdrawal. Any CE (european compliance)-marked stent retriever device is then deployed across the occlusion. A contact aspiration large bore catheter can be used in association with the stent retriever. A minimum of 3 attempts with Stent retriever should be performed. A revascularization score will be recorded after each device attempt.
224095026|NCT05595876|PROCEDURE|contact aspiration thrombectomy|A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch microwire inside is then introduced into a large-bore aspiration catheter and this construct is introduced into the long sheath as a unit. A large bore balloon guide catheter has to be placed into the cervical internal carotid artery. The microcatheter is then advanced close to the thrombus and the large-bore aspiration catheter is advanced as close to the proximal aspect of the thrombus as possible. A control angiogram may be used to document the extent of occlusion and thrombus. After a 3 min waiting period, the large-bore aspiration catheter is connected to a continuous aspiration from the dedicated aspiration pump while simultaneously advancing the aspiration catheter up to the face of the thrombus. Once thrombus will be close to the aspiration catheter, then the system will carefully removed as a unit under continuous aspiration.
224095027|NCT00562419|DRUG|CT-322|IV solution, weekly
224095028|NCT00562419|DRUG|irinotecan hydrochloride|IV solution, biweekly
224095029|NCT02024776|BEHAVIORAL|Prehabilitation|Tailored exercise training program
224283281|NCT05965102|DRUG|Tirelizumab；Chemotherapy monotherapy|Tirelizumab combined with chemotherapy in first-line treatment of relapsed/metastatic non-small cell lung cancer with ECOG PS score of 2
224283282|NCT04817215|DRUG|ORMD-0801|Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
224283283|NCT00604903|DEVICE|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
223929567|NCT06782555|DRUG|Zalifrelimab|Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.
224283284|NCT02464826|DRUG|Nailprotex|Nailprotex apply to the abnormal nail twice daily
224283285|NCT00006387|BIOLOGICAL|QS21|
223929568|NCT06782555|DRUG|Balstilimab|Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
224283286|NCT00006387|BIOLOGICAL|ras peptide cancer vaccine|
224283287|NCT05956964|BEHAVIORAL|Sleep Restriction|5 hours of sleep for 3 days
223532799|NCT02549066|DRUG|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) \< 12 %."
223532800|NCT03767868|OTHER|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
223929569|NCT06768814|BEHAVIORAL|Sub-acute stabilization|The sub-acute stabilization center (SASC) is for people who have had or are at risk for having an opioid overdose and have an encounter with Seattle Fire Department emergency medical services (EMS) in Seattle, WA. Those transported to the SASC are the intervention participants and two comparison groups will be utilized: eligible Seattle EMS patients who opt not to go to the SASC and King County residents, outside of Seattle, who meet the same eligibility criteria. A comparative interrupted time series analysis is planned to study the main effectiveness outcomes. Seattle Fire EMS will assess, refer, and arrange transport participants to the SASC. The SASC will offer an array of services including post-overdose monitoring, utilization of buprenorphine and methadone for the treatment opioid use disorder and opioid withdrawal, linkage to ongoing care for OUD, and provision of harm reduction services and supplies. The length of stay in the SASC will be limited to less than 24 hours.
223929570|NCT06769295|DRUG|AK112|non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK112 plus Pemetrexed until progression.
223941119|NCT02824198|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
224095030|NCT02589977|DRUG|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
224095031|NCT01025635|DRUG|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
224095032|NCT01025635|DRUG|Vehicle foam|Applied topically twice daily for 12 weeks
224283288|NCT05956964|BEHAVIORAL|Sleep Adequate|9 hours of sleep for 3 days
224283289|NCT06363526|OTHER|Digital respiratory intervention program|"A 4 times a week for a period of 5 weeks will be done, for a duration of 55-60 minutes (20 sessions), with an intensity adapted to the characteristics of each participant. Moreover, an intervention program will be used based on respiratory muscle training exercises, upper limb strength work, yoga, diaphragmatic awareness exercises, always trying to do them through the use of games, and even try to include exercises that use motor imagery.~The intervention program is carried out and stimulated through videos and therapeutic teaching to the caregivers in the first evaluation session, as well as as well as with a weekly follow-up using WhatsApp or Zoom as forms of communication, or a telephone call to ensure correct follow-up of the intervention program. Moreover, YouTube videos, own videos prepared by the physiotherapy will be used to help optimally resolve doubts that arise when carrying out the program by video call."
224283290|NCT04380038|DRUG|Dupilumab Injectable Product|Nasal inoculation, single dose 300 TCID50 in 1ml.
224283291|NCT02051660|BEHAVIORAL|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
224283292|NCT02051660|BEHAVIORAL|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
224283293|NCT00153439|BEHAVIORAL|Motivational enhancements, parent training|
224283294|NCT00361387|DRUG|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
224283295|NCT05476133|OTHER|Executive functions training-elementary and Promoting executive function in in the classroom|evidence based practice that target executive function skills in early elementary years.
224283296|NCT00709137|DRUG|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
224283297|NCT00709137|DRUG|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
224283298|NCT04854408|OTHER|healthcare workers with the coronavac vaccine|Health workers who are vaccinated will fill in the 20-question survey electronically.
224283299|NCT04223284|OTHER|D-Limonene|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% D-Limonene in the nose for 15 minutes
224283300|NCT04223284|OTHER|SLVO|Patient will put the aspUraclip®, a commercially available mini-inhalator filled for our study purpose filled with 1% SLVO in the nose for 15 minutes
224283301|NCT00386815|DRUG|pemetrexed|
224283302|NCT00386815|DRUG|cisplatin|
224283303|NCT04594720|OTHER|Identification group|papillary thyroid cancers (n=10) and benign thyroid tumors (n=10)
224283304|NCT04594720|OTHER|Validation group|papillary thyroid cancers (n=45) and benign thyroid tumors (n=35)
224283305|NCT01740791|DRUG|Velpatasvir|Tablets administered orally
224283306|NCT01740791|DRUG|Placebo|Tablets administered orally
224283307|NCT02676960|OTHER|MRI without sedation|
224283308|NCT04366180|DIETARY_SUPPLEMENT|Probiotic|The probiotic group will received one capsule with Lactobacillus K8 per day (3x10\^9 cfu/day) during 2 months
224283309|NCT04366180|DIETARY_SUPPLEMENT|Control|The control group will received one placebo capsule per day during 2 months
223532801|NCT00624845|DRUG|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
223532802|NCT00624845|DRUG|Vehicle|Maximum of 6 bags of vehicle irrigation solution
223532803|NCT05871957|DRUG|Vitamin D Drops|Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
223532804|NCT03763578|OTHER|Licorice|Natural herbal product
224283310|NCT02735694|DRUG|Cycloserine|Capsule containing 250 mg of Cycloserine
224283311|NCT02735694|DRUG|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
223532805|NCT02168556|BEHAVIORAL|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
223532806|NCT02168556|BEHAVIORAL|Video|Subject watches an informational video prior to undergoing urodynamic testing.
223532807|NCT02168556|OTHER|Standard of care|Standard of care
223532808|NCT03387956|DRUG|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
223532809|NCT03387956|DRUG|dexamethasone|intravenous 8 mg dexamethasone (2ml).
224095033|NCT06322082|DEVICE|The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG)|"The LiESWT was applied to Pilates and Shock Wave group and Shock Wave group with 0.25 mJ/mm2 of intensity, 3000 pulses of shock, and 3 pulses/s of frequency, applicator was placed on the suprapubic skin area one session in the week for twelve weeks, totaling 12 sessions.~Pilates exercises were performed to Pilates and Shock Wave group and Pilates group. The sessions of Pilates were applied twice a week for twelve weeks, totaling 24 sessions. The 50 min Pilates sessions were divided into three phases: warm-up, strengthening, and stretching. They also received written orientations to perform three exercises and two of the Pilates session at home every day - Conventional pelvic floor exercises performed for all groups include Kegel exercise, squats, bridging, and squeeze and release exercises. These exercises were performed 3 times per day, lasting for 12 consecutive weeks"
223532810|NCT02063451|DIETARY_SUPPLEMENT|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
223532811|NCT02239926|DRUG|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
223532812|NCT02239926|DRUG|Placebo|
223532813|NCT02542618|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
223532814|NCT02542618|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
223532815|NCT05077969|DRUG|Famotidine|80 mg tablet, QID for 14 days
223532816|NCT05077969|DRUG|Celecoxib|400 mg (initial dose), then 200 mg capsule, BID for 5 days
223532817|NCT05077969|DRUG|Placebo|tablet, QID for 14 days; capsule, BID for 5 days
223532818|NCT01889992|RADIATION|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short \& long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 \>/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
223718200|NCT07014839|PROCEDURE|Endovascular Aortic Intervention|This intervention involves EVAR or TEVAR for the treatment of abdominal or thoracic aortic aneurysms, respectively. The procedures were performed using commercially available stent-grafts via a transfemoral approach under standard perioperative protocols. The study specifically focuses on the systemic inflammatory response following these interventions, with close monitoring of laboratory parameters including IL-6, neutrophil-to-lymphocyte ratio (NLR), CRP, leukocyte count, and procalcitonin during the early postoperative period. No adjunctive anti-inflammatory or immunomodulatory therapies were administered.
224095034|NCT04621903|OTHER|Shanshamani Vati Plus|Shanshamani Vati Plus was given as combination of Guduchi (Tinospora Cordifolia; 300 mg) and Pipli (Piper Longum 75 mg) twice daily.
224095035|NCT05763602|DRUG|povidone-iodine topical ointment|Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing HELEF orthopedic repair.
224095036|NCT01511731|DRUG|Famotidine|Famotidine Tablets 40 mg
224095037|NCT01511731|DRUG|Pepcid|40mg tablets
224095038|NCT03716479|OTHER|Low Fiber|20 g of acacia gum will be added to orange juice
224095039|NCT03716479|OTHER|High Fiber|40 g of acacia gum will be added to orange juice
224095040|NCT03716479|OTHER|Placebo/Control|No acacia gum will be added to orange juice.
224095041|NCT05887999|DRUG|LY3532226|Administered subcutaneously (SC).
224095042|NCT05887999|DRUG|Placebo|Administered SC.
224095043|NCT00929240|DRUG|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
224095044|NCT00929240|DRUG|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
224095045|NCT01270334|OTHER|PH meassurment|meassuring ph USING PROBE
224095046|NCT00002283|DRUG|Trimethoprim|
224095047|NCT00002283|DRUG|Sulfamethoxazole|
224095048|NCT00002283|DRUG|Dapsone|
224095049|NCT03500744|PROCEDURE|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
224095050|NCT03500744|PROCEDURE|Sham block|Skin infiltration only
224095051|NCT04210726|DRUG|25% Hypertonic Saline Bath|25% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 25%).
224095052|NCT04210726|OTHER|0.9% Isotonic Saline Bath|0.9% Sea Salt (mainly Sodium Chloride - NaCl) in Tap Water Immersion Bath (made by adding Sodium Chloride in the form of Sea Salt to Tap Water to a concentration of 0.9%).
224095053|NCT00001189|PROCEDURE|radiotherapy|
224095054|NCT05292755|DRUG|Carboxymethylcellulose (CMC) Artificial Tears|A pack of 21 vials of artificial tears containing carboxymethylcellulose 0.5% will be given to subjects in the treatment group.
224095055|NCT05292755|DRUG|Preservative-free, CMC-free Artificial Tears (control)|A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
224095056|NCT00005912|DRUG|Voriconazole|
224095057|NCT01026584|DRUG|Aripiprazole|6 week prospective study
224095058|NCT02155400|DEVICE|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
224095059|NCT02155400|DEVICE|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
224095060|NCT05078489|OTHER|Action-observation therapy|Action observation therapy involves the observation and perception of human movement performed by others. The observation of actions performed by others activates in the perceiver the same neural structures responsible for the actual execution of those same actions.
223532819|NCT01889992|PROCEDURE|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
223929571|NCT06764563|BEHAVIORAL|Mediterranean Medical Nutrition Therapy (counselling)|The participants in the intervention group will receive dietary guidance on the Mediterranean diet during 9 sessions over six months. The sessions which will be held in groups of ten individuals. In-person group sessions will be held three times: at the first meeting, after three months, and after six months. During the remaining six sessions, 6 online video sessions (by the institutional telemedicine program) will be delivered and include 60 minutes of nutritional educational sessions with a registered dietitian once a month
223929572|NCT06767904|DEVICE|Continous Oxygen by Bottles|Oxygen delivery by bottles giving a continous flow.
224095061|NCT05078489|OTHER|Placebo|Participants will watch a natural landscape without any human.
224095062|NCT06292897|OTHER|observational study|observational study
224283312|NCT00877994|BEHAVIORAL|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
224283313|NCT00877994|BEHAVIORAL|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
224283314|NCT01463982|DRUG|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~* Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1\~Day5~* HM30181AK Tablet - Fixed dose 15 mg, Day1\~Day5~* Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1\~Day14"
224283315|NCT02577068|DRUG|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
224283316|NCT02577068|DRUG|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
224283317|NCT02123524|DRUG|Rivaroxaban|
224283318|NCT02123524|DRUG|Placebo|
224283319|NCT02505724|BEHAVIORAL|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
224283320|NCT02505724|BEHAVIORAL|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
224283321|NCT02423317|DEVICE|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
224283322|NCT02423317|DEVICE|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
223532820|NCT01889992|OTHER|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
223929573|NCT06767904|DEVICE|Demand oxygen by Portable Concentrator|Oxygen delivery by consentrators, giving oxygen only when inhaling.
223929574|NCT06259929|DRUG|Abemaciclib 150 MG + Giredestrant 30 MG|Enrolled patients will receive 6 cycles of treatment in the absence of disease progression or unacceptable toxicity for a total of 24 weeks (2 weeks of opportunity phase and 22 weeks of neoadjuvant phase) before surgery
224095063|NCT00175305|DRUG|Sandostatin LAR|
224095064|NCT03171922|BEHAVIORAL|Internet Diet|ID group have online dietary coach every 2 weeks
224095065|NCT03171922|BEHAVIORAL|Clinic Diet|CD group have every 2 weeks visit at clinic
224095066|NCT02586480|DEVICE|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
224095067|NCT05437887|DIETARY_SUPPLEMENT|Fucoidan|All patients consumed fucoidan.
224095068|NCT01193686|OTHER|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
224283323|NCT00916695|DEVICE|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
224283324|NCT03532750|DEVICE|Particle|"1. 300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~2. 300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~3. Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~4. Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
224283325|NCT03532750|DEVICE|Coil|Ruby or Interlock detachable coils
224283326|NCT03245216|BEHAVIORAL|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
224283327|NCT03245216|BEHAVIORAL|rest|Seated rest before motor learning
224283328|NCT03245216|BEHAVIORAL|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
224283329|NCT02824887|OTHER|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
224283330|NCT02824887|OTHER|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
223929575|NCT06796933|OTHER|Silicon based products (silicon gel)|The participants will be treated with cosmetic creams such as Silicone-based products (silicone gels twice a day) for one month.
223929576|NCT06796933|DEVICE|Bioptron (polarized light therapy)|The participants will be treated by polarized light therapy (Bioptron) for 15 minutes, 3 sessions per week, for one month.
223532821|NCT01889992|DRUG|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
223929577|NCT06359782|DRUG|C1 Esterase Inhibitor Injection [Cinryze]|C1 Esterase Inhibitor Injection \[Cinryze\]
223929578|NCT06359782|DRUG|Placebo|Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
223929579|NCT06719544|DRUG|lithium carbonate|Oral capsule
223929580|NCT06719544|DRUG|enlicitide|Oral tablet
223929581|NCT04299191|DRUG|LAM561|"Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561."
223929582|NCT06835660|DEVICE|procedure of DCB implantation|Patients assigned to the DCB group (study group) will receive DCB inflation(s) at the level of the lesions according the DCB instructions for use (120 seconds inflation minimum). One or several DCBs will be inflated at the level of the lesions depending on lesions' lengths. The DCB diameter(s) will be the one(s) of the index diameter of the artery. Overlaps between zones that will receive DCB inflations will be of 10 mm to avoid any geographic miss.
223929583|NCT06835660|DEVICE|procedure of SEDES implantation|"SEDES implantation wille be performed according to the SEDES instructions for use. Stent(s) oversizing will be of 1 mm maximum. Overlaps between stents will be of 10 mm.~Completion angiogram will assess the technical success of the procedure (see endpoints definitions). The physician may then decide to add a bailout SEBMS because of flow limiting dissection and/or a new stenosis \>30%."
224283331|NCT00144079|PROCEDURE|external beam radiotherapy|
224283332|NCT03187587|DEVICE|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
224283333|NCT03187587|DRUG|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
224283334|NCT05363579|OTHER|Physiotherapy|Physiotherapy can be defined as a treatment method that focuses on the science of movement and helps people to restore, maintain and maximize their physical strength, function, motion and overall well-being by addressing the underlying physical issues.
224283335|NCT05363579|OTHER|Tuina therapy|Tuina is mainly applied to the meridians or acupoints by manipulation techniques such as pushing, grasping, pressing and rubbing of the soft tissues or muscles of the body. It is reported to improve circulation and the qi in the body.
224283336|NCT05363579|OTHER|Physio and Tuina therapy|Physiotherapy mixed with Tuina
224283337|NCT04598633|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
224283338|NCT04598633|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia) 2 times per day for 12 weeks
223929584|NCT06793501|OTHER|Reablement intervention|Reablement's implementation in this study is characterized by a comprehensive assessment of the older person's everyday activities, both current and past. This is done through a person-centered interview using the Canadian Occupational Performance Measure (COPM). The COPM is based on the assumptions described in the theoretical framework of CMOP-E. Based on the assessment, the older adult selects a personal activity goal, which consists of an activity they consider meaningful and wish to improve. In collaboration with the older adult and staff, a goal-oriented support plan, also referred to as a training program, is developed to achieve the goal. Nursing assistant staff support the older persons in performing defined training activities and receive supervision from rehabilitation staff. The support plan and progress toward the activity goal are evaluated through regular reassessments during a fixed intervention period of eight weeks.
223929585|NCT06793501|OTHER|Control group|TAU includes a general approach where all activities that the older adult engages in during everyday life are considered rehabilitative. The staff are encouraged to motivate the older adult to do as much as possible independently, in order to prevent loss of function and maintain the ability to perform activities. The approach does not involve any direction toward specific activities where there is a rehabilitative need. It does not include any formulated goals or follow-up. Additionally, there is no specific education offered to the nursing assistants on how to encourage the older adult or how to follow-up up on the extent to which the approach is applied.
223929586|NCT06845085|PROCEDURE|Intervention|pulmonary vein re-isolation plus Vein of Marshall ethanol ablation in combination with block of mitral and tricuspid isthmuses and dome line
223929587|NCT06845085|PROCEDURE|Control|pulmonary vein re-isolation
223929588|NCT06844981|BEHAVIORAL|Latin Dance|Latin Dance intervention
223929589|NCT06845267|BEHAVIORAL|Chronotherapy|This study utilize and test different combinations of three types of interventions (zeitgebers) to entrain the circadian rhythm: 1) Light being the primary photic zeitgebers that directly entrain the SCN, 2) physical activity and 3) timing of eating) being non-photic zeitgebers that drive peripheral rhythms.
223929590|NCT06845267|BEHAVIORAL|Control|Control condition
223929591|NCT06845709|OTHER|gaze stabilization exercise|Patients in group A will receive Gaze Stabilization Exercises with conventional baseline treatment
223929592|NCT06845709|OTHER|otago exercise|group B patients will receive Otago Exercises with conventional baseline treatment
223929593|NCT04707937|OTHER|Online education|Access to online modules about brachytherapy education in addition to receiving regular standard of care education
223929594|NCT04707937|OTHER|Regular standard of care education|Access only to regular standard of care education
223929595|NCT04003857|BIOLOGICAL|PNEUMOSTEM®|A single intratracheal administration of PNEUMOSTEM® (1.0 x 10\^7 cells/kg)
223929596|NCT04003857|BIOLOGICAL|normal saline|A single intratracheal administration of normal saline
223929597|NCT06815562|OTHER|Clinical team access to Placement Success Predictor (PSP) results|PSP is a machine-learning based clinical decision support tool that is designed to assist clinical team members in making placement decisions for youth.
224095069|NCT03401749|DRUG|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
224095070|NCT03401749|OTHER|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
224283339|NCT04983342|DEVICE|Apollo Armband|The Apollo armband is approximately the size of an Apple Watch and can be worn on the ankle, wrist, or arm with two adjustable fabric straps. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy, combatting fatigue and pain. In addition to the wearable, Apollo is a software system that curates music for the body, rather than for the ears.
224283340|NCT03237299|OTHER|Collection of data|Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
223532822|NCT01889992|PROCEDURE|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
223929598|NCT06725862|PROCEDURE|Retrolaminar Block (RLB)|This intervention involves administering 0.25% bupivacaine (0.1 mL/kg) into the retrolaminar space at the L4 vertebral level using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
223929599|NCT06725862|PROCEDURE|Caudal Block (CB)|This intervention involves administering 0.125% bupivacaine (1 mL/kg, maximum 20 mL) into the sacral canal using a 22-G insulated needle under ultrasound guidance in pediatric patients after induction of general anesthesia.
223929600|NCT01001364|DRUG|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
223929601|NCT01001364|DRUG|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
223929602|NCT06833385|DIAGNOSTIC_TEST|Intraoral Scanning|Participants will first undergo intraoral scanning using a digital scanner to capture a 3D image of their dental arches. The procedure is non-invasive and requires no impression material. After one week, the same participants will undergo a polyvinyl siloxane (PVS) impression using conventional impression trays and materials
223929603|NCT06833385|DIAGNOSTIC_TEST|PVS Impression|Participants will first undergo a polyvinyl siloxane (PVS) impression, where an impression tray filled with PVS material is used to capture the shape of their dental arches. After one week, the same participants will undergo intraoral scanning using a digital scanner for a 3D image of their dentition.
223929604|NCT05899153|DEVICE|Biomotum Spark: Robotic ankle resistance|Robotic ankle exoskeleton that provides resistance to ankle plantarflexion.
224283341|NCT03237299|OTHER|No collection of data|The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
224283342|NCT04220775|DRUG|Bintrafusp Alfa|Given IV
224283343|NCT04220775|OTHER|Quality-of-Life Assessment|Ancillary studies
224283344|NCT04220775|OTHER|Questionnaire Administration|Ancillary studies
224283345|NCT04220775|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224283346|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
224283347|NCT03749733|DRUG|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
224283348|NCT06300606|DEVICE|NOL monitoring|Prospective observational study to assess pain during regional anesthesia for upper limb orthopedic surgery using NOL monitoring and the Algoplus pain scale
224283349|NCT04756778|PROCEDURE|Aortic surgery +/- aortic valve replacement|Replacement of aneurysmal proximal thoracic aorta +/- replacement of diseased bicuspid aortic valve
224283350|NCT04362332|DRUG|Chloroquine Sulfate|cluster randomized
224283351|NCT04362332|DRUG|Hydroxychloroquine|cluster randomized
224283352|NCT04362332|OTHER|Standard supportive care|cluster randomized
224283353|NCT05303961|DRUG|SA001 240mg + Rebamipide 200mg or Placebo|Cohort 1 in the Part1(Single dose): Study drug(SA001 240mg + Rebamipide 200mg), Comparator: Placebo
224283354|NCT05303961|DRUG|SA001 480mg or Placebo|Cohort 2 in the Part1(Single dose): Study drug(SA001 480mg), Comparator(Placebo)
224283355|NCT05303961|DRUG|SA001 710mg + Rebamipide 600mg or Placebo|Cohort 3 in the Part1(Single dose): Study drug(SA001 720mg + Rebamipide 600mg), Comparator(Placebo)
224283356|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 4 in the Part1(Single dose): Study drug(SA001 1,080mg), Comparator(Placebo)
224283357|NCT05303961|DRUG|SA001 360mg or Placebo|Cohort 5 in the Part2(Multiple dose): Study drug(SA001 360mg), Comparator(Placebo)
223929605|NCT05899153|DEVICE|Audiovisual Biofeedback|Electromyography recordings from the plantarflexor muscles are used to provide audio feedback via a sound that plays when muscle activity is above target and a visual bar that displays real-time muscle activity.
224095071|NCT03804151|BEHAVIORAL|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
224095072|NCT05490992|OTHER|Behavioral Skills Training In-person|"Both an in-person and virtual telehealth version of Behavioral Skills Training (BST) was compared to the Car seat check-up traditional car seat educational method and BST telehealth was compared to BST in-person."
224095073|NCT05987215|COMBINATION_PRODUCT|Radiologic diagnosis|Each CT scan is interpreted by a radiologist and is assigned as positive or negative for the diagnosis of otosclerosis
224095074|NCT05987215|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Each CT scan is screened by the deep learning algorithm and is assigned as positive or negative for the diagnosis of otosclerosis
224095075|NCT01418755|BIOLOGICAL|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
224095076|NCT00432809|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
224095077|NCT00432809|PROCEDURE|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
224095078|NCT05199584|DRUG|ENV-101 (taladegib)|tablets dosed once-daily
224095079|NCT03142607|DRUG|Metronidazole gel|1% Metronidazole gel
224095080|NCT03142607|DRUG|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
224283358|NCT05303961|DRUG|SA001 720mg or Placebo|Cohort 6 in the Part2(Multiple dose): Study drug(SA001 720mg), Comparator(Placebo)
224283359|NCT05303961|DRUG|SA001 1,080mg or Placebo|Cohort 7 in the Part2(Multiple dose): Study drug(SA001 1,080mg), Comparator(Placebo)
224283360|NCT03307811|OTHER|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
224283361|NCT01432028|DRUG|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
224283362|NCT01432028|DRUG|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
224283363|NCT00004988|DRUG|VNP20009|
224283364|NCT00089076|BIOLOGICAL|ipilimumab|Given IV
224283365|NCT00089076|OTHER|laboratory biomarker analysis|Correlative studies
223929606|NCT05899153|PROCEDURE|Multilevel Orthopedic Surgery|Musculoskeletal surgeries to address alignment, contracture, and other lower-extremity impairments. This study does not impact surgical decision making but evaluates changes in gait before and after surgery.
224283366|NCT06216171|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy
223929607|NCT06747897|DEVICE|MINERAL OIL + PETROLATUM (DIPROBASE® Advanced Eczema Cream, BAY987534, UI 1613882)|Product experience is assessed based on the answers provided by participants on the questions provided to them using an online questionnaire.
223929608|NCT06815315|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation|The multiple micronutrient supplementation composition follows the United Nations International Multiple Micronutrient Antenatal Preparation. Each MMS tablet contains 15 micronutrients, including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg) and is consumed daily.
223929609|NCT06815315|DIETARY_SUPPLEMENT|Iron Folic Acid Supplementation|One IFAS tablet contains Iron (60 mg) and Folic Acid (2800 μg) and is taken weekly.
224095081|NCT04810273|BEHAVIORAL|Early progressive mobilization|The goal will be to achieve a mobilization level of at least Level III (sitting on the edge of bed) during the ICU stay (within 7 days).
224095082|NCT04980131|DEVICE|Pointed lotus root regulator and guide template aided PPSF|20 patients in group C received PPSF with pointed lotus-style regulator
224095083|NCT04980131|DEVICE|Flat ended lotus root regulator and guide template aided PPSF|20 patients in group B received PPSF with flat ended lotus-style regulator
224095084|NCT03860506|DRUG|PSI-697|
224095085|NCT03860506|DRUG|Placebo|
224095086|NCT03075839|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes for a period of two weeks
224095087|NCT04748029|OTHER|Systemic immune inflammation index|The systemic immune inflammation index (SII) was calculated using the formula, SII = platelet count x neutrophil count / lymphocyte count. Systemic immune inflammation index (SII) is a new index related to systemic inflammation calculated by the numbers of lymphocytes, neutrophils and platelets in peripheral blood.
224095088|NCT05878509|OTHER|conducting questionnaires|The patients were administered TSK, Pain Catastrophizing Scale (PCS), Beck Anxiety Inventory (BAI) by face to face interview technique.
224283367|NCT06216171|RADIATION|image guided radiotherapy without online adaptation|image guided radiotherapy without online adaptation
224283368|NCT03285464|OTHER|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
224283369|NCT00931463|DRUG|raltegravir|400 mg raltegravir tablet taken every 12 hours
224283370|NCT00931463|DRUG|2N(t)RTI|2N(t)RTIs as prescribed
224283371|NCT00931463|DRUG|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
224283372|NCT02802215|DRUG|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
224283373|NCT02802215|DRUG|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
223929610|NCT06815315|BEHAVIORAL|Adolescent Nutrition Curriculum|The Adolescent Nutrition Curriculum includes five modules focused on promoting healthy behaviors to enhance nutrition, with an emphasis on consuming iron-rich foods.
223929611|NCT00743951|BEHAVIORAL|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
223929612|NCT00743951|BEHAVIORAL|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
224095089|NCT05878509|OTHER|assesment of the severity and pain|The Modified Hand Injury Scoring System (MHISS) to determine the severity of the injury, and Visual Analog Scale (VAS) to evaluate perceived pain levels were used.
224095090|NCT04613011|DEVICE|Ultrasound|Checking vein width snd copression using US
224095091|NCT04433117|BIOLOGICAL|Shefabone|Silica-calcium phosphate composite.
224283374|NCT03327350|DEVICE|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
224283375|NCT03327350|DRUG|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
224283376|NCT04053673|DRUG|RBN-2397|an oral PARP7 Inhibitor
224283377|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
224283378|NCT02666027|DEVICE|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
224283379|NCT03822273|PROCEDURE|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
224283380|NCT03822273|PROCEDURE|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
224283381|NCT03822273|PROCEDURE|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
224283382|NCT02625376|DIETARY_SUPPLEMENT|Resvega|Dietary supplementation with Resvega BD
224283383|NCT02625376|DIETARY_SUPPLEMENT|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
224283384|NCT02625376|DIETARY_SUPPLEMENT|placebo|Dietary supplementation with a placebo BD
224283385|NCT04381676|OTHER|Flipped Classroom Approach|In the Flipped Classroom, participants form groups of 2-3 and are instructed to work together through clinical cases of the in-class case based activity, committing to group answers to the clinical questions before advancing to the next case. At the end of class, the faculty instructor facilitated a short interactive group discussion.
224283386|NCT01410760|OTHER|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
224283387|NCT05529368|BEHAVIORAL|Conventional Exercise and Tai Chi Exercise interventions|Subjects diagnosed with IAD were randomly assigned to the exercise group, the tai chi group, or the control group. The exercise group and tai chi group received conventional exercise and tai chi for 8 weeks.
224095092|NCT04433117|BIOLOGICAL|Bio-Oss|Xenograft Bone substitute. Bone from animals.
224095093|NCT01073150|DRUG|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
224095094|NCT04833036|DRUG|Irinotecan|180 mg/m2, ivgtt d1，q2w
224095095|NCT04833036|DRUG|cetuximab|500 mg/m2, ivgtt d1，q2w
223929613|NCT06849141|OTHER|Role Performance Strenghthening Program|This intervention was developed by the researcher within the scope of her doctoral dissertation. The intervention is an individual psychoeducation program; it was written and structured within the framework of cognitive behavioral therapy, based on the Roy Adaptation Model. The intervention was structured on the idea of empowering nurses working in pandemic units.
223929614|NCT06393725|BEHAVIORAL|Asynchronous Remote Lifestyle Intervention|A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered asynchronously via a private Facebook group led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
223929615|NCT06393725|BEHAVIORAL|Synchronous Remote Lifestyle Intervention|A 1 year lifestyle intervention based on the Diabetes Prevention Program to be delivered synchronously via weekly videoconference group meetings led by a professional weight loss counselor. In the subsequent year, a Peer-Led Maintenance Phase will occur in which a participant volunteer will lead the group after receiving a brief training.
223929616|NCT06803303|DEVICE|sonoelastography|"Sonoelastography examination\[10,11\] will be performed using (GE logiqs8,) device system with a high-frequency (a 5-12 MHz linearMHz) linear probe. The procedure will be carried out by a radiologist , who is blinded to the MRI results.~Magnetic resonance imaging (MRI) \[12\] will be performed on the patients in our radiology department using a Philips Achieva 1.5 Tesla superconducting magnet (The Netherlands), shoulder joint MRI protocol included several imaging sequences, included coronal oblique T1 and T2 weighted fast spin-echo, coronal oblique proton density fat suppressed, oblique sagittal T2-weighted spin-echo and axial T1-weighted spin-echo Image evaluation will be conducted by experienced musculoskeletal radiologist, Then we correlate results of sonoelastography to that of MRI ."
223929617|NCT00115934|PROCEDURE|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
223929618|NCT00115934|PROCEDURE|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
223929619|NCT03646292|DRUG|Pioglitazone|The investigators will compare the degree of liver fat before and after pioglitazone monotherapy.
223929620|NCT03646292|DRUG|Empagliflozin|The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.
223929621|NCT03646292|DRUG|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.
223929622|NCT03710928|OTHER|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
223929623|NCT03710928|OTHER|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
223929624|NCT06850532|OTHER|IGF-1|The effects of NMES coupled with HIIT and MICT on IGF-1 and substrate metabolism has not been studied earlier.
223929625|NCT06846190|OTHER|mCIMT|mCIMT+ Hot pack will be applied and unaffected hand will be immobilized by a volar resting splint extending from finger tips to the proximal forearm. Use splint every day for at least 5 waking hours daily for 4 weeks and perform daily activities. Program of mCIMT every other day, 3 times per week during a 4-week period.
223929626|NCT06846190|OTHER|VR|VR+ Hot pack will be applied. 25 minutes of VR program, every other day, 3 times per week for 4 weeks. Each VR session continued for 10 minutes then 5 minutes rest after that again 10 minutes VR session will do.
223929627|NCT06846502|PROCEDURE|Pulmonary vein isolation|Compared to conventional radiofrequency (RF) ablation, which is performed with a power set of 30-40 Watt for a duration of 20-30 seconds, ablation with higher power and shorter duration (vHPSD, 90W/4sec) may result in more continuous and more durable ablation lesions with a similar safety profile, while reducing procedure duration.
223929629|NCT06844747|OTHER|erector spinae plane block(ESPB)|ESPB group received US-guided plane block, WI group received local anaesthetic wound infiltration
223929630|NCT06846021|OTHER|Disease status|According to the disease status, patients are divided into four groups including healthy donors, initial patients with high activity, patients with deformities and patients with clinical remission
223929631|NCT06818955|DRUG|Orlistat 120 mg|Orlistat 120 mg po tid
223929632|NCT06459388|OTHER|Stabilizing Reversals and Rhythmic Stabilization|3 sets with 15 repetitions in each session, 5 days per week for 8 weeks.
223929633|NCT06459388|OTHER|Pelvic Proprioceptive Neuromuscular Facilitation|The treatment protocol will be followed 5 days a week for 8 weeks (i.e. 20 sessions) and each session will last for 30 minutes.
223929634|NCT06293651|DRUG|DA-4505|Phase 1a: Dose escalation Phase 1b: OBD and MTD Phase 2a: RP2D
223929635|NCT06293651|DRUG|DA-4505 + Pembrolizumab|Phase 1a/b: OBD, MTD of DA-4505 + 200mg of Pembrolizumab Phase 2a: RP2D of DA-4505 + 200mg of Pembrolizumab
223929636|NCT04040764|PROCEDURE|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
223532823|NCT01889992|GENETIC|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
224095096|NCT03758586|OTHER|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
223929637|NCT06802484|OTHER|Experimental: Pre-Menopausic|The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
223929638|NCT06802484|OTHER|Experimental: Post- Menopausic|The physical exercise program, lasting for 26 weeks, was conducted with an uninterrupted weekly frequency of 3 sessions, on non-consecutive days, in the late afternoon (at 7:30 PM), each lasting 60 minutes.
223929639|NCT06802614|DEVICE|BLEACHING GEL A|Carbomer 940 hydrogel + 6% Hydrogen Peroxide
223929640|NCT06802614|DEVICE|5% NF_TiO2|Bioactive nanoparticles
223929641|NCT06802614|DEVICE|BLEACHING GEL B|Hyaluronic Acid hydrogel + 6% Hydrogen Peroxide
223929642|NCT06802614|RADIATION|VISIBLE LIGHT IRRADIATION|Low intensity visible light irradiation (405 nm)
223929643|NCT06802614|DEVICE|Whiteness HP 35%|Commercially available bleaching gel
223929644|NCT06802614|DEVICE|Whiteness HP Automixx 6%|Commercially available bleaching gel
223929645|NCT06804174|OTHER|use of gonadotropins|Comparison of endometrial proteome during the window of implantation between stimulated and spontaneous cycles.
223929646|NCT06267924|DEVICE|Otoband Experimental|Participants will be randomly assigned to use the Otoband Experimental device to determine effectiveness in providing temporary relief to symptoms of vertigo.
224095097|NCT03758586|OTHER|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
224095098|NCT03360812|OTHER|Online training resource|Please see information included in the description of the intervention group.
224095099|NCT00839631|DRUG|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
223929647|NCT06267924|DEVICE|Otoband Sham|Participants will be randomly assigned to use the Otoband Sham device to determine effectiveness in providing temporary relief to symptoms of vertigo.
224095100|NCT00558090|DRUG|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
224095101|NCT00707577|BEHAVIORAL|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
223929648|NCT05599048|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
224095102|NCT03853694|DRUG|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
223929649|NCT05599048|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging procedure
223929650|NCT05599048|DRUG|13C,15N-Urea|Given IV
224283388|NCT03170869|DEVICE|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
224283389|NCT02314494|BEHAVIORAL|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
224283390|NCT02495376|BEHAVIORAL|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
223929651|NCT06804369|BEHAVIORAL|Intensive psychodynamic therapy (PDT)|The KLIPP treatment unit (UPC KU Leuven, campus Kortenberg) provides intensive psychodynamic treatment (PDT) for patients with different types of PDs. There are three different programs that differ in treatment intensity: (1) inpatient treatment program (5 days a week), (2) day treatment program (4 days a week), and (3) a part-time outpatient treatment program of two half days per week. Patients attend one of these programs and stay in the program for at least 6 months (with an average duration of 8 months). The programs include individual and group psychodynamic psychotherapy as well as art, music and psychomotor therapy.
223929652|NCT06753422|DIETARY_SUPPLEMENT|Kefir|"200 ml/day kefir~The primary intervention in our study is the daily consumption of kefir (200 ml/day). No additional drug or medical device was used during the intervention or data collection process. The study focused solely on kefir consumption and its effects on athletic performance and gut microbiota."
223929653|NCT06744114|DIAGNOSTIC_TEST|Consciousness in the Emergency Department|To determine the common and definitive etiologies of altered level of consciousness in emergency department.
223929654|NCT06892951|DRUG|Caspofungin Acetate 50 MG|The experimental treatment will be administered once daily for up to seven days, through the nebulization route by the means of a disposable vibrating mesh Aeroneb solo® nebulizer with the valved mask (Galway, Ireland). Before generating aerosol, resuspension of the caspofungin powder will be carried out in the same manner than for the IV route, into 10.5 mL saline serum. Preparation of the experimental drug (re-suspension) will be unblindly carried out in a distinct medical office by a nurse neither involved in the healthcare of the included patients, nor in the other parts of the study, data recording or outcome assessment. Once reconstituted, the suspension is expected to be limpid, with neither odour nor foam. Thereafter, its administration will be blindly completed by the clinical staff in charge of the enrolled patient.
224095103|NCT03853694|DRUG|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
224095104|NCT03853694|DRUG|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
224283391|NCT02828280|DEVICE|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
224283392|NCT02828280|DEVICE|Traditional mask|A traditional air inflated facemark used to ventilate patients
224283393|NCT00116480|DRUG|Misoprostol|600 mcg of sublingual misoprostol
224283394|NCT02064140|DRUG|Rocuronium|
224283395|NCT06165692|BIOLOGICAL|PRF|Post-operative PRF placement in the post-extraction socket after third molar surgery
223929655|NCT06892951|DRUG|Physiologic saline|Procedures will be exactly the same than those described above for the experimental group, but caspofungin will be replaced during the seven days of intervention by 10mL of 0.9% saline nebulized in the control group for a 15 minute-long process of nebulization (from d-1 to d-7).
223929656|NCT05338632|DRUG|Narcan 40 MG/ML Nasal Spray|naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
223929657|NCT05338632|DRUG|Naloxone Hydrochloride|Naloxone 0.4mg/mL
224283396|NCT03884725|DRUG|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
223929658|NCT05338632|DRUG|Nalmefene HCl injection|Nalmefene 1 ng/mL
223929659|NCT06892886|DEVICE|Virtual Reality|Four tasks, uni and bi-manuals, will be proposed for the treatment of the patient's paretic upper limb in virtual-apartment for improving the relevance and the transferability of the movements requested.
223929660|NCT06895044|OTHER|ophtalmologic follow-up|alls exams included in ophtalmologic follow-up every 6 months for 5 years
223929661|NCT06895044|OTHER|ophtalmological follow-up|all exams included in ophtalmological follow-up including axial length mesurment every 6 moths
223929662|NCT06742658|OTHER|Rapid Move|A short-stay PACU where patients recover from anaesthesia, are continuously monitored, and prepared for discharge within an hour after surgery.
223941120|NCT03689946|DRUG|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
223941121|NCT03689946|DIAGNOSTIC_TEST|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
223941122|NCT03689946|DIAGNOSTIC_TEST|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
223941123|NCT03689946|DRUG|Omnipaque|contrast agent for CCTA
223941124|NCT03689946|DRUG|Metoprolol|beta blocker to optimize heart rate during CCTA
223941125|NCT03689946|DRUG|Nitroglycerin|premedication for CCTA
223941126|NCT01673399|DRUG|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
223941127|NCT01673399|DRUG|placebo|
223941128|NCT00252005|DRUG|Apixaban|
223941129|NCT04788810|OTHER|Administration of d12-Cl2BPA|Administration of d12-Cl2BPA
223941130|NCT03376659|DRUG|Durvalumab|750mg IV q2 weeks
223941131|NCT03376659|BIOLOGICAL|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
223941132|NCT03376659|DRUG|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
223941133|NCT03376659|DRUG|Bevacizumab|5mg/kg IV q2weeks
223941134|NCT01681823|DIETARY_SUPPLEMENT|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
223941135|NCT00942344|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
223941136|NCT00942344|DRUG|Amlodipine|amlodipine 5mg, 10mg
223941137|NCT00942344|DRUG|Losartan|Losartan 50mg, 100mg
223941138|NCT05135234|BEHAVIORAL|Muscular Exercise|Sedentary time (muscular inactivity when sitting) will be replaced with low effort muscular activity
223941139|NCT01801800|PROCEDURE|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
223941140|NCT01223274|DEVICE|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
223941141|NCT01223274|DEVICE|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
223941142|NCT04969666|DRUG|IPED2015|Active treatment
223941143|NCT04969666|DRUG|Placebo|Placebo
223941144|NCT01784328|DEVICE|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
223929663|NCT06748482|BEHAVIORAL|Counseling|a 15-minute-consultation session with the clinical pharmacist will include detailed and personalized advice on how each patient should take his prescribed medications, the best time to take them, the possible drug-drug interactions, the possible adverse effects such as post operative nausea and vomiting (PONV), bleeding, fever and infection and the required action. A written paper outlining the main points including the detailed protocol with times and doses will be handed to the patient at the end of the consultation. Moreover, a recorded voice note with the detailed protocol will be sent to the patients via the WhatsApp application
223929664|NCT06749782|RADIATION|TC|Radiation: Computed Tomography (CT)
223929665|NCT06744517|OTHER|Sprint Interval Training|6 sessions of sprint interval training over 2 weeks. Each session involves 4-6 x 30 second Wingate sprints with 4 minutes of recovery in between on a stationary bike
223929666|NCT06754553|BEHAVIORAL|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
223929667|NCT06754553|BEHAVIORAL|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
223929668|NCT06754553|BEHAVIORAL|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) administered at day 0, day 28 (Week 4) and day 56 (Week 8)
223929669|NCT06754553|BEHAVIORAL|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) administered at day 0 and day 56 (week 8)
223929670|NCT06754553|BEHAVIORAL|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) assessed at day 0
223929671|NCT06754553|BEHAVIORAL|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) administered at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
223929672|NCT06754553|PROCEDURE|Cardiac monitoring|Electrocardiogram realized at day 0, 28 and 56.
223929673|NCT06766331|OTHER|Integrated care|Receipt of infectious diseases laboratory testing and/or PrEP for HIV within a single substance use disorder clinic appointment.
223929674|NCT06760117|DRUG|Irinotecan (CPT-11)|Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.
223929675|NCT06760117|DRUG|Temozolomide (TMZ)|TMZ：100mg/m2/d，d1-5
223929676|NCT06760117|DRUG|Vincristine|VCR: 1.5mg/m2/d(≯2mg), d1
224095105|NCT02934607|DRUG|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
224095106|NCT02934607|DRUG|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
223929677|NCT06766513|OTHER|Actimetry|actimetry will be performed continuously during these 104 hours.
223929678|NCT06766513|OTHER|Subjective assessments|The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).
223929679|NCT06766513|OTHER|questionnaire|MOCA : Montreal Cognitive Assessment
223929680|NCT06766513|OTHER|questionnaire|SF-36 The Short Form (36)
223929681|NCT06766513|OTHER|questionnaire|CRS-R (Coma Recovery Scale-Revised)
223929682|NCT06766513|OTHER|questionnaire|GOSE (Glasgow Outcome Scale-Extended)
223929683|NCT06766513|OTHER|questionnaire|GCS (Glasgow Coma Scale)
223929684|NCT06847581|DEVICE|JAME|JAME is a wearable device able to monitor movements of the upper limbs and, through an ad-hoc algorithm based on machine learning, can recognize tremor and suppress it through TENS
223929685|NCT06347601|OTHER|Without Intervention|Without Intervention
223929686|NCT06649864|DRUG|Autologous adipose derived mesenchymal stromal cells (AMSC)|Adipose derived autologous mesenchymal stromal cells; \[\~500,000 cells/cm2\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.
223929687|NCT05917522|BIOLOGICAL|Abatacept|Injection: 125 mg/mL of a clear to slightly opalescent, colorless to pale-yellow solution in a single-dose prefilled ClickJect autoinjector
223929688|NCT05917522|PROCEDURE|Standard of Care at US Transplant Centers|Control group, remaining on SOC (Tacrolimus/ Mycophenolic Acid (MPA)/ Prednisone (Pred))
223929689|NCT01251562|DRUG|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
223929690|NCT03295773|DIAGNOSTIC_TEST|3DRA|
223929691|NCT05661682|DRUG|Tralement|Tralement with Manganese Sulfate
223929692|NCT05661682|DRUG|Fixed-dose trace element combination product of zinc, copper, and selenious acid|Tralement without Manganese Sulfate
224095107|NCT05089708|DRUG|Trifarotene Cream|Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream on the face once daily, in the evening for 24 weeks
224095108|NCT05089708|DRUG|Trifarotene Vehicle Cream|Participants will apply a thin a layer of trifarotene vehicle cream on the face once daily, in the evening for 24 weeks
224095109|NCT01819792|OTHER|Multiplex respiratory viral PCR|
224095110|NCT04265391|DIETARY_SUPPLEMENT|cookies|Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
224095111|NCT00227058|DRUG|Orotic acid and Glutathione-(Nutritional Supplements)|
224095112|NCT02038062|PROCEDURE|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
223532824|NCT01889992|OTHER|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
223532825|NCT03759496|BIOLOGICAL|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
223532826|NCT05557396|OTHER|Internal Tube Length Measurement Procedures for Nazogastric Tube|Different Internal Tube Length Measurement Procedures will used for the correct placement of nasogastric tube.
223929693|NCT06491381|PROCEDURE|Cesarean delivery|The cesarean section will begin with a Pfannenstiel incision above the pubic bone, followed by blunt dissection to separate tissue layers and retracting the rectus muscles for peritoneal cavity access. A transverse or vertical peritoneal incision will expose the uterus, and a transverse incision on the lower uterine segment will be made for delivery. The baby will be delivered, the umbilical cord clamped and cut, and the baby handed to the pediatric team. The placenta will be detached and delivered, and the uterus will be closed with multiple layers of sutures. The abdominal layers will be closed with absorbable Polyglactin (Vicryl) sutures for the rectus sheath and subcutaneous tissue, and non-absorbable Polypropylene sutures for the skin. A sterile dressing will be applied to protect the wound and promote a clean healing environment, ensuring proper surgical technique, tissue handling, and minimizing post-operative complications.
223929694|NCT06439823|DEVICE|ActiMyo®/Syde®|Subjects will be equipped with magneto-inertial sensors (ActiMyo®/Syde®) and passive reflective markers belonging to the MoCap® motion capture system.
223929695|NCT06282055|OTHER|No intervention|Observational prospective longitudinal data collection
223929696|NCT06613867|OTHER|Wakobotikodro|Wakobotikodro : an intervention combining (i) training matrons to identify and monitor high-risk pregnancies, (ii) integrating them into the healthcare system and (iii) using a digital decision-support application installed on a smartphone and adapted to their profile, could improve the identification and monitoring of high-risk pregnancies.
223929697|NCT03999983|OTHER|Observational Prospective Registry|This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
223929698|NCT06761235|DIAGNOSTIC_TEST|Standard BP intervention|Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure.
223929699|NCT06761235|DIAGNOSTIC_TEST|EVA intervention|Behavioral: lifestyle counseling will be given according to international guidelines to reduce blood pressure. In contrast to BP arm, EVA arm will additionally reciuve counseling about vascular age.
223929700|NCT06762522|OTHER|Nonlinear dynamical neurofeedback (NLD)|NeurOptimal nonlinear dynamical (NLD) neurofeedback brain training works as a detection and monitoring system of changes in cortical patterns within the brain, mirroring the brain activity that can be undermining optimal brain function, providing the brain with the information it needs to make its own adjustments which over time results in the brain functioning more efficiently and effectively. Two scalp sensors at C3 \& C4 and two earclips at tops of ears (reference) and one on the earlobe (ground) are used to read EEG activity which is analyzed by the NeurOptimal software. As participants listen to music through earbuds, information is fed back to the individual by slight interruptions in the music. One session lasts 33.5 minutes.
223929701|NCT06762522|OTHER|Low energy neurofeedback system (LENS)|Low energy neurofeedback system (LENS) therapy is an EEG-based direct neurofeedback system that stimulates the brain to reset itself and achieve optimal performance. Therapy consists of delivery of a tiny electromagnetic field carrying the feedback signal down the electrode wires for only one second at each of the chosen electrode sites during every session. Generally, between one and seven of the ordinary electrode sites are utilized during each session. Therapy is adapted to the participant's reactivity/sensitivity and the response of their nervous system.
223929702|NCT06762522|OTHER|Brain Music|Chen Medimo Corp (CMC) Brain Music neurofeedback analyzes an individual's EEG brainwave patterns and translates them into orchestral music. Listening to this personalized brain music allows the individual to gain self-awareness and rewire and alter their own mental states. The Brain Music protocol requires regular in-person follow-ups for optimal results. Generally, the number of sessions varies based on individual needs and the progress made in response to the CMC Brain Music. A minimum of once a week in-person sessions is recommended for qEEG model updating to accurately track progress. Each session may last 30 minutes. Additionally, participants are advised to listen to their personalised music at least once a day, with a minimum of two listens per session. In general, participants may start to detect a change in their neurodevelopmental or cognitive function in 4-6 weeks.
223929703|NCT06762522|OTHER|Usual Care|The Usual Care control group will be followed in the Memory clinic at intervals determined by their clinician. Usual Care for individuals with mild cognitive impairment (MCI) at the The Memory Clinic consists of inter-professional assessment, diagnosis and recommendations. There are currently no drugs approved to treat MCI. Therapy is aimed at managing treatable causes and contributors including medication side effects, thyroid problems, sleep apnea, vitabim B deficiency, depression, anxiety, and unrecognized or untreated difficulties with hearing or vision. Neurofeedback is not a component of the standard of care.
223929704|NCT06761820|DEVICE|Echocardiogram|Echo : for evaluation anatomical and functional alteration LV and diastolic dysfunction and myocardial reserve measure by LVEF by M-mode before the study and follow up echo assessment 3 months after glycemic control
223532827|NCT04487444|DRUG|Thymalfasin|Synthetic 28 amino acid peptide identical to naturally circulating compound
223532828|NCT02018211|OTHER|control|passive recovery following exercise test
223532829|NCT02018211|DEVICE|graduated compression socks|graduated compression socks worn after test exercise
223532830|NCT02018211|DEVICE|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
223532831|NCT01937065|OTHER|No treatment|
224095113|NCT06137352|OTHER|Follow up|Each subject was recruited in 30-60 days after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, and followed up at 12 months (window period ± 1 month) and 36 months (window period ± 1 month) after the last dose of domestic bivalent HPV vaccine or imported HPV vaccine, with a total of two follow-up visits. At enrollment and both follow-up visits, subjects were required to collect 2 tubes of peripheral venous blood each.
224095114|NCT03333577|DEVICE|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
224095115|NCT01768299|DRUG|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
224095116|NCT01768299|DRUG|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
224095117|NCT02209766|DRUG|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
223532832|NCT01020357|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
223929705|NCT06199349|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
224283397|NCT03884725|OTHER|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
224283398|NCT04608201|DRUG|Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour|"Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)"
223929706|NCT06199349|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
224283399|NCT04608201|DRUG|Placebo of NICOTINE Transdermal patch|Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
223532833|NCT01020357|DRUG|placebo|normal saline
223929707|NCT06779643|DEVICE|General Anesthesia (GA)|Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
224095118|NCT02209766|DRUG|Placebo|"1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
224283400|NCT05337644|DRUG|Indocyanine green solution|"5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration."
223532834|NCT05821855|DEVICE|XEN45 Glaucoma Treatment System|Ab interno implantation
223532835|NCT05821855|PROCEDURE|Trabeculectomy|Surgical Intervention
223929708|NCT06779643|DEVICE|Continuous Brachial Plexus Block|Patients were positioned supine with the head slightly turned to the contralateral side to expose the supraclavicular fossa. The injection site was prepared using standard aseptic techniques. Under ultrasound guidance, a needle was advanced to the vicinity of the brachial plexus. Aspiration was performed to confirm the absence of blood return before the slow, incremental injection of either liposomal bupivacaine \[adult dose: 133 mg (10 mL) to 266 mg (20 mL)\] or ropivacaine \[adult dose: 20 mL of 0.5% ropivacaine, administered via continuous infusion at a rate of 5-10 mL/h; pediatric dose: 0.1% ropivacaine at 0.1-0.2 mL/kg, administered via continuous infusion at 0.05-0.15 mL/kg/h\]. Patient responses were closely monitored throughout the procedure.
223929709|NCT06738953|BEHAVIORAL|Cognitive-Behavioral Intervention to increase Self Efficacy|Participants in the intervention group will receive a brief (6 sessions of 75-90 min each) cognitive-behavioral intervention. The intervention will be delivered in an online group format (subgroups of 8-12 participants). The courses will be structured according to well-established self-efficacy interventions with proven effectiveness (Bresó et al., 2011; Cieslak et al., 2016; Luszczynska et al., 2007), targeting Bandura's four key sources of self-efficacy (i.e., mastery experience, vicarious experience, verbal persuasion, and physiological/emotional arousal). Each session will consist of a theoretical and a practical part and be structured as follows: opening, discussion of homework (with special emphasis on participants' progress and sharing of experiences), introduction to the topic, practice, answering open questions, closing. The course sessions are accompanied by weekly homework assignments to be completed at home.
223929710|NCT06738953|BEHAVIORAL|Placebo: Weekly Recap and Group Discussion on Psychological Experiments|Participants in the control group will meet in small groups (8-12 participants per group; 6 sessions, similar to the intervention group). They will receive a brief introduction to well-known psychological experiments and findings (e.g., the Asch experiment, selective attention) and discuss their perspectives on these topics, including personal implications of the experiments. Content related to self-efficacy or cognitive-behavioral interventions will be explicitly avoided. To prevent expectancy effects and other biases, participants will not be informed that they are part of the control group. If suspicions arise, participants will be told that group leaders are not allowed to disclose this. Group sessions will be led by a psychologist. The course materials (workbook, slides, and course instructions) will be shared on OSF.
223929711|NCT06843993|BIOLOGICAL|MK-2060|Single doses of MK-2060 administered via IV infusion on Day 1 according to randomization.
223929712|NCT06843993|BIOLOGICAL|Placebo|Single doses of placebo administered via IV infusion on Day 1 according to randomization.
223929713|NCT01207336|DEVICE|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
223929714|NCT06134453|OTHER|Reiki/Sham Reiki|Reiki will be applied to the patients by the research nurse who is at the Reiki master level. Sham Reiki will remain in the same position and for the same duration as if Reiki was performed by a healthcare professional who has not received Reiki training, but Reiki energy will not be given to the patient. No intervention will be made to the control group.
223929715|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
223929716|NCT06524804|RADIATION|palliative radiotherapy|Undergo palliative radiotherapy
223929717|NCT06524804|DRUG|BY101298 Capsules|An oral DNA-PK Inhibitor
223929718|NCT06524804|RADIATION|curative radiotherapy|Undergo curative radiotherapy
223929719|NCT06229106|DEVICE|Symfony IOL|The Symfony IOL is a lens designed to provide high quality vision up tp 26 inches reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
223929720|NCT06229106|DEVICE|Vivity IOL|The Vivity IOL is a lens that provides extended range of vision ranging from distance to near reducing the need for glasses after routine cataract surgery in patients with or without astigmatism.
223929721|NCT06841978|DRUG|Intravenous Thrombolysis|Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
223929722|NCT03399500|BEHAVIORAL|In-Person Case Management at Homeless Recovery Program|In-Person Case Management at Homeless Recovery Program
223929723|NCT03399500|BEHAVIORAL|Unlimited Smartphone|Smartphone with unlimited calls, texts, and data plan
223929724|NCT03399500|BEHAVIORAL|Smartphone Based Case Management (SPCM) app|Smartphone Based Case Management app
223532836|NCT00642044|PROCEDURE|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
223532837|NCT04313465|OTHER|Immediate discharge|Participants discharged after initial blood test for cardiac troponin and risk stratification using the T-MACS decision aid
223929725|NCT06818136|DIAGNOSTIC_TEST|Bladder EpiCheck|The participant will provide a voided urine sample, which will be tested using the Bladder EpiCheck test. The clinical care team and the participant will not be informed of the result, and the standard of care will not change.
223532838|NCT05159674|DEVICE|Dexmedetomidine+electroacupuncture compound anesthesia|Dexmedetomidine and acupuncture were given together to induce anesthesia
223532839|NCT05428644|BEHAVIORAL|massage therapy|In addition to the standard nursing care of the hospital, individuals in the reflexology hand massage and placebo hand massage group will be given a 10-minute massage for both hands, a total of 20 minutes, after the extubation procedure.
223532840|NCT02068144|DIETARY_SUPPLEMENT|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
223929726|NCT06885346|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
223929727|NCT06885346|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
223929728|NCT06234631|DRUG|Epidiolex oral solution|"Participants assigned to CBD will take the medication one hour before or two hours after eating a meal.~If participants can't tolerate the full-strength dose, the participant can decrease the dosing to 0.75 milliliter twice a day. If this is still not well tolerated, dosing can further be decreased to 0.75 milliliter once per day in the evening."
223929729|NCT06234631|OTHER|Placebo|Participants will be instructed to take one hour before or two hours after eating a meal.
223929730|NCT06790797|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
223929731|NCT06745505|PROCEDURE|Bowel Preparation|Group A received bowel preparation and Group B did not.
223929732|NCT06329245|OTHER|Do not take any interventions|Do not take any interventions
223929733|NCT06791811|OTHER|OFA|"Prior to the induction of anesthesia the patients in OFA group will receive Dexmedetomidine loading dose 1 μg/kg i.v. infusion, and Lidocaine loading dose 1.5 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine will be prepared in a 20 ml syringe and infused over 10 minutes prior to induction.~Then after induction maintenance drugs will be infused as follow:~Dexmedetomidine 0.25-0.5 μg/kg/h (200 micogram in 50cc syrige with infusion rate 0.125-0.250ml/kg/h), and Lidocaine 2mg/kg/h (400mg in 20cc syringe with infusion rate 0.1 ml/kg/h)"
224283401|NCT04346940|OTHER|Telerehabilitation|15 volunteers aged 65 and over will be included in this group. An online exercise program has been created for individuals who will participate in the study. It is planned that this program will continue for 3 days a week, 6 weeks, and the duration of exercise will reach 45 minutes in the last week due to the increase in the number of repetitions about 30 minutes at the beginning. The treatment sessions will start with warm-up exercises, complete with posture exercises, joint range of motion exercises, stretching exercises, and cool-down exercises in the main program.
224283402|NCT04346940|OTHER|Exercise brochure|The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.
224283403|NCT05678517|DRUG|Anti-VEGF|intravitreal ranibizumab or intravitreal aflibercept
224283404|NCT05371639|DRUG|Tian Ma Bian Chun Zhi Gan Tablets|Tian Ma Bian Chun Zhi Gan Tablets, 0.1g per pill which contains 14mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
224283405|NCT05371639|DRUG|Placebo|Placebo identified to Tian Ma Bian Chun Zhi Gan, 0.1g per pill which contains 0mg Tian Ma Bian Chun Zhi Gan, 3 pills per time, 2 times per day for 36 weeks.
224283406|NCT02421016|DEVICE|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
224283407|NCT02421016|DEVICE|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
224283408|NCT04743817|DEVICE|OtoSet - Ear Cleaning System|Up to five (5) cleaning cycles using the OtoSet - Ear Cleaning System
224283409|NCT01716676|OTHER|Telemedicine CPAP monitoring (webpage and televisit)|
224283410|NCT01716676|OTHER|Standard CPAP monitoring|
224283411|NCT01601938|DIETARY_SUPPLEMENT|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
224283412|NCT01601938|DIETARY_SUPPLEMENT|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
224283413|NCT05328700|OTHER|Kinesiotaping|Perform a neuromuscular bandage with kinesiotape in patients with plantar fasciitis
224283414|NCT05328700|OTHER|Tape|Perform a neuromuscular bandage with tape (Hipofix(R)) in patients with plantar fasciitis
224283415|NCT06465875|OTHER|Reading a book|Individuals in the intervention group will be read a storybook for three nights.
224283416|NCT05589259|PROCEDURE|Axillary Brachial Plexus Block plus Physiotherapy|"Participants will receive a single-shot axillary-approach brachial plexus block. For the procedure, a 22g or larger peripheral intravenous cannula will be placed, and skin will be sterilized with chlorhexidine. Using aseptic technique, the anesthesiologist will anesthetize the skin and tract with 5cc of 1% lidocaine using a 25g 1.5 needle. After this, a 50mm 21g Pajunk needle will be guided under ultrasound with an in-plane technique to anesthetize the median, ulnar, radial, and musculocutaneous nerves. Identification of the axillary artery, vein and surrounding vessels will be done to ensure an intravascular injection is avoided. Once proper location is confirmed, the anesthesiologist will aspirate to ensure the needle is not intravascular. Once aspiration is confirmed negative, bupivacaine 0.25% 1.5mg/kg (lean body weight) will be injected in divided doses.~30 minutes after placement of the block, the standardized physiotherapy protocol will begin."
224283417|NCT05589259|PROCEDURE|Physiotherapy alone|"Participants in the EXP arm and the CON arm will complete the same physiotherapy program.~PHYSIOTHERAPY PROTOCOL The physiotherapy program will include manipulation with or without a block. The goal of manipulation is to break up adhesions, possibly overcoming microvascular dysfunction. After the manipulation, participants will take part in a 6-week program which will include a weekly one-hour session with a physiotherapist at the KHSC-CPC and a home exercise program (HEP). During each session, the physiotherapist will work with the participants to increase ROM and limb function using manual therapy, stretching, and strengthening exercises specific to the affected joint(s) and most importantly using GMI. At the end of each session, the physiotherapist will prescribe exercises to complete at home."
224283418|NCT05623852|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
224283419|NCT02354807|DRUG|Mirabegron|One-time dose of 100mg of Mirabegron
224283420|NCT02354807|OTHER|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
224283421|NCT02289937|DRUG|Ropivacaine|
223532841|NCT02068144|OTHER|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
223532842|NCT00565565|DRUG|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
223532843|NCT00506623|DRUG|Capecitabine, Irinotecan|
223532844|NCT02001168|DRUG|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
223532845|NCT02001168|DRUG|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
223532846|NCT02001168|DRUG|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
223532847|NCT02001168|DRUG|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
223532848|NCT04347421|DIETARY_SUPPLEMENT|Krill oil group|This group takes 500 mg/day Krill oil for 12 weeks.
223532849|NCT04347421|DIETARY_SUPPLEMENT|Placebo group|This group takes 500 mg/day Placebo for 12 weeks.
223532850|NCT02315092|DEVICE|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
223929734|NCT06791811|OTHER|OA|In the opioid anaesthesia group patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h (200 micograms in 50 cc syringe with infusion rate 0.125-0.250ml/kg/h).Placebo (saline infusion) in 20 cc syringe with rate infusion rate 0.1 ml/kg/h.
223929735|NCT06820047|PROCEDURE|Laparoscopic sleeve gastrectomy|"Patients underwent SG, involving longitudinal resection of approximately 75% of the stomach along its greater curvature, with excision of the fundus and part of the body and antrum, preserving a portion of the latter and the pylorus itself. This results in a vertical tube-shaped gastric tube sleeve. After surgery, patients followed a free diet. Patients were evaluated at baseline and at 1, 3, 6, 9, and 12 months after starting the intervention."
224095119|NCT02832050|BEHAVIORAL|Play therapy|See previous description of play therapy intervention arm.
224095120|NCT02832050|BEHAVIORAL|Standard of care|See previous description of comparator arm.
224283422|NCT02289937|DRUG|Placebo|
224283423|NCT02289937|DEVICE|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
223532851|NCT01069913|DRUG|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation."
223532852|NCT01899547|PROCEDURE|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
223532853|NCT01899547|PROCEDURE|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
223532854|NCT00822094|DRUG|CPX-351|
223532855|NCT00822094|DRUG|Intensive Salvage Therapy|
223532856|NCT02455869|DRUG|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
224283424|NCT06030115|OTHER|Exercise Component Of Cardiac Rehabilitation (Hybrid Model) Intensity Recovery Progression Protocol (IRPP)|Data collected on participants who completed the intensity recovery progression protocol program
224283425|NCT01009515|DRUG|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
224283426|NCT05442437|BIOLOGICAL|hUCMSCs|Human umbilical cord mesenchymal stem cell preparation, 100ml/ bag, containing 2.5×107 cells, 5.0×107 cells, 1.0 x 108 cells
224283427|NCT01321437|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224283428|NCT01321437|OTHER|laboratory biomarker analysis|Correlative studies
224283429|NCT01321437|DRUG|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
224283430|NCT01321437|OTHER|pharmacological study|Correlative studies
224283431|NCT04234061|COMBINATION_PRODUCT|ibrutinib and Tisagenlecleucel|Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment
224283432|NCT03668951|DRUG|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
224283433|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
224283434|NCT03668951|DRUG|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
224283435|NCT01966809|DRUG|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
224283436|NCT00466843|DRUG|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
224283437|NCT00466843|DRUG|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
223532857|NCT02455869|DRUG|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
223929736|NCT06820047|OTHER|Obesity pharmacotherapy|Patients underwent 1 month of a very low calorie diet (VLCD) with 813 kcal/day, followed by a low calorie diet (LCD) for 11 months together with intensive physical exercise (30 min/day of brisk walking plus at least 3 h/week of aerobic exercise) with 2.4 mg/week of semaglutide (Ozempic®), given once weekly as subcutaneous injections. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months after starting the interventions.
224283438|NCT06222229|OTHER|Control|"All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention."
224283439|NCT06222229|PROCEDURE|Functional bandage|"The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended"
224283440|NCT02024594|DRUG|Nitrous Oxide-Oxygen conscious sedation|
224283441|NCT02024594|BEHAVIORAL|cognitive-behavioral therapy|
224283442|NCT00206596|DRUG|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
224283443|NCT00206596|DRUG|Placebo|Once daily via subcutaneous injection for up 22 weeks
224283444|NCT03420768|DRUG|BMS-986263|Administered by intravenous (IV) infusion
224283445|NCT03420768|OTHER|Placebo|Administered by intravenous (IV) infusion
224283446|NCT00983476|BEHAVIORAL|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
224283447|NCT00983476|BEHAVIORAL|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
224283448|NCT05044494|PROCEDURE|non-prompt surgery|
224283449|NCT00779220|DRUG|placebo|Intravenous repeating dose
223532858|NCT02455869|DRUG|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
223532859|NCT01269684|DRUG|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
223532860|NCT04648020|DRUG|Clonidine HCl Mucoadhesive Buccal Tablet|100 μg of clonidine per tablet
223532861|NCT04648020|DRUG|Placebo Mucoadhesive Buccal Tablet|Placebo
223532862|NCT01534559|OTHER|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
223532863|NCT01621646|OTHER|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
223929737|NCT06782711|PROCEDURE|cranioplasty|In this pivotal study of a medical device, patients with bone loss undergo a computed tomography scan, which is used to create a three-dimensional model of the lesion. After validation, the model is printed using PEEK material, and subsequently, the skull is repaired through cranial reconstruction (cranioplasty).
223929738|NCT06782711|DEVICE|customized skull implants made of polyetheretheretherketone (PEEK) using 3D printing|customized skull implants made of polyetheretheretherketone by three-dimensional printing in patients undergoing cranioplasty
224283450|NCT00779220|DRUG|methotrexate|Oral repeating dose
224283451|NCT00779220|DRUG|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
224283452|NCT00779220|DRUG|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
224283453|NCT00779220|DRUG|ocrelizumab 500mg|Intravenous repeating dose (500mg)
224283454|NCT01405274|OTHER|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
224283455|NCT02969876|DRUG|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
224283456|NCT00531362|DRUG|Plain aspirin|Plain aspirin 75 mg or 150 mg
224283457|NCT00083694|DRUG|Thalidomide|
224283458|NCT01575262|BEHAVIORAL|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
224283459|NCT01575262|BEHAVIORAL|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
224283460|NCT00637091|DRUG|Cetuximab, irinotecan|cetuximab, irinotecan
224283461|NCT02675374|DRUG|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
224283462|NCT02675374|DRUG|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
224283463|NCT02090231|DEVICE|rTMS, Magstim Rapid2|5 Hz rTMS
224283464|NCT06026631|PROCEDURE|Lipidomic analysis for breast cancer patients|Lipidomic analysis for breast cancer patients
224283465|NCT05062148|OTHER|Float-REST|Subjects receiving Float-REST will float for 60 minutes three times a week.
223532864|NCT02724839|BEHAVIORAL|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Three non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (Arm 1), monthly (Arm 2) and weekly (Arm 3).
223532865|NCT02724839|DEVICE|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 9 months.
223532866|NCT05878574|DRUG|Low molecular weight heparin|Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
223929739|NCT05197530|DRUG|Indocyanine green|A trained physician will inject 0.1 ml of the ICG in to the web spaces of the hands in both upper extremities.
224283466|NCT05062148|OTHER|Photobiomodulation|Subjects receiving photobiomodulation will undergo a 20-minute therapy session three times a week.
224283467|NCT01175473|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
224283468|NCT01175473|DEVICE|Pen auto-injector|
224283469|NCT01175473|DRUG|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
224283470|NCT01175473|DEVICE|Pre-filled pen injector|
224283471|NCT01175473|DRUG|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
224283472|NCT05964673|DEVICE|bioptron light therapy|patients will receive patient education program and bioptron light therapy for four weeks
224283473|NCT00760786|DRUG|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
224283474|NCT00760786|DRUG|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
224283475|NCT00760786|DRUG|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
224283476|NCT00760786|DRUG|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
224283477|NCT02887924|DEVICE|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
224283478|NCT01705002|DRUG|Promitil|2 mg/kg dose IV
224283479|NCT01705002|DRUG|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
224283480|NCT01705002|DRUG|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
223929740|NCT05197530|DEVICE|MultiSpectral Imaging System|Once the ICG is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
223929741|NCT03373552|DIAGNOSTIC_TEST|Platelet function assay|Platelet function assay
223929742|NCT06785493|DRUG|Optimized Treatment (OPT)|After the first sufficient intravenous infusion of UST (6 mg/kg), the patient's response was assessed based on PRO2 at week 8, and an individualized treatment plan was developed. At week 8, the patients with incomplete response of PRO2 (a decline of PRO2 was less than 50% from baseline or still in moderate to severe active phase of PRO2) were given one or more UST intravenous re-induction (6 mg/kg) every 4 or 6 weeks.
224283481|NCT01236417|BEHAVIORAL|Exercising block|Exercising for 8 weeks using an elastic band
224283482|NCT05099510|BIOLOGICAL|NatrunixTM|The active ingredient in the drug product NatrunixTM is XB2001, a recombinant human IgG4 monoclonal antibody specific for human interleukin-1-alpha (IL-1-alpha). The entire XB2001 heavy and light chain sequences are identical to those found in naturally-occurring human IgG4-kappa, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual.
224283483|NCT05099510|BIOLOGICAL|Placebo|Placebo control for NatrunixTM subcutaneous injection.
224283484|NCT01083238|DRUG|AZD5069|120mg single oral dose
224283485|NCT02091349|OTHER|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
224283486|NCT02091349|OTHER|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
224283487|NCT01996423|DIETARY_SUPPLEMENT|Vitamin D3|
224283488|NCT01996423|DIETARY_SUPPLEMENT|Placebo|
224283489|NCT01857206|BIOLOGICAL|Mammalian cell based flu vaccine|
224283490|NCT01857206|BIOLOGICAL|Egg based flu vaccine|
224283491|NCT05518032|PROCEDURE|Biopsy|Undergo biopsy
224283492|NCT05518032|BIOLOGICAL|Pembrolizumab|Given IV
224283493|NCT05518032|BIOLOGICAL|Therapeutic Autologous Dendritic Cells|Given intratumorally
224283494|NCT02656654|OTHER|Whole-body compression|
224283495|NCT03776929|BEHAVIORAL|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
224283496|NCT02588820|DRUG|Antiretroviral Therapy (Experimental)|"1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day"
224283497|NCT01857973|DEVICE|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
224283498|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
224095121|NCT02421861|BEHAVIORAL|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
224095122|NCT02421861|OTHER|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C\&L service; (2) referral to psychiatry C\&L service; or (3) pharmacologic management.
224095123|NCT03384043|BEHAVIORAL|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
224095124|NCT03384043|BEHAVIORAL|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
224095125|NCT02541630|BEHAVIORAL|Big Mind|mindfulness based intervention
224095126|NCT05418712|DRUG|Placebo|Placebo matched to VX-150 for oral administration.
224095127|NCT05418712|DRUG|VX-150|Solution or Suspension for oral administration.
224095128|NCT01645163|BEHAVIORAL|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
224095129|NCT06001606|DRUG|Shingrix|Shingrix vaccination
224095130|NCT06001606|DRUG|Placebo|Placebo vaccination
224095131|NCT03978650|OTHER|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
224095132|NCT00805207|DRUG|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
224283499|NCT01634412|DRUG|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
224095133|NCT00805207|DRUG|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
224095134|NCT00805207|DRUG|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
223532867|NCT02143284|DEVICE|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
224095135|NCT00805207|DEVICE|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
224095136|NCT00805207|DRUG|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
224095137|NCT00805207|OTHER|Control|No treatment with studies performed 31 to 72 days apart
224095138|NCT00064701|DRUG|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
224283500|NCT01634412|DRUG|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
224283501|NCT01634412|DRUG|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
224283502|NCT00908882|BEHAVIORAL|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
224283503|NCT05787067|BEHAVIORAL|Health Belief Model-Based Mobile Online Training|Health Belief Model-Based Mobile Online Training
224283504|NCT00117117|DRUG|Aranesp|
224283505|NCT01662934|DEVICE|I RUNE|
224283506|NCT01662934|DEVICE|sham|
223929743|NCT06791720|BEHAVIORAL|music-based cognitive-motor dual-task training/exercise|Participants is engaged in 4 sessions for each training, including rhythmic marching, singing familiar songs, dance workout with elastic bands and stretching exercise with relaxing music. This combination of physical and cognitive activities aims to improve overall well-being by integrating music and movement, making the exercise both enjoyable and beneficial for mental and physical health. Rhythmic aerobic exercises to music focuses on rhythm and movement accuracy. Listening and singing familiar songs is cognitively stimulating. Dance workout allows strength and endurance training with music. Stretching exercise with relaxing music improves the range of movement in major muscle and tendon groups.
223929744|NCT06791720|BEHAVIORAL|Social Gatherings|Participants in the social control group will have a social gathering at the participating center once weekly over the 16 weeks. They will also continue to receive the usual care offered by the centers, such as social support, and health education.
223929745|NCT06786858|DEVICE|HandMate|HandMate device is used for 20 hours in 4 weeks. Device is then used in the home for 3 months at discretion of participant.
223929746|NCT06789822|DEVICE|Invitation to wear the smartwatch|During a consultation with the psychiatrist, and after verifying the eligibility criteria, the patient will receive oral information about the study from the psychiatrist.
223929747|NCT06788301|PROCEDURE|Inferior Alveolar Nerve Block|local anesthesia administration (inferior alveolar nerve block)
223929748|NCT06788301|DEVICE|VR eyeglasses|VR eyeglasses was used to distarct patients from dental environment during inferior alveolar nerve block.
223929749|NCT06788301|DEVICE|Buzzy device|Buzzy device was used to distarct patients from dental environment during inferior alveolar nerve block.
223929750|NCT06794346|DRUG|Transdermal testosterone|women will receive 300mcg of transdermal testosterone in cream daily for six months
223929751|NCT06794346|DRUG|Vaginal testosterone gel|women will receive 300mcg of vaginal gel testosterone daily for six months
223929752|NCT06794346|DEVICE|Placebo group|women will receive both vaginal gel and transdermal cream placebo for six months
223929753|NCT06718192|OTHER|Bleomycin injection|Wart injection (0.2 mL \<5 mm; 0.5 mL 5-10 mm; 1ml for \>10 mm) were injected at a depth of 1.5mm, diluted with normal saline at a concentration of 3u/ml=3mg/ml, and the maximum amount of each wart was 1ml until the wart turned white
223929754|NCT06718192|OTHER|Cryotherapy|The wart was frozen by liquid nitrogen until a circle of frozen tissue appeared around the wart for about 10s, with an interval of 30s, for a total of 2 times
223929755|NCT06755086|DRUG|18-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
223929756|NCT05733494|OTHER|Administration of Clinical Assessment of Dysphagia in Neurodegeneration (CADN)|the CADN will be administrated to each patient at the enrolment
223929757|NCT05827068|BIOLOGICAL|mRNA-1011.1|Sterile liquid for injection
223929758|NCT05827068|BIOLOGICAL|mRNA-1011.2|Sterile liquid for injection
223929759|NCT05827068|BIOLOGICAL|mRNA-1012.1|Sterile liquid for injection
223929760|NCT05827068|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223929761|NCT05827068|BIOLOGICAL|mRNA-1010.2|Sterile liquid for injection
223929762|NCT05827068|BIOLOGICAL|mRNA-1010.3|Sterile liquid for injection
223929763|NCT06832319|BEHAVIORAL|PERSONALIZED FEEDBACK|Students in the study group will be asked to intervene in a simulated situation in the management of bleeding during pregnancy. It will be filmed with a camera so that students can see their own mistakes after the simulated scenario. After the scenarios are completed by the students in the control group, the mistakes in the clinical situations will be analyzed by the researchers and students in the form of questions and answers and the necessary feedback will be given to them.
223929764|NCT06809712|DRUG|Busulfan (Busulfex)|Myeloablative conditioning: Busulfan (Bu，3.2 mg/kg/d IV -8d \~-6d); Reduced intensity conditioning: Busulfan (Bu，3.2 mg/kg/d IV -7d\~-5d);
223929765|NCT06809712|DRUG|Cyclophosphamide (CTX)|Myeloablative conditioning: Cyclophosphamide (Cy，1.8g/m2, -5d, -4d) Cyclophosphamide is not used for reduced intensity conditioning
224095139|NCT00064701|DRUG|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
224095140|NCT00064701|DRUG|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
224095141|NCT00064701|DRUG|mycophenolate mofetil|Oral
224095142|NCT00002676|DRUG|carmustine|
224095143|NCT00002676|DRUG|cyclophosphamide|
223929766|NCT06809712|DRUG|Fludarabine (Fludara)|Myeloablative conditioning: Fludarabine (Flu，30 mg/m2/d IV -6d \~ -2d); Reduced intensity conditioning: Fludarabine (Flu，30mg/m2 /d IV -10d\~-5d);
223929767|NCT06809712|DRUG|Semustine (MeccNU)|"For both myeloablative and reduced intensity conditioning:~Semustine (MeCCNU: 250 mg/m2 orally-3d)"
224095144|NCT00002676|DRUG|cytarabine|
224095145|NCT00002676|DRUG|dexamethasone|
224095146|NCT00002676|DRUG|doxorubicin hydrochloride|
224095147|NCT00002676|DRUG|methotrexate|
224095148|NCT00002676|DRUG|vincristine sulfate|
224095149|NCT00002676|RADIATION|low-LET cobalt-60 gamma ray therapy|
224095150|NCT00002676|RADIATION|low-LET photon therapy|
224095151|NCT01405079|DRUG|Gefitinib|Gefitinib 250 mg/day oral daily
224095152|NCT01405079|DRUG|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
224095153|NCT02249052|DRUG|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
224095154|NCT02249052|DRUG|placebo|Placebo
224095155|NCT00588679|OTHER|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
224283507|NCT00129116|BIOLOGICAL|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
224283508|NCT00129116|BIOLOGICAL|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
223532868|NCT05456048|DRUG|VAH regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
223532869|NCT05456048|DRUG|VEN+HMA regimen|VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
223532870|NCT00241150|DRUG|VALSARTAN|
223532871|NCT00433485|DRUG|sirolimus|
223532872|NCT00433485|GENETIC|comparative genomic hybridization|
223532873|NCT00433485|GENETIC|gene expression analysis|
223532874|NCT00433485|GENETIC|microarray analysis|
223532875|NCT00433485|GENETIC|protein expression analysis|
223532876|NCT00433485|GENETIC|proteomic profiling|
223532877|NCT00433485|OTHER|laboratory biomarker analysis|
223532878|NCT00433485|OTHER|mass spectrometry|
223532879|NCT00433485|PROCEDURE|biopsy|
223532880|NCT02428426|OTHER|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
223929768|NCT06651814|BEHAVIORAL|Supervised Exercise Group|A supervised exercise program will consists of 10 sessions. The 1st exercise station will be a 5-minute warming up of the jaw with a heat lamp. The 2nd station will involve jaw opening-closing movements (TMJ rotation) with the mandible in a slightly protruded position for 6 minutes. The 3rd and 4th exercise stations will comprised of jaw opening and jaw protrusion, respectively, against resistance for 4 minutes each. Measurements will be done before the trial started and after 3 months.
223929769|NCT06651814|BEHAVIORAL|Home Exercise Group|Patients will received a home regime of jaw exercises. They will be instructed to do two different trainings. The 1st type of exercise will be jaw opening and closing movements daily for 5 minutes after each meal with the mandible and the head of the TMJ in a slightly protruded position. This exercise should not produce any clicking sounds. The 2nd type of exercise will be isometric exercises; this entailed jaw opening and jaw protrusion against resistance with their hand for 10 seconds with 10 repetitions each daily. All the patients will receive a training brochure with photos of the exercises and detailed information on frequency and exercise time. The brochure will include a diary. After 6 weeks, the subject and the assistant will check the performance of the exercise and the diary
223929770|NCT06750757|BIOLOGICAL|Bone marrow aspirate concentrate|145cc of BMAC/PRP/PPP injection.
223929771|NCT06750757|PROCEDURE|Hip arthroscopy|Both groups will undergo a hip arthroscopy to treat their condition. However, the control group will not receive a BMAC injection during the surgery.
223929772|NCT03867201|BIOLOGICAL|Erenumab|Administered by pre-filled syringe
223929773|NCT03867201|OTHER|Placebo|Administered by pre-filled syringe
224095156|NCT01432639|OTHER|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
224095157|NCT03135093|OTHER|No intervention|No Intervention
224095158|NCT04536194|DRUG|norepinephrine|to treat hypotension under general anesthesia with norepinephrine
224095159|NCT04536194|DRUG|dopamine|to treat hypotension under general anesthesia with dopamine
224095160|NCT03540095|DRUG|Erector Spinae Plane Block|See arm description
224095161|NCT03540095|DRUG|Paravertebral Nerve Block|See arm description
223929774|NCT06762665|PROCEDURE|Spinal injection|Patients underwent a spinal injection procedure under CT scan
224095162|NCT00000899|DRUG|Nelfinavir mesylate|
224095163|NCT00000899|DRUG|Lamivudine|
224095164|NCT00000899|DRUG|Filgrastim|
224283509|NCT00129116|BIOLOGICAL|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
224283510|NCT00129116|BIOLOGICAL|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
224283511|NCT00129116|BIOLOGICAL|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
224283512|NCT00334763|BIOLOGICAL|bevacizumab|
224283513|NCT00334763|DRUG|carboplatin|
223532881|NCT01510093|DRUG|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
224095165|NCT00000899|DRUG|Stavudine|
224283514|NCT00334763|DRUG|chemoprotection|
223532882|NCT05964569|OTHER|model-guided optimization of treatment plan|original treatmant plans are optimized based on model-based NTCP
223532883|NCT05964569|OTHER|standard treatment plan, no optimization|original treatment plans are not optimized
223532884|NCT03082924|DEVICE|Control group|Neither cycle training nor inspiratory muscle training.
223532885|NCT03082924|DEVICE|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
223532886|NCT03082924|DEVICE|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
223532887|NCT03082924|DEVICE|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
223532888|NCT03542617|DRUG|Dexamethasone|
223532889|NCT03542617|DRUG|Normal Saline Solution|
223532890|NCT00618761|OTHER|hyperglycemic clamp test|hyperglycemic clamp test
224283515|NCT00334763|DRUG|paclitaxel|
224283516|NCT00334763|RADIATION|radiation therapy|
224283517|NCT03493321|OTHER|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
223532891|NCT00070304|BIOLOGICAL|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
223532892|NCT00070304|DRUG|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
223532893|NCT00070304|DRUG|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
223532894|NCT02283034|DEVICE|The CPRmeter|Feedback device - 1
223532895|NCT02283034|DEVICE|The PocketCPR|Feedback device - 2
223532896|NCT02283034|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
223532897|NCT02283034|DEVICE|The CPREazy|Feedback device - 3
223532898|NCT02283034|DEVICE|The CPR PRO APP|Feedback device - 4
223532899|NCT02283034|DEVICE|The CardioPump|Feedback devices - 5
223532900|NCT02283034|DEVICE|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
223929775|NCT06762665|OTHER|pre-operative consultation|Pre-operative consultation, in person or by teleconsultation, consists of an interview about the patient's history and symptoms. This is followed by a clinical examination and consultation of the patient's imaging file, to confirm the request for paraspinal infiltration and its location. In addition, the radiologist explains the procedure to the patient, supplementing the explanatory documents already provided at the time of the appointment, and outlines the results that may be expected and any complications.
224095166|NCT00000899|DRUG|Cyclophosphamide|
224283518|NCT05279638|DIAGNOSTIC_TEST|serum ATG5|This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid
224283519|NCT06025552|DRUG|TU7710|In each dose level, 6 subjects will be assigned to TU7710. Anticipated escalating dose levels are 100mcg/kg, 200mcg/kg, 400mcg/kg, 800mcg/kg and the last dose will be decided after assessing cohort 1\~4 PK, PD, safety, and exploratory efficacy data.
224283520|NCT06025552|DRUG|Normal saline|Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
224283521|NCT04741152|PROCEDURE|Pancreatic resection|Different pancreatic resections
224283522|NCT05247073|PROCEDURE|patients of controlled group with routine closure of episiotomy|"Perineal trauma is traditionally repaired in three stages: a continuous locking stitch is inserted to close the vaginal trauma, commencing at the apex of the wound and finishing at the level of the fourchette with a loop knot. The perineal muscles are then re-approximated with three or four interrupted sutures and finally, the perineal skin is closed by inserting continuous subcutaneous or interrupted transcutaneous stitches.~The skin is then closed with inverted interrupted stitches placed in the subcutaneous tissue a few millimeters under the perineal skin edges (not transcutaneously)."
224283523|NCT05247073|PROCEDURE|The Mostafa Maged four-stitch technique fore closure of the episiotomy|"Identification of the apex of the episiotomy, then a simple suture is taken (0.5 cm) behind the apex of the episiotomy. First, the needle is inserted at the vaginal mucosa of the right edge of the episiotomy then extract the needle.~The second stitch is inserted on the deep muscle layer of the same side (Right side) of the episiotomy cutting edge then extracting the needle.~Then, insert the needle again on the left side of the episiotomy incision in the deep muscle layer on the left side of the episiotomy incision directing the tip of the needle upwards parallel to the second stitch taken.~The fourth step is inserting the needle in the vaginal mucosa of the left side parallel to the first stitch. Continue suturing the episiotomy incision continuously in the same way till reaching the remnant of the hymen.~Then suture the superficial perineal muscle in a continuous manner and the skin in a subcuticular manner as well."
224283524|NCT05587257|DEVICE|Fractional CO2 laser|"Each patient will receive 6 sessions 2 weeks apart, after the laser treatment, a topical 5% minoxidil tincture will immediately applied.~All patients will advised not to use any other treatment during the study"
224283525|NCT05587257|DEVICE|Derma pen|, will be treated by microneedling using dermapen ( automated Derma Pen, DR Pen Ultima A6, China) which under complete aseptic precaution with a cartridge containing 12 needles moved diagonally, vertically, and horizontally for 4-5 times in each direction with 1.5 mm depth and speed 4-5(new cartridge every session), the application has been extended 1-2 cm perilesionally. The pinpoint bleeding will be considered an endpoint. topical 5% minoxidil tincture will immediately applied. Each patient will receive 6 sessions 2 weeks apart.
224283526|NCT05587257|DRUG|Niosome minoxidil|The patient of alopecia areata will be treated by topical nanominoxidil preparation twice daily for 3 months with no other treatment.
224283527|NCT05587257|DRUG|Minoxidil Topical Spray|The patient of alopecia areata will be treated by topical minoxidil 5% preparation twice daily for 3 months with no other treatment.
224283528|NCT00869440|DRUG|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
224283529|NCT00869440|DRUG|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
224283530|NCT03558139|DRUG|Magrolimab|Administered intravenously
224283531|NCT03558139|DRUG|Avelumab|Administered intravenously
224283532|NCT02752802|DEVICE|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
224283533|NCT02963584|OTHER|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
224283534|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
224283535|NCT02808819|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
224283536|NCT03143517|DIAGNOSTIC_TEST|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
224283537|NCT04305990|DEVICE|Demand-driven delivery method|The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.
224283538|NCT04305990|DEVICE|Free-flow delivery method|The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
224283539|NCT05899920|DIAGNOSTIC_TEST|Blood samples will be taken for pharmacokinetics and pharmacogenetics|To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
224283540|NCT01953094|PROCEDURE|Screening Anal Pap Smear - No High Resolution Anoscopy|
223929776|NCT05557045|DRUG|JZP815|JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
223929777|NCT06750198|OTHER|Hip focused|"Group A will be treated with hip focused exercises and standard rehabilitation protocol.~Hip focused exercises will be comprised of following exercises in phase 1 will be Side lying hip abduction, Hip abduction in standing, Hip extension from prone, Single leg bridge, Side lying clam with resistance while exercises in phase 2 will be same with more repetitions in addition to Side lunges, Forward lunges"
223929778|NCT06750198|OTHER|Standard rehabilitation|Group B will be only be treated with standard rehabilitation protocol. When participant reach full ROM of knee, perform four sets of 20 repetitions of straight leg raising with full extension, and maintain one minute single leg balance on a solid surface with the affected side, subject can transfer to phase 2
223929779|NCT05954585|BEHAVIORAL|Treatment as usual|Emergency department treatment as usual
223929780|NCT05954585|BEHAVIORAL|Family Navigator|Family Navigator will speak with families about individual and systemic issues for linkage to mental health care biweekly for 3 months or until the youth's first mental health appt has been attended, whichever comes first.
223929781|NCT05365997|OTHER|Default Nudge|For patients whose clinician pods are randomized to the intervention arm, the care team pod will receive a message indicating that the patient is eligible for palliative care and that a default referral order has been pended for that patient. Clinicians will be given an opportunity to respond if they do not want their patient to be referred to palliative care. For clinicians who do not respond, after the allotted time, the Clinical Research Coordinator will reach out to the patient to introduce palliative care and ask if staff can schedule an appointment. For clinicians who respond no, the pended order will be removed and no patient contact by the research team will occur.
223929782|NCT06091124|DRUG|Adebrelimab|Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
223929783|NCT06091124|DRUG|Etoposide|Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
223929784|NCT06091124|DRUG|Cisplatin|Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)
223929785|NCT06091124|PROCEDURE|Radical Cystectomy|Radical cystectomy should be performed within 4-6 weeks after completion of last dose
223929786|NCT06080074|DEVICE|Cardiohelp device (VA-ECMO)|In children receiving the Cardiohelp device for severe heart failure, participants will be consented to a systematic data collection to describe the safety and effectiveness of the device in children.
223929787|NCT03274297|DRUG|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
223532901|NCT05951426|PROCEDURE|1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage|"1. removal of the uterus with both ovaries and fallopian tubes and pelvic lymph nodes~2. exploration of the uterine cavity and removal of the endometrium"
223532902|NCT00557193|DRUG|Asparaginase|Given IV, IM, or PO
224095167|NCT00482846|BIOLOGICAL|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is \>40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
223532903|NCT00557193|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223532904|NCT00557193|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223718201|NCT07016607|DEVICE|GPIV|The investigational device is a peripheral intravenous catheter with a passive fully automatic needlestick protection, with a glide-on-contact design of the plastic cannula tip featuring asymmetry, with the negative, convex slope in the plane perpendicular to the longitudinal axis of the tip resulting in bottom part of the cannula being shorter.
223929788|NCT03274297|DRUG|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
223929789|NCT06755931|BEHAVIORAL|quilling set|After the intervention group is determined in randomization, half an hour before the cardiac catheterization and angiography procedure, without premedication treatment, the researcher will be asked to choose 2 animal and plant figures, samples of which have been previously made, through a quilling set, in cooperation with the researcher. It will be done with the child in a 15-20 minute period, accompanied by the researcher, with 2 figures chosen by the child. With the opportunity for the child to choose the color and figure he/she wants, the child will be at the center of the work. The figure will be given as a gift to the child and the survey forms will be filled out again 5 minutes after the application, before the premedication treatment. In order to prevent bias in the research, the descriptive information form and fear and anxiety scales will be taken by the evaluation of three people: the researcher, the parent and the child.
223929790|NCT06755931|BEHAVIORAL|Control|Before the procedure, while the child is in the patient room, the details of the research will be explained, their consent will be obtained and the Introductory Information Form will be filled in by the parent, and the Fear Scale and State Anxiety Scale will be filled in by the child and the parent. After the control group is determined in randomization, the researcher will apply the posttest without premedication treatment half an hour before the cardiac catheterization and angiography procedure. No separate intervention will be applied. In accordance with ethical principles, after the procedure, 2 Quilling figures chosen by the control group and the child will be prepared with the help of the researcher, and the prepared figures will be gifted to the child.
224095168|NCT00482846|DRUG|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. \<60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
224095169|NCT00482846|OTHER|questionnaire administration|Day -5 to Day +28
224095170|NCT00482846|PROCEDURE|autologous peripheral blood stem cell transplantation|Day 0
224095171|NCT00482846|OTHER|quality-of-life assessment|Day -5 to Day +28
224283541|NCT01953094|PROCEDURE|Screening Anal Pap Smear - With High Resolution Anoscopy|
224283542|NCT02244931|DEVICE|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
224283543|NCT02244931|DEVICE|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
224283544|NCT02244931|DEVICE|Standard manual Wheelchair|Standard manual Wheelchair
224283545|NCT02013531|DRUG|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
224283546|NCT00400582|DRUG|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
224283547|NCT02502331|BIOLOGICAL|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
224283548|NCT02502331|BIOLOGICAL|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
223532905|NCT00557193|DRUG|Cyclophosphamide|Given IV
223532906|NCT00557193|DRUG|Cytarabine|Given IV or IT
224283549|NCT04476186|DRUG|Acyclovir|oral syrp
224283550|NCT04476186|DRUG|KOH 10 %|solution for local application
224283551|NCT05454358|DRUG|Letrozole 2.5mg|Letrozole 0.5mg qd po for 2 years after postoperative adjuvant therapy
224283552|NCT04307472|BEHAVIORAL|Clinician Nudge|Active choice intervention in the electronic health record and peer comparison messaging on performance
224283553|NCT04307472|BEHAVIORAL|Patient Nudge|Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
224283554|NCT01567241|OTHER|clinical hypnosis or relaxation music|25 minute tape recording
224283555|NCT00932217|DRUG|filgrastim|subcutaneous filgrastim administration
224283556|NCT00932217|DRUG|lenograstim|subcutaneous lenograstim administration
224283557|NCT00005075|PROCEDURE|high-intensity focused ultrasound ablation|
224283558|NCT05118477|DEVICE|Ambulatory monitoring system|Patients will use AMS.
224283559|NCT05118477|DEVICE|Active alerting system|Clinical staff alerted if AMS detects deterioration
224283560|NCT00193973|DRUG|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
224283561|NCT00193973|RADIATION|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
223532907|NCT00557193|DRUG|Daunorubicin Hydrochloride|Given IV
223532908|NCT00557193|DRUG|Dexamethasone|Given IV or PO
223532909|NCT00557193|PROCEDURE|Echocardiography|Undergo ECHO
223532910|NCT00557193|DRUG|Etoposide|Given IV
223532911|NCT00557193|BIOLOGICAL|Filgrastim|Given IV or SC
223532912|NCT00557193|OTHER|Laboratory Biomarker Analysis|Correlative studies
223929791|NCT06155695|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be administered using the Starstim system. We will use the freely available Simulation of Non-Invasive Brain Stimulation (SimNIBS) software to optimally target the rVLPFC and left TPJ in each subject. Finite element models will be generated using T1 and T2 scans. We will generate multiple models to maximize on-target stimulation and minimize off-target stimulation, as determined by ratio of the summed current density within and beyond target regions of interest (ROIs). tDCS current in the active stimulation condition will be maintained at 2.0 milliamps (mA) for the first 45 minutes of each one-hour training session. Sham stimulation the same current, only the current will be ramped down to 0 mA after 30 seconds. Our previous research has shown this method to produce indistinguishable skin sensation. During tDCS, patients will be monitored for possible negative side effects.
223929792|NCT06155695|BEHAVIORAL|Auditory Cognitive Control Training (ACCT)|ACCT incorporates a subset of components from Cognitive Enhancement Therapy found to have early benefits on the cognitive deficits of interest to the proposed studies and can be conducted more time-efficiently to achieve our specific goals. ACCT involves approximately 3 hours of computerized neurocognitive training using cognitive control and processing speed training software developed by Ben-Yishay and colleagues. Deficits in cognitive control are addressed with computer training exercises containing simple stimuli with little inherent emotional or motivational salience. ACCT requires individuals to be vigilant, inhibit irrelevant stimuli, and shift attention between auditory and visual modalities. Computer training exercises facilitate reaction time in a temporal mode using auditory cues (The Attention Reaction Conditioner), spatial focusing with visual cues (the Zero Accuracy Conditioner), and temporal vigilance with auditory and visual cues (Time Estimates).
223929793|NCT06766383|BEHAVIORAL|GPT-simulated patients|GPT-simulated patients
223929794|NCT06766383|BEHAVIORAL|traditional role-playing|traditional role-playing
223929795|NCT04447209|OTHER|2-weekly Food baskets|2 weekly Food basket containing fresh foods or minimally processed foods.
223929796|NCT06812546|DRUG|Vericiguat|Patients enrolled in the experimental group will receive 26 weeks of oral vericiguat on top of the standard treatment, with vericiguat at a dose of 2.5 mg once a day, doubled every fortnight to a maximum dose of 10 mg once a day at the end of week 6 of the visit, which will be maintained for the duration of the treatment.
223929797|NCT06778564|DRUG|CBD 100 mg/mL Oral Solution|Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
223929798|NCT06778564|OTHER|Placebo|5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 6 weeks
223929799|NCT06779370|DRUG|Calcium Silicate|Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium silicate-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
224095172|NCT01491945|DEVICE|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
224095173|NCT05787704|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
224095174|NCT05460208|DIETARY_SUPPLEMENT|Enriched spread|The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added.
224095175|NCT05460208|DIETARY_SUPPLEMENT|Control spread|The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols.
224095176|NCT02603523|BEHAVIORAL|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
224095177|NCT02137668|DRUG|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
224095178|NCT04670653|DRUG|MAGNÓLIA NASAL GEL|Magnólia nasal gel spray
224095179|NCT04670653|DRUG|MOMETASONE FUROATE|Mometasone furoate nasal spray
224095180|NCT02575209|OTHER|GENDER|
224095181|NCT01524380|DRUG|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
224283562|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
224283563|NCT03546647|DEVICE|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
224283564|NCT00351286|DRUG|L-citrulline tablets, 1000 mg|
223532913|NCT00557193|DRUG|Lestaurtinib|Given PO
224095182|NCT01524380|DRUG|Placebo|twice a day, 10 weeks
224283565|NCT00351286|DRUG|Placebo tablets matching L-citrulline tablets|
224283566|NCT00351286|DRUG|Background simvastatin at a stable dose of 40 mg qHS|
223532914|NCT00557193|DRUG|Leucovorin Calcium|Given IV
223532915|NCT00557193|DRUG|Mercaptopurine|Given PO
223532916|NCT00557193|DRUG|Methotrexate|Given IV, IT, or PO
223532917|NCT00557193|DRUG|Methylprednisolone|Given IV
223532918|NCT00557193|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223532919|NCT00557193|DRUG|Pegaspargase|Given IM
223929800|NCT06779370|DRUG|Calcium hydroxide|Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
223929801|NCT06812104|DRUG|KK2845_1|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
223929802|NCT06812104|DRUG|KK2845_2|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
223929803|NCT06812104|DRUG|KK2845_3|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
223929804|NCT06812104|DRUG|KK2845_4|KK2845 will be administered at several dose levels to determine maximum tolerated dose (MTD).
223929805|NCT06830382|DIAGNOSTIC_TEST|Positron emission tomografy with [68Ga]Ga-ABY-025|Investigational Medicinal product (IMP):\[68Ga\]Ga-ABY-025 (all patients)
223929806|NCT02254746|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
223929807|NCT05277519|DEVICE|Vibrations|Sequenced muscle vibrations during 30 min., 3 times a week during 5 weeks
223929808|NCT06516627|BEHAVIORAL|Positive Labels|"Products that meet Guiding Stars' criteria for earning 1 or more Guiding Star will display labels indicating their healthfulness using star ratings: 1 star (Good), 2 stars (Better), or 3 stars (Best)."
223929809|NCT06516627|BEHAVIORAL|Spectrum Labels|"All products will display an expanded Guiding Stars label that show an overall rating indicating their healthfulness using star ratings: 1 star (Poor), 2 stars (Fair), 3 stars (Good), 4 stars (Better), or 5 stars (Best)."
223929810|NCT06516627|BEHAVIORAL|FDA High In Labels|Products that contain high levels (i.e., ≥20% DV per serving) of saturated fat, sodium, or added sugars will display a label indicating which of these nutrients the product is high in.
223929811|NCT06516627|BEHAVIORAL|FDA Traffic Light Labels|"All products will display a Nutrition Info label showing whether the amount of saturated fat, sodium, and added sugars in 1 serving of the product is low (\<5% DV), medium (≥5 to \<20% DV), or high (≥20% DV). Low will be shown in green, Medium in yellow, and High in red."
223929812|NCT06892457|OTHER|TMS-EEG|Evoked brain activity is measured with the help of TMS-EEG in epilepsy patients OFF and ON medication.
223929813|NCT05943522|OTHER|Asciminib|There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
223929814|NCT06790446|OTHER|Eccentric training group (ECC)|"The first, preparatory phase, lasts two weeks, aiming at making the participant familiar with the principles of eccentric training. Participants first experience the muscle recruitment patterns (during two sessions), then are prepared to induce protective response from the plantar flexors, conditioning these muscles for higher subsequent eccentric intensities.~The aim of the second, training phase per se, which lasts six weeks, is to induce muscular and neurological adaptations through a steady increase in work intensity to stimulate muscle plasticity until the end of the program - varying volume, load and speed.~Perceived exertion is quantified using Borg's scale (expected rating between 3 and 6) to ensure sufficient work intensity and prevent excessive fatigue. Musculoskeletal pain is assessed before and after each session through a Visual Analog Scale (0-10). Verbal encouragements and advising on correct exercise execution are provided by the therapist along each session."
223929815|NCT06790446|OTHER|Conventional therapy|The participant visits a physiotherapist depending on the prescription, as in current practice
223929816|NCT06880081|DRUG|PN20 treatment|Three dose cohorts, single dose, subcutaneous injections
223929817|NCT06740903|DRUG|inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. dexmedetomidine infusion @ 0.2-0.4 μg/kg/h intraoperatively
223929818|NCT06740903|DRUG|inj. lignocaine infusion @1-2 mg/kg/h|Anesthesia induction will be done by doing pre-oxygenation for 3 minutes with 100% oxygen, propofol 2-2.5 mg/kg intravenous (IV) and nalbuphine 0.1mg/kg intravenous (IV). Tracheal intubation will be facilitated by succinylcholine 1.5 mg/kg IV. Anaesthesia will be maintained with isoflurane 0.6 mac, 60% nitrous oxide, 40% oxygen, atracurium 0.5mg/kg bolus followed by 0.15mg/kg maintenance dose every 30 mints until completion of surgery. Patients Intraoperative monitoring will include electrocardiogram leads II and V5, non-invasive blood pressure at 5 min intervals, oxygen saturation, end-tidal carbon dioxide and nasopharyngeal temperature. Patients will be ventilated by intermittent positive pressure ventilation using a circle system to maintain normocapnia. In group A, patients will be given inj. lignocaine infusion @ 1-2 mg/kg/h intraoperatively
223929819|NCT06766227|BEHAVIORAL|iEndSmokin App|Mobile Health App that includes educational material and psychological programs based on CBT.
223929820|NCT06766227|BEHAVIORAL|Educational Session|It will include lectures and distribution of educational material about smoking health risks and strategies to quit.
223929821|NCT05349006|DRUG|Azathioprine|Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
223929822|NCT05349006|OTHER|Placebo|Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
224095183|NCT05681715|DRUG|Rozanolixizumab|Rozanolixizumab self-administration via Syringe Driver or Manual Push.
223929823|NCT06806098|BEHAVIORAL|Truth Initiative Digital Cessation Program|Truth Initiative's digital cessation program is a multimodal evidence-based, digital tobacco cessation program. Accessible on any web-enabled device, it was developed with the Mayo Clinic around tobacco dependence treatment guidelines, Social Cognitive Theory, and the Mayo Clinic model for engaging tobacco users in cessation treatment. It includes a personalized quit plan with AI-driven content recommendations, interactive exercises, educational videos, and emails; a dynamically tailored, bidirectional text message program; the longest-running online community dedicated to tobacco cessation; synchronous live chat coaching (sponsored version only); and pharmacotherapy decision support and delivery (sponsored version only).
224095184|NCT01148173|DRUG|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
224095185|NCT03770403|BIOLOGICAL|ARGX-113|Intravenous administration of ARGX-113
224095186|NCT03633084|DRUG|RBM-007 Injectable Solution|(No additional description)
224095187|NCT00183742|DRUG|liposomal doxorubicin and docetaxel|
224095188|NCT04409704|DEVICE|Repetitive Transcranial Magnetic Stimulation|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week, 20-30 sessions.
224283567|NCT03705871|DEVICE|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
224283568|NCT03705871|DEVICE|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
224283569|NCT02400476|DRUG|Neratinib|
224283570|NCT02400476|DRUG|Loperamide|
224283571|NCT02400476|DRUG|Colestipol|2 g twice daily with or without food for one 28 day cycle
224283572|NCT02400476|DRUG|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
224283573|NCT04462744|OTHER|educational program|an oral health educational program regarding the emergency management of traumatic dental injuries.
224283574|NCT02604576|DRUG|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
224283575|NCT02604576|DRUG|Bromopride 10 mg|Bromopride 10 mg
224283576|NCT00003862|DRUG|cisplatin|
224283577|NCT00003862|DRUG|fluorouracil|
224283578|NCT00003862|DRUG|leucovorin calcium|
224283579|NCT00003862|DRUG|paclitaxel|
224283580|NCT00003862|PROCEDURE|conventional surgery|
224283581|NCT00003862|PROCEDURE|neoadjuvant therapy|
224283582|NCT00003862|RADIATION|radiation therapy|
224283583|NCT03396874|DRUG|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
224283584|NCT00003531|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224283585|NCT02803931|DEVICE|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
224283586|NCT02803931|DEVICE|12-lead ECG|
224283587|NCT02601768|DEVICE|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
224283588|NCT04906330|DIAGNOSTIC_TEST|Oncoliq: test for early breast cancer detection.|Oncoliq is a novel early detection breast cancer test based on liquid biopsies and miRNAs. The main advantage of this test is that miRNAs released from the tumor into the bloodstream can be detected in the plasma of patients even when the tumor is undetectable by other methods.
224283589|NCT00588731|DRUG|Cannabidiol|Active Cannabidiol daily over 6 weeks
224283590|NCT00588731|DRUG|Placebo|Placebo
224283591|NCT06678165|DRUG|YOLT-204|The intervention group will receive YOLT-204 on day0
224283592|NCT00094367|DRUG|Abacavir/Lamivudine|
224283593|NCT06406322|OTHER|PFMT|Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
224283594|NCT06406322|OTHER|Aerobic Exercise|Aerobic exercise will be applied as a progressive program in the form of a walking program, at least 4 days a week for 8 weeks. There will be 5-minute warm-up and cool-down periods (walking at a light pace) before and after exercise.
224283595|NCT05361486|OTHER|Training on revised algorithm|relevant HCP working in study facilities will be trained on the relevant aspects of performing the G6PD testing, interpreting its result, evaluating patient's eligibility for RC and choosing the appropriate treatment as per their role accordingly
224283596|NCT05361486|OTHER|Enhancing Pharmacovigilance|Refresher training on PV reporting in the selected facilities. National PV forms will be reviewed and if required, modified in consultation with the national PV system.
224283597|NCT05361486|OTHER|Supervision of malaria services in selected facilities.|Supervisors in target regions will be trained as for the HCPs.
224283598|NCT05361486|DIAGNOSTIC_TEST|G6PD testing|G6PD test after Malaria Vivax diagnosis
224283599|NCT05361486|DRUG|Tafenoquine|300 mg (2x150mg tablets) tafenoquine
224283600|NCT05361486|DRUG|Primaquine|0.5mg/kg/7 days
224283601|NCT05361486|OTHER|Follow Up Visit at Day 3 [+2 days] after treatment start|It will be checked if all patients have a Follow Up Visit at Day 3 \[+2 days\] after treatment start
224283602|NCT00251316|DRUG|Lithium Carbonate|30 mCi of 131I
223929824|NCT06806098|BEHAVIORAL|Usual Care|Smokefree.gov is a web-based tobacco cessation platform run by the National Cancer Institute of the National Institutes of Health since 2003 and represents the current standard of care for digital tobacco cessation in the U.S. As of 2020, the SmokeFree.gov Initiative (SFGI) consisted of a multimodal suite of interventions - 6 mobile-optimized websites, 9 text messaging programs, 2 mobile apps, and social media platforms.
224283603|NCT00251316|DRUG|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
224283604|NCT03463018|DIETARY_SUPPLEMENT|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
223532920|NCT00557193|OTHER|Pharmacological Study|Correlative studies
223929825|NCT06704698|DRUG|Liposomal bupivacaine|Thoracic paravertebral block with liposomal bupivacaine.
224283605|NCT03463018|DIETARY_SUPPLEMENT|Placebo|Placebo tablet containing matching excipients to the active intervention
224283606|NCT05549050|OTHER|interdialytic weight gain|interdialytic weight gain during hemodialysis
224283607|NCT01739413|PROCEDURE|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
224283608|NCT00346164|DRUG|doxorubicin hydrochloride|Given IV
224283609|NCT00346164|OTHER|clinical observation|Patients undergo observation
224283610|NCT00346164|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
224283611|NCT00346164|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
224283612|NCT00346164|DRUG|ifosfamide|Given IV
224283613|NCT00444821|DEVICE|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
224283614|NCT03788135|BEHAVIORAL|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
224283615|NCT01010035|OTHER|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
223532921|NCT00557193|DRUG|Prednisone|Given PO
223532922|NCT00557193|DRUG|Therapeutic Hydrocortisone|Given IT
223532923|NCT00557193|DRUG|Vincristine Sulfate|Given IV
223532924|NCT00284128|DRUG|AVE7688|oral administration (capsules)
223532925|NCT00284128|DRUG|Losartan-potassium|oral administration (capsules)
223532926|NCT00906061|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
223532927|NCT02983409|RADIATION|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
223929826|NCT06704698|DRUG|Bupivacaine Hydrochloride|Epidural block with plane bupivacaine.
223929827|NCT06758141|OTHER|3D printed educational model|3D Printed Advanced Cardiac Model
223929828|NCT06758141|OTHER|Slide-based presentation|Slide-based presentation
223929829|NCT06892743|PROCEDURE|US-guided external oblique intercostal plane block (EOIPB)|US Guided external oblique intercostal plane block (EOIPB) or Posterior TAP Block:
223929830|NCT06302140|DRUG|[14C]-Nanatinostat|A single oral dose administered on Day 1 in a fasted state.
223929831|NCT06302140|DRUG|Nanatinostat (free base) tablets in combination with Valganciclovir|Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
223929832|NCT06302140|DRUG|Nanatinostat mesylate tablets in combination with Valganciclovir|Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
223929833|NCT06302140|DRUG|Single-agent Nanatinostat (free base) tablets|40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
223929834|NCT06000787|RADIATION|External beam radiotherapy|Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
223929835|NCT06000787|RADIATION|131I-Metaiodobenzylguanidine (MIBG)|Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
223929836|NCT06778317|DIAGNOSTIC_TEST|Circulating mSEPT9 Biomarker Testing|"This intervention involves the analysis of the circulating epigenetic biomarker mSEPT9 through plasma samples collected from patients with cirrhosis. The mSEPT9 test evaluates the methylation status of the SEPT9 gene promoter using a triplicate assay. A switch in the test status, defined as a transition from triple-negative (no methylation detected in any triplicate) to at least one positive triplicate, is being investigated as a prognostic marker for the development of hepatocellular carcinoma (HCC).~The mSEPT9 test is conducted on plasma samples collected during routine blood draws at each of the 11 scheduled study visits. Samples are processed and analyzed in batches using specialized high-throughput equipment provided by Epigenomics/New Day Diagnostics. Results of the mSEPT9 test are not shared with clinicians during the study period to avoid influencing patient management, ensuring the test is purely investigational in this context."
223929837|NCT06302530|PROCEDURE|Stayer|"In group A, the intervention involves using the Strayer technique, an echo-guided recession of the gastrocnemius tendon, with local anesthesia and sedation as needed. The patient can be in a prone or supine position. Ultrasound will identify the sural nerve and blood vessels to prevent damage. The entry point is 2-3 cm distal to the medial head of the gastrocnemius. Local anesthetic is infiltrated, and blunt dissection creates a working space. V-shaped curettes widen the entry point without harming noble structures.~Under direct ultrasound control, a curved scalpel is inserted until reaching the medial border of the gastrocnemius tendon. Transection occurs progressively from medial to lateral while flexing the foot. Verification of complete tendon transection is done with a blunt dissector. Finally, a dressing with adhesive strips and an elastic bandage is applied, eliminating the need for sutures."
223929838|NCT06302530|PROCEDURE|Plantar transection|In group B, an echo-guided transection of the plantar tendon will be performed. Local anesthesia and sedation will be used as needed. The patient will be in prone or supine position. The plantar tendon will be identified ultrasonographically on the medial aspect of the gastrocnemius distal to the myotendinous junction. Local anesthetic will be infiltrated at that point to isolate the plantar tendon. An ultrasound-guided retrograde hook is introduced until the plantar tendon is engaged. Then proceed to retrograde transection of the tendon from lateral to medial, verifying complete section. At the end, a dressing with adhesive strips and elastic bandage, without sutures, will be performed.
223929839|NCT06302530|PROCEDURE|Baumann|It consists of an ultrasound-guided recession of the anterior gastrocnemius aponeurosis. Under local anesthesia, the myotendinous junction is accessed 3 cm proximal to the myotendinous junction, using saline for hydrodissection. Under ultrasound guidance, the entry portal is enlarged and a scalpel is introduced for transection of the aponeurosis and plantar tendon. The procedure is verified with a buttoned probe and does not require sutures. The patient wears a Walker boot for 4 weeks and follows a stretching protocol.
223929840|NCT06302530|PROCEDURE|Gastro-Soleus|This technique adapts the Strayer technique to include the soleus. Under local anesthesia, access is gained 4-5 cm distal to the medial head of the gastrocnemius. Transection of the gastrocnemius aponeurosis and a superficial section of the soleus tendon are performed, all under ultrasound guidance. Without the need for sutures, the patient wears a Walker boot for 4 weeks and follows a progressive rehabilitation protocol.
223929841|NCT03424525|DRUG|11C-Trimethoprim|\[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
223929842|NCT06830434|PROCEDURE|Crown lengthening surgery|Following clinical and radiographic examinations and thorough case planning, surgical procedures were performed under local anesthesia by a single operator. After anesthesia, the distance from the gingival margin to the cementoenamel junction will be measured, and these values will be transferred to the gingival tissue to guide the procedure. Excess gingival tissue will be excised, and, when necessary, an osteotomy will be performed to re-establish the supracrestal attachment tissues.
223929843|NCT05862324|BIOLOGICAL|TAC01-CLDN18.2|TAC01-CLDN18.2 preceded by lymphodepletion with fludarabine or clofarabine, cyclophosphamide, and nab-paclitaxel.
224095189|NCT05678803|OTHER|xrays and CT|A dedicated sheet will be used to record patients' data including all demographic data, detailed analysis of the mechanism of injury, time of injury, time and details of surgery (if any), neurological status on admission and all radiological findings. All patients will undergo plain X-rays and CT imaging. Patients with suspected discoligamentous injuries and/or neurological deficits will also be assessed by MRI.
224095190|NCT03591900|DEVICE|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
223718202|NCT07014397|DRUG|Valacyclovir|valacyclovir group received 2 g (two 1 g tablets) one hour prior to treatment, followed by 2 g 12 hours later, and 1 g at both 24 and 36 hours post-treatment
223929844|NCT06401031|DEVICE|Press Needle|Press needle is patch-type acupuncture needle which has a very small needle. This is placed onto acupuncture point and give a simultaneous stimulation, which is held in place with a small, sterile surgical adhesive patch.
223929845|NCT06401031|DEVICE|Sham Press Needle|Sham press needle is a surgical adhesive patch without needle, that is placed onto acupuncture point
223929846|NCT05169112|DRUG|Lupron Depot|Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
223929847|NCT05065281|OTHER|Education|Training for health care professionals on how to identify and manage cases of elder abuse among their patients
223929848|NCT06818721|DRUG|Intravitreal topotecan|Patients who meet all inclusion criteria and none of the exclusion criteria will receive intravitreal topotecan (8 µg in 0.05 mL). The treatment will be administered within one week before retinal detachment surgery (pneumatic retinopexy, pars plana vitrectomy, and/or scleral buckling) and one week after surgery, for a total of two injections.
224095191|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
224095192|NCT04070794|DRUG|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
224095193|NCT03696472|PROCEDURE|robotic assisted surgery|robotic assisted surgery was benefit to operation
224095194|NCT03696472|PROCEDURE|laparoscopic|conventional laparoscopic surgery
224095195|NCT03758560|OTHER|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
224095196|NCT02548702|BEHAVIORAL|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
224283616|NCT02266849|DRUG|Loperamide|12 mg Loperamide each day for three days
224283617|NCT02266849|DRUG|Placebo|6 tablets daily for three days
224283618|NCT02917252|OTHER|3-hydroxybuturate|Drink of ketone bodies
223718203|NCT07014397|DRUG|Placebo|The control group received a placebo identical in appearance and administration schedule
224283619|NCT02917252|OTHER|Placebo|Drink of saline
223929849|NCT06818721|PROCEDURE|Retinal detachment surgery|Standard retinal detachment surgery (pneumatic retinopexy, three-port pars plana vitrectomy, and/or scleral buckling).
224283620|NCT03370107|DEVICE|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
224283621|NCT04464109|PROCEDURE|Evisceration with orbital implantation|Evisceration will be performed. Alloplastic orbital implant will be inserted either posterior to the sclera or partly within the scleral canal.
224283622|NCT02025088|PROCEDURE|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
224283623|NCT02025088|PROCEDURE|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
224283624|NCT02283593|BEHAVIORAL|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
224283625|NCT06616493|OTHER|kinesio taping|measure the subjects' lower extremity biomechanical characteristics with 3 different conditions respectively (kinesio taping, placebo kinesio taping, no taping)
224283626|NCT06533371|DIAGNOSTIC_TEST|Relationship between lung ultrasound and computed tomographic scan|"Ultrasonographic findings will be obtained with clinical machines. Additionally, US scans as acquired with the Ula-Op open research platform will also be gathered. For both scanners, 10seconds videos will be recorded and stored in each landmark.~To correlate LUS artefactual patterns with peripheral parenchymal changes evaluated by HRCT of the chest, all chest CT findings will be analysed by an image processing platform designed to provide visualization and quantification of areas with abnormal CT tissue density indicative of emphysema and air trapping. Post-processing image analysis will be performed on images by using automated detection of potential emphysema systems."
224283627|NCT05118360|DRUG|ASC41 2 mg|2mg of ASC41 orally once daily for 52 weeks
224283628|NCT05118360|DRUG|ASC41 4 mg|4mg of ASC41 orally once daily for 52 weeks
223929850|NCT06736587|DRUG|DWP212525 10mg|DWP212525 10mg
223929851|NCT06736587|DRUG|DWP212525 30mg|DWP212525 30mg
223929852|NCT06736587|DRUG|DWP212525 50mg|DWP212525 50mg
223929853|NCT06736587|DRUG|DWP212525 100mg|DWP212525 100mg
224095197|NCT00582894|DRUG|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
224095198|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
224283629|NCT05118360|DRUG|Placebo|Matching placebo orally once daily for 52 weeks.
224283630|NCT05085769|PROCEDURE|Bariatric surgery|A procedure for morbidly obese patients whose body mass index (BMI) is higher than 40 kg/m2 or 35 kg/m2 and having comorbidities of obesity.
224283631|NCT00724620|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
223718204|NCT07016256|DEVICE|intraoral devices|Intraoral devices not registed with a patent
223929854|NCT06736587|DRUG|DWP212525 200mg|DWP212525 200mg
223929855|NCT06736587|DRUG|DWP212525 400mg|DWP212525 400mg
223929856|NCT06736587|DRUG|DWP212525 placebo|DWP212525 placebo
223929857|NCT06889558|PROCEDURE|tenting titanium technique|technique used to increase bone augmentation and increase bone volume
223929858|NCT06889558|PROCEDURE|tenting titanium screw|technique used for increase bone voliume
223929859|NCT06763718|OTHER|Modified Qigong Breathing Exercise|"The exercise is recommended to be performed standing, or modified standing with trunk leaning forward and bilateral upper extremities support on countertop. Initial position: Stand up with feet shoulder-width apart, hands down along the body, or put palms on the abdomen. Take a deep breath, squaring shoulders, and pull in belly at the same time. Hold breath for 3 to 4 seconds, while keeping abdomen retracted with maximally contracting abdominal muscles. Exhale, so the shoulders go back to the starting position, while chest and abdominal muscles relax. Repeat this exercise 10 times. Note. If the stomach is difficult to draw in a standing position, it is possible to perform the exercise with both hands resting on support.~Duration: 30 minutes, 3 days/ week for 8 weeks"
223929860|NCT06763718|OTHER|Control|No exercise will be given to the participants in the control group
223929861|NCT06787846|OTHER|Experimental: Group TP|Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day
223929862|NCT06787846|DRUG|Active Comparator: Group HQ: Hydroquinone 4%|Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day
224095199|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
224095200|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
224095201|NCT00511420|DIETARY_SUPPLEMENT|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
223929863|NCT06858384|OTHER|Control (Standard treatment)|Participants in this arm will continue with their usual care without any pharmacist-led intervention during the 6-month study period. Physicians and patients will follow the standard clinical practice for PPI prescriptions. At the end of the 6-month period, the educational materials provided to the intervention group will be offered to the control group.
223929864|NCT06858384|OTHER|Pharmacist-Led Educational Intervention|Physicians and patients in this arm will receive a multi-faceted pharmacist-led educational intervention. This includes evidence-based deprescribing guidelines, brochures, videos, and decision aids to promote appropriate use of PPIs and reduce unnecessary prescriptions. The intervention is delivered in four parts: educational brochures, deprescribing algorithm, patient action plans, and video-based education sessions.
223929865|NCT06801600|DRUG|Weight-based dosing|Hyperbaric bupivacaine 0.5% dosage will be calculated and administered intrathecally as 0.4 mg/kg or 0.08 ml/kg if body weight ≤ 15 kg and 0.3 mg/kg or 0.06 ml/kg if body weight \> 15 kg
223929866|NCT06801600|DRUG|Age-based dosing|Hyperbaric bupivacaine 0.5% will be administered at the dose of age divided by 5 (in ml). The age in months after the completion of a year was noted and considered as the next age if it is more than 6 months and the same age if it is ≤ 6 months.
223929867|NCT03422432|PROCEDURE|HIPEC|All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
223929868|NCT01968109|BIOLOGICAL|Relatlimab|
224095202|NCT00006187|DRUG|Investigational drug|
224095203|NCT03341884|DRUG|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
224095204|NCT02682836|BEHAVIORAL|Walk with Ease|
224095205|NCT06418620|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
224095206|NCT04284540|RADIATION|Adjuvant hypofractionation|15 fractions of 2.7 Gy per fraction daily over 3 weeks for a total of 40.5 Gy to the post-operative bed and/or necks.
224095207|NCT04284540|RADIATION|Definitive Hypofractionation|15 fractions of 3 Gy per fraction daily over 3 weeks for a total of 45 Gy to regions of gross disease. Elective areas can be treated to 37.5 Gy in 15 fractions.
224095208|NCT02840136|DRUG|Piperacillin-tazobactam combination product|
224095209|NCT02840136|DRUG|Meropenem|
224095210|NCT02840136|DRUG|Ceftazidime|
224095211|NCT00308724|BEHAVIORAL|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
223929869|NCT01968109|BIOLOGICAL|Nivolumab|
223929870|NCT01968109|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab
223929871|NCT06723522|DEVICE|HD-tDCS|2 mA HD-tDCS of right inferior frontal gyrus lasting for 10 days, each stimulation lasted for 20 min, with 30 s of ramp-up and ramp-down before and after the 20-min stimulation, respectively.
223929872|NCT06723522|DEVICE|Sham (No Treatment)|Received 1 min of ramping up/down without experiencing 2 mA HD-tDCS stimulation lasted for 20 min.
223929873|NCT06834958|PROCEDURE|Appendectomy|Open surgery for appendix which is inflamed
223929874|NCT04039113|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
224095212|NCT00308724|BEHAVIORAL|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
224095213|NCT05535179|DRUG|honeysuckle and semen oroxyli solution|The patients in the treatment group were instructed to gargle the solution containing honeysuckle and semen oroxyli (25 mL) four times a day for 2 weeks.
224095214|NCT02305563|DRUG|BMS-936564|
224095215|NCT02305563|DRUG|Cytarabine|
224283632|NCT00724620|DRUG|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
224283633|NCT05487755|DRUG|Tadalafil 20Mg Oral Tablet|Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor used mainly in erectile dysfunction and pulmonary hypertension by a mechanism involving increase(NO-cGMP-PKG) signaling pathway.(8) Tadalafil is a powerful pleiotropic drug that it can be used in DN as it can target more than pathway involved in pathogenesis of DN include hyperglycemia and endothelial dysfunction through increase (NO-cGMP) signaling pathway as well as hyperlipidemia
224283634|NCT05487755|DRUG|Pentoxifylline 400 MG Oral Tablet|Pentoxifylline is a methyl xanthine derivative, non selective phosphodiesterase enzyme inhibitor used mainly to treat peripheral vascular diseases by improve blood flow
224283635|NCT03337217|PROCEDURE|Position during colonoscopy|Position during colonoscopy
224283636|NCT00006143|DRUG|Somatropin|
224283637|NCT05183087|DIAGNOSTIC_TEST|3T Connectome MRI|MRI scan of structural connectivity
224283638|NCT05183087|DIAGNOSTIC_TEST|7 Tesla MRI|MRI scan of functional connectivity
224283639|NCT05183087|DIAGNOSTIC_TEST|TSPO PET|PET scan of neuroinflammation
224283640|NCT05183087|DIAGNOSTIC_TEST|Tau PET|PET scan of tau deposition
224283641|NCT05183087|DIAGNOSTIC_TEST|Cognitive and Behavioral Assessments|Assessments of memory, attention, complex reasoning, mood and other cognitive/behavioral domains
223929875|NCT04039113|OTHER|Placebo|Placebo subcutaneous injection
224095216|NCT02643095|DEVICE|scleral contact lens|Scleral contact lens
224095217|NCT01207466|DEVICE|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
224095218|NCT01207466|DEVICE|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
224095219|NCT02847884|BIOLOGICAL|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
224095220|NCT05785884|BEHAVIORAL|Diet|A 6 week randomized diet
224095221|NCT02707185|BEHAVIORAL|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
224095222|NCT02463461|DEVICE|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
224095223|NCT02463461|DEVICE|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
223929876|NCT06725017|DRUG|Live SK08 powder|SK08 is an investigational live biotherapeutic product containing a nontoxigenic B. fragilis(NTBF) strain as an active ingredient.
223929877|NCT06725017|DRUG|Placebo|Placebo
223929878|NCT00353496|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
223929879|NCT00353496|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
223929880|NCT06886490|OTHER|Mediterranean diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Mediterranean diet: Animal : vegetable protein ratio - 70:30.
223929881|NCT06886490|OTHER|Planetary diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Planetary diet: Reduce consumption of red meat, moderate consumption of poultry, fish and seafood and their products, and eggs and dairy. Animal : vegetable protein ratio - 50:50
223929882|NCT06886490|OTHER|Lactovegetarian diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Lactovegetarian diet: Reduce consumption of meat, fish and seafood and their preparations, and eggs and dairy products. Animal : vegetable protein ratio - 30:70.
223929883|NCT06886490|OTHER|Vegan diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Vegan diet: Excludes all animal and animal-derived products (meat, fish, seafood, dairy, eggs, honey).
223929884|NCT06886490|OTHER|Control diet|VEGPREV study is a randomized intervention trial with an intervention period of 12 weeks, and follow-up after another 12-14 weeks conducted at the Department of Social Medicine and Public Health at Warsaw Medical University. Study aim is to evaluate the efficacy of the following plant-based diet: Control diet: Reduce consumption of red meat, consumption of poultry, fish and seafood and their products, regular consumption of eggs and dairy products.
223929885|NCT06790108|DEVICE|Artificial intelligence device|This AI device can provide prompts for standard sites of pancreatic scans and anatomical structures. It may also suggest the next operation methods.
223929886|NCT05662904|BIOLOGICAL|Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion|CD33-deleted CD34+ hematopoietic stem cells derived from the initially matched family donor
223929887|NCT05662904|DRUG|Gemtuzumab Ozogamicin|Intrapatient intra-individual dose escalation Level 0: GO day 1 Level 1: GO day 1, day 4 Level 2: GO day 1, day 4, day 7 with repetition after 21 to 28 days up to 84 days.
223929888|NCT06575595|BIOLOGICAL|Tulisokibart|single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
223929889|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for Very-low dose group|Very-low dose group will receive medication on arrival before completing the relevant assessment tests; the very-low dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch and replaced with a 0mg patch before returning home from the examination.
223929890|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for Lower dose group|The lower dose group will be administered 1/9 of a 5mg buprenorphine transdermal patch.
223929891|NCT06772324|DRUG|NORSPAN Buprenorphine Transdermal Patchs for higher dose group|The higher dose group will be administered 1/3 of a 5mg buprenorphine transdermal patch.
223929892|NCT06181500|OTHER|Home-based multicomponent exercise intervention program|A novel home-based multicomponent exercise intervention program was designed using a multimodal training circuit. This 24-week circuit program was created to improve functional (resistance) and aerobic health. Participants will be asked to train two to three times a week for 45 minutes. They will be supervised via videoconference by a trained kinesiologist from the EPIC Center at the Montreal Heart Institute. If desired, participants can complete their exercises with a partner, friend, or relative to facilitate communication. Participants will be asked to document the perceived intensity of their exercises in a booklet after each workout. The perceived intensity of their exercises will be measured by a validated effort perception scale graduated from 0 to 10 (Borg scale; Williams, 2017). Progressions will increase every five weeks and will be subject to modification if not properly tolerated or if found to be below a 3 on the Borg rate of perceived exertion scale (moderate intensity).
223929893|NCT01906853|BIOLOGICAL|BCG|
223929894|NCT01746849|BIOLOGICAL|Palifermin|
223929895|NCT01746849|BIOLOGICAL|Lupron|
223929896|NCT01746849|PROCEDURE|peripheral blood stem cell transplantation|
223929897|NCT01746849|RADIATION|Total-Body Irradiation (TBI)|
223929898|NCT01746849|DRUG|Thiotepa|
223929899|NCT01746849|DRUG|Cyclophosphamide|
223929900|NCT01746849|DRUG|Degarelix|
223929901|NCT06825455|DRUG|Fludarabine|Intravenous infusion group:30mg/m2 x 3 days (Day-4\~-2)
223929902|NCT06825455|DRUG|Cyclophosphamide|Intravenous infusion group:500mg/m2 x 3 days (Day-4\~-2)
223929903|NCT06825455|BIOLOGICAL|B7H3 CAR-γδT cells|A single infusion of 6.0×107 CAR+ cells, 2.0×108CAR+ cells, and 6.0×108CAR+ cells
223929904|NCT06883370|COMBINATION_PRODUCT|ultrasound-guided transversals fascia plane block with ropivacaine|using 0.375% ropivacaine of 0.4mls/kg
223929905|NCT06788925|DEVICE|Patients support with survival coverage|"Following calls to emergency medical services, handled by the ground SMUR/SAMU or the air SMUR (HéliSMUR), the operator collects essential information on the nature of the incident and the apparent condition of the injured. A medical team is thus mobilized on site. It takes over from the rescue team (e.g. the SDIS fi refi ghters) who are generally the fi rst to arrive on the scene.~Eligible patients will be randomly assigned consecutively to one of two groups: control (use of the survival blanket) and experimental (use of the Therm'Up breastplate).~Any traumatized person at risk of hypothermia or in hypothermia in a pre-hospital environment, having given verbal consent to participate in the study and meeting the inclusion criteria"
224095224|NCT02463461|DEVICE|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
223929906|NCT06788925|DEVICE|Patients support with active thermic jacket|The intervention Description is exactly the same, except that the patient will be given a ThermUp jacket
223929907|NCT06746142|RADIATION|Deep inspiration breath hold radiotherapy|Participants will be trained for 2-3 days for obtaining the desired breathing cycle by trained technologists. No extra equipment will be needed. At first, they will be assured and asked to relax. Then instructed to breath in and out twice followed by a slow, deep breath in to a comfortable higher level than normal and to hold it for at least 20 seconds then again breath normally. Once they are ready with expected breath holding, simulation will be done. Treatment will also be given in this breath holding position.
223929908|NCT06746142|RADIATION|Free breathing radiotherapy|Patient will be advised for free breathing during simulation and treatment.
223929909|NCT05186636|OTHER|KPI reports|Quarterly
223929910|NCT05186636|OTHER|Prescriber reports|Individualized prescriber reports for acute RRT initiation patterns along with targeted education to ensure that align with best evidence-based practices
223929911|NCT06768151|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
223929912|NCT06768151|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
223929913|NCT01952873|OTHER|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with \<0.3 atm drop during that period.
223929914|NCT01952873|OTHER|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but \<30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
223929915|NCT06802952|DEVICE|rTMS|RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
223929916|NCT06256718|OTHER|Educational Intervention|Evidence-based strategy (PC TEACH)
223929917|NCT05587374|DRUG|Cadonilimab|Cadonilimab 10mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 14 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
223929918|NCT05587374|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
223929919|NCT05587374|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
223929920|NCT05587374|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
224095225|NCT02463461|DEVICE|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
224095226|NCT02463461|DEVICE|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
224283642|NCT05183087|DIAGNOSTIC_TEST|Blood Biomarkers|Blood-based assessments of proteomic and metabolic biomarkers of brain injury
224283643|NCT05049811|BEHAVIORAL|mini program|To design, construct, and test the mini program in patients managing cancer pain
224283644|NCT05049811|BEHAVIORAL|conventional pharmaceutical care|Regular education includes medication guidance from doctors, nurses and pharmacists.
224283645|NCT02883517|GENETIC|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
224283646|NCT00108576|DRUG|Divalproex|anticonvulsant; mood stabilizer
223929921|NCT06928389|DRUG|Ivonescimab, docetaxel|Patients will receive ivonescimab and docetaxel as an IV injection
223929922|NCT06928389|DRUG|Placebo, docetaxel|Patients will receive placebo and docetaxel as an IV injection
223929923|NCT06786715|DEVICE|Retrograde intrarenal surgery using DISS|Retrograde intrarenal surgery using Direct in scope suction for renal stone up to 3 cm
223929924|NCT06786715|DEVICE|Retrograde intrarenal surgery using FANS|Retrograde intrarenal surgery using Flexible and navigable suction for renal stone up to 3 cm
223929925|NCT01470144|DRUG|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
223929926|NCT03871036|DRUG|Tremelimumab|See experimental arm description for more details.
223929927|NCT03871036|DRUG|Durvalumab|See experimental arm description for more details.
223929928|NCT03871036|DRUG|Paclitaxel|See experimental arm description for more details.
223929929|NCT06935994|DRUG|Aspirin 81 mg Enteric Coated Tab - 1 tablet|Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
223929930|NCT06935994|DRUG|Placebo|Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
223929931|NCT01663363|DEVICE|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
223929932|NCT06788795|DEVICE|Device with Phone App|This is the intervention where the patients will be given both the wearable dehydration device as well as the phone app
223929933|NCT06788795|DEVICE|Device without Phone App|This is the intervention where the patients will receive the device alone
224095227|NCT02700451|DRUG|Ketorolac|"Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed."
224283647|NCT00108576|OTHER|placebo|Look-a-like placebo
224283648|NCT00004294|GENETIC|human glucocerebrosidase gene into autologous peripheral blood stem cells|
224283649|NCT00003894|DRUG|thalidomide|
224283650|NCT00200317|BEHAVIORAL|Internet and print-based interventions|
224095228|NCT02700451|DRUG|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
223929934|NCT06789874|PROCEDURE|Intralesional Saline|Intralesional Saline injected in scars
223929935|NCT06789874|PROCEDURE|35% trichloracetic acid peel|35%Trichloracetic acid peel was applied to scars monthly for 3 months
223929936|NCT06798194|DIAGNOSTIC_TEST|Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.|"This study developed an AI model that can provide optimal highly conformal ablation thermal field for HCC patients using ultrasound and MRI. Post-ablation MRI is used to evaluate whether the ablation area of the tumor is consistent with the highly conformal ablation thermal field provided by the AI model.~The patients were divided into:~1. Actual ablation zone of the tumor was consistent with the highly conformal ablation thermal field (consistent group);~2. Actual ablation zone of the tumor was inconsistent with the highly conformal ablation thermal field (inconsistent group)."
223929937|NCT06856148|BEHAVIORAL|Intervention: RPC Group|"The RPC model entails seven interrelated steps including a capacity building and collaboration phase. Throughout the implementation, researchers are provided direct access to intermediary support from our trained RPC fellows who facilitate RPC activity at each step coordinated by an implementation supervisor. Importantly, this model does not involve any lobbying. Consistent with NIH guidelines for grantees, the RPC instead aims to highlight and translate public health evidence…; conduct coalition building…; provide leadership and training, and foster safe and healthful environments. Specifically, implementation of the RPC model explicitly does not attempt to influence legislative actions, but instead facilitates honest brokerage in which researchers discuss evidence without indicating opinion or stance on how legislators should change specific policies, programs, or regulations."
223929938|NCT06856148|BEHAVIORAL|Active Comparator: Control Group|"Control group participants will receive light touch research support, similar to previous work (e.g., an RPC associate will send publicly available research materials in response to research requests). This light touch control condition will increase responsiveness of state officials to survey follow up requests."
223929939|NCT06342973|DEVICE|Xenograft and allograft|For the guided bone augmentation procedure, a crestal incision with one or two vertical incision will be made and a full thickness mucoperiosteal flap will be elevated. Decortication will be performed and the patient will receive grafting with DFDBA with a buccal overlay of xenograft. A bi-layered native collagen membrane will be used and fixed with tacks or sutures. Periosteal incisions will be made to get tension free primary closure. The flap will be closed with sutures. Patients will be prescribed antibiotics, analgesics and mouth rinses as appropriate.
223929940|NCT01356524|DRUG|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
223929941|NCT00389194|DRUG|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
223929942|NCT04761042|OTHER|WAYA-Wilderness|"The wilderness intervention includes challenging tasks in order to help participants' overcome and master new physical and psychological challenges in an unknown environment, with the idea to support self-efficacy, self-esteem, and ability to recover from adversity. The program is designed to encourage participants to connect with nature as to experience gratitude for the richness of the natural world, a sense of calmness and trust upon spending time in nature, and to be more physically active in nature.~Elements previously described Participants will continue in a three-month program at home (on-line supported) after the initial 8-days in order to empower participants to incorporate elements of the onsite wilderness program into their daily life. An individualized a plan for activities will be developed together with the participant.~After three months, there will be a re-visit with follow up on outcome measures and reconnection."
223929943|NCT04761042|OTHER|WAYA-Holiday|"An attention control group (information in Detailed description)"
223929944|NCT05889299|DRUG|OMS906 study drug|OMS906 study drug dose repeat-dose 5mg/kg SC administration at 4-week intervals
223929945|NCT06433713|DRUG|Lidocaine IV|They received IV infusion of 2 mg/kg per hour of lidocaine starting with skin incision, which was maintained until skin closure. This was done using a syringe pump with the calculated amount of lidocaine added to 50 ml of normal saline infused at a rate of 50 ml/hr.
223929946|NCT06433713|DRUG|Placebo|0.9% normal saline infusion
223929947|NCT01053325|DRUG|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
223929948|NCT01053325|DRUG|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
223929949|NCT00000119|DEVICE|Heparin Surface-Modified Intraocular Lens|
223929950|NCT02132455|PROCEDURE|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
223929951|NCT05416827|PROCEDURE|slow-release dexamethasone implant|Epiretinal membrane eyes underwent PPV combined with Ozurdex implant
223929952|NCT02348632|DRUG|JZP-110|
223929953|NCT05661708|DRUG|Chitosan|Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect
224095229|NCT02700451|DRUG|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
224095230|NCT04573101|OTHER|Music listening / EEG recording|Participants listen to 24 different audio clips of 1 min long each, and select emotion in between. EEG is recorded while participants are listening. Participants select the emotion that best describes their feeling from Table 1 of the PANAS-X. https://www2.psychology.uiowa.edu/faculty/clark/panas-x.pdf
224095231|NCT03835091|OTHER|BRASS score|Brainstem response on neurologic examination
224283651|NCT03118219|OTHER|Positive adjustment coping intervention|see arm description
224283652|NCT03118219|OTHER|Brainteaser|see arm description
224095232|NCT00588367|DEVICE|Mayo Interactive Breath Hold Monitor|Biofeedback device
224283653|NCT05563688|OTHER|Hypoxia exposure|"Each participant will be exposed to the hypoxic environment on 2 occasions (one after a normal sleep night and one after sleep deprivation).~Each exposure will be for 5 hours at a FiO2 of 13.2% (3500 m simulated altitude).~This exposure will be carried out in a normobaric hypoxic tent (Sporting Edge®)."
223929954|NCT02572700|OTHER|Clinical examination, blood sampling, ultrasonic assessment, and questionnaires|Visits include clinical examination, questionnaires (pain, comorbidity, lifestyle, work status) and ultrasonography of joints and entheses, blood samples, and only at baseline x-ray of hands and feet.
223929955|NCT01925144|DRUG|Baricitinib|Administered orally
224283654|NCT05563688|OTHER|Sleep deprivation|"Each participant will be exposed to sleep deprivation on 2 occasions (one before normoxia exposure and one before hypoxia exposure).~Each sleep deprivation involves a time spent in bed of 3 hours (03h00 - 06h00). Sleep deprivation will be carried out in a sleep apartment. Sleep duration and quality will be assessed using a sleep headband (Dreem®), actigraphs Actiwatch® and E4 Empatica®) and a sleep diary."
224283655|NCT05563688|BEHAVIORAL|Cognitive tasks|"Participants will perform several cognitive tasks in the following conditions:~* in normoxia (FiO2 = 21%) after a night of usual sleep (\> 6 hours) ;~* in normoxia (FiO2 = 21%) after a night of reduced sleep (3 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of normal sleep (\> 6 hours);~* in normobaric hypoxia (FiO2 = 13.2%) after a night of reduced sleep (3 hours)."
223929956|NCT01925144|DRUG|Omeprazole|Administered orally
223929957|NCT00312208|DRUG|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
223929958|NCT00312208|DRUG|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
223929959|NCT01094626|DRUG|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
223929960|NCT02098837|DRUG|Dolutegravir|Dolutegravir 50mg once daily
223929961|NCT01488656|DIETARY_SUPPLEMENT|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
224095233|NCT01554657|OTHER|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
224095234|NCT01554657|OTHER|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
224095235|NCT01938287|DEVICE|SENSIMED Triggerfish|
224095236|NCT04613986|DEVICE|therapeutic plasmaexchnage|established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)
224095237|NCT00977392|BEHAVIORAL|compliance monitoring|
224095238|NCT00977392|OTHER|cervical Papanicolaou test|
224095239|NCT00977392|OTHER|educational intervention|
224095240|NCT00977392|OTHER|screening questionnaire administration|
224095241|NCT00977392|OTHER|survey administration|
224095242|NCT00977392|PROCEDURE|colposcopy|
224095243|NCT00454207|DRUG|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
224095244|NCT02553135|BIOLOGICAL|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
224095245|NCT02964598|BEHAVIORAL|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
224095246|NCT02964598|BEHAVIORAL|Sleep coaching|A new personalized program, duration 4-6 weeks
224095247|NCT02964598|DEVICE|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
224095248|NCT02964598|OTHER|Control|Minimal information on sleep timing and advancing the sleep rhythm
224283656|NCT05612087|DEVICE|Confocal laser endomicroscopy|Confocal laser endomicroscopy at jejunum, duodenum and stomach
224283657|NCT00612677|DRUG|Oxaliplatin|Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days
223929962|NCT01488656|DIETARY_SUPPLEMENT|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
223929963|NCT06116929|OTHER|Morphological and functional magnetic resonance imaging (MRI)|"Patients will undergo 3 morphological and functional MRI scans (during rest and activity) on the 3T MRI scanner at St Philibert Hospital (Lille, France) at 0 (M0), 6 (M6) and 12 (M12) months.~The controls will perform a single functional MRI on the 3T MRI."
224095249|NCT02964598|OTHER|Psychoeducation|An extensive information platform in the internet created for this purpose
224095250|NCT01166048|DRUG|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
224095251|NCT01166048|DRUG|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
224095252|NCT05345470|OTHER|140 calories per 30 gram test meal|Food
224095253|NCT06644989|PROCEDURE|Spencer Technique|Spencer technique on the hip
224095254|NCT06644989|OTHER|Sham (No Treatment)|Spencer technique position but no pressure
224095255|NCT05159414|DEVICE|Pulse Electrical Stimulation|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
224283658|NCT00612677|DRUG|Pemetrexed|Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days
224283659|NCT02810249|OTHER|No intervention used|
223718205|NCT07015684|DRUG|131I-apamistmab|131I-apamistamab is a drug construct consisting of the apamistamab monoclonal antibody (mAb) and radioactive isotope iodine 131 (131I). The study drug will be patient-specific and will be manufactured for dosing on a specific date. The antibody dose will be at least 0.5mg/kg, however the final antibody amount may be higher if necessary based on the target radioactivity level. The 131I-apamistamab study drug requires patient details such as height, weight, a calculation to determine weight for use in calculating antibody amount for the dose. 131I-apamistmab will be given via intravenous (IV) infusion.
223929964|NCT06116929|OTHER|Neuropsychological assessment|"3 neuropsychological assessments will be carried out at M0, M6 and M12, by the same neuropsychologist for all patients included.~Controls will undergo the same neuropsychological assessments, but only once."
223929965|NCT02955563|OTHER|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
223929966|NCT03907306|PROCEDURE|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
223929967|NCT05899699|DRUG|DAP-FLU ME|Combination therapy of topical anti-inflammatory agent (Dapsone 5%) and anti-androgenic agent (Flutamide 2.5%) with anti-bacterial agent of micro-emulsion component (tea tree oil 5%)
223929968|NCT05899699|DRUG|Adapalene .1% gel|Adapalene .1% gel
223929969|NCT02284113|DEVICE|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
223929970|NCT02284113|DEVICE|iovera° Sham|iovera° device used for sham treatment
223929971|NCT02624141|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
223929972|NCT05570305|DRUG|Zibotentan|Zibotentan 1.5 mg once per day as a hard capsule.
224095256|NCT05383924|PROCEDURE|postplacental IUD insertion|"patients will have immediate postplacental IUD insertion as follows: The IUD is inserted after removal of the placenta and after the uterus has become hemostatic. After initiating closure of the uterine incision, the IUD is placed at the top of uterine fundus manually. Before closing the uterine incision, the strings are placed gently in the lower uterine segment manually. After this is accomplished, the uterine incision closure can be completed. The strings will usually descend spontaneously through the cervix during the puerperal period. If the cervix is closed, it'll be dilated from above with ring forceps. Strings can be passed through the cervix with ring forceps. If this is done, the surgeon will recheck to make sure IUD remains at the fundus of the uterus prior to closing the uterine incision. Strings can be trimmed at a follow-up visit.~Ultrasound will be done after the CS to ensure proper placement of the IUD."
224095257|NCT05383924|PROCEDURE|delayed IUD insertion|cesarean section will be done, then contacts will be taken to arrange for delayed IUD insertion at the 6th week postpartum visit as follows: Prepare IUD prior to starting procedure Place vaginal speculum then prepare vaginal wall with betadine Apply tenaculum at anterior cervical position then insert and remove uterine sound Place IUD according to package insert then cut threads 2-3 cm from cervical os. Ultrasound will be done to ensure proper placement of the IUD.
224095258|NCT04909905|DIETARY_SUPPLEMENT|Standard enteral nutrition|Standard enteral nutrition according to ICU nutrition protocol for 7 days
224095259|NCT04909905|COMBINATION_PRODUCT|Glutamine|Intravenous glutamine supplementation to enteral nutrition in a dose of dose of glutamine of 0.4 g/kg/day for 7days
224095260|NCT01557790|RADIATION|Proton Radiation Therapy|
224283660|NCT04751630|OTHER|Therapeutic Exercise|Online and structured exercise therapeutic program based on flexibility, strength, balance and aerobic exercises. The program have been supervised by an expert on the field and it participants will perform it under the supervision of an expert physiotherapist.
224283661|NCT01253395|BEHAVIORAL|Strength training|Daily supervised strength training.
224283662|NCT01253395|BEHAVIORAL|Aerobic exercise|Daily supervised aerobic exercise.
223718206|NCT07015684|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. It is an immunosuppressant agent. Sirolimus is to be given orally either as tablet or solution form. Dosage will be adjusted to a therapeutic target of 10-15 ng/mL in first 6 months post-transplant and 5-10 ng/mL after 6 months.
223929973|NCT05570305|DRUG|Dapagliflozin|Dapagliflozin 10 mg once per day as a tablet.
223929974|NCT05570305|DRUG|Placebo|Matching placebo.
223929975|NCT05570305|DRUG|Dapagliflozin and Zibotentan|Dapagliflozin 10 mg once per day as a tablet in combination with zibotentan 1.5 mg once per day as a hard capsule.
224095261|NCT04178655|DRUG|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
224095262|NCT04178655|DRUG|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
224095263|NCT05451719|DRUG|Fruquintinib Plus Capecitabine|Fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W). Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
224283663|NCT03417830|DRUG|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
224283664|NCT03417830|DRUG|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
223532928|NCT03984825|DRUG|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
223532929|NCT03984825|DRUG|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
223532930|NCT03044795|DRUG|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
223532931|NCT05090787|DEVICE|Investigational mDCB00|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
223532932|NCT05090787|DEVICE|Control DCB00|Control intraocular lens replaces the natural lens removed during cataract surgery in both eyes
223929976|NCT03744559|BEHAVIORAL|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
223929977|NCT03744559|BEHAVIORAL|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
223929978|NCT03541525|OTHER|Biological sampling|Biological samples including blood, surgical remainder, urine,...
223929979|NCT03006367|DRUG|NFC-1 100 mg|
223929980|NCT03006367|DRUG|NFC-1 200 mg|
224283665|NCT03417830|DRUG|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
223929981|NCT03006367|DRUG|NFC-1 400 mg|
223929982|NCT03006367|DRUG|NFC-1 800 mg|
223929983|NCT03756896|DRUG|Carfilzomib|Given IV
223929984|NCT03756896|DRUG|Dexamethasone|Given PO
223929985|NCT03756896|DRUG|Pomalidomide|Given PO
223929986|NCT03032458|DRUG|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
223929987|NCT03032458|DRUG|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
223929988|NCT03032458|DRUG|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
223929989|NCT04165564|OTHER|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
223929990|NCT04165564|OTHER|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
223929991|NCT02901522|OTHER|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
223929992|NCT02901522|OTHER|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
223929993|NCT02901522|OTHER|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
223929994|NCT02901522|OTHER|Teleconsultation|The general practioner received phone call to asthma care.
223929995|NCT00571298|PROCEDURE|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
223929996|NCT00571298|DRUG|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
223929997|NCT00571298|DRUG|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
223929998|NCT00571298|DRUG|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
223929999|NCT00571298|DRUG|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
223930000|NCT00571298|PROCEDURE|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
223930001|NCT00051298|DRUG|Olanzapine|
223532933|NCT04754464|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8-Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in water
223930002|NCT00051298|DRUG|Placebo|
223930003|NCT05410106|DEVICE|PneuX Endotracheal Tube|The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.
223930004|NCT05410106|DEVICE|Standard care (Taperguard, Covidien)|Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
223930005|NCT02779478|PROCEDURE|Bronchoscopy|
223930006|NCT06461910|DRUG|Serplulimab|200 mg, i.v., D1, Q3W
223930007|NCT06461910|DRUG|thymalfasin|4.8mg,sc,biw
223930008|NCT06461910|DRUG|Oxaliplatin|130 mg/m2, i.v., D1, Q3W
224095264|NCT05451719|DRUG|Capecitabine|Capecitabine at the dose 850mg/m2, orally twice daily, d1-7 and d15-21, given every 4 weeks (Q4W)
223532934|NCT04754464|DIETARY_SUPPLEMENT|microcrystalline cellulose|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in water
223532935|NCT04109300|GENETIC|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1\*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
223532936|NCT04109300|OTHER|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
223532937|NCT02892370|DRUG|SHR0302|SHR0302 tablets (10 mg)
223532938|NCT01817387|BEHAVIORAL|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
223930009|NCT06461910|DRUG|Tegafur|oral administration: body surface area \< 1.25, 40 mg each time; body surface area ≥ 1.25 to \< 1.5, 50 mg each time; body surface area ≥ 1.5, 60 mg each time, twice daily for each treatment cycle at D1-D14
223930010|NCT03885232|BEHAVIORAL|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
223930011|NCT03885232|OTHER|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
223930012|NCT04612244|DEVICE|FARAPULSE Pulsed Field Ablation System|Ablation using the FARAPULSE Pulsed Field Ablation System
223930013|NCT04612244|DEVICE|RadioFrequency and Cryoballoon Ablation|Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
223930014|NCT05613296|DRUG|Fostamatinib|Patients with Chronic ITP, refractory to other treatment who received at least one dose of Fostamatinib outside clinical trials in Italy will be enrolled and observed for at least 6 months.
223930015|NCT06179992|DEVICE|GGED mobile app|The intervention will be done through an app named GGED, which is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in CBT in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
223930016|NCT01315132|DEVICE|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
223930017|NCT03260569|DRUG|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
223930018|NCT03260569|DRUG|Placebo|Nitrogen plus oxygen
223930019|NCT05770895|BIOLOGICAL|GS-2829|Administered intramuscularly
223930020|NCT05770895|BIOLOGICAL|GS-6779|Administered intramuscularly
223930021|NCT05770895|BIOLOGICAL|Placebo for GS-2829|Administered intramuscularly
223930022|NCT05770895|BIOLOGICAL|Placebo for GS-6779|Administered intramuscularly
223930023|NCT05718791|DIAGNOSTIC_TEST|blood sample|blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant
223930024|NCT06521151|DIETARY_SUPPLEMENT|egg based diet|egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).
224095265|NCT04770519|GENETIC|whole genome sequencing or whole exome sequencing|Whole genome sequencing or whole exome sequencing will be performed for all enrolled participants.
224283666|NCT01419899|BEHAVIORAL|Brief motivational intervention|A 20-30 minute motivational based discussion
224283667|NCT00823199|DRUG|Allopurinal|300mg once daily by mouth for four weeks
224283668|NCT01758237|DEVICE|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
224283669|NCT01758237|PROCEDURE|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
224283670|NCT02360306|PROCEDURE|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
224283671|NCT02248506|OTHER|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
224283672|NCT01529931|DEVICE|Hair2Go|Hair2Go treatment once a month for 6 months
224283673|NCT02725424|DRUG|S-1|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
224283674|NCT02725424|DRUG|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Trastuzumab: 8mg/kg (loading dose), 6mg/kg subsequently ivgtt d1 Every 3 weeks.
224283675|NCT02725424|DRUG|Oxaliplatin|Her-2 Positive patients with SOX Oxaliplatin：130 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks.
224283676|NCT02725424|DRUG|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1：twice a day depending on BSA po from d1-14, 80mg(BSA \<1.25m2) , 100mg(BSA ≥1.25m2, \<1.5 m2), 120 mg(BSA≥ 1.5m2), Every 3 weeks
224283677|NCT01415050|DEVICE|Whole body vibration|15 times WBV
224283678|NCT00305916|PROCEDURE|Multislice spiral computed tomography coronary angiography|
224283679|NCT00305916|PROCEDURE|conventional coronary angiography|
223930025|NCT02731599|PROCEDURE|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
223930026|NCT03840902|DRUG|M7824|Participants received intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
223930027|NCT03840902|DRUG|Placebo|Participants received intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
224095266|NCT03189979|BEHAVIORAL|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
224283680|NCT01998243|DEVICE|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
224095267|NCT04376450|PROCEDURE|Experimental- Nonincised papillae surgical approach|"The basic principle of the technique is the placement of only one buccal horizontal or oblique incision in the mucosa, as apically as possible from the periodontal defect and the marginal tissues, and the raising of a mucoperiosteal flap coronally, which permits apical access to the defect but leaving the marginal tissues intact, acting as a dome for the protection of the clot."
224095268|NCT04376450|PROCEDURE|Active comparator- Entire papilla preservation technique|The entire Papilla Preservation Technique is to preserve the whole integrity of the defect- associated papilla providing a tunnel-like undermining incision. The completely preserved interdental papilla provides an intact gingival chamber to stabilize the blood clot and improve the wound healing process. To provide adequate access for debridement, EPP requires a short buccal vertical releasing incision on the buccal side of the neighboring tooth extending just beyond the mucogingival line.
224095269|NCT01992822|OTHER|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
224095270|NCT05397314|DIETARY_SUPPLEMENT|Punalpin|
224095271|NCT05397314|OTHER|Placebo|
224095272|NCT03668756|PROCEDURE|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
224095273|NCT03622281|OTHER|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
224095274|NCT01413893|DRUG|linifanib|QD daily
224095275|NCT02340650|DEVICE|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
224095276|NCT03326934|DIETARY_SUPPLEMENT|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
224095277|NCT03326934|DIETARY_SUPPLEMENT|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
224095278|NCT00340470|BEHAVIORAL|Driver Education|
224095279|NCT01337401|DRUG|Cediranib|30mg once daily, oral until disease progression
224095280|NCT01337401|DRUG|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
224095281|NCT00981526|DRUG|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
224095282|NCT00981526|DRUG|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
224283681|NCT01998243|OTHER|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
224283682|NCT05516459|BIOLOGICAL|Pfizer BNT162b2 Vaccine|The Pfizer-BioNTech COVID-19 vaccine (INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. It is authorized for use in people aged five years and older in some jurisdictions, twelve years and older in some jurisdictions, and for people sixteen years and older in other jurisdictions, to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. The vaccine is given by intramuscular injection. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada
224283683|NCT04187209|DEVICE|Use of the Atalante exoskeleton|A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
224283684|NCT03359837|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
224283685|NCT03359837|DRUG|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
224283686|NCT03359837|DRUG|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
224283687|NCT03359837|DRUG|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
224283688|NCT03359837|DRUG|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
224283689|NCT03359837|DRUG|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
224283690|NCT05197829|DEVICE|Continuous Glucose Monitoring|Participants in the experimental arm will receive an unblinded flash continuous glucose monitor.
224283691|NCT05197829|OTHER|Care Coordination|All participants will receive diabetes education, written handouts, and help setting up ambulatory appointments.
224095283|NCT00981526|DRUG|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
224095284|NCT00981526|DRUG|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
223930028|NCT03840902|DRUG|Durvalumab|Participants received intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
224095285|NCT00887952|PROCEDURE|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
224095286|NCT00887952|PROCEDURE|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
224095287|NCT01564784|DRUG|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
224095288|NCT01564784|DRUG|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
224095289|NCT01564784|DRUG|HIDAC (high dose cytarabine)|cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times
224095290|NCT01564784|DRUG|cytarabine and mitoxantrone|mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
224095291|NCT00324103|DRUG|Structured Treatment Interruptions|
224095292|NCT02682329|OTHER|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
224095293|NCT02682329|OTHER|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
224095294|NCT01883037|OTHER|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
224283692|NCT04615845|BIOLOGICAL|Cellgram-DC-PC|Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
223930029|NCT03840902|DRUG|Etoposide|Participants received etoposide 50 mg/m\^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
223930030|NCT03840902|DRUG|Pemetrexed|Participants received pemetrexed at a dose of 500 mg/m\^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
224095295|NCT04934293|PROCEDURE|Virtual reality|Before proton therapy, virtual reality sessions will be performed.
224095296|NCT02977715|BIOLOGICAL|JYNNEOS (Liquid Formulation)|Two doses of attenuated live virus smallpox vaccine (JYNNEOS liquid formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
224095297|NCT02977715|BIOLOGICAL|JYNNEOS (Lyophilized Formulation)|Two doses of attenuated live virus smallpox vaccine (JYNNEOS lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 10\^8 Tissue Culture Infectious Dose 50 \[TCID50\] per 0.5 mL). A subset of participants will receive a booster dose.
224095298|NCT06583343|DRUG|OnabotulinumtoxinA|Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
224283693|NCT01908894|DRUG|BIOD-123|
224095299|NCT06583343|OTHER|Conventional Physical Therapy|Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
224283694|NCT01908894|DRUG|BIOD-125|
223532939|NCT01817387|BEHAVIORAL|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
223532940|NCT00906763|DIETARY_SUPPLEMENT|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
223930031|NCT03840902|DRUG|Carboplatin|Participants received carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
223930032|NCT03840902|DRUG|Paclitaxel|Participants received paclitaxel intravenously at a dose of 45 mg/m\^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
223930033|NCT03840902|DRUG|Cisplatin|In combination with etoposide, participants received cisplatin 50 mg/m\^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants received cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
223930034|NCT03840902|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants received IMRT 5 fractions per week for about 6 weeks (Total 60 gray \[Gy\]).
223930035|NCT03244813|OTHER|Personalized activity program|Targeted physical activity
223930036|NCT00003593|DRUG|asparaginase|Given IV
224095300|NCT05143021|OTHER|Multidisciplinary Sickle Cell Disease- Obstetric Team|Modified multidisciplinary teams for pregnant women with sickle cell disease including members from an obstetrics team and sickle cell disease team.
224283695|NCT01908894|DRUG|Humalog|
224283696|NCT00455026|DRUG|remifentanil|target effect site concentration during induction
224283697|NCT01048463|DRUG|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
223930037|NCT00003593|DRUG|cytarabine|Given IT
223930038|NCT00003593|DRUG|daunorubicin hydrochloride|Given IV
223930039|NCT00003593|DRUG|methotrexate|Given IV
223930040|NCT00003593|DRUG|therapeutic hydrocortisone|Given IT
223930041|NCT00003593|DRUG|thioguanine|Given IV
223930042|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
223930043|NCT02717468|DEVICE|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
223930044|NCT01170624|DEVICE|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
224095301|NCT03871491|DRUG|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
224095302|NCT03871491|DRUG|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
224095303|NCT00142948|DRUG|Naltrexone|naltrexone
223930045|NCT03660930|DRUG|Sirolimus Albumin-bound Nanoparticles|Given IV
223930046|NCT03660930|DRUG|Pazopanib hydrochloride|Given PO
224095304|NCT00142948|DRUG|Placebo|placebo
224095305|NCT01082484|DRUG|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
224095306|NCT01082484|DRUG|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
224095307|NCT01082484|DRUG|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
223930047|NCT05813795|DRUG|Ecnoglutide Low Dosage|Subcutaneous Injection
223930048|NCT05813795|DRUG|Ecnoglutide Medium Dosage|Subcutaneous Injection
223930049|NCT05813795|DRUG|Ecnoglutide High Dosage|Subcutaneous Injection
223930050|NCT05813795|DRUG|Placebo|Subcutaneous Injection with matched volume
223930051|NCT04100538|BEHAVIORAL|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
223930052|NCT06447389|OTHER|retraction cordu (SURE-CORD®PLUS)|The evaluation of the effectiveness of retraction cords in determining the restoration margin in the fabrication of short fixed partial dentures for patients with missing teeth.
223930053|NCT03432338|OTHER|inquiries|Inquires reported to clinician.
223930054|NCT01289314|PROCEDURE|TLH|Total laparoscopic hysterectomy (TLH)
223930055|NCT01289314|PROCEDURE|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
223930056|NCT05681234|RADIATION|18F-RD2|Patients will receive 5-10 mCi 18F-RD2
224095308|NCT05238584|PROCEDURE|Partial omentectomy|Partial omentectomy: with preservation of the greater omentum at \>2 cm from the gastroepiploic arcade.
224095309|NCT03594994|BEHAVIORAL|Sleep extension|Extend time-in-bed by one hour
224095310|NCT05919797|DRUG|Naltrexone-Bupropion Combination|Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
224095311|NCT05838417|BEHAVIORAL|REDS survey|R - Reactance, E - self-Exemption, D - Disbelief, S - Source derogation
224095312|NCT05292196|DRUG|TQC3721 suspension for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
224095313|NCT05292196|DRUG|TQC3721 suspension placebo for inhalation|TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
224095314|NCT05202808|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
224095315|NCT05202808|DEVICE|Control IOL|Control treatment group will receive a Control IOL
224095316|NCT06439862|OTHER|Children with PUV|Male children aged 6 to 17 years old treated for PUV in their first year of life between 2006 and 2018 in Lyon, and managed in the Femme-Mère-Enfant Hospital in Lyon
223930057|NCT00649805|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
223930058|NCT00649805|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
223930059|NCT06251674|OTHER|long-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
223930060|NCT06251674|OTHER|short-axis needle release|The participants received one session of ultrasound-guided long-axis TCL needle release.
223930061|NCT06302842|DIETARY_SUPPLEMENT|Bioritmon Immuno Defend|Bioritmon Immuno Defend daily oral preparation for 24 days.
223930062|NCT06251869|PROCEDURE|total hip arthroplasty with electrocoagulation|using normal technique
223930063|NCT06251869|PROCEDURE|total hip arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
224095317|NCT05879159|BEHAVIORAL|Questionnaires|Survey
224095318|NCT04439331|DRUG|Defactinib Hydrochloride|Given PO
224095319|NCT05519215|DEVICE|ECHELON 3000 Stapler|There is no intervention, beyond necessary clinical care, in this study. Echelon 3000 Stapler is used for transection and resection in LSG or lung surgical procedure per its IFU.
224095320|NCT05618197|OTHER|Passive heating|\~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
224095321|NCT06201936|BEHAVIORAL|Preliminary information on neuroaxial procedures|Pre-existing information of pregnant women on neuroaxial pain-relieving procedures for childbirth and their informative sources
224095322|NCT02882256|OTHER|Video discharge instructions|Discharge instructions provided in video form
223718207|NCT07015684|DRUG|Campath|Campath is a recombinant DNA-derived humanized monoclonal antibody that is directed against the 21-28 kD cell surface glycoprotein, CD52. CD52 is expressed on the surface of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and tissues of the male reproductive system. Campath will be given via IV at a total dose of 1 mg per kilogram of body weight.
223718208|NCT07015684|DRUG|Total Body Irradiation|Radiation dose is 3Gy (Gy is a radiation unit of measurement). Radiation source and dose rates will be according to institutional practice. Total Body Irradiation (TBI) may be delivered from either linear accelerator or Cobalt sources.
223930064|NCT06251869|PROCEDURE|total knee arthroplasty with electrocoagulation|using normal technique
223930065|NCT06251869|PROCEDURE|total knee arthroplasty without electrocoagulation|using only scalpel and pean as hemostasis and incision
223930066|NCT06486532|BEHAVIORAL|HeartBeet Clinic|16 weeks of group based lifestyle medicine coaching covering the six pillars of lifestyle medicine. The six pillars of lifestyle medicine include regular physical activity; a whole-food plant-based diet; restorative sleep; limiting substance use (e.g., tobacco and alcohol use); having meaningful social connections; and stress management. Groups will be led by clinician or health coach expert.
223930067|NCT06486532|BEHAVIORAL|Self-paced education|Self-paced course and workbook with no contact with study clinician or health coach expert
223930068|NCT04580888|PROCEDURE|early transthoracic echocardiography|In the intervention arm, echocardiography will be performed immediately and potentially repeated to confirm the need for additional fluid resuscitation up to 30 mL/kg in the presence of persisting hypovolemia, or not (e.g., severe ventricular dysfunction). A therapeutic algorithm will allow standardized impact on ongoing management according to the hemodynamic profile identified by early echocardiography. After the completion of initial fluid resuscitation up to 30 mL/kg if required, a new echocardiographic assessment will be systematically performed by the same operator to stop or not fluid resuscitation, and to potentially initiate another treatment according to both the hemodynamic profile and clinical context.
223930069|NCT04580888|PROCEDURE|standards of care|In the control arm, patients will be treated according to standards of care based on current SSC recommendations, including a fluid resuscitation of 30 mL/kg.
224283698|NCT01048463|DRUG|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
224283699|NCT01048463|DRUG|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
224283700|NCT01048463|DRUG|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
224283701|NCT01048463|DRUG|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
224283702|NCT04569786|BIOLOGICAL|V590|Single dose of V590 administered via intramuscular (IM) injection with dosage levels of 5.00x10\^5 pfu/mL (Panels A, E), 2.40x10\^6 pfu/mL (Panels B,F), 1.15x10\^7 pfu/mL (Panels C, G), 5.55x10\^7 pfu/mL (Panels D, H, I).
224283703|NCT04569786|OTHER|Placebo|Placebo administered via IM injection.
224283704|NCT02403739|OTHER|No Intervention|No Intervention
224283705|NCT01301924|DRUG|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
224283706|NCT01640184|PROCEDURE|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
224283707|NCT01640184|DRUG|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
224283708|NCT01640184|PROCEDURE|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
224283709|NCT06126861|DRUG|[14C]LP-168|single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
224283710|NCT00539708|PROCEDURE|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
224283711|NCT01684878|DRUG|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
224283712|NCT01684878|DRUG|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m\^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
224283713|NCT01684878|DRUG|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
224283714|NCT01684878|DRUG|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
224283715|NCT01684878|DRUG|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m\^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
224283716|NCT00810888|DRUG|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
224283717|NCT00810888|DRUG|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
224283718|NCT04060511|DRUG|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
223930070|NCT06608446|OTHER|Telerehabilitation|"The telerehabilitation intervention will begin from 10 days post-surgery, the operation will be carried out at home from Monday to Friday via the TeleHab device (Vald Performance) up to 2 months after the surgery.~Exercises for ROM recovery and strength recovery will be carried out three days a week and only exercises for ROM recovery will be carried out two days a week. The progression of the exercises will be carried out taking into account the pain and fatigue recorded by the patient at the end of each exercise session."
223930071|NCT06608446|OTHER|Standard Care|Standard care intervention follow the usual treatment according to current clinical practice, no structured physiotherapeutic interventions will be carried out. It consists of the delivery of two booklets, with the aim of informing and educating, regarding the most frequent complications after breast cancer surgery and how to avoid its possible onset through the demonstration of exercises to be carried out at home, self-massage techniques for the scar, behaviors and lifestyle to be adopted immediately after surgery.
223930072|NCT06456723|DRUG|[18F]-FET-βAG-TOCA|Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA). Patients will receive a maximum injected dose of 370MBq and will subsequently undergo PET/CT imaging.
223930073|NCT06826781|DEVICE|Q30 Q-Collar|Participants will complete a series of tests (sit-to-stand, resistive breathing, and graded bike test) while wearing a Q-Collar.
223930074|NCT06826781|OTHER|Not wearing Q-Collar|Participants will undergo the same study procedures without wearing the Q-Collar.
223930075|NCT06890507|DRUG|N-Acetylcysteine (NAC)|The investigational product for this study is NAC 600 mg capsules. The NAC drug substance is sourced from a Good Manufacturing Practice (GMP)-certified supplier by Syntro Health Pty Ltd and tested on receipt
223930076|NCT06890507|DRUG|Placebo|To ensure appropriate blinding and to match the physical characteristics of the NAC capsules, the placebo capsules will be filled with dicalcium phosphate (DCP). DCP has been selected over microcrystalline cellulose due to the weight requirements of the NAC formulation.
223930077|NCT06699550|OTHER|Haptonomy|The session transitioned to energy work and dream visualization. The researcher and the pregnant participant placed their left hands on each other's hearts. The goal was for the participants to feel the energy flowing between them, sense their hearts, open their third eye, and prepare their hands. This exercise aimed to enhance the pregnant participant's confidence in her own emotions and body by recognizing her feelings and physical sensations. Next, the researcher and the pregnant participant placed their right hands on the participant's forehead and their left hands over their hearts. This positioning facilitated the pregnant participant in visually sensing the presence of her baby. It was intended to promote communication between the mother and her baby at both a physical and spiritual level.
224095323|NCT00283556|DRUG|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
224095324|NCT06302257|DRUG|Chlorprocaine|we aim to examine whether selective nociceptive analgesia can be obtained in epidural analgesia for women in labor by using a combination of lidocaine (opens TPRV-1 and TPRA-1 channels) and chlorprocaine (polarized local anesthetic)
224095325|NCT06302257|DRUG|Lidocaine|Study participants will receive lidocaine alone
224095326|NCT06302257|DRUG|Lidocaine-chlorprocaine combination|study participants randomized to this study arm will receive a a 50:50 mixture of both drugs - where all drugs are administered in concentrations based on their ED50 doses, together with epidural opioids (fentanyl)
224095327|NCT01009528|DEVICE|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
224095328|NCT04612738|BEHAVIORAL|Hello (serious game)|Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with \>100 patients/caregivers from diverse backgrounds.
224283719|NCT03639974|OTHER|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
223532941|NCT06528691|DRUG|Entrectinib|Given orally (PO) or enterally
223532942|NCT06528691|DRUG|Cyclophosphamide|Given intravenous (IV)
223532943|NCT06528691|DRUG|Etoposide|Given IV
223532944|NCT06528691|DRUG|Carboplatin|Given IV
223532945|NCT06528691|BIOLOGICAL|G-CSF|Given subcutaneous (SQ) or IV
223532946|NCT06528691|BIOLOGICAL|Pegfilgrastim|Given SQ as part of recommended Bridging Therapy instead of G-CSF.
223532947|NCT06528691|PROCEDURE|Surgery|A gross total resection or significant debulking may become possible if a response to entrectinib is seen.
223718209|NCT07015684|PROCEDURE|Exchange Transfusion|Patient will undergo a red blood cell (RBC) exchange transfusion to achieve a Hemoglobin S (HgbS) level \< 20% prior to starting therapy to prevent the development of a vaso-occlusive Crisis (VOC).
224095329|NCT04612738|BEHAVIORAL|The Conversation Project (CP) Starter Kit|"The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program."
224095330|NCT04612738|OTHER|Table Topics (general conversation game)|Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
223532948|NCT04398576|BEHAVIORAL|Training and support|GP's receive the tools to make early identification of harmful and hazardous alcohol use possible. They are given guidelines to apply a brief intervention. At the start of the study, the T\&S-group receives two face-to-face educational trainings of two hours each. Another two face-to-face booster sessions will follow at 6 and at 12 months.
223930078|NCT06699550|OTHER|Mindfulness-Based Stress Reduction Program|Participants were introduced to each other and provided with information related to pregnancy. The Mindfulness-Based Stress Reduction Program (MBSR) was introduced. The participants shared their levels of well-being, stress, coping mechanisms for fear of childbirth, and their expectations from the MBSR program. Awareness of habitual behaviors was facilitated. Afterwards, breath-focused meditation and dried fruit meditation were practiced. Participants were encouraged to maintain awareness of activities performed at any time during the day. Lastly, body scan meditation was taught, and participants were instructed to repeat the practice throughout the week using audio recordings.
223930079|NCT06880107|BIOLOGICAL|blood withdrawal|blood withdrawal
223930080|NCT03623295|OTHER|Blood sample|Blood withdrawal.
223930081|NCT03623295|OTHER|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
223930082|NCT03623295|OTHER|MRI-imaging|MRI imaging of joints.
223930083|NCT03623295|OTHER|Physical examination|Physical examination of joint status.
223930084|NCT07032571|BEHAVIORAL|Core Behavioral Weight Loss Intervention|All participants receive a 12-week core behavioral weight loss intervention consisting of the following: daily self-monitoring of weight; weekly behavioral lessons and action plans to promote healthy eating and physical activity; and tailored feedback. The intervention will be delivered remotely via email and/or text message.
223930085|NCT07032571|BEHAVIORAL|Limit Red Zone Foods|Participants randomized to receive this component are given a goal to limit their Red Zone Foods (i.e., foods high in calories and low in nutrition) and are instructed to self-monitor them daily.
223930086|NCT07032571|BEHAVIORAL|Limit Eating Window|Participants randomized to receive this component are given a goal to limit their eating windows (i.e., follow time-restricted eating) and are instructed to self-monitor them daily.
223930087|NCT07032571|BEHAVIORAL|Increase Protein|Participants randomized to receive this component are given a goal to increase their protein intake and are instructed to self-monitor it daily.
223930088|NCT07032571|BEHAVIORAL|Increase Fiber Intake|Participants randomized to receive this component are given a goal to increase their fiber intake and are instructed to self-monitor it daily.
223930089|NCT06881563|DRUG|Intrathecal Morphine|In this group, 300 μg of preservative-free morphine (Morphine Kalceks ®, Kalceks, AS, Riga, Latvija, 10mg/ml) diluted with sterile saline to a volume of 3 mL will be injected intrathecally.
223930090|NCT06881563|PROCEDURE|Epidural Analgesia|"Epidural analgesia with levobupivacaine and fentanyl mixture. For intraoperative intermittent analgesia, Epidural group will be given a loading dose of 5-10 milliliters of a mixture of 10 micrograms per milliliter (μg/mL) of fentanyl (Fentanyl Piramal Critical Care, 50 mcg/ml) and 0.25% levobupivacaine (Levobupivakain Kabi 5 mg/ml), followed by intermittent 4-5 mL boluses as needed throughout the surgery.~Postoperative continuous epidural analgesia in the epidural group will consist of 2 μg/mL fentanyl added to 0.1 % levobupivacaine at the rate 5-8 mL/h during the first 24 hours after surgery."
223930091|NCT06882265|BEHAVIORAL|Group Monitoring|In the intervention group (IG), participants receive a HR and SPO2 monitor watch and a pulse oximeter and will be monitored every 15 days by a nurse to check for non-adherence and/or technical failure, and/or exacerbations, and monthly to apply questionnaires.
223930092|NCT06882265|BEHAVIORAL|Control Group|In the control group (CG), participants receive only a pulse oximeter and will be monitored monthly by a nurse to administer the questionnaires.
223930093|NCT07029529|DRUG|Apremilast 60mg|Apremilast 60mg/day
223930094|NCT07029529|DRUG|Apremilast 90mg|Apremilast 90mg/day
223930095|NCT07029529|OTHER|Placebo|Placebo
223930096|NCT07038421|OTHER|Cognitive level|The cognitive function was assessed with the Montreal Cognitive Assessment (MOCA). The total score ranges from 0 to 30, and scores of 21 and above indicate normal cognitive status
223930097|NCT07038421|OTHER|Gait|The Dynamic Gait Index (DGI) was assessed for gait. The maximum total score is 24, with a lower DGI score indicating greater impairment in functional mobility and gait
223930098|NCT07038421|OTHER|Spasticity|Spasticity was assessed using the Modified Ashworth Scale (MAS). In the MAS, muscles were recorded as 0, 1, 1, 1+, 2, 3, and 4 according to the resistance they gave to passive movement.
223930099|NCT07038421|OTHER|Position sense|The position sense was measured using a dual digital inclinometer. The mean absolute error from three trials was recorded. As the mean absolute error increased, position sense deteriorated.
223532949|NCT04398576|BEHAVIORAL|Community actions|There will be embedded community-based actions within a local strategy.
223532950|NCT04906694|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
223532951|NCT04906694|DRUG|Placebo|Diluent solution
223532952|NCT00095550|DRUG|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
223930100|NCT07038421|OTHER|Plantar sense|Plantar sensation was evaluated with the Semmes-Weinstein monofilament test (SWMT). The smallest monofilament value felt and correctly identified was recorded as the patient's threshold for light touch and pressure sensation. As the value increases, the underfloor sensation worsens.
223930101|NCT07039474|DRUG|18F-G1|18F-G1 is injected intravenously with a dose of 0.06-0.08mCi/kg
223930102|NCT07039279|BEHAVIORAL|Multicomponent Integrated Care Program|The multicomponent integrated care program is supported by a team of endocrinologist, dietitian, psychologist and research assistant with elements including medical therapy, cognitive behavioural therapy, e-care (TourHeart + platform), artificial intelligence chatbot, biofeedback, peer support
223930103|NCT07039279|OTHER|TourHeart + platform|TourHeart+ is a web-based program that provides mental health services that integrate both online and offline elements, opening up new possibilities for mental well-being. Participants will be introduced to the platform but the control group will not receive follow-up action. The platform is part of the multi-intervention care program and the participants in the intervention will receive follow-up action to engage their usage of the platform.
223930104|NCT07037992|DRUG|injection of local anesthesia solution|Injection of 30 mL local anesthetic solution bupivacaine 0.25%
223930105|NCT07037992|DRUG|Injection of normal saline|Injection of 30 mL normal saline Natrium Chloride (NaCl) 0.9%
223930106|NCT07038772|OTHER|Orthodontic treatment|Undergoing orthodontic treatment
223930107|NCT07039006|BEHAVIORAL|Training with EA feedback|Subjects will undergo reaching training that includes a 30-degree elbow flexion error 3 times in 1 week.
223930108|NCT07039006|BEHAVIORAL|Training without EA feedback|Subjects will undergo reaching training that does not include EA feedback 3 times in 1 week.
223930109|NCT07038499|OTHER||Participants are not assigned an intervention as part of the study.
223930110|NCT07038655|DIETARY_SUPPLEMENT|Randomised 20g Protein Supplement|Participants receive a 20g protein feed of their randomised blend over the course of five hours split into aliquots every twenty minutes. The drink also contains a top up of 13C2 leucine stable isotope tracer, as well as uniformly labelled 13C spirulina and 2H labelled free amino acids for quantification of digestibility.
223930111|NCT07037914|BEHAVIORAL|Education and Counseling|"The researcher will inform the mothers (n=25) that the My Baby is Safe Educational Program will be delivered individually through distance education via Microsoft Teams at times convenient for them, and that the program will be completed over 5 days. The scheduling will ensure that all modules included in the My Baby is Safe Educational Program are completed within one week at the latest. Mothers will be informed that they can receive telephone counseling from the researcher until their infants reach two months of age, and the researcher's phone number will be provided to them. During this period, the researchers will send weekly reminder messages to the mothers' phones, encouraging them to read the provided educational booklet and to watch the educational videos.~The researcher will maintain communication with the mothers and conduct a home visit on the 15th day postpartum. During this home visit, the researcher will assess the infant's sleep environment for safe sleep practices."
223930112|NCT07037914|OTHER|Leaflet|"No structured or planned education will be provided to the control group by the researchers during the study period. After the first assessment, the mothers in the control group will receive a brochure prepared by the researchers based on the literature, containing brief informational notes on SIDS and SBS.~The researcher will maintain communication with the mothers and conduct a home visit on the 15th day postpartum. During this visit, the researcher will observe the home environment where the infant resides and evaluate the infant's sleep environment in terms of safe sleep practices.~After data collection from the intervention group has been completed, the same intervention (My Baby is Safe Educational Program) will also be delivered to the mothers in the control group."
223930113|NCT07038122|PROCEDURE|Laparoscopic resection|Laparoscopic resection of bowel and corresponding mesentery.
223930114|NCT07038122|OTHER|Neoadjuvant Therapy|Neoadjuvant Therapy aims to downstage the tumor including different chemotherapy, targeted therapy and immunotherapy.
223930115|NCT07038486|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
224095331|NCT05615428|DIAGNOSTIC_TEST|LS-ratio|Included infants will have a gastric aspirate sampled via an NG tube at birth. This sample will be analyzed to determine the LS-ratio The LS-ratio will retrospectively be compared to RDS development and need for surfactant treatment to establish the cut-off ratio for LS-ratio with respect to surfactant treatment.
224095332|NCT04149314|OTHER|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
224095333|NCT02495948|DEVICE|Lotrafilcon B contact lenses|
224095334|NCT02495948|DEVICE|Samfilcon A contact lenses|
224095335|NCT02495948|DEVICE|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
224095336|NCT02495948|DEVICE|Saline solution|Used for rinsing contact lenses, as needed
224095337|NCT01701622|DRUG|febuxostat|"If baseline allopurinol dose \< 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose \> 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
224095338|NCT02920125|DRUG|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
224095339|NCT02920125|COMBINATION_PRODUCT|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
224095340|NCT02920125|OTHER|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
223930116|NCT07038161|PROCEDURE|Modified Cattell-Warren duct-to-mucosa pancreaticojejunostomy|Technical modification of the original Cattell-Warren technique in all the stitches of both posterior and anterior duct-to-mucosa layer, taking the pancreatic duct with more than 5mm of pancreatic parenchyma adjacent to the duct and towards the jejunal side, taking more than 5 mm of full-thickness jejunum including mucosa.
223930117|NCT07038161|BEHAVIORAL|Institutional Prehabilitation Protocol|Routine perioperative incentive spirometry, four extremities exercise, and nutritional optimization with albumin and Total Parenteral Nutrition
224095341|NCT01931046|DRUG|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
224095342|NCT04073667|BEHAVIORAL|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~* To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~* Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~* Teaching the correct scapular position, D. Postural correction exercises;~* Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~  a. Joint position sense:~* Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~  b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~  a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
224095343|NCT01752283|PROCEDURE|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
224095344|NCT01752283|PROCEDURE|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
224095345|NCT01936038|OTHER|CPAP|CPAP
224095346|NCT01936038|PROCEDURE|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
224095347|NCT02747004|DRUG|Abemaciclib|Administered orally
224283720|NCT03639974|OTHER|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
223930118|NCT06882174|DRUG|Scheduling of the time of pembrolizumab infusions|The intervention in this study is scheduling of the time of pembrolizumab infusions.
223930119|NCT06889896|DIAGNOSTIC_TEST|After Blood samples collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau|The CLEAR-AD study is an ongoing population-based cross-sectional study, currently recruiting 400 participants in ten centers in China. The study includes cognitively normal controls, individuals with mild cognitive impairment (MCI) - categorized as amyloid-positive and amyloid-negative - as well as patients with dementia, also divided into amyloid-positive and amyloid-negative groups. All participants undergo amyloid PET scans using tracers such as AV1, AV45, and PIB. Blood samples are collected within three months prior to the PET scan or from existing samples collected after January 1, 2024, that meet quality standards. After collection, these samples are analyzed at a central laboratory under blinded conditions using multiple detection methods to measure plasma levels of Aβ40, Aβ42, t-tau, and p-tau181/217. The detection technologies included single-molecule immunoassay, digital immunoassay chips, magnetic particle chemiluminescence, and flow cytometry fluorescence. The objective i
224095348|NCT02747004|DRUG|Tamoxifen|Administered orally
224095349|NCT02747004|DRUG|Prophylactic Loperamide|Administered orally
224095350|NCT04899908|RADIATION|Stereotactic Radiation|Focused radiation beams to treat tumors
224095351|NCT04899908|DRUG|AGuIX gadolinium-based nanoparticles|Intravenous injection
224095352|NCT04899908|OTHER|Placebo|Intravenous infusion
224095353|NCT05327062|DEVICE|CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment|"The following information and data will be obtained from the routine clinical work up of the patients: Patient demographics, cardiovascular medical history, and clinical examination; 12-lead ECG; Standard echocardiography; Computed tomography angiography for visualization of atria, ventricle, and coronary sinus.~Imaging data will be transferred to the cloud-based web-platform using a dedicated software provided by study sponsor. Data processing includes evaluating the quality of the data and calculation of various anatomical and electrical parameters, and identification of the target zone as a point in the target vein closest to the latest activation zone.~LV-lead location is based on the information provided by the dedicated software followed by visual X-ray based verification of anatomically suitable/most desirable position.~The patient will undergo CRT device implantation according to local protocols."
224095354|NCT02749305|OTHER|Collection of patient-reported outcome measures|Preoperative and postoperative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
224095355|NCT06160466|DEVICE|CADe colonoscopy using GI Genius device|We wanted to compare the diagnostic yield obtained by using CADe colonoscopy to the yield obtained by the standard colonoscopy (SC) in a follow-up pateints in the screening population.
224095356|NCT06160466|DEVICE|White light|White light endoscopy
224095357|NCT02998385|DRUG|Cisplatin|intravenous, concomitant to irradiation
223930120|NCT06730672|DRUG|Volonib combined with Everolimus Formation|Volonib 200mg once daily and Everolimus 5mg once daily
223930121|NCT06730958|DIAGNOSTIC_TEST|serum Follistatin-like protein 1|Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
223930122|NCT06733428|DEVICE|Pachymeter|Measure the thickness of the cornea
224283721|NCT03639974|OTHER|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
224283722|NCT01435031|DEVICE|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~* XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~* HT PROGRESS and/or HT PILOT guide wires in recanalization~* MINI-TREK Coronary Dilatation Catheter in predilatation"
224283723|NCT04995120|DRUG|chemotherapy TP regimen combined with Toripalimab|"Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles."
224283724|NCT02927834|DRUG|6 day Prednisone|6 day prednisone burst
224283725|NCT02927834|DRUG|Augmentin|Antibiotic augmentin for 3 weeks
224283726|NCT02927834|DRUG|21 day Prednisone|21 day prednisone burst
224283727|NCT04818996|BEHAVIORAL|Mediterranean Diet|"While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated."
224283728|NCT04825717|OTHER|Nutrition and fluid plans prepared using calorimetry-based measurements.|Nutrition and fluid plans prepared using calorimetry-based measurements.
224283729|NCT03752554|PROCEDURE|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
224283730|NCT01161394|DRUG|Pioglitazone 15mg|
224283731|NCT01161394|DRUG|pioglitazone 30mg|
224283732|NCT01161394|DRUG|placebo|
224283733|NCT02390648|DRUG|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
224283734|NCT02390648|DRUG|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
223930123|NCT06423300|DEVICE|LIFT Implant|The LIFT implant provides a less invasive option for treatment of patellofemoral cartilage degeneration in the knee. the LIFT implant unloads the patellofemoral joint by elevating the patellar tendon to unload the joint compartment and realign the kneecap toward healthier cartilage
224283735|NCT02396082|BEHAVIORAL|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
223930124|NCT06423300|OTHER|Tibial Tubercle Osteotomy|Tibial Tubercle Osteotomy
223930125|NCT07038759|DEVICE|the Motion Estimation and Motion Compensation|Motion Estimation and Motion Compensation (MEMC) is a video processing technology designed to enhance display quality by interpolating additional frames, thereby reducing motion blur and stuttering in fast-moving scenes. This is achieved by estimating motion between video frames and generating intermediate frames, effectively increasing the frame rate (e.g., from 30 FPS to 120 FPS) and display refresh rate (e.g., from 30 Hz to 120 Hz).
224095358|NCT02998385|RADIATION|radiotherapy|66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
223930126|NCT07039799|BEHAVIORAL|Virtual Reality + Conventional Physiotherapy|This intervention involves the use of fully immersive virtual reality (VR) applications delivered through the Meta Quest 3 headset, integrated with hand-tracking technology. Participants engage in three custom-designed VR games aimed at improving shoulder, elbow, wrist, and hand functions. The games are tailored to individual functional levels and include progressive difficulty. Sessions are conducted twice per week for 8 weeks, each lasting approximately 40 minutes, under the supervision of a physiotherapist. This intervention is combined with conventional physiotherapy (excluding functional upper extremity exercises).
223930127|NCT07039799|BEHAVIORAL|Conventional Physiotherapy|This intervention consists of a standard physiotherapy program for individuals with Duchenne Muscular Dystrophy. It includes aerobic exercises, strengthening exercises, stretching routines, postural training, respiratory exercises, and functional upper extremity exercises. The sessions are delivered by a physiotherapist twice weekly for 8 weeks, with each session lasting approximately 40 minutes.
223930128|NCT07039578|BIOLOGICAL|CM336 Injection(Low dose group)|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
223930129|NCT07039578|BIOLOGICAL|CM336 Injection(High dose group)|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.
223930130|NCT06729892|DRUG|Esketamine at low dose|Esketamine at low dose was administered(0.2mg· kg-1, 5 ug· kg-1 continuous infusion) and drug dosage was adjusted(propofol and remifentanil) based on the new BIS baseline ( calculated from the pilot study).
223930131|NCT06729892|DEVICE|new BIS baseline|Close-loop TCI control was under new BIS baseline(calculated from pilot study) in the presence of esketamine at low dose.
223930132|NCT06729892|DRUG|an equivalent dose of saline|An equivalent dose of saline was given and closed-loop control stared.
223930133|NCT06729892|DEVICE|original BIS baseline|Drug dosage was adjused under close-loop control based on original BIS baseline.
224283736|NCT02396082|OTHER|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
224283737|NCT04661826|DRUG|Oncofid-P-B|Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.
224283738|NCT04359563|BEHAVIORAL|Mindfulness-Based Intervention|"The MBI consists of four 2h online group sessions spread over eight weeks. In between sessions, online support will be offered to assist participants in their practice. Each session consists of guided mindfulness exercises (e.g., focus on the breath, body scan, breathing space, mindful yoga, insight meditation, walk meditation), sharing of experiences of these exercises, reflections in small groups, psycho-education (e.g., stress, depression, self-care), and review of home practices. An overview of core elements is given in Van der Gucht et al. (2017b).~The MBI is supported by homework assignments and audio material. Groups will include 5 participants, yielding 6 groups in total. The MBI will be delivered by highly qualified certified trainers with more than 10 years of experience in mindfulness meditation and extensive experience working with adolescents. Trainers will attend inter- and supervision moments on a regular basis to check treatment fidelity and trainer adherence."
224283739|NCT03275584|DRUG|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
224283740|NCT01878721|RADIATION|PET/CT|positron emission tomography/computed tomography
224283741|NCT01211951|DRUG|KCT-0809|
224283742|NCT01211951|DRUG|KCT-0809|
224283743|NCT01211951|DRUG|KCT-0809|
223930134|NCT06716450|DEVICE|Multiplo TP/HIV Antibody Test|"The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually."
223930135|NCT05733611|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus
223930136|NCT05733611|BIOLOGICAL|RP3|Genetically modified herpes simplex type 1 virus
223930137|NCT05733611|BIOLOGICAL|atezolizumab|anti-PD-L1 monoclonal antibody
223930138|NCT05733611|BIOLOGICAL|bevacizumab|anti-VEGF therapy
224283744|NCT01211951|DRUG|Placebo|
224283745|NCT01995331|DRUG|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was \>1×109/L."
224283746|NCT02543151|PROCEDURE|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
224283747|NCT05460962|OTHER|Deep breathing excercises|Deep breathing, which is also known as diaphragmatic breathing, is a technique that is based on the notion that mind and body integration produces relaxation technique requires participants to contract the diaphragm, slowly inhaling and exhaling. Deep breathing appears to amplify blood oxygen levels, massages the inner organs located in or close to the abdomen, and possibly stimulates the vagus nerve
224283748|NCT05460962|OTHER|Deep breathing exercises +and progressive muscle relaxation techniques|Begin with a deep breathing exercise. Inhale deeply through your nose, feeling your abdomen rise as you fill your body with air. Then slowly exhale out the mouth, the navel pulling in toward the spine as you expel the stale air out. Repeat 3-5 cycles
223930139|NCT06732284|OTHER|Psychomotor vigilance task|Five PVT tests (before sleep at 7pm, 7am, 7:30am, 8am and 11am). The PVT is a 10-minute test designed to assess the vigilance and sustained attention by measuring reaction times (RT) to visual stimuli. During the test, participants are required to monitor the computer screen and press the response button as soon as a millisecond counter appears which will stop the counter and display the RT in milliseconds. The stimuli are randomly presented.
223930140|NCT06732284|OTHER|Video-polysomnography|Performed overnight as part of routine care (11 p.m. to 7 a.m.).
223930141|NCT06732284|OTHER|Sleep and activity monitoring|Actimeter and sleep diary to assess the sleep-wake patterns of the participants in their natural environments over a two-week period.
224095359|NCT06090994|DRUG|Huaier granule|Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.
224095360|NCT06090994|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
224095361|NCT01444300|DRUG|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
224095362|NCT01444300|DRUG|Placebo|placebo pill, bid for 12 weeks
224095363|NCT05607628|COMBINATION_PRODUCT|Low Calorie Animal Protein Meals|Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
224095364|NCT05607628|COMBINATION_PRODUCT|Low Calorie Plant Protein Meals|Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
224095365|NCT05254795|OTHER|Molecular tumor board assisted care|Participants in this group will obtain recommendations for care from the molecular tumor board.
224095366|NCT03884465|DRUG|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
224095367|NCT04284657|DRUG|Pravastatin|Pravastatin 40 mg QD
224095368|NCT04284657|DRUG|sodium citrate|sodium citrate up to 30 ml TID
223930142|NCT06738901|BIOLOGICAL|SKP-0141|Human plasma-derived coagulation factor VIII concentrate
223930143|NCT06889233|BEHAVIORAL|measuring cognitive functions, severity of autism , gross and fine motor skills|measuring cognitive functions by RAVEN measuring severity by CARS measuring fine and gross motor functions by BOT2
224095369|NCT01517035|PROCEDURE|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
224283749|NCT00777855|DRUG|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
223930144|NCT06737796|BEHAVIORAL|Finger Feeding|feeding method
223930145|NCT06737796|BEHAVIORAL|syringe feeding|feeding method
223930146|NCT02652052|OTHER|Standard of Care - Observation Only|Control Arm - Observation only
223930147|NCT02652052|DRUG|Group 2: Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
223930148|NCT02652052|DRUG|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
224095370|NCT00898547|OTHER|immunoenzyme technique|
224095371|NCT00898547|OTHER|laboratory biomarker analysis|
224095372|NCT02598414|PROCEDURE|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
224095373|NCT02598414|PROCEDURE|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
224095374|NCT02598414|DEVICE|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
224095375|NCT02113293|DRUG|CyclASol®|Cyclosporine A Solution
224095376|NCT02113293|DRUG|Placebo (vehicle)|Vehicle Solution
224095377|NCT05506943|DRUG|CTX-009|IV infusion on day 1 and 14 of every 28 day cycle
224095378|NCT05506943|DRUG|Paclitaxel|IV infusion on day 1, 8, and 15 of every 28 day cycle
224095379|NCT02390518|RADIATION|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a and 1a Expansion (starting at Dose Level 3) Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a \*Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a~\*\*Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
224095380|NCT01813994|DRUG|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
224283750|NCT00777855|DRUG|warfarin|warfarin 7.5mg po x 1
224283751|NCT01878513|DRUG|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
224283752|NCT01264198|BEHAVIORAL|Resistance Training|Supervised Resistance Training
224283753|NCT03655119|BEHAVIORAL|Parent toolkit|The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
223930149|NCT05942911|DRUG|IHL-675A|Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
223930150|NCT05942911|DRUG|Cannabidiol|Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding
223930151|NCT05942911|DRUG|Hydroxychloroquine|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
223930152|NCT05942911|DRUG|Placebo|Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
223930153|NCT00326677|BEHAVIORAL|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
223930154|NCT00326677|BEHAVIORAL|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
223930155|NCT06673368|DRUG|NRCT-101SR, NRCT-202XR|NRCT-101SR in combination with NRCT-202XR or NRCT-202XR alone
223930156|NCT06756464|DEVICE|ROHKEA: Virtual Reality Therapy|Using Interpretative Phenomenological Analysis (IPA): an exploration of the therapeutic benefits of a Virtual Reality enhanced Cognitive Behavioural Therapy (CBT) and movement (graded exposure) therapy 60-day chronic pain management programme (CPMP). Using the ROHKAE device and undertaking semi structures interviews, pain questionnaires and patient diaries to measure patient experience and pain management
223930157|NCT04990921|COMBINATION_PRODUCT|Palliative Radiation and Pembrolizumab|Stereotactic radiation therapy will be administered as clinically indicated.
223930158|NCT05043077|DRUG|Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (6.5 μL) for 3 doses with 5-minute intervals
223930159|NCT05043077|DRUG|Standard drop administration of phenylephrine 1.67% and tropicamide 0.33%|1 drop (28-34 μL) for 3 doses with 5-minute intervals
224095381|NCT01813994|DRUG|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
223930160|NCT06826547|DRUG|Adjustment of insulin doses DAR|"Patients will be hospitalized at La Rabta Hospital from February 15 to February 28, 2025 for clinical (weight, BP, SF-12), biological (HbA1c, lipid profile) assessments and inflammatory markers (Interleukin 6 and TNF alfa) DAR Group: Insulin will be adjusted per DAR 2021 guidelines. Patients will track insulin doses, glycemic cycles, hypoglycemia episodes, fasting interruptions, and hospital visits in a dedicated log. They will receive weekly calls for insulin adjustments and continuous support.~During the last week of Ramadan, clinical and biological data including inflammatory markers will be collected. Two months post-Ramadan, HbA1c, fasting glucose, and lipid profile will be reassessed to evaluate glycemic control."
224095382|NCT03843047|DRUG|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
224095383|NCT03843047|DRUG|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
224095384|NCT03843047|DRUG|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
224095385|NCT03843047|DRUG|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
224095386|NCT02132442|DIETARY_SUPPLEMENT|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
224095387|NCT02617355|DEVICE|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
224095388|NCT02617355|DEVICE|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
224095389|NCT02617355|DEVICE|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
224095390|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
224095391|NCT02617355|DEVICE|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
224095392|NCT03216629|BEHAVIORAL|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
224095393|NCT03658954|BEHAVIORAL|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep health advice.
224095394|NCT03658954|BEHAVIORAL|Self-monitoring|Participants will complete daily smartphone-based sleep and alcohol diaries for two weeks.
224095395|NCT03658954|BEHAVIORAL|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Philips actiwatches and SCRAM ankle biosensors \& smartphone diaries \& tailored coaching with a health coach
224095396|NCT01908348|DIETARY_SUPPLEMENT|Erythritol|
224095397|NCT06089044|DRUG|Dalbavancin Injection|Dalbavancin as long-term suppressive therapy.
224095398|NCT01260558|DEVICE|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
224095399|NCT01260558|DEVICE|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
224095400|NCT03286673|DIETARY_SUPPLEMENT|calcium phosphate|
224095401|NCT03286673|DIETARY_SUPPLEMENT|Tricalcium Phosphate|
224095402|NCT03286673|DIETARY_SUPPLEMENT|Calcium carbonate|
224095403|NCT03286673|DIETARY_SUPPLEMENT|Placebo|
224283754|NCT03655119|BEHAVIORAL|Enhanced Care|PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
223930161|NCT06826547|DRUG|Adjustment of insulin doses CFT|"Patients will be hospitalized at La Rabta Hospital from February 15 to February 28, 2025 for clinical (weight, BP, SF-12) and biological (HbA1c, lipid profile) assessments and inflammatory markers (Interleukin 6 and TNF alfa) .~CFT Group: Insulin adjusted after a Carbohydrate Fasting Test. Patients will track insulin doses, glycemic cycles, hypoglycemia episodes, fasting interruptions, and hospital visits in a dedicated log. They will receive weekly calls for insulin adjustments and continuous support.~During the last week of Ramadan, clinical and biological data including inflammatory markers will be collected. Two months post-Ramadan, HbA1c, fasting glucose, and lipid profile will be reassessed to evaluate glycemic control."
223930162|NCT06758050|OTHER|Core strengthening exercises|By core strengthening exercise, could be improved pain, balance, and function in patients with patellofemoral pain syndrome. In that case, this will not only improve their postural stability and neuromuscular control, but we believe it will improve their overall functional, performance, and quality of life. Currently, limited evidence exists about the effectiveness of core strengthening exercises on pain, function and dynamic balance in patellofemoral pain syndrome. By addressing core strengthening exercise, physical therapists can advise new treatment methods for patellofemoral pain syndrome (Chevidikunnan et al., 2016)
223930163|NCT06758050|OTHER|Traditional treatment|hip and knee-focused exercises
223930164|NCT06735768|DEVICE|rTMS treatment|Brightmind.AI´s rTMS protocol is applied
223930165|NCT06735768|DEVICE|Determination of motor hotspot and motor treshold|Determination of motor hotspot and motor treshold
223930166|NCT06734429|OTHER|Urinary Artificial Sphincter|Urinary Artificial Sphincter is a device used for patients with urethral sphincter incompetence
223930167|NCT06734806|DIAGNOSTIC_TEST|Radiographic Imaging and Digital STL Analysis|This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.
223930168|NCT06734806|DIAGNOSTIC_TEST|FDI Criteria Evaluation and Plaque Index Measurement|This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.
224095404|NCT03971721|DEVICE|Wave 4.3|The Wave 4.3 mattress support is an insert, placed underneath the user's existing mattress, that when inflated increases the longitudinal incline of the mattress support, increasing in inclination in the direction of the head of the bed. The resulting mattress contours are such that the mattress has a lateral inclination of approximately 15 degrees in the head section and 10 degrees in the torso section. In addition to the features allowing the user to activate and deactivate creation of this Graduated Lateral RotationTM orientation, this device has sensors and monitoring system allowing for remotely monitoring the status of the system, including confirming that the supports are achieving the prescribed support angles, and that the system is working as planned.
224095405|NCT01848275|DEVICE|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
224095406|NCT01848275|DEVICE|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
224095407|NCT04429022|DRUG|Gabapentin|600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op
224095408|NCT04429022|DRUG|Acetaminophen|Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op
224095409|NCT04429022|DRUG|Celecoxib|Celecoxib 200mg PO q 12h x 7d post op
224095410|NCT04429022|DRUG|Ketorolac|30mg IV once at end of hysterectomy procedure
224095411|NCT04429022|PROCEDURE|Paracervical block with ropivacaine|0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL
224095412|NCT04429022|PROCEDURE|Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites|0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total
224095413|NCT04429022|DRUG|Hydromorphone|1mg IV PRN q3h, post op, while inpatient
224095414|NCT04429022|DRUG|Oxycodone|To be discharged home with: 12 tabs of 5mg PRN q4h
224283755|NCT03655119|BEHAVIORAL|Caring Follow-Up Messages|Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
224283756|NCT05312086|OTHER|MRI|"Performing the muscle MRI requires the cooperation of the child in order to remain lying down and motionless throughout the duration of the MRI, about 45 minutes.~Performing MRI does not require the injection of contrast products or radiopharmaceuticals."
224283757|NCT00556101|PROCEDURE|Whole body magnetic resonance angiography|
224283758|NCT03357354|BEHAVIORAL|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
224283759|NCT04470531|DRUG|oral co-trimoxazole|oral co-trimoxazole + standard therapy
224283760|NCT04851275|BEHAVIORAL|Physicians trained in shared decision making|Physicians in this group were trained in shared decision making
224283761|NCT04851275|BEHAVIORAL|Physicians were not trained in shared decision making|Physicians did not receive training in shared decision making
224283762|NCT04590768|OTHER|Fermotein based meals|various meal products: bread, soup and an occasional burgers
224283763|NCT04590768|OTHER|Matching control meals with whey protein and wheat bran|various meal products: bread, soup and an occasional burgers
223930169|NCT06734949|OTHER|AI-guided patient classification|The intervention consist in firstly obtaining clinical, genetic, histopathological, MRI data from total 500 patients coming from the defined Cohorts. The adaptative AI-tool developed, based on data provided, will then identify multi-modal characteristics that will support patients' superclusters and their multi-omics signatures.
223930170|NCT06735066|PROCEDURE|Ascending urethrocystography|"It will be performed after instructing the patient to evacuate the bladder. A contrast agent will be infused through the urethra under fluoroscopy, using a urethral catheter or Knutson's clamp at the external urethral meatus. When the bladder is full, an anteroposterior film and two oblique films will be taken. Voiding cystourethrography will be performed as a part of this imaging examination. From this procedure, the following findings may be diagnosed:~* Upper urinary tract: Vesicoureteral reflux (VUR); laterality and degrees of VUR will be defined.~* Bladder: Capacity (defunctionalized, Small-sized or contracted bladder), neurogenic bladder, bladder diverticulum, filling defects, etc.~* Urethra: Stricture and filling defects."
223930171|NCT06810297|PROCEDURE|Therapeutic Exercise|It will consist of an 8-week intervention divided into 2 weekly sessions, in which functional exercise will be combined with aerobic exercise. A progressive protocol will be carried out.The sessions will last approximately 60 minutes divided into a first aerobic part which will serve as a warm-up for the functional part, then a main part with approximately 6 exercises and, finally, a cool-down of 3 to 5 minutes with relaxation exercises and stretching.
224095415|NCT02590393|COMBINATION_PRODUCT|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
224095416|NCT01984021|DEVICE|Acupuncture|
224095417|NCT01984021|DEVICE|Sham acupuncture|
224095418|NCT01769105|DEVICE|Lipiflow|Patients receive a single Lipiflow-treatment
224095419|NCT01769105|BEHAVIORAL|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
224095420|NCT01495143|PROCEDURE|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
224095421|NCT02784093|DRUG|Gastrograﬁn|
224095422|NCT02784093|PROCEDURE|enemas|
224095423|NCT06127329|PROCEDURE|BAI combine with DEB-BACE|"1. First treatment. Only infusion chemotherapy (THP + Platinum + Letitrexed), THP 20 \~30mg/m2, Nedaplatin 40mg/m2, Letitrexed 3mg/m2.~2. Second treatment. After infusionchemotherapy, EqualSpheres microsphere used for embolization: EqualSpheres microspheres (400 μm) 1tube was loaded and adsorbed THP (40 \~ 60mg/m2). End point of embolization: stagnation of blood flow in tumor feeding artery."
224095424|NCT01374061|DEVICE|Classical intubation|Classical intubation
224095425|NCT01374061|DEVICE|GLIDESCOPE|GLIDESCOPE intubation
224095426|NCT00963807|DRUG|Cisplatin|Given IV
224095427|NCT00963807|PROCEDURE|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
224095428|NCT00963807|DRUG|Docetaxel|Given IV
224283764|NCT05924334|OTHER|reiki|"Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average."
224283765|NCT05924334|OTHER|placebo|placebo
224095429|NCT00963807|DRUG|FDG|Undergo FDG PET/CT
224095430|NCT00963807|DRUG|FLT|Undergo FLT PET/CT
224095431|NCT00963807|PROCEDURE|PET/CT|Undergo FDG PET/CT and FLT PET/CT
224095432|NCT00963807|PROCEDURE|Surgery|Undergo surgery
224283766|NCT02483338|BEHAVIORAL|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
224283767|NCT05839145|OTHER|Strength force measurment|The grip and pinch strength of the patient will be evaluate using dedicated devices (MyoGrip and MyoPinch)
224283768|NCT05839145|OTHER|Time tests|Lower and upper limb capacities of the patients will be measured during timed tests
224283769|NCT05839145|OTHER|Motor scales|Patient's motor functional abilities will be evaluated using specific motor scales (MFM32, RULM)
224283770|NCT05839145|OTHER|Questionnaires|Patients and caregivers quality of life will be measured with different questionnaires (SMA-FRS, QOL-gNMD, SMAIS, PREM)
224283771|NCT05839145|DEVICE|Accelerometry|Patients physical activity will be measured at home using accelerometer sensors
224283772|NCT05839145|OTHER|MNR|Sub-group of patients will perform an NMR imaging to evaluate the intramuscular fatty infiltration in thighs and muscle volume in thighs
224283773|NCT05839145|OTHER|Bio-impedance analysis|The patients' muscular and fatty volume will be evaluated using BIA technic (compared to MNR)
224283774|NCT00484991|DRUG|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
224283775|NCT05057026|OTHER|Training Program Adult Mental Health Practice Support Program|"The Adult Mental Health Practice Support Program (PSP) was designed in 2009 by the General Practice Services Committee (GPSC) to address needs expressed by the province's family physicians to improve patient care in British Colombia. Its content and delivery model has been designed using evidence-based key ingredients and implication factors understood to be important for effective stigma reduction. These include the following:~* the use of contact-based education,~* skills-building to increase confidence and provide another management option with or without drugs particularly if access to mental health support services is difficult or absent~* tools - using the principles of cognitive behavioural theory~The training will be delivered virtually over a total of 4 sessions two weeks apart, covering an 8-week period. A two hour virtually delivered booster session will be provided to students approximately one year after the delivery of the initial training."
224283776|NCT06609434|PROCEDURE|Radiofrequency ablation|This study is the first to apply radiofrequency ablation to multiple recurrent intrahepatic lesions of colorectal cancer liver metastases.
224283777|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 1 (Reference)|Formulation 1 (FM1) powder for oral suspension.
224283778|NCT06609161|DRUG|Tedizolid Phosphate Oral Formulation 2 (Test)|Formulation 2 (FM2) powder for oral suspension.
223930172|NCT06810297|COMBINATION_PRODUCT|Therapeutic exercise and sexual education|"The sexual education part will consist of a 4-week intervention divided into 1 session every two weeks in an online format, in which topics related to the pathology and self-knowledge will be addressed. The sessions will last approximately 60 minutes, divided into a first part of reception and welcome of the group (lasting approximately 5-10 minutes), then the main content will be divided differently in each session (the explicit content of each session will be detailed later) and will end with a farewell and closing of the online session (lasting approximately 5-10 minutes) together with the explanation of the homework.~In addition, they will also carry out the therapeutic exercise protocol."
223930173|NCT06744088|COMBINATION_PRODUCT|Del Nido cardioplegia|To assess the clinical outcomes of modified Del Nido cardioplegia in cardiac surgeries across different age groups,
223930174|NCT06743893|OTHER|Diagnosis and outcome of non traumatic chronic subdural haematoma in pediatric age groups|Diagnosis and outcome of non traumatic chronic subdural haematoma in pediatric age groups
223930175|NCT06737393|PROCEDURE|Backfill|Participants undergoing laparoscopic hysterectomy have the bladder filled with 200 mL saline prior to Foley removal at the end of surgery.
224095433|NCT03770143|OTHER|Feeding with palm olein formula|
224095434|NCT00245232|BEHAVIORAL|Cognitive Therapy|
224283779|NCT03171064|BEHAVIORAL|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
224283780|NCT04736758|DRUG|GP681 tablet|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
224283781|NCT04736758|DRUG|GP681 Simulant|influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
223930176|NCT06894927|DIAGNOSTIC_TEST|Screening HHIA questionnaire|"Completion of the abbreviated (screening) version of the standardized HHIA questionnaire (Czech version)."
223930177|NCT06894927|DIAGNOSTIC_TEST|Whispered voice test|Whispered voice test conducted following the standardized protocol.
223930178|NCT06894927|DIAGNOSTIC_TEST|Screening pure tone audiometry|Screening pure-tone audiometry at a level of 35 dB at the frequencies: 500, 1000, 2000, and 4000 Hz.
223930179|NCT06894927|DIAGNOSTIC_TEST|Pure Tone Audiometry|Clinical Pure Tone Audiometry
223930180|NCT06894927|DIAGNOSTIC_TEST|Tympanometry|Clinical Tympanometry
223930181|NCT06894459|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, 3 cycles
223930182|NCT06894459|DRUG|Cisplatin|cisplatin 75mg/m2, IV, 3 cycles
223930183|NCT06894459|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg, IV, 3 cycles
223930184|NCT06893588|DEVICE|NEVA VS|cerebral artery dilation device
223930185|NCT06894485|OTHER|Conventional therapy|"* Conventional range of motion (ROM) exercises~* Muscle strengthening exercises~* Fine motor skill exercises~* Functional rehabilitation exercises"
223930186|NCT06894485|OTHER|Sensory Training|"* Desensitization training (exposure to various textures and stimuli to improve sensory tolerance)~* Proprioceptive exercises (closed-eye position sense training, weight transfer exercises)~* Tactile stimulation"
223930187|NCT06894797|RADIATION|Concurrent Chemoradiotherapy（Radiation + Capecitabine）|Capecitabine 825 mg/m\^2 Po BlD, Monday-Friday, on days of radiation treatment only, throughout the duration of RT Radiation：45-50Gy/25fractions/5 weeks，5fractions/week
224283782|NCT05002114|DRUG|Cannabidiol|Topical CBD cream - special formulation
224283783|NCT05002114|OTHER|Placebo|Not the drug
224283784|NCT06175715|PROCEDURE|carotid endarterectomy|carotid endarterectomy under local or general anethesia
223930188|NCT06894797|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
223930189|NCT06894797|DRUG|Oxaliplatin|Oxaliplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
223930190|NCT06894797|DRUG|5-FU|5-FU (2400mg/m\^2) will be administered by intravenous infusion on 46h in a 2-week treatment cycle.
223930191|NCT06746948|OTHER|dyadic psychological distress|There is no intervention among the cross-sectional study.
223930192|NCT06747819|DIAGNOSTIC_TEST|Cervical Epidural Steroid Injection (CESI)|Participants in this group received CESI to reduce inflammation and alleviate pain in the cervical nerve roots.
223930193|NCT06747819|COMBINATION_PRODUCT|Neural Mobilization (NM)|Participants in this group underwent NM exercises aimed at improving nerve mobility and reducing symptoms related to nerve compression.
223930194|NCT06785246|OTHER|Grasshopper dashboard|Computer dashboard application for radiologists that displays relevant clinical information directly from the medical record
223930195|NCT06740279|OTHER|Assessment of upper limb function|Observational study of the changes in upper limb after SCI paralysis
224095435|NCT00245232|BEHAVIORAL|Cognitive Processing Therapy|
224095436|NCT00245232|BEHAVIORAL|Written Exposure|
224095437|NCT03088514|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
224095438|NCT05166707|DEVICE|BIXINK OC Free|OC Free is a 6-week ERP-based intervention to deliver Exposure and Response Prevention (ERP) to reduce the anxiety from obsessive thoughts and compulsive rituals.
224095439|NCT02054858|PROCEDURE|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
223930196|NCT05018143|BEHAVIORAL|STARS|This intervention will use an online mobile application for teach life skills, coupled with peer mentoring to support the use of safety planning.
223930197|NCT05018143|BEHAVIORAL|Control condition|In this intervention, participants will receive the safety planning intervention.
223930198|NCT05270109|PROCEDURE|BiZact|"In the hot group the peritonsillar space is dissected and sealed in one step by a bipolar instrument (BiZactTM). The instrument uses Valley Lab adjustable bipolar energy. Energy is automatically adjusted and delivered to the tissue in order minimize thermal tissue damage and seal blood vessels less than 3mm in diameter while dividing the soft tissue."
223930199|NCT05270109|PROCEDURE|Cold Steel|"In the cold steel group the peritonsillar space is dissected with metal instruments, and bleeding is typically controlled by ligation or electrocautery."
223930200|NCT06846567|DRUG|BM2216 Extended-Release tablets（5.5mg）|5.5mg BM2216 Extended-Release ,test drug
223930201|NCT06846567|DRUG|Mirogabalin Besilate Tablets|15mg of Mirogabalin Besilate Tablets,reference drug
223930202|NCT06846567|DRUG|BM2216 Extended-Release Tablets(11mg)|11mg of BM2216 Extended-Release,test drug
223930203|NCT06846567|DRUG|BM2216 Extended-Release Tablets(16.5mg)|16.5mg of BM2216 Extended-Release Tablets,test drug
223930204|NCT06835309|OTHER|Pelvic floor muscles exercises|The exercises for strengthening the PFM were 10 contractions of 5 seconds, 15 contractions of 3 seconds, 20 contractions of 2 seconds, 20 contractions of 1 second (equal rest time between contractions), and 5 repetitions of maximum contractions while coughing (1-minute interval).25 The level of difficulty of the exercises throughout the 20 sessions was determined by the patient's position, starting in a supine position, then progressing to a sitting position and, finally, to a standing position
223930205|NCT06835309|OTHER|Pelvic floor muscles exercises and isokinetic strengthening of hip muscles|The hip muscle strengthening exercise was executed on Biodex multi-joint system isokinetic dynamometer. Muscle tension of the lower limbs was relieved by executing 5-minute warm-up exercises using a cycle ergometer before execution of the isokinetic exercise For each hip muscle group, eight repetitions per set for 4 sets were carried out for a single exercise with a 30 second break between each set. The patient's position were the same positions used in the testing procedure. The exercises were carried out 3 times a week and the hip muscles strength evaluation was conducted after the end of the program intervention
223930206|NCT05578846|DRUG|Treatment A|Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
224095440|NCT04293016|BEHAVIORAL|Support as usual|This group receives current best practice which includes participation in ICU support groups and provision of community support resources
224283785|NCT02568007|DRUG|Cyproheptadine|
223930207|NCT05578846|DRUG|Treatment B|Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
223930208|NCT05578846|DRUG|Treatment C|Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
223930209|NCT06688357|DEVICE|Active NIR-PBM (MedX 1116, MCT502)|Near infrared light was delivered using two MedX Rehab Console systems (MedX Health, 1116). Each MedX console included a control unit and 3 superluminous light emitting diode (LED) clusters. Each LED cluster (3MedX MCT502) consisted of 52 near infrared diodes and 9 visible red diodes. The 9 red diodes were deactivated. The energy delivered by each cluster was 1 joule \[J\]/cm2 in 45 sec at treatment wavelength of 870 nm per each 20 min. The LED cluster has an irradiance of 22.2 mW/cm2, treats an area of 22.48 cm2, with an energy density of 26.64/cm2 per cluster (total energy of 599J/cluster). During each session, the 6 clusters were arrayed on the scalp in 2 configurations, 20 minutes per array. Each configuration targeted 6 transcranial sites, guided by the 10-20 system, for a total of 12 sites during the 40-min session. Total energy delivered was 599J/cluster X 12 sites = 7188J. Dosing was based on a pilot study. This intervention was given 3 times/week for 2 weeks.
223930210|NCT06688357|DEVICE|Sham NIR-PBM (MedX 1116, MCT502)|The MedX sham intervention device is identical in all respects to the active device, except that the MedX console and diode clusters were modified to NOT deliver NIR light when turned on. The sham MedX devices were modified to deliver 'warmth', similar to that of the active devices. As with the active condition, a total of six sham interventions were given over a 2-week period, following the identical procedures described in the active condition.
223930211|NCT05717686|DRUG|AHB-137 injection|AHB-137 will be administered
224095441|NCT04293016|BEHAVIORAL|Problem solving therapy|This group will receive one on one therapy based on identifying stressors and solutions to those stressors
224095442|NCT04293016|BEHAVIORAL|ICU diary|This group will be provided with a structured written diary that includes identification of stressors and development of solutions to those stressors
224283786|NCT03296735|PROCEDURE|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
224283787|NCT03296735|PROCEDURE|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
224283788|NCT02571933|OTHER|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
224283789|NCT02571933|OTHER|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
224283790|NCT02571933|OTHER|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
224283791|NCT06873035|DRUG|infigratinib 0.128 mg/kg/day|Oral infigratinib 0.128 mg/kg/day
224283792|NCT06873035|DRUG|infigratinib 0.25 mg/kg/day|Oral infigratinib 0.25 mg/kg/day
224283793|NCT03179748|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
224283794|NCT00198536|DRUG|Ecabet 2.83%|
224283795|NCT00198536|DRUG|Ecabet 3.70%|
224283796|NCT00198536|DRUG|Vehicle|
224283797|NCT04614857|OTHER|Inclined treadmill gait|All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
223930212|NCT05717686|DRUG|Placebo|Placebo will be administered
223930213|NCT06734546|OTHER|Exercise intervention|The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week
223930214|NCT06734091|DIAGNOSTIC_TEST|PrestoCHILL|PrestoCHILL (Milestone Medical Technologies, Inc.MI 49009, USA)which by reducing the tissue freezing time to less than 60 seconds should eliminate freezing artefacts and improve the quality of sections for morphological and IHC examination. In selected cases and according to the diagnostic algorithm required for the diagnosis of specific neoplasms, rapid IHC analysis will be performed with the Benchmark ULTRA® immunostainer (Ventana Medical Systems), which is already in place to confirm or exclude the suspected neoplasm, as well as to confirm the histotype. For the latter purpose, commercially available antibody panels for routine examinations will be used (Ventana/Roche,Ventana Medical Systems, USA).
223930215|NCT06746012|PROCEDURE|Discussion|Participate in think-aloud sessions
223930216|NCT06746012|OTHER|Educational Activity|Receive health coaching
223930217|NCT06746012|OTHER|Internet-Based Intervention|Use Healthy Buckeyes app
224095443|NCT06607991|DRUG|Blinatumomab Treatment|Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
224095444|NCT03765593|PROCEDURE|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
224095445|NCT02760290|PROCEDURE|Extraperitoneal cesarean section|
224095446|NCT02760290|PROCEDURE|Intraperitoneal cesarean section|
224095447|NCT06127797|BEHAVIORAL|Questionnaire/Interview|Participation on this study will be over as soon as you complete the questionnaire/interview after your scheduled scans.
224095448|NCT03431233|DIETARY_SUPPLEMENT|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
224095449|NCT00045032|DRUG|Herceptin|Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
224095450|NCT00045032|DRUG|Herceptin|Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
224095451|NCT05906914|DRUG|cladribine + homoharringtonine + cytarabine|CHA Protocol: cladribine (5mg/m2, d1-3) + homoharringtonine (2mg/m2, d1-5) + cytarabine (100mg/m2 d1-7).
223930218|NCT06746012|OTHER|Internet-Based Intervention|Watch videos
223930219|NCT06746012|OTHER|Interview|Complete semi-structured interview
223930220|NCT06746012|OTHER|Medical Device Usage and Evaluation|Wear Fitbiit and use exercise bands
223930221|NCT06746012|OTHER|Questionnaire Administration|Ancillary studies
224095452|NCT03709992|DRUG|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
224095453|NCT03709992|DRUG|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
224095454|NCT06930937|OTHER|Lixiana® Film Coated Tablet|Lixiana® 60 mg filmtabletten (Film Coated Tablet) (Edoxaban)
224283798|NCT04807062|PROCEDURE|surgery|tunnel bone tamps method (TBTM) was used to reduce the depressed articular fragments and then structural bicortical autologous ICBG was used to fill the valley tunnel.
223532953|NCT00095550|DRUG|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
223930222|NCT06746012|OTHER|Supportive Care|Receive caregiver support
223930223|NCT06746012|OTHER|Survey Administration|Complete surveys
223930224|NCT06754475|OTHER|Low-volume, high-intensity interval training|Low-volume, high-intensity interval training with an arm ergometer will be given two days a week for a total of eight weeks.
223930225|NCT06754475|DRUG|Standart medical treatment|Standart medical teatment
223930226|NCT06757894|DRUG|Zuberitamab|375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)
223930227|NCT06757894|DRUG|Bendamustine|90 mg/m², administered on D1-2 of C1-C6
223930228|NCT02879318|DRUG|Gemcitabine|
223930229|NCT02879318|DRUG|Nab-paclitaxel|
223930230|NCT02879318|DRUG|Durvalumab|
223930231|NCT02879318|DRUG|Tremelimumab|
224095455|NCT06930937|OTHER|Edoxaban Film Coated Tablet|Edoxaban 60 mg Film Coated Tablet
224095456|NCT06936826|OTHER|Delphi Consensus Process|Round 1: Evaluation of current Medical Screening Tools and Scoping Review Results Round 2: Rating previous Statements from Round 1 Round 3: Consensus Round 4: Testing Content and Construct Validity of the new Medical Screening Tool with Clinical Vignettes
224095457|NCT06935721|DRUG|Y-4 tablet|Subjects will be admitted to research center in the afternoon of Day-1 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 1), subjects will be administered with one tablet of Y-4 , then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 4.
224095458|NCT06935721|DRUG|Pregabalin capsule|Subjects will be admitted to research center in the afternoon of Day 7 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 8), subjects will be administered with one pregabalin capsule , then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 11.
224095459|NCT06935721|DRUG|Riluzole tablet|Subjects will be admitted to research center in the afternoon of Day 14 prior to the dosing day and fasting for the next 10 hours overnight. In the morning of the following day (Day 15), subjects will be administered with one riluzole tablet, then subjects will be monitored and blood samples will be collected for the following 72 hours. Subjects will be discharged on Day 18 after safety evaluation.
224095460|NCT06936345|BEHAVIORAL|Cawthorne-Cooksey Exercises|A set of vestibular rehabilitation exercises aimed at improving balance and reducing dizziness through repeated head and body movements, delivered via home-based digital instructions.
224095461|NCT06936345|BEHAVIORAL|Brandt-Daroff Exercises|A traditional home-based vestibular exercise program for treating positional dizziness, involving repetitive lateral head movements performed daily.
224283799|NCT00000953|DRUG|Sorivudine|
223930232|NCT06755788|DEVICE|RT-CGM|In the RT-CGM group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. RT-CGM monitoring will also be employed during surgery. A tablet in the operating room will be configured with low and high glucose alerts set at 3.9 mmol/L and 10.0 mmol/L, respectively. When an alarm is triggered, arterial blood gases will be rechecked, and glucose levels will be adjusted based on the arterial blood glucose results. If interstitial glucose values do not reach the intervention threshold, arterial blood gas measurements are recommended every 30 minutes.
223941145|NCT06297057|OTHER|Neurophysiological Recordings|"Eyes-open resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes open and staring at a white cross in the center of a light grey screen to limit their eye movements.~Eyes-closed resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes closed.~ASSR: this block will last approximately 6 minutes. Stimuli will consist of a train of sounds presented repeatedly at high frequency.~MMN: this block will last approximately 3 minutes. Stimuli will consist of a train of equal sounds presented alternating with a 'deviant' (rarer frequency) sound."
224095462|NCT06936345|OTHER|Theta Binaural Beats|A digital auditory stimulation using two tones of slightly different frequencies to create a theta-frequency beat, intended to modulate anxiety and enhance vestibular rehabilitation effects.
224283800|NCT00000953|DRUG|Acyclovir|
224283801|NCT03695211|PROCEDURE|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
224283802|NCT03695211|PROCEDURE|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
224283803|NCT03391115|BEHAVIORAL|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
224283804|NCT03391115|BEHAVIORAL|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
224283805|NCT01066130|BEHAVIORAL|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
224283806|NCT01066130|BEHAVIORAL|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
224283807|NCT01680367|PROCEDURE|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
224283808|NCT01680367|PROCEDURE|wound care management|Receive native collagen wound dressing
224283809|NCT01680367|OTHER|questionnaire administration|Ancillary studies
224283810|NCT02401841|DRUG|Two different types of drug for resolution of neuro-muscular blockade|
224283811|NCT01629537|PROCEDURE|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
224283812|NCT01629537|PROCEDURE|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
224283813|NCT00862537|DEVICE|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
224283814|NCT01114581|DRUG|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
224283815|NCT01114581|DRUG|Placebo|Placebo given as 2 tablets
224283816|NCT05355519|OTHER|Electronic curriculum and instructor-led course, then placebo|Electronic curriculum and instructor-led course
223930233|NCT06755788|DEVICE|Control|In the control group, patients will wear a CGM sensor the day before surgery. Before entering the operating room, capillary blood glucose will be measured and compared with CGM interstitial glucose values for calibration. The target range for intraoperative blood glucose management is 3.9-10.0 mmol/L, with arterial blood gas measurements required at least every 2 hours. Following the administration of insulin or glucose, arterial blood gases should be retested at least every hour. CGM monitoring will also be employed during surgery, but the CGM interstitial glucose readings and alerts will be masked during the operation. The final intraoperative glucose management approach will be determined by the anesthesiologist, considering the patient's condition and surgical circumstances. The anesthesiologist can choose the intravenous insulin adjustment protocol we recommend.
223930234|NCT06752161|OTHER|Urine analysis|Urine analysis and culture for Screening and diagnostic tools for UTI in pregnant women
223930235|NCT06751875|DRUG|Lithium|Patients are randomized to either receive lithium or not.
223930236|NCT00177268|OTHER|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
223930237|NCT06755307|DIETARY_SUPPLEMENT|OMNiBiOTiC® Panda|Multistrain Probiotic OMNiBiOTiC® Panda containing: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactococcus lactis W58 and sunflower oil
223930238|NCT06755307|OTHER|Placebo|Placebo containing sunflower oil and maltodextrin
223930239|NCT06841250|PROCEDURE|intravitreal injection of anti-VEGF|Ranibizumab is injected into the vitreous under aseptic conditions as part of routine DME treatment
224283817|NCT05355519|OTHER|Placebo, then electronic curriculum and instructor-led course|Electronic curriculum and instructor-led course
224283818|NCT05094570|DRUG|Dupilumab Prefilled Syringe|Dupilumab 300 mg
224283819|NCT05271227|OTHER|Transthoracic echocardiography and Carotid artery doppler (PHILIPS HD11 XE ultrasound device) before and after PLR test.|VTI-LVOT was measured by echo by placing the pulsed wave Doppler sample gate in the LVOT diameter in apical-5-chamber window. VTI-LVOT was obtained by manually tracing the Doppler velocity spectrum. LVOT velocity time integral was recorded before and after PLR test within 2 minutes. Carotid blood flow was measured by using two-dimensional image, the optimal image of the long-axis view was obtained at the common carotid artery. The sample volume was placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination,The angle correction cursor was placed parallel to the direction of blood flow. A PLR will be performed in 2 sequential steps, first step patient is seated in the semi recumbent position (45°) then using an automatic bed elevation technique, the lower limbs will be then raised to a 45° angle while the patient's trunk will be lowered in supine position. Thus, the angle between the trunk and the lower limbs will remain unchanged (135°).
224283820|NCT03485001|OTHER|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
224283821|NCT03485001|PROCEDURE|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
224283822|NCT05397301|PROCEDURE|Controlled sedoanalgesia|Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
224283823|NCT02375945|DEVICE|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
224283824|NCT02375945|DEVICE|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
224283825|NCT04204096|BIOLOGICAL|Vi-DT (Multi-dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (multi dose Vi-DT with preservative 2 PE)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2 to 45 years~* Storage Conditions: +2 to +8°C"
224283826|NCT04204096|BIOLOGICAL|Vi-DT (Single dose formulation)|"* Manufacturer: SK bioscience Co., Ltd.~* Dose formulation: 25 µg Vi polysaccharide /0.5 mL, presented in Type I glass vial (single dose Vi-DT without any preservative)~* Mode of Administration: 0.5 mL by intramuscular injection in the left anterolateral thigh or left arm deltoid region in participants below 2 years of age, less dominant arm deltoid region in age group 2-45 years~* Storage Conditions: +2 to +8°C"
224283827|NCT04204096|BIOLOGICAL|Control Vaccine|"* For participant ≥ 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered~* For participants 6 months to 1 year one dose of locally licensed Meningococcal conjugate vaccine will be administered during the study and the next dose will be provided after the study unblinding at the completion of 6 months follow up of last subject."
224283828|NCT04975724|DRUG|Liposom Forte|Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
224283829|NCT04975724|DRUG|Citalopram|The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC
223532954|NCT00095550|DRUG|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
223532955|NCT01862003|DRUG|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
223532956|NCT01862003|DRUG|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
223532957|NCT01862003|DRUG|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
223532958|NCT01862003|DRUG|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
223532959|NCT01862003|DRUG|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
223532960|NCT05820503|PROCEDURE|Ultrasound-guided lower abdominis rectus sheath block|Under ultrasound guidance, the probe was transversely placed at the lateral level of the umbilicus . Using the in-plane technique, the needle was advanced until the posterior aspect of the rectus muscle was penetrated. No blood and no gas were drawn back; furthermore, a small volume of saline was initially injected to ensure that the needle tip was correctly positioned. When the needle was located between the posterior rectus muscle and posterior sheath, 5ml of 0.25% ropivacaine was injected bilaterally
223930240|NCT06841757|BEHAVIORAL|Remote ischemic preconditioning|Patients will undergo Remote Ischemic Preconditioning using a blood pressure cuff inflated on the upper limb to induce ischemia and reperfusion, 40 mmHg above systolic pressure. The procedure will involve 3 cycles of inflation (5 minutes each) and deflation (5 minutes each) post intubation
223930241|NCT06646107|DEVICE|MInimed 780G|Minimed 780G HCL system (Metronic, Northridge, Ca, USA) is ConformitèEuropëenne(CE)-marked and includes additional functionality aiming to provide further protections from high glucose levels. When the system is used in Auto Mode automatically calculate the insulin dose based on information received from CGM. Signals are converted by the transmitter to sensor glucose values. Sensor values are then transmitted to the insulin pump. Sensor glucose and insulin delivery data are stored by the pump and may be uploaded. The HCL system can be programmed to automatically calculate insulin doses (both basal insulin and correction boluses) based on information received from CGM780G and the adherence to MD.
223930242|NCT06813157|OTHER|MSC|The overall test process is as follows: screening period (V1): sign ICF, check the screening period, judge the criteria, record the baseline demographic information and the status of the subjects. Baseline period (V2): pre-transfusion assessment was performed to record the safety and other examinations of the subjects. During the treatment period (V3): according to the method and dose specified in the scheme, MSCs was treated for 5 times. Follow up period (V5): Safety and efficacy follow-up will be conducted at D14, M1, M2, M3, M6, M9, and M12 during the follow-up period.The subjects were followed up to M12 or those who met the withdrawal criteria withdrew early, whichever occurred first.
223930243|NCT06882837|BEHAVIORAL|BUMP app|Participants in the experimental group will have access to the BUMP app, which aims to support them to control the amount and rate of weight gain during pregnancy, from baseline (early or mid-pregnancy) until they give birth. The app will prompt participants to regularly self-monitor their weight gain during pregnancy, and will provide access to a weight gain chart for tracking. Participants will receive feedback notifications about their weight gain trajectory, and will have access to information and tips on weight management during pregnancy.
223930244|NCT06885983|PROCEDURE|implant placement|Late implant placement without regenerative therapy
223930245|NCT06885983|PROCEDURE|Guided bone regeneration|Application of collagen membrane after implant placement.
223930246|NCT06766591|DRUG|Ivonescimab combined with chemotherapy|Ivonescimab combined with chemotherapy. The specific chemotherapy regimen is based on the real world.
223930247|NCT06769373|DEVICE|Whirlpool Bath|This group of participants will receive an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, whirlpool bath (32-38 °C) 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
223930248|NCT06769373|DEVICE|Contrast Bath|This group of participants will recieve an exercise program consisting of 40 minutes hand-wrist range of motion exercises (passive, active assistive), stretching, strengthening exercises, contrast bath therapy which consist of 4 minutes hot water (38°C) followed by 1 minute cold water (10°C) periods for 20 minutes in total, transcutaneous electrical nerve stimulation (TENS) 20 minutes in total for 4 weeks. 5 sessions per week for 20 sessions in the Physical Therapy department.
223930249|NCT06782594|DRUG|Mosapride Citrate Injection(high)|Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days
223930250|NCT06782594|DRUG|Mosapride Citrate Injection(low)|Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days
223930251|NCT06782594|DRUG|Placebo|Placebo, iv, bid, for 3 to 5 days
223930252|NCT06766032|DEVICE|CELL-Saver|The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.
223930253|NCT06766032|DEVICE|SAME|The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
223930254|NCT06790459|DEVICE|UlfTens (Ultra-low-frequencies Transcutaneous electrical nervous stimulation)|ULFTENS device will be administered in the experimental group for 15 minutes
223930255|NCT06769464|BEHAVIORAL|odor|present odor
223930256|NCT06790771|DIETARY_SUPPLEMENT|High Dose Supplement|Participants in this intervention receive approximately 10 grams of the supplement, containing 9,000 mg of L-arginine, 200 mg of resveratrol, 500 mg of tart cherry, and 100 mg of vitamin C. The supplement is consumed in powdered form after an 8-hour fasting period. Following a 60-minute rest, participants eat an ad libitum meal to assess the supplement's effect on hunger and food intake. Blood samples are collected at eight specific time points to measure metabolic markers, including GLP-1 levels, while hunger is tracked using a 7-point satiety scale. This intervention aims to determine the effects of a high dose of the supplement on appetite suppression and metabolic responses.
223930257|NCT06790771|DIETARY_SUPPLEMENT|Low Dose Supplement|In this intervention, participants consume approximately 5 grams of the supplement, which contains 4,500 mg of L-arginine, 100 mg of resveratrol, 250 mg of tart cherry, and 50 mg of vitamin C. The protocol mirrors that of the high-dose intervention: participants arrive after fasting for 8 hours, consume the supplement, rest for 60 minutes, and eat the standardized ad libitum meal. Blood samples are taken at the same eight time points to assess metabolic responses, and hunger levels are measured using the same satiety scale. This intervention investigates whether a lower dose of the supplement can still significantly affect hunger and GLP-1 secretion.
223941146|NCT00790699|DEVICE|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
223941147|NCT00790699|OTHER|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
223941148|NCT04412005|OTHER|No intervention|No intervention
223941149|NCT01420497|DRUG|intra-articular infiltration|intra articular infiltration
223532961|NCT05820503|PROCEDURE|Local anesthesia infiltration|Local anesthesia drugs were injected into the peri-umbilicus cord
223532962|NCT05155111|DIAGNOSTIC_TEST|Telemedicine consult|A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
223532963|NCT02818517|OTHER|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
223930258|NCT06790771|DIETARY_SUPPLEMENT|Placebo|The placebo intervention involves participants consuming a \~5 g inert powder with no active ingredients. Participants follow the same protocol as the other two interventions, including fasting, baseline blood collection, supplement (placebo) consumption, a 60-minute rest, and an ad libitum meal. Blood samples are collected at eight time points, and hunger levels are assessed with the 7-point scale. This intervention serves as a control, helping to determine whether observed effects in the other two interventions are attributable to the active supplement ingredients.
223930259|NCT06768541|PROCEDURE|THA using a short stem|Total Hip Arthroplasty using a collarless, triple-tapered cementless short stem (Optimys, produced by Mathys).
223930260|NCT06767670|OTHER|stainless steel crown|familiar method of managing multi-surface carious lesions in primary teeth
223930261|NCT06767670|OTHER|bioflex crown|aesthetic preformed pediatric crowns that offer the properties of both stainless steel and zirconia crowns
223930262|NCT06739148|DEVICE|Low Level Laser Therapy|Low-level laser therapy can increase cellular energy production, making it useful as a pre-conditioning treatment to prevent muscle contraction fatigue or as a post-contraction therapy to accelerate fatigue recovery.
223718210|NCT07015684|RADIATION|Planar gamma imaging|Dosimetric imaging will be performed using quantitative planar gamma camera acquisition. Planar gamma imaging is a technique used in medical imaging to take pictures of the inside of the body, particularly to look at how certain organs or tissues are functioning. This allows the study doctor to evaluate how the study drugs are absorbed into the body.
223930263|NCT06739148|DEVICE|blood flow restriction|Its advantage is that during training, it can surpass the \&#34;overload principle,\&#34; allowing for effective muscle cross-sectional area growth with relatively light weight training (20%-50% of 1RM or 20%-40% of MVC).
223930264|NCT06739148|DEVICE|Neuromuscular Electrical Stimulation|It is a strength training method that uses electrical currents to stimulate nerve and muscle activation, helping to maintain muscle mass, increase blood flow, and slow down or prevent muscle atrophy.
223930265|NCT05067478|DRUG|Vibegron|Vibegron to be administered.
223930266|NCT06845124|DRUG|Cannabidiol capsules|800mg (trial arm 1) or 1200mg (trial arm 2) Cannabidiol capsules will be administered daily over the course of 14 days.
223930267|NCT06845124|DRUG|Naltrexone (drug)|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study.
223930268|NCT06845124|DRUG|Placebo|Placebo capsules matching the cannabidiol capsules will be administered daily.
223930269|NCT02739477|DRUG|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
223941150|NCT01420497|DRUG|epidural infiltration|epidural infiltration
223941151|NCT00729898|DRUG|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223941152|NCT05884515|DIAGNOSTIC_TEST|SARS CoV-2 antigen tests|The intervention is to compare antigen tests
223941153|NCT06092476|DEVICE|Revita® DMR Treatment|"The Revita® System is an endoscopic treatment consisting of a single catheter and console designed to lift the duodenal mucosa with saline followed by controlled circumferential hydrothermal ablation of the mucosa. For this study Revita® DMR procedure will be conducted as follows:~DMR Treatment Paradigm 1- After initial 2 Lift and Ablate step, remaining Lift: Ablate steps will be conducted in 1:1 manner."
223941154|NCT06092476|OTHER|Sham procedure|The sham control for the Revita DMR procedure.
223941155|NCT00296790|DRUG|zolpidem tartrate|
223941156|NCT03844685|DRUG|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
223941157|NCT03844685|DRUG|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
223941158|NCT06272591|OTHER|Preliminary search in the patient's file|"Details of the information previously sought in the patient's file :~age profession gender/parity physiological or pathological pregnancy indication for induction of labour gestational age at time of induction"
223941159|NCT06272591|OTHER|A posteriori research in the patient's file|Data on maternal and foetal morbidity and mortality following childbirth will be collected.
223941160|NCT06272591|OTHER|First questionnaire : choice of induction method reason for choice|Given on arrival at the maternity unit to begin induction.
223941161|NCT06272591|OTHER|Second questionnaire : experience of induction|Given post-partum in the maternity unit.
223941162|NCT05416476|DRUG|Anisodine Hydrobromide|Anisodine Hydrobromide 1 mg oral tablet, twice times a day
223941163|NCT05416476|DRUG|Anisodine Hydrobromide placebo|Anisodine Hydrobromide Placebo 1 mg oral tablet, twice times a day
223941164|NCT00220532|DRUG|Folic acid with riboflavin|
223941165|NCT01046292|DRUG|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
223941166|NCT02708394|DRUG|olanzapine|atypical antipsychotic
223941167|NCT02708394|DRUG|placebo|placebo control
223941168|NCT02745990|DRUG|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
223941169|NCT02745990|DRUG|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
223941170|NCT04654390|DRUG|DWP16001 Amg|Tablets, Orally, Once daily
223941171|NCT00364975|BEHAVIORAL|gourmet cooking workshop|
223941172|NCT04274790|PROCEDURE|Scheduled and planned surgery|Collection of tumour samples from samples collected as part of standard patient management. Diagnostic pathological analysis will be a priority. These samples will be taken by experienced staff during the hospital visit scheduled as part of standard care.
223941173|NCT04608409|DRUG|Lapatinib and Paclitaxel|Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.
223941174|NCT04242524|BEHAVIORAL|Circadian Clock Alignment|Use timed lights and meals to align the circadian clock
223941175|NCT04242524|BEHAVIORAL|Circadian Clock Control|No circadian clock alignment
223930270|NCT03311451|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
223532964|NCT02818517|OTHER|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
223532965|NCT02975960|BIOLOGICAL|injection of autologous stromal vascular fraction|"1. Acquiring autologous stromal vascular fraction (SVF) from liposuction~2. purifying SVF from lipoaspirates and making syringe filled with SVF~3. SVF injection - Inject SVF on fingers subcutaneously."
223532966|NCT02668666|DRUG|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
223532967|NCT02668666|DRUG|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
223930271|NCT06758167|DRUG|XingpiJieyu formula|XingpiJieyu formula is a traditional Chinese medicine. It pays attention to the regulation of qi and blood. Previous studies have shown that its clinical effect of treating mild and moderate depression is significant, for example, it can effectively improve depressive mood and somatic symptoms, and increase peripheral blood ATP levels in patients with depression.
223930272|NCT06758167|DRUG|Placebo|Placebo, no therapeutic effect.
223930273|NCT06758167|DRUG|Escitalopram|A commonly used drug in MDD treatment.
223930274|NCT06768034|PROCEDURE|Intervention Group|Patients being referred to an internist or cardiologist after myocardial injury after noncardiac surgery
223930275|NCT06758609|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy
223930276|NCT06758609|DRUG|4°C saline infusion|Patients received a total of 350 ml of 4°C saline infusion in addition to mechanical thrombectomy (MT).
223930277|NCT06758609|DRUG|Normothermic saline infusion|Patients received a total of 350 ml of roomtemperature saline infusion in addition to mechanical thrombectomy (MT).
223930278|NCT06809868|GENETIC|RNA and DNA Sequencing|DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.
224095463|NCT06936293|BEHAVIORAL|Mindfulness Meditation|"The experimental group received 30 minutes of mindfulness meditation according to Smith's (2005) protocol, which is a standardized theory-based intervention. Smith's (2005) protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email to be accessed by their cell phones and headsets. The audio-recorded intervention contents were validated by two psychologists and experts in meditation."
224095464|NCT06935942|BIOLOGICAL|Ustekinumab - Standard Dosage|Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
224095465|NCT06935240|DEVICE|Treatment|Nöromusculer and Transcutaneus Electrical Neuron stimulations
223532968|NCT03220009|PROCEDURE|Conventional Surgery|Undergo surgery
223532969|NCT03220009|BIOLOGICAL|Ipilimumab|Given IV
223532970|NCT03220009|OTHER|Laboratory Biomarker Analysis|Correlative studies
223532971|NCT03220009|BIOLOGICAL|Nivolumab|Given IV
223930279|NCT06163092|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
223930280|NCT06761651|DRUG|TAVO412|Biologic
223930281|NCT06600789|DRUG|CT7439 Capsules (0.5 mg, 1mg, 3mg)|CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed.
223930282|NCT05791396|BIOLOGICAL|Donor - FMT|this intervention is represented by the administration, in the recipients' gut, of donor microbiota through FMT
223930283|NCT05791396|OTHER|Placebo FMT|This intervention is represented by the administration, in the recipients' gut, of a placebo through colonoscopy
223930284|NCT06405984|DEVICE|Fetal Oxygenation Measurements|The Lumerah device, and Oxiplex ISS will be positioned on the maternal abdomen in various locations depending on the sonographic evaluation. The transvaginal sensor will be placed after rupture of the maternal membranes and appropriate descent of the fetus.This study is for data collection purposes only. Neonates of this study arm will also be monitored with the Oxiplex ISS system. This study is for data collection purposes only.
223930285|NCT06883851|OTHER|Structured pelvic floor rehabilitation|"The classic DDVAP therapy will be administered by the pediatric urologist. The classic urotherapy training recommended for enuresis will be provided by the physiotherapist. In addition, structured pelvic floor muscle rehabilitation (SPFMR) will be provided by the physiotherapist for 10 weeks. Each session is planned to last approximately 60 minutes.~SPFMR will include multiple interventions combined. Below is information about the brief interventions.~* Diaphragmatic Breathing Training~* Pelvic Floor Training with Biofeedback~* Core Stabilization Exercises~* Squat Exercises~* External Rotator Strengthing~* Adductor Strengthing~* Balance Training~* Home Exercises"
223532972|NCT03220009|OTHER|Patient Observation|Undergo active surveillance
223532973|NCT03220009|RADIATION|Radiation Therapy|Undergo RT
223532974|NCT01483170|DRUG|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
223532975|NCT01483170|DRUG|Placebo|Placebo fexinidazole
223532976|NCT02656056|OTHER|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
223532977|NCT05630456|OTHER|Receving feedback|Receving regular feedback from a health provider
223532978|NCT05630456|OTHER|No regular feedback|No regular feedback from a health provider
223930286|NCT06757621|RADIATION|Regional Nodal Irradiation|Patients will receive chest wall / breast radiation with or without regional nodal irradiation
223930287|NCT06758024|DRUG|Infliximab|IFX therapeutic drug monitoring before the second and third infusion and subsequent dashboard-guided dosing regimes suggested to attending gastroenterologists based on clinical and pharmacokinetics data
223930288|NCT06758024|DRUG|Infliximab|No IFX therapeutic drug monitoring before the second and third infusion and subsequent dosing regimes based on clinical data
223930289|NCT06891508|OTHER|Venous blood sampling|Venous blood sampling (3 mL) via venipuncture from the antecubital fossa at the time of delivery
223930290|NCT06891508|OTHER|Tissues sampling|Sampling of the placenta and amniochorionic membranes (hAM) at delivery
223930291|NCT06891508|OTHER|Umbilical cord blood sampling|Umbilical cord blood sampling from the residual cord attached to the placenta immediately after clamping.
223930292|NCT06891534|OTHER|Continuous Feeding|Participants will receive 24-hour continuous feeds through an NG tube
223930293|NCT06891534|OTHER|Intermittent feeding|Participants will receive 3 boluses of feeding per day at regular meal times through an NG tube to mimic normal meals.
223930294|NCT06895564|RADIATION|Spinal Proton SBRT|Patients will be treated with spinal proton SBRT over 5 fractions, with a prescription dose of 6 Gray equivalent (GyE) per fraction to the planning target volume.
223930295|NCT05383495|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg \[100 mcg/mL (max 200 mcg or 2 mL)
223930296|NCT05383495|DRUG|Midazolam Nasal Spray|Intranasal midazolam 0.4 mg/kg \[5 mg/mL (max 10 mg or 2 mL)
223930297|NCT05383495|DRUG|Nitrous oxide|50% nitrous oxide in 50% oxygen by face mask
223930298|NCT06765200|BEHAVIORAL|Self-administered psychosocial intervention delivered via smartphone.|The treatment includes a smartphone-based psychosocial program designed to improve the quality of life of adolescents with chronic pain.
223930299|NCT06764108|BEHAVIORAL|Self-monitoring|Self-monitoring will involve completing one brief smartphone-based survey (at a fixed time) per day on suicidal thoughts and related affect states and experiences over the past day during the four weeks after psychiatric hospitalization.
223930300|NCT06764108|BEHAVIORAL|JITAI|The JITAI will involve prompts to complete additional randomly timed self-monitoring surveys throughout the day. When suicidal thoughts are reported on any self-monitoring survey, random assignment to receive or not receive a series of automated smartphone-based messages that recommend using specific coping strategies from either a personalized safety plan or general evidence-based coping strategies that others tend to find helpful.
223941176|NCT05300672|DRUG|fibrinogen infusion|fibrinogen infusion (2 g) in stroke patients with secondary post-rtPA hypofibrinogenemia
223930301|NCT06764108|BEHAVIORAL|Self-guided SSI|The brief (10-12 minute) online self-guided SSI will help individuals identify and address barriers to using coping strategies for suicidal thoughts. It may be delivered up to three times during the four weeks after hospitalization for those who do not sufficiently respond to the initial (self-monitoring only or self-monitoring plus JITAI) interventions.
223930302|NCT06764108|BEHAVIORAL|Clinician-delivered SSI|The clinician-delivered SSI will consist of a brief (30-minute) Zoom or phone meeting in which a study clinician will help individuals identify and address barriers to using coping strategies for suicidal thoughts. Those who do not sufficiently respond to the initial (self-monitoring only or self-monitoring plus JITAI) interventions may receive up to three clinician-delivered SSIs during the four weeks after hospitalization.
223930303|NCT06764537|PROCEDURE|Blood collection|Blood collection (40 mL) in glioblastoma patients
223930304|NCT06766630|DEVICE|Silk fibroin surgical mesh|This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein
223930305|NCT06610344|DIETARY_SUPPLEMENT|R-1,3-Butanediol|R-1,3-Butanediol 35 mL
223930306|NCT06821386|DIAGNOSTIC_TEST|Genetic study with nanopore sequencing|The study targets critically ill children under 18 months of age, employing third-generation genome sequencing technology to complete long-read sequencing within 8-11 days, analyzing single nucleotide variants, small insertions/deletions, and structural variations. Through this research, we aim to enhance diagnostic accuracy, enabling ICUs to provide personalized and precision care and treatment based on genetic information, thereby ensuring a greater level of health security for these children. We only draw 3-5cc whole blood once for exam.
223930307|NCT06766097|DIETARY_SUPPLEMENT|mastic toothpaste|All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
223930308|NCT06766097|DIETARY_SUPPLEMENT|Placebo toothpaste|All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
223930309|NCT06768684|BEHAVIORAL|Brief behavioral counseling|Participants receive a two-session phone-based alcohol risk reduction intervention based on principles of harm reduction. Participants receive personalized feedback regarding how alcohol use may impact their health. Following a motivational enhancement exercise, participants are advised to reduce alcohol intake to within recommended limits. Evidence-based strategies are discussed (e.g., goal setting, self-monitoring, identifying and avoiding triggers, dealing with urges, pacing and spacing drinks, managing high risk situations, finding alternatives to alcohol, developing refusal skills, and enlisting social support). Educational materials addressing methods for cutting down are also provided, along with information about other available resources to support their efforts.
223930310|NCT06756659|OTHER|Center-based exercise training|All participants will undergo a spot jogging cardiopulmonary exercise test and a six-minute walking test. The outpatient center-based cardiac rehabilitation group will perform moderate-intensity stationary biking or treadmill exercise for 30 minutes, twice a week, under the supervision of a physical therapist in the outpatient cardiac rehabilitation room.
224283830|NCT04975724|OTHER|Placebo|Liposom Forte Placebo (2 ampoules of 2 ml solution for injection)
224283831|NCT03234608|BEHAVIORAL|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
224283832|NCT04593394|DIAGNOSTIC_TEST|Continous laryngoscopy exercise test|Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored
224283833|NCT04593394|DIAGNOSTIC_TEST|Overnight respiratory polygraphy|Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea
224283834|NCT04802551|OTHER|Sensory integration therapy|Sensory integration disorder is defined as the inability of a person to use the information he / she receives through his / her senses properly in order to continue his daily life properly. Intervention group have some therapy sessions which include sensory integration therapy exercises.
224283835|NCT00703131|DEVICE|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
224283836|NCT04618419|DIAGNOSTIC_TEST|internal jugular vein distensibility index|It is a prospective observational clinical study to correlate hemodynamic monitoring between Electrical Cardiometry and internal jugular vein distensibility index by sonogram
224283837|NCT05659524|OTHER|Nasal saline irrigation|"The following nasal care recommendations have been approved by the study protocol committee for patients randomized to the treatment arm with saline irrigations:~* Postoperative days 1 through 3: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily.~* Postoperative day 3 to week 12: patients will begin twice daily sinus irrigation rinse (e.g., NeilMed Sinus Rinse). They will perform 240 mL sinus rinses BID. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative."
223718211|NCT06679894|PROCEDURE|Implant site preparation with osteotomes and electrified mallet|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~A pilot osteotome (100-P) was used to easily perforate the cortical plate. Subsequently, osteotomes with gradually increasing diameters were employed until the final diameter of 3.2 mm was reached.~The sequence of osteotomes and their respective diameters were as follows:~1. Osteotome 100-P: At a height of 8.5 mm, the diameter was 2.2 mm;~2. Osteotome 160: At a height of 8.5 mm, the diameter was 2.8 mm;~3. Osteotome 200: At a height of 8.5 mm, the diameter was 3.2 mm. Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
223930311|NCT06756659|OTHER|Home-based spot jogging|The home-based spot jogging cardiac rehabilitation group will receive exercise intensity guidance in the outpatient cardiac rehabilitation room for 30 minutes of spot jogging and treadmill exercise during the first, fourth, and seventh weeks. They will then perform moderate-intensity spot jogging at home for 30 minutes, twice a week, at a perceived exertion level of 13 out of 20 on the RPE scale.
223930312|NCT06757842|BEHAVIORAL|Mindfulness in Students|The mindfulness intervention includes eight 90-minute group sessions held weekly at Universidad de los Andes, co-facilitated by two instructors. One leads the activities, while the other assists with technical aspects, monitors adverse events, and provides participant support. Participants will receive mindfulness worksheets and are required to practice at home for 15 minutes daily. They will have access to an online platform with audiovisual materials to guide their practice and will complete home practice logs online. Skills taught include sitting meditation (focused on breathing, thoughts, emotions, or sensations), body scan meditation, standing meditation, and mindfulness of daily activities. Group discussions will cover topics such as defining mindfulness, managing stress and pain, the difference between mindfulness and being on 'autopilot,' and how perceptions affect stress, as well as the relationship between pain and suffering, and the acceptance of unwanted experiences.
223930313|NCT06756971|DRUG|Propofol|Propofol will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
223930314|NCT06756971|DRUG|Dexmedetomidine|Dexmedetomidine will be administered until the patients is in an optimal plane that mimics natural sleep while spontaneously breathing to allow for a DISE evaluation
223930315|NCT06762015|BEHAVIORAL|Positive Nursing Practice Environments Promotion Program|A multi-component intervention program aimed at promoting positive nursing practice environments.
223930316|NCT06764745|DEVICE|PC Ventilation Modes|Following induction, Group I patients received mechanical ventilation using the PC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
223930317|NCT06764745|DEVICE|VC Ventilation Modes|Following induction, Group II patients received mechanical ventilation using the VC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
223930318|NCT06764745|DEVICE|PRVC Ventilation Modes|Following induction, Group III patients received mechanical ventilation using the PRVC mode. The anesthetic machine (MAQUET Flow-I, Italy) parameters were set as follows: The inspiratory pressure (Pins) was adjusted to maintain an end-tidal carbon dioxide concentration (ETCO2) of 4.0-5.0 kPa. Pure oxygen and air were utilized at 0.3 L/min each, with an oxygen content of 41%. The positive end-expiratory pressure (PEEP) was set at 10 cmH2O, with an inspiration-to-expiration ratio of 1:2, a respiratory rate of 16 breaths per minute, and an oxygen content of 41%.
223930319|NCT06768086|PROCEDURE|Hysteroscopic myomectomy|"The hysteroscopic myomectomies were conducted during the follicular phase of the menstrual cycle. Throughout the surgical procedure, the intrauterine pressure was meticulously maintained at less than 80 mm Hg. Data on the duration of the surgical intervention, the volume of fluid administered, and the volume of fluid absorbed were collected. Complete resection was characterized as the total excision of the myoma. The determination of the completeness of myomectomy was made by the experienced surgeon during the surgical process. In instances where the resection was deemed incomplete, the decision to pursue a secondary surgical intervention was predicated on ultrasonographic evaluations, the symptomatic presentation of the patients, and, in certain circumstances, the findings from diagnostic hysteroscopy. Cases in which access to the uterine cavity was unfeasible were classified as failed procedures and were subsequently excluded from the study."
223930320|NCT06768424|DEVICE|Guided biofilm therapy|Use of Airflow Plus powder subgingivally on teeth with deep periodeontal pockets
223930321|NCT06768424|PROCEDURE|Platelet Rich Fibrin|Pack Platelet Rich Fibrin chops into the intrabony periodontla defect
223930322|NCT06768424|PROCEDURE|Minimally Invasive Surgical Technique|Periodontal intrabony defect is treated by minimally invasive surgical intervention
223941177|NCT00599196|DRUG|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
223532979|NCT01190527|RADIATION|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
223532980|NCT00556114|DEVICE|Optical Coherence Tomography|Optical Coherence Tomography
223532981|NCT03769688|DRUG|Cervicovaginal secretions|Same as arm descriptions
223532982|NCT03769688|DRUG|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
223930323|NCT06827041|BIOLOGICAL|Phage (Cytophage Technologies)|"Our phage is a new type of investigational treatment for bacterial infections. Our lytic, monophage preparation was provided by Cytophage Technologies and underwent rigorous testing to ensure final product potency (7 x 10\^9 PFU/dose), purity, fidelity, and safety; laboratory tests demonstrate phage in vitro efficacy against the S. epidermidis strain.~Phage prepared in injection-grade saline will be given via two routes: a) intravenously twice daily, and concomitantly, b) intraarticularly twice daily, for a total duration of 14 days."
223930324|NCT06203041|DIETARY_SUPPLEMENT|Vitamin D|Orally administered, daily dose of 5000 IU (125 mcg) Vitamin D3 for 28 days.
223930325|NCT03936933|DRUG|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
223930326|NCT03936933|DRUG|ZOLADEX® 3.6mg Injection|3.6 mg, Subcutaneously at every 28 days
223930327|NCT06774183|OTHER|Near vision glasses for presbyopia correction|Provision of near vision glasses for presbyopia correction to individuals who did not previously have glasses and have correctable presbyopia
223930328|NCT06774898|DEVICE|Custom-molded lumbar-sacral orthosis|A custom-molded lumbar-sacral orthosis made according to the Vésinet method associated with measures designed to enhance adherence based on goal-setting techniques (i.e. personalized advice, self-determination of the wearing time, hotline) techniques and monitoring of adherence using a temperature sensor chip to provide feedbacks to participants on the wearing time at follow-up visits, and usual care (i.e. a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises).
223930329|NCT06774898|OTHER|Usual Care|Usual care consisting in a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises
223930330|NCT06774261|DRUG|Phenserine|"Phenserine is a next generation AChE inhibitor being developed for the treatment of AD. Unlike currently marketed AChE inhibitors, it has additional mechanisms of action that also include a mediating effect on cell death pathways and anti-amyloid activity, which may confer disease-modifying effects in people with AD.~Phenserine was originally identified and developed by the United States (U.S.) National Institute of Aging (NIA), part of the U.S National Institute of Health (NIH).~The study intervention will be open label. No blinding will be performed. Participants and site staff will, however, will be blinded to the results of the exosome and blood/CSF biomarker evaluations until the study is completed."
223930331|NCT06774261|DRUG|Donepezil (Aricept®)|"The substance donepezil (under the brand name Aricept®) is a resale product. No additional manufacturing or labeling measures is necessary for this study.~The NIMP, donepezil will be available in 5 mg and 10 mg strengths (table 3) and will be dispensed by the local pharmacy at the hospital where the participant in the donepezil arm is included. We have based the use of donepezil as a treatment in the study on the original product from Pfizer, but it is also possible to use generic products of donepezil if this is what the local pharmacy has for dispensing. Participants randomized to treatment with donepezil will follow the treatment plan according to the patient information leaflet. . These tablets are approved for clinical use and comply with all relevant safety and efficacy standards."
223930332|NCT06775093|DRUG|GLP-1 receptor agonist|3 months
223930333|NCT06775093|DRUG|Metformin|3 months
223930334|NCT06775093|BEHAVIORAL|healthy lifestyle education|3 months
223930335|NCT06770478|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT Scan|The imaging agent 68Ga-MY6349 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.
223930336|NCT06774950|BEHAVIORAL|Physician-patient quality circle|"Intervention: (To be compared with standard care)~1. Interprofessionnal meeting per neighbourhood: (beforehand) Therapeutic patient education (TPE) training for healthcare professionals~2. Physician-patient quality circle t0 Group sessions (n= 3 to 6 patients) with doctor and therapeutic patient education specialist Clinical measurements - CM (incl. HbA1c, body composition, blood pressure). PROM evaluation questionnaires (EQ5D\&DIABQ)~3. Development of individualised T2D programme: with case manager~4. Quarterly follow-up: t3, t6, t9 months PROM follow-up (DIABQ\&PHQ9) +CM.~5. Evaluation of experience: t12 \& t18 months PREM\&PROM evaluation questionnaire +CM"
223532983|NCT03769688|DIAGNOSTIC_TEST|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
223930337|NCT06771050|PROCEDURE|Debridement and Implant Retention (DAIR)|"Intervention 1: DAIR- cleaning of infected joint including irrigation, debridement and exchange of modular components (those not fixed to bone) with implant retention.~Intervention 2: Single stage revision - cleaning of infected joint including irrigation, removal and placement of definitive new components which could be primary or revision components."
223930338|NCT06771050|DRUG|Antibiotic Choice|"No intervention: Backbone antibiotic therapy only depends on the organism and is detailed in the protocol.~Intervention: Backbone antibiotic therapy plus rifampicin. Dosage 600-900mg per day orally for as long as oral antibiotic treatment continues, but not more than 12 weeks. Prescribed according to local recommended practices and dosed as per local therapeutic guidelines."
223930339|NCT06771050|DRUG|Antibiotic duration Part A - Single stage revision|"Intervention Arm: Short course 6-week (42 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors.~Intervention Arm: Long course 12- week (84 +/- 7 days) antibiotic course - combined intravenous and oral with antibiotic choice according to organism and patient tolerability factors."
223930340|NCT06771050|DRUG|Antibiotic Duration Part B - Two stage revision|"Intervention Arm: Extended prophylaxis for 12 weeks after the 2nd stage revision surgery.~Intervention Arm: No extended antibiotic prophylaxis after the 2nd stage revision surgery.~Antibiotic choice by treating team with reference to the original causative organism(s), susceptibility and patient tolerability."
223930341|NCT06772948|OTHER|Asynchronised group|Health workers with musculoskeletal system disorders will be given pilates exercises asynchronously using the YouTube application.
223930342|NCT06772948|OTHER|Synchronized group|Using the Zoom application, healthcare workers with musculoskeletal disorders will perform pilates exercises synchronously.
223930343|NCT06772909|OTHER|No intervention (observational study)|no intervention
223930344|NCT06770725|BEHAVIORAL|Temporal Adaptation Intervention|The research on temporal adaptation intervention will be conducted through activities and individual sessions within the framework of temporal adaptation intervention. The activities included in the temporal adaptation intervention used in our research have been adapted for ADHD by referencing temporal adaptation training models in the literature.
223930345|NCT06770725|BEHAVIORAL|Conventional Occupational Therapy|The control group will be given a 10-week-long conventional occupational therapy intervention by the investigator (Fatma Temizkan). The intervention will consist of occupational therapy approaches such as; obstacle courses, sensory integration, motor skills training, cognitive skills training, sequenced activities and so on.
223930346|NCT06771063|DRUG|WXSH0102/placebo|Administer WXSH0102 tablets/placebo orally.
223930347|NCT06771063|DRUG|fluconazole capsules/placebo|Administer fluconazole capsules/placebo orally
223930348|NCT06775756|RADIATION|IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation|For N0 disease, only cover bilateral RPN and level II. For N1 disease, cover ipsilateral involved level plus subsequent level downword, and cover contralateral level RPN and level II. For N2 disease, cover ipsilateral involved level plus subsequent level downword. For N3 disease, cover ipsilateral involved level plus subsequent level downword, and ensuring a 2cm margin below GTVn if GTVn reach or near the sternoclavicular joint. Notably, for unilateral N3, the contralateral neck would only include RPN and level II. Prescribing dose for CTVn2 was 50Gy/33Fx.
223930349|NCT06310343|DRUG|Alemtuzumab|Licensed dose
223930350|NCT06774118|OTHER|Data collection|Data collection
223930351|NCT05175404|DIAGNOSTIC_TEST|PET/CT scan F18-PSMA-11|PET/CT scan with F18-PSMA-11
223930352|NCT06777966|DRUG|nebulized tranexamic acid|patients will receive a preoperative nebulizer session of 500 mg of tranexamic acid. To ensure the blinding of the participating anesthetist and patient, patients in this group will receive an intravenous drip of 100 ml of 0.9% normal saline.
223930353|NCT06777966|DRUG|intravenous tranexamic acid|patients will receive a preoperative intravenous drip of TXA at a dose of 15 mg/kg in 100 ml of normal saline. To ensure blinding this group patients will receive 5 ml of 0.9% normal saline nebulizer session.
223930354|NCT06764199|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT), a relatively new psychotherapy, incorporates psychopathological hypotheses and interventions based on contextual behavioral sciences and Relational Frame Theory.
223930355|NCT06782464|PROCEDURE|Treatment|Treatment
223930356|NCT06776744|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|Eye Movement Desensitization and Reprocessing (EMDR) treatment. EMDR is one of the first-choice evidence based treatments for PTSD. During an EMDR session, the traumatic memory is brought to the surface including associated images, thoughts, feelings and body sensations, while simultaneously focusing on an external distracting stimulus (e.g., lateral eye movements).
223930357|NCT06808594|DEVICE|APSI prosthesis implant|The adaptative proximal scaphoid implant (APSI) is a pyrocarbon partial scaphoid prosthesis, ovoid and unfixed, which replaces the proximal pole of the scaphoid and allows adaptative mobility in the movements of the first chain and restores the geometry of the carpus, thus preventing the evolution in SNAC (Scaphoid Non-union Advanced Collapse). Pyrocarbon has good compatibility with joint cartilage and bone, a modulus of elasticity similar to bone minimizing stress shielding effects and resorption. The implant is designed with two radii of curvature: in the frontal plane, the smaller radius of curvature corresponds to the scaphoid fossa, and the larger radius of curvature is directed anteroposteriorly to the transverse plane. When it's correctly positioned, the smallest radius of the curvature is visible in the anteroposterior view, whereas it's greater in the lateral view. These two axes of the implant make it adaptable to the kinematics of the wrist.
223941178|NCT00703352|DRUG|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
223941179|NCT02683174|DEVICE|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
223941180|NCT02683174|BIOLOGICAL|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
223532984|NCT03769688|BEHAVIORAL|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
223532985|NCT03769688|OTHER|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
223532986|NCT06142864|OTHER|Data collection|Data collection
223532987|NCT01344148|DRUG|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
223532988|NCT03700229|DRUG|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
223930358|NCT03081403|DEVICE|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
223930359|NCT06771999|OTHER|Educational intervention by a clinical pharmacist|All participants will respond to two questionnaires, both validated in Romanian and some demographic information. One is the rPATD questionnaire that investigate attitudes towards deprescribing of medication and the other one is the HLS-EU-Q16 that investigates medical literacy of participants. After completion, the clinical pharmacist will give a brochure and a video about the process of deprescribing, information about the efficacy and the adverse reactions of medicines and the role of pacient in treatment decision. When participants come to another cancer treatment (after 14 , 21 or 28 days), the rPATD will be completed again.
224095466|NCT06936956|OTHER|Acupressure|Acupressure is a noninvasive type of acupuncture. It is applied using fingers, joints or a suitable acupressure tool.
224283838|NCT01097551|DRUG|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
224283839|NCT01097551|DRUG|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
224283840|NCT01097551|DRUG|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
224283841|NCT01097551|DEVICE|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
224283842|NCT05958056|OTHER|Resistance exercise|The training session included leg curl and leg extension exercises with 4 sets each. Participants started with leg extension exercise for 4 sets with a 30-second rest periods between the sets. Then, participants took a rest for 60 seconds. Afterward, participants performed leg curl exercise for 4 sets with a 30-second rest periods between the sets. Exercises in each set were performed continuously (uninterrupted) with a speed of 2 seconds for each repetition and a medium exercise performance speed.
224283843|NCT05327439|OTHER|Nicotine (electronic cigarette)|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at in-person and phone assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose one of two e-liquid flavors (tobacco, menthol) at baseline.
224283844|NCT05327439|OTHER|Nicotine (nicotine pouch)|Participants will be provided with 4mg nicotine pouches for 8 weeks and encouraged at in-person and phone assessments to use the nicotine pouches any time they would normally smoke. Participants will be able to choose one of two nicotine pouch flavors (tobacco, mint) at baseline.
224283845|NCT06627894|BEHAVIORAL|Therapist-Assisted Internet Cognitive-Behavioral Therapy for Depression|Good Days Ahead (MindStreet, Inc.)
224283846|NCT06627894|BEHAVIORAL|Active Control|Depression education, symptom monitoring, and standard depression care
224283847|NCT04403945|DEVICE|Sidestream dark field(SDF) imagining|SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
224283848|NCT04034654|OTHER|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
224283849|NCT03066934|OTHER|noninvasive ventilation respiratory support|
224283850|NCT05694117|BEHAVIORAL|self-determine sequence exercise program|The Taichi exercise utilized the simplified eight styles of Taichi. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
224283851|NCT05694117|BEHAVIORAL|resistance training|The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions). Participants in the RTG completed four sets of each movement, with two to three minutes of rest between each set.
224283852|NCT05694117|BEHAVIORAL|Taichi exercise and resistance training|The training of the Taichi exercise and resistance training group consisted of two cycles, the first cycle was aimed at learning and consolidating Taichi exercise, and the second cycle was aimed at improving and consolidating. The Taichi exercise and resistance training group was scheduled for 30 min of Taichi exercise per training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
223532989|NCT03700229|DRUG|Rituximab|rituximab intravenously 500 mg for one dose
223532990|NCT04778150|DEVICE|VO 100 medical device from Mespere LifeSciences|The investigators want to show a positive relationship between SjvO2 and SvO2 in order to possibly use in the future SjvO2 measured by VO 100 as a noninvasive surrogate of SvO2 in patients undergoing liver transplantation surgery.
223532991|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|50 mg twice-daily (BID)
223532992|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|150 mg quaque die (QD)
223930360|NCT06626685|OTHER|Clinical and instrumental examination|Each patient, consecutively afferent to the SC Cardiologia I of the ASST-PG23 in Bergamo with the diagnosis of acute or chronic HF, at enrollment will undergo to routine clinical and instrumental examination.
223930361|NCT03655561|OTHER|Non interventional research|Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
223930362|NCT06746558|COMBINATION_PRODUCT|Potassium Nitrate Gel and Diode Laser Therapy|Participants in the experimental group receive treatment combining a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to affected teeth and diode laser therapy (980 nm). The laser is used with specific power settings (0.3W, 0.5W, 0.7W) for 20 seconds at each setting, followed by a second application of the gel and irradiation. The treatment aims to reduce dentinal hypersensitivity by occluding dentinal tubules and altering neural responses.
223930363|NCT06746558|DRUG|Potassium Nitrate Gel Alone|Participants in the control group receive treatment with a desensitizing gel containing 5% potassium nitrate (Emoform Actisens) applied to the teeth. The gel is applied twice using a microbrush in a rubbing motion for 2 minutes each time. No diode laser therapy is administered. This intervention aims to evaluate the standalone efficacy of the gel in reducing dentinal hypersensitivity.
223930364|NCT06889441|BEHAVIORAL|Test of sensory function in infants|It was planned to use the Test of sensory function in infants to evaluate the sensory development of infants. The test of sensory function in infants is frequently used to evaluate the sensory processing functions of infants aged 4-18 months. It is used to determine whether an infant has a sensory processing problem and to what extent. It consists of 24 items. The test of sensory function in infants requires the infant to be stimulated and interacted with various materials. The total score varies between 0-49 and the test has normative values for different age groups. Although it is used from the fourth month onwards, the most reliable and valid results are obtained between 7-18 months.
223930365|NCT06889441|BEHAVIORAL|The Peabody Developmental Motor Scales-Second Edition|The Peabody Developmental Motor Scales-Second Edition is a standardized, norm-referenced assessment instrument designed to evaluate both gross and fine motor skills in children aged 0 to 71 months. It is frequently employed in clinical, educational, and research contexts to detect motor developmental delays, monitor developmental trajectories, and inform intervention strategies. Notably, higher scores on the scale reflect superior motor performance, indicating better developmental outcomes
223930366|NCT06889441|BEHAVIORAL|Infant/toddler sensory profile|"The infant/toddler sensory profile is a questionnaire filled out by the child's primary caregiver to collect information about sensory processing abilities. The test evaluates sensory processing in 6 different areas. These items consist of general, visual, auditory, vestibular, tactile and oral sensory processing. The caregiver evaluates the child's behavior on a 5-point scale. One point means almost always and five points means almost never. The caregiver's responses are summarized using standard scoring procedures and then interpreted in terms of the impact of a child's sensory processing abilities on the child and their family's lives. The scores are normative for age and are important in assessing sensory development."
224095467|NCT06936995|DRUG|Preemptive Multimodal Intravenous Analgesia|Combination of opioids, NSAIDs, and adjunctive medications to manage postoperative pain before and during surgery.
224283853|NCT05694117|BEHAVIORAL|Randomly selected exercise program|Participants in the randomly selected exercise program group who chose Yijinjing exercise were required to complete one hour of Yijinjing exercise training, and those who chose Yijinjing exercise hybrid strength training had to complete half an hour of Yijinjing training. The resistance training program consisted of three cycles. In the first cycle, investigators used a light load but high repetitions (ranging from 40% to 60% of one repetition maximum and 12-20 repetitions). During the second phase of our training, investigators raised the training load by doing sets of moderate intensity and a medium number of repetitions (ranging from 60% to 80% of one repetition maximum and 5-12 repetitions). In the third cycle, investigators aimed to improve the participants' maximal muscular resistance by using a greater training load and fewer repetitions (ranging from 70% to 85% of one repetition maximum and 5-8 repetitions).
224283854|NCT01981317|BEHAVIORAL|Stepped Care Cognitive Behavioral Therapy|
224283855|NCT01981317|BEHAVIORAL|Cognitive Behavioral Therapy|
223532993|NCT04034134|DRUG|Jaktinib Hydrochloride Tablets|200 mg quaque die (QD)
223532994|NCT04899765|BIOLOGICAL|BCG vaccine|It is an attenuated live bacterial vaccine. This vaccine is a freeze-dried product that must be reconstituted.
223532995|NCT04899765|BIOLOGICAL|Measles vaccine|It is an attenuated live virus vaccine. This vaccine is a freeze-dried product that must be reconstituted.
223532996|NCT04899765|OTHER|Placebo|Saline
223532997|NCT01848093|OTHER|sputum collection|collecting of spontaneous sputum from the patient
223532998|NCT00716001|DRUG|N-acetylcysteine|
224283856|NCT04715906|BEHAVIORAL|UP-Caregiver|The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
223532999|NCT03748914|OTHER|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
223533000|NCT03748914|OTHER|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
223533001|NCT03768037|DRUG|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
223533002|NCT03768037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
223718212|NCT06679894|PROCEDURE|Implant site preparation with osseodensification drills|"Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~The implant site preparation was realized using osseodensification burs at a rotation speed of 1200 rpm. The osseodensification burs sequence was as follows:~1. Initial pilot hole (rotated clockwise);~2. WT1828 bur (rotated counterclockwise),~3. WT2838 bur (rotated counterclockwise). Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment."
223718213|NCT05814783|BEHAVIORAL|supported digital CBTI|in session support for adherence to and engagement with digital CBTI
223718214|NCT05814783|DEVICE|digital CBTI|CBTI app
223718215|NCT07016451|PROCEDURE|Li-ESWT|The intervention treatment uses Li-ESWT. (Dornier Aries® devices, Power 0.29mj/m² and 3000 shocks per week for 4 weeks)
223930367|NCT06754202|OTHER|Social activities with cognitive stimulation|"The nine-month program will include social activities following the Montessori action in the context of the agricultural multifunctionality such as horticulture, pet therapy, occupational therapy, sensory labs, physical activity held three days a week for five hours each day."
223930368|NCT06784661|DRUG|Lipid-Based Artificial Tear|This intervention consists of a lipid-based artificial tear formulation containing mineral oil and hydroxypropyl guar. It is designed to enhance the tear film's lipid layer and improve ocular surface stability. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
223930369|NCT06784661|DRUG|Non-Lipid Artificial Tear|This intervention consists of a non-lipid artificial tear formulation containing hydroxypropyl guar. It is intended to stabilize the aqueous layer of the tear film and maintain optical quality. Participants in this group will receive a single drop in each eye, and corneal aberrations will be measured at baseline and 15 minutes after instillation.
223941181|NCT03912909|DRUG|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
224095468|NCT06936995|PROCEDURE|Femoral Triangle Block|Local anesthetic injection around the femoral nerve to manage postoperative pain via regional anesthesia.
224283857|NCT03683329|OTHER|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
224283858|NCT03683329|OTHER|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
224283859|NCT03236363|BEHAVIORAL|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
224283860|NCT03236363|BEHAVIORAL|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
224283861|NCT03200535|OTHER|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
224283862|NCT03200535|OTHER|Bulk outreach|A bulk letter or email will be sent
224283863|NCT03200535|OTHER|Dietician call|Patients will receive a personalized call by a registered dietitian
224283864|NCT06695117|BIOLOGICAL|IIV-HD|Inactivated, split-virion
224283865|NCT06695117|BIOLOGICAL|rC19 (dose 1)|Protein subunit
224283866|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 1)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
224283867|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 2)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
224283868|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 3)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
224283869|NCT06695117|BIOLOGICAL|IIV-HD + rC19 (dose 4)|IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit
224283870|NCT06695117|OTHER|Placebo (0.9% NaCl)|Normal saline
224283871|NCT06631274|BEHAVIORAL|counseling|The intervention (IVY; Intervention for Victimized Youth) is an 8 week group counseling intervention delivered in a virtual environment.
224283872|NCT05966987|COMBINATION_PRODUCT|Low-level Laser Therapy vs. Injectable Platelets-rich Fibrin|laser and platelet rich fibrin
224283873|NCT06155773|PROCEDURE|Highly viscous glass ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
224283874|NCT06155773|PROCEDURE|Low shrinkage Flowable Composite (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
224283875|NCT06155773|PROCEDURE|Resin Modified Glass Ionomer (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
224283876|NCT06155773|PROCEDURE|Bioactive Ionic Resin (cervical margin relocation)|different dental restorative materials used to relocate deep cervical margins before receiving onlay restorations
224283877|NCT01314768|BEHAVIORAL|Brief intervention|Structured behavioural Brief intervention given by trained GPs
224283878|NCT01314768|OTHER|Business as usual|GPs to treat patient as they have until now based on best established practice
223533003|NCT04541524|DEVICE|Santen Preserflo Microshunt|The PMS is 8.5 mm long has an outer diameter of 350 μm and a lumen diameter of 70 μm. It has a fin sized 1.1 mm located 4.5 mm distally from the internal tip of the device and it consists of poly(styrene-b-isobutylene-b-styrene) SIBS. The device was implanted 1 year prior to the present study via an ab externo approach. At the beginning of the surgery, the conjunctiva was opened. In the first group of patients (group 1) we made a fornix based conjunctival opening, prepared a 1mm wide and long scleral pocket in 3mm distance from limbus and placed the PMS in the anterior chamber via a 25G needle track. In the second group (group 2) the conjunctival opening was 3.5 mm from the limbus, the scleral pocket was prepared at 3.5 mm distance from the limbus and a 27G needle was used. PMS guides aqueous humor from the anterior chamber to the subconjunctival space. The forming filtering bleb absorbs aqueous humor which leads to IOP reduction.
223533004|NCT00976456|DRUG|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
223930370|NCT06835166|PROCEDURE|12-lead electrocardiography measurement|"Intraoperative 12-lead electrocardiography (EKG) measurement during laparoscopic sleeve gastrectomy in morbidly obese patients:~In all patients, pneumoperitoneum CO₂ intraabdominal pressure will be studied as 15 cmH₂O.~Intraoperatively, 12-lead ECG will be obtained at five position measurement points:~Procedure1. Supine-monitored; Procedure 2. After induction; Procedure 3. Under general anesthesia-Supine-abdominal inflated; Procedure 4. Abdominal inflated-(30% vertical) Reverse Trendelenburg; Procedure 5. Abdominal deflated-(30% vertical) Reverse Trendelenburg.~Hemodynamic monitoring \[systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate \] was recorded at 5 simultaneous measurement points.~All hemodynamic measurements and ECG recordings will be performed 3 minutes after the position change to ensure standardization, to allow the response to settle after the position change, and to prevent the possibility of exaggerated-incorrect data."
223930371|NCT05530421|DRUG|Selinexor|Selinexor tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
223930372|NCT05530421|DRUG|Venetoclax|Venetoclax tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
223930373|NCT05530421|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally (PO) once per day at assigned dosage and frequency per protocol.
223533005|NCT00976456|DRUG|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
223533006|NCT06087380|PROCEDURE|auricular acupressure|Auricular pressure The experimental group commenced auricular acupressure intervention post-surgery. Questionnaire assessments and heart rate variability measurements were conducted in the experimental group on the first, second, third, and fourth days before discharge.
223930374|NCT03307382|DEVICE|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
223930375|NCT01084863|DRUG|CT-P6|CT-P6: administered every 3 weeks
223930376|NCT01084863|DRUG|Herceptin|Herceptin: administered every 3 weeks
223930377|NCT01084863|DRUG|Paclitaxel|Paclitaxel: administered every 3 weeks
223930378|NCT02845596|DRUG|cyclosporine|cyclosporine
224095469|NCT06946160|DRUG|Abobotulinumtoxin A (Espad Pharmed Darou Co.)|Vial of Abobotulinumtoxin A (produced by Espad Pharmed Darou Co.), administered via deep intramuscular injection
223533007|NCT06087380|OTHER|standard ward care|standard ward care
223533008|NCT01631968|PROCEDURE|Cement without antibiotic.|
223533009|NCT01631968|PROCEDURE|Cement with erytromycin and colistin.|
223533010|NCT02474810|DRUG|Alteplase|Alteplase for CVC dysfunction.
223930379|NCT02845596|PROCEDURE|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
223930380|NCT02845596|DRUG|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
223930381|NCT02845596|DRUG|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
223930382|NCT02845596|DRUG|methotrexate|methotrexate
223930383|NCT02845596|DRUG|fludarabine|fludarabine
223930384|NCT02845596|DRUG|cyclophosphamide|cyclophosphamide
223930385|NCT02845596|RADIATION|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
223930386|NCT02845596|PROCEDURE|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
223930387|NCT03253835|DIAGNOSTIC_TEST|Single Group Assignment|
223930388|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype AA|
223930389|NCT02377622|DEVICE|THERANOVA 400 dialyzer prototype BB|
223930390|NCT02377622|DEVICE|FX CorDiax 80 Dialyzer|
223930391|NCT02377622|DEVICE|FX CorDiax 800 Dialyzer|
223930392|NCT06812416|DIETARY_SUPPLEMENT|Qualia NAD+|Qualia NAD+
223930393|NCT06812416|DIETARY_SUPPLEMENT|Rice Flour Placebo|Rice Flour Placebo
223930394|NCT06873815|DRUG|Fluorescein Sodium|Patients will receive IV fluorescein sodium in the operating room before the vulvectomy procedure.
224095470|NCT06946160|DRUG|Abobotulinumtoxin A (Ipsen Co.)|Vial of AbobotulinumtoxinA (Dysport®, produced by Ipsen Co.), administered via deep intramuscular injection
224095471|NCT06951893|OTHER|Hospital Anxiety and Depression Scale|It is a self-assessment questionnaire to identify the existence of anxious and depressive symptoms and to assess their severity.
224095472|NCT06951893|OTHER|Dutch Eating Behaviour Questionnary|"It allows the assessment of 3 distinct factors of eating behavior: cognitive restriction, emotional eating and externality. This tool was developed to better characterize the eating habits of obese subjects.~10min"
224283879|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
224283880|NCT01314768|OTHER|Screening and outcome evaluation only|No additional intervention
224283881|NCT05515107|DEVICE|Videolaryngoscope size 1 Miller blade|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
224283882|NCT03666325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
223533011|NCT01528592|DRUG|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
223533012|NCT05303883|OTHER|Pediatric Constrained Induced Movement Therapy|Constraint of the child's less-impaired upper extremity for first 17 days of treatment. Children wear a removable, lightweight constraint for the first 17 of 20 therapy sessions.
223533013|NCT01088685|DEVICE|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
223930395|NCT06744270|OTHER|i-PRF group|"In the i-PRF group, 10 ml of venous blood taken from the patient immediately after the SDG operation will be transferred to a tube that does not contain any anticoagulant. The collected venous blood will be centrifuged for 3 minutes at 2300 rpm in a centrifuge device and two layers will be obtained: the lower layer is red blood cells and the upper layer is i-PRF. 20-25 minutes will be waited for polymerization. After polymerization, the polymerized i-PRF will be applied to the wound surface in the donor area. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days and their photographs will be taken and the following parameters will be evaluated.~* Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using the Image program from patient photographs~* Edema and erythema scores will be assessed visually."
223930396|NCT06744270|OTHER|low-dose laser group|"In the laser group, low-dose laser will be applied to the palatal donor area immediately after SDG surgery, on the 3rd, 5th, 7th and 14th days. A GaAlAs diode laser (CHEESETM, GIGAA Laser, Wuhan Gigaa Optronics Technology Co., Ltd., China) with a wavelength of 810 nm and a low-dose diode laser application tip with a fiber diameter of 950 µm will be used. A low-dose diode laser will be applied to the surgical operation area in accordance with the manufacturer's instructions, with a non-contact regional 0.3 W power and an intensity of 4 J/cm2 in continuous mode for 1 min. Following the operation, patients will be called for check-ups on the 3rd, 5th, 7th, 14th, 21st and 30th days, and their photographs will be taken and the following parameters will be evaluated. • Pain assessment and analgesic intake~* H2O2 Foaming Test (to assess epithelialization)~* Wound healing will be assessed using Image program from patient photographs~* Edema and erythema scores will be assessed visually."
223930397|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 2 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 3 receives treatment in accordance with health recommendations as part of prophylactic treatment for acute rejection after allogeneic solid organ transplantation, at the minimum dose, i.e., 2 to 5 mg/kg/day for 5 to 21 days."
223930398|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 1 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 2 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation."
223930399|NCT06744400|DRUG|Grafalon® administered during 5 consecutive days at 0,5 mg/kg/j|"This de-escalation study was planned to investigate 3 doses level of Grafalon® administered during 5 consecutive days, i.e.:~Group 3 : 2 mg/kg/j, Group 2 : 1 mg/kg/j, Group 1 : 0,5 mg/kg/j.~Group 1 receive treatment at lower doses than the recommended dose for the same duration (5 days). Treatment begins on the day of transplantation immediately before the procedure at induction of sedation"
223930400|NCT06669572|DRUG|Pembrolizumab|"Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.~Pembrolizumab will be given for a maximum of 2 years (total 35 cycles) with dosing every 3 weeks."
223930401|NCT06669572|DRUG|Lenvatinib|Lenvatinib will be taken once daily, with or without food, at the same time each day.
223533014|NCT01088685|DEVICE|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
224283883|NCT03666325|DRUG|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
224283884|NCT02769741|OTHER|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
223533015|NCT05177250|DEVICE|HPLC|taking urine samples from participants and analyze these samples to detect bisphenol A and paraben
223533016|NCT01959685|DRUG|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
223533017|NCT01959685|DRUG|Placebo|Placebo, single dose
223533018|NCT03527784|DEVICE|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
223533019|NCT03527784|DEVICE|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
223533020|NCT03527784|DEVICE|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
223533021|NCT06461780|OTHER|Line-based questionnaire follow-up|The participant will use LINE group to report irAE severity, distress, financial toxicity and change trajectory of quality of life in one-year follow-up. If the severity grade of irAE reach the threshold and require referral, an alarm will appear to notify the research team to conduct and transfer to a clinical specialitst, or refer to the emergency room for treatment. Additionally, the Line group will also provide clinical relevant immunotherapy health education information currently and routinely used in study site. Patients can view it according to their interests, but the APP will not actively promote it.
223533022|NCT00637910|DRUG|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
223718216|NCT07016451|DRUG|Medication|"The medication treatment of Radiation cystitis and relevant symptoms such as Antimuscarinics, Beta3 agonist, and pain control, as listed. Antimuscarinic Agents~* Oxybutynin~* Tolterodine~* Solifenacin~* Darifenacin~* Trospium~* Fesoterodine β3-Adrenergic Agonists~* Mirabegron Pain Control Medications~* Paracetamol~* NSAIDs (e.g., Ibuprofen, Diclofenac)~* Phenazopyridine~* Amitriptyline~* Gabapentin / Pregabalin"
223930402|NCT06767033|DEVICE|Ultrasound Guided Inferior Vena Cava Collapsibility Index Assessment|Before spinal anaesthesia, inferior vena cava collapsibility index was measured for all patients using Ultrasound device.
223930403|NCT06784232|PROCEDURE|BARP|deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
223930404|NCT06784232|PROCEDURE|Modified Periosteal Inhibition Technique|Cortical lamina stabilized with human fibrin glue to preserve the buccal wall of the socket. The socket was then filled with collagen.
223930405|NCT06784700|OTHER|Massage|Participants will be positioned inside a massage chair for a 30-min, followed by an additional 30-minute period of lying down on a proper double bed.
223930406|NCT06784700|OTHER|No intervention|Subjects will not receive any massage program; instead, they will be rested for 30 minutes on an automatic switch-off electric massage chair and subsequently lay down for an additional 30 minutes on a proper double bed;
223930407|NCT06786650|DRUG|Tenoxicam Injectable Product|Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
223930408|NCT06786650|DRUG|ibuprofen|Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
223930409|NCT02112214|DRUG|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
223930410|NCT02112214|OTHER|Placebo|Placebo for bismuth-based quadruple therapy
223930411|NCT06768294|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib is a JAK1/JAK2 inhibitor approved for use in Rheumatoid Arthritis. It is under investigation for use in several inflammatory diseases, including Psoriasis and Psoriatic Arthritis, Atopic Dermatitis, Inflammatory Bowel Disease and Systemic Lupus Erythematosus, with encouraging results. As IL-6 plays a central role in CPPD inflammatory process, a broad spectrum of interleukins and other proinflammatory proteins (including interferons) could be involved. A drug that acts by blocking more than one proinflammatory cytokine could be a promising treatment for a multifaceted disease such as CPPD.
223930412|NCT06768294|DRUG|Methylprednisolone (Corticosteroid)|The initial dosage of methylprednisolone may vary depending on the entity of inflammation and the patient's comorbidities. Usually in CPPD a short-term administration of methylprednisolone starts with 16 mg per day after breakfast decreasing the initial dosage in small decrements at appropriate time intervals until discontinuation, in about 2 weeks. Methylprednisolone will be given in combination with gastroprotective agents such as proton pump inhibitors.
223930413|NCT06768294|DRUG|Colchicine 1 MG Oral Tablet|1 or ½ tablet (depending on individual tolerance) daily after breakfast
223930414|NCT06768294|DRUG|Hydroxychloroquine 200 mg|1 tablet daily after lunch
223930415|NCT06768294|COMBINATION_PRODUCT|Methotrexate + Folic Acid|MTX 2.5 mg tablets, from 2 to 4 tablets (5-10mg), depending on disease severity, to be administered once weekly after dinner, always in the same day of the week. One tablet of folic acid (folina 5 mg) will be administered the day after MTX administration, after breakfast, to reduce and prevent the common side effects of MTX.
223930416|NCT06772142|DEVICE|Peripheral Nerve Stimulation|Peripheral Nerve Stimulation
223930417|NCT03907826|DRUG|PD-1 blocking antibody|Toripalimab 240mg, D1, every 3 weeks per cycle
223930418|NCT03907826|DRUG|GP|Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
223930419|NCT03907826|RADIATION|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
223930420|NCT06781671|BEHAVIORAL|ComfortTheory|"Structured nursing interventions based on the Comfort Theory were applied to patients in the intervention group.~Patients were mobilized at least once during the day. Auxiliary materials believed to increase patient comfort, such as tablet computers, wired headphones, sleep headphones, and sleep masks, were provided.~Patients had face-to-face meetings with their families during the day and video calls in the evening.~Care interventions were minimized as much as possible for patients between 24:00-07:00 at night, and treatments were carefully planned around these hours.~Blood sampling was performed at 23:00 at night, and X-rays were taken at 07:00 in the morning.~The Patient Identification Form, General Comfort Scale, and Intensive Care Unit Environmental Stressor Scale were administered face-to-face by the researcher 48 hours after the patient\&amp;amp;amp;#39;s admission to the intensive care unit."
223930421|NCT06770920|OTHER|use of an observer tool when not role-playing|Observers will use an observer tool (based on technical skills and specifically related to airway management during BLS) when they will be not role role-playing.
223930422|NCT06678217|OTHER|Stroop task|The Stroop task will be used as a mild, acute stressor since it has effects on anxiety and autonomic response. In each Stroop task condition, four coloured visual stimuli will be presented on a computer screen for 3 s with 7 s inter-stimulus interval. The stimuli will be coloured words naming the colour of the ink in the nonconflict task condition (e.g. GREEN written in green ink) and a different colour in the conflict task condition (e.g. GREEN written in red ink). The participants were asked to name the colour of the stimuli. The test will be administered using the online version of PsyToolKit (Stoet, 2021).
223930423|NCT06678217|OTHER|Cold pressor test|The participant lowers their hand in icy water to induce temporary tonic pain
224095473|NCT06951893|OTHER|Impact of Weight on Quality Of Life|The EQVOD is a validated French scale created from the Impact of Weight on Quality of Life (IWQOL) questionnaire. This self-administered questionnaire is specific to the sociocultural factors of obesity and its dietary treatment in France. The questionnaire is composed of five dimensions: physical impact (11 items), psychosocial impact (11 items), impact on sexual life (4 items), dietary well-being (5 items), and experience of diet/dietetics (5 items). The total number of items is 36.
224095474|NCT06951893|OTHER|body schema|Tactile assessment of the body schema using a motorized caliper applied to different parts of the individual's body. The caliper is connected to a touch pad on which the person can report the difference felt between the two pressure points on their skin, using their thumb and index finger.
224095475|NCT06951893|OTHER|body mass index|patient weighing at each visit
224095476|NCT06951893|OTHER|waist size|waist size measure
224099685|NCT06127602|BEHAVIORAL|Reactive balance training without Neuromuscular Electrical Stimulation|REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
223930424|NCT06030635|DEVICE|Measurement of compartment compressibility using the CPMX1 device|Patients will be monitored about every hour (+/- 30 min) for a total of 8 hours. Measurement time might be extended in case the patient undergoes trauma-related surgery during the measurement period and/or in case measurements are spaced further apart. Remaining measurements will be completed after the surgery. At each time point, three measurements of compartment compressibility will be conducted using the CMPX1 on both the affected (potential ACS) and healthy limb.
223930425|NCT06811766|OTHER|Strain-counterstrain|This is a technique that uses gentle body positioning passively to treat muscles and joints pain. So, this can be effective for neck pain in patients with CGH
223930426|NCT06811766|OTHER|Muscle energy techniques|This technique uses patient's own muscles to treat muscles and joint restrictions. So, this technique can be prove affective for neck pain and limited range in patients with CGH
223930427|NCT06812065|DRUG|Hydrogen Peroxide 3 % Topical Solution|"Dressing: Like the Local Hyperthermia Group, use a cotton ball soaked in 3% hydrogen peroxide.~Irradiation: For seven sessions in three weeks, use simulated infrared light (without heat) with the same frequency as the Local Hyperthermia Group.~Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts."
223930428|NCT06812065|DEVICE|Local Hyperthermia at 44℃|"(Patent No: ZL 200820231952.4, Model: YY-WRY-V01, Liaoning Yanyang Medical Instrument Co., Ltd., China) An infrared hyperthermia device was used to apply local hyperthermia at 44°C to the largest wart. The device includes a heating source, an infrared temperature monitor, an adjusting arm, a control circuit for temperature stabilization, and a display. It uses a tungsten-halogen lamp (wavelength: 760-2300 nm, peak at 1200 nm) to maintain the temperature of a 0.5\*0.5 cm skin area within ±0.1°C using a non-contact infrared feedback system.Hyperthermia: Conduct 44-degree Celsius, 30-minute sessions. Do it daily for the first 3 days, then 2 sessions every 7 days for 3 weeks, for a total of 7 sessions.~Dressing: Apply a cotton ball soaked in 0.9% saline to the warts, wrap it with plastic film for 1 hour, and do this once a day for 6 weeks. Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts."
223930429|NCT06657612|OTHER|No intervention|No intervention
223930430|NCT06813391|OTHER|Patient Reported Outcome (PRO)|after enrollment, patient will answer to several PRO to assess their pain and overall well-being after their stroke
223930431|NCT06806670|BEHAVIORAL|lifestyle intervention|exercise and dietary counselling
223930432|NCT06819644|DRUG|high flow oxygen therapy rate adjusted of lung volumes measured|Use of a technique based on non-contact measurement of lung volumes by depth camera in order to optimise the use of hihg flow oxygen therapy, with adaptation of the flow rate.
223930433|NCT04969146|BEHAVIORAL|Dyadic Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
223930434|NCT04969146|BEHAVIORAL|Patient Only Intervention|The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
223930435|NCT06891898|DEVICE|iLet Dosing Decision Software|Interoperable alternate glycemic controller
223930436|NCT06745336|DRUG|CS-001|CS-001 Topical Treatment
223930437|NCT06745336|DRUG|Placebo Topical Solution|Placebo Topical Solution
223930438|NCT06762093|PROCEDURE|surgical repaire|"* Primary closure of lacerations~* Eyelid margin repair~* Eyelid crease reconstruction~* Eyelid transposition flaps or grafts~* Tarsorrhaphy"
223930439|NCT06761066|DIETARY_SUPPLEMENT|NVP-NK4146|BID for 36 weeks orally
223930440|NCT06761066|DIETARY_SUPPLEMENT|NVP-NK4146 Placebo|BID for 36 weeks orally
224099686|NCT06418308|DRUG|Dexmedetomidine|5 mcg of dexmedetomidine
224099687|NCT06418308|DRUG|Epinephrine|200 mcg of epinephrine
223930441|NCT06760559|PROCEDURE|Intra-articular corticosteroid injection|Intra-articular hip injections with and without local anastesia and questionnaire about pain and anxiety related to the procedure was administered before and after the injection to the study and control groups.
223930442|NCT06761586|DRUG|AUR104|Once or twice a day
223930443|NCT06761924|PROCEDURE|Ultrasound-Guided Thoracic Paravertebral nerve block|The patients will receive ultrasound-guided TPVB with 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone (10 mL volume)
223930444|NCT06761924|PROCEDURE|Ultrasound-Guided Thoracic Paravertebral nerve block|ultrasound-guided TPVB with 10 mL of saline without knowing which treatment they are receiving, maintaining blinding throughout the study.
223930445|NCT06773104|PROCEDURE|immediate implant and grafting with autogenous tooth bone graft|"In autogenous tooth bone graft group:~Any restorations, caries, cementum, periodontal ligament and pulp tissue will be removed .The tooth will be grinded using dental bone mill and bone crusher Tooth particles will be sieved to particles size 300 to 1200 microns. The sorted particles will be immersed in 70 % ethanol and 5% Peracetic acid\* in a sterile container for 10 minutes to remove any soft tissue remnants, bacteria and smear layer (defatting and sterilization).~Tooth particles will be demineralized using 2% HNO3‡ for 20 minutes to expose the dentine organic matrix.~The bacteria-free particulate dentin will be washed with phosphate buffered saline‡ twice for 5 minutes to restore the PH balance to 7.4. In the same setting, after atraumatic extraction immediate implant will be inserted with graft"
223930446|NCT06773104|PROCEDURE|immediate implant with allogenic bone graft|after atraumatic extraction immediate implant will be inserted with allogenic bone graft
224099688|NCT06418308|DRUG|Standardized Spinal Mixture|Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
224099689|NCT06807164|DRUG|Capsaicin 8% Patch|One or two capsaicin patch (8%) are applied for 60 minutes to the site of neuropathic pain, in day-hospital. An oral, antalgic pre-medication may be done with one of the following medications (alone or association): paracetamol 1g, nefopam 30 mg, tramadol 100 mg, morphine 10mg, oxycodone 5mg. Capsaicin will be administered in addition to a systemic treatment that has been ongoing for at least 4 weeks. If pain persists, the capsaicin patch application may be repeated at 12 weeks.
223533023|NCT00637910|DRUG|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). \_Until disease progression or unacceptable toxicity develops
223533024|NCT02526914|DRUG|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
223533025|NCT02526914|DRUG|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
223533026|NCT02526914|DRUG|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
223930447|NCT06773585|DIAGNOSTIC_TEST|Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI|"This study is a minimal-risk study involving non-invasive, non-pharmacological interventions. Participants will continue receiving their usual medication or counseling treatments as part of their routine care during the study.~When participants come to the hospital for assessments, they will engage in clinical assessments and complete questionnaires over a period of 1-2 hours, undergo MRI scans, and participate in virtual environment-based behavioral assessments. They will have the option to take breaks during the assessments and can withdraw from the study at any time without providing a reason."
223930448|NCT06773156|DRUG|Adebrelimab + Apatinib|"Adebrelimab: Administered by intravenous infusion at a fixed dose of 1200 mg. The infusion should be completed within 30-60 minutes, with a maximum duration of 2 hours. The first dose is given on Day 1, with subsequent doses repeated every 3 weeks. Dose adjustments (either up or down) are not allowed during the study. A maximum delay of 9 weeks for treatment is allowed, or treatment may be terminated.~Apatinib: 250 mg, taken orally after meals, once daily, continuously. The investigator may temporarily pause the dose or adjust the administration schedule based on symptomatic treatment, such as changing to an every-other-day (qod) schedule or a 5-day-on, 2-day-off regimen. Once toxicity resolves, treatment may resume at the original dose.~The combined treatment of Adebrelimab + Apatinib for consolidation therapy should not exceed 24 months in total."
223930449|NCT06818786|OTHER|Branded pack with new PHWs covering 50% of the pack without quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 50% of the pack, without quitline information.
223930450|NCT06818786|OTHER|Branded pack with new PHWs covering 85% of the pack without quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, without quitline information.
223930451|NCT06818786|OTHER|Branded pack with new PHWs covering 85% of the pack with quitline information|Participants received and were required to view six images depicting a branded cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, with quitline information
223930452|NCT06818786|OTHER|Plain pack with new PHWs covering 85% of the pack with quitline information|Participants received and were required to view six images depicting a plain cigarette pack with a new set of six pictorial health warnings covering 85% of the pack, with quitline information
223930453|NCT06818786|OTHER|Branded pack with the current set of PHWs covering 50% of the pack without quitline information|Participants received and were required to view 6 images depicting a branded cigarette pack with a current set of 6 pictorial health warnings covering 50% of cigarette packs without quitline information (It is the current pictorial health warnings implemented in Vietnam)
223930454|NCT06772974|DRUG|Doxylamine Succinate USP|Tab. Doxylamine Succinate
223930455|NCT06772974|DIETARY_SUPPLEMENT|Ginger|Ginger (zingiber officinale)
223930456|NCT05720507|BEHAVIORAL|Cafe Move|Participants will be offered the opportunity to choose from a number of physical function assessments and subsequently provided personalized reports of performance results.
223930457|NCT03834740|DRUG|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
224095477|NCT04355988|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
224283885|NCT02769741|OTHER|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
224283886|NCT01965626|DRUG|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
224283887|NCT01965626|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
224283888|NCT01662362|DEVICE|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
224283889|NCT04306172|OTHER|An US Readmission Risk Prediction Model|Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
223533027|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
223533028|NCT01332916|PROCEDURE|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
223930458|NCT03834740|DRUG|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
223930459|NCT06781060|DEVICE|Faradic Nerve Stimulation Therapy+Standard Physiotherapy|This is electrical nerve stimulation with faradic type current to the injured nerve for conservative treatment of post injection sciatic nerve injury.
223930460|NCT06781060|DEVICE|Physiotherapy Standard Treatment with TENS machine therapy|The control group in which Standard Physiotherapy + TENS therapy will be provided to the participants.
223930461|NCT06810661|BEHAVIORAL|Mobility promotion|At the Georges-L. Dumont hospital, a patient mobilization program has been introduced on floor 4C that embeds Kinesiologists within care to visit patients daily. A team of Kinesiologists visit the patients daily to promote movement and help them mobilize to the best of their capabilities (e.g., walking, standing, or sitting on the edge of the bed). The investigators propose to continue this individualized model but incorporate activity and frailty measures in males and females with cardiovascular disease.
223930462|NCT03275285|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223930463|NCT03275285|DRUG|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223930464|NCT03275285|DRUG|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
224095478|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.|At-home remotely supervised tDCS delivered over the dorsolateral prefrontal cortex with the anode on the left, cathode on the right, at an intensity of 2 mA, delivered for 30 minutes five times per week (Monday-Friday) for 26 weeks (6 months).
224095479|NCT04404153|DEVICE|tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.|Sham treatment will consist of the current ramped up to 2mA over 30 seconds, ramped down over 30 seconds and stay at 0 current for the remaining time of the 30-minute application period five times per week (Monday-Friday) for 26 weeks (6 months).
224095480|NCT04052828|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
224095481|NCT04567251|OTHER|Noona® application|A digital symptom tracking application focused on Health-Related Quality of Life (HRQOL) and cognition in cancer survivors who received brain irradiation
224095482|NCT04987281|PROCEDURE|Computed Tomography|Undergo CT
224095483|NCT04987281|DRUG|Indocyanine Green Solution|Given via injection
224095484|NCT04987281|DEVICE|Therapeutic Bronchoscopy|Undergo bronchoscopy using Ion robotic bronchoscope
224095485|NCT06394063|BIOLOGICAL|Telitacicept|Telitacicept 160 mg SC every other week
224095486|NCT06394063|DRUG|Placebo|Placebo to Telitacicept
223930465|NCT03621670|BIOLOGICAL|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
224095487|NCT05324072|OTHER|no intervention|observational study
224095488|NCT06118879|DEVICE|Transcutaneous electrical stimulation|sensory level stimulation, one-leg standing and Y-balance training
224095489|NCT05034679|BIOLOGICAL|Vcinated|Patients who were vacinated.
224095490|NCT04677842|DRUG|ART Therapy|
224283890|NCT04306172|OTHER|LACE+ score|The LACE+ score is a point score that can be used to predict the risk of post-discharge death or urgent readmission. It was developed based on administrative data in Ontario, Canada.
224283891|NCT04306172|OTHER|SQLAPE model|The readmission risk model (Striving for Quality Level and analyzing of patient expenditures), is a computerized validated algorithm and was developed in 2002 to identify potentially avoidable readmissions.
224283892|NCT00170144|DRUG|Branchamin 4%|
224095491|NCT02864875|DRUG|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
224095492|NCT00229840|PROCEDURE|Functional MRI, Diffusion Tensor Imaging|
224095493|NCT02553603|DRUG|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
224095494|NCT02553603|DRUG|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
224095495|NCT02203370|DEVICE|NIRS - Near-infrared spectroscopy|
224095496|NCT06152120|OTHER|Nurse-facilitated advance care planning intervention|"The intervention consists of two components:~Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations.~Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences."
224095497|NCT04146688|OTHER|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
224095498|NCT04831450|DRUG|Cemiplimab-Rwlc|350 mg Cemiplimab administered via intravenous infusion over 30 minutes on Day 1 of a 21-day cycle.
224095499|NCT03088501|BEHAVIORAL|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
224283893|NCT01451996|DRUG|Claritin|Subject will be given 10mg Claritin tablet.
224283894|NCT00932724|DRUG|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
224283895|NCT00932724|DRUG|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
223930466|NCT03621670|BIOLOGICAL|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
223533029|NCT02188966|DEVICE|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
223718217|NCT07015658|PROCEDURE|Baduanjin|The Baduanjin protocol, based on China's 2003 General Administration of Sport standard, was modified by professional physiotherapists for targeted adaptations, with nurses receiving specialized training. Patients viewed step-by-step instructional clips upon admission alongside a full-length routine video. Standard postoperative rehabilitation was maintained during Weeks 1-2. At Week 3, patients demonstrating adequate wound healing and unimpaired static lumbar muscle contraction performed Baduanjin exercises wearing a lumbar brace, supervised by trained nurses for movement correction. The brace was discontinued after 8 weeks. Modified professional videos with background music were distributed via WeChat/official accounts twice daily (30min/session, 5 days/week) for 13 weeks (total ≥2000min). Duration/frequency adjustments were permitted based on individual recovery and physician recommendations post-intervention.
223718218|NCT07015658|PROCEDURE|Moxibustion|Moxibustion was performed at acupoints including Yaoyangguan (GV3), Shenshu (BL23), Dachangshu (BL25, affected side), Chengfu (BL36), Mingmen (GV4), Weizhong (BL40, affected side), Taixi (KI3), Fuliu (KI7), Zhishi (BL52), Zusanli (ST36), and Ashi points. Using five-year-aged Qizhou mugwort, the patient's treatment areas were fully exposed in a comfortable position. The moxa stick was held 3-4 cm from the skin with intensity adjusted to patient tolerance to prevent burns. The circular moxibustion technique was applied for 3-5 minutes per acupoint until the skin exhibited erythema, perspiration, or mottling, or until the patient experienced warmth, distension, itchiness, or perceived moxa-heat propagation. Treatment commenced at postoperative Week 3 following evaluation of satisfactory wound healing, administered three times weekly for four consecutive weeks.
223930467|NCT03621670|BIOLOGICAL|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
223930468|NCT03621670|BIOLOGICAL|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
223930469|NCT03621670|BIOLOGICAL|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
223930470|NCT03621670|BIOLOGICAL|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
223930471|NCT03621670|BIOLOGICAL|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group.
223930472|NCT03621670|BIOLOGICAL|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group.
223930473|NCT03621670|BIOLOGICAL|Prevnar 20|Prevnar 20 (PCV13) is to be administered intramuscularly as a booster dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group who have received 3 PCV13 doses before 12 months of age but have not received their fourth booster dose.
223930474|NCT06191679|BEHAVIORAL|Decision Aid for Education and Support about Cancer Treatment (DECIDES Intervention)|"DECIDES is a developmentally appropriate, engaging, and interactive web-based decision support intervention for AYA diagnosed with cancer (and their caregivers) that includes components written for low health literacy. Components include:~* Education on cancer and cancer treatments, including clinical trials~* An exercise to identify perceived barriers and benefits to treatment options~* An exercise to clarify personal goals for treatment that align with life goals~* Resources to support communication with the oncology health care team"
223930475|NCT04699747|DRUG|F-18 3F4AP|Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
223930476|NCT04996134|DRUG|Domperidone Oral Product|10-30 mg of oral domperidone administered QID.
223930477|NCT03656718|BIOLOGICAL|nivolumab|(Subcutaneous) Specified dose on specified days
223930478|NCT03656718|DRUG|rHuPH20|Specified dose on specified days Permeation enhancer
223930479|NCT03656718|BIOLOGICAL|nivolumab|(IV) Specified Dose on Specified Days
223930480|NCT06826352|BEHAVIORAL|Active Distraction|The video games will be played by children during the procedure.
223930481|NCT06826352|BEHAVIORAL|Passive Distraction|The cartoons will be selected by the children related to their interests. The cartoons are included Pepee, Niloya, Tom and Jerry, Masha and The Bear and others.
224095500|NCT03088501|BEHAVIORAL|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
224095501|NCT06236217|OTHER|Carotid Ultrasound|The carotid artery corrected flow time (FTc) was used in patients to optimize the volume status before performing spinal anesthesia.
223533030|NCT04562415|DEVICE|Active Repetitive Transcranial Magnetic Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and inhibitor rTMS was applied with a frequency of 1 Hz consisting of 1200 pulses for 20 minutes. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
223930482|NCT06854120|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
223930483|NCT06819683|DEVICE|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA. The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
223930484|NCT06827574|OTHER|Sciatic nerve flossing technique|Group A 16 subjects were treated with Sciatic Nerve Flossing Technique. Subjects were in sitting position. Nerve Flossing Technique was performed actively with the participant sitting on a chair. The participant was flex the knee of the target lower extremity backwards beside the chair, as far back as possible and flex the neck at the same time, holding both the flexed knee and neck in this position for 10 seconds. The participant in turn will extend the neck and the knee of the target lower extremity, abduct and then flex the hip until pain is felt and do not push beyond that point. This extended position was maintained for 10 seconds. The above procedure of Nerve Flossing Technique was repeated for 15 times, 3 sets with an interval of 5 minutes between each set. As the nerve becomes less sensitive, the participant can increase the stretching effect by dorsiflexion the ankle and extending the toes of the foot upward towards the shin.
223930485|NCT06827574|OTHER|Active Release Technique|Group B 16 subjects were treated with Active Release Technique. Subjects were in prone position. ART was performed actively by the participant lying on a bed. The participant was dorsiflex the foot of the target lower extremity, holding the dorsiflexion foot in this position for 10 seconds. The participant in turn was plantar-flexed the foot of the target lower extremity. This dorsiflexion position was maintained for 10 seconds. The above procedure of Active Release Technique was repeated for 15 times, 3 sets with an interval of 5 minutes between each set. As the muscles becomes more flexible, the participant can increase the flexibility effect by plantar flexing the foot.
223930486|NCT06863519|PROCEDURE|Endoscopic treatment|After the patient is enrolled, HVPG testing is performed, and appropriate endoscopic treatment is selected as a secondary prevention method. HVPG testing is performed again after regular endoscopic treatment.
223930487|NCT06877013|OTHER|Placebo challenge|2 sachets per day over 7-day challenge
223930488|NCT06877013|OTHER|Fiber's mix (among 4 doses) - intervention phase 1|2 sachets per day over 7-day challenge
223930489|NCT06877013|OTHER|Best fiber's mix - intervention phase 2|2 sachets per day over 7-day challenge
223930490|NCT06866704|PROCEDURE|catheter ablation|In the experimental group, patients receive pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI), circumferential BOX ablation around bilateral pulmonary veins, and mitral isthmus ablation. In the control group, anhydrous alcohol is first injected into the Marshall vein, followed by radiofrequency catheter ablation to complete PVI, BOX lesion sets, and mitral isthmus ablation.
223930491|NCT06713447|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.
223930492|NCT06740981|OTHER|Food diary|A food and beverage diary will be collected for five days starting from the initiation of noninvasive ventilation, with caloric and protein intake quantified by a Nutrition Physician Specialist.
223930493|NCT06748612|BIOLOGICAL|Pentavalent vaccine|Whole-cell pertussis pentavalent vaccine (wP-Penta): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate
223930494|NCT06748612|BIOLOGICAL|Hexavalent vaccine|Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated polioviruses to all three poliovirus types: type 1 , 2 and 3
223930495|NCT06748612|BIOLOGICAL|Inactivated poliovirus vaccine (IPV)|one dose of IPV (0.5 mL) contains inactivated polioviruses to all three poliovirus types: type 1, 2 and 3
223930496|NCT06748612|BIOLOGICAL|Bivalent oral polio vaccine (bOPV)|Contain two poliovirus types: type 1 and 3
223930497|NCT06748612|BIOLOGICAL|Fractional IPV( fIPV)|The dose of fIPV is 0.1 mL or 1/5th of a full dose
223930498|NCT06765876|BIOLOGICAL|Autologous CAR123 T lymphocytes|Anti-CD123 Chimeric Antigen Receptor (CAR) T-Cells (CART123)
223930499|NCT06767787|PROCEDURE|laparoscopic sleeve gastrectomy|Participants undergoing laparoscopic sleeve gastrectomy (LSG) will be clinically assessed and provided consent to this procedure by one of the bariatric surgeons affiliated with the bariatric surgery program. LSG will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once they can tolerate a liquid diet. Patients will then attend regular follow-ups with their surgeons and the bariatric surgery program, in accordance with a standardized clinical pathway protocol.
223930500|NCT06767787|PROCEDURE|total knee arthroplasty|Patients undergoing unilateral total knee arthroplasty (TKA) will be clinically assessed and provided consent to their procedure by an orthopaedic surgeon trained in joint arthroplasty. TKA will be performed at a local tertiary care hospital as either a day procedure or as an overnight stay if medically indicated. Patients will be discharged once physiotherapy clears them. Patients will attend regular follow-ups with their surgeon in accordance with a standardized clinical pathway protocol.
223930501|NCT06763757|BEHAVIORAL|Art Therapy Program|The Art Therapy Program consists of 12 weekly group sessions, each lasting 90 minutes, designed to improve emotional well-being and quality of life in solitary older adults. Participants engage in structured activities that include creating art (e.g., drawing and painting), observing and interpreting art pieces, and reflective discussions to explore personal emotions and experiences. The sessions are led by trained facilitators under the supervision of licensed occupational therapists. This intervention follows a thematic progression: initial sessions focus on building trust and self-expression, mid-sessions deepen emotional awareness, and final sessions culminate in a creative project reflecting the participant's personal growth. Unlike other interventions, this program is tailored specifically for older adults living alone, addressing their unique challenges of isolation and reduced social interaction.
224095502|NCT06236217|OTHER|Electrical cardiometry|Stroke volume variation (SVV) measured by electrical cardiometry (EC) was used to optimize the volume status before performing spinal anesthesia.
224095503|NCT00473694|DRUG|sugammadex|Administered as an intravenous (IV) infusion
223930502|NCT06777095|OTHER|Routine Treatment + I Taping|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, I taping (a total of 5 times every 3 days) was performed. Two I-shaped kinesio tapings were applied on the paraspinal muscles from the posterior superior iliac spine to the T12 level. 50% tension was applied to the area of the tapes outside the anchor points.
223930503|NCT06777095|OTHER|Routine Treatment + Star Taping|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. In addition to routine treatment, star taping (a total of 5 times every 3 days) was performed. Four I tapes, one vertical, one horizontal and two at a 45° angle to the vertical tape, were applied to the point of maximum pain in the lumbar region. 25% tension was applied to the midpoint of the tapes except for the ends.
223930504|NCT06777095|OTHER|Routine Treatment|Routine physical therapy program (10 sessions of hotpack, Transcutaneous electrical nerve stimulation (TENS), and ultrasound every day for 2 weeks) was applied. No taping was applied.
223930505|NCT06894667|DRUG|Antioxidant gel|An intraoral gel containing Tea Tree oil (Tebodont®, Dr. Wild \& Co. AG, Basel) would be applied to the gingival pockets after scaling and root planing
223930506|NCT06894667|DRUG|Antimicrobial gel|An intraoral gel containing 0.5% Chlorhexidine (PERIOPLUS+ FORTE, Curaprox, Curaden) would be applied to the gingival pockets after scaling and root planing
223930507|NCT05841927|DIETARY_SUPPLEMENT|Docosahexaenoic acid supplement|Docosahexaenoic acid supplement
224095504|NCT00473694|DRUG|neostigmine|Administered as an IV infusion
224095505|NCT00473694|DRUG|vecuronium|Administered as an IV infusion
224095506|NCT00473694|DRUG|rocuronium|Administered as an IV infusion
224095507|NCT00473694|DRUG|glycopyrrolate|Administered as an IV infusion
224095508|NCT03062917|DIAGNOSTIC_TEST|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
224095509|NCT02502929|BEHAVIORAL|Social Services|
224095510|NCT02502929|BEHAVIORAL|Lifestyle|
224095511|NCT02502929|BEHAVIORAL|Lifestyle Plus Medication Therapy Management|
224283896|NCT02197208|PROCEDURE|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
224283897|NCT02197208|PROCEDURE|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is \>/= 17 mm and the endometrium measures \>/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
224283898|NCT02197208|DEVICE|ultrasound|
224283899|NCT01181531|DRUG|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
224283900|NCT01181531|DRUG|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
224283901|NCT06010745|DIETARY_SUPPLEMENT|Biotin and silicon|The active ingredient contains a standardized level of biotin (10 mg) and silicon (10 mg) per serving.
224283902|NCT06010745|DIETARY_SUPPLEMENT|Placebo|Inert ingredients only
224283903|NCT03788356|DEVICE|Inspiratory muscle training|Inspiratory muscle training with a device
224283904|NCT03788356|OTHER|Diaphragmatic breathing|Diaphragmatic breathing exercise
224283905|NCT00987831|OTHER|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
224283906|NCT00987831|OTHER|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
223930508|NCT05841927|DIETARY_SUPPLEMENT|ASD placebo|ASD placebo
224095512|NCT04368754|OTHER|Questionnaire|Patients evaluated with different questionnaire.
224095513|NCT03285529|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
224095514|NCT03285529|DEVICE|VICRYL|Vicryl #1
224095515|NCT06246682|PROCEDURE|Transcanal Endoscopic removal of atticoantral cholesteatoma|removal of the cholesteatoma presented in the atticoantral region by otoendoscope
224095516|NCT06380140|PROCEDURE|Open Tension-free Inguinal Hernia Repair|A blood sample is taken the day after surgery
224095517|NCT04410302|PROCEDURE|Biospecimen Collection|Undergo collection of tumor tissue, blood, saliva, and urine samples
224095518|NCT00559338|DRUG|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
223718219|NCT07015658|PROCEDURE|Conventional intervention|Postoperative Rehabilitation Exercises: Week 1: Ankle Pump Exercises: Start after anesthesia. Slowly rotate/invert, dorsiflex/plantarflex ankles. Hold each position 10-15s. 30 min/set, 6 sets/day, until ambulation. Straight Leg Raising (SLR): Start Day 2, supine. Elevate leg \>30°. Progress from passive to active hold. Hold 5-10s/rep, 10-20 reps/set. 3 sets (morning/noon/night) daily for 15 days. Week 2: Supine hip/knee flexion exercises in bed. Hold each flexion 3-5s. 30-50 reps/set. 2 sets/day. Weeks 3-4: Start back muscle training (e.g., bridge/bird-dog poses). Months 1-3: Gradually increase back exercise frequency/difficulty. Perform flexion, extension, lateral flexion, and rotation wearing a lumbar brace. Intensity/reps based on tolerance.
223930509|NCT05071482|DRUG|Flumatinib|Flumatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Flumatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
223930510|NCT05071482|DRUG|Imatinib|Imatinib 600 mg qd will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Imatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy. Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients in whom MCR was achieved within 3 months after treatment and continued until transplantation can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation and maintenance chemotherapy.
223930511|NCT06758674|OTHER|education|Prepared in clear language and supported with visuals in line with guidelines and studies (Kottner et al. 2019, Orhan 2017, APUPA 2011, EPUAP and NPUAP 2009, EPUAP 2019, Arıkan and vanGiersbergen 2019, Arslantaş et al. 2018) training will be given to prevent pressure ulcers. Training content will be sent to expert opinion for content validity. In the content of the training, the definition of pressure ulcers, how they develop, high-risk areas for wound formation, identification of risks, evaluation of the skin, skin care, lying positions and position changes, supporting bone protrusions with pillows, lying on a support surface, nutritional status and content, fluid intake will be discussed.
224095519|NCT00559338|DRUG|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
224095520|NCT06187506|DRUG|Disitamab vedotin|2.0 mg/kg, administered intravenously every three weeks
224095521|NCT06187506|DRUG|Bacillus Calmette Guerin Vaccine|Induction therapy, i.e., intravesical therapy once a week for 6 weeks. maintenance therapy, i.e., one course of maintenance therapy at three, six and twelve months after surgery, each course once a week for 3 weeks.
224095522|NCT01046318|DRUG|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
224095523|NCT04079777|DRUG|Clinical treatment|Liquid Resuscitation, Anti-infection
224095524|NCT05619926|DRUG|STSP-0601 for Injection|Intravenous Injection
224095525|NCT00345072|DEVICE|Web-based decision aid system|
224095526|NCT05598086|DRUG|Tranexamic acid|local infiltration of TXA or normal saline in the post-operation would
224095527|NCT00652821|DRUG|Tramadol/ APAP|Tablets 37.5mg /325mg
224095528|NCT00652821|DRUG|Ultracet|Tablets, 37.5mg/325mg
224095529|NCT01817257|DRUG|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
224095530|NCT00506389|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name corn starch), magnesium stearate, and lactose monohydrate.
224095531|NCT00506389|DRUG|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
224095532|NCT04634669|DRUG|AXS-05 (dextromethorphan-bupropion)|\- AXS-05 tablet, taken daily (up to 15 months)
224095533|NCT02424370|PROCEDURE|TAVR|Percutaneous aortic valve replacement
224095534|NCT05224258|DEVICE|MiniMed 780G System|780G System used with Insulin Fiasp® (Insulin Aspart Injection)
224095535|NCT05476796|DRUG|Trifluridine/Tipiracil|Trifluridine/Tipiracil will be administered with a 14-day schedule (35 mg/m² BID for 5 days followed by 9 days of recovery) until disease progression or intolerable toxicity.
224095536|NCT05476796|DRUG|Oxaliplatin|Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
224095537|NCT05476796|DRUG|FOLFOX regimen|Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
223930512|NCT06822465|OTHER|P. aeruginosa using in vitro and in vivo assays|This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The investigators also plan to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.
223930513|NCT06822140|DEVICE|transcutaneous auricular vagus nerve stimulation|"Stimulation parameters:~* Stimulating side: ipsilateral to the infarcted brain hemisphere~* Location of pStimulation: Cymba conchae~* Impulse shape: bi-phasic~* Impulse intensity: at least 0.5 mA (max. 2.0 mA).~* Impulse duration: 28 sec on, 32 sec off~* Impulse frequency: 20-30 Hz."
223930514|NCT06822140|DEVICE|sham-stimulation|An electrode is only attached to the ear without applying electrical impulses.
223930515|NCT06591715|OTHER|Home exercise program|The home exercise program routinely given to individuals with knee OA in addition to their medical treatment will consist of exercises routinely used in the BETY innovation.
223930516|NCT06728215|DEVICE|CRET 1|Fisiowarm 7.0 and the new capacitive/resistive electrode, for 15' at a frequency of 300 KHz (Treated Group).
223930517|NCT06728215|DEVICE|CRET 2|Classical methodology using the monopolar electrode Activ CT8 INDIBA® at a frequency of 448 KHz in both resistive and capacitive modes, for 10 min each mode with two different electrodes. (Control group).
223930518|NCT06183645|DEVICE|Actimyo|Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223930519|NCT06658145|DEVICE|Vnotes surgery using fully visualised surgical instruments|Vnotes surgery using fully visualised surgical instruments
223930520|NCT06658145|DEVICE|Vnotes surgery using traditional surgical instruments|Vnotes surgery using traditional surgical instruments
223930521|NCT06761482|PROCEDURE|monitoring by dd-cfDNA|monitoring by dd-cfDNA
223930522|NCT06761482|PROCEDURE|monitoring by T-Vis|monitoring by T-Vis
223930523|NCT06761482|PROCEDURE|monitoring by dd-cfDNA+ T-Vis|monitoring by dd-cfDNA+ T-Vis
223930524|NCT06889506|PROCEDURE|skin biopsy and serum sample|skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control
223930525|NCT06837649|BEHAVIORAL|The mindfulness-based Tai Chi Chuan|Studies have shown that compared with the Tai Chi Chuan, MTCC is more relaxing to practitioner. The Tai Chi Chuan section is based on the Yang's movements, which not only conform to the basic technical characteristics, such as the steps, stance, techniques, movement of the center of gravity, and the coordination of the whole body between the movements, but also are clear, smooth, simple, easy to learn, and beautiful. The mindfulness section is complemented by soothing, soft music to guide the practitioner to focus on himself and return to inner peace. The essence of the program is to help practitioners focus their attention and achieve inner peace during practice. Through the practice of MTCC, practitioners are encouraged to face the difficulties they encounter in reality and to develop a positive and open mind to deal with negative emotions and thoughts in daily life.
223718220|NCT07014761|OTHER|No Intervention: Observational Cohort|No Intervention
223718221|NCT07015411|DIETARY_SUPPLEMENT|Neuro-Complex and Multi|"Participants will orally consume 2 caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).~Participants will take 1 cap of each product simultaneously twice a day directly in their mouth."
223930526|NCT06766370|PROCEDURE|Ultrasound-guided nerve hydrodissection treatment|Under ultrasound guidance, a mixed solution of corticosteroids and local anesthetics is injected around the nerve, followed by release of the transverse carpal ligament.
224095538|NCT05476796|DRUG|Nivolumab|Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
224095539|NCT06387615|OTHER|Active cTBS|Active stimulation
224095540|NCT06387615|OTHER|Sham|Control stimulation
223930527|NCT02500576|BIOLOGICAL|Aldesleukin|Given IV or SC
224095541|NCT01381094|DRUG|AKB-6548|oral dose administered once daily for 42 days
223930528|NCT02500576|DRUG|Cyclophosphamide|Given IV
223930529|NCT02500576|DRUG|Fludarabine Phosphate|Given IVPB
223930530|NCT02500576|OTHER|Laboratory Biomarker Analysis|Correlative studies
223930531|NCT02500576|BIOLOGICAL|Pembrolizumab|Given IV
223930532|NCT02500576|OTHER|Quality-of-Life Assessment|Ancillary studies
223930533|NCT02500576|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
224095542|NCT01381094|DRUG|Placebo|oral Placebo administered once daily for 42 days
224095543|NCT01501487|DRUG|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
224095544|NCT01501487|DRUG|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
224095545|NCT01501487|DRUG|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
224095546|NCT01501487|DRUG|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
223930534|NCT06792305|PROCEDURE|Starting by anterior ring fixation in vertical shear pelvic ring injuries|The procedure will involve addressing the pelvic ring anteriorly with open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate. The goal isto achieve anatomical reduction and stable fixation to restore the integrity of the pelvic ring. Fixation of the posterior ring will be achieved using a single sacroiliac screw in S1. The goal of posterior fixation is to achieve stability and alignment of the posterior pelvic structures.
223930535|NCT06792305|PROCEDURE|Starting by posterior ring fixation in vertical shear pelvic ring injuries|the procedure will involve fixation of the posterior ring which will be achieved by using a single sacroiliac screw in S1. Then open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate.
223533031|NCT04562415|DEVICE|Active Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
223533032|NCT04562415|DEVICE|Sham Continuous Theta Burst Stimulation Therapy|10 sessions of intact hemispheric upper extremity motor area (M1) were targeted and sham cTBS was administered for a total of 600 pulses consisting of 3 burst stimulations of 50 Hz repeated every 200 milliseconds for 40 seconds. In addition, within 30 minutes after TMS sessions, all patients underwent 10 sessions of joint range of motion, stretching, strengthening, balance and coordination exercises, hand rehabilitation and daily living activities.
223533033|NCT04435158|DRUG|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous injection
223533034|NCT04435158|DRUG|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous injection
223533035|NCT01501357|BEHAVIORAL|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
223533036|NCT01501357|BEHAVIORAL|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
223930536|NCT06805695|OTHER|No Intervention|No Intervention
223930537|NCT06828536|OTHER|Gynecology consultation|Gynecology consultation M0 - M3 - M6 - M12
223930538|NCT06828536|OTHER|Transvaginal ultrasound|Transvaginal ultrasound
223930539|NCT06828536|OTHER|PCR Schistosoma spp|PCR Schistosoma spp Colposcopy Cervical biopsy Cervical smear
223930540|NCT06833346|OTHER|Hip belt squat exercise|Hip belt squat exercise performed twice per week for 12 weeks
223930541|NCT06828497|PROCEDURE|Technique of posterior quadratus lumborum block (QL 2 block):|The patient was in the lateral position, and the US probe was placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe was placed in the midaxillary line, and at this juncture, the layers of abdominal layers started to taper. When the probe was placed in the posterior axillary line as per the posterior approach, sonoanatomy showed first the transversus abdominis disappearing, then the internal oblique and external oblique forming aponeurosis, and the appearance of the QL muscle was noticed. The posterior aspect of the QL muscle was confirmed, and a 22-G block needle was guided, in plane, and the needle tip was inserted into this aspect of the QL muscle. Following aspiration, the local anesthetic was injected into the lift behind the QL muscle. The same procedure was performed bilaterally
223930542|NCT06828497|PROCEDURE|Technique of erector spinae plane block:|The patient will be placed in a sitting position. Under aseptic conditions, a high-frequency linear transducer will be placed on the spinous process at the T8 level on the parasagittal plane and then slide 2.5-3 cm laterally to visualize the transverse process and erector spinae muscle. Using the in-plane technique, the needle was advanced between the transverse process and erector spinae muscle. The correct location was confirmed, and local anesthetic was injected between the muscle and transverse process. The same procedure was performed bilaterally
223533037|NCT02073474|DRUG|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
223533038|NCT00799565|GENETIC|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
223533039|NCT00765414|BIOLOGICAL|Myozyme|30 mg/kg qow f and 40 mg/kg qow
223533040|NCT03178409|PROCEDURE|Hepatectomy|Removal of a part of the liver
224095547|NCT01501487|DRUG|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
223533041|NCT02920320|OTHER|Internet-based self-help program|
223533042|NCT02212860|RADIATION|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (randomized to single dose of 21 Gy or three 10 Gy doses) followed by lumpectomy for early stage breast carcinoma
223533043|NCT02735200|DRUG|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
223533044|NCT02735200|OTHER|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
224283907|NCT00987831|DRUG|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
224283908|NCT04593147|OTHER|BBN|BBN to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
224283909|NCT04593147|OTHER|Brand|Brand to be fed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks
224283910|NCT02246686|DRUG|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
224283911|NCT02246686|DRUG|Placebo|Application over 12 weeks 20 drops three time daily
223718222|NCT07015775|PROCEDURE|Neurostimulation|Procedure guided by neurostimulation
223930543|NCT03305549|OTHER|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~* Blood urea nitrogen \>112 mg/dL (40 mmol/L)~* Serum potassium concentration \>6 mmol/L~* Serum potassium concentration \>5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~* Arterial blood gas pH \<7.15 in a context of pure metabolic acidosis (PaCO2 \<35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate \<12 mmol/L~* Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate \>5 L/min to maintain SpO2 \>95% or requiring FiO2 \>50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
223930544|NCT03305549|OTHER|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
223930545|NCT06654141|PROCEDURE|Alveolar ridge preservation|Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement at 2 different time intervals (3 and 6 months)
223930546|NCT05001087|OTHER|Observation|Not applicable-Observational study
223930547|NCT06838585|PROCEDURE|infusion therapy|Monitoring patients with fluid overload and fluid accumulation
223930548|NCT06760520|DRUG|Ivonescimab (SMT112 or AK112) Injection|Eligible subjects will receive short-course radiotherapy (SCRT), 25Gy/5f/1 week. 1-2 weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 850-1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
223930549|NCT06886347|DRUG|Penplimab Injection|"Penplimab Injection: Intravenous infusion of Penplimab 200 mg Q3W, with a 3-week treatment cycle.~Anlotinib Hydrochloride Capsules: 10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.~Gemcitabine injection: Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles."
223930550|NCT06886347|DRUG|Antitinib Hydrochloride Capsules|10 mg, taken orally on an empty stomach before breakfast once a day (the daily medication time should be the same as much as possible), delivered in warm water, continuously used for 2 weeks and stopped for 1 week, with a treatment cycle of 3 weeks.
223930551|NCT06886347|DRUG|Gemcitabine|Intravenous infusion of 1000mg/m2, administered on the 1st and 8th days of each cycle, 3 weeks per cycle for 4-6 cycles.
223930552|NCT03400150|DEVICE|balloon|balloon implantation
223930553|NCT03400150|OTHER|Control|Control - Marking \& IMRT are standard of care for prostate cancer - there is no study-specific intervention
223930554|NCT05556746|DRUG|Bedaquiline|Daily therapy for 12 weeks
223930555|NCT05556746|DRUG|Clofazimine|Daily therapy for 12 weeks
223930556|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 12 weeks
223930557|NCT05556746|DRUG|Delamanid|Daily therapy for 12 weeks
223930558|NCT05556746|DRUG|Rifampin|Daily therapy for 26 weeks
223930559|NCT05556746|DRUG|Isoniazid|Daily therapy for 26 weeks
223930560|NCT05556746|DRUG|Ethambutol|Daily therapy for 8 weeks
223930561|NCT05556746|DRUG|Pyrazinamide|Daily therapy for 8 weeks
223930562|NCT06812455|DRUG|Rivaroxaban|Patients with RAO that will receive p.o. tabs Rivaroxaban 20 mg q.d.
224283912|NCT04243096|BEHAVIORAL|Exercise-based Physical Therapy|Exercises for pain modulation, strengthening, and neuromuscular control
223930563|NCT05410860|DRUG|Etripamil NS 70 mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223930564|NCT05410860|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223718223|NCT07015775|PROCEDURE|Ultrasound|Procedure guided by ultrasound
223930565|NCT06767176|DIETARY_SUPPLEMENT|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|7 doses, taken daily, 70 ml shots, consumed in the morning before the start of fasting
223930566|NCT06811012|DRUG|Contezolid|"This study intends to enroll 24 patients with bone and joint tuberculosis, who will be randomly divided into two groups: the contezolid monotherapy group and the linezolid monotherapy group. Patients will receive oral contezolid or linezolid monotherapy for 14 consecutive days, and data on treatment safety, pharmacokinetics, and preliminary efficacy will be collected before and after administration.~Study Medications:~Contezolid 800mg QD for 14 days; Linezolid 600mg QD for 14 days."
223930567|NCT06811012|DRUG|Linezolid (LZD)|Linezolid 600mg QD for 14 days.
223930568|NCT06840730|DRUG|Botulinum Toxin A (Botox )|TX-A will be injected into the masseter and temporalis muscles (30 and 15 units per side, respectively) following a standardized protocol.
224283913|NCT05982249|DEVICE|Hypnosis|Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten BM examinations at the hematology institute. The length of the recording is about 7 minutes.
223533045|NCT01217034|DRUG|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
223930569|NCT06747962|PROCEDURE|A1 pulley release and pull out tenolysis|A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley under direct vision. Flexor digitorum superficialis and flexor digitorum profundus tendons or flexor pollicis longus tendon (for the thumb) will be gently pulled out of the wound with two mosquito forceps to break any adhesions. The wound will be closed primarily with sutures. The patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
223930570|NCT06747962|PROCEDURE|Simple A1 pulley release|A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley vision. After release, the patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
224095548|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
224095549|NCT01501487|DRUG|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
224283914|NCT05982249|DEVICE|Virtual reality (VR)|Patients will be connected to a VR device that will transmit to the patient's choice a 3D screen and soothing noise for about 7 minutes.
223533046|NCT01217034|PROCEDURE|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
223533047|NCT04065321|PROCEDURE|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
223930571|NCT06623357|OTHER|Pilot Training Protocol|The pilot training protocol uses principles based on evidence-based research on factors that support caregiver learning of and adherence to home-therapy techniques/recommendations.
223930572|NCT06623357|OTHER|Standard Training Protocol|The standard training protocol uses the caregiver training methods that are currently used in our clinics.
224283915|NCT04552912|BEHAVIORAL|Build Stamina Program|Build StaMINA intervention is a self-management intervention that provides information, motivation, behavioral skills to engage in PA, and ultimately a tailored PA program for adults with AL who are receiving consolidation/maintenance chemotherapy.
224283916|NCT05338476|DRUG|Midazolam|Administered orally.
223930573|NCT06790199|BEHAVIORAL|"Incredible Years® Helping Preschool Children with Autism program (IY-HPCA)"|The IY-HPCA® program is a face-to-face 6-session group-based intervention for preschool teachers of children aged 2-5 with ASD or language and communication difficulties. Sessions last 3 hours, are delivered weekly, and are led by two trained co-leaders who have experience working with children on the autism spectrum. The program covers three main topics: (1) language development, (2) social interactions, and (3) emotion literacy and self-regulation. Teachers learn about coaching language, imitation, sensory routines, social communication, use of pretend and puppet play, and self-regulation skills. Visual supports such as picture schedules, choice cards, command and feelings cards are used, and practices are tailored to children's communication and play level stages. The intervention is structured and includes role-playing techniques and video visualization.
224283917|NCT05338476|DRUG|Selpercatinib|Administered orally.
224283918|NCT02792218|DRUG|Ofatumumab subcutaneous injection|Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter
224283919|NCT02792218|DRUG|Teriflunomide-matching placebo capsules|Placebo capsule, matching in appearance to teriflunomide, taken orally once daily
224283920|NCT02792218|DRUG|Teriflunomide capsule|Teriflunomide 14 mg oral capsule taken once daily
224283921|NCT02792218|DRUG|Matching placebo of ofatumumab subcutaneous injections|Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter
224283922|NCT00810602|PROCEDURE|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
224283923|NCT00810602|DRUG|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
224283924|NCT00810602|DRUG|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
223533048|NCT04065321|PROCEDURE|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
223533049|NCT05239078|DRUG|local anaesthetic injection|Inferior alveolar nerve block
223533050|NCT06351514|DEVICE|Accelerated iTBS|Patients will be assigned to receive iTBS over the left dorsolateral prefrontal cortex or Frontal Medea with 5 sessions a day, every weekday for 1 week and total of 25 sessions. Each iTBS session is approximately 10 minutes (depth corrected Resting Motor Threshold of 100%, 60 cycles of 10 bursts of three pulses at 50 Hz, repeated at 5 Hz; 2s on and 8s off; 1800 pulses per session; with a 50-minute interval between sessions. All TBS sessions will be performed by staff trained and credentialed in TMS according to Singapore College of Psychiatrists guidelines.
224095550|NCT01501487|DRUG|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
224095551|NCT00221676|BIOLOGICAL|Alfarix|
224095552|NCT02986672|DIETARY_SUPPLEMENT|Calanus oil|Omega-3 oil in form of calanus oil
224095553|NCT02986672|OTHER|Medical Paraffin|2ml per day
224095554|NCT04092257|PROCEDURE|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
224095555|NCT05354960|OTHER|Questionnaire validation|Validation and cultural adaption of the German version of the LIMB-Q
224283925|NCT00810602|DRUG|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher \[probably or definitely related to the drug\] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
224283926|NCT03167502|OTHER|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
224283927|NCT03167502|OTHER|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
224283928|NCT01745952|DEVICE|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
224283929|NCT01745952|DEVICE|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
224283930|NCT01745952|DEVICE|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
223533051|NCT01621100|DRUG|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
223930574|NCT05981664|DEVICE|One Handed Video Game Controller Adapter|The one handed video game controller adapter was designed and 3D printed at Rehabilitation Centre for Children. It is a simple model that snaps onto an XBox One controller and uses a series of levers to allow access to almost all buttons of the controller from one side. There is both left and right sided versions
223930575|NCT02828202|OTHER|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
224283931|NCT00824369|DRUG|No drug will be administered|No drug will be administered.
223930576|NCT02828202|OTHER|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
223930577|NCT02828202|OTHER|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
223930578|NCT04882917|DRUG|M4076|M4076 was administered orally.
223533052|NCT00374647|DRUG|mycophenolate mofetil|
223533053|NCT00374647|DRUG|sirolimus|
223533054|NCT00004157|BIOLOGICAL|filgrastim|
223930579|NCT06811506|PROCEDURE|Anatomical size patella component|After the patella was resurfaced, surgeon evaluated the symmetry through haptic feedback and assessed the thickness by measuring the distance from the anterior to posterior center of the patella. An inset, single pegged patella component was cemented after milling the patella. The patella was medialized as the patella bone would allow. Synovium laying on top of the femoral component with the knee in extension was routinely excised. Lateral facetectomy and restoration of native patella thickness were performed in all knees. In the control group, anatomically sized patella components were used.
223533055|NCT00004157|BIOLOGICAL|recombinant interleukin-11|
223533056|NCT00151177|DEVICE|non-invasive continuous positive airway pressure ventilation|
223930580|NCT06811506|PROCEDURE|Reduced size patella component|The same procedure of patella resurfacing as control group was done, then 3 mm reduced size patella component was used in the intervention group.
223930581|NCT05417321|DRUG|HB0036|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
223930582|NCT05807321|DEVICE|Fecobionics|Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
223941182|NCT03912909|DRUG|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
223941183|NCT04038190|BEHAVIORAL|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
223941184|NCT05488405|DRUG|Mesalamine Oral Product|Mesalamine oral suspension for oral use
223941185|NCT01894399|DRUG|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
223533057|NCT00151177|DEVICE|CPAP-treatment|night time CPAP-mask ventilation
223533058|NCT04552002|DIETARY_SUPPLEMENT|Synbiotic group|Probiotics and prebiotics
223533059|NCT03044444|DIETARY_SUPPLEMENT|citrus extract|Participants will receive either a low or high dose citrus extract
223533060|NCT03044444|OTHER|placebo|participants will receive 500mg of maltodextrin
223533061|NCT01478984|PROCEDURE|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
223941186|NCT01204996|DRUG|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
223941187|NCT01204996|DRUG|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
223941188|NCT01204996|DRUG|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
223941189|NCT01204996|DRUG|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
223941190|NCT06961305|DEVICE|Cross-linked Hyaluronic Acid Gel|This intervention involves the injection of Alexa Medium, a sterile, cross-linked hyaluronic acid gel (17.5 mg/mL). The gel is administered into the mucous membrane of the lips for aesthetic restoration of lip volume loss. The product is supplied in a pre-filled 1 mL syringe and injected by a trained medical professional. One or two injections were administered per participant, with the second injection performed at the investigator's discretion at Visit 2. The device is manufactured by Diaco Biofarmaceutici S.r.l., Italy.
223941191|NCT03311880|BEHAVIORAL|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
223941192|NCT00849238|DRUG|mycophenolate mofetil|
223941193|NCT03819543|DEVICE|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
223941194|NCT02220452|OTHER|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
223941195|NCT02220452|OTHER|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
223941196|NCT01517503|BEHAVIORAL|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
223941197|NCT01517503|BEHAVIORAL|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
223941198|NCT05283018|DEVICE|Electroencephalogram recording|Brain function monitoring using a Sedline® module (Masimo corporation) to evaluate the state of the brain under anesthesia
223941199|NCT05283018|OTHER|Auditory stimulation|Monotonous sounds are sent via binaural headphones: a standard item and a distractor item (rough sound). Each stimulus lasts about 300 ms and they are separated by 1.5 to 2 seconds between them; the deviant sound/standard sound ratio is fixed between 1/5 and 1/6.
223941200|NCT05283018|DEVICE|Transcranial Doppler|Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography. For all patients, CFV (unit cm/s) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at inspired oxygen fraction (FiO2) of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period.
223930583|NCT06894121|OTHER|Greater Occipital Nerve Pulsed Radiofrequency (Unilateral)|Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) treatment is performed under sterile conditions in the operating room. The patient is positioned in the prone position with neck flexion. Under ultrasound guidance at the proximal (C2) level, the needle is carefully placed near the GON, targeting the space between the Obliquus Capitis Inferior (OCI) muscle and C2's bifid spinous process. After proper sterilization, a linear ultrasound probe is used transversely over the occipital protuberance to locate the C1 and C2 vertebrae. Once identified, the RF needle and electrode are inserted laterally to medially using in-plane technique. A sensory stimulation test is done, and the PRF therapy is applied at a 45V setting, 5 Hz, and 5 ms pulse width for 360 seconds, with a maximum temperature of 42°C. No drug injections are administered during the procedure. Post-procedure, the patient is monitored for at least 1 hour before discharge after a general and neurological evaluation.
223930584|NCT06894121|OTHER|Bilateral GON PRF Treatment:|"Greater Occipital Nerve (GON) Pulsed Radiofrequency (PRF) treatment is performed under sterile conditions in the operating room. The patient is positioned in the prone position with neck flexion. Under ultrasound guidance at the proximal (C2) level, the needle is carefully placed near the GON, targeting the space between the Obliquus Capitis Inferior (OCI) muscle and C2's bifid spinous process. After proper sterilization, a linear ultrasound probe is used transversely over the occipital protuberance to locate the C1 and C2 vertebrae. Once identified, the RF needle and electrode are inserted laterally to medially using in-plane technique. A sensory stimulation test is done, and the PRF therapy is applied at a 45V setting, 5 Hz, and 5 ms pulse width for 360 seconds, with a maximum temperature of 42°C. No drug injections are administered during the procedure. Post-procedure, the patient is monitored for at least 1 hour before discharge after a general and neurological evaluation.~Bilater"
223930585|NCT06276621|BEHAVIORAL|Family Bridge Program|The Family Bridge Program consists of 7 components, delivered by a trained lay navigator, the Guide. The program includes: (1) orientation to the hospital, unit, room, and hospital resources (e.g., toiletries, loaner phone chargers); (2)unmet social needs assessment, followed by connection to appropriate resources (e.g., food vouchers, community-based transportation); (3)communication and cultural preference assessment (eg, preferred language, comfort asking questions, and health-related cultural beliefs), which is communicated to the medical team and documented in the electronic health record;(4)communication coaching for parents/caregivers to help them clarify and practice asking questions of the medical team; (5)emotional support via daily check-ins during the hospital stay; (6)assistance with logistics ; and (7)one follow-up phone call, 2 days post-discharge, to address remaining questions and connect families to ongoing services if needed.
223941201|NCT05283018|DEVICE|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over four distinct periods: 1/ baseline or during pre-oxygenation at FiO2 of 21% in awake patients; 2/ during anesthetic induction; 3 /deep sleep; 4/ recovery period."
223941202|NCT03246750|DRUG|B-MAD chemotherapy|B-MAD chemotherapy
223941203|NCT02798900|OTHER|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
223941204|NCT02798900|DEVICE|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
223941205|NCT01824225|DRUG|Aflibercept|
223941206|NCT00431054|DRUG|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
223941207|NCT00431054|DRUG|Docetaxel|75 mg/m\^2 by vein over 1 hour every 4 weeks
223941208|NCT02301806|OTHER|dieting|
223941209|NCT02301806|DRUG|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
223941210|NCT02301806|DRUG|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
223941211|NCT01379651|OTHER|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
223941212|NCT02160119|OTHER|MRI-based techniques|fMRI, DTI
223941213|NCT02160119|OTHER|EEG|ERP
223941214|NCT05985265|PROCEDURE|Fat grafting|Nano fat grafting followed by fractional carbon dioxide laser resurfacing
223941215|NCT00224835|BEHAVIORAL|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
223941216|NCT00224835|BEHAVIORAL|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
223941217|NCT03775252|DIETARY_SUPPLEMENT|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
223941218|NCT05794594|DEVICE|3D printed personalized extendable prosthesis|3D printed personalized extendable prosthesis replacement for limb preservation in children
223941219|NCT01556594|DRUG|Nasal Glucagon 1 mg|
223941220|NCT01556594|DRUG|Nasal Glucagon 2 mg|
223941221|NCT01556594|DRUG|SC Glucagon|
223941222|NCT01556594|DRUG|Nasal Glucagon 3 mg|
223941223|NCT03110809|DIETARY_SUPPLEMENT|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
223941224|NCT03110809|DIETARY_SUPPLEMENT|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
223941225|NCT04169828|DRUG|Methotrexate|Children in both the intervention and control group will receive Methotrexate dosed as prescribed by the attending rheumatologist
223941226|NCT04169828|DRUG|Ondansetron|"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
223930586|NCT06276621|BEHAVIORAL|Care as usual - resources only|Families randomized to the control arm will receive FBP written resources, which the Guide (and interpreter, as needed) will review with them over \~5-15 minutes one time. This includes information on hospital services (e.g., cafeteria coupons), community resources (e.g., food and housing support), the structure and roles of the medical team, and the daily hospital schedule. Parents will be informed that their child's nurse is available to help them.
223930587|NCT06894706|BEHAVIORAL|Control （CON） group|Both groups were given arthroscopy and meniscoplasty. After operation, the control group received active knee flexion and extension exercise, ankle pump training, quadriceps muscle training and other routine rehabilitation training.
224283932|NCT04752488|OTHER|Telerehabilitation (TR)|The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
224283933|NCT04752488|OTHER|Conventional Rehabilitation (CR)|The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
224283934|NCT05520606|PROCEDURE|pancreatoduodenectomy|Pancreatoduodenectomy (Whipple surgery) is a complex surgical procedure and has been accepted as the gold standard treatment for resectable lesions of the pancreatic head and periampullary region
224283935|NCT00392782|BIOLOGICAL|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
224283936|NCT00392782|DRUG|fludarabine phosphate|Fludarabine 40 mg/m\^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m\^2).
224283937|NCT00392782|DRUG|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
224283938|NCT00392782|PROCEDURE|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
223930588|NCT06894706|BEHAVIORAL|Functional exercise training (FET) group|Patients in the observation group were supplemented with neuromuscular training on the basis of routine rehabilitation training, and received rehabilitation education before training. The patients were informed of the specific content, frequency, expected effect and importance of training in various forms such as on-site demonstration combined with publicity brochures and playing videos, so as to improve patient cooperation.
224283939|NCT00392782|RADIATION|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
224283940|NCT00101413|DRUG|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
224283941|NCT06188052|DRUG|Tranexamic acid|Comparing the 3 groups regarding intraoperative bleeding, hemoglobin level pre and postoperative and the need of blood transfusion
224283942|NCT03201354|PROCEDURE|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
224283943|NCT03201354|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
224283944|NCT03201354|PROCEDURE|Cataract extraction|Cataract surgery and IOL implantation
224283945|NCT02736630|OTHER|body temperature|intermittant tympanic temperature measurement during surgery
223941227|NCT04169828|DRUG|Folic/folinic acid|Children in both intervention and control group will receive folic acid or folinic acid dosed as prescribed by the attending rheumatologist.
223941228|NCT06950710|OTHER|NAFLD|This study is an observational one with no intervention
223533062|NCT01478984|PROCEDURE|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
223941229|NCT05031780|DRUG|Mitapivat|Mitapivat tablets
223941230|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 50 mg or 100 mg tablets
223941231|NCT05031780|OTHER|Mitapivat-matching placebo|Placebo to match 100 mg tablets
223941234|NCT06107933|OTHER|Observational only|Exposure to micro and nano plastics
223941235|NCT05791162|OTHER|Blood collection|Collection of 3 blood tubes at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2)
223941236|NCT05791162|OTHER|Urine sample|Collection of 20 cc of urine at inclusion and relapse (arm 1) or at inclusion, initiation of treatment and at 3 and 6 months post-diagnosis (arm 2) or at inclusion only (arm 3)
223941237|NCT06462963|RADIATION|single-fraction SBRT|Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.
223941238|NCT06462963|RADIATION|multiple-fraction SBRT|Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
223930589|NCT06819059|BEHAVIORAL|Pediatric Cardiac Telerehabilitation|The program was entirely virtual except for pre and post program cardiopulmonary exercise testing. Patients were provided a stationary bicycle, hand weights, and resistance training bands. They exercised over zoom with a physical therapist or exercise physiologist weekly and were also asked to exercise independently 2x per week. Electrocardiograms (ECGs) were provided to the patients as a single lead monitor and results were shared with the study team after each session or during sessions if the patient reported symptoms. Compliance and activity data were recorded using Fitbit activity trackers.
223930590|NCT06819059|BEHAVIORAL|Fitness Tracker Only|Control participants were provided fitness trackers and weekly text messaging from the study team to synch their devises but no formal exercise training. They were allowed to enroll in the exercise training after completing 3 months as a control.
223930591|NCT00319020|DRUG|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
224283946|NCT00700245|BEHAVIORAL|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
223930592|NCT06877559|OTHER|balloon-assisted enteroscopic treatment for phytobezoar|The endoscopists applied balloon-assisted enteroscopy for the treatment of the phytobezoar
223930593|NCT05501600|DEVICE|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using an electric nerve stimulator.
223930594|NCT05501600|DRUG|Lidocaine IV|Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
223941239|NCT06554431|BEHAVIORAL|Self-Driven Repetitive Artmaking|Three (3) art kits which all use repetitive artmaking processes (e.g., materials for mandalas, stamp making kit, weaving kit)
223941240|NCT04812314|BEHAVIORAL|Exercise|Participants will complete a moderate intensity continuous exercise 4 days/week.
223941241|NCT04812314|BEHAVIORAL|No exercise|Participants will remain sedentary throughout the duration of the study.
223941242|NCT06478290|COMBINATION_PRODUCT|curcumin, omega-3, and vitamin D (COD)|Combination of curcumin, omega-3, and vitamin D supplements (COD). Theracurmin Double Strength/Natural Factors Canada 180 mg/day (oral, 3 tablets of 60 mg taken by mouth) Vitamin D: 2000 IU/day LipoMicel/Natural Factors Canada (oral, 1 tablet taken by mouth) Omega-3: 900 mg day (oral, 1 tablet taken by mouth)
223941243|NCT04495257|DRUG|Nivolumab|Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
223941244|NCT04495257|DRUG|Ipilimumab|Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
223941245|NCT04495257|DRUG|APX005M|APX005M 0.3mg/kg intravenously (IV) every 3 weeks
223941246|NCT04174339|DRUG|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
223941247|NCT04174339|DRUG|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
223941248|NCT04174339|DRUG|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
223941249|NCT03932513|DRUG|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
223941250|NCT03187678|DRUG|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
223941251|NCT03187678|DRUG|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
223941252|NCT04105816|DEVICE|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
223941253|NCT04105816|DIAGNOSTIC_TEST|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
223941254|NCT05209555|DIAGNOSTIC_TEST|MoCA|MoCA test to identify Mild Cognitive Impairment
223941255|NCT05209555|DEVICE|BAMCOG|Three games, compared to the MoCA to identify Mild Cognitive Impairment
223941256|NCT05209555|DIAGNOSTIC_TEST|DeltaScan|EEG to detect acute encephalopathy
223941257|NCT05209555|DIAGNOSTIC_TEST|Salivette|To collect saliva for cortisol analysis
223941258|NCT05209555|DIAGNOSTIC_TEST|Pilocarpine iontophoresis|To collect sweat for cortisol analysis
223941259|NCT02920034|DEVICE|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
223941260|NCT02920034|DEVICE|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
223941261|NCT02920034|DEVICE|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
223941262|NCT00204685|DRUG|dornase alfa|
223941263|NCT02446340|DRUG|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
223941264|NCT02446340|DRUG|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
223941265|NCT06008236|BEHAVIORAL|Progressive Muscle Relaxation and Breathing Exercises|Progressive relaxation exercise is a method that provides relaxation in the whole body by voluntary, regular relaxation of large muscle groups in the human body. Exercise helps individuals to be able to feel the difference between tension in the muscles and relaxation, and to learn to relax on their own in case of tension. Deep breathing exercise supports the maximum ventilation of the lung by correct breathing using the diaphragm.
223941266|NCT00000852|PROCEDURE|Allogeneic lymphocyte transfer|
223930595|NCT06275217|BEHAVIORAL|Mindfulness-based yoga program|The intervention includes mindfulness-based components and yoga practice. Once a week for 10 weeks, with 1.5 hours in each session (30 minutes mindfulness-based practice and 1 hour yoga practice). A well-trained research personnel will facilitate the mindfulness-based section, and a qualified yoga instructor will facilitate the yoga section.
223533063|NCT02791243|DRUG|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
223930596|NCT06275217|OTHER|Psychoeducation|Knowledge of perinatal mental health, stress-related management, postnatal nutrition, exercise habit and sleep hygiene will be provided to the participants in the psychoeducation group. It is a group-based intervention delivered in hybrid mode including face-to-face and online group-based class. Once a week for 10 weeks, with 1.5 hour in each session.
223930597|NCT05613413|DRUG|Cabozantinib 40 MG|Cabozantinib is taken my mouth
223930598|NCT05613413|DRUG|Pembrolizumab 200mg|Pembrolizumab is given intravenously
223930599|NCT05613413|DRUG|Pembrolizumab 400mg|Pembrolizumab is given intravenously
223930600|NCT06851299|DRUG|trop2-ADC|Accept ADC monotherapy
223930601|NCT06851299|DRUG|ADC +anti-angiogenic drug|Accept ADC combined with anti-angiogenic drug
223930602|NCT06851299|DRUG|ADC + PD1 monoclonal antibody +anti-angiogenic drug|ADC combined with PD1 monoclonal antibody and anti-angiogenic drug
223930603|NCT06865469|DRUG|Dexmedetomidine|dexmedetomidine will be administered by i.v. infusion at 0.4 μg/kg/h
223930604|NCT06865469|DRUG|Lidocaine Hydrochloride 2%|lidocaine hydrochloride 2% (400 mg/20 mL) 1.5 mg/kg/h by i.v. infusion.
223930605|NCT06519123|OTHER|Ambient Digital Scribes|AI technology used to populate clinical notes.
223533064|NCT02791243|DRUG|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
223533065|NCT02791243|DRUG|Negative Control|0.9% aqueous NaCl
223930606|NCT06888479|BIOLOGICAL|hepatitis B vaccine|Three doses of hepatitis B vaccine
223930607|NCT06769191|BIOLOGICAL|CD7 CAR-T cells injection|Intravenous infusion, single dose
223930608|NCT06769191|PROCEDURE|Allo-HSCT|allogeneic hematopoietic stem cell transplantation
223930609|NCT06769191|PROCEDURE|Kidney Transplantation|Kidney Transplantation
223930610|NCT06423157|OTHER|Intervention|The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each. All interventions will take place at the Palacio de los Deportes de Murcia. All interventions will be carried out by the same physiotherapist, following the same protocol. The intervention of the experimental group will consist of a protocol using plyometric and stability exercises.
223930611|NCT06734325|BEHAVIORAL|Mobile Oral Health Intervention|46 messages delivered over a 3-month period (12 weeks) via WhatsApp
223930612|NCT06070857|DRUG|LV232|Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
223533066|NCT02196753|OTHER|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient's weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV\> 40% of the background."
223533067|NCT01507701|DRUG|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
223930613|NCT06070857|DRUG|Placebo|Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
223930614|NCT06893120|OTHER|BETY|The cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) will be applied for 24 one-hour sessions, two days a week.
223930615|NCT06022107|BEHAVIORAL|LDART|LDART is a newly developed web-based social support intervention that can be accessed by smartphone or computer. Each night, the participant sets a recovery goal for the next day (e.g., drink less than usual, go to a support group meeting). The next night, they log on to LDART to indicate whether they reached their goal for the day. Depending on their response, they will be shown either a celebratory or encouraging message from someone in the addiction recovery community, along with specific information on that person's recovery organization.
223930616|NCT06408428|DEVICE|PANAXIUM MicroECoG|The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
223930617|NCT04586478|BIOLOGICAL|single dose of CNCT19|Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
223930618|NCT05147909|DIETARY_SUPPLEMENT|Sodium Phosphate|Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
223930619|NCT05147909|DIETARY_SUPPLEMENT|Sodium Chloride|Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
223930620|NCT03416530|DRUG|Dordaviprone (ONC201)|Dordaviprone is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
223930621|NCT06770595|BEHAVIORAL|breastfeeding positions and attachment practice.|Breastfeeding clinical demonstration is a method of presentation of skills that shows how a particular procedure is performed in position and attachment breastfeeding. Respondents in this group will receive education provided face-to-face once with a duration of 40 minutes, with the following details: first, 25 minutes of education about breastfeeding position and attachment. In this case, the lactation counselor first explains the correct position and attachment for breastfeeding. Respondents were asked to carry out a practical simulation regarding the correct breastfeeding position and attachment using a doll, in this case, the lactation counselor will assess how the mother is positioned and attached. second, 10 minutes of education about swollen breasts and how to deal with them. third, a 10-minute question and answer session related to the educational material provided.
223930622|NCT05953948|OTHER|Intelligent Case Manage Platform (ICMP) and self-management program|This platform includes information and instruction related to the care of liver transplantation. Participants could gain knowledge and skill to manage their conditions after liver transplantation.
223941267|NCT03973034|DIAGNOSTIC_TEST|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
223941268|NCT04587219|BIOLOGICAL|Gam-COVID-Vac|combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
223941269|NCT03640299|PROCEDURE|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
223941270|NCT01809275|DRUG|QBECO|
223941271|NCT01809275|DRUG|Placebo|
223941272|NCT00795184|DEVICE|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
223941273|NCT00795184|DEVICE|HDWLE|
223941274|NCT00795184|DEVICE|pCLE|
223941275|NCT02695264|DEVICE|HS-1000 recording|
224283947|NCT00700245|BEHAVIORAL|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
224283948|NCT00700245|BEHAVIORAL|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
224283949|NCT01449045|DRUG|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
224283950|NCT01449045|DRUG|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
223930623|NCT06759402|BEHAVIORAL|Family based treatment|FBT is an intensive, manualized therapy in which the parents of those affected are closely involved in a resource-oriented manner by FBT-certified therapists. FBT takes place in 3 phases: in phase 1, the parents take responsibility for their child's weight gain. Phase 2 involves the gradual transfer of responsibility for eating back to the patient. Phase 3 focuses on individual issues of the children and adolescents, e.g. catching up on important developmental steps missed due to the illness.
223930624|NCT06759402|BEHAVIORAL|Inpatient multimodal therapy|comprehensive, patient-oriented and multidisciplinary approach to address eating disorders following the S3 joint German treatment guidelines in specialized hospitals. Includes individual psychotherapy, family sessions, body-oriented therapy, nutritional counseling, group therapy sessions, relaxation techniques, mindfulness practices, and skills training. Targeted weight gain per week is at least 500g.
223930625|NCT06777342|BEHAVIORAL|Cognitive behavioral therapy intervention|The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.
223930626|NCT06777342|DIETARY_SUPPLEMENT|Melatonin intervention|Patients in the melatonin intervention group are required to take an oral melatonin of 5 mg at 30-60 minutes before sleep (administered at 21:00) nightly for 7 to 14 days before surgery. The melatonin was provided by Kangenbei Pharmaceutical Co., LTD. (Hangzhou, Zhejiang, China).
223930627|NCT06777342|OTHER|Placebo intervention|Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).
223930628|NCT05589831|DEVICE|Non-invasive Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort
224283951|NCT02608840|OTHER|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
224283952|NCT02608840|OTHER|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
224283953|NCT00332267|PROCEDURE|Endotoxin infusion, Normobaric hypoxia|
224283954|NCT06840093|BEHAVIORAL|Limited Restrictions|Patients will receive a handout with the following instructions: After discharge from the hospital, resume your normal activities as soon as you feel comfortable. There is no weight limit on lifting. There are no specific activities you should avoid (other than pelvic rest as described below). We recommend pelvic rest, nothing in the vagina (no intercourse, hot tubs, tub bathing or swimming) for 2 weeks.
224283955|NCT06840093|BEHAVIORAL|Standard Restrictions|Patient will receive a handout with the following instructions: After discharge from the hospital, avoid doing any strenuous activity (any activity that requires so much exertion that you cannot have a conversation comfortably while doing it). Do not lift anything over 15 pounds for 6 weeks after surgery. For 6 weeks, we recommend complete pelvic rest, nothing in the vagina (no intercourse, hot tubs, tub bathing or swimming).
224283956|NCT06646887|OTHER|Electroporation|Unlike traditional thermal ablation techniques such as radiofrequency (RF) and cryoablation, the electroporation systems used in this study rely on pulsed electric fields (PEF) to selectively target and ablate cardiac tissue. This non-thermal mechanism reduces the risk of collateral damage to nearby structures, such as the esophagus, phrenic nerve, and coronary arteries.
224283957|NCT06874842|BIOLOGICAL|Low dose antigen and low dose adjuvant of LYB004|0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01C.
224283958|NCT06874842|BIOLOGICAL|Low dose antigen and high dose adjuvant of LYB004|0.5 mL per dose, containing a total of 25 μg VZV-gEM adjuvanted with A01B.
224283959|NCT06874842|BIOLOGICAL|High dose antigen and low dose adjuvant of LYB004|0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01C.
224283960|NCT06874842|BIOLOGICAL|High dose antigen and high dose adjuvant of LYB004|0.5 mL per dose, containing a total of 50 μg VZV-gEM adjuvanted with A01B.
224283961|NCT06874842|BIOLOGICAL|Placebo|0.5 mL per dose, without antigen and adjuvant.
224283962|NCT06874842|BIOLOGICAL|Positive control|0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
224283963|NCT06555289|DEVICE|Clareon PanOptix IOL|Spherical and toric T3
224283964|NCT03169621|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
224283965|NCT01523236|DRUG|Mometasone furoate|50 mcg/actuation Nasal Spray
224283966|NCT01523236|DRUG|Nasonex®|50 mcg/actuation Nasal Spray
224283967|NCT01523236|DRUG|Placebo|Nasal Spray
224283968|NCT00519103|OTHER|exercise|
224283969|NCT00711841|DRUG|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
223718224|NCT07014657|BEHAVIORAL|Digital Combined Decongestive Therapy|Participants received digital combined decongestive therapy, which included an initial face-to-face session where skin care and risk reduction training were provided. Self-bandaging and self-manual lymphatic drainage techniques were demonstrated and practiced under supervision. Additionally, decongestive and breathing exercises were taught to both patients and caregivers. Following this, the intensive treatment phase was conducted remotely using electronic communication technologies over a period of 4 weeks to monitor and guide the therapy. After the intensive phase, participants continued with maintenance therapy, which involved the use of compression stockings. The therapy aimed to reduce limb volume and improve symptoms related to breast cancer-related lymphedema.
223718225|NCT07014644|DRUG|0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo|0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo
223718226|NCT07014644|DRUG|1.5g Naltrexone Implant|1.5g Naltrexone Implant
223718227|NCT06205316|DRUG|Antiandrogen Therapy|Receive ADT
223718228|NCT06205316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223718229|NCT06205316|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223718230|NCT06205316|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224283970|NCT00711841|DRUG|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
224283971|NCT00711841|DRUG|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
224283972|NCT06905665|DEVICE|Virtual reality group|For the VR group, the purpose of the study was explained before the procedure, and both verbal and written informed consent were obtained. Additionally, patients were provided with detailed information about how to use the headset, what to expect, and the content of the video before viewing. Data collection forms and the State-Trait Anxiety Inventory (STAI I-II) were completed using a face-to-face interview technique before the procedure.During the urodynamic procedure, an Efnan G04EA VR Shinecon 3D headset was used. The patient was positioned appropriately on the examination table, and the VR headset was fitted onto their head with a smartphone placed inside. A thin pillow was placed under the patient's head, and efforts were made to ensure their privacy and comfort. Throughout the urodynamic procedure (approximately 30 minutes),
224283973|NCT06904976|BEHAVIORAL|Nature-focused mindfulness|The intervention consisted of a daily 30-minute self-guided practice structured in three parts: (1) participants first walked mindfully for 10 minutes in a natural environment of their choosing (e.g., local park, forest, garden), (2) upon reaching a suitable location, they engaged in a 10-minute guided mindfulness practice, and (3) concluded with a 10-minute mindful walk back.
224283974|NCT06904976|BEHAVIORAL|Noticing-nature|Participants allocated to the noticing-nature active control group will be instructed to walk in nature for 30 minutes per day and pay attention to how the natural objects/scenes they encounter in their daily surroundings make them feel over the 14-day period.
224283975|NCT06905431|DIAGNOSTIC_TEST|Plyometric Training|"Frequency: Three sessions per week on non-consecutive days to allow for adequate recovery.~Intensity: High-intensity exercises performed at 80-90% of maximum effort. Exercises include box jumps, depth jumps, lateral bounds, and tuck jumps targeting explosive power and agility.~Time: Each session lasts approximately 45-60 minutes, including: Warm-up (10 minutes), Core Plyometric Exercises (30-40 minutes), Cool-down (5-10 minutes) Type: Explosive lower-body movements utilizing the stretch-shortening cycle (SSC) to improve neuromuscular coordination, sprint speed, and power."
224283976|NCT06905431|COMBINATION_PRODUCT|(High-Intensity Interval Training (HIIT)|Frequency: Three sessions per week (e.g., Tuesday, Thursday, Saturday) with a rest day between sessions. Intensity: Alternating between 85-95% of maximum heart rate during high-intensity intervals and 50-60% of maximum heart rate during recovery periods. Work-to-rest ratio of 1:2 (e.g., 30 seconds of high-intensity sprints followed by 60 seconds of low-intensity walking). Time: Each session lasts approximately 45-50 minutes, including: Warm-up (10 minutes), HIIT Intervals (25-30 minutes with 8-12 work-rest cycles), Cool-down (5-10 minutes) Type: Cardiovascular exercises such as sprinting, cycling, or shuttle runs designed to enhance anaerobic capacity, agility, and sprint speed.
223718231|NCT06205316|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223718232|NCT06205316|OTHER|Survey Administration|Ancillary study
223718233|NCT06205316|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223718234|NCT06629207|DEVICE|PET/CT with 18-FDG|FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.
223718235|NCT06629207|DEVICE|SPECT : 123 I-FP-CIT (DATSCAN)|DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.
223718236|NCT06629207|DEVICE|MRI|MRI examination to exclude structural brain anomalies.
223718237|NCT06881979|DEVICE|High-tech rehabilitative treatment|Virtual Reality (e.g., VRRS Evo): Provides an engaging and immersive environment for cognitive and motor exercises. Stabilometric Platform (e.g., Gea Master or Prokin Technobody): Used for balance and postural control training. Treadmill System (e.g., Walkerview Technobody): Used for aerobic exercises with gait analysis and feedback
223718238|NCT06881979|OTHER|Rehabilitation|Traditional rehabilitative treatment
223718239|NCT03330821|DRUG|Cytarabine|Given IV
223718240|NCT03330821|DRUG|Idarubicin|Given IV
223930629|NCT05663346|OTHER|Cannabis & Cancer digital educational intervention|The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.
223930630|NCT05663346|OTHER|Standard information regarding cannabis use in oncology|Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
223941276|NCT04595461|OTHER|Video Education|Patients receive four short YouTube videos explaining chronic rhinosinusitis and endoscopic sinus surgery
223941277|NCT04595461|OTHER|Control|Standard patient education with verbal and written education
223941278|NCT05031234|DRUG|anaesthesia without opiates|Anaesthesia without opiates for patients undergoing laparoscopic colectomy
223941279|NCT05031234|DRUG|anaesthesia with morphine|anaesthesia with morphine for patients undergoing laparoscopic colectomy
224283977|NCT06905756|DIAGNOSTIC_TEST|Accelerated rehabilitation|15 subjects in group A will be receiving Accelerated Rehabilitation protocol alongwith baseline treatment. Accelerated rehabilitation consisting of three phases, following 12 week exercise regime. Pain reduction, mobility, strengthening, and functional recovery are part of the accelerated rehabilitation protocol for Achilles tendinopathy. Ice, TENS, range-of-motion exercises, isometric calf contractions, and a progressive transition to full weight-bearing based are the mainstays of Phase 1 (Weeks 1-4). Phase 2 (Weeks 5-8) focuses on balance training, resistance band exercises, and seated and standing calf raises as well as light functional workouts like cycling or walking. Phase 3 (Weeks 9-12) progresses to sport-specific and endurance exercises like swimming or running after including plyometric drills, eccentric heel drops, and advanced strengthening. Each exercise will be performed under supervision of skilled physiotherapist for 2 times daily, 2 sets of 5 repetitions.
224283978|NCT06905756|COMBINATION_PRODUCT|Eccentric strengthening exercises|Group B will be receiving eccentric strengthening exercises alongwith baseline treatment. Techniques of Curwin, Stanish et al will be used for eccentric training. For every exercise, participants do three sets of 15 repetitions, with a 30-second break in between. Weight is added gradually to enhance resistance (5-10 lbs or more, depending on tolerance). The eccentric strengthening regimen for Achilles tendinopathy advances every week. Participants use both feet without dorsiflexion to perform eccentric contractions in Week 1. By Week 3, the focus of the workouts is on the injured foot in maximum dorsiflexion. In Week 4, 10% body weight resistance is introduced, and in Week 5, an extra 5-10 pounds. From Week 6 to Week 8, resistance rises every two weeks. From Weeks 9 to 12, functional motions like hopping, single-leg heel drops, and sport-specific drills are incorporated, all of which are customized to meet individual goals.
224283979|NCT06905080|DEVICE|Catheter Caps Case (C3)|The nursing team will then assess the participant's catheter, catheter site, and lumens. The C3 device will be placed on the distal lumens and hub caps of the participant's hemodialysis catheter using clean technique and left in place for approximately 15 minutes. During this time, the participant will be asked to lay, sit, and stand while wearing the C3 device. The RN will stay with the participant during the entire time and will write down any comments or requests regarding the C3 made by the participant. After 15 minutes, the nursing team will remove the C3 device and reassess the condition of the catheter site and lumens, noting any changes. Finally, the participant will complete a 10 item post- intervention survey, developed by the study team and evaluated for face validity by all members of the team to provide feedback on the design of the C3 device.
224283980|NCT06256549|DRUG|GZR18|Titrated to low dose or middle or high dose
224283981|NCT06256549|DRUG|Semaglutide|Titrated to 1.0 mg once a week
224283982|NCT00550888|PROCEDURE|suture techniques|
224283983|NCT03146273|DIETARY_SUPPLEMENT|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
224283984|NCT05724498|BEHAVIORAL|Brief CBT-I|4 session CBT-I
224283985|NCT05724498|BEHAVIORAL|Standard CBT-I|Standard VA 6 session CBT-I
224283986|NCT01303237|DRUG|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
224283987|NCT01619579|DEVICE|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
224283988|NCT03907241|DRUG|Octanorm 16.5%|Human normal immunoglobulin
224283989|NCT02717078|OTHER|Diet Therapy|The intervention for both study groups will be a change in diet.
224283990|NCT02872051|BEHAVIORAL|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
223718241|NCT03330821|OTHER|Laboratory Biomarker Analysis|Correlative studies
223718242|NCT03330821|DRUG|Pevonedistat|Given IV
223718243|NCT03330821|OTHER|Pharmacological Study|Correlative studies
223941280|NCT02220959|OTHER|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
223941281|NCT02526576|BIOLOGICAL|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
224283991|NCT02872051|OTHER|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
223718244|NCT06709248|BEHAVIORAL|Life Coping Program|The Life Coping Program is built around a coordinated 5-day Life Coping Course. Participants included are grouped by their primary condition, meaning the diagnosis or illness reasoning the referral. Each family is assigned a dedicated Primary Contact throughout the program, and the program consists of three phases: Phase 1: Preparation - Written/visual materials and questionnaires are provided to motivate and inform. A digital consultation occurs 3-5 weeks before the Life Coping Course, covering goals, commitment, and follow-up. Materials are offered in paper or digital formats. Phase 2: Life Coping Course - The 5-day course includes individual consultations, group activities, education, and medical follow-ups, focusing on coping strategies and well-being. Phase 3: Implementation - A summary meeting is conducted, including key persons for further implementation in own local area. Digital follow-ups at 3-4 weeks and 6 months post course assess progress and guide goal achievement.
223930631|NCT06513663|BEHAVIORAL|Exercise Intervention|"Eligible and consented participants randomized to the exercise arm will work with an exercise trainer three times weekly for 12 weeks. Training sessions will be delivered virtually using HIPPA Complaint IU Health Zoom. These sessions will last 60 minutes and include cardiovascular exercise, resistance training, and balance or stretching exercise. The participants will be able to use any equipment they already have at home but will be provided a heart monitor and a set of resistance bands.~All sessions will have a moderate-intensity training goal, defined as 40-80% of heart rate reserve (HRR). Cardiovascular exercise will include any at-home equipment available to the participants or follow a Tabata-style program. Resistance training will include a full body workout, emphasizing all major muscle groups. Trainers will progress or regress intensity levels based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session."
223930632|NCT04092192|DEVICE|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
223930633|NCT04663061|BEHAVIORAL|Medical weight loss|Participants will be prescribed intensive medical weight loss with the goal of achieving 15% weight loss from initial weight
223930634|NCT04663061|BEHAVIORAL|Diabetes education|Participants will receive standard of care diabetes education
223930635|NCT04663061|BEHAVIORAL|Continuous glucose monitoring|Participants will use CGM devices to track blood glucose levels in near real time
223930636|NCT05357989|DRUG|buntanetap/posiphen|HPMC (vegetarian source) capsule shells
223930637|NCT05357989|DRUG|Placebo|HPMC (vegetarian source) capsule shells
223930638|NCT05694715|DRUG|Niraparib|Given orally
224283992|NCT02012452|BEHAVIORAL|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
223930639|NCT05694715|DRUG|Irinotecan|Given intravenously (IV)
223941282|NCT02526576|PROCEDURE|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
223941283|NCT00507494|DRUG|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
224283993|NCT02012452|BEHAVIORAL|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
224283994|NCT04244006|DRUG|Dupilumab Prefilled Syringe|administration of dupilumab corresponding to dupilumab arm
224283995|NCT04244006|OTHER|Placebo Prefilled Syringe|administration of placebo corresponding to placebo arm
224283996|NCT03636087|PROCEDURE|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
223941284|NCT05573724|DRUG|AZD5305|"In Part A, the participants will receive a single dose of AZD5305 on Day 1 and Day 7.~In Part B, the participants will receive AZD5305 once daily."
223941285|NCT05573724|DRUG|Itraconazole|In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
223941286|NCT02553889|DRUG|ISIS 416858|subcutaneous injection
224283997|NCT03636087|PROCEDURE|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
223941287|NCT02553889|DRUG|Placebo|subcutaneous injection
223941288|NCT01082575|DEVICE|Oxygen Monitoring|No intervention
223941289|NCT01928459|DRUG|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
223941290|NCT01928459|DRUG|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
223941291|NCT00205179|DRUG|Novasoy|100mg/day soy isoflavones
223941292|NCT00205179|DRUG|Placebo|100mg/day matching placebo
223941293|NCT02763449|BEHAVIORAL|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
223941294|NCT00586313|DEVICE|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
223941295|NCT00586313|PROCEDURE|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
223941296|NCT00227175|BEHAVIORAL|Semi-structured, open ended interview|
223941297|NCT02079649|DRUG|AL-53817 Ophthalmic Solution, 0.1%|
223941298|NCT02079649|DRUG|AL-78843 Ophthalmic Solution, 0.03%|
223941299|NCT02079649|DRUG|Dexamethasone Ophthalmic Suspension, 0.1%|
223941300|NCT02079649|DRUG|AL-53817 Vehicle|Inactive ingredients used for masking purposes
223941301|NCT02831231|DRUG|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
223941302|NCT02831231|DRUG|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
223941303|NCT00622856|BEHAVIORAL|psychological intervention|Psychological intervention
223941304|NCT00622856|BEHAVIORAL|Diabetes education|5 sessions with diabetes nurse
223718245|NCT06743295|DEVICE|DEEPSONIC™ Deep Sound Optimized Neural Integrated Chip Artificial intelligence-based noise reduction|"Participants with hearing loss will be fitted with the Phonak Audéo Sphere™ Infinio (PAI) hearing aid with artificial intelligence (AI)-based noise reduction, which incorporates deep neural networks (DNN) technology to reduce background noise.~Speech stimuli, presented at a comfortable level of approximately 60 dB SPL (like normal conversation), will be delivered via a loudspeaker positioned directly in front of the participant.~They will be tested in 3 listening environments: quiet, moderate noise, high noise.~Speech perception scores will be measured as a function of each hearing aid program setting: quiet setting, moderate noise, and advanced AI-based reduction for high noise."
224283998|NCT03636087|PROCEDURE|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
223930640|NCT05853055|PROCEDURE|Respiratory training|Respiratory training will be included in the rehabilitation program of a subgroup of post-COVID-19 patients. The intervention group will train twice daily for the length of their rehabilitation stay using an incentive spirometer (Voldyne 5000 R, Sherwood Medical, St. Louis, USA). Subjects will be instructed to first completely exhale slowly. Then inspire slowly up to 70% of their vital capacity, producing a constant flow controlled via feedback from the device. This procedure will be repeated every 30 s (paced by a metronome) for 15 min. The training will be conducted twice a day, resulting in a total of 60 inspirations per day.
223930641|NCT02609750|OTHER|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
223930642|NCT02609750|OTHER|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
223930643|NCT04153890|BEHAVIORAL|FamPALcare|Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care.
223930644|NCT06892353|DIAGNOSTIC_TEST|AI-powered fundus camera screening|All the participants will undertake an AI-powered fundus camera screening, physician/optometrist consultation, survey with questionnaires and a phone interview three months after their baseline assessment.
223941305|NCT02909959|DRUG|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
223941306|NCT02909959|DRUG|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
223941307|NCT02394106|DRUG|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
223941308|NCT02394106|OTHER|Placebo|Normal saline, 1000 ml, administered once
223941309|NCT05202366|DRUG|CGB-400 Topical Gel|CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.
223941310|NCT06511284|OTHER|High protein dose|High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition
223941311|NCT06511284|OTHER|Usual protein dose|Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition
223941312|NCT04352400|DRUG|Nafamostat Mesilate|administered intravenously as a continuous infusion
223941313|NCT04352400|DRUG|Placebo|administered intravenously as a continuous infusion
223941314|NCT04877756|DRUG|OLX10010|Lyophilized cake reconstituted with WFI and injected intradermally
223941315|NCT06635759|OTHER|Upper trapezius low-load endurance exercise|Participants in the EE group will perform the overhead shrug exercise for the affected side using a green Thera-Band Elastic Band. To perform this exercise, the subject will stand and place one arm of the affected side in an overhead position against the wall. The middle portion of the theraband will be placed on the floor, and the subject will stand on the middle portion of the theraband to fixate it in place with both feet shoulder-width apart. Then, the subject grasp both tails of the theraband and perform the shoulder shrug movement for the affected side with a 3-second elevation, hold at the end range for 5 seconds, and then return back to the starting position with a 3-second depression. The subject will perform this exercise for 20 repetitions per set, 3 sets a day with 1-minute rest between sets, 3 alternate days a week, for 5 weeks. They will be instructed to record all training sessions in a diary.
223941316|NCT06635759|OTHER|Upper trapezius stretching exercise|Participants in the SE group will perform static upper trapezius stretching exercise for the affected side. To perform the stretch, participants will be asked to sit upright on a chair and look straight ahead. To reduce scapular elevation and upward rotation, the ipsilateral hand should be placed below the buttock. The subject will then be asked to perform deep neck flexion, neck rotation towards the affected side, and contralateral side flexion using the opposite hand in a diagonal direction until the position of 'mild discomfort' is attained. They should maintain the deep neck flexion when performing the stretch. The stretch will be held for 30 seconds each set, 3 sets a day, daily for 5 weeks.
223941317|NCT04934033|OTHER|Neurological assessments|The participants will have a MRI, and language and cognitive assessments.
223941318|NCT05230264|OTHER|Elective AAA Repair|Elective AAA Repair - Observation of Stress Response
223941319|NCT05481346|PROCEDURE|Multidomain training|"The training program has a duration of 18 weeks with 2 training sessions per week. The training will have a gradual progression of intensity. One day they train two blocks of strength and one block of cognitive exercises and on the second day, they train one block of power, one block of strength+cognitive and one block of aerobic training.~All sessions are 60 minutes long (10 minutes of warm-up, 40 minutes of training and 10 minutes of cool-down). Classes are in small groups of no more than 8 members."
223930645|NCT06664242|DEVICE|Placebo|these patients will be subjected to the same usual routine of pharmacological analgesia, consisting of the administration of 1g of dipyrone at the discretion, with escalation to tramal (dose) and physiotherapy in the hospital ICU, in addition to an application of TENS, with the device turned on, with programming on channels that are not connected to the patients, so as to generate visual and auditory feedback.
223930646|NCT06664242|DEVICE|TENS low frequence group|Patients in this group will undergo the hospital usual analgesia and physiotherapy routine, in addition to conventional TENS with a low frequency of 5 Hz and a pulse width of 250 µs.
223930647|NCT06664242|DEVICE|Conventional TENS|In this group, patients will undergo the usual routine of analgesia and hospital physiotherapy, in addition to TENS with a frequency of 140 Hz, pulse width of 50 µs.
224095556|NCT03744650|BEHAVIORAL|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
224095557|NCT06276569|DRUG|Sivelestat|(1)Experimental group: Received intravenous sivelestat sodium admission to the ICU. Sivelestat sodium was dissolved in 0.9% sodium chloride injection and a one-day dose (4.8mg/kg) was diluted in 50ml of 0.9% sodium chloride injection, which was then sealed for continuous intravenous administration at a rate of 0.2 mg/kg/h for seven consecutive days.
224095558|NCT06276569|OTHER|placebo|2)Control group: Receiving the same dose of placebo, 50 ml of saline, were administered intravenously at a rate of 0.2 mg/kg throughout the treatment period without any discernible impact on patient's regular treatment regimen.
224283999|NCT03636087|PROCEDURE|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
224284000|NCT03636087|PROCEDURE|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
224284001|NCT03636087|OTHER|Changing gloves before obturation|The treating dentist will change gloves before obturation
224284002|NCT03636087|OTHER|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
224284003|NCT03636087|OTHER|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
224284004|NCT03636087|RADIATION|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
224284005|NCT03636087|RADIATION|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
223930648|NCT06782828|OTHER|observe results of FNAC|observe results of FNAC and compare it with results of histopathological examination to detect accuracy of FNAC in diagnosis of thyroid nodules.
223930649|NCT06893289|OTHER|Exercise|Balance and proprioceptive exercises
223930650|NCT06893289|OTHER|Muscle strengthening|Strengthening of the lower limb muscles
224095559|NCT05147246|BEHAVIORAL|ParentCorps-Professional Development (PD)|PD is a school-based evidence-based-intervention (EBI) and preventive service provision model that supports teachers and school personnel to apply EBI strategies to promot young children's medical health in impoverished areas. Teachers and PTAs will participate in a 4-day training before the 1st school term. Teachers in the intervention condition will also receive 8 sessions (8 hours) of face-to-face group-based coaching during the 1st and 2nd terms. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
224095560|NCT01934504|PROCEDURE|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
224284006|NCT02688387|DRUG|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
224284007|NCT02688387|DRUG|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
224284008|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present \[10\]. At least 30 seconds of observation per ostia is performed if patency is not observed.
224284009|NCT04077242|DIAGNOSTIC_TEST|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
224284010|NCT04529395|OTHER|Blending of essential oils|The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
224284011|NCT04529395|OTHER|Apricot vegetable oil|The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
224284012|NCT03813225|OTHER|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
223718246|NCT04034836|DRUG|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
223930651|NCT06791967|BEHAVIORAL|home-based walking program|The home-based walking intervention involves five walking sessions per week over 12 weeks, with a target of 3,000 additional steps per session beyond daily activities. In the first week, participants in the experimental group will wear a smart wristband upon waking to record their average daily steps, which will guide their walking goals. By the 7th week, participants are expected to achieve at least 3,000 extra steps per session, completed in 30 continuous minutes. The wristband, synced via Bluetooth to its companion app, can store up to one month of walking data. Weekly phone follow-ups will record participants' daily step counts. No additional cloud uploads of personal data are required.
223930652|NCT06877468|BEHAVIORAL|Associative conditioning|Child is offered a vegetable to taste with a palatable dip, over 8 occasions. Vegetable is served at home by parent/caregiver following standard script.
223930653|NCT06877468|BEHAVIORAL|Modeling|Child is offered a vegetable to taste while their parent/caregiver also tastes it and models enjoying it, over 8 occasions. Vegetable is served at home with parent/caregiver following standard scripting.
223930654|NCT06885801|DEVICE|use of an anatomically designed nasal conformer|this study will evaluate the use of a nasal conformer that has been designed to match the internal airway anatomy of the anterior nose rather than the standard hollow, conical conformer currently available on the market
223930655|NCT06745635|OTHER|Usual Care|Usual care for immunizations.
223930656|NCT06745635|OTHER|Multifaceted intervention|The multifaceted quality improvement intervention includes: video-based training on vaccine management in SUS, an optimized Cold Chain Manual schema, technical documents on proper vaccine handling and immunization schedules, and checklists for managing post-vaccination errors and corrective procedures. Videos will focus on six key points (right person, vaccine, dose, time, route, and documentation), with each lasting about 2 minutes and accessible on-demand. The Cold Chain schema will cover storage, monitoring, transport, conservation, and handling, with checklists for each category. Standardized technical documents will align with video themes, ensuring protocol adherence. An error identification and management schema will address issues like improper vaccine administration, cold chain violations, and incorrect dosages. This schema will be reviewed by staff and made available in health units.
223930657|NCT06748027|OTHER|Fasting|Long-term fasting (\&gt;3d)
223930658|NCT06773455|DRUG|tralokinumab|600mg at week 0 followed by 300mg Q2W for 24 weeks
223930659|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine|NAC capsules
223930660|NCT05986318|DRUG|Dexamethasone Oral|Dexamethasone tablets
224095561|NCT05452382|PROCEDURE|Partial colecctomy|Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
224095562|NCT05452382|PROCEDURE|Hemicolectomy|Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
223930661|NCT05986318|DIETARY_SUPPLEMENT|N-Acetyl cysteine Placebo|Matching placebo for NAC capsules
224095563|NCT06398730|DRUG|GEH200520 Injection and GEH200521 (18F) Injection|Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
224284013|NCT03388502|OTHER|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
224284014|NCT03388502|OTHER|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
224284015|NCT03730779|DRUG|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
223930662|NCT05986318|DRUG|Dexamethasone Placebo|Matching placebo for dexamethasone tablets
224095564|NCT06398730|DIAGNOSTIC_TEST|Static - PET/CT scan|Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
224284016|NCT04490473|OTHER|survey work|Survey forms will be sent to individuals online. Information about the study will be given to individuals with the informative text at the beginning of the questionnaire form. Individuals who agree to participate in the study will fill in the questionnaire and send it back online.
224095565|NCT04406571|OTHER|Data record|Data record
224284017|NCT00172068|DRUG|Zoledronic acid + Calcium/Vitamin D|
224284018|NCT01938352|BIOLOGICAL|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
224284019|NCT01938352|BIOLOGICAL|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
224284020|NCT00613860|DEVICE|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
224284021|NCT01115855|DRUG|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
224284022|NCT01115855|DRUG|Placebo|Placebo once daily or every once daily
224284023|NCT02765672|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
224284024|NCT02765672|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
224284025|NCT02765672|BEHAVIORAL|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
224284026|NCT02765672|BEHAVIORAL|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
223930663|NCT05986318|RADIATION|Radiation Therapy|All participants will receive radical pulmonary radiation therapy. Conventional techniques or stereotactic ablative radiotherapy will be used.
223930664|NCT06889181|OTHER|Plasma Rich in Growth Factors (PRGF)|using prgf with closing primary cleft palate - isolated cleft palate Minutes before the surgery, 10-20 ml of venous blood from each patient. -The blood is centrifuged to obtain PRGF. -Fixed between nasal and palatal mucosa
223930665|NCT06889181|OTHER|Placebo|primary closing cleft palate-isolated cleft palate
223930666|NCT06793683|DRUG|Bladder chemodenervation (Botox)|BoNT-A (Botox) 200 U will be injected into the detrusor (bladder wall muscle).
223930667|NCT06793683|PROCEDURE|Bladder Sham (Saline) Injection Procedure|20mL placebo (saline only), will be injected into the detrusor (bladder wall muscle).
223930668|NCT05634005|BEHAVIORAL|Clinical Decision Support|In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).
223930669|NCT06818630|OTHER|SkinCeuticals combination skin care products|"1. CE Ferulic Serum,~2. Discoloration Defense (3% Tranexamic Acid),~3. Triple Lipid Restore 2:4:2"
223930670|NCT06818630|OTHER|Regular skin care procedure|"1. Regular moisturizing product (Phyto Corrective Gel),~2. sunscreen (Advanced Brightening UV Defense SPF50 PA++++)"
224095566|NCT05122806|GENETIC|RNAseq|"1. Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.~2. ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples"
223533068|NCT05508828|PROCEDURE|Percutaneous Continuous Irrigation assisted Vacuum Drainage Combined With Transgastric Necrosectomy|All patients with SAP were given contrast enhanced CT scan within 48 hours after admission to identify the location and range of the necrosis. If the patient's condition progressively worsened, a multifunctional irrigation-assisted vacuum drainage tube was placed by the CT-guided Seldinger technique in each of the necrosis cavity. Subsequently, transgastric necrosectomy were performed by one or two experienced endoscopist under conscious sedation. The procedure was repeated until all loosely adherent necrotic material were cleared and replaced by granulation tissue. Percutaneous irrigation was stopped and replace with simple drainage if the patient's condition continues to improved and the cavity confirmed by CT was resolution. If the drainage volume was less than 10 mL/day for 3 consecutive days, clamp the drainage tube and remove it finally.
223533069|NCT04044963|BEHAVIORAL|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
223533070|NCT01463527|DEVICE|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
223533071|NCT05136170|DRUG|Cenegermin|Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
223533072|NCT05136170|OTHER|Vehicle|Vehicle was instilled with the same scheme of the test product
223533073|NCT03420365|BEHAVIORAL|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
223533074|NCT01493414|DRUG|INC424|All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
223533075|NCT04926116|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
223533076|NCT04926116|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
223533077|NCT03443635|BEHAVIORAL|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
223930671|NCT04884542|DEVICE|Revision Total Knee Arthroplasty|Total Knee Arthroplasty in case of failure of a previous operation.
223930672|NCT06909227|PROCEDURE|surgery under general anesthesia|Only in children, \< 1 year old non-cardiac surgery
224095567|NCT01295333|DRUG|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
224095568|NCT01295333|DRUG|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
224284027|NCT02765672|BEHAVIORAL|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
224284028|NCT02765672|BEHAVIORAL|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
224284029|NCT02765672|PROCEDURE|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
224284030|NCT02765672|PROCEDURE|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
224284031|NCT02765672|PROCEDURE|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
223533078|NCT01072526|DRUG|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
223533079|NCT01072526|DRUG|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
223533080|NCT05589454|DRUG|Atorvastatin Calcium tablets 80mg|Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
223533081|NCT05589454|DRUG|Atorvastatin Calcium tablets 20mg|Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
223533082|NCT04402710|BEHAVIORAL|Self-compassion|Six week behavioural change program plus a self-compassion intervention aimed to increase physical activity among individuals with prediabetes
223533083|NCT04402710|BEHAVIORAL|Control Group|Six week behavioural change program aimed to increase physical activity plus information on general health topics.
223533084|NCT03593174|DEVICE|Ossur Rigid Dressing|Removable Rigid Dressing
223533085|NCT03593174|DEVICE|Elastic Bandage|Usual modality: Elastic bandage
223533086|NCT00689806|DRUG|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not \> 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
223533087|NCT00689806|DRUG|Placebo|Placebo by mouth once daily for weeks 1-4.
223930673|NCT02666898|DRUG|GA101|"Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD \>10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
223930674|NCT02666898|DRUG|Ibrutinib|"Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~* patients in CR with BM MRD \< 10-4 : Ibrutinib alone 420mg daily~* patients with BM MRD \>10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
223930675|NCT02666898|DRUG|Cyclophosphamide|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
223930676|NCT02666898|DRUG|Fludarabine|"PART 2 :~patients with BM MRD \>10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
223930677|NCT05252390|DRUG|NUV-868|NUV-868 is an investigational drug for oral dosing.
223930678|NCT05252390|DRUG|Olaparib|Olaparib
223930679|NCT05252390|DRUG|Enzalutamide|Enzalutamide
223930680|NCT05353257|DRUG|HLX10|"Serplulimab is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
223930681|NCT05353257|DRUG|carboplatin/cisplatin-etoposide|"Etoposide: 100 mg/m2, IV, on Days 1, 2, and 3 of each cycle. Carboplatin: AUC = 5, IV, on Day 1 of each cycle up to a dose of 750 mg. investigator's choice.~Cisplatin: 75mg/m2, IV, on Days 1 of each cycle. investigator's choice."
223930682|NCT05353257|RADIATION|Thoracic radiotherapy|Standard Thoracic Radiotherapy
223930683|NCT05353257|DRUG|Placebo|Placebo Q3W
223930684|NCT05353257|RADIATION|Prophylactic Cranial Irradiation (PCI)|PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
223930685|NCT03997474|BIOLOGICAL|ATL001|ATL001 infusion
223930686|NCT03997474|DRUG|Checkpoint Inhibitor|Nivolumab
223930687|NCT03691220|BEHAVIORAL|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
224284032|NCT02765672|PROCEDURE|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
224284033|NCT02765672|PROCEDURE|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
223533088|NCT02336061|BEHAVIORAL|Evaluation of gender differences on the psychosocial and economic impact.|
223533089|NCT00414570|DRUG|[18]F-FLT PET scan|Injection of \[18\]F-FLT radiopharmaceutical followed by PET imaging.
223930688|NCT06215469|DEVICE|Amma Portable Scalp Cooling System (PSCS)|The unit is a compact, mobile refrigeration unit which circulates liquid coolant at low pressure through a special cooling cap on the participant's head, administered during non-investigational, cancer treatment.
223930689|NCT06215469|OTHER|Questionnaires|Quality of Life (QoL) and device usage questionnaires
223930690|NCT05617300|BEHAVIORAL|Mindfulness-Based Dementia Caregiving|Mindfulness Based Stress Reduction (MBSR) is a standardized program that is both psychoeducation and skills-based, which uses mindfulness meditation practices to help people better cope with their emotions. This study uses a version of MBSR designed specifically for care partners of people living with dementia (PLWD) called Mindfulness Based Dementia Caregiving. Mindfulness Based Dementia Caregiving (MBDC) is a program with 8 weekly 2 hour sessions (plus one extended practice 4 hour retreat) including both formal and informal mindfulness practices, role play, and lectures combined with some dementia-specific education. Participants learn how to incorporate mindfulness practices into day-to-day life to help cope with the challenges and stresses of dementia care.
223930691|NCT04734821|PROCEDURE|Near Infra-Red Fluorescence Guided Surgery|ICG injection around tumor each four direction by endoscopy followed by NIR fluorescence guidance laparoscopic or robotic esophagectomy or gastrectomy
223930692|NCT06864507|DRUG|HS-10561|Single and multiple doses of HS-10561 orally
223930693|NCT06864507|DRUG|Placebo|Placebo
224284034|NCT02294448|DRUG|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
224284035|NCT02946606|DRUG|GX-H9|Human growth hormone
224284036|NCT02946606|DRUG|Genotropin|Human growth hormone
224284037|NCT02376660|OTHER|Oats|
224284038|NCT01675076|DRUG|Dabigatran|NOAC
224284039|NCT01675076|DRUG|Rivaroxaban|NOAC
224284040|NCT01675076|DRUG|Apixaban|NOAC
224284041|NCT04893122|OTHER|COVID-19 pandemic|Study focuses on the impact of the COVID-19 pandemic on emergency attendances and admissions.
223718247|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
224095569|NCT04696549|BEHAVIORAL|Virtual visual art experience guided by Visual Thinking Strategies|All study dyads (where study dyad consists of a participant with dementia and his/her care-partner) will participate in 3 scheduled virtual visual art sessions via Zoom. Each session will last about an hour and will include a guided discussion of pre-selected visual art using the Visual Thinking Strategies approach. It is anticipated that two pieces of art will be shown during each art session. The three sessions will be scheduled one month apart.
223930694|NCT05892055|OTHER|MRI Procedure|All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
223930695|NCT06774924|DEVICE|Echoscopy examination using the echOpen probe|"In addition to standard care, each patient will have a systematic 4-point echoscopy examination using the echOpen probe: liver, spleen, lymph nodes, thyroid and, depending on symptoms, lung, kidney, bladder, abdomen.~The echOpen probe is CE marked. It will be used for all indications except certain areas of the body (thyroid, lymph nodes, bladder, liver, spleen, kidney, bladder and lymph nodes).~In addition to echoscopy with the echOpen probe, patient and physician satisfaction questionnaires will be used as part of this study."
223930696|NCT06773624|OTHER|PET/CT-enterography with 68Ga-DOTATOC|Patients underwent to PET/CT-enterography with 68Ga-DOTATOC
223930697|NCT06752252|PROCEDURE|ultrasound guided paravertebral block|after sterilization and identifying the level of T10 ,linear ultrasound probe will be placed in the midline over the spinous process at the chosen level, then the probe will be moved laterally to view the lamina and hyperechoic transverse process ,the pleural should be visible as a bright white line .The needle should be inserted in -plane from lateral to medial and the needle tip should end in a hypoechoic triangular space. Correct needle placement should be confirmed by anterior displacement of pleura with injection of small volume of saline then 0.5 ml/kg of a mixture of 0.25 ℅ bupivacaine and 1℅ lidocaine (1:1) will be injected
223930698|NCT06752252|PROCEDURE|Ultrasound guided erector spinae plane block|After sterilization, the linear ultrasound probe will be placed over transverse process of T10 ,after optimizing the image in sagittal or transverse scanning ,A 50 mm 22-G needle will be placed under the erector spinae muscle in -in plane orientation until it contacted T8 transverse process in the cranial caudal direction ,after hydro dissection and confirmation that the tip of the needle is between the transverse process and the fascia of the erector spinae muscle group, 0.5 ml/kg of a mixture of 0.25 ℅bupivacaine and 1℅ lidocaine (1:1) will be injected
223930699|NCT06752252|PROCEDURE|control group C|will receive standard general anesthesia with pain management protocol without regional block.
223930700|NCT06734637|DRUG|Peginterferon α-2b injection|Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).
223930701|NCT06842784|OTHER|Ambient heat stress|3-hour ambient heating in 44°C and 20% relative humidity
223930702|NCT06818604|DEVICE|CPAP|Participants randomized to this group will receive auto-CPAP therapy. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre. Settings will be adjusted to achieve a device efficacy index \< 5 events per hour.
223930703|NCT06818604|DEVICE|BiPAP|Participants will receive BiPAP S mode therapy for 4 weeks. The device will be initiated by a respiratory therapist at GF Strong Rehabilitation Centre with initial settings of IPAP 8 cmH2O and EPAP 3 cmH2O. Settings will be modified to a maximum tolerated level to achieve a tidal volume of 8 mL/kg ideal body weight and SpO2 \> 95%. Overnight oximetry will be performed to ensure at least 4 hours of device use, and settings will be adjusted to achieve a DEI \< 5 events per hour.
223930704|NCT06885099|DEVICE|FemPulse System|Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
223930705|NCT06860802|DRUG|Cefoxitin|Cefoxitin 2000 mg Bolus Injection
223930706|NCT06864260|OTHER|Built Environment|Built environment modifications include sidewalks, sidewalk cuts, traffic-calming devices, crosswalks, transit improvements, green space, street trees, beautification, signage, lighting, wellness van
223930707|NCT06864260|OTHER|Social Environment|Neighborhood coalition, Community Leadership Academy (LHSA), community-led events, community health workers
223930708|NCT04670536|DEVICE|PASS LP implants|Thoraco lumbar arthrodesis
223930709|NCT04670536|DEVICE|PASS DEGEN|Thoraco lumbar arthrodesis
223930710|NCT04670536|DEVICE|PASS TULIP PRIME|Thoraco lumbar arthrodesis
224095570|NCT00541307|DEVICE|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
224095571|NCT03750825|DEVICE|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
224284042|NCT02096367|OTHER|Gait analysis|
224284043|NCT02096367|OTHER|Kinematic gait analysis in lower limb|
224095572|NCT01217749|DRUG|PCI-32765|420 mg PO daily
224284044|NCT02096367|OTHER|Analysis of static posture|
224284045|NCT02096367|OTHER|Gait on treadmill|Treadmill during 2 minutes
224284046|NCT02096367|DEVICE|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
224284047|NCT02612181|DRUG|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
224095573|NCT01217749|DRUG|ofatumumab|per package insert as an IV infusion
223930711|NCT03263546|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
223930712|NCT03263546|BEHAVIORAL|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
223930713|NCT06746714|BEHAVIORAL|Proactive population care (active application of HOAP principles in patients flagged as high risk for hypoglycemia)|The Hypoglycemia Champion (HC) pharmacist reviewed patient charts before conducting proactive outreach. They did not contact subjects with active psychiatric issues or those admitted to a skilled nursing facility. The patient's care team (PCP and APM) were also contacted for peer consent. The outreach process involved an initial phone call with a secure electronic message or mailed letter (for those without secure KPNC patient portal access) if the initial call was unsuccessful. A second and third phone call attempt was made for non-responders.
223930714|NCT06746714|BEHAVIORAL|Usual care, after system-side dissemination of HOAP|Patients had their diabetes treated as usual by their diabetes care provider or primary care physician, after system-wide dissemination of HOAP.
224095574|NCT00437905|PROCEDURE|angioplasty|
224095575|NCT00810797|DRUG|exemestane|Given orally
224095576|NCT00810797|OTHER|laboratory biomarker analysis|One year after completion of study treatment
224095577|NCT00810797|PROCEDURE|quality-of-life assessment|One year after completion of study treatment
224095578|NCT00810797|OTHER|immunohistochemistry staining method|Correlative studies
224284048|NCT04729608|DRUG|Batiraxcept|Batiraxcept is an experimental drug
224284049|NCT04729608|DRUG|Paclitaxel|Paclitaxel is the standard of care, background therapy
224284050|NCT04729608|OTHER|Placebo|Matching placebo
224284051|NCT03512912|DEVICE|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
224284052|NCT02806687|DRUG|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
224284053|NCT02806687|DRUG|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
224284054|NCT01505361|BIOLOGICAL|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
224284055|NCT01505361|BIOLOGICAL|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
224284056|NCT05276505|OTHER|Lavender Aromatherapy Tablet|Before the breast biopsy, aromatherapy tablets was adhered to the patient's shoulder in the waiting room and were asked to sniff
224284057|NCT03068845|DEVICE|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
224284058|NCT03068845|DEVICE|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
223930715|NCT05652400|OTHER|Exposure to antiretroviral therapy|Outcomes will be compared with regard to current or previous exposure to antiretroviral therapy.
224095579|NCT02481765|DEVICE|High definition transcranial direct current stimulation|
224095580|NCT00418288|DRUG|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
224095581|NCT00418288|DRUG|placebo|intravenous infusion of 1.2pmol/kg/min
224095582|NCT03895203|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
224095583|NCT03895203|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
224095584|NCT03895203|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points.
224099690|NCT06807164|PROCEDURE|Serratus Plane Block|The Serratus Plane Block (SPB) is a nerve block performed by a trained anesthesiologist to provide localized pain relief. It involves the injection of a local anesthetic: Maximum 150 mg naropeine combined with 150 μg clonidine hydrochloride into the serratus anterior plane under ultrasound guidance. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation.The SBP will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks. The SPB may be repeated every two weeks up to four times in the initial 8-week period, with an additional repeat at 12 weeks if pain control remains insufficient.
223930716|NCT06740188|DRUG|5-hydroxytryptamine balanced antidepressants trazodone|The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
224095585|NCT06258278|PROCEDURE|Arthroscopic-assisted lower trapezius tendon transfer surgery|The procedure, conducted under general anesthesia, starts with diagnostic arthroscopy followed by excision of the posterior bursa and preparation of the rotator cuff footprint. Attention then shifts to harvesting the low trapezius tendon, accessed through a 10cm incision over the spina scapula. The tendon is detached, dissected, and released from adhesions, ensuring not to damage its pedicle. A fascia lata graft is harvested from the ipsilateral thigh and sutured to the low trapezius tendon in a continuous, locking manner to aid fixation on the humeral head. A subdeltoid tunnel is formed, and the graft is shuttled into the subacromial space and fixed at the bicipital groove and tuberculum majus with knotless anchors. The stability of fixation and mobility of the low trapezius muscle are verified, and the graft and tendon are sutured together with tension, with the arm held in 90° abduction and maximum external rotation.
224095586|NCT00996840|DRUG|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
224095587|NCT00996840|DRUG|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
224095588|NCT00996840|DRUG|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
224095589|NCT00996840|DRUG|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
224095590|NCT00996840|OTHER|Placebo|Placebo to match intervention
224095591|NCT03125642|DRUG|Etoposide|"BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
224095592|NCT03125642|DRUG|BCNU|BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6
224095593|NCT03125642|DRUG|AraC|BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
223930717|NCT06740188|DRUG|Citalopram hydrobromide combined with zolpidem|the control group was given citalopram hydrobromide combined with zolpidem
223930718|NCT04980300|BEHAVIORAL|Intervention|Participants in the Intervention arm will receive five virtual consultation sessions, delivered by a physical therapist over 12 weeks (at Weeks 1, 2, 4, 7, and 10) and lasting approximately 45-60 minutes each. Each session will focus on lower extremity strengthening exercises, physical activity (i.e., walking), and education about knee osteoarthritis. Participants will be provided with an exercise manual, tracking log, educational manual, and a step counter. Participants will be prescribed up to 6 exercises (quadriceps, hip abductor/gluteal, hamstrings/gluteal, calf, balance) and daily walking step goals. Progression will be a joint decision by the participant and physical therapist. Education will include information on knee osteoarthritis, managing pain, being active, weight loss, dealing with setbacks, and progressing activity. The physical therapist will also discuss barriers and facilitators to meeting and progressing goals as appropriate.
223930719|NCT04980300|BEHAVIORAL|Control|Participants in the Control arm will receive access to a study-specific website that navigates them to a variety of web-based resources on knee osteoarthritis. Topics for the various resources include an overview of knee osteoarthritis, brief anatomy of the knee and how that is related to pain, different types of arthritis pain and how to manage it, and how to be active with arthritis. Sessions range from 20 - 70+ minutes.
223930720|NCT05128006|OTHER|New patient teledermatology visit|new patient teledermatology visits
223930721|NCT05883358|DRUG|Clonidine, Buprenorphine|Each patient receives rotational treatment using Buprenorphine 5cmg/hr patch; or Clonidine tablet 0.1mg 4hourly; or combined Clonidine tablet 0.1mg 4hourly + Buprenorphine 5cmg/hr patch.
224095594|NCT03125642|DRUG|Melphalan|BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1
224095595|NCT03125642|PROCEDURE|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
224095596|NCT03125642|BIOLOGICAL|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3
224095597|NCT03125642|DRUG|Cyclophosphamide|"CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
224095598|NCT03125642|RADIATION|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
224095599|NCT02601417|OTHER|Ignoring result of bile culture|the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
224284059|NCT02284347|DEVICE|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
224284060|NCT04628845|DEVICE|Endo-perio therapy with laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals with using laser 940nm.
224284061|NCT04628845|DEVICE|Endo-perio therapy without laser 940nm|Periodontal pockets's treatment of scaling, root debridement and endodontic treatment of root canals
224284062|NCT03185182|DRUG|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
224095600|NCT00863616|DEVICE|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
224095601|NCT03317587|BEHAVIORAL|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
223930722|NCT04248335|DRUG|Pantoprazole|single-dose administration
224095602|NCT02065778|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
224095603|NCT02914626|DRUG|Intravitreal ranibizumab|Intravitreal ranibizumab injection
223930723|NCT04248335|DRUG|Midazolam injection|single-dose administration
223930724|NCT05665049|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Using results from a qualitative study, we identified the following culturally grounded social transfer options that is responsive to the identified needs of new mothers. Based on the monthly Lao PDR minimum wage and an estimated 15 full working days needed to exclusively breastfeed over a 6-month period, a social transfer of approximately $75 would fairly subsidize women's breastfeeding efforts. Therefore all social transfer options equate to approximately 75 USD. The options include: diapers, child developmental toys, cash, or a combination of these.
223930725|NCT05556629|OTHER|No Intervention|This is a non-interventional study.
224095604|NCT05388357|OTHER|Intervention Procedure: PCI|Percutaneous Coronary Intervention
224095605|NCT02975128|DEVICE|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
224095606|NCT03445481|DEVICE|Medacta femoral prosthesis|patients' treatment with a new implant prosthesis
224095607|NCT01774916|GENETIC|blood samples|
224095608|NCT01655407|DRUG|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
224095609|NCT01655407|DRUG|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
224095610|NCT04439669|DEVICE|Sham nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to sham. In the following open phase stimulation the treatment targets are the right S2-contralateral M1-left S2."
224284063|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
224284064|NCT00648245|DRUG|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
223930726|NCT04588506|PROCEDURE|Lower Trapezius Tendon Transfer Technique|Lower Trapezius tendon used in repairing cuff tear
223930727|NCT04588506|PROCEDURE|Latissimus Dorsi Tendon Transfer Technique|Latissimus Dorsi tendon used in repairing cuff tear
223930728|NCT04588506|PROCEDURE|Pectoralis Tendon Transfer Technique|Pectoralis tendon used in repairing cuff tear
223930729|NCT04528459|DEVICE|Stryker© ADAPT™ platform|The ADAPT system is a software platform that utilizes augmented reality to assist surgeons with implant alignment, lag screw length and positioning, and distal interlocking screw placement for cephalomedullary fixation of peritrochanteric femur fractures.
224095611|NCT04439669|DEVICE|Active nrTMS and open phase|"Navigated repetitive TMS treatment (10 sessions during a three-week period) randomized to S2. In the following open phase stimulation the treatment targets are contralateral M1 and left S2. If the patient benefited from active S2 stimulation, but the treatment effect faded in follow-up, the open phase stimulation starts with right S2."
224284065|NCT00648245|DRUG|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
224284066|NCT00648245|DRUG|Placebo|Placebo given once daily for 21 days by nebulizer
224284067|NCT00648245|DRUG|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
224284068|NCT06613269|DRUG|68Ga-NY104 PET/CT|"68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104."
223930730|NCT04528459|RADIATION|Traditional fluoroscopy|For patients in the control group, traditional fluoroscopy will be utilized for placement of the cephalomedullary nail.
223930731|NCT04303260|BEHAVIORAL|Physical exercises|The interventional exercise regimen will include specific exercises postulated to increase blood flow to the intestine and colon and thereby promote normal peristaltic s and decrease inflammation.
223930732|NCT04972292|DRUG|FDC of codeine 30 mg/dipyrone 500 mg|Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
223930733|NCT04972292|DRUG|Tylex|Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
223930734|NCT05935644|BEHAVIORAL|ORCHID|The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.
223930735|NCT06733740|PROCEDURE|ultrasound-guided thermal ablation|ultrasound-guided thermal ablation to treat tumor
223930736|NCT06819748|DRUG|The cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone|The patient receive the cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone as incision local anesthesia at the end of surgery
223930737|NCT06819748|DRUG|0.5% ropivacaine|The patient receive 0.5% ropivacaine as incision local anesthesia at the end of surgery
223930738|NCT06611111|DRUG|Ceftriaxone (Rocephin®)|Slightly yellow liquid.
223533090|NCT01977365|BEHAVIORAL|Growth promotion based on child centered approach|"\- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~\- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
223930739|NCT06611111|DRUG|Dextrose 5% (D5W)|Colorless liquid
223930740|NCT06936124|PROCEDURE|Deep Brain Stimulation of the Pedunculopontine Nucleus|The DBS implantation procedure targeting the PPN involves a neurosurgical operation performed under general anesthesia. During the procedure, thin electrodes are implanted in the PPN with the aid of advanced pre-operative imaging (MRI and CT scan) to confirm precise targeting. This device generates and transmits electrical impulses to the PPN, which can be adjusted to optimize therapeutic outcomes.
223930741|NCT06938984|DEVICE|Sham Comparator|Massaging the quadriceps with one of the Human TECAR probes with the device turned off for 10 minutes
223930742|NCT06938984|DEVICE|Capacitive mode before|Capacitive mode applied to the quadriceps for 10 minutes
223930743|NCT06938984|DEVICE|Resistive mode before|Resistive mode applied to the quadriceps for 10 minutes
223930744|NCT06938984|DEVICE|Capacitive mode after|Capacitive mode applied to the quadriceps for 10 minutes
223930745|NCT06938984|DEVICE|Resistive mode after|Resistive mode applied to the quadriceps for 10 minutes
223930746|NCT06890585|DRUG|ZCR-CHOP|Zanubrutinib, Chidamide, and Rituximab Induction Therapy Sequentially Combined With or Without CHOP
223930747|NCT06890585|DRUG|R-CHOP|R-CHOP
223533091|NCT01977222|DEVICE|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
223930748|NCT05774002|BEHAVIORAL|Aims to Decrease Anxiety and Pain Treatment (ADAPT)|One pre-operative and 4 post-operative sessions of cognitive behavioral therapy (CBT) treatment in the first two months, beginning 2-3 weeks after surgery, will be completed.
223930749|NCT03580655|DRUG|Avapritinib|Avapritinib tablet
223930750|NCT06291233|BEHAVIORAL|Virtual Interview Training (VIT)|Teachers will administer the intervention (Virtual Interview Training) with the student participants. University of Michigan research staff will train all teachers (including sites in California) and will provide support as necessary throughout the intervention delivery process. Surveys will be captures several times throughout delivery as delivery is expected to be anywhere between 4 to 6 weeks long.
223930751|NCT06291233|BEHAVIORAL|Services-as-usual|Participants will receive services-as-usual at participants school or program for approximately 6 weeks. Those that are in the active control group will receive access to the e-learning content of the Rita/Travis intervention (not the practice interviews) and will be able to review the e-learning content with teacher's supervision. In addition, this group will review a series of video conversations with autistic adults about navigating the pathway to a career. Surveys will be collected at different time points after randomization.
223930752|NCT06324240|BIOLOGICAL|Ipilimumab|Given IV
224095612|NCT06432959|BEHAVIORAL|Psychotherapy, Positive Affect Promoting Activities|"The specific activities that constitute the positive affect interventions will be determined by the therapist and participant collaboratively. Some examples of positive affect promoting activities are:~* Watch videos of animals and babies~* Eat a piece of candy~* Recall and describe a past positive experience~* Describe the positive attributes of the participant~* Engage in gratitude practice~* Do something nice for someone~The in-session positive affect activities will last approximately five minutes. For the first four weeks, the positive affect activities will be completed at the beginning of the session. After that, therapists will look for opportunities to incorporate positive affect activities at stuck points or before learning a new skill in-session. Additionally, therapists will work with participants to identify ways in which the participants can incorporate positive affect activities into their lives between sessions."
224095613|NCT06432959|BEHAVIORAL|Psychotherapy|Meet with treatment providers individually or in group to learn skills to address symptoms associated with depression and emotion dysregulation
224284069|NCT06613269|DRUG|18F-FDG PET/CT|18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.
224284070|NCT06613269|RADIATION|Radiation Therapy|Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.
224284071|NCT06613269|DRUG|Systemic therapy|Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
224284072|NCT01562626|DRUG|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
224284073|NCT01562626|DRUG|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
224284074|NCT01562626|DRUG|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
224284075|NCT01328912|OTHER|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
224284076|NCT01328912|OTHER|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
224284077|NCT03489226|DIETARY_SUPPLEMENT|Capsimax|Capsimax
224284078|NCT03489226|DIETARY_SUPPLEMENT|Placebo|Placebo
224284079|NCT03489226|OTHER|Meal|Meal
224284080|NCT02801435|DRUG|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
224284081|NCT02801435|DRUG|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
224284082|NCT02801435|DRUG|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
224284083|NCT02801435|DRUG|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
224284084|NCT02801435|DRUG|Placebo|Topical administration for twice daily
224284085|NCT02541084|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
224284086|NCT01533649|BEHAVIORAL|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
223930753|NCT06324240|BIOLOGICAL|Pembrolizumab|Given IV
223930754|NCT06324240|BIOLOGICAL|Vaccine Therapy|Given TMV vaccine ID
224284087|NCT01533649|BEHAVIORAL|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
223930755|NCT01078909|BIOLOGICAL|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
223930756|NCT05605613|DRUG|PD-1 Antibody|PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
223533092|NCT01713439|BIOLOGICAL|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10\^7/kg, 10\^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10\^4/kg and rising to 10\^7/kg (10\^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10\^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be \<1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
223533093|NCT02146443|OTHER|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
223533094|NCT02146443|OTHER|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
223930757|NCT05605613|DEVICE|BACE|Bronchial Arterial Chemoembolization
223930758|NCT03140670|DRUG|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
224284088|NCT04487899|DEVICE|Analysis of heart rate variability|The HR HRV interval of the heartbeat (variations in the time interval between beats) was used as a measure of autonomous modulation, and the Firstbeat Bodyguard monitor (Firstbeat Technologies, Jyväskylä, Finland) was used to record HRV data during the session with emergency situations in the flight simulator. Data was downloaded from the devices to a computer using Firstbeat Uploader software (Firstbeat Technologies), and all R-R interval series were imported into the Kubios software package (University of Eastern Finland, Kuopio, Finland). To calculate the autonomous equilibrium, the commonly used HRV method based on the Poincaré graph was used (Brennan et al., 2001; Mourot et al., 2004).
223533095|NCT02146443|DEVICE|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
223930759|NCT04668729|OTHER|Chiropractic Manipulation|"Lumbar vertebrae and sacroiliac joints of the participants that have lost their normal joint motion will be detected by static and dynamic palpation techniques.~Lumbal Chiropractic HVLA Spinal Manipulation: HVLA manipulation will be applied in the left transverse process of the lumbar vertebra (mammillary process) of the participants whose problem is to the left of the lumbar vertebra.~Sacroiliac Chiropractic HVLA Manipulation: Participants who lost normal joint motion in the anterior and superior directions in the left sacroiliac joint will be treated with HVLA manipulation in the left PSIS (Posterior Superior Iliac Spine: PSIS). Participants who have lost normal joint motion in the left sacroiliac joint in the posterior and inferior directions will be applied HVLA manipulation in the left ischial tuberosity.~For both applications, it will be positioned in the opposite position for the problems on the right and the application will be made in the opposite position."
223930760|NCT01577524|DRUG|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
224095614|NCT06502990|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
224095615|NCT02848755|DEVICE|Cranial ultrasonography|
224095616|NCT01290926|DRUG|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
224095617|NCT06054217|DRUG|Vehicle of TP-03|The Exploratory Vehicle is the vehicle of TP-03 (lotilaner ophthalmic solution, 0.25%)
224095618|NCT04791384|DRUG|Abemaciclib|taken orally
224284089|NCT06334861|BIOLOGICAL|Herpes Zoster adjuvanted recombinant vaccine|patients will receive two doses of vaccine with an interval between the first and second dose of 2 months
224284090|NCT00698087|BIOLOGICAL|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
224284091|NCT00698087|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 or 3 doses
223533096|NCT04851574|DRUG|Sugammadex Injection|Sugammadex was administered in the dose of 0.5 Mg/kg or 1.0 Mg/kg or 2.0 Mg/kg to reverse neuromuscular blockade.
223533097|NCT02514343|DRUG|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
223533098|NCT02514343|DRUG|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
223533099|NCT04330976|BEHAVIORAL|Nutrition and physical activity intervention|Messages sent on nutrition and physical activity in pregnancy
223533100|NCT04330976|BEHAVIORAL|Control|Messages sent on general health during pregnancy
224284092|NCT04206722|DEVICE|Shock Wave Therapy|Shock Wave therapy - hip osteoarthritis program
223533101|NCT05378412|BEHAVIORAL|3Cs|The 3Cs program is an educational strategy aimed at fostering resilience and compassion in people. It is based on improving the mental well-being of the participants by transforming their attitudes and behaviors through increased consciousness.
224095619|NCT04791384|DRUG|Elacestrant|taken orally
224284093|NCT04206722|DEVICE|Ultrasound|Ultrasound 0.7W/cm2
224284094|NCT04868864|DIAGNOSTIC_TEST|CT scan|Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system
224284095|NCT04868864|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards
224284096|NCT05301686|PROCEDURE|Patients with Cyclop lesion|Arthroscopy with resection of Cyclop formation
224284097|NCT01087021|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
223930761|NCT01577524|DRUG|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
223930762|NCT00792337|DRUG|simvastatin|10 mg per oral once daily for 8 weeks
223930763|NCT00792337|DRUG|B1-6-12|1 table per day for 8 weeks
223930764|NCT00569634|PROCEDURE|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always \< 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
223930765|NCT02377193|DRUG|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
223930766|NCT02377193|DRUG|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
223930767|NCT00220805|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
223930768|NCT00220805|DRUG|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
223930769|NCT02325466|DRUG|Aspirin|Aspirin 81mg
223930770|NCT02325466|DRUG|Ticagrelor|ticagrelor 90 mg
223930771|NCT02325466|DRUG|Aspirin Placebo|
224095620|NCT05383820|DRUG|Ketorolac|The first group will be administered with Placebo (calcined magnesia), the second group with Ketorolac and the third group with Paracetamol, for all groups the medication will be one capsule every 6 hours for 5 days all study subjects will be sampled Gingival Crevicular Fluid (LGC), Visual Analogue Pain Scale (APS) and Intermolar Space (IS).
224095621|NCT02016014|DEVICE|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
224095622|NCT02016014|BEHAVIORAL|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
224095623|NCT00251602|DRUG|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
224284098|NCT03221452|BEHAVIORAL|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
224284099|NCT03451604|OTHER|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
224284100|NCT06084169|DEVICE|Intra Ocular Lens (IOL) Implant|Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
224284101|NCT06071195|DIAGNOSTIC_TEST|Prostate Cancer Patients|see arm/group description
223930772|NCT02325466|DRUG|Ticagrelor Placebo|
224284102|NCT02960438|DRUG|E6011|subcutaneous administration
223930773|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + Arthroscopic Subacromial Decompression|In addition to the glenohumeral athroscopy a lateral portal will be used to access the subacromial space. The subacromial space will be decompressed with removal of inflamed bursal tissue and acromioclavicular osteophytes, release of the coracoacromial ligament, and, if deemed necessary by the surgeon, acromioplasty performed ad modum Caspari.
223930774|NCT04644042|PROCEDURE|Glenohumeral arthroscopy + lateral skin incision|Glenohumeral arthroscopy is performed as a standard investigational procedure. The patient is put under general anesthesia and positioned in the 'beach chair position'. An anteriorsuperior portal and a posterior mid-glenoid portal are used as entry to the joint. The following structures are investigated as a minimum: the articular surface of the humeral head and the glenoid, labrum, the long biceps tendon and its attachment at the superior labrum, the undersurface of the supraspinatus and the infraspinatus tendon, the subscapularis tendon and the glenohumeral ligaments. To allow for the best possible blinding a skin incision (mimicking the one used for arthroscopic subacromial decompression) is performed on the lateral side of the shoulder of the participants in the control group. The obturator is introduced in the subcutaneous tissue and a slight circular release is performed. The deltoid fascia is not perforated and the subacromial space is not entered.
223930775|NCT06454474|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states.
223930776|NCT01355172|BIOLOGICAL|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
223930777|NCT03351400|BIOLOGICAL|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
224095624|NCT00251602|DRUG|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
224095625|NCT00251602|DRUG|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
224095626|NCT00886938|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
224284103|NCT02960438|DRUG|Placebo|subcutaneous administration
224284104|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) orally
224284105|NCT04815395|DRUG|Oxytocin|Administration of oxytocin (24IU) intranasally
224284106|NCT04815395|DRUG|Placebo|Administration of placebo orally
224284107|NCT02749760|OTHER|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
223930778|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
223930779|NCT02032836|DRUG|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
223930780|NCT02984345|OTHER|Mycoprotein beverage|Mycoprotein protein beverage
223930781|NCT02984345|OTHER|Milk protein beverage|Milk protein beverage
223930782|NCT02867982|PROCEDURE|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
223930783|NCT02867982|PROCEDURE|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
223930784|NCT02867982|DRUG|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
223930785|NCT02867982|DEVICE|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
223930786|NCT02867982|RADIATION|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
223930787|NCT06453174|OTHER|Adherence to the first prescribed antipsychotic medication|We shall compare adherence to the first prescribed antipsychotic medication and pragmatic clinical and functional outcomes between two cohorts of patients with first-episode psychosis. One cohort will be comprised of patients treated before the implementation of an early intervention in psychosis model of Personalised Precision Psychiatry including pharmacogenetics, and the other of patients treated under this new model. Also, we shall compare the pharmacogenetic profiles and possible phenocopies (variations of phenotypes produced environmentally, e.g., due to polypharmacy, rather than genetically) between these first episode psychosis patients and a national cohort of patients with longer-term psychotic disorders or with other mental health conditions, to evaluate potential implications for clinical management at different stages of a psychotic illness, and across mental disorders.
223930788|NCT01818180|DIETARY_SUPPLEMENT|URELL|
223930789|NCT01818180|OTHER|Placebo|
223930790|NCT05370378|OTHER|Hold Relax with Agonist Contraction|"1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished."
223930791|NCT05370378|OTHER|Active Release Therapy|"1. Specific muscle will be warmed up by applying heating pad for 10 to 15 minutes.~2. Patient will be positioned prone lying and the therapist will be standing at the side of affected limb.~3. Therapist will apply deep pressure at the area of tenderness while patient will actively move the limb from internal to external rotation repeatedly.~4. This maneuver will take about 15 minutes to complete in one session and will be applied alternatively 3 days a week for two weeks.~5. After this, cold pack is applied and general ROMs and strengthening exercises are performed to prevent soreness"
223930792|NCT05456932|DRUG|Intravenous iron|Included participants will receive intravenous iron therapy, the dosage will be based on national pharmaceutical formulary.
223930793|NCT05456932|DRUG|Ferric maltol|Included participants will receive oral iron therapy with ferric maltol (twice a day 30mg for 12 weeks)
223930794|NCT05456932|DRUG|Ferrous fumarate|Included participants will receive oral iron therapy with ferrous fumarate (twice a day 100mg for 12 weeks)
223930795|NCT05320094|DRUG|Mavacamten|Specified dose on specified days
223930796|NCT05320094|DRUG|Activated Charcoal with Sorbitol|Specified dose on specified days
223930797|NCT05044598|OTHER|RAFT-OS|RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) is an artificial tissue, populated with limbal epithelial cells and stromal cells.
223930798|NCT06450587|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP)
223930799|NCT06450587|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
223930800|NCT06450587|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
223930801|NCT06450587|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
224095627|NCT03492164|DRUG|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
223930802|NCT05142215|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.
223930803|NCT05142215|PROCEDURE|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.
223930804|NCT06579157|OTHER|Pressure-Sensing Mattresses|using ballistocardiography (BCG) for monitoring respiration and heart rate in neonates
223930805|NCT05971875|PROCEDURE|vNOTES vs Vaginal Hysterectomy|Comparison of vNOTES vs VH
223930806|NCT05971875|PROCEDURE|vNOTES vs Laparoscopic Hysterectomy|Comparison of vNOTES vs LH
223930807|NCT00387452|BEHAVIORAL|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
223930808|NCT00387452|BEHAVIORAL|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
223930809|NCT04029909|DRUG|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
223930810|NCT04029909|DRUG|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
224095628|NCT04234438|DEVICE|SL-MPL treatment protocol was performed with a 577 nm yellow laser (EasyRet, Quantel Medical, Cedex, France)|Macular laser treatment was applied after pupil dilation and topical anesthesia. Laser application was performed with a Mainster Standard contact laser lens (Volk Optical, Mentor, OH, USA). To determine the appropriate personalized calibration value, single-spot test shot was applied under the green filter to a non-edematous area of the macula outside the temporal vascular arcade. The laser power was gradually increased until it formed a barely visible laser spot. The power of the micropulse pattern laser was set at 50% of the power needed to form a barely visible laser spot. Laser parameters used were 200 ms duration, 160 µm spot diameter, low operating cycle (5%), and zero spacing with 5x5 pattern shape. SL-MPL was applied to the areas where edema was detected in OCT and examination.
224095629|NCT04732663|OTHER|No Intervention|Cross-sectional study, no intervention.
224095630|NCT03456479|DIAGNOSTIC_TEST|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
224095631|NCT01179295|DRUG|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
224095632|NCT01179295|DRUG|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
224095633|NCT01179295|DRUG|BAY86-9766|BAY86-9766 100 mg once a day (od)
224095634|NCT01179295|DRUG|BAY86-9766|BAY86-9766 60 mg once a day (od)
224095635|NCT00363415|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
224095636|NCT00363415|DRUG|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
224095637|NCT00363415|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
224095638|NCT04802837|DRUG|Ridinilazole|Ridinilazole 200mg dosed BID for 10 days.
224095639|NCT04802837|DRUG|Vancomycin|Vancomycin 125mg dosed QID for 10 days.
224095640|NCT00117767|DRUG|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
224095641|NCT00117767|DRUG|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
224095642|NCT01722006|BEHAVIORAL|Pairing condition|
224095643|NCT01722006|BEHAVIORAL|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
223533102|NCT00680628|DRUG|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: \<60Kg=30mg; ≥60Kg to \<70Kg=35mg; ≥70Kg to \<80Kg=40mg; ≥80Kg to \<90Kg=45mg; ≥90Kg=50mg"
223533103|NCT00680628|DRUG|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
223533104|NCT06303427|OTHER|Modified constraint-induced movement therapy|"The unaffected arm will be restricted by using an upper extremity sling that will strap to the child's trunk with a distal end fastened to prevent the movement of the unaffected limb.~The modified constraint-induced movement therapy will include these exercises.~1. Playing with ball.~2. Playing with modeling clay.~3. Playing with LEGOS (building towers or different shapes from the toy bricks).~4. Tearing a paper towel from a roll.~5. Holding and eating biscuits.~6. Eating with a spoon.~7. Drinking from a glass.~8. Combing hair.~9. Brushing teeth.~10. Making bubbles using a bubble blower.~11. Pulling a toy.~12. Placing a hat or piece of cloth on the head.~13. Applying lotion to the trained caregiver."
224095644|NCT05449392|DRUG|Neosporin|Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
224095645|NCT05449392|OTHER|Vaseline|The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
224095646|NCT04475094|DRUG|Rubidium-82|Consented subjects will undergo a rest/regadenoson stress myocardial perfusion PET study.
223533105|NCT06303427|OTHER|Electrical stimulation|The participants in this group will first receive a 20-minute session of electrical stimulation (on time of 10 s, off time of 30 s, pulse rate of 35 Hz, the pulse width of 300 µs).
223533106|NCT03243773|OTHER|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
223533107|NCT01612676|DRUG|FE 202158|
223930811|NCT04029909|DRUG|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
223930812|NCT05611060|BEHAVIORAL|Building Healthy Life Skills Program|The intervention provides education and training in the long-term mental and physical health consequences of childhood adversity and emotion regulation skills.
223930813|NCT04657172|DRUG|Pilocarpine Ophthalmic|Pilocarpine 1% or 2% ophthalmic solution administered with the Optejet microdose dispenser
223930814|NCT04657172|DRUG|Placebo|Vehicle ophthalmic solution administered with the Optejet microdose dispenser
224095647|NCT04475094|BEHAVIORAL|Seattle Angina Questionnaire-7|Consented subjects will complete a SAQ-7.
224095648|NCT04475094|BEHAVIORAL|Rose Dyspnea Scale|Consented subjects will complete a RDS.
224095649|NCT05022446|OTHER|Survey Administration|Complete survey
224095650|NCT01128985|DRUG|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
224095651|NCT01128985|DRUG|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
224095652|NCT01128985|DRUG|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
224095653|NCT01128985|DRUG|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
224095654|NCT05988814|DRUG|FOLFIRINOX treatment|"Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.~Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression"
224095655|NCT06962878|PROCEDURE|Xenograft|The jumping gap and surrounding space will be augmented and packed with Xenograft
224095656|NCT06962878|PROCEDURE|Allograft|The jumping gap and surrounding space will be augmented and packed with Allograft
224095657|NCT03220477|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
223930815|NCT04327843|BEHAVIORAL|Customized Adherence Enhancement|Customized Adherence Enhancement (CAE): CAE targets key areas relevant to adherence in chronic psychotic disorders (CPD): 1.) inadequate understanding of mental disorder, 2.) lack of adequate medication-taking routines, 3.) poor communication with care providers and 4.) substance use which interferes with adherence and recovery. CAE delivered components are selected based upon findings from the ROMI and AMSQ. CAE will be delivered in approximately 8 sessions by a nurse interventionist, ideally at the same time that the long-acting injectable (LAI) is administered.The intervention is guided by a detailed manual and uses components and resources that are available in lower- and middle-income countries (LMICs). Social worker interventionists will be trained to deliver CAE-L.
223941320|NCT00691691|RADIATION|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
223533108|NCT04319809|DEVICE|Object recognition subsystem|The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
223533109|NCT04831671|OTHER|Surgical Approach - Infra-patella nailing|The intra-medullary nail will be introduced via an infra-patella incision.
223533110|NCT04831671|OTHER|Surgical Approach - Supra-patella nailing|The intra-medullary nail will be introduced via a supra-patella incision.
223533111|NCT05064722|DEVICE|Self Forming Magnets (SFM)|To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
223533112|NCT03231553|OTHER|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
223930816|NCT04327843|DRUG|Haloperidol Decanoate|Long-acting injectable (LAI): Patients on oral haloperidol will be switched to haloperidol decanoate per manufacturer's package insert. Individuals not on antipsychotic medication at the time of screening assessment or who are on a different antipsychotic medication, will receive an oral tolerance test (OTT) consisting of up to 14 days of oral haloperidol 2-5 mg once or twice daily. If the OTT suggests good tolerability, the participant will then receive LAI (haloperidol decanoate) intramuscularly after completion of baseline assessments. Dosing of LAI will be as clinically indicated using conservative dosing to minimize drug-related adverse effects. In the CWRU studies, mean end-point dose of haloperidol decanoate was 68.0 mg, SD 21.1, Range 50-100 mg/monthly injection. It is anticipated that patients will continue on the same dose for 6 months, although dose changes will be permitted based upon clinical status. Each study participant will receive up to 8 injections during the study.
223533113|NCT05859113|DEVICE|Ziacom Galaxy dental implant with internal connical prosthetic connection|Placement and restoration of a single Ziacom Galaxy dental implant with internal connical prosthetic connection
223533114|NCT05859113|DEVICE|Ziacom Zinic dental implant with internal hexagonal prosthetic connection|Placement and restoration of a single Ziacom Zinic dental implant with internal hexagonal prosthetic connection
223533115|NCT04824833|PROCEDURE|Serratus anterior plane block|local anesthetic application between serratus anterior muscle and 5th rib
223930817|NCT05967858|OTHER|observation|no intervention
223930818|NCT05274321|DEVICE|Nanodropper|Device used for administering eye drops
223930819|NCT05274321|DEVICE|Standard Eye Dropper|Standard Eye Dropper used for administering eye drops
223930820|NCT01223924|OTHER|placebo|placebo
223930821|NCT01223924|DRUG|M2ES|M2ES IV 7.5mg-90mg
223930822|NCT06112600|PROCEDURE|VR|Virtual reality glasses were used as a distraction method for children during vaccination.
224095658|NCT03220477|DRUG|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
224095659|NCT03220477|DRUG|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
224095660|NCT03457961|DRUG|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
224095661|NCT06643455|BEHAVIORAL|Behavioral Dietary Intervention|Participate in the MIND program
224095662|NCT06643455|OTHER|Best Practice|Participate in SOC
224095663|NCT06643455|OTHER|Electronic Medical Record|Ancillary studies
223533116|NCT00641264|DRUG|Omeprazole|
223533117|NCT00641264|BEHAVIORAL|Quality of Life questionnaire|
223533118|NCT03383042|DRUG|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
223533119|NCT03383042|DRUG|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
223930823|NCT06112600|PROCEDURE|Kaleidoscope|Kaleidoscope toys were used as a distraction method for children during vaccination.
223930824|NCT04738201|OTHER|Proprioceptive thumb exercises.|Exercises for recognition of thumb position and thumb force sense.
223930825|NCT03791996|PROCEDURE|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
223930826|NCT01105975|DRUG|LY2484595|Administered daily by mouth for 12 weeks
223930827|NCT01105975|DRUG|Atorvastatin|Administered daily by mouth for 12 weeks
223930828|NCT01105975|DRUG|Simvastatin|Administered daily by mouth for 12 weeks
223930829|NCT01105975|DRUG|Rosuvastatin|Administered daily by mouth for 12 weeks
223930830|NCT01105975|DRUG|Placebo for LY2484595|Administered daily by mouth for 12 weeks
223930831|NCT01105975|DRUG|Placebo for Statins|Administered daily by mouth for 12 weeks
223930832|NCT00902213|BEHAVIORAL|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
223930833|NCT00902213|BEHAVIORAL|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
223930834|NCT05909449|OTHER|exercises|participants will be given a structured home exercise program
224284108|NCT02749760|OTHER|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
224284109|NCT01647711|DRUG|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
224284110|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M2
224284111|NCT02322788|DRUG|Terbutaline sulphate|Bricanyl Turbuhaler M3
224284112|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
224284113|NCT02322788|DRUG|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
224284114|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
224284115|NCT01578668|DRUG|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
224284116|NCT01578668|DRUG|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
224284117|NCT01578668|DRUG|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
224284118|NCT02611011|DEVICE|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
224284119|NCT01556282|DEVICE|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
224284120|NCT01014416|DRUG|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
224284121|NCT00754013|DRUG|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
223533120|NCT03383042|DRUG|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
223533121|NCT03383042|DRUG|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
223533122|NCT03383042|DRUG|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
223533123|NCT03383042|DRUG|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
223533124|NCT03383042|DRUG|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
223930835|NCT06062641|DRUG|SR-GDP|Selinexor 40mg/d，po d1,8,15; rituximab 375mg/m2, iv d1; gemcitabine 1g/m2, iv d1,8; cisplatin 25mg/m2, iv d1-3; dexamethasone 40mg，po/iv d1-4 (If patient\>70y, the dosage should be changed to 20mg). Each cycle lasts for 21 days, with a maximum of 6 cycles of combination therapy. For patients who achieved PR or better response at the end of combination therapy, they will start receiving single-agent selinexor 40mg treatment (qw) in cycles of 28 days until disease progression (PD) or unacceptable toxicity occurs.
223930836|NCT06234683|OTHER|Web-based educational video on pneumococcal vaccination|Participants will receive a link to view a short video on pneumococcal vaccination.
223930837|NCT06234683|OTHER|Reminder email to be vaccinated|Participants will receive a reminder email to be vaccinated.
223930838|NCT05647889|DRUG|Jet lidocaine|Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
223930839|NCT05647889|COMBINATION_PRODUCT|Ice|Ice will be applied for 1 minute before PVC, and then PVC will be performed.
223930840|NCT05647889|OTHER|Standard PVC procedure|Standard PVC procedure will be applied
223941321|NCT03726593|DRUG|Artesunate and Pyronaridine|Standard weight based dosing
223941322|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
224095664|NCT06643455|OTHER|Questionnaire Administration|Ancillary studies
224284122|NCT00754013|DRUG|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
224284123|NCT04039919|DRUG|Padsevonil|Padsevonil will be administered in predefined dosages.
224284124|NCT04039919|DRUG|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
224284125|NCT05406024|DEVICE|Digital platform|The digital platform consists of 84 exercise sessions of progressive intensity. Each day, the tool offers 8 exercise sessions of about 5 to 10 minutes each, spaced out over an hour. One session can represent several exercises. The patient is asked to perform them daily.
224284126|NCT00983918|DRUG|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
224284127|NCT00983918|DRUG|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
223533125|NCT03383042|DRUG|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
223930841|NCT06637111|PROCEDURE|Ultrasound guided office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem. The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia.~Transabdominal ultrasound will be used to guide the access of the hysteroscope to the uterine cavity"
223930842|NCT06637111|PROCEDURE|Conventional office hysteroscopy group|"One hour before office hysteroscopy, 100 mg of diclofenac potassium will be administered per orem . The patients will be asked to drink about one liter of water and to avoid urination before the procedure Moreover, a few minutes prior to the office hysteroscopy, 3 ml of 5% lidocaine and prilocaine topical cream will be introduced into the endocervical canal.~All the procedures will be performed using the vaginoscopic technique. A rigid 2.9-mm hysteroscope with a 30° lens and a 5-mm outer sheath (Karl Storz GmbH, Tuttlingen, Germany) will be used in all procedures.~A 5 Fr grasper and 5 Fr scissors will be used to widen the stenotic internal or external ostia."
223930843|NCT03658616|DRUG|WO3970|Application of cream to each axilla
223930844|NCT03658616|DRUG|Placebo (WO3988)|Application of cream to each axilla
223930845|NCT00179751|DRUG|CC-5013|
223930846|NCT00179751|DRUG|gemcitabine|
223930847|NCT03562338|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
223930848|NCT03562338|OTHER|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
223533126|NCT03383042|DRUG|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
223533127|NCT06105866|DIAGNOSTIC_TEST|Tricuspid Annular Plane Systolic Excursion|Transthoracic echocardiography will be performed on patients during hospitalization and preoperatively to investigate the relationship between preoperative fasting and right ventricular functions. This will be examined by looking at TAPSE
223533128|NCT01605669|OTHER|Tranthoracic Echocardiogram|standard measurement
223533129|NCT01605669|DEVICE|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
223533130|NCT04675827|DRUG|Pertuzumab and tratuzumab fixed dose combination|Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
223533131|NCT04675827|DRUG|Trastuzumab emtansine|Treatment administration: adjuvant T-DM1 for 14 cycles.
223533132|NCT04589897|DEVICE|Manuka honey sinus rinse|Will follow a modified NHS nasal rinse protocol with the addition of manuka honey
223533133|NCT04589897|DEVICE|Standard sinus rinse|will follow the standard NHS nasal rinse protocol
223533134|NCT04389073|DRUG|Vinorelbine 40mg|Two tablets per day, three times a week. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223533135|NCT04389073|BIOLOGICAL|Toripalimab 240mg|Toripalimab 240 MG IV infusion every 3 weeks. Toripalimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223533136|NCT04389073|BIOLOGICAL|Bevacizumab 5 mg/kg|Bevacizumab 5 mg/kg IV infusion every 3 weeks. Bevacizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223930849|NCT00612209|DRUG|ARQ 197|Treatment with ARQ 197
223930850|NCT05088798|DRUG|18F-Fluoro Dopa PET/MRI Imaging|The purpose of this research study is to provide access to an imaging study of the pancreas that uses 6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET) and assess the accuracy of this 18F-DOPA-PET/MRI test on distinguishing what part of the pancreas is affected in patients with Hyperinsulinism.
223930851|NCT00570466|BEHAVIORAL|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
223930852|NCT00570466|BEHAVIORAL|Web and DVD knowledge|Web and DVD based knowledge games
223930853|NCT00982644|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
223930854|NCT00982644|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
223930855|NCT02695134|OTHER|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
223930856|NCT03765658|DRUG|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
223533137|NCT04389073|DRUG|Cyclophosphamide 50 mg|50 mg per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
224095665|NCT06577675|BEHAVIORAL|Group programme for DBT training|This programme comprises 16 sessions over approximately 5 to 6 months, with one 2.5-hour session every week in a closed group of 8 patients. These sessions will be supervised by two or four carers trained in DBT.
224095666|NCT05027802|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day.
224095667|NCT04318366|OTHER|Observational Study|Not required
224284128|NCT00983918|DRUG|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
223930857|NCT03765658|DRUG|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
223930858|NCT00909649|PROCEDURE|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
223930859|NCT04994795|OTHER|Predictive models (data collection)|Machine learning predictive models
223930860|NCT00477893|DRUG|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
223930861|NCT00477893|DRUG|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
223930862|NCT03997994|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
223930863|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management and Dietary Fiber|Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
223930864|NCT04690075|DIETARY_SUPPLEMENT|Nutrition Management|Routine nutrition management for 12 weeks.
223930865|NCT05599815|DRUG|ADX-629|ADX-629 (250 milligrams) administered twice daily
223930866|NCT00943917|OTHER|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
223930867|NCT00943917|DRUG|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
223930868|NCT00943917|OTHER|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
224095668|NCT03797560|OTHER|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
224095669|NCT03797560|DRUG|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
224095670|NCT05898074|DEVICE|Non-Absorbable Packing (Silastic Splint)|Participant will have silastic splint applied to nasoseptal flap harvest site
224095671|NCT05898074|DEVICE|PuraGel (RADA16) Hydrogel|Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site
224095672|NCT06059586|BEHAVIORAL|Pelvic health therapy|Female Sexual Function Index (FSFI) and VAS Pain Scale Questionnaires, Physical Therapy Evaluation including Pelvic Floor Muscle Examination, Dilator Education
224095673|NCT06059586|DEVICE|Dilator feasability|Patient Adherence to Vaginal Dilation Questionnaire
224095674|NCT05932732|DEVICE|HydraFacial Syndeo System|Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
224095675|NCT05932732|DRUG|ReGen-GF|The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
224095676|NCT05932732|DEVICE|HydraFacial Elite MD System|Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.
224284129|NCT00983918|DRUG|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
223930869|NCT02766296|BEHAVIORAL|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
223930870|NCT02766296|BEHAVIORAL|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
223930871|NCT05538494|OTHER|BFR intervention|"Training is applied to this group using low-load exercises with restriction of blood flow. Based on the variables used by the major part of the protocols used in studies on the ERFS, the protocol that will be applied to this group will consist of the following parameters.~* Training: 1 series of 30 repetitions followed by 3 series of 15 repetitions of squats~* Rest between series: Duration of 45 seconds.~* Workload: 30% of 1RM.~* Cadence: 2 seconds for the concentric phase and 2 seconds for the eccentric phase (2:2).~* Cuff pressure: The inflation pressure will be individualized for each individual.~A pressure equivalent to 80% of the minimum pressure necessary for the total occlusion of the femoral artery.~• Cuff placement: proximal quadriceps."
223930872|NCT05538494|OTHER|High load intervention|"A program will be applied to this group of exercise with high loads as a method of treatment in which the following will be applied parameters:~* Training: 4 series of 12 repetitions of squats.~* Rest between series: Duration 2 minutes.~* Workload: 70% of 1RM."
223930873|NCT00068458|DIETARY_SUPPLEMENT|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
223930874|NCT00068458|OTHER|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
223930875|NCT00068458|OTHER|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
223930876|NCT06133530|DIETARY_SUPPLEMENT|Human milk oligosaccharides|Prebiotic
223930877|NCT06133530|DIETARY_SUPPLEMENT|Maltose|Control
223930878|NCT05150873|OTHER|CTA evaluation|Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
223930879|NCT01171976|DRUG|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
224284130|NCT03736187|DRUG|Cephalexin|Giving cephalexin and metronidazole in one group \&cephalexin alone in another group
223533138|NCT04389073|DRUG|Capecitabine 500Mg Oral Tablet|500mg three times a day. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223533139|NCT04389073|DRUG|Cisplatin|Cisplatin 50mg/m2 IV infusion every 3 weeks. Cisplatin will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223533140|NCT00107276|DRUG|capecitabine|
223930880|NCT00288288|PROCEDURE|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
223930881|NCT00288288|PROCEDURE|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
223930882|NCT05093062|OTHER|Tian Jiu Therapy|
223930883|NCT01241526|OTHER|Disease Management|"* Individual, group and phone education sessions~* Telephone supporter follow-up~* LTOT monitoring"
223930884|NCT01241526|OTHER|Usual site management|"* Usual education as per site protocol~* Usual follow-up as per site protocol~* LTOT monitoring"
224095677|NCT05347407|PROCEDURE|Colonoscopy|Patients will be provided with a kit and be asked to bring a stool sample to their colonoscopy appointment. Mucosal biopsies will be collected with standard forceps during colonoscopy. If the physician determines that the patient will need colonoscopy with biopsy as part of their routine clinical care, they will take 6-8 additional biopsies for use in the research study. If the physician determines that the patient will need colonoscopy without biopsy as part of their routine clinical care, they will take 6-8 biopsies for use in the research study only. The collection of additional biopsies will add an estimated two minutes to the whole procedure.
224095678|NCT05753254|OTHER|Firefighting training exercises with no fire|The participants will be performing firefighting equivalent work in a clean environment, without fire (no ambient temperature, soot or smoke).
224095679|NCT05753254|OTHER|Firefighting training exercises under wood fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under wood fire conditions.
224095680|NCT05753254|OTHER|Firefighting training exercises under gas fire|The participants will be in teams performing pre-defined tasks (knocking down the fire, moving heavy objects, and searching and rescuing metal stand in models), under gas fire conditions.
224095681|NCT03452839|DRUG|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
224095682|NCT06150599|DEVICE|Sacral neuromodulation|Interstim X, which includes an implantable pulse generator and lead, will be implanted surgically in a single-stage procedure.
224095683|NCT03826875|DRUG|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
223533141|NCT00107276|DRUG|cyclophosphamide|
223533142|NCT06476678|DEVICE|Speedboat™ Ultraslim|Use of Speedboat™ Ultraslim for performing endoscopic submucosal dissection of esophageal lesions.
224095684|NCT03826875|DRUG|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
223533143|NCT02980107|OTHER|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
223533144|NCT02980107|OTHER|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
223533145|NCT00945659|DEVICE|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
223930885|NCT04473703|DRUG|renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor|Patients with odd random number will treat with RASI（renin-angiotensin system inhibitors）, and those with even random number will treat with ARNI（angiotensin-receptor-neprilysin inhibitor）
223930886|NCT04640584|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
224095685|NCT04889274|BIOLOGICAL|COVID-19 vaccine|COVID-19 vaccine as offered by NHS England
224095686|NCT04889274|BIOLOGICAL|Concentrate beetroot Juice|Beetroot juice containing approximately 5mmol/l nitrate
224095687|NCT04889274|BIOLOGICAL|Nitrate-deplete beetroot juice|Beetroot juice with nitrate removed
224095688|NCT06093672|DRUG|Givinostat|Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.
224284131|NCT02477852|DRUG|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
224284132|NCT02477852|DRUG|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
224284133|NCT02477852|DRUG|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
224284134|NCT02477852|DRUG|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
224284135|NCT05918822|DRUG|Maribavir Commercial Tablet Formulation|Maribavir commercial tablet.
224284136|NCT05918822|DRUG|Maribavir Pediatric Powder-for-oral Suspension Formulation|Maribavir pediatric powder-for-oral suspension.
224284137|NCT05918822|DRUG|Rabeprazole|Rabeprazole tablet.
224284138|NCT01739725|DEVICE|Stent insertion|The patient will receive the helical stent
223533146|NCT00945659|OTHER|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
224284139|NCT02804555|OTHER|Oxygen|Oxygen administration
224284140|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules|As previously published
224284141|NCT01205841|PROCEDURE|Buffalo Rule|As previously published
223533147|NCT00945659|BEHAVIORAL|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
223533148|NCT04626102|BEHAVIORAL|Healthy Eating Attitudes and Behaviours Group Program (Experimental Group Condition)|"The program has been developed by Clinical Psychologist Başak İnce and Psychiatrist Prof. Dr Başak Yücel. The session topics and contents of this program were based on the Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and 10-week online version of StudentBodies program designed by Saekow and her colleagues (2015). Program protocol was written based on Fairburn (2008)'s book titled Cognitive- Behavior Treatment and Eating Disorders and Fursland and her colleagues (2007)'s book titled Overcoming Disordered Eating.~This program aimed to inform participants about the causes and consequences of eating disorders, teach cognitive and behavioural techniques to change their unhealthy eating attitudes and behaviours, and provide support during their attitudinal and behavioural changes. Each week, participants were asked to complete homework activities which were related to topics covered in each session."
223930887|NCT04030585|DEVICE|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
223930888|NCT04030585|OTHER|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
224095689|NCT06093672|DRUG|Hydroxyurea|Oral. The dosage must be modified, according to the manifestation of toxicities or lack of efficacy, with the aim to achieve an optimized dose.
223941323|NCT03726593|DRUG|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
223941324|NCT02980588|DEVICE|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
223941325|NCT04482413|DRUG|AstroStem|Treatment group receive AstroStem(Autologous adipose tissue derived mesenchymal stem cells, AdMSCs) every 4 weeks from Week 0 to Week 36.
223941326|NCT04482413|DRUG|Placebo|Placebo control group receive 20 mL of Saline and auto serum every 4 weeks from Week 0 to Week 36.
223930889|NCT04740944|BEHAVIORAL|Salutogenic Approach Based Interview|Salutogenic Approach Based Interview has five basic components. (1) Continuity of health, (2) The story of the person, (3) Health promoting factors, (4) Understanding the health promoting power of tension and strain, (5) Active adaptation In traditional therapy recommended for recovery, more emphasis is placed on negative life events, diagnosis and medication. In the salutogenic approach-based interview, the resources and coping potential of the person are discussed and three healing factors are focused on for the recovery process. These factors are that the participants (1) perceive themselves as more than just a diagnosis and disease, (2) self-discovery and respect for other people's self-discovery, (3) control over their own lives. In the intervention, mental health nurses take part as group leaders. The focus in interviews is therapeutic conversations.
223930890|NCT05443464|BIOLOGICAL|OSSM-001|Direct IV infusion of OSSM-001
223930891|NCT03948542|OTHER|Outcome|"Nerve Recovery~* NCV~* Funcional assessment"
223930892|NCT06570629|DEVICE|Oronasal CPAP|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
223930893|NCT06570629|DEVICE|Nasal CPAP plus Chinstrap|In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.
224095690|NCT06108050|DRUG|JZP898|Investigational drug monotherapy
224095691|NCT06108050|DRUG|Pembrolizumab|Anti-PD1 antibody
223930894|NCT05378347|DEVICE|Medtronic Endurant II or Endurant IIs Stent Graft System|EVAR treatment with Medtronic Endurant II/IIs Stent Graft System
223930895|NCT05378347|DEVICE|Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis|EVAR treatment with Excluder / Excluder Conformable Stent Graft System
224095692|NCT05344833|DRUG|Isatuximab|Isatuximab 10mg/kg IV Days 1,8, 15, 22 Cycle 1 (all cycles 28 days). Isatuximab 10mg/kg Days 1, 15 Cylces 2 and 3. Isatuximab 10mg/kg Day 1, Cylces 4-39.
224095693|NCT05344833|DRUG|Lenalidomide|Lenalidomide 15mg PO Days 1-21 Cycle 4 and can continue until disease progression.
224095694|NCT02884635|DRUG|ASP1707|Oral
224095695|NCT02884635|DRUG|Placebo|Oral
223718248|NCT04034836|DRUG|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
223930896|NCT04436250|DRUG|Active comparator|The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
223930897|NCT04436250|DRUG|S-Ketamine Low dose|The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
223930898|NCT04436250|DRUG|S-Ketamine High dose|The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
223930899|NCT06239831|DEVICE|ExSpiron and ActivPAL Monitors|ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
224095696|NCT02884635|DRUG|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
224095697|NCT03872180|DRUG|Bendamustine|Given IV
223718249|NCT06774872|DRUG|Doravirine 100Mg Tab and Lamivudine 300 Mg Tab|"Participants randomised in the arm 1 will receive the DORAVIRINE/LAMIVUDINE combination: doravirine (PIFELTRO®) 100 mg 1 pill a day + lamivudine 300 mg 1 pill a day"
223930900|NCT02711332|OTHER|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
223930901|NCT02711332|OTHER|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
224095698|NCT03872180|BIOLOGICAL|Obinutuzumab|Given IV
224095699|NCT03872180|DRUG|Venetoclax|Given PO
224095700|NCT03733041|DEVICE|rTMS|This group will receive rTMS treatment
224095701|NCT03733041|DEVICE|Sham|This group will receive sham treatment
224095702|NCT03733041|OTHER|No intervention|This group will receive no intervention
224095703|NCT01506141|DRUG|Idursulfase-IT|Idursulfase-IT once monthly via IDDD.
224095704|NCT01506141|DRUG|Elaprase|Weekly IV infusions of commercially available Elaprase.
223533149|NCT04626102|BEHAVIORAL|Eating Disorders and Body Dissatisfaction: A Group Work (Active Control Group Condition)|"This single-session group program was designed as an active control group for the purpose of this study. The content of the program was prepared based on Stice and his colleagues (2013)'s four - sessions Body Project eating disorders prevention program. This single-session program aimed to inform participants about causes and consequences of eating disorders, and discuss thin ideal messages created by media and the negative impact of these messages on women's body images, and address possible ways of countering these messages. Detailed information regarding the covered topics and video presentations in the group session is provided below."
223533150|NCT03064828|RADIATION|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
223533151|NCT03064828|RADIATION|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
223533152|NCT05184556|BEHAVIORAL|Family-based treatment (FBT)|FBT is a structured behavioral treatment focused on empowering caregivers to take charge of the adolescent's eating behavior and return him/her to a normative weight and developmental trajectory. FBT involves three consecutive phases: 1) caregivers are fully in control of the adolescent's eating; 2) control of eating is gradually returned to the adolescent; and 3) developmental issues are explored. In the current study, FBT is adapted for delivery in the home setting in the following ways: intensified dose of treatment (2-6 hours of therapy per week over 10 - 32 weeks); use of clinician as an additional support to the family; multiple family meals in the home and community; sociocultural tailoring; and inclusion of supplemental individual work with the adolescent to improve emotion regulation/distress tolerance.
223718250|NCT06774872|DRUG|Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab|"Participants randomised in the arm 2 will receive the DTG/3TC combination: dolutegravir 50 mg/lamivudine 300 mg (DOVATO®) 1 pill a day"
223718251|NCT06511037|DRUG|Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging|Given IV
224095705|NCT05561751|DRUG|GPC-100|GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min
224095706|NCT05561751|DRUG|Propranolol|propranolol
224095707|NCT05561751|DRUG|G-CSF|G-CSF
223930902|NCT03433794|BEHAVIORAL|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
223533153|NCT05184556|BEHAVIORAL|Integrative family therapy|The integrated family therapy approach includes psychoeducation, supportive family therapy, and elements of cognitive-behavioral interventions. Families may be referred for additional nutritional counseling and prescribed a meal plan as indicated. Typical strategies include educating families on the presentation and prognosis of adolescent AN; identifying dysfunctional family structures/alliances and communication patterns; using reflective listening to engage and validate family members; challenging maladaptive beliefs about eating and weight; and supporting families in developing strategies for management of both general and eating disorder-specific distress. Treatment is generally non-directive.
223533154|NCT02041767|DRUG|Ertapenem|One single injection of 1g of ertapenem before surgery
223930903|NCT03433794|BEHAVIORAL|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
224095708|NCT06408363|BEHAVIORAL|Maneuver group|These maneuvers for Eustachian tube opening will be performed continuously during the compression phase of the hyperbaric chamber, every 30 minutes after reaching the desired pressurization level, and continuously during the decompression phase.
224095709|NCT04677647|OTHER|OurChild mHealth Digital Platform|The intervention being created and tested in this study is OurChild an integrated mHealth/EHR app, initially designed for the Chinese American community in Sunset Park, Brooklyn. All participants will be assigned to either beta versions undergoing development, or to version 1.0.
223930904|NCT03433794|BEHAVIORAL|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
224095710|NCT04607408|BIOLOGICAL|CH505TF gp120|HIV-1 CH505 transmitted/founder virus Env gp120 immunogen
223533155|NCT05514288|PROCEDURE|Endobariatric procedure|Endoscopic sleeve gastroplasty or transoral outlet reduction
223533156|NCT03108196|PROCEDURE|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
223930905|NCT05425953|OTHER|No intervention other than obtaining biopsies|Biopsies will be obtained.
223930906|NCT02754596|DRUG|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
224095711|NCT04607408|BIOLOGICAL|GLA-SE adjuvant|An oil-in-water stable emulsion (SE) containing the immunological adjuvant Glucopyranosyl Lipid A (GLA)
224095712|NCT04607408|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9% USP
224095713|NCT06273527|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
224095714|NCT06273527|OTHER|Sham Program|The Sham Program will be a similar task which researchers think will be less effective in training thinking skills.
224095715|NCT05910892|DRUG|Aromatherapy packet|5 deep breaths from packet prior to treatment
224095716|NCT05910892|DRUG|Placebo packet|5 deep breaths from packet prior to treatment
224284142|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
224284143|NCT01205841|PROCEDURE|Thompson Test|As previously published
224284144|NCT01205841|PROCEDURE|Palpation of the fibula|Palpation of the fibula over its entire length.
224284145|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
224284146|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
224284147|NCT01205841|PROCEDURE|Malleolar Zone Algorithm|As previously published
224284148|NCT01205841|PROCEDURE|Low Risk Exam|As previously published
224284149|NCT01205841|PROCEDURE|Bernese Ankle Rules|As previously published
224284150|NCT01205841|PROCEDURE|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
224284151|NCT02604472|OTHER|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
224284152|NCT02604472|OTHER|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
224284153|NCT01572519|DRUG|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
224284154|NCT01572519|DRUG|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
224284155|NCT01572519|DRUG|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
224284156|NCT01572519|DRUG|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
224095717|NCT04726748|PROCEDURE|Comparisons between the Prostatic urethral lift (PUL) and the TURP/Laser cohorts|"Comparison between the PUL and the TURP/Laser cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables."
224095718|NCT04726748|PROCEDURE|Comparison between the Prostatic urethral lift (PUL) and the SNDS cohorts|"Comparison between the PUL and the SNDS cohorts will be performed after 1 year and 3 years of follow-up in a intention-to-treat analysis using:~* a linear regression model when it involves quantitative variables,~* a logistic regression model adjusted on potential confounding when it involves qualitative variables."
223930907|NCT02754596|DRUG|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
224284157|NCT01572519|DRUG|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
224284158|NCT02560974|DRUG|Capecitabine|Capecitabine will be administered orally at 1000 mg/m\^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
224284159|NCT02560974|DRUG|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m\^2 on Day 1 of each 3-week cycle for 8 cycles.
224284160|NCT01106521|RADIATION|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
223930908|NCT02754596|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
223930909|NCT03778515|DIAGNOSTIC_TEST|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
223930910|NCT05461235|DRUG|Pembrolizumab|2mg/kg or 200mg,iv,q3w
223930911|NCT05461235|DRUG|Nivolumab|3mg/kg or 240mg,iv,q2w
223930912|NCT05461235|DRUG|Sintilimab|200mg,iv,q3w
223930913|NCT05461235|DRUG|Toripalimab|3mg/kg or 240mg,iv,q2w
223930914|NCT05461235|DRUG|Camrelizumab|200mg,iv,q2w or q3w;3mg/kg,iv,q3w
224284161|NCT00832221|DRUG|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
224284162|NCT00832221|DRUG|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
224284163|NCT00832221|DRUG|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
223930915|NCT05461235|DRUG|Tislelizumab|200mg,iv,q3w
223930916|NCT05461235|BIOLOGICAL|NK-Cell or DC-Cell|50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.
223930917|NCT04086849|DIAGNOSTIC_TEST|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
223930918|NCT02804074|OTHER|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
223930919|NCT02804074|OTHER|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
223930920|NCT04042532|DEVICE|Theta-burst stimulation (TBS)|We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
223930921|NCT03049072|RADIATION|Protons and Carbon Ions|
223930922|NCT06153628|OTHER|Virtual reality glasses|Videos consisting of nature and undersea images will be played through virtual reality glasses, which the woman wants to watch and can change whenever she wants.
224284164|NCT00374075|DRUG|Valproic Acid|
224284165|NCT06052020|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
223930923|NCT05783869|DEVICE|Echocardiography|echocardiographic study of both groups
224284166|NCT06052020|DRUG|Atorvastatin|Atorvastatin 20-40mg
224284167|NCT06403072|DIAGNOSTIC_TEST|The Gynecologic Imaging-Reporting and Data System (GI-RADS)|The Gynecologic Imaging-Reporting and Data System (GI-RADS) using ultrasound
224284168|NCT00699530|OTHER|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
224284169|NCT03100890|OTHER|Preoperative training (hospital)|Preoperative hospital training
224284170|NCT03100890|OTHER|Preoperative training (home)|Preoperative in-home training
224284171|NCT02380079|DRUG|SCD-101|Administered as gelatin capsules
224284172|NCT05619159|DEVICE|microscopic pathological evaluation|description of moesin expression between endometrial hyperplasia and endometrial carcinoma
223533157|NCT03108196|PROCEDURE|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
224284173|NCT01757899|DRUG|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
223533158|NCT06746428|BEHAVIORAL|Exercise Coaching|An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.
223533159|NCT05140239|OTHER|No Intervention|Non Interventional
223930924|NCT05468034|BEHAVIORAL|Exercise Intervention|Eligible and consented participants randomized to the exercise arm (EX) will work with an exercise trainer 3x weekly for 16 weeks. Training sessions are 60 min. Schedules are determined by participant and trainer with oversight by the study team, ideally occurring at similar times each day in line with IBC theory. Each training session will be delivered virtually over a HIPAA compliant IU Health Zoom platform. The virtual exercise sessions include 3 parts: cardiovascular exercise, resistance training, and balance or stretching exercise. During sessions, patients will wear provided heart rate monitors with a training goal of moderate intensity, defined as 40-60% of heart rate reserve. Based on the participant's rate of perceived exertion (RPE), heart rate, and individual response during each session, trainers will follow an algorithm designed by the PI and collaborators to progress or regress intensity level. Participant will attend a class on creating and maintaining behavior changes.
223930925|NCT06454604|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
223930926|NCT00104741|DRUG|flutamide|
223930927|NCT00104741|DRUG|triptorelin|
223930928|NCT00104741|RADIATION|radiation therapy|
223930929|NCT03357952|DRUG|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
223930930|NCT03357952|DRUG|JNJ-63723283|Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
223930931|NCT04144907|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
223930932|NCT02533973|DRUG|Xamiol® gel|
223930933|NCT02533973|DRUG|Daivonex® scalp solution|
224284174|NCT01757899|DRUG|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc \[methylprednisolone + diluting fluid\], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
223533160|NCT03232918|DRUG|Half dose Oxytocin|Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
223533161|NCT00216190|DRUG|Dexmedetomidine HCL Injection|
223533162|NCT00216190|DRUG|Midazolam Injection|
223533163|NCT02026167|BEHAVIORAL|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
223533164|NCT05601128|DRUG|CAB + RPV|At Day 1 all participants will initiate oral CAB 30 mg + RPV 25 mg once daily for at least 28 days during the Oral Phase. Participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections at month 1 visit followed by CAB LA 400 mg + RPV LA 600 mg IM injections monthly at M2, M3, M4 and M5 visits. Then, starting at month 6 visit, participants will receive CAB LA 600 mg + RPV LA 900 mg IM injections every 2 months at M6, M8, M10 and M12.
223533165|NCT06572072|DEVICE|Negative Pressure Ventilation|Substitution of positive pressure ventilation by negative pressure ventilation
223533166|NCT05905172|DRUG|Hydronidone capsules|After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
223930934|NCT06827067|BEHAVIORAL|Simulation application with standard patient|Before the encounter with the standard patient (SH), a preliminary interview was held with the nurses in the briefing room, where the content and purpose of the application were explained to the nurses, and the story of the SH was told to the nurses in line with the prepared scenario. Three nurses were interviewed for each scenario. The nurses communicated with the SH for 10-15 minutes and each interview was conducted using video recordings. Those who finished the interview with the SH watched the scenario of the other group as observers, and at the end of each 3 scenarios, the debriefing phase was carried out for an average of 60-90 minutes.
223930935|NCT06827067|BEHAVIORAL|Theoretical training|The trainings, each of which lasted 40-45 minutes on average, were conducted in a total of 7 sessions.
223930936|NCT01371994|DRUG|solifenacin succinate|oral
224095719|NCT04986007|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia|Digital cognitive behavioral therapy for insomnia is an automated, internet-based delivery system for the core components of cognitive behavioral therapy for insomnia (CBT-I). For this trial, dCBT-I will be delivered using Sleep Healthy Using the Internet (SHUTi), which delivers the core content of CBT-I in 6 interactive lessons called Cores: Getting Ready; Sleep Scheduling; Sleep Practices; Thinking Differently; Sleep Hygiene; and Moving On. The primary therapeutic approaches deployed through these cores are stimulus control and sleep restriction. The minimum acceptable dose for this study is completion of 4 out of 6 cores; completion of fewer than 4 cores will be considered a dropout.
224095720|NCT06304233|DIAGNOSTIC_TEST|Echocardiography|ultrasound assessment of heart structure, volume and function
224095721|NCT06304233|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|MRI assessment of heart structure, volume, function and tissue characteristics
224095722|NCT06304233|DIAGNOSTIC_TEST|Electrocardiography|Assessment of cardiac rhythm and electrical activity
224095723|NCT06304233|OTHER|Blood sampling|To measure DISC1 mRNA expression and other potential biomarkers
224095724|NCT04497285|OTHER|blood sample collection and collection of tumor tissue block|blood sample collection and collection of tumor tissue block
224095725|NCT05491200|DRUG|Prasugrel based short DAPT|Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus
224095726|NCT05491200|DRUG|Prasugrel based standard DAPT|Prasugrel based DAPT for 1 year
224095727|NCT05491200|DEVICE|OCT guided revascularization|OCT guided revascularization of the non-culprit lesions
224095728|NCT05491200|DEVICE|Angio guided revascularization|Angio guided revascularization of the non-culprit lesions
224095729|NCT06334939|DEVICE|Bispectral Index Monitoring|"Study patients will undergo perioperative bispectral index and BIS suppression ratio (SR) monitoring under anesthesia. The lowest BIS and BIS SR values and the values taken at 10-minute intervals will be recorded throughout the case.~The Richmond agitation scale will be calculated in the recovery room after anesthesia."
224284175|NCT06130787|BIOLOGICAL|Blood and bone marrow sample|"Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36"
224284176|NCT03328728|DEVICE|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
224284177|NCT03328728|DEVICE|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
224284178|NCT02994628|OTHER|Water|Water only without carbohydrate
224284179|NCT02994628|OTHER|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
224284180|NCT02994628|OTHER|Cavendish banana|Ingest Cavendish banana (common banana)
224284181|NCT02994628|OTHER|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
223533167|NCT05905172|DRUG|The placebo capsules|After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
223533168|NCT04562116|DRUG|Nemolizumab|Nemolizumab 30 mg will be administered as SC injections.
223533169|NCT04562116|DRUG|CYP 450 Substrates|CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.
223533170|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
223533171|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
223930937|NCT01371994|DRUG|Placebo|oral
223930938|NCT03151798|BEHAVIORAL|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
223930939|NCT03151798|BEHAVIORAL|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
223930940|NCT03151798|OTHER|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
223930941|NCT06827587|DRUG|Efgartigimod + Telitacicept (1-week interval) group|"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 25 weeks (Week 5 to Week 29)"
223930942|NCT06827587|DRUG|Efgartigimod + Telitacicept (2-week interval) group|"Drug 1: Efgartigimod~Generic Name: Efgartigimod Formulation: Injection (Intravenous) Dose: 10 mg/kg Frequency: Once a week Route of Administration: Intravenous infusion Duration: 4 weeks (Week 0 to Week 4) Drug 2: Telitacicept~Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 24 weeks (Week 6 to Week 29)"
223930943|NCT06827587|DRUG|Telitacicept-only group|Drug: Telitacicept Generic Name: Telitacicept Formulation: Injection (Subcutaneous) Dose: 240 mg Frequency: Once a week Route of Administration: Subcutaneous injection Duration: 30 weeks (Week 0 to Week 29)
223930944|NCT06819137|OTHER|Gingival visibility exceeding 3 mm during smiling|Obtaining gummy smile photographs in accordance with the inclusion criteria specified in the study's materials and methods section.
223930945|NCT05689073|DEVICE|Conversational AI system|The conversational AI system based on LLM processes user queries with a sophisticated generation, decision, action, and safety framework to provide optimal feedback. The system has several key features. Firstly, it utilizes retrieval-augmented in-context learning to enhance responses generated by the LLM, sourcing information from trustworthy websites. Secondly, it includes Guardrail module that addresses potential harmful content in the LLM-generated responses by clarifying and validating the content before delivery. Furthermore, the AI system is equipped with Self-checking memory module that retains essential clinical characteristics across multi-turn dialogues, ensuring the continuity and consistency of its interactions with users. The educational content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
223930946|NCT05689073|OTHER|Printed educational Brochure|A printed brochure whose content about vaccination was derived from the official website of World Health Organization (https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination).
223930947|NCT07038031|BEHAVIORAL|Promotion a food habits|They develop the service learning project to promote a healthy food habits in diferent social organitzations of the territory. It consists to do an interview to identify nutritional educational needs, and do 3 nutritional workshops to participants from this organitzations. Each workshop has 1 hour, and is addreced to a small group of participants (8-15 maximum), always with the supervision of the professional of the social organitzation.
223930948|NCT06888583|PROCEDURE|Transpedicular fixation|Patients underwent transpedicular sacral fixation.
223930949|NCT06778161|PROCEDURE|nerve block|Nerve block for providing analgesia after thoracotomy
224095730|NCT05848622|BEHAVIORAL|Real-time gait biofeedback|The RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
224095731|NCT05848622|BEHAVIORAL|Sham real-time gait biofeedback|The Sham RTGBF interventions will include eighteen step gait training sessions. The intervention will gradually increase to 3,000 steps at the 5th session with 100% feedback. During the remaining sessions, the intervention will include 3,000 steps, but the feedback will be gradually tapered off starting with the 11th session.
224095732|NCT04845347|DEVICE|Bright Light Therapy|Participants will be provided with active, unaltered Re-Timer glasses that will be worn in the morning daily for 60 minutes for 5 weeks on study.
224095733|NCT04845347|DEVICE|Dim Light Therapy|Participants on this arm will wear the placebo version of the Re-Timer fitted with neutral density filters. These will be worn in the morning daily for 60 minutes for 5 weeks on study.
224095734|NCT05698732|DEVICE|Coroflex® ISAR NEO coronary stent system|Patients in whom treatment with Coroflex® ISAR NEO coronary stent system has been attempted
224095735|NCT04586504|DRUG|Intranasal midazolam|5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
224095736|NCT06035887|DIAGNOSTIC_TEST|Hand-Held Full-Field Skin-Electrode Electroretinography (Device to be evaluated)|RETEval Complete hand-held electroretinogram
224284182|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
224284183|NCT03856684|BEHAVIORAL|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
223533172|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
223533173|NCT01149694|DRUG|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
223533174|NCT04258748|BEHAVIORAL|Motivational Interviewing (MI)|In each of the four MI counseling sessions that were delivered, the researcher approached mothers in small groups of 5 via three phases, in 15-30 minutes, to establish rapport/ alliance in the first phase, to identify health needs in the second phase and finally to reinforce dental needs in the third phase.
223533175|NCT04258748|BEHAVIORAL|Gaming and MI|In each of the four MI counseling sessions, the researcher approached mothers via three phases, in 15-30 minutes, to establish rapport/ alliance, to identify and finally reinforce dental needs in the same pattern as MI group. In addition, the children were engaged in 'Happy Teeth, Healthy Kids' which is an android tablet game that was included in the MI session scheduled for the mothers. Children were told to follow correct steps of brushing in order to obtain happy bright teeth. This helped the children realize that brushing teeth will give them a bright smile.
223718252|NCT04669639|OTHER|Block procedures for shoulder surgery analgesia|"The patients in group (a) will be placed in lateral decubitus. Then, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used to locate the transverse process of T2, where a needle will be inserted in a cephalocaudal direction until reaching the space between the fascia of the erector spinae and the transverse process of T2 and 30 ml of local anesthetic of bupivacaine 0.5% will be injected.~* In group (b), SSC nerve block will be done as follow: In the suprascapular notch, an ultrasound-guided aseptic technique with a high-frequency linear transducer will be used. The linear probe, enveloped in a sterile sheath, will be placed parallel to the spine of the scapula to visualize it and then will be moved cephalic to the supraspinatus fossa. The probe will then be moved laterally up to the scapular notch, where the nerve will be identified by its round hyperechogenic shape 4 cm deep.~* control group: patients will receive only general anesthesia"
223718253|NCT02753023|OTHER|no intervention|No intervention related
223930950|NCT06887179|PROCEDURE|HF focused POCUS|"* POCUS findings guide diuretic therapy adjustments by treating physicians~* POCUS is performed with handheld device Vscan air SL® or Vscan extend®, GE Healthcare.~* Sector probe and abdominal preset are used. Only B-mode is used.~* The image depth is 15 cm or more to evaluate the structures sufficiently.~* Patient position is supine or semirecumbent. For the pleural effusion exam, the preferred position is sitting.~  1. Lungs: Assessment of B-lines in midclavicular and midaxillary zones.~ 2. Pleural Effusion~ 3. Inferior Vena Cava~ 4. Ascites"
223930951|NCT06887179|PROCEDURE|Standard Care (in control arm)|Standard care assessment with NT-proBNP on every scheduled visit.
223930952|NCT02044497|DRUG|oral oxycodone|
223930953|NCT06753097|DEVICE|Continuous finger-cuff arterial pressure monitoring|Arterial pressure will be monitored using continuous non-invasive finger-cuff arterial pressure monitoring.
223930954|NCT06892171|BIOLOGICAL|Blood sample|blood sample for genetic analysis
223930955|NCT06742697|BEHAVIORAL|Flexibility, Resistance, Aerobic, Movement Execution training|"Flexibility: static and dynamic stretching combined with sensory, high-frequency electrical stimulation to reduce spasticity and improve mobility.~Resistance training: core stability and lower limb strength training in conditions of instability, to improve strength, coordination, and balance.~Movement execution training: gait training according to motor learning principles.~Aerobic exercise: in the form of high-intensity interval training at the end of each session, to improve cardiovascular status and foster motor learning consolidation (probably due to the release of brain derived neurothrophic factors)."
223930956|NCT06045507|DRUG|MK-8527|MK-8527 capsule
223930957|NCT06045507|DRUG|Placebo to MK-8527|Placebo capsule matched to MK-8527
223930958|NCT06736938|DRUG|Propofol 1%|Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.
223930959|NCT06736938|DRUG|Midazolam|Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.
224095737|NCT06035887|DIAGNOSTIC_TEST|Trolley-Mounted Multifocal Skin-Electrode Electroretinography (Device to be evaluated)|UTAS multifocal electroretinogram
223718254|NCT06037434|DRUG|Captopril Tablets|0.3mg/kg, tid
223930960|NCT06736938|DRUG|Pethidine|Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.
223930961|NCT06738511|DIAGNOSTIC_TEST|blood sampling|Molecular signature using plasma sample
223930962|NCT06738511|OTHER|stool sampling|Stool sampling (by the participant)
223930963|NCT06738511|OTHER|colonoscopy|Colonoscopy will be performed in the course of a screening programme
223930964|NCT06747832|DRUG|iNK cells|Intravenous infusion of iNK cells is given to the subject, 5\*108 to 1\*109 cells/dose, three doses per week, a total of 6 doses. And then 1\*109 cells/dose, one doses every 4 weeks , a total of 5 doses.
224095738|NCT06035887|DIAGNOSTIC_TEST|Spectral-Domain Optical Coherence Tomography (Standard of Care test)|Heidelberg Engineering Spectralis Spectral-Domain Optical Coherence Tomography (macular structural scan)
224095739|NCT06035887|DIAGNOSTIC_TEST|Macular Autofluorescence (Standard of Care test)|Heidelberg Engineering Spectralis Autofluorescence imaging (macular structural image)
224095740|NCT03279094|BIOLOGICAL|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
224284184|NCT03856684|BEHAVIORAL|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
224095741|NCT05899322|BEHAVIORAL|Primary Care Intervention for PTSD Spanish Speaking Adolescents|This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
224095742|NCT05899322|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
223718255|NCT06037434|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
223718256|NCT06037434|DRUG|Spironolactone Tablets|2-4mg/kg, bid
223718257|NCT06037434|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
223930965|NCT06843096|DIAGNOSTIC_TEST|Contrast-Enhanced Mammography (CEM)|"The intervention in this study involves Contrast-Enhanced Mammography (CEM), a specialized imaging technique that combines standard mammography with contrast-enhanced imaging to detect neo-angiogenesis, which is a characteristic of malignancy. Unlike traditional mammography, CEM utilizes both low-energy and high-energy images to provide enhanced visualization of tissue vascularity, aiding in the identification of occult primary tumors, particularly in patients with Cancer of Unknown Primary (CUP) syndrome.~Patients who present with CUP syndrome, suspected of having a primary breast malignancy, will undergo CEM as part of their diagnostic workup. The CEM findings will be compared with other conventional imaging modalities, including ultrasound and MRI, to assess the diagnostic accuracy of CEM in detecting primary breast tumors. The intervention will also involve correlating the imaging results with histopathological findings from biopsy or surgical specimens.~This study aims to demons"
223930966|NCT06753552|OTHER|Underwater US|7 min per session with an intensity of 0.9 W/cm2 for 20 sessions
224284185|NCT03856684|BEHAVIORAL|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
223718258|NCT06037434|DRUG|Potassium citrate powder|0.06g/kg, tid
223930967|NCT06753552|DEVICE|CFO|Custom made orthotics
223930968|NCT06810739|DIAGNOSTIC_TEST|Cervical Cancer Screen-Triage-Treat Care Cascade|Cervical Cancer Screen-Triage-Treat Care Cascade: After providing informed consent, the study clinician will open a Case Report Form (CRF) for each patient which starts with a brief questionnaire, which will include the participant's demographic information and medical history, including HIV viral load and cluster of differentiation 4 (CD4) counts, previous cervical cancer screening results if previously screened, and result of rapid pregnancy test performed that day. Each participant will then be accompanied to a private location where the study nurse will provide counseling and instruction on how to appropriately perform the self-collection vaginal swab technique.
223930969|NCT06763367|OTHER|Face mask containing Centella sinensis|A half-face control test was used in this study. One side of the face was treated with a mask containing Asiaticum asiatica and the other side was treated with a mask without Asiaticum asiatica
223930970|NCT06763562|OTHER|Carbohydrate-first meal|Rice eaten first (150 grams), followed by edamame (150 grams) and butter (10 grams)
223930971|NCT06763562|OTHER|Carbohydrate-last meal|Edamame (150 grams) and butter (10 grams) eaten first, followed by rice (150 grams)
223930972|NCT06763978|DEVICE|Transcatheter PDA closure|Transcatheter PDA closure
223930973|NCT06819826|DRUG|SC0062 strength 10mg|Subjects will take 20 mg once daily for 108 weeks during the treatment period.
223930974|NCT06819826|DRUG|Placebo matched to SC0062|Subjects will take 20 mg once daily for 108 weeks during the treatment period.
224095743|NCT06294587|PROCEDURE|FGG Before GBR|Free Gingival Graft before the guided bone regeneration,
224095744|NCT06294587|PROCEDURE|FGG after GBR|Free Gingival Graft after the guided bone regeneration,
224284186|NCT03325972|DRUG|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
224284187|NCT03325972|OTHER|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
223718259|NCT05872646|DIAGNOSTIC_TEST|clinical assessment|clinical staging
223718260|NCT04666051|BIOLOGICAL|Application of fibrin glue sealant|
224284188|NCT02373995|BIOLOGICAL|LAB4|Additional treatment with the specific LAB4 probiotic preparation
224095745|NCT06197984|PROCEDURE|ERCP|ERCP will serve as the exclusive therapeutic modality, aided by a therapeutic duodenoscope to access the common bile duct using a guidewire.
224095746|NCT05917145|DRUG|WSD0628|A non-toxic compound and inhibits the DNA damage response associated with radiation therapy. • WSD-0628 radio sensitizes Glioblastoma cells.
224284189|NCT02826941|OTHER|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
224284190|NCT02826941|OTHER|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
224284191|NCT00794417|DRUG|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
223718261|NCT04519125|DRUG|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
223718262|NCT04519125|OTHER|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)|Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)
223718263|NCT03684395|DRUG|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
223718264|NCT03684395|DRUG|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
223718265|NCT05627154|DRUG|Citalopram|Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.
223718266|NCT05627154|BEHAVIORAL|Behavioural Activation|A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.
223718267|NCT05627154|DRUG|Placebo|A lactose-based tablet.
223930975|NCT06767332|OTHER|eye movement desensitization and reprocessing (EMDR)|"EMDR is a psychological intervention that has historically been applied to the treatment of Post-Traumatic Stress Disorder (PTSD), but has since then been shown to be effective for a variety of anxiety disorders (e.g. fear of illness and specific phobia) (Logie \& de Jongh, 2014) and somatic complaints such as post-operative pain, medically unexplained symptoms and seizure-related post-traumatic stress (Dautovic, de Roos, van Rood, Dommerholt, \& Rodenburg, 2016; van Rood \& de Roos, 2009; Maroufi, Zamani, Izadikhah, Marofi, \& O'Connor, 2016).~With more than 25 randomized clinical trials, EMDR has been established as an evidence-based intervention for PTSD and PTSD symptomatology including physical symptoms and fear of future catastrophes (Balkom van et al., 2013)."
223930976|NCT06794645|DRUG|Pembrolizumab|pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle
223930977|NCT06794645|DRUG|Pemetrexed Phase 2|pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).
223930978|NCT06740422|DRUG|Xuanhuang Runtong Tablet|A synthetic tablet is mainly composed of Radix Rehmanniae, Radix Scrophulariae, Radix Angelicae Sinensis, Semen Persicae, Herba Cistanches, Fructus Cannabis, Semen Cassiae, Fructus Aurantii Immaturus and Aloe.
223930979|NCT06740422|DRUG|Xuanhuang Runtong Tablet Simulator|Xuanhuang Runtong Tablet Simulator
223930980|NCT06760169|DEVICE|Surgery with ELIOS laser|This surgery involves visualizing the iridocorneal angle before or after cataract surgery, inserting the ELIOS laser probe into the anterior chamber to come into slight contact with the trabecular meshwork, then pressing the foot pedal, the surgeon activates the laser, which creates a microchannel by photoablating the trabecular meshwork and inner wall of Schlemm´s canal (trabeculostomy) ± 210 um in diameter. This gesture is repeated until 10 microchannels are created. The creation of these microchannels enhances the natural outflow of aqueous humor by bypassing the site of major resistance in the system. The usual duration of the ELIOS procedure is typically few minutes). The rest of the surgery does not deviate from standard phacoemulsification.
224095747|NCT05414071|DEVICE|NMS Assist|The system enables people with Parkinson's and their care partners to complete questionnaires about symptoms and burden and share that information with their care team. They can also access self-help resources and materials about managing non-motor symptoms. Healthcare providers have a dashboard that flags any worsening symptoms or discrepancies between PwP and CP reports, enabling their to prioritise care and quickly see the status of their patients. The system also enables PwP or CPs to request healthcare contact.
223533176|NCT04258748|BEHAVIORAL|Conventional dental health education|It was delivered through a 15-minutes oral health session given to mothers of preschoolers. Mothers were given brief information about causes of dental caries and role of plaque, toothbrush size, diet / frequency of sweet snacks, brushing technique, toothpaste and fluoride use as well as regular dental visits. Participants were then shown a short educational video about prevention of dental caries among children coupled with oral hygiene instructions. At the end of the session, participants were given a leaflet reinforcing the information to take home.
223533177|NCT03525847|DIAGNOSTIC_TEST|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
223930981|NCT06762704|OTHER|Video recording|Videos of rotating the blastocysts will be recorded during the preparation stage of trophectoderm (TE) biopsy. The focal plane starts from the middle plane of the blastocyst. and then moves downwards until individual TE cells and inner cell mass (ICM) are clearly visible. A biopsy micropipette is used to gently push the blastocyst and rotate the blastocyst each time by a small angle, for instance, smaller than 35° such that more than 10 images can be captured for the entire 360° rotation to achieve high-accuracy measurement. After the first 360° rotation, the second one will be conducted around the axis perpendicular to the previous axis to ensure the whole surface of the blastocyst is captured. The entire rotation process will be video recoded.
223930982|NCT06753968|PROCEDURE|Laparoscopic Right Hemicolectomy With Transrectal/transvaginal Specimen Extraction (NOSES)|Transvaginal extraction, begins with the irrigation and disinfection of the vagina, followed by a transverse incision in the posterior fornix. The assistant then utilizes oval forceps to carefully extract the specimen bag through the incision, which is subsequently closed with continuous full-thickness sutures, using barbed sutures to ensure secure closure. Similarly, transrectal extraction begins with irrigation of the rectum using a dilute iodine solution, followed by a longitudinal incision along the anterior wall of the upper rectum. The specimen, along with the protective sleeve, is then removed using oval forceps, and the incision is closed with a continuous full-layer running suture once the specimen has been completely extracted.
223930983|NCT06753968|PROCEDURE|Totally laparoscopic right hemicolectomy (TLRH)|Totally laparoscopic right hemicolectomy (TLRH), which involves performing intracorporeal anastomosis and specimen extraction through a small abdominal incision, further enhances the benefits of minimally invasive surgery. In the TLRH group, following the stapled side-to-side anastomosis, a small horizontal incision is made about 2 to 3 cm above the symphysis pubis, at the junction of the pubic hairline, to allow for specimen removal.
224284192|NCT00794417|DRUG|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
224284193|NCT00794417|DRUG|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
224284194|NCT05187858|DRUG|LNP3794|LNP3794 capsules administered orally once daily
224284195|NCT02139618|DRUG|Methyl Aminolevulinate (MAL)|
224284196|NCT02139618|DRUG|Placebo|
224284197|NCT04491578|BEHAVIORAL|"ACP programme Have a Say"|Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
224284198|NCT05139277|DIAGNOSTIC_TEST|CONVIVO system|Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Again this will only be in regions that would normally be resected or sampled in routine clinical care. Following image acquisition, a neuropathologist present in the operating room, will review and capture each image.
224284199|NCT05139277|OTHER|Conventional histologic evaluation|Following image acquisition, the tissue region imaged with the CONVIVO system will then be biopsied using biopsy forceps. This will be passed immediately off the surgical field as a research specimen and provided to a member of the research team to be prepared for conventional histologic evaluation. The specimen will be labeled with the deidentified subject and sample number. This sequence will then be repeated for each successive sample.
224284200|NCT06092190|DEVICE|EMG|Electrodiagnostic testing (electromyography and nerve conduction velocity) can objectively verify the tibial nerve dysfunction. Electrodiagnosis rests upon demonstrating impaired tibial nerve conduction across the tarsal tunnel in context of normal conduction
224284201|NCT06196944|BEHAVIORAL|Augmentative Alternative Communication|Traditional Method
224284202|NCT06196944|OTHER|Augmentative Alternative Communication Device|Augmentative Alternative Communication Device 3 session for 40 minutes
224284203|NCT02052791|DRUG|nusinersen|Administered by intrathecal (IT) injection
224284204|NCT00005026|DRUG|carboplatin|
224284205|NCT00005026|DRUG|paclitaxel|
224284206|NCT00005026|DRUG|topotecan hydrochloride|
224284207|NCT04286919|BEHAVIORAL|A Randomized Controlled Trial Comparing the Physical Activity Guidelines for Americans to a New Method of Exercise Prescription Among College Students|A randomized controlled trial comparing the 2018 Physical Activity Guidelines for Americans weekly recommendations of 150-minutes of moderate intensity physical activity plus 2 days of muscle-strengthening physical activity to the Move Your Way Campaign message of increasing any and all physical activity to accumulate more movement throughout the week across all types and intensities.
223930984|NCT06751667|DEVICE|Urinary biomarkers|In a bid to reduce or replace surveillance cystoscopies multiple urinary biomarkers have been evaluated for the follow-up of the bladder cancer patients. These device will reduce the number of cystoscopies
223718268|NCT00719251|DEVICE|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
223930985|NCT06758037|DRUG|Drug therapy|"All patients will receive one cycle of HiR (Zebtorizumab, Lenalidomide) induction therapy. On the first day of enrollment, tissue NGS and peripheral blood ctDNA will be submitted for testing. For the remaining six cycles, the added drug (X) will be determined based on the NGS molecular typing results. Please refer to the grouping scheme for details.~HiR+X Dosing Scheme:~Hi: Zebtorizumab 375mg/m², d1; R: Lenalidomide 10-25mg d1-10 (maximum tolerated dose)~X:~For MCD/BN2/TP53: Ocalivumab 150mg qd For EZB: Chidamide 30mg biw~For N1-like and nonspecific types:~If EBV-positive: PD-1 monoclonal antibody 200mg Q3W"
223930986|NCT06757751|DIETARY_SUPPLEMENT|EVOO diet supplement|For 24 weeks, subjects in intervention arm will have their diet supplemented, daily, with an amount of 30 ml of EVOO (Extra Virgin Olive Oil).
223930987|NCT06750354|PROCEDURE|papworth technique|For Group A: The Papworth breathing technique consists of a series of diaphragmatic breathing and relaxation exercises, and teaches patients which muscles to use when breathing and how to avoid breathing too or too fast by emphasizing nose breathing. The technique is altered to suit activity; this allows the technique to be integrated by patients into their everyday lives with subsequent improvements in quality of life.
223930988|NCT06750354|PROCEDURE|aerobic training|"Aerobic training exercises are any activities that raise heart rate and make breathing somewhat harder. The activity you are doing must be constant and continuous. Examples of aerobic activities are~Walking or hiking Jogging or running Biking Swimming Rowing In-line skating Cross-country skiing Exercising on a stair-climber or elliptical machine"
223930989|NCT04099823|OTHER|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
223930990|NCT04099823|DIAGNOSTIC_TEST|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
223930991|NCT04099823|DIAGNOSTIC_TEST|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
223930992|NCT03280030|DRUG|Midostaurin|Midostaurin 50 mg \[two 25 mg capsules\] were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
223930993|NCT03280030|DRUG|Placebo|Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
223930994|NCT06767839|OTHER|Transcutaneous Electrical Nerve Stimulation|The current parameters for the TENS to be applied in the study were determined as 100 Hz, 100 microsecond pulse duration, and asymmetric biphasic waveform. The current intensity will be increased until the person feels a tingling sensation and will be applied for a total of 20 minutes. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
223930995|NCT06767839|OTHER|High Voltage Pulsed Galvanic Stimulation|YVKGS is a monophasic waveform current with double peaks, short pulse duration and a voltage higher than 100 Volts, the frequency of which can be adjusted optionally. In the study, the current parameters of YVKGS were determined as a frequency of 100 Hz, continuous pulse, double peak monophasic waveform. The current intensity will be applied for 20 minutes at the voltage at which the person feels a tingling sensation. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.
223930996|NCT06767839|OTHER|Sham TENS|The current will be applied to the sham TENS group with the same parameters as the TENS group, and will be reduced and turned off after a while. In TENS application, people normally report that they no longer feel tingling after a few minutes of starting the application. Therefore, it will be explained to the sham TENS group that this situation is normal, and that they no longer feel tingling because they have become accustomed to the applied current.
223930997|NCT00878319|PROCEDURE|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
223930998|NCT00878319|OTHER|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
224095748|NCT03896763|OTHER|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
224095749|NCT05085366|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline)
224095750|NCT05085366|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223718269|NCT00719251|DEVICE|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
223930999|NCT06832852|OTHER|Stepped care|During the first education session, participants will be provided with information pertaining to painful area, basic pain science, injury specific advice on load management, pain and activity management, lifestyle factors and physical activity. A general physical activity will be recommended (150-300 minutes of moderate-intensity activity per week). Then, participants will be directed to a website developed by the research team and patient partners. The website includes explanations of the various topics discussed during the session , explanatory videos, and summarized information. During the second educational session, the participant's condition will be reviewed, and their understanding of the topics covered in the first session and on the website will be assessed. A follow-up on the website will also be conducted. The physiotherapist will then answer the participant's questions and provide personalized advice based on their condition, along with long-term recommendations.
223931000|NCT06832852|OTHER|Rehabilitation Care|The pragmatic rehabilitation program will include exercises aimed at improving strength, endurance, flexibility, capacity to sustain mechanical load and dynamic control. Manual therapy may be provided during the sessions, based on pragmatic clinical decision-making. Participants will also receive information pertaining to the painful area and advice on pain and load management, and on activity modification, integrated across the sessions.
223931001|NCT06832852|OTHER|Medical Care|The pragmatic medical intervention may include pharmacological management, education, physiotherapy referral or referral to a specialist as deemed necessary.
223931002|NCT06771232|PROCEDURE|Subdural pressure measurement|Subdural intracranial pressure (SDIP) will observed during an alveolar recruitment maneuver and best PEEP titatration. SDIP will be measured while mechanical ventilation is maintained using the identified best PEEP.
223931003|NCT06775600|PROCEDURE|Hip Replacement|Total Hip Arthroplasty where the Femoral Head will be used to harvest stem cells post-extrication from the individual.
224095751|NCT06213883|OTHER|Biobehavioral Response to in-lab exposure to physical activity|ED severity, biological and affective markers of physical activity response, and both exercise-specific and general positive (reward) and negative (avoidance/escape) valence sensitivities associate with physical activity will be comprehensively examined.
224095752|NCT05416060|BEHAVIORAL|Dulce Digital Text-Based Education|Participants will be enrolled in the digital texting platform, Dulce Digital in which they will receive on-going support via text messages for 6 months, derived from the Project Dulce curriculum. Topics include medication reminders, motivational prompts, nutrition and stress reduction tips and request to submit weekly blood glucose numbers.
224095753|NCT05416060|BEHAVIORAL|Project Dulce Telehealth|Project Dulce will consist of a group-based telehealth diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
224095754|NCT05416060|BEHAVIORAL|Project Dulce Live|Project Dulce will consist of a group-based diabetes self-management education program consisting of a 5 -week curriculum delivered by a peer educator in English or Spanish. The curriculum provides skills and tools needed to adapt to a life with diabetes and change behaviors. The curriculum covers diabetes and its complications, the role of diet, exercise, and medication, and the importance of self-monitoring. It is presented over 5 weeks where participants learn and practice self-management skills, and help one another address family, cultural or health system barriers to managing your diabetes.
224095755|NCT05469984|DRUG|Ampicillin Only Product|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
224095756|NCT05469984|DRUG|ampicillin plus gentamicin|women will be randomize to receive Ampicillin Only Product or ampicillin plus gentamicin
224095757|NCT06379347|DIAGNOSTIC_TEST|POCUS performed on clinical indication|POCUS performed on clinical indication
224095758|NCT05372159|OTHER|none, observational study|none, observational study
224095759|NCT05286047|DIETARY_SUPPLEMENT|Bifidobacterium longum CCFM1029|Subjects take one capsule containing Bifidobacterium longum CCFM1029 daily at bedtime.
223931004|NCT05120232|BEHAVIORAL|Unified Protocol|A transdiagnostic, cognitive behavioral therapy.
223931005|NCT05120232|BEHAVIORAL|Modified Unified Protocol (UP+)|A transdiagnostic, cognitive behavioral therapy.
224095760|NCT05286047|DIETARY_SUPPLEMENT|Placebo|Subjects take one capsule containing maltodextrin daily at bedtime.
224095761|NCT06508892|BEHAVIORAL|risk of fall|Gather information that will assist in determining risk of fall. The researchers will ask the subjects to perform several motor tests and study-related questionnaires.
224095762|NCT02725788|DEVICE|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
224095763|NCT02725788|DEVICE|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
224095764|NCT05275101|BEHAVIORAL|Crisis Response Planning|Individuals complete an experimental collaborative suicide intervention.
223931006|NCT06775054|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain. It is primarily used to treat depression, particularly in patients who have not responded to traditional treatments such as selective serotonin reuptake inhibitors (SSRIs) or psychotherapy. The most common target area is the dorsolateral prefrontal cortex, which is often underactive in individuals with depression. TMS devices, such as the FDA-approved Magventure system, deliver magnetic pulses to stimulate or inhibit brain activity in the targeted region. This process is believed to help reset or normalize patterns of neural activity associated with depression and other psychiatric disorders. TMS offers a promising alternative for individuals struggling with depression, providing a non-invasive approach with relatively few side effects and notable potential benefits.
223931007|NCT06770894|DRUG|Sitagliptin 100 mg|The study population will be randomly allocated in either intervention or placebo arm (1:1). Treatment (sitagliptin 100 mg) and placebo will be provide in identical packages by an experienced independent pharmacist. The recommended intake is one tablet a day, equivalent to sitagliptin 100 mg in the active-treated group, for the duration of the study (52 weeks)
223931008|NCT06770894|DRUG|Placebo Tablets|Placebo tablets 1 a day, provided in identical blisters.
223931009|NCT06777680|DIETARY_SUPPLEMENT|co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)|oral suspension, 10 ml twice a day (every 12 hours) for 7 days
223931010|NCT06777680|OTHER|Placebo|oral suspension,10 ml twice a day (every 12 hours) for 7 days
223931011|NCT06777680|PROCEDURE|Thrombectomy|Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
223931012|NCT06822946|DRUG|zhibitai capsule|2 capsule of Zhibitai capsule/time, 2 times/day, oral
223931013|NCT06822946|DRUG|zhibitai capsule|(1 capsule of Zhibitai capsules+1 capsule of Zhibitai capsule simulant)/time, 2 times/day, oral
223931014|NCT06655610|DEVICE|External Trigeminal Nerve Stimulation|Active eTNS will be provided by applying single, bipolar pulses of 0.5 milliseconds duration at a frequency of 125 hertz, with an active period of 30 seconds on/off. Stimulation current will range from 0.2 mili ampere (mA) to 10 mA. The level of current, which is noticeable, yet within the level of comfort, will be identified for each patient by titration at baseline. Depending on the perception of stimulation, the level of current may be altered during the four weeks of treatment, by either the guardian or adolescent in control of the settings.
223931015|NCT06655610|DEVICE|Sham device|The stimulator and patches will be identical in appearance to the active treatment. The guardian/the adolescent will be informed to administer the device in the same fashion as with active treatment. The sham device will however be programmed to only apply stimulation for 30 seconds every hour during sleep, optimally at a frequency of maximum 2 Hz. As with the active eTNS, the sham stimulation current will range from 0.2 to 10 mA. Such settings have previously been considered to induce the sensation of a current applied to the forehead as seen with active treatment, yet without it being therapeutically effective. Stimulation will be directed through an internal resister, which ensures draining of batteries and need for recharging after each session. The manufacture of the eTNS device (Neurosigma) will oversee the programming the sham device.
223931016|NCT06655272|DRUG|Bacterial Lysate|Administration p.o. for 10 days per month for 3 months, two consecutive cycles.
223931017|NCT06655272|DRUG|Placebo|Matching placebo.
223931018|NCT06655714|OTHER|No intervention|No intervention
223931019|NCT06654401|DIAGNOSTIC_TEST|Transthoracic echocardiography|Standard assessment of the parameters of the left atrium: size, volume, volume indices
224095765|NCT05275101|BEHAVIORAL|Crisis Risk Counseling|Individuals complete a standard crisis risk management intervention.
223931020|NCT06654401|DIAGNOSTIC_TEST|24-hour ECG Monitor|Assessment of cardiac arrhythmias according to 24-hour monitoring data
223931021|NCT06654401|PROCEDURE|Electroanatomic mapping|Intraoperative assessment of low voltage areas (potential fibrosis zones)
223931022|NCT06631586|BIOLOGICAL|MTP-101C|MTP-101C composed of double-encapsulated freeze-dried healthy donor microbiota. The fecal microbiota is frozen in the presence of a lyoprotectant (trehalose), freeze-dried, and double encapsulated into hypromellose capsules (Lonza, Morristown, NJ). Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
223931023|NCT06631586|BIOLOGICAL|MTP-101S|MTP-101S contains identical healthy donor microbiota double encapsulated in VCaps Plus (Lonza). These capsules are also composed of hypromellose but disintegrate in the proximal small bowel. Each capsule contains ≥ 1 x 10 11 and ≤ 2.0 x 10 11 bacterial cells.
223931024|NCT06856031|DRUG|Optimized Treatment (OPT)|After induction therapy with intravenous vedolizumab (300 mg) at weeks 0, 2, and 6, PRO2 was assessed to determine the patient's response and an individualized treatment plan was formulated: vedolizumab was reinfused intravenously (300 mg) every 4 weeks if PRO2 was reduced by \<50% from baseline or was still in the moderately-severe active phase of PRO2.
224095766|NCT05662592|DEVICE|Broadband Light|Broadband Light device will be used for treatment of pigmented skin lesions
224095767|NCT04274322|OTHER|Nutrition support|Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement
224095768|NCT04548076|OTHER|Block group|Control group
224099691|NCT06807164|PROCEDURE|Botulinum Toxin A|Botulinum Toxin A (Botox-A) is injected into the affected area, with a total of 300 units administered across up to 60 injection sites. An anesthesiologist will perform the procedure in a post-interventional recovery room, with light sedation. This intervention will be carried out in addition to a systemic treatment that has been ongoing for at least 4 weeks, and is aimed at providing prolonged pain relief for post-mastectomy neuropathic pain. Light sedation is provided, and injections may be repeated at 12 weeks if necessary.
223931025|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 4 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file.
223931026|NCT06893263|PROCEDURE|Clamp placement on canine and 2nd molar teeth and rubberdam rubber band insertion|The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the canine and 2nd molar teeth. It was aimed to facilitate the second scanning process by expanding the isolation area to include 3 teeth. A flowable composite was applied by placing Teflon tape on the occlusal surface of the 1st molar to create a difference in its morphology.This stage was repeated in 2 different treatment sessions, blue rubber dam was preferred in one of the appointments and black rubber dam was preferred in the other.
223931027|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|The patients' mandibular arches were scanned with 2 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
223931028|NCT06893263|DEVICE|Taking images from the right lower jaw with an intraoral scanner|scanned with 2 different intraoral scanners (IOS) (Primescan, Dentsply; Element 5D) prior to the procedure, and the obtained digital impressions were stored as a standard tessellation language (STL) file. The 2nd premolar, 1st, and 2nd molar teeth were isolated with a rubber dam (medium; Nic Tone, Manufacturera Dental Continental) to be included in the operation field. Clamps were placed on the 2nd premolar and 2nd molar teeth. Subsequently, the mesh hole area was rescanned starting on the occlusal surface of the second molar, moving toward the occlusal of the first molar to the occlusal of the second premolar, then the buccal surfaces of the second premolar, followed by the first molar and second molar.
224284208|NCT02317679|DRUG|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
224284209|NCT02317679|DEVICE|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
224284210|NCT05557448|DRUG|TYNADOTE|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
224284211|NCT05557448|DRUG|Placebo Oral Tablet|Subjects will take 200 mg/every 4 hours, with a loading dose (400 mg) and then followed by 17 maintenance doses
223931029|NCT06751888|OTHER|Controlled CO2 delivery|The use of a controlled CO2 delivery offers a straightforward way to increase arterial CO2. Controlled CO2 inhalation may offer a novel hemodynamic therapy for patients with Neurogenic Orthostatic Hypotension
223931030|NCT06751888|DEVICE|Controlled CO2 delivery (Sham)|For this intervention, we will be using this device set at 0% CO2 for our sham comparison.
224095769|NCT04866927|DIETARY_SUPPLEMENT|Use of stable isotopic dilution to assess protein digestibility from Faba bean and to evaluate amino acid bioavailability|Each participant will receive a test meal containing 13C labelled spirulina, 2H labelled Fava bean and 13C phenylalanine. The test meal will be divided on 11 subdoses: 3 sub-doses will be administrated at T0 and 1 subdose will be administrated at 1, 2, 3, 4, 5, 6 and 7h. The remaining sub-dose will be kept for measurement of IAA in the test meal. After eating the test meal, blood, urine and breath samples will be collected from each participant at the baseline (T0) and after 5-6, 7h and 8h.
224099692|NCT04885257|DRUG|Methylphenidate|Methylphenidate oral pill. Dosing instructions given to
224099693|NCT04885257|DRUG|Placebo|Placebo arm
224099694|NCT01746433|OTHER|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
224099695|NCT00256295|DRUG|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
224099696|NCT00256295|DRUG|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
224099697|NCT05982340|DIAGNOSTIC_TEST|Lithium clearance|Blood and urine samples
224099698|NCT01868360|DRUG|Subconjunctival aflibercept|subconjunctival aflibercept injection
224099699|NCT01868360|OTHER|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
224099700|NCT04760145|OTHER|Multicomponent Exercise with Blood Flow Restriction|"* 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed with blood flow restriction."
223931031|NCT06762223|DRUG|Henagliflozin 10 mg daily|Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.
223931032|NCT06762223|DRUG|Metformin 1700 mg daily|The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.
223931033|NCT06762223|OTHER|Placebo of Henagliflozin|The placebo was supplied by the pharmaceutical company responsible for Henagliflozin, ensuring that both the placebo and Henagliflozin were indistinguishable in terms of appearance, taste, and odor, while lacking any significant pharmacological effect. Administration of the placebo was recommended to occur in the early morning.
223931034|NCT06762288|DEVICE|Ultrasound|Sedation and local anesthesia to the surgical field will be applied as standard procedure and unilateral USG-guided TAP block will be performed to the patients who will undergo TAVİ.
223931035|NCT06762288|PROCEDURE|Local anesthesia and sedation|Sedation and local anesthesia to the surgical field will be applied to the patients who will undergo TAVİ.
223931036|NCT06774560|OTHER|CAD/Cam milled onlays|"The digital workflow in dentistry has proven in the past decades to be a time-efficient, multifunctional, effortless, and accessible approach. The inherited shortages milling machines represented by the incapability to produce accurate complex hollow structures may give preference to modern 3D ceramic printing.~Computer-aided-design/computer-aided-manufacturing (CAD/CAM) in dentistry is a digital subtractive approach for manufacturing indirect restorations. Nevertheless, waste materials and milling burs wearing are considered as key disadvantages of CAD/CAM technology, and are the main drive to improve 3D printing technology (additive manufacturing) as the latter has shown considerable efficiency in minimising wasted materials."
223931037|NCT06774560|OTHER|3D printed onlays|"3D printing technologies are developing more intensively in dentistry as this technology has the capacity to produce shapes or models with high accuracy and in a short time. This method of fabrication takes less time and money and saves on materials compared to CAD/CAM.~Although it seems that digital manufacturing technology has made great changes in the restorative dentistry field, this technology is still not fully in use. This is possibly because of the lack of studies and research on this technology, particularly in terms of clinical performance and patient-centred outcomes. 3D printing technologies are novel technologies with a lack of research; therefore, the processing of 3D printing materials is still controversial."
223931038|NCT06773884|OTHER|"Observational Analysis of Primary Hip Fracture Surgery Outcomes"|This study examines outcomes following standard primary hip fracture surgery by analyzing retrospective data from national health registries. The focus is on identifying perioperative and patient-related risk factors that influence outcomes such as reoperation rates, mortality, and secondary fractures within one year of surgery. No experimental or new intervention is introduced in this study.
223931039|NCT06773416|COMBINATION_PRODUCT|CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health|Participants in Group 1 will receive CPAP therapy immediately upon enrollment alongside web-based sleep education through the Brain Health Pro (BHP) platform. The CPAP intervention includes a study-provided auto-titrating device, in-person mask fitting, and ongoing support from a study sleep technologist. Adherence will be monitored via remote data uploads. The BHP platform is a 45-week web-based formal educational program program designed to increase dementia literacy, foster engagement, and convey best available evidence for lifestyle changes that can mitigate dementia risk. This combined approach ensures simultaneous initiation of CPAP and educational reinforcement to optimize adherence and cognitive outcomes.
223931040|NCT06773416|COMBINATION_PRODUCT|Delayed CPAP Therapy Combined with Web-Based Sleep Education for Cognitive and Sleep Health|Participants in Group 2 will begin with 4 months of BHP web-based sleep education before adding CPAP therapy for the remaining 4 months. CPAP setup and support are identical to the Early CPAP group. Participants in Group 2 will experience procedure similar to current clinical practices.
223931041|NCT06773351|DRUG|Sevoflurane 0 + different doses of ciprofol|Sevoflurane 0% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.6mg/kg, respectively.
223931042|NCT06773351|DRUG|Sevoflurane 0.7% + different doses of ciprofol|Sevoflurane 0.7% combined with ciprofol 0.1, 0.2, 0.3, 0.4, 0.5mg/kg, respectively.
223931043|NCT06773351|DRUG|Sevoflurane 1.0% + different doses of ciprofol 0.05|Sevoflurane 1.0% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
223931044|NCT06773351|DRUG|Sevoflurane 1.5% + differnet doses of ciprofol|Sevoflurane 1.5% combined with ciprofol 0.05, 0.1, 0.2, 0.3, 0.4mg/kg, respectively.
223931045|NCT06773351|DRUG|Sevoflurane 2.0% + different doses of ciprofol|Sevoflurane 2.0% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
223931046|NCT06773351|DRUG|Sevoflurane 2.5% + different doses of ciprofol|Sevoflurane 2.5% combined with ciprofol 0.05, 0.1, 0.15, 0.2, 0.3mg/kg, respectively.
223931047|NCT06773351|DRUG|Ciprofol 0 + different end-expiratory concentration of sevoflurane|Ciprofol 0 combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5%, respectively.
223931048|NCT06773351|DRUG|Ciprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.05 mg/kg combined with sevoflurane 0.7, 1.5, 2.0, 2.5, 3.5 %, respectively.
224095770|NCT02980614|DEVICE|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
224095771|NCT00116454|DRUG|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
224095772|NCT03681717|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
223931049|NCT06773351|DRUG|Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.1mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
223931050|NCT06773351|DRUG|Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.2 mg/kg combined with sevoflurane 0.5, 1.5, 2.0, 2.5, 3.0 %, respectively.
223931051|NCT06773351|DRUG|Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.3 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
223931052|NCT06773351|DRUG|Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane|Ciprofol 0.4 mg/kg combined with sevoflurane 0.5, 1.0, 1.5, 2.0, 2.5 %, respectively.
223931053|NCT06773572|PROCEDURE|Autologous Exososomes procedure obtained from the patients' own platelets.|Intraovarian injection (into the ovarian cortex) was performed over four cycles, once a month in each ovary on days 7, 8, or 9 of the menstrual cycle. Blood was drawn using the selected PRP kit; in this case, all the PRP was placed into two 20 cc syringes, and the exosomes were filtered using the EXOSMAT kit for autologous platelet exosomes. A total of 5 to 6 cc of liquid composed exclusively of platelet-derived exosomes was obtained, with a concentration of 5 to 6 trillion exosomes per milliliter. Finally, 2 to 3 cc were administered to each ovary via the transvaginal route.
223931054|NCT06773572|PROCEDURE|Patient group for activated platelet growth factors|the plasma was placed in two 5 cc injectors to place 2 to 3 cc in each ovary (in the ovarian cortex) with the patient sedated. The PRP was placed transvaginally and using a follicular aspiration needle for the PRP group. All biostimulations were performed in early follicular phase (day 7, 8 or 9) in all groups according to their assigned technique.
223931055|NCT06773572|PROCEDURE|the control group|Finally, the control group received 2 to 3 cc of physiological solution in each ovarian cortex for 4 cycles as the two previous groups. All these procedures were performed transvaginally under controlled surgical sedation with follicular aspiration needle in the ovarian cortex and guided by transvaginal echosonogram
223931056|NCT06712940|BEHAVIORAL|Motivational Interviewing and Firearm Safety Training, with Case Management|"The basic principles of MI as applied to violence risk reduction in victims of gun violence are as follows: Express Empathy, Develop Discrepancy, Roll with Resistance, and Support Self-Determination/Self- Efficacy. MI practitioners offer themselves as a consultant while respecting the participant as the real expert in their own life. MI also affirms the patient's ability to make changes and communicates trust in the patient's judgments about readiness and plans for change. Motivational interviewing sessions will occur once a month, for six months with a licensed clinical social worker (LCSW).~The LCSW will additionally provide case management over the course of the six month study, and a one time firearm safety training that covers safe storage methods. At the end of the firearm safety training, the participant will be offered a biometric lock box for free."
223931057|NCT03981380|DRUG|11C-PIB|Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
223931058|NCT06765018|DEVICE|Tongue Brush (Orabrush)|Patients in this group uses the Tongue Brush (Orabrush) 2 times a day for a duration for 3-5 days until the follow-up-screening takes place.
223931059|NCT06749691|DRUG|Liposomal Irinotecan and Apatinib|Liposomal Irinotecan in Combination With Apatinib
223931060|NCT06749158|PROCEDURE|spontaneous bone regeneration|"stage 1 surgery:~1. after administration of Local anesthesia (articaine hydrochloride 68 mg/1.7 ml + adrenaline 0.017 mg/1.7 ml injectable solution), sulcular incision will be done , extending two teeth beyond the area of interest followed by two oblique incisions on either side of the flap~2. after flap elevation, enucleation of the cystic lesion and extraction of the non-restorable teeth related to the lesion will be done.~3. titanium mesh will be tailored with 3 mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws.~This will be followed by:~* proper decompression of soft tissue to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(after 6 months):~  1. titanium mesh and screws will be removed.~ 2. core biopsy will be obtained for histological assessment~ 3. implant/s placement."
224095773|NCT06323824|DRUG|Methadone|"Drug: Methadone~Possible formulations:~10 and 50 mg tablets"
224095774|NCT06323824|DRUG|Buprenorphine (BUP)|"Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)"
224095775|NCT02506738|DEVICE|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
224095776|NCT03078062|DRUG|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
224095777|NCT03078062|DRUG|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
224095778|NCT06131710|OTHER|Isolated Strengthening Exercises|Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.
224095779|NCT06131710|OTHER|Combined Strengthening Exercises|Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
224095780|NCT05069779|DRUG|Diazepam|Oral administration of 10 mg of diazepam
224095781|NCT00206973|PROCEDURE|mannitol test|
224284212|NCT02385201|DEVICE|Senza|Spinal Cord Stimulation
224095782|NCT01178021|DRUG|Chloroquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2
224284213|NCT01477502|OTHER|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
224284214|NCT01477502|OTHER|standard treatment without homeopathy|participants receive standard UTI prophylaxis
224284215|NCT04372849|OTHER|Human nasal insulin|single dose of 160 U of human insulin as nasal spray
224284216|NCT04372849|OTHER|Placebo|Single dose of placebo solution as nasal spray
223931061|NCT06749158|PROCEDURE|guided bone regeneration|"stage 1 surgery after cyst enucleation and extraction of the non-restorable teeth related to the lesion, The intra-bony defect will be filled with Deproteinized Bovine Bone.~* Titanium mesh will be tailored with 3mm overlap at the edges to cover the bone window completely and fixed to the bone using mono-cortical titanium screws. This will be followed by:~* proper decompression of soft tissue will be applied to achieve tension-reduced suture.~* Primary closure will be performed using 4-0 vicryl sutures.~* Sutures will be removed one week postoperatively. stage 2 surgery(6 months later) :~  1. titanium mesh will be removed.~ 2. core biopsy will be obtained for histological assessment.~ 3. implant/s placement."
223931062|NCT06749522|RADIATION|high resolution ultrasonography|to compare high resolution ultrasonography finings with other imaging modalities(CT and MRI)
223931063|NCT06769828|DRUG|Ga-68-FAPI-46|Ga-68-FAPI-46 PET scan in colorectal cancer
223931064|NCT06772467|BEHAVIORAL|Intervention (Reiki)|Reiki was applied to this group twice a week for 4 weeks by a researcher who had a Reiki application certificate. Reiki sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Reiki is applied to the seven major chakras and many minor chakras in the body. The chakras are located in the centre of the body, on a vertical line, in the front and back of the body. In this study, Reiki was applied to the patients twice a week for 4 weeks. Reiki sessions were performed before haemodialysis and each session lasted approximately 35-40 minutes. The vital signs of the patients were measured and recorded 3 times: before each Reiki session, after the Reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale.
223931065|NCT06772467|BEHAVIORAL|EFT|"Emotional Freedom Technique (EFT) is a method that helps people manage their emotions and disturbing thoughts, helping to reduce their stress and anxiety. EFT is also called tapping.~EFT sessions were applied to the patients before haemodialysis and the session duration was approximately 35-40 minutes. Patients received 8 sessions of EFT. The vital signs of the patients were measured and recorded 3 times: before each EFT session, after the reiki session, just before the patient entered haemodialysis and after the haemodialysis session. After each session, patients with fistula were asked to mark the level of pain felt during catheter insertion on a visual analogue scale."
223931066|NCT06775977|DIAGNOSTIC_TEST|Contrast Enhanced Ultrasound (CEUS)|Contrast Enhanced Ultrasound (CEUS) refers to the observation under ultrasound after the injection of ultrasound contrast agents, such as SonoVue or Lumason.
223931067|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $333|These subjects receive $333 each month for 76 months via debit card.
223931068|NCT03593356|BEHAVIORAL|Monthly cash gift payments of $20|These subjects receive $20 each month for 76 months via debit card.
223931069|NCT06778213|BIOLOGICAL|NovoHelisen Depot|allergen immunotherapy treatment for 12 months with house dust mite allergen preparation
223931070|NCT06776536|DIAGNOSTIC_TEST|Transrectal ultrasound of the bowel endometriosis during operation|"This is a prospective, single-arm study aimed at evaluating the efficacy of intraoperative transrectal ultrasound (TRUS) in assessing rectal infiltration depth and length in patients with bowel involvement due to deep infiltrative endometriosis (DIE). The study will include 15-40 female patients aged 18-55, diagnosed with intestinal endometriosis preoperatively using transvaginal ultrasound and MRI, and scheduled for bowel resection.~Preoperative evaluations will include pelvic examination, imaging (TVUS and MRI), and pain assessment using a visual analog scale (VAS). During surgery, TRUS will be used to measure the depth and length of rectal involvement, and findings will be compared with preoperative MRI results."
223931071|NCT06776094|OTHER|One-legged-knee extensor exercise|1 hour of one-legged-knee-extensor exercise followed by 4 hours of rest
223931072|NCT06776094|PROCEDURE|Insulin infusion|"The hyperinsulinemic-euglycemic clamp is a well-established and recognized method for determining glucose uptake at a specific insulin infusion rate. It is a technique with which we have 25 years of uncomplicated experience. During the clamp, insulin (human recombinant insulin) is infused (1.42 mU/kg/min) into an arm vein (antecubital vein), while glucose (20% solution) is administered in an amount adjusted to maintain blood glucose (plasma glucose concentration) at basal levels.~The amount of insulin administered raises the participant's plasma insulin concentration (blood concentration) to approximately 100 μU/mL, which is considered within the physiological range. Blood samples are collected and analyzed continuously for glucose content, allowing for the determination of glucose uptake at the whole-body level and across the legs.~Later, these blood samples will also be analyzed for relevant metabolites and proteins, including insulin, to assess the metabolism of these substances."
224095783|NCT01178021|DRUG|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
224095784|NCT04017403|DRUG|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
224095785|NCT04017403|DRUG|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
224095786|NCT03431610|DRUG|SB414 2%|Twice daily
224095787|NCT03431610|DRUG|SB414 6%|Twice daily
224095788|NCT03431610|DRUG|Vehicle|Placebo comparator
224095789|NCT00605826|DEVICE|NASHA/Dx (Solesta) Gel|Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
224095790|NCT00605826|DEVICE|Sham Injection|Sham injection at the start of the blinded phase.
224095791|NCT00099671|DRUG|Recombinant human interleukin-7|
224095792|NCT04919564|DRUG|Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)|Furosemide 2 mg/hour infusion for 12 hours since induction
224095793|NCT04919564|DRUG|NaCl 0.9%|NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
224095794|NCT04523662|DRUG|Camrelizumab Apatinib Mesylas|This study intends to use the PD-1 antibody carrelizumab combined with apatinib and radiotherapy to treat patients with advanced liver cancer with extrahepatic metastasis
223931073|NCT06776094|PROCEDURE|Muscle Biopsy Medication: Lidocaine|"During supine rest, the skin on the outer thigh, approximately 15 cm above the knee, is disinfected with chlorhexidine alcohol. Subsequently, 3-4 mL of local anesthetic (lidocaine 20 mg/mL) is administered into the skin, subcutaneous tissue, and the upper portion of the muscle using a very thin needle. A pinprick test is performed after a few minutes to ensure the anesthetic is effective.~A small incision is then made in the skin and subcutaneous tissue to allow the biopsy needle to pass through to the muscle. Using the biopsy needle, a small sample of muscle tissue (approximately 150 mg) is collected. This may cause some discomfort but is very brief (\~1-2 seconds). The needle is removed, a sterile dressing is applied, and the participant can leave the facility after completing the study.~The biopsy may result in mild muscle soreness for 2-3 days, similar to a minor muscle bruise. Regular physical activities can be resumed after the biopsy. However, it is advised to avoid swimming."
223931074|NCT06776094|OTHER|Exercise|The participants' maximal oxygen uptake is determined through a test on a cycle ergometer before the start of the experiment. The test begins with a 20-minute warm-up at two different low workloads, after which the workload is gradually increased until the predetermined cadence can no longer be maintained, or the participant indicates exhaustion. During the test, the participant's exhaled air is collected. After completing the warm-up, it typically takes between 4 and 7 minutes to complete the test.
223931075|NCT06806839|PROCEDURE|dual plating|surgical fixation of the distal femur using two plates to enhance stability and fracture healing.
223931076|NCT06806839|PROCEDURE|single plating|surgical fixation of the distal femur using a single plate according to standard fixation protocols.
223931077|NCT01208974|PROCEDURE|Nipple-Sparing Mastectomy|Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
223931078|NCT01208974|PROCEDURE|Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
223931079|NCT01208974|PROCEDURE|Axillary Surgery|Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
223931080|NCT01208974|RADIATION|Prophylactic Nipple-Areolar Complex RT|Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
223931081|NCT06733766|PROCEDURE|ultrasound-guided thermal ablation|microwave ablation, radiofrequency ablation, laser ablation
223931082|NCT05500417|DRUG|ALFQ|ALFQ (Army Liposome Formulation containing QS-21) is composed of ALF55 (cGMP-manufactured Army Liposome Formulation), QS-21 (purified extracted saponin), and Sorensen's Phosphate Buffer. Full dose of AFLQ compromised of 200 microgram 3D-PHAD and 100 microgram QS-21, co-administered with main intervention.
223931083|NCT05500417|BIOLOGICAL|CJCV2|Vaccine comprised of C. jejuni capsule conjugated to Cross-Reactive Material 197 (CRM197), a non-toxic mutant protein of diphtheria toxin. CJCV2 will be reconstituted in 1 mL of sterile water for injection (SWI). The resuspended CJCV2 product will be diluted with sterile 0.9% Sodium Chloride for Injection. 3 dosages for administration: 1 microgram, 3 micrograms, and 10 micrograms.
223931084|NCT06832865|DRUG|elranatamab|"Subcutaneously injected study drug, usually into the abdomen or lower stomach. Each vial of elranatamab contains a sufficient amount of product to ensure an extractable volume of 1.9 mL at a concentration of 40 mg/mL. The dosing is as follows:~* Cycle 1 Day 1: 12 mg/0.3 mL~* Cycle 1 Day 4: 32 mg/0.8 mL~* Cycle 1 Day 8, 15, 22: 76 mg/1.9 mL~* Cycles 2-6, Day 1 and 15: 76 mg/1.9 mL~* Cycles 7+, Day 1: 76 mg/1.9 mL"
223931085|NCT06832865|DRUG|Isatuximab SC|"Isatuximab (SAR650984) is an IgG1 derived monoclonal antibody binding selectively the human CD38 membrane protein. Subcutaneously (SC) injected study drug with each vial containing 140 mg/mL (1400 mg/10mL) isatuximab. Isatuximab SC will be injected using the investigational OBDS and in the following doses:~* Cycles 2-6, Day 1 and 15: 1400 mg/10 mL~* Cycles 7+ Day 1: 1400 mg/10 mL"
223533178|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the modified approach|The modified approach includes the ipsilateral calf venous access and the contralateral femoral venous access. Through contralateral femoral venous access, a hydrophilic guide wire and a catheter will be crossover through the thrombus side to the distal calf vein. The ipsilateral calf venous access will be punctured under the guidance of ascending venography. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
223718270|NCT00719251|OTHER|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
224095795|NCT01241786|DRUG|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and \< 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
224095796|NCT01241786|DRUG|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
224095797|NCT04853940|OTHER|Data collection and clinical testing of subjects|6-months follow-up with clinical testing at 3 and 6 months
224095798|NCT03030287|DRUG|OMP-305B83|intravenous (in the vein) infusion
224095799|NCT03030287|DRUG|Paclitaxel|administered intravenously
224095800|NCT04796402|BIOLOGICAL|Bamlanivimab|700 mg/20mL IV over at least one hour OD
224095801|NCT04796402|OTHER|Standard of Care|Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
224095802|NCT04520477|DIAGNOSTIC_TEST|Bio Impedance assesement (BIA)|BIA every 5 minutes od the test protocol. Patients stood up for 5 minutes, laid down for 70 minutes, followed by 5 minutes in a seated position and ending with 30 minutes standing. BIA was done every 5 minutes.
224095803|NCT04520477|DIAGNOSTIC_TEST|Blood and salava sample|Blood Samples were done at the initation of the protocol, and every 10 minutes after ingestion of the deutarated water
224284217|NCT03610828|OTHER|Vegetarian or Vegan Diets|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
223931086|NCT06832865|DEVICE|Isatuximab SC-OBDS|The On Body Delivery System (OBDS) also called Isatuximab SC Wearable Injection System, is a sterile, single-use, disposable, elastomeric, user-filled investigational medical device. The OBDD has a reservoir for the drug product (isatuximab). A self-contained, integrated needle (with manual insertion and automatic retraction mechanism) is provided within the OBDS. The OBDS will be used to inject isatuximab each time the participant receives isatuximab in this study. Study drug administration will be done by trained medical professionals in the clinic. The OBDS device will be prepared by the medical professional, placed on the abdomen using the adhesive (sticky) pads that are on the device, the study drug (isatuximab) will be injected, and then the device will be removed.
223931087|NCT02616666|DRUG|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
223931088|NCT02616666|DRUG|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
223931089|NCT06854744|PROCEDURE|lesion sterlization and tissue repair|evaluate and compare the clinical and radiographic effect of zinc oxide-ozonated olive oil (ZnO-OO) versus Modified Triple Antibiotic Paste (MTAP) as a Lesion Sterilization and Tissue Repair Technique in Primary Molars.
223931090|NCT06854744|OTHER|Zinc Oxide Ozonated Oil|Zinc Oxide Ozonated Oil
223931091|NCT06854744|OTHER|Modified Triple Antibiotic Paste|Modified Triple Antibiotic Paste
223931092|NCT06870721|PROCEDURE|arthroscopic dynamic anterior stabilization for recurrent anterior shoulder dislocation|arthroscopic dynamic anterior stabilization transferring long head of biceps to the anterior glenoid in patients with recurrent anterior shoulder dislocation
223931093|NCT06745557|BIOLOGICAL|denovoSkin(TM)|Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area
223931094|NCT06745557|OTHER|STSG|Transplantation of autologous split-thickness skin to the control area
223931095|NCT06754826|OTHER|AI-generated questions and feedback as a spaced repetition|Participants in the intervention group will undergo structured learning sessions consisted of AI-generated questions and feedback as a spaced repetition.
223931096|NCT06842550|BEHAVIORAL|MAintAin Activity with Arthritis|Participants will receive up to five health coaching sessions led by a trained provider. The aim is to motivate people to meet their physical activity goals, look at their options, make choices and plans, identify challenges, and help them through these changes related to their physical activity and maintenance. Session 1: One to one session with a physical activity coach Session 2-5: Group sessions with approx. 8-10 other people living with arthritis. In the sessions participants will: • Set, reflect and adapt your activity goals • Learn to problem solve • Develop action plans to build new habits. • Learn about opportunities such as walking groups, aqua aerobics and yoga classes are available in your community • Have the support of peers in the group. Please note that these sessions are not exercise classes.
223931097|NCT06845540|DRUG|Metformin|Participants received oral metformin tablets for the treatment of melasma. The initial dose was 500 mg once daily for four weeks. At week 4, participants who tolerated the medication well increased their dose to 500 mg twice daily for the remaining eight weeks of the study. Participants were instructed to avoid other melasma treatments during the trial and to use sunscreen (SPF 30 or higher) daily.
223931098|NCT06798818|DEVICE|Ultra-rapid therapeutic hypothermia induction by total liquid ventilation|Vent2Cool System is a targeted temperature management device used to induce ultra-rapid therapeutic hypothermia by total liquid ventilation.
223931099|NCT06849570|OTHER|Minimal distension|Patients receive tidal volume (VT) of 6 mL/kg and conservative positive end-expiratory pressure (PEEP) setting.
223931100|NCT06849570|OTHER|Maximal Recruitment|Patients receive tidal volume adjusted to limit plateau pressure (∆P) to 14 cmH2O and the highest possible PEEP while maintaining plateau pressure (PPLAT) ≤ 27 cmH2O.
223931101|NCT06849570|OTHER|Prone position + early NMBAs|NMBAs given as soon as possible after randomization
223931102|NCT06849570|OTHER|Prone position + rescue NMBAs|NMBAs given only as a rescue
223931103|NCT06845917|DEVICE|Remote Patient Monitoring system|"RMS consists of an initial assessment visit and system installation: A nurse trained by the EPOCA team will conduct a comprehensive assessment of the patient's needs during a home visit within 48 hours of enrollment. This includes collecting biometric measurements, socio-economic profile, and completing a questionnaire with the patient. The initial visit also includes a consultation with a physician. All the information is transmitted to a digital platform accordingly a personalized care plan (PCP) will be defined. The nurse installs a telemonitoring kit for the patient and gives them instructions on how to use it.~The PCP manager will be responsible for implementing and overseeing the patient care plan, including informing the relevant stakeholders. Patients will be monitored via regular data feedback from the connected devices, the physician and the PCP manager. The PCP manager will treat any identified anomalies or abnormalities and implement the necessary changes on the PCP."
223931104|NCT05763966|OTHER|No intervention|Observational study where participants are followed over time
224284218|NCT00856505|DRUG|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
224284219|NCT01239446|OTHER|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
224284220|NCT03479931|PROCEDURE|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
224284221|NCT03479931|PROCEDURE|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
224284222|NCT05952089|DRUG|Danicamtiv|Specified dose on specified days
224284223|NCT05952089|DRUG|Midazolam|Specified dose on specified days
223533179|NCT06124768|PROCEDURE|Percutaneous mechanical thrombectomy (PMT) by the traditional approach|The traditional approach will be punctured from the ipsilateral popliteal vein under ultrasound guidance. A hydrophilic guide wire and a catheter will be used to pass through the thrombus antegrade to the inferior vena cava. Percutaneous mechanical thrombectomy (PMT) catheter will be used to clear the thrombus. After PMT treatment, residual thrombus will be reevaluated by ascending venography. Catheter-directed thrombolysis (CDT) will be conducted if there is residual thrombus. Percutaneous balloon angioplasty (PTA) and stenting will be conducted if there is \>50% stenosis of the diameter of the iliac vein.
223533180|NCT02898948|BIOLOGICAL|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
223533181|NCT05964686|COMBINATION_PRODUCT|Conventional group (NaOCl/EDTA)|conventional disinfection using 2.5% sodium hypochlorite and 17% EDTA
223533182|NCT05964686|COMBINATION_PRODUCT|Dual laser group (Er,Cr:YSGG/Diode):|Er,Cr:YSGG intracanal laser irradiation to remove smear layer followed by diode laser for disinfection
223931105|NCT05338008|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
223931106|NCT05838846|DRUG|Inhaled Milrinone|Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter.
223931107|NCT05838846|DRUG|IV Milrinone|Patients will receive intravenous milrinone infusion at dosage of 0.3 - 0.75 mcg/kg/min with loading dose of 50 mcg/kg over 10 min. After cross clamp off and temperature of 32 degree, Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.
223931108|NCT00214708|PROCEDURE|Screening for Tuberculosis|
223931109|NCT06792903|DRUG|CG101 high dose + artificial tear|Patient in this group received high dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive placebo CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
223931110|NCT06792903|DRUG|CG101 low dose + artificial tear|Patient in this group received low dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive high dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
224095804|NCT04520477|DIETARY_SUPPLEMENT|Ingestion of deuterated water|15 minutes after the intiation of the test protocol, participants drink an amount of deuterated water corresponding with 0.25% of their TBW calculated using the Watson Formula
224095805|NCT04520477|DIAGNOSTIC_TEST|Urine sample|A urine sample is taken at the initiation and after termination of the protocol.
224095806|NCT03018548|OTHER|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
224095807|NCT02343692|PROCEDURE|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
224095808|NCT06353672|DEVICE|Robotic liver resection|Liver resection using Da Vinci robotic system
224095809|NCT00632580|DRUG|intraarticular injection with ropivacaine|
224095810|NCT00632580|DRUG|extraarticular injection with ropivacaine|
224284224|NCT01999426|OTHER|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
224284225|NCT04681625|BEHAVIORAL|Pelvic floor muscle training (PFMT) with suppressive urgency technique|"Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day."
224284226|NCT03925935|BIOLOGICAL|AB-205|Engineered human umbilical vein endothelial cells
224284227|NCT02166034|BEHAVIORAL|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
224284228|NCT01529658|PROCEDURE|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
224284229|NCT04449224|DRUG|Adalimuab, Etanercept, Tocilizumab, or Abatacept|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
224284230|NCT04449224|DRUG|Tofacitinib or Baricitinib|A specific targeted therapy wil be decided by shared-decision making, a bidirectional process in which clinicians and patients make decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
224284231|NCT06290219|COMBINATION_PRODUCT|platelet-rich plasma combined with hyaluronic acid|The project investigator injects plasma mixed with hyaluronic acid into the nasal septum and the medial side of the middle turbinate of the patient's nasal cavity under a nasal endoscope.
224284232|NCT06290219|DRUG|Zinc Gluconate 10 MG Oral Tablet|one tablet three times a day for a period of 12 weeks
224284233|NCT06290219|DEVICE|4 bottles of phenyl ethyl alcohol, lemon, eucalyptus, and clove oil|Sniffing each odorant for 10 seconds, twice a day for 12 weeks
223533183|NCT05964686|COMBINATION_PRODUCT|Combined group (EDTA/Diode):|17% EDTA was used to remove smear layer followed by diode laser for disinfection
223931111|NCT06792903|DRUG|placebo + artificial tear|Patient in this group received placebo dose CG101 eyedrops twice daily and artificial tear three times a day during week 0 to week 4, after 4 week washout, patient in this group cross over to receive low dose CG101 eyedrops twice daily and artificial tear three times a day during week 8 to week 12.
223931112|NCT05198960|DRUG|Direct Oral Anticoagulants|Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
223931113|NCT05198960|DRUG|Low-dose aspirin|Patients allocated to receive LDA: Aspirin 100 mg OD once daily.
223931114|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
223931115|NCT03211247|BIOLOGICAL|Part A Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
224284234|NCT05693818|OTHER|Clinical Limping Evalution|"Patients will be asked to perform a Clinical Limping Evaluation in the clinic during their post-operative follow-up visit. This will be performed in a controlled environment within the physician's clinic. Each patient will be asked to walk at their normal walking speed down a hallway for at least 7 consecutive steps and back toward the physician. Walking down the hallway and back is one walking trial. Each patient will be asked to perform 2 walking trials. The health care provider will assess the patient's limp using a 3-point Likert scale (0=No limp, 1=mild/moderate limp, 2=severe limp).~If required, patients may use an assistive device and the type of device should be documented. If a patient requires assistance, only the minimum amount of assistance required for a patient to complete the task should be provided."
224284235|NCT05356936|DIETARY_SUPPLEMENT|Vitamin K2 (MK-7)|Participants will receive Vitamin K2 (MK-7) daily by mouth.
224284236|NCT05356936|DIETARY_SUPPLEMENT|Vitamin D3|Participants will receive Vitamin D3 daily by mouth.
224284237|NCT03104621|DRUG|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
224284238|NCT03104621|DRUG|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
224284239|NCT00384384|DRUG|oral 18B Glycyrrhetinic acid versus placebo|
224284240|NCT02471079|RADIATION|Radiotherapy|
224284241|NCT04625322|OTHER|HCV care provided by hospitalist during acute psychiatric admission|HCV diagnosis and treatment will be conducted by a hospitalist during an acute psychiatric admission at CAMH
224284242|NCT03887416|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
224284243|NCT03887416|DRUG|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
224284244|NCT04523324|BIOLOGICAL|Flublok™ Quadrivalent by Sanofi, Inc.|0.5 mL intramuscular dose of Flublok
224284245|NCT04523324|BIOLOGICAL|VaxigripTetra™ by Sanofi, Inc.|0.5 mL intramuscular dose of Vaxigrip
224284246|NCT02349243|DRUG|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
224284247|NCT02349243|DRUG|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
224284248|NCT05717270|PROCEDURE|Two-layered suture repair|The ruptured Achilles tendon will be sutured in two-layer.
223931116|NCT03211247|BIOLOGICAL|Part A Placebo|Placebo patch, once daily
223931117|NCT03211247|BIOLOGICAL|Part B Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
223931118|NCT03211247|BIOLOGICAL|Part B Placebo|Placebo patch, once daily
223931119|NCT06748651|DRUG|Allocetra|Intra-articular injection of Allocetra performed once on Day 1 of the study
224095811|NCT04438421|DRUG|Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid|Subjects will then be given the test product, BMG0703, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
224284249|NCT00288665|DEVICE|Export catheter (Medtronic)|
224284250|NCT02588066|PROCEDURE|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
224284251|NCT01563926|DRUG|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
224284252|NCT04569513|BIOLOGICAL|Thyroid and parathyroid disease|To analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.
224284253|NCT04813016|DRUG|Tramal 1|Early intraperitoneal injection of tramal and bupivacaine
224284254|NCT04813016|DRUG|Tramal 2|Late intraperitoneal injection of tramal and bupivacaine
224284255|NCT04813016|DRUG|Dexmedetomidine 1|Early intraperitoneal injection of dexmedetomidine and bupivacaine
224284256|NCT04813016|DRUG|dexmedetomidine 2|Late intraperitoneal injection of dexmedetomedine and bupivacaine
224284257|NCT00607152|DRUG|Rasburicase|0.20mg/kg per day IV
224284258|NCT00607152|DRUG|Allopurinol|100mg tablets
224284259|NCT00804141|DRUG|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
224284260|NCT03642353|DRUG|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
224284261|NCT03642353|DRUG|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
223931120|NCT06748898|OTHER|TENS-WAA|Before anesthesia induction, two paired of electrode pads will be placed on the upper area 1 and 2 with the skin of the treatment area exposed, and the upper and lower juxtaposition method will be adopted. The electrodes were placed close to the skin and connected with TENStem eco basic (Wuxi Jiajian Medical Device Co., Ltd.). Upper area 2 is at the middle of the palmar side of the forearm, between the palmaris longus and flexor carpi radialis.Upper area 1 is between the ulnar border on the little finger side and the flexor carpi ulnaris tendon.Stimulation parameters of TENS-WAA are alternating dense-disperse wave with a frequency of 2Hz and a pulse width of 200μs, and a frequency of 100Hz with a pulse width of 150μs, alternating every 3 seconds ，intensity required to reachthe maximum tolerable level without causing pain, continuous stimulation until the end of surgery.
223931121|NCT06748898|OTHER|non TENS-WAA|Before anesthesia induction, two paired of electrode pads will be placed on the same position without current stimulation.
223931122|NCT06854991|OTHER|Active VR-PAT|Virtual Reality Pain Alleviation Tool (VR-PAT) hosted on a Pico Neo 3 Pro Eye headset. Both engagement and immersion.
223931123|NCT06854991|OTHER|Passive VR-PAT|VR-PAT hosted on a Pico Neo 3 Pro Eye headset, with the active game participation removed. Immersion with engagement removed.
223931124|NCT06854991|OTHER|iPad|VR-PAT hosted on an Apple iPad. Engagement with immersion removed.
223931125|NCT06815887|DRUG|Bupivacaine|Patients received the combined pectoralis nerve block II (PECS II) (20 mL) and stellate ganglion block (5 mL) using 0.5% bupivacaine (local anesthetic) without magnesium sulfate.
223931126|NCT06815887|DRUG|Bupivacaine + Magnesium sulfate|Patients received the combined (20 mL) pectoralis nerve block II (PECS II) and stellate ganglion block (5 mL) using 0.5% bupivacaine (local anesthetic) mixed with 2.5 mL magnesium sulfate (10%), i.e., 250 mg.
223931127|NCT06826534|BEHAVIORAL|Cardio-oncology rehabilitation|Least 60 minutes of physical activity each day including vigorous-intensity and strengthening activities at least 3 days per week
223931128|NCT06878742|DRUG|Intravenous dobutamine 5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 5 mcg/kg/min.
223931129|NCT06878742|DRUG|Intravenous dobutamine 7.5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 7.5 mcg/kg/min.
223931130|NCT06878742|DRUG|Intravenous dobutamine 10 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 10 mcg/kg/min.
223931131|NCT06878742|DRUG|Intravenous dobutamine 12.5 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 12.5 mcg/kg/min.
223931132|NCT06878742|DRUG|Intravenous dobutamine 15 mcg/kg/min|Intravenous dobutamine will be administered at a dose of 15 mcg/kg/min.
223931133|NCT06754774|DIAGNOSTIC_TEST|Shoulder Endurance Test|Each patient receive the same intervention, the Shoulder Endurance Test (SET). The Shoulder Endurance Test assesses the endurance of the shoulder muscles in an open kinetic chain.
223931134|NCT06755801|DRUG|Nevibolol|Beta-blockers are the first-line treatment for patients with stable angina secondary to classic epicardial atherosclerotic disease, where their clinical benefits are well-established (4). However, their efficacy has not yet been demonstrated in ANOCA patients with MVD, where beta-blockers are frequently used due to their physiological plausibility. Beta-blockers act by competitively inhibiting catecholamine receptors. The therapeutic benefits of beta-blockade in patients with stable angina are mediated by a reduction in myocardial oxygen demand. Myocardial oxygen demand depends on heart rate, contractility, and left ventricular wall tension, all of which are reduced with beta-adrenergic blockade. The reduction in wall tension is partly mediated by the antihypertensive action of these drugs. The decrease in heart rate occurs both at rest and during sympathetic activation such as exercise or stress. The negative inotropic effect of these drugs also contributes to reducing myocardial oxyg
223931135|NCT06755801|DRUG|Placebo|Placebo
224284262|NCT02148679|OTHER|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
223533184|NCT00534001|DRUG|bupropion hydrochloride|Given orally
223533185|NCT00534001|OTHER|placebo|Given orally
223931136|NCT06743724|DEVICE|repeated transcranial magnetic stimulation treatment|Patients with low score of Maternal Care Rating Scale received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 2 week.
223931137|NCT06764082|DIETARY_SUPPLEMENT|high MCT formula|"Energy Intake: The tube-feeding formula was a special medical-purpose formula food with high MCT and deep hydrolyzed milk protein (Alfare, Nestlé, Switzerland), which contained hydrolyzed whey protein, maltodextrin, vegetable oil, and MCT, etc. At a high-calorie concentration, each 1000 mL could provide 800 kcal, 15.8 g MCT, and 21.5 g protein (osmotic pressure 227 mOsm/kg).~Feeding Procedure: On the basis of 130 - 150% DRI, a high-calorie formula feeding amount of 160 ml/kg/d could provide 2.7 g/kg/d MCT. After the operation, starting from when oral nutrition was feasible, the amount gradually increased from the initial amount until the expected amount was reached, and this continued until 6 months after the operation. The difference between the estimated feeding amount and the actual feeding amount could be selectively supplemented with enteral nutrition (nasogastric tube)."
223931138|NCT06764082|DIETARY_SUPPLEMENT|normal oral intake of the traditional formula|For the children in the control group, there were no special restrictions before the operation. After they were able to have a normal diet postoperatively, they were encouraged to have a normal oral intake of the traditional formula. The recommended energy input for the formula was 130 - 150% of the reference intake (DRI) based on age and gender as per the World Health Organization (WHO). The final dosage and schedule were determined by the children and their parents or caregivers. The feeding route and the schedule for complementary feeding were the same as those in the experimental group.
223931139|NCT06765239|DIETARY_SUPPLEMENT|Hayfever Care|"Powdered natural food supplement provided as a decoction, to be taken twice daily.~Personalized Diet and Nutrition Guidance along with Lifestyle Advice"
223931140|NCT06765239|OTHER|Wait-list Control|Personalized Diet and Lifestyle Advice
223931141|NCT06763172|DRUG|Caffeine (200 mg)|Caffeine (200mg) will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
223718271|NCT06397014|PROCEDURE|D-type stoma lateral hernia repair|underwent D-type stoma lateral hernia repair
224284263|NCT02148679|OTHER|Usual care|Standardized advice to restrict dietary sodium intake to \< 2000 mg/day
224284264|NCT00572039|BEHAVIORAL|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
224284265|NCT00572039|BEHAVIORAL|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
223931142|NCT06763172|DRUG|Placebo|Lactose tablet will be administered per os 20 minutes prior to the PET/fMRI data acquisition.
223931143|NCT06774508|OTHER|HIFE+cog|Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Simultaneous cognitive exercises are added to static and dynamic balance exercises. Relative exercise intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
223931144|NCT06774508|OTHER|HIFE|Each session will consist of individually tailored exercises performed at weight- bearing positions and covering lower leg strengthening exercises, as well as static- and dynamic balance exercises. Relative exercises intensity is encouraged to be moderate to high, and progressively adjusted by for example altering load or difficulty of the exercise. Session duration is 1 hour, including warm-up.
223931145|NCT06765577|OTHER|Finger Blood Pressure Measurement|Finger Blood Pressure Measurement were taken from three digits: the thumb (F1), the middle finger (F2), and the little finger (F3) from both arms.
223931146|NCT05296187|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
223931147|NCT06758466|PROCEDURE|Prostate surgery|Prostate removal
223931148|NCT06752525|DRUG|Bupivacaine|patients will receive SPGB block with 2 ml volume on each side (1.5 mL of bupivacaine 0.5% + 0.5 mL of magnesium sulphate 10%).
223931149|NCT06752525|DRUG|Magnesium Sulphate 500 mg|patients will receive SPGB block with 2 ml volume on each side (1.5 ml bupivacaine 0.5% plus 0.5 ml saline).
223931150|NCT06775210|OTHER|supportive sleep care|sleep bundle
223931151|NCT06775210|OTHER|care bundle|sleep bundle
223931152|NCT06773923|DEVICE|PCL Scaffold|patients with their jaw/maxilla in which the 3D scaffold with PCL will be inserted.
223931153|NCT06773923|DEVICE|PTFE + Bio-Oss®|patients with jaw/maxilla which will be regenerated using the conventional technique using a titanium reinforced polytetrafluoroethylene (PTFE) membrane (Cytoplast® brand) and filling the space with Bio-Oss xenograft (Geistlich
224284266|NCT03984123|DEVICE|Brachial cuff, in order to achieve ischemic stimuli|Standard treatment with no brachial cuff inflation
224284267|NCT03852524|DRUG|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
224284268|NCT03852524|OTHER|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
224284269|NCT02310516|DEVICE|preoperative adequate explanations about awake surgery|
224284270|NCT02310516|OTHER|no preoperative explanation|
224284271|NCT05453786|DRUG|SID1903|Single oral administration of SID1903 after an overnight fast
224284272|NCT05453786|DRUG|SID1903-R1/SID1903-R2|Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
224284273|NCT02973321|DRUG|SAR425899|Self-administered by SC injection using a solution for injection in cartridge.
224284274|NCT02973321|DRUG|Placebo|Self-administered by SC injection using a solution for injection in cartridge.
224284275|NCT02973321|DRUG|Liraglutide|Self-administered by SC injection using a pre-filled pen.
224095812|NCT04438421|DRUG|Chlorhexidine mouthwash|Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
224284276|NCT02973321|DRUG|Metformin|Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.
223931154|NCT06771310|OTHER|Endurance exercise|"The exercise-training program will be consisted of 10 minutes warming up, 30 minutes of treadmill walking, and 10 min cooling down three times per week.~Warming up: It will be in the form of stretching of muscle groups for 10 minutes (3-5 stretch for the key muscle group (iliopsoas muscle, gluteus maximus ,quadriceps ,tibialis anterior , calf muscle, hold for 20-30 seconds), before the actual aerobic training session.~Actual session: Participants will receive aerobic exercises in the form of Moderate aerobic exercise training in the form of 30 min of treadmill walking and corresponding to a target heart rate of 65% to 75% of HR max (Maximum HR = 220 - Age ) to be gradually achieved and maintained throughout the training program.~Cooling down: It will be in the form of a treadmill walking at very slow speed for ten minutes."
223931155|NCT06771310|OTHER|Kinesiotaping|"The participants will be asked to assume standing position then to flex back to reach its maximum point.~* Two bands, 1 on each side of the lumbar spine, will be applied vertically from the lower posterior iliac crest region to the upper twelfth rib region, with inhibition technique.~* The remaining 2 bands will be attached horizontally, with space correction technique.~* All 4 bands will be placed to allow for 50% longitudinal stretching. The stretching directions for the vertical and horizontal applications were bottom-up and sideways, respectively."
224095813|NCT04438421|DRUG|Placebo|Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
223931156|NCT06725173|GENETIC|Targeted Long-read sequencing|All patient's will undergo targeted long-read sequencing to resolve genomic and epigenomic signatures of the RB1 gene
223931157|NCT04352166|DRUG|extended-release buprenorphine (BXR)|Three monthly injections will be provided during the course of the 12 week trial.
223931158|NCT04352166|DRUG|sublingual buprenorphine (BSL)|On a weekly basis patients will be provided with sublingual buprenorphine to take up to 24 mg daily.
223931159|NCT06242873|OTHER|Gait training with/without TSCS|To assess the safety and impact of paired stimulation and training on gait in children with iSCI, participants will participate in 24 total sessions. Two sessions will involve assessment only and 22 sessions will include two hours of therapy. Sessions will occur at least three times per week, but may be scheduled as many as five times per week. In each session, participants will receive 60 minutes of treadmill training followed by strengthening, segmental task practice, and gait-based interventions. Participants will receive stimulation based on their group assignment (TSCS or sham).
223931160|NCT02962973|DEVICE|CARMAT TAH|
223931161|NCT02962973|PROCEDURE|Surgical intervention|
223931162|NCT04656340|OTHER|non-medication, non-interventional therapies|non-medication, non-interventional therapies
223931163|NCT06891482|BEHAVIORAL|Telerehabilitation|Intervention: Each enrolled participant within the telerehabilitation + usual care rehabilitation part will be provided a Fitbit® Charge 5 tracker, connected with the smartphone application Fitbit on the participant\&#39;s smartphone by creating a Fitbit user account, and the tracker will be configured for each participant. A smartphone will be provided if the participant does not have a smartphone. Participants will be asked to continue wearing their tracker on their non-access arm at all times, other than bathing, for the 3-months study duration. Each week during this telerehabilitation phase, the physiotherapist (PT) will follow-up the participants' step counts during hemodialysis. Participants will receive feedback on their activity level and will be motivated by the PT, along with specific step goals for the upcoming week. The PT gives advise on how to incorporate more walking into participants' daily routine with specific attention for shared decision making during this feedback
223931164|NCT00898365|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223931165|NCT00898365|OTHER|Laboratory Biomarker Analysis|Correlative studies
223931166|NCT06878976|DRUG|Solriamfetol 75mg, 150 mg, or 300 mg|Taken once daily.
224095814|NCT01152853|DRUG|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
224095815|NCT00535340|DRUG|SR58611A|
224095816|NCT05313438|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
224095817|NCT01051739|PROCEDURE|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
223718272|NCT03566394|DRUG|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
224095818|NCT04381000|OTHER|Exercise Group|The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
224095819|NCT02293681|DRUG|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
224284277|NCT04685694|DRUG|Misoprostol|sl 800 mcg misoprostol
224284278|NCT03785769|PROCEDURE|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
224284279|NCT03785769|PROCEDURE|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
224284280|NCT02066337|PROCEDURE|scaling and root planing|
224284281|NCT02066337|DRUG|placebo gel|
224284282|NCT02066337|DRUG|Ozonated olive oil gel|
224284283|NCT00149149|OTHER|Zinc Carnosine coadministered with Indomethacin|
224284284|NCT00149149|OTHER|Placebo coadministered with Indomethacin|
224284285|NCT02827890|DRUG|Januvia Tab. 100mg|Januvia Tab. 100mg\*1T/day for 5days, QD, PO
223718273|NCT04445922|DRUG|test-anastrozole tablet (Salutas Pharma GmbH)|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
224095820|NCT02293681|DRUG|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
224095821|NCT02293681|DRUG|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
224095822|NCT02499952|DRUG|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
224095823|NCT03754985|DEVICE|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
224284286|NCT02827890|DRUG|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
224284287|NCT02407171|DRUG|MK-3475|200 mg every 2 weeks by IV infusion
224284288|NCT02407171|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
224284289|NCT05460221|DIETARY_SUPPLEMENT|Optimized oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
224284290|NCT05460221|DIETARY_SUPPLEMENT|Functional oil group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
224284291|NCT05460221|DIETARY_SUPPLEMENT|Control group|"This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months."
224284292|NCT02714296|DRUG|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
224284293|NCT02714296|DIETARY_SUPPLEMENT|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
224284294|NCT03124134|DEVICE|Gelesis200|Encapsulated hydrogel
224284295|NCT03124134|OTHER|Water, only (placebo)|300 mL of water
224284296|NCT02666924|DIETARY_SUPPLEMENT|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
224284297|NCT02666924|OTHER|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
224284298|NCT00146796|DEVICE|Rapid diagnostic test for malaria|
224284299|NCT02833207|DRUG|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
223718274|NCT04445922|DRUG|reference-anastrozole tablet|Subjects were allocated to one of two groups randomly and equally with a 21-day washout interval between the two periods.All of them were randomized (1:1) to receive anastrozole as a single oral dose of the test drug or a single 1.0-mg oral dose of Arimidex
223718275|NCT02348827|BEHAVIORAL|Family psychoeducation|
223718276|NCT02348827|BEHAVIORAL|Social support group|
223718277|NCT01651195|DIETARY_SUPPLEMENT|Probiotic|
224095824|NCT04938856|DRUG|Lamotrigine tablet|Lamotrigine 100 mg immediate release Tablet
224095825|NCT00507247|DRUG|Daptomycin|6mg/kg/day IV for at least 10 days.
224095826|NCT00599768|OTHER|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
223931167|NCT06740591|DEVICE|HD-tDCS|The HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
224284300|NCT02833207|DRUG|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
224284301|NCT03318887|DRUG|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
223931168|NCT06740591|DEVICE|Sham High-Definition Transcranial Direct Current Stimulation(sham HD-tDCS)|The Sham HD-tDCS stimulation was applied for 20 minutes, 5 times a week, for a total of 10 sessions.
223931169|NCT06742476|DEVICE|nasal cannula|In the apneic oxygenation group, nasal cannula will be employed to administer continuous oxygenation, utilizing a flow rate of 0.2 L/kg, during the apneic phase while tracheal intubation is performed. Successful intubation will be confirmed by auscultation and the appearance of a square wave capnogragh.
223931170|NCT06700980|OTHER|Focus Group|Dutch-speaking patients, Dutch- and/or French-speaking general practitioners and Dutch- and/or French-speaking representatives from pertinent organizational and policy sectors will be questioned in heterogeneous focus groups, identifying barriers and facilitators to the use of technological translation tools in Brussels out-of-hours primary care services for Dutch-speaking patients and French-speaking general practitioners.
223931171|NCT06618976|DRUG|Sotagliflozin|Sotagliflozin 400 mg, P.O. once daily for 1 month.
223931172|NCT06618976|DRUG|Empagliflozin|Empagliflozin 10 mg, P.O. once daily for 1 month.
223931173|NCT06284941|DRUG|Ropivacaine combined with methylene blue for iliac fascia block|Ultrasound guided iliac fascia block, administered with 30ml of 0.25% ropivacaine+0.05% methylene blue
223931174|NCT06829927|BEHAVIORAL|e-book|Patients with pilot application will not be included in the study. Patients who agree to participate in the study will be informed by the researcher about the purpose and process of the study, and their written and verbal informed consent will be obtained. Patients will be informed that the decision on whether or not to participate in the study is entirely their own, that no money will be deducted from their health insurance or any money will be paid to them, that the data to be collected from this study will only be used within the scope of the research, and that confidentiality will be strictly ensured. Pretests (Personal Information Form, Urinary Catheter Self-Efficacy Scale and Comfort Scale) will be administered to the patients whose consent is obtained.
223931175|NCT06827899|DRUG|veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)|Specified dose on specified days
223931176|NCT04671771|DEVICE|InnAVasc Arteriovenous Graft (IG) surgical implant|The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
223931177|NCT02819882|OTHER|No intervention|
223931178|NCT06262776|BIOLOGICAL|Recombinant zoster vaccine adjuvanted (SHINGRIX)|2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.
223931179|NCT03673280|PROCEDURE|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
223931180|NCT05160012|BEHAVIORAL|Peer Comparison Message|"In addition to usual care, PCPs will receive a monthly report as an EPIC in basket message describing what category they are in:~1. If HTN control rate \<50th percentile, PCP is told they are below median~2. If HTN control rate is between 50-89th percentile , PCP is told they are below top performer~3. If HTN control rate is between 90-100th percentile, PCP is told they are a high performer"
223931181|NCT02998164|BEHAVIORAL|augmentative and alternative communication technology|
223931182|NCT02998164|BEHAVIORAL|Usual Care|No change to the therapy care received
223931183|NCT06463015|PROCEDURE|ultrasound-guided posterior tibial nerve pulsed radiofrequency|The posterior tibial nerve (PTN) was identified with a 5-12 MHz linear ultrasonography (US) probe at the level of the medial malleolus, where it runs posterior to the posterior tibial artery. Using the in-plane technique, a 22-gauge, 10-cm radiofrequency cannula was inserted under US guidance and advanced until the tip was adjacent to the nerve. Pulse radiofrequency was applied at 42°C for 240 s with a pulse width of 20 ms
223931184|NCT05014178|DIAGNOSTIC_TEST|Sodium-23 MRI|Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.
224095827|NCT05416892|OTHER|Pharmaclass® software|Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.
224095828|NCT02764879|DIETARY_SUPPLEMENT|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
224095829|NCT02764879|PROCEDURE|scaling and root planing|
224095830|NCT02764879|OTHER|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
224095831|NCT04582240|OTHER|no intervention|no intervention
224095832|NCT01440101|DRUG|Natalizumab (BG00002)|
224095833|NCT01440101|DRUG|Placebo|
224284302|NCT05722028|PROCEDURE|hysteroscopy|Surgical hysteroscopy without anaesthesia for removal of uterine polyp / retained products of conception.
224284303|NCT01501968|DRUG|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
223718278|NCT01651195|OTHER|Placebo|
224284304|NCT01501968|DRUG|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
224284305|NCT00003317|DRUG|carboplatin|
224284306|NCT00003317|DRUG|paclitaxel|
224284307|NCT00003317|RADIATION|radiation therapy|
224284308|NCT00003317|PROCEDURE|surgery|
224284309|NCT00350987|BEHAVIORAL|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
224284310|NCT05380219|OTHER|dual task strength training|strength training and dual task
224284311|NCT01790113|DEVICE|Univers™|Control
224284312|NCT01790113|DEVICE|Eclipse™ Total Shoulder Replacement|Investigational
224284313|NCT04157478|DRUG|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
224284314|NCT04157478|RADIATION|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
223533186|NCT05831943|DIAGNOSTIC_TEST|Contrast enhanced Kidney CT|"* Test group : Patient undergoing CT scan with 80kVP protocol and using low concentration intravascular contrast media ( Iobrix 270 mgl/MI , Taejoon pharm, Seoul, South Korea)~* Control group : Patient undergoing CT scan with 120kVP protocol and using high concentration intravascular contrast media ( Iobrix 320 mgl/MI , Taejoon pharm, Seoul, South Korea)"
223533187|NCT05439980|OTHER|Knowledge questionnaire|Completion of a questionnaire at baseline
223533188|NCT05439980|OTHER|Focus groups|structured interviews
223533189|NCT00317837|PROCEDURE|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
223533190|NCT00317837|PROCEDURE|bipolar hemiarthroplasty|bipolar hemiarthroplasty
224095834|NCT00677261|PROCEDURE|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
224095835|NCT00677261|PROCEDURE|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
224095836|NCT00677261|PROCEDURE|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
224095837|NCT00046566|DIETARY_SUPPLEMENT|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
224095838|NCT00046566|DIETARY_SUPPLEMENT|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
224095839|NCT00046566|BEHAVIORAL|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
224095840|NCT00636818|DRUG|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
224095841|NCT00074958|BIOLOGICAL|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
224095842|NCT06535997|OTHER|Questionnaire|For patients alive only at the time of inclusion, completion of a quality-of-life questionnaire and a medico-economic interview (prospective).
224095843|NCT01919892|DRUG|Lithium|
224095844|NCT02835430|PROCEDURE|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
223533191|NCT02412670|DRUG|Methotrexate|Given IV
223533192|NCT02412670|DRUG|Vinblastine|Given IV
223533193|NCT02412670|DRUG|Doxorubicin|Given IV
223533194|NCT02412670|DRUG|Cisplatin|Given IV
223533195|NCT02412670|DRUG|Gemcitabine|Given IV
223533196|NCT02412670|DRUG|Carboplatin|Given IV
223533197|NCT02412670|DRUG|Pegfilgrastim|Administered subcutaneously
223533198|NCT02412670|PROCEDURE|Nephroureterectomy|Undergo nephroureterectomy and lymph node dissection
224095845|NCT02835430|PROCEDURE|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
224095846|NCT00184457|BEHAVIORAL|Strength training intervention|
224095847|NCT05798520|DRUG|BIIB091|Administered as specified in the treatment arm.
224095848|NCT05798520|DRUG|DRF|Administered as specified in the treatment arm.
224095849|NCT05798520|DRUG|Placebo|Administered as specified in the treatment arm.
224095850|NCT00842933|DRUG|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
224095851|NCT00842933|DRUG|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
224095852|NCT01852084|DEVICE|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
224095853|NCT01852084|DEVICE|enVista control lens|Spherical Control lens
224095854|NCT04371796|DRUG|Sintilimab injection|Sintilimab injection 200mg, 2cycles of treatment before surgery
224095855|NCT01205009|DRUG|Ovitrelle|One dose of Ovitrelle 250 mcg
224095856|NCT01339442|DRUG|BKM120|
224095857|NCT01339442|DRUG|Fulvestrant|
224095858|NCT01339442|PROCEDURE|biopsy|Correlative studies
224095859|NCT01578902|RADIATION|Stereotactic ablative body radiotherapy|35Gy/5 fractions/29 days
224095860|NCT01364805|DRUG|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
224099701|NCT04760145|OTHER|Multicomponent Exercise without Blood Flow Restriction|"* 10 minutes of initial warm-up.~* 20 minutes of strength exercises.~* 10 minutes of resistance exercises.~* 10 minutes of coordination and balance exercises.~* 5 minutes of flexibility.~* 5 minutes of return to calm and relaxation.~All of this multicomponent training will be performed without blood flow restriction."
224099702|NCT04109599|BEHAVIORAL|PlaySmart|Participants played the developed PlaySmart game over the course of a week.
223718279|NCT02417974|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
224284315|NCT04157478|DRUG|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
223533199|NCT01593371|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
223533200|NCT01593371|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
223533201|NCT00508456|DRUG|Temodar (Temozolomide)|150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).
223533202|NCT00508456|DIETARY_SUPPLEMENT|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
224284316|NCT00552149|DRUG|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
223533203|NCT05746559|DRUG|Placebo|Participants will receive a single weight-based dose of placebo via intravenous infusion.
223533204|NCT05746559|DRUG|Ravulizumab|Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
223533205|NCT02363166|OTHER|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
224284317|NCT01935648|DRUG|Ropivacaine|
224284318|NCT03278509|DRUG|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
224284319|NCT03278509|DRUG|Bisoprolol|Please see the section above.
224284320|NCT03444441|PROCEDURE|Foot or ankle surgery|Surgery for foot or ankle
224284321|NCT00697970|BIOLOGICAL|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
224284322|NCT00697970|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
224284323|NCT02129309|PROCEDURE|Forearm plethysmography|Dose response study
224284324|NCT02129309|PROCEDURE|Haemodynamic studies|Dose response study
224284325|NCT02582788|OTHER|Bathing Additive|
224284326|NCT04783116|DIETARY_SUPPLEMENT|Plant stanols (3g/day)|Oral consumption of 6 plant stanol enriched chews per day for 6 months (total dosage is 3g/day). Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
224284327|NCT04783116|DIETARY_SUPPLEMENT|Placebo|Oral consumption of 6 placebo chews per day for 6 months. Chews are consumed with main meals: two with breakfast, two with lunch and two with dinner.
224284328|NCT01570816|DEVICE|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
224284329|NCT00139724|DRUG|tolterodine extended release capsule|
224284330|NCT00092950|BEHAVIORAL|Physical activity|
224284331|NCT05435586|OTHER|Web Based Breastfeeding Education and Counseling with Digital Game Support|The educational content prepared by the researcher on the web page will be integrated into the game program designed with the gamification technique. In this designed program, users will be notified at appropriate times to enter the system and play games from the link sent via e-mail. After the users have finished the game, they will fill the scale in the relevant week and will only be able to exit the system in that way.
224284332|NCT01885416|OTHER|consumption of test meal based on dairy products|
224284333|NCT01885416|OTHER|consumption of high fat test meal without dairy products|
224284334|NCT01885416|OTHER|consumption of high fat test meal with dairy products|
224284335|NCT04554095|OTHER|Clinical data collection|Respiratory parameters, analytic values, lung ultrasound and echocardiography
224284336|NCT00010413|DRUG|cyclophosphamide|
224284337|NCT00010413|DRUG|filgrastim|
224284338|NCT03527251|DRUG|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
224284339|NCT03527251|DRUG|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
224284340|NCT00865514|DRUG|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
224284341|NCT00865514|GENETIC|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
224284342|NCT00865514|OTHER|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
223533206|NCT03549325|BIOLOGICAL|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
223718280|NCT00963196|DIETARY_SUPPLEMENT|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
223718281|NCT00963196|DRUG|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
223718282|NCT00000443|DRUG|ondansetron (Zofran)|
223718283|NCT00164554|BEHAVIORAL|Parent-child Interaction Therapy (PCIT)|
223533207|NCT00227253|PROCEDURE|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
223533208|NCT00227253|PROCEDURE|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
223533209|NCT00227253|PROCEDURE|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
223533210|NCT00227253|PROCEDURE|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
223533211|NCT00227253|PROCEDURE|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
223718284|NCT02297477|DRUG|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
223718285|NCT02297477|DRUG|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
223718286|NCT03440710|PROCEDURE|BET|Balloon Eustachian Tuboplasty
223718287|NCT04546438|DEVICE|miraDry®|"MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions)."
223718288|NCT02697864|DRUG|tafamidis|
223718289|NCT00811369|DRUG|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
223931185|NCT06805526|BEHAVIORAL|Intermittent Islamic fasting with lifestyle modification|"Both groups followed a healthy lifestyle for 6 months including:~Diet: The participants' habitual total energy expenditure was estimated using the standard Harris-Benedict equation. To achieve a reduction of over 500 kcal/day, a daily intake of 1,200 to 1,500 kcal is typically recommended for women and 1,500 to 1,800 kcal for men .~Physical Activity: Moderate physical activity is advised. This includes engaging in exercise for 30 to 60 minutes, five days a week. Additionally, incorporating resistance training is recommended twice a week .~* stress management How to cope with stress, relaxation technique, quality and quantity of sleep,~* Drinking enough water 30-40ml/kg/day. Followed Intermittent Islamic fasting which meant fasting two days per week (Monday and Thursday) with fasting (13, 14, 15) middle of lunar months. (during Intermittent Islamic fasting caloric requirement was distributed as 30-40~For Group I (intervention group) only, Followed Intermittent Islamic fasting wh"
223931186|NCT06805526|BEHAVIORAL|Lifestyle modification only|"The participants' habitual total energy expenditure was estimated using the standard Harris-Benedict equation. For men, the formula is: BMR = 66.4730 + 13.7516 × weight (kg) + 5.0033 × height (cm) - 6.7550 × age (years). For women, the formula is: BMR = 655.0955 + 9.5634 × weight (kg) + 1.8496 × height (cm) - 4.6756 × age (years) \[27\]. To achieve a reduction of over 500 kcal/day, a daily intake of 1,200 to 1,500 kcal is typically recommended for women and 1,500 to 1,800 kcal for men \[28\].~Physical Activity: Moderate physical activity is advised. This includes engaging in exercise for 30 to 60 minutes, five days a week. Additionally, incorporating resistance training is recommended twice a week \[29\].~* stress management How to cope with stress, relaxation technique, quality and quantity of sleep,~* Drinking enough water 30-40ml/kg/day."
224099703|NCT04109599|BEHAVIORAL|PlaySmart Storyline|Participants played through one PlaySmart Storyline during one 1-1.5 hour session.
224099704|NCT04109599|BEHAVIORAL|Play Smart Mini-Game|Participants played through all levels of the PlaySmart Risk Sense mini-game during one 1-1.5 hour session.
224099705|NCT05564559|OTHER|multifamily group psychoeducation|The intervention involves 8 weeks of multifamily psychoeducation for families. Duration of sessions: 75 minutes on average Context: First session: psychoeducation on substance-abuse disorders; second session; effects of addiction on the family; third session; illness management; fourth session; supporting recovery; fifth session; improving stress coping skills/stress management; sixth session; developing problem-solving skills; seventh session; strengthening the family; eighth session; working with stigma Preferred approach: face-to-face, multi-family Approach: Psychoeducation
224284343|NCT00865514|OTHER|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
224284344|NCT03920280|DEVICE|LID015385 contact lenses|Investigational silicone hydrogel contact lenses
224284345|NCT03920280|DEVICE|Comfilcon A soft contact lenses|Commercially available silicone hydrogel contact lenses
224284346|NCT03920280|DEVICE|CLEAR CARE|Hydrogen peroxide-based cleaning and disinfecting system
224284347|NCT03634059|DRUG|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
224284348|NCT00258778|DRUG|Human Glucocerebrosidase (prGCD)|
224284349|NCT05070962|OTHER|clinical population|or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.
224284350|NCT00650273|DRUG|Azithromycin Tablets 600 mg|600mg, single dose fasting
224284351|NCT00650273|DRUG|Zithromax® Tablets 600 mg|600mg, single dose fasting
224284352|NCT03996616|DEVICE|Head UP Position|"CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a \<10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
224284353|NCT03996616|DEVICE|Impedance Threshold Device|An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
224284354|NCT03996616|DEVICE|New Automated CPR|Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).
224284355|NCT05183711|BEHAVIORAL|Questionnaires|The Numerical Rating Scale (range from 1-10, 1= least competency, 10 =highest competency) will be used for any anesthesia skills evaluation. (download the self-evaluating form via QR code)
224284356|NCT04114942|BEHAVIORAL|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
224284357|NCT04114942|BEHAVIORAL|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
224284358|NCT04114942|BEHAVIORAL|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
223533212|NCT00227253|PROCEDURE|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
223533213|NCT00227253|PROCEDURE|Neurology examination|physical examination including observation of balance, coordination and reflexes.
223931187|NCT06822673|BEHAVIORAL|Mindfulness Based Intervention|The Mindfulness-Based Intervention will include techniques derived from the Mindfulness Matters Program protocol (for Children and Adolescents, 2019). It will consist of both formal and informal practices, which participants will engage in during sessions and at home. These practices will encompass body scan meditation, mindful eating, mindful sitting, walking exercises, attention-focusing activities, and more. The intervention will be delivered over eight weekly sessions, following a skill-building, educational approach.
223931188|NCT05184504|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
223533214|NCT00227253|PROCEDURE|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
223931189|NCT05275686|DRUG|Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray|Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
223931190|NCT05275686|OTHER|Placebo Nasal Spray|The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
224099706|NCT03590860|DRUG|LY3322207|Administered by SC injection
224099707|NCT03590860|DRUG|Placebo|Administered by SC injection
223533215|NCT00227253|PROCEDURE|Speech pathology evaluation|Standardized speech \& language tests and naturalistic assessment procedures.
223533216|NCT00227253|PROCEDURE|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
223533217|NCT00227253|PROCEDURE|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
223533218|NCT00227253|PROCEDURE|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
223533219|NCT00227253|PROCEDURE|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
223931191|NCT04252235|DEVICE|Air purifier|The intervention is the placement of active HEPA air purifiers in the bedroom and living room of the true air purifier arm. These air purifiers have been shown to reduce levels of particles in the home.
223533220|NCT05385822|BEHAVIORAL|Pelvic Floor Muscle Training|"* Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~* Constant tension for 30 seconds twice, with a 30-second pause~* Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months"
223533221|NCT04770207|DRUG|Injection of drug-eluting microspheres with multiple drugs into solid tumors|Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor
223533222|NCT00934921|DRUG|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
223931192|NCT04252235|DEVICE|Sham air purifier|The intervention is the placement of sham HEPA air purifiers in the bedroom and living room. These purifiers look identical to real HEPA air purifiers, but do not filter the air.
223931193|NCT05162352|DRUG|Donafenib+sintilimab|"Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity."
223533223|NCT00934921|DRUG|Zofran®|1 x 8 mg ODT
223931194|NCT06759064|DRUG|zoledronic acid plus Sintilimab intraperitoneal injection|At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
223931195|NCT06791759|OTHER|The course on technology use in nursing|Students attended in the course technology use in nursing. The course consisted of 2 hours per week over 14 weeks. The course aims to provide students with an understanding of fundamental technological developments in nursing, highlighting the importance and impact of technology in nursing education and practice.Theoretical lessons were delivered by two nurse educators over 8 weeks through PowerPoint presentations and interactive discussions. For the remaining five weeks, students were given some assignments to increase their interaction with digital technological tools. Three assignments were planned for each of the students. In this context, microsoft teams, canva, microsoft powerpoint, kahoot, mentimeter, quizlet, ed-puzzle, capcut, mobile health applications, google classroom, discord and artificial intelligence applications were used for assignments.
223533224|NCT04336189|DRUG|Sulfadoxine-pyrimethamine (SP)|SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.
223533225|NCT04336189|DRUG|Dihydroartemisinin-piperaquine (DP)|DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
223931196|NCT06738212|OTHER|Group A aerobic exercises|"Group A will perform the aerobic exercises (such as bicycling, treadmill and running) Aerobic exercises 15min/session for each exercise, 2 times/week. Frequency: 2 times /week Intensity: Easy to moderate about 60 to 75% of maximum heart rate Type: treadmill, bicycling, running Time: 45min/session~Bicycling:~15~\- Start with gentle, low-intensity cycling and gradually increase as comfort allows - Aim for regular, consistent cycling sessions (e.g., 2-3 times a week,15min/session) - Consider incorporating other exercises, like stretching or yoga, to complement cycling.~Running~To get started with running for dysmenorrhea:~1. Start with short distances and gradually increase as comfort allows~2. Aim for regular, consistent running sessions (e.g., 2-3 times a week,15 minute/session)~3. Consider incorporating other exercises, like stretching or yoga, to complement running."
223931197|NCT06738212|OTHER|Group B Aviva exercises|"Group B will perform the Aviva exercises in 18 different movements. Aviva exercise intervention method is based on a carefully structured, mild-to-moderate intensity series of 18 movement sequences and aerobic exercises 30min/session, 2 times/week (20)~Aviva Methods of exercises:~These exercises are a carefully structured, intense, and methodical series of movement sequences, including a 5 min warm-up exercise at the beginning and 5 min cooling-down exercises at the end of the session. These exercises are performed in Standing, Sitting, Supine lying, prone lying"
224095861|NCT01364805|DRUG|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
224095862|NCT02115308|DRUG|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
224095863|NCT03544580|PROCEDURE|immediate implant with dentine chips|Using dentin chips
224095864|NCT03544580|PROCEDURE|conventional immediate implant|using xenograft
224095865|NCT01575613|DRUG|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
224095866|NCT01575613|BIOLOGICAL|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
224095867|NCT01575613|BIOLOGICAL|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
224095868|NCT01575613|BIOLOGICAL|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
224095869|NCT03322358|OTHER|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
224095870|NCT03322358|DEVICE|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
224284359|NCT03969316|PROCEDURE|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
224284360|NCT01677208|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
224284361|NCT01677208|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
223931198|NCT06753019|OTHER|survey assessment tools|Functional and psychological status and the level of somatosensory amplification in patients with knee osteoarthritis will be evaluated with questionnaires.
224095871|NCT03322358|OTHER|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
224095872|NCT03666351|DRUG|Amlodipine 5mg|Amlodipine 5 mg
224095873|NCT03666351|DRUG|Losartan|Losartan Potassium 50 mg
224095874|NCT03666351|DRUG|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
224095875|NCT03666351|DRUG|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
224095876|NCT03666351|DRUG|current treatment|treatment is done by maintaining the current treatment
224095877|NCT02107755|BIOLOGICAL|ipilimumab|Given IV
224095878|NCT02107755|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
224095879|NCT02107755|OTHER|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
224095880|NCT03670355|DRUG|Tenofovir (TFV) IVR|Contains 1.4 g TFV
224095881|NCT03670355|DRUG|Placebo IVR|Contains placebo
224095882|NCT03543813|DRUG|CX-2029|CX-2029 Monotherapy
224284362|NCT01677208|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
224284363|NCT02487082|DRUG|Melatonin and Donepezil|10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
224284364|NCT02487082|OTHER|Placebo|For both groups: 5 weeks of Placebo in the Run-In Phase. For Group B: an addition 5 weeks of Placebo in Phase 1.
224284365|NCT03668431|DRUG|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
223533226|NCT03652155|PROCEDURE|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
223533227|NCT06565273|DRUG|FBL-MTX|Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
223533228|NCT02239003|DRUG|DAOIB|
223533229|NCT02239003|DRUG|Placebo|
223533230|NCT03781479|DRUG|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
223533231|NCT03781479|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
223533232|NCT03152201|DIAGNOSTIC_TEST|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
223533233|NCT02921256|DRUG|Capecitabine|Given PO
223533234|NCT02921256|DRUG|Fluorouracil|Given IV
223931199|NCT06774833|BEHAVIORAL|Self-initiated perturbation-based balance training|This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be required to recover their balance upon self-initiated perturbation.
223931200|NCT06774833|BEHAVIORAL|Conventional balance training|This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be instructed to perform balance and strength training. The same training duration and format will be used as the Self-initiated perturbation-based balance training group.
224095883|NCT06129630|PROCEDURE|Conventional occupational therapy sessions.|Occupational therapy sessions are based on cognitive stimulation, manipulative dexterity training and psychomotor skills.
224095884|NCT06129630|PROCEDURE|Conventional occupational therapy sessions + Nintendo Switch|Occupational therapy sessions are based on cognitive stimulation, manipulative skill training and psychomotor skills. In addition, 2 sessions per week are conducted with two Nintendo Switch games.
224095885|NCT01649336|DRUG|MEK162, MEK inhibitor; oral|multiple dose, escalating
223931201|NCT05113862|BIOLOGICAL|LD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
224095886|NCT01649336|DRUG|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
223931202|NCT05113862|BIOLOGICAL|LD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
223931203|NCT05113862|BIOLOGICAL|HD Vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
224095887|NCT06582342|PROCEDURE|Three dimensional imaging technology (3D-PANC MSP model)|The processing of the CT images obtained in each center for the creation of the 3D model will be performed centrally by the team of radiologists and computer scientists of the company Cella Medical Solutions. This team will be blinded to the reports of the CT scans.For each patient 4 NCCN check-lists will be filled in without knowing the result of the surgery or the AP study: 2 based on the conventional CT and two based on the 3D-MSP study.
224284366|NCT03668431|DRUG|Trametinib|Trametinib will be taken once a day for 28 consecutive days
224284367|NCT03668431|DRUG|PDR001|PDR001 will be administered IV every 28 days
224284368|NCT02369120|OTHER|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
223931204|NCT05113862|BIOLOGICAL|HD PepGNP-Covid19|Two intradermal injections in the upper arm spaced 21 days apart
224099708|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
224099709|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
224099710|NCT01027117|DRUG|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
224099711|NCT00803114|DRUG|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
224099712|NCT00803114|DRUG|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
224284369|NCT02369120|OTHER|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
224284370|NCT03160586|DIAGNOSTIC_TEST|Stuttering severity instrument-3|To measure of degree of stuttering in child
224099713|NCT04474730|DEVICE|BMT Physical Activity app|This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
224099714|NCT04474730|OTHER|Watch Only|A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
224099715|NCT03704337|DIETARY_SUPPLEMENT|Commercially Available Food Bar|Active
224099716|NCT03704337|DIETARY_SUPPLEMENT|Placebo|Placebo
224099717|NCT06239194|DRUG|MDX2001|MDX2001 intravenous infusion
224099718|NCT04444570|DEVICE|Continuous glycemia measuring device (Dexcom) implantation into the subcutaneous tissue|14 days before the date of the surgery and after the surgery patient will have implemented the device for continuous glycemia measurement (Dexcom). During standard control visit 14 days after the surgery for skin sutures removal the device will be taken out and data of whole period of time will be collected
223533235|NCT02921256|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
223533236|NCT02921256|DRUG|Leucovorin|Given IV
223533237|NCT02921256|DRUG|Oxaliplatin|Given IV
223533238|NCT02921256|BIOLOGICAL|Pembrolizumab|Given IV
223533239|NCT02921256|DRUG|Veliparib|Given PO
223931205|NCT06708962|OTHER|Mulligan's mobilization|Mulligan mobilization isthe concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient.
223931206|NCT06708962|OTHER|corticosteroid injection for rotator cuff tendinopathy|corticosteroid injection for rotator cuff helps resolving inflammation which occur for paraplegic patients from overuse of the crutches
223931207|NCT06717373|DEVICE|AutoAS|AutoAS is an artificial intelligence algorithm that will be tested retrospectively on the images acquired as part of the study
223931208|NCT06361173|OTHER|BMT4me|Caregivers will pilot test a Spanish version of the BMT4me app at a single time point.
223931209|NCT05629689|DRUG|GEH200520 Injection / GEH200521 (18F) Injection - Part A|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
224095888|NCT06582342|PROCEDURE|Computerized tomography group (conventional CT)|A multiphase CT (venous phase and pancreatographic phase) with 1mm thick slices and series of images in coronal, axial and sagittal reconstructions will be performed. This CT model will be performed at disease diagnosis and after completion of neoadjuvant chemotherapy treatment. Both CT scans will be independently reported by a radiologist from the hospital of origin. The preoperative CT scan will also be evaluated a posteriori by a radiologist from the sponsoring center with expertise in PAC. Both reports (the one from the radiologist of the center and the one from the radiologist of the sponsoring center) will be used to fill out the imaging study variables sheet based on the latest version of the NCCN 2022 guidelines. The radiologists will not know the outcome of the surgery or the anatomic pathology study at the time of the completion of the report.
224095889|NCT01658514|DRUG|Met DR|metformin delayed-release tablets
224095890|NCT01658514|DRUG|Met XR|metformin extended-release tablets
224095891|NCT01658514|DRUG|Placebo|
223533240|NCT00001055|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223533241|NCT00001055|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
223533242|NCT00001055|BIOLOGICAL|rgp120/HIV-1 SF-2|
223533243|NCT03917615|OTHER|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
223533244|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (1)|"Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
223533245|NCT06375681|BEHAVIORAL|Visual and / or Auditory Cognitive Tasks (2)|"Two sets of 10 sessions (\~20 minutes) of cognitive tasks either at home or in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements."
223533246|NCT05092750|DEVICE|FerroTraceTM|A magnetic
223533247|NCT05092750|DRUG|indocyanine green (ICG)|Given by SC injection
223533248|NCT05459662|DIETARY_SUPPLEMENT|oat based porridge|Consume one preparation per day, orally
223931210|NCT05629689|DIAGNOSTIC_TEST|Dynamic and Static - PET/CT scan|Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
223931211|NCT05629689|DRUG|GEH200520 Injection / GEH200521 (18F) Injection - Part B|Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
223931212|NCT05629689|DIAGNOSTIC_TEST|Static - PET/CT scan|Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
223931213|NCT06569914|BEHAVIORAL|Humanized care|(1) Humanized environmental care；(2) Humanized medical guidance；(3)Humanized psychological nursing；(4) Humanized and standardized management of IVGTT treatment process
223931214|NCT06570577|PROCEDURE|Inter-semispinalis Plane Block|A nerve block targeting the dorsal rami of the cervical spinal nerves can help alleviate postoperative incisional pain.
223931215|NCT06570577|DRUG|Opioids|Routine Pain Management
223931216|NCT06832709|OTHER|a program of rehabilitation|physical activities, health education, psychosocial and motivational support
223931217|NCT06890533|DRUG|Experimental: YZJ-4729|Loading dose + demand dose
223931218|NCT06890533|DRUG|Placebo Comparator: Saline|Loading dose + demand dose
223533249|NCT05459662|DIETARY_SUPPLEMENT|plant based preparation|Consume one preparation per day, orally
223533250|NCT05316844|OTHER|There will be no interventions.|Measurements and performance tests were conducted to investigate predictors of work-related performance
223533251|NCT03956160|OTHER|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~* Define the case-manager's profile, and required knowledge and skills~* Identify the resources and tools to be proposed on the Internet platform~* Test the tools and content~* Refine the program evaluation criteria~* Test and validate the study procedures."
223533252|NCT02865174|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
223931219|NCT06890533|DRUG|Active Comparator: Morphine|Loading dose + demand dose
223533253|NCT02865174|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
223533254|NCT02865174|DRUG|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
223931220|NCT06791876|BEHAVIORAL|Nurture and Play (NnP)|"The NnP group Intervention is a group-based, manualized parenting intervention initiated during pregnancy and continued into the postnatal period until infant age seven months. The program is designed to enhance parenting abilities focusing on three domains: Emotional availability, parental reflective functioning, and the ability to regulate own emotions. During NnP, the parents are supported in enhancing their emotional availability through caring and playing activities.~The intervention has been developed in Finland by Dr. Saara Salo and colleagues and tested in a randomized controlled trial among pregnant women with depression and it is now being implemented in Finland. The results from the study showed that mothers in the intervention group showed more emotional availability and higher levels of reflective functioning and experienced fewer depressive symptoms compared to mothers in the control group."
223931221|NCT06763016|BEHAVIORAL|Cognitive Behavioural Theory-based group consultation|"The sessions focused on various topics, such as sexuality, sexual health, gender roles, and sexual violence. Participants were encouraged to engage in group discussions and complete weekly tasks, which allowed them to interact and reflect on the material presented. The intervention aimed to address and challenge prevalent sexual myths, encourage open discussions about sexuality, and foster healthier sexual attitudes through evidence-based counseling.~The content of the digital interventions was structured on the basis of a semi-structured interactive group counseling. It was supported by sharing content on Instagram, one of the most widely used social media tools of the generation representing.~For three days a week over six weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous consultation session was held once a week. The participants were connected to the live broadcast of the research team."
223931222|NCT00129038|DRUG|modified-release dipyridamole/aspirin|
223931223|NCT00129038|DRUG|aspirin|
223931224|NCT06867263|PROCEDURE|Fulguration|Posterior urethral valve fulguration
223931225|NCT06848673|OTHER|Office-Based Vergence/Accommodative Therapy with Movement (OBVAM)|Head and body movements are incorporated into some therapy procedures in Phases 3 and 4. Additional details are provided in the Overall Program Narrative. Participants undergoing office-based VAM therapy will be prescribed home therapy procedures including the HTS2 Home Vision Therapy System (https://htsvision.com/) thrice weekly to support their in-office VAM therapy. This software progressively increases fusional convergence and divergence demands, offers instant user feedback, and will allow us to track participants' usage and progress. Basic procedures like free-space fusion cards and Brock String will also be prescribed for home therapy.
224095892|NCT01219556|DRUG|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
223533255|NCT05121350|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.
223533256|NCT05121350|DRUG|Epirubicin|Epirubicin can inhibit the synthesis of DNA and RNA.
223533257|NCT05121350|DRUG|Arotinib hydrochloride capsule placebo|Placebo of Anlotinib hydrochloride capsule
223533258|NCT06146816|DEVICE|photobiomodulation treatment in the infrared (IR) range.|The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
224284371|NCT03160586|DIAGNOSTIC_TEST|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
224284372|NCT01906424|DEVICE|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
224284373|NCT00965016|PROCEDURE|hypothermia|Core temperature --\> 34.9℃ within 30 min --\> 33.5℃ within 120min --\> 33℃for 24 H Decrease temperature in 0.9℃/hour
224284374|NCT00798681|DIETARY_SUPPLEMENT|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
224284375|NCT00798681|OTHER|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
223533259|NCT02248571|DRUG|Bevacizumab|administered as combined therapy with Capecitabine
223533260|NCT02248571|DRUG|Capecitabine|administered as combined therapy with Bevacizumab
223533261|NCT02248571|DRUG|Everolimus|administered as combined therapy with Exemestane
223533262|NCT02248571|DRUG|Exemestane|administered as combined therapy with Everolimus
223533263|NCT02248571|OTHER|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
224284376|NCT00798681|OTHER|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
224284377|NCT02629250|PROCEDURE|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR \<100 bpm, Hb \>8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV \>10% or blood loss \>250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
224284378|NCT02629250|PROCEDURE|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
223931226|NCT06109090|OTHER|Neuropsychological testing|"In this study, the Vineland Adaptive Behavior Scale is administered, which evaluates the child's adaptive functioning, particularly in four areas: communication, socialization, daily living skills, and motor activities. The Child Behavior Checklist (CBCL) questionnaire is also administered, which is a questionnaire given to parents that highlights elements related to internalizing and externalizing behavioral disorders.~For the assessment of executive functions, a series of tests are administered to evaluate specific functions. These tests are chosen from a list of available tests according to the document from the Italian Society of Child Neuropsychiatry, titled Assessment of attention and executive functions in developmental age: review of Italian instruments and proposal of a battery for in-depth analysis."
223931227|NCT06816706|PROCEDURE|Modified high flow tracheal oxygen-40L/min|Modified high-flow tracheal oxygen with a flow rate of 40L/min will be performed.
223931228|NCT06816706|PROCEDURE|Standard high flow tracheal oxygen-40L/min|Standard high-flow tracheal oxygen with a flow rate of 40 L/min will be performed.
223931229|NCT06816706|PROCEDURE|T-piece|T-piece will be performed.
223931230|NCT06816706|PROCEDURE|Modified high-flow tracheal oxygen-60L/min|Modified high-flow tracheal oxygen with a flow rate of 60L/min will be performed.
223931231|NCT06816706|PROCEDURE|Standard high-flow tracheal oxygen-60 L/min|Standard high-flow tracheal oxygen with a flow rate of 60 L/min will be performed.
223931232|NCT06873230|OTHER|The study will utilize the Jefferson Scale of Empathy-Health Profession Students (JSE-HPS) as the primary instrument for measuring empathy.|This cross-sectional observational study utilizes the Jefferson Scale of Empathy-Health Profession Students (JSE-HPS) as the primary instrument for measuring empathy, distinguishing itself as the first of its kind to be conducted among Dental Hygiene students and interns in Saudi Arabia. The unique focus on this specific population in the Saudi context sets this research apart from previous studies in the field.
223931233|NCT06875648|OTHER|Not applicable (observational study)|Retrospective analysis of gut microbiota in CRC patients vs. healthy controls. No interventions were administered; data were collected from archived samples and medical records.
223931234|NCT06735924|DIETARY_SUPPLEMENT|Low-oxalate fixed diet|Ingestion of a low-oxalate (\< 60 mg/day) , normal calcium (800-1200 mg/d) eucaloric diet for 5 days
223931235|NCT06744478|DEVICE|Misight 1 Day Contact Lens|Misight 1 Day Contact Lens wearing for myopia control
223931236|NCT06854445|DRUG|TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection|"Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection;~Other Name:~Gemcitabine Hydrochloride for Injection, Zefei; Oxaliplatin for Injection, Aihen~TQB2825 injection is Cluster of Differentiation 3 (CD3) and and Cluster of Differentiation 20 (CD20) bispecific antibody; Gemcitabine hydrochloride for injection is a cell cycle-specific antimetabolite; Oxaliplatin for Injection is a platinum chemotherapy drug."
223931237|NCT03691493|DRUG|Anastrozole|Given PO
223931238|NCT03691493|DRUG|Exemestane|Given PO
223931239|NCT03691493|DRUG|Fulvestrant|Given IM
223931240|NCT03691493|DRUG|Letrozole|Given PO
223931241|NCT03691493|DRUG|Palbociclib|Given PO
223931242|NCT03691493|RADIATION|Radiation Therapy|Undergo radiation therapy
223931243|NCT03691493|DRUG|Tamoxifen|Given PO
223931244|NCT06891079|DIAGNOSTIC_TEST|Videodensitometric guided|"In the experimental arm, a TAVI device is implanted according to the local practice. Immediately after implantation, aortography is performed to quantitatively assess the aortic regurgitation (qAR). The aortography is analyzed using CAAS A-Valve (Pie-Medical, Maastricht, The Netherlands).~•If qAR is \>17%, we recommend that corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed and angiography is repeated for the assessment of aortic regurgitation. If the qAR ≤17%, whether corrective post-TAVI manoeuvres (post-dilatation, valve-in-valve, etc.) will be performed is left to the discretion of the operators. Inform operators of the results of qAR and the threshold criteria. Continuous qAR was stratified into categorical variables according to the following pre-determined threshold criteria: (1) none or trace (qAR \<6%); (2) mild (6% to ≤17%); and (3) moderate or severe (\>17%).~At discharge, all the patients will undergo Cardiac magnetic resonance, the Car"
223931245|NCT06891079|DIAGNOSTIC_TEST|Stand of care guided|"In the control arm, a TAVI device is implanted according to local practice. Immediately after implantation, TEE/TTE or aortography is performed as a part of usual practice.~* The requirement of post-dilatation or any additional procedure is left to the discretion of the operator.~* The operator judges the sufficient procedural outcome to end the procedure according to local practice.~At discharge, all the patients will undergo Cardiac magnetic resonance, the Cardiac magnetic resonance-derived regurgitation fraction (CMR-RF) will be analyzed as the primary endpoint."
223931246|NCT04338399|DRUG|Buparlisib & Paclitaxel|Investigation drug plus paclitaxel
223931247|NCT02806570|DEVICE|Mitral valve repair|
223931248|NCT06787300|BEHAVIORAL|Stories that Empowered Mother|this intervention is made by resercher for this research.
223931249|NCT06780462|DRUG|Corticosteroids + Rivaroxaban|Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban
224095893|NCT00738816|OTHER|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
224095894|NCT05427474|DRUG|Propranolol , gabapentin|The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
224095895|NCT00158366|BEHAVIORAL|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
224095896|NCT00158366|BEHAVIORAL|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
224095897|NCT00158366|BEHAVIORAL|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
224095898|NCT03452267|DRUG|Metformin|oral, 850 mg twice daily
224095899|NCT03452267|DRUG|Pioglitazone|oral, 45 mg daily
224095900|NCT03452267|DRUG|Placebo|oral, once daily
224095901|NCT00265655|DRUG|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
224095902|NCT01572155|PROCEDURE|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
224095903|NCT01572155|PROCEDURE|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
224095904|NCT00222079|DRUG|Esomeprazole (Nexium)|
224095905|NCT01677845|RADIATION|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
224095906|NCT02658461|DRUG|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
224095907|NCT00384579|DRUG|Botulinum toxin B|Botulinum Toxin B
224095908|NCT00384579|DRUG|Placebo|Placebo
223931250|NCT06780462|DRUG|Corticosteroids alone|Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)
223931251|NCT04557423|BEHAVIORAL|Community-Based Education|A previously evaluated educational intervention delivered in community settings. Includes culturally- and linguistically-appropriate materials.
223931252|NCT04557423|BEHAVIORAL|Navigation to Screening|Community health educators provide navigation assistance to access clinic-based cervical cancer screening.
223931253|NCT04557423|BEHAVIORAL|HPV Self-Sampling|An HPV self-sampling kit will be provided for home-based collection of cervical samples. Samples will be sent for analysis of HPV subtypes.
224284379|NCT03225014|DEVICE|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
223931254|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water, fasted.
223931255|NCT05507970|DRUG|Placebo|Single Dose dispersed in sterile water, fasted.
223931256|NCT05507970|DRUG|MMV367 (Fed 440mg)|Single dose dispersed in sterile water with a high fat meal.
223931257|NCT05507970|DRUG|MMV367|Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
223931258|NCT05507970|DRUG|Placebo|Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
223931259|NCT05507970|DRUG|MMV367 (Fasted 440mg)|Single dose dispersed in sterile water fasted.
224095909|NCT06261879|DEVICE|Special sanitary pad|The special sanitary pad is similar to the normal sanitary pad with 0.01 agar gel only. The agar gel is an approved source of food.
224284380|NCT03225014|DIAGNOSTIC_TEST|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
224284381|NCT06603181|OTHER|conventional treatment|exercise and splint
224284382|NCT06603181|OTHER|phonophoresis|exercise, splint and phonophoresis
224284383|NCT06603181|OTHER|extracorporeal shock wave therapy|exercise, splint and ESWT
224284384|NCT04922450|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/3weeks)
224284385|NCT04922450|DRUG|Albumin Paclitaxel|Albumin Paclitaxel(260mg/m²),every 3 weeks
223533264|NCT04026802|OTHER|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
223931260|NCT05956795|DIAGNOSTIC_TEST|Ultrasound|Sonographic imaging will be performed of lymph node basins
223931261|NCT05599412|DRUG|Lorviqua|As provided in real world practice
223931262|NCT06842979|DEVICE|Inspiratory Muscle Training (IMT)|The IMT protocol will consist of home-based high-intensity daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure measured and adjusted weekly based on the modified Borg scale from 4 to 6 regarding respiratory effort performed during the session. Patients were also informed to perform knack maneuver in daily activities that may cause sudden intra-abdominal pressure overload.
223931263|NCT06842979|DEVICE|Sham IMT|The IMT protocol will consist of home-based daily training - two cycles of 30 breaths with a 1-min rest between sets, twice a day for 8 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to the lowest intensity of the IMT Threshold device. Patients were also informed to perform knack maneuver in daily activities that may cause sudden intra-abdominal pressure overload.
223931264|NCT06804408|BEHAVIORAL|Qigong|12-week training of Baduanjin (or named Eight-Section Brocades), with two sessions per week. Each session lasts for 60 min.
223931265|NCT06804408|BEHAVIORAL|Mindfulness-based training|12-week training of mindfulness-based breathing, walking, and stretching practices, with two sessions per week. Each session lasts for 60 min.
223931266|NCT06804408|BEHAVIORAL|Low-to-moderate intensity physical exercise|12-week training of stretching, flexibility exercise, and balance exercise, with two sessions per week. Each session lasts for 60 min.
223931267|NCT06750887|OTHER|Normal condition|The normal condition IS measured as a lumbar extension without VR until the onset of pain.
223931268|NCT06750887|OTHER|Understated condition|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% less movement in the VR (understated visual feedback)
224284386|NCT04922450|DRUG|Cisplatin|Cisplatin（80mg/m²）, every 3 weeks
224284387|NCT05178108|OTHER|Real-time MRI of swallowing|"The examination recording a total of 9 sequences of less than 30 seconds will be performed, in transverse section (passing through the epiglottis), frontal section, in the plane of the posterior pharyngeal wall, and in median sagittal section.~Each bolus of 20 ml will be administered in full, in one go, using a syringe. It is kept in the mouth for a few seconds and swallowed on demand.~The semi-liquid bolus of 20 ml comes from the mixture of 198 ml of pineapple juice to 10 gr of Nutilis Powder (NUTRICIA), food thickener containing neither gluten, nor lactose.~Ingredients: Dextrin-maltose, thickeners (modified starch (corn), tara gum, xanthan gum, guar gum).~* 3 sequences with no food~* 3 sequences with ingestion of a liquid bolus of 20 ml (pineapple juice) mouth closed~* 3 sequences with ingestion of a semi-liquid bolus of 20 ml (pineapple juice + Nutilis Powder) mouth closed"
223931269|NCT06750887|OTHER|OVERSTATED CONDITION|It involves an illusion with virtual reality where the patients perform a lumbar flexion until the onset of pain and they feel a 20% more movement in the VR (understated visual feedback)
223533265|NCT04026802|OTHER|Standard of Care|Does not include early implementation of physical therapy
223533266|NCT05932498|PROCEDURE|Hip surgery|"Ultrasound-guided PENG block was administered to patients undergoing hip surgery intraoperatively.~OR~Ultrasound-guided QL block was administered to patients undergoing hip surgery intraoperatively."
223533267|NCT04658485|DEVICE|Active tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of the primary motor cortex (M1) with the cathode located over the right primary somatosensory cortex (S1).
223718290|NCT00811369|DRUG|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
223931270|NCT06770114|DRUG|Cetylpyridinium Chloride and Zinc Lactate Mouthwash|0 .075 % cetylpyridinium chloride and 0 .28 % zinc lactate
223931271|NCT06770114|DRUG|PhosFlur Mouthwash|0 .044 % sodium fluoride
223931272|NCT03133195|DRUG|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
223931273|NCT03133195|DRUG|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
223931274|NCT03133195|DIETARY_SUPPLEMENT|Calcium supplement|1000 mg/day of elemental calcium
224284388|NCT02748655|OTHER|Alkaline ionized water|
224284389|NCT02748655|OTHER|Tap water|
224284390|NCT00692952|DRUG|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
224284391|NCT00692952|DRUG|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
223533268|NCT04658485|DEVICE|Sham tDCS|Using the 2-channel neuro-stimulator Sooma tDCS equipment we provide a sham stimulation with the anode place over the primary motor cortex (M1) and cathode located over the right primary somatosensory cortex (S1). The sham stimulation consists of 30 seconds of stimulation ramping up to a maximum of 2 mA, then 19 minutes of the device providing no stimulation and then ramping down from 2 mA intensity to 0 in the last 30 seconds. This configuration is designed to mimic the sensory experience of active tDCS.
223533269|NCT05547672|DEVICE|UroMems artificial urinary sphincter|Implantation of the device
223533270|NCT00003562|DRUG|carboplatin|
223533271|NCT00003562|DRUG|docetaxel|
223533272|NCT03822611|BEHAVIORAL|Targeted Subsidy|Voucher
223533273|NCT02943473|DRUG|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
223931275|NCT03133195|DIETARY_SUPPLEMENT|Vitamin D|20,000 IU/week of vitamin D2
223931276|NCT06767085|DRUG|Lidocaine-Prilocaine Topical|lidocaine-prilocaine spray on the cervix and cervical canal 5-7 minutes prior to the procedure
223931277|NCT06767085|DRUG|Saline spray|saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
223931278|NCT06637800|DEVICE|Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)|The Seraph 100 is part of the Seraph platform technology that was developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens, bacteria, viruses, fungus, and other sepsis mediators from the bloodstream. In addition, it has been demonstrated that Seraph 100 is also capable of removing circulating tumor cells from the whole blood.
223931279|NCT06772779|DRUG|Warfarin|single oral dose
223931280|NCT06772779|DRUG|Enlicitide Decanoate|single oral dose
223931281|NCT06772779|DRUG|Lisinopril|single oral dose
223931282|NCT06747221|OTHER|Systems Analysis and Improvement Approach (SAIA)|"SAIA is a 5-step implementation strategy that is repeated every 4-6 weeks for continuous quality improvement. It will be implemented by Kenyan public health workforce and frontline clinical care personnel to systematically identify and address bottlenecks to develop and implement solutions to delivery of HIV Testing Services during emergency department (ED) interactions.~Step 1: Understanding the cascade of ED patient flow from triage through care conclusion with focus on HTS opportunities. This will support identification of bottlenecks where patients are missed and provides data on potential increases in efficiency if misses are addressed.~Step 2: Use process mapping to identify modifiable bottlenecks.~Step 3: Define and implement workflow adaptations to mitigate modifiable bottlenecks.~Step 4: Monitor changes in performance.~Step 5: Repeat the analysis and improvement cycle (steps 1-4)."
223931283|NCT06759285|BEHAVIORAL|Experimental (cradle position)|The newborn in cot bed was swaddled freely with the help of a thin blanket during feeding. Then, the nurse, wearing a box apron, took the baby in her arms and gave it a cradle position. The baby's physiological parameters and Comfort Scale were filled in before feeding began. The baby was kept in a cradle position on the researcher's lap during feeding. Immediately after feeding, without changing the baby's position, the physiological parameters and Comfort Scale were evaluated a second time, and again 15 minutes after feeding, without changing the position, the physiological parameters and Comfort Scale were evaluated a third time and recorded. Then, the baby was gently and slowly laid down on the denim bed as usual (right lateral).
224095910|NCT05124626|PROCEDURE|MIRPE with two bars|Minimally invasive repair of pectus excavatum utilizing two metallic bars
224095911|NCT05124626|PROCEDURE|MIRPE with one bar|Minimally invasive repair of pectus excavatum utilizing one metallic bar
224095912|NCT05159193|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m\^2, i.v., d1, q3w
223533274|NCT00158106|PROCEDURE|Speech and Language therapy for dysarthria and/or aphasia|
223533275|NCT06296680|OTHER|Reiki|The patients in the intervention group received Reiki to the seven chakra regions and additional areas with pain for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
224095913|NCT05159193|DRUG|cyclophosphamide (C)|cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q3w
224095914|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
224095915|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
224095916|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 90\~100 mg/m\^2, i.v., d1, q3w
223718291|NCT03715881|DRUG|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
223931284|NCT06763159|DRUG|HS-20124 (Phase Ia：Dose escalation )|Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
223533276|NCT06296680|OTHER|Sham Reiki|The patients in the placebo group received Sham Reiki to the seven chakra regions for a total duration of 25-30 minutes for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
223718292|NCT03715881|DRUG|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
223931285|NCT06763159|DRUG|HS-20124 (Phase Ib: Dose expansion)|Participants will receive HS-20124 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
223931286|NCT06208904|OTHER|Intravenous infusion of GIPRA|Intravenous infusion of GIP(3-30)NH2 in a concentration of 1,000 pmol/kg/min during experimental days
224095917|NCT05159193|DRUG|docetaxel (T)|docetaxel (T) 75 mg/m\^2, i.v., d1, q3w
223533277|NCT06296680|OTHER|Progressive Relaxation Exercise|PRE group patients received PRE for four consecutive days. On the 4th day, pain and anxiety levels of the patients were evaluated after the last applications. On the 21st day, pain and anxiety levels were evaluated, State Anxiety Scale and Perceived Stress Scale were administered, and serum cortisol level was evaluated in the morning before the start of chemotherapy. At the 3rd month follow-up, pain and anxiety levels, state anxiety scale and perceived stress scale were evaluated.
223533278|NCT00969020|PROCEDURE|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
223533279|NCT05392816|OTHER|Single meal non-heme iron absorption|Two study groups, each designed as cross-over single-blinded iron isotope trials in apparent healthy Swedish women of the ages 18-45 years. Each participant serves as their own control. Meals are tagged with radiolabeled non-heme iron 55Fe and 59Fe.
223533280|NCT02103465|DRUG|Rotigotine|transdermal patch
223931287|NCT06208904|OTHER|Intravenous infusion of saline|Intravenous infusion of isotonic saline 9 mg/ml added 0,5% human serum albumin during experimental days
223931288|NCT06848426|DRUG|Xingbaiji Formula|"Patients were randomized into two groups:~Control Group:~Non-squamous NSCLC: Sintilimab (200 mg) combined with pemetrexed + cisplatin/carboplatin, administered intravenously (IV) every 3 weeks (Q3W) for 4 cycles. After 4 cycles, maintenance therapy with sintilimab (200 mg Q3W, up to 24 months) + pemetrexed Q3W continued until disease progression, intolerable toxicity, death, or voluntary withdrawal.~Squamous NSCLC: Sintilimab (200 mg) combined with gemcitabine + cisplatin/carboplatin, IV Q3W for 4-6 cycles. Post-induction, sintilimab (200 mg Q3W) maintenance continued until progression, intolerance, or ≤2 years of treatment.~Experimental Group:~The control regimen plus Xingbaiji Formula:~Xingbaiji Granule 1: 10 g/bag, dissolved in warm water, 1 bag twice daily (morning and evening) after meals.~Xingbaiji Granule 2: 5 g/bag, dissolved in warm water, 1 bag twice daily (morning and evening) after meals."
224095918|NCT05159193|DRUG|carboplatin (Cb)|carboplatin (Cb) AUC 6, i.v., d1, q3w
224095919|NCT05159193|DRUG|trastuzumab (H)|trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1, q3w
224095920|NCT05159193|DRUG|pertuzumab (P)|pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1, q3w
224095921|NCT00830921|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
224095922|NCT02344576|BEHAVIORAL|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
224095923|NCT00468897|DRUG|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
224095924|NCT03773952|DRUG|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
224095925|NCT03773952|DRUG|Placebo oral capsule|Oral capsules
223533281|NCT02103465|DRUG|Placebo|transdermal patch
223533282|NCT01891279|OTHER|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
223533283|NCT01891279|OTHER|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
223533284|NCT03534492|DRUG|Durvalumab|Infusion
223533285|NCT03534492|DRUG|Olaparib|P.O.
223533286|NCT06547606|OTHER|Usual Care|Participants in the control group will recieve usual care.
223533287|NCT03157947|BEHAVIORAL|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
223533288|NCT03157947|BEHAVIORAL|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
223533289|NCT03157947|BEHAVIORAL|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
223533290|NCT03747055|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
223533291|NCT03747055|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
224095926|NCT05240144|OTHER|IHG|Isometric handgrip exercises will be performed for 4 x 2 min with the frequency of 3 days per week for a period of 6 weeks.
224095927|NCT05240144|OTHER|Aerobic exercises|Aerobic exercise according to the American College of Sports Medicine (ACSM) guidelines that provide the specific criteria as 50 minutes exercises for 3 days a week for a period of 6 weeks.
224095928|NCT05240144|OTHER|Sham IHG|Isometric handgrip exercises will be performed in 4 sets for 2 min at 5% MVC on both hands with the frequency of 3 days per week for a total 6-week period
224095929|NCT04760184|OTHER|Autologous stem cell transplantation|The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
224095930|NCT02295202|DEVICE|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
223533292|NCT05678426|BEHAVIORAL|Smoking cessation|Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
223533293|NCT05678426|BEHAVIORAL|Intermittent fasting|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
223533294|NCT05678426|BEHAVIORAL|Intermittent fasting with ketogenic supplement|The dietary intervention encompasses induction (1 month) and maintenance (5 months) of a 16:8 intermittent fasting regime (time restricted eating to 8 h a day, fasting for remaining 16 h). During the introductory month, participants will only maintain a 14:10 intermittent fasting regime. Participants receive a ketogenic supplement, medium-chain triglyceride fiber, to use daily. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
223931289|NCT06849362|DRUG|Bevacizumab|"Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody used in combination with chemotherapy or immunotherapy for the treatment of metastatic colorectal cancer (CRC). In this study, bevacizumab is administered as part of combination therapy in certain patient groups to assess its impact on treatment efficacy in MSS/MSI-L/pMMR advanced colorectal cancer.~Patients receiving bevacizumab will be evaluated for treatment response, survival outcomes, and potential biomarkers predictive of therapeutic efficacy. The study will compare the clinical benefits of immunotherapy alone, immunotherapy + bevacizumab, and immunotherapy + chemotherapy + bevacizumab to determine the optimal treatment strategy.~The dose and administration schedule of bevacizumab will follow standard clinical guidelines as per institutional protocols."
223931290|NCT02110004|PROCEDURE|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
223931291|NCT02110004|DEVICE|Picasso NAV Catheter|
223931292|NCT01983683|DRUG|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
223931293|NCT01983683|DRUG|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
223931294|NCT01983683|DRUG|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
223931295|NCT01983683|DRUG|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
224095931|NCT02295202|DEVICE|Nasal strips|
224095932|NCT05059990|OTHER|Low Intensity Aerobic Exercises Group|Intervention Low Intensity Aerobic Exercises i.e. stationary cycle(supervised) Intensity 55-65% of HRmax Frequency 3 times a week Duration 30 min each session
223931296|NCT06749951|OTHER|Cognitive Behavioural Therapy for insomnia (CBT-I)|Five 60-90 minutes weekly sessions delivered by an appropriately trained cardiac nurse at a cardiology department. The CBT-I intervention will follow a manualized treatment protocol developed by Espie and colleagues (Espie et al. 2001, 2007, 2008) and evaluated in a number of published RCTs using CBT-I. The key components of this intervention include sleep hygiene advice, stimulus control, sleep restriction, relaxation training, and cognitive restructuring.
223931297|NCT06749951|OTHER|Sleep Hygiene Advice|"Sleep well is a 16-page written brochure developed by the Directorate of Health in Norway for dissemination to patients with sleep problems including insomnia. It covers general sleep hygiene advice (setting a regular bed-time, avoiding stimulants, alcohol and exercise in the evening, sleeping in a quiet bedroom, advice of practicing relaxation technique and postpone worries)."
223931298|NCT01644669|RADIATION|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
224095933|NCT05059990|OTHER|Active Exercises Group|Intervention Upper and lower limb ROM \& stretching exercises Intensity As per tolerance Frequency 12 repetition/4sets per exercise 3 times/week Duration 30 minutes each session
224284392|NCT01402154|BIOLOGICAL|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
224284393|NCT01402154|BIOLOGICAL|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
224284394|NCT06617377|OTHER|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan|advanced whole-brain sMRI/fMRI/contrast-enhanced MRI scan (estimated total scanning time = 45 min for all centers except for Toulouse = 60min) will be acquired at least after 72h from complete withdrawal of sedation in normothermia condition (between Day 1 and Day 7 after inclusion).
224284395|NCT03297294|DRUG|EMA401|capsules, oral
224284396|NCT03297294|DRUG|Placebo|Placebo to EMA401 capsules, oral
224284397|NCT03367689|DRUG|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
224284398|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
224284399|NCT01021631|OTHER|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
224284400|NCT02506231|DRUG|Folinic acid|
224284401|NCT02506231|DRUG|Placebo|
224284402|NCT04575714|OTHER|Data record|Data record
224284403|NCT03777345|DEVICE|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
224284404|NCT03777345|DEVICE|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
224284405|NCT02345291|DRUG|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
224284406|NCT02345291|DRUG|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
224284407|NCT02896543|OTHER|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
224284408|NCT00368563|DRUG|Helioblock SX|
223931299|NCT06827366|BEHAVIORAL|Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy|Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'
224095934|NCT04514614|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of arthritis by PET/CT.
224284409|NCT06503549|OTHER|Assessments|Only the current assessments will be made
224284410|NCT04580849|OTHER|telerehabilitation with dance|Dance classes will be provided through a online platform. Each class will last 60 minutes, twice a week, during 8 weeks.
224284411|NCT05365152|DIETARY_SUPPLEMENT|Meal Replacement|Meal Replacement
224284412|NCT03902899|OTHER|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
224284413|NCT06616233|DEVICE|Remote Ischaemic Conditioning with exercise|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm). During the cuff deflation phase, participants will undergo handgrip exercise at 20-30% of their maximal voluntary contraction for 3 minutes. There will be a total of 4 cycles of exercise.
224284414|NCT06616233|DEVICE|Other: Remote Ischaemic Conditioning|Participants will receive RIC through an automated device that will provide cycles on ischaemia/reperfusion to the target organ (arm).. There will be a total of 4 cycles.
224284415|NCT01198873|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
224284416|NCT01198873|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
224284417|NCT02004067|DRUG|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
224284418|NCT02004067|DRUG|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
224284419|NCT03139240|DRUG|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
223931300|NCT06751940|COMBINATION_PRODUCT|Conventional second-line therapy|Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
223931301|NCT06751940|DRUG|Neoantigen-loaded DC vaccine|The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223931302|NCT06756516|OTHER|Feldenkrais Method and Core stabilization|Balance exercises from supine lying position using Feldenkrais style, plus core stabilization exercises.
224095935|NCT00302393|DRUG|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
223931303|NCT06756516|OTHER|Core stability exercises|trunk deep muscles activation and engaging using exercises as bridging, side bridging, plank, side plank and McGill Abdominal
223931304|NCT06758297|OTHER|AI-Powered Motivational Speech|"It is known that patients with knee prosthesis have difficulty in the first standing process due to fears of falling, not being able to walk again, and recurrence of their disease. For this purpose, a speech text that will motivate patients was prepared with the support of ChatGPT. Expert opinions were obtained from 2 orthopedic specialists and 2 specialist psychiatric nurses for this speech text. Later, the speech text was converted into an audio video with the ElevenLabs application. Thus, it was planned to make it easier for patients to listen to it again. Patients will listen to this motivational speech in their own patient rooms and using their own headphones."
223931305|NCT04632810|OTHER|Ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks
223931306|NCT04632810|OTHER|non-ketogenic low energy diet|Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks
224095936|NCT00302393|DRUG|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
224095937|NCT00216034|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
224095938|NCT00216034|DRUG|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
224095939|NCT00854269|PROCEDURE|surgery|cervical biopsy or specimen of hysterectomy
224095940|NCT02823457|BEHAVIORAL|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
224095941|NCT01778244|DRUG|metformin|1000mg/day for 24 weeks
224095942|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
224095943|NCT02319369|DRUG|AZA|AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
224284420|NCT03139240|OTHER|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
224284421|NCT05340192|DRUG|Octreotide 1 MG/ML|100 mcg (1 ml) of Octreotide
224095944|NCT02319369|DRUG|Milademetan|Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 mg, 80 mg, and/or 100 mg milademetan may be utilized.
224095945|NCT02323022|DRUG|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
224095946|NCT02323022|DRUG|IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
224284422|NCT06814470|OTHER|Virtual reality guided imagery acupuncture treatment (VRGAIT)|Subject watching Virtual reality video of acupuncture needle stimulation
224095947|NCT04839861|BEHAVIORAL|Mightier Family Games|Mightier Family Games includes five offline card games that can be played by two or more people. During card game play, one player wears the Mightier heart rate monitor, and can see a representation of their heart rate on a separate screen within the Mightier app. Each game includes elements that are tied to heart rate.
224284423|NCT06814470|OTHER|Virtual reality guided imagery acupuncture treatment control|Subject watching VR video of swab touching
224284424|NCT06655974|OTHER|Health-related social needs decision support system|"The clinical decision support intervention will present emergency department clinicians at an Indianapolis, IN ED with a likelihood score for an adult patient screening positive for the following health-related social needs (HRSNs): housing instability, food insecurity, transportation barriers, financial strain, and history of legal involvement. For each HRSN, the likelihood of screening positive is reported as high, medium, or low. These categorizations are the product of logistic regression models. The clinical decision support intervention will be delivered through an existing FHIR (Fast Healthcare Interoperability Resources) standards-based clinical decision support platform."
224284425|NCT04051216|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention
224284426|NCT04051216|OTHER|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
223931307|NCT06173063|DEVICE|Mobility+ Enteral Feeding System|Enteral feeding using a continuous feeding, self-powered, discreet, silent enteral feeding system.
223931308|NCT06779305|PROCEDURE|Minimally invasive surgical application of Calcanail®|The procedure involves making small incisions to insert a specialized nail into the bone to realign and stabilize the fracture. This approach minimizes damage to surrounding tissues, reduces the risk of wound complications, and allows for quicker recovery compared to traditional open surgery. after surgery, the patient will benefit from an immobilisation with a plaster boot without support for 3 weeks, followed by immobilisation with a removable walking boot for 3 weeks with partial support depending on the patient's pain.
223931309|NCT06779305|PROCEDURE|Immobilisation by cast boot|The patient will be immobilised in a plaster cast without support for 3 weeks, followed by immobilisation in a removable walking boot for 3 weeks with partial support depending on the pain.
223931310|NCT06779513|DIAGNOSTIC_TEST|Echocardiohraphy|Transthoracal echocardiography for diastolic function assessment
223931311|NCT06435312|DRUG|Zilucoplan|Zilucoplan will be administered subcutaneously to pediatric study participants
223931312|NCT05315206|DIETARY_SUPPLEMENT|Citicoline|"The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine."
223931313|NCT05315206|DIETARY_SUPPLEMENT|Placebo|The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
223931314|NCT05742269|DIAGNOSTIC_TEST|89Zr-atezolizumab PET/CT|All patients undergo a 89Zr-atezolizumab PET/CT. Allocation to chemotherapy + atezolizumab in case of a PD-L1 positive tumor (on IHC and/or PET)
223931315|NCT06024473|DEVICE|rTMS|Transcranial Magnetic Stimulation
223931316|NCT06024473|DEVICE|rTMS+iVCT|Transcranial Magnetic Stimulation and immersive virtual reality
223931317|NCT06902051|DEVICE|Lateral Decubitus position|Lateral Decubitus position with a special device
223931318|NCT06902051|DEVICE|Lateral Decubitus device|Lateral Decubitus postion with a special device
223931319|NCT05209802|OTHER|Group A: High intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
223931320|NCT05209802|OTHER|Group B: moderate intensity exercise training|Both group will receive aquatic exercise training twice a week for 12 weeks at different intensities
223931321|NCT05310786|OTHER|Pharmacist-integrated Medication Treatment for Opioid Use Disorder (PrIMO)|This is not a true intervention, but rather a clinical model of care established at an FQHC in Maine.
223931322|NCT05111600|DRUG|Transplantation|Implantation of autologous cultured grafts containing genetically modified stem cells for restoration of functional skin on pre-selected areas
223931323|NCT06269198|DEVICE|WARD-CSS|"Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded."
223931324|NCT06429228|PROCEDURE|Catheter removal after surgery|Removal of catheter placed during the procedure in first or second post-surgical days.
223931325|NCT06931054|OTHER|Acupuncture|"The principle of traditional acupuncture and auricular acupressure is to alleviate withdrawal symptoms. Acupuncture therapy for smoking cessation is generally considered safe, but some people may experience mild side effects. These can include soreness, bruising, or bleeding at the needle insertion sites, dizziness, fatigue, or lightheadedness after treatment. Occasionally, individuals may feel nausea or discomfort during or after the session. In rare cases, infections can occur if proper hygiene protocols are not followed. Overall, most side effects are temporary and resolve shortly after treatment.~Primary Acupoints The selection of body acupuncture points follows specific guidelines\[11-12\], including three head points (Baihui, Shenting, Yintang ), three hand points (Neiguan, Kongzui, Lieque), and three foot points (Zusanli, Sanyinjiao, Taichong). For auricular acupoints, selection is based on corresponding areas (Mouth), syndrome differentiation of zang-fu organs and meridians (Hea"
223931326|NCT06931054|DRUG|Nicotine Replacement therapy|Each eligible participant will be prescribed a two-week supply of NRT by a registered smoking cessation nurse following the initial counseling session. The nurse will determine the appropriate type and dosage of NRT based on the participant's level of nicotine dependence and lifestyle habits, and provide instructions on how to use the medication. NRT can cause some potential side effects such as nausea, headaches, dizziness, and insomnia, with vivid dreams being common for those using patches. Method-specific side effects include skin irritation from patches, mouth or throat irritation from gums or lozenges, and nasal or throat discomfort from inhalers and sprays. These symptoms usually lessen as the body adjusts, but persistent or worsening side effects may require medical attention. According to current smoking cessation medication guidelines from the Department of Health\[10\], participants who smoke 20 or more cigarettes per day will be prescribed 4 mg nicotine gum (or lozenges) or 2
223931327|NCT06931054|BEHAVIORAL|Smoking cessation counseling|The first step for smoking cessation nurses is to assess each participant's smoking behavior using a baseline questionnaire. In the second step, informed consent will be obtained from the participants. The third step involves smoking cessation counseling using the 5A (Ask, Advise, Assess, Assist, Arrange) and 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) frameworks as outlined in the smoking cessation manual published by the Department of Health. During this step, the nurse will also assess the type and dosage of NRT suitable for the participant. In the fourth step, participants will be introduced to TCM therapies, and arrangements will be made for consultations with a TCM practitioner.
223931328|NCT06931054|OTHER|Auricular acupressure|First, one ear will be routinely disinfected with 75% medical ethanol. In the experimental group, the auricular acupressure tape contains Semen Vaccariae. Using forceps or tweezers, an auricular acupressure tape will be applied to specific acupoints on one ear for participants in the experimental group, followed by pressing the tape for 1 minute. The auricular tape will remain in place for two days, and participants will be instructed to self-press the acupoints 3 to 5 times daily, for 1 minute per acupoint each time. During the use of the auricular acupressure, if withdrawal symptoms occur, participants can immediately press the acupoints. The pressure applied should be tolerable, and the pressing duration should last until the withdrawal symptoms subside. Participants will also record the number of presses each day.
223931329|NCT06931054|OTHER|Sham acupressure|"The sham tape resembles the genuine auricular acupressure tape with Semen Vaccariae but is a regular adhesive tape designed to minimize stimulation of the acupoints.~The sham auricular tape will be applied to non-smoking cessation acupoints, including:~* Elbow Acupoint located in the third section of the triangular fossa between the middle cartilage and the rim cartilage of the ear, primarily used for treating elbow pain.~* Ankle Acupoint located near the apex of the superior crus of the antihelix, used for treating arthritis.~* Urethra Acupoint located on the helix above the rectum acupoint, used for treating symptoms such as frequent urination or painful urination."
223533295|NCT00593619|DRUG|Iron dextran|300mg in 250cc normal saline given over 2 hours
223931330|NCT06931054|OTHER|Sham acupuncture|"The TCM practitioner will perform needle insertion 2-3 mm beside the selected acupoints (at non-specific sham points) using normal needling techniques but without manipulating the needles, in order to minimize any physiological effects."
224095948|NCT04839861|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own."
224095949|NCT04325503|DRUG|carbidopa|carbidopa and carbidopa-levodopa standard treatment
224095950|NCT03832387|DEVICE|Non-invasive mechanical ventilation|
224095951|NCT03832387|DEVICE|Continuous positive airway pressure|
224095952|NCT03832387|DEVICE|Venturi mask|
224095953|NCT03832387|DEVICE|Reservoir mask|
224095954|NCT04297943|DEVICE|Orthosis fabrication|see summary
224095955|NCT04297943|DEVICE|Thermal Sensor Monitoring of Orthosis Use|see summary
224095956|NCT04297943|DIAGNOSTIC_TEST|4D CT Scan|see summary
224095957|NCT05607134|OTHER|selected physical and occupational therapy program|The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.
224095958|NCT05607134|DEVICE|Radial Extracorporeal Shock Wave|The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.
224095959|NCT05607134|DEVICE|Peripheral magnetic stimulation|"The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity."
224095960|NCT04604925|BEHAVIORAL|Remote patient monitoring for hypertension|Intervention involves practices making available remote physiologic monitoring treatment management services allowable under Medicare for blood pressure (and weight if desired) to Medicare patients in the practice when ordered by the patient's clinician.
224095961|NCT01992029|OTHER|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
224095962|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy at M0
224095963|NCT01992029|PROCEDURE|Lumbar puncture|Lumbar puncture at M0 and M12
224095964|NCT01992029|PROCEDURE|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
224095965|NCT01992029|OTHER|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
224095966|NCT01992029|PROCEDURE|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
224095967|NCT01992029|PROCEDURE|Muscular biopsy|Muscular biopsy for patient explored for myopathy
224095968|NCT01992029|PROCEDURE|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
224095969|NCT01992029|DEVICE|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
224095970|NCT00849589|BEHAVIORAL|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
224095971|NCT00849589|BEHAVIORAL|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
224284427|NCT04051216|OTHER|Interview|Participants will be interviewed about their experience using the device(s)
224284428|NCT04051216|OTHER|Survey Administration|Participants will receive surveys
223931331|NCT04032106|OTHER|Best Practice|Receive standard information about HPV and HPV vaccine
223931332|NCT04032106|OTHER|Informational Intervention|Receive Outsmart HPV intervention
223931333|NCT04032106|OTHER|Questionnaire Administration|Ancillary studies
223931334|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive unidirectional text message vaccine reminders
223931335|NCT04032106|BEHAVIORAL|Text Message-Based Intervention|Receive interactive text message vaccine reminders
224284429|NCT04051216|OTHER|Laboratory Biomarker Analysis|Correlative studies
224284430|NCT05583682|OTHER|Dental restoration|Restoration of carious mandibular first molar teeth are restored either with nano-filled resin modified glass ionomer or sub-micron resin composite restorative material
224284431|NCT00265044|BEHAVIORAL|Provider Education|
224284432|NCT00265044|BEHAVIORAL|Hypertension Alert|
224284433|NCT00265044|BEHAVIORAL|Patient Education|
224284434|NCT01584895|BEHAVIORAL|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
223931336|NCT06750978|BEHAVIORAL|Self-reflection|Participants will be guided to identify goals of daily PSU reduction. o Participants will be guided to actively review their smartphone usage data each day.
223931337|NCT06750978|BEHAVIORAL|Self-reflection + Alternative activity engagement|Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will be guided to develop a plan for alternative activity engagement and confirm their engagement in the alternative activities as planned.
223931338|NCT06750978|BEHAVIORAL|Self-reflection + Contingency management|Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will receive an incentive ($8) if they meet the daily PSU reduction goal.
223931339|NCT06761963|OTHER|Whole-body electrical stimulation|Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
223931340|NCT06761963|OTHER|Rehabilitation|Pulmonary rehabilitation program.
223931341|NCT06885398|OTHER|treatment|"* Endotracheal Tube Ventilation with an endotracheal tub~* Laryngeal tube Ventilation with a laryngeal tube~* Laryngeal mask Ventilation with a laryngeal mask~* I-Gel-Laryngeal Mask Ventilation with an I-Gel-laryngeal mask"
223931342|NCT06847321|DRUG|LHP588|25 mg
223931343|NCT06847321|DRUG|LHP588|50 mg
223931344|NCT06847321|DRUG|Placebo Drug|Placebo
224284435|NCT03020784|DRUG|Placebo|Placebo
224284436|NCT03020784|DRUG|PF-06818883|Treatment
224284437|NCT01576302|BEHAVIORAL|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
224284438|NCT01576302|BEHAVIORAL|Muscle relaxation|Progressive passive muscle relaxation
224284439|NCT03345264|BEHAVIORAL|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
224284440|NCT02146976|DRUG|propofol|introvenious infusion of propofol
224284441|NCT02146976|DRUG|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
224284442|NCT03585426|DRUG|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
224284443|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
224284444|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
224284445|NCT00268892|DRUG|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
224284446|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity and stigma content|Participants viewed an interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
224284447|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with stigma content only|Participants viewed a non-interactive stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
224284448|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with interactivity only|Participants viewed an interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
224284449|NCT05333848|BEHAVIORAL|Internet-based storytelling programs with no interactivity and no stigma content|Participants viewed a non-interactive non-stigma content website. Within 10 minutes post-experiment, participants completed the post-experiment questionnaire. One week after the experiment, participants completed the follow-up questionnaire.
224284450|NCT00489164|DEVICE|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
224284451|NCT01521078|BEHAVIORAL|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
224284452|NCT01305876|BEHAVIORAL|yoga intervention|yoga session 2 x week over 3-1/2 months
224284453|NCT01413282|RADIATION|Cardiac CT|Calcium scan and CT coronary angiography
224284454|NCT05596292|DEVICE|Immersive Virtual Reality glasses|The immersive virtual reality glasses support a smartphone device, allowing videos to be used with 360º rotation and earpods headphones with bluetooth for sound. Video options will be offered to participants according to the exercise performed, ie: a cycling video for activities with a cycle ergometer; video with people walking for ambulation; and videos of the patient's choice, such as forest, beach or city scenarios, for other moments.
224284455|NCT05596292|OTHER|early mobilization protocol|Three days of an early mobilization protocol. The exercises will be progressed every day, starting in the first day with active movements of lower and upper limbs with cycle ergometer; in the second day repeat the first day exercise and do orthostasis training; and in the last day training ambulation.
223931345|NCT06768450|BEHAVIORAL|Online mindfulness meditation|"The mindfulness meditation program is adapted from the Breathwork Mindfulness for Stress program. However, it uses shorter meditations designed for individuals who cannot sit for 40 minutes. The mindfulness meditation program encourages greater self-acceptance, kindness, and compassion toward oneself. It builds on this concept by helping participants find pleasure in life despite suffering, fostering kindness and compassion toward others, and increasing social connections to counteract the social isolation common among individuals with chronic and long-term illnesses.~The program will be led by a well-trained Breathwork mindfulness instructor and conducted remotely via Microsoft Teams once a week for 8 weeks. Each session will last 2 to 2.5 hours and consist of body scans, mindful movements, and various meditations, introducing new ideas every week."
223931346|NCT03682172|DRUG|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
223931347|NCT03682172|DRUG|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
223931348|NCT03682172|DRUG|Placebo|Four hour intravenous infusion with saline water
223931349|NCT06765629|DEVICE|Non-invasive Percutaneous Tibial Nerve Stimulation (TTNS) group|After obtaining informed consent from the subjects, the researchers screen the subjects based on the inclusion and exclusion criteria. The wearable non-invasive percutaneous tibial nerve stimulator is placed on the area where the tibial nerve runs at the medial malleolus of the subjects. Once the wearable stimulator is properly fitted, stimulation parameter programming and treatment record management are conducted through the programming software running on the mobile phone.
223931350|NCT06766526|BEHAVIORAL|Internet-based cognitive behavioral therapy|An eight week ICBT treatment. The treatment is modular and tailored to the problem profile of the participant. One module will be administered every week during the treatment phase.
223931351|NCT06766526|BEHAVIORAL|Non-directive support|Participants randomized to this condition will receive weekly support and contact with a therapist via the treatment platform. They will not have access to the treatment modules during the treatment phase.
223533296|NCT00593619|DRUG|Iron sucrose|300mg in 250cc normal saline given over 2 hours
223533297|NCT03261830|DRUG|Cefazolin|Primary intervention
223931352|NCT06561555|DRUG|RC48|RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
223931353|NCT06628843|OTHER|cesarean section rate|Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
223931354|NCT03005652|BEHAVIORAL|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
223533298|NCT03261830|DRUG|Clindamycin|For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
223533299|NCT03261830|DRUG|Saline|Placebo Intervention
223533300|NCT00897026|DRUG|cyclophosphamide|
223931355|NCT03005652|BEHAVIORAL|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
223931356|NCT06736964|DEVICE|Giomer|based on Pre-reacted glass ionomer (PRG)
223931357|NCT06734962|PROCEDURE|Apical surgery procedure using A-PRF|Participants will undergo an apical surgery procedure using A-PRF. Before the surgery and at follow-ups, patients will undergo comprehensive evaluation using clinical, radiological, and ultrasonographic techniques.
223931358|NCT06734962|PROCEDURE|Apical surgery without using A-PRF|Participants will undergo an apical surgery procedure without using A-PRF. Patients will undergo comprehensive evaluation before the surgery and at follow-ups using clinical, radiological, and ultrasonographic techniques.
224284456|NCT00608595|DRUG|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
224284457|NCT00608595|GENETIC|gene expression analysis|not noted
224284458|NCT00608595|GENETIC|protein expression analysis|Not noted
224284459|NCT00608595|OTHER|immunohistochemistry staining method|not noted
224284460|NCT00608595|OTHER|laboratory biomarker analysis|not noted
224284461|NCT00608595|OTHER|mass spectrometry|
224284462|NCT00608595|PROCEDURE|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
224284463|NCT00608595|PROCEDURE|neoadjuvant therapy|not noted
223533301|NCT00897026|DRUG|doxorubicin hydrochloride|
223533302|NCT00897026|DRUG|paclitaxel|
223533303|NCT00897026|GENETIC|fluorescence in situ hybridization|
223533304|NCT00897026|OTHER|immunohistochemistry staining method|
223718293|NCT01140243|DIETARY_SUPPLEMENT|LCPUFA|premature infant formula supplemented with LCPUFA
223718294|NCT02356575|OTHER|Acupuncture|
224284464|NCT00608595|PROCEDURE|therapeutic conventional surgery|not noted
224284465|NCT00913796|DRUG|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
224284466|NCT00913796|DRUG|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
224284467|NCT05909917|OTHER|Half-Day First Responder Training|Participants in both study arms will undergo a half-day first responder training course designed for laypeople. The course will consist of five curricular categories: scene management, airway and breathing, hemorrhage control, fracture management, and victim transport. Course material will not differ between in-person and virtual arms, however the method of information dissemination will vary.
224284468|NCT02492841|DRUG|Mineral trioxide aggregate|Mineral trioxide aggregate
224284469|NCT02492841|DRUG|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
223931359|NCT06765720|OTHER|Intermittent feeding method with nasogastric tube|"30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool."
223931360|NCT06765720|OTHER|Intermittent feeding method with orogastric tube|"30 Minutes Before Feeding: No invasive procedures will be performed 30 minutes before the daily 1:00 PM feeding.~5 Minutes Before Feeding: To measure physiological variables, the pulse oximeter probe will be attached to the baby's foot. Oxygen saturation and heart rate will be measured for 2 minutes before feeding.~Feeding Phase: Measurement values will be taken from the pulse oximeter during feeding.~Post-Feeding Phase: Any interventions that could affect physiological values will be prevented, and oxygen saturation and heart rate will continue to be measured during the 2-minute period. The baby will be scored using the Early Feeding Skills Assessment Tool."
223931361|NCT06792383|DIAGNOSTIC_TEST|quality of life|"The following assessment tools will be proposed to patients:~* Quality of Life in Epilepsy (QOLIE-31)26~* Dissociative Experience Scale (DES)27~* Symptom Checklist-90 (SCL-90)28~* Irritability Questionnaire (I-EPI)29~* Beck Depression Inventory II (BDI-II)30~* State-Trait Anxiety Inventory Y-1 e Y-2 (STAI)31~* Epilepsy Stigma Scale modificata32 These assessment tools are validated and used universally, and will allow the collection of information on the psychological and psychiatric functioning of the patients."
223931362|NCT06758102|BEHAVIORAL|Dance Program|A 12-week, virtual dance program consisting of seated and standing choreography and contemporary style elements will be taught by a certified dance instructor. Sessions will be conducted by the HIPAA-compliant, video-conferencing platform, Zoom.
223931363|NCT06866639|BEHAVIORAL|Cognitive behavioral therapy|The CBT is based on the treatment manual written by Fennell (1997). The patients receiving CBT will be treated for 8 sessions, with weekly session of 45-60 minutes duration.
223931364|NCT06866639|BEHAVIORAL|Metacognitive therapy|The meta-cognitive treatment program is based on Wells's metacognitive therapy (Wells, 2013). The patients receiving meta-cognitive therapy will be treated for 8 sessions, with weekly session of 45-60 minutes duration.
224095972|NCT01106001|DRUG|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
224095973|NCT01106001|DRUG|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
224095974|NCT05991024|BEHAVIORAL|the incisional hernia recurrent|Recurrence after repair was the main outcome
224095975|NCT00144170|DRUG|Tipranavir (with low dose ritonavir)|
224095976|NCT00144170|DRUG|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
224095977|NCT04753125|BEHAVIORAL|follow-up by telephone|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
224095978|NCT04753125|BEHAVIORAL|follow-up via a game in a smartphone app|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
224095979|NCT04753125|BEHAVIORAL|conventional follow-up by a health professional|The SIM study is a single-centre, randomized, controlled trial with a 12-month follow-up period. The aim is to determine which of the 3 methods of follow-up is the most effective in promoting patient treatment compliance
224095980|NCT03512236|DRUG|BC Pram Ins|Injection of BC Pram Ins
224095981|NCT03512236|DRUG|Symlin® and Humulin®|Injection of pramlintide and human insulin
224095982|NCT03512236|DRUG|Humalog®|Injection of lispro
224095983|NCT03512236|DRUG|Placebo|Injection of 0.9% NaCl
224095984|NCT00831376|DRUG|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
224284470|NCT02492841|DRUG|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
224284471|NCT02868541|OTHER|Naso pharyngeal swab|Naso pharyngeal swab
223718295|NCT02356575|OTHER|Cognitive Behavior Therapy|
223931365|NCT06879704|OTHER|Imaging assessment|The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan
224095985|NCT00831376|DRUG|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
224095986|NCT00831376|DRUG|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
224095987|NCT04074486|DEVICE|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
224095988|NCT04074486|DIAGNOSTIC_TEST|SCAT5|Sports Concussion Assessment Tool 5
224095989|NCT04074486|DIAGNOSTIC_TEST|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
224095990|NCT02066064|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
224095991|NCT02066064|PROCEDURE|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
224284472|NCT03746002|DRUG|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
223931366|NCT06619574|DEVICE|3D Analysis Group|Dental Compass and Dental Compass software used for therapeutic splint fabrication
223931367|NCT06619574|OTHER|Manual Analysis Cohort|Manual methods used for therapeutic splint fabrication
224095992|NCT00730093|DIETARY_SUPPLEMENT|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
224095993|NCT02347293|OTHER|High levels of indigestible carbohydrates|
224095994|NCT02347293|OTHER|Low levels of indigestible carbohydrates|
224095995|NCT00679887|PROCEDURE|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
224095996|NCT04519944|DRUG|Edoxaban|This is an observational, prospective study; no treatment will be administered.
223718296|NCT04506372|DRUG|Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers|Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.
224095997|NCT04126837|OTHER|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
224095998|NCT00702143|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
224095999|NCT05546489|BEHAVIORAL|Lymfit intervention|Wearable activity trackers (Fitbit) were given to participants as a motivational tool and for data collection purposes. Participants received a personalized exercise prescription designed by a kinesiologist. Physiologic metrics were collected by the Fitbit monitors and were stored in the Lymfit database. Self-reported questionnaires measuring health outcomes were collected at baseline and post-intervention.
224284473|NCT03746002|DRUG|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
224284474|NCT03544814|DRUG|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
223931368|NCT06623370|DRUG|methylprednisolone|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
223931369|NCT06623370|OTHER|Saline (NaCl 0,9 %) (placebo)|Patients will undergo standard noninvasive blood pressure monitoring, electrocardiogram, peripheral oxygen saturation (SpO2), and capnography. After anesthesia induction, neuromuscular monitoring will also be applied. Anesthesia induction will be performed with 2-4 mg/kg propofol and 1 mcg/kg fentanyl. First group (Group M), patients will receive 1 mg/kg methylprednisolone , while in the second group (Group C), patients will receive 5 ml of normal saline. Immediately afterward, the neuromuscular monitor will be set to measure the Train of Four (TOF). Following this, 0.6-1.2 mg/kg of rocuronium will be administered intravenously. If necessary, additional doses of 0.15 mg/kg rocuronium will be given during the operation when TOF count reaches T2. For postoperative analgesia, 15 mg/kg of i.v. paracetamol will be administered. At the end of the surgery, when anesthesia is terminated and T2 reappears in TOF count, all patients will receive a single bolus injection of sugammadex.
223931370|NCT06779812|PROCEDURE|Carpal Tunnel Surgery|Carpal tunnel surgery is performed endoscopically, using smaller incisions. Endoscopic surgery is a minimally invasive method that allows for faster and less painful recovery
223931371|NCT06779812|OTHER|real auricolothery|3 days before the intervention, patients will have an auriculotherapy session with an experimental group
223931372|NCT06779812|OTHER|sham auriculotherapy|3 days before the intervention, patients will have an auriculotherapy session with an sham group
224096000|NCT04825054|DEVICE|Mechanical ventilation with NAVA mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
224096001|NCT04825054|DEVICE|Mechanical ventilation with PCV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
224284475|NCT03544814|DRUG|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
224284476|NCT02826291|DEVICE|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
223718297|NCT04506372|DIAGNOSTIC_TEST|Blood draw|Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery
223718298|NCT04506372|BEHAVIORAL|Diary to register drug adherence|To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.
223931373|NCT06785857|OTHER|mHealth Supportive Care Program|On the basis of monthly home visits in the control group, a weekly mHealth supportive care intervention program was added through the medium of Xiamen iHealth, with one supportive care item every two weeks for 12 weeks, for a total of 12 online interventions, as well as the provision of online consulting and booking services for caregivers at any time.
224096002|NCT04825054|DEVICE|Mechanical ventilation with PSV mode|"To compare the hemodynamic and pulmonary effect in patients after surgical repair with right ventricular hypertrophic ventilated with PCV, PSV and NAVA by a crossover study.~Each patient will undergo three 60-min trials during the study period in randomized order. The cardiac output and volume status will be evaluated by a transpulmonary thermodilution device through a pulse contour cardiac output (PiCCO) catheter at the last 10min of each trial. At the mean while an arterial blood gas and echocardiography will perform."
223931374|NCT06785857|OTHER|Offline supportive care|"This was done routinely in accordance with the requirements of public health services for chronic diseases in the community elderly. In addition, health education on diabetes mellitus and dementia was provided to the caregivers during their monthly home visits.~① the content of diabetes health education: the researcher gave the caregivers education and training on the care of diabetes patients: the main points of care in diet, sleep, exercise, etc.~② The content of dementia health education: the researcher gave the caregivers education and training related to the care of dementia patients: instructing the caregivers in the basic life care skills of patients' diet, sleep, exercise, etc."
223931375|NCT06854575|DIETARY_SUPPLEMENT|Dietary Supplement|Oral dietary supplement
223931376|NCT06854575|OTHER|Placebo|Placebo pill
223931377|NCT06893367|DEVICE|IMU and RealSense Cameras|Each participant will perform the FMA-sens, with their most affected hand, followed by the FMA-sens with the less affected hand.
223931378|NCT05686668|OTHER|assessment by scales|Assessment from many scales: AASP, HARS, HDRS, CORE, EES, CISS, SHAPS at V1 Assessment from many scales: AASP, HARS, HDRS, CORE, EES, SHAPS at V2
223931379|NCT02405169|DEVICE|4 vs 6 implant treatment in the maxilla|
223931380|NCT05064293|BEHAVIORAL|Navigation Arm|Families will be offered a formal assessment to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to the navigator for connection to care or study-provided tele-video visits. Navigators will outreach families monthly during the 6-month study period. The navigator will inquire about the child's status and re-evaluate barriers to access. When barriers exist, the navigator will help in facilitating specialty treatment initiation and assess appropriateness of tele-video therapy sessions until ongoing MH services can be arranged. Families/patients reporting that index symptoms have resolved will be offered a 'watchful waiting' approach. Subjects accepting 'watchful waiting' will be outreached quarterly, but not beyond the end of the 6-month follow-up period.
223931381|NCT05064293|BEHAVIORAL|Control Arm|Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders (e.g., substance use). After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider. Control arm participants do not receive navigation.
223931382|NCT06687941|DRUG|AST-201|AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
223931383|NCT06688903|BEHAVIORAL|App-based diabetes management and community-based health coaching|All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
223931384|NCT06751303|OTHER|Patients that are HRP are given a decision aid for PARPi use|Study created patient decision aid if the first for HRD tested Ovarian Cancer patients
223931385|NCT06766734|PROCEDURE|Tendon Dry Needling|Tendon dry needling procedure is that repetitively passing the needle though the area of supraspinatus tendon. Tendon dry needling was performed under sterile conditions with real-time imaging guidance using an ultrasound probe. The supraspinatus tendon was scanned from anterior to posterior, and tendon dry needling was applied to the identified lesion (tendinozis or partial tear) area. This treatment method was applied twice, with a one-month interval between sessions.
223931386|NCT06766734|PROCEDURE|Sham Tendon Dry Needling|In this treatment subcutaneous sham tendon dry needling was performed by randomly holding the ultrasound probe in the area corresponding to the same anatomical localization. Sham tendon dry needling performed to subcutaneus tissue not tendon.
224096003|NCT01254903|PROCEDURE|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
224096004|NCT03911414|DRUG|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
224096005|NCT03911414|DRUG|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
224096006|NCT03114033|OTHER|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg
224284477|NCT01841216|DEVICE|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
224284478|NCT02156921|OTHER|App-based training|
224284479|NCT05122221|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 500mg/m²/day×3 days
224284480|NCT05122221|DRUG|Interleukin-2|Interleukin-2 20,000,000 IU/time infused within 15 minutes approximately every 8 hours (according to the subject's tolerance, the interval between medications can be extended to 24 hours) for a maximum usage time up to 14 days.
224284481|NCT05122221|BIOLOGICAL|CRTE7A2-01 TCR-T Cell|On day 0, the TCR-T cells will be administered one time, each bag of cell intravenously within 20 minutes.
224284482|NCT01494441|PROCEDURE|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
223931387|NCT06767384|RADIATION|X-ray|To determine diagnostic accuracy of x-ray KUB in diagnostic renal and ureter calculi keeping CT scan KUB as a gold standard.
223931388|NCT06137638|DRUG|ENA-001|ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
223931389|NCT04234646|BEHAVIORAL|Patient Navigation (PN) 2.0 Checklist|The PN 2.0 Checklist intervention is centered on a learning health system checklist that enumerates a patient's Social Determinants of Health (SDoH) related barriers and tracks completion of services to address SDoH (at community oncology and community social service settings) as well as completion of USPSTF recommended cancer-related screenings, behavioral counseling, and immunizations.
223931390|NCT04234646|BEHAVIORAL|One-on-one Patient Navigation (PN)|The one-on-one Patient Navigation will be based on a Case Management Model where PNs perform appointment scheduling and reminders; facilitate communication between patients and care teams; and identify and reduce patient barriers through education, outreach, and referrals to community, local, and state resources
223931391|NCT05544045|DEVICE|Surpass Streamline Flow Diverter System|The Surpass Streamline FDS is indicated for use in the endovascular treatment of adults (age 18 years or older) with unruptured large (≥ 10 mm) saccular, wide-neck (neck width ≥ 4 mm or dome/neck ratio \< 2 mm) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm to ≤ 5.3 mm.
224096007|NCT03114033|OTHER|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg.
224096008|NCT04766853|DRUG|Dexamethasone|Dexamethasone 5mg/ml
224096009|NCT04766853|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
224096010|NCT05116384|DEVICE|catheter ablation|cryo energy via cryoballoon
224096011|NCT05116384|DEVICE|renal artery denervation|RF energy delivery to multiple sites within each major renal artery
224096012|NCT06218251|DRUG|BOTOX|Intramuscular Injections
224096013|NCT04930770|DRUG|MRNA-1273|Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified.
224096014|NCT05087030|DRUG|RGB-14-P|Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
224096015|NCT05087030|DRUG|Prolia®|Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
224096016|NCT03653520|DRUG|Diazepam|5 or 10mg
224096017|NCT03653520|DRUG|Tramadol|50mg or 100mg
224096018|NCT03653520|DRUG|Ondansetron|1 or two tabs
224096019|NCT03653520|DRUG|MKO melt|1 or 2 MKO melts
223533305|NCT00660218|DRUG|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
223533306|NCT00660218|BIOLOGICAL|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
223931392|NCT05019742|DRUG|SPH3127|SPH3127 - selective renin inhibitor
223931393|NCT05019742|DRUG|Placebo|Placebo
223931394|NCT06653062|OTHER|Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis|"Targeted Analysis of Mitochondrial Mutations: Unlike many interventions that may focus on nuclear DNA or general tumor markers, this intervention specifically analyzes mutations within the mitochondrial genome. This focus on mtDNA is based on evidence suggesting that mtDNA mutations are more frequent and may serve as more sensitive indicators of minimal residual disease (MRD) in cancer patients.~Liquid Biopsy Approach: The intervention utilizes a liquid biopsy technique, which involves the collection and analysis of peripheral blood samples to detect circulating tumor DNA (ctDNA). This non-invasive method contrasts with traditional tissue biopsy interventions, offering a less intrusive approach to monitor disease progression and recurrence."
223931395|NCT06894940|BEHAVIORAL|Active Comparator #1|task oriented rehabilitation
223931396|NCT06894940|BEHAVIORAL|Placebo|passive rehabilitation
223931397|NCT06894940|BEHAVIORAL|Experimental|rehabilitation with virtual reality
223931398|NCT03959423|DEVICE|AHCL insulin pump system|670G 4.0 system with GS3; 780G system with G4S (continued access phase);
223931399|NCT06341647|DRUG|AB-201|NK Cell Therapy
223931400|NCT06341647|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
224096020|NCT01048346|BEHAVIORAL|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
224096021|NCT06194877|DRUG|BGB-3245|Oral capsule
224096022|NCT06194877|DRUG|Panitumumab|Intravenous (IV) infusion via an infusion pump
224096023|NCT06649058|OTHER|Systemic Therapy|Participants will receive systemic therapy as a standard of care therapeutic option
224096024|NCT06649058|RADIATION|Stereotactic Radiosurgery|Participants will receive systemic therapy as a standard of care therapeutic option
224096025|NCT05178420|OTHER|Statin discontinuation|Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
224096026|NCT03158766|OTHER|Microdiscectomy|It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
224096027|NCT03860922|DEVICE|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
223931401|NCT06341647|DRUG|Fludarabine|Lymphodepleting chemotherapy
223931402|NCT06786000|DEVICE|Anodal tDCS combined with mCIMT|20 minutes of anodal tDCS followed by 1 hour of the mCIMT program. The anodal electrode will be placed over the ipsilesional M1 (primary motor cortex, C3 or C4 according to EEG 10/20 system), and the cathodal electrode over the contralateral supraorbital area (Fp1 or Fp2) ). Leading to subthreshold depolarization to promote cortical excitation. And twelve different oriented tasks will be used during the 1-hour training period.
223931403|NCT06786000|DEVICE|Cathodal tDCS combined with mCIMT|20 minutes of cathodal tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the contralesional M1, and the anodal electrode over the contralateral supraorbital area (Fp1 or Fp2). leading to subthreshold polarization to promote cortical inhibition. And twelve different oriented tasks will be used during the 1-hour training period.
223931404|NCT06786000|DEVICE|Bihemispheric tDCS combined with mCIMT|20 minutes of Bihemispheric tDCS followed by 1 hour of the mCIMT program. the cathodal electrode will be placed over the primary motor cortex (M1) of the contralesional hemisphere and the anodal electrode will be placed above the ipsilateral M1 position (C3 or C4 positions, according to the 10/20 EEG system). And twelve different oriented tasks will be used during the 1-hour training period.
223931405|NCT06786000|DEVICE|Sham tDCS combined with mCIMT|20 minutes of sham tDCS followed by 1 hour of the mCIMT program. the same stimulation place and parameters will be used as in the anodal group. However, after 30 seconds of stimulation, the stimulator will switch off. This provides the participants with the experience of the initial itchy sensation that occurs during tDCS, which is required for efficient masking. And twelve different oriented tasks will be used during the 1-hour training period.
223931406|NCT06744075|OTHER|Blood assessment|ctDNA collection (venous blood draw) will occur at baseline, mid-treatment, and at the end of treatment
223931407|NCT04683250|DRUG|TAS0953/HM06|Phase 1: oral, starting dose 20mg twice a day, until recommended phase 2 dose, continuous daily dosing, cycles lasting 21 days
223931408|NCT04683250|DRUG|TAS0953/HM06|Phase 2: oral, recommended dose twice a day, continuous daily dosing, cycles lasting 21 days
223931409|NCT06783855|PROCEDURE|suspension uretheroileal technique|The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra
223931410|NCT06783855|PROCEDURE|conventional radical cystectomy and ileal neobladder|After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra, including the mucosa and muscularis of the neobladder neck, ensuring mucosa-to-mucosa anastomosis
223931411|NCT04328532|DEVICE|MRI|MRI examination (45 min max) with potential oxygen delivery for 10 min
223931412|NCT06222346|BEHAVIORAL|CommonGround|"Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support."
223931413|NCT06222346|BEHAVIORAL|NHS Mental Health|"Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements."
223931414|NCT06877338|OTHER|Loaded breathing on stable and unstable surfaces|Participants will be instructed to perform 10 loaded breaths via a threshold inspiratory load device on both a stable surface (sitting on a chair, Protocol 1) and an unstable surface (sitting on a soft pad, Protocol 2) in random order. The inspiratory load/resistance will be set at 50% of the maximum inspiratory pressure (MIP).
223931415|NCT04588038|BIOLOGICAL|Efineptakin alfa|Given via intramuscular injection
223931416|NCT06864429|PROCEDURE|Radiofrequency catheter ablation|Radiofrequency (RF) catheter ablation is a minimally invasive procedure that targets and eliminates certain types of cardiac arrhythmias. RF became effective as the first-line treatment for ventricular arrhythmias in some circumstances.
223931417|NCT06863506|DRUG|befotertinib|Befotertinib will be administered orally at an initial dose of 75 mg once daily for 21 days, with escalation to 100 mg if tolerated. Treatment continues until disease progression, unacceptable toxicity, or withdrawal.
224096028|NCT01501591|DRUG|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
224096029|NCT01501591|OTHER|Placebo|Matching placebo once on two different days, 72 hours apart.
224096030|NCT01501591|DRUG|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
224096031|NCT04992702|BEHAVIORAL|Animated Video|Animated video to improve learning and motivation
224284483|NCT01494441|DEVICE|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
224284484|NCT01494441|DEVICE|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
224284485|NCT03966859|DRUG|Atorvastatin 20mg|oral dose, once daily for 7 days
223931418|NCT06870045|OTHER|Physical examination|The physical examination will included Timed Up and Go Test (TUG), Walking speed, Wong-Baker FACES Pain Scale, Pediatric balance scale and CHAQ (Childhood Health Assessment Questionnaire).
224096032|NCT06255873|DIETARY_SUPPLEMENT|L- Carnitine|L-carnitine was taken after feeds in the form of tablets or dissolved tablets in a dose of 50 mg/kg/day, with maximum dose of 2 g/day.
224096033|NCT06255873|OTHER|ketogenic diet|ketogenic diet (KD) initiated under supervision of expert physician who considered patient's age, type of feeding, needs and preferences of the child and his/her family to select the type and initial ratio of KD therapy, KD ratio ranged from 1:1 to 4:1 of lipids to carbohydrates plus proteins in grams.
224096034|NCT01289496|DRUG|Peg-interferon alpha-2a, Ribavirin|"* 4 weeks RBV priming;~* 24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~* 24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets"
224096035|NCT05338229|DEVICE|the engineer-built system, video-game based Kinect sensor|The engineer-built system, video-game based Kinect sensor was developed by the researcher team.
224096036|NCT02740309|BEHAVIORAL|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
224096037|NCT02740309|BEHAVIORAL|Treatment as usual|Facilitated community referral for mental health treatment
224096038|NCT00004826|DRUG|clozapine|
224096039|NCT04826900|PROCEDURE|BoNT-A injections|Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
224096040|NCT04826900|OTHER|Robotic therapy (RT)|A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
224096041|NCT04826900|OTHER|Robotic mirror therapy (RMT)|Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
224096042|NCT04826900|OTHER|Functional task training|After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
224096043|NCT03746470|PROCEDURE|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
224284486|NCT03966859|OTHER|Lactose placebo|oral dose, once daily for 7 days
224284487|NCT02187107|DRUG|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
224284488|NCT02187107|DRUG|rtv|100 mg tablet of Norvir®
223931419|NCT06870045|OTHER|Dynamic Gait Index|The DGI, whose validity and reliability will be investigated, consists of 8 items: walking on level ground, walking with changing speed, walking with sideways head turns, walking with vertical head turns, walking with pivot turns, walking over obstacles, going around obstacles, and climbing stairs. Performance on each item is rated on a 4-point scale ranging from 0 (severe impairment) to 3 (normal walking ability without a walking aid). The total score is 24. Scores below 19 indicate a risk of falling, while scores above 22 define safe ambulation.
223931420|NCT00627432|DRUG|gemcitabine hydrochloride|
223931421|NCT00627432|DRUG|oxaliplatin|
223931422|NCT06851208|OTHER|Emotional intervention|Emotional intervention Description: The participant will watch a short video-clip with negative emotional content while simultaneously experience experimentally induced pain.
223931423|NCT06851208|OTHER|Emotional intervention|Description: The participant will watch a short video-clip with positive emotional content while simultaneously experience experimentally induced pain.
224284489|NCT02355756|DRUG|Maxadilan|
224284490|NCT02355756|DRUG|Placebo|
224284491|NCT04127292|BEHAVIORAL|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
224284492|NCT02563769|DRUG|Clavulanic acid|Clavulanic acid will be administered orally in 250mg capsules
224096044|NCT03746470|PROCEDURE|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
223533307|NCT00660218|RADIATION|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
223931424|NCT06851208|OTHER|Emotional intervention|Description: The participant will watch a short video-clip with neutral emotional content while simultaneously experience experimentally induced pain.
224096045|NCT01879657|DRUG|68Ga-DOTATATE|68Ga-DOTATATE (3-5 mCi ±25%; 111-185 MBq) is administered as a single intravenous bolus injection in each participant. These injections were performed within 28 days after the Octreoscan.
224096046|NCT01879657|DIAGNOSTIC_TEST|PET/CT|68Ga-DOTATATE PET images will be acquired 60 ±30 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET images were performed within 28 days after the Octreoscan.
224096047|NCT01879657|DIAGNOSTIC_TEST|111In-pentetreotide OctreoScan|OctreoScan™ was performed after intravenous injection of 111In-pentetreotide, a radiopharmaceutical that binds to somatostatin receptors, if the patient had not undergone such imaging as a standard of care. Subsequent planar and/or SPECT imaging was used to detect somatostatin receptor-positive lesions.
223931425|NCT02298348|DRUG|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
223931426|NCT02298348|DRUG|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
223931427|NCT02298348|DRUG|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
224096048|NCT01879657|DIAGNOSTIC_TEST|MRI|MRI (Standard of Care)
224096049|NCT02680353|PROCEDURE|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
224284493|NCT02563769|DRUG|Intravenous cocaine|20/40mg Cocaine will be administered by IV
224284494|NCT02563769|DRUG|Placebo|Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
224284495|NCT06043622|OTHER|Optical coherence tomography angiography|Optical coherence tomography angiography
224284496|NCT06043622|OTHER|ophthalmological exam|ophthalmological exam
223931428|NCT06085300|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax .
223931429|NCT06748820|BEHAVIORAL|Remote Therapeutic Patient Education (e-TPE)|TPE is a set of practices aiming at allowing a patient to acquire and preserve abilities and skills to manage actively their disease, cares, and surveillance, in collaboration with the caregivers
223931430|NCT06894823|OTHER|Creation of a laboratory network|Creation of a laboratory network in Central-Southern Italy capable of performing complex genomic analyses.
223931431|NCT06894823|OTHER|Mapping of genomic alterations|Mapping of genomic alterations aimed at precision medicine and personalized diagnostic and therapeutic approaches.
223931432|NCT06894823|OTHER|Creation of a bioinformatics network among the participating institutions.|Creation of a bioinformatics network among the participating institutions.
223931433|NCT06894823|OTHER|Development of a platform for the collection of clinicopathological and genetic-molecular data.|Development of a platform for the collection of clinicopathological and genetic-molecular data.
223931434|NCT06894823|OTHER|Identification of prognostic and predictive factors for the implementation of precision oncology strategies based on genomic profiling.|Identification of prognostic and predictive factors for the implementation of precision oncology strategies based on genomic profiling.
224096050|NCT00686543|DRUG|Posaconazole|Posaconazole will be used for prophylaxis
224096051|NCT00609622|DRUG|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
224096052|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
224096053|NCT00609622|DRUG|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
224284497|NCT00566280|PROCEDURE|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
224284498|NCT05184179|DRUG|Olmesartan Medoxomil|Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca
223533308|NCT04211363|DRUG|Roflumilast 0.3% cream|Roflumilast 0.3% cream for topical application.
223533309|NCT04211363|DRUG|Vehicle Cream|Vehicle cream for topical application.
224284499|NCT04229290|DRUG|Dolutegravir|Switch of virally suppressed participants to Dolutegravir
224284500|NCT03401554|PROCEDURE|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
224284501|NCT03401554|PROCEDURE|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
224284502|NCT02078921|DRUG|Sodium Nitrate|
224284503|NCT02078921|DRUG|Placebo|
224284504|NCT04709224|DRUG|Lumateperone Long-Acting Injectable|Lumateperone Long-Acting Injectable
223533310|NCT03035630|DRUG|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
223533311|NCT03035630|DRUG|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
223533312|NCT02007941|DRUG|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
223718299|NCT04506372|BEHAVIORAL|Quality of life questionnaire|Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery
223533313|NCT03097289|DEVICE|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
223533314|NCT02160821|PROCEDURE|Caudal Epidural|Ultrasound Guided Caudal Block
223533315|NCT02160821|PROCEDURE|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
223533316|NCT02835469|DRUG|Menotrophin|
223533317|NCT01302002|DRUG|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
223931435|NCT06827288|BEHAVIORAL|SUN|The SUN helps patients initiate buprenorphine treatment in the hospital, connects patients to follow-up care by facilitating appointments at outpatient clinics, addresses barriers to care, and serves as a resource for patients and clinicians. The SUN also advocates for a harm-reduction culture, models respectful interactions with people who use drugs and provides technical assistance to hospital staff to reduce stigma and discrimination.
223931436|NCT06827288|BEHAVIORAL|SUN + Telebridge|TeleBridge consists of an immediate telehealth connection to a buprenorphine provider affiliated with the CA Bridge program who has expertise facilitating pharmacotherapy with individuals with OUD. TeleBridge addresses barriers to initiation of buprenorphine by reducing long wait times and the inability of the outpatient setting to initiate treatment on demand. TeleBridge also eliminates the need for patients to meet system-level requirements (e.g. on time for appointments during working hours while wearing appropriate attire) to obtain follow-up care. TeleBridge is a more resource-intensive form of care because it involves developing formalized relationships with outpatient providers and implementing telehealth protocols. TeleBridge is feasible based on the increased use of telehealth to expand post-ED care pathways.
223931437|NCT06827288|BEHAVIORAL|ED-ITT|Enrolled patients who have not filled an outpatient buprenorphine (BUP) prescription at 30 days, return to the ED with an OUD-related event, or self-report nonadherence to the prescribed BUP are considered non-responders, and randomly assigned to a second stage intervention. For non-responders randomized to receive ongoing BUP treatment by an ED-based interim treatment team (ED-ITT), the SUN and Site PI (an ED physician with expertise in addiction medicine) will meet weekly to review the SUN's caseload, using a patient registry that has been modified for the trial. The registry: 1) prompts/documents proactive SUN outreach up to 3 additional months for non-responders, with an emphasis on prioritizing subsequent outreach to patients who have not yet engaged with outpatient care, or who are at risk of dropping out if the patient have transitioned; and 2) documents when the ED provider prescribes transitional BUP and when the patient would be due for a new prescription.
223931438|NCT06827288|BEHAVIORAL|ED-ITT + BHS|Enrolled patients who have not filled an outpatient buprenorphine (BUP) prescription at 30 days, return to the ED with an OUD-related event, or self-report to the SUN nonadherence to the prescribed BUP will be considered non-responders, and randomly assigned to a second stage intervention. For non-responders randomized to receive ongoing BUP treatment from the ED-ITT+BHS, Behavioral Health Support (BHS) will be added to ED-ITT and include a weekly caseload review with an externally-affiliated psychiatrist with expertise in addiction medicine who will make mental health and substance use treatment recommendations, both pharmacological and behavioral, to the ED provider and SUN for up to 3 months. The consultant may also ask the SUN to do a more detailed behavioral health assessment, if insufficient information is available to make treatment recommendations. All prescriptions will be written by the ED provider.
223931439|NCT06757114|OTHER|High altitude|High altitude is defined as a long-term residence with an altitude of 1500m and above
224096054|NCT00609622|DRUG|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
224096055|NCT03498820|DEVICE|Analgesia Nociception Index|: Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity
224096056|NCT03498820|DRUG|Remifentanil|intravenous short-acting opioid routinely administered during general anesthesia
224096057|NCT06296563|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion for 2 times.
224096058|NCT06296563|DRUG|Adebrelimab|Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
224096059|NCT06296563|DRUG|Apatinib|Apatinib 250mg, po, qd,q3w,up to one year of use at most.
224096060|NCT04093830|DEVICE|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
223533318|NCT06155357|BEHAVIORAL|Multicomponent lifestyle intervention program|The multicomponent lifestyle intervention program is targeted at risk factor management, increased exercise capacity, and weight loss. The program will commence upon order/referral for ablation. Ablation would occur during the lifestyle program and the program will be continued after the ablation to complete 12 weeks or up to 36 exercise sessions.
223533319|NCT01823289|DRUG|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
223718300|NCT04506372|BEHAVIORAL|WHODAS questionnaire|Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery
223718301|NCT06211166|DIAGNOSTIC_TEST|Digital PCR|digital Polymerase Chain Reaction (dPCR)
224096061|NCT03107195|DRUG|Imaging Time|Participants will be asked to be imaged at an additional time point.
224096062|NCT04356456|DIETARY_SUPPLEMENT|Lumenato|tomato oleoresin obtained from yellow dry tomato pulp
223533320|NCT01428791|BEHAVIORAL|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
223718302|NCT06211166|DIAGNOSTIC_TEST|Quantitative PCR|Real-time Polymerase Chain Reaction (real-time PCR)
223931440|NCT06741592|DEVICE|EDDY Group|The EDDY activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
223931441|NCT06741592|DEVICE|PUI Group|The passive ultrasonic activation of the irrigation solutions used is performed to achieve root canal disinfection and enhance antibacterial effectiveness once the root canal preparation is completed.
223931442|NCT06748014|DRUG|Aescin in Horse Chestnut|Patient will recived MPFF 3000 mg for 7 day then 1000 mg for 2 month + Aescin 60 mg for 2 month
223931443|NCT06748014|DRUG|MPFF|MPFF 3000 mg 7 day then 1000 mg 2 months
223931444|NCT06762834|COMBINATION_PRODUCT|Ginger tea|determine the optimal dosage of ginger tea that produces significant blood pressure reduction without adverse effects.
223931445|NCT06762834|COMBINATION_PRODUCT|self administred Ginger tea|To identify consumption and its correlation with blood pressure outcomes using a self- reported diary and periodic clinical assessments.
223931446|NCT06747169|DRUG|Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin|All patients were treated with a combination therapy consisting of sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin. The study is designed to assess the efficacy and safety of this treatment regimen in the specified population.
223718303|NCT06211166|DIAGNOSTIC_TEST|MFC|Multicolor Flow Cytometry
223931447|NCT06775795|DIETARY_SUPPLEMENT|Oat milk|Participants will consume one portion of plant-based milk alternative (oat) which will provide approximately 200 µg of iodine
223931448|NCT06775795|DIETARY_SUPPLEMENT|Soya milk|Participants will consume one portion of plant-based milk alternative (soya) which will provide approximately 200 µg of iodine
223931449|NCT06775795|DIETARY_SUPPLEMENT|Cow's milk|Participants will consume one portion of semi-skimmed cow's milk which will provide approximately 200 µg of iodine
223931450|NCT06750952|DRUG|Ivonescimab Combined With Chemotherapy|Ivonescimab injection is an IgG1 subtype humanized bispecific antibody targeting human vascular endothelial growth factor-A (VEGF-A) and programmed death protein-1 (PD-1). It can bind to VEGF-A and PD-1 at the same time, and competitively block the interaction between VEGF-A, PD-1 and their ligands, exerting antitumor activity.
223931451|NCT06596317|PROCEDURE|Chromoendoscopy|Patients will undergo chromoendoscopy with spraying indigo carmine.
223931452|NCT06596317|PROCEDURE|Conventional colonoscopy|Patients will undergo conventional colonoscopy.
223931453|NCT06114498|DIAGNOSTIC_TEST|Echocardiography|Transthoracic echocardiography at rest: with determination of epicardial fat tissue thickness, intensity of mitral regurgitation.
223931454|NCT06114498|DIAGNOSTIC_TEST|Bioimpedance|Bioelectrical impedance analysis research
223931455|NCT06114498|DIAGNOSTIC_TEST|Immunoassay|Enzyme immunoassay of heat shock proteins in blood serum
223931456|NCT06114498|DIAGNOSTIC_TEST|Routine biochemistry|Measuring of routine biochemical parameters (glucose, total protein, creatinine, urea, uric acid, total bilirubin, direct bilirubin, total cholesterol, triglycerides, low and high density lipoprotein cholesterol, Lactate dehydrogenase, creatine phosphokinase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium and special (C-reactive protein, N-terminal pro b-type natriuretic peptide)
223931457|NCT06431113|COMBINATION_PRODUCT|Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )|treatment for 4 months and then cross over to the other therapy
223931458|NCT05566262|DRUG|Bodewell Calming Cream|Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
223931459|NCT05786612|DEVICE|Biatain® Silicone|Wound care dressing
223931460|NCT05786612|DEVICE|Mepilex Border with Aquacel Extra Hydrofiber|Wound care dressing
223931461|NCT05818319|OTHER|12 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting 12 hours.
223931462|NCT05818319|OTHER|36 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
223931463|NCT05818319|OTHER|60 hours ETI pause|Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
224096063|NCT05195606|OTHER|Auditory stimulus|Auditory stimulus will be applied to the patients in intervention group A. For the auditory stimulus, the sound recording of the relatives of the patients will be taken and the patients will be listened to with headphones.
224096064|NCT05195606|OTHER|Tactile stimulus|Tactile stimulus will be applied to the patients in the intervention group B. The tactile stimulus will be performed by the researcher with a foot massage to be applied to the patient.
224096065|NCT05239689|BIOLOGICAL|CD38 CAR T-cells|Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
224096066|NCT02139150|RADIATION|[18F] FLT|
224096067|NCT02139150|DEVICE|PET/CT scans|
224096068|NCT03280251|DRUG|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
224096069|NCT03280251|DRUG|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
224284505|NCT05227677|OTHER|GA guided anti-diabetic therapy adjustment|The GA concentration will be measured at 4-week intervals in both groups. The anti-diabetic treatment regimen will be strengthened when GA value is higher than 16% at 4 weeks.
224284506|NCT05227677|OTHER|current guidelines to adjust treatment|The GA concentration will be measured at 4-week intervals. Investigators will be not aware of the GA value and rely on the current guidelines to adjust treatment.
224096070|NCT03280251|OTHER|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
223931464|NCT04926740|OTHER|Ringer's lactate|Ringer's lactate is the most commonly used balanced crystalloid. Compared to normal saline, balanced crystalloids have chloride concentrations similar to human plasma; therefore, treatment with balanced crystalloids may lead to faster DKA resolution.
223931465|NCT04378400|PROCEDURE|Sacrocolpopexy|Sacrocolpopexy is offered to patients with symptomatic prolapse (≥stage II) of the vaginal apex (vault or cervix). The procedure involves dissection of the promontory and the vaginal vault, suturing of two meshes to the anterior and posterior aspect of the vagina using minimally three rows of sutures on each side, and one row at the apex. Thereafter the mesh is fixed with staples to the promontory and the peritoneum closed, with staples and a running suture.
223931466|NCT06119295|BEHAVIORAL|Portion size manipulation|The intervention will be administered via changing portion sizes of foods served to participants. Depending on the condition participants are in, they will be served either a portion size which consists of the amount of food they consumed in the first test session, or a reduced portion size. Within these two reduced portion size conditions, one group of participants will be made aware that their portion size has been reduced, the other will not and instead will be told that this portion size is the same as the amount of food they consumed in the previous session.
223931467|NCT02549352|DRUG|LEO43204 gel|
223931468|NCT02549352|DRUG|Vehicle gel|
223931469|NCT06765603|DRUG|Atropine 0.025%|Atropine 0.025%
223931470|NCT06765603|DEVICE|Multizonal contact lens|Multizonal CL
223931471|NCT06765603|DRUG|Placebo|Placebo
223931472|NCT06765603|DEVICE|Single vision Contact lens|Single vision contact lens
223931473|NCT06762938|BEHAVIORAL|ShotBlocker|Apply ShotBlocker
223931474|NCT06764212|DIAGNOSTIC_TEST|Ultrasound|M-mode ultrasonography images of the fascia under the trapezius muscle will be recorded during 3 different movements.
223931475|NCT06764043|OTHER|Clinical evaluation|In this study, it was aimed to measure the levels of MMP-8, MMP-20, and TGF-β1 in GCF together with the volume of GCF to investigate the effect of MIH on oral hygiene, and gingival health, and also to evaluate the relationship between MIH, and various biomarkers.
223931476|NCT06359314|BEHAVIORAL|ALDER|The ALDER skills are delivered over approximately 5 weeks. A week consists of learning at least one skill and then applying that skill(s) in daily home practice throughout the week. Skill lessons and daily home practice exercises are housed on the ALDER website. Participants have the option to share their home practice responses with fellow participants by posting them to the discussion board, where they can like and comment on each other's posts.
224096071|NCT03280251|OTHER|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
224096072|NCT00004987|DRUG|Dextrin 2-sulfate|
224096073|NCT04143633|OTHER|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
223718304|NCT05403281|DRUG|DW6012|"Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast"
224096074|NCT04143633|OTHER|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
224096075|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/p|solution for intramuscular injection, 0.5 ml
224096076|NCT05308212|BIOLOGICAL|Flu-M Tetra [Inactivated split influenza vaccine] w/o/p|solution for intramuscular injection, 0.5 ml
224096077|NCT05308212|BIOLOGICAL|Ultrix [Inactivated split influenza vaccine]|solution for intramuscular injection, 0.5 ml
223718305|NCT00000688|DRUG|Ganciclovir|
223718306|NCT00105469|DRUG|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
223931477|NCT04538352|DRUG|Semaglutide|Medication for type 2 diabetes management
224096078|NCT04684199|DIETARY_SUPPLEMENT|Melatonin|Comparison between melatonin and placebo (2 weeks each) with active and placebo crossover during the study period of 34-36 days.
224284507|NCT03710317|DRUG|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
224284508|NCT03710317|DRUG|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
224284509|NCT03710317|DRUG|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
223931478|NCT04538352|DRUG|Insulin Degludec|Medication for type 2 diabetes management
223931479|NCT04538352|DRUG|Insulin aspart|Medication for type 2 diabetes management (rapid-acting)
223931480|NCT06801405|DRUG|antibiotic prophylaxis|Antibiotic prophylaxis before percutaneous nephrostomy
223931481|NCT06790225|OTHER|Glucose-dependent Insulinotropic Polypeptide (GIP)|Recombinant human GIP (1-42)
223931482|NCT02427724|DRUG|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
223931483|NCT02427724|DRUG|lidocaine 7%/tetracaine 7% topical anesthetic|
223931484|NCT02427724|DRUG|placebo vehicle|
223931485|NCT02427724|DEVICE|Q-switched 532nm Laser|
224096079|NCT04684199|DIETARY_SUPPLEMENT|Placebo|
224096080|NCT04894955|DEVICE|MARIA|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to ascertain their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® participant bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts and array are brought into contact with the breast. A scan sequence comprising of two complete scan rotations will then be performed, which takes around 5 minutes. The participant will then be assisted to adjust their positioning, and the scan sequence performed on the other breast.
224284510|NCT00690482|DRUG|AZD1981|Oral tablet, twice daily
224284511|NCT00690482|DRUG|Placebo|Placebo Oral tablet, twice daily
223931486|NCT06829680|OTHER|Pilates|"The participants were given a total of 12 sessions of Pilates training, applied twice a week for 6 weeks, and each session lasted approximately 60 minutes. The 60-min session consisted of warm up and cool down (5 min each) and the main active phase (50 min).~In the main active phase; One leg stretch, Double leg stretch, One leg circle, Heels together toes apart, Shoulder bridge, The hundreds, Chest lift, Criss cross, Clam, Side bend, Arm opening, Cobra, Breast stroke, Swimming, Modified push-up, Plank, Leg pull prone and Squat exercises were performed. The exercises were applied with 10 repetitions in the first 3 weeks and with 20 repetitions in the last 3 weeks."
223931487|NCT06829680|OTHER|Whole Body Vibration|"The participants were given a total of 12 sessions of WBV training, applied twice a week for 6 weeks.~The vibration parameters were set as frequency: 20 Hz, amplitude: 2-3 mm, duration: 30-60 s and rest period: 60 s. The application time of the WBV training was 30 s for the first two weeks, 45 s for the next two weeks and 60 s for the last two weeks.~The individuals were asked to maintain squat, shoulder bridge and quadruped positions statically for the first two weeks. Starting from the third week, they were asked to perform reciprocal upper extremity flexion and extension movements during the positions. The application was repeated 3 times in each position."
223931488|NCT06222489|DRUG|89Zr-Patritumab deruxtecan|Day 1, day 3, day 6, day 11 and day 26 of first course
223931489|NCT06828367|BEHAVIORAL|Online family educational intervention and cooking workshop|Registration for the educational platform will be open for 3 months from the start of the school year. Over the first 2-3 months, the contents of each topic will be activated weekly, and family participation will be encouraged through reminders. In the following 3 months, the platform will remain open, allowing families who did not follow the weekly content to catch up. Participation reminders will continue. From the 3rd to 6th month, the cooking workshop will be held in person. Throughout the intervention, activities will promote participation, and a Q\&A channel with an expert (nutritionist) will remain open. Total intervention time: 6 months.
223931490|NCT06827730|DIAGNOSTIC_TEST|Point of care ultrasound|The investigator uses PoCUS to investigate thoracic or abdominal pain after anamnesis and clinical examination. The investigator reports the anamnesis, clinical examination, and PoCUS results in the patient's medical file. PoCUS images are recorded according to the procedures of the study centers and the capacities of the ultrasound machines.
223931491|NCT06799039|DRUG|Xylitol|Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
223931492|NCT06759766|COMBINATION_PRODUCT|Garlic-Lemon Extract irrigant|"garlic (Allium sativum) Shows a wide range of therapeutic effects due to the presence of allicin, ajoene \& other thiosulfinates. It has antibacterial effect against wide range of gram-positive and gram-negative bacteria, anti-inflammatory, antioxidant, antiviral, antifungal, antitumor, immunomodulatory effects and tissue-dissolving capacity (Siddique, et al., 2020). According to (Elheeny., 2019) Allium sativum extract can be used efficiently as an irrigant for pulpectomy of primary molar root canals.~Lemon (Citrus Limon) as well has curative properties such as, antibacterial, antiviral, antifungal, anti-inflammatory, anti-cancerous activities and removal of the smear layer as well. Due to presence of ascorbic acid, phenolic acids, polyphenols, and dietary fibers.~the combination of Garlic-Lemon has been tested in adult teeth as an irrigant and showed an effective result equal to NaOCl (Siddique, et al., 2020)."
223931493|NCT06759766|OTHER|physiological saline|Normal saline solution exhibits no adverse effects on the developing successors; Serves primarily to facilitate root canal cleaning during the irrigation process, in comparison to other commercial synthetic irrigants such as Sodium hypochlorite (NaOCl), Chlorhexidine (CHX), Ethylenediamine tetra acetic acid (EDTA) which exhibit potential side effects and cytotoxic reactions (Sayadizadeh et al., 2019).
224096081|NCT06299943|OTHER|Biofeedback gait training by biomechanical target parameter|The patient walks using a treadmill at a comfortable speed until he gets tired. The patient is instructed that when performing a virtual task (in a virtual environment on the screen), his walking will be harmonized (without informing him on what parameter). If it fails to cope, then the zones of permissible changes (on the information columns) will expand, and the virtual task will signal its incomplete completion.
224096082|NCT00988390|BEHAVIORAL|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
224096083|NCT03784196|OTHER|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
224096084|NCT06213636|BIOLOGICAL|CD19/CD22-CAR T cells|"The intervention in this clinical trial involves a novel approach using CD19/CD22-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/CD22-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/CD22-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/CD22-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses."
224096085|NCT00000191|DRUG|Carbamazepine|
224096086|NCT02370121|DRUG|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
224096087|NCT02370121|DRUG|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
223718307|NCT00105469|DRUG|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
223533321|NCT01428791|BEHAVIORAL|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health \& health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
223533322|NCT03057756|COMBINATION_PRODUCT|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
223533323|NCT05748821|DEVICE|Delfi Personal Tourniquet Systems|Measure within \& between differences in acute vascular compliance from pre- to post-training with autoregulated BFR, nonautoregulated BFR and no BFR conditions.
223533324|NCT01736917|DRUG|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
223533325|NCT01736917|DRUG|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
223533326|NCT01736917|DRUG|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
223533327|NCT01392157|DEVICE|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
223533328|NCT01392157|DEVICE|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
223533329|NCT01392157|DEVICE|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
223533330|NCT01392157|DEVICE|LNG-IUS|100 women will receive an LNG-IUS
223533331|NCT01734902|DRUG|Hyoscine butylbromide|sugar coated tablets for oral administration
223533332|NCT01734902|DRUG|Hyoscine butylbromide|drops for oral administration
223533333|NCT00060944|DRUG|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
223533334|NCT00060944|DRUG|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
223533335|NCT00060944|DRUG|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
223931494|NCT06758765|PROCEDURE|Erector Spinae Plane Block|ESPB was applied to the patients in a sitting position. A high-frequency linear probe was used. Under sterile conditions, the USG probe was placed longitudinally approximately 2 cm lateral to the T4 spinous process. Skin, subcutaneous fat tissue, m. trapezius, rhomboid muscles, erector group muscles, transverse process, intercostal muscles, pleura and lung movements were visualized from superficial to deep structures. 1 ml of 2% lidocaine was injected into the estimated needle entry area. Then, with the block needle the m. trapezius, mm. rhomboidei and erector spinae muscles were passed in order with the in-plane method and the needle was brought into contact with the transverse process. Fascial separation was confirmed with 1-2 ml of saline solution and the block was performed by injecting 20 ml of 0.375% bupivacaine. The distribution of the drug was confirmed by observing it with USG.
223533336|NCT00060944|DRUG|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
223931495|NCT06758765|PROCEDURE|Pectoral Nerve Block|"The PECSI and PECSII blocks were applied concurrently.~In patients who will undergo PECS II, sterile conditions were prepared with the arm on the side to be operated on in the supine position and 90 degrees of abduction. The lateral and pectoral branches of the thoracoacromial artery were visualized between the PM and Pm muscles at the level of the 4th rib under USG guidance. The blocking needle was directed between the PM and Pm muscles for PECS I, 1-2 ml of saline was injected to verify fascial spread, and 10 ml of 0.375% bupivacaine was applied. Afterwards, fascial spread was confirmed by injecting 1-2 ml of saline between the pectoralis minor muscle and the serratur anterior muscle, and PECS II was performed by injecting 10 ml of 0.375% concentration bupivacaine. The distribution of the drug was confirmed by observing it with USG."
223931496|NCT06839833|DIAGNOSTIC_TEST|APOL1 Genotyping|The APOL1 Genotyping CTA will identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2). The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
223931497|NCT06891378|OTHER|Intrevention group (mHealth group)|"1. Receive a customized rehabilitation exercise program after surgery and perform rehabilitation exercises while watching videos~2. Check recovery of shoulder joint range of motion~3. Write an exercise diary (check exercise schedule and post-exercise condition)~4. Check activity level through step count collection~5. Check exercise records and contact to confirm reason if exercise was not performed"
223931498|NCT06891378|OTHER|control group (usual care)|"This group performs home rehabilitation exercises using in-hospital educational materials.~Control group data are retrospectively collected and matched using propensity score methods."
223931499|NCT06764420|DIETARY_SUPPLEMENT|Glutamine Oral Suspension|Participants in this group will receive an oral suspension containing 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. This control intervention serves to compare the effects of glutamine alone with the combined arginine and glutamine treatment. In addition to the glutamine suspension, patients in this group will receive general measures and analgesic drugs according to the WHO scale to manage symptoms of mucositis.
223931500|NCT06764420|DIETARY_SUPPLEMENT|Arginine and Glutamine Oral Suspension|Participants in this group will receive an oral suspension containing 5 grams of arginine and 5 grams of glutamine dissolved in cold water. This solution is administered 30 minutes before meals, three times per day, using the swish and swallow technique throughout the radiotherapy period. The swish and swallow technique involves patients swishing the solution around the oral mucosa to ensure even distribution before swallowing. This intervention aims to evaluate the combined effect of arginine and glutamine on reducing the severity of radiation-induced mucositis, improving mucosal healing, and providing symptomatic relief.
223931501|NCT06839014|OTHER|Exercise|Perform 30 minutes of TENS unit exercise muscle stimulation each day for 3 days a week for the duration of cancer treatment.
223931502|NCT06430684|DRUG|Empagliflozin 10 MG|Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older
223931503|NCT02278185|DRUG|Enzalutamide|Given PO
223931504|NCT02278185|DRUG|leuprolide acetate|Given SC or IM
223931505|NCT02278185|DRUG|goserelin acetate|Given SC or IM
223931506|NCT02278185|DRUG|histrelin acetate|Given SC or IM
223931507|NCT02278185|DRUG|triptorelin|Given SC or IM
223931508|NCT02278185|DRUG|degarelix|Given SC or IM
223931509|NCT06918340|DRUG|Diclofenac|Group II: 5-6 puffs of topical 1% diclofenac spray will be applied before radial artery blood gas sampling.
223533337|NCT03969173|PROCEDURE|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
223931510|NCT06918340|DRUG|Lidocaine spray|Group I: 5-6 puffs of topical 10% lidocaine spray will be applied before radial artery blood gas sampling.
224096088|NCT03388814|DRUG|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
224096089|NCT03388814|DRUG|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
223533338|NCT03969173|PROCEDURE|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
224096090|NCT01540643|DEVICE|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
223718308|NCT05577442|DRUG|Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy|Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
223533339|NCT03969173|PROCEDURE|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
223931511|NCT06918340|OTHER|Placebo|Group III: 5-6 puffs of topical 70% alcohol solution spray will be applied before radial artery blood gas sampling.
223931512|NCT06473974|DRUG|Test cosmetic product|"Test cosmetic product: Test cosmetic product will be applied to affected hyperpigmented areas twice daily at AM and PM.~Cleanser and sunscreen: A facial cleanser will be used twice daily (morning and evening) by gently rubbing it on face and neck, then rinse and pat dry. Sunscreen of SPF 50, apply evenly on face and neck, 20 minutes before stepping out."
223931513|NCT05927194|BEHAVIORAL|Using the Connect|Using the Connect (UTC) is an innovative, game-based intervention for youth to develop skills in adulthood preparation topics such as communication, decision making and accessing information.
223533340|NCT03381989|DEVICE|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
223931514|NCT04107233|BEHAVIORAL|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
223931515|NCT06931717|DRUG|Cemiplimab|Cemiplimab, 350 mg i.v., every 3 weeks (±3 days), for 4 cycles, followed by 700 mg i.v., every 6 weeks (±1 week) for 6 cycles or until relapse or unacceptable toxicities, whichever occurs first.
223718309|NCT00844389|DEVICE|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
223718310|NCT00844389|DEVICE|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
223718311|NCT01104506|PROCEDURE|fMRI|
223931516|NCT05683873|PROCEDURE|Electrocardiogram|Inclusion visit, V1, V2 and V3
223931517|NCT05683873|PROCEDURE|transthoracic echocardiography|V1, V2 and V3
224096091|NCT04915287|DRUG|Avatrombopag maleate|"1. Mean baseline platelet count 40 to less than 50 × 10\^9/L: 40mg Avatrombopag QD × 5 days from 10-13 days pre-procedure~2. Mean baseline platelet count less than 40 × 10\^9/L: 60mg Avatrombopag QD × 5 days from 10-13 days pre-procedure"
224096092|NCT04915287|BIOLOGICAL|Platelet transfusion|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: platelet transfusion if needed
224096093|NCT04915287|DRUG|Medicine|Mean baseline platelet count less than 50 × 10\^9/L pre-procedure: rhuTPO, rhIL-11, Romiplostim, Eltrombopag, or Lusutrombopag, etc.
224096094|NCT04087226|DEVICE|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
223931518|NCT05683873|BIOLOGICAL|standard biology|Inclusion visit
223931519|NCT05683873|BIOLOGICAL|determination of serum GDF-15, osteoprotegerin and ST-2|Inclusion visit, V1, V2 and V3
224096095|NCT03121391|PROCEDURE|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
224096096|NCT05104944|RADIATION|Serial MRIs|Serial use of MRI at 3, 6, 9 and 12 months to identify disease resolution and thus discontinuation of immobilisation plus standard care.
224096097|NCT03776656|DRUG|Allopurinol|Daily oral administration
223718312|NCT01104506|PROCEDURE|mTMS|
223931520|NCT05683873|BIOLOGICAL|Ultrasensitive Troponin-Ic|Inclusion visit, V1, V2 and V3
223931521|NCT05683873|OTHER|Collection of clinical and radiological data|Inclusion visit, V1 and V3: clinical data only V2: clinical and radiological data
223931522|NCT05683873|OTHER|72-hour continuous Holter-ECG recording|V1
223931523|NCT05747794|BIOLOGICAL|eftilagimod alpha|APC activator, MHC II agonist
223931524|NCT05747794|DRUG|Paclitaxel|paclitaxel will be given as standard of care (chemotherapy)
223931525|NCT05747794|OTHER|placebo|placebo matching eftilagimod alpha
223931526|NCT06401759|BEHAVIORAL|Podcast|Routine maintenance will be applied.
223931527|NCT06072092|DEVICE|BIS Monitor|No interventions will be administered, but in addition to the standard of care according to the Guidelines of the European Resuscitation Council 2021, a frontal EEG-monitoring (BIS), a CPRMeter and a FlowMeter will be installed. The study will be observational only; the readings of the BIS monitor will be blinded to the treating PRU team.
224096098|NCT05232734|DRUG|Caffeine Citrate 20 MG/ML Oral Solution|Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
223931528|NCT03130452|DRUG|Lansoprazole 30mg|lansoprazole 30 mg tablet
223931529|NCT03130452|DRUG|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
223931530|NCT03130452|DRUG|Clarithromycin 500mg|Clarithromycin 500mg tablet
223931531|NCT03130452|DRUG|Metronidazole 500 mg|Metronidazole 500 mg tablet
223533341|NCT06074432|OTHER|Emergency Colorectal Resection|Patients underwent resection due to colorectal carcinoma in emergency surgery
223533342|NCT06459440|BEHAVIORAL|Group Task oriented Training|Group Task-Oriented Training for individuals with Down syndrome is an approach that focuses on improving specific skills and promoting social interaction through collaborative activities. This training method involves organizing individuals with Down syndrome into small groups to work on tasks that target various developmental areas, such as motor skills, communication, and socialization. The tasks are designed to be meaningful, engaging, and relevant to the participants' daily lives.
223533343|NCT06459440|OTHER|Routine Treatment|"1.Week 1-2 : Foundation building (4 sessions per week) Gentle stretching exercises (20 minutes). Basic strengthening exercises (20 minutes) (26). Weeks 3-4: Balance and coordination (4 sessions per week ) Balance exercises and core stability (20 minutes). Coordination drills (20 minutes) (26). Weeks 5-6: Functional activities (4 sessions per week )~Incorporate functional activities into therapy (e.g., walking, reaching) (20 minutes)"
223533344|NCT05541848|OTHER|Cervical supervised exercises with laser-guided feedback (ELGF)|"Cervical supervised exercises with laser-guided feedback (ELGF) is defined as a procedure of proprioceptive training based on a type of therapeutic exercise that provides external feedback to exercise, achieving an improvement in range of motion and postural control in subjects with spinal pain. For the performance of the exercise program, Motion Guidance Clinician Kit (Motion Guidance LLC, Denver, CO, USA.) was used. The program consisted of 4 exercises, which progressed in difficulty according to the tolerance achieved over the course of the sessions: a) Maintaining the head position (cervical stabilisation); b) Cervical flexion-extension; c) Right-left rotations; d) Right-left lateral-flexions. Each exercise consisted of 4 series of 8 repetitions, except the first one, in which the head position is maintained by pointing the laser at the centre of the panel for 30 seconds (4 series). The average time to complete the entire program did not exceed 14 minutes."
223718313|NCT04254471|DRUG|AL3810|5mgQD, 7.5mgQD, 10mgQD
223931532|NCT06941753|OTHER|Off-script diagnosis & differential diagnosis (D&D) training|"1. Training Timeline: Must be completed within 72 hours post-randomization; Requires standardized structured off-script D\&D analysis.~2. Structured Analysis Framework: 1)Epidemiology: Incidence, mortality, and disability rates; 2) Etiologic Classification: TOAST classification system; 3) Vascular Mechanisms: Culprit vessel, vascular territory, pathophysiology; 4) Differential Diagnosis: Stroke mimics and stroke subtype differentiation; 5) Acute Management: Hyperacute interventions (thrombolysis/EVT), secondary prevention strategies, and evidence-based case analysis; 6) Patient Education: Stroke prevention education for patients/public; 7) Research Gaps: Current limitations and future directions.~3. Presentation Requirements: 1)Mandatory off-script delivery (no prepared text); 2) Time limit: 15+3 minutes for complete analysis."
223931533|NCT06773468|BEHAVIORAL|stress management|These different stress management modalities have been developed to ensure equivalent content across: (a) psychoeducation and strategy introduction; and (b) skills-based practice of strategies. Stress management strategies touched on 4 main areas which included (a) pause/break; (b) positive awareness; (c) kindness to self; and (d) social support.
223931534|NCT05377736|GENETIC|Molecular analyses|Collect thyroid tissue for molecular analysis from the histological specimen collected by routine surgery
223931535|NCT06944899|DEVICE|NO Sensor|NO sensor measuring wound characteristic data in wound bed
224096099|NCT05983848|RADIATION|99mMaracticaltide imaging|7.3.1 99mTc-maraciclatide imaging This will be undertaken at baseline and optionally at 8-12 weeks. Not more than 75 µg of 99mTc-maraciclatide will be administered intravenously with an activity as close as possible to 740 MBq. Static whole-body imaging will be undertaken after a maximum of 2 hours with further dedicated views of the hands and feet. Total image acquisition time will be approximately 30 minutes. Images will be scored by quantitative and semi-quantitative methods by a blinded observer.
224096100|NCT06078176|OTHER|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility and facilitate bowel emptying. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
224096101|NCT01417754|DRUG|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
224284512|NCT04178031|DEVICE|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
223718314|NCT04254471|DRUG|carboplatin + etoposide|Carboplatin and etoposide are background treatment.
223718315|NCT04254471|DRUG|Placebo|Placebo
223718316|NCT03444961|DEVICE|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
223533345|NCT05541848|OTHER|Interferential current electro massage (ICE)|Interferential current electro-massage (ICE) is defined as a technique which combines simultaneously manual therapy (massage) and ICT. We used a current bipolar mode, using a carrier frequency of 4000 Hz at constant voltage and an amplitude-modulated frequency of 100 Hz (Sonopuls 692®; Enraf-Nonius BV, Rotterdam, The Netherlands), was administered. The intensity was set to provide a strong and comfortable tingling, without evoking muscle twitches even though a slight vibration (fasciculation) was allowed. The sequence combined (A) superficial stroke over the neck-shoulder for 30-45 seconds; (B) deep sliding movements, alone or (C) combined with shoulder drop, for 4-5 minutes; (D) bilateral kneading of the upper trapezius (4-5 minutes); (E) slight stretching of cervical muscles (upper trapezius, sternocleidomastoid, and levator scapulae); and repetition of step (A). The electro-massage protocol lasted 15 minutes.
223533346|NCT01485848|DRUG|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
223533347|NCT01485848|DRUG|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
223931536|NCT06793293|DEVICE|High level laser|It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) in addition to High level laser for 5 minutes on days 1 st , 2 nd , and 3 rd , after cesarean section (3 sessions)
223931537|NCT06793293|DRUG|Non-steroidal anti- inflammatory drugs and antibiotics|It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
223931538|NCT06797323|BEHAVIORAL|Web-Based Application for Pelvic Floor Health|A user-friendly web application designed to provide educational resources, exercises, and interactive tools aimed at improving pelvic floor health in pregnant women.
224096102|NCT03818698|OTHER|Eplets mismatching numbers|In this study, the HLA high-resolution typing data of kidney transplant recipients from 2014 to the end of 2017 were analyzed with HLA Matchmaker for eplets mismatching number. To analyze the incidence of dnDSA and AMR after kidney transplant recipients with different eplets mismatching number posttransplant, and to elucidate the important role of tissue configuration patterns based on HLA eplets matching in long-term graft survival.
224096103|NCT00519870|DRUG|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
224284513|NCT01610063|OTHER|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
224284514|NCT04405739|DRUG|EIDD-2801|Oral capsule of EIDD-2801
223533348|NCT02847897|DEVICE|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
223718317|NCT02598544|OTHER|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
223718318|NCT02467868|BIOLOGICAL|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
223718319|NCT02467868|BIOLOGICAL|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
223718320|NCT01437722|DRUG|1% SPL7013 Gel|vaginal gel
223718321|NCT01437722|DRUG|3% SPL7013 Gel|vaginal gel
223718322|NCT01437722|DRUG|placebo gel|vaginal gel
224096104|NCT00519870|DRUG|losartan|II: losartan
224096105|NCT00519870|DRUG|Nifedipine, losartan|I: nifedipine II: losartan
224096106|NCT06657755|DIAGNOSTIC_TEST|Immunohistochemistry|This intervention will specifically focus on evaluating the role of ENPP1 in bladder cancer patients, distinguishing it from other interventions by targeting immune evasion and chemoresistance pathways. The intervention will include a combination of targeted molecular therapies and immunotherapy, aimed at assessing the therapeutic potential of ENPP1 inhibition in improving treatment outcomes for bladder cancer patients. This differs from previous studies by integrating advanced biomarker analysis and personalized treatment approaches based on ENPP1 expression levels.
224096107|NCT06657495|DRUG|TD0015|TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.
224096108|NCT06657495|DRUG|TD0015 Placebo|Placebo was packed in pack 5g
224284515|NCT04405739|DRUG|Placebo|Oral placebo capsule
224284516|NCT01436643|DRUG|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
224284517|NCT01436643|DRUG|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
224284518|NCT01436643|DRUG|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
224284519|NCT01436643|DRUG|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
224284520|NCT04252716|DEVICE|OVD|Intraocular administration
224284521|NCT01246713|DRUG|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
224284522|NCT01246713|DRUG|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
223533349|NCT03213509|OTHER|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
223533350|NCT06449560|OTHER|Practice Group|Participants in this group engage in the traditional core course (1-hour lecture on upper limb soft tissue differential diagnosis and assessment techniques. They have the opportunity to observe teacher demonstrations, and the course content and instructional demonstrations are consistent and delivered by the same therapist), followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
223533351|NCT06449560|OTHER|Video Feedback Group|Participants receive the traditional core course (as the same in the practice group) along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
223718323|NCT03205033|DRUG|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
223931539|NCT06947317|PROCEDURE|Arthroscopic anterior talofibular ligament repair|This intervention involves an isolated all-inside arthroscopic repair of the anterior talofibular ligament (ATFL) without addressing the coexisting osteochondral lesion of the talus. It is intended for patients with chronic ankle instability and a concomitant talar osteochondral lesion, where only the ligamentous injury is treated. Patients follow a standard rehabilitation protocol with return to sports allowed after 3 months.
224096109|NCT00013078|PROCEDURE|Physical restoration intervention|
223718324|NCT03205033|DRUG|Placebo oral capsule|1 capsule/day 1 hour before go to bed
224096110|NCT06580327|DRUG|programmed intermittent Bolus epidural analgesia|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
224096111|NCT06580327|DRUG|continuous epidural infusion|"About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study."
224096112|NCT06550661|BEHAVIORAL|Ba duan jin|a kind of exercise
224284523|NCT03459352|OTHER|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
224284524|NCT02056652|DEVICE|Bioteque cup pessary|
223931540|NCT06947317|PROCEDURE|Talar chondral lesion treatment using microfracture technique|This intervention consists of an arthroscopic debridement and microfracture of a symptomatic osteochondral lesion of the talus. Postoperative rehabilitation is extended due to the cartilage procedure, delaying return to sports until 4 months.
223931541|NCT06950138|DRUG|Triticum aestivum|During the intervention period, the aim is to evaluate changes in the patient's vascular function.
223931542|NCT06950138|DRUG|calcined magnesia|During the intervention period, the aim is to evaluate changes in the patient's vascular function.
223533352|NCT04951193|BEHAVIORAL|Behavioral Activation Therapy app|Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
223533353|NCT04951193|BEHAVIORAL|Treatment as Usual|Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
223533354|NCT05791513|OTHER|Using the MAP-Knee Tool|Using the MAP-Knee Tool
223533355|NCT05791513|OTHER|Usual practice|The consultation between clinician and adolescent is conducted as per usual practice.
223931543|NCT06950723|OTHER|Chest Physical Therapy (CPT) modalities , Medical Treatment|Chest Physical Therapy (CPT) modalities in the form of postural drainage, percussion and vibration.
223931544|NCT05246709|DEVICE|Cyanoacrylate glue|"Adhesive to be applied on the PICC line site prior to usual standard film dressing over the site, such as SecurePortIV® Catheter Securement Adhesive by Adhezion Biomedical® Cyanoacrylate adhesive that is FDA-approved for securement of vascular access devices.~Securement method that provides microbial protection by sealing the insertion site."
223931545|NCT05246709|DEVICE|Standard transparent film dressing|A standard transparent polyurethane film dressing, such as 3M TEGADERM Film, for dressing the PICC line area.
223931546|NCT03459196|DEVICE|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
223931547|NCT05970042|BEHAVIORAL|GameDay Ready|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. The GameDay Ready program promotes increasing physical activity, reducing sedentary time, and improving dietary habits through education, behavioral self-monitoring, and goal setting. Each 60-minute intervention session includes a brief educational component followed by a group discussion of weekly progress. Following a short warmup walk, participants engage in group-based competitive physical activities and then a short cooldown walk. Participants then set individual and group-based goals for the upcoming week and discuss strategies for overcoming barriers to achieving goals. The program is sensitive to intersectional influences of gender, race, and rurality on health; and strategies to enhance motivation are threaded throughout the program.
223931548|NCT05970042|BEHAVIORAL|Walking and General Health Education|Participants receiving the comparison program will complete a 12-week walking and general health education program. Group sessions meet once per week at a publicly accessible walking track, and each 60-minute session consists of a brief educational component on a health topic followed by walking and socializing during the remainder of the session.
224096113|NCT06657521|DIETARY_SUPPLEMENT|osteoimplant|Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement.
224096114|NCT06657521|DIETARY_SUPPLEMENT|Placebo Oral Tablet|2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.
223533356|NCT01841242|DRUG|alcoholic povidone iodine|
223533357|NCT01841242|DRUG|alcoholic chlorhexidine|
223533358|NCT05507242|BIOLOGICAL|Tezepelumab|Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously
223533359|NCT05507242|OTHER|Placebo|Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
223533360|NCT01706185|OTHER|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
223533361|NCT01784302|DIETARY_SUPPLEMENT|Multivitamins|
223533362|NCT01784302|DIETARY_SUPPLEMENT|Sodium bicarbonate|
223533363|NCT01784302|DRUG|Maalox Plus extra|
223533364|NCT01784302|DRUG|Raltegravir 400 mg|
223533365|NCT00574015|DRUG|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
223533366|NCT00574015|DRUG|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
223533367|NCT02362685|DEVICE|functional test|subjects perform a metabolic exercise testing
223533368|NCT02362685|GENETIC|matching genotype with phenotype|
223931549|NCT05452941|DIAGNOSTIC_TEST|Diagnostic test on urine samples|Testing by BinaxNOW® S. pneumoniae and serotype-specific urine antigen detection (UAD) assays (UAD-1 and UAD-2).
223931550|NCT02377700|DEVICE|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
223931551|NCT05152849|DRUG|AXA1125|AXA1125 administered BID with or without food
223931552|NCT05152849|DRUG|Placebo|Matching Placebo administered BID with or without food
224096115|NCT05075161|DRUG|Pirfenidone|From days 1-7: 801mg/day; from days 8-14:1602mg/day, from day 15 to ICU discharge 2403 mg/day. All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
224284525|NCT03680261|RADIATION|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
224284526|NCT03680261|DRUG|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
224284527|NCT00039910|DRUG|(PN-152,243)/ PN-196,444|
223931553|NCT06360133|DRUG|VVN001 Ophthalmic Solution, 5%|VVN001 Ophthalmic Solution, 5%
223931554|NCT06360133|DRUG|VVN001 Ophthalmic Solution, Vehicle|VVN001 Ophthalmic Solution, Vehicle
224284528|NCT04232540|DEVICE|MedViewer report|Results from the analysis of hair samples performed using the MedViewer
224284529|NCT02105701|DRUG|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
224284530|NCT02105701|DRUG|Ribavirin|200 mg capsule
224284531|NCT02148445|OTHER|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
224284532|NCT02148445|OTHER|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
224284533|NCT02148445|DRUG|Nicotine replacement therapy|
224284534|NCT03105973|BEHAVIORAL|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
224284535|NCT03652831|OTHER|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
223931555|NCT01203722|DRUG|Fludarabine|Fludarabine 30 mg/m2/day
223931556|NCT01203722|DRUG|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
223931557|NCT01203722|RADIATION|Total Body Irradiation|400 cGy TBI administered in a single fraction
223931558|NCT01203722|PROCEDURE|Allogeneic Blood or Marrow Transplant|
223931559|NCT01203722|PROCEDURE|Peripheral Blood Stem Cell Transplant|
223931560|NCT01203722|DRUG|Mycophenolate Mofetil|15mg/kg by mouth three times daily
223931561|NCT01203722|DRUG|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
223931562|NCT01203722|DRUG|Tacrolimus|Tacrolimus 1mg intravenously, daily
223931563|NCT06275464|COMBINATION_PRODUCT|BT-600|NaviCap device containing liquid formulation of Tofacitinib
223931564|NCT06275464|COMBINATION_PRODUCT|BT-600 Placebo|NaviCap device containing placebo formulation
223931565|NCT06060977|DRUG|IMG-007|Intravenous Infusion
223931566|NCT00146172|DRUG|neratinib|HKI-272
224096116|NCT05075161|DRUG|Placebo|All drugs will be delivered by a nasogastric tube divided in 3 daily doses.
224096117|NCT06661239|BEHAVIORAL|benson relaxation|"The benson relaxation consisted of the following steps: (1) Sitting or lying down quietly in a comfortable position; (2) Closing eyes; (3) Deeply relaxing all muscles, beginning at the feet and progressing up to the face. Keeping them relaxed; (4) Breathing through the nose. (5) Maintaining a passive attitude and permitting relaxation to occur at its own pace; (6) Continuing for 15 minutes. When finished, sit quietly for several minutes, at first with eyes closed and later with eyes opened. Do not stand up for a few minutes.~According to the agreement, the patients in both groups were required to perform the Benson relaxation technique regularly twice daily (morning and evening) for seven days in a row. Each session lasted 15 minutes"
224096118|NCT06661239|BEHAVIORAL|Routine care in unit|The routine care include in the unit will be delivered to control group
224096119|NCT05198713|DEVICE|New hearing aid|Participants will complete testing while using a novel hearing aid which has been fit to compensate for their hearing loss.
223931567|NCT05786378|BIOLOGICAL|Platelet Rich Plasma|"Sample of patient's blood drawn at time of Treatment; the blood drawing occurs with addition of anticoagulant such as citrate dextrose A to prevent platelet activation prior to its use.~Obtain whole blood by venipuncture in acid citrate dextrose (ACD) tubes. Centrifuge the blood using a 'soft' spin. Transfer the supernatant plasma containing platelets into another sterile tube (without anticoagulant).~Centrifuge tube at a higher speed (a hard spin) to obtain a platelet concentrate.~The lower 1/3rd is PRP and upper 2/3rd is platelet-poor plasma (PPP). At the bottom of the tube, platelet pellets are formed.~PRP activation prior to injection. PRP can be activated exogenously by calcium chloride."
223931568|NCT05786378|DRUG|local anesthesia in external auditory canal|local anesthesia cream (lidocaine cream) will be applied in external auditory canal for 15 minutes
223931569|NCT05786378|PROCEDURE|Intratympanic Injection|0.5-1 ml of PRP will be injected in middle ear cavity in round window niche Using microscope or endoscope.
223931570|NCT05766202|OTHER|An group intervention for multiparas with fear of childbirth|The intervention consists of 4 group meetings, three during pregnancy and once after giving birth. It also includes a phone call.
223931571|NCT06951178|DEVICE|TMJ Total Arthroplasty System (TMJ System)|All patients treated or to be treated with the TMJ Total Arthroplasty System for TMJ reconstruction. The TMJ Total Arthroplasty System (TMJ System) is a medical device intended to restore the TMJ. It comprises two articulating components: a temporal component and a mandibular component. The TMJ System is patient-specific based on the patient's anatomy and surgical treatment. Different shape designs are possible depending on the patient's anatomy and the type of surgery performed.
223931572|NCT06950515|PROCEDURE|Peripheral EBUS under Concious sedation|In the conscious sedation group, the procedure will be performed through the nose or mouth at the discretion of the endoscopist. The patient will remain breathing spontaneously throughout the procedure and will be administered oxygen through a nasal cannula at an initial flow rate of 2L/min. A combination of propofol, fentanyl and midazolam boluses will be used to maintain moderate sedation. At IUCPQ-UL, fentanyl and midazolam will be used as in our routine practice. The boluses will be prescribed by a doctor experienced in conscious sedation (anesthesiologist, intensivist or pulmonologist) according to the patient's state of wakefulness assessed by the Richmond Agitation-Sedation Scale (RAS) .Centers will decide, prior to initiating recruitment locally, the drug combination used to sedate patients and they will maintain the use of the same drug combination throughout the study
223931573|NCT06950515|PROCEDURE|Peripheral EBUS under General Anesthesia|In the general anesthesia group, an endotracheal tube larger than 7 will be used. The patient will be kept non-arousable to non-nociceptive stimulation (RAS = -5) by a perfusion including, at the anesthesiologist's discretion: fentanyl, sufentanyl, remifentanyl, midazolam or propofol. The sedation of this group will not be protocolized given the wide variety of practices in the participating centers, but the targeted level of sedation will be and the medication administered will be adjusted according to this target. The RAS will be evaluated every 5 minutes, or earlier if signs of arousal are present, to ensure that the intended target is maintained and adjustments to the rate of infusions as well as boluses may be made/administered by the anesthesiologist to maintain the targeted level of sedation. Patients may be paralyzed at the discretion of the anesthesiologit. The ventilatory parameters will be standardized according to the VESPA protocol
223931574|NCT03684590|DEVICE|ANI-guided opioid administration|Intraoperative opioid will be administered guided by analgesia nociceptive index (ANI) values measured by ANI monitor (MetroDoloris Medical Systems, Lille, France)
223931575|NCT03684590|OTHER|Standard opioid administration|Intraoperative opioid will be administered according to standard practice during surgery.
223931576|NCT03876457|DEVICE|Endovascular Thrombectomy|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent-retrievers or aspiration devices) currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are FDA-approved stent retrievers: the Trevo Retriever, the Solitaire Revascularization Device, EmboTrap Revascularization Device and Tigertriever Revascularization Device; and/or the aspiration devices approved by the FDA (e.g. MicroVention SOFIA Catheter, and the Penumbra thrombectomy system). The choice of thrombectomy method, primary approach/technique, whether primary aspiration or primary stent-retriever with or without aspiration, will be left up to the interventionalist, with any of the FDA-approved devices approved in the study protocol or a combination of them.
223931577|NCT03876457|OTHER|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV thrombolytic therapy available for use according to practice guidelines in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria, or up to 4.5 hours from last-seen-normal and meeting other AHA guidelines. For non-thrombolysis treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-thrombolysis patients will be treated based on standard study site protocols for these patients.
223931578|NCT00990808|DRUG|anacetrapib|\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
223931579|NCT00990808|DRUG|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
223931580|NCT00990808|DRUG|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
223931581|NCT00990808|DRUG|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
224284536|NCT03652831|OTHER|Soft Tissue Mobilization without Neural Mobilization|"* Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack for 10mints~* Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
224284537|NCT05741931|DEVICE|mobile application REST (Risk identification, Evaluation counseling, Systematic monitoring, Troubleshooting)|The mobile application will be installed on the mobile phone. The application is used to monitor pregnant women. Users of the application are midwives and pregnant women. The application contains documentation of the health condition of pregnant women.
223533369|NCT00718432|BEHAVIORAL|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
223931582|NCT01184326|DRUG|pazopanib|
223931583|NCT01184326|DRUG|everolimus|
224096120|NCT01077765|DEVICE|Eutrophill|Polyacrylamide Hydrogel
224096121|NCT03534648|DRUG|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
224096122|NCT03534648|DRUG|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
224096123|NCT03534648|DRUG|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
224096124|NCT03534648|DRUG|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
224096125|NCT06606028|PROCEDURE|Blood Specimen Collection|Approximately 20 mL of peripheral blood (10 mL per tube, x 3 Streck tubes) will be drawn at each time point
224096126|NCT06606028|PROCEDURE|Tumor Tissue Collection|Formalin-fixed paraffin embedded tumor tissue samples (tissue blocks of 12 x 10 millimeter (mm) unstained slides) derived from biopsy or surgical resection will be collected at screening
224096127|NCT06606028|OTHER|Medical Record Review|Medical records will be reviewed to collect standard of care p16 staining by immunohistochemistry and/or high-risk human papillomavirus (HPV) DNA or RNA testing that is performed as part of standard of care
224096128|NCT06988462|OTHER|Bottarga|Participants will consume prepackaged daily doses of Bottarga, each containing the required amount (20 grams/day) for 8 weeks.
224096129|NCT06988462|OTHER|Comparator|Participants will consume 28g of cream cheese/day for 8 weeks.
224096130|NCT06592638|DRUG|ZG006|ZG006 will be administered as an intravenous (IV) infusion.
224284538|NCT03799822|DRUG|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
224284539|NCT03799822|DIETARY_SUPPLEMENT|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
224284540|NCT03799822|DRUG|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
224284541|NCT06468722|BEHAVIORAL|Exercise-based rehabilitation|Patients performed regular physical exercise during inpatient rehabilitation
224284542|NCT06350617|DEVICE|High-Frequency, ipsilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
223931584|NCT01739244|DRUG|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
223931585|NCT01739244|DRUG|Placebo|Ocular topical administration of placebo for 14 consecutive days
223931586|NCT01321164|DEVICE|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
223931587|NCT01321164|DRUG|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
223718325|NCT03023475|DEVICE|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
223718326|NCT03023475|DEVICE|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
223931588|NCT03755752|PROCEDURE|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
223931589|NCT00220675|DRUG|Erythropoietin infusion|
223931590|NCT01288443|DRUG|Alirocumab|Two SC injections in the abdomen only.
223931591|NCT01288443|DRUG|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
224096131|NCT06478368|DIAGNOSTIC_TEST|Laparoscopic exploration|Laparoscopic exploration
224096132|NCT00844233|DEVICE|Irinotecan Bead|Irinotecan eluting bead
224096133|NCT03228121|PROCEDURE|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
224096134|NCT03228121|PROCEDURE|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
224096135|NCT01360203|OTHER|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
224284543|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
224284544|NCT06350617|DEVICE|High-Frequency, Lt. DLPFC|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: Lt. DLPFC~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
224284545|NCT06350617|DEVICE|High-Frequency, bilateral M1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease."
224284546|NCT02170831|DRUG|BIBR 1048 MS low|
224284547|NCT02170831|DRUG|BIBR 1048 MS medium 1|
224284548|NCT02170831|DRUG|BIBR 1048 MS medium 2|
224284549|NCT02170831|DRUG|BIBR 1048 MS high|
224284550|NCT02170831|DRUG|BIBR 1048 MS placebo|
224284551|NCT00083434|DRUG|Epoetin alfa|
224284552|NCT03076749|OTHER|Creating models for the diagnosis of BL allergy|
224284553|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Suspension|PDP-716
224284554|NCT03450629|DRUG|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
224284555|NCT01348204|OTHER|quercetin|health food supplement
224284556|NCT00325104|PROCEDURE|Parathyroid hormone testing|
224284557|NCT00325104|PROCEDURE|Serum calcium testing|
224284558|NCT04984187|OTHER|high intensity laser plus exercise|high intensity laser plus exercise
224284559|NCT04984187|DEVICE|high intensity laser only|high intensity laser only
224284560|NCT04984187|OTHER|exercise|exercise only
224284561|NCT05568173|OTHER|Boxing Training|"In addition to boxing training, stretching exercises and posture training will be given at BG. A physiotherapist with a boxing training certificate will perform modified boxing training that progresses according to the degree of difficulty. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~In the first level, patients will be asked to punch the fixed boxing mat hanging on the wall with various instructions. Then, in levels 2-4, target gloves and heavy punching bags will be used to increase the difficulty level. As the sessions progress, the resistance and frequencies between the levels will be increased by the physiotherapist. There will be 3 sessions of 30-minute boxing training per week for 8 weeks at BG."
223931592|NCT01288443|DRUG|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
224284562|NCT05568173|OTHER|Scapular Stabilization|"In addition to scapular stabilization training, stretching exercises and posture training will be given in SSG. Progressive strengthening training for the scapular muscles will be used in the SSG. There will be four difficulty levels. The complexity of the exercises will increase at 2-week intervals as the patient progresses. As a result, 0-2 weeks 1st level, 2-4 weeks 2nd level, 4-6 weeks 3rd level and 6-8 weeks 4th level exercises will be done.~At the first level, scapular clock exercise, obstacle crossing exercise, wall gliding exercise with teraband, push up exercise, trunk rotation and maximum hip flexion will be performed. Then at levels 2-4, as the levels increase, the exercises at the first level will be more difficult (ball weight, surface, number of hurdles and hurdle crossing exercise position, by changing the teraband elasticity, push-up position). In SSG, 3 sessions of 30-minute scapular stabilization training will be applied per week for 8 weeks."
224284563|NCT01047033|BEHAVIORAL|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
223931593|NCT00168415|BIOLOGICAL|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
224284564|NCT01047033|OTHER|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
224284565|NCT02636673|PROCEDURE|Sigmoid Resection|
224284566|NCT03568604|DRUG|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
224284567|NCT04646694|DRUG|Ketamine|The use of oral Ketamine in this study is experimental.This study will look at how effective and safe Ketamine.
224284568|NCT04646694|OTHER|Placebo|A placebo is given in this study to reduce the chances of believing that pain after surgery is getting better because one is receiving oral Ketamine
224284569|NCT00411333|DRUG|triamcinolone acetonide (Kenalog)|
224284570|NCT02272894|PROCEDURE|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
224284571|NCT03485027|DRUG|the rechallenge regimen|XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
224284572|NCT05705791|DEVICE|QuiremSpheres|166Holmium selective internal intra-arterial radiation therapy at C1D15 of the Atezolizumab and Bevacizumab therapy
224284573|NCT04230876|BEHAVIORAL|Auditory Brian Training Games/Activities|Game-based activities that encourage listening to words and sentences in noisy situations. Participants will receive subscriptions to the clEAR online auditory training activities and recommended protocol for those who recently received new hearing aids.
223533370|NCT00718432|BEHAVIORAL|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
223931594|NCT04139005|BEHAVIORAL|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
223931595|NCT04139005|BEHAVIORAL|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
224284574|NCT02369354|BEHAVIORAL|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
223931596|NCT04139005|BEHAVIORAL|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
223931597|NCT00042731|DIETARY_SUPPLEMENT|Lycopene|Daily administration as outlined in treatment arm(s)
223931598|NCT00042731|DIETARY_SUPPLEMENT|Multivitamin|Daily administration as outlined in treatment arm(s)
223931599|NCT00042731|DIETARY_SUPPLEMENT|Soy isoflavones|Daily administration as outlined in treatment arm(s)
223931600|NCT02203500|DRUG|Lacidipine|
223931601|NCT02203500|DRUG|Telmisartan|
223931602|NCT00283205|BEHAVIORAL|Yoga|
223931603|NCT02201888|BEHAVIORAL|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
223931604|NCT02201888|OTHER|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
224096136|NCT01726179|DEVICE|Resin infiltration|Proximal caries lesions that are selected for this intervention will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, local anesthesia of the gingival papila, application of rubber dam, etching of the lesion surface for 120 s using 15%HCl gel, washing the lesion with water spray for 30 s, drying the lesion with 100% ethanol for 30 s and subsequent air blowing, application of the infiltrant for 180 s using an applicator provided with the kit, removing excess material from the lesion surface by air blowing and flossing, light curing of the infiltrant for 40 s, repeated application for 60 s, light curing for 40 s, polishing, and removal of the rubber dam.
224284575|NCT02369354|OTHER|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
224284576|NCT03248986|OTHER|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
224284577|NCT05783856|COMBINATION_PRODUCT|LiveSpo X-secret|In Vietnam, LiveSpo X-secret is manufactured as a Class-A medical device product (Product declaration No.220003286/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
224284578|NCT05783856|DRUG|0.9% NaCl physiological saline|Vaginal-spraying 0.9% NaCl physiological saline is prepared by extracting 10 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque metallic spraying 15 mL-bottle that is used for LiveSpo X-secret.
223931605|NCT02201888|OTHER|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
223931606|NCT03985774|PROCEDURE|Transcarotid revascularization|The ENROUTE Transcarotid Neuroprotection System (NPS) has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease The ENROUTE Transcarotid Neuroprotection System is intended to provide transcarotid vascular access, introduction of diagnostic agents and therapeutic devices, and embolic protection during carotid artery angioplasty and stenting procedures for patients diagnosed with carotid artery stenosis
224096137|NCT01726179|DEVICE|Control|Proximal caries lesions do not recieve a placebo treatment, but simply left untreated.
223533371|NCT00718432|BEHAVIORAL|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
223533372|NCT00004264|DRUG|amifostine trihydrate|
223533373|NCT00004264|DRUG|cisplatin|
223931607|NCT04502381|DRUG|Inhaled amp B deoxycholate+intravenous liposomal amp B|"Intravenous liposomal amphotericin B (beginning with 3mg/kg) along with inhaled amphotericin as below: Amp-B deoxycholate 50 mg (Amphotret™ Bharat serums and vaccines limited), will be dissolved in 10 mL distilled water. 2 mL of the reconstituted amphotericin B solution will be transferred into the drug chamber of a breath actuated nebulizer (Lupineb Ultra kit breath actuated nebulize which contains aeroclipse XL Reusable Breath Actuated Nebulizer and DeVilbiss 3655 compressor). 3 mL of distilled water is added to 2 mL of the reconstituted amphotericin B. The nebulization is continued till the chamber is emptied of the drug or the patient does not tolerate the therapy.~The first three doses of amphotericin B nebulization will be under the direct supervision of a physician. If tolerated, nebulization will be continued twice a day till tolerated or till response.The patient will complete a VAS score for cough after nebulization."
223931608|NCT04502381|DRUG|Intravenous liposomal amphotericin B alone|Intravenous liposomal amphotericin B (beginning with 3mg/kg, up to 5 mg/kg), with or without surgery or other antifungals as clinically indicated
223931609|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
223931610|NCT01153113|BIOLOGICAL|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
223931611|NCT00176800|DRUG|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
223931612|NCT00176800|PROCEDURE|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
223931613|NCT00176800|PROCEDURE|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
223931614|NCT04633941|OTHER|Standard Care|Standard Care
223931615|NCT03555175|OTHER|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
223931616|NCT03555175|OTHER|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
223931617|NCT03555175|OTHER|Control group|Any exercise
223931618|NCT02446145|DRUG|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine/Azacitidine~\- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
223533374|NCT00004264|DRUG|docetaxel|
223533375|NCT02498366|OTHER|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
223533376|NCT04549454|BEHAVIORAL|FITSTART+ PBI|Personalized normative feedback on other parents behaviors + alcohol-specific parenting advice + general parenting advice
223533377|NCT04549454|BEHAVIORAL|General Parenting Advice|General parenting advice
223718327|NCT02417597|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
223931619|NCT02446145|DRUG|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine/Azacitidine~\- concomitant medication: either Decitabine days 1-5 of each cycle: 20 mg/sqm i.v. over 30 minutes or Azacitidine (AZA) days 1-7 of each cycle: 75 mg/sqm s.c."
223931620|NCT06367023|BEHAVIORAL|Rajyoga Meditation Practice|The intervention will be given for 3 months, For 6 days one hour per day Rajyoga meditation basic course will be provided, followed by 1 hour daily spiritual lesson, Positive thinking and motivation classes will be provided to the intervention group and in control group standard treatment will be given.
223931621|NCT04129203|DEVICE|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
223931622|NCT04826822|DRUG|Spironolactone + Dexamethasone|Low doses of orally administered spironolactone and dexamethasone
223931623|NCT04826822|DRUG|Standard-of-care SARS-CoV-2 treatment|Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
223931624|NCT05136066|OTHER|massage with peppermint oil|Peppermint oil diluted with 1/10 pure olive oil will be applied to the pregnant to reduce labor pain.
223931625|NCT06094166|DIAGNOSTIC_TEST|MRI|Quantitative imaging MR parameters
223931626|NCT03827200|DRUG|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
223931627|NCT04801706|DIAGNOSTIC_TEST|Ultrasound|Association of each ultrasonographic parameter with FIGO clinical grading of placenta accreta and with histopathological diagnosis of placenta accreta in hysterectomy specimens
223931628|NCT01006772|OTHER|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
224284579|NCT01029509|DRUG|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
224284580|NCT03895229|DRUG|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
223533378|NCT00867035|DRUG|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
223533379|NCT00867035|DRUG|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
223931629|NCT05106842|OTHER|Hydrotherapy|Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
223931630|NCT05106842|OTHER|Land-based Therapy|Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
223931631|NCT01964300|BIOLOGICAL|peginterferon alfa-2b|Given subcutaneously (SC)
223931632|NCT01964300|OTHER|laboratory biomarker analysis|Correlative studies
223931633|NCT06210659|BEHAVIORAL|Theory of Planned Behavior Based Training Program|"Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles."
223931634|NCT02387606|DRUG|Placebo|Participants will receive placebo once daily.
223931635|NCT02387606|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
223931636|NCT05362942|DRUG|Venetoclax, Decitabine, Azacytidine, Cytarabine|Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days (n=3) or azacytidine (n=8) was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician. Cytarabine was given at a dose of 10 mg/m2 twice daily for 7 days.
223931637|NCT04425980|OTHER|Modified Constraint-Induced Movement Therapy|intensive use of more affected arm in structured setting
223931638|NCT06314932|OTHER|MD high in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).
223931639|NCT06314932|OTHER|MD low in UPF|A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
223931640|NCT04495426|OTHER|Non-interventional study|There are no treatments to stop or even slow down the progression of this disease although there are treatments that temporarily improve the symptoms, such as anti-seizure medications.
223931641|NCT00557492|DRUG|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
223931642|NCT00557492|DRUG|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
223931643|NCT00557492|RADIATION|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
223931644|NCT01884805|DEVICE|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
223931645|NCT05025813|DRUG|Pembrolizumab|Delivery of neo-adjuvant Pembrolizumab
223931646|NCT03142672|PROCEDURE|pulpotomy|vital endodontic procedure
223931647|NCT03142672|PROCEDURE|tooth filling|tooth filling
223931648|NCT04394897|COMBINATION_PRODUCT|Remifentanil-Propofol admixture|
224096138|NCT06661538|BEHAVIORAL|Food Security Screening & Referral Program|The I-FRESH (Implementing Food Referrals for Equity and Sustained Health) program is the food security nutrition support program that involves some combination and form of: 1) screening and identification of families experiencing food insecurity; 2) discussions with families to determine readiness to engage with nutrition support programs and other community resources; 3) referrals and support to engage with a program; and 4) conducting follow-up assessments to determine fit of program, track utilization, and assess need for additional referrals. The exact implementation and workflow for this program will be optimized for each clinic.
224096139|NCT06856187|DRUG|TAS-102+bevacizumab+local treatment|patients achieve disease control after second-line induction therapy with standard therapy(FOLFOX/FOLFIRI/XELOX/ mXELIRI＋bevacizumab/cetuximab), then achieve TAS-102+bevacizumab+local treatment
224096140|NCT06856187|DRUG|Standard chemotherapy|Standard therapy：FOLFOX/FOLFIRI/XELOX/ mXELIRI±bevacizumab/cetuximab
224096141|NCT06858488|PROCEDURE|Extremity Surgery|Patients 18 years of age or older with high energy closed extremity fractures. Provision of informed consent.
224096142|NCT01783665|OTHER|aerobic exercise|
223931649|NCT01574716|DRUG|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
223931650|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
223931651|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
223931652|NCT01574716|DRUG|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
223931653|NCT01574716|DRUG|Docetaxel|IV, Day 8 of every cycle until disease progression
223931654|NCT01574716|DRUG|Placebo|
223931655|NCT02208596|DRUG|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
223931656|NCT02208596|DRUG|propofol|
223931657|NCT02208596|DRUG|Etomidate|
223931658|NCT01645124|DRUG|Hydroxyurea|
223931659|NCT01645124|PROCEDURE|Phlebotomy|
224096143|NCT01783665|OTHER|home exercise program|
224096144|NCT02730546|DRUG|Carboplatin|Given IV
223533380|NCT06564116|BIOLOGICAL|Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.
223533381|NCT06564116|BIOLOGICAL|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of licensed hepatitis E vaccine intramuscularly at month 0, 1 and 6
223533382|NCT02446002|DRUG|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
223533383|NCT05023161|BIOLOGICAL|Blood samples|Performed a 10 ml blood sample in each of the 200 patients included.
223931660|NCT02438137|DRUG|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
223931661|NCT02438137|DRUG|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
223931662|NCT03447496|PROCEDURE|Closed reduction|The children were treated with closed reduction.
224096145|NCT02730546|PROCEDURE|Computed Tomography|Undergo CT scan
224284581|NCT03438006|OTHER|Safety data collection (following routine vaccination)|"This study assessed the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consisted in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine was administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes were collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
224284582|NCT05542849|DRUG|Acarbose Tablets 50mg|"Acarbose is an Alpha-glucosidase inhibitor. It is a compound also known under the names Glucobay, Precose, and Prandase. Acarbose is used (with diet and other medications) to treat type 2 diabetes (condition in which the body does not use~insulin normally and therefore cannot control the amount of sugar in the blood). Acarbose works by blocking α- glucosidase, which breaks down starch (aka amylose) into glucose (sugar) into your blood. Slowing food digestion~helps keep blood glucose from rising very high after meals."
224284583|NCT04646525|DIAGNOSTIC_TEST|Physical examination|Pediatric patients diagnosed with COVID-19 and who have had infection will be examined, adenoid and tonsillar tissues will be evaluated in terms of hypertrophy, chronic, or recurrent infection.
224284584|NCT05697757|OTHER|Dynamic Lighting|This will be an eighteen-hour lighting scheme that includes three modes: morning (6:00 - 12:00), afternoon (12:00 - 18:00), and evening (18:00 - 24:00). It mimics natural lighting by providing blue-enriched high-intensity lighting in the morning and neutral white medium-intensity lighting in the afternoon to maintain alertness without exerting substantial circadian effects. The biodynamic lighting will provide yellowish low-intensity lighting in the evening to minimize any circadian effect.
223533384|NCT06529484|OTHER|Warm Water Foot Bath Intervention|Participants will take a warm water foot bath at 38-40ºC for 20 minutes nightly for 7 days.
223533385|NCT06532188|PROCEDURE|Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep"
224284585|NCT05697757|OTHER|Placebo Lighting|We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness from morning to evening. The numbers of CCT and illuminance levels are selected based on the average room lighting
224284586|NCT05734209|BEHAVIORAL|Virtual food|Virtual food eaten using immersive virtual reality equipment
224284587|NCT05734209|BEHAVIORAL|Real food|Real food eaten using regular utensils
223533386|NCT06532188|PROCEDURE|Sham Hypno-ear-acupuncture|"5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~\- story without trance induction and suggestions"
223931663|NCT03447496|PROCEDURE|Open reduction|The children were treated with Open reduction.
223931664|NCT02802488|PROCEDURE|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
224096146|NCT02730546|DRUG|Fluorouracil|Given IV
224096147|NCT02730546|OTHER|Laboratory Biomarker Analysis|Correlative studies
224096148|NCT02730546|DRUG|Leucovorin Calcium|Given IV
224096149|NCT02730546|DRUG|Oxaliplatin|Given IV
223931665|NCT00186784|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
223931666|NCT03592797|OTHER|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
223931667|NCT03592797|OTHER|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
223931668|NCT00359606|DRUG|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
223931669|NCT00359606|OTHER|Laboratory Biomarker Analysis|Correlative Studies
224284588|NCT00440609|DRUG|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
224284589|NCT02720133|BIOLOGICAL|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
223931670|NCT00359606|OTHER|Pharmacological Study|Correlative Studies
223931671|NCT00359606|DRUG|Tetrahydrouridine (THU)|Given PO and IV
223931672|NCT00202436|PROCEDURE|Phlebotomy|Removal of 500 ml whole blood
223931673|NCT00202436|PROCEDURE|Erythrocytapheresis|machinal removal of erythrocytes
223931674|NCT04484675|DRUG|Milrinone inhalation|After induction of anesthesia and stable hemodynamics inhaled milrinone( 1 mg/ml) is initiated and intravenous placebo ( normal saline )infusion are administered
223533387|NCT04621877|BEHAVIORAL|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
223533388|NCT04621877|BEHAVIORAL|Master's level clinician-delivered Behavioral Activation|Behavioral Activation as delivered by trained master's level clinicians
223931675|NCT04484675|DRUG|Milrinone infusion|After induction of anesthesia and stable hemodynamics inhaled placebo( normal saline) is initiated and intravenous ( 1 mg/ml) (0.5 μg/kg/min)infusion are administered
223931676|NCT02512250|OTHER|Registry|
223931677|NCT02111096|DRUG|LY2409021|Administered orally
223931678|NCT02111096|DRUG|Sitagliptin|Administered orally
223931679|NCT02111096|DRUG|Placebo|Administered orally
223931680|NCT02111096|DRUG|Metformin|Administered orally
224284590|NCT03026309|OTHER|no intervantion|no intervention is being performed, only observational evaluations.
224284591|NCT04169555|PROCEDURE|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
224284592|NCT04169555|OTHER|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
224284593|NCT01177163|DRUG|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
224284594|NCT01177163|DRUG|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
224284595|NCT01177163|DRUG|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
224284596|NCT01921231|DRUG|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
224284597|NCT01921231|DRUG|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
224284598|NCT00487331|OTHER|Acupuncture|Acupuncture sessions 1-3 times per week.
224284599|NCT00487331|BEHAVIORAL|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
224284600|NCT04651595|PROCEDURE|Caudal block|caudal block with low dose bupivicaine 0.25% to preserve tone
224284601|NCT04651595|DRUG|Morphine|morphine to control pain and avoid using muscle relaxant
224284602|NCT03255863|OTHER|Questionnaire|Patient Self reported questionnaire filled in.
224284603|NCT01447225|DRUG|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
224284604|NCT01447225|DRUG|Carboplatin|administered at AUC 6
224284605|NCT01447225|DRUG|Pemetrexed|administered IV at 500 mg/m2
224284606|NCT01447225|DRUG|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
224284607|NCT01447225|DRUG|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
224284608|NCT03569488|DIAGNOSTIC_TEST|FT-LARS questionnaire|FT-LARS questionnaire
223533389|NCT05667532|DIAGNOSTIC_TEST|Contrast Enhanced Mammography|Screening Modality
223931681|NCT02111096|DRUG|Sulfonylurea|Administered orally
223931682|NCT03753932|DEVICE|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
223931683|NCT00926354|DRUG|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
223931684|NCT02035605|DRUG|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
224284609|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
224284610|NCT00915837|DRUG|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
224284611|NCT00739973|DRUG|Placebo|
224284612|NCT00739973|DRUG|Aliskiren 150 mg tablet|
224284613|NCT00739973|DRUG|Aliskiren 300 mg tablet|
224284614|NCT00739973|DRUG|Amlodipine 5 mg capsule|
224284615|NCT00739973|DRUG|Amlodipine 10 mg capsule|
224284616|NCT00739973|DRUG|Aliskiren/amlodipine 150/5 mg tablet|
224284617|NCT00739973|DRUG|Aliskiren/amlodipine 150/10 mg tablet|
224284618|NCT00739973|DRUG|Aliskiren/amlodipine 300/5 mg tablet|
223931685|NCT02035605|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
224096150|NCT02730546|DRUG|Paclitaxel|Given IV
224096151|NCT02730546|BIOLOGICAL|Pembrolizumab|Given IV
224096152|NCT02730546|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224284619|NCT00739973|DRUG|Aliskiren/amlodipine 300/10 mg tablet|
224284620|NCT00109486|DRUG|GW685698X|
224284621|NCT03476031|DIAGNOSTIC_TEST|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
224284622|NCT01010789|DRUG|Armodafinil|flexible dose 150-250mg/day
224284623|NCT01010789|DRUG|Armodafinil|150-250mg/day; flexible dose
224284624|NCT01010789|DRUG|Matching placebo|Placebo comparator
224284625|NCT05210712|DEVICE|RS001.2 Respiree Cardio-Respiratory Monitor|The RS001.2 Respiree Cardio-Respiratory Monitor is intended as a noninvasive multiparameter monitor on the adult population
224284626|NCT05988424|OTHER|Left atrial mapping|Creation of a left atrial voltage map
224284627|NCT02240004|DEVICE|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
224284628|NCT04691440|DRUG|Hyperbaric oxygen|The course of hyperbaric oxygen treatment comprises a total of 6 pressure exposures, distributed 2 times daily, for 3 days.
224284629|NCT04108962|DRUG|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
224284630|NCT04118868|COMBINATION_PRODUCT|Pembrolizumab administered using the Sofusa® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
223931686|NCT03621735|DEVICE|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
223931687|NCT03621735|DEVICE|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
223931688|NCT05708365|OTHER|Standard-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
223931689|NCT05708365|OTHER|Ultra-Lung Protective Ventilation|"ICU ventilator protocol adhering to the following lung protective ventilation strategy:~* Plateau Pressure ≤ 30 cm of water~* PEEP and FiO2 set according to ARDSnet table~* Driving Pressure ≤ 15 cm of water~* Respiratory rate between 8 and 30 breaths per minute"
224096153|NCT02730546|RADIATION|Radiation Therapy|Undergo radiation therapy
224096154|NCT02730546|PROCEDURE|Therapeutic Conventional Surgery|Undergo curative-intent surgery
224096155|NCT05821270|OTHER|Ashtanga Vinyasa Yoga Supta|Ashtanga (asta - eight, anga - parts); Vinyasa (freely sequenced practice); Yoga (practice for evolution); Supta (closed eyes)
223931690|NCT00913289|BIOLOGICAL|adipose tissue derived stromal cells|dosage
223931691|NCT04805736|PROCEDURE|Microwave Ablation|Image-guided microwave ablation 7-10 days prior to surgery
223931692|NCT04805736|DRUG|Camrelizumab|Camrelizumab 200 mg was given a few days after microwave ablation
223931693|NCT04805736|PROCEDURE|Breast Surgery|Standard of care breast conserving surgery or radical mastectmoy
224096156|NCT05798988|BEHAVIORAL|Neurophysiology-based exercise program|Neurophysiology-based exercise program combines physiotherapy exercises and neuro-physiology principles with focus on foot and core functional stabilisation and balance training.
224096157|NCT00000479|DRUG|Aspirin|Participants will receive 100 mg of aspirin every other day.
224096158|NCT00000479|DRUG|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
224096159|NCT00000479|BEHAVIORAL|Placebo|Participants will receive placebo.
224096160|NCT04203173|BEHAVIORAL|FINANCE-DM|The FINANCE-DM intervention is comprised of: 1) nurse education, 2) home telemonitoring, and 3) structured financial incentives. Patients randomized to FINANCE-DM will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session. Participants will also receive financial rewards for: 1) uploading glucose measurements; 2) participating in telephone delivered educational sessions; and 3) absolute percentage drops in HbA1c from baseline at each 3-month follow-up intervals.
224096161|NCT04203173|BEHAVIORAL|Active Comparator|Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
223533390|NCT05880810|DEVICE|Continuous Glucose Monitor Dexcom G6 PRO|Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
223533391|NCT06461533|DRUG|Susoctocog Alfa (Genetical Recombination)|Susoctocog Alfa (Genetical Recombination), Intravenous injection
223931694|NCT00575016|BIOLOGICAL|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor
224096162|NCT04103918|DEVICE|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
224096163|NCT03435900|DRUG|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
224096164|NCT03435900|DRUG|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
224096165|NCT02282787|DRUG|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
224096166|NCT06238999|DEVICE|Restoration of non-carious cervical lesions|Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
224096167|NCT03740334|DRUG|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
224096168|NCT03740334|DRUG|Dexamethasone|Corticosteroids are commonly used to treat ALL.
224096169|NCT03740334|DRUG|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
224096170|NCT05803564|DEVICE|Thoracoabdominal aortic stent system|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with thoracoabdominal aortic stent system.
224096171|NCT06614855|DRUG|C134|Initial Treatment . C134 Dose #1
224096172|NCT06614855|DRUG|C134|2nd Treatment. C134 Dose #2
224096173|NCT05211778|BEHAVIORAL|Digital Education Group|Multimedia education provided to the intervention group via a digital tablet
224096174|NCT05791058|PROCEDURE|ultrasound guided pericapsular nerve group shoulder block|The patient's arm is placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and 20 cc of 0.25% bupivacaine hydrochloride with 4mg dexamesathone will be injected
224096175|NCT05791058|PROCEDURE|ultrasound guided suprascapular and axillary nerve block|The patient will be positioned in a semi-recumbent position with the operating arm on the contralateral shoulder. The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected below the supraspinatous fascia then the posterior surface of the humerus will be visualised in the short axis view. So, the AN and posterior circumflex artery will be visualised longitudinally. 10 ml of 0.25% bupivacaine with 2mg dexamethasone will be injected into space
224096176|NCT05791058|OTHER|general anesthesia without nerve block|this group will receive general anesthesia without nerve block
224096177|NCT06676514|DIETARY_SUPPLEMENT|Probiotic Clostridium butyricum CBM588®|This group received probiotic Clostridium butyricum CBM588® treatment for IBS-D as three tablets daily for 8 weeks.
224096178|NCT06676514|OTHER|Standard of care IBS-D treatment|Patients in this group received standard of care IBS-D treatment of Trimebutine maleate maleate and followed a lactose-free, no-slag diet.
224096181|NCT04708041|BIOLOGICAL|9vHPV vaccine|9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
224096184|NCT06688942|BEHAVIORAL|Horizons App Intervention|Participants will receive access to the Horizons app intervention. The intervention pairs patient-centered information about chronic graft-versus-host disease with self-management strategies. Within each module, patients will engage in didactics and exercises that are relevant to the participant's chronic graft-versus-host disease concerns. The app contains 6 digital modules delivered via tablet over approximately 6 weeks. Each module should take up to approximately 20 minutes and are self-guided.
224096185|NCT07013019|OTHER|Measures of overall (internal+external) knee rotational amplitudes|Measures of overall (internal+external) knee rotational amplitudes by Dyneelax
224096186|NCT07021066|DRUG|BL-M05D1|BL-M05D1 will be administered on D1 every 3 weeks.
224096187|NCT05698589|BEHAVIORAL|Compassion Focused Therapy|CFT is an experiential therapy. As such, in addition to psychoeducation components (e.g.: compassion from an evolutionary and neuroscientific perspective, the tricky brain problem, emotion regulation systems) and explicit learning of emotion regulation skills (in particular, shame), experiential exercises are provided in-sessions (e.g. : chair work, role plays, guided mental imagery, …) and between sessions practices will be provided with video guides, made available for the participants online (e.g. : soothing rhythm breathing, safe place imagery, compassionate self-imagery, …). The overall aim of the CFT program is to help participants shift from a hostile and critical self-to-self relationship to a more compassionate relationship to self.
224096188|NCT05698589|BEHAVIORAL|Ending Self Stigma|Psychoeducation sessions cover topics such as the path from public stigma to self-stigma and modifying self-stigmatizing thoughts. Participants will be encouraged to do home practices (e.g. writing about the pros and cons of self-stigmatizing thoughts) between sessions. The overall aim of the ESS program is to help participants address self-stigma with concrete tools to increase their self-esteem and achieve their goals
224096189|NCT02926807|OTHER|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
224096190|NCT02926807|OTHER|MDCT|a MDCT to calculate the Agatston score
224096191|NCT02926807|OTHER|biopsy and blood collection|biopsy and blood collection to assess biomarkers
224096192|NCT04488458|DIAGNOSTIC_TEST|MIC or MBEC+MIC based treatment algorithm|"i) Non cell wall active standard of care antibiotic combination (MIC-guided) for 6 weeks.~ii) Non cell wall active antibiotic combination according to a MBEC-based decision algorithm for 6 weeks."
223718328|NCT02787668|OTHER|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO \<10%; fat \>65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
224096193|NCT02489214|DRUG|donafenib tosilate tablets|200mg bid
223931695|NCT00575016|BIOLOGICAL|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
223931696|NCT00575016|BIOLOGICAL|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
223931697|NCT00575016|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor
223931698|NCT01149759|DRUG|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
223931699|NCT02307396|DRUG|Olanzapine|
223931700|NCT02307396|DRUG|Amisulpride|
223931701|NCT02307396|DRUG|Risperidone|
223931702|NCT02307396|DRUG|Haloperidol|
223931703|NCT02307396|DRUG|Quetiapine|
223931704|NCT02307396|DRUG|Perphenazine|
223931705|NCT02307396|DRUG|Sulpiride|
223931706|NCT02307396|DRUG|bromperidol|
223931707|NCT02307396|DRUG|Zuclopenthixol|
223931708|NCT02307396|DRUG|Thioridazine|
223931709|NCT02307396|DRUG|Paliperidone|
223931710|NCT02307396|DRUG|Ziprasidone|
223931711|NCT02307396|DRUG|Benperidol|
223931712|NCT02307396|DRUG|Fluspirilene|
223931713|NCT02307396|DRUG|Pimozide|
223931714|NCT02307396|DRUG|Perazine|
223931715|NCT02307396|DRUG|Fluphenazine|
223931716|NCT02307396|DRUG|Flupentixole|
223931717|NCT02307396|DRUG|Sertindole|
223931718|NCT02350400|DEVICE|DEBIRI|DEBIRI TACE
223931719|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
223931720|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
223931721|NCT00692120|DIETARY_SUPPLEMENT|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
223931722|NCT00692120|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
223931723|NCT00692120|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule once daily for 12 months
224096194|NCT07107464|DEVICE|Short Neck Implant - Crestal Placement|A one-piece endosseous dental implant with a 1.8 mm short convergent neck, placed at the bone crest. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface treatment.
224096195|NCT07107464|DEVICE|Standard Neck Implant - 1 mm Subcrestal Placement|A one-piece endosseous dental implant with a standard-length neck (2.8 mm total; 0.8 mm cylindrical + 2 mm convergent), placed 1 mm subcrestally. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface.
223931724|NCT00936182|DRUG|Fluconazole|Fluconazole daily for 30 days
223931725|NCT04630509|PROCEDURE|traumatic cataract extraction|Irrigation/aspiration of traumatic cataract in children with posterior chamber intraocular lens implantation
223931726|NCT01032668|DRUG|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
223931727|NCT03709706|DRUG|Lete-cel|lete-cel will be administered to eligible participants.
223931728|NCT03709706|DRUG|Pembrolizumab|Pembrolizumab will be administered to eligible participants.
223931729|NCT06397196|OTHER|Laser guided proprioceptive exercises|Participants will receive Laser guided Proprioceptive exercises on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
223931730|NCT06397196|OTHER|Routine Physical therapy|Participants will receive routine physical therapy on alternate days (3 days a week) for 3 weeks. Total number of sessions will be 9
223931731|NCT04868617|DEVICE|ATTRACT-I|The aim of this investigation is to evaluate the performance and safety of an ostomy baseplate with a novel skin protection technology and its ability to reduce peristomal skin complications compared to SenSura® Mio. The subject will be randomized to either test product or comparator at enrollment. The subject will wear the test product for approximately 35 days and then cross-over to the comparator (or vice-versa) for approximately 35 days. At each baseplate change, the subject will answer questions about their skin, and take pictures of their stoma and used baseplate. They will also answer quality of life questionnaires at each study visit.
223931732|NCT03222934|DEVICE|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
223931733|NCT03779672|DRUG|Memantine Hydrochloride 10 mg|"* Week #1: 5 mg id (am), 1 caps~* Week #2: 5 mg bid (am and pm), 2 caps~* Weeks #3-6: 5 mg am \& 2x 5 mg pm, 3 caps~* Weeks #7-8: Washout~Placebo~* Week #9: id (am), 1 caps~* Week #10: bid (am and pm), 2 caps~* Weeks #11-14: 1 caps am \& 2 caps pm, 3 caps~OR Placebo~* Week #1: id (am), 1 caps~* Week #2: bid (am and pm), 2 caps~* Weeks #3-6: 1 caps am \& 2 caps pm, 3 caps~* Weeks #7-8: Washout~Memantine~* Week #9: 5 mg id (am), 1 caps~* Week #10: 5 mg bid (am and pm), 2 caps~* Weeks #11-14: 5 mg am \& 2x 5 mg pm, 3 caps"
223931734|NCT04163237|DRUG|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
223931735|NCT04163237|DRUG|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
223931736|NCT05145205|PROCEDURE|Sleeve gastrectomy|"Bougie was applied over the lower curvature to adjust the gastric tube then longitudinal amputation of the stomach was performed for about 4 to 6 cm per pecker of the pylorus to the corner of His. No supportive materials were used, and over-suturing of the basic line performed only over the points of bleeding.~All resected specimens were sent to histopathology laboratory for examination."
223931737|NCT05145205|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|An antecolic and antegastric RYGB become executed with a 150 cm alimentary limb with both a linearly or circularly kink (25 mm) gastrojejunostomy in step with the desire of the surgeon. A 50-cm-lengthy biliopancreati
223931738|NCT00505336|DRUG|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
223931739|NCT00505336|OTHER|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
223931740|NCT00505336|DRUG|Atorvastatin|oral Atorvastatin 40mg
223931741|NCT05561231|PROCEDURE|Intubation with C blade|Intubation with C blade of CMAC videolaryngoscope
223931742|NCT05561231|PROCEDURE|Intubation with D blade|Intubation with D blade of CMAC videolaryngoscope
223931743|NCT03183050|BEHAVIORAL|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
223931744|NCT01692769|DRUG|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
223931745|NCT01692769|DRUG|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
223931746|NCT01281657|DRUG|fingolimod|
224096196|NCT07107464|DEVICE|Long Neck Implant - 2 mm Subcrestal Placement|A one-piece endosseous dental implant with a long transmucosal neck (3.8 mm total; 0.8 mm cylindrical + 3 mm convergent), placed 2 mm subcrestally. Implant used: PRAMA implant (Sweden \& Martina, Italy) with UTM surface.
224284631|NCT04718649|DRUG|Celebrex with Joins or not|The enrolled patienst will be divided into the group taking celecoxib 200mg with Joins tab together and the group taking celecoxib 200mg with Joins placebo in the same probability of 2:1 according to the randomization table at the first outpatient visit. Among the co-researchers, one researcher who is in charge of patient assignment will create a randomization table through computer generated randomization. And this researcher who is charge of the patient assignment will not intervene in any other process of this study, and only participates in the task of selecting the assigned group using random checks. The evaluation will be evaluated by an researcher who is not aware of the patient allocation according to the randomization table among researchers participating in the clinical study
224284632|NCT00230191|DRUG|RK-0202|
223931747|NCT03472352|BIOLOGICAL|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
223931748|NCT05357677|DRUG|SR419|SR419 capsule
223931749|NCT02797132|DRUG|LUM/IVA|
223931750|NCT03239704|BEHAVIORAL|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
223931751|NCT03239704|OTHER|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
223931752|NCT03239704|BEHAVIORAL|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
223931753|NCT03388840|BIOLOGICAL|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
223931754|NCT03388840|BIOLOGICAL|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
223931755|NCT01215747|DRUG|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
223931756|NCT01215747|DRUG|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
223931757|NCT02347332|DRUG|Vinflunine|
223931758|NCT02347332|DRUG|Methotrexate|
223931759|NCT02705976|OTHER|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
223931760|NCT02705976|OTHER|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
223931761|NCT00253266|DRUG|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
223931762|NCT00253266|DRUG|Quetiapine|Quetiapine up to 200 mg/d for four weeks
223931763|NCT04574466|BEHAVIORAL|Problem Management Plus|Problem Management Plus (PM+) is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
223931764|NCT01970007|DEVICE|Zilver Vena Venous Self-Expanding Stent|stenting
224096197|NCT06628713|DRUG|Sebetralstat|Oral Plasma Kallikrein Inhibator
223931765|NCT04996407|DEVICE|survival thermal blanket|patients were given a thermal blanket
223931766|NCT04996407|DEVICE|draping fabric|Patients were given a draping fabric
224096198|NCT06686108|DRUG|Azacitidine (AZA) Days 1 - 5|Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle
224096199|NCT06686108|DRUG|Decitabine (DAC)|decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.
224096200|NCT06686108|DRUG|Venetoclax|venetoclax, 400mg/d, days 1-7 of each 28-day cycle
224096201|NCT06235229|BIOLOGICAL|GC012F|GC012F is a BCMA/CD19 dual CAR product
224096202|NCT07021859|DRUG|Calcitonin-gene related peptide (CGRP)|The participants will receive a continuous intravenous infusion of 1.5 μg/min of CGRP over 60 minutes.
224096203|NCT07021859|DRUG|Placebo|The participants will receive a continuous intravenous infusion of 60 mL of placebo (isotonic saline) over 60 minutes.
224096204|NCT02747524|OTHER|Vita Mamba peanut butter paste|
224096205|NCT06699563|BEHAVIORAL|Mobilization Motivation Card|On the morning of the surgery, the Mobilization Motivation Card and Pedometer will be introduced and the patient will be informed. On the morning of the first postoperative day, before the patient's first mobilization, pain assessment will be made with the Visual Analog Scale (VAS), and the Mobilization Motivation Card will be hung at the bedside during the day and will help increase the patient's participation in mobilization. Later, after a pedometer is attached to the patient's waist, the patient will be mobilized.
224096206|NCT06698822|DRUG|tofacitinib 2% cream|Given topical
224096207|NCT03136029|DIETARY_SUPPLEMENT|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
224096208|NCT03136029|DIETARY_SUPPLEMENT|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
224096209|NCT03136029|OTHER|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
224096210|NCT05516914|DRUG|LBL-007 Injection|Initial dose - MTD; Q3W; intravenous infusion
224096211|NCT05516914|DRUG|Tislelizumab Injection|Initial dose; Q3W; intravenous infusion
223931767|NCT03941106|DEVICE|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
223931768|NCT03878979|DRUG|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
223931769|NCT05643521|OTHER|Dietary composition of macronutrients and calories|Carbohydrate restriction
223931770|NCT04813991|DRUG|Ibuprofen 600 mg|Ibuprofen 600 mg for breakthrough pain.
223931771|NCT04813991|DRUG|OxyCODONE 5 Mg Oral Capsule|OxyCODONE 5 Mg Oral Capsule for breakthrough pain.
223931772|NCT04569188|BIOLOGICAL|Convalescent plasma|COVID-19 elderly patients treated with convalescent plasma
224096212|NCT05516914|DRUG|Cisplatin Injection|Initial dose；Q3W; intravenous infusion
224096213|NCT05516914|DRUG|Gemcitabine Hydrochloride for Injection|Initial dose；Q3W; intravenous infusion
224096214|NCT05516914|DRUG|Docetaxel injection|Initial dose；Q3W; intravenous infusion
224096215|NCT06438757|DRUG|JYB1904|Participants will receive JYB1904 every 8 weeks for 24 weeks.
224096216|NCT06438757|DRUG|Omalizumab|Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
224096217|NCT07029152|DIAGNOSTIC_TEST|Anal smear|"The intervention in this study involves the anal smear collection using the FLOQSwab® (COPAN, pouch type 502CS01). The swab is inserted 3-5 cm into the anal canal, reaching the transitional zone, the pressed against the canal wall and withdrawn in a spiral motion over approximately 20 seconds. After collection, the swab is immediately placed into a ThinPrep vial containing 20 ml of PreservCyt® and rinsed vigorously.~The procedure is performed by a physician or trained study team member and is designed to be quick, minimally invasive, and comfortable for participants. The FLOQSwab®'s patient-friendly design reduces irritation and false-positive results in comparison to earlier methods.~Samples collected in the ThinPrep PreservCyt® solution should be stored at room temperature and transferred to AML within a maximum of six weeks"
224096218|NCT07029152|BEHAVIORAL|Self-administered questionnaire|"It includes questions related to:~Socio-demographic characteristics Health-related issues Past HPV vaccination (indication? age at vaccination?) History of condylomata and/or other STIs Drug use, tobacco use, alcohol use Anal symptoms: discomfort, itch, pain, nodules, blood loss/discharge, constipation Sexual behavior Insertive/receptive intercourse, chemsex, number of sex partners (stable, occasional, anonymous), condom use."
224096219|NCT07029152|BEHAVIORAL|EQ-5D-5L questionnaire|"This questionnaire will be used after a negative HRA or during the communication of the results (per telephone) and during the treatment if indicated. This questionnaire assesses the impact of health conditions and treatments on person's quality of life. We will use an adapted version of the EQ-5D-5L. This modified version includes additional questions tailored to assess specific domains highlighted in the A-HRSI.~The additional items cover:~* Physical Symptoms: Question on anal symptoms such as pain, discharge, and burning sensations.~* Impact on Physical Functioning: Question on how these symptoms affect daily activities, including work, sitting, and social interactions.~* Impact on Psychological Functioning: Question on psychological and sexual well-being, including enjoyment and desire for sex, as well as challenges with intimacy."
224096220|NCT07029152|DIAGNOSTIC_TEST|High Resolution Anoscopy (HRA)|"HRA will be conducted using advanced tools, such as the Zeiss Extaro at UZ Brussel.~HRA will be conducted at participating centers with expertise in the technique, including UZ Brussel, UZ Gent, UZ Leuven, UZ Antwerpen, CHU St Pierre, AZ Sint-Jan Brugge, and Citadelle Liège. However, all biopsy specimens will be sent to AML Lab for analysis and stored in the biobank (BB190002).~In certain centers, HRA is performed using high-resolution scopes."
224096221|NCT07023016|DRUG|Sacubitril / Valsartan|Patients will receive sacubitril/valsartan at an initial dose of 24/26 mg Bid.
224096222|NCT07023016|DRUG|Ramipril (ACE-inhibitor)|Patients will receive ramipril at an initial dose of 2.5 mg Bid.
224096223|NCT06691958|OTHER|Tortilla corn chips 4-5 pieces, eat one piece at time|Snack
224096224|NCT06691958|OTHER|Tortilla corn chips 90 grams|Snack
224096225|NCT06691958|OTHER|Extruded corn chips 90 grams|Snack
224096226|NCT06691958|OTHER|Extruded corn chips 4-5 pieces, eat one piece at time|Snack
224284633|NCT03078478|DRUG|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
224284634|NCT03078478|DRUG|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
224284635|NCT06397222|DRUG|Sin-Bev-SIRT|Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
224284636|NCT04350008|DEVICE|Renamic Neo programmer device, including software; PK-222-L ECG cable|Patients were enrolled either for implantation including subsequent pre-hospital discharge or for a follow-up visit only. ICM patients were included for follow-ups only. Implants were programmed and interrogated by using the investigational devices.
224284637|NCT00905788|PROCEDURE|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
224284638|NCT01000688|DRUG|vildagliptin + acarbose|4 week treatment
224284639|NCT01000688|DRUG|acarbose + vildagliptin|4 week treatment
224284640|NCT02498249|DEVICE|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
224284641|NCT02498249|DEVICE|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
224284642|NCT03253094|DRUG|Fluconazole|Oral Antifungal comparator
224284643|NCT03253094|DRUG|SCY-078|Investigational Antifungal
224284644|NCT00559026|BIOLOGICAL|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
224284645|NCT00559026|OTHER|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
224096227|NCT06683612|DRUG|PIPE-791|Subjects will receive a single oral dose of PIPE-791.
224096228|NCT06682299|DEVICE|Transmagnetic Stimulation|TMS will be given for the maintenance treatment of treatment resistant depression following successful course of ECT (8-12 treatments).
224096229|NCT06682299|DEVICE|Electroconvulsive Therapy|Patients will remain in standard of care treatment and receive maintenance ECT treatments for treatment resistant depression
224096230|NCT03079440|DRUG|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
224096231|NCT06697171|OTHER|Group 1 Not an ad disclosure|Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #NotAnAd in the narrative body of the social media post
224096232|NCT06697171|OTHER|Group 2 Basic Disclosure|Same social media post viewed as all other groups. @brandname in the narrative body of the social media post; #ad in the narrative body of the social media post
224096233|NCT06697171|OTHER|Group 3 Basic + Paid Partnership Disclosure|"Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post;~#ad and #sponsored at the bottom of the narrative body of the social media post."
224096234|NCT06697171|OTHER|Control|No COI disclosure elements (i.e. no hashtags ). Only the @brandname is included within the narrative body of the social media post.
224096235|NCT06697171|OTHER|Group 4 Basic + Paid Partnership + Image label|"Same social media post viewed as all other groups. COI disclosures include paid partnership in the header and a tag for the industry partner; @brandname and #ad immediately at the beginning of the narrative body of the social media post; #ad and #sponsored at the bottom of the narrative body of the social media post; #ad (black text, white background) appears on the photo associated with the social media post"
224096236|NCT05818124|DRUG|Molnupiravir|Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
224096237|NCT05818124|DRUG|Placebo molnupiravir|Four placebo capsules matched to molnupiravir taken twice daily by mouth.
224096238|NCT05818124|DRUG|Placebo oseltamivir|Placebo capsule matched to oseltamivir taken twice daily by mouth.
224096239|NCT05818124|DRUG|Oseltamivir|One capsule of oseltamivir 75 mg taken twice daily by mouth.
224096240|NCT05818124|BIOLOGICAL|Influenza A Virus|Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
224096241|NCT07030140|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT to the primary tumor and metastatic lymph node at a dose of either 5 Gy × 5-8 fractions or 4 Gy × 15 fractions, delivered prior to systemic therapy.
224096242|NCT07030140|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously every 3 weeks (on Day 1 of each 21-day cycle), for three to six cycles depending on surgical eligibility.
224096243|NCT07030140|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² administered intravenously on Days 1 and 8 of each 21-day cycle, for three to six cycles.
224096244|NCT07030140|DRUG|Cisplatin or Oxaliplatin|Cisplatin 25 mg/m² on Days 1 and 8 or oxaliplatin 100 mg/m² on Day 1 of each 21-day cycle, selected based on patient condition, for three to six cycles.
224284646|NCT02339090|DRUG|Somavaratan|Somavaratan will be administered per dose and schedule specified in the arm description.
224284647|NCT02339090|DRUG|rhGH|rhGH will be administered per dose and schedule specified in the arm description.
224284648|NCT01168687|DRUG|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
224284649|NCT01168687|DRUG|Placebo|
224284650|NCT02123732|DIETARY_SUPPLEMENT|DbXell|
224284651|NCT02123732|DIETARY_SUPPLEMENT|Placebo|
224284652|NCT00433277|DRUG|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
224284653|NCT02737592|DEVICE|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
224284654|NCT02593344|DEVICE|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
223931773|NCT04559633|OTHER|cognitive and behavioral therapy (CBT)|"The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work."
223931774|NCT04890938|COMBINATION_PRODUCT|Sputum-guided management and comprehensive care management|Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils \>3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells \>10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.
223931775|NCT04890938|OTHER|Usual Care|As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.
223931776|NCT06199115|PROCEDURE|Photobiomodulation|"In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy. Photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies.~Patients in the experimental group will receive 3 photobiomodulation sessions per week during their oxaliplatin treatments (6 months), for a total of 72 sessions. Exposition to laser light is 30 minutes for each session."
223931777|NCT00362960|DRUG|Olmesartan medoxomil|
223931778|NCT00362960|DRUG|Losartan|
223931779|NCT01847456|DRUG|human insulin as nasal spray|
224096245|NCT07032129|BIOLOGICAL|BCMA/GPRC5D CAR-T cells|"The intervention in this clinical trial involves a novel approach using BCMA/GPRC5D Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/GPRC5D Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/GPRC5D CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/GPRC5D CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses."
224096246|NCT06688435|BIOLOGICAL|SYS6020 injection|The SYS6020 is an injection of autologous CAR-T cells that have been temporarily transfected with LNP-mRNA targeting BCMA. Before each dosing, the infusion eligibility of SYS6020 is assessed by the investigator, and the eligible participants will receive 3 dosing SYS6020 injection treatment. The dosing interval is 7 days according to the protocol design.
223931780|NCT01847456|DRUG|Placebo|
223931781|NCT01331499|DEVICE|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
224096247|NCT06687837|BIOLOGICAL|autologous dopaminergic cell implantation|Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low dose and the other high dose (4 and 8 million cells, respectively)
224096248|NCT06707142|DRUG|TBD11|TBD11 will be administered orally.
224096249|NCT06707142|DRUG|Placebo|Placebo will be administered orally.
224096250|NCT07099963|OTHER|one lung ventilation|Arterial blood gases during one lung ventilation
224096251|NCT07099677|DRUG|Beta Blocker|Participants in this group will receive standard antihypertensive treatment with a beta-adrenergic receptor blocker. The exact agent and dosage will be determined by the cardiology clinic according to clinical guidelines. Balance and fall risk assessments will be conducted at baseline (T0), week 2 (T1), and week 4 (T2).
224096252|NCT07099677|DRUG|ACE inhibitor|Participants in this group will receive standard antihypertensive treatment with an angiotensin-converting enzyme inhibitor. The dose and specific agent will be prescribed based on routine clinical criteria. Assessments will take place at T0, T1, and T2.
224096253|NCT07099677|DRUG|Calcium channel blocker|This group will receive a calcium channel blocker as part of their standard hypertension management. Dosage and agent will follow standard cardiology practice. Postural balance and fall risk will be measured at all study time points.
224096254|NCT07094711|BIOLOGICAL|Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine|"Subjects will be randomized to a single intradermal injection of BCG or placebo vaccine.~Participants randomized to the BCG arm will receive TICE® BCG. Freeze-dried vaccine is produced in vials, each containing 1 to 8 x\^108 colony forming units (CFU). A vial will be reconstituted in 20 mL of preservative-free saline. Administration of 0.1 mL will contain \~2x\^106 CFU, which accounts for approximately 0.25 mg of the attenuated Mycobacterium bovis. Administration of 0.1 mL of diluted vaccine will be given per dose, intradermally."
224096255|NCT07094711|DRUG|preservative-free saline|Patients randomized to the placebo arm will receive 0.1 mL preservative-free saline alone.
224096256|NCT07100691|DRUG|Metoclopramide|Oral metoclopramide 10 mg, administered as three doses the day before surgery and one dose on the morning of surgery (total four doses over 24 hours). Used to enhance gastric emptying in patients taking GLP-1 receptor agonists.
224284655|NCT03220126|BIOLOGICAL|LY3074828|Administered IV
224284656|NCT03220126|BIOLOGICAL|LY900021|Administered SC
224284657|NCT05675358|BEHAVIORAL|Virtual Reality|Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
224284658|NCT02425501|DRUG|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
224284659|NCT01784198|DIETARY_SUPPLEMENT|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
223931782|NCT01331499|PROCEDURE|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
224096257|NCT07089823|DRUG|YP05002|Tablet, QD
224096258|NCT07089823|OTHER|Placebo|Tablet, QD
224096259|NCT00648401|DRUG|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
224096260|NCT00648401|DRUG|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
223533392|NCT06445777|BEHAVIORAL|Mental Health Prevention and Promotion|The Inner Lion Programme is made up of 12 interactive workshops which are based on four key pillars: building confidence by identifying strengths and personal qualities; improving emotional intelligence and self-awareness; establishing adaptive coping strategies and channels of support; and boosting resilience. Professionally created by Child Psychologist Stijn de Leeuw together with an advisory team of psychologists from the Netherlands and South Africa, the programme follows a carefully structured and curated prevention and promotion mental health curriculum with games, crafting activities, psycho-educational stories, dance, movement, and breathing exercises. Workshops are led by local role models (a male-female duo) with lived experience trained to be mental health coaches.
223533393|NCT00016354|DRUG|benzoylphenylurea|
223533394|NCT03110562|DRUG|Selinexor|oral 100 mg dose
223533395|NCT03110562|DRUG|Bortezomib|subcutaneous dose of 1.3 mg/m2
223533396|NCT03110562|DRUG|Dexamethasone|oral dose of 20mg
223931783|NCT03078205|OTHER|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
223931784|NCT03078205|OTHER|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
223931785|NCT06633926|BEHAVIORAL|Nutrition Education|Given nutrition education
223931786|NCT06633926|BEHAVIORAL|Lifestyle Counseling|Given lifestyle recommendations
223931787|NCT06633926|OTHER|Yoga|Participate in yoga
223931788|NCT06633926|PROCEDURE|Marma therapy|Participate in marma therapeutic touch
223931789|NCT06633926|OTHER|Educational Intervention|Attend online HEI sessions
223931790|NCT06633926|OTHER|Quality of Life Questionnaire Administration|Self-reported questionnaires are given to participants to complete
223931791|NCT06951646|DRUG|Ivonescimab plus docetaxel|"For ctDNA-positive patients, escalation treatment will be administrated~1. Ivonescimab: Intravenous infusion (IV), 20 mg/kg, Day 1, every 3 weeks (Q3W);~2. Docetaxel: IV, 75 mg/m², Day 1, Q3W (The investigator may adjust the chemotherapy dose and schedule based on the patient's tolerance during treatment.)~All enrolled participants will continue treatment until one of the following occurs, whichever comes first:~* The investigator determines that there is no longer clinical benefit (based on imaging assessments and clinical status)~* Unacceptable toxicity~* Completion of 24 months of treatment~* Other discontinuation criteria specified in the protocol are met."
224096261|NCT06249139|BEHAVIORAL|Compass for Care (Well-being intervention)|Participants receive 12 weekly modules containing interactive activities and static content and tailored messages delivered via text message or email. The intervention focuses on five self-care behaviors critical to ADRD caregiver well-being: 1) taking time to recharge; 2) finding information about your loved one's diagnosis and needs; 3) discovering your strengths and limits; 4) exploring outside help; and 5) seeking emotional support.
224096262|NCT06249139|BEHAVIORAL|Compass for Care (Safety intervention)|Participants receive 12 weekly modules and tailored messages delivered via text message or email. The intervention focuses on safety behaviors (e.g., weather safety, first aid, home safety, etc.)
224284660|NCT02285205|DRUG|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
224284661|NCT04593303|PROCEDURE|Internal iliac artery ligation with cervicoisthmic compression suture|Retroperitoneal approach will be performed to ligate both internal iliac arteries before bladder dissection followed by cervicoisthmic compression suture application at placental bed
224284662|NCT04593303|PROCEDURE|Cervicoisthmic compression suture without Internal iliac artery ligation|Bladder dissection followed by cervicoisthmic compression suture application at placental bed without Internal iliac artery ligation
224284663|NCT02571803|BEHAVIORAL|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
224284664|NCT02571803|OTHER|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
224284665|NCT00576303|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
224284666|NCT05057793|DEVICE|geko|The geko device will be self-administered and deliver 12 hours of therapy daily.
224284667|NCT03955939|DRUG|LY3295668 Erbumine|Administered orally.
224284668|NCT03955939|DRUG|Endocrine therapy|Administered according to label instructions.
224284669|NCT03955939|DRUG|Midazolam|Administered orally.
224284670|NCT04452695|DEVICE|Doctor Spot|Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
224284671|NCT05792319|DIAGNOSTIC_TEST|24 hour copper in urine and liver function test|sampling 24 hour copper in urine and liver function test
224284672|NCT00864617|DRUG|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
224284673|NCT00864617|DRUG|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
224284674|NCT00297245|DRUG|cognitive function|
224284675|NCT03684681|BEHAVIORAL|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
224284676|NCT03684681|BEHAVIORAL|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
224284677|NCT00061217|DEVICE|Unrectified prosthetic socket|
224284678|NCT00061217|DEVICE|Rectified prosthetic socket|
224284679|NCT02418624|DRUG|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
223931792|NCT06951646|OTHER|Standard Treatment|"For ctDNA-positive patients, continuing the original immunotherapy maintenance or immunotherapy combined with chemotherapy~• In the event of clinical progression, consider switching to treatment with Ivonescimab plus docetaxel, administered every 3 weeks."
223931793|NCT01816971|DRUG|dexamethasone|Given IV or PO
223931794|NCT01816971|DRUG|carfilzomib|Given IV
223931795|NCT01816971|DRUG|lenalidomide|Given PO
223931796|NCT01816971|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
223931797|NCT01816971|OTHER|laboratory biomarker analysis|Correlative studies
223931798|NCT05994131|DRUG|IN10018|orally taken once daily
223931799|NCT05994131|DRUG|Furmonertinib|orally taken once daily
223931800|NCT04416321|DEVICE|Surgery with the Keos Lumbar Interbody Fusion Device|All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
223931801|NCT05586503|DIAGNOSTIC_TEST|ECG-gated CTAs|ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
223931802|NCT00754065|DRUG|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
223931803|NCT00754065|DRUG|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
223931804|NCT06432192|DIAGNOSTIC_TEST|APO-Easy|Testing for the APOE genotype using the APO-Easy Genotyping test
223931805|NCT06457971|DEVICE|Robotic Ventral Hernia Repair|The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
223931806|NCT00110552|DRUG|Salvia officinalis (sage)|oral dosage
223931807|NCT00435318|PROCEDURE|Iontophoresis|
223931808|NCT00832169|DRUG|AZD1386|1 dose of oral solution
223931809|NCT03279224|BIOLOGICAL|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3\. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
223931810|NCT03279224|BIOLOGICAL|Autologous FMT|"1\. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3\. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
223931811|NCT00436631|BEHAVIORAL|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
223931812|NCT05845515|PROCEDURE|laparoscopic orchiopexy|laparoscopic or open orchiopexy and comparison between the two groups
224096263|NCT07107048|DEVICE|Pacemaker and defibrillator|Patients will be randomly assigned at enrollment (1:1) to undergo either LBBAP or CRT with biventricular stimulation. The devices implanted maybe defibrillators or pacemekers.
224284680|NCT06887322|DRUG|Ciplukan|A minimum amount of 20 psoriasis vulgaris lesion treated with the topical formulation containing 20% ciplukan (Physalis angulata Linn.) extract, applied twice a day for 14 days.
224284681|NCT06887322|DRUG|Bethametasone valerate 0,1% cream|A minimum amount of 20 psoriasis vulgaris lesion treated with the bethametasone valerate 0,1% cream, applied twice daily for 14 days.
224284682|NCT06474481|DRUG|Zanubrutinib|Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
223931813|NCT03910855|BEHAVIORAL|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
224096264|NCT07105540|DRUG|5% Dextrose|Ultrasound-guided hydrodissection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. 2.5 ml of 5% dextrose will be injected via an in-plane ulnar approach to mechanically separate the median nerve from the transverse carpal ligament. Subsequently, an additional 2.5 ml of 5% dextrose will be administered to separate the nerve from adjacent flexor tendons. The total injection volume will be 5 ml.
224284683|NCT06474481|DRUG|Obinutuzumab|Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
224284684|NCT06474481|DRUG|Prednisone|Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
224284685|NCT06474481|DRUG|Cyclophosphamide|Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
224284686|NCT06474481|DRUG|Vincristine|Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
223931814|NCT03910855|OTHER|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
223718329|NCT02787668|OTHER|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
223931815|NCT05551286|OTHER|A rehabilition programme for young adult cancer survivors|The programme consists of 22 sessions focusing on; 1) everyday life (energy conservation, cognitive challenges, fatigue); 2) Physical activity; 3) psychological issues; 4) work and study d; 5) sexuality and relationship; 7) rights and finance, and 8) goal setting. The sessions include both education, workshops, and engagement in different activities and will be delivered by a multidisciplinary team.
223931816|NCT04544982|OTHER|Blue fenugreek kale extract|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
223931817|NCT04544982|OTHER|Placebo|One capsule to be taken orally before breakfast and one capsule after lunch, with water.
223931818|NCT00802126|DRUG|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
223931819|NCT04678375|DIAGNOSTIC_TEST|Retinal diseases diagnosed by artificial intelligence algorithm|An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
223931820|NCT05260398|BEHAVIORAL|Mightier Online Gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
223931821|NCT00002381|DRUG|Nelfinavir mesylate|
223931822|NCT00002381|DRUG|Nevirapine|
223931823|NCT00002381|DRUG|Stavudine|
223931824|NCT06515678|DRUG|arm A - angiotensin converting enzyme inhibitors (ACEi)|"Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril"
223931825|NCT06515678|DRUG|arm B - calcium channel blockers (CCBs)|"Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine"
224284687|NCT06474481|DRUG|Doxorubicin|Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
224284688|NCT01007279|DRUG|ROSUVASTATIN|40 mg before procedure
224284689|NCT00955721|DRUG|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
224284690|NCT00955721|DRUG|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
224284691|NCT00955721|DRUG|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
224284692|NCT02306837|DRUG|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
224284693|NCT06889935|OTHER|Exercise diary|The respiratory exercise diary was prepared by reviewing the literature in order to record the time, number and frequency of respiratory exercises performed by patients with the use of a spirometer. On the first page of the diary consisting of two pages; the patient's name and surname, date of surgery, date of birth, how and how often to use the spirometer, and a pictorial information note to remind the position to be taken were included, while on the second page; the chart in which the patients would write the number of exercises they performed with the spirometer during the first three postoperative days opposite the relevant hour was included.
224284694|NCT00986024|BEHAVIORAL|aerobic exercise|carried out 3 times per week for 12 weeks
224284695|NCT00986024|BEHAVIORAL|strength training|carried out 3 times per week for 12 weeks
224284696|NCT03512002|DEVICE|HIRREM|Technology
224284697|NCT03512002|OTHER|Continued Current Care|Continue their current clinical care.
224284698|NCT05338372|BEHAVIORAL|Two days forest therapy|Participants attend two days (with a break day in between) of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
224284699|NCT05338372|BEHAVIORAL|Three days forest therapy|Participants attend three days of two-hour forest therapy at the Friedrichsruh, Barntrup or Wernigerode sites, led by an INFTA-certified forest therapy guide.
224284700|NCT01363466|PROCEDURE|hysterectomy|
224284701|NCT00145613|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
224284702|NCT00145613|DEVICE|Miltenyi Biotec CliniMACS|stem cell selection device
224284703|NCT00145613|DRUG|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
224284704|NCT02280226|DEVICE|magnetic resonance imaging (MRI)|
223931826|NCT06515678|DRUG|arm R - angiotensin receptor blockers ARB|"Patients with angiotensin receptor blocker (ARB) before or within 6 months following debulking surgery.~ARBs will be defined as any drugs from the Anatomical Therapeutic Classification C09CA with an indication for hypertension, including but not limited to: losartan, valsartan, irbesartan, candesartan or olmesartan medoxomil."
223931827|NCT00954668|PROCEDURE|immediate angiography and revascularization|immediate angiography \< 2 hours after randomization
223931828|NCT00954668|PROCEDURE|early invasive angiography|early invasive angiography 12-72 h after randomization
223931829|NCT03484910|OTHER|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
223931830|NCT00557596|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
223931831|NCT06398600|PROCEDURE|Caudal|In the prone position , linear transducer will be first positioned transversely on the middle line. The two sacral cornua appear as two hyperechoic structures ,two hyperechoic band structures are present between the two sacral cornua. The superficial is the sacrococcygeal ligament (SCL) and the deep is the dorsal surface of the sacrum. The sacral hiatus is a hypoechoic area between two band-like hyperechoic structures. In longitudinal view, the block needle will be inserted using the in plane technique .The block needle can be visualized in real time piercing the SCL entering the hiatus but cannot be visualized beyond the apex of the hiatus. It is therefore proposed to limit the extension of the needle tip beyond the tip of the sacral hiatus to 5 mm to avoid perforating the dura mater. After the needle is inserted in the caudal canal, 20 ml of 0.25% bupivacaine will be injected.
223931832|NCT06398600|PROCEDURE|Quadratus lumborum plane block|The patient is placed in the prone position , under aseptic conditions with the sterile convex probe is placed in a transverse view at the triangle of the QL muscle and the middle thoracolumbar fascia. The projected needle path is advanced in-plane until the needle tip is visualized between the middle thoracolumbar fascia and the QL muscle . After confirming the location of the needle with 2-3 ml of saline and then aspiration, 20 ml of 0.25% bupivacaine is injected in this plane with confirmation by visualizing hydro dissection . the procedure is applied to the opposite side using the same dose to achieve bilateral block.
223533397|NCT05198570|OTHER|Pharmacokinetic analysis|Population pharmacokinetic analysis of plasma concentrations of aciclovir obtained during routine therapeutic drug monitoring
223533398|NCT02160808|DRUG|Secretin|Drug to stimulate pancreatic secretion
223931833|NCT02362139|DRUG|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation\<4cm).
223533399|NCT02160808|DRUG|Placebo|
223533400|NCT06645184|DIETARY_SUPPLEMENT|Oral nutritional supplement|During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
223533401|NCT05452668|DEVICE|Laser Therapy|\- Laser will be applied with the specified wave length using a diode laser device over 4 consecutive days.
223533402|NCT05452668|DEVICE|Sham procedure|Seventeen patients will receive mock treatment which is the exact repetition of the treatment modality but without any laser emission plus the current Protocol(antifungal +/- antiviral and analgesics) used by CCHE which will be recorded in the patient's file
223533403|NCT05343988|DEVICE|Percutaneous Electrical Nerve Field Stimulation (PENFS) device application|PENFS device will be used to treat children with paroxysmal sympathetic hyperactivity (PSH) due to acute severe brain injury.
223533404|NCT06176547|DIAGNOSTIC_TEST|HbA1c|Blood glucose in last 3 months
223533405|NCT04866563|DRUG|AX-8, Part 1 of the study|orally disintegrating tablets, BID
223533406|NCT04866563|DRUG|Placebo, Part 1 of the study|orally disintegrating tablets, BID
223533407|NCT04866563|DRUG|AX-8, Part 2 of the study|orally disintegrating tablets, TID
223931834|NCT06562907|DRUG|GS-4571|Administered orally
223931835|NCT06562907|DRUG|Placebo|Administered orally
223931836|NCT06562907|DRUG|Omeprazole|Administered orally
223931837|NCT01074294|DRUG|OPDC-34712|OPDC-34712 tablets, daily, Orally.
223931838|NCT01074294|DRUG|Placebo|Matching-placebo tablets, daily, Orally.
223931839|NCT01074294|DRUG|Stimulant Therapy|Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
223931840|NCT04185181|OTHER|virtual reality|wii video game based exercise
223931841|NCT04185181|OTHER|proprioceptive neuromuscular facilitation|PNF with breathing
223931842|NCT04185181|OTHER|complete decogestive therapy|pneumatic compression, manual lymph drainage, skin care and home exercise program
223931843|NCT01834846|PROCEDURE|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
223931844|NCT01834846|PROCEDURE|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
223931845|NCT02109575|DIAGNOSTIC_TEST|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
223931846|NCT00874536|DIETARY_SUPPLEMENT|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
223931847|NCT00874536|DIETARY_SUPPLEMENT|Placebo|
224096265|NCT07105540|DRUG|Betamethasone and local anesthetic|Ultrasound-guided perineural injection is performed using a 12 MHz linear transducer (GE Logiq P9, GE Healthcare) via an in-plane ulnar approach under sterile conditions. A total of 2 ml solution (1 ml betamethasone and 1 ml 2% lidocaine) is injected perineurally around the median nerve under ultrasound guidance at the scaphoid-pisiform level.
224096266|NCT07107581|DEVICE|Prospective / Subjects Knee Arthroplasty|Knee Arthroplasty
224096267|NCT07107581|DEVICE|Retrospective to Prospective|Knee Arthroplasty
224096268|NCT07107581|DEVICE|Retrospective Only Subjects|Knee Arthroplasty
224096269|NCT07107594|BEHAVIORAL|Multimodal prehabilitation|Multimodal prehabilitation program during NACT (4-6 months) that will combine: 1) Physical exercise: cardiovascular and strength exercises designed by specialized physiotherapists, structured in 1-hour sessions twice a week. The characteristics of the activity will be adapted to the treatment phase and the physical condition of each woman. 2) Psychological therapies: standardized mindfullness practice by a specialized psychologist. As an alternative, patients who refuse mindfullness could receive psychological sessions on stress and anxiety management. 3) Nutritional counseling: periodic sessions with a specialized nutritionist providing dietary recommendations and nutritional advice adapted to the disease and condition of the patients.
224096270|NCT07106840|OTHER|No intervention (observational study)|This is an observational study with no intervention applied.
224096271|NCT07106749|BIOLOGICAL|CD180 CART|Subjects screened to meet the requirements for CD180 CART use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to CD180 CART infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of CD180 CART must be performed 24 hours after completion of chemotherapy preconditioning. CD180 CART can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
224096272|NCT07106918|BIOLOGICAL|SIBP-A16 injection|Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
224096273|NCT07106918|BIOLOGICAL|Nirsevimab|Single administration via intramuscular.
224096274|NCT07106918|OTHER|SIBP-A16 buffer solution|Single administration via intramuscular or intravenous injection. All participants received a single injection of the corresponding dose.
224096275|NCT07108218|PROCEDURE|lateral postion|The children will be positioned on their sides with their heads elevated by 30°, a thin pillow behind their backs, the upper legs bent, and the lower legs straightened.
224096276|NCT07108218|PROCEDURE|supine position|The children will be changed to a supine flat-lying position for extubation.
224096277|NCT07106736|BIOLOGICAL|BCMA CAR-T|Patients will receive single-dose infusion of autologous BCMA-directed CAR-T cellsBCMA CAR-T single dose (3.0 x 10\^6 cells /kg).
224096278|NCT07106736|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion.
224096279|NCT07106307|OTHER|Bioceramic Sealer|This intervention involves the use of Bioceramic Sealer during root canal obturation. The sealer will be combined with the cold lateral compaction or warm vertical compaction technique depending on the study arm.
224096280|NCT07106307|PROCEDURE|Warm Vertical Compaction|Warm vertical obturation is performed using a heat delivery device, which thermosoftens gutta-percha and allows vertical compaction into the root canal system. This technique will be used in combination with either resin-based or bioceramic sealers, depending on the study group.
224096281|NCT07106307|OTHER|Epoxy Resin-Based Sealer|This intervention involves the use of an epoxy resin-based root canal sealer during root canal obturation. The material will be applied in combination with either cold lateral compaction or warm vertical compaction techniques, depending on the study group.
224096282|NCT07106307|PROCEDURE|Cold Lateral Compaction|Cold lateral compaction is a root canal obturation technique in which a master gutta-percha cone is placed to working length and compacted laterally using a finger spreader. This method will be used in combination with either resin-based or bioceramic sealers, depending on the study group.
223533408|NCT04866563|DRUG|Placebo, Part 2 of the study|orally disintegrating tablets, TID
223533409|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.
223718330|NCT03517098|PROCEDURE|The ERAS group|"ERAS pathway for orthopedic surgeons:~1. Shortened preoperative fasting from intake.~2. Preoperative tranexamic acid administration.~3. No indwelling catheters.~4. No tourniquet used for TKA.~5. No drainage tube.~6. Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~1. Intravenous 20 mg of dexamethasone before anesthetic induction.~2. Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~3. Laryngeal mask for airway.~4. Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~5. Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
223931848|NCT05435794|DEVICE|CPAP|Fixed-pressure CPAP device for the treatment of sleep apnea with optional humidification and heated circuit. This device is a Class II device. It has a remote monitoring function allowing service providers to track the use of the device.
223931849|NCT05435794|DEVICE|MAD|mandibular device orthosis made to measure from the dental impressions of patients, made by the specialist in the masticatory apparatus for the treatment of sleep apnea.
224096283|NCT07108088|DEVICE|NEUROSWING Orthosis (experimental) : carbon orthosis with an active ankle articulation|"The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in :~* Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days~* Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days"
224096284|NCT07108088|DEVICE|Carbon orthosis (control)|"The patients will use the experimental device during 14 days straight as well, then a washout period of 7 days with no interventons and then the comparator during 14 days straight. The order in which they will use each device will depend on the groupe they have been randomized in :~* Arm 1 : Control device during 14 days, followed by a 7 day washout period, then exerimental device during 14 days~* Arm 2 : Experimental device during 14 days, followed by a 7 day washout period, then control device during 14 days"
224096285|NCT07108023|OTHER|No intervention (Observational Study)|This is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only
224284705|NCT03518216|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a remotely delivered tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be interactive with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist support. The intervention is delivered through a HIPAA compliant video platform.
224284706|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
224284707|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
224284708|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
224284709|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
224284710|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
224284711|NCT00984516|DRUG|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
224284712|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
224284713|NCT00984516|DRUG|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
223533410|NCT02936323|DRUG|PEN-221|PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
223533411|NCT05806190|DEVICE|Continuous Glucose Monitoring|Continuous Glucose Monitoring using a Dexcom G6 Continuous Glucose Monitoring Device
223533412|NCT04139408|DEVICE|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
223533413|NCT04980157|BEHAVIORAL|CARES-HCV|CARES-HCV is an educational intervention to promote both hepatitis c screening and colorectal cancer screening among diverse baby boomers in the area.
223533414|NCT04717401|PROCEDURE|Strain-Counterstrain|Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
223931850|NCT02839395|OTHER|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
223931851|NCT02839395|OTHER|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
224284714|NCT06880796|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy provided in a group format.
224284715|NCT06880796|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usually provided.
224284716|NCT03672305|BIOLOGICAL|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
224284717|NCT00749411|DRUG|Placebo|matching placebo
224284718|NCT00749411|DRUG|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
224284719|NCT01008137|BIOLOGICAL|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
224284720|NCT01008137|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
224284721|NCT00096122|DRUG|cytarabine|Given IV
224284722|NCT00096122|DRUG|idarubicin|Given IV
224284723|NCT00096122|DRUG|tipifarnib|Given orally
224284724|NCT02214706|DRUG|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
224284725|NCT02214706|OTHER|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
224284726|NCT02214706|DEVICE|Pulsed Dye Laser|
224284727|NCT06767943|DIAGNOSTIC_TEST|12-lead electrocardiography|All patients were admitted to the intermediate care unit for the 1st 24-h PO for follow-up for the possibility of developing acute myocardial infarction (AMI), which was diagnosed according to the 2017 ESC Guidelines; by 12- lead electrocardiography
224284728|NCT06895486|BIOLOGICAL|Novel Oral Polio Vaccine Type 1 (nOPV1)|nOPV1 containing \>10\^7.0 CCID50 per dose
224284729|NCT06895486|BIOLOGICAL|Novel Oral Polio Vaccine Type 2 (nOPV2)|nOPV2 containing ≥10\^5.0 CCID50 per dose
224284730|NCT06895486|BIOLOGICAL|Placebo (Sterile Water)|Sterile, nonpyrogenic preparation of water which contains no bacteriostat, antimicrobial agent, or added buffer
224284731|NCT06778265|BIOLOGICAL|UX-DA001|"UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery.~Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001."
224284732|NCT03183141|BIOLOGICAL|SER-109|SER-109, an oral, biologically derived, live microbiome therapeutic that comprises purified bacterial spores
224284733|NCT05049668|DRUG|ATGAM plus CsA with or without Eltrombopag|Standard treatment with or without Eltrombopag
224284734|NCT03111667|BEHAVIORAL|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
224284735|NCT03111667|OTHER|Treatment as Usual|Referral to community resources
224284736|NCT03111667|BEHAVIORAL|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
224284737|NCT03111667|BEHAVIORAL|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
224284738|NCT04846647|BEHAVIORAL|unexplained hypophoshatemia|Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
224284739|NCT02853864|DRUG|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
224284740|NCT02853864|DRUG|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
224284741|NCT02853864|DRUG|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
224284742|NCT02853864|DRUG|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
224284743|NCT02853864|DRUG|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
224284744|NCT01637831|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
224284745|NCT03319095|DEVICE|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
223931852|NCT02839395|OTHER|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
223931853|NCT00112359|DRUG|AZLI 75 mg three times a day (TID)|
223931854|NCT00112359|DRUG|Placebo three times a day (TID)|
223931855|NCT05652075|PROCEDURE|pericapsular nerve group and lateral femoral cutaneous nerve block|Will undergo pericapsular nerve group block (PENG) combined with lateral femoral cutaneous nerve under ultrasound guided block with 20 mL of 0.25% bupivacaine.
223931856|NCT05652075|PROCEDURE|lumbar plexus block|Will undergo Lumbar plexus block (LPB) under ultrasound guided block with 20 mL of 0.25 % bupivacaine.
223533415|NCT04717401|PROCEDURE|Muscle Energy Technique|Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
223533416|NCT00002487|DRUG|dipyridamole|
223533417|NCT00002487|DRUG|methotrexate|
223931857|NCT00623194|DRUG|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
223931858|NCT00623194|DRUG|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
223931859|NCT02576275|DRUG|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
224284746|NCT04052698|DRUG|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
224284747|NCT02500615|OTHER|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
224284748|NCT05194449|OTHER|Comfort Talk® App|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
224284749|NCT05194449|OTHER|Placebo App|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
224284750|NCT04292366|PROCEDURE|Invitation procedure|Optimised invitation procedures in an organised colorectal cancer screening programme
223533418|NCT05613231|BEHAVIORAL|Aerobic plus muscle-strengthening physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting both aerobic and muscle-strengthening physical activity for Latina women.
223533419|NCT05613231|BEHAVIORAL|Original physical activity intervention|The intervention is a 12-week Spanish language, Internet-based intervention promoting aerobic physical activity for Latina women.
223718331|NCT03517098|PROCEDURE|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
223931860|NCT02576275|DRUG|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
223931861|NCT02576275|DRUG|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
223931862|NCT02576275|DRUG|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
223931863|NCT06798545|DEVICE|endoscopic ultrasound with navigation system|Use of the EZ-EUS navigation system during the procedure
223931864|NCT01467128|OTHER|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
223931865|NCT01467128|OTHER|No Intervention|Normal hospital pharmaceutical care
223931866|NCT02530190|DEVICE|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
223931867|NCT02530190|PROCEDURE|massage|20 minutes of massage to lower extremities
223931868|NCT05985408|DEVICE|left ventricular septal pacing|For left bundle branch pacing (LBBP) failure cases, use left ventricular septal pacing instead of LBBP; others were same as traditional CRT.
223931869|NCT05985408|DEVICE|right ventricular apical pacing|For left bundle branch pacing (LBBP) failure cases, use right ventricular apical pacing instead of LBBP; others were same as traditional CRT.
223931870|NCT01988402|DRUG|allopurinol|
223931871|NCT01988402|DRUG|Placebo (sugar pill)|
223931872|NCT01961609|BIOLOGICAL|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
223533420|NCT05478317|PROCEDURE|ECL- mPZ|"Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin."
223931873|NCT05566444|DEVICE|Heat stimulus|Contact heat pain stimulus with a termode set at 46 degrees and contact warm stimulus with a termode set at 40 degrees
223931874|NCT05430087|DRUG|Observe the clinical outcome and inflammatory cytokines levels in patients with systemic lupus erythematosus (SLE) after being supplemented with Cholecalciferol (Vitamin D3) and Curcumin-Piperine.|All patients and physicians were blinded to group assignment and treatment allocation. All subjects received the tablets for three months. All subjects were still required to consume their routine medications during the supplementation according to the disease activity. Patients were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters. Adherence to therapy was assessed by monthly pill counts of returned tablets and biweekly phone calls to the patients.
223931875|NCT03197649|PROCEDURE|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
223533421|NCT05478317|PROCEDURE|ECL-OF|"Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured."
223533422|NCT06545032|PROCEDURE|lumbar fusion|Minimal Invasive Transforaminal Lumbar Interbody Fusion
223931876|NCT02043041|OTHER|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
223718332|NCT00501670|PROCEDURE|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
223718333|NCT00501670|PROCEDURE|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
223718334|NCT06247020|DIETARY_SUPPLEMENT|Supplementation with sodium- butyrrate|Oral supplementation with sodium butyrrate capsules
223931877|NCT01970553|DRUG|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
223931878|NCT01970553|DRUG|Gemcitabine|1000 mg vial, powder for injectable solution
223931879|NCT01357512|DEVICE|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
223931880|NCT05325541|DEVICE|Visual Biofeedback Therapy|Visual Biofeedback intervention will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
223931881|NCT05325541|BEHAVIORAL|Conventional Balance exercise|Conventional Balance exercises will be given for 24 sessions, comprising of 45-50 minutes, 3 times/week for the duration of 8 weeks.
224096286|NCT05968209|DIETARY_SUPPLEMENT|Lab4P|Multi-strain Probiotic Product: Lactobacillus acidophilus CUL-60, Lactobacillus acidophilus CUL-21, Lactobacillus plantarum CUL-66, Bifidobacterium bifidum CUL-20, Bifidobacterium animalis subsp lactis CUL-34 (total 50 billion bacteria), Vitamin D (400 IU), Vitamin C (80 mg) \& Zinc (10 mg)
224096287|NCT07105774|BEHAVIORAL|stress inoculation training program|The intervention group received the SIT program for 12 weeks. From 1st-2nd weeks, participants were admitted to an online training group set up via DingTalk, attending an offline stress reduction workshop were grouped into groups of 5-6, with games and small activities to promote group bonding. Psychiatric-psychological nurse specialist introduced the participants to the concept of SIT, the curriculum, and asked them to describe their initial knowledge and understanding of SIT. In addition, through cognitive restructuring training, the participants were made to review their work experience, understand the work stress and psychological pain they faced, and correctly recognize the role of cognition and emotion in causing and maintaining stress. From 3rd-6th weeks, participants were portrayed and discussed through videos and images, exploring personal, organizational and environmental stressors for new psychiatric nurses. Psychiatrists led relaxation exercises (e.g. positive thinking, med
224096288|NCT07105774|BEHAVIORAL|routine training|"The control group received training in accordance with the New Entry Nurse Training Syllabus (Trial), which included routine theoretical knowledge training and clinical practice training."
224096289|NCT07107022|DEVICE|Penumbra System ®|Neurovacular Mechanical Thrombectomy with the Penumbra System®
224096290|NCT07106996|DRUG|red yeast rice，RYR|Participants will take 6 grams of red yeast rice daily for 6 months.
224096291|NCT07105618|DRUG|Dexmedetomidine|Dexmedetomidine as an adjunct to total intravenous anesthesia.
224096292|NCT07105618|DRUG|Fentanyl|Fentanyl as an adjunct to total intravenous anesthesia.
224096293|NCT07105618|DRUG|Magnesium|Magnesium sulphate as an adjunct to total intravenous anesthesia.
224096294|NCT06914856|BEHAVIORAL|Financial Capability Support with Peer Support Services|The participants in this arm will receive one-on-one financial coaching, which entails monthly or more frequent meetings with a financial coach. Participants will also receive access to safe and affordable financial services, which includes support with managing any existing bank accounts, or supporting a person to open a new overdraft-free account. Coaches can also help people to access other financial products such as free tax preparation (VITA), credit builder loans, online bank accounts, or other products recommended by our Justice Tech partner. The participants will also receive will receive the additional services of one-on-one peer support provided by a trained Recovery Support Specialist. Recovery Support Specialist, also referred to as Wellness coaches, will provide weekly meetings (30-60 minutes in duration) to the participants.
224096295|NCT06111209|DRUG|Testosterone cypionate|weekly by intramuscular injection
224096296|NCT06111209|DRUG|Placebo|weekly by intramuscular injection
224096297|NCT03404362|PROCEDURE|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
224096298|NCT05060861|OTHER|ChAdOx1 nCoV-19 vaccine|covid-19 vaccine
224284751|NCT05497141|DEVICE|Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System|Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
224284752|NCT04731584|BIOLOGICAL|Blood sample|Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke
224284753|NCT03973099|DIETARY_SUPPLEMENT|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
224284754|NCT02900482|OTHER|Sampling saliva|
224284755|NCT06152705|DEVICE|repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Typical treatments involve 30 to 45 minutes daily sessions delivered over 4 to 6 weeks. Recent technical advances allowed the development of theta burst stimulation (TBS), a novel rTMS paradigm that reduces daily sessions to 3 to 4 minutes while maintaining the same clinical efficacy. This study will specifically be administering intermittent TBS (iTBS), which is a novel refinement of conventional rTMS and consists of bursts of 3 stimulations at 50 Hz at theta frequency (5 Hz).
224284756|NCT02521753|DRUG|Metformin|Intervention also includes weight reduction diet and exercise therapy
224284757|NCT02521753|DIETARY_SUPPLEMENT|Magnesium|Intervention also includes weight reduction diet and exercise therapy
224284758|NCT02521753|DIETARY_SUPPLEMENT|PUFA|Intervention also includes weight reduction diet and exercise therapy
224284759|NCT06902168|OTHER|Intensive swimming program|The participants will be enrolled in an intensive swimming program for 8 weeks (45 minutes) in the swimming pool. The swimming program will be to improve safety and functional independence in the water. The hydrotherapy will be performed at a swimming pool temperature suitable for the weather temperature.
223931882|NCT03117582|OTHER|Stool specimen|"The following stool specimen will be collected for this study:~1. 4, 3mL stool specimen from patient~2. 1, 25mL stool aliquot from donor"
223718335|NCT06247020|DIETARY_SUPPLEMENT|Placebo|Oral supplementation with placebo capsules
223931883|NCT05246943|DIAGNOSTIC_TEST|D-dimer and lower limb venous duplex|D-dimer blood test- The D-dimer assay detects the presence of fibrin degradation products, which can indicate the breakdown of a fibrin clot Lower Limb Venous Duplex- Using an ultrasound to visually look for a clot
223931884|NCT05605925|DRUG|Artemether/lumefantrine|4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
224096299|NCT00643539|DRUG|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
224096300|NCT00643539|DRUG|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
224096301|NCT00745030|DRUG|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
224096302|NCT00745030|DRUG|Placebo|Placebo 8 mg tablets
224096303|NCT02759822|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
224096304|NCT03018015|DRUG|Ibuprofen 400 mg oral powder|
223718336|NCT00552721|OTHER|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
223718337|NCT00552721|OTHER|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
223718338|NCT04678271|BEHAVIORAL|AFIX-OB Quality Improvement Package|Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
224096305|NCT03018015|DRUG|Ibuprofen 400 mg film-coated tablet|
224096306|NCT03018015|DRUG|Ibuprofen 400 mg soft capsule|
224096307|NCT01024244|DRUG|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
224096308|NCT01024244|DRUG|LY2599506|Administered po for 12 weeks
224096309|NCT02981212|DRUG|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
224096310|NCT02981212|DRUG|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
224096311|NCT02981212|DRUG|Corticosteroid|combination with Mycophenolate Mofetil
224096312|NCT02981212|DRUG|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
224096313|NCT00539344|DRUG|ANG1005|IV infusion once every 21 days
224096314|NCT03120910|DEVICE|Pulse CO-Oximeter Sensor|Investigational Pulse Oximeter Sensor will measure hemoglobin (SpHb), pulse rate (PR), perfusion index (PI), pleth variability index (PVI), oxygen reserve index (ORI), etc.
224096315|NCT01753492|DEVICE|Ologen|
224096316|NCT03328039|DEVICE|Garmin wearable device|Physiological data capture only
223931885|NCT05605925|DRUG|Ivermectin|IVN 600 mcg/kg/day for 3 days
223931886|NCT04491201|OTHER|Customized questionnaire|A customized questionnaire will be delivered by the social software WeChat to the specific hospital which has been randomly sampled, and all physicians of Obstetrics and Gynecology in this hospital will fill the questionnaire anonymously.
224096317|NCT01232946|DRUG|liraglutide|1.8mg subcutaneous qd for 3 months
224096318|NCT01232946|DRUG|insulin detemir|5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months
224096319|NCT01232946|DRUG|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.
224096320|NCT06512402|DRUG|Norepinephrine|patients will receive norepinephrine infusion at rate of 0.05 mcg/Kg/min
224096321|NCT06512402|DRUG|Epinephrine|patients will receive epinephrine infusion dose of 0.03 mcg/Kg/min
224096322|NCT01526226|DEVICE|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
224096323|NCT01526226|DEVICE|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
224096324|NCT02748369|DRUG|Somatostatin|Somatostatin infusion to create a low insulin state.
224096325|NCT02748369|DRUG|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
224096326|NCT05675709|BEHAVIORAL|Training and Education|Undergo group trainings
224096327|NCT04886414|OTHER|Phone-based monitoring|Study staff will perform daily phone-based assessments using standardized electronic study tools (tablets). Clinical features will be documented on a phone-based patient monitoring form.
224096328|NCT04886414|OTHER|Oxygen saturation monitoring|Oxygen saturation will be monitored and recorded at regular intervals.
224096329|NCT04886414|OTHER|Alcohol-based hand sanitizer|Alcohol-based hand sanitizer will be distributed to subjects.
224096330|NCT00852644|PROCEDURE|computed tomography|Standard CT scans
224096331|NCT00852644|RADIATION|fludeoxyglucose F 18|standard doses with CT scans
224096332|NCT00852644|RADIATION|hypofractionated radiation therapy|4 doses over 2 weeks
224096333|NCT00852644|RADIATION|stereotactic radiosurgery|CyberKnife radiosurgery
224096334|NCT00006418|PROCEDURE|DNA collection|
224096335|NCT03237676|OTHER|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
224096336|NCT03237676|OTHER|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
223718339|NCT03947372|PROCEDURE|Appendectomy|removal of acutely inflamed appendix
224284760|NCT05264831|PROCEDURE|Pulmonary Vein Isolation (PVI) alone|PVI procedures correspond to point-by-point 50W AI-guided RF applications (400 posterior LA wall, and 550 elsewhere). The PVI will be validated by the absence of any activity recorded inside the PV encirclement by a multipolar catheter (either a Lasso catheter or a Pentaray catheter) (entrance block) and by the non-capture of the LA despite pacing maneuvers from inside the encirclement (exit block). The bidirectional block will be validated again after a 15-minutes waiting period.
224284761|NCT05264831|PROCEDURE|PVI procedure associated with substrate modulation|PVI procedure associated with substrate modulation
224284762|NCT06904560|OTHER|phacoemulsification|one group with BSS at room temperature and the other group with cold BSS
224284763|NCT06904573|DRUG|Probiotics Compound (Biolosion)|15g, PO, qd
224284764|NCT06904573|DRUG|Nab-paclitaxel|230mg/m2, IV, days 1, 8, q3w
224284765|NCT06904573|DRUG|Cisplatin|70mg/m2, IV, days 1-3, q3w
224284766|NCT06904573|DRUG|Gemcitabine|1.2g/m2, IV, days 1, 8, q3w
224284767|NCT06904573|DRUG|Disitamab vedotin|2.5mg/kg, IV, q2w
224284768|NCT06904573|DRUG|Enfortumab Vedotin|1.25mg/kg, IV, days 1, 8, q3w
224284769|NCT06904573|DRUG|Pembrolizumab|200mg, IV, q3w
224284770|NCT06904573|DRUG|Toripalimab|240mg, IV, q3w
224284771|NCT06904144|BEHAVIORAL|Health Coaching|12 virtual health coaching sessions will be provided over a 16 week period by a certified health coach.
224284772|NCT06904716|OTHER|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation
224284773|NCT06904768|DEVICE|Shoulder Sling|Use of a shoulder sling (Reh4mat AM-SOB) on the affected upper limb during mobility and balance testing.
224284774|NCT06904768|OTHER|No Sling|Functional mobility tests performed without the use of any assistive shoulder device.
224284775|NCT06905769|COMBINATION_PRODUCT|Aquatic Therapy|Group A was treated with Aquatic Therapy for 30-45 minutes for 3 sessions per week for 8 weeks . Patient should Seated .Therapist will standing or seated beside the patient Therapist Perform gentle stretching on wrist, hand, and finger joints. Exercises to improve range of motion and reduce stiffness. Then perform aquatic therapy for 10 minutes. Therapist instruct patients hands in bath tube. Water temperature 88°F - 94°F (31°C - 34°C).Water depth is Waist-deep or deeper depending on patient comfort
224284776|NCT06905769|DIAGNOSTIC_TEST|Neuro-Dynamic Technique|Group B (Neuro-Dynamic Technique) Group B was treated with Neuro-Dynamic Technique for 15 minutes 3 sessions per week for 8 weeks. Patient should Seated or supine with the affected hand relaxed. Therapist will standing or seated beside the patient. Techniques Time duration is 3 minutes for each technique. wrist distraction 3 sets for 3 minute rhythmic and gentle stretching of the transverse carpel ligament Release of palmar fascia gliding of finger flexor tendons release of upper forearm muscle and fascia.
224284777|NCT06905301|DRUG|Ribociclib|CDK4/6 inhibitor
224284778|NCT06905301|DRUG|Letrozole|Aromatase inhibitor
224284779|NCT06905301|DRUG|Anastrozole|Aromatase inhibitor
224284780|NCT06904092|DEVICE|Transcranial ultrasound stimulation|The TUS was administered using Transcranial Ultrasound Stimulator UNS-III (model UNS-III), which has passed the safety test for medical electrical equipment (GB9706.1-2007). Transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
223718340|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
224284781|NCT06904950|BEHAVIORAL|Nightmare Deconstruction and Reprocessing|Eight-sessions that include 1 session of psychoeducation and treatment orientation and 7 sessions of NDR. NDR consists of three stages: (1) nightmare image deconstruction, (2) meaning making and reprocessing of cognition and emotions related to images, (3) rescripting new dream images and rehearsal of new images.
224284782|NCT06905808|DEVICE|eSense 7Fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted into the body to measure pressure for urodynamics.
223718341|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
223718342|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
223718343|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
224284783|NCT06905236|BEHAVIORAL|walking intervention|Moderate intensity intermittent walking training for a period of 10 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is four times a week.
224284784|NCT06904014|PROCEDURE|HAIC|FOLFOX-hepatic artery infusion
224284785|NCT06904014|DRUG|Sintilimab|200mg, ivgtt, D1, Q3W
224284786|NCT06904014|DRUG|Lenvatinib|8 mg，qd，D1-D21,Q3W
223718344|NCT00599924|DRUG|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
223718345|NCT00599924|DRUG|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
224284787|NCT06904014|PROCEDURE|surgery|surgery
224284788|NCT06905106|BIOLOGICAL|Collection of tube bottoms from blood samples taken in the clinic|Collection of tube bottoms from blood samples taken in the clinic
224284789|NCT06905145|OTHER|Biomarkers evaluation|Evaluate the prognostic role of the markers TP53, P16, Cyclin D1, EGFR, Akt, PDL-1, ERCC1 examined on biopsy samples.
224284790|NCT03757091|DEVICE|Laryngoscopy|Undergo video laryngoscopy
223931887|NCT01211184|DIETARY_SUPPLEMENT|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
223931888|NCT01211184|DIETARY_SUPPLEMENT|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
223931889|NCT01211184|BEHAVIORAL|Fasting.|The patient is fasting from midnight before the surgery.
223931890|NCT04291027|OTHER|Land Based Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
223931891|NCT04291027|OTHER|Aquatic Exercise|Group exercise intervention will be held 2 times per week for 12 weeks and will include balance training, strengthening, gait training, and cardiovascular training.
223931892|NCT06150833|BIOLOGICAL|Boya IVIG|"The initial dose and other dose changes will be determined by the investigator on a case-by-case basis aiming to prevent infection and minimum serum IgG levels of 5 g/L. The total number of doses administered will depend on the treatment regimen and run-in period:~* Between 16 and 20 intravenous injections for participants receiving infusions every 28 days, or;~* Between 21 and 25 intravenous injections for participants receiving infusions every 21 days"
223931893|NCT05283408|DRUG|Dexmedetomidine infusion|Patients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
223931894|NCT05283408|DRUG|Co-administration dexmedetomidine and low-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
223931895|NCT05283408|DRUG|Co-administration dexmedetomidine and high-dose esketamine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
223931896|NCT04060212|OTHER|Tuna fish|Six meals of tunafish (\~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
223931897|NCT04060212|DIETARY_SUPPLEMENT|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
223931898|NCT02192242|OTHER|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
223931899|NCT03617315|DRUG|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
223931900|NCT01009424|DRUG|R7103|escalating inhaled dose
223931901|NCT06572839|OTHER|Amnio-Maxx|Amnio-Maxx Dual Layer Amnion Patch is processed using aseptic techniques, treated with a saline solution and dehydrated.
224096337|NCT02281812|PROCEDURE|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
224096338|NCT03455387|DIAGNOSTIC_TEST|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
223931902|NCT00789542|DEVICE|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
224284791|NCT03757091|PROCEDURE|Tracheal Intubation|Undergo flexible scope intubation
224284792|NCT06903806|OTHER|Treadmill Exercise|Participants perform moderate to strenuous exercise for up to 20 minutes on a treadmill after swallowing a microbiome sampling capsule.
224284793|NCT06903806|DEVICE|Cooling Gloves|Cooling gloves to prevent rise in core body temperature during exercise
224284794|NCT06903806|DEVICE|Microbiome Capsule|Capsule used for collecting intestinal tract contents
223931903|NCT00789542|OTHER|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
223931904|NCT02238769|DEVICE|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
223931905|NCT03500549|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
223931906|NCT03500549|DRUG|Soliris|Complement (C5) Inhibitor
223931907|NCT04522570|DEVICE|Laser ablation|Single session with Diode laser ablation system; one or two applicators will be used for treatments; one to three illuminations; fixed output power of 3 watts (W); pullback technique; delivered energy: 1200-1800 Joules (J) varying according to tumor volume; treatment under local anesthesia +- conscious or moderate sedation;
223931908|NCT04522570|DEVICE|Cryoablation|Single session with Argon-based cryoablation system; one 17 Gauge (G) V-probe applicator will be used for treatments; fixed gas delivery of 100%; treatment under local anesthesia +- conscious or moderate sedation;
223931909|NCT04522570|DEVICE|Radiofrequency ablation|Single session with radiofrequency generator; one 17 Gauge (G) V-tip applicator with a 1 to 4cm active tip; moving-shot technique or multiple overlapping shot technique with 60 Watts (W) output power; treatment under local anesthesia +- conscious or moderate sedation;
223931910|NCT02371512|DEVICE|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
224096339|NCT05526560|DEVICE|MITRIS RESILIA Mitral Valve, Model 11400M|Replacement of mitral valve with MITRIS RESLIA Mitral Valve
224284795|NCT06905743|DIAGNOSTIC_TEST|Isometric Contraction-Based Pain Modulation Protocol for Achilles Tendinopathy|The standard recommendation for tendinopathy rehab became 30 to 45 second heavy isometric contractions repeated for 3 to 5 repetitions
224284796|NCT06905743|COMBINATION_PRODUCT|Eccentric Strengthening (Alfredson's Protocol for Achilles Tendinopathy )|The eccentric loading protocol, popularized by the research of Alfredson, consisted of 3 sets of 15 for both bent knee and straight knee heel raises with each heel lowering lasting 3-seconds
224284797|NCT05828303|DRUG|TPX-0005|Oral TPX-0005 capsules
224284798|NCT05828303|DRUG|Metformin Hydrochloride|oral solution
223533423|NCT06650410|OTHER|Virtual Intervention for Vertebral Fractures (VIVA)|VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. An exercise professional leads 1:1 once-weekly sessions (in person or virtual) over eight weeks. Sessions start with brief education on a topic, followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. The exercise professional prescribes resources using an app or that can be emailed or mailed. Exercises are tailored to the participant's abilities, and target balance, muscle strength, and endurance of back extensor muscles and scapular stabilizers.
223533424|NCT00743470|DRUG|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
223533425|NCT00743470|DRUG|rifabutin|rifabutin capsule; see arms for intervention description
223533426|NCT02720458|OTHER|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
223718346|NCT00599924|DRUG|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
223718347|NCT01806298|DRUG|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
223931911|NCT02371512|PROCEDURE|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
223931912|NCT00404742|DRUG|Placebo|PO BID
223931913|NCT00404742|DRUG|LX211|0.2 mg/kg, twice a day (BID)
223931914|NCT00404742|DRUG|LX211|0.4 mg/kg, twice a day (BID)
223931915|NCT00404742|DRUG|LX211|0.6 mg/kg, twice a day (BID)
223931916|NCT04888104|PROCEDURE|Index or revision spine surgery for complex adult spinal deformity|Adult patients receiving minimum 5 level posterior spinal fusion with pedicle screw fixation supplemented at the proximal aspect of the construct with the VersaTie System.
223931917|NCT02961868|OTHER|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
223931918|NCT02961868|GENETIC|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
223931919|NCT02961868|OTHER|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
223931920|NCT02961868|OTHER|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
223931921|NCT02107261|DRUG|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
224284799|NCT05828303|DRUG|Digoxin|oral tablet
224284800|NCT05828303|DRUG|Rosuvastatin Calcium|oral tablet
224284801|NCT06904040|BIOLOGICAL|CM313 injection|600 mg (4 mL per vial), administer once at Week 0, 1, and 2, and then every 6 months thereafter or determined based on clinical assessment
224284802|NCT06904040|BIOLOGICAL|glucocorticoids|Administer medium- or long-acting glucocorticoids 1-3 hours before injection
224284803|NCT06905795|DIAGNOSTIC_TEST|Fibroscan test|Perform Fibroscan testing on the study subjects every six months.
224284804|NCT06905795|BEHAVIORAL|Nutrition guidance|Each family will be matched with a nutritionist, who will provide daily online dietary guidance for parents and students during the first 21 days, followed by weekly sessions thereafter.
224284805|NCT06905795|BEHAVIORAL|Increase physical activity|Increase physical activity time in and out of school by professional sports trainer.
224284806|NCT06905795|OTHER|Health education|Knowledge of healthy lifestyle will be delivered in various forms such as health lectures, brochures, posters, etc.
223931922|NCT02107261|DRUG|Placebo|matching placebo
223931923|NCT02137616|DRUG|risperidone|Risperdal tablets
223931924|NCT02137616|DRUG|olanzapine|olanzapine tablets
223931925|NCT02137616|DRUG|Quetiapine|quetiapine tablets
223931926|NCT02137616|DRUG|Aripiprazole|Aripiprazole tablets
223931927|NCT05297214|DIAGNOSTIC_TEST|serum creatinine and Other investigations will be done according to the case|following up AKI patients with serum creatinine,Urine out put, CBC,Serum electrolytes,renal functin test,Liver function test,urine analysisand specific investigations according to case
224284807|NCT03769831|DRUG|SHR2285|Ascending dose oral adminstration
224284808|NCT03769831|DRUG|Placebo|Ascending dose oral adminstration
224284809|NCT00924586|DRUG|ONO-1101|Placebo for one minute IV
224284810|NCT00924586|DRUG|ONO-1101|0.125 mg/kg for one minute IV
224284811|NCT02435316|OTHER|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
224284812|NCT02435316|OTHER|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
224284813|NCT06611150|DRUG|Nab-paclitaxel|All participants enrolled in the study will be treated with nab-paclitaxel during radical radiotherapy following induction chemotherapy. The doses are increased progressively (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²).
223931928|NCT06140732|DRUG|camrelizumab and apatinib|camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd
223931929|NCT01511159|DRUG|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
223931930|NCT01511159|DRUG|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
223931931|NCT01511159|DRUG|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
223931932|NCT01511159|DRUG|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
223931933|NCT01511159|DRUG|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
223931934|NCT01511159|DRUG|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
224284814|NCT04014582|BEHAVIORAL|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages-one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
224284815|NCT04014582|BEHAVIORAL|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
224284816|NCT04750668|OTHER|Multisensory Balance Training|Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
224284817|NCT04034355|DRUG|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a solution in 20 mL single dose glass vials.
224284818|NCT04034355|OTHER|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a solution in 20 mL single dose glass vials.
224284819|NCT03182751|DRUG|Tranexamic Acid (TXA)|Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
224284820|NCT03182751|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
224284821|NCT06508840|OTHER|Verbal Health Literacy training session|"Five respiratory physiotherapists and half (6/12) weight management programme advisors, will receive a two hour Verbal Health Literacy training session. The training session will focus on three techniques: simple language, 'Teachback' and 'Chunk and check'. They will also receive implementation support from a Health Literacy Officer.~All pulmonary rehab patients will attend programmes run by physiotherapists trained in Verbal Health Literacy techniques.~Weight management programme service users will attend programmes run by trained and untrained staff."
224284822|NCT06471595|BEHAVIORAL|Partnership for Improving Lifestyle Intervention (PILI) Lifestyle Program + Social Determinants of Health (SDOH) Component|The PILI Lifestyle Program (PLP) is an adapted 3-month behavioral lifestyle intervention focused on addressing and initiating weight loss in Native Hawaiians and Pacific Islanders (NHPIs). The PLP covers 8 lessons that offer empirically supported strategies (e.g., plate method, stimulus control) based on the social cognitive theory to improve healthy eating, physical activity, and time and stress management across the 3 months. In this study, the PLP will be enhanced with social determinants of health (SDOH) components that address challenges such as access to healthy foods, housing, and employment issues. There will be 4 SDOH activities relevant to participants' needs and lives. These activities will be delivered during the 3-month PLP.
224284823|NCT06380374|OTHER|Gamification in Disaster Nursing Education|The contact information of the students who meet the inclusion criteria will be collected by the researchers. The topic of disaster nursing will be explained to all students enrolled in the course by the researcher in the classroom environment. Pre-tests will be taken from students attending the course on disaster nursing. Randomization will be carried out by the researcher, who does not have an active role in the research process. Students in the experimental and control groups will be hidden from the researchers, who will conduct the application until it begins. The Program will be carried out face-to-face. Students in the experimental group will be on the playground. Students will attend the sessions in groups of 6. Each student will compete independently within the group, and each group will have a winner. Students will encounter a total of 30 questions in each game round. The entire game process consists of 7 sessions. After the game process is completed, post-tests will be taken.
224284824|NCT06322966|OTHER|Air Action Curriculum|"The goal of integrating a new curriculum into classrooms is to improve student knowledge on the health effects of air pollution, specifically of wildfire smoke.~The goal is to implement a student-designed and student-driven air quality study in each school that will lead to improved air quality and health impacts in schools, promote health equity, and train young people to be more informed about their health and proactive citizens in their school community and beyond."
224284825|NCT05565105|RADIATION|Total Body Irradiation (TBI)|Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.
224284826|NCT05565105|DRUG|Thiotepa|Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
224284827|NCT05565105|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
224284828|NCT05565105|DRUG|Busulfan|Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
224284829|NCT05565105|DRUG|Melphalan|Melphalan: 70 mg/m\^2/day x 2
224284830|NCT05565105|DRUG|Fludarabine|Fludarabine: 25 mg/m\^2/day x 5
223931935|NCT01511159|DRUG|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
223931936|NCT00111683|DRUG|MK0457|
223931937|NCT03468634|DIAGNOSTIC_TEST|endoscopy|Oesophageal endoscopy with biopsy
223931938|NCT05443945|DEVICE|Nasal Spray|3 sprays in each nostril 3 times per day
223533427|NCT02720458|BEHAVIORAL|Short-term simple self-help program|"The short-term simple self-help program consists in:~* Restriction of time in bed~* Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
223533428|NCT06989580|DEVICE|BIOMONITOR IV with study software|Participants are inserted with a BIOMONITOR IV which is then turned into the investigational device by replacing the firmware with the study software.
223533429|NCT07002957|OTHER|Spiritual Music Therapy|In the first session of the spiritual music therapy application, information was given about music, music therapy and its history, and information was given about the Turkish Music makam structure and makam differences and the traces these makams leave on the person's body and soul. In addition, the technique of receiving and giving sound was taught. In the next five sessions, Rast, Uşşak, Segâh, Hüseyni and Hicaz makams were listened to, accompanied by the sound of kanun and water. Information was given about the musical and therapeutic status of the makams, 3 works related to the relevant makam were taught, performed and information was given about the spiritual messages of the piece, its composer and lyricist. At the same time, rhythm studies were done with the bendir to accompany the relevant makam. At the end of each session, the makam of the day was listened to, accompanied by the sound of kanun and water.
223533430|NCT07004257|DIETARY_SUPPLEMENT|tributyrin|tributyrin (875 mg, BID)
223718348|NCT03588039|DRUG|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
223718349|NCT03588039|BIOLOGICAL|Pembrolizumab|Intravenously administered
223718350|NCT05581420|DRUG|Ferrous fumarate|Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
223931939|NCT03611088|OTHER|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
223931940|NCT04066075|BEHAVIORAL|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
223931941|NCT00309166|BIOLOGICAL|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
224284831|NCT04974736|BEHAVIORAL|iEHR + Navigator|"The iEHR + Navigator intervention consists of an iEHR part of the intervention in the pediatric primary care setting which will include routine screening of families for tobacco use and treatment delivery to parents who smoke and will be linked to the child's electronic health record.~The enrolled parents will also be offered support from Community Health Navigators, who will work with offices to provide customized cessation support to tobacco users, ensuring access to medications and services."
223931942|NCT00309166|BIOLOGICAL|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
224284832|NCT03581188|DEVICE|Patient-led surveillance|Usual care plus reminders, ASICA instructional videos, a mobile dermatoscope, an app that facilitates store-and-forward teledermatology, and fast-tracked unscheduled clinic visits.
223931943|NCT06819449|DRUG|Dapsone|To evaluate the effect of the multi drug therapy in leprotic patients and their side effects and to assess the role of Rab 32 gene in leprosy prognosis and to know its association with the multi drug therapy.
223931944|NCT06306924|RADIATION|Radiation therapy|Subjects with metastatic cancer receive radiation therapy.
223931945|NCT05966064|DRUG|Denosumab 120 Mg/1.7 Ml Inj|Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
223931946|NCT05966064|DRUG|Placebo|placebo randomized at baseline and after 3 months
224284833|NCT03581188|BEHAVIORAL|Clinician-led surveillance|Usual care (scheduled clinician visits)
224284834|NCT04757181|OTHER|The IBD-AID|Subjects will meet with study personnel for to fill out baseline questionnaires (approximately a 1-hour visit). Subjects will be instructed to make dietary changes based one the IBD-AID guidelines. Dietary instruction will be delivered via individual and group sessions led by trained study personnel. Participants will be expected to learn the skills of dietary change to the IBD-AID and will begin their 8 weeks compliance period followed by endpoint measures. Participants are encouraged to attend 3 cooking classes (1.5 hours duration) in our teaching kitchen.
224284835|NCT03354455|DEVICE|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
224284836|NCT05752708|DIAGNOSTIC_TEST|Diagnostic Test|Evaluation of perioperative anxiety in parents of children undergoing thoracic surgery using standardized tests: The Amsterdam Preoperative Anxiety and Information Scale (APAIS), the State-Trait Anxiety Inventory (STAI).
224284842|NCT05028062|DRUG|XR-NTX 380 mg, intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
224284843|NCT05028062|BEHAVIORAL|Medical Management|All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
224284844|NCT05028062|DRUG|Placebo intramuscular injection|Two doses of XR-NTX 380 mg, intramuscular injection.
224284845|NCT03535857|DEVICE|PTNS|Use of PTNS on the ankle for 30 minutes
223533431|NCT07003126|BEHAVIORAL|Circadian Rhythm Intervention Combined with Bladder Training|Participants diagnosed with primary nocturnal enuresis will be screened at Shanghai Children's Medical Center, and eligible patients will be enrolled. Participants will be randomly assigned to the Bladder Training Combined with Circadian Rhythm Intervention Group, which will receive a 6-month integrated protocol encompassing bladder training and circadian rhythm intervention. The bladder training component includes fluid intake restriction, micturition desire-relaxation training, and sphincter control training. Circadian rhythm interventions involve sleep hygiene education, chronotype-guided bedtime scheduling, and morning bright light therapy.
223931947|NCT06698978|OTHER|Simplified protocol (PS)/Conventional protocol (PC)|Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).
223931948|NCT06698978|OTHER|Conventional protocol (PC)/Simplified protocol (PS)|Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS)in period 2 (3 months).
223931949|NCT06888531|COMBINATION_PRODUCT|Neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors for the treatment of locally advanced resectable esophageal squamous cell carcinoma|Toripalimab: intravenous infusion, 240mg, D1, Q3W, for 2 consecutive doses; or Envorimab: subcutaneous injection, 400mg, D1, Q3W, for 2 consecutive doses. Albumin-bound paclitaxel: intravenous infusion, 50mg/m2, D1, QW, for 5 consecutive doses. Carboplatin: intravenous infusion, AUC=2, D1, QW, for 5 consecutive doses. Radiotherapy: 41.4Gy/1.8Gy/23F, D1-5, 5 times per week.
223931950|NCT06893601|DRUG|Parasternal block|A block containing 0.9% NaCl solution was applied to the Saline group just before the sternum was closed by the surgeon, while a bilateral parasternal block using 0.25% bupivacaine was applied to the bupivacaine group. The solutions used for the parasternal block were colorless and indistinguishable to ensure blinding.
224096340|NCT02433509|OTHER|hUCB|"1. The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million \~ 500 million will used.~2. 20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
224096341|NCT02146781|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
224096342|NCT02146781|OTHER|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
224096343|NCT03038724|DIAGNOSTIC_TEST|Rapid HIV test|
224096344|NCT04645797|DRUG|APR003|This portion of the study further explores the clinical activity, safety, pharmacokinetics and pharmacology of APR003 monotherapy at the RP2D and to assess the antitumor activity of APR003 in subjects with unresectable CRC with liver metastases.
224096345|NCT06324149|DIAGNOSTIC_TEST|completion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis|The sub-investigator performs a multidimentional geriatric evaluation
224096346|NCT03975998|PROCEDURE|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
224096347|NCT05904392|OTHER|Music|Music played prior to injection
224096348|NCT03424109|BEHAVIORAL|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
224284846|NCT05909059|DRUG|Fludarabine|Received IV on Days -5 to -3 before CAR T cell therapy
224284847|NCT05909059|DRUG|Cyclophosphamide|Received IV on Days -5 to -3 before CAR T cell therapy
224096349|NCT03755622|DEVICE|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
224284848|NCT02374203|DIETARY_SUPPLEMENT|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
224284849|NCT03762837|OTHER|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
224284850|NCT02124902|DRUG|Docetaxel|
224284851|NCT02124902|DRUG|Carboplatin|
224284852|NCT02124902|PROCEDURE|FDG-PET/MR|"* Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study"
224284853|NCT06318832|OTHER|ICBT|ICBT: Participants will receive the 10-week tailored ICBT Wellbeing program consists of 1) education about how taking on the role of care-partner can impact emotional and cognitive wellbeing through introduction to the CBT model; 2) structured problem solving; 3) cognitive therapy and thought challenging to manage one's wellbeing and impact of caregiving; 4) building communication and intimacy; 5) physical symptoms of depression (i.e., hypo-arousal), anxiety/anger (i.e., hyper-arousal); practicing behavioural activation and controlled relaxation; 6) overdoing-underdoing cycle of activity levels and issues around the fear avoidance of social, physical, and cognitive activities; practicing activity pacing and gradually tackling avoidance; 7) occurrence of setbacks in thought, physical, behavioural, and cognitive symptoms; signs of setbacks and creating setback plans.
224284854|NCT03164837|DRUG|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
224284855|NCT04769115|DEVICE|Alert for temperature delta|If alert for potential complications refer to appropriate specialist
224096350|NCT03755622|DEVICE|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
224096351|NCT01283256|DRUG|zonisamide|zonisamide 100mg tablets
224284856|NCT02190279|DRUG|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
223931951|NCT06146556|PROCEDURE|catheter based ablation|electrophysiological catheter based ablation of ventricular arrhythmia
224096352|NCT03604731|DEVICE|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
224096353|NCT05206461|OTHER|Trunk Control Measurement Scale|Trunk Control Measurement Scale, easy and simple to use, was used to evaluate trunk control
224096354|NCT03180814|OTHER|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
224096355|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
224096356|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
224284857|NCT02190279|DRUG|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
224284858|NCT02209116|OTHER|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
224284859|NCT02938442|BIOLOGICAL|P10s-PADRE with MONTANIDE™ ISA 51 VG|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
224284860|NCT02938442|DRUG|Doxorubicin|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
224284861|NCT02938442|DRUG|Cyclophosphamide|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
224284862|NCT02938442|DRUG|Paclitaxel|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
224284863|NCT04403399|DRUG|Varenicline|Initial 0.25 mg oral dose of varenicline administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final 0.5 mg BID oral varenicline administered for the remaining 3 weeks.
224284864|NCT04403399|DRUG|Placebo|Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
224284865|NCT02928536|OTHER|no intervention|This is an observational study. No intervention is considered
224284866|NCT03093935|DEVICE|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
224284867|NCT01606228|DRUG|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
224284868|NCT00546910|DRUG|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
224284869|NCT00546910|DRUG|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
224284870|NCT00116493|DIETARY_SUPPLEMENT|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
224284871|NCT00116493|DRUG|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
224284872|NCT00116493|DIETARY_SUPPLEMENT|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
224284873|NCT00116493|DRUG|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
224284874|NCT01974076|DEVICE|Active tDCS + CBT|
224284875|NCT01974076|DEVICE|Sham tDCS + CBT|
224284876|NCT02997137|DIETARY_SUPPLEMENT|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
224284877|NCT02997137|OTHER|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
223931952|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. The 1+1 control group continued to infuse 1g TXA within 8 h.
224284878|NCT06504498|DEVICE|0.5 mm-thick Duran® clear aligner|0.5 mm-thick clear aligner was used for orthodontic treatment.
224284879|NCT06504498|DEVICE|0.75 mm-thick Duran® clear aligner|0.75 mm-thick clear aligner was used for orthodontic treatment.
224284880|NCT04649489|DRUG|Atezolizumab|atezolizumab 1200mg and bevacizumab 15mg/kg
224284881|NCT04649489|PROCEDURE|Surgery|hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
224284882|NCT06617091|DRUG|GRAdHIVNE1 Vaccine|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
224284883|NCT06617091|OTHER|Placebo|This is a dose ranging study that will allow for simultaneous enrollment of participants in both low and high dose groups.
224284884|NCT03407612|DEVICE|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
223931953|NCT06736860|DRUG|Tranexamic acid (TXA) injection|All enrolled patients with acute trauma were given 1 g tranexamic acid (TXA) within 3 h after trauma, which was infused intravenously within 10 min, and randomized into groups. After admission, the first laboratory examination was conducted for both groups. the 1+x study group was subjected to thromboelastography (TEG) without TXA for the time being, and the coagulation and fibrinolytic status of the patients was judged according to the results of TEG (LY30, EPL value), and the patients diagnosed with hyperfibrinolysis continued to be infused with 1g TXA, and the patients diagnosed with normal or reduced fibrinolysis were not infused with TXA. TEG was rechecked after 4 h, and the decision of whether to use TXA was based on the TEG results.
223931954|NCT06738524|BEHAVIORAL|Fighting with Digital Addiction|The purpose of this training is to raise awareness among young people about the signs, causes and consequences of addictive use of technology and how to avoid excessive use of technology and technology addiction.
223931955|NCT06894693|BIOLOGICAL|RS001 injection|CD19-CAR-mbIL15-DNT Cells.
223931956|NCT06837779|DRUG|Fluoride Iontophoresis with Acidulated Phosphate Fluoride|Application of fluoride gel and activated with Iontophoresis electrical pole
223931957|NCT06837779|DRUG|Remineralization with sodium fluoride varnish|CASIN PHOSPHOPEPTIDE AMORPHOUS CALCIUM PHOSPHATE
223931958|NCT06763523|PROCEDURE|arthroereisis of the subtalar joint|arthroereisis alone versus arthroereisis combined with corrective osteotomies
223931959|NCT06767631|DIAGNOSTIC_TEST|threedimensional freehand ultrasound and instrumented spasticity assessment|To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
223931960|NCT05933941|OTHER|Virtual reality|"This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility."
223931961|NCT05933941|OTHER|Exercises|The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
223931962|NCT05301842|DRUG|Tremelimumab|Tremelimumab IV (intravenous)
223931963|NCT05301842|DRUG|Durvalumab|Durvalumab IV (intravenous)
223931964|NCT05301842|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
224096357|NCT00733902|BIOLOGICAL|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
224096358|NCT00733902|BIOLOGICAL|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
224096359|NCT03467620|DRUG|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
223533432|NCT07003126|BEHAVIORAL|Bladder Training (basic treatment for enuresis)|Participants diagnosed with primary nocturnal enuresis will be screened at Shanghai Children's Medical Center, and those meeting eligibility criteria will be enrolled. Participants will be randomized to the Bladder Training Only Group, which will receive a 6-month intervention comprising fluid intake restriction, micturition desire-relaxation training, and sphincter control training.
223718351|NCT05581420|DRUG|MonoFer|Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
223931965|NCT05301842|DRUG|Lenvatinib|Lenvatinib (oral)
223931966|NCT06770374|PROCEDURE|Control group: silicone adhesive sutureless fixation device|"The standard care consists of:~* Application of hemostasis at the point of insertion for 2 minutes post puncture or until bleeding stops.~* Fix with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and silicone adhesive sutureless fixation device (3300MWA Grip-Lok®)."
224096360|NCT03467620|DRUG|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
224096361|NCT02891421|BEHAVIORAL|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
224096362|NCT02891421|OTHER|Standard Care|Standard Care: Participants received standard care
224096363|NCT01938183|PROCEDURE|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
224096364|NCT01938183|DRUG|Metronidazole tablet|750 mg metronidazole tablets
224096365|NCT01938183|DRUG|placebo gel|semi-solid suspension containing carbopol
224096366|NCT01938183|DRUG|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
224096367|NCT03529656|BEHAVIORAL|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
224096368|NCT01477021|DRUG|cyclophosphamide|Given IV
224096369|NCT01477021|BIOLOGICAL|NY-ESO-1-specific T cells|Given IV
223931967|NCT06770374|PROCEDURE|Intervention Group: zinc oxide sutureless fixation device|"Alternative care consisted of:~* Application of haemostasis at the insertion site for 2 minutes post-puncture or until cessation of bleeding.~* Fixation with clear polyurethane dressing (3M®-1655 Tegaderm™ IV), cyanoacrylate glue (SecurePortIV®) and zinc oxide sutureless fixation device (2200NUZA Grip-Lok®)."
223931968|NCT06770374|DEVICE|PICC|"The PICC lines used in the study will all be third-generation polyurethane and of the commercial brands:~* PowerPICC™ 4, 5 and 6 Fr from BD~* Maxflo expert™ 5 and 6 Fr from Vygon"
224096370|NCT01477021|OTHER|laboratory biomarker analysis|Correlative studies
223931969|NCT06770374|DEVICE|Midline|"The midline lines used in the study will be second or third generation polyurethane and of the commercial brands:~* PowerMidline™ 4 Fr from BD~* Arrow® Midline 4Fr from Arrow"
223931970|NCT06770374|OTHER|Ultrasound scanner|All punctures will be performed under ultrasound guidance.
223931971|NCT03222609|DRUG|Ruxolitinib|Tablet; Oral
223931972|NCT03222609|DRUG|Navitoclax|Film-coated tablet; Oral
223931973|NCT06760780|OTHER|Experimental|The experimental group will first be given a theoretical lesson prepared in line with the current literature on osteoporosis. At the end of the lesson, a prepared scenario example on osteoporosis will be covered.
223931974|NCT06760780|OTHER|Control|The control group will only be given a theoretical lesson prepared in line with the current literature on osteoporosis. No other intervention will be made.
223931975|NCT06768567|PROCEDURE|effect of hemostasis time on outcome of partial pulpotomy in teeth with clinical signs indicative of irreversible pulpitis.|After caries removal and pulp exposure pulp tissue is amputated and pulpal wound will be irrigated with 3% NaOCl, and bleeding will be controlled by placing a cotton pellet soaked with 3% NaOCl over the pulpal wound for 2 to 3 minutes and will be repeated if required and time taken to achieve hemostasis will be recorded using stop watch. Teeth in which bleeding will be controlled within 6 mins will be placed in Group A, while those in which it gets controlled between 7 to 12 mins will be included in Group B. Root canal therapy will be initiated in cases in which haemostasis is not achieved even after 12 minutes. Followed by capping with 2-3mm layer of MTA. A layer of RMGIC will be placed over the MTA. Then the tooth will be permanently restored with composite resin.
223931976|NCT06781047|OTHER|Trunk Focused Rehabilitation (TFR)|"Abdominal stabilization progression for TFR is applied with simultaneous breathing exercise for 3 days a week, 45 minutes a day, 8 weeks (24 sessions in total)(8).~1. Basic Abdominal Stabilization Training, Task-Focused Exercises (without spinal diagonal and rotational components)(8,12).~   Warm-up: 5 minutes, Global Stretching and Relaxation(9,10,11). Extremity load, elastic band, and unstable surface are added as stabilization is achieved in neurodevelopmental positions. Task-oriented exercises(12).~   Cooling Down: Warm-up exercises are repeated.~2. General Posture and Asymmetry Training Brochure (includes adolescent, family, and team members)(13-17).~The exercise starts with 3 seconds and gradually progresses to 10 seconds, 10 repetitions, and 3 sets.~The TFR group also receives Conventional Treatment 2 days a week, 40 minutes per day, for 8 weeks. The same treatment protocol is applied as the control group). Routine physiotherapists apply conventional treatment."
224096371|NCT03840629|OTHER|No study intervention.|
224096372|NCT02406664|PROCEDURE|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
224096373|NCT03763786|DRUG|Cetrorelix Acetate|Used a standard
224096374|NCT01162850|DIETARY_SUPPLEMENT|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
224096375|NCT01162850|DIETARY_SUPPLEMENT|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
224096376|NCT00049127|DRUG|Imatinib Mesylate|Given PO
224096377|NCT00049127|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224096378|NCT00049127|OTHER|Pharmacological Study|Optional correlative studies
224096379|NCT00006383|DRUG|liposomal vincristine sulfate|
224096380|NCT00889356|DRUG|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
224096381|NCT00889356|DRUG|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
224096382|NCT01209858|DRUG|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
224096383|NCT01209858|DRUG|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
223931977|NCT06781047|OTHER|Conventional Rehabilitation (CR)|"Conventional treatment is applied to the group, 2 days a week, 40 minutes each session, for 8 weeks. It is an intervention performed by a physiotherapist who regularly follows up in a special education and rehabilitation center.~1. Normal Joint Movement (NEH)~2. Stretching for the lower, and upper extremities and around the hips~3. Lying activities~4. Curl up (assisted, unaided)~5. Bridging exercise, cat camel exercise, posterior pelvic tilt exercise~6. Walking training~7. Climbing and descending stairs~8. Weight transfer exercises at standing, sitting"
223931978|NCT06820372|OTHER|Electronic Drug Dosing and Decision Support Kidney (eDoseCKD) Tool|Thirty evidence, expert informed and validated computerized drug decision support algorithms of high risk medications will be utilized by community pharmacists for individuals with an eGFR \< 60 ml/min who are on one of the 30 target algorithms. The will be followed up to 3 months to assess effectivess, safety and whether the dose change was maintained.
224096384|NCT02582515|DRUG|D-cycloserine|
224096385|NCT02582515|DRUG|Placebo|
224096386|NCT04548310|OTHER|Muscles Fatigue|An exhaustion protocol that reduces knee joint flexor and extensor torque will be applied.
224096387|NCT01093495|DEVICE|CPAP|CPAP
224096388|NCT01093495|DEVICE|Nasal Cannula|Nasal Cannula
224096389|NCT01029561|DEVICE|CPAP|Treatment with Continuous Positive Airway Pressure
224096390|NCT01029561|BEHAVIORAL|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
224096391|NCT06059885|DRUG|Tislelizumab plus tyrosine kinase inhibitor|Lenvatinib, tyrosine kinase inhibitor (TKIs)
224096392|NCT03465956|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
224096393|NCT00775021|DEVICE|etafilcon A|Contact Lens
224096394|NCT00775021|DEVICE|nelfilcon A|Contact Lens
224096395|NCT03394222|DRUG|preoperative budesonide inhalation|
224096396|NCT03394222|DRUG|preoperative normal saline inhalation|
223931979|NCT06832384|PROCEDURE|intensive physiotherapy|"the dosing of the intensive physiotherapy is of 2 sessions a day, lasting 45 minutes each, administered 5 days a week, for a period of 4 weeks.~the physiotherapy is mainly addressed to the improvement of gross motor movement and balance and the training is designed according to the specific need of the subject recruited. it is not allowed the use of technological devices, excepted treadmill training."
224096397|NCT00997074|DRUG|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
224096398|NCT01969656|DRUG|2MD|
224284885|NCT06163872|BEHAVIORAL|survey study|survey study
224284886|NCT02972021|DEVICE|High-flow nasal cannula|
224284887|NCT05172102|OTHER|breathing exercise, Aerobic exercises|6 min of quiet breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing (3 sets of 2 min each), 6 min of diaphragmatic breathing plus pursed-lips breathing (3 sets of 2 min each).
224284888|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
223931980|NCT06819215|DRUG|VB15010|Oral PARP1 inhibitor
223931981|NCT06767982|DRUG|Bacillus Calmette-Guerin (BCG)|In this study we compared the efficacy and side effects of two different strains of BCG (RIVM and RUSSIAN strains) in non muscle invasive bladder cancer patients
224096399|NCT01969656|DRUG|Calcitriol|
224096400|NCT01969656|DRUG|Placebo|
224284889|NCT03009487|DRUG|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
224284890|NCT03009487|DRUG|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
224284891|NCT03400917|BIOLOGICAL|AV-GBM-1|Investigational treatment with AV-GBM-1
224284892|NCT05507034|DIAGNOSTIC_TEST|Biomarkers|Each intervention is performed at 4 timepoints namely: before surgery, i.e. baseline (T0), 1-3 weeks post-surgery (T1), 3 months post-surgery (T2) and 1 year post-surgery (T4)
223941327|NCT03696056|BEHAVIORAL|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
224284893|NCT03550534|DRUG|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
224284894|NCT03550534|DRUG|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
224284895|NCT03297567|BEHAVIORAL|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
224284896|NCT04514055|PROCEDURE|De-epithelialized connective tissue graft wall|A de-epithelialized free gingival connective tissue graft will be used to treat Cairo's recession type 2 and type 3 associated with inta-bony defects
224284897|NCT00401284|DRUG|EVT 201|
224284898|NCT06417164|BEHAVIORAL|Functional Movement Training Group|The program control group will use traditional physical training methods, while the experimental group will use a training program based on FMS functional movement design. The experimental group will receive a 12-week FMS functional movement training intervention, with each session lasting 40 minutes. The experimental group will be divided into two phases, a corrective intervention phase and a capacity enhancement phase, and the main assessment criteria will include the seven movements of the FMS Functional Movement Test (squat, hurdle step, deep squat, shoulder mobility, active straight leg raise, trunk stabilizing push-ups, and trunk rotational stabilization), as well as the ability to control the body's dynamic and static postures during aerobic exercise.
224096401|NCT00188188|DRUG|quinipril|
224096402|NCT00870688|DRUG|sodium valproate|valproate sustained release minitablets, once daily.
224284899|NCT06400108|OTHER|Dementia Moves|"Dementia Moves: Dementia Moves is a multicomponent exercise program that can be individually tailored to the abilities of LTC residents with more advanced dementia and focuses on moderate- to high-intensity strength and balance activities with an aim to improve ADLs. Individualized strategies are implemented throughout the intervention to support and promote participation of individuals with more advanced dementia.~Each exercise will be individually prescribed for each participant by the physiotherapists (PT) at the beginning of the program. The intensity of the exercise will be adjusted throughout the program by the PT to ensure the target intensity of moderate to high intensity balance and strength exercises. The intervention will be provided face to face in groups of 4 residents with the PT, PTA, and three volunteers. Though the intervention is delivered in a group setting, the specific exercises that the participants complete are individualized based on their abilities."
224284900|NCT03232255|OTHER|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
224284901|NCT00517543|DRUG|GW856553|
224284902|NCT06064734|DEVICE|LF-rTMS|H 4 Coil (stimulation site: prefrontal cortex, insular lobe),1-Hz rTMS, stimulation intensity RMT 100%,1200 pulses/session, two sessions (2400 pulses)/day (interval ≥2 hours), lasting about half an hour each time, the total duration of treatment was 3 days (6 sessions,7200 pulses).
224284903|NCT04825041|DIAGNOSTIC_TEST|Patency test|Successive flow test, bubble flow test and peristalsis test
224284904|NCT03326986|DRUG|MK-7252|1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
224284905|NCT03326986|DRUG|Placebo|Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
224284906|NCT06446310|DRUG|QLG2198|Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
224284907|NCT06446310|DRUG|Placebo|Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
224284908|NCT05618535|DEVICE|Transcranial Doppler.|"Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size.~Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler."
224284909|NCT04645979|OTHER|Online survey|Participants will be invited to complete an online questionnaire about their experience of product use.
224284910|NCT01316419|DRUG|Telmisartan|Telmisartan 40mg or 80mg
224284911|NCT01316419|DRUG|amlodipine|amlodipine 5mg or 10mg
224284912|NCT03363477|DRUG|Enoxaparin|
224284913|NCT03363477|DRUG|Clexane|
224284914|NCT01304420|DEVICE|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
224284915|NCT04877171|OTHER|telemedicine neurology consultation|consultations via phone-only at 12-14-day post-discharge. Consultations via phone both audio and video at 1, 3 and 6 months
224284916|NCT04877171|OTHER|in-person neurology consultation|consultation in-person at Hospital Internacional de Colombia
224284917|NCT00513552|DRUG|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
224284918|NCT00455962|DRUG|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
224284919|NCT00455962|DRUG|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
224284920|NCT00002829|BIOLOGICAL|Recombinant Interferon Alfa|Daily
224284921|NCT00002829|DRUG|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
224284922|NCT00002829|DRUG|Etoposide|Administered intravenously on Day -8
224284923|NCT00002829|DRUG|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
224284924|NCT00002829|PROCEDURE|Bone Marrow Transplantation|Infusion on Day 0.
224284925|NCT00002829|RADIATION|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
224284926|NCT03609281|RADIATION|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
224284927|NCT00388895|DRUG|chemotherapy|
224284928|NCT00388895|DRUG|Glivec|
224284929|NCT05118516|DRUG|ASC43F|One dose of oral ASC43F FDC tablet containing ASC41 5mg and ASC42 15mg.
224284930|NCT01882179|DRUG|Mineralocorticoid receptor antagonist potassium-canrenoate|
224284931|NCT01882179|DRUG|placebo|
224284932|NCT02310789|DRUG|Ivacaftor|150mg administered orally twice daily.
224284933|NCT02310789|DRUG|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
224284934|NCT02310789|DRUG|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
224284935|NCT02310789|DEVICE|Macroduct sweat stimulator|
224284936|NCT02704234|OTHER|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
224284937|NCT02704234|OTHER|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
224284938|NCT05703035|PROCEDURE|standby while firing staple|VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
224284939|NCT02575508|DRUG|Fluorouracil|Given IV
224284940|NCT02575508|DRUG|Irinotecan Hydrochloride|Given IV
224284941|NCT02575508|OTHER|Laboratory Biomarker Analysis|Correlative studies
224284942|NCT02575508|DRUG|Oxaliplatin|Given IV
224284943|NCT02575508|DRUG|pan FGFR Kinase Inhibitor BGJ398|Given IV
224284944|NCT02575508|OTHER|Pharmacological Study|Correlative studies
224284945|NCT01197417|DRUG|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
224284946|NCT01197417|DRUG|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
223931982|NCT06770829|BEHAVIORAL|DiaFOOTCare Program|The DiaFOOTCare Program includes initiatives to support diabetic foot self-management. An e-booklet on type 2 diabetes management and preventive foot care will be shared via WhatsApp or email, along with audio modules for convenient access. An interactive video featuring a simulated patient will visually demonstrate preventive foot care practices and will also be shared digitally. A 25-30-minute face-to-face training session will provide personalized education using a tablet. Goal-tracking cards will be introduced to collaboratively set three-month behavioral goals, with patients documenting their progress during the follow-up. SMS reminders will be sent three times weekly to reinforce adherence. Patients will have digital access to all DiaFOOTCare resources, including the e-booklet, audio modules, and video, for 12 weeks, ensuring accessibility via WhatsApp or email. These measures aim to enhance knowledge, behavior, and self-management practices in preventive diabetic foot care.
223941328|NCT03696056|BEHAVIORAL|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
223941329|NCT00388726|DRUG|E7389|1.4 mg/m\^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
224284947|NCT03082235|DRUG|E6742|gelatin capsules
224284948|NCT03082235|DRUG|Placebo|gelatin capsules
224284949|NCT02771106|OTHER|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
224284950|NCT05558449|DEVICE|Hypnosedation|"Hypnosedation session with a virtual reality headset during the regional anesthesia technique and during the surgery (approximately 60 minutes). The VRH module used will be Silva, i.e. the same scenario of a walk in the forest through the 4 seasons with a voice accompanying the hypnosis session."
224284951|NCT05558449|DRUG|Midazolam injection|Midazolam intravenous injection 1 mg until RASS -3
224284952|NCT05558449|DEVICE|Virtual reality|"Only virtual reality without a hypnosedation session. The virtual reality headset will be used on these patients without external voice or hypnosis device. The virtual reality module used will be Silva, i.e. a scenario of a walk in the forest through the 4 seasons."
224284953|NCT05709769|OTHER|There are no interventions.|There are no interventions.
224284954|NCT06334419|DRUG|Gaboxadol|Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)
224284955|NCT06334419|DRUG|Placebo|Two placebo capsules
224284956|NCT01580657|BEHAVIORAL|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
224284957|NCT01580657|BEHAVIORAL|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
224284958|NCT01580657|BEHAVIORAL|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
224284959|NCT01580657|BEHAVIORAL|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
224284960|NCT01580657|BEHAVIORAL|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
224284961|NCT01580657|BEHAVIORAL|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
224284962|NCT03919448|BIOLOGICAL|Bevacizumab|Single-dose infusion
224284963|NCT03704857|OTHER|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
224284964|NCT03704857|OTHER|Photobiomodulation|aPDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
224284965|NCT03704857|OTHER|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
224284966|NCT03704857|OTHER|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
223533433|NCT07004738|OTHER|Pelvic floor exercises|The bladder should be emptied before the exercise. In order to correctly identify the pelvic floor muscles, it is necessary to initially try to hold urine while emptying the bladder. If the result is successful, it means that the correct muscles have contracted. During the learning phase, the exercise can be done in a supine position with the legs bent at the knees or in a sitting position. Initially, the pelvic floor muscles should be contracted for 5 seconds by pulling them inward as if stopping the passage of urine or gas, and then rested for 5 seconds.
223931983|NCT06770829|BEHAVIORAL|Ministry of Health and Education|The active control group will receive routine outpatient follow-ups and a diabetic foot care brochure from the Ministry of Health, explained by the researcher and shared via WhatsApp or email for reference. Goal-tracking cards from the DiaFOOTCare program will be used to set individual diabetic foot self-management behavioral goals collaboratively during the initial interview. Patients will be instructed on how to complete the cards and maintain them over a three-month period. At the end of the follow-up, post-tests will assess outcomes using the Glycemic Control Form, Goal-Tracking Card, Diabetic Foot Knowledge Scale, Foot Care Behavior Scale, Nottingham Functional Foot Care Diagnostic Form, Diabetic Foot Development Follow-up Form, and Diabetic Foot Self-Management Scale. Educational resources, including the e-booklet, audio modules, and video developed in DiaFOOTCare, will also be shared via WhatsApp or email to provide additional support and enhance diabetic foot self-management.
223931984|NCT06744868|DRUG|THDBH120 injection (SAD)|Participants received escalating single doses of THDBH120 by subcutaneous injection.
224096403|NCT03963583|BEHAVIORAL|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
224096404|NCT06483074|DRUG|Empagliflozin 10 MG|empagliflozin oral 10mg daily for 6 months
224096405|NCT05218811|DEVICE|Cryoablation Assisted Partial Nephrectomy|Cryoablation Assisted Partial Nephrectomy is monitored under Ultrasound guidance, A Cryoablation machine (FDA Approved Device) along with its Cryoprobes are used in the study The Cryoprobes are placed in close to the endophytic tumor margins. The tumor boundary area will undergo one freezing cycles. Tumor is excised after 5 minutes of freezing cycle. Thawing process is passive, renal defect repair is conducted during thawing process.
224096406|NCT06278519|BIOLOGICAL|Blood, urinary and feces collection|Blood, urinary and feces collection, at inclusion during acute phase of STEMI, and one year after inclusion visit.
224096407|NCT06278519|DEVICE|Cardiac MRI|Cardiac MRI at the acute phase of STEMI (Day 5 +/- 3) and at 1-year follow-up
224096408|NCT06278519|OTHER|Quality of life and cognitive status questionnaire|Quality of life and cognitive status questionnaire at the acute phase of STEMI and at 1-year follow-up
224096409|NCT06642480|DRUG|Post Operative Analgesia|administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
224096410|NCT06642480|DRUG|Post Operative Analgesia|VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
224096411|NCT05426057|BEHAVIORAL|eHealth Familias Unidas Mental Health|eHealth Familias Unidas is a program designed to target mental health and suicide ideation and behavior. It focuses on promoting mental health by strengthening family and interpersonal protective factors. The program is provided online over a total of 13 sessions: 9 video parent group sessions, each lasting 20-40 minutes in Spanish and 4 web family sessions lasting 45 minutes in either Spanish or English, depending on participant language preference. The video parent group sessions consist of: 1) culturally syntonic telenovela/soap opera series, 2) videotaped parent group discussions, 3) interactive exercises. Web family sessions will be conducted by a trained pediatric staff member.
224096412|NCT06578078|DRUG|Sodium Zirconium Cyclosilicate|Use of sodium zirconium cyclosilicate to optimize RAASi therapy, through up-titration of ACEi, ARB, ARNI or MRA therapy according to clinical guidelines
224096413|NCT06578078|DRUG|Standard of care treatment (RAASi therapy)|Standard of care treatment (RAASi therapy) without use of sodium zirconium cyclosilicate
224096414|NCT06379698|OTHER|personalized 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a personalized 3D models will be presented to the patients according to the allocated study group
224284967|NCT03704857|OTHER|Assessment of pain and edema|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
224284968|NCT03704857|OTHER|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
224284969|NCT03704857|OTHER|Longevity of rehabilitations|The teeth will be rehabilitated with resin and glass fiber post. The longevity of rehabilitations will be performed clinically and radiographically for 24 months.
224284970|NCT03704857|OTHER|Cryotherapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
224284971|NCT03704857|OTHER|Ozone therapy|The analysis of the postoperative symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the clinical evaluation of edema in 48 and 72 hours.
223533434|NCT07004738|OTHER|Control group|Women in this group who have been diagnosed with pelvic floor dysfunction will not be given any exercises. Women will continue their routine lives and their evaluations will be made.
223931985|NCT06744868|DRUG|Placebo of THDBH120 injection (SAD)|Participants received single dose of placebo by subcutaneous injection.
223931986|NCT06744868|DRUG|THDBH120 injection (MAD)|Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
223931987|NCT06744868|DRUG|Placebo of THDBH120 injection (MAD)|Participants received placebo once weekly for four weeks by subcutaneous injection.
223931988|NCT06790615|DRUG|methyl prednisolone acetate|methyl prednisolone acetate was injected after the aspiration
223931989|NCT06790615|OTHER|Silk suture|The silk suture was used for threading technique
223931990|NCT06762743|DRUG|Brivaracetam Oral Solution (Test Formulation)|The drug is manufactured by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
223931991|NCT06762743|DRUG|Brivaracetam Oral Solution (Reference Formulation)|The drug is manufactured by UCB Pharma S.A. under the trade name Briviact®. The formulation is provided as a 300 mL: 3 g solution, with a dosage of 10 mL (100 mg) per single oral dose. The drug will be administered to participants in the fasting group during the first phase of the study and to participants in the high-fat meal group during the second phase of the study.
223931992|NCT06769698|DRUG|FDC fianlimab+cemiplimab|Fixed-Dose Combination (FDC) Administered per the protocol
223931993|NCT06769698|DRUG|Cemiplimab|Administered per the protocol
223931994|NCT06769698|DRUG|Placebo|Administered per the protocol
223931995|NCT06764823|OTHER|Cryotherapy|In the cryotherapy group, after completing the biomechanical preparation, the root canals will be irrigated with 5 mL of 0.9% physiological saline solution at 2.5°C for 5 minutes; the solution will be stored in the refrigerator until use.
223931996|NCT06764823|OTHER|Control|In the control group, the final irrigation will be performed using 5 mL of 0.9% physiological saline solution at room temperature for 5 minutes.
223931997|NCT06762197|OTHER|Conventional treatment|Physical therapy can be beneficial for patients with piriformis syndrome, including stretching exercises, local massage, and superficial heat. Traditional stretching techniques include external rotation, hip flexion, and adduction. A hot pack on the trigger point area for 10 minutes followed by passive stretching for 30 seconds each.
223931998|NCT06762197|DEVICE|shockwave therapy|Shockwave therapy is a non-invasive alternative treatment for muscle disorders like sports and traumatic injuries, as it reduces pain and promotes soft tissue repair. In a study, patients in group A were treated with three sessions of Storz Medical Shock Wave MP100, each consisting of 2000 pulses with a total energy dose of 1080 mJ / mm. The study aimed to determine the location of the piriformis muscle in the prone position.
223931999|NCT06762197|DEVICE|low level laser therapy|Low Level Laser Therapy, also known as Photo-biomodulation, is a low-intensity light therapy that triggers biochemical changes within cells, similar to photosynthesis in plants. It can treat nociceptive and neuropathic pain, but central pain has not been proven responsive to low level laser therapy.
223932000|NCT06762587|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered on the first day following the close contact's enrollment in this study. Participants weighing ≤80 kg will receive 40 mg of baloxavir marboxil, while those weighing ≥80 kg will receive 80 mg.
223932001|NCT06762587|DRUG|Oseltamivir|Oseltamivir will be administered once daily for 5 consecutive days following the close contact's enrollment in this study. Participants will receive 75 mg of oseltamivir once each day.
223932002|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_L|subject will receive a low-dosage (1\*10\^5) of Bifidobacterium. animalis subsp.Lactis A6 Strain
223932003|NCT06779214|DIETARY_SUPPLEMENT|resveratrol_L|subject will receive a low-dosage (300mg/d) of resveratrol
223932004|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_M|subject will receive a medium-dosage (1\*10\^8) of Bifidobacterium. animalis subsp.Lactis A6 Strain
224096415|NCT06379698|OTHER|generic 3D model pré-opérative education|Before surgery, during a preoperative therapeutic education consultation, a generic 3D models will be presented to the patients according to the allocated study group
224096416|NCT05000905|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
224096417|NCT05000905|BEHAVIORAL|Questionnaires|Computer based assessments measuring attention, memory, daily habits, and mental health
224096418|NCT03464045|DRUG|empagliflozin|empagliflozin
224096419|NCT03464045|DRUG|DPP-4 inhibitors|DPP-4 inhibitors
224096420|NCT04218370|PROCEDURE|Dialysis|Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
224284972|NCT05143203|OTHER|Self-hypnosis training|Self-hypnosis training will be conducted in two phases and the evaluation of effectiveness of the training will be measured using GAD7, PHQ9 and PROQOL questionnaires
224284973|NCT01139749|DRUG|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
224284974|NCT01139749|DRUG|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
224284975|NCT03481413|DEVICE|Ablation|Ablation therapy for cardiac arrhythmias
224284976|NCT01812135|BIOLOGICAL|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
224284977|NCT02533284|DRUG|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
224284978|NCT02533284|DRUG|bupevecaine|US guided TAP using Bupevecaine 0.25 %
224284979|NCT02533284|DRUG|saline|US guided TAP using placebo (saline)
224284980|NCT03399994|DEVICE|device implantation during coronary angioplasty|device implantation during coronary angioplasty
224284981|NCT03013881|BIOLOGICAL|UB-921|150 mg/vial
224284982|NCT03013881|BIOLOGICAL|Herceptin|440 mg/vial
224284983|NCT02516384|BIOLOGICAL|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (\>18 year old) patients with active ulcerative colitis (UC).
224284984|NCT01652729|DRUG|Exenatide once weekly suspension|
224284985|NCT01652729|DRUG|Sitagliptin|
223932005|NCT06779214|DIETARY_SUPPLEMENT|Prebiotic_H|subjects will receive a high-dosage (1\*10\^10) of Bifidobacterium. animalis subsp.Lactis A6 Strain
223533435|NCT07003009|DIAGNOSTIC_TEST|Malign Lymph Node Washout|During routine axillary lymph node sampling, which is performed as part of standard staging using imaging methods, a washout sample (which is not not routinely applied ) will be obtained by injecting 1 cc of 0.9% saline into axillary lymph nodes suspected to be metastatic. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 1.
223533436|NCT07003009|DIAGNOSTIC_TEST|Benign Lymph Node Washout|Description: During the biopsy performed to histopathologically confirm the benign nature of a radiologically presumed benign axillary lymph node, a washout sampling will also be conducted by injecting 1 cc of 0.9% saline into benign lymph node. The aspirated washout sample will be placed in a biochemistry gel tube labeled as Sample 2.
223533437|NCT07003555|DRUG|Dual-targeting BCMA-CD19 CAR-T cell infusion|Approximately 3-5 days prior to BCMA-CD19 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
223533438|NCT07004569|DEVICE|Percutaneous coronary intervention (PCI)|Patients is under Percutaneous coronary intervention (PCI) by using contemporary drug eluting stent (DES). Angiolite is a thin-strut cobalt-chromium durable fluoroacrylate polymer-based, sirolimus-eluting stent that is CE marked and commercially available. Stent sizes 2.0mm to 4.5mm in 9mm to 49mm lengths will be used.
223533439|NCT07002827|DRUG|Darbepoetin|Darbepoetin will be given s/c at dose of 40 mcg once a week (total 4 doses) for 1 month
223533440|NCT07002827|DRUG|G-CSF|G-CSF will be given at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
223533441|NCT07002827|DRUG|Lactulose|Standard Medical Tretament part
223533442|NCT07002827|BIOLOGICAL|Albumin|Standard Medical Tretament part
223533443|NCT07002749|DRUG|Tranexamic Acid (TXA)|I would like to see the effect of prophylactic tranexamic acid in women undergoing ELLSCS in preventing PPH in my setup.
223533444|NCT07002749|DEVICE|Placebo|one group will get placebo
223932006|NCT06779214|DIETARY_SUPPLEMENT|resveratrol_H|subject will receive a low-dosage (600mg/d) of resveratrol
223932007|NCT06779214|OTHER|placebo_Bif|subjects will receive placebo (one look-alike sunbstance that contains no prebiotics)
223932008|NCT06779214|OTHER|placebo_resveratrol|subjects will receive placebo (one look-alike sunbstance that contains no resveratrol)
224096421|NCT05375201|OTHER|VR skateboarding training|The virtual reality skateboard training (VR-skate) is used treadmill-based training. Virtual reality system is integrated into the split-belt treadmill for VR-skate. Participants slide the swing leg (sliding leg) along with the moving treadmill belt at a comfortable speed (same as walking speed).
224096422|NCT04663750|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy
224096423|NCT04663750|DRUG|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12|Intravitreal 2 mg aflibercept (Eylea, Bayer) will be injected at baseline then monthly for two further doses, then 2-monthly until month 12.
223932009|NCT06778850|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
223932010|NCT06778850|DRUG|palcebo|Administered orally placebo
223932011|NCT05616260|DRUG|Acetazolamide|Acetazolamide tablet (encapsulated)
223932012|NCT05616260|DRUG|Placebo|Sugar capsule manufactured to match encapsulated Acetazolamide
223932013|NCT05616260|DEVICE|Continuous Positive Airway Pressure|Standard CPAP device
224284986|NCT01652729|DRUG|Placebo|Placebo oral capsule once daily
224284987|NCT01491308|OTHER|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
224284988|NCT02382549|DRUG|BRAF inhibitor|BRAF inhibitor
223932014|NCT06511726|DRUG|Cadonilimab|Induction chemotherapy and immunotherapy: Cadonilimab + cisplatin + albumin-bound paclitaxel, for a total of 2 cycles (cisplatin 75 mg/m² + albumin-bound paclitaxel 260 mg/m² q3w, Cadonilimab 10 mg/kg q3w).
224284989|NCT02382549|BIOLOGICAL|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
224284990|NCT02382549|DRUG|MEK inhibitor|MEK Inhibitor
224284991|NCT06405542|BEHAVIORAL|EX-CIPN|"The 10-week intervention includes:~Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises and will be adjusted to the needs of the patient.~Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change and allows for self-monitoring and feedback to the participant.~Remote Person-to-Person Clinical Support: Participants will have scheduled remote check-ins and health coaching sessions with their assigned RKin over Microsoft Teams (MSTeams) on weeks 2, 3, 4, 6, and 8 of the intervention. During these calls, the RKin will review, adapt, and progress the exercise program as needed, discuss and develop goals for the following week, and identify potential barriers and solutions in achieving their goals."
224284992|NCT02948920|DRUG|Ephedrine|9 mg of ephedrine (3 ml)
224284993|NCT02948920|DRUG|NSS|3 ml of normal saline
224284994|NCT04364737|BIOLOGICAL|Convalescent Plasma|SARS-CoV-2 convalescent plasma (1-2 units; \~250-500 mL) with antibodies to SARS-CoV-21 per April 13, 2020 directive by the FDA, obtained from New York Blood Center will be administered to eligible candidate
224284995|NCT04364737|OTHER|Saline solution|Equivalent volume of saline solution (defined as half-,quarter-, or normal saline) will be administered to eligible candidate as a placebo control group.
223932015|NCT05091632|PROCEDURE|Electroencephalography|Undergo EEG
224096424|NCT04663750|DRUG|subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls|Subretinal injection of recombinant TPA (Alteplase, Actilyse, Boehringer Ingelheim) up to a maximum of 25 micrograms in 0.2 mls.
224284996|NCT01220609|DRUG|Ixabepilone|Given IV
224284997|NCT01220609|OTHER|Laboratory Biomarker Analysis|Correlative studies
223932016|NCT05091632|OTHER|Questionnaire Administration|Complete questionnaires
223932017|NCT06739616|BEHAVIORAL|AUTOSIB across time|Intervention will be in place across increasing time frames.
223932018|NCT06739616|BEHAVIORAL|AUTOSIB diminished reinforcement|Intervention will be in place with decreasing levels of reinforcement
223533445|NCT07004920|OTHER|IPOS-ICU|This is a prospective observational study. Health care providers will be asked to will out the IPOS-ICU for patients in the intensive care unit.
223932019|NCT06756152|DRUG|Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150|The most significant adverse events limiting the use of HSCT from an unrelated donor are graft-versus-host disease (GVHD) and prolonged immunodeficiency associated with the development of severe infectious complications. The use of post-transplant cyclophosphamide for the prevention of GVHD during allogeneic HSCT from unrelated and haploidentical donors has reduced the incidence of acute clinically significant GVHD in children to 25%, chronic GVHD to 12-30%, but the issue of GVHD control still remains extremely relevant. Emerging data on the use of abatacept, a selective blocker of the costimulatory signal from an antigen-presenting cell, in the prevention of intestinal GVHD and data on the effectiveness of Janus-kinase type 1/2 inhibitors (JAK-1/2) in the treatment and prevention of acute GVHD allow us to justify the use of these drugs in combination with post-transplant cyclophosphamide as a promising pharmacological platform for the prevention of GVHD.
223932020|NCT05521516|DEVICE|Active Percutaneous Auricular Neuromodulation with NSS-2 Bridge|Application of 5 days of percutaneous auricular neuromodulation with NSS-2 Bridge device
224096425|NCT04663750|DRUG|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade|Intravitreal 20% sulfahexafluoride (SF6) gas tamponade.
223533446|NCT05919563|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Observational study; annual MRI for first 5 years only to monitor changes in the injection site
223932021|NCT05521516|DEVICE|Sham Treatment|Application of 5 days of a nonfunctional sham device
224284998|NCT02777515|BEHAVIORAL|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~1. A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~2. measurement of blood pressure~3. An electrocardiogram~4. A Holter-ECG 10 minutes~5. A transthoracic echocardiogram"
224284999|NCT00474435|DRUG|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~* emtricitabine 200 mg~* tenofovir DF 300 mg~* efavirenz 600 mg"
224285000|NCT05983666|DIAGNOSTIC_TEST|Ultrasound Oesophageal Intubation|Ultrasound Oesophageal intubation detection
224285001|NCT02106650|DRUG|Folotyn and Leucovorin|
224285002|NCT02106650|DRUG|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
224285003|NCT02106650|DRUG|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
224285004|NCT02986035|OTHER|ECA cream|
224285005|NCT03456024|OTHER|Questinnaire|
224285006|NCT00070616|DRUG|Palifermin 6 x 60 μg/kg/day|
224285007|NCT00070616|DRUG|Palifermin 2 x 180 μg/kg/day|
224285008|NCT00070616|RADIATION|radiotherapy|
224285009|NCT00070616|DRUG|Chemotherapy|
224285010|NCT01825135|DEVICE|Neuromuscular electrical stimulation|
224285011|NCT01825135|DEVICE|sham stimulation|sham stimulation will be applied to the quadriceps
224285012|NCT05723718|OTHER|Observational Survey|Evaluation of the nutritional status and body composition on tumor regression grade in gastric cancer patients scheduled for multimodal treatment. Nutritional status assessment will include: selected clinical variables evaluation (weight, BMI, nutritional status scales), bioelectrical impedance analysis and selected laboratory parameter assessment. After inclusion in the study, each patient will have four consecutive nutritional status assessments: (1) one day prior staging laparoscopy or during qualification to neoadjuvant chemotherapy, (2) one day before the gastrectomy, (3) one month after the gastrectomy, (4) after the last cycle of adjuvant chemotherapy.
224285013|NCT05265819|DEVICE|X-BOX kinetic360|1\) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
224285014|NCT05265819|DIETARY_SUPPLEMENT|mediterranean diet|Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
224285015|NCT05265819|DRUG|thyroid hormone replacement therapy|thyroid hormone replacement therapy
224285016|NCT00289003|DRUG|Soluble beta-1,3/1,6-glucan|
224285017|NCT02621801|BEHAVIORAL|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
223533447|NCT04066829|BEHAVIORAL|Default setting intervention|The new default settings will be implemented only for patients in the experimental arm.
223533448|NCT00775671|DRUG|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
223533449|NCT00775671|DRUG|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
223533450|NCT00775671|DRUG|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
223533451|NCT06456541|OTHER|Experimental Extensively Hydrolyzed Formula|Experimental powder formula
224285018|NCT02199015|DEVICE|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
224285019|NCT04147988|OTHER|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
224285020|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
224285021|NCT00431275|DRUG|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
224285022|NCT00004175|DRUG|cyclophosphamide|
224285023|NCT00004175|DRUG|docetaxel|
224285024|NCT00004175|DRUG|doxorubicin hydrochloride|
224285025|NCT00004175|PROCEDURE|conventional surgery|
224285026|NCT02225665|GENETIC|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
224285027|NCT02225665|GENETIC|SB-728mR-T|\- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
224285028|NCT02225665|DRUG|Cyclophosphamide|\- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
223932022|NCT06860737|DEVICE|Novel plano spectacle lenses|Use of novel plano spectacle lenses for at least 8 hours a day with objective wearing time measured by smart frame and objective outdoor time measured by smart bracelet.
223932023|NCT06771986|OTHER|Observation|sRAGE levels were studied in three different groups
223533452|NCT06456541|OTHER|Placebo Extensively Hydrolyzed Formula|Placebo powder formula
223533453|NCT06899165|DRUG|Psilocybin|Psilocybin 25mg, capsules taken orally under the supervision of two trained study therapists
224096426|NCT06457126|BEHAVIORAL|Attention Training Technique|"Phase 1: Non-concurrent multiple baseline design A-B design where the ATT (B) is introduced sequentially across participants. ATT and baseline (A) will be alternated on a weekly basis.~Phase 2: Alternating treatment design where an active (B) and passive (C) version of the ATT are rapidly and frequently alternative within the same participant on a weekly basis (e.g., A-B-A-C-A or A-C-A-B-A)."
223533454|NCT06899165|BEHAVIORAL|Integration sessions|weekly integration sessions (therapy) for 6 weeks
223932024|NCT06866873|BIOLOGICAL|CAR-T|CAR-T cell (CHXCART01) infusion intravenously once at a dose of 0.2-2 million cells/kg recipient body weight
223932025|NCT06778395|DRUG|Dexlansoprazole 60 mg|once daily for 8 weeks
223932026|NCT06778395|DRUG|Vonoprazan 20 mg bid|twice daily for 8 weeks
223932027|NCT06745739|BEHAVIORAL|Life Skills Training Workplace Prevention Program|A workplace health promotion intervention for youth age 16-24, adapted from the school-based Life Skills Training program. The program teaches participants the skills necessary to be productive in work and personal settings while also promoting healthy behaviors and preventing or reducing health risk behaviors. Program content focuses on goal-setting and problem-solving skills, stress and anger management skills, effective communication and conflict management skills, time and financial management, substance use risk reduction, and how to contribute to a healthy, safe, and drug-free workplace.
223932028|NCT06745830|OTHER|No intervention|No intervention
223932029|NCT06893848|OTHER|Culture Care program|"The Culture Care program modernizes the in-hospital environment by including art and culture proposed in the form of an individualized pathway. It will be offered primarily to hospitalized patients, but also available to families, caregivers and healthcare professionals. It will aim to create a new hospital experience, different from the one we've always known.~The Culture Care program will display posters illustrating works of art (paintings, drawings, photographs, etc.) along the hallways. These posters will be interactive, so that a QR code can be scanned to access musical content and audio podcasts (interviews and documentaries) accessible via bone-conduction headphones.~The Culture Care program is likely to reduce the sedentary behavior of hospitalized patients, by providing an attractive in-hospital environment that is likely to produce both physical and psychological benefits."
223932030|NCT06884696|OTHER|Blood samples for inflammatory markers|Blood sampling
223932031|NCT06884696|OTHER|Placental Extract|Placental sampling after caesarean section
224096427|NCT04927312|DRUG|PF-06947386|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
224096428|NCT04927312|DRUG|Metronidazole|Metronidazole 0.5 g solution for injection.
224096429|NCT00893711|OTHER|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
224096430|NCT00893711|OTHER|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
224096431|NCT00893711|DIETARY_SUPPLEMENT|L.reuteri + Vit D|
224096432|NCT00893711|DIETARY_SUPPLEMENT|Vit D placebo|
224096433|NCT03062501|DRUG|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
224096434|NCT05966818|DRUG|Dapagliflozin and Standard therapy (ACEI or ARB).|Dapagliflozin (Diglifloz) 10 mg orally once daily for 24 weeks and the standard therapy (ACEI or ARB).
224096435|NCT05966818|DRUG|Standard Therapy (ACEI or ARB).|Standard Therapy which include either ACEI or ARB for 24 weeks.
224096436|NCT00224562|DRUG|TNF-alpha antagonists|
223533455|NCT06763081|OTHER|Not applicable- observational study|It's an observational study. Participants are not assigned an intervention as part of the study.
223533456|NCT06399484|OTHER|Manual mobilizations of the median nerve|"Slippage of the median nerve in the wrist: the subject's starting position (P0) will be recumbent supine with the cervical spine in a neutral position, the shoulder girdle in neutral position, 30º of glenohumeral abduction in neutral rotation, 90º of elbow flexion, prone-supination of the neutral forearm, wrist and fingers in neutral position. From this position the movements will be 1) Glenohumeral abduction up to 90º; 2) Glenohumeral external rotation to the frontal plane; 3) Supination of the forearm; 4) Extension of the wrist and fingers; 5) Elbow extension. This position is will combine with an ipsilateral cervical inclination (distal sliding). The proximal slide is carried out bringing the fingers of the hand towards the flexion while performing a contralateral cervical tilt.~Median nerve tension: the starting position and movements are the same described above but this time it will be done with contralateral cervical tilt."
223533457|NCT06399484|OTHER|Wrist movements|Movements of the wrist joint will be performed as a placebo treatment
223932032|NCT06883539|DRUG|LXP1788 is administered intravenously via Port-A|LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.
223533458|NCT05547867|PROCEDURE|Radial head prosthesis|Radial head arthroplasty in comminuted radial head fractures.
223533459|NCT03499743|DRUG|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
223533460|NCT03499743|DRUG|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
223533461|NCT03499743|DRUG|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
223533462|NCT05424705|DIAGNOSTIC_TEST|OCT, NIRS|
223533463|NCT03186820|OTHER|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
223533464|NCT03676387|OTHER|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation \[ETT OD=0.55\*(subglottic diameter)+1.16\] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
223533465|NCT02719509|PROCEDURE|Cardiac Ultrasound|
223533466|NCT05243459|BEHAVIORAL|Gaze-Contingent Feedback Training|Feedback according to participants' viewing patterns, in order to modify their attention away from threat face stimuli.
223533467|NCT05243459|BEHAVIORAL|Attention Bias Modification|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
223533468|NCT05243459|BEHAVIORAL|Non-Contingent Feedback Training|Participants listen to a musical track they chose while viewing the face matrices. The music is played throughout and is not contingent upon gaze behavior.
223932033|NCT06747104|OTHER|Manual therapy|This technique involves a low-amplitude, high-velocity push on the shoulder and elbow joints with an additional two-second tension
223932034|NCT06747104|OTHER|Placebo|Performing manipulations without a two-second preliminary tension of the joint capsule in the shoulder and elbow joints.
223932035|NCT06750575|DIAGNOSTIC_TEST|Invasive measurements|Blood and urine samples will be collected during the study.
223941330|NCT00388726|DRUG|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
223941331|NCT03905278|BEHAVIORAL|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
223533469|NCT06581848|DRUG|Elranatamab|According to the approved label, the recommended doses are step-up doses of 12 mg on day 1 and 32 mg on day 4, followed by a full treatment dose of 76 mg weekly from week 2 to week 24. For patients who have received at least 24 weeks of treatment and have achieved a response, the dosing interval should transition to an every two week schedule.
223533470|NCT06831422|DEVICE|Povidone-Iodine|Following electrocautery opening of the dermal layer, patients in the povidine-iodine group (Group B) will receive application of 10% sterile povidone-iodine along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of betadine, a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
223533471|NCT06831422|DEVICE|Hydrogen Peroxide|Following electrocautery opening of the dermal layer, patients in the hydrogen peroxide group (Group A) will receive application of 3% sterile-filtered hydrogen peroxide along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of hydrogen peroxide a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
223533472|NCT06831422|DEVICE|Xperience Antimicrobial Wash|Following electrocautery opening of the dermal layer, patients in the patients in the Xperience group (Group C) will receive application of the Xperience antimicrobial wash (NextScience, Jacksonville, FL) (32.5 g/L citric acid, 31.3 g/L sodium citrate, and 1.00 g/L sodium lauryl sulfate in sterile water) along the entire dermis using a soaked surgical sponge. Approximately 120 seconds after application of Xperience, a culture of the dermis will then be taken by dragging the culture swab along the length of the exposed dermis (dermis culture).
223932036|NCT06752226|OTHER|action observation trainingAOT refers to an observational practice that has been used extensively for the goal of motor programming and enhances motor learning and performance|In AOT, motor-related information can be available through the visual function by encoding into the mental representation of the memory to organize the intended action
223932037|NCT06809569|DRUG|Allyl Isothiocyanate (AITC)|Topical administration
223932038|NCT06809569|DRUG|Capsaicin|Intradermal administration
223932039|NCT06809569|OTHER|Vehicle for AITC|Topical administration
223932040|NCT06809569|OTHER|Vehicle for Capsaicin|Intradermal administration
223932041|NCT06744569|DRUG|CU-10101|0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
223932042|NCT06763276|OTHER|Virtual Reality Group|In the study, a 400-gram virtual reality (VR) headset with an anti-reflective lens system was used, compatible with all earphones with screens ranging from 4.5 to 7.0 inches. The virtual reality (VR) headset, which was lightweight enough for children to wear, was supported on three sides to fit securely on the children's heads and was disinfected after each use. For the experimental group, the compartment at the front of the virtual reality (VR) headset was removed. The earphone was placed into the removed compartment, which was then reinserted. Subsequently, the YouTube virtual reality (VR) feature was activated on the phone, making it ready for viewing.
223932043|NCT06763731|DRUG|Systane COMPLETE|Preop dry eye management using Systane COMPLETE can help to optimize the ocular surface.
223932044|NCT06765135|BEHAVIORAL|Clinician Survey|At the conclusion of the intervention period, practice stakeholders, including survey providers and practice managers in the intervention sites will be surveyed to identify their degree of satisfaction with the intervention and suggestions for improvement.
223932045|NCT06765135|BEHAVIORAL|Focus Group|Prior to installing the device in each primary care practice, trained moderators will conduct focus groups with clinicians and practice staff to to elicit provider perceptions of POC testing for respiratory pathogens, including feasibility and acceptability of integration of testing into routine workflows.
223932046|NCT06765135|DIAGNOSTIC_TEST|Biofire Spotfire Respiratory (R) panel|Eligible patients will be offered testing with the BioFire Spotfire Respiratory (R) Panel, which is an FDA-cleared, CLIA waived test. This is a multiplexed polymerase chain reaction (PCR) test intended for use with the BioFire Spotfire System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal (NP) swab specimens obtained from individuals with signs and symptoms of respiratory tract infection, including COVID-19. This testing will be made available in participating practices along with clinical guidance about use and interpretation. Clinicians will administer the tests to patients who agree to be tested. Results will be shared with patients, who can discuss the results with their clinicians. Clinicians can use the test results to guide their treatment decisions.
223932047|NCT06765135|BEHAVIORAL|Patient Survey|During the intervention period, patients who undergo POC RPP testing will be surveyed soon after their visit to elicit their opinions about the test.
223932048|NCT06766786|DRUG|Magnesium Sulfate high dose|Patients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.
223932049|NCT06758817|OTHER|MedDiet+ intervention|Study arm will consume a Mediterranean like style diet enriched in fermented foods for 12 weeks
223932050|NCT06758817|OTHER|General dietary recommendations|Study arm will be given general healthy eating advice at baseline.
223932051|NCT06766617|OTHER|75 gr Glucose|75g of anhydrous glucose dissolved in 375 ml of water (Vittel) mixed with 150mg of U-13C\]-glucose (stable isotope from Eurisotope, France). will be orally taken
223932052|NCT06755541|DRUG|Fenofibrate in Combination With Ursodeoxycholic Acid|Experimental: Fenofibrate 200 mg Capsules
223932053|NCT06753006|DEVICE|Neurorehabilitation simulator|The participant must complete a mental task - imagine the movement of his arm. If successful, the robotic simulator moves the paralyzed limb.
223932054|NCT06753006|PROCEDURE|Standard course|The participant receives a standard course of intervention as prescribed by the attending physician in accordance
223932055|NCT06775223|OTHER|Cardiac implantable electronic devices|validity and reliability study
223932056|NCT06767735|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
223932057|NCT06767735|DRUG|Insulin Glargine U100|Insulin Glargine U100 s.c.,once-daily，treat-to-target dose
224096437|NCT01122927|DRUG|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
223932058|NCT06780605|GENETIC|niPGT-A|"After being thawed following the standard lab practice, any donated blastocyst usable for the study will be washed individually to remove any trace of cumulus DNA and will be transferred to a new culture dish with a drop of 10-15µl. Day-5 blastocysts with proper re-expansion after thawing, will be cultured overnight (≈24 hours) before media collection and TE/ICM biopsies. Day-6 blastocysts will be cultured a total of 8 hours after thawing, before media collection and TE/ICM biopsies.~On day 6/7, the embryos' media will be collected with an automatic pipette for niPGT-A and additional genetic analysis. The same protocol will be used to analyze SBM and blastocyst biopsies."
223932059|NCT06780605|GENETIC|Multifocal TE biopsies and ICM biopsy|"For biopsy, blastocysts will be transferred to the biopsy dish and multi-focal TE biopsies will be performed in three locations related to the position of the ICM. ICM biopsies will be performed following a published protocol provided to the participant centers. ICM and TE sections will be aspirated with the use of micropipettes adapted to a micromanipulation and laser microscope system.~For the genetic study of the samples, the same protocol will be used to analyze embryo biopsies and SBM."
223932060|NCT06654947|DRUG|Surufatinib+Toripalimab+GEMOX|Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）
223932061|NCT06771271|DRUG|RO7200220|RO7200220 was administered as IVT injection.
223932062|NCT06771271|DRUG|Ranibizumab|Ranibizumab was administered as IVT injection.
223941332|NCT05141539|DEVICE|Rehabilitation assessment software|"In phase 2, this software will be tested in occupational therapists, and head and neck cancer patients results for reliability and validity.~In phase 3, the experiment in the oropharyngeal dysphagia specialists results in content validity, the comparison between the developed software, and VFSS and FOIS results in criterion-related validity, and the experiment in head and neck cancer patients results in reliability."
223941333|NCT05141539|DEVICE|VFSS and FOIS|In phase 3, this study applies VFSS and FOIS for the head and neck cancer patients for comparison with the developed rehabilitation assessment software for criterion-related validity.
223932063|NCT06775119|OTHER|Test of neuromuscular fatigue and associated hemodynamic responses|"Baseline measurements of neuromuscular function and hemodynamic responses will be done. Investigators will then assess the mechanoreflex activation using the experimental technique of passive leg movement (PLM).~Following the PLM and the neuromuscular function baseline assessments, participants will perform four consecutive blocks, each consisting of a fatigue task followed by post-exercise circulatory occlusion (PECO). Neuromuscular function, assessed through maximal voluntary contraction (MVC) and quadriceps twitch techniques, will be measured before the fatigue task and after PECO in each block. Participants will perform 2-minutes isometric quadriceps sustained contraction at 20% MVC to induce exercise-induced neuromuscular fatigue. Hemodynamic responses will be measured during the PECO to isolate to the metaboreflex by inflating a cuff over the right thigh for a 2 minutes duration. After the PECO, the thigh cuff will be deflated, and neuromuscular function will be reassessed."
223932064|NCT06852573|BIOLOGICAL|ZM001 Injection|ZM001 injection, 2.5× 10\^7 CAR-T cells, 5× 10\^7 CAR-T cells, 1× 10\^8 CAR-T cells and 2× 10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
223932065|NCT06797427|DRUG|DPH001|100 mg
223932066|NCT06797427|DRUG|Nexavar (Sorafenib)|200 mg
223932067|NCT00747565|DEVICE|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
223932068|NCT00747565|DEVICE|CeeOn 911A monofocal IOL|Monofocal Control IOL
223932069|NCT06851520|PROCEDURE|Anterior Quadratus Lumborum Block (QLB)|A regional anesthesia technique where local anesthetic is injected anterior to the quadratus lumborum muscle under ultrasound guidance for postoperative pain management.
223932070|NCT06851520|PROCEDURE|Posterior Quadratus Lumborum Block (QLB)|A regional anesthesia technique where local anesthetic is injected posterior to the quadratus lumborum muscle under ultrasound guidance for postoperative pain management.
223932071|NCT05755204|DRUG|LA-CAB|Intramuscular LA-CAB for PrEP
223932072|NCT05755204|DRUG|TDF/FTC|Oral TDF/FTC for PrEP
223932073|NCT05008276|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
223932074|NCT05008276|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
223932075|NCT05008276|DRUG|Dextran 40|Diagnostic aid/agent used to measure glomerular size and selectivity
223932076|NCT03777657|DRUG|Tislelizumab|200 mg intravenously (IV) on Day 1 of each 21-day cycle
223932077|NCT03777657|DRUG|Placebo|Placebo to match tislelizumab IV on Day 1 of each 21-day cycle
223932078|NCT03777657|DRUG|Cisplatin|80 mg/m² IV on Day 1 of each 21-day cycle
223932079|NCT03777657|DRUG|Oxaliplatin|130 mg/m² IV on Day 1 of each 21-day cycle
223932080|NCT03777657|DRUG|Capecitabine|1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) of each 21-day cycle
223932081|NCT03777657|DRUG|5-Fluorouracil|800 mg/m²/day IV using continuous infusion on Days 1 to 5 of each 21-day cycle
223932082|NCT05077748|OTHER||
223932083|NCT03672201|BEHAVIORAL|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
223932084|NCT03672201|OTHER|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
223932085|NCT06704464|OTHER|Manual Dexterity|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT, 9-HPT, ABILHAND, and JTHFT.
223932086|NCT06704464|OTHER|Manual Dexterity (only MMDT)|Individuals who meet the inclusion criteria will be evaluated for manual dexterity using MMDT on a predetermined day.
223932087|NCT06704464|OTHER|disability level|Individuals who meet the inclusion criteria will be evaluated for disability level using EDSS
223932088|NCT03654716|DRUG|ALRN-6924|ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
223932089|NCT03654716|DRUG|Cytarabine|Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
223932090|NCT04104139|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
223932091|NCT04104139|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223932092|NCT04104139|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223932093|NCT06833164|DIAGNOSTIC_TEST|endoplasmic reticulum Aminopeptidase 1 and 2|endoplasmic reticulum aminopeptidase1 and 2 serum levels determination via ELISA
223932094|NCT06833164|DIAGNOSTIC_TEST|endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA|endoplasmic reticulum aminopeptidase 1 and 2 serum levels determination via ELISA
223932095|NCT06129942|DEVICE|Bright light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
223932096|NCT06129942|DEVICE|Dim Light box|The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
223932097|NCT06802068|DIETARY_SUPPLEMENT|whole salmon oil|A minimally processed whole salmon oil
223932098|NCT06802068|DIETARY_SUPPLEMENT|Cod liver oil|Standard, processed omega-3 cod liver oil
223932099|NCT03665922|DIETARY_SUPPLEMENT|BroccoMax®|Nutraceutical neoadjuvant
223932100|NCT03665922|OTHER|Placebo|control
223718352|NCT05503394|BEHAVIORAL|Peer support WeChat platform intervention|Primary caregivers of children with biliary atresia are selected as the study population and divided into intervention and control groups in chronological order at a children's hospital in Shanghai. Primary caregivers who visit the hospital between August 2022 and October 2022 are assigned to the control group and primary caregivers who visit the hospital between January 2023 and March 2023 are assigned to the intervention group. The intervention group will receive a peer support WeChat platform intervention from the day of surgery to one month postoperatively. The level of negative emotions and caregiver burden will be compared between the two groups after the intervention. The intervention group receives the same routine care as the control group.
223932101|NCT06294990|DRUG|Testosterone gel|Two years treatment with testosterone
223932102|NCT06294990|OTHER|Placebo|Two years treatment with placebo
223932103|NCT05785221|BEHAVIORAL|General lifestyle and nutritional education|Participants will receive general dietary advice, behavior guidance and nutritional and lifestyle education based on dietary guidelines.
223932104|NCT05785221|BEHAVIORAL|Personalized nutritional and lifestyle weight reduction intervention|Participants will receive personalized dietary advice, behavior guidance and nutritional and lifestyle education by dietitian and physicians. APP-connected wearable devices will be utilized to monitor their dietary intakes, physical activities and sleep conditions and APP-connected scale will be used to monitor their weight changes during interventions.
223932105|NCT03574493|PROCEDURE|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
223932106|NCT06071130|BEHAVIORAL|Fit and Strong|Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
223932107|NCT06333457|DEVICE|VR Cue-Exposure Therapy|Standard VR Cue Exposure Therapy (VR-CET) for the treatment of alcohol dependence
223932108|NCT06821672|PROCEDURE|Chronobiological Group|In the intervention group, a label containing the time of expressed breastmilk will be affixed. In the milk preparation room, breast milk will be stored in a separate refrigerator as 08:00-19:59 day milk and 20:00-07:59 night milk.
223932109|NCT05802264|COMBINATION_PRODUCT|ABCI|Subjects will receive ABCI via oral inhalation
223932110|NCT05802264|COMBINATION_PRODUCT|Placebo|Subjects will receive ABCI via oral inhalation
223932111|NCT06812845|OTHER|eye investigations|BY data entry ,measuring the visual acuity ,measuring IOP, doing refraction and recording eye investigations results to reach the final diagnosis
223932112|NCT06764433|PROCEDURE|GONPRF|GON PRF treatment, which we apply by imaging the target nerve and surrounding structures with the proximal technique (at C2 level) under USG guidance in patients who do not respond to conservative treatments for cervicogenic headache.
223932113|NCT06764433|PROCEDURE|Proximal GONPRF|Ultrasound-guided pulsed radiofrequency treatment of the greater occipital nerve at the C2 level
223932114|NCT06762067|OTHER|mirror therapy|Participants will undergo physiotherapy exercises in a mirror alongside post-surgery care. The program includes palming exercises, eye exercises, pencil push-ups, Brock string exercises, thumb exercises, and proprioceptive neuromuscular facilitation exercises. The first exercise warms up extra ocular muscles, the second improves eye coordination, the third motivates the lazy eye, the fourth strengthens eye muscles, and the fifth involves a near-distance jump for oblique muscles.
223932115|NCT06762067|OTHER|traditional therapy|The patients within the control group will receive traditional care post-strabismus operation as eye glasses and eye drops and regular exercise
223932116|NCT05687292|DEVICE|Clinical decision support system (CDSS) for ventilator weaning|A clinical decision support system (CDSS) will be integrated into a software program (the T3 platform) that is present on all patient bedside computers. The T3 platform is a tool that compiles data from a patient's existing physiologic monitors, ventilator, and laboratory results and graphically displays them on a bedside monitor. The CDSS will be active on all patients receiving mechanical ventilation, but primary use and evaluation will focus on patients meeting study criteria. Twice daily (on morning rounds and evening rounds), patients will be screened for eligibility. During each rounds, teams will review the CDSS and associated risk analytics data used to inform the associated recommendations for ventilator weaning, extubation readiness assessment, and extubation. The clinical team will consider the CDSS in decision making around ventilator weans. If the decision is made not to follow the CDSS recommendations, the clinician will complete a brief survey with rationale.
223533473|NCT06831422|DIAGNOSTIC_TEST|Bacterial Cultures|Four C. Acnes cultures will be obtained for every patient. Once the skin has dried, a culture swab will be applied along the planned incision for all patients (skin culture). Approximately 120 seconds after application of Xperience, hydrogen peroxide or betadine, or after initial incision in the case of the control group, a culture of the dermis will then taken by dragging the culture swab along the length of the exposed dermis (dermis culture). Once the glenohumeral joint is exposed, the surgeon will apply new surgical gloves, and a culture swab will be placed into the joint and along the humeral head (glenohumeral joint culture). An additional culture will then be taken from the air in the operative suite (air culture)
223533474|NCT06831422|PROCEDURE|Shoulder Arthroplasty|All patients will undergo hemiarthroplasty, anatomic total shoulder arthroplasty, or reverse total shoulder arthroplasty in accordance with the appropriate indications and enrollment in this study.
223533475|NCT06815575|DRUG|RC220|Administered by intravenous infusion over 60 minutes.
223932117|NCT06764667|PROCEDURE|Spinal anesthesia adjuvant|Patients in this arm will receive 10 mg 0.5% hyperbaric Bupivacaine, 100 mcg Morphine, 100 mcg Sulfas Atropine, and 0.9% normal saline to total volume of 4 ml before induction of anesthesia.
223932118|NCT06764667|PROCEDURE|Quadratus Lumborum Block (QLB)|Patients in this arm will receive quadratus lumborum block with 20-30 ml of 0.25% Bupivacaine after induction of anesthesia and after operation.
223533476|NCT06815575|DRUG|Doxorubicin (Adriamycin)|60 mg/m2 administered by intravenous infusion over 10 minutes following adminstration of intravenous RC220 on Day 1 of the combination cycles.
223533477|NCT06669754|DRUG|Deucrictibant|Deucrictibant 40mg extended-release tablet for once daily oral use
223533478|NCT06669754|DRUG|Placebo|Placebo
223533479|NCT05442736|DRUG|Ciprofloxacin|studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
223533480|NCT06262542|OTHER|moxibustion and Chinese herbal medicine group|"Apply 15g of Chinese herbal powder (a mixture of scientific Chinese herbs: Jiseng Shenqi Pill, Xuanfu Daizheshi Tang, and Wendi Tang mixed in a 1:1:1 ratio, mixed with water to form a paste) to the Shénquè acupoint. Then, use 3g of 80:1 moxa wool placed in a moxibustion box for moxibustion on the lower abdomen (between the Guānyuán, Zhōngjí, and Shénquè acupoints) for 1 hour, once a day, six times a week, for a total of 12 sessions.~sham moxibustion and placebo herbal medicine group): Same acupoint frequency, but use 15g of flour instead of herbal paste and replace moxibustion with a heated nightlight for sham moxibustion."
223533481|NCT06811584|DEVICE|Peanut ball|"Participants will be provided with a mani ball, which will be covered by a cover provided by the investigator. This cover will be changed for each patient. The ball will be placed between the participant's knees, and she will be allowed to use it at least every two hours for a period of 30 minutes. Participants will also have the option to use the balloon more frequently if they wish. Balloon use will be discontinued when the cervical os reaches 10 cm dilation or when the participant is ready to begin the pushing process.~* The positions to be performed with the peanut ball will be:~* Side lying~* Bent position~* Semi-sitting position~* Taylor position."
223533482|NCT00122889|DRUG|Garlic powder with high allicin content|
223533483|NCT00122889|DRUG|Garlic powder with low allicin content|
223533484|NCT00122889|DRUG|Garlic oil|
223533485|NCT00122889|DRUG|Aged garlic|
223533486|NCT06802055|DRUG|Sirolimus (Rapamune®)|Sirolimus 1-3 mg once daily orally, with a target trough blood concentration of 4-12 ng/ml.
223533487|NCT06802055|DRUG|Cyclosporin A (CsA)|Cyclosporine A 25-150 mg orally every 12 hours, with the dose adjusted based on renal function and trough concentration. For patients with normal renal function, the target trough concentration is approximately 150 ng/ml. For patients with impaired renal function, the cyclosporine A dose is reduced to 25-50 mg every 12 hours, aiming for recovery or stabilization of renal function.
223932119|NCT06764667|PROCEDURE|General Anesthesia|The subject will undergo preoxygenation with 100% oxygen for 3 minutes. Following preoxygenation, anesthesia induction will be performed using lidocaine at a dose of 1.5 mg/kg, fentanyl at 1.5 mcg/kg, and propofol at 2.0 mg/kg. Once the subject is adequately sedated, baseline neuromuscular monitoring using the train-of-four (TOF) technique will be conducted, followed by the administration of rocuronium at a dose of 0.8 mg/kg. Endotracheal intubation will be performed using direct laryngoscopy once the TOF value reaches 0, utilizing an appropriately sized endotracheal tube (ETT). Ten milligrams of intravenous dexamethasone is administered after induction.
223932120|NCT06734273|DRUG|Mounjaro|In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.
224285029|NCT06525922|BEHAVIORAL|Center M|Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks. Participants joined group sessions on their personal computer, tablet, or phone. Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials. Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
223932121|NCT06734273|PROCEDURE|Sleeve Gastrectomy|Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy.
223932122|NCT04779697|DRUG|GLP-1 analogue - semaglutide|GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
223932123|NCT04779697|OTHER|Placebo|Placebo - administered once weekly for a total of 12 weeks
223533488|NCT05063786|BIOLOGICAL|Trastuzumab|"6 mg/kg IV every 3 weeks (3-weekly schedule), or 4 mg/kg IV loading dose, followed by 2mg/kg IV weekly (weekly schedule)\*, or 600 mg SC every 3 weeks.~\* If using trastuzumab IV, a loading dose of 8 mg/kg (for the 3-weekly schedule), or 4 mg/kg (for the weekly schedule) is necessary if more than 6 weeks have passed since the previous trastuzumab dose."
223533489|NCT05063786|DRUG|Alpelisib|300 mg oral once daily.
223533490|NCT05063786|DRUG|Fulvestrant|500 mg intramuscular every 4 weeks plus loading dose on day 15 cycle 1.
224285030|NCT00724490|PROCEDURE|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
223533491|NCT05063786|DRUG|Vinorelbine|Oral (60 mg/m2) or IV (25 or 30 mg/m2 per investigator preference) on days 1 and 8, every 3 weeks.
224285031|NCT05182619|PROCEDURE|ultrasound-guided stellate ganglion block|under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
224285032|NCT05775822|DIAGNOSTIC_TEST|CT scan and blood sample collection|"Each enrolled patient performs:~* preventive clinical cardiology assessment visit, addressed to individualized risk profile assessment and addressed to chest CT scan.~* a blood sampling (1 citrate tube of 5 ml) will be done the same day just the chest CT scan and analyzed locally also for future research of biomarker discovery (single sample, for those patients who agree in ICF)~* CT scan"
224285033|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
224285034|NCT01311557|BIOLOGICAL|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
223533492|NCT05063786|DRUG|Capecitabine|1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
223533493|NCT05063786|DRUG|Eribulin|1.23 mg/m2 IV on days 1 and 8, every 3 weeks.
223932124|NCT05857397|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
223718353|NCT05503394|BEHAVIORAL|Routine nursing care group|Provide routine inpatient education and post-discharge follow-up to primary caregivers of biliary atresia.
223932125|NCT06238908|DRUG|NGGT003|Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)
223932126|NCT03417336|RADIATION|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
223932127|NCT06791512|DRUG|mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody|Participants in the experimental group will receive the neoadjuvant therapy regimen of mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody. And the first five doses received the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) combined with sintilimab (200 mg, intravenous) and Bevacizumab (5 mg/kg, intravenous), and the sixth dose received the same regimen of mFOLFOX6 and PD-1 monoclonal antibody but not plus bevacizumab, in order to allow sufficient withdrawal time of Bevacizumab for surgery.
223932128|NCT06791512|DRUG|mFOLFOX6|Participants in the control group will receive the neoadjuvant therapy regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2, and 5-fluorouracil 2400 mg/m2 continuous pumping for 48 hours) alone.
224096438|NCT04836286|BEHAVIORAL|Emotive Intelligent Spaces (EIS)|The EIS leverages innovations across multiple disciplines, including sensory environment, computer science, psychology, and real-time human-computer interface. The colors of the LED lights on the EIS wooden panels are controlled by an artificial intelligence computer algorithm that will translate children's physiological responses (Galvanic skin response, body temperature, and blood volume pulse), captured by a digital wristband, into their emotional state and the associated preferred colored lighting. The algorithm was created in a co-investigator's published study11, using fuzzy logic and machine learning techniques (i.e., Decision Tree; accuracy 86%).To successfully carry out this project, our team blends expertise in educational psychology, early intervention, computer science, architecture, and interior design.
224096439|NCT04290637|OTHER|Cold-water sea swimming|Continue sea swimming for 4-6 weeks
224096440|NCT04290637|OTHER|No cold-water sea swimming|Discontinue sea swimming for 4-6 weeks
224096441|NCT01656525|DRUG|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
224285035|NCT03642522|DEVICE|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
224285036|NCT03119506|BEHAVIORAL|Recess|Recess timing and duration effects on lunch intake
224285037|NCT00365937|BIOLOGICAL|Immunological peptides and immunological adjuvants|
224285038|NCT00365937|BIOLOGICAL|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
224285039|NCT00365937|BIOLOGICAL|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
224285040|NCT00365937|BIOLOGICAL|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
224285041|NCT04257383|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
224285042|NCT04127214|OTHER|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
224285043|NCT01936311|BEHAVIORAL|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
224285044|NCT03478865|DRUG|Vitamin A palmitate|Provide vitamin A to participants with pre/post assessments of vision.
224285045|NCT01470417|DRUG|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
224285046|NCT01470417|DRUG|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
224285047|NCT00002616|BIOLOGICAL|aldesleukin|
224285048|NCT00002616|BIOLOGICAL|filgrastim|
224285049|NCT00002616|DRUG|carboplatin|
224285050|NCT00002616|DRUG|cyclophosphamide|
224285051|NCT00002616|DRUG|thiotepa|
224285052|NCT00002616|PROCEDURE|peripheral blood stem cell transplantation|
223718354|NCT01497691|DEVICE|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
223932129|NCT06759896|DEVICE|Protraction facemask|Patients assigned to intervention 1 will utilize the Petit protraction facemask, in conjunction with a rapid maxillary expansion (RME). This facemask consists of a forehead pad and chin pad linked by a sturdy steel support rod.
223932130|NCT06759896|DEVICE|Upper partial fixed appliance|Upper partial fixed appliance / 2 by 4 appliance will be used in this study by using bracket set (119-142 Unitek™ Gemini Bracket MBT™ U/L 5x5 0T-Cuspid 3Hk) with molar bands (3M™ Victory Series™ First Molar Bands) or buccal tubes (3M™ Victory Series™ Superior Fit Buccal Tubes) and upper nickel titanium archwires (3M™ Unitek™ Nitinol Heat-activated Archwire) and upper stainless steel archwires (3M™ Unitek™ Permachrome Standard Archwire) .
223932131|NCT05169697|DRUG|A:YH002+YH001|YH002 on CnD1,YH001 on CnD8,Q3W
223932132|NCT05169697|DRUG|B:YH002+YH001|YH002 and YH001 on same day,Q3W
223932133|NCT05169697|DRUG|YH002+YH001|A traditional 3+3 dose escalation algorithm
223932134|NCT00545545|BIOLOGICAL|Imprime PGG 2 mg/kg|Infusion of 2mg/kg on Day 1 of each week for 6 weeks (one cycle) Number of Cycles: until progression or unacceptable toxicity develops.
223932135|NCT00545545|BIOLOGICAL|Imprime PGG 4 mg/kg|Infusion of 4mg/kg on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
223932136|NCT00545545|BIOLOGICAL|Cetuximab|Infusion 400 mg/m2 over 2 hours on Day 1, then 250 mg/m2 over 1 hour on Days 8, 15, 22, 29, and 36 of each 6-week treatment cycle;
223932137|NCT00545545|DRUG|Irinotecan|Infusion 125 mg/m2 i.v. over 1.5 hours on Days 1, 8, 15, and 22 of each 6-week treatment cycle
223932138|NCT00545545|BIOLOGICAL|Imprime PGG 6mg/kg|Infusion of 6mg/kg on Day 1 of each week for 6 weeks (one cycle) Number of Cycles: until progression or unacceptable toxicity develops.
223941334|NCT04884165|DEVICE|Remote monitoring of home mechanical ventilation (NIV) using SRETT|Patients will use the SRETT device attached to their home ventilator.
223941335|NCT04884165|OTHER|Home mechanical ventilation (NIV) without remote monitoring|Usual care
224285053|NCT02288494|OTHER|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia \< 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
223941336|NCT04033315|DEVICE|L-PLUS meter|Blood Glucose Monitoring System
223941337|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
223941338|NCT00983294|DRUG|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
224285054|NCT05309720|PROCEDURE|Glyaderm|All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.
224285055|NCT03500367|DRUG|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
224285056|NCT02418455|DRUG|UX003|solution for intravenous infusion
224285057|NCT02539784|DEVICE|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
224285058|NCT05927779|DRUG|TFX06 tablet|TFX06 tablet taken orally
224285059|NCT00270933|DEVICE|Registry|
224285060|NCT06037278|DEVICE|MyPAO|use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
223941339|NCT00983294|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
223941340|NCT06272188|OTHER|web-based online preconceptional counselling|web-based online preconceptional counselling
223533504|NCT05050084|DRUG|Bicalutamide|Drug
223533505|NCT05050084|DRUG|Buserelin|Drug
223533506|NCT05050084|DRUG|Darolutamide|Given PO
223533507|NCT05050084|DRUG|Degarelix|Drug
223533508|NCT05050084|DRUG|Flutamide|Drug
223533509|NCT05050084|DRUG|Goserelin|Drug
223533510|NCT05050084|DRUG|Histrelin|Drug
223941341|NCT00853593|DEVICE|Pacing Lead|implant and follow-up of study device
223941342|NCT02193932|OTHER|EEG Triggered fMRI using Micro Maglink|
223941343|NCT03978065|DIAGNOSTIC_TEST|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
223941344|NCT05715684|OTHER|Exercise Training|Virtually supervised exercise training for four weeks prior to cystectomy
223941345|NCT05715684|DIETARY_SUPPLEMENT|Nutritional Intervention|Patients scheduled to undergo cystectomy will receive liquid Ensure supplemental shakes for 2 weeks prior to surgery and liquid Ensure supplemental shakes for 1 week postoperatively
223941346|NCT04171011|DEVICE|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
223941347|NCT00540111|DIETARY_SUPPLEMENT|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
223533511|NCT05050084|DRUG|Leuprolide|Drug
223932139|NCT06836297|DEVICE|Transcranial Magnetic Stimulation Sham|Participants will be asked to perform various behavioral tasks involving the use of action observation or motor imagery. During these tasks, transcranial magnetic stimulation will be used.
223932140|NCT06793761|DRUG|Pembrolizumab|Pembrolizumab 200mg, IV, 3 cycles
223932141|NCT06793761|DRUG|Cisplatin|cisplatin 75mg/m2, IV, 3 cycles
224096442|NCT01656525|DRUG|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
224285061|NCT03966391|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
224285062|NCT04000191|PROCEDURE|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
224285063|NCT04000191|OTHER|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
224285064|NCT02057536|OTHER|Arm A Directed exercise program|
224285065|NCT02057536|OTHER|Observation|
224285066|NCT01514825|DRUG|YM150|oral
224285067|NCT01514825|DRUG|Placebo|oral
224285068|NCT05871086|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 soft gelatin capsules daily for 3 months
224285069|NCT05871086|OTHER|Placebo|Placebo Capsules
224285070|NCT05871086|DRUG|Standard Regimen|"Patients may be receiving any of these commonly used JIA treatments including:~* Ibuprofen - 30 to 40 mg/kg/day in 3 to 4 divided doses~* Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily~* Methotrexate - Initial: 10 to 15 mg/m2 once weekly; adjust gradually up to 20 to 30 mg/m2 once weekly~* Leflunomide - Weight based, 10-20 mg once daily~* Sulfasalazine - 30 to 50 mg/kg/day in 2 divided doses~* Etanercept - 0.8 mg/kg/dose once weekly~* Adalimumab - Weight based, 10-40 mg every other week"
224285071|NCT01934738|DRUG|PF-06273340|Tablets, 100 mg TID, 14 days
224285072|NCT01934738|DRUG|Placebo|Tablets, TID, 14 days
224285073|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
224285074|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
224285075|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
224285076|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
224285077|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
224285078|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
224285079|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
224285080|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
224285081|NCT01934738|DRUG|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
224285082|NCT01934738|DRUG|Placebo|Tablets, TID or titration, 14 days
224285083|NCT01834209|DRUG|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
223533512|NCT05050084|RADIATION|Radiation Therapy|Undergo RT
223533513|NCT05050084|DRUG|Relugolix|Drug
223533514|NCT05050084|DRUG|Triptorelin|Drug
223533515|NCT01920243|BEHAVIORAL|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
223533516|NCT01005290|DRUG|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
223533517|NCT01005290|DRUG|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
223533518|NCT04885621|DIETARY_SUPPLEMENT|nutrisystem-D|Nutrisystem meal replacements and Glytec glucomander-outpatient algorithm for insulin management decisions
223932142|NCT06793761|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg, IV, 3 cycles
223932143|NCT06840678|DEVICE|Transcranial static magnetic field stimulation (tSMS) of the supplementary motor area|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. The investigators will use a cylindrical neodymium magnet of 60 mm diameter and 30 mm of thickness (MAG60r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the supplementary motor area (SMA) using an ergonomic helmet (MAGsv1.1, Neurek SL, Toledo, Spain).
223941348|NCT06434584|OTHER|without AI assistance|provide insulin dosage and confidence score without AI assistance
224285084|NCT01834209|DRUG|Prednisone or prednisolone|5 mg tablet taken orally once daily
224285085|NCT02668042|BIOLOGICAL|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
224285086|NCT02538835|BEHAVIORAL|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
224285087|NCT02538835|BEHAVIORAL|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel \& Segal.
224285088|NCT02538835|BEHAVIORAL|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
224285089|NCT00841152|DEVICE|Bioactive glass|Surgical implantation
224285090|NCT00841152|DEVICE|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
224285091|NCT00841152|PROCEDURE|Autograft|Surgical transplantation from iliac crest
224285092|NCT00841152|PROCEDURE|Allograft (frozen femoral head)|Surgical transplantation
223533519|NCT06523231|BIOLOGICAL|Shigella4V2|Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.
223533520|NCT06523231|BIOLOGICAL|MenACWY|Control vaccine
223533521|NCT05466383|BEHAVIORAL|Exercise|Exercise rehabilitation with Schroth method
223533522|NCT05466383|DEVICE|Brace|Wear an orthopedic brace
223533523|NCT06735859|BEHAVIORAL|Comparison of eating windows intervention|Participants will be randomized into two groups to follow either eating window for 12 months, with normocaloric meal plans based on the Mediterranean diet adapted to Brazilian culture. After 12 months, a 3-month washout period will follow, during which participants return to their usual eating patterns. The groups will then be swapped to follow the opposite eating window for another 12 months. Finally, a new data collection will be conducted 3 months post-intervention to analyze the stability of behavior.
223533524|NCT06846359|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
223533525|NCT06846359|BEHAVIORAL|Educational module|self-guided online module reviewing chronic GI conditions, pathophysiology, and alternative treatment options.
223533526|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
223533527|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
223932144|NCT04895956|PROCEDURE|Intra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered directly into the abductor pollicis longus/ extensor pollicis brevis sheath.
224096443|NCT01656525|DRUG|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
224096444|NCT01656525|DRUG|Placebo|subcutaneous doses every 4 weeks for 24 weeks
224096445|NCT01774448|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
224096446|NCT02747082|PROCEDURE|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
224096447|NCT00278525|DRUG|standard of care|standard of care medication will be given
224285093|NCT03059485|BIOLOGICAL|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
224285094|NCT03059485|OTHER|Observation|Traditional care provided by the hospital.
224285095|NCT03093272|DRUG|Leuprolide Acetate|a GnRH agonist
224285096|NCT03093272|DRUG|Prednisone|Prednisone is a corticosteroid
224285097|NCT03093272|DRUG|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
224285098|NCT03093272|DRUG|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
224285099|NCT01368926|DRUG|RO4917523|single oral doses
224285100|NCT01368926|DRUG|RO4917523|multiple oral doses
224285101|NCT01368926|DRUG|placebo|oral doses
223533528|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
223533529|NCT06461221|DEVICE|Transcranial Focused Ultrasound|Using MRI-guided targeting, we will administer focused ultrasound in one of the 4 stimulation conditions
223533530|NCT07094997|OTHER|Guidline-basaed massage therapy|Massage protocol based on guidelines from the Polish Society of Physiotherapy, the Polish Society of Family Medicine, the College of Family Physicians in Poland, and the European Rural and Isolated Practitioners
223718355|NCT01497691|DEVICE|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
223932145|NCT04895956|PROCEDURE|Extra-sheath injection|Ultrasound guided corticosteroid injection composed of 1ml of 1% lidocaine and 1ml (20mg) of dexamethasone. Injection will be administered surrounding the abductor pollicis longus/ extensor pollicis brevis sheath.
223932146|NCT04895956|DEVICE|Ultrasound|To ensure accuracy of fluid deposition into the tendon sheath in the intra-sheath injection arm and outside of the tendon sheath in the extra-sheath injection arm, all injections will be performed under ultrasound guidance. The ultrasound machine used will be a portable ultrasound machine located at the UC Davis orthopaedic clinic in Sacramento
224096448|NCT00278525|PROCEDURE|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
224096449|NCT05616143|DEVICE|Isthmus Logic|Patient implanted with Isthmus Logic stent for the treatment of peripheral iliac artery disease
224285102|NCT00951951|PROCEDURE|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
224285103|NCT00951951|PROCEDURE|Posterior Approach|
224285104|NCT02054013|PROCEDURE|Prostatic artery embolization|
224285105|NCT02054013|PROCEDURE|monopolar transurethral prostatectomy|
224285106|NCT05064748|DRUG|Benvitimod|Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
224285107|NCT00272506|DRUG|inhaled corticosteroid|
224285108|NCT00272506|DRUG|long-acting beta2-agonist|
224285109|NCT06586151|BEHAVIORAL|Transcendent Health|Gender-inclusive HIV prevention program: Text messaging-based program that lasts 5 months. Content includes information, motivation and behavioral skills about how to prevent HIV, as well as information about healthy and unhealthy romantic relationships, and navigating issues related to one\&#39;s gender.
224285110|NCT06586151|BEHAVIORAL|Text Messaging with Information|Text messaging-based program that lasts 5 months. Content includes information about HIV prevention and aspects of a healthy adolescent lifestyle (e.g., self-esteem).
223932147|NCT06866782|DIAGNOSTIC_TEST|Imaging|Imaging will be done according to local protocols and/or guidelines of EAU
223932148|NCT06763458|PROCEDURE|Submaximal balloon angioplasty|The goal of submaximal balloon angioplasty is to use the balloon to improve the stenosis of the criminal artery by more than 20%.
223932149|NCT06426329|BEHAVIORAL|Therapeutic Touch|Therapeutic touch, as meaningful touch, is included in complementary medicine in the literature. It provides physical, emotional and spiritual relief, improves physiological health, makes the person feel valuable, gives confidence, peace, calmness and increases self-confidence.
223932150|NCT06675019|OTHER|Manual therapy|Manual therapy group: will have manual therapy and relaxation training three times per week in addition to their medications as needed. Manual therapy will include stretching exercises, strengthening exercises, soft tissue manipulation in the form of myofascial release and deep friction massage, and postural correction.
223932151|NCT06675019|OTHER|Kinesio taping|Kinesio taping group: will have kinesio taping (KT), and relaxation exercises three times per week in addition to their medication as needed, One I-shaped tape was used to apply KT to the upper trapezius muscle that was 50 mm broad and 0.5 mm thick. The tape was measured from the acromion to the hairline in the back, and the upper trapezius fibers were stretched in the extended position, i.e., the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation positions. The band was secured to the acromion's insertion site in its first resting position. The muscle was lengthened, and the band was fixed with the initial skin shift, after which the band was fixed to the origin of the hairline from the muscle with a 10% stretch. The tape was massaged with the muscle in the extended position.
223932152|NCT06675019|OTHER|Control (Standard treatment)|The control group will just receive relaxation exercises three times per week, in addition to their medications as needed.
223932153|NCT06850519|GENETIC|Exome Sequencing and Sanger Sequencing|Exome Sequencing and Sanger Sequencing
223932154|NCT06734819|BEHAVIORAL|Storytelling Video|The Living Donation Storytelling Project (LDSP) is an online video library of living donation first-person narratives aiming to inspire more people to consider LDKT (https://livingdonationstories.org/).17 As of 2020, the library has 118 stories from living donors and kidney recipients sharing their experiences with the pursuit, challenges and outcomes of transplant.18,19 Four videos were selected from the LDSP and edited to standardized duration and thematic content. Videos were cut to three minutes in length and covered the topics of 1) challenges faced when seeking LDKT, 2) life after LDKT and 3) advice for other patients considering LDKT.
223932155|NCT06734819|BEHAVIORAL|Standard Patient Education|Standard of care patient education materials include verbal didactic offered during the surgical consult and pamphlets produced by Vancouver Coastal Health.
223932156|NCT06744153|PROCEDURE|Space Maintainer|Fabrication of KOS\&MET functional space maintainer and its cementation.
223932157|NCT06772935|BEHAVIORAL|Electro-acupuncture|A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body.
223932158|NCT06832774|PROCEDURE|Local treatment|For bone lesions, radiotherapy or orthopedic surgery may be selected. For lymph node lesions, radiotherapy or high-energy focused ultrasound (HIFU) maybe selected. The specific treatment plan will be determined by the researcher and based on the patient's clinical condition.
223932159|NCT06832774|DRUG|Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).|"The intervention contains gonadotropin releasing hormone analog (GnRHa) and novel hormone therapy. For GnRHa, there are 3 options available. 1. Leuprorelin/Prostap or Staladex. 2. Goserelin/Zoladex. 3. Triptorelin /LiverTox. For novel hormone therapy, there are also 3 options available. 1. Abiraterone/ ZYTIGA®. 2. Apalutamide/ERLEADA®. 3. Rezvilutamide/ARIANE®. The specific treatment plan will be designed according to patients' clinical conditions based on EAU guidelines."
223932160|NCT06795789|DIETARY_SUPPLEMENT|Vitals+ (combined multivitamin and polyphenol supplement)|Multivitamin with 19 essential nutrients combined with Bilberry polyphenols
224096450|NCT02735213|DEVICE|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
224096451|NCT02735213|DEVICE|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.
223932161|NCT06752486|DRUG|Giving post photorefractive keratectomy for pain relief|We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
223932162|NCT06828458|OTHER|Biological sampling|"Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites)~At day 0, day 3, day 7, day 14, day 21"
224096452|NCT03771872|DEVICE|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
224096453|NCT03771872|DEVICE|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
224096454|NCT00201539|DRUG|single dose Morphine|
224096455|NCT00201539|DRUG|double dose Morphine|
224096456|NCT00201539|DRUG|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
224096457|NCT02277171|DEVICE|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
224096458|NCT01676961|BIOLOGICAL|romiplostim|Given SC
224096459|NCT06172101|OTHER|Free fat flap|Free fat flap In Recurrent neurogenic thoracic outlet syndrome Surgical Treatment
224096460|NCT03582111|OTHER|Study of medical records|Study of medical records
223718356|NCT01497691|DEVICE|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
224096461|NCT01239927|PROCEDURE|Primary sigmoid resection with end colostomy (Hartmann)|
223932163|NCT06843187|DRUG|Lemborexant|Dayvigo (lemborexant compound) is an orexin antagonist that acts on the arousal and sleep neural networks of the brain to regulate sleep-wake cycles and is used in the treatment of insomnia characterized by difficulties with sleep.
223932164|NCT06843187|OTHER|Placebo|The placebo is an inactive sugar pill that looks and tastes identical to the lemborexant pill.
224096462|NCT01239927|PROCEDURE|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
223533531|NCT07094997|OTHER|Swedish massage|A classical form of therapeutic massage that uses a combination of long, flowing strokes, kneading, friction, tapping, and gentle stretching to promote relaxation, improve circulation, and reduce muscle tension. It is typically performed using oil or lotion to reduce friction on the skin. Techniques are applied with light to moderate pressure and are designed to enhance general well-being and support recovery from muscular discomfort or stress
223533532|NCT07096453|DRUG|Cytogam|Cytogam is used for the prevention of cytomegalovirus (CMV) disease in kidney, lung, liver, pancreas, heart and bone marrow transplantation. We do not yet have data about how much cytogam reduces CMV in blood, or how quickly it reduces CMV in blood.
223932165|NCT06810700|DEVICE|MiniMed 780G|patients aged \>12 years old with T1DM who are on MiniMed 780G
223932166|NCT05120856|BEHAVIORAL|AAT-App|Participants will receive the active AAT-App on their smartphone, which includes ApBM training, and prompted to engage with the app during the 28-day intervention period.
223932167|NCT05120856|BEHAVIORAL|Minimal AAT-App|Participants will receive the minimal version of AAT-App, which does not include ApBM training, on their smartphone and prompted to engage with the app during the 28-day intervention period.
223932168|NCT06302452|BEHAVIORAL|Adopting Comprehensive Training for FireArm Safety in Trauma Centers|Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
223932169|NCT06747520|DRUG|ET-26HCl|The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
223932170|NCT06618950|BEHAVIORAL|physical activity|The key factor that distinguishes this study from others is its comprehensive examination of the effects of regular physical activity on late adolescents, not only in terms of physical health but also regarding healthy lifestyle behaviors, self-esteem, and psychological well-being. While other studies typically focus on the benefits of physical activity for physical health, this research considers the broader psychological and social development of adolescents, offering a wider perspective. Additionally, its emphasis on the sustainability of a planned and structured physical activity regimen, along with its approach to transforming physical activity into a lifestyle, represents a significant difference.
224285111|NCT00614822|DRUG|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
224285112|NCT00028535|BIOLOGICAL|trastuzumab|Given IV
224285113|NCT00028535|DRUG|paclitaxel|Given IV
224285114|NCT00028535|BIOLOGICAL|recombinant interleukin-12|Given SC
224285115|NCT00755768|BEHAVIORAL|additional review by dietician|
224285116|NCT00335335|DRUG|iodixanol|
224285117|NCT03601546|OTHER|Clinical examination|Blood test and patient interview as for standard patient care
224285118|NCT00097045|DRUG|omega interferon|
224285119|NCT00097045|DRUG|Ribavirin|
224285120|NCT06324786|BEHAVIORAL|IBMT|IBMT is an effortless mindfulness technique
224285121|NCT06324786|BEHAVIORAL|NF|NF is a mental training technique.
224285122|NCT05155527|DRUG|Ivermectin Tablets|6 mg/tablet
224285123|NCT05155527|OTHER|Placebo|The placebo has same form as Ivermectin.
224285124|NCT01557920|DRUG|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
224285125|NCT01557920|DRUG|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
224285126|NCT00673192|PROCEDURE|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
224285127|NCT03584217|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
224285128|NCT03584217|DRUG|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
224285129|NCT03584217|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
224285130|NCT04339595|BIOLOGICAL|Tildrakizumab|Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.
224285131|NCT01072799|BIOLOGICAL|Placebo|Two doses (Day 1 and Day 22); 0.5mL
224285132|NCT01072799|BIOLOGICAL|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 \& Day 22); 0.5mL
224285133|NCT04157972|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
224285134|NCT04157972|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
224285135|NCT01309724|OTHER|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
224285136|NCT05458037|PROCEDURE|Speed of tenaculum application|Fast or slow closure of the tenaculum for application to the uterine cervix
224285137|NCT04948671|OTHER|there will be no intervention, this is an observational study|this is an observational study
224285138|NCT03290313|DRUG|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
223932171|NCT06889519|BEHAVIORAL|MBT Lighthouse Parenting Program|Lighthouse Parenting Programme, a 12-week intervention for parents, focusing on enhancing mentalizing abilities. It includes weekly group sessions (2hrs) led by 3 trained MBT psychotherapists for 8-12 parents, and fortnightly individual parenting sessions (1hr) with a practitioner. The programme, rooted in Mentalization-Based Treatment (MBT) skills, explores parents mentalizing and their childrens mentalizing and attachment styles through a variety of interactive methods, including multimedia resources and creative activities to stimulate mentalizing. Central to the programme is the metaphor of the parent as a lighthouse, guiding their child. Training for practitioners spanned 4 days, covering MBT and Lighthouse Parenting skills, with an emphasis on experiential learning and self-reflection. Ongoing weekly group supervision will ensure the quality and fidelity of the intervention. Delivered in person at University Diego Portales.
223932172|NCT06889519|BEHAVIORAL|Psychoeducational cards|They will receive weekly information on parenting in the first 3 years of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
223932173|NCT06752291|DEVICE|water flosser|A water flosser will be provided for use throughout the study, with participants instructed to use it once daily, specifically at the end of the day before bedtime.
223932174|NCT00227266|DRUG|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
223932175|NCT00227266|DRUG|Placebo|
223932176|NCT04584983|DRUG|usual prescribed intralipid (UL) regimen|Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
223932177|NCT04584983|DRUG|restricted prescribed intralipid (RL) regimen|Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
223932178|NCT06747728|DRUG|Bevacizumab|Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.
223932179|NCT06782477|DRUG|STAR-0310|STAR-0310 will be administered as a subcutaneous bolus injection.
223932180|NCT06782477|DRUG|Placebo|Placebo will be administered as a subcutaneous bolus injection.
223932181|NCT04787341|DRUG|Regorafenib|"regorafenib administered until progression, unacceptable toxicity or patient's refusal followed after progression by panitumumab until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
223932182|NCT04787341|DRUG|Panitumumab|"panitumumab administered until progression, unacceptable toxicity or patient's refusal followed after progression by regorafenib until further progression, unacceptable toxicity or patient's refusal in RAS and BRAF wt mCRC patients with the following characteristics:~1. previous treatment with, or not considered candidates for, fluoropyrimidine, oxaliplatin, irinotecan and anti-angiogenic agent (bevacizumab or aflibercept);~2. RECIST response or stable disease lasting at least 6 months to a previous first-line anti-EGFR-based treatment;~3. RAS and BRAF wt ct-DNA at the time of screening."
223932183|NCT06765408|OTHER|facial yoga exercise program|An exercise programme consisting of basic yoga movements such as swan neck exercise, fist exercise, hand to head exercise, jowl drawer exercise, tongue and palate exercise, lip curling exercise, ceiling kissing exercise, namaste exercise, balloon inflation, spider and fish exercise, lip spray, Chinese moustache, binocular exercise, gaze exercises and lion pose was applied. Each session was approximately 30 minutes and all exercises were accompanied by breathing exercises on the basis of exercising all facial muscles. The exercise programme was performed for 8 weeks, 2 days a week face-to-face and 5 days at home, for a total of 16 sessions face-to-face and 40 sessions at home. Participants were given verbal, written and video explanations and instructions about the exercise protocol. Every day in a WhatsApp group where all participants take part, Assist. Prof. Dr. Hazel Çelik Güzel provided information and reminders and ensured the continuity of the exercises. Participants were al
223941349|NCT06434584|OTHER|with AI dosage assistance|provide insulin dosage and confidence score with AI dosage assistance
223941350|NCT06434584|OTHER|with explainable AI assistance|provide insulin dosage and confidence score with explainable AI assistance
223941351|NCT06434584|OTHER|with faulty explainable AI assistance|provide insulin dosage and confidence score with faulty explainable AI assistance
224096463|NCT02498210|OTHER|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
223932184|NCT06775990|OTHER|Blood sample|Children were not given any medication in the study. Peripheral blood samples from the children were collected, centrifuged and stored in the biochemistry laboratory in deep freezers at -80 degree celcius. From stored serum samples leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, Peroxisome proliferator-activated receptor gamma (PPAR γ), nod-like receptor pyrin domain-containing 3 (NLRP3), interleukin-18 (IL-18) levels were determined by ELISA in thirty obese and thirty healthy children.
223932185|NCT06454669|DRUG|Dronabinol|Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
223932186|NCT06454669|DRUG|Placebo|Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
223932187|NCT06750991|DRUG|CDR-CHOP|Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1
224096464|NCT05035498|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
224096465|NCT05035498|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
224096466|NCT04003714|DEVICE|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
223932188|NCT06111248|OTHER|Training|Staff training on the use of surgical plethysmographic index (SPI) state entropy (SE) and train-of-four (TOF) intraoperative monitors and AoA software.
223932189|NCT02678689|BIOLOGICAL|BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
223932190|NCT02678689|DEVICE|Intracerebroventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
223941352|NCT03800212|DRUG|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
224096467|NCT04003714|DEVICE|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
224096468|NCT01215084|DRUG|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
224096469|NCT01811914|OTHER|intraoperative TTE|
224096470|NCT02224950|DEVICE|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
224096471|NCT02224950|OTHER|Non-medicated Emollient plus Cotton Sleeve|
224096472|NCT02224950|OTHER|Placebo Sleeve|
224096473|NCT04012255|DRUG|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
223932191|NCT06777199|PROCEDURE|Microscopic Selective Dorsal Neurectomy (SDN)|"Selective dorsal neurectomy (SDN) involves microsurgical dissection and partial transection of the dorsal penile nerves to reduce glans sensitivity.~The procedure is performed under spinal anesthesia or local anesthesia with 1% lidocaine.~A midline or dorsal sub-coronal incision is made 1 cm proximal to the coronal sulcus.~The skin is retracted, exposing the Dartos fascia and Buck's fascia to reach the neurovascular bundle (two dorsal penile nerves lateral to two dorsal penile arteries).~Every other nerve on either side of the corpora cavernosa is transected to damage approximately 50% of the nerve supply to the glans.~Suturing is done using 7-0 or 8-0 prolene sutures, and the incision is closed. Patients are evaluated at 1 month and 3 months post-procedure for IELT, AIPE, and PEDT scores to determine success."
223533538|NCT07140172|PROCEDURE|Axillary lymph node dissection (ALND)|Surgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)
223533539|NCT07140172|PROCEDURE|Axillary radiotherapy (ART)|Axillary irradiation
223533540|NCT07141082|OTHER|Art therapy combined with Exercise|The intervention program consists of one hour of expressive art intervention followed by one hour of exercise training. Art therapy sessions will be conducted in small groups of eight participants, facilitated by a part-time registered expressive art therapist. Each session begins with a 5-minute introduction and check-in, welcoming participants and encouraging them to share their current status. This is followed by a 10-minute mindfulness exercise designed to center participants and promote relaxation, preparing them for the creative activities ahead. The core of each session features a 20-minute art-making process focused on specific themes that guide participants in exploring their pain and personal narratives.
223533541|NCT07141082|OTHER|Exercise|each one-hour session in the exercise control group will involve progressive back and general reconditioning exercises, along with back care education to support self-management of LBP.
223533542|NCT07147855|BEHAVIORAL|Take your sexuality back|A 12 weeks group program.
223533543|NCT07148115|OTHER|Collect data on all pregnancies before and after diagnosis of SLE.|"For participants who are still alive, data are collected from interviews with patients using a prepared questionnaire that asks about all pregnancies and obstetrical events prior to and following the diagnosis of SLE.~For deceased patients, data are taken from the medical records of obstetrical events.~Data will be collected on anthropometric, biological, immunological, and histological features before and after the diagnosis of SLE, if available.~The activity and severity of the disease after diagnosis will be assessed using the recommended tools."
223533544|NCT07148076|BEHAVIORAL|Education Program|This intervention consists of a structured educational program specifically designed for educational staff in primary schools and kindergartens, focusing on the care of children with type 1 diabetes. The program includes interactive lectures, practical workshops, and case studies covering diabetes management, symptom recognition, emergency procedures, and day-to-day support for children with type 1 diabetes in educational settings. Unlike standard informational sessions or general health education, this intervention is tailored to address the unique challenges and responsibilities faced by school and kindergarten staff. The program is delivered in-person by certified diabetes educators and includes pre- and post-training assessments to measure changes in knowledge, perceptions, and attitudes. Participants are tracked using unique codes to allow for longitudinal comparison of results before, immediately after, and three months following the intervention.
223533545|NCT07148583|DIETARY_SUPPLEMENT|BioAmicus Complete|Oral liquid probiotic (multistrain) administered by caregivers per protocol/label for 42 days to infants with functional GI symptoms. Given as drops by mouth; dosing and administration instructions per protocol. No other probiotic products allowed during the study. Concomitant medications and routine management may be used as clinically indicated. Adherence is recorded; lot/batch number captured.
223533546|NCT07148583|OTHER|Usual Care (No Probiotic)|Standard clinical management for infant functional gastrointestinal symptoms per local practice. No probiotic supplementation is provided during the study period. Participants follow the same visit and assessment schedule as the intervention arm. Concomitant medications and supportive care may be used as clinically indicated.
223718357|NCT03808545|BEHAVIORAL|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
223932192|NCT06777199|PROCEDURE|Pulsed Radiofrequency (PRF) Nerve Ablation|"Pulsed radiofrequency (PRF) nerve ablation aims to reduce sensitivity of the dorsal penile nerves using low-energy radiofrequency pulses.~Under sterile conditions, a 22-gauge RF cannula (5-cm-long, 10-mm active tip) is inserted into the flaccid penile skin at the 1-o'clock position for the right dorsal penile nerve.~Sensory stimulation testing is performed at 50 Hz to identify the point of maximum glans sensitivity.~Pulsed radiofrequency is applied at an energy output of 45 V for 180 seconds at 42°C (using the NeuroTherm generator).~The procedure is repeated at the 11-o'clock position for the left dorsal penile nerve, ensuring both sides are treated.~The goal is to ablate sensation over as large an area of the glans as possible without causing permanent nerve damage.~Post-procedure, patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores."
223932193|NCT06777199|PROCEDURE|Intraglanular Hyaluronic Acid (HA) Injection|"Intraglanular hyaluronic acid (HA) injection involves administering HA gel into the glans penis to reduce its sensitivity.~The circumference of the glans penis is divided into three circles (1 cm apart, starting from the base), and each circle is further divided into quarter circles.~Topical anesthetic cream (Emla®, lidocaine 25 mg + prilocaine 25 mg) is applied for 30 minutes to numb the glans.~Using two prefilled syringes of HA gel (Hyabell Ultra® 24 mg/ml with 0.3% lidocaine), 12 injections are administered into the deep dermis of the glans using a 27-G needle.~Each injection site receives 0.25 ml of HA gel following the multiple puncture technique.~Patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores to assess efficacy."
223932194|NCT06532396|DRUG|QRL-101|Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.
223932195|NCT06532396|DRUG|Placebo|Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
223932196|NCT06756555|DIAGNOSTIC_TEST|efficacy of Incentive spirometer|The main objective of this research is to check the efficacy of Incentive spirometer on pulmonary complication after bariatric surgrey
223932197|NCT06756919|BEHAVIORAL|Music intervention|Music therapy ( nature sounds) during the endoscopy procedure
224096474|NCT04012255|DRUG|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
224096475|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
224096476|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
224096477|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
224096478|NCT00117312|DRUG|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
224096479|NCT00195650|BIOLOGICAL|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
224096480|NCT05653895|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
224096481|NCT05653895|DRUG|Metformin|Metformin
224096482|NCT05653895|COMBINATION_PRODUCT|Acetyl-L-Carnitin, L Arginine, Co-Q10|Treatment of PCOS with combination of Acetyl-L-Carnitin, L Arginine, Co-Q10
224096483|NCT02602067|COMBINATION_PRODUCT|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
224099719|NCT05519631|OTHER|electroencephalogram|The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
224099720|NCT04032340|OTHER|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
224099721|NCT03501927|DIAGNOSTIC_TEST|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~* Left ventricular systolic function~* Left ventricular diastolic function~* Right ventricular systolic function~* Right ventricular pressure overload~* Biventricular sizes~* Pathology of the mitral- and aortic valves~* Pericardial fluid~* Gross fluid status~* Pleural effusion"
224099722|NCT01571479|PROCEDURE|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
224099723|NCT00797121|PROCEDURE|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
224099724|NCT05437796|DEVICE|Hypnotic virtual reality support using hypnosis software Hypno-VR®|Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)
224099725|NCT05437796|DEVICE|No Hypnotic virtual reality|Group without Hypnotic virtual reality
224099726|NCT01659151|DRUG|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
224099727|NCT01659151|PROCEDURE|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
224099728|NCT01659151|DRUG|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
224099729|NCT01659151|DRUG|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
224099730|NCT06745947|BEHAVIORAL|EFT|Participants who meet the eligibility criteria will receive the EFT intervention, a cognitive training exercise designed to help them generate and visualize future events or goals. The intervention will be administered individually, in person, by a trained counselor
224099731|NCT00138762|DRUG|torcetrapib/atorvastatin|
224099732|NCT00138762|DRUG|atorvastatin|
223533547|NCT07147868|BEHAVIORAL|Structured Education Program for Caregivers of Chemotherapy Patients|A structured educational intervention designed for caregivers of cancer patients undergoing chemotherapy, delivered in 30-45 minute sessions to groups of 4-5 participants. The program includes modules on self-efficacy, stress management, healthy lifestyle behaviors, interpersonal relationships, and nutrition based on the Mediterranean diet. Content covers evidence-based strategies for improving family health, psychological well-being, and dietary adherence. Sessions are conducted by a certified practitioner with 480 hours of family counseling training in a university hospital's medical oncology unit seminar room. The intervention aims to reduce caregiver burden, enhance psychological well-being, improve adherence to the Mediterranean diet, and promote family health, as assessed by the Family Health Scale (ASÖ), Mediterranean Diet Adherence Scale (MEDAS), and Psychological Well-Being Scale (PİO) at baseline (t0), post-intervention (t1), and 6 weeks follow-up (t2).
223533548|NCT07148895|PROCEDURE|Post-surgical drain|During surgery, at the completion of the Sistrunk procedure, participants in the drain cohort will have a suction drain placed, which will be removed based on standard criteria prior to discharge from the hospital. Wound care following drain removal will be standardized, with instructions for patients to allow the area to heal naturally and to follow a regimen of cleaning and applying topical antibiotic ointment for several days.
223533549|NCT07148895|PROCEDURE|No post-surgical drain|Patients will be recovered in SOC manner from Sistrunk surgery without drain placement
223533550|NCT07150338|DRUG|QRX-3|Compounded new drug regime
223533551|NCT07150338|DRUG|Eseronate|Neukidney innovative drug
223533552|NCT07149753|DRUG|MILTEFOSINE gel|Each patient will receive a 30 g tube of G-MTF with instructions and recommendations for use. The first dose will be in the FOSCAL clinical studies unit; subsequent doses will be applied at the patient's site of origin based on their autonomy, once a day (morning or night). Instructions include washing hands thoroughly, cleaning the lesion, applying a thin layer of gel, leaving it uncovered for at least 15 minutes, avoiding contact with water until the next dose, and storing the gel properly during treatment.
224099733|NCT00138762|DRUG|placebo|
223533553|NCT07150663|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nanocrystalline Megestrol Acetate Oral Suspension Nanocrystalline Megestrol Acetate Oral Suspension (125 mg/mL) was administered to the study group at 5 mL orally once daily (equivalent to 625 mg/day) until disease progression or completion of 8 weeks (maximum treatment duration: 8 weeks), whichever occurred first.
223533554|NCT07150663|OTHER|Standard Therapy|Standard Therapy
223533555|NCT07158073|DEVICE|FiO₂ titration, under the guidance of ORI|In Group R, FiO₂ was titrated between 30% and 50% under the guidance of ORI and SpO₂ values. Accordingly, if SpO₂ was ≥ 98%, FiO₂ was reduced in 5% increments to a minimum of 30%, aiming to achieve an ORI value of 0 or as close to 0 as possible.
223533556|NCT07158073|DEVICE|Conventional oxygen administration|In Group C, FiO₂ was maintained at 50% throughout the surgery, provided that SpO₂ remained ≥ 98%.
223533557|NCT07161453|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
223533558|NCT07161453|DRUG|PD-1 / PD-L1 monoclonal antibody|PD-1/PD-L1 monoclonal antibody
223533559|NCT07161453|DRUG|SOX Chemotherapy|SOX or XELOX
223533560|NCT07161453|DRUG|Tegafur-Ugotex or Capecitabine|Tegafur-Ugotex or Capecitabine
223533561|NCT07160933|OTHER|No Intervention: Observational Cohort|This study phase is a qualitative exploration of participants' preferences and recommendations for a psychosocial intervention.
223533562|NCT07159048|DEVICE|Multimodal Tumor Thermal Therapy System|All subjects were treated with a multi-modal thermal therapy system (Shanghai MAaGI Medical Technology Co., Ltd.) following a temperature-controlled tumor ablation protocol. Complete ablation of intrahepatic lesions was achieved, resulting in no evidence of disease (NED) within the liver. For lesions that could not be fully ablated in a single session, two treatment sessions were performed to attain intrahepatic NED status.
223533563|NCT07159048|DEVICE|Radiofrequency Ablation System or Microwave Ablation System|All subjects were treated with a radiofrequency ablation system or microwave ablation System. Complete ablation of intrahepatic lesions was achieved, resulting in no evidence of disease (NED) within the liver. For lesions that could not be fully ablated in a single session, two treatment sessions were performed to attain intrahepatic NED status.
223718358|NCT03808545|BEHAVIORAL|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
223718359|NCT03229278|DRUG|Enzyme Inhibitor Therapy|Given trigriluzole PO
223932198|NCT06756334|DRUG|[18F]AlF-PSMA-N5|Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.
223932199|NCT06756334|DRUG|[18F]F-DCFPyL|Each subject receive a single intravenous injection of \[18F\]F-DCFPyL, and undergo PET/CT imaging within the specificed time.
223932200|NCT06760221|RADIATION|stereotactic body raiotherapy|Neoadjuvant stereotactic body radiation therapy followed by radical surgery for soft tissue sarcoma.
223932201|NCT06736834|OTHER|Babao Congee and Youtiao(deep-fried dough sticks) with different cooking conditions|Babao Congee and deep-fried dough sticks with different cooking conditions
223932202|NCT06774170|BEHAVIORAL|structured follow-up intervention|"The intervention has been created in light of the studies including type 1 and type 2 diabetes patients and experiences of the project team with patients after PD. Theoretical background of the intervention is based on the interventions developed for glucose management in type 1 and type 2 diabetes patients and the effect of the intervention will be evaluated by using the plan-do-check-act model."
223932203|NCT06780774|DIETARY_SUPPLEMENT|Caffeine, Vitamins, Minerals and Botanical Blend|"Blend containing 120mg of caffeine, vitamins, minerals and botanical extracts in capsule form.~Other Names: Active Treatment"
223932204|NCT06780774|DIETARY_SUPPLEMENT|Placebo|Blend containing 17mg Marigold Extract and Brown rice flour. Other Names: Placebo Treatment
223932205|NCT06564454|OTHER|No intervention|Assessment of knowledge, attitude and practice of green Dentistry
223932206|NCT06210243|BIOLOGICAL|C752|C752 will be administered on Day 0
223932207|NCT06619327|BEHAVIORAL|Resilient Together for Dementia|RT-D has been developed based on feedback from couples and dementia clinicians as well as prior successful dyadic interventions. RT-D was developed based on the Recovering Together (RT) dyadic intervention for acute neurological illnesses and is being adapted to address the needs of couples navigating new dementia diagnoses.
223533564|NCT07159321|OTHER|Comprehensive geriatric assessment|Functional status will be evaluated using Activities of Daily Living (ADL) (assessing bathing, dressing, toileting, transferring, eating, and continence; Katz, 1970) and Instrumental ADL (IADL) (assessing shopping, cooking, medication management, phone use, housework, laundry, transportation, and finances; Lawton \& Brody, 1969). Nutritional status will be measured via the Mini-Nutritional Assessment-Short Form (MNA-SF) (Arabic version; Abd-Al-Atty et al., 2012), a 6-item tool (appetite, weight loss, mobility, illness, neuropsychological issues, BMI) scored 0-14, classifying patients as well-nourished (≥12), at risk (8-11), or malnourished (0-7; Rubenstein et al., 2001). Cognition will be assessed using the Saint Louis University Mental Status (SLUMS) exam (Arabic version; Abdelrahamn et al., 2014), a 30-point test evaluating calculation, orientation, memory, fluency, and visuospatial function, with dementia thresholds at \<20 (\<12 years education) or \<21 (≥12 years; Tariq et al., 2006).
223533565|NCT07159321|OTHER|European Organization for Research and Treatment-Quality of life questionnaire|"Quality of life assessment by European Organization for Research and Treatment-Quality of life questionnaire and breast cancer-specific module (EORTC QLQ-C30)and QLQ-BR23)~EORTC QLQ-C30 is a validated tool designed to measure cancer patients' physical, psychological and social functions. It consists of 30 items measuring Global Health status (2 items), Functional scales (15 items) and Symptoms scales/items (13 items). Items were measured using a 4-point Likert Scale ranging from Not at all (1) to Very much (4).~EORTC-BR23 consists of 23 items which measure two main scales Functional Scale (8 items) and Symptoms scales (15 items). Items measured using 4-point Likert Scale ranging from Not at all (1) to Very much (4)."
223718360|NCT03229278|OTHER|Laboratory Biomarker Analysis|Correlative studies
223718361|NCT03229278|BIOLOGICAL|Nivolumab|Given IV
223718362|NCT03229278|BIOLOGICAL|Pembrolizumab|Given IV
223932208|NCT06619327|BEHAVIORAL|MEUC|The MEUC condition was also developed based on the comparison trial in the Recovering Together dyadic intervention, and was adapted based on feedback from prior studies. The program is self-guided and provides educational information similar to the RT-D condition, but with no skills practice or weekly sessions with a therapist.
223932209|NCT06117111|DEVICE|PaMo monitoring device|Comparison of the device to standard monitoring
223932210|NCT05239793|DRUG|NJOY e-cigarette|NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
223932211|NCT04007796|BEHAVIORAL|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
223932212|NCT04007796|BEHAVIORAL|Sleep Education (SE)|This treatment will be offered over six sessions. All appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
223932213|NCT05958030|DEVICE|Placebo|The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
223932214|NCT05958030|DEVICE|GyroGlove|GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).
223932215|NCT06862102|BIOLOGICAL|HPV vaccine|vaccine administration
223932216|NCT06839352|DRUG|Vitamin K1|10 mg intravenous infusion daily for three days
223932217|NCT06111872|DRUG|Ketamine|Administration described in arm/ group description
223718363|NCT00630981|BEHAVIORAL|Psychotherapy|Specific psychotherapy for dissociative disorders
223718364|NCT00630981|DRUG|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
223718365|NCT03504475|DRUG|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
223718366|NCT03504475|DRUG|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
223932218|NCT06111872|DRUG|Midazolam|Administration described in arm/ group description
223718367|NCT01502098|PROCEDURE|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
223932219|NCT06111872|DRUG|Pethidin|Administration described in arm/ group description
223932220|NCT06639425|DIETARY_SUPPLEMENT|Lactobacillus paracasei LC19 supplementation|Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).
223932221|NCT06639425|DIETARY_SUPPLEMENT|Placebo probiotic milk powder|Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).
223932222|NCT06801964|OTHER|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
223932223|NCT06801964|DIETARY_SUPPLEMENT|Protein and Fish Oil|milk/carbohydrate mixture and supplementation of 3.5g of EPA+DHA (7g of fish oil)
223533566|NCT07159321|OTHER|Clinical Frailty Scale|Frailty will be assessed using the Clinical Frailty Scale (CFS), a validated and widely used tool developed by (Rockwood et al., 2005). The CFS is a 9-point ordinal scale that categorizes older adults based on their level of physical fitness, functional independence, and comorbidities, ranging from 1 indicate very fit to 9 indicate terminally ill. Participants were evaluated by trained clinicians based on their clinical judgment, incorporating information from patient interviews. The scale provides a practical and reliable measure of frailty in geriatric populations and has demonstrated strong predictive validity for adverse health outcomes including hospitalization, institutionalization, and mortality.
223533567|NCT07159659|DIETARY_SUPPLEMENT|MCT Diet|MCT diet for patients following lung resection
223533568|NCT07160010|DIAGNOSTIC_TEST|Sophia Herditary Cancer Solution|To compare the performance of MGI's DNBSEQ-G400 sequencing instrument with the gold standard Illumina instruments (MiSeq and NextSeq 550) using the same capture DNA libraries constructed with Sophia Genetics assays.
223533569|NCT07159165|PROCEDURE|Minimally invasive surgical treatment for benign prostatic obstruction|"Surgical management of BPO using contemporary minimally invasive procedures, including but not limited to: Transurethral resection of the prostate (TURP), Holmium laser enucleation of the prostate (HoLEP), Thulium laser enucleation of the prostate (ThuLEP), Rezum® water vapor thermal therapy.~Procedures are performed according to standard clinical practice at each participating center, with perioperative and follow-up data prospectively recorded in the MIUS registry."
223533570|NCT07158619|DIETARY_SUPPLEMENT|OIT with cashew nut protein|After 8 months of continued oral immunotherapy (OIT) with cashew nuts, patients will undergo hospital-based assessments, including skin prick testing, laboratory evaluations, and an open Oral Food Challenge (OFC) to assess desensitization. Patients who had a negative OFC after 3 months in the initial phase-confirming desensitization-will skip the pre-break OFC and proceed directly to the next stage. Following a 4-week interruption in OIT, patients will return for a final hospital visit, during which a concluding OFC will be conducted to evaluate sustained unresponsiveness. Additional laboratory tests and skin prick testing will also be performed during this visit.
223533571|NCT07159022|PROCEDURE|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
223533572|NCT07159022|PROCEDURE|Face Mask Oxygenation|conventional oxygen therapy will be administered through common mask with a flow up to 6 Liters per minute
223932224|NCT06801964|DIETARY_SUPPLEMENT|Protein and Olive Oil|milk/carbohydrate mixture with olive oil
223932225|NCT06801964|DIETARY_SUPPLEMENT|Carbohydrate and Olive Oil|carbohydrate mixture with olive oil
224285139|NCT03290313|DRUG|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
224285140|NCT03290313|OTHER|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
224285141|NCT03063216|PROCEDURE|intraocular lens implantation|1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation
224285142|NCT00263627|BIOLOGICAL|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
224285143|NCT00263627|OTHER|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
224285144|NCT05633082|DEVICE|Lens 1 (omafilcon B)|Toric daily wear contact lens for 15 minutes
224285145|NCT05633082|DEVICE|Lens 2 (fanfilcon A)|Toric daily wear contact lens for 15 minutes
224285146|NCT02349074|PROCEDURE|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
224285147|NCT04479748|DRUG|Dexamethasone|Treatment of pain and inflammation following ophthalmic surgery
224285148|NCT04479748|DRUG|Prednisolone Acetate 1% Oph Susp|Topical steroid
224285149|NCT02194140|OTHER|oral iodinated contrast material|diluted in water
224285150|NCT00001873|DEVICE|Isolex 300i plus MoAbs|
223932226|NCT06767137|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|Cognitive Behavioral Therapy for Insomnia (CBT-I) is a gold-standard, evidence-based treatment combining techniques to improve the clinical symptomatology of insomnia. Delivered in six 90-minute group sessions over six weeks, it includes: sleep education (i.e. understanding sleep mechanisms and influencing factors), bedtime restriction (i.e. aligning bedtimes with reported sleep duration), stimulus control (i.e. getting out of bed when unable to sleep), cognitive therapy (i.e. addressing dysfunctional sleep beliefs), relaxation techniques (i.e. using methods like progressive muscle relaxation).
223941353|NCT06098482|DEVICE|Mobile Research App (MRA)|The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.
224285151|NCT00024388|DRUG|DHA-paclitaxel|
224285152|NCT00596206|DRUG|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
223533573|NCT07159282|OTHER|XWRAP|Application of XWRAP + standard of care for up to 12 weeks.
223533574|NCT03419234|DRUG|Abiraterone Acetate|Given PO
223533575|NCT03419234|DRUG|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
223533576|NCT03419234|DRUG|Cabazitaxel|Given IV
223533577|NCT03419234|OTHER|Laboratory Biomarker Analysis|Correlative studies
223533578|NCT03419234|PROCEDURE|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
223533579|NCT03419234|OTHER|Pharmacological Study|Correlative studies
223533580|NCT03419234|DRUG|Prednisone|Given PO
223932227|NCT06767137|BEHAVIORAL|Bedtime restriction (BRT)|"Bedtime Restriction Therapy (BRT): A behavioral intervention aimed at improving the clinical symptomatology of insomnia by aligning time spent in bed with reported sleep duration. Participants attend four 60-minute group therapy sessions over six weeks. The intervention includes: setting individualized sleep windows based on sleep diaries, regular adjustment of sleep schedules to enhance sleep pressure, group discussions to address implementation challenges and maintain motivation.~BRT focuses exclusively on bed time restriction without additional cognitive or relaxation components, making it a simplified, resource-efficient approach to treating insomnia."
223932228|NCT06637969|BEHAVIORAL|mindfulness-based|The experimental group was also provided with a total of 30 minutes of mindfulness training once a day for seven consecutive days. The content included mindful breathing awareness for 8 minutes while resting and lying in bed, 10 minutes of mindfulness meditation, 12 minutes of mindfulness body scanning, and 10 minutes of mindful walking and breathing. The control group The group received routine care, and a pre-test was conducted before the implementation of the interventional measures (from 7 pm to 9 pm the day before the operation), and a post-test was conducted after the seven-day intervention (from 7 pm to 9 pm on the seventh day of the interventional treatment). Comparison between the experimental group and the control group group differences
223932229|NCT06778629|PROCEDURE|Transversalis Fascia Plane Block|After the wound closure is completed and the patient is still under general anesthesia the TFPB will be performed. As the patient is in the supine position, the high-frequency linear US probe (11-12 MHz, Vivid Q) and a 22-G 80-mm needle (Stimuplex® Ultra 360®, Braun, USA) will be placed longitudinally, 2-3 cm laterally, just above the iliac crest at the mid-axillary line. After the external oblique, internal oblique, and transversus abdominis muscles are distinguished, the common aponeurosis of the transversus abdominis and the internal oblique muscle will be found. The block needle will be directed from anterior to posterior, using an in-plane technique, the block needle will be advanced and the block location will be confirmed by injecting 5 ml of saline. Once the block location is confirmed, 30 ml of 0.25% bupivacaine (Buvicaine, Polifarma ®) will be applied between the transversus abdominis muscle and transversalis fascia.
223941354|NCT06098482|OTHER|SOC/validated delivery of the speech perception test material|This involves the delivery of speech perception test material in the sound booth in a clinic.
224285153|NCT04250831|DIETARY_SUPPLEMENT|agglomerated glucomannan, oligofructose and chromium mixture|Participants visited the University of Roehampton on three separate occasions: visit 1 (screening), visit 2 (baseline), and visit 3 (end of the trial) in total over a period of 4-weeks. During the 4-week study period, participants were instructed to replace breakfast and lunch with a shake (206 kcal/shake) each delivering 3g of the active ingredient (Mix: agglomerated glucomannan, oligofructose and chromium picolinate), and one snack bar each delivering 1.5g of the active ingredient (112 kcal/bar) in between breakfast and lunch, and lunch and dinner following by a selection of healthy dinner according to standard nutritional guidance not exceeding 1500 kcal/day. All subjects were instructed to prepare shakes by using a shaker or blender by mixing all ingredients with 200 ml of water. Participants were also instructed to consume all shakes and bars with an extra 200 ml glass of water throughout the study period.
224285154|NCT01309217|BEHAVIORAL|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
224285155|NCT01309217|OTHER|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
224285156|NCT02075606|DRUG|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
224285157|NCT00877617|BEHAVIORAL|QOL Questionnaire|Mailed survey.
224285158|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
223533581|NCT05056896|DRUG|Aspirin|Capsule taken orally
223533582|NCT05056896|OTHER|Placebo|Capsule taken orally
224285159|NCT03314363|DEVICE|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
224285160|NCT03314363|DEVICE|IC|monitor patients during the whole study period with indirect calorimetry
224285161|NCT03314363|DRUG|NaCl predilution|Replace citrate predilution with NaCl
224285162|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
223533583|NCT06433700|OTHER|BAS|NOMESCO (Nordic Medico-Statistical Committee) Classification of Surgical Procedures (KJDF10 \& KJDF11 \[gastric bypass\]; KJDF20 \& KJDF21 \[gastric banding\]; KJDF40, KJDF41, KJDF96 \& KJDF97 \[gastric sleeve\]).
223533584|NCT06433700|OTHER|Non-BAS|Patients without BAS codes
223533585|NCT00492453|PROCEDURE|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
223533586|NCT01334918|DRUG|regadenoson|Administered by intravenous bolus.
223533587|NCT01334918|RADIATION|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
223533588|NCT01334918|RADIATION|Contrast|Administered by intravenous infusion.
223533589|NCT01334918|PROCEDURE|Single Photon Emission Computed Tomography|Procedure/Surgery
224285163|NCT03314363|DRUG|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
224285164|NCT03314363|DIAGNOSTIC_TEST|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
224285165|NCT03314363|DIETARY_SUPPLEMENT|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
224285166|NCT03314363|DIAGNOSTIC_TEST|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
224285167|NCT05504824|OTHER|Case-based education|"The education phase This stage included the explanation of the CR process, the analysis of CR cases, the drafting of new cases suitable for the CR process by students, and the analysis process.~The education program was carried out on a web platform (Zoom) consistent with the changes in the COVID-19 pandemic process. The CR cases to be used in case-based education were sent to the students via e-mail before the group interview to make sure students came prepared for the group discussion. In case-based education, after the students read the case, they were asked some questions to determine their decisions and reasoning."
224285168|NCT01544517|DRUG|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
224285169|NCT04636541|BEHAVIORAL|Goal Management Training|Goal Management Training® (GMT) has been developed to improve executive functions. It was validated in patients presenting executive dysfunction following many conditions: acquired traumatic brain injury, neurodevelopmental spina bifida, attention deficit and hyperactivity disorder (ADHD), subjective cognitive complaints and multiple sclerosis. GMT includes self-instruction strategies, self-monitoring exercises, cognitive training techniques, psychoeducation on cognitive processes, mindfulness exercises and assignments between sessions. It has been shown to increase patient awareness of deficits and improve cognitive control in goal-directed behaviors. The original GMT is a nine-week program administered to dysexecutive patients in 90-to-120-minute group sessions. Thus, it might be suitable for PD-MCI patients presenting with executive dysfunction.
223533590|NCT01334918|PROCEDURE|Multidetector Computed Tomography|Procedure/Surgery
223533591|NCT03172143|PROCEDURE|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
223533592|NCT03172143|PROCEDURE|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
223533593|NCT02273089|DEVICE|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
223533594|NCT02200601|DEVICE|Seipher Wellness|
223718368|NCT01502098|OTHER|Sling|Sling for 4 weeks
223718369|NCT03313791|DIETARY_SUPPLEMENT|Whey protein concentrate|see arm description
223718370|NCT03313791|DIETARY_SUPPLEMENT|Yoghurt|see arm description
223932230|NCT06778629|PROCEDURE|Post Operative Pain Management|Acetaminophen 1 gr (Paracerol, Polifarma®) intravenous (IV), and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be administered to all patients 30 minutes before wound closure. After surgery, Acetaminophen (Paracerol, Polifarma®) 1 gr IV, and tramadol (Contramal, Abdi İbrahim®) 100 mg IV will be given three times a day. Another anesthesiologist will assess patients after surgery. If the patient's pain score (NRS) is 4 or higher, IV pethidine (Aldolan, Liba Laboratory ®) 0,5 mg/kg will be given as a rescue analgesic.
223932231|NCT06778629|PROCEDURE|Port Site Infiltration|A total of 20 ml of 0.25% bupivacaine ( (Buvicaine, Polifarma ®) will be applied to the trocar entry points by the surgeon at the beginning of the operation, before entering the trocars.
223932232|NCT06660836|DEVICE|Mouthguard|After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.
223932233|NCT06660836|OTHER|Performance test|Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
223932234|NCT05681156|OTHER|N/A- There is no intervention.|There is no intervention.
223932235|NCT06777732|DRUG|Keverprazan|Potassium-competitive acid blocker
223932236|NCT06777732|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223932237|NCT06777732|DRUG|Furazolidone|Antibiotic for H. pylori eradication
223932238|NCT06777732|DRUG|Colloidal Bismuth Pectin|Gastric mucosal protectant
223932239|NCT06750419|DRUG|89Zr-TLX250 PET/CT|"89Zr-TLX250, is a chimeric monoclonal antibody (INN name: girentuximab) with specificity for the CAIX (carbonic anhydrase 9) antigen, radiolabelled with the positron emitting radiometal zirconium- 89. Girentuximab has a CAS number of 916138-87-9. The chemical formula, without the 89Zr and the desferrioxamine, is C6460H1006N1718O2018S48 with a molecular mass of 146.5 kg/mol.~89Zr-TLX250 is formulated as a solution for IV administration in glass vials at the nominal dosage strength of 37 MBq (±10%) for single IV use. The mass dose of 89Zr-TLX250 to be used in this Phase 3 study will be 10 mg, labelled with 37 MBq (±10%) 89Zr per dose."
223932240|NCT04483115|DRUG|TPN171H|Tablets; Oral; Single dose
223932241|NCT04483115|DRUG|Placebo|Tablets; Oral; Single dose
223932242|NCT04483115|DRUG|Tadalafil|Tablets; Oral; Single dose
223932243|NCT05327504|BEHAVIORAL|Written Exposure Therapy|Written Exposure Therapy is a 5 session treatment in which individuals write about their trauma event in a specified manner.
223932244|NCT05327504|BEHAVIORAL|Neutral Topic Writing|Treatment as Usual augmented by 5 sessions of Neutral Topic Writing which involves writing about specific objects (e.g., what they have eaten over the past week) or events (e.g., what they did since yesterday) in detail without discussing thoughts or feelings.
223932245|NCT06094218|BEHAVIORAL|Brief Cognitive Behavioral Therapy (BCBT)|BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.
223932246|NCT06094218|BEHAVIORAL|Treatment as usual (TAU)|Behavioral health treatment as it is typically provided at the treatment site.
223932247|NCT01347255|DRUG|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
223932248|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
223932249|NCT01347255|DRUG|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
224285170|NCT04636541|BEHAVIORAL|Psychoeducation|See the Arm section for full details. For a justification of how we designed this intervention: Many clinical guidelines include general recommendations about giving information to PD patients and family so they can take part into decision process. However, few standardized psychoeducation interventions are available, and they don't include information on PD cognitive decline. Some studies investigated Mindfulness Based Stress Reduction (MBSR) and other related mindfulness interventions in PD patients. In this approach, formal meditative exercises are included to develop non-judgmental attention to experiences in the present moment. In elderly patients with MCI unrelated to PD, mindfulness interventions show positive effects on cognitive functioning, including attention, executive functioning and memory (Gard et al., 2014). Therefore, non-pharmacological interventions for PD-MCI including both education on cognitive symptoms, as well as mindfulness exercises, are promising.
224285171|NCT00944684|DRUG|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
224285172|NCT00944684|DRUG|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
224285173|NCT04393623|BEHAVIORAL|Cognitive Reappraisal|This cognitive reappraisal microintervention lasts 45-60 minutes.
224285174|NCT04393623|BEHAVIORAL|Psychoeducation|This psychoeducational microintervention lasts 45-60 minutes.
224285175|NCT00307970|DRUG|HFA FP MDI|
224285176|NCT00307970|DEVICE|conventional chamber/mask; anti-static chamber/mask|
224285177|NCT02681406|BEHAVIORAL|ACHESS|Smartphone based additions focused application, encouraging social support
224285178|NCT02681406|BEHAVIORAL|TMC|Brief telephone monitoring and counseling
223932250|NCT01347255|DRUG|Daivobet® ointment|once daily application, 4 weeks
223932251|NCT06299020|BEHAVIORAL|intermittent fasting|fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.
224285179|NCT01082224|DRUG|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
224285180|NCT01082224|DRUG|motexafin gadolinium|motexafin gadolinium
224285181|NCT01082224|OTHER|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
224285182|NCT04226339|PROCEDURE|total knee arthroplasty with a kinetic alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~it will be set to reproduce the preoperative constitutional deformity in varus or valgus as it was measured before surgery"
223533595|NCT06718738|BIOLOGICAL|IM96 CAR-T Cells|IM96 CAR-T Cells, 12×10\^8 CAR-T cells, 20×10\^8 CAR-T cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
223533596|NCT01583673|OTHER|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
223533597|NCT01583673|OTHER|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
224099734|NCT06384872|OTHER|Shoe Cushioning Position and Properties|The three running shoe models will be exactly the same, except for their foam properties at the rear and forepart of the shoe, which will differ by 33 and 37%, respectively, while remaining within the range of values of shoes available on the market (linear equivalent stiffness: about 40 to 60 and 50 to 80 N/mm, at the rear and forepart of the shoe, respectively). We expect a difference in shoe weight lower than 30 g between the three versions (for size 42). The difference in cushioning properties between shoe versions will be created by modifying the type of foam and the foaming process.
223533598|NCT05807568|OTHER|NCAEM EM-SART Pre-Screen|Participants will be verbally asked the 3 participant questions on the NCAEM EM-SART Pre-Screen either directly or with support of hospital approved telephonic interpreters. Answers will be documented by the investigator digitally. Participants will be interviewed one time for a duration of approximately 15 minutes. No further action will be taken on study participants with negative elder mistreatment screens, unless findings concerning for emotional distress are identified by the investigator. If emotional distress is identified, these observations will be communicated to Geriatric Medicine team in person or via secure/encrypted email, with recommendations to follow-up with the participant about the results and take appropriate care actions. Study participants with positive elder mistreatment will have results shared with the study participant directly and with the Geriatric Medicine primary team via secure/encrypted email.
223533599|NCT01317303|PROCEDURE|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
223533600|NCT01317303|PROCEDURE|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
223533601|NCT01317303|PROCEDURE|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
223533602|NCT01317303|PROCEDURE|iTBS|190 seconds of intermittent theta-burst stimulation
223533603|NCT00765219|BEHAVIORAL|CBT|10-12 weekly sessions of CBT in person or over the telephone.
223533604|NCT00765219|OTHER|Usual Care|Treatment as usual provided by participants' physician(s)
223932252|NCT06323460|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223932253|NCT06323460|DRUG|Carboplatin|Given IV
224285183|NCT04226339|PROCEDURE|total knee arthroplasty with a mechanical alignment|"During surgery, a SPHERE prosthesis will replace the knee and the femorotibial alignment.~It will be set to 180° as defined for a mechanical femorotibial alignment"
224285184|NCT02310763|BIOLOGICAL|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
224285185|NCT02310763|DRUG|Placebo|
224285186|NCT00090116|DRUG|Neramexane|
224285187|NCT00273416|DRUG|PF-00592379|
224285188|NCT00273416|DRUG|Sildenafil 100mg|
224285189|NCT04329299|DIAGNOSTIC_TEST|blood-based biomarkers analyses|Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
224285190|NCT04029454|BIOLOGICAL|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~* training on hepatitis B awareness and management~* training on EPI vaccination and cold chain~* training on the modalities for the birth dose administration~* the use of a monovalent unidose vaccine against Hepatitis B"
224285191|NCT04837027|BEHAVIORAL|Aerobic training|Aerobic training on stationary bike 5x a week for 30 minutes a day
224285192|NCT04837027|BEHAVIORAL|Balance training|Training 5x a week for 30 minutes. Standard of care
224285193|NCT01118845|DRUG|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
224285194|NCT01118845|DRUG|Rituximab|The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
224285195|NCT05806931|DRUG|TAS-102, oxaliplatin, irinotecan with bevacizumab|Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
224285196|NCT02291367|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
224285197|NCT02291367|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
224285198|NCT00574067|DRUG|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
224285199|NCT00574067|DRUG|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
224285200|NCT00574067|DRUG|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
224285201|NCT00574067|DRUG|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
224285202|NCT02215772|DRUG|BI 44370 BS|
224285203|NCT06157463|RADIATION|Ga-68 FAPI|FAPI PET scans will be performed in addition to other staging/restaging work-up
223932254|NCT06323460|DRUG|Cisplatin|Given IV
223932255|NCT06323460|PROCEDURE|Computed Tomography|Undergo PET/CT
223932256|NCT06323460|RADIATION|External Beam Radiation Therapy|Undergo external beam radiotherapy
223932257|NCT06323460|DRUG|Paclitaxel|Given IV
224285204|NCT00271024|DRUG|Naltrexone (drug)|50 mg q.d. for 13 weeks
224285205|NCT00271024|DRUG|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
224285206|NCT04225286|OTHER|Human breast milk|Intranasal human breast milk
224285207|NCT03739216|DEVICE|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
224285208|NCT04152369|PROCEDURE|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
224285209|NCT00807209|DRUG|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
224285210|NCT00807209|DRUG|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
224285211|NCT00807209|DRUG|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
224285212|NCT00807209|DRUG|Fentanyl via PCA|Fentanyl via PCA
223932258|NCT06323460|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223932259|NCT06323460|OTHER|Questionnaire Administration|Ancillary studies
223932260|NCT06826469|DEVICE|Temporal Interference Stimulation|During the treatment period, all subjects were treated with a fixed time interference stimulation (TI) device at a frequency of 30 minutes twice a day, 5 days a week, for a total of 10 treatments. The output current intensity during treatment is 3.64 mA+4.36 mA.
223932261|NCT05781360|DRUG|SIM0237|SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens
223932262|NCT05567692|DIAGNOSTIC_TEST|OGTT|Oral Glucose Tolerance Test
223932263|NCT05567692|OTHER|HbA1c|HbA1c measurement
223932264|NCT05567692|OTHER|Questionnaire|Follow-up questionnaire
223932265|NCT05709860|BEHAVIORAL|EMC2 PrEP Educational Tool|Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.
223932266|NCT05709860|BEHAVIORAL|Discrete Scheduling of a Dedicated PrEP Visit|Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
223932267|NCT05691192|BEHAVIORAL|Cognitive Leisure Activities|Participants in the active phase of the study will be asked to increase engagement in certain cognitive leisure activities. The activities are chosen on the basis of previous research and measures of cognitive reserve-building activities.
223533605|NCT05188638|DRUG|SoftOx Inhaled Solution (SIS)|SIS consists of the active compound, hypochlorous acid (HOCl). Concentrations of SIS refer to the concentration of HOCl in parts per million (ppm).
223932268|NCT06833489|OTHER|ARN extraction from muscle biopsies|"There will be no visits from participants, so we will be using samples already in the Biological Resources Centre (CRB).~RNA will be extracted from muscle biopsies taken as part of the treatment. RNAseq libraries will be sequenced by the Genomics and Bioinformatics Platform (GBiM) at Marseille Medical Genetics (MMG, U1251, AMU). Sequencing will be performed in paired-end (2\*100 bp) on Illumina's Novaseq 6000 system (50 million clusters per sample, 100 M paired-end reads) and then analysed by bioinformatics."
223932269|NCT05985850|DRUG|Aurora 1:1 Drops (Indica)|Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.
223932270|NCT05985850|DRUG|Placebo|Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
223932271|NCT06827301|DEVICE|Non Invasive vagus nerve stimulation|Transcutaneous Auricular Vagus Nerve Stimulation
223932272|NCT06778603|DRUG|a targeted probe B7H3-IRDye800CW|B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
223932273|NCT06791837|BEHAVIORAL|EXERCISE|each group will undergo a max test and a submaximal exercise test
223932274|NCT06891586|DIAGNOSTIC_TEST|echocardiographic evaluation and blood phoenixin-14 level|For participants who provide consent, blood samples will be collected at 6 hours postpartum. Additionally, infants included in the study will undergo an echocardiographic evaluation by a pediatric cardiologist between postnatal days 3 and 5.
223932275|NCT02622581|OTHER|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
223932276|NCT04559581|DRUG|Nintedanib|Capsules
223932277|NCT04214210|OTHER|Adapted Family Gene Toolkit|Five web-based modules designed to increase knowledge of cancer genetics (Module 1); provide decisional support for genetic testing (Module 2); increase active coping to common challenges faced by HBOC families (Module 3); provide a five-steps, skills-building communication training (Module 4); increase knowledge about management of hereditary cancer risk based on the most updated recommendations from the National Comprehensive Cancer Network (Module 5).
223932278|NCT04214210|OTHER|Targeted intervention|The comparison website will provide targeted information about HBOC and enable sharing genetic test results.The Korean team will define the contents of the comparison website that will mimic the structure and function of a website already available in the US. The Korean team will create a translation process protocol, and share this guide for further translations from English into Korean and three Swiss national languages. The tailored and the targeted platform will be technically implemented in the same system, to track access and usage of the platform and provide a user-friendly experience.
223533606|NCT05188638|DRUG|Placebo|Sterile isotonic saline
223932279|NCT04318717|DRUG|Pembrolizumab|Pembrolizumab is commercially available
223533607|NCT02275507|DEVICE|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
223533608|NCT01619917|DEVICE|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
223533609|NCT03088787|DEVICE|Nexfin measuremtents|There will be only observational recordings, no interevntion
223533610|NCT03362268|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
223533611|NCT03362268|DRUG|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
223932280|NCT04318717|RADIATION|Hypofractionated radiation therapy|It is preferred to leave at least 48 hours between fractions. Daily imaging to verify accurate set-up is mandatory.
224285213|NCT00807209|DRUG|Bupivacaine via epidural|Bupivacaine via epidural
224285214|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
224285215|NCT01040793|DRUG|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
224285216|NCT01040793|DRUG|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
224285217|NCT01040793|DRUG|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
224285218|NCT01040793|DRUG|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
224285219|NCT04689893|DRUG|68Ga-Dotatate|68Ga-Dotatate was injected into the patients before the PET/CT scans
224285220|NCT04689893|DRUG|68Ga-DOTA-JR11|68Ga-DOTA-JR11 was injected into the patients before the PET/CT scans
224285221|NCT04285827|BIOLOGICAL|CSL889|Administered as an IV infusion
224285222|NCT05777382|OTHER|inquiry to postnatal mothers|structured questionnaires was asked to postnatal mothers
224285223|NCT01922960|OTHER|micro-imaging|micro-imaging
224285224|NCT01456429|PROCEDURE|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
224285225|NCT04643392|PROCEDURE|Complex decongestive physiotherapy|Each patient received a treatment protocol of Complex decongestive physiotherapy for 5 days a week until they were discharged from the clinic. All patients fully completed all components of the treatment routine daily. The treatment was performed by a physiotherapist who was certified with Manual Lymph Drainage Combined Decongestive Physiotherapy. After the daily treatment protocol was completed, patients wore standard or individually sized compression grade II or III medical compression stockings for the rest of the day.
223533612|NCT00286299|OTHER|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
223718371|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Standard)|see arm description
223932281|NCT05211115|PROCEDURE|Split thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the split thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a micro-blade, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
223718372|NCT03313791|DIETARY_SUPPLEMENT|50%whey-50% casein (Alternative)|see arm description
223718373|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate- WPH|see arm description
223932282|NCT05211115|PROCEDURE|Full thickness flap|Palatally displaced crestal incision at the edentulous site, combined with the full thickness elevation of a buccal flap, extended to the sulcus of the adjacent mesial and distal tooth. Flap elevation performed with a fine periosteal elevator, in a buccal and apical direction, for approximately 15mm apical to the crestal incision.
223932283|NCT05211115|PROCEDURE|Autogenous sub epithelial connective tissue graft|Harvest of a sub epithelial connective tissue graft using a double incision technique, approximately 2-3 mm apical to the palatal gingival margins of the first and second premolars. Graft dimension standardised as 10mm (mesio-distally) by 6-8mm (apico-coronally) by 1,5mm (thickness). Graft stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
223932284|NCT05211115|PROCEDURE|Volume stable collagen matrix|Geistlich Fibro-Gide® matrix shaped at a standardised dimension of 10mm (mesio-distally) by 6-8mm (apico-coronally) by 6mm (thickness). Matrix stabilised at the inner aspect of the buccal flap, 1mm apical to the flap margin, using one mesial and one distal horizontal mattress sutures.
223932285|NCT06824610|DEVICE|capnography|measurment of end-tidal carbon dioxide
224285226|NCT02309424|DIETARY_SUPPLEMENT|Vinegar|0,50mmol vinegar (6% acetic acid)
224285227|NCT02309424|OTHER|Placebo|50 ml water
224285228|NCT03946917|DRUG|JS001|JS001 3 mg/kg, iv drip, d1, d15, q4w
224285229|NCT03946917|DRUG|regorafenib tablet|80/120/160 mg, po, d1-d21, Q4w.
224285230|NCT04071054|DIAGNOSTIC_TEST|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
224285231|NCT01780376|PROCEDURE|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
224285232|NCT04750382|DRUG|HX008+Cisplatin+Gemcitabine|Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m\^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m\^2, Day 1, Day 8, Q3W for up to 6 cycles
224285233|NCT06615934|OTHER|Aerobic and resistance exercise|"From the first day of transplantation in the ICU until 10 days after transfer to the ward or discharge from the hospital, if needed, the patients of the group will undergo respiratory physiotherapy once a day. The process of this program includes patient assessment, clinical decision-making, and implementation of therapeutic interventions.~The interventions of the therapeutic exercise group are divided into three phases:~1. From the time the patient enters the ICU until the time of extubation;~2. From the time of extubation to the time of transfer to the ward;~3. Duration of the patient's stay in the ward."
224285234|NCT06615934|OTHER|Respiratory physiotherapy|The participants of this group will receive respiratory physiotherapy daily after transplant until discharge.
224285235|NCT04533906|DEVICE|Coldamaris lozenges|sucking carageenan containing lozenge
224285236|NCT00001554|DEVICE|intraoperative infrared (IR) neuroimaging|
224285237|NCT03795389|DRUG|DM199|Single SC dose
224285238|NCT03695809|BIOLOGICAL|G9a protein|To assess G9a protein expression on vulvar cancer
223932286|NCT06827223|DEVICE|computer-controlled Starpen Automatic Injection Device|using computer-controlled Starpen Automatic Injection Device during inferior alveolar nerve block anesthesia and extraction of mandibular primary molars
224096484|NCT04824989|BEHAVIORAL|Sleep Health in Preschoolers (SHIP)|SHIP is an 8 session home visiting intervention to reduce child sleep problems using a framework that draws from motivational interviewing and social cognitive theory, and effectively improves sleep timing, duration, and quality. Following ecological assessment of child sleep and sleep routines, feedback is provided on family strengths and challenges in the child sleep domain, with motivational interviewing to increase parent knowledge of sleep, correct misperceptions, and raise outcomes expectations. The remaining sessions are targeted modules that give tailored feedback and education, and coach the parent in setting manageable goals, identifying action steps, anticipating barriers, and supporting positive behaviors. Targets: bedtime scheduling, consistency, and routines; media use, independent sleep onset, nightmares and fears, night wakings, and early waking; sleep location, nap issues, engaging other caregivers.
224285239|NCT05424731|COMBINATION_PRODUCT|DBV712 250 mcg|Daily epicutaneous delivery.
223932287|NCT06827223|DEVICE|Traditional Syringe|nerve block anesthesia and extraction of mandibular primary molars using Traditional Syringe
224096485|NCT04824989|BEHAVIORAL|Family Check-Up (FCU)|FCU is an 8 session home visiting intervention to reduce behavior problems for children through improved parenting. Over 30 years of research establishes its efficacy in reducing behavioral and emotional problems, including in low income toddlers. Following ecological assessment of behavior management and child behavior, family receives feedback on family strengths and challenges within the behavioral domain via a motivational interviewing approach. The remaining sessions are targeted modules drawn from the Everyday Parenting curriculum, individualized based on parent goals and identified challenge areas. Each session begins by establishing a collaborative skill set, involves teaching the rationale for a skill, teaching and modeling effective use of the skill, and then role play and experiential practice to coach the parent to success. Targets can include Positive Behavior Support, Limit Setting and Monitoring, Family Routines, Communication, and Problem Solving.
224285240|NCT06461377|DRUG|Glucagon-like peptide-1 receptor agonist：Semaglutide|The GLP-1RA intervention group was given subcutaneous injection of GLP-1RA for 3 months, while the control group was not given GLP-1RA intervention
224285241|NCT04721496|BEHAVIORAL|Power and Speed|"Analysis of the power and speed of execution in 6 conditions of increasing instability Situation 1 is stable and basic execution. Condition 6 is the most unstable.~The participants performed 2 series of 3 repetitions in each of the situations. All the exercises were executed on the same day."
224285242|NCT03345758|OTHER|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
224285243|NCT03427476|DRUG|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
224285244|NCT01352182|DRUG|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
224285245|NCT00672776|DRUG|paroxetine|
224285246|NCT00672776|DRUG|placebo|
224285247|NCT04897191|OTHER|Age|Determination of age-dependence
224285248|NCT00946491|DRUG|Haloperidol 10 mg Tablets (Cord Laboratories)|
224285249|NCT00946491|DRUG|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
224285250|NCT05445531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Functional and morphologic imaging of the lungs
224285251|NCT05445531|DIAGNOSTIC_TEST|Nailfold capillaroscopy|Imaging of nailfold microvasculature
224285252|NCT05445531|DIAGNOSTIC_TEST|Spiroergometry|Cardiopulmonary exercise testing
223718374|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate - Na-caseinate|see arm description
223718375|NCT03313791|DIETARY_SUPPLEMENT|Micellar Casein Isolate|see arm description
223718376|NCT03313791|DIETARY_SUPPLEMENT|UHT milk|see arm description
223718377|NCT03313791|DIETARY_SUPPLEMENT|Recombined milk|see arm description
223932288|NCT06565442|DEVICE|NeuraSignal transcranial doppler robot|measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves
223932289|NCT04579952|DEVICE|transcranial Direct Current Stimulation|The current stimulation will be applied using 35 squares cm wide sponge electrodes
224285253|NCT05445531|DIAGNOSTIC_TEST|Realtime deformability cytometry|High-throughput measurement of cell deformability and physical properties
224285254|NCT02893280|DRUG|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
223932290|NCT05044845|BEHAVIORAL|Interview|Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
223718378|NCT03313791|DIETARY_SUPPLEMENT|Recombined 50%whey milk|see arm description
223718379|NCT03313791|DIETARY_SUPPLEMENT|Ca-caseinate|see arm description
223718380|NCT03313791|DIETARY_SUPPLEMENT|Milk protein isolate|see arm description
223932291|NCT02754583|BEHAVIORAL|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
223932292|NCT02754583|BEHAVIORAL|Standard of care WASH intervention|Stand of care WASH arm
223932293|NCT02754583|DRUG|Azithromycin|20mg/kg
223932294|NCT02754583|DRUG|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
223932295|NCT02754583|OTHER|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
224285255|NCT06076369|PROCEDURE|The tubular adenoma group|Biopsy or removal of polyps for pathological examination. Collect baseline data such as gender, age, BMI, etc. If the pathology confirms a pure tubular adenoma, the observed object will be included in the group for final comparative analysis.
224285256|NCT05857462|PROCEDURE|Post-admission FICB|Post-admission supra-inguinal FICB in hip fracture patient with 0.33% bupivacaine 30 ml
224285257|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
224285258|NCT01629576|OTHER|economic incentive|economic incentive for weight loss
224285259|NCT01877460|OTHER|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
224285260|NCT00939627|BIOLOGICAL|cetuximab|Given IV
224285261|NCT00939627|OTHER|placebo|Given orally
224285262|NCT00939627|DRUG|sorafenib tosylate|Given orally
224285263|NCT00939627|OTHER|laboratory biomarker analysis|Correlative studies
224285264|NCT00939627|PROCEDURE|quality-of-life assessment|Ancillary studies
224285265|NCT02918682|OTHER|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
224285266|NCT02918682|OTHER|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
223718381|NCT00041990|DRUG|decitabine (5-aza-2'deoxycytidine)|
223718382|NCT03517956|DRUG|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
223718383|NCT03517956|DRUG|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
223718384|NCT00983021|DRUG|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
223718385|NCT00983021|DRUG|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
223932296|NCT02334865|BIOLOGICAL|Incomplete Freund's Adjuvant|Given SC
223932297|NCT02334865|OTHER|Laboratory Biomarker Analysis|Correlative studies
223932298|NCT02334865|DRUG|Lenalidomide|Given PO
223932299|NCT02334865|BIOLOGICAL|Sargramostim|Given SC
223932300|NCT02334865|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
223932301|NCT04728295|DEVICE|Exablate 4000|Exablate Pallidothalamic Tractotomy
223932302|NCT06688409|DIAGNOSTIC_TEST|awake ABPM|Comparison of a BP measured with the home BP devices and the average awake ABPM performed immediately after
223932303|NCT05386316|OTHER|Multilevel intervention for racial disparities in severe maternal morbidity and mortality|"In addition to standard enhance prenatal care (EPC) services, the following will be offered.~Community level. We will make EPC services (i.e., MIHP and Healthy Start) available via telehealth with flexible hours to women who are eligible for Healthy Start (primarily minority women) who decline traditional (i.e., home visiting) services.~Provider/practice level. We will provide actionable maternal health-focused anti-racism training to health system administrators, physicians, residents, midwives, nurses, front desk staff, schedulers, public health officers, EPC staff, doulas, WIC staff, and lactation consultants.~System level. Counties will implement equity focused community care maternal safety bundles. Community care is care provided by outpatient, EPC, community-based organizations, and linkages between hospital care and these settings."
223533613|NCT00286299|OTHER|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
223932304|NCT05386316|OTHER|Standard Enhanced Prenatal Care (EPC) services|"Pregnant women in comparison counties will receive whatever EPC services (MIHP and/or Healthy Start) they naturalistically choose to receive.~Maternal Infant Health Program (MIHP). All women in Michigan who are Medicaid insured are eligible for MIHP. MIHP offers monthly home visiting and care coordination to supplements regular care during pregnancy and up to 12 months post birth. MIHP offers care coordination; risk assessment; individual care plan; evidence-based interventions; transportation; education; and referrals.~Healthy Start. Health Start is a federally funded program for minority women that offers more intensive EPC services delivered by race/ethnicity matched community health workers. Community health workers offer peer support; resilience and problem solving; risk assessment; facilitating provider-client communication; collaborative care; system navigation, including transition from prenatal care to postnatal primary care; and supportive referrals."
224096486|NCT04824989|BEHAVIORAL|Oral Health, Child Safety, and Environmental Health Intervention (Active Control)|This intervention serves as an active control condition to ensure that observed effects are due to the intervention content, rather than to study processes, staff attention, or general support and problem solving. The intervention is designed to be comparable to SHIP and FCU in intensity, personal contact, session structure and approach, but focused on Oral Health, Child Safety, and Environmental Health, domains which should not immediately affect study outcomes.
223533614|NCT00286299|OTHER|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
223533615|NCT04948112|DEVICE|real time continuous glucose monitor|CGM sensor will read blood glucose every 10 minutes
223533616|NCT04948112|DEVICE|blinded continuous glucose monitor|CGM that records blood glucose but not visible to patient
223533617|NCT06102655|DRUG|Jiajian Guishen Formulation|Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
223533618|NCT06403449|BEHAVIORAL|Group-delivered guided written exposure therapy-revised version|Group-Delivered guided WET-R (G-WET) is a manualized exposure-based therapy program consisting of 5-8 sequential sessions. The interval between every 2 consecutive sessions is 0-2 days. There will be 5-8 group-delivered sessions in total (only one index trauma will be discussed), and 1-2 weeks to complete.The first and last sessions are scheduled to last for 1.5 hours each, while the other sessions will be 50 minutes in duration.
223718386|NCT00983021|DRUG|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
223533619|NCT06403449|BEHAVIORAL|Waiting-List (WL) condition|Participants assigned to WL will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 2-week WL period. After the one-month follow-up of the WET-R group, they will receive the same treatment (Group-Delivered guided written exposure therapy-revised version).WL participants will also be given contact information to use in case of worsening symptoms or increasing distress.
223533620|NCT04372485|BEHAVIORAL|mHealth Intervention|Adolescents will receive text messages to facilitate treatment adherence
223533621|NCT03185221|DEVICE|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
224096487|NCT03325764|OTHER|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
224096488|NCT05564338|DRUG|Sitravatinib|Administered orally
224096489|NCT05564338|DRUG|Tislelizumab|Administered intravenously
224285267|NCT02918682|OTHER|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
223533622|NCT03185221|DEVICE|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
223533623|NCT06413732|OTHER|Conventional physiotherapy|Conventional physiotherapy was applied for approximately 1 hour, 5 days a week.
223533624|NCT02670902|BEHAVIORAL|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
223533625|NCT02670902|BEHAVIORAL|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
224096490|NCT05564338|DRUG|sitravatinib-matching placebo|administered orally
224096491|NCT05564338|DRUG|tislelizumab-matching placebo|administered intravenously
224096492|NCT01916577|DRUG|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
224096493|NCT00104130|DRUG|KOS-862|
223533626|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
223718387|NCT00983021|DRUG|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
223932305|NCT05048394|DEVICE|Semi-autonomous myoelectric control algorithm|The semi-autonomous myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
224096494|NCT04737044|OTHER|Study 1: MRBS|MRBS as added sugar based on their habitual diet
224096495|NCT04737044|OTHER|Study 2: White sugar & education module|White sugar for daily usage (\<10% daily energy intake)
224096496|NCT04737044|OTHER|Study 2: MRBS & education module|MRBS for daily usage (\<10% daily energy intake)
223533627|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
223533628|NCT00647543|DRUG|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
223718388|NCT05426902|BEHAVIORAL|SLE@Duke|SLE@Duke is a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting. The model includes an Electronic Medical Record (EMR) note template, patient-reported outcome measure, and training on how to discuss Type 1 \& 2 SLE.
223718389|NCT06217055|DRUG|remimazolam based MAC|The surgery will be performed under monitored anesthesia care by maintaining spontaneous breathing using remimazolam.
223718390|NCT06217055|DRUG|general anesthesia with sevoflurane|The surgery will be performed under mechanical ventilation with inhalation general anesthesia
223932306|NCT05048394|DEVICE|Standard-of-care myoelectric control algorithm|The standard of care myoelectric control algorithm will be implemented on a by-pass prosthetic socket with a sensorized TASKA prosthetic hand.
223932307|NCT06886620|DRUG|Cilostazol 200 mg|Provided as 1# placebo tablet in the morning and 1# PMR 200 mg/tablet in the evening, orally, for 24 weeks.
223932308|NCT06886620|DRUG|Cilostazol 100 mg|Provided as 1# Pletaal® 100 mg/tablet, orally twice a day, for 24 weeks.
223932309|NCT06259097|DRUG|Misoprostol|25 mcg vaginally every 6 hours
223718391|NCT02968953|DRUG|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
223718392|NCT02673437|OTHER|This is a non-interventional study|This is a non-interventional study
223932310|NCT06259097|DRUG|Pitocin|3-6 mL intravenously every hour
223932311|NCT06808945|OTHER|Prehabilitation program|Participants will be subjected to an eight week home-based multimodal prehabilitaiton program. The program consists of an exercise program, nutritional support, smoking cessation and psychological counselling.
224096497|NCT00420030|DRUG|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
223932312|NCT05662397|DRUG|HST-1011|HST-1011 given orally
223932313|NCT05662397|BIOLOGICAL|Cemiplimab|Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
223533629|NCT05324241|DIETARY_SUPPLEMENT|Fat Microcapsules|Consumption of a drink that contains microencapsulated fat that will be released either in the stomach or in the distal small intestines.
223533630|NCT03721250|OTHER|epidural|thoracic epidural analgesia
223533631|NCT02605902|BEHAVIORAL|(i)Comprehensive Behavioral Intervention for Tics|
223533632|NCT02605902|BEHAVIORAL|internet-delivered psychoeducation and relaxation training|
223533633|NCT06131658|OTHER|Functional motor control excercise|This include functional motor control thrice a week for six weeks
223533634|NCT06131658|OTHER|convectional excercise|This include convectional exercise thrice a week for six weeks
223533635|NCT03348124|BEHAVIORAL|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
223533636|NCT01599884|DRUG|N-acetylcysteine|1800 mg twice daily for 8 weeks
223533637|NCT01599884|DRUG|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
223533638|NCT00093366|BIOLOGICAL|etanercept|
223533639|NCT00093366|DRUG|arsenic trioxide|
223533640|NCT05091411|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223718393|NCT04950309|DEVICE|SQUID MEG|MEG recordings acquired on a standard whole brain SQUID MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
223718394|NCT04950309|DEVICE|OPM MEG|MEG recordings acquired on an investigational OPM MEG system. Stimuli will be used, including auditory, visual, or somatosensory stimuli. Language stimuli and median nerve stimulation may also be used.
223718395|NCT04187014|DRUG|Aminocaproic Acid 1000Mg Tab|Oral administration of a total 6 g of aminocaproic acid to reduce blood loss
223718396|NCT04187014|DRUG|Tranexamic acid tablets|Oral administration of 3.9 g of tranexamic acid to reduce blood loss
223718397|NCT03041597|PROCEDURE|placement of implants|surgical procedure and placement of implants
223718398|NCT03041597|PROCEDURE|immediate loading|cone-anchored implant supported removable dental prostheses placement
223932314|NCT05954481|OTHER|Stress echocardiography|After a rest trans thoracic echocardiography (usual follow-up), eligible patients will have a stress ultrasound echocardiography on a dedicated cycle ergometer
224285268|NCT02918682|OTHER|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
224285269|NCT00124462|DEVICE|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
224285270|NCT00124462|DEVICE|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
223718399|NCT03041597|PROCEDURE|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
223718400|NCT03041597|DEVICE|Ankylos implant|
223718401|NCT02891759|OTHER|Alloderm RTU|-Most commonly used acellular dermal matrices
224285271|NCT06617676|DEVICE|Transcutaneous tibial nerve stimulation|Two electrodes will be place over the tibial nerve over the medial ankle. The electrical stimulation will be turned up to patient tolerance at a sensory level only.
223718402|NCT02891759|OTHER|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
224285272|NCT02152462|OTHER|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain \>150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
224285273|NCT01816568|PROCEDURE|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
224285274|NCT01816568|PROCEDURE|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
224285275|NCT04733248|OTHER|Kinesiotaping group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHING EXERCISES(10 reps 3sets) hold for 2 sec~* Apply KINESO- TAPE on upper trapezius (from I-O for Inhibition purpose)~HOME PLAN OF EXPERIMENTAL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec (In neck flexion, In neck extension, In side bending) In experimental group kinesiotape was applied on upper trapezius from insertion to origin for inhibition purpose. As it had increased the functional status of the patient. Post -intervention assessment was taken on 1 st, 2nd and 3rd visit."
223718403|NCT02891759|PROCEDURE|Skin or nipple-sparing mastectomy|-Standard of care
223718404|NCT02891759|OTHER|Breast Q|"* 15 questions~* 10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~* Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
223533641|NCT03908203|PROCEDURE|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
223718405|NCT02891759|PROCEDURE|Surgery|"* To address the tissue expander~* Standard of care"
223718406|NCT00889460|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
223718407|NCT00889460|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
223718408|NCT06457321|PROCEDURE|Sequence in receiving the fabricated dentures made using the conventional and partial digital method|Participants is not informed on the sequence they have been randomized hence they are not able to determine which denture is fabricated from which method. This would reduce bias when collecting the participants' responses in the satisfaction questionnaire during the review visits.
223932315|NCT06920433|BIOLOGICAL|UCAR T-cell group|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
223932316|NCT05220332|BEHAVIORAL|Heart to Heart|The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
223533642|NCT00212836|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
223533643|NCT00212836|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
223718409|NCT05443789|BEHAVIORAL|Proton pump inhibitor education|A 15 minutes (preferable) one-on-one educational visit about deprescription of proton pump inhibitor
223718410|NCT05443789|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
223932317|NCT05220332|BEHAVIORAL|Money Smart|The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
224096498|NCT03456492|DIAGNOSTIC_TEST|serum sodium|Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
224096499|NCT00312520|DRUG|prednisolone|
224096500|NCT00312520|DRUG|methylprednisolone|
223718411|NCT02837016|DEVICE|Wearable biofeedback|
223718412|NCT02837016|BEHAVIORAL|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
223932318|NCT06769009|BEHAVIORAL|Educational intervention measures on iodine, iodine deficiency and iodine intake|The intervention consist of an educational intervention which will educate the young women on the importance of iodine, the consequences of iodine deficiency, dietary iodine sources and the iodine in pregnancy. The educational intervention consist of four intervention components: an iodine feedback tool, and educational iodine conversation with a healthcare professional, an iodine factsheet and an iodine video. The healthcare professionals who carry out the educational conversation will receive a specially designed training program.
223932319|NCT06781372|BIOLOGICAL|Development and characterization of PDOs|An amount of tissue of approximately 2-3 cm3, if available, will be allocated to the study. The specimen will be divided in three parts (depending on the volume of the biopsy) and used to: a) obtain PDOs according to established procedures (Chadwick, et al., 2020; Gamboa, et al., 2021); b) flash-frozen for molecular analysis of original tissue; c) used to isolate GSCs by flow-cytometry cell sorting. Only PDOs characterized by histological and molecular conformity with primary tumors will be used. The mutational status of genes frequently associated with GBM onset and progression will be analyzed in PDOs, and compared with data derived from tumor DNA, in order to assess their representation of the genetic heterogeneity of original tumors. These studies will allow us the set up a reliable procedure for the ex-vivo establishment of pre-clinical models of GBM.
223932320|NCT06781372|BIOLOGICAL|Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs|PDOs and GSCs representing different GBM molecular subtypes will be treated with epigenetic modulators , with spliceosome inhibitors or with drugs that indirectly target the splicing machinery, such as PRMT5 inhibitors. These drugs will be tested for their ability to suppress growth and/or induce cell death, when administered either alone or in combination with standard chemotherapy. Furthermore, the investigators will perform RNA sequencing experiments to identify TE-derived transcripts and splice variants induced by the treatments. By employing a computational pipeline developed in our laboratory (Pieraccioli and Sette, unpublished), the investigators will also characterize the affinity for MHC-I and immunogenicity of neoepitopes encoded by the treatment-induced TE-derived transcripts and splice variants. The results of these analysis will allow to identify neoepitopes to be used for designing immunotherapy approaches.
223932321|NCT00593840|RADIATION|Intensity modulated radiation therapy|
223932322|NCT06789497|DRUG|Lovastatin 60 MG|Participants were given lovastatin 60 mg/day for three consecutive days.
223932323|NCT06789497|DRUG|Placebo|Participants were given placebo 60 mg/day for three consecutive days.
223932324|NCT05254496|BEHAVIORAL|Dietary Intervention Classes|Participants will attend classes once per week for 6 months and then bi-weekly for 6 months.
223932325|NCT06767527|DRUG|AK112|AK112 via intravenous (IV) infusion
223932326|NCT06767527|DRUG|Nab-paclitaxel|Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
223932327|NCT06767527|DRUG|Placebo|Placebo via IV infusion
223932328|NCT05372549|OTHER|Oxidative stress|Oxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
223932329|NCT05372549|OTHER|cf-DNA|cfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
223932330|NCT05372549|OTHER|MAGENTA AI|Non-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality
223932331|NCT05271331|DRUG|ESP block with saline|Bilateral ultrasound guided injection of saline in the erector spinae plane (below erector spinae plane muscle group and above the transverse process of the vertebra)
223932332|NCT05271331|DRUG|Wound infiltration with saline|Blinded injection of saline in the skin, subcutaneous tissue and muscles at the site of surgical incision
223932333|NCT05271331|DRUG|ESP block with local anesthetic|Bilateral ultrasound guided injection of local anesthetic (ropivacaine 0.35%, 40ml) in the erector spinae plane (below erector spinae plane muscle group and above the tranverse process of the vertebra)
223932334|NCT05271331|DRUG|Wound infiltration with local anesthetic|Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
223932335|NCT03911466|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
223932336|NCT03911466|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
223932337|NCT05028881|OTHER|blood sampling|blood sampling for determining antibody responses
223932338|NCT06940180|DRUG|Toripalimab|An anti-PD-1 monoclonal antibody, single-use vial, via intravenous (into the vein) infusion per protocol.
223932339|NCT06940180|DRUG|Carboplatin|An antineoplastic agent, multi-dose vials, via intravenous (into the vein) infusion per standard of care.
223932340|NCT06940180|DRUG|Docetaxel|A taxoid antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.
223932341|NCT06940180|RADIATION|Radiation Therapy|per standard of care
223932342|NCT06940180|DRUG|Cisplatin|An antineoplastic agent, single-dose vials, via intravenous (into the vein) infusion per standard of care.
223932343|NCT06795308|OTHER|Bed Position and Head Elevation|The first group will remain in the supine position for 6 hours after the Angiography procedure, and the treated leg will be kept straight and immobile. Patients will not move their legs during this period. A sandbag weighing approximately 4 kg will be placed over the catheter dressing for 6 hours to prevent bleeding and subcutaneous blood accumulation. For the first two hours, the patient will lie on his back and on a flat surface with his legs extended straight. During the remaining 4 hours, investigators will monitor the patient's bed head by raising it 15 degrees intermittently under the supervision of the doctor, and at the end of the 6th hour, the sandbag on the leg will be removed. Blood pressure, pulse rate, respiratory rate, body temperature, as well as pain level will be measured every two hours.
224096501|NCT05157425|DIETARY_SUPPLEMENT|Food Supplement|Probiotic multistrain formulation containing Lactiplantibacillus plantarum CECT30292, CECT7484, CECT7485 and P. acidilactici CECT7483 for 28 days, starting the same day of influenza vaccination
223533644|NCT05975658|DEVICE|Gabi SmartCare Pediarity System [Gabi Band, Gabi Monitor App, Gabi Analytics]|Gabi SmartCare has created a monitoring system named Pediarity System that obtains pediatric vitals data through non-invasive means through a Gabi band. When paired with a proprietary algorithm and software - Gabi Analytics - the cloud-based platform measures blood oxygen levels, pulse rate (and variability), respiratory rate, actigraphy, inter-beat interval, and tracking for the time the device is worn (or not worn by the child). Three LEDs on the monitor are used for capturing this information. Peak wavelengths for the red, infrared, and green LEDs operate at 660nm, 950nm, and 526nm respectively. The Gabi band features an optical front end coupled with an analog front end using 24 bits. Bluetooth data transmission is utilized on a mobile phone application with a tablet-based system in a CSV format for the purpose of offline data processing.
223533645|NCT06345768|OTHER|Stress Ball|It is a ball 5-6 cm in size and not too hard. It will be given to both hands of the patients and they will be asked to count from 1 to 5. This application will be repeated for 15 minutes.
223533646|NCT05000983|DRUG|PluroGel|A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
223533647|NCT05000983|DRUG|Standard dressing|Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
223533648|NCT04504955|OTHER|Observational Non-Interventional Registry|Observational Non-Interventional Registry
223533649|NCT06070662|DIAGNOSTIC_TEST|Coronary microvascular disease testing during coronary angiography|During invasive coronary angiography, in addition to coronary angiography performed as per routine clinical care, participants will have angiographic testing for coronary microvascular disease using routine clinical procedures. This will consist of fractional flow reserve (FFR), coronary flow reserve, index of microvascular resistance and vasospasm provocation testing with acetylcholine (Ach).
223533650|NCT06070662|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan including exercise|Participants will undergo a cardiac magnetic resonance scan compromising 1) T1 mapping, 2) oxygenation-sensitive MRI and 3) perfusion imaging. All will be obtained at rest and during exercise using a step ergometer.
223533651|NCT06070662|DIAGNOSTIC_TEST|Additional analysis of already acquired CT scan|Previously acquired CTCA images from the main research study will be transferred to Heartflow for computation of coronary blood volume.
223932344|NCT06796413|PROCEDURE|Loop Resection or Cold-cup biopsy|Loop Resection or cold-cup biopsy of bladder tumor base - thus after the tumor has been resected and the deep muscle specimen needed to be obtained, the Loop Cautery or Lowsley Forceps (for cold-cup biopsy) was used to obtain the deep muscle specimen
223932345|NCT06940297|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224096502|NCT05157425|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule/day for 28 days, starting the same day of influenza vaccination
223533652|NCT04083417|DRUG|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
223932346|NCT06940297|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223932347|NCT06940297|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223932348|NCT06940297|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223932349|NCT06940297|BIOLOGICAL|Ciltacabtagene Autoleucel|Given IV
223932350|NCT06940297|PROCEDURE|Computed Tomography|Undergo CT scan
223932351|NCT06940297|DRUG|Cyclophosphamide|Given IV
223932352|NCT06940297|DRUG|Dasatinib|Given PO
223932353|NCT06940297|DRUG|Fludarabine|Given IV
223932354|NCT06940297|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223932355|NCT06940297|DRUG|Quercetin|Given PO
223932356|NCT06046690|DEVICE|Mechanical Ventilation Device|"During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
224096503|NCT01588821|DRUG|Cabozantinib|60 mg daily by mouth
224096504|NCT02093611|DIETARY_SUPPLEMENT|Placebo|
224096505|NCT02093611|DIETARY_SUPPLEMENT|ATP|400 mg of ATP
224096506|NCT02886429|DRUG|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
224096507|NCT02886429|DRUG|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
223533653|NCT04083417|OTHER|No antibiotic treatment|No prescription of antibiotics
223932357|NCT06046690|DEVICE|External Device|"The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily."
223533654|NCT05484128|DIETARY_SUPPLEMENT|Gastrus|"Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475.~Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus."
223932358|NCT05664243|BIOLOGICAL|Autologous genetically modified gamma-delta T cells|Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance
223932359|NCT05664243|BIOLOGICAL|Allogeneic genetically modified gamma-delta T cells|"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"
223932360|NCT05836025|DRUG|Rapamycin|5mg/week of rapamycin orally for 12 weeks
223932361|NCT05836025|OTHER|Placebo|5mg/week of placebo orally for 12 weeks
223932362|NCT04692181|BIOLOGICAL|SYN-004, Ribaxamase or Placebo|SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
223932363|NCT06048380|DRUG|Ripasudil|"Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil."
223932364|NCT06048380|OTHER|Placebo|Saline eye drops
223932365|NCT06946602|PROCEDURE|Bu/Flu/Cy/ATG|The Bu/Flu/Cy/ATG conditioning regimen consists of the following components: Ara-C (2 g/m²/day, injected i.v.) on days-10 and-9; Bu (0.8 mg/kg, q6h, injected i.v.) on days -8 to -6; Flu (30 mg/m²/day, injected i.v.) from day-6 to day-2; Cy (1.0 g/m²/day, injected i.v.) on days-5 and-4; and ATG (2.5 mg/kg/day) on days-5 to -2.
224285276|NCT04733248|OTHER|stretching group|"* HOT PACK (10 MINTS)~* TENS(10 MINTS)~* STRETCHINGS EXERCISES (10 reps 3sets) hold for 2 sec 5.9HOME PLAN OF CONTROL GROUP:~* SELF STRECHINGS (10 reps 3 sets)~* AROMS~* NECK ISOMETRICS (10 reps 3 sets)hold for 10 sec In neck flexion In neck extension In side bending Post-intervention assessment was taken on 1 st, 2nd and 3 rd visit"
223533655|NCT05484128|OTHER|Placebo|placebo has an identical preparation to Gastrus
223932366|NCT06946602|PROCEDURE|Bu/Cy/ATG|The Bu/Cy/ATG conditioning regimen consists of the following components: Ara-C (4 g/m²/day, injected i.v.) on day-9; Bu (0.8 mg/kg, q6h, injected i.v.) on days -8 to -6; Cy (1.8 g/m²/day, injected i.v.) on days-5 and-4; and ATG (2.5 mg/kg/day) on days-5 to -2.
223932367|NCT06948643|OTHER|Play the Oculus Quest 2|Every three to four days (roughly 72 to 96 18 19 hours), a session was held. Students were required to use the Oculus Quest 2 and touch controllers to play immersive exergames for thirty minutes during each session. In each session, they were asked to play the games Dance Central (https://www.dancecentral.com/ ) and CREED: Rise to Glory (which the researchers loaded into the Oculus Quest 2) via the Meta Quest Gaming platform (https://www.meta.com/tr-tr/experiences/creed-rise-to27 glory-championship-edition/2366245336750543/ ).
223533656|NCT03323957|DIAGNOSTIC_TEST|nutritional screening tool|screening of disease associated malnutrition in sick infants
223533657|NCT04682665|DRUG|Icosapent Ethyl Oral Capsule|Soft gelatin capsules containing 1g pure EPA-EE. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
223932368|NCT04599036|DEVICE|MARK|EMG controlled arm orthosis
223932369|NCT06950801|BEHAVIORAL|outdoor-horticultural therapy|Students are randomly assigned to the Outdoor Horticultural Therapy group, where they will receive outdoor horticultural therapy for eight weeks
223932370|NCT06950801|BEHAVIORAL|indoor-Horticultural Therapy group|Students are randomly assigned to the indoor horticultural therapy group, where they will receive indoor horticultural therapy for 8 weeks
223932371|NCT06950801|BEHAVIORAL|General Psychological Group Counselling Team|Students were randomly assigned to general group groups to participate in an 8-week mental health group activity
223932372|NCT06950203|DIETARY_SUPPLEMENT|Very Long Chain Polyunsaturated Fatty Acids|Fish oil with DHA and VLCPUFA
223932373|NCT06950203|DIETARY_SUPPLEMENT|Comparator arm (DHA)|Oil containing equal DHA content to active arm
223932374|NCT06880965|DIAGNOSTIC_TEST|testing implant stability|testing implant stability by using the periotest device
223533658|NCT04682665|OTHER|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
224285277|NCT03588650|DRUG|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
224285278|NCT04845516|OTHER|Efficacy of apheresis|Efficacy of apheresis
223533659|NCT02136992|DRUG|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
223533660|NCT02136992|DRUG|placebo|placebo will be taken two tablets 3 times a day during the whole study process
223932375|NCT06880965|DRUG|use concentrated growth factor.|short implants assisted over denture in combination with concentrated growth factor.
223932376|NCT06880965|RADIATION|marginal bone loss calculation|marginal bone loss calculation by digitized periapical radiograph
224096508|NCT03735940|OTHER|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
224096509|NCT02850796|BEHAVIORAL|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
224096510|NCT02850796|OTHER|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
224285279|NCT03600181|DEVICE|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
224285280|NCT03669016|BEHAVIORAL|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams \& Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
224285281|NCT03669016|BEHAVIORAL|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
224285282|NCT06146855|PROCEDURE|Tunneling procedure with Amnion Membrane|Root Coverage by tunneling procedure with the addition of Amnion Membrane as a soft tissue substitute
224285283|NCT06146855|PROCEDURE|Tunneling procedure with De-epithelialized Free Gingival Graft|Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
224285284|NCT01049347|DRUG|amitriptyline|150 mg oral, daily, single evening dose, 35 days
224285285|NCT01049347|DRUG|paroxetine|40 mg oral, single dose, morning, 35 days
223533661|NCT01161771|PROCEDURE|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
223533662|NCT04585308|DEVICE|transShield Embolic Protection System|Used for embolic protection during TAVR.
223533663|NCT03516721|OTHER|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
223932377|NCT06952920|DEVICE|electroacupuncture|The acupuncturist applied needles at four acupoints: Zusanli (ST36), Neiguan (PC6), Hegu (LI4), and Zhaohai (KI6), with insertion depths of approximately 20 mm, 15 mm, 20 mm, and 5 mm respectively. Electrical stimulation was delivered in continuous wave mode at 2 Hz frequency with current intensity ≤10 mA (adjusted according to patient tolerance), administered for 30 minutes per session.
223932378|NCT06952920|DRUG|standard quadruple antiemetic therapy|Olanzapine 2.5 mg orally daily on days 1 to 4; dexamethasone 10 mg intravenously on day 1, and 7.5 mg intravenously on days 2 to 3; palonosetron 0.25 mg intravenously on day 1, or ondansetron 8 mg intravenously on day 1, or tropisetron 5 mg intravenously on day 1; and fosaprepitant 150 mg intravenously on day 1, or aprepitant 130 mg intravenously on day 1, or aprepitant 125 mg orally on day 1 followed by 80 mg orally on days 2 to 3.
224096511|NCT02950506|DEVICE|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
224096512|NCT02950506|OTHER|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
224285286|NCT02412462|DRUG|AB-16B5|
224285287|NCT03485482|DRUG|Bisoprolol|bisoprolo 5 mg tablets
224285288|NCT03485482|DRUG|Ivabradine|Ivabradine 10 mg tablet
224285289|NCT03485482|DRUG|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
224285290|NCT02061176|PROCEDURE|Transanal Haemorrhoidal Dearterialization|
224285291|NCT02061176|PROCEDURE|Open Haemorrhoidectomy|
224285292|NCT04424966|DRUG|Infigratinib|The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
224285293|NCT01221831|DRUG|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P1 tablet per day~* Days 25-28: two placebo tablets per day"
224285294|NCT01221831|DRUG|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-24: one estetrol tablet and one P2 tablet per day~* Days 25-28: two placebo tablets per day"
224285295|NCT01221831|DRUG|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~* Days 1-26: one tablet of Estradiol valerate/dienogest per day~* Days 26-28: one placebo tablet per day"
224096513|NCT04722978|DRUG|Gemcitabine and carboplatin plus antibiotic (moxifloxacin)|Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
224096514|NCT04722978|DRUG|Gemcitabine combined with carboplatin plus placebo|Standard chemotherapy (gemcitabine and carboplatin) plus placebo
223533664|NCT01658046|OTHER|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
223533665|NCT01658046|OTHER|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
223533666|NCT01658046|OTHER|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
224096515|NCT01159262|DRUG|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
224096516|NCT01159262|DRUG|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
224096517|NCT01159262|DRUG|Dexmedetomidine|
224096518|NCT05162157|DEVICE|NuvoAir platform|Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
224096519|NCT05282940|DRUG|Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Investigational Medicinal Product
224096520|NCT05282940|DRUG|Microgynon CD|Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
224096521|NCT06228157|BEHAVIORAL|Routine therapy|The study lasts 20d for each patient. During the treatment, All the participants are provided with the routine therapy, which included routine rehabilitation, cognitive training.
224285296|NCT02127073|DRUG|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
224285297|NCT02039063|DRUG|E6011 2 mg/kg|
224285298|NCT02039063|DRUG|E6011 5 mg/kg|
224285299|NCT02039063|DRUG|E6011 10 mg/kg|
224285300|NCT02039063|DRUG|E6011 15 mg/kg|
224285301|NCT02621463|DEVICE|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
224285302|NCT06596499|DEVICE|CH-VAD|The CH-VAD pump is a fully magnetically levitated (maglev), centrifugal continuous-flow blood pump.
224285303|NCT00005086|DRUG|cisplatin|
224285304|NCT00005086|DRUG|docetaxel|
224285305|NCT00005086|DRUG|gemcitabine hydrochloride|
224285306|NCT00005086|DRUG|methotrexate|
224285307|NCT01884402|DRUG|Peginterferon alfa-2a|Treatment as usual clinical practice
224285308|NCT01884402|DRUG|Ribavirin|Treatment as usual clinical practice
224285309|NCT05321823|DEVICE|iBreast device|The iBreast (iBE) device is an automated, battery powered, portable device designed to be used by community health nurses as a screening and triage tool. The iBE is designed to be used by a community health worker or lay person after appropriate training. In resource-limited settings, it potentially provides an easily accessible, low-cost method to assess the breast for findings that warrant further evaluation.
224285310|NCT05321823|OTHER|Clinical Breast Examination|The standard clinical breast examination (CBE) will be performed by the community health nurses in the selected primary health care centers where patients will present for screening or diagnostic workup in the intervention community
224285311|NCT05321823|DIAGNOSTIC_TEST|Breast ultrasound|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have ultrasound with or without ultrasound-guided breast biopsy if indicated by the radiologist using portable ultrasound tablets that will be brought to the intervention community.
224285312|NCT05321823|DIAGNOSTIC_TEST|Mammography|Women in the intervention community who have positive iBE and/or CBE findings will be navigated by the community health nurses to have mammography done using a mobile mammography van that will be brought to the intervention community.
224285313|NCT01491633|DRUG|Dasatinib|140 mg orally, daily in 28 day cycles
224285314|NCT06000761|PROCEDURE|Standardized oral Care|One sponge-tipped swab, saturated with sterile water or human milk, will used clean the oral cavity with 15 seconds each area. Surfaces include all 4 quadrants of the gum surface and upper posterior part of the oropharynx. A second swab, with sterile water or milk will be used on the ventral and posterior surfaces of the tongue. A third swab, saturated with sterile water or human milk, will be used to clean the outer surface of any dwelling oral tubes (endotracheal tube, NAVA or feeding tube). Lips will be cleaned with a sterile gauze saturated with sterile water or human milk. Oral cavity will be suctioned as needed with an oral suction devise to remove secretions.
224285315|NCT02341521|DRUG|OC000459|Taken orally for 8 days
224285316|NCT02613078|BEHAVIORAL|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
224285317|NCT02613078|DIETARY_SUPPLEMENT|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10\^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
224285318|NCT02613078|BEHAVIORAL|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
224285319|NCT01698593|DRUG|Bupivacaine 0.5%|
224285320|NCT01698593|DRUG|Bupivacaine 0.5% + Epinephrine (1:200,000)|
224285321|NCT04958382|DRUG|ciprofol|intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
224285322|NCT04958382|DRUG|medium/long chain fat emulsion injection (C8-24Ve)|at the infusion rate of 25-30 mL/h
223932379|NCT06952920|DEVICE|sham electroacupuncture|The same acupoints as the electroacupuncture group were referenced, but with sham acupuncture (minimal insertion at non-acupoint locations) and sham electrical stimulation, while maintaining the same treatment duration and course as the electroacupuncture group.
223932380|NCT06952920|DRUG|standard quadruple antiemetic therapy|Olanzapine 2.5 mg orally daily on days 1 to 4; dexamethasone 10 mg intravenously on day 1, and 7.5 mg intravenously on days 2 to 3; palonosetron 0.25 mg intravenously on day 1, or ondansetron 8 mg intravenously on day 1, or tropisetron 5 mg intravenously on day 1; and fosaprepitant 150 mg intravenously on day 1, or aprepitant 130 mg intravenously on day 1, or aprepitant 125 mg orally on day 1 followed by 80 mg orally on days 2 to 3. All the antiemetic drugs used are the same as those in the true acupuncture group.
223932381|NCT06953700|DIAGNOSTIC_TEST|Test of hearing function|These are measurements of hearing acuity and spatial hearing.
223932382|NCT06952556|DRUG|ACB|15 mL of 0.25% Bupivacaine block of the saphenous nerve injected under ultrasound guidance via adductor canal.
224096522|NCT06228157|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224096523|NCT00251069|DRUG|Glucosamine sulphate|
224285323|NCT04431414|OTHER|Sample collection|"* blood, nasal swab, nasal wash, and saliva~* optional stool swab"
224285324|NCT05048641|OTHER|Whatsapp reminder|Subjects who are allocated to the intervention group received reminder via WhatsApp Messenger at one month before the scheduled calendar month of biannual mammography follow-up.
224285325|NCT04351841|OTHER|arabinogalactan|A beverage will be prepared by thoroughly mixing the 15 g of arabinogalactan with water and Crystal Light flavoring
223718413|NCT05779293|DEVICE|Non-invasive auricular vagus nerve stimulation|The only cutaneous nerve of the N. vagus, ramus auricularis, receives sensation from the posterior surface of the auricle, the posterior part of the external auditory canal and the adjacent part of the eardrum. Non-invasive transcutaneous devices stimulate the vagus nerve via the auricular route or from the carotid. This device non-invasively stimulates the auricular branch of the vagus nerve without any action. As a result, it was found that the pain threshold increased and the mechanical pain sensitivity decreased. The application will take 30 minutes three days a week for four weeks.
223932383|NCT06952556|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
223932384|NCT06954688|OTHER|dry needling|Dry Needling: The puncture is intramuscular and is performed with a non-beveled, filiform, solid needle, similar to those used in acupuncture, which has been shown to produce less damage at the muscle level. It does not infiltrate any substance. As many entries as necessary are made until the local twitch response (LTR) is exhausted.
223932385|NCT06952725|BEHAVIORAL|online quit-smoking support group with intelligent chatbot|In the intervention arm (N=60), each quit-smoking peer support group will be connected to an intelligent chatbot running on a secure local server as a trained LLM (large language model). This chatbot will monitor all posts in the group and seek to comprehend these posts using the training it has been provided. If a group member makes a post and no one responds with about 10 seconds, the chatbot will respond using one of its 25 response libraries created from knowledge bases, which contain over 1k responses in total. In effect, the intelligent chatbot will function as an additional member of the GroupMe support group, but a member that only responds if no human does so.
224285326|NCT04351841|OTHER|maltodextrin|A beverage will be prepared by thoroughly mixing the 15 g of maltodextrin with water and Crystal Light flavoring
224285327|NCT04925713|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
224285328|NCT02489591|DEVICE|Oral appliance|Patients will bring their prescribed oral appliance.
223932386|NCT06952725|BEHAVIORAL|online quit-smoking support group with unintelligent bot|In the control arm (N=60), the support groups will be connected to our original automated message-posting bot running on our secure local server. This automated message-posting bot will lack the response capabilities of the intelligent chatbot; it will not respond to posts if no human group member does but, instead, remain silent. However, it will post the same daily discussion topic, and at the same time of day, as the intelligent chatbot.
223932387|NCT06952621|DRUG|3 cycles (Toripalimab + chemotherapy)|Toripalimab: 240mg, intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Nab-paclitaxel: 125mg/m², intravenous infusion, on Day 1 and Day 8, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Cisplatin: 75mg/m², intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment;
223932388|NCT06952621|DRUG|3 cycles（DCF）|Docetaxel: 70mg/m², intravenous infusion, on day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; Cisplatin: 70mg/m², intravenous infusion, on day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment; 5-FU (5-fluorouracil): 750mg/m², intravenous infusion, on day 1 to day 5, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment
224096524|NCT02696083|DEVICE|Provant Therapy System|
224096525|NCT01664026|BEHAVIORAL|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
223932389|NCT06955819|OTHER|Placebo Intervention|Subjects will be given a blank matrix powder with the same appearance as the products in the experimental groups, which does not contain probiotics or herbal powder. The dosage, frequency, and administration method are exactly the same as those in Experimental Group. Intervention duration will be 12 weeks, carried out synchronously with the experimental groups to ensure the consistency of research conditions.
224096526|NCT01664026|BEHAVIORAL|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
224096527|NCT01497392|DRUG|dovitinib lactate|Given PO
224096528|NCT01497392|DRUG|gemcitabine hydrochloride|Given IV
224096529|NCT01497392|DRUG|capecitabine|Given PO
224096530|NCT01497392|OTHER|laboratory biomarker analysis|Correlative studies
224096531|NCT01497392|OTHER|enzyme-linked immunosorbent assay|Correlative studies
224096532|NCT01497392|OTHER|pharmacological study|Correlative studies
224096533|NCT02522819|DEVICE|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
224096534|NCT03820492|DIAGNOSTIC_TEST|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
224096535|NCT00294125|DRUG|Flavocoxid|Daily flavocoxid for 12 weeks
224096536|NCT00294125|DRUG|Placebo|Daily placebo for 12 weeks
223533667|NCT01741961|PROCEDURE|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
223932390|NCT06955819|DIETARY_SUPPLEMENT|Probiotic Intervention|Subjects will take Zhigu Zhijian (QingzhiningTM) probiotic powder, 2g per sachet, twice a day, one sachet after breakfast and one after dinner, taken with lukewarm water (water temperature ≤ 30℃). Intervention duration will also be 12 weeks, for parallel comparison with other groups.
223932391|NCT06955819|DIETARY_SUPPLEMENT|Probiotic with Herbal Powder Intervention|Subjects in this group will be given Zhigu Zhijian (QingzhiningTM) probiotic powder and Zhigu Zhijian (QingzhiningTM) herbal powder. The probiotic powder is 2g per sachet, taken twice a day, one sachet after breakfast and one after dinner, and should be taken with lukewarm water (water temperature ≤ 30℃). The herbal powder is 15g per sachet, taken once every other day before breakfast, and should be taken after being brewed with boiling water. Intervention duration will be last for 12 weeks to ensure sufficient time to observe the long - term effects on defecation and gut microbiota.
223932392|NCT06952946|OTHER|0.5 lt/dk fresh gas flow|Fresh gas flow will be set to 0.5 l/min in the low flow anesthesia group.
223932393|NCT06952946|OTHER|2 lt/dk fresh gas flow|Fresh gas flow will be set to 2 lt/min in the medium flow anesthesia group.
223932394|NCT06952946|OTHER|4 lt/dk fresh gas flow|Fresh gas flow will be set to 4 lt/min in the high flow anesthesia group.
223932395|NCT06953869|DRUG|Tasimelteon Oral Suspension|Single daily dose, weight-based liquid suspension formulation.
223932396|NCT06953869|DRUG|Placebo|Placebo comparator.
223932397|NCT06953830|DEVICE|Vibration-controlled transient elastography|Liver and spleen stiffness measurements using vibration-controlled transient elastography
223932398|NCT06952075|DRUG|GR1803|D1 given at a dose of 10ug/kg, D4 given at a dose of 30ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks
223932399|NCT06951607|OTHER|Coban wrap|A Coban bandage or wrap is a self-adhering elastic wrap that sticks to itself but not to skin or clothing. It is commonly used as a wrap on limbs due to its ability to adhere to itself and not loosen. Coban is often used as a compression bandage
224096537|NCT00635622|DRUG|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10\^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
224096538|NCT00635622|DRUG|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
223533668|NCT03007771|DEVICE|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
223533669|NCT00163644|PROCEDURE|aereobic plus resisted exercise|
223533670|NCT00163644|PROCEDURE|aerobic plus active exercise|
223932400|NCT06951607|OTHER|Neoprene sleeve|Neoprene sleeve is an innovative treatment approach, it consists of a synthetic rubber-like material used to provide compressive support. Neoprene sleeves can provide protection, light compression and mild extension support while allowing full finger flexion.
223932401|NCT06951451|BEHAVIORAL|smartphone application (MED-AD)|"1. Medication Reminders: The oral medication list of the patient (names, doses, times, and frequency of administration) will be entered manually in the application by the RA in agreement with the patient during the medication prescription refill. This application will then send reminders, as notifications and voice notes, to take medications. An example of the reminder is take lisinopril, one tablet, 10 mg at 9:00 am. The reminders will be categorized as normal, urgent \& critical. Normal is a reminder sent on the normal medication timing. An urgent reminder is when the patient misses confirming a reminder more than once, which will be set as an alert on the phone. Critical reminder is when the patient misses confirming a reminder multiple times, which will be as an alert or an alarm on the phone. In addition, the application will notify a family member in case of urgent and critical reminders.~2. Medication Adherence Report: The application will generate a weekly report on medication"
223533671|NCT00163644|OTHER|No formal exercise plus phone calls|
223533672|NCT00992550|DRUG|Cigarette|
223533673|NCT00992550|DRUG|Hookah|
223533674|NCT01081392|BIOLOGICAL|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
223533675|NCT01636284|BIOLOGICAL|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
223533676|NCT03577899|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
224096539|NCT02226354|DIETARY_SUPPLEMENT|Ahiflower oil|9.73 ml per day for 28 days
224096540|NCT02226354|DIETARY_SUPPLEMENT|Flaxseed oil|9.73ml per day for 28 days
224096541|NCT05705726|DEVICE|ultrasound guided facia iliaca block|Patient will received ultrasound guided fascia iliaca block by 20 ml Bupivacaine 0,25% .
224096542|NCT05705726|DRUG|Intravenous drug|Patient will received intravenous injection of precedex 0.25mic/Kg and ketamine 0,2 mg/kg .
224285329|NCT02489591|DEVICE|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
223533677|NCT03577899|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
223533678|NCT03577899|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
223932402|NCT06951451|BEHAVIORAL|Short Text-message Reminders|"Participants will receive short text message (SMS) reminders to remind them to take medications as prescribed ONCE daily. However, the SMS will be general and not specify taking particular medicine compared to the application reminders. An example of the SMS message will be Remember to take your medicines of the day? The research team will pilot the MED-AD application on the same population and modify it before the implementation of the study."
223932403|NCT05551507|DRUG|IN10018 in combination with PLD|IN10018 in combination with PLD to treat subjects with platinum-resistant recurrent ovarian cancer
223932404|NCT06523270|RADIATION|Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI)|"All adult (≥18 y.o) subjects (until 50000 individuals) presenting to the U.O of Radiologia DiMer Advanced Imaging for Personalized Medicine to be submitted to imaging study on advanced scanner"
223932405|NCT03561818|OTHER|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
223932406|NCT03561818|OTHER|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
223932407|NCT05370612|DEVICE|Dexcom G6 CGM|"Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data.~Experimental Group will wear CGM for the duration of their pregnancy.~Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy."
224285330|NCT03923231|DRUG|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
224285331|NCT03923231|DRUG|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
223932408|NCT05370612|OTHER|Participant Finger Stick Glucose Monitoring|Standard of care for individual participant
224285332|NCT04331964|PROCEDURE|partial pulpotomy|Removal of a small portion of coronal pulp tissue after exposure, followed by application of a biomaterial directly onto the remaining pulp tissue prior to placement of a permanent restoration.
223533679|NCT05878067|DRUG|ABBV-444|Lubricant Eye drops
223533680|NCT00949533|DRUG|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
223533681|NCT05024513|DRUG|oxaliplatin and 5-fluorouracil|Intra-arterial chemotherapy consisted of Oxaliplatin (40mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for22 hours) on days 1-3 every 4 weeks.
223533682|NCT05024513|PROCEDURE|Biliary Drainage|External biliary drainage, or biliary stent placement; Biliary stent placement plus Iodine-125 seed strands is allowed
223533683|NCT05024513|OTHER|Best Supportive Care|Nutrition support, symptomatic treatment, and other supportive treatments
223718414|NCT05779293|OTHER|Conventional therapy|"Conventional approaches are approaches that cover range of motion, strength, balance and ambulation training, continuing from passive to resistant exercises.~Neuromuscular electrical stimulation; It is applied to reduce pain, prevent spasticity and strengthen muscles. This newly formed type I fiber functionally shows an increase in resistance to fatigue and a decrease in maximum contraction velocity. The application will take 30 minutes three days a week for four weeks."
223718415|NCT00007969|BIOLOGICAL|Detox-B adjuvant|
223718416|NCT00007969|DRUG|verteporfin|
223718417|NCT03552653|DIETARY_SUPPLEMENT|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
223718418|NCT04039815|DRUG|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
223718419|NCT04039815|DRUG|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
223718420|NCT02174120|DRUG|propofol|
223718421|NCT02174120|DRUG|etomidate|
223718422|NCT05349916|OTHER|Control|300 g rice porridge + 150 ml drinking water
223718423|NCT05349916|OTHER|Isomaltodextrin Low Dose|300 g rice porridge + (5 g IMD in 150 ml drinking water)
223718424|NCT05349916|OTHER|Isomaltodextrin High Dose|300 g rice porridge + (10 g IMD in 150 ml drinking water)
223718425|NCT05349916|OTHER|GPC partially digestible maltodextrin|300 g rice porridge + (15 g GPC fiber in 150 ml drinking water)
223533684|NCT05024513|PROCEDURE|External biliary drainage|External biliary drainage
223718426|NCT05349916|OTHER|Resistant Starch Type 4|300 g rice porridge + (15 g RS4 starch in 150 ml drinking water)
223718427|NCT06201377|OTHER|Periodontal Access Surgery+ Suture with chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture coated with chlorhexidine (Novosyn Chlorhexidine). Standardized post-surgical recommendations will be followed.
223718428|NCT06201377|OTHER|Periodontal Access Surgery+ Suture without chlorhexidine|Periodontal conventional surgery will be performed as treatment of periodontal diseases in patients who present active periodontal pockets. At the end of the surgery, the surgeon will suture the flap with the absorbable polyglactin 910 suture (Novosyn). Standardized post-surgical recommendations will be followed.
223718429|NCT03102372|DIETARY_SUPPLEMENT|Whey protein supplementation|
223718430|NCT03102372|OTHER|walking program|
223718431|NCT03102372|OTHER|Very Low Calorie Diet|
223718432|NCT01344005|OTHER|caregiver-related intervention or procedure|
223718433|NCT01344005|OTHER|questionnaire administration|
223718434|NCT01344005|PROCEDURE|quality-of-life assessment|
223718435|NCT01344005|PROCEDURE|radiography|
223718436|NCT03074591|DRUG|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
223718437|NCT03074591|DRUG|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
223533685|NCT02030626|DEVICE|active or placebo rTMS or active or placebo tDCS|
223718438|NCT00957775|BEHAVIORAL|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
223718439|NCT00957775|BEHAVIORAL|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
223718440|NCT00284271|DRUG|Cyclophosphamide|
223718441|NCT00284271|DRUG|Adramycin|
223932409|NCT05458258|DEVICE|Bioelectrical Impedence Analysis Device|A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.
223932410|NCT05458258|OTHER|6 Minute Walk Test|Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.
223533686|NCT03183310|DRUG|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
223533687|NCT03183310|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
223718442|NCT00284271|DRUG|Procarbacine|
223718443|NCT00284271|DRUG|Prednisone|
223718444|NCT00284271|DRUG|Vincristine|
223718445|NCT00284271|DRUG|Bleomycin|
223718446|NCT00284271|DRUG|Erythropoietin beta|
223718447|NCT03773081|DEVICE|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
223718448|NCT00036738|DRUG|Cyclosporine|Given IV or PO
223718449|NCT00036738|DRUG|Dasatinib|Given PO
223718450|NCT00036738|DRUG|Fludarabine Phosphate|Given IV
223718451|NCT00036738|DRUG|Imatinib Mesylate|Given PO
223718452|NCT00036738|DRUG|Mycophenolate Mofetil|Given PO
223932411|NCT05458258|DIAGNOSTIC_TEST|Computed Tomography Scans to Measure Skeletal Muscular Index|Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).
223533688|NCT03183310|DRUG|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
223533689|NCT03896191|PROCEDURE|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
223533690|NCT03896191|OTHER|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
223932412|NCT05458258|DIAGNOSTIC_TEST|Blood Test/Blood Draw|Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.
223533691|NCT01959529|DRUG|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
223932413|NCT05458258|OTHER|Hand Grip Strength Test|Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.
223932414|NCT00683670|DRUG|cyclophosphamide|
223932415|NCT00683670|BIOLOGICAL|Mature dendritic cell vaccine|
223932416|NCT05854212|BEHAVIORAL|Behavioral economics-enhanced user interface|The intervention changes the ordering platform visible to food agencies using behavioral economics strategies to promote healthier food choices.
223932417|NCT05787054|OTHER|Third trimester ultrasound|Single scan versus Longitudinal scan
223932418|NCT04530487|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223932419|NCT04530487|DRUG|Cyclosporine|Given IV and PO
223932420|NCT04530487|DRUG|Etoposide|Given IV
223932421|NCT04530487|DRUG|Fludarabine Phosphate|Given IV
223932422|NCT04530487|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
223932423|NCT04530487|DRUG|Melphalan|Given IV
223932424|NCT04530487|DRUG|Mycophenolate Mofetil|Given IV or PO
223932425|NCT04530487|DRUG|Tacrolimus|Given IV and PO
223932426|NCT04530487|DRUG|Thiotepa|Given IV
223932427|NCT06432998|OTHER|Perineal massage|The technique will be applied for approximately twenty minutes and will be carried out as follows: the vaginal dilator is introduced progressively using crescent-shaped movements. Once the dilator is fully inserted, movements will be made from bottom to top and from one side to the other, and then continue with the crescent-shaped movements.
223932428|NCT06432998|OTHER|Standard treatment|The treatment will consist of the use of vaginal dilators according to the gold standard proposed in the literature. It will consist of introducing the same dilators as for the experimental group, with the same time schedule, but without massage, only introducing the dilator and keeping it in the vagina for 20 minutes.
223932429|NCT04926324|DRUG|Niraparib|Niraparib is a drug FDA-approved for use in maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
223932430|NCT04926324|DRUG|Dostarlimab|Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody medication used for the treatment of endometrial cancer.
223932431|NCT04926324|RADIATION|Short course radiation|Participants will be treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) to minimize mean dose to femoral, pelvic, and lumbar bone marrow. The entire mesorectum will be treated to a total dose of 25 Gy.
223932432|NCT05023434|PROCEDURE|Intraoperative Brain Simulation - Alternate Stimulation Parameters|Additional stimulation parameters outside of standard of care during intraoperative brain stimulation to aid in motor mapping.
223932433|NCT04356729|DRUG|Atezolizumab|Atezolizumab will be administered intravenously at a fixed predetermined dose every three weeks ith 21 consecutive days defined as a treatment cycle.
223932434|NCT04356729|DRUG|Bevacizumab|Bevacizumab will be administered intravenously at a fixed predetermined dose every three weeks, with 21 consecutive days defined as a treatment cycle.
223932435|NCT01595451|PROCEDURE|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
223932436|NCT06326788|BEHAVIORAL|Short Duration Moderate Intensity Soleus Push-ups|"Participants will start soleus pushups in sitting positions. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Soleus push-ups will be performed with moderate intensity using weights which will be placed on their laps.~Participants will perform this activity till 60-70% of their maximum heart rate is achieved and maintained."
224285333|NCT03851588|OTHER|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
223932437|NCT06326788|BEHAVIORAL|SUSTAINED SOLEUS PUSH-UPS|"Participants will start soles push-ups in sitting. To do so, the participants will be in a seated position, the legs will be at 90 degrees to the floor, and the feet will be placed flat on the ground.~Participants will then move their heels up and down continuously. Sustained soleus push-ups will be performed with light intensity for up to 270 mins.~No external resistance will be added. Participants will be provided with a maximum 4-minute break time after every 90 mins intervention. In the meantime, their blood sample will be collected."
223932438|NCT00655499|DRUG|Panitumumab|6 mg/kg
223932439|NCT00655499|DRUG|Irinotecan hydrochloride|180 mg/kg
223932440|NCT00655499|GENETIC|Chromogenic in situ hybridization|
223932441|NCT00655499|GENETIC|Fluorescence in situ hybridization|
223932442|NCT00655499|GENETIC|Gene expression analysis|
223932443|NCT00655499|OTHER|Laboratory biomarker analysis|
223718453|NCT00036738|DRUG|Nilotinib|Given PO
224285334|NCT03851588|DRUG|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
224285335|NCT05117047|PROCEDURE|liver resection|After adequate periods of follow-up, the long-term oncological outcomes of the three different surgical approaches were compared, providing a higher level of evidence using a non-randomized comparative study based on propensity score matching (PSM) analysis.
224285336|NCT02330744|BEHAVIORAL|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
224096543|NCT03754153|DEVICE|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
224096544|NCT03754153|OTHER|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
224285337|NCT02330744|BEHAVIORAL|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
224285338|NCT02220595|PROCEDURE|Carotid endarterectomy vs. carotid stenting|
223932444|NCT05863234|DRUG|PPMX-T003|The therapeutic agent is administered continuously intravenously
223932445|NCT06074744|OTHER|SSNB + IPACK|already included in arm/group description
223932446|NCT06074744|OTHER|FNB + IPACK|already included in arm/group description
223932447|NCT06098105|PROCEDURE|Ultrasound-guided transversus abdominis plane block|This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.
223932448|NCT06098105|PROCEDURE|Laparoscopic-assisted transversus abdominis plane block|Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.
223932449|NCT06098105|PROCEDURE|Laparoscopic-assisted intraperitoneal instillation|This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.
223932450|NCT06098105|DRUG|Bupivacaine|bupivacaine
223932451|NCT06091449|OTHER|High fidelity simulation|Within the scope of high reality simulation application; The ideal number of students to take part in each simulation was determined to be 10. On the simulation day, the researchers responsible for the simulation application will introduce the environment and the tools and equipment they will use in the simulation application, so that they can make preliminary preparations for the students. It will last 60 minutes in total, including preliminary information (10 minutes), simulation time (15 minutes) and evaluation/analysis session (35 minutes).
223932452|NCT06091449|OTHER|Virtual reality|"For the virtual reality-based simulation application, students can log in to the virtual reality-based simulation program prepared in line with the Diabetes Mellitus scenario using their username and password; They will receive modular training integrated into the simulation. The expected time for students to complete the modular training is 30 minutes. Students who complete the module will be asked to take a 10-minute break and then participate in a virtual reality-based simulation application.The application of high-fidelity simulation is the same in both groups."
223932453|NCT06519617|DRUG|Yi Qi Yang Yin Decoction|The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.
223932454|NCT06519617|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
223932455|NCT03572803|OTHER|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
223932456|NCT03572803|OTHER|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
223932457|NCT03572803|OTHER|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
223932458|NCT06411041|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT) and yoga|The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
223932459|NCT01902914|PROCEDURE|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
223932460|NCT00838461|DRUG|HSD-016|
223932461|NCT00838461|DRUG|placebo|
223932462|NCT00772044|DEVICE|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
223932463|NCT00772044|DEVICE|Sham Device|Sham device will be applied
223932464|NCT06950307|RADIATION|Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer patients|Hypofractionated radiotherapy for low- and intermediate-risk prostate cancer will be treated with 20x3 Gray (Gy), 5 days/week
223932465|NCT06950307|RADIATION|Hypofractionated radiotherapy for high-risk prostate cancer patients|Hypofractionated radiotherapy for high-risk prostate cancer will be treated with 20x3.1 Gy, 5 days/week
223932466|NCT05677269|PROCEDURE|Laparoscopic excision of endometriosis, including colorectal endometriosis|Laparoscopic resection of deep endometriosis, including colorectal endometriosis, in a (candidate) level 2 centre of expertise. Complete resection can exist of either 'shaving' of the nodule from the bowel (leaving the lumen closed), discoid excision or segmental resection, depending on the nodule size and extent of disease.
223932467|NCT05677269|PROCEDURE|In vitro fertilisation or intracytoplasmic sperm injection|IVF/ICSI treatment trajectory (maximum of 3 cycles), according to the local protocol. Preferably preceded by 3 months downregulation with either Gonadotrophin-releasing hormone (GnRH) analogue or oral contraceptive pill. One IVF/ICSI cycle is defined as the transfer of all the embryos created after one follicle puncture until pregnancy confirmation or failure of the last embryo transfer.
223932468|NCT04421365|DEVICE|neurofeedback brain-computer interface (BCI)|The integrated components of BCI system include the high-density EEG, 3D-VR, and a built-in ML platform as a real-time neural signal decoder and neurofeedback controller.
223932469|NCT03718013|DEVICE|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
223932470|NCT03718013|DEVICE|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
223932471|NCT01036724|DEVICE|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
224096545|NCT00222911|DEVICE|dorsiflexion night splint|
224096546|NCT00222911|DEVICE|medial arch support|
223932472|NCT02863315|DEVICE|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
223932473|NCT01048476|DIETARY_SUPPLEMENT|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
224096547|NCT02371629|DRUG|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
224096548|NCT02371629|DRUG|Placebo|Placebo to NVA237
224096549|NCT02371629|DRUG|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
224285339|NCT02479477|OTHER|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
224285340|NCT02260258|DRUG|Rocuronium|Neuromuscular Blockade
224285341|NCT02260258|DRUG|Normal Saline|Normal Saline
223932474|NCT01048476|DIETARY_SUPPLEMENT|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
223932475|NCT01048476|DIETARY_SUPPLEMENT|placebo|Dietary Supplement: placebo; daily supplementation one year
223932476|NCT01048476|DRUG|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
224096550|NCT05844384|DEVICE|Nanodropper|Nanodropper delivers 1/5 of eye drop volume compared to regular droppers
224096551|NCT05844384|DEVICE|Regular dropper|Delivers full eye drop volume
224096552|NCT00371319|DRUG|tacrolimus|0.06-0.1 mg/kg/day
224096553|NCT00371319|DRUG|mycophenolate mofetil|2-3 gm/day
224096554|NCT06203431|DRUG|ET-26|freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.
224096555|NCT06203431|DRUG|Etomidate Injectable Emulsion|lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
224096556|NCT00312130|DRUG|Vildagliptin|
224096557|NCT01995890|DRUG|nepafenac|
224285342|NCT04004845|DRUG|Cytotec|Misoprostol 25mcg vaginal
224285343|NCT04004845|DRUG|oxytocin|Oxytocin 10 IU/ml Solution for infusion
224285344|NCT04004845|DEVICE|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
224285345|NCT01898234|DEVICE|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
224285346|NCT01898234|DEVICE|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
224285347|NCT01898234|DEVICE|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
224285348|NCT01898234|DEVICE|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
223932477|NCT01617369|DEVICE|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
223932478|NCT04689178|OTHER|Invitation letter + GP reminder|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years
224096558|NCT04837612|OTHER|No intervention nor exposure|As an observational study, no intervention nor exposure is interested.
224096559|NCT03662295|BEHAVIORAL|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
224096560|NCT04740229|BEHAVIORAL|Yoga|Moderate-intensity flow-based yoga movements, breathing, and relaxation for 50 minutes, 3 times per week, for 8 weeks
224096561|NCT01118910|DRUG|Vusion|Vusion will be applied to areas of intertrigo
224096562|NCT00599651|DEVICE|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
224096563|NCT00599651|OTHER|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
224096564|NCT04673383|DRUG|SPL026|Intravenous solution
224096565|NCT04673383|DRUG|Placebo|SPL026-matched placebo
224096566|NCT04685148|DRUG|Transdermal patch estradiol|Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
224096567|NCT04685148|DRUG|Transdermal patch placebo|Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
224096568|NCT00201851|DRUG|Tamoxifen|20 mg po daily x 5 years
224096569|NCT00201851|PROCEDURE|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
224096570|NCT03257046|DRUG|ITI-214|Oral
224096571|NCT03257046|OTHER|Placebo|Oral
224285349|NCT05925725|DRUG|• harpagozid • boswellin = LOXACON|Exercise therapy
224285350|NCT00611325|DRUG|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
224285351|NCT00611325|DRUG|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, \& 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs \& 2.5 mg/m2 for patients taking EIAEDs.
223932479|NCT04689178|OTHER|Invitation letter|40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.
223932480|NCT06232681|BEHAVIORAL|Progressive relaxation exercise|The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
223932481|NCT01887275|DEVICE|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
223932482|NCT01887275|DRUG|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
223932483|NCT04480385|OTHER|Remote Automated Monitoring System|The patient will be monitored with conventional monitoring devices as well as the MultiSense patch
223932484|NCT00557284|DRUG|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
223932485|NCT00557284|DRUG|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
223932486|NCT03001440|OTHER|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
223932487|NCT05106049|DIAGNOSTIC_TEST|serum Adiponectin|serum adiponectin as early marker for renal impairment. Adiponectin is a recently identified adipose tissue-derived protein (adipocytokine) with important metabolic ,antiinflammatory, anti-atherogenic, and reactive oxygen species protective actions.
223932488|NCT01211106|BEHAVIORAL|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
223932489|NCT01211106|BEHAVIORAL|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
223932490|NCT02906657|OTHER|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
223932491|NCT01411137|DRUG|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
223932492|NCT05420480|PROCEDURE|Two-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
223932493|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has no metastasis, patients will be randomized to two groups at 1:1 ratio and receive esophagectomy with Two-Field or Three-Field lymph node dissection."
223932494|NCT05420480|PROCEDURE|Three-Field lymph node dissection|"The right recurrent laryngeal nerve lymph node (106recR) will be dissected and subjected to the intra-operative frozen section pathology. If the 106recR lymph node has metastasis, esophagectomy and Three-Field lymph node dissection will be performed."
223932495|NCT01678079|DIETARY_SUPPLEMENT|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
223932496|NCT01678079|DIETARY_SUPPLEMENT|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
223932497|NCT01558908|BIOLOGICAL|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
223932498|NCT06461585|OTHER|Sprint interval training|Group A the Interventional group will receive SIT . Group A will perform SIT 3 times a week for 30-second sprints on a cycle ergometer with 4 minutes of rest between each sprint, complete session will be for 30 -40 minutes. Group B will receive the aerobic exercise. Group B will perform the aerobic exercise for 30-40 minutes of moderate-intensity continuous exercise on a treadmill and stationary cycle
223932499|NCT05917015|DIETARY_SUPPLEMENT|Treatment|Participants will receive daily 2 tablets of Proglucamune for a duration of 6 weeks. Each tablet contains \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
224096572|NCT05917743|OTHER|Mat Pilates|Duration: 50 minutes per session Repetitions: 8-12 repetitions per exercise Sets: 2-3 sets per exercise Rests: 30-60 seconds rest between sets Frequency: 3 times per week for 4 weeks Exercises: A series of Mat Pilates exercises targeting core strength, flexibility, and muscle control
224285352|NCT05210049|DIAGNOSTIC_TEST|Esocheck/Esoguard|All enrolled patients will complete the Esocheck screening test. EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus. The collected cell material is examined with a two marker panel combining methylated CCNA1 and VIM. These methylated markers have 95% sensitivity and 91% specificity for detecting BE and EAC with an AUC=0.95 in studies performed among white men. Diagnostic yield of this test among Veterans is unknown.
223533692|NCT01959529|DRUG|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
223932500|NCT05917015|OTHER|Placebo|Participants will receive daily 2 placebo tablets containing microcrystalline cellulose. The size, shape and appearance of the placebo tablet is identical to the treatment tablet.
223932501|NCT00936416|PROCEDURE|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
223932502|NCT04327752|OTHER|dermatological consultation|Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
223932503|NCT02549807|DEVICE|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
223932504|NCT00083967|DRUG|denufosol tetrasodium (INS37217) Intravitreal Injection|
223932505|NCT01637402|DRUG|Abiraterone Acetate|"Standard dose participants:~1,000 mg, once daily, oral administration.~Dose escalation participants:~1,000 mg, twice daily, oral administration"
223932506|NCT01637402|DRUG|Prednisone|5 mg, twice daily, oral administration
223932507|NCT02436174|DEVICE|novel device|novel device being used to measure shivering
223932508|NCT02285270|DEVICE|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
223932509|NCT00862706|DRUG|Telbivudine/LDT600A|Oral once daily
223932510|NCT06458179|PROCEDURE|Ultrasound-guided proximal greater occipital nerve radiofrequency ablation|In the prone position with the head slightly flexed and the US probe was placed in the neck transversely and then was located the bifid spinous process of C2 and the probe was lateralized (toward the affected side). At this level, the GON is located above the obliquus capitis inferior muscle and deeper than the semispinalis capitis muscle. The in-plane approach from medial to lateral was employed to treat the nerve with a 21 G 5-mm active tip radiofrequency needle. Sensory stimulation was administered at 50 Hz for 1 ms to induce paresthesia, pain, or irritation. A motor stimulus was applied at 2 Hz for 1 ms and up to 2 volts to see if fasciculation was absent. Then 1 mL of 2% lidocaine was administered through the RF cannulas to alleviate procedure related pain. Conventional RFA was conducted for 60 seconds at a temperature of 60 degrees. Following the procedure, 2 mg of dexamethasone was administered per lesion site.
223932511|NCT06026800|BIOLOGICAL|iNeo-Vac-R01|Personalized mRNA vaccine encoding neoantigen, IH injection
223932512|NCT00143130|DRUG|Pregabalin|Pregabalin
223932513|NCT01780649|PROCEDURE|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
223932514|NCT01780649|PROCEDURE|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
223932515|NCT00201149|BEHAVIORAL|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
223932516|NCT03085433|DEVICE|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
223932517|NCT03085433|PROCEDURE|in vitro fertilization|ivf/icsi
223932518|NCT00635869|BEHAVIORAL|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
223932519|NCT00635869|BEHAVIORAL|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
223932520|NCT00635869|BEHAVIORAL|Placebo|didactic education sessions on physical assessment
223932521|NCT02987218|DRUG|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
223932522|NCT02987218|DRUG|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
223932523|NCT00442637|DRUG|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
223932524|NCT00442637|OTHER|observation|observation after induction treatment
223932525|NCT00649272|DRUG|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
223932526|NCT00649272|DRUG|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
223533693|NCT01597817|OTHER|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
223533694|NCT01597817|OTHER|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
224096573|NCT05917743|OTHER|General Exercises|General exercise is a structured exercise program designed to help individuals with back pain improve their fitness levels. The program comprises of a series of exercise classes that are led by a physiotherapist. The classes involve a combination of aerobic, strength, and flexibility exercises, and aim to improve overall physical fitness, reduce pain, and improve function. The program is specifically designed for individuals with back pain, and the exercises are tailored to meet the needs of each participant. The Back to Fitness Program is based on the principles of exercise prescription and is intended to be a safe and effective way to manage back pain through exercise.
224096574|NCT03289689|DEVICE|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
224096575|NCT03758937|PROCEDURE|volume-controlled ventilation|
224285353|NCT04701424|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data."
223932527|NCT01575015|DEVICE|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
223932528|NCT01575015|PROCEDURE|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
223932529|NCT03239301|PROCEDURE|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
223932530|NCT03239301|PROCEDURE|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
223932531|NCT00018096|BIOLOGICAL|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
223932532|NCT01943305|BIOLOGICAL|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
223932533|NCT01943305|BIOLOGICAL|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
223932534|NCT00777049|DRUG|Panobinostat|Hard gelatine capsule - 5mg and 20mg
223932535|NCT00246805|DEVICE|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
223932536|NCT02620449|OTHER|Diet|Participants will be fed a low-additive diet as the primary intervention
223932537|NCT05923190|DRUG|Enfortumab vedotin|EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
224285354|NCT04701424|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
224285355|NCT06412302|OTHER|Whey Protein+Resistance Training|WP group received 25g protein on one scoop of Whey Protein Isolate (Iso100 Dymatize) with 8 weeks of resistance training 3 days a week.
224285356|NCT06412302|OTHER|High protein yogurt+Resistance Training|PY group received 24.6g protein on two High Protein yogurts (Lonco Leche) with 8 weeks of resistance training 3 days a week.
224285357|NCT05105919|DRUG|Aspirin 80 mg EC Tab|Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
223932538|NCT05923190|DRUG|Pembrolizumab|Pembrolizumab will be administered on day 1 of a 21-day cycle
224096576|NCT03758937|PROCEDURE|pressure-controlled ventilation|
224096577|NCT03035812|DRUG|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
224096578|NCT03094247|DRUG|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
224096579|NCT03094247|DIETARY_SUPPLEMENT|HO-RUTF|HO-RUTF: Milk, perilla oil, palm oil, white sugar, high oleic peanuts
224096580|NCT03094247|DIETARY_SUPPLEMENT|D-HO-RUTF|D-HO-RUTF: DHA, milk, perilla oil, palm oil, white sugar, high oleic peanuts
224096581|NCT03094247|DIETARY_SUPPLEMENT|S-RUTF|S-RUTF: Milk, canola oil, palm oil, white sugar, standard peanuts
224285358|NCT00429624|PROCEDURE|Chiropractic manipulation|
224285359|NCT00429624|DRUG|acetaminophen|
224285360|NCT02596633|BEHAVIORAL|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
224285361|NCT00382629|DRUG|BHT-3009 0.5 mg|
224285362|NCT00382629|DRUG|BHT-3009 1.5 mg|
224285363|NCT00382629|DRUG|Placebo|
224285364|NCT01722682|BIOLOGICAL|Human pancreatic islet transplantation|
224285365|NCT05295654|OTHER|Kinect validation|Participants will perform several movements while both the vicon and kinect are measuring.
224285366|NCT04144426|BEHAVIORAL|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
224285367|NCT04144426|BEHAVIORAL|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
224285368|NCT05098457|DEVICE|GP0112|Injectable gel
224285369|NCT05098457|DEVICE|Restylane Lyft Lidocaine|Injectable gel
224285370|NCT04221126|DEVICE|TMFI|Tixel rapidly transfer thermal energy by a metallic pyramid tip that enable skin contact through integrated pulsed movements. The rapid heating dehydrates he epidermis and superficial dermis and creates micropores with no coagulative damage of surronding tissue.
224285371|NCT04221126|DRUG|ALA cream|ALA compounded in a cream
224285372|NCT04221126|DRUG|ALA gel|ALA compounded in a gel
224285373|NCT01978652|BIOLOGICAL|Peginterferon Beta-1a|As specified in the treatment arm
223533695|NCT01440764|DRUG|Furosemide|
223533696|NCT01440764|DRUG|Saline|
223533697|NCT00406861|DRUG|montelukast in treatment of ENL reaction|
223533698|NCT00668629|DRUG|Lactic acid (Dermacid)|
223932539|NCT04132167|PROCEDURE|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
223932540|NCT04775810|DEVICE|The device is an algorithm designed to enhance speech intelligibility of speech-in-noise signals|Normal-hearing and hearing-impaired subjects will listen to speech-in-noise audio files that are either unprocessed or processed in order to increase speech intelligibility.
223932541|NCT01627561|BIOLOGICAL|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.
223932542|NCT01627561|BIOLOGICAL|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.
223932543|NCT01627561|BIOLOGICAL|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
223932544|NCT03588832|DIAGNOSTIC_TEST|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
223932545|NCT04242212|BEHAVIORAL|Misoprostol sourced from clinics|One cohort of women using misoprostol sourced from clinics
223932546|NCT04242212|BEHAVIORAL|Misoprostol sourced from PMVs|One cohort of women using misoprostol sourced from PMVs
223932547|NCT00856700|DRUG|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
223932548|NCT03661463|DRUG|Aspirin|Drug
223533699|NCT02815163|OTHER|Empowerment education|"1. admission (1 hour)~   ▪partnership~2. 2 ds after THR (30-45min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~3. 2 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~4. 6 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback~5. 10 WKs after THR (30 min)~   * listening~  * dialogue~  * reflection~  * action~  * feedback"
223533700|NCT00633841|BIOLOGICAL|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
223533701|NCT00399035|DRUG|Cediranib|oral tablet
224096582|NCT02756455|OTHER|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
224096583|NCT02688075|OTHER|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
223533702|NCT00399035|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
223533703|NCT00399035|DRUG|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m\^2(day 1) followed by oral capecitabine 1,000 mg/ m\^2twice daily (day 1 to day 15)
223533704|NCT00399035|DRUG|Cediranib Placebo|oral tablet
223533705|NCT00854360|DRUG|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
223533706|NCT00854360|DRUG|Placebo|HFA Vehicle Aerosol
223533707|NCT05694247|DEVICE|CorNeat KPro|The optical component of the CorNeat KPro will be implanted into a circular disc of the cornea (as performed in standard penetrating keratoplasty surgery) and the skirt component will be embedded under a 360º conjunctival flap.
223533708|NCT01651468|DIETARY_SUPPLEMENT|HEMOFIX|unique complex herbal mixture
223718454|NCT00036738|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
223718455|NCT00036738|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
223718456|NCT00036738|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
224096584|NCT06175624|OTHER|Clinically Helathy|"Our study will include 25 people with clinically healthy patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
224096585|NCT06175624|OTHER|Gingivitis|"Our study will include 25 people with gingivitis patients.~Gingival crevicular fluid and serum will be collected during the clinical measurements Biomarkers in serum and gingival crevicular fluid samples will be examined by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and sample will be taken from all individuals at the beginning of the study."
224285374|NCT04558333|OTHER|blood and exhaled breath specimens|identification of possible biomarkers
224285375|NCT01509482|OTHER|blood samples|blood samples to test for primary and secondary outcome measures
223718457|NCT00036738|RADIATION|Total-Body Irradiation|Undergo TBI
223718458|NCT05234151|OTHER|NEWS|Newborn Early Warning Score
224285376|NCT01509482|OTHER|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
224285377|NCT01886937|DRUG|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
224285378|NCT01886937|DRUG|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
224285379|NCT00925756|DRUG|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment (150 mg, 300 mg, or 600 mg twice daily)
224285380|NCT04108832|DRUG|TCM OA2|Usage: 3g twice daily
224285381|NCT04108832|DRUG|PLACEBO|Usage: 3g twice daily
224285382|NCT01411488|DEVICE|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
223718459|NCT03598621|DRUG|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
223932549|NCT00192218|BIOLOGICAL|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
223932550|NCT01912300|BEHAVIORAL|experimental condition: Passvice Video game; Avtive Video game; Exercise|
223932551|NCT04936386|BEHAVIORAL|Survey|The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
223932552|NCT03422549|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
223932553|NCT01099566|DRUG|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
223932554|NCT01099566|DRUG|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
223932555|NCT01310166|DRUG|Fingolimod|
223932556|NCT03516370|DRUG|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
223932557|NCT00009932|DRUG|cisplatin|
223932558|NCT00009932|DRUG|fenretinide|
223932559|NCT00009932|DRUG|paclitaxel|
223932560|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 60mj|
223932561|NCT02358005|PROCEDURE|Extracorporeal shock wave therapy 120mj|
224285383|NCT03944109|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
224285384|NCT03944109|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
223932562|NCT02358005|PROCEDURE|non extracorporeal shock wave therapy|
223932563|NCT00382941|DEVICE|Red and near infrared LED phototherapy device|
224285385|NCT06128187|OTHER|Control Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of virtual reality training will be given.
224285386|NCT06128187|OTHER|Study Group|Participants will receive treatment 5 days a week, 45 minutes a day for 6 weeks. After the traditional rehabilitation program, 30 minutes of dual-task training will be given
224285387|NCT02060045|OTHER|Bundle implementation|
223718460|NCT03598621|DRUG|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
223718461|NCT03598621|DRUG|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
223718462|NCT03598621|DRUG|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
223932564|NCT04221659|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². The cathode, reference electrode (5x7cm), will be positioned in the occipital region. These parameters are within the safe limits established in previous human studies.
223932565|NCT05892562|OTHER|No intervention|As this study is purely observational, no intervention is involved.
223932566|NCT03194659|DIETARY_SUPPLEMENT|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
223932567|NCT00890591|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
223932568|NCT04898569|DRUG|Ferinject|Ferric carboxymaltose injection
223932569|NCT04898569|DRUG|Normal Saline Flush|placebo
223932570|NCT05694832|BEHAVIORAL|Expressive Writing|Creative writing, discussion and social support, in a group setting via videoconference
223932571|NCT05031923|PROCEDURE|SMV and antimicrobial photodynamic therapy|Application of SMV and antimicrobial photodynamic therapy in intrabony defects
223932572|NCT05031923|PROCEDURE|SMV application|Application of SMV without antimicrobial photodynamic therapy in intrabony defects
224285388|NCT02777684|OTHER|Qualitative study|
224285389|NCT04565496|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 3 cycles prior to RP and ePLND
224285390|NCT06278038|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
224285391|NCT06278038|DRUG|Venlafaxine hydrochloride sustained-release tablets|75 mg or 150 mg or 225 mg orally once daily dosing for 8 weeks
223533709|NCT04747301|DEVICE|Double-balloon catheter (UTAH CVX-RIPE) for cervical ripening|"Sweeping the membranes by UTAH CVX-RIPE® (Utah Medical Products, Inc, 7043 South 300 West, Midvale, Utah 84047 USA). The catheter will be inserted manually until the proximal balloon is in the cervical canal, the distal balloon should be intrauterine and in the extra-amniotic space. The intrauterine balloon is inflated with 40mL saline and retracted so that it rests against the internal oz. The proximal balloon should now be outside the external oz and is inflated with 20mL saline. If the balloons are correctly situated on both ends of the cervix, they can be inflated with up to 80mL saline each.~Cardiotocograph will be performed 30min, 2 hours after insertion and every 6 hours. The balloon is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another balloon is placed for a maximum of another 24 hours.~The patients will be examined in case of extremely painful or membranes ruptured."
223718463|NCT03598621|DEVICE|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
223718464|NCT03598621|DEVICE|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
223932573|NCT03234374|COMBINATION_PRODUCT|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
223932574|NCT03234374|DRUG|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
223932575|NCT03294967|DIETARY_SUPPLEMENT|Caffeine|As in group descriptions
223932576|NCT03294967|DIETARY_SUPPLEMENT|Vitamin E|As in group descriptions
223932577|NCT00259792|DRUG|Budesonide/formoterol Turbuhaler|
223932578|NCT00739934|DRUG|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
223932579|NCT01023698|PROCEDURE|laser photocoagulation|Laser photocoagulation
223932580|NCT03455985|OTHER|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
223932581|NCT03455985|OTHER|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
223932582|NCT01579318|BIOLOGICAL|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
223932583|NCT01579318|DEVICE|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
223932584|NCT06498817|BEHAVIORAL|Standard Recommendation|Standard recommendation given by government of Bangladesh on the use of oral rehydration solution (ORS) and a flyer on water treatment and handwashing with soap given at the health facility during the time of diarrhea patient treatment.
223932585|NCT06498817|BEHAVIORAL|CHoBI7 Scale-Up Program|Health promoter delivery of handwashing with soap, water treatment, and safe water storage module in the health facility to diarrhea patients and the patient's household members during the time of treatment. This module includes video testimonials from diarrhea patient households on how the patient benefits from adhering to the promoted behaviors, and a demonstration on how to construct homemade handwashing washing stations. This in-person module is reinforced by weekly voice, interactive voice response, and text messages for three months sent to the mobile phones of diarrhea patient household members from a doctor at diarrhea ward at local hospital.
223932586|NCT05161000|OTHER|Oral Nutritional Supplement|ONS plus dietary counseling
223932587|NCT05161000|OTHER|Dietary counseling|dietary counseling
223932588|NCT02435485|DEVICE|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
223932589|NCT02435485|OTHER|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
224285392|NCT04301245|OTHER|Educational program|"The educational program (EP) was offered during the initial session of the pulmonary rehabilitation. According to the french law, patients were free to participate or not.~The EP consisted of an educational diagnosis, educational workshops and an individual final assessment."
224285393|NCT05799027|DIAGNOSTIC_TEST|Raman spectrum|The bronchoscopic biopsy sample of patients with visible lesions in the airway would undergo raman spectrum analysis.
224285394|NCT03314662|BIOLOGICAL|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
224285395|NCT03314662|BIOLOGICAL|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
224285396|NCT03314662|BIOLOGICAL|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
224285397|NCT00052026|DRUG|carvedilol|low-dose carvedilol administered twice daily for 8 months
224285398|NCT00052026|DRUG|placebo|administered twice daily for 8 months
224285399|NCT00052026|DRUG|carvedilol|high-dose carvedilol administered twice daily for 8 months
223533710|NCT04747301|DRUG|Dinoprostone 10mg (Propess)|"Propess® 10mg Vaginal delivery system (Ferring Controlled Therapeutics Ltd., 1 Redwood Place, Peel Park Campus, East Kilbride, Glasgow, G74 5PB, UK) is a vaginal insert containing 10mg of dinoprostone in a timed-release formulation (the medication is released at 0.3 mg/hour).~A Propess vaginal system is inserted by a research doctors. As in the catheter procedure, Fetal Heart Rate is monitored 30min before and 2 hours after placement. Cardiotocograph and vaginal examination will be performed every 6 hours. The vaginal system is placed for a maximum of 24 hours.~If it is expelled in the first 12 hours and the patient has no contractions or still shows an unfavorable cervix, another vaginal system is placed for a maximum of another 24 hours.~The patients will be examined in case of extreme pain or membranes ruptured."
223533711|NCT00470015|BIOLOGICAL|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
223533712|NCT00470015|BIOLOGICAL|IL-2|0.5x10\^6/m\^2
223932590|NCT04239768|DEVICE|MonoDermà HA gel combined to a low level laser|"Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously."
223932591|NCT02977832|DIETARY_SUPPLEMENT|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
223932592|NCT02977832|DRUG|Alfuzosin|10Mg Oral Tablet, Extended Release
224096586|NCT06175624|OTHER|Periodontitis|"Our study will include 25 people with periodontitis patients.~Non-surgical periodontal treatment will be applied to individuals with periodontitis, serum and gingival crevicular fluid samples will be collected before the treatment, clinical measurements and gingival crevicular fluid and serum collection will be repeated 12 weeks after the treatment. CTRP-1 analysis will be performed by ELISA.~CTRP-1 levels will be examined to evaluate the effects of periodontal treatment in periodontal health, gingivitis and periodontitis.~Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study."
224096587|NCT03227874|DIETARY_SUPPLEMENT|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
223932593|NCT02502526|DEVICE|Centurion® Vision System, 45° Balanced Tip|
223932594|NCT02502526|DEVICE|Centurion® Vision System, 45° MFK Tip|
223932595|NCT02502526|DEVICE|lnfiniti® Vision System, 45° MFK Tip|
224096588|NCT03227874|DIETARY_SUPPLEMENT|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
223533713|NCT00470015|BIOLOGICAL|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
223533714|NCT00470015|BIOLOGICAL|GM-CSF|300mcg
223533715|NCT00470015|BIOLOGICAL|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
223533716|NCT05015231|DIAGNOSTIC_TEST|Echocardiography and MRI|Echocardiography and renal MRI before and after fistula closure
223533717|NCT01334255|DRUG|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
223533718|NCT03825705|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223533719|NCT03825705|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
223533720|NCT04586933|DIETARY_SUPPLEMENT|Omega-3|It will be investigated whether diet optimization and supplementation of omega-3s can reduce disease activity in patients with inflammatory arthritis. A new omega-3 high concentrate from GC Rieber Oils will be used.
223533721|NCT04586933|DIETARY_SUPPLEMENT|Placebo (soya)|Placebo (soya)
223932596|NCT02502526|DEVICE|INTREPID® Ultra infusion sleeve|
223932597|NCT02502526|DEVICE|Ultra infusion sleeve|
223932598|NCT03604809|OTHER|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
223932599|NCT01567787|RADIATION|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
223533722|NCT04586933|BEHAVIORAL|Dietary guidance|Dietary guidance
223932600|NCT01567787|RADIATION|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
224096589|NCT01894672|DRUG|LGX818|
224096590|NCT06080594|BEHAVIORAL|High-intensity exercise training|Eight sessions of high-intensity interval exercise using a single-leg cycle ergometer are conducted on separate days over a 2-week period.
224285400|NCT02919826|BEHAVIORAL|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
224285401|NCT06180408|OTHER|manual therapy and exercise for the big toe|Maitland mobilization (Grade 3,4), Mulligan mobilization with movement techniques, muscle energy techniques, manual therapy for plantar fascia, strengthening exercises and self-stretching exercises was performed
224285402|NCT06180408|OTHER|lumbar stabilization exercise|core training and myofascial release therapy
224285403|NCT06425445|PROCEDURE|Measurement of maximal expiratory pressures during forced static expiratory maneuvers sustained over 5 seconds|Participants perform forced static expiratory maneuvers sustained over a five second period
224285404|NCT00920088|DRUG|darunavir/ritonavir|DRV/RTV 600/100mg
224285405|NCT00920088|DRUG|lopinavir/ritonavir|LPV/RTV 400/100mg
224285406|NCT00920088|DRUG|Midazolam|Midazolam 3mg
224285407|NCT00920088|DRUG|Dextromethorphan|Dextromethorphan 30mg
224285408|NCT00920088|DRUG|Flurbiprofen|Flurbiprofen 50mg
224285409|NCT00920088|DRUG|GSK2248761|NNRTI under investigation
224285410|NCT00056745|BIOLOGICAL|TBC-3B|
223932601|NCT06073184|DRUG|Mounjaro|Weekly subcutaneous injection of 2.5mg tirzepatide at baseline with dose escalation by 2.5mg every 4 weeks to reach 15mg or the maximum tolerated dose, by Week 20
224285411|NCT03544398|OTHER|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
224285412|NCT02079337|DRUG|Rocuronium|
223533723|NCT03687281|OTHER|Survey|"The questionnaire consists of three parts:~* knowledge assessment;~* socio-demographic, medical and lifestyle data;~* use of Chemsex."
223533724|NCT00711373|PROCEDURE|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
223932602|NCT06073184|DRUG|Mirena|Levonorgestrel-releasing Intrauterine System (52mg) to deliver up to 20 mcg levonorgestrel per day
223932603|NCT04551651|DEVICE|ApplTree|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
223932604|NCT04551651|DEVICE|Google Calendar|App downloaded on the participants phone, a short video tutorial session to explain use, and technical support throughout trial period.
223932605|NCT06639035|OTHER|External oblique intercostal plane block|The external oblique intercostal plane block is applied to the patients at the end of the surgery.
223932606|NCT06639035|OTHER|intavenous tramadol|Intravenous tramadol will be administered with patient-controlled analgesia
223932607|NCT01342367|DRUG|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
223932608|NCT01342367|DRUG|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
223932609|NCT01342367|DRUG|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
223932610|NCT01342367|RADIATION|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
223932611|NCT03035851|BEHAVIORAL|Aerobic exercise|
223932612|NCT03035851|BEHAVIORAL|Stretch and Strength|
223932613|NCT03402854|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
223932614|NCT03402854|BEHAVIORAL|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
223932615|NCT01262339|DRUG|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
223932616|NCT02491489|OTHER|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (\~50 degrees abduction, slight horizontal adduction, external rotation).
223533725|NCT01927913|DRUG|SPD602|32, 50 or 75 mg/kg/day BID, capsule
223533726|NCT01927913|DRUG|Deferasirox|Per approved country specific label
223718465|NCT03598621|DEVICE|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
223718466|NCT03598621|DEVICE|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
223718467|NCT02902419|OTHER|Wound dressing removal.|
223718468|NCT00134095|DRUG|irinotecan hydrochloride|
223718469|NCT00134095|DRUG|tegafur-gimeracil-oteracil potassium|
223718470|NCT00134095|PROCEDURE|adjuvant therapy|
223718471|NCT00134095|PROCEDURE|conventional surgery|
223932617|NCT03664882|DRUG|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
223932618|NCT03664882|DRUG|Placebo|Pharmaceutical form: tablet Route of administration: oral
223932619|NCT05374642|BEHAVIORAL|cognitive training|tablet-based cognitive training for 12 weeks, 30 minutes each time, at least 5 times a week
223932620|NCT05374642|BEHAVIORAL|active control|tablet-based cognitive training tasks with weak or no difficulty changes, 5 times a week, 30 minutes each time for 12 weeks
224285413|NCT02079337|DRUG|sugammadex|
224285414|NCT02079337|DRUG|placebo|
224285415|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
224285416|NCT03658473|DRUG|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
224285417|NCT03658473|DRUG|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
224285418|NCT03658473|DRUG|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
224285419|NCT00925301|DRUG|migalastat hydrochloride|Oral capsule QOD
224285420|NCT00925301|DRUG|Placebo|Oral capsule QOD
223718472|NCT00134095|PROCEDURE|neoadjuvant therapy|
223932621|NCT01693822|DRUG|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
223932622|NCT02844439|DRUG|Tesevatinib|
223932623|NCT03041155|BEHAVIORAL|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
223932624|NCT06311396|GENETIC|genetic model|Create a complete molecular-level description of the heterogeneous population of cells that are capable of giving rise to tumor transformation in the liver.
223932625|NCT04496024|DRUG|ofloxacin|ofloxacin treatment in patients with bone and joint infections
223932626|NCT04496024|OTHER|questionnaire|questionnaire of ofloxacine side effects will be completed by the clinician at Day 3, Day 21 and Day 42
223932627|NCT04496024|BIOLOGICAL|Ofloxacin Serum concentration|Serum concentration of ofloxacin will be measured at Day 3 (Cmin and Cmax), Day 21 and Day 42 (Cmin).
223932628|NCT04614454|DEVICE|High Frequency Impulse Therapy|The home TENS unit device is an at-home transcutaneous electrical nerve stimulation unit in that it provides non-invasive transcutaneous electrical impulses to reduce pain. It is a small, wearable device that utilizes both high and low frequencies to create a nerve-block effect based on the same gating theory.
224285421|NCT04890080|OTHER|Pulmonary Rehabilitation|Exercise training consisted of supervised breathing, aerobic, strengthening and stretching exercises for 8 weeks, 2 days a week. Breathing exercises included pursed lip, diaphragmatic, thoracic expansion and basal expansion exercises. Strength training included the lower and upper extremities, and it was performed 8-10 repetitions, either against gravity or using free weight, according to patient tolerance.
223932629|NCT04614454|DEVICE|High Frequency Impulse Therapy - Sham|This device looks like the experimental device but does not provide the electrical current.
223932630|NCT06298253|BEHAVIORAL|Behavioral economics-enhanced SWAP implementation|Intervention will include behavioral nudges at baseline and over 12 months to promote use of the SWAP nutrition program for pantries.
224096591|NCT06278688|DIETARY_SUPPLEMENT|Precision probiotics|The precision probiotics will be designed based on the results of probiotic signatures and consensus clustering described in the PRELIMINARY AND SUPPORTING Data section and available probiotics from GenMont Biotech Inc. (https://www.genmont.com.tw/) The individual gut microbiota will determine the supplement and composition of probiotics.
224285422|NCT04062994|BEHAVIORAL|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
224285423|NCT02662166|DEVICE|MR imaging|3 T MRI of the urinary bladder
224285424|NCT01117766|DRUG|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
224285425|NCT01117766|DRUG|Placebo|BID dosing for 28 days
224285426|NCT05310617|OTHER|Survey|Survey on the parental project and its realisation
224285427|NCT02312479|DEVICE|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
224285428|NCT00438659|DRUG|mometasone furoate|Applied to treatment area
224285429|NCT00438659|OTHER|placebo|Applied to treatment area
223932631|NCT06298253|BEHAVIORAL|Basic SWAP implementation|Intervention will include basic information about the SWAP program and encouragement to obtain SWAP toolkits.
223932632|NCT06355063|DEVICE|CellFX® nsPFA™ Cardiac Surgery System|Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.
223932633|NCT00317720|DRUG|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
223932634|NCT00317720|DRUG|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
224285430|NCT03844230|OTHER|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
224285431|NCT03844230|OTHER|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
224285432|NCT03844230|OTHER|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
224285433|NCT03844230|OTHER|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
224285434|NCT03844230|OTHER|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
224285435|NCT03844230|OTHER|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
224285436|NCT03844230|OTHER|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
224285437|NCT03195452|DRUG|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
224285438|NCT00003822|DRUG|apomine|
224285439|NCT05482425|OTHER|Autologous facial fat graft injection|Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
224285440|NCT01358396|OTHER|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
223932635|NCT05103345|DRUG|SGN1|SGN1,will be administered intratumorally,which dosage is 0.9-2.0×109 cfu /vial.
223932636|NCT06405841|OTHER|Survey|All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life
223932637|NCT06405841|OTHER|Pain management|All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
223932638|NCT03357926|DIAGNOSTIC_TEST|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
223932639|NCT04259047|BEHAVIORAL|Diabetes Regulation for Eyesight and Memory|Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.
223932640|NCT04259047|BEHAVIORAL|Enhanced Usual Care|Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
223932641|NCT06066268|DIAGNOSTIC_TEST|Critical limb ischemia: analysis of RNAs|analysis of miRNA expression levels
223932642|NCT06066268|DIAGNOSTIC_TEST|Controls: analysis of RNAs|analysis of miRNAs expression levels
223932643|NCT06478667|DRUG|levosemindan|inotropic agent
223932644|NCT04199338|OTHER|The Effect of Web Based Education Based on Self-Care Deficiency Theory on Self-Care Power and Self-Efficacy and Perceived Social Support in Patients Receiving Peritoneal Dialysis|"In the study, which will last for 3 months, the patients in the intervention group will receive pre-test Web-based training based on the Self-Care Deficiency Theory. And an intervention group will be expected to use the website weekly. Also weekly reminder messages will be sent regularly.~Following the final test, individuals in the enterprise group will be asked to evaluate their views on the website in writing with the WAMMI test."
223932645|NCT00137800|DRUG|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
224096592|NCT03779438|DRUG|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
224096593|NCT03779438|DRUG|placebo to 17-OHPC|patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
224096594|NCT06319300|DEVICE|AI-assisted insulin dose adjustment model|We use an artificial intelligence-assisted insulin dose adjustment system to adjust insulin doses in hospitalised patients
224096595|NCT06319300|OTHER|doctor's insulin dose adjustment|participants' insulin doses are adjusted by doctors
224096596|NCT00749203|DRUG|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
224096597|NCT00749203|DRUG|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
224096598|NCT00426673|DRUG|Brivaracetam (ucb34714)|
224096599|NCT00441688|DRUG|GI265235|
224096600|NCT04994925|OTHER|Control ready meal|Supermarket brand lasagne ready meal
224096601|NCT04994925|OTHER|Test ready meal|The Slimming World lasagne ready meal
224096602|NCT01833871|OTHER|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
224096603|NCT01833871|OTHER|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
224096604|NCT04295590|BEHAVIORAL|Frequency comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).
224285441|NCT00294892|DRUG|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
224096605|NCT04295590|BEHAVIORAL|Intensity comparison|One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
224285442|NCT00294892|DRUG|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
224285443|NCT03825744|DRUG|Hetrombopag Olamine+Standard Therapy|once daily
223932646|NCT05985499|PROCEDURE|"Suturing of ileostomy using Dumpling suture method"|"Suturing of ileostomy using Dumpling suture method"
223932647|NCT05985499|PROCEDURE|Suturing of ileostomy using Traditional suture method|Suturing of ileostomy using Traditional suture method
223932648|NCT04531800|PROCEDURE|Concentrated growth factor|In the concentrated growth factor (CGF) group, CGF was applied to the surgical area (n=14), and the area was primarily closed after additional releasing incisions.
223932649|NCT04531800|PROCEDURE|Non-concentrated growth factor|In the non-CGF group, the surgical area was only primarily closed without any mobilization of the flap following sequestrectomy and bone curettage as a traditional surgical therapy.
223932650|NCT01934036|DIETARY_SUPPLEMENT|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
223932651|NCT01934036|DRUG|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
224096606|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
224096607|NCT00559689|DRUG|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
224096608|NCT02853760|BEHAVIORAL|walking|
224096609|NCT02853760|DEVICE|Treadmill|
224096610|NCT00240435|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
224096611|NCT00240435|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
224285444|NCT03825744|DRUG|Placebo+Standard Therapy|once daily
224285445|NCT00494351|PROCEDURE|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
223533727|NCT05140343|DIAGNOSTIC_TEST|KARDIA Mobile ECG Monitoring (KMCM)|The KMCM will be introduced to the patient of the KMCM arm in the outpatient clinic. The activation and configuration will be done together with the physician in the outpatient clinic (installation of the ECG app, enabling heart rate rhythm notification). Patients are requested to acquired ECGs twice weekly plus additional ECGs if symptomatic. In case of symptoms the patient is asked to generate an ECG and communicate the event timely to the investigator and to the treating physician by sending a report through the ECG app. An e-mail account created for the study will be checked at least once a day. The arrhythmia diagnosis will be performed by the clinician based on the ECG information, independently of the arrhythmia classification automatically performed by the device. In case of stronger symptoms of any kind at any time the patient is asked to request medical help regardless of the KMCM notifications. Change of management will be collected.
223533728|NCT03859076|BEHAVIORAL|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions \& a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, \& specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, \& stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
223932652|NCT01785446|DRUG|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
223932653|NCT01785446|DRUG|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
223932654|NCT06440226|BEHAVIORAL|Eye Movement Technique|Participants were instructed to move their eyes as much as possible with their eyes closed just before falling asleep. This technique aimed to mimic the Rapid Eye Movement (REM) sleep phase, which is often associated with more vivid and memorable dreams.
223932655|NCT06440226|BEHAVIORAL|Memory Recall of Previous Night's Thoughts|Another intervention involved asking participants to recall and think about their thoughts or events from the previous night before going to sleep. This method engaged cognitive processes related to memory and reflection, potentially setting the stage for increased awareness during sleep.
223932656|NCT06440226|BEHAVIORAL|Recall of Previous Lucid Dreams|Participants were also asked to recall their lucid dreams from previous nights. This intervention seemed to activate memory and awareness related to dreaming, which significantly increased the likelihood of experiencing lucid dreams the following night.
223932657|NCT02748226|PROCEDURE|endovascular treatment|endovascular treatment
223932658|NCT06091995|BEHAVIORAL|impact of administering one dose of belatacept on Estimated Glomerular Filtration Rate(eGFR)|Evaluate the clinical impact of administering one dose of belatacept on eGFR at one-year post-transplant, patient and graft survival outcomes, graft rejection, and incidences of BK virus, EBV and CMV infections.
223932659|NCT05615623|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
223932660|NCT05615623|DRUG|Doxorubicin|Doxorubicin infusion
223932661|NCT03170648|DEVICE|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
224096612|NCT00277758|BIOLOGICAL|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
224096613|NCT00277758|DRUG|Ribavirin|Ribavirin @ 800 mg daily (\< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (\> 85 kg)
224096614|NCT00277758|BIOLOGICAL|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
224096615|NCT00277758|BIOLOGICAL|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
224285446|NCT04761471|DEVICE|TI transcranial electrical stimulation|"Participants will undergo transcranial electrical stimulation, which will be delivered with low current amplitudes (\<= 2 mA) established with international safety guidelines for electrical stimulation. Threshold for the current amplitude will be established by participants themselves, such that they cannot distinguish when stimulation is applied and not applied.~Duration of stimulation will not last longer than 30 minutes."
224285447|NCT00238563|DRUG|Triamcinolone injection, sub-tenon|
224285448|NCT04771247|PROCEDURE|Cardia Band Ligation|Patients will undergo cardia band ligation at the level of the GEJ.
224285449|NCT01109758|DRUG|Fenofibrate|145 mg
224285450|NCT01117987|DRUG|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
224285451|NCT01117987|DRUG|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
223932662|NCT06279793|DRUG|Fish Oil|"Omegaven® is a 10% fish oil emulsion with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe: Day -1: 0.20 g fish oil/kg BW/d (the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion); intraoperative day 0: no dose; postoperative day 0: 0.20 g fish oil/kg BW/d; postoperative days 1 to max. 7): 0.20 g fish oil/kg BW/d"
223932663|NCT06279793|DRUG|Intravenous 0.9% Sodium Chloride|Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d) provided at the same timepoints as the intervention.
223932664|NCT03509909|BEHAVIORAL|Hatha yoga|Manualized hatha yoga
223932665|NCT03509909|BEHAVIORAL|Supportive physical activity|Manualized stretching and strengthening
223932666|NCT01858285|GENETIC|Exome and/or whole genome sequencing|
223932667|NCT03831334|DRUG|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
223932668|NCT04410146|DEVICE|SQUID Embolization|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent
223932669|NCT04410146|DEVICE|SQUID Embolization and Surgical Evacuation|Embolization of the Middle Meningeal Artery using the SQUID non-adhesive liquid embolic agent and the surgical evacuation of the sub-dural hematoma
223932670|NCT04410146|PROCEDURE|Surgical Evacuation|Surgical evacuation of the sub-dural hematoma
223932671|NCT04410146|OTHER|Other: Medical Management|Standard
223932672|NCT02496325|PROCEDURE|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
223932673|NCT06623305|DEVICE|Photobiomodulation|Light therapy will be administered using the cluster probe on the external cheeks bilaterally and intraorally using the lollipop probe for patients ≥7 years of age. Patients \&lt; 7 years of age will not receive intraoral treatment with the lollipop. Instead, they will be asked to open their mouth while the covered cluster probe is held externally to treat their intraoral membranes. Each treatment (both external cheeks and intraoral buccal region) will be administered over 1 min with a Modulation Frequency 2.5Hz, Skin Conduction nS 001, and Beam Power mW 000, for a total treatment time of 3 minutes.
223932674|NCT06008301|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) has 20 items for assessing trait anxiety and 20 for state anxiety.
223932675|NCT05784259|BEHAVIORAL|Transdiagnostic single-session treatment|Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
224285452|NCT00440115|BEHAVIORAL|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
224285453|NCT00440115|BEHAVIORAL|Low intensity disease management|Health education mailings, one motivation interview/counseling
224285454|NCT00440115|BEHAVIORAL|Comparison group|Health education mailings
224285455|NCT00440115|DRUG|Bupropion|Buproprion or Nicotine Replacement Therapy
224285456|NCT02317250|PROCEDURE|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
224285457|NCT02317250|PROCEDURE|FDG-PET|\[F-18\] FDG-PET brain scans are administered once to all arms.
224285458|NCT03754387|DRUG|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
224285459|NCT03754387|PROCEDURE|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
224285460|NCT00987142|DRUG|CX501|Cultured chimeric skin
224285461|NCT00987142|DEVICE|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
224285462|NCT02571309|DEVICE|Asthmatuner|Asthmatuner is an app for self-management of asthma.
224285463|NCT01839695|DEVICE|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
224285464|NCT00042549|DEVICE|Extracorporeal Shock Wave Lithotripsy|
224285465|NCT00042549|DRUG|ursodiol|
224285466|NCT03069417|BEHAVIORAL|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
224285467|NCT02244424|BEHAVIORAL|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
224285468|NCT00615524|DRUG|exemestane and pazopanib|
224285469|NCT04991012|DEVICE|PDT Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
224285470|NCT04991012|DRUG|Triamcinolone (Substance) therapy side|th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
224285471|NCT01850719|PROCEDURE|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
223533729|NCT03859076|OTHER|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
223932676|NCT05931627|PROCEDURE|Patients undergoing ACL reconstruction with or without a tourniquet|Patients undergoing ACL reconstruction with or without a tourniquet
223932677|NCT03335397|DEVICE|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
223932678|NCT03335397|OTHER|Traditional learning process|Traditional content available in university library.
223932679|NCT04251442|DEVICE|OrthoSensor Verasense Technology|IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
223932680|NCT05461313|OTHER|Constrained Liner|Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)
223932681|NCT05461313|OTHER|Dual Mobility|Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
223932682|NCT00756067|BIOLOGICAL|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
223932683|NCT00756067|BIOLOGICAL|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
223932684|NCT00979121|DRUG|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
223932685|NCT00979121|DRUG|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
223932686|NCT00933257|DRUG|LACTIC ACID(ND)|Treatment duration 5 weeks
223932687|NCT03920592|BEHAVIORAL|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~1. Classmates steal her personal diary~2. Classmates tear her clothing~3. Classmates insult her and steal her belongings~4. Classmates deliberately exclude her in class~Boys:~1. Classmates exclude him while playing with a ball~2. Classmates bother him in the dining room~3. Classmates insult and steal him in class~4. Classmates insult him and steal his belongings"
223932688|NCT01039155|DRUG|Azacitidine|Given IV
223932689|NCT01039155|OTHER|Laboratory Biomarker Analysis|Correlative studies
223932690|NCT01039155|DRUG|Oxaliplatin|Given IV
223932691|NCT01039155|OTHER|Pharmacological Study|Correlative studies
223932692|NCT01208116|OTHER|Cardiovascular events|"* Coronary intervention~* Infarction~* Congestive heart failure~* Stroke~* Cardiac death"
223932693|NCT01913314|DRUG|[^14C]-LY2835219|Administered as oral solution
223932694|NCT03836222|DRUG|PCS499|MR tablet
224096616|NCT00277758|DRUG|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight \<65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight \>85 kg.
223932695|NCT03836222|DRUG|Trental|comparator tablet
223932696|NCT03874819|DEVICE|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
223932697|NCT03874819|DEVICE|High-flux dialyzer|Treatment using a high-flux dialyzer
223932698|NCT00359658|DRUG|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
223932699|NCT00359658|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
223932700|NCT00359658|DRUG|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
223932701|NCT02431273|DRUG|TDF IVR|
223932702|NCT02431273|DRUG|TDF-FTC IVR|
223932703|NCT02431273|DRUG|TDF-FTC-MVC IVR|
223932704|NCT01138254|DEVICE|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
223932705|NCT01138254|OTHER|no intervention|no intervention
223932706|NCT04337931|DRUG|sotigalimab|Sotigalimab is a CD40 agonistic monoclonal antibody
223932707|NCT05599282|DRUG|Amino Acid Supplement|Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
223932708|NCT05599282|OTHER|Placebo|Four capsules of Placebo will be taken once a day for 90 days.
223932709|NCT01435252|DRUG|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
223932710|NCT01738438|DRUG|Cabozantinib|
223932711|NCT04436289|BEHAVIORAL|Home Link|In the Home Link intervention, a team will conduct home visits to (1) provide a structured clinical assessment; (2) reconcile medications, (3) provide psychosocial support through patient-centered counseling, and (4) assess home needs (food security). These visits will start one week after discharge and be repeated every two weeks until the participant is stabilized and ready to initiate lower intensity clinic-based services or three months have elapsed.
223932712|NCT03323203|DEVICE|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
223932713|NCT04437641|OTHER|Tobacco questionnaire|"A questionnaire on smoking habits was given to all parents of children being followed in consultation for cystic fibrosis or type 1 diabetes, or whose child was hospitalized for the first time for bronchiolitis.~Provision of minimal advice (oral and a leaflet from the anti-smoking centre) to parents who smoke by the paediatrician following the child.~For parents who smoke, evaluation at 3 months of the impact of this minimal advice by another questionnaire during the usual follow-up of the patient at 3 months or by telephone contact."
223932714|NCT02673216|OTHER|No intervention|
223932715|NCT05769413|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
223932716|NCT05751161|OTHER|conventional gait training|The experimental group received circuit gait training with auditory stimuli using a smartphone metronome application. The training program consisted of eight different activities i.e. tandem walk, one-leg standing, military march, sitting up and forward walk, lateral walk, kicking a ball towards the wall, walking on a set pattern and obstacle walk .Patient will practice each task for 3-4 mints and three times per week.
223932717|NCT03137836|BEHAVIORAL|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
223932718|NCT02928172|DEVICE|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
223932719|NCT02928172|DEVICE|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
224096617|NCT03333473|BEHAVIORAL|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
224096618|NCT03333473|BEHAVIORAL|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
224096619|NCT02043886|DRUG|Acarbose|Acarbose 50 mg by mouth given during Meal Test
224096620|NCT02043886|DRUG|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
224096621|NCT02095301|OTHER|Herbal Beverage|
224096622|NCT01061281|DEVICE|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
224096623|NCT01061281|DEVICE|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
223533730|NCT03534882|OTHER|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
223533731|NCT04792385|DRUG|E4/DRSP 15/3 mg combined tablet|One E4/DRSP 15/3 mg combined tablet once per day for 24 days followed by 4 days of placebo tablets; this 28-day cyclic regimen should be taken for 6 consecutive cycles.
223932720|NCT02282657|DEVICE|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
223932721|NCT02282657|OTHER|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
223932722|NCT02282657|DEVICE|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
223932723|NCT02282657|OTHER|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
223932724|NCT02282657|OTHER|Respiratory Rate|RR will be kept what it was at baseline
223932725|NCT02282657|OTHER|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
223932726|NCT02282657|OTHER|Ventilation will be adapted|If PaCO2\> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
223932727|NCT02282657|OTHER|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
223932728|NCT03484949|DIAGNOSTIC_TEST|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
223932729|NCT02961634|DEVICE|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
223932730|NCT02961634|DRUG|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
223932731|NCT00327119|DRUG|ABX-EGF (panitumumab)|
223932732|NCT04310514|DIETARY_SUPPLEMENT|Fructose/glucose/xylitol/saccharose|"1. Intervention: rehydration with glucose solution. Glucose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~2. Intervention: rehydration with fructose solution. Fructose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~3. Intervention: rehydration with xylitol solution. Xylitol will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m.~4. Intervention: rehydration with sucrose solution Saccharose will be administered at a dose of 35 mg (500 ml of 7% solution) taken orally once, in the middle of soccer training session, at approximately 10.00 a.m."
223932733|NCT04861805|DEVICE|Vienna Aortic Valve SE System|Vienna Aortic Valve SE system for TAVI.
223932734|NCT05827796|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
223932735|NCT05827796|DRUG|Albumin-Bound Paclitaxel|Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
223932736|NCT05827796|DRUG|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
224096624|NCT06028620|BEHAVIORAL|Trauma Focused-Cognitive Behavior Therapy|TF-CBT consisted of 8 units in which different issues realted to trauma are reviewed. Units are: psychoeducation and parenting skills, relaxation techniques, affective expression and regulation, cognitive coping and processing, trauma narrative and processing, in vivo exposure, co-joint sessions and enhancing safety and future growth.
224096625|NCT03097887|PROCEDURE|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
223932737|NCT05827796|DRUG|KN046|KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
223932738|NCT05835570|DIAGNOSTIC_TEST|PET/CT scans|Diagnostic Test: For 68Ga-Trivehexin PET/CT, no special preparation was required. Approximately 50 min after an i.v. administration of \[68Ga\]Ga-Trivehexin with a dose of 1.85-2.22 MBq/kg, and the PET acquisition time was 2.5 min per bed.
224285472|NCT01850719|OTHER|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
224285473|NCT00206102|DRUG|quetiapine fumarate|flexible dose oral
224285474|NCT00206102|DRUG|risperidone|flexible dose oral
224285475|NCT04399265|DIETARY_SUPPLEMENT|Trehalose|A disaccharide sugar usually used as food preservative, but for this study it is given at a higher dose
224285476|NCT04399265|DIETARY_SUPPLEMENT|Maltose|Maltose power
224285477|NCT01332786|DRUG|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest"
224285478|NCT01398202|DIETARY_SUPPLEMENT|vitamin D3|20 micrograms per day for 10 weeks
224285479|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
224285480|NCT01398202|DIETARY_SUPPLEMENT|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
223932739|NCT04177147|OTHER|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
223932740|NCT03492866|DRUG|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
223932741|NCT06048588|DRUG|YN001|In single ascending dose (SAD) part of study in health subjects, YN001 will be administrated one time with dosage from 10 mg to 120 mg (planned). In multiple ascending doses (MAD) part of study in health subjects, YN001 will be given twice a week from 5 mg to 40 mg up to 15 days. In MAD part of study in patients with coronary atherosclerosis, YN001 will be injected weekly or twice a week from 5mg to 40mg up to 85 days.
223932742|NCT06048588|DRUG|Placebo for YN001|The injection solution to mimic the YN001
223533732|NCT00085527|DRUG|depsipeptide|
223535283|NCT03291132|OTHER|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
223932743|NCT06048588|DRUG|rosuvastatin calcium tablets|In MAD part of study in patients with coronary atherosclerosis, Rosuvastatin calcium tablets will be taken orally by 10 mg daily up to 85 days
223932744|NCT06648837|PROCEDURE|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy, additional tubes of blood drawn during normal clinical vist.
223932745|NCT06648837|OTHER|Collection of relevant information|Collect relevant information to ensure potential participant meets all inclusion/exclusion criteria.
223932746|NCT03664635|BIOLOGICAL|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
223932747|NCT06610162|OTHER|Eucalaloric feeding|Participants will complete a 3-day diet run-in followed by an 24-hr in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. The energy content of the diet will be 1.3 x REE (\~30% fat, 55% carbohydrate, and 15% protein at each meal). Breakfast will account for \~25% and lunch and dinner \~30-35% of total energy needs. Meals will be provided at 0900, 1300, and 1800, and a light snack will be provided at 2000.
223932748|NCT06610162|OTHER|Acute Fasting|Participants will complete a 3d diet run-in followed by an 24h in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. Participants will complete a 24 hour fast while in the calorimeter. They will be permitted to consume non-caloric beverages (i.e., water, non-caloric and non-caffeinated soft drinks, caffeine-free tea, or decaffeinated coffee) but refrain from consuming any caloric food or beverages. Upon exiting the calorimeter, participants will be provided a meal from the University of Colorado Hospital Patient Kitchen.
224096626|NCT03097887|DEVICE|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
224096627|NCT03097887|DEVICE|V-Loc|Sewing device to perform the anti-reflux sutures.
224096628|NCT05962008|DIETARY_SUPPLEMENT|DHAPS® product|Take 4 capsules per day after breakfast with warm water.
224096629|NCT05962008|DIETARY_SUPPLEMENT|BioPS® product|Take 4 capsules per day after breakfast with warm water.
223932749|NCT06610162|OTHER|Acute Overfeeding|Participants will complete a 3d diet run-in followed by an 24h in-patient visit in the room calorimeter. The energy content of the diet will be REE x 1.5 (30% fat, 55% carbohydrate, 15% protein). On the study day, will arrive at 7 AM and an IV catheter will be placed for blood draws, as described in the research plan. Participants will then enter the calorimeter at 0800, exit at 0700 the following day. Participants will be instructed to engage in primary sedentary behaviors. The energy content of the diet will be 200% of energy requirements, based on EE measured during the eucaloric condition. Macronutrient intake will be 3% protein, 51% carbohydrate, and 46% fat. Breakfast will account for \~25% and lunch and dinner \~30-35% of total energy needs. Meals will be provided at 0900, 1300, and 1800, and a light snack will be provided at 2000.
223932750|NCT03224481|OTHER|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
223932751|NCT05743205|BEHAVIORAL|voluntary consultative wellness session|Professional wellness counseling sessions provided to health care professionals through voluntary enrollment. Consultative sessions will conducted throughout the course of 1 year and number of subsequent sessions will be determined by the participant.
223932752|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
223932753|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 2
223932754|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 3
223932755|NCT05881837|DRUG|HRS9531 injection|HRS9531 injection: dose level 4
223932756|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks
223932757|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks
223932758|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks
223535284|NCT02146924|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given IV
223932759|NCT05881837|DRUG|HRS9531 injection Placebo|Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
223932760|NCT06048055|OTHER|Transcutaneous auricular vagus nerve stimulation|Patients in this group will be treated with 12 sessions of transcutaneous auricular nerve stimulation, three sessions per week for four weeks. The stimulation of the left auricular branch of the vagus nerve will be performed by conventional transcutaneous electrical nerve stimulation (TENS) through a Gamna Duo 200 electrotherapy device with one channel and two electrodes (5mm diameter disposable adhesive stimulation electrodes). The TENS parameters will be used: 30 30-minute treatment time, a pulse width of 200 milliseconds, and a pulse frequency of 20 hertz. The intensity of stimulation will be individually adjusted according to the patient's perceptual threshold. The perceptual threshold (PT) is defined as the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. The stimulation intensity will be set at super-threshold levels, such as 200% of the patient's perceptual threshold.
223932761|NCT06048055|OTHER|selected physical therapy program|The selected physical therapy program session will be from 25 to 30 minutes, three sessions per week for four weeks. The program will be selected mainly for stretching for shortened upper limb muscles, strengthening for weak upper limb muscles, occupational therapy for hand, trunk, and pelvic control exercises, and gait training.
223932762|NCT00859781|DRUG|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
223932763|NCT00859781|DRUG|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
223932764|NCT00859781|DRUG|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
223932765|NCT00859781|DRUG|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
223932766|NCT01219790|RADIATION|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
223932767|NCT01219790|DRUG|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
223932768|NCT03759678|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
223932769|NCT02016872|DRUG|18F-FMISO|
223932770|NCT02016872|OTHER|PET/CT|
223932771|NCT06696599|PROCEDURE|Serum and corporal irisin|measure serum and corporal irisin
223535285|NCT02146924|BIOLOGICAL|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
223932772|NCT06698692|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib Combined chemoradiotherapy
224096630|NCT05962008|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules per day after breakfast with warm water.
223932773|NCT06698848|DRUG|ketamin|Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
223932774|NCT06798025|PROCEDURE|Punctal dilation|Patients were treated with punctal dilatation only.
223932775|NCT06798025|DRUG|Punctal dilation and topical medication|Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate (0.1%) and preservative-free artificial tears based on sodium hyaluronate, polyethylene, and propylene Glycol.
223932776|NCT06798025|DRUG|Triamcinolone acetonide|Patients were treated with a peri-punctual injection of Triamcinolone acetonide.
223932777|NCT06893250|BIOLOGICAL|PRP injection|Platelet rich plasma, blood from the patient that is centrifuged.
223932778|NCT06893250|BIOLOGICAL|ADSTEM Inj. (Adult human mesenchymal stem cells)|Adipose tissue stem cells, from abdominal fat.
223932779|NCT06893250|BIOLOGICAL|Injection|PRP + adipose tissue stem cells
223932780|NCT06893250|BIOLOGICAL|Saline (NaCl 0,9 %) (placebo)|Sterile saline injection.
223932781|NCT06741566|DRUG|intranasal saline group|3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)
223932782|NCT06741566|DRUG|intranasal insulin|20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
223932783|NCT06741566|DRUG|Intranasal dexmedetomidine|1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
223932784|NCT05642936|BEHAVIORAL|didactic health education control|didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
223932785|NCT05642936|BEHAVIORAL|Transcendental Meditation technique|a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting
223932786|NCT06754488|PROCEDURE|Posterior Reconstruction|"Reconstruct the bladder neck using the inverted tennis racket method to narrow the bladder neck opening and lengthen the posterior bladder wall. Measure the length of the extended part."
223932787|NCT06754488|PROCEDURE|anterior suspension|The anterior wall of the bladder was continuously sutured and fixed onto the muscular membrane of the lower margin of the symphysis pubis using a 3-0 barb suture.
223932788|NCT06312514|BEHAVIORAL|LAFIYA|The Lafiya intervention is a comprehensive program designed to address the intersectional stigma and discrimination challenges faced by marginalized communities, particularly among Gay, Bisexual, and other Men who have Sex with Men (GBMSM). It aims to enhance HIV prevention, care, and treatment outcomes, with a focus on increasing HIV self-testing (HIVST) uptake among these key populations in Ghanaian urban slum settings.
223932789|NCT06773715|DEVICE|KindVR Aqua Program|For this study, patients will be introduced to a virtual reality software program called Aqua, created by the company KindVR. This software program was designed specifically for use in pediatric patients. The software has been programmed into the Pico Neo 3 headset and provides an immersive 3D experience during which the patients explore a virtual underwater world inside a submarine with a goal of providing more color to treasure and different sea animals that they will engage with along their journey. The VR experience itself lasts approximately 15 minutes
223535286|NCT02146924|OTHER|Laboratory Biomarker Analysis|Correlative studies
223535287|NCT02252315|OTHER|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
223535288|NCT02252315|OTHER|Verbal education module|A structured in-person education module about mild traumatic brain injury.
223932790|NCT03029286|BEHAVIORAL|Usual Care Arm|Health information provided by the American Cancer Society Website
223932791|NCT03029286|BEHAVIORAL|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
224096631|NCT01574573|BEHAVIORAL|Self support, group sessions|Self support,group sessions
224096632|NCT00346827|DRUG|Apomorphine Nasal Powder|
223932792|NCT06777550|OTHER|SimucaseTM|experiment group - who will receive the clinical learning method using SimucaseTM
223932793|NCT06777550|OTHER|Conventional Clinical Learning|Problem-based learning case-study case studies
223932794|NCT06762119|DRUG|CAR-T cell|CAR-T cell
223932795|NCT06767592|DIETARY_SUPPLEMENT|Bio-Kult Advanced|Bio-Kult Advanced will be provided as capsules and can be stored at room temperature. Participants will be instructed to swallow two capsules in the morning and two capsules in the evening, with food.
224096633|NCT00187590|BEHAVIORAL|Case manager phone call after an ER visit|
224096634|NCT00743704|OTHER|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
224096635|NCT00156663|BEHAVIORAL|Caring for Women Veterans|
224096636|NCT02191748|PROCEDURE|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
224096637|NCT02191748|DRUG|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
224096638|NCT00049348|BIOLOGICAL|epoetin alfa|
224096639|NCT00049348|BIOLOGICAL|filgrastim|
224096640|NCT00049348|DRUG|cisplatin|
224096641|NCT00049348|DRUG|fluorouracil|
224096642|NCT00049348|DRUG|gemcitabine hydrochloride|
224096643|NCT00049348|PROCEDURE|adjuvant therapy|
224096644|NCT00049348|PROCEDURE|conventional surgery|
224096645|NCT00049348|PROCEDURE|neoadjuvant therapy|
224096646|NCT00049348|RADIATION|radiation therapy|
224096647|NCT04681261|OTHER|this study is not an intervention study|this study is not an intervention study
223535289|NCT05257382|PROCEDURE|ENB followed by trans-bronchial biopsy and trans-bronchial cryobiopsy|After having performed the ENB procedure to reach the identified lung lesion, biopsies will be performed (six forceps trans-bronchial biopsies and one trans-bronchial lung cryobiopsy)
223932796|NCT06380166|DIAGNOSTIC_TEST|Hepatitis C core antigen|Semi-quantitative, automated immunoassay detecting core antigen of hepatitis C virus.
224096648|NCT00123929|DRUG|docetaxel|100 mg/m2 every 3 weeks times 4
224096649|NCT00123929|DRUG|doxorubicin|75 mg/m2 every 3 weeks times 4
224096650|NCT03205787|DIETARY_SUPPLEMENT|Trifolium pratense|Red Clover extract standardized to isoflavone content.
224096651|NCT06427109|DIETARY_SUPPLEMENT|Dietary intake of omega-3 fatty acid|Participants were stratified into omega-3 consumption quartiles to assess colorectal adenoma incidence trends
224096652|NCT00663130|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
224096653|NCT00663130|DRUG|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
224096654|NCT04449692|DRUG|Dasiglucagon|Abdominal s.c. administration
223535290|NCT02916511|DRUG|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
223535291|NCT02916511|DRUG|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw\*5
223535292|NCT02916511|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
223535293|NCT03117647|PROCEDURE|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
223932797|NCT06859125|DEVICE|Endo-Wing™ (Shangxian Minimal Invasive Inc, China)|Endo-Wing™ (Shangxian Minimal Invasive Inc, China) is a medical-grade soft silicone rubber device that is attached at the end of a colonoscope. It has 6 soft wing-like projections that are bendable and pliable, giving the endoscopist a superior visualization directly from its action of flattening the colonic folds and maintaining the central view of the colonoscope during withdrawal. This can improve the endoscopist's ADR.
223932798|NCT06859125|DEVICE|Standard Colonoscopy|Colonoscopies performed using Olympus Evis Exera III 90 series or Olympus Evis Lucera 260 series colonoscopes without Endo-Wing attached at the tip of the colonoscope
224096655|NCT04449692|OTHER|Carbohydrate (dextrose tablets)|Oral administration
224096656|NCT05619848|DRUG|Rocuronium Bromide|0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
224096657|NCT01243268|DRUG|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
224096658|NCT01931514|DRUG|Torrent's Montelukast Sodium chewable Tablets 5mg|
224096659|NCT01931514|DRUG|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
224096660|NCT03315429|DIAGNOSTIC_TEST|stress echocardiography|stress testing of patients with functional mitral regurgitation
224096661|NCT03394950|DRUG|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
224096662|NCT03394950|DRUG|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
224096663|NCT01620125|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
224096664|NCT01501643|DEVICE|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
224096665|NCT01501643|DEVICE|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
224096666|NCT00957853|DRUG|Cetuximab|First dose of 400 mg/m\^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m\^2 on week 2 and 3 (if applicable) given over 1 hour.
224096667|NCT00957853|DRUG|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
224096668|NCT00957853|PROCEDURE|Surgical tumor resection|Surgical tumor resection on Day 10.
224096669|NCT00004980|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
223932799|NCT06831292|DIETARY_SUPPLEMENT|Diet intervention NMR|Participants will receive groceries to their homes with planned recipes. The recipes are planned by using the Nordic nutrition councils recommendations.
223932800|NCT06831487|DEVICE|Line-Field Confocal Optical Coherence Tomography (LC-OCT)|Analysis of Line-Field Confocal Optical Coherence Tomography (LC-OCT) in separate groups of patients with gingivitis, periodontitis and healthy patients
223932801|NCT03125954|OTHER|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
223932802|NCT02636569|DRUG|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
223932803|NCT02636569|DRUG|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
223932804|NCT04457284|DRUG|Temozolomide (TMZ)|"TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +"
223932805|NCT04457284|DRUG|Cisplatin|Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +
223932806|NCT04457284|DRUG|Nivolumab|Nivolumab 480 mg Q4W IV infusion Cycle 1 +
223932807|NCT06514664|OTHER|Using Probiotic Toothpaste|"Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day"
223932808|NCT04875078|DEVICE|UVA-1 Phototherapy|UVA-1 Phototherapy treatments
223932809|NCT06753084|PROCEDURE|Alloderm|the study is done to patient who lacks of keratinized mucosa width by apically positioned flap and using of FGG as gold standard and Mucoderm as compartive group
223932810|NCT06153485|DEVICE|AutoO2|Automated Titration of Oxygen (Auto-O2) using a closed-loop system in which the oxygen flow to the participant is continuously adjusted on the basis of pulse oximetry signals to maintain a target range of oxygen saturation to meet the participant's immediate needs.
223932811|NCT06153485|OTHER|FixedO2|Fixed flow oxygen delivery administered using manual flow meters according to standard clinical procedures.
223932812|NCT06873386|DEVICE|Valera & Minaya protocol|"Valera \& Minaya protocol:~US-guided PNM with the conventional frequency of the Valera Minaya protocol, with localised location on the peripheral nerve. Stimulation of the upper gluteal nerve and lower gluteal nerve will be performed, with 10 stimulations, with 10 seconds of stimulation and 10 seconds of rest, at a frequency of 10 Hz, with a pulse amplitude of 250 μs, and of maximum intensity tolerable by the patient that causes an exacerbated muscle contraction.~The specific device used will be an electric needle stimulator, AS Super 4 Digital, Schwa-medico Holistic Health, Ehringshausen, Germany."
223932813|NCT06873386|DEVICE|High-frequency US-guided PNM|"High-frequency US-guided PNM with localised peripheral nerve location. Ten 10-second stimulations of the upper gluteal nerve and lower gluteal nerve will be performed, with frequency sweeps of 20Hz -100Hz with a pulse amplitude of 250 μs, and of maximum intensity tolerable by the patient that causes an exacerbated muscle contraction, with 10 seconds of rest between each stimulation.~The specific device used will be an electric needle stimulator, AS Super 4 Digital, Schwa-medico Holistic Health, Ehringshausen, Germany."
223932814|NCT06874088|PROCEDURE|Pulpotomy with Calcium Silicate-Based Bioceramics in Permanent Teeth|This intervention involves performing pulpotomy using calcium silicate-based bioceramic materials, MTA and Biodentine™, in both mature and immature permanent teeth diagnosed with reversible or irreversible pulpitis. The study uniquely evaluates the long-term clinical and radiographic success of these materials by assessing pulp healing, dentin bridge formation, and periapical healing over a 24-month follow-up period. Additionally, this study compares clinical survival rates between mature and immature teeth, contributing to the growing body of evidence on the efficacy of pulpotomy in cases traditionally considered for root canal treatment. Unlike conventional pulpotomy studies, this research incorporates retrospective data analysis to align with international standards, addressing gaps in existing literature.
223932815|NCT06745349|BEHAVIORAL|Sleep Course|The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria. The Sleep Course is four lessons long and is offered with once weekly therapist support for 8 weeks where clients are encouraged to email the assigned therapist for support each week. The therapist reviews client progress in the Course and emails clients once per week on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
224096670|NCT00004980|DEVICE|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
224096671|NCT05707130|OTHER|gaze stabilization exercises|patients will perform gaze stabilization exercise, Static neck exercise, and Habituation exercise. Neck isometric exercises like isometric flexion, extension, lateral bending will be performed.
224096672|NCT05707130|OTHER|neck isometrics|Patients in Conventional group will get neck isometric exercises like isometric flexion, extension, lateral bending.
224096673|NCT01245244|DRUG|Morphine|Morphine oral mixture
223535294|NCT02225652|DRUG|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
223535295|NCT05745610|DRUG|Shen Hai Long Capsule|3 times/day (9 capsules/day) for 12 weeks
223535296|NCT05745610|DRUG|Sheng Jing Capsule|3 times/day (12 capsules/day) for 12 weeks
223535297|NCT00002395|DRUG|Topotecan|
223535298|NCT04691388|DRUG|sintilimab combined with anlotinib|All patients will receive sintilimab combined with anlotinib every 3 weeks
223932816|NCT06745700|BEHAVIORAL|Brief Behavioural Activation|"Behavioral: Brief Behavioral Activation.~A five-session telephone-based brief behavioral activation treatment.~Session 1: Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log.~Session 2: Discussion of life goals and values; planning of activities aligned with life goals and values for coming week.~Session 3-4: Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 5: Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned. with life goals and values; creating a a maintenance plan.~Other group: care as usual."
223932817|NCT06745700|OTHER|Care as usual|Care as usual provided by Region Västamanland,
223932818|NCT02793492|DEVICE|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
223932819|NCT06764862|DRUG|HSK44459 dose 1|HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
223932820|NCT06764862|DRUG|HSK44459 dose 2|HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
223932821|NCT06764862|DRUG|Placebo|Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
223932822|NCT06767189|DIAGNOSTIC_TEST|ECG monitoring|R-test or ECG patch for up to 28 days
223932823|NCT06792123|OTHER|pre-op VR application group|VR application group during preoperative process
223932824|NCT06792123|OTHER|intra-op VR application group|VR application group during intraoperative process
223932825|NCT06768762|BEHAVIORAL|Phone Coaching|Participants will receive 11 coaching calls with a health coach. Calls will occur weekly during the first month, twice/month during months 2-3, and once/month during months 4-6. Each call is expected to last 10-15 minutes.
223932826|NCT06768762|BEHAVIORAL|Progress reports to providers|Progress reports on physical activity and program adherence will be sent to participants providers at 3 and 6 months.
223932827|NCT06768762|BEHAVIORAL|'Hear from Others' Videos|Participants will receive monthly 'Hear From Others' videos. The videos will include other adults with knee replacement discussing the challenges they have faced and strategies to overcome barriers to activity.
223932828|NCT06768762|BEHAVIORAL|Individualized Feedback|Participants will receive individualized feedback from a coach via email. The feedback will specifically focus on participant responses to the 'Apply Your Knowledge' activities and will correspond with the video lessons. Feedback will be weekly during months 1-3 and monthly during months 4-6.
223932829|NCT06768762|BEHAVIORAL|Online exercise program|MOST Energized! Online Exercise Program
223932830|NCT06769087|DEVICE|Immediate urinary catheter removal|A urinary catheter is removed immediately after surgery and before general anesthesia wears off in the operating room.
223932831|NCT06769087|DEVICE|urinary catheter removal within postoperative 1day|The urethral catheter will be removed in the ward within 1 day after surgery (within 24 hours after surgery).
223932832|NCT06831032|RADIATION|Adaptive radiotherapy using SBRT|Adaptive External beam radiotherapy using SBRT 30-40Gy to the tumor nodal GTV volume(s) plus 25 Gy in 5 fractions ENI to PA nodes (+ common iliac nodes)
223932833|NCT05702281|DEVICE|ReLARC|ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.
223932834|NCT06838390|DEVICE|Microcurrent Therapy|The study uses a four-channel microcurrent therapy device to treat pressure ulcers. The treatment involves applying four electrodes to the area around the ulcer, ensuring microcurrent passage throughout the wound bed. The treatment is done three times a day, lasting 35-40 minutes. The microcurrents are delivered in a monophasic, pulsed, square-form wave pulse with a voltage of 21 mV, an intensity of 42 µA, and a current density of 4.2 µA/cm.
223932835|NCT06838390|DEVICE|Transcutaneous electrical nerve stimulation|The study aimed to treat ulcers with TENS using a two-channel device, delivered three times a day, for 8 weeks. The device induced peripheral vasodilation and activate local blood flow, potentially promoting wound healing. The treatment was delivered using a pulse train duration of 300 ms, with an internal frequency of 100 Hz and a burst frequency of 2 Hz.
223932836|NCT06838390|OTHER|physical therapy program|The physiotherapy program included circulatory circulatory exercises, stretching exercises, and ROM exercises.
223932837|NCT06838390|DRUG|medial treatment|patients was given their drugs from their physicians
223932838|NCT06248762|OTHER|Adappt|An app to support parents of children with a NDD
224285481|NCT01398202|DIETARY_SUPPLEMENT|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
223932839|NCT06785701|PROCEDURE|Upper Gastrointestinal Endoscopy|After Entering to emergency based on time of hemetemsis and based on presentation to ER , patient will be assessed and based on hemodyamic stability patient can be taken Early/Emergent endoscopy.
223932840|NCT04823650|DEVICE|COHORT A: Actigraph|The ActiGraph CentrePoint Insight Watch is a small worn activity monitor designed for documenting physical movement associated with applications in physiological monitoring.
223932841|NCT04823650|DEVICE|Panoramic Bracelet and GENEActiv|"Panoramic Bracelet:~The Panoramic Digital Health Bracelet is a wearable inertial measurement unit intended for use by researchers and healthcare professionals for high frequency or continuous collection of physical data in home and professional healthcare settings during research studies. It includes a 3 axis accelerometer and gyroscope, as well as magnetometer, pressure, and temperature sensors. The bracelet has no interface or screen for participants to interact with.~GENEActiv:~The GENEActiv device is a wearable inertial measurement unit designed for public health research and clinical trials. The device is a circular unit with attachable wrist-bands, and has no interface or screen for participants to interact with. The GENEActiv device is FDA 510(k) exempt. The device records acceleration data and can collect data remotely for up to 1 month."
223932842|NCT06753409|DEVICE|Processed electroencephalography (pEEG) Guided General Anesthesia|"Processed electroencephalography (pEEG) can guide the optimization of anesthesia depth, potentially preventing overly deep anesthesia and, in turn, reducing the incidence of IOH and the need for vasopressors .~Depth of anesthesia will be managed based on pEEG monitoring using Entropy with a target range of 40-60."
223932843|NCT06753409|DEVICE|Non-pEEG-Guided General Anesthesia (with blinded pEEG monitoring)|Depth of anesthesia will be managed based on clinical judgment, informed by clinical perception and vital signs.
223932844|NCT06762249|OTHER|CIMT + Brunnstrom therapy + routine physical therapy|this therapy will be given for 5 days per week for 4 weeks.
223932845|NCT06762249|OTHER|CIMT + routine physical therapy|this therapy will be given for 5 days per week for 4 weeks
223932846|NCT06749093|OTHER|Filtered Air (FA)|Exposure to HEPA filtered air, as a control
223932847|NCT06749093|OTHER|Wood Smoke (WS)|Wood smoke (WS) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
223932848|NCT06749093|OTHER|Diesel Exhaust (DE)|Diesel exhaust (DE) standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
223932849|NCT06749093|OTHER|Diesel Exhaust and Wood Smoke (DEWS)|Combined diesel exhaust and wood smoke standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
223932850|NCT06748859|OTHER|Counterstrain technique|In this group, participants will receive counterstrain technique on the Psoas major muscle and exercise training within two weeks.
223932851|NCT06748859|OTHER|Exercise therapy|participants who will assign to this group will receive exercise therapy within two weeks.
223932852|NCT06748326|PROCEDURE|Laparoscopy|Intussusception reduction by laparoscopy in children in failed non surgical procedures and in recurrence
223932853|NCT06775873|PROCEDURE|Modified diaphragmatic plication|Modified diaphragm plication (MDP) using a cutting stapler consists of four steps: clamping and lifting, depressing and resecting, cutting and verifying, and hemostasis and reinforcement.
223932854|NCT05139992|BIOLOGICAL|COVID-19 Vaccine|Vaccination against SARS-CoV-2 administered as part of standard of care
223932855|NCT06850441|OTHER|Psychoeducation|"The education is a group psychoeducation. Education methods such as role-play, discussion, demonstration, and narration will be applied. The education will be held once a week and will be completed in 7 weeks.~Psychoeducation topics include adaptation to stigma in type 1 diabetes, coping, diabetes management, social life, self-esteem, roles in life and impact on life. Concepts such as stigma, blame, judgment, discrimination, shame and stereotyped thoughts will be included."
223932856|NCT06737276|OTHER|Interactive fiction activities|The case studies were prepared using interactive fiction through Twine. Each case simulated a nursing consultation with a patient requiring dietary advice, and the patient's evolution depended on the students' choices. All cases created had similar structures, durations, and difficulties to avoid complexity-related bias. For each circumstance, three possible dietary advice options were offered to the patient: one option that would be ideal, one suitable option, and one unsuitable option.
223941355|NCT04230941|BEHAVIORAL|MAAT-G|Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.
224096674|NCT01245244|OTHER|orange juice|orange juice
224096675|NCT02229773|DRUG|BIBB 1464 MS low dose|
224285482|NCT02693431|OTHER|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
224096676|NCT02229773|DRUG|Placebo|
224096677|NCT02229773|DRUG|Pravastatin|
224096678|NCT02229773|DRUG|BIBB 1464 MS medium dose|
224285483|NCT02838251|OTHER|No intervention|
224285484|NCT04117945|BIOLOGICAL|Cetuximab|Given IV
224285485|NCT04117945|DRUG|Irinotecan|Given IV
224285486|NCT04117945|BIOLOGICAL|Panitumumab|Given IV
224285487|NCT04117945|DRUG|Regorafenib|Given PO
223932857|NCT06737276|OTHER|Role-play simulation|Role-play activity of the nursing consultation on dietary advice according to Nemec et al. (2021) recommendations. Ten case studies of a nursing consultation on dietary advice involving a nurse and a patient were designed with the consensus of a group of nursing professionals with expertise in food and nutrition, health literacy, and communication. Each student was assigned a role and provided with the necessary information to play their character or understand their patient's context. The information provided was different according to the role assigned. They had to perform a simulation of eight minutes, similar to the time available in the student's primary care consultations in the referral health system. Thus, the patient and the family member had to explain the situation or health problem, the professional would analyse it, and together, they would try to reach a therapeutic agreement. After the consultation, a debriefing was carried out.
223932858|NCT04532970|BEHAVIORAL|Cessation Counseling|Two different types of smoking cessation counseling
223932859|NCT05963165|BEHAVIORAL|Non-phonatory exercises|Muscle exercises that favor glottic adduction without vocal emissions
223932860|NCT04305327|DRUG|Brodalumab|Solution for subcutaneous injection.
223932861|NCT04305327|DRUG|Ustekinumab|Solution for subcutaneous injection.
223932862|NCT04305327|DRUG|Placebo|The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
223932863|NCT06777927|OTHER|Exercise|The participants would be playing exergames using XBOX-360 Kinect. Multiple games would be selected for the participants to play. The player would be upgraded to next levels of games after completing the initial levels.
223932864|NCT06777927|OTHER|Exercise|The subjects would be doing treadmill training within moderate intensity target heart rate.
223932865|NCT06777927|OTHER|No intervention|The subjects would not be given any intervention and would be used as controls.
223932866|NCT05561673|COMBINATION_PRODUCT|GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide|Three doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide administered intramuscularly in the non-dominant arm, one each at Day 1, Day 31 and Day 181.
223932867|NCT05561673|BIOLOGICAL|GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system|Two doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
223941356|NCT03927196|BEHAVIORAL|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
223941357|NCT06348771|BEHAVIORAL|monounsaturated fatty acids (MUFA) peanut meal|mixed meal tolerance test and postprandial measurements
223535299|NCT05192915|DEVICE|Modular customized AFO|Walks better at self selected speed with a modular customized AFO than with a conventional AFO.
223535300|NCT06477627|OTHER|change of environment|The participants will change from inland to coastal environment to see the effect. We will take VAMS blood samples and nose swabs from the participant to measure this effect.
223941358|NCT04197037|PROCEDURE|Evaluation of sialorrhea through questionnaires that measure daytime and nighttime sialorrhea and the impact on quality of life.|Sialorrhea will be evaluated by the Nocturnal hypersalivation rating scale (NHRS) and Drooling Severity and Frequency Scale (DSFS)
223941359|NCT00082836|BIOLOGICAL|rituximab|
223535301|NCT06477627|OTHER|no intervention|reference groups, stay in their coastal or inland environment
223932868|NCT05561673|BIOLOGICAL|GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system|Two doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
223932869|NCT05561673|BIOLOGICAL|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
223932870|NCT05561673|BIOLOGICAL|GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2|Two doses of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 31.
223932871|NCT06755398|OTHER|Exercise|During the exercises based on the protocol developed by the Royal Dutch Society for Physical Therapy (KNGF) following anterior cruciate ligament (ACL) surgery, additional cognitive tasks will be assigned to the patients.
223932872|NCT06755398|OTHER|Exercise|The protocol developed by the Royal Dutch Society for Physical Therapy (KNGF) will be applied following anterior cruciate ligament (ACL) surgery.
223932873|NCT03767348|BIOLOGICAL|RP1|Genetically modified herpes simplex type 1 virus
223932874|NCT03767348|BIOLOGICAL|nivolumab|anti-PD-1 monoclonal antibody
223932875|NCT06793345|OTHER|Moderate intensity intermittent walking training|The intensity of the training is 60 to 80% of 6MWTdistance.
223535302|NCT06064487|DIAGNOSTIC_TEST|renal cell arrest and damage biomarkers assessment|measurement of TIMP2 and IGFBP7, KIM-1
223932876|NCT06767930|BEHAVIORAL|Hand and Arm Bimanual Intensive Therapy Including Lower Extremities|The HABIT-ILE (Hand-Arm Bimanual Intensive Therapy Including Lower Extremities) program is an intensive rehabilitation therapy designed to improve motor functions and promote functional independence. Participants in this arm will engage in 6.5 hours of structured activities per day for two weeks (10 days). The therapy focuses on bimanual coordination combined with constant stimulation of the trunk and/or lower extremities, using task-oriented exercises tailored to individual goals. Each participant will be supported by one or two therapists and supervised by a trained team to ensure the program is delivered effectively and safely. The therapy emphasizes engaging, play-based activities to maximize motivation and active participation.
223932877|NCT06767930|BEHAVIORAL|Conventional intervention|Participants in the control group will continue their usual care, which includes conventional physical and occupational therapy, for a duration of two weeks. They will follow their regular therapy schedules without any changes to their routines or treatment habits. This approach ensures that the control group reflects standard rehabilitation practices, allowing for a direct comparison with the intervention group.
223941360|NCT00082836|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223941361|NCT03805672|DRUG|Low Dose Enoxaparin|
224096679|NCT02229773|DRUG|BIBB 1464 MS high dose|
223535303|NCT01732536|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
223535304|NCT01732536|PROCEDURE|Sham procedure|In-office bilateral sham procedure
223535305|NCT01732536|DRUG|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
223941362|NCT03805672|DRUG|High Dose Enoxaparin|
223941363|NCT00775866|PROCEDURE|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
223941364|NCT03104530|OTHER|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
223941365|NCT05541289|BIOLOGICAL|BBV152|Single Arm; BBV152 (COVAXIN™)
223941366|NCT00139360|DRUG|Bevacizumab|Anti angiogenesis treatment
223941367|NCT00600353|DRUG|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
223941368|NCT00600353|DRUG|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
223941369|NCT00600353|DRUG|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
223941370|NCT06498414|DRUG|rifampin standard arm|120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)
223941371|NCT06498414|DRUG|rifampin double dose|60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)
223941372|NCT06498414|DRUG|levofloxacin and rifapentine|30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)
223941373|NCT00870064|PROCEDURE|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
223941374|NCT00870064|PROCEDURE|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
223941375|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)
223941376|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum
223941377|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum
223932878|NCT06767826|BEHAVIORAL|Salutogenesis Models|On the basis of the Salutogenesis Model, this study is based on the development of individuals' internal and external resources for game addictions and strengthening their sense of integrity. It has been determined that digital game addiction and problematic internet use in adolescents form the basis of seven problems. These problems have been identified as mental health, vision, pain, sleep and rest patterns, nutrition, social contact and physical activity. Encouraging behavioral changes regarding internet use and teaching adolescents how to deal with these problems becomes a necessity in today's technology. In the literature, counseling has been provided for families and adolescents to prevent digital game addiction in adolescents.
223932879|NCT05337826|DEVICE|Continuous Glucose Monitor|Participants will enroll in a series of remote educational visits conducted by CDCES to assess readiness and barriers to CGM initiation and utilization, with the goal to sustain use of CGM Technology over time in older populations on complex insulin regimen.
223932880|NCT06844799|DRUG|HS-20137|HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.
223932881|NCT06844799|DRUG|Placebo&HS-20137|Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter
223932882|NCT06816160|PROCEDURE|tru-cut biopsy|needle biopsy from the tumor
223932883|NCT06837610|PROCEDURE|Inverted T trabeculectomy|"* Fornix-based conjunctival incision along with the opening of Tenon's capsule and dissection along the area of the potential bleb.~* A 4 x 4 mm limbal-based scleral flap was fashioned using a crescent knife. Dissection was carried out up to the clear cornea.~* A longitudinal tunnel was made through the scleral bed, starting from the limbus and extending 1 mm beyond the end of the scleral flap. Afterwards, the horizontal limb of the Inverted T was created. (Figure 2)~* A paracentesis was made using an MVR blade.~* The anterior chamber was entered using an MVR blade. Kelly's punch was used to excise 1.5 x 1.5 mm of scleral bed at the limbus at the base of the vertical limb of the figure (T), and then a peripheral iridectomy was performed using Vannas scissors.~* The scleral flap was then closed using two fixed 10/0 Nylon sutures, one at each corner."
223932884|NCT04567680|BEHAVIORAL|Acceptance and Commitment Therapy to Improve Social Support for Veterans with PTSD|This treatment is designed to help Veterans with PTSD increase social support in family, partner, and peer relationships by reducing experiential avoidance. ACT-SS is specifically designed to address deficits in the entire social support network for Veterans with PTSD.
223932885|NCT04567680|BEHAVIORAL|Present-Centered Therapy|"PCT is designed to provide the emotional support for individuals with PTSD that will assist with recovery. The focus of PCT is on the here and now, including current life difficulties that are directly or indirectly related to the experience of trauma. PCT aims to help the patient consider ways to react to these difficulties."
223932886|NCT04322305|DRUG|Pregabalin|Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.
223932887|NCT04322305|OTHER|Placebo|Placebo capsules will be provided twice daily over 8 weeks and one week taper..
223932888|NCT06037980|DRUG|Gemcitabine|◦ Gemcitabine 800 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
223932889|NCT06037980|DRUG|Nab paclitaxel|◦ Nab-paclitaxel 100 mg/mq, day 1 and 8 of 21-day cycles, for 3 cycles
223932890|NCT06037980|DRUG|Cisplatin|◦ Cisplatin 25 mg/mq iv, day 1 and 8 of 21-day cycles, for 3 cycles
223535306|NCT02202564|PROCEDURE|LT|Orthotopic LT
223932891|NCT06037980|PROCEDURE|Curative Surgery|Curative surgery on primary tumor
223932892|NCT06037980|DRUG|Capecitabine|1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
223932893|NCT06846177|OTHER|Graded Activity Training|"4 types of progressive activities of 2 hour session two times/week with resting periods of 30 mins. Activities consist of treadmill walk ,walk on floor, core muscles exercises ,home tasks .~To ensure the proper heart rate and loads during the exercises, measurements of individual heart rate and muscle strength are taken during the first session (baseline) with HR Tracking portable device and also during the session to continuously monitor HR of the Patient. To withdraw or adjust the training intensity for each patient Borg's Scale of Perceived Exertion is used throughout the session for monitoring Training intensity of endurance, muscle training, individual's effort and exertion level."
223932894|NCT06846177|OTHER|Task-Oriented Training|4 task oriented physical fitness activities which include walk on floor, walk on inclined surface using treadmill ,sit to stand , stair climbing and descending for duration of 2 hour session with frequent breaks. Each treatment session began with 10 minutes of warm-up exercise, which consisted of passive stretching of the calf muscles, hamstring, and hip adductors. The level of difficulty and frequency for each task were gradually increased during the 6 weeks with the patients consent.10 minutes of cool down at the end of each treatment session.
224096680|NCT02631304|PROCEDURE|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
224096681|NCT03381443|OTHER|different assessments|coded survey about NTS and assessment
224096682|NCT03671122|DIAGNOSTIC_TEST|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
224285488|NCT01784237|PROCEDURE|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
223535307|NCT02202564|DRUG|ADV-TK|
223535308|NCT02202564|DRUG|ganciclovir|
223535309|NCT02612246|DRUG|GLPG1972 single ascending doses|single dose, oral solution
223535310|NCT02612246|DRUG|Placebo single dose|single dose, oral solution, matching placebo
224096683|NCT03671122|OTHER|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
224096684|NCT03671122|PROCEDURE|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
223932895|NCT06838052|OTHER|Strong Woman, Safe Life Training Program Supported by Laughter Yoga|The training program consists of 8 modules, each module consists of two sessions. A session will last 45 minutes. The program includes the following topics: Self-Awareness and Importance of Communication (Module 1), Stress and Coping Techniques (Module 2), Gender (Module 3), Women's Empowerment (Module 4), Violence and Its Effects on Women's Health (Module 5), Non-Violent Communication (Module 6), Combating Violence (Module 7), Psychological Health (Module 8). In addition, a laughter yoga session will be held in the second session of each module.
224096685|NCT04351659|OTHER|Blood donation from convalescent donor|Donation of 1 unit of blood or leukapheresis
223932896|NCT02235857|DEVICE|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
223932897|NCT04110340|DRUG|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
223932898|NCT04110340|DRUG|Streptomycin|"Adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
223932899|NCT04110340|DRUG|Gentamicin|"Adults: 2.5mg/kg IV gentamicin twice daily for 3 days followed by ciprofloxacin 500 mg orally twice daily (or ciprofloxacin 400 mg twice daily IV for those who cannot take oral) for a further 7 days.~Children: 2.5mg/kg IV gentamicin twice daily for 3 days, followed by ciprofloxacin 15mg/kg (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take the oral route) for a further 7 days."
223932900|NCT06850311|DRUG|herbal ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 4 weeks
223932901|NCT06850311|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 4 weeks.
223932902|NCT06846801|PROCEDURE|Balloon Dilation Under Portable X-ray System|"* All the esophageal dilation procedures will be performed using rigid hypopharyngoscope and / or oesophagoscope with endotracheal intubation under general anesthesia by experienced surgical and anesthesia team.~* The rigid hypopharyngoscope / oesophagoscope (Storz, germany) will be introduced through the mouth to whole through examination to localize the site of the stenosis then a contrast material will be injected via the endoscope and picture taken with X-DR portable x-ray system.~* After that a guide wire 0.035mm will be passed through the endoscope till the stomach. The guide wire site will be confirmed by with X-DR portable x-ray system and then a suitable size balloon catheter will be passed over the guide wire (Boston Scientific, Cork, Ireland), then the balloon catheter will be advanced through the stricture confirmed by taking a photo by the x-ray system. The balloon will be inflated with radiopaque contrast solution using EncoreTM 26 inflation device."
223932903|NCT03936790|OTHER|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
223932904|NCT03936790|OTHER|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
224096686|NCT02145130|BIOLOGICAL|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
224096687|NCT02145130|BIOLOGICAL|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
223533733|NCT05940350|BEHAVIORAL|Telerehabilitation Stroke Coaching of Program (TeleSCoP) group|"The sampling criteria will be assigned to the intervention (TeleSCoP) and control groups by stratified randomization (1:1) in patients with acute ischemic stroke. A three-month telerehabilitation-based coaching intervention will be applied to stroke patients in the intervention group. Within the scope of telerehabilitation-based coaching initiative, coaching initiatives will be planned for the management of symptoms and complications for modifiable risk factors. Patients in the intervention group will receive discharge education with the education booklet prepared on the 4th or 5th day in the hospital, and informative videos prepared in cooperation with the multidisciplinary team will be shared with the patients. Patients will be called by phone at weeks 1, 2, 3, 4, 6, 8, and 10. The patients in the control group will be given the Stroke Education Brochure of the Ministry of Health and they will benefit from routine hospital services for three months."
223533734|NCT00409955|PROCEDURE|Lamellar transplant with lyophilized corneas|
223533735|NCT01151657|DIETARY_SUPPLEMENT|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
224096688|NCT02800174|DEVICE|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
223932905|NCT06850142|PROCEDURE|Discopexy to external ear cartilage|stabilizing the articular disc within the temporomandibular joint (TMJ) in patients experiencing TMJ disorders (TMD) to external ear cartilage
223932906|NCT06850142|PROCEDURE|Discopexy to temporal fascia|stabilizing the articular disc within the temporomandibular joint (TMJ) in patients experiencing TMJ disorders (TMD) to temporal fascia
223932907|NCT06447272|OTHER|sham inspiratory muscle training|This group will receive conventional treatment + sham IMT (with 10% MIP as the training intensity)
223932908|NCT06447272|OTHER|target inspiratory muscle training|This group will receive conventional treatment + target IMT (the IMT identified as optimal intensity based on the results of our undergoing study).
223932909|NCT05537142|DRUG|BV100|Rifabutin for Infusion
223932910|NCT01173341|DIAGNOSTIC_TEST|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
223932911|NCT01173341|OTHER|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
223932912|NCT01173341|OTHER|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
223932913|NCT05376462|DIAGNOSTIC_TEST|Quantra System with the QStat Cartridge|Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.
223932914|NCT06405113|COMBINATION_PRODUCT|Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy|Participants received Fecal Microbiota Transplantation (FMT) combined with (Oxaliplatin + S-1)+Sintilimab
223932915|NCT03875144|PROCEDURE|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
223932916|NCT03875144|DRUG|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
223932917|NCT03875144|DRUG|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
223932918|NCT03778944|PROCEDURE|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
223932919|NCT03778944|PROCEDURE|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
223932920|NCT03778944|PROCEDURE|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
223932921|NCT02415127|DRUG|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
223932922|NCT02415127|DRUG|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
223932923|NCT06811974|PROCEDURE|Impacted lower wisdom tooth extraction|One of the most frequently performed procedures in maxillofacial surgery is impacted wisdom tooth surgery. An impacted tooth is defined as a tooth that is not fully or partially erupted and is blocked from eruption by another tooth, bone, or soft tissue, and thus has a low probability of eruption. The tooth is blocked from eruption by adjacent hard or soft tissue, including bone or dense soft tissue. The most common complications after impacted wisdom tooth surgery are pain, edema, trismus, and alveolar osteitis.
223932924|NCT06840665|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
223932925|NCT06840665|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223932926|NCT06840665|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
223932927|NCT06860139|BEHAVIORAL|Health literacy intervention|The intervention will be developed in co-creation with patients and nurses in the clinic, based on their needs.
223932928|NCT06617923|DRUG|Senaparib|Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
223932929|NCT06617923|DRUG|Temozolomide|Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
223932930|NCT06891339|OTHER|mobile application|The aim is to evaluate whether a patient-centered mobile application with smartphone-based systematic follow-up assessment during the perioperative period can improve surgery-related anxiety, complications, comfort, and patient satisfaction compared to standard care. This thesis will be one of the pioneering studies in this field.
223932931|NCT06752720|DRUG|Stem cell Transplantation|Manufactured autologous mescenchymal stem cell (HUNS001-01) in our cell processing center will be injected into the brain, totally 4 x 10\^7 cells, in 2 brain sites.
223932932|NCT06766903|BEHAVIORAL|Exercise training|"All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions.~The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume."
223932933|NCT06753513|OTHER|99mTc-FDPH46 SPECT/CT Imaging|99mTc-FDPH46 SPECT/CT Imaging
223932934|NCT05139225|DRUG|TTI-622|"(-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions."
223533736|NCT01151657|DIETARY_SUPPLEMENT|Placebo|Placebo capsules containing maltodextrin
223533737|NCT01093014|BEHAVIORAL|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
223533738|NCT01093014|BEHAVIORAL|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
223533739|NCT01093014|BEHAVIORAL|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
223535311|NCT02612246|DRUG|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
223932935|NCT05139225|DRUG|Daratumumab Hyaluronidase-fihj|Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.
223932936|NCT06826586|DIAGNOSTIC_TEST|Measuring the microplastics|Measuring the type, nature, and abundance of microplastics in stomach, liver, feces, and blood
223932937|NCT06773091|BIOLOGICAL|NK042|NK042 is an allogeneic, off-the-shelf cellular therapy derived from healthy donors and enriched with NKR+ NK cells.
223932938|NCT06773091|DRUG|Fludarabine (FLU)|Fludarabine (FLU) is administered as a lymphodepletion regimen prior to NK042 infusion.
223932939|NCT06773091|DRUG|Cyclophosphamide (CTX)|Cyclophosphamide (CTX) is administered as a lymphodepletion regimen prior to NK042 infusion.
223932940|NCT06809218|DRUG|Inhaled isoflurane administered by Sedaconda ACD-S|Intervention: isoflurane
223932941|NCT06809218|DRUG|Intravenous infusion of propofol|Intervention: propofol
223932942|NCT06604364|DEVICE|hypno VR|pre-surgery sedation using virtual reality headset
223932943|NCT06831097|BEHAVIORAL|"Comidas Para Salud (Food for Health), Pasos Para Salud (Steps for Health), Jardines Para Salud (Gardens for Health)"|"Comidas Para Salud (Food for Health), Pasos Para Salud (Steps for Health), Jardines Para Salud (Gardens for Health)~Description: Arm Description: Comidas Para Salud (Food for Health), will focus on assisting young children to learn skills in healthy eating. The Bienestar Preschool Curriculum is home-based and directed to both the primary caregivers as well as the child participants. The Pasos Para Salud (Steps for Health), which will use IVG/exergaming to increase children's physical activity level and reduce their sedentary behavior. Jardines Para Salud (Gardens for Health), will involve planting gardens in the HS settings and supervised home gardening projects for the preschool participants and their parents/guardians. This will instill the value of gardening and gardening skills in promoting a healthy lifestyle."
223932944|NCT05305664|DRUG|Pelacarsen (TQJ230) 80 mg s.c.|Pelacarsen (TQJ230) 80 mg s.c. Q4W
223932945|NCT05305664|DRUG|Corresponding Placebo|Placebo to Pelacarsen
223932946|NCT06792045|OTHER|Physiotherapist assessment|"* Tongue motor skills (Tongue pressures and tongue mobility, assessed through the Iowa Oral Performance Instrument and the Motricité Bucco-Linguo-Faciale tongue subscore, respectively)~* Tongue restriction of mobility due to its frenulum (assessed through the Quick Tongue-Tie assessment tool)~* Breathing Pattern (questionnaire from Abreu RR, Rocha RL, Lamounier JA, Guerra AF. Etiology, clinical manifestations and concurrent findings in mouth-breathing children. J Pediatr (Rio J). 2008;84(6):529-535.)."
223932947|NCT06792045|OTHER|ENT assessment|Data from the ENT appointment will be collected (e.g., sex, height, weight)
223932948|NCT06792045|DIAGNOSTIC_TEST|Drug-Induced Sleep Endoscopy|A Drug-Induced Sleep Endoscopy will be performed, recorded, and evaluated by two blinded raters using the IPSES scale.
223932949|NCT04516720|OTHER|data collection|Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
223932950|NCT03987009|DEVICE|Without RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning without RAMP device
223932951|NCT03987009|DEVICE|With RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning with RAMP device
223932952|NCT03987009|DEVICE|Without RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning without RAMP device
223932953|NCT03987009|DEVICE|With RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning with RAMP device
223932954|NCT03789110|DRUG|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
223932955|NCT03789110|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
223932956|NCT06821789|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
223932957|NCT06821789|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
223932958|NCT06265740|OTHER|vaginal swab|Any pregnant woman attending the obstetrics department of Clermont-Ferrand University Hospital who requires a vaginal swab (VS) for her clinical situation (routine care) will be offered the study. If the participant accepts, the usual swab will be doubled and performed simultaneously in a single procedure using two swabs. The first swab will be sent to the laboratory and used for diagnosis. The second swab will be used for microbiota analysis.
223941378|NCT05071079|BIOLOGICAL|An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum|An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum
224096689|NCT02800174|DRUG|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
224285489|NCT01784237|PROCEDURE|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
223932959|NCT05375851|OTHER|Digital Interventions|"The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management."
223932960|NCT05375851|DRUG|Treatment as Usual|"The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil."
223932961|NCT06797492|DIAGNOSTIC_TEST|Shoulder Physical Examination|shoulder physical examination is conducted to assess the patient's musculoskeletal condition and to track progress throughout the rehabilitation phases
223932962|NCT06797492|PROCEDURE|Shoulder Rehabilitation in a Virtual Environment|The rehabilitation protocol for shoulder disorders is executed using a Virtual Reality (VR) system, where patients perform customized exercises tailored to their physical characteristics.
223535312|NCT02612246|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
223535313|NCT03906526|DRUG|VTX-2337|Motolimod
223932963|NCT06797492|OTHER|Usability assessment and presence and co-presence evaluation|The usability of the VR system, along with the sense of presence and co-presence during rehabilitation, is assessed using validated scales
223932964|NCT06783257|DRUG|Vonorasan fumarate injection1|40 mg (20 mg bid, 6 hours apart, Day1) + 20 mg (Day2\&3, q24h), ivd, 30 min, administered for 3 days
223932965|NCT06783257|DRUG|Vonorasan fumarate injection2|40mg（Day1）+20mg（Day 2\&3），ivd，30min，q24h，administered for 3 days
223932966|NCT06783257|DRUG|Esomeprazole sodium for injection|80mg，iv，30±3min； Followed by 8 mg/h, ivd, 71.5 h
224096690|NCT00655720|OTHER|infant formula|"1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics"
224096691|NCT04472689|DRUG|Lidocaine|patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.
224096692|NCT04472689|DRUG|Normal saline|patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
224285490|NCT01594034|PROCEDURE|expired air|collection of expired air from ventilator
224285491|NCT04686994|DRUG|ASC 41|Oral tablets
224285492|NCT04686994|DRUG|ASC 41 Placebo|Oral tablets
224285493|NCT03204474|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
224285494|NCT03204474|DRUG|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
224285495|NCT06616038|OTHER|Data collection|Given the observational nature of the study, the intervention is a simple data collection
224285496|NCT06617403|OTHER|non|non
224285497|NCT06616519|DEVICE|BenQ Materials MSENCI soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
224285498|NCT06616519|DEVICE|Visco Oxypure Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
223932967|NCT06712901|BEHAVIORAL|Median Ranked Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.
223932968|NCT06712901|BEHAVIORAL|Overall Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.
223932969|NCT06712901|BEHAVIORAL|Black American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.
223932970|NCT06712901|BEHAVIORAL|White American Preferred Cancer Screening Messaging|Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.
223932971|NCT06712901|BEHAVIORAL|Control|There will be no message content of cancer screening and sharing intentions in this arm.
223932972|NCT03912194|BEHAVIORAL|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
223932973|NCT03912194|BEHAVIORAL|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
223932974|NCT03912194|BEHAVIORAL|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
223932975|NCT06760494|DIAGNOSTIC_TEST|the MAPUSE model|Using the MAPUSE model to predict MVI status before surgical resection for HCC patients
223932976|NCT06890962|DIETARY_SUPPLEMENT|Energy drink consumption|Participants will consume an energy drink (or placebo) and then undergo experimental testing after a 40 minute rest period following drink consumption.
223932977|NCT05786157|OTHER|Alcohol Administration|Participants will complete an alcohol administration paradigm (peak breath alcohol concentration=.09-.10 g/dL BrAC)
223932978|NCT06806059|BEHAVIORAL|Physical Activity|The intervention group will engage in increased physical activity, aiming for a daily step count of at least 8,000, with a target of 10,000 steps, over a four-week preoperative period. Weekly supervised phone consultations will be conducted to provide guidance and support.
223932979|NCT06808178|DEVICE|Low Level Laser Therapy|"The device has the following treatment parametes :~* Maximum average power \> 500 milli watts~* Wave length combined (904-808) nm~* Maximum repition rate (1-2000) Hz~* Energy density : 4:6 J per cm per session"
223932980|NCT06808178|OTHER|kinesio taping|"* the material used is 100%acrylic,latex free and heat activated with 10-15% stretch.~* It is made of 100% cotton to allow quickening of the drying process.~* Ability to stretch to 120-140% of its original length~* Recoil back to the anchor that is applied without stretch~* Heat-activated adhesive~* Hypoallergenic dyes that make the tape safe for most users~* Latex-free~* Drying time after being wet is about 5-10 minutes~* Can be worn for several days"
223932981|NCT06748560|OTHER|Neurodynamics|Following Castellote-Caballero et al., the neurodynamic sliding technique (NST) was applied to the dominant leg's sciatic nerve in the NST and ETNST groups. The technique involves alternating stress proximally and distally to promote nerve sliding. Participants performed two sets of movements-cervical flexion with knee and ankle flexion, and cervical extension with knee and ankle extension-repeated actively for 60 seconds, five times per session. Over six weeks, both groups underwent three supervised sessions per week led by an experienced researcher.
223932982|NCT06748560|OTHER|Eccentric training|The Nordic exercise served as the foundation for the intervention, focusing on eccentric loading as participants resisted falling forward. To minimize DOMS and ensure adherence, a two-week preparatory phase of mixed concentric/eccentric leg curls using a stability ball was implemented. Following this, the gradual progression outlined by Mjolsnes et al. led to a four-week Nordic hamstring curl regimen. Weekly supervision ensured proper technique and compliance throughout the program.
223932983|NCT06761079|PROCEDURE|Thoracolumbar interfascial plane block|Ultrasound-guild bilateral Thoracolumbar interfascial plane block with a total 40 ml, 0.25% bupivacaine by anesthesiologist
223932984|NCT06761079|PROCEDURE|Local anesthetic infiltration|0.25%bupivacaine infiltration at surgical wound site by orthopedic surgeon
223932985|NCT06739512|PROCEDURE|Extensive Electro-Anatomical Guided Ablation|Ablation using PFA. Combination of anatomical and electrogram-guided ablation techniques.
223932986|NCT06739512|PROCEDURE|Anatomical Guided Ablation|Ablation using PFA. Guided by anatomical landmarks without potential mapping
223932987|NCT06739512|PROCEDURE|Electrogram Guided Ablation|Ablation using PFA. Guided by real-time electrogram characteristics from a multi-electrode catheter.
224285499|NCT06615999|PROCEDURE|Simple fracture Tension band wiring|OPS 5-793.27
224285500|NCT06615999|PROCEDURE|Simple fracture locked plate fixation|OPS 5-793.k7
224285501|NCT06615999|PROCEDURE|Multi-fragmented tension band wiring|OPS 5-794.17
224285502|NCT06615999|PROCEDURE|Multi-fragmented locked plate fixation|OPS 5-794.k7
224285503|NCT01044134|BEHAVIORAL|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
224285504|NCT01388452|DEVICE|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
224285505|NCT02128009|OTHER|osteoporosis|
223533740|NCT01649193|OTHER|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
223533741|NCT01128569|DRUG|Fluticasone Furoate|FF
223533742|NCT01128569|DRUG|FF/Vilanterol (VI; GW642444M)|FF/VI
223533743|NCT01128569|DRUG|Placebo|Placebo Inhaler
223533744|NCT04753775|DRUG|Aloe vera gel|
223533745|NCT02236676|BEHAVIORAL|Nap after rehearsal trials|Behavioral
223533746|NCT02805140|BEHAVIORAL|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
223533747|NCT02805140|BEHAVIORAL|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
223533748|NCT02805140|BEHAVIORAL|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
223535314|NCT03906526|DRUG|Nivolumab|IV Nivolumab
223533749|NCT02768207|DRUG|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
223932988|NCT06763185|OTHER|Dietary Supplement: conventional cow's milk consumption, and then A1PF milk consumption|Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
223932989|NCT06763185|OTHER|Dietary Supplement: A1PF milk consumption, and then conventional cow's milk consumption|Milk was consumed three times per day after meals, with 250 mL provided at each administration. During washout periods, participants were required to avoid all dairy products and use only rice milk.
223932990|NCT06763315|DRUG|Selumetinib|Use of the internationally recommended standard dose and low dose of the same drug
223932991|NCT06747702|OTHER|Injury prevention workout|The injury prevention workout consisted on engaging on a prevention program from 1 day to 8 weeks where the participants will develop functional sport exercises to prevent shoulder injuries or pain in overhead sports.
223932992|NCT05268237|DRUG|Liraglutide|Sublingual or subcutaneous liraglutide
223932993|NCT05268237|DRUG|Placebo|Sublingual placebo
223932994|NCT06761222|OTHER|The use of ultrasound in central blocks|Ultrasonography was conducted using a convex probe in the paramedian and transverse planes.
223932995|NCT06752798|DRUG|Trilaciclib + Cisplatin|Trilaciclib: 240 mg/m², intravenous infusion over 30 minutes, administered within 4 hours prior to each chemotherapy session. Cisplatin: 40 mg/m², intravenous infusion over 2-3 hours, once a week, for a total of 6-7 times.
224285506|NCT02752386|BEHAVIORAL|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
223932996|NCT05633836|PROCEDURE|Fluorescence guided surgery|During exploratory laparoscopy or at the end of macroscopically complete cytoreduction surgery, indocyanine green fluorescence-guided surgery is performed to identify peritoneal carcinoma lesions not visible in white light
223932997|NCT03328663|OTHER|CARE|Promote effective coping and reduce caregiving burden.
223932998|NCT03328663|OTHER|Standard Transplant Care|Standard cared administered by the hospital.
223932999|NCT06776900|PROCEDURE|Supine position|"An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved."
223933000|NCT06776900|PROCEDURE|Lateral position|"An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved."
224285507|NCT02767934|OTHER|Laboratory Biomarker Analysis|Correlative studies
224285508|NCT02767934|BIOLOGICAL|Pembrolizumab|Given IV
224285509|NCT05846256|OTHER|Sperm DNA Fragmentation|Sperm DNA Fragmentation analysis.
224285510|NCT00402025|BIOLOGICAL|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
224285511|NCT02631252|DRUG|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
224285512|NCT02631252|DRUG|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
224285513|NCT02631252|DRUG|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
224285514|NCT02617082|RADIATION|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
224285515|NCT01443689|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
224285516|NCT01443689|BIOLOGICAL|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
224285517|NCT01443689|DRUG|Conventional therapy|Participants will be given conventional therapy only.
224285518|NCT03529565|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224285519|NCT03529565|OTHER|Laboratory Biomarker Analysis|Correlative studies
224285520|NCT03529565|OTHER|Quality-of-Life Assessment|Ancillary studies
223533750|NCT02768207|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
224285521|NCT03529565|OTHER|Questionnaire Administration|Ancillary studies
224285522|NCT00190489|DRUG|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
224285523|NCT00190489|DRUG|Docetaxel 60mg/m2 every 21 days for 6 cycles|
224285524|NCT00190489|DRUG|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
224285525|NCT01917968|DEVICE|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
224285526|NCT01917968|PROCEDURE|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
224285527|NCT05255302|DRUG|Pembrolizumab before randomization|Pembrolizumab 200 mg every 3 weeks before randomization
224285528|NCT05255302|DRUG|Chemotherapy|Platinum doublet - 4 cycles: either paclitaxel-carboplatin for patient with SCC or pemetrexed-platinum salt followed by 2 cycles of pemetrexed until reaching the 6 months time-point for randomization Carboplatin AUC 5 for non-squamous cell carcinoma and AUC6 for squamous cell carcinoma every 3 weeks or cisplatin 75 mg/m² every 3 weeks Pemetrexed 500 mg/m² every 3 weeks or paclitaxel 175 mg/m² every 3 weeks
224285529|NCT05255302|DRUG|Pemetrexed|Maintenance pemetrexed after randomization Pemetrexed 500 mg/m² every 3 weeks
224285530|NCT05255302|DRUG|Pembrolizumab after randomization|Pembrolizumab 200 mg every 3 weeks after randomization
224285531|NCT03400215|DIAGNOSTIC_TEST|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
224285532|NCT03400215|DIAGNOSTIC_TEST|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
224285533|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation without the support of the RAYVOLVE app|"Phase 1 does not involve any intervention: residents, emergency physicians, and radiologists will interpret the x-rays without the support of the RAYVOLVE application.~The emergency physician interprets the x-ray and manage the case as per protocol, all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated."
223533751|NCT06341894|DRUG|Dalpiciclib|CDK4/6 inhibitor dalpiciclib, 100mg orally qd
223933001|NCT06772844|DIAGNOSTIC_TEST|fecal DNA methylation testing|Three rounds of screening were performed. In the first year, colonoscopy was conducted along with concurrent fecal DNA testing performed prior to the colonoscopy. In the second year, fecal DNA testing was performed only if no polyps were detected during the colonoscopy in the first year; otherwise, both colonoscopy and fecal DNA testing were conducted. In the third year, a colonoscopy was performed with concurrent fecal DNA testing conducted before the procedure
223933002|NCT06756958|OTHER|No intervention (observational study)|No intervention (observational study: The study participants were inpatient and were given robot-assisted gait training routinely.)
223933003|NCT06753344|BEHAVIORAL|Intervention app|The app-based intervention, co-designed with the V-YAC, aims to introduce life skills and self-management skills to promote general mental well-being and resilience among Vietnamese youth. With this app, youth users will have a fun and safe space to learn and practice six life skills areas (Problem-solving, Social Media and Well-being, Communication and Interpersonal Skills, Realistic Thinking, Coping with Emotions and Stress, and Goal Setting). Lessons (in the form of short texts) and activities (ex. multiple choice activities, blank worksheets, reflection questions) were adapted from evidence-based interventions developed in other contexts to be culturally appropriate to the Vietnamese youth context. Youth users are free to explore the app at their own pace. Gamification features will also allow youth users to collect points in the app for completing each lesson, activity, or challenge.
223933004|NCT06894264|BEHAVIORAL|Emotion regulation|The intervention is an adapted version of skills training that stems from DBT. The text has been simplified, and illustrations have been added to facilitate learning. In addition, metaphors have been removed, making it more user-friendly for the targeted populations. It consists of 12 modules that are delivered during 12 weeks, one module per week. A licensed psychologist are responsible for each individual treatment. Care givers or relatives are encouraged to participate and help the study participant to complete their homework assignments.
223933005|NCT06866223|BEHAVIORAL|Sentence recast|Recast therapy is a well-established treatment for grammar in children with DLD. In this treatment, the adult repeats the child's own utterance, altering it to include the taught structure. It yields consistent large effect sizes (Hedge's g = 0.7-1.0) when focused on a single target and provided at a high dose (10-20 hrs. of therapy at a rate of \~1 recast/minute or \~600-1000 recasts total) for both morphology and syntax
223933006|NCT06667661|BEHAVIORAL|Shining Star mHealth App|The Shining Star mHealth App Intervention is a 12-week mobile health program designed to improve adherence to the 24-Hour Movement Guidelines (physical activity, screen time, and sleep) among preschool-aged children (3-4 years old). The intervention delivers weekly behavior-related goals and educational lessons to parents through a mobile app, including concise messages (\&lt;500 characters) and links to additional resources. The app also includes gamification features, behavior trackers, and a \&#34;Kids Corner\&#34; for child-friendly content. Parents receive reminders and can engage with other participants through an optional chat forum.
223933007|NCT04399473|BEHAVIORAL|Pain Neuroscience Education (PNE)|Participates in the experimental group will receive 15mins X 4 sessions of pain education by the eligible trained physical therapist in addition to usual care PT treatment.
223933008|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on nature|Reading journalistic posts and articles, published on social media, regarding nature.
223933009|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on deaths by suicide|Reading journalistic posts and articles, published on social media, regarding deaths by suicide.
223933010|NCT06255171|BEHAVIORAL|Reading journalistic posts and articles on social media on traffic-related deaths|Reading journalistic posts and articles, published on social media, regarding traffic-related deaths
223933011|NCT05464732|DEVICE|Vivity IOL emmetropia|The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to bilateral emmetropia.
223933012|NCT05464732|DEVICE|Vivity IOL monovision|The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to emmetropia in the dominant eye and -0.50 in the non-dominant eye.
224285534|NCT05187585|DIAGNOSTIC_TEST|radiograph interpretation with the support of the RAYVOLVE app|The residents interpret the X-ray with the RAYVOLVE application's support and indicate the presence or not of a fracture without sharing it with the senior emergency physician. A senior emergency physician manages the case as usual, and all the x-rays will be reinterpreted by the radiologist only later, usually the day after. In case of missed fractures, the physician is notified of the error by the radiologist, and patients will be informed and recalled to the hospital to be reevaluated
224285535|NCT05486845|OTHER|survey|We are planning a questionnaire survey. We combine our own questions with validated, official questionnaires. Validated forms ask for an assessment of the extent of low back pain and the quality of experienced stress.
224285536|NCT03371329|BIOLOGICAL|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
224285537|NCT01222949|DRUG|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
224285538|NCT05668026|DRUG|Venetoclax|In this study participants will receive venetoclax 200 mg, 400 mg or 800 mg once daily for 14 days in the dose-escalation phase. In the expansion cohort, the selected max-tolerated dose will be given for three cycles, each consisting of venetoclax daily for 14 days followed by 14 days off.
224285539|NCT02214563|DIETARY_SUPPLEMENT|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
223533752|NCT06341894|DRUG|Endocrine therapy|Fulvestrant/AI
223533753|NCT00563732|DRUG|Lecozotan|
223933013|NCT06435663|OTHER|Different methods of efficacy evaluation|When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
223933014|NCT06495372|DRUG|Experimenta group (standard of care + Methoxyflurane).|standard of care + Methoxyflurane
223933015|NCT06495372|DRUG|control group (standard of care + placebo).|standard of care + placebo
223933016|NCT06843603|BEHAVIORAL|culturally informed care coordination intervention|Culturally Informed Care Coordination Strategies
223933017|NCT06843603|OTHER|No Intervention - Usual Care Group|No Intervention - Usual Care Group
223933018|NCT06757517|DRUG|Oxytocin nasal spray|Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).
223933019|NCT06757517|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline intranasal placebo comparator
223933020|NCT06789055|OTHER|Cold Spray|Before the capillary blood glucose measurement, cold spray will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
224285540|NCT02214563|DIETARY_SUPPLEMENT|Olive oil|
224285541|NCT02528058|PROCEDURE|Vitrectomy with internal limiting membrane peeling|
224285542|NCT04920058|DEVICE|Continuous Glucose Monitor|Continuous glucose monitor - a device that monitors blood glucose levels in a continuous closed-loop manner. This can also refer to the process of continuous glucose monitoring
224285543|NCT04920058|OTHER|<Active Comparator?>|\<describe, Comprehensive Wellness Program incorporating a low carbohydrate diet (\<50g/day) and associated education \>
224285544|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
223933021|NCT06789055|OTHER|Placebo|Before the capillary blood glucose measurement, placebo will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
223933022|NCT06829212|DEVICE|WRS|WRS is a minimally invasive, wireless brain-machine interface system, consisting of a wireless implanted neural signal collector(Model: WRS64), data energy transmitter(Model: DTC01/02), and a brain function information management platform software(Model: SW01).
223933023|NCT06828250|DEVICE|intradermal needle therapy|In addition to conventional treatment, patients in the treatment group received intradermal needle therapy after returning to the ward safely. Bilateral Hegu (LI4) and Zusanli (ST36) acupoints were selected for this therapy. Patients were positioned in a supine position, and after locating the acupoints, the skin of the acupoint areas was sterilized with 75% ethanol using a medical cotton swab. The intradermal needle was then removed along with the adhesive tape, inserted into the acupoints, and pressed every 4 hours for approximately 60 presses each time, excluding nighttime sleep. The pressure was applied until an acid, swelling, or numb sensation was felt at each acupoint. The intradermal needle therapy was administered only once and continuously pressed for 3 days.
223933024|NCT05424055|BEHAVIORAL|Multicomponent exercise|The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
223933025|NCT05489289|BIOLOGICAL|AK104|Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
223933026|NCT05489289|BIOLOGICAL|placebo|Subjects will receive placebo until disease progression or for a maximum of 16 cycles
224285545|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
224285546|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
224285547|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
224285548|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
224285549|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
224285550|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
224285551|NCT01226693|DRUG|PH-797804 material sparing tablet|oral, 6mg, single dose
224285552|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
224285553|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
224285554|NCT01226693|DRUG|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
224285555|NCT01226693|DRUG|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
224096693|NCT03577990|BEHAVIORAL|Interactive Technology Enhanced Coaching (ITEC)|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
224096694|NCT03577990|BEHAVIORAL|Interactive Technology-No Coaching (IT)|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
224096695|NCT04178148|OTHER|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
224096696|NCT00463437|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
224096697|NCT00463437|BIOLOGICAL|Prevenar|Intramuscular injection, 1 dose.
223933027|NCT00902044|GENETIC|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
223535315|NCT05323890|DRUG|Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy|Patients received tislelizumab at a fixed dose of 200 mg every three weeks (q3w, 21 days) for 2 cycles.
223933028|NCT00902044|DRUG|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes"
223933029|NCT00902044|DRUG|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes"
223933030|NCT00902044|GENETIC|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
223933031|NCT06584682|OTHER|Sub-occipital muscle inhibition technique|Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
223933032|NCT06584682|OTHER|conventional therapy|stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
223933033|NCT06782984|OTHER|Organoid-based drug sensitivity test|"The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis.~The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis."
224096698|NCT00463437|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
224096699|NCT00463437|BIOLOGICAL|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
224096700|NCT00463437|BIOLOGICAL|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
224096701|NCT00463437|BIOLOGICAL|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
224285556|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive bilateral ultrasound guided QLB
224285557|NCT04720287|DRUG|bupivacaine/ neostigmine.|will receive ultrasound guided CB.
224096702|NCT00463437|BIOLOGICAL|Meningitec|Intramuscular injection, 1 dose.
224096703|NCT00463437|BIOLOGICAL|NeisVac-C|Intramuscular injection, 1 dose.
224096704|NCT00463437|BIOLOGICAL|Menitorix|Intramuscular injection, 1 dose.
224096705|NCT05052203|OTHER|Exposure of interest: study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes|The primary objective is to study DNA methylation (epigenetics) and gene expression (transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge
224096706|NCT03694158|DRUG|Dupilumab|anti-IL4 receptor antagonist
224096707|NCT03694158|OTHER|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
224285558|NCT00973310|OTHER|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
223933034|NCT06808490|BEHAVIORAL|Moderate Intensity Exercise|Participants randomized to the moderate intensity exercise condition will complete a 30 min session on a motor driven treadmill. Participants will complete a 3-minute warm-up at low speed on a treadmill. Speed and incline will be increased in 3-minute increments until moderate-intensity exercise, defined as the goal of participants staying within a target zone of 50-70% AAMHR while briskly walking and/or jogging depending on current fitness status.
223933035|NCT06808490|BEHAVIORAL|Light Intensity Stretching|Participants randomized into the light stretching condition will complete a 30-minute video, tailored for 9-17-year-olds. This video leads participants through a series of seated arm, torso, leg, knee and shoulder stretches on a yoga mat. Participants will be monitored throughout the stretching session by a trained research assistant, and HR and perceived exertion will also be measured throughout. The research assistant may make modifications to the poses in real-time to ensure that AAMHR is kept below 40%.
223933036|NCT06808490|BEHAVIORAL|Seated Meditation|Participants randomized into the meditation condition will complete a 30-minute video, tailored for 9-17-year-olds. This video leads participants through a seated guided meditation on a yoga mat. This includes a series of breathing, visualization, and body awareness exercises. Participants will be monitored throughout the meditation session by a trained research assistant, and HR and perceived exertion will also be measured throughout, to ensure that AAMHR is kept below 30%.
223933037|NCT06888128|DRUG|Psilocybin 15mg|Each participant will have a low dose (15 mg) psilocybin session to establish basic skills with session format, psilocybin effects, and continue to build rapport with session facilitators. Given the potential intensity of the psilocybin and the reality of experiencing significant trauma memories, the purpose of the first psilocybin session is to familiarize participants with the drug effects that may be encountered at a higher dose of psilocybin. The first psilocybin session will also allow for assessment of both the suitability of each participant to the study procedures and drug effects, and the safety of administering a higher dose to each participant.
223933038|NCT06888128|DRUG|Psilocybin 25mg|The second psilocybin session will utilize a high dose (25mg) and take place approximately 2 weeks after the first psilocybin session.
223933039|NCT06780280|OTHER|Overground Walking|Overground walking with an exoskeleton
223933040|NCT06868160|BEHAVIORAL|Rehabilitation|"Two cycles of dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises.~Three 1-hour sessions per week for 6 weeks. Cycle repeated after 8-week washout period."
223933041|NCT06868160|DEVICE|SHAM tDCS|SHAM stimulation will be performed using the same montage used for transcranial and spinal stimulation, however an initial current is delivered and programmed to fade off in a brief period of time.
223933042|NCT06868160|DEVICE|tDCS|Anodic tDCS with the anode placed on the of the left DorsoLateral Prefrontal Cortex. Patients will undergo 30 minutes tDCS session preceding rehabilitation
223533754|NCT04907071|DEVICE|Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)|The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
223533755|NCT04767711|DIETARY_SUPPLEMENT|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri with cholecalciferol compared to cholecalciferol only.
223533756|NCT04767711|DRUG|Prednisolone|Oral glucocorticoid 25 mg daily for 7 days.
223718473|NCT04650360|BEHAVIORAL|Postoperative Intervention Educational Program|The health educational program consisted of a single training session offered by a nursing professional to each patient and caregiver. In each educational session, the following topics were addressed: objectives for functional recovery (early mobilization, recovery of functional capacity lost prior to the fracture, etc.), mobilization exercises to start the day after the surgical procedure (lower limb exercise, respiratory physiotherapy, etc.), and tips to prevent future falls. The educational session was implemented during the postoperative hospital stay, with an approximate duration of 30-45 min. The session ended with a summary of the content and comments from the patient and relative in order to ensure understanding of the program. Written information was provided on the aspects addressed in the session (brochures). These patients were treated according to routine protocols. All patients were monitored during admission, at 1 month, at 6 months, and at 1 year after the intervention
223718474|NCT06131177|DIETARY_SUPPLEMENT|Nutritional supplement|Protein supplement
223933043|NCT06868160|DEVICE|tsDCS (first cycle)|Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the first cycle (6 weeks)
223933044|NCT06868160|DEVICE|tsDCS (second cycle)|Anodic spinal cervical stimulation with anode electrode placed on the spinous process of C3 vertebra and cathode placed on T3. Patients will undergo 30 minutes stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
223933045|NCT06868160|DEVICE|SHAM tsDCS (first cycle)|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the first cycle (6 weeks)
223933046|NCT06868160|DEVICE|SHAM tsDCS (second cycle)|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation during the second cycle (6 weeks after 8-week washout)
224285559|NCT02556853|DEVICE|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
223533757|NCT03737552|OTHER|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
223933047|NCT06868160|DEVICE|SHAM tsDCS|SHAM stimulation will have the same montage as tsDCS but run in SHAM more with an initial stimulation at standard intensity, followed by a programmed fade off after a brief time period. Patients will undergo 30 minutes of SHAM stimulation session preceding rehabilitation
223933048|NCT06892262|OTHER|Athletes|The group was included in strength assessment using an isokinetic dynamometer and postural stability evaluation. (high level training group)
223933049|NCT06783777|DEVICE|Esophageal pressure monitoring|Esophageal pressure and Tracheotomy tip pressure were measured simultaneously in patients with off-line tracheotomy to verify the correlation
223933050|NCT06783777|DEVICE|Tracheotomy tip pressure|Esophageal pressure and tracheotomy tip pressure were measured simultaneously in patients with off-line tracheotomy to verify the correlation
223933051|NCT06089915|BEHAVIORAL|Standard occupational therapy|Standard occupational therapy as part of inpatient rehabilitation
223933052|NCT06089915|DEVICE|Robot-assisted exercise using Amadeo device and Armeo Spring exoskeleton|Exercise for fingers and hand using Amadeo device plus gross-motor exercise using Armeo Spring exoskeleton
223933053|NCT06887855|PROCEDURE|Neuromuscular Electrical Stimulation|NMES is a modality for stimulating muscles through electrical pulses, is used widely in the rehabilitation of stroke patients with pharyngeal dysphagia. It reinforces the strength of the muscles for swallowing and smooths the swallowing reflex through sensory stimulation. Clinically, NMES is applied to depolarize nerve fibers at the point of engagement, involving muscle contraction (Park et al. 2019). NMES includes the placement of electrical stimuli to the skin around the face and neck through surface electrodes. Stimulation intensity can be diverse depending on the treatment objectives. Low-intensity (sensory) NMES lets patients feel the tingling sensation on the skin, whereas high-intensity (motor) NMES can stimulate muscle contractions (Cheng et al. 2022).
223933054|NCT06887855|PROCEDURE|Neuromuscular Taping|NMT is similar to kinesiology taping but specifically focuses on neuromuscular re-education and it is a commonly used therapy approach for various neuromuscular problems. The neuromuscular tape can be easily applied to skeletal muscles to induce or inhibit muscle activity and to support the stabilization of structures such as joints and ligaments. The elasticity and adhesion properties of NMT can be used to restrain the anterior-upward movement of the hyolaryngeal complex during spontaneous swallowing. This effect increases the load on the suprahyoid muscles and consequently, the patient spends more effort to overcome this movement while swallowing. Resistance exercises provided with NMT activate the suprahyoid muscle and contractions for the muscles of the tongue.
223933055|NCT06887855|PROCEDURE|Swallowing exercise (Expiratory Muscle Strength Training)|IN EMST the patients blow into a one-way spring-loaded apparatus calibrated to a percentage of maximum expiratory pressure until the valve opens with adequate effort. Four to eight weeks of EMST exercises increased the maximum expiratory pressure (MEP), maximum hyoid displacement, suprahyoid muscle action, and swallowing safety in patients with amyotrophic lateral sclerosis, stroke, and neck cancer.
223933056|NCT06887855|PROCEDURE|Swallowing exercise (Chin Tuck Against Resistance)|CTAR exercise is performed by an inflatable 12 cm rubber ball. The patients are directed to sit upright on a chair and hold the rubber ball between the base of the chin and the manubrium sterna. This exercise is composed of isometric and isotonic movements. The isometric movement will be performed for 10 seconds, whereas the isokinetic movement will be successively repeated 10 times to strengthen the suprahyoid and infrahyoid muscles (Kagaya \& Inamoto, 2022).
223941379|NCT01605409|PROCEDURE|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
224096708|NCT03836144|DIETARY_SUPPLEMENT|Potassium citrate|
224096709|NCT00361530|DRUG|Statin|
223533758|NCT03912870|OTHER|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
224096710|NCT04388384|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
224096711|NCT04266938|BEHAVIORAL|Rapid start of antiretrovirals|Utilize health navigators to link patients with newly diagnosed HIV into care and treatment within 7 days
224096712|NCT04266938|BEHAVIORAL|Retrospective analysis|Review historical standard of care relative to time to start antiretrovirals and impact on retention in care.
224096713|NCT04266938|BEHAVIORAL|Non- RAPID start|Review of patients who failed to establish care and start ART within 7 days of HIV diagnosis and analyze impact on retention in care.
223533759|NCT01295710|BIOLOGICAL|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
224096714|NCT06561087|DRUG|Nivolumab|Given by injections
224096715|NCT04990167|DRUG|Tiotropium Bromide|Using Tiotropium as a single agent asthma controller medication
224096716|NCT05936580|DRUG|Nuwiq|Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
224096717|NCT02758769|BIOLOGICAL|ORENCIA Subcutaneous Injection|
224096718|NCT04432012|DRUG|Dexamethasone Sodium Phosphate 4 mg/ml intravenous|Perioperative intravenous injection of 3 ml of solution (9mg of dexamethasone)
224096719|NCT04432012|DRUG|Dexamethasone Sodium Phosphate 4 mg/ml intra-articular|Perioperative intra-articular injection of 3 ml of solution (9mg of dexamethasone)
224096720|NCT04996797|DRUG|Tulisokibart|Administered by IV infusion
224096721|NCT04996797|DEVICE|Companion Diagnostic (CDx) Testing|PRA023 CDx Genotyping Assay
224096722|NCT04996797|OTHER|Placebo|Placebo administered by IV infusion
224096723|NCT02793544|DRUG|Fludarabine|"* Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~* The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~* creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
224096724|NCT02793544|DRUG|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"* Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
224096725|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy on Day -1|"* 200 cGy TBI is administered in a single fraction on Day -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
224096726|NCT02793544|PROCEDURE|Infusion of non-T-cell depleted bone marrow on Day 0|"* On Day 0, the harvested bone marrow is infused.~* Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~* The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
224096727|NCT02793544|DRUG|Busulfan|"* Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM\*min (Perkins et al., 2012))~* Busulfan dosing is based on adjusted IBW (Appendix K)"
224096728|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
224096729|NCT02793544|DRUG|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"* Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~* Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Hydration prior to Cy may be given according to institutional guideline.~* Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
224285560|NCT02556853|OTHER|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
224285561|NCT01795235|DRUG|Saline|Saline s.c.
224285562|NCT01795235|DRUG|Glucagon|Glucagon s.c.
224285563|NCT01795235|DRUG|Placebo|Sugar Pill
224285564|NCT01795235|DRUG|Atenolol|Beta-1 receptor antagonist
224285565|NCT00834236|OTHER|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
224285566|NCT00834236|OTHER|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
223533760|NCT01295710|BIOLOGICAL|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
223533761|NCT00671086|DRUG|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
223533762|NCT00671086|DRUG|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
223933057|NCT06892912|OTHER|Diaphragmatic ultrasound|"Sample:~Given the observational nature of the study, a convenience sample will be obtained from all patients admitted to the emergency services and/or ICU with respiratory failure over the course of 1 year.~Inclusion Criteria:~* Age ≥ 18 years~* Hypoxemic respiratory failure (SpO2 \< 88% - PaO2 \< 60 mmHg) or hypercapnic (PaCO2 \> 40)~* Need for NIMV and/or HFNC.~Exclusion Criteria:~* Neuromuscular disease~* Pregnancy~* Tracheostomy~* Rib fractures~* Cervical injuries~* Diaphragmatic paralysis~* Diaphragmatic malformations~* Hemodynamic instability~* Morbid obesity (BMI \> 35)~* Use of sedation and neuromuscular relaxants~* Pneumothorax or pneumomediastinum~* Poor acoustic window~* Critically ill patients with a prognosis of less than 24 hours of life~* Patients receiving palliative interventions."
223933058|NCT06769360|PROCEDURE|PMI-targeted PSV setting|The pressure support is adjusted according to PMI between 0 and 2 cmH2O. After application of PSV mode in mechanically ventilated patients, the initial PS level was first set based on respiratory rate (RR) \<35 beats/min and 6-8 ml/Kg tidal volume (Vt) per predict body weight (PBW), and then modified according to PMI at a frequency of twice a day (morning and afternoon bedside rounds)# 1) Perform three end- inspiratory occlusions, with at least 1 minute between each measurement, and calculate the mean PMI. 2) Determine whether the PMI is within the target range (0≤PMI≤2cmH2O). 3) If the PMI is not within the target range, adjust the PS level up or down by 1-3 cmH2O and balance for 3-5 minutes. 4) Repeat the above steps until PMI reaches the target. 5) Additional: During PS adjustment, if Vt≤4ml/Kg, respiratory acidosis, respiratory distress, Vt≥8ml/Kg, respiratory alkalosis occurs, return to the safe PS level before adjustment and optimize other treatments.
223933059|NCT06769360|PROCEDURE|VT/RR-targeted PSV setting|Standard of care: the pressure support is adjusted to obtain a VT between 6 and 8 ml/kg PBW and RR between 20 and 35 breaths/min.
223933060|NCT06836336|BEHAVIORAL|Hybrid therapy|Hybrid intervention that combined face-to-face educational sessions with the integration of technological advancements. They attended weekly 40-minute interactive educational sessions over the course of a month. The educational materials encompass information regarding the components of a healthy balanced diet and an active lifestyle.Throughout the intervention, participants were provided with a range of behavior change techniques to support participants in applying the educational content to improve their dietary and lifestyle habits. The employed behavior change techniques were SMART (specific, measurable, achievable, relevant, time-bound) goal setting, reviewing behavioral goals, problem-solving and environmental restructuring. The technological support for this intervention included the use of a smartphone diet tracker app called MyFitneesPal as well as communication with the interventionists via WhatsApp.
224285567|NCT03133728|DIAGNOSTIC_TEST|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
224285568|NCT02921516|BEHAVIORAL|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
224285569|NCT02921516|BEHAVIORAL|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
224285570|NCT02921516|BEHAVIORAL|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
224285571|NCT05907148|OTHER|Sensory integration training|"Sitting position:~1. Sit in a chair without a backrest while the feet on firm surface. without backrest while the feet on soft surface.~2. Sit on a ball while the feet on firm surface. while feet on soft surface.~3. Sit in a chair without a backrest with the feet on firm surface and perform sit-to-stand motion.~   without a backrest with the feet on soft surface and perform sit-to-stand motion.~4. Sit on a ball with the feet on the firm surface and perform sit-to-stand motion. with the feet on the soft surface and perform sit-to-stand motion.~5. Perform bipedal standing on a firm surface. on a soft surface.~6. Perform a semi-tandem stance on firm surface. on soft surface.~7. Walk forward on firm surface. on soft surface.~8. Walk forward on firm surface, cross obstacle, and continue to walk.~9. Walk forward on the soft surface, cross obstacle, and continue to walk."
224285572|NCT05907148|OTHER|Routine physical therapy|It consist of active joint mobilization, muscle stretching, motor coordination exercises and general balance training
224285573|NCT05907148|OTHER|General coordination exercise|"In supine lying:~1. Patients are told to place heel of one leg on shin or knee of the other leg,~2. Patient bends one leg and extends the other leg like bicycling motion.~3. Flexing one leg while extending other leg~4. Flexing and extending of one leg while abduction and adduction of other leg.~In sitting:~1. Patient performs marching without backrest or back support,~2. Patient reaches forward and sideways with arms~3. Rotation of trunk with physioball in hand without back support.~4. Patient reaches with legs to marked point in sitting.~In standing:~Patient performs 10 repetitions of~1. Clock Reach~2. Side Leg Raises~3. Leg Swings and~4. Ball catch and throw"
224285574|NCT05904262|OTHER|Foot Sole Sensation Evaluation|Type 2 Diabetes Mellitus. In this prospective study based on face-to-face interview method; body fat (%), skeletal muscle mass (%) (with Omron BF511 Body Composition Monitor), waist and hip circumference, lower extremity muscle strength (for quadriceps and biceps muscles) (with muscle hand held dynamometer), It is planned to measure upper extremity muscle strength (grip strength) (with hand grip dynamometer), functional capacity (with 6 Minute Walk Test), postural stability, stability limits and sensory integration of balance (with Biodex Balance System®). In addition, individuals are expected to answer the questions of the International Physical Activity Questionnaire-Short Form (IPAQ) to evaluate their physical activity levels.
224285575|NCT01174667|PROCEDURE|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
224285576|NCT01174667|OTHER|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
224096730|NCT02793544|RADIATION|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"* 200cGy TBI is administered in twice daily on Days -3, -2, and -1.~* Radiation sources, dose rates, and shielding follow institutional practice."
223535316|NCT03855566|BEHAVIORAL|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
224096731|NCT02793544|DRUG|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"* Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~* Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~* Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~* Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
224096732|NCT02793544|DRUG|Sirolimus|"* Sirolimus dosing is based on adjusted IBW (Appendix K).~* Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~* A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects \< 18 years old:~* A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~* Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
223933061|NCT06836336|BEHAVIORAL|Fully digital|Fully digital intervention, where they received the same educational materials through WhatsApp twice a week over the course of one month. The educational materials were presented through easily understandable posters, brief videos, and followed by short quizzes to reinforce the acquired knowledge. Additionally, the digital intervention incorporated the same behavior change strategies that were utilized in the hybrid group. Participants were also introduced to MyFittnessPal application in order to help them track their dietary habits and monitor their progress since it is considered a tool for self-monitoring and promoting healthy dietary behaviors throughout the intervention period.
223933062|NCT05971602|DRUG|Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)|D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
224096733|NCT02793544|DRUG|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
224096734|NCT02793544|DRUG|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
224096735|NCT02793544|DRUG|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
224096736|NCT02793544|DRUG|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
224096737|NCT02793544|DRUG|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
224096738|NCT02793544|DRUG|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
224096739|NCT04174599|DRUG|F-627|Day 3 of each cycle, i.e., 48 ± 4 h after starting chemotherapy
224285577|NCT03408431|DEVICE|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
224285578|NCT03408431|PROCEDURE|neck extension|Patients' neck will be maximally extended (\~60°) during blind intubation.
223535317|NCT02845986|PROCEDURE|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
224285579|NCT00268515|DRUG|cyclosporine|
224285580|NCT00268515|DRUG|tacrolimus|
224285581|NCT00268515|DRUG|prednisone|
223535318|NCT02845986|DRUG|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
223933063|NCT05971602|DRUG|Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)|P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration
224285582|NCT00268515|DRUG|azathioprine|
224285583|NCT05652309|PROCEDURE|spinal block and obturator nerve block|spinal block and obturator nerve block
223533763|NCT04147273|DEVICE|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
223533764|NCT00003616|DRUG|irinotecan hydrochloride|
223933064|NCT05971602|DRUG|Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)|Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
223933065|NCT05971602|DRUG|Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)|X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration
224285584|NCT00328484|BEHAVIORAL|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
224285585|NCT00328484|BEHAVIORAL|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
223933066|NCT05971602|DRUG|Isoniazid and Rifampicin (HR)|Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
223933067|NCT06776042|OTHER|Nasal brushing of the olfactory cleft|Nasal brushing of the olfactory cleft
223933068|NCT06776042|OTHER|Smell testing|Smell testing using the Sniffin' Sticks Test
223533765|NCT04501432|OTHER|No intervention|This study does not include an intervention
223533766|NCT00859833|DRUG|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
223533767|NCT00859833|DRUG|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
223533768|NCT02493764|DRUG|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
223933069|NCT06750029|OTHER|Medical clown visits|The intervention is 15-minute visits from MCs twice daily during the first two days of admission. The clowns use various techniques to relax the patients (e.g. music, singing, playing, humor, guided imagination) and helpe encourage children to begin drinking and eating on their own.
223933070|NCT06774599|DEVICE|music combined with lavender essential oil group|listening of 30 mins ocean wave music, aromatherapy of lavender essential oil, and eye masks and earplugs.
223933071|NCT04452097|BIOLOGICAL|Human umbilical cord mesenchymal stem cells + best supportive care|hUC-MSC product will be administered intravenously in addition to the standard of care treatment.
223933072|NCT04452097|OTHER|Placebo control + best supportive care|Placebo control will be administered intravenously in addition to the standard of care treatment.
223933073|NCT06411132|OTHER|observational study|observational study
223933074|NCT02761187|OTHER|No Intervention|As this was an observational study, no intervention was administered.
223533769|NCT02493764|DRUG|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
223533770|NCT02493764|DRUG|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
223533771|NCT02493764|DRUG|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
223533772|NCT02493764|DRUG|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
223533773|NCT02493764|DRUG|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
223933075|NCT01297166|DRUG|LEO 27989 ointment|once daily application, 3weeks
223933076|NCT01297166|DRUG|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
223933077|NCT01297166|DRUG|Calcipotriol ointment|once daily application, 3weeks
223933078|NCT01297166|DRUG|Vehicle ointment|once daily application, 3weeks
223933079|NCT03978637|DRUG|Itacitinib|Itacitinib administered orally at the specified dose.
224285586|NCT00120276|DEVICE|Less invasive mitral valve repair|
223933080|NCT04731558|DRUG|enoxaparin or tinzaparin or dalteparin|Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
223933081|NCT04731558|DRUG|No intervention|No preoperative thromboprophylaxis.
223933082|NCT03184922|PROCEDURE|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
223933083|NCT06662123|DRUG|Anifrolumab|Participants will receive a single SC or IV dose of anifrolumab at day 1
223933084|NCT06828146|OTHER|a quasi-experimental one-group pretest-posttest design to evaluate the effectiveness of Freirean dialogue-based critical pedagogy in fostering social justice advocacy among nursing students.|a quasi-experimental one-group pretest-posttest design to evaluate the effectiveness of Freirean dialogue-based critical pedagogy in fostering social justice advocacy among nursing students.
223933085|NCT05929118|OTHER|Aquatic Rehabilitation|Reviewing the existing literature studies and related books, and combining the post-operative rehabilitation process of ACLR with the opinions of experts from the China Aquatic Rehabilitation Association, the Aquatic rehabilitation program of this study was designed.
223933086|NCT05929118|OTHER|Land-based Rehabilitation|Peking University Third Hospital Anterior Cruciate Ligament (ACL) Postoperative Rehabilitation Guidelines.
223933087|NCT03431818|OTHER|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
223933088|NCT06028334|BEHAVIORAL|GetUp&Go|A behavioral treatment combining personalized activity planning and a mobile health application for supporting adherence to activity plans.
223933089|NCT06028334|BEHAVIORAL|GetUp&Go with 10-Week Delay|No assigned treatment during the waitlist phase. Participants in the WL group will be offered the GetUp\&Go intervention, which combines personalized activity planning and a mobile health application, after collection of the primary outcome measure.
223933090|NCT06305364|DEVICE|Gixam|Participants will be required to extend their tongue in the Gixam device. Six images will be obtained and analyzed by the artificial intelligence (AI) model generating a prediction score for the presence of colorectal adenoma.
223933091|NCT06444152|OTHER|Sample analysis|This study is analyzing stored samples
223933092|NCT04909268|DIAGNOSTIC_TEST|HIV testing|serology for HIV testing
223933093|NCT06487572|DRUG|Risankizumab|Intravenous (IV) Infusion
223933094|NCT06487572|DRUG|Risankizumab|Subcutaneous (SC) Injection
223933095|NCT06740084|BEHAVIORAL|Y-MIND Intervention|All participants in the intervention arm will receive the EUC plus the Y-Mind intervention. Y-Mind intervention will be delivered by trained and supervised Guidance and Counselling Coordinators (GCC) at schools in 6 sessions. The six sessions will include a) psychoeducation on depression, b) behavioural activation (helping the participant see the connection between their behaviour, daily activities, and low mood and activity scheduling) and c) problem-solving therapy (the GCC helps the participant identify and define a specific problem to work on, evaluate the potential solutions to the problem, and carry out the selected solution(s)).
223933096|NCT06740084|OTHER|Enhanced Usual Care|Enhanced Usual Care (EUC): Guidance and counselling coordinators in the schools provide some counselling to students who need it. Building on the existing structure, enhanced usual care in the Y-mind programme, will be enhanced in three ways: 1) Teaching staff will receive basic training on common mental health conditions affecting youth in Ghana with an emphasis on depression and suicidal symptoms and treatment. The WHO guidelines for school health services will form the basis for the training for teachers. 2) Nurses in all schools and other relevant local health care professionals will be trained in mental health, substance-use and self-harm including guidelines on when and where to refer young people for psychiatric care. The World Health Organization (WHO) Mental Health Gap intervention guide (mhGAP) will be used for training of nurses and other health care professionals . 3) The study team will provide a letter for the Guidance and Counselling Coordinators for the participant.
223933097|NCT06498661|PROCEDURE|Biospecimen Collection|Undergo collection of cervical samples by clinician
223933098|NCT06498661|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy conducted by clinician
223933099|NCT06498661|PROCEDURE|Colposcopy|Undergo colposcopy conducted by clinician
223933100|NCT06498661|OTHER|Electronic Health Record Review|Ancillary studies
224096740|NCT04174599|DRUG|GRAN®|Since day 3 of each cycle, i.e., 48 ± 4 h after starting chemotherapy, continuous treatment for ≤ 2 weeks or until ANC recovers to 5.0 × 10\^9/L from nadir (investigators may refer to ANC test results from the Department of Laboratory Medicine of each study sites to decide when to discontinue GRAN®)
224096741|NCT06428045|PROCEDURE|Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)|Participants will be administered MR-guided Laser Interstitial Thermal Therapy (LITT) as a single procedure, following stereotactic needle biopsy.
224096742|NCT06428045|DRUG|Abacavir|Participants will take one 600mg tablet of Abacavir orally once daily, as part of combination antiretroviral therapy (ART).
224096743|NCT06428045|DRUG|Lamivudine|Participants will take one 300mg tablet of Lamivudine orally once daily, as part of combination antiretroviral therapy (ART)
224285587|NCT02188082|DRUG|IvabRadine hemisulfate Sustained-release Tablets|
224285588|NCT02188082|DRUG|placebo|
224285589|NCT02563821|PROCEDURE|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
223535319|NCT06049147|DRUG|MBF-015 4 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
224096744|NCT06428045|DRUG|Ritonavir|"Participants will take one tablet of Ritonavir (RTV) orally twice daily, as part of combination antiretroviral therapy (ART), at one of the following dose levels:~* Dose Level 1: 100mg~* Dose Level 2 (starting dose): 300mg~* Dose Level 3: 400mg~* Dose Level 4: 600mg"
224285590|NCT02563821|DRUG|Levobupivacaine|
224285591|NCT02563821|DRUG|sufentanil|
224285592|NCT02563821|DRUG|clonidine|
224285593|NCT02563821|DEVICE|epidural catheter|
224285594|NCT04979845|OTHER|Telerehabilitation|Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises
224285595|NCT04979845|OTHER|Video exercise|Patients will receive video instructions for home based exercises
224285596|NCT05187325|OTHER|no intervention|there is no intervention
223533774|NCT04883268|OTHER|Expand Your Horizon|Expand Your Horizon is an online programme, comprising three 15min writing exercises delivered over the course of 1 week. In each writing exercise, participants are asked to describe the functions of their body, and why those are personally meaningful to them.
223933101|NCT06498661|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage conducted by clinician
224096745|NCT06428045|DRUG|Temozolomide|Participants will take Temozolomide (TMZ) via capsule orally, during and after focal radiotherapy, as part of standard of care adjuvant therapy. During focal radiotherapy, Temozolomide will be administered at a dose of 75 mg/m2 once daily for six weeks (42 days) on a continuous dosing regimen, including weekends and holidays. After completion of focal radiotherapy, Temozolomide will be administered at 150 mg/m\^2 on days 1 through 5 of Cycle 1, and at 200 mg/m\^2 on days 1 through 5 of Cycles 2 through 6, for a total of six 28-day cycles of maintenance therapy.
224096746|NCT06428045|RADIATION|Focal Radiotherapy|Participants will be administered focal radiotherapy for six weeks (42 days), as part of adjuvant therapy, at a total dose of 50-60 grays (Gy) in 1.8-2.0 Gy fractions, depending on prognosis and as determined by the treating radiation oncologist.
224096747|NCT05090345|OTHER|Biorepository Trial|participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
223933102|NCT06498661|PROCEDURE|Excision|Undergo cervical excisional procedure conducted by clinician
223933103|NCT06498661|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal samples
224096748|NCT05638568|DIAGNOSTIC_TEST|LS test|If the LS test indicated surfactant deficiency based on the cut off ratio early surfactant treatment will be done for patients in the intervention group If the LS test indicated no surfactant deficiency routine surfactant treatment will be done as per European RDS guidelines based on oxygen requirement (FiO2 \> 0.30)
224096749|NCT04680650|DRUG|Anesthesia was maintained with sevoflurane|After endotracheal intubation, anesthesia was maintained with 1.5-3% sevoflurane, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DS.
224096750|NCT04680650|DRUG|Anesthesia was maintained with propofol|After endotracheal intubation, anesthesia was maintained with 2-4 μg/mL target-controlled infusion of propofol, 0.3-0.5 μg/kg/h dexmedetomidine and 2-4 μg/mL target-controlled infusion of remifentanil in the group DP.
224096751|NCT00217633|PROCEDURE|Conventional Surgery|
224096752|NCT00363961|BEHAVIORAL|Resistance exercise|resistance exercise vs sham comparison
224096753|NCT03437187|PROCEDURE|Cholecystectomy|Laparoscopic technique
224096754|NCT03399383|OTHER|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
224096755|NCT05922553|BEHAVIORAL|Active Ingredient Mukbang|Mukbang videos include the items which can truly improve the appetite of children with cancer, such as food images, eating sound and interactivity.
224096756|NCT05922553|BEHAVIORAL|General short videos|Short videos that don't contain any food cues.
224285597|NCT06679764|PROCEDURE|Anterior quadratus lumborum block technique (AQLB)|"AQLB performed in the lateral position. A low-frequency convex probe for the abdomen (2-5) MHz convex probe, (Siemens ACUSON X300 Ultrasound System) was placed horizontally above the iliac crest. On ultrasound, The psoas major was located on the ventral side of the transverse process, the erector spinae was located on the dorsal side of the transverse process, and the quadratus lumborum was located on the lateral side of the transverse process.~A 38-mm 22-gauge regional block needle was advanced in-plane from posterior to anterior directing the needle tip in the fascial plane between the psoas major and the quadratus lumborum that was confirmed by injecting 1 ml saline and watchingt the fluil fting the muscle while not distending any of the two muscles (hydro-localization). Then 30mL of local anaesthetic (29ml of 0.25% bupivacaine + 1 ml of dexamethasone (4mgs) was injected with observation of local anaesthesia spread in the fascial plane."
223933104|NCT06498661|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
223533775|NCT04929964|PROCEDURE|MRM , Toilet Mastectomy , BCS|MRM , modified radical mastectomy : removing breast and axilla toilet mastectomy : palliative removal of tumor load BCS ,Breast conservative surgery
223933105|NCT06498661|OTHER|Questionnaire Administration|Ancillary studies
223933106|NCT06498661|OTHER|Survey Administration|Ancillary studies
223933107|NCT06791200|DIAGNOSTIC_TEST|biochemical indices|some biochemical indices for prediction of Acute kidney Injury
223933108|NCT06889259|BEHAVIORAL|CBT based digital therapeutics|The mobile-based digital therapeutic intervention integrated video education, thought record sheets, and sound therapy. This comprehensive treatment was administered five times weekly. The program consisted of a total of 30 sessions.
223933109|NCT06889259|BEHAVIORAL|Conventional CBT|The cognitive behavioral therapy program for tinnitus, based on a paper manual, was administered five times per week. The treatment regimen consisted of a total of 30 sessions,.
224096757|NCT06821464|DRUG|HRS-9813|Initial dose to planned dose（low dose）
224096758|NCT06821464|DRUG|HRS-9813|Initial dose to planned dose（high dose）
224096759|NCT04863885|DRUG|Ipilimumab|Participants will receive Ipilimumab 3 mg/kg
224096760|NCT04863885|DRUG|Nivolumab|Participants will receive Nivoumab 1mg/kg
224096761|NCT04863885|DRUG|Sacituzumab govitecan|Participants will be treated at 1 of 2 dose levels of Sacituzumab govitecan, either at 8 mg/kg, 10 mg/kg, or 6 mg/kg.
224096762|NCT06645509|DRUG|TTB gel (dose 1)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
224096763|NCT06645509|DRUG|TTB gel (dose 2)|A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days
224096764|NCT06645509|DRUG|Placebo|A topical administration of a vehicle (Placebo) gel to both hands, once daily for 28 days
224096765|NCT04034017|OTHER|no intervention|descriptive study, no intervention
224096766|NCT01006343|OTHER|Higher Protein (HP)|
223933110|NCT06807320|DRUG|MTA pulp dressing material|MTA powder ( ProRoot; Dentsply ⁄ Tulsa Dental, Tulsa, OK,USA) was added to sterile water. The mixture was left to achieve a sandy consistency for about thirty seconds. Then, the material was applied to the cavity using a ball condenser.
223933111|NCT06807320|DRUG|Calcium Hydroxide (Ca(OH)2)|For Group I patients, Calcium hydroxide (Dycal\_ Ivory,Dentsply Caulk, Dentsply, L.D. Caulk, Milford, DE,USA ) was used. The catalyst and paste were mixed as per the manufacturer's recommendations.
223933112|NCT06867393|DRUG|HL-003 tablet Placeco|100mg、250mg、500mg、1000mg、1500mg，SAD
223933113|NCT06867393|DRUG|HL-003 tablet|25mg、100mg、250mg、500mg、1000mg、1500mg，SAD
223933114|NCT04725110|DRUG|Instilled T3|The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.
223933115|NCT04725110|OTHER|Placebo Therapy|A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
223933116|NCT03656081|DRUG|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
223933117|NCT03656081|DRUG|inhaled placebo|inhaled isotonic saline
223933118|NCT03656081|DRUG|Itraconazole|Itraconazole tablet
223933119|NCT05630833|DRUG|Gepotidacin|Gepotidacin will be administered.
223933120|NCT05630833|DRUG|Nitrofurantoin|Nitrofurantoin will be administered.
223933121|NCT05630833|DRUG|Placebo|Placebo will be administered.
223933122|NCT03654001|BIOLOGICAL|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
223933123|NCT03654001|OTHER|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
223933124|NCT06620276|BEHAVIORAL|Acceptance and Commitment Therapy|8 sessions of one hour of Acceptance and Commitment Therapy delivered one on one by a licensed psychologist with experience and training in this intervention.
223933125|NCT05214391|DRUG|Zanubrutinib|"The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate."
223933126|NCT06827444|OTHER|Placebo|Participants will be provided with a chest strap for heart rate measurement (the strap will be washed and disinfected after each session), connected to the Polar Beat app downloaded by the researcher. Subsequently, each participant will perform an initial 10-minute baseline warm-up session (a cadence of 70-80 RPM will be requested). From the cycle ergometer display, values for watts (the amount of work done per second), power (the amount of work done over a certain period of time), and speed (expressed in kilometers per hour) will also be extracted. During the test, no visual or verbal feedback will be provided. Participants will be blind to the cycle ergometer screen, so the data will not influence their behavior. Heart rate will be continuously recorded throughout the exercise period and during the participant's recovery. Participants will then be randomized to one of the following manipulations.
223933127|NCT03905694|DRUG|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
223933128|NCT03384238|PROCEDURE|Fluorescence Imaging|Undergo fluorescence imaging
223933129|NCT03384238|BIOLOGICAL|Panitumumab|Given IV
223933130|NCT03384238|DRUG|Panitumumab-IRDye800|Given IV
223933131|NCT05711550|DEVICE|Real Neurofeedback|Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
223933132|NCT05711550|DEVICE|Sham Neurofeedback|The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
224096767|NCT01006343|OTHER|Lower Protein (LP)|
223533776|NCT02468583|DRUG|FX006 32 mg|Experimental
223533777|NCT02468583|DRUG|TCA IR 40 mg|Comparator
223933133|NCT06575530|DRUG|Remimazolam Besylate|patients will be sedated with remimazolam via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if remimazolam fails to achieve a satisfactory RASS score (0 to -2 points) within its upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
223933134|NCT06575530|DRUG|Dexmedetomidine Hydrochloride|patients will be sedated with dexmedetomidine hydrochloride via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if dexmedetomidine fails to achieve a satisfactory RASS score (0 to -2 points) within the upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
223933135|NCT04384367|DRUG|Rizatriptan 10 mg + Naproxen 550mg|oral - single dose
223933136|NCT04384367|DRUG|Maxalt 10Mg Tablet|oral - single dose
223933137|NCT04384367|DRUG|Flanax 550mg|oral - single dose
223933138|NCT04384367|DRUG|Placebo oral tablet|oral - single dose
223933139|NCT06379750|OTHER|Nurse-delivered care using WelTel check-ins and BCC SMS|Nurse-delivered HTN, DM and CVD risk assessment, diagnosis and Management (through NIMONCD) using WelTel check-ins and BCC SMS
223933140|NCT06379750|OTHER|Community-based peer-support model|Community-based peer- support model using Weltel check-ins and BCC SMS and facilitated group self monitoring
223933141|NCT06817616|BIOLOGICAL|Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell|"Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 2.5X10 cells/0.5mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   \- High dose: 5X10 cells/1mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator"
223933142|NCT03680456|DRUG|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
223933143|NCT03680456|DRUG|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
223933144|NCT06534710|DEVICE|electronic moxibustion apparatus|The experimental group used the electronic moxibustion instrument every day on the basis of the control group
223933145|NCT05061316|DIETARY_SUPPLEMENT|Nestlé Impact Advanced Recovery|Immunonutrition drink that helps support the immune system: reduces risk of prolonged hospital stay and complications after surgery.
223533778|NCT01561976|DRUG|Metformin hydrochloride prolonged release|1000mg in fasting state
223533779|NCT01561976|DRUG|metformin hydrochloride prolonged release|1000mg in fed state
223533780|NCT01561976|DRUG|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
223533781|NCT00863161|DRUG|AZD3355|capsule, oral, single dose
223533782|NCT04124627|PROCEDURE|Ultrasound guidance in addition to radiographic guidance|Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
223535320|NCT06049147|DRUG|MBF-015 16 mg oral capsule|MBF-015 oral capsules Histone deacetylase inhibitor
223535321|NCT06049147|DRUG|Placebo|Hard gelatin capsules filled with cellulose microcrystalline
223535322|NCT05373485|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
223535323|NCT05373485|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
223535324|NCT03916809|OTHER|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
223535325|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
223535326|NCT01581684|DRUG|Placebo|Solution for oral administration
223535327|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
223933146|NCT06831721|BEHAVIORAL|Unstable Strength Training|Sixty-two participants were divided into an experimental group and a control group. 31 participants in the experimental group were in an unstable condition, with the help of unstable equipment such as BOSU balls, balance capsules and Swiss balls. The training program was designed according to the actual situation and characteristics of the participants to meet the characteristics of the volleyball sport. The remaining 31 participants in the control group underwent a conventional strength training routine.
223933147|NCT06773988|DIAGNOSTIC_TEST|Monitoring of NIV at home|Monitoring of NIV at home
223933148|NCT04041050|DRUG|Navitoclax|Tablet; Oral
223933149|NCT04041050|DRUG|Ruxolitinib|Tablet; Oral
223933150|NCT04041050|DRUG|Celecoxib|Capsule; Oral
223933151|NCT06759038|DEVICE|C-MAC blade D video laryngoscope|C-MAC blade D Video Laryngoscope is used for difficult intubation and for better glottic view
223933152|NCT06759038|DEVICE|Macintosh Laryngoscope|Macintosh Laryngoscope is conventional laryngoscope used generally for intubations
223933153|NCT03170349|DEVICE|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
223933154|NCT05783908|COMBINATION_PRODUCT|With non-magnetic screen|Radiotherapy treatment with Linac MRI is performed with a non-magnetic screen that will guide the patient to block the breathing
223933155|NCT04013152|OTHER|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
223933156|NCT05661136|DEVICE|Warm air blower|Lower body blanket with warm air blower set at 44 deg c started after spinal anesthesia when patient placed in supine/left lat position
223933157|NCT05661136|OTHER|Control: Lower body blanket not attached to warm air blower|Control: Lower body blanket placed, not attached to warm air blower
223533783|NCT04403919|DEVICE|Conventional Closure: Knee|Traditional closure will consist of arthrotomy (deep layer) closed with figure of eight number 1 vicryl plus followed by closure of the intermediate layer with 0 Vicryl plus. The intermediate layer will be performed at surgeon's discretion especially in thin patients. Subdermal layer with 2-0 vicryl suture followed by subcuticular 3-0 monofilament suture (monocryl PLUS, Ethicon; Johnson \& Johnson) and Dermabond advanced.
223933158|NCT06827639|PROCEDURE|blood collection|Blood sampling is performed during Scrrening / visit 1 for patients enrolled in cohort 1, cohort 2 and cohort 3
223933159|NCT06827639|PROCEDURE|tissue specimen collection|In Cohort 1- patients with solid tumor undergoing surgery, fresh tissue specimen is collected during surgery
223933160|NCT06830512|PROCEDURE|Echocardiography-guided percutaneous radiofrequency ablation for cardiac tumors|In the parasternal long-axis section, the cardiac puncture guide line was used to locate the puncture, and the best puncture path through the chest wall was selected. The coaxial biopsy needle was punctured through the guide frame, and then through the skin and subcutaneous tissue into the heart tumor tissue to take 2-10 biopsy samples, which were sent for pathological examination. The biopsy needle was extracted, and the radiofrequency electrode needle was punctured along the coaxial sheath to the planned ablation site of the heart tumor. The radiofrequency ablation device was started and the ablation treatment was performed.
223933161|NCT03750331|OTHER|Ap'Telecare|an internet application on a computer, tablet or smartphone
223933162|NCT03750331|OTHER|traditional schedule|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
223933163|NCT03868943|DRUG|Soliramfetol|Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
223933164|NCT06074575|BEHAVIORAL|Emotion induction|The participants will receive different emotion inductions through short video clips.
223933165|NCT04957342|DEVICE|amnion-chorion membrane|allograft to be placed on palate
223933166|NCT04957342|PROCEDURE|Sutures|Sutures (e.g. interrupted, crisscross compression) to be placed on palate
223933167|NCT06830070|OTHER|subjective pain score assessment|a questionnaire assessing subjective pain during surgery, using the Visual Analogue Scale with values from 0 to 10
223933168|NCT00833742|BEHAVIORAL|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
223933169|NCT04789070|DRUG|Sirolimus|Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
223933170|NCT04789070|DRUG|Placebo|Placebo
223933171|NCT06779552|DEVICE|CardioMEMS HF System|PA Pressure Sensor
223933172|NCT04782232|OTHER|No intervention|No intervention due to observational design
223933173|NCT06038032|BEHAVIORAL|Digital wellness platform|A digital wellness platform based on preventive self-care that contains tools to monitor nutrition, physical activity, and mental wellbeing will be accessed daily for 24 weeks.
223933174|NCT06038032|BEHAVIORAL|Online healthcare professional support|Individual sessions with a registered dietitian, an exercise professional, and a mental health therapist for 16 weeks.
223933175|NCT06826885|RADIATION|Postoperative radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed. A tumor bed boost will be provided to patients with high-risk factors following breast-conserving surgery, at the discretion of the radiation oncologist. The tumor bed boost regimen may consist of a sequential boost of 10-16 Gy (RBE) in 5-8 fractions, or 10-13.35 Gy (RBE) in 4-5 fractions or 10.4 Gy (RBE) in 2 fractions, or a simultaneous integrated boost of 48-49.5 Gy (RBE) in 15-16 fractions.
223933176|NCT06826885|RADIATION|Preoperative Radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the ipsilateral whole breast, chest wall, and/or regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions is preferred. A conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions is also allowed.
223933177|NCT06826885|RADIATION|Definitive Radiotherapy|Radiotherapy was delivered using IMPT or IMRT. The target volume encompassed the ipsilateral whole breast and regional lymph nodes. A hypofractionated regimen of 40-42.5 Gy (RBE) in 15-16 fractions was preferred. Alternatively, a conventional fractionated regimen of 45-50.4 Gy (RBE) at 1.8-2 Gy per fraction in 25-28 fractions or an ultra-hypofractionated regimen of 26 Gy (RBE) in 5 fractions was permitted. Dose escalation was applied in high-risk areas, resulting in a total prescribed dose exceeding 66 Gy (RBE) when calculated as equivalent doses in 2-Gy fractions (EQD2), with an α/β ratio of 4.
223933178|NCT06338293|DRUG|Inclisiran sodium|The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.
223933179|NCT06338293|DRUG|Rosuvastatin|Rosuvastatin
223933180|NCT06798415|DRUG|Metronidazole|"Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia will be added. The solutions will be injected intralesionally and not subcutaneously."
223933181|NCT06829654|OTHER|Step 1|Cryopreservation of ovarian tissue
223933182|NCT06829654|OTHER|Step 2|Analysis of tumor markers in the primary tumor
223933183|NCT06829654|OTHER|Step 3|Search for neoplastic cells in cryopreserved ovarian tissue
223933184|NCT06829654|OTHER|Step 4|Cryopreserved ovarian tissue autotransplantation
223933185|NCT05856396|BIOLOGICAL|Triaxis® (Pertussis-containing vaccine)|"Triaxis® (Pertussis-containing vaccine) will be administered:~* in non-pregnant women presenting to the Travel and Vaccine clinic for pertussis immunization only or hospital member staff requiring Tetanus Toxoid (TT)-booster immunisation~* in Pregnant women between 16 and 29 weeks of gestation."
223533784|NCT04403919|DEVICE|Barbed suture closure: Knee|The barbed suture closure will consist of number 2 Stratafix symmetric PDS PLUS for the arthrotomy, intermediate layer will be performed at surgeon's discretion in thin patients, if performed will entail stratafix spiral, subdermal 2-0 stratafix spiral monocryl plus. Followed by subcuticular 3-0 stratafix spiral monocryl plus suture and Dermabond advance.
223535328|NCT01581684|DRUG|BI 411034|Low dose solution for oral administration
223535329|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
223535330|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
223535331|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
223535332|NCT01581684|DRUG|BI 411034|High dose solution for oral administration
223535333|NCT01581684|DRUG|BI 411034|Medium dose solution for oral administration
223535334|NCT06095895|OTHER|venipuncture|An additional measurement of exposure of mycophenolic acid and/or tacrolimus will be performed
223535335|NCT03728933|DRUG|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm\^2) patch size).
223533785|NCT04403919|DEVICE|Conventional Closure: Hip|"1. The capsule will be closed with Vicryl Plus number 1~2. Deep fascia with figure of eight interrupted number 1 braided absorbable suture (Vicryl plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal fat layer simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl plus)~4. Subcuticular 3-0 monofilament suture (monocryl plus , Ethicon; Johnson \& Johnson)~5. followed by the use of skin adhesive (Dermabond Advanced, Ethicon; Johnson \&Johnson)."
223533786|NCT04403919|DEVICE|Barbed suture closure: Hip|"1. The capsule will be closed with stratafix symmetric PDS Plus~2. Deep fascia will be closed with Stratafix Symmetric PDS Plus (Stratafix symmetric PDS plus, Ethicon; Johnson \&Johnson, Somerville, NJ)~3. Subdermal layer with running number 2-0 barbed suture (stratafix spiral monocryl plus, Ethicon; Johnson \& Johnson, Somerville, NJ)~4. Subcuticular suture with stratafix spiral monocryl plus, Ethicon~5. followed by the use of skin adhesive (Dermabond advanced, Ethicon; Johnson \&Johnson)."
223933186|NCT05856396|BIOLOGICAL|Vaxelis® (Pertussis-containing vaccine)|Vaxelis® (Hexavalent vaccine) will be proposed in infants at 8, 12 and 16 weeks of life.
223933187|NCT06780124|DRUG|ZE63-0302 or placebo|The participants will receive ZE63-0302 or placebo
223933188|NCT06773650|OTHER|Completion of online survey|The online survey aims to reach a representative sample of the Italian population to identify their knowledge regarding LI
223933189|NCT06780631|OTHER|Web-based diabetic foot education based on health promotion model|The first group can access the training at any time and repeat the training thanks to web-based training.
223933190|NCT06780631|OTHER|Face to face diabetic foot education based on health promotion model|Individuals with Type 2 diabetes in the face-to-face training group will receive face-to-face diabetic foot training in line with the training booklet for approximately 45 minutes, one by one.
223933191|NCT06827977|DRUG|PRIM-DJ2727|"For oral administration, each dose will contain the number of capsules needed to deliver the lyophilized intestinal bacteria powder derived after lyophilization of 60 g of filtered stool in 300 mL 0.85% NaCl and 2% mannitol. Participants will take the capsules (5-6 capsules twice weekly) from week 2 through week 10. Capsules will be taken over a period of up to one hour to maximize tolerance and ensure the capsules are not expelled by vomiting.~For administration via retention enema, which will be done at baseline and week 11, 50 g of filtered, frozen stool in 250 mL of 0.85% sodium chloride (NaCl) will be used."
223933192|NCT06827977|DRUG|Placebo|Placebo will be administered as capsules from week 2-10 and as enema at baseline and week 11.
223933193|NCT05120947|RADIATION|42 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.2 Gy.
223933194|NCT05120947|RADIATION|39 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 4.875 Gy.
223933195|NCT05120947|RADIATION|32.5 Gy Radiation Therapy|Radiation Therapy: Dose per fraction of 6.5 Gy.
223933196|NCT06775418|PROCEDURE|Ultrasound erector spinae plane block|"Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group U (15 patients):will receive bilateral US guided single shot ESPB, 30 ml of bupivacaine 0.25% on each side after induction of anesthesia."
223933197|NCT06775418|PROCEDURE|dexamedotomidine infusion after induction of anesthesia|"Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group D (15 patients):will receive the study drug infusion (Dexmedetomidine) after induction of anesthesia."
223933198|NCT06922279|RADIATION|Radiation Therapy + standard sistemic therapy (chemoteraphy)|Standard systemic therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist considers most useful) + combination of RT on the primary gastroesophageal Gross Tumor Volume (GTV) + SBRT on each of the distal lesions for oligometastatic or limited metastatic spread patients (to be delivered prior to initiation of systemic therapy).
223933199|NCT06922279|DRUG|Standard systemic therapy (chemotherapy)|The patients will go to standard therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful.) without RT/SBRT combination
223933200|NCT04871594|DRUG|Nivolumab|On day 1, 22, and 43 240mg
223933201|NCT03636607|DIAGNOSTIC_TEST|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
223933202|NCT06758648|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|"Dynamic retinal vessel analysis (DVA) is an established, non-invasive technique for evaluating the responsiveness of retinal vessels to flickering light stimuli. This technique allows for the measurement of changes in retinal vessel diameter in response to changes in blood flow, providing insight into the microcirculatory function of the retina. In the case of DVA, patients will asked to focus on a needle, and one arteriole and venule diameter were automatically and continuously recorded. Arteriole and venule segments between 0.5 to 1 mm will be analyzed approximately 2-disc diameters away from the optic nerve in a lower-temporal direction. The baseline recording will be 50 seconds, followed by a flickering phase of 20 seconds and then a recovery period of 80 seconds. Three of these cycles were performed.~Based on this, we will calculate the percentage of maximum arteriolar (aFID) and venular dilation (vFID) to baseline."
223933203|NCT06758648|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Collection of blood samples from participants for the purpose of performing clinical chemistry analysis. Peripheral blood mononuclear cells (PBMCs) will be isolated from the collected blood samples using standard techniques, such as density gradient centrifugation, and will be analyzed using fluorescence-activated cell sorting (FACS)
223533787|NCT03630146|BEHAVIORAL|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
223533788|NCT03630146|OTHER|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
223533789|NCT03109405|DEVICE|Stimulation-assisted venous access|Stimulation-assisted venous access
223533790|NCT03109405|OTHER|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
223933204|NCT06758648|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|This study involves a comprehensive evaluation of life quality, pain, and gastrointestinal (GI) symptoms using a set of established and validated questionnaires. The tools employed include the SF-36 (Short Form-36 Health Survey) to assess overall health-related quality of life across multiple domains, the COMPASS-31 (Composite Autonomic Symptom Score) to evaluate autonomic dysfunction symptoms, and the Brief Pain Inventory (BPI) to measure pain severity and its impact on daily activities. Additionally, the Gastrointestinal Symptom Rating Scale (GSRS) is used to quantify the severity and frequency of GI symptoms, covering dimensions such as reflux, abdominal pain, indigestion, diarrhea, and constipation. Together, these questionnaires provide a multidimensional assessment of the patient's physical, emotional, and symptomatic experiences, allowing for a robust understanding of their health status and quality of life.
223933205|NCT06758648|DIAGNOSTIC_TEST|Cardio MRI|Cardiovascular magnetic resonance imaging (CMR or cardio MRI) will be utilized in patients with Fabry disease. This imaging technique will enable detailed assessment and monitoring of key cardiac abnormalities, including thickening of the heart walls, left ventricular hypertrophy, and decreased blood flow in the coronary vessels. Additionally, T1 relaxation time measurement will be conducted, offering a non-invasive means to detect myocardial tissue abnormalities such as fibrosis and sphingolipid accumulation, which are hallmarks of Fabry disease. Together, these measures provide a comprehensive evaluation of cardiac structure, function, and tissue characteristics in affected patients.
223933206|NCT06758648|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) is a non-invasive, high-resolution imaging technique that utilizes low-coherence light to capture cross-sectional images of the ocular fundus. Based on the principle of interferometry, OCT employs low-coherence light, which is scattered by the tissue, to produce detailed, high-resolution images of the retina and its layers. This technology enables precise visualization of the different retinal layers, including the nerve fiber layer, the ganglion cell layer, and the inner and outer plexiform layers. Additionally, OCT can be used to detect and monitor subtle structural changes in the retina, offering critical insights into retinal microarchitecture and potential manifestations of systemic diseases such as Fabry disease.
223933207|NCT06758648|DIAGNOSTIC_TEST|Echocardiography|Detection of signs of left ventricular hypertrophy, diastolic dysfunction, and valvular disease, which are common cardiac complications associated with Fabry disease, will be a key focus of the assessment. These abnormalities are indicative of the progressive cardiac involvement characteristic of the disease. Left ventricular hypertrophy reflects the thickening of the heart muscle, often caused by sphingolipid accumulation, while diastolic dysfunction highlights impaired relaxation and filling of the left ventricle. Valvular disease, including regurgitation or stenosis, further contributes to the cardiac burden in Fabry disease. Identifying and monitoring these conditions are essential for timely intervention and effective management of cardiac manifestations in affected patients.
223933208|NCT06758648|DIAGNOSTIC_TEST|24 hour pulse wave analysis|Pulse wave analysis (PWA) is a non-invasive method used to assess the cardiovascular system. It uses a sensor to measure the pressure waves generated by the heart's contraction and the subsequent blood flow through the peripheral vessels. By analyzing these pressure waves, PWA can provide information about the elasticity of the arterial walls, the blood flow in the peripheral vessels, the blood pressure, and the arterial stiffness.
223933209|NCT06758648|DIAGNOSTIC_TEST|24-hour blood pressure measurement|Blood pressure measurement to asses cardiovascular risk.
223933210|NCT06758648|DIAGNOSTIC_TEST|1 hour ECG|One hour ECG to asses autonomic dysfunction in patients with Fabry disease.
223933211|NCT06758648|DIAGNOSTIC_TEST|Ophthalmological consultation|Evaluation and monitoring of ocular manifestations of Fabry disease.
223933212|NCT06758648|DIAGNOSTIC_TEST|Static retinal vessel analysis (SVA)|"Comparable to DVA, SVA is a non-invasive and quick tool to examine the retinal microvasculature. SVA pictures will be analyzed using Vesselmap 2® (IMEDOS Systems GmbH, Jena, Germany). One eye will be examined, and three images will be taken with a focus on the optic disc at an angle of 50°. Roughly one disc diameter away from the optic disc, retinal veins and arterioles segments will be semi-automatically labeled. The Paar-Hubbard formula averages the central retinal arteriolar (CRAE) and central venular (CRVE) equivalents.~The arteriolar-venular ratio will be calculated as CRAE/CRVE."
223933213|NCT06758713|BIOLOGICAL|CAR-T|CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.
223933214|NCT06813794|BEHAVIORAL|Gain- Framed Messages|Patients will be recruited to whatsapp group based on gain framing about diabetic foot care skills. Gain framing messages and videos will be delivered to patients via whatsapp 3 times a week for 3 months.
223933215|NCT06813794|BEHAVIORAL|Lost Framed Messages|Patients will be included in whatsapp group based on Lost framing about diabetic foot care skills. Patients will receive loss framing messages and videos 3 times a week for 3 months via whatsapp.
223535336|NCT03728933|DRUG|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm\^2) patch size).
223535337|NCT03728933|DRUG|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
223535338|NCT04236999|BEHAVIORAL|Yo Sé Lo Que Quiero (YSLQQ)|"This program is organized in 12 sessions around three themes:~* Knowledge and attitudes (sessions 1, 3, 5 and 9): Students reflect on their knowledge of legal and illegal drugs, using critical thinking to obtain an objective assessment of this knowledge.~* Intrapersonal skills (sessions 4, 6, 8, 10. 11. and 12): Activities are carried out where students can put themselves in everyday situations and develop skills such as assertiveness, problem solving, among others.~* Interpersonal skills (sessions 2 and 7): Students are instructed to practice refusal skills, assertiveness, and analyze coping strategies."
223535339|NCT01784029|DRUG|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
223535340|NCT04551300|DRUG|VS-505|4 dosages of experimental drug
223535341|NCT04551300|DRUG|Sevelamer Carbonate|Active Comparator
223535342|NCT02838641|DEVICE|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
224285598|NCT06679764|PROCEDURE|Pericapsular Nerve Group (PENG) block|With the patients in supine position, A low-frequency convex probe (2-5 MHz) in was placed in a transverse plane over the anterior inferior iliac spine and then it was rotated 45 degrees in counter-clockwise direction to be aligned with the pubic ramus. In this view, the ilio-pubic eminence, iliopsoas muscle tendon, femoral nerve and vessels was observed. With in-plane approach, a 38-mm 22-gauge (22-G, 50-mm) regional block needle inserted in-plane, from lateral to medial to place the needle tip underneath the iliopsoas tendon, exactly between the ilipsoas fascia anteriorly and the pubic ramus posteriorly. Following negative resistance and aspiration tests, correct location of the needle tip was confirmed by injecting 1 ml saline. Then, 30mL of local anaesthetic (29ml of 0.25% bupivacaine+ 1ml of dexamethasone (4mgs) was injected while observing for adequate fluid spread.
223533791|NCT00579644|DRUG|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
224285599|NCT06679764|DRUG|Control Group|Pataints received opioid analgesia with genaral anesthesia
223533792|NCT00579644|DRUG|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
223933216|NCT06778473|DEVICE|Active Intradermal Acupuncture|"Depending on acupoints' location, φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Insert the Active IA vertically into the acupoint and retain it in the skin.~Active IA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be required to press the Active IA 4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours."
223933217|NCT06778473|DEVICE|Sham Intradermal Acupuncture|Sham intradermal acupuncture will be attached to the acupoints and retained for 72 hours with a day's rest after removal. During the period of sham needle retention,pressing times and frequencies are identical to those in the active intradermal acupuncture group.
223933218|NCT06778473|OTHER|Guided self-rehabilitation management program|Self-rehabilitation techniques are taught in individual sessions of about 40 minutes at each outpatient clinic visit, as detailed below: Analysis of the problem, Education, Massage, Facial muscles exercise,Synkinesis or spasticity management, Homework. Participants are requested to perform daily facial muscle exercises as prescribed by the therapist and keep the written diary on a daily basis. The therapists retrieve and evaluate the diaries at each visit.
223933219|NCT06778473|OTHER|Health Education|Health education knowledge about the disease such as etiology, pathology,clinical symptoms of Bell's palsy, Bell's palsy diagnosis and role of medical tests;medication education;complications and sequelae,etc
223933220|NCT04036812|PROCEDURE|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
223933221|NCT04036812|OTHER|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed with infusion of 10 ml normal saline.
223933222|NCT04557501|DIAGNOSTIC_TEST|PSMA PET/CT guided intensification of therapy|PSMA PET/CT prior to treatment.
223933223|NCT04557501|OTHER|Control Arm|Control - Treatment without PSMA PET/CT
223933224|NCT06352632|DRUG|Standard-dose intravenous tenecteplase|Standard-dose intravenous tenecteplase (0.25 mg/kg body weight); one-time IV bolus injection soon after randomisation
223933225|NCT06352632|DRUG|Low-dose intravenous tenecteplase|Low-dose intravenous tenecteplase (0.18 mg/kg body weight); one-time IV bolus injection soon after randomisation
223933226|NCT06352632|OTHER|No intravenous tenecteplase|No intravenous tenecteplase only in subjects on direct oral anticoagulant (DOACs) or those planned for emergency endovascular thrombectomy (EVT)
224285600|NCT05306951|DIAGNOSTIC_TEST|Computed tomography|Head computed tomography
224285601|NCT06739304|BEHAVIORAL|Mindfulness-based Relapse Prevention|250 adult USD females of Intervention group received the 8-week Group mindfulness intervention performed by psychiatrists.
224285602|NCT01084018|BEHAVIORAL|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
223933227|NCT06352632|OTHER|Conservative Blood Pressure Control|No or minimal Systolic Blood Pressure (SBP) control; SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP (≥180mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
223933228|NCT06352632|OTHER|Moderate Blood Pressure Control|SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP (150-160mmHg); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
223933229|NCT06352632|OTHER|Intensive Blood Pressure Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher after endovascular thrombectomy (EVT); the timing of administration of interventions is specified to be immediately after randomisation; the intervention target is to be achieved ideally at 1 hour after randomisation and maintained for 24 hours (or until hospital discharge or death if this should occur earlier)
223933230|NCT06352632|OTHER|Placebo|100 mL of 0.9% normal saline, administered as a single IV infusion with a 20-minute dosing duration.
223933231|NCT06352632|DRUG|NoNO-42|NoNO-42 at weight-based dosing - 2.6 mg/Kg, administered as a single IV infusion with a 20-minute dosing duration
223933232|NCT06352632|OTHER|No deferoxamine mesylate and no colchicine|No deferoxamine mesylate and no colchicine
223933233|NCT06352632|DRUG|Deferoxamine mesylate only|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days
223933234|NCT06352632|DRUG|Colchicine only|0.5mg of oral colchicine daily for 30 days
223933235|NCT06352632|DRUG|Both deferoxamine mesylate and colchicine|Deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days
223933236|NCT06230510|BEHAVIORAL|Introduction of Milk Type|Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
223933237|NCT06230510|BEHAVIORAL|Child Nutrition Counseling|Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
223933238|NCT05995795|DEVICE|ARTHROSCOY|arthroscopy
223933239|NCT04255316|PROCEDURE|Modified method of eversion carotid endarterectomy|Mini approach for CCA bifurcation - Clamping ICA, ECA and CCA - ICA is cut off with a scalpel at the mouth itself - Dissection of the ICA and ECA in the distal direction to the distal border of the atherosclerotic plaque - Endarterectomy - Performing of a new bifurcation of the CCA with prolene 7/0
223933240|NCT04255316|PROCEDURE|Standard method of eversion carotid endarterectomy|standard eversion technic
224096768|NCT04870424|DRUG|Colchicine|Colchicine in a loading dosage of 1mg single dose per os the day before TAVI and 1mg single dose at the day of procedure. Thereafter, colchicine 0.5mg once daily per os up to post-procedural day 12.
223933241|NCT03871439|DRUG|PF-05221304 Formulation A|50mg
223933242|NCT03871439|DRUG|PF-05221304 Formulation B|50mg
223933243|NCT05429164|OTHER|Self Myofascial Release|In the self-myofascial release technique, a tennis ball will be placed on the 4th rib on the shoulder side to be applied on the wall, and the participants will be asked to move the ball using their body along the pectoralis minor.
223933244|NCT05429164|OTHER|Myofascial Release|A slight caudal force will be applied by the physiotherapist until the pectoralis minor muscle meets the comfortable elastic limit of the soft tissue.
223933245|NCT05429164|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument-assisted soft tissue mobilization will be performed with the specified instruments for the pectoralis minor muscle.
224096769|NCT04870424|DRUG|Placebo|Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.
224096770|NCT06466733|PROCEDURE|Embolization of the middle meningeal artery|Embolization of the middle meningeal artery ipsilateral to the chronic subdural hematoma is performed infusing embolic polyvinyl alcohol (PVA) microparticles.
224096771|NCT06466733|PROCEDURE|Surgical Evacuation via burr hole or craniotomy|The standard of care for chronic subdural hematoma, burr hole or craniotomy are performed ipsilateral to the lesion.
224285603|NCT01507090|DEVICE|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
224285604|NCT06905548|BEHAVIORAL|climate change awareness training|The climate change training planned for nurse managers consists of 4 sessions of 2 days, each lasting 40 minutes.
224285605|NCT06905782|PROCEDURE|AI chatbot study arm|Intervention arm will have to undergo bowel preparation using standard polyethylene glycol solution (Fortrans)
224285606|NCT06905782|PROCEDURE|Traditional counselling study arm|Intervention arm will have to undergo bowel preparation using standard polyethylene glycol solution (Fortrans)
224285607|NCT06903871|DRUG|TORIPALIMAB INJECTION(JS001 )|Participants will receive toripalimab 240 mg IV once every 3 weeks. Treatment continued until disease progression, death, unacceptable toxicity, investigator decision, withdrawal, or completion of 1 years of treatment, whichever occurred first.
223933246|NCT02432300|BEHAVIORAL|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
223933247|NCT01266369|DRUG|masitinib|
223933248|NCT01792557|DRUG|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
223933249|NCT01792557|PROCEDURE|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
223933250|NCT01792557|PROCEDURE|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
223933251|NCT01792557|PROCEDURE|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
223933252|NCT00395759|DRUG|Optiva artificial tear by Allergan|
223933253|NCT04213807|BIOLOGICAL|MAA868 Cohort 1|Subcutaneous injection: low dose
223933254|NCT04213807|BIOLOGICAL|MAA868 Cohort 2|Subcutaneous injection: high dose
223933255|NCT04213807|BIOLOGICAL|MAA868 Cohort 3|Subcutaneous injection: Dose to be determined.
223933256|NCT04213807|OTHER|Placebo|Subcutaneous injection: Placebo
223933257|NCT03784170|DEVICE|FemPulse System|Device therapy with the FemPulse System
223933258|NCT02809755|DRUG|4% Lidocaine|
223933259|NCT02809755|OTHER|Saline|
223933260|NCT03987243|BEHAVIORAL|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
224285608|NCT06904989|DEVICE|Silicone orthosis|"in addition to standard treatment, shoe and insole treatment, a new type of treatment for CIPN is being evaluated, a silicone orthosis.The silicone orthosis consists of a half-sock designed for indoor use.~The participants feet are examined, and the foot shape is scanned barefoot using a three-dimensional foot scanner from Volumental. This is performed to use a basis for manufacturing individual silicone orthoses. Activity measurement with an activity sensor, attached to the thigh with tape, is planned for two weeks after receiving the assistive device.~Participants who receive a silicone orthosis are asked to keep a diary of how much they have used it. The follow-up takes place at the Oncology Department 3-6 weeks after the participant has received the assistive device."
224285609|NCT06904989|DEVICE|Standard Treatment|"The standard treatment is that patients are provided with customized insoles and shoes. Foot status is recorded during the orthopedic technical assessment at OTA, identifying signs of neuropathy, impaired blood circulation, foot deformities, and skin pathologies. A modified version of the validated D-Foot instrument is used to assess the risk of foot ulcers, especially in diabetic patients. The evaluation also includes lower extremity function, gait abnormalities, and existing footwear and insoles.~Differences in foot anthropometry are compared between scanned foot measurements of the study group and those of a control group representing a female Swedish normal population.~ActivePal is a reliable method for measuring and classifying activity levels. Activity measurement is conducted over two weeks."
223933261|NCT03987243|OTHER|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
223933262|NCT05596331|OTHER|eye-tracker|Eye-tracker recordings of eye movements, gaze direction and pupillary reactivity
223933263|NCT02866942|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
223933264|NCT01143142|BEHAVIORAL|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
223933265|NCT00862030|PROCEDURE|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
223933266|NCT02917512|DRUG|HU00701|Cyclosporine 0.01% + 3% trehalose
223933267|NCT02917512|DRUG|HU007|Cyclosporine 0.02% + 3% trehalose
223933268|NCT02917512|DRUG|Restasis|Cyclosporine 0.05%
223933269|NCT02917512|DRUG|Placebo|Vehicle
223933270|NCT02854241|PROCEDURE|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
223933271|NCT02854241|PROCEDURE|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
223933272|NCT02854241|PROCEDURE|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
223933273|NCT04752072|BEHAVIORAL|Enhanced Skills Training in Affective and Interpersonal Regulation|"The first (formulation) session enables linking present difficulties and traumatic events, identifying current issues/concerns, and collaboratively agreeing on the order of modules based on symptom severity and client readiness.~The PTSD module provides narrative exposure to the traumatic memories and targets re-experiencing, avoidance and hyperarousal symptoms. The AD module focuses on identifying and labelling feelings, emotion management, distress tolerance, acceptance of feelings and experiencing positive emotions. The NSC module focuses on staying in the present moment and combating dissociation; self-compassion and mindfulness skills; challenging thinking patterns and developing a balanced view of self. The DR module focuses on exploring and revising maladaptive schemas; effective assertiveness; awareness of social context; and flexibility in interpersonal expectations and behaviours displayed in social interactions."
223933274|NCT04752072|BEHAVIORAL|Treatment as usual|The first session will involve a mental health assessment by either a psychiatrist or psychologist. A treatment package will be developed based on the information collected during the assessment. Details of the interventions delivered to each participant receiving TAU, which will include elements of psychoeducation, symptom-management and trauma-focused cognitive behaviour therapy, will be recorded.
223933275|NCT03614663|DRUG|ZYN002 - Cannabidiol Transdermal Gel|Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
223933276|NCT03614663|OTHER|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
223933277|NCT04039906|DEVICE|Removal of needle with using ANDYs|"1. ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~2. Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~   Identify the number of syringes processed by ANDY.~3. After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
223933278|NCT05604755|DRUG|HQP1351( Olverembatinib dimesylate)|HQP1351 was initiated at a dose of 40mg every two days
223933279|NCT06275659|DEVICE|CT-100-004-A|Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
223933280|NCT06275659|DEVICE|CT-100-004-B|The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
224096772|NCT06265558|PROCEDURE|Negative pressure therapy (NPT)|Negative pressure therapy (NPT) involves placing the surface of a wound under a pressure lower than the ambient atmospheric pressure. To achieve this, a specially designed dressing is connected to a vacuum source and an exudate collection system.
224096773|NCT06265558|PROCEDURE|Dressing|Fatty dressing or hydrocellular dressing
224096774|NCT04828226|DRUG|Clonidine|Clonidine 2mcg/kg Body Weight diluted in 100ml sodium chloride 0.9% compared to placebo (sodium chloride 0.9% alone) given over 10 minutes, 10 minutes prior to electroconvulsive therapy.
224285610|NCT06904742|DRUG|Tea tree oil|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily . Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s. In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
224285611|NCT06904742|DRUG|Thyme oil hydrosol|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily (Santi et al., 2019). Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s (Santi et al., 2019). In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
224096775|NCT04828226|DRUG|Placebo|Sodium chloride 0.9% 100ml given over 10minutes, 10 minutes prior to electroconvulsive therapy.
224096776|NCT05293249|COMBINATION_PRODUCT|dMAb AZD5396|Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
223533793|NCT03923868|DRUG|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
224096777|NCT05293249|COMBINATION_PRODUCT|dMAb AZD8076|Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.
224096778|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
224285612|NCT06904742|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Our study's findings might have a important impact on the field of periodontology, providing valuable insights into the potential of herbal mouthwashes as an adjunct to NSPT in gingivitis treatment. A literature review reveals that regarding the mouthwash protocols, most studies mentioned use twice daily. Most studies used 10-15 ml as a dose, and rinsing time ranged from 30-90 s . In this study, similar to the literature, patients were prescribed to rinse twice daily, 15 ml for 30 s. The operator explained information about oral hygiene practices at baseline. With this approach, adequate mechanical cleaning action was obtained, and participants became more aware of importance of oral hygiene. Low scores of PI and GI in placebo group at 3rd month can be attributed to this interaction and can mask the maximum effects of herbal mouth rinses.
223533794|NCT01156844|DRUG|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
223533795|NCT01156844|DRUG|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
223933281|NCT03980613|OTHER|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
223933282|NCT05953363|DEVICE|BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes|Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
223933283|NCT04147637|COMBINATION_PRODUCT|FreeStyle Libre with MiaoMiao|Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
224285613|NCT06904742|DRUG|Placebo|Placebo mouthwash had been used in 13 patients for 3 months
224285614|NCT06904898|DEVICE|Cougar LS/Syncage ALIF or CONDUIT LLIF/ALIF cage|Comparison between cages to determine the effectiveness and cost related to the study procedures.
223933284|NCT04147637|DEVICE|FreeStyle Libre alone|Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
223933285|NCT00702884|DRUG|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
223933286|NCT01841671|BIOLOGICAL|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
223933287|NCT01841671|BIOLOGICAL|bOPV|As indicated
223933288|NCT01841671|BIOLOGICAL|mOPV type 2|Administered at 28 weeks of age to all study participants
223933289|NCT01841671|BIOLOGICAL|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
223933290|NCT05220111|PROCEDURE|Cardiac surgical operation (valve, aorta, coronary arteries)|Quality of life assessment using EQ-5D-3L
224285615|NCT06903858|DRUG|Toripalimab combined with celecoxib|Toripalimab is administered via intravenous infusion at 3 mg/kg over 30 minutes (initial infusion time is 60 minutes), once every two weeks, for a total of 12 doses before surgery. Celecoxib is taken orally at 200 mg per dose, twice daily, for a duration of 6 months.
224285616|NCT06903858|PROCEDURE|Curative resection of colorectal cancer|Patients who do not achieve cCR based on radiographic imaging (CT/MRI of chest, abdomen, pelvis, and rectal MRI), endoscopy, and digital rectal examination (if applicable) are recommended to undergo curative resection of colorectal cancer.
224285617|NCT06903858|OTHER|Watch-and-wait strategy|Patients achieving clinical complete response (cCR) based on radiographic imaging (CT/MRI of chest, abdomen, pelvis, and rectal MRI), endoscopy, and digital rectal examination (if applicable) are recommended to adopt a watch-and-wait strategy.
223933291|NCT04900467|BIOLOGICAL|Pfizer|BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
223933292|NCT04900467|BIOLOGICAL|Moderna|mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
223933293|NCT02185794|DRUG|Voxilaprevir|Voxilaprevir tablets administered orally once daily
223933294|NCT02185794|DRUG|Placebo to match voxilaprevir|Placebo to match voxilaprevir tablets administered orally once daily
223933295|NCT02185794|DRUG|SOF/VEL|400 mg/100 mg FDC tablet administered orally once daily
223933296|NCT03406169|DRUG|Sildenafil 25 MG Oral Tablet|twice a day dosing
223933297|NCT03406169|DRUG|Pentoxifylline|400mg twice a day
223933298|NCT03406169|OTHER|Placebo|placebo twice a day
224096779|NCT05293249|DRUG|Hylenex|Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.
224096780|NCT05293249|COMBINATION_PRODUCT|CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device|The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.
224096781|NCT05723484|DEVICE|GIFT Device|The GIFT device - immune-based lateral flow test for reproductive-aged, non-pregnant in resource-limited settings attending sexual reproductive health (family planning) clinics, community health centers, hospitals, and mobile clinics. The test involves the qualitative detection of genital inflammation caused by asymptomatic STIs and BV in self- or clinician-collected lateral vaginal wall swabs, with results available in less than 20 minutes.
223533796|NCT06446583|OTHER|Chewing sugar-free gum|Upon arrival at the preoperative preparation room, patients begin chewing sugar-free gum provided by the preoperative nurse. They continue chewing until they enter the operating room (for at least 15 minutes). Before entering the operating room, it is confirmed that the gum has been discarded.
223535343|NCT03496116|OTHER|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
223535344|NCT01317992|DRUG|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
223533797|NCT03264144|BEHAVIORAL|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
223933299|NCT05141136|PROCEDURE|Ultrasound probe sagittal group|Place the ultrasound probe vertically against the patient's spine and insert the needle in-plane. The width of insertion of the needle is usually approximately 5 cm from the midline. After the needle penetrates the superior costovertebral ligament and pops, when it reaches the thoracic paravertebral space, perform aspiration and inject 10 mL of 1% lidocaine. At this time, it can be observed in real time as the infusion fluid pushes the bright pleura away from the needle.
223933300|NCT05141136|PROCEDURE|Ultrasound probe transverse group|Place the ultrasound probe transverse to the spine and insert the needle in-plane. The reflection of a transverse process is a common landmark. The needle goes in from lateral to in plane. The goal is a triangle between the parietal pleura anteriorly and the internal intercostal membrane and intercostal muscle posteriorly. The final point of the needle is the transition zone from the intercostal to the thoracic paraspinal space, just anterior to the transverse process. When it is confirmed that the tip of the needle has reached the paravertebral space, 10 mL of 1% lidocaine is injected after checking the negative pressure, and after confirming the spread of the drug in real time with ultrasound.
223533798|NCT01726764|OTHER|St John's Wort|
223933301|NCT00073372|DRUG|Abciximab|
223933302|NCT04720612|BIOLOGICAL|Omalizumab|Single subcutaneous dose of 375mg of omalizumab and standard of care.
223933303|NCT04720612|OTHER|Placebo|Single subcutaneous dose of normal saline in a syringe identical to that of the omalizumab arm and standard of care.
223933304|NCT06151301|DIAGNOSTIC_TEST|serum procalcitonin|predicting the severity of intoxication
223933305|NCT06151301|DIAGNOSTIC_TEST|C-reactive protein|predicting the severity of intoxication
223933306|NCT01064999|DRUG|Oxaliplatin|CRT:50mg/m2,IV,weekly\*5 cycle CT: 130mg/m2,IV,d1,q 21 day
223933307|NCT01064999|DRUG|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
223933308|NCT01064999|RADIATION|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
223933309|NCT01064999|PROCEDURE|Surgery|Lower anterior resection or abdominoperineal resection
223933310|NCT01319838|DRUG|Isotretinoin|\>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
223933311|NCT00336505|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
223933312|NCT00336505|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
223933313|NCT04155905|PROCEDURE|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures
223933314|NCT04155905|PROCEDURE|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
223933315|NCT05909670|BEHAVIORAL|Family Advice and Support Text and Telephone (FASTT) program|The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
223933316|NCT04407884|DEVICE|Soovu Labs Inc. Pain Relief System|Longnitual follow-up
223933317|NCT01092416|DEVICE|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
223933318|NCT01624493|DRUG|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
223933319|NCT01624493|DRUG|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
223933320|NCT01624493|DRUG|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
223933321|NCT01624493|DRUG|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
223533799|NCT01726764|DRUG|Metformin|
223533800|NCT02249078|DRUG|E6011|E6011 solution for injection
223533801|NCT02249078|DRUG|Placebo|Placebo 2-mL vial solution for injection
223933322|NCT01624493|DRUG|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
223933323|NCT01939691|DRUG|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
223933324|NCT01939691|DRUG|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
223933325|NCT01939691|DRUG|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
223933326|NCT01185041|DIETARY_SUPPLEMENT|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
223933327|NCT02877641|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
223933328|NCT02877641|OTHER|Laboratory Biomarker Analysis|Correlative studies
223933329|NCT02877641|DIETARY_SUPPLEMENT|Multivitamin|Given PO
223933330|NCT02877641|OTHER|Placebo|Given PO
223933331|NCT02877641|OTHER|Questionnaire Administration|Ancillary studies
223933332|NCT05535959|DRUG|VX-121/TEZ/D-IVA|FDC tablet for oral administration.
223933333|NCT03067857|BIOLOGICAL|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
223933334|NCT05465018|DEVICE|Happy Flow / Baseline|Baseline (without make-up or mask)
223933335|NCT05465018|DEVICE|Make-up|To test device on participant who is wearing facial make-up
223933336|NCT05465018|DEVICE|Sunglasses|To test device on participant who is wearing sunglasses
223933337|NCT05465018|DEVICE|Face mask|To test device on participant who is wearing a facial mask
223933338|NCT05465018|DEVICE|Minimum requirements camera|To test the minimum requirements of the camera
223933339|NCT05465018|DEVICE|Worst case hardware|To test if software still works with an older smartphone
223933340|NCT05465018|DEVICE|Damaged lens|To test if software is still working when the lens of the smartphone is damaged
223933341|NCT05465018|DEVICE|Face or chest outside test frame|To test software if the participants face or chest is outside the test frame
223933342|NCT04046159|DRUG|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
223933343|NCT04046159|RADIATION|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
223933344|NCT02005159|OTHER|Microbiological studies|
223933345|NCT04169256|DRUG|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
223933346|NCT04169256|DRUG|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
223933347|NCT04169256|OTHER|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
223933348|NCT02105259|BEHAVIORAL|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
223933349|NCT02105259|OTHER|Waiting list|Waiting list, where participants wait for delayed treatment
223933350|NCT00570388|DRUG|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
223933351|NCT02326181|DEVICE|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
223933352|NCT02326181|DEVICE|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
223933353|NCT00199056|DRUG|Dexamethasone / Prednisolone|
223933354|NCT00199056|DRUG|Cyclophosphamide|
223933355|NCT00199056|DRUG|Methotrexate|
223933356|NCT00199056|DRUG|Vincristine / Vindesine|
223533802|NCT01204788|PROCEDURE|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
223533803|NCT01204788|PROCEDURE|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
223533804|NCT05460182|OTHER|CAF+CTG|Coronally Advanced Flap + Connective Tissue Graft
223533805|NCT05460182|OTHER|CAF|Coronally Advanced Flap
223933357|NCT00199056|DRUG|Daunorubicin|
223933358|NCT00199056|DRUG|Asparaginase|
223933359|NCT00199056|DRUG|G-CSF|
223933360|NCT00199056|DRUG|Cytarabine|
223933361|NCT00199056|DRUG|6-Mercaptopurine|
223933362|NCT00199056|DRUG|VP16|
223933363|NCT00199056|DRUG|Adriamycin|
223933364|NCT00199056|DRUG|Thioguanine|
223933365|NCT00199056|DRUG|VM26|
223933366|NCT00199056|DRUG|Idarubicin|
223933367|NCT00199056|DRUG|Fludarabine|
223933368|NCT00199056|DRUG|Ifosfamide|
223933369|NCT00199056|PROCEDURE|CNS irradiation|
223933370|NCT00199056|PROCEDURE|Mediastinal irradiation (if residual tumor)|
223933371|NCT00199056|PROCEDURE|stem cell transplantation|
223933372|NCT02379000|DRUG|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
223933373|NCT02379000|PROCEDURE|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
223933374|NCT00547066|BIOLOGICAL|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
223933375|NCT00366249|DRUG|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
223933376|NCT00366249|DRUG|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
223933377|NCT04383067|PROCEDURE|Tumor Infiltrating Lymphocytes (TIL)|Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
223933378|NCT04383067|DRUG|Proleukin|high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
223933379|NCT03648190|DIAGNOSTIC_TEST|Flowcytometry analysis of platelets surface receptors|"BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs)."
223933380|NCT05600387|DRUG|Empagliflozin 10 MG|subjects in Empagliflozin group take 10mg Empagliflozin per day
224096782|NCT00656890|BIOLOGICAL|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
223933381|NCT01561300|OTHER|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
224096783|NCT00656890|BIOLOGICAL|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
223533806|NCT04846231|DIETARY_SUPPLEMENT|Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
223933382|NCT01561300|OTHER|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
223933383|NCT02221505|DRUG|LOP628|
223933384|NCT05706246|DIAGNOSTIC_TEST|diagnostics|Serum tryptase levels were evaluated in all suspected children with perioperative hypersensitivity
223933385|NCT00051584|DRUG|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
223933386|NCT00051584|DRUG|Gemzar (Gemcitabine)|
223933387|NCT06250868|DEVICE|Kerato-Refracto Tonometer|measures pressure inside the eye and thickness of the cornea.
223933388|NCT03454113|DEVICE|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
223933389|NCT05121142|DRUG|Ruxolitinib|Ruxolitinib will be given by mouth or enteral tube (if applicable).
223933390|NCT00609869|DRUG|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
223933391|NCT00609869|DRUG|Rituximab|Rituximab was administered at 375 mg/m\^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
223933392|NCT06371456|PROCEDURE|epidural catheter placement|after sterilization of the back, local anesthesia injection (xylocaine 5 ml) at lumbar 4-5 level, then advancing the epidural needle till loss of resistance by air occurs and the epidural catheter inserted then aspiration through the catheter will be done to confirm that no accidental cerebrospinal fluid or blood are aspirated and to observe the dew sign inside the outer portion of the epidural catheter near the back of the patient
223933393|NCT04773145|PROCEDURE|Hemiarthroplasty with hydroaxyapatite coated stem|Hemiarthroplasty with non cemented femoral stem, using the hydroxyapatite-coated femoral stem Pharo
223933394|NCT04955951|DEVICE|polarized light|A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm2, energy density 2,4 J/cm2 per minute
223933395|NCT04955951|DRUG|Topical corticosteroid ointment|corticosteroid 1 %.
223933396|NCT00914641|DRUG|Apixaban IR|immediate release tablet, 10 mg, single dose
223933397|NCT00914641|DRUG|Apixaban MR1|modified release tablet 1, 10 mg, single dose
223533807|NCT04846231|DRUG|Rosuvastatin|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
223533808|NCT04846231|OTHER|Placebo|Subjects will be randomized to a Statin (Rosuvastatin 5 mg), a placebo, or a dietary supplement (Fish oil, Cinnamon, Garlic, Turmeric, Plant sterol, Red yeast rice).
223535345|NCT01317992|DRUG|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
223933398|NCT00914641|DRUG|Apixaban MR2|modified release tablet 2, 10 mg, single dose
223535346|NCT01155557|DEVICE|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
223535347|NCT01155557|BEHAVIORAL|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
223933399|NCT00914641|DRUG|Apixaban MR3|modified release tablet 3, 10 mg, single dose
223933400|NCT03281603|DEVICE|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
223933401|NCT00724126|DRUG|Rifaximin|
223933402|NCT00724126|DRUG|Placebo|
224096784|NCT03726775|DRUG|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
224096785|NCT06459674|DEVICE|PrO2 Fit (IMT Trainer)|The device is used four times a week over a period of 8 weeks.
224096786|NCT04447053|DRUG|Belimumab Injection [Benlysta]|Belimumab, IV infusion, 10mg/kg on days 0, 14, 28 then every 28 days until week 48.
224285618|NCT01117844|RADIATION|Proton Radiation|Protons have been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
224285619|NCT06905639|BEHAVIORAL|Aerobic and Strength Exercise|A supervised physical exercise intervention was carried out, specifically designed to improve post-breast cancer lymphedema. The program will include a combination of strength exercises and aerobic exercises, with the aim of improving mobility, reducing inflammation, and increasing muscle strength in the arm affected by lymphedema
224285620|NCT06905522|DRUG|Bedaquiline (B)|The initial dose of bedaquiline is 400 mg daily for 2 weeks, followed by 200 mg three times a week.
223933403|NCT02867956|DRUG|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
223933404|NCT02867956|DRUG|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
223933405|NCT06372340|PROCEDURE|Personalized pelvic floor rehabilitation program generated by the intelligent diagnosis and treatment system.|Utilizing machine learning to process and analyze vast amounts of previously collected data, the investigators will establish an intelligent system that can generate personalized pelvic floor exercise prescription by matching factors such as general clinical information and pelvic floor muscle strength data. The experimental group will receive tailored program, including pelvic floor muscle training with diverse intensity and frequency, electrical stimulation, magnetic stimulation, biofeedback and other treatments. The results will ultimately be compared with those taking standardized pelvic floor muscle training only.
223933406|NCT06372340|PROCEDURE|Standard pelvic floor muscle training(PFMT) program|Participants will be given handbooks with detailed training program: the basic regimen consists of 3 sets of 8 to 12 contractions sustained for 8 to 10 sec each, performed 3 times a day. Patients should try to do this every day and continue for at least 15 to 20 weeks.
223933407|NCT00635700|DRUG|ziprasidone|20-160 mg/d
223933408|NCT00635700|DRUG|placebo|placebo
223933409|NCT02315118|DRUG|T-cell therapy + Rituximab + IL-2|"* T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients"
223933410|NCT04869605|DIAGNOSTIC_TEST|1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin ratio|the role of 1,5 anhydroglucitol and 1,5 anhydroglucitol / HbA1c ratio as a potential biomarker for islet β-cell function and insulin resistance among patients with type 2 diabetes
223933411|NCT01929291|BIOLOGICAL|Boostrix|Single intramuscular injection
223933412|NCT01929291|OTHER|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
223933413|NCT04353050|PROCEDURE|Non-invasive adhesive system (patch)|The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
223933414|NCT03267537|BEHAVIORAL|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
223933415|NCT03267537|BEHAVIORAL|Conventional office-based CBT-I|Conventional office-based CBT-I
223933416|NCT00278928|DRUG|Liposyn III 20% (lipid infusion)|
223933417|NCT00278928|DRUG|Intralipid 20% (lipid infusion)|
224096787|NCT05366309|OTHER|Tailored education|Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.
224096788|NCT05366309|OTHER|Standard care education|Participants randomised to this group will receive usual care in terms of their education.
224096789|NCT01281176|DRUG|Carboplatin|Given IV
224096790|NCT01281176|OTHER|Laboratory Biomarker Analysis|Correlative studies
224096791|NCT01281176|DRUG|Paclitaxel|Given IV
224285621|NCT06905522|DRUG|Sitafloxacin (S)|200mg once daily
223933418|NCT06822933|DEVICE|Urika|Self-management application for patients with gout receiving urate lowering therapy. The 'Urika'-app includes films and written information about gout and gout management, reminders for blood-tests and medication, a visualisation of serum urate level over time, and an algorithm to calculate the medication drug-dose escalation. The app also includes a chat function and a secure web-platform for remote monitoring and communication between the participant and nurse. The study nurse will log into the web-platform on weekdays to check patient-reported side effects, adherence to medication, the current dose, and the need for a renewal of urate lowering therapy prescription.
223933419|NCT06822933|OTHER|Nurse-led follow-up with telephone consultations.|Nurse-led follow-up in specialist healthcare with monthly blood tests and telephone consultations until the treatment target is reached.
223933420|NCT03918096|OTHER|Questionnaire|Questionnaire to the parents after the hospital discharge
223933421|NCT02191670|DRUG|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
223933422|NCT00893698|PROCEDURE|bilateral allotransplantation|bilateral allotransplantation of upper limbs
223933423|NCT01806207|DEVICE|Durolane injection|
223933424|NCT01806207|OTHER|Saline injection|
223933425|NCT05197127|DEVICE|exoskeleton-based gait training|Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
223933426|NCT06517914|DRUG|YH35995|Oral administration of YH35995
223933427|NCT06517914|DRUG|Placebo|Oral administration of Placebo
223933428|NCT06700720|DRUG|Dose 1 YN001|Dose 1 YN001 will be administered on Day 1 and Day 5 of each week from Week 1 to Week 12, and on Day 1 of Week 13, 25 times in total.
223933429|NCT06700720|DRUG|Dose 2 YN001|Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.
223933430|NCT06700720|DRUG|Evolocumab|Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
223933431|NCT06432790|BEHAVIORAL|CHAMPION|The CHAMPION program is an intensive health behavior and lifestyle treatment (IHBLT), formed through the integration of the Healthy Weight Clinic IHBLT and with MGB's pediatric Asthma Population Health Management Program. It consists of 30 hours of contact time with the CHAMPION team (physician, dietician, community health worker), consistent with the USPSTF and AAP recommendations, monthly individual clinic visits with the team (in person or virtual, per randomization), health coaching calls with a community health worker and/or registered dietician, monthly group sessions (in the first six months), and educational materials for families that reinforce healthy lifestyle behaviors and provide self-management education. In this study, all participants will participate in CHAMPION, but one arm will receive the experimental form (delivery via telehealth) and the other arm will receive the active comparator (delivery via telehealth).
223933432|NCT04261309|OTHER|Usual care|Since this is an observational study there will be no interference with the care given by the primary healthcare providers. However, the usual care provided by these and other healthcare utilization used by the patients during follow-up will be recorded during the follow-ups.
223933433|NCT06202378|DRUG|3 ampoules of SHPL-49 Injection|3 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
224096792|NCT01281176|OTHER|Pharmacological Study|Correlative studies
224096793|NCT01281176|DRUG|Vorinostat|Given PO
224096794|NCT02527213|DRUG|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
224096795|NCT02527213|DRUG|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
224096796|NCT06975735|PROCEDURE|TAP Plane Block|The transversus abdominis plane block (TAPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
224096797|NCT06975735|PROCEDURE|TFP Block|The transversalis fascia plane block (TAPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
223933434|NCT06202378|DRUG|6 ampoules of SHPL-49 Injection|6 ampoules of SHPL-49 Injection in 100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
223933435|NCT06202378|DRUG|0.9% Sodium Chloride Injection|100 mL 0.9% sodium chloride will be administered as a 30-minute IV infusion and applied twice daily for 7 days.
224096798|NCT03267524|BEHAVIORAL|Exercise Intervention|Receive Walking for Recovery from Surgery prehabilitation intervention
224096799|NCT03267524|OTHER|Quality-of-Life Assessment|Ancillary studies
224096800|NCT03267524|OTHER|Survey Administration|Ancillary studies
224096801|NCT06973837|OTHER|Real-life monitoring, experimental pain testing, brain imaging, blood and stool sampling.|See detailed study description and outcome measures.
224285622|NCT06905522|DRUG|Linezolid (L)|600mg once daily
224285623|NCT06905522|DRUG|Pyrazinamide (Z)|20-30 mg/kg/day; 1000 mg for patients weighing \<50 kg, 1500 mg for patients weighing ≥50 kg but \<75 kg, and 2000 mg for patients weighing ≥75 kg.
224285624|NCT06905522|DRUG|Isoniazid (H)|4-6 mg/kg once daily, 300 mg once daily
224285625|NCT06905522|DRUG|Rifampicin (R)|8-12 mg/kg once daily, 450 mg for patients weighing \<50 kg, 600 mg for patients weighing ≥50 kg but \<75 kg, and 750 mg for patients weighing ≥75 kg.
224285626|NCT06905522|DRUG|Ethambutol (E)|15-25 mg/kg once daily, 750 mg once daily
224285627|NCT06905522|DRUG|Moxifloxacin (M)|400mg once daily
224285628|NCT06905522|DRUG|Pretomanid (Pa)|200mg once daily
223533809|NCT06353815|OTHER|4% articaine infiltration|Two injections using short needle and dental syringe will be given , the first injection is 1.5 ml out of 1.8 ml of 4% articaine with 1:100,000 epinephrine (ARTINIBSA 4% 1:100,000) in the mucobuccal fold adjacent to the mandibular first Molar, the second injection is 0.3 ml in the lingual side for lingual soft and hard tissues .
223933436|NCT03703440|OTHER|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
223933437|NCT03703440|OTHER|Control arm|Usual diabetes care, every 3-month for 12 months
223933438|NCT06117085|DEVICE|CellFX® Percutaneous Electrode (PE) System|Percutaneous treatment with CellFX® Percutaneous Electrode using nanosecond pulse field ablation (nsPFA) technology
223933439|NCT05402384|DRUG|AVTX-801|"Medical grade D-galactose~dosage:2.0 g/kg/day"
223933440|NCT05402384|DRUG|Placebo|Matching placebo
223933441|NCT06797999|BIOLOGICAL|Antibody-drug conjugate (ADC)|ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.
223933442|NCT04265794|BEHAVIORAL|H2GO!|Child participants will participate in a 6-week behavioral intervention consisting of 12 group-based weekly sessions (1-hour sessions twice a week) delivered by trained staff in the Boys and Girls Club setting. Each week consisted of a 1-hour health session and a 1-hour narrative session (delivered on separate days). Child participants will also receive reusable water bottles and a pictorial intervention booklet, which includes worksheets and parent-child take-home activities targeting attitudes, knowledge, and skills related to sugar-sweetened beverage and water consumption. Parent participants will be exposed to intervention messages (e.g., reduce SSB intake) through weekly parent-child take-home activities, child sharing of narratives produced, and a culminating open house event.
224096802|NCT05167227|OTHER|Extension for Community Healthcare Outcomes|ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
224096803|NCT06376422|PROCEDURE|Spongioflex®|partial meniscal replacment during surgery, follow-up visits at the end of hospital stay and after 6 weeks, MRI evaluation and questionnaires after 6, 12, 24 and 60 months.
224096804|NCT06376422|OTHER|non-operated|no surgery, MRI evaluation and questionnaires follow-up after 6, 12, 24 and 60 months
224096805|NCT04524585|DRUG|Neuromuscular blockade|Cisatracurium will be infused to achieve esophageal pressure targets and maintain a Riker Sedation-Agitation Scale (SAS) score of 1-2. Additional boluses of cisatracurium will be delivered as required and adjustment of continuous infusion rate. After establishing a sedation and NMB strategy at which safe spontaneous breathing is achieved, we will seek to determine whether these targets can be maintained over a 24-hour period.
224096806|NCT00697996|DRUG|Rituximab for transplant rejection|
224096807|NCT03011645|DRUG|Ziprasidone|Given by mouth, single dose of 60 mg.
224096808|NCT03011645|DRUG|Lorcaserin|Given by mouth, single dose of 20 mg.
224096809|NCT03011645|DRUG|Placebo Oral Tablet|Given by mouth, single dose.
224096810|NCT03772912|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
224096811|NCT03372941|DRUG|Dalbavancin|Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
224285629|NCT02331238|BEHAVIORAL|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
224285630|NCT02406638|OTHER|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
224285631|NCT02247050|BEHAVIORAL|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
224096812|NCT00741819|DRUG|Inhaled treprostinil|
224096813|NCT01921998|PROCEDURE|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
224096814|NCT01126580|DRUG|Metformin|
224096815|NCT01126580|DRUG|LY2189265|
224096816|NCT01126580|DRUG|Placebo (oral)|
224096817|NCT01126580|DRUG|Placebo (subcutaneous)|
224096818|NCT00877344|PROCEDURE|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
224096819|NCT00877344|PROCEDURE|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
224096820|NCT02550899|PROCEDURE|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
224285632|NCT04222114|DRUG|Catumaxomab|The starting dose of catumaxomab for intra-peritoneal infusion will be 10μg, gradually increased to 20μg, 50μg and 150μg, respectively. From the second cycle, catumaxomab will be changed to 20μg,50μg,150μg on days 1,4 and 8.
224096821|NCT02550899|PROCEDURE|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
224096822|NCT02550899|PROCEDURE|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
224096823|NCT00926926|DRUG|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
224096824|NCT00926926|DRUG|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
224096825|NCT06247969|DEVICE|endotracheal tube|Endotracheal Tube (ETT) is a flexible plastic tube that is inserted through the mouth or nose into the trachea to establish an artificial airway.
224096826|NCT01708057|DRUG|AZD8683|AZD8683 administered via inhalation
224096827|NCT01708057|DRUG|Placebo|Placebo administered via inhalation
224096828|NCT01708057|DRUG|Tiotropium|Tiotropium administered via inhalation
224096829|NCT04095520|PROCEDURE|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
224096830|NCT04095520|PROCEDURE|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
224285633|NCT04222114|DRUG|The treatment of investigator choice|the localized supportive treatment which has been approved or recommended by local gastric cancer guidance to treat the peritoneal metastasis.
224285634|NCT02449473|BIOLOGICAL|Tralokinumab|Subcutaneous Injection
224285635|NCT02449473|OTHER|Placebo|Subcutaneous Injection
224285636|NCT04712734|DRUG|Iloperidone|oral tablet, long-acting injection
224285637|NCT05774652|BEHAVIORAL|Lifestyle intervention Dietary advise and/or advise on physical activity|Lifestyle intervention Dietary advise and/or advise on physical activity
224285638|NCT06002217|DRUG|Levobupivacaine|Patients in the tap block arm will receive an injection of levobupivacaine 2.5mg/ml
224285639|NCT06002217|OTHER|Placebo Tap block|Patients in the placebo arm will receive an injection of salin solution 2.5mg/ml , in the same way as tap block
224285640|NCT05138926|OTHER|Cervical Manipulation|high speed, low amplitude cervical manipulation
223533810|NCT05361174|BIOLOGICAL|IOV-4001|A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
223533811|NCT06186232|PROCEDURE|guided bone regeneration (GBR).|guided bone regeneration (GBR) using polymethylmethacrylate (PMMA) polymer as membrane.
223533812|NCT06163287|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen
224096831|NCT05718362|BEHAVIORAL|Ayres Sensory Integration Therapy|It is an intervention method whose effectiveness is questioned. It is a therapy program applied according to Ayres Sensory Integration Fidelity Measure.
224096832|NCT05718362|BEHAVIORAL|Home Program|These are the activities created for the participants (both intervention and control groups) and to be done in the home environment.
224099735|NCT07107477|PROCEDURE|Tailored antibiotic and steroid therapy based on the IL-6 value in amniotic fluid obtained by amniocentesis in patients with premature rupture of membranes|"In Arm A, Amniocentesis will be performed once a week until delivery, with a maximum of seven procedures per patient. If the pregnancy continues beyond this period, follow-up will proceed without further amniocentesis.~* If IL-6 ≥ 2600:~* steroids and initial broad spectrum ABX will be administered,~* rotation of ABX according to cultures and PCR.~* If steroids already administered, a second course can be administered prior to 34+0 if at least 7 days have passed after the previous course."
224285641|NCT05138926|OTHER|Sham Cervical Manipulation|Cervical mobilization without performing spinal manipulation
224285642|NCT04819373|DRUG|BDB001|BDB001 is an immunotherapy agent.
224285643|NCT05247931|DIAGNOSTIC_TEST|TXB2 assay of serum , and 11-dehydro-TXB2 assay of urine|Blood samples are analyzed for the assay of serum TXB2, and urine samples for the assay of 11-dehydro-TXB2
224285644|NCT01831986|DIETARY_SUPPLEMENT|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
224285645|NCT01831986|OTHER|Placebo|Caps
224285646|NCT00972907|DRUG|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
224285647|NCT00689845|BIOLOGICAL|bleomycin sulfate|Given IV
224285648|NCT00689845|BIOLOGICAL|filgrastim|Given subcutaneously
224285649|NCT00689845|BIOLOGICAL|rituximab|given IV
224285650|NCT00689845|DRUG|cyclophosphamide|Given IV
223533813|NCT06163287|DIETARY_SUPPLEMENT|Placebo|Inert substance
224285651|NCT00689845|DRUG|cytarabine|Given subcutaneously
224285652|NCT00689845|DRUG|doxorubicin hydrochloride|Given IV
224285653|NCT00689845|DRUG|etoposide phosphate|Given IV
224285654|NCT00689845|DRUG|ifosfamide|Given IV
224285655|NCT00689845|DRUG|methotrexate|Given IV
224285656|NCT00689845|DRUG|prednisolone|Given orally
224285657|NCT00689845|DRUG|prednisone|Given orally
224285658|NCT00689845|DRUG|vincristine sulfate|Given IV
224285659|NCT00689845|DRUG|vindesine|Given IV
224285660|NCT02107079|DRUG|Melatonin|swallowing 1 piece, collecting saliva afterwards
224285661|NCT01751919|DRUG|Imatinib mesylate tablet 400 mg, 1 Tablet|
224285662|NCT01751919|DRUG|Glivec film-coated tablet 100 mg, 4 Tablets|
224285663|NCT05276687|DRUG|Betadine|Wound irrigation
224285664|NCT05276687|DRUG|Vancomycin|instillation in the wound
224285665|NCT06378788|OTHER|Demographic information form|aims to collect basic demographic data( Age reported by years , weight and height will be combined to report Body Mass index (BMİ) in kg/m2, Smoking habit reported as smoker or non-smoker , Level of Education reported as illiterate, literate, Primary school, Middle school, High school, University or Post-graduate, Profession type, Significant medical records and Medications.
224096833|NCT02522637|OTHER|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
224096834|NCT03563300|OTHER|Wheat flour|Wheat flour will be administered once daily for 7 days
224096835|NCT03563300|OTHER|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
224096836|NCT00538681|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
224096837|NCT00538681|DRUG|pemetrexed|500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
224096838|NCT00538681|DRUG|cisplatin|75 mg/m², IV, every 21 days, for each 21-day cycle
223933443|NCT05695196|BIOLOGICAL|nasal microbiota transplant (NMT)|nasal microbiota transplant
224096839|NCT00538681|DRUG|placebo|po, QD
224096840|NCT00986531|DRUG|AZD8529|2 capsules by mouth for 3 days
224096841|NCT00986531|DRUG|Placebo to match AZD8529|2 capsules by mouth for 3 days
224096842|NCT05718401|DEVICE|NMR|nuclear magnetic resonance in genomics
224096843|NCT04447547|BIOLOGICAL|CD19 CAR-T|Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
224096844|NCT01798303|DRUG|LY2940094|Administered orally
224096845|NCT01798303|DRUG|Placebo|Administered orally
224096846|NCT02970929|DRUG|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
223933444|NCT05695196|BIOLOGICAL|Placebo|Placebo sterile saline
223933445|NCT06397118|BEHAVIORAL|Maternal Nutrition Education|Community Health Worker delivered Maternal Nutrition Education
224096847|NCT00291343|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
224096848|NCT00291343|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
224096849|NCT00291343|BIOLOGICAL|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
224096850|NCT01209715|DRUG|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
224285666|NCT06378788|DIAGNOSTIC_TEST|widespread pain index (WPI)|"The Widespread Pain Index is a 19-point checklist that assesses the presence of pain or tenderness (within the prior seven days) in 19 specific areas of the body; each affected area receives one point. The 19 regions on the WPI include the following:~Right and left jaw, Right and left shoulder girdle, Right and left upper arm, Right and left lower arm, Right and left hip/buttock Right and left upper leg Right and left lower leg Upper and lower back Neck Chest Abdomen A fibromyalgia diagnosis is confirmed if a WPI is ≥7 with an SS scale ≥5 OR a WPI range between 4-6 with an SS scale ≥ 9."
223933446|NCT06397118|BEHAVIORAL|Standard Care|Standard care in the sickle cell disease (SCD) clinic
223933447|NCT03822988|OTHER|no intervention, only complete a survey|we will ask patients to answer to a survey
223933448|NCT03484988|DIETARY_SUPPLEMENT|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223933449|NCT03484988|DIETARY_SUPPLEMENT|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
224096851|NCT01209715|DRUG|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
224096852|NCT03895138|OTHER|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
224096853|NCT03895138|OTHER|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
224096854|NCT03321799|DEVICE|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
224096855|NCT03321799|DEVICE|Sterile Antimicrobial Dressings|Control group, current hospital standard.
224096856|NCT00302640|DRUG|Alinia (nitazoxanide)|
224096857|NCT02812004|DEVICE|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
223933450|NCT03484988|DIETARY_SUPPLEMENT|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223933451|NCT03971851|OTHER|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
223933452|NCT05766319|DEVICE|Withings ScanWatch|"Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)"
223933453|NCT05766319|DEVICE|Withings BPM Connect|"Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)"
223933454|NCT05766319|DEVICE|Withings Body|"Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)"
223933455|NCT04699058|DIAGNOSTIC_TEST|COVID-antibody test|Questionnaire and COVID-antibody test for all participants
223933456|NCT00515814|DEVICE|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
223933457|NCT05403476|DRUG|FE 999049|FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
223933458|NCT05403476|DRUG|Placebo|Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
223933459|NCT05692817|DEVICE|Low-Intensity Pulsed Ultrasound|"The total sample will be randomly divided into two equal groups (according to method of application of the lipus on the intervention side)as follows: ■ Group I: will include 8 patients who will receive lipus with maxillary canine retraction that will be performed every (3 weeks) on intervention 6 sides according to a standardized protocol.~▪ Group II: will include 8 patients who will receive lipus that will be performed every (1 week) on intervention sides according to a standardized protocol."
223933460|NCT03053505|BIOLOGICAL|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
223933461|NCT03053505|DRUG|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
223933462|NCT04755504|DIAGNOSTIC_TEST|EEG behind the ear|2 additional electrodes behind each ear will record EEG
223933463|NCT02766946|DEVICE|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
223933464|NCT02766946|DEVICE|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
223933465|NCT02766946|OTHER|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
223933466|NCT02766946|OTHER|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
223933467|NCT03132688|DRUG|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
223933468|NCT00571649|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
223933469|NCT00571649|DRUG|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
223933470|NCT00571649|DRUG|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
223933471|NCT00571649|DRUG|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
223933472|NCT00582972|DRUG|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
224285667|NCT06378788|DIAGNOSTIC_TEST|symptom severity scale (SSS)|SS scale score: Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The SS scale score sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.
223933473|NCT02206815|DRUG|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
223933474|NCT02206815|DRUG|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
223933475|NCT05305391|OTHER|Dietary intervention|The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
223933476|NCT00588406|DRUG|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
223933477|NCT00588406|DRUG|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
223933478|NCT00588406|DRUG|Ipratropium bromide|2.5 mg, one dose
223533814|NCT04972851|BEHAVIORAL|Self-Determined Learning Model of Instruction (SDLMI)|"SDLMI is a teaching model that enables providers to teach students to:~* make choices and decisions about setting a goal~* develop action plans for academic or other goals~* self-monitor and self-evaluate progress toward goal attainment~* adjust the goal or plan"
223533815|NCT03325504|BIOLOGICAL|Cultured Mesenchymal Stem Cells|Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
223933479|NCT00588406|DRUG|Prednisone|60mg PO
223933480|NCT03342820|PROCEDURE|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
223933481|NCT01566890|DRUG|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
223933482|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
223933483|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
223933484|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
223933485|NCT01566890|PROCEDURE|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
223933486|NCT03983434|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
223933487|NCT04968886|DIAGNOSTIC_TEST|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)|Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
223933488|NCT06387576|BEHAVIORAL|Behaviorally informed pre-discharge iPad video scheduling|The iPad video scheduling process will occur prior to patient discharge from the hospital. This intervention harnesses behavioral principles, such as commitment (patient committing to scheduled appointment), social accountability (patients feeling more accountable after scheduling their appointment via the video visit), and social support (patients feeling more supported after engaging in this conversation with a scheduler via video).
223933489|NCT03934528|DEVICE|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
223933490|NCT05559801|DRUG|Bone marrow-derived mesenchymal stromal cells (MSCs)|Mesenchymal stromal cells (MSCs) are cells of non-hematopoietic stromal origin that reside in bone marrow and a variety of tissues. MSCs will be prepared in a GMP Cell Production facility and administered to children age 3-10 years (at time of enrollment) with Osteogenesis Imperfecta Type III.
223933491|NCT05780762|OTHER|IMPACT Program|"care at 3 levels:~(1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and with the team caring for him or her, and incorporating evidence-based measurement tools."
223933492|NCT05780762|OTHER|usal care|usual management with a Nurse in Advanced Practice.
223933493|NCT04004325|DRUG|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
223533816|NCT03325504|PROCEDURE|Autologous iliac crest graft|Autologous iliac crest grafting
223533817|NCT03352765|DRUG|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
223533818|NCT03352765|DRUG|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
223933494|NCT04004325|DRUG|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
223933495|NCT04004325|OTHER|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
223933496|NCT03589625|OTHER|Solar Suitcase|"The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly."
224285668|NCT06378788|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes. The FIQ is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression.
224285669|NCT06378788|DIAGNOSTIC_TEST|Tender Point examination|Tender points are specific sites on the body that cause pain when pressed.. There are 9 pairs of tender points. Each pair has one point on each side of the body, for a total of 18 points.Prior to 2010, the diagnosis of fibromyalgia required at least 11 painful point of 18 but now tender points are no longer used as a diagnostic tool. The score will be reported as the number of tender points found with palpation.
224285670|NCT06378788|OTHER|Muscle Architecture visualized with ultrasound|The three head of Quadratus femoris ( Vastus lateralis, Vastus Medialis and Rectus Femoris), Tibialis Anterior, the two heads of Gastrocnemius ( vastus Lateralis and vastus Medialis) ultrasonography will be performed to evaluate muscle thickness, pennation angle and fascicle length.
223533819|NCT03352765|DRUG|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
223533820|NCT03352765|PROCEDURE|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
223533821|NCT04401462|PROCEDURE|Tension band wiring or plate fixation|Operative fixation of olecranon fracture with either of the methods mentioned in the intervention name
223933497|NCT03575936|DEVICE|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
223933498|NCT03575936|PROCEDURE|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
223933499|NCT01421667|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
223933500|NCT01421667|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion
223933501|NCT01324310|DRUG|Romidepsin|Romidepsin 8 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
223933502|NCT01324310|DRUG|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
223933503|NCT00291954|BIOLOGICAL|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
223933504|NCT00291954|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
223933505|NCT00137098|DRUG|Caffeine|
223933506|NCT02999763|DEVICE|SlimShape|SlimShape radiofrequency treatment to the abdomen
223933507|NCT01951807|BEHAVIORAL|Psychotherapy|
223933508|NCT06162702|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
223933509|NCT03095872|DEVICE|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
223933510|NCT03095872|DRUG|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
224285671|NCT06378788|OTHER|Sarcopenia assessed by measuring isometric strengths of different parts of the body|Cervical Flexion (CF), Cervical Extension (CE), Right and Left Cervical Lateral Flexion (CLF R/L), Truncal flexion (TF), Truncal extension (TE), Shoulder flexion (SF), Shoulder extension (SE), Shoulder abduction (SAB), Shoulder internal rotation (SIR) and Shoulder external rotation (SER), Hip flexion (HF), Hip extension (HE), hip abduction (HAB), hip internal rotation (HIR), hip external rotation (HER), knee extension (KE), Knee Flexion (KF), Ankle Dorsiflexion (ADF) and Ankle Plantar flexion (APF) muscle strengths will be evaluated with hand held dynamometer
224285672|NCT06378788|OTHER|Timed Up & Go (TUG)|The test will be used by investigators as a simple evaluative test used to measure participants functional mobility.
224285673|NCT06185972|DRUG|Definity|Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature
224285674|NCT06185972|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
224285675|NCT05898763|DRUG|TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)|Patients will receive three rounds of vaccination three weeks apart via one subcutaneous (SC) injection in an alternating limb. Patients in the extension cohort will receive the highest safest dose in combination with pembrolizumab (a CPI).These patients will receive three rounds of combination treatment with TEIPP24 vaccination and pembrolizumab every three weeks. Pembrolizumab will be administered as per standard of care.
224285676|NCT04864808|BEHAVIORAL|Behavioral Parent Training|Parents will receive sessions of behavioral parent training with components specifically targeted toward parents with ADHD. The number of sessions will be informed based on stakeholder feedback. Treatment will be delivered via telehealth.
224285677|NCT05358704|DRUG|combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)|To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
224285678|NCT04678817|DEVICE|Etonogestrel contraceptive implant with oral levonorgestrel|Participants who present for emergency contraception and select the Etonogestrel contraceptive implant with oral levonorgestrel
224285679|NCT04678817|DEVICE|Levonorgestrel intrauterine device|Participants who present for emergency contraception and select the Levonorgestrel intrauterine device
224285680|NCT04678817|DEVICE|Copper T380A intrauterine device|Participants who present for emergency contraception and select the Copper T380A intrauterine device
224285681|NCT03520491|DRUG|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
224285682|NCT03520491|DRUG|Ipilimumab|Ipilimumab 3 mg/kg
224285683|NCT03520491|PROCEDURE|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
223933511|NCT03095872|DRUG|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
223933512|NCT00708045|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer to assess brain tumor metabolism
223933513|NCT03930940|DEVICE|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
223933514|NCT03930940|OTHER|Regular treatment|Regular treatment is based on associated guidelines for ICH.
223933515|NCT02540369|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
224096858|NCT05369806|BEHAVIORAL|Interactive two-way SMS dialogue|This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
224096859|NCT00859755|DRUG|ARRY-403, glucokinase activator; oral|single dose, escalating
223533822|NCT04401462|BEHAVIORAL|Sling or a long-arm plaster|Non-operative treatment and progressive range of motion as tolerated. A long-arm plaster will be used, if necessary, for pain relief.
223533823|NCT06638476|OTHER|Perturbation Induced Step training|A sudden lateral displacement of the treadmill.
223933516|NCT01074359|DRUG|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
223933517|NCT01074359|DRUG|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
223933518|NCT00231504|PROCEDURE|Blood samples|Blood samples
223933519|NCT03170882|DRUG|Ixazomib|Ixazomib capsules
223933520|NCT03170882|DRUG|Pomalidomide|Pomalidomide capsules
223533824|NCT06638476|OTHER|Voluntary step training|Voluntary steps emphasizing speed, movement of center of mass and taking larger steps.
223533825|NCT04299984|PROCEDURE|Open Conversion after EVAR|"See Open Conversions group description."
223533826|NCT04299984|PROCEDURE|SemiConversion after EVAR|"See SemiConversions group description."
223533827|NCT06644820|DIAGNOSTIC_TEST|radiology|"Chest x ray posteroanterior view and lateral view.~CT. chest without contrast:~To assess the underlying lung pathology e.g. multiple bullae, interstitial lung disease (ILD) , cavitating lesions or nodules."
223533828|NCT05978934|BEHAVIORAL|Static Lighting Condition (L1)|This indoor lighting condition keeps a constant brightness and correlated color temperature.
223533829|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L2)|This indoor lighting condition has increased brightness and more blue correlated color temperature in the morning hours followed by decreased brightness and less blue correlated color temperature in the afternoon and evening hours.
223933521|NCT03170882|DRUG|Dexamethasone|Dexamethasone tablets
223933522|NCT03865004|DRUG|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
223933523|NCT03865004|DRUG|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
223933524|NCT03865004|DRUG|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
223933525|NCT02356055|BEHAVIORAL|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
223933526|NCT06622057|DRUG|D07001-Softgel Capsules|D07001-softgel capsule is an oral gemcitabine.
223933527|NCT06622057|DRUG|Placebo|Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)
223933528|NCT06622057|COMBINATION_PRODUCT|Capecitabine|Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.
223933529|NCT04027439|DRUG|Part A: RPL554|1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
223933530|NCT04027439|DRUG|Part B: RPL554|Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
224096860|NCT00859755|DRUG|Placebo; oral|matching placebo
224096861|NCT05422976|DEVICE|EVI-01|High molecular weight Hyaluronic Acid
224096862|NCT03987945|DEVICE|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
223533830|NCT05978934|BEHAVIORAL|Dynamic Lighting Condition (L3)|This exploratory indoor lighting condition matches the same pattern as L2 except the brightness in the morning hours is increased.
223533831|NCT01136369|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
223933531|NCT04027439|DRUG|Placebos|"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."
223933532|NCT03664011|DRUG|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
223933533|NCT03598946|DEVICE|Urinary test|Women use a home urinary test themselves
223933534|NCT03450460|BEHAVIORAL|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
223933535|NCT02631668|DRUG|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
224096863|NCT00977652|PROCEDURE|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
224096864|NCT00977652|PROCEDURE|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
224096865|NCT01511757|DRUG|Fluconazole|Fluconazole Tablets, 200 mg
224096866|NCT01511757|DRUG|Fluconazole|fluconazole 200 mg
224096867|NCT02168582|BEHAVIORAL|physiotherapy as usual in primary care|
224096868|NCT03376633|BEHAVIORAL|Working on Womanhood (WOW)|A trauma-informed group counseling and clinical mentoring intervention for young women
224096869|NCT03929250|DRUG|2g Centella asiatica water extract product|2g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
224096870|NCT03929250|DRUG|4g Centella asiatica water extract product|4g Centella asiatica water extract product is a powder containing Centella asiatica water extract (CAW) and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
224096871|NCT03399461|OTHER|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
224096872|NCT03399461|OTHER|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
224096873|NCT03399461|OTHER|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
223533832|NCT03501628|DIETARY_SUPPLEMENT|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
223933536|NCT02631668|DRUG|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
223933537|NCT02631668|DRUG|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
224096874|NCT03399461|OTHER|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
224096875|NCT03399461|OTHER|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
224096876|NCT02643550|BIOLOGICAL|Monalizumab|
224096877|NCT02643550|BIOLOGICAL|Cetuximab|
224096878|NCT02643550|BIOLOGICAL|Anti-PD(L)1|
224096879|NCT01262430|PROCEDURE|OtisMed|OtisMed Custom-fit Shapematching Guides
224096880|NCT01262430|PROCEDURE|Computer Assisted Surgery (CAS)|Stryker Navigation System
224096881|NCT00025038|DRUG|tipifarnib|Given orally
224285684|NCT03377387|DRUG|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
224285685|NCT03377387|DRUG|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
224096882|NCT00025038|DRUG|isotretinoin|Given orally
224096883|NCT00025038|DRUG|fludarabine phosphate|Given IV
224096884|NCT00025038|DRUG|cytarabine|Given IV
224096885|NCT00025038|RADIATION|radiation therapy|Undergo total body irradiation
224096886|NCT00025038|DRUG|cyclophosphamide|Given IV
224096887|NCT00025038|BIOLOGICAL|anti-thymocyte globulin|Given IV
224285686|NCT03377387|BEHAVIORAL|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
224285687|NCT01901172|DRUG|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
224285688|NCT01901172|DRUG|RO5503781|Daily for 5 days followed by 23 days rest per cycle
224096888|NCT00025038|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
224096889|NCT00025038|PROCEDURE|double-unit umbilical cord blood transplantation|
224096890|NCT00025038|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
223933538|NCT06298266|BIOLOGICAL|infusion of GPRC5D-CD19 CAR T injection|Infusion of GPRC5D-CD19 CAR T cells injection by dose of 1.0×10\^6 /kg±20 % CAR-T ，3.0×10\^6 /kg±20%、6.0×10\^6 /kg±20%. Administration method: intravenous infusion. Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223933539|NCT03738709|BEHAVIORAL|Falls prevention and education giving a demonstration of the usage of technical assistance.|"* Ecological trail to work on balance and walking.~* Technical assistance presentation and try-outs within the therapeutic apartment.~* Discussion on the perceived feelings over the exercises and the technical assistance submitted.~* Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
223933540|NCT04023175|OTHER|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
223933541|NCT04023175|OTHER|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
223933542|NCT01077700|DRUG|ABT-288 Low Dose|
223933543|NCT01077700|DRUG|Placebo|inactive substance
223933544|NCT01077700|DRUG|ABT-288 High Dose|
223933545|NCT05907603|DRUG|RD13-02 cell infusion|CAR-T cells
223933546|NCT06424652|OTHER|Blood draws|After passing the screening, participation in the research study will be approximately three weeks. The participant will have seven study visits all at the Pennington Center. On five occasions, the participant will have a five-hour visit in the inpatient unit. At the study visit blood will be drawn. The total amount of blood drawn during the study is approximately 12 fluid ounces.
223933547|NCT06424652|OTHER|Hyperinsulinemic Euglycemic Clamp Technique Insulin Sensitivity test|This procedure measures how the body responds to insulin. Insulin is normally produced by the body during meals and helps the body use sugar. There will be two IV lines, one in the participant's arm and one in the participant's hand on the opposite side. Small amounts of glucose and insulin will be infused into the participant's arm. The participant's blood sugar level will be checked every 5-10 minutes from the IV in the hand to determine how much glucose the participant should have to keep blood sugar at a normal level. The participant's hand will be placed inside a warming box to increase skin temperature to about 105 degrees Fahrenheit. The temperature will be warm, but not uncomfortable. During the IV procedure, a small amount of the participant's own blood (less than 1 teaspoon) will immediately be returned into the vein through the IV after each specimen is collected.
224096891|NCT00025038|OTHER|laboratory biomarker analysis|Correlative studies
224096892|NCT02532049|BIOLOGICAL|ChAd63 Pfs25-IMX313|
224285689|NCT01901172|DRUG|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
224285690|NCT01901172|DRUG|RO5503781|Single doses Days 1 and 11
224285691|NCT01901172|DRUG|posaconazole|Multiple doses Days 8-14
224285692|NCT06063174|BEHAVIORAL|Education Program|12-week online psychoeducation program on environmental pollution exposures, the health impacts and sources of these exposures, and practical ways to reduce these exposures. Participants in the active control group will receive this form of intervention.
224285693|NCT06063174|BEHAVIORAL|Think Well Program|12-week online program in which participants learn to identify negative emotion and thinking patterns and participate in live online group coaching. Participants whose thinking style domain is dysregulated will be assigned to this intervention program.
223933548|NCT06424652|OTHER|Resting Metabolic Rate (RMR)|After the participant rests for 30 minutes, a clear plastic hood will be placed over the participant's head and chest area. The hood is ventilated with fresh air. The participant's oxygen intake and carbon dioxide output will be measured for 30 minutes to determine how many calories the participant burns during the time they are being tested.
223933549|NCT06487507|BEHAVIORAL|Low fat diet|Prior to surgery, participants complete diet records for 7 days. After, participants will receive one shipment containing prepared meals (refrigerated, frozen and fresh) low fat Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
223933550|NCT06487507|BEHAVIORAL|Lower carbohydrate diet|Prior to surgery, participants complete diet records for 7 days. After, participants will receive one shipment containing prepared meals (refrigerated, frozen and fresh) lower carbohydrate Mediterranean that will be tested on this trial. The dietary intervention will be followed daily for two (2) weeks. Participants will complete a food frequency questionnaire to track food consumption. The diet will focus on including lean protein sources, high-quality fat and high-quality carbohydrate sources among others, and will limit refined sugars and high glycemic carbohydrates.
224096893|NCT02532049|BIOLOGICAL|MVA Pfs25-IMX313|
224096894|NCT00991900|DEVICE|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
224096895|NCT01583036|DRUG|Digoxin Alone|Single administration of digoxin 0.25mg
224096896|NCT01583036|DRUG|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
224096897|NCT06812715|DRUG|Pirtobrutinib|Pirtobrutinib is a first-in-class, oral noncovalent Bruton tyrosine kinase (BTK) inhibitor (BTKi) that was approved in January 2023 in the United States for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL) and later that same year CLL. It is currently being investigated across several global randomised phase III trials for frontline and R/R chronic lymphocytic leukaemia (CLL).
224096898|NCT05728814|DRUG|Dostarlimab|"The treatment under observation is dostarlimab administered on day 1 of each treatment cycle until disease progression, unacceptable toxicity or patient/doctor's decision.~The recommended dose for dostarlimab is 4 cycles of 500 mg every 3 weeks followed by 1000 mg every 6 weeks for all subsequent cycles."
223718475|NCT06957912|DEVICE|Transcutaneous auricular vagus nerve stimulation|"Transcutaneous auricular vagus nerve stimulation is performed using earphone-shaped stimulators (tVNS501, Ruishenan Medical Device, Inc. JiangSu, China) on the left tragus areas of the outer ear for a total of 30 min. Using parameters we have identified through systematic review, electrical stimulation (pulse width: 200-300 μs; frequency: 25 Hz; duty cycles: 50%) is initiated at 200% perceptual threshold (PT) which means the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. All conscious patients will be told they may or may not feel any sensation from the stimulation.~The stimulation will be performed between 15:00 and 17:00 on the first day before surgery, at least 30 minutes before the start of surgery and between 08:00 and 10:00 on the first to third day after surgery."
223718476|NCT06957912|DEVICE|Sham stimulation|Sham stimulation is performed using earphone-shaped stimulators (tVNS501, Ruishenan Medical Device, Inc. JiangSu, China) on the left tragus areas of the outer ear for a total of 30 min. Using parameters we have identified through systematic review, electrical stimulation (pulse width: 200-300 μs; frequency: 25 Hz; duty cycles: 50%) is initiated at 200% perceptual threshold (PT) which means the minimum amount of electricity required to perceive electrical stimulation on the skin described as a pricking or tingling sensation. And the current will be automatically switched off after 15 s. All conscious patients will be told they may or may not feel any sensation from the stimulation. The stimulation will be performed between 15:00 and 17:00 on the first day before surgery, at least 30 minutes before the start of surgery and between 08:00 and 10:00 on the first to third day after surgery.
223718477|NCT02706470|DRUG|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
223718478|NCT02706470|DRUG|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
223933551|NCT06110468|OTHER|CoreDISTParticipation|CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
224096899|NCT06657404|DRUG|use Amiodarone, Bisoprolol and Digoxin|"Amiodarone 200mg tid orally for 1 week, then reduced to 200mg bid orally for another week.~The dose of amiodarone will be reduced to 200mg bid orally for 1 week, and then 200mg qd maintenance treatment will be started in the 3rd week of dosing.~Bisoprolol 2.5-5mg qd oral treatment, the specific dose is decided by the investigator.~Digoxin 0.125mg qd orally."
224096900|NCT06656767|OTHER|No intervention|This study utilises pre-collected samples only.
223718479|NCT03398967|BIOLOGICAL|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"1. Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~2. Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~3. Other: Laboratory Biomarker Analysis"
223933552|NCT03960099|BEHAVIORAL|Pictograph in Banner and Verification Alert|Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
223933553|NCT05690945|DRUG|QL1706|QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
223933554|NCT05690945|DRUG|Tilesizumab|Tilesizumab will be administered by IV infusion at 200mg on Day 1 of each 21-day cycle until unacceptabletoxicity or loss of clinical benefit.
224096901|NCT04194944|DRUG|Selpercatinib|Administered orally
223718480|NCT01127074|BIOLOGICAL|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
224096902|NCT04194944|DRUG|Carboplatin|Administered IV
224096903|NCT04194944|DRUG|Cisplatin|Administered IV
224096904|NCT04194944|DRUG|Pemetrexed|Administered IV
224096905|NCT04194944|DRUG|Pembrolizumab|Administered IV
224096906|NCT06158100|DRUG|Venetoclax|Venetoclax will be given orally (PO) at the assigned doses of 50 or 100 mg once daily for 7, 14 or 21 days starting at day 1 of each 28-day cycle, for up to 12 cycles.
224096907|NCT06158100|DRUG|Azacitidine|Azacitidine will be administered at a dose of 20mg/m\^2 once daily subcutaneously (SC) or intravenously (IV) for five days (Days 1-5) of each 28-day cycle.
224096908|NCT06158100|BIOLOGICAL|Donor Lymphocyte Infusion|"Donor lymphocyte infusions (DLI) may be administered at the discretion of the treating physician, if certain criteria are met. Participants may receive up to three (3) infusions of donor lymphocytes (a type of white blood cell) at the following dose levels and study timepoints:~* DLI 1: 1x10\^6 cluster of differentiation 3+ (CD3+) cells/kg, after cycle 3~* DLI 2: 5x10\^6 CD3+ cells/kg, after cycle 5, if there is persistent MRD~* DLI 3: 1x10\^7 CD3+ cells/kg, after cycle 7, if there is persistent MRD."
224096909|NCT06710847|DRUG|GSK4418959|GSK4418959 will be administered.
224285694|NCT06063174|BEHAVIORAL|Be Well Program|12-week online program in which participants learn about the importance of social relationships, connectedness, and interpersonal conflicts, and participate in live online group coaching. Participants whose social relationship/conflict domain is dysregulated will be assigned to this intervention program.
224285695|NCT06063174|BEHAVIORAL|Eat Well Program|12-week online program in which participants learn about mindful eating and participate in live online group coaching. Participants whose diet domain is dysregulated will be assigned to this intervention program.
223933555|NCT05884164|PROCEDURE|Thoracic erector spinae plane block|After induction of general Anaesthesia,a high frequency ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinal muscle and the transverse processes are identified, spinal needle will be inserted after standard skin disinfection in a caudal to cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep to the erector spinal muscle. After hydrolocalization with ml normal saline, this plane will be opened and 20 ml of 0.25 %bupivacaine will be administered for block performance
223933556|NCT05884164|PROCEDURE|Thoracic paravertebral plane block|After induction of general Anaesthesia ,with the probe in the longitudinal paramedian position, it is then moved from medial to lateral direction to appreciate the saw tooth appearance of the facet joints close to the midline which changes to long finger-like shadow of the transverse process as the probe is moved slightly laterally. Repositioning the probe over the transverse process ensuring the space of interest is in the middle of the probe once again one should appreciate the intercostal muscles and the dense bright white line of the pleura in between the shadows of the transverse processes. The needle is then introduced at the caudal end of the probe in plane in a caudal to cranial direction aiming for the angle between the bottom of the transverse process and the pleura. Once position is confirmed, 20 ml of 0.25% bupivacaine will be administered for the block performance.
223933557|NCT06166836|DRUG|D1553|D1553 orally taken，600mg twice a day
223933558|NCT06166836|DRUG|IN10018（Ifebemtinib）|IN10018 orally taken once daily at approximately the same time each day
223933559|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
223933560|NCT05779761|BEHAVIORAL|Online, Self-Directed Attention & Reflective Thought Skills Training with Coaching Support|The initial set of modules focus on psychoeducation about distress, the impact that cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/rumination/self-criticism. The next set of modules focus on the development of attention and reflective thinking skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
223933561|NCT05779761|BEHAVIORAL|Online, Self-Directed Health & Wellness Education Training with Coaching Support|The initial set of modules focus on psychoeducation about stress, the impact that stress has on one's life, and self-monitoring of stress. The next set of modules focus on sleep, time management, nutrition, and exercise. All modules will be online and self-directed. An internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, worksheets). Brief, weekly coaching support (from a trained, masters-level student) will be provided to promote engagement and to help clarify concepts.
223933562|NCT02787005|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223933563|NCT01231971|DRUG|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
223933564|NCT01231971|DRUG|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
223933565|NCT04817020|OTHER|%2 Klorheksidin|Effect on phlebitis
223933566|NCT05461885|BEHAVIORAL|Supervised exercise|The exercise sessions start with warm-up exercises, followed by 10-20 minutes resistance training (Part A), 10-20 minutes High Intensity Functional Training (HIFT) (Part B) and cool down. Instructors are allowed to make local adjustments as the delivery of the intervention is considered pragmatic. The participants can either perform the exercise together as one group, in pairs or one-by-one depending on individual needs and requests.
223933567|NCT05176392|DEVICE|Active rTMS|Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.
223933568|NCT05176392|BEHAVIORAL|Headache Management Therapy|Therapy will be provided on headache management.
224096910|NCT06710847|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor will be administered.
224285696|NCT06063174|BEHAVIORAL|Sleep Well Program|12-week online program in which participants learn about the importance of good sleep and participate in live online group coaching. Participants whose sleep domain is dysregulated will be assigned to this intervention program.
223533833|NCT03501628|DIETARY_SUPPLEMENT|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
223533834|NCT03501628|DIETARY_SUPPLEMENT|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
223533835|NCT03501628|DIETARY_SUPPLEMENT|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
223933569|NCT05176392|DEVICE|Sham rTMS|Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.
223933570|NCT05176392|BEHAVIORAL|Headache Education Control|In the control, educational sessions on headaches will be provided.
223933571|NCT05784194|PROCEDURE|Intervention for correct discharge medication list|As above
223933572|NCT06843824|DEVICE|a custom-made graphene therapy cap|The GFII involved the use of a custom-made graphene therapy cap. The cap consisted of 3 parts: the main body of the cap, the thermostat and the power adapter. One end of the thermostat was connected to the main body of the cap, and the other end was connected to the power adapter; the adapter was plugged into a 220 V household power outlet. This turned on the cap, and the temperature could be adjusted. The light energy conversion rate of the graphene coating material used in the cap reached 90%, generating a temperature of 40 °C. Five caregivers were responsible for providing care for the elderly individuals. We will provided standardized training on the GFII to their caregivers. Each caregiver was responsible for assisting with the intervention of the elderly individuals that they usually cared for.
223933573|NCT06843824|DEVICE|A regular cap that generates heat|The rest of the procedure is the same as the GFII group, but the cap used is a regular cap that can heat up to 40°C.
223933574|NCT05580003|DRUG|PF-07817883|Oral suspension or solid oral formulation(s)
223933575|NCT05580003|DRUG|Placebo|Placebo suspension
223933576|NCT05580003|DRUG|Midazolam|midazolam oral solution
223933577|NCT05580003|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablet
223933578|NCT04717544|BEHAVIORAL|Intervention Arm|The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
223933579|NCT04116372|BEHAVIORAL|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
223933580|NCT00516477|BIOLOGICAL|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
223933581|NCT02402569|DEVICE|32 channels Deep Brain Stimulator|
223933582|NCT04896736|OTHER|Multisite tissue oxygenation-guided care|"The following intervention algorithm is intended to be used as a guidance only. We emphasize the different aspects that can cause changes in SctO2/SstO2 in a systematic approach. We avoid recommending a concrete drug and method of dosing for a specific condition.~Manage tissue perfusion Preload: overall picture including direct observation of the heart, findings of echocardiography, urine output, blood loss, labs results, HR, BP, PPV, SVV, fluid responsiveness (SV increase \>/= 10% following 250 ml fluid bolus) Contractility: direct observation of the heart, findings of echocardiography Stroke volume and heart rate: important determinants of CO Systemic vascular resistance: important determinant of BP Regional vascular resistance: important determinant of tissue perfusion along with perfusion pressure Maintain autoregulation: normalize CO2, avoid potent vasodilators~Manage arterial blood oxygen content~Manage tissue metabolic activity"
223933583|NCT04896736|OTHER|Usual care|Usual care in this study means the standard perioperative care. Patients who are meant to receive usual care will receive both cerebral and muscular tissue oxygen saturation monitoring; however, the monitor screen will be covered and the monitoring data will not be used to guide clinical care.
223718481|NCT01023750|DRUG|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
223933584|NCT02029235|DRUG|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
223933585|NCT02029235|DRUG|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
223933586|NCT02246075|DRUG|EVP-6124|
223933587|NCT01387516|BEHAVIORAL|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
223933588|NCT01387516|BEHAVIORAL|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
223933589|NCT01387516|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
223933590|NCT01387516|BEHAVIORAL|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
223933591|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's Parent Toolkit 2.0|Parent Toolkit 2.0 is designed to equip parents and caregivers with skills to talk to their teens about sex and contraception and ultimately influence their teens' decision-making and behaviors around sex. The Georgia Campaign for Adolescent Power \& Potential (GCAPP) developed the Parent Toolkit intervention. Morehouse School of Medicine's (MSM) Health Promotion Research Center tested and adapted it through an OPA Innovation Network grant, creating Parent Toolkit 2.0.
223933592|NCT06579781|BEHAVIORAL|Morehouse Family Health Study's General Health Guide|General Health Guide provides information to parents on how to promote health in their families.
223933593|NCT06032377|BEHAVIORAL|cognitive behavioral therapy for sleep, anxiety, and depression|This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
223933594|NCT06032377|BEHAVIORAL|education about healthy nutrition habits and communication in older age|This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
223933595|NCT04694365|DRUG|Fluzoparib|A single oral dose of 50 mg Fluzoparib will be administered.
223933596|NCT03249142|DRUG|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
223933597|NCT03249142|DRUG|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~1. If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~2. If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
223933598|NCT04755920|DRUG|SGM-101|Fluorescence-guided surgery
223933599|NCT03736564|COMBINATION_PRODUCT|68Ga-DOTATATE PET/CT|Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
223933600|NCT06648265|DRUG|Tranexamic Acid (Topical)|Add 250 mg of TXA per liter of Klein\&#39;s Tumescent solution for arm liposculpture
223933601|NCT06648265|DRUG|Tumescent solution with dilute lidocaine and epinephrine|Arm infiltration with traditional Klein\&#39;s tumescent solution
223718482|NCT00314665|DRUG|Thalidomide|
223533836|NCT03501628|DIETARY_SUPPLEMENT|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
223533837|NCT02117102|OTHER|Bladder and lumbar stimulation technic|
223533838|NCT04256655|DRUG|cohort 1 0.225g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
223533839|NCT04256655|DRUG|Cohort 2 0.75g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
223533840|NCT04256655|DRUG|Cohort 3 2.25 g|Drug: CDX 6114 CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug. Matching Placebo The placebo oral dosing solution will also be supplied as an oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
223533841|NCT04306328|DEVICE|Neurostimulation|Implantation of 2 multicontact cuff electrodes in the upper limb of patients with tetraplegia and control of the stimulation by contralateral shoulder movements
223533842|NCT01946334|DEVICE|anorectal manometry and high-resolution three-dimensional|
223533843|NCT04152239|PROCEDURE|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
223533844|NCT01836757|DRUG|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
223533845|NCT01836757|DRUG|Placebo|
223533846|NCT06241300|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program is an evidence-based group parenting intervention designed to reduce disruptive behavior in young children (2-8 years old).
223933602|NCT04068506|DRUG|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
223933603|NCT04793100|OTHER|Ophthalmologic exam at inclusion and 12 months after CRVO|"As part of routine care : OCT-B (Optical coherence tomography-B), OCT-angiography (Optical coherence tomography and fluorescein angiography after pupillary dilatation (at inclusion only)~Added by the study :~* Assessment of best corrected visual acuity in letters read and validated using the ETDRS scale ;~* The shooting of a 10 second infrared movie by the Heidelberg Spectralis device centered on the head of the optic nerve (at inclusion only)~* A measurement of the eye tension with an air tonometer (at inclusion only)~* A blood pressure measurement (diastolic and systolic) and pulse measurement (at inclusion only)~* A color retinophotography (Optos) with autofluorescence images~* A color Doppler ultrasound of the optic nerve of both eyes will be performed, for patients treated at the Foundation A de Rothschild Hospital only."
223933604|NCT04793100|DRUG|Treatment standardization with aflibercept|For patients requiring intravitreal injection
223533847|NCT05951907|PROCEDURE|Maxillary extraction without palatal injection|Extraction of maxillary premolars by only buccal injection without palatal by using articaine 4% HCL with epinephrine (1:100,000)
223533848|NCT05951907|PROCEDURE|Maxillary extraction with buccal and palatal injection|Extraction of maxillary premolars by only buccal and palatal injection by using lidocaine 2 % HCL with epinephrine (1:80,000)
223533849|NCT04349969|DRUG|AK117|All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal.
223933605|NCT06463977|OTHER|Survey|The study consisted of a 3 × 3 online factorial experiment employing a survey instrument hosted via Qualtrics presenting describing three patient vignettes. The three patient vignettes varied by various clinical characteristics including age, gender, performance status, smoking history, extent of disease, symptoms and molecular status. Each patient had advanced non-small cell lung cancer (aNSCLC). Each vignette had two parts: Part 1 described the case history for one of the three patients, after which prognostic estimates and medical decision-making was assessed (i.e. 1, 2, 3). Part 2 immediately followed and described the same vignette from the same patient with added information from a hypothetical ML predictive algorithm (i.e. A, B, C). The order of the vignettes in each survey was randomized with regard to presentation strategies for the ML risk predictions, so that there were 6 versions of the survey to which each participant was randomized.
223933606|NCT02911441|BEHAVIORAL|Cognitive Behavioral Therapy|
223933607|NCT03956628|BEHAVIORAL|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
223933608|NCT05948449|DRUG|S-1, Oxaliplatin, Cadonilimab|3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
223933609|NCT01715194|DEVICE|Telemedicine intervention|Patients undergoing telemedicine intervention
223933610|NCT05960539|PROCEDURE|surgical training|surgical residency focussed on visceral robotic procedures
223533850|NCT04349969|DRUG|AK117+AK104|All Subjects will receive 3 weekly infusions of AK117 (Days 1, 8, and 15) and 1 infusion of AK104 (on Day 1) as combination therapy in each 21-day treatment cycle until unacceptable toxicity, documentation of confirmed PD, or subject withdrawal.
223533851|NCT05210816|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
223933611|NCT06509529|OTHER|Motivational Interviewing Based on the COM-B Model|Motivational Interviewing Based on the COM-B Model will be applied to the women in the experimental group.
223933612|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Cyclophosphamide: 250 mg/m\^2 IV q4w after Myozyme infusion for 6 months.
223933613|NCT00701701|BIOLOGICAL|Myozyme® (alglucosidase alfa)|Myozyme®: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m\^2 IV weekly beginning the day after Myozyme infusion for 4 weeks (an optional additional 2nd cycle could be administered at the discretion of the investigator); Methotrexate: 15 mg/m\^2 subcutaneous qow on the day after Myozyme infusion for 6 months.
223933614|NCT01155206|DRUG|glucagon|glucagon 3ng/kg/min
223933615|NCT00589875|BIOLOGICAL|CAN-2409|Single dose of 3x10e11 vector particles of CAN-2409 delivered to the tumor bed after resection on day 0.
223933616|NCT00589875|DRUG|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
223933617|NCT00589875|DRUG|Temozolomide|Concomitant TMZ will be administered orally once a day at a dose of 75 mg/m2 starting the next day after completing prodrug and continued for 6 weeks. Adjuvant TMZ will be administered days 1 to 5 of a 28-day cycle for 6 cycles with 150 mg/m2 administered for cycle 1, and 150 to 200 mg/m2 administered for cycles 2 to 6. Adjuvant treatment will start 1 month following completing RT.
223933618|NCT00589875|RADIATION|Radiation therapy|Radiation will be administered to up-front patients as per standard of care for the patient. It will start 3-7 days after CAN-2409 injection, preferably closer to 3 days. It will consist of standard external field radiation, limited to the area of tumor and brain adjacent to tumor, fractionated at doses of 200cGy per day for approximately 6 weeks to a total of 5500-6000 cGy.
223933619|NCT05786352|PROCEDURE|ERAS protocol|The combination of interventions explained in arm descriptions.
223933620|NCT06698588|DIETARY_SUPPLEMENT|Omega 3 Fish Oil supplements|Wileys Easy Swallow Mini Softgel capsules, dose 3 caps/day, providing 945mg/day long-chain omega-3 (540mg EPA, 405mg DHA).
223933621|NCT06698588|DIETARY_SUPPLEMENT|Placebo|Placebo: high-oleic sunflower oil (which broadly matches the overall fatty acid composition of typical UK diet), matched with active treatment for appearance and taste.
223933622|NCT06789250|BEHAVIORAL|Internet-based cognitive behavior therapy|The intervention within this study is based on cognitive behavioral therapy principles and adapted to target harmful alcohol use and mild to moderate alcohol use disorder co-occuring with psychological symptoms of depression, anxiety, stress and/or sleeping disorder. The 10 weeks of individually tailored treatment include psycho-educational texts as well as examples and exercises supported by a therapist.
223933623|NCT06879067|DRUG|Placebo|Placebo nasal spray
223933624|NCT06879067|DRUG|Foralumab Nasal|foralumab nasal spray
223933625|NCT06829732|DEVICE|closed-loop oxygen control (CLOC)|HAMILTON-C6 (Hamilton Medical, Bonaduz, Switzerland) ventilators will be used. It allows for O2 Assist software, that will be installed on all C6 ventilators before the start of this study. Automatic Oxygen management sets the Oxygen control according to the patient's measured SpO2 and the operator-set SpO2 target range. The Oxygenation controller will be activated for 4h and adjusts the Oxygen according to patient's measured SpO2.
223933626|NCT06829732|DEVICE|2. manual oxygen titration (MOT)|O2 will be manually set according to SpO2 target during a 4h period.
223533852|NCT01448616|DRUG|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
223718483|NCT05004766|OTHER|Robot assisted gait training with virtual reality|Using the VR system during robot training, the auditory stimulation of VR was applied along with the image of walking of a forest road or coastal road at the same speed as the robot walking speed. The VR programs are a composition of scenic beaty with sounds of nature. Each program is a blend of scenes such as the ocean, desert, forest, flowers, waterfalls, and wildlife.
223718484|NCT02224040|DRUG|ceftriaxone|
223718485|NCT02224040|DRUG|ceftriaxone and azithromycin|
223718486|NCT02224040|DRUG|azithromycin|
223933627|NCT06772350|PROCEDURE|examinations|Echo-Doppler and blood samples
223933628|NCT06777381|PROCEDURE|single visit root canal treatment using ProTaper Universal rotary system|single visit endodontic treatment will be performed using ProTaper Universal rotary system for root canal preparation.
223718487|NCT02224040|DRUG|azithromycin and cefixime|
223718488|NCT05168488|BEHAVIORAL|Fasted morning resistance exercise|On three separate occasions, participants will perform a standardized resistance exercise protocol in the morning while fasting.
223718489|NCT05168488|BEHAVIORAL|Afternoon resistance exercise|On three separate occasions participants will perform a standardized resistance exercise protocol in the afternoon after eating their regular lunch
224096911|NCT07036796|DRUG|Melatonin|"Melatonin (N-acetyl-5-methoxytryptamine), also called the hormone of darkness, secreted primarily by the pineal gland. Possesses antioxidant, anti-inflammatory, anti-diabetic and neuroprotective effects. All of which could be explained by its activation of Nrf2 signaling pathway.~Melatonin administration has shown to improve motor nerve conduction velocity and nerve blood flow, reduce the levels of pro-inflammatory cytokines, reinforce antioxidant defense, and decrease DNA fragmentation through upregulating nrf2 pathway, when tested in mice with diabetic peripheral neuropathy. Moreover, early treatment with melatonin has shown to prevent developing diabetic neuropathy in streptozotocin induced diabetic mice."
224096912|NCT06718491|BEHAVIORAL|Managing Physical Reactions to Overwhelming Emotions (IMPROVE)|Participants may be randomized to IMPROVE. IMPROVE is a three session virtual intervention delivered by research clinicians and augmented by a mobile application. The treatment is designed to target and reduce distress contributing to heavy alcohol use during medication for opioid use disorder treatment.
224096913|NCT06718491|BEHAVIORAL|Health Education Training (HET)|Participants may be randomized to HET. HET is an active control intervention that is equally intensive as IMPROVE It includes three virtual sessions and a mobile application. HET is designed to target healthy lifestyle behaviors such as diet and sleep.
224096914|NCT07040930|DRUG|GenSci120|a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
224096915|NCT07040930|DRUG|Placebo|a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
224096916|NCT07037784|OTHER|Continuous monitoring of vital constants with OXYFLEX® biosensor.|The comparison of physiological data (heart rate, respiratory rate, temperature, pulse oxygen saturation, hemoglobin levels) collected by the OXYFLEX® biosensor with those obtained through standard monitoring over a maximum duration of 10 hours.
224096917|NCT06723171|DRUG|IRX4204|Active Treatment
224096918|NCT06723171|OTHER|Placebo|Placebo
224096919|NCT06723691|DRUG|Acetaminophen|Acetaminophen
224285697|NCT06063174|BEHAVIORAL|Move Well Program|12-week online program in which participants learn about the importance of adequate physical activity for health and participate in live online group coaching. Participants whose physical activity domain is dysregulated will be assigned to this intervention program.
224285698|NCT03081728|DEVICE|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
224285699|NCT03081728|DRUG|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
224285700|NCT01086345|RADIATION|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
223718490|NCT00617565|DRUG|biphasic insulin aspart|
223933629|NCT06777381|PROCEDURE|single visit root canal treatment using M-Pro rotary system|single visit endodontic treatment will be performed using MPro rotary systems for root canal preparation.
223933630|NCT06776939|DEVICE|Oxygen therapy|All patients are subject to both oxygen therapy groups in this randomized cross-over study. Study measurements are performed during several different disconnection sessions. Disconnection sessions can either be short (\<90 min) or long (12 hours). Both short and long disconnection sessions are performed twice; once with conventional oxygen, and once with high-flow tracheal oxygen as respiratory support.
223933631|NCT06775821|DEVICE|Ultrasound or CT of the abdominal aorta|Patient underwent ultrasound or CT of the abdominal aorta
223933632|NCT06738225|DIAGNOSTIC_TEST|certain serum MicroRNA biomarkers (miR-15b and miR-21)|miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer
223933633|NCT06765473|DRUG|Misoprostol|preoperative vaginal and postoperative sublingual administration of misoprostol (800 μg) to reducing the amount of blood loss during and 24 hours after CS to determine the optimum time for drug administration.
224096920|NCT06723691|DRUG|Metformin|Metformin
224096921|NCT06723691|DRUG|Warfarin|Warfarin
224096922|NCT06723691|DRUG|Atorvastatin|Atorvastatin
224096923|NCT06723691|DRUG|Digoxin|Digoxin
223933634|NCT06759922|DRUG|Tab Metformin + Tab Glimepiride|Tab Metformin 500mg+ Tab Glimepiride 2mg (FDC) once per orally for 90 days.
223933635|NCT06759922|DRUG|Tab Metformin + Tab Empagliflozin|Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) once per orally for 90 days.
223933636|NCT06759922|DRUG|Tab Metformin +Tab Sitagliptin|Tab Metformin 500mg+Tab Sitagliptin 50mg (FDC) once per orally for 90 days.
223933637|NCT06759922|DRUG|Tab Metformin + Tab Empagliflozin + Tab Sitagliptin|Tab Metformin 500mg+Tab Empagliflozin 12.5mg (FDC) + Tab Sitagliptin 50mg once per orally for 90 days.
224096924|NCT06723691|DRUG|HRS9531|HRS9531
224096925|NCT06884072|DRUG|Pimicotinib capsule|Pimicotinib capsule
224096926|NCT07043803|OTHER|Reduction of anticholinergic medication|Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.
224096927|NCT06884449|DIETARY_SUPPLEMENT|Arrabina P Prebiotic 5.0 g|Active Powder
224096928|NCT06884449|DIETARY_SUPPLEMENT|Arrabina P Prebiotic 3.5 g|Active Powder
224096929|NCT06884449|OTHER|Placebo|Placebo Powder
224096930|NCT06926296|OTHER|Self-Questionnaires for Healthcare Workers|Health workers will be invited to complete an online self-questionnaire.
224285701|NCT01086345|BIOLOGICAL|bevacizumab|Given IV
224285702|NCT01086345|DRUG|irinotecan hydrochloride|Given IV
223718491|NCT00617565|DRUG|biphasic human insulin|
224285703|NCT05601076|PROCEDURE|fixed with the triple-buffer system|The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
223933638|NCT06825182|DRUG|Outpatient newly diagnosed type 2 diabetes subjects|Outpatient newly diagnosed type 2 diabetes subjects, who have signed the informed consent form, meet the inclusion and exclusion criteria, and have their demographic data collected, including height, weight, systolic and diastolic blood pressure, and calculation of the body mass index (BMI) = weight/height\^2 (kg/m\^2). Fasting and postprandial 120-minute glucose, insulin (INS), C-peptide (Cp), and glucagon (GCG) levels are measured, or an Oral Glucose Tolerance Test (OGTT) is performed, measuring glucose, INS, Cp, GCG at 0, 30, and 120 minutes, and renal function and HbA1c are tested, with eGFR calculated. Type 2 diabetes patients are treated with GLP-1RA for three months, and then the aforementioned indicators are retested to complete the study.
223933639|NCT06825182|DRUG|Inpatient newly diagnosed type 2 diabetes subjects|Demographic data are collected. Fasting and postprandial 120-minute glucose, insulin (INS), C-peptide (Cp), and glucagon (GCG) levels are measured, or an Oral Glucose Tolerance Test (OGTT) is conducted, measuring glucose, INS, Cp, GCG at 0, 30, and 120 minutes, and renal function and HbA1c are tested. During hospitalization, if hypoglycemic symptoms occur or peripheral blood glucose or continuous glucose monitoring is ≤3.9 mmol/L, immediate venous blood is drawn for glucose, GCG, adrenocorticotropic hormone (ACTH), cortisol (Cor), growth hormone (GH), and Cp testing. Patients are treated with GLP-1RA for three months, then the aforementioned indicators are retested to complete the study and hypoglycemia (including hypoglycemic clamp and hypoglycemia tests) is assessed for glucose and GCG, with additional tests for ACTH, Cor, GH, and Cp if conditions permit, to complete the study.
223933640|NCT06817122|BEHAVIORAL|Let's Talk Tech|Let's Talk Tech is a self-administered dyadic education and communication tool delivered as a web application to support shared decision making about technology use.
223933641|NCT06745596|PROCEDURE|cataract surgery 1|Cataract with limited anterior pars plana vitrectomy
223933642|NCT06745596|PROCEDURE|cataract surgery 2|cataract without limited anterior pars plana vitrectomy
223933643|NCT06750705|OTHER|PechaKucha|The PechaKucha format consists of 20 slides, each displayed for 20 seconds, focusing on vital signs measurement skills. The method emphasizes a fast-paced, engaging, and visual learning experience designed to enhance retention and improve students' practical knowledge and skills in measuring vital signs.
223933644|NCT06750705|OTHER|PowerPoint|The PowerPoint presentation will cover the same vital signs measurement content but in a more conventional, linear format. The intervention will aim to reinforce students' understanding of vital signs through text and images, with a slower pace compared to the PechaKucha method.
223933645|NCT06754748|OTHER|Caffeinated coffee|11 g caffeinated coffee made with 200 ml water was given to participants.
223933646|NCT06754748|OTHER|Decaffeinated coffee|11 g decaffeinated coffee made with 200 ml water was given to participants.
223933647|NCT06754748|OTHER|Water|200 ml water was given to participants.
223933648|NCT03593226|DRUG|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
223933649|NCT06775366|DRUG|Remimazolam|Remimazolam 6mg/kg/h was pumped intravenously for 2.5 min, Sufentanil 0.5 μg/kg and rocuronium 0.6mg/kg were injected intravenously, and endotracheal intubation was performed 3 minutes later. Remimazolam was then pumped at 1 mg/kg/h, the BIS was kept in the range of 40-60 through general anesthesia, and the remimazolam infusion rate was adjusted (0.5-3 mg/kg/h).If the BIS cannot be maintained at ≤ 60 or there are signs of potential inadequate anesthesia (such as cough, sweating, and patient movement), and the maximum infusion dose of remimazolam has been given, supplemental sedation with the remedial drug sevoflurane or propofol is used and the case is dismissed.
223933650|NCT06775366|DRUG|propofol|Propofol (2-3mg/kg), Sufentanil (0.5μg /kg), rocuronium (0.6mg/kg) were injected intravenously, and endotracheal intubation was performed for 3 minutes. Subsequently, propofol was pumped at 4-10mg/kg/h to maintain the BIS in the range of 40-60.
223933651|NCT04057820|OTHER|Finnegan Neonatal Abstinence Scoring Tool|The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
223933652|NCT04057820|OTHER|Eat, Sleep, Console (ESC) care tool|The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
224285704|NCT05601076|PROCEDURE|fixed using the conventional lifting platform method|In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
224285705|NCT03879096|OTHER|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
224285706|NCT03162068|OTHER|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
223718492|NCT03906123|DRUG|NBP|NBP soft capsules
223718493|NCT03906123|DRUG|Placebos|Soft capsules manufactured to mimic NBP
223718494|NCT01235247|BEHAVIORAL|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
223933653|NCT06809348|BEHAVIORAL|PRECISE|"PRECISE includes aspects of several evidence-based approaches, such as Safety Planning and DBT to manage and reduce suicide risk. During the initial visit, staff train participants how to complete EMAs. Participants then complete two weeks of five-times per day EMAs regarding their emotions, emotion regulation strategies as well as SITBs. Following an initial learning period, participant data is analyzed via GIMME to determine the within-person correlates of SITBs. Data is processed through a real-time pre-programmed data cleaning and analysis script. Coaches then teach a selection of skills in collaboration with the client."
223933654|NCT04517435|DRUG|ME-401|ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design
223933655|NCT04517435|DRUG|Rituximab|"375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines."
223933656|NCT04517435|DRUG|Cyclophosphamide|750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle
223933657|NCT04517435|DRUG|Doxorubicin|50 mg/m2 IV Doxorubicin day 1 of 21-day cycle
223933658|NCT04517435|DRUG|Vincristine|1.4 mg/m2 (max 2 mg) IV Vincristine
223933659|NCT04517435|DRUG|Prednisone|100mg PO Prednisone Days 1-5 of 21-day cycle
223933660|NCT06810921|PROCEDURE|lateral sinus lift|"A rectangular shaped osteotomy was performed using a low-speed surgical handpiece and round diamond bur, with copious cooled normal saline irrigation.~The Schneiderian membrane (SM) was gently elevatated using Frios Sinus Set elevators for implant placement"
223933661|NCT06754540|DRUG|Azacitidine (AZA)|Azacitidine 32mg/m2
223933662|NCT06753773|DEVICE|Repeated Low-Level Red-Light|All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.
223933663|NCT06818149|DIAGNOSTIC_TEST|Biomarker Analysis for Severity Assessment|Blood samples will be collected at baseline and at follow-up time points (3 days, 7 days, and before discharge). Traditional myocardial injury biomarkers, iron metabolism-related biomarkers, and immunological biomarkers will be tested.
223933664|NCT06868745|DRUG|Experimental: melatonin treatment group|Each participant received melatonin 5 mg for a period of 30 days
223933665|NCT06868745|DRUG|Placebo comparator: placebo treatment group|Each participant received placebo for a period of 30 days
223933666|NCT06816251|DRUG|HRS-1893|HRS-1893 tablet.
224096931|NCT06409208|BEHAVIORAL|mHealth intervention (video and reminder SMSs)|intervention includes educational video related to postnatal care and reminder SMSs related to postnatal visits, family planning adoption and exclusive breast feeding practice.
224096932|NCT06668805|DRUG|Vosoritide Injection|Modified recombinant human C-type natriuretic peptide Vosoritide
224096933|NCT06668805|DRUG|Human Growth Hormone|Commercial product containing somatotropin.
224096934|NCT06732466|DRUG|Chlorhexidine toothpaste|A toothpaste containing 0.3% chlorhexidine + 3% AmCl
223933667|NCT06816251|DRUG|HRS-1893 placebo|HRS-1893 tablet placebo.
224096935|NCT06732466|DEVICE|Toothbrush|Commercially available adult soft bristle toothbrush
224096936|NCT06732466|DRUG|Placebo toothpaste without chlorhexidine and AmCl|Negative Control Group assigned to use a placebo toothpaste without chlorhexidine and AmCl and brushing with a commercially available adult soft bristle toothbrush.
224285707|NCT05886309|DIAGNOSTIC_TEST|Collection of Blood samples|"The following samples will be drawn from each study participant immediately after the venipuncture performed for the whole blood donation:~* 1 sample with no anticoagulant (5 ml) for SF measurement with the CDMS method~* 1 EDTA (Ethylendiamintetraazetat) sample (7,5 ml) for a complete blood count with red blood cell indices and reticulocytes~* 1 EDTA sample (2,7 ml) for the measurement of hepcidin~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of SF with the ECLIA (Electrochemiluminescence-enzymeimmunoassay) and of the complete set of iron biomarkers (Transferrin Saturation, serum iron, Soluble Transferrin Receptor)~* 1 Li-Heparin-Gel sample (4.7 ml) for the measurement of CRP (C-reactive Protein)~* 1 sample with no anticoagulant (5 ml) for the measurement of SF with the CMIA (Chemiluminescence Immunoassay)~* 1 sample with no anticoagulant (5 ml) for storage"
223718495|NCT03015389|PROCEDURE|Diagnostic Test|WATS3D brush biopsy
223933668|NCT04968964|DEVICE|DiviTum® TKa assay|-Determines serum enzymatic activity of TK1
223933669|NCT04968964|OTHER|Study Care Plans|-Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
223933670|NCT06783400|BEHAVIORAL|SASA! Together|"SASA! Together is a community mobilisation approach that engages communities to create positive and sustainable changes around norms and behaviors that perpetuate violence against women. Some new features in this revision of SASA! include a distinct focus on IPV, including sexual decision-making; three strategies aligned to the socio-ecological model that reach across the whole community (individuals, groups, and institutions); and more support to get organisations and communities started and to sustain change.~The evidence- and theory-based SASA! approach is grounded in: (1) benefits-based activism, (2) a gender-power analysis, (3) four phases of change (start, awareness, support, action) according to the stages of behaviour change, (4) holistic community engagement, (5) local activism, (6) community leadership, and (7) institutional strengthening."
223933671|NCT06763887|OTHER|No Interventions|No intervention
223718496|NCT02552199|OTHER|gravimetric|
223933672|NCT04194424|OTHER|Multidisciplinary weight loss program|Diet and behavioral therapy,and supervised exercise sessions
223933673|NCT04194424|OTHER|Standard Care|General lifestyle tips
223933674|NCT04194424|DRUG|Metformin Hcl 850Mg Tab|1 tablet, twice daily
224096937|NCT06887829|RADIATION|Low dose radiotherapy|Participants will receive low dose radiotherapy (0.5 Gy) 3 times per week, for two weeks delivered via the X-Strahl Orthovoltage device.
224096938|NCT06887829|OTHER|Sham comparator|Participants will receive identical treatment 3 times per week, for two weeks delivered via the X-Strahl Orthovoltage device, without radiation.
223933675|NCT06844786|OTHER|Physical activity program|SCORE! Club is offered twice a week for enrolled participants. Modules will include soccer, arts and health, Sportball, and nature-based activities.
223933676|NCT06844786|OTHER|Navigation|Participants will have access to a navigator from the study team who will help them access resources relating to recreation and physical activity in their communities. For example, the navigator will help direct families with low income to the recreation assistance program if they are interested in such a service.
223933677|NCT06844786|OTHER|Health promotion|Health promotion messaging will be provided to participants via social media and other physical methods (i.e., flyers). Topics will include diet, sleep, physical activity, and other related items.
223933678|NCT05958940|PROCEDURE|Bright Light Therapy|In this study, Bright Light Therapy (BLT) will be administered according to Dutch depression guidelines, using Innolux LED light lamp (3800K, 10,000 lux). BLT will be given for one work week (Mon-Fri), 7:30-10:30 AM, 30 mins/session. Patients can have breakfast, read, or use devices. Treatment effectiveness will be evaluated using Self-Rated Quick Inventory of Depressive Symptoms (QIDS-SR). If remission is achieved (QIDS-SR \< 6), no additional treatment is given. If response is insufficient (QIDS-SR ≥ 6), 5 more sessions will be added in the following week, with maximum two extensions (1-3 weeks total).
223933679|NCT05958940|DEVICE|Blue Light Blocking Glasses|Plastic, orange-coloured glasses that primarily block blue light. To be worn in the evening.
223933680|NCT05308121|OTHER|Evaluation of biomechanics and viscoelastic properties of Achilles tendon|The biomechanical and viscoelastic properties of the Achilles tendon will be measured in the side lying position. Measurements will be taken from two different points with the ankle in the neutral position.
223933681|NCT05308121|OTHER|Evaluation of foot characteristics|The mobility of foot, morphological changes of foot and foot posture will be evaluated
223933682|NCT06745895|BEHAVIORAL|MATCHES|"Participants will be asked to complete a survey with specific topics including Hepatitis C (HCV) and Colorectal (CRC) knowledge and health beliefs, screening intentions and demographic characteristics.~Participants will be provided with education intervention materials (for example, a booklet) either in-person or via mail, access to free stool-based CRC screening, and access to free HCV screening.~Approximately 1-2 weeks after receiving the education materials, participants will be asked to complete a post-intervention survey about the same specific topics (for example, HCV and CRC knowledge, HCV and CRC health beliefs, HCV and CRC screening intentions, healthcare experiences, perceptions of the educational materials) over the phone with a trained study staff.~Participants with a positive HCV screening and/or CRC screening result will be navigated to follow-up care as needed."
223933683|NCT06743555|OTHER|Observation without surgery|Patients randomized to this arm will forego standard-of-care thoracic surgery and will undergo strict surveillance based on serial radiological follow-up and ctDNA monitoring
223933684|NCT06743555|PROCEDURE|Standard-of-care surgery|Patients randomized to this arm will undergo standard-of-care thoracic surgery and undergo post-operative surveillance with serial radiological follow-up and ctDNA monitoring
223933685|NCT03291522|PROCEDURE|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
223933686|NCT06889792|OTHER|Theory of planned behaviour|This theory holds that an intention to engage in a health-related behaviour is determined by the proximal factors of attitudes, subjective norms, and perceived behavioural control. Attitudes represent individuals perceived likelihood of performing and appraisal of the consequences of performing a health-promoting behaviour. Subjective norms are the social pressure perceptions to either perform or not perform a health-promoting behaviour. Finally, perceived behavioural control is an individual's perception of control regarding performing the behaviour.
223933687|NCT06889792|OTHER|Foot-in-the-door technique|The foot-in-the-door technique, which was introduced by Freeman and Fraser, emphasises the notion that individuals who initially comply with a small, easy request are more likely to later comply with a larger request. Compliance with the first request or target increases the individual's confidence and alters their self-perceived capability and willingness regarding further requests or targets. This technique can facilitate the recruitment process and enhance compliance.
223933688|NCT06889792|OTHER|Self-determination theory|"According to self-determination theory, behavioural regulation is more autonomous when it is internalised, as opposed to being regulated by external factors. Compared with external regulation, autonomous regulation is associated with increased self-efficacy, greater behavioural persistence, longer-term behavioural changes and more positive health behaviour. Autonomy is another influential determinant of behaviour that is emphasised by freedom of choice. There is some evidence that people who have greater autonomy demonstrating greater competence and self-efficacy in achieving behavioural change compared with those with less autonomy. As a result, increased autonomy will facilitate a gradual change in risky behaviours.~Our intervention aims to first change the participants' attitudes and their subjective norms through risk communication. Using foot-in-the-door technique and self-determination theory, it will then increase participants' willingness to adopt a healthy lifestyle."
223933689|NCT06889792|OTHER|Follow-up booster intervention|Staff will send WhatsApp/WeChat messages approximately once a week to remind the participants to adhere to their desired health-related lifestyle for the first 6 months. In addition, during the first week, the RA will send participants a link via WhatsApp/WeChat to a 1-minute video developed by the research team comprising content relevant to their selected health-related lifestyle. Four separate 1-minute videos will be compiled, each focusing on a different healthy lifestyle. These videos will indicate the health hazards of continuing this health risk behaviour and the benefits of adopting a healthy lifestyle. Moreover, the RA will encourage the participants to watch the video and ask any questions regarding the video content via WhatsApp/WeChat.
223533853|NCT01448616|DRUG|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects - negative or positive - on study endpoints."
223533854|NCT01448616|DRUG|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
224096939|NCT06744413|BEHAVIORAL|Multimodal prehabilitation program|"A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of these three domains will be utilized to maximize their synergistic anabolic effect.~The duration of the program will be set at 4 weeks."
224096940|NCT06733974|OTHER|Multi-faceted Intervention|The participant, i.e. relative, will receive the multifaceted intervention which include: a first meeting with the healthcare team including written information about palliative care for dying patients, information on possibility to participate in care, pro-active communication, and dedicated interview and brochure after the patient's death with possibility of psychological follow up.
223533855|NCT01448616|DRUG|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
223533856|NCT02630641|DRUG|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
223533857|NCT00773084|DRUG|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
223933690|NCT06889792|OTHER|Practical Resource Hub for Healthy Life leaflet|The participants will be provided a Practical Resource Hub for Healthy Life leaflet containing information on various applications, including (i) 'Move Your Body', (ii) 'Eat Healthy', (iii) 'Live Alcohol Free', and (iv) 'Stay Away from Tobacco', which were developed by the Hong Kong Department of Health
223933691|NCT06889792|OTHER|a brief intervention using the Ask, Warn, Advise, Refer and Do-it- again (AWARD) model|The participants will receive a brief intervention using the Ask, Warn, Advise, Refer and Do-it- again (AWARD) model : (1) Ask about and assess health-risk behaviours; (2) Warn about the high morbidity and mortality risks associated with health-risk behaviours; (3) Advise on adopting healthy lifestyles to improve the participant's health; (4) Refer to hotline services, such as those for smoking cessation and alcohol treatment or the nearest district health centre to follow up their health status; and (5) Do it again if participants have not adopted a healthy lifestyle at follow-ups.
223933692|NCT06751160|OTHER|Dry Needling|"Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Dry Needling will be given to group A along with baseline treatment through following protocol:~Patient will be in prone lying. Sterilized disposable dry needles of 0.25\*60mm will be used. Dry needling will be performed on three points on Hamstring muscle for one minute each. We considered a line between ischial tuberosity and head of fibula to target long head of bicep femoris (60% of line) and short head of bicep femoris (30% of line). Semitendinosus and Semi Membranosus were targeted at a point of 60% of line from ischial tuberosity to medial epicondyl of femur.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks."
224096941|NCT06895681|PROCEDURE|Blood Sample|Obtained at the time of non-study related routine blood draw.
224096942|NCT06895681|PROCEDURE|Tissue Sample|Obtained at the time of non-study related routine biopsy or surgical procedure.
224096943|NCT06895681|PROCEDURE|Excess fluid Sample|Obtained at the time of non-study related routine biopsy, surgical procedure, paracentesis, or thoracentesis procedure.
223533858|NCT02083978|OTHER|MRI scanning|
224096944|NCT06895681|OTHER|Medical Chart Review|Demographic, clinical, and pathologic information will be extracted from the medical record
224096945|NCT06702995|DRUG|XNW5004|Oral continuous
224096946|NCT06702995|DRUG|enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
224096947|NCT06751030|BEHAVIORAL|The Mother Mentor program|The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
224096948|NCT06751030|DIAGNOSTIC_TEST|GeneXpert HPV test|A cervical cancer screening tool.
224285708|NCT06316804|BEHAVIORAL|Video Intervention 1|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
224285709|NCT06316804|BEHAVIORAL|Video Intervention 2|A self-administered video-based mobile app with narratives on mental illness. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
224285710|NCT06316804|BEHAVIORAL|Video Intervention 3|An experimental self-administered video-based mobile app with narratives on mental illness after the waitlist period has been completed. The content of the videos consists of individuals sharing their personal experiences with depression and anxiety.
224285711|NCT03938415|PROCEDURE|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
223533859|NCT06120322|OTHER|Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies|During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
223933693|NCT06751160|OTHER|Soft Tissue Mobilization|"Baseline Treatment: Hot pack will be applied for 15 minutes on Hamstrings and lower back and transcutaneous electrical nerve stimulation (TENS) at lower back for warm up and pain relief to both groups. Then spinal mobilization (Poster lateral glide) of grade 1 and 2 (3 sets of 6 repetitions) i.e. within the spine resistance.~Soft Tissue Mobilization will be given to Group B along with Baseline treatment.~Subject will be in prone lying position with knee bent at 30 to 60 degrees. Soft tissue mobilization will be applied on hamstring muscle through Graston technique. Massage cream will be applied on hamstring muscle and Graston Instrument will be rubbed from gluteal line to politeal fossa 30 times for 60 seconds.~Sessions: Total 8 sessions will be given 2 sessions per week for 4 weeks."
223933694|NCT06743386|DEVICE|Therapeutic procedure combines EUS-Guided Radiofrequency Ablation (RFA)|It will be performed under general anesthesia with intubation, using a sectorial probe echoendoscope to target pancreatic tumors. Prophylactic measures, including intrarectal Diclofenac and antibiotics, are used to prevent complications. A high-frequency monopolar electrode needle is inserted into the lesion under ultrasound guidance, avoiding critical structures like pancreatic and biliary ducts. Energy is delivered until specific safety parameters are met, with multiple applications to maximize tumor coverage. RFA sessions are scheduled before, midway, and after chemotherapy cycles, and progress is monitored with routine imaging. Post-procedure care includes fasting, pain management, and standard blood tests. Patients are typically discharged the day after the procedure if no complications occur. Further treatment plans, including continuation or modification of chemotherapy and RFA, are determined based on disease progression observed in follow-up scans.
223933695|NCT02423629|DEVICE|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
223933696|NCT06754410|DRUG|Tamsulosin|group A take tamsulosin once daily
223933697|NCT06754410|DRUG|Cetirizine|give cetirizine once dailly
223933698|NCT06754410|COMBINATION_PRODUCT|Cetirizine + Tamsulosin|both once daily
223933699|NCT06754410|OTHER|Placebo|once dailly
223933700|NCT06502418|OTHER|Acupuncture therapy|7 acupuncture points will be used to managed pain and improved patient's experience
223933701|NCT06550687|OTHER|Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis|Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
223933702|NCT06588673|OTHER|Art Thrapy|Art therapy at Art Therapy Studio, a well-established recommended art therapy leader since 1967 with extensive experience in virtual therapy for patients with medical needs. Cheryl Pete, MA ATR-BC, a board-certified art therapist and the Clinical Director will complete the art therapy sessions. The art therapy will be a 1-hour sessions, once a week for a total of 8 weeks (or 8 sessions). Cheryl Pete's role will solely involve providing a service. Chery will complete the Art Therapy according to her standard practices. Cheryl's Art Therapy will not be altered in any way as a part of this research study. Cheryl will not collect any research data. As research participants are referred to Cheryl for the Art Therapy, the research participant's name and contact information will be shared.
223933703|NCT06753786|DRUG|Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.|Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
223933704|NCT06753786|DRUG|Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.|Prophylactic dosage and administration of unfractionated heparin or low molecular weight heparin according to their official prescribing information.
223933705|NCT06776055|BIOLOGICAL|HPV-16/18 vaccine|Recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast)
223933706|NCT06776055|BIOLOGICAL|Placebo|Placebo containing the same formulation as the active vaccine (Type 16 and 18 L1 proteins, Yeast) but without the active substance.
223933707|NCT06780345|DRUG|Placebo|Mechanically ventilated neonates will receive the usual protocol of sepsis and a placebo without vitamin C.
223933708|NCT06780345|DRUG|Vitamin C|Mechanically ventilated neonates will receive the usual protocol of sepsis plus vitamin C with a loading dose of 0.5 gm /kg and a maintenance dose of 0.5 gm /kg/hour adjusted for six hours for 7-10 days.
223933709|NCT06832839|PROCEDURE|Revascularization|Revascularization
223933710|NCT05162326|BIOLOGICAL|BC-101|Human umbilical cord tissue derived mesenchymal stem cells (hUC-MSC) suspension at concentration of 2, 4, or 6 million cells/mL.
223533860|NCT02690142|DRUG|Placebo|Single dose i.v.
223533861|NCT02690142|DRUG|ABY-035 i.v.|Single dose i.v.
223533862|NCT02690142|DRUG|ABY-035 s.c.|Single dose s.c.
223533863|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
223533864|NCT02450825|PROCEDURE|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
223933711|NCT06767163|DEVICE|iBalance|"Participants will engage in the device test, clinical assessment tests. The whole test will last twelve months, and the outcome will be assessed pre- and post-implementation for comparison and validation.~The intervention results are used to compared with traditional tests and clinical diagnosis, to identify whether the sensor provides a higher accuracy in predicting fall risk, and to explore the feasibility of the sensor in clinical scenarios."
223933712|NCT06841588|OTHER|Mulligan's Mobilization with Movement and Dry Needling|"the intervention group 1 was treated using Mulligan Mobilization with Movements and Dry Needling (DN\&MWM) for soft tissue trigger points, (N=15).~The treatment duration was 6 sessions, 3 sessions per week ( day after day)."
223933713|NCT06841588|OTHER|Dry Needling (DN)|The intervention group 2 was treated using Dry Needling (DN) for soft tissue trigger points, (N=15). The treatment duration was 6 sessions, 3 sessions per week ( day after day).
223933714|NCT04686877|PROCEDURE|STAPLE|Stereotactic aspiration plus urokinase clot irrigation
224096949|NCT06753136|DEVICE|percutaneous, laparoscopic or laparotomy lesion electrochemotherapy|All patients will receive Bleomycin intravenously with a dosage of 15.000 IU/m2. After a drug distribution time of 8 minutes, the lesions will be electroporated using the Cliniporator (IGEA S.P.A., Carpi, Italy), applying special handpieces depending on the route used: laparoscopic electrode, flexible and expandable for the laparoscopic procedure, linear or hexagonal electrode for laparotomy surgical access, variable geometry electrode for percutaneous access. The ECT procedure must be completed within 40 minutes.
224096950|NCT06764992|OTHER|Questionnaire|Participants will be asked to complete a questionnaire on demographics, risk beliefs and perception and prostate cancer screening behaviors, intentions and awareness of informed decision making.
224096951|NCT06764992|OTHER|Saliva Sample|Participants will be asked to provide a saliva sample for genetic risk testing to generate a SNP risk profile using a saliva sample collection kit with collection, storage and mailing instructions. We will assess the proportion of consented men who will provide a saliva sample.
224096952|NCT05006794|DRUG|zamzetoclax|Tablet(s) administered orally
224096953|NCT05006794|DRUG|Docetaxel|Administered intravenously
224096954|NCT05006794|DRUG|sacituzumab govitecan-hziy|Administered intravenously
224096955|NCT06589414|OTHER|Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)|"A summary consultation with the patient's general practitioner (GP) will take place within 15 days of the consultation to announce the cancer diagnosis. This patient-general practitioner consultation will complement the initial consultation.~At the end of the summary consultation, the patient's satisfaction and that of the GP will be assessed using satisfaction questionnaires.~In addition, patients will be asked to complete a patient diary for the duration of their participation in the study (6 months), in order to record the dates of consultations with the GP and the dates of consultations and/or hospitalisations at the referral care centre."
224096956|NCT07064187|DRUG|Cationorm single-dose eye drop|Cationorm single-dose eye drop is a preservative-free, cationic oil-in-water nano-emulsion.
224096957|NCT07064187|DRUG|Artificial tear eye drop|Artificial tear eye drops are hyaluronic acid, polymers or cellulose derivatives eye drops
224096958|NCT07061145|DRUG|Tirosin Kinase Inhibitors|Tyrosine kinase inhibitor (TKI) administered as part of standard clinical care for CML. No experimental treatment is applied. Exposure to the drug will be analyzed in association with erectile dysfunction outcomes.
223533865|NCT02450825|DEVICE|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
223533866|NCT02170064|DRUG|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
223533867|NCT03808571|OTHER|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
223933715|NCT06757335|DRUG|HP568|In the I/II stage: HP568 administered QD or BID for 28 day cycles.
223933716|NCT06757335|DRUG|HP568 in combination with palbociclib|In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
223933717|NCT06742528|DRUG|Ferrous sulfate|ferrous sulphate in a dose of 6mg/kg/day of elemental iron once daily for 8 weeks orally in syrup form.
223933718|NCT06742528|DRUG|Iron Polymaltose Complex|Iron Polymaltose complex in a dose of 6mg/kg/day of elemental iron once daily orally for 8 weeks.
223533868|NCT00628381|DIETARY_SUPPLEMENT|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
223933719|NCT06685744|DEVICE|Telerehabilitation_TRsA|Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach.
223933720|NCT06685744|BEHAVIORAL|Educational treatment|Home rehabilitation indications according to a conventional approach, customized according to the disease.
223933721|NCT06685744|DEVICE|Telerehabilitation_TRcA|Frequency: 5 weeks (4 sessions/week) of Telerehabilitation intervention provided according to a mixed model (3 asynchronous sessions + 1 synchronous session/week); Intensity: customized according to the patient's functional abilities (system's feedback); Time: 50 minutes/session; Type: a combination of exercises aimed at improving functional mobility and physical capacity according to a Task-oriented approach together with exercises aimed at recovering muscle strength (resistance) and improving endurance (endurance) using an Impairment-oriented approach.
223933722|NCT06747143|DIETARY_SUPPLEMENT|Lactobacillus casei DN-114001|Probiotic
223933723|NCT03219879|BEHAVIORAL|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
223933724|NCT03219879|OTHER|Usual care|Usual care without any study-related intervention
223933725|NCT06668402|DEVICE|Utilizing a smartwatch to gather data on individuals receiving treatment for rectal neoplasm.|Employing a smartwatch to monitor steps, sleep quality, intense physical activity, and vital signs in persons undergoing treatment for rectal carcinoma.
223933726|NCT06746701|DRUG|Peg-IFNα-2b combined with NA|From baseline day 1, take NA orally once daily until the drug can be discontinued. Concurrently, combine with Peg-IFN α-2b 180μg, administered subcutaneously once a week for 48-96 weeks (if the surface antigen is not converted to negative at week 48, continue Peg-IFN α-2b treatment, but the course of treatment should not exceed 96 weeks). Discontinue Peg-IFN α-2b (while maintaining continuous oral administration of NA), and continue taking NA orally.
223933727|NCT06746701|DRUG|Nucleotide Analogues|Starting from the first day of enrollment, take NA orally once a day.
223933728|NCT06758739|DRUG|Curcumin (Turmeric)|Curcumin Capsule will be given two per day for three months. Patient Recovery progress will be monitored month on month basis for consecutive three month.
223933729|NCT06758739|DRUG|Intralesional Steroid Injection|Intralesional Steroid Injection (1cc), one per week, will be administered in the fibrous bands wherever formed in the oral cavity. Patient recovery progress will be monitored on monthly basis for three months.
223933730|NCT04057131|DRUG|Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
223933731|NCT06836934|DEVICE|soft knee brace|A commercially available soft brace (orthomedics ser. number 86) plus traditional physiotherapy
223933732|NCT06836934|DEVICE|lateral wedge foot insole|Wearing Lateral wedge insole 5mm for 8 weeks Standardized non-customized laterally wedged insoles were evaluated. Insoles were made of high-density ethyl vinyl acetate, were wedged approximately 5°
223933733|NCT06836934|PROCEDURE|convential physical therapy program|"Strengthening Exercises:~* Quadriceps Strengthening: Exercises like straight leg raises, quadriceps sets, and seated knee extensions help strengthen the quadriceps muscle, which supports the knee joint.~* Hamstring Strengthening: Hamstring curls and bridges target the hamstrings to enhance stability and support for the knee.~* Hip Strengthening: Exercises such as hip abductions, adductions, and clamshells strengthen the hip muscles (each 3 sets, 10 reps). (Deyle et al ., 2005)~Flexibility Exercises:~* Hamstring Stretch: Gentle stretching of the hamstrings can alleviate tension around the knee.~* Quadriceps Stretch: Stretches like the standing quadriceps stretch help maintain flexibility in the front of the thigh.~* Calf Stretch: Stretching the calf muscles can prevent tightness (J. D. Deyle et al 2005) TENS (Transcutaneous Electrical Nerve Stimulation): Helps manage pain by sending electrical impulses to the affected area."
223933734|NCT06762535|DEVICE|repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 10 sessions of rTMS, stimulation protocol included 10 sessions within 14 days (once a day, 5 days/week, 2 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
223933735|NCT06762535|DEVICE|Sham repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 10 sessions of rTMS, stimulation protocol included 10 sessions within 14 days (once a day, 5 days/week, 2 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session).But there's no real pulse output,Just set the same conditions.
223933736|NCT05554510|OTHER|Observational|No interventions planned. Observational data collection only.
223933737|NCT02898610|DRUG|Colchicine|
223933738|NCT06786026|DRUG|bevacizumab|bevacizumab
223933739|NCT06786026|DRUG|QL1706|Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
223933740|NCT06786026|DRUG|Nab paclitaxel|albumin-bound paclitaxel
223933741|NCT04466150|DRUG|Ocrelizumab|open label biomarker study
223533869|NCT00628381|DIETARY_SUPPLEMENT|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
223533870|NCT03195569|DRUG|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
223533871|NCT03195569|DRUG|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
223533872|NCT03195569|DRUG|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
223533873|NCT03195569|DRUG|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
223533874|NCT03323164|DRUG|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
223533875|NCT03323164|DRUG|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
223533876|NCT06071676|OTHER|conventional impression group|Silicon impression material loaded on plastic tray and inserted inside the patient mouth
223718497|NCT05035550|BEHAVIORAL|Non-Deceptive Placebo|"The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening."
223933742|NCT06789146|PROCEDURE|Serratus posterior superior intercostal plane block|"Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223933743|NCT06789146|PROCEDURE|Thoracic Paravertebral Block|"Thoracic paravertebral block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
223933744|NCT06815419|OTHER|spiritual care education program|The spiritual care education program to improve nurses ability to provide spiritual care. Education includes; Program orientation, an introduction to spiritual care, the concepts of spiritual care, the significance of spiritual care, the theoretical underpinnings of spirituality in mental health, practical strategies for integrating spiritual care in psychiatric nursing, reflective practice, and self-care for enhancing personal spirituality were all covered in the program's weekly two-hour sessions.
223933745|NCT04846881|DRUG|Iclepertin|Iclepertin
223933746|NCT04846881|DRUG|Placebo|Placebo
223933747|NCT06735599|DIETARY_SUPPLEMENT|Wild Blueberry|Daily consumption of 22 g of freeze-dried wild blueberry freeze-dried powder for 8 weeks
223933748|NCT06735599|DIETARY_SUPPLEMENT|Placebo|Daily consumption of 22 g of freeze-dried macronutrient-matched placebo powder for 8 weeks
223933749|NCT06745817|DIAGNOSTIC_TEST|Assessement of nutritional status|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
223933750|NCT06745817|DIAGNOSTIC_TEST|Dermis density and thickness|Dermis density and thickness will be measured using ultrasonography with Cortex DermaLab 20 MHz US probe.
223933751|NCT06745817|DIAGNOSTIC_TEST|Skin elasticity|Skin elasticity will be measured using Cortex DermaLab elasticity probe.
223933752|NCT06745817|DIAGNOSTIC_TEST|Body composition measurement|Body composition will be measured using Biostat Multiscan 5000.
223933753|NCT06745817|DIAGNOSTIC_TEST|Screening questionnaire|Screening questionnaire: assessment of socio-demographic parameters, use of food supplements, health status, dietary habits
223933754|NCT06740864|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
223933755|NCT06740864|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current will be delivered utilizing a Starstim 8-channel constant current, battery-powered electric stimulator (Neuroelectrics, Barcelona, Spain). Circular carbon rubber electrodes (2cm radius, 12,57 cm2) are used throughout the stimulation.
223933756|NCT06740864|DEVICE|Sham Transcranial alternating current stimulation|Sham tACS will be applied by only ramping the current for 15 seconds up and 15 seconds down at the beginning and end of the stimulation respectively.
223933757|NCT06734442|OTHER|Video-Assisted Thoracoscopy with blebectomy and pleural abrasion|Thoracoscopic management of pneumothorax
223933758|NCT06809920|PROCEDURE|Group 1 ACL reconstruction with quadruple flexor tendons and conventional physiotherapy|Group 1 will undergo conventional ACL reconstruction with quadruple flexor tendons (double gracilis and semitendinosus). All the participants will receive conventional physiotherapy.
223933759|NCT06809920|PROCEDURE|Group 2 ACL reconstruction with quadruple flexor tendons + ALL reconstruction|Group 2 will undergo conventional ACL reconstruction with quadruple flexor tendons (double gracilis and semitendinosus) + ALL reconstruction. All the participants will receive conventional physiotherapy.
223933760|NCT05972772|DRUG|Doxycyclin|100-mg film-coated tablets; Pfizer
223933761|NCT05972772|DRUG|Azithromycin|250-mg capsules; Pfizer
223933762|NCT06787183|RADIATION|Short course radiotherapy|CTV 25Gy/5Fx.
223933763|NCT06787183|DRUG|Capecitabine|1000mg/m2, d1-14，bid, q3w, 2 cycles.
223533877|NCT06071676|OTHER|digital impression group|direct scanning was done using intraoral scanner to the female housing of the attachments on position
223533878|NCT01669512|BIOLOGICAL|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
223533879|NCT01669512|BIOLOGICAL|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
223533880|NCT01669512|BIOLOGICAL|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
223718498|NCT01179854|DRUG|Remegal|Drug/ placebo
223718499|NCT03174236|DRUG|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
223718500|NCT03174236|DRUG|Benzyl penicillin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
223933764|NCT06787183|DRUG|Oxaliplatin|130mg/m2, d1, q3w, 2 cycles
223933765|NCT06787183|DRUG|QL1706|5.0 mg/kg, q3w
223533881|NCT04748887|OTHER|oxidative stess markers|markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
224096959|NCT06773780|DRUG|local infiltration|The block procedure will be performed before the surgical procedure, following the induction of sedoanalgesia. Under sterile conditions, 30 mL of 0.25% bupivacaine will be administered to the targeted infiltration area. The local anesthetic will be specifically applied around the arterial and venous puncture sites.
223933766|NCT06844591|OTHER|Conditioning Exercises/ Aerobic Interval Training|Aerobic interval training (AIT), which included rest intervals in between sessions of aerobic activity on a stationary bike and treadmill, was administered to the control group. A 10-minute warm-up, or a maximum of 50% to 60% of HR, preceded the program. The next activity round consisted of six x six-minute intervals of cycling and walking/uphill running on a treadmill at 60% to 85% of THR, separated by three minutes of rest/recovery. A ten-to fifteen-minute cool- down period followed the session.
223933767|NCT06844591|OTHER|Resistance Interval Training|Resistance interval training for post-coronary artery bypass grafting (CABG) patients requires careful consideration and should be conducted under the supervision of healthcare professionals, such as cardiac rehabilitation specialists or physiotherapists. Exercise programs for individuals recovering from cardiac surgery must be tailored to their specific needs, taking into account their overall health, medical history, and current fitness level. Before beginning any exercise program, it's essential to obtain clearance from a healthcare provider. The workout lasted thirty to forty minutes in total. To fit the training load, resistance and intensity were gradually raised. For six weeks, this supervised training program was adhered to three times a week on alternate days
223933768|NCT06766565|DRUG|QYJD Compound Preparation|The intervention group was treated with 2 capsules (g) of expelling stasis and QYJD compound preparation orally for 4 days before thoracoscopic radical surgery for lung cancer, 3 times a day. The blank control group had no oral drug treatment before surgery.
223933769|NCT04363827|DRUG|Hydroxychloroquine|Hydroxychloroquine
223933770|NCT06765460|BEHAVIORAL|Medical prescription of exercise|MPE consists of dedicating a specific time to establish a specific and individualized exercise plan for the patient, with the premises of fully assessing their physical fitness, motivation, adaptability to change and the possibility of exercising within their social environment, as well as the achievement of specific objectives within an agreed follow-up period
223933771|NCT06765460|BEHAVIORAL|Health Advice|HA consists of providing the patient with information and motivation in line with general international recommendations to try to increase PA levels in their daily life. This advice can be given in a short period of time (up to three minutes) during any medical consultation
223933772|NCT06762860|DRUG|Dexmedetomidine|label sticker
223933773|NCT06762860|DRUG|Granisetron|label sticker
223933774|NCT06762860|OTHER|Placebo|label sticker
223933775|NCT06766760|DEVICE|Da Vinci SP Surgical System, Model SP1098|The da Vinci SP Surgical System is intended to assist in the accurate control of the da Vinci SP endoscope and instruments during minimally invasive endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, and breast surgical procedures. The system is indicated for adult use. It is intended to be used by trained physicians in an operating room environment.
223933776|NCT04109950|DRUG|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
223933777|NCT05611632|DEVICE|Multi-cancer early detection test (Galleri test)|Blood collection and multi cancer early detection testing with return of positive test results.
223933778|NCT03160885|DRUG|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
223933779|NCT03160885|DRUG|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
223933780|NCT03499691|DEVICE|Theranova 500 medium cut-off dialyzer|The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
223933781|NCT03499691|DEVICE|Hemodiafiltration|The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
223933782|NCT05164601|OTHER|No Intervention - Observational Only|Clinical Follow-Up
223933783|NCT02994459|OTHER|Weight Loss|Diet-induced weight loss (obese only)
223933784|NCT05979116|OTHER|myofascial release|MFR in its simplest form targeted restoration of mobility of myofascial and fascial layers from within, and with the surrounding structure. MFR techniques utilized with the cases include different variations of application: 1. Muscle was stroked in a long
224096960|NCT06773780|DRUG|PENG|With the patient in the supine position, a convex ultrasound (US) probe (4-8 MHz, Vivid Q) will be covered with a sterile sheath. An 80-mm block needle (Braun 360°) will be used. The probe will be placed transversely over the anterior inferior iliac spine. Subsequently, the probe will be rotated 45 degrees to visualize the pubic ramus. Once the femoral artery, iliopubic eminence, and psoas muscle are identified under ultrasound guidance, the needle will be advanced using an in-plane technique and positioned between the pubic ramus and the psoas tendon. After confirming the block site with 5 mL of saline, 30 mL of 0.25% bupivacaine will be injected as the local anesthetic.
224096961|NCT06773780|DRUG|FİB|The patient's legs will be positioned slightly externally rotated. A high-frequency ultrasound probe will be placed transversely along the inguinal ligament. Under ultrasound guidance, the femoral artery, iliopsoas muscle, and fascia iliaca will be identified. The needle will be advanced parallel to the ultrasound probe using the in-plane technique and positioned beneath the fascia iliaca. After confirming negative aspiration, 30 mL of 0.25% bupivacaine will be injected, and the spread of the solution beneath the fascia iliaca will be verified using ultrasound.
223718501|NCT03174236|DRUG|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
223718502|NCT03174236|OTHER|Placebo|Suspension manufactured to match metronidazole
223933785|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment, DCOOP Product, Hydroxytyrosol extract|Intervention group will receive a nutritional formula from DCOOP (Spain).
223933786|NCT05472753|DIETARY_SUPPLEMENT|Experimental Treatment,Indukern product, Curcumin and selenium extract|Intervention group will receive a nutritional formula from Indukern (Spain).
224096962|NCT06781190|BEHAVIORAL|Green motherhood education|Pregnant women selected for the experimental group will receive 4 weeks of green motherhood training.
224096963|NCT07072624|DRUG|Phenytoin|The Phenytoin group will be given a loading dose of phenytoin 20 mg/kg intravenously (maximum, 2 gm) at 50 mg per minute and then started on a maintenance dose (5-6 mg/kg/d, rounded to the nearest 100 mg, intravenously administered every 8 hours). The intravenous will be switched to oral once the patient is fit to take it orally or via Ryles tube. The oral dose would be a single 300 mg ER (extended-release) tablet per day. Both IV and/or oral doses of phenytoin will be given only for 1 week after head trauma. Patient= Patients with Traumatic brain injury as per eligibility criteria. Intervention= Phenytoin loading dose IV (20 mg/kg) followed by 100 mg IV TDS till patient accepts orally. Oral dose will be administered as a single 300 mg ER tablet per day. Both IV and oral phenytoin will be given for 1 week after traumatic brain injury and then stopped. Comparator= Matching Placebo
224285712|NCT03938415|OTHER|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
224285713|NCT00380757|PROCEDURE|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
224285714|NCT03854344|DRUG|Lidocaine Hydrochloride|Injected subcutaneously for skin graft harvesting
224285715|NCT03854344|DRUG|Liposomal bupivacaine|Injected subcutaneously for skin graft harvesting
223933787|NCT05472753|OTHER|Control Treatment|Control group will receive a placebo (product loading substance)
223933788|NCT02868970|BIOLOGICAL|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
223933789|NCT02868970|BIOLOGICAL|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
224096964|NCT07072624|DRUG|Levetiracetam|The Levetiracetam group will receive 25-30 mg/kg/d in two divided doses (rounded to 750 mg, administered intravenously every 12 hourly). The intravenous dose will be switched to oral form once the patient is fit to take it orally or via Ryles tube. The oral dose would be two tablets of 750 mg ER (extended-release) levetiracetam daily. Both IV and/or oral doses of levetiracetam will be given only for 1 week after head trauma. Patient= Patients with Traumatic brain injury as per eligibility criteria. Intervention= Levetiracetam IV dosing will be 25-30 mg/Kg/d in 2 divided doses (rounded to 750 mg IV BD) followed by 2 tablets of 750 mg ER once patient fit to take orally or via Ryles tube. Comparator= Matching Placebo.
224096965|NCT07072624|DRUG|Placebo|The Placebo group will be administered normal saline intravenously of similar amount that of intervention group and matching placebo tablets orally (double dummy) once the patient is fit to take orally. Similar to the intervention group, both IV and oral placebo will be given till 1 week after traumatic brain injury.
224285716|NCT03854344|DRUG|Bupivacaine Hydrochloride|Used for regional nerve block for skin graft harvesting
223533882|NCT02635295|BEHAVIORAL|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
223933790|NCT02868970|BIOLOGICAL|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
223933791|NCT02868970|BIOLOGICAL|Meningococcal ACWY|Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.
223933792|NCT02868970|BIOLOGICAL|Herpes Zoster|Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).
224285717|NCT06324409|BEHAVIORAL|Reminder telephone call|A reminder telephone call with information on colorectal cancer screening in the language of origin (Urdu or Somali) in addition to the reminder letter in Norwegian (usual care)
224285718|NCT00101842|DRUG|Pemetrexed|
224285719|NCT00101842|DRUG|Gemcitabine|
224285720|NCT00101842|DRUG|Platinol|
224285721|NCT04407299|BEHAVIORAL|self-administered structured questionnaire|It was designed as a self-administered questionnaire with closed questions (yes/no questions, rating scale and multiple choice questions) and some open ended questions.
224285722|NCT05692076|DEVICE|High Velocity Nasal Insufflation|High-flow humidified oxygen with flow rates from 30 to100 L/min with high fraction of inspired oxygen( FiO2) is able to be delivered.
224285723|NCT02486913|OTHER|Enhanced Health Check|National Health Service Health Check enhanced by risk report
224285724|NCT04892121|OTHER|Prevention exercises|Participants will have to follow a warm-up prevention program (15 minutes) twice a week
223933793|NCT02868970|BIOLOGICAL|Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)|Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
223933794|NCT06758154|DEVICE|"TXJN electro-acupuncture"|Firstly, EA treatment will be administered at the Neiguan (PC6, bilateral), Shenting(GV23), Yingxiang(LI20, bilateral), Yintang(GV29) acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensations of achiness, heaviness, and numbness (known as de qi) at all above-mentioned acupoints. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at PC6, GV23, LI20, GV29, with a dilatational wave of 5 Hz and a current intensity of 2 \~ 4 mA depending on the patient's tolerance. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
223933795|NCT06758154|DEVICE|sham acupuncture|Firstly, EA treatment will be administered at the non-acupoints near above-mentioned real acupoints. Disposable stainless-steel needles (0.25 mm × 25 mm; Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Suzhou City, China) will be used. After skin disinfection, the acupuncturists will take the needle into the acupoints without the sensations of de qi. Following needle manipulations, EA instruments (SDZ-V, Hwato brand, Suzhou Medical Supplies Factory Co., Ltd., Suzhou City, China) will be used to attach the needle handles at non-acupoints without the current. The needles will be removed after 30 min. Participants will receive 24 sessions over 8 weeks at a frequency of 3 times per week.
223933796|NCT06806969|DEVICE|Decision support|Patients will digitally fill out forms, which will go into the decision support tool integrated in the electronic health record journal, which predicts outcome of surgery for the patient, to inform shared decision making.
223933797|NCT06814015|DEVICE|Hands-free exoskeleton|"A device trainer specialist from the investigation site will deliver training sessions with the exoskeleton to pair of participants (a pair corresponds to an individual with SCI and his/her companion). The device trainer will follow the progression of the pair through the training program and ensure they learn all the device basic skills. Each training session lasts an average of 1.5 hours, variations according to the user's learning pace and tolerance. During the sessions with the exoskeleton, the participants will engage in mobility activities on different surfaces and perform Activities of Daily Living in simulated environments such as kitchen, bathroom, elevators and outdoor spaces."
224096966|NCT06420765|DRUG|VX-150|Suspension for oral administration.
224096967|NCT06420765|DRUG|VX-548|Solution or suspension for oral administration.
224096968|NCT06420765|DRUG|VX-993|Suspension for oral administration.
224096969|NCT06420765|DRUG|Placebo|Suspension for oral administration.
224096970|NCT06761404|DEVICE|taVNS|Experimental. The current will be increased gradually for both sham and real stimulation at the beginning of the 90-minute stimulation to lessen the itchy/numb skin sensation and to create the same skin sensation for subject blinding.
224096971|NCT06900569|DIETARY_SUPPLEMENT|Ashwagandha|600 mg/d Ashwagandha
224096972|NCT06900569|DIETARY_SUPPLEMENT|Placebo|600 mg/d placebo
224096973|NCT06842589|BIOLOGICAL|anti-CD19 CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
224096974|NCT06758063|OTHER|exercises therapy|exercises to improve balance of the body
224096975|NCT07074379|BEHAVIORAL|Lifestyle modifications|Lifestyle modifications primarily include quitting smoking and alcohol consumption, as well as engaging in physical exercise.
224096976|NCT07074379|DRUG|Pancreatic enzyme (Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose , Metformin, Glimepirde Tablets, Insulin)|"This intervention involves the use of medications to control the pancreatic exocrine and endocrine dysfunction caused by chronic pancreatitis.~1. Pancreatic enzyme therapy: Patients will use pancreatic enzymes (pancreatin enteric-coated capsules or oryz-aspergillus enzyme and pancreatin tablets) to control the symptoms of exocrine pancreatic insufficiency.~2. Diabetes treatment: Patients with diabetes will also use antidiabetic medications (such as oral hypoglycemic drugs or insulin, depending on glycemic control needs)."
224096977|NCT07074379|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or Extracorporeal Shockwave Lithotripsy (ESWL)|This intervention involves the application of endoscopic retrograde cholangiopancreatography (ERCP) and/or extracorporeal shockwave lithotripsy (ESWL), conducted in accordance with established clinical guidelines. The procedures are tailored to the individual patient's condition, which may include sphincterotomy, balloon dilation of pancreatic duct strictures, stone extraction, and stent placement as indicated. ESWL may be used prior to ERCP to fragment pancreatic duct stones, facilitating their removal.
224096978|NCT03781986|DRUG|APG-115|APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
224096979|NCT03781986|DRUG|Carboplatin|Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
224096980|NCT06809010|BIOLOGICAL|Whole blood donation|This intervention involves the collection of a whole blood bag.
223533883|NCT03493646|DRUG|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
223933798|NCT04827615|BEHAVIORAL|Ambuja Cement Foundation's Non Communicable Disease Program|"Government level: Strengthening linkages with Govt; Ensuring availability \& affordability of NCD diagnostics and treatment; Establishing a follow-up mechanism with patients to ensure continuity of care \& medication compliance~Provider level: Capacity building of frontline workers; Promotion of interface between community \& service provider~Community level: Screening of hypertension \& diabetes for all adults ≥30 years in the village in coordination with Govt under 'population based screening'; Create awareness of modifiable risk factors and lifestyle change among high-risk population; Community mobilization \& active participation in various health marker days; Formation of support groups, women's groups, self help groups, with involvement of people living with NCDs~Individual level: Behavior change communication with messages on NCD risk factors; Nutrition awareness on healthy and unhealthy food practices"
223933799|NCT00463983|DRUG|octreotide|
223933800|NCT06651567|DRUG|ITI-1284|ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration
224096981|NCT06809010|BIOLOGICAL|Apheresis donation|This procedure involves the collection of a plasma/platelets bag by apheresis
224096982|NCT06922825|DRUG|68Ga-FAPI-46|Participants will receive an IV injection of 68Ga-FAPI-46. Then, shortly after will undergo a PET/CT imaging using the 68Ga-FAPI-46. Additionally, MRI or contrast CT imaging will be conducted, either on the same day or within 14 days.
224096983|NCT06931015|OTHER|No interventions|No interventions
224096984|NCT06386978|PROCEDURE|Transverse Facia Plane Block (TAP Block)|Spinal Anesthesia + TAP block
224096985|NCT06386978|PROCEDURE|Transversalis Facia Plane Block (TFP Block)|Spinal Anesthesia + TFP block
223933801|NCT06651567|DRUG|Placebo|Placebo rapidly disintegrating tablet, taken once daily, sublingual administration
223933802|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel vehicle|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX® oral gel vehicle) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
224096986|NCT06386978|PROCEDURE|Control|Spinal anesthesia + No block
224096987|NCT03683186|DRUG|Ralinepag|Active
224096988|NCT07084298|DIETARY_SUPPLEMENT|Oral iron supplement|Encapsulated ferrous sulphate (150mg elemental iron)
224096989|NCT07084298|OTHER|Placebo|Encapsulated polysaccharide (maltodextrin)
224096990|NCT06398431|DEVICE|Walking analysis sensor|Participant gait analysis with the inertial sensor
224096991|NCT01075347|OTHER|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
223533884|NCT03493646|DRUG|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
223718503|NCT03174236|DRUG|Gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
224096992|NCT01075347|OTHER|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
224096993|NCT03275909|BEHAVIORAL|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
224096994|NCT06905327|DRUG|QCZ484|doses of 50, 150, 300 or 600 mg via subcutaneous injection
223718504|NCT04769440|DRUG|mg sulphate|mgso4 infusion will start 15 minutes after intubation , 30 mg/kg LBW of 10%mgso4 in 100 ml normal saline I.V ,over 30 minutes followed by 10 mg/kg LBW for 90 minutes
223718505|NCT00754819|DRUG|Colchicine|1mg once daily
224096995|NCT06905327|DRUG|Placebo|via subcutaneous injection
224096996|NCT05266872|OTHER|Observational study with sample and data collection|Observational study with sample and data collection
224096997|NCT04869137|DRUG|Lenvatinib Oral Product|20mg of Lenvatinib will be taken orally once daily
224096998|NCT04869137|DRUG|Pembrolizumab|200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
224096999|NCT07082530|PROCEDURE|Labor Induction at 39 Weeks|Labor induction at 39 weeks 0 days to 39 weeks 4 days
224097000|NCT07082530|PROCEDURE|Expectant management|Expectant management until spontaneous labor or induction at 41 weeks.
224097001|NCT06755996|DRUG|Dexmedetomidine injection|Dexmedetomidine injection 3μg/kg
224097002|NCT06755996|DRUG|Remimazolam|remimazolam 0.5mg / kg
224097003|NCT07088471|DRUG|Sacubtril/Valsartan|Angiotensin-receptor blocker and neprilysin inhibitor therapy
224097004|NCT07097376|BEHAVIORAL|Purposeful Pathways|Purposeful Pathways is a manualized intervention to assist Veterans in aspiring and pursuing meaningful employment. Purposeful Pathways is an individual counseling protocol delivered weekly for up to 12 sessions (50 minutes per session) focused on career exploration, goal clarity, job-searching, and self-regulation.
224097005|NCT07097376|OTHER|Transitional Work|Provides individuals with immediate access to a non-competitive, paid job contracted by the VA. Positions are typically housed within a VA hospital (e.g., housekeeping, grounds, kitchens, and construction), but are sometimes located in the community. TW is time-limited. TW is staffed by vocational rehabilitation specialists (VRS).
223718506|NCT00754819|DRUG|Placebo|1 capsule daily
223718507|NCT03354611|RADIATION|Contrast Enhanced Cone Beam Breast CT Scan|"* Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
224097006|NCT07095296|BEHAVIORAL|Health Education|"The intervention-a culturally tailored and redesigned health education-will be guided by established behavioral theories, namely the Theory of Planned Behavior (TPB) and Social Cognitive Theory (SCT) and implemented in a culturally sensitive manner. The TPB focuses on attitudes toward utilizing PNC services, the influence of subjective norms such as cultural norm, and their perceived behavioral control including transportation (34), while SCT emphasizes self-efficacy, social modeling, and reinforcement(35). Both TPB and SCT have been extensively validated in various health behavior studies, supporting their relevance and applicability in this context(36, 37).~Our intervention will consist of a structured training and mentorship program for midwives, focusing on health education delivery. The intervention package, including the training curriculum and implementation manual, will be developed in accordance with guidelines from the World Health Organization (WHO) and the Federal Ministry"
224097007|NCT04634539|DRUG|Gemcitabine|Gemcitabine will be administered at 600, 800, or 1000 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Gemcitabine will be administered immediately after the infusion of nab-paclitaxel. Pre-medication with may be administered per institutional standard practice at the investigator's discretion with gemcitabine.
224097008|NCT04634539|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 75, 100, or 125 mg/m2 intravenous (IV) infusion over 30 minutes on days 1, 8, and 15 (every 28-day cycles) during the treatment period. Nab-paclitaxel will be given first, before infusion of gemcitabine. Pre-medication for nab-paclitaxel may be administered per institutional standard practice at investigator's discretion.
224097009|NCT04634539|DRUG|L-glutamine|The dose levels of L-glutamine in this study will be 0.1, 0.2, and 0.3 g/kg oral twice daily (rounded to nearest 5 g with an upper limit of 15 g twice daily (30 g/day) for any dose level) taken at the same time each day during the treatment period. L-glutamine will be administered for 1 week (+/-1 day) prior to addition of gemcitabine/nab-paclitaxel. Each dose of L-glutamine should be mixed immediately before ingestion with 8 oz. (240 mL) of a cold or room temperature beverage, such as water, milk or apple juice, or 4 oz. (120 mL) to 6 oz. (177 mL) of food such as applesauce or yogurt. L-glutamine is formulated in 5 gram packets as a white crystalline powder in paper-foil-plastic laminate. Complete dissolution is not required prior to administration.
224097010|NCT07106476|OTHER|Single-Leg Squat with Internal Focus Intervention|"Administration: Participants were instructed to focus on specific muscular or joint movements during single-leg squats (3 sets of 8 repetitions on the affected side, 1-minute rest between sets). Verbal cues included contract your glutes or keep your knee aligned. Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
224097011|NCT07106476|OTHER|External Focus Intervention|"Administration: Participants were instructed to focus on the environmental effects of single-leg squats (3 sets of 8 repetitions on the affected side, 1-minute rest between sets). Verbal cues included push against the floor or drive your foot downward. Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
223533885|NCT01675947|DRUG|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
223533886|NCT01675947|DRUG|Lidocaine|Lidocaine 2%
223533887|NCT02645799|DRUG|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
223718508|NCT03354611|DRUG|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement."
223718509|NCT04610840|PROCEDURE|Puncture of the caliceal system|Puncture of the caliceal system under ultrasound/Xray control
224097012|NCT07106476|OTHER|No Focus Intervention|"Administration: Participants performed single-leg squats naturally without specific attentional instructions (3 sets of 8 repetitions on the affected side, 1-minute rest between sets).~Data Collected: Surface EMG (Gluteus Medius, Biceps Femoris, Lateral Gastrocnemius, Peroneus) and pedobarographic parameters."
224097013|NCT07105436|DIAGNOSTIC_TEST|Persistent air leak quantification|"In this trial, patients with PALs will have their chest tubes connected to the Thopaz+ system. The Thopaz+ will continuously quantify the volume of air leaks, providing real-time data for analysis.~Data from both the Thopaz+ and standard serial occlusion test with Fogarty balloon will be combined and integrated to provide a comprehensive assessment of the air leak source. The bronchoscopic will perform standard visual assessment of changes in air leak during serial balloon occlusion in order to identify the best region for endobronchial treatments; use of measurements from the Thopaz and serial balloon occlusion test will be allowed as part of clinical reasoning but are not required to be used by the treating clinician."
224097014|NCT07105488|BIOLOGICAL|BFB759|BFB759 is a human mAb that inhibits multiple pro-inflammatory cytokines that contribute to the pathogenesis of multiple disease processes characterized by aberrant inflammation, including atopic dermatitis
224097015|NCT07105488|DRUG|Placebo|Placebo for BFB759
224097016|NCT07107178|DRUG|BT02|monoclonal antibody injection with intravenous administration every 2 or 3 weeks
224097017|NCT06233331|DRUG|Dose Level 1 ACU-D1 ointment|"ACU-D1 is a topical therapeutic agent that has pentaerythritol tetrakis (3-(3,5-di-tert-butyl-4-hydroxyphenyl) propionate) (PTTC) as its major active ingredient. PTTC is a novel proteasome inhibitor that has antiangiogenic and anti-inflammatory activities that reduce pro-inflammatory cytokines. ACU-D1 ointment contains a range of 2.5% to 10% weight by volume of PTTC.~Level 1 will consist of 2.5% ACU-D1 ointment, used twice daily for 4 weeks."
223933803|NCT06731777|PROCEDURE|Scaling and root planing plus 0.12% chlorhexidine oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (0.12% chlorhexidine oral gel) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
223718510|NCT00295841|DRUG|clofarabine|
223718511|NCT00295841|DRUG|cytarabine|
223718512|NCT01325415|DRUG|NKTR-118|25 mg tablet
223718513|NCT01325415|DRUG|moxifloxacin|400 mg tablet
224097018|NCT06233331|DRUG|Dose Level 2 ACU-D1 ointment|Level 2 will consist of 5% ACU-D1 ointment, used twice daily for 4 weeks.
224097019|NCT06233331|DRUG|Dose Level 3 ACU-D1 ointment|Level 3 will consist of 10% ACU-D1 ointment, used twice daily for 4 weeks.
223718514|NCT01325415|DRUG|Placebo|tablet
223718515|NCT04233151|DRUG|QL1203|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
223718516|NCT04233151|DRUG|Placebo|6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
224097020|NCT06233331|PROCEDURE|Vulvar/ Perianal Biopsy|3 vulvar or perianal biopsies are to be performed at the screening as well as at the end of the study (week 4).
224097021|NCT07107373|DRUG|Mavacamten|According to the product label
224097022|NCT07108062|OTHER|Experimental|(lifestyle + dietary advice)
224097023|NCT07108062|OTHER|Placebo|No intervention
224097024|NCT07106931|OTHER|This is an observational study with no intervention|This is an observational study with no intervention
224097025|NCT07107880|OTHER|Communication Assessment through AI and Human|Participants will remotely engage in an AI-generated simulation that presents an voice-based conversation with a simulated parent of a pediatric patient. The scenario involves discussing a clinical scenario concerning their child. Following the simulation, the participant's communication skills will be assessed using an artificial intelligence (AI) system trained to evaluate the key aspects of communication using standardized rating scales. In addition, two human evaluators will assess the participant's communication skills using the same rating scales.
223933804|NCT06731777|PROCEDURE|Scaling and root planing plus PHTALOX® oral gel|Root scaling and planing (RAR) will be performed following the full-mouth disinfection (FMD) protocol. After anesthesia using the regional block technique \[2% lidocaine solution with 1:100,000 epinephrine (Nova DFL)\], RAR will be conducted by an experienced professional using an ultrasonic scaler and periodontal curettes (Millenium Curettes, Golgran, São Paulo, Brazil). The time spent per quadrant will be approximately one hour. Polishing will then be performed using a rubber cup and prophylactic paste (Odahcam, Dentsply Sirona, USA). The oral gel (PHTALOX®) should be applied to all free dental surfaces using a plastic applicator with cotton tips. The contact between the gel and the tooth surface must last for 5 minutes. After this time, the patient should spit out the excess gel without rinsing the mouth. This process should be performed after the last brushing of the day for a period of 45 days.
223933805|NCT06702124|DRUG|Rotigotine 4Mg/24Hrs Patch|Rotigotine 4 mg/24Hrs administration for 24 weeks
223933806|NCT06702124|DRUG|Placebo|Placebo administration for 24 weeks
224097026|NCT07107165|BEHAVIORAL|Dyadic Problem Solving Training|DPST consists of teaching the patient and family caregiver problem-solving skills that they can apply to help them manage the medical regimen after stem cell transplant.
223933807|NCT06786559|BEHAVIORAL|Assistive Device and health Education|After discharge they will be assessed and followed by RA nurses through home visit and tele services for 2 months. The nurses will contact the patients periodically over telephone, and follow up their regular self-care activities, adjustment to devices, exercise and adaptive behavior.
223933808|NCT04160507|OTHER|Biorepository|To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
223933809|NCT06644196|DEVICE|Acquisition of images/videos of the bilateral fundus with the holographic doppler laser|Acquisition of images/videos of the bilateral fundus with the holographic Doppler laser
223933810|NCT06662136|BEHAVIORAL|motivasional intereview|No application will be made to the participants in the control group
223933811|NCT06791603|OTHER|Standardized chemotherapy education + video|Videos will be provided with patients and they will watch videos during the visit. The information regarding the prevention and management of side effects and further instructions when to visit hospital. Patients will have access to videos and watch videos after leaving the hospital for the entire treatment course
224097027|NCT07107165|BEHAVIORAL|Supportive Care|Supportive Care consists of providing support to the patient and family caregiver as they manage the medical regimen after stem cell transplant
224097028|NCT07106723|DRUG|ASCT+CD7-CART|Intravenous infusion of CD7-CART 3 days after ASCT
224097029|NCT07108179|DEVICE|Continuous Glucose Monitoring (CGM) System|Continuous Glucose Monitoring (CGM) System
223533888|NCT02645799|DRUG|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
223533889|NCT03140618|OTHER|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
223535348|NCT06078826|OTHER|passive music therapy|30 minutes before tracheal aspiration to intubated patients connected to mechanical ventilator treated in the 3rd step intensive care unit. and music between 60-74 dB will be played via headphones and MP3 player during aspiration (Şahin, 2018). This music is a 30-minute Hüseyni makam mp3 music recording . Hüseyni makam is effective in the morning and at dawn, and its effect is high between morning and noon. For this reason, passive music therapy practice in the research will be done by the researcher in the morning and afternoon. This maqam has beauty, benevolence, silence, comfort, a sense of peace and a refreshing feature. It has positive effects on the liver, heart, internal organs and spirit and unites with nature.
224285725|NCT02503475|OTHER|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
224285726|NCT02503475|BEHAVIORAL|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
224285727|NCT02503475|DEVICE|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
224285728|NCT03064438|DRUG|ACCU-D1|ACCU-D1
224285729|NCT03064438|DRUG|Vehicle|Placebo Comparator
223933812|NCT06749262|OTHER|walking on incline or walking at increasing speed for 36 visits|Subjects will be prepared for data collection by wearing an exercise suit and obtaining height and body weight. Breathing sensors and foot switches will be worn to measure breathing and walking performance.
223933813|NCT04056013|DEVICE|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
223933814|NCT06147076|BEHAVIORAL|Social Support Network Counseling Intervention|Social support counseling intervention for kidney transplant candidates along with their social support networks.
223933815|NCT06820229|PROCEDURE|Enucleation|The entire cyst lining was radically enucleated, followed by thorough curettage of the cavity with meticulous evaluation of any residual daughter cyst lining followed by reduction of lingual and buccal walls bony undercuts to remove any residual cystic epithelium
224097030|NCT07106164|PROCEDURE|total body massage|Massage was done using the Field's Technique after starting phototherapy till discontinuation of phototherapy for 15 - 20 minutes, three times daily 1 hour after the morning, mid- day feeds and at night.
224097031|NCT07106164|DEVICE|photo therapy|neonates received phototherapy for the neonatal hyperbilirubinemia
224097032|NCT07106112|PROCEDURE|Ultrasound-guided carbon suspension (Black Eye) injection|"Under ultrasound guidance, 0.5 mL of sterile carbon particle suspension (Black Eye) is injected into the capsule of the metastatic axillary lymph node(s).~Technique: Performed using a high-frequency linear ultrasound probe (e.g., 12 MHz) and a 22G needle.~Target: Up to 3 pathologically confirmed metastatic lymph nodes. Timing: Performed before initiation of neoadjuvant systemic therapy (NST).~Rationale:~Carbon suspension provides long-term visual localization due to its black staining properties.~Inert and biocompatible, with minimal risk of allergic reactions. Patients proceed to standard NST based on tumor subtype (chemotherapy, targeted therapy, or endocrine therapy).~Post-NST imaging (ultrasound, CT, or PET-CT) to assess treatment response.~Surgical Intervention:~Targeted axillary dissection (TAD) with removal of marked nodes + sentinel lymph node biopsy (SLNB) using fluorescent dye.~Intraoperative frozen section analysis (hematoxylin \& eosin staining) of excised nodes."
224097033|NCT07106112|PROCEDURE|Ultrasound-guided metallic marker (TWIRL ULTRACOR) placement|"A 4-mm nitinol (nickel-titanium alloy) marker (TWIRL ULTRACOR) is deployed into the metastatic lymph node(s) under ultrasound guidance.~Technique: Uses a specialized introducer kit for precise placement. Target: Up to 3 pathologically confirmed metastatic lymph nodes. Timing: Performed before initiation of NST.~Rationale:~Nitinol markers are radiopaque, MRI-compatible, and resistant to migration. Standard method for tumor localization in breast cancer.~Post-Marking Protocol:~Identical NST and imaging follow-up as Group 1.~Surgical Intervention:~TAD with marker localization (palpation/imaging-guided excision) + SLNB. Intraoperative frozen section analysis."
224097034|NCT07107438|OTHER|The interventional group will be trained on ECG interpretation through thinqi digital interactive platform|The conventional group will be trained on ECG interpretation through handout exercises
224285730|NCT05574894|DRUG|Growth hormone|Growth hormone is supplemented during the ovarian stimulation till the day of trigger
224285731|NCT05574894|DRUG|GnRH antagonist|GnRH antagonist protocol for ovarian stimulation
224285732|NCT01937351|DEVICE|Pantheris System|Atherectomy using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries.
224285733|NCT01961687|DEVICE|Resorbable Mesh|Phasix Mesh
224285734|NCT02107222|DEVICE|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
224285735|NCT03658863|PROCEDURE|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
224285736|NCT03658863|PROCEDURE|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
224285737|NCT03658863|PROCEDURE|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
224285738|NCT03658863|DEVICE|Ultrasound endoscope|Endoscope with built-in ultrasound function
224285739|NCT03482219|OTHER|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
224285740|NCT03482219|OTHER|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
224285741|NCT06616259|DRUG|mCapOX plus Cetuximab|"mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
223933816|NCT06820229|PROCEDURE|cyst enucleation|"The entire cyst lining was radically enucleated, followed by thorough curettage of the cavity with meticulous evaluation of any residual daughter cyst lining followed by reduction of lingual and buccal walls bony undercuts to remove any residual cystic epithelium.~Using coarse round surgical carbide burs under copious normal saline irrigation, peripheral ostectomy was done for all bony walls to remove any microscopic daughter cyst, with isolation, retraction, and preservation of the lingual and inferior alveolar bundle. The bony septa were removed using rotary Lindemann fissure burs in case of multilocular lesions.~After enucleation and peripheral ostectomy a sterile radiopaque gauze coated with 5-fluorouracil cream 5% and put into the surgical cavity."
223933817|NCT06749626|OTHER|progressive relaxation exercise|Relaxation exercises CD developed by the Turkish Psychologists Association; It consists of muscle exercises, rhythmic breathing and music recital. The CD content, which includes relaxation exercises accompanied by music, was prepared by Psychologist Elif Kabak and voiced by Tülay Bursa. The CD, which includes deep breathing and muscle relaxation exercises, consists of three parts. The first section includes the definition of deep relaxation, the purpose of relaxation exercises and the rules to be considered in exercise practice. In the second part; There are relaxation exercises with audio instructions accompanied by streaming sounds. The third part contains relaxation music without instructions. After the information in the first part of the CD is explained to the patients in the experimental group, the second part, which lasts only approximately 30 minutes, will be administered under the supervision of the researcher. However, since the patients have undergone abdominal surgery, the
223933818|NCT05240924|BEHAVIORAL|Exposure and Response Prevention|ERP is a specialized cognitive behavioral intervention conducted over the course of 8-16 therapy sessions. ERP is based upon exposure principles and the idea that people can habituate to the distress caused by OCD triggers and learn to cope with anxiety about feared consequences without engaging in compulsive behaviors to 'neutralize' the obsession. ERP begins with psychoeducation about OCD and exposure, followed by construction of a hierarchy, or list, of situations that are feared, avoided, or trigger OCD rituals such as washing or checking. Then, the therapist and client begin in-session exposures to hierarchy items utilizing response or ritual prevention techniques to avoid reinforcing the ritual. Exposures can be in vivo, such as touching a contaminated item, or imaginal, such as visualizing a feared consequence happening.
223933819|NCT05240924|OTHER|Stress Management Training|The stress management training intervention will be based on that delivered by Simpson in an ERP trial. It will be delivered by PhD and Master's level therapists from each site's clinics. The stress management training intervention will begin with an introductory session providing psychoeducation about OCD, followed by 15 sessions covering stress management skills such as deep breathing progressive muscle relaxation, positive imagery, assertiveness training, and problem solving. Each session will contain an extended practice of the selected skill and will end with homework assignments to practice the stress management skills and monitor symptoms.
223933820|NCT06757803|PROCEDURE|rertrolaminar block|"Positioning~The patient is positioned in a lateral decubitus position with the affected side up. The patient's arm on the affected side is placed behind the head. The patient's spine is aligned and the shoulder is elevated to expose the paravertebral space.~\*Ultrasound imaging~A high-frequency linear ultrasound probe (5-12 MHz) is placed in a paramedian sagittal plane at the desired level of block. The probe is oriented so that the transverse processes are visualized on the lateral side of the screen and the vertebral laminae are visualized on the medial side of the screen. The interlaminar space is visualized as a hypoechoic region between the laminae.~\*Needle insertion~A short bevel block needle (20-22 G) is inserted through the skin at the caudal end of the ultrasound probe, aiming cephalad. The needle is advanced under real-time ultrasound guidance until the tip of the needle contacts the lamina. The needle is then slightly withdrawn and the local anesthetic is injected into t"
223933821|NCT06757803|PROCEDURE|paravertebral block|"* Patient Preparation~* Place the patient in the lateral decubitus position with the side of the block facing up.~* Position the patient's arm so that it is resting comfortably on the operating table.~* Prepare the skin over the block site with an antiseptic solution.~* Sterilely drape the area.~* Ultrasound Imaging~* Place the ultrasound probe in a transverse plane at the level of the desired block.~* Identify the following anatomical landmarks:~* Vertebral body~* Transverse process~* Pleura~* Intercostal space~* Needle Insertion~Use a sterile ultrasound-guided needle. Insert the needle in-plane from a lateral to medial direction, aiming for the apex of the paravertebral space.~The needle should be advanced until it is just beyond the transverse process.~\*Test Aspiration~Aspirate to ensure that the needle is not in a blood vessel.~* Local Anesthetic Injection~* Inject the local anesthetic slowly, aspirating frequently.~* The local anesthetic should be injected int"
223933822|NCT06754072|OTHER|Virtual Keyboard (VK) System|Participants underwent a 4-week training program comprising 12 one-hour sessions to enhance finger individuation and motor control using a virtual reality platform.
223933823|NCT06762821|PROCEDURE|Single-visit revascularization|Revascularization protocol will be performed in single visit
223933824|NCT06762821|PROCEDURE|Multiple-visit revascularization|Revascularization protocol will be performed in multiple visit
223933825|NCT06763679|OTHER|mobilization|"Acromioclavicular joint mobilization:~* The patient is placed in the supine position and the upper limb is placed in a physiological position with the patient's arm clinging to the body and the hand on the abdomen, which causes the capsule to stretch less and the technique to be less painful.~* The therapist placed the tips of his both thumbs on the anterior surface of the clavicle adjacent to the ACJ and spread his other fingers out for stability and his forearm was situated in line with the posterior movement at the ACJ.~* ACJ mobilization was performed in up to 30-minute individual sessions by a single trained therapist.~* The treatment techniques were anterior to posterior passive accessory glides of the distal end of the clavicle categorized from Grade III~* Grade III is used at a large amplitude from the middle of the joint ROM to the start of the constraint. Grade III will apply for stimulating a stretching to relieve joint stiffness in a shorter tissue"
224099736|NCT07107477|DRUG|Antenatal steroids administration|"1. Clinical and/or laboratory signs of chorioamnionitis will result in an intervention consisting of the course of antenatal steroids (if not already administered, or as a single course prior 34+0 if at least 7 days have passed after the previous course), initial broad spectrum antibiotics, or delivery, depending on the week of pregnancy and clinical status.~2. Uterine activity with progression of vaginal finding will result in course of antenatal steroids (if not already administered, or as a single course prior 34+0 if at least 7 days have passed after the previous course) and tocolysis"
223933826|NCT06763679|OTHER|traditional physical therapy|"Spencer technique:~* The patient was resting on their side, with the affected shoulder raised.~* In 7 separate movements, the therapist used the proximal hand to stabilize the shoulder girdle, while the distal hand applied force to the restrictive barrier of the shoulder.~* Shoulder extension, circumduction with compression, shoulder flexion, circumduction with distraction, abduction, adduction with internal rotation, and glenohumeral pump were the exercises performed.~* The patients were advised to employ their muscle energy technique against the small resistance provided by the therapist for 3-5 seconds throughout each movement.~* Over the course 5 days a week, the exercise was repeated 3-5 times per session, with rest breaks."
223933827|NCT06795464|DEVICE|Immersive Virtual Reality|"Participants in the experimental group will follow a treatment program that combines standard care with an immersive virtual reality (IVR) intervention. During the first 4 weeks, participants will undergo the IVR intervention, followed by the same standard treatment as the control group for the subsequent 8 weeks.~IVR Intervention Protocol:~Sessions and Equipment: Participants will attend up to 12 IVR sessions using a head-mounted device (HMD), the Meta Quest III, equipped with a hand-tracking system (Meta VR, Facebook, California) to enable interaction with the therapeutic software Dynamics PainRehab (Dynamics VR Rehab, Seville, Spain). The Meta Quest III HMD is chosen for its commercial availability, widespread use, minimal visual latency, and user-friendly interface. The software application, Hombro PainRehab, features multisensory inputs (vision and sound), high-quality graphics, head and hand tracking, and provides a highly immersive experience. The IVR intervention incorporate"
223933828|NCT06795464|PROCEDURE|Exercise|Participants assigned to the control group will receive standard treatment for rotator cuff-related shoulder pain. This will consist of standardized therapeutic exercise performed for 25 minutes, 3 times per week, over a 12-week period. The exercise regimen will be individualized based on intensity, utilizing the Rate of Perceived Exertion (RPE) scale, with the goal of achieving intensity levels of 6-8 on a scale of 0 to 10.
223933829|NCT04615260|DEVICE|NanoBone|Nanobone® Synthetic Bone Graft is a nanocrystalline hydroxyapatite imbedded in a silica gel matrix. The nanocrystalline structure accurately replicates autologous hydroxyapatite and the silica gel matrix that rapidly transforms into an osteogenic matrix post-implantation. NanoBone promotes remodeling by acting as a strong osteoinductive material. NanoBone® is available as a putty.
223933830|NCT06764290|OTHER|pedal walking|Pedal walking is a challenging walking task that can be used as a form of physical therapy for stroke participants.
223933831|NCT06764290|OTHER|visual occlusion|Walking with eyes-covered is a challenging walking task that can be used as a form of physical therapy for stroke participants.
223933832|NCT06766578|RADIATION|Neoadjuvant Therapy(5×3Gy radiotherapy)|Radiotherapy: 5×3Gy. The preoperative radiotherapy target was outlined by radiotherapy physicians according to the NCCN Guidelines for Gastric/esophagogastric Junction Tumor 2024 edition and the surgeon's opinions. The first and third cycles were 5×3Gy.
223933833|NCT06766578|DRUG|Neoadjuvant Therapy(tirelizumab, oxaliplatin, S-1)|The first and third cycles are 5×3Gy radiotherapy D1 to 5, intravenous administration for tirelizumab 200 mg D6, intravenous administration for oxaliplatin 130 mg/m2 D6, and oral administration twice a day for S-1 40 mg/m2 D6 to 19. The second and fourth cycles are intravenous administration for tirelizumab 200 mg D1, intravenous administration for oxaliplatin 130 mg/m2 D1, and oral administration twice a day for S-1 40 mg/m2 D1 to 14. Every treatment cycle is spaced 1 week apart.
223933834|NCT06766578|PROCEDURE|Surgical treatment|Surgical treatment is completed within 3-5 weeks after the end of neoadjuvant therapy.
223933835|NCT06766578|DRUG|Adjuvant therapy(SOX chemotherapy)|Postoperative adjuvant therapy is 4 cycles of SOX chemotherapy.
223933836|NCT02307682|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection
224097035|NCT07107503|PROCEDURE|Radiofrequency ablation alone|RFA was performed by four US physicians with ≥ 10 years of experience in in-terventional US. Before ablation, the patients were placed in the supine position with the neck extended, and local anesthesia was administered with lidocaine (1%). RFAs were performed using the hydro-dissection, trans-isthmic and moving-shot techniques according to previously published guidelines. Ablation was terminated when the target tumor changed to a transient hyperechoic zone. Contrast-enhanced US (CEUS) was performed immediately after ablation to evaluate the ablation area. The presence of complications during or after thermal ablation and corresponding treatments was carefully evaluated. All patients were closely observed for 1-2 h after ablation in the hospital.
223718517|NCT04233151|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
223933837|NCT02307682|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection
223933838|NCT04272827|PROCEDURE|Liposuction|"Liposuction treatment will be performed according to the study protocol using the wet technique depending on the amount of fat to be removed, if necessary in several sessions."
223933839|NCT06861205|OTHER|This is an observational study|This is an observational study
223933840|NCT06615505|OTHER|VIA Disc NP|Participants will receive a single dose, intradiscal injection of 100 mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered to the affected level(s), L1-S1 (1 or 2 levels).
223933841|NCT06615505|OTHER|Sham Injection|"Participants will receive the sham procedure at 1 or 2 levels.~The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc."
223718518|NCT03793231|COMBINATION_PRODUCT|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
223718519|NCT00952679|DEVICE|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
224097036|NCT07107503|PROCEDURE|surgical resection|SR was performed under general anesthesia by surgeons with\>15 years of expe-rience in thyroid surgery. The decision to perform total thyroidectomy or lobectomy was made by individual surgeons and patients, based on patient preferences in consu
224097037|NCT07107308|DEVICE|Microfocused Ultrasound|Before treatment, clean the treatment area, mark the treatment zone, and evenly apply a layer of ultrasound coupling agent about the thickness of a coin on the treatment area. The patient's face was treated with S1.5, S2, N3, N4.5, P1.5, P2.0, P3.0 and P4.5 treatment heads respectively. After the treatment, the face was cleaned and a medical mask was applied for 15 minutes. After the treatment, attention was paid to moisturizing and sun protection.
223933842|NCT06770621|DIAGNOSTIC_TEST|Insulin-induced hypoglycemia test|For these tests, multiple blood samples will be collected during insulin-induced hypoglycemia (stage 1 hypoglycemia is defined as a blood glucose level below 70 mg/dL, while stage 2 corresponds to values below 54 mg/dL). The tests will be conducted on patients who have fasted for at least 12 hours and will be supervised by a medical staff member trained to manage severe hypoglycemia.
223933843|NCT06770621|DIAGNOSTIC_TEST|Glucagon profile|The subject must fast before the consultation and follow a specific diet the day before; after an initial blood draw (P1), the patient will have breakfast and take any required insulin, followed by two additional blood draws 1.5 hours after breakfast (P2) and 1.5 hours after P2 (P3)
223933844|NCT06770621|OTHER|Biological sample once|The exome of each patient will then be analyzed from the blood sample taken beforehand.
223933845|NCT06770621|OTHER|Observation-questionnaire|only the answer to a questionnaire
223933846|NCT06740786|DRUG|Dapagliflozin Treatment Group|"This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.~Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day)."
223933847|NCT06817200|DRUG|Amantadine (100mg) as add on therapy.|Amantadine will be administered at the dose of 100 mg t.i.d or b.i.d. (if t.i.d. is not tolerated) over 12 weeks, after a period of 3 weeks of titration.T he study treatment will be stopped after a dose decrease of 100 mg / day every 3 days.
223933848|NCT06817200|DRUG|Placebo|Placebo tablets will be also administered b.i.d. or t.i.d over 12 weeks after a period of 3 weeks of titration. Placebo tablets will be indistinguishable from amantadine ones.
223933849|NCT02125149|OTHER|Exercise Intervention|
223933850|NCT06778707|PROCEDURE|External Oblique Intercostal Block|In group E, a needle will be used to pierce the skin, subcutaneous tissue then external oblique muscle to hydrodissect the fascial plane between external oblique muscle and intercostal muscles with 25 ml bupivacaine 0.25 % and 4 mg dexamethasone added to it.
223933851|NCT06778707|PROCEDURE|Subcostal Transversus Abdominis Plane Block|In group T, a needle will be used to pierce the skin, subcutaneous tissue then rectus muscle and 25 ml of 0.25 % bupivacaine with 4 mg dexamethasone will be injected between rectus muscle and transversus abdominis muscle.
223933852|NCT06830824|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
223933853|NCT06830824|OTHER|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
223933854|NCT06760286|DIETARY_SUPPLEMENT|Lung Care Solution|"Participants in the Breathe-Easy group received the food supplement solution designed to improve lung health and respiratory function. The supplement includes natural ingredients known for their potential to reduce inflammation, improve oxygen utilization, and support overall lung capacity.~Participants used 1 teaspoon of the supplement, prepared as a tea decoction, twice daily."
223933855|NCT06760286|OTHER|Support treatment|Participants in this group engaged in guided lifestyle modifications aimed at improving respiratory health. This included dietary recommendations as part of clinical practice.
223933856|NCT05140902|DEVICE|Point-of-care Portable Perfusion Phantom (P4)|P4 is a perfusion phantom developed by Dr. Harrison Kim that can significantly reduce variation in quantitating perfusion of human abdominal tissues across MRI scanners.
223933857|NCT04003480|DEVICE|FRAME|External support for vein grafts in peripheral bypass surgery
223933858|NCT06808412|DRUG|sintilimab combined with bevacizumab and XELOX|Patients with locally advanced low rectal cancer receiving sintilimab combined with bevacizumab and XELOX as a neoadjuvant regimen during the perioperative period.
223933859|NCT06771349|PROCEDURE|sigmoidopexy|"Both Sigmoidectomy and sigmoidopexy can be used for the treatment of sigmoid volvulus. The former is the treatment of sigmoid volvulus by removing a portion of the sigmoid colon, and depending on the patient's condition, a bowel reconstruction or anastomosis may be performed to reattach the healthy bowel segment. The procedure may result in long-term bowel changes and may even require an stomy. sigmoidopexy is a procedure that immobilizes the sigmoid colon to the abdominal wall or pelvic structure, preventing it from twisting again.~The goal of sigmoidectomy is primarily to remove damaged or necrotic portions of the sigmoid colon and to treat complications resulting from sigmoid volvulus, especially when the volvulus results in intestinal necrosis, ischemia, or other serious complications. The goal of sigmoidopexy is to prevent the sigmoid from re-twisting by immobilizing the sigmoid, and it is suitable for those cases of sigmoid torsion without severe ischemia or necrosis."
223933860|NCT06666439|DIAGNOSTIC_TEST|circulating tumor DNA (ctDNA)|Signatera is based on a custom-designed multiplex polymerase chain reaction (mPCR) assay for each patient, targeting up to 16 mutations found in the patient's tumor during whole exome sequencing (WES) to create a unique tumor mutation signature.
224099737|NCT07107477|DRUG|Neuroprotection|In patients with imminent preterm birth prior 32+0 week of pregnancy, foetal neuroprotection will be administered consisting of MgSO4 in an intravenous loading dose of 4 g (administered slowly over 20-30 min), followed by a 1 g per hour maintenance dose. This regimen should continue until birth but should be stopped after 24 h if undelivered.
224099738|NCT07107477|DRUG|antibiotic prophylaxis|Antibiotics - Group B Streptococcus (GBS) prophylaxis + macrolides, always at admission.
224097038|NCT07107308|DEVICE|Erbium-Doped Fiber Laser|Doctors and patients wear corresponding protective glasses. Apply cold gel to the treatment area on the patient's face and select certain treatment parameters based on the patient's skin lesion condition and skin type. After the treatment, clean your face. Decide whether to apply ice based on the severity of the skin lesion reaction. If ice application is necessary, the regular ice application time is 15 to 30 minutes, and apply a medical mask for 15 minutes. After the treatment, pay attention to moisturizing and sun protection.
224097039|NCT07105943|OTHER|Control|"The intervention will be implemented in the 8 weeks phase 2 cardiac rehabilitation program.~Both groups will receive a pre-exercise evaluation and 16 individualized training sessions (two per week) based on FITT-VP principles and according to the European Association of Preventive Cardiology (EAPC) guidelines. A complementary physical activity program integrated into their daily life will be prescribed. It will receive regular briefing sessions regarding the health-related benefits of exercise. After these sessions, it will be recommended to maintain physical activity aiming to reach at least 150 min/week of moderate intensity PA."
223933861|NCT06773312|BIOLOGICAL|BC001+Sintilimab+XELOX|patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg（body weight\<60kg）or 200mg（body weight≥60kg）intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.
223933862|NCT05874492|OTHER|Thermal cure with a primary dermatological indication|The thermal treatment combines baths which have a sedative, muscle-relaxing effect and encourage joint mobilisation, sprays which have a decongestant effect and, above all, thread-like showers which are carried out by jets of thermal water under high pressure for several minutes plus educational workshops (relaxation, sophrology, hygiene...)
223933863|NCT06235905|DRUG|NV-5138|NV-5138 is a novel , orally bioavailable, activator of mTORC1
223933864|NCT04568473|OTHER|PRG Barrier Coat (By SHOFU Inc., Japan)|PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol
223718520|NCT01396148|DRUG|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m\^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
223718521|NCT01396148|DRUG|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
223718522|NCT03910842|BIOLOGICAL|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
223933865|NCT04568473|OTHER|EMBRACE™ Varnish by (Pulpdent Corporation, USA)|5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
223933866|NCT06459973|DRUG|intravenous (IV) infusion|YL205 is provided in the form of lyophilized powder under a strength of 160 mg/vial. Each vial should be reconstituted to 20 mg/mL. Prior to IV infusionSubjects will be treated with YL205 via intravenous (IV) infusion, once every 3 weeks (Q3W) as a treatment cycle
223933867|NCT05704725|DRUG|ABP 938|IVT injection
223933868|NCT05704725|DRUG|Aflibercept|IVT injection
224097040|NCT07105943|OTHER|Experimental|As for the experimental group, in the 16 individualized training sessions (two per week), attention will be given to exercise intensity assessment and manipulation, with the goal of optimizing the affective experience of exercise, while also respecting minimum and maximum intensity thresholds as proposed by the EAPC (self-selected intensity within individually defined limits). The pre-exercise evaluation, the number of sessions, and methodological approach will be the same to the control group. In this group it will be presented some awareness of the potential of choosing fun and pleasant activities.
224097041|NCT07106827|DRUG|GV20-0251|Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks
224097042|NCT07107620|DIAGNOSTIC_TEST|one task|Single task tests consist of measuring walking times with normal walking (easy), walking with a 50% reduction in the base of support measured between the medial malleoli (medium difficulty) and tandem walking (difficult) tasks while applying the 10 meter walk test and time up go tests.
224097043|NCT07107620|DIAGNOSTIC_TEST|dual task|Dual task consists of single task plus tests of carrying glasses of water or counting backwards from a given number.
224285742|NCT06616259|DRUG|mFOLFOX6 plus Cetuximab|"mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy."
224285743|NCT01467479|DRUG|Telaprevir|Tablet
224285744|NCT01467479|DRUG|Ribavirin|Tablet
224285745|NCT01467479|BIOLOGICAL|Pegylated Interferon Alfa-2a|Subcutaneous Injection
224285746|NCT01467479|DRUG|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
224285747|NCT03815240|OTHER|No dressing|no dressing at sacrum
224285748|NCT03815240|OTHER|Mepilex® Border Sacrum|adhesive sacrum dressing
224285749|NCT03815240|OTHER|ALLEVYN Life Sacrum|adhesive sacrum dressing
224285750|NCT03815240|OTHER|Optifoam® Gentle Sacrum|adhesive sacrum dressing
224285751|NCT04828434|OTHER|Virtual Individual Cognitive Simulation Therapy|Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
223933869|NCT06826573|DIAGNOSTIC_TEST|Intraocular pressure|Intraocular pressure will be measured and recorded at 1 day, 1 week, 1 month, 3 months, 6 months postoperatively, and before silicone oil removal.
223933870|NCT06826573|DIAGNOSTIC_TEST|retinal recovery status|Measure and record the retinal recovery status 1 day, 1 week, 1 month, 3 months, 6 months after surgery and before silicone oil removal.
223933871|NCT04597671|DRUG|Durvalumab|Durvalumab is used as standard of care
223933872|NCT04597671|RADIATION|low-dose PCI|PCI will be given concurrently with durvalumab. PCI will be given to a dose of 15 Gy in 10 fractions
223933873|NCT06739707|DRUG|MD-18|MD-18 administered subcutaneously to healthy individuals with overweight or obesity.
223933874|NCT04233190|DRUG|Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg|one inhalation, twice daily
223933875|NCT06813898|PROCEDURE|Computed Tomography|Undergo PET/CT
223933876|NCT06813898|OTHER|Electronic Health Record Review|Ancillary studies
224097044|NCT07106047|BEHAVIORAL|Nurse-Led Climate-Responsive Asthma Management Program|A structured behavioral intervention delivered by trained nurses, focusing on climate-adapted asthma self-management for older adults. The program includes personalized coaching on symptom monitoring, environmental risk response, inhaler technique, and safe physical activity planning during climate stress events. Intervention is delivered weekly over 12 weeks through a combination of phone and in-person sessions, supported by tools such as symptom diaries, air quality alerts, and peak flow meters.
224097045|NCT07105553|DEVICE|Surgical Glove Compression|Participants wore two tight-fitting surgical gloves (one size smaller than standard) on the non-dominant hand. The gloves were applied 30 minutes prior to each paclitaxel infusion, remained in place during the infusion, and were removed 30 minutes afterward. The dominant hand remained ungloved and served as an internal control. This intervention was entirely non-pharmacologic and was integrated into routine chemotherapy sessions.
223933877|NCT06813898|OTHER|Flotufolastat F-18 Gallium|Given IV
224097046|NCT07107451|DIETARY_SUPPLEMENT|OIT with low dose sesame protein|"After 8 months of continued low-dose sesame OIT, patients will undergo hospital-based assessments, including skin prick testing, laboratory evaluations, and an open Oral Food Challenge (OFC) to evaluate desensitization.~Patients who had a negative OFC after 3 months in the initial phase of the study-and thus confirmed desensitization-will skip the pre-break OFC and proceed directly to the next stage.~Following a 4-week interruption in OIT, patients will return for a final hospital visit, during which a concluding OFC will be conducted to assess sustained unresponsiveness. Additional laboratory tests and skin prick testing will also be performed at this visit."
224097047|NCT07105800|BEHAVIORAL|Music-based dance|The dance routines emphasized perceptual-motor training through mutual physical guidance, spatial coordination, and social interaction among participants. The intervention aimed to enhance executive function, balance, and lower limb mobility by incorporating dual-task elements that challenge memory, attention, and physical control in a dynamic, enjoyable setting.
224097048|NCT07105800|BEHAVIORAL|Control|The training content is delivered through standardized, non-musical instructional videos. Participants in the control group follow fixed video demonstrations to perform functional lower limb exercises. The movement components include independent lower limb strength training and balance training.
224097049|NCT07107100|OTHER|a silicon jig/key is used to place/bond fixed retainer on teeth|a silicon jig/key is used to place/bond fixed retainer on teeth
224097050|NCT07101367|DRUG|Normal saline|After induction of anesthesia give 10 ml of normal saline then followed by infusion of normal saline till extubation of patient in ICU
224097051|NCT07101367|DRUG|Dexmedetomidine|After induction of anesthesia give loading dose of precedex 1 mcg/kg diluted in 10 ml normal saline then attach syringe pump of precedex infusion of 0.5mcg/kg/hr till extubation in ICU
223933878|NCT06813898|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223933879|NCT06811311|BEHAVIORAL|Ericksonian Hypnotherapy|Ericksonian hypnotherapy is a therapeutic approach that utilizes indirect suggestion, storytelling, and metaphorical language to induce a trance state and facilitate psychological change. This intervention aims to reduce anxiety symptoms, improve emotional regulation, and alter neurophysiological responses as measured by EEG. Participants will undergo 12 individual sessions, each lasting 90 minutes, over a period of 12 weeks.
223933880|NCT06774287|BEHAVIORAL|Karman Line memory strategy training|The memory strategy training consists of six weekly face-to-face treatment sessions. After sessions 3-5, the participant will play 8 levels in total of the Karman Line memory game on their computer or mobile device. In these levels they practice the strategies that are introduced in the face-to-face treatment in a safe digital environment. Also, the Karman Line memory app is provided.
223933881|NCT06774287|BEHAVIORAL|Treatment as usual|Treatment as usual contains ten sessions, with nine obligatory sessions supplemented with 1 (of five) non-obligatory sessions. Which non-obligatory sessions is chosen is dependent on the patients treatment goals.
223933882|NCT04444778|DEVICE|CPAP|Continuous positive airway pressure
224285752|NCT03446365|BEHAVIORAL|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
224285753|NCT03446365|BEHAVIORAL|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
223718523|NCT06280937|OTHER|Wearing a tie|Individuals in the study group will be asked to wear a tie during one office working day.
223933883|NCT06059651|PROCEDURE|Metabolic & Bariatric Surgery|Roux-en-Y metabolic and bariatric surgery
223933884|NCT06812559|DRUG|Progesterone|compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved, percentage of MII oocytes, and the rate of good quality blastocysts available for cryopreservation.
223933885|NCT06812559|DRUG|GnRH antagonist (Cetrorelix)|Subcutaneous injection
223933886|NCT06779227|BEHAVIORAL|Hospital family transitional nursing intervention|The intervention group received a transitional care intervention mainly focused on the transitional care model (TCM).
224097052|NCT07101367|DRUG|Methylprednisolone|After induction of anesthesia give solumedrol of a dose 10mg/kg diluted in 10ml of normal saline followed by a normal saline infusion till the extubation of the patient in the ICU
224097053|NCT07107789|OTHER|Diabetes education with video animation|Providing diabetes education to the experimental group through a video animation Following the routine diabetes education provided by the hospital, the experimental group will receive diabetes education using a video animation prepared and staged by the researcher and approved by experts.
224097054|NCT07106190|OTHER|Patients will be informed during the rehabilitation process|Patients will be informed during the rehabilitation process about secondary complications of stroke
224097055|NCT07106684|PROCEDURE|Autologous hematopoietic stem cell transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.
224097056|NCT07106684|BIOLOGICAL|BCMA CAR-T|Patients will receive BCMA CAR-T single dose (3.0 x 10\^6 cells /kg) infusion 3 days after ASCT.
224097057|NCT07106684|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion and continuing for at least 2 years
224097058|NCT07105852|DRUG|Sacituzumab tirumotecan (iv)+Putolizumab injection (iv)|"When administering sacituzumab tirumotecan and putolizumab on the same day, the drugs should be given sequentially. Putolizumab is administered first. For the first co-administration, a 4-hour interval is required. If no severe infusion reactions or allergic reactions occur, subsequent administrations may proceed with a minimum interval of 60 minutes before administering sacituzumab tirumotecan.~Putolizumab dosing:~Dosage: 200 mg, intravenous (IV) infusion Dosing cycle: Every 3 weeks (administered on Day 1 of each cycle) Dose interruptions due to adverse events (AEs): Refer to the prescribing information.~Sacituzumab tirumotecan dosing:~Dosage: 4 mg/kg, intravenous (IV) infusion Dosing cycle: Every 2 weeks (administered on Day 1 of each cycle, with a permissible dosing window of 14 ± 3 days between doses) Dose interruptions due to adverse events (AEs): Refer to the prescribing information."
224097059|NCT07105813|DEVICE|Navigational Positioning System for Puncture Surgery|Suitable for puncture surgery navigation and localization systems to assist in the procedure
223933887|NCT04713033|DIAGNOSTIC_TEST|surface electromyogram (sEMG)|A device that measures electrical signals from your skin will be connected to those stickers and will make a graph that is characteristic to your vocal function.
223933888|NCT04713033|DIAGNOSTIC_TEST|flexible laryngoscopy|"A device that examines the throat and nasal passages. The flexible laryngoscope or scope consists of an eyepiece and a fiber-optic light enclosed in a thin, flexible tube. The scope looks like a strand of black spaghetti with a tiny light on the end of it. The scope is inserted through the nose, and can be moved around to help the doctor see all areas of the nasal passages and throat."
223933889|NCT06464861|BIOLOGICAL|CD19-CAR-NK/T|Cord blood derived CD19 CARNK sequential Treatment with 7x19 CAR-T
224097060|NCT06755437|DEVICE|Rehabilitation with a computerized device (in the morning)|Each group received face-to-face cognitive rehabilitation with the electronic device for 45 min. The exercises were selected by the therapist and divided into four sessions of 2 to 3 days each. Each session included 40 min of activity and 5 minute of break
224285754|NCT02269956|BEHAVIORAL|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
224285755|NCT03442010|OTHER|Detection of adverse drug events|Detection of adverse drug events
224285756|NCT01682642|DRUG|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
224285757|NCT05951348|PROCEDURE|Delayed cord clamping for 30 seconds|waiting for 30 seconds after delivery of the fetus or milking of the cord in the direction of the fetus 10 times in time frame 10-15 seconds
223718524|NCT00777712|OTHER|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
223933890|NCT02645851|DRUG|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
224097061|NCT06755437|DEVICE|Self-treatment with a computerized device (in the afternoon)|In the afternoon, the experimental group performed 60 min. self-guided treatment with the electronic device.
224097062|NCT06755437|BEHAVIORAL|self-treatment with pencil-and-paper exercises (in the afternoon)|In the afternoon, the control group performed 60 min of cognitive self-treatment with conventional paper-and-pencil instruments. The therapist created a variety of exercises every day
224097063|NCT04362540|DIAGNOSTIC_TEST|MRI scan|On attendance to antenatal clinic with confirmed diagnosis of gestational diabetes based on OGTT and following informed consent: Ultrasound scan: Those with positive OGTT results (i.e. GDM positive) will attend an appointment for an ultrasound scan, as per routine practice. These women will,at that appointment, be assessed for presence/absence of NAFLD as well as undergoing their routine foetal assessment. This is a simple addendum to the existing scan, taking no more than 5 minutes. Participants will have been informed during the consent process that the results (regarding the presence / absence of NAFLD) will be compared to MRI after delivery.
224097064|NCT07106671|DRUG|Siltuximab|Siltuximab 11mg/kg
223933891|NCT02645851|DEVICE|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
223933892|NCT02645851|DEVICE|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
223933893|NCT02645851|OTHER|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
223933894|NCT06022081|DIAGNOSTIC_TEST|Lung ultrasound to detect pneumothorax.|Within a maximum of two hours after chest tube removal, the sonographic exam will be performed with an ultrasound device to assess residual PNX using a portable ultrasound device. The examination will require patients to lie face upward and will be performed at three different sites on both sides of the patient's chest. Each chest site will be imaged for approximately 10-20 seconds, allowing a complete examination of each side in approximately 30-60 seconds. The total study time for the LUS exam is approximately 2 minutes. The results of this assessment will be compared to the standard chest x-ray performed by a radiologist who is unaware of the study.
224097065|NCT06918327|OTHER|Concentrated Growth Factor|Bilaterally impacted third molar of the patients are removed surgically and concentrated growth factor is placed in one of the extraction sockets.
224097066|NCT06918327|OTHER|non-CGF|The other extraction socket is left empty for control purposes.
224097067|NCT07106541|BEHAVIORAL|Replicating Effective Programs (REP)|The study team will deploy this stakeholder informed REP package across the 68 sites in the MSQC-COHR collaborative. The REP program uses a blend of formats including didactics, flipped classroom design, and narrative storytelling, the REP will address key barriers to adherence previously identified by surgeons.
224097068|NCT07106541|BEHAVIORAL|REP with facilitation (REP-PLUS)|This intervention is a stepped-up REP plus virtual facilitation. The facilitator will: 1) Initiate implementation and benchmark goals: The facilitator will partner with the identified site champions but be masked to primary and secondary outcomes. Together, the facilitator and site champions will review processes to organizationally embed clinical practice guidelines into practice, assess potential barriers and facilitators to these processes, and set measurable goals for adherence to recommendations; 2) Track adherence and provide feedback: Facilitators will use abstracted MSQC-COHR and site-specific operative data to track adherence to clinical practice guidelines, identify barriers to adherence, provide solutions to identified barriers, re-engage stakeholder groups responsible for unsatisfactory measurements, and continuously promote awareness of the guidelines.
224097069|NCT07106619|DEVICE|Isokinetic Exercises|Exercises will be performed at three different angular speeds (90 ̊/sec, 5 repetitions, 5 sets; 120 ̊/sec, 8 repetitions, 5 sets; 150 ̊/sec, 10 repetitions, 5 sets).
224097070|NCT07106619|OTHER|Conventional rehabilitation program|Ambulation and balance exercises
224097071|NCT07106346|PROCEDURE|The timing of endoscopic intervention for necrotizing pancreatitis is determined based on the degree of encapsulation|In the encapsulation-oriented group, participants undergo EUS-guided drainage of necrotizing pancreatitis when the degree of encapsulation reaches ≥80%, as confirmed by cross-sectional imaging (preferably contrast-enhanced CT). Imaging is repeated every 7-10 days after enrollment to assess encapsulation. Once sufficient encapsulation is observed and the patient presents with symptoms such as infection, abdominal pain, GOO or biliary obstruction, endoscopic drainage is performed. Drainage is typically performed using a lumen-apposing metal stent (LAMS) placed under EUS guidance, often accompanied by placement of an external drain. Step-up therapy, including endoscopic necrosectomy or additional drainage procedures, may be used if symptoms do not improve. If the patient improves with conservative therapy before encapsulation is achieved, drainage may be deferred. Endoscopic/percutaneous interventions should, in principle, be discussed with the expert panel beforehand.
224285758|NCT03102151|OTHER|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
224285759|NCT04359537|DRUG|Hydroxychloroquine Sulfate 200 MG|Hydroxychloroquine Sulphate 200 mg tablets will be prescribed and instituted orally at the doses and regimens described
224285760|NCT04359537|OTHER|Placebo|Control group will receive a Placebo tablet. Placebo 200mg will be given on Day 1 followed by Placebo 200mg every three weeks.
224285761|NCT04403516|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg|To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
224285762|NCT04403516|DRUG|Prednisolone Acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.
224285763|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
224285764|NCT01401387|OTHER|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
224285765|NCT02327793|DRUG|Nitroglycerin|
224285766|NCT02327793|DRUG|Labetalol|
224285767|NCT01915940|DRUG|Bimatoprost|Bimatoprost ocular insert
224285768|NCT01915940|DRUG|Timolol 0.5%|Timolol 0.5% solution
224285769|NCT01915940|DRUG|Placebo Eye Drops|Placebo topical eye drops
224285770|NCT01915940|DEVICE|Placebo Ocular Insert|Ocular insert without any active drug
224285771|NCT02619448|DRUG|Carboplatin|chemotherapy
224285772|NCT02619448|DRUG|Paclitaxel|chemotherapy
223933895|NCT06024785|PROCEDURE|Vertebropexy|microsurgical (i.e., the use of a microscope or magnifying glasses during decompression) lumbar laminotomy with partial removal of the medial facet joint by preserving the midline structures (supraspinous-interspinous ligament complex); approach: bilateral or ipsilateral with cross-over to the contralateral side. Additional stabilization of the spine with a ligament (for instance semitendinosus donor allograft), which connect the postoprior structures (Proc. Spinosus and/or Lamina) of the vertebrae . Situation-related application of laminar bands or analogous suture material (for instance FiberTape, Arthrex, Naples or Nile Band, K2M, Virginia)
224285773|NCT02619448|RADIATION|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
224285774|NCT05686148|OTHER|Vibration|The device used for vibration application is produced to control pain and direct attention by providing 6000/min vibration. According to Melzack and Wall's Gate Control Theory, the application of local vibration reduces perceived pain by stimulating nerve fibers. Therefore, it should be ensured that the device is in full contact with the skin. The device can be used again by wiping with 70% alcohol. The device is placed 3 cm above the area to be injected. Vibration is applied to the area for 5 minutes before the procedure.
224285775|NCT04933786|BEHAVIORAL|Digital Health Nudging|Short daily text messages with information and motivation concerning physical activity.
223718525|NCT01752127|PROCEDURE|percutaneous coronary intervention using drug eluting stent|"1\. Intracoronary stenting~1. The procedure could be conducted via brachial, radial or femoral approaches.~2. There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~3. When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~4. Direct stenting or bifurcation stenting is allowed.~5. Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
223718526|NCT02759432|OTHER|High-intensity interval exercise training|
223718527|NCT04970797|DRUG|Xinglouchengqi decoction|the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
223933896|NCT04484623|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.
224285776|NCT03380520|DRUG|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
224285777|NCT03380520|DRUG|Placebo|IV nacl 0.9%
223933897|NCT04484623|DRUG|Pomalidomide|Immunomodulatory drug (IMiD) will be administered.
223933898|NCT04484623|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity will be administered.
223933899|NCT04484623|DRUG|Bortezomib|Proteasome Inhibitor will be administered.
223933900|NCT06795776|DRUG|Eschscholzia tablets|"The intervention will be provided as swallowable Eschscholzia tablets (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material."
223933901|NCT06795776|DRUG|Placebo Tablets|A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants.
223933902|NCT06775106|OTHER|There is no intervention in this observational study|No direct intervention will be done to patients eligible for the study. There will be a shunt placed to divert 5-15% of exhaled breath into a collection tube. This will not affect the patient's existing standard medical care.
223933903|NCT06767878|BEHAVIORAL|PORTiSOFIE|"This treatment is based on the Clark and Wells model of social phobia, and it is constituted by 9 modules:~1. Introduction of the program and overview of social anxiety disorder and symptoms~2. Negative automatic thoughts~3. Challenging negative automatic thoughts~4. Behavioral experiments~5. Exposure~6. Exposure and self-focus attention~7. Exposure and get closer to fears~8. Social skill training~9. Maintenance plan"
223933904|NCT04895917|DRUG|daratumumab and pomalidomide|Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
223933905|NCT05397457|DEVICE|low-level light therapy|"Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks."
223933906|NCT06775483|DRUG|JSKN016|Administered intravenously according to protocol.
223933907|NCT06775483|DRUG|Docetaxel|Administered intravenously according to protocol.
224285778|NCT06614660|OTHER|Metabolism genomics and imaging genomics|Pre-operative imaging images of the patient were collected prior to surgery, and 2 ml of the patient\&#39;s blood specimen was collected to collect metabolism genomics and imaging genomics.
224285779|NCT01546324|PROCEDURE|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
223933908|NCT05995860|BEHAVIORAL|Intervention group triads|The intervention consists of a rapid (less than 10-minute) communication intention elicitation exercise (via Freelisting), which is conducted independently with the patient, caregiver, and provider immediately prior to the outpatient oncology encounter. Patients, caregivers, and providers will not be instructed to endorse the Freelist responses that were generated by the intervention prior to the outpatient encounter-leaving the decision to discuss elicited communication intentions during the encounter up to individuals as the conversation naturally occurs. As with the control group, post-encounter survey data will also be collected independently from the patient, caregiver, and the provider, followed by a post-encounter qualitative interview conducted jointly with the patient and caregiver.
223933909|NCT05929339|DRUG|Oxytocin|Intravenous oxytocin
223933910|NCT06752759|DRUG|nebulized ketamine|The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
224097072|NCT07106346|PROCEDURE|EUS-guided drainage based on the interval from the onset of acute pancreatitis|In the timing-oriented group, participants undergo EUS-guided drainage of necrotizing pancreatitis at 4 to 5 weeks after the onset of acute pancreatitis, regardless of the degree of encapsulation. Drainage is performed only in symptomatic patients who meet predefined clinical criteria, such as signs of infection, significant pain, GOO, or biliary obstruction. Imaging is performed before the procedure. The standard approach involves placing a LAMS under EUS guidance, optionally supplemented by external drains. If symptoms do not improve, step-up interventions such as endoscopic necrosectomy, percutaneous drainage may be considered. If inflammation and symptoms improve with conservative treatment (e.g., antibiotics), EUS-guided drainage may be omitted. Conversely, even before 4-5 weeks from onset, early drainage is allowed if conservative treatment is deemed insufficient by the attending physician. In principle, intervention decisions should be discussed with the expert panel.
223933911|NCT05701150|OTHER|Minimal documentation|Minimal data documentation only of patients without targeted therapy based on NGS results
223933912|NCT05701150|OTHER|Extended documentation|Extended data documentation of patients with targeted therapy based on NGS results
224097073|NCT07106372|BIOLOGICAL|Stapokibatrt|Stapokibatrt Subcutaneous injection
224097074|NCT07108140|BIOLOGICAL|Anti ALPP CAR-T cells treatment|anti ALPP CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.
224097075|NCT03905434|GENETIC|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
224097076|NCT06923111|DRUG|Xromi|Xromi is indicated for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 9 months of age as part of standard clinical practice
224097077|NCT07108127|DRUG|Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX|Trastuzumab biosimilars and pertuzumab biosimilars combined with oxaliplatin and capecitabine
224097078|NCT06916767|DRUG|BAFF CAR-T|Single infusion
224097079|NCT06916767|DRUG|Obinutuzumab|IV administered
224097080|NCT06916767|DRUG|Cyclophosphamide|500mg/m2 on days -5 to -3
224097081|NCT06916767|DRUG|Fludarabine|30mg/m2 daily on days -5 to -3
224097082|NCT06915298|BEHAVIORAL|Alcohol health warning label - cancer|A sticker with health information on alcohol causing cancer is applied to alcoholic beverage containers purchased by the participants.
224097083|NCT06915298|BEHAVIORAL|Responsibility message on alcohol label|A sticker with a message to drink responsibly will be applied to alcoholic beverage containers purchased by the participants.
224097084|NCT06915298|BEHAVIORAL|Front label|A sticker will be applied to the front of the alcoholic beverage containers purchased by the participants.
224097085|NCT06915298|BEHAVIORAL|Back label|A sticker will be applied to the back of the alcoholic beverage containers purchased by the participants.
224097086|NCT06915298|OTHER|Outcome pre-testing|Primary outcome (knowledge of alcohol related harms) is tested at baseline.
224097087|NCT06915298|OTHER|No outcome pre-testing|Primary outcome (knowledge of alcohol related harms) is not tested at baseline.
224097088|NCT06932575|DEVICE|Andullation Therapy Bed|andullation therapy applied for 30 minutes after oocyte retrieval
224097089|NCT03311971|DEVICE|Virtual reality glasses|Patients will be treated with virtual glasses
224097090|NCT03311971|DEVICE|No VR glasses|Patients will not use VR glasses
224097091|NCT05639413|OTHER|Collection of blood samples|A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
223933913|NCT05496829|BEHAVIORAL|Multicomponent Adherence Intervention|The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
223933914|NCT05496829|OTHER|Usual Care|Receipt of usual care from providers
223933915|NCT06758570|DIETARY_SUPPLEMENT|Pectin dosages|15 individuals were provided with increasing doses of pectin: 5g for 2 weeks 10g for 2 weeks 15 for 2 weeks
223933916|NCT06771778|OTHER|Survey using a questionnaire.|A Qualtrics link was provided for current and former NICU RDNs to complete a 10-minute online survey that provided an optional gift card for completion. Part 1 of the survey had eight questions, and part 2 had eleven additional questions.
223933917|NCT06742203|DIETARY_SUPPLEMENT|Whey Protein Milk-Derived EVs|WPMDE1 - Whey Protein Milk-Derived EVs, is a white powder obtained by filtration, concentration, and dehydrating whey solution, with the addition of sweeteners and flavorings to balance the taste. The WPMDE1 contains a known concentration of EVs (also known as milk exosomes).
224097092|NCT06935916|PROCEDURE|pedicled or free tissue transfer|pedicled or free tissue transfer
224097093|NCT06935968|DEVICE|Levonorgestrel intrautrine system|Insertion of levonorgestrel intrautrine system and take a blood sample from the women to analyse it
224097094|NCT06936215|DRUG|tab baricitinib 4 mg daily|Group A participants will be given tab. Baricitinib 4 mg daily
224097095|NCT06936215|DRUG|tab methotrexate 25 mg weekly with folic acid 5 mg weekly|group A participants will be given tab. baricitinib 4 mg daily and group B participants will be given tab. methotrexate 25 mg weekly with folic acid 5 mg weekly
224097096|NCT06941727|DIAGNOSTIC_TEST|ultrasonographic imaging|masseter muscle elasticity
224097097|NCT06943716|PROCEDURE|Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)|A modified bilateral catheter antegrade cerebral perfusion technique used for acute Type A aortic dissection repair. This approach aims to reduce surgical trauma by avoiding additional right axillary access while maintaining stable cerebral perfusion.
224097098|NCT06943716|PROCEDURE|Conventional Brain Perfusion|Patients receiving the conventional perfusion strategy for aortic arch surgery, which may include standard bilateral ACP based on the surgeon's preference and the patient's condition.
223933918|NCT06775197|PROCEDURE|partial meniscal replacement with Spongioflex®|for any surgical procedure, the patient receives an antibiotic shot NIMP) just before surgery. The patient will be arthroscopically treated via the arthroscopic portal with implantation of a demineralized bone block (IMP: Spongioflex ®, appropriate size (DIZG gGmbH, Berlin, Germany)) as a partial meniscus substitute. The block will be adapted to the defect size and secured with 2-4 inside-out sutures (Etibond 0, Ethicon, Somerville, NJ). No dosing, the IMP has no systemic effect. The surgery (Intervention) will last between 60-90 minutes. The hospital stay is between 2-3 days after surgery. Follow-up visits: at the end of the hospital stay, after 6 weeks, after 6, 12 and 24 months and after 5 years for the operated group.
223933919|NCT04551066|DRUG|parsaclisib|parsaclisib will be administered QD orally
223933920|NCT04551066|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
223933921|NCT04551066|DRUG|placebo|placebo will be administered QD orally
223933922|NCT05011721|DEVICE|Activity tracker|"Participants will receive a Withings Steel HR activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the NeoFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure NeoFit space."
223933923|NCT06936475|DRUG|Povidone-Iodine|5% povidone iodine
223933924|NCT06936475|DRUG|Chlorhexidine Gluconate|0.5% chlorhexidine
223933925|NCT06935799|PROCEDURE|One minute intercostal nerves cryoanalgesia|One-minute cryoanalgesia will be applied bilaterally to each of the intercostal nerves from Th3 to Th7
223933926|NCT06935799|PROCEDURE|Two minutes intercostal nerves cryoanalgesia|Two-minutes cryoanalgesia will be applied bilaterally to each of the intercostal nerves from Th3 to Th7
223933927|NCT06939842|OTHER|Menthol ice|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Identification Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with the Numerical Pain Scale (NPS) will be evaluated. In the second stage, evaluation will be made according to the Safety Protocol for the Management of Immediate Postoperative Thirst and menthol ice will be applied if the patients meet the criteria in the protocol. Thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes after the first application. Immediately after this evaluation, menthol ice will be applied for the second time. After the second application, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
224097099|NCT06936085|OTHER|Training|The Crime Scene Forensic Evidence Management training, which included theoretical knowledge and the presentation of sample cases, was completed for 144 volunteer participants. The content of the training includes topics such as forensic incidents, evidence, crime scene management, and evidence management, as well as the roles and responsibilities of paramedics in forensic cases such as injuries, violence, abuse, sexual assault, and suicide. Training was given to 4 groups of 35-37 students in each group in the classroom environment in two class hours (30+ 30 minutes + 1 break). Trainings were given by a single lecturer to avoid bias and ensure standardization.
224097100|NCT06935409|DRUG|HS-20093|Study participants in the experimental group shall continue to receive HS-20093 by intravenous infusion at a dose of 12.0 mg/kg, once every 3 weeks (Q3W) with a 21-day treatment cycle. Treatment shall continue until objective disease progression (excluding cases of treatment beyond PD or crossover treatment) or until other criteria for termination of study treatment specified in the protocol are met.
224285780|NCT02999984|GENETIC|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)|autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously
223718528|NCT03351803|OTHER|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
223933928|NCT06939842|OTHER|Frozen saline|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Identification Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with the Numerical Pain Scale (NPS) will be evaluated. In the second stage, evaluation will be made according to the Safety Protocol for the Management of Immediate Postoperative Thirst and frozen saline will be applied if the patients meet the criteria in the protocol. Thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes after the first application. Immediately after this evaluation, frozen saline will be applied for the second time. After the second application, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
224285781|NCT02999984|DRUG|busulfan|Busulfan is used for non-myeloablative conditioning
224285782|NCT02999984|DRUG|PEG-ADA ERT|PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment
224285783|NCT05402306|OTHER|Treatment group|Group metacognitive therapy, mainly with attention training technique over two weeks.
224285784|NCT00347529|BIOLOGICAL|pPML7789 with and without pPJV2012 administered by PMED|
224285785|NCT02049021|DEVICE|MECTA SPECTRUM 5000Q ECT|
224285786|NCT02049021|PROCEDURE|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
224285787|NCT01347658|DIETARY_SUPPLEMENT|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
224285788|NCT00164034|DEVICE|Real time computer prompted trauma algorithms|
223933929|NCT06939842|OTHER|No Interventions|When patients are brought from the operating theatre to the surgical clinic, patients will be waited until they are able to communicate. In the first stage, after filling in the Patient Introduction Form before the intervention, thirst status with Perioperative Thirst Discomfort Scale (PTDS) and sore throat status with Numerical Pain Scale(NPS) will be evaluated. Patients in the control group will be waited for approximately 10 minutes, taking into account the application times in the intervention groups. No intervention will be applied during the waiting period. After 10 minutes of waiting time, thirst will be re-evaluated with PTDS and sore throat will be re-evaluated with NPS at 30th and 60th minutes. Considering the 2nd application time in the intervention groups, it will be waited again for approximately 10 minutes without any intervention. After the waiting period, thirst will be re-evaluated with PTDS at 30th and 60th minutes and sore throat will be re-evaluated with NPS.
223933930|NCT05529992|DRUG|Velaglucerase Alfa|VPRIV intravenous infusion every other week for 60 minutes.
223933931|NCT06836895|BEHAVIORAL|HIIT and IMT|The HIIT protocol involved four intervals, each lasting 4 minutes, beginning at 70% of maximum power and building to a target intensity of at least 85% HRmax. The IMT sessions included 2-3 sets of 30 breaths (totaling 60-90 breaths per session), with a two-minute rest between sets, three days per week starting with 30% of PImax and reaching 60% of PImax.
223933932|NCT06836895|OTHER|walking|30-min walking
223933933|NCT06949475|DIAGNOSTIC_TEST|Single Task (Box and Block Test)|The test requires a wooden box divided into two compartments and 150 blocks (2.5 cm tall). When administering the test, the evaluator should be aware of whether the child's fingertips move from one compartment to the other. The number of blocks passed from one side of the box to the other in one minute determines the level of the skill. It is done separately for right and left hand. The number of cubes thrown in 1 minute gives the score.
223933934|NCT06949475|DIAGNOSTIC_TEST|Single Task (Nine Hole Peg Test)|The 9-hole peg test is a standardized test that measures fine dexterity against time. It is simple to administer and is a valid and reliable method of assessment. Both hands are tested in the assessment. The child is first asked to place 9 sticks of 3.2 cm in length into the holes on the platform as quickly as possible with the dominant hand and the time from the start command until the last stick is placed is recorded. Then, with the same hand, he/she is asked to pick up the sticks in order and the time to remove all the sticks is recorded in seconds. The same procedure is repeated with the other hand.
223933935|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Box and Block Test-Kognitif Task)|Box Block Test-for the cognitive task assessment, the individual will be asked to count animal names while performing the test.
223933936|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Nine Hole Peg Test-Kognitif Task)|9 Hole Peg Test-for the cognitive task assessment, the individual will be asked to count backwards from 20 one by one while performing the test
223933937|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Box and Block Test-Motor Task)|For the Box Block Test-motor task assessment, the individual will be asked to keep a rhythm by tapping the table with the fingers on the other side while performing the test. The number of blocks passed from one side to the other side of the box divided into two in one minute will be determined and recorded.
224097101|NCT06935409|DRUG|Gemcitabine combined with docetaxel|Study participants in the control arm will receive gemcitabine in combination with docetaxel. Gemcitabine (1000 mg/m2) will be administered intravenously over approximately 30 minutes on Days 1 and 8 of each 21-day treatment cycle, followed by docetaxel (75 mg/m2) on Day 8, intravenously over approximately 1 hour until objective disease progression or other criteria for treatment discontinuation are met.
224097102|NCT06935305|DEVICE|OSNA|The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the OSNA method
224285789|NCT05649735|DEVICE|Logusgyn ovules|"LOGUSGYN ovules is a CE certified Class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a vaginal ova dressing for topical use containing tindalised cultures, Guar fibre, Lactic acid and Calendula.~It is supplied in a container with 10 vaginal ova. For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
224285790|NCT05649735|DEVICE|Logusgyn Lavander|"LOGUSGYN lavage is a CE certified class I medical device, according to MD Directive 93/42 / EEC as amended by Directive 2007/47 / EC, manufactured by ERBOZETA S.p.a. designed for its intended use. It consists of a gynaecological lavage dressing containing Chlorhexidine 0.2% and tindalised ferments, lactic acid, bisabolol.~It is supplied in a container with 5 vaginal douches.~For this study, LOGUSGYN/CANDIDEP ova/wash will be packaged according to good manufacturing practice and local regulatory requirements and will be labelled in accordance with local regulatory requirements and according to GMP Annex 13."
223718529|NCT05572450|OTHER|Infectious Titre 1|Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
223933938|NCT06949475|DIAGNOSTIC_TEST|Dual Task (Nine Hole Peg Test-Motor Task)|9 Hole Peg Test-for motor task assessment, the individual will be asked to bend and unbend the other elbow while performing the test.
224097103|NCT06935305|DEVICE|Ultrastaging|The search for lymph node metastases in surgically removed sentinel lymph nodes will occur using the ultrastaging method
224097104|NCT06936033|OTHER|Kinesiology taping|This study used Kinesio taping as an intervention to compare the biomechanical effects of stair descent in patients with acute ankle injuries before and after taping. Participants participated in two intervention conditions: the KT experimental group (Kinetoscopy taping) and the ST control group (no Kinesio taping), and each condition performed 20 separate stair descent tests.
223718530|NCT05572450|OTHER|Infectious Titre 2|Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
223718531|NCT05572450|OTHER|Infectious Titre 3|To be determined (TBD), depending on outcome of Part A
223718532|NCT05572450|OTHER|Infectious Titre 4|TBD, depending on outcome of Part A
224097105|NCT06935383|DEVICE|Therapeutic sequence|the required dose of treatment is administered through the CoFI system
223718533|NCT02314416|BIOLOGICAL|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix'. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
224097106|NCT06935383|DEVICE|Diagnostic sequence|Diagnostic sequence to detect MVO
223718534|NCT04525417|DIAGNOSTIC_TEST|AAZ Covid-19 rapid test|To assess the immune status
223933939|NCT06949475|DIAGNOSTIC_TEST|ABILHAND-Kids|The Abilhand Kids Hand-Related Ability Scale will be used to assess the use of upper extremities in Activities of Daily Living (ADL). The scale includes 21 sub-items. Sub-items are scored as 0; cannot do, 1; has difficulty in doing and 2; can easily do. The questions are usually answered by the parent, but can also be answered by the child if the child is old enough and cognitive level is appropriate.
223718535|NCT05117437|OTHER|Physiological test|This test was conducted to determine the endurance levels of the participants.
223933940|NCT06949475|DIAGNOSTIC_TEST|Functional Mobility Scale (FMS)|The child's walking ability is assessed at 3 different distances (5 meters (home), 50 meters (school), 500 meters (community)). The assessment at all three distances is graded on a scale of 1-6, with wheelchair mobilization 1 and independent ambulation 6. It is indicated as (C) if the distance can be covered by crawling and (N) if the distance cannot be covered by any other means. The assessment is done through an interview with the family. The child is not observed.
223933941|NCT06949475|DIAGNOSTIC_TEST|Myelomeningocele Functional Classification System (MMFC)|The Myelomeningocele Functional Classification System (MMFC) is a 4-level system that classifies individuals with myelomeningocele according to their functional capacity. The functional status of children in Level 1 is more inadequate than in other levels. Functional status improves as the level increases.
223933942|NCT06949475|DIAGNOSTIC_TEST|Modified Mini Mental Test (MMMT)|The Modified Mini Mental Test (MMMT) is used to screen for cognitive dysfunctions in children, to assess the severity of impairments and to determine changes over time. It has been reported that the test is a suitable tool for examining cognitive functions in children from the age of 4 and can be easily included in general neurological examinations of children. The test, which takes 5 to 10 minutes to administer, assesses 5 cognitive domains, including orientation, memory, concentration, language function and measures of structural ability. The total score in this test reaches a plateau at approximately 9-10 years of age. In children over 10 years of age, scores below 27 out of a total of 35 points are indicative of mental retardation.
223718536|NCT05117437|OTHER|Physical test|Height, weight, and BMI were determined
223718537|NCT05117437|OTHER|Biochemical tests|BMP9, CTX1, COMP, oxLDL protein levels, ALP, GGT, TAS, TOS, OSI, NO, calcium, T-C, LDL-C, Triglyceride, HDL-C, glucose, CRP, AST, ALT, erythrocyte, mean erythrocyte volume (MCV), hematocrit, leukocyte, thrombocyte levels were determined from blood samples.
223933943|NCT06766279|PROCEDURE|Osteopathic Manipulative Treatment|"The OMT intervention in this study will be comprised of an occipitoatlantal (OA) decompression and treatment of the nasal Chapman point. The OA decompression will be applied for 2 minutes with 12N of pressure as this pressure has been determined to produce the greatest effect. Treatment at this level reduces congestion of nasal mucosa. The suboccipital decompression technique is generally considered to bear minimal risks and is perceived by most patients as a pleasant experience. This technique is considered to be a basic skill among osteopathic physicians. It is usually taught within the first semester of the first year at Colleges of Osteopathic Medicine.~The other intervention technique will be addressing the nasal Chapman points that are found at the tip of the transverse process of C1 and the costochondral junction of the first rib on each side. Both techniques are performed while the subject is supine."
223933944|NCT06766279|PROCEDURE|Sham treatment|The sham intervention will consist of the subject lying supine with the investigator's hands resting gently on both sides of subject's neck for 5 minutes.
223933945|NCT06847737|DIAGNOSTIC_TEST|perfusion index|To compare the incidence of hypotension after spinal anesthesia and the values of perfusion index, pleth variability index, tissue oxygen saturation and tissue hemoglobin index between those who developed hypotension and those who did not develop hypotension over time.
223933946|NCT05453695|DRUG|Intravenous DNase I|Dose-escalating intravenous infusion of DNase I
223933947|NCT06953232|DIETARY_SUPPLEMENT|Whey protein-enriched milk fat globule membrane supplement|Participants will consume a high-fat, mixed meal containing approximately 75 g of test fat (refined palm oil), supplemented with a whey protein-enriched milk fat globule membrane (providing \~5 g of milk polar lipids) powdered ingredient. The experimental and placebo meals will be isoenergetic and protein-matched, and will be administered in a randomised order, with a washout period of at least 21 days between sessions.
223933948|NCT06953232|DIETARY_SUPPLEMENT|Whey protein-based supplement|Participants will consume a high-fat, mixed meal containing approximately 75 g of test fat (refined palm oil) supplemented with a whey protein-based powdered ingredient without milk fat globule membrane (placebo) The experimental and placebo meals will be isoenergetic and protein-matched, and will be administered in a randomised order, with a washout period of at least 21 days between sessions.
223933949|NCT06954207|DEVICE|Non interventional. Data collection concerns routine procedures and monitoring devices|Non interventional. Physiological parameters under general anesthesia are collected (arterial pressure, heart rhythm, bispectral index, NOL index, temperature, total dose of remifentanil infusion, analgesic drugs infusions). After surgery, pain scores (NRS), motor function and time to ambulation are also collected.
223933950|NCT06953193|PROCEDURE|General Anesthesia|"Patients will undergo balanced general anesthesia for pancreatoduodenectomy. Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg.~Anesthesia maintenance will be achieved with sevoflurane (variable concentration as per anesthesiologist discretion) and continuous fentanyl infusion according to the attending anesthesiologist's judgment.~No epidural catheter will be placed."
223933951|NCT06953193|PROCEDURE|Combined General Anesthesia (Thoracic Epidural)|"Patients will undergo combined general anesthesia (thoracic epidural) for pancreatoduodenectomy.~Induction will include: fentanyl 4 mcg/kg, lidocaine 1 mg/kg, propofol 1.5 mg/kg, and rocuronium 0.6 mg/kg.~A thoracic epidural catheter will be placed at the best palpable intervertebral space between T6-T9 by the attending anesthesiologist.~Anesthesia maintenance will include sevoflurane (variable concentration), fentanyl infusion at the anesthesiologist's discretion, and continuous infusion of 0.25% bupivacaine via the epidural catheter throughout the surgery."
223933952|NCT06953856|OTHER|occlusal reduction|Occlusal reduction is a procedure that applied patients for different aims. One of these aims is pain relief after endodontic treatment and there are some studies about this topic however, there is no consensus about it. This discrepency could be related to differences of the inclusion criteria for this reason this study aimed to get a reliable result.
224285791|NCT05649735|OTHER|Placebo|Sterile saline solution
224285792|NCT00282750|DEVICE|Bar coded sponge and scanner|
224285793|NCT02265172|PROCEDURE|Physiotherapy screening|Physiotherapy screening.
223933953|NCT06953011|OTHER|music application|Patients were met within 1 hour preoperatively. Vital signs, pain score, blood glucose were checked and state anxiety scale was applied. Music was played through headphones and speakers for at least 20 minutes according to the type of music preferred by the patients and the preferred way of listening to music, and the state anxiety scale was applied again. Patients' questions were answered and they were encouraged to share any concerns. Patients were prepared for surgery and transferred to the operating room. Considering the patient's recovery from anesthesia, patients were visited again the day after surgery, vital signs, pain score, blood glucose were checked and the perianesthesia comfort questionnaire (PCQ) was applied.
223933954|NCT06953999|DRUG|Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
223933955|NCT06953999|DRUG|Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab: a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo: a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
223933956|NCT06953999|DRUG|Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine|"Ivonescimab Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~AK117 Placebo : a specified dose and frequency administrated by intravenous infusion (IV).~Albumin-bound Paclitaxel: 125 mg/m2 weekly for 3 weeks followed by 1 week of rest.~Gemcitabine: 1000 mg/m2 weekly for 3 weeks followed by 1 week of rest."
223933957|NCT06766825|DRUG|Plitidepsin 1.5 mg/day|"Receive 1.5 mg/day of plitidepsin intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
223933958|NCT06766825|DRUG|Placebo|"Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during 4 treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
223933959|NCT06766825|DRUG|Placebo and Plitidepsin 1.5mg/day|"Receive placebo intravenously (IV) over a 1-hour infusion for 3 consecutive days every 15 days during two treatment periods and receive plitidepsin 1.5mg/day during the last two treatment periods.~The participant will receive the following pre-medication before receiving the study treatment:~* Palonosetron 0.25 mg IV~* Dexchlorpheniramine maleate 5 mg IV (or equivalent to H1 receptor antihistamines)~* Famotidine 40 mg oral (60 minutes before starting the plitidepsin/placebo infusion)~* Dexamethasone phosphate 8 mg IV (equivalent to 6.6 mg of dexamethasone)~Premedication should be completed 20-30 minutes before starting the plitidepsin/placebo infusion."
223933960|NCT06765746|PROCEDURE|Ventricular tachycardia ablation|"All ventricular tachycardia (VT) ablation procedures will be performed under general anesthesia. An epicardial approach will be performed, if clinically needed, when a detailed endocardial mapping during VT fails to reveal the complete VT critical isthmus. In case of epicardial mapping, the pericardium will be accessed percutaneously using the method described by Sosa et al.~VT activation mapping will be performed and the critical isthmus will be defined as the diastolic pathway.~Ablation will be performed at 50 W (temperature limit of 43 °C) using an irrigated ablation catheter (TactiFlex, Abbott, MN). Ablation will be aimed at VT isthmus transection. Substrate modification will be added if the patient is still inducible or in the absence of any inducible/tolerated VT. Substrate ablation will be performed based on sinus rhythm mapping, aiming at non-inducibility of any VT. At the end of procedure, programmed ventricular stimulation will be repeated."
223933961|NCT06765148|OTHER|Retrospective radiologic study|Retrospective radiologic study
223933962|NCT06954519|OTHER|Mental imagery|The principle of guided mental imagery and helping students to mentally represent the key stages of a process, using an animated slideshow full of evocative elements, which we created specifically for this study. The mental imagery will be repeated by the students several times independently until the evaluation simulation at 6 months based on reminders via messages from investigators.
223933963|NCT06954519|OTHER|Cognitive aid reading|Participants of the control group will only read the cognitive aid on neonatal resuscitation at the same intervalls than the experimentation group
223933964|NCT06953349|PROCEDURE|Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis|The use of combination Phacoemulsification, OMNI Canaloplasty and Hydrus microstent successfully lowers IOP in ethnically-diverse patients with Open Angle Glaucoma
224285794|NCT02265172|PROCEDURE|Standard practice|Orthopaedic surgeon assessment
224285795|NCT02656082|DRUG|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
224285796|NCT04086641|DEVICE|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
224285797|NCT04086641|DEVICE|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
224285798|NCT06355479|DRUG|OsrHSA|Recombinant Human Serum Albumin from Oryza Sativa
224285799|NCT06355479|DRUG|Plasbumin®-20|Albumin (Human) 20%, USP
223718538|NCT05217147|OTHER|Obtaining blood samples|Blood samples were obtained at time of diagnosis and will be analyzed for the levels of biomarker candidate molecules.
223933965|NCT06954155|DRUG|Tenecteplase (0.25mg/kg)|Each vial of tenecteplase is reconstituted with 3 ml sterile water for injection and adjusted to a concentration of 5.33 mg/ml. Calculate the total amount of drug according to the subject's actual body weight and measure the required drug volume. The maximum dose should not exceed 25mg. Tenecteplase should be given as a single, intravenous bolus (within 5-10 seconds).
223933966|NCT06954155|DRUG|Standard medical treatment|Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone after randomization at the discretion of site researchers according to Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023.
223933967|NCT06954363|PROCEDURE|Mulligan Mobilization|Mulligan Mobilization involves manual tibial glides (medial and lateral) using a mobilization belt. The patient lies supine with the knee flexed between 30°-45°. The therapist applies a sustained glide while the patient actively moves the knee into flexion and extension. The treatment is delivered in 3 sets of 10 repetitions per session, 5 days per week for 3 weeks, along with a conventional physical therapy protocol.
223933968|NCT06954363|PROCEDURE|Muscle Energy Technique (MET)|Muscle Energy Technique involves the application of post-isometric relaxation targeting hamstring muscles. The therapist applies a 10-second isometric contraction at the resistance barrier, followed by a 20-second passive stretch, progressing into a new range of motion. This technique is applied 3 times per session, 5 days per week for 3 weeks, in combination with a conventional physical therapy protocol.
223933969|NCT06953037|OTHER|acupressure|The application will be made to the women in the acupressure group after applying the data collection forms (Personal Information Form, STAI-1 and Physiological Parameters and Fetal Heart Rate Chart) 1 hour before the cesarean section. The application will be made to the women in the acupressure group by manually pressing the SP6 and HT7 points with the index or middle finger for 5 seconds to a depth of 1-1.5 cm in the order determined by lot, then resting for 2 seconds and continuing the application for 2 minutes. Anxiety, physiological parameters and fhr will be measured again 40 minutes after the application. The data collection forms (descriptive characteristics form, loss, physiological parameters, fhr) will be applied to the women in the control group 1 hour before the cesarean section. No intervention will be made to the women in the control group. Anxiety, physiological parameters and fhr will be measured again 40 minutes later.
223933970|NCT06953271|DRUG|Methenamine Hippurate|Drug: Methenamine hippurate 1 gram by mouth twice daily for three days.
223933971|NCT06953271|DRUG|Typically prescribed oral antibiotic prophylaxis|Drug: typically prescribed oral antibiotic prophylaxis following intradetrusor BOTOX-A injections. This includes, but is not limited to, antibiotic medications such as nitrofurantoin, amoxicillin/clavulanic acid, and trimethoprim/sulfamethoxazole. Dosage will be determined per usual care. Duration of treatment will be standardized to three days.
223933972|NCT06954389|OTHER|Hyperbaric oxygen therapy|Patients received hyperbaric oxygen therapy using a monochamber hyperbaric chamber in addition to conventional rehabilitation.
223933973|NCT06954389|OTHER|Conventional rehabilitation|Patients received conventional rehabilitation alone.
223933974|NCT06953804|OTHER|Antimicrobial stewardship activities delivered through Virtual Network|"Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (\~7 hours).~Participants in the Virtual Newtwork arm will primarily receive these interventions online."
223933975|NCT06953804|OTHER|Antimicrobial stewardship activities delivered through Integrated Network activities|"Participants will receive online self-paced education modules regarding antimicrobial interventions, guided self-audit and reflection regarding intervention use, and reinforcement podcasts (\~7 hours).~Participants in the Integrated Network arm will primarily receive these interventions face-to-face and active online activities."
223933976|NCT06946511|DRUG|Peptide PMS-001 Intravenous Injection|Participants will receive intravenous injections of PMS-001.
223933977|NCT06946511|DRUG|Placebo|The control group will receive a placebo, which is the blank excipient (mannitol) of the injectable PMS-001.
223933978|NCT06949163|OTHER|Homemade formula|Patients will receive enteral feeding with a polymeric formula made from blended natural foods (apple, chayote, cookie, chicken and olive oil), adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
223933979|NCT06949163|DIETARY_SUPPLEMENT|Commercial formula|Patients will receive enteral feeding with a commercial polymeric formula, adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
223933980|NCT06950970|BEHAVIORAL|Tion-Emo therapy and technique for depression and anxiety Improvement|From 10 a 12 sessions once a week and one hour each session , for a positive result and development it is necessary to practice the technique
223933981|NCT06954129|DRUG|Vancomycin|Vancomycin is a glycopeptide antibiotic used to treat infections caused by Gram-positive bacteria, including those due to methicillin-resistant Staphylococcus aureus. Dosing of vancomycin will follow standard of care procedures, including the use of individualized dosing regimens developed in consultation with clinical pharmacists, based on participant body weight and renal function, and dosage titration guided by therapeutic drug monitoring. Vancomycin is administered via intermittent intravenous infusions of 60-90 minutes.
223933982|NCT06954129|DRUG|Piperacillin-tazobactam|Piperacillin-tazobactam is an anti-pseudomonal penicillin with a dose range of 2.25 g or 4.5 g and frequency of every 6 or 8 hours based on a participant's body weight, renal function, and clinician discretion. Piperacillin-tazobactam is administered via extended-duration (4 hours) intravenous infusions
223933983|NCT06954129|DRUG|Cefepime|Cefepime is an anti-pseudomonal cephalosporin with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 8, 12, or 24 hours based on a participant's body weight, renal function, and clinician discretion. Cefepime is administered via extended-duration (4 hours) intravenous infusions
223933984|NCT06950437|DEVICE|active iTBS|Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.
223933985|NCT06950437|DEVICE|Sham iTBS|Participants will undergo three sham iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.
223718539|NCT03939260|OTHER|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume \< 6 ml/kg and Pplat \<20-25 cmH2O).
223933986|NCT06950437|BEHAVIORAL|speech therapy|Speech therapy will be delivered between iTBS/sham sessions. Two 30-minutes trainings every day.
223933987|NCT06950632|DIETARY_SUPPLEMENT|Pepppermint oil inhalation|Participants in the experimental group will inhale five drops of 100% pure peppermint essential oil placed on a cotton ball inside a container for ten minutes before each chemotherapy session and every two hours during the chemotherapy infusion.
223933988|NCT06950632|DIETARY_SUPPLEMENT|Placebo|The control group will follow the same procedure using five drops of distilled water placed on a cotton ball inside a container for ten minutes before each chemotherapy session and every two hours during the infusion
223933989|NCT06953024|DIAGNOSTIC_TEST|INSTI HIV/syphilis Point of Care Self-Test Administration|The INSTI Human Immunodeficiency Virus (HIV)/syphilis POCT is a rapid, single-use, flow-through immunoassay that is Health Canada-approved as a screening test for detecting antibodies to HIV1/2 and syphilis using a fingerstick blood sample.
223933990|NCT06950268|DEVICE|ICAMS Splinting Protocol|The ICAMS protocol consisted of a daytime yoke splint maintaining the injured finger in 20° more extension than adjacent fingers, combined with a nocturnal static splint in the intrinsic plus position. The splinting was applied for 4 weeks following extensor tendon tenorrhaphy.
223933991|NCT06950268|DEVICE|Classic Plaster Immobilization|Participants received a classic plaster splint in the intrinsic plus position worn continuously for 4 weeks following extensor tendon tenorrhaphy.
223933992|NCT06954649|DIETARY_SUPPLEMENT|Plant based extract rich in phytosterols and phytostanols resveratrol and hydroxytyrosol.|Individuals will take two capsules daily of the phytosterol-rich extract for 56 days. Two capsules will be taken daily in the evening, after dinner
223933993|NCT06954649|OTHER|Placebo|Individuals will take two capsules daily of the placebo capsule for 56 days. Two capsules will be taken daily in the evening, after dinner
223933994|NCT06953531|DEVICE|Cold Application (Local Skin Cooling Device)|Immediately before the blood collection procedure, cold application will be made to the area with a local skin cooling device.
223933995|NCT06953531|BEHAVIORAL|Distraction Method (Bubble Machine)|A bubble machine will be used to distract children during the blood collection process.
223933996|NCT06953531|BEHAVIORAL|Distraction Method (Simulative Toy)|A simulative toy will be used to distract children during the blood collection process.
223933997|NCT06950580|OTHER|abdominal massage|In addition to routine physiotherapy, abdominal massage will be applied by the physiotherapist. The patient is positioned supine. The abdominal muscles are stroked three times, followed by colon stroking performed three times, and colon kneading performed three times. The massage is concluded by repeating the colon and abdominal stroking techniques in the same manner. Patients hospitalized in the intensive care unit will routinely receive abdominal massage twice daily by the physiotherapist
223718540|NCT01113281|BIOLOGICAL|VPM1002 live vaccine|
223933998|NCT02631733|DRUG|Ferumoxytol|Given IV
223933999|NCT02631733|DRUG|Irinotecan Sucrosofate|Given IV
223934000|NCT02631733|OTHER|Laboratory Biomarker Analysis|Correlative studies
223934001|NCT02631733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223934002|NCT02631733|DRUG|Veliparib|Given PO
223934003|NCT03301467|DRUG|Avacopan|Orally administered
223934004|NCT03301467|DRUG|Avacopan Matching Placebo|avacopan matching placebo
223934005|NCT06124820|DEVICE|Deka SmartXide Touch C60 (MonaLisa Touch)|Intravaginal micro-ablative fractional CO2 laser technology Deka SmartXide Touch C60 (MonaLisa Touch)
223934006|NCT06124820|DEVICE|Sham|Participants receiving sham treatment will have the probes advanced in the same manner without the use of a laser energy device.
223934007|NCT05628207|OTHER|Observational|There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
223934008|NCT05628207|OTHER|Observational-control|There is no intervention, the hospitals will not use the CDS system.
223934009|NCT05831254|OTHER|Health education:Interactive group training|"1. To introduce e-pulse software, which is a personal health record system, to show its use, to provide training materials such as video-brochures about e-pulse. This program will be done as interactive group training~2. Six modular interactive group training, each of which includes the steps of the European Health Literacy Scale of 90 minutes."
223934010|NCT05831254|OTHER|Health education: Individually training|To introduce e-pulse software, which is a personal health record system, to provide training materials such as video-brochures about e-pulse. This education will be done individually.
223934011|NCT05737108|DIETARY_SUPPLEMENT|Bilberry capsule product|A specific bilberry capsule product, containing bilberry dried extracts at 23.2 mg and bilberry powder at 3.2 mg will be given to participants for oral intake for 30 days. 30 days of Bilberry capsule product or placebo with crossover to the other.
223934012|NCT05737108|DIETARY_SUPPLEMENT|Placebo(starch)|30 days of placebo or Bilberry capsule product with crossover to the other.
223934013|NCT03610971|DRUG|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
223934014|NCT03610971|DRUG|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
223934015|NCT05820711|DRUG|MSC|"Injection of MSCs into submandibular glands at pre-specified dose level:~* Dose -1: 5 (4 - 6) x10\^6 MSCs (to be used only if Dose level 1 is not tolerated) per gland (0.5 ml)~* Dose 0: 10 (8 - 12) x10\^6 MSCs per gland (1 ml)~* Dose 1: 20 (16 - 24) x10\^6 MSCs per gland (2 ml)"
223934016|NCT02755896|RADIATION|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
224097107|NCT06936046|DRUG|Dual antibody A|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. After completing synchronous radiotherapy and chemotherapy for 28 days, TMZ combined with PD-1/VEGF dual antibody will be used as adjuvant therapy. PD-1/VEGF dual antibody 20mg/kg intravenous infusion once, with a cycle of 21 days.
224097108|NCT06936046|DRUG|Dual antibody B|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. After completing synchronous radiotherapy and chemotherapy for 28 days, TMZ combined with PD-1/CTLA-4 dual antibody will be used as adjuvant therapy. PD-1/CTLA-4 dual antibody 6mg/kg intravenous infusion once, with a cycle of 14 days.
223718541|NCT01113281|BIOLOGICAL|commercially available live vaccine BCG|
223934017|NCT02755896|RADIATION|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
223934018|NCT05419726|DRUG|Semaglutide Injectable Product (not provided by the study)|"Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall."
224285800|NCT01317784|DEVICE|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
224285801|NCT01317784|DEVICE|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
224285802|NCT01317784|DEVICE|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
224285803|NCT01317784|DEVICE|HIV only|Choice of 4 different tests for HIV only.
223718542|NCT04020965|BEHAVIORAL|Water Treatment|"Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers."
223934019|NCT06524089|OTHER|Pilate training|Pilates based training exercises group will perform Pilates divided into two levels (beginner and intermediate). Each level will last for six sessions.
223934020|NCT06524089|OTHER|eccentric training|eccentric trunk training exercises group:The course of the intervention period is 12 sessions total, exercises performed for two to three sets with 10 to 15 repetitions each set and 2 min rest between each set
223934021|NCT06525129|OTHER|Cerebellar stimulation group (CbSG)|Anodal transcranial direct current stimulation was given using a portable battery-driven brain stimulator (The Brain Stimulator v3.0 Deluxe tDCS Kit, using Professional 3x3 inches Amrex Sponge Electrodes). Skin was prepared before application of electrodes by cleaning the skin surface using alcohol swabs. In cerebellar stimulation group (CbSG) a stimulation intensity of 2mA for duration of 20 minutes. In order to avoid sudden initiation and termination of the stimulation the first and last 10 seconds of anodal tDCS application, current will gradually fade in/fade out to avoid any sudden starting or stopping of the stimulation. For the CbSG active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right buccinator muscle.
223934022|NCT06525129|OTHER|Cerebral (M1) Stimulation group (MSG)|In the M1 Stimulation Group (MSG) a similar intensity of current with 2mA was applied for a period of 20 minutes. Skin was cleaned with alcohol swab ahead of placing the electrodes. The anode was positioned over the lesioned M1 motor cortex area (C3, International 10-20 system) while the cathode was placed over the contra-lateral supraorbital area. Due to the large size of electrodes, the active electrode covered the area of M1 for the hand, arm, trunk, and the LL. Ten sessions of anodal tDCS were applied over a duration of 2 weeks. The stimulation was applied during active participation of patients in Biodex balance training.
223934023|NCT06525129|OTHER|Sham Stimulation group (SSG)|In Sham Stimulation group (SSG) Ten sessions of anodal tDCS were applied over a duration of 2 weeks having same intensity i.e., 2 mA stimulation was used for a period of 30 seconds and then gradually ramped-down and turned off for the rest of the treatment time of 20 minutes. The same procedure for skin preparation was used as in the other two groups. Electrode placement for SSG was same as in MSG for half of the patients i.e. 8 participants; anode will be placed over the left (dominant) lesioned M1 whereas the cathode will be positioned over the right (contralateral) supraorbital area. For the other 8 participants the stimulation montages were similar to cerebellar stimulation group. The active anodal electrode was placed over the cerebellum with about 1-2 cm below inion occipital protuberance, whereas the returning cathodal electrode was placed on right Buccinator Muscle.
223934024|NCT04550169|OTHER|Intensive Care Coordination|"Intensive care coordination will include:~* Discharge instructions and contacts for following up on care and treatment~* Referral information~* Appointment scheduling~* Medication instructions~* Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~* Information about other health and social resources, such as transportation and housing~* Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable"
223934025|NCT05458323|DEVICE|Free near and Distance Vision glasses|Intervention Description: All participants randomised to the intervention group will be provided with free near and/or distance spectacles based on the results of refraction.Glasses will be provided at the time of enrolment in the study.
223934026|NCT05804032|DRUG|Isatuximab|IV isatuximab will be administered weekly in the first cycle (Cycle 1) on days 1, 8, 15, 22, 29, and biweekly on the 2 subsequent cycles at days 1, 15 and 29, at the dose of 10 mg/kg.
223934027|NCT05804032|DRUG|Isatuximab|SC isatuximab will be administered on days 1, 8, 15, 22, 29 of cycle 1, and on days 1, 15 and 29 of cycles 2-3, at the dose of 1400 mg
224285804|NCT03432988|BEHAVIORAL|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
224285805|NCT06214611|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy in the head and neck region
224285806|NCT00067171|BEHAVIORAL|Behavior Therapy|
223934028|NCT05804032|DRUG|Lenalidomide|Both arms: 25 mg per os on day 1-14 and d22-35 in induction cycle 1-3
223934029|NCT05804032|DRUG|Bortezomib|Both arms: 1.3 mg/m\^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
223934030|NCT05804032|DRUG|Dexamethasone|20 mg per os on day 1-2, 4-5, 8-9, 11-12, 15; and 22-23, 25-26, 29-30, 32-33 in induction cycles 1-3.
223934031|NCT05699564|OTHER|Early biomarker-based cardiological assessment|We will perform cardiac biomarker testing with NT-proBNP and hs-cTnT measurements on emergency department admission in all participants, regardless of randomization status. The results will be provided in the patient's EHR, regardless of randomization status. For patients randomized to the intervention group, we will provide a note in the patient's EHR that includes assessment of probability that myocardial injury or dysfunction are the underlying pathophysiology responsible for tachypnea, as evaluated by the cardiac biomarker algorithm of the study. We will inform on general recommendations for work up and treatment.
223934032|NCT03672058|OTHER|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
223934033|NCT03672058|OTHER|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
223934034|NCT03801434|DRUG|Ruxolitinib|Given PO
223934035|NCT05551104|DRUG|Oral Nifedipine|Administration of oral nifedipine to control postpartum hypertension.
223934036|NCT05551104|DRUG|Oral Labetalol|Administration of oral labetalol to control postpartum hypertension.
223934037|NCT03955991|BEHAVIORAL|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
223934038|NCT03955991|BIOLOGICAL|Influenza vaccine|Standard of care Influenza vaccine for that given year.
223934039|NCT05278104|DRUG|Zentiva®|Zentiva®
223934040|NCT05278104|DRUG|Placebo|Placebo
223934041|NCT05517265|DRUG|Calquence|acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
223934042|NCT05517265|DRUG|Calquence|acalabrutinib according to Calquence® SmPC.
223934043|NCT04207736|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.
223934044|NCT04207736|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
223934045|NCT06148740|OTHER|Manuka Health Pro Vitality Daily Restorative Face Serum with Propolis & Vitamin C|Skin serum containing propolis, vitamin C, and manuka honey.
223934046|NCT03674372|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).
223934047|NCT00979459|DRUG|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
223934048|NCT00979459|DRUG|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
223934049|NCT01823406|PROCEDURE|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
223934050|NCT01823406|PROCEDURE|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
223934051|NCT00773500|OTHER|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
223934052|NCT03956095|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
223934053|NCT03956095|OTHER|Daily Food Intake form|On the day of surgery, the patient will return her Daily Supplement/Food Intake Forms and complete the Day of Surgery Intake Form can also be completed the day before surgery and the Daily Supplement/Food Intake Forms can be returned at the patient's postoperative appointment.
223934054|NCT01630902|DRUG|Torrent's Felodipine Extended-Release Tablets|
223934055|NCT04515667|BEHAVIORAL|Mindfulness|Participants will view a brief mindfulness video
223934056|NCT04515667|BEHAVIORAL|Video|Participants will view a control video
223934057|NCT02896907|DRUG|Oxaliplatin|Given IV
223934058|NCT02896907|DRUG|Irinotecan Hydrochloride|Given IV
224097109|NCT06936046|RADIATION|Modified Stupp|Starting 2-6 weeks after surgery, synchronous TMZ radiotherapy and chemotherapy will be performed. For partially resected lesions or short-term recurrence and progression lesions after surgery, high-dose PGTV 66Gy/30Gy will be given locally. PTV1 in high-risk areas around the tumor bed will be 60Gy/30F, and in low-risk areas will be 54Gy/30F. After completing synchronous radiotherapy and chemotherapy for 28 days, 6 cycles of adjuvant TMZ chemotherapy will be started.
223934059|NCT02896907|DRUG|Leucovorin Calcium|Given IV
223934060|NCT02896907|DRUG|Fluorouracil|Given IV
223934061|NCT02896907|DIETARY_SUPPLEMENT|Ascorbic Acid|Given IV
223934062|NCT04503681|OTHER|Enhanced compassion video|"Added five additional sentences to the standard introduction video. Those five sentences were compassion-focused statements. The compassionate statements added to the enhanced compassion video were based on the results of a recent systematic review of clinician compassionate behaviors, which found incorporating statements of support, acknowledgement, patient's perspective, emotion naming, and validation increased patient perception of compassion."
223934063|NCT04503681|OTHER|Standard introduction video|Standard introduction video sent to a new patient via email introducing the new patient to the cancer center prior to the initial consultation.
223934064|NCT01782846|DRUG|Ixprim®|
223934065|NCT01782846|DRUG|Dafalgan-Codeine®|
223934066|NCT03986359|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
223934067|NCT00028548|DRUG|R(+)XK469|
223934068|NCT03933371|DEVICE|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
223934069|NCT03737487|PROCEDURE|Multidisciplinary fall risk and geriatric comprehensive assessment|"* Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~* Calculation of BMI~* A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~* A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~* A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~* A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~* A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
223934070|NCT05724966|DEVICE|mHealth app|We wish to examine the perspectives of patients with multiple myeloma and healthcare professionals of this new method for reporting side effects, and to assess organizational aspects. Usual procedure to assess side effect prior to cancer treatment with Bortezomib is a telephone call the day before.
223934071|NCT05935969|PROCEDURE|ERCP(Endoscopic retrograde choangiopancreatography), ETGBD(endoscopic transpapillary gallbladder drainage)|For transpapillary gallbladder drainage, biliary cannulation was performed with a duodenoscope (JF-260V or TJF-260V; Olympus Optical). After successful deep cannulation of the CBD, we checked the cholangiogram, performed endoscopic sphincterotomy, and removed the CBD stone using a memory basket and/or retrieval balloon. Cholangiography was then performed again to locate the cystic duct orifice, and a guide wire (Jagwire; Boston Scientific, Marlborough, Massachusetts, USA or Visiglide; Olympus, Tokyo, Japan) was inserted into the gallbladder with different types of catheters (standard catheter, pull-sphincterotome, or rotating sphincterotome) under fluoroscopic guidance. After placement of the guide wire into the gallbladder, contrast dye was injected to confirm good entry into the gallbladder. Once the gallbladder was selected and the guidewire was coiled in the GB, a 7Fr 12-15cm double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Winston-Salem, NC) was inserted into the GB.
223934072|NCT01419808|PROCEDURE|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
223934073|NCT01419808|PROCEDURE|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
223934074|NCT00753337|DEVICE|Assurant® Cobalt Iliac Stent System|Iliac Stenting
223934075|NCT00210106|DEVICE|Ablathermy|
223934076|NCT00091689|DRUG|852A|
224097110|NCT06936046|DRUG|Stupp protocol|Synchronized TMZ radiotherapy and chemotherapy will begin 2-6 weeks after surgery, and 6 cycles of adjuvant TMZ chemotherapy will begin 28 days after completing the synchronized radiotherapy and chemotherapy. Radiotherapy regimen: PTV1 60Gy/30F in high-risk areas around the tumor bed, 54Gy/30F in low-risk areas. TMZ synchronous chemotherapy regimen: 75mg/m2 po qd. TMZ adjuvant chemotherapy regimen: The first cycle is 150mg/m2 po qd on d1-5,28 days; Cycle 2-6: Cycle 1: 200mg/m2 po qd for d1-5,28 days.
224097111|NCT06935695|DEVICE|Bronchoscopy|Bronchoscopy is a procedure that uses a bronchoscope (a thin, tube-like instrument with a light and a lens for viewing) to examine the inside of the trachea, bronchi (air passages that lead to the lungs), and lungs. The bronchoscope is inserted through the nose or mouth.
224097112|NCT06935981|OTHER|school-based mental health program|Week 1 Session 1-Beginning-Getting Acquainted Week 2 Session 2-Emotion, Thought and Behavior Wheel Week 3 Session 3- Optimism Week 4 Session 4- Forgiveness Week 5 Session 5- Saying No Week 6 Session 6- Effective Communication Week 7 Session 7- Problem Solving Week 8 Session 8- Saying Goodbye
223934077|NCT00825344|DRUG|Etanercept|50 mg subcutaenous preoperatively
224097113|NCT06935851|BEHAVIORAL|VOCAB +|"The purpose of the study is to investigate how word characteristics (e.g., phonotactic probability) and orthography effect vocabulary learning by children with low oral language levels. We will be using a 2 x 2 within-subjects factorial design where every participant serves as their own control. This 12-week study aims to improve the Efficiency of vocabulary learning for children with low oral language levels.~The four interventions that are all participants will be exposed to are the following: high pp words with orthography; high pp words without orthography; low pp words with orthography; low pp words without orthography."
224097114|NCT06935214|DIETARY_SUPPLEMENT|Caffeine|5 mg/kg of caffeine in pill form
224097115|NCT06935214|DIETARY_SUPPLEMENT|Placebo|5 mg/kg dose of maltodextrin in pill form
224097116|NCT06935214|DIETARY_SUPPLEMENT|Caffeine|5 mg/kg dose of caffeine in pill form
223934078|NCT00825344|DRUG|Saline|Given subcutaneously preoperatively
223934079|NCT00609050|BEHAVIORAL|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
223934080|NCT00609050|BEHAVIORAL|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
223934081|NCT00609050|BEHAVIORAL|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
224097117|NCT06936488|DRUG|Ivonescimab,TAS-102|Ivonescimab,20mg/kg,i.v.,D1,Q3w TAS-102,35mg/m2,bid,D1-5,Q2W
224097118|NCT02581995|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
223934082|NCT04357158|DEVICE|AeonoseTM|All participants will be asked to breathe into an electronic nose (eNose, the AeonoseTM, The eNose Company, Zutphen, the Netherlands) for 5 minutes during the pre-colonoscopy intake and just prior to the procedure to assess reproducibility (with \>2 weeks in between).
223934083|NCT06952309|DRUG|Intracheal dexmedetomidine|Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
223934084|NCT06952309|DRUG|Intravenous lidocaine|Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
223934085|NCT06952309|DRUG|Intravenous lidocaine combined with intracheal dexmedetomidine|Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
223934086|NCT06952309|DRUG|Saline (NaCl 0,9 %) (placebo)|Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
223934087|NCT06030258|DRUG|IN10018|orally taken once daily
223934088|NCT06030258|DRUG|Tislelizumab|200mg D1, Q3W, intravenously
223934089|NCT06030258|DRUG|Carboplatin|AUC 5 mg/ml/min, D1, Q3W, intravenously
224097119|NCT00452725|DRUG|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
224097120|NCT06946875|OTHER|Pain Threshold|The pain thresholds of the participants will be measured with an algometer device. With this device, the minimum pressure threshold that causes pain is recorded.
224097121|NCT01374282|DRUG|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
224097122|NCT05457595|RADIATION|carbon ion radiation therapy|"CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted."
224097123|NCT02412280|OTHER|retrospecive observational|
224097124|NCT04855656|DRUG|RP-6306|Oral PKMYT1 Inhibitor
224097125|NCT04855656|DRUG|RP-3500|Oral ATR Inhibitor
224097126|NCT04855656|DRUG|Debio0123|Oral WEE1 Inhibitor
224285807|NCT06449872|DEVICE|Obstetrics and Gynecology clinical applications for ultrasound diagnostic systems|Up to 5 healthcare professionals trained and experienced in Obstetrics and Gynaecology ultrasound qualitatively assessed the diagnostic image quality of the Kosmos Diagnostic Ultrasound System against the benchmark Mindray M9 Ultrasound System.
224097127|NCT04907045|BEHAVIORAL|Health Coaching|The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
224097128|NCT04907045|BEHAVIORAL|Practice Facilitation|In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
224097129|NCT04907045|BEHAVIORAL|Standard Implementation|Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
224285808|NCT01042535|BIOLOGICAL|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
224285809|NCT01042535|DRUG|1-methyl-d-tryptophan|Given orally (PO)
223934090|NCT06030258|DRUG|Etoposide|Etoposide 100 mg/m2, D1-D3, Q3W, intravenously
223934091|NCT01675063|DEVICE|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
223934092|NCT00130546|DEVICE|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
223934093|NCT00130546|DEVICE|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
223934094|NCT06197217|DRUG|WPV01|Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
223934095|NCT06197217|DRUG|Placebo|Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
223934096|NCT05562427|BEHAVIORAL|Gold-Standard Online Behavioral Obesity Treatment|Rx Weight Loss (RxWL) is an online BOT that consists of: (a) tailored weight loss, calorie, and physical activity goals. (b) 12 weekly 10-15 minute multimedia lessons for training in behavioral weight loss skills followed by 9 monthly lessons for continued weight loss. Lessons incorporate video, animation, audio, quizzes, and exercises for goal setting, planning, and problem-solving. Example topics include restaurant eating, changing the home environment, and obtaining social support. (c) Online tools for self-monitoring weight, diet, and physical activity that interface with popular tracking apps; and (c) Weekly, and eventually monthly, automated feedback on progress to date (delivered as text appearing on the platform). If goals are not met participants receive strategies to improve weight loss, along with encouragement. To ensure engagement, email reminders are sent to participants who have not visited the platform on a given week.
223934097|NCT00206986|DRUG|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
223934098|NCT00206986|DRUG|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
224285810|NCT01042535|OTHER|Laboratory biomarker analysis|Correlative studies
223934099|NCT03238261|RADIATION|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
223934100|NCT01078285|BEHAVIORAL|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
223934101|NCT01078285|BEHAVIORAL|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
223934102|NCT03363529|DEVICE|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
223934103|NCT03363529|DEVICE|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
223934104|NCT02795754|DRUG|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
224097132|NCT02912871|OTHER|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
224097133|NCT05659121|DEVICE|robotic exoskeleton training|robotic exoskeleton training using EksoGT will be incorporated into subject's conventional physiotherapy training.
223718543|NCT04020965|BEHAVIORAL|Sanitation|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits."
223934105|NCT02795754|DRUG|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
223934106|NCT02795754|DRUG|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
223934107|NCT02795754|DRUG|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
223934108|NCT02795754|DRUG|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
223934109|NCT02967458|DRUG|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
223934110|NCT01505712|GENETIC|gene expression analysis|
223934111|NCT01505712|OTHER|laboratory biomarker analysis|
223934112|NCT04886505|DEVICE|Electrolytic eCLIPs Bifurcation System|The electrolytic eCLIPs bifurcation system will be implanted into patients with bifurcated saccular intra-cranial aneurysms.
223934113|NCT06515873|DEVICE|Virtual Reality Headset|The virtual reality headset, which will display one of the 3 available scenarios, will be placed on the patient head during a surgery under spinal anesthesia.
223934114|NCT05866536|BIOLOGICAL|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
224097134|NCT02094846|BEHAVIORAL|Voice messages|Voice messages reinforced with self-efficacy
224097135|NCT02194881|DRUG|CF patients with a G551D mutation and treated with Ivacaftor|
223934115|NCT05866536|BIOLOGICAL|Saline Injection|2 BCG vaccinations spaced 4 weeks apart at the beginning of the trial
223934116|NCT06135922|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.
223934117|NCT00003867|DRUG|capecitabine|
223934118|NCT00003867|DRUG|irinotecan hydrochloride|
223934119|NCT02113826|DRUG|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
223934120|NCT05538000|OTHER|Face to face and telephonic interviews|"face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment.~Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment."
223934121|NCT06162182|DIAGNOSTIC_TEST|electrical impedance device,|The electrical resistance of the residual dentine underneath each measurement point was determined between an electrode and the crown pulp (Prepometer, Hager \& Werken, Duisburg, Germany). Assigning the electrical resistance of the dentin. high values are considered to represent more residual dentine than low values.
223934122|NCT06162182|DIAGNOSTIC_TEST|Reference test: Digital Radiographic examination|A digital periapical radiograph using paralleling technique was taken
224097136|NCT01213810|BIOLOGICAL|Zostavax|Biological/Vaccine
224097137|NCT05780840|OTHER|Dihydroxyacetone|Application of 10% dihydroxyacetone (2 mg per square cm skin)
224097138|NCT05780840|OTHER|Placebo|Application of lotion to the skin (2 mg per square cm skin)
224285811|NCT04801719|DEVICE|Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK|Randomised patients in selected arm received endoluminal RFA by 8F catheter (Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK) before stenting procedure. Repeated ablations were processed through stenotic areas of bile ducts (10W, 90-120s, Rita 1500, Angiodynamics Ltd), all drained biliary tracts were used for introducing catheter and performance of ablation. Ablation procedure was followed with uncovered self-expandable metal stent insertion.
224285812|NCT00682617|BEHAVIORAL|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
223934123|NCT06509828|BIOLOGICAL|AVB-114|AVB-114 is a mesenchymal cell substrate system comprised of autologous mesenchymal cells incubated with a 3-dimensional bioabsorbable substrate. The drug substance is expanded, pure mesenchymal stem cells (MSC) which are known to modulate local inflammation and orchestrate tissue healing. By incubating cells with a 3-dimensional bioabsorbable substrate designed for anal fistula geometry, cells are locally delivered into the fistula tract to promote healing.
223934124|NCT00701259|DRUG|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
223934125|NCT00701259|DRUG|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
223934126|NCT00701259|DRUG|placebo|
223934127|NCT00290537|DRUG|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
223934128|NCT00290537|DRUG|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
223934129|NCT00290537|DRUG|Paclitaxel|200 mg/m\^2 IV Over 3 Hours On Day 1
223934130|NCT01354782|DRUG|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
223934131|NCT03067974|DRUG|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
223934132|NCT01240707|OTHER|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
223934133|NCT06130228|DIETARY_SUPPLEMENT|Multi-ingredient supplement (PDT-MIS)|Supplementation with active PDT-MIS daily
224097139|NCT04243044|DEVICE|Transcutaneous spinal stimulation|Transcutaneous spinal stimulation will be delivered for 30 minutes using biphasic stimulation with a single round electrode as the cathode placed directly over the spine at the T11/T12 (and the lumbar spine for dual-site stimulation) spinous interspace, and two interconnected dispersive (reference) electrodes placed on the abdomen, lateral to the umbilicus. Stimulation intensity will be set to the specified level determined through a pre-stimulation assessment (0.8x reflex threshold). Treatments will be a minimum of 48 hours apart.
224097140|NCT04600999|DRUG|Favipiravir|Name: AVIGAN Generic name: Favipiravir Content: T-705a tablets \[200\]
224097141|NCT01086683|BEHAVIORAL|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
224097142|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
223934134|NCT06130228|DIETARY_SUPPLEMENT|Placebo (PLA)|Supplementation with inactive placebo
223934135|NCT01911156|DRUG|Continue NA treatment|Prescribed NA during the 72 week study period
223934136|NCT01911156|DRUG|Discontinue NA Treatment|Discontinue NA Treatment
223934137|NCT00955162|DRUG|Buprenorphine (Subutex)|Sublingual tablet
223934138|NCT00955162|DRUG|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
224097143|NCT02133937|DRUG|gantenerumab|Single subcutaneous injection of a lyophilized formulation
224097144|NCT05976737|DRUG|Test (T) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.
224097145|NCT05976737|DRUG|Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)|Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.
224097146|NCT00749099|DRUG|pancrelipase|"The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
224097147|NCT00749099|DRUG|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
223934139|NCT00945321|DRUG|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
223934140|NCT00945321|DRUG|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
223934141|NCT00945321|DRUG|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
223934142|NCT00945321|DRUG|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
223934143|NCT02633215|DEVICE|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
223934144|NCT02969759|OTHER|Skin Biopsy|
223934145|NCT03658915|DEVICE|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
223934146|NCT00279981|DEVICE|Diagnostic|
223533890|NCT01958086|DEVICE|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. The Neural Communication system is primarily composed of two NeuroPort Arrays. The two arrays of one MultiPort device will be placed in the primary motor cortex for recording (Platinum-tipped electrodes); and the two arrays of the additional MultiPort device be placed in the superior parietal lobule for recording (Platinum-tipped electrodes). Each MultiPort device consists of two arrays, each with 100 electrodes in a 10 x 10 configuration, with dimensions 4 mm x 4 mm x 1.5 mm (W x H x D) or 4 mm x 4 mm x 1.0 mm, and a titanium percutaneous connector, 19 mm diameter at the base. Each MultiPort can have a total of 128 active channels (capable of transmitting neural signals to the percutaneous connector) across the two arrays. In our design, we will split active channels evenly between the two arrays resulting in 64 active channels per array.
223533891|NCT06479356|BIOLOGICAL|Relma-cel|Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells
223533892|NCT00654732|DRUG|Bleomycin|Given IV
223533893|NCT00654732|DRUG|Dacarbazine|Given IV
223934147|NCT02503397|DEVICE|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
223934148|NCT05673109|DRUG|AC176|AC176 will be given orally (PO) on a 28-day cycle.
223934149|NCT04017611|DEVICE|INVSENSOR00038|Noninvasive regional oximeter
223934150|NCT00692913|DRUG|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
223934151|NCT00692913|DIETARY_SUPPLEMENT|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
223934152|NCT00692913|OTHER|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
223934153|NCT05891405|PROCEDURE|Cardiac surgery|Operations for congenital heart diseases
224097148|NCT06223425|BEHAVIORAL|virtual reality Situation-Based Flipped Learning|Situation-Based Flipped Learning, and Gamification have gained attention as promising tools to engage nursing students and promote a deeper understanding of complex concepts. This study aims to investigate the effectiveness of combining these strategies in a virtual reality Situation-Based Flipped Learning environment with elements of Gamification on nursing students' learning attitudes, problem-solving abilities, and empathetic skills.
224097149|NCT01324830|DRUG|day 1 to day 5|low to high dose
224097150|NCT01324830|DRUG|day 1 to day 14|low to high dose
224097151|NCT01485614|DRUG|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
223533894|NCT00654732|DRUG|Doxorubicin Hydrochloride|Given IV
223934154|NCT02291913|DRUG|Everolimus|
223934155|NCT02291913|DRUG|Exemestane|Anti-estrogen therapy
223934156|NCT02291913|DRUG|Tamoxifen|Anti-estrogen therapy
223934157|NCT02291913|DRUG|Fulvestrant|Anti-estrogen therapy
224097152|NCT01485614|DRUG|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
224097153|NCT01485614|DRUG|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
223934158|NCT02291913|DRUG|Anastrozole|Anti-estrogen therapy
223533895|NCT00654732|BIOLOGICAL|Rituximab|Given IV
223533896|NCT00654732|DRUG|Vinblastine|Given IV
223934159|NCT02291913|DRUG|Letrozole|Anti-estrogen therapy
223934160|NCT02291913|DRUG|Toremifine|Anti-estrogen therapy
223934161|NCT04703283|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including exercise, diet, stress management, and sleep management
223934162|NCT02246946|DEVICE|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
223934163|NCT02246946|OTHER|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
223934164|NCT02246946|PROCEDURE|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
224097154|NCT01485614|DRUG|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
223718544|NCT04020965|BEHAVIORAL|Handwashing|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
223934165|NCT05835375|OTHER|EQ-778|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
223934166|NCT05835375|OTHER|Placebo|"1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)"
223934167|NCT04095884|PROCEDURE|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
223934168|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol - duration 3 weeks|Standard metabolic integrated rehabilitation protocol
223934169|NCT06296407|OTHER|Standard metabolic integrated rehabilitation protocol + respiratory exercises - duration 3 weeks|Standard metabolic integrated rehabilitation protocol + respiratory exercises (12 sessions \[5 sessions/week for 3 weeks\])
223934170|NCT04463875|DIETARY_SUPPLEMENT|magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10|Supplementation per os
223934171|NCT06330298|BEHAVIORAL|Treatment social cognition and emotion regulation (T-ScEmo)|T-ScEmo is a multifaceted treatment protocol that has the overall aim to improve social cognition, regulation of social behaviour and social participation in everyday life (Westerhof et al., 2017; 2019). The treatment includes, in addition to practicing social cognitive skills throughout the treatment, close involvement of a significant other, and homework assignments. The treatment consists of three modules that address 1) perception of social information including facial expressions of emotions, 2) perspective taking and understanding of social information and 3) regulation of social behaviour. The treatment contains 15-one hour live treatment sessions with a neuropsychologist and 5 online practice sessions, once or twice a week. In the online sessions, the patient can practice the information at home as a neuropsychologist is available for questions. When patients find it too difficult to practice individually at home, there is a opportunity to offer these sessions as live sessions
224097155|NCT01485614|DRUG|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
223934172|NCT03513692|DEVICE|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
223934173|NCT03287713|DRUG|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
223934174|NCT00000234|DRUG|Buprenorphine|
223934175|NCT00001968|DRUG|Amprenavir|
223934176|NCT00001968|DRUG|Ritonavir|
223934177|NCT00001968|DRUG|Abacavir|
224097156|NCT01485614|BIOLOGICAL|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
224097157|NCT03677674|OTHER|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
224097158|NCT03538028|BIOLOGICAL|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
224097159|NCT02210780|DRUG|Dupilumab|Administered via subcutaneous injection.
224097160|NCT02210780|DRUG|Placebo|An inactive substance containing no medicine administered via subcutaneous injection.
224285813|NCT00682617|BEHAVIORAL|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
224285814|NCT06468306|PROCEDURE|non-invasive ventilation teraphy, NIV|Routine management regimes of NIV
224285815|NCT02216799|DRUG|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
224285816|NCT02216799|DRUG|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
224285817|NCT04531670|BEHAVIORAL|iRaPID|Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30
224285818|NCT04531670|OTHER|Standard of Care|PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.
224285819|NCT01679197|DRUG|Metreleptin|
224285820|NCT00406588|DRUG|Levodopa (Pardoprunox)|12-42mg
224285821|NCT00406588|DRUG|Placebo Comparator|Placebo
224285822|NCT00521989|DRUG|CRx-102 (2.7/90)|CRx-102 dose 1
223934178|NCT00001968|DRUG|Lamivudine|
223934179|NCT01268306|DEVICE|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
224285823|NCT00521989|DRUG|Prednisolone|Prednisolone
224285824|NCT00521989|DRUG|Placebo|Placebo
224285825|NCT00521989|DRUG|CRx-102 (2.7/180)|CRx-102 dose 2
224285826|NCT00521989|DRUG|CRx-102 (2.7/360)|CRx-102 dose 3
224285827|NCT01699919|DRUG|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
224285828|NCT05287152|DEVICE|titanium tacks or pins|using tacks or pins made of titanium 2.5 mm diameter and 4mm length for free gingival graft fixation.
224285829|NCT03271606|COMBINATION_PRODUCT|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
224285830|NCT03271606|COMBINATION_PRODUCT|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
224285831|NCT00143299|DRUG|varenicline (CP-526,555)|
223934180|NCT00294736|DRUG|Tarceva|Dose Escalation: 150-350+ mg/day
223934181|NCT04334317|DRUG|TAK-071|TAK-071 tablet.
223934182|NCT04334317|DRUG|Placebo|TAK-071 placebo-matching tablet.
223934183|NCT02993211|DEVICE|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
223934184|NCT02993211|DEVICE|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
223934185|NCT00804219|BIOLOGICAL|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
223934186|NCT00147719|DRUG|Colesevelam hydrochloride|
223934187|NCT03035084|DRUG|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
223934188|NCT03035084|DRUG|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
223934189|NCT03035084|DRUG|Placebo oral capsule|Placebo oral capsule
223934190|NCT05804994|DEVICE|Elgydium Clinic Sensileave Gel (V063B - DP3003)|Tested product is applied/used only once a day before whitening tray wear.
223934191|NCT02747394|OTHER|Working Memory Training|
223934192|NCT00724399|BEHAVIORAL|Survey on womens health Issues.|Cardiovascular health.
223934193|NCT00990600|OTHER|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
223934194|NCT01521169|OTHER|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
223934195|NCT01521169|OTHER|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
223934196|NCT01521169|OTHER|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
223934197|NCT03600844|BEHAVIORAL|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
223934198|NCT00862043|DRUG|Sildenafil Citrate|40 mg t.i.d.
224285832|NCT03679273|DIETARY_SUPPLEMENT|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
224285833|NCT02286973|DRUG|Tranexamic Acid|
224285834|NCT03438539|BEHAVIORAL|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
223934199|NCT00862043|DRUG|Placebo|Placebo t.i.d.
223934200|NCT03420196|OTHER|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
223934201|NCT03420196|OTHER|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium"
223934202|NCT02523170|DEVICE|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
223934203|NCT02085772|OTHER|Blood samples at 37-38 Weeks of amenorrhea|
223934204|NCT02085772|OTHER|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
223934205|NCT02085772|OTHER|Blood samples at the time of delivery|
223934206|NCT02084420|DRUG|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
223934207|NCT02084420|DRUG|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
223934208|NCT00002236|DRUG|Indinavir sulfate|
223934209|NCT00002236|DRUG|Delavirdine mesylate|
223934210|NCT00002236|DRUG|Zidovudine|
223934211|NCT00145587|PROCEDURE|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
223934212|NCT00145587|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
223934213|NCT00145587|DRUG|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
223934214|NCT01128595|DRUG|FF/GW642444M|
223934215|NCT01128595|DRUG|GW642444M|
223934216|NCT01128595|DRUG|Fluticasone Furoate|
223934217|NCT01128595|DRUG|Placebo|
223934218|NCT04359017|DRUG|Lidocaine 1% Injectable Solution|The lidocaine will be injected into the fracture hematoma using buffered 1% lidocaine solution at a dose of 2.5 mg/kg (0.25 mL/kg), maximum dose 100 mg (10 mL). Using a 30-gauge needle to minimize pain, a small skin wheal of lidocaine will be injected over the fracture site. A 21-gauge needle will then be attached to the lidocaine filled syringe and passed through the skin wheal used to inject the lidocaine into the fracture hematoma. To confirm the needle is in the fracture hematoma, a small amount of blood from the hematoma will be aspirated into the syringe filled with lidocaine before injecting the lidocaine, as in standard practice.
223934219|NCT00605306|DRUG|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
223934220|NCT00605306|DRUG|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
223934221|NCT05001659|OTHER|computer simulator and mannequin simulator|compared two different training simulators with respect to training effectiveness in ACLS training.
223934222|NCT06444984|OTHER|Fasting Trial|Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
223934223|NCT06444984|OTHER|Fed Trial|Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
223934224|NCT00372775|DRUG|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
223934225|NCT05854446|OTHER|Survey|In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
223934226|NCT01970410|DRUG|teriflunomide|14 mg oral teriflunomide daily
223934227|NCT03443700|DEVICE|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
223934228|NCT03443700|PROCEDURE|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
223934229|NCT04257487|DRUG|Sulodexide|2 soft capsules of Vessel® 250 LSU BID for 12 months
223934230|NCT04257487|DRUG|Sulodexide and placebo|1 soft capsule of Vessel® 250 LSU and 1 soft capsule of placebo BID for 12 months
223934231|NCT04257487|DRUG|Placebo|Sugar pill manufactured to mimic sulodexide 250 LSU
223934232|NCT00733811|DRUG|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
223934233|NCT00733811|DRUG|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
223934234|NCT02568215|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
223934235|NCT02568215|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
223934236|NCT02691169|DRUG|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
223934237|NCT02132559|DRUG|DHEA|
223934238|NCT02403375|DEVICE|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
223934239|NCT04214756|PROCEDURE|Acute Pancreatitis|All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
223934240|NCT01436175|DRUG|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
223934241|NCT01214759|DRUG|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
223934242|NCT01214759|DRUG|Raltegravir|Raltegravir 400mg twice a day
223934243|NCT05981352|PROCEDURE|mineral trioxide aggregate pulpotomy|"* After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline.~* Then Mineral trioxide aggregate will be placed directly on the pulp stumps."
223934244|NCT05981352|PROCEDURE|Dehydrated amniotic membrane pulpotomy|"* After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute.~* Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber."
223934245|NCT05981352|PROCEDURE|Hyaluronic acid pulpotomy|"* After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) .~* The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol ."
223934246|NCT05201599|DEVICE|Flexible ureteroscope with intelligent control of renal pelvic pressure|After adjusting the UAS in suitable position, the pressure sensory and suctioning channels are connected to the irrigation and suctioning platform. After being injected with water, a zero calibration is performed for the pressure sensory system. A fully automatic mode is selected on the platform. The perfusion flow is set between 50 to 150 mL/min. The RPP control value is set between -15 to -5 mmHg. The renal pelvic pressure alarm value is set between 20 to 30mmHg. During the operation, a holmium laser is used to break stones into powder (fiber diameter 200 µm), and the flexible ureteroscopy is moved back and forward slightly to suck out the stone particles inside the sheath gap. Particles larger than the sheath gap but smaller than the UAS is sucked out by intermittently withdrawing the flexible ureteroscope without basket.
223934247|NCT05206981|DEVICE|IlluminOss Device|Patients may enroll in the registry if they have been implanted (retrospective) or will be implanted (prospective) with the IlluminOss device.
223934248|NCT03856619|DRUG|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
223934249|NCT03418922|DRUG|Lenvatinib|Specified doses will be administered orally on specified days.
223934250|NCT03418922|DRUG|Nivolumab|Specified doses will be administered intravenously on specified days.
223934251|NCT03577106|DEVICE|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
223934252|NCT03135782|OTHER|Communication Skills Training|Undergo motivational interviewing training
223934253|NCT03135782|OTHER|Medical Chart Review|Undergo medical chart review
223934254|NCT03135782|OTHER|Questionnaire Administration|Ancillary studies
223934255|NCT03135782|OTHER|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
223934256|NCT03461666|BEHAVIORAL|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
223934257|NCT03461666|BEHAVIORAL|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
223934258|NCT03461666|BEHAVIORAL|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
223934259|NCT03461666|BEHAVIORAL|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
223934260|NCT04269694|DRUG|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
223934261|NCT04269694|DEVICE|Medihoney dressing|Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
223934262|NCT05625230|BEHAVIORAL|Behavioral Activation plus Dynamic Mental Imagery|This intervention consists of an 8-session behavioural activation treatment with an added dynamic imagery exercise after each session. The dynamic imagery exercise is structured as follows: (1) the therapist explains the intervention; (2) the therapist models dynamic simulation skill (dynamic imagery) and repeats with the participant while giving appropriate feedback; (3) the participant completes a 10-minute Kinect training; (4) the participant completes a short Actfulness exercise that involves focusing on the feelings of movements of breathing and hands and dynamic imagery of one planned activity. From the second session, participants memorize daily activities forming a short dynamic memory of the activity focusing on feelings of movements.
223934263|NCT05625230|BEHAVIORAL|Behavioral activation|"The BA intervention is a short 8 session behavioural intervention. Participants learn to monitor the activities, plan anti-depressant activities for the next week and find support for the implementation of the activity."
223934264|NCT04237857|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
223934265|NCT04801823|OTHER|Home introduction|Cautious, graded introduction of individual tree nuts
223934266|NCT04801823|OTHER|Multi Nut oral food challenge|In hospital multi nut oral food challenge (almond, cashew, hazelnut, walnut)
223934267|NCT03241940|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
223934268|NCT03241940|DRUG|Cyclophosphamide|Given IV
223934269|NCT03241940|DRUG|Fludarabine Phosphate|Given IV
223934270|NCT03241940|OTHER|Laboratory Biomarker Analysis|Correlative studies
223934271|NCT03241940|OTHER|Questionnaire Administration|Ancillary studies
223934272|NCT05945849|BIOLOGICAL|CD33KO-HSPC; CART33|"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
223934273|NCT05484648|DRUG|Dexamethasone|"Dexamethasone has been used to generally favorable results in peripheral nerve blocks as adjunct. Several studies have reported prolongation in the duration of ropivacaine, mepivacaine and bupivacaine when used in combination with dexamethasone.~Various mechanisms for the beneficial adjunctive effect of dexamethasone with Local Anesthetics (LA) have been proposed. One theory suggests that the improved analgesia and increased blockade duration is due to its anti-inflammatory properties. It also acts as a local vasoconstrictor and thus may act by reducing LA absorption. Furthermore, it also increases the activity of inhibitory potassium channels on nociceptive C-Fibers."
223934274|NCT05484648|DRUG|Dexmedetomidine|Dexmedetomidine is another promising drug being used as a local anaesthetic adjuvant in peripheral nerve blocks. It is an alpha-2 agonist, which has shown to have prolonged duration of postoperative analgesia when given with LA for peripheral nerve blocks with other beneficial effects such as reducing the opioid consumption. Alpha-2-agonists such as dexmedetomidine cause hyperpolarization-activated cation currents which inhibit the transmission of nociceptive fibers.
223934275|NCT00002156|DRUG|Fomivirsen sodium|
223934276|NCT00002156|DRUG|Ganciclovir|
223934277|NCT05869617|OTHER|Aquatic exercise|"Participants in the aquatic therapy group will receive aquatic therapy in a HydroWorx aquatic therapy pool at Hydrathletics.~In the aquatic therapy group the 20 minutes of aerobic exercise at each visit will involve walking on an underwater treadmill. The intensity of the walking will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on movement patterns that simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or increasing resistance."
224097161|NCT00942409|BIOLOGICAL|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
224097162|NCT03537664|PROCEDURE|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
224097163|NCT03537664|PROCEDURE|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
224097164|NCT06486831|OTHER|Squeeze the stress ball.|The child and parents will be taken to the procedure room for the casting procedure. The plastering process in children takes an average of 10-15 minutes. In the experimental group, the stress ball selected by the child will be started 1-2 minutes before the casting process and will be watched for an average of 10 minutes. If the procedure is prolonged, the time for squeezing and playing with the stress ball will be extended.
224097165|NCT06245356|DRUG|Lonsurf|Trifluridine/tipiracil orally 35 mg/m²/dose (D1-D5 twice daily, D1=D15)
224097166|NCT06245356|DRUG|Oxaliplatin|Oxaliplatin intravenous injection 85 mg/m² every 2 weeks (D1=D15)
224097167|NCT06245356|DRUG|Panitumumab|Panitumumab intravenous injection 6 mg/kg (D1=D15)
224097168|NCT06245356|DRUG|Bevacizumab|Bevacizumab intravenous injection 5 mg/kg (D1=D15)
223934278|NCT05869617|OTHER|Land-based Exercise|"Traditional land-based training will take place the Hydrathletics gym with similar exercises provided to the aquatic therapy group.~The aerobic exercise for the land-based therapy group will be 20 minutes of treadmill walking. The intensity will be determined by the participant at self-selected intensities that are not perceived to cause a lasting increase in pain for one hour after the exercise session.~The 20 minutes of strengthening exercise will focus on similar movement patterns to the aquatic therapy group to simulate common daily functional activities. Initial intensity of exercises will be determined in collaboration between the health professional and patient by testing the intensity of the exercise that allows the participant to perform 8 repetitions without experiencing a lasting increased in pain. Exercise intensity will be increased weekly by either increasing the number of repetitions or the resistance used for the exercise."
224097169|NCT06245356|DRUG|Trastuzumab|Trastuzumab intravenous injection 4 mg/kg (D1=D15)
223934279|NCT06108024|DRUG|SM-020 gel 1.0%|SM-020 gel 1.0% will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
223934280|NCT06108024|DRUG|Vehicle gel|Vehicle gel will be applied topically. Subjects will be treated with twice daily application to 5 to 10 SKTLs for approximately 28 days.
224097170|NCT06245356|DRUG|Nivolumab|Nivolumab intravenous injection 240 mg (D1=D15)
224097171|NCT00235157|DEVICE|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
224097172|NCT01455350|PROCEDURE|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
223934281|NCT01300975|DRUG|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
223934282|NCT01300975|PROCEDURE|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
223934283|NCT01300975|DRUG|placebo cream|topical emollient crean 3 times a day during 21 days
223934284|NCT04670887|PROCEDURE|Delayed surgery|Delayed surgery is performed if cystic mass radiologically upgrades into Bosniak 4 or solid mass in the active surveillance.
223934285|NCT04670887|PROCEDURE|Immediate surgery|Partial or radical nephrectomy is performed as treatment of Bosniak 3 cystic mass
224097173|NCT01455350|DRUG|lidocaine|10 weeks of daily topical 5% lidocaine application
224097174|NCT00475163|BEHAVIORAL|Behavior modification|
224097175|NCT06488950|BIOLOGICAL|GC203 TIL(gene-edited TIL) or autologous TILs|the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample
224097176|NCT02510807|OTHER|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
224097177|NCT05026073|BEHAVIORAL|Information about clinical risk factors for endometrial cancer and endometrial hyperplasia|age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
224097178|NCT05026073|PROCEDURE|Blood and endometrial tissue sampling|"* All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation."
224285835|NCT03438539|BEHAVIORAL|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
224285836|NCT03438539|BEHAVIORAL|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
223934286|NCT03205072|DEVICE|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
223934287|NCT01718600|BEHAVIORAL|Neuropsychological testing|
223533897|NCT05923723|OTHER|FIBNUTRITION|"The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant)."
223533898|NCT05923723|OTHER|Placebo|The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
223533899|NCT06557304|DRUG|BTK inhibitor|patients with treatment naive or R/R CLL who treatment with BTK inhibitor
223718545|NCT04020965|DIETARY_SUPPLEMENT|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
223718546|NCT03254836|OTHER|Standard of care|Elective radical surgery for adenocarcinoma.
223718547|NCT05473702|DEVICE|Nanowear SimpleSense Wearable monitoring device|The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
223718548|NCT02807532|OTHER|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
223718549|NCT02807532|OTHER|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
223934288|NCT04037813|PROCEDURE|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
223934289|NCT00621673|DRUG|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
223533900|NCT05334940|OTHER|not applicable, observational study|Patients do not receive intervention
223533901|NCT00143884|PROCEDURE|Reduced intensity conditioning|
223934290|NCT04441775|OTHER|AI-assisted RT modelling|Artificial Intelligence assisted Radiation Treatment
223533902|NCT00143884|PROCEDURE|Prophylactic donor leukocyte infusions|
223533903|NCT04847882|BEHAVIORAL|Questionnaire|Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
223533904|NCT01966146|DEVICE|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
223533905|NCT02647684|BEHAVIORAL|Self-Directed Triple P|10 Week Triple P Self directed workbook
223533906|NCT01959932|OTHER|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
223533907|NCT01959932|OTHER|Smoking abstinence (SA)|SA for 5 days in confinement
223533908|NCT01959932|OTHER|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
223533909|NCT04838067|DEVICE|Cefaly|Transcutaneous trigeminal nerve electrical neuromodulation
223533910|NCT00397540|PROCEDURE|PEIT|Percutaneous Ethanol Injection Therapy
223533911|NCT00397540|PROCEDURE|RFTA|Radiofrequency Thermal Ablation
223533912|NCT00758563|DRUG|Fluoride|Brush twice daily
223533913|NCT00758563|DRUG|Triclosan/Fluoride|Brush twice daily
223718550|NCT02067338|DRUG|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
223718551|NCT02067338|DRUG|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
223718552|NCT06499597|OTHER|Observation|All individuals included in the study will be included in this group and evaluations will be made.
223718553|NCT01354990|DRUG|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
223718554|NCT00027898|DRUG|bortezomib|Given IV
223718555|NCT00027898|DRUG|carboplatin|Given IV
223934291|NCT04860505|DRUG|Doxycycline|Doxycycline (DOX \[200 mg\]) is an oral medication used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections.
223934292|NCT04860505|DRUG|Biktarvy|Biktarvy (200mg) is an oral combination anti-HIV medication that contains the drugs tenofovir alafenamide, emtricitabine, and bictegravir.
223934293|NCT06196749|PROCEDURE|Perform distal radial arterial cannulation using modified ultrasound-guided dynamic needle tip positioning technique|This study employs a modified ultrasound-guided dynamic needle tip positioning technique for distal radial arterial cannulation. The technique uses an ultrasound probe with two wires to create an acoustic shadow, improving needle tip visibility. Real-time dynamic tracking assists in precise needle placement within the distal radial artery through the nose-horn region. This method is used for coronary angiography and potential percutaneous coronary interventions, aiming to increase success rates and reduce complications like hematoma, nerve injury, and arterial spasm, thus enhancing safety and efficiency.
224097179|NCT05026073|PROCEDURE|Lymph node sampling|"Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation."
224097180|NCT02488278|DEVICE|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
223533914|NCT04268238|PROCEDURE|Hygiene Guidance|Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).
223533915|NCT04268238|PROCEDURE|Sealant Application|Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.
224097181|NCT00928915|DRUG|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
223533916|NCT04268238|RADIATION|Low Level Laser Application|Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.
223533917|NCT02375074|BEHAVIORAL|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
223533918|NCT02375074|BEHAVIORAL|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
223533919|NCT00499525|DRUG|paclitaxel|given IV
223533920|NCT00499525|DRUG|sorafenib tosylate|given orallly
223533921|NCT00499525|OTHER|placebo|given orally
223718556|NCT00027898|DRUG|etoposide|Given IV
224097182|NCT05124808|OTHER|Intensive glycemic targets|Fasting blood glucose \<90 mg/dL, 1 hour post-prandial blood glucose \<120 mg/dL
224097183|NCT05124808|OTHER|Standard glycemic targets|Fasting blood glucose \<95 mg/dL, 1 hour post-prandial blood glucose \<140 mg/dL
224097184|NCT06121232|DEVICE|Abbott® DRG / Abbott®/Medtronic® SCS|Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
224097185|NCT06121232|OTHER|Control Group|Participants will not receive any intervention
224097186|NCT04975958|DRUG|AN2025|oral administration
224097187|NCT04975958|DRUG|AN0025|oral administration
223533922|NCT03791879|DRUG|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
223533923|NCT00776230|BIOLOGICAL|IC51|6 mcg im. at day 0 and day 28
223533924|NCT04951349|DRUG|GX-03|Same dosage used in Bactroban Nasal studies.
223718557|NCT00027898|OTHER|laboratory biomarker analysis|Correlative studies
223718558|NCT00027898|OTHER|pharmacological study|Correlative studies
223718559|NCT04366102|OTHER|Multisensory stimulation with soft tissue therapy|Multisensory stimulation with soft tissue therapy will be given. Multisensory stimulation consists of Auditory, vestibular, tactile, olfactive, oromotor, Visual, and Kinesthetic stimulation. Soft tissue therapy consists of stroking, effleurage, fingertip kneading, tapping, and skin rolling will be given. Total intervention will be given for 30 min. 5 times per week
223718560|NCT04366102|OTHER|Routine hospital care|Routine hospital care will be given to the preterm neonates
223718561|NCT04293120|OTHER|Training with weighted ball|Participants will stop or catch a weighted ball
223718562|NCT02115893|DIETARY_SUPPLEMENT|Sodium Nitrate|
223718563|NCT02115893|DIETARY_SUPPLEMENT|Sodium Chloride|
223718564|NCT02469753|DRUG|NSAIDs|continuous daily
223718565|NCT02469753|DRUG|NSAIDs|on demand
223718566|NCT02469753|DRUG|anti-TNF|
223934294|NCT06196749|PROCEDURE|Palpation guided puncture|Perform distal radial arterial cannulation under palpation guidance
223934295|NCT02741505|DEVICE|Actigraph|Participants will be asked to wear an actigraph
223934296|NCT01462799|BEHAVIORAL|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
223934297|NCT01462799|BEHAVIORAL|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
223934298|NCT04812249|OTHER|Clinical assessment|Clinical assessment and follow up of oral feeding ability
223934299|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 40 mg every other week, subcutaneous
223934300|NCT00647400|BIOLOGICAL|adalimumab|Adalimumab 80 mg every other week, subcutaneous
223934301|NCT02340013|DRUG|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
223934302|NCT03547102|DIETARY_SUPPLEMENT|Cherry concentrate|
223934303|NCT03547102|DIETARY_SUPPLEMENT|Placebo concentrate|
223934304|NCT05100797|DEVICE|Vyntus CPX|To study the validity, precision and accuracy of the Vyntus CPX metabolic cart using both, in-vitro and in-vivo (i.e., human study) measures.
223934305|NCT00198419|DRUG|Vitrase|
223934306|NCT04373694|PROCEDURE|vaginoscopy|vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
223934307|NCT04373694|PROCEDURE|standard hysteroscopy|speculum, paracervical block before hysteroscopy morcellation
223934308|NCT03066609|DRUG|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
223934309|NCT03066609|DRUG|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
223934310|NCT03066609|DRUG|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
223934311|NCT02551237|RADIATION|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
223934312|NCT02551237|DRUG|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
223934313|NCT02551237|RADIATION|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
223934314|NCT01465152|DRUG|metformin|Adminstered orally during the three main meals for 24 weeks
223934315|NCT01465152|DRUG|repaglinide|Administered orally before the three main meals for 24 weeks
223934316|NCT02568306|DRUG|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
223533925|NCT04951349|DRUG|Petrolatum ointment|Viscous ointment similar in form to study drug.
223533926|NCT01228214|DRUG|Placebo|Placebo 5mg/daily for 12 months
223934317|NCT02568306|DRUG|placebo|Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
223934318|NCT04004494|OTHER|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
223934319|NCT06085729|DRUG|ADI-PEG 20|Given by Injection
223934320|NCT06085729|DRUG|Cabazitaxel|Given by IV (vein)
223533927|NCT01228214|DRUG|amiloride|5mg/daily for 12 months
223533928|NCT00746811|DRUG|P-OM3|4 grams/day - 4 one gram capsules
223533929|NCT00746811|DRUG|Placebo|4 grams/day - 4 one gram capsules
223533930|NCT04069442|OTHER|This is a non-interventional study|This is a non-interventional study
223533931|NCT03573050|DRUG|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
223533932|NCT03573050|DRUG|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
223533933|NCT05748002|OTHER|Pentacam and Corvis ST|morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
223533934|NCT05455892|OTHER|Clinical data collection during hospitalization in short geriatric units.|Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
223533935|NCT06030518|DIAGNOSTIC_TEST|Magnet Assisted Capsule Endoscopy|Procedures will be performed in the morning after an overnight fast. Patients wear a belt containing sensors and a data recorder. The patient will be asked to drink 500-1000ml (containing 80mg simethicone; volume depending on tolerance) immediately before swallowing the capsule. Gastric examination will proceed as previously described for a robot-controlled magnetic assisted capsule endoscopy. The whole procedure is anticipated to take 30-60 minutes. The patient will be discharged from hospital on completion of gastric examination but if clinically indicated will wear the belt for small bowel capsule study for eight hours to allow small bowel examination before detaching the equipment and returning it the following day. On completion of examination, the patient will be asked to complete a questionnaire about their capsule endoscopy experience. The full study (upper GI tract and small bowel) will then be downloaded onto the computer for formal reading and reporting.
223533936|NCT01879007|DRUG|Factive® Tab / Factive IV|
223934321|NCT06085729|DRUG|Carboplatin|Given by IV (vein)
223934322|NCT03855293|PROCEDURE|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
224097188|NCT04975958|DRUG|Atezolizumab 1200 mg in 20 ML Injection|infusion
223934323|NCT05558358|DEVICE|Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation|6 months of active stimulation -- \> 6 months of sham stimulation
224097189|NCT05448079|OTHER|Sexual counseling according to the PLISSIT model, randomized pretest-posttest|experimental and control ,a randomized pretest-posttest study to examine
224097190|NCT02363205|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
224097191|NCT01486264|BIOLOGICAL|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
224097192|NCT05819229|DRUG|Oral antibiotic therapy|"Empirical choice: amoxicillin-clavulanic acid 50 mg/kg/day divided into three doses.~If the sensitivity pattern is available, another oral antibiotic, preferably smaller-spectrum, can be used instead.~Total duration of antibiotic therapy will be 10 days."
224097193|NCT01783834|DRUG|Gefitinib|compare progression free survivla rate and safety to both drugs
224097194|NCT01783834|DRUG|Pemetrexed|compare PFS rate, safety to both drugs
224097195|NCT04179903|OTHER|Physical activity|Physical Activity program is performed in a group in a gym and at home
224097196|NCT01706913|OTHER|Dermatology consult|
224097197|NCT02351115|DRUG|A=Placebo|
224097198|NCT02351115|DRUG|B=Inhaled Alprazolam 0.5 mg|
224097199|NCT02351115|DRUG|C=Inhaled Alprazolam 1 m|
224097200|NCT02351115|DRUG|D= Inhaled Alprazolam 2 mg|
224097201|NCT02351115|DRUG|E=Placebo|
224097202|NCT04435340|DIAGNOSTIC_TEST|Selective Sonography of the ventral abdominal hernia level|The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
224097203|NCT02667184|DIETARY_SUPPLEMENT|Low FODMAP Oral Nutrition Supplement|
224097204|NCT06226402|DRUG|Hypertonic saline 3% nebulizer|Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
224097205|NCT06226402|DRUG|Intravenous hypertonic saline 3%|Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
224097206|NCT00389155|DRUG|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
224097207|NCT00389155|DRUG|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
224097208|NCT00389155|OTHER|Placebo|
224097209|NCT06393283|BEHAVIORAL|Diaphragm Training|Diaphragm training includes both active and passive methods. Passive training involves placing weights on the participant's abdomen to provide resistance during breathing. Active training involves instructing participants to practice diaphragmatic breathing techniques.
224097210|NCT06310369|RADIATION|radiation therapy|"Radiation therapy will be given in 20 fractions of 2.75 Gy covering the whole bladder over 4 weeks.~The use of a radiosensitizing agent is mandatory. Each recruiting center will have to choose 2 options of radiosensitizing agents."
224285837|NCT05319613|OTHER|Virtual clinical visits with home lab kits and mailed HIV PrEP|Rural participants who enter PrEP care with University of Colorado HIV Prevention Program will receive PrEP services via telemedicine with home lab kits and mailed HIV PrEP
224285838|NCT00389779|DRUG|Darusentan|Darusentan capsules administered orally once daily
224285839|NCT00389779|DRUG|Guanfacine|Guanfacine capsules administered orally once daily
223934324|NCT05558358|DEVICE|Experimental 2 - DBS of bilateral NAc - 6 months of sham stimulation -- > 6 months of active stimulation|6 months of sham stimulation -- \> 6 months of active stimulation
223934325|NCT06000202|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.
223934326|NCT06000202|DEVICE|Sham|Er:YAG laser is applied with sham handpiece.
224097211|NCT06185920|OTHER|Description of severe infection|Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.
224097212|NCT01012908|DIETARY_SUPPLEMENT|Norzyme - Bergamo|2 - 8 tablets per day.
224097213|NCT01012908|DIETARY_SUPPLEMENT|Creon|2 - 8 tablets pet day
224097214|NCT03273621|PROCEDURE|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
224097215|NCT04271163|DEVICE|MemorEM|The MemorEM device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range to the entire forebrain, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. Everyday for the 12M treatment period, the subject's caregiver will administer one or two 1-hour treatments (two daily treatments during the first 2M period).
224097216|NCT05319964|BEHAVIORAL|Anti-gravity treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound, 3 days a week for 8 weeks.~Participants were provided 30 minutes anti-gravity treadmill sessions including a 5 minutes warm - up and cool - down period for each session, 3 days a week, for 8 weeks"
224097217|NCT05319964|BEHAVIORAL|Conventional treadmill|"Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.~The moderate-intensity aerobic exercise program will be performed for 30 minutes at an intensity of 65-80% of the maximum heart rate, consisting of a 5-minute warm-up and cool-down period."
224285840|NCT00389779|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
224285841|NCT04213209|DRUG|Brentuximab Vedotin (Genetical Recombination)|Brentuximab Vedotin Intravenous Infusion
224285842|NCT05329285|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Alternative treatment
224285843|NCT01886482|OTHER|nutrition intervention|high protein diet
224285844|NCT02130531|DRUG|Emixustat HCl Tablet|Tablet for oral administration
223934327|NCT04512456|BEHAVIORAL|Exercise training|Exercise training performed during 12 weeks, 3 sessions per week of 60 minutes of strength and aerobic exercises.
223934328|NCT00135200|DRUG|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
223934329|NCT02389855|PROCEDURE|NeuroBlate® System Therapy|
223934330|NCT01404585|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
223934331|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
223934332|NCT01404585|DRUG|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
223934333|NCT05715502|RADIATION|brachytherapy|Radiation: focal low dose rate or high dose rate brachytherapy for the lesion with appropriate margin, defined in magnetic resonance or positron emission tomography All recruited participants will be treated with interstitial brachytherapy for local recurrence of prostate cancer. The low dose rate of brachytherapy is used with a total dose of 145 Gy in the clinical target volume for participants after hypofractionated radiotherapy, a high dose rate brachytherapy as monotherapy or boost with external beam radiotherapy The high dose rate brachytherapy with two fractions of 13 Gy in the clinical target volume with a 3 to 14 days break is used after primary low dose rate brachytherapy or external beam radiotherapy alone.
223934334|NCT05357911|DRUG|AB-106, digoxin|Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
223934335|NCT06518772|OTHER|hot application|The application procedure started with the application of hot gel packets at a temperature of 40-42°C to the soles of the feet of the women in the intervention group for 20 minutes when cervical dilation reaches 5 cm.
223934336|NCT01595789|DRUG|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
223934337|NCT01595789|DRUG|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
223934338|NCT00115089|DRUG|R926112|
223934339|NCT00115089|DRUG|Beclomethasone dipropionate|
223934340|NCT02099123|DRUG|Atorvastatin|Atorvastatin 20 mg tablet
223934341|NCT02099123|DRUG|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
223934342|NCT03477305|BEHAVIORAL|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
223934343|NCT00588471|DRUG|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
223934344|NCT00588471|DRUG|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
223934345|NCT05783791|DIAGNOSTIC_TEST|Newborn Screening Assay|"The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:~* Is noninvasive~* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)~* Does not by design or intention introduce energy into a subject, and~* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study."
223934346|NCT00409799|DRUG|I-0401 (a new bone graft substitute)|1 time application
223934347|NCT02379936|DEVICE|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
223934348|NCT02379936|PROCEDURE|Traditional evaluation|Traditional way of evaluation
223934349|NCT02379936|DEVICE|iPhone 4S|
223934350|NCT02477514|DRUG|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
223934351|NCT02477514|DRUG|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
223934352|NCT02477514|DRUG|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
223934353|NCT05216796|BEHAVIORAL|Diet Intervention|Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
224285845|NCT02130531|OTHER|Placebo Tablet|Tablet for oral administration
224285846|NCT01206049|DRUG|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
224285847|NCT01206049|DRUG|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
224285848|NCT01206049|DRUG|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
224285849|NCT01206049|DRUG|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
224285850|NCT01206049|DRUG|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
224097218|NCT05319964|BEHAVIORAL|Control|Patients in all three study groups will receive hot pack, transcutaneous electrical nerve stimulation (TENS), therapeutic ultrasound 3 days a week for 8 weeks.
224097219|NCT05657769|DEVICE|Medwell Preventive Care Application|Regular diabetes treatment with additional Medwell application and wearable device.
224097220|NCT05657769|DEVICE|Manual Records|Regular diabetes treatment only with a diary card to record daily activities manually.
224097221|NCT04716322|BEHAVIORAL|Adapted Physical Activity|A 16-week health-adapted physical activity program, individualized from baseline evaluation of participants including the specificities of their pathologies
223533937|NCT02872038|DRUG|Cefepime|Cefepime intraperitoneal continuous dosing
223934354|NCT01854151|OTHER|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
223934355|NCT01089335|PROCEDURE|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
223934356|NCT05529420|OTHER|measurement of the depth of neuromuscular blockade|time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.
223934357|NCT04845386|DEVICE|TOF Cuff on arm|The TOF Cuff will be installed on one arm in opposite of TOF Scan. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
224097222|NCT01814657|DRUG|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
224097223|NCT01814657|DRUG|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
223533938|NCT02872038|DRUG|Cefazolin plus Ceftazidime|
223718567|NCT00844714|DRUG|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
224097224|NCT01612234|DIETARY_SUPPLEMENT|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
224285851|NCT00743509|DRUG|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
223718568|NCT00477243|BEHAVIORAL|Questionnaire|8 questionnaires will take about 40 minutes to complete.
223718569|NCT04810312|OTHER|Combined exercise and nutrition intervention|Back extensor strengthening exercise and nutritional supplementation for 12 weeks
223718570|NCT02732119|DRUG|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
223718571|NCT02732119|DRUG|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
223934358|NCT04845386|DEVICE|TOF Cuff on lower leg|The TOF Cuff will be installed on one lower leg. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
223934359|NCT04845386|DEVICE|TOF Scan on toe|The TOF Scan will be installed on hallux . After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
223934360|NCT04845386|DEVICE|TOF Scan on adductor pollicis|The TOF Scan will be installed on Thumb. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
223934361|NCT04845386|DEVICE|TOF Scan on corrugator supercilii|The TOF Scan will be installed on corrugator supercilii. After intubation dose of mivacurium continuous monitoring of neuromuscular block started until complete recovery of neuromuscular block.
224285852|NCT01002794|PROCEDURE|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital and Martina Hansens Hospital.
224285853|NCT01002794|OTHER|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training. Carried out at Nimi Ullevaal Oslo or Gnist trending- og fysioterapi, Baerum
224285854|NCT02825329|DEVICE|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
224285855|NCT03451240|BEHAVIORAL|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
224285856|NCT03740620|PROCEDURE|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
224285857|NCT03740620|PROCEDURE|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
223718572|NCT02732119|DRUG|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
224097225|NCT01021566|DEVICE|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
224097226|NCT01021566|DRUG|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
223934362|NCT04244058|DRUG|Amantadine + L-DOPA|Amantadine 150 mg L-DOPA 375mg/carbidopa 75mg
223934363|NCT04244058|DRUG|NMDA blocker|NMDA blocker
223934364|NCT00930306|DRUG|AZD2066|12 doses, Given as capsule, 2 mg \& 8 mg
223934365|NCT00930306|DRUG|Caffeine|2 doses, Given as Tablet, 2x50 mg
223934366|NCT00930306|DRUG|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
223934367|NCT00930306|DRUG|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
223718573|NCT02556814|DRUG|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
223718574|NCT02556814|DRUG|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
223934368|NCT00930306|DRUG|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
223934369|NCT02476435|DEVICE|Active rTMS|Strong electromagnetic fields (\~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
223934370|NCT02476435|DEVICE|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
223934371|NCT02920710|DRUG|Repository Corticotropin Injection|"* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
224097227|NCT00336102|OTHER|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
224097228|NCT00336102|PROCEDURE|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
224097229|NCT00336102|PROCEDURE|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
224285858|NCT03778723|DRUG|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
223718575|NCT02556814|DRUG|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
224285859|NCT03778723|DRUG|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
224285860|NCT03778723|DRUG|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
223718576|NCT04522960|DIAGNOSTIC_TEST|MEG+hdEEG+MRI|"We will perform several tests:~* Neuropsychological testing to evaluate evolution of cognition during our study.~* Lumbar puncture, blood sampling, saliva and urine collection to assess melatonin levels at several timepoints within these biological fluids.~* MEG+hdEEG and MRI (to project MEG information) ; LTM-EEG to detect epileptiform activity in patients and healthy controls"
223934372|NCT00293397|DEVICE|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
223934373|NCT03717467|DRUG|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
223934374|NCT03717467|DRUG|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
223934375|NCT05142046|DRUG|Fluid balance|The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
223934376|NCT01237067|DRUG|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
223934377|NCT01237067|DRUG|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 \> carbo d8; B: carbo d1 \> olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
223934378|NCT05769244|OTHER|near-infrared spectroscopy (NIRS)|NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
223934379|NCT04124432|DRUG|Cannabis|Cannabis will be smoked
223934380|NCT04124432|DRUG|Nicotine|Nicotine will be smoked or vaporized
223934381|NCT02311452|DEVICE|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
224285861|NCT06616935|OTHER|Intervention group one, community activities.|"Intervention group one: participants will have a list of free activities in the community provided by third sector organisations to choose from. Participants will be referred to their chosen activities and expected to attend for six months.~Intervention group two: Participants will attend weekly online exercises and activities led by the researcher."
224285862|NCT06616935|OTHER|Intervention group two|Online exercises and activities
224285863|NCT01820858|DRUG|Paclitaxel|175 mg/m(2), intravenously (IV)
224285864|NCT01820858|DRUG|Paraplatin (Carboplatin Injection)|AUC=5, IV
224285865|NCT01820858|RADIATION|Pelvic Radiation|45-50 Gy
224285866|NCT01820858|RADIATION|Vaginal Brachytherapy 1|5 Gy, 3 times
224285867|NCT01820858|RADIATION|Vaginal brachytherapy 2|5 Gy, 2-4 times
223934382|NCT05719519|PROCEDURE|Initial periodontal therapy and 3D intraoral scanning|Initial periodontal therapy using GBT ( guided biofilm therapy) principle and 3D intraoral scanning
223934383|NCT00523419|DRUG|Pemetrexed|500 mg/m\^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
223934384|NCT02876016|DEVICE|functional MRI|locate the cerebral bases in functional imaging
223934385|NCT02162225|DRUG|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
223934386|NCT03058445|DEVICE|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
223934387|NCT03058445|DEVICE|CVC|Injection of 5 ml of saline
223934388|NCT02189174|DRUG|CLR457|
223934389|NCT02540824|DRUG|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
223934390|NCT01611493|DEVICE|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
223934391|NCT01611493|DEVICE|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
223934392|NCT03830567|OTHER|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
223934393|NCT03830567|OTHER|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
223934394|NCT04017793|BEHAVIORAL|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
223934395|NCT04017793|BEHAVIORAL|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
223934396|NCT00674752|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
223934397|NCT00674752|DRUG|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
223934398|NCT00674752|DRUG|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
223934399|NCT04688060|DIAGNOSTIC_TEST|Falls Efficacy Scale-International (FES-I)|The FES-1 was used to assess the fear of falling level of participants about falling during indoor or outdoor activities. It has 16 items scored on a four-point Likert scale. The Turkish validated version of the FES-I was used in this study. The total score (sum of the 16 responses) ranging from 16 to 64 points was used for data analysis. A higher score indicates better mobility performance. A cut-off score of 27 points on the 16- item FES-I was used to differentiate high concern for falling from low concern
223934400|NCT00698113|PROCEDURE|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
223934401|NCT00698113|OTHER|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
223934402|NCT04623489|BEHAVIORAL|¡Vivir Mi Vida! Lifestyle Intervention|
223934403|NCT02379260|OTHER|Interview with a sociologist|
223934404|NCT06299670|DRUG|Thalidomide|Patients will get only Thalidomide
223533939|NCT05032586|DEVICE|wearing virtual reality headsets|"When the patient adapted to the headset and started to play games, he was taken to the dressing room with the VR headset and the application continued until the process was completed. Before starting the study, a pilot study was conducted to determine the time to wear headsets in ten children. It was observed that the children who were taken to the dressing room without wearing VR headsets refused to wear it. In order to prevent the child from experiencing anxiety in the dressing room, the child was put on VR headset in the patient room and then taken to the dressing room. After the procedure was completed, the VR headset was removed and the patient's oxygen saturation and heart rate were recorded on the Application Registration Form. The patients were asked regarding the pain and anxiety levels felt during dressing before and after the procedure and marked on the Wong Baker Scale, State-Trait Anxiety Inventory for Children and Children's Fear Scale."
223718577|NCT03481322|DIETARY_SUPPLEMENT|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
223934405|NCT06299670|DRUG|Hydroxy Urea|Patients will get only Hydroxyurea
223934406|NCT06299670|DRUG|Combinations|Combination Of Thalidomide \& Hydroxyurea
223934407|NCT06054841|BEHAVIORAL|Postpartum follow up card|The intervention will consist of a card given to patients at time of discharge. One side of the card will list the patient's name and a list of recommended postpartum follow-up appointments based on their diagnoses at the time of discharge. The back of the card will list relevant phone numbers to assist patients with scheduling.
223934408|NCT06054841|OTHER|Control|No deviation from standard discharge education
223934409|NCT00822120|BIOLOGICAL|bleomycin sulfate|
223934410|NCT00822120|BIOLOGICAL|filgrastim|
223934411|NCT00822120|DRUG|ABVD regimen|
223934412|NCT00822120|DRUG|BEACOPP regimen|
223934413|NCT00822120|DRUG|cyclophosphamide|
223934414|NCT00822120|DRUG|dacarbazine|
223934415|NCT00822120|DRUG|doxorubicin hydrochloride|
223934416|NCT00822120|DRUG|etoposide|
223934417|NCT00822120|DRUG|prednisone|
223934418|NCT00822120|DRUG|procarbazine hydrochloride|
223934419|NCT00822120|DRUG|vinblastine sulfate|
223934420|NCT00822120|DRUG|vincristine sulfate|
223934421|NCT01218009|DRUG|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
223934422|NCT01218009|DRUG|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
223934423|NCT03491540|DRUG|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
223934424|NCT03491540|DRUG|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
223934425|NCT03491540|DRUG|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
223934426|NCT03491540|DRUG|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
224097230|NCT06326944|PROCEDURE|Ultrasound- guided Fascia Transversalis plane block|Ultrasound probe will be placed in a transverse orientation above the iliac crest; and the external oblique, internal oblique (IO), and transversus abdominis TA muscles will be identified and traced posteriorly until first the TA muscle and then the IO muscle tapered into their common aponeurosis, adjacent to the quadratus lumborum muscle. The tip of a 22-gauge 80-mm block needle will be positioned just deep to the TA muscle and its aponeurosis at the point where the TA is tapered off. 0.4 ml/kg bupivacaine 0.25% will be injected into the plane between the TA and underlying transversalis fascia
224097231|NCT06326944|PROCEDURE|Ultrasound-guided Transversus abdominus plane block|the probe will be placed transversely in the mid-axillary line between the iliac crest and the costal margin at the level of the umbilicus. The external oblique, internal oblique and transversus abdominis muscles and their fascias will be visualized. A 22 gauge, 80 mm needle will be introduced anteriorly and in the plane of the ultrasound probe, and on entering the plane between IO and TA, 2 ml of 0.9% saline will be injected to verify the correct position of the needle. Following negative aspiration, 0.4 ml/kg of bupivacaine 0.25% will be injected.
224097232|NCT06326944|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
224097233|NCT06326944|DRUG|Pethidine|Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.
223533940|NCT01229124|GENETIC|RNA analysis|
223533941|NCT01229124|GENETIC|nucleic acid sequencing|
223533942|NCT01229124|GENETIC|reverse transcriptase-polymerase chain reaction|
223533943|NCT01229124|OTHER|laboratory biomarker analysis|
223934427|NCT03491540|DRUG|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
223934428|NCT04929106|DEVICE|mHealth support tool|The final app is named Active Leisure and consists of an advanced activity planner based on the platform developed by the ideal company Smart Cognition AS. The app offers different interface options (symbols only, easy to read text, plain text, and read aloud). The activity planner will mostly be used by the individual with IDs and a support person (caregiver or health care provider). After completing an activity, a simple reward is available (e.g., a smiling face or to share a picture with other users of the app). The use of tailored communication through personalization: the use of individuals first name in the activity planner, adaptation: individually chosen activities, adjusted communication (symbols, easy-to-read text or plain text), preparation and planning, and feedback: rewarding and positive feedback (after activities have been performed) is expected to increase motivation, and thereby lead to higher levels of PA.
223934429|NCT00503906|DRUG|Avastin|
223934430|NCT00503906|DRUG|Gemcitabine|
223934431|NCT00503906|DRUG|Abraxane|
223934432|NCT06461390|DRUG|Norepinephrine|NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\&gt;5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
223934433|NCT06461390|DRUG|Ringer's Lactate|Fluid Group will receive ringer lactate bolus 20 ml/ kg only. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed
223934434|NCT05462067|DEVICE|AT LARA IOL|EDOF IOL for treatment of cataract
223934435|NCT05462067|DEVICE|AT LISA Tri IOL|Trifocal IOL for treatment of cataract
223934436|NCT01630824|OTHER|Structured education program|structured education program after kidney transplantation
223533944|NCT00725088|BEHAVIORAL|Exercise training|Exercise training
223533945|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
223533946|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
223533947|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
223533948|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
223533949|NCT03304964|DRUG|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
223533950|NCT04554004|DIAGNOSTIC_TEST|CCTA, CT-MPI, DSA, FFR|The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)
223533951|NCT00833521|DRUG|Zolpidem 10 mg tablets|1 x 10 mg
223533952|NCT00833521|DRUG|AMBIEN® 10 mg tablets|1 x 10 mg
223533953|NCT03832985|GENETIC|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
223533954|NCT03832985|GENETIC|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
223533955|NCT03832985|GENETIC|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
223533956|NCT06643091|DRUG|Nintedanib|Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
223533957|NCT06642077|DRUG|LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml|A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
223533958|NCT06644443|BIOLOGICAL|BCMA-GPRC5D CAR-T cells|patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
223533959|NCT03524599|OTHER|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
223533960|NCT03602508|DRUG|mirabegron|oral
223533961|NCT03602508|DRUG|solifenacin|oral
223934437|NCT05850975|OTHER|intervention with this name in MindEase app|MindEase is an app which provides interventions against anxiety. The interventions are based on mindfulness, acceptance and commitment therapy, and cognitive behavioural therapy.
223934438|NCT05850975|OTHER|reading about anxiety|Participants are given an educational text to read about anxiety.
223934439|NCT02582424|OTHER|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
223934440|NCT02582424|OTHER|placebo|placebo
223934441|NCT00255307|DRUG|CVT-E002 ginseng extract|
223533962|NCT03602508|DRUG|darifenacin|oral
223533963|NCT03602508|DRUG|imidafenacin|oral
223533964|NCT03602508|DRUG|tolterodine|oral
223533965|NCT03602508|DRUG|oxybutynin|oral
223533966|NCT03602508|DRUG|trospium|oral
223934442|NCT02040363|PROCEDURE|Muscular biopsy|
223934443|NCT02040363|OTHER|5-10 weeks sport training|
223934444|NCT00008242|DRUG|dexamethasone|
223533967|NCT03602508|DRUG|fesoterodine|oral
223934445|NCT00008242|DRUG|doxorubicin hydrochloride|
223934446|NCT00008242|DRUG|thalidomide|
223934447|NCT02492412|DRUG|HE 10|
223934448|NCT02492412|DRUG|Restasis|
223934449|NCT03003286|BEHAVIORAL|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
223934450|NCT03003286|BEHAVIORAL|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
223934451|NCT02095717|DRUG|Curcumin|
223934452|NCT02095717|DRUG|Placebo|
223533968|NCT03602508|DRUG|propiverine|oral
223533969|NCT06293781|DEVICE|Web-based ACT|ACT program delivered online
223533970|NCT06293781|BEHAVIORAL|Treatment as usual|Treatment as usual for major depressive disorder
223533971|NCT06545006|OTHER|isometric contractions|Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
223934453|NCT02095717|DRUG|Taxotere|
223934454|NCT02505191|DRUG|St. John's wort prolonged-release tablet 500 mg|
223934455|NCT02505191|DRUG|St. John's wort film coated tablets 250 mg|
223934456|NCT03954275|OTHER|no intervention|no intervention
223934457|NCT03447457|DEVICE|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
223934458|NCT03447457|DEVICE|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
223934459|NCT06512181|OTHER|Conservative/Expectant Management|At time of caesarean section, participants will not have a hysterectomy, but will be treated clinically to preserve their uterus.
223934460|NCT00115011|DRUG|Escitalopram|
223934461|NCT02540031|DRUG|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
223934462|NCT02540031|DRUG|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
223934463|NCT02631369|DEVICE|Heidelberg Spectralis OCT device|
223934464|NCT00336349|DRUG|Botulinum Toxin Type A|Botulinum Toxin Type A
223934465|NCT04661306|BEHAVIORAL|SHUTi (Sleep Healthy Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
223934466|NCT05489913|OTHER|cardiac rehabilitation support program|First of all, a preliminary interview was made with the patients in the experimental group, and their information needs were evaluated individually. Which trainings he should receive and his priorities were determined with the patient. After the training requirements were determined, the general introduction of the website was made and they were allowed to register. Experimental group patients received both training on the website and counseling over the phone for 12 weeks after they started working. A total of 3 phone calls were made with the patients in the first week, 4th and 8th weeks. The interviews lasted an average of 20 minutes. In each phone call, patients were informed and reminded. When patients needed, an average of 2-3 more phone calls were made and information was provided on the subjects they needed.
223934467|NCT01974843|DRUG|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
223934468|NCT01974843|DRUG|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
223934469|NCT03959813|OTHER|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~* A questionnaire, based on the physical experience,~* The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
223934470|NCT05282966|DIAGNOSTIC_TEST|QSant-TM Urine Test|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
223934471|NCT02715518|DEVICE|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~1. FFR-guided strategy arm~2. Angiography-guided strategy arm"
224097234|NCT06326944|DRUG|Acetaminophen|patients will be given paracetamol (15 mg /kg/8 hrs ).
224097235|NCT03455946|BEHAVIORAL|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
224097236|NCT03592862|DRUG|HTL0018318|Oral capsule
224097237|NCT03592862|DRUG|Placebo|Oral capsule
224097238|NCT02612597|OTHER|Bedrest|
224097239|NCT02612597|OTHER|Exercise Training|
224097240|NCT03253640|OTHER|Exposure|Healthcare associated infection (HAI)
224097241|NCT03217760|PROCEDURE|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
223533972|NCT06545006|OTHER|stroboscopic glasses|"This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport."
223934472|NCT00811941|DRUG|Placebo|as-needed use, tablets, orally, 52 weeks
224097242|NCT03217760|OTHER|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
224097243|NCT03217760|OTHER|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
223934473|NCT00811941|DRUG|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
223934474|NCT05911867|OTHER|combination of mobilization with movement and muscle energy techniques|"The examiner passively abducts the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.~Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range."
223934475|NCT05911867|OTHER|muscle energy techniques Interventions:|The examiner passively abduct the arm in the horizontal plane until the first barrier to motion by applying pressure to the distal humerus. This passive stretch will be held for three seconds. The examiner then instruct the participant to attempt to horizontally adduct the test arm at 25% of their maximal effort while the examiner applied manual resistance at the distal humerus to create an isometric contraction lasting five seconds. The participant then actively abduct the arm in the horizontal plane for a three-second active-assisted stretch.
223934476|NCT05911867|OTHER|mobilization with movement|Regarding the cervical spine, the second technique, Cervical Self-Natural Apophyseal Glides (SNAG), involves the therapist standing behind the patient and applying force to the spinous process of each vertebra using a thumb-over-thumb technique. The patient actively performs repeated flexion or extension of their neck, returning back to the neutral position. The passive gliding is maintained in the anterosuperior direction along the facet joint line while flexing or extending the neck throughout the range.
223934477|NCT02620306|DRUG|Fimsartan 60mg~120mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
223934478|NCT02620306|DRUG|Fimsartan 60mg~120mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
223934479|NCT02620306|DRUG|Losartan 50mg~100mg|Standard BP control group (SBP \< 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
223934480|NCT02620306|DRUG|Losartan 50mg~100mg|Strict BP control group (SBP \< 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
223934481|NCT03802994|DRUG|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
223934482|NCT03802994|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
223934483|NCT03802994|OTHER|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
223934484|NCT01201772|DRUG|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
223934485|NCT05909072|DRUG|Hyaluronic acid combined with tranexamic acid microneedling|1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry
223934486|NCT05909072|DRUG|tranexamic acid microneedling|On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
223934487|NCT00949364|DRUG|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
223934488|NCT06308406|DRUG|Bevacizumab； HRS-1167|Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
224097244|NCT03217760|OTHER|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
224097245|NCT03217760|OTHER|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate \[HR\], systolic blood pressure \[SBP\], and diastolic blood pressure \[DBP\]) are monitored during each of the 6 steps.
224097246|NCT03217760|OTHER|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
224097247|NCT03217760|OTHER|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
223934489|NCT01341132|PROCEDURE|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
223934490|NCT03418610|DRUG|Azelaic Acid foam 15%|mild to moderate rosacea
223533973|NCT06545006|OTHER|Quick Release|"The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement"
223934491|NCT05680857|OTHER|Placebo|Product doesn't have active ingredients i.e. marine collagen peptide and Coenzyme Q10.
223934492|NCT05680857|OTHER|Product containing marine collagen peptide and Coenzyme Q10.|Product containing marine collagen peptide and Coenzyme Q10.
223934493|NCT02614911|OTHER|Biological sampling|Biological sampling including blood, feces, biopsies...
223934494|NCT04777383|DRUG|Acetylcholine|Iontophoretic administration of 5 different concentrations of acetylcholine
223934495|NCT04777383|DRUG|Norepinephrine|Iontophoretic administration of 5 different concentrations of norepinephrine
223934496|NCT04777383|DRUG|Phenylephrine|Iontophoretic administration of 5 different concentrations of phenylephrine
223934497|NCT04777383|DRUG|Atropine|Iontophoretic administration of 5 different concentrations of atropine
224097248|NCT03217760|OTHER|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
224097249|NCT03217760|OTHER|student preferences.|"When the treatment is complete the students are asked to report:~1. his/her level of satisfaction with the course of treatment,~2. whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~3. whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
224097250|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
224097251|NCT00684814|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
224097252|NCT02224430|DEVICE|schizophrenia/schizoaffective disorder.|Participants with schizophrenia/schizoaffective disorder will be observed remotely and at weekly/biweekly laboratory visits over a period of 16 weeks or until relapse occurs.
223533974|NCT00646230|DRUG|fenretinide|
223533975|NCT00646230|OTHER|high performance liquid chromatography|
223533976|NCT00646230|OTHER|pharmacological study|
223934498|NCT04777383|DRUG|Neostigmine|Iontophoretic administration of 5 different concentrations of neostigmine
223934499|NCT04777383|DRUG|Sterile water|Iontophoretic administration of sterile water
223934500|NCT04881409|DEVICE|Respiratory support with nasal high-flow (NHF)|Patient with AECOPD is treated with NHF.
223934501|NCT04881409|DEVICE|Respiratory support with non-invasive ventilation (NIV)|Patient with AECOPD is treated with NIV.
223934502|NCT00622700|DRUG|Teriflunomide|Film-coated tablet Oral administration
223934503|NCT00622700|DRUG|Placebo|Film-coated tablet Oral administration
223934504|NCT01602185|DRUG|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
223934505|NCT01602185|DRUG|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
223934506|NCT01602185|DRUG|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
223934507|NCT05314049|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
224285868|NCT01538836|BEHAVIORAL|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
224285869|NCT01538836|BEHAVIORAL|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
223934508|NCT05314049|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
223934509|NCT05314049|DEVICE|inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
223934510|NCT05314049|DEVICE|Heat Therapy|superficial heating for 20 minutes
223934511|NCT00861003|DEVICE|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
223934512|NCT00284752|DRUG|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
224097253|NCT01880450|BEHAVIORAL|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
224097254|NCT01880450|BEHAVIORAL|TEEN|Control condition the promote communication, decision-making skills etc.
224285870|NCT05205018|BEHAVIORAL|Motivational interviewing performed remotely through videocalls|Remote motivational interviewing will be performed seven time over 12 months, through videocalls. The first four interventions will be performed within two months and the following three will be performed at five, eight and eleven months from enrollment.
224285871|NCT00609284|DRUG|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
223533977|NCT01280942|BEHAVIORAL|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
223934513|NCT06246890|OTHER|Autism ALERT|Autism Access Link for Early Referral and Treatment \[ALERT\], the intervention proposed in this application, is a novel state-wide referral and case management platform that PCPs can activate to ensure that a child with suspected ASD receives all necessary ASD diagnosis and treatment resources in a single referral, radically simplifying a complex diagnostic and treatment process.
223934514|NCT05508854|GENETIC|prenatal genetic counselling|Prenatal genetic counseling is a consultancy service that covers the evaluation of the risk status of the baby in the mother's womb in terms of genetic diseases, the tests and risks that can be done for the diagnosis of the disease, the test results and information about the disease in case of illness and the presentation of options.
223934515|NCT01199315|DRUG|AZD1446|oral capsule, Moderate Release
223934516|NCT01199315|DRUG|Placebo|oral capsule
223934517|NCT04867824|DIETARY_SUPPLEMENT|Case (use of inhaled vanilla essential oil)|Use of inhaled vanilla essential oil during frenotomy for a tongue-tie
223934518|NCT04867824|DIETARY_SUPPLEMENT|Control (use of inhaled lavender essential oil)|Use of inhaled lavender essential oil during frenotomy for a tongue-tie
223934519|NCT02646618|BEHAVIORAL|Get Social|Online-delivered weight loss intervention
223934520|NCT02646618|BEHAVIORAL|Traditional|Group-delivered weight loss intervention
223934521|NCT02646618|DEVICE|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
223934522|NCT03960359|OTHER|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
223934523|NCT05729503|DRUG|Lidocaine 2% Injectable Solution|Cotton tip applicator pre-soaked with lidocaine
223934524|NCT05729503|DRUG|Placebo|Cotton tip applicator pre-soaked with saline
223533978|NCT01280942|DEVICE|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
223533979|NCT05283889|PROCEDURE|Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
223533980|NCT05283889|PROCEDURE|Sham Genicular Radiofrequency Ablation|After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
223934525|NCT00898352|PROCEDURE|regional lymph node dissection|
223934526|NCT00898352|RADIATION|radiation therapy|
223934527|NCT05503368|PROCEDURE|surgical treatment of vitiligo using NCES|NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
223934528|NCT03896659|DRUG|Hydrocortisone Oral|Hydrocortisone 160 mg tablet
223934529|NCT03896659|DRUG|Placebo Oral Tablet|Hydrocortisone-matched Placebo tablet
223934530|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
223934531|NCT00390884|BIOLOGICAL|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
223533981|NCT06455904|PROCEDURE|Training sessions|The training program will be performed during 15 weeks, with one session per week.
223934532|NCT01299194|DRUG|ATORVASTATIN|80mg once daily for 3 months
223934533|NCT06343493|DRUG|Normal saline heated up to 50 °C|Saline heated up to 50 °C used for irrigation
223934534|NCT00236535|DRUG|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
223934535|NCT05697705|OTHER|ChAdOx1 nCOV-19 vaccine (Vaxzeria)|Used as 2nd booster, 1st booster, or primary series
223934536|NCT05697705|OTHER|BNT162b2 (Pfizer)|Used as 2nd booster, 1st booster, or primary series.
223934537|NCT05697705|OTHER|Ad26.COV2.S (Janssen)|Used as 2nd booster, 1st booster, or primary series.
223934538|NCT05697705|OTHER|CoronaVac (Sinovac)|Used as 2nd booster, 1st booster, or primary series.
223934539|NCT04035447|BEHAVIORAL|Behavioral Symptom Management for Young Adult Cancer Survivors|The intervention includes group sessions held over Zoom along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). The developed intervention includes 8 face-to-face group sessions (12 therapy hours). Sessions are delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants receive secure access to a study-specific mobile application that includes: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
223934540|NCT05628064|DEVICE|1C70|Investigational energy storage and return prosthetic foot with using novel elastic elements.
223934541|NCT05628064|DEVICE|Pro-Flex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects.
224097255|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 50% MIP|Patients received IMT exercise program at a 50% MIP intensity for 12 weeks
224097256|NCT05241652|OTHER|Inspiratory Muscle Training with an intensity of 10% MIP|Patients received IMT exercise program at a 10% MIP intensity for 12 weeks
224285872|NCT00609284|DRUG|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
223934542|NCT03304587|DIAGNOSTIC_TEST|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
223934543|NCT03304587|DIAGNOSTIC_TEST|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
223934544|NCT03304587|OTHER|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
223934545|NCT03304587|OTHER|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
224097257|NCT00608140|PROCEDURE|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
224097258|NCT00608140|DRUG|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
224097259|NCT01129947|DRUG|DHEA|DHEA 25 mg tid
224097260|NCT03812510|DRUG|A-101|hydrogen peroxide topical solution 45%
224097261|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
224097262|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
223533982|NCT06278051|DRUG|Rivaroxaban granules for oral suspension|Treatment dose and period decided by its prescription
224097263|NCT00768560|DRUG|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
224097264|NCT04237493|DRUG|Metformin and Glimepiride (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 1.5 or 3 mg \[75% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
224097265|NCT04237493|DRUG|Metformin and Vildagliptin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; OD \[with Ifṭār\])"
223533983|NCT06278051|DRUG|Warfarin|Treatment dose and period decided by its prescription
223533984|NCT04336826|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
223934546|NCT03304587|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
223934547|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|"8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
224097266|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 9-33 units \[75% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
224285873|NCT00609284|RADIATION|Radiotherapy|70 Gy in 7 weeks
224285874|NCT04104984|DEVICE|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
224285875|NCT04104984|DRUG|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
224285876|NCT04104984|PROCEDURE|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
224285877|NCT04104984|OTHER|digital vaginal exam|vaginal examination to detect short cervix
224285878|NCT04104984|DEVICE|abdominal ultrasound|use abdominal ultrasound to measure cervical length
224285879|NCT04104984|DRUG|Tocolytic Agents|a medication is given to prevent uterine contraction
223934548|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|"8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
223934549|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|"8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
223934550|NCT03304587|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|"8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.~PROMIS measures provide a common metric: the T-score (mean = 50, standard deviation = 10). A mean of 50 equals the mean in the U.S. general population.~Higher scores means more the attribute to be measures: e.g., for fatigue, sleep disturbance, depression, higher scores mean worse fatigue, worse sleep disturbance, worse depression.~But for physical function, higher scores mean better functioning."
223934551|NCT03304587|OTHER|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
223934552|NCT03304587|OTHER|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
223934553|NCT03304587|OTHER|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
223934554|NCT03304587|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
223934555|NCT03304587|OTHER|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue \& sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
223934556|NCT05880108|BEHAVIORAL|12-weeks of Weight Loss|Participants will be asked to participate in a 1x/week center-based or tele-health nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for \~12 weeks.
223934557|NCT05880108|BEHAVIORAL|12-weeks of Weight Stability|Participants will be asked to participate in a 1x/week center-based or tele-health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for \~12 weeks.
223934558|NCT04289324|PROCEDURE|regular lung recruitment|stepwise oxygenation-guided lung recruitment at regular (twelve hours) intervals during high frequency oscillation ventilation
224285880|NCT05540821|DIAGNOSTIC_TEST|Hysterosalpingo-contrast sonography and sonoPODography|"Before operation, phloroglucinol 40mg of antispasmolysis was injected intramuscular, and then cervical dilation was performed according to aseptic operation requirements. A 12G double-lumen catheter was inserted into the uterine cavity, and 1.5-1.8ml of normal saline was injected into the sacculus.~Transvaginal 2/3/4D hysterosalpingo-contrast sonography: One operator extracted 2ml of Sonovue and injected 18ml of normal saline through a dual-lumen catheter, and the other operator started the four-dimensional ultrasound mode to collect dynamic volume data.~sonoPODography: Sterile saline was injected into the intrauterine cavity, with an upper limit of 20ml. The normal saline flowed from the intrauterine cavity into the pelvic cavity through the bilateral fallopian tubes, forming a good acoustic window. Pelvic observation was then performed."
224285881|NCT03662308|DEVICE|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
224285882|NCT03662308|DEVICE|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
224285883|NCT01672359|DIETARY_SUPPLEMENT|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
224285884|NCT01672359|DIETARY_SUPPLEMENT|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
224285885|NCT01672359|DIETARY_SUPPLEMENT|Placebo|
224285886|NCT02065713|DRUG|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
224285887|NCT02065713|DRUG|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
223718578|NCT03258021|DEVICE|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
223934559|NCT06799962|OTHER|Enhanced Body-Swap for Anorexia Nervosa|The protocol begins with a baseline session, where participants familiarize themselves with their virtual body and provide anamnesis and therapeutic efficacy baseline data. The treatment phase includes 12 bi-weekly sessions where participants embody a virtual avatar in a VR environment. During each session, the Body Mass Index (BMI) of the virtual body is incrementally increased toward a target BMI approximating normal weight (18.5). Follow-ups are conducted at 4, 8, and 12 weeks to assess long-term effects.
223934560|NCT06799962|OTHER|Emotional Rescripting for Bulimia Nervosa|The protocol starts with an assessment phase (1 session), gathering anamnesis and baseline therapeutic efficacy data. This is followed by an evaluation phase (2 sessions), where participants rate craving responses for virtual foods and environments in immersive VR, with physiological data collected via biosensors. Using this data, a personalized exposure hierarchy is created, combining the most craving-inducing foods and environments into 40 interactive 3D scenarios. The treatment phase involves 9 VR sessions focusing on emotional regulation and craving management. Follow-ups at 4, 8, and 12 weeks evaluate progress.
223934561|NCT06799962|OTHER|Standard Therapy for Anorexia Nervosa (Control)|Participants follow a similar structure with a baseline session to collect anamnesis and baseline data, but without VR immersion. The treatment phase consists of 12 bi-weekly sessions of standard cognitive-behavioral therapy (CBT), focusing on addressing maladaptive thought patterns, promoting healthy eating behaviors, and reducing body image disturbances. Follow-ups are conducted at 4, 8, and 12 weeks to monitor progress. No VR or AI technologies are integrated.
223934562|NCT06799962|OTHER|Standard Therapy for Bulimia Nervosa (Control)|Participants undergo an assessment phase (1 session) to collect baseline data and an evaluation phase (2 sessions) using standard craving questionnaires without VR immersion or biosensors. The treatment phase includes 9 sessions of traditional CBT targeting binge-purge cycles and emotional triggers. Follow-ups at 4, 8, and 12 weeks monitor progress without the integration of VR or AI technologies.
223934563|NCT05840887|PROCEDURE|Knee osteotomy associated with meniscal allograft transplantation|Patients will undergo knee osteotomy associated with meniscal allograft transplantation, which will be implanted by arthroscopic technique with body fixation by all-inside and transosseous sutures to the posterior horn and if necessary to the anterior horn.
223934564|NCT05840887|PROCEDURE|Knee osteotomy|Knee osteotomy
223934565|NCT01458366|DRUG|Bendamustine|"Phase 1: Given via IV at the following dose levels:~* Level 1: 70 mg/m2~* Level -1: 50 mg/m2~* Level 2: 90 mg/m2~* Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
223934566|NCT01458366|DRUG|Ofatumumab|"Phase II~* Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~* Cycles 2 and 3: 1000 mg via IV on Day 1"
223934567|NCT01458366|DRUG|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
223934568|NCT01458366|DRUG|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
223934569|NCT01458366|PROCEDURE|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
223934570|NCT01458366|PROCEDURE|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
223934571|NCT01458366|GENETIC|Stem Cell Transplant (STC)|"For potential transplant candidates:~* Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~* Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
223934572|NCT04572906|COMBINATION_PRODUCT|NTX-001|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. An isolation chamber medical device (device) is utilized to focus the application of PEG (Solution #2) on the coapted nerve for the required amount of exposure time.
223934573|NCT01753999|DEVICE|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
223934574|NCT01753999|DEVICE|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
223934575|NCT02610426|OTHER|Laboratory Biomarker Analysis|Correlative studies
223934576|NCT00328692|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
223934577|NCT00328692|DRUG|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
223934578|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 100 mg/day
223934579|NCT01821989|DIETARY_SUPPLEMENT|Lactoferrin|dose of 150 mg/kg/ twice daily
223934580|NCT01821989|DIETARY_SUPPLEMENT|Placebo|in form of distilled water
223934581|NCT00228475|DRUG|Pulmicort (budesonide) Turbuhaler|
223934582|NCT05492604|OTHER|Clinical examination|Cinical examination carried out during a consultation for the follow-up of the patient
223934583|NCT05492604|OTHER|Functional scales|The Clinical scales are as follows : MRC (Medical Research Scale), ONLS (Overall Neuropathy Limitations Scale), R-ODS (Rasch-built Overall Disability Scale) , INCAT (Inflammatory Neuropathy Cause and Treatment) The functional scales are used as part of the usual care of the patient in the neurology department
223934584|NCT05492604|DIAGNOSTIC_TEST|Walking test|Walking test over 10 metres at a comfortable speed on the GAITRITE® walkway, fitted with FEETME® soles at the same time. The 10-metre test will be repeated 5 times, with a 2-minute break between each test.
223934585|NCT00163046|DRUG|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
223934586|NCT00163046|DRUG|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
223934587|NCT02130557|DRUG|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.\[1\] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
223934588|NCT02130557|DRUG|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
223934589|NCT01183767|DRUG|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
223934590|NCT01183767|DRUG|Placebo|
223533985|NCT04332783|BEHAVIORAL|psychophysics of sequential biases (no drug or patient work)|Psychophysical experiment on sequential effects in medical image perception. Observers, including clinicians, perform psychophysical continuous report match-to-sample and forced-choice discrimination judgments of medical images, including radiographs and photographs. Observer discrimination accuracy is measured on a trial-wise basis and sequential effects in those judgments are measured. Images can be presented with different interstimulus intervals and in different spatial locations and in different orders. Accuracy, and other signal detection metrics are computed as a function of these factors.
223934591|NCT05738369|DIETARY_SUPPLEMENT|Biogaia L. reuteri Prodentis® lozenges|Participants were instructed to use the lozenges twice daily after brushing their teeth; once in the morning and once in the evening
223934592|NCT05738369|DIETARY_SUPPLEMENT|Hersheyland Ice Breakers Mints sugar free lozenges|Hersheyland Ice Breakers Mints sugar free lozenges
223934593|NCT02408887|PROCEDURE|Total Thyroidectomy (TT)|Total removal of thyroid
223934594|NCT02408887|PROCEDURE|Prophylactic central neck lymph node dissection (pCND)|Lymph node dissection
223718579|NCT04579705|OTHER|Using a brush|Surgical hand scrubbing will be performed in 1 minute and 2 minutes using a disposable nail brush.
223718580|NCT02554357|DRUG|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
223934595|NCT04474496|OTHER|Assessing the impact of COVID-19|Surveying Marshallese adults in the U.S. to determine the impact of COVID-19
223934596|NCT03959384|DRUG|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
223934597|NCT03959384|OTHER|Ambient Air|Ambient air aspirated in sterile syringes
223934598|NCT03333109|BIOLOGICAL|Erenumab|70 mg/mL pre-filled syringe administered subcutaneously
223934599|NCT03333109|OTHER|Placebo|Matching placebo in pre-filled syringe administered subcutaneously
223934600|NCT01447706|DRUG|MM-121|MM-121 (SAR256212) (IV)
223934601|NCT01447706|DRUG|Paclitaxel|Standard dosing Paclitaxel (IV)
223934602|NCT01870830|OTHER|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
223934603|NCT01647932|DRUG|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; \>50ml/min 25mg daily, 20-50ml/min 50mg daily amd \<20ml/min 100mg daily.
223934604|NCT01647932|DRUG|Placebo|Placebo according to clearance of creatinine; \>50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd \<20ml/min 2 pills daily.
223934605|NCT04801199|DRUG|CPL-2009-0031 140 mg|Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
223934606|NCT04801199|DRUG|Sitagliptin 100mg|Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
223934607|NCT03989388|BEHAVIORAL|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
223934608|NCT03989388|BEHAVIORAL|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
223934609|NCT03989388|BEHAVIORAL|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
223934610|NCT06129500|BEHAVIORAL|Cognitive Behavioural Therapy for Problematic Impulsive Behaviours|Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.
223934611|NCT06453577|DRUG|Recompensation (guideline directed medical therapy)|Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
223934612|NCT06875921|OTHER|McKenzie Exercise Group|"The intervention will last 7 minutes and will consist of the following exercises:~* Four Extension Exercises: Lying Face Down, Lying Face Down in Extension, Repeated Lumbar Extension in Lying, Repeated Lumbar Extension in Standing.~* Two Flexion Exercises: Repeated Lumbar Flexion in Lying, Repeated Lumbar Flexion in Sitting."
223934613|NCT06875921|OTHER|Pilates Exercise Group|The intervention will last 20 minutes and will include Pilates exercises focused on mobility and strengthening.
223934614|NCT06879301|DRUG|Intravitreal injection of aflibercept 8 mg|"Preoperative preparation: Patients were prepared by applying topical fluoroquinolone eye drops (moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) 4 times daily for three days before injection.~Procedure: The intravitreal injection was carried out in the operating room under complete aseptic techniques with an operating microscope. After the topical application of anaesthetic drops (benoxinate hydrochloride 0.4%, Benox, Epico, Egypt) to the ocular surface followed by the topical application of 10% povidone-iodine (Betadine) to the periocular area, lids and eye lashes, 5% povidone iodine was administered inside the conjunctival sac for three minutes before the intravitreal injection. 0.07 ml of aflibercept (8 mg) was injected into the vitreous cavity in the inferotemporal quadrant of the globe using a 30-gauge needle 4 mm from the limbus.~Postoperative care: After injection, topical antibiotic drops (moxifloxacin hydrochloride 0.5% Vigamox, Alcon, USA) were applied, and the eye was"
223934615|NCT06751420|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging Time Of Flight Angiography
223934616|NCT06750159|OTHER|No intervention (observational study)|no intervention(observational study)
223934617|NCT06549049|BEHAVIORAL|TranS-C for PTSD|The Transdiagnostic sleep and circadian intervention (TranS-C), developed by Allison Harvey, Ph.D. and Daniel Buysse, M.D., involves a patient-centered, module-based, flexibly structured approach that tackles numerous sleep disturbances using evidence-based strategies with the goal of improving sleep and related impairments in daytime functioning. It is thus well-suited for tackling sleep disturbances and the associated impairments in social, occupational and overall functioning in veterans with PTSD. The proposed study is a randomized, controlled clinical trial examining the effectiveness of a modified TranS-C intervention for veterans with PTSD. The modified approach, TranS-C for PTSD (TSC-PTSD), elevates the importance of nightmare-focused, apnea-focused, and insomnia-focused modules relative to the standard intervention, incorporates an evidence-based relaxation module, and modifies the nightmare and apnea modules based on strategies used for veterans in the VA healthcare system.
223934618|NCT06549049|BEHAVIORAL|Sleep Psychoeducation Control|Participants will receive psychoeducation about sleep.
223934619|NCT06763510|DRUG|Chirocaine|Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Isobaric levobupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
224097267|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 6-39 units (75% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 15-33 units before Ifṭār and 6-18 units before Suḥūr \[75% of the pre-Ramadan doses\])"
224097268|NCT04237493|DRUG|Metformin and Glimepiride (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Glimepiride (PO; 2 or 4 mg \[100% of the pre-Ramadan dose\]; OD \[with Ifṭār\])"
224097269|NCT04237493|DRUG|Metformin and Vildagliptin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Vildagliptin (PO; 50 mg; BID \[with Ifṭār and with Suḥūr\]\])"
224097270|NCT04237493|DRUG|Metformin and Insulin Glargine U100 (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 11-44 units \[100% of the pre-Ramadan dose\]; OD \[at 10 P.M.\])"
224097271|NCT04237493|DRUG|Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)|"* Metformin (PO; 850 mg; BID \[with Ifṭār and with Suḥūr\])~* Insulin Glargine U100 (SC; 8-52 units (100% of the pre-Ramadan dose); OD \[at 10 P.M.\])~* Human Regular Insulin (SC; 12-40 units before Ifṭār and 7-28 units before Suḥūr \[100% of the pre-Ramadan doses\])"
224097272|NCT02543242|DEVICE|InToneTM (InControl Medical, LLC) - Medical Device|
224097273|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
224097274|NCT03629509|BEHAVIORAL|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
224097275|NCT03629509|BEHAVIORAL|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
224097276|NCT05957874|OTHER|Combined package program|"Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles."
224097277|NCT01128387|DRUG|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
224285888|NCT02065713|DRUG|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
223718581|NCT02554357|DRUG|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
224285889|NCT00782028|OTHER|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
224285890|NCT00782028|OTHER|Standard Care|
224285891|NCT03115528|BEHAVIORAL|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
224285892|NCT04351230|DRUG|Abemaciclib|Given IV
224285893|NCT04351230|BIOLOGICAL|Trastuzumab Emtansine|Given PO
224285894|NCT03614494|DRUG|Piroxicam 40 mg|Additional co-treatment
223718582|NCT02460302|DRUG|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
223718583|NCT02460302|DRUG|Placebo|Placebo suppository inserted vaginally
224285895|NCT03614494|DRUG|Levonorgestrel 1.5mg|Standard treatment
224285896|NCT00418522|DRUG|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
224285897|NCT00418522|DRUG|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
224285898|NCT03715322|DRUG|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
224285899|NCT03715322|OTHER|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
224285900|NCT03715322|DRUG|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
224285901|NCT05253222|DIAGNOSTIC_TEST|retrograde image by colonic TET|"Delivery of contrast fluid by colonic TET Each participant will receive one delivery of 200 ml contrast fluid by colonic TET to the distal portion of the lesion.~One group will be taken CT investigation, another group will be taken X-ray fluoroscopy.~Imaging parameters will be collected and evaluated."
224285902|NCT00949455|DRUG|lapatinib ditosylate|Given orally
224285903|NCT00949455|OTHER|Placebo|Given orally
224285904|NCT03331614|DEVICE|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
223533986|NCT03158831|DRUG|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
223533987|NCT02419495|DRUG|Capecitabine|Given PO
223533988|NCT02419495|DRUG|Carboplatin|Given IV
223533989|NCT02419495|DRUG|Cyclophosphamide|Given IV
223533990|NCT02419495|DRUG|Doxorubicin|Given IV
223533991|NCT02419495|DRUG|Eribulin|Given IV
223934620|NCT06763510|DRUG|Bupivacaine|Our study was conducted on forty full-term pregnant women scheduled for elective cesarean sections under spinal anesthesia. At an operating room temperature of twenty-four degrees Celsius, peripheral body temperature was measured using temperature probes attached to the lower medial parts of the same side's lower and upper extremities, and central body temperature was measured with a tympanic thermometer. Hyperbaric bupivacaine was used in spinal anesthesia applications. After spinal anesthesia, tympanic temperature, arm and leg temperatures, mean arterial pressure, heart rate, and oxygen saturation were measured and recorded at baseline, the first, third, and fifth minutes, and every five minutes thereafter until the end of surgery.
223934621|NCT06754306|OTHER|normal diet (100% energy)|Daily intake of 100% energy requirements, adjusted individually based on each participant's basal metabolic rate (BMR).
223934622|NCT06754306|OTHER|16+8 time-restricted eating group (100% energy)|Participants will consume 100% energy within an 8-hour eating window and fast for the remaining 16 hours.
223934623|NCT06754306|OTHER|16+8 time-restricted eating group (75% energy)|Participants will consume 75% of their energy requirements within the 8-hour eating window.
223934624|NCT06754306|OTHER|Alternate-day fasting group (75% energy)|"Participants alternate between feeding days (125% energy requirements) and fasting days (25% energy requirements)."
223934625|NCT06754306|OTHER|5+2 intermittent fasting group (75% energy)|Participants consume 95% energy requirements for 5 consecutive days and 25% energy requirements for 2 fasting days.
223934626|NCT06754306|OTHER|Low-calorie diet group (75% energy)|Participants will reduce daily caloric intake to 75% of energy requirements, consumed evenly across three meals.
223934627|NCT06754306|OTHER|Very low-calorie diet group (45% energy)|Participants will reduce daily caloric intake to 45% of energy requirements (\~800 kcal/day)
223934628|NCT06814158|DRUG|Ivonescimab Combined With Chemotherapy|Ivonescimab 20mg/kg + CT Q3W, 3cycles
224097278|NCT06464211|BEHAVIORAL|Cognitive Behavioral Model-Based Family Counseling Program|A Cognitive Behavioral Model-Based Family Counseling Program is a therapeutic approach that focuses on identifying and changing negative thought patterns and behaviors within the family unit, using principles of cognitive-behavioral therapy to improve communication, resolve conflicts, and enhance overall family functioning.
224097279|NCT00146042|DRUG|Docetaxel|
224285905|NCT04997395|DRUG|MediCabilis Cannabis sativa 50|Already described
224285906|NCT00933881|OTHER|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
224285907|NCT03781024|COMBINATION_PRODUCT|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
224285908|NCT02695719|DRUG|Placebo|Lubiprostone placebo-matching capsules
224285909|NCT02695719|DRUG|Lubiprostone|Lubiprostone capsules
223533992|NCT02419495|DRUG|Fluorouracil|Given IV
223533993|NCT02419495|BIOLOGICAL|Ipilimumab|Given IV
223533994|NCT02419495|DRUG|Irinotecan Hydrochloride|Given IV
223533995|NCT02419495|DRUG|Leucovorin Calcium|Given IV
223533996|NCT02419495|BIOLOGICAL|Nivolumab|Given IV
223533997|NCT02419495|DRUG|Olaparib|Given PO
223533998|NCT02419495|DRUG|Oxaliplatin|Given IV
223533999|NCT02419495|DRUG|Paclitaxel|Given IV
223534000|NCT02419495|BIOLOGICAL|Pembrolizumab|Given IV
223534001|NCT02419495|DRUG|Pemetrexed|Given IV
223534002|NCT02419495|DRUG|Selinexor|Given PO
223534003|NCT02419495|DRUG|Topotecan|Given IV
223534004|NCT06421350|DEVICE|Spinal Cord Stimulation Device|The closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
223534005|NCT05261711|DRUG|AB1|This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
223534006|NCT06422247|DRUG|Systemic therapy|Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
223534007|NCT03409770|OTHER|Therapeutic hypothermia|Whole body cooling using a servo controlled device
223934629|NCT06729255|DEVICE|EpiZact-assisted epidural placement|The standard epidural kit used with the EpiZact device to place a midline epidural using the landmark technique between the L2 and L5 vertebral bodies. The patient's back will be sterilized with a 2% chlorhexidine/70% isopropyl alcohol applicator. The epidural will be placed with a 17-gauge 3.5-inch Tuohy needle. Once the Tuohy needle is appreciated to be engaged in ligament the EpiZact device will be filled with sterile and attached to the Tuohy via a Luer connector. The green button on the EpiZact device will then be pressed to prime the device. The EpiZact device and Tuohy needle will be advanced as a unit in continuous fashion or with intermittent advancement. Upon sensing a loss of resistance, the EpiZact device will provide a visual and tactile signal, halting needle advancement and signaling that the epidural catheter should be threaded through the Tuohy needle.
223934630|NCT06849518|DIAGNOSTIC_TEST|Circulogene liquid biopsy testing|A Circulogene liquid biopsy testing for plasma NGS ctDNA and plasma cfRNA PD-L1 expression.
223934631|NCT06384976|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
223934632|NCT06384976|DRUG|Standard lymphodepletion regimen|CYC/FLU
223934633|NCT06384976|DRUG|Anti-CD20 mAB|Anti-CD20 mAB
223934634|NCT06850740|DRUG|Ondansetron 8mg|Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)
223934635|NCT06850740|DRUG|Normal Saline|Patients will be managed by administering 100 ml of normal saline solution as placebo
223934636|NCT06811220|DRUG|Hespiridin and Diosmin|Daflon® (50 mg Hesperidin and Micronized purified flavonoid fraction (MPFF) 450 diosmin combination one film coated tablet)
223934637|NCT06855173|DEVICE|Active external rewarming device|Electrical heating blanket
223934638|NCT06855173|DEVICE|Active external rewarming device 2|Electrical heating blanket
224097280|NCT00146042|DRUG|Trastuzumab|
224097281|NCT00146042|PROCEDURE|Erythromycin Breath Test (ERMBT)|
223934639|NCT06855173|DEVICE|Active external rewarming device 3|Electric heating blanket
223934640|NCT06855173|DEVICE|Active external rewarming device 4|Electric heating blanket
223934641|NCT06842030|DIAGNOSTIC_TEST|Darwin OncoTarget and OncoTreat|Darwin OncoTarget and OncoTreat predict potential drugs with early markers of efficacy in early human clinical trials. Specifically, OncoTarget identifies high-affinity inhibitors of master regulator proteins, while OncoTreat identifies tumor-checkpoint module inhibitors that modulate the transcriptional activity of hyper-connected master regulators. These tests are now commercially available with Clinical Laboratory Improvement Amendments (CLIA) approval through Columbia Presbyterian Medical Center.
223934642|NCT06593392|DRUG|Difelikefalin|The study includes a screening period of up to 4 weeks (including a 7-day run-in period during the week prior to enrolment), a study treatment period of 12 weeks, and a safety follow-up visit at 7 (up to 10) days after EoT. Total study duration for a single participant is up to 17 to 18 weeks.
223934643|NCT06072703|DEVICE|Magstim Rapid2 System|"The Magstim Rapid2 system is the most commonly used magnetic stimulation system for rTMS clinical studies and therapeutic investigations, capable of selectively inducing, modulating or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS and a sham coil, The placebo coil looks identical to its active version and replicates pulse noise without producing the magnetic field necessary to modulate cortical neurons. Additionally, the investigators will be utilizing the StimGuide navigation system (currently available at the HMRI) to accurately target the proposed regions of interest.~The Magstim Rapid2 system is indicated to be used in Multiple Sclerosis patients as target users with lower urinary tract symptoms such as urinary frequency, urinary urgency, urinary incontinence and voiding dysfunction."
223934644|NCT05085886|BEHAVIORAL|DepCare|Primary Care Provider (1) One-time presentation or video with education and motivational messaging around collaborative care, functionality of the DepCare patient tool and optimal management of depression and comorbid anxiety (2) Quality improvement/ implementation team meetings on optimizing mental health treatment in primary care and DepCare (i.e., multi-level, multi-component intervention) implementation (3) Automatically-generated decisional support on individual patient treatment preferences (i.e., for every patient who receives the DepCare patient tool) Patient: Tool comprised of enhanced depression and anxiety screening (includes option for voice-over questions, point-and-click responses), and for those who screen positive for depressive symptoms (with or without comorbid anxiety), diagnosis recognition support, psycho-education, videos promoting patient engagement in treatment, and personalized medication selection support.
224097282|NCT04957173|OTHER|Lifestyle intervention|"The intervention includes a total of 17 virtual meetings and aims to achieve a weight loss of 0.8 to 1% of the initial weight per week.~This will include 3 successive phases:~1. A significant calorie restriction (A minimum deficit of 800 kcal / day of their daily energy expenditure) for a period of 4 weeks;~2. A moderate calorie restriction (minimum deficit of 500 kcal / day of their daily energy expenditure) for a period of 4 weeks;~3. A maintenance phase of weight loss for 16 weeks.~4. An optional phase of monthly follow-ups for a period of 3 months (no intervention)"
224097283|NCT04446208|PROCEDURE|Endoscopy|Endoscopic treatment will consist in placement of a metal stent in a patient with early fistula (\< 15 days) and/or a large fistula orifice, and no abscess, or double pigtail plastic stents if the fistula is older than 15 days and the orifice is small.
224285910|NCT00483548|DRUG|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
224285911|NCT00483548|DRUG|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
223534008|NCT05273567|DRUG|guanfacine-ER|guanfacine-er dispensed daily, starting at 1mg and increasing to 4mg/day or the maximum tolerated dose.
223534009|NCT05273567|OTHER|Placebo|placebo will be dispensed similar to the active arm.
223534010|NCT06640439|DEVICE|photobiomodulation|830 nm LED was used to irradiate the post-extraction area
223534011|NCT06640439|DRUG|Antibiotic|ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
223534012|NCT06535009|DRUG|ONO-7914|Specified dose on specified days
223534013|NCT06535009|DRUG|ONO-4538|Specified dose on specified days
223534014|NCT05965700|DRUG|NVG-291|A once daily injection
223534015|NCT05605249|DEVICE|Cue X|The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
223534016|NCT06975800|BEHAVIORAL|Low social feedback|Social information is provided to participants signaling that the upcoming trial will be low in negative affect and cognitive effort.
223534017|NCT06975800|BEHAVIORAL|High social feedback|Social information is provided to participants signaling that the upcoming trial will be high in negative affect and cognitive effort.
223534018|NCT03874559|DIAGNOSTIC_TEST|Blood Draw|Serum samples will be obtained from each patient enrolled
223934645|NCT05085886|BEHAVIORAL|Enhanced Usual Care|Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization
223934646|NCT06742060|DIAGNOSTIC_TEST|serum copeptin levels|For children who met the entry criteria, the blood samples were collected preoperatively (T0), 1h postoperatively (T1), 1 day postoperatively (T2), 2 days postoperatively (T3), 3 days postoperatively (T4), 4 days postoperatively (T5), 5 days postoperatively (T6) to test serum and peptide levels.
223718584|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation|A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
223934647|NCT06741982|BIOLOGICAL|Lysogenic HSV virus.|Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.
223934648|NCT06741982|DRUG|Tislelizumab|200mg IV Q3W
223934649|NCT06741982|DRUG|Afatinib|30mg PO QD
223934650|NCT06751277|DRUG|QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706|QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706
223934651|NCT06752564|BEHAVIORAL|Goal-Oriented Care Model|"The experimental group : Goal-Oriented Care (GOC) The concept of Goal-Oriented Care (GOC) was first introduced by Mold et al. in 1991, addressing the limitations of problem-oriented care, which focuses on eradicating diseases and preventing death. GOC is defined as a process of reaching a consensus on health-related goals between the healthcare team and the patient (Vermunt et al., 2017). It is based on patients' core values and priorities within a clinical context, guiding medical interventions and specific treatment decisions (Secunda et al., 2020).~Healthcare professionals using GOC aim to help patients achieve their maximum personal health potential, aligning care with individual goals. The clear direction provided by GOC fosters teamwork and interdisciplinary collaboration (Gray et al., 2020). When establishing long-term goals with patients, it is crucial to revisit and adjust these goals, considering realistic survival timelines, as time plays a vital role in goal-setting."
224097284|NCT02898012|DRUG|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
224097285|NCT02898012|DRUG|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage \> grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
223934652|NCT06752564|BEHAVIORAL|standard health education|The control group received standard health education. The content of the standard health education included verbal instructions provided by nurses during the general hospital stay, as well as the distribution of educational pamphlets. These instructions covered topics such as the frequency of dialysis and dietary control. The standard health education was generic, without a specific schedule or structured content.
223934653|NCT06751771|OTHER|comprehensive correcting exercise program|Group A will be treated with comprehensive correcting exercise program (three times a week for 6 weeks) into 3 phases with different intensity and frequency
224097286|NCT03883893|DRUG|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
224097287|NCT03883893|OTHER|Normal saline|Normal saline will given if randomized to this group.
224097288|NCT02635204|DRUG|DFD06 Cream|Twice daily topical application for 14 days.
223534019|NCT03314805|DRUG|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
223534020|NCT03314805|DRUG|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
223534021|NCT03314805|PROCEDURE|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
223534022|NCT04267445|PROCEDURE|Embolization of prostatic artery under ultrasound guidance|Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
223534023|NCT00860600|DRUG|PG2|500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
223534024|NCT01321580|DEVICE|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
223534025|NCT06220318|DRUG|C019199|The C019199 will be taken orally, once a day
223534026|NCT06220318|DRUG|Sintilimab|Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
223934654|NCT06751771|OTHER|McKenzie's method of exercises|Group B will receive the McKenzie's method of exercises that include Deep neck flexor (chin tucks), Shoulders shrug McKenzie exercise for neck, Repeated shoulder flexion/Extension, Neck flexion McKenzie exercises
223934655|NCT06766240|DEVICE|MRI on lumbosacral spine|MRI imaging on lumbosacral spine using Philips Achieva1.5T MRI device (Philips Achieva, Netherlands) or Siemens Magnetom Altea1.5T MRI device (Siemens Healthineers, Germany). the sequences used are Axial T2W; Sagittal T1W, T2W, Sagittal STIR, Coronal STIR and post gadolinium if needed.
223934656|NCT04566887|DRUG|Acalabrutinib|Administered as 100mg tablets.
223934657|NCT04566887|DRUG|R-CHOP chemotherapy|R-CHOP chemotherapy
223934658|NCT06855966|OTHER|250 ml crystalloid bolus infusion|In thoracic surgical setting, restrictive fluid replacement is widely accepted. However, goal directed fluid therapies can provide a more precise and tailored fluid replacement for each patient. Although ERAS protocols emphasize otherwise, patients still arrive in the operating room with certain deficite, due to prolonged fasting or advanced age. PLR is used as a reversible fluid challenge since the blood which is pooled in the lower extremities as well as splancnic area. End tidal carbon dioxide is monitorized at each patient per American Society of Anesthesia Guideline. In this study, we aimed to assess the feasibility of end tidal carbondioxide changes as a response to passive leg raise maneuer (PLR) for preload optimization in thoracic surgical practice.
223934659|NCT06753526|DRUG|NSAID|For 1st group of patients
223934660|NCT06753526|DRUG|L-Arginine, 500 Mg Oral Capsule|group 2by twice dose
223718585|NCT05777876|DEVICE|Sham stimulation|Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
223718586|NCT05777876|DEVICE|Motor cortex stimulation|Receive stimulation in the motor cortex stimulation instead of deep brain.
223934661|NCT06753526|DRUG|Tamsulosin 0.4 mg QD|group 3 by once per day
223934662|NCT06754436|BIOLOGICAL|Determination of blood drug concentration|Collecting blood samples from patients and determining blood drug concentrations. Patients were intravenously titrated after 3 doses of maintenance dose titration of L-AmB. The time points of sample collecting were 30 minutes before and 1, 2, 3, 6, 9, 12, 16, 20, 24 hours after administration. Then, the blood concentrations were determined according to the established method.
223934663|NCT06740513|PROCEDURE|Endovascular Treatment|Medical Therapy plus Stent/Balloon Angioplasty
223934664|NCT06789263|DIETARY_SUPPLEMENT|Collagen hydrolyzed peptides|Dissolved in flavoured water, single dose, 10 g
223934665|NCT06789263|OTHER|Placebo|Single dose
223934666|NCT06776354|BEHAVIORAL|GPT-based training|GPT-based training whether could improve the ability of students to develop effective hypertension management plans
223934667|NCT06776354|BEHAVIORAL|traditional training|traditional teaching methods
223934668|NCT06829225|DRUG|Tulisokibart|SC Injection or IV Infusion
223934669|NCT06829225|DRUG|Placebo|Tulisokibart-matched Placebo SC Injection or IV Infusion
223934670|NCT06770907|OTHER|Blood, stool and saliva collection|Blood, stool and saliva collection
223934671|NCT06770907|OTHER|Questionnaire completion|"Questionnaire on:~* Hospital Anxiety and Depression Score (HADS) for adults~* Total glucose and fructose and excess fructose, lactose, sorbitol, mannitol, oligosaccharides (Fructans and GOS) as measured by CNAQ questionnaire for adults and children~* Patient Health Questionnaire 12 (PHQ-12) Somatic Symptom scale"
223934672|NCT06770907|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) and Breath test|MRI scans and breath test samples collected after drink test with sucrose
223934673|NCT01855750|DRUG|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
223934674|NCT01855750|DRUG|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
223934675|NCT01855750|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223934676|NCT01855750|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223934677|NCT01855750|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223934678|NCT01855750|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223934679|NCT01855750|DRUG|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
223934680|NCT04300023|BEHAVIORAL|Social Cycling Group|engaged with a research staff member for 30 minutes of cycling
223934681|NCT04435756|OTHER|Biomarker Analysis|Correlative study
223934682|NCT04435756|PROCEDURE|Blood Product Collection|Undergo collection of blood
223718587|NCT05777876|DEVICE|non-invasive transcranial deep brain stimulation with closed-loop|Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
223934683|NCT05525572|DEVICE|Shockwave Therapy (SWT)|"Shockwave Therapy (SWT):~720 shocks will be administered administered in every session to each treated region (left and right corpora cavernosa and crura). Each session will last approximately 20 minutes. A total of 3600 shocks will be administered over 5 weekly sessions."
223934684|NCT05525572|DRUG|Autologous Platelet-Rich Plasma (PRP)|"Autologous Platelet Rich Plasma (PRP):~5 mL PRP will be administered via intra-cavernous penile injection with a 30 ± 7 day treatment interval."
223934685|NCT01181544|PROCEDURE|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
223934686|NCT06247254|BEHAVIORAL|Intensive Clinic Management|Blood pressure management at in-person follow-up visits occurring every 2 months when systolic blood pressures are at target (i.e., \< 130 mmHg), and monthly when systolic blood pressure is ≥ 130 mmHg. Participants will also receive low-touch health promotion messaging via text messaging, with reminders focused on medication adherence, healthy diet, and physical activity and a tailored Blood Pressure Care Plan for managing stroke recovery. Participants will be encouraged to monitor their blood pressure at home and record values in logs.
223934687|NCT06247254|BEHAVIORAL|Intensive Tailored Telehealth Management|Tailored Blood Pressure Care Plan and health coaching contracted through INTERVENT.
223934688|NCT06889103|OTHER|Observation|observation during eating
224097289|NCT02635204|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
224097290|NCT03534037|DRUG|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
224097291|NCT03534037|DRUG|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
224097292|NCT03534037|OTHER|Control|Dietary control only
224097293|NCT01535235|DRUG|Lisinopril|Lisinopril 20mg QD x 24 weeks
223534030|NCT03344705|BIOLOGICAL|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
223934689|NCT06726993|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty (TKA) is a common orthopaedic surgery that involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic
223534031|NCT03344705|DRUG|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
223534032|NCT03344705|DRUG|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
223718588|NCT06352203|DIETARY_SUPPLEMENT|Probiotic|1 dose of the probiotic every 24 hours, for 6-months.
223718589|NCT06352203|DIETARY_SUPPLEMENT|Placebo|1 dose of the placebo every 24 hours, for 6-months.
223718590|NCT02612662|DRUG|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
223934690|NCT06192615|DRUG|Intravenous Dexmedetomidine|Intravenous dexmedetomidine (1 μg/kg over 40 minutes, a maximal dose of 80 μg)
223934691|NCT06192615|DRUG|Sublingual Dexmedetomidine|Sublingual dexmedetomidine (120 μg)
223934692|NCT06192615|DRUG|Intravenous Placebo|Intravenous placebo of 0.9% saline administered over 40 minutes
223934693|NCT06192615|DRUG|Sublingual Placebo|Inert sublingual film
223934694|NCT04950764|DRUG|Seladelpar 10 mg|Seladelpar 10 mg single oral dose
223934695|NCT04950764|DRUG|Seladelpar 10 mg or less|Seladelpar 10 mg or less, once daily for 28 days
223934696|NCT06765538|OTHER|Video consultation|Preanaesthetic videoconsultation
223934697|NCT04081428|RADIATION|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
224097294|NCT01535235|DRUG|Placebo|Placebo QD x24wks
224097295|NCT00858832|DRUG|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
224097296|NCT01021111|DEVICE|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
224097297|NCT03853421|DRUG|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
224097298|NCT01796132|DRUG|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
224097299|NCT03717740|DRUG|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
224097300|NCT03717740|DRUG|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
224097301|NCT03475225|DRUG|Cholecalciferol|Cholecalciferol delivery
224097302|NCT03475225|DRUG|Placebo Oral|manufactured to mimic Cholecalciferol
224097303|NCT00416533|DRUG|docetaxel|
224097304|NCT00416533|DRUG|doxorubicin hydrochloride|
224097305|NCT00416533|DRUG|prednisone|
224097306|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
224097307|NCT00702676|DRUG|Quetiapine Fumarate|Tablet, Oral, once daily
224097308|NCT04800380|OTHER|Edpuzzle interactive videos|The effectiveness of the Edpuzzle application will be evaluated in developing the metric and drug dose calculation skills of first year nursing students.
223934698|NCT03404778|DEVICE|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
223934699|NCT06619600|DRUG|Dapagliflozin|Dapagliflozin 10 mg qd
223934700|NCT06619600|DRUG|Placebo|Matched placebo qd
223934701|NCT04040452|DRUG|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
223934702|NCT04077346|DEVICE|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
223934703|NCT04077346|OTHER|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
223934704|NCT03425682|OTHER|ViBone|Viable Bone Allograft
223934705|NCT03117946|OTHER|Biological samples|blood and tumor tissue sample
223934706|NCT05128513|DEVICE|DELP|The blood was pumped into the PCS2 plasma separator through one side of the forearm vein. The plasma was separated by pump and then sent to the DELP system (Shanghai Jiangxia Blood Technology Co.). After purification, the plasma was returned to the patient via another forearm vein. The total treatment plasma volume was 800-1,000 mL; the anticoagulant 4% sodium citrate dehydrate solution with a ratio of 1:16 to plasma, was dropped before pumping. To prevent hypocalcemia, 500 mg CaCl2 diluted with 250 mL physiological saline was infused at a rate of 150 mL/h, in the first cycle of the returning blood transfusion.
223934707|NCT03906292|DRUG|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
223934708|NCT03906292|DRUG|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
223934709|NCT03906292|DRUG|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
223934710|NCT03906292|DRUG|Asciminib|Asciminib 80 mg QD Monotherapy
223934711|NCT06768333|DIETARY_SUPPLEMENT|45 grams Voom Pocket Rocket Electro Energy|Participants will be required to consume 45 grams (in carbohydrates) of the Voom Pocket Rocket Electro Energy on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
223934712|NCT06768333|DIETARY_SUPPLEMENT|45 grams Maurten Gel 160|Participants will be required to consume 45 grams (in carbohydrates) of the Maurten Gel 160 on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
224097309|NCT03944837|OTHER|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
224097310|NCT00389207|DRUG|nevirapine bid|nevirapine twice daily
224097311|NCT00389207|DRUG|nevirapine qd|nevirapine once daily
224097312|NCT00389207|DRUG|atazanavir|atazanavir once daily
224097313|NCT03973814|DEVICE|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
224097314|NCT06349629|DEVICE|3D printed WE43 magnesium alloy|This 3D printed WE43 magnesium alloy has porous structure and suitable mechanical strength, can be stable in the bone support, and gradually degrade to promote bone healing.
224097315|NCT02970773|DRUG|Rivaroxaban Oral Tablet|oral application of Xarelto
224097316|NCT00584974|DRUG|SEP-225289|0.5 mg SEP-225289
223718591|NCT02612662|DRUG|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
223718592|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills|Mongolian Medicine ZhenBao Pills, orally, 15 pills each time, twice a day.
223718593|NCT06049498|DRUG|Mongolian Medicine ZhenBao Pills Placebo|Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
223718594|NCT03781115|DRUG|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
224097317|NCT00584974|DRUG|SEP-225289|2.0 mg SEP-225289
224097318|NCT00584974|DRUG|Venlafaxine|150 mg Venlafaxine
224097319|NCT00584974|DRUG|placebo|Placebo
223718595|NCT03781115|DRUG|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
223934713|NCT06768333|DIETARY_SUPPLEMENT|45 grams SIS Go Isotonic Energy Gel|Participants will be required to consume 45 grams (in carbohydrates) of the SIS Go Isotonic Energy Gel on one of the three experimental visits. Participants will have blood glucose, blood lactate, and electrolytes sampled throughout five 15-second repeated cycling intervals interspersed with 3 minutes active recovery. Gas exchange will also be monitored throughout the 1-hour study visit.
223934714|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype AA|Hemodialysis
223934715|NCT02377570|DEVICE|THERANOVA 400 dialyzer prototype BB|Hemodialysis
223934716|NCT02377570|DEVICE|THERNOVA 400 dialyzer prototype CC|Hemodialysis
223934717|NCT02377570|DEVICE|FX CorDiax 80 dialyzer|Hemodialysis
223934718|NCT06659055|RADIATION|DXA Imaging|DXA imaging: lumbar spine, bi-lateral femoral necks
223934719|NCT06659055|RADIATION|EOSedge imaging|Full body or full spine image
223934720|NCT05637970|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
223934721|NCT05637970|DEVICE|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
223934722|NCT05668819|DEVICE|TH-001|TH001 is a software program intended to treat adults with prediabetes.
223934723|NCT06044324|DEVICE|Repetitive Transcranial Magnetic Stimulation|"Participants in the active stimulation group will receive the high frequency rTMS to left middle temporal visual area. The left middle temporal visual area will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 100% of RMT.~Stimulation will be delivered to the left middle temporal visual area using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
223718596|NCT03781115|DRUG|Placebo Comparator|A non drug oral placebo capsule will be given as a control
223718597|NCT05525208|BIOLOGICAL|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
223934724|NCT06837441|PROCEDURE|Atrial Fibrillation Termination|Pursuing Atrial Fibrillation Termination as a Procedural Endpoint
223934725|NCT06837441|PROCEDURE|Prespecified Ablation|Prespecified Ablation Strategy Followed by Cardioversion
223934726|NCT04015700|BIOLOGICAL|Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.
223934727|NCT04015700|DEVICE|CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
223934728|NCT04015700|DRUG|Plasmid encoded IL-12|The INO-9012 vials will be supplied by Geneos Therapeutics
223934729|NCT06750744|RADIATION|chest x ray|chest X ray identify severity of pneumonia
223934730|NCT06750744|RADIATION|chest X ray|chest radiological evaluation via x ray
223934731|NCT06750744|DRUG|Tigecycline (Tygacil)|selective antibiogram
223934732|NCT06391853|DRUG|Insulin|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
223934733|NCT06391853|DRUG|Placebo|"A venous line will be installed and an MRI-compatible EEG Cap (32 scalp electrodes) will be installed with conductive gel between the scalp and the electrode.~Participants will receive 2 Intranasal spray. Participants will then be installed in the PET/MRI camera. At 30 min post INI administration, a continuous infusion of FDG will be started, along with dynamic PET acquisition while recording EEG and fMRI sequences. Participant will be asked to rest, eyes opened and awake to stay awake during the 55 minutes.~At the end of the neuroimaging data acquisition, participants will be freed from EEG Cap and will undergo neuropsychologic evaluation.The final part of neuropsychological evaluation will be performed on week later, on the phone.. The total study time for each scanning day will be around 3h."
223534033|NCT05721079|DEVICE|ECP (Extracorporeal Photopheresis System)|Patients who are assigned to the ECP group receive treatments by means of the THERAKOS ® CELLEX ® Photopheresis System (Mallinckrodt Pharmaceuticals Inc.) with either double- or single-needle access. During the leukapheretic processing, 1500 ml of whole blood is processed, and peripheral blood mononuclear cells (MCNs) are separated by centrifugation and collected in the buffy coat. 8-methoxypsoralen (Uvadex®, Mallinckrodt Pharmaceuticals Inc.) at a dose of 20 μg/ml is added to the MNC collection bag and cells are irradiated with ultraviolet A light (1.5 J/cm2) in a 1-mm-thick film through a photoactivation plate. After exposure of the cells to the ultraviolet light, the buffy coat is reinfused into the patient.
223934734|NCT06303687|OTHER|VR-PAT|Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
224097320|NCT05026775|BEHAVIORAL|Initial Medication Adherence (IMA)|"The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals."
224097321|NCT05026775|OTHER|Usual care|Health professionals in the usual care group will prescribe medication and provide information as usual.
224097322|NCT02085811|OTHER|radiography standard|
224097323|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
224097324|NCT05227729|DIAGNOSTIC_TEST|Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique|While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
224097325|NCT02421874|BEHAVIORAL|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
224097326|NCT02421874|BEHAVIORAL|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
224097327|NCT04067336|DRUG|Ziftomenib|Oral administration
224097328|NCT04067336|DRUG|Midazolam|Oral administration
224097329|NCT04067336|DRUG|Itraconazole|Oral administration
224097330|NCT05241587|OTHER|Gum Group:|"Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010)."
223718598|NCT05525208|BIOLOGICAL|Active Comparator|The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).
223718599|NCT06636786|DRUG|Cyclobenzaprine HCl|TNX-102 SL (cyclobenzaprine HCl sublingual tablets) taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
223934737|NCT06734247|DIAGNOSTIC_TEST|Coronary computer tomography angiography (CCTA)|Use of standard equipment for usual care
223934738|NCT06734247|OTHER|Photoplethysmography (PPG) and single-lead ECG|Physiological data acquisition equipment
223934739|NCT06734247|DEVICE|Brachial single cuff-based arterial stiffness|Use of standard equipment
224097331|NCT05241587|OTHER|Mouth Spray Group:|"Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request."
224097332|NCT03394495|OTHER|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
224097333|NCT03232307|DRUG|Dexamethasone|Given PO
224097334|NCT03232307|DRUG|Ibrutinib|Given PO
224097335|NCT03232307|DRUG|Lenalidomide|Given PO
224097336|NCT03232307|BIOLOGICAL|Rituximab|Given IV
224097337|NCT01296906|BEHAVIORAL|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
224097338|NCT01296906|BEHAVIORAL|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
224097339|NCT01644877|DRUG|DAS181 dry powder, formulation F02|
224097340|NCT01644877|DRUG|Lactose Placebo|
224097341|NCT02366962|BIOLOGICAL|ASP7374|subcutaneous
224097342|NCT06213571|OTHER|Exercise Counseling|Participate in exercise coaching sessions
224097343|NCT06213571|OTHER|Exercise Intervention|Participate in home-based exercise program
223934740|NCT06854705|OTHER|Continuity of Midwifery care model|The intervention group will receive a continuity of midwifery care model organized by a team of qualified midwives. In this model, antenatal, intrapartum, and postnatal care will be provided by a named (or primary) midwife, who works within a small team (4-8) of CoMC midwives to their cohort of women and will refer or consult an obstetrician in case of complications that requires specialized care. Each named midwife will be backed up by a partner midwife and other team colleagues. The CoMC team comprises 8 whole-time equivalent midwives, including an experienced senior midwife, who leads the team. Following a training needs assessment by the team leader, midwives will receive specialist training, provided by a team of clinical experts and educators, on how to work in midwife continuity models. Pregnant women receive their entire antenatal, intrapartum, and postnatal care from one of the participating CoMC midwives.
224097344|NCT06213571|OTHER|Health Promotion and Education|Receive resistance band and exercise booklets
224097345|NCT06213571|OTHER|Interview|Ancillary studies
224097346|NCT06213571|OTHER|Physical Performance Testing|Ancillary studies
224097347|NCT06213571|OTHER|Questionnaire Administration|Ancillary studies
224097348|NCT06213571|OTHER|Telemedicine|Participate in sessions remotely
224097349|NCT01220219|DRUG|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
224097350|NCT01220219|DRUG|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
223534034|NCT06245655|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS 7000 digital TENS unit, a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
223534035|NCT00561379|DRUG|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
223534036|NCT00561379|DRUG|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
224097351|NCT01220219|DRUG|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
224097352|NCT03792503|DRUG|Apatinib|Apatinib 500 mg Po qd
224097353|NCT03792503|DRUG|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
224097354|NCT01794780|DRUG|LABA based treatment: indacaterol|LABA based treatment: indacaterol
224097355|NCT01794780|DRUG|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
224097356|NCT01794780|DRUG|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
224097357|NCT01794780|DRUG|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
224097358|NCT01794780|DRUG|theophylline based treatment|theophylline based treatment
224097359|NCT01794780|DRUG|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
224097360|NCT04462237|PROCEDURE|Root coverage procedures|Treatment of multiple adjacent gingival recession using a coronally advanced flap
223534037|NCT06080204|DRUG|Octreotide LAR|Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
223534038|NCT04941885|DRUG|Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI|Each participant receives Inetetamab plus cyclophosphamide metronomic chemotherapy plus AI.
223534039|NCT03240328|BIOLOGICAL|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
223534040|NCT02458118|DRUG|Secretin|Secretin 1 IU/kg over 3 min
223534041|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Verum Tablets"|The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
223534042|NCT05757050|DIETARY_SUPPLEMENT|"Re-Focus Placebo Tablets"|The placebo will be a matched control.
223534043|NCT06068192|OTHER|no intervention|no intervention
223534044|NCT05150626|DRUG|DBPR108 tablets|Drug: DBPR108, tablets, oral
223534045|NCT06530459|DRUG|Menopausal hormone therapy|Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily Ingest Micronized Progesterone 200mg daily for 12 days each month
223718600|NCT06636786|DRUG|Placebo|Placebo sublingual tablets taken sublingually (under the tongue) in the ED and each day at bedtime for a total of 2 weeks.
224097361|NCT05077514|BEHAVIORAL|Experimental: Cognitive Behavior Therapy|Participants assigned to Group A were asked to participate in a talking session with a psychologist regarding thoughts about treatment. This session is designed to explore thoughts about behavioral health therapy for suicidality. The session was administered by phone, initially and again one month later. Participants discussed current functioning and their thoughts about seeking help with the goal of modifying thoughts about treatment. This phone session lasted approximately 45 to 60 minutes.
224097362|NCT05077514|BEHAVIORAL|Active comparator: National Crisis Line|Participants assigned to Group B received information about the VA's National Crisis Line.
224097363|NCT02803216|DRUG|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
224097364|NCT02803216|DRUG|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
224097365|NCT02803216|DRUG|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
224097366|NCT04814537|DRUG|Bupivacaine Hydrochloride|Local Anesthetic Agent
224097367|NCT03545243|DRUG|Pantoprazole 40mg|Peroral Pantoprazole 40mg once daily during 28 days
224097368|NCT03545243|OTHER|PPI withdrawal|PPI withdrawal for 8 weeks
224097369|NCT05059132|BEHAVIORAL|Tele-rehabilitation|The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.
223534046|NCT06530459|BEHAVIORAL|Exercise training|Exercises would focus on upper and lower body strength generally. It is anticipated that the participants ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week.
223934741|NCT06854705|OTHER|Standard care model|Pregnant women who receive antenatal, intrapartum, and postnatal care following standard practice in Ethiopia will be assigned to the control group. An established practice followed the shared model of care in which responsibility is shared among different staff members, including midwives, nurses, health officers, and medical doctors. Midwives and other health care providers worked conventional eight-hour shifts and handed over care to the next health care provider coming on duty during the next shift. In this model of care, each unit of care had its staff working independently. Besides, the health care provider assigned to the postnatal ward will be responsible for immediate postnatal care. After discharge, each woman in this group become the responsibility of a different group of healthcare providers (usually midwives or nurses) in the family planning and immunization room.
223934742|NCT05551754|DIETARY_SUPPLEMENT|Ketone Supplement|Drink a single dose of ketone supplement 25g
223934743|NCT05551754|OTHER|Alcohol Beverage|Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
223934744|NCT06817187|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Administer 0.5ml of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) separately at different locations upon enrollment. Both vaccine were immunized according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
223934745|NCT06817187|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Vaccination with 15-Valent Pneumococcal Conjugate Vaccine with a 7-day interval (+15 day window period) followed by vaccination with Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed). Both vaccine were immunized according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
223934746|NCT06817187|BIOLOGICAL|Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)|Only administer the Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed) and according to the 0, 1, and 2 month procedures (calculated as 30 days per month).
223934747|NCT05332093|DIAGNOSTIC_TEST|skin biopsy|4mm skin biopsy
223934748|NCT05332093|DIAGNOSTIC_TEST|venous blood sample (plasma, PBMC, WB)|venous blood sample to acquire plasma, PBMCs and whole blood
223934749|NCT05332093|GENETIC|venous blood sample (HLA)|venous blood sample used for HLA typing
223934750|NCT05332093|GENETIC|skin slit|genome sequencing of parasite DNA that is extracted from the skin slit
223934751|NCT02331979|DEVICE|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
223934752|NCT06098118|BEHAVIORAL|MyMammogram decision aid|An online breast cancer screening decision aid that includes personalized risk assessment, information on benefits and risks of mammography screening, values clarification, outcome expectancies, and a summative document with participant responses.
223934753|NCT06828614|DRUG|Chemotherapy|"The present approved ethics committee includes the conduct of two studies. In the first one, a cross-sectional study, breast cancer patients will be distributed in the study groups according to the moment of their chemotherapy treatment (group 1: pre-chemotherapy, group 2: during chemotherapy, group 3: post-chemotherapy). Each patient will undergo a single evaluation session, which will include the variables detailed in the following section.~In the second, a longitudinal study, patients from the previous study in group 1 (pre-chemotherapy) will be followed up. Patients will receive three assessments of the variables detailed in the following section: 1) during the time prior to the start of chemotherapy (assessment that will coincide with study 1), 2) assessment during chemotherapy treatment and, 3) assessment after the end of chemotherapy treatment."
223934754|NCT06822114|DRUG|Methoxyethyl Etomidate Hydrochloride|The dose is 50 μCi/48 mg，in the fasting state, a single intravenous injection was given slowly
223934755|NCT04046692|OTHER|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
223934756|NCT04046692|OTHER|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
223934757|NCT04046692|OTHER|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
223934758|NCT04046692|OTHER|Hospital School Experience, point of view of parents|Operators interview parents
224097370|NCT05059132|OTHER|Education only|The education only arm will receive information on the importance of general exercise following lung cancer treatment.
223534047|NCT06530459|COMBINATION_PRODUCT|Menopausal hormone therapy + exercise training|"1. Apply 17 beta-Estradiol topical gel (1.25-2.5 gms) daily and Ingest Micronized Progesterone 200mg daily for 12 days each month~2. Exercises would focus on upper and lower body strength generally. It is anticipated that patients ideally should exercise at least 3 times per week based on the strength training prescription. They could potentially exercise everyday, alternating between upper and lower body strength training. In all, there are up to 1-2 in-person therapy sessions and home sessions at least 3 times per week."
223534048|NCT03713801|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
224097371|NCT05696340|OTHER|semi-structured interview|"Subjects will be recruited in a purposive, non-randomized manner. Data will be collected to obtain a sufficient diversity of perspectives on the topic, while maintaining sufficient homogeneity for analysis.~The number of participants cannot be determined in advance; it will be determined after data saturation."
224097372|NCT03527043|DRUG|Escitalopram|10mg by mouth daily for 6 weeks
224097373|NCT03527043|OTHER|Placebo|matched placebo control by mouth for 6 weeks
223534049|NCT03713801|DRUG|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
223934759|NCT03054831|DRUG|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
223934760|NCT03436992|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
223934761|NCT03436992|DIETARY_SUPPLEMENT|Resveratrol|1500 mg trans-resveratrol
223934762|NCT03436992|OTHER|Placebo|placebo
223934763|NCT06812130|OTHER|This is a non-interventional study.|This is a non-interventional study.
223934764|NCT02778425|PROCEDURE|Endoscopic therapy+ beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.
223934765|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE+beta blockers|Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (propranolol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
223934766|NCT02778425|PROCEDURE|beta blockers|A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
223934767|NCT02778425|PROCEDURE|Endoscopic therapy|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
223934768|NCT02778425|PROCEDURE|Endoscopic therapy+ PSE|Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
223934769|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).
223934770|NCT02778425|PROCEDURE|Somatostatin+Endoscopic therapy+PSE|The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
223934771|NCT05902325|DRUG|Mepolizumab 100 MG Injection|Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
224097374|NCT00668005|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
224097375|NCT00668005|DRUG|Placebo|Matching placebo
224285912|NCT01998386|OTHER|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
223534050|NCT02625779|DRUG|Valproate and Placebo|
223534051|NCT02625779|DRUG|Valproate and Cytidine-containing Drug|
223534052|NCT02625779|DRUG|Valproate and Creatine-containing Drug|
223534053|NCT01296165|BEHAVIORAL|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value \<0.05 will be deemed to represent statistical significance.
223534054|NCT06109727|DEVICE|cerebellar transcranial electrical stimulation|Cerebellar transcranial electrical stimulation - 20 mA - 20 min
223534055|NCT03202173|DIAGNOSTIC_TEST|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
224097376|NCT05328947|OTHER|Modified Functional Reach and Functional Reach|Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.
224097377|NCT03120143|OTHER|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
224285913|NCT01998386|OTHER|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
224285914|NCT01998386|OTHER|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
224285915|NCT01998386|OTHER|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
224097378|NCT03120143|OTHER|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
224285916|NCT04904016|DEVICE|FlowOx™|The FlowOx™ system generates a negative oscillating pressure which cause rapid fluctuations in blood flow in the leg and foot.
224285917|NCT02418117|OTHER|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
224285918|NCT02980302|PROCEDURE|Cutaneous biopsy|Under local anesthesia
224285919|NCT00006108|BIOLOGICAL|trastuzumab|
224285920|NCT00006108|DRUG|capecitabine|
224285921|NCT00006108|DRUG|paclitaxel|
224285922|NCT00705120|OTHER|Bone Marrow Cell Transplantation|
224285923|NCT00705120|RADIATION|Irradiation, Total Body|
223934772|NCT06239896|BEHAVIORAL|Facilitated Group ACP Session|Group Facilitators will adhere to the standardized scripts and protocols to engage participants in ACP through group sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
224097379|NCT04697225|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to increase physical activity, decrease caloric intake, monitor their weight, and track the related behaviors and progress.
224097380|NCT04697225|BEHAVIORAL|weight loss coaching sessions and email support|Participants will receive weekly coaching sessions and tailored support emails.
224097381|NCT05220150|DEVICE|FFC-MRI scan|Undergo one FFC-MRI scan.
224097382|NCT02120417|DRUG|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
224097383|NCT02120417|DRUG|Capecitabine|Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
224097384|NCT02120417|DRUG|Placebo|5 mg matching placebo tablets to be administered by mouth
224285924|NCT00705120|DRUG|Cyclophosphamide|
224285925|NCT00705120|DRUG|Cyclosporin|
224285926|NCT00705120|PROCEDURE|Mesenchymal Stem Cell Transplantation|
224285927|NCT00705120|DRUG|Busulfan|
224285928|NCT00126126|OTHER|EBAR Program|Evidence Based Amputee Rehabilitation Program
224285929|NCT00002351|DRUG|Indinavir sulfate|
224285930|NCT01435447|DRUG|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
224097385|NCT02286102|DEVICE|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
224097386|NCT02286102|DEVICE|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
224097387|NCT04541069|BEHAVIORAL|Social Communication and Emotional Skill Development (SCESD) module|The intervention, Social Communication and Emotional Skill Development (SCESD) module, is based on the basics of the neuroscience of child development. The module has focused on these basic behaviors of infants, and has incorporated strategies to enhance the five basic behaviors i.e. eye contact, attention to others, joint attention, imitation and non-verbal communication.
224097388|NCT02448550|DRUG|Bivalirudin|
224097389|NCT02448550|DRUG|Unfractionated heparin|
224285931|NCT06082297|DEVICE|Chattanooga Physio, DJO, neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) was applied with a device called Chattanooga Physio (DJO), testing 10 different combinations of parameter-settings. The parameter-settings that were varied and combined were frequency (1Hz and 36Hz) and plateau times (0.5s, 1.5s, 3s, 5s, 7s). The NMES was applied to the calf of the participants via transversally placed textile electrodes (3x3 cm) integrated in a sock starting with very low current amplitude followed by gradual small increases in current amplitude until induction of ankle plantar flexion, at which time-point the outcomes where measured.
223934773|NCT06239896|BEHAVIORAL|Facilitated one-on-one ACP visits|Facilitator adheres to the scripts and protocols to engage participants in advance care planning through one-on-one ACP sessions. Participants will view the movie version of the PREPARE program (about how to choose a medical decision maker and how to decide what matters most in life), including a new PSH-specific video. Participants are provided with a workbook that they can use to follow along with the movies. They are also provide the PREPARE easy-to-read advance directive legal forms that they can fill out when they are ready. These forms include new PSH-specific content and a PSH-specific cover letter.
223934774|NCT04180267|DEVICE|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
224097390|NCT03114761|RADIATION|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
224097391|NCT05400460|PROCEDURE|Anatomical single-bundle reconstruction（ASBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the ASBR group to receive anatomic single-bundle reconstruction.We used hamstring as an autograft in the operation, and we chose the anatomical footprint of the anterior cruciate ligament for the positioning of the bone tunnel.Arthroscopic ASB ACL reconstruction was conducted with AMP technique.
224097392|NCT05400460|PROCEDURE|Double-bundle reconstruction （DBR method）|406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to the DBR group to receive double bundle reconstruction.The hamstring autograft is still used for double-bundle reconstruction. The surgical approach is to treat the native ligaments as anteromedial bundles and posterolateral bundles and restore the structure of the two bundles of ligaments in the process of a
224285932|NCT02682186|DRUG|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
224097393|NCT05400460|PROCEDURE|Central axial single-bundle reconstruction（CASBR group）|"406 people were enrolled in the outpatient clinic, after screening for inclusion and exclusion. Of the remaining 243 patients who participated in this RCT, 81 were randomly assigned to CASBR group.Arthroscopic ASB ACL reconstruction was conducted with transtibial technique and using Hamstring as autograft.Single-bundle reconstruction is used in CASBR reconstruction surgery.~The footprint of the implant on the lateral femoral condyle was chosen to be the location of the AMB bone canal in DB reconstruction surgery while the footprint of the implant on the tibial plateau was chosen to be the location of the bone canal of the PLB in DB reconstruction surgery."
224285933|NCT02343757|DEVICE|PET/MRI|
224285934|NCT02339610|DEVICE|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
224285935|NCT00685490|PROCEDURE|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
224285936|NCT06063096|DIETARY_SUPPLEMENT|D-allulose|Fruit-flavoured drink with d-allulose at 2 dosages
224285937|NCT06063096|DIETARY_SUPPLEMENT|Placebo|Fruit-flavoured drink with high fructose corn syrup
224285938|NCT01389934|DRUG|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
224285939|NCT01389934|DRUG|Placebo|Women of this group be infused saline 2 ml / h for 48h.
224285940|NCT00567736|DRUG|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
223934775|NCT05439850|PROCEDURE|arthroscopic rotator cuff repair|This procedure is the standard of care for rotator cuff tears who fail conservative treatment options.
223934776|NCT05439850|BIOLOGICAL|Bioinductive implant|A bioinductive implant that is designed to promote healing of the torn rotator cuff tendon after surgery.
223934777|NCT05439850|DIAGNOSTIC_TEST|Ultrasound Imaging|An ultrasound will be performed on each patient one year postoperatively.
223934778|NCT06826872|DRUG|SPC 1001 Mid2|low-dose combination therapy
223934779|NCT06826872|DRUG|SPC 2002|low-dose combination therapy
223934780|NCT06826872|DRUG|SPC 2003|low-dose combination therapy
223718601|NCT03502239|OTHER|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
223934781|NCT06826872|DRUG|SPC 2004|low-dose combination therapy
223934782|NCT06821217|DEVICE|NALU Endo Flow App|NALU Endo Flow App is a mobile application for women with endometriosis. The App provides educational information through videos, audios, and texts. Women learn about endometriosis in general with its symptoms, diagnosis, and therapy options such as lifestyle and mindset modification, endometriosis-specific diets, physical and mindfulness exercises. The App includes a diary to track the menstrual cycle and symptoms. Furthermore, access to a WhatsApp community of people with endometriosis is provided and a peer-group call is performed once monthly, as well as one additional monthly Q\&A (Question\&Answer) call moderated by certified health coaches.
223934783|NCT06823063|BIOLOGICAL|MSC|a single injection dose i.v.
223934784|NCT06757296|PROCEDURE|Endoscopic SASI|Endoscopic conversion to sleeve gastrectomy to SASI
223934785|NCT06831214|OTHER|(pericardial) collagen membrane|bone gain following composite graft rehabilitation of horizontal maxilla atrophy with sausage technique utilizing (pericardial) collagen membrane
223934786|NCT06831214|OTHER|periosteal Membrane harvested from anterior iliac bone|The choice of comparators in clinical studies involving guided bone regeneration (GBR) often includes both nonresorbable and resorbable membranes. Resorbable membranes have demonstrated better soft tissue compatibility compared to nonresorbable options, making them a preferred choice in many cases. For instance, studies have shown that using an organic bovine bone-derived mineral (ABBM) in conjunction with a rapidly resorbing natural collagen membrane is effective for horizontal ridge augmentation, as evidenced by positive histologic outcomes.
223934787|NCT06829134|PROCEDURE|laparoscopic renal artery perivascular nerve blockade|"1. When only the main renal artery is present: The complete dissection of the renal artery should be performed in the distal 2/3 portion, close to the renal hilum. The connective tissue and nerve tissue within a 1 cm radius from the center of the renal artery lumen must be completely separated (using instruments such as an ultrasonic scalpel or monopolar hook, etc.). The length of the dissected renal artery should be at least 0.5 cm, forming a dissection ring.~2. When accessory renal arteries are present: In addition to the main renal artery meeting the aforementioned standards, the accessory renal arteries must also be dissected. The radius of the dissection ring should be 0.7 cm, with a length ranging from 0.3 to 0.5 cm.~3. When renal polar arteries are present: Dissection may be performed appropriately based on the surgical conditions.~4. The prerequisite is to ensure the safety of the surgery, specifically the safe resection of the primary lesion."
223934788|NCT06829134|PROCEDURE|surgery related to the primary disease|The surgeries related to the primary disease include laparoscopic partial nephrectomy, laparoscopic adrenalectomy, and other similar procedures.
223934789|NCT06763926|DRUG|Subcutaneous Triptorelin|"Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection."
223934790|NCT06763926|DRUG|Intranasal nafarelin|"Oocyte donors will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. Specifically, on day 1 or 2 of the menstrual cycle, a transvaginal ultrasound will be performed to check the antral follicle count (AFC) and the absence of follicles \>10mm. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.~Once 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.~In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection."
223934791|NCT05843786|DRUG|Interferon gamma|Daily subcutaneous administration of Interferon gamma during 5 days
223934792|NCT05843786|DRUG|Placebo|Placebo during 5 days
223934793|NCT05124041|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
223934794|NCT06320041|DRUG|Low dose oxelidine group|Analgesic dose
223934795|NCT06320041|DRUG|High dose oxelidine group|Analgesic dose
223934796|NCT06320041|DRUG|Hydromorphone group|Analgesic dose
223934797|NCT06531018|DRUG|Eltrombopag 25 MG|Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
224097394|NCT05400460|OTHER|rehabilitation training protocol|The rehabilitation program for all patients followed a standardized Process. The first day after surgery, quadriceps sets, straight-leg raises, and prone hangs were initiated. All of the patients were allowed to walk with crutches and braces but with no weightbearing. The range of motion (ROM) progressed from 0 to 90 degrees 3 to 7 days postoperatively and reached 115 degrees within fourth week. Closed kinetic chain exercises and full weightbearing were started in the sixth week. Patients progressed to running without braces at 4 to 6 months.
224097395|NCT05400460|OTHER|Educate patients on return to sports and the importance of quadriceps strength|"Patients were interviewed by telephone preoperatively, 6 months postoperatively, and 1 year postoperatively to ask about Tegner scores and to encourage reasonable return to sports from 6 months postoperatively.~Inform patients of the possibility of osteoarthritis in patients undergoing ACL reconstruction preoperatively, 6 months postoperatively, and 1 year postoperatively in telephone interviews.Tell the patient that return to sports and quadriceps strength is a must if the knee cartilage damage is to improve."
224285941|NCT00567736|DRUG|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
224285942|NCT01173913|DRUG|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
223934798|NCT06531018|DRUG|Prednisolone|Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
223718602|NCT04895722|BIOLOGICAL|Pembrolizumab|400 mg or 200 mg pembrolizumab administered via IV infusion.
223934799|NCT03227861|DRUG|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
223934800|NCT06065800|DEVICE|STEELEX® Sternum Set|Sternal Closure with stainless steel suture (STEELEX®) in patients undergoing cardiac surgery
224097396|NCT05215522|DEVICE|The BCI-FES Intervention|To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
224097397|NCT01962142|OTHER|Assessment of activity capacities|
224097398|NCT02822365|PROCEDURE|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
224097399|NCT02822365|DEVICE|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
224097400|NCT02822365|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
224097401|NCT05695547|OTHER|VR educational video|Patients will be educated with our specifically made VR video in the settings of our hospital to make patients more familliar with the spaces and to explain them the procedure.
224097402|NCT00615537|PROCEDURE|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
223718603|NCT04895722|BIOLOGICAL|Pembrolizumab/Quavonlimab|Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
223934801|NCT03078010|DRUG|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
224097403|NCT05387655|BIOLOGICAL|BCG|BCG vaccination
224097404|NCT05387655|BIOLOGICAL|Placebo vaccine|Placebo vaccination
224097405|NCT05493514|DEVICE|Robotic Assisted Gait Training with G-EO system|Robotic-assisted gait training is a rehabilitation treatment that applies robotic technologies to improve mobility of patients with stroke or other neurological disorders. In this study, participants will use the G-EO system robotic device according to the daily clinical practice of the Don Gnocchi Foundation.
224097406|NCT03411343|PROCEDURE|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
223718604|NCT04895722|BIOLOGICAL|Pembrolizumab/Favezelimab|Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
223718605|NCT04895722|BIOLOGICAL|Pembrolizumab/Vibostolimab|Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
223718606|NCT04895722|BIOLOGICAL|MK-4830|800 mg MK-4830 administered via IV infusion
223718607|NCT06642571|DRUG|NNC0519-0130 B|NNC0519-0130 B will be administered subcutaneously.
223718608|NCT06642571|DRUG|NNC0519-0130 C|NNC0519-0130 C will be administered subcutaneously.
223934802|NCT03078010|DRUG|cefepime|(2 gm IV q 8 hrs)
223934803|NCT06793735|DEVICE|Telerehabilitation with Virtual Reality|Participants assigned to the experimental group will engage in a six-week telerehabilitation program utilizing two non-immersive Virtual Reality (VR) applications, NeuroNation and The Sims Mobile. These apps are designed to enhance cognitive performance and social cognition skills through interactive and scientifically validated exercises. NeuroNation focuses on improving memory, attention, reasoning speed, and mental flexibility, while The Sims Mobile engages participants in realistic social scenarios that challenge their empathy, communication, and problem-solving abilities. The intervention involves three 30-minute sessions per week, which participants will complete remotely using smartphones or tablets. Therapists will provide weekly virtual check-ins to monitor progress, address questions, and ensure adherence to the protocol. This program aims to create an engaging and accessible rehabilitation experience while promoting real-life application of cognitive and social skills improv
224097407|NCT03411343|PROCEDURE|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
223718609|NCT00003479|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
223718610|NCT04538261|DEVICE|Fetal Pillow insertion|Inflation of balloon device used to elevate fetal buttocks prior to performing external cephalic version procedure
223934804|NCT06793735|OTHER|Traditional Cognitive Rehabilitation|Participants in the control group will follow a traditional rehabilitation protocol that relies on paper-based cognitive exercises. This program targets cognitive domains such as attention, memory, and executive functions through tasks like puzzles, memory challenges, and problem-solving activities. The intervention also spans six weeks, with participants completing three 30-minute sessions per week. During an initial session, participants will receive all necessary materials and instructions for completing the exercises independently at home. Therapists will provide weekly remote support via phone or video to track progress and address any concerns. This conventional approach serves as a baseline for comparison with the innovative telerehabilitation method in the experimental group.
223934805|NCT06358612|OTHER|Stress Balls|Patients in the experimental arm will receive a foam stress ball to squeeze during their biopsy procedure.
224097408|NCT02626377|BEHAVIORAL|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
224097409|NCT02626377|OTHER|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
224097410|NCT04763525|BEHAVIORAL|Pythagorean Self-Awareness Intervention(PSAI)|The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
223534056|NCT05913674|DRUG|Modified early post-operative intraperitoneal chemotherapy (mEPIC)|"On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2."
223534057|NCT02565459|BIOLOGICAL|Mesenchymal Stromal Cells|
223534058|NCT05137158|DEVICE|Intermittent theta burst stimulation|Intermittent theta burst stimulation(iTBS) on the left DLPFC, the left DLPFC will be targeted utilizing the localite neuronavigation system. The stimulation intensity is set at 80% of resting motor threshold(RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 600 pulses per session, total duration of 3 minutes and 20 seconds.
223534059|NCT05137158|DEVICE|Sham stimulation|The same procedure will be performed in sham group including the RMT assessment and the neuronavigation system for target localization, but the sham coil will vertical to the brain surface and deliver a very slight magnetic field, which have the same appearance and sound, and provide the same tactile sensations as the active coils.
223534060|NCT02993263|DEVICE|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
223934806|NCT06765278|OTHER|Interscalene brachial plexus block|Patients will receive an Interscalene brachial plexus block.
223934807|NCT06765278|OTHER|Anterior glenoid nerve block|Patients will receive an anterior glenoid nerve block.
224097411|NCT01368068|DRUG|Tibolone|2.5mg/oral/daily
224097412|NCT01368068|DRUG|Escitalopram|10mg/oral/daily
224097413|NCT01368068|DRUG|Natvia|serving size: 0.09g per tablet
224097414|NCT01420575|BEHAVIORAL|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
223534061|NCT06565143|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation tool that alters cortical excitability and activity via application of weak alternating currents.
223534062|NCT06565143|DEVICE|Sham transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
223934808|NCT06765278|OTHER|Pericapsular nerve group block|Patients will receive a pericapsular nerve group (PENG) block.
224097415|NCT01420575|BEHAVIORAL|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
223934809|NCT06746584|BEHAVIORAL|benson relaxation exercise|BRT is one of the behavioural intervention techniques developed by Herbert Benson in 1975. BRT is based on the principle of deep breathing and relaxing all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it. This exercise, which has no side effects on patients and can be applied for patients of all age groups, is more widely used because it is a simple and easy-to-learn method compared to other relaxation methods all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it.
223934810|NCT06757738|DRUG|TRX-100|CEN inhibitor, dosage form - capsules, dosing regimen - QD
223934811|NCT06757738|DRUG|Placebo|Placebo, dosage form - capsules, dosing regimen - QD
223934812|NCT06477536|DRUG|HB0034|300mg, i.v. Q4W
223934813|NCT06830421|DRUG|R-MP and Procarbazine maintenance|Firstline systemic treatment with conventinal immunochemotherapy (3 cycles of Rituximab-MTX-Procarbazine) followed by Procarbazine maintenance
223934814|NCT06830421|DRUG|R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT|Firstline systemic treatment with age-adjusted MTX based induction (2 cycles of Rituximab-Methotrexate-Cytarabin) followed by consolidating aged-adapted high-dose chemotherapy and autologous stem cell transplantation
223934815|NCT06827821|DRUG|18F-CP6A|For pharmacokinetics, healthy volunteers underwent PET imaging targeting α-synuclein. Blood samples were collected at before and 2 ± 1, 5 ± 2, 10 ± 2, 30 ± 5, 60 ± 5, 90 ± 5, and 120 ± 10 min after imaging agent injection, and urine specimens were collected at before and 0-1.5, and 1.5-3 h after injection to measure radioactivity in blood and urine. PET/MR and PET/CT scans were performed at 0 ± 10, 30 ± 10, 60 ± 10, and 100 ± 10 min after injection to understand distribution for healthy volunteers and synucleinopathy patients. A separate 10-minute PET scan of the brain is required of each acquisition. Blood tests, liver and kidney function, and other biochemical markers must be performed one week prior to and after imaging.
223934816|NCT05236699|COMBINATION_PRODUCT|DEB-TACE combined with Surufatinib and Camrelizumab|"1. All patients will be treated with standard DEB-TACE on the first day (D1).~2. After DEB-TACE, if the liver function is Child-PughA grade, they will be treated with Camrelizumab on the same day, 200mg/ times, intravenous injection, once every 3 weeks.~3. Surufatinib capsule will be given orally to 250mg within 1 hour after breakfast on the second day (D2) after the first DEB-TACE. The drug will be given continuously once a day and stopped on the same day of each DEB-TACE.~4. The combination of drugs for 3 weeks is a cycle.The treatment will continue until the patient developed the disease or met the other criteria for terminating the study."
224097416|NCT01953315|BIOLOGICAL|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
224097417|NCT06192121|OTHER|Web Based Education|In this research, a reminder message will be sent 3 times a week along with web-based training.
223718611|NCT06125145|BEHAVIORAL|Geriatric Assessment and Promotora Coaching|In Visit 1 the community health worker/promotora will assess frailty, cognition, polypharmacy, depression, symptom burden, and social support. In Visits 2 and 3 the community health worker will deliver interpersonal communication techniques to deliver the problem solving coaching format, leverage cultural congruence with clients, and provide social support to assist in adopting healthy behaviors.
223718612|NCT03102255|PROCEDURE|Sniffing position|All procedure is done under sniffing position.
223934817|NCT06583070|RADIATION|Radiation therapy|Administer radiation therapy to achieve as complete coverage as possible of all identifiable primary and metastatic lesions in conjunction with targeted and immunotherapy
223934818|NCT06583070|DRUG|Targeted and immunotherapy|Targeted and immunotherapy
223934819|NCT06284252|OTHER|Virtual Gaming Simulation|Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
223934820|NCT06831045|PROCEDURE|Bikini Incision|Participants will receive the bikini incision in person during THA. A one-time incision will be made along the groin line before standard of care THA surgery. The surgery takes approximately two hours.
224097418|NCT01261676|OTHER|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
224097419|NCT03025581|OTHER|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
223718613|NCT03102255|PROCEDURE|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
223934821|NCT06831045|PROCEDURE|Longitudinal Incision|Participants will receive the longitudinal incision in person during THA. A one-time linear incision will be made along the thigh before standard-of-care THA surgery. The surgery takes approximately two hours.
223934822|NCT05696561|DEVICE|Canaloplasty Device|Canaloplasty
223934823|NCT05812183|DEVICE|Bariatric surgery|Gastric sleeve resection will be performed by experienced surgeons. Postoperative care will follow UCLA's postoperative care pathways for gastric sleeve resection.
223934824|NCT05812183|DRUG|Medical weight loss|The medical weight loss intervention will follow UCLA's RFO standard protocol. Over a period of 12 months, patients in the medical weight loss group will follow a very low caloric diet (VLCD) at the UCLA RFO program. All study patients will be prescribed a VLCD, an exercise regimen and will participate in group classes on behavioral modification. The caloric intake consists of a commercially prepared meal replacement powder supplying 700-800 cal/day. Each formula packet provides 100kcal and 15g of high biological value protein, and the daily allowance of required minerals and vitamins. Some patients may recieve adjuvant drug therapy including Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), Naltrexone-bupropion (Contrave), Liraglutide (Saxenda), Semaglutide (Wegovy), Tirzepatide (Zepbound) or Setmelanotide (Imcivree).
223934825|NCT06077461|BEHAVIORAL|mandala painting|Patients in this group will be subjected to mandala painting.
223934826|NCT05630183|DRUG|Botensilimab|A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
223934827|NCT05630183|DRUG|Gemcitabine|Standard-of-care chemotherapy administered intravenously.
223934828|NCT05630183|DRUG|Nab-paclitaxel|Standard-of-care chemotherapy administered intravenously.
223934829|NCT06586645|BEHAVIORAL|Safety Planning|Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.
223934830|NCT06586645|BEHAVIORAL|Give to Others Module|"The Give to Others Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief phone follow-up."
223934831|NCT06826651|PROCEDURE|laparoscopic appendectomy|By using laparoscopy, after achieving conclusive identification of the mesoappendix
224097420|NCT04180605|OTHER|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
224097421|NCT04180605|PROCEDURE|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
224097422|NCT05931770|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by the child. will be determined by children preference
224097423|NCT05931770|PROCEDURE|Parent (mother or father) selection according to parents' preference|Accompanying parentwho will accompany during the perioperative period will be determined by the parents. to be determined by
224097424|NCT03921112|DEVICE|lung ultrasound|bedside lung ultrasound will be done for patients
224097425|NCT03921112|OTHER|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
224097426|NCT06279923|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
224097427|NCT03716791|DIETARY_SUPPLEMENT|methylsulfonylmethane|3g per day
224097428|NCT03716791|DIETARY_SUPPLEMENT|placebo|white rice flour
224097429|NCT06456710|BEHAVIORAL|Conventional IBS Health Education|Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.
224099739|NCT07107477|DRUG|Antibiotics administration|"1. GBS prophylaxis + macrolides: Penicillin G (benzylpenicillin) 5mil IU IV initially and then 2-3 IU (dose adjusted to body weight) IV every 4h twice, then every 6h + Clarithromycin 500mg po every 12h for 7-10 days or till delivery.~2. Initial broad spectrum ABX: Ampicillin/sulbactam 3g IV every 6 hours + Gentamicin 5 mg/kg IV (\<60 kg 240 mg, 61-80 kg 320 mg, \>80 kg 400 mg) every 24h for 5-7 days according to the clinical state.~Comments:~Alternative ABX in patients with allergy to PCN/AMP: Vancomycin 1g IV every 12 h or Clindamycin 600-900g IV every 8h taking antibiotic sensitivity into account.~Before administering the third dose of gentamicin, its serum level should be determined (at a level \>4 umol/l, the dose must be reduced)."
223534063|NCT01364831|BEHAVIORAL|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
223534064|NCT01221116|DRUG|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
223534065|NCT04035031|DRUG|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
223534066|NCT04035031|DRUG|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
223534067|NCT00545779|DRUG|Ibandronate|150 mg orally once monthly for 6 months
223534068|NCT02076711|DRUG|Metoprololsuccinate|
223934832|NCT06826651|PROCEDURE|bipolar diathermy|the mesoappendix coagulated using bipolar diathermy, then cut with scissor.
223934833|NCT06826651|PROCEDURE|clips closure|mesoappendix will be divided between 3 clips, two placed distally and one proximally. The mesoappendix will be cut in between the clips.
223934834|NCT05079399|OTHER|Blood draw|Blood samples will be collected via venipuncture
223934835|NCT06253585|OTHER|Algorithm Alarm- Crystalloids|"The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution)."
224097430|NCT06456710|BEHAVIORAL|Based on ACT Theory of Psychological Intervention|"On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT."
223934836|NCT06253585|OTHER|Standard of Care|Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
223934837|NCT03877653|DEVICE|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
223934838|NCT06359821|DRUG|ZA-001|Study drug ZA-001 administered via intravenous injection.
223934839|NCT06780618|OTHER|RICE|150 g of brown rice from Aek Sibundong variant at once
224097431|NCT06197607|OTHER|theraputty hand exercises|Theraputty hand exercises will be done in following manners: Finger flexion, Metacarpophalangeal joint flexion, Interphalangeal joint flexion, Finger grip strengthening, Finger abduction and Rolling putty into ball and pinching it between, thumbs and finger with both the hands. There will be 20 repetitions with one set of each
223934840|NCT06780618|OTHER|rice wheat (placebo)|150 g of white rice from Setra Ramos variant at once
223934841|NCT06808243|PROCEDURE|connective tissue graft|10 patients received mVIP-CTG
223934842|NCT06808243|DEVICE|xenogenic collagen membrane|10 patients received XCM
223934843|NCT04372914|DIETARY_SUPPLEMENT|BRB Lozenges|Each lozenge is made from 1 gram of freeze-dried black raspberry powder (equivalent to \~5 black raspberries) in the form of a dissolvable slow-release lozenge.
223934844|NCT06891287|COMBINATION_PRODUCT|RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity|RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity.
223934845|NCT06891287|DRUG|PG-102|PG-102 is a drug for the treatment of obesity.
223934846|NCT06891287|OTHER|Placebo|The placebo is the RaniPill with saline instead of a drug.
223934847|NCT05349838|DRUG|Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy|Daily oral tablet
223934848|NCT05943197|DIAGNOSTIC_TEST|dental prosthetics, biofilm response and oral microbiota|microbiota, biofilm, oral mucosa
223934849|NCT03289949|DRUG|Psilocybine|Oral dose of psilocybine.
223934850|NCT03289949|DRUG|Ketanserin|Oral dose of ketanserin.
223934851|NCT06922240|DRUG|Riociguat|On the basis of the comprehensive treatment in line with the guidelines, including conventional diuresis, anticoagulation, oxygen inhalation, etc., continue oral administration of riociguat for treatment.
223934852|NCT06922240|DRUG|Routine Treatment|On the basis of the comprehensive treatment in line with the guidelines, including conventional diuresis, anticoagulation, oxygen inhalation, etc, and stop taking riociguat
223934853|NCT05071430|DRUG|HB-01|HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
223934854|NCT05071430|DRUG|Placebo|HB-1 matched placebo
223934855|NCT05644275|OTHER|Data collection (demographic, clinical, functional and biomechanical outcomes in patients after ACL injury (conservative therapy and/or surgery) in patients of different ages and healthy controls)|Analysis of existing data from previous research projects MechSens (EKNZ 2019-01315) and RetroBRACE I and II (EKNZ 2019-00491 and EKNZ 2020-00551) as descriptive statistics (mean, standard deviation, range) for all parameters (for female or male patients with ACL injury and healthy subjects).
223934856|NCT06917703|OTHER|E-learning|in experience group
223934857|NCT00961792|DRUG|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
223934858|NCT00961792|DRUG|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
223934859|NCT00961792|DRUG|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
223934860|NCT00961792|DRUG|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
223534069|NCT02076711|DRUG|Placebo|Placebo
223934861|NCT06745232|DEVICE|FAST MAP|Patients with complete arch restorations loaded immediately with a full digital workflow using stereophotogrammetry Intraoral impression
223934862|NCT05958823|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block
223934863|NCT05958823|PROCEDURE|PECS I-II|PECS I-II
223934864|NCT05662098|DRUG|Hydroxyurea|All participants will receive an individualized PK hydroxyurea assessment. Participants for whom the PK-process successfully generates a dose in the predicted treatment range of 15-35 mg/kg/day, will start on that personalized dose. Participants for whom the process does not generate a starting hydroxyurea dose in the predicted treatment range, due to potential pitfalls in lab draws, serum storage, sample processing, or hydroxyurea analysis, will start at a default dose of 20.0 ± 2.5 mg/kg/day. For all participants, the hydroxyurea dose will be adjusted as needed based on blood counts to establish the optimal dose. Where necessary, a weekly dosing average will be determined, so that treatment can occur solely with locally available and affordable 500mg hydroxyurea capsules.
223934865|NCT04888338|OTHER|Data Capture|Treatment related data is collected
223934866|NCT04888338|OTHER|Electronic Medical Record|Medical records are reviewed
223934867|NCT05182008|OTHER|Decision aid|Online interactive decision aid on method of early abortion
223934868|NCT05182008|OTHER|Usual care|Patients will be directed to the abortion clinic website
223934869|NCT04152551|DRUG|Risedronate Oral Tablet|Oral bisphosphonate
224097432|NCT06197607|OTHER|sensory stimulation|Sensory Stimulations (30 min) will be given following forms; All and single joint shaking, Multivariate sensory stimulations, Skin stretch in the muscular region, Fast stretch of the upper limb joints in different directions of motor action, brushing on the large muscles of arm and forearm, brushing on the fingers, Circular massage of the thenar and hypothenar area and pressing the tip of fingers.
224097433|NCT01104831|DEVICE|Cryotherapy|cooled sleeve placed over fracture site.
224097434|NCT01104831|DEVICE|Room temperature cuff|sleeve with room temperature water placed over fracture site.
224097435|NCT03007277|OTHER|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
224097436|NCT02450253|DRUG|Tadalafil|single dose, 20 mg capsule p.o.
224097437|NCT02450253|DRUG|Placebo|single dose, matching capsule p.o.
224097438|NCT02450253|BEHAVIORAL|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
224097439|NCT02450253|BEHAVIORAL|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
223934870|NCT03980717|DEVICE|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
224097440|NCT02450253|OTHER|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
224097441|NCT02469246|DRUG|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
224097442|NCT02469246|DRUG|ABC/3TC|600/300 mg FDC tablets administered orally once daily
224097443|NCT02469246|DRUG|ABC/3TC Placebo|Tablets administered orally once daily
224097444|NCT02469246|DRUG|F/TAF Placebo|Tablets administered orally once daily
224097445|NCT02469246|DRUG|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
224097446|NCT01588080|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
224097447|NCT01588080|DEVICE|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
224097448|NCT03293680|DRUG|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
224097449|NCT06683521|OTHER|Supervised Low-Dose Oral Food Challenge (OFC)|All participants will undergo a supervised Low Dose OFC (300 mg food protein or amended) on Day 1.
224097450|NCT06683521|OTHER|At-Home Low-Dose Oral Food Challenge (OFC)|Participants who tolerate the Day 1 Low Dose OFC will undergo a daily Low-Dose OFC (300 mg food protein or amended) at home on Days 2-7.
224097451|NCT06683521|OTHER|Supervised High-Dose Oral Food Challenge (OFC)|Participants who tolerate the Days 1-7 Low Dose OFC will undergo a supervised High Dose OFC (maximum 3000 mg food protein) on Day 8.
224097452|NCT00942682|DRUG|Sorafenib|Taken orally twice daily
224097453|NCT00942682|DRUG|RAD001|Taken orally once daily in the morning
224097454|NCT02557503|DRUG|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
224097455|NCT03287492|OTHER|Informational Intervention|Receive QPS
224097456|NCT03287492|OTHER|Informational Intervention|Receive GIS
224097457|NCT03287492|OTHER|Questionnaire Administration|Ancillary studies
224097458|NCT06448377|PROCEDURE|Videolaryngoscopy|Situations in which the practitioner performs endotracheal intubation using a videolaryngoscope during airway intervention will be included in this group.
224097459|NCT06448377|PROCEDURE|FOB|Situations in which the practitioner performs endotracheal intubation using a fiberoptic bronchoscope during airway intervention will be included in this group.
224097460|NCT06448377|PROCEDURE|FOB+Aintree|Situations in which the practitioner performs endotracheal intubation using a Fiberoptic intubation via LMA with aintree catheter during airway intervention will be included in this group.
224097461|NCT06448377|PROCEDURE|Classic intubation with laryngoscopy|Situations in which the practitioner performs endotracheal intubation using a macintosh laryngoscope during airway intervention will be included in this group.
224097462|NCT06448377|PROCEDURE|Others|Cases in which intubation cannot be performed, those who are awakened from anesthesia, or those in whom a surgical method is used for airway access will be included in this group.
224097463|NCT05928884|OTHER|There is no intervention. It is a phenotyping study only|See above, this is only a phenotyping study but NIH required us to register it as a trial.
224097464|NCT05071131|DIETARY_SUPPLEMENT|Inulin|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
223934871|NCT05014503|OTHER|Adaptive Therapeutic gaming|All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
224097465|NCT05071131|DIETARY_SUPPLEMENT|Placebo|1 sachet à 15 grams daily for 7 days, followed by 2 sachets à 15 grams daily for 28 days
224097466|NCT01883505|DRUG|Levodopa and carbidopa|Subcutaneous continuous administration
224097467|NCT01883505|DRUG|Placebo|Subcutaneous continuous administration
224097468|NCT02404987|OTHER|Nutritional Supplement|
224097469|NCT03709927|DRUG|ZTI-01|6g IV fosfomycin
224097470|NCT03709927|DRUG|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
224097471|NCT03709927|OTHER|Placebo IV|IV Placebo (0.9% Normal Saline)
224097472|NCT01425099|DRUG|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
224097473|NCT01425099|DRUG|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
224097474|NCT04030000|DRUG|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
224097475|NCT04030000|RADIATION|Pelvic radiation therapy|EBRT and vaginal brachytherapy
224097476|NCT03437603|DRUG|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
224097477|NCT04869241|DIAGNOSTIC_TEST|surface EMG|Carrying backpacks forward or backward
224097478|NCT03352245|BEHAVIORAL|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
224097479|NCT03782337|BEHAVIORAL|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
223534070|NCT01616147|BEHAVIORAL|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
223534071|NCT01616147|BEHAVIORAL|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
223534072|NCT00058747|DRUG|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
224097480|NCT03619629|OTHER|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
224097481|NCT03619629|OTHER|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
224097482|NCT03619629|OTHER|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
224097483|NCT03619629|OTHER|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
224097484|NCT00940277|BEHAVIORAL|Group Counseling|Group counseling
224285943|NCT01173913|DRUG|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
223534073|NCT02149966|DRUG|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
223534074|NCT02149966|DRUG|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
223534075|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
223534076|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
223534077|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
224097485|NCT03635931|PROCEDURE|Concentrated Growth Factor|surgical treatment with CGF for papilla regeneration
224097486|NCT02771834|OTHER|Biomechanical analysis|
224097487|NCT02771834|OTHER|Kiphosis analysis|
224097488|NCT02771834|OTHER|Vitamin D level|
224097489|NCT05123560|OTHER|Anonymous online questionnaire|A QR code qill be provided to access the online questionnaire
224097490|NCT06031415|DRUG|GS-0272|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
224097491|NCT06031415|DRUG|Placebo|Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
224097492|NCT02690701|DRUG|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
224285944|NCT01173913|DRUG|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
223934872|NCT05014503|OTHER|Non-adaptive Therapeutic gaming|All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
223934873|NCT00085982|DRUG|Metreleptin|Administered SC twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin receptor mutation
223934874|NCT06759818|DEVICE|transcutaneous vagus nerve stimulation|①The first adjustment requires electrical stimulation to break through the skin barrier. The first intervention is the day before the operation. The initial electrical stimulation frequency is 30Hz and the pulse width is 300μs. The frequency and pulse width are adjusted according to the individual feelings of the subject until they are tolerated by the subject. Maximum current stimulation without discomfort and lasting for 30 minutes; ② second time For the intervention, the subject is connected to the monitor after entering the surgery room. After observing that the subject\&#39;s vital signs are within the normal range, the same stimulation frequency as the first time is immediately given for 30 minutes; ③ The third intervention is after the subject\&#39;s surgery is completed. The same stimulation frequency was given in the resuscitation room until the patient was extubated and resuscitated.
223934875|NCT06759818|DEVICE|Sham stimulation group|① The first intervention is also the day before the operation. The frequency and pulse width are adjusted three times without turning on the machine, and the subject is asked if they have any feelings. After adjusting the frequency three times, no operation is performed for 30 minutes; ② The second intervention For the first intervention, after the monitor is connected in the operating room, the frequency and pulse width are not set, and it lasts for 30 minutes before being taken out; ③ For the third intervention, after the subject\&#39;s surgery, earplugs are inserted in the recovery room, and the frequency and pulse width are not set. Remove the earplugs after extubation resuscitation is completed.
223934876|NCT06759012|OTHER|EyeTeacher|Participants randomized to the intervention group will receive access to the EyeTeacher system, along with their username, password, and a user manual, one week before the start of the course. They will follow instructions on the website and complete a quiz before and after each course. After completing the EyeTeacher curriculum, they will take the first examination (Examination 1) and complete a set of questionnaires. A classroom will be provided for study purposes, but no restrictions will be imposed on the study location. Following the EyeTeacher section, participants will attend the ophthalmology course in the regular training program, with support from the EyeTeacher system. They will be evaluated according to the ophthalmology posting's evaluation criteria (Examination 2).
223934877|NCT01371045|OTHER|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
223934878|NCT05859750|DRUG|AK104|AK104 (6mg/kg) on day 1, IV, Q2W
223934879|NCT05859750|DRUG|AK104|AK104 (10mg/kg) on day 1, IV, Q2W
223934880|NCT05859750|DRUG|Gemcitabine|Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
223934881|NCT05859750|DRUG|Nab-Paclitaxel|Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
223934882|NCT05859750|DRUG|Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate|liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
223934883|NCT05859750|DRUG|Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin|oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
223934884|NCT00490139|DRUG|Lapatinib|Small molecule inhibitor
223934885|NCT00490139|BIOLOGICAL|Trastuzumab|Antibody
223934886|NCT05999526|OTHER|Reconnection to mechanical ventilation for 1 hour|As soon as the success of the spontaneous breathing trial is confirmed, the participant will be kept on the mechanical ventilator for 1 hour using the previous ventilatory parameters and, afterwards, extubated.
224285945|NCT03629613|DIETARY_SUPPLEMENT|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
223534078|NCT01405196|BIOLOGICAL|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
223534079|NCT05540483|DRUG|Disitamab Vedotin combined with Zimberelizumab|Treatment regimen: Disitamab Vedotin , 2.5mg/kg, intravenously D1, once every 14 days (Q2W), combined with Zimberelizumab, 240mg, intravenously D1, once every 14 days (Q2W).
223718614|NCT01293175|DIETARY_SUPPLEMENT|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
223718615|NCT02128113|DRUG|Vehicle Ophthalmic Solution|Opthalmic suspension manufactured to mimic RTA 408 suspension
223934887|NCT05999526|OTHER|Direct extubation|The participant will be extubated immediately after the spontaneous breathing trial.
223934888|NCT01638533|OTHER|Pharmacological Study|Correlative studies
223934889|NCT01638533|DRUG|Romidepsin|Given IV
224285946|NCT03629613|OTHER|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
224285947|NCT02217696|OTHER|Computerized reading training|
223718616|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 0.5%|0.5% ophthalmic suspension of RTA 408
223934890|NCT06751901|RADIATION|Radiotherapy|Radiotherapy will be completed prior to the administration of personalized tumor neoantigen-based peptide vaccine and PD-1 inhibitors. The treatment cycle, frequency, and dosage are determined by the subject's primary physician based on the specific conditions of the participant.
223934891|NCT06751901|DRUG|PD-1 inhibitor|Treatment with PD-1 inhibitors will begin after the completion of radiotherapy, with a treatment cycle of 3 weeks. On the first day (D1) of each treatment cycle, the drug is administered intravenously, with the dosage according to the instructions.
223934892|NCT06751901|DRUG|Neoantigen-based peptide vaccine|The treatment with personalized tumor neoantigen-based peptide vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
223934893|NCT06773234|OTHER|Questionnaire|DREEM Tool
223934894|NCT06776497|DEVICE|VIRTUAL REALITY GLASSES (VRG)|Individuals who met the inclusion criteria and signed the informed consent form were assigned to the study groups based on a list which was numbered and generated in the computer environment before the arteriovenous fistula (AVF) procedure. According to the results given by the computer programme, the individuals were assigned to the control group and the virtual realitiy group (VRG)group. While the control group included patients who underwent AVF procedure with the standard method, the virtual reality headset group included patients who underwent AVF procedure during the VRG application.
223934895|NCT06945783|DEVICE|Kinesiology Taping|Kinesiology taping was applied to the lumbar area of the participants in the intervention group. The taping aimed to improve posture, reduce pain, and enhance balance and functional performance.
223934896|NCT06945783|OTHER|Physiotherapy|The physiotherapy program included therapeutic exercises and physical modalities (such as stretching, strengthening, and posture training) tailored for individuals with nonspecific low back pain.
223934897|NCT02798471|DRUG|Edoxaban|15 or 30 mg tablets for participants 12 years of age to \<18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
223934898|NCT02798471|DRUG|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
223934899|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40\& of the contralateral MVIC.
223934900|NCT03626857|OTHER|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
223934901|NCT03626857|DEVICE|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
223934902|NCT03626857|OTHER|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
223934903|NCT05848674|OTHER|CArdiac Brief INtervention (CABIN)|CABIN is designed as a brief intervention with a facilitated discussion between a patient and a nurse, with the provision of a short leaflet that summarises information and acts as an aide memoir. The discussion takes place in a quiet area and is intended to last 15-20 minutes. CABIN involves a nurse listening to the patient and recognising any concerns he / she may have and / or identifying erroneous beliefs. It also provides the patient with personalised education on coronary artery disease and cardiac rehabilitation (i.e., information about stenting, stent placement, medication, and purpose / potential benefits of cardiac rehabilitation), along with facilitating psychological and emotional support discussions with a nurse (i.e., explaining causes of a STEMI, discussing support / treatment options, and exploring methods of improving health).
224097493|NCT02690701|BIOLOGICAL|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
224097494|NCT05865184|OTHER|Data collection|Data collection of clinically relevant signals using home-based sensor system
224285948|NCT03274713|DEVICE|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
224285949|NCT03274713|DEVICE|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
224285950|NCT02694549|DEVICE|CaveoVasc|
224285951|NCT03445299|BEHAVIORAL|Music|Listening to music for 30 minutes at bedtime
224285952|NCT02784678|PROCEDURE|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
224097495|NCT02790489|DIETARY_SUPPLEMENT|Valedia|
224097496|NCT03091023|PROCEDURE|Endometrial Biopsy and endometrial fluid collection|
223934904|NCT05848674|OTHER|Refined version of CABIN|Participants of the control group will receive a refined version of CABIN, which excludes psychological and emotional support discussions with a nurse and details some standard discharge information (information about coronary artery disease and stenting / stent placement).
223934905|NCT02731612|DRUG|lurasidone|Atypical Antipsychotic
223934906|NCT02731612|OTHER|Placebo|Inactive substance
223934907|NCT05549661|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223934908|NCT05549661|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224097497|NCT06443658|OTHER|Hypertonic saline|Patients from intervention group will inhale hypertonic saline solution 5 minutes before performing the morning ELTGOL technique
224097498|NCT06443658|DRUG|Isotonic saline|Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
224097499|NCT06443658|OTHER|ELTGOL|Patients from control group will perform the ELTGOL technique twice-daily
224097500|NCT00797420|DRUG|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
224097501|NCT00797420|DRUG|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
224097502|NCT05426356|DEVICE|Surgical Intervention|Surgical sacral fracture fixation and SI joint fusion using iFuse-TORQ
223718617|NCT02128113|DRUG|Omaveloxolone Ophthalmic Suspension 1%|1% ophthalmic suspension of RTA 408
223934909|NCT05549661|DRUG|Onvansertib|Given PO
223934910|NCT05549661|PROCEDURE|Ultrasound Imaging|Undergo ultrasound imaging
223934911|NCT05741112|DEVICE|Wearable device|The treatment group will receive their wearable device and the enhanced education at the start of the study. Their outcomes will be compared with the control group who will receive at 3 months.
223934912|NCT06454617|OTHER|Phantom|The patients will be simultaneously scanned with a QCT phantom
223934913|NCT03485287|DRUG|Midomafetamine HCl|Three sessions of MDMA-assisted therapy with flexible dose of midomafetamine HCl from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
223934914|NCT03485287|BEHAVIORAL|Manualized therapy|Non-directive therapy
223934915|NCT06334601|DIAGNOSTIC_TEST|Tests of upper airway collapsibility and muscle responsiveness.|"Upper airway collapsibility, upper airway muscle responsiveness and loop gain will be assessed during single study visit.~Polysomnography"
223934916|NCT04477200|DRUG|Mycophenolate Mofetil|500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
223934917|NCT04477200|RADIATION|Radiation Therapy|40.5 Gy in 15 fractions
223934918|NCT04477200|PROCEDURE|Re-resection (as part of standard of care)|Re-resection or biopsy of tumor as part of standard of care
223934919|NCT04477200|DRUG|Temozolomide|Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
223934920|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT.
223934921|NCT04477200|DRUG|Mycophenolate Mofetil|250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
224097503|NCT05426356|OTHER|Non-Surgical Management|Non-surgical management (NSM) is any treatment deemed appropriate for the subject that does not involve surgery.
224097504|NCT04828824|DRUG|Ethinyl Estradiol / Norgestimate Oral Tablet|Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.
224097505|NCT03821584|OTHER|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
224097506|NCT02614209|DEVICE|In Vitro diagnostic tests|Prospective blood collection
224097507|NCT00511303|DRUG|STI571|
224097508|NCT02214849|BEHAVIORAL|LATCH Intervention|
224097509|NCT01993979|DRUG|Chemotherapy|
224097510|NCT01993979|OTHER|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
224285953|NCT02784678|DEVICE|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
224097511|NCT02509208|DEVICE|SurgiClot haemostatic dressing|haemostatic dressing
224285954|NCT01534078|DRUG|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
224285955|NCT01534078|DRUG|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
224285956|NCT04026373|BEHAVIORAL|modified Prolonged Exposure|
224285957|NCT04026373|BEHAVIORAL|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
224285958|NCT04911465|DEVICE|Flashback CRI T1 Tablet|Collect continuous data on the compensatory reserve index, a measurement of a patient's central volume status.
224097512|NCT04493047|BEHAVIORAL|Mobile health (mHealth) for pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.
224097513|NCT00284830|DEVICE|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
224097514|NCT02913989|OTHER|Smoking habits characterization|
223534080|NCT04321655|OTHER|High Intensity LASER Therapy (HILT)|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ (millijoule)/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J"
223534081|NCT04321655|OTHER|Ibuprofen Gel Phonophoresis (IGP)|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. (8 min/ one session each day for 3 days/week for 8 weeks).
223934922|NCT04477200|RADIATION|Radiation Therapy|60 Gy in 30 fractions
223934923|NCT04479696|OTHER|Educational Intervention|Receive standard of care verbal and written education materials
223934924|NCT04479696|OTHER|Questionnaire Administration|Ancillary studies
223934925|NCT04479696|OTHER|Survey Administration|Complete optional survey
224097515|NCT04476264|PROCEDURE|Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection|The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.
224097516|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
223934926|NCT04479696|OTHER|Video|Watch NIRS video
223934927|NCT05030493|DRUG|mFOLFOX6 + panitumumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
223934928|NCT05030493|DRUG|mFOLFOX6 + bevacizumab combination therapy|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
223934929|NCT05971342|DRUG|Gelatin sponge-loaded apoptotic vesicle complex（Kuaikang®)|The experimental group
223934930|NCT05971342|DRUG|Gelatin sponge only （Kuaikang®)|The positive control group
224285959|NCT05122767|DRUG|Dolutegravir|"Groups 1a/1b: Participants will take the FDA-approved weight-based DTG once daily + either TDF/FTC, TDF/3TC, ABC/3TC or AZT/3TC x 4 weeks. During HP treatment and for two weeks afterward, DTG dose will be increased to twice daily.~Participants will continue with the NRTI regimen they have previously tolerated, except where their age and weight allow them to transition from either AZT or ABC to TDF, as per South African National ART Guidelines. HLA-B\*5701 screening will therefore not be performed, as children will be currently taking and tolerating an ABC-containing regimen at enrolment. If any clinically suspected hypersensitivity reaction to ABC is suspected by history, ABC will not be continued.~Groups 2a/2b: Participants will take weight-based DTG dosing twice or once daily, depending on the results of the modelled data for the Group 1a (for Group 2a) and/or Group 1b (for Group 2b) participants in the interim analysis."
224285960|NCT05122767|DRUG|3HP|3HP Dosing is by Age and Weight Children 2-15 years of age: 10-15kg (P 300mg, H 300mg); 16-23kg (P 450mg, H 500mg); 24-30kg (P 600mg, H 600mg); 31-34kg (P 750mg, H 700mg). Children 15-17 years, \>=30kg (P 900mg, H 900mg)
223934931|NCT05464368|DRUG|[18F]RO-948|"Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
223934932|NCT05464368|DRUG|18F-MK6240|"18F-MK6240 is an investigational PET radiotracer discovered by Merck Research Laboratories and is being developed by Cerveau Technologies, Inc.,for imaging neurofibrillary tangles (NFTs)in the brains of people withAlzheimerdisease.18F-MK6240 has been reported to exhibit good kinetics with high binding levels to brain regions associated with deposition of neurofibrillary tangles in people with AD(35,36).The tracer has been used to monitor the progression of AD.The injected activity for18F-MK6240 will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose will be 185MBq(5mCi) has been selected based on the radiation dose estimates gathered in human subjects(37)and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy."
223934933|NCT05464368|DRUG|18F-GTP1|"18F-GTP1is anInvestigational tau PET radiotracer being developed by Genentech for imaging intraneuronal neurofibrillary tangles in patients with AlzheimerDisease. 18F-GTP1 has been reported to exhibit high affinity and selectively for tau pathology, favorable dosimetry and brain kinetics. Degree of 18F-GTP1-specific binding increased withAD severity, could differentiate diagnostic cohorts, and monitor longitudinal change in tau burden.~18F-GTP1 will be provided from LMI sourced through Illinois or New Jersey certified location."
224097517|NCT03063749|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
224097518|NCT00372892|DRUG|Rituximab|375mg/m2 per week for 4 consecutive weeks
224097519|NCT00372892|DRUG|Placebo|Saline IV placebo once per week for 4 consecutive weeks
224097520|NCT05422092|DRUG|Canagliflozin|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
224097521|NCT05422092|DRUG|Pioglitazone|40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
223934934|NCT04919811|DRUG|Taletrectinib|400mg or 600mg QD
223934935|NCT06290570|DIAGNOSTIC_TEST|12-Lead ECG|A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.
223934936|NCT06290570|DIAGNOSTIC_TEST|Apple Smart Watch Single Lead ECG|A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.
223934937|NCT06290570|DIAGNOSTIC_TEST|AliveCor KardiaMobile 6-Lead ECG|A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.
223534082|NCT04321655|OTHER|Transcranial Direct Current Stimulation (tDCS)|Anode electrode -C3/C4 (contralateral side of the most affected knee), Cathode electrode- contralateral supraorbital area. (2 mA intensity for 20 minutes, one session/day for 3 days/week for 8 weeks)
223934938|NCT06379932|OTHER|Surveys completion|"A questionnaire (including the NRS) will be given to the patient on the day of the procedure, immediately after the biopsy, in the treatment room and without staff intervention (responses will be analyzed by two study investigators at a later date).~The patient health questionnaire (PHQ-9) will also be provided at the same time as the self-report questionnaire, for the assessment of depressive symptoms.~Assessment of the participant's frailty using the Clinical Frailty Scale (CFS) will be carried out prior to the procedure.~Further data will be collected by telephone by a study investigator 15 +/- 2 days after the biopsy and 30 +/- 2 days after the biopsy."
223934939|NCT04406272|DRUG|VB11|Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
223934940|NCT04406272|PROCEDURE|Surgery|Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
223934941|NCT04406272|OTHER|Placebo|Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
223934942|NCT04406272|DRUG|Bevacizumab|A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
223934943|NCT00083590|DRUG|Huperzine A|
223934944|NCT06253299|OTHER|marble stone|"Marble stones with dimensions of 4x5 cm will be used for cold application. When placed in the freezer compartment of the refrigerator at -10°C (Celsius) for 4 minutes, they cool down to 11°C. Subsequently, in 1 minute, the temperature rises to 12°C when held in the palm. After being placed on a table at room temperature, it reaches 18°C in 5 minutes."
223934945|NCT04555668|OTHER|Global Postural Reeducation Program|Global Postural Reeducation Program with hamstring stretch The lying posture with flexion of the legs aimed to stretch the posterior chain (upper trapezius, levator scapulae, sub occipital, erector spinae, gluteus maximus, ischio-tibial, triceps surae, and foot intrinsic muscles). The initial position will lying with the hip flexed and progression consisted of increasing hip flexion, knee extension, and dorsiflexion of the ankle All above exercises will be given and to be held for 15 minutes each. 40 min/session, 3 times/week for 6 weeks
223934946|NCT04555668|OTHER|Hamstring Stretch Program|Hamstring Stretch Program 3 times for 30 seconds hold, subjects rested for 15 seconds between stretches. Knee -flexor eccentric training to prevent hamstring muscle strain 10-15 rep 40 min/session, 3 times/week for 6 weeks
223934947|NCT04826159|DRUG|IMB-1018972|Modified release tablet for oral administration
224097522|NCT03170830|DIAGNOSTIC_TEST|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
224097523|NCT00667706|PROCEDURE|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
224097524|NCT00667706|PROCEDURE|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of \<50, and \>50, respectively.
224097525|NCT04658602|PROCEDURE|Preformed stainless steal crown cemented by glass ionomer lutting cement (Ketac cem,3M Espe)|Covering the affected molar with preformed metal crown cemented by glass ionomer lutting cement
223934948|NCT06000956|DRUG|Jitongning tablets|The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
223934949|NCT06000956|DRUG|a simulated agent of Jitongning tablets|The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.
223934950|NCT06033105|DEVICE|ELISA|Enzyme-linked immunosorbent assay (ELISA) was used following manufacturer's instructions. This test uses a competitive ELISA-based technique that was designed to quantitatively determine the concentration of 1,25-dihydroxyvitamin D3/D2 in human serum.
223934951|NCT02388828|BIOLOGICAL|lentiviral-based CART meso therapy|
223934952|NCT04094519|DRUG|enzalutamide|oral
223934953|NCT04094519|DRUG|enzalutamide Placebo|oral
223934954|NCT04094519|DRUG|digoxin|oral
223934955|NCT04094519|DRUG|rosuvastatin|oral
223934956|NCT05747014|DEVICE|Novapak Nasal Sinus Packing and Stent|Potential subjects will have the need to undergo nasal/sinus surgery using a space-occupying stent and will perform daily self-saline nasal irrigations.
223934957|NCT04682288|DRUG|Levofloxacin Ocular Implant|Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
223934958|NCT02961075|OTHER|local surface anesthesia|Airway anesthesia for Bronchoscopy
223934959|NCT02961075|DEVICE|Laryngeal tube|
224097526|NCT05872048|DEVICE|periodontal distractor|custom made device from hyrex screw
224097527|NCT01642212|DRUG|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
224097528|NCT01642212|DRUG|Placebo|
224097529|NCT02896478|OTHER|No intervention. Only observational study|
224097530|NCT05106387|DRUG|Noninterventional|No investigational treatment will be given in this noninterventional extension study
224097531|NCT05118204|DRUG|BUP microdose induction|"Participants will be started on a 5-day BUP microdose induction protocol (without stopping full agonists).~Day 1: participants will receive buprenorphine (Belbuca) 225 mcg mg every 12 hours Day 2: participants will receive buprenorphine (Belbuca) 450 mcg every 8 hours Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours Day 4: participants will receive buprenorphine-naloxone 4-1 mg every 8 hours Day 5: participants will receive buprenorphine-naloxone 8-2 mg every 12 hours"
224097532|NCT05118204|DRUG|TAU|2-day standard BUP induction protocol (with stopping full agonists) Day 1: hold all opioids Day 2: buprenorphine-naloxone 2-0.5 mg every 6 hours Day 3: buprenorphine-naloxone 8-2 mg every 12 hours
224097533|NCT05118204|BEHAVIORAL|Linkage to outpatient BUP treatment|Participants will be given an expedited appointment (within 2 weeks) to continue BUP treatment at a Montefiore community health center
224097534|NCT05979259|OTHER|Serious game nutrition education intervention|"Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will play the Foodbot Factory nutrition education serious game for 10-15 minutes. The Foodbot Factory serious game and lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide."
224097535|NCT05979259|OTHER|Conventional nutrition education intervention|Classrooms will receive nutrition education lessons for 35-40 minutes for 5 consecutive days. As part of each lesson, students will use conventional learning activities, such as worksheets, sourced from an online teaching resource repository. The lessons are based on Ontario curriculum requirements and aligned Canada's Food Guide.
224097536|NCT06581393|DEVICE|Moda-flx Hemodialysis System|All participants will complete up to 4 dialysis treatments on the Moda-flx Hemodialysis System over a period of up to 2 weeks.
223534083|NCT04321655|OTHER|Conventional Physiotherapy (CPT)|"1. Warm-up exercises: Walking at the usual speed on a flat surface for 10 min ( 3sets X10 Reps X 3 min rest in between)~2. Hamstring and calf gentle stretches. ( 3sets X10 Reps X 3 min rest in between)~3. Straight leg raise (SLR) ( 3sets X10 Reps X 3 min rest in between)~4. Quadriceps setting ( 3sets X10 Reps X 3 min rest in between)~5. Pillow squeeze ( 3sets X10 Reps X 3 min rest in between)~6. Heel raise ( 3sets X10 Reps X 3 min rest in between)~7. One leg balance ( 3sets X10 Reps X 3 min rest in between)~8. Step ups ( 3sets X10 Reps X 3 min rest in between)~9. Quadriceps strengthening exercises ( 3sets X10 Reps X 3 min rest in between)"
223534084|NCT05221892|DRUG|Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin|Tablets to be taken 30 minutes before each of 4 trips.
223534085|NCT05221892|DRUG|Ginger|Tablets to be taken 30 minutes before each of 4 trips.
223534086|NCT03732469|DRUG|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
223534087|NCT03732469|DRUG|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
223534088|NCT03732469|DRUG|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
223934960|NCT04359069|OTHER|Urinary catheter removal on postoperative day 1|Urinary catheter will be removed on day 1 (experimental) instead of day 3 (standard of care).
223934961|NCT04359069|OTHER|Urinary catheter removal on postoperative day 3|Urinary catheter will be removed on day 3 (standard of care)
224285961|NCT02459665|BIOLOGICAL|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
224285962|NCT02459665|DRUG|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
224285963|NCT02459665|BIOLOGICAL|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
223534089|NCT02434861|DRUG|Rolapitant|
223934962|NCT02394054|DRUG|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
223934963|NCT02394054|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
224097537|NCT04451863|DRUG|Low THC|Vaporized THC (5 mg)
224097538|NCT04451863|DRUG|High THC|Vaporized THC (15 mg)
224097539|NCT04451863|DRUG|Low Myrcene|Vaporized Myrcene (0.5 mg)
224097540|NCT04451863|DRUG|High Myrcene|Vaporized Myrcene (12.0 mg)
224097541|NCT04451863|DRUG|Low Beta-Caryophyllene|Vaporized Beta-Caryophyllene (0.5 mg)
224285964|NCT03532230|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
223534090|NCT02434861|DRUG|Digoxin|P-gp substrate
223934964|NCT04277156|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063|7 drops contain Lactobacillus rhamnosus GG 5x10\^9 CFU; and Lactobacillus reuteri 1x10\^8 CFU.
223534091|NCT02434861|DRUG|Sulfasalazine|BCRP substrate
223534092|NCT02434861|DRUG|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
223534093|NCT01480778|DRUG|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
223534094|NCT01480778|DRUG|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
223534095|NCT03540680|OTHER|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
223534096|NCT05695105|DEVICE|Electric Toothbrush-Generated Vibration|Testing electric toothbrush handle-generated vibration to treat ankylosis of teeth
224097542|NCT04451863|DRUG|High Beta-Caryophyllene|Vaporized Beta-Caryophyllene (7.5 mg)
224097543|NCT04451863|DRUG|Placebo|Vaporized Placebo
223934965|NCT04277156|DIETARY_SUPPLEMENT|L rhamnosus ATCC 53103|5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
224097544|NCT06344130|RADIATION|Radiation Therapy|Radiation therapy will be administered via a linear accelerator using 6 megavoltage (MV) photons or greater.
224097545|NCT06303505|DRUG|TUB-040|A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
223934966|NCT02305511|DEVICE|Peripheral venous catheterization|Cannulation using standard method
223934967|NCT02305511|DEVICE|Jamshidi|intraosseous access using the Jamshidi device
223934968|NCT02305511|DEVICE|BIG|intraosseous access using the BIG device
223934969|NCT02305511|DEVICE|Cook|intraosseous access using the Cook device
223934970|NCT02305511|DEVICE|EZIO|intraosseous access using the EZIO device
223934971|NCT05047458|DRUG|ALXN2050|Powder-in-capsule (PIC).
223934972|NCT05047458|DRUG|Placebo|PIC.
223934973|NCT01262963|DRUG|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
223934974|NCT00357916|DRUG|PEP005 Topical Gel (0.01% concentration)|
223934975|NCT01961466|OTHER|psychological and social self-administered questionnaires|
223934976|NCT03752684|DIETARY_SUPPLEMENT|Moderately high oxalate/low calcium diet non-colonized|Subjects will be instructed to ingest a controlled diet moderately high in oxalate before colonization
223934977|NCT03752684|DIETARY_SUPPLEMENT|Oxalobacter formigenes|Subjects will ingest live preparation of O. formigenes
223934978|NCT03752684|DIETARY_SUPPLEMENT|Moderately high oxalate/low calcium diet colonized|Subjects will be instructed to ingest a controlled diet moderately high in oxalate after colonization
224097546|NCT05259566|BEHAVIORAL|menthol ban in cigarettes only|menthol ban in cigarettes only, menthol available in e-cigarette
223534097|NCT05695105|DEVICE|Mini-Implant-Assisted Orthodontic Treatment|Testing mini-implant-assisted heavy force application to treat ankylosis of teeth
223534098|NCT05311423|DIAGNOSTIC_TEST|QuantiFERON-TB test & endometrial pathology & endometrial tissue GeneXpert Ultra|Endometrial biopsy is required to diagnose LTBI, SGTB and FGTB, which is an invasive operation and increases patients' economic burden. A screening method has been established that uses the interferon gamma release test as the primary screening test, and those who are positive undergo endometrial biopsy. Therefore, this project will use QFT to screen participants with Mtb infection, and further endometrium biopsy will be performed for QFT positive patients to diagnose LTBI, FGTB and SGTB. For participants with negative results for all diagnostic tests but QFT (defined as LTBI), close follow-up is necessary according to WHO guidelines.
223934979|NCT01214031|DEVICE|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
223934980|NCT03260452|PROCEDURE|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
223934981|NCT01413659|BIOLOGICAL|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
223934982|NCT03301870|DRUG|ATx201 Gel 2%|2% active gel
223934983|NCT03301870|DRUG|ATx201 Gel 4%|4% active gel
224097547|NCT05259566|BEHAVIORAL|total menthol ban|menthol ban in both cigarettes and e-cigarettes
224097548|NCT06348355|DRUG|[11C]savolitinib|Radiopharmaceutical; IMP; Sterile solution for IV injection, not more than 10 μg, single administration
224097549|NCT06348355|DRUG|Savolitinib|IMP; 300 mg tablet, oral single administration
224097550|NCT06567327|DRUG|Danuglipron|Danuglipron oral tablets
224097551|NCT06567327|DRUG|Atorvastatin|Atorvastatin oral tablets
223534099|NCT00572559|DRUG|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
223934984|NCT03301870|DRUG|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
223934985|NCT03301870|DRUG|Negative Control|Water for Injection, USP
223934986|NCT03301870|DRUG|ATx201 Placebo|matching placebo gel
223934987|NCT03835559|PROCEDURE|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
223934988|NCT03835559|PROCEDURE|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
223934989|NCT03179046|DIAGNOSTIC_TEST|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
223934990|NCT01252420|DRUG|Enoxaparin|1.5mg/kg daily for 2 weeks
223934991|NCT02919787|DRUG|5-FU|Neoadjuvant treatment
223934992|NCT02919787|DRUG|Oxaliplatine|Neoadjuvant treatment
223934993|NCT02919787|DRUG|Irinotecan|Neoadjuvant treatment
223934994|NCT02919787|PROCEDURE|Pancreatic surgery|All patients
224097552|NCT06567327|DRUG|Rosuvastatin|Rosuvastatin oral tablets
224097553|NCT06090552|BEHAVIORAL|Letter|Letter about ACP
224097554|NCT06090552|BEHAVIORAL|AD|PREPARE advanced directive (AD)
224097555|NCT06090552|BEHAVIORAL|PREPARE website|PREPARE website
224097556|NCT06090552|BEHAVIORAL|reminders|reminders to complete the advance directive
224097557|NCT06090552|BEHAVIORAL|healthcare navigator|healthcare navigators provide assistance to complete the advance directive
223934995|NCT02919787|DRUG|5-FU|Adjuvant treatment
223934996|NCT02919787|DRUG|Oxaliplatine|Adjuvant treatment
223934997|NCT02919787|DRUG|Irinotecan|Adjuvant treatment
223934998|NCT03450642|OTHER|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
223934999|NCT01726998|OTHER|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
223935000|NCT01726998|OTHER|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
223935001|NCT03849937|BEHAVIORAL|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
223935002|NCT03507504|OTHER|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
223935003|NCT04926597|DIETARY_SUPPLEMENT|nutritional supplement|daily use of one or more specific oral nutritional supplement with high energy/protein content (i.e., Resource Ultra, Resource 2.0 (Fibre), Resource Ultra Fruit).
223935004|NCT04926597|OTHER|individualized nutritional guidelines|nutritional plan supervised by an experienced study dietician based on the usual home nutrition with possibility to increase intake by adaptation to patient preferences, between meal snaking and food enrichment/fortification. Every 2-4 weeks phone call by unblinded study dietician to follow nutritional intervention.
223935005|NCT04926597|OTHER|general nutritional information|general information about health food behavior upon hospital discharge
223935006|NCT04284878|GENETIC|PCR-RFLP|PCR-Restriction fragment length polymorphism
224097558|NCT06471205|DRUG|BL-B01D1|Administration by intravenous infusion on D1 and D8, or D1 for a cycle of 3 weeks.
224097559|NCT06471205|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks (Q3W).
224097560|NCT04714086|DRUG|Avapritinib|Avapritinib will be administered orally at 300 mg QD.
224097561|NCT04888611|BIOLOGICAL|Camrelizumab plus GSC-DCV|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and GSC-DCV IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
224097562|NCT04888611|BIOLOGICAL|Camrelizumab plus Placebo|Prior to scheduled surgery, patients need to receive Camrelizumab IV (3mg/kg, up to 200mg). After surgery, patients receive Camrelizumab IV (3mg/kg, up to 200mg) and Placebo IH every 3 weeks in the absence of disease progression or unacceptable toxicity.
223935007|NCT05902845|DRUG|RD13-02 cell infusion|CAR-T cells
224097563|NCT01639820|PROCEDURE|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
224097564|NCT01639820|PROCEDURE|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
224097565|NCT06159114|DRUG|Ningmitai capsule|Ningmitai capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.
224097566|NCT06159114|DRUG|Celecoxib capsule|Celecoxib is one of NSAIDs recommended by the CUA Prostatitis Guidelines for alleviating pain symptoms in CP/CPPS patients. The instruction of Celecoxib capsule is 1 capsule at a time, 1 time a day.
224097567|NCT06159114|DRUG|Ningmitai placebo|Ningmitai placebo, a look-alike substance that contains no active drug, similar to Ningmitai capsule in color, smell, taste, shape, texture and other characteristics, 0.38g/ capsule.
223935008|NCT05716113|DRUG|RD13-02 cell infusion|CAR-T cells
223935009|NCT03407144|BIOLOGICAL|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
223935010|NCT03407144|DRUG|doxorubicin|"25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
223935011|NCT03407144|DRUG|vinblastine|"6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
223935012|NCT03407144|DRUG|dacarbazine|"375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
223935013|NCT03407144|DRUG|cyclophosphamide|500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
224097568|NCT06159114|DRUG|Celecoxib placebo|Celecoxib placebo, a look-alike substance that contains no active drug, similar to Celecoxib capsule in color, smell, taste, shape, texture and other characteristics, 0.2g/ capsule.
224097569|NCT04222023|DRUG|Intravenous immunoglobulins (IVIG)|"Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day."
224097570|NCT05425459|DEVICE|Corvia Atrial Shunt System / IASD System II|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
224097571|NCT05425459|OTHER|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
224097572|NCT05692830|DRUG|Alcohol|Alcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
223935014|NCT03407144|DRUG|vincristine|"1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
223935015|NCT03407144|DRUG|prednisone/prednisolone|"60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
223935016|NCT03407144|DRUG|bleomycin|10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
223935017|NCT03407144|DRUG|etoposide|125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
223935018|NCT03407144|RADIATION|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
223935019|NCT01982682|RADIATION|Total-Body Irradiation (TBI)|Undergo TBI
223935020|NCT01982682|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
223935021|NCT01982682|DRUG|Cyclophosphamide|Given IV
223935022|NCT01982682|PROCEDURE|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
223935023|NCT01982682|DRUG|Mycophenolate mofetil|Given IV
223935024|NCT05788965|DRUG|Semaglutide|glucagon-like peptide 1 (GLP-1) receptor agonist
223935025|NCT00277914|DRUG|Flibanserin|flibanserin flexible dosing
224097573|NCT06645756|OTHER|Test meal|Test meal consisting of fries, chicken nuggets and eggs
223935026|NCT03865199|BEHAVIORAL|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
223935027|NCT06514391|PROCEDURE|compressive single piece dental implant|4 inter-foraminal single piece compressive dental implants were placed in the mandible via flapless protocol by the aid of stereolithographic surgical guide
223935028|NCT05662436|OTHER|Open Sky School program|Teachers lead students in 2 hours of outdoor activities per week for 12 weeks, as detailed in the arm description
223935029|NCT03259269|OTHER|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
223935030|NCT02760654|DEVICE|Proactive Self Management Program for Effects of Cancer Treatment|
223935031|NCT00224432|DRUG|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
223935032|NCT04515992|BEHAVIORAL|High Intensity Body-weight Circuit Training (HIBC)|HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
223935033|NCT05188066|DIAGNOSTIC_TEST|Histology|Collect the placenta and fetal membranes and perfor either tissue culture or fixation for further analyses
223935034|NCT06566339|DEVICE|Robotically Aligned Eye Imaging System|Robotically Aligned Eye Imaging System is a non-contact, micrometer scale imaging technique that provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D. The study team will develop hardware systems and software algorithms necessary for acquiring ocular anterior segment images for those seeking eye care in emergency department settings.
224097574|NCT06217783|DEVICE|Introcan Safety IV Catheter|Given by IV
224097575|NCT05332769|GENETIC|FLIM parameters|Cumulus samples (CCs) will be collected following the protocol on the day of oocyte pick up (OPU). CCs are frozen by the cryo-tech method, then stored in liquid nitrogen at -196oC. Information of CC samples and processed date/time is recorded. After all, samples are collected, they will be transferred to The Needleman Lab, Northwest Lab Building 359,52 Oxford Street Cambridge MA 02138 to measure mitochondria metabolism using FLIM.
223935035|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) food introduction-1st|1 serving size of food proven to induce histologic and clinical symptoms in EoE
223935036|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (E0E) food introduction-2nd|Either 1 serving size of different food (not food in arm 1) to induce histologic and clinical symptoms in EoE or Increase the food in arm 1 to 2 serving size a day
224097576|NCT01016626|DRUG|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~* 500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
223935037|NCT05247866|DIETARY_SUPPLEMENT|Eosinophilic Esophagitis (EoE) Food introduction-3rd dose|Either 1 serving size of different food (not food in arm 1 or 2) to induce histologic and clinical symptoms in EoE or Increase the food in arm 2 to 2 serving size a day or unlimited amounts of food arm 1
223935038|NCT05247866|DRUG|Dupilumab|"All patients will receive open label dupilumab at the following doses \>12 years of age \> 40 kg 300 subcutaneous (SQ) weekly~6-11 years of age 5-15 kg 100 mg SQ every 2 weeks (Q2W) 15-30 kg 200 mg SQ Q2W \>30-60 kg 300 mg SQ Q2W"
223935039|NCT01532310|DRUG|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
223935040|NCT01501617|BIOLOGICAL|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
223935041|NCT01501617|DEVICE|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
223935042|NCT02186509|RADIATION|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
223935043|NCT02186509|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
223935044|NCT02186509|DRUG|Alisertib|Given PO
223935045|NCT02186509|PROCEDURE|Quality-of-life assessment|Ancillary studies
223935046|NCT01163981|OTHER|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
223935047|NCT03500822|PROCEDURE|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
223935048|NCT03500822|PROCEDURE|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
223935049|NCT04715269|DRUG|Alprazolam|Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency
223935050|NCT04715269|OTHER|Placebo|Empty capsule
223935051|NCT02482701|DEVICE|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
224285965|NCT05528640|OTHER|Mental Health Literacy Program|Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
223935052|NCT06407804|OTHER|Thrower's Ten Exercise Program|No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 2 sets for 10 repetitions with 1 minute rest between sets.
223935053|NCT06407804|OTHER|Routine physical therapy.|"In this, the exercises will be performed in 2 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min Per Session)"
223935054|NCT03039296|PROCEDURE|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
223935055|NCT04235998|DIAGNOSTIC_TEST|Systematic lung ultrasound|"Patients will undergo a systematic lung ultrasound including review of:~* Sonographic characteristic of effusion~* Parietal, diaphragmatic and visceral pleura~* Pleural nodules~* Lung parenchyma~* Extra pulmonary findings: Hepatic pathology, enlarged lymph nodes of the neck and a cardiac assessment."
223935056|NCT00325767|DRUG|nebulized albuterol (2.5 mg/3ml/dose)|
223935057|NCT00325767|DRUG|nebulized levalbuterol (1.25 mg/3ml/dose)|
223935058|NCT00325767|DRUG|nebulized placebo (3ml/dose)|
223935059|NCT02261805|DRUG|Ganetespib|
223935060|NCT02261805|DRUG|Doxorubicin|
223935061|NCT00895609|DRUG|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
223935062|NCT01292863|OTHER|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
223935063|NCT01292863|OTHER|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
223935064|NCT00963092|GENETIC|DNA analysis|
223935065|NCT00963092|GENETIC|RNA analysis|
223935066|NCT00963092|GENETIC|microarray analysis|
223935067|NCT00963092|GENETIC|protein analysis|
223935068|NCT00963092|OTHER|cytology specimen collection procedure|
223935069|NCT00963092|OTHER|laboratory biomarker analysis|
223935070|NCT00963092|OTHER|questionnaire administration|
223935071|NCT01389921|OTHER|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
223935072|NCT05328258|DRUG|Triptorelin Embonate|"11.25 mg will be given for subjects having at least 3 months gonadotoxic treatment, one injection of 11.25 mg will compensate for 3 months' effect of the study drug.~3.75 mg will be given for subjects during one-month of gonadotoxic treatment, one injection of 3.75 mg will compensate for 1 month' effect of the study drug."
223935073|NCT05328258|DRUG|Sodium Chloride solution 0.9%|One injection compensating for 3 months' effect OR one injection compensating for 1 month' effect to maintain the study blind.
224097577|NCT01016626|DRUG|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~* 250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
223935074|NCT04553549|DEVICE|Transradial approach|"Patients who are undergoing endovascular intervention will be enrolled into the study. As the metrics analyzed in this study are already normally collected, this study can be considered as a secondary use of the data. The procedure will be done using standard criteria as per operator preference. All interventional cases at the study institution undergo a radial first approach, meaning that the access site of choice is the radial artery. The investigators will measure the radial artery size to ensure that the artery is greater than 2.4 mm in order to use the Infinity catheter (8Fr)."
223935075|NCT01296100|BEHAVIORAL|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
223935076|NCT01296100|BEHAVIORAL|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
223935077|NCT02893800|DEVICE|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
223935078|NCT02430766|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
223935079|NCT02430766|DEVICE|NanoKnife|
223935080|NCT06402552|DIAGNOSTIC_TEST|bp-MRI prostate|Biparametric MRI is considered less comprehensive compared to multiparametric MRI (mp-MRI), which includes additional parameters like dynamic contrast-enhanced MRI (DCE-MRI). However, bp-MRI offers a simpler, faster, and often less expensive alternative that still provides critical diagnostic information, particularly in the detection of clinically significant prostate cancer. It's commonly used where less comprehensive assessment is sufficient or in situations where contrast use is contraindicated.
223935081|NCT06402552|DIAGNOSTIC_TEST|mp-MRI prostate|Multiparametric MRI is highly valued for its ability to improve the detection and characterization of clinically significant prostate cancer, aid in biopsy guidance, and help in treatment planning and monitoring. Its comprehensive approach provides crucial insights that are not as readily available through simpler imaging modalities like biparametric MRI (bp-MRI).
223935082|NCT02593760|OTHER|Placebo|Placebo will be administered PO QD for up to 48 weeks.
223935083|NCT02593760|DRUG|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
223935084|NCT02593760|DRUG|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
223935085|NCT00065182|DRUG|Topotecan/Docetaxel combination|
223935086|NCT00065182|DRUG|Docetaxel|
223935087|NCT00564421|DRUG|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
223935088|NCT00564421|OTHER|placebo nasal spray|2 sprays in each nostril, dosed twice a day
223935089|NCT00564421|DRUG|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
223935090|NCT00564421|DRUG|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
223935091|NCT00564421|DRUG|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
223935092|NCT04684095|BEHAVIORAL|electronic patient report outcome|ePRO was conducted every two weeks in addition to routine follow-up
223935093|NCT04707807|DIAGNOSTIC_TEST|IIEF-5|IIEF-15 form will be filled out by all participants
223935094|NCT01946594|OTHER|Acetaminophen|
223935095|NCT01946594|OTHER|Placebo|
224097578|NCT00100048|DRUG|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
224097579|NCT00100048|DRUG|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
223935096|NCT05097638|DIAGNOSTIC_TEST|spirometry|Patient do spirometry
223935097|NCT02097381|DRUG|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
223935098|NCT03117426|DEVICE|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
223935099|NCT03117426|DEVICE|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
224097580|NCT00100048|DRUG|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
224097581|NCT00100048|DRUG|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
224097582|NCT00100048|DRUG|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
224097583|NCT00100048|DRUG|Placebo monotherapy|Placebo to MK0518 twice daily
224097584|NCT00646659|BIOLOGICAL|cetuximab|
224097585|NCT00646659|DRUG|carboplatin|
224097586|NCT00646659|DRUG|cisplatin|
224097587|NCT00646659|DRUG|docetaxel|
224097588|NCT00646659|DRUG|fluorouracil|
224097589|NCT00646659|GENETIC|fluorescence in situ hybridization|
224097590|NCT00646659|GENETIC|molecular genetic technique|
224097591|NCT00646659|GENETIC|reverse transcriptase-polymerase chain reaction|
224097592|NCT00646659|OTHER|immunoenzyme technique|
224097593|NCT00646659|OTHER|immunohistochemistry staining method|
224097594|NCT00646659|OTHER|laboratory biomarker analysis|
224097595|NCT00646659|PROCEDURE|biopsy|
224097596|NCT00646659|RADIATION|3-dimensional conformal radiation therapy|
224097597|NCT00646659|RADIATION|intensity-modulated radiation therapy|
224285966|NCT05500092|DRUG|Nivolumab|Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
224285967|NCT05500092|RADIATION|(8gy x 3)|sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
223935100|NCT01608568|DEVICE|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
223935101|NCT05343494|BEHAVIORAL|Lifestyle Intervention|"The intervention has been modified from a subset of sessions from the National DPP Prevent T2 Curriculum (an adapted DPP for community settings that improves cardiometabolic outcomes and is implemented nationwide).~The intervention will consist of 8 weekly sessions. The first session will be one-on-one and subsequent sessions will be in small groups. Sessions 1, 2, and 6 will be in-person and other sessions will be held by Zoom."
223935102|NCT00754325|DRUG|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
223935103|NCT00754325|DRUG|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
223935104|NCT03964740|OTHER|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
223935105|NCT01146522|DRUG|LCQ908|
223935106|NCT01146522|DRUG|Placebo|
223935107|NCT04980638|BIOLOGICAL|ER004|Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
223935108|NCT01768793|BEHAVIORAL|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
223935109|NCT01768793|BEHAVIORAL|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
223935110|NCT00351299|DRUG|Dexmedetomidine|dexmedetomidine infusion titrated to effect
224285968|NCT05500092|DRUG|Platinum Doublet|Standard of care doublet platinum therapy
224285969|NCT01749748|PROCEDURE|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
224285970|NCT02900274|DEVICE|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
224285971|NCT03023657|OTHER|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
224285972|NCT02839668|DRUG|Lidocaine|Continuous infusion of lidocaine
223534100|NCT00572559|DRUG|Linezolid|600 mg every 12 hours (intravenously \[IV\] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
223935111|NCT00351299|OTHER|Standard of Care|Standard of care per treating physician preference
223935112|NCT03442777|DEVICE|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith\&Nephew (Allevyn® brand).
223935113|NCT03442777|DEVICE|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
223935114|NCT04876417|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
223935115|NCT04876417|DEVICE|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
224285973|NCT02839668|DRUG|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
224285974|NCT02839668|DRUG|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
224285975|NCT02839668|DRUG|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
223534101|NCT03181984|DRUG|Hemoporfin|Hemoporfin mediated photodynamic therapy
223534102|NCT01356147|DRUG|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
223534103|NCT01356147|DRUG|Placebo|No therapy will be given to placebo arm
224285976|NCT02839668|DRUG|Tramadol|administration of tramadol for postoperative analgesia
224285977|NCT02839668|DRUG|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
223935116|NCT03155113|OTHER|blood drawing|Before starting therapy a blood sample will be collected from any subject.
224097598|NCT03878485|DEVICE|MRIdian Linac System from ViewRay|"* 0.35T MRI combined with a linear accelerator~* This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
224097599|NCT03878485|RADIATION|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
223935117|NCT01441284|DRUG|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
223935118|NCT01441284|DRUG|placebo|placebo
223935119|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
223935120|NCT03801148|DRUG|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
223935121|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
223935122|NCT03801148|DRUG|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
223935123|NCT02127749|DRUG|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
223935124|NCT02127749|DRUG|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
223935125|NCT00439270|DRUG|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
223935126|NCT00439270|DRUG|Docetaxel|Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
223935127|NCT06337058|BEHAVIORAL|Experimental group (motivational interview)|"For the menopausal women with sexual dysfunction in the experimental group, pre-test data were obtained by applying the 'Personal Information Form', the 'Sexual Quality of Life Scale-Woman' and the 'Sexual Self-Efficacy Scale' before starting the motivational interviews. After the pre-test data were obtained, a total of 4 sessions of motivational interviews were provided, one session per week for four weeks. At the end of four weeks, post-test data were obtained by applying the Arizona Sexual Experiences Scale, Sexual Quality of Life Scale-Women and Sexual Self-Efficacy Scale.~The researcher received a training on motivational interview techniques before implementing the intervention for menopausal women in the experimental group."
223935128|NCT06031116|PROCEDURE|depigmentation|gingival depigmentation
223935129|NCT04316936|DRUG|Omidria|phenylephrine 1% and ketorolac 0.3% intraocular solution
223935130|NCT04316936|DRUG|Dextenza (dexamethasone ophthalmic insert) 0.4mg|intracanalicular dexamethasone insert
223935131|NCT04316936|DRUG|Dexycu, 9% Intraocular Suspension|dexamethasone intraocular suspension
223935132|NCT04316936|DRUG|Prednisolone Acetate 1%|standard postoperative ophthalmic drop regimen
223935133|NCT06274099|OTHER|nursing care|It is thought that this study, in which individualized care will be based on comfort theory, will lead to individualized care in chronic diseases.
223935134|NCT01290003|DRUG|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
224097600|NCT01624142|BIOLOGICAL|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
223935135|NCT00188045|DRUG|Propranolol - Spironolactone|
223935136|NCT02672891|DEVICE|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
224097601|NCT01054066|BEHAVIORAL|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
224097602|NCT04992988|DRUG|Toripalimab|Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT
224097603|NCT00879450|OTHER|Booklet|booklet given to parents for home exercises
224097604|NCT01822561|DRUG|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
223935137|NCT04593238|DRUG|Double Antibiotic paste|Metronidazole and Ciprofloxacin
223935138|NCT04593238|DRUG|Calcium Hydroxide Paste - Non-Setting|Calcium hydroxide paste to be delivered inside the canal as an intra-canal medication
223935139|NCT03311360|DEVICE|drug-coated balloon|Orchid and Dahlia DCB
223935140|NCT03311360|DEVICE|bare metal stent|any type of bare metal stent
223935141|NCT01750684|DRUG|AC105|
223935142|NCT01750684|OTHER|Placebo|
223935143|NCT03793413|PROCEDURE|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
224097605|NCT05807308|BEHAVIORAL|Technology-based cognitive and artistic therapeutic activities|Therapeutic and artistic activities within the program (drawing, mandala, etc.). The program will be implemented in 6 sessions in two weeks. At the beginning and end of the program, children's anxiety and spiritual well-being levels will be evaluated.
224097606|NCT00900003|GENETIC|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
224285978|NCT02839668|DRUG|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
224285979|NCT02839668|DEVICE|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
224285980|NCT03039348|OTHER|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
224285981|NCT01349101|RADIATION|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
223935144|NCT00428805|BEHAVIORAL|classroom curriculum|"classroom curriculum for 3 \& 4 year old children includes activities to increase intake of fruits, vegetables, \& whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
223935145|NCT00428805|BEHAVIORAL|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
223935146|NCT00428805|BEHAVIORAL|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
223935147|NCT00428805|BEHAVIORAL|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
223935148|NCT00428805|BEHAVIORAL|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
223935149|NCT00428805|BEHAVIORAL|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
223935150|NCT00428805|BEHAVIORAL|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
223935151|NCT03916341|OTHER|EC with nicotine|Use an EC with nicotine for up to 30 minutes
223935152|NCT03916341|OTHER|EC without nicotine|Use an EC without nicotine for up to 30 minutes
223935153|NCT03916341|OTHER|control|sham control
223935154|NCT03916341|OTHER|TC with nicotine (own brand)|smoke a TC
223935155|NCT03916341|OTHER|research TC with very low level nicotine|smoke a research TC with very low level nicotine
223935156|NCT03188341|OTHER|vascular surgery procedure|"* an elective open vascular surgery procedure~* ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
223935157|NCT02765594|DRUG|Hydroxychloroquine Sulfate|200mg bid
223935158|NCT02765594|DRUG|Valsartan|160mg qd
223935159|NCT03478969|DEVICE|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
223935160|NCT03478969|DEVICE|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
223935161|NCT03478969|OTHER|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
223935162|NCT01185600|BIOLOGICAL|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
223935163|NCT01185600|BIOLOGICAL|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
224097607|NCT00900003|OTHER|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
223935164|NCT03673566|DEVICE|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
223935165|NCT05749224|DIAGNOSTIC_TEST|Helkimo Index|Helkimo Index is comprised of five items, with each assessment having three possible answers, scored as 0, 1 or 5. The first item is related to the limitation in the range of jaw movement. The second item evaluates the alterations of joint function that produce deviations, sounds and/or joint locks or blockages; the third item evaluates the presence of pain when performing some movements; the fourth item evaluates muscular pain in the masticatory muscles; and the fifth item evaluates the presence of discomfort or pain in the prearticular area of the temporomandibular joint (TMJ) through palpation. From the sum of the 5 items, we identify no TMJ involvement if the score is 0, mild TMJ involvement when the score ranges from 1 to 9, moderate TMJ involvement if the score ranges between 10 and 19 and severe TMJ involvement for a score between 20 and 25.
223935166|NCT01164488|DRUG|danoprevir|Repeated daily doses
223935167|NCT01164488|DRUG|ketoconazole|Repeated daily doses
223935168|NCT01164488|DRUG|ritonavir|Repeated daily doses
223935169|NCT04638738|DEVICE|SensiumVitals wearable patch sensor|Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
223935170|NCT05089266|DRUG|CAR T cells|αPD1-MSLN-CAR T Cells
223935171|NCT01540500|DRUG|Tasimelteon|5.66 mg dose on Day 1 and Day 8
223935172|NCT01540500|DRUG|Fluvoxamine|50 mg Dose on Days 2-8
223935173|NCT00661336|DRUG|buthionine sulfoximine|
223935174|NCT00661336|DRUG|melphalan|
223935175|NCT00661336|GENETIC|microarray analysis|
223935176|NCT00661336|OTHER|high performance liquid chromatography|
223935177|NCT00661336|OTHER|laboratory biomarker analysis|
223935178|NCT00661336|OTHER|pharmacological study|
224097608|NCT04116099|OTHER|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
224097609|NCT04116099|DEVICE|Flexitouch Plus|Flexitouch Plus treatment.
223935179|NCT00661336|PROCEDURE|biopsy|
223935180|NCT05179265|DRUG|recombinant human serum albumin|10 g/bottle (20%, 50 mL)
223935181|NCT05179265|DRUG|Human serum albumin|10 g/bottle (20%, 50 mL)
223935182|NCT05405244|DRUG|Placebo|2 capsules, orally administered once
224097610|NCT03991637|DEVICE|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
224285982|NCT01349101|DRUG|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
224285983|NCT01349101|DRUG|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
223935183|NCT05405244|DRUG|Bromocriptine-QR|1.6mg (2 0.8mg capsules), orally administered once
223935184|NCT01410409|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
223935185|NCT01410409|DRUG|Paracetamol|1 g x 4/day
223935186|NCT01410409|DRUG|Burana|400 mg x 3/day for three weeks
223935187|NCT01410409|DRUG|Pantoprazol|20mg x 1/day for three weeks
223935188|NCT01410409|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
224097611|NCT06107192|OTHER|Dietary intervention - apple catechin diet|The intervention will provide a catechin-containing apple juice, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
224097612|NCT06107192|OTHER|Dietary intervention - low catechin diet|The intervention will provide a nutritionally-matched beverage without catechins, for consumption alongside a low catechin diet tailored to participants calorie needs for weight maintenance.
224097613|NCT05088148|OTHER|. Pesticide and Pharmaceutical analysis|Pesticide and Pharmaceutical analysis will be done with LC-MS/MS device.
224097614|NCT06584591|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and the transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
224097615|NCT06584591|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training administered by the Physical therapist.
224097616|NCT05350150|DEVICE|Auricular Vagal Nerve Stimulation|The Parasym device will be placed on the patient's left tragus to provide transcutaneous electrical stimulation to the auricular branch of the vagus nerve.
224285984|NCT01349101|DRUG|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
224285985|NCT01349101|DRUG|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
224285986|NCT01349101|DRUG|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
223935189|NCT01410409|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
223935190|NCT01410409|PROCEDURE|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
223935191|NCT01410409|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
223935192|NCT01702376|DRUG|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
223935193|NCT01702376|DRUG|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
223935194|NCT01702376|DRUG|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
224097617|NCT06665074|BIOLOGICAL|Endotoxin (E. coli O:113, Reference Endotoxin)|Dosage of endotoxin is 0.8 ng/Kg body Weight
223935195|NCT01702376|DRUG|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
223935196|NCT00055991|DRUG|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
223935197|NCT03158506|DRUG|HMS5552|\[14C\]-labelled HMS5552
223935198|NCT05267769|DRUG|AP707|Preparation of Cannabis flowers (Cannabis flos)
223935199|NCT00010088|DRUG|fluorouracil|
224097618|NCT06665074|OTHER|Saline (Placebo)|Volume of saline to be the same as volume of endotoxin
224097619|NCT06974396|BIOLOGICAL|Prothrombin time|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
224097620|NCT06667843|BEHAVIORAL|Lifestyle Management|Behavioral intervention for lifestyle change
224285987|NCT01349101|GENETIC|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
224285988|NCT04153448|OTHER|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
223935200|NCT00010088|DRUG|gemcitabine hydrochloride|
223935201|NCT00010088|DRUG|leucovorin calcium|
223935202|NCT00010088|PROCEDURE|conventional surgery|
223935203|NCT00010088|RADIATION|radiation therapy|
223935204|NCT01788371|DRUG|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
223935205|NCT01788371|DRUG|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
223935206|NCT00278135|DIETARY_SUPPLEMENT|DHA (nutritional supplement) or placebo|oral 900mg/day
224285989|NCT04681196|OTHER|patients shifted to nasal mask after persistent OSA with oronasal mask|In this group were selected OSA patients exhibiting persistent obstructive events and paradoxical obstruction with oronasal masks during CPAP , that were fully recovered (no more OSA detected) with the shift to nasal one
224285990|NCT02358850|DRUG|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
224285991|NCT02358850|DRUG|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
223935207|NCT00918333|DRUG|panobinostat|Given PO
223935208|NCT00918333|DRUG|everolimus|Given PO
223935209|NCT00918333|OTHER|laboratory biomarker analysis|Correlative studies
223935210|NCT00918333|OTHER|pharmacological study|Correlative studies
223935211|NCT04092322|DEVICE|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
223935212|NCT04092322|OTHER|PASE|Physical Activity Scale for Elderly
223935213|NCT06236984|OTHER|multiFiltratePRO with all CKRT treatment modes|Retrospective Data Analysis of CKRT treatments in adult mode with multiFiltratePRO
223935214|NCT03225625|PROCEDURE|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
223935215|NCT03225625|PROCEDURE|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
223935216|NCT03225625|PROCEDURE|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
223935217|NCT06226441|PROCEDURE|Continuous Renal Replacement Therapy|CRRT
223935218|NCT06950814|PROCEDURE|postoperative adjuvant therapy|Given the rarity and high aggressiveness of PHSC, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines.
223935219|NCT05775757|RADIATION|Hypofractionated radiation therapy|Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
223935220|NCT04825379|DEVICE|bioactive composite|Cention N
223935221|NCT04825379|DEVICE|posterior composite|G-ænial Posterior
223935222|NCT05065957|DRUG|D07001-softgel capsules + Xeloda (or TS-1)|"D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle).~Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)"
223935223|NCT05065957|DRUG|mFOLFOX|intravenous infusion on Day 1 for 14-day cycle
223935224|NCT06261710|OTHER|Sonography in labour|Using intrapartum sonography parameters in labour
223935225|NCT05374889|OTHER|Open Kinetic Chain Proprioception Exercises|basketball-specific target shooting in open kinetic chain
223935226|NCT02352675|OTHER|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
223935227|NCT01446497|DRUG|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
223935228|NCT01446497|DRUG|Timolol|Twice per day, 1 drop at each time
223935229|NCT01693211|DEVICE|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
223935230|NCT01693211|DEVICE|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
223935231|NCT06435650|COMBINATION_PRODUCT|Cannabis suppositories and mindful-compassion for anal pain|This is a combined intervention that includes mindful-compassion and cannabis suppositories for anal pain
223935232|NCT06435650|BEHAVIORAL|Mindful-compassion|Mindful-compassion
223935233|NCT04248998|DIETARY_SUPPLEMENT|Fasting-mimicking diet|Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
223935234|NCT04248998|DRUG|Metformin|Metformin 850 mg twice a day
224097621|NCT06667843|DEVICE|Intervention|Full access to DTx function in the app, and digital follow up/communication with helthcare professionals at the Healthy Lives Center
223935235|NCT04248998|DRUG|Preoperative chemotherapy|"Chemotherapy will consist of:~* four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by~* twelve consecutive cycles of weekly paclitaxel 80 mg/mq"
223935236|NCT01236846|DIETARY_SUPPLEMENT|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
223935237|NCT01236846|DIETARY_SUPPLEMENT|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
223935238|NCT04621435|DRUG|Gallium-68 labelled (68Ga-) FAP-2286|The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
223935239|NCT04621435|PROCEDURE|Positron Emission Tomography (PET) imaging|Participants will be scanned for approximately 30 to 45 minutes
223935240|NCT04621435|DRUG|Copper-64 labeled (64Cu-) FAP-2286|The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging
223935241|NCT06379516|OTHER|Moisturising Cream (5%)|This intervention is a moisturiging cream of concentration 5% for topical application to the respective test sites.
223935242|NCT06379516|OTHER|Moisturising Cream (10%)|This intervention is a moisturiging cream of concentration 10% for topical application to the respective test sites.
223935243|NCT06379516|OTHER|Coconut Oil|This intervention is a 100% pure coconut oil product (Parachute Pure Coconut Oil) for topical application to the respective test sites.
223935244|NCT02097069|DIETARY_SUPPLEMENT|Folic acid|Folic acid 400 mcg/day
223935245|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol|myo-inositol 2000 mg twice a day
223935246|NCT02097069|DIETARY_SUPPLEMENT|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
223935247|NCT02097069|DIETARY_SUPPLEMENT|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
224097622|NCT06667843|DEVICE|Control|Basic access to the app (daily logging functions). No digital follow up or communication with healthcare professionals at the Healthy Lives Center.
224097623|NCT02954380|DEVICE|Zio|long term continuous monitoring
224097624|NCT01696357|DEVICE|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
224285992|NCT02358850|DRUG|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
224285993|NCT02358850|DRUG|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
224285994|NCT04217655|DIAGNOSTIC_TEST|Low-dose computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
224285995|NCT04217655|DIAGNOSTIC_TEST|Standard-dose computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
223935248|NCT02796729|PROCEDURE|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
223935249|NCT02796729|DRUG|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
223935250|NCT02796729|DRUG|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
223935251|NCT02325349|DRUG|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
223935252|NCT01638975|BEHAVIORAL|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
223935253|NCT04218383|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC and cathode placed over the right primary motor cortex.
223935254|NCT00402428|DRUG|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
223935255|NCT00402428|DRUG|peginterferon alfa-2a|180 mcg once a week for 48 weeks
223935256|NCT00402428|DRUG|Ribavirin|"1000 mg/day(for subjects \<75kg) or 1200 mg/day (for subjects~=,\> 75kg)"
224097625|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every week|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224097626|NCT05793619|DEVICE|Prototypes (816-v1 301) to (816-v1 355) every two weeks|Application on brown spots located on the face (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face. Subjects will be lying down, and the prototypes will be administered upside down. During applications, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224097627|NCT04320836|PROCEDURE|Cervical epidural steroid injection|Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
224097628|NCT00202592|DRUG|Perindopril|
224097629|NCT04699630|DRUG|U3-1402|All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.
224097630|NCT02348073|DRUG|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
224097631|NCT02348073|DRUG|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
224097632|NCT04671797|BEHAVIORAL|Early dinner|Dinner at DLMO-3, sleep at DLMO+2
224097633|NCT04671797|BEHAVIORAL|Late Dinner|Dinner at DLMO+1, sleep at DLMO+2
223718618|NCT03195998|DIAGNOSTIC_TEST|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
223935257|NCT01560494|OTHER|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
223935258|NCT02964741|DEVICE|Active Comparator|non-invasive brain stimulation (active protocol)
223935259|NCT02964741|DEVICE|Sham Comparator|non-invasive brain stimulation (sham protocol)
224097634|NCT04671797|BEHAVIORAL|Late Dinner + Late Sleep|Dinner at DLMO+1, sleep at DLMO+6
224097635|NCT03947229|DRUG|Clopidogrel mono-therapy|Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
224097636|NCT03947229|DRUG|Dual-antiplatelet therapy|Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
224097637|NCT04495660|DEVICE|Near InfraRed Spectroscopy (fNIRS)|Functional neuroimaging examination by fNIRS at each follow-up visit for all children of both cohorts: this non-invasive imaging technique involves the installation of a cap carrying electrodes to collect brain activity on the surface of the scalp , during stimulation. It is very insensitive to movement and therefore represents a method particularly suitable for its use in children. In addition, this technique is compatible with the cochlear implant. It will be used during 6 tasks adapted to each cohort
224097638|NCT04495660|BEHAVIORAL|Passive perceptual stimulation|Passive perceptual stimulation: For this passive task the child is on his parents' lap in front of a screen. He will see images, hear everyday noises and watch small videos. Duration 8-10 minutes.
224097639|NCT04495660|BEHAVIORAL|Task A not B|Task A not B: the child will play with an adult who will hide an object under a cloth several times. The child will have to find the hidden object. Duration 10 minutes maximum
223718619|NCT01061177|DRUG|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
223718620|NCT03375775|DRUG|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
223935260|NCT02840929|PROCEDURE|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
223718621|NCT03375775|OTHER|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
224097640|NCT04495660|BEHAVIORAL|VSWMT task|VSWMT task: the child will be on the parents' lap in front of a screen and will watch a monkey hiding bananas in the trees several times. Duration of 10 minutes maximum.
224097641|NCT04495660|BEHAVIORAL|Perceptual Go-No-Go|Perceptual Go-No-Go: This perceptual task consists in the discrimination of images (faces) and sounds (words) through 3 conditions (auditory, visual and visuo-auditory) presented independently of each other and lasts 15 to 20 minutes in total. It is presented by means of a computer
224097642|NCT04495660|BEHAVIORAL|Verbal memory task|Verbal memory task :the child will be presented with 5 lists of 5 words which he will have to restore after a predefined delay of a few seconds. Its duration does not exceed 10 minutes.
223935261|NCT02840929|DRUG|Esomeprazole|
223935262|NCT01332175|DEVICE|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
223935263|NCT01332175|DEVICE|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
223935264|NCT01332175|PROCEDURE|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
224097643|NCT04495660|BEHAVIORAL|The sensory room|The sensory room: the child will sit in the middle of a carpet and play with the adult. He will hear everyday noises and see light effects. Duration 8-10 minutes
224097644|NCT06314126|DIETARY_SUPPLEMENT|D-Chiro-Inositol|Patients in the experimental group will receive 1200 mg of oral D-Chiro-Inositol per day.
223935265|NCT04674995|PROCEDURE|Stent placement|All interventional procedures have been performed in the operating room with a Dumon rigid bronchoscope under general anesthesia. Neodymium-doped yttrium aluminium garnet laser photoresection was performed at 15-30 watts and pulse duration of 0.5-1.0s whenever indicated. A silicone stent was placed.
223935266|NCT00640159|DRUG|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
223935267|NCT00076648|DRUG|Poly SFH-P Injection|
223935268|NCT00212251|BEHAVIORAL|moderate exercise and healthy, low-fat diet|
223935269|NCT01500200|DRUG|ALKS 5461|Two active tablets, given daily
223935270|NCT01500200|DRUG|Placebo|Two placebo tablets, given daily
223935271|NCT00455650|DRUG|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
223935272|NCT00455650|DRUG|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
223935273|NCT00455650|DRUG|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
223935274|NCT02412033|DRUG|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
223935275|NCT02412033|DRUG|Placebo|This group will receive placebo
223935276|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
223935277|NCT00914771|BIOLOGICAL|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
224097645|NCT06314126|OTHER|Placebo|Patients in the control group will receive 1200 mg of placebo per day.
224097646|NCT05119556|BEHAVIORAL|Video Telehealth Pulmonary Rehabilitation|Participant will be asked to exercise 3 times a week at their home for 60 minutes each session, via live two-way videoconferencing using a data-enabled smart phone or similar device. A total of 36 sessions will be administered over 13 weeks post-discharge. Sessions will be administered by exercise physiologists located at the University of Alabama at Birmingham. Each session will be scheduled with up to three other participants at a time to mimic group sessions as delivered at center-based pulmonary rehabilitation programs. Exercise sessions will include aerobics, strength or resistance training, breathing exercises, and education sessions. The exercise plans will be tailored according to the participants' baseline exercise tolerance as determined by an initial six minute walk test and their answers to the questionnaires at the baseline visit.
223718622|NCT03680105|DRUG|RJX|RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
223935278|NCT00606333|DEVICE|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
224097647|NCT06581484|BEHAVIORAL|Digital patient empowerment intervention|The intervention has features such as a digital medical passport, updated health-related information, community support and patient/peer stories and advice
224097648|NCT06359340|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
224097649|NCT05646836|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
224097650|NCT05646836|DRUG|XmAb24306|XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
224097651|NCT05646836|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
223534104|NCT03741270|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
223534105|NCT00741078|DRUG|statin, amlodipine|
223534106|NCT05983705|BEHAVIORAL|AFFEKT - a manual based brief parent program for parents of children (aged 6-12 years) with externalizing behaviors.|The AFFEKT program includes five group sessions, two hours each, provided on a weekly basis. The program is delivered by therapist trained in Cognitive and Behavioral Therapy (CBT) and AFFEKT. The participants also receive a participation material, covering the same themes that are addressed in the program and working sheets for the home-assignments that are provided in-between sessions.
223935279|NCT00606333|DEVICE|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
223935280|NCT05419466|DIETARY_SUPPLEMENT|dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm|dietary supplement is dosed at 1.9 mg of melatonin, 10 mg of zinc and 200 mg of lemon balm for one tablet
223935281|NCT06303674|BEHAVIORAL|Physical activity with engaging cognitively|"This experimental condition will follow the following structure: involving 10 consecutive, 30 second-blocks of physical activity. This experimental condition will focus on aerobic metabolism. The total exercise time commitment is 10 minutes (30 seconds of working - 30 seconds of executing an engaging cognitive task, 1:1 work-to-rest ratio), plus 5 minutes of warm-ups and 5 minutes of cool-down activities. The cognitive task consists of solving various tangrams."
223935282|NCT06303674|BEHAVIORAL|Physical activity without engaging cognitively|This experimental condition will replicate the structure of the preceding one. Participants will engage in physical activity, guided by video observation and imitation. However, during the rest periods, they will refrain from engaging in cognitive tasks
224097652|NCT06314243|DIETARY_SUPPLEMENT|"Pumpkin Seed Oil  Ronkin®, KMT PHARMA, Egypt. "|Ronkin soft gelatin capsules, each containing 1010 mg of pumpkin seed oil (Latin name: Curcurbita pepo), standardized to contain palmitic acid (8-15%), stearic acid (3-8%), oleic acid (15-35%), linoleic acid (40-65%), and other fatty acids (≤ 2.4%)
224285996|NCT06529939|DRUG|Psilocybin|"Individuals will be given 15 milligrams (mg) of psilocybin orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) brain scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
224285997|NCT06529939|OTHER|Placebo|"Individuals will be given a placebo orally, and will be asked to lay flat in a functional magnetic resonance imaging (fMRI) scanner. The following scans will be collected: anatomical and resting state; while they watch a scrambled film clip; while they watch an intact film clip; while they perform a mental imagery task; while they listen to two pieces of music.~Participants will then be given two questionnaires: one assessing their overall plot comprehension, and the other asking about their experience in the scanner. They will then be asked to perform a series of visual illusions tasks, and following, play a variety of web-based games assessing their cognitive function. After this, they will be interviewed by one of the study researchers about their overall experience before/during/after the scan."
224285998|NCT01364324|DRUG|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
223718623|NCT03680105|DRUG|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
224097653|NCT01357811|DRUG|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
224097654|NCT01357811|DRUG|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
224285999|NCT04273919|DEVICE|HTC Vive with Karuna Virtual Reality Program|HTC Vive head-mounted display and an HTC Vive body tracker adhered to a belt on the patient's low back, which will be placed 2 inches below the waist
223718624|NCT03612791|DRUG|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
224097655|NCT05131607|PROCEDURE|Supine MRI|After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
224097656|NCT03550560|PROCEDURE|EUS-Guided drainage|Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
224097657|NCT02597062|DRUG|Carfilzomib|
224097658|NCT02597062|DRUG|Cyclophosphamide|
224097659|NCT02597062|DRUG|Dexamethasone|
224097660|NCT04025645|DIAGNOSTIC_TEST|MEASUREMENT OF COMMON BILE DUCT PRESSURES|THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED
224097661|NCT02804360|DEVICE|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
224097662|NCT02034045|OTHER|Community Paramedicine|
224097663|NCT02034045|OTHER|Usual Care|
224286000|NCT04273919|DEVICE|HTC Vive with Lumen Program|HTC Vive head-mounted display with Lumen program
224286001|NCT02573935|DRUG|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
223935283|NCT01905800|DEVICE|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
223935284|NCT03001206|DEVICE|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
223935285|NCT01209195|DRUG|MM-121|increasing doses of MM-121 IV QW
223935286|NCT01209195|DRUG|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
223935287|NCT03471585|DRUG|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
223935288|NCT03471585|DRUG|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
223935289|NCT01212744|DRUG|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
224097664|NCT06273969|OTHER|Osteopathic Manipulative Treatment (OMT)|"The OMT protocol is designed to target the somatic dysfunction associated with TOS. The somatic dysfunction associated with TOS include muscular hypertonicity of the anterior and middle scalene muscles, hypertonicity of the pectoralis muscles, and tension in the fascia of the supraclavicular area between the clavicle and first rib. The OMT protocol will consist of the following four techniques:~Direct Thoracic Inlet Myofascial Release (TIMFR) - Reduce tension at the thoracic inlet fascia located between the thoracic outlet and the cervical spine.~Direct Muscle Energy for the Scalene Muscles -Reduce tension within the scalene muscle group~Direct Muscle Energy for the Pectoralis Muscles - Reduce tension within the pectoralis muscle group~Supraclavicular Fascial Release - Reduce fascial tension within the supraclavicular fossa"
224097665|NCT00212407|BIOLOGICAL|Umbilical Cord Blood Transplantation|
224097666|NCT00423826|DRUG|Busulfan|3 mg/kg intravenously over 3 hours
224097667|NCT00423826|DRUG|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
224097668|NCT00423826|DRUG|Fludarabine phosphate|25 mg/M2/day IV
224097669|NCT00423826|DRUG|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
224286002|NCT02573935|DRUG|Placebo|Placebo tablet twice daily for 63 days
223935290|NCT01749319|DRUG|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
223935291|NCT01749319|DRUG|Intervenous baclofen|
223935292|NCT06274203|DRUG|Vitamin D3|Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (\>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (\<20 ng/mL): 200,000 IU.
223935293|NCT02588313|DIETARY_SUPPLEMENT|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
223935294|NCT02167451|DRUG|Maraviroc|
223935295|NCT05237999|BEHAVIORAL|KopOpOuders-PTSD|See arm description
223935296|NCT01935063|BEHAVIORAL|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
224097670|NCT00423826|DRUG|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
224097671|NCT00423826|PROCEDURE|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
224097672|NCT00423826|PROCEDURE|umbilical cord blood transplantation|10 days post drug intervention
224097673|NCT00423826|RADIATION|total-body irradiation|10 days post drug intervention
224097674|NCT01106547|DRUG|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
224097675|NCT01106547|DRUG|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
224097676|NCT03461055|OTHER|Lavender|Lavender aromatherapy
224097677|NCT03461055|OTHER|Water|Water
224097678|NCT02948166|PROCEDURE|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
224099740|NCT04325594|BIOLOGICAL|Intracoronary administration of umbilical cord-derived MSCs|A suspension of 1×10⁷ umbilical cord-derived mesenchymal stromal cells in 20 ml of heparinized saline was administered by intracoronary infusion into the left coronary artery via a standard 6 Fr catheter over 10 minutes (2 ml/min). The infusion was performed without balloon occlusion or interruption of coronary blood flow.
224099741|NCT05591911|DIAGNOSTIC_TEST|Urine PCR testing|The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
224099742|NCT04790591|PROCEDURE|Same-day surgery|To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
224099743|NCT06303349|OTHER|Samples collection|"from D1 to D10, 1 SSTII (Serum separator tubes II) dry tube of 6 mL blood and 1 EDTA (Ethylenediamine tetraacetic acid) tube of 6 mL blood are collected.~1 SSTII dry tube of 6 mL cerebral spinal fluid will be collected distally in external ventricular drain, after eliminating the dead volume of the collection burette, for patients with it."
224099744|NCT06871670|OTHER|Submaximal isometric contractions of knee extensors|Brief isometric contractions performed at 10, 20, 30, 40, 50 and 60% of maximal voluntary force in a random order.
224286003|NCT02573935|DRUG|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
223935297|NCT01935063|OTHER|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
223935298|NCT03510416|DRUG|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
223935299|NCT03510416|RADIATION|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
223935300|NCT02631655|OTHER|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
223935301|NCT03297138|PROCEDURE|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
223935302|NCT01218659|DRUG|migalastat hydrochloride|150-mg capsule administered orally QOD
223935303|NCT01218659|BIOLOGICAL|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
224097679|NCT02948166|PROCEDURE|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
224097680|NCT01917786|DEVICE|ECG|
224097681|NCT02221609|OTHER|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
224097682|NCT02221609|OTHER|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
224097683|NCT02631720|PROCEDURE|Blood Draw|
224097684|NCT02631720|PROCEDURE|Bronchoscopy|
224097685|NCT01696461|DRUG|Plerixafor|
224286004|NCT01223235|BIOLOGICAL|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
224286005|NCT04975321|DEVICE|Nu Smile Zirconia crown|Placement of an anterior primary crown restoration
224286006|NCT04975321|DEVICE|Nu Smile Pre Veneered crown|Placement of an anterior primary crown restoration
224286007|NCT04975321|DEVICE|Composite strip crown|Placement of an anterior primary crown restoration
224286008|NCT02207335|DRUG|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
223935304|NCT04796792|DEVICE|Break Wave Lithotripsy and Ultrasonic Propulsion|Novel ultrasound technologies to facilitate passage of stones.This includes Burst Wave Lithotripsy (BWL), a technology to noninvasively fragment urinary calculi within the kidney and ureter, and ultrasonic propulsion, a technology to non-invasively reposition stones within the kidney and ureter. BWL uses short multi-cycle bursts of low amplitude ultrasound to induce stone fracture. This is in contrast to traditional extracorporeal shock wave lithotripsy (SWL), which employs a brief single compression/tensile cycle of high amplitude (shock) waves to achieve stone fracture. Ultrasonic propulsion uses long multi-cycle bursts of low amplitude ultrasound to move stones within the collecting system.
223935305|NCT01440166|DRUG|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
223935306|NCT01440166|OTHER|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
223935307|NCT05770492|DIAGNOSTIC_TEST|anterior segment optical coherence tomography|Two different optical systems (MS-39, Costruzione Strumenti Oftalmici Italy; Anterion optical coherence tomographer, Heidelberg Engineering) will be used for acquisition of cross-sectional scans. Radial scan patterns will be used for acquisition.
223935308|NCT02555306|DRUG|0.5 mg of DE-122|DE-122 Injectable Solution
223935309|NCT02555306|DRUG|1.0 mg of DE-122|DE-122 Injectable Solution
224097686|NCT02770157|DRUG|DA-3002|
224097687|NCT02770157|DRUG|Genotropin®|
223935310|NCT02555306|DRUG|2.0 mg of DE-122|DE-122 Injectable Solution
223935311|NCT02555306|DRUG|4.0 mg of DE-122|DE-122 Injectable Solution
224097688|NCT02504255|BIOLOGICAL|Biological samplings|Blood, urine and faecal sampling every 3 months
224097689|NCT02504255|OTHER|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
224097690|NCT03184948|DEVICE|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
224097691|NCT05646810|DIAGNOSTIC_TEST|Lidocaine (10 mg/ml)|Lidocaine (10 mg/ml) will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
224097692|NCT05646810|DIAGNOSTIC_TEST|Isotonic saline|Isotonic saline will be injected according to established protocols using ultrasound guidance and an aseptic technique by an experienced anesthesiologist.
224097693|NCT02288637|OTHER|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
223935312|NCT04650191|OTHER|Identification of genetic variants|DNA will be extracted from whole blood from study subjects
223935313|NCT04497337|PROCEDURE|Complete excision to superficial lesions around the ear|Complete excision of these lesions and histopathology
223935314|NCT02298166|DRUG|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~* Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT) d 1-3~* Cytarabine 1000 mg/m² IV (500 mg/m² for patients \> 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (\> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
223935315|NCT02298166|DRUG|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
224097694|NCT02288637|OTHER|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
224286009|NCT02207335|DRUG|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
224286010|NCT03286608|OTHER|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
224286011|NCT01271179|PROCEDURE|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
223935316|NCT02298166|DRUG|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
224286012|NCT01271179|PROCEDURE|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
224286013|NCT03399617|DIETARY_SUPPLEMENT|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
224286014|NCT03399617|BEHAVIORAL|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
224286015|NCT03399617|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
224286016|NCT02044432|OTHER|ginger compress|Kidney ginger compress
224097695|NCT02288637|OTHER|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
224097696|NCT04740411|BEHAVIORAL|The Common Elements Toolbox (COMET)|COMET is an online unguided self-help intervention that lasts approximately 60-80 minutes.
224286017|NCT01258088|DRUG|AN2728 Ointment|5mg/cm2, BID
224286018|NCT01258088|DRUG|AN2728 Vehicle|5mg/cm2 BID
224286019|NCT02540499|RADIATION|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
223935317|NCT02298166|OTHER|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
223935318|NCT01940107|OTHER|evaluations|Only evaluations
223935319|NCT01940107|PROCEDURE|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
224097697|NCT03240900|DEVICE|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
224097698|NCT03240900|PROCEDURE|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
224097699|NCT00682630|DRUG|pyronaridine artesunate clinical trial reference tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
224097700|NCT00682630|DRUG|pyronaridine artesunate to-be-marketed tablets|Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
224097701|NCT04635176|DRUG|Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)|real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
224097702|NCT04635176|DRUG|Sham iPACK block with 20ml normal saline|Sham iPACK block with 20 ml Normal saline
224097703|NCT04769557|DRUG|paracetamol|tablet paracetamol 500 mg
224097704|NCT04769557|DRUG|Placebo|placebo
224097705|NCT00843570|DRUG|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
224097706|NCT03941002|DIAGNOSTIC_TEST|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
224097707|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
224097708|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
224286020|NCT00156715|DRUG|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
224286021|NCT01030211|PROCEDURE|Platelet transfusion|4 units of platelets for patients with platelet count \<20x10\^3/uL
224286022|NCT01030211|OTHER|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
224097709|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
224097710|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
224097711|NCT00947349|DRUG|BI 201335 NA low placebo|Placebo
224097712|NCT00947349|DRUG|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
224286023|NCT05349578|DIAGNOSTIC_TEST|swab RUT|rapid urease test using swab instead of biopsied tissue
224286024|NCT05342311|DIAGNOSTIC_TEST|preoperative ultrasonographic evaluation of right common femoral vein diameter|preoperative ultrasonographic evaluation of right common femoral vein diameter to predict spinal anesthesia-induced hypotension in elderly patients
224097713|NCT00947349|DRUG|ribavirin (RBV)|ribavirin (RBV)
224097714|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
224097715|NCT00947349|DRUG|BI 201335 NA low|BI 201335 NA
224097716|NCT00947349|DRUG|BI 201335 NA high placebo|placebo
224097717|NCT00947349|DRUG|BI 201335 NA high|BI 201335 NA high
224097718|NCT00947349|DRUG|Placebo|
224097719|NCT06201143|OTHER|BREATHING EXERCISE AND MOBILIZATION TRAINING|After cesarean mobilization and breathing exercise training, the number of breathing exercises performed and the duration of mobilization will be recorded. Thus, the effectiveness of the training will be examined in detail.
224097720|NCT06201143|OTHER|KINESIOLOGICAL TAPING + BREATHING EXERCISE AND MOBILIZATION TRAINING|It will be the first study to use kinesiotaping, breathing exercise and mobilization training together.
224097721|NCT03880877|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
224097722|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
224097723|NCT03880877|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
224097724|NCT03880877|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
224097725|NCT03880877|DRUG|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
224097726|NCT00794586|DRUG|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
224097727|NCT00794586|DRUG|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
224286025|NCT01088282|PROCEDURE|Cataract surgery|Implantation of multifocal or monofocal IOL
223534107|NCT01729039|BEHAVIORAL|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
223935320|NCT01617707|DRUG|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
223935321|NCT01617707|DRUG|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
223935322|NCT02534285|DEVICE|hearing protection|Attenuation of hearing during surgery
223935323|NCT04191824|OTHER|Timing of return of results|Participants will be randomized to immediate versus delayed APOL1 return of results
224097728|NCT03354845|OTHER|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
224097729|NCT04407169|OTHER|no intervention|There will be no intervention. It is only an observationnal study
224097730|NCT00140855|BIOLOGICAL|ipilimumab|
224097731|NCT01815957|DRUG|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
224097732|NCT01245647|DRUG|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
224097733|NCT01245647|OTHER|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
224097734|NCT04416022|DIAGNOSTIC_TEST|Ultrasound examination|Women that are planned for labour induction, will undergo a routine ultrasound examination prior to the initiation of the induction process.
224097735|NCT00342355|DRUG|Zidovudine|600 mg once daily
223935324|NCT00909324|DRUG|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
223935325|NCT00909324|DRUG|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
223935326|NCT04428710|OTHER|assessment with psychometric questionnaire|"At the initial genetic consultation patients are informed about hereditary cancer risk and the genetic testing process. At the second genetic counseling appointment, after patients done tests, all participants were informed about the study purpose, and they signed the informed consent before the psychometric assessment. Those patients who agreed to participate, they were given the questionnaires to fill in. Also, background characteristics were reported including age, marital relationship, level of education, psychiatric antecedents.~The time for completion the self-report measures was about 10 minutes. The psychometric assessment was occurred prior to delivering the results of genetic testing."
223935327|NCT04305821|OTHER|Dosage of S100β protein|Dosage of S100β protein
223935328|NCT01378416|DRUG|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.
223935329|NCT06270524|PROCEDURE|Blood sampling|Blood sampling will be taken for further analysis
224097736|NCT00342355|DRUG|Stavudine|40 mg once daily
224097737|NCT00342355|DRUG|Didanosine|\<60 kg/125 mg twice daily or \>60kg/200 mg twice daily
224097738|NCT00342355|DRUG|Lamivudine|300 mg once daily
224097739|NCT00342355|DRUG|Efavirenz|600 mg once daily
224097740|NCT00342355|DRUG|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
224097741|NCT03072602|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
224097742|NCT03072602|OTHER|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
224097743|NCT00000984|DRUG|CD4 Antigens|
224097744|NCT02876978|GENETIC|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
224097745|NCT02876978|DRUG|Fludarabine|30 mg/m\^2/day x 4 days
224097746|NCT02876978|DRUG|Cyclophosphamide|500 mg/m\^2/day x 2 days
224097747|NCT05843214|OTHER|Non-invasive neuromonitoring evaluation (transcranial doppler, optic nerve envelope diameter and quantitative pupillometry)|4 days Post-operation follow-up. Data will be gathered before the surgery and at regular times after the surgery until day 4
223935330|NCT01760382|DEVICE|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
223935331|NCT00415649|BIOLOGICAL|VRC-HIVDNA016-00-VP|
223935332|NCT00415649|BIOLOGICAL|VRC-HIVADV014-00-VP|
223935333|NCT00415649|BIOLOGICAL|Vaccine placebo|Placebo comparator
223935334|NCT06494566|DIETARY_SUPPLEMENT|Omega-3|Omega-3 capsule
223935335|NCT06494566|DIETARY_SUPPLEMENT|Mineral Oil|Mineral Oil Capsule
223935336|NCT03496545|DRUG|Bromocriptine 5 MG|Bromocriptine 5 mg every 4 hours PO/NG/FT
223935337|NCT03496545|DRUG|Acetaminophen 650 MG|Acetaminophen 650 mg every 4 hours PO/NG/FT for 48 hours
223935338|NCT04729855|DIAGNOSTIC_TEST|PBMCs and Tissue expression of HOTTIP ,EIF4EBP1 and serum SNP HOTTIP rs1859168|5 ml fresh blood sample, normal and CRC tissue
223935339|NCT03247842|PROCEDURE|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
223935340|NCT01437319|DEVICE|lotrafilcon A|To be used during run-in phase only.
223935341|NCT01437319|DEVICE|comfilcon A|To be assigned at randomization at phase 2 only.
223935342|NCT01437319|DEVICE|balafilcon A|To be assigned at randomization during phase 2 only.
223935343|NCT01437319|OTHER|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
223935344|NCT01499849|DRUG|Rolapitant|(4 X 50 mg capsules) 200 mg PO
224097748|NCT00482716|BIOLOGICAL|epoetin alfa|
224097749|NCT00482716|BIOLOGICAL|epoetin beta|
224097750|NCT00482716|DIETARY_SUPPLEMENT|iron dextran complex|
224097751|NCT00482716|DIETARY_SUPPLEMENT|iron sucrose injection|
224097752|NCT06653621|DRUG|Bupivacaine liposome|Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
224097753|NCT06653621|PROCEDURE|Nerve block mode : adductor block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.
223935345|NCT01499849|DRUG|Granisetron|10 mcg/kg IV
223935346|NCT01499849|DRUG|dexamethasone|20 mg PO and 8 mg PO
223935347|NCT01499849|DRUG|Placebo|(4 X 0 mg capsules) 0 mg PO
223935348|NCT03282045|DRUG|Lysobact Complete Sprey|Inhaling spray
223935349|NCT03282045|DRUG|Tantum Verde® Spray|Inhaling spray
223935350|NCT03282045|DRUG|Pharyngal® Oromucosal Spray|Inhaling spray
223935351|NCT03282045|DRUG|Placebo|Inhaling spray
223935352|NCT00174252|DRUG|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
223935353|NCT06395571|DIETARY_SUPPLEMENT|Goat milk-based infant formula|Goat milk-based infant formula fed at age appropriate quantities for 24 weeks
223935354|NCT06395571|DIETARY_SUPPLEMENT|Cow's milk-based infant formula|Cow's milk-based infant formula formula fed at age appropriate quantities for 24 weeks
223935355|NCT05298371|BEHAVIORAL|Corrected Sitting postures|Change after being in Corrected Sitting postures
223935356|NCT05298371|BEHAVIORAL|Natural / relaxed sitting postures|Change after being in relaxed sitting postures
223935357|NCT05298371|BEHAVIORAL|Corrected Standing posture|Change after being in Corrected Standing posture
224097754|NCT06653621|DRUG|Bupivacaine|Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.
224097755|NCT06653621|PROCEDURE|Nerve block mode: femoral triangle block|Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
223935358|NCT05298371|BEHAVIORAL|Natural / relaxed standing postures|Change after being in relaxed standing postures
223935359|NCT04737291|DEVICE|drug coated balloon|use of drug coated balloon in treatment of critical limb ischemia
223935360|NCT04544319|DRUG|Zemiglo 50mg and Forxiga 10mg|Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD
223935361|NCT04544319|DRUG|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg|Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD
223935362|NCT01233934|DRUG|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
223935363|NCT01233934|DRUG|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
223935364|NCT05823818|DEVICE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
223935365|NCT00154115|DRUG|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
223935366|NCT00154115|DRUG|placebo|Placebo
223935367|NCT04056702|DRUG|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
223935368|NCT02061124|DRUG|Sevelamer 1600 mg TID for 7 days|
223935369|NCT02061124|DRUG|Placebo 1600 mg TID for 7 days|
223935370|NCT05562102|BIOLOGICAL|Typbar-TCV, Bharat Biotech|Typhoid conjugate vaccine
223935371|NCT02958800|OTHER|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
223935372|NCT03042741|BIOLOGICAL|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
223935373|NCT03042741|BIOLOGICAL|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
224097756|NCT03912584|DEVICE|P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
224097757|NCT03912584|DEVICE|P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
224097758|NCT04101175|PROCEDURE|Evaluation of the procedure of abortion|Observational study using questionnaires
223935374|NCT05206240|OTHER|Radial extracorporeal shock wave therapy and conventional physical therapy|"The conventional physical therapy program will consist of verticalization strategies, range of motion exercises, muscle stretching and strengthening exercises, stance and balance training, core stability exercises, gait training, functional training, cryotherapy or local heat for 1h/day, 5 days/week for 2 weeks.~Regarding the rESWT delivery, 2000 shots will be applied on the triceps surae myotendinous junction with a frequency of 10 Hz and an energy density of 60 mJ, 7 min/session, 1 session/week for 2 weeks."
223935375|NCT03938337|DRUG|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
223935376|NCT03938337|DRUG|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
223935377|NCT05480540|BEHAVIORAL|Serious game|According to the curriculum, as of the third week, a serious game-based web application on Sterile Dressing and Surgical Instrument Preparation Training, which is prepared in accordance with the formal education curriculum and prepared as a support for formal education, will be downloaded to the mobile phones of the students in the intervention group as of the third week. Students would be informed that they could use the application for two weeks whenever they wanted and as much as they wanted.
223935378|NCT01961076|OTHER|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
223935379|NCT03611556|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arm description.
223935380|NCT03611556|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
223935381|NCT03611556|DRUG|Gemcitabine|Participants will receive IV infusion of gemcitabine as stated in arm description.
224097759|NCT02071238|BEHAVIORAL|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
224097760|NCT02071238|BEHAVIORAL|Group Consultation|Informed consent discussion in group-format
224097761|NCT06451874|BEHAVIORAL|Functional Power Training (FPT)|Participants will receive twice weekly FPT, a progressive functional-based exercises that target optimizing leg force production and leg velocity.
223935382|NCT03611556|DRUG|Nab-paclitaxel|Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
223935383|NCT03611556|DRUG|Oxaliplatin|Participants will receive IV infusion of oxaliplatin as stated in arm description.
223935384|NCT03611556|DRUG|Folinic acid|Participants will receive IV infusion of folinic acid as stated in arm description.
223935385|NCT03611556|DRUG|5-FU|Participants will receive IV infusion of 5-FU as stated in arm description.
223935386|NCT03766191|BEHAVIORAL|Food Ads|Exposure to foods ads embedded in an age-appropriate TV program
223935387|NCT03766191|OTHER|Non-food Ads|Exposure to non-food ads embedded in an age-appropriate TV program
223935388|NCT05609929|DRUG|Multiple administration of omeprazole Single administration of AB-106|Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
224097762|NCT06451874|BEHAVIORAL|Music-Based Digital Therapy (MBDT)|Participants will receive twice weekly MBDT, a technology-driven gait training that is grounded in evidence-based rehabilitation treatment, rhythmic auditory stimulation.
224097763|NCT06451874|BEHAVIORAL|FPT + MBDT|For non-responders who were randomized to augment treatment, they will receive combined FPT and MBDT treatment.
224097764|NCT05040529|PROCEDURE|pure laparoscopic donor hepatectomy|pure laparoscopic donor hepatectomy: patients who underwent pure laparoscopic right or right extended hepatectomy for liver donation at gangnam severance hospital
223935389|NCT04564443|OTHER|Medaxis Debritom+|Advanced micro fluid jet therapy to clean and stimulate wound
223935390|NCT04564443|OTHER|Sharp Surgical Debridement|Scalpel or Curette to clean and debride wound
223935391|NCT04564443|OTHER|Additional Outer Dressing Application|Application of moisture retentive dressing, and a multi layer compression dressing
223935392|NCT04564443|OTHER|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
223935393|NCT04564443|OTHER|Fibracol Wound Dressing|Application of a collagen alginate dressing
224097765|NCT05040529|PROCEDURE|conventional open donor hepatectomy|conventional open donor hepatectomy: patients who underwent conventional right or right extended hepatectomy for liver donation at gangnam severance hospital
224097766|NCT01236391|DRUG|PCI-32765|560 mg daily
224097767|NCT05262764|DRUG|JARDIANCE®|Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).
224097768|NCT00820430|OTHER|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
223935394|NCT06402422|DEVICE|Theta-burst stimulation|TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz). iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). Concurrent iTBS/fNIRS stimulation will be applied over the left DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.
223935395|NCT04515238|DRUG|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
224097769|NCT05242887|DIAGNOSTIC_TEST|Delirium screening using 3D-CAM and UB-CAM|Patients will be evaluated with 3D-CAM and UB-CAM by a trained examiner (geriatrician, resident or neuropsychologist). On the same day, they will be given a reference diagnosis of delirium based on DSM-V criteria by another trained examiner, blind to the results of the UB-CAM and 3D-CAM.
224097770|NCT00670787|DRUG|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
223935396|NCT04515238|BIOLOGICAL|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
223935397|NCT04515238|BIOLOGICAL|Zanubrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 160mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 160mg p.o"
223935398|NCT04515238|BIOLOGICAL|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
223935399|NCT04187573|DEVICE|Neqstent|Adjunctive device providing stable aneurysm neck coverage for the placement of embolization coils within the aneurysm sac and long term stable occlusion of the aneurysm.
223935400|NCT06044441|BEHAVIORAL|ENABLE-SG model|Patients and caregivers will receive individual structured psycho-educational sessions with a health coach. These sessions will be primarily delivered over the phone. Patient and caregiver dyads will have different health coaches. Patients will have six sessions on the topics of maintaining positivity, self-care, coping with stress, managing symptoms, exploring what matters most, and life review. Caregivers will have four sessions on the topics of maintaining positivity, self-care, coping with stress, and managing symptoms. All sessions will begin with screening for distress using the Distress Thermometer and Problem List culturally adapted from the National Comprehensive Cancer Network. From screening results, the health coach can flexibly change the order of the topics to address specific problems. It will take approximately three months to complete all sessions.
223935401|NCT06044441|OTHER|Wait-list control|"* 6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval.~* Interventions: ENABLE-SG model"
223935402|NCT06803134|OTHER|Selected physical therapy program|Both groups will receive a selected physical therapy program in the form of trans-cutaneous electrical nerve stimulation (TENS), moist hot pack, posture education, and strengthening exercises for deep neck flexors, for 30 minutes, 3 sessions per week, for 8 weeks.
224097771|NCT01392183|DRUG|Pazopanib|800 mg by mouth daily in 4 week study cycle.
224097772|NCT01392183|DRUG|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
224097773|NCT01392183|BEHAVIORAL|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
224097774|NCT01392183|DRUG|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
224097775|NCT00001303|DRUG|Reference Endotoxin|
224097776|NCT00001303|DRUG|Inhaled Nitric Oxide|
224097777|NCT04792294|DEVICE|Extracorporeal photopheresis|ECP can be used as second-line treatment in patients unresponsive to azithromycin. ECP has been firstly developed for treatment of cutaneous T cell lymphomas and later used in a variety of other indications including solid organ transplantation. The process starts with leukapheresis, followed by incubation of the isolated cells with 8-methoxypsoralen (8-MOP) and subsequent activation of 8-MOP with ultraviolet A radiation. At the end, the cells are reinfused into the patient. 8-MOP is a biologically inert substance, but in the presence of UVA light it cross-links DNA by forming covalent bonds with pyrimidine bases and causes apoptosis.
224097778|NCT04321343|DRUG|PXL065|PXL065 oral tablet
224097779|NCT04321343|DRUG|Placebo oral tablet|Placebo oral tablet
224097780|NCT04419103|OTHER|no intervention|Natural exposure of iodine.
224097781|NCT01261403|BIOLOGICAL|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
223935403|NCT06803134|OTHER|Kinetic control retraining|"Each patient in the experimental group will receive kinetic control retraining for 30 minutes, 3 sessions per week, for 8 weeks. Each session is based on the progression on the motor control rating scale (MCRS) related to kinetic control management frame. For each movement direction, specific control tests will be conducted. The direction and site of the uncontrolled movement will be evaluated using special tests in accordance with the pain history of the patient. The tests will be chosen according to the patients symptoms; screening of all patients will be done through at least three tests in each direction according to the patients symptoms."
223935404|NCT06494189|BIOLOGICAL|Tislelizumab|200mg IV Q3W
223935405|NCT06494189|DRUG|Afatinib|30mg PO QD
223935406|NCT06494189|RADIATION|Low dose radiotherapy|The phase Ia clinical trial took low dose radiotherapy doses of 2Gy/1f (on day 1) for group 1, 4Gy/2f (from days 1 to 2) for group 2, and 10Gy/5f (from days 1 to 5) for group 3. The radiotherapy doses in phase Ib were judged according to the efficacy and toxicity of phase Ia.
223935407|NCT04589598|DEVICE|Femoral Neck System|femoral neck system using bolt and antirotation screw with one/two hole plate
223935408|NCT04589598|DEVICE|Multiple Cannulated Screw|multiple cannulated screw using 3 or 4 cannulated screw
223935409|NCT06088758|DEVICE|Normothermic machine perfusion (NMP) of steatotic liver|Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
223935410|NCT05615051|DEVICE|Surface decontamination procedure aiming at reconstructive therapy|Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
223935411|NCT04540588|DEVICE|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
223935412|NCT06107842|BEHAVIORAL|Gerofit exercise|Individualized exercise prescription as well as a group exercise class based on physical function assessments offered 3x/week
223935413|NCT06107842|BEHAVIORAL|Health education|Scheduled monthly in-person health education discussion sessions covering 12 different health topics not including a physical activity/exercise promotion session
223935414|NCT02397096|DRUG|Doravirine, Tenofovir, Lamivudine|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
223935415|NCT02397096|DRUG|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
223935416|NCT02397096|DRUG|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
223935417|NCT02397096|DRUG|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
223935418|NCT02397096|DRUG|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
223935419|NCT01705886|PROCEDURE|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
223935420|NCT01705886|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
223935421|NCT01705886|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
223935422|NCT01705886|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
223935423|NCT01705886|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
223935424|NCT05321992|BEHAVIORAL|eCHEC program|The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
223935425|NCT03842085|DRUG|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 8 dose groups based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patient will be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
223935426|NCT06228573|PROCEDURE|Yoga|Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
223935427|NCT05760248|DRUG|10XB-101 Solution for Injection, 6.0%|The active drug (adipolytic) given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
223935428|NCT05760248|DRUG|Placebo Solution for Injection (no active ingredient)|Placebo given as subcutaneous injection on either the right or left flank every 4 weeks for 20 weeks.
224286026|NCT03144817|OTHER|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
224286027|NCT03653624|OTHER|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
224286028|NCT00868296|DRUG|pantoprazole|
224286029|NCT02262858|DRUG|Telmisartan and HCTZ|
224286030|NCT02262858|DRUG|Telmisartan|
224286031|NCT02262858|DRUG|HCTZ|
223935429|NCT06418334|DIAGNOSTIC_TEST|Thoracal hyperkyphosis study form|Thoracal hyperkyphosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with chest deformity will be filled in detail.
223935430|NCT06418334|DIAGNOSTIC_TEST|Scoliosis graphy|Patients whose forward bending test and clinical evaluation results are compatible with hyperkyphosis and scoliosis radiographs are requested. Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
223935431|NCT06418334|DIAGNOSTIC_TEST|Pulmonary function test|"Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help participant healthcare provider diagnose and decide the treatment of certain lung disorders.~The investigators will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken."
223935432|NCT06418334|DIAGNOSTIC_TEST|Ultrasonographic Measurement|Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter-cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
223935433|NCT05805826|BIOLOGICAL|C. difficile vaccine (previously studied formulation).|Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection
223935434|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 1.|C. difficile vaccine formulation 1 given as an intramuscular injection
223935435|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 2.|C. difficile vaccine formulation 2 given as an intramuscular injection
223935436|NCT05805826|BIOLOGICAL|C. difficile vaccine formulation 3.|C. difficile vaccine formulation 3 given as an intramuscular injection
223935437|NCT05805826|OTHER|Saline Placebo.|0.9% sodium chloride solution given as an intramuscular injection
223935438|NCT05933733|OTHER|Salvage treatment (surgery and/or radiation therapy)|Appropriate salvage treatment (surgery and/or radiation therapy) will be selected by the treating clinicians considering the disease status.
223935439|NCT00495976|OTHER|A commercially produced cordial drink|
224097782|NCT01261403|DRUG|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
224097783|NCT03981601|DRUG|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
224097784|NCT03981601|PROCEDURE|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
224097785|NCT01916772|OTHER|no interventions|no interventions
224097786|NCT00011115|BEHAVIORAL|Weight loss motivations|
224097787|NCT06593652|BEHAVIORAL|Teen Intervene - Adolescent Only|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills.
224097788|NCT06593652|BEHAVIORAL|Teen Intervene with Caregiver Session|Teen Intervene (TI) is delivered over two or three, 45- to 60-minute sessions (2 teen sessions +/- 1 caregiver session) to reduce youth substance use, increase motivation for abstinence, and promote use of existing coping strategies. TI is an adolescent-appropriate adaptation of motivational enhancement therapy (MET), and includes a discussion of readiness to change, goal setting, personal feedback, a functional analysis of substance use, and a review of coping skills. In this condition, the caregiver session will address caregiver expectations around youth substance use and strategies for promoting positive youth behavior change including reduced substance use.
224286032|NCT06224621|PROCEDURE|Percutaneous Endocardial Septal Radiofrequency Ablation|Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
224097789|NCT06593652|BEHAVIORAL|Family Check Up|Family Check-Up Online (FCU-O) is a self-paced, parent-driven, fully HIPAA compliant online version of the Family Check-Up (FCU), a brief intervention that integrates assessment, motivation-enhancement, and skill building to help parents effectively manage behavior and build positive relationships with their children aged 2-17 in order to reduce emotional and behavioral problems among youth.
224097790|NCT05602428|DRUG|esketamine sub-anesthetic,|the use of esketamine sub-anesthetic dose combined with hip capsule peripheral nerve block
224097791|NCT05602428|DRUG|esketamine sub-anesthetic|Esketamine subanesthetic dose combined with lumbar plexus block was used
224097792|NCT05602428|DRUG|esketamine sub-anesthetic|general anesthesia was performed with esketamine subanesthetic dose.
224097793|NCT05243771|PROCEDURE|Rectal resection with diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
224097794|NCT05243771|PROCEDURE|Rectal resection without diverting stoma|Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
224286033|NCT01094249|DRUG|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
224286034|NCT04529226|DRUG|Clozapine|Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
224097795|NCT05243771|PROCEDURE|Rectal resection with permanent colostomy|Patients in this group will receive a rectal resection and a permanent colostomy will be created
224097796|NCT03810989|DEVICE|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
223935440|NCT01379482|DRUG|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
223935441|NCT02392234|DRUG|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
223935442|NCT02392234|DRUG|Ivacaftor|Tablet, oral use
223935443|NCT02392234|DRUG|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
223935444|NCT02392234|DRUG|Placebo matched to Ivacaftor|Tablet, oral use
223935445|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received one drain.|patients who underwent two level lumbar decompression with BESS procedure received one drain.
223935446|NCT06290791|PROCEDURE|two level lumbar decompression with BESS procedure received two drain.|patients who underwent two level lumbar decompression with BESS procedure received two drains
223935447|NCT00948168|DRUG|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
223935448|NCT00112034|DRUG|Methotrexate|
223935449|NCT00112034|DRUG|IV methylprednisolone|
224097797|NCT03810989|DEVICE|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
224097798|NCT03810989|DEVICE|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
223935450|NCT02313675|DRUG|Acetaminophen|
223935451|NCT02313675|DRUG|Ketorolac Tromethamine|
224097799|NCT05003362|BEHAVIORAL|ACT|mindfulness intervention for patients with pain/migraine
224097800|NCT02691000|DEVICE|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
223935452|NCT02313675|DRUG|Saline|
223935453|NCT02052440|DRUG|Baclofen|Treatment arm: baclofen 10mg tid
223935454|NCT02052440|DRUG|Placebo|Sugar pill by mouth three times daily
223935455|NCT00697060|DRUG|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
223935456|NCT06615232|BEHAVIORAL|Vaginal washing cessation|Participants will attend weekly small group (\~10 women per group) sessions that are structured using the transtheoretical model of behavioral change to promote vaginal washing cessation.
223935457|NCT02190149|BIOLOGICAL|ADVATE (Antihemophilic Factor [Recombinant])|
224097801|NCT02691000|DEVICE|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
224097802|NCT04604327|DRUG|Bemiparin sodium|Prophilactic vs full-dose for 10 days
224097803|NCT06249529|DEVICE|Airway Bypass|Bypass stent(s) are implanted to allow air trapped in the parenchyma to escape
224097804|NCT03430310|OTHER|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
224286035|NCT04529226|DRUG|haloperidol, pimozide, olanzapine, risperidone, amisulpride|Treatment as usual using first-generation or second-generation antipsychotics
224286036|NCT05026931|OTHER|Foam rolling|Group A will be treated with foam rolling effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
223935458|NCT02190149|BIOLOGICAL|RIXUBIS (Coagulation Factor IX [Recombinant])|
223935459|NCT02707666|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
223935460|NCT02707666|DRUG|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
223935461|NCT05916768|OTHER|Pelargonium sidoides extract EPs® 7630|Kaloba® solution, a standardized alcoholic extract obtained from the roots of Pelargonium sidoides (EPs® 7630).
223935462|NCT05916768|OTHER|usual care|symptomatic treatments
223935463|NCT00928824|DIETARY_SUPPLEMENT|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
223935464|NCT05296772|BIOLOGICAL|JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody|Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years
223935465|NCT05296772|BIOLOGICAL|Pembrolizumab - anti-PD-1 antibody|200 mg, once every three weeks until disease progression, withdrawal or up to two years
223935466|NCT05973279|OTHER|Tecno Body Prokin Isokinetic Balance System|It provides objectively measurable data in static and dynamic balance measurements. The moving balance platform of the system, which is driven by air piston servo motors, can measure at a working angle of 15 degrees in all directions. The results can be monitored and recorded live on the screen on the device. From these data, each individual's static and dynamic balance score is obtained by summing the forward-backward standard deviation and right-left standard deviation.
223935467|NCT05973279|OTHER|Restorative Therapies RT300 leg/arm/cor:|RT300 is a motorised treatment system. In general there are 3 systems; Passive therapy, Active therapy and a combination of active therapy with some assistance from the motor. The device can be used from a chair, wheelchair or bed and there are two variants that can be used separately; Leg system, Arm system. Electrodes placed on the skin over specific muscle groups are connected via a cable or wirelessly to the RT300. These are used to stimulate peripheral motor nerves, causing the muscles to work. The software of the SAGE controller unit of the RT300 monitors the treatment process, including the stimulation patterns sent to the arms or legs, and the operation of the ergometer motor to produce smooth cycling motion. Contraindicated in the presence of lower limb fractures or pregnancy.
223935468|NCT05973279|OTHER|CSMI (CYBEX) Humac Norm Isokinetic Test and Exercise System|22 isolated joint movement models, 4 resistance modes (isokinetic, isotonic, isometric and passive) and a large number of reports to meet the measurement and exercise needs of today's clinicians and researchers. The exercise modes of the device include; Continuous passive movement, multi-angle isometry, proprioception training, standard and eccentric focused isokinetic strengthening, deceleration training, dynamic isotonic training, strength training. Test modes of the device include; Proprioceptive, co-measured, standard isokinetic, concentric/eccentric isokinetic, intermittent stroke isokinetic test.
223935469|NCT02867072|PROCEDURE|Open appendectomy|
223935470|NCT02867072|PROCEDURE|Laparoscopic appendectomy|
223935471|NCT01222442|DRUG|AZD3199|Single dose, oral inhalation
223935472|NCT01222442|DRUG|Moxifloxacin|Single dose, oral encapsulated tablet
223935473|NCT01222442|OTHER|Placebo comparator|Single dose, oral inhalation
223935474|NCT00694889|BEHAVIORAL|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
223935475|NCT00694889|BEHAVIORAL|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
224286037|NCT05026931|OTHER|Stretching exercises|Group B will be treated with stretching exercises effect on quadriceps, hamstring and calf muscle length. 5 min cycle ergometry, 6 min foam rolling 3 times for 30sec.For three session per week will be given atleast for 2 months.
224286038|NCT05387148|DRUG|Cannabidiol (CBD)|Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
223935476|NCT03024034|DRUG|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
223935477|NCT06321952|DEVICE|ROSA robotic assist TKA|total knee replacement with ROSA robotic assist
223935478|NCT06321952|PROCEDURE|iassist TKA|total knee replacement with iassist
223935479|NCT04124887|DRUG|Sodium Fluoride|Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
223935480|NCT04124887|DRUG|Tricalcium Phosphate|Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
223935481|NCT04124887|DRUG|Xylitol-coated calcium and phosphate|Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
223935482|NCT04124887|DRUG|Casein phosphopeptide amorphous calcium phosphate|Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
223935483|NCT00402259|DRUG|Esomeprazole IV|
223935484|NCT00402259|DRUG|Omeprazole IV|
223935485|NCT03486600|OTHER|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
223935486|NCT04646733|OTHER|High Protein Diet Group|The high protein diet (HPD) group is instructed to follow a low carbohydrate, high protein ketogenic diet. This diet has 4 phases, two of weight loss until reaching the ideal weight (attack and cruise) and two of maintenance (consolidation and stabilization). During the first 2 phases, it allows 100 foods (28 vegetables). The first phase lasts 3-10 days and 72 high-protein, low-fat foods are allowed. In the second phase, there are alternate days between consuming the low glycemic index vegetables plus protein and the next day with just protein. The first two phases are ad libitum. Phase 3 (consolidation) aims to avoid rebound and begins the introduction of complex carbohydrates and legumes in individual servings. In phase 4 (stabilization), the subject returns to a free diet. However, three basic rules are introduced: protein one day a week, the exercise of at least 20 min/day (optional) and consumption of 3 tablespoons of oat bran/day.
223935487|NCT04646733|OTHER|No High Protein Diet Group|No high protein diet (NHPD) group received an oat beverage consisted of 55 g of oats in 250 ml of water. Beverage contained 1.6 g of betaG per portion according to FDA recommendations corresponding to 50 % of betaG required per day. Weekly bags containing oat mixture were provided on day 0 and in the third week of the trial. No additional instructions about diet, exercise program or pharmacological treatment was implemented.
223935488|NCT05759260|OTHER|Observation|Observation
223935489|NCT01180231|DRUG|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
223935490|NCT01180231|OTHER|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
223935491|NCT04411888|OTHER|observation|observation
224286039|NCT05387148|DRUG|Placebo|The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
224286040|NCT05790148|DEVICE|3Shape|original (Straumann), non-original (Medentika) and generic scan-bodies (3Shape) were utilized for direct digitalization using intraoral scanner with image stitching algorithm. Full contour temporary restorations were fabricated from each digital record, and were evaluated in terms of clinical and analytical.
224286041|NCT00750022|BEHAVIORAL|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
223935492|NCT02134262|DRUG|Cyclophosphamide or Bendamustine|Cyclophosphamide \[1.5 g/m\^2 x 1 day Intravenous (IV)\] or Bendamustine \[120 mg/m\^2 x 2 days Intravenous (IV)\] is administered as Pre-treatment medication of CD19-CAR-T.
223935493|NCT02134262|GENETIC|Dose Level -1|CD19-CAR-T \[1 x 10\^5 cells/kg x 1 day and 2 x 10\^5 cells/kg x 1 day Intravenous (IV)\] are administered.
224097805|NCT03430310|OTHER|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
224097806|NCT05462093|DEVICE|Liver Multiscan sequences|Additional Liver Multiscan sequences will be performed after the MRI liver with MRCP is performed, taking approximately 15 minutes.
224097807|NCT05462093|DEVICE|Liver Multiscan analysis|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
224097808|NCT05462093|DEVICE|MRCP+|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
224097809|NCT01960010|DRUG|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
223935494|NCT02134262|GENETIC|Dose Level 1|CD19-CAR-T \[1/3 x 10\^6 cells/kg x 1 day and 2/3 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
224286042|NCT00750022|BEHAVIORAL|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
223935495|NCT02134262|GENETIC|Dose Level 2|CD19-CAR-T \[1 x 10\^6 cells/kg x 1 day and 2 x 10\^6 cells/kg x 1 day Intravenous (IV)\] are administered.
224097810|NCT01960010|DRUG|Vehicle|Vehicle dosed BID
224097811|NCT01305915|BEHAVIORAL|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
224097812|NCT02134886|DRUG|Erlotinib Hydrochloride|Given PO
224286043|NCT01843686|DEVICE|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
224286044|NCT01843686|OTHER|Placebo Saline Gel and Usual and Customary Standard of Care|
224286045|NCT06309316|BEHAVIORAL|Person-centred care (PCC)|In addition to usual care, patients will receive PCC through physical visits, telephone and through a web-based platform for 15-months. Primary outcome is after 3 month (we expect the need of support is largest in the beginning) but the intervention will continue for the period of care 12-18 months, increasing transferability to regular care.
224286046|NCT05675241|DIAGNOSTIC_TEST|Clinical examination of a dental implant|Clinical examination includes bleeding on probing, pocket depth, gingival biotype, suppuration, gingival index
224286047|NCT05675241|DIAGNOSTIC_TEST|Radiological Examination|A standardized periapical radiograph in parallax technique will be taken.
224286048|NCT05675241|DIAGNOSTIC_TEST|Peri-implant crevicular fluid sample collection|A sample of the peri-implant crevicular fluid will be collected using paper strip for 60 seconds. The sample of the fluid will be a resultant of inserting six different strips at the same time in six sites of the implant including mesiobuccal, midbuccal, distobuccal, distopalatal/distolingual, midpalatal/midlingual, mesiopalatal/mesiolingual sites of the implant.
224286049|NCT03712241|DRUG|K-285|Topical
224286050|NCT03712241|DRUG|Indomethacin|Capsule
224286051|NCT01974024|DRUG|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
224286052|NCT04906317|DRUG|midazolam and dezocine|Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
224097813|NCT02134886|OTHER|Laboratory Biomarker Analysis|Correlative studies
224286053|NCT04906317|DRUG|Propofol|standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
224097814|NCT02134886|OTHER|Pharmacological Study|Correlative studies
224097815|NCT02134886|OTHER|Quality-of-Life Assessment|Ancillary studies
224097816|NCT00765765|DRUG|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
223935496|NCT02134262|GENETIC|Dose Level 3|CD19-CAR-T \[1/3 x 10\^7 cells/kg x 1 day and 2/3 x 10\^7 cells/kg x 1 day Intravenous (IV)\] are administered.
223935497|NCT00369109|OTHER|biologic sample preservation procedure|
223935498|NCT00369109|OTHER|immunohistochemistry staining method|
223935499|NCT00369109|OTHER|laboratory biomarker analysis|
223935500|NCT00369109|PROCEDURE|biopsy|
223935501|NCT02928250|DIETARY_SUPPLEMENT|Carnosine|Patients in intervention group received carnosine capsules orally daily
223935502|NCT02928250|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
224097817|NCT00765765|DRUG|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
223935503|NCT02957799|BEHAVIORAL|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
223935504|NCT02957799|BEHAVIORAL|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
223935505|NCT01645046|DRUG|Coenzyme A|Coenzyme A 200mg per day.
223935506|NCT01645046|DRUG|Coenzyme A|Coenzyme A 400mg per day.
223935507|NCT01645046|DRUG|Placebo|Capsule without coenzyme A.
223935508|NCT00993174|PROCEDURE|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
223935509|NCT00993174|PROCEDURE|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
223935510|NCT05853861|BEHAVIORAL|JASPER|JASPER is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.
223935511|NCT05853861|BEHAVIORAL|Babble Bootcamp|Babble Bootcamp is a new intervention focusing on the speech-motor system and aims to improve babbling and early word use in infants known to be at risk for language delay.
223935512|NCT06403540|DIAGNOSTIC_TEST|ultrasonography|Using ultrasonography to measure diaphragm thickness
223935513|NCT00225407|DRUG|Smoking of cannabis cigarettes (different strength)|
223935514|NCT00138541|DRUG|vildagliptin|
223935515|NCT06812429|DRUG|Dapagliflozin (DAPA)|Participants will receive 10mg of Dapagliflozin per day for three days.
224097818|NCT06654648|OTHER|Combined exercise nutrition intervention group|Combination Product: Combined exercise and nutrition intervention Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
224097819|NCT06654648|OTHER|Conventional medial care group|"Conventional medial care Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
224097820|NCT02342834|DIETARY_SUPPLEMENT|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
224097821|NCT01331161|BIOLOGICAL|ZOSTAVAX|shingles vaccine, one dose
223935516|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus.|Minimally invasive procedures for the Hallux Abductus Valgus
223935517|NCT06243471|PROCEDURE|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.|Minimally invasive procedures for the Hallux Abductus Valgus and a zig-zag tenotomy for the extensus hallux longus.
223935518|NCT06748456|BEHAVIORAL|Podcast|A pre-recorded podcast with a urologist and a GP discussing the theme to promote preparatory reflections among the GPs before the cluster meeting
223935519|NCT06748456|BEHAVIORAL|Cluster meeting|A two-hour meeting facilitated by either the GPs cluster coordinator, another GP from the cluster or a facilitator outside the cluster chosen by the cluster itself with specific slides about PSA in general, guidelines, expert videos, data from the clinics, cases, and group discussions
223935520|NCT06748456|BEHAVIORAL|Hand-out material 1|Hand-outs of the main take-home messages to facilitate further discussion in their respective GP offices
223935521|NCT06748456|BEHAVIORAL|Hand-out material 2|Hand-outs to be used by GP and patients to facilitate communication about the relevance of taking a PSA-test
223935522|NCT06753617|PROCEDURE|Cryoablation of brain neoplasm|The procedure begins with standard surgical exposure of the tumor, followed by a biopsy. Next, one or more cryoprobes will be positioned directly into the tumor for ablation. Once positioned, the cryoablation process will commence. A maximum of 2x10 minutes cryoablation cycles will be established followed by active thawing. Following ablation, resection of the tumor will be performed, after which patients will receive standard treatment and follow-up care. Ice formation around the cryoprobes will be monitored using intraoperative ultrasound to optimize the ablation process.
223935523|NCT06754267|DRUG|Venetoclax|BCL-2 inhibotor
223935524|NCT06754267|DRUG|Olverembatinib|Tyrosine kinase inhibitor
223935525|NCT06754267|DRUG|Predinisone|Glucocorticoids
223935526|NCT06751641|OTHER|patient participating in a clinical trial incorporating decentralized elements.|participating in a clinical trial incorporating decentralized elements.
223935527|NCT06754085|DRUG|Florastamin[18F] Injection|The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
223935528|NCT06756217|DIAGNOSTIC_TEST|68Ga-grazytracer PET/CT|68Ga-grazytracer is designed to target granzyme B, and showed excellent in vivo metabolic stability and favorable targeting efficiency during immune responses. 68Ga-grazytracer PET/CT could directly display the killing effect of CD8+T cells on tumor. All enrolled patients underwent the same 68Ga-grazytracer PET/CT imaging.
223935529|NCT06764355|DRUG|Tislelizumab|200 mg, 1h-IVF, Q3W on day 1 for 2 cycles
223935530|NCT06764355|DRUG|Paclitaxel|Paclitaxel 175 mg/m2, 3h-IVF, Q3W on day 1 for 2 cycles
223935531|NCT06764355|DRUG|Cisplatin|Cisplatin 75 mg/m2, 2h-IVF, Q3W on day 1 for 2 cycles
223935532|NCT06764355|RADIATION|Chemoradiotherapy|"Chemoradiotherapy~* Paclitaxel 50 mg/m2, 1h-IVF, on days 1, 8,15, 22, and 29;~* Cisplatin 30 mg/m2,1h-IVF, on days 1, 8,15, 22, and 29;~* RT: 1.8 Gy/fraction, 5 days a week, for 25 fractions (total dose= 45 Gy)."
224097822|NCT01865734|OTHER|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
224097823|NCT01865734|OTHER|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
224097824|NCT01920906|PROCEDURE|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
224097825|NCT01097044|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
224097826|NCT01097044|DRUG|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
224286054|NCT03068650|BIOLOGICAL|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
224286055|NCT02536235|OTHER|heat|activated heating pad to lower abdomen
223935533|NCT06761495|PROCEDURE|Baseball Suturing Technique|(Baseball Suturing Technique): A corner suture was placed at the right corner of the incision. Next, the second stitch was placed at the apex of the left corner and tied with a knot. Then, the free end of the suture was cut and running baseball stitch pattern was started. The suturing pattern was performed by taking bites from the inside out through the upper and lower lips of the wound at approximately 1 cm intervals with a 1 cm margin from the wound edges
223935534|NCT06761495|PROCEDURE|Single-Layer Locked Continuous Suturing Technique|(Single-Layer Locked Continuous Suturing Technique): A corner suture was placed at the right corner of the incision. Next, the second stitch was placed at the apex of the left corner and tied with a knot. Then, the free end of the suture was cut and single-layer-locked continuous suturing was started. The suturing pattern was performed by taking bites from outside to inside through the lower lip and inside to outside through the upper lip of the wound. Each time, a lock was formed by passing through the loop formed by the previous suture. The suturing was performed at approximately 1 cm intervals with a 1 cm margin from the wound edges
223935535|NCT06761495|PROCEDURE|Single-Layer Unlocked Continuous Suturing Technique|(Single-Layer Unlocked Continuous Suturing Technique): The uterotomy line was closed in a single-layer continuous suturing pattern that is explained above as group 2 but without passing the needle through the loop formed by the previous sutu
223935536|NCT04616209|BIOLOGICAL|donor-derived NK cell infusion|PB103 administrations will be separated by 4-week interval
223935537|NCT06773247|OTHER|I. Myofascial Release Technique ,Cupping Technique and II. Conventional Physical Therapy|"The cupping procedure was performed as follows: Massage oil was applied over the area first to improve contact and makes it easier to move the cup's position. double-walled glass cups (6 glasses with diameters from 75 to 100 mm) were held inverted, after which each glass was placed on an afflicted area overlying the low back muscle (acupoint: BL23).~Myofascial Release Technique Vertical stroking technique was performed in lumbar region to quadratus lumborum. AIt was performed as follow; Quadratus lumborum is palpated in prone and side lying for trigger points. The technique is applied by the patient positioned in side lying with a pillow under waist to exaggerate stretch of the muscle. The therapist stands at level of patient's hip posterior and counter pre"
224097827|NCT06792539|DEVICE|Polymotion Hip Resurfacing (PHR) System|Surgical
223935538|NCT06770192|OTHER|Calisthenics|Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.
223935539|NCT06770192|OTHER|Plyometric|: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump
223935540|NCT06770192|OTHER|Control|compare with other groups
223935541|NCT06771141|BEHAVIORAL|Virtual Reality Video Session|This intervention involves a 10-minute virtual reality (VR) video session designed to reduce pre-procedural anxiety and promote relaxation in pediatric patients. The video immerses participants in a calming virtual environment with interactive and visually engaging content tailored for children. It is administered prior to the endoscopy procedure to help manage anxiety and stabilize vital signs, such as blood pressure, heart rate, and oxygen saturation. The VR session serves as a non-pharmacological approach to anxiety management during medical procedures.
223935542|NCT06775457|OTHER|sample collection|Blood samples and fecal samples will be taken from patients during evaluation visits. Blood samples will be analyzed for the study of HERVs. While fecal samples will be analyzed for the characterization of gut microbiota.
224286056|NCT01183117|DEVICE|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
224286057|NCT01183117|DEVICE|PTA|balloon angioplasty
224286058|NCT05319834|DRUG|Aspirin tablet|group1: oral aspirin at a dose of 100mg once daily at the same time with progesterone
224286059|NCT05319834|DRUG|Placebo|group 2: oral placebo once daily at the same time with progesterone
224286060|NCT03829358|DRUG|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
224286061|NCT03829358|DRUG|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
224286062|NCT04707586|OTHER|Cold Application|Created by the researcher; A bandage with 3 pieces of 13x10 cm cold gel and a cold gel container in which they are placed will be used, which can be adjusted according to the head circumference of the patient between 60-80 cm in length. The ability of the cold gel cups of the bandage to be moved on the bandage will allow comfortable cold application to the patient's bilateral frontotemporal and occipital areas at the same time. After waiting for 20 minutes in the freezer part of the refrigerator, the temperature and temperature of the gels applied and the cold application area before and after each application will be measured and recorded. An Infrared Non-Contact Food Thermometer will be used for temperature measurement of cold gel packs, and an Infrared Non-Contact Thermometer device will be used for temperature measurement of the cold application area.
224286063|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group I: 10 patients will be treated with Lysis and lavage
224286064|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group II: 10 patients will be treated with operative arthroscopy
224286065|NCT06013059|PROCEDURE|three levels of TMJ arthroscopy|Group III: 10 patients will be treated with operative arthroscopy + discopexy
224286066|NCT05156424|OTHER|Exercise|An individualised, progressive and autoregulated exercise programme, supervised by a trained professional.
224286067|NCT02947724|DRUG|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
223935543|NCT02078648|DRUG|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated)."
223935544|NCT02078648|DRUG|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
223935545|NCT02078648|DRUG|SL-701 + GM-CSF|"1.0 mL injection taken from 0.7 mL of SL-701 mixed at a 1:1 (v/v) ratio with 0.7 mL of Montanide. Preferred site of SC injection is in the right or left upper arms.~150 μg GM-CSF should be administered as a SC injection immediately after SL-701 emulsion administration and within 1 cm from the center of the SL-701 emulsion injection site."
223935546|NCT02078648|DRUG|Imiquimod|Within 5 minutes following the administration of the SL-701 emulsion, approximately 125 mg of imiquimod cream will be applied topically on the injection site. The imiquimod cream should be rubbed in until the cream is no longer visible.
223935547|NCT06799546|DRUG|HSK39297 tablets|200mg QD for 24 weeks
223935548|NCT06799546|DRUG|Eculizumab Injection|Eculizumab Injection for 24 weeks
223935549|NCT04088227|DRUG|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
223935550|NCT04088227|OTHER|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
223935551|NCT05451290|DRUG|Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur|Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
224097828|NCT01167296|DEVICE|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
224286068|NCT02434224|PROCEDURE|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
223935552|NCT06162338|BIOLOGICAL|LY-M001 Injection|With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
223935553|NCT06186973|OTHER|Monitoring with Neobeat heart rate meter|"At the designated time for cord clamping as per clinical indication, a 10 cm segment of the umbilical cord will be double-clamped and 5 ml of preferably arterial blood will be obtained.~In infants brought to the resuscitation table, six ECG electrodes will be placed on the skin and cardiac output will be measured with a hemodynamic monitor (PhysioFlow®) for at least 10 min, or until the end of resuscitation/stabilization."
223534108|NCT01729039|BEHAVIORAL|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
223935554|NCT06186973|OTHER|Maternal arterial blood gases|Arterial blood gases will be drawn from a radial artery line and analyzed at the end of a contraction at pre-specified time points during labor.
223935555|NCT06186973|OTHER|Amniotic fluid lactate|Amniotic fluid will be collected (2mL) and analyzed at pre-specified time points after rupture of the membranes.
223935556|NCT03747133|RADIATION|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
224097829|NCT06656403|DRUG|0.1% sodium hyaluronate|After baseline measurement, 0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
224097830|NCT06657573|BEHAVIORAL|An AI-enabled chatbot tailored for influenza vaccine consultation|The AI-enabled influenza vaccine chatbot can be accessed online through WeChat or any web browsers. The foundation of this chatbot is an expansive knowledge database, constructed with information sourced exclusively from healthcare authorities such as China CDCs and Health Departments, and thoroughly verified by public health experts. This database integrates data on the disease's burden, susceptibility, and severity, along with in-depth details about the vaccines, including their importance, efficacy, safety, and recommended demographics and timing for vaccination. It also covers types and costs of vaccines, societal norms such as vaccination guidelines, expert recommendations, and vaccination trends both in China and internationally. It also includes misinformation and fact-checking contents and provides information about vaccination services such as locations and appointment scheduling.
224097831|NCT06656832|OTHER|Heart Failure network care|Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
224099745|NCT07010133|BEHAVIORAL|A workplace-based depression intervention for low-wage hospital workers|This intervention is a remotely delivered workplace-based depression intervention that is tailored to the specific social and behavioral needs of low-wage hospital service workers. The intervention involves assessment of depression-related work impairment, work-focused cognitive behavioral therapy, work coaching, social needs screening and referral, and text message support for mood and physical activity.
223534109|NCT01729039|BEHAVIORAL|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
223935557|NCT06847386|PROCEDURE|Hysterocopic metroplasty|If the uterine cavity is normal during intraoperative hysteroscopy, the operation will be finished and embryo transfer will be scheduled in 1 month after the operation; if the uterine cavity is narrowed or the uterine wall is coalesced, hysteroscopic metroplasty and IUD placement will be performed, and a second hysteroscopy with IUD retrieval will be performed after 2-month postoperative estrogen-progesterone treatment, then embryo transfer will be scheduled after 1-month estrogen-progesterone treatment.
223935558|NCT06740734|BEHAVIORAL|Stress ball|Sterile Stress ball for pregnant women during mediolateral episiotomy repair. Participants in the stress ball group will be asked to squeeze and loosen the stress ball in their hands.
223935559|NCT06740734|BEHAVIORAL|Expressive touch applications|During the mediolateral episiotomy repair, expressive touch will be applied to one hand of the mother by the researcher, lasting approximately 15-20 minutes
223534110|NCT06592079|PROCEDURE|Immediate implant and connective tissue graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
223718625|NCT03612791|RADIATION|Radiotherapy|"* Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~* Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~* Total duration of RT (including brachytherapy) should be ≤ 55 days."
223935560|NCT06748404|DRUG|Tricalm Hydrogel|TriCalm Hydrogel® is a topical gel that allows rapid administration to areas of the skin. TriCalm Hydrogel® is available over-the-counter and contains the active ingredient, aluminum acetate 0.2%, and inactive ingredient, strontium chloride hexahydrate.
223935561|NCT06748404|DRUG|Triamcinolone acetonide 0.1% cream|Triamcinolone acetonide 0.1% cream is a topical steroid cream that will be applied directly to the skin.
223935562|NCT06752889|OTHER|Group( 1): Control Group (pulpectomy using zic oxide eugenol based sealer Zical):|Zinc oxide eugenol based sealer (Zical) will be mixed into a thick paste and packed into the pulp chamber to fill the canal.
223935563|NCT06752889|OTHER|Group ( 2) Experimental group modified 3-MIX-TATIN):|Modified 3Mix-tatin will be prepared by mixing three commercially available antibiotics with simvastatin. This powder will be mixed with zinc oxide eugenol based sealer called Zical which will act as a carrier or vehicle to form a creamy paste of 3Mixtatin at the time of application
223935564|NCT06764329|BIOLOGICAL|Mesenchymal Stem Cells|allogeneic bone marrow-derived mesenchymal stem cells therapy
223935565|NCT06764329|OTHER|0.9 % saline|0.9% Saline as placebo
224097832|NCT06855836|BEHAVIORAL|MI-CHANCE (TS + FTIR + MI)|MI-CHANCE was built following key principles of MI (partnership, acceptance, compassion and evocation) to empower PWUD, help them identify potential benefits of DCS and strategies to integrate these into their daily lives. The manual follows three key stages: 1) introducing DCS, 2) generating change talk, and 3) verbalizing commitment, using open questions, affirmations, reflections and summaries. Pros and cons for regularly using CheckSD and changing drug use behaviors accordingly were identified in the literature and through discussions with PWUD and HRCSD staff. Peer support specialists are urged to mirror participants' own language (e.g., oxy or M30s=oxycontin; carga= heroin; malilla=withdrawal, fetty=fentanyl). Challenges were categorized into 8 key areas: legal, financial, scheduling, transportation, ability to change drug use behaviors, communication with SSP staff, managing mood and substance use.
224097833|NCT06855836|BEHAVIORAL|TS + FTIR + Flu and Hepatitis A Education|Naloxone and educational materials (i.e. pamphlets) on overdose prevention, videos (English or Spanish) on naloxone, flu and Hepatitis A education.
223935566|NCT06774092|OTHER|Data collection|Data collection
224097834|NCT05114772|DIAGNOSTIC_TEST|Measuring Serum bio-markers|ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
224099746|NCT07015840|BEHAVIORAL|Visual perceptual learning|Evaluation of the effect of visual training on cortical activity during sleep
224099747|NCT01381081|BIOLOGICAL|platelet-rich plasma|a single intra-articular injection
224286069|NCT01057381|DRUG|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
224286070|NCT01057381|DRUG|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
223935567|NCT02510625|PROCEDURE|Anatomic Glenoid Reconstruction|Distal tibia bone graft
223935568|NCT02510625|PROCEDURE|Arthroscopic bankart Repair|Arthroscopic bankart Repair
223935569|NCT04520217|DRUG|4% Imipramine Cream|4% Imipramine Cream
223935570|NCT04520217|DRUG|Base Cream|Base Cream
224099748|NCT01381081|DRUG|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
224099749|NCT01901328|DRUG|CB-5945|
224099750|NCT01901328|DRUG|Placebo|
224099751|NCT04865731|DRUG|Dermaprazole|Patients will be managed with twice daily prophylactic use of the proposed intervention (Dermaprazole) topical cream for radiation dermatitis. The amount of cream will be 2cc per application and will be measured in pre-filled capped syringes for every application.
224099752|NCT04865731|DRUG|Aquaphor|Patients will be managed with twice daily prophylactic use of Aquaphor. The amount of Aquaphor will be 2cc per application and will be measured in pre-filled capped syringes for every application.
224286071|NCT01057381|DRUG|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
224286072|NCT01057381|DRUG|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
224097835|NCT03614247|PROCEDURE|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
223935571|NCT06547827|OTHER|robotic rehabilitation|"Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
224097836|NCT03614247|PROCEDURE|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
224097837|NCT03614247|PROCEDURE|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
224097838|NCT03614247|PROCEDURE|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
224097839|NCT03614247|PROCEDURE|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
224097840|NCT04535063|BIOLOGICAL|COVID19 convalescent plasma infusion|intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott)
223935572|NCT06547827|OTHER|traditional rehabilitation|"A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients."
224097841|NCT06985914|PROCEDURE|CT scan|CT scan in the emergency department
224097842|NCT02205450|DRUG|Recombinant Somatropin|
224097843|NCT02837679|OTHER|Geriatric Follow up|
224097844|NCT06411444|DEVICE|Grape Design Nasal Stent|Grape Design Nasal Stent
223534111|NCT06592079|PROCEDURE|Immediate implant with connective tissue graft and bone graft|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supra-periosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Xenograft will placed to fill the jumping gap.Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
223534112|NCT06074263|DRUG|Dexamethasone 8mg|Dexamethasone 8mg will be taken orally just prior to surgery.
223534113|NCT06074263|OTHER|Placebo|Placebo capsule which looks identical to dexamethasone capsule
223534114|NCT06596642|DRUG|Luspatercept|As per product label
223534115|NCT06982105|DRUG|Trimethoprim Sulfamethoxazole|"* For osteoarticular infections- 4-5 mg/kg/dose (based on TMP) PO every 8 hours (max dose 320mg/dose)~* For head and neck infections- 5-6 mg/kg/dose (based on TMP PO every 12 hours (max dose 320mg/dose)~Duration will be at the discretion of the treating provider"
223534116|NCT05218161|DRUG|Dexmedetomidine alone|All the patients in group DA will be sedated using dexmedetomidine 1mcg/kg IV bolus, followed by 0.3-0.7mcg/kg/h infusion to maintain Ramsay sedation score ≥4 during assisted ventilation.
223534117|NCT01772251|DRUG|Oshadi Icp|
223534118|NCT03624556|DIETARY_SUPPLEMENT|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
223534119|NCT03624556|OTHER|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
223534120|NCT06650384|DRUG|Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin|Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day
224097845|NCT05622500|PROCEDURE|Deep venous stenting|Endovascular reconstruction encompasses balloon venoplasty and venous stenting. A dedicated venous stent will be used, the brand of which the individual interventionist will decide.
223935573|NCT06533436|PROCEDURE|Corded tube care|The caregiver cut a 6 cm strip of Tensoplast® and wrapped it around the intubation probe at the level of the prescribed fixation mark at the corner of the mouth. The cord strands are placed around the patient's head, tightened, and a double knot is tied at the patient's cheek. Compresses are placed over the ears to protect them from possible lesions caused by the cords.
223935574|NCT06533436|DEVICE|Tube care attached by AnchorFast|"Shaving is recommended for patients with beards, and prior family consent is required for patients with beards.~AnchorFast is Suitable for intubation probes from 5 to 10 mm in diameter, it adapts to different morphologies thanks to hydrocolloid dressings bonded to the face and an adjustable cord around the neck. Due to its rigidity, this device is not recommended for patients whose condition requires them to be positioned in the ventral decubitus (VD) or lateral decubitus position."
223935575|NCT06533436|OTHER|Caregiver's evaluation on each tube fixation|The caregivers who performs the interventions according to the study will fill question form to assess the worload and the confort of the tube care for each intervention type The caregivers are both a research actor and a study population. One of the secondary aims of this study is to evaluate the two types of tube-fixing with regard to caregiver workload and comfort in performing care. Caregivers will complete identical questionnaires assessing their satisfaction with the two types of tube fixation studied in arms 1 and 2.
223935576|NCT05189496|BEHAVIORAL|hyperbaric oxygen therapy|hyperbaric oxygen therapy
223935577|NCT04972097|DEVICE|Irreversible Electroporation|IRE of the prostate is typically performed with the subject in the lithotomy position, with 2-6 monopolar probes placed through the perineum using a brachytherapy grid and ultrasound or CT guidance. IRE supplies the targeted tissue with high voltage (2-3 kV) direct current pulses lasting up to 100 microseconds through the electrode probes.
223935578|NCT05423145|BEHAVIORAL|self-administered acupressure|The acupressure intervention is self-administered. The intervention group receives an app that instructs them on how to perform a stimulating acupressure protocol, consisting of six acupoints with four of the acupoints performed on both the left and the right sides of the body for a total of ten points. Each of the ten acupoints is to be stimulated for 3 minutes per point for a total treatment time of 30 minutes daily for 6 weeks.
223935579|NCT06749509|OTHER|Face-to-face musculoskeletal rehabilitation|Kela's rehabilitation course for those with MSD includes two 5-day periods and one 3-day period of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation center over a 9-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation course is group-based and provided free of charge. The 9-month rehabilitation period also includes calls to the participants before and after rehabilitation. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A medical statement is required when applying for the rehabilitation course.
224097846|NCT05622500|COMBINATION_PRODUCT|Best medical therapy|Compression stockings encompass a range of therapies used to provide an externally applied graduated-pressure up the length of the limb aiming to improve venous function and decrease lower limb swelling. Compression stockings can be classified by size and grade, i.e. the pressure the stockings applies to the limb. For the purpose of this trial Class II and Class III graduated compression stockings should be used, with the aim of providing Class III if tolerated. Antithrombotic agents include, but are not limited to: warfarin (titrated to international normalised ratio, INR), apixaban, rivaroxaban, aspirin, and clopidogrel.
224097847|NCT07107633|DRUG|Technetium [99mTc]-H7ND injection|Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor
224097848|NCT06861608|BEHAVIORAL|Screening Questionnaire|"Individuals will complete an online screening survey through an online study advertisement to determine initial eligibility. The screening survey will ask participants to report their gender and age and complete the Eating Attitudes Test - 26-item (EAT-26). EAT-26 scores equal to or greater than 20 indicate risk for an eating disorder. EAT-26, participants will meet the referral criteria which includes a score of 20 or more or meeting frequency criteria on bingeing, purging, laxative/diuretic use, and/or exercise. If an interested individual is not eligible, they will be notified that they are not currently eligible for the study and provided with resources."
224097849|NCT06861608|BEHAVIORAL|Pre-Intervention Questionnaires (~10 minutes)|Eligible participants will complete pre-intervention questionnaires including demographics and symptom measures.
224097850|NCT06861608|BEHAVIORAL|SSI (Single-session intervention (~30 minutes) Active arm|The SSI will consist of four components: 1)psychoeducation, 2) real-life examples, 3) common questions and misconceptions, and 4) providing advice to other young adults. Psychoeducation will focus on the brain bases of habit formation and EDs, as per REACH+ treatment manual. Participants will then be asked to think of a real-life example of an eating habit in which they have been engaged, such as limiting their intake of dessert foods. Participants will then be provided with REACH+ developed psychoeducation regarding changing habits, including information on competing responses, stimulus control, and exposure. Participants will have the opportunity to write out how they could use one of these strategies to tackle the habit that they previously wrote about. They will be provided with a worksheet to help them move through each aspect of changing their habit based on what they learned.
224097851|NCT06861608|BEHAVIORAL|SSI (Single-session intervention (~30 minutes) control arm|The control condition will be matched to the SSI by including both reading and writing exercises. The control intervention will consist of supportive therapy focusing on sharing emotions and include an introduction to emotions, writing about emotions, testimonials from other adolescents about the power of sharing emotions, and an exercise asking adolescents how different situations might make them feel.
224097852|NCT06861608|BEHAVIORAL|End-of-Intervention Questionnaires (~5 minutes)|Participants will complete additional questionnaires at the end of the intervention, including acceptability ratings and program feedback. Participants will provide an email address at the end of the questionnaires for receipt of four-week follow-up questionnaires.
224097853|NCT03507140|OTHER|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
224097854|NCT04984889|DRUG|TAK-662|Lyophilized, sterile concentrate of human protein C
224286073|NCT05889234|DEVICE|Modified Electroconvulsive Therapy|MECT is performed using the Thymatron System IV (Somatics LLC, LakeBluff, IL, USA) electroconvulsive therapy (ECT) machine. Prior to ECT, all patients undergo laboratory tests such as routine blood, liver, kidney and thyroid function and an ECG and remain fasted for 12 hours. Initial treatment power is considered by age: percentage of power = age x 0.7. Stimulation power is adjusted according to seizure duration. If the seizure duration is less than 25 seconds, the energy is increased by 5% in the subsequent treatments. Anaesthesia and muscle relaxation were administered with propofol (1.5-2 mg/kg) and succinylcholine (0.5-1 mg/kg), respectively, and subjects were awakened after ECT treatment and adverse effects, such as subjective memory impairment, headache or nausea/vomiting, were recorded. Frequency of ECT treatment: 3-4 times per week for a total of 6-8 sessions
224286074|NCT05889234|DRUG|Conventional pharmacotherapy|Conventional pharmacotherapy: SSRIs including fluoxetine, paroxetine, sertraline, cetinopram, fluvoxamine, vortioxetine, escitalopram; SNRIs including venlafaxine, duloxetine; NaSSA including mirtazapine; other antidepressants including trazodone, bupropion, agomelatine; potentiators including aripiprazole, olanzapine, quetiapine, risperidone.
224286075|NCT03362996|DIETARY_SUPPLEMENT|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
224286076|NCT03362996|COMBINATION_PRODUCT|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
223935580|NCT06749509|OTHER|Musculoskeletal telerehabilitation|Kela´s MSD telerehabilitation course is arranged entirely as telerehabilitation, and it includes videoconferencing, online rehabilitation, and group-based rehabilitation days implemented by a multidisciplinary team of rehabilitation experts. Participation does not require particular IT skills, but appropriate equipment (e.g., mobile phone, laptop, tablet computer) is needed. The rehabilitation course is free of charge, and the total duration, including the calls before and after rehabilitation, is approximately 7 months. The course is intended for persons over the age of 18 with diagnosed MSD and difficulties coping with work or studies. The course provides support, tools, and coaching to help manage daily life and work with MSD. Self-rehabilitation is an important component of the program. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. A physiotherapist's recommendation is required when applying for the telerehabilitation course
223935581|NCT06749509|OTHER|Controls|The control participants have an MSD diagnosis and musculoskeletal symptoms. Based on an occupational physiotherapist's brief evaluation they are eligible to apply for Kela's musculoskeletal rehabilitation (the interventions below). By them own choice, however, they will not participate in these rehabilitation programs in the near future. The controls are recruited via two occupational health care producers in the private sector.
223935582|NCT06777277|OTHER|Cognitive-behavioral therapy|The intervention will be delivered in 16, 60-minute sessions (1st session 90 mins). The treatment manual was informed by a 12-session (75 min each) CBCT developed by our team for genito-pelvic pain. The SIAD manual focuses on empirically supported interpersonal factors relevant to SIAD, informed by the Interpersonal Emotion Regulation Model of women's sexual dysfunction. The goals of the CBCT are to: (1) re-conceptualize low sexual desire/arousal as multidimensional in which both partners affect and are affected by the SIAD symptoms (2) modify and/or accept those factors that are associated with low sexual desire/arousal to increase adaptive coping, facilitate sexual desire/arousal, and reduce sexual distress, (3) as per our theoretical model, improve couple interactions related to sexuality (e.g., communication, intimacy) via enhanced emotion regulation, and (4) consolidate skills.
224286077|NCT03362996|OTHER|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
224286078|NCT05613725|OTHER|Blood sample collection|Blood sample collection
224286079|NCT00602134|DRUG|6-Mercaptopurine|
224286080|NCT01129934|DRUG|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
224286081|NCT01129934|DRUG|morphine|Administration of intravenous morphine 0.1 mg/kg
223718626|NCT03612791|DRUG|Cisplatin|"* Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~* Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
224286082|NCT00541164|DRUG|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
223718627|NCT05802511|DEVICE|Exablate treatment|Exablate treatment for Neuropathic Pain
224286083|NCT00541164|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
224286084|NCT05532579|OTHER|Invasive Physiotherapy Group|The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.
223935583|NCT04282356|DRUG|Intraperitoneal chemotherapy during surgery|During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection). They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel, 60mg/m2 on D8) with at least 3 courses performed (up to 4-6 allowed).
223935584|NCT05637177|BEHAVIORAL|Anging Wisely|The program includes 11 meetings of two hours in a group of up to eight people. The sessions are held weekly. Each lesson is given a homework assignment. A total of 10 groups will take place.
224097855|NCT06994507|DRUG|GM1|GM1 was administered intravenously one day before the administration of each cycle of chemotherapy. The experimental group was given 400 mg of GM1 injection. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
223935585|NCT05637177|BEHAVIORAL|Music therapy|Music therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 12. A total of 10 groups will be implemented.
223935586|NCT05637177|BEHAVIORAL|Reminiscence therapy|Reminiscence therapy sessions are held once a week for 60 minutes for 12 weeks. The maximum number of participants per group is 10. A total of 5 groups will be implemented.
223935587|NCT05637177|BEHAVIORAL|Cognitive training|"Intervention cognitive training will take place once a week for 45 minutes for 20 weeks. Seniors can choose from two options: 1. group training full-time or home training (online) using the comprehensive training program MENTEM."
224097856|NCT06994507|DRUG|Placebo|Placebo was administered intravenously one day before the administration of each cycle of chemotherapy. The control group was given placebo. Administration was carried out at D-1, D1, D2 in each cycle, with a cumulative administration of 3 times per cycle.
224097857|NCT05818670|DRUG|Tamsulosin|long term follow up
224097858|NCT05818670|DRUG|Tadalafil|long term follow up
224097859|NCT00562809|DRUG|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
223935588|NCT05637177|BEHAVIORAL|Educational activities|Interventions in educational activities will run for one academic year. In total, seniors will attend 16 lectures in each educational module. The lectures will run 1 x 14 days for 90 minutes.
224286085|NCT05532579|OTHER|Sham Group|Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
224286086|NCT03425487|BEHAVIORAL|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
224286087|NCT03425487|BEHAVIORAL|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
224286088|NCT03425487|OTHER|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
224286089|NCT04746599|PROCEDURE|Autologous Fat Grafting|The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
224286090|NCT03896282|OTHER|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
223534121|NCT06650384|DRUG|Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin|Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
223534122|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
223534123|NCT01412216|DIETARY_SUPPLEMENT|Fish Oil (Omega-3 Fatty Acids)|
223935589|NCT04440735|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
224097860|NCT06863246|OTHER|Evaluation of cognitive task on static balance|Static balance with and without cognitive task (i.e., 1-back task)
224097861|NCT06863246|OTHER|Evaluation of visual feedback on static balance|Static balance with and without visual feedback (i.e., eyes closed and open).
224097862|NCT06322810|PROCEDURE|Erector spinae plane block (ESPB)|Bilateral ESP: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
224097863|NCT06322810|PROCEDURE|Pecto-intercostal fascial plane blok (PIFB)|Bilateral PIFB: 0.5% ropivacaine 0.3 ml per kg (ideal body weight) each side, 30 min before skin excision. After surgery, use pump to deliver an intermittent automatic bolus of 0.3 ml per kg 0.16% ropivacaine every 4 hours each side.
224097864|NCT06251011|BEHAVIORAL|Exercise training|"1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation"
224286091|NCT00573170|DRUG|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
224286092|NCT00573170|DRUG|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
223935590|NCT04440735|BIOLOGICAL|Atezolizumab|Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
223935591|NCT06778408|RADIATION|Hybrid Palliative Radiation Therapy|Hybrid Palliative Radiation Therapy will be administered to all patients.
223935592|NCT06560138|DRUG|SHR-4602|SHR-4602 will be administered through IV infusion.
223935593|NCT06838455|OTHER|Spinopelvic mobility exercise|Participants will complete a 15-20 min session of therapeutic exercises performed by patients with assistance of a pre-recorded video. The exercise regimen has been developed by the investigators of this study to incorporate exercises to increase a patient's spinopelvic mobility. Study staff that has been properly trained will be present to guide the patient through the exercise regimen and ensure the exercises are being performed accurately.
223935594|NCT06392958|OTHER|Traditional Chinese Medicine exercises - Baduanjin|According to the four steps of the cross-theoretical model, the behavior stage (pre-intention stage, intention stage, preparation stage, action stage and maintenance stage) and the family empowerment (clarify the problem, express the emotion, formulate the plan, implement the plan, and evaluate the effect). Combined with the characteristics of elderly patients after PCI, the cardiac rehabilitation management plan was designed focusing on the timing of cardiac rehabilitation, the way of health guidance, safety and compliance management.
223935595|NCT06618755|OTHER|Experimental group : PSH (usual care) with motivational interviewing|The experimental group will begin follow-up after the 1st inclusion visit, during hospitalisation for withdrawal. The first motivational interview will take place 1 to 4 days before discharge from full hospitalisation. The following 10 motivational interviews will be held 2 weeks apart and will follow a framework based on the following objectives: to create a relationship of trust and an effective and lasting therapeutic alliance from the first interview; to create personalised objectives for the user, in line with their addictive pathology; to support the user as they modify, 'fail' and 'succeed' in achieving these objectives; to encourage the emergence and maintenance of the user's desire to change.
223935596|NCT06759636|DRUG|Romiplostim N01|3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
223935597|NCT06759636|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|25-50μg/kg, subcutaneous injection, once a day
223935598|NCT06716333|OTHER|Experimental Group (12-Week Wrestling Training)|The intervention consists of a structured 12-week intensive wrestling training program designed specifically for male wrestlers aged 12-14 years. This program was conducted at athlete training centers equipped with international standard facilities, and led by professional coaches. The training included 5 sessions per week, each lasting approximately 80 minutes, with a total weekly duration of 400 minutes. Each session consisted of 20 minutes of gymnastic warm-up, 50 minutes of basic technical and strength exercises (e.g., squats, push-ups, deadlifts), and 10 minutes of stretching.
223935599|NCT06776445|DRUG|minocycline combined with hydroxychloroquine|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
223935600|NCT06776445|DRUG|gabapentin 300mg bid|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
224097865|NCT06546839|DRUG|SPSIPB blcok|A high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The procedure will be performed with the patient in the lateral decubitus position. After the scapula is shifted slightly laterally, the US probe is placed sagittal at the upper corner of the spina scapula, and the serratus posterior superior muscle is visualized with the third rib. The in-plane technique will be used. The block needle will be advanced in the craniocaudal direction to enter between the serratus posterior superior and the third rib. The block location will be confirmed by injecting 5 ml of saline between the rib and the muscle. After the block location is confirmed, 30 ml of 0.25% concentration bupivacaine will be used.
224097866|NCT06546839|DRUG|SAPB block|In the lateral decubitus position, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane concerning the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be injected for correction. Following confirmation of the correct position of the needle, 30 ml %0.25 bupivacaine will be administered for the block.
224097867|NCT06546839|DRUG|Postoperative analgesia management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
224286093|NCT00573170|DRUG|placebo|placebo
224286094|NCT03010982|DRUG|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
224286095|NCT04132401|DIAGNOSTIC_TEST|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
223718628|NCT06390306|DRUG|Ponatinib|Ponatinib is recommended orally (PO) daily continuously on days 1-28 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
223718629|NCT06390306|DRUG|Azacitidine|Azacitidine is recommended 75mg/m2 subcutaneously on days 1-7 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
223935601|NCT06776445|DRUG|gabapentin 300mg tid|Patients with rosacea were collected and randomly divided into three groups for treatment, one group was treated with minocycline combined with hydroxychloroquine, one group was treated with gabapentin 300mg Bid, and the other group was treated with gabapentin 300mg tid. Before treatment, 4 weeks after treatment, and 8 weeks after treatment, the patient's condition score was statistically analyzed, and the efficacy and difference of each group were observed
223935602|NCT04965155|DRUG|Isatuximab-dexamethasone|Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
223935603|NCT04449146|DIAGNOSTIC_TEST|Scapular positioning in Standing position using Sonography|The localizer ultrasound of the shoulder is performed in an unclothed patient (at the shoulders) and comes to locate bony landmarks using the ultrasound probe as a Transcutaneous localizer.
223935604|NCT06856525|DRUG|Hyperpolarized Xe129|Determine the impact of e-cigarette use on pulmonary gas exchange capacity in interstitial tissues and capillaries using hyperpolarized xenon-129 MRI.
223935605|NCT06856525|DIAGNOSTIC_TEST|Cardiopulmonary Stress Test|Exercise stress test to evaluate cardiac and pulmonary fitness.
223935606|NCT06856525|DIAGNOSTIC_TEST|Pulmonary Function Test|Standard clinic pulmonary function test to evaluate lung function
223935607|NCT06856525|DIAGNOSTIC_TEST|Chest CT|Clinical standard chest computer tomography to evaluate any lung tissue scars or air movement.
223935608|NCT06750874|BEHAVIORAL|Acceptance and Commitment Therapy|One day workshop + telephone booster
223935609|NCT06817421|BIOLOGICAL|Pneumococcal conjugate vaccine|10-valent pneumococcal polysaccharide conjugate vaccine at a dosage of 2μg for each serotype polysaccharide for 1, 5, 6A, 7F, 9V, 14, 19A, 19F, 23F, and 4μg for serotype 6B, conjugated to a carrier protein (CRM197), polysorbate 20 and aluminium phosphate as an adjuvant. Administered as an intramuscular injection of 0.5mL.
223935610|NCT06817421|BIOLOGICAL|Typhoid conjugate vaccine|Typhoid conjugate vaccine at a dosage of 25μg purified Vi capsular polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid with preservative (2-Phenoxyethanol). Administered as an intramuscular injection of 0.5mL.
223935611|NCT05972525|BEHAVIORAL|Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee|The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
223935612|NCT06816784|DRUG|Autologous serum therapy|5 ml of blood will be collected and centrifuged at 3000 r.p.m for 10 min to obtain serum,2 ml of the serum will be injected into the gluteus muscle. We will give the patients 9 injections of Autologous Serum intramuscularly once a week
223935613|NCT06816784|DRUG|Oral levocetirizine|Group B will receive oral levocetirizine 5mg 1 tablet HS.
223935614|NCT06763835|DIAGNOSTIC_TEST|Blood is drawn to test for specific biomarkers|After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.
223935615|NCT06812741|DRUG|Transversus abdominis plane (TAP) block with 0.25 % bupivacaine|The probe was placed in a plane transverse to the lateral abdominal wall in the mid-axillary line immediately cephalad to the iliac crest. The needle was advanced immediately anterior to the probe using the in-plane needle-probe orientation and advanced posteriorly until the needle was observed to penetrate the interface between the internal oblique and transversus abdominis muscles. Thereafter, a local anesthetic (0.2 mL/kg of 0.25 % bupivacaine) was injected incrementally, and the spread was observed within the plane.
223718630|NCT06390306|DRUG|Venetoclax|Venetoclax is recommended orally (PO) daily on days 1-14 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
223935616|NCT06812741|DRUG|Ilioinguinal/iliohypogastric Nerve Block with 0.25 % bupivacaine|The ultrasound probe was placed immediately medial and slightly cephalad to the upper aspect of the anterior superior iliac spine to obtain a short-axis view of the nerves situated between the two abdominal muscles (internal oblique and transversus abdominis), A 22 G needle tip \~1 cm caudal to the probe surface was introduced and was advanced until a characteristic 'tenting' of the interface between the two muscles was seen and was then further advanced deep to this interface until a pop was felt and then the injectate (0.2 mL/kg of 0.25 % bupivacaine) was observed spreading between these two layers.
223935617|NCT05021562|DRUG|Niraparib|Niraparib capsules
223935618|NCT06817655|BEHAVIORAL|PaRole OncO France : Individual peer support|"Following the development of the peer support program PaRole OncO France, we are now proceeding with its implementation and evaluation through a pilot study. This study aims to derive both implementation-related and clinically relevant results.~Prior to their assignment, all peer helpers undergo a comprehensive training course to ensure they are well-equipped for their role.~Patients receive individual peer support during their treatment visits, providing real-time assistance and support within the clinical setting.~The study incorporates three key measurement time points:~1. Baseline measurement (before the intervention)~2. After the intervention~3. Follow-up measurement (1months after the first intervention)~4. Follow-up measurement (6 months after the first intervention)~At each time points, participants will complete a set of standardized questionnaires. These instruments are designed to capture relevant outcomes and experiences related to the peer support intervention."
224097868|NCT06867627|BEHAVIORAL|Moderate-intensity combined aerobic and resistance exercise training|Training sessions begin with a 10-minute warm-up period that includes jogging and dynamic muscle stretching. This is followed by 20 minutes of running/jumping rope on the playground. Each intervention participant will wear a heart rate armband (Polar OH1, Finland) for real-time heart rate detection to maintain achievement of a predetermined target heart rate and training intensity. Then, after 10 minutes of rest adjustment and preparation, a 20-minute resistance training session will be performed, including all major muscle groups. Resistance training will start at 50% of 1RM and increases intensity by 10% after every three sessions, with two sets of repetitions and 60-90 seconds of rest between sets. By the third week, it will reach 70% of 1RM, and repeat 3 sets at 70% of 1RM starting at week 4. After the end of week 6, re-evaluate the RM every 3 weeks and repeat 3 sets at 70% of the new 1RM (i.e., starting from Week 7 and Week 10), maintaining a 60-90 second rest between each sets.
223718631|NCT06390306|DRUG|Olverembatinib|Olverembatinib is recommended orally (PO) every other day on days 1-28 in 28-day cycle. Treatment repeats every 28 days in the absence of disease progression, unacceptable toxicity or HSCT.
224286096|NCT00311350|DRUG|MOA-728|
223935619|NCT05927350|OTHER|Survey|Survey asking about sociodemographics, pediatric research participation, experience with research, gender minority stress and resilience, vaccine hesitancy, medical mistrust, and connectedness to the LGBT community
223935620|NCT06765187|BIOLOGICAL|RIV3|intramuscular injection
223935621|NCT06831370|DRUG|Brentuximab Vedotin|Brentuximab Vedotin IV infusion
223935622|NCT06831370|DRUG|Doxorubicin|Doxorubicin IV infusion
223935623|NCT06831370|DRUG|Vinblastine|Vinblastine IV infusion
223935624|NCT06831370|DRUG|Dacarbazine|Dacarbazine IV infusion
223935625|NCT06254872|BEHAVIORAL|Peer Mentors|Peer mentors provide daily guidance and encouragement to mentees via smartphone app based on training.
224286097|NCT03914235|COMBINATION_PRODUCT|Tumescent Anesthesia|A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
223935626|NCT06749171|PROCEDURE|coronary artery bypass grafting|ONCAB (on-pump coronary artery bypass grafting), OPCAB (off-pump coronary artery bypass grafting), NTA (no-touch aorta technique), MICSCAB (minimally invasive multiple coronary artery bypass grafting)
223935627|NCT06446284|BEHAVIORAL|EWM Training|Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
224286098|NCT03914235|DRUG|Lidocaine|Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
223534124|NCT06569810|DEVICE|Repeated Low-Level Red Light (RLRL) therapy|In our study, we do not implement any interventions; rather, we collect follow-up information from patients who, due to insufficient response to traditional myopia control therapies, have transitioned to Repeated Low-Level Red Light (RLRL) therapy. The data gathered will reflect treatment patterns as per the approved indications for RLRL therapy, where subjects may have undergone treatment sessions twice daily, each lasting for 3 minutes with a minimum interval of 4 hours between sessions. Our analysis will focus on the real-world outcomes, specifically evaluating the proportion of participants who have achieved effective myopia control (defined as AL elongation of less than 0.1mm per year or SER progression of less than 0.25 diopter per year) after 12 months of documented RLRL therapy use among the collected data from eligible subjects.
223935628|NCT06446284|BEHAVIORAL|Placebo Training|Computerized tasks with comparable engagement that do not tap executive working memory processes
223935629|NCT05360329|PROCEDURE|Transarterial geniculate artery embolization|The procedure will be performed in local anaesthesia. An antegrade percutaneous transfemoral approach with super-selective catheterisation of geniculate neovesselswill be performed and subsequently the target will be pruned with microspherical embolic material.
223935630|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 0.8 mg/kg|Biological: single 1-hour intravenous infusion of 0.8 mg/kg ilofotase alfa
223935631|NCT05890794|BIOLOGICAL|Ilofotase Alfa, 3.2 mg/kg|Biological: single 1-hour intravenous infusion of 3.2 mg/kg ilofotase alfa
223935632|NCT02673476|DRUG|ALS-008176|ALS-008176 tablets
223935633|NCT02673476|DRUG|Placebo|Identical placebo tablets
223935634|NCT06778980|OTHER|The chin tuck posture|A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.
223935635|NCT05881265|DRUG|Chidamide+venetoclax|Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
223935636|NCT05319496|DEVICE|Intermittently scanned continuous glucose monitor (isCGM)|"A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL)."
223935637|NCT05319496|BEHAVIORAL|Education and coaching|Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
223935638|NCT06751004|OTHER|BALLISTIC SIX EXERCISES|Ballistic six exercises will be given to group A and exercises of 3 sets of 10-20 repetitions will be completed, with each series offering 30-60 seconds of rest. The ballistic Six exercise uses resistance-band latex tube and fitness balls.
223935639|NCT06751004|OTHER|RESISTANCE-BAND EXERCISES|Resistance-band exercises will be given to group B and the duration of training sessions will be 3 sets of 10-20 repetitions
223935640|NCT05127161|BEHAVIORAL|Broad Implementation of Outpatient Stewardship (BIOS) intervention|The BIOS intervention consists of 3 components: (1) online educational modules covering topics related to appropriate antibiotic prescribing for ARTIs, (2) individualized audit and feedback reports displaying clinicians' rates of antibiotic prescription with peer comparison, (3) facilitation provided by the study team and by health system champions to support effective implementation of the intervention and to encourage clinicians to engage meaningfully in the intervention activities.
223935641|NCT05843708|DRUG|Vorasidenib 40 mg Oral Tablet|"Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)"
223935642|NCT05843708|DRUG|Ciprofloxacin 500 mg Oral Tablet|Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)
223935643|NCT05843708|DRUG|Vorasidenib 10 mg Oral Tablet|Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
223935644|NCT04261855|DRUG|Avelumab|All patients will receive avelumab intravenously (IV) at 10 mg/kg every 2 weeks for 24 months or until unacceptable toxicity or evidence of disease progression
223935645|NCT04261855|RADIATION|External Beam Radiation Therapy (EBRT)|Patients allocated to Arm A will receive EBRT on 2 occasions, 8-10 weeks apart
224286099|NCT03914235|DEVICE|Pneumatic tourniquet|Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
223935646|NCT04261855|RADIATION|Lutetium-177 (177Lu)-DOTATATE|"Patients allocated to Arm B will receive 177-Lu-DOTATATE treatment on 2 occasions, 8-10 weeks apart.~This treatment arm is now closed to recruitment."
223935647|NCT06779656|DEVICE|General Anesthesia (GA)|Following administration of the regional anesthesia, general anesthesia with endotracheal intubation will be performed. Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.
223935648|NCT06779656|PROCEDURE|Paravertebral Block (PVB)|The patient will be positioned in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe (6-13 MHz) will be used to visualize the transverse processes, ribs, and pleura adjacent to the thoracic transverse processes on the operative side. Under ultrasound guidance, a needle will be inserted from posterior to anterior, advancing just superior to the tip of the transverse process, 1-2 mm, avoiding the pleura, and entering the paravertebral space. For ropivacaine, either 0.375% or 0.5% will be administered at a dose of 3-5 mL per segment, according to the patient's height and the extent of surgery. The block will target the T2-T6 nerve distribution, with a total dose not exceeding 20 mL. Alternatively, for liposomal bupivacaine (10-26.6 mg/mL), the dose will be determined based on the patient's weight and surgical extent, typically a total dose of 100-200 mg, diluted with normal saline to a total injection volume of 10-20 mL.
223935649|NCT06779656|PROCEDURE|Rhomboid Intercostal and Subserratus Plane Block (RISS)|The patient will be positioned in the lateral decubitus position with the operative side up. A high-frequency ultrasound probe will be used to locate the medial border of the scapula and identify the rhomboid, intercostal, and serratus anterior muscles. Under ultrasound guidance, the needle will be advanced into the plane between the rhomboid and intercostal muscles, or the plane between the intercostal and serratus anterior muscles. Ropivacaine 0.25% will be administered with an injection volume of 15-20 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 15-20 mL.
223935650|NCT06779656|PROCEDURE|Pectoral Nerves Block II (PECS II)|The patient will be placed in the supine position with the operative side arm slightly abducted. A high-frequency ultrasound probe will be used to locate the pectoralis major, pectoralis minor, and serratus anterior muscles. Under ultrasound guidance, the needle will be advanced into the plane between the pectoralis minor and serratus anterior muscles. Ropivacaine 0.25% will be administered with an injection volume of 20-30 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 20-30 mL.
223935651|NCT06779656|PROCEDURE|Intercostal Nerve Block (INB)|The patient will be positioned in the lateral decubitus or supine position. A high-frequency ultrasound probe will be used to locate the ribs and intercostal muscles. Under ultrasound guidance, the needle will be advanced to the inferior margin of the rib, in the intercostal muscle plane. Ropivacaine 0.25% will be administered at a dose of 2-5 mL per intercostal space, typically targeting 3-5 intercostal spaces. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered at a dose of 2-5 mL per intercostal space, with a total dose not exceeding 200 mg, and a total injection volume of 5-20 mL.
223935652|NCT06779656|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The patient will be positioned in the lateral decubitus or supine position with the operative side arm slightly abducted. A high-frequency ultrasound probe will be used to locate the serratus anterior muscle. Under ultrasound guidance, the needle will be advanced either superficial or deep to the serratus anterior muscle. Ropivacaine 0.25% will be administered with an injection volume of 20-30 mL. Alternatively, liposomal bupivacaine (10-26.6 mg/mL) will be administered according to the manufacturer's recommended dosage, usually a total dose of 100-200 mg, with an injection volume of 20-30 mL.
224097869|NCT05929924|DIETARY_SUPPLEMENT|Extra virgin olive oil|EVOO will be included in the participant's daily diet for 6 months
224097870|NCT06867055|BIOLOGICAL|Injectable platelet-rich fibrin (I-PRF)|I-PRF were produced with 11-mL plastic tubes (16\*10 mm) using a Nuve NF 200 centrifugation device with a rotor angulation with a radius of 101 mm at the clot (Nuve NF 200, Nuve Industrial Materials Manufacturing and Trade Company, Ankara, Türkiye). The I-PRF at the top of the tube was collected with a syringe and transferred to the metal bowl. It was held for 20-25 min for polymerization.
224097871|NCT06867055|DRUG|0.8% hyaluronic acide (HA)|0.8% polyvinylpyrrolidone sodium hyaluronate (HA) (Gengigel Prof, Ricerfarma SRL.) gel was impregnated on a sterile gelatin sponge and sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Türkiye) on the palate area and bleeding control was provided with SX bioplast plate.
224097872|NCT06867055|OTHER|control group|Sterile gelatin sponge was sutured with 4/0 silk suture (4/0 Sterisilk, SSM Medical Equipment, Turkey) in the palatal region where FGG was taken and bleeding was controlled with SX bioplast plate.
224097873|NCT05885009|GENETIC|Liquid Biopsy|Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy
224286100|NCT03914235|PROCEDURE|Open release of the tendon|Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
224286101|NCT02446834|BEHAVIORAL|intensive lifestyle intervention|3 months low GI diet and exercise
224286102|NCT02446834|DRUG|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
224286103|NCT02446834|DRUG|Metformin|Use metformin 3 months to treat PCOS
224286104|NCT02446834|DRUG|Acarbose|Use acarbose 3 months to treat PCOS
224286105|NCT03432234|OTHER|Biomarkers|This is an observational study, there is no intervention
224286106|NCT00288717|DRUG|Candesartan|
224286107|NCT00288717|DRUG|Telmisartan|
223935653|NCT06779656|PROCEDURE|Epidural Block|The patient will be positioned in the sitting or lateral decubitus position. The area will be prepped and draped using standard aseptic technique. Either the thoracic or lumbar region will be selected, with the T4-T5 level often chosen. An epidural needle will be inserted into the epidural space, and an epidural catheter will be placed, using standard epidural techniques. Ropivacaine 0.1% or 0.083% will be administered as an initial bolus of 5-10 mL, followed by a continuous infusion at a rate of 5-10 mL/h. Alternatively, bupivacaine 0.1% or 0.0625% will be administered as an initial bolus of 5-10 mL, followed by a continuous infusion at a rate of 5-10 mL/h. These can be used in combination with opioid medications such as fentanyl or sufentanil to enhance analgesia.
224286108|NCT03346252|DRUG|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
224286109|NCT02019082|DEVICE|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
224286110|NCT02019082|DEVICE|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
224286111|NCT05990582|DIAGNOSTIC_TEST|CBCL|A questionnaire on behaviour
224286112|NCT05990582|DIAGNOSTIC_TEST|SDQ|A questionnaire on behaviour
224286113|NCT05990582|DIAGNOSTIC_TEST|CCC-2-NL|A questionnaire on communcational skills
223534125|NCT03490565|BEHAVIORAL|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
223935654|NCT06636487|BEHAVIORAL|pulmonary tele-rehabilitation (PTR)|"PTR is delivered from promoter hospital to a group of 3 - 5 patients who exercise at home and communicate via tablet-camera. Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks.~Specific exercises are evidence-based; been used in several intervention studies on patients with CRD (eg. COPD). Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations. The education sessions consist of dialogue, reflections around empowerment and better living with CRD. Every sixth education session consists of 25 min Mindfulness exercises developed for CRD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
223935655|NCT06636487|BEHAVIORAL|Home-based pulmonary rehabilitation (HPR)|"HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle endurance based exercise; 3-days/weekly for 10-weeks. Exercises are evidence based; used in several intervention studies on patients with CRD (eg. COPD) and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of access to mindfulness exercises and an educationbook. The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to CRD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period"
223935656|NCT06636487|BEHAVIORAL|Control|Receive usual care; medication, scheduled follow up visit and possible phone contact with GP and the outpatient respiratory department. Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered. If a patient changes their decision and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
223534126|NCT01348893|BEHAVIORAL|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
223534127|NCT00698841|DRUG|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m\^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m\^2 over 60 minutes.
223534128|NCT06984510|OTHER|Observational|Observational
223534129|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - fast|Continuous passive motion device (CPM) of ankle at 1HZ(60rpm) for 10 repetitions
223935657|NCT06117436|DRUG|Cilostazol|Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant
223935658|NCT06117436|DRUG|Selenium|Selenium 200 mcg oral tablet once daily
223935659|NCT03086421|BEHAVIORAL|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
223935660|NCT05466396|BEHAVIORAL|smoking|Smoking history and spirometry are used to define groups
223935661|NCT06830486|OTHER|No intervention|No intervention is performed. Participants who have been treated with either a SERM or aromatase inhibitor are recruited and analyzed in separate groups, but the study design for all participants is identical.
223935662|NCT05429138|OTHER|biological sampling|Biological sampling: blood and semen
223935663|NCT06550934|PROCEDURE|Fracture stabilization|isolated posterior surgical fracture stabilization vs. combined anterior-posterior surgical fracture stabilization
223935664|NCT06425900|DRUG|Winlevi (Clascoterone) cream 1%|Dosed twice daily (BID)
223935665|NCT06222099|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
223935666|NCT06222099|OTHER|Standard care|RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.
223935667|NCT06222099|DEVICE|Heartfelt-guided care|Volume measurements and health alerts transmitted to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
223935668|NCT06222099|OTHER|Questionnaires|Patients were presented with one or more optional questionnaires (some validated, some bespoke)
224097874|NCT05885009|GENETIC|Archival Tumor DNA sequencing|Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis
224097875|NCT06683482|OTHER|No intervention|No study drug will be administered as a part of this study.
224097876|NCT06685120|COMBINATION_PRODUCT|PRP + HA injection|Following autologous PRP harvesting and production, 5 mL of PRP and 40 mg/2 mL of HA will be infiltrated into the knee joint affected by gonarthrosis. The combined procedure will be performed by first infiltrating the hyaluronic acid, and next, leaving the needle inserted into the joint to avoid a second needle insertion, the PRP will be infiltrated, respecting the conditions of sterility. In this way, the two products will not be mixed in the same syringe.
224097877|NCT06685120|BIOLOGICAL|PRP injection|Following autologous PRP harvesting and production, patients randomized into control group 1 will undergo single intra-articular PRP infiltration. Five mL of PRP will be infiltrated into the knee joint affected by gonarthrosis.
223935669|NCT03516942|OTHER|Quality-of-Life Assessment|Ancillary studies
223935670|NCT03516942|OTHER|Questionnaire Administration|Ancillary studies
223935671|NCT02401815|DRUG|CGT9486|CGT9486 will be administered per dose and schedule specified in the arm.
223935672|NCT02401815|DRUG|Pexidartinib|Pexidartinib capsules will be administered per dose and schedule specified in the arm.
223935673|NCT02401815|DRUG|Sunitinib|Sunitinib will be administered per dose and schedule specified in the arm.
224097878|NCT06685120|DEVICE|HA injection|Patients randomized into control group 2, will undergo similar blood sampling as the PRP+ HA group and the PRP group to maintain blinding. They will then undergo intra-articular infiltration of 40 mg/ 2 ml HA into the knee with gonarthrosis.
224286114|NCT05990582|DIAGNOSTIC_TEST|MCH Feeding scale|A questionnaire on feeding problems
224286115|NCT05990582|DIAGNOSTIC_TEST|TRF|A questionnaire on behaviour
224286116|NCT05990582|DIAGNOSTIC_TEST|WISC-5-NL|An IQ test for children
224286117|NCT05990582|DIAGNOSTIC_TEST|Movement ABC|A test to assess motor function
224286118|NCT05990582|DIAGNOSTIC_TEST|CELF-5-NL|A test to assess language development
224286119|NCT05990582|DIAGNOSTIC_TEST|Emma Toolbox|Test of executive functions
224286120|NCT00986570|BIOLOGICAL|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
223534130|NCT06596187|PROCEDURE|Continuous passive motion device (CPM) of ankle - slow|Continuous passive motion device (CPM) of ankle 0.25HZ (15rpm) for 10 repetitions
223534131|NCT06817603|DEVICE|Procedural Oxygen Mask|Procedural Oxygen Mask will be used
223935674|NCT05580770|DRUG|Mirdametinib|Mirdametinib administered orally
223935675|NCT05580770|DRUG|BGB-3245|BGB-3245 administered orally
223935676|NCT06257537|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
223935677|NCT06257537|DEVICE|Sustained Acoustic Device with 0% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
223935678|NCT06257537|DRUG|2.5% Diclofenac Patches|Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
223935679|NCT06257537|OTHER|SAM Patch|Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
223935680|NCT05613907|OTHER|CLTI Clinic|This is a specialist clinic designed to assess and manage patients with CLTI. Patients are assessed and imaged, and undergo elective revascularization procedures if appropriate
223935681|NCT05662371|DEVICE|Nociception Level monitor (NOL)|NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuously monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics, and avoiding overdose or underuse of these drugs. The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation).
223935682|NCT05662371|DEVICE|Standard care|Hemodynamic changes outside of the normal range i.e., hypertension (systolic blood pressure greater than 140 mm Hg), tachycardia (heart rate greater than 90 min-1) and hypotension (mean arterial pressure less than 60 mm Hg) will be first assessed using the guidance of Bispectral index and Train of four monitors. Sufentanil in doses of 2.5 to 5 mcg (maximum of 0.6-1.2 mic/kg for the entire surgery) is administered if the Bispectral index and Train of four monitor values are within normal range and if required vasopressor infusion is used. Vasoconstrictors may be given as a continuous infusion of norepinephrine, or bolus doses of ephedrine or phenylephrine. Only when blood pressure remains, low additional crystalloids will be given. Finally, in case of bradycardia (heart rate less than 30 min-1), atropine may be given
223935683|NCT06827093|OTHER|Skill Building Dyadic Intervention|The focal point of skill-building interventions contains some strategies that facilitate problem-solving, goal setting, communicating with care experts, stress management, hands-on training in such skills (lifting and mobility techniques and assistance with activities of daily living), and modification of communication according to the needs of stroke survivors.
223935684|NCT06461052|PROCEDURE|music therapy|The patient will benefit from viewing the video and the music therapy session in the waiting room of the operating room. The patient will be asked again for their anxiety score using an anxiety scale. This will define the main outcome of the study. Following this collection and in order not to influence the response, investigators will collect from the patient his compliance with the two proposed techniques as well as his appreciation of the tool.
224097879|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order A-B|Research participants will be assigned to day shift condition and Diet A-B order condition.
224097880|NCT05862818|BEHAVIORAL|Day shift protocol - Diet order B-A|Research participants will be assigned to day shift condition and Diet B-A order condition.
224097881|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order A-B|Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
223534132|NCT06817603|DEVICE|High-Flow Nasal Cannula|High-Flow Nasal Cannula (HFNC) will be used.
223534133|NCT06817642|OTHER|Data recovery from language and cognitive assessment|Data recovery from language assessment: Core Assessment of LAnaguage Processing, and from neuropsychological assessment : Montreal Cognitive Assessment, Trail Making Test, Batterie Rapide d'Efficience Frontale (BREF), animal fluency, 5 words of Dubois, Ne
224097882|NCT05862818|BEHAVIORAL|Night shift protocol - Diet order B-A|Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
223935685|NCT06621511|BEHAVIORAL|OurSleepKit|OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
223935686|NCT03626571|OTHER|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
223935687|NCT04627883|OTHER|Inspiratory-to-expiratory (I : E) ratio of 1:2|After preoxygenation and induction of anesthesia, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 1:2 for 5 min before endotracheal intubation.
223534134|NCT06662279|DEVICE|Removable Rapid Palatal Expander|Removable palatal expander where expanders are changed to obtain up to .25mm expansion per expander
223534135|NCT06662279|DEVICE|Banded Palatal Expander|Palatal expander cemented into mouth where a screw is turned to obtain .25mm expansion per turn
223935688|NCT04627883|OTHER|Inspiratory-to-expiratory (I : E) ratio of 2:1|After preoxygenation and induction of anesthesian, noninvasive positive pressure ventilation with inspiratory-to-expiratory (I : E) ratio of 2:1 for 5 min before endotracheal intubation.
223935689|NCT05580978|BEHAVIORAL|GEM|The intervention group will be given Libre 2 supplies for 4 months, an activity monitor, and the 4-chapter GEM paper guide. The intervention group will complete a virtual or inperson study visit where they will receive instructions on how to apply their unblinded Freestyle Libre and connect it to the study account, as well as how to register their Fitbit to the study account. Participants will receive one telephone call to review use of the GEM Guide and call at two weeks and six weeks later when the probability of dropouts from lifestyle intervention peaks. Participants will follow the self-directed GEM guide for 4 months (a 1-month treatment period followed by a 3-month maintenance period) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM.
223534136|NCT06655740|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
223935690|NCT05580978|OTHER|Routine Care|Participant's current prediabetes treatment.
223935691|NCT02751528|BIOLOGICAL|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
223935692|NCT03936101|DIAGNOSTIC_TEST|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
223935693|NCT06738290|BEHAVIORAL|Targeted home-based touchscreen training|Participants will practice the Swipe-Slide Pattern (SSP) task independently at home in both ST and DT condition, offered in a random order. During this task, participants perform different pre-defined patterns by moving their finger over a touchscreen, resembling a touchscreen unlock trace. The DT condition includes the SSP-task while counting either red or green lights illuminated on the screen. They will receive 10 training sessions of the SSP-task over a period of two weeks. Each week will consist of 5 consecutive days of training for approximately 10 min. per session. Participants will perform 9 trials of 12 patterns each, alternated with rest periods of 14s. Instruction and answers are also included. Feedback will be provided during the rest periods.
223935694|NCT06056570|DRUG|dontinurad|dotinurad alone
223935695|NCT06056570|DRUG|dotinurad + allopurinol|dotinurad + allopurinol 300mg
223935696|NCT06056570|DRUG|allopurinol|allopurinol 300 mg alone
223935697|NCT06763471|DEVICE|Neuropixels recording intraoperatively during planned neurosurgery|"The SUNAN study is a basic science study involving a procedure to record single-unit neurophysiological activity with human participants who are already undergoing a transcranial neurosurgical procedure on the brain.~As part of the surgery, a region of cerebral cortex on the convexity of the brain will be:~* Resected e.g., as removal of part of a tumour or epilepsy focused. Or~* Transgressed as part of the surgical approach to reach a deeper target e.g., resection of a deep tumour or cavernoma.~Or~• Transgressed by the passage of a surgical implant e.g., a ventriculoperitoneal shunt catheter or deep brain stimulation electrode.~Within this region of the brain that is going to be resected or transgressed, the research team will undertake a single-unit resolution neurophysiological recording (NR) using a digital neural probe (Neuropixels) for a maximum of 15 minutes."
223935698|NCT06723080|DRUG|VC005 low dose group|VC005 low dose group repeat administration
224286121|NCT01884922|DRUG|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
224286122|NCT01884922|DRUG|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
223534137|NCT06453772|PROCEDURE|Liposuction|Primary or secondary liposuction is performed by the surgical staff. The study analyzed variables including weight, height, BMI, preoperative hemoglobin, and aspirated volume. Additionally, preoperative hemoglobin (Hb), hematocrit (Hto), platelets, prothrombin time (Tp), partial prothrombin time (TpT), and International Normalized Ratio (INR) were evaluated. Hb and Hto levels were reassessed 24 hours post-surgery to monitor changes.
223534138|NCT06603493|OTHER|Assessment of sleep disorders|: Sleep disturbances will be assessed with the Pittsburgh Sleep Quality Index
223534139|NCT06603493|OTHER|Assessment of Central Sensitization|Central sensitization will be assessed with the Central Sensitization Inventory
224286123|NCT05315622|OTHER|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy|Bilateral vertebral manipulation of the T12-L1 vertebra through manual therapy
224286124|NCT05315622|OTHER|Placebo|"Manual tension without reaching the manipulation thrust"
224286125|NCT04060342|DRUG|GB1275|Oral
224286126|NCT04060342|DRUG|nab-paclitaxel and gemcitabine|IV infusion
223534140|NCT06603493|OTHER|Assessment of depression, anxiety and stress levels|Depression, anxiety and stress levels will be assessed using the Depression, Anxiety, Stress Scale (DASS-21)
223935699|NCT06723080|DRUG|VC005 high dose group|VC005 high dose group repeat administration
223935700|NCT06723080|DRUG|VC005 Placebo group|VC005 Placebo group repeat administration
223935701|NCT04402151|DRUG|PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC|"Patients enrolling on the protocol will undergo prostate-specific membrane antigen (PSMA) Positron Emission Tomography (PET)/Magnetic Resonance(MR) prior to start of the radiation treatment planning process. PSMA tracer is administered by IV injection and PET images are acquired.~Any patients found to have possible metastatic disease will undergo a standard of care confirmatory biopsy (if feasible) and receive treatment appropriate for their stage.~The PSMA PET/MR scan will be performed prior to initiation of androgen deprivation therapy (ADT)."
223935702|NCT04402151|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive standard of care radiation therapy (SBRT)
223534141|NCT00697385|DRUG|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
223935703|NCT04218357|DRUG|Probenecid or placebo single administration|study drug administration with alcohol in the laboratory
223935704|NCT06446154|DRUG|Fruquintinib|Fruquintinib was given orally for 5mg/ days. After 3 weeks, the drug was stopped for 1 week.
223935705|NCT06019377|BEHAVIORAL|Stronger Youth Networks and Coping (SYNC)|SYNC is a 8-module online curriculum adapted from evidence-based cognitive change methods, including Coping Effectiveness Training (CET), co-facilitated by service providers in Independent Living Programs (ILPs; federally-funded transition skill-building services accessed by most foster youth in the US) and near-peers (have lived experience in foster care). SYNC aims to increase youth capacity to appraise stress and regulate emotional responses, to flexibly select adaptive coping strategies, and to specifically promote informal and formal help-seeking as an effective coping strategy.
223935706|NCT05348577|DRUG|capivasertib|"320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle.~Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment."
223935707|NCT05348577|DRUG|docetaxel|Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.
224097883|NCT07016672|PROCEDURE|intra-articular injection of HA|3 injections at 7-day intervals
224286127|NCT04060342|DRUG|pembrolizumab|IV infusion
224286128|NCT03780946|PROCEDURE|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
224286129|NCT03780946|PROCEDURE|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
224286130|NCT05685901|DIETARY_SUPPLEMENT|High polyphenolic olive oil. (Early harvest olive oil).|High polyphenolic olive oil is normal olive oil obtained from early harvest olives, this early harvest olive oil has been widely used for culinary purposes for centuries. The investigators wanted to study if oromucosal immunoprophylaxis with small quantities of high polyphenolic olive oil (2 mL of olive oil equivalent to 5 mg of polyphenols) adiministered twice a day could have clinical mitigating effects on the disease caused by SARS-CoV-2 infection.The primary outcome was to determine the effect of high polyphenolic olive oil on Coronavirus disease incidence, duration and severity.
224286131|NCT03072199|DRUG|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
224286132|NCT00000674|DRUG|Pyrimethamine|
224286133|NCT00000674|DRUG|Leucovorin calcium|
224286134|NCT00000674|DRUG|Clindamycin|
223534142|NCT00650507|PROCEDURE|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
223534143|NCT00650507|PROCEDURE|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
224286135|NCT04862156|DEVICE|Normothermic Machine Perfusion (NMP)|Storage and transportation of the donated liver using the OrganOx metra device.
223534144|NCT05751577|PROCEDURE|TAVI WITHOUT ON-SITE SURGERY|After randomization, study TAVI operators of the participating center will schedule the patient for TAVI in their hospital without on-site surgery
223935708|NCT05348577|OTHER|placebo|matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.
223935709|NCT05075395|DEVICE|PARO therapy seal|PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.
223935710|NCT05411484|DRUG|NanoDOX® Hydrogel|NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
223935711|NCT05411484|DEVICE|CO2 Ablative Fractional Laser|CO2 Ablative Fractional Laser will be applied to healthy skin areas
223935712|NCT01958021|DRUG|Ribociclib|Ribociclib (600 mg, in three 200 mg hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
223935713|NCT01958021|DRUG|Letrozole|Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
223935714|NCT01958021|DRUG|Placebo|Placebo (hard gelatin capsules or tablets) was administered orally once daily on Days 1-21 of each 28-day cycle.
223935715|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
223935716|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
223935717|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
223534145|NCT05751577|PROCEDURE|TAVI WITH ON-SITE SURGERY|After randomization, the patient will immediately be placed on the waiting list of the referring center with on-site cardiac surgery. Study TAVI operators of the participating center will perform the TAVI procedure in the hospital with on-site surgery according to the waiting list schedule of the latter
223935718|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
223935719|NCT06924385|DRUG|Telpegfilgrastim Injection|Telpegfilgrastim will be administered as subcutaneous (SC) injection.
223935720|NCT06828081|OTHER|Range of Motion Exercises|Will get standard shoulder muscle exercises, including rigid and stretchy ones with bands that offer resistance.
223935721|NCT06828081|OTHER|Strengthening exercises with theraband|They will go through the GRASP method, which involves special workouts just for them, teaching them about their health and ways to deal with pain.
223935722|NCT01009177|DRUG|Bosentan|Bosentan 500 mg bid
224097884|NCT07016672|PROCEDURE|intra-articular injection of PRP|3 injections at 15-day intervals
224097885|NCT05405231|BEHAVIORAL|Crisis Line Facilitation (CLF)|Crisis Line Facilitation (CLF) is a promising translational strategy designed to increase MVCL use among NG members during periods of elevated suicidal risk by addressing individual-level barriers.
223534146|NCT05574881|DRUG|Dalpiciclib|150 mg qd
223534147|NCT05574881|DRUG|Fulvestrant|500mg d1, 15, 29, and then q4w
223935723|NCT01009177|DRUG|Placebo|Placebo
223935724|NCT00548236|BEHAVIORAL|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
223935725|NCT05248503|BEHAVIORAL|Complex Care Training of Hereditary Epidermolysis Bullosa|Training in the care of epidermolysis bullosa by combining theoretical content on the disease and practical workshops.
223935726|NCT06936020|OTHER|deep peripheral sensory stimulation|The proprioceptive stimulus will consist of intermittent mechanical pressure on the skin, localized at the neuromuscular motor points of the rectus femoris, vastus lateralis, and vastus medialis of the quadriceps. The tissue subjected to this precise pressure in areas of high neuromuscular innervation facilitates the stimulation of kinesthetic cortical sensitivity. The experimental group (EG) will be randomly and crosswise subdivided into two groups, so that both receive the intervention in two different modalities at two different times.
223935727|NCT06936111|DIAGNOSTIC_TEST|Assessment of residual cholesterol and inflammatory risk factors|The prespecifed risk factors include CRP, SAA, TNF-α, IL-6, MCP-1, Lp-PLA2, PCSK-9, Lp(a)
223935728|NCT00872729|DRUG|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
223935729|NCT00872729|DRUG|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
223935730|NCT06939725|OTHER|Transversus abdominis plane (TAP) block|We apply different nerve blocks to patients for pain relief after cesarean surgery. Transversus abdominis plane block was applied to this group
224097886|NCT05405231|BEHAVIORAL|Passive Implementation|The PI condition includes an educational resource brochure describing the MVCL, including the phone number for the crisis line, as well as other mental health services available to National Guard members.
224286136|NCT03805308|PROCEDURE|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
223534148|NCT05574881|DRUG|Pertuzumab|840mg q3w, and then 420 mg q3w
223534149|NCT05574881|DRUG|Trastuzumab|8 mg/kg q3w, and then 6 mg/kg q3w
223534150|NCT02611037|DRUG|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
223935731|NCT06939725|OTHER|Transversalis Fascia Plane Block|We apply different nerve blocks to patients for pain relief after cesarean surgery. Transversalis Fascia Plane Block was applied to this group
223935732|NCT03664804|OTHER|No Study Drug was Administered in this Study|No study drug was administered in this study
223935733|NCT04701203|COMBINATION_PRODUCT|TransCon PTH|TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
223935734|NCT04701203|COMBINATION_PRODUCT|Placebo|Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
223935735|NCT05553418|DEVICE|In-clinic wear first|Participant will remain in clinic and wear devices adhered on abdomen or arm approximately 27hrs prior to injection
223935736|NCT05553418|DEVICE|Home wear first|Device will be applied to the abdomen or arm to deliver placebo subcutaneously. After device application, participant will go home and return to clinic before delivery.
223935737|NCT06508450|BEHAVIORAL|Just Do You|Just Do You Core Intervention utilizes creative arts and a provider team of a licensed clinician and professional peer to increase young adult engagement in adult outpatient mental health programs. Content addresses recovery, advantages of using mental health services, working with providers, stigma, and mental health literacy.
223935738|NCT06508450|BEHAVIORAL|Component A|Content addresses participant cultural identities and how they may be barriers and facilitators to on-going engagement with services.
223935739|NCT06508450|BEHAVIORAL|Component B|Content addresses identity-based motivations for on-going engagement with services and hope for the future.
223935740|NCT06508450|BEHAVIORAL|Component C|Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
223935741|NCT06935513|BEHAVIORAL|Wearable Devices|Participants utilize wearable devices (smart wristbands) 24 hours a day for 6 months. Wearable devices can provide medication reminders for each use and heart rate monitoring.
223935742|NCT05738720|DEVICE|Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer)|Pulmonary Function Test (PFT): Pulmonary function test will be performed with a Teknikel Spirobank home pulmonary function test device. In the study group, the patient will make weekly measurements at home and send it to the physiotherapist. In the control group, evaluation will be made with the device only at the beginning and end of the treatment.
223935743|NCT05738720|OTHER|Exercise Programme|"Exercise Program~* Breathing exercises: Chest, diaphragmatic breathing and lower basal breathing exercises will be performed with 10 repetitions.~* Resistance exercises: Strengthening exercises will be performed on the major muscle groups of the upper and lower extremities by using medium hardness therabant. During the exercises, the patient's fatigue and dyspnea levels will be questioned using the Borg scale, and breaks will be given when necessary. The exercises will be performed with a medium-hardness therabband. Exercises will be given for the upper extremity and lower extremity, and the patients will be asked to do 10 repetitions.~* Gait training: In line with the data obtained from the 6-minute walking test, gait training will be given on flat ground at 60% workload (land-based walking). Patients will be allowed to walk on flat ground at 60% workload, at a time calculated based on the results of the 6-minute walk test."
223935744|NCT06744010|PROCEDURE|Sub sartorial canal block and popliteal block in ankle surgeries|"All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4."
223935745|NCT06744010|PROCEDURE|femoral block and popliteal block in ankle surgeries|"* All patients will be anesthetized with PNBs for surgery.~* PNBs will be performed in a block room at least 30minute preoperatively.~* All PNBs will be performed under ultrasound guidance (LOGIQ P6, GE Healthcare; Chicago, IL) using a high-frequency linear transducer (3.4-10.8MHz).~* All blocks will be performed after skin preparation with 2% chlorhexidine gluconate by 1 orthopedic surgeon (YUP) with vast experience in ultrasound-guided nerve block techniques.~* A 22-ga Tuohy needle will be introduced in-plane and 2 to 3mL of saline will be used to confirm the correct position of the needle tip near the target nerve.~* The study medication will be administered through the needle as a bolus of 20mL of a 1:1 mixed solution of bupivacaine 0.75% and lidocaine 1%.~* The total volume per every block will be 20 ml in the form of bupivacaine 1.25% with 1:200,000 epinephrine and 250 mg Mgso4."
223935746|NCT06727448|OTHER|SRQ questionnaire|SRQ questionnaire administered at inclusion visit and 14 days after inclusion
223935747|NCT04257994|DIAGNOSTIC_TEST|obtaining a buccal smear sample|A sample will be taken from the inside of the participants' cheeks using a soft brush
223935748|NCT06140290|DRUG|Etrasimod Immediate Release (IR)|An immediate release tablet
223935749|NCT04243226|DEVICE|telehealth-based aerobic walking exercise|The aim of this study is to develop exercise prescription of TBI patients and then to evaluate the effectiveness of programmed aerobic exercise to improve psysical-psycho-social health such as cognitive status, 6 minutes walk test, depression relief, motivation, symptom, resilience and quality of life.
223935750|NCT06828575|OTHER|predictions|predictions of learning language models
223935751|NCT06760793|OTHER|manual static stretching exercises on plantar flexors|A manual static stretching exercises was performed on the plantar flexors in both knee extension and flexion. The stretch was applied while the participant was in a prone position
223935752|NCT06760793|OTHER|deep friction massage on plantar flexors|Deep Friction Massage was applied to both the gastrocnemius muscle and the Achilles tendon. Participants were positioned in a prone posture for both applications
223534151|NCT02611037|DRUG|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
223534152|NCT02611037|DRUG|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
223534153|NCT02611037|OTHER|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
223534154|NCT06992024|COMBINATION_PRODUCT|Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody|Electroacupuncture (EA) Combined With Paclitaxel Protein-bound (Chemo) and PD-1 Antibody (IO) for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer. Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1, d7, d8 + Paclitaxel Protein-bound (125mg/m2) d1, d8 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W. If the diseases are well controlled after 6 cycles, maintenance treatment, namely Electroacupuncture stimulates specific acupoints（dense-sparse wave，30min）d0, d1 + PD-1 Antibody (not limited to specific drugs，dosages should be calculated according to corresponding drug instructions) d1, Q3W, will be continually conducted until the diseases progress.
223935753|NCT06745869|BEHAVIORAL|Diaphragmatic breathing exercise training|"At the end of the training, participants will be asked to do an exercise session and this session will be observed. Training will continue until participants learn and apply the exercise correctly.~5-minute warm-up and cool-down periods will be applied at the beginning and end of each exercise session. Exercises will be done twice a day, morning and evening, for 8 weeks.~In order to follow the exercise, participants will be given diaphragmatic breathing exercise tracking cards with date and session information. In addition, participants will be followed up weekly on one of the rehearsal days to ensure their adaptation to the exercise."
224097887|NCT07023536|BEHAVIORAL|TELEREHABILITATION-YES|This intervention consists of a structured 8-week cardiac rehabilitation program performed at the patient's home using a certified telemedicine platform. Sessions are delivered in synchronous mode with real-time supervision by a physiotherapist through secure video conferencing. Each session includes warm-up, endurance training, and cooldown exercises, with personalized intensity based on cardiopulmonary exercise testing. Patients are equipped with wearable medical devices for continuous monitoring of vital signs (ECG, heart rate, blood pressure, oxygen saturation) and motion sensors to assess exercise execution and adherence. All data are transmitted securely and stored automatically in the system's database. In addition to the exercise protocol, participants undergo baseline and follow-up assessments including blood biomarkers, echocardiography, cardiopulmonary exercise testing, and quality-of-life questionnaires.
224097888|NCT07023536|BEHAVIORAL|TELEREHABILITATION-NO|This intervention involves a traditional 8-week cardiac rehabilitation program carried out at a hospital-based outpatient facility. Patients attend sessions in person under the direct supervision of a physiotherapist. Each session includes warm-up, endurance training using a stationary bike, and cooldown. Vital signs (e.g., heart rate, blood pressure, oxygen saturation) are monitored manually by the physiotherapist, and exercise tolerance is assessed using standardized clinical scales (e.g., Borg and RPE). In addition to the exercise protocol, participants undergo baseline and follow-up assessments including blood biomarkers, echocardiography, cardiopulmonary exercise testing, and validated quality-of-life questionnaires. This group serves as the control for evaluating the effectiveness of the home-based telerehabilitation model.
224097889|NCT07024056|PROCEDURE|coracoclavicular ligaments reconstruction associated with acromioclavicular ligament reconstruction|The Gracilis or SemiT graft will be harvested from the ipsilateral knee. An oblique skin incision will be made starting from the ACJ and extended distally towards the tip of coracoid process. 2 drill holes will be prepared on the superior cortex of the clavicle at the footprint of the original 2 ligaments, using a 4.5-mm drill bit. The 2 holes will be around 1 cm apart and the lateral hole was around 2 to 2.5 cm proximal to the distal end of the clavicle. Another 4.5 mm drill bit hole was created in the acromion. The graft exiting laterally around the coracoid will be then passed through the conoid tunnel from inferior to superior and then passed through the acromial tunnel from superior to inferior. The graft exiting the acromion tunnel will be passed through the trapezoid tunnel from superior to inferior. The two free ends of the hamstring graft will be tied to one another with Ethibond No.2 sutures
224286137|NCT04091958|PROCEDURE|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
223534155|NCT06988735|PROCEDURE|Nonrobotic TCRAT|Nonrobotic TCRAT for CABG
223935754|NCT06745869|BEHAVIORAL|Aerobic exercise training|The intensity of the aerobic exercise program will be calculated for each participant using the Karvonen formula. Accordingly, each participant will be given a brisk walking program on a suitable surface, which will be created specifically for the individual to reach the target heart rate range within the scope of the aerobic exercise program; they will apply a 45-minute session, 3 days a week, for 8 weeks.
223935755|NCT06941766|DRUG|QL1706|5 mg/kg, IV infusion, Q3W (D1)
223534156|NCT06988735|PROCEDURE|Robotic TCRAT|Robotic TCRAT for CABG
223534157|NCT02976805|DRUG|4L PegLyte + 15 mg bisacodyl|Randomized
223534158|NCT02976805|DRUG|6L PegLyte + 15 mg bisacodyl|Randomized
223534159|NCT06994416|DEVICE|novel fluorescent localization marker needle|novel fluorescent localization needle, which features a controllable shedding quantum dot chiral nanofluorescent coating
223935756|NCT06941766|DRUG|Chemotherapy|FAEV, EMA/EP, EMA/CO, or TP/TE.
223935757|NCT05754593|BIOLOGICAL|Anti-Mullerian hormone (AMH) level|Measure of Anti-Mullerian hormone (AMH) level by blood sample
223935758|NCT05754593|OTHER|Antral follicle count (AFC)|Measure of Antral follicle count (AFC) by ultrasound imaging
223534160|NCT06994416|DEVICE|conventional localization marker needle|conventional localization marker needle, without any coating
223935759|NCT05754593|OTHER|Clinical assessment|MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded
223935760|NCT06942507|DRUG|Zanubrutinib|zanubrutinib 160mg po bid d1-28
223935761|NCT06942507|DRUG|Bendamustine + Rituximab|bendamustine 70-90mg/m2 ivgtt d1-2, rituximab 375mg/m2 ivgtt d1
223935762|NCT06180486|OTHER|Mindfulness Meditation Intervention|The mindfulness intervention is a scripted, \~12min audio recording based on core tenets of mindfulness meditation and contextualized for patients undergoing total knee arthroplasty. It teaches sustained attention on the present, body awareness, acceptance of the body's current state, and transformational strategies to cope with emotional or physical stimuli as they arise. It has been created by the study team based on the teachings of Jon Kabat Zinn (founder of mindfulness meditation) and the PI's history teaching yoga and meditation. Patients will be encouraged to review the audio recording once a week.
223935763|NCT06761625|DIETARY_SUPPLEMENT|SanProbi® Barrier capsules|The probiotic group received SanProbi® Barrier capsules
223935764|NCT06761625|OTHER|Placebo|The placebo group received capsules filled mainly with maize starch and maltodextrins.
223935765|NCT06043609|OTHER|This is an observational cohort study|This is an observational cohort study
223935766|NCT04042402|DRUG|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
223935767|NCT05292937|DIAGNOSTIC_TEST|Measurement of body temperature|The patients' body temperature will be measured pre-, intra- and post-operatively via an infrared thermometer.
223935768|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Preperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
223935769|NCT04718168|DEVICE|Gore ENFORM Biomaterial (Intraperitoneal)|ENFORM Biomaterial bioabsorbable hernia mesh
223935770|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
223534161|NCT00829998|DRUG|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
223935771|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
223935772|NCT05681260|DRUG|Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide|High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
223935773|NCT04294446|DEVICE|Biodesign Hernia Graft|The Biodesign Hernia Graft is comprised of 8 layers of decellularized porcine small intestinal submucosa (SIS) that has been pressed-lyophilized (i.e., freeze-dried under vacuum pressure) to laminate the component sheets (i.e., layers) together. In addition, it is perforated and sewn with 4-0 Trisorb suture (polyglycolic acid (PGA); Samyang Corporation, Seoul, South Korea). The suture is distributed in a diamond pattern across the graft and along the periphery and is intended to mitigate delamination of the layers upon rehydration and/or manipulation during implantation. Being a completely biologic device, the Biodesign Hernia Graft is considered MR safe.
223935774|NCT06789679|DRUG|Gemcitabine, albumin-bound paclitaxel, S-1|Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w
223935775|NCT06789679|DRUG|Gemcitabine, albumin-bound paclitaxel|Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w
223935776|NCT06749353|DEVICE|Virtual reality|We will use a virtual reality glasses with the 'Lending Moments' program, where patients can experience a sunset on a paradise beach while listening to a soothing voice that guides them through the experience with relaxation and meditation techniques. During this time, we will proceed with the surgical intervention.
224097890|NCT07024056|PROCEDURE|coracoclavicular ligaments reconstruction with acromioclavicular temporary k wire fixation|Two 2.4-mm tunnels corresponding to the origins of the conoid and trapezoid ligaments will be created through the distal clavicle, approximately 1.5cm apart from each other. The distal tunnel will be 2.5cm away from the AC joint. After harvesting the Gracilis or Semitendinosus from the ipsilateral leg, the graft was prepared with no. 2 Ethibond sutures and passed beneath the coracoid. Both ends of the graft will be passed inside out through the tunnels after enlarging the tunnels by 4.5 drill bit making a figure of 8 sling. The AC joint will be provisionally reduced with two 1.5/1.8-mm smooth K-wires while keeping the graft ends under adequate manual tension. The ends of the graft will be sutured onto themselves and the surrounding soft tissues. The wound will be closed in layers.
223534162|NCT00829998|DRUG|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
223534163|NCT03159988|DRUG|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
223534164|NCT03159988|BEHAVIORAL|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
223534165|NCT06459804|PROCEDURE|Electro Dry Needling|"Standard Physiotherapy:~It will include Hot pack (10 min), Stretching of levator scapulae (3 times with 30 seconds hold), Scapular stabilization exercises (10 times with 5 seconds hold).~Scapular Stabilization exercises will be comprised of four exercise programs. The participants will sit on the knees in 90° flexion position, and a Swiss ball will be propped up between the stomach and chest."
223534166|NCT06459804|PROCEDURE|Dry Needling|Dry Needling
223935777|NCT06953557|DIAGNOSTIC_TEST|To compare the effect of salivary glycine , proline , lysine and alanine concentration between participants with high caries activity and participants with negative caries activity|The investigators will measure Salivary-free amino acids by using reverse phase high performance liquid chromatography
223534167|NCT00933478|DEVICE|Clay|Small dime sized piece of clay.
223534168|NCT05132296|BEHAVIORAL|Behavioral Intervention|Undergo behavioral counseling
223534169|NCT05132296|OTHER|Best Practice|Receive usual care supportive services
223534170|NCT05132296|DEVICE|FitBit|Receive FitBit
223534171|NCT05132296|BEHAVIORAL|Nutrition Education|Receive nutrition education
223534172|NCT05132296|OTHER|Physical Activity|Undergo physical activity
223935778|NCT06953401|OTHER|Muscle contraction protocol for electromyographic assessment|Participants will perform a set of standardized lower limb muscle contractions (isometric, concentric, and eccentric) involving the gastrocnemius and soleus muscles while lying on an examination table and in standing position both static and dynamic as well as walking. Surface electromyography (mDurance® sEMG system) will be used to record muscle activation during each phase. The task is designed for physiological measurement only and does not constitute a therapeutic intervention. Protocol includes 3 trials per muscle and side, using standardized test conditions.
223935779|NCT06954506|BEHAVIORAL|Reiki Group|Patients were informed about the application, and a Reiki application video prepared/selected by the researchers was shared with the patients. Patients were asked to perform Reiki every day for a week following each chemotherapy session for 4 cycles. A reminder message was sent to the patients the day before each cycle for the Reiki application. The level of hopelessness was reassessed at the end of each week.
223935780|NCT03158818|OTHER|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
223935781|NCT06554509|DRUG|SHR-1819 injection|SHR-1819 injection
223935782|NCT06554509|DRUG|Placebo|placebo
223935783|NCT05671510|DRUG|Gotistobart|Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
223935784|NCT05671510|DRUG|Docetaxel|Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
223935785|NCT06699771|DRUG|GCC2005|CAR-NK Cell Therapy
223935786|NCT06699771|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
224286138|NCT05568693|BIOLOGICAL|0.3ml of mRNA vaccine|Subjects received 0.3ml of mRNA vaccine intramuscularly
224286139|NCT05417360|DIETARY_SUPPLEMENT|Akkermansia muciniphila|"During the weight management period (weeks 8 to 32), the pasteurized A. muciniphila product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks) capsules. It appears as a white homogenous powder.~."
224286140|NCT05417360|DIETARY_SUPPLEMENT|Placebo|During the weight management period (weeks 8 to 32), the placebo product will be orally consumed in water at least 15 min before breakfast for a period of 6 months (24 weeks). It appears as a white homogenous powder.
224286141|NCT03795714|DIAGNOSTIC_TEST|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
224286142|NCT06311019|DEVICE|Continuous glucose monitoring and use of connected insulinpen for bolus insulin|Continuous glucose monitoring (Abbott Freestyle Libre 2) and use of connected insulinpen (Novopen 6) for bolus insulin
224286143|NCT02872350|DEVICE|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
224286144|NCT02622659|DRUG|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
224286145|NCT02622659|DRUG|Xiaoer Jiebiao Oral Liquid|"1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day"
224286146|NCT06351696|DIETARY_SUPPLEMENT|Bromlein|1500 mg/day
224286147|NCT06351696|OTHER|Placebo|Placebo (1500 mg/day)
224286148|NCT03889834|PROCEDURE|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
223534173|NCT05132296|OTHER|Questionnaire Administration|Ancillary studies
223534174|NCT06996808|DEVICE|Bakri Baloon|Bakri Balloon Standard insertion and inflation as per hospital protocol following delivery.
223534175|NCT06996808|DEVICE|Celox gauze|Celox gauze will be placed intrauterine according to manufacturer instructions, post-vaginal or cesarean delivery. Duration and removal will follow standardized clinical guidelines
223935787|NCT06699771|DRUG|Fludarabine|Lymphodepleting chemotherapy
223935788|NCT05721573|DRUG|ABC008|Given by subcutaneous injection
223935789|NCT05301101|RADIATION|Re-irradiation|Patients will undergo re-irradiation following treatment planning based on current standard practice as determined by treating physicians and multidisciplinary teams.
223935790|NCT03223688|BEHAVIORAL|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
223935791|NCT03223688|BEHAVIORAL|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
224097891|NCT05898126|PROCEDURE|Renin-guided hemodynamic management|If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.
224097892|NCT05898126|PROCEDURE|Usual care|Standard of care
224097893|NCT07031856|OTHER|3D printer partial crown|Comprasion of partial restorations made with 3D printer
224097894|NCT07031856|OTHER|Treatment as usual|Cad-cam printer partial crown
224097895|NCT07030920|DRUG|Fostemsavir|Addition of fostemsavir to the patient's current antiretroviral regimen: once daily oral administration (Rukobia 600 mg extended-release tablets) for 24 months
224097896|NCT07031791|OTHER|PETRA questionnaire|The questionnaire is given to the patient to complete in the waiting room. The completed questionnaire is given to the doctor at the end of the consultation.
224097897|NCT07031908|PROCEDURE|Minimally invasive cytoreduction|Minimally invasive cytoreduction in patients with advanced ovarian cancer treated with 6 cycles of neoadjuvant chemotherpy
224286149|NCT03889834|OTHER|No transfusion|no transfusion
224286150|NCT02875041|DEVICE|Transcranial Magnetic Stimulation (TMS)|
223935792|NCT03223688|BEHAVIORAL|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
223935793|NCT06387810|DRUG|irinotecan liposome II combined with 5-FU/LV and oxaliplatin|"irinotecan liposome II: 60mg/m2, intravenously for at least 90min, D1, administered every 2 weeks; oxaliplatin: 85 mg/m2, intravenous infusion, D1, every 2 weeks; calcium leucovorin: 400 mg/m2, 30±10min intravenously, D1, every 2 weeks; 5-fluorouracil: 2400 mg/m2 intravenously for 46-48 hours or according to study Center clinical practice, D1, administered every 2 weeks.~Irinotecan liposome II, oxaliplatin, LV and 5-FU were given successively, and corresponding prophylactic administration could be selected according to clinical needs."
223935794|NCT04720794|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
224097898|NCT06717321|PROCEDURE|(Arm 1): PEG|A 20-French pull type percutaneous endoscopic feeding tube placed into the stomach using endoscopic guidance
224097899|NCT06717321|PROCEDURE|(Arm 2): PEG-J|24-French pull type percutaneous endoscopic feeding tube placed into the stomach with a 12-French jejunal extension tube advanced through the PEG and positioned post-pyloric in the small bowel using endoscopic guidance
224097900|NCT06434077|BIOLOGICAL|GcMAF injections (100 ng)|The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.
224097901|NCT06434077|OTHER|placebo|the placebo solution will be injected subcutaneously 100 ng.
224097902|NCT06732518|DRUG|Fluoride Toothpaste|Fluoride toothpaste containing 1000 ppm MFP and 1.5% arginine in a PCC/RNCC base
224286151|NCT02875041|DEVICE|MAGSTIM Rapid2|
224097903|NCT06732518|DRUG|Fluoride free toothpaste in a chalk base|Fluoride free toothpaste in a chalk base with herbal ingredients
224097904|NCT06732518|DRUG|Fluoride free toothpaste in a PCC/RNCC base|Fluoride free toothpaste in a PCC/RNCC base
224097905|NCT06732518|DEVICE|Toothbrush|A commercially available adult soft bristle toothbrush
224097906|NCT07049744|DEVICE|XII Medical HGNS System|XII Medical HGNS System
224097907|NCT07053852|DRUG|Ameluz|broad band light (BBL) with the use of Ameluz
224097908|NCT07053852|DEVICE|Sciton HEROic|Each subject will receive 2 treatments of photodynamic therapy using Ameluz and HEROic BBL to treat facial AK and signs of photodamage.
224097909|NCT06162624|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in behavior change. Delivered over 8 weeks of self-guided study and homework assignments.
224097910|NCT06162624|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|As control condition, reflective journaling will be used.
224097911|NCT06857396|PROCEDURE|PREPA-TRACH|Tracheal exposure without tracheostomy completion during trans-oral robotic oncologic surgery
224097912|NCT06578520|DRUG|Dapagliflozin|10 mg once per day, oral tablets
224097913|NCT06591468|DRUG|Prednisone|Prednisone 30-40 mg/day, at 7am in the morning, gradually reduced after 1 month (5mg every 7-14 days) to 5-10 mg for maintenance treatment
224097914|NCT06591468|DRUG|UDCA (Ursodeoxycholic acid)|13-15 mg/kg/day
224286152|NCT03662256|OTHER|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
223935795|NCT03352713|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
223935796|NCT01812759|DRUG|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
223935797|NCT01812759|DRUG|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
223935798|NCT01812759|OTHER|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
223935799|NCT04300244|BIOLOGICAL|UV1 vaccine + leukine|The mode of action of UV1 is to activate the immune system to induce T cells directed against telomerase (hTERT). UV1 vaccination amplifies the pool of hTERT specific tumor-reactive T cells from the naive repertoire and has the potential to increase the breadth and diversity of the tumor-reactive T cell response (epitope spreading). Vaccination with UV1 can thus provide the basis for increased efficacy of checkpoint inhibition therapy, by augmenting the pool of tumor specific T cells in patients with limited or insufficient numbers of T cell clones spontaneously primed by tumor antigens. Reciprocally, the efficacy of UV1 vaccination may be enhanced in combination with checkpoint inhibitors, since the clonal expansion and effector activity of UV1 induced T cells will otherwise be restricted by intrinsic immune regulatory and tumor induced suppressor mechanisms.
223935800|NCT04300244|BIOLOGICAL|ipilimumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
223935801|NCT04300244|BIOLOGICAL|nivolumab|The responses to ipilimumab and nivolumab combination therapy seen in MPM is encouraging.
223935802|NCT06380478|DEVICE|aspicio Monofocal IOL|A bi-aspheric monofocal IOL is implanted through preloaded IOL Delivery System in the capsular bag in the posterior chamber of the eye during cataract surgery
223935803|NCT02819999|DRUG|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
223935804|NCT02819999|DRUG|Cisplatin|
223935805|NCT02819999|DRUG|Etoposide|
223935806|NCT00716170|BIOLOGICAL|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
223935807|NCT06179446|BIOLOGICAL|pdmFlu vaccine|Intramuscular injection
223935808|NCT06179446|BIOLOGICAL|Placebo|Intramuscular injection
223935809|NCT06179446|BIOLOGICAL|Licensed influenza vaccine|Intramuscular injection
223935810|NCT01015872|DEVICE|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
223935811|NCT00536120|BIOLOGICAL|BG00002 (natalizumab)|
223935812|NCT00536120|BIOLOGICAL|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
224097916|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
223935813|NCT00536120|BIOLOGICAL|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
223935814|NCT01038934|PROCEDURE|samples collected by buccal cytobrush|
223935815|NCT02722434|OTHER|Laboratory Biomarker Analysis|Correlative studies
223935816|NCT02722434|OTHER|MC5-A Scrambler Therapy|Undergo Scrambler therapy
223935817|NCT02722434|OTHER|Questionnaire Administration|Ancillary studies
223935818|NCT02722434|OTHER|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
223935819|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs SARS-CoV-2|Evaluation of cellular immunity vs SARS-CoV-2 by ELISpot assay
223935820|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs SARS-CoV-2|Evaluation of Humoral immunity vs SARS-CoV-2 by ELISA assay (IgG anti-RBD and anti-N)
223935821|NCT06070961|DIAGNOSTIC_TEST|Cellular immunity vs Varicella Zoster Virus|Evaluation of cellular immunity vs VZV by Enzyme-Linked immunoSPOT (ELISPOT) assay
223935822|NCT06070961|DIAGNOSTIC_TEST|Humoral immunity vs Varicella Zoster Virus|Evaluation of humoral immunity vs VZV by ELISA (VZV gE-binding IgG)
223935823|NCT06070961|DIAGNOSTIC_TEST|Diphtheria toxin-binding IgG|Evaluation of diphtheria toxin-binding IgG by ELISA assay
223935824|NCT06070961|DIAGNOSTIC_TEST|Tetanus toxoid-binding IgG|Evaluation of tetanus toxoid-binding IgG by ELISA assay
223935825|NCT06070961|DIAGNOSTIC_TEST|T-cell populations and markers characterization|Characterization of T-cell populations and markers by flow cytometry
223935826|NCT02243800|OTHER|cholecalciferol versus placebo|
223935827|NCT00360269|DRUG|Atomoxetine|25 to 100 mg daily
223935828|NCT00360269|PROCEDURE|Motivational enhancement therapy|Three sessions
223935829|NCT00360269|DRUG|Placebo|25 to 100 mg daily
223935830|NCT02378922|BIOLOGICAL|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
223935831|NCT02378922|OTHER|Laboratory Biomarker Analysis|Correlative studies
223935832|NCT02378922|OTHER|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
223935833|NCT02704052|DRUG|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
223935834|NCT02704052|DRUG|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
223935835|NCT00300404|DRUG|daraprim|
223935836|NCT00300404|DRUG|pyrimethamine|
223935837|NCT00300404|DRUG|folinic acid|
223935838|NCT06352905|OTHER|Whole body vibration (WBV)|WBV is a platform that vibrates while a person stands or sits and performs exercises. The WBV session will consist of 5 sets of 60 seconds set at 6 Hertz (frequency), 3 mm (amplitude) while performing mid-squats. There will be a 1 minute rest in between each set. These parameters were chosen as commonly used parameters in previous studies of WBV in people with PD.
223935839|NCT06352905|OTHER|Control|Mid-squats performed on level ground 5 repetitions of 60 seconds with 1 minute rest in between each set.
223935840|NCT05160779|OTHER|Analysis of genetic polymorphisms of vasoactive peptides in COVID-19|Evaluate the frequency of the insertion/deletion (I/D) polymorphism in the ACE gene; to assess the frequency of polymorphism in the bradykinin B2 receptor gene; to assess the frequency of the polymorphism in the CK-M gene and compare the frequencies of these polymorphisms between patients with severe and mild conditions.
223935841|NCT05600114|DRUG|Cannabidiol oral solution|CBD 150 mg BID
223935842|NCT05600114|DRUG|Cannabidiol oral solution|CBD 300 mg BID
223935843|NCT05600114|DRUG|Placebo|Placebo BID
223935844|NCT04779645|DRUG|REMD-477|12-Week, once weekly subcutaneous injection with 70mg REMD-477
223935845|NCT04779645|DRUG|Placebo|12-Week, once weekly subcutaneous injection with placebo
223935846|NCT04655833|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
223935847|NCT04999007|OTHER|Artificial intelligence algorithm|Temporary ileostomy will be performed in the patients with high-risk of anastomotic leakage and not performed in the patients with low-risk of anastomotic leakage.
223935848|NCT04989816|DRUG|Trastuzumab Deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
223935849|NCT06385002|DRUG|Remimazolam|After tracheal intubation, the experimental group will maintain oxygen-air (O2-Air) at 2 liters/minute, and remimazolam will be infused at 1.0mg/kg/h, while adjusting the concentration of sevoflurane to maintain the depth of anesthesia with a bispectral index (BIS) of 40-60.
223935850|NCT05930197|DRUG|Bismuth subsalicylate|BSS is a commonly used, widely available, OTC medication for a variety of gastrointestinal GI symptoms. It is available in the generic form, but also under the more commonly known brands: Bismatrol; Diotame; Geri-Pectate; Kao-Tin; Peptic Relief; Pepto-Bismol; Pink Bismuth and Stomach Relief. It received approval by the US Food and Drug Administration (FDA) in 1939.
223935851|NCT06385262|DRUG|Alirocumab|300 mg subcutaneously every 4 weeks prior to surgery
223935852|NCT06385262|DRUG|Cemiplimab|350mg IV every 3 weeks prior to surgery
223935853|NCT06385262|DRUG|Chemotherapy|Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
223935854|NCT05485532|DEVICE|Telemonitoring System using Cosinuss° Two and/or Garmin Vivoactive 4|Development and validation of a telemonitoring system using smart devices
224097917|NCT06115369|DIETARY_SUPPLEMENT|Medically Tailored Meals Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of twice-daily prepared medically tailored meals (MTM). Participants will receive this supplement unconditionally for the entire study duration.
223935855|NCT06074679|PROCEDURE|Open cholecystectomy|The experimental group and the control group were changed to open cholecystectomy when the operation was difficult to complete.
223935856|NCT00416858|DRUG|cisplatin|
223935857|NCT00416858|DRUG|fluorouracil|
223935858|NCT00416858|PROCEDURE|adjuvant therapy|
223935859|NCT00416858|PROCEDURE|conventional surgery|
223935860|NCT00416858|PROCEDURE|neoadjuvant therapy|
224097918|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes delivered Conditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement conditioned on continued participation and engagement in their healthcare, including attending all scheduled office visits and refilling prescription medications. If participants do not refill their prescriptions or do not attend their office visits, the shipments of medically tailored meals will be paused. These will be restarted when the participant's appointment is rescheduled or when the participant's prescription is refilled.
224097919|NCT06115369|DIETARY_SUPPLEMENT|Produce Boxes Delivered Unconditionally|Season Health, our food intervention partner, will provide participants with weekly deliveries of fresh produce and pantry staples. Participants will receive this supplement unconditionally throughout the entire study period.
224097920|NCT06842082|DEVICE|Intubation with standard laryngoscope|Anesthesia resident will intubate using a standard laryngoscope.
223935861|NCT00416858|RADIATION|radiation therapy|
223935862|NCT03595969|DIAGNOSTIC_TEST|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
223935863|NCT06148441|DIAGNOSTIC_TEST|bone morphogenetic protein-2 (BMP-2)|novel biomarkers associated with in-stent restenosis after percutaneous coronary intervention
223534176|NCT06675721|OTHER|Study Questionnaire|A survey questionnaire to assess factors related to vaccination adherence, including factors such as vaccine novelty, cost, and prior knowledge among vulnerable populations.
223534177|NCT06674902|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
223534178|NCT06675201|BIOLOGICAL|neoantigen-loaded dendritic cell vaccine (NeoDC-Vac)|"Experimental Group: Neoantigen Vaccine Combined with Immune Checkpoint Inhibitors (ICIs) Neoantigen Vaccine: Administered via subcutaneous injections at multiple sites, including bilateral axillary and bilateral inguinal regions. The initial phase consists of 5 injections during the first cycle, given at weeks 1, 2, 4, 6, and 8. Thereafter, the vaccine is administered once every 4 weeks, continuing for 1 year, or until disease progression, intolerable adverse events, or death from any cause.~ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause.~Control Group: ICIs ICIs: Administered intravenously once a month, with a maintenance duration of 1 year, or until disease progression, intolerable adverse events, or death from any cause."
223935864|NCT04093609|GENETIC|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
223935865|NCT04307056|PROCEDURE|Radical Prostatectomy|The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA \> 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.
223935866|NCT04307056|PROCEDURE|High Intensity Focused Ultrasound (HIFU) Treatment|The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
223935867|NCT02852252|DRUG|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
223935868|NCT02852252|DRUG|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
223935869|NCT02359929|BIOLOGICAL|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
223935870|NCT03394534|OTHER|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
223935871|NCT05437770|OTHER|BFR (Blood-Flow Restricted exercise)|The BFR group performs unilateral training with the knee-OA diagnosed leg first. BFR exercise is performed with a pneumatic cuff placed at the top of the thigh on the leg being trained. The cuff will be inflated to 60-80 % of the total arterial occlusion pressure (AOP). The participant will afterwards perform training of the knee extensors in a leg press exercise machine and a leg extension exercise machine with a load corresponding to 30 % of the maximal load (1RM = Repetition Maximum).
224097921|NCT06842082|DEVICE|Intubation with video laryngoscope|Anesthesia resident will intubate using a videolaryngoscope (Storz C-MAC, McGrath, Glidescope or other videolaryngoscope)
224097922|NCT04468360|BEHAVIORAL|3-day differential fear conditioning, extinction, and extinction retention testing paradigm|Day 1: Fear acquisition involving the pairing of a brief, noxious but not painful air blast to the neck (unconditioned stimulus; US) to a conditioned stimuli (CS) (Expts. 1 and 2). The CS will be different colored shapes appearing on a computer monitor. An auditory stimulus will serve as the startle probe. Day 2: Either extinction training (Expt. 1) or fear memory reactivation by a single CS+ with no US (Expt. 2) will occur followed by IV Allo vs. IV placebo administration. Day 3: The effects of IV Allo vs. IV placebo (administered on Day 2) on extinction retention (Expt. 1) or reconsolidation blockade (Expt. 2), as well as reinstatement of conditioned fear (Expts. 1 and 2) will be assessed.
224097923|NCT04468360|DRUG|Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
224097924|NCT04468360|OTHER|Matching IV Placebo|Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of the matching placebo formulation will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of the matching placebo formulation will be infused over 30 minutes immediately following presentation of a single CS+.
224097925|NCT07094776|OTHER|No intervention (observational study)|This is an observational study. No drugs, devices, or treatments are administered. Participants only provide a single blood sample for MG53 and routine metabolic measurements.
224097926|NCT07105696|OTHER|Web-Based CORE|"The intervention planned for the study is a web-based digital CORE method. Students in the intervention group taking the Health Diagnosis course will be administered a web-based digital CORE to assess the cardiovascular, respiratory, musculoskeletal, and gastrointestinal systems.~Students in the experimental group will be administered the web-based digital CORE exam. Students in the control group will be asked the same multiple-choice questions in a digital environment. Two weeks later, students in the experimental and control groups will be administered another exam. Differences in achievement scores between the two groups will be evaluated."
224097927|NCT07107724|OTHER|Noradrenalin|"After inclusion, patients will be tested for fluid responsiveness. Pulse pressure variation (PPV) will be evaluated.~In case of PPV\> 13% a fluid bolus of 500 mL of Lactated Ringer's will be administered in 10 minutes.~If PPV\< 8% Norepinephrine will be administered or increased. If PPV is in the gray zone, a PLRT will be performed and if CO increases more than 10% a fluid bolus will be prescribed, otherwise norepinephrine increased."
223534179|NCT06998615|OTHER|shoulder impingement group|"the Patients with shoulder impingement syndrome in this group had at least 3 out of the following 6 criteria 1) positive Neer's sign; 2) positive Hawkins' sign; 3) pain on active shoulder elevation in the scapular plane, 4) pain on the C5-C6 dermatome; 5) pain on palpation of the rotator cuff tendons and 6) pain with resisted isometric abduction."
223534180|NCT06998615|OTHER|normal subjects|the subjects in this group had no pain or disability in shoulder
223935872|NCT05437770|OTHER|Standard rehabilitation|The GLA:D programme involves a circuit training program with four stations. Each station involves two to six exercises where the participants perform 10-15 repetitions over 2-3 sets, which depends on the participants pain- and functional level. Following the 8 weeks GLA:D programme, participants will continue 4 weeks of team group training performing similar neuromuscular lower limb exercises as for the first 8 weeks.
223935873|NCT00139165|DRUG|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
223935874|NCT00139165|PROCEDURE|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
223935875|NCT05359536|BEHAVIORAL|Training Early Childhood educators in PA|The four module e-learning course was developed using the Delphi technique and covers physical activity and sedentary guidelines, physical activity and sedentary behaviours in the childcare environment, how to promote physical activity and reduce sedentary behaviours in young children, and a resource library.
223935876|NCT03901989|DEVICE|zeolite|given for a period of 12 months
223935877|NCT03901989|DEVICE|cellulose|given for a period of 12 months
223935878|NCT00470314|DRUG|L-Ornithine L-Aspartate|
223935879|NCT04325711|DRUG|CSPCHA131|CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.
224097928|NCT07107724|OTHER|Fluid bolus|"After inclusion, patients will be tested for fluid responsiveness. Pulse pressure variation (PPV) will be evaluated.~In case of PPV\> 13% a fluid bolus of 500 mL of Lactated Ringer's will be administered in 10 minutes.~If PPV\< 8% Norepinephrine will be administered or increased. If PPV is in the gray zone, a PLRT will be performed and if CO increases more than 10% a fluid bolus will be prescribed, otherwise norepinephrine increased."
224286153|NCT03662256|OTHER|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
223935880|NCT01641900|DRUG|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
224097929|NCT07106567|BEHAVIORAL|Mediterranean diet education|The General Information Form, Physical Activity Questionnaire, Perceived Stress Scale, SF-36 Quality of Life Scale, and Mediterranean Diet Adherence Scale will be administered to hypertensive patients at each interview (at 0, 1, and 3 months). The intervention group will be trained on the Mediterranean Diet at the first meeting.
224286154|NCT04017559|BEHAVIORAL|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
224286155|NCT00493454|DRUG|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
224286156|NCT00493454|DRUG|Rituximab|250 mg/m\^2 IV Over 6 to 8 Hours
224286157|NCT00493454|DRUG|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
223534181|NCT06998485|BEHAVIORAL|Arm Basis Training|This program is a systematic training regimen specifically designed to improve proximal motor control for patients with severe upper extremity hemiparesis. The core principles of the Arm Basis Training Program focus on rebuilding the fundamental capacity for specific and selective motor control before progressing to more complex motor patterns.
223935881|NCT01641900|DRUG|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
223935882|NCT03056313|BEHAVIORAL|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
223935883|NCT03056313|BEHAVIORAL|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
223935884|NCT00005921|DRUG|L-743,872|
223935885|NCT03209700|DRUG|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
223935886|NCT04051333|DEVICE|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
223935887|NCT03022968|DRUG|[18F]T807 PET|Imaging with \[18F\]T807 PET
223935888|NCT04325217|DRUG|Nintedanib|Capsules
223935889|NCT03378791|DRUG|Iron bisglycinate Oral Tablet|
223935890|NCT03378791|DRUG|Ferrous Fumarate Oral Tablet|
223935891|NCT04246866|BIOLOGICAL|GEM103|GEM103
223935892|NCT05886972|BEHAVIORAL|Awareness about propofol injection induced pain|The aim of the study is to observe the effect of patient awareness about the possibility of occurrence of pain during propofol injection on the rate of incidence and severity of pain during injection as a primary goal as the pain score of propofol injection pain is the main end point of the study .
223935893|NCT02146469|BIOLOGICAL|2 doses with an 3 months interval|varicella vaccination
223935894|NCT02146469|BIOLOGICAL|A second dose with an 1 year interval|varicella vaccine
223935895|NCT02146469|BIOLOGICAL|A second dose with an 3 year interval|varicella vaccine
223935896|NCT02146469|BIOLOGICAL|A second dose with an 5 year interval|varicella vaccine
223935897|NCT02146469|BIOLOGICAL|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
223935898|NCT02146469|BIOLOGICAL|1 dose MMR|MMR
223935899|NCT02941549|OTHER|Placebo capsules|
223935900|NCT02941549|DRUG|Epeleuton|
223534182|NCT05946018|OTHER|Educational video on ergonomics|A 6-8 minute education video that includes information on why ergonomics is important and recommendations for how to arrange the operating room to reduce the risk of injury.
223534183|NCT05946018|OTHER|Verbal physical therapy coaching sessions|Physical therapy coaching sessions include a standard assessment with individualized instruction on range of motion, strength, endurance, and flexibility.
223935901|NCT02994407|DRUG|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
223935902|NCT03451422|DRUG|Efavaleukin Alfa|Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
223534184|NCT06245434|BEHAVIORAL|Repeated behavioural assessment|"One CRS-R per visit~* 4 SECONDs~* Eye tracking during every clinical assessment~* Recording every 2-4h of the Glasgow Coma Score~* Recording every 2h of the temperature and pupillometer reactivity to light"
223935903|NCT03451422|DRUG|Placebo|The placebo will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
223935904|NCT01584466|DRUG|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
223935905|NCT03148652|OTHER|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
223935906|NCT04132154|PROCEDURE|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
223935907|NCT03387540|DRUG|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
223935908|NCT06017700|BEHAVIORAL|Interpersonal Psychotherapy Group|IPT is a psychological intervention that focuses on four common problems that trigger depression: grief, disputes, role transitions and social isolation. Using techniques and strategies such as linking mood to event and event to mood, role play and skill-building, IPT encourages the individual to analyse and improve their interpersonal relationships context. IPT was developed in the USA to treat depressed adults but it has also been used to treat other mental disorders and among different age groups.
223935909|NCT06017700|BEHAVIORAL|Enhanced Usual Care|Participants attending schools in the control arm will receive enhanced usual care. In intervention and control arms, we will train health workers in health posts and primary care centres using the WHO mental health GAP Action training package (mhGAP). Participants in the control clusters will receive a handout with information about the location of these trained health workers and how they can access treatment. Adolescents in the control cluster reporting a current suicide plan (i.e. in the past 2 weeks) or suicide attempt in the past three months will be assessed by a psychosocial counsellor employed through the project and offered counselling or referral to other services as per need.
223935910|NCT03213028|OTHER|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
223935911|NCT05901532|DRUG|Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol|The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.
223935912|NCT05901532|DRUG|edible caramel|The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
223935913|NCT00653172|DRUG|NXL103|600mg orally twice daily
223935914|NCT00653172|DRUG|comparator|comparator twice daily
223935915|NCT00653172|DRUG|NXL103|500mg orally twice daily
223935916|NCT04495140|DRUG|[14C]PF-06882961, 50 mg|A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
223935917|NCT04495140|DRUG|PF-06882961, 50 mg and [14C]PF-06882961, 100 ug|A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
223935918|NCT03601715|OTHER|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
224097930|NCT07106567|OTHER|Control|The General Information Form, Physical Activity Questionnaire, Perceived Stress Scale, SF-36 Quality of Life Scale, and Mediterranean Diet Adherence Scale will be administered to hypertensive patients at each interview (at 0, 1, and 3 months).
223935919|NCT03601715|OTHER|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
223935920|NCT03601715|OTHER|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
223935921|NCT00123409|BEHAVIORAL|Telephone disease management|Telephone based care management
223935922|NCT00123409|BEHAVIORAL|Usual Care|Usual care
223935923|NCT05153681|OTHER|Peloid Therapy|Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
223935924|NCT05458466|OTHER|Pilates training|Eighteen children with autism did not meet the inclusion criteria, ten children did not want to participate in the study, and five children were not included in the study due to different reasons. A total of 22 children between the age of 7 and 12 years were participated in this study. The inclusion criteria were (i) being diagnosed with autism, (ii) not having physical disabilities or neurological disorders, (iii) having the ability to follow the instructions given during evaluations and training, and (iv) having the ability to perform the requested training. All parents of participants signed an informed consent form for participation. were divided into two groups including Aerobic Training (n=11) and Pilates Training (n=11) groups by simple randomization method (internet-based). Since one child in the experimental group did not continue Pilates Training, the study was completed with the participation of 21 children with autism.
223935925|NCT04881305|DIAGNOSTIC_TEST|questionnaires and neuropsychological assessment|Participants will undergo: (1) An evaluation of COVID-19-related symptoms such as fatigue, post-exertional malaise, dizziness, etc. (2) A comprehensive evaluation of behavioral measures (e.g., hearing, vision, olfaction, sleep, social engagement) (3) A short validated neuropsychological evaluation, of multiple cognitive domains, with an emphasis on the memory domain; motivational factors will also be taken into account using performance validity tests (4) A thorough well-being and emotional state assessment, including the evaluation of mood disturbance and quality of life. The assessment will involve both self-report and cognitive tasks, previously associated with psychopathology. In addition to the above-mentioned evaluations, a subgroup of participants will undergo either MRI examination or FDG PET-CT, with the aim of clarifying the neural mechanisms underlying the neurologically-related symptoms.
223935926|NCT01267643|DRUG|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
223935927|NCT06837259|DRUG|PF-07328948|single oral dose day 1 and day 12 (Part A) and day 4 (part B)
223935928|NCT06837259|DRUG|cyclosporine|600 mg capsule day 12 (Part A)
223935929|NCT06837259|DRUG|clarithromycin|500 mg tablets twice daily day 1 to day 6 (Part B)
223935930|NCT01313884|DRUG|Irinotecan|50 mg/m2/day x 5 days
223935931|NCT01313884|DRUG|Vincristine|2 mg/m2 to a maximum of 2 mg
223935932|NCT01313884|DRUG|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
223935933|NCT01313884|DRUG|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
223935934|NCT01313884|DRUG|Cytoxan|1200 mg/m2
223935935|NCT01313884|DRUG|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
223935936|NCT04056754|DRUG|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
223935937|NCT04056754|DRUG|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
223935938|NCT04056754|DRUG|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
223935939|NCT00263757|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
223935940|NCT00263757|OTHER|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
223935941|NCT00347061|DRUG|afuzosin|
223935942|NCT04700410|DEVICE|Pure-Vu System|All patients willing to participate will receive a limited bowel preparation (2-days of dietary restrictions + 2x 150ml picoprep) followed by intra-procedural bowel cleansing with the Pure-Vu System.
223935943|NCT06506175|DRUG|HRS9531 tablets|HRS9531 tablets
223935944|NCT00315185|DRUG|Cetuximab|
223935945|NCT05840185|DEVICE|Test myopia control lenses (DAL)|A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
223935946|NCT04887337|PROCEDURE|Arthroscopic stabilization|Early arthroscopic stabilization with Bankart repair
224097931|NCT07106255|OTHER|Task-oriented training|"Participants included in the experimental group will underwent an 8-week TOT intervention, administered twice weekly, with each session lasting 45 minutes.~Within this framework, the intervention will comprise sessions involving meaningful and repetitive activities tailored to both the patient and their specific context. The occupations will be selected by each participant through the Canadian Occupational Performance Measure (COMP) tool in the initial assessment. The activities were randomly ordered and focused on the reconstruction of complete tasks. To support task segmentation, a range of custom-designed materials will be employed, alongside therapeutic tools and materials such as therapeutic putty, TheraBand, and others commonly used in physical rehabilitation interventions. Throughout the intervention, participants will receive positive reinforcement that will fade over the time to prevent unnecessary dependency."
224097932|NCT07106255|OTHER|Standar medical care and leaflet fatigue management|Participants included in the control group will continue with their usual treatment and will receive a pamphlet containing information on fatigue management.
224097933|NCT07107672|DRUG|[14C]X842|50 mg/100 µCi \[14C\] X842 suspension
223534185|NCT06245434|BEHAVIORAL|Act-Pass paradigm|Before and after sedation withdrawal Assessment of infra-clinical response to an active paradigm (attention focalisation or diversion).
223534186|NCT06245434|BEHAVIORAL|Biological measures of circadian and monoamines biomarkers|Systematic urinary sampling every 2 hours for melatonin, cortisol and monoamines metabolites
223935947|NCT04887337|OTHER|Rehabilitation including a period of immobilization followed by physical therapy|Rehabilitation including a period of immobilization followed by physical therapy
223935948|NCT05943652|DIAGNOSTIC_TEST|Neurological examination|A neurological examination following a protocol to detect positive signs of functional neurological disorders.
223935949|NCT05943652|DIAGNOSTIC_TEST|Anamnesis|"A standardized question about the patient´s history. The response time is measured.~Question: Could you tell me about the problems with the movement disorder you are experiencing?"
223935950|NCT05943652|DIAGNOSTIC_TEST|Neuropsychological testing|"Neuropsychological cognitive testing including:~* Montreal Cognitive Assessment (MOCA)~* Rey-Osterrieth Complex Figure Test (ROCFT)~* Wechsler Memory Scale IV~* Comprehensive Trail Making Test (CTMT)~* semantic and phonematic fluency tests"
224097934|NCT07106710|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.
224097935|NCT07106710|BIOLOGICAL|BCMA CAR-T|Patients will receive BCMA CAR-T single dose (3.0 x 10\^6 cells /kg) infusion 3 days after ASCT.
223935951|NCT05943652|DIAGNOSTIC_TEST|Questionnaires|"* Short Form 36 (SF 36)~* Somatic Symptom Disorder - B Criteria Scale (SSD 12)~* Patient Health Questionnaire 9 (PHQ 9)~* Patient Health Questionnaire 15 (PHQ 15)~* Generalized Anxiety Disorder 7 (GAD 7)~* Fatigue Severity Scale (FSS)~* Psychosomatic Competence Inventory (PSCI)~* Work Ability Index (WAI)~* Level of Personality Functioning Scale~* Toronto Alexithymia Scale~* Levels of Emotional Awareness Scale (short version)~* Certainty About Mental States Questionnaire~* Somatosensoric Amplification Scale~* Personality Inventory for DSM-5 short version (PID5BF+M)~* Childhood Trauma Questionnaire~* European Quality of Life 5 Dimensions 5 Level Version (EQ5D5L)"
223935952|NCT05943652|DIAGNOSTIC_TEST|Tremor recording|Accelerometry following a standardized protocol, using a triaxial accelerometer transducer (Biometrics ACL300, Sensitivity 6 100 mV/G, Biometrics Ltd, UK)
224097936|NCT07106710|DRUG|GPRC5D/CD3 BiTEs|Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion and continuing for at least 2 years
224097937|NCT07106060|DEVICE|EEG-based rehabilitation training device (L-B300)|Participants will use an EEG-based rehabilitation training device (L-B300). After wearing an EEG cap and lying supine, their lower limbs will be positioned on a pedal with the hip, knee, and ankle joints of the unaffected (stronger) leg maintained at 90°. The leg support will be adjusted to the mid-calf and secured with straps. Participants will be instructed to focus on a screen and perform MI training. If they fail to activate the device within 30 seconds under guidance, the EEG difficulty level will be reduced until successful activation within 30 seconds. The EEG difficulty level will be adjusted throughout the trial based on the participant's MI ability.
223534187|NCT06245434|BEHAVIORAL|Transcriptomic and genomic analysis|Definition of the peripheral cellular clock by 2 transcriptomic measures Constitution of a genomic biobank to analyse the cofounding factors for circadian disruption and differential clinical recovery
223534188|NCT06245434|BEHAVIORAL|Polysomnography with concomitant environment recording|"One 48h polysomnography for the first visit~\+ 3\* 24h polysomnography for each visit Synchronised recordings of light, sound, activity in patients' rooms"
223935956|NCT06145984|BEHAVIORAL|Mindfulness|Participants receive a two-hour professional training to get familiar with the basic techniques of mindfulness. The training is given by a mindfulness professional and consists of psycho-education, instructions for mindfulness and guided practice. It focuses mainly on attending to stimuli such as breathing, external sounds or bodily sensations and becoming aware of where one's attention is. After the professional training, participants receive instructions about the audio application with which participants continue performing short exercises using the learned technique every day guided by an application on their smartphone customized for this research. Specifically, participants perform one short exercise (10 min) per day for in total six days. The exercises that are being performed are: attention to breathing part 1, attention to breathing part 2, attention to sounds, attention to bodily sensations, attention to thoughts, attention to emotions and feelings.
223935957|NCT06145984|BEHAVIORAL|Positive Fantasizing|"In a two-hour training session by a professional trainer, participants get familiar with the positive fantasizing technique. Participants receive psycho-education about the role of dysfunctional beliefs. The positive fantasizing technique starts with identifying dysfunctional beliefs and schema and subsequently fantasize about a positive fantasy belief. Participants are guided by the professional using imagery and experiencing thoughts and feelings that would be elicited when using their fantasy belief as if in an ideal world. After using imagery techniques, participants are asked, with help of the professional, to reflect on their experience during the fantasizing exercise and to think of how they could implement this fantasy belief more in their daily life, by adapting their fantasy belief into a more practical belief. After the training, participants are asked to perform one exercise per day using the fantasizing technique using a mobile application for six days in total."
223935958|NCT03230643|DEVICE|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
223935959|NCT03106922|DRUG|PMF104|"Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
223935960|NCT03106922|DRUG|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
223935961|NCT01238146|DRUG|bendamustine hydrochloride|Given IV
223935962|NCT01238146|DRUG|obatoclax mesylate|Given IV
223935963|NCT01238146|BIOLOGICAL|rituximab|Given IV
223935964|NCT05533658|DIETARY_SUPPLEMENT|VisionPure Dietary Supplement|Subjects will consume two softgels capsules of the Treatment (VisionPure) once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
223935965|NCT05533658|DIETARY_SUPPLEMENT|Placebo|Subjects will orally consume two softgel capsules of Placebo once daily for 60 days. At Day 0, they will come in for a Comprehensive Eye Exam, a National Eye Institute Visual Functioning Questionnaire, and a series of Cognitive Function Exams. After 60 days, subjects will return and repeat the same questionnaires and exams from Day 0.
223935966|NCT00790413|DRUG|iodine I 131 metaiodobenzylguanidine|
223935967|NCT00790413|DRUG|Fludarabine|
223935968|NCT00790413|DRUG|Thiotepa|
223935969|NCT00790413|PROCEDURE|T-cell depletion|
223935970|NCT00790413|PROCEDURE|Haploidentical stem cell transplantation|
223935971|NCT00790413|PROCEDURE|Donor Lymphocyte Infusion|
223935972|NCT00790413|DRUG|Rituximab|
223935973|NCT00790413|PROCEDURE|Co-transplantation of mesenchymal stem cells|
223935974|NCT04449835|PROCEDURE|Intracept Procedure|radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain
223935975|NCT06152640|DEVICE|Deep transcranial magnetic stimulation|"Neuronavigation: The coil is positioned 4cm in front of the scalp point and foot motor cortex, corresponding to the ACC. The Brainways H7 coil with fluid cooling is used to obtain a greater depth of stimulation, up to about 6 cm below the cortex.~dTMS intervention: The intervention targets are at the left and right ACC, once per day, for 28 days. A total of 28 treatments are given. Stimulation mode: stimulation frequency 1Hz, stimulation intensity 100% RMT, number of pulses 150, sequence interval 20s, total 6 trials, 900 pulses."
223534189|NCT06245434|BEHAVIORAL|Actimetry|Continuous recording of movements at the wrist during 7 days after sedation withdrawal
223935976|NCT06152640|DEVICE|Sham deep transcranial magnetic stimulation|"Neuronavigation: The sham coil is positioned 4 cm in front of the scalp point and foot motor cortex, corresponding to the ACC.~Sham dTMS intervention: The intervention targets are at the left and right ACC (The sham coil has the same parameters as real dTMS and generating the same noise as real coils, but without the magnetic field), once per day, for 28 days. A total of 28 treatments are given."
224097938|NCT07106060|DEVICE|EEG-based rehabilitation training device (L-B300)（Not connected）|Participants will lie supine, with their lower limbs fixed to the L-B300 device using the same method as Group A. The computer screen will be turned off, and the machine will be set to drive passive or active cycling movements of the lower limbs.
223534190|NCT06245434|BEHAVIORAL|Morphological MRI|Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal
223534191|NCT06245434|BEHAVIORAL|Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.|Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.
223935977|NCT06152640|OTHER|Basic treatment|According to national and international guidelines for the treatment of eating disorders, the basic treatment for patients is nutritional therapy, that is, regular and quantitative dietary treatment, with three regular meals followed by a snack meal 2 hours after the regular meal. Both groups received the same nutritional treatment.
223935978|NCT00885313|DRUG|DHA250|DHA 250 mg/kg/d
223935979|NCT00885313|DRUG|DHA500|DHA 500 mg/kg/d
223935980|NCT00885313|DRUG|PLACEBO|placebo
223935981|NCT00885313|BEHAVIORAL|Lifestyle intervention|lifestyle intervention \[including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity\], for 12 months.
223935982|NCT03551379|DEVICE|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
223935983|NCT05493644|OTHER|Remedial treatment within 3 months|Remedial therapy was performed within 3 months
223935984|NCT05493644|OTHER|Remedial treatment within 3 to 6 months|Remedial therapy was performed within 3 to 6 months
223935985|NCT05493644|OTHER|Remedial treatment within 6 to 12 months|Remedial therapy was performed within 6 to 12 months
223935986|NCT05493644|OTHER|Remedial treatment after 12 months|Remedial therapy was performed after 12 months
223935987|NCT05408624|PROCEDURE|ultrasound transvaginal drainage|Ultrasound-guided transvaginal drainage of TOA by a puncture under simple sedation or analgesia with/or under general anesthesia
223935988|NCT05408624|PROCEDURE|laparoscopy|Laparoscopy for drainage of TOA under general anesthesia
224097939|NCT07107360|OTHER|Pain Neuroscience Education|The study included two groups, consisting of participants who met the inclusion criteria and adhered to the procedures. Participants in the intervention group received a 20-minute Pain Neuroscience Education (PNE) session delivered face-to-face one hour prior to their scheduled surgery. The PNE focused on the biopsychosocial aspects of pain and included both theoretical and practical strategies for postoperative pain management.
223534192|NCT07004140|OTHER|3T MRI research scan|Baseline MRI scan
223534193|NCT07004140|OTHER|Field-Cycling Imaging research scan|Baseline FCI scan
223534194|NCT07004140|OTHER|Follow up 3T MRI research scan|Day 30 3T MRI scan
223534195|NCT07004140|OTHER|Follow up Field-Cycling Imaging research scan|Day 30 FCI scan
223534196|NCT07004140|OTHER|Blood samples for clotting experiments in vitro|Thrombi from whole blood from ischaemic stroke patients will be formed and examined using bench top nuclear magnetic resonance (NMR) assays. At baseline and 30 days after stroke onset.
223935989|NCT02463448|BIOLOGICAL|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the sample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
223935990|NCT01307085|PROCEDURE|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
223935991|NCT01650896|OTHER|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
223935992|NCT05166590|BEHAVIORAL|Sleep Restriction|Sleep Deprivation
223935993|NCT01911767|DRUG|Dimethyl fumarate|Administered as specified in treatment arm.
223935994|NCT01911767|DRUG|Peginterferon beta-1a|Administered as specified in treatment arm.
223935995|NCT05623436|BEHAVIORAL|Nursing students will be trained through virtual reality.|Nursing students will be trained through virtual reality.
223935996|NCT06195813|DIETARY_SUPPLEMENT|Asparagus capsule|Asparagus capsule is categorized as dietary supplement.
223935997|NCT06195813|OTHER|Placebo capsule|Placebo capsule is categorized as other.
223935998|NCT00610558|DEVICE|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
223935999|NCT00610558|DEVICE|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
223936000|NCT00610558|DEVICE|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
223936001|NCT05645068|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography
223936002|NCT05645068|OTHER|multidisciplinary care program|multidisciplinary care program including sports activity
223936003|NCT01557036|DEVICE|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
223936004|NCT01291628|DEVICE|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
223936005|NCT00857766|DRUG|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
223936006|NCT00857766|OTHER|Placebo|COPD subjects-Placebo DISKUS
223936007|NCT02565966|OTHER|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
223936008|NCT03781349|DEVICE|MENS|
223936009|NCT03781349|DEVICE|TENS|
223936010|NCT05437666|OTHER|Education and booklet|The education program was given both an educational presentation accompanied by a physiotherapist once a week for six weeks and a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
223936011|NCT05437666|OTHER|Booklet|The control group will be given a booklet related to the pelvic floor health (pelvic floor, urinary incontinence, risk factors, treatment options, healthy behavioral strategies etc.)
223936012|NCT03072888|DEVICE|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
223936013|NCT03537326|DRUG|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
223936014|NCT00131274|DRUG|Imatinib Mesylate (Gleevec)|
223936015|NCT02455765|OTHER|Rice and Amino Acid mixtures|Rice and amino acid mixture
223936016|NCT06021275|OTHER|Microneedling with topical application of regular insulin|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
223936017|NCT06021275|OTHER|Microneedling with topical application of saline|Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
224286158|NCT06615765|OTHER|Acupuncture|"Acupuncture sessions will use sterile, disposable stainless-steel needles (0.3 mm × 40 mm and 0.3 mm × 75 mm). Each session has two phases:~Supine Position:~* Needles (0.35 mm × 75 mm) are inserted into ST25, ST15, and SP14, reaching the abdominal muscle layer.~* Needles (0.30 mm × 40 mm) are inserted into CV12, CV4, ST36, ST37, and SP6.~* Electroacupuncture (EA) at ST25, SP15, and ST36 uses a continuous 5 Hz wave, 0.1 to 2.0 mA.~Prone Position:~* Needles are inserted into BL32, BL33, and BL35 with precise angles and depths.~* EA at BL32, BL33, and BL35 uses a continuous 5 Hz wave, 2.0 to 6.5 mA. Sessions occur three times a week for the first 4 weeks, then twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions."
224286159|NCT06615765|OTHER|Sham acupuncture|Sterile, disposable stainless-steel needles (0.30 mm × 25 mm) will be used. After skin sterilization, needles will be inserted into the same points as the acupuncture group but to a shallow depth of 2 to 3 mm and lightly manipulated for blinding. Paired alligator clips will be attached to the same points, but the sham EA apparatus will have no current output, though it mimics the active EA apparatus in appearance and sound. Sham sessions will follow the same schedule as the acupuncture group: three times a week for the first 4 weeks and twice a week for weeks 5 to 8, each lasting 40 minutes, totaling 20 sessions.
224286160|NCT01197768|BEHAVIORAL|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
223936018|NCT06327282|BEHAVIORAL|education on pain and related knowledge|Before surgery, pain related knowledge was educated.
223936019|NCT01611337|OTHER|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
223534197|NCT07002866|BEHAVIORAL|HIV Risk Reduction (HIVRR)|This is an intervention comprised of 5 sessions of an evidence-based, HIV/STI risk reduction with PrEP to strengthen HIV prevention knowledge and behavioral skills intervention. Session content cover harm reduction, social support networks, HIV knowledge, transmission risks and testing procedures for HIV/STIs, build enthusiasm for condom use, alternatives to unsafe sex, importance of safer sex negotiations, strategies to negotiate safer sex, setting appropriate risk reduction goals, introduction to PrEP, PrEP screening and eligibility; monitoring and managing PrEP side effects and stigma, recognizing and understanding consequences of abusive behavior by any sexual partners or others; build safety plan skills; review and identify ways to increase social support; build skill in communication with health care professionals.
223936020|NCT00877019|DEVICE|Sonicare elite medium brush head|
223936021|NCT00877019|DEVICE|Sonicare elite mini brushhead|
223936022|NCT00877019|DEVICE|GABA Elmex sensitive extra soft toothbrush|
223936023|NCT00877019|DEVICE|ADA reference toothbrush|
223936024|NCT04378413|OTHER|exercise|exercise for low back pain
223936025|NCT02776982|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
223936026|NCT02776982|PROCEDURE|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
223936027|NCT02776982|PROCEDURE|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
223936028|NCT02776982|PROCEDURE|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
223936029|NCT02564705|PROCEDURE|Anterior Lumbar Interbody Fusion (ALIF)|
223936030|NCT02564705|PROCEDURE|Posterior Fusion|"* Posterolateral Fusion (PLF)~* Posterior Lumbar Interbody Fusion (PLIF)~* Transforaminal Lumbar Interbody Fusion (TLIF)"
223936031|NCT03355573|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
223936032|NCT05335044|DRUG|CKD-331|QD, PO
223936033|NCT05335044|DRUG|EX5619|QD, PO
223936034|NCT04730206|DRUG|Camostat|100 milligram tablets
223936035|NCT04730206|DRUG|Placebo|oral tablets, identical in size and shape
223936036|NCT04730206|DRUG|Molnupiravir|200 milligram tablets
223936037|NCT01025167|DIETARY_SUPPLEMENT|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
223936038|NCT01025167|DIETARY_SUPPLEMENT|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
224097940|NCT07107360|OTHER|Conventional preoperative education|Participants in the experimental group received pain neuroscience education, while participants in the control group received a booklet summarizing this education in addition to routine preoperative care.
223936039|NCT01567605|DRUG|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
223936040|NCT01567605|OTHER|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
223936041|NCT00059826|BIOLOGICAL|interferon-alfa-2b|IV
223936042|NCT00059826|DRUG|cisplatin|IV
224097941|NCT07105449|DRUG|Cannabis (30% THC Concentrate)|Participants will vape 30% THC concentration of liquid cannabis ad libitum.
224097942|NCT07105449|DRUG|Cannabis (60% THC Concentrate)|Participants will vape 60% THC concentration of liquid cannabis ad libitum.
224097943|NCT07105449|DRUG|Cannabis (90% THC Concentrate)|Participants will vape 90% THC concentration of liquid cannabis ad libitum.
224097944|NCT07107490|DRUG|ALPS12|ALPS12 as an IV infusion
224286161|NCT01253928|DRUG|Pioglitazone|45mg qd for 4 months
224286162|NCT04627831|DRUG|CE-Iohexol|Captisol-Enabled™ Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
224286163|NCT04627831|DRUG|Iohexol|Iohexol as needed for the diagnostic procedure. Volume will be determined according to medical need.
224286164|NCT05650086|DEVICE|Thermalytix|One-time Thermal imaging is performed for this cohort.
224286165|NCT03146637|BIOLOGICAL|Activated CIK|Activated CIK armed with bispecific antibody were infused for 3 days，after 2 days，bispecific antibody was infused separately for 3 days
224286166|NCT03146637|BIOLOGICAL|CIK|Traditional CIK were infused for 3 days
224286167|NCT00504803|PROCEDURE|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
223936043|NCT00059826|DRUG|5-fluorouracil|IV
223936044|NCT00059826|RADIATION|radiation therapy|
223936045|NCT01536093|OTHER|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
224097945|NCT07107490|DRUG|obinutuzumab|Obinutuzumab as an IV infusion
224097946|NCT07108101|BEHAVIORAL|tDCS stimulation (sham)|"Participants will receive sham tDCS stimulation in a 20 minute long task.~Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Sham tDCS will target the motor cortex at 2mA for 15 sec at the beginning of the session, and then the stimulator will turn off. The participant will then sit for the remaining time of the session with the electrode cap on their heads but turned off and not delivering stimulation.~All participants will receive sham tDCS stimulation (n=120)."
224097947|NCT07108101|BEHAVIORAL|tDCS stimulation (real)|"In their second session, participants will receive real tDCS stimulation in a 20 minute long task.~Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Real tDCS stimulation will target the motor cortex at 2mA for 20 minutes (full duration of task).~All participants will receive real tDCS stimulation (n=120)."
223936046|NCT01536093|OTHER|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
223936047|NCT02209246|OTHER|PROMIS CAT Pain Interference|
223936048|NCT02209246|OTHER|PROMIS CAT Pain Behavior|
223936049|NCT02209246|OTHER|PROMIS CAT Physical Function|
223936050|NCT02209246|OTHER|MISS-21|
223936051|NCT03666468|OTHER|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
223936052|NCT03666468|OTHER|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
223936053|NCT03666468|OTHER|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
223936054|NCT06124573|DRUG|Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
223936055|NCT06143501|DIAGNOSTIC_TEST|Blood Sample|6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
223936056|NCT06143501|DIAGNOSTIC_TEST|Stool Sample|pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
224286168|NCT06142188|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
224286169|NCT02244294|DRUG|FLOMAX® capsules|
224286170|NCT02244294|DRUG|Placebo capsules|
224286171|NCT05844631|DIETARY_SUPPLEMENT|Release|One capsule of Release will be taken three times per day for 180 days in combination with the G4LP.
224286172|NCT06227117|DRUG|Disitamab Vedotin Injection （18 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 3 cycles (18 weeks) of treatment are performed.
224286173|NCT06227117|DRUG|Toripalimab （18weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks
224286174|NCT06227117|DRUG|Carboplatin|AUC 3 Q2W or AUC1.5 QW intravenous infusion
224286175|NCT06227117|DRUG|Disitamab Vedotin Injection （12 weeks）|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
224286176|NCT06227117|DRUG|Sequential Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
224286177|NCT06227117|DRUG|Sequential CTX|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks, A total of 12 weeks of treatment are performed.
223936057|NCT06143501|DIAGNOSTIC_TEST|Urine Sample|8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
224097948|NCT07108101|BEHAVIORAL|Mindful state induction|"Experimenters trained in high-competence and high-warmth will train Group 1 participants on mindful state induction (n=60). Participants will undergo two stages for this training: 1) pain education to increase beliefs in endogenous brain regulatory capacities; and 2) the Stanford Hypnotic Induction Profile (HIP) test of hypnotizability and hypnotic induction of a relaxed state receptive to suggestion.~In Stage 1, participants will receive education that pain and affect are processes designed to protect the body from danger, which are transmitted rapidly and automatically to the brain. In Stage 2, participants are (a) seated in an upright, alert posture; and (b) receive suggestions that the ability to attend to and discriminate affective perceptions is achievable and that suppressing attention to the body and focusing on the task will allow them to perform optimally under pressure. Mindful state induction will only be explicitly instructed during session 1 for Group 1 participants."
224097949|NCT07108101|BEHAVIORAL|No minfulness induction|Participants in the No-mindfulness group will go through comparable stages but with different instructions. In the first stage, they will receive education about pain and affect as protective processes of the body. In the second stage, they will be seated in an upright, alert posture and receive suggestions to focus on the task and suppress attention to the body.
223936058|NCT00587275|DRUG|AST-120|Oral, sachet, 2 grams daily for 4 weeks
223936059|NCT00587275|DRUG|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
223936060|NCT01065649|DRUG|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
223936061|NCT01065649|DRUG|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
223936062|NCT01082900|OTHER|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
223936063|NCT01023542|DRUG|delayed, low-dose CNI|immunosuppression
223936064|NCT01023542|DRUG|BU-CNI|Immunosuppression
223936065|NCT01023542|DRUG|BU-Everolimus|Immunosuppression
223936066|NCT03631407|DRUG|Vicriviroc|Vicriviroc tablets administered orally, QD at dose level 1 or 2.
223936067|NCT03631407|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.
223936068|NCT02008669|PROCEDURE|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
224097950|NCT07105462|DEVICE|Arm 1 - Experimental Group Intervention Name: ADRRPs Vergence Training Intervention Description: Participants wore an Automatic Dual Rotational Risley Prism (ADRRPs) headset to perform vergence eye|"ADRRPs Vergence Training~Intervention Description:~Participants wore an ADRRPs headset that applied alternating base-in and base-out prism power to stimulate vergence eye movements. Prism levels were customized based on each participant's fusional vergence. Training was performed twice weekly for 15 minutes over four weeks while viewing a near video target.~Sham Visual Training with Plano Lenses~Intervention Description:~Participants wore an identical ADRRPs headset fitted with plano lenses that produced no prism effect. The procedure and schedule matched the experimental group but provided no vergence stimulation, serving as a sham control."
224097951|NCT07105462|DEVICE|1. Experimental Group Intervention Name: ADRRPs-Based Vergence Training; 2. Control Group Intervention Name: Sham Training with Plano Lenses.|"ADRRPs-Based Vergence Training This intervention used the Automatic Dual Rotational Risley Prisms (ADRRPs) system to deliver alternating base-in and base-out prism stimulation for vergence training. Prism levels were customized based on each participant's fusional vergence. Training was conducted twice per week for four weeks, 15 minutes per session, while participants viewed a near video target. This protocol provides automated and symmetric vergence demand, distinguishing it from conventional near-point or static prism exercises.~Sham Training with Plano Lenses Participants used the same ADRRPs headset as the experimental group but with plano lenses that produced no prism effect. The training schedule and visual tasks matched the experimental condition, but no vergence stimulus was applied. This design enabled participant masking while providing no active optical stimulation, serving as a sham comparator distinct from both active training and no-treatment controls."
224097952|NCT07108192|OTHER|Hand Holding|Hand holding intervention will be performed by the researcher. Before cataract surgery, the researcher will sit in a chair next to the patient and warm his/her hands to a level that does not disturb the patient. 1-2 minutes before cataract surgery, the researcher will hold the patient's hand without gloves, with one hand, with moderate pressure, without rubbing or squeezing it uncomfortably. The hand holding intervention will continue until the cataract surgery is completed
224097953|NCT07108192|OTHER|Stress Ball|According to the randomization, the patient in the stress ball group will first be taught the use of stress balls face to face by the researcher. The researcher will place a round, medium-hard, high-quality stress ball of the same brand in the patient's active hand 1-2 minutes before the cataract surgery is started. The patient will be asked to squeeze and relax the stress ball by counting to 5 during cataract surgery. After squeezing the stress ball, he/she should count to 5 and then loosen it. The patient will be asked to continue this process until the cataract surgery is completed.
224097954|NCT07108192|OTHER|Control Group|Patients who did not receive any intervention other than standard treatment and care during cataract surgery were defined as the control group.
223936069|NCT02008669|OTHER|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
223936070|NCT02008669|OTHER|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~* Fatigue (EMIF-SEP)~* Dysphagia (DYMUS)~* Food intake (semi-structured questionnaire)~* Depression (BDI-II)~* Daily energy expenditure (NAP)~* Visual analog scale to study quality of sleep"
223936071|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 50 mg
223936072|NCT05948059|DRUG|SHR-2106 injection or placebo|starting dose from 300 mg
224097955|NCT06911983|DRUG|Metformin|Metformin • Initial dose: 500 mg twice daily • Titration: increased to 1,000 mg twice daily by Week 2 if tolerated • Maximal dose: 2,000 mg/day
223936073|NCT00131209|DIETARY_SUPPLEMENT|fortified spread (RUTF)|
223936074|NCT00131209|DIETARY_SUPPLEMENT|maize and soy flour|
223936075|NCT03746938|DEVICE|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
223936076|NCT01182649|DEVICE|coronary stent|coronary angioplasty with stent implantation
223936077|NCT01182649|DEVICE|stent|coronary angioplasty with stent implantation
223936078|NCT05782699|DEVICE|BP monitoring during tilt testing|BP measure at various times during tilt testing
223936079|NCT03794219|OTHER|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
223936080|NCT03794219|DRUG|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
223936081|NCT00002281|DRUG|Filgrastim|
223936082|NCT00002281|DRUG|Epoetin alfa|
223936083|NCT00002281|DRUG|Zidovudine|
223936084|NCT00942266|DRUG|fluorouracil|Given IV
223936085|NCT00942266|DRUG|leucovorin calcium|Given IV
223936086|NCT00942266|DRUG|vorinostat|Given orally
224097956|NCT06911983|DIETARY_SUPPLEMENT|Berberine|"Berberine~* Dose: 500 mg three times daily (1,500 mg/day total)~* Formulation: standardized berberine HCl tablets~* Duration: 12 weeks"
224097957|NCT07107399|OTHER|microfragmented adipose tissue|"Receive micro fragmented adipose tissue obtained from the buccal pad of fat after arthrocentessis.~* Direct access to the buccal fat pad, is found at distobuccal depth of the maxillary tuberosity.~* It may be dissected during the resection an upper mucosal incision posterior to the second molar~* After a single scissor stab through the periosteum the (BFP)extrude into the operative site.~* Closure of the flap by suitable suture.~* Collection of lipids then manually manipulated with two syringes connecting together and pushing the lipids against each other to receive the injectable amount of micro fragmented adipose tissue .~* Ready for TMJ injection."
224286178|NCT06227117|DRUG|Toripalimab （12weeks）|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, A total of 2 cycles (12 weeks) of treatment are performed.
224286179|NCT03893734|DRUG|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
224286180|NCT03893734|DRUG|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
224286181|NCT00103038|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
223936087|NCT00942266|OTHER|pharmacological study|Correlative study
224286182|NCT00103038|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
223936088|NCT02506452|OTHER|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
223936089|NCT02506452|OTHER|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
223936090|NCT04567459|DIETARY_SUPPLEMENT|Premium Amino Acids|after Chemotherapy ang surgery one pack of Premium Amino Acids in the morning and evening
223936091|NCT06274060|BEHAVIORAL|Case management|Participants will receive case management delivered by a peer with PrEP experience/success for seven months, with the goal of improving self-efficacy to take PrEP. The intention of this intervention is to help participants to develop individualized strategies to address and overcome barriers to PrEP use, as well as develop disclosure strategies. This strategy includes weekly face-to-face support with the case manager for the first month of the trial, followed by monthly face-to-face support for the remainder of the trial follow up period. The strategy will also include client-initiated on-demand phone consultation with the case manager and mental health/substance use screening and referrals. Participants randomized to this strategy may also opt into daily timed PrEP pill-taking reminders via short message service (SMS).
223936092|NCT06274060|BEHAVIORAL|Food vouchers|Participants will be given food vouchers with a value of 200 South African Rand at the time of PrEP initiation and at 1- and 4-month standard of care visits at which clinical checkups and PrEP refills are provided. The goal of these vouchers is to improve participants' capacity to persist on PrEP. While PrEP can be taken without food, some experience increased side effects or prefer to take pills with food, making adherence difficult if they cannot afford food at times.
224286183|NCT00103038|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
224286184|NCT00103038|DRUG|Ferumoxytol|Given IV
224286185|NCT00103038|DRUG|Gadolinium|Given IV
223936093|NCT06274060|BEHAVIORAL|PrEP support buddy|Participants will identify a person in their network (such as a friend, partner, parent) that they wish to support them in their PrEP usage, with the goal of improving participants' motivation and self-efficacy to persist on PrEP and providing social support to facilitate ongoing PrEP use. Support buddies selected by FSW and AGYW randomized to this intervention will receive a one-time training session on PrEP and support strategies as well as informational materials and text reminders to assist them in providing ongoing PrEP support.
223936094|NCT06274060|BEHAVIORAL|Community-based PrEP pickup points|Participants will be able to pick up PrEP from alternative pick-up points within the community that are convenient for them, with the goal of making PrEP more accessible to participants. Ten pickup points will be established at existing Hubs of Hope throughout the subdistricts served by the TB HIV Care programme. Hubs of Hope are based in the War Rooms within subdistricts, where the TB HIV Care programme operates, and serve as meeting places for service users to receive support searching for jobs, completing online courses, and other personal development activities to support a multi-sectoral approach to health. A TB HIV Care ambassador is based at each Hub of Hope to coordinate activities and provide support to service users. Participants who choose to use pick-up points will have the option of either completing an HIV self-test or testing with the on-site TB HIV Care staff to confirm HIV-negative status prior to receipt of PrEP refills.
223936095|NCT03068988|BIOLOGICAL|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
223936096|NCT03068988|PROCEDURE|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
223936097|NCT00584675|DEVICE|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
223936098|NCT02979184|OTHER|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
223936099|NCT02139436|OTHER|FES-row-training|
223936100|NCT02139436|OTHER|Arms-only-row training|
223936101|NCT02139436|OTHER|Time Control|
223936102|NCT02550951|PROCEDURE|lymphangiography|
223936103|NCT00257881|DRUG|CMD-193|
223936104|NCT05162560|OTHER|patients with acute diverticulitis|registry and hospital charts of patients with acute diverticulitis
223936105|NCT00317395|DRUG|Otamixaban (XRP0673)|intravenous administration
223936106|NCT00317395|DRUG|unfractionated heparin|intravenous administration
223936107|NCT00317395|DRUG|eptifibatide|intravenous administration
224097958|NCT07107399|OTHER|platelet-rich plasma|I - double-puncture arthrocentesis technique was followed, and 300 mL of Ringer's lactate solution was used to irrigate the joint space through the marked points . After arthrocentesis PRP was prepared from 5 mL of autologous venous blood sample taken from the antecubital vein. The collected blood was then transferred to a test tube containing 0.5 mL of sodium citrate (anticoagulant) (0.5 mL) and was centrifuged at a rate of 2100 rpm for 15 min. The plasma from the first harvest was fractionated by centrifugation at 3500 rpm for 10 min to prepare PRP.
224097959|NCT07106411|DIAGNOSTIC_TEST|Endoscopic Ultrasound|Conventional EUS will be performed to evaluate lesion size, echogenicity, border, and layer of origin for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
224286186|NCT00103038|PROCEDURE|MRI-Based Angiogram|Undergo MRA
224286187|NCT03301103|BIOLOGICAL|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
223936108|NCT01697891|DEVICE|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
223936109|NCT03317652|OTHER|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
223936110|NCT03317652|OTHER|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
223936111|NCT03317652|DRUG|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
223936112|NCT02230046|DRUG|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
223936113|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
224286188|NCT03301103|DEVICE|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
224286189|NCT03678779|BEHAVIORAL|Incentive|$5 grocery gift card
224286190|NCT03678779|BEHAVIORAL|Education|Video-based brief nutrition education
224286191|NCT03678779|BEHAVIORAL|Combined|Both Incentive and Education interventions received
224286192|NCT06177002|DIAGNOSTIC_TEST|Collection of biological data|Biological sample will be collected from the COVID19 patients and from healthy donors
224286193|NCT06012721|DRUG|ORIC-114|Food effect healthy subjects
224286194|NCT04036149|DEVICE|Intraocular lens|Implantation as part of cataract surgery
223936114|NCT02230046|DRUG|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
223936115|NCT03910738|DRUG|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
223936116|NCT03910738|DRUG|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
223534198|NCT07002866|BEHAVIORAL|PrEP Peer Supporters (PS)|PrEP peer supporter are women currently on PrEP willing to share their lived experiences. Women will meet with peer supporters in a group at least 8 times during the intervention period (every 2-3 months). Sessions with peers will involve unstructured, in-depth discussions that integrate peers' own lived experiences and emerging PrEP-related issues as raised by participants. These may include, how to mitigate PrEP stigma and disclosure, creating PrEP adherence strategies, navigating family and intimate relationship issues, and navigating provider attitudes. At each stage of the facility visit (waiting space, consultation, and pharmacy), peer supporters will explain facility protocols, and strategies women can use to overcome facility-level barriers to care.
223534199|NCT07002866|BEHAVIORAL|Matched Savings Accounts + Financial Literacy (FL)|A matched savings account (MSA) is a savings account held at a local bank whereby deposits made by the participants are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce participants to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each participant will receive an account held in her own name, and will be allowed to save an equivalent of US$10 a month or US$200 for the 20-months intervention period. During the intervention period, participants will have direct access to both their personal savings deposited in the accounts and the match provided by the study. In addition, participants will also receive six 1-2-hour financial literacy (FL) workshop sessions that cover components on saving, and financial management.
223718632|NCT06294145|BEHAVIORAL|Savoring Intervention|The savoring intervention is the first module of the Positive Affect Treatment (PAT) developed by Michelle Craske and colleagues to treat anhedonia, or loss of interest or pleasure in usual activities. The investigators focus here on the behavioral activation and savoring components of the intervention, which are administered first and are considered the basis for other components. Of note, a variety of other positive psychology interventions include a savoring component, but PAT is unique in its inclusion of six sessions devoted to savoring. These sessions involve pleasant events scheduling in which participants: 1) plan activities that generate anticipation of reward, 2) engage in activities that generate reward and 3) practice therapist-guided-in-the-moment recounting of positive emotions, sensations, and thoughts generated by these activities. The investigators will additionally include an introductory psychoeducation session before the savoring module, as PAT does.
223718633|NCT03222960|DRUG|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
223718634|NCT03222960|DRUG|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
223718635|NCT03636984|DRUG|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
223718636|NCT06047483|DRUG|HRF2105 patch|HRF2105 patch ，external use，once a day
223936117|NCT03910738|PROCEDURE|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
223936118|NCT03910738|BEHAVIORAL|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
223936119|NCT03910738|BEHAVIORAL|Assessment of disability|EDSS (Baseline, week 30 and 66)
223936120|NCT00756574|DEVICE|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
223936121|NCT00756574|DEVICE|N95 mask|N95 mask worn for patients with febrile respiratory illness
223936122|NCT04845321|DRUG|VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
223936123|NCT04845321|DRUG|Placebo for VNRX-9945|Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
223936124|NCT03605901|DRUG|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
223936125|NCT03605901|DRUG|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 5-10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
223936126|NCT05777200|BEHAVIORAL|Supportive psychotherapy|Counselling patients, providing supportive psychotherapy to help them detox their illicit drug usage, and help them rehabilitate again into society.
223936127|NCT05517655|DRUG|129Xe|Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
223936128|NCT05263830|OTHER|Quantitative assay of GlypicanPC-3|Quantitative assay of GlypicanPC-3 in human serum is performed by direct sandwich immunoassay ( CanAg Glypican3 EIA - Fujirebio ) on microplate using two mouse monoclonal antibodies against two epitopes of the Glypican-3 core protein
223936129|NCT05384223|BEHAVIORAL|RRFT (Risk Reduction through Family Therapy)|RRFT is an adaptation and integration of existing empirically-supported interventions with similar theoretical rationales targeting similar populations, particularly Multisystemic Therapy principles (MST)for adolescent SUP and Trauma Focused-Cognitive Behavioral Therapy (TF-CBT) components for PTSD in youth. RRFT consists of seven primary components: Psychoeducation and Engagement, Coping, Family Communication, Substance Use, PTSD, Healthy Dating and Sexual Decision-Making, and Revictimization Risk Reduction.
223936130|NCT05384223|BEHAVIORAL|ENCOMPASS (Integrated Treatment for Adolescents and Young Adults)|Encompass is currently a research to practice treatment for adolescents with co-occurring substance use disorders and mental health problems and is used as the standard treatment in the target study settings.
223936131|NCT04524247|DEVICE|Physician Modified Endografts|"Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs"
223936132|NCT04326140|DEVICE|mirror therapy|The affected side wears the machine, assists by the machine, and performs the same action with the good hand. According to the posture condition, selects two suitable actions in the three actions (all fingers open, all fingers close, all fingers open and close). The action is 10 minutes each.
224286195|NCT01218984|DRUG|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
224286196|NCT01218984|DRUG|Medisorb naltrexone 150 mg|Single administration via IM injection.
224286197|NCT01218984|DRUG|Medisorb naltrexone 300 mg|Single administration via IM injection.
223936133|NCT04326140|DEVICE|robotic-assisted training|The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
223936134|NCT04326140|DEVICE|sham mirror therapy|The mirror was masked. The intervention was the same as the mirror therapy.
223936135|NCT03660618|DEVICE|laser speckle flowgraphy|blood flow state of the skin as real time two dimensional image
223936136|NCT04415307|OTHER|Acupuncture|Acupuncture over acupoints.
223936137|NCT04415307|OTHER|Far-Infrared heat-patch attachment|Far-Infrared heat-patch attachment over acupoints.
223936138|NCT04415307|OTHER|Acupuncture and Fir-Infrared heat-patch attachment|Acupuncture and Far-Infrared heat-patch attachment over acupoints.
223936139|NCT04415307|OTHER|Far-Infrared heat-patch attachment over acupoints without electric current passing.|Far-Infrared heat-patch attachment over acupoints without electric current passing.
223936140|NCT04010136|OTHER|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
223936141|NCT04231279|DRUG|synthetic human secretin|Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
223936142|NCT06163391|DRUG|SOT201|intravenous infusion
223936143|NCT04197648|DEVICE|Exercise group|24 week supervised exercise program (strength and cardiovascular program).
223936144|NCT04857983|DRUG|Memantine|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
223936145|NCT04857983|DRUG|Placebo|Subjects will be assigned to take memantine or placebo and will complete 30 hours of targeted cognitive training in order to assess whether memantine enhances cognitive training performance
223936146|NCT04958317|OTHER|Early exercise|Participants will exercise for 30 minutes prior to an evening meal.
223936147|NCT04958317|OTHER|Late exercise|Participants will exercise for 30 minutes after an evening meal.
223936148|NCT02440672|DEVICE|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
223936149|NCT04210037|DRUG|APG-1252|APG-1252 (Ascentage Pharma) is a highly potent Bcl-2 family protein inhibitor with high binding affinity for Bcl-2, Bcl-xL and Bcl-w. APG-1252 possesses strong antitumor activity as a single-agent against tumor cells addicted to Bcl-2/Bcl-xL, and exhibits a much broader antitumor activity when combined with chemotherapeutic agents.
223936150|NCT04210037|DRUG|Paclitaxel|80 mg/m˄2 on days 1 and 8 of a 21-day cycle
223936151|NCT03699410|RADIATION|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
223936152|NCT03699410|DRUG|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
223936153|NCT03699410|PROCEDURE|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
224286198|NCT01218984|DRUG|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
223534200|NCT07004166|OTHER|Z-track method|Z-track method, the skin will be pulled laterally by 2.5-3.5 cm before needle insertion at a 90-degree angle. After aspiration and injection, the needle will be withdrawn and the skin released immediately.
223718637|NCT06047483|DRUG|Loxoprofen patch|Loxoprofen patch ，external use，once a day
223718638|NCT06047483|DRUG|placebo|placebo ，external use，once a day
223936154|NCT04200287|BEHAVIORAL|Online decision aid tool|The decision aid intervention will be presented via a website
223936155|NCT01297894|DRUG|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
223936156|NCT01297894|DRUG|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
223936157|NCT04453332|DRUG|Oral hormone therapy (estradiol and micronized natural progesterone)|Oral hormone therapy - estradiol 1mg every day and micronized natural progesterone 200mg only 14 days a month
223936158|NCT04453332|DRUG|Non-oral hormone therapy (estradiol and micronized natural progesterone)|Percutaneous estradiol gel 1.5mg every day and micronized progesterone 200mg vaginal only 14 days a month
223936159|NCT00918203|BIOLOGICAL|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
223936160|NCT00918203|DRUG|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
223936161|NCT00918203|DRUG|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
223936162|NCT01084941|BEHAVIORAL|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
223936163|NCT01084941|BEHAVIORAL|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
223534201|NCT07004166|OTHER|TPR method|TPR method, while the needle is inserted at a 90-degree angle, deep pressure will be applied to the muscle, then rapidly released to create a snapping motion that facilitates the injection. This technique relies on rapid muscle relaxation rather than needle movement by the dominant hand.
223534202|NCT07003048|BEHAVIORAL|Singing, dancing in small groups and active listening to live music at the Berlin Philharmony building|"Pregnant women are invited from 12 gestational weeks onwards to participate in active and passive interventions following a protocol derived from our feasibility study. The following interventions take place:~LIVE GROUP~1. concerts customized for pregnant women by professionals. They talk before and in between the concerts about the meaning of the music with the study attendants. The sessions take around one hour.~2. workshops in singing led by professional coaches performed in small groups within the Philharmonic building involving pregnant women to actively learn melodies of songs which they can repeat at home on a daily basis.~3. workshops in dancing led by professional coaches performed in small groups within the Philharmonic building involving pregnant women to actively learn to move with music which they can repeat at home on a daily basis.~DIGITAL GROUP The described interventions are all digitalized with interviews encouraging the second group to participate from home."
223936164|NCT02788019|DRUG|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
223936165|NCT06132594|PROCEDURE|Conventional arthrocentesis followed by I-PRF injection|An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.
223936166|NCT06132594|PROCEDURE|3d surgical guided Arthrocentesis followed by I-PRF injection|Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
223936167|NCT06137898|BIOLOGICAL|biological check-up|Blood sampling
223936168|NCT04694014|BEHAVIORAL|EI Open ended Pre-Survey and Semi Structured Interview|Provide Interview questions via online survey with informed consent to the participants then contact a 60 minute member checking interview in person or virtually via recorded Zoom sessions for each participant
223936169|NCT04694014|BEHAVIORAL|Behavioral and Cognitive Assessment|Use Predictive index for both cognitive and behavioral assessment of the paticipants
224097960|NCT07106411|DIAGNOSTIC_TEST|Contrast-Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS)|CEH-EUS will be conducted using a contrast agent to assess vascularity and enhancement patterns of the lesion for differentiation between GISTs and leiomyomas and risk stratification of GISTs.
224097961|NCT07106606|BEHAVIORAL|Mandala coloring activity|This technique is a creative art-based relaxation method that aims to reduce children's anxiety and fear levels. The application was carried out to make children feel psychologically safer and calmer before the examination. The selected mandala forms were created in accordance with the attention span, motor skill capacity and visual perception development of children between the ages of 9 and 12 by choosing simple but symbolic structures with moderate level of detail.
223534203|NCT07003958|OTHER|application of deproteinization agents|Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.
223718639|NCT03739593|DRUG|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
223718640|NCT03739593|DRUG|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
223718641|NCT03210571|DEVICE|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
223936170|NCT04694014|BEHAVIORAL|Geneva Emotional Competence Test (GECO)|Administer the Geneva Emotional Competence Test to each participant
223936171|NCT04979715|PROCEDURE|physitherapy follow-up|preoperative patient informaiton, information leaflet and Physiotherapy meeting will be held every 2 weeks for 3 months
223936172|NCT04979715|OTHER|control|no intervention; preoperative patient informaiton and information leaflet
223936173|NCT05225376|OTHER|Physical activity sessions for pregnant women|"The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level."
224097962|NCT07106697|BEHAVIORAL|First Aid Training Combined With Video-Assisted Guidance|Participants received a 45-minute structured first aid training session on unconscious victim management, followed by a 15-minute video-guidance instruction. During simulation, children received real-time video guidance from a dispatcher via smartphone.
223718642|NCT00109083|DRUG|RWJ-333369|
223718643|NCT02759783|RADIATION|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
223718644|NCT02759783|OTHER|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
223718645|NCT06065943|OTHER|Palpation and Fluoroscopy|Vessel puncture guided palpation and fluoroscopy only
223718646|NCT06065943|PROCEDURE|Ultrasound guidance|Vessel puncture guided by Ultrasound
223936174|NCT03273894|DIAGNOSTIC_TEST|Coagulation testing|"* body temperature before the intervention~* body temperature during the intervention including the way of measuring, each 15 minutes~* body temperature at the end of surgery, signs of the patient's heat discomfort~* body temperature during resting time in the postanesthesia care~* standard coagulation tests + EXTEM, FIBTEM - after anesthesia induction~* blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM.~* if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
224286199|NCT01218984|DRUG|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
224286200|NCT03476317|DRUG|Vancomycin|Oral suspension 4 times daily (Day 1-14)
223534204|NCT07005024|DRUG|Apixaban 2.5 mg twice daily|Apixaban, a direct oral anticoagulant (DOAC), will be administered at a prophylactic dose of 2.5 mg by mouth twice daily for 6 months. This dose is guideline-recommended for VTE prevention in high-risk ambulatory cancer patients. Participants will continue their cancer-directed therapy during this time. No study-mandated visits or labs are required beyond standard care.
223534205|NCT07005024|DRUG|Apixaban 5 mg once daily|Apixaban will be administered at 5 mg by mouth once daily for 6 months. This alternative prophylactic schedule is being studied to assess its effectiveness and adherence in patients with a Khorana Risk Score of 2. Participants will continue their usual cancer treatment. This arm evaluates a simplified dosing strategy in a real-world, pragmatic design.
223534206|NCT07005024|DRUG|No anticoagulation|Participants randomized to this arm will not receive apixaban or any other anticoagulant for VTE prevention. This reflects current standard care for many cancer outpatients with moderate risk (Khorana Score = 2). Outcomes will be monitored through routine care and medical record abstraction.
223936175|NCT02859844|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS)|
223936176|NCT06813027|BIOLOGICAL|EV|"Extracellular secretomes ( extracellular vesicles EV) derived from mesenchymal stroma cells (MSCs)"
223936177|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
223936178|NCT00258830|BIOLOGICAL|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
223936179|NCT03488719|DRUG|Metoprolol Succinate 25 MG|A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
223936180|NCT03488719|DRUG|Metoprolol Succinate 50 MG|A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
223936181|NCT03488719|DRUG|Metoprolol Succinate 100 MG|A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.
223936182|NCT06842537|DRUG|SYH2062 injection|SYH2062 for sc injection
223936183|NCT06842537|DRUG|SYH2062-Matching placebo|Normal saline matching volume of SYH2062 doses will be administered
223936184|NCT06598553|BEHAVIORAL|Projet Jeune Leader Comprehensive Sexual Education|PJL provides trained educators to deliver a 22 week comprehensive sexual education (CSE) curriculum in participating middle schools. All adolescents enrolled in the school receive the CSE program.
223936185|NCT06978296|RADIATION|Stereotactic body radiotherapy (SBRT)|"The acceptable regimens are:~* 27 Gy / 3 fractions / 3 fractions per week~* 35 Gy / 5 fractions / 3 fractions per week An interval of at least 24 hours should be kept between two consecutive fractions.~Prescription must be defined on 80% isodose or higher, maximum dose up to 130% of the isodose prescription. At least 90% of the Planning Target Volume should receive the prescribed dose. A coverage of \<90% of the Planning Target Volume will be considered as acceptable deviation, and coverage of \<80% of the target volume as an Unacceptable Deviation. At least 90% of the Gross Tumoral Volume should receive the prescribed dose.~Only a part of the Gross Tumoral Volume\_Total could be considered for radiation, depending on the ratio with Bone Marrow Reserve. High-risk and/or symptomatic metastases will be prioritized over other metastases.~Anatomic bone marrow reserve (BMR) will be first determined for each patient:~BMR = Total trabecular bone - (Total trabecular bone ∩ GTV\_Total)"
223936186|NCT04321603|BEHAVIORAL|Walking|Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
223936187|NCT01939288|DEVICE|Neuromuscular stimulation, followed by intermittent pneumatic compression|
223936188|NCT01939288|DEVICE|Intermittent pneumatic compression, followed by neuromuscular stimulation|
223936189|NCT05567497|PROCEDURE|trigeminal nerve block|ultrasound guided trigeminal nerve block
223936190|NCT06824155|DRUG|177Lu-RAD202|177Lu-RAD202 administered at Imaging (im) and Treatment (tr) doses
223936191|NCT06952218|PROCEDURE|Injection of cross linked hyaluronic acid filler|Injection of cross linked hyaluronic acid filler
224286201|NCT03476317|DRUG|Neomycin|Oral three times daily (Days 1-3)
224286202|NCT03476317|DRUG|Ciprofloxacin|Oral twice daily (Days 4-14)
224286203|NCT03476317|DRUG|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
224286204|NCT03476317|DRUG|Fluconazole|Orally once daily (Day 1-14)
224286205|NCT02772952|OTHER|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
224286206|NCT02772952|OTHER|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
223936192|NCT00585156|DRUG|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
224097963|NCT07106697|BEHAVIORAL|Video-Assisted Guidance Without Prior Training|Participants received a 15-minute instruction on video-assisted guidance use, without prior first aid training. During simulation, real-time video guidance was provided by a dispatcher via smartphone to assist with first aid tasks.
223936193|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
223936194|NCT01118754|DRUG|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
223936195|NCT01118754|DRUG|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
223936196|NCT06590064|DEVICE|Non-invasive Blood Pressure Measurement|Non-invasive Blood Pressure Measurement in Both Upper and Lower Limbs
223936197|NCT06861335|OTHER|Exercise|For each participant included in the exercise group, an individualized pelvic floor muscle exercise program will be created based on the results of digital palpation and the PERFECT assessment system. The first exercise session will be conducted with the physiotherapist, and the participant will be provided with a home-based program. During pregnancy check-ups, the pelvic floor muscles will be re-evaluated, and the exercise program will be updated according to the new evaluation results. To monitor the home-based program, participants will be given an exercise tracking chart that they will be asked to fill out daily
223936198|NCT06861335|BEHAVIORAL|Control|Participants in the control group of our study will receive standard pregnancy care and check-ups. Within this scope, the general health status of the pregnant women will be evaluated during routine antenatal follow-up visits, check-ups appropriate to their gestational weeks will be performed, and necessary medical interventions will be carried out. Additionally, participants will receive detailed education about pelvic floor anatomy, the functions of the pelvic floor muscles, and the changes that occur in these muscles during pregnancy. Within the scope of general health education, information will be provided about nutrition, hygiene, exercise, and other lifestyle recommendations during pregnancy. The participants in the control group will not be given the specific pelvic floor muscle training program applied in the experimental arm of the study; they will only receive standard pregnancy care and general information
223936199|NCT06416839|BEHAVIORAL|VR exercise|Participation in high intensity interval training delivered on a virtual reality headset over six-week period. Participants may exercise with others in the multiplayer mode and use any feature of the application.
223936200|NCT03534726|DEVICE|7 T CMR|7 tesla MRI device
223936201|NCT06677710|DRUG|IDP-023|NK cell therapy
223936202|NCT06677710|DRUG|Ocrelizumab|Anti-CD20 antibody therapy
223936203|NCT06677710|DRUG|Interleukin-2|Immune cytokine
223936204|NCT06677710|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223936205|NCT06677710|DRUG|Fludarabine|Lymphodepleting chemotherapy
224097964|NCT07107750|DRUG|CA-4948|Provided by Curis.
223534207|NCT07004933|DRUG|bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)|Rapid antiretroviral treatment initiation with BIC/FTC/TAF
223534208|NCT07002944|OTHER|Brachial plexus pulsed radiofrequency|Patients will receive pulsed radiofrequency of brachial plexus with steroids injection.
223936206|NCT06677710|DRUG|Mesna|Chemoprotectant
223936207|NCT05677451|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
223936208|NCT05677451|DRUG|placebo|matching active drug
223936209|NCT06699459|DRUG|Irinotecan Liposome|②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
223936210|NCT06699459|DRUG|Capecitabine|① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
223936211|NCT06714552|DIETARY_SUPPLEMENT|Galacto-Oligosaccharide|24.0 g Oligomate® in 100 mL water
223936212|NCT06714552|OTHER|Glucose|17.8 g glucose in 100 mL water
224097965|NCT07107750|DRUG|Gemcitabine|Standard of care.
224097966|NCT07107750|DRUG|Cisplatin|Standard of care.
224097967|NCT07107750|BIOLOGICAL|Durvalumab|Standard of care.
224097968|NCT06930105|DRUG|Blinatumomab plus Reduced-dose Chemotherapy|"Newly diagnosed Philadelphia chromosome-negative acute B-cell lymphoblastic leukemia (Ph-negative B-ALL) patients aged 18-60 years were enrolled.~Treatment Protocol~1. Low-intensity chemotherapy (VIP regimen)~   * V (Vincristine): 1.4 mg/m² (max 2 mg) on days 1 and 8.~  * I (Idarubicin): 8 mg/m²/day on days 1 and 8.~  * P (Prednisone): 60 mg/m²/day (max 100 mg/day) or equivalent dexamethasone dose on days 1-14.~2. Sequential induction therapy:~   * Blinatumomab administered for 2 weeks following the VIP regimen.~3. Consolidation therapy for morphological complete remission (CR)~   * Patients achieving CR receive two cycles of consolidation chemotherapy:~  * Cycle 1: VDCP regimen (Vincristine, Daunorubicin, Cyclophosphamide, Prednisone).~  * Cycle 2: VP + HD-MTX regimen (Vincristine, Prednisone + High-Dose Methotrexate).~4. Allogeneic hematopoietic stem cell transplantation (allo-HSCT):~   * Patients with multiparameter flow cytometry-confirmed minimal res"
224097969|NCT06936852|PROCEDURE|Serratus posterior superior intercostal plane block|Under complete aseptic technique, a high frequency linear probe will be placed adjacent to upper medial part of scapula to visualize the second and third ribs. The needle will be introduced with in plane approach, from caudal to cranial and 30 ml of 0.25% bupivacaine will be injected in the fascial plane between serratus posterior superior and intercostal muscles at the level of second and third ribs.
224286207|NCT03184259|DEVICE|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
224286208|NCT03184259|DEVICE|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
223936213|NCT06714461|DRUG|Leflunomide|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
223936214|NCT06444451|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
223936215|NCT06444451|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: SC injection
224286209|NCT02795637|DRUG|dasotraline|dasotraline 8mg capsule/day
223936216|NCT07043543|RADIATION|Adaptive radiotherapy|"Patient will be treated by concomitant:~* adaptive radiotherapy 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB).~* chemotherapy if not contraindicated :~  * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or~ * Gemcitabine: 80 to 100 mg/m2/week Or~ * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)"
224286210|NCT02334111|BEHAVIORAL|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
224286211|NCT03649412|DRUG|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
223936217|NCT07043543|RADIATION|standard radiotherapy|"Patient will be treated by concomitant:~* standard 5 days a week for 4 weeks with hypofractionated irradiation 55 Gy / 20 fractions +/- pelvic inclusion 44 Gy/20 fractions (SIB).~* chemotherapy if not contraindicated :~  * Cisplatin : 20 mg/m2/day on day 1 to day 4 and day 22 to day 25 (or 80 mg/m2 during week 1 and 4 of radiotherapy) Or~ * Gemcitabine: 80 to 100 mg/m2/week Or~ * Mitomycin C: 12 mg/m2 on day 1 only + 5FU infusion 500 mg/m2/day during 5 days on week 1 and 4 of radiotherapy (alternatively : capecitabine taken twice daily at a dose of 825 per square meter per day on the days of radiotherapy)"
223936218|NCT07043764|OTHER|Caring Contacts Text Messages|Caring Contacts are brief, hopeful, supportive text messages.
223936219|NCT07043842|OTHER|Shoulder circumference exercises|They are strengthening and stretching exercises that support the range of motion of the shoulder joint.
223936220|NCT07043842|OTHER|Scapular stabilization exercises|Changes in the biomechanics of the scapula affect the function of the shoulder. Biomechanical correction will be attempted with these exercises aimed at correcting the posture of the scapula.
223936221|NCT07043842|OTHER|Thoracic mobility exercises|Changes in the biomechanics of the thoracic spine affect the function of the shoulder. Biomechanical correction will be attempted with these exercises aimed at correcting the posture of the thoracic spine.
223936222|NCT07044258|PROCEDURE|trans-tarsal stair-step lateral extension of the transconjunctival approach|patients presented with oribto-zygomaticomaxillary complex fractures that requires open reduction and internal fixation via trans-tarsal stair-step lateral extension of the transconjunctival approach
223936223|NCT07044258|PROCEDURE|transconjunctival approach|patients presented with oribto-zygomaticomaxillary complex fractures that requires open reduction and internal fixation via trans-tarsal stair-step lateral extension of the transconjunctival approach
223936224|NCT07043634|COMBINATION_PRODUCT|FDC (24 mg ER torsemide and 30 mg Spironolactone) without food|FDC without food
223936225|NCT07043634|COMBINATION_PRODUCT|FDC (24 mg ER torsemide and 30 mg Spironolactone) with food|FDC with food
223936226|NCT07042789|OTHER|Material source: AI generated ads vs existing ads by health agency|Each participant evaluated 50 ads in random order, of which 25 were AI-generated through youth co-design process, and 25 were existing ads from official health agencies.
223936227|NCT07042789|OTHER|source labelling conditions: control condition, AI condition, health agency condition, combined condition|"Participants were randomly assigned to one of four source labelling conditions: (1) Control (ads presented without any source labelling), (2) AI condition (ads labelled with the text Made with AI), (3) Health agency condition (ads labelled with the text Made by the World Health Organization (WHO)), and (4) Combined condition (ads labelled with the text Made with AI, by the World Health Organization (WHO))."
223936228|NCT06925620|OTHER|Multimodal Information Technology-based Hand Hygiene Strategies|The intervention, adapted from the WHO's multimodal strategy, incorporated IT-based components to enhance hand hygiene compliance. A one-time, 1-hour online education session via Google Meet covered the WHO's Five Moments and seven-step handwashing technique, with real-time feedback using fluorescent dye and UV light. Post-session videos were available on tablets for review. Visual reminders, such as screensavers and digital posters, reinforced learning. Smart sanitizer dispensers with seven-step lights and a 20-second countdown were installed at five key sites, RFID-linked to staff badges for automatic tracking. Monthly performance data were shared via bulletin boards and LINE, with SMS feedback to top and bottom performers. Daily audio reminders played at 9 a.m. and 5 p.m., and high performers were recognized in monthly meetings.
223936229|NCT06922526|DEVICE|Pacemaker implantation|Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing
223936230|NCT06892691|PROCEDURE|Pleuroscopy first|Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis.
223534209|NCT07002944|OTHER|Sholder individual nerves pulsed radiofrequency|Patients will receive shoulder individual nerves pulsed radiofrequency with steroids injection.
223534210|NCT07002944|OTHER|Control|Patients will receive conservative treatment (paracetamol 1000 tid and pregabalin 75 mg bid; can be increased to 150 mg bid , oxycodone 10 mg oral every 12 hrs .
223936231|NCT06892691|PROCEDURE|Thoracentesis first|Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis.
223936232|NCT06741293|OTHER|No intervention: observational study|No intervention: observational study
223936233|NCT06763848|DEVICE|Protein A immunoadsorption|The experimental group was treated with a combination of protein A immunoadsorption and intravenous methylprednisolone. The methylprednisolone was administered following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day. Protein A immunoadsorption was conducted every other day, unless a physician determined that the patient's condition was unsuitable for treatment, in which case treatment was administered according to medical advice. A total of 5 treatments were given, with each session involving the regeneration of plasma at 1 to 3 times the plasma volume.
224286212|NCT03649412|DRUG|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
224286213|NCT04597398|DEVICE|Evaluation of blood flow with indocyanine green|
224286214|NCT04570397|DRUG|Ravulizumab|Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
224286215|NCT02865395|DRUG|Belladonna and Opium Suppository|
224286216|NCT02865395|PROCEDURE|Rectal Exam|
223534211|NCT07002840|OTHER|Cross- legged sitting position|CLS in which the legs were crossed with hip and knee joints flexed
223534212|NCT07002840|OTHER|Physical Therapy Rehabilitation Program|Strengthening Exercises Stretching Exercises Range of Motion Exercises
223534213|NCT07004101|OTHER|virtual reality|virtual reality and biodex training
223534214|NCT07004101|OTHER|biodex training|biodex training
223534215|NCT07004101|OTHER|conventional balance exercises|conventional balance exercises
223534216|NCT07003867|OTHER|Ventilator inspiratory trigger sensitivity adjustment , threshold device training|Ventilator inspiratory trigger sensitivity adjustment threshold device training
223936234|NCT06763848|DRUG|intravenous methylprednisolone|The control group was treated with intravenous methylprednisolone, following a regimen of 1g for 5 days, 0.5g for 3 days, 0.25g for 2 days, and 0.12g for 1 day.
223936235|NCT06778772|BEHAVIORAL|transition pathway to adult care services for epilepsy patients.|This proposal aims to create a coordinated and shared transition pathway between pediatric and adult epilepsy services, addressing the needs of patients with chronic conditions. The primary objective is to assess the readiness of both patients and their caregivers for the transition, by comparing the Transition Readiness Assessment (TRAQ) questionnaire results between the last pediatric neuropsychiatric visit and the first adult neurology visit. Secondary objectives include evaluating changes in emotional-behavioral issues and quality of life, using the CBCL, YSR, and PedsQoL questionnaires. Assessments will be conducted at both pediatric and adult epilepsy services. The ultimate goal of the transition protocol is to improve care and outcomes for adolescents and young adults during the transition, focusing on emotional-behavioral and psychosocial aspects, and to develop a best-practice model that could influence future guidelines.
223936236|NCT06775080|DRUG|propranolol (beta-blocker used treat high blood pressure)|Enrolled patients began receiving propranolol alone orally twice daily (10 mg bid) 10-14 days prior to surgery, and after 3 days of treatment, the dose of propranolol was increased to 20 mg bid daily until the day of surgery if the following three predefined criteria were met: systolic blood pressure greater than 90 mmHg, heart rate greater than 60 bpm, and no significant symptoms (e.g., syncope, insomnia, fatigue). The patient continues to be treated from 1 week after surgery.From 1 week after surgery, patients continue propranolol for 3 weeks. Patients will be monitored daily for symptoms, blood pressure, and heart rate and will be followed for observation at 6, 12, and 24 months after surgery until disease progression or clinical death, unless intolerable toxicity occurs and the patient refuses to continue treatment. The efficacy and safety of the preoperative propranolol β-blockade regimen in patients with gastrointestinal tract tumors was evaluated using the study objectives in S
224286217|NCT06531915|DRUG|Ciprofol|Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).
224286218|NCT06531915|DRUG|Remimazolam|Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).
224286219|NCT00292331|PROCEDURE|cyanoacrylate injection to treat gastric variceal hemorrhage|
224286220|NCT06679465|DRUG|Tiotropium (Spiriva®)|2 puffs tiotropium prior to allergen challenge
223534217|NCT07003646|PROCEDURE|Catheter directed intervention, any device|Catheter directed intervention for treatment of pulmonary embolism
224286221|NCT06679465|DRUG|Placebo|2 puffs placebo
224286222|NCT06535464|DEVICE|Hypotension Prediction Index|Fluid management guided by Hypotension Prediction Index
224286223|NCT06535464|DEVICE|No Hypotension Prediction Index|Fluid management not guided by Hypotension Prediction Index
224286224|NCT00635336|BIOLOGICAL|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
224286225|NCT01109017|DRUG|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
223534218|NCT07003646|DRUG|Alteplase|Systemic thrombolysis
223936237|NCT00972621|DEVICE|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
223936238|NCT00972621|DEVICE|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
223936239|NCT06838364|OTHER|Infrared peripheral venous technique|use a infrared device for venous peripheral visualisation and catheter insertion
223534219|NCT07002892|DRUG|Ozon treatment|Each patient will receive 2 ml 10 μg/ml ozon perineural injection into the median nerve under US guidance, for 1 session.
223936240|NCT06838364|OTHER|Ultrasound-guided peripheral venous technique|Use the ultrasound-guided technique for venous peripheral visualisation and catheter insertion
223936241|NCT06838364|OTHER|Landmark technique|the gold standard technique with observationnal and palpation
223936242|NCT03477175|DRUG|E7080|Oral Administration.
223936243|NCT03477175|DRUG|Comparator Drug|Per parent study.
223534220|NCT07002892|DRUG|Steroid treatment|Each patient will receive 2 ml:(1 ml betamethasone dipropionate+1ml saline) perineural injection into the median nerve under US guidance, for 1 session.
223936244|NCT03477175|DRUG|Comparator Drug: Sorafenib|Per parent study.
224097970|NCT06936852|PROCEDURE|PECS II block|. Under complete aseptic technique, a high frequency linear probe will be placed in the infraclavicular region, angulated and directed laterally towards the axilla to visualize the third and fourth ribs with pectoralis major, minor and serratus anterior muscles from superficial to deep. The needle will be introduced with in plane approach from medial to lateral, 10 ml of 0.25% bupivacaine will be injected in the fascial plane between pectoralis major and pectoralis minor then the needle will be further introduced to the fascial plane between pectoralis minor and serratus anterior muscles with injection of 20 ml of 0.25% bupivacaine.
223534221|NCT07002892|DRUG|Dextrose 5%|Each patient will receive 2 ml %5 dextrose perineural injection into the median nerve under US guidance, for 1 session.
224097971|NCT06935669|DRUG|Ketamine|Patients in this group will receive a transversalis fascia plane block using a combination of bupivacaine and ketamine.
224286226|NCT06077929|OTHER|No intervention done|No interventions done
224286227|NCT01692886|BIOLOGICAL|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
223534222|NCT07003880|DRUG|Methoxyflurane anesthesia|A single Penthrox (3mL) self-inhaler will be administered 5-minutes prior to the onset of the procedure, before local anesthesia. Patients will undergo the procedure, have post-procedural vital signs, and remain in clinic for observation for 30 minutes post-procedure per our usual post-procedure monitoring.
223534223|NCT07003568|DRUG|Dual-targeting BCMA-GPRC5D CAR-T cell infusion|Approximately 3-5 days prior to BCMA-GPRC5D CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
223534224|NCT07004517|DIAGNOSTIC_TEST|peri-implant probing before and after crown removal|"Before removal of the prosthetic reconstruction:~* Measurement of PPD-1: The PPDs at 6 site were measured as the distance from the mucosal margin to the base of the peri-implant pocket.~* Measurement of BOP-1：Bleeding sites after gentle probing within 15s were recorded as BOP scores. A positive score (1 point) was recorded if bleeding was observed during either of probing assessment by two researchers.~After removal of the prosthetic reconstruction, PPD-2 and BOP-2 were recorded following the same protocol."
223534225|NCT07003113|DEVICE|Ischemic Preconditioning|The intervention arm will include full blood flow occlusion in one thigh for 5 minutes followed by 5 minutes of reperfusion for a cycle of 50 minutes.
223534226|NCT07003113|DEVICE|Sham Intervention|This intervention includes 25mmHg of pressure, which is not sufficient for blodo flow occlusion.
223534227|NCT07004855|OTHER|30 hr Respite Service|Caregivers will be provided with 30 hours of respite service within 6 months. Trained substitute caregivers will provide in-home elderly-sitting service.
223936245|NCT06855485|DEVICE|HANAROSTEN® HOT Plumber™ with Z-EUSIT™|An electrocautery-enhanced lumen-apposing metal stent designed for the drainage of pancreatic pseudocysts. The stent is delivered using a system that allows for single-step deployment without the need for guidewire exchanges or tract dilation.
223936246|NCT06762314|DRUG|Insulin|Insulin is a naturally occurring hormone your pancreas makes that's essential for allowing your body to use sugar (glucose) for energy.
223936247|NCT06762314|DRUG|Semaglutide|Semaglutide is long acting glucagon like peptide which is parenterally administered as subcutaneous injection once weekly with a half-life of about 7 days
223936248|NCT06762314|DRUG|Empagliflozin|Empagliflozin lowers blood glucose levels by preventing glucose reabsorption in the kidneys, thereby increasing the amount of glucose excreted in the urine
223936249|NCT05771844|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
223936250|NCT06765967|OTHER|displaying virtual reality images|Patients were shown content filmed in 4K resolution through the glasses.
224097972|NCT06935669|DRUG|Bupivacaine|Control group to evaluate the additional effect of ketamine in the experimental arm.
224097973|NCT06935669|DRUG|Bupivacain|Patients in this group will receive a transversalis fascia plane block using a combination of bupivacaine and ketamine.
224097974|NCT06935123|DIETARY_SUPPLEMENT|Sleep Supplements|Sleep supplements
224097975|NCT06935123|OTHER|Placebo|Matching placebo
224097976|NCT06936839|OTHER|Obversation|Observing the optimal flow rate to reduce left ventricular stress and enhance peripheral organ perfusion during ramp tests (conducted at QECMO levels of 100%, 75%, 50%, and 25%, provided that SVO₂ remains \>55% and NIRS rSO₂ remains \>50%)
224286228|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
224286229|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
224097977|NCT06935786|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Single appointment with a registered physiotherapist educating the patient for rehabilitating physical training and exercise to be performed independently and regularly by the patient at home, minimum of three times a week, during the study period.
224097978|NCT06935448|OTHER|enhanced recovery after surgery|ERAS group follows the enhanced recovery after surgery program which involves 20 elements
224097979|NCT06935487|DIAGNOSTIC_TEST|transrectal ultrasound of prostate (TRUS) with AI software algorithm|Transrectal ultrasound of prostate (TRUS) with AI software algorithm for detection of lesions suspected for prostate cancer
224097980|NCT06935487|DIAGNOSTIC_TEST|MRI prostate|MRI for detection of lesions suspected for prostate cancer
223534228|NCT07004855|OTHER|Case follow-up|Case follow-up service provided by social workers. Social workers will call the caregiver regularly to see if situation changes.
223936251|NCT06765967|OTHER|music playback|With the permission of the Turkish Music Research and Promotion Group (TÜMATA), 'Acemaşiran Makamı' was played.
223936252|NCT06765369|OTHER|Mediterranean diet|The MD is characterized by increased consumption of legumes, whole grains, vegetables, fruits, nuts, seeds and olive oil, moderate consumption of fish, poultry and dairy foods, with low consumption of processed foods and red meat. The nutritional profile of the MD intervention will consist of 46% carbohydrates, 17% protein, and 35% fat. A significant focus on dietary fat consumption with maintaining an omega 6:3 ratio of approximately 3:1 or lower. The MD will provide fibre-rich foods to meet the fibre recommendations for Canadians (males: 30 grams/day, females: 21 grams/day)
223936253|NCT06765369|OTHER|Westernized Diet|The WD is characterized by increased consumption of highly processed foods, refined grains, red meats, processed meats, added sugars, added salt, high intake of omega-6 PUFA, accompanied by a reduction in fibre, fruits and vegetables, whole grains, fish, as well as nuts and seeds.The nutrition composition of the WD intervention will consist of 46% of calories derived from refined carbohydrates and added sugars, 17% protein (sourced from red and processed meats) and 35% fat. The fatty acid profile will be characterized by higher amounts of n-6 PUFAs while lacking in n-3 PUFAs and MUFAs, with a omega 6:3 ratio of 15-20:1.
223936254|NCT06769477|OTHER|Experimental Group|individuals will receive diabetes education with motivational interviewing technique based on health belief model
224097981|NCT06943898|OTHER|Core Egzercise|The core exercise group will perform core stabilization exercises for a total of 15 sessions, five days a week for three weeks. Exercises will include pelvic tilt, bridge, dead bug, bird dog, mini squats on a balance board, and wall planks. The number of repetitions will be increased from 10 to 20, and plank duration will be increased from 30 seconds to 45 seconds. A 5-minute warm-up and cool-down session will be included.
224097982|NCT06943898|OTHER|Core Exercises + Breathing Exercises|"This group will perform core stabilization exercises combined with the 360-degree breathing technique, for a total of 15 sessions over three weeks (five days a week).~360-degree breathing is a novel breathing method targeting deep and controlled inhalations into various regions of the body. Unlike traditional breathing exercises, 360-degree breathing ensures that all directions of the lungs are equally ventilated."
224097983|NCT04547582|DEVICE|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
224097984|NCT02770807|DRUG|EryDex Low dose DSP|EDS-EP dose range of \~5-10 mg DSP/infusion
224097985|NCT02770807|DRUG|EryDex High dose DSP|EDS-EP dose range of \~14-22 mg DSP/infusion
224097986|NCT02770807|DRUG|Pooled Placebo|EDS processed autologous erythrocytes using a sodium chloride \[NaCl\] solution.
224097987|NCT06947356|DRUG|TAF group|Pregnant women will start TAF treatment (25 mg tablet taken orally once daily) from 28 weeks of gestation until delivery. After that, they will be randomly assigned to two subgroups among postpartum mothers without treatment indications: one subgroup will stop treatment, while the other subgroup will continue with an additional 12 weeks of TAF treatment. The mothers and their infants will be followed up at 28 weeks postpartum. Infants will receive the hepatitis B vaccine and HBIG within 12 hours after birth, as well as booster doses of the hepatitis B vaccine at 4 weeks and 24 weeks.
224286230|NCT01692886|BIOLOGICAL|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
224286231|NCT05628441|OTHER|Computer Aided Detection system for Barrett's neoplasia|CADe system running in the back, not directly interfering with patient care
224286232|NCT02746419|DEVICE|Vessix|Renal denervation using radio-ablation
224286233|NCT01439724|DEVICE|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
224286234|NCT01439724|DEVICE|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
224286235|NCT01397955|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
224286236|NCT01767610|DRUG|micronized fenofibrate 160mg|
224286237|NCT01767610|DRUG|pitavastatin Ca 2mg|
224286238|NCT01767610|DRUG|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
224286239|NCT03319069|RADIATION|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
224286240|NCT03319069|RADIATION|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
224286241|NCT01997723|DEVICE|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
224286242|NCT01997723|OTHER|Polysomnography|One attended diagnostic sleep study.
223936255|NCT06769061|PROCEDURE|Acupuncture|Patients will receive 6 weeks of electroacupuncture, 2 sessions per week, 30 min per session Stainless steel, single-use, sterile, and disposable needles will be used. We will use the bilateral acupoints LI4 (He-Gu), TE5 (Wai-Guan), LI11 (Qu-Chi), and LU5 (Chi-Ze) for upper limbs. For lower limb numbness, we will use the bilateral acupoints of LV3 (Tai-Chong), ST41 (Jie-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan) for the numbness of back of feet, or the bilateral acupoints of KI1 (Yong-Quan), KI3 (Tai-Xi), SP6 (San-Yin-Jiao), and GB34 (Yang-Ling-Quan). After skin disinfection, sterile adhesive pads will be placed on bilateral LI4 (Hegu), TE5 (Waiguan), LI11 (Quchi), and LU5 (Chize). Following each needle insertion, acupuncturists will perform equal manipulations of twirling, lifting, and thrusting on the needle by acupuncturists to achieve the de qi sensation. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be electrically stimulated for 30 min.
223936256|NCT06769061|DEVICE|sham acupuncture|Patients will receive 6 weeks of sham acupuncture, 2 sessions per week, 30 min per session. The Streitberger sham acupuncture needle designed specifically for sham acupuncture trials will be used. Patients will feel the needle on the skin, but the needle actually will not puncture the skin. These 4 acupoints (He-Gu, Qu-Chi, San-Yin-Jiao, Yang-Ling-Quan) will be connected to the electrical stimulation device KWD-808I MULTI-PURPOSE Health device (Great Wall Company), but not stimulated. The needle will remain for 30 minutes. without stimulating the acupoints. The sham acupuncture will be used within the trocar. The trocar will be fixed by a base on the skin with sticker. The trocar-base-sticker will be used for both acupuncture group and sham acupuncture control group, so they are exactly the same in appearance. Patients cannot see if there is acupuncture or sham acupuncture within the trocar.
223936257|NCT06769451|RADIATION|Stereotactic Arrhythmia Radioablation (STAR) with Proton Therapy|STAR with a single dose of 25Gy(RBE) Proton Therapy
223936258|NCT06761430|DEVICE|ClearPlasma|ClearPlasmais an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasmaTM is a non-pyrogenic, sterile, single-use medical device.
223936259|NCT06649149|OTHER|Genially|In the study, an educational intervention will be prepared with the https://genially.com/ program, which is one of the interactive learning methods.
223936260|NCT06649149|OTHER|Education|In the study, a case study prepared for the management of an aggressive individual will be discussed in a classroom environment.
223936261|NCT05468320|DRUG|Caplacizumab|Lyophilized powder for solution for injection.
223936262|NCT05468320|DRUG|Corticosteroids|Solution for injection or Tablet
223936263|NCT05468320|BIOLOGICAL|anti-CD20 antibody|Solution for injection
223936264|NCT06768528|DIAGNOSTIC_TEST|Galectin-3 dosage|Peripheral blood sample will be collected in the 24h before CABG
223936265|NCT06768697|BIOLOGICAL|KFD1(0µg )|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(0µg + 80µg)
223534229|NCT07004855|OTHER|Crisis management|Crisis management and councelling provided by social workers and professionals.
223718647|NCT01435369|DRUG|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
223936266|NCT06768697|BIOLOGICAL|KFD1(20µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(20µg + 80µg)
223936267|NCT06768697|BIOLOGICAL|KFD1(40µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(40µg + 80µg)
224097988|NCT06947356|DRUG|TDF group|The mother will start receiving TDF treatment (300 mg tablet taken orally once daily) at 28 weeks of pregnancy until delivery. After that, mothers without treatment indications will be randomly assigned to two subgroups: one subgroup will stop treatment, while the other subgroup will receive an additional 12 weeks of TDF treatment. Infants will be vaccinated with the hepatitis B vaccine and HBIG within 12 hours after birth, as well as receive booster doses of the hepatitis B vaccine at 4 weeks and 24 weeks.
224097989|NCT00341328|BIOLOGICAL|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
224097990|NCT06948682|DEVICE|Occlusal Splint and Bite Correction Therapy|Participants receive individualized occlusal therapy involving occlusal splint use and bite correction (if needed). The treatment is applied continuously over a 6-month period. Monthly follow-up visits are conducted to monitor symptoms, adjust therapy, and evaluate radiographic changes in the TMJ.
224097991|NCT06948682|OTHER|Conventional TMJ Therapy|Participants undergo a 6-month conventional management program including pain medication (NSAIDs), physical therapy (jaw exercises, hot/cold therapy), and lifestyle guidance (diet modifications, stress reduction). Monthly clinical evaluations assess functional improvement and symptom reduction.
224097992|NCT06948682|OTHER|Routine TMJ Care (Medication Only)|Participants receive standard pharmacological management for TMJ disorders (e.g., NSAIDs or analgesics) with no occlusal or physical therapy interventions. Follow-up assessments occur monthly for 6 months to monitor symptom progression and response to minimal intervention.
224097993|NCT06946862|OTHER|no treatment, medication or intervention|will make an observational assessment of the participants' treatment expectations. Participants will not be subjected to any treatment or intervention, only their current situation will be observed.
224097994|NCT06952686|BIOLOGICAL|SRP-9005|Solution for single IV infusion
223534230|NCT07004855|OTHER|Phone Check-in|Regular phone check-in and on-demand services (e.g., escort to hospital) provided by volunteers.
223534231|NCT07004114|OTHER|Neurocognitive training group|Neurocognitive training is a rehabilitation approach that, unlike traditional treatment methods which primarily focus on improving physical performance, emphasizes cognitive functions and psychometric skills. It is a program developed by integrating motor learning strategies and cognitive challenges into neuromuscular training. These cognitive challenges include tasks requiring quick reactions, motor-motor or cognitive-motor tasks (dual-task), congruent and incongruent tasks, exercises involving mathematical calculations (working memory), and response inhibition tasks.
223718648|NCT00454012|PROCEDURE|biophysical profile|
223718649|NCT06313775|PROCEDURE|bilateral orchiectomy|Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
224097995|NCT06952686|DRUG|Corticosteroid|Oral tablet (prophylactic)
224097996|NCT00047567|DRUG|zonisamide|
224286243|NCT01997723|DEVICE|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
223936268|NCT06768697|BIOLOGICAL|KFD1(80µg)|SARS-CoV-2 subunit mucosal vaccine adjuvanted with flagellin protein(80µg + 80µg)
223936269|NCT06760650|DIAGNOSTIC_TEST|Fluorescein angiography|Fluorescein angiography
223936270|NCT06761456|OTHER|Providing training models|The experimental group was trained using the Clinical Education Module on 3 Parenteral Interventions in the Nursing Fundamentals laboratory.
223936271|NCT06761456|OTHER|Control|The control group was trained using standard training models.
223936272|NCT06762132|BIOLOGICAL|CD33 CAR T-cells|Each subject receive CD33 CAR T-cells by intravenous infusion
223936273|NCT06767865|OTHER|online support programe|Individuals in the experimental group received online training and were subsequently provided with continuous follow-up, counseling, motivation and informative message support for three months. In addition, patients were given a target board containing a daily diabetes management program and were asked to use it for three months.
223936274|NCT06720961|PROCEDURE|Collection of surgical specimen|Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
223936275|NCT06720961|PROCEDURE|Collection of stool sample|One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
223936276|NCT05709574|DRUG|Tadalafil 20 MG|Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
223936277|NCT06791161|DRUG|Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor|BRCA1/2 mutated hormone receptor-positive HER2-negative early high-risk breast cancer is treated with 3 3 treatment options after surgery：Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
223936278|NCT04043494|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
223936279|NCT04043494|DRUG|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
223936280|NCT04043494|DRUG|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
223936281|NCT04043494|DRUG|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
223936282|NCT04043494|DRUG|Doxorubicin|Part of standard chemotherapy
223936283|NCT04043494|DRUG|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
223936284|NCT04043494|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
223534232|NCT07002736|OTHER|The Biodex training|Participants will undergo balance training using the Biodex Balance System plus Traditional balance training
223936285|NCT04043494|DRUG|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
223936286|NCT04043494|DRUG|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib\* (Randomization R2)
223936287|NCT04043494|DRUG|Prednisone|Part of standard chemotherapy
223936288|NCT04043494|DRUG|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
223936289|NCT04043494|DRUG|Thioguanine|Part of standard chemotherapy
223936290|NCT04043494|DRUG|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
223936291|NCT04043494|DRUG|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
224097997|NCT03396575|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
224097998|NCT03396575|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
224097999|NCT03396575|DRUG|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
224098000|NCT03396575|DRUG|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
224098001|NCT03396575|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
224098002|NCT03396575|BIOLOGICAL|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
224098003|NCT03277196|DRUG|IVA|Granules for oral administration.
224098004|NCT06159335|RADIATION|F-Fluciclovine radiotracer|Participants will receive PET radiotracer and MRI
224098005|NCT01979510|DRUG|MK-0663B|MK-0663B once daily for 8 days.
224286244|NCT01997723|DEVICE|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
224286245|NCT00964106|DRUG|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
224286246|NCT00964106|DRUG|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
224286247|NCT00964106|DRUG|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
224286248|NCT00964106|DRUG|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
223936292|NCT04550377|DRUG|Cannabidiol|The drug product to be used in this study is an oral formulation of CBD
224286249|NCT00964106|DRUG|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
224286250|NCT00964106|DRUG|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
224286251|NCT00964106|DRUG|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
224286252|NCT00964106|DRUG|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
224286253|NCT00964106|DRUG|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
223534233|NCT07002736|OTHER|Traditional balance training|Traditional balance training only
223936293|NCT04550377|DRUG|Placebo|non-active medication
223936294|NCT06770868|DEVICE|Patient specific reconstruction plate for patients suffering from mandibular segmental defects|Patients with mandibular segmental defect including coronoidectomy managed with patient specific reconstruction plate with custom made temporalis tendon enthesis
223936295|NCT06770504|BIOLOGICAL|YTS109|In this study, subjects will receive YTS109 Cell Injection(0.5-1E6 STAR+T cell/kg) once.
224286254|NCT00964106|DRUG|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
223534234|NCT07002970|OTHER|aerobic exercise program|All study group patients performed aerobic exercise on a treadmill. approved by the American College of Sports Medicine.
223534235|NCT07002970|OTHER|Mediterranean diet|received a Mediterranean diet for 12 weeks tailored according to patients caloric needs
223534236|NCT07002775|DEVICE|Transesophageal ultrasound|Transesophageal ultrasound with built-in ultrasound software (Philips QLAB 3D quantification advance, Philips Healthcare, USA, speckle tracking echocardiography (STE,Speckle tracking echocardiography) to evaluate stroke volume and cardiac output in different position with the same person
223936296|NCT06771713|BEHAVIORAL|Brief Pain Reprocessing Therapy (BPRT)|"Participants will have three 90-minute behavioral intervention sessions over a 3-week period, completing 35 days of brief daily assessments, and one additional set of questionnaires.~Participants will also complete study questionnaires at 1, 2, 3, and 6 months after attending the 3 behavioral intervention sessions."
223936297|NCT06775275|DRUG|Adebellizumab|adebrelimab
223936298|NCT06775275|DRUG|Bevacizumab|bevacizumab
224098006|NCT01979510|DRUG|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
224098007|NCT01979510|DRUG|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
224098008|NCT04329936|BEHAVIORAL|Retention center Geispolsheim population|All recently held individuals in the retention center can be included in the study after signing the information and consent protocol.
224098009|NCT02821286|OTHER|Observational study|Blood sampling
224286255|NCT00964106|DRUG|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
224286256|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
224286257|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
224286258|NCT00665951|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
224286259|NCT00489749|PROCEDURE|Protected early weightbearing/Achilles tendon surgery|
224286260|NCT04561336|DRUG|Avelumab|avelumab in combination with cetuximab
224286261|NCT04561336|DRUG|Cetuximab|avelumab in combination with cetuximab
223936299|NCT06775275|DRUG|Platinum-based chemotherapy|paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
223936300|NCT06775470|DIAGNOSTIC_TEST|Patients must have been diagnosed with ovarian cancer and be BRCA positive|Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.
223936301|NCT06775470|DIAGNOSTIC_TEST|BRCA1 and BRCA2 positive, and be affected by Ovarian Cancer|Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.
223936302|NCT06774716|BEHAVIORAL|Internet-based cognitive behavioural treatment and relapse prevention|A self help program consisting of 12 modules and access to therapist guidance through messages. Including three video session.
223936303|NCT06774716|BEHAVIORAL|Face-to-face cognitive behavioural treatment or short-term psycodynamic therapy with relapse prevention|Face-to-face therapy with a licenced psychologist or licenced psychotherapist, including 10-15 sessions.
224286262|NCT02598245|DEVICE|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
224286263|NCT02598245|DEVICE|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
224286264|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
224286265|NCT04019054|DEVICE|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
224286266|NCT03738527|DRUG|Tranexamic Acid 100mg/mL, 20mL topical|"Drug: Tranexamic Acid~20 mL TXA (100 mg/mL injection solution, total 2g TXA) applied topically to the mastectomy cavity for 5 minutes before wound closure"
223936304|NCT06778993|OTHER|Breastfeeding Education Program Accompanied by a Wearable (Hybrid) Simulator|This training is conducted in both theoretical and practical formats. The theoretical training consists of two sessions, each lasting 25 minutes, with a 10-minute break in between, totaling 60 minutes. Following the theoretical training, simulation-based skill training is conducted. This phase also comprises two sessions of 25 minutes each, with a 10-minute break, making a total duration of 60 minutes.
223936305|NCT06777836|DEVICE|Personalised Discharge training|Discharge education also contributes to the empowerment of diabetic surgery patients in diabetes management. During the training process, patients will be informed about blood glucose control, diet, exercise and medication management.
223936306|NCT06770465|DRUG|Different categories of antibiotics|Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
223936307|NCT06771089|OTHER|Manual therapy and bandaging|The MTG group received an intervention based on anterior-posterior mobilizations of the talus and fibula and taping, both based on Mulligan® techniques Individually, participants received Grade IV passive mobilizations lasting approximately 30 seconds, totalling 12 active mobilizations performed by the participant. Furthermore, a tape was applied, placed on the anterior part of the talus with a posterior and caudal direction, with its ends anchored near the heel. Due to its placement, this taping maintained a sustained posterior force on the talus throughout the training session. This intervention was conducted on the affected limb(s) with DF deficits.
223936308|NCT06771089|OTHER|Therapeutic exercise|"Therapeutic exercise protocol lasting approximately 5-10 minutes, performed before regular training sessions. It included 2 exercises, each performed in 3 sets of 10 repetitions with 1-minute rest intervals.~Exercise 1: Weighted DF in a kneeling position. From this position, ankle DF is performed with the front leg, on which the weight of the arms and the torso is placed to force the movement.~Exercise 2: Ankle lunge with band resistance at the ankle. The player performs ankle DF with a medium-resistance green Theraband® providing a posterior force vector on the talus.~This intervention was applied to the affected limb(s) with ankle DF limitations and was supervised by a physiotherapist. It was performed before training session at each club's facilities."
223936309|NCT06771089|OTHER|No specific treatment|The Control group received no specific treatment; they only participated in the current training sessions.
223936310|NCT06752460|DEVICE|EF192B|EF192B will be applied after the tape strriping procedure and will be reapplied after 12 hours.
223936311|NCT06264362|BEHAVIORAL|Tailored Physical Activity Program|Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
223936312|NCT06709404|OTHER|Telemedicine|Receive telehealth navigation intervention
223936313|NCT06709404|OTHER|Survey administration|Ancillary studies
223936314|NCT06709404|OTHER|Electronic health record review|Ancillary studies
223936315|NCT06709404|OTHER|Best Practice|Receive standard caregiving experience
223936316|NCT04099992|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
224098010|NCT03984526|DRUG|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
224098011|NCT03984526|DRUG|atropine 0.5mg|intravenous atropine 0.5mg pretreatment at the onset of dexmedetomidine infusion
224286267|NCT03738527|DRUG|Normal Saline Flush, 0.9%, 20mL topical|"Drug: Normal Saline~20 mL 0.9% NaCl (normal saline) applied topically to the mastectomy cavity for 5 minutes before wound closure"
224286268|NCT02277431|DIETARY_SUPPLEMENT|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am \& pm) offering a total daily serving of:~* Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units \[CFU\])~* Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~* Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
223718650|NCT05528185|OTHER|Direct participation of the family member in the daily rounds|When the team arrives at the participating family member's room, the family member will be invited by a member of the healthcare team to come out of the room. The rounding team and structure will be the same as the usual care group with the following exceptions: (1) the family member will be invited to participate in the rounds outside their relative's room; (2) the family member will be provided with an orientation to the medical team members; (3) the family member will be allowed to engage and participate throughout the rounds; (4) at the end of the rounds, the team will summarize the patient's daily care plan; (5) the family member will be prompted to ask questions.
223936317|NCT04099992|BEHAVIORAL|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
223936318|NCT04099992|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|Participants self-administer tVNS twice per day for 8 weeks. tVNS is delivered using a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
223936319|NCT04099992|DEVICE|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Participants self-administer sham-tVNS twice per day for 8 weeks. Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
223936320|NCT01675492|DEVICE|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
223936321|NCT06893770|BEHAVIORAL|Quran recital|standard treatment and care
223936322|NCT06893770|OTHER|standard treatment and care|standard treatment and care
223936323|NCT06842342|PROCEDURE|Lumber plexus block|LPB Group: All members of this group will receive ipsilateral lumber plexus after induction of general anesthesia. The LPB will be performed by using 30 ml mixture of lidocaine 2% (10 ml), bupivacaine 0.25%(10 ml) and 10-mL normal saline will be injected at that point after repeated negative aspiration.
223936324|NCT06842342|PROCEDURE|Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)|ESB Group: All members of this group will receive ipsilateral sacral erector spinae block after induction of general anesthesia. The ESB will be performed by using 30 ml mixture of lidocaine 2% (10 ml), bupivacaine 0.25%(10 ml) and 10-mL normal saline will be injected at that point after repeated negative aspiration.
223936325|NCT06842342|PROCEDURE|PENG Block|PENG block: All members of this group will receive PENG block in the supine position after general anesthesia, The PENG will be performed by using 40 ml mixture of, 20 mL of 0.5 bupivacaine,10 mL of 2% lidocaine, and 10 mL of normal saline.
224286269|NCT02277431|DIETARY_SUPPLEMENT|placebo|
224286270|NCT05368558|DRUG|Cariprazine|Oral Capsule
224098012|NCT03984526|DRUG|ephedrine 8mg|intravenous ephedrine 8mg pretreatment at the onset of dexmedetomidine infusion
224098013|NCT02108457|RADIATION|[18F]Fluorothymidine (FLT) PET/CT Imaging|
224286271|NCT05368558|DRUG|Placebo|Oral Capsule
224286272|NCT01731886|PROCEDURE|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
224286273|NCT01731886|DRUG|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
224286274|NCT01731886|DRUG|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
224286275|NCT01731886|PROCEDURE|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.
224286276|NCT01731886|DRUG|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
224286277|NCT01731886|DRUG|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
224286278|NCT01731886|DRUG|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
224286279|NCT01731886|DRUG|Mesna|Mesna will be provided with the cyclophosphamide.
223936326|NCT06828627|PROCEDURE|TLSA|"TLSA surgery procedure. (A) On the greater curvature of the stomach, the gastrocolic ligament is incised along the avascular area between the left and right gastric omentum vessels, and the gastric fundus is separated upward to the cardia to protect the vagus nerve.~(B) The cardia, lower esophagus, and diaphragm is exposed, and the confluence of the left and right crus of the diaphragm is revealed.~The retroperitoneum at the left and right crus of the diaphragm is incised, and the lower esophagus is dissociated for about 3-5 cm. The gastric fundus and the posterior wall of the esophagus are fully dissociated from the upper spleen. (C) Non-absorbable thread is used to intermittently suture the left and right crus of diaphragm in order to reconstruct the esophagus hiatus with a diameter of about 1.5 cm. (D) Then, the surgeon inserts the patch and fixes it on the crus of diaphragm if the hiatal hernia is larger than 5 cm or the diaphragm on both sides is weak. (E) A small incisio"
223936327|NCT06828627|PROCEDURE|TBSA|Traditional bilateral surgical approach (TBSA) surgery procedure. (A) Separation is initiated from the avascular area of the lesser omentum, and the hepatic branch of vagus nerve is preserved as far as possible. Careful separation is performed upward to expose the right crus of diaphragm. (B) At the greater curvature of the stomach, two to three short gastric vessels are cut off to expose the left crus of diaphragm, and the space between the anterior and posterior of esophagus is dissociated. (C) The diaphragmatic esophageal membrane is incised and the lower part of the esophagus is dissociated about 4-5 cm, then the gastroesophageal valve flap is reformed and the His angle is restored. During the operation, it mainly protects the anterior and posterior trunk of the vagus nerve. The anterior and posterior trunk of the vagus nerve are mainly protected during the operation. (D) Both sides of the crus of the diaphragm are intermittently sutured with non-absorbable thread to reconst
224098014|NCT06793644|DRUG|Immunofluorescence Imaging|Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
224098015|NCT02655198|DRUG|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
224098016|NCT02592564|BEHAVIORAL|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
224098017|NCT03050684|PROCEDURE|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
224098018|NCT03050684|PROCEDURE|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
224098019|NCT04782739|OTHER|None - Descriptive study|Descriptive study
224098020|NCT03545516|DRUG|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
224098021|NCT03545516|DRUG|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
224098022|NCT03545516|DRUG|Placebo|Injection of a placebo into the surgical wound
223718651|NCT03895385|DRUG|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
224286280|NCT01749358|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
224286281|NCT01749358|BEHAVIORAL|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
224286282|NCT05260034|OTHER|FAST Program|This program aims to teach how to effectively reduce impact forces during a sideways fall by 1) changing the trunk/knee angles during descent to decrease body acceleration, 2) using a rolling movement to allow for an optimal distribution of impact forces applied to any site along the contact path; and 3) tucking the chin to protect the head.
224286283|NCT05260034|OTHER|Otago Exercise Program|The Otago Exercise Program (OEP) was chosen, rather than no control intervention, to increase the level of evidence required to demonstrate efficacy, and because, similar to the safe fall training used here, it was designed to be performed individually or in small groups.
224286284|NCT06365294|PROCEDURE|Rescue extracranial stenting|Rescue extracranial stenting in tandem occlusions
224286285|NCT02740907|PROCEDURE|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
224286286|NCT00843830|RADIATION|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
223936328|NCT04699786|OTHER|Arm A , Arm B, Arm C, & Arm D|All arms will receive the same intervention, but at different time points. All arms will be offered the option to learn their research results in personalized five-year risk estimate of getting Alzheimer disease dementia. Arms A \& C participants will receive their risk estimate about two weeks after consent is signed and Arms B\& D will receive their risk estimate about one year after consent is signed. The risk estimate returned to participants is based on research results from individual genotyping results, imaging or plasma amyloid testing \& demographic characteristics. All arms will complete psychosocial and cognitive testing. Also, surveys used in this study will ask about participants' experiences and feelings after learning their risk estimate. All arms will receive follow up calls at one week post disclosure of the risk estimate and surveys two, six, and twelve months post disclosure. Arms A \& C will have extra surveys at twenty-four months post disclosure.
223936329|NCT06765486|OTHER|Lower limb resistance training|Exercise intervention with leg extensions on the dominant quadriceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
223936330|NCT06765486|OTHER|Upper limb resistance training|Exercise intervention with brachial biceps curl on the dominant brachial biceps, doing 3 sets of 5 repetitions with the 5RM after a 5-minute warm-up with a cycle ergometer at 1 watt per kg and 60-80 revolutions per minute and 1 set of 5 repetitions with the 10RM. Previously, 72 hours before, the 5RM would have been calculated progressively approaching in sets of 5 repetitions, starting with the lower weight and stopping the test when obtaining an unsuccessful trial (the participant could not manage to lift the weight five times). The previous successful set would be established as the 5RM.
223936331|NCT06206252|OTHER|Medical Cannabis|Participants will be restricted to specific medical cannabis products from Ethos Dispensary. They will be randomized to one medical cannabis formulation (tincture or vaporization) for the duration of the study. Each month for three months, they will purchase a different composition (predominantly THC, predominantly CBD, or balanced products) of their designated formulation. The order of compositions will be randomized and double-blinded, so participants and the research team will not know which compositions of medical cannabis they are using each month.
223936332|NCT03718364|PROCEDURE|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
223936333|NCT05360849|BEHAVIORAL|Practice Facilitation|Participating clinics will work with a Practice Facilitator to modify clinic processes to improve delivery of PrEP to women who inject drugs
223936334|NCT06822244|BEHAVIORAL|Pranayama exercise|"The people in the pranayama experimental group were first informed about the practice (At the deepest point of the breath, the left nostril is closed with the index finger of the right hand and exhaled through the right nostril. When it reaches the deepest point, close the nostril with the thumb and exhale through the left nostril. At least 3 more rounds are continued in this way.~one Pranayama session (approximately 30 minutes). The people in the experimental group were taught pranayama exercises during the application and were given a brochure with written instructions on home application and were info"
223936335|NCT06822244|BEHAVIORAL|normal breathing|normal breathing 20 breath per min
223936336|NCT06812195|DEVICE|Plate and nail|spinal anesthesia in supine position, lateral approach to the femur is used to do corrective osteotomies and introduction of nail according to preoperative plan. After that, plate is applied to lateral border to the femoral shaft
223936340|NCT02659293|DRUG|Lenalidomide|"* Cycle 1: 15 mg days 1-21~* Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~* Cycles 5 and beyond: best tolerated dose days 1-21"
223936341|NCT02659293|DRUG|Carfilzomib|"* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~* Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~* Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
223936342|NCT02659293|DRUG|Dexamethasone|"* Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~* Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
223936343|NCT02659293|DRUG|Lenalidomide (Control)|"* Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~* Cycles 5 and beyond: best tolerated dose days 1-28"
223936344|NCT06822582|BEHAVIORAL|Pelvic Health Module|Telerehabilitation program involving pelvic floor exercises, education and counselling.
223936345|NCT06881927|DRUG|Hydrocortisone Hemisuccinate: 200 mg per day.|The hydrocortisone hemisuccinate is a powder and solvent for injectable solution at 100 mg. The powder must be dissolved in the solvent to ensure final isotonicity. The solution must be used within 24 hours. The injection is performed as a slow direct IV injection, either via an electric syringe pump or as a bolus of 50 mg every 6 hours
223936346|NCT06881927|OTHER|reduction of the level of immunosuppression|"In this arm, the usual immunosuppressive treatment of the patients will be discontinued.~Patients will receive hydrocortisone hemisuccinate 200 mg per day (slow direct intraveinous injection of 50 mg four times a day, or through an electric syringe pump)."
223936347|NCT06810050|DRUG|CGB-500 with 0.5% tofacitinib|CGB-500 is a proprietary ointment formulation
223936348|NCT06810050|DRUG|CGB-500 Ointment with 1% tofacitinib|CGB-500 is a proprietary ointment formulation
223936349|NCT06810050|DRUG|Vehicle (placebo)|placebo ointment
224098023|NCT03410147|DIAGNOSTIC_TEST|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
224098024|NCT05600010|OTHER|Microplastics|Detection of microplastics as a yes/no value
224098025|NCT04558008|BEHAVIORAL|Online MBSR|Described previously
224098026|NCT04086043|DEVICE|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
224098027|NCT06394622|COMBINATION_PRODUCT|Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells|Biological: CD70 CAR-NKT cells. Drug: Cyclophosphamide. Drug: Fludarabine.
224098028|NCT01344122|OTHER|KPI training only|See comparison arm description.
223718652|NCT05801874|DIAGNOSTIC_TEST|Movement analysis|Qualitative and quantitative computerized and instrumental assessment of gait and posture.
223718653|NCT05154591|GENETIC|Adipose-derived stromal vascular fraction cells|Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
223936350|NCT06750926|DIAGNOSTIC_TEST|video image through laryngeal mask specific channel|patients placed SaCoVLM will be checked the proper position of placement by native camera through specific video channel and fiberoptic endoscopy through ventilation channel perspectively
223936351|NCT05025384|OTHER|Acupressure|"Acupressure stickers will be applied to one ear in accordance with the NADA protocol acupuncture technique. Application will occur at designated points including Shen Men, Liver, and Lung: in the room with the mother; and potentially during breast feeding, holding, skin to skin contact or bottle feeds. Stickers will remain in place for 24 hours.~At 24 hours, skin will be assessed, and stickers will then be rotated to the opposite ear every 48 - 72 hours if there are no adverse effects such as skin irritation."
223936352|NCT06235411|DRUG|Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 25 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
223936353|NCT06235411|DRUG|Inactive Psilocybin therapy|"Two administrations of psilocybin given 3 weeks apart. The treatment day will begin around 9 a.m. with a brief interview. Patients will be invited to relax and music will be played through speakers and headphones.~One 1 mg capsule of Psilocybin will be given approximately 30 minutes to 1.5 hours later.~The patient is accompanied throughout the session (minimum 6 hours depending on the effects felt). The patient will benefit from a preparation session the day before dosing, and an integration session the day after. Intensive relapse prevention program will be dispensed between the 2 dosing sessions (treatment as usual)."
223936354|NCT06235411|OTHER|Electroencephalogram|"* Rest EEG prior to first treatment administration~* EEG during first treatment administration~* Rest EEG during integration session after second treatment administration"
223936355|NCT06235411|OTHER|Blood samples for the analysis of immune and inflammatory profiles|Three 7ml EDTA tubes will be taken in the morning on an empty stomach at day 0 and at 3 weeks.
223936356|NCT06235411|OTHER|stool samples|Stool sampling at day 0 and 3 weeks Analysis of intestinal microbiota is carried out on a stool sample, which is stored at -20°C for a maximum of 24 hours. The sample is then transferred cold to the CRB of the Nîmes University Hospital, where it is stored at -80°C until the microbiology laboratory can perform a group analysis.
223936357|NCT06235411|OTHER|MRI functional and cerebral|MRI functional and cerebral at day 0 and 3 weeks
223936358|NCT05961553|BEHAVIORAL|Physical Activity Counseling session|The counseling session on physical activity was carried out individually, six weeks after starting the respiratory rehabilitation program, with an average duration of 30 minutes, based on the guidelines of the Living Well with COPD program. The main objective of the session was: to help the participant and family members to increase physical activity levels and their integration in the long term and as secondary objectives; reinforce the importance and benefits of physical activity in the management of the health condition/symptoms; plan daily/weekly moments of physical activity; define daily goals (physical activity time/sitting time) attainable for each participant; integrate family members/companions into the user's physical activity plan; clarify doubts of the user/relative about the theme.
223936359|NCT05961553|OTHER|Pulmonary Reabilitation|The program comprises a hospital group exercise program, twice a week, on alternate days, for 1h30 to 2h, each session.
223936360|NCT06619613|BIOLOGICAL|Alzheimer Disease (AD)|CM383 injection
223936361|NCT06619613|OTHER|Placebo|Matched placebo
223936362|NCT05575752|OTHER|high temperature (32℃) group|The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.
223936363|NCT05575752|OTHER|moderate temperature (22℃) group|The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
223936364|NCT05637489|BEHAVIORAL|PING|Brief survey of goals and preferences
224098029|NCT01344122|OTHER|KPI plus OLI|See experimental arm description.
224098030|NCT01471327|BIOLOGICAL|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
224098031|NCT01471327|OTHER|Placebo|Saline IV, single dose at Day 1
224098032|NCT03361670|OTHER|Observational Study|
224098033|NCT01056107|DRUG|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
223936365|NCT06471504|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
224098034|NCT01056107|DRUG|Placebo|Placebo subcutaneous injection daily
224098035|NCT06382688|DIETARY_SUPPLEMENT|NAD+ (nicotinamide adenine dinucleotide) IV|NAD+ enables cells to generate cellular energy from the food that one eats
224098036|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) IV|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.
224098037|NCT06382688|DIETARY_SUPPLEMENT|Niagen® (nicotinamide riboside) oral|NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.
224286287|NCT00843830|BIOLOGICAL|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
224286288|NCT00504478|DIETARY_SUPPLEMENT|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
224286289|NCT00504478|OTHER|high complex carbohydrate diet|
224286290|NCT00464139|PROCEDURE|Laparoscopy|Laparoscopy
224286291|NCT01826916|DRUG|DX-88 (ecallantide)|solution for injection 10 mg/mL
224286292|NCT01913795|OTHER|integrated pest management|integrated pest management and environmental strategy
224286293|NCT01913795|OTHER|air purifier|air purifiers
224286294|NCT01913795|OTHER|Sham air purifier|sham air purifiers
223936366|NCT02781857|OTHER|No intervention|
223718654|NCT01294631|DRUG|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
223936367|NCT05431946|BEHAVIORAL|Advance Care Planning and the consequent actions|"The palliative care intervention is based on the advance care planning process and the actions taken as a consequence of these conversations. The goal is the identification, assessment, and treatment of physical, psychosocial, or spiritual symptoms and problems.~Advance care actions~These are the actions taken to fulfill the advance care plan and can include, but are not limited to:~treatments: pharmacological, psychosocial (priest, psychologist, etc.) referrals: rehabilitation, specialized palliative care team, hospice, etc. communication initiatives with relatives, primary care, public authorities"
224098038|NCT06382688|OTHER|Placebo|These individuals received a saline IV
224098039|NCT05195359|BEHAVIORAL|Dein Schlaf. Dein Tag. sleep improvement application powered by SleepScore|The Dein Schlaf. Dein Tag. application powered by SleepScore is a validated sleep measurement application using sonar technology that also provides evidenced-based sleep advice and sleep education content based on a user's objectively measured nightly sleep data. As participants engage with the app, the Dein Schlaf. Dein Tag. application provides personalized and dynamic sleep content and sleep and circadian rhythm improvement advice based in the principles of sleep hygiene, sleep-circadian science, and cognitive behavioral psychology. Participants will also receive personalized sleep challenges tailored to improve their sleep and circadian rhythms. Each challenge lasts for 7 tracked nights, ranging from optimizing sleep habits to limiting caffeine intake, and more. Additional sleep improvement features embedded within the app include sleep sanctuary bedroom checks, sleep sounds, smart alarms, bedtime reminders, and sleep education blogs and science content.
224286295|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment A|Single oral dose
224286296|NCT04845841|DRUG|Elinzanetant (BAY3427080) treatment B|Single oral dose
224286297|NCT05363995|BEHAVIORAL|i-Sleep & BioClock Intervention|"The 'i-Sleep \& BioClock' intervention aims at improving sleep and the biological clock among university students. It is incorporates evidence-based techniques such as cognitive behavioural therapy for insomnia (CBTi). The intervention has a duration of 5 weeks and consists of five modules:~1. psychoeducation on insomnia, sleep hygiene and the biological clock,~2. stimulus control and sleep restriction therapy,~3. worrying and relaxation exercises,~4. cognitive therapy to change dysfunctional thoughts about sleep, and~5. summary module, relapse prevention, and plan for the future.~The intervention is supported by e-coaches who give personalized written feedback. Students will fill in a sleep \& light exposure diary daily."
224286298|NCT00855764|DRUG|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
224286299|NCT01794754|OTHER|Care as usual|
224286300|NCT01794754|OTHER|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
224286301|NCT01275560|DRUG|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
223718655|NCT03699657|DEVICE|DSM|Monopolar RFA using dual switching mode (DSM)
223718656|NCT03699657|DEVICE|SSM|Monopolar RFA using single switching mode (SSM)
224286302|NCT01275560|DRUG|CArbosylane|
223936368|NCT06351709|OTHER|Stretching|Static stretching technique was applied to the quadriceps and hamstring muscle groups in both the dominant and non-dominant extremities of the participants in the stretching group. All stretches were performed twice for 20 seconds with a 3-second rest.
223936369|NCT06351709|OTHER|Hot pack application|Hot pack application was applied to the participants in the hot group to warm the extremities locally after the pre-tests were completed. For the application of hotpack, which is a superficial and moist temperature agent, a Chattanooga ® brand hotpack pad (DJO Global, Chattanooga; CA, USA) with 10 slices and a size of 28 cm x 39 cm was used. The hotpack pad was taken with the help of tongs from the Chattanooga ® brand hot pack boiler (DJO Global, Chattanooga; CA, USA) at 80° temperature and wrapped in a total of 5 layers with the help of 2 towels. A hotpackpad was placed on each knee of the participant. Hotpack pads were applied for 15 minutes in total.
223936370|NCT06351709|OTHER|Cold pack application|For participants in the cold group, MSD ® brand cold pack gel (MVS Inmotion, MSD cold pack; Weftdijk 1502830, Belgium), 15 cm x 25 cm in size, was used to cool the extremities locally. The cold pack gel, kept in the freezer, was wrapped in a paper towel and placed on the knee area. Cold pack was applied to both knees for a total of 15 minutes.
223936371|NCT03610581|BIOLOGICAL|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
223936372|NCT03610581|BIOLOGICAL|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
223936373|NCT03610581|BIOLOGICAL|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
223936374|NCT03610581|BIOLOGICAL|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
223936375|NCT02045381|PROCEDURE|MRI Group|A single research MRI
223936376|NCT03312920|DEVICE|active anodal tDCS|active anodal tDCS with memory task
223936377|NCT03312920|DEVICE|sham tDCS|sham tDCS with memory task
223936378|NCT03312920|DEVICE|active cathodal tDCS|active cathodal tDCS with memory task
223936379|NCT06214819|DEVICE|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion|VIVO ISAR DES implanted in the First lesion, XIENCE Skypoint DES implanted in the Second lesion
223936380|NCT06214819|DEVICE|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion|XIENCE Skypoint DES implanted in the First lesion, VIVO ISAR DES implanted in the Second lesion
223936381|NCT06766708|OTHER|self-management lymphedema (SML) education program|The content of the booklet was prepared based on literature review.. In addition to the above intervention methods, the phone number of each patient was taken and the patients were followed up by phone for 12 months. For this purpose, the patient was asked to fill in the compliance chart prepared in order to monitor the patient's compliance and was checked by the researcher every two weeks by phone call. By phone call; compliance with skin care, SLD, compression garments and exercise practices included in the SMLEP were evaluated and recorded. Within the scope of the SMLEP, the patients were asked to do exercises and SLD at least 3 days a week and 2 times a day (morning and evening) for 12 months. It was recommended to wear compression garments, especially during exercises and throughout the day.
223936382|NCT05630651|GENETIC|ZS801|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant. The dose level is 5.0×10\^12vg/kg.
223936383|NCT06800859|DRUG|Supplement fluids|To ensure optimal recovery and manage potential complications, patients are advised to supplement fluids by increasing their oral intake or receiving intravenous fluids as necessary. Bed rest is recommended to reduce physical strain and promote healing. Additionally, a blood patch procedure may be performed to alleviate symptoms such as headaches that can occur after certain medical procedures, particularly spinal taps. This involves injecting a small amount of the patient's own blood into the epidural space to seal any leaks of cerebrospinal fluid, thereby providing relief and aiding in recovery. Proper monitoring and follow-up care are essential to ensure the effectiveness of these interventions
223936384|NCT06837584|OTHER|Questionnaire and Physical Exam|Questionnaire and Physical Exam
223936385|NCT06814782|OTHER|Action Observation Training|Action Observation Training (AOT) consists of patients observing videos of specific movements, followed by practice of those movements
223936386|NCT06814782|OTHER|Action Observation and Motor Imagery|Action Observation and Motor Imagery (AOMI) consists of patients observing videos of specific movements, followed by mental rehearsal of those movements
223936387|NCT06814782|OTHER|Exercise|After watching a landscape video, patients will have to perform specific postural and balance exercises
223936388|NCT05080504|DEVICE|Eko DUO|"Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days."
223936389|NCT06811831|DRUG|Macitentan 10 mg tablet, once daily.|After the patient signed an informed consent form, Macitentan was given as an oral medication (10 mg once daily) for a period of 4 weeks
223936390|NCT06749340|OTHER|Assigned Interventions|"Psychometric Hepatic Encephalopathy Scoring (PHES) Test~* Digit Symbol Test~* Number Combination Test-A~* Number Combination Test-B~* Serial Punctuation Test~* Line Drawing Test~  6 Minute Walk Test~  5 Times Sit and Stand Test~Manual Muscle Test~Hand Grip Strength Test~Quadriceps muscle thickness measurement with ultrasonography~All evaluations will be repeated 5 times."
223936391|NCT06749340|OTHER|Face-to-face Exercise|Participants will undergo exercise sessions 3 days a week for 12 weeks. Sessions will include a warm-up, upper and lower extremity strengthening (1/3 set - 8/12 repetitions) and cool-down program. Theraband will be used in strengthening exercises. Theraband offers different resistance levels with its different colors. In order from lightest to heaviest; skin color, yellow, red, green, blue, black, grey, gold. Exercises (theraband color, intensity, number of sets and repetitions) will be made into a personalized program according to the tolerance level of the participants in the first session. Exercise intensity will be determined using the OMNI - Resistance Exercise Scale (OMNI - RES). The warm-up and cool-down periods in the exercise program will be carried out at levels 9 - 12 according to the Borg Scale.
224098040|NCT01839994|RADIATION|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
223936392|NCT06749340|OTHER|Home-based Exercise|Participants will follow the same program as in the face-to-face exercise group. The first meeting with the participants will be held face to face and the details of the study will be explained. Home-based exercises will be carried out with the Fiziu (Fiziu Sağlık Hizmetleri Teknoloji A.Ş., Istanbul, Türkiye) program and the exercise program will be delivered to the participants through this program. Therabands with which the participants will do their exercises will be provided by the researchers. The progression program will be determined in line with the difficulty and effort felt by the participants through weekly meetings.
223936393|NCT06749340|OTHER|Control|Participants assigned to the control group will have the same evaluation sessions as participants assigned to the experimental groups. The first evaluation will be made at the beginning of the study, the second evaluation after the 8-week period, the third evaluation after the 12-week period, the fourth evaluation after the 6-month follow-up, and the fifth evaluation after the 12-month follow-up. Participants who will not be included in any study sessions during this process will be included in the study program that appears to be effective as a result of the study. Participants in this group will be offered the program recommended by the US Office of Disease Prevention and Health Promotion and used in individuals who have previously had a liver transplant. This program consists of aerobic exercises (walking, cycling, etc.) starting from 60-65% of the maximum heart rate and progressing to 75-80%.
223936394|NCT06754007|PROCEDURE|ROPES Training Programme|ROPES is a training programme that involves resistance training, whole-body exercises and HIIT aerobic sessions with each session lasting no longer than 45 minutes.
223936395|NCT04477629|DRUG|Belatacept|Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.
223936396|NCT04477629|DRUG|Tacrolimus|Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.
223936397|NCT04477629|DRUG|Mycophenolate Mofetil|Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).
223936398|NCT04477629|DRUG|Corticosteroid|Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
223936399|NCT06752655|OTHER|Curcumin with photodynamic thearpy|root canals will irrigated with final irrigation procedure: curcumin+photodynamic therapy. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
224098041|NCT01839994|RADIATION|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
224098042|NCT01839994|DRUG|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
224098043|NCT04219306|OTHER|Alert on dispatchers screen 'Suspect cardiac arrest'|Alert on dispatchers screen 'Suspect cardiac arrest'
224098044|NCT04275752|OTHER|Exercise Program|Perform endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training twice a week for a period of one hour per session, for a total of 16 sessions.
224286303|NCT03877926|BIOLOGICAL|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
224286304|NCT03877926|BIOLOGICAL|BioThrax|BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
224098045|NCT02017444|DRUG|AZD4017|
224098046|NCT02017444|OTHER|Placebo|Matched placebo (matched to AZD4017 arm)
224098047|NCT05679882|OTHER|Masking Sounds|Masking sounds will be played from outdoor speakers.
224286305|NCT04155073|BEHAVIORAL|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
224098048|NCT05679882|OTHER|No Masking Sounds|No masking sounds will be played from outdoor speakers.
224098049|NCT01568216|DRUG|AMG 747|Three dose levels once-daily oral administration
224098050|NCT01568216|DRUG|Placebo|Once-daily oral administration
224098051|NCT02197325|DEVICE|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
224098052|NCT06282692|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA-SARS CoV-2 (Vero Cell Inactivated) 5 µg|Dose : 1 dose 0.5 ml containing 5 µg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
224286306|NCT04155073|OTHER|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
224286307|NCT02240186|DEVICE|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
224286308|NCT02240186|DEVICE|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
223936400|NCT06752655|OTHER|Control group|root canals will irrigated with routine root canal final irrigation with NaOCl and EDTA. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
223936401|NCT06809374|DRUG|gemcitabine|neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel
223936402|NCT06465576|DRUG|Solifenacin|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
223936403|NCT06465576|DRUG|Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
223936404|NCT06465576|DRUG|Solifenacin + Mirabegron|"Abrupt withdrawal indicates stopping the medication on the date of withdrawal initiation.~Gradual withdrawal involves taking the applied dosage of the medication every other day over a period of 14 days, with the complete cessation of the medication occurring 14 days after the gradual withdrawal process begins."
223936405|NCT06777563|BEHAVIORAL|Brief psychological counselling and health education|This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
223936406|NCT06777563|BEHAVIORAL|2 Weeks of Ecological Momentary Assessment (EMA)|The 2-week EMA period will start the next day. Participants will be prompted to answer questions about emotion (e.g. worry, enjoyment, anxiety, etc.) and other lifestyle and environmental triggers through the smartphone notification function. There will be a 2-hour window for each assessment before expiration and total 5 assessments a day.
223936407|NCT06777563|BEHAVIORAL|10 weeks of mobile health psychological support|A total of 20 regular instant messages (e.g., via WhatsApp) personalised by baseline demographic characteristics (current pregnancy details, history of postpartum mental illness) and results of EMA will be sent to the participants in multi-media formats.
223936408|NCT06777563|BEHAVIORAL|CBT-guided telephone counselling booster|A 45-minute telephone counselling based on CBT.
223936409|NCT06649500|OTHER|Treadmill|The Walker View system is a treadmill equipped with a loaded cell sensor belt and a 3D camera that allows you to detect every single angular movement of the subject. Furthermore, thanks to the two optics, a classic one for 2D shooting in high resolution, and a revolutionary one for infrared rays, it is possible to reconstruct the position of the subject in space in three-dimensional mode and in real time. The reflected image reconstructed by the system helps to improve movement through the \&#34;continuous feedback system\&#34; method.
223936410|NCT06649500|OTHER|conventional therapy|Conventional therapy intervention will follow the usual treatment according to current clinical practice. This treatment will be delivered to patients in a group session in order the balance disorders.
223936411|NCT05359133|DRUG|Tetrodotoxin|TTX for Injection, 30 µg/mL, is a sterile, nonpyrogenic, white, lyophilized powder provided in a 5 mL glass single-use vial with a rubber stopper and aluminum overseal. Upon reconstitution of the lyophilized product with 1.1 mL of sterile water for injection, each vial delivers 1 mL of fluid containing 30 µg of TTX with a pH of 4.0 to 5.5
223936412|NCT05359133|DRUG|Placebo|"Placebo for injection is a sterile 0.9% sodium chloride injection or normal saline for injection. To ensure blinding, subjects receiving placebo will receive the same volume (1.0 mL) for injection to match the volume used for the cohorts assigned to receive active trial drug.~Route and frequency: 1.0 mL of placebo, SC injection in the thigh or abdomen, twice daily for 4 Days in each treatment Cycle."
223936413|NCT06205550|DRUG|Flecainide|Flecainide monotherapy
223936414|NCT06205550|DRUG|Flecainide + beta-blocker|Flecainide + beta-blocker
223936415|NCT06800781|PROCEDURE|Prolonged treatment with posterior pericardial chest tube plus standard care|Prolonged treatment with posterior pericardial chest tube plus standard care All patients will receive chest tubes based on each surgeon's preference. Usually, 1 or 2 tubes are inserted in the mediastinum, and 1 is inserted into each open pleural cavity. Patients in the intervention arm will receive an additional posterior 20Ch chest tube. In cases where the surgeon routinely inserts 2 mediastinal chest tubes, they will use 1-2 anterior mediastinal tubes in the intervention group, based on their preference. The posterior chest tube will be positioned between the inferior aspect of the heart and the pericardium and connected to an active suction system per routine. Once the remaining chest tubes are extracted, the posterior chest tube will remain positioned in the pericardium and be reconnected from active suction to a collection bag for passive drainage. The chest tube will be removed on postoperative Day 3 or when chest tube output is \<50 mL/24 h.
223936416|NCT06831123|BEHAVIORAL|L2B|a 6-session, group-based intervention that helps youth develop mindfulness skills
224098053|NCT02870673|DRUG|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
223718657|NCT03699657|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
223718658|NCT04449900|OTHER|This is observational study with the examination of OCTA|This is observational study with the examination of OCTA
223718659|NCT03184831|PROCEDURE|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
223718660|NCT03184831|PROCEDURE|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
223718661|NCT01595932|DIETARY_SUPPLEMENT|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
223718662|NCT01595932|DIETARY_SUPPLEMENT|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children \< 20kg: 4 drops;~children \> 20kg and \< 40kg: 8 drops;~children \> 40kg: 1 tablet."
223718663|NCT02244606|DRUG|SCY-078|
223718664|NCT02244606|DRUG|Fluconazole|
223718665|NCT02244606|DRUG|Micafungin|
223718666|NCT01970215|DRUG|TA-8995|
223718667|NCT01970215|DRUG|Atorvastatin|
223718668|NCT01970215|DRUG|Rosuvastatin|
223718669|NCT01970215|DRUG|TA-8995 0mg (placebo)|
223718670|NCT01970215|DRUG|Placebo Statin|
223718671|NCT03622944|PROCEDURE|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
223718672|NCT03622944|PROCEDURE|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
223718673|NCT03622944|PROCEDURE|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
223936417|NCT06831123|BEHAVIORAL|L2B + App|the Learning to Breathe plus App condition, the 6-session L2B intervention augmented by a mobile application designed to support the use of mindfulness skills in daily life
223936418|NCT06831123|BEHAVIORAL|skills for success|a 6-session life skills intervention designed to support decision making and healthy relationships
223936419|NCT06667817|BEHAVIORAL|Exercise|16 weeks of exercise training (Exercise Group) will be prescribed via a smart phone application. Results from this group will be compared to results of the sedentary control group.
223936420|NCT05760846|DEVICE|REAplan®|motor skill learning with the REAplan® rehabilitation robot, to be performed with both arms
223718674|NCT04483271|DIETARY_SUPPLEMENT|300 mg of omega3-FA|"The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.~Baseline and follow-up serum levels of IL-1,IL-6, and TNF will be measured."
223718675|NCT01905813|DRUG|INCB040093|Escalating doses starting at 100 mg every day (QD)
223718676|NCT01905813|DRUG|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
223718677|NCT02824952|DRUG|Tagrisso|taking orally everyday for 6 or 12 weeks.
223718678|NCT05948020|BIOLOGICAL|CBT102-A capsule|"Orally CBT102-A will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with 1.25×10\^11 live cell. The shelf life is 6 months.~Subjects receive oral dose of 1 capsule CBT102-A (1.25 x 10\^11 live cell) before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule CBT102-A (2.5 x 10\^11 live cell) before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule CBT102-A (5 x 10\^11 live cell) before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule CBT102-A (1 x 10\^12 live cell) before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
223718679|NCT05948020|OTHER|Placebo capsule|"Orally placebo will be supplied by CommBio Therapeutics. It is an enteric-coated capsule with Lactose powder filler. The shelf life is 6 months. The color, condition, smell and other appearances are exactly the same as CBT102-A.~Subjects receive oral dose of 1 capsule placebo before three meals per day on Day 1 to Day 4; Subjects receive oral dose of 2 capsule placebo before three meals per day on Day 5 to Day 8; Subjects receive oral dose of 4 capsule placebo before three meals per day on Day 9 to Day 12; Subjects receive oral dose of 8 capsule placebo before three meals per day on Day 13 to Day 20; All subjects will be observed for 3 days (Day 21\~Day 23) without intervene in hospital and will be followed up weekly for 4 consecutive weeks after discharge（Day 51）."
223718680|NCT02295488|PROCEDURE|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
223718681|NCT02295488|BIOLOGICAL|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
223718682|NCT02509273|DRUG|Clonidine|
223718683|NCT02509273|DRUG|Midazolam|
223718684|NCT03493594|OTHER|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
223936421|NCT05760846|DEVICE|Dextrain Manipulandum®|motor skill learning with the Dextrain Manipulandum® dexterity tool to be performed with both hands
223936422|NCT05485805|DRUG|Naproxen sodium and caffeine (BAY2880376)|Tablet, oral use, single dose
223936423|NCT05485805|DRUG|Naproxen sodium (Aleve)|Tablet, oral use, single dose
223936424|NCT05485805|DRUG|Caffeine|Tablet, oral use, single dose
223936425|NCT05485805|DRUG|Placebo|Tablet, oral use, single dose
223936426|NCT06575621|BEHAVIORAL|Support program|education, medical navigation, exercise
223936427|NCT02625441|DRUG|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
223936428|NCT02625441|DRUG|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
223936429|NCT03481491|OTHER|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
224098054|NCT02870673|DRUG|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
224098055|NCT02870673|DEVICE|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
224098056|NCT02870673|DEVICE|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
223718685|NCT02535117|PROCEDURE|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
223718686|NCT02535117|PROCEDURE|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
223718687|NCT03370601|DRUG|Infliximab|Infliximab 10mg/kg every 8 weeks
223718688|NCT03370601|DRUG|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
223936430|NCT03420404|OTHER|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
223936431|NCT06864130|DRUG|Alendronate 70mg weekly|The intervention is discontinuation of Alendronate
223936432|NCT06516497|OTHER|Group using traditional method in long bone deformity correction|Osteotomy will be performed from the deformity center after two coring wires are placed in the same plane from the proximal and distal of the determined osteotomy line to the femur or tibia of the patients in the control group with deformity. While the degree of deformity is corrected, the determination will be made after the amount of deformity determined preoperatively is determined visually.
224098057|NCT03325309|OTHER|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
223718689|NCT03370601|DRUG|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
223718690|NCT03370601|DRUG|Infliximab|Infliximab 5mg/kg every 8 weeks
223718691|NCT01980368|OTHER|Educational Intervention|Receive readings and attend book club
223718692|NCT01980368|BEHAVIORAL|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
223718693|NCT01980368|OTHER|Questionnaire Administration|Ancillary studies
223718694|NCT00553644|DRUG|Bortezomib|Given IV
223718695|NCT00553644|OTHER|Laboratory Biomarker Analysis|Correlative studies
223718696|NCT00553644|DRUG|Lenalidomide|Given PO
224098058|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
224098059|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
223718697|NCT06354595|DEVICE|Multidimensional Rehabilitation in the Metaverse|Using the multidimensional rehabilitation space in the metaverse, evaluate the platform after use.
223718698|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
223718699|NCT02197247|DRUG|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
224098060|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Radicle GI Health Placebo Control Form 2 as directed for a period of 6 weeks.
224098061|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
224098062|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.2 Usage|Participants will use their Radicle GI Health Active Study Product 2.2 as directed for a period of 6 weeks.
224098063|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Radicle GI Health Placebo Control Form 3 as directed for a period of 6 weeks.
224098064|NCT06009614|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
224098065|NCT04689308|DRUG|MH048|Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
224098066|NCT02372162|OTHER|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
224098067|NCT02372162|OTHER|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
224098068|NCT02132221|BEHAVIORAL|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
224098069|NCT03893292|PROCEDURE|Total knee replacement|Patients will undergo total knee replacement surgery.
224098070|NCT03893292|DEVICE|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
224098071|NCT05738863|DEVICE|Low Frequency rTMS Protocol|"It was planned to apply 1 Hz low-frequency inhibition protocol to the primary motor cortex 5 days a week for 3 weeks, for a total of 15 sessions.~rTMS application Magventure MagPro R30 device is planned to provide magnetic stimulation with its stimulator. The stimulation pattern was shaped according to the protocols used in previous studies.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
224098072|NCT05738863|DEVICE|Sham rTMS Protocol|"It was planned to apply the recorded beat sound to the primary motor cortex area daily 5 days a week for 3 weeks, for a total of 15 sessions by turning the TMS coil with the reverse side and in a 90-angle upright position.~All patients were planned to continue the neurological rehabilitation program throughout the study.~Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment they are using and the drugs started for incontinence at the same effective dose, and no new incontinence medication will be started and the dose will not be changed during the rTMS sessions."
223718700|NCT02197247|DRUG|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
223718701|NCT02197247|PROCEDURE|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
224286309|NCT05804435|DEVICE|iNod™ System|The iNod™ Ultrasound Imaging System enables visualization of endobronchial lesions, peripheral lung nodules, or lung masses (referred to as lesions) using R-EBUS and performance of lung biopsy under direct R-EBUS visualization.
224286310|NCT00272649|BIOLOGICAL|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
224286311|NCT02618226|DEVICE|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
223718702|NCT02197247|PROCEDURE|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
224286312|NCT02610270|DIETARY_SUPPLEMENT|2 Gums|760 mg DHA
223718703|NCT03857958|PROCEDURE|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
224286313|NCT02610270|DIETARY_SUPPLEMENT|3 Gums|1140 mg DHA
223718704|NCT04446000|BIOLOGICAL|CSL730|solution for injection and infusion
223718705|NCT04446000|DRUG|Placebo|A solution matching the excipient profile of CSL730 without the active substance
223718706|NCT04343547|DRUG|DWP16001|Tablets, Oral, once daily single dose
223718707|NCT04343547|DRUG|DWC202001+DWC202002|Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
223718708|NCT04343547|DRUG|DWP16001+DWC202001+DWC202002|Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
223718709|NCT05417139|OTHER|Immunotherapy+induction chemotherapy+radiotherapy|All enrolled patients received Sintilimab (200mg, d1, q3w) + GP (gemcitabine 1000mg / m2, d1, d8 + cisplatin 80mg / m2, d1, q3w) for 4-6 cycles followed by radiotherapy of primary site and cervical metastasis, and Sintilimab (200mg, q3w) treatment was continued during and after radiotherapy until disease progression or toxicity or up to 2 years.
223936433|NCT06516497|DEVICE|Group using computer-aided sensors in long bone deformity correction|After 2 wires are placed in the same plane from the proximal and distal parts of the osteotomy line determined on the deformed femur or tibia of patients who underwent general anesthesia during the surgery, motion sensors will be placed on the wires. Osteotomy will be performed on the bone with deformity from the deformity center. When correcting the degree of deformity, the detection will be performed after the correction is achieved by the amount of deformity determined preoperatively.
223936434|NCT05787795|OTHER|biological samples|blood draw, oral swab, optional stool samples, spinal fluid sample, fat biopsy, tonsil biopsy, lymph node tissue sample, MRI
223936435|NCT04160455|BIOLOGICAL|expression of a panel|Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
224098073|NCT04775823|PROCEDURE|Hybrid composite nano-ceramic|Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
224098074|NCT05928143|PROCEDURE|Traditional corticotomy|A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.
224098075|NCT05928143|PROCEDURE|Flapless corticotomy|Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
224098076|NCT04036084|DIAGNOSTIC_TEST|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
224286314|NCT00921284|DRUG|NaCl 9/00|Same volume as in the dexmedetomidine group
223718710|NCT05288920|PROCEDURE|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection|Radiofrequency pulsed mode on dorsal root ganglion combined with transforaminal steroids injection
223718711|NCT05288920|DRUG|Transforaminal injection of Steroids alone|Transforaminal injection of Steroids alone
223718712|NCT00977860|RADIATION|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
223718713|NCT03822078|DRUG|Placebo|Administered by subcutaneous injection
224286315|NCT00921284|DRUG|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
224286316|NCT03186599|BEHAVIORAL|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
223718714|NCT03822078|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
223718715|NCT00851747|DRUG|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
223718716|NCT00851747|DRUG|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
223936436|NCT06504979|OTHER|Telehealth follow-up of post-intensive care syndrome|Using a telehealth platform for the detection of the emotional, neuropsychological and physical PICS-related sequelae along 12 months in ICU survivors
223534237|NCT07004387|DRUG|Amino acid solution|Adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.
223534238|NCT07004387|DRUG|Amino Acid infusion|adult patients scheduled for orthotopic liver transplant to receive an intravenous infusion of a mixture of amino acids including L arginine, at a dose of 2 g per kg of ideal body weight up to a maximum of 100 g per day, from their admission to the operating room until three days after surgery; the infusion will begin in the operating room prior to the start of the surgery, will be administered through an exclusive lumen of a central venous catheter (CVC) immediately after the CVC is in place; the infusion will continue when the patient is in the intensive care unit (ICU); as soon as the patient begins enteral nutrition, the infusion will be reduced to meet the dose of 2 g per kg of protein intake per day up to a maximum of 100 g daily, until completing 72 H of infusion. The Control Group consists of previously transplanted patients at this institution who did not receive this type of therapy.
223534239|NCT07003087|OTHER|Shoe's sole modification|Shoe's sole modification by insertion of supporting materials
223534240|NCT07004985|BEHAVIORAL|Kahoot Reinforcement|"Students in this group will complete four interactive reinforcement sessions using the Kahoot platform, following the theoretical content of the Normal Birth and Postpartum Period course. Each session includes 25 multiple-choice questions delivered in a gamified format, with real-time feedback and scoring. The intervention aims to increase motivation, focus, and retention of knowledge."
223534241|NCT07004985|BEHAVIORAL|Google Forms Reinforcement|Students in this group will complete four structured reinforcement sessions using Google Forms, after participating in the same theoretical course content. Each session consists of 25 multiple-choice questions, delivered in a self-paced online format. The intervention supports repetition and reflection, aiming to improve academic performance and motivation.
223534242|NCT07003737|DRUG|Blinatumomab|"Blinatumomab is administered starting approximately one month before allogeneic hematopoietic stem cell transplantation (allo-HSCT).~For participants weighing ≥45 kg: 9 μg/day is administered on Days 1-3, followed by 28 μg/day on Days 4-14.~For participants weighing \<45 kg: 5 μg/m²/day (based on body surface area) is administered on Days 1-3, followed by 15 μg/m²/day on Days 4-14. The total dose must not exceed the dosage used for participants ≥45 kg."
223936437|NCT04677153|OTHER|Test and treat plus peer mentors|Rapid start of HCV treatment at OTP within days of HCV diagnosis. Participants will receive 8 weeks of glecaprevir/pibrentasvir and will work with a peer mentor during and after treatment.
223534243|NCT07003737|OTHER|Consolidation Chemotherapy or Direct Allogeneic HSCT|Participants in the Non-BiTE group will either proceed directly to allogeneic hematopoietic stem cell transplantation (allo-HSCT) or receive one additional cycle of consolidation chemotherapy prior to
223534244|NCT07003152|DIAGNOSTIC_TEST|diagnosis of endolymphatic hydrops in hydrocephalus patients|the hydrocephalus could be associated with endolymphatic hydrops, this study designed to show the relationship between both of these diseases by special tests for diagnosis
223534245|NCT07003243|DRUG|Local melatonin powder|A single topical dose of 3 mg of pure melatonin powder was mixed with particulate bone graft and normal saline, then packed into the jumping gap around immediately placed dental implants. The intervention was performed at the time of surgery following atraumatic tooth extraction. The aim was to enhance osseointegration and minimize crestal bone loss over a 6-month healing period.
223936438|NCT04677153|OTHER|Usual care|Participants are referred to another location for HCV treatment.
223936439|NCT05178030|OTHER|vena punction|Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis. Blood for analysis of mutation in ctDNA will be collected at the same moment a CT-scan is performed
223936440|NCT03186391|OTHER|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
223936441|NCT04640974|DEVICE|Cingal|Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).
223936442|NCT06791915|PROCEDURE|Radiofrequency Ablation with FCV.|Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Flow Controlled Mechanical Ventilation (FCV).
223936443|NCT06791915|PROCEDURE|Radiofrequency Ablation with VCV.|Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Volume Controlled Mechanical Ventilation (VCV).
223936444|NCT06795672|BEHAVIORAL|Telerehabilitation|Three hours of cognitive rehabilitation per week, performed remotely and independently, using a computerized device, which is pre-programmed based on the patient's needs.
223936445|NCT06795672|BEHAVIORAL|Traditional in-person rehabilitation.|Three hours of in-person cognitive rehabilitation per week using a computerized device.
223936446|NCT02577185|DRUG|Botulinum Toxin Type A|
223936447|NCT02577185|DRUG|Sodium chloride 9 mg/ml|
223936448|NCT05486507|DIETARY_SUPPLEMENT|Montmorency tart cherry|US grown Montmorency tart cherry 60ml per day for 6 weeks.
223936449|NCT05486507|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
223936450|NCT05562960|PROCEDURE|Plasmapheresis|Regular plasmapheresis to remove anti-NRIP autoantibody
223936451|NCT00149175|OTHER|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
224098077|NCT04087499|DEVICE|Acupuncture|acupuncture treatment on selected acupoint
224098078|NCT00015548|DRUG|Olanzapine|
224098079|NCT00015548|DRUG|Quetiapine|
224098080|NCT00015548|DRUG|Risperidone|
224098081|NCT00015548|DRUG|Citalopram|
224098082|NCT04909567|BEHAVIORAL|Optimisation|Defined optimisation
223534246|NCT07004959|PROCEDURE|Vaginal ultrasound-guided ethanol sclerotherapy|Use of an endovaginal ultrasound probe combined with a puncture guide. The technique involves locating the endometriosis cyst, echo-guided drainage via the endovaginal route, sclerotherapy (replacement of 60% of the punctured volume with 95% ethanol left in place for 10 minutes) and then reaspiration of the ethanol.
223534247|NCT07004959|PROCEDURE|Laparoscopic cystectomy|Conventional laparoscopy, with the laparoscope introduced through a 10mm incision at the umbilicus, and the laparoscopic instruments used through two or three 5mm incisions (suprapubic and right and left fossa iliaca). The surgical technique may vary according to the patient and the surgeon's preferences or habits, but must necessarily include a cystectomy (cyst wall sent for anatomopathology).
223534248|NCT07004088|BEHAVIORAL|Mandala coloring|"Female patients undergoing dialysis treatment in the dialysis unit were informed about the study. After women are informed about the effects of mandala application on health and how to paint mandala; voluntary consent form, personal information form, Dialysis Symptom Index Scale, Self-Care Power Scale for Chronic Dialysis Patients were filled. One hour after the start of each dialysis session, the patients were given mandalas for 20-30 minutes and asked to paint. The women's own paints and mandalas were preserved for the next session. After the sixth dialysis session , the patients were asked to refill the scales with one-on-one interviews, and the verbal opinions and feedback of the patients about the application were taken."
223534249|NCT07004478|OTHER|Translating the Generic Functional Index into Turkish and Related Processes|The translation process will follow a specific protocol in accordance with the guidelines. It will include two independent forward translations and one back-translation, conducted after obtaining written permission from the original authors. Discrepancies between translations will be reviewed by an expert committee to resolve terminological and cultural differences. The process will ensure conceptual and cultural equivalence between the original English version and the Turkish version. The final version of the questionnaire will be adapted to the target population and finalized in consultation with the original authors.
223534250|NCT07004478|OTHER|Validity|Content validity will be calculated with the Content Validity Index, which is a result of expert opinions in terms of clarity, difficulty, and suitability of the Turkish version of the Generic Functional Index.
223534251|NCT07004478|OTHER|Internal consistency and Reliability|The internal consistency of the items will be tested with Cronbach alpha. Test-retest reliability will be tested with intraclass correlation coefficient.
223534252|NCT07003971|BEHAVIORAL|counselling|After the participants in the experimental group signed the 'Informed Consent Form', the Instagram addresses actively used by the pregnant women participating in the study will be taken, the Instagram account created by the researcher will be shared with the pregnant women in the experimental group, the participants will be ensured to follow the Instagram address created by the researcher and join the Instagram DM group. After the participation to the platform is completed, the visibility of the participants in the account will be checked. After the visibility of all participants is ensured, pre-tests created in Google Forms and uploaded to WhatsApp and Instagram DM group will be applied.
223936452|NCT04920006|BEHAVIORAL|Enhancing Active Caregiver Training|The intervention has three components within each session. Step 1, View, involves group viewing of a caregiving scenario, developed during previous research, which portrays a situation in which a caregiver is dealing with a challenging behavioral symptom. Step 2, Practice, involves small-group rehearsal activities that facilitate understanding, making choices, and examining possible responses. Step 3, Reflect, involves self-reflection and group processing surrounding choices and observations.
223936453|NCT04419480|DEVICE|CardioMEMS implantation with routine ambulatory pulmonary artery pressure monitoring and medication optimization|Implantation of CardioMEMS Device in patients following admission for Cardiogenic shock, with regular ambulatory pulmonary artery pressure monitoring and medication optimization for the treatment of heart failure.
223936454|NCT03254914|PROCEDURE|Home Blood Pressure|Measure Home Blood Pressure
223936455|NCT04840134|BEHAVIORAL|From Hardship to Hope: A Peer-led intervention to reduce financial hardship and suicide risk|"The intervention will be delivered in three consecutive phases:~1. Intensive Intervention Phase (weeks 1 to 6), consisting of 6 weekly group sessions and 4 one-on-one coaching sessions to navigate financial resources.~2. Intermediate Phase (weeks 7 to 12), consisting of 3 biweekly group sessions, and either 3 biweekly or 2 monthly one-on-one coaching sessions, based on participant preference.~3. Follow up Phase (weeks 13 to 24), consisting of 3 monthly group sessions, and either 3 monthly or 6 biweekly one-on-one coaching sessions based on participant preference.~Key intervention components:~1. Peer-led group sessions~2. Individual peer coaching sessions to complement group sessions"
223936456|NCT02655575|BEHAVIORAL|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
223936457|NCT02655575|BEHAVIORAL|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
223936458|NCT06756399|OTHER|Questionnare, hand grip and respiratory muscle strength|Upper extremity strength will be assessed using the Jamar hand dynamometer to measure hand grip strength. For lower extremity muscle strength, participants will undergo the five-repetition sit-to-stand test. Respiratory muscle strength, both inspiratory and expiratory, will be measured through mouth pressure assessments. Additionally, participants will complete a questionnaire addressing components related to sarcopenia diagnosis, including questions on strength, assistance with walking, rising from a chair, climbing stairs, and incidence of falls.
223936459|NCT02767999|DRUG|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
223936460|NCT02767999|DRUG|Placebo|cellulose placebo per day from D0 to D90
223936461|NCT02767999|RADIATION|fMRI|functional resting state MRI
223936462|NCT06043791|RADIATION|1.5 Tesla magnet MR arthrography|MR arthrogram is an invasive procedure where the patient's joint is injected with a mixture of dilute gadolinium, iodinated contrast medium, local anesthetic, and saline solution followed by imaging with 1.5 Tesla MRI.
223936463|NCT06043791|RADIATION|3 Tesla magnet non-contrast MRI|3T MRI uses very powerful magnets that produce a 3-tesla magnetic field. A 3-tesla magnetic field is twice as powerful as the fields used in conventional high-field MRI scanners, and as much as 15 times stronger than low-field or open MRI scanners. This results in a clearer and more complete image. Studies have shown that it is highly sensitive and specific in detecting labral and cartilage pathology
223936464|NCT06934798|DRUG|Vasopressin intravenous infusion|Vasopressin will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 0.12 U/mL. The infusion will begin at 5 mL/h and be increased by 2.5 mL/h every 10 minutes during the first hour, up to a maximum rate of 30 mL/h (equivalent to doses from 0.01 to 0.06 U/min). The target is to reach and maintain mean arterial pressure (MAP) ≥65 mmHg. If this is not achieved, open-label norepinephrine may be added. Hemodynamic and echocardiographic parameters will be measured before and after the target MAP is reached.
223534253|NCT07003971|OTHER|Control|After the 'Informed Consent Form' is signed by the pregnant women in the control group, the telephone numbers of the participants will be taken and recorded in the directory. Participants will also be asked to save the researcher's phone number. After being registered in the phone book, questionnaires and scales will be shared via WhatsApp and asked to answer the pre-tests prepared in Google Forms. Pregnant women who answer will be asked to return with a WhatsApp message in the form of 'I answered' or 'I sent'. The control group will not be trained on Instagram, but will be provided with standardised medical care established by the Turkish Ministry of Health during the follow-up period.
223936465|NCT06934798|DRUG|Norepinephrine intravenous infusion|Norepinephrine will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 120 µg/mL. The infusion will begin at 5 mL/h and be increased by 2.5 mL/h every 10 minutes during the first hour, up to a maximum rate of 30 mL/h (equivalent to doses from 10 to 60 µg/min). The goal is to reach and maintain MAP ≥65 mmHg. If the MAP target is not reached, open-label norepinephrine may be initiated. Clinical and hemodynamic parameters will be collected at baseline and after MAP stabilization.
223936466|NCT06766396|DEVICE|Postpartum Intrauterine Contraceptive Device (PPIUCD).|Participants in the intervention arm will receive a postpartum intrauterine contraceptive device (PPIUCD) immediately after delivery. For vaginal deliveries, the PPIUCD will be inserted manually using Kelly's forceps under aseptic conditions, while for cesarean deliveries, the device will be inserted before uterine incision closure. All insertions will be performed by trained healthcare professionals
224098083|NCT05170737|DRUG|AEF0217|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD."
224286317|NCT04532398|OTHER|Gugging swallowing screen - ICU (GUSS-ICU) index test|"Gugging swallowing screen - ICU (GUSS-ICU) index test:~Screening for post-extubation dysphagia: GUSS-ICU performed by 2 speech therapists independently. The GUSS-ICU model contains the core features of the original GUSS tool with the added assessment items specific to the ICU Patient (RASS score (Richmond Agitation and Sedation Scale)).~Stage one of the screen focuses on the preliminary investigation of indirect swallowing. Stage two is comprised of varying steps that directly test swallowing. This would include the administration of semisolids, water and bread with four distinct signs that were being assessed for - deglutition, coughing, drooling and voice change. The GUSS test is evaluated using a points system (0-10) which determines the severity of dysphagia and recommends a diet form that largely minimizes the risk of aspiration. (e.g. 10 points: No dysphagia = normal food)."
224286318|NCT04532398|OTHER|Flexible Endoscopic Evaluation of Swallowing (FEES) reference test|"Flexible Endoscopic Evaluation of Swallowing (FEES) reference test:~Flexible Endoscopic Evaluation of Swallowing (FEES) is a technique to directly view the pharynx, larynx and esophagus during swallowing. The swallowing test is carried out first with saliva and then with different consistency (liquid, pulpy, solid) and different sized swallowing portions. This reference test is performed independently from the GUSS-ICU index test."
224286319|NCT02026544|DEVICE|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
223534254|NCT07003607|BEHAVIORAL|Control group (placebo)|Children in the control group received routine health education, which included cancer-related treatment, care, and general health education (e.g., treatment-related, diet, and exercise) without systematic PA health education. Every four weeks, knowledge related to sports activities, the harms of insufficient physical activity, and the benefits of increasing physical activity were pushed through the WeChat platform. During the hospitalization of the child patient, they can voluntarily participate in the activities organized by social workers.
223534255|NCT07003607|BEHAVIORAL|In-Hospital Program|"Researchers will conduct a comprehensive evaluation for each pediatric patient, including:~* Disease status and clinical characteristics~* Patient and family knowledge regarding physical activity (PA)~* Availability of social support systems"
223534256|NCT07003607|BEHAVIORAL|In-Hospital Program|"Based on assessment findings, two structured educational sessions (20-30 minutes each) will be delivered, covering:~* Disease-specific knowledge and PA guidelines~* Practical strategies for safe exercise (e.g., intensity adjustment, injury prevention)~* Interactive demonstrations of age-appropriate movement techniques"
223936467|NCT06747546|PROCEDURE|"goal-directed treatment strategy based on oxygen supply and consumption balance"|"The oxygen extraction rate immediately after CPB is set as E1, the oxygen extraction rate at 4 hours after surgery is E2, and the oxygen extraction rate at 8 hours after surgery is E3. A goal-directed treatment strategy based on oxygen supply and consumption balance is defined as: Combined with the value of E2 at 4 hours after CPB, the increasing oxygen consumption (VO2) after CPB is compensated by increasing oxygen delivery (DO2) to different degrees. The goal of E3 not increasing significantly compared with E1 is achieved at 8 hours after CPB, and the severity of low cardiac output is finally reduced within the golden 8 hours after CPB."
223936468|NCT06747546|PROCEDURE|Conventional Treatment group|Ventilation support is adjusted to maintain arterial oxygen partial pressure and oxygen saturation. Appropriate fluid infusion to stabilize central venous pressure and ensure preload; Combined use of vasoactive drugs to maintain heart rate and blood pressure; Appropriate diuresis can improve urine output and reduce cardiac afterload. Blood transfusion is used to improve coagulation function and maintain appropriate hematocrit.
223936469|NCT06755112|OTHER|Placebo cream|Placebo cream application
223936470|NCT06755112|OTHER|active cream|Active cream application
223534257|NCT07003607|BEHAVIORAL|In-Hospital Program|"Patients will co-develop personalized PA plans using the six-step self-regulation framework from the ITHBC (Integrative Theory of Health Behavior Change), including:~* Short/long-term goal formulation~* Progress monitoring tools~* Barrier problem-solving protocols"
223936471|NCT06714578|OTHER|Questionnaire and Physical Exam|The investigators use questionnaire to assess biological factors (sleep quality, externalizing problem behavior, prosocial tendencies, sensation seeking, and hedonic hunger), psychological factors (risk awareness of drug misusing, indulgence of drug misusing, self-efficacy of drug misusing, and ACEs), and social factors (whether work in a special place, whether have drug-addicts around, cognition of traditional drug types, and cognition of NPS types) and demographic data
223936472|NCT02488408|DRUG|Bemcentinib|
223936473|NCT02488408|DRUG|Cytarabine|
223936474|NCT02488408|DRUG|Decitabine|
223936475|NCT06748807|PROCEDURE|APRVplus|Early Pathophysiology-driven Airway Pressure Release Ventilation (APRVplus)
223936476|NCT06748807|PROCEDURE|TCAV|Time-Controlled Adaptive Ventilation (TCAV)
223936477|NCT06757309|BEHAVIORAL|Mediterranean Diet|Intervention consists in personalized counseling to adopt the Mediterranean diet, focusing on whole foods, healthy fats, and lean proteins. Participants receive tailored meal plans, educational materials, and practical tips. Follow-up sessions at weeks 4 and 12 offer support, progress reviews, and goal-setting to ensure adherence and improved health outcomes
223936478|NCT06507150|OTHER|AI-assisted migraine education (AIME)|AIME Group will undergo the established migraine education plus AI-assisted education.
223936479|NCT03110575|DRUG|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
223936480|NCT04161755|DRUG|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
223936481|NCT04161755|BIOLOGICAL|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
223936482|NCT04161755|DRUG|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
223936483|NCT05886777|BIOLOGICAL|Combination [RSVpreF+BNTb162b2]|Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
223936484|NCT05886777|BIOLOGICAL|Bivalent BNT162b2 (original/Omi BA.4/BA.5)|Bivalent BNT162b2 given as an intramuscular injection
223936485|NCT05886777|BIOLOGICAL|RSVpreF|RSVpreF given as an intramuscular injection
223936486|NCT05886777|BIOLOGICAL|QIV|Licensed QIV given as an intramuscular injection
223936487|NCT05886777|BIOLOGICAL|Normal Saline Placebo|Normal saline (0.9% sodium chloride solution for injection)
223936488|NCT06007053|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning.
223936489|NCT06007053|BEHAVIORAL|Supportive Therapy|The supportive therapy treatment consists of 12 sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
223936490|NCT03884543|PROCEDURE|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
223936491|NCT06840795|OTHER|conventional physiotherapy|Conventional physiotherapy methods will be applied. Pain relief, electrotherapy, hot applications, ultrasound etc.
223936492|NCT06840795|OTHER|Vibration Massage Therapy|The device-assisted massage therapy will be applied by the physiotherapist with its gun-shaped form that massages through vibration.
223936493|NCT06724926|DRUG|Azeliragon|"Azeliragon is orally administered. Patients start Azeliragon 7 days before CSI and take their last dose 7 days post-CSI.~The first 6 patients will start at Dose Level 1 \[DL1\] (Loading dose for 7 days: 30 mg twice daily; Concurrent/adjuvant dose: 20 mg once daily).~If 1 or fewer of 6 patients develop dose-limiting toxicity (DLT) then the recommended dose will be DL1. If at least 2 of 6 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -1 \[DL-1\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 10mg once daily).~If 1 or fewer out of 6 patients at DL-1 develop DLT, then the recommended dose will be DL-1. If at least 2 of 6 at DL-1 develops a DLT, then an additional 6 patients will be enrolled at Dose Level -2 \[DL-2\] (Loading dose for 7 days: 15mg twice daily; Concurrent/adjuvant dose: 5mg once daily).~At the recommended dose, an additional 14 patients will be enrolled for the Dose Expansion portion."
223936494|NCT06724926|PROCEDURE|CSI|Patients will receive CSI.
223936495|NCT06310681|BEHAVIORAL|"Encompass group programme"|"* Groups will take place over ten modules~* They will take place in-person at a local community venue~* The groups will be two hours long, with a break for refreshments in the middle. They will take place every fortnight in term-time only over approximately 6 months.~* The groups predominantly follow a participatory learning approach and although the facilitators have manuals, the activities tend to include some imparting of information, key points for discussion, examples from other settings and activities for the group to practice.~* They are run by two facilitators - one parent with lived experience and one healthcare professional"
223936496|NCT06875453|OTHER|Exercise|The Schroth Best Practice program, which is widely used in the conservative treatment of scoliosis, consists of 6 modules including physiological exercises to correct the sagittal plane, activities of daily living, 3D correction techniques, powerful Schroth exercises, de-tethering exercises and gait rehabilitation. Detethering exercises in this program will be performed in this study.
223936497|NCT04273022|OTHER|Exercise|A single bout of standardized, moderate exercise
223936498|NCT06484517|DEVICE|Hugemed Videolaryngoscope|After general anesthesia induction, the first group of patients (Group M, n=20) was intubated with the McGrath videolaryngoscope. For the second group (Group H, n=20), the Hugemed videolaryngoscope was used. Patients were intubated using one of the appropriate blades numbered 1, 2, or 3 based on their height, weight, and age.
224286320|NCT00467831|DRUG|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
224286321|NCT00467831|DRUG|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
224286322|NCT00467831|DRUG|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
224098084|NCT05170737|DRUG|Placebo|"PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort."
223936499|NCT05911230|DIAGNOSTIC_TEST|Advanced diffusion-weighted MRI (ADW-MRI)|An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
223936500|NCT06949371|OTHER|Morning chronotype|All assessment measurements determined for individuals with morning chronotype will be performed first at 09:00 in the morning and then again at 19:00 in the evening. Muscle strength balance assessments performed in the morning and evening will be compared.
223936501|NCT06949371|OTHER|Evening chronotype|All assessment measurements determined for individuals with evening chronotype will be performed first at 09:00 in the morning and then again at 19:00 in the evening. Muscle strength balance assessments performed in the morning and evening will be compared.
223936502|NCT06951334|DRUG|Vildagliptin 50 mg bid|Vildagliptin 50 mg bid for 12months
223936503|NCT06950866|BEHAVIORAL|Home-based executive function training therapy|Parents receive a 2-week, 20-session online child executive function training program, delivered by a systematically trained and supervised therapist.
224098085|NCT05178537|OTHER|AAS users|no intervention
224098086|NCT03001544|BIOLOGICAL|TS23|comparison of different doses
224098087|NCT00609921|DRUG|ARQ197|treatment
224098088|NCT04662593|BEHAVIORAL|Whole Health Program|A mind-body-spirit intervention to improve health and well-being including weight loss.
224286323|NCT00467831|DRUG|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
223936504|NCT06950866|BEHAVIORAL|Home-based executive function training therapy|After the postintervention data collection, parents in the waitlist group receive a 2-week, 20-session online child executive function training program, delivered by a systematically trained and supervised therapist.
223936505|NCT06951074|BIOLOGICAL|Insulin producing stem cells infusion|"1. Liposuction of the anterior abdominal subcutaneous fat layer of participant~2. Characterization and Identification of mesenchymal stem cells~3. Differentiation of mesenchymal stem cells into insulin producing stem cells~4. In vitro detection of Insulin and c-peptide in differentiated MSC (Confirmatory tests for the insulin producing cells)~5. In vitro Insulin and c-peptide release detection in differentiated MSC in response to increasing glucose concentrations Differentiated MSCs injection in human subjects~6. Followup"
223936506|NCT06950463|OTHER|Group A (control group): It will be consisted of twenty two post menopausal women who will receive daily dosage of vitamin D3 supplement (600 IU/day) (Schleicher et al., 2016), for 6 week|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl for scratch resistance and to provide them with a firm grip, even if their hands are sweaty. This dumbbell set consists of two dumbbells weighing 2 kg each, with dimensions of 21.7 x 15.7 x 8.5 cm; 4 kg.
224098089|NCT03874234|DRUG|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
224098090|NCT03874234|DRUG|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
224098091|NCT02303587|DRUG|methylprednisolone|
224286324|NCT00467831|DRUG|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
224098092|NCT05580289|OTHER|half-shower and hot pack|The patients in the experimental group will be given hot application and half shower applications and the pain levels of the patients and the development of bladder retention will be followed.
224098093|NCT00087295|DRUG|Depsipeptide|Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
224098094|NCT02803034|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
224098095|NCT01104389|DEVICE|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
224098096|NCT02211339|BEHAVIORAL|Peer facilitator training|Peer facilitation of a project-based activity without staff present
224286325|NCT02326363|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
223534258|NCT07003607|BEHAVIORAL|Post-Discharge Program|Patients will perform PA 3-5 times weekly (20-30 minutes/session) aligned with individualized goals, adhering to oncology-specific safety guidelines
224098097|NCT02211339|OTHER|Usual care|Staff-led social activity
224098098|NCT04113629|DEVICE|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
224098099|NCT04438655|DRUG|Oral antibiotic drugs|"Oral antibiotic drugs:~\- Bimixin (Neomicin + Bacitracin tablet) 25000 UI + 2500 UI: h. 8-16-24 the day before surgery if the procedure takes place in the morning; h. 16-24-8 if the procedure takes place in the afternoon."
223936507|NCT06950463|DEVICE|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl fo|1-Dumbbells (set B08Z7SY6SP ,Gymbit , made in China) :They will be used for the treatment procedures of circuit training for all postmenopausal women in group B. Its surface is coated with vinyl for scratch resistance and to provide them with a firm grip, even if their hands are sweaty. This dumbbell set consists of two dumbbells weighing 2 kg each, with dimensions of 21.7 x 15.7 x 8.5 cm; 4 kg.
224286326|NCT02326363|BEHAVIORAL|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
223534259|NCT07003607|BEHAVIORAL|Post-Discharge Program|"Mondays: Curated PA educational content (e.g., home-based exercise videos, fatigue management tips) will be disseminated via the WeChat platform.~Sundays: Scheduled telehealth check-ins with patients and caregivers to:~* Review PA adherence and experiential feedback~* Address knowledge gaps through tailored coaching~* Reinforce behavior change techniques (e.g., self-monitoring logs)"
223936508|NCT06952127|OTHER|Rehabilitation program|"* 5-minute warm-up including easy global exercises~* 5 resistance training exercises targeting upper and lower muscle groups~* 30 secondes break between sets~* Cooldown with breathing and stretching exercises"
223936509|NCT06951204|PROCEDURE|Adductor Canal Block (ACB) Only|All patients will receive adductor canal block under complete aseptic conditions using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ). while patient is laying supine lower limbs will slightly abducted at the hips and flexed at the knees , using linear ultrasound probe(2.5-7.5MHZ) on the anterior aspect of the patient's thigh, At the level of mid-thigh, by moving probe medially until the boat shaped Sartorius muscle is visualized , at which the adductor canal is identified beneath the sartorius muscle, 20ml bupivacaine (0.25%) will be injected in the canal after a careful negative aspiration. The spread of the drug lateral and around the femoral artery will be seen real time on ultrasound
223936510|NCT06951204|PROCEDURE|Adductor canal block (ACB) combined with Genicular nerve block (GNB)|All patients will receive adductor canal block as described above under complete aseptic conditions then they will receive the genicular nerve block using a high-frequency ultrasound guidance (Sonosite turbo M, Bothell, Washington,USA ), genicular nerve block will be done at three locations, i.e., superomedial, superolateral, and inferomedial locations of the condyle-shaft junction, while patient is lying supine linear ultrasound probe(2.5-7.5MHZ) will be used to target the superomedial, superolateral, and inferomedial genicular nerves,2ml bupivacaine (0.25%) will be injected in the 3 mentioned points after a careful negative aspiration
223936511|NCT06951503|DRUG|AK112|iv, q2w
223936512|NCT06951503|DRUG|Oxaliplatin|iv, q2w
223936513|NCT06951503|DRUG|Irinotecan|iv, q2w
223936514|NCT06951503|DRUG|Leucovorin and 5-FU|iv, q2w
223936515|NCT06951503|DRUG|Bevacizumab|iv, q2w
223936516|NCT06952582|BEHAVIORAL|The IMB model-based safer sexual dual protection educational intervention|The IMB model based safe sexual dual protection education was designed to provide factual information about sexual risks of STI/HIV and unwanted pregnancy and the benefits of safer sexual dual protection behaviors including abstinence and dual protection use, enhance motivation to practice primary sexual abstinence for sexually inexperienced youth and dual protection use for sexually experienced young women, and teach specific behavioral skills required for practicing abstinence and/or negotiate safer sex with partners to use condoms/dual protection for simultaneous prevention of both risks of STI/HIV and unwanted pregnancy among youth at risk.
224098100|NCT04438655|DRUG|Parenteral prophylaxis|"Amoxicillin - Clavulanic Acid 2000/200 mg at induction of anesthesia, redosing with prolonged surgery.~in case of allergy to penicillin: Clindamycin 600 mg + Gentamycin 2 mg/kg."
224098101|NCT04101890|DRUG|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
224098102|NCT02085577|DRUG|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
224098103|NCT02085577|DRUG|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
224098104|NCT02085577|DRUG|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
224098105|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
223936517|NCT06952959|OTHER|Acupuncture|Cosmetic acupuncture
223936518|NCT06953115|OTHER|Vagal stimulation physiotherapy with trigger point release|"The patient will be instructed to remain in a seated position, with the knee slightly ahead of the feet and the feet firmly planted on the floor, with the hips higher than the knees. The therapist will stand behind the patient. Myofascial release will be performed on the upper trapezius (UT) while the patient slowly turns their head from side to side and lets it drop forward. The therapist will then apply pressure on the opposite side of the rotation.~* Therapist's position: Behind the patient.~* Patient's position: Seated with the spine in a neutral position."
224098106|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
224098107|NCT02085577|DRUG|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
224286327|NCT03907917|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
224286328|NCT05592249|OTHER|Dual Task MC|Dual Task MC group will receive 60 minutes motor - cognitive dual task intervention 5 day per week for 6 weeks in clinic.
224286329|NCT05592249|OTHER|Dual Task MM|Dual Task MM group will receive 60 minutes motor - motor dual task intervention 5 day per week for 6 weeks in clinic.
223936519|NCT06953115|OTHER|Positional Release Therapy|"A 30-minute session of positional release therapy will be provided every two weeks, in addition to personalized antihypertensive treatment, from the start of treatment (T0) until the final measurement (days 28 to 35 after obstetric resolution).~Keeping the cervical spine in a neutral position, the participant will be asked to lie down in a relaxed supine position. The therapist will progressively apply more pressure to the trigger points identified with their thumb. In the next step, the therapist will move to a more comfortable position that exerts less stress. The therapist will passively hold the patient's upper limbs in an abducted position, with a rest period between each repetition.~* Therapist's position: On the side of the patient.~* Patient's position: Supine."
223936520|NCT06954415|OTHER|No intervention (observational study)|Questionnaire without intervention
223936521|NCT06953765|OTHER|PSQI|Prospective observational cohort study: Cohort o: Stratified according to baseline sleep disorder severity (PSQI score ≥7 vs. \<7).
223936522|NCT06953765|OTHER|PQSI|PQSI-Sleep quality assessment scale
224098108|NCT02085577|DRUG|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
224098109|NCT02085577|DRUG|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
224098110|NCT02085577|DRUG|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
224098111|NCT00281450|BEHAVIORAL|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
224286330|NCT03309917|OTHER|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
224286331|NCT03309917|OTHER|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
224286332|NCT03309917|OTHER|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
224286333|NCT05814133|DEVICE|Thulium Fiber Laser|Thulium Fiber Laser will be used to break renal stones \< 2 cm into fragments small enough to remove or pass spontaneously through the ureter.
224286334|NCT06368752|BIOLOGICAL|GIP[3-30]NH2|GIP\[3-30\]NH2 is the naturally occurring shorter (truncated) variant of GIP\[1-42\]. GIP\[3-30\]NH2 also stimulates the GIP receptor and therefore acts like a GIP receptorantagonist
224286335|NCT06368752|OTHER|Saline|Sodium chlorid with 0,5% human serum albumin.
224286336|NCT06322459|BEHAVIORAL|Sport Education Curriculum|The six characteristics of The Sport Education Model include season, affiliation, formal competition, culminating event, Record-keeping, and Festivity. The intensity of the training is increasing in the first 30 minutes, and the intensity is gradually decreasing in the next 10 minutes.
223936523|NCT06953596|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Eight rTMS sessions will be administer per day at 60-minute intervals for 5 consecutive days.~Each rTMS session will consist of 600 pulses of theta-burst stimulation (iTBS), a pattern of 3 TMS pulses every 200 milliseconds for 2 seconds (i.e., 3 x 50 Hz bursts repeated at 5 Hz) for 3 minutes at 100% of resting motor threshold. The left dorsomedial prefrontal cortex (DMPFC) will be targeted via the Fz EEG site (30% of the nasion-inion distance posteriorly along the nasion-inion line)."
223936524|NCT06954701|DEVICE|Novel Personalizable Pessary|Novel personalizable pessary.
223936525|NCT06954090|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide will be introduced at a dose of 0.25 mg/week subcutaneous injection, escalated to 0.5 and 1.0 mg/week after 4 and 8 weeks if tolerated.
224098112|NCT03648450|OTHER|Propeller EMD|Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
224098113|NCT05918510|DIAGNOSTIC_TEST|Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx|The prospective observational study involves the collection of tissue, blood and saliva samples from OPSCC and occult T patients for detection of HPV-DNA/RNA, miRNA and mutation profile from DNA with centralized analysis of samples at IRCCS Regina Elena National Cancer Institute.
224098114|NCT01821963|DRUG|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
224286337|NCT06322459|BEHAVIORAL|Normal teaching|The intervention content, frequency, and intensity were the same as those in the experimental group, but the type of intervention was different. The most significant difference between the two teaching methods lies in delivering basic content. The Sport Education Model includes Teacher-directed learning (10 minutes) and Team practice (10 minutes); Normal Teaching includes Teacher-directed learning (10 minutes) and Individual practice (10 minutes).
224286338|NCT03340987|PROCEDURE|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
224286339|NCT03340987|PROCEDURE|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
224286340|NCT02251977|DRUG|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
224286341|NCT02251977|DRUG|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
223936526|NCT06954090|DRUG|Finerenone Oral Tablet|Finerenone will be introduced at a dose of 10 mg/day in patients with a serum potassium level \< 4.8 mmol/l and eGFR \< 60 ml/min/1.73 m2 and escalated to 20 mg/day after 4 weeks if the serum potassium level is still \< 4.8 mmol/l. Starting dose is 20 mg/day if eGFR ≥ 60 ml/min/1.73 m2. The dosage will be reduced or discontinued in patients who develop hyperkalemia (serum potassium \> 5.5 mmol/l).
223936527|NCT06954090|DRUG|Dapagliflozin (DAPA)|Dapagliflozin will be introduced at a dose of 10 mg/day. The dose can be reduced at any time during the trial if required by the subject's tolerance to the product.
223936528|NCT06952842|DRUG|ZVS203e|ZVS203e injection is a clear, transparent liquid containing a recombinant adeno-associated virus serotype 8 (rAAV8) vector that expresses humanized SauriCas9 protein and single guide RNA (sgRNA) targeting specific mutations in the RHO gene.
223936529|NCT01318486|OTHER|Heparin free dialysis technique|Saline flushes or predilution
223936530|NCT01318486|DEVICE|Evodial|Evodial dialyer
223936531|NCT06765616|DRUG|Adebrelimab Injection combined with radiotherapy and chemotherapy|"Radiotherapy regimen: SCRT short-term radiotherapy of 5 × 5Gy Immunotherapy regimen: Adebrelimab Injection 1200 mg or 20 mg/kg, iv., followed by administration on the 1st day of each subsequent chemotherapy cycle.~Chemotherapy regimen: CAPOX regimen (chemotherapy cycle d1, to chemotherapy cycle d14):~Oxaliplatin 130 mg/m2 iv d1~Capecitabine 1000 mg/m2 po bid d1\~14~Repeat every 3 weeks for 6 cycles~After completing 6 cycles of chemotherapy, the patient underwent TME surgery 2-3 weeks later."
223936532|NCT06765655|DRUG|Insulin Lispro Injection|point-of-care glucose monitoring via fingerstick perioperatively
223936533|NCT06765655|DIAGNOSTIC_TEST|glucose testing|POCT glucose testing via fingerstick
224098115|NCT01821963|DRUG|Ribavirin|Starting dose: 1,000 mg by mouth daily.
224098116|NCT01821963|DRUG|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
224098117|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
224098118|NCT00332657|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
224098119|NCT00332657|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
224098120|NCT00783289|OTHER|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
224098121|NCT00783289|BIOLOGICAL|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
224098122|NCT00783289|BIOLOGICAL|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
224098123|NCT00783289|BIOLOGICAL|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
223936534|NCT06765824|DEVICE|Repetitive Transcranial Magnetic Stimulation|The protocol will be applied with the MagVenture R30 stimulation device and the cool-B70 coil for active treatment. The protocol will consist of two sessions per day, with a 50-minute break between sessions, every day of the week (Monday to Friday) for three and a half weeks (a total of 36 sessions). Each session will consist of the application of a 1Hz protocol (2000 pulses at 120% of the motor threshold) in the right dorsolateral prefrontal cortex (F4) followed by an intermittent theta-burst protocol (1800 pulses at 90% of the motor threshold) in the left dorsolateral prefrontal cortex (F3). The cortical target localization will be performed using the beam-F3/F4 technique that combines different electroencephalographic positioning parameters and measurements to accurately locate said cortical targets. The motor threshold of each patient will be calculated at the beginning of each week of treatment using an electromyography system.
223936535|NCT06765824|DEVICE|Transcranial Magnetic Stimulation Sham|The same protocol described in the intervention group will be carried out in the control group. The device used is the same, the difference is the coil that maintains the same appearance and generates the same sound as the active treatment coil, but unlike the latter, it does not produce an effective magnetization to depolarize the cerebral cortex on which we act.
223936536|NCT06767241|DEVICE|Non-invasive auricular vagus nerve stimulation|Non-invasive transcranial direct current auricular vagus nerve stimulation (tDC-aVNS)
223936537|NCT06767241|OTHER|Standard Medical Therapy|Standard of care treatment for moderate to severe COVID-19
223936538|NCT06766877|OTHER|core stability exercise|"1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps"
224098124|NCT03195101|PROCEDURE|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
224098125|NCT05704530|OTHER|Blood sample|Retrospective collection of leftover tissue from standard of care biopsies or resection specimens and prospective collection of additional blood samples for study-specific analyses at specific timepoints, at the same time as routine labs are foreseen. No additional venipunctures are expected.
224098126|NCT03021837|OTHER|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
224098127|NCT01896232|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
224098128|NCT01896232|DRUG|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
224098129|NCT01896232|DRUG|Oral Placebo|Administered orally once a day.
224098130|NCT01896232|DRUG|Intravenous Placebo|Administered intravenously (IV) three times per week.
224098131|NCT05375292|OTHER|PREHABILITATION|"Customized program made by the physical therapist based on the first visit.~It includes 3 parts :~1. Nutrition advices that ensures adequate caloric and protein intake to support muscle anabolism~2. Muscle building over a few sessions with a physiotherapist to learn exercises and then independently redo them~3. Cardio-respiratory endurance exercises."
224098132|NCT03088241|OTHER|switch|switch to second-line ART
224098133|NCT03848520|PROCEDURE|TKA|TKA performed in the past
223936539|NCT06766877|OTHER|foot-ankle strengthening exercise|"1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps"
223534260|NCT07003607|BEHAVIORAL|Post-Discharge Program|Regular monitoring and evaluation will be conducted to assess PA outcomes: comprehensive evaluations will identify barriers (e.g., treatment-related fatigue) and guide real-time adjustments to the exercise plan based on the patient's physical condition and performance. To enhance adherence, families will collaboratively set alarm reminders for PA sessions, and caregivers will be invited to supervise daily activities.
223534261|NCT00834197|DRUG|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
223936540|NCT06766318|DEVICE|group A will receive cryo-ultrasound therapy combined with conventional physical therapy for two months|Cryo-ultrasound therapy combines two therapeutic methods: cryotherapy (using cold) and ultrasound (using sound waves). The ultrasound component provides a therapeutic heating effect, improving blood circulation and tissue flexibility, while the cold component reduces pain and inflammation
223936541|NCT06766318|DEVICE|LASER therapy|group B will receive LASER therapy combined with conventional physical therapy.
223936542|NCT06737263|DEVICE|BioHPP abutment|Patients in the test group receive abutments made of BioHPP
223936543|NCT06737263|DEVICE|Titanium abutment|Patients in the control group receive abutments made of titanium
223936544|NCT06737263|DEVICE|Zirconia abutment|Patients in the control group receive abutments made of zirconia
223936545|NCT06953102|OTHER|Survey using a questionnaire.|Survey was conducted to collect their responses to PSQI and BAI questionnaires.
223936546|NCT06952543|DIAGNOSTIC_TEST|Ultrasound Imaging|"Non-invasive ultrasound will be performed using Angio Flow Reactivity Analysis (AFRA)~The ultrasound probe will be attached to the subject's calf muscle and a pressure cuff will be secured around thigh. Ultrasound data will be collected for 1 minute.~The cuff will then be induced to a tolerable pressure of no more than 160 mm Hg, and ultrasound data will be collected for 3 minutes while cuff is inflated.~The cuff pressure will be released, and ultrasound data will be collected for 2 minutes after the release.~Subject will be asked to perform 1 minute plantar flexion exercise, and ultrasound data will be collected for two minutes after the completion of exercise"
223936547|NCT06834750|OTHER|Experimental Group|"The application methods of kinesiology tape for the experimental group are as follows:~1. Promoting supraspinatus muscle: Use an I-shaped tape (with natural tension).~2. Promoting the anterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).~3. Promoting the posterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).3. Promoting the posterior fibers of the deltoid muscle: Use an I-shaped tape (with natural tension).~4. Fixing the shoulder joint: Use an I-shaped tape (with moderate tension).~5. Inhibiting biceps brachii muscle / promoting triceps brachii muscle (depending on the patient's recovery stage and different functional impairments, different taping methods are used).~6. Promoting wrist extensor muscles / inhibiting wrist flexor muscles (depending on the patient's recovery stage and different functional impairments, different taping methods are used)"
223936548|NCT06834750|OTHER|Control group (placebo)|The control group was pasted with sports white tape (the pasting method was the same as above, replaced with sports white tape).
223936549|NCT06771440|OTHER|EPR search|A stored query in the EPR, that checks for re-exposure to the culprit antibiotic or class-member, from the date of AAL registration to the date of patient inclusion
223936550|NCT06951841|DRUG|Liposome Irinotecan|Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
223936551|NCT06951841|DRUG|Platinum|Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
223936552|NCT06951841|DRUG|Tislelizumab|Tislelizumab (200mg) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
223936553|NCT06951841|DRUG|Anlotinib|Anlotinib (8mg) will be administered orally in a 3-week treatment cycle, once a day from day 1 to day 14 of each cycle
223936554|NCT06950359|DEVICE|Gelatin Sponge Dressing (Cutanplast®)|Absorbable gelatin-based hemostatic sponge used for all study groups as a wound contact dressing.
223936555|NCT06950359|DEVICE|Cyanoacrylate Tissue Adhesive (PeriAcryl®)|High-viscosity N-Butyl Cyanoacrylate/2-Octyl Cyanoacrylate adhesive applied as a topical barrier to the palatal wound site in the Cyanoacrylate Group.
223936556|NCT06950359|DEVICE|Polyglycolic Acid Sheet (Neoveil®)|Bioresorbable PGA sheet placed over the gelatin sponge in the Polyglycolic Acid Group to enhance wound protection and healing.
223936557|NCT06950424|DIETARY_SUPPLEMENT|black cumin seed oil|500mg of black cumin seed oil standardized for 3% thymoquinone)
223936558|NCT06951087|DRUG|Dexamethasone sodium phosphate|In patients with stable DR and no significant macular edema, intravitreal anti-VEGF injections after phacoemulsification surgery can prevent the worsening of postoperative macular edema and potentially improve final visual outcomes while maintaining safety. Laser coagulation and intravitreal anti-VEGF injections are currently considered the standard treatments for PDR. However, the cost of anti-VEGF drugs often prevents many patients from receiving regular and timely injections. Intravitreal corticosteroids may be used as an alternative to anti-VEGF agents.
223936559|NCT06951256|DRUG|Scalp block with bupivacaine alone|In Group SB: (LA) was done by 20ml of Bupivacaine 0.25%. maximal dose of Bupivacaine did not exceed (2.5 mg/kg) Scalp nerve block will be done by anesthesiologist who is blind to the drug being injected and under complete septic condition where local infiltration of local anesthetic (LA) will be done guided by bony superficial landmarks to block the supraorbital, supratrochlear, auriculotemporal, occipital, and post auricular branches of the greater auricular nerves
223936560|NCT06951256|DRUG|Scalp block by adding dexmedetomidine as an adjuvant to bupivacaine|local infiltration of total volume 20ml which include (Bupivacaine 0.25%. + Dexmedetomidine 1mcg/kg) was done Dexmedetomidine preparation was done by 2ml (200 mcg) diluted by 18 ml normal saline in 20 ml syringe as 1ml was contain 10 mcg and injected at same points as above
223936561|NCT06954012|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|ice every 2 waking hours during the first 24 to 48 hours,a brace early in rehabilitation , strain counters strain technique
223534262|NCT00834197|DRUG|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
223936562|NCT06954012|OTHER|Exercise|RICE, anterior-to-posterior talar mobilization, orthoses
223936563|NCT06953544|BEHAVIORAL|Father-Sensitive Education|he father-sensitive education program preserves the basic structure of the Childbirth Preparation Education program, but has been enriched with original content that supports the active emotional and functional participation of fathers-to-be in the birth process.
223936564|NCT06953544|BEHAVIORAL|Standardized birth education|The control group received a total of 12 hours of standard childbirth preparation training, consisting of four three-hour sessions.
223936565|NCT06951776|BEHAVIORAL|Morning administration group of teriparatide|Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
224098134|NCT04185467|OTHER|Intervention (rehabilitation exercise)|Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
224098135|NCT01972477|DRUG|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
224098136|NCT01972477|OTHER|Placebo|Placebo will be given every day for 8 weeks.
224098137|NCT02721004|DRUG|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
224098138|NCT00686205|DEVICE|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
224286342|NCT02251977|DRUG|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
224286343|NCT04973098|BIOLOGICAL|CT0181 Cells|5 dose levels each with or without lymphocyte clearance were tentatively determined.
223534263|NCT06997107|OTHER|Health promotional messages generated by Artificial Intelligence|Short (850 characters) and long (1 page) messages will be generated by a Generative Artificial Intelligence (ChatGPT 4.0) on different health-related topics
223534264|NCT06997107|OTHER|Health promotional messages generated by humans|Short (850 characters) and long (1 page) messages will be generated by a primary care and/or public health human expert on different health-related topics
224286344|NCT02199119|BEHAVIORAL|Exercise|30 min of moderate exercise on a treadmill
224286345|NCT02199119|BEHAVIORAL|TV viewing|watching TV (animated children's programming) for 30 min
224286346|NCT02199119|BEHAVIORAL|Sitting quietly|Sitting quietly for 30 min
223534265|NCT06545617|DRUG|BAT8006 for Injection|Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
223534266|NCT05889507|PROCEDURE|Whole body hypothermia|Whole-body hypothermia (33.5±0.5°C) initiated within 6 hours of birth and continued for 72 hours. The rectal temperature will be maintained at 33.5±0.5°C using a servo-controlled cooling machine.
223534267|NCT05889507|PROCEDURE|Targeted normothermia|The axillary temperature will be maintained at 37±0.5°C for the first 80 hours and any hyperthermia will be treated with a standardised protocol.
223534268|NCT05889507|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
223534269|NCT05889507|DIAGNOSTIC_TEST|Follow up assessment at 2 years of age|The assessment will be carried out using the Bayley Scales of Infant and Toddler Development IV. In addition, all infants will have a detailed neurological examination, including Gross Motor Function Classification System (GMFCS) for cerebral palsy, vision, and hearing assessment. Babies who die or who cannot be assessed with the Bayley-IV due to severe disability will be allocated a Cognitive Scale Composite score one point below the basal test score. PARCA-R will be completed by the parents immediately.
223534270|NCT05622942|BIOLOGICAL|PBPV|Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
223936566|NCT06951776|BEHAVIORAL|Evening administration group of teriparatide|Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m. in the morning (Group A) and subcutaneous injection of 20 μg teriparatide at 20:00 p.m. in the evening (Group B).
223936567|NCT06954558|DRUG|GK01 Injection|Autologous tumor-reactive T cells injection
223936568|NCT06952322|OTHER|Questionnaire and Physical Exam|Questionnaire results of groups will be compared.
223936569|NCT05042973|DRUG|Empagliflozin 10 MG|Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
223936570|NCT05042973|DRUG|Placebo|Placebo matches the active drug in appearance, odor and labelling.
223936571|NCT03243175|DRUG|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
223936572|NCT03243175|DEVICE|left atrial appendage closure|left atrial appendage closure
223936573|NCT05989659|OTHER|Exposure: Home dialysis or facility-hemodialysis|Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or facility-hemodialysis
223936574|NCT06817408|OTHER|Observation|One additional blood draw in the Emergency Department as part of their standard of care visit.
224098139|NCT04150432|DEVICE|Edmon|New device for exhaled propofol concentration measurements
224098140|NCT00265941|DRUG|cetuximab|Cetuximab 400 mg/m\^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m\^2 IV weekly for 7 weeks
224098141|NCT00265941|DRUG|cisplatin|Cisplatin 100 mg/m\^2 IV on days 1 and 22
224286347|NCT04581876|DRUG|raltitrexed for injection|Patients receive raltitrexed 2mg/m2 (iv, 15min) on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
224098142|NCT00265941|RADIATION|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
224098143|NCT00265941|RADIATION|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
224098144|NCT03741439|DEVICE|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
224098145|NCT03741439|DEVICE|Sham|Sham treatment
224098146|NCT04154553|DIAGNOSTIC_TEST|Buccal swab|Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.
223936575|NCT06443008|DEVICE|Observation Group|On the basis of myoelectric biofeedback treatment in the control group, the control group was trained alternately in each muscle group (triangle muscle, triceps brachii muscle group and forearm extensor muscle group). For example,After disinfection of the triangular, triceps and extensor muscles of the patient, the feedback electrode was attached to the area. The stimulation frequency was set at 50 Hz and the stimulation pulse width was set at 200 μs.During treatment, the patient is instructed to listen carefully to the device's password, drive the affected limb according to the specific password, and then perform tension and relaxation training.For each muscle group, the training time of each muscle group is about 0.5 h, 1 / d.In the later stage of treatment, the training intensity can be increased appropriately, so that the patient can carry out weight lifting during the feedback treatment, and listen to the password issued by the device to carry out muscle strength exercise.
223936576|NCT05879068|DRUG|PM8002|IV infusion
224098147|NCT04154553|DIAGNOSTIC_TEST|EDTA Blood sample (4.9mL)|Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.
224098148|NCT04154553|DIAGNOSTIC_TEST|Serum sample (7.5mL)|blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).
224286348|NCT04581876|DRUG|nab-paclitaxel|Patients receive nab-paclitaxel at 125 mg/m2 on day 1 and day 15, q4w. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity, death or begin a novel treatment.
224286349|NCT05220969|GENETIC|Total Genotype Risk Score|A total genotype risk score has been generated based on the results of previously observed genetic association studies
224286350|NCT01772355|DEVICE|semi automated core needle biopsy of orbital tumors|
223936577|NCT05879068|DRUG|Paclitaxel|IV infusion
223936578|NCT06063746|DRUG|Vidutolimod|
223936579|NCT05293717|DRUG|Ruxolitinib|1.5% Ruxolitinib cream
224098149|NCT04154553|OTHER|communication of test results|Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician
224098150|NCT04154553|OTHER|unstructured interview|One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes
224098151|NCT02373930|DRUG|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
224098152|NCT02373930|DRUG|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
224098153|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
224098154|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
224098155|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
224098156|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
224098157|NCT02373930|DRUG|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
224098158|NCT00898053|OTHER|laboratory biomarker analysis|Correlative studies
224098159|NCT01583647|DRUG|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
224098160|NCT01583647|DRUG|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
224286351|NCT02676791|DRUG|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
224286352|NCT05369091|DRUG|Simvastatin 10mg|Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
224286353|NCT00625755|BIOLOGICAL|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
223936580|NCT05036291|DRUG|NB004 tablets|"Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA ."
223936581|NCT05017532|BEHAVIORAL|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)|The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
223936582|NCT04297605|DRUG|Pembrolizumab|Pembrolizumab 200 mg
223936583|NCT04297605|OTHER|Pemetrexed (Chemotherapy)|500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
223936584|NCT04297605|OTHER|Nab-paclitaxel (Chemotherapy)|100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
223936585|NCT04091295|DRUG|DNG64|Intravenous infusions of DNG64 for treatment of advanced pancreatic cancer, sarcoma and carcinoma of breast
223936586|NCT05374785|DRUG|CPL409116|CPL409116 contained in the tablet called PG242 (60 mg)
223936587|NCT05374785|OTHER|Placebo|Tablets without CPL409116 as an active substance
223936588|NCT06441149|OTHER|AI-based informed consent|Patients receiving personalized data-based informed consent procedure before bronchoscopy
223936589|NCT06441149|OTHER|Standard informed consent|Standard informed consent
223936590|NCT06084416|DRUG|Sovilnesib|Sovilnesib tablets will be given orally.
223936591|NCT05536076|OTHER|Hypercapnia treatment|Intermittent hypercapnia treatment five days per week for two weeks.
223936592|NCT01162096|DEVICE|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
223936593|NCT05413798|OTHER|Urine HPV testing|Human papillomavirus (HPV) testing in urine sample.
223936594|NCT05413798|OTHER|Self-collected cervicovaginal specimen|Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
223936595|NCT05413798|OTHER|Provider-collected cervical samples|Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
223936596|NCT05377060|BEHAVIORAL|Plasma p-tau risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.
223936597|NCT05377060|BEHAVIORAL|Standard risk disclosure|Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
223936598|NCT03762850|DRUG|sparsentan|Target dose of 400 mg daily
223936599|NCT03762850|DRUG|irbesartan|Target dose of 300 mg daily
223936600|NCT03762850|DRUG|Dapagliflozin|Target dose of 10 mg daily
223936601|NCT02398786|OTHER|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
224098161|NCT00173953|PROCEDURE|immune response|
224098162|NCT03816995|DEVICE|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
224098163|NCT03816995|DEVICE|Alexis O Wound Protector|wound retraction
224098164|NCT03691558|OTHER|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
224098165|NCT03691558|OTHER|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, \& Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
224098166|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at T0|
223534271|NCT05622942|BIOLOGICAL|PPV23|Intramuscular injection, 1 dose of 0.5ml inoculated on day 0
223936602|NCT05606614|GENETIC|TSHA-102|TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.
223936603|NCT04398095|RADIATION|Hypofractionated radiotherapy|Resectable or marginally resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.
223936604|NCT04398095|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
223936605|NCT04398095|RADIATION|Hypofractionated radiotherapy with boost|"Non-resectable/inoperable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.~Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification."
223936606|NCT05746429|BEHAVIORAL|Cognitive Behavior Therapy|Receive mobile CBT
223936607|NCT05746429|DEVICE|Transcranial Direct Current Stimulation|Undergo active tDCS
223936608|NCT05746429|OTHER|Interview|Attend virtual meetings and focus groups
223936609|NCT05746429|DRUG|Placebo Administration|Undergo sham tDCS
223936610|NCT05746429|OTHER|Questionnaire Administration|Ancillary studies
223936611|NCT06715033|DIAGNOSTIC_TEST|y balance and SLS|for assessment of static and dynamic balance
223936612|NCT03083366|DEVICE|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
224286354|NCT04031092|DEVICE|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
223936613|NCT05570617|BEHAVIORAL|Transition Coach Intervention|The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
223936614|NCT05570617|BEHAVIORAL|Standard of Care- Youth Transition Roadmap|All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
223936615|NCT05810363|DRUG|Etomidate - propofol mixture|Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
223936616|NCT05810363|DRUG|Propofol|Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
223936617|NCT05841706|BIOLOGICAL|Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL)|Receive conservative transfusion strategy (Hgb \< 7 g/dL)
223936618|NCT05841706|BIOLOGICAL|Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL)|Receive liberal transfusion strategy (Hgb \< 9 g/dL)
223936619|NCT05841706|PROCEDURE|Computed Tomography|Undergo CT scan
223936620|NCT05841706|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224098167|NCT03123523|DIAGNOSTIC_TEST|Exercise test|
224098168|NCT03123523|BIOLOGICAL|Biological assays|Creatinin, hematocrit and BNP assays
224098169|NCT03123523|DEVICE|MRI with contrast agent injection|With injection of gadolinium
224098170|NCT03123523|DEVICE|MRI without contrast agent injection|Without injection of gadolinium
224098171|NCT03123523|DIAGNOSTIC_TEST|Echocardiography at M24|
224098172|NCT01864577|OTHER|Negative Pleural Suction at -20 cm H2O|
224286355|NCT04031092|DEVICE|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
223936621|NCT05841706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223936622|NCT05841706|OTHER|Survey Administration|Ancillary studies
223936623|NCT05841706|PROCEDURE|Pancreatectomy|surgical removal of all or part of pancreas
223936624|NCT06784180|DRUG|Morphine|200 mcg intrathecal morphine
223936625|NCT06784180|DRUG|Bupivacaine|Intrathecal 0.75% bupivacine in 8.25% dextrose (Dose determined by weight, height, gestational age)
223936626|NCT06784180|DRUG|Fentanyl|15 mcg intrathecal fentanyl
223936627|NCT06784180|DRUG|Hydromorphone|100 mcg intrathecal hydromorphone
223936628|NCT05652218|DEVICE|LB-CRT|LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)
223936629|NCT05652218|DEVICE|BIV-CRT|BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).
223936630|NCT03668899|PROCEDURE|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
223936631|NCT05490732|BIOLOGICAL|Blood sampling|"Patient will be subjected to 3 blood sampling over 24hours. At H0, H4 and H12-24.~For each one, one microsampling and one venipuncture"
223936632|NCT06416072|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
223936633|NCT04367675|DRUG|INO-5401|INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.
223936634|NCT04367675|DRUG|INO-9012|INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.
223936635|NCT04367675|DEVICE|Cellectra 2000|The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.
223936636|NCT03220074|DRUG|Oral Tablet|study drug given and monitored for efficacy and tolerability
223936637|NCT06307938|DIAGNOSTIC_TEST|liquid biopsy|based on a panel of circulating tumor DNA markers
223936638|NCT02475343|DEVICE|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
224098173|NCT01864577|OTHER|Water seal|
224098174|NCT06082778|BEHAVIORAL|Fermented food intake above habitual level|Participants increase their habitual intake of fermented foods by three portions per day, compared to their habitual intake level at baseline.
224098175|NCT03109951|DRUG|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
224286356|NCT04031092|BEHAVIORAL|Rehabilitation program|traditional inpatient rehabilitation program.
224286357|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
224286358|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
224286359|NCT04813562|BIOLOGICAL|a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
224286360|NCT04813562|BIOLOGICAL|a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
223534272|NCT06863753|OTHER|Kangoroo mother care|Kangaroo mother care will be practiced once, when the service, mother and baby are available, and then the training will be given. For skin-to-skin contact, the newborn will be laid naked on the mother's bare chest in the prone position, the newborn's abdomen and chest will be in contact with the mother's skin. Subsequently, the newborn's head will be turned to the side so that the airway remains open. The newborn will stay in this position for at least 45 minutes.
223936639|NCT02475343|DEVICE|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
223936640|NCT02475343|DEVICE|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
223936641|NCT02475343|DEVICE|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
223936642|NCT02475343|DEVICE|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
223936643|NCT02475343|DEVICE|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
223936644|NCT06950736|DIETARY_SUPPLEMENT|NR|600 mg/d of oral NR for two months
223936645|NCT06950736|DIETARY_SUPPLEMENT|Vit E|200 mg/d of oral Vitamin E for two months
223936646|NCT04966858|OTHER|Individualized Caloric Refeeding (ICR)|Meal-based refeeding in hospital, starting at 50 calories per kilogram of body weight, and increasing by 200 calories per day until caloric goal achieved
223936647|NCT04966858|OTHER|Higher Calorie Refeeding (HCR)|Meal-based refeeding in hospital, starting at 2000 calories per day, and increasing by 200 calories per day until caloric goal achieved
223936648|NCT06782165|PROCEDURE|Arthroscopy & saline irrigation alone|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly
223936649|NCT06782165|PROCEDURE|Discectomy|Discectomy refers to open temporomandibular joint surgery where the joint disc is completely removed without being replaced.
223936650|NCT06057974|OTHER|Close Collaboration with Parents|"The Close Collaboration with Parents intervention is an educational model for healthcare staff working in NICUs. It aims to improve the ability of the members of the NICU healthcare team to I) observe the infants' individual behaviors and needs, II) support parents to take the initiative and share their observations and understanding of their infant's behaviors and to collaboratively plan the infant's care with the healthcare staff, III) understand the individual story of the family regarding parenthood through a dialogue with parents, and IV) involve parents in the decision-making about the care of their baby from an early stage of care through to the preparation for discharge. The final goal is to improve the care culture in the NICUs by changing the attitudes of the healthcare staff and the care practices of the unit to be more in line with family-centered care principles.~It usually takes 1.5 years for each NICU to complete the intervention."
223936651|NCT06782191|PROCEDURE|Arthroscopic lysis and lavage|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.
223936652|NCT06782191|PROCEDURE|Operative arthroscopy|Operative arthroscopy refers to an arthroscopic procedure where the temporomandibular joint is accessed via two ports of entry. The joint is rinsed with saline solution and the anterior disc attachment is released with cold ablation where after the posterior attachment is sclerosed with the coagulation mode on the coblator.
223936653|NCT02036970|DRUG|Bardoxolone methyl|
223936654|NCT02036970|DRUG|Placebo|
223936655|NCT02266654|OTHER|IV fluids|Normal Saline 0.9%
223936656|NCT02266654|OTHER|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
223936657|NCT02298842|DEVICE|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
224286361|NCT04813562|BIOLOGICAL|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
224286362|NCT04813562|BIOLOGICAL|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
224286363|NCT04813562|BIOLOGICAL|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
224286364|NCT04813562|BIOLOGICAL|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56|60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
224286365|NCT02137694|OTHER|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
224286366|NCT00003430|DRUG|L-778,123|
224286367|NCT03321994|DEVICE|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
224286368|NCT03321994|DEVICE|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
224286369|NCT03605524|OTHER|Sensory training|12 weeks sensory training
224286370|NCT05861219|BEHAVIORAL|water immersion|mild physical activity then water immersion in tub
224286371|NCT05164913|OTHER|Achenbach Child Behavior Checklist （CBCL）scale|Use the Achenbach Child Behavior Checklist （CBCL）scale to assess children's behavior
224286372|NCT00860743|DRUG|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
224286373|NCT03439579|BEHAVIORAL|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
224286374|NCT00467987|DRUG|androgel|androgel 1%
224286375|NCT00467987|DRUG|placebo|placebo
224286376|NCT02776553|OTHER|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
224286377|NCT02776553|BEHAVIORAL|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
224286378|NCT02776553|BEHAVIORAL|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
224286379|NCT01396382|RADIATION|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
224286380|NCT03762746|DEVICE|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
224286381|NCT03762746|DRUG|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
224286382|NCT00190580|DRUG|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
224286383|NCT00190580|DRUG|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
223936658|NCT02298842|DEVICE|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
223936659|NCT02386098|DRUG|BMS-955176|HIV Maturation Inhibitor
223936660|NCT02386098|DRUG|Atazanavir (ATV)|Atazanavir
223936661|NCT02386098|DRUG|Ritonavir (RTV)|Ritonavir
223936662|NCT02386098|DRUG|Dolutegravir (DTG)|Dolutegravir
223936663|NCT02386098|DRUG|Tenofovir (TDF)|Tenofovir
223936664|NCT06699628|DRUG|IRL757|IRL757 capsules
224098176|NCT05258461|OTHER|use of a smartphone app for adverse event management|At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q\&A platform.
224098177|NCT05258461|OTHER|conventional adverse event management|Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
224098178|NCT03747445|PROCEDURE|Roux-en-Y gastric bypass|laparoscopic surgical procedure
223936665|NCT03287232|DRUG|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
223936666|NCT03287232|DRUG|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
223936667|NCT05955040|DRUG|Nifedipine|Standard of care for treatment of elevated blood pressure during pregnancy
223936668|NCT05955040|DRUG|Labetalol|Standard of care for treatment of elevated blood pressure during pregnancy
223936669|NCT06129838|DRUG|[11C]-CS1P1|Participants will receive a single intravenous bolus injection of 12.0 - 17.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a brain \[11C\]-CS1P1 PET scan
223936670|NCT05013216|DRUG|Cohort A: Patients at high risk of developing pancreatic cancer.|"1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC"
223936671|NCT05013216|DRUG|Cohort B: Patients must have evidence of a pancreatic cystic neoplasm|Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
223936672|NCT04280718|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous administration of efgartigimod
223936673|NCT06792994|OTHER|Observational|The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively
224098179|NCT05159180|DEVICE|cardioz mapping|Patients will be submitted to mapping of both voltage and tissue impedance.
224286384|NCT02123420|DEVICE|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J\&J International, St-Stevens-Woluwe, Belgium)."
223936674|NCT06518551|DRUG|Elotuzumab|Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.
223936675|NCT06518551|DRUG|Iberdomide|A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.
223936676|NCT06518551|DRUG|Dexamethasone|Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
223936677|NCT06296992|BEHAVIORAL|12-week TEAM peer mentor program|A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
224098180|NCT06098014|DRUG|Thalidomide Capsules|To see safety and efficacy of Thalidomide in Transfusion depended thalassemia
224098181|NCT06098014|DRUG|Placebo|compare with Thalidomide
224098182|NCT01154413|BEHAVIORAL|Intensive education of the doctor/nursing team on the protocol|
224098183|NCT02795234|OTHER|Blood samples|
223936678|NCT05897294|DRUG|Voriconazole Inhalation Powder|dry powder inhalation of voriconazole
223936679|NCT04000750|OTHER|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
223936680|NCT04000750|OTHER|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
223936681|NCT04000750|OTHER|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
223936682|NCT04000750|DIETARY_SUPPLEMENT|Whey Protein|Consumed on all exercise days.
223936683|NCT05020496|DRUG|Diphenylcyclopropenone (DPCP)|Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
223936684|NCT04539704|DEVICE|magnet and sham|In same subject some areas will have magnet and others will have sham
223936685|NCT05861570|DRUG|normal saline|Ultrasound guided injection using 3ml normal saline
223936686|NCT05861570|DRUG|(Sodium Hyaluronate (Hyruan One , LG)|Ultrasound guided injection using 3ml of Sodium Hyaluronate
223936687|NCT05861570|DRUG|lidocaine hydrochloride|Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
223936688|NCT05861570|DRUG|Triamcinolone Acetonide|ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide
223936689|NCT03065049|BEHAVIORAL|Peer-Facilitated Counseling|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
223936690|NCT03065049|BEHAVIORAL|Fitbit activity tracker|Participants will be given a Fitbit activity tracker to monitor physical activity.
223936691|NCT01492049|BEHAVIORAL|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
224098184|NCT01146470|DIETARY_SUPPLEMENT|RGC|dosage of Red Grape Cells once a day, during 3 months
224098185|NCT01146470|DIETARY_SUPPLEMENT|Placebo|dosage of Placebo once a day, during 3 months
224286385|NCT05304026|DEVICE|Technique 1|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F pigtail catheter placed at the level of renal arteries to identify the lowest renal artery.
223936692|NCT01492049|BEHAVIORAL|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
223936693|NCT01492049|BEHAVIORAL|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
223936694|NCT06219434|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
223936695|NCT06219434|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI
223936696|NCT06219434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223936697|NCT06219434|OTHER|Questionnaire Administration|Ancillary studies
223936698|NCT00506844|DRUG|Cetuximab, Irinotecan, Capecitabine|
223936699|NCT06523478|PROCEDURE|Intratonsillar immunotherapy (ITIT)|During injection, the operator needs to gently shake the injection bottle about 20 times, the drug must be mixed to ensure the consistency of allergen concentration, and carefully check the patient's name and concentration on the bottle. Allergy extracts should not be injected intravenously, so the syringe will be aspirated to avoid inadvertent intravascular injection. Before each injection, after inserting the needle into the selected tonsil, before injecting the dose, the investigator will slightly pull the plunger of the syringe. If blood returns from the syringe, the syringe, and its contents will be discarded. The other tonsil will be selected and a new syringe will be prepared.
223936700|NCT06523478|PROCEDURE|Subcutaneous immunotherapy (SCIT)|Injection requires shaking bottle 20x to mix drug for consistency. Verify patient name \& concentration. Use 1 ml skin test syringe for deep subcutaneous injection at 45° angle, 1 cm into outer upper arm. Lift skin folds for deeper injection, avoid subcutaneous, muscular or intravascular. Inject slowly, 1 min for 1 ml. Avoid shallow injections which may cause local side effects. Alternate between left \& right arm for 5 min after injection for compression.
223936701|NCT04382313|PROCEDURE|the adequate hydration group guided by Vigileo|If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
224098186|NCT02406755|OTHER|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
224098187|NCT02406755|OTHER|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
224098188|NCT02406755|OTHER|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
224098189|NCT05381961|DEVICE|Bioimpedance spectroscopy (BIS) measurement, SOZO device|All patients enrolled in this study will undergo BIS measurement before and after 12 hemodialysis sessions (pre-dialysis and post-dialysis BIS measurements for each session). Measurements are not provided to treating physicians and are not used to guide clinical decisions; i.e., BIS measurements are collected for observational purposes only.
224098190|NCT02353949|DRUG|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
224286386|NCT05304026|DEVICE|Technique 2|It refers to CO2 digital subtraction angiographies performed at the beginning of the procedure through a 5F introducer placed at the end of the proximal sealing zone to identify the lowest renal artery.
224286387|NCT05304026|DEVICE|Technique 3|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F pigtail catheter through the pigtail catheter placed at the level of renal arteries.
224286388|NCT05304026|DEVICE|Technique 4|It refers to CO2 digital subtraction angiographies performed at the end of the procedure through a 5F introducer placed at the level of the contralateral iliac limb.
223936702|NCT03496558|OTHER|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
223936703|NCT02053298|DRUG|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
223936704|NCT00235937|DRUG|Anastrozole and goserelin|
223936705|NCT03965949|DRUG|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
223936706|NCT03965949|DRUG|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
223936707|NCT05333367|OTHER|Samples collection|Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)
224098191|NCT04240743|DEVICE|cephalomedullary nail|For patients in the cephalomedullary nail group, an incision was made in the gluteal area from the tip of the greater trochanter in proximal orientation. A guidewire was placed into the medullary canal from slightly medial to the exact tip of the greater trochanter. The entry point of the greater trochanter and proximal medullary canal were reamed. The cephalomedullary nail was then inserted and fixed to the femoral head with a double screw. The cephalomedullary nail was then locked distally using a guide arm. These cephalomedullary nails were not locked proximally to maintain dynamization and to allow compression across the basicervical fracture line.
224098192|NCT04240743|DEVICE|sliding hip screw|For patients in the sliding hip screw group, a lateral incision was made over the lateral proximal aspect of the femur. Under fluoroscopic guidance, the lag screw was placed centrally in the femoral head over the guidewire. A side plate with three holes was then attached to the hip screw.
223936708|NCT01596231|DIETARY_SUPPLEMENT|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
223936709|NCT01596231|DIETARY_SUPPLEMENT|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
223936710|NCT03790215|DRUG|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
223936711|NCT03002194|DEVICE|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
223936712|NCT03002194|OTHER|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
223936713|NCT02351791|OTHER|Patch 1|Patch 1:standard adhesive with own feces in sleeve
223936714|NCT02351791|OTHER|Patch 2|Patch 2:standard adhesive with own feces mixture in sleeve
223936715|NCT02351791|OTHER|Patch 3|Patch 3: standard adhesive with simulated feces in sleeve
223936716|NCT02351791|OTHER|Patch 4|Patch 4:standard adhesive with simulated feces mixture in sleeve
223936717|NCT02351791|OTHER|Patch 5|Patch 5:standard adhesive with buffer in sleeve
224098193|NCT00432198|DRUG|Zolpidem (Myslee®)|Oral
224098194|NCT00432198|DRUG|placebo|Oral
223936718|NCT02351791|OTHER|Patch 6|Patch 6:standard adhesive with buffer mixture in sleeve
223936719|NCT01905566|DRUG|Clopidogrel|75mg once a day
223936720|NCT01905566|DRUG|Ticagrelor|90mg twice a day
223936721|NCT02720432|OTHER|CIMT|Constraint-induced movement therapy
223936722|NCT02720432|OTHER|HABIT|hand-arm bimanual intensive training
223936723|NCT02720432|OTHER|baby-massage|instructions for baby-massage
223936724|NCT00048932|DRUG|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
223936725|NCT00048932|DRUG|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
223936726|NCT00048932|DRUG|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
223936727|NCT04436549|PROCEDURE|Stab Avulsion of varicose veins|Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
223936728|NCT04436549|DIAGNOSTIC_TEST|Histopathologic evaluation of varicose veins|Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
223936729|NCT04196309|DRUG|low molecular weight heparin|LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)
223936730|NCT01444690|DRUG|Dimiracetam|Capsules for oral administration twice daily
224098195|NCT02997930|BEHAVIORAL|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
224098196|NCT02997930|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
224098197|NCT02997930|BEHAVIORAL|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
224098198|NCT02997930|BEHAVIORAL|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
224098199|NCT02997930|BEHAVIORAL|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
224098200|NCT02997930|BEHAVIORAL|General Depression Scale (GDS)|A measure of the of presence of depression.
224098201|NCT06056973|DRUG|jinghua weikang capsule|Oral Jinghua Weikang Capsule, two capsules each time, three times a day
224098202|NCT01441544|BEHAVIORAL|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
223936731|NCT01444690|DRUG|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
223936732|NCT03270709|DRUG|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
223936733|NCT05291403|OTHER|Medical thoracoscopic cryotherapy combined with standard first-line therapy for advanced non-cell lung cancer|"Medical thoracoscopic cryotherapy: medical thoracoscopy biopsy hole insert bendable freezing probes, place the frozen probe placed in the center of the tumor at the top will be frozen carbon dioxide gas source pressure adjustment to the bar of 50-60 bar, tread down switch, foot pedal to start the probe, after about 30 s at the top of the probe to form a ice hockey, local tissue after frozen white, sometimes a small amount of bleeding; Fix the probe, loosen the pedal, and wait 30 seconds for automatic melting and rewarming (bleeding probability is low after full rewarming). Freeze 5 to 10 at a time.~In addition, all patients were treated with standard first-line regimens according to guidelines of non small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) scores."
223936734|NCT05291403|OTHER|Sequential intrathoracic injection of cisplatin/erythromycin combined with standard first-line therapy for advanced non-cell lung cancer|"The pleural effusion was fully drained and cisplatin 40mg/m2 was given, dissolved in 100mL 0.9% sodium chloride (NaCl) solution 100 mL, then injected into the pleural cavity and retained for 24 hours. Erythromycin was sequentially injected into the thorax to seal the pleural cavity.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
223936735|NCT05291403|OTHER|Standard first-line therapy for advanced non-cell lung cancer without intrathoracic treatment|"Only intrathoracic tube was used to drain pleural effusion, and local pleural cavity was not treated.~In addition, all patients were treated with standard first-line regimens according to guidelines of NSCLC and ECOG scores."
223936736|NCT04062578|BEHAVIORAL|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
223936737|NCT02822703|DEVICE|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
223936738|NCT02822703|DEVICE|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
223936739|NCT02232737|OTHER|Very low nicotine content cigarettes|
224098203|NCT00098631|DRUG|lapatinib ditosylate|Given orally
224098204|NCT00098631|OTHER|laboratory biomarker analysis|Correlative studies
224098205|NCT04345549|OTHER|Individualised Ayurveda|Saline warm water gargle, Steam, Paracetamol for body temperature and plenty fluid and rest, Food and herbs recommendation as per individual Ayurveda constitution, Using Ginger/ lemon/ turmeric/ honey recommended as per individual, Yoga breathing
224286389|NCT02012231|DRUG|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
224286390|NCT00171340|DRUG|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
224098206|NCT06510478|BEHAVIORAL|Group Life Skill Intervention|This 13-session life skills program covers essential topics in one-hour sessions. It starts with introductions and team building, then progresses through leadership, self-esteem, communication, stress management, positive thinking, confidence building, volunteering, decision-making, problem-solving, conflict resolution, and negotiation. Each session includes ice-breakers, discussions, and targeted exercises. Each session incorporates ice-breakers, open discussions, and targeted exercises to ensure active learning and skill internalization. Duration of each session was 1 hour.
224098207|NCT06510478|BEHAVIORAL|Treatment as Usual for Control Group|Standard psychological interventions i.e. Debreathing, Meditation, supportive counseling, or psychoeducation.
224098208|NCT04436913|OTHER|Himalaya complete care toothpaste|Herbal toothpaste as a part of a caries preventive regimen
223936740|NCT04559698|BEHAVIORAL|LGBTQ-affirmative CBT training|Participants will take part in 11-week LGBTQ-affirmative CBT training via Zoom for 1-hour per week.
223936741|NCT03971539|DRUG|BI 894416|BI 894416 film-coated tablet.
223936742|NCT03971539|DRUG|Placebo|Placebo film-coated tablet matching BI 894416.
223936743|NCT01147757|DRUG|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
223936744|NCT03733574|DRUG|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
223936745|NCT03733574|DRUG|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
223936746|NCT05615337|BEHAVIORAL|MBSR|"The MBSR is an eight-week group-based psychoeducational program. It is performed in weekly group sessions with the duration of 2.5 hours and a half-day retreat of 4 hours.~The program involves focused attention, consisting of body scan, yoga, and meditation. This program trains participants to be attentive to their thoughts, emotions, and sensations. There are also discussions on relevant topics related to the physiology of stress and strategies of coping. Materials for home practice are provided."
224098209|NCT04436913|OTHER|Signal toothpaste|fluoride based toothpaste as a part of a caries preventive regimen
224098210|NCT04436913|OTHER|Signal toothpaste and fluoride varnish|application of fluoride varnish and using fluoride based toothpaste
224098211|NCT04731064|PROCEDURE|HAL (Hemorrhoidal Artery Ligation) - RAR (Recto-Anal Repair)|The patient is operated on in the first perineal position, under general anesthesia or under locoregional or even local anesthesia, after rectal preparation by simple enema. The HAL equipment included a disposable transparent rectoscope fitted near its end with a centimeter window through which wire stitch ligatures will be made. A light source facilitating the exposure of the internal face of the rectum and a Doppler transducer secured to the base of the rectoscope containing the Doppler system. Everything is connected to a generator which transmits Doppler noises to the surgeon. A printer on the generator makes it possible to map ligatures and note the depth of linked arteries. Equipment includes needle holder, knot pusher, scissors and dissecting forceps. The material for HAL is identical, except for the disposable rectoscope which is more indented at its end and on one side.
224098212|NCT05887635|DEVICE|RF Vapor Ablation|RF Vapor ablation of the duodenum
224098213|NCT02217735|BEHAVIORAL|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
224098214|NCT03780517|DRUG|BOS172738|Oral capsules
224286391|NCT00171340|DRUG|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
224286392|NCT02235584|DRUG|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
224286393|NCT00006245|DRUG|alvocidib|
224286394|NCT00006245|DRUG|paclitaxel|
224286395|NCT01056640|DEVICE|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
224286396|NCT01056640|OTHER|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
224286397|NCT02845726|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
224286398|NCT05717244|DEVICE|2WIN-S|Determining pupil diameter by 2WIN-S
224286399|NCT05717244|DEVICE|OPD|Determining pupil diameter by OPD
224286400|NCT05601960|OTHER|anti-acne dermocosmetic|Topical application once daily for 2 months
224286401|NCT00316394|DEVICE|Preventive Care Checklist Form|
224286402|NCT05015374|DIETARY_SUPPLEMENT|Astaxanthin|350 mg/capsule (2mg Astaxanthin)
224286403|NCT05015374|DIETARY_SUPPLEMENT|Placebo|Placebo
224286404|NCT01720420|DEVICE|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
224286405|NCT03030326|BEHAVIORAL|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
223936747|NCT05615337|BEHAVIORAL|HPP|The HPP has the same structure of MBSR, including different components such as music, nutrition, cognitive enhancement, risk factors for dementia, and physical activity. During the half-day retreat participants are involved in watercolor painting activities. Materials for home practice are also provided.
223936748|NCT02200705|DEVICE|Ice-Sense3TM/ ProSenseTM|
223936749|NCT03437733|DEVICE|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
223936750|NCT05982522|DRUG|IN10018|orally taken once daily
223936751|NCT05982522|DRUG|Nab-paclitaxel|125 mg/m2 D1, 8 Q3W, Intravenously
223936752|NCT05982522|DRUG|Tislelizumab|200mg Q3W, Intravenously
223936753|NCT04956887|BEHAVIORAL|AKL-T01|The study intervention, AKL-T01 (Akili Interactive), is a digital, app-based intervention designed to target and improve cognition through an engaging video game-based software experience delivered on an iPad.
223936754|NCT04956887|OTHER|Control Group|Patients assigned to the control group will receive no intervention, as is typical for those with Covid-19 with respect to cognitive functioning
223936755|NCT05943795|DRUG|SI-B001|Administration by intravenous infusion
223936756|NCT05943795|DRUG|Docetaxel|Administration by intravenous infusion
223936757|NCT03786211|PROCEDURE|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
223936758|NCT03786211|PROCEDURE|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
223936759|NCT00715351|DRUG|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
223936760|NCT00715351|DRUG|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
223936761|NCT02490956|BIOLOGICAL|Verorab® (PVRV; Purified Vero Cell Vaccine)|"* Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~* Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
223936762|NCT01872494|OTHER|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
223936763|NCT01872494|OTHER|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
223936764|NCT01872494|DRUG|0.33% ropivacaine 250ml|
223936765|NCT01872494|DRUG|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
223936766|NCT00786864|OTHER|exercise programme|Specific low back pain exercise programme for children
223936767|NCT00368394|DRUG|Insulin glulisine|
223936768|NCT05249153|DRUG|low dose of dexmedetomidine with sufentanil|low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
223936769|NCT05249153|DRUG|high dose of dexmedetomidine with sufentanil|high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
223936770|NCT03102853|OTHER|Nordic diet|
224098215|NCT05051085|BEHAVIORAL|"Internet-delivered treatment: SpilleFri."|The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
224286406|NCT00867841|PROCEDURE|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
224286407|NCT01709812|OTHER|individualized patient support program|individualized patient support with compliance supporting tools
224286408|NCT01709812|OTHER|Standard care|
223534273|NCT06673498|DRUG|Lusutrombopag combined with recombinant human thrombopoietin|After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
223936771|NCT03102853|OTHER|Control diet|
223936772|NCT03987581|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
223936773|NCT03987581|BEHAVIORAL|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
223936774|NCT03987581|BEHAVIORAL|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
223936775|NCT01087359|DRUG|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
223936776|NCT02746926|DRUG|tafamidis|
223936777|NCT02387658|PROCEDURE|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
223936778|NCT02359448|DRUG|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
223936779|NCT06332677|DIAGNOSTIC_TEST|the main genes and expression by comparing the transcriptomic lipidomic profile|To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
223936780|NCT02310152|BEHAVIORAL|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
223936781|NCT02310152|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
224286409|NCT04028154|PROCEDURE|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
223936782|NCT03322995|DRUG|First-line Chemotherapy|The first-line therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or best available standard of care.
224286410|NCT04028154|PROCEDURE|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
224286411|NCT02266394|DRUG|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
224286412|NCT02266394|PROCEDURE|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
224286413|NCT02624167|DRUG|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
224286414|NCT02624167|DRUG|Placebo|Patients will be given oral dose of matching Placebo
224286415|NCT02257619|DRUG|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
224286416|NCT02257619|DRUG|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.
224286417|NCT03648879|DEVICE|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo Confocal Endoscopic Microscopy (CEM) using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
224286418|NCT03708159|DEVICE|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
224286419|NCT03708159|OTHER|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
224286420|NCT06616480|DEVICE|BenQ Materials DSFNC1 soft hydrophilic contact lenses|Test lenses were to be worn for approximately 90 days.
224286421|NCT06616480|DEVICE|Visco SiHy Color soft hydrophilic contact lenses|Control lenses were to be worn for approximately 90 days
223936783|NCT03322995|DRUG|Second-line Chemotherapy|Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial endoscopic ultrasound (EUS)/ fine needle aspirate (FNA) biopsy may be used at the discretion of the treating physician.
224286422|NCT03812991|DRUG|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
224286423|NCT04740931|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.
224286424|NCT04740931|DRUG|Aflibercept|Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).
223936784|NCT03322995|RADIATION|Chemoradiation|50.4 Gy in 28 fractions.
223936785|NCT03594305|BEHAVIORAL|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
223936786|NCT04762914|OTHER|Prehabilitation|Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
223936787|NCT03026920|PROCEDURE|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
223936788|NCT01083732|DRUG|dabigatran etexilate|Experimental dose chosen based on age and weight
223936789|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
223936790|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
223936791|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
223936792|NCT00788541|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
223936793|NCT00788541|OTHER|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
223936794|NCT02455427|DEVICE|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
223936795|NCT02455427|OTHER|Physical Therapy|Physical therapy will be administered for 60 minutes
223936796|NCT02455427|DEVICE|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
223936797|NCT02433782|OTHER|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
223936798|NCT01199185|BEHAVIORAL|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
223936799|NCT01199185|BEHAVIORAL|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
223936800|NCT00978016|DRUG|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
223936801|NCT00978016|DRUG|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
223936802|NCT00978016|DRUG|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
223936803|NCT00978016|DRUG|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
223936804|NCT00978016|DRUG|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
223718717|NCT06014203|DIAGNOSTIC_TEST|Edema measurement|"Subcutaneous fluid measurements will be made 3 times in total, before the surgery, immediately after the surgery and 24 hours after the surgery. Measurements will be made with the MoistureMeterD Compact local edema measuring device.~Points to be measured:~1. Midpoint of the upper trapezius muscle~2. 5 cm distal to anterior acromion~3. 5cm distal to lateral acromion~4. 5cm distal to posterior acromion~5. 3cm medial to the axilla~6. Anterior cubital fossa~7. Carpal tunnel"
223936805|NCT00978016|DRUG|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
223936806|NCT00545519|DRUG|thymoglobulin|
224098216|NCT04933097|DEVICE|Microfet2®|"Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity"
224098217|NCT01268397|PROCEDURE|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
224098218|NCT01268397|PROCEDURE|closed reduction and plaster treatment|closed reduction, below elbow plaster cast, semicircular for 5 week
224098219|NCT06281873|PROCEDURE|closure by PRF membrane|Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint
224098220|NCT02513940|DRUG|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
224098221|NCT02513940|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
224098222|NCT02513940|DRUG|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
224098223|NCT02513940|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
224286425|NCT04740931|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
224286426|NCT00304707|DRUG|Bupropion|300 mg QD
224286427|NCT00304707|DRUG|placebo|placebo
224286428|NCT00345215|BEHAVIORAL|High Sodium Diet|250-350 mmol
224286429|NCT00345215|BEHAVIORAL|Low Sodium Diet|25-35 mmol
224286430|NCT02237547|BIOLOGICAL|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
224286431|NCT06677658|DIETARY_SUPPLEMENT|Olive Oil|Group 1 included patients who consumed at least 20 ml of oral olive oil daily. Group 2 included patients who did not consume olive oil.
224286432|NCT06677658|DRUG|Methylprednisolone|Both groups were diagnosed with Covid-19 pneumonia and were given pulse steroid ( methylprednisolone ) treatment at 250 mg/day for 3 days.
224286433|NCT02812654|DRUG|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
224286434|NCT02812654|DRUG|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
224286435|NCT02812654|RADIATION|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
224286436|NCT03916562|BEHAVIORAL|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
224286437|NCT01391845|DRUG|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
224286438|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
224286439|NCT01391845|DRUG|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
224286440|NCT01391845|DRUG|placebo|placebo orally in a unique dose the day of hCG injection
223718718|NCT04344392|DIAGNOSTIC_TEST|Ultrasonographic study|Thyroid hyoid approximation and hyoid anterior replacement during swallowing. Tongue thickness in rest.
223718719|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study temporal parameters|Glossopalatine junction opening and closing time, velopharyngeal junction opening and closing time, laryngeal vestibule opening and closing time, upper esophageal sphincter opening and closing time in seconds.
223718720|NCT04344392|DIAGNOSTIC_TEST|Videofluoroscopic study distance parameters|Hyoid bone horizontal and vertical replacement, thyroid-hyoid approximation (THA) in millimeters.
223936807|NCT02829398|PROCEDURE|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
223936808|NCT02958696|DRUG|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
223936809|NCT04580459|BEHAVIORAL|CARE Parenting Group Treatment|The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
223936810|NCT04580459|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
223936811|NCT05304624|DEVICE|laser|these lasers are routinely used in dental practice
224098224|NCT03976401|DRUG|EFX|Administered by subcutaneous injection
224098225|NCT03976401|DRUG|Placebo|Administered by subcutaneous injection
224286441|NCT03460145|OTHER|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
224286442|NCT03460145|OTHER|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
224286443|NCT03460145|DRUG|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
224286444|NCT00895037|DRUG|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
224286445|NCT05822674|DRUG|Sitagliptin/metformin ( 50/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
224286446|NCT05822674|DRUG|Empagliflozin/metformin(10/500mg) Oral Tablet|The drug was prescribed once daily per oral for 10 weeks
223936812|NCT04402112|DRUG|Pitavastatin|1mg, 2mg, or 4mg, Once a day, at least 8 weeks
223534274|NCT06674174|OTHER|lower limb strength training|Experimental group will receive lower limb strength training treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
223936813|NCT03551600|PROCEDURE|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
223936814|NCT06389890|PROCEDURE|Pancreatic resection procedure|Pancreatic resection procedure
223936815|NCT02458924|BIOLOGICAL|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
224098226|NCT00862381|DRUG|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
224098227|NCT00862381|DRUG|Placebo|NaCl 0.9%
224098228|NCT03367845|BEHAVIORAL|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
224098229|NCT03367845|BEHAVIORAL|Sensitivity Intervention|4 home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
224098230|NCT03367845|BEHAVIORAL|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session. Because of COVID-19, we now conduct remote visits using Zoom.
224098231|NCT03367845|BEHAVIORAL|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention). Because of COVID-19, we now conduct remote visits using Zoom.
223936816|NCT02187536|DRUG|Telmisartan|
223936817|NCT02187536|DRUG|Simvastatin|
223936818|NCT02187536|DRUG|Telmisartan placebo|
223534275|NCT06674174|OTHER|endurance training|Control group will receive endurance training, treatment for three days a week and each session will last for an hour for 3 consecutivemonths. Measurement will be recorder pre-treatment and post treatment of both groupsat baseline,3rd, and 6th week.
223534276|NCT05790356|DRUG|Fecal Microbial transplant|Fecal microbial transplant will be investigated for its effect on gut bacterial composition in patients with rheumatoid arthritis.
223534277|NCT05790356|OTHER|Placebo capsules|The placebo capsules will not contain FMT but will have the same appearance.
223936819|NCT03167944|DEVICE|Low thermal electrosurgery system|PEAK Plasmablade
223936820|NCT03167944|DEVICE|Conventional Electrocautery|Conventional Electrocautery
223936821|NCT06244875|OTHER|Sampling|Blood and cerebrospinal fluid sampling during the diagnostic visit
223936822|NCT05352308|BEHAVIORAL|Common Sense Model Guided Narrative Video|The narrative video will address illness risk representations and information on HPV, the HPV vaccine, and HPV-related cancers
223936823|NCT01611545|GENETIC|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
223936824|NCT04304937|OTHER|patient reported outcome measure|2 questionnaires are tested against each other
223936825|NCT03484741|BIOLOGICAL|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
223936826|NCT05440058|DEVICE|Bispectral Index (BIS) monitoring system|Left and right sensors to record EEG activity and muscle reaction to anesthesia utilized in the operating room by anesthesia providers to assess the depth of sedation in patients with anesthesia.
224098232|NCT05613270|DIAGNOSTIC_TEST|18F-FES PET/CT scan|Patients with suspected metastatic ER-positive breast cancer underwent 18F-FES PET/CT after an injection of 185-222 MBq (5-6 mCi) 18F-FES to image lesions of metastatic breast cancer.
223936827|NCT05485818|DRUG|Low Dose|12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
224098233|NCT06408844|BEHAVIORAL|Physical activity behavior change program implemented with 5A model|"According to the 5A model, the personal action plan includes the following items:~1. List specific goals by behavioral period~2. List obstacles and strategies to address them~3. Determine follow-up plan~4. Sharing the plan with the child and family In accordance with this plan, it is aimed to increase physical activity behavior in the classroom and during online meetings for 8 weeks. Additionally, after the training, motivational reminders will be held at regular intervals until the 28th week."
223936828|NCT05485818|DRUG|Middle Dose|12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
223936829|NCT05485818|DRUG|High Dose|12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
223936830|NCT05485818|OTHER|Placebo|15 subjects will be randomly assigned to the placebo for 7 days
223936831|NCT04149132|DEVICE|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
223936832|NCT04149132|DIAGNOSTIC_TEST|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
223936833|NCT02103556|OTHER|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
223936834|NCT02103556|DIETARY_SUPPLEMENT|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
223936835|NCT02103556|DIETARY_SUPPLEMENT|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
224098234|NCT04548843|PROCEDURE|Bone Marrow mobilization|"During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis"
223936836|NCT05783531|OTHER|VMood|VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
223936837|NCT05783531|OTHER|Enhanced treatment as usual|Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
223936838|NCT04939909|DRUG|Botulinum toxin type A|Patients were treated with Botulinum toxin type A applications on the Orbicularis oculi and glabellar complex
223936839|NCT00180791|DRUG|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
223936840|NCT04210258|DEVICE|Etermis 3|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling facial moderate wrinkles (marionette lines) and/or to increase lip volume
224098235|NCT04548843|PROCEDURE|Apheresis|Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
224098236|NCT04548843|BIOLOGICAL|MNV-BM-PLC infusion|"The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks."
224098237|NCT00112476|DRUG|bryostatin 1|Given IV
224098238|NCT00112476|DRUG|temsirolimus|Given IV
224098239|NCT03118622|DEVICE|Pentax|Intubation using Pentax video laryngoscope in Pentax group
223936841|NCT04210258|DEVICE|Etermis 4|Cross-linked hyaluronic dermal filler. Treatment and follow-up according to standard of care and instruction of use for filling deep and severe volume loss (nasolabial folds and/or marionette lines) and/or to increase lip volume
223936842|NCT04162210|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered.
223936843|NCT04162210|DRUG|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide and Dexamethasone will be administered.
224098240|NCT01419509|GENETIC|DNA methylation analysis|
224098241|NCT01419509|GENETIC|microarray analysis|
224098242|NCT01419509|GENETIC|polymerase chain reaction|
224098243|NCT01419509|OTHER|laboratory biomarker analysis|
224098244|NCT02781974|OTHER|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
224098245|NCT04700267|DRUG|GLPG3970 film-coated tablet|GLPG3970 for oral administration
224098246|NCT04700267|DRUG|Placebo film-coated tablet|Placebo for oral administration
224098247|NCT06196411|BEHAVIORAL|Task-oriented Training|Task-oriented training will be applied to study group 5 days a week, for a total of 6 weeks, in addition to Bobath training. Task-oriented training will consist of performing the lying, sitting, standing and walking exercises by performing tasks for specific goals. Exercises will be perform by accomplishing tasks such as touching the ball with the upper or lower extremities, reaching for the ball, crossing various tracks to move blocks from one place to another, walking through obstacles or climbing stairs.
224286447|NCT05259904|DRUG|L-citrulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
224286448|NCT05259904|DRUG|Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
224286449|NCT03467282|DIETARY_SUPPLEMENT|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
224286450|NCT03467282|DIETARY_SUPPLEMENT|Placebo|1g polydextrose/maltodextrin - twice day
224098248|NCT06196411|BEHAVIORAL|Bobath Training|Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.
223534278|NCT07004803|OTHER|Virtual reality video watching|The children in the VR experimental group of the study will be subjected to the clinic's routine venipuncture procedure and the video-watching intervention with virtual reality headset. Routine care includes informing the child and parents about the procedure and questions that strengthen communication and distract attention. For example, it consists of questions such as 'How old are you?', 'Do you go to school?', 'Can you tell me the name of your favorite friend?'. Virtual reality headset will be introduced to the child before the procedure and information about how to use them will be given. After the measurements, intravenous access will be started. During the procedure, children will be shown a roller coaster video on virtual reality headset. The video-viewing process will be started 2 minutes before the venipuncture procedure. The video viewing time is planned to last an average of 4 minutes. Measurements were made during and after the procedure
223718721|NCT04176757|DRUG|ZN-c5|ZN-c5 study drug to be administered orally daily
223936844|NCT04789759|DEVICE|Socket Preservation - Bond Apatite synthetic bone substitute|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth. If 1/3 of the buccal plate is missing, considered a class 2 alveolar socket.~Extraction of tooth and place 2/3 biphasic calcium sulfate cement matrix's with Hydroxyapatite (HA granules) , condensed , and covered with a resorbable membrane suture to the adjacent tissue.~At implant placement ,take bone for histological preparation and histomorphometric analysis of the healing pattern.~At T0, T1 and T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements, will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material.~Primary and secondary stability will be measured by ISQ units with a RFA machine, that will include the machine to measure and the magnetic tip to be screwed in the implant platform."
223936845|NCT04789759|PROCEDURE|Socket healing - No Filler|"Pre-op CBCT scanner for evaluating bone conditions around hopeless tooth, at extraction day, no flap opening , atraumatic extraction, no biomaterial filler, At T0, T2 measure adjacent teeth periodontal status , Probing Depth , bleeding on probing.~Volumetric measurements will include an intramural scanner from all the stages , we will use fixed landmarks (ex. adjacent teeth) to calibrate the STL measurements. Calculate the difference between pre-extraction socket and the post treatment with the alloplastic material."
223936846|NCT02810600|OTHER|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
224098249|NCT03864276|DRUG|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
224098250|NCT03864276|DRUG|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
224098251|NCT03339141|PROCEDURE|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
224098252|NCT01240070|OTHER|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
224098253|NCT03617926|DEVICE|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
224098254|NCT03617926|OTHER|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
224098255|NCT03550248|BEHAVIORAL|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
223936847|NCT01005849|DIETARY_SUPPLEMENT|Protecflor|1 Capsule to be taken once a day during the entire study period
223936848|NCT01005849|DIETARY_SUPPLEMENT|Placebo|1 Capsule to be taken once a day during the entire study period
223936849|NCT04790331|DRUG|Verapamil|Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina
224098256|NCT06491043|OTHER|UMC119-06-05|Human Umbilical Cord Derived-Mesenchymal Stem Cells
224098257|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 1|"The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix."
224098258|NCT05520879|DIETARY_SUPPLEMENT|Sharnali 2|Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
224098259|NCT01503021|DRUG|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
224286451|NCT04376359|PROCEDURE|hyperbaric oxygen therapy|Hyperbaric oxygen therapy is the patient put in airtight oxygen tank, by increasing the air pressure in the environment (1.5 to 3.0) under atmospheric pressure, to give 100% oxygen, the patient treatment time is approximately 60 minutes to 120 minutes in this way, can achieve the purpose of greatly increase the oxygen partial pressure in the organization, so as to achieve reverse brain edema, reduce lipid peroxidation, inhibiting leukocyte hyperactivity, rebuild the blood brain barrier.
224286452|NCT00298987|DRUG|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
224286453|NCT01043926|DRUG|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
223936850|NCT04790331|DRUG|Diltiazem|"Diltiazem is a calcium channel blocker. It works by relaxing the muscles of your heart and blood vessels.~Diltiazem is used to treat hypertension and angina."
223936851|NCT04790331|DRUG|Placebo|Placebo oral tablet
223936852|NCT03723031|DRUG|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
223936853|NCT02330588|BEHAVIORAL|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
224098260|NCT01503021|OTHER|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
224286454|NCT04263233|OTHER|Analysis using descriptive statistics of patient clinical outcomes.|"Evaluation of the following:~* Laboratory values at admission, week 4, and day 90.~* Pre and post blood pressure at week one and week 4.~* Intradialytic hypotension at week one and week 4.~* Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~* Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~* Dialysis access type at week one and day 90.~* Hospitalization and mortality rates."
224098261|NCT00817414|DRUG|LCI699-matching placebo|LCI699-matching placebo oral capsules
224098262|NCT00817414|DRUG|LCI699|LCI699 oral capsules
224098263|NCT01802944|DRUG|Intranasal Insulin|
223534279|NCT07004803|OTHER|Tablet video watching|The children in the experimental group of the study will be subjected to the clinic's routine venipuncture procedure and the video-watching intervention with Tablet. Routine care includes informing the child and parents about the procedure and questions that strengthen communication and distract attention. For example, it consists of questions such as 'How old are you?', 'Do you go to school?', 'Can you tell me the name of your favorite friend?'. Tablet will be introduced to the child before the procedure and information about how to use them will be given. After the measurements, intravenous access will be started. During the procedure, children will be shown a roller coaster video on tablet. The video-viewing process will be started 2 minutes before the venipuncture procedure. The video viewing time is planned to last an average of 4 minutes. Measurements were made during and after the procedure.
223718722|NCT02215512|DRUG|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
223936854|NCT02330588|BEHAVIORAL|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention\*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~\*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
223936855|NCT02330588|BEHAVIORAL|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
224098264|NCT01802944|DRUG|Placebos|
224098265|NCT06075056|OTHER|No Intervention|No intervention is planned as part of this study, this is a feasibility/pilot study
224098266|NCT05015387|PROCEDURE|Minimally invasive non-surgical therapy|Under local anesthesia subgingival instrumentation with ultrasonic and hand instruments and magnification (4.5x) was performed.
224098267|NCT05015387|COMBINATION_PRODUCT|Subgingival application of collagen hydrogels with proanthocyanidins|Patients received collagen hydrogel chips with proanthocyanidins from Pelargonium sidoides root extract, placed subgingivally in periodontal pockets with PPD≥4mm after minimally invasive non-surgical therapy.
224098268|NCT05015387|DIAGNOSTIC_TEST|Collection of saliva samples|For MMP-3/TIMP-1 detection, the collection of saliva samples was performed using Salivette (SARSTEDT AG and Co, Germany) saliva sample collection kit. Saliva samples were collected at the baseline for all patients and 8 weeks after treatment. Samples were centrifuged at 3500 rpm (2 min), aliquoted and protease inhibitors cocktail (1 mg/ml) was added to each sample. All samples were stored at -80oC. MMP-3, TIMP-1 concentration in saliva samples was examined using commercial ELISA kits (Elabscience, USA) and Multiskan Microplate Photometer (Thermo Fisher Scientific) at 450 nm wavelength. Saliva MMP-3/TIMP-1 samples were collected before treatment and 8 weeks after treatment.
224098269|NCT01449838|DRUG|Colistimethate sodium|active
224098270|NCT01449838|DRUG|Saline|placebo
224098271|NCT02339714|OTHER|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
224098272|NCT02339714|DRUG|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
224286455|NCT04263233|OTHER|Surveys with participants using validated survey tools.|Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
223936856|NCT03220724|BIOLOGICAL|CH505TF|Administered by intramuscular (IM) injection in the thigh
224098273|NCT01552876|DEVICE|etafilcon A|A daily wear contact lens
224098274|NCT01552876|DEVICE|nelfilcon A|A daily wear contact lens
224098275|NCT01552876|DEVICE|Filcon II 3|a daily disposable
224098276|NCT02809248|DEVICE|ZES|stent implantation (zotarolimus eluting stent)
224098277|NCT02809248|DEVICE|BMS|stent implantation (bare metal stent)
224098278|NCT00097539|BIOLOGICAL|Somatrem|
224098279|NCT00097539|BIOLOGICAL|Somatropin|
224098280|NCT01478555|DRUG|ISV 101|Bromfenac in DuraSite
224098281|NCT06022770|DIETARY_SUPPLEMENT|Nutritional counseling，Enteral Nutrition|patients with esophageal cancer and gastric cancer undergoing chemotherapy were selected as the study objects for nutritional risk screening, malnutrition assessment and quality of life assessment. Randomly enter the nutrition consultation group (NC) and nutrition support treatment group (NST)
224098282|NCT00054470|BIOLOGICAL|trastuzumab|
224098283|NCT00054470|DRUG|tipifarnib|
224098284|NCT03941548|DRUG|CTP-543|Administered as 12 mg tablets.
224098285|NCT03941548|DRUG|CTP-543 Matching Placebo|Administered as tablets to aid treatment masking.
224098286|NCT02081963|DRUG|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
224098287|NCT02081963|DRUG|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
224098288|NCT01898663|BIOLOGICAL|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
224098289|NCT01128712|DRUG|Pregabalin|150 mg /day
224098290|NCT01128712|DRUG|Pregabalin|450 mg/day
224098291|NCT00358163|DRUG|PTK787/ZK 222584|Taken in tablet form daily
224098292|NCT00358163|DRUG|paclitaxel|Given as a 3-hour infusion once every 21 days
224098293|NCT01331395|OTHER|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
224286456|NCT04263233|OTHER|Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.|Data will be collected using tracking tools throughout the program.
224098294|NCT01079715|DRUG|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~* Atropine.~* Isoproterenol hydrochloride (isoprenaline.~* Terlipressin.~* Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
224286457|NCT00142987|DRUG|Tegaserod|
223718723|NCT02908360|GENETIC|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
223936857|NCT03220724|BIOLOGICAL|CH505w53|Administered by IM injection in the thigh
224098295|NCT01971879|PROCEDURE|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
224098296|NCT01971879|PROCEDURE|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
224098297|NCT06328010|BIOLOGICAL|Advanced Treatment Modalities for wound and injuries|Synthetic, Amniotic, Bovine, Porcine, or other non-human biological grafts or scaffolded grafts
223936858|NCT03220724|BIOLOGICAL|CH505w78|Administered by IM injection in the thigh
223936859|NCT03220724|BIOLOGICAL|CH505 M5|Administered by IM injection in the thigh
223936860|NCT03220724|BIOLOGICAL|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
223936861|NCT03220724|BIOLOGICAL|Placebo|Administered by IM injection in the thigh
223936862|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
224098298|NCT06328010|BIOLOGICAL|Standard of care|Standard of care without use of grafts or scaffolded grafts
224098299|NCT06328010|OTHER|Retrospective wound treatment data collection|Completed wound care treatment regardless of modality.
224098300|NCT06645340|OTHER|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length|This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length, and routine laboratory parameters.
224098301|NCT05071664|DRUG|Guselkumab|Guselkumab will be administered as a SC injection.
224098302|NCT05071664|DRUG|Golimumab|Golimumab will be administered as a SC injection.
224098303|NCT05071664|DRUG|Placebo|Placebo will be administered as a SC injection.
224098304|NCT06544837|DIAGNOSTIC_TEST|Window of Implantation|Determine the subject's window of implantation through testing and adjust the embryo implantation time
224098305|NCT02372968|OTHER|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
224098306|NCT06022783|OTHER|Virtual reality intervention|Watching a relaxing video with using VR-G for 20 minutes
224286458|NCT02346149|OTHER|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
224286459|NCT04093154|DEVICE|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
223936863|NCT02208414|PROCEDURE|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
223936864|NCT00449774|DRUG|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
223936865|NCT00449774|DRUG|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
223936866|NCT05085535|OTHER|Manual Therapy|Exercises for body mobility and muscle toning, Sophrology, musculoskeletal oscillatory manual therapy
223936867|NCT05085535|OTHER|Exercise|Exercises for body mobility and muscle toning, Sophrology
224286460|NCT06677840|OTHER|probiotic (GKB7/placebo)|The objectives of this double-blind randomized placebo-controlled trial are to evaluate the tolerability, safety, and efficacy of the probiotic intervention with Clostridium butyricum GKB7 among 90 4-15-year-old children and adolescents with a clinical diagnosis of ASD according to the DSM-5
224098307|NCT02662478|PROCEDURE|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
224286461|NCT01931527|DRUG|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
224286462|NCT00604227|OTHER|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
224286463|NCT06214416|BEHAVIORAL|Abstention|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
224286464|NCT06214416|BEHAVIORAL|Mediterranean alcohol-drinking pattern|All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
224286465|NCT05370261|DIETARY_SUPPLEMENT|Berberine LipoMicel|Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine
224286466|NCT05370261|DIETARY_SUPPLEMENT|Regular Berberine hard-gels|Total dose of 500 mg of berberine
224286467|NCT02018094|DRUG|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
223936868|NCT04383184|PROCEDURE|tracheoplasty|tracheoplasty and only left pulmonary artery transplantation
224286468|NCT02018094|DRUG|Iodine|Intra-operative skin preparation prior to incision to skin.
224286469|NCT02018094|DRUG|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
224286470|NCT02018094|DRUG|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
224286471|NCT02018094|DRUG|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
224286472|NCT02018094|DRUG|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
224286473|NCT00738361|DRUG|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
224286474|NCT05178576|DRUG|Gevokizumab|120mg IV on day 1 of every 28-day cycle for 1 year (maximum of 13 cycles)
223936869|NCT05626374|BEHAVIORAL|Basic Case Management|Usual case management support during 12-week training program
223936870|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool|Usual case management support during 12-week training program plus daily self-reports of distress using Distress Thermometer tool
224286475|NCT05178576|DIAGNOSTIC_TEST|Signatera test|ctDNA monitoring at weeks 8, 12, 24, 36, 48, 60 and 72 unless disease recurrence is documented.
224286476|NCT04072315|DRUG|PLN-74809|PLN-74809
224286477|NCT04072315|RADIATION|Knottin tracer|Radiotracer
224286478|NCT02159287|DRUG|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
223936871|NCT05626374|BEHAVIORAL|Basic Case Management plus rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus rapid access referral process for healthcare crisis services
223936872|NCT05626374|BEHAVIORAL|Basic Case Management plus Distress Tool and rapid mental health & addictions healthcare access|Usual case management support during 12-week training program plus daily distress self-reports plus rapid access referral process for healthcare crisis services
223936873|NCT01584167|DRUG|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
223936874|NCT01584167|DEVICE|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
223936875|NCT05483985|DEVICE|Hera Score|The device uses patient metadata (patient age, day of image capture) and a software algorithm to analyze features of the blastocyst morphology to provide adjunctive information that may predict further development of the embryo to clinical pregnancy after embryo transfer.
224286479|NCT02159287|DRUG|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
223718724|NCT02798133|PROCEDURE|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
223718725|NCT02798133|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
224286480|NCT05683210|BEHAVIORAL|Cup feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The feeding process was completed at the end of 30 minutes even if the infant did not take all of the food. The infant was followed up for 30 minutes after the end of feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
223936876|NCT06476769|OTHER|blow bottle technique|There were 20 patients in group A received blow bottle device and postural drainage for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
223936877|NCT06476769|OTHER|percussion|Group B: There were 20 patients in group B received postural drainage with percussion for 20- 25 minutes per session twice a day for 4 days per week, for 8 weeks.
223936878|NCT03562325|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
223936879|NCT02479672|DEVICE|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
223936880|NCT02479672|PROCEDURE|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
223936881|NCT02479672|DEVICE|VividTrac®|
223936882|NCT05838781|DIAGNOSTIC_TEST|Risk prediction model|A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
223936883|NCT05838781|DIAGNOSTIC_TEST|14-days continuous ECG monitoring|14-days continuous ECG monitoring with an ECG patch.
223936884|NCT03789734|BIOLOGICAL|BLS-M22|BLS-M22 250mg/capsule
223936885|NCT03789734|OTHER|Placebo|BLS-M22 placebo 250mg/capsule
223936886|NCT04639869|DRUG|Phenyramydol HCl 400 mg Film Tablet|Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
223936887|NCT04639869|DRUG|Cabral 400 mg Film Tablet|Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
223936888|NCT04802018|DEVICE|Clinical decision support system based on non-invasive multimodal monitoring|Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
223936889|NCT04718610|OTHER|Osteopathic intervention|Nerve vagus stimulation
223936890|NCT04718610|BIOLOGICAL|CRP assessment|Blood CRP will be assessed during trial
223936891|NCT04718610|BEHAVIORAL|QLQ-C30 questionnaire|Completion of QLQ-C30
223936892|NCT03452254|DEVICE|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
223936893|NCT03452254|DEVICE|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
223936894|NCT03452254|OTHER|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~1. Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~2. Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
223936895|NCT01150656|GENETIC|gene expression analysis|
223936896|NCT01150656|GENETIC|microarray analysis|
223936897|NCT01150656|GENETIC|protein expression analysis|
223936898|NCT01150656|GENETIC|reverse transcriptase-polymerase chain reaction|
223936899|NCT01150656|GENETIC|western blotting|
223936900|NCT01150656|OTHER|laboratory biomarker analysis|
223936901|NCT01150656|OTHER|pharmacological study|
223936902|NCT00144040|BEHAVIORAL|Physician & patient education on appropriate antibiotic use|
223718726|NCT03273114|BEHAVIORAL|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
223936903|NCT00144040|PROCEDURE|Rapid C-reactive protein testing to guide antibiotic treatment|
223936904|NCT00609297|OTHER|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
223936905|NCT00609297|OTHER|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
223936906|NCT00609297|OTHER|survey administration|Given to patient and caregivers throughout the study
223936907|NCT03380494|OTHER|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
223936908|NCT03380494|OTHER|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
223936909|NCT03739658|OTHER|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
223936910|NCT01384890|RADIATION|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
223936911|NCT01384890|RADIATION|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
223936912|NCT01767467|BIOLOGICAL|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
223936913|NCT01767467|DRUG|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
223936914|NCT03504904|BEHAVIORAL|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
223936915|NCT03958773|DEVICE|Cardiovalve transfemoral Mitral valve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
223936916|NCT00569387|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
223936917|NCT04160936|DRUG|Marcaine Injectable Product|Following PCNL under general anesthesia, patients will receive 0.25% Bupivacaine ( Marcaine) local anesthetic infiltration
223936918|NCT05808205|DEVICE|• ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume|"According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips."
223936919|NCT06511089|PROCEDURE|carotid artery stenting during EVT|"Patients with an ipsilateral high grade carotid artery stenosis or occlusion of presumed atherosclerotic origin and an proximal intracranial large vessel occlusion in the anterior circulation will be randomized using a web-based randomization tool to immediate carotid artery stenting or deferred treatment strategy of carotid artery stenosis.~In the intervention group, the cervical carotid artery lesion will be treated with a stent during the EVT (just before or directly after intracranial thrombus removal), the control group will be treated according to the national guidelines with carotid endarterectomy of carotid artery stenting (for patients with non-disabling stroke) or medical management alone (for patients with severe disabling stroke)."
223936920|NCT06511089|OTHER|no carotid artery stenting during EVT|A deferred treatment approach: carotid revascularization within two weeks after stroke onset or best medical management only, depending on the functional recovery of the patient.
223936921|NCT01640951|DRUG|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
223936922|NCT01640951|DRUG|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
223936923|NCT01640951|DRUG|Placebo|
223936924|NCT06463145|DIETARY_SUPPLEMENT|Vanizem|Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol
223936925|NCT06463145|DIETARY_SUPPLEMENT|Placebo|Food grade Maltodextrin 12
223936926|NCT04830124|DRUG|Nemvaleukin Alfa Subcutaneous|Subcutaneous injection of nemvaleukin every 7 days
223936927|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days
223936928|NCT04830124|DRUG|Nemvaleukin Alfa Intravenous Less Frequent Dosing|Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)
223936929|NCT04830124|DRUG|Pembrolizumab|Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle
223936930|NCT04971733|DRUG|E2814|E2814 intravenous infusion.
223936931|NCT05891132|DRUG|10 ml of lidocaine 2%|10 ml of lidocaine 2% for perineal infiltration at the time of crowning
223936932|NCT05891132|DRUG|lidocaine prilocaine cream 15gm|Lidocaine prilocaine cream, an eutectic mixture, is composed of Lidocaine-25 mg, Prilocaine-25 mg, Arlactone 289 -19 mg, Carbopol-10 mg, Sodium hydroxide to make a pH of 9.6 mg and purified water to produce l gram.
223936933|NCT06015308|DRUG|Amlitelimab|Subcutaneous injection in abdomen, outer thigh, or upper arm
223936934|NCT06015308|DRUG|Placebo|Subcutaneous injection in abdomen, outer thigh, or upper arm
223936935|NCT06015308|BIOLOGICAL|Tdap vaccine|Intramuscular (IM) injection into the deltoid muscle of the upper arm
224098308|NCT03822949|DEVICE|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
224098309|NCT03822949|DEVICE|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
224098310|NCT03822949|DEVICE|ICU Intense Light|ICU Patients are exposed to daylight for up to 10 days after surgery
224098311|NCT03822949|DEVICE|ICU Placebo light|ICU Patients are exposed to placebo light for up to 10 days after surgery
224098312|NCT02421198|BEHAVIORAL|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
224286481|NCT05683210|BEHAVIORAL|Bottle feeding|The preterm infant was put on pulse oximetry and monitored, and heart rate and oxygen saturation began to be monitored. The infants' heart rate and oxygen saturation were recorded 30 minutes before feeding, and their signs of preparedness for oral feeding were monitored. After the data were recorded for 30 minutes, the infant was taken out of the incubator and his/her body weight was measured naked with only a clean diaper to determine the test weight. During the feeding period, heart rate and oxygen saturation were continuously recorded. Feeding time was limited to 30 minutes, including the infants' resting time. When the infant was no longer sucking, the stopwatch was stopped, and the feeding phase was terminated. The infant was followed up for 30 minutes after the end of the feeding. During this time, the pulse oximetry continued to record and no intervention was made in order to avoid any effect on physiological values.
223534280|NCT07004543|PROCEDURE|Standard Silicone Toe Separator Application|Participants will be instructed to wear standard, commercially available silicone toe separators during a single evaluation session. The intervention consists of applying the separators between the toes while the participant is barefoot, both in static standing and while walking on a treadmill equipped with a Zebris pressure analysis system. Measurements will be taken immediately before and after the application, including plantar pressure distribution, intermetatarsal spacing (via imaging), digital circulation (via thermography and visual assessment), foot posture (using the Foot Posture Index - FPI-6), and subjective comfort levels (via Visual Analog Scale). The toe separators are not customized and reflect common consumer-grade devices marketed for podiatric or wellness purposes.
223534281|NCT06681272|OTHER|Questionnaire|sleep quality assessment using the PROMIS (Patient-Reported Outcomes Measurement Information System) item Bank score
223534282|NCT06681272|OTHER|Questionnaire|assessment of emotional state using the Neuropathic Pain Symptom Inventory score (NPSI)
223936936|NCT06015308|BIOLOGICAL|PPS vaccine|Intramuscular or subcutaneous injection into the deltoid muscle of the upper arm
223936937|NCT03904069|DRUG|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
223936938|NCT02406092|DRUG|Rituximab|Rituximab SC 1400 mg
223936939|NCT02406092|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
223936940|NCT02406092|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice.
223936941|NCT02406092|DRUG|Vincristine|Vincristine will be administered as per standard local practice.
223936942|NCT02406092|DRUG|Prednisone|Prednisone will be administered as per standard local practice.
223936943|NCT02406092|DRUG|Fludarabine|Fludarabine will be administered as per standard local practice.
223936944|NCT04074096|RADIATION|Stereotaxic radiosurgery (SRS)|For patients randomised to arm B only: Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases \>5 mm).
223936945|NCT04074096|DRUG|Binimetinib Oral Tablet|All patients: binimetinib 45 mg PO BID.
223936946|NCT04074096|DRUG|Encorafenib Oral Capsule|All patients: encorafenib 450 mg PO QD
223936947|NCT04074096|DRUG|Pembrolizumab|All patients: pembrolizumab 200 mg IV Q3W
223936948|NCT04592185|DEVICE|Fenestrated Anaconda™ Device|Treatment of complex abdominal aortic aneurysms
223936949|NCT04769596|DEVICE|NEUROMARK™ System|The NEUROMARK™ System is designed to deliver energy to the nasal cavity intended to interrupt nasal nerves aimed to reduce symptoms related to Chronic Rhinitis.
223936950|NCT04769596|DEVICE|Sham Device|A Sham device will be used in the nasal cavity
223936951|NCT03214172|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
223936952|NCT05459350|DIAGNOSTIC_TEST|Safe Discharge Classification|Safe Discharge Classification
223936953|NCT02513043|DRUG|medical abortion|medical abortion
223936954|NCT00002945|BIOLOGICAL|aldesleukin|IV
223936955|NCT00002945|BIOLOGICAL|filgrastim|IV
223936956|NCT00002945|DRUG|cyclophosphamide|IV
224098313|NCT00803556|DRUG|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
224098314|NCT00803556|DRUG|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
224098315|NCT00803556|DRUG|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
224098316|NCT05916352|DIETARY_SUPPLEMENT|Caffeine Supplement|Caffeine tablet
224098317|NCT02945657|DRUG|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
223534283|NCT06681272|OTHER|Questionnaire|To assess whether pain measured by a Numercial rating scale (NRS) predicts chronic postoperative pain.
223534284|NCT06623201|DRUG|aminolevulinic acid HCL (ALA)|Prior to ALA application, the areas will be cleaned with alcohol and debrided gently with prep tape. ALA will then be applied to each of the study lesions and allowed to incubate for 3 hours with occlusion prior to the PDT.
223936957|NCT00002945|DRUG|cytarabine|IV
223936958|NCT00002945|DRUG|etoposide|IV
223936959|NCT00002945|DRUG|idarubicin|IV
223936960|NCT00002945|DRUG|melphalan|IV
223936961|NCT00002945|PROCEDURE|peripheral blood stem cell transplantation|IV
223936962|NCT00002945|RADIATION|radiation therapy|delivered to the cancer cells
223936963|NCT03773549|OTHER|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
224098318|NCT03424226|DRUG|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
224098319|NCT03553173|OTHER|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
224098320|NCT03553173|BEHAVIORAL|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
224286482|NCT05487768|OTHER|EEG measurement|"EEG measurement to evaluate functional connectivity in the brain during 3 motor tasks:~* Knee extension while sitting (10x left - right)~* Bipodal squatting (10x)~* Unipodal stance (5x30 seconds left-right)"
223534285|NCT06623201|DEVICE|BLU-U device model 4170E|Participants will be subjected to dose illumination with blue light (BLU-U Model 4170E) at a power fluence of 20 mW/cm2 for a total time of 16 minutes and 40 seconds (1,000 seconds). This will result in a total light delivery dose of 20 J/cm2.
223534286|NCT07004816|OTHER|Uncover mutation profiles|Uncover mutation profiles
223534287|NCT07003230|DIETARY_SUPPLEMENT|vegan and omnivorous diet|Participants underwent a 2-week omnivorous diet intervention, followed by a 2-week vegan diet intervention
223936964|NCT01411566|BEHAVIORAL|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
224286483|NCT05095649|BIOLOGICAL|Regulatory T-cell enriched infusion|Enrichment of cluster of differentiation 25hi regulatory T cells from cluster of differentiation antigen 8 and/or cluster of differentiation antigen19 pre-depleted leukapheresis products.
224286484|NCT00104247|DRUG|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
224286485|NCT00496028|DRUG|AZD0530|oral tablet
224286486|NCT00496028|DRUG|Carboplatin|intravenous infusion
223534288|NCT07004725|DRUG|niacin sustained release capsules|The first stage: the niacin group was given niacin sustained-release capsules for 3 months, and the control group was given placebo for 3 months. The second stage: Both groups were given niacin sustained-release capsules for 3 months. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks
223534289|NCT07004725|DRUG|Placebo|The group was given oral placebo for 3 months in the first stage and niacin sustained-release capsules for 3 months in the second stage. Dosage of niacin sustained-release capsules and placebo: 500mg once a day for week 1-4; The dose is 1000mg once a day for 5 to 12 weeks.
223534290|NCT07003828|DIAGNOSTIC_TEST|CEUS examinations|CEUS examinations were performed at three predetermined time points during each HD session: immediately before, 3 hours after HD initiation, and 15 minutes post-dialysis.
223534291|NCT06370208|DIETARY_SUPPLEMENT|Probiotic Bactoblis® EVOL (Streptococcus salivarius eK12)|Bactoblis® EVOL: containing one billion CFU of probiotic Streptococcus salivarius eK12
223718727|NCT03273114|OTHER|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
223936965|NCT01411566|BEHAVIORAL|regular treatment|regular treatment
223936966|NCT00156208|DRUG|Asoprisnil|10mg Tablet, oral Daily for 18 months
223936967|NCT00156208|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 18 months
223936968|NCT03710252|DRUG|paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin|OMB/PTV/r + DSV +/- RBV
223936969|NCT00005869|DRUG|gemcitabine hydrochloride|
223936970|NCT00005869|DRUG|rubitecan|
223936971|NCT00482911|DRUG|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
223936972|NCT00482911|DRUG|lenalidomide|10 mg by mouth once daily on days 1-28.
223936973|NCT00482911|DRUG|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
223936974|NCT01456156|RADIATION|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
223936975|NCT00833313|PROCEDURE|Atrial biopsy|Biopsy of left atrial free wall and possibly left atrial appendage
223936976|NCT05615220|DRUG|Ecopipam Hydrochloride|Selective dopamine D1 and D5 receptor antagonist
223936977|NCT04000516|BEHAVIORAL|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
223936978|NCT02955719|DRUG|Sertraline|
223936979|NCT02955719|DRUG|Venlafaxine|
223936980|NCT02955719|OTHER|CBT/Psychological Therapy|
223936981|NCT02955719|OTHER|Psychiatric Consultation|
223936982|NCT02955719|OTHER|Lifestyle Intervention Resources|
223936983|NCT05910203|OTHER|The effectiveness of education|Training will be provided on smoking cessation.
223936984|NCT00211549|DRUG|IDEA-033|
224286487|NCT00496028|DRUG|Paclitaxel|intravenous infusion
224286488|NCT02598895|DRUG|Carboplatin|Given IV
224286489|NCT02598895|DRUG|Docetaxel|Given IV
224286490|NCT02598895|OTHER|Laboratory Biomarker Analysis|Correlative studies
223936985|NCT05841407|DIETARY_SUPPLEMENT|High nitrate isotonic drink|High nitrate (12.9 mmol) drink with carbohydrate and minerals
223936986|NCT05841407|DIETARY_SUPPLEMENT|No nitrate isotonic drink|Carbohydrate and mineral isotonic drink
224286491|NCT03142659|OTHER|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
224286492|NCT02210052|DEVICE|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
223718728|NCT01385215|DRUG|Fluzone|0.5 ml/15 micrograms
223936987|NCT02503722|OTHER|Laboratory Biomarker Analysis|Correlative studies
223936988|NCT02503722|DRUG|Osimertinib|Given PO
223936989|NCT02503722|OTHER|Pharmacological Study|Correlative studies
223936990|NCT02503722|DRUG|Sapanisertib|Given PO
223936991|NCT04706754|OTHER|Questionnaires|Participants will complete the survey(s) at the initial visit and every 3 months and/or whenever there is an update in their treatment protocol. Patients may also choose to opt out of the surveys and only consent to primary data collection at the site.
223936992|NCT05806515|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223936993|NCT05806515|DRUG|Carboplatin|Given IV
224286493|NCT04691700|DRUG|Goreisan|Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
224286494|NCT04691700|DRUG|Standard Treatment|Standard therapy without Goreisan
224286495|NCT02851732|BEHAVIORAL|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
224286496|NCT05040126|DRUG|Linezolid|"Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment"
224286497|NCT05040126|DRUG|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms
224286498|NCT05040126|DRUG|Pretomanid|Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
224286499|NCT04146831|DRUG|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
224286500|NCT01051180|PROCEDURE|HALO|Ligation of haemorrhoidal arteries
224286501|NCT04798482|DRUG|Dexmedetomidine|Patients will undergo the usual anal manometry study, with no adjuvant medications, per routine practice currently in the gastrointestinal unit. Following completion of manometry, 0.5 mcg/kg DEX will be administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Manometry measurements will be followed for 15 minutes in response to DEX.
224286502|NCT03496987|DEVICE|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
223718729|NCT01385215|DRUG|Fluzone|0.5 ml/60 micrograms
223718730|NCT05065632|DIAGNOSTIC_TEST|Wantai kit Elisa|to mesure antibodies against SARSCov-2 recombinant antigen
223718731|NCT00816530|DEVICE|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density \> 50% is confirmed by routine digital screening mammography, ABUS will be performed.
223718732|NCT01288235|RADIATION|Proton radiotherapy|5 days a week
223718733|NCT03984240|DRUG|Midazolam|Participant will be sedated by midazolam.
223718734|NCT03984240|DRUG|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
223936994|NCT05806515|PROCEDURE|Chest Radiography|Undergo chest X-ray
223936995|NCT05806515|PROCEDURE|Computed Tomography|Undergo CT
223936996|NCT05806515|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223936997|NCT05806515|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
223936998|NCT05806515|PROCEDURE|Surgical Procedure|Undergo surgery
223936999|NCT06243770|DRUG|mRNA-0184|Intravenous infusion
223937000|NCT06545344|OTHER|Best Practice|Receive usual care
223937001|NCT06545344|PROCEDURE|Palliative Care Consultation|Attend a palliative care visit
223937002|NCT06545344|OTHER|Survey Administration|Ancillary studies
223937003|NCT06545344|OTHER|Tumor Board Review|Undergo evaluation by tumor board
223937004|NCT06253546|DRUG|TV-44749|"Pharmaceutical form:~extended-release injectable suspension~Route of administration: subcutaneous injection"
223937005|NCT06253546|DRUG|Oral Olanzapine|"Pharmaceutical form:~tablet~Route of administration:~oral"
223937006|NCT00091988|BEHAVIORAL|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
223937007|NCT00091988|BEHAVIORAL|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
223937008|NCT01765374|DEVICE|ESAOTE MyLab60|US evaluation at different time points
223937009|NCT01765374|DRUG|Rituximab|
223937010|NCT00291694|DRUG|celecoxib|Celecoxib 400 mg BID
223937011|NCT00291694|OTHER|placebo|placebo
223937012|NCT02813525|OTHER|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
223937013|NCT03658109|DRUG|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
223937014|NCT03658109|PROCEDURE|QL block|Patients will undergo a posterior QL block pre-operatively
223937015|NCT03658109|DRUG|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
223937016|NCT03658109|PROCEDURE|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
223937017|NCT04149119|DEVICE|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
223937018|NCT00401479|DRUG|Placebo|
224098321|NCT03553173|DRUG|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
223534292|NCT06675591|OTHER|Rapid sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
224098322|NCT03553173|DRUG|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
224098323|NCT00184587|DRUG|candesartan cilexetil|
224098324|NCT00184587|DRUG|placebo|
224098325|NCT03728049|DIAGNOSTIC_TEST|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
224098326|NCT03728049|OTHER|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
224098327|NCT01779609|DRUG|Bosentan|
224098328|NCT01779609|DRUG|Placebo|
223937019|NCT00401479|DRUG|Solabegron (GW427353)|
223937020|NCT06466512|BEHAVIORAL|Midwifery-embodied care|The midwife will provide ANC, delivery and PNC. The Community Healthcare Provider, Health Assistants will act as auxillary staff. Local transports will be integrated into the system. Coordination committee will see through that the interventions are carried out properly.
223937021|NCT00343408|DRUG|cediranib maleate|
223937022|NCT00343408|DRUG|cisplatin|
223937023|NCT00343408|DRUG|fluorouracil|
223937024|NCT00343408|DRUG|gemcitabine hydrochloride|
223937025|NCT00343408|DRUG|leucovorin calcium|
223937026|NCT00343408|DRUG|oxaliplatin|
223937027|NCT02262299|DRUG|Pirfenidone|Receive tablets with pirfenidone
223937028|NCT02262299|DRUG|Placebo|Recieve tablets with placebo
223937029|NCT06239064|DIAGNOSTIC_TEST|Genetic testing via blood collection|blood collection
223937030|NCT02972424|DRUG|Teriparatide Prefilled Syringe|TPTD 20 mcg
223937031|NCT02972424|DRUG|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
223937032|NCT05859659|DIAGNOSTIC_TEST|This study does not intervene in this process.|This study does not intervene in this process.
223937033|NCT06510829|DEVICE|Diode laser|Application of laser waves on the lesion
223937034|NCT04594694|DRUG|Obeticholic acid|5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
223937035|NCT04594694|DRUG|Bezafibrate 200 MG|200 mg IR tablet of Bezafibrate once daily for the remainder of the study
223937036|NCT04594694|DRUG|OCA Placebo|One tablet daily for the remainder of the study
223937037|NCT04594694|DRUG|Bezafibrate 200 mg Placebo|One tablet daily for the remainder of the study
223937038|NCT04594694|DRUG|Bezafibrate 400 MG|400 mg SR tablet of Bezafibrate once daily for the remainder of the study
223937039|NCT04594694|DRUG|Bezafibrate 400 mg Placebo|One tablet daily for the remainder of the study
223937040|NCT04594694|DRUG|OCA|OCA one tablet will be administered.
223937041|NCT04594694|DRUG|Bezafibrate|Bezafibrate one tablet will be administered.
223937042|NCT05027906|DRUG|AT-1501|Investigative Arm
223937043|NCT04204941|DRUG|Tazemetostat|400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.
224098329|NCT01779609|BEHAVIORAL|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
224098330|NCT00606515|DRUG|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
224098331|NCT00606515|DRUG|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
224098332|NCT02748343|DEVICE|allograft bone|Use of the allograft bone to treat the bone defect in patients
224098333|NCT02748343|DEVICE|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
224098334|NCT04894383|DEVICE|Aetrex L420 Compete Orthotic|An orthotic insole to be inserted into shoes. Orthotic for low arches to flat feet with no forefoot pain, featuring a posted heel to control over-pronation and provide balance. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia.
223937044|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
223937045|NCT04204941|DRUG|Tazemetostat|800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.
223937046|NCT04204941|DRUG|Placebo|Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond
223937047|NCT04204941|DRUG|Doxorubicin HCl|75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
223937048|NCT04240613|DEVICE|TVT-O|TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
223937049|NCT01855516|DRUG|Heparin|
223937050|NCT04895696|DRUG|Afimetoran|Specified dose on specified days
223937051|NCT04895696|OTHER|Placebo|Specified dose on specified days
223937052|NCT04764175|BEHAVIORAL|Telephone All Nations Breath of Life|Same as described above.
223937053|NCT04764175|BEHAVIORAL|Comparison Program|Same as described above.
223937054|NCT04719936|PROCEDURE|inferior capsulotomy|inferior capsulotomy will be conducted during posterior approach.
223937055|NCT04719936|PROCEDURE|superior capsulotomy|superior capsulotomy was conducted during posterior approach. (These control group is consisted of patients who received bipolar hemiarthroplasty using superior capsulotomy from January 2010 to December 2020)
223937056|NCT01858012|BEHAVIORAL|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
223937057|NCT03821506|DEVICE|Dynamic Light|Dynamic Lighting system
223937058|NCT03821506|DEVICE|Usual care|Standard lighting system
223937059|NCT06971042|RADIATION|Lung Ultrasound|Patients were examined in supine position, using a portable ultrasound machine equipped with a curvilinear transducer (5-3 MHz)
223937060|NCT06421285|BEHAVIORAL|Aerobic exercise, Strength training, Flexibility exercise|"Aerobic exercise: 30-40 minutes/time, 3-5 times a week, intensity of 4-6 points on the Rating of Perceived Exertion(RPE) 10-point scale(A simple conversation is possible during exercise, but the intensity is such that you feel out of breath) Strength training: 2-3 times a week, 3 sets of 10 repetitions per movement~* Upper extremities: Biceps brachii, triceps brachii, deltoid, pectoralis muscle exercise~* Lower extremities: gluteus maximus, hamstrings, quadriceps exercise Flexibility exercise: Stretching and mobility exercises reflecting post-surgery rehabilitation"
223937061|NCT03882450|PROCEDURE|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
223937062|NCT03882450|PROCEDURE|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
223937063|NCT01368744|DEVICE|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (\>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (\> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (\> 2 mm).~Groups: OSNA Breast Cancer System"
223937064|NCT00423020|DRUG|Erythropoietin|
223937065|NCT06221215|PROCEDURE|trauma|The main purpose of this study is to observe whether the early hormone changes and trends in the two groups of patients with or without trauma.
223937066|NCT00679770|DRUG|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
223937067|NCT00679770|DRUG|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
223937068|NCT00679770|DRUG|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
223937069|NCT00679770|DRUG|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
223937070|NCT00736463|DRUG|Simvastatin|One arm of randomized crossover
224098335|NCT04894383|DEVICE|Aetrex indoor comfort sandal with built-in arch support|An indoor comfort sandal with built-in arch support to be used at home. Provides extreme cushioning, shock absorption and durability. Arch support helps to stabilize and align feet and also helps to relieve common foot pain \& plantar fasciitis.
223937071|NCT00736463|DRUG|Atorvastatin 80 mg|Second arm of randomized crossover
223937072|NCT03919721|BEHAVIORAL|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
224098336|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
224098337|NCT02890719|DRUG|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
224098338|NCT02890719|DRUG|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
224098339|NCT02890719|DRUG|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
224098340|NCT02890719|DRUG|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
224098341|NCT01517438|BEHAVIORAL|agitation|agitation score after desflurane anesthesia
224098342|NCT05280561|DIETARY_SUPPLEMENT|DHM|DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
224098343|NCT05280561|DIETARY_SUPPLEMENT|Placebo|Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
224098344|NCT05957081|DRUG|PMC-309 monotherapy|PMC-309 will be administered intravenously.
224098345|NCT05957081|DRUG|PMC-309 Dose Escalation in Combination with Pembrolizumab|Both PMC-309 and pembrolizumab will be administered intravenously. At the time of the combination therapy (Week 1/Day 1 of each cycle), participants will be dosed with pembrolizumab first, administered over 0.5 hours (± 10 minutes). Following an interval of 1 hour (± 15 minutes), participants will be dosed with PMC-309 administered over 1 hour (± 0.5 hours), after which participants will be observed for a period of 1.5 hours post administration.
224098346|NCT05957081|DRUG|PMC-309 Dose Expansion|"Phase 1b will enroll participants with advanced or metastatic tumor types into 1 of 2 cohorts:~* Cohort A: PMC-309 monotherapy therapy~  \- PMC-309 dosing will be at the preliminary RP2D, as identified in Phase 1a: Part A~* Cohort B: PMC-309 plus pembrolizumab combination therapy - PMC-309 dosing will be as identified in Phase 1a: Part B in combination with 200 mg pembrolizumab"
224098347|NCT00327392|DRUG|AQUAVAN® (fospropofol disodium) Injection|
224098348|NCT04779502|OTHER|oregawash|mouthwash containing oregano essential oil
224098349|NCT04779502|OTHER|corsodyl|0.2% chlorhexidine mouthwash
224286503|NCT04456933|PROCEDURE|Extracorporeal left hemicolectomy anastomosis|"Standard surgical technique protocolized in the unit for laparoscopic surgery of the left colon, sigma and high rectum for the last 10 years.~After sectioning the distal colon using a mechanical stapler (60mm blue load), a pfannestiel-type suprapubic accessory incision is made, with externalization of the tumor under wound protection with a ringed retraction device. Both the resection of the left mesocolon or mesosigma, and the placement of the head of the circular stapler are performed extracorporeally by proximal section of the colon with a pursetring® self-suturing device, removal of the piece, placement of the head, and reconnection of the pneumoperitoneum for colorectal anastomosis with Circular Stapler Curved B. Braun®"
224286504|NCT04456933|PROCEDURE|Intracorporeal left hemicolectomy anastomosis|"o Intracorporeal resection of the left mesocolon~The mesocolon resection will be performed totally intracorporeally to its proximal end. The distal colon section will be performed using a mechanical stapler (blue charge 60mm)~o Preparation of Intracorporeal Anastomosis~The anastomosis will be performed in a mechanical end-to-end manner using a Circular Stapler Curved B. Braun®.~The Insertion of the stapler head into the proximal colon will be placed intracorporeally with an incision distal to the staple section. Once the head has been exteriorized at the terminal end of the proximal colon, a circular purse-type suture with prolene 2.0 will be made.~Once the mechanical colorectal anastomosis is performed, 4-6 stitches of anastomotic reinforcement with silk 2.0 will be placed.~The extraction of the piece will be carried out with endobag protection and with an accessory incision (pfannestiel or other location depending on the patient)"
224286505|NCT01192399|BIOLOGICAL|Eculizumab|
224286506|NCT06552104|BEHAVIORAL|ACUPRESSURE APPLI ACUPRESSURE APPLICATION|Pre-test data were collected from participants who met the inclusion criteria and volunteered to participate in the study by researcher BI in the LDP rooms during the latency period of labor. Post-test data were obtained by the same researcher 16 hours after the cesarean section. Data were obtained using the Personal Information Form, Episiotomy Evaluation Form (EEF), Visual Analog Scale (VAS), and Spielberger Manual for State-Trait Anxiety Inventory (STAI).
224286507|NCT01859026|DRUG|MEK162|Treatment as outlined in study arms.
224286508|NCT01859026|DRUG|Erlotinib|Treatment as outlined in study arms.
223718735|NCT03985904|OTHER|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly 2 hour group carried out by a mental health nurse, a social monitor and a museum educator.
223718736|NCT00251784|DRUG|Sildenafil|
223718737|NCT00549081|DIETARY_SUPPLEMENT|DHEA|oral DHEA tablets 75 mg daily
224098350|NCT04779502|OTHER|placebo|distilled water
224098351|NCT00215930|DRUG|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
224098352|NCT00215930|DRUG|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
224286509|NCT01021267|DRUG|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
224286510|NCT01930175|DRUG|VAY736|
224286511|NCT01930175|DRUG|Placebo|
224286512|NCT02820740|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
224286513|NCT01651546|BEHAVIORAL|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
224286514|NCT04507594|PROCEDURE|Lung lobectomy OR esophagus cancer resection|Lunge lobectomy (total) Resection of esophagus cancer
224098353|NCT00215930|DRUG|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
223941380|NCT01605409|PROCEDURE|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
224098354|NCT00215930|DRUG|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
224098355|NCT03494647|DEVICE|Cheetah Heel Cup|The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
223718738|NCT06620146|OTHER|mechanical bathing|Providing mechanical bathing (MB) is a commonly used strategy to maintain cleanness and comfort in patients with terminally illness. The electric medical bathtub (ARJO, Rhapsody) provides functions such as showering, bathing, and water massage. The MB will be operated by 2-3 nursing staff, trained hospice volunteers, or researchers. Each patient\&amp;#39;s MB process lasts about 20 minutes, including washing the hair and body with a handheld showerhead, followed by soaking in warm water for about 5-10 minutes. Based on the patient preference, the water temperature is adjusted between 38 to 40 degrees Celsius.
224098356|NCT03494647|DEVICE|The X Brace|The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
223937073|NCT02727634|OTHER|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
223937074|NCT04006834|OTHER|No intervention involved|No intervention involved
223937075|NCT06510790|DEVICE|Double J stent|Double J ureteral catheter has been used to prevent upper urinary tract obstructions or strictures and to facilitate stone clearance after procedures such as percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), and ureteroscopic lithotripsy (URSL).
223937076|NCT01595282|DRUG|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
223937077|NCT01595282|DRUG|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
223937078|NCT06458010|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
223937079|NCT02227706|BIOLOGICAL|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
223937080|NCT02227706|DEVICE|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
223937081|NCT02794363|BIOLOGICAL|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
223937082|NCT04932018|BEHAVIORAL|Virtual Community of Support|The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
223937083|NCT04932018|BEHAVIORAL|Mentorship Incubator|The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
223937084|NCT02792907|DEVICE|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
223937085|NCT01534091|BEHAVIORAL|Pedometer with supervision|
223534293|NCT06675591|OTHER|Slow sodium correction|"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \&lt; 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."
223534294|NCT07003750|OTHER|Surgical wound infection prevention bundle|utilization of locally customized surgical wound infection bundle to prevent and or control of infection in patients undergoing CABG surgery
223937086|NCT01534091|BEHAVIORAL|Pedometer without supervision|
223937087|NCT02848560|DRUG|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
223937088|NCT01593020|DRUG|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
223937089|NCT01593020|DRUG|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
223937090|NCT01593020|DRUG|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
223937091|NCT01593020|DRUG|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
224098357|NCT00651040|DRUG|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
223718739|NCT01930123|DRUG|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning."
223937092|NCT01593020|DRUG|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
223937093|NCT01593020|DRUG|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
223937094|NCT00900900|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
223937095|NCT00900900|DIETARY_SUPPLEMENT|pregnenolone|one-time 400mg oral dose of pregnenolone
223937096|NCT00900900|DRUG|Placebo|one-time dose oral dose
223937097|NCT03186326|DRUG|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
223937098|NCT03186326|DRUG|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
224098358|NCT00651040|DRUG|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
224098359|NCT05802329|DRUG|OCU200|Intravitreal Injection
224098360|NCT03614936|OTHER|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
224098361|NCT03614936|OTHER|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~* the socio-cultural evaluation scale,~* the ADL autonomy questionnaire,~* assessment of locomotor disorders,~* nutritional assessment,~* the MMSE Cognitive Function Evaluation Questionnaire,~* the GDS-4 mood rating scale,~* the comorbidity assessment test (Charlson Index)"
223718740|NCT01930123|OTHER|Blood Draw|Fasting bloodwork will be obtained before and after the IV fructose challenge.
223718741|NCT04171050|DRUG|Local anaesthetic|Local anesthesia injections
224098362|NCT03563534|DRUG|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
224098363|NCT03563534|DRUG|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
223937099|NCT03186326|DRUG|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
223718742|NCT04171050|DRUG|Pudendal Nerve Block plus anesthesia|Local anesthesia injections plus a pudendal nerve block
223718743|NCT01447433|DRUG|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
223937100|NCT03186326|DRUG|Panitumumab|Administered at 6 mg/Kg
224098364|NCT02060422|BEHAVIORAL|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
223718744|NCT01447433|BEHAVIORAL|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
223718745|NCT00036270|DRUG|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
223718746|NCT00036270|DRUG|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
223937101|NCT03186326|DRUG|Cetuximab|Administered at 500 mg/m²
223937102|NCT03186326|DRUG|Bevacizumab|Administered at 5 mg/Kg
223937103|NCT03186326|DRUG|Aflibercept|Administered at 4 mg/Kg
223937104|NCT04144868|DEVICE|Oxygen storage face masks and nasal catheter|Giving high-flow mask oxygen via oxygen storage face masks (100% O2, flow rate 8 L/min, 1 hour, four times daily, and 2 L/min via nasal catheter during intermittent periods, for 7 days) immediately at admission.
223937105|NCT04144868|DEVICE|Nasal catheter|Giving 2 L/min flow of 100% O2 via nasal catheter at admission for 24 hours daily for 7 days.
224098365|NCT02060422|BEHAVIORAL|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
224098366|NCT01069848|DEVICE|Vedera KXS|One treatment session with Vedera KXS
223937106|NCT04203394|OTHER|Schroth Exercise Group|12 week , Exercises 1 hour, 2 times for a week with physiotherapist 20 minutes home exercise
223937107|NCT04203394|OTHER|Home Exercise Group|Home exercise 20 min at home Once, one hour to determine the Schroth program + teaching home exercises 20 minutes home exercise
223937108|NCT00348751|DEVICE|CholGate|
223937109|NCT05423119|BEHAVIORAL|conventional therapy|upper limb rehabilitation with and without technologies
223937110|NCT06482632|PROCEDURE|Discectomy of Omohyoid|Will be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
223937111|NCT06482632|PROCEDURE|Control group no discectomy of Omohyoid|Will not be removing the Omohyoid during an anterior cervical discectomy and fusion to compare its effect of dysphagia.
223937112|NCT05587699|DRUG|CKD-843 A 45mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
223937113|NCT05587699|DRUG|CKD-843 A 45mg|Single Injection
223937114|NCT05587699|DRUG|CKD-843 A 55mg(Multiple dose)|1 Injection/3 Month, 3 times Injections
223937115|NCT05587699|DRUG|CKD-843 A 55mg|Single Injection
223937116|NCT05587699|DRUG|CKD-843-R|0.5mg/day, 9 Month
223937117|NCT04190108|DIAGNOSTIC_TEST|Fecal calprotectin assay|FC levels were measured at baseline with Bühlmann fCAL Turbo, Switzerland® kit.
223937118|NCT03190603|DRUG|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
223937119|NCT06102616|DIAGNOSTIC_TEST|measure Osteocalcin level|in gingival crevicular fluid before and during orthodontic tooth movement
223937120|NCT00575419|DRUG|N-acetylcysteine|"* Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day"
223937121|NCT04570358|OTHER|Static stretching|During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.
223937122|NCT04570358|OTHER|Proprioceptive neuromuscular facilitation stretching|During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
223937123|NCT02071316|DRUG|Hexacapron( Tranexamic acid)|1\. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
223937124|NCT02071316|DRUG|esomeprazole|2\. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
223937125|NCT03933137|OTHER|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
223937126|NCT02645942|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
223937127|NCT02645942|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
223937128|NCT00732966|DRUG|losartan|with losartan 50 mg once daily for one month
223937129|NCT00732966|DRUG|valsartan|valsartan 160 mg once daily
223937130|NCT06321224|OTHER|Breathing exercises|Breathing exercises will be performed 3 days a week during 2 menstrual periods.
223937131|NCT06321224|OTHER|Control|No intervention will be made to the control group and they will be asked to continue their routine lives.
223937132|NCT00645359|PROCEDURE|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
223937133|NCT02595346|DRUG|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
223937134|NCT02595346|DRUG|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
223937135|NCT02660294|BIOLOGICAL|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
223937136|NCT00429338|PROCEDURE|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
223937137|NCT00429338|PROCEDURE|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
223937138|NCT00370942|DRUG|GW823093C A|A=45 mg
223937139|NCT00370942|DRUG|GW823093C B|B=30 mg
223937140|NCT00370942|DRUG|GW823093C C|C=25 mg
223937141|NCT00023920|BIOLOGICAL|bevacizumab|Given IV
223937142|NCT00023920|DRUG|idarubicin|Given IV
223937143|NCT00023920|DRUG|cytarabine|Given SC
223937144|NCT06514183|OTHER|Clinical diagnosis of recurrence|Clinical diagnosis of recurrence
224098367|NCT01871792|DRUG|Pitavastatin|
224098368|NCT01871792|DRUG|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
224098369|NCT00470496|DRUG|HPPH|Given IV
224098370|NCT00470496|DRUG|photodynamic therapy|Undergo laser light exposure
223534295|NCT07004530|PROCEDURE|Magnetically Controlled Capsule Endoscopy (MCCE)|. The MCCE used in this study is the magnetically controlled capsule endoscopy (MCE, AnPx USA) which is a capsule measuring 28x12mm, and contains a permanent magnet inside its dome. Images are captured and recorded at 2 frames/s
223937145|NCT02080585|BEHAVIORAL|Physical Activity advice.|Subjects receive advice regarding physical activities.
223937146|NCT00401869|DRUG|Epoetin alfa|
223937147|NCT04518813|DEVICE|Prototype 0.5|Investigational Medical Device collecting Raman data from tissue
223937148|NCT04245995|DIAGNOSTIC_TEST|Feature Extraction Technology|The study´s aim was evaluation of the clinical applicability of the Feature Extraction Technology (FET) during a simulated blood loss scenario in comparison to visual estimation.
223937149|NCT01432769|DIETARY_SUPPLEMENT|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
223937150|NCT01541059|DRUG|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
223937151|NCT01541059|DRUG|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
223937152|NCT05454475|OTHER|Change the water injection temperature|Water injection is a routine procedure for endoscopy of small probe ultrasound, and our intervention is to change the water temperature and observe the effects of different water temperatures on patient safety and comfort.
223937153|NCT02910973|DEVICE|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
223937154|NCT02910973|DEVICE|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
224098371|NCT00470496|PROCEDURE|conventional surgery|Undergo surgery
223534296|NCT07004530|PROCEDURE|Esophageal-gastro-Duodenoscopy (EGD)|Esophageal-gastro-Duodenoscopy (EGD) is commonly performed to look for source of bleeding in patients with anaemia. However, from our own analysis and from retrospective studies of EGD in patients with ACS, EGD finding was normal or non-significant in 20-80% patients14-16. Moreover, EGD was associated with non-negligible periprocedural risks in patients with ACS, including death directly attributed to EGD (9.1%; 95% CI 7.6-10.9%), hypotension (24.1%; 95% CI 17.0-32.9%), arrhythmias (8.3%; 95% CI 4.5-15.1%) and recurrent ACS (6.5%; 95% CI 3.2-12.8%)
223534297|NCT05788991|DRUG|Dequalinium Chloride|Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
223937155|NCT05979038|DRUG|Metformin|Patients in the intervention arm will take metformin 500mg three times a day
223937156|NCT01800487|DRUG|silymarin|140 mg three times a day for 4 weeks
223937157|NCT01800487|DRUG|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
223937158|NCT00528320|DEVICE|Ovatio CRT|
223937159|NCT04910685|DRUG|Elenestinib|Elenestinib oral tablet
223937160|NCT04910685|DRUG|Placebo|Placebo oral tablet
223937161|NCT06571058|OTHER|Assistance|Assist patient with walking approximately 90 feet
223937162|NCT06571058|OTHER|Educational Intervention|Receive a short instructional session
223937163|NCT06571058|DEVICE|Medical Device Usage and Evaluation|Wear the B3 Buddy device
223937164|NCT06571058|OTHER|Medical Device Usage and Evaluation|Secure the urinary drainage bag to the patient using the B3 Buddy device
223937165|NCT06571058|OTHER|Questionnaire Administration|Ancillary studies
223937166|NCT06571058|PROCEDURE|Remove|Remove the device and return urinary drainage bag to the standard position
223937167|NCT06571058|OTHER|Walking|Walk approximately 90 feet
223937168|NCT06312254|DRUG|Topical lidocaine 5%|Drug is used to pharmacologically modulate peripheral sensory afferents
223937169|NCT06312254|DRUG|Topical Phenytoin 10%|Drug is used to pharmacologically modulate peripheral sensory afferents
223937170|NCT06312254|DRUG|Topical Mepyramine 2%|Drug is used to pharmacologically modulate peripheral sensory afferents
223937171|NCT06312254|OTHER|Topical Placebo|Drug is used as control
223937172|NCT00507884|PROCEDURE|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
223937173|NCT03169413|GENETIC|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
223941381|NCT01728974|OTHER|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
223941382|NCT06294223|DEVICE|Exercise follow up with near-infrared spectroscopy|Exercises will be followed by near-infrared spectroscopy. Fatigue protocol will be applied.
223941383|NCT03604146|BEHAVIORAL|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
223941384|NCT00124254|PROCEDURE|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
223941385|NCT00124254|OTHER|Usual care|Non-surgical usual care
223941386|NCT03683576|DRUG|GB001|film-coated oral tablet
223941387|NCT03683576|DRUG|Placebo|film-coated oral tablet
223941388|NCT04873206|OTHER|routine stain by H&E.|formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.
223937174|NCT03657316|BEHAVIORAL|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
223937175|NCT06652750|OTHER|Routine Management|Conducting routine in-office follow-up for CIED paitents
224286515|NCT05670145|OTHER|PRECISE|"The target group is working pregnant women. Further, a smaller group of non-pregnant women from the same workplaces and with the same work tasks (colleagues) will be included. Around 95% of pregnant women in Denmark have a 1st trimester ultrasound scan.(17) To ensure a representative population, the recruitment to the project takes place at four obstetric departments. After giving informed written consent for participation, the pregnant women receive a baseline questionnaire followed by short weekly questionnaires by SMS until maternity leave.~Exposure to occupational standing/walking and bending are measured by use of triaxial accelerometers (Axivity sensors) worn on the back and thigh for 24 hours/day. Exposure to lifting is quantified through continuous observations during a workday with registration of number of lifts, weight of burdens, and number of person-liftings."
223937176|NCT06652750|DEVICE|5G Cloud Follow-up|This study employed a 5G-cloud follow-up platform, a research tool that allows a device specialist to test, and program CIEDs in real-time from a remote location via an internet connection or mobile wireless network. Consistent with of the 5G remote support terminal externally connected to the programmer, a PAD was installed with a 5G-cloud follow-up app. The onsite medical staff began the cloud follow-up session by contacting the remote device specialist via video call. The connection to the CIED was made by the medical staff through the use of a standard programmer. He was in charge of turning on the programmer and applying the programmer wand to the patient's device. After an initial introduction, communication was established and continued via the wand connection. The remote device specialist logged into the 5G-cloud follow-up app with two-step verification. The remote device specialist then had complete control of the programmer to check and reprogram the device as needed.
223937177|NCT00787709|BEHAVIORAL|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
224286516|NCT04062682|BEHAVIORAL|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
224286517|NCT01229644|DRUG|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
224286518|NCT05785689|DRUG|Dexmedetomidine|To reduce postoperative agitation
224286519|NCT05785689|DRUG|Placebo|Placebo bolus saline
224286520|NCT03409991|BEHAVIORAL|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
224286521|NCT02692729|PROCEDURE|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
224286522|NCT02692729|PROCEDURE|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
224286523|NCT01631526|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
223534298|NCT05788991|DRUG|Metronidazole Oral|Metronidazole oral tablets (500 mg) taken twice a day for 7 days
224098372|NCT02335684|OTHER|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
224098373|NCT02335684|OTHER|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
224286524|NCT05382520|DIAGNOSTIC_TEST|Questionares and practice|Questionares and practice
223534299|NCT01325233|DRUG|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
223534300|NCT01325233|DRUG|Placebo|500 ml normal saline, tiw, 2 weeks
223534301|NCT05270863|DRUG|BRIMOCHOL™ PF|A single drop in each eye at a visit.
224286525|NCT03433131|DRUG|Pitolisant|Tablets
224286526|NCT01393457|DRUG|levodopa/carbidopa|800/200 mg/d
224286527|NCT01393457|DRUG|Ropinirole 2 mg/d|2 mg/d
224286528|NCT01393457|DRUG|Placebo|sugar pill
224286529|NCT01393457|DRUG|Ropinirole 4 mg/d|4 mg/d
224286530|NCT01211782|DRUG|caprylic triglyceride|oral, 20 gm, daily x 6 months
224286531|NCT01211782|DRUG|long-chain triglyceride|oral, 14 gm, daily x 6 months
224286532|NCT03858426|OTHER|no intervention|no intervention
224286533|NCT03770078|DEVICE|Test Product A|The test product is a newly developed ostomy product
224286534|NCT02428179|PROCEDURE|StOP? - Control group|Control group - Surgical procedure without Study Intervention
224286535|NCT02428179|PROCEDURE|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
224286536|NCT01207999|PROCEDURE|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
224286537|NCT01207999|OTHER|Data collection|Questionnaire completion
224286538|NCT00772720|DRUG|raltegravir|raltegravir 400 mg BID for 7 days
224286539|NCT00772720|DRUG|Placebo|Placebo BID for 7 days
224286540|NCT00211991|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
224286541|NCT02293616|DIETARY_SUPPLEMENT|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
224286542|NCT02293616|DIETARY_SUPPLEMENT|Placebo|
224286543|NCT01872845|DRUG|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
223534302|NCT05270863|DRUG|Carbachol PF|A single drop in each eye at a visit.
223937178|NCT06613048|OTHER|Breathing exercise|"The researcher has a certificate in breathing exercises. Those who consent to participate in the study that meets the research criteria will be given training with a prepared training brochure about correct breathing technique, introduction and function of the diaphragm muscle, box breathing technique, diaphragm breathing technique and benefits of correct breathing before the exercise.~Box breathing technique will be applied in addition to standard treatment, 3 sets per day (morning, noon and evening) for 6 weeks, 10 repetitions in each set.~Diaphragm breathing exercise will be applied in addition to standard treatment, lasting 2 minutes in the first week, then increasing each week and reaching 12 minutes in the 6th week, as 3 sets (morning, noon and evening)."
223937179|NCT06232408|DRUG|RP-1664|RP-1664 will be supplied as immediate-release solid dosage form for oral self-administration.
223937180|NCT00062660|DRUG|Tipranavir|Tipranavir 250 mg soft elastic capsules
223937181|NCT06812754|DRUG|Fezolinetant|oral
223937182|NCT06812754|DRUG|Placebo|oral
223937183|NCT06981208|OTHER|ChatGPT-generated patient education|This is created by entering the patient's age, medical history, social history, and case-specific details into Washington University ChatGPT Beta (HIPAA and FERPA compliant) by a study team member.
223937184|NCT06981208|OTHER|Usual patient education|Usual patient education will include description of breast reconstruction options, with further elaboration on which option are more suitable to the patient. This include also review of risk of complications and expected recovery after surgery.
223937185|NCT04724759|DRUG|Dexmedetomidine / Ketamine / Lidocaine|Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
223937186|NCT06856733|BEHAVIORAL|Person-centred team-based approach|"Phase 1 (investigation and assessment, week 1-3):~* A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist.~* A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms.~* A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities.~* A visit to a psychologist for diagnostics and treatments regarding psychological and social factors.~* A visit to a care manager~Phase 2 (treatment plan, week 3-4):~\- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made.~Phase 3 (treatment and follow-up, week 4-24):~* Implementation of the individualized rehabilitation plan.~* Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager.~* A second team consultation half-way"
223937187|NCT05361733|DRUG|XFB-19|XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
223937188|NCT05361733|DRUG|Placebo|No active ingredient drug use to blind participants and investigators
223937189|NCT06864546|BEHAVIORAL|Physical activity intervention|"In the first week, patients will be asked to maintain their normal sedentary life, spending most of the waking day sitting. During the second week, participants will be asked to take at least 10,000 steps/day, with sitting replaced by standing and light-intensity walking.~See doi: 10.1007/s00125-016-4161-7"
223937190|NCT07013812|DRUG|Tranexamic Acid (IV)|One gram (10 ml) intravenous injection
223937191|NCT07013812|DRUG|Dextrose 5% (D5W)|5% dextrose water intravenously
223937192|NCT07012590|DRUG|Morphine|Patients received erector spinae plane block with morphine 2 mg as an adjuvant to bupivacaine 30 ml 0.25%.
223937193|NCT07012590|DRUG|Dexmedetomidine|Patients received erector spinae plane block with dexmedetomidine 100 µg as an adjuvant to bupivacaine 30 ml 0.25%.
223937194|NCT07012590|OTHER|Erector spinae plane block|Patients received erector spinae plane block with bupivacaine 30 ml 0.25% only.
223937195|NCT02520791|BIOLOGICAL|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
223937196|NCT02520791|OTHER|Laboratory Biomarker Analysis|Correlative studies
223937197|NCT02520791|OTHER|Pharmacological Study|Correlative studies
223937198|NCT07013435|OTHER|Health Education Program|8 weekly sessions that include education on the co-occurrence of mental and physical problems, goal setting for health behavior change, and self-monitoring. Each session includes basic didactic information, interactive application of the information, and open discussion of didactic material.
223937199|NCT07013435|OTHER|SMART3RP-Lymphoma|The SMART3RP-lymphoma is a group program that, through a variety of mind-body approaches, such as imagery, relaxation, and yoga, seeks to buffer stress and promote psychological resiliency and physical well-being.
224286544|NCT01872845|DRUG|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
223534303|NCT05270863|DRUG|Brimonidine tartrate|A single drop in each eye at a visit.
224286545|NCT05065437|OTHER|Active (Virtual reality and spinal stimulation)|Each session is 25 minutes; 5 minutes of setup, and 20 minutes of simultaneous spinal stimulation at the cervical level and immersive virtual experience/gameplay.
224286546|NCT06904443|OTHER|PsySon is an innovative device that uses music in crisis management in hospitals|"during his hospitalization, the patient can benefit from listening sessions thanks to an original and innovative device, a sort of listening chair equipped with high-quality speakers, thus offering an immersive and enveloping experience (see photo). These sessions aim to anticipate or manage a moment of crisis, of less well, which patients often face in institutions."
224286547|NCT06458244|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
224286548|NCT06458244|DRUG|Chemotherapy|Chemotherapy for AML consolidation treatment
224286549|NCT06905418|DIAGNOSTIC_TEST|Clinic|group A will get treatment in clinic
224286550|NCT06905418|COMBINATION_PRODUCT|Mobile App|group B will use mobile application for treatment
223534304|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose A|Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
223534305|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose B|Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
223534306|NCT06194656|DRUG|HER3 Monoclonal antibodies-Dose C|Dose C, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
223937200|NCT07011758|DRUG|Medication for opioid use disorder|A medication treatment component delivered in Week 1 as part of a 2×2 factorial SMART design. The exact content (e.g., treatment modality or intensity) will be finalized based on model results from Aim 1, which identifies optimal dynamic treatment regimes.
223937201|NCT07011758|BEHAVIORAL|psychotherapy|A behavioral treatment component delivered in Week 1 as part of a 2×2 factorial SMART design. The exact content (e.g., treatment modality or intensity) will be finalized based on model results from Aim 1, which identifies optimal dynamic treatment regimes.
223937202|NCT07012044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223937203|NCT07012044|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223937204|NCT07012044|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223937205|NCT07012044|DRUG|Decitabine|Given PO
223937206|NCT07012044|DRUG|Decitabine and Cedazuridine|Given PO
223937207|NCT07012044|BIOLOGICAL|Filgrastim|Given SC or IV
223937208|NCT07012044|PROCEDURE|Imaging Procedure|Undergo diagnostic imaging
223937209|NCT07012044|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223937210|NCT03373968|DRUG|Givinostat|suspension of givinostat (10 mg/mL)
223937211|NCT06688370|DEVICE|Petit Drill|Day 1: 2-4 doses, including one of the daily doses taken at bedtime. Days 2 and 3: 3 to 4 doses on days 2 and 3, including one of the daily doses taken at bedtime.
223937212|NCT06686667|BEHAVIORAL|Time Restricted Eating|The intervention arm will consist of a time-restricted eating protocol with fasting between 11:00 PM to 6:00 AM. Ad libitum eating will be allowed outside these times and the protocol will be administered during day and night shifts over a 2 week period.
223937213|NCT04934995|OTHER|Blood Pressure Cuff|"After obtaining consent and confirming eligibility, Blood Pressure cuffs will be used as specified below:~Cuff size: large BP cuffs will be the default size for both arm and ankle measurements, but can be changed as clinically indicated based on circumferences of limbs Cuff location: BP cuffs will be placed on the contralateral arm to the main peripheral IV following standard procedures. Left ankle cuff will be placed underneath intermittent pneumatic compression cuffs Ankle blood pressure monitor screen will be covered. Thus, anesthesia providers will not be able to make any clinical decisions based on ankle blood pressures but arm blood pressure (standard) instead."
223937214|NCT06697132|PROCEDURE|laparoscopic dismembered pyeloplasty|Modified antegrade stenting in laparoscopic pediatric pyeloplasty
223937215|NCT06698874|OTHER|ds-MCE and EGD examinations|Sequentially performing ds-MCE and EGD examinations on enrolled participants.
223937216|NCT03598907|OTHER|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
223937217|NCT06699446|OTHER|pre rehabilitation|preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app
223937218|NCT06705582|OTHER|Fortified Bread|Intervention group will be supplied with fortified bread delivering 10 -15 μg (400-600 IU) vitamin D3 in a daily portion and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
223937219|NCT06705582|OTHER|Unfortified bread|Placebo control group will be supplied with unfortified bread and will receive dietary advice to incorporate fortified foods that are commonly available on the market in their diet.
223937220|NCT07044232|COMBINATION_PRODUCT|Nicardipine|Nicardipine infusion based acute blood pressure lowering treatment
223937221|NCT07044232|COMBINATION_PRODUCT|Glyceryl trinitrate|Glyceryltrinitrate based acute blood pressure lowering treatment
224286551|NCT01684215|DRUG|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
224286552|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
224286553|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
223534307|NCT06194656|OTHER|HER3 Monoclonal antibodies-Dose D|The optimal recommended dosage (RP2D) of SIBP-03intravenous, infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
223534308|NCT06194656|OTHER|Placebo|SIBP-03 solvent without HER3 antibody, intravenous infusion (IV), once every one weeks, 21 days as a cycle.
223534309|NCT06194656|COMBINATION_PRODUCT|Cetuximab injection|Medications used for combination therapy, intravenous infusion (IV). Administer once a week.
223937222|NCT06895200|DEVICE|CVS-Notifier SaMD|The CVS-Notifier SaMD reminds surgeons to time-out to check the CVS before the division of the cystic duct.
223937223|NCT06811857|DEVICE|hyperbaric oxygen therapy and povidone-iodine wet compresses|The hyperbaric oxygen group receives 30-40 sessions of hyperbaric oxygen therapy (100% oxygen at a pressure of 2.0 ATA) and povidone-iodine wet compresses.
223937224|NCT06811857|OTHER|wet compresses of povidone-iodine|wet compresses of povidone-iodine
223937225|NCT06752018|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass or sleeve gastrectomy
223937226|NCT06755944|DRUG|XY03-EA|"The sample size was 360 patients, and 72patients were treated with XY03-EA 150 mg, 300mgA group ,300mgBgroup,450mg and placebo respectively. The 150mg group took two tablets of placebo and one tablet of XY03-EA once, three times a day. For 90 days The 300mg A-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. For 90 days The 300mg B-group took one tablet of placebo and two tablets of XY03-EA once,three times a day. Use continuously for 14 days.Placebo is used for 15-90 days.~The 450mg group took three tablets of XY03-EA once,three times a day. For 90 days.~The placebo group took three tablets of placebo once ,three times a day.For 90 days."
223937227|NCT06769919|RADIATION|Neoadjuvant radiotherapy|The experimental group will receive neoadjuvant systemic therapy combined with neoadjuvant radiotherapy before undergoing surgery
224286554|NCT01684215|DRUG|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
224286555|NCT01684215|DRUG|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
224286556|NCT00835939|DRUG|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
224286557|NCT00835939|DRUG|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
224286558|NCT00835939|PROCEDURE|sclerotherapy|
223937228|NCT06780488|OTHER|Real Visual-Vestibuar Rehabilitation|"The Real Visual-Vestibular Rehabilitation protocol will consist of specific exercises aimed at stimulating the visuo-vestibular function within immersive virtual reality environments replicating daily life situations. Patients will perform exercises in two types of contexts. In all exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the exercises can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation.The protocol will last 20 minutes, with 10 minutes dedicated to each exercise."
223937229|NCT06780488|OTHER|Sham Rehabilitation|"The Sham Vestibular Rehabilitation protocol will involve the use of the same immersive virtual reality contexts and will aim to achieve the same objectives as the Real Visual-Vestibular Rehabilitation protocol, but without the unexpected stimuli. In both exercises, patients will be free to move within a room large enough to complete the tasks. Walking during the session can also be performed with assistive devices, to make the context as close as possible to the patient's daily life. During the exercises, patients will be supervised by a physiotherapist specialized in neurological and vestibular rehabilitation. The protocol will last 20 minutes, with 10 minutes dedicated to each exercise."
223718747|NCT00593502|DRUG|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; \> 40 kg, 75 mg twice daily, for 5 days
223718748|NCT00593502|DRUG|placebo|The dosage of placebo will be similar to the active drug
223718749|NCT03689348|DIETARY_SUPPLEMENT|Avena sativa|A supplement derived from wild green oat
223718750|NCT03689348|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223937230|NCT04525092|DEVICE|Online Pre-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>44L/session reinjected in pre-dilution mode. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
223937231|NCT04525092|DEVICE|Conventional Hemodialysis|Using the following parameters: maximum Blood flow rate allowed by vascular access, dialysate rate of 500 mL/min, no convection. The dialysate composition, net ultrafiltration rate and use of anticoagulation will be prescribed according to participant's characteristics.
223937232|NCT04525092|DEVICE|Online Post-dilution Hemodiafiltration|The following parameters: maximum Blood flow rate allowed by vascular access, dialyste rate of 500 mL/min and average convective volume of \>22L/session reinjected in pre-dilution mode. The dialysate composition and net ultrafiltration rate will be prescribed according to participant's characteristics. Usage of intra-dialysis anticoagulation is mandatory.
223937233|NCT05190172|RADIATION|Radiation therapy|Radiation therapy either with protons or photons
223937234|NCT06597201|DRUG|amino acid (15) peritoneal dialysis solution|Subjects were treated with 1 bag of amino acid (15) peritoneal dialysis solution (2L) once every morning, and then with conventional glucose peritoneal dialysate (lactate).
223937235|NCT06597201|DRUG|glucose peritoneal dialysis solution|Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
223937236|NCT06743581|DRUG|Cemiplimab|Cemiplimab 350 mg administered intravenously on day 1
223937237|NCT06743581|DRUG|Dupilumab|Dupilumab 600 mg administered subcutaneously on day 1
223937238|NCT05240352|DEVICE|active tDCS|Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
223937239|NCT05240352|DEVICE|sham tDCS|"Subjects will receive a dose from a sham-tDCSthat is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later"
223937240|NCT06823635|DEVICE|Transcatheter device closure of perimembranous ventricular septal defects (PmVSDs)|Transcatheter closure of perimembranous ventricular septal defects (PmVSDs) using an occluder device either specifically designed for this purpose or used off-label.
223937241|NCT06821724|DRUG|Casein phosphopeptide-amorphous calcium phosphate|Intervention
223937242|NCT06821724|DRUG|Casein phosphopeptide-amorphous calcium phosphate + fluoride|Intervention
223937243|NCT06821724|DRUG|Nano hydroxyapatite paste|Intervention
223937244|NCT06821724|DRUG|Fluoride gel|Positive control
223937245|NCT05447208|DRUG|Growth Hormone|Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
223937246|NCT05447208|DRUG|GnRH antagonist|GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
223937247|NCT06237673|DIAGNOSTIC_TEST|CT|CT-directed clinical management strategy
223937248|NCT06237673|DIAGNOSTIC_TEST|invasive coronary angiography (ICA)|Standard clinical management directed by conventional invasive coronary angiography (ICA).
223534310|NCT05509127|DRUG|Modified universal adhesive|Application of the modified universal adhesive is done according to manufacturer's instructions using a micro-brush. It is actively rubbed for 20 seconds, gently air-dried for 5 seconds then light cured for 20 seconds.
223937249|NCT06828900|BEHAVIORAL|Written Decision Aid|Participants will receive a structured booklet developed based on IPDAS guidelines to support informed decision-making regarding medication vs. no medication for ADHD treatment. The booklet provides a clear explanation of ADHD, the role of medication, and the option of not using medication, including the potential benefits, risks, and uncertainties of each choice. It presents evidence-based information in a balanced manner, helping parents understand possible outcomes such as symptom management, side effects, and long-term considerations. The booklet also includes value clarification exercises to help parents align their decision with personal preferences and concerns.
223937250|NCT06828900|BEHAVIORAL|Decision Aid + Decision Coaching|Participants will receive the written decision aid booklet, developed based on IPDAS guidelines, along with a one-on-one decision coaching session. The decision coaching will follow a structured script based on the Ottawa Personal Decision Guide (OPDG), refined through training with the principal investigator (PI). The decision coach will not give medical advice but will help parents clarify their values, address uncertainties, and weigh the benefits and risks of medication vs. no medication. Through guided value clarification exercises, parents will explore their concerns and preferences to make a well-informed decision.
223937251|NCT06828900|BEHAVIORAL|AI-Driven Support|"Participants will interact with a large language model-based AI tool (Claude) to assist in their decision-making process regarding medication vs. no medication for ADHD treatment. This AI-driven intervention is designed to provide structured, personalized decision support while maintaining an unbiased, evidence-based approach.~Participants will receive 10 structured prompts to ask the AI, covering key aspects of ADHD treatment (e.g., benefits and risks of medication, long-term outcomes, alternatives).~Following this structured phase, participants will have 15 minutes of free interaction with the AI to explore any remaining questions or concerns.~At the end of the session, they will receive a summary output of their AI interactions to review.~The AI tool is designed to translate complex medical information into user-friendly language, provide comparative treatment insights, and help parents clarify their values and concerns. However, it will not offer direct medical recommendations."
223937252|NCT06877208|OTHER|Glucagon (part C)|90 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).
223937253|NCT06877208|OTHER|Glucose clamp (part C)|90 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).
223937254|NCT06877208|OTHER|Saline (part C)|90 minutes intravenous infusion with isotonic NaCl.
223937255|NCT06877208|OTHER|Glucagon (part D)|210 minutes intravenous infusion with glucagon (infusion rate of 10 ng/kg/min).
223937256|NCT06877208|OTHER|Glucose clamp (part D)|210 minutes intravenous infusion of 20 % weight/volume glucose (in an ajustable rate to match the glucose levels achieved during the glucagon infusion).
223937257|NCT06877208|OTHER|Saline (part D)|210 minutes intravenous infusion with isotonic NaCl.
223937258|NCT06810817|COMBINATION_PRODUCT|tDCS & cognitive behavioral programme with home-based physical training|Participants will receive 16 sessions of tDCS and 7 sessions of cognitive behavioral programme over 8 weeks and have physical training at home for 8 weeks.
223937259|NCT06810817|BEHAVIORAL|sham tDCS & cognitive behavioral programme with home-based physical training|Participants will receive 16 sessions of sham-tDCS and 7 sessions of cognitive behavioral programme over 8 weeks and have physical training at home for 8 weeks.
223937260|NCT06810817|BEHAVIORAL|physical training|Participants will have physical training at home for 8 weeks.
223937261|NCT05251363|DEVICE|Solia S lead|The Solia S pacing lead will be implanted in the LBB area for patients who meet all inclusion/exclusion criteria and give written informed consent.
223937262|NCT06785298|DRUG|Levodopa/carbidopa|A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD
223937263|NCT06785298|DRUG|Fexofenadine|Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
223937264|NCT06019247|OTHER|Individual placement support (IPS)|IPS is the most studied psychiatric rehabilitation intervention in the world. It is based on eight principles: inclusion of all clients who have declared a desire to work, no pre-vocational training, benefits counseling, rapid job search, treatment team-level integration of vocational and clinical services, consideration of client preferences in all decisions, assistance in job development, provision of follow-up supports after finding employment, and a focus on competitive employment. We propose to adapt and pilot the IPS to improve employment and health among people with severe mental disorders in Mexico.
223937265|NCT06186128|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
223937266|NCT03253172|DIETARY_SUPPLEMENT|Potassium Chloride|Two potassium supplements with varying anions.
223937267|NCT03253172|DIETARY_SUPPLEMENT|Potassium Citrate|Potassium Citrate
223937268|NCT03253172|DIETARY_SUPPLEMENT|Placebo|Placebo
223937269|NCT04247191|BEHAVIORAL|P-Chat|The P-Chat is a brief individually delivered intervention based on the principles of Motivational Interviewing (MI) and focuses on increasing parents' motivation to reduce permissiveness toward underage alcohol use while reducing defensiveness and barriers to implementing these rules with their teen.
224286559|NCT01789957|DRUG|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
223534311|NCT05509127|DRUG|Conventional universal adhesive|Application of the conventional Single Bond Universal adhesive is done using a micro-brush followed by rubbing for 20 seconds, gentle air drying for 5 seconds then light curing for 20 seconds.
224286560|NCT00401167|DRUG|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
223534312|NCT05493657|DRUG|Aspirin single antiplatelet therapy|Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
223718751|NCT01964430|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 on Days 1, 8, and 15 of every 28 day treatment cycle by intravenous (IV) administration for a total of 6 cycles.
224098374|NCT01727960|BEHAVIORAL|Education and posture correction|a lecture concerning the fine posture for health and exercises
224098375|NCT04947202|DEVICE|Hernioplasty|Hernioplasty is the repair of the defect using mesh patches.
223937270|NCT04247191|BEHAVIORAL|PBI|"The PBI is currently a model prevention resource at NIAAA's College Alcohol Intervention Matrix and the research was discussed in the most recent Surgeon General's Report as one of the two prevention approaches that met the rigorous criteria to be considered efficacious. The first section of the PBI provides an introduction to the problem of substance use. The second section focuses on specific skill building strategies that parents can use to improve communication channels with their teen. Third, is a section that addresses peer influence and provides strategies for developing assertiveness. The fourth section is an in-depth discussion of underage drinking, physiological and psychological effects, mixing alcohol with other drugs, motives for why students drink and don't drink, warning signs, risky binge-type drinking, impaired driving, riding with impaired drivers, alcohol and sexual assault, and how to communicate about parents' experiences when they were young."
224098376|NCT00143325|DRUG|varenicline (CP-526,555)|
224098377|NCT05983640|OTHER|Video|Just in time training video on hands only CPR
224098378|NCT05983640|OTHER|AHA course|AHA Heartsaver CPR course
224098379|NCT06449339|DRUG|Carvedilol|Patients in the NSBB arm will receive generic carvedilol. The starting dose of oral carvedilol is 6.25mg daily (to be taken once or twice per day) and can be adjusted at each scheduled visit (either by increasing the dosage or frequency of dose administration) according to patients' tolerance, as well as the blood pressure and pulse rate that the systolic blood pressure should be not lower than 90 mmHg and pulse rate not lower than 55 beats per minute. The dosage of carvedilol can also be titrated or discontinued at unscheduled visit according to patient's condition. In case carvedilol is discontinued, it can be resumed from the starting dose at next scheduled visit if there is no contraindication for carvedilol. The dose of carvedilol will be kept at 6.25-12.5mg per day unless there are additional non-hepatic indications such as arterial hypertension or cardiac disease warranting higher carvedilol dosage. The maximum allowed dose of carvedilol is 50mg daily as per drug instruction.
224098380|NCT02585557|OTHER|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
224098381|NCT06042374|OTHER|Progressive Core Stabilization Training|The Progressive Core Stabilization Training was applied to study group as a group exercise with 5-10 athletes which was planned in the form of 3 days/week for a total of 9 weeks and 27 sessions. A session consisted of warm-up, core stabilization (30-40 min.), and cool-down exercises. During the training period, exercise volume, degree of difficulty, additional weight, and level of instability (contralateral limb movements and reduction of the support surface, etc.) for each exercise were incrementally increased in four steps.
224286561|NCT00503230|BEHAVIORAL|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
224286562|NCT00503230|BEHAVIORAL|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
224286563|NCT01301482|DEVICE|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
224286564|NCT01272089|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
224286565|NCT06404541|DRUG|Dexamethasone, tobramycin, netilimicin|Group A: Dexathalm single dose Group B: Tobradex Group C: Dexathalm multi-dose
224286566|NCT05866718|BEHAVIORAL|Self-Compassionate Touch Intervention|Participants will be taught the micropractice (\<20-second/day personal practice) via video recording.
224286567|NCT05866718|BEHAVIORAL|Habit Formation Tools|Participants will receive evidence-based tools for promoting habit-formation.
224286568|NCT00005090|BIOLOGICAL|bleomycin sulfate|10 U/m\^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
224286569|NCT00005090|DRUG|carmustine|150/m\^2 on days -6 to -4 (4-6 days before transplant).
224286570|NCT00005090|DRUG|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
224286571|NCT00005090|DRUG|dacarbazine|375 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
224286572|NCT00005090|DRUG|doxorubicin hydrochloride|25 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
223718752|NCT01964430|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles.
224286573|NCT00005090|DRUG|etoposide|60 mg/kg on day -4 (4 days before transplant).
224286574|NCT00005090|DRUG|vinblastine|6 mg/m\^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
224286575|NCT00005090|PROCEDURE|peripheral blood stem cell transplantation|2 x 10\^6 CD34+ blood mononuclear cells/kg of actual body weight
224286576|NCT00480324|BIOLOGICAL|Rotarix|Two-dose oral vaccination.
224286577|NCT00480324|BIOLOGICAL|Placebo|Two-dose oral administration.
224286578|NCT00784134|DRUG|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
223534313|NCT05493657|DRUG|Clopidogrel single antiplatelet therapy|Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
223534314|NCT04464473|DEVICE|transcranial magnetic stimulation|Transcranial magnetic stimulation delivered to the scalp targeting specific brain structures via stereotactic guidance.
223534315|NCT06623019|DIAGNOSTIC_TEST|Validation and reliability|As this is a cross-sectional validation study, there is no intervention.
223534316|NCT06630156|BIOLOGICAL|Revascularization of Immature Young Permenant Teeth|"An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C"
223937271|NCT04247191|BEHAVIORAL|P-Chat+|The P-Chat+ is a combination of the P-Chat and PBI described above. Parents in this arm of the study will receive both interventions.
223937272|NCT06356012|DRUG|Imiquimod|Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
223937273|NCT06356012|PROCEDURE|Loop Electrosurgical Excision Procedure|Active comparator group will be treated with LEEP.
223937274|NCT03480698|DRUG|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
223937275|NCT06489431|DRUG|Chlorhexidine|Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
223718753|NCT00561808|OTHER|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
223937276|NCT06489431|DRUG|Gentamicin|Aminoglycoside antibiotic irrigation
223937277|NCT06489431|DRUG|Rifampin|Antibacterial known to inhibit DNA-dependent RNA polymerase
223937278|NCT05073003|DRUG|altSonflex Placebo|2 doses of altSonflex Placebo, administered intramuscularly, in the non-dominant arm, either at Day 1 and Day 85 or at Day 1 and Day 169 (depending on the vaccination schedule) to adults in the ST1\_Adults\_Placebo\_GR1 and ST1\_Adults\_Placebo\_GR2 groups in Stage 1 (Europe).
223937279|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose C|2 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to adults in the ST1\_Adults\_Dose C\_GR1 and ST2\_Adults\_Dose C groups in Stage 1 and 2 (Europe and Africa) and children in the ST2\_Children\_Dose C group in Stage 2 (Africa), and at Day 1 and Day 169 to adults in the ST1\_Adults\_Dose C\_GR2 group in Stage 1 (Europe); 3 doses of altSonflex1-2-3 Dose C administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose C\_Safety and ST2\_Infants\_Dose C\_Dose find groups in Stage 2 (Africa).
223937280|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose B|2 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to children in the ST2\_Children\_Dose B group in Stage 2 (Africa); 3 doses of altSonflex1-2-3 Dose B administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose B\_Safety and ST2\_Infants\_Dose B\_Dose find groups in Stage 2 (Africa).
223937281|NCT05073003|BIOLOGICAL|altSonflex1-2-3 Dose A|3 doses of altSonflex1-2-3 Dose A administered intramuscularly, in the non-dominant arm, at Day 1, Day 85 and Day 253 to infants in the ST2\_Infants\_Dose A\_Safety and ST2\_Infants\_Dose A\_Dose find groups in Stage 2 (Africa).
223937282|NCT05073003|BIOLOGICAL|GSK's Meningococcal A, C, Y and W-135 conjugate vaccine|1 dose of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 to adults in the ST2\_Adults\_Control C group and children in the ST2\_Children\_Control B and ST2\_Children\_Control C groups in Stage 2 (Africa); 2 doses of GSK's Meningococcal A, C, Y and W-135 conjugate vaccine administered intramuscularly, in the non-dominant arm, at Day 1 and Day 85 to infants in the ST2\_Infants\_Control A\_Safety, ST2\_Infants\_Control B\_Safety, ST2\_Infants\_Control C\_Safety and ST2\_Infants\_Control\_Dose find groups in Stage 2 (Africa).
223937283|NCT05073003|COMBINATION_PRODUCT|GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to adults in the ST2\_Adults\_Control C group in Stage 2 (Africa).
223718754|NCT00321308|DRUG|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
223718755|NCT00321308|DRUG|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
223718756|NCT04589078|DEVICE|GI Genius CADe system|Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.
223937284|NCT05073003|COMBINATION_PRODUCT|GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine|1 dose of GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine administered intramuscularly, in the non-dominant arm, at Day 253 to infants in the ST2\_Infants\_Control A\_Safety, ST2\_Infants\_Control B\_Safety, ST2\_Infants\_Control C\_Safety and ST2\_Infants\_Control\_Dose find groups in Stage 2 (Africa).
223937285|NCT05073003|COMBINATION_PRODUCT|Sanofi Pasteur's Typhoid Vi polysaccharide vaccine|1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, in the non-dominant arm, at Day 85 to children in the ST2\_Children\_Control B and ST2\_Children\_Control C groups in Stage 2 (Africa).
224098382|NCT06042374|OTHER|Standard Core Strengthening Exercises|The athletes included in the CG performed only Standard Core Strengthening Exercises which is the first phase of the Progressive Core Stabilization Training on fixed surfaces (i.e. without pads and balls, with a flat floor and a bench) for 3 days/week and totally 9-week.
224286579|NCT00784134|OTHER|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
224286580|NCT03105934|PROCEDURE|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
224286581|NCT03785145|DRUG|MT10109L|MT10109L will be injected into the LCL.
223937286|NCT05073003|BIOLOGICAL|Serum Institute of India's Measles and rubella vaccine|2 doses of Serum Institute of India's Measles and rubella vaccine administered subcutaneously, in the non-dominant arm, at Day 29 and Day 281 to infants in the safety groups, and at Day 1 and Day 253 to infants in the dose-finding groups, in Stage 2 (Africa).
223937287|NCT03835754|DEVICE|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
223937288|NCT05347927|DEVICE|water resistante padding|"* Delta-Dry® Softliner~* Tensoban®~* Delta-Dry®"
223937289|NCT05347927|DEVICE|non water resistante padding|"* Delta-Net® Stockinette~* Delta-Rol®"
223937290|NCT06856265|PROCEDURE|radiofrequency ablation|Radiofrequency Ablation is a minimally invasive interventional technique performed via catheter guidance. It utilizes thermal energy (50-80°C) generated by high-frequency alternating current (typically 300-750 kHz) to induce coagulative necrosis or electrophysiological isolation in targeted tissues, thereby eliminating abnormal electrical activity or mechanical obstruction. In the treatment of cardiomyopathy, RFA is applied to ablate hypertrophied myocardial tissue (e.g., the ventricular septum) to alleviate left ventricular outflow tract (LVOT) obstruction.
223937291|NCT06856265|DRUG|Mavacamten|"Initial Dose: Both groups received a starting dose of Mavacamten 2.5 mg orally once daily.~Dose Titration: Adjustments were made based on a previously published titration protocol, guided by correlations among resting left ventricular ejection fraction (LVEF), LVOT gradient during Valsalva maneuver, and pre-dose Mavacamten plasma concentrations."
223937292|NCT05168384|COMBINATION_PRODUCT|Extracorporeal Photopheresis|"ECP procedures will be performed using a Therakos Cellex integrated, closed photopheresis system (Therakos, Inc., a Mallinckrodt Pharmaceuticals Company).~ECP will administered according to the following schedule (Group A):~Weeks 1-8: Twice per week (16 sessions). Weeks 9-16: Once per week (8 sessions). Weeks 17-24: Once every 2 weeks (4 sessions). Total: 28 sessions (within 24 weeks)."
223937293|NCT05168384|COMBINATION_PRODUCT|MS standard of care|Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
223937294|NCT05577910|DEVICE|Vectored thermal pulsation (VTP) therapy|VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
223937295|NCT05577910|DEVICE|Intense pulsed light with meibomian gland expression (IPL+MGX) therapy|"IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3)."
223937296|NCT05577910|BEHAVIORAL|Eyelid Warm Compress Therapy (EW)|EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
223937297|NCT05577910|DRUG|Topical eye drops (Hypromellose, 3mg/ml)|All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
223937298|NCT06749548|RADIATION|Group 1|the study is to emphasize the role of Computed Tomography Angiography (MDCTA) and Transthoracic Echocardiography (Echo) in the diagnosis of congenital cyanotic heart diseases.
223937299|NCT06777628|DRUG|Immunochemotherapy combined with antiangiogenic|Immunochemotherapy combined with antiangiogenic
223937300|NCT06763549|DEVICE|SUBPROTOCOL A|A 30-minute COR ECG recording will be performed, including 15 minutes of continuous sitting data used for clinical indication analysis through CardioMIND software. Data collection can occur in-clinic, via PHS, or using a shipped device with telehealth support. Sleep, HRV, and AFIB risk analysis will not be included.
223937301|NCT06763549|DEVICE|SUBPROTOCOL B|Subjects will undergo 24 hours of COR ECG recording, which must include at least one 15-minute unsupervised sitting session. Data analysis will include sleep patterns, HRV, and AFIB risk. ECG acquisition may take place in-clinic, via Patient Home Setup (PHS), or with a shipped device.
224286582|NCT03785145|DRUG|Placebo|Placebo will be injected into the LCL.
224286583|NCT02009709|DRUG|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
224286584|NCT02009709|DEVICE|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
224286585|NCT02009709|DEVICE|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
224286586|NCT00388934|DEVICE|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
223534317|NCT05968963|BEHAVIORAL|Mindfulness-based Music Therapy (MBMT)|Participants will receive 8 music therapy sessions that will last approximately 60 minutes in length. A Music therapist will conduct the sessions. These sessions will be in person and/or virtual depending on patient status and the time between sessions will vary based on patient response to treatment.
223534318|NCT05968963|BEHAVIORAL|Mindfulness Meditation (MM)|Participants will receive 8 mindfulness meditation sessions that will last approximately 60 minutes in length. These sessions will be participant led virtually.
223534319|NCT06696209|OTHER|Analysis of the withdrawal time of the Upper Gastrointestinal Endoscopy|Time of last esophageal image - time of first image of the second portion of the duodenum.
223534320|NCT06696209|OTHER|Analysis of the total time of the Upper Gastrointestinal Endoscopy|Time of last esophageal image - time of first esophageal image
224098383|NCT02595242|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
223937302|NCT06763549|DEVICE|SUBPROTOCOL C|COR 1.0 ECG recordings will be conducted over 2 to 7 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants subjects will also wear a cleared wrist or finger device to track SpO2 during sleep. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
223937303|NCT06763549|DEVICE|SUBPROTOCOL D|COR 2.0 (CORMDX) recordings will be conducted over 2 to 14 days, with at least one 15-minute unsupervised sitting session. At least 25% of randomly selected trial participants will also wear a cleared wrist or finger device to track SpO2 during sleep nights. PI or Sub-Investigator will assign the number of wear days to the subject. The analysis will include sleep data, HRV, and AFIB risk assessment.
223718757|NCT02516163|DEVICE|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
224286587|NCT03670134|DEVICE|The Nvision VLE Imaging System|Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
224286588|NCT04079049|PROCEDURE|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
224286589|NCT04079049|DRUG|Control|Oncological treatment in control group
223718758|NCT01832974|DRUG|IL-13-PE|IL-13-PE intravenous infusion
223718759|NCT03723941|DRUG|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
223718760|NCT03723941|OTHER|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
223718761|NCT02801396|DEVICE|Etafilcon A Design 1 (Test 1)|
223937304|NCT06763549|DEVICE|SUBPROTOCOL E|Subjects will complete a 30-minute CORMDx (COR 2.0) ECG recording, with 15 minutes of continuous sitting data used for clinical indication analysis. Sleep, HRV, and AFIB risk analysis will not be performed.
223937305|NCT06763549|DEVICE|SUBPROTOCOL F|A 30-minute COR 2.0 ECG recording will be completed, along with a 12-lead resting ECG using an FDA-cleared reference device. Sleep, HRV, and AFIB analysis will not be performed.
223937306|NCT06763549|DEVICE|SUBPROTOCOL G|A 40-minute COR 2.0 recording will be conducted in two phases: 15 minutes of upright sitting and 15 minutes in a supine position. Hemodynamic monitoring, including blood pressure, cardiac output, and stroke volume variation, will be conducted using an FDA-cleared reference device. No sleep, HRV, or AFIB analysis will be performed.
223937307|NCT06763549|DEVICE|SUBPROTOCOL H|Subjects will undergo a 40-minute COR 2.0 recording, followed by a 40-minute COR 1.0 recording. Hemodynamic monitoring using an FDA-cleared reference device will be performed during both sessions. The transition between devices must occur within 60 minutes if the same adhesive is reused. Sleep, HRV, and AFIB analysis will not be performed.
223937308|NCT06792227|BEHAVIORAL|FBT-H|"FBT is a structured treatment lasting 6-12 months, typically in an outpatient setting, with weekly sessions that gradually decrease in frequency over time (Lock \& Le Grange, 2015). It empowers parents to manage their child's recovery from the ED. The first phase focuses on weight restoration, with parents responsible for all eating decisions and restricting physical activity to reduce ED's influence. In the second phase, eating responsibility gradually shifts back to the adolescent. The final phase supports healthy adolescent development as ED symptoms subside.~The FBT-H adapts FBT to a home setting, with treatment led by family counselors and psychologists as part of a multidisciplinary team, including therapists, psychologists, a psychiatrist and a nurse specialist."
223937309|NCT03706014|BEHAVIORAL|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
223937310|NCT03706014|BEHAVIORAL|Control|Contact-equivalent attention control program in which students play educational games
224098384|NCT02595242|DRUG|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
224098385|NCT02595242|DRUG|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
224098386|NCT01767233|PROCEDURE|ERCP and pancreatic stenting|
224098387|NCT02793284|RADIATION|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
224098388|NCT03584009|DRUG|Venetoclax|Venetoclax was administered orally, 800-mg tablet beginning on Cycle 1 Day 1 until the 9th October 2020.
224098389|NCT03584009|DRUG|Fulvestrant|Fulvestrant was administered orally, 500 mg administered as two 250-mg IM injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
223534321|NCT06696209|OTHER|Upper gastrointestinal endoscopy: Common Practices|"Execution of UGE using high-resolution endoscopes, with the option of virtual chromoendoscopy, according with the physician's preference. Possible optimization of visualization with washing and/or the use of simethicone or similar, as pre-medication or during the examination, according with the physician's preference. Patients will be randomised to one of the following measurements-total time versus withdrawal time-in a parallel 1:1 scheme.~The allocation of the randomisation group will be computer-generated. The endoscopist must record the time at which the following three anatomical structures are reached (either by noting during the procedure or based on the information in the photographic documentation), before any biopsies or therapeutic interventions, in the format xxh:xxmin:xxsec:~1. First esophageal image;~2. First image of the second portion of the duodenum;~3. Last esophageal image."
223534322|NCT03246906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
223937311|NCT04148495|DRUG|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
223937312|NCT04148495|DRUG|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
223937313|NCT06735027|OTHER|intraarticular corticosteroid injection (IACI)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the glenohumeral joint. The injection site will then be disinfected with an alcohol wipe. A 21, 22, or 23-gauge needle (depending on provider preference) will be advanced into the glenohumeral joint under direct ultrasound visualization. After entry into the glenohumeral joint, a negative aspiration will be performed. At that time, up to 1 mL of 40mg/mL methylprednisolone acetate will be injected be injected into the joint space.
223937314|NCT06735027|OTHER|suprascapular nerve block (SSNB)|The patient will be in a seated position. Correct patient, laterality, and procedure will be performed during the timeout. Ultrasound guidance will be used to identify the suprascapular nerve in its path at the suprascapular notch. After disinfection of the injection site with alcohol, anatomic landmarks for SSNB as described by Dangoisse et al. \[10\] will be marked with a marking pen. Ultrasound will be utilized to guide the tip of a 21, 22, or 23 gauge (depending on provider preference) needle to the floor of the suprascapular fossa while avoiding neurovascular structures. At that time, a mixture of up to 10 mL of 0.5% bupivacaine and 20 mg triamcinolone will be slowly injected to fill the fascial contents of the suprascapular fossa under direct ultrasound guidance.
223937315|NCT05917860|DRUG|Degarelix|Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
223937316|NCT05917860|DEVICE|MRI-guided transurethral ultrasound ablation (TULSA)|MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
223937317|NCT06753253|BEHAVIORAL|Cycling Exercise|Each arm will perform a 20-minute cycling intervention on an airdyne bike at different exercise intensity levels. Participants will perform the intervention three times over the course of one week.
224098390|NCT00446030|DRUG|Docetaxel|"75 mg/m\^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
224098391|NCT00446030|DRUG|Doxorubicin|50 mg/m\^2 administered IV on Day 1 for Cycles 1-6
224098392|NCT00446030|DRUG|Carboplatin|6 mg/mL/min (target area under the curve \[AUC\] dose) administered IV on Day 1 for Cycles 1-6
224098393|NCT00446030|DRUG|Cyclophosphamide|500 mg/m\^2 administered IV on Day 1 for Cycles 1-6
224098394|NCT00446030|DRUG|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
224098395|NCT00446030|DRUG|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
223718762|NCT02801396|DEVICE|Etafilcon A Design 2 (Test 2)|
223718763|NCT02801396|DEVICE|Etafilcon A (Control)|
224098396|NCT02683369|DIETARY_SUPPLEMENT|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root"
224098397|NCT02420457|PROCEDURE|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
224098398|NCT02420457|DRUG|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
224098399|NCT02886715|DRUG|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
224098400|NCT02886715|DRUG|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
224286590|NCT00951184|BEHAVIORAL|telephone-based intervention|
224286591|NCT00951184|OTHER|screening questionnaire administration|
224286592|NCT00951184|OTHER|study of socioeconomic and demographic variables|
224286593|NCT00951184|PROCEDURE|assessment of therapy complications|
224286594|NCT00951184|PROCEDURE|psychosocial assessment and care|
224286595|NCT06389916|DEVICE|Euclid orthokeratology MAX (current design)|The current lens design
224286596|NCT06389916|DEVICE|Euclid orthokeratology MAX Phoenix (new design)|The new lens design
224286597|NCT00561171|DRUG|SPP635|oral once daily
224286598|NCT02234752|DRUG|Galantamine ER|
224286599|NCT02234752|DRUG|Memantine XR|
224286600|NCT01582919|OTHER|Neuroimaging|
224286601|NCT02946684|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
224286602|NCT02946684|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
224098401|NCT02886715|DRUG|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
223534323|NCT03246906|DRUG|Cyclophosphamide|Given IV
223534324|NCT03246906|DRUG|Cyclosporine|Given PO
223534325|NCT03246906|DRUG|Mycophenolate Mofetil|Given PO
223534326|NCT03246906|DRUG|Sirolimus|Given PO
223937318|NCT05908227|OTHER|NHF high|Nasal high flow therapy 8L/min.
223937319|NCT05908227|OTHER|NHF low|Nasal high flow therapy 6L/min.
223937320|NCT05908227|OTHER|NCPAP|Nasal continuous positive airway pressure 6 cm H20
223937321|NCT06714240|DIETARY_SUPPLEMENT|Nutritionally complete Tube Feed with standard protein levels|Containing standard protein levels to target normal protein amount of 0.8 g of protein/kg body weight/day
223937322|NCT06714240|DIETARY_SUPPLEMENT|Nutritionally complete Tube Feed with higher protein levels|Containing higher protein levels to target elevated protein amount of 1.3 g of protein/kg body weight/day.
223534327|NCT01681641|OTHER|A psycho-social intervention|
223534328|NCT06868459|OTHER|Data Collection|Subjects with planned PED-TAE delivered via TriNav will receive their treatment following routine standard of care procedures. Post-procedural data obtained by a patient chart review will be collected in a study database. No additional study-specific interventions or visits outside of the routine clinical treatment will be performed.
223937323|NCT06128980|DRUG|GDMT|Sequential weaning starting with SGLT2i - MRA - BB - ACEi/ARB/ARNi
224098402|NCT03473873|OTHER|Measures of muscle function|The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
224098403|NCT00222105|DRUG|Doxil|Doxil 40 mg/m2 IV day 1
224286603|NCT02406430|PROCEDURE|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
223534329|NCT07029971|BIOLOGICAL|BB-TL1A-VIAL-HLE|Anti-TL1A monoclonal antibody
223534330|NCT04264260|DRUG|Colchicine Tablets|three times or two times per day after meal with the daily total dose ranging from 1.5 to 3 mg
223937324|NCT02291848|BIOLOGICAL|TAA-specific CTLs|"Groups A and B only: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10\^6 cells/m2 and Day 14: 5 x 10\^6 cells/m2~Dose Level Two:~Day 0: 1 x 10\^7 cells/m2 and Day 14: 1 x 10\^7 cells/m2~Dose Level Three:~Day 0 2 x 10\^7 cells/m2 and Day 14 2 x 10\^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
223937325|NCT02291848|BIOLOGICAL|TAA-specific CTLs- fixed dose|"Fixed dose of 2 infusions of 2 x 10\^7 cells/m2 administered 2 weeks apart.~If patients without measurable disease remain in complete remission or those patients with measurable active disease (for multiple myeloma, MGUS or smoldering myeloma) at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
224098404|NCT00222105|DRUG|Thalidomide|50-100 mg day 1-28
224098405|NCT00222105|DRUG|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
224098406|NCT00503399|DRUG|Teriparatide|20 µg/day sc for 18 months
224098407|NCT00503399|DRUG|Risedronate|35 mg/week po for 18 months
224098408|NCT03783910|DRUG|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
224098409|NCT03783910|DRUG|Placebo|Placebo matching GRT9906 tablets
223534331|NCT04824092|DRUG|Tafasitamab|Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
223534332|NCT04824092|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
223534333|NCT04824092|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
223534334|NCT04824092|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
223534335|NCT04824092|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
223534336|NCT04824092|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
224098410|NCT04724889|DIAGNOSTIC_TEST|blood test|Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
224098411|NCT00204087|BEHAVIORAL|Cognitive behavioral therapy (CBT)|
224098412|NCT00204087|BEHAVIORAL|Supportive Counselling (SC)|
224098413|NCT01172067|DEVICE|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
224098414|NCT01172067|DEVICE|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
223534337|NCT04824092|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223534338|NCT04824092|DRUG|Tafasitamab placebo|0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
223534339|NCT04824092|DRUG|Lenalidomide placebo|Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
223534340|NCT06612970|DRUG|HB0056|HB0056 Injection
223534341|NCT06612970|DRUG|Placebo|Placebo
223534342|NCT07032376|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
223534343|NCT07032376|BEHAVIORAL|Rectal Expulsion Device use|"During the participant's clinic visit for constipation, the Rectal Expulsion Device will be available for the gastroenterology care provider to use if the decision is made to use this during the clinic visit.~In addition, the care provider will have access to the RED brochure and the Michigan Chart (MICHART) Our Practice Advisory (OPA) - a decision support tool in MiChart to support care navigation using RED."
223534344|NCT07032636|BEHAVIORAL|Crisis Intervention - The First Line Leaders (FLL) program will utilize templated guides developed with stakeholders from the Idaho Army National Guard (ARNG), known as the Total Health Action Plan (T|The Investigators are developing training programs for soldiers and leaders to enhance their communication skills, problem-solving abilities, and approachability. They will be randomized to one of three different groups.
223534345|NCT07117838|OTHER|virtual reality|Virtual reality application were applied to patients during coronary angiography.
223534346|NCT07117838|OTHER|music|Patients will listen to music during coronary angiography.
223534347|NCT05422612|DRUG|Intervention A Fluoxetine Hydrochloride (HCl)|Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
223534348|NCT05422612|DRUG|Intervention A Placebo|A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
223534349|NCT05422612|DRUG|Intervention B Vilazodone Hydrochloride (HCl)|Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
223534350|NCT05422612|DRUG|Intervention B Placebo|A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
223534351|NCT05422612|DRUG|Intervention C Daridorexant|Daridorexant will be administered 50 mg once daily.
223534352|NCT05422612|DRUG|Intervention C Placebo|A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
223534353|NCT05422612|DRUG|Intervention D SLS-002|• SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
223534354|NCT05422612|DRUG|Intervention D Placebo|A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
223534355|NCT06892093|DIETARY_SUPPLEMENT|Probiotics|Participants in this group will receive a daily dose of probiotics as an adjunct to standard Neratinib therapy. The probiotics will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks (two treatment cycles). Loperamide will be administered prophylactically according to the FDA-recommended schedule to prevent Neratinib-associated diarrhea. The aim is to assess the efficacy of probiotics in reducing Neratinib-induced diarrhea and improving quality of life.
223534356|NCT06892093|DIETARY_SUPPLEMENT|Placebo|Participants in this group will receive a daily dose of a placebo that is identical in appearance, taste, and administration method to the probiotic granules, in addition to standard Neratinib therapy. The placebo will be administered orally as a granule formulation dissolved in water, for a total duration of 6 weeks. Loperamide will also be administered prophylactically to all participants in accordance with FDA recommendations. This group will serve as a control to evaluate the true effect of probiotics on Neratinib-induced diarrhea.
223534357|NCT06892093|DRUG|Loperamide|All participants will receive prophylactic loperamide to reduce the risk of Neratinib-induced diarrhea. Loperamide will be administered according to the FDA-recommended schedule: 4 mg TID for the first 14 days of treatment, then 4 mg BID from Day 15 to Day 42. This intervention is implemented as a standard supportive therapy and not as a randomized variable.
223534358|NCT06574529|DEVICE|Video-observed therapy (vDOT)|All participants are required to send 5 times per week a short video showing they are actually taking their treatment for tuberculosis via a dedicated application on their cellphone
223534359|NCT04558229|OTHER|Additional Standardized Counseling|Research staff will follow a script designed to give unbiased, medically accurate information regarding bleeding changes that may occur with use of a contraceptive ENG implant.
223534360|NCT06762002|OTHER|blood sample|After signature of consent form,blood samples will be collected for full blood cell count;classical autoimmune investigations, immunophenotyping;auto-Abs against type IIFNs, other cytokines, or other target proteins ,Genetic explorations by whole-exome or whole-genome sequencing;Biobanking
223534361|NCT07065617|DRUG|[14C]BI 1819479|\[14C\]BI 1819479
223534362|NCT07065617|DRUG|BI 1819479|BI 1819479
223534363|NCT07065617|DRUG|BI 1819479 (C-14)|BI 1819479 mixed with \[14C\]BI 1819479
223534364|NCT01580787|DEVICE|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
223534365|NCT01580787|OTHER|Physical Therapy|Patients of the control group was trained with balance exercises.
223534366|NCT00004682|DRUG|immune globulin|
223534367|NCT00244192|DRUG|infliximab (Remicade)|
223534368|NCT03252093|DRUG|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
223534369|NCT03252093|DRUG|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
223534370|NCT05714514|DRUG|Imlifidase administered in the ConfIdeS study|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc- fragment and efficiently neutralizes Fc-mediated activities of IgG.
223534371|NCT05714514|OTHER|Best available treatment administered in the ConfIdeS study|Institution-specific desensitization treatment prior to kidney transplantation in the ConfIdeS study OR remain on wait list for a more compatible organ offer if desensitization with institutional protocol is not appropriate
223937326|NCT06224660|GENETIC|SRD-001|SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.
223937327|NCT05604326|BEHAVIORAL|Pathways Intervention|Pathways-trained research clinicians will conduct 90-minute weekly coaching sessions with caregivers (in English or Spanish) in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual in English or Spanish, depending on the family's home language. Sessions will review information about autism, interactional strategies, and Applied Behavioral Analysis (ABA) techniques from the program manual, demonstrate intervention strategies, and provide caregivers with practice feedback and self-reflection.
224286604|NCT03827941|OTHER|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
224286605|NCT03827941|OTHER|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
223534372|NCT05017558|DIAGNOSTIC_TEST|point of care|"HIV-1 infected women will benefit from a viral load measurement by POC (Cepheid GenXpert HIV-1 viral load) at the time of delivery.~Newborns will benefit :~1. Antiretroviral preventive treatment differentiated according to their risk of infection in accordance with national recommendations:~   * High risk (maternal VL ≥1000 cp/ml): AZT/NVP for 12 weeks.~  * Low risk (maternal VL \<1000 cp/ml): NVP for 6 weeks.~2. virological screening for HIV by qualitative POC (Cepheid GenXpert HIV-1 qual) from birth (for high-risk newborns) at 6 weeks, at 9 months and at any time in the event of clinical manifestations suggestive of HIV infection.~3. In the event of a positive HIV test, the child will initiate immediately AZT/3TC/LPV/r~4. support from volunteers to improve retention in care, promotion of exclusive breastfeeding and family nutritional support"
223937328|NCT05604326|BEHAVIORAL|Parent Education Intervention (PEI)|Caregivers will access a 20-30-minute video lesson and associated handouts (in English or Spanish, depending on the parent's home language) every other week for 24 weeks. On the off week, the caregiver will meet with a trained clinician (in English or Spanish) for 30 minutes without the child. Lessons will cover autism, social attention delays, evidence-based interventions, self-regulation, talking with your child, playing with your child, principles of managing behavior, knowing your rights, and self-care. The first and last visit will occur in the family's home or another convenient location. All other visits will take place over Zoom videoconferencing software.
223937329|NCT03894215|DRUG|AGEN2034|PD-1 antibody
223937330|NCT03894215|DRUG|AGEN1884|CTLA-4 antibody
223937331|NCT04971785|DRUG|Semaglutide (SEMA)|Administered as subcutaneous (SC) injection
223937332|NCT04971785|DRUG|Cilofexor (CILO)/Firsocostat (FIR)|Tablets administered orally
223937333|NCT04971785|DRUG|PTM SEMA|Administered as SC injection
223937334|NCT04971785|DRUG|PTM CILO/FIR|Tablets administered orally
223937335|NCT04332471|PROCEDURE|Radial shockwave therapy|Target intensity will be within a range of 3.5-5.0 bar at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
223937336|NCT04332471|PROCEDURE|Focused shockwave therapy|Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, titrated up to patient tolerance within 100 pulses. Total of 3000 pulses.
223937337|NCT04332471|DEVICE|Shockwave therapy device|The shockwave therapy device will be used to administer either radial or focused shockwave therapy.
223937338|NCT04332471|OTHER|Home therapy|Stretching and ice massage
223937339|NCT06646692|BEHAVIORAL|Mindful Self Compassion|(MSC) is a mind-body integrative health intervention that utilizes meditations, other contemplative practices, home practices, and experiential exercises (including group discussions) to increase SC. MSC can be done in groups of 10-25. To increase feasibility of MSC for use in residential drug treatment facilities, we will aim to adapt MSC to 7 sessions (6 weekly sessions in alignment with the MSC short course plus the half day retreat included in the full course to facilitate skill consolidation). Sessions will be conducted in a group-based format: prior research found group-based formats equivalent to individual-level interventions for PTSD/SUD.
223941389|NCT03839550|COMBINATION_PRODUCT|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
224098415|NCT02406157|DEVICE|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
224286606|NCT03716531|RADIATION|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
224286607|NCT03400280|OTHER|Best practice algorithm for postoperative care|See arm/group description
224286608|NCT02776813|BIOLOGICAL|ACTR087|
224286609|NCT02776813|BIOLOGICAL|rituximab|
224286610|NCT06176625|BEHAVIORAL|Communication Signage|Signage regarding effective communication strategies posted on door to patient's room.
224286611|NCT06176625|BEHAVIORAL|Amplifier Use|Patient is provided amplification device and signage regarding effective communication strategies with reminder to utilize the amplification device posted on door to patient's room.
224286612|NCT01559987|OTHER|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
224286613|NCT01559987|OTHER|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
223937340|NCT06646692|BEHAVIORAL|Treatment as Usual (TAU)|"Selecting appropriate attention control groups for behavioral intervention research, particularly for mindfulness-based interventions, can be problematic. Comparator groups often also improve as they tend to target related mechanisms (e.g., social support, health behaviors, improved attention). After weighing the pros and cons, a treatment as usual (TAU) approach was selected, whereby the MSC will be compared to TAU. However, to control for the confound of weekly compensation, TAU participants will meet with study staff seven times over the 6-week period and fill out short psychosocial surveys on non-distressing topics (e.g., personality tests, attitudes surveys) in exchange for compensation commensurate with the MSC group. We believe this will also help with retention of the TAU group over time and strike an appropriate balance between controlling for the effects of study participation while minimizing confounds that often occur with active control groups in behavioral trials."
223534373|NCT06932835|DRUG|Transversus Abdominis Plane (TAP) Block|Transversus Abdominis Plane (TAP) Block is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position.
223937341|NCT06320262|PROCEDURE|Wet cupping therapy (WCT)|"Type of cupping: Triple-stage wet cupping therapy (Hijama) will be used; sucking, scarification, sucking.~Cupping points will include one cup on the posterior median line, in the depression below the processus spinosus of the 7th cervical vertebra (Alkahil area); two points in the inter-scapular region 3cm lateral to the lower border of the spinous process of the 3rd thoracic vertebra, two points at inferior angle of the scapula (3cm lateral to lower border of the spinous process of the 7th thoracic vertebra, 2 points at lumbar regions, in addition to the most painful areas.~After the procedure: Areas of cupping will be covered using sterile gauze. All used tools and materials will be collected in red bags to ensure proper waste disposal. Sharp objects will be disposed of in the sharps disposal box. Telephone follow-up with all patients 48 hours after cupping will be done."
223937342|NCT05908955|PROCEDURE|PVI|pulmonary vein isolation
223937343|NCT05908955|PROCEDURE|PVI+ quantitative SVCI|pulmonary vein isolation and superior vena cava isolation guided by quantitative ablation index
223937344|NCT06832124|PROCEDURE|Sham alpha-tACS|A sinusoidal ± 2mA current adjusted to the individual alpha peak frequency with in-phase stimulation at parieto-occipital brain areas and anti-phase stimulation in frontal brain areas. The stimulation will involve a 10s ramp-up, followed by an immediate 10s ramp-down (no stimulation afterwards).
223937345|NCT06832124|PROCEDURE|alpha-tACS|Active tACS with a sinusoidal ± 2mA current adjusted to the individual alpha peak frequency with a 10s ramp-up and 10s ramp-down after stimulation. In-phase stimulation will be applied to parieto-occipital brain areas and anti-phase stimulation will be applied to frontal brain areas
223937346|NCT06776770|DRUG|Adebrelimab|"Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.~Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.~XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1\~14."
223937347|NCT06759181|DRUG|anti-BCMA/FcRL5 CAR T|"anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:"
223937348|NCT06748378|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait.|66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
223937349|NCT06748378|PROCEDURE|Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait parameters.|66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure the gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
223937350|NCT05162261|DEVICE|Tixel C|Tixel C by Novoxel®, Israel is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
223937351|NCT05162261|DEVICE|LipiFlow|Thermal pulsation (LipiFlow) consists of the localized application of heat and therapeutic pressure on the four eyelids (upper and lower) with the aim of improving drainage of the Meibomian glands.
223937352|NCT06747923|DRUG|SB17170|Taking SB17170 orally once a day
223937353|NCT06747923|DRUG|Placebo|Taking Placebo orally once a day
224098416|NCT02406157|DEVICE|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
224098417|NCT01152099|OTHER|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
224286614|NCT01559987|OTHER|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
223534374|NCT06932835|DRUG|Modified Thoracoabdominal Nerve Block (M-TAPA)|Modified Thoracoabdominal Nerve Block (M-TAPA) is performed under ultrasound guidance before the surgical procedure and anesthesia induction, with the patient in the supine position.
223534375|NCT04838704|DRUG|Ruxolitinib+Calcineurin inhibitor+Methotrexate|low-dose ruxolitinib combine with calcineurin inhibitor and short course of methotrexate.
223534376|NCT04838704|DRUG|Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil|calcineurin inhibitor and short course of methotrexate and mycophenolate mofetil
223937354|NCT05885763|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0,5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
223937355|NCT06168851|DRUG|Anti-CD38 antibody Injection|"intravenous Anti-CD38 antibody administration~This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with Anti-CD38 antibody (16mg/kg/w) for 8 weeks.~The first stage is the main research stage (d1-w8), which is the core treatment period. The subjects will receive intravenous infusion of 16mg/kg Anti-CD38 antibody once a week for 8 weeks to observe the safety and efficacy during treatment.~The second stage (w9-w24) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Anti-CD38 antibody after treatment."
223937356|NCT02215928|GENETIC|mutation analysis|Correlative studies
223937357|NCT02215928|OTHER|cytology specimen collection procedure|Correlative studies
223937358|NCT02215928|OTHER|laboratory biomarker analysis|Correlative studies
223937359|NCT05143866|BEHAVIORAL|Cognitive behavioral therapy guided self help (CBTgsh)|Based on evidence based cognitive behavioral treatment for eating disorders. Self-help version described in self-help book. Participant follows self-help program with encouragement and support of a non specialist guide
223937360|NCT05578976|DRUG|Epcoritamab|Subcutaneous Injection (SC)
223937361|NCT05578976|DRUG|Cyclophosphamide|Intravenous (IV) Injection
223937362|NCT05578976|DRUG|Rituximab|IV Infusion
223937363|NCT05578976|DRUG|Vincristine|IV Infusion
223937364|NCT05578976|DRUG|Doxorubicin|IV Infusion
223937365|NCT05578976|DRUG|Prednisone|Oral; Tablet
224098418|NCT01152099|OTHER|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
224098419|NCT00597649|DRUG|Bicifadine|SR dosage form of 400 mg bid or tid for one year
224098420|NCT03003819|DEVICE|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
224098421|NCT03003819|DEVICE|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
224098422|NCT02473406|DRUG|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
224098423|NCT02473406|DRUG|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
223534377|NCT01589614|DRUG|PH-797804|Tablet, 6mg, single
223534378|NCT01589614|DRUG|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
223937366|NCT06424340|BIOLOGICAL|MB-dNPM1-TCR.1|T Cell Receptor (TCR) T cell therapy
224098424|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
224098425|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
224098426|NCT01442025|DRUG|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
224286615|NCT06182904|DEVICE|Dynamic compression plate|Fixation of fibula in some cases with dynamic compression plate
224286616|NCT04808830|OTHER|Evaluation of musculoskeletal pain prevalence|Prevalence of musculoskeletal pain will be evaluated over 9 body regions using The Nordic Musculoskeletal Questionnaire.
223534379|NCT06941857|DRUG|Oxaliplatin|65mg/m2 will be administered as a 120 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223534380|NCT06941857|DRUG|Irinotecan|150 mg/m2 will be administered as a 90 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223534381|NCT06941857|DRUG|Folinic Acid|50 mg will be administered as a 15 minute IV infusion (-5/+20 min) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. Folinic acid can be given concurrent with irinotecan. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223937367|NCT03011541|PROCEDURE|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
223937368|NCT06402344|OTHER|Hormonal implant|History of at least 1 hormonal implant with gestrinone in the last 6 months, applied by the participant's private doctor.
223937369|NCT06402344|OTHER|Control group|Young women who never used any hormonal implant.
223937370|NCT06772272|DRUG|Roxadustat|Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) used to treat anemia. Participants in the Roxadustat group will receive 100mg of Roxadustat orally three times per week for three weeks (two weeks prior to surgery and one week post-surgery). The dosage may be adjusted based on hemoglobin levels during the perioperative period: if hemoglobin rises above 150g/L, the drug will be stopped; if hemoglobin increases by more than 20g/L from baseline but is still below 130g/L, the dosage will be reduced to 70mg; if hemoglobin drops by more than 20g/L from baseline, the dosage will be increased to 120mg.
223937371|NCT05203198|BEHAVIORAL|Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training|Self-directed, technology-based, depression prevention program for adolescents and parents.
223937372|NCT04327635|DRUG|PEP|A biological drug made of certain parts of blood from living blood donors obtained from a certified blood bank. At the time of cardiac catheterization patients will undergo one-time intracoronary infusion of 10 milliliters of PEP dosage consisting of approximately 5%, 10%, or 20% PEP. PEP dose will be infused immediately distal to the newly placed stent over approximately 5 minutes.
223937373|NCT06113705|DIAGNOSTIC_TEST|18F-GE-180 PET|PET examination of glioblastoma using 18F-GE-180 PET radio-metabolic marker
223937374|NCT06113705|DIAGNOSTIC_TEST|Advanced MRI|MRI examination using advanced sequences to characterize tumor microstructure and function
223937375|NCT06113705|OTHER|Collection of hematopoietic stem cells|Hematopoietic stem cells will be collected by the aspiration of bone marrow during the surgical intervention for tumor resection
223937376|NCT06113705|OTHER|Blood withdrawal|blood withdrawal for evaluation of plasma biomarkers of inflammation, circulating microvesicles, and RNA
223937377|NCT06113705|OTHER|Collection of Cancer Stem Cells|Glioblastoma stem cells (GSCs) will be isolated from the tumor
223937378|NCT06270251|BEHAVIORAL|CBIT|"8sessions of CBIT following a published treatment manual delivered over 10 weeks (the last two sessions are biweekly)~CBIT is a well-established behavioral treatment that is considered by the American Academy of Neurology to be the first-line intervention for tics."
223937379|NCT06828289|DRUG|Rivastigmine Mini-Tablet|Treatment group: Rivastigmine Mini-Tablet
223937380|NCT06828289|DRUG|Donepezil Hydrochloride|Control group: Donepezil Hydrochloride
223937381|NCT04686266|BEHAVIORAL|Health Information + Health Coaching|Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research
223937382|NCT06827665|BIOLOGICAL|DDA|: demineralized dentin allografts (DDA) allografts from human extracted teeth will be prepared and evaluated in a prospective clinical trial to assess their efficacy for alveolar ridge preservation. The reconstruction and preservation of the alveolar ridge after tooth extraction are essential for future prosthetic rehabilitation. Autogenous bone grafts, while effective, are limited by donor site morbidity and insufficient graft quantity. Allogenic dentin grafts, derived from healthy human donors, present a scalable solution.
223937383|NCT06827665|BIOLOGICAL|WTA|whole tooth allografts (WTA) allografts from human extracted teeth will be prepared and evaluated in a prospective clinical trial to assess their efficacy for alveolar ridge preservation. The reconstruction and preservation of the alveolar ridge after tooth extraction are essential for future prosthetic rehabilitation. Autogenous bone grafts, while effective, are limited by donor site morbidity and insufficient graft quantity. Allogenic dentin grafts, derived from healthy human donors, present a scalable solution.
223937384|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Low dose of ACI-35.030
223937385|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a Medium dose of ACI-35.030
223937386|NCT04445831|BIOLOGICAL|ACI-35.030|Administration of a High dose of ACI-35.030
223937387|NCT04445831|OTHER|Placebo|Administration of Placebo
223937388|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Low dose of JACI-35.054
223937389|NCT04445831|BIOLOGICAL|JACI-35.054|Administration of a Medium dose of JACI-35.054
223937390|NCT03697304|DRUG|BI 754091|Solution for infusion
224098427|NCT03864965|OTHER|Advance Care Planning|The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
224098428|NCT01636557|DRUG|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
224286617|NCT04808830|OTHER|Evaluation of quality of life|Quality of life will be evaluated using The EmPHasis-10 questionnaire and The Minnesota Living with Heart Failure Questionnaire.
224286618|NCT04808830|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity will be evaluated using 6-min walk test.
223937391|NCT03697304|DRUG|BI 754111|Solution for infusion
223937392|NCT03697304|DRUG|BI 836880|Solution for infusion
223937393|NCT06831630|OTHER|Holmich protocol exercise|The treatment consisted of exercise therapy (ET) protocol suggested by Holmich et al and was started under the supervision of a trained sport physiotherapist who ensured that the exercise was carried out correctly and adhered to the original protocol. No treatment other than ET was applied. Although the ET protocol exactly mirrored the randomised clinical trial of Holmich et al, details such as the perceived resistance or weights (in exercise 3 in module 2) and the rest period between the exercise sets and repetitions, which were not defined in the Holmich study, were explained here for the athletes' benefit (tables 1 and 2). Treatment was administered three times a week (on even or odd days). The duration of each session was about 90 min for module 1 (first two weeks) and 120 min for module 2 (from the third week). From the third week, the athletes were asked to perform exercises from module 1 every other day, between the treatment sessions. Although adductor muscle stretching was for
223941390|NCT03839550|PROCEDURE|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
223941391|NCT02659124|DEVICE|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
224098429|NCT01636557|DRUG|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
224098430|NCT01636557|DRUG|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
224098431|NCT01636557|DRUG|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
224098432|NCT01636557|DRUG|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
223534382|NCT06941857|DRUG|5-Fluorouracil (5-FU)|2400 mgm2 will be administered as a continuous IV Infusion (-120/+ 120 minutes) over approximately 46 hours on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223534383|NCT06941857|DRUG|NC410|100 mg will be administered as a 60 minute IV Infusion (-10/+ 20 minutes) on day 1 of each cycle every 2 weeks. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223534384|NCT06941857|DRUG|Nivolumab|400 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223937394|NCT06831630|OTHER|Joint Mobilization|"Focus of treatment was on reducing hip joint pain using joint mobilization techniques provided by the physical therapist and exercises performed in the HEP. Based on published literature, we developed a standard set of mobilizations to target hip joint motion limitations, defined as stiffness or pain that limited joint range of motion. Joint mobilization techniques were prioritized based on patient-specific tasks and the motion used during those tasks, followed by the hip motion limitations. The choice of joint mobilization techniques and grade used was based on direction of hip motion limitation and the relationship of pain and stiffness during hip motion assessment. The HEP included commonly used joint motion and stretching exercises to complement techniques performed during supervised sessions.~The exercises will be conducted over a period of 12 weeks, which is explained below Techniques will be prioritized based on restrictions noted on baseline examination.~1. Caudal glide~2. Lat"
223937395|NCT05579730|DRUG|Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%|combination ophthalmic solution
223937396|NCT05579730|DRUG|Brimonidine Tartrate 0.025%|ophthalmic Solution
223937397|NCT05579730|DRUG|Ketotifen Fumarate 0.035%|ophthalmic Solution
223937398|NCT05579730|DRUG|Vehicle|ophthalmic Solution
223937399|NCT06832930|PROCEDURE|unicorn robotic bronchoscopy system|cryobiopsy with the help of robotic bronchoscopy system
223937400|NCT06832930|PROCEDURE|Conventional navigation bronchoscopy|cryobiopsy with the help of Conventional navigation bronchoscopy
223937401|NCT06827925|OTHER|Distance Digital Learning|receiving Distance Digital Learning of Flipped Education
223937402|NCT06138340|DRUG|Dexmedetomidine|Participants will be sedated and maintained by dexmedetomidine during the surgery.
223937403|NCT06138340|DRUG|Propofol|Participants will be sedated and maintained by propofol during the surgery.
223937404|NCT06138340|DRUG|Remimazolam Injection|Participants will be sedated and maintained by remimazolam during the surgery.
223937405|NCT06829940|OTHER|Baduanjin exercise training (BET)|Baduanjin Exercise Training (BET) is a traditional Chinese exercise focused on improving physical health, flexibility, balance, and mental well-being. It involves a 10-minute warm-up, a 40-minute core session practicing eight distinct postures, and a 10-minute cool-down. The postures, based on the Baduanjin form, target different body parts and promote strength, flexibility, and circulation. The exercises are synchronized with deep breathing to enhance relaxation and stress reduction. BET is especially beneficial for joint health, mobility, and mental clarity, making it suitable for individuals of all ages and fitness levels
223937406|NCT04306367|DRUG|Pembrolizumab|200 mg given intravenously.
223937407|NCT04306367|DRUG|Olaparib|300 mg given orally.
223937408|NCT05829824|BEHAVIORAL|CareConnect|A combination of the Ask-Advise-Connect (AAC) with an Interactive Voice Response (IVR)
223937409|NCT05829824|OTHER|AutoReach|Phone call / SMS Text
223534385|NCT06941857|DRUG|Ipilimumab|50 mg will be administered as a 30 minute IV Infusion (-5/+20 minutes) once on Cycle 1 Day 1. Each cycle length is 14 days. The two arms will enroll sequentially (starting with Arm 1 followed by Arm 2).
223534386|NCT07143617|BIOLOGICAL|STR-P004|STR-P004 Intravenous infusion
223534387|NCT07149506|OTHER|Epicatechin|A comparison will be made between oral catechin (epicatechin) from two approaches: a preventive approach and a therapeutic approach.
223937410|NCT05829824|PROCEDURE|Biospecimen samples|Optional saliva sample
223937411|NCT06763094|DRUG|Calcium dobesilate (Doxium)|This intervention is unique because Calcium Dobesilate is not a hormonal agent and does not carry the risks associated with hormonal therapies, such as potential impact on fertility or long-term endocrine effects. Additionally, it may be more suitable for patients who cannot tolerate hormonal treatments due to contraindications such as previous thrombotic events or risk factors for thrombosis.
223937412|NCT06763094|DRUG|Tranexamic Acid|Tranexamic Acid stands out due to its non-hormonal action in managing menorrhagia, providing an alternative for women who are contraindicated for hormonal treatments or prefer non-hormonal solutions. Unlike other hormonal treatments, Tranexamic Acid does not impact fertility or have significant endocrine effects.
223937413|NCT04665297|BEHAVIORAL|International Guide for Monitoring Child Development|Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.
223937414|NCT06828341|BIOLOGICAL|CAR-T|allogeneic CAR-T targeting CD70 that cultured from heathy adults.
224098433|NCT01636557|DRUG|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
224098434|NCT04130815|DRUG|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
224098435|NCT01120626|DRUG|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
223937415|NCT06753461|PROCEDURE|intrahepatic blood flow occlusion|The specified blood vessel is temporarily clamped to achieve the intended blockage of blood flow.
223937416|NCT05790018|DEVICE|PREGNANT PILLOW|First of all, questionnaire forms and scales will be applied to the pregnant women included in the experimental group in the pre-test (at 29-30 weeks). Then the pregnant pillow will be given and necessary explanations will be given about its use. Second follow-up 33-34. It will be done at the gestational week and the scales will be repeated. The final test is 37-38. It will be done at the gestational week (before birth) and the research will be completed.
223937417|NCT06382818|RADIATION|COHORT A|"IMRT radiotherapy on whole breast according to the investigator's decision among:~* Moderate whole breast hypofractionated RT according to the START B schema with Fixed Field IMRT Technique: 40.05 Gy in 15 daily fractions over 3 weeks and a Sequential boost (+ 16 Gy/8 fr) or (+13.5/5 fr) if applicable.~* Extreme whole breast hypofractionated RT according to :~  * The FAST schema: Once-a-week ultra-HypoRT with Fixed Field IMRT Technique, 28.5 Gy in 5 fractions in 5 weeks~ * The FAST-Forward schema: Very accelerated course of HypoRT with Fixed Field IMRT Technique, 26 Gy in 5 fractions in 5 consecutive days"
223937418|NCT06382818|RADIATION|COHORT B|"Breast radiotherapy according to the investigator's decision among:~* External partial VMAT: 40 Gy in 15 fractions to the partial breast only (tumorectomy bed).~* Exclusive Brachytherapy: 30.1 Gy in 7 fractions or 32.0 Gy in 8 fractions of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days.~* Whole Breast Normo fractionated IMRT with Fixed Field IMRT Technique: 50 Gy in 25 daily fractions over 5 weeks +/- Sequential (+ 16 Gy/8fr) or SIB (60 Gy/25 fr) treatment for boost if applicable."
223937419|NCT06382818|RADIATION|COHORT C|"Whole breast and nodes Hypofractionated VMAT and a localized simultaneous boost according to the HypoG01 schema protocol:~VMAT Technique, 42.3 Gy in 18 fractions on all target volume on 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fractions)."
223937420|NCT06382818|RADIATION|COHORT D|"Breast radiotherapy based on available clinical trials:~\- Whole Breast and Nodes Hypofractionated VMAT with adaptive treatment (margin reduction): HypoG01 Schema with VMAT Technique, 42.3 Gy in 18 fractions on all target volume over 3.5 weeks +/- SIB boost if need (52.2Gy in 18 fr) In case of patient refusal or technique unavailable, a standard treatment available in the center for this indication will be delivered."
223937421|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants A|Peer participants in group A will self select a peer coach and will be contacted weekly by peer coaches.
223937422|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants B|Peer participants in group B will self select a peer coach and will be contacted bi-weekly by peer coaches.
223937423|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants C|Peer participants in group C will be matched with a peer coach and will be contacted weekly by peer coaches.
224098436|NCT01120626|DRUG|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
224098437|NCT03069911|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
224098438|NCT03069911|BIOLOGICAL|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
224098439|NCT05638321|DEVICE|MIMS|sterile surgical device made of stainless steel and plastic, which is coupled to a rotating system. The surgical device consists of stainless steel micro trephine, covered by a small needle and rotating mechanism behind it. Mechanical rotation of the surgical device is achieved by the rotating system which is comprised of a 1) Controller which dictates the activation pulse duration and RPM, 2) a Motor, and 3) Footswitch.
224286619|NCT04808830|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire- Short Form
224098440|NCT02469129|DRUG|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of \[18F\]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
224098441|NCT00962715|BIOLOGICAL|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
224098442|NCT00962715|DRUG|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
224286620|NCT04711967|BIOLOGICAL|Fecal Microbiota Transplantation|fecal microbiota transplantation
224286621|NCT04711967|DRUG|drug|drug
224286622|NCT05082324|OTHER|Adapted physical activity|Patient participates in an adapted physical activity program for 3 months, with 2 one-hour sports sessions per week
224286623|NCT04027374|PROCEDURE|Fetal surgery for MMC repair|Fetal surgery for MMC repair
224286624|NCT04341259|DRUG|Ipatasertib|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.
224286625|NCT00384475|DRUG|Ciclesonide Nasal Spray|
224286626|NCT05523570|DRUG|HNC364|2 subjects (both male and female) to receive 20 mg HNC364 intramuscular administration to evaluate the safety and tolerability of HNC364 injectable suspension. Then 8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 20 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
224286627|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 40 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
223937424|NCT06003634|BEHAVIORAL|Peer Coaching - Peer Participants D|Peer participants in group D will be matched with a peer coach and will be contacted bi-weekly by peer coaches.
224098443|NCT00962715|DRUG|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
224098444|NCT01343615|PROCEDURE|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
223937425|NCT03044158|DEVICE|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
223937426|NCT03044158|BEHAVIORAL|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
223937427|NCT03044158|OTHER|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
223937428|NCT06825312|BIOLOGICAL|Japanese Encephalitis Vaccine (Vero Cell), Inactivated|0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology Co., Ltd., administered in the deltoid area of lateral arm by intramuscular injection.
223937429|NCT06825312|BIOLOGICAL|Japanese Encephalitis Vaccine, Live|0.5ml for each dose, manufactured by Chengdu Institute of Biological Products Co., Ltd., administered subcutaneously in the lower part of the deltoid area of lateral arm.
223937430|NCT05426785|DEVICE|1:1 ratio for Treatment Group and Control Group|Randomization also will be performed at latest 10 days after ICD implantation, and the specified device programming settings for the allocated group will be set after successful implantation of the investigational devices.
223937431|NCT05794009|OTHER|Immersive Virtual Reality Exercise (IVRE)|The IVRE program will include aerobic exercise, muscle strengthening exercise, balance and flexibility exercise.
224098445|NCT01343615|PROCEDURE|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
224098446|NCT03140826|DRUG|meropenem|Antibiotics to treat infections.
224098447|NCT04265664|BEHAVIORAL|Telerehabilitation|Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
224098448|NCT05461443|DIETARY_SUPPLEMENT|Probiotic|
224098449|NCT03676309|DRUG|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
224098450|NCT03676309|DRUG|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
224098451|NCT05316896|OTHER|Internal Perturbation|"* Raising and lowering arms 90 degrees forward and sideways with eyes open and closed.~* In tandem stance with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* While standing on one leg with eyes open and closed, arms are raised and lowered 90 degrees forward and to the side.~* Step forward and backward with right and left foot alternately~* Take a step back and step back alternately with right and left foot~* Put the right foot on the step and take it back, then do the same with the left foot and ask the patient to do it quickly.~* First step on the step with the right foot and put the left foot next to it, then step down with the right foot and take the left foot with it, repeat the same with the left foot and ask the patient to do this. rapidly.~* Normal gait, sideways gait, tandem gait, backward gait, raising and lowering the arms forward and sideways 90 degrees, respectively, during back-to-back tandem gait."
224286628|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 60 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
223534388|NCT07149506|OTHER|Epigallocatechin Gallate (EGCG)|A comparison will be made between topical catechin (EGCG) from two approaches: a preventive approach and a therapeutic approach.
223937432|NCT05794009|OTHER|Home Exercise|Aerobic exercise, muscle strengthening exercise, balance and flexibility exercise at home.
223937433|NCT06839898|DEVICE|EYECRYLTM Phakic Toric Intraocular Lens Treatment Arm|The patients will be implanted with Eyecryl Phakic IOL at this arm based on randomization.Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.
223534389|NCT07149506|OTHER|Microcrystalline Cellulose NF (placebo)|A comparison will be made between oral placebo (microcrystalline cellulose) from two approaches: a preventive approach and a therapeutic approach.
223937434|NCT06839898|DEVICE|Visian® Toric ICL Treatment Arm|The patients will be implanted with Visian® Toric Implantable Contact Lens at this arm based on randomization. Phakic intraocular lenses are clear implantable lenses that are surgically placed either in anterior chamber (AC) or posterior chamber (PC) without removing the natural lens, enabling light to focus on the retina for improved uncorrected visual acuity. Phakic intraocular lenses demonstrate high optical quality and potential gain in visual acuity in myopic patients due to retinal magnification. Toric version of phakic intraocular lens is intended to correct both myopia and astigmatism.
223937435|NCT06761053|DIAGNOSTIC_TEST|Intervention/Exposure for the GDM Group (Experimental Arm)|"Gestational Diabetes Diagnosis: The intervention for this group involves the diagnostic procedure of the 100-gram oral glucose tolerance test (OGTT) after an initial glucose challenge test (GCT) with a result equal to or greater than 140 mg/dL. The test assesses fasting plasma glucose and post-glucose consumption plasma glucose levels at 1 hour and 2 hours, which is used to diagnose GDM.~Biomarker Analysis: The albumin to high-sensitivity C-reactive protein (hsCRP) ratio is measured as a biomarker to explore its potential role in GDM diagnosis and related pregnancy outcomes."
223937436|NCT06761053|DIAGNOSTIC_TEST|Intervention/Exposure for the Control Group|"Glucose Challenge Test (GCT): The control group participants are exposed to the glucose challenge test (GCT), where plasma glucose levels are measured one hour after the consumption of 50 grams of glucose. If their glucose levels are below 140 mg/dL, they are categorized as not having GDM.~Biomarker Analysis: Similar to the GDM group, the albumin to hsCRP ratio is measured for participants in the control group to compare the biomarker levels between those with and without GDM."
223937437|NCT06832969|PROCEDURE|cryoablation|Lung cancer patients undergo treatment for peripheral malignant lung tumors using cryoablation technology under the guidance of bronchoscopy.
223937438|NCT03268421|BEHAVIORAL|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
223937439|NCT03268421|BEHAVIORAL|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
223937440|NCT03268421|BEHAVIORAL|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
223937441|NCT06826521|PROCEDURE|Single construct versus dual constructs will give satisfactory radiological and functional outcomes|Single construct like cephalomedullary nail or long DHS in fixation of both neck and shaft fractures, dual constructs like DHS or cannulated screws and retrograde nail or DHS or cannulated screws and dymanic compression plate in fixation of both fractures.
223937442|NCT00667121|DRUG|citalopram hydrobromide|
223937443|NCT00667121|DRUG|escitalopram oxalate|
223937444|NCT00667121|DRUG|gabapentin|
223937445|NCT00667121|DRUG|sertraline hydrochloride|
223937446|NCT00667121|DRUG|tamoxifen citrate|
224286629|NCT05523570|DRUG|HNC364|8 subjects are planned for enrollment in each cohort (the ratio of male to female is as close as possible) to receive 80 mg HNC364 intramuscular administration. The proposed dose levels for use were determined to be appropriate based on the collective nonclinical data (pharmacology and toxicology) for HNC364 and the nonclinical and clinical data of the marketed drug rasagiline.
224286630|NCT01010022|DRUG|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
224286631|NCT01010022|DRUG|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
224286632|NCT00953472|DRUG|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
224286633|NCT00953472|OTHER|no-added salt diet|instruction to reduce salt for one week prior to study
224286634|NCT04821752|BEHAVIORAL|Avoidance Education|Reduction of environmental toxins exposure from the diet will be achieved by switching to organic foods. Reduction of residential and occupational exposure to toxins from household cleaning products, cosmetics, personal care products, and other sources will be achieved by switching to safer products or avoidance of the toxic exposure.
224286635|NCT04070339|OTHER|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
224286636|NCT03250299|DRUG|Microtubule-Targeted Agent BAL101553|Given PO
224286637|NCT03250299|RADIATION|Radiation Therapy|Undergo radiation therapy
223534390|NCT07149506|OTHER|Saline (0.9% NaCl)|A comparison will be made between topical placebo (0.9% saline solution) from two approaches: a preventive approach and a therapeutic approach.
223937447|NCT00667121|DRUG|venlafaxine|
223937448|NCT00667121|GENETIC|molecular genetic technique|
224098452|NCT05316896|OTHER|Eksternal Perturbation|"* Front, side, and rear loading and release, pushing and pulling while standing with eyes open and closed~* Front, side and rear loading and release, pushing and pulling while standing in tandem with eyes open and closed~* Loading and releasing from the front, sides and back, pushing and pulling while turning the head left and right while standing~* Front, side and rear loading and release, pushing and pulling while standing up and down with eyes open and closed~* Front, side, and rear loading and release, pushing and pulling while standing on one leg with eyes open and closed~* Holding the ball thrown by physiotherapist~* Kicking a ball thrown by physiotherapist~* Holding the ball thrown by the physiotherapist while standing in tandem, walking, walking sideways, walking in tandem, walking backwards."
223534391|NCT07150442|PROCEDURE|POP surgery and PRP injection|Patient who undergo POP surgery will receive PRP injection
223534392|NCT07150442|PROCEDURE|POP surgery and placebo injection|patient who receive POP surgery and placebo injection
223937449|NCT00667121|OTHER|high performance liquid chromatography|
223937450|NCT00667121|OTHER|laboratory biomarker analysis|
223937451|NCT00667121|OTHER|pharmacological study|
223937452|NCT00667121|PROCEDURE|adjuvant therapy|
223937453|NCT06812949|DIAGNOSTIC_TEST|PEEP Titration with Echocardiographic, Hemodynamic, and Ventilatory Measurements|This intervention consists of clinical recruitment maneuvers performed in mechanically ventilated patients by adjusting positive end-expiratory pressure (PEEP) at two levels: low PEEP (5 cmH₂O) and high PEEP (15 cmH₂O). Throughout these maneuvers, echocardiographic imaging, hemodynamic assessments, and ventilatory measurements are performed to evaluate the cardiorespiratory effects of PEEP adjustments. Transthoracic echocardiography (TTE) is used to assess right ventricular function, pulmonary pressures, and venous congestion, while mechanical ventilator parameters are recorded to monitor lung mechanics and compliance.
223937454|NCT06823921|OTHER|Exercise|HIIT will include aerobic, strength, and balance exercises and boxing
224286638|NCT02087124|OTHER|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
224286639|NCT01202071|DRUG|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
223937455|NCT04049890|OTHER|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
223937456|NCT04049890|OTHER|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
223937457|NCT04049890|OTHER|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
223937458|NCT06797284|DEVICE|Transcranial Magnetic Stimulation|repetitive transcranial magnetic stimulation, or transcranial direct current stimulation, or daytime timed bright light exposure
223937459|NCT06830564|DRUG|we will give the patient 0.1 mg nalbuphine 15 min before the end of the procedure|The study medications will be prepared by the local pharmacy as 10 ml syringes of nalbuphine IV that will be handled to the anesthesiologist in charge in OR room who will be blinded to the nature of the medications used, and study medications will be given 15 minutes before the end of surgical procedure and it will be given slowly for five minutes. . After extubation, patients will be taken to postanesthetic care unit . on arrival vital data will be measured. The anesthesiologist following up the patient will be blinded to the groups. The time of extubation will be defined as zero and after 15 minutes will be defined as one . Assessment of agitation will be done at time zero and time 1 and every fifteen minutes for 30 minutes using paediatric anaesthesia Emergence delirium scale (PAEDS)
223937460|NCT06830564|DRUG|we will give the patient 0.5 mg dexmedetomidine 15 min before the end of the procedure|The study medications will be prepared by the local pharmacy as 10 ml syringes of dexmedetomidine IV that will be handled to the anesthesiologist in charge in OR room who will be blinded to the nature of the medications used, and study medications will be given 15 minutes before the end of surgical procedure and it will be given slowly for five minutes. . After extubation, patients will be taken to postanesthetic care unit . on arrival vital data will be measured. The anesthesiologist following up the patient will be blinded to the groups. The time of extubation will be defined as zero and after 15 minutes will be defined as one . Assessment of agitation will be done at time zero and time 1 and every fifteen minutes for 30 minutes using pediatric anesthesia Emergence delirium scale (PAEDS) .
223937461|NCT05310734|DRUG|Spinosad Topical|A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
223937462|NCT06814821|OTHER|Web-based rehabilitation|Participants perform their rehabilitation independently with the instructions from the web-based platform.
223937463|NCT06814821|OTHER|Standard rehabilitation|Participants attend physical visits at the clinic to get instructions and support in their rehabilitation. Written and verbal instructions will be given.
223937464|NCT06831500|DRUG|Administration of Carbidopa/levodopa|Participants will perform beat-by-beat orthostatic tests (Schellong tests) before and after intake of single doses of carbidopa:levodopa combinations at 3 different ratios
223937465|NCT05913752|DRUG|CMND-100|The investigational product CMND-100 consists of gelatin capsules, each containing the active ingredient (either 20 or 60 mg) 5-methoxy-2-aminoindane (MEAI) and excipients (stabilizers). MEAI is a psychoactive compound of the aminoindane class
223937466|NCT03474159|DEVICE|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
224286640|NCT01202071|DRUG|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
223534393|NCT07149714|DEVICE|iVAC 2L|The goal of this study is to investigate the safety and clinical efficacy of temporary mechanical support system with the iVAC 2L transaortic device in high-risk percutaneous coronary intervention (PCI) in Russia and Belarus. The POTOK trial will include patients with indications for elective, urgent and emergency PCI.
223534394|NCT07150273|DEVICE|UNIVELO Sub-Q 2mL|Test device
223534395|NCT07150273|DEVICE|Restylane Sub-Q 2mL|Comparator Device
223534396|NCT07148349|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223534397|NCT07150910|BEHAVIORAL|Interdental brush|In accordance with the manufacturer's recommendations, the IDBs were stated to be suitable for multiple uses. Participants were advised to replace the IDB once the bristles lost their shape or if the metal wire became damaged.
223937467|NCT03474159|DEVICE|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
223937468|NCT03474159|DEVICE|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
223941392|NCT02659124|PROCEDURE|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
223941393|NCT01818869|DRUG|AZD8848|Multiple doses inhaled IMP via a nebulizer
223941394|NCT01818869|DRUG|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
223941395|NCT01687751|DRUG|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
223941396|NCT01687751|DRUG|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~* The study drug will be started at a rate of 1.0 mL/hr.~* The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate \< 40) or hypotension (systolic blood pressure \< 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
223937469|NCT06827600|BEHAVIORAL|Structured breastfeeding education and follow-up|"Breastfeeding education was provided face-to-face to mothers assigned to the experimental group. The authors developed a breastfeeding education program and prepared a booklet. This booklets were distributed to experimental group.Follow-up were carried out on the 3rd day and at the 1st, 3rd, and 6th months postpartum. each follow-up session, the educational program's core components were reinforced through a standardized summary, ensuring continuity and clarity in the information provided.~Training Content~* Significance of Breastfeeding~* Advantages of Breastfeeding~* Overview of Colostrum~* Duration for Breastfeeding~* Breastfeeding Positions~* Strategies for Enhancing Breast Milk Production~* Increasing Breast Milk Supply~* Techniques for Placing the Baby on the Breast~* Implications of Improper Baby Positioning~* Indicators of Sufficient Breast Milk for the Infant~* Expressing Breast Milk~* Recommendations for Storing Expressed Milk"
223937470|NCT06696352|BEHAVIORAL|Partners4Pain|This is a group program that will teach participants about different things they can do to manage their pain. They will watch educational videos and do workbook activities. They will learn and practice different exercises and mind-body strategies for pain including back and neck exercises (like strengthening and stretching), mind-body exercises (like meditation, relaxed breathing, guided imagery, and muscle relaxation), problem solving, and how to communicate with others about your pain. They will also have an opportunity to take part in discussions with other group members. The program will be delivered via weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
223937471|NCT06696352|BEHAVIORAL|Keys to Wellbeing|This is a group program that will teach participants about different things they can do to improve their health and wellbeing. Participants will watch educational videos and do workbook activities. They will learn different back and neck exercises (like strengthening and stretching) and be introduced to different health-related topics including information and tips about health, pain and wellbeing; keeping active and well; the importance of rest and relaxation; and working with meaning and purpose in your life. They will also have an opportunity to take part in discussions with other group members. The program will be delivered in weekly 90 minute sessions over 9 weeks and will be offered in-person or via videoconference.
223937472|NCT06832215|DIAGNOSTIC_TEST|Blood and urine samples collection|Blood and urine were collected at a single time point for all participants, from the tree study groups. Fasting for blood collection and the first urine in the morning were required.
223937473|NCT06456515|DRUG|Regorafenib and Sintilimab in combination with electroacupuncture|Regorafenib, take for 2 weeks and stop for 1 week; Sintilimab, intravenous, every 3 weeks; Electroacupuncture was performed 1 day before, on the day of, and on the 2nd day after each cycle of Sintilimab administration, and patients completed 3 treatments in week 1, followed by 1 treatment per week for 2 weeks, with 5 treatments per dosing cycle.
223937474|NCT06828315|OTHER|Reflexology|Reflexology is a practice based on the fact that the organs in the body are connected to the reflex areas in the hands and feet.
223937475|NCT06319170|DRUG|Olanzapine Extended Release|Powder and vehicle for injectable suspension
223937476|NCT06319170|DRUG|Olanzapine|IntraMuscular Injection
223937477|NCT05427487|BIOLOGICAL|IVX037|Bioselected oncolytic RNA virus
224098453|NCT04626830|OTHER|Mobile Application Intervention|Participants appointed to the intervention group will receive the mobile application intervention for six months after enrollment. The mobile app (OKTED) intervention will consist of completing responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses.
224098454|NCT00515125|BEHAVIORAL|Dietary Advice|Dietary Advice sheet
224098455|NCT00515125|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
224098456|NCT05258227|OTHER|Conservational Physical Therapy and Proprioceptive Strength Training|The proprioceptive training cycle consist of squats, single leg stand, slide steps , forward and backward step, toe walking , heel walking , side sway etc.
224098457|NCT05258227|OTHER|Conservational Physical Therapy and Core Instability Strength Training|Core stability is essential part of lower limb rehabilitation; it is also known protocol which includes group of exercises in both standing and sitting improving biomechanics and functional performance of the body.
224098458|NCT01496664|PROCEDURE|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
224098459|NCT00326820|DRUG|ibandronate sodium|
224098460|NCT00326820|DRUG|zoledronic acid|
223534398|NCT07150910|BEHAVIORAL|Rubber bristles interdental cleaner|Two sizes were selected for the study: XS/S - Orange, designed for narrow and very narrow interdental spaces, and M/L - Turquoise, suitable for medium to large spaces. Since the tested RBICs were designed by the manufacturer for single use, participants were instructed to use a new RBIC at each application.
224286641|NCT01202071|DRUG|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast."
224286642|NCT01202071|DRUG|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast."
224286643|NCT00031811|DRUG|raloxifene|
224286644|NCT00031811|PROCEDURE|quality-of-life assessment|
223534399|NCT07156071|OTHER|Serum 1|Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 1 group.
223937478|NCT05427487|BIOLOGICAL|Sintilimab|An immune checkpoint inhibitor
223937479|NCT04912856|DRUG|XEN496|XEN496 sprinkle capsules. Parents / caregivers will be instructed to sprinkle and mix the contents of the capsules into soft foods or liquids and feed it to the child.
223937480|NCT05949593|DRUG|Tinlarebant|5 mg tablet taken orally once a day
223937481|NCT05949593|DRUG|Placebo|Placebo tablets for tinlarebant 5 mg prepared similarly.
223937482|NCT06075732|BEHAVIORAL|Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to reduce Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccine hesitancy and increase willingness and uptake in Influenza, Pneumonia, Meningitis, HZV, and COVID-19 vaccination.
223937483|NCT04238715|DRUG|E7090|E7090 tablets orally.
223937484|NCT06762405|RADIATION|radiotherapy|short course of radiotherapy (5 grays × 5 days)
223937485|NCT06762405|DRUG|Dostarlimab|dostarlimab 500 mg intravenous infusion every 3 weeks for 6 months (nine cycles)
223937486|NCT06762405|BIOLOGICAL|Biological study on circulating tumor DNA (optional for the patient)|"* Tissue collection (3 time points: baseline, w12 and 25) for:~* Exome (on tumor and normal tissue),~* 3'RNAseq,~* Hiplex Immunofluorescence~* In addition, 48 patients will be tested for Spatial transcriptomics assuming that 24 patients may have non-complete response and/or local recurrence and/or metastatic recurrence and will be paired with 24 patients with complete response and free of any disease at 2 years.~* Blood collection (5 time points: baseline, w3, 6, 12 and 24) for:~* ctDNA~* Cytokine dosage~* Proteomic analyses~* Stool collection (3 time points: baseline, w3 and 24) for:~Microbiota analyses"
223937487|NCT06824428|OTHER|Pain perception threshold|The patients' pressure pain threshold will be evaluated with a manual pressure algometer (Baseline Dolorimtre®).The patients' pain perception thresholds will be measured bilaterally in the midfrontal region, the midpoint of the trapezius muscle, the lateral epicondyle, the midpoint of the web between the 1st and 2nd fingers, the greater trochanter, and the medial crease of the knee.
223937488|NCT04728711|DRUG|ADX-629|ADX-629, 600 mg administered orally twice daily (PO bid) for a minimum of 1 week
223937489|NCT04728711|DRUG|Placebo|Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
223937490|NCT00748709|DRUG|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
224098461|NCT00326820|DRUG|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
224098462|NCT04516304|DIETARY_SUPPLEMENT|Placebo|4 tablets/d (2 in the morning and 2 in the evening)
224098463|NCT04516304|DIETARY_SUPPLEMENT|S-equol|4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
224098464|NCT00089557|DRUG|Capsaicin Dermal Patch|
223937491|NCT04660721|COMBINATION_PRODUCT|sFilm-FS|sFilm-FS is a sterile bio-compatible bio-absorbable patch embedded with lyophilized powders of Human Fibrinogen, Human Thrombin and calcium chloride.
223937492|NCT04660721|COMBINATION_PRODUCT|TACHOSIL®|TACHOSIL® is a fibrin sealant patch composed of an equine collagen patch coated with Human Fibrinogen and Human Thrombin.
223937493|NCT03546335|DRUG|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under Current Good Manufacturing Practice (CGMP) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at University of California, San Francisco (UCSF).
223937494|NCT03809715|DEVICE|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
223937495|NCT05483517|DEVICE|High energy density pulse electromagnetic field|The treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. A normal energy of high-PEMF with a rate of 2 pulse per second is applied to the patient.
223937496|NCT05483517|DEVICE|sham High energy density pulse electromagnetic field|The sham treatment coil is placed over the shoulder region at the maximum pain point for 9 minutes. The setting is the same as the experimental group(normal energy, a rate of 2 pulse per second) with the difference that the energy output doesn't export to the patient.
223937497|NCT05483517|BEHAVIORAL|physiotherapy|Physiotherapy includes shoulder range of motion (ROM), stretching and muscle strengthening exercises. Under the physiotherapist's guidance, the patient receives the training session about 30 minutes every time.
223937498|NCT05653440|BEHAVIORAL|Accuracy-maximized condition|Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
223941397|NCT00223756|OTHER|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
223941398|NCT00873782|OTHER|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
223941399|NCT05359796|BIOLOGICAL|Chronic hyperglycemia|For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.
223941400|NCT05359796|BIOLOGICAL|Residual islet function|For each follow-up, fasting and stimulated C-peptide levels will be measured.
223941401|NCT05359796|GENETIC|Genetic variation|Genetic variations of interest will be detected with the blood sample collected at baseline.
223941402|NCT05359796|DIETARY_SUPPLEMENT|Dietary constitutes|For each follow-up, the dietary constitutes for the past 3 days will be recorded.
223941403|NCT05359796|GENETIC|Microbiome composition and function|For each follow-up, the fecal and oral samples will be collected for measurement.
223941404|NCT05359796|BIOLOGICAL|Metabolome composition|For each follow-up, the serum and urine samples will be collected for measurement.
223941405|NCT05359796|BIOLOGICAL|Composition of peripheral blood immune cells|For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
223941406|NCT03507972|RADIATION|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
223941407|NCT03507972|RADIATION|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
223941408|NCT02533232|DRUG|Minocycline|Minocycline 200mg per day
223941409|NCT01894217|GENETIC|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
223941410|NCT03853538|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
223941411|NCT03853538|OTHER|Semisolid vaseline|Product is applied to one hemiface.
223941412|NCT05508607|OTHER|CDI-risk Classification Tool|This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
223937499|NCT05653440|BEHAVIORAL|Effort-maximized condition|Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
224098465|NCT03104582|PROCEDURE|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
223937500|NCT05653440|BEHAVIORAL|Effort-accuracy balanced condition|Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
223937501|NCT06768866|BEHAVIORAL|Gruop 1|To determine factors influencing Postsurgical acute pain
223937502|NCT06951230|DRUG|Fentanyl injection|Fentanyl 1mcg/kg will be given before skin incision and Mayfield placement and followed up by fentanyl 1mcg/kg/hr, along the operation.
223937503|NCT06951230|PROCEDURE|scalp block|The scalp block procedure is performed with the patient in the supine position, utilizing surface landmarks for guidance. The local anesthetic is injected into the nerves after careful aspiration and under strict aseptic technique. The nerves that are typically injected include the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, as well as the lesser and greater occipital nerves, with or without the inclusion of the third occipital nerve. The volume of 0.5% bupivacaine injected should not exceed 2 ml at each site.
223937504|NCT06950164|OTHER|observation group|in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)
223937505|NCT06950164|OTHER|control group|in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)
223937506|NCT05864209|OTHER|Phthalate- and Bisphenol-free Baby Products|3-month supply. Products include wipes and diaper cream.
223937507|NCT05864209|OTHER|Cloth Diapers|Subscription to cloth diaper service.
223937508|NCT05864209|OTHER|Conventional Disposable Diapers|3-month supply.
223937509|NCT05864209|OTHER|Conventional Baby Products|Products include wipes and diaper cream.
223937510|NCT04257747|OTHER|MRI acquisitions|MRI acquisitions will be performed on the ACHIEVA 3T TX DStream Philips® Research MRI of the GIE Faire Faces.
224098466|NCT03104582|PROCEDURE|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
223937511|NCT04257747|OTHER|Doppler ultrasound procedure|The Doppler ultrasound procedure will be conducted in the traditional way in the Vascular Medicine Department of the Amiens-Picardie University Hospital
223937512|NCT06566950|PROCEDURE|Low load-BFRt|The participants' two legs will be subjected to 70% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
223937513|NCT06566950|PROCEDURE|Sham Low load-BFRt|The participants' two legs will be subjected to 10% arterial occlusion pressure when the physical therapist applies the BFR cuffs. After that, participants will be required to complete eccentric exercises with a maximum repetition count of 30%, such as stairs, single leg squat, and single leg deadlift.
223937514|NCT06566950|PROCEDURE|High load-Eccentric training|The physical therapist will instruct the participants to complete eccentric exercises at a maximum of 70% repetitions, such as stairs, single leg squat, and single leg deadlift.
223937515|NCT03762395|DRUG|CXA-10|6 weeks of treatment with 150 mg/day of orally administered CXA-10
224098467|NCT01744561|BEHAVIORAL|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
224286645|NCT03346070|DRUG|Sugammadex 2 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by ABW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
224286646|NCT03346070|DRUG|Sugammadex 2 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex (2 mg/kg by IBW) for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
224286647|NCT03346070|DRUG|Sugammadex 4 mg/kg ABW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex (4 mg/kg by ABW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
223534400|NCT07156071|OTHER|Serum 2|Applied topically on the full face in the morning and evening for 12 weeks during the treatment period. Used by participants in the Serum 2 group.
223937516|NCT03762395|DRUG|Matching Placebo|6 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
223937517|NCT06314672|PROCEDURE|Accrual|Participate in AEP
223937518|NCT06314672|PROCEDURE|Discussion|Participate in implementation discussions
224098468|NCT01989663|DRUG|1% vaginally applied tenofovir gel|
224098469|NCT01989663|DRUG|Tenofovir film- 10mg|
224098470|NCT01989663|DRUG|Tenofovir Film-40 mg|
224286648|NCT03346070|DRUG|Sugammadex 4 mg/kg IBW|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by IBW) for reversal of deep NMB.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
224286649|NCT03346070|DRUG|Neostigmine + Glycopyrrolate|"Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 µg/kg; 5 mg maximum) and Glycopyrrolate (10 µg/kg; 1 mg maximum), dosed according to participant ABW for reversal of moderate NMB.~Moderate NMB is defined as the reappearance of T2 in response to TOF stimulations."
223937519|NCT06314672|OTHER|Educational Activity|Participate in educational sessions/activities
223937520|NCT06314672|OTHER|Interview|Undergo interview
224098471|NCT01989663|OTHER|HEC Placebo Gel|
224098472|NCT01989663|OTHER|Placebo Vaginal Film|
224098473|NCT03431220|DEVICE|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
223937521|NCT06314672|OTHER|Review|Undergo data capture review
223937522|NCT06314672|OTHER|Survey Administration|Ancillary studies
223937523|NCT02465307|BEHAVIORAL|Confusion Assessment Method|Confusion Assessment Method (CAM) score
223937524|NCT02465307|DEVICE|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
223937525|NCT02465307|DEVICE|Commercially available camera|As part of facial recognition video system
223937526|NCT02465307|DEVICE|Internet Pod (iPod)|Monitors noise levels in the room
223937527|NCT02465307|DIAGNOSTIC_TEST|Cortisol Swab|Cortisol level collected through self administered salivary swab
223937528|NCT02303392|DRUG|Selinexor|Given PO
223937529|NCT02303392|DRUG|Ibrutinib|Given PO
224098474|NCT02413658|DRUG|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
223937530|NCT02303392|OTHER|Pharmacological Study|Correlative studies
223937531|NCT02303392|OTHER|Laboratory Biomarker Analysis|Correlative studies
224098475|NCT02413658|DRUG|Sugar solution|
224098476|NCT03932240|DRUG|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
223937532|NCT03937713|DRUG|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
223937533|NCT03937713|BEHAVIORAL|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
223937534|NCT03876288|DEVICE|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
223937535|NCT03876288|DRUG|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
223937536|NCT03876288|PROCEDURE|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
223937537|NCT00092534|BIOLOGICAL|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|A 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
223937538|NCT00092534|BIOLOGICAL|Matching Placebo|A placebo 0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study.
223937539|NCT00869232|DRUG|Velcade|1.0mg/m2 days 1, 5, 8, \& 11
223937540|NCT00869232|DRUG|Melphalan|10 mg/m2 day 3
223937541|NCT00869232|DRUG|Thalidomide|200 mg days 5-8
223937542|NCT00869232|DRUG|Dexamethasone|40 mg day 5-8
223937543|NCT00869232|DRUG|Cisplatin|10 mg/m2 day 5-8
223937544|NCT00869232|DRUG|Adriamycin|10 mg/m2 day 5-8
223937545|NCT00869232|DRUG|Cyclophosphamide|400 mg/m2 day 5-8
224098477|NCT03932240|DRUG|Cryoprecipitate|The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
224286650|NCT03346070|DRUG|Rocuronium or Vecuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide or Vecuronium Bromide administered via i.v. infusion and dosed according to participant ABW. NMBAs were concomitant medications used per label as adjunct to general anesthesia.
224286651|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
224286652|NCT03092739|DIAGNOSTIC_TEST|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
224286653|NCT04935788|DIETARY_SUPPLEMENT|milk protein|milk protein supplement
224286654|NCT04935788|DIETARY_SUPPLEMENT|micellar casein|micellar casein supplement
224286655|NCT04935788|DIETARY_SUPPLEMENT|pea protein|pea protein supplement
223937546|NCT00869232|DRUG|Etoposide|40 mg/m2 day 5-8
224286656|NCT04935788|DIETARY_SUPPLEMENT|milk/pea protein blend|milk/pea protein supplement
224286657|NCT00798382|OTHER|soy protein formula|ad lib for 0-35 days of age
224286658|NCT00798382|OTHER|Commercially available soy formula|ad lib for 0-35 days of age
224286659|NCT00798382|OTHER|Soy formula experimental #2|ad lib for 0-35 days of age
223937547|NCT06601998|OTHER|Blood samples and Oropharyngeal swab|Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)
224098478|NCT05696938|DIETARY_SUPPLEMENT|Wonderlab Nicotinamide Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
224098479|NCT05696938|DIETARY_SUPPLEMENT|Ordinary Drink|Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
224098480|NCT04154098|DEVICE|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
224098481|NCT04154098|PROCEDURE|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
224098482|NCT04154098|OTHER|No assistance|Participants are elevating their arm without being assisted
224098483|NCT04154098|OTHER|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
224098484|NCT05288465|DRUG|Cerebrolysin|Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
223534401|NCT07150403|DRUG|Oxaliplatin intravenous|85 mg/m² IV over 2 hours ; 1 cycle each 15 days
223937548|NCT06601998|OTHER|Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms|"* Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max"
224098485|NCT00666744|OTHER|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
224098486|NCT04657848|PROCEDURE|proximal gastrectomy combined with Cheng's Giraffe reconstruction|proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
224286660|NCT02253069|DEVICE|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
224286661|NCT02253069|DEVICE|Applying Placebo to tie-over dressings|Placebo control
223937549|NCT05350371|DRUG|Pirfenidone Oral Tablet|Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.
223937550|NCT05350371|DRUG|Placebo|The placebo tablets will be an exact replica of the pirfenidone tablet.
223937551|NCT04754321|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223937552|NCT04754321|RADIATION|Intraoperative Radiation Therapy|Undergo IORT
223937553|NCT04754321|BIOLOGICAL|Pembrolizumab|Given IV
223937554|NCT04754321|OTHER|Quality-of-Life Assessment|Ancillary studies
224098487|NCT00318955|DRUG|Dexmedetomidine|
224286662|NCT00977548|DRUG|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
224286663|NCT02948257|DEVICE|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
224286664|NCT04714281|DEVICE|Dialyser|Three consecutive treatment periods of four weeks, one last study week where the patient is re-assigned to the same type of dialyzer used before beginning the study and one follow-up week per patient. Each treatment period includes 12 hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX CorAL 600 Fresenius Medical Care, comparator FX CorDiax 600 Fresenius Medical Care and comparator xevonta Hi 15 (B. Braun).
224098488|NCT00318955|DRUG|Propofol|
224098489|NCT03348514|DRUG|CPX-POM - 30 mg/m^2|CPX-POM
224286665|NCT03936179|RADIATION|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
224286666|NCT02370459|OTHER|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
224286667|NCT02370459|OTHER|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
224286668|NCT06456619|OTHER|Tooth restoration|Comparison of composite resin and CAD-CAM supported restorations for hypomineralized molar teeth in children
224286669|NCT05151393|DIAGNOSTIC_TEST|Measuring vitamin D3 level|Measuring vitamin D3 in both groups
224286670|NCT04333472|DRUG|Piclidenoson|Piclidenoson 2 mg orally every 12 hours for up to 28 days
224286671|NCT04333472|DRUG|Placebo|Placebo orally every 12 hours for up to 28 days
224286672|NCT00633516|DEVICE|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
224286673|NCT04796636|DRUG|Sodium Ascorbate|As previously described
224286674|NCT05085795|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
224286675|NCT03529643|DRUG|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
224286676|NCT03529643|OTHER|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
224286677|NCT00555035|DRUG|GSK1349572|
223937555|NCT04754321|PROCEDURE|Salvage Surgery|Undergo salvage surgery
224098490|NCT03348514|DRUG|CPX-POM - 60 mg/m^2|CPX-POM
224098491|NCT03348514|DRUG|CPX-POM - 120 mg/m^2|CPX-POM
224098492|NCT03348514|DRUG|CPX-POM - 240 mg/m^2|CPX-POM
224098493|NCT03348514|DRUG|CPX-POM - 360 mg/m^2|CPX-POM
224098494|NCT03348514|DRUG|CPX-POM - 600 mg/m^2|CPX-POM
224098495|NCT03348514|DRUG|CPX-POM - 900 mg/m^2|CPX-POM
224098496|NCT03348514|DRUG|CPX-POM - 1200 mg/m^2|CPX-POM
224098497|NCT02053974|DRUG|Spironolactone|Spironolactone
224098498|NCT02053974|OTHER|Placebo|Placebo
224098499|NCT01883570|OTHER|training in visual search strategy|
223937556|NCT05641987|BEHAVIORAL|Healthy Workplace Participatory Program|The Center for the Promotion of Health in the New England Workplace's (CPH-NEW's) Healthy Workplace Participatory Program (HWPP) is a participatory process in which end-users design TWH interventions that simultaneously change organizational and individual behavior to improve the health, safety and well-being of their workforce. The HWPP uses a process to empower workers to identify the root causes of health and safety concerns and then design, implement and evaluate interventions to address those problems. The Total Teacher Health Project adapted the HWPP for educators and refer to it as the Educator Well-being Program.
223937557|NCT02107989|DEVICE|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
223937558|NCT02107989|DEVICE|MEG|MEG/EEG: Magnetoencephalography (MEG) is commonly used during epilepsy pre-surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only.
223937559|NCT02446262|BEHAVIORAL|Instructions|In sub-study 1, half the participants are instructed about outcomes, half learn through experience.
223937560|NCT02446262|BEHAVIORAL|Attention|In sub-study 4, participants learn about outcomes and we manipulate attention toward or away from the pain.
223937561|NCT02446262|BEHAVIORAL|Thermal Pain|In sub-studies 2 and 3, participants are exposed to thermal stimuli and/or tastants (sugar water, salt water, neutral rinse) and we are measuring how learning varies based on the type of outcome.
223937562|NCT02446262|BEHAVIORAL|Placebo instructions|In sub-study 5, we test whether placebo effects and expectancy cues modulate pain through similar mechanisms.
223937563|NCT05044403|PROCEDURE|Extracorporeal support with haemoperfusion|Use of extracorporeal support with haemoperfusion
223937564|NCT05044403|PROCEDURE|Conventional treatment|Conventional treatment
224098500|NCT01883570|OTHER|access to a library of chest x-rays without search strategy|
224286678|NCT02551679|BIOLOGICAL|ACP-01|Injection into lower extremity
224286679|NCT02551679|BIOLOGICAL|Placebo|Injection into lower extremity
223534402|NCT07150403|DRUG|5 FU bolus|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous)
223534403|NCT07150403|DRUG|Folinic acid|400 mg/m² in intravenous
223937565|NCT04773275|DEVICE|Pulsed electric field treatment using the Aliya system|Patients will undergo pulsed electric field (PEF) treatment of up to 5 tumors (new or progressing) measuring ≤ 2cm in longest diameter.
223937566|NCT05050266|BEHAVIORAL|EBQI|"EBQI is a systematic quality improvement method for engaging frontline practices in improvement that introduces best science and evidence in the service of operational goals. EBQI has been tested in several VA implementation trials. Sites randomized to EBQI will meet monthly with the implementation support team (i.e., high-intensity)."
224098501|NCT03497299|DEVICE|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
224098502|NCT03497299|DEVICE|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
224098503|NCT02700529|DRUG|ubenimex|
224098504|NCT02700529|OTHER|placebo|
224286680|NCT02150772|PROCEDURE|Shear Wave Elastography (SWE)|
224286681|NCT05394766|OTHER|Omada Hypertension Program|The Omada Program: an online program that offers comprehensive lifestyle self-management support for hypertension.
224286682|NCT06617117|OTHER|High-intensity combined exercise|The main part consisted of interval cycling exercise, comprising 5x2 min at the second ventilatory threshold interspersed with 4x2 min at the first ventilatory threshold, followed by 2-min unloading pedalling. Subsequently, participants completed resistance exercises (2 sets of 12 repetitions), targeting the same muscle groups of the moderate-intensity exercise, at an intensity of 80% of their 1 repetition maximum.
224286683|NCT06617117|OTHER|Moderate-intensity combined exercise|The main part of the exercise session consisted of an 18-min cycling continuous aerobic exercise at the first ventilatory threshold, followed by 2-min of unloading cycling. Subsequently, participants engaged in resistance exercises - 2 sets of 12 repetitions at 60% of their one repetition maximum. These resistance exercises were part of a machine-assisted circuit training program, encompassing Chest Press, Leg Curl, Low Row, Leg Press, Lat Pull-down, and Leg Extension.
224286684|NCT01546142|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
223534404|NCT07150403|DRUG|5 FU continuous|2400 mg/m² intravenously over 46 hours
223534405|NCT07150403|DRUG|Irinotecan|180 mg/m² IV over 1h30
224286685|NCT01546142|DRUG|Placebo|Phosphate buffered saline placebo for injection
224286686|NCT05577806|DRUG|Dydrogesterone|progestin primed ovarian stimulation
223937567|NCT05050266|BEHAVIORAL|REP|The REP framework consists of 4 phases: pre-conditions, pre-implementation, implementation and maintenance/evolution. REP has a strong evidence-base and application in VHA health services research in promoting uptake of EBPs. Sites randomized to REP will meet quarterly with the implementation support team (i.e., low-intensity).
223937568|NCT05127057|OTHER|PRIME Parkinson Care|A novel model of care
224098505|NCT01073943|DRUG|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
224098506|NCT01073943|DRUG|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
224098507|NCT01073943|DRUG|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
224098508|NCT03668132|OTHER|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
223534406|NCT07150403|DRUG|FRUQUINTINIB|5 mg capsule, taken orally, once daily for 3 weeks, followed by a 7-day break, then resumed (Day 1= Day 29).
223534407|NCT07150403|DRUG|BEVACIZUMAB|5 mg/kg over 90 minutes for the 1st course and in case of good tolerance the 2nd course should be administered over 60 minutes. The next courses should be administered in 30 minutes in case of good tolerance during the 2nd course
223937569|NCT05127057|OTHER|Usual Care|Usual NHS Care
224098509|NCT05412706|DRUG|Niraparib|"Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles."
224098510|NCT03823664|DIAGNOSTIC_TEST|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
224098511|NCT01571492|PROCEDURE|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
224098512|NCT01571492|PROCEDURE|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
224098513|NCT01126229|DIETARY_SUPPLEMENT|Placebo|2 capsules of placebo daily for 12 weeks
224286687|NCT02855619|PROCEDURE|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
224286688|NCT02855619|PROCEDURE|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
224286689|NCT02855619|PROCEDURE|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2\<150)."
224286690|NCT05842304|DEVICE|active cTBS|Each patient will receive three 600-pulse cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
224286691|NCT05842304|DEVICE|sham cTBS|Each patient will receive three 600-pulse sham cTBS stimulations per day, parted by two 15-minute rest periods (a total of 1800 pulses daily), for 21 consecutive days (3 weeks).
223937570|NCT05845970|OTHER|Pamprin Botanicals|Participants will take Pamprin Botanicals only. Participants will take 450mg of Pamprin Botanicals two days before their predicted period and then take it every day during their period. Participants can also take Pamprin Botanicals two days after the bleeding has concluded.
223937571|NCT05845970|COMBINATION_PRODUCT|Pamprin Botanicals + Pamprin Menstrual Pain Relief|Participants will repeat taking Pamprin Botanicals two days before their second predicted period and continue to take it each day during their period. However, during the second period, participants will also take Pamprin Menstrual Pain Relief per the over-the-counter directions (2 tablets every 6 hours with water).
223937572|NCT02677766|OTHER|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
224098514|NCT01126229|DRUG|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
224098515|NCT01126229|DRUG|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
224098516|NCT03016611|DRUG|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
224098517|NCT03016611|DRUG|Chewing Prasugrel LD|60 mg Chewing Prasugrel
223534408|NCT07149974|DEVICE|EEG and fNIRS|For EEG and fNIRS, EEG signals will be recorded using the ANT Neuro eego rt 8 amplifier device (ANT Neuro, Hengelo, The Netherlands), with electrodes placed at C3, C4, F3, F4, Fpz, M1, M2, and GND (ground). fNIRS signals will be recorded using the Artinis Brite Lite fNIRS device(Artinis Medical Systems, The Netherlands). The overall channel configuration consists of eight sources and four detectors. Among these, four sources (T2a-d) and four detectors (R1-4) form four short-separation channels, while the remaining four sources and four detectors constitute six long-separation channels (T1-R1, T3-R1, T3-R2, T4-R3, T5-R3, T5-R4). The overall configuration is approximately arranged in two L-shaped layouts surrounding the F3 and F4 regions.
223534409|NCT07149974|DEVICE|EEG|EEG signals will be recorded using the ANT Neuro eego rt 8 amplifier device (ANT Neuro, Hengelo, The Netherlands), with electrodes placed at C3, C4, F3, F4, Fpz, M1, M2, and GND (ground).
223937573|NCT02677766|OTHER|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
223937574|NCT05346588|OTHER|Anesthetic technique Propofol TIVA|Propofol TIVA no inhaled agent
223937575|NCT05346588|OTHER|Anesthetic technique inhaled agent|must administer inhaled agent.
224098518|NCT04874272|OTHER|Chaplain led post-code debrief|an emotional debrief (a discussion to process the emotional, existential impact of a medical code/cardiopulmonary arrest), which will be led by a chaplain
224098519|NCT03116880|PROCEDURE|Endovascular aortic repair|Endovascular aortic repair
224098520|NCT05445193|BEHAVIORAL|PEaters Choice Module|There will be nine sessions conducted throughout the intervention period, which include module activity, assessment sessions and follow-up sessions. This module will have four primary sub modules (SM): SM1- An overview of picky eaters, SM2-Healthy eating for children, SM3-Parental Strategies and SM4- Sensory perception.
224098521|NCT03202654|OTHER|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
224098522|NCT03202654|OTHER|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
224098523|NCT00001923|PROCEDURE|Transcranial magnetic stimulation|
224098524|NCT00710190|DEVICE|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
224098525|NCT00824421|DRUG|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
224098526|NCT00824421|DRUG|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
224098527|NCT00824421|DRUG|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
224286692|NCT01797926|DRUG|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
223937576|NCT05141968|DIETARY_SUPPLEMENT|vitamin D supplements (2000 IU/day)|The interventional (experimental) group received vitamin D supplements (2000 IU/day). According to previous studies and after the direct supervision from the treating pediatrician and endocrinologist, the best preparation and dosage of vitamin D was used (According to FDA the recommended dose for children age 1 year and older is 2,000 IU/day).
223937577|NCT02824926|DRUG|Dapaconazole|
223937578|NCT02824926|DRUG|Ketoconazole|
223937579|NCT05121636|DEVICE|MetaFix Collared Stem|Patients received the MetaFix Collared stem during there Total Hip Arthroplasty
223937580|NCT05224024|PROCEDURE|Retzius-repairing robot-assisted radical prostatectomy|Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
223937581|NCT04828096|OTHER|Orthodontic retention|The stability of the mandibular anterior teeth after two resp. 5 years of retention
223937582|NCT05877872|PROCEDURE|Reduced-target resection|Patients receive surgery according to pSTV-post-IC.
223937583|NCT05877872|PROCEDURE|Full-target resection|Patients receive surgery according to pSTV-pre-IC.
223937584|NCT05877872|DRUG|Adjuvant immunotherapy|Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
223937585|NCT00238485|DRUG|Licarbazepine|
223937586|NCT03021512|PROCEDURE|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
223937587|NCT03021512|PROCEDURE|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
224098528|NCT04820270|OTHER|Autologous T regulatory cells|Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation
224098529|NCT06292481|OTHER|Brunnstorm movement therapy|this group received Brunnstorm Movement therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
224098530|NCT06292481|OTHER|Combined Brunnstorm Movement therapy and low level laser therapy|this group received Combined Brunnstorm Movement therapy and low level laser therapy for 3 to 5 sessions per week, each lasting approximately 30 to 60 minutes for 6 weeks
224098531|NCT05495607|DEVICE|CARPEDIEN|Continuous renal replacement therapy
224098532|NCT02704104|DEVICE|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
224098533|NCT01027689|DRUG|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
224098534|NCT01027689|DRUG|alprazolam test sublingual tablet|1 mg tablet, single dose
224098535|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
224286693|NCT01797926|DRUG|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
224286694|NCT01797926|DRUG|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
224286695|NCT01797926|DRUG|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
224286696|NCT04663438|DRUG|Chemotherapy Drugs, Cancer|Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
224286697|NCT06077734|OTHER|In vitro analyse|In vitro analysis on isolated mesoangioblasts obtained from muscle biopsies
223937588|NCT01480375|DEVICE|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
223718764|NCT05214456|OTHER|Dry needling|The method of performing the dry needling technique will be based on the method presented by Dommerholt and Fernandez-de-las-Penas. The length of the needle (Tony, china) for each patient will be selected based on the size of the patient: 1) Multifidus: the patient will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. The needles will be inserted into the lumbar multifidus muscles, 1.5 to 2 cm lateral to the spinous process of all lumbar vertebrates, perpendicular to the lamina (after piercing the skin, needles are directed inferomedially). 2) Quadratus lumborum: The patient will be placed in the side lying position with the side to be treated facing up. After identifying the lateral border of the quadratus lumborum muscle, the needle will be aimed straight downward in the direction of the transverse process, followed by slight anterior, posterior, and caudal needling to explore the entire muscle.
223937589|NCT02031185|BEHAVIORAL|FitBit only|Participants will use the FitBit device
224098536|NCT00983775|DEVICE|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
223937590|NCT02031185|BEHAVIORAL|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
224098537|NCT04046302|DRUG|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
224098538|NCT04046302|DRUG|placebo|one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
224098539|NCT04407377|DRUG|Tolperisone Hydrochloride|Study Drug
224098540|NCT04407377|DRUG|Cyclobenzaprine Hydrochloride 10 MG|Active Comparator
224098541|NCT04407377|OTHER|Placebo|Placebo Comparator
224098542|NCT03205969|DEVICE|Functional mobile game|Functional mobile game for chemotherapy side effect education
224286698|NCT03333499|DRUG|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
224286699|NCT03333499|DRUG|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
224286700|NCT03333499|DRUG|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
224286701|NCT03333499|DRUG|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
224286702|NCT04424849|DIAGNOSTIC_TEST|CT-Scan|Chest CT scan on admission to the intensive care unit
224286703|NCT01771315|BEHAVIORAL|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
224286704|NCT02667678|BIOLOGICAL|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
224286705|NCT00384488|BEHAVIORAL|Interactive Voice Response System (IVR)|
224286706|NCT00385788|DRUG|Gemcitabine|800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)
224286707|NCT00385788|DRUG|Fludarabine|33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)
223937591|NCT01697683|DRUG|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
223937592|NCT01697683|DRUG|Placebo|
223937593|NCT04618250|OTHER|SOFIA model|A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
223937594|NCT06509165|PROCEDURE|Modified coronally advanced flap technique|Subepithelial connective tissue graft was applied to the relevant areas with a modified coronally placed flap technique to cover the gingival recession.
223937595|NCT06509165|PROCEDURE|Tunnel technique|Subepithelial connective tissue graft was applied to the relevant areas with the tunnel technique to cover the gingival recession.
223937596|NCT01935375|BEHAVIORAL|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
223937597|NCT01935375|BEHAVIORAL|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
223937598|NCT04589975|PROCEDURE|laparoscopic surgery|
223937599|NCT02103166|DRUG|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
224098543|NCT04871815|DRUG|sodium pyruvate nasal spray|Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
224098544|NCT05344547|DIAGNOSTIC_TEST|Cardiac risk ratio (CRR)|Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
224098545|NCT03839602|RADIATION|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
224098546|NCT01906840|DRUG|Turmeric|
224098547|NCT01906840|DRUG|placebo|
224098548|NCT00125333|DRUG|NF-kappaB Decoy|
224286708|NCT00385788|DRUG|Melphalan|70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
224286709|NCT00385788|DRUG|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
224286710|NCT00385788|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
224286711|NCT00385788|DRUG|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
224098549|NCT02195843|OTHER|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
223937600|NCT02103166|DRUG|Physiological serum|100 ml of physiological serum (0.9% NaCl).
223937601|NCT02903875|OTHER|Patient therapeutic education (PTE) programme|
223937602|NCT03136172|DEVICE|NIRS (near Infra-red spectroscopy)|"1. NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~2. Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~3. Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
223937603|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
223937604|NCT00743574|DRUG|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
224098550|NCT02195843|OTHER|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
224098551|NCT02195843|DEVICE|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
224098552|NCT04339504|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
224098553|NCT04339504|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
224098554|NCT04339504|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
224098555|NCT00138840|DRUG|STA-5326 mesylate|
224098556|NCT02605577|PROCEDURE|new systemic nutrition management protocol|a new established systemic nutrition management protocol
224098557|NCT03844438|DRUG|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
224098558|NCT03906877|PROCEDURE|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
224098559|NCT03906877|BEHAVIORAL|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
224098560|NCT03906877|OTHER|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
224098561|NCT03906877|OTHER|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
224286712|NCT00385788|DRUG|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
224286713|NCT00385788|DRUG|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
223937605|NCT00743574|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
223937606|NCT00743574|DIETARY_SUPPLEMENT|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
223937607|NCT00980213|DRUG|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
223937608|NCT02138994|DEVICE|Next Science Wound Gel|
223937609|NCT02138994|DRUG|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~* Subject may continue the application of Neosporin until wound closure or~* Subject may cross over to the treatment group for 3 months"
223937610|NCT02897206|DRUG|Imipenem|A wide-spectre antibiotic from the carbapenem group
223937611|NCT02897206|DRUG|Placebo|An imipenem-matching placebo
223937612|NCT02803749|DRUG|Buspirone|
223937613|NCT02803749|DRUG|Placebo|
223937614|NCT01329406|DRUG|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
223937615|NCT01329406|DRUG|Placebo|1 tablet by mouth twice daily for 28 days
223937616|NCT01458600|DRUG|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
223937617|NCT01458600|DRUG|Methimazole|T Methimazole 5 mg 3x2 for 18 months
223937618|NCT01458600|DRUG|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
223937619|NCT01458600|DRUG|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
223937620|NCT01458600|DRUG|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
223937621|NCT01507506|RADIATION|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~\+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
223937622|NCT01507506|RADIATION|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA\> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~\+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~* during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~* post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
223937623|NCT03908606|PROCEDURE|Scaling and root planing|Supra and subgingival scaling and root planing.
223937624|NCT00232375|DRUG|Insulin|
223937625|NCT00369902|PROCEDURE|acupuncture|
223937626|NCT03842332|BEHAVIORAL|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
223937627|NCT00371345|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months)
223937628|NCT00371345|DRUG|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)
223937629|NCT03529305|DEVICE|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
223937630|NCT03529305|OTHER|Physical therapy|Receive physical therapy
223937631|NCT05421117|PROCEDURE|Laparoscopic adnexal mass extraction|Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
224286714|NCT06471309|DEVICE|Theta burst transcranial magnetic stimulation|The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
224286715|NCT04684693|DEVICE|Laser|Laser puncture and exercise
224286716|NCT04684693|PROCEDURE|Control|Exercise
224286717|NCT06598293|BEHAVIORAL|PRO-CTCAE, Pain NRS|The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
224286718|NCT02555293|DRUG|XIFAXAN® (Rifaximin)|
224286719|NCT06403683|DIAGNOSTIC_TEST|WaLIDD score / Insomnia Severity Index (ISI) / International Physical Activity Questionnaire (Short-form) / Six-Minute Walk Test|Case control trial study
224286720|NCT01013428|OTHER|Ultrasound|Ultrasound will be used to evaluate tendons.
224286721|NCT01747382|PROCEDURE|Renal denervation|
224286722|NCT01443377|BIOLOGICAL|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
224286723|NCT04281394|DEVICE|Robot assisted gait training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT group received RAGT 5 sessions per week at duration 30 minutes with 30 minutes conventional physical therapy in 12 weeks.
224286724|NCT04281394|OTHER|conventional gait training|even level gait training and range of motion exercises
223937632|NCT03204032|DRUG|Tegafur|Tegafur 40-60mg po bid(d1-d14);
223937633|NCT03204032|DRUG|Temozolomide|200mg po qd(d10-d14)
223937634|NCT03204032|DRUG|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
223937635|NCT05969899|DRUG|FOLFIRI+Bevacizumab|irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
223937636|NCT04526951|DRUG|Intravenous injection of Tenecteplase and one dose of placebo tablet|Drug: Tenecteplase Tenecteplase administered as an intravenous injection (0.25 mg/kg body weigh; maximum 25 mg)
223937637|NCT04526951|DRUG|One tablet of Acetylsalicylic Acid and one dose of IV placebo|300 mg Acetylsalisylic acid
223937638|NCT04819698|OTHER|Troponin I (cTnI ) monitoring|cTnI will be measured at baseline prior to surgery, as well as on 1h,12h, 24h and 72h after surgery for each patient in study B.
223937639|NCT05316259|DRUG|BPI-16350|Administered orally
223937640|NCT01664741|DRUG|Nicotine patch - transdermal|21 mg patch
223937641|NCT01664741|DRUG|placebo|
223937642|NCT04535856|DRUG|allogeneic mesenchymal stem cell|"Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)"
223937643|NCT04535856|OTHER|Placebo|Control group (placebo)
223937644|NCT02448069|DRUG|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
223718765|NCT05214456|OTHER|Mobilization|To perform Maitland's mobilization for lumbar spine, the anterior-posterior mobilization technique will be used and it is performed by pushing the heel (pisiform grip) or thumbs (thumb grip) to the vertebrae and can immediately reduce pain and restore motor function. First, the complete physical orthopedic evaluation of manual therapies will be performed using the Maitland evaluation method. Then, based on the findings of the patient evaluation, the severity, rhythm, duration and the degree of the mobilization and the place of force (spine or lamina) will be determined. To apply mobilization, the person will sleep in a prone position and the physiotherapist will use the heel of the hand or the thumbs to apply force to the first to fifth vertebrae of the lumbar spine. In segments that do not have a problem based on evaluation, first grade of the anterior-posterior Maitland's mobilization will be applied to the spinous process of the segment.
223937645|NCT05132049|DRUG|DA-5211|single dose administration (DA-5211 one tablet once a day)
223937646|NCT05132049|DRUG|DA-5211-R1 + DA-5211-R2|single dose administration (DA-5211-R1 one tablet once a day + DA-5211-R2 one tablet once a day)
223937647|NCT03212885|DEVICE|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
223937648|NCT05211232|DRUG|Tislelizumab|GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
223937649|NCT05211232|DRUG|Placebo|GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
223937650|NCT01809457|OTHER|educational poster|educational poster for dental trauma
223937651|NCT05511545|OTHER|Patient Education Booklet|Excretory system organs, signs and symptoms to be seen in kidney and ureteral stones, treatment methods, ureteroscopy procedure, what to do before and on the morning of surgery, and surgery, using the training booklet prepared by the researchers in line with the recommendations of the European Association of Urology and the relevant literature. An average of 25-30 minutes of training was given in the patient's room in an encouraging language, allowing the patient to ask questions about the situations he would encounter in the clinic after the surgery. She started asking questions she didn't understand. Afterwards, the questions of the patients were answered and the patient was given a training booklet.
223937652|NCT04243200|OTHER|Hypos can strike twice|"The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover."
223937653|NCT02180815|DEVICE|ReVENT Sleep Apnea System|
223937654|NCT06000800|OTHER|Group B|Umbilical cord clamping at 30 seconds
223937655|NCT06000800|OTHER|Group C|Umbilical cord clamping at 60 seconds
223937656|NCT06000800|OTHER|Group D|Umbilical cord clamping at 90 seconds
223937657|NCT06000800|OTHER|Group A|Umbilical cord clamping immediately after birth (5 second)
223937658|NCT01171638|DEVICE|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
223937659|NCT04433780|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC
223937660|NCT01026805|DEVICE|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
223937661|NCT05168397|OTHER|RV4857A|RV4857A formula CD2110 is a sunscreen product
223718766|NCT00993083|BIOLOGICAL|MVA-NP+M1|Intramuscular injection at 1.5 x 10\^8 pfu/ml at day 0
223718767|NCT05343845|OTHER|Observational study|After approval of the institution's ethics committee, 100 patients will be divided in two groups as pregnant women who did not smoke during pregnancy and pregnant women who smoked 5 or more cigarettes in a day. The local anesthetic, which dose will adjusted according to height and weight, and 20 µg fentanyl will be administered intrathecally to both groups. Results on the effectiveness of spinal anesthesia will be monitored.
223937662|NCT00442104|DRUG|Ganaxolone|
223937663|NCT01131546|DRUG|Levamlodipine besylate|Once daily, 7AM - 10AM
223937664|NCT01131546|DRUG|Amlodipine maleate|Once daily, 7AM - 10AM
223937665|NCT00236847|DRUG|topiramate|
224098562|NCT05990530|BIOLOGICAL|YD02-2022|Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.
224098563|NCT02112110|DRUG|BMS-791325|
224098564|NCT02112110|DRUG|[13C]-BMS-791325|
224098565|NCT04169477|DEVICE|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~\[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
223937666|NCT05991804|OTHER|Transcutaneous spinal cord stimulation added to inpatient rehabilitation|Non-invasive electrical stimulation delivered over the spine, targetting movement of the upper limbs
223937667|NCT05991804|OTHER|Inpatient rehabilitation alone|Standard inpatient rehabilitation given at the Royal National Orthopaedic Hospital NHS Trust
223937668|NCT04905784|BEHAVIORAL|Differential learning|The patient will be requested to perform different exercises, each exercise one time a day for 3 days in a row before moving to the next exercise. All patient will be asked to do the exercises in the same sequence.
223937669|NCT04905784|BEHAVIORAL|Usual toothbrushing|The patients in this group will be provided with the regular oral health instructions, including the traditional toothbrushing recommendations.
223534410|NCT07149974|DEVICE|fNIRS|fNIRS signals will be recorded using the Artinis Brite Lite fNIRS device(Artinis Medical Systems, The Netherlands). The overall channel configuration consists of eight sources and four detectors. Among these, four sources (T2a-d) and four detectors (R1-4) form four short-separation channels, while the remaining four sources and four detectors constitute six long-separation channels (T1-R1, T3-R1, T3-R2, T4-R3, T5-R3, T5-R4). The overall configuration is approximately arranged in two L-shaped layouts surrounding the F3 and F4 regions.
223937670|NCT06465550|GENETIC|BD211|Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.
223937671|NCT03936166|DRUG|CRN01941 Oral Solution|Investigational drug
223937672|NCT03936166|DRUG|CRN01941 Oral Capsule|Investigational drug
223937673|NCT03936166|DRUG|Placebo Oral Solution|Placebo
223937674|NCT03936166|DRUG|Placebo Oral Capsule|Placebo
223937675|NCT06415994|DRUG|Buprenorphine or Methadone Treatment|Pregnant mothers must be taking Buprenorphine or Methadone
223937676|NCT06415994|DIAGNOSTIC_TEST|Fetal and Placental MRI|"Two MRIs :~* Second Trimester~* Third Trimester"
223937677|NCT06415994|BEHAVIORAL|Child Developmental Assessment|At 1 year of life child will receive a developmental assessment
223937678|NCT06415994|BEHAVIORAL|Questionnaires|Participants will answer questionnaires on their medical history, pregnancy, substance use, and after birth: their child's development
223937679|NCT06415994|OTHER|Blood and Placental Samples|"At each MRI visit a blood sample will be collected for substances, DNA, RNA, epigenetics, and placental biomarkers.~At delivery: A sample of placenta will be collected for RNA, DNA, and epigenetic analysis."
223937680|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
223937681|NCT01529944|DRUG|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
224098566|NCT03830281|DRUG|Ultra-Rapid Lispro|Administered SC
223937682|NCT06835920|BEHAVIORAL|Front-of-package health warning|Participants will receive 3 different health warnings about alcohol consumption. The warnings will discuss health risks of alcohol including cancer, high blood pressure, and scarring of the liver. Labels will be placed on the front of participants' alcohol containers.
223937683|NCT06835920|BEHAVIORAL|Control label|Participants will receive a label displaying a barcode. Labels will be placed on the front of participants' alcohol containers.
223937684|NCT00686465|OTHER|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
223937685|NCT04516226|OTHER|Vaginal cleansing with chlorhexidine gluconate solution|Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
223718768|NCT02446483|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
223937686|NCT02432066|DRUG|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
223937687|NCT02432066|DRUG|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
223937688|NCT04178421|OTHER|Computerized training program|Eye-gaze fixation computer based training program
223718769|NCT02446483|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
223718770|NCT04968301|DEVICE|ultrasound Doppler|A cross-sectional study:the development of the hip joint was studied by measuring the anatomical circumference of the capsular muscle of the iliac joint with ultrasound Doppler
223937689|NCT04178421|OTHER|Placebo|Pac-Man, Zookeeper, Tetris
223937690|NCT03884842|BIOLOGICAL|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
223937691|NCT03884842|BIOLOGICAL|Placebo|Matched placebo
223937692|NCT01478594|DRUG|Tivozanib|Capsules for oral administration
224098567|NCT03830281|DRUG|Insulin Lispro|Administered SC
224098568|NCT00594399|BEHAVIORAL|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
224286725|NCT03224247|PROCEDURE|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
224286726|NCT03224247|PROCEDURE|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
223937693|NCT01478594|DRUG|Bevacizumab|Solution for intravenous infusion
223937694|NCT01478594|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
223937695|NCT00830856|DRUG|Fluconazole|Fluconazole 800mg po qday
223937696|NCT00830856|DRUG|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
224098569|NCT03304808|DEVICE|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
224098570|NCT03304808|BEHAVIORAL|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~1. Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~2. Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~3. Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~4. Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
223534411|NCT07149610|DEVICE|M-health solution classified as Class I Medical Devices, equipped with a CE certificate. The m-health solution will be integrated with the EPR currently used by the CADs of the Marche region|"The m-health solution used in the study includes the following interfaces:~1. for the HCPs of the CADs:~   * a section of the EPR currently used (Metaclinic), to set the mobile application and to collect clinical data recorded by the patients;~  * a software to develop and monitor personalised diets (MetaDieta);~2. for the patients: two mobile applications, one for the monitoring of the clinical data and life style (DiaWatch Meteda) and one for the monitoring of the diet (MyDiet), with the latter accessible from a 'button' included in the first one.~The HCPs of the CADs, already having access to the EPR Metaclinic, will access a dedicated section for the setting of the target values and goals (e.g., glycaemia, physical activity, etc.) and for the activation of the app DiaWatch Meteda. After the connection of the app with Metaclinic, the data registered in the apps by the patients will be visible by the HCPs in the EPR dashboard."
223534412|NCT07155161|OTHER|Assesment|assessment
223534413|NCT07159542|BEHAVIORAL|listening intervention|Music or podcast listening intervention
223534414|NCT07159542|BEHAVIORAL|Neuropsychology assessment|Neuropsychology assessment
223534415|NCT07159542|OTHER|brain imaging examination|EEG: recording of neural dynamic
223534416|NCT07159087|DEVICE|Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB)|Drug Coated Balloon
223718771|NCT03802669|OTHER|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
223937697|NCT00830856|DRUG|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
223937698|NCT05080998|DIAGNOSTIC_TEST|CxBladder Monitor/Monitor+|CxBladder Monitor/Monitor+ is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
223937699|NCT03268135|DIAGNOSTIC_TEST|measurement of RNAs|
223937700|NCT03044652|DEVICE|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
223937701|NCT03044652|DRUG|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
223937702|NCT02142309|DRUG|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
223937703|NCT02142309|DRUG|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) \<45 mL/min
223937704|NCT02142309|DRUG|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
223534417|NCT07159087|DEVICE|Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)|Drug Coated Balloon
223718772|NCT01658072|PROCEDURE|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
223718773|NCT01658072|PROCEDURE|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
223718774|NCT03910062|PROCEDURE|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
223718775|NCT05758298|OTHER|Non-medicated gum|Non-medicated, regular chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
223718776|NCT05758298|DRUG|NICOTINE 2MG GUM|Nicotine 2mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
223718777|NCT05758298|DRUG|NICOTINE 4MG GUM|Nicotine 4mg chewing gum in mint flavor (6 pieces of gum per day given, but used as needed).
223937705|NCT02142309|DRUG|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
223937706|NCT02747537|DRUG|Sorafenib|
223937707|NCT02747537|DRUG|Irinotecan|
223937708|NCT01857076|PROCEDURE|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
223937709|NCT01857076|PROCEDURE|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
223937710|NCT01857076|OTHER|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
223937711|NCT06834282|DRUG|CER-1236|an autologous chimeric engulfment receptor T-cell
223937712|NCT06834282|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223937713|NCT06834282|DRUG|Fludarabine|Lymphodepleting chemotherapy
223937714|NCT06834282|DRUG|Mesna|Chemoprotectant
223937715|NCT02530892|PROCEDURE|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
223937716|NCT02576691|DEVICE|percutaneous coronary intervention|
223937717|NCT00713596|DRUG|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
224098571|NCT00761111|BEHAVIORAL|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
224098572|NCT04910750|DEVICE|Pulse oximetry|Pulse oximeters are a non-invasive, accurate and easy to use method of evaluating blood oxygen saturation
224098573|NCT04910750|DEVICE|Clinical Decision Support Algorithm|Tablet-based clinical decision support algorithms, based on guidelines for the assessment and management of sick children under 5 years of age at primary care
224098574|NCT01018407|BEHAVIORAL|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
224098575|NCT01018407|BEHAVIORAL|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
224098576|NCT01965925|DRUG|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
224098577|NCT01965925|DRUG|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
224098578|NCT02226068|DRUG|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
224098579|NCT02226068|OTHER|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
224286727|NCT03416491|DRUG|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
223534418|NCT07161232|BEHAVIORAL|Standardized Postoperative Rehabilitation Protocol|"This intervention is a standardized, progressive rehabilitation protocol for patients after lumbar disc herniation surgery, delivered under the guidance of a senior physical therapist. The protocol aims to improve pain, restore function, and prevent complications through core stability exercises and neurodynamic techniques. The exercises are performed once daily and progressed based on patient tolerance. The protocol consists of two phases:~Initial Phase ( commencing postoperatively): Includes: 1) Transverse abdominis activation; 2) Sit-to-stand training with abdominal bracing; 3) Four-point kneeling rockbacks for spinal mobility; 4) Neural mobilization techniques (performed in sitting); 5) Neural sliding techniques (performed in sitting).~Progressive Phase: Builds upon the initial exercises by increasing the range of motion, adding isometric hold times, and integrating cervical movement with neural techniques to increase difficulty and intensity."
224286728|NCT03416491|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
224286729|NCT06329791|DRUG|AZR-MD-001|AZR-MD-001 sterile ophthalmic ointment 0.5%
224286730|NCT06329791|OTHER|Vehicle|AZR-MD-001 Vehicle
224286731|NCT06525272|DRUG|Recombinant Human Chymotrypsin(OsrhCT)|Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.
223937718|NCT00713596|PROCEDURE|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
223937719|NCT00713596|PROCEDURE|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
223937720|NCT00713596|PROCEDURE|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
223937721|NCT00713596|OTHER|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
223937722|NCT04275583|DRUG|TQB3602|This is a kind of proteasome inhibitor.
223937723|NCT06158672|BEHAVIORAL|Emotional freedom technique group|Menopausal women in the emotional freedom technique group will be administered the emotional freedom technique by the researcher a total of 4 times at one week intervals.
223937724|NCT06158672|BEHAVIORAL|Sham emotional freedom technique group|Menopausal women in the sham emotional freedom technique group will be administered sham emotional freedom technique by the researcher a total of 4 times with one week intervals.
223534419|NCT07159672|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy (classic Whipple or pylorus-preserving) performed as part of standard clinical care for patients with periampullary malignant neoplasms. This procedure is not assigned by the study protocol, but is the exposure of interest. The study observes nutritional, metabolic, molecular, and imaging outcomes at baseline (preoperative), and at 3 and 6 months after hospital discharge.
223937725|NCT05555095|BEHAVIORAL|digital health delivered multicomponent intervention|The MIC program will have set minimum levels of connectivity for each of the three defined conditions under study.
223937726|NCT01642719|BEHAVIORAL|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
223937727|NCT01642719|BEHAVIORAL|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
223937728|NCT05340738|OTHER|LyssnCBT|LyssnCBT is a technology that allows therapists and supervisors access to tools that assist with assessing CBT session fidelity, including speech-to-text transcription, annotation tools, and AI-generated metrics.
223937729|NCT06149299|PROCEDURE|Greater occipital nerve block|Greater occipital nerve block using ultrasound guidance
223937730|NCT04545619|DEVICE|QDOT MICRO System|QDOT Micro Catheter with nGEN Generator
223937731|NCT03578978|OTHER|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
223937732|NCT05518214|DIETARY_SUPPLEMENT|Beetroot|Participants receive a 12-week supply of beetroot juice.
224098580|NCT04265612|PROCEDURE|"Pico® negative pressure dressing"|"Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed"
224098581|NCT04265612|PROCEDURE|"Aquacel Surgical® hydrogel dressing"|"Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed."
224098582|NCT06231043|DRUG|Diclofenac/Tramadol|"Arm Drug1 :Diclofenac 75 mg (3 ml) IM injection by doctor, then followed by normal saline 20 ml IV injection (equal to Tramadol diluted) by nurse.~Arm Drug2 :Normal saline 3 ml IM injection by doctor (equal to Diclofenac 75 mg), then followed by Tramadol 50 mg (1 ml) dilute with normal saline 19 ml (total 20 ml )IV injection by nurse."
224098583|NCT02362373|DRUG|levonorgestrel IUS|placement of levonorgestrel intrauterine system
224098584|NCT00659438|DRUG|ZD6474 (Vandetanib)|300mg orally, once daily
224098585|NCT00659438|DRUG|Bicalutamide|150mg orally, once daily
224098586|NCT00659438|DRUG|Placebo|orally, once daily
224098587|NCT01462513|BIOLOGICAL|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
224098588|NCT01462513|BIOLOGICAL|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
224098589|NCT02126488|BEHAVIORAL|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
224098590|NCT02126488|BEHAVIORAL|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
224098591|NCT02126488|BEHAVIORAL|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
224098592|NCT05712668|BEHAVIORAL|Preoperative counseling|Providers will review the diagnosis, surgical planning, risks/benefits/alternatives to surgery, post-operative care, and long term scope of care.
224098593|NCT05712668|BEHAVIORAL|Asynchronous telemedicine|An asynchronous video will be delivered by Mytonomy. This platform allows investigators to track user analytics relating to the time, frequency, or duration watched by the user.
224098594|NCT06423417|BEHAVIORAL|LifeHack|See arm description
224098595|NCT00013052|BEHAVIORAL|Peer led classes. Led by trained veterans with a chronic disease.|
224098596|NCT04438135|OTHER|Repeated open application test|parallel application of two different types of lotion with and without aluminium.
224098597|NCT05597748|DEVICE|Modified Herbst Approach|A modified hybrid Herbst appliance approach (same hybrid Herbst appliance approach but with the addition of temporary anchorage devices (TADs) in both arches) will be used (alternative treatment). In the upper arch, the TADs would be inserted in the paramedical palatal area. In the lower arch, they would be inserted buccally between the roots of the lower second premolar and the first permanent molar. Elastomeric chains will be used to link these TADs to the first molars in the upper arch and to a buccal bottom on the lower canines. Upper brackets will be initially bonded and upper incisors proclined until normal inclination values are attained.
224098598|NCT05597748|DEVICE|Conventional Herbst Approach|A hybrid Herbst appliance approach will be used (current available conventional treatment). The upper jaw component will be a maxillary expander secured on the first molar bands. The lower arch would have an uncemented lower acrylic full-coverage splint-type. In between Herbst-type pistons will be used.
224098599|NCT05112731|DIAGNOSTIC_TEST|BAFF and MGO|measurement of BAFF and MGO levels before reperfusion and after 3 months
224098600|NCT03192904|DEVICE|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
223937733|NCT05518214|DIETARY_SUPPLEMENT|Placebo|Participants receive a 12-week supply of placebo beetroot juice.
223937734|NCT02381028|OTHER|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
223937735|NCT02381028|OTHER|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
223937736|NCT00143286|DRUG|varenicline (CP-526,555)|
224098601|NCT03192904|DEVICE|Stapling Device|Stapling Device, including linear stapler and curved stapler.
224098602|NCT04045067|PROCEDURE|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
224098603|NCT04045067|PROCEDURE|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
224098604|NCT05607550|DRUG|furmonertinib 240 mg oral, daily|furmonertinib tablet
224098605|NCT05607550|DRUG|furmonertinib 160 mg oral, daily|furmonertinib tablet
223937737|NCT04660812|DRUG|AB680|AB680 is a cluster of differentiated CD73 Inhibitor
223937738|NCT04660812|DRUG|Etrumadenant|Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist
223937739|NCT04660812|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
223937740|NCT04660812|DRUG|Bevacizumab|Bevacizumab is administered as part of standard chemotherapy regimen
224098606|NCT05607550|DRUG|platinum-based chemotherapy|(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)
223937741|NCT04660812|DRUG|m-FOLFOX-6 regimen|mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen
223937742|NCT04660812|DRUG|Regorafenib|Regorafenib is administered as part of standard chemotherapy regimen
223937743|NCT02011360|OTHER|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
223937744|NCT02011360|OTHER|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
223937745|NCT02798653|DRUG|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
223937746|NCT02798653|DRUG|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
223937747|NCT02798653|DRUG|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
223937748|NCT06850792|BEHAVIORAL|Telemedicine-Based Adherence Support|The intervention consists of biweekly teleconsultations for six months, conducted by healthcare professionals, focusing on medication adherence, patient education, side effect management, and remote support for individuals with pulmonary arterial hypertension (PAH). Patients will receive structured guidance on treatment adherence, tailored counseling, and real-time problem-solving strategies. The goal is to improve adherence to oral PAH therapy and enhance clinical outcomes compared to standard care.
223937749|NCT06849687|DEVICE|Whole body vibration|Participants will be asked to sit on an chair without armrests close to the platform and will be asked to perform 90° shoulder flexion, bend both elbows slightly, flex the trunk forwards and place both hands on the platform.
223937750|NCT06849687|DEVICE|Sham Whole body vibration|Participants will receive the vibration with the device turned off.
223937751|NCT06849687|OTHER|Strengthening exercises|Participants will use elastic resistance for the finger extension and flexion exercises, and ball to strength wrist flexors for two sets of 10 repetitions within a training session.
224098607|NCT04765137|DRUG|Atorvastatin Oral Tablet|Atorvastatin pill 40 mg to be taken every night
224098608|NCT03648164|OTHER|CHAT-CS Survey|Students will complete a computer-based survey
224098609|NCT02747914|DEVICE|Transcranial magnetic stimulation|TMS 1Hz under the motor zone of cortex.
224098610|NCT02747914|OTHER|Conventional exercise|Exercise will be administrated in a conventional way.
224098611|NCT03097380|DRUG|AZD2115|AZD2115
224098612|NCT03097380|DRUG|SPIRIVA|Tiotropium
224098613|NCT03097380|RADIATION|[11C]AZ13754366|Radioligand
223534420|NCT07160556|OTHER|Observational|no intervention was required for this cross sectional study
223534421|NCT07160842|BEHAVIORAL|Hand hygiene intervention|The educational intervention consisted of a two-part training session: (i) a thirty-minute didactic session introducing the 7-step alcohol-based hand rub (ABHR) technique (14), the importance of proper hand hygiene for infection prevention; and (ii) a practical component on hand hygiene with real-time feedback.
223534422|NCT07161375|DEVICE|Infrared Thermography|Infrared thermography will be used to predict the success of an erector spinae block by measuring the temperature difference between the blocked and unblocked sides.
223534423|NCT07160816|DRUG|Insulin icodec|Participants with T1D will be treated with commercially available insulin icodec.
223937752|NCT06125197|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
223937753|NCT06125197|BIOLOGICAL|KEYTRUDA®|pembrolizumab, a monoclonal antibody binding PD-1
223937754|NCT04885998|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
223937755|NCT04885998|DRUG|AMG 404|AMG 404 will be administered as an intravenous (IV) infusion.
223937756|NCT05230433|DIETARY_SUPPLEMENT|High-fat Challenge|The shake will be composed of a mixture of BOOST Glucose Control(R) (Nestlé Products) supplemented with palm oil. Each participant will consume a volume of liquid equivalent to 25% of their estimated daily caloric needs, calculated by the USDA Dietary Reference Intakes using a moderate activity factor.
224098614|NCT01309737|DRUG|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
224098615|NCT01309737|DRUG|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
223937757|NCT04680845|BEHAVIORAL|Self-affirmation|According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
223937758|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
223937759|NCT00987272|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
223937760|NCT00987272|DRUG|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
223937761|NCT00987272|DRUG|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
223937762|NCT03328364|DRUG|enzalutamide|oral
223937763|NCT03328364|DRUG|docetaxel|intravenous infusion
223937764|NCT05358249|DRUG|JDQ443|KRAS G12C inhibitor, oral
223937765|NCT05358249|DRUG|trametinib|MEK inhibitor, oral
223937766|NCT05358249|DRUG|Ribociclib|CDK4/6 inhibitor, oral
223937767|NCT05358249|BIOLOGICAL|cetuximab|EGFR inhibitor, intravenous
223937768|NCT03712371|DRUG|Chitosan|Increasing dose levels from 500mg twice daily to 2000mg twice daily for up to 85 days.
223937769|NCT02723929|DEVICE|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
223937770|NCT02723929|DEVICE|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
223937771|NCT06522568|BEHAVIORAL|MyMammogram|An online breast cancer screening decision aid
224098616|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
224098617|NCT01309737|DRUG|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
224098618|NCT01442181|PROCEDURE|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
224098619|NCT01442181|OTHER|Medical therapy|Patients are treated with rhythm and rate control medications.
224098620|NCT00539019|OTHER|calories measured 5x following wound healing|measure REE at various time points postburn
224098621|NCT01907165|DRUG|Temozolomide|
224098622|NCT01907165|DRUG|Disulfiram|
223534424|NCT07159412|DRUG|Vonoprazan-amoxicillin combined with Huazhi Rougan Granule|Vonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule
223937772|NCT06522568|OTHER|Provider communication|Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
223937773|NCT03636295|DRUG|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
223937774|NCT05995262|OTHER|Chart Review|Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
223937775|NCT06950749|PROCEDURE|Robotic Gloves assisted Task-oriented mirror therapy|"Robotic gloves assissted task-oriented Mirror therapy along with conventional therapy.~Conventional therapy consists of stretching exercises,active assisted and active ROMS of shoulder along with weight bearing and reaching activities.~Robotic gloves assisted task-oriented Mirror therapy will be delivered by syrebo robotic hand rehabilitation device.~it has different training modes including Mirror mode and task-oriented training.~5 sessions per week will be provided for 8 weeks exercises: 30 minutes (3 sets of 10 reps)~* In mirror training mode: Synchronized flexion and extension training with both hands."
223937776|NCT06950749|PROCEDURE|Task-Oriented Mirror Therapy|"Interventional group (B) will receive Task-Oriented Mirror Therapy along with conventional therapy.~To perform Task-Oriented Mirror Therapy both the extremities of the subject will be placed on the table and the mirror (40×60 cm) will be placed in the patients' mid-sagittal plane. Mirror will be placed in such a way that the reflection of the non-affected arm can be seen. The subjects will be instructed to perform the movement bilaterally. The movement on the impaired limb will be performed. Affected arm is involved in exercise therapy either through patients trying to move themselves or with a therapist in assisting movement.~5 sessions per week will be provided for 8 weeks.~* Task-Oriented Mirror therapy exercises: 30 minutes. (3 sets of 10 reps)~* Hand flexion and extension through the tennis ball.~* Grasping and releasing (cylindrical grasp, spherical grasp, hook grasp, pincer grasp)~* Task oriented activities: positioning the cup upright, carrying a woode"
224098623|NCT01907165|DIETARY_SUPPLEMENT|Copper gluconate|
224098624|NCT02150031|DRUG|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
224098625|NCT02150031|DRUG|1% Chlorhexidine|subgingival irrigation
224098626|NCT02150031|DRUG|1% Chlorhexidine|supragingival irrigation
224098627|NCT02150031|PROCEDURE|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
224098628|NCT02150031|DRUG|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
224098629|NCT02150031|PROCEDURE|Tooth extraction|dental extraction
224098630|NCT00882414|DRUG|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
224098631|NCT00882414|DRUG|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
223534425|NCT07159412|DRUG|Vonoprazan-amoxicillin combined with Huazhi Rougan Granule placebo|Vonoprazan-amoxicillin dual therapy combined with Huazhi Rougan Granule placebo
223937777|NCT04584658|DIAGNOSTIC_TEST|Fibreoptic Endoscopic Evaluation of Swallowing (FEES)|This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
223937778|NCT04584658|DIAGNOSTIC_TEST|Videofluoroscopy|A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
223937779|NCT04584658|OTHER|Dysphagia Handicap Index (DHI)|This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
223937780|NCT04584658|OTHER|Voice Symptom Scale (VoiSS)|This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
223937781|NCT04732000|DRUG|N-acetyl cysteine|Intravenous infusion started during the clinically indicated surgery at a rate of 50mg/kg over 1 hour followed by 50mg/kg over 3 hours. This will be an accumulated total of 100 mg/kg over 4 hours.
223937782|NCT04732000|OTHER|Normal Saline|Intravenous infusion at a time and rate to mimic the active treatment. The infusion will be given over 4 hours beginning during the clinically indicated surgery
223937783|NCT03431584|DRUG|infiltration of corticosteroids|infiltration of corticosteroids
224286732|NCT06525272|DRUG|Placebo for Recombinant Human Chymotrypsin(OsrhCT)|Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
223534426|NCT07161544|BIOLOGICAL|AAVB-039|Single subretinal administration
223937784|NCT03431584|DRUG|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
224098632|NCT00709202|DRUG|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
224098633|NCT00709202|DRUG|Placebo Oral Tablet|
224098634|NCT02903004|DRUG|Trabectedin|
224098635|NCT02903004|DRUG|Pegylated Liposomal Doxorubicin|
224098636|NCT02903004|DRUG|Topotecan|
224098637|NCT02903004|DRUG|Gemcitabine|
224098638|NCT02903004|DRUG|Weekly Paclitaxel|
224098639|NCT02903004|DRUG|Carboplatin|
224098640|NCT02184637|DRUG|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
224098641|NCT02184637|DRUG|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
224098642|NCT02184637|DRUG|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
224098643|NCT00989599|OTHER|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
224098644|NCT00989599|OTHER|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
224098645|NCT04558502|DRUG|Minocycline hydrochloride capsule|Antibiotic for H. pylori eradication
223534427|NCT07159516|DIAGNOSTIC_TEST|Diagnostic interview|SCID-5 Clinician Version (SCID-5-CV) was used as gold standard method for determining if diagnostic criteria of PTSD was met or not (First, 2023). SCID-5-CV has been validated for use via telephone with good results for PTSD (Osorio et al., 2019). Only the PTSD-chapter was used, and exclusively birth-related traumatic experiences were considered. This was done achieved by adding a question to the interview guide, addressing potentially traumatic experiences associated with healthcare during a physical examination, operation, intensive care or childbirth.
224098646|NCT04558502|DRUG|Clarithromycin|Antibiotic for H. pylori eradication
224098647|NCT04558502|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
224098648|NCT04558502|DRUG|colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
224098649|NCT04558502|DRUG|esomeprazole|Proton pump inhibitor
224286733|NCT06446466|DEVICE|PEMF ON-OFF|"In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session."
223718778|NCT06163729|DRUG|Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy|Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks
223718779|NCT00888862|DRUG|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
223718780|NCT01805154|DEVICE|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
223718781|NCT01874054|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
223937785|NCT05140226|BEHAVIORAL|Physical Training|Eight weeks of home-based physical exercise training. Aerobic training will be performed 5 times per week using a foot peddler for a minimum of 30 minutes at a moderate intensity (Borg Exertion Scale: between 4 and 6; pedaling speed: 50 RPM). Strength training will be performed 2 times per week, with 1-3 sets of 10-12 repetitions per exercise. Strength exercises will include training with resistance bands and bodyweight exercises. Participants will be instructed to reduce the intensity of their training if they reach a score of 7 on the Borg Exertion Scale, if oxygen saturation is less than 85%, or if they experience any symptoms. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials.
223937786|NCT05140226|BEHAVIORAL|Cognitive-Physical Training|Eight weeks of home-based cognitive and physical training. Cognitive training sessions will be performed 5 times per week using the Brain HQ platform (Posit Science; San Francisco, CA, USA) and will have a duration of approximately 60 minutes. The cognitive training program will be tailored by using the Personal Trainer function which presents an automated sequence of exercise levels to participants based on selected exercises. Participants will have identical sessions initially, but schedules will diverge as participants progress and as the algorithm considers their individual performance history. The Personal Trainer program will be customized to the abilities of each user and will include a focus on the following domains: sustained attention, executive function, short and long-term memory, and anxiety and depression. Participants in this group will also engage in the same exercise training intervention as participants in the Physical Training group.
223937787|NCT05154214|PROCEDURE|Adenotonsillectomy|Removal of tonsils and adenoids
223937788|NCT05154214|PROCEDURE|Drug-induced sleep endoscopy directed surgery|Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
223937789|NCT04111978|DRUG|Letrozole 2.5mg|Aromatase inhibitor
223937790|NCT04111978|OTHER|Placebo|Placebo tablet of Femara
223937791|NCT03039855|DEVICE|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
223937792|NCT06349317|COMBINATION_PRODUCT|Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib|"1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week;~2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle)."
223937793|NCT06132958|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg of sacituzumab tirumotecan by IV infusion
223718782|NCT01874054|DRUG|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
223718783|NCT03563976|OTHER|Retrospective Study|The medical charts are the subjects. The institutional charts will be identified by the use of definitive radiation therapy correlating with an early stage lung cancer diagnosis during the above time frame. The data from these charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number. These are all patients treated by all hospitals and clinics affiliated with UTSW and Parkland. At the time of study, some of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent. The NLST external dataset is proved by the NCI, with no identifying characteristics.
223718784|NCT01769989|PROCEDURE|Electrodermabrasion|
223718785|NCT01769989|PROCEDURE|Dermabrasion|
224286734|NCT06446466|DEVICE|PEMF OFF-ON|"In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session."
224286735|NCT03393416|BIOLOGICAL|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
223937794|NCT06132958|DRUG|Doxorubicin|60 mg/m\^2 of doxorubicin by IV Infusion
224286736|NCT03393416|DRUG|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
224286737|NCT00440466|DRUG|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
223937795|NCT06132958|DRUG|Paclitaxel|80 mg/m\^2 of paclitaxel by IV infusion
223937796|NCT06132958|DRUG|Nab-paclitaxel|100 mg/m\^2 of nab-paclitaxel by IV infusion
223937797|NCT04063215|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
223937798|NCT02788981|DRUG|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
223937799|NCT02788981|OTHER|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
223937800|NCT02788981|DRUG|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
223937801|NCT06022393|BEHAVIORAL|Cognitive Reappraisal|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.
223937802|NCT06022393|BEHAVIORAL|Reflection|Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
223937803|NCT04098393|DRUG|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
223937804|NCT04098393|DRUG|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
223937805|NCT04098393|DRUG|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
223937806|NCT04098393|DRUG|Antithymocyte globulin (ATG)|ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
223937807|NCT04098393|DRUG|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
223937808|NCT04098393|PROCEDURE|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
223937809|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
223937810|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
223937811|NCT04481087|DEVICE|Clearfil Universal Bond Quick|Adhesive systems
223937812|NCT04481087|DEVICE|Clearfil SE Bond|Adhesive systems
223937813|NCT04481087|DEVICE|Tetric N-Bond|Adhesive systems
223937814|NCT04250194|DEVICE|CT-Guided Biopsy|Images will be generated by a CT scanner to accurately insert a needle into the lung nodule allowing a sample to be removed for testing
223937815|NCT04250194|DEVICE|Navigation bronchoscopy|A virtual three-dimensional map of the lung will be generated enabling the physician to perform an anatomically precise biopsy
223937816|NCT06462222|DRUG|Toripalimab, pemetrexed|Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy
223937817|NCT05426733|DRUG|Odevixibat|Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
223937818|NCT06441786|BEHAVIORAL|A metacognitive group therapy of depression and anxiety in youth with autism|"The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) Metacognitive therapy for anxiety and depression. The group treatment is delivered in 10 weekly sessions."
224286738|NCT00440466|DRUG|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
224286739|NCT00440466|DRUG|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
224286740|NCT00563017|DRUG|Long-acting Risperidone microspheres injection|
224286741|NCT02283190|DRUG|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
224286742|NCT00002352|DRUG|Lobucavir|
224286743|NCT01421199|PROCEDURE|Myringotomy|tube placement for children with multiple ear infections
223534428|NCT07160166|OTHER|Prototype 1|Subjects will brush and rinse with their assigned mouthwash twice daily.
223937819|NCT02639637|DRUG|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
223937820|NCT02639637|DRUG|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
223937821|NCT02639637|DRUG|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
223937822|NCT02639637|DRUG|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
223937823|NCT02639637|DRUG|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
224098650|NCT01070420|OTHER|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
223937824|NCT06457516|COMBINATION_PRODUCT|Mirror Therapy|A mirror is used to create a reflective illusion of an affected limb in order to trick the brain into thinking movement has occurred without pain, or to create positive visual feedback of a limb movement. It involves placing the affected limb behind a mirror.
223937825|NCT06457516|OTHER|Music Therapy|Music therapy, an allied health profession, the clinical and evidence-based use of music interventions to accomplish individualized goals
223937826|NCT03253367|OTHER|Blood is obtained, mostly during routine venipuncture|
223937827|NCT04478487|DIETARY_SUPPLEMENT|Medolac human milk based human milk fortifier (MHMHMF)|MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
223937828|NCT00463229|OTHER|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
223937829|NCT00982436|DRUG|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
223937830|NCT00982436|RADIATION|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
223937831|NCT00982436|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
223937832|NCT05090631|GENETIC|DNA analysis|GWAS
223937833|NCT02809599|BEHAVIORAL|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
223937834|NCT01594957|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
223937835|NCT04228913|OTHER|Root Canal Obturation Technique|This study aims to compare the effects of three different obturation techniques(cold lateral condensation,thermoplasticized solid-core carrier method, cold free flow compaction technique) on postoperative pain following the endodontic therapy
223937836|NCT01932970|DRUG|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
223937837|NCT01362075|PROCEDURE|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
223937838|NCT01362075|PROCEDURE|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
223937839|NCT00978588|DRUG|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
223937840|NCT03177590|OTHER|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~1. an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~2. an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~3. Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
223937841|NCT01359150|DRUG|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
224286744|NCT01839370|DEVICE|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
223937842|NCT01359150|DRUG|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
223937843|NCT03656042|DRUG|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~1. 10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~2. Non-treatment"
223937844|NCT01358669|DRUG|Denosumab|60mg denosumab by injection as a single dose
223937845|NCT01358669|OTHER|Placebo|Placebo by injection as a single dose
224286745|NCT04811365|OTHER|Screening|After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms
223937846|NCT06226155|BEHAVIORAL|TENDAI4PrEP|An adapted problem-solving PrEP use intervention for HIV negative pregnant persons living with psychological distress, their partners, and antenatal care providers.
224286746|NCT03472742|DRUG|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
223937847|NCT06226155|OTHER|Enhanced treatment as usual|"Includes monthly visits to the ANC plus a pamphlet of information that describes PrEP efficacy.~safety during pregnancy/postpartum, and PrEP availability at the ANC."
223937848|NCT02188836|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
223937849|NCT02188836|DEVICE|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
223937850|NCT01513616|OTHER|Pulmonary rehabilitation|8-week program, 3 supervised session per week
223937851|NCT01513616|OTHER|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
223937852|NCT04105387|PROCEDURE|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
223937853|NCT04767815|DRUG|Diet A group|Fasting + DWN12088 200 mg
223937854|NCT04767815|DRUG|Diet B group|30 minutes after a high-fat meal + DWN12088 200 mg
223937855|NCT04767815|DRUG|Diet C group|2 hours after a high-fat meal + DWN12088 200 mg
223937856|NCT06120218|PROCEDURE|Emergent Stenting|Emergent Stenting in acute ischemic stroke caused by tandem occlusions
223937857|NCT03542305|DRUG|Lorlatinib|Lorlatinib single oral dose
223937858|NCT02575924|DRUG|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
224098651|NCT01070420|OTHER|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
224098652|NCT04623957|DEVICE|ForgTin©|"The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.~The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises."
224098653|NCT01175369|BEHAVIORAL|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
224098654|NCT02240706|PROCEDURE|Best Supportive Care|At Discretion of the Investigator (Transfusions)
224286747|NCT03416556|PROCEDURE|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
223937859|NCT02575924|DRUG|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
223937860|NCT03872063|OTHER|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
223937861|NCT03872063|OTHER|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
223937862|NCT05240794|DEVICE|ABM-01|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT)
223937863|NCT05240794|DEVICE|Digital Control|Placebo control for ABM-01
223937864|NCT00690131|BEHAVIORAL|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
223937865|NCT06175299|BEHAVIORAL|Adherence Promotion With Person-centered Technology (APPT) System with Social Functions|The system has seven games for cognitive training and two social interactions functions: a chat function and a leaderboard function.
223937866|NCT00690404|DRUG|AZD2066|single oral dose
223937867|NCT02477813|DRUG|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
223937868|NCT04804566|OTHER|This is a non-interventional study|This is a non-interventional study
223937869|NCT03113409|DRUG|Buprenorphine|Buprenorphine will be administered daily
223937870|NCT03113409|DRUG|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
223937871|NCT03113409|DRUG|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
224098655|NCT02240706|DRUG|BI 836858|Monotherapy with BI 836858
224098656|NCT05328050|OTHER|Registry|observational, data collection
224098657|NCT00109811|BIOLOGICAL|PSA:154-163(155L) peptide vaccine|Given subcutaneously
223937872|NCT01016457|DEVICE|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
223937873|NCT05555901|DRUG|Fruquintinib+ chemotherapy|"Second-line treatment : Fruquintinib+FOLFIRI Drug: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off, q4w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Fruquintinib+Capecitabine Drug: Fruquintinib 4mg, orally, once daily, 2 weeks on/ 1 week off, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
223937874|NCT05555901|DRUG|Bevacizumab+ chemotherapy|"Second-line treatment : Bevacizumab+FOLFIRI Drug: Bevacizumab 5mg/kg on day 1, q2w~Drug: FOLFIRI regimen Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48-hour continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w~Maintenance treatment：Bevacizumab+Capecitabine Drug: Bevacizumab 7.5mg/kg on day 1, q3w Drug: Capecitabine 825 mg/m2, orally, twice daily, q3w"
223937875|NCT02170259|OTHER|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
223937876|NCT02170259|OTHER|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
223937877|NCT02170259|OTHER|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
223937878|NCT02785159|DRUG|IDP-118 Lotion|Lotion
223937879|NCT02785159|DRUG|Tazorac Cream|Cream
223937880|NCT02785159|DRUG|IDP-118 Vehicle Lotion|Lotion
223937881|NCT02785159|DRUG|IDP-118 Vehicle Cream|Cream
223937882|NCT01544907|DEVICE|Conventional PTA|Use of conventional balloon for angioplasty only
223937883|NCT01544907|DEVICE|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
223937884|NCT03578965|DRUG|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
223937885|NCT01787032|DRUG|BI 113608|tablet
223937886|NCT01787032|DRUG|BI 113608|tablet
223937887|NCT01787032|DRUG|BI 113608|tablet
223937888|NCT01787032|DRUG|Ketoconazole|tablet
223937889|NCT01787032|DRUG|Voriconazole|tablet
223937890|NCT01487837|DRUG|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
223937891|NCT00776009|DRUG|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
223937892|NCT00776009|DRUG|Placebo|Placebo Comparator
224098658|NCT00109811|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
223937893|NCT02401932|OTHER|Hemophagocytosis|Best supportive care and immunosuppressive treatments
224098659|NCT00109811|OTHER|laboratory biomarker analysis|Correlative studies
223937894|NCT02040870|DRUG|LDK378|750 mg once daily
223937895|NCT04447898|DRUG|PPV-06 10 μg|Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
223937896|NCT04447898|DRUG|PPV-06 50 μg|High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
223937897|NCT04447898|DRUG|Placebo|Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
223937898|NCT00775892|DEVICE|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
223937899|NCT02851134|GENETIC|genetic analysis|genetic (Whole Exome Sequencing )
223937900|NCT02851134|BIOLOGICAL|blood and stools samples|biological collection
223937901|NCT00630357|DRUG|Levetiracetam (Keppra)|
223937902|NCT00463502|DRUG|Metformin|
223937903|NCT04036955|OTHER|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
224098660|NCT00553995|DRUG|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
224098661|NCT00553995|DRUG|Placebo|
224098662|NCT03270748|DRUG|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
224098663|NCT02655484|DEVICE|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
224286748|NCT03416556|PROCEDURE|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
224286749|NCT03416556|OTHER|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
224286750|NCT04375709|OTHER|Physical exercise|The intervention consists out of combined aerobic and strength exercise supervised and guided by specialized physical therapists; additional methods like functional electrical stimulation or oxygen supplementation are added during the main training if indicated.
223937904|NCT02169869|DEVICE|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
223937905|NCT02169869|DEVICE|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
223937906|NCT03792932|PROCEDURE|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
223937907|NCT03792932|PROCEDURE|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
223937908|NCT02275611|DRUG|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
223937909|NCT02275611|DRUG|Intranasal Placebo Spray|Intranasal Placebo Spray
223937910|NCT06175520|BEHAVIORAL|Preconception care (PCC)|The investigators will introduce PCC through the existing public health system. At the community level facility, healthcare providers will screen the women for some specific health problems and provide necessary supplements. Healthcare providers will screen for health problems such as- infectious diseases (e.g., Tuberculosis), Hypertension, Anaemia, Diabetes Mellitus, Thyroid problems, Sexually Transmitted Infection/Reproductive Tract Infection/Urinary Tract Infection, Nutritional status (e.g., Body mass index), Thalassemia symptoms, Thyroid symptoms, severe Dysmenorrhea, Immunization status, and Symptoms of acute Hepatitis B Virus infection, etc. The provider will also consider age, menstrual history, and reproductive history during preconception screening. If the provider finds any abnormality from the screening test which is a risk for a woman to become pregnant and for her newborn; the woman will be provided proper counseling, treatment, and referral to the appropriate facility.
223937911|NCT04110301|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
223937912|NCT04110301|DRUG|Lenalidomide|Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
223937913|NCT03911271|DRUG|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
223937914|NCT03911271|DRUG|0.01% atropine|0.01% atropine for 24 months
223937915|NCT03911271|DRUG|0.9% Sodium-chloride|Placebo for 24 months
223937916|NCT06364852|DRUG|LY007|FC and LY007 infusion
224098664|NCT03379519|BEHAVIORAL|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
224098665|NCT03379519|BEHAVIORAL|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
224098666|NCT03328819|OTHER|Acupuncture|The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
224098667|NCT01090557|OTHER|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
224286751|NCT04375709|BEHAVIORAL|Education sessions|Sessions include information on physical activity (behaviour), coping with stress and anxiety, dyspnoe, or fatigue; Professional support is given in case of risk for nutritional deficits or post-traumatic stress; sessions are conducted by medical specialists or specialized physiotherapists. All sessions are individually-tailored. In case of nutrition or psychological issues individual sessions are guided by specific health-professionals.
223937917|NCT04641247|DRUG|Niraparib|Niraparib tablets or capsules will be given once a day via the oral route.
223937918|NCT02195232|DRUG|Isoquercetin|
223937919|NCT01391767|DEVICE|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
224098668|NCT03679403|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
224098669|NCT02998502|DEVICE|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
223937920|NCT04510324|OTHER|Red meat patties group|"1\. Baseline Visit: day -7 before randomization~* Clinical history~* Refrain from seafood, eggs, fish or meat, for 7-day (washout) prior to Day 1. 2. Day 1 Randomization~* Randomization to 1 of 2 interventions: plant-based or meat burgers~* 6 days-worth of burgers will be delivered to the participant's house 3. Day 1-6:~* The participant will be asked to eat a specific randomized diet for 6 days 5. Days 7~* Physical exam (weight, BP, HR)~* Food questionnaire~* Blood draw: Circulating TMAO, Total, LDL, and HDL cholesterol, Creatinine, High-sensitivity c-reactive protein~* Urine Collection - TMAO 6. Day 7-14: Washout 7. Day 14: Patties delivery 8. Day 14-20: Assigned diet for 6 days 9. Days 20: Same as day 7"
223937921|NCT04510324|OTHER|Plant-based patties group|Same as above
223937922|NCT05326789|DEVICE|REBOA catheter|balloon occlusion of the aorta during cardiac arrest to optimize coronary and cerebral perfusion.
223937923|NCT03329482|OTHER|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
223937924|NCT03329482|OTHER|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
223937925|NCT01354574|OTHER|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
223937926|NCT01354574|OTHER|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
224286752|NCT05449093|OTHER|Periodontal clinical measurements and gingival crevicular fluid sampling|"Periodontal clinical meaurements including the probing depth, clinical attachment loss, the dichotomous recording (present/absent) of bleeding on probing, gingival index, and the plaque index at six sites (distobuccal, buccal, mesiobuccal, distopalatinal/lingual, palatinal/lingual, mesiopalatinal/lingual) on all teeth, except third molars, were performed using manuel periodontal probe.~Standardized absorbent paper strips were used for gingival crevicular fluid sampling. A sterile paper strip was gently inserted into the gingival sulcus/periodontal pocket until mild resistance was felt and were kept in place for 30 seconds. The absorbed fluid volume was measured by a precalibrated electronic device."
224286753|NCT00423683|DRUG|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
223937927|NCT03865875|BEHAVIORAL|Exercise Program|Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
223937928|NCT03865875|BEHAVIORAL|Nutrition Program|Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
223937929|NCT02937493|BEHAVIORAL|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
223937930|NCT04353089|OTHER|Basic life support courses|4 hours certified basic life support courses
224286754|NCT00423683|DEVICE|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
224286755|NCT03769883|BEHAVIORAL|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
224286756|NCT03769883|BEHAVIORAL|Diet|Dietary intervention
223937931|NCT01759862|DRUG|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
223937932|NCT01759862|OTHER|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
223937933|NCT01759862|DRUG|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
223937934|NCT01756924|DRUG|CEM-102|
223937935|NCT01756924|DRUG|IV or Oral standard of care antibiotics|
223937936|NCT01756924|DRUG|Rifampin|
223937937|NCT02254759|DRUG|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
223937938|NCT02254759|DRUG|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
223937939|NCT02254759|DRUG|RO5186582|RO5186582 120 mg film-coated release tablet.
223937940|NCT01235806|RADIATION|MRI|MRI of the scaphoid bone fracture suspicion
223937941|NCT03741621|DIETARY_SUPPLEMENT|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
223937942|NCT03741621|DIETARY_SUPPLEMENT|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
223937943|NCT03741621|DIETARY_SUPPLEMENT|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
223937944|NCT00731614|BEHAVIORAL|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
223937945|NCT00731614|BEHAVIORAL|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
223937946|NCT00731614|BEHAVIORAL|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
223937947|NCT00213395|DEVICE|Interface for noninvasive ventilation|
223937948|NCT05014035|BEHAVIORAL|Resistance Exercise|This is an 8-week exercise program, delivered using a hybrid approach of in-person, in-home supervised exercise, and virtual delivery of exercise via zoom. Individuals will participate in resistance exercise 3 days per week for 8 weeks.
223937949|NCT00821301|DRUG|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
224098670|NCT03339895|OTHER|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value \<%13 and if MAP\>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value \<%13 and if MAP\>65mmHg 5 mcg efedrin intravenous bolus till MAP\>65 mmHg If PVI value \>%13 and MAP\>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value \>%13 and MAP \<65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
223937950|NCT03190850|OTHER|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
223937951|NCT03190850|OTHER|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
223937952|NCT00421759|DEVICE|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
223937953|NCT01141803|DIETARY_SUPPLEMENT|Apples|550g of apples/day
223937954|NCT01141803|DIETARY_SUPPLEMENT|Apple pomace|22g apple pomace/day
223937955|NCT05063864|OTHER|Nursing Support Program|"Within the scope of the nursing support program, counselling services were provided to women by making regular phone calls that lasted 15-20 minutes once a week. Within the scope of the support program, two training booklets titled Life After Hysterectomy Surgery and Women's Health During Menopause were prepared by reviewing the literature."
223937956|NCT06121479|DRUG|Branched-chain amino acid|Oral branched-chain amino acid is provided to the patients with a recommended daily intake of approximately 13.68 grams per day. Each sachet contains 6.84 grams of BCAA (valine 1.82 grams, leucine 3.29 grams, isoleucine 1.72 grams), total protein 17.08 grams, carbohydrates 25.48 grams, fat 5.66 grams, providing 221.2 kcal of energy. Each sachet weighs 52 grams and should be mixed with 150 ml of water. The recommended daily intake is 2 sachets, to be consumed after breakfast and dinner. The BCAA provided to the patients comes in pre-packaged silver sachets, with the manufacturing date and expiration date indicated.
223937957|NCT06079671|BIOLOGICAL|Volrustomig|IV Infusion
223937958|NCT06079671|OTHER|Placebo|IV Infusion
223937959|NCT06042751|BEHAVIORAL|Exercise Therapy|Six online consultations will take place on the basis of the sports medicine assessment every two weeks, resulting in 300 min in 3 months. For the home-based implementation, participants receive wearables with which the activity and training data are collected. In conjunction with feedback, the goal is to ensure that the interventions lead to improvements in self-control, reduced resilience, and fatigue without overwhelming participants with volume or intensity. Due to the expected large differences in personal performance, determined in the initial assessment, the exercise plan is individually designed and regularly adjusted. This includes control of everyday activity as well as moderate endurance and strengthening exercises totalling up to 30min daily. The individual training intensity is below the aerobic lactate threshold so that overload is avoided. The average training heart rate is planned to be in the range between 50 and 70% of the maximum heart rate.
224098671|NCT03339895|OTHER|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP \<65 mmHg or \<30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP\>65 mmHg no intervention
224098672|NCT00211003|DRUG|doripenem|
224098673|NCT05072405|DRUG|Simvastatin 20 mg (Zocor®, MSD)|Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
224098674|NCT05072405|DRUG|rosuvastatin 10 mg (Crestor®, Astra Zeneca)|rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
223937960|NCT06042751|BEHAVIORAL|Psychotherapy|Six online consultations will take place based on the psychosocial assessment and the initial psychosomatic interview every two weeks, resulting in 300 min in 3 months. A structured, telemedicine-supported, modularized, brief psychosomatic intervention is planned with a focus on psychoeducational elements, promotion of self-management, improvement of illness acceptance, modification of self-monitoring, and learning to cope with altered performance levels. The six modularized telemedical sessions taking into account the specific deficits identified in the psychosomatic evaluation. Within the sessions, starting points are identified with the patients, which the patients can work on independently between the sessions.
223937961|NCT04870944|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223937962|NCT04870944|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspirate
223937963|NCT04870944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223937964|NCT04870944|PROCEDURE|Echocardiography Test|Undergo ECHO
224098675|NCT03746730|DEVICE|ultrasound|gray scale and doppler ultrasound
224098676|NCT04661696|DRUG|Paclitaxel (albumin-bound)|The dose of intravenous chemotherapy drug is calculated according to the body surface area.When patients have serious adverse events, dose suspension and dose reduction are allowed. Paclitaxel (albumin-bound) was allowed to be reduced only twice (20% standard dose reduction in the first dose and 20% lower in the second dose).Once the dose is reduced, all subsequent doses should be maintained at reduced dosage.
224098677|NCT01117376|DRUG|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
224098678|NCT01117376|DRUG|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
224098679|NCT04976465|DRUG|Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH"
224098680|NCT04976465|DRUG|Without Anticoagulation|"Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~Other Names: HCQ"
224098681|NCT03744689|PROCEDURE|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
224098682|NCT03744689|PROCEDURE|Sham block|Sham block will be done with serum physiologic.
224286757|NCT05466344|DEVICE|Herbst Group|"1. Two mini plates are chosen, the last hole in every plate is used to solder the ball housing of type IV Herbst appliance.~2. The two mini plates are placed bilateral at the mandibular symphysis and fixed by at least 3 screws, the surgical wound is sutured leaving an extended part of the plate in the oral cavity which contain the soldered ball housing.~3. The surgical wound is left for 2 weeks for proper soft tissue healing, in the meantime separation in the arch, band placement on the first premolar and molar bilateral followed by impression for construction of the upper Herbst splint.~4. Cementation of upper Herbst splint with connecting the telescopic piston through fitting of the plunger into the tube bilaterally.~5. When reactivation of the telescopic piston is needed, extension rings are used."
223937965|NCT04870944|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IV
223937966|NCT04763759|DRUG|TRL1068, a human monoclonal antibody|A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
223937967|NCT03890289|DRUG|Idelalisib|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
223937968|NCT03890289|DRUG|Obinutuzumab|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
223937969|NCT06447415|DRUG|HRS-7450|HRS-7450 Injection
223937970|NCT06447415|DRUG|0.9% sodium chloride injection|0.9% sodium chloride injection
223937971|NCT05741060|DRUG|S-equol|Experimental drug
223937972|NCT05741060|DRUG|Placebo|Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
223937973|NCT01981603|OTHER|navigator|
223937974|NCT04477707|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO or FIGARO clinical trial.
223937975|NCT02075723|DIETARY_SUPPLEMENT|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
224098683|NCT03744689|DRUG|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
224098684|NCT03744689|DEVICE|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
224098685|NCT00260130|OTHER|food in fluid form|dietary intake of fluid forms of vegetables
224098686|NCT00260130|OTHER|food in solid form|dietary intake of solid forms of vegetables
224098687|NCT01042262|OTHER|Oxygen|100% Oxygen at a flow of 2 L/min
224098688|NCT01042262|OTHER|Placebo|No oxygen flow
223937976|NCT02075723|BEHAVIORAL|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
223937977|NCT01672333|DRUG|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
223937978|NCT02816398|DEVICE|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
223937979|NCT03440996|OTHER|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
223937980|NCT03440996|OTHER|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
223937981|NCT03440996|OTHER|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
223937982|NCT04217694|BEHAVIORAL|Cogstate Assessment Battery|Complete CogState testing
223937983|NCT04217694|DRUG|Memantine|Given PO
223937984|NCT04217694|DRUG|Memantine Hydrochloride|Given PO
223937985|NCT00464893|DRUG|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
223937986|NCT00464893|DRUG|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
223937987|NCT00853606|DRUG|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
223937988|NCT00140491|DEVICE|Vision Restoration Therapy (NOVAVISION)|
223937989|NCT04958798|BEHAVIORAL|Culturally Centered MOUD Implementation Intervention|Support clinical sites to culturally center the delivery of medications for opioid use disorder through evidence-based implementation strategies tailored to local needs
223937990|NCT05787808|DIETARY_SUPPLEMENT|Calsium, Vitamin D, Jarlsberg cheese|Oral
223937991|NCT03980418|PROCEDURE|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
223937992|NCT01613053|DRUG|Glivec|800 mg per day
223937993|NCT06561841|DRUG|HSK39297|HSK39297 tablets for 24 weeks
223937994|NCT03192007|DEVICE|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
223937995|NCT06974383|OTHER|Training with Virtual Laparoscopic Hiatal Hernia Simulator (VLaHHS)|For the training phase, participants in Group 1 will perform the tasks on VLaHHS for an hour a day for a maximum of 15 sessions over 3 weeks.
223937996|NCT06965296|BEHAVIORAL|AI-enhanced smartphone app|"A smartphone app has been developed and is in keeping with guideline recommendations for the treatment of e-cigarette products. This app has a user-friendly Graphic User Interface (GUI) to allow users to build their own accounts and individualized contents conveniently, based on the input the users initially provide including e-cigarette use patterns, readiness to quit e-cigarette, beliefs about e-cigarette, nicotine addiction, self-efficacy, other substance use status, and parental or peer e-cigarette use status.~The proposed AI model in this app will learn information from the input data, including progress toward e-cigarette cessation (e,g, changes of readiness of quitting, quit attempts), and additional data including emotional status, stress level, feedback to the previous learning modules, and then predict the result on the fly. Based on the predicted result, the app will send in-time motivational messages and mindfulness training modules."
223937997|NCT06965296|BEHAVIORAL|AI-enhanced smartphone app, but with delayed access|Participants in the control group will be placed on a three-month waitlist. After this period, they will receive access to the same app-based intervention as the immediate intervention group, allowing a comparison between immediate and delayed access.
223937998|NCT06078709|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224098689|NCT01999738|DRUG|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
224098690|NCT00279747|DRUG|meloxicam 0.25 mg/kg|
224098691|NCT00279747|DRUG|meloxicam 0.125 mg/kg|
224098692|NCT00279747|DRUG|naproxen 10 mg/kg|
224098693|NCT06853171|DRUG|KarXT|Specified dose on specified days
224098694|NCT06853171|DRUG|KarX-EC|Specified dose on specified days
224098695|NCT06197126|RADIATION|Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .|The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.
224286758|NCT05466344|DEVICE|TFBC Group|"1. The patients will be treated by fixed orthodontic appliance with using series of orthodontic NiTi arch wires for levelling and alignment.~2. Installation of series of orthodontic stainless steel arch wires until 0.0019 x 0.0025 inch for both arches.~3. Installation of the Twin Force Bite Corrector appliance for 4 to 6 months.~4. Using of class ΙΙ intra-oral elastics for both sides for 2 to 3 months.~5. Finally follow finishing steps for each patient."
223937999|NCT06078709|PROCEDURE|Computed Tomography|Undergo CT and PET/CT scan
223938000|NCT06078709|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
223938001|NCT06078709|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
223938002|NCT06078709|DRUG|Fluorouracil|Given IV
224098696|NCT05641688|DRUG|[18F]PI-2620|The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
224098697|NCT02215681|DEVICE|acupuncture|
224098698|NCT00779168|DRUG|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
224098699|NCT00779168|OTHER|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
224098700|NCT00779168|OTHER|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
224098701|NCT00779168|OTHER|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
224286759|NCT02601274|DRUG|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
223938003|NCT06078709|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223938004|NCT06078709|DRUG|Leucovorin Calcium|Given IV
223938005|NCT06078709|DRUG|Oxaliplatin|Given IV
223938006|NCT06078709|PROCEDURE|Positron Emission Tomography|Undergo PET and PET/CT scan
223938007|NCT06078709|OTHER|Survey Administration|Ancillary studies
223938008|NCT06078709|DRUG|Docetaxel|Given IV
223938009|NCT06078709|BIOLOGICAL|Durvalumab|Given IV
223938010|NCT06271668|OTHER|Naloxone Co-prescribing Clinical Decision Support (CDS)|Clinical decision support in the form of an EHR-integrated, provider facing alert suggesting (a) the opioid medication order is considered high risk for overdose and (b) to nudge providers to add a naloxone prescription to the opioid prescription to mitigate risk in the event of an overdose.
223938011|NCT02707198|DRUG|kefir|4 ounces of kefir 3 times a day, with or without food.
223938012|NCT03383874|COMBINATION_PRODUCT|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10\^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10\^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
223938013|NCT03383874|OTHER|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
223534429|NCT07160166|OTHER|Prototype 2|Subjects will brush and rinse with their assigned mouthwash twice daily.
223938014|NCT05857137|DEVICE|Active TMS|Continuous theta burst stimulation (cTBS) will be administered over the left inferior parietal lobule for approximately 3 minutes at 120% of the resting motor threshold.
224098702|NCT00779168|OTHER|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
224286760|NCT00845325|BEHAVIORAL|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
224286761|NCT00845325|BEHAVIORAL|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
224286762|NCT01674439|PROCEDURE|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
224286763|NCT01674439|PROCEDURE|Without supplementation of ADRC|Standard fat graft preparation
224286764|NCT01407224|BEHAVIORAL|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
224286765|NCT05557903|BIOLOGICAL|Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection|Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
224286766|NCT04782128|BIOLOGICAL|RC28-E injection|a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
223534430|NCT07160166|OTHER|Marketed Comparator|Subjects will brush and rinse with their assigned mouthwash twice daily.
223534431|NCT07160374|PROCEDURE|Transradial drug-eluting beadsTransarterial Chemoembolization (DEB-TACE)|Transarterial chemoembolization performed through the radial artery using HepaSphere drug-eluting microspheres in patients with hepatocellular carcinoma.
223534432|NCT07161297|DRUG|Intravenous remimazolam (5 mg initially, with optional 2.5 mg boluses) plus fentanyl (100 mcg) for procedural sedation.|\- Remimazolam + Fentanyl IV fentanyl 100 mcg is given first, followed after 1 minute by IV remimazolam 5 mg over 1 minute. Additional 2.5 mg boluses may be given every 2 minutes as needed. Colonoscopy starts 1 minute after sedation. Vital signs are monitored throughout.
223938015|NCT05857137|DEVICE|Placebo TMS|Placebo TMS will be applied over the left inferior parietal lobule for approximately 3 minutes.
223938016|NCT05555485|DEVICE|transcutaneous Auricular neurostimulation - Active|Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved
223938017|NCT05555485|DEVICE|transcutaneous auricular neurostimulation - Sham|Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
223938018|NCT05250414|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
223938019|NCT06481982|DIAGNOSTIC_TEST|MRI|MRI sequences
224098703|NCT00779168|OTHER|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
223938020|NCT05956158|BEHAVIORAL|Behavioral Treatment|This treatment is designed to help participants make changes to behavior patterns and thoughts that contribute to insomnia.
223938021|NCT05956158|BEHAVIORAL|Sleep Education Treatment|This treatment is designed to help participants understand the relationships among sleep, pain, and Crohn's disease and to make changes to insomnia-related behaviors.
223938022|NCT05437263|DRUG|Brepocitinib|Oral Brepocitinib
223938023|NCT05437263|DRUG|Placebo|Oral Placebo
223938024|NCT05339347|DEVICE|Photoneuromodulation|Treatments were administered daily for a period of 2 weeks (10 sessions) with a Light-Aid (Bright Photomedicine, SP, Brazil), continuous wave, 300 LED wavelength 850 nm) or with a placebo probe of the same appearance and display. The irradiation parameters created will be based on the disease, pain intensity and skin phototype. Each session has from 10 to 15 min, depending on skin phototype
223938025|NCT05703165|BEHAVIORAL|animal-assisted intervention|horse-assisted intervention
223938026|NCT05703165|BEHAVIORAL|watching the countryside|just watching the countryside
223938027|NCT06351579|OTHER|Control|This is an observational (registry) study for data collection only. No device or intervention will be used in this study.
223938028|NCT05536804|DRUG|Tirzepatide|Administered SC
223938029|NCT05536804|DRUG|Placebo|Administered SC
223938030|NCT06389357|BEHAVIORAL|training and counselling|It includes 4 modules that develop children's communication, coping and social life skills and psychosocial preparation for the return to school process. The modules include theoretical explanations, stories, workshops and counselling sessions. Separate educational modules have been developed for parents, teachers, and peers.
223938031|NCT06389357|OTHER|Interview|As part of the needs assessment in Phase 1, individual interviews with children with cancer and their parents lasting approximately 20-30 minutes were conducted.
223938032|NCT06335875|DIETARY_SUPPLEMENT|Ketone Ester Beverage|Participants will consume ketone ester (KE) beverage, consisting of 19 g (=12.5 g active C8-KE) of Juvenescence Cognitive Switch™ diluted in water, twice per day
223938033|NCT06335875|BEHAVIORAL|Low Glycemic Index Diet|Participants will practice four dietary changes: 1. Not consuming sweets/candy, 2. Not consuming soda, 3. Replacing 'white' grains with complex carbohydrates such as brown rice or quinoa, and 4. Reserving any fruit consumption for the end of meals.
223938034|NCT05168085|DIETARY_SUPPLEMENT|Eggs|Providing 1 egg per day fo 6 months to infants
223938035|NCT05616754|BIOLOGICAL|Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|The antigen protein of this product is designed to be expressed in tandem with Delta variant R319-N356 and Omicron variant R319-N356. The antigen is called DO-RBD for short.
223938036|NCT05616754|BIOLOGICAL|Recombinant Novel Coronavirus Protein Vaccine (CHO cells)|This strain was made from the NCP-RBD receptor binding region of the spike glycoprotein of novel coronavirus expressed in recombinant CHO cells, which was purified and added with aluminum hydroxide adjuvant
223938037|NCT06649045|DRUG|Orforglipron|Administered orally.
223938038|NCT06649045|DRUG|Placebo|Administered orally.
223938039|NCT05843240|PROCEDURE|Repetitive transcranial magnetic stimulation|After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
223938040|NCT05843240|PROCEDURE|Sham repetitive transcranial magnetic stimulation|After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
223938041|NCT00837954|DEVICE|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
223938042|NCT00837954|DEVICE|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
223938043|NCT00837954|PROCEDURE|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
224286767|NCT03897478|DIAGNOSTIC_TEST|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
223938044|NCT04611373|DRUG|Acetazolamide Levamisole|Acetazolamide tablet 25mg/ tablet, 2 tablets a day Levamisole 25mg/ tablet, 6 tablets/day Continue treatment until the disease progresses
223938045|NCT05777304|DEVICE|wearable device|IMU sensors and EMG sensors
224286768|NCT03447340|BEHAVIORAL|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
223938046|NCT01588951|DRUG|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
223938047|NCT01588951|DRUG|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
223938048|NCT01917994|BEHAVIORAL|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
223938049|NCT01917994|BEHAVIORAL|Appointment Reminders|
223938050|NCT01830049|OTHER|Take blood|
223938051|NCT06650202|DEVICE|The Tethered Pelvic Assist Device (TPAD)|a light-weight cable-driven robotic stand trainer that (i) can provide assistance-as-needed by applying corrective forces on the trunk and pelvis in response to their movement outside a pre-programmed area, and (ii) can apply controlled forces on the trunk and pelvis to perturb them from their nominal configuration during standing.
223938052|NCT02628626|DRUG|Colesevelam|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
223938053|NCT02628626|DRUG|Clonidine|Participants who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
223938054|NCT02628626|OTHER|Placebo|Placebo will be identical in appearance to the active drug.
223938055|NCT06035809|BEHAVIORAL|SMART|A movement and body-based intervention in which participants are encouraged to explore the use of sensory equipment, which may help reduce symptoms related to psychological trauma/PTSD. Sensory equipment includes exercise balls, mini-trampoline, weighted blankets, and a hammock swing.
223938056|NCT02196623|OTHER|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
223938057|NCT02196623|OTHER|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
223938058|NCT04472767|DRUG|Nivolumab|Given IV
223938059|NCT04472767|DRUG|Ipilimumab|Given IV
223938060|NCT04472767|DRUG|Cabozantinib|Given PO
223938061|NCT04472767|PROCEDURE|Transarterial Chemoembolization|TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.
223938062|NCT05694689|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
223938063|NCT05694689|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/ day are provided as part of usual care. At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
223938064|NCT05694689|OTHER|Usual Care|Co-interventions will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices
223938065|NCT06499441|OTHER|Myofascial induction in gastrocnemius|A 3-pass shallow leg gliding technique was applied first, followed by 5 minutes of the deep myofascial calf induction technique described by Pilat.
223938066|NCT06499441|OTHER|Preassure release|Also called ischaemic pressure. Three cycles of pressure are applied to the trigger point of the gastrocnemius muscle until the pain disappears on pressure.
223938067|NCT03411941|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
223938068|NCT06425250|OTHER|Management, progression and risk factors for failure of BJI caused by Campylobacter spp.|Description of demographic data (sex, age), comorbidities (ASA and Charlson scores), orthopedic and septic history, and surgical and medical management (antibiotic therapy)
223938069|NCT06425250|OTHER|Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.|"Failure of treatment: defined according to a composite criterion bringing together~* persistence of the infection under treatment, and/or~* recurrence of the infection after stopping antibiotic therapy, and/or~* need for surgical revision for septic reasons more than 5 days after initial treatment, and/or~* superinfection, and/or~* definitive explantation of the material, and/or~* decision for suppressive antibiotic therapy, and/or~* amputation, and/or~* death linked to infection"
223938070|NCT01732120|PROCEDURE|Off-clamp partial nephrectomy|
223938071|NCT00575549|OTHER|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
223938072|NCT00180934|PROCEDURE|Reirradiation with concomitant chemotherapy|
223938073|NCT02143375|DEVICE|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
223938074|NCT00032435|DRUG|PAL-40 Active|
223938075|NCT00032435|DRUG|PAL-40 Placebo|
223938076|NCT02766517|DRUG|Capsaicin|Administered topically
223938077|NCT03329612|PROCEDURE|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
223938078|NCT02190708|DRUG|PQ912|from day2 up to day6 twice daily oral dose of PQ912
223938079|NCT02190708|DRUG|Midazolam|single oral dose on day1 and day 6
224286769|NCT03447340|OTHER|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
224286770|NCT00992095|DRUG|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
224286771|NCT03441295|PROCEDURE|Dynamic Intraligamentary Stabilization|DIS, Ligamys
224286772|NCT03441295|PROCEDURE|Internal Brace Ligament Augmentation|IBLA
223938080|NCT02190708|DRUG|Omeprazole|single oral dose on day1 and day6
224286773|NCT03441295|PROCEDURE|ACL Reconstruction|Conventional
223938081|NCT01232959|DEVICE|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
223938082|NCT04379375|BEHAVIORAL|Nudge|Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
223938083|NCT01333800|DRUG|Beclomethasone|200 to 400 mcg per day for 6 months
223938084|NCT01333800|DRUG|Ciclesonide|80 to 160 mcg per day for 6 months
223938085|NCT05113810|DRUG|HCQ01|HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
223938086|NCT05113810|OTHER|standard of care (SOC) for COVID-19|Standard of care (SOC) for COVID-19
223938087|NCT02378649|DRUG|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
223938088|NCT02378649|DRUG|Placebo|Placebo comparator concomitant with best practice usual care
223938089|NCT00056966|DRUG|ANTI-CD45|400ug/kg Day-5 through Day-2
223938090|NCT00056966|DRUG|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
223938091|NCT00056966|DRUG|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
223938092|NCT00056966|DRUG|Fludarabine|Day-8 through Day-5 30 mg/m2
223938093|NCT00056966|RADIATION|Total Body Irradiation|Day-1 single dose 450 cGy
223938094|NCT00056966|PROCEDURE|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
223938095|NCT00754000|OTHER|Observation|AE monitoring and EPIC QOL survey
223938096|NCT01662154|DEVICE|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
223938097|NCT01662154|DEVICE|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
223938098|NCT01780675|RADIATION|Radiation Prophylactic Cranial Irradiation|
223938099|NCT01780675|RADIATION|Radiation Hippocampal Avoidance PCI|
223938100|NCT02972359|DRUG|Neridronic acid|Neridronic acid administered as intravenous infusion.
224098704|NCT03934684|DRUG|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously."
223938101|NCT06033040|OTHER|MRI|Functional sequence imaging (MDME, IVIM) sequences were added to the routine MRI scan of patients with bladder tumor
223938102|NCT02063659|DRUG|Telotristat etiprate|Telotristat etiprate tablets
223938103|NCT02063659|DRUG|Placebo|Placebo-matching telotristat etiprate tablets
223938104|NCT06267300|DRUG|Hyperbaric oxygen|Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
223938105|NCT01532999|BEHAVIORAL|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
224098705|NCT03934684|DRUG|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously."
223938106|NCT01532999|BEHAVIORAL|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
223938107|NCT03366506|OTHER|Observation|
223938108|NCT00311714|DRUG|CS-8958 formulated as dry powder|
223938109|NCT00311714|OTHER|Placebo|
223938110|NCT00002095|DRUG|Ganciclovir|
223938111|NCT01298076|DRUG|bevacizumab|Anti-VEGF drug for intravitreal injection
224286774|NCT06193824|DEVICE|Experimental: downhill treadmill walking at -10% and -20% gradient|The subjects will perform downhill walking at 6 km/h for 45 min on a treadmill (-10% or -20% incline)
223938112|NCT01298076|DRUG|dexamethasone|Slow-release steroid formulation for intravitreal injection
223938113|NCT04409470|DIAGNOSTIC_TEST|Blood gas sampling from artery and vein|Patients included in this study are treated according to clinical routine. After inclusion, sampling of an arterial blood gas and a venous blood gas is performed simultaneously or as close in time as possible. Because the venous blood gas analysis sample can be taken directly from the patient's peripheral venous catheter, no additional venous puncture is usually required and the additional amount of blood that may be required is approx. 1 ml (the assay requires about 500 µl). In the very rare cases where it is not possible to establish a peripheral venous catheter within a reasonable time, the sample will be acquired from a new venous puncture together with other venous routine samples.
223938114|NCT05996393|DRUG|Ciclosporin|3-5 mg/kg/d orally, trough concentrations: 100-200 ng/ml
223938115|NCT05996393|DRUG|Avatrombopag|60 mg/d orally, 24 weeks
223938116|NCT05996393|DRUG|Anti-Human Thymocyte Immunoglobulin, Rabbit|rabbit anti-human thymocyte immunoglobulin (r-ATG 3mg/kg/d), intravenously, 5 days;
223938117|NCT02072499|PROCEDURE|KTP Green Light Prostatectomy|
223938118|NCT02072499|DEVICE|Green Light|
223938119|NCT02072499|PROCEDURE|Open prostatectomy|
223938120|NCT02700269|OTHER|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
224286775|NCT01739634|DRUG|CASAD|CASAD is provided in 500mg capsules.
223938121|NCT05733559|DEVICE|QIAstat-Dx® Respiratory Panel Plus (RPP)|An observational prospective performance evaluation study of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target against a marketed comparator, using NPS collected per the manufacturer's instructions and eluted in Universal Transport Media (UTM) from subjects with signs and symptoms of respiratory infection
223938122|NCT02355041|BEHAVIORAL|Meal Replacement-based Weight Loss Diet|
223938123|NCT02355041|BEHAVIORAL|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
223938124|NCT06809907|DEVICE|Kintsugi Voice Device|The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression. The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs.
223938125|NCT06977984|BEHAVIORAL|Integrative Breathwork Intervention|The breathwork intervention involves a sustained conscious connected breathing pattern where there is no pause between inhale and exhale. During the breathing, a participant is guided to pay attention to the strongest sensation from moment-to-moment (e.g., mindfulness of somatic sensations) and relax unnecessary effort or tension. Participants lay supine throughout the 60 minute session. The session ends with spontaneous, relaxed breathing and an opportunity to briefly share one's experience.
223938126|NCT06854432|OTHER|Biometrological measurements|Measurements will be taken from the scalp: on the vertex and occiput areas.
223938127|NCT06854432|OTHER|Biological sampling|Samples will be taken from the scalp: on the vertex and occiput areas.
223938128|NCT02404870|DRUG|Placebo|Placebo
223938129|NCT02404870|DRUG|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
223534433|NCT07161297|DRUG|Intravenous midazolam (3 mg initially, with optional 3 mg boluses) plus fentanyl (100 mcg) for procedural sedation.|\- Midazolam + Fentanyl (≤1000 caratteri) IV fentanyl 100 mcg is given first, followed after 1 minute by IV midazolam 3 mg over 1 minute. Additional midazolam may be administered based on clinical judgment. Colonoscopy starts 1 minute after sedation. Vital signs are monitored throughout.
223534434|NCT07160686|DRUG|Apixaban|apixaban 2.5mg twice a day for 6 months
223938130|NCT06888544|BEHAVIORAL|HIIT program for 24 weeks with a frequency of 2 times per week.|Participants will receive a 24-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 37 to 40 minutes with progression of training. Each HIIT section will include six high-impact weight-bearing exercise. For Weeks 1-4, the HIIT section will include 12 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 11 intervals of 60 seconds of active recovery. To ensure the subjects' safety, a chair will be used for assistance during training in the first month. Additionally, a 3 kg weight will be incorporated for the training in the final two months.
223938131|NCT06888544|BEHAVIORAL|Non-exercise control|Workshop participants in the non-exercise control group will receive a series of workshops related to daily recreation.
223938132|NCT05605496|DRUG|NP137|IV infusion, 14mg/kg, Q3W
223938133|NCT05605496|DRUG|anti-PD-1/PD-L1|IV infusion, Q3W or Q6W anti-PD1/PDL1 are standard treatments and are prepared and administred as per respective SmPC and institutional practice.
224098706|NCT06506136|DRUG|Fluoxetine|"Participants will receive fluoxetine tablets, 40 mg once daily, administered 30 minutes after breakfast for 12 weeks.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~polyethylene glycol：13.7 g enema Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
224286776|NCT03717519|DIAGNOSTIC_TEST|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
224286777|NCT00825552|DRUG|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
224286778|NCT04446988|DEVICE|Sacroiliac joint injection|Injection of sacroiliac joint with local anesthetic and steroid
224286779|NCT01005329|BIOLOGICAL|Bevacizumab|Given IV
224286780|NCT01005329|DRUG|Carboplatin|Given IV
224286781|NCT01005329|DRUG|Cisplatin|Given IV
224286782|NCT01005329|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224286783|NCT01005329|DRUG|Paclitaxel|Given IV
223534435|NCT07160686|OTHER|Placebo|Placebo twice a day for 6 months
223534436|NCT07160881|BEHAVIORAL|Pillow maniquin training|In this initiative, participants will be trained with a low-cost mannequin in addition to standard training.
223938134|NCT06814613|OTHER|Exercise|For the next 4 weeks, every night, 1 hour before the routine bedtime (or the time when the student planned to sleep), a video call (via the Google Meet application) was made with the student, and progressive relaxation exercises were performed. The exercise took approximately 20 minutes and followed the implementation protocol (Davis et al., 2008; Payne, 2000). Group interviews were conducted for students with similar sleep hours. They were asked to move to a ventilated room away from noise so that the exercises could be practiced comfortably and not interrupted.
223938135|NCT06764641|DIAGNOSTIC_TEST|Breath test|Participants must be fasted for a minimum of six hours prior to breath sample collection. Breath samples will be collected prior to the reference test for each participant (i.e. upper/lower gastrointestinal endoscopy, CT/MRI/ultrasound ± histological/cytology)
223938136|NCT01093612|PROCEDURE|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
223938137|NCT01093612|RADIATION|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
223938138|NCT01093612|PROCEDURE|Biopsy|Correlative Studies
223938139|NCT01093612|OTHER|Immunohistochemistry staining method|Correlative studies
223938140|NCT01093612|OTHER|laboratory biomarker analysis|Correlative studies
223938141|NCT01093612|GENETIC|mutation analysis|Correlative studies
223938142|NCT00521846|DEVICE|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
223938143|NCT02928978|DRUG|Ruxolitinib|tablet (taken by mouth)
223938144|NCT02928978|DRUG|Placebo (for Ruxolitinib)|tablet (taken by mouth)
223938145|NCT03381300|PROCEDURE|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
223938146|NCT06511700|PROCEDURE|It is a implementation a program incorporating nurses trained in administering intravitreal injections within the functional unit of Ophthalmology following the usual technique|Internationally, some experiences demonstrate that the administration of intravitreal injections, especially by nurses trained in aseptic techniques, is feasible without compromising patient safety. Although there is already some experience in Spain, it is a new procedure within the nursing field of the Ophthalmology service for which no results have been reported.
223938147|NCT06512051|DRUG|SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin|"Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin"
223938148|NCT04982406|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
223938149|NCT03984565|DRUG|Cannabidiol|High-CBD, low-THC sublingual product formulated in palm oil
223938150|NCT03984565|DRUG|Placebo|Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
223938151|NCT06778954|PROCEDURE|Arm I (Peritoneal application group)|At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is applied on space between peritoneum and fascia in Arm I.
223938152|NCT06778954|PROCEDURE|Arm II (Subcutaneous injection group)|At the end of gastrectomy, during closure of incision, peritoneum and fascia are closed by suture, layer by layer. Skin approximation is doen with skin stapler. Ropivacaine-Poloxamer 407 hydrogel is injected on subcutaneous area in Arm II.
223938153|NCT06016257|OTHER|Use of VirtuaCare™ for home program|Use of VirtuaCare™ system for the Home Program.
223938154|NCT02944500|DRUG|liraglutide|
223938155|NCT02944500|OTHER|Placebo|
223938156|NCT03880383|BEHAVIORAL|Coaching|Parents will interact and communicate regularly with a coach in person or by telephone. Coaches will be responsible for: identifying developmental concerns, proactive health promotion, guidance and training for developmental stimulation, parent support and education about child development, navigation of the health care system and self-management techniques. The frequency of coaching will be: once a month (minimum), for 18 months, at an average of 2.5 hours per month.
224098707|NCT06506136|DRUG|Placebo|"Participants in the Placebo Control Group will receive placebo tablets that are identical in appearance and taste to the fluoxetine tablets. They will take one placebo tablet orally twice a day for 12 weeks, following the same schedule as the treatment group to maintain blinding.~Emergency Rescue Medications: For participants in both groups who cannot have a bowel movement for three consecutive days or have intolerable symptoms, the following rescue medications will be provided:~polyethylene glycol：13.7 g enema Use of rescue medications must be recorded in the bowel movement diary and CRF, including date, time, and dosage. Rescue medications will be provided throughout the study but are not allowed within 48 hours before and after the first treatment. Distributed every two weeks, any bowel movements within 24 hours after rescue medication use will not count as CSBM."
224098708|NCT00458471|DEVICE|Insertion of a urinary catheter coated with benign E. coli|
224098709|NCT06146101|DRUG|IHL-42X Low Dose|Softgel capsule
224098710|NCT06146101|DRUG|IHL-42X High Dose|Softgel capsule
223534437|NCT07161635|DEVICE|Clareon PanOptix Pro/Pro Toric Trifocal IOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.
223938157|NCT03880383|BEHAVIORAL|Online parent education|Parents will be provided access to an online platform which will provide educational resources and access to parent-parent support. Online resources on child development are curated by researchers and representative of parent groups, and linked to this online platform. The themes covered in the online tool include resources on child development, accessing health care services and managing emotions and family dynamics. These topics range from: practical tips for managing day-to-day challenges, strategies to cope and support the child's transitions from one stage to another, practical tips when looking for developmental services for the child: knowing where and how to access services.
223938158|NCT03880383|BEHAVIORAL|Online peer support|Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge. This will put each family at the centre of each network (family, friends, health providers), allowing family networks to link with one another. Families will be able to find resources, create connections with the coach, health providers and other families, thus creating a network to support one another.
223938159|NCT02413736|DRUG|Imatinib|Imatinib 400 mg/day
223938160|NCT02830204|DEVICE|Mitral Valve Replacement (MVR) with Sapien3|subjects with surgical MVR with Sapien3
223938161|NCT04225442|OTHER|Fatty meal to challenge the physiological chronobiome in healthy young and old|The intervention consists of a fatty meal
223938162|NCT01713660|DEVICE|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
223938163|NCT05344339|PROCEDURE|Distal gastrectomy|Reconstruction after Distal Gastrectomy
223534438|NCT07161635|PROCEDURE|Phacoemulsification|Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for IOL implantation.
223938164|NCT04359732|OTHER|hybrid PET/MRI|An additional intermediate 18-FDG PET/MRI will be performed during neoadjuvant chemo-radiation therapy. Routine pre-treatment work-up PET/MRI will replace PET alone.
223938165|NCT02921555|DRUG|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
223938166|NCT02921555|DRUG|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
223938167|NCT05753930|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
223938168|NCT02986243|OTHER|Exercise|6 months worth of exercise regimen
223938169|NCT02986243|DIETARY_SUPPLEMENT|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
223938170|NCT05953116|DIETARY_SUPPLEMENT|Nutrition supplementation|Blinded researchers will provide the randomly assigned supplement product to the trial participants for a period of 90 days. Used packaging will be collected at the end of every week from each trial participant to monitor compliance.
223938171|NCT05953116|OTHER|Exercise|Trained researchers will facilitate resistance-based exercises two to three times a week in an enclosed venue (gym). Trial participants will be assessed at baseline for one repetition maximum (1RM) which will serve as a basis for load progression. A target of 3 sets and 6-15 repetitions with at least 30 seconds rest in between sets will be performed by the trial participants under supervision of a trained researcher.
223938172|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at different speeds (slow, comfortable and fast)
223938173|NCT06138925|OTHER|Analysis of running|analysis of running on flat ground at different speeds (comfortable and fast)
223938174|NCT06138925|OTHER|Analysis of walking|3-dimensional gait analysis with inertial measurement units (IMUs) on flat ground at spontaneous speed (comfortable).
223938175|NCT03246802|RADIATION|HDR partial prostate brachytherapy|temporary radioactive implant
223938176|NCT06777992|OTHER|Home topographic scans|Patients randomized to the Intervention arm of the trial will additionally use Momentum SpineTM assessment from home at 2-month intervals. If a progression is detected using Momentum SpineTM the participant will be promptly invited to acquire a second set of scans for confirmation. In case of confirmation of the progression using the images from the repeated scans, the scan results will be sent to their local orthopedic surgeon.
223938177|NCT06778694|OTHER|Motor control exercises|Bridging Dead bug Plank Pelvic tilts Squatting and lunges
223938178|NCT06778694|OTHER|Isolated strengthening lumbar exercises|Child pose Mckenzie Lat pull down Russian twist
223938179|NCT02952144|DEVICE|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
223938180|NCT06507501|OTHER|Low Load Blood Flow Restriction Exercise Training (LL-BFRE)|Blood Flow Restriction exercise training, also known as occlusion training or KAATSU training, is a contemporary exercise training method based on partially restricting arterial and venous blood flow for short periods.
223938181|NCT06507501|OTHER|High Load Resistive Exercise Training (HL-RE)|HL-RE is a conventional, well known exercise method to enhance muscle strength and improve physical performance. It's performed by using resistance bands or weights applying on the extremity.
223718786|NCT00702923|DRUG|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
223938182|NCT05854160|PROCEDURE|Electrical Pulse Train Stimulation|sEEG provides the ability to stimulate neural circuits via implanted electrodes by delivering mild intra-cranial electrical stimulations in different brain structures to estimate their impact on cognitive tasks.
224098711|NCT06146101|DRUG|Placebo|Softgel capsule
224098712|NCT06146101|DRUG|IHL-42X (Optimal Dose)|Softgel capsule
224098713|NCT06146101|DRUG|Dronabinol|Softgel capsule
224098714|NCT06146101|DRUG|Acetazolamide|Softgel capsule
224098715|NCT06146101|DRUG|Placebo|Softgel capsule
224098716|NCT01978002|BEHAVIORAL|Pain sensitivity testing|
224098717|NCT01978002|BEHAVIORAL|Urodynamic testing|
223718787|NCT00702923|DRUG|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
223718788|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
224286784|NCT03720574|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
223534439|NCT06152107|PROCEDURE|BTVA treatment plus optimal medical therapy (GOLD guidelines)|"Patients in experimental group will be treated with the InterVapor System in at least 2 subsegments of different segments(unless the two most severe subsegments are located in the same segment). Patients in control group will be treated with the InterVapor System in at least 1 segment.~A sequential procedure allows for at least 6 weeks and no longer than 6 months after the first procedure. Patients in both groups will receive ipsilateral hemithorax treatment per procedure, with a treatment volume (air + tissue) of ≤1700 mL per procedure and ≥1000 mL cumulatively across two procedures. All patients will continue to receive optimal medical therapy (GOLD guidelines) for the duration of the study.~Follow-up visits will be scheduled at 1, 3, 6 and 12 months following the second procedure with examination of pulmonary function tests, HRCT, 6-minute walk test, SGRQ-C, mMRC, CAT questionnaires. All adverse events during the study will be recorded."
223534440|NCT06160427|BIOLOGICAL|CTM Boost|Connective Tissue Matrix (CTM) Boost is a decellularized Human Cellular and Tissue Based Allograft derived from placental connective tissue. It is considered a minimally-manipulated biologic by the FDA and is marketed as an allograft for repairing connective tissue. It is administered via injection.
223534441|NCT06160427|BIOLOGICAL|PRP|"PRP is derived by a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing.~At baseline, a blood draw of 60 milliliter (mL) will be obtained and concentrated in an Angel System to yield 5 cc of PRP and a supra-physiological concentration of white blood cells. All injections will be done under ultrasound guidance. A two-part injection process will be used. An advancing 20 gauge 1.5-inch needle first placed 3 mL of 1% xylocaine proximal to the tendinopathic area or tear. The needle will then be re-inserted at the proximal aspect of the lesion and slowly removed while infiltrating of 5 mL of PRP without activation with Calcium Chloride/thrombin at the lesion and surrounding tendon."
223534442|NCT05530733|PROCEDURE|Pacifier|Pacifiers produced for premature babies will be used in the study. Pacifiers will be made of silicone material suitable for premature baby health and will not contain any harmful substances. A separate pacifier will be used for each baby, and pacifiers will be sterilized before use.
223534443|NCT05530733|PROCEDURE|Breast milk|For babies assigned to the pacifier with breast milk group, their own breast milk will be applied by dripping 1 ml into the pacifier.
223938183|NCT05929794|DRUG|Metronidazole 0.75% Topical Gel|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole gel and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or gel). At 48 hours occlusive coverings and gel are removed and electrical resistance measurements are repeated. Fresh gel and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
223938184|NCT05929794|DRUG|Metronidazole 0.75% Topical Cream|Half of enrolled subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm. Color will only be measured at baseline. Micropatch application will occur at 2 sites, followed by application of metronidazole cream and then covered with an occlusive covering. One site will be covered with an occlusive covering only (no micropatch or cream). At 48 hours occlusive coverings and cream are removed and electrical resistance measurements are repeated. Fresh cream and occlusive patches are reapplied. At 96 hours the patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis. After a minimum 7 days washout period, all of these procedures will be repeated again except that there will be no micropatch application at any of the 3 sites.
223534444|NCT03693495|DIAGNOSTIC_TEST|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
223534445|NCT03693495|DIAGNOSTIC_TEST|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
223938185|NCT05929794|DIAGNOSTIC_TEST|Transdermal water loss measurement|Baseline measurements of transepidermal water loss will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied).
224098718|NCT06503016|DRUG|Phosphocreatine|Administration of Phosphocreatine
224098719|NCT06503016|DRUG|Placebo|Saline solution of NaCl 0.9%
224286785|NCT03720574|DRUG|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
224286786|NCT01264640|DRUG|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
224286787|NCT03032861|OTHER|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
223938186|NCT05929794|DIAGNOSTIC_TEST|Electrical Resistance|Baseline measurements of electrical resistance will be made at 3 sites on the upper arm. In the study periods that have micropatch application, the measurements will be repeated after micropatch application and removal (before any metronidazole product is applied). In all study periods the measurements will also be repeated at 48 hours and 96 hours, when metronidazole product and occlusive coverings are removed from the skin.
223938187|NCT05929794|DIAGNOSTIC_TEST|Skin color measurement|Baseline measurements of skin color will be made at 3 sites on the upper arm.
223938188|NCT05929794|OTHER|Micropatch application|All subjects will undergo this intervention. Baseline measurements of transepidermal water loss, electrical resistance, and color will be made at 3 sites on the upper arm (color only measured at baseline). Two sites will have micropatch application + metronidazole product with occlusive covering. One site will have micropatch application + occlusive covering, no metronidazole product. Micropatch application will only occur on day 1 (a micropatch is a patch of 50 microneedles). Transepidermal water loss and electrical resistance are repeated after micropatch application and removal. At 48 hours occlusive coverings and metronidazole are removed; electrical resistance measurements are repeated. Metronidazole product and fresh occlusive patches are reapplied. At 96 hours patches are removed and electrical resistance measurements repeated. Blood samples are taken daily for 5 days. Measurements from the 3rd site allow each subject to serve as their own control in data analysis.
223534446|NCT03693495|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
223938189|NCT05336344|BEHAVIORAL|ENCODE|a cognitive behavioral intervention for family caregivers to improve pain management skills and overall coping
223938190|NCT06818266|DRUG|Tocilizumab (RoActemra®, 20 mg/mL).|One single intravenous infusion at 8 mg/kg (up to a maximum of 800 mg) for patients ≥ 30 kg and 12 mg/kg for patients \< 30 kg
223938191|NCT06818266|DRUG|Placebo (NaCl 0.9%)|One single intravenous infusion
223938192|NCT05908331|DEVICE|Sirolimus Drug Coated Balloon|Magic TouchTM (Concept Medical) is a semi-compliant sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and nanocarrier based drug delivery technology.
223938193|NCT05908331|DEVICE|Plan balloon Angioplasty (POBA)|Plan balloon used to open clogged or narrow coronary arteries due to underlying atherosclerosis
223938194|NCT06758700|DRUG|Teniposide administration|Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 5 consecutive days, with 21 days as one cycle of treatment.
223938195|NCT04108351|OTHER|Road-tracking test|Driving with simulator program for SDLP measurement
223938196|NCT04108351|OTHER|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
223938197|NCT04108351|OTHER|Harsh-braking test|Driving with simulator program for BRT measurement
223938198|NCT06487819|PROCEDURE|Application of a rubber dam during dental treatments for varying durations.|Patients in each group will undergo dental procedures (either operative or endodontic treatment) with rubber dam isolation. The rubber dam will be applied for the specific durations mentioned in each group to evaluate the impact of mouth opening on the temporomandibular joint (TMJ).
223534447|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
223938199|NCT06453018|DEVICE|Positional device, Rematee Bumper Belt or Night Shift|Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention
223534448|NCT02114177|DRUG|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
223938200|NCT06829121|DIAGNOSTIC_TEST|Ultrasound|The thickness of the psoas muscle and the musculus quadriceps femoris will be measured by ultrasound
223938201|NCT05038709|DEVICE|The Pink Pad Hip Kit|The pad is placed between the patient and the traction table to reduce pressure to the pudendal nerve exerted by the perineal post.
223938202|NCT05184933|OTHER|At-home Polysomnography|Participants will complete one night of unattended polysomnography in their home environment (SOMNOtouch RESP, SOMNOmedics America Inc., FL, USA).
223941413|NCT03711084|DIETARY_SUPPLEMENT|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
223534449|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
223534450|NCT02114177|DRUG|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
223534451|NCT03929003|BEHAVIORAL|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
223534452|NCT06028828|DRUG|Fludarabine|Given Day-5, Day-4, Day-3, Day-2
223534453|NCT06028828|DRUG|Melphalan|Given Day-5
223534454|NCT06028828|RADIATION|Total Body Irradiation|Given Day-1
223534455|NCT04104347|OTHER|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
223938203|NCT05184933|OTHER|Circadian Protocol|Participants will spend 4 days/3 nights in the laboratory to uncover circadian rhythms. After 2 nights for acclimatization and baseline measurements, participants will stay awake for 28 hours in dim light, constant temperature, and semi-recumbent posture. Participants will be provided with standardized snacks regularly. Polysomnography, core body temperature, sleep, finger oximetry, electrocardiogram (ECG), and beat-to-beat BP will (except microneurography) be measured throughout. Blood will be drawn every 2-4h to analyze catecholamines, renin activity, and aldosterone. All other measurements, including BP, heart rate (HR), and flow-mediated dilation will be performed regularly. Salivary samples will be collected every 2hrs (when awake) to analyze melatonin levels. A recovery sleep period will be provided and baseline testing procedures will be performed. Investigators may acquire direct recordings of sympathetic activity using microneurography.
223938204|NCT05184933|OTHER|Rested Wakefulness Trial|Participants will start wearing an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm. Participants will receive a standardized snack, and dinner \~4 hours before the start of the trial. Participants will be instrumented for microneurography. Participants will be awake in bed in dim light (\<8 lux). An investigator will constantly be present in the control room to monitor and ensure constant supine posture and wakefulness. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Flow-mediated dilation will be conducted before bed and after bed. The two trials will be conducted \~one month apart to accommodate the menstrual cycle phase in pre-menopausal females.
223938205|NCT05184933|OTHER|Overnight Sleep Trial|Participants will wear an ambulatory BP monitor upon admission. Participants will be instrumented with full polysomnography (except leg myogram), and an intravenous catheter will be placed in the non-dominant arm, and then participants will receive a standardized snack, and dinner 4 hours before the start of the trial. Polysomnography, beat-by-beat BP, and neurogram for microneurography will be done throughout each trial into awakening; blood will be sampled before, during, and immediately after each trial (total of 8 samples in each trial). Participants will be instrumented for microneurography. Participants will begin an 8-hour sleep opportunity (\<0.1 lux) at their chosen sleep time. At the end of the sleep episode, participants will be gently awoken in a standardized fashion by use of a mild auditory stimulus. Flow-mediated dilation will be conducted before bed and after sleep. The two trials will be conducted one month apart to accommodate the menstrual cycle.
223938206|NCT05184933|BEHAVIORAL|Regularized Sleep Schedule|All participants will be asked to maintain a self-selected bedtime (sleep duration not controlled) for two weeks as an intervention after the completion of the constant routine and both the resting wakefulness and overnight sleep trials. During this time, participants will be asked to call a time-stamped voicemail box upon waking and going to bed, as well as complete a daily sleep diary and wear an Actigraph device on their wrist. Ambulatory blood pressure will be measured at home before and at the end of the two-week intervention.
223938207|NCT06826937|BEHAVIORAL|Reconsolidation based short term therapy|This is a behavioral intervention that uses imaginal and in vivo exposure in daily meetings.
223938208|NCT06329856|BEHAVIORAL|Administering of artificial hydration|Administering of artificial hydration to terminal cancer patients
223938209|NCT06828354|DRUG|SHR-A1811|SHR-A1811.
223938210|NCT06828354|DRUG|Paclitaxel Injection|Paclitaxel Injection.
223938211|NCT06828354|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection.
223938212|NCT06828354|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection.
223938213|NCT06828354|DRUG|Topotecan Hydrochloride for Injection|Topotecan Hydrochloride for Injection.
223938214|NCT04705415|DRUG|Niclosamide|Niclosamide is an antihelmintic with in-vitro antiviral activity
223938215|NCT04705415|DRUG|Placebo|Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients
223938216|NCT06748768|DIAGNOSTIC_TEST|group 1|To determine the optimal treatment for dry eyes in term of cost effectiveness and time efficiency by comparing omega 3 supplements versus warm compression
223938217|NCT06828107|DEVICE|SENSE device|The SENSE Device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage and/or cerebral edema.
223938218|NCT01586104|RADIATION|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
223718789|NCT00702923|DRUG|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
223938219|NCT06230705|OTHER|Guided management|Guided Management
223938220|NCT06230705|OTHER|Self management|Self management
223938221|NCT04828577|BEHAVIORAL|Real Time Neurofeedback|Participants receive feedback from own brain activity.
223534456|NCT04104347|OTHER|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
223718790|NCT00702923|DRUG|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
224098720|NCT01042379|DRUG|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
224098721|NCT01042379|DRUG|AMG 386 with or without Trastuzumab|Arm is closed.
223938222|NCT04828577|BEHAVIORAL|"Idealized/Sham Neurofeedback"|Participants receive idealized feedback not related to their own brain activity.
223938223|NCT05742165|BEHAVIORAL|Time Restricted Eating (TRE)|TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.
223938224|NCT06753994|DRUG|SGLT-2 inhibitor|Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia. In this study, participants will start with a dose of 2.5 mg of empagliflozin for four weeks, which will then be increased to 10 mg for the following nine weeks.
223938225|NCT06760104|DIAGNOSTIC_TEST|Dental Plaque Detection Using AI Models|"1. AI Model Analysis:~   Description: Intraoral images of participants will be captured using standardized imaging techniques. These images will then be analyzed using various artificial intelligence models specifically designed for detecting dental plaque. The AI models will process the images to identify and quantify the presence of dental plaque.~2. Clinical Assessment:~Description: A qualified dentist will perform a traditional clinical examination of the participants to assess dental plaque using standard examination techniques. This will serve as the reference standard against which the AI models will be compared.~Study Procedures Image Acquisition: Intraoral images will be taken of each participant using \[ intraoral camera\].~AI Model Evaluation: The captured images will be analyzed using different AI algorithms, which may include."
223938226|NCT06719492|BEHAVIORAL|nutrition education|15 minutes of surgery specific nutrition education provided by a Registered Dietitian.
223938227|NCT06763263|BEHAVIORAL|Experimental|Children and their parents in this group will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. Then, the child will be allowed to choose one of the superhero clothes he/she wants in his/her room and will be allowed to wear the clothes. The superhero figure will be shown to him/her and he/she will be allowed to play with the clothes and the figure for 2 hours.
223938228|NCT06763263|BEHAVIORAL|Control|The children in this group and their parents will be informed about the research and their verbal and written consent will be obtained. A questionnaire will be filled out before the application. The children will be evaluated in terms of their reactions after their hospitalization, they will not be dressed in any clothing and no superhero figures will be used. Then the questionnaire will be filled out again and scoring will be done. In order to prevent ethical bias before discharge, the child will be dressed in a superhero costume and will be allowed to spend time with the clothing and figure.
223938229|NCT06820827|OTHER|Myofascial release|The participants will receive myofascial release (MFR) on erector spinae, quadratus lumborum, piriformis and gluteus medius. The duration of MFR for each muscle will be 90 to 120 seconds, three times/week for eight weeks.
223938230|NCT06820827|DEVICE|High-power pain threshold ultrasound|The participants will receive high-power pain threshold ultrasound on sacroiliac joint, 20 minutes, three times/week for eight weeks.
223938231|NCT05470114|DRUG|LEO 138559|LEO 138559 is an antibody given by subcutaneous injection.
223938232|NCT05470114|DRUG|Dupixent®|Dupixent® is an antibody given by subcutaneous injection.
223938233|NCT04649047|BEHAVIORAL|Goal-oriented episodic future thinking|All participants will receive a 3-week web-based intervention plus individual health coaching. The intervention topics include stress management, healthy eating, and physical activity
223938234|NCT03324425|DRUG|Simvastatin 80mg|Participants will receive simvastatin 80 mg by mouth daily at bedtime
224098722|NCT01042379|DRUG|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
224098723|NCT01042379|DRUG|MK-2206 with or without Trastuzumab|Arm is closed.
224098724|NCT01042379|DRUG|AMG 386 and Trastuzumab|Arm is closed.
223938235|NCT04314219|DRUG|Cyclophosphamide 50mg|Cyclophosphamide as GVHD prophylaxis will be on day +3 and day +5
224098725|NCT01042379|DRUG|T-DM1 and Pertuzumab|Arm is closed.
224098726|NCT01042379|DRUG|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
224098727|NCT01042379|DRUG|Ganetespib|Arm is closed.
224098728|NCT01042379|DRUG|ABT-888|Arm is closed.
224098729|NCT01042379|DRUG|Neratinib|Arm is closed.
224098730|NCT01042379|DRUG|PLX3397|Arm is closed.
224098731|NCT01042379|DRUG|Pembrolizumab - 4 cycle|Arm is closed.
224098732|NCT01042379|DRUG|Talazoparib plus Irinotecan|Arm is closed.
224098733|NCT01042379|DRUG|Patritumab and Trastuzumab|Arm is closed.
224098734|NCT01042379|DRUG|Pembrolizumab - 8 cycle|Arm is closed.
223938236|NCT04314219|DRUG|Methotrexate|Methotrexate as GVHD prophylaxis will be on day +1, day +3, and day +6
223938237|NCT05200572|BEHAVIORAL|Dyadic Life Review (DLR)|DLR will consist of 8 sessions delivered by a trained licensed clinician (i.e, the PI or other trained clinician) via video-conferencing in weekly sessions of 60 minutes. Each session will facilitate a recall of each phase of life: childhood, adolescence, young adulthood, mid-life, earlier later life, and later life. While together, the patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life.
223938238|NCT06934616|DRUG|GB268|GB268 will be administered via intravenous infusion once every 3 weeks on Days 1 of each 21-day cycle
223938239|NCT06839521|OTHER|Walk Test-T|6MWT will be conducted according to traditional protocols. During the test, parameters such as heart rate, oxygen saturation, and walking distance will be measured and compared with traditional methods.
223938240|NCT06839521|OTHER|Walk Test-A|In order to develop Android-based 6DYT, the system will be designed with a multidisciplinary team consisting of software engineer and physiotherapist. In this programme, separate algorithms will be developed for indoor and outdoor environments so that individuals can be evaluated in a hospital environment, at home or in daily life. In indoor environments, the GPS signal is lost or there is not enough signal strength. For this reason, the programme will be developed so that the gyroscope of the phone can be used for distance measurement. GPS signals will be used outdoors. In this way, the physical activity level of the individual both in the hospital and in daily life will be measured.
223938241|NCT00719888|DRUG|Cyclophosphamide|Given IV
223938242|NCT00719888|DRUG|Cyclosporine|Given IV and PO
223938243|NCT00719888|PROCEDURE|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
223938244|NCT00719888|DRUG|Fludarabine|Given IV
223938245|NCT00719888|OTHER|Laboratory Biomarker Analysis|Correlative studies
223938246|NCT00719888|DRUG|Mycophenolate Mofetil|Given IV and PO
223938247|NCT00719888|RADIATION|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
223938248|NCT00719888|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo UCBT
223938249|NCT00719888|DRUG|Thiotepa|Given IV
223938250|NCT05037513|BEHAVIORAL|SBCM-PrEP|Multi-session SBCM intervention adapted for PrEP initiation focus
223938251|NCT05037513|BEHAVIORAL|CDC-PrEP|1 session PrEP education following CDC guidelines
223938252|NCT06769789|OTHER|Drug free invitro activation Ovary|Drug free invitro activation Ovary
223938253|NCT03773107|DRUG|Carfilzomib|Irreversible proteasome inhibitor
223938254|NCT03773107|DRUG|Ruxolitinib|Oral JAK inhibitor
223938255|NCT03773107|DRUG|Dexamethasone|glucocorticoid
223938256|NCT06759493|DIAGNOSTIC_TEST|Retinol isotope dilution technique|A group of 60 school children will be recruited through a stratified sampling. To this first group of 60 school children a retinol isotope dilution (RID) test for total body store assessment will be applied. The remaining 98 school children will be recruited according to stratified sampling and divided into two groups of 49 children (females and males). To these groups of children, the modified relative dose response (MRDR) test, a qualitative measure of vitamin A status will be used to investigate the absorption of 3,4-didehydroretinyl acetate in oil.
223938257|NCT00984815|DRUG|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
223938258|NCT06944795|DEVICE|SWIR device|A Short Wave Infrared (SWIR) Otoscope will record images for both the SWIR and white light video otoscopes. These images of the middle ear will be recorded in AVI format.
223938259|NCT06945809|DEVICE|WeFlow-EndoPatch Aortic Endovascular Patch System|The WeFlow-EndoPatch Aortic Endovascular Patch System for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
223938260|NCT06945809|OTHER|Conventional Treatment group|Doctors prescribe conventional medicines and regular imaging tests.
223534457|NCT05198258|OTHER|Implementation strategy - experimental group|On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
223938261|NCT06944548|BIOLOGICAL|Lipidomic analyses|"3 blood samples taken from 2 x 6 mL EDTA tubes for patients~* At baseline~* Week 5 of the adapted physical activity protocol~* Follow-up visit for adapted physical activity~  1 blood sample taken from 2 x 6 mL EDTA tubes for volunteers~* At baseline"
223938262|NCT06944548|OTHER|Adapted physical activity program|8-week adapted physical activity program. This program will be adapted to each group
223938263|NCT06945341|BEHAVIORAL|Focus-Group discussion|Focus-Group discussion on factors that could lead to an increase in the adoption of neuromuscular monitoring taking into account different country-specific contexts.
223938264|NCT05001139|DEVICE|Relizema ecofoam|DermoRelizema ecofoam, class II a medical device, topical compact mousse, to be applied 2 times per day during the 42 days of study duration
223938265|NCT06943950|DRUG|SYHX1901|Administered orally, once daily (QD)
223938266|NCT02891967|OTHER|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
223938267|NCT02891967|OTHER|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
223938268|NCT05539209|BEHAVIORAL|OKquit|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys plus OKquit Smartphone App including tailored messages and on-demand content designed to assist participants in their cessation attempt.
223938269|NCT05539209|BEHAVIORAL|Standard Helpline Care|Standard Oklahoma Helpline care plus smartphone-based daily check-ins and weekly surveys.
223938270|NCT05223387|DEVICE|Axiom TL REG|"Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
224098735|NCT01042379|DRUG|SGN-LIV1A|Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
224098736|NCT01042379|DRUG|Durvalumab plus Olaparib|Arm is closed.
223938271|NCT05223387|DEVICE|Axiom BL REG|"Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis"
223938272|NCT06950320|DEVICE|P-STIM (Biegler, Mauerbach, Austria) is a battery-operated micro-stimulation appliance|P-STIM (Biegler, Mauerbach, Austria) is a battery-operated micro-stimulation appliance weighing 5 grams, designed as a disposable product for a single use. P-STIM is placed behind the patient's ear and connected to stimulation needles (usually 3 needles) on the auricle. For the study, only one stimulation needle was needed. P-STIMTM offers regular therapy over several days. The appliance transmits low frequency electric pulses to exposed nerve endings. The built-in microchip creates periods of stimulation and rest, each lasting approximately 3 hours. Stimulation was performed with a frequency of 1Hz for 40min followed by a break of 20 min.
223938273|NCT06950320|DEVICE|Placebo|The placebo device is a look-a-like, that stimulates only for 1h hour and then stops.
223938274|NCT06950931|DIAGNOSTIC_TEST|uPTM-FeA|In this monocentric prospective cohort study, we will measure uPTM-FeA by enzyme-linked immunosorbent assay (ELISA) kit DNLite IVD 103 in cooperation with PromedeusLab. Human uPTM3-DKD ELISA is a colourimetric immunoassay for quantitatively determining human unique Fetuin-A with specific post-translational modification (PTM) in urine.
223938275|NCT06951516|BEHAVIORAL|Linguistic simplification|Children will participate in screen-based language processing and word learning tasks in which they hear utterances with different types and amounts of linguistic simplification (i.e., a within-group manipulation).
223938276|NCT06951022|OTHER|Sujok therapy|Participants in the intervention group will receive seed therapy using apple seeds applied to specific hand points corresponding to the bladder area.
223938277|NCT06952101|PROCEDURE|Sparing Approach|Accurate staging with Pelvic MRI, CT scan, PET total body have to be performed before local excision in order to exclude false positive mesorectal lymph nodes. Subsequent Wait and See (W\&S) approach could be proposed.
223938278|NCT06952101|PROCEDURE|experimental chemoradiotherapy|Participants with cT2N0 rectal tumors are typically candidates for upfront surgical resection. The investigators propose an alternative approach based on experimental chemoradiotherapy (spCRT). Literature suggests that pathologic complete response (pCR) rates after CRT are significantly higher than the 25% described for intermediate-advanced tumors. The investigators will assess clinical complete response (cCR) or complete metabolic response (cMR) through a multidisciplinary restaging process, including MRI, PET, thorax-abdomen CT scan, ERUS, and rectoscopy. In participants achieving cCR or cMR, a Watch and Wait (W\&S) strategy or Local Excision/Transanal Minimally Invasive Surgery (LE/TAMIS) may be proposed to avoid the physical and psychological consequences of major surgery, followed by a rigorous surveillance program.
223938279|NCT06952101|PROCEDURE|Standard Chemotherapy|Tumors will be initially treated with standard CRT (stCRT). Patients who reach cCR-cMR at restaging they are already candidates to sparing approaches with W\&S/LE/TAMIS according to Multicentric Resarch Study Protocol
223938280|NCT06950372|DRUG|Ropivacaine concentration low|Brachial plexus nerve block with ropivacaine 3.75 mg/ml
223938281|NCT06950372|DRUG|Ropivacaine concentration high|Brachial plexus nerve block with ropivacaine 7.5 mg/ml
223938282|NCT06950684|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants will take a daily supplement of whey protein powder (Easy Whey) providing 25 grams of protein each day for the duration of 6 months
223938283|NCT06950684|BEHAVIORAL|Resistance Training Program|Participants will engage in resistance training consisting of one guided online session each week and two additional independent resistance training sessions weekly, totaling three sessions per week, for a duration of 6 months.
223938284|NCT06951802|DRUG|Ketamine|Low-dose administration of ketamine during laparoscopic surgery
223938285|NCT06951802|DRUG|Propofol|Control group
223938286|NCT06952283|BEHAVIORAL|Inducing mental fatigue|"During the mental fatigue induction phase, a 30-minute Stroop task will artificially induce mental fatigue, simulating the mental fatigue state that athletes experience during competitions or training sessions. The Stroop task is a classic cognitive control task widely used for inducing mental fatigue. Research in sports science has shown that a 30-minute Stroop task significantly increases subjective fatigue and reduces physical performance. This study will use a smartphone-based version of the Stroop task (with brightness and touch sensitivity standardised), where colour words (such as red and blue) are displayed continuously, but the font colour does not match the word's meaning. Participants must ignore the word's meaning and respond only based on the font colour. The Stroop task requires sustained attention, conflict resolution, and cognitive inhibition, leading to cognitive resource depletion and mental fatigue accumulation."
224286788|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
223534458|NCT05198258|OTHER|Implementation - control group|Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
223534459|NCT04446403|PROCEDURE|Suprascapular Nerve Block|The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .
223534460|NCT04446403|PROCEDURE|Axillary Nerve Block|Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.
223534461|NCT04446403|PROCEDURE|posterior cord block|Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.
223938287|NCT06952283|BEHAVIORAL|Music intervention|During the music intervention phase, participants will listen to 15 minutes of classical music to facilitate mental fatigue recovery. This study selects Mozart's Eine Kleine Nachtmusik as the intervention music, a piece that has been applied in previous mental fatigue recovery studies and has been validated as an effective intervention. The intervention duration is set at 15 minutes, as multiple studies have confirmed this duration to be sufficient to produce recovery effects without causing additional cognitive load or auditory fatigue. The music will be played through a smartphone, with the intervention volume controlled at 50-60 dBA. Considering that the maximum volume of a smartphone is approximately 105-113 dBA, the standardised intervention volume is set at 50% (52.5-56.5 dBA) of the smartphone's maximum volume to ensure consistency among all participants.
223534462|NCT04446403|PROCEDURE|General anesthesia|General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
223938288|NCT06953492|OTHER|PSQI|PSQI
223938289|NCT06952465|DRUG|Deucravacitinib|As per product label
223938290|NCT06952465|BIOLOGICAL|Any biologic treatment for psoriasis|According to the product label
223938291|NCT06951971|DRUG|dose-modified E-Ru|Emapalumab (1-2 mg/kg intravenously once weekly for 8 weeks) + Ruxolitinib (15-30 mg orally twice daily for 8 weeks)
223938292|NCT06951971|OTHER|Salvage treatment and follow-up|1\) for patients who did not respond to the E-Ru regimen after 7 days or who relapsed at any point during treatment, a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP) was administered; 2) for patients diagnosed with lymphoma after enrollment, chemotherapy was initiated; 3) for patients who completed 8 weeks of treatment without recurrence and had no detected HLH-related gene mutations, follow-up was initiated; and 4) for patients who met the criteria for allo-HSCT, allo-HSCT was performed.
223938293|NCT06950996|OTHER|Risk in prostate cancer|the prediction involves the classification of the prostate cancer according to the level of prostatic antigen (PSA), the biopsy classification of the aggressiveness of the tumour, and also the localisation of the tumour
223938294|NCT06950996|OTHER|Life expectancy in lung cancer|Clinicians will evaluate life expectancy in lung cancer using CTs, together with some clinical information.
223938295|NCT06950996|OTHER|Histological subtype|An assessment by pathology of the subtype of breast tumour
223938296|NCT06950996|OTHER|Staging of colon cancer|classify size, lymph node involvement and possibility of metastasis in medical images (computerized tomosynthesis) of thorax and pelvis region
223938297|NCT06950996|OTHER|invasion in rectum cancer|assess whether vascular extramural o mesorectal fascia has been invaded in the tumour using magnetic resonance medical images taken at diagnosis in the pelvic region
223938298|NCT06952374|DEVICE|SmartWave Lithotripsy balloon|ntravascular lithotripsy is an approved adjunct interventional therapy in treating calcified lesions to facilitate stenotic lesion opening in peripheral vascular disease and coronary artery disease. The off-label use of current peripheral lithotripsy balloon in mitral valve as a compassionate treatment or as an adjunct treatment before mitral balloon valvuloplasty and transcatheter mitral valve replacement has been reported with success . A possible mechanism is that lithotripsy preferentially impacts hard tissue, disrupts calcium, and leaves soft tissue undisturbed, improving valve pliability, preventing leaflet damage, and making subsequent valvuloplasty safer.
224286789|NCT01060475|DRUG|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
224286790|NCT01060475|DRUG|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
224286791|NCT01060475|DRUG|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
224286792|NCT00280072|DEVICE|Renal Assist Device|
224286793|NCT03525730|DRUG|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
224286794|NCT03525730|DRUG|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
224286795|NCT00269542|DRUG|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
224286796|NCT00269542|DRUG|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
224286797|NCT00608517|BIOLOGICAL|anti-thymocyte globulin|Given IV
224286798|NCT00608517|DRUG|cyclophosphamide|Given IV
224286799|NCT00608517|DRUG|fludarabine phosphate|Given IV
224286800|NCT00608517|DRUG|methylprednisolone|Given IV
224286801|NCT00608517|RADIATION|total-body irradiation|Given daily for 1-4 days
224286802|NCT04686838|BEHAVIORAL|READyR II: A|Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.
224286803|NCT04686838|BEHAVIORAL|READyR II: B|Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.
224286804|NCT04031638|OTHER|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
224286805|NCT06557278|BIOLOGICAL|AlloStim|experimental immunotherapy to prime for checkpoint inhibitor
224286806|NCT06557278|DRUG|Bavencio|anti-PDL1 checkpoint inhibitor
223938299|NCT06950528|BEHAVIORAL|Control group|Control Group consists of six motion videos, including: crossover steps, high knees, lateral raises, punching movements, downward leg punches from a standing position, and elbow-to-chest expansions
223938300|NCT06950528|BEHAVIORAL|Kinect group|Kinect Group features the same software functionality and design as the application based on bullet-screen cameras, but the hardware is built using a Kinect sensor. The gamified platform is primarily developed and presented using Unity software. The Kinect 3D motion-sensing camera incorporates real-time dynamic capture and image recognition capabilities, offering new possibilities for interactive approaches to motion therapy
223938301|NCT06950528|BEHAVIORAL|Monocular group|The game employs a virtual avatar to replicate users' movements, thereby fostering an immersive and engaging experience. A monocular camera captures users' movements in real time, which are analyzed through pose estimation algorithms and subsequently mapped onto the virtual avatar. Users interact with the game by following on-screen visual demonstrations, presented as either static images or animations, to perform the prescribed exercises. Movement accuracy is evaluated by the system, with scores awarded based on performance. To enhance user motivation and adherence, the game incorporates a reward system, where points earned through accurate execution can be redeemed for in-game rewards, such as unlocking background music, avatar customization options, and new virtual environments.
223938302|NCT06950333|OTHER|POCUS education curriculum|The training includes a 4-hour curriculum consisting of a 1-hour didactic session covering ultrasound principles and key applications, followed by 3 hours of hands-on practice using standardized models or phantoms under instructor supervision. Core scanning topics include Focused Assessment with Sonography for Trauma (FAST), lung ultrasound for dyspnea, carotid Doppler for suspected stroke, and focused cardiac ultrasound for cardiac arrest. Post-training assessments include a written test and an Objective Structured Clinical Examination (OSCE).
223938303|NCT06951633|OTHER|Subterranean, pulmonary rehabilitation|Pulmonary rehabilitation in the underground Health Resort of the 'Wieliczka' Salt Mine
224286807|NCT02862249|BIOLOGICAL|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
223534463|NCT00331032|DRUG|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
223534464|NCT00331032|DRUG|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
223534465|NCT06289465|OTHER|Observation|Seasonal workers will be assessed in the assessment area established in the hazelnut field and healthy controls will be assessed in their homes.
223938304|NCT06952036|PROCEDURE|Standard Direct-acting antivirals (DAA) treatment procedures for patients with hepatitis C|Initiated Standard DAA treatment among HCV RNA positive patients.
223938305|NCT06745622|DRUG|HSK39297 tablets|HSK39297 tablets until the end of treatment
223938306|NCT05961995|BEHAVIORAL|Heartfulness meditation|Heartfulness meditation is a secular, specific, guided meditation technique that includes progressive relaxation with a concentrated focus on the heart. The HFN meditation will last 30 minutes. There will be a prescribed progressive relaxation technique which will last for \~ 5-10 minutes followed by the heart-based meditation.
223938307|NCT05650736|DRUG|Abrocitinib 200 mg|Abrocitinib (Cibinqo) is FDA approved at 200 mg dose once daily for the treatment of atopic dermatitis. It is not currently FDA approved for the treatment of GA.
224098737|NCT01042379|DRUG|SD-101 + Pembrolizumab|Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
224098738|NCT01042379|DRUG|Tucatinib plus trastuzumab and pertuzumab|Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
224286808|NCT02862249|BIOLOGICAL|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
223534466|NCT02207543|OTHER|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
224286809|NCT05343221|DEVICE|High Fidelity Simulator|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
224286810|NCT05343221|DEVICE|Haptic|First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
224286811|NCT00478049|DRUG|Gefitinib|250 mg oral tablet
224286812|NCT00478049|DRUG|Docetaxel|intravenous infusion
224286813|NCT04686513|OTHER|Observation|observational study
224286814|NCT02152202|OTHER|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
224286815|NCT02152202|OTHER|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
224286816|NCT01363141|OTHER|Regular AGE Diet|Regular AGE Diet
224286817|NCT01363141|OTHER|Low AGE Diet|One year reduction in dietary AGE intake.
223534467|NCT04055753|DRUG|Doxil|Doxil 50 mg/m2, as per institutional standard
223534468|NCT04055753|DRUG|Doxorubicin|Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
223534469|NCT05731271|DRUG|TST003|IV humanized anti-GREM1 monoclonal antibody
223938308|NCT06951867|DRUG|Tezepelumab|The exposure of primary interest is tezepelumab for severe asthma. Exposure will be assessed based on prescriptions or administrations depending on the data source. A comparable cohort of unexposed patients treated with high-intensity SOC will be identified based on the presence of a trigger exposure (i.e., augmentation or change of the non-biologic high-intensity treatment that does not represent treatment de-escalation) to mirror tezepelumab start in the exposed cohort. Due to the limited knowledge of the cardiovascular profile of biologics, SOC for comparative analyses will only include non-biologic high-intensity treatment.
223938309|NCT06950294|DRUG|High dose inhaled nitric oxide|Inhaled nitric oxide starting at 250-300 ppm, 40min, every 6 hours, from day 1 to day 5
223938310|NCT06950294|OTHER|Sham treatment|Sham treatment with nitric oxide delivering and monitoring devices connected as the intervention group
223938311|NCT06950294|OTHER|standard therapy|Standard therapy pneumonia and critical illness
223938312|NCT06948045|PROCEDURE|PLLA application to the mandibular angle|The investigator will mark the application area by palpating the inferior and posterior boundaries of the face and the mandibular ramus, approximately 1 cm from these anatomical landmarks. The second PLLA injection point will be marked 1 cm from the inferior bony border of the mandible, anterior to the mandibular ligament. The demarcated area will be anesthetized with a local infiltration of 0.3-0.5 mL of 1% lidocaine with epinephrine, using a 30G needle. PLLA will then be reconstituted in 10 mL of sterile water for injection. Administration will be performed with a 30G needle inserted perpendicularly into the marked area until the supraperiosteal plane of the mandibular angle is reached, delivering a 0.7 mL bolus of the reconstituted product. At the second site-1 cm from the inferior bony border of the mandible, anterior to the mandibular ligament-a 0.2 mL dose of the reconstituted product will be injected.
223938313|NCT06951724|DEVICE|Aspiration Catheter|Thrombus aspiration using Aspiration Catheter
223938314|NCT06951724|DEVICE|Export Advance Aspiration Catheter|Thrombus aspiration using Export Advance Aspiration Catheter
223938315|NCT06952296|DRUG|Dydrogesterone|"The duration of treatment with dydrogesterone is determined by the physician before inclusion in the study and will last for 6 menstrual cycles (Cycle used in the protocol refers to menstrual cycle. 1 cycle is 28 days on average)"
223938316|NCT06953258|OTHER|Home-based eccentric training at long muscle length|The training program will include conventional resistance exercises, with progressive increases in intensity and volume tailored to each participant's capabilities. In this condition, specific to the Arm #1, four specific exercises targeting the knee extensors and plantar flexors will be performed at long muscle lengths.
223938317|NCT06953258|OTHER|Conventional home-based training|The training program will include conventional resistance exercises, with progressive increases in intensity and volume tailored to each participant's capabilities. In this condition, specific to the Arm#2, four specific exercises targeting the knee extensors and plantar flexors will be performed in a conventional manner (i.e., at neutral or shorter muscle lengths).
223938318|NCT06951529|OTHER|Reproductive violence education|The training content, which was created by obtaining expert opinions based on literature, will cover the violence that women are exposed to or may be exposed to according to the cycles they experience during their reproductive years. Definition of Violence and Its Effects on Women's Health, Adolescence and Menstruation Period Violence, Family Planning and Infertility Violence, Pregnancy and Birth-Related Violence, Menopause-Related Violence, Legal Processes in Combating Reproductive Violence.
223938319|NCT05385588|OTHER|cognitive functional assessment|"* Self-administered questionnaire~* Cognitive and functional tests~* Medical questionnaire~* Sampling for biobank (28-32 ml will be collected)"
223938320|NCT01563185|DRUG|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
223938321|NCT02259855|DRUG|Tipranavir|
223938322|NCT02259855|DRUG|Ritonavir|
223938323|NCT02259855|DRUG|Pegylated interferon|
223938324|NCT02259855|DRUG|Ribavirin|
223938325|NCT05994833|BEHAVIORAL|VPT|The VPT will be comprised of weekly virtual visits with the participant for one month. During the visits, the physical therapist will review the exercises that were prescribed, adherence, provide feedback to the participant as they execute the exercises onscreen and make corrections, make any progression or adjustments to the exercises, review running cues they learned from the testing session and answer any questions. The therapist will also review any new activities that are initiated during the previous week (to control for confounders), changes in musculoskeletal pain and participation in running volume.
223938326|NCT06264258|BEHAVIORAL|DVx-T1D™ app|The intervention group will be introduced to the DVx-T1D™ app and the participants will go home with the tablets that has the game installed. Participants will be asked to play the game for 20 mins or more daily. The aim of the app is to impart good behavioral changes in children with T1D in terms of diabetes education, on how to treat a low or a high blood sugar event and make healthy eating choices.
223938327|NCT06202079|DRUG|GZR4 Injection|GZR4 injection s.c., once-weekly, treat-to-target dose
223938328|NCT06202079|DRUG|Insulin Degludec|Insulin Degludec s.c., once-daily, treat-to-target dose
223938329|NCT05697068|BEHAVIORAL|COVID Prevention Program (CPP)|This project is a promotor/a-led COVID-19 Prevention Program (CPP) for Latino patients of a Federally Qualified Health Center (FQHC) who are recently diagnosed with SARS-CoV-2. The program will implement immediate risk reduction strategies to prevent household spread of COVID-19, followed by risk reduction strategies to prevent community spread. Patients and household members who agree to participate will be patients of the FQHC (the covered entity) and will have completed a broad consent that authorizes program activities (e.g., COVID-19 testing, individualized counseling). Patients are free to refuse to participate in the CPP without impact on other services they may receive at the clinic. Research activities will be managed by study's measurement team, which involves surveys conducted on index patients at baseline, 1-, 6-, 12-, and 24-months. Written informed consent will be obtained for all research activities occurring outside of clinical care.
223938330|NCT00840047|DRUG|Methionine|Intravenous injection
224098739|NCT01042379|DRUG|Cemiplimab|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
224286818|NCT04722328|DIAGNOSTIC_TEST|CSF metagenomic next generation sequencing (mNGS)|TestCSF routine, biochemical, smear staining (Gram staining, acid fast staining, ink staining), culture and mNGS。
224286819|NCT05646628|BEHAVIORAL|Qualitative Interviews|Semi-structured Qualitative Interviews
223938331|NCT03955627|BEHAVIORAL|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks conducted by Zoom video, followed by an 8-week home-based version of the same program participants do on their own with bi-weekly coaching calls.
223938332|NCT06000410|BIOLOGICAL|Amniotic Suspension Allograft|This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.
223938333|NCT06000410|DRUG|Placebo|Matching placebo is 0.9% normal saline: 4 mL to be injected IA.
223938334|NCT04192773|DRUG|IV Lidocaine|IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
223938335|NCT02511574|DRUG|natural progesterone|
223938336|NCT02511574|DEVICE|cervical pessary|
223938337|NCT04542031|OTHER|Questionnaire|Questionnaire to be completed at 6 and 12 months
223938338|NCT04424303|DRUG|Tofacitinib|Observational study
223938339|NCT06550804|BEHAVIORAL|A-TEAM|Participants randomized to the intervention arm will receive the proposed intervention, which involves an electronic adherence device called Wisepill and triaged text alerts to the user, the social support, and the case manager for same day, two day, and seven day device non-openings.
223938340|NCT05712317|BEHAVIORAL|Exergame Intervention|8-week exergame-based intervention 3x per week
223938341|NCT05712317|BEHAVIORAL|Moderate-intensity endurance exercise|8-week moderate-intensity endurance exercise 3x per week
223938342|NCT03547947|DEVICE|Medacta Shoulder System|Total Shoulder Arthroplasty
223938343|NCT06056310|DRUG|Xevinapant|Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
223938344|NCT06056310|DRUG|Cisplatin|Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).
223938345|NCT06056310|RADIATION|intensity-modulated radiation therapy (IMRT)|Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
223938346|NCT04121806|OTHER|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
223938347|NCT04803370|OTHER|Convalescent Plasma with antibody against SARS-CoV-2.|"Convalescent plasma plus standard treatment for COVID-19. The convalescent plasma is from patients recovered from COVID-19 and negative viremia in the test detection COVID-19.~The infusions will be given on days 1 and 2, of the study, after the positive result for COVID-19 of the recipient patient."
223938348|NCT04803370|OTHER|Standard treatment for COVID-19|The patients will receive the standard treatment for COVID-19, according to guidelines for COVID-19 (retrovirals drugs, interferon-α / β, anti-Interleukin-6 monoclonal antibody, oxygen therapy, etc..)
224286820|NCT02253602|DRUG|Ferumoxytol|maximum rate of administration 1 ml/sec
224286821|NCT04121117|OTHER|Chronic obstructive pulmonary disease screening|"To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire."
224286822|NCT04128202|BEHAVIORAL|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
223534470|NCT05544721|DRUG|Ropivacaine|0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
223534471|NCT03801512|OTHER|Steroid|Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
223534472|NCT03801512|OTHER|Acupuncture|1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
223938349|NCT06527079|OTHER|Opioid Tapering Pathway Clinical Decision Support (CDS)|Clinical decision support in the form of an electronic health record (EHR)-integrated, provider facing notification suggesting the provider utilize a clinical care pathway that provides resources and decision support in opioid tapering in line with CDC guidelines.
223938350|NCT06963476|DEVICE|repetitive transcranial magnetic stimulation (rTMS) for AUD|Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode locations: FP1 for mPFC and F3 for l-dlPFC.
223938351|NCT06963476|DEVICE|repetitive transcranial magnetic stimulation (rTMS) for OUD|Description: Transcranial magnetic stimulation (TMS) is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction. To administer TMS, a stimulator equipped with a figure-8 coil will be used. Two separate coils will be used that are similar in appearance and acoustic properties. One active, unblinded, coil will be used to determine resting motor threshold (RMT) and deliver pulses for the recruitment curves; the other coil will be used to deliver rTMS. rTMS stimulation will be targeted using standard EEG electrode location F3 for l-dlPFC.
223938352|NCT05592886|OTHER|SMT04 formula|The SMT04 formula is a synbiotic containing probiotics and prebiotics
223938353|NCT05592886|OTHER|Active placebo|The active placebo is 2 mg Vitamin C with an inert substance made of starch filler. The flavor, coloring and appearance are unidentifiable to the study product.
223938354|NCT05370430|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-NHL
223938355|NCT04365569|BEHAVIORAL|Nutrition and physical activity counseling program|"6-month interventional, counseling program based on nutrition and physical activity consisting of:~1\. Nutritional counseling by a Registered Dietitian (RD) 2) Implementation of an adequate physical activity program"
223534473|NCT03801512|OTHER|Platelet Rich Plasma|Inject investigators Platelet Rich Plasma at neuritis nerve roots
223534474|NCT04122378|OTHER|acupuncture|The acupuncture will be provided by the licensed acupuncturist using standard methods.
223938356|NCT01176006|PROCEDURE|Reduced-intensity hematopoietic stem cell|stem cell transplant
223938357|NCT01176006|DRUG|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
223938358|NCT01176006|DRUG|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
223938359|NCT01176006|PROCEDURE|Total Body Irradiation (TBI)|200 cGy on Day -1
223938360|NCT01176006|DRUG|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 3 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
223938361|NCT01176006|PROCEDURE|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
223938362|NCT01176006|PROCEDURE|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
223938363|NCT06444607|PROCEDURE|Venepuncture|Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
223938364|NCT06444607|PROCEDURE|Venepuncture|Volunteering for blood draw.
223938365|NCT05910528|DRUG|Afimkibart|Afimkibart will be administered during the Induction, Maintenance and OLE period.
223938366|NCT04264572|OTHER|Medically Tailored Meals|MTM are meals designed by a Registered Dietitian Nutritionist to reflect appropriate dietary therapy according to evidence-based nutrition practice guidelines. They address medical diagnoses, symptoms, allergies, inability to chew or swallow, medication management, and side effects to ensure the best possible nutrition-related health outcomes.
223938367|NCT04264572|BEHAVIORAL|Tele-Medical Nutrition Therapy (tele-MNT)|Medical nutrition therapy (MNT) is offered as a component of usual care in many health systems, and consists of individuals receiving nutrition education tailored to their unique medical needs. Tele-MNT is the use of video technology to deliver MNT.
223938368|NCT06056193|PROCEDURE|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list
223938369|NCT05555628|OTHER|Mandibular Exercise|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
223938370|NCT05555628|OTHER|Mandibular Exercise and Postural Exercise Group|Patients will receive exercise treatment twice weekly for 6 weeks period. Every session will last approximately 40 minutes
223938371|NCT05555628|OTHER|Occlusal Splint Group|Patients will use occlusal splints for 6 weeks. The occlusal splints will be used only sleep time.
223938372|NCT04772378|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
223938373|NCT04984837|DRUG|Lacutamab|750 mg/IV
223534475|NCT03838744|DRUG|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy
223534476|NCT03838744|DRUG|Experimental arm: Trabectedin + Olaparib|Trabectedin given in combination to olaparib
223718791|NCT04312048|DRUG|Isosorbide mononitrate|one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to copper IUD insertion
223718792|NCT04312048|DRUG|placebo|one tablet of placebo vaginally 3 hours prior to copper IUD insertion
223938374|NCT04984837|DRUG|Gemcitabine|1000 mg/m²
223938375|NCT04984837|DRUG|Oxaliplatine|100 mg/m²
223938376|NCT06029283|DIETARY_SUPPLEMENT|dietary nitrate|dietary nitrate in a chewing gum delivery vehicle
223938377|NCT06029283|OTHER|Placebo chewing gum|placebo chewing gum
223938378|NCT04891068|DRUG|Azacitidine|5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
223938379|NCT05720117|DRUG|PYX-201|IV infusion
223938380|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose A Unit/Injection (U/I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
223938381|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
223938382|NCT06047444|OTHER|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
223938383|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose A U/I, IM at Week 24 and Week 36 with a total of 2 injections."
223938384|NCT06047444|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM at Week 24 and Week 36 with a total of 2 injections."
223938385|NCT05627440|DIETARY_SUPPLEMENT|Ensure Max Protein|Ensure Max Protein, 1 bottle daily (330 mL), 30 grams protein
223938386|NCT05627440|DIETARY_SUPPLEMENT|Ensure Original|Ensure Original, 1 bottle daily (237 mL), 9 grams protein
223938387|NCT04563143|OTHER|Novel DBS Stimulation|Stimulation patterns will vary from the standard therapeutic approach in terms of frequency, contact location, and/or temporal pattern.
223938388|NCT05267262|DRUG|R3R01|R3R01 administered orally for 12 weeks
223938389|NCT05390411|BEHAVIORAL|SOCIAL HF|participate in SOCIAL HF training
223938390|NCT04389437|PROCEDURE|Ophthalmological exam|OCT-A and AO
223938391|NCT04389437|PROCEDURE|Blood pressure measurement|Blood pressure measurement before the ophthalmological exam
223938392|NCT06097143|OTHER|Flowable Giomer|Pre-reacted Glass Ionomer (PRG) filler is added to resin to create giomer, a dental adhesive material. Fluoride release and recharge, acid resistance, an anti-plaque effect, dentin remineralization, and acid buffering capacity are some of the benefits of giomer.
224098740|NCT01042379|DRUG|Cemiplimab plus REGN3767|Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
223938393|NCT06097143|OTHER|Flowable Nano-filled composite with S-PRG barrier coat|"Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.~The PRG Barrier Coat is a resinous coating substance that shields the enamel surface from demineralization brought on by acidic attack. Near the coated surface, S PRG filler ions in PRG Barrier Coat have been found to have an acid-neutralizing effect. F and Sr released by PRG Barrier Coat can be effectively absorbed by the tooth substrate to prevent demineralization thus hindering the progression of caries."
223534477|NCT05906771|DIETARY_SUPPLEMENT|Metabolaid(R)|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~The nutraceutical has been elaborated by Monteloeder, S.L. It is a combination of Hibiscus sabdariffa flowers and Lippia citriodora leaves. The dose that the participants of the experimental group will receive will be 300mg plus 20mg of microcrystalline cellulose. The product is presented in an unflavored capsule, it is a reddish-brown powder with a characteristic odor and a slightly bitter taste. The manufacturing date of the product was 01/12/2022 and the expiration date was 30/11/2024."
223718793|NCT04688970|OTHER|no intervention|no intervention
223718794|NCT02187497|DRUG|Low dose of BIBR 277|
223938394|NCT06097143|OTHER|Flowable Nano-filled composite|Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.
223938395|NCT06474871|DEVICE|Khymeia®-Virtual Reality rehabilitation System (VRRS EVO SYSTEM or COMPACT VRRS ENGINE)|fully immersive VR software created by clinicians and experts specialized in cognitive rehabilitation. Khymeia Devices are Medical Class 1 devices according to MDR. VRRS systems consist of a central process unit, complete with a capacitive touch screen LCD monitor.
223938396|NCT06474871|BEHAVIORAL|Traditional cognitive training (TCT)|face-to-face approach between the therapist and the patient using paper and pencil tools and other traditional materials. The training of the executive abilities is carried out by working on categorization, planning, association processes, analogical reasoning, problem solving and coping strategies to simulate problematic situations, tailored on patients' deficits
223938397|NCT06183437|OTHER|Stopping Heart Failure Medication(s)|This group will stop their heart failure medication(s) under the supervision of the study team.
223938398|NCT04438525|DIAGNOSTIC_TEST|sting challenge|At the Moment, sting challenges are the only reliable method to identify patients who are not protected by insect venom immunotherapy.
223938399|NCT04438525|OTHER|blood donation|To perform BAT Inhibition Tests, blood samples of patients with confirmed vespid venom allergy, who have not undergone venom immunotherapy, are necessary.
223938400|NCT05317832|BEHAVIORAL|WI program|This 14-week web-based physical activity intervention (WI) program was developed by the National Center on Health, Physical Activity and Disability. The WI program was developed with guidance from literature and practice in health behavior change and internet-based health promotion programming. The content and features of the WI program include motivational resource, updated weekly resources, and customizable features.
224286823|NCT04128202|BEHAVIORAL|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
224286824|NCT02712437|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
224286825|NCT00682214|DRUG|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
224286826|NCT00682214|DRUG|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
224286827|NCT03091413|DIAGNOSTIC_TEST|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
224286828|NCT01356784|OTHER|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
224286829|NCT01356784|BEHAVIORAL|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
224286830|NCT01356784|BEHAVIORAL|Health counselling|Health guidance (1,5h)
223938401|NCT05317832|BEHAVIORAL|WI Program Reminder|Participants will be provided with reminders to use the WI program
223938402|NCT05317832|BEHAVIORAL|JITAI Goal Setting|Participants will be provided with standard, tailored, or no goal for the day. The goal will focus on recommending minutes of moderate-intensity (or higher) physical activity and a reminder to perform strength exercises.
223938403|NCT05317832|BEHAVIORAL|JITAI physical activity message|Participants will be provided with minutes of moderate-intensity (or higher) physical activity achieved, minutes of physical activity remaining, or no message.
223938404|NCT05317832|OTHER|Notification EMA|Participants will be inquired through an ecological momentary assessment (EMA) if they received a JITAI physical activity message.
223938405|NCT05317832|OTHER|End of day EMA|Participants will be inquired, through an ecological momentary assessment (EMA), if they performed aerobic and/or strength exercises for the day.
223938406|NCT05317832|OTHER|Wake up time EMA|Participants will be inquired, through an ecological momentary assessment (EMA), about the time they plan to wake up next day. This information will be used to provide a goal setting message for next day.
223938407|NCT05317832|OTHER|Weekly PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the last 7 days.
223938408|NCT05317832|OTHER|Daily PA Information|Participants will have access to minutes of moderate-intensity (or higher) physical activity performed over the day.
223938409|NCT06088472|BIOLOGICAL|TIL injection|Autologous tumor infiltrating lymphocyte injection
223938410|NCT06839937|BEHAVIORAL|REVISE - Virtual Reality Gender-Swap with Harassment Exposure|Participants will embody a virtual avatar of their female partner in a sexual harassment scenario using full-body tracking, and identity exchange in virtual reality (VR). The goal is to assess whether experiencing harassment from a first-person perspective increases empathy and decreases tolerance toward sexual harassment.
223938411|NCT06839937|BEHAVIORAL|REVISE - Virtual Reality Gender-Swap without Harassment|Participants will embody a virtual avatar of their female partner in a neutral social interaction scenario using VR-based identity exchange. This condition controls for the effect of perspective-taking alone, without exposure to harassment, to evaluate its impact on empathy and gender attitudes.
223938412|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection."
223938413|NCT06628375|OTHER|Consultation visit (Visit 1)|"During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the absence of hypospadias. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.~A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.~From the child, a blood sample will be taken for hormonal evaluation of minipuberty."
223938414|NCT05665491|BEHAVIORAL|HabitWorks|Smartphone app-delivered interpretation bias intervention
223938415|NCT05665491|BEHAVIORAL|Self-Assessment|Self-assessment of parenting behaviors and anxiety symptoms
224286831|NCT04487743|DRUG|Liraglutide|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
223938416|NCT05029284|BEHAVIORAL|teleABLE|Participants will be guided to self-monitor their daily activities, schedule personally meaningful non-sedentary activities, collaboratively problem solve to overcome barriers to the activity, and self-assess their progress. Participants may be asked to self-monitor their activity levels and complete planned activities between sessions.
223938417|NCT04297813|COMBINATION_PRODUCT|Advanced medicinal Therapy (MSC combined with biomaterial)|Augmentation of alveolar ridge with MSC and biomaterial
223938418|NCT04297813|PROCEDURE|Autologous bone graft|Augmentation of the alveolar ridge with bone graft
223938419|NCT06090240|OTHER|MI-based ACP intervention|Motivational Interviewing on Advance Care Planning Intervention: Dyads of older adults and family caregivers will receive three MI-based ACP counselling sessions: (1) a preparatory session, (2) motivation session, and (3) planning session. The preparatory session will take 10-15 minutes, and the following two sessions in weeks 2 and 3 will last 30-45 minutes each. Before each session, the nurse interventionist will first assess the dyad's readiness to engage in ACP based on the state of change algorithm. Participants who have never thought about ACP will be in the pre-contemplation state, those who are willing to discuss EOL care and preferences to be in the contemplation state, those ready to talk about EOL planning to be in the preparation state, and those in the action state have a confirmed action plan on signing up their ADs. Readiness-based ACP goals will be established, and state-matched MI counseling will be customized for each participant.
223938420|NCT05366088|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|"MBCT is an 8-week therapy integrating formal mindfulness meditation (e.g. breath and body awareness) and informal mindfulness (e.g. eating, walking). Participants are taught to attend non-judgmentally to present moment experiences. MBCT includes cognitive therapy techniques to target the ruminative thought processes and identification with negative emotions seen in depression. MBCT teaches participants how to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns that perpetuate depressive symptoms and increase vulnerability to relapse."
224286832|NCT04487743|DRUG|placebo|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
224286833|NCT02794259|DEVICE|tDCS|
224286834|NCT02794259|DEVICE|sham-tDCS|
224286835|NCT05015335|DRUG|Adalimumab|ADA 40mg q2w
223718795|NCT02187497|DRUG|Medium dose of BIBR 277|
223718796|NCT02187497|DRUG|High dose of BIBR 277|
223938421|NCT05366088|BEHAVIORAL|Health Enhancement Program|HEP teaches health-enhancing techniques and was designed by University of Wisconsin and NIH as a manualized active control group program for mindfulness-based intervention trials (53,54). We have tailored HEP to be structurally equivalent to MBCT. HEP will be delivered by social workers (or equivalent) who have received the official training course from HEP's developers at the University of Wisconsin. Participants will learn about health promotion, healthy diet, music, and gentle exercise, but not about breathing techniques or meditation.
224286836|NCT05015335|DRUG|Methotrexate|MTX 10mg qw
224286837|NCT05558995|OTHER|ketogenic diet|All the subjects will be instructed by a nutrition professional to have at least 3 meals per day consisting of 20 g to 30 g of carbohydrate in the form of green vegetables and salad, and 80 g to 100 g of protein in the form of meat, fish, fowl, eggs, shellfish and cheese for 12 weeks. Polyunsaturated and monounsaturated fats will also be included in the diet. Micronutrients (vitamins and minerals) will be given to each subject in the form of one capsule per day. The adherence to diet will be confirmed weekly through a food log and urinary ketones assessment using dipstick to ensure that all individuals remain in a ketotic state.
224286838|NCT01714349|PROCEDURE|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
224286839|NCT02842723|RADIATION|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
224286840|NCT00466804|PROCEDURE|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
224286841|NCT03589196|PROCEDURE|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
224286842|NCT03589196|PROCEDURE|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
224286843|NCT03589196|PROCEDURE|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
224286844|NCT01501110|DRUG|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
223534478|NCT05906771|DIETARY_SUPPLEMENT|Nutraceutical placebo|"The participating subjects will have to follow the intake of the nutraceutical for 3 months, as well as attend the stipulated visits. Participants will be given a register to control their daily intake of the nutraceutical. They should not change their daily habits.~Nutraceutical placebo contains microcystalline cellulose (185mg) and maltodextrin (185mg)."
223938422|NCT04001829|DRUG|Docetaxel|Given IV
223938423|NCT04001829|DRUG|Paclitaxel|Given IV
223938424|NCT04001829|OTHER|Quality-of-Life Assessment|Ancillary studies
223938425|NCT04001829|OTHER|Questionnaire Administration|Ancillary studies
223938426|NCT06425614|PROCEDURE|Autotransfusion|"ANTIFIBRINOLYTIC THERAPY :~tranexamic acid as antifibrinolytic therapy : dose after anaesthesia induction followed by continuous intravenous infusion until end~INTRAOPERATIVE MANAGEMENT :~* Routine monitoring : five lead-ECG, pulse oximeter, non-invasive arterial pressure will be instituted. A peripheral venous catheter and an arterial catheter~* The general anaesthesia :~* propofol and Remifentanil or sufentanil both simultaneously administered .~* monitoring of the bispectral index~* Triple lumen central venous catheter~* Heparinization (300 UI/kg)~* Aortic and right auricular cannulations~TRANSFUSION PROTOCOL :~* During CPB, PRBC transfusion if necessary~* In the postoperative period if necessary~In bleeding patients:~The perioperative use of blood products will be managed according to results of conventional haemostasis tests or viscoelastic point of care tests when available in the center."
223938427|NCT05757141|DRUG|Fosigotifator|Oral Use
223938428|NCT06481306|DRUG|BMS-986470|Specified dose on specified days
223938429|NCT06481306|DRUG|Placebo|Specified dose on specified days
223938430|NCT04688684|BEHAVIORAL|Family-based diet and exercise intervention|The participants will meet together weekly as a family unit to receive education and planning to implement diet and lifestyle changes under the supervision of a health coach. This coach will also be available during the week by telephone or messaging for additional individualized support if needed.
223938431|NCT01632956|BEHAVIORAL|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
223938432|NCT01632956|BEHAVIORAL|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
223938433|NCT00489879|DEVICE|Mobile Health Care System (DrUB)|
223938434|NCT02959411|DRUG|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
223938435|NCT02959411|DRUG|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
223938436|NCT05863741|DEVICE|Implantation of GMK Sphere with conventional instrumentation|Implantation of GMK Sphere with conventional instrumentation (control group)
223938437|NCT05863741|DEVICE|Implantation of GMK Sphere using the NextAR guidance system|Implantation of GMK Sphere using the NextAR guidance system (NextAR group)
223938438|NCT05947305|PROCEDURE|Surgical Blade|Using a 15c blade to de-epithelialize the soft tissue extra-orally
223938439|NCT05947305|PROCEDURE|Mucotome|Using Megagen Mucotome to de-epithelialize the soft tissue intra-orally
224286845|NCT02504814|DEVICE|Nasal Highflow (NHF)|changes in breathing physiology in NHF
224286846|NCT03220113|COMBINATION_PRODUCT|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
224286847|NCT03589131|PROCEDURE|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
224286848|NCT03589131|PROCEDURE|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
223938440|NCT05947305|PROCEDURE|Diamond Bur|Using a surgical diamond bur to de-epithelialize the soft tissue intra-orally
223938441|NCT05947305|PROCEDURE|Er:YAG Laser|Using an Er:YAG Laser to de-epithelialize the soft tissue intra-orally
223938442|NCT04164446|DRUG|Placebos|The placebo that will be used contains starch and glucose.
223938443|NCT04164446|DIETARY_SUPPLEMENT|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
223938444|NCT04072133|BEHAVIORAL|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
223938445|NCT03349944|BEHAVIORAL|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
223938446|NCT02162082|DEVICE|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
223938447|NCT01259570|DIETARY_SUPPLEMENT|Group 1|Skimmilk enriched with VD encapsulated in CM
223938448|NCT01259570|DIETARY_SUPPLEMENT|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
223938449|NCT01259570|DIETARY_SUPPLEMENT|group 3|3% fat milk wherein the VD will be in CM
223938450|NCT01259570|DIETARY_SUPPLEMENT|Group 4|Placebo: un-enriched skimmilk.
223938451|NCT06270953|DEVICE|Dozee Pro NX|Dozee Pro NX to measure Heart Rate, Respiratory Rate, SPO2 and movements
224098741|NCT01042379|DRUG|Trilaciclib with or without trastuzumab + pertuzumab|"Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization"
224098742|NCT01042379|DRUG|SYD985 ([vic-]trastuzumab duocarmazine)|SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
224286849|NCT03589131|PROCEDURE|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
223938452|NCT05960669|PROCEDURE|3D model guided secondary resection|A prostate model was 3D printed from preoperative pelvic MRI data and used during robot-assisted radical prostatectomy to mark a positive surgical margin and guide secondary resection.
223938453|NCT04336722|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
224286850|NCT03589131|PROCEDURE|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
224286851|NCT03589131|PROCEDURE|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
224286852|NCT03589131|PROCEDURE|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared
224286853|NCT04973813|BEHAVIORAL|Guideline + Active Choice + action&coping planning (GA+)|Web-based intervention consisting of information and assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; action planning; identifying barriers to physical activity; coping planning
223938454|NCT04336722|DRUG|Placebo|Placebo identical in appearance to experimental drug (odevixibat).
223938455|NCT06510140|BEHAVIORAL|Detection of the Post-operative delirium (POD)|Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
223938456|NCT05479565|DIAGNOSTIC_TEST|venous blood sample for determining the value of highly sensitive C-reactive C protein from serum|The non-invasive oscillometric device Arteriograph (TensioMedTM Kft, Budapest, Hungary) will be used to measure the arterial stiffness. In a quiet room at room temperature, the subjects will lie relaxed for 15 minutes before the start of the measurement. After that, the distance between the jugulum and the symphysis, which represents the approximate length of the aorta, will be measured with a gynecological compass, and the resulting value will be entered into the device.
223938457|NCT02588443|DRUG|RO70097890|
223938458|NCT02588443|DRUG|nab-paclitaxel|
223938459|NCT02588443|DRUG|gemcitabine|
223938460|NCT05895344|RADIATION|Proton-therapy|Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)
223938461|NCT05895344|RADIATION|Photon radiotherapy|Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
223938462|NCT02192632|DRUG|Epiduo once daily with detailed instruction for how to apply it|
223938463|NCT02192632|DRUG|Epiduo- once daily, simple instruction for application|
223938464|NCT02192632|DRUG|BPO once daily|
223938465|NCT00985088|BIOLOGICAL|GSK2340274A|one or two intramuscular injections
223938466|NCT00985088|BIOLOGICAL|GSK2340273A|one or two intramuscular injections
223938467|NCT00985088|BIOLOGICAL|Saline placebo|One injection
223938468|NCT00502684|DRUG|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
223938469|NCT00260442|BEHAVIORAL|Resistance Training|12 weeks, 3 times a week whole body resistance training
223938470|NCT00260442|BEHAVIORAL|Sedentary|Absence of physical activity
223938471|NCT05795088|DEVICE|Continuous theta burst stimulation|Two sessions of continuous theta burst stimulation over primary motor cortex to explore synaptic plasticity in Patients with Parkinson's disease
223534479|NCT05578066|OTHER|Developing teams of Local Leaders|A team of local leaders, consisting of 3-5 PHC providers and 1-2 users at each CESFAM will be developed in months 1-3 of the intervention.The teams will comprise some individuals who have provided critical support and input, including participating in the exploratory research phase and the Community-Based Participatory Research (CBPR) adaptation of the intervention framework for the Chilean context developed previously. The teams will assist with the data collection process throughout the study by encouraging colleagues to complete questionnaires and recruit users, as well as oversee and implement the intervention at their respective CESFAM. They will receive training to develop their skills as leaders and support the implementation process at their respective CESFAM.
223938472|NCT06445140|BEHAVIORAL|Collecting the variables and Implementation of a behavioural intervention|"The observational phase (during 15 days)~* Two measurements per day for motivational variables and physical activity and nutrition~* Two measurements per day for nutrition~* Three measurements per day for fatigue~* Continuous PA measurement by accelerometer~The interventional phase :~Part A (during 7 days)~* measuring physical activity (PA)~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue~Part B: BEHAVIORAL INTERVENTION (10 weeks),the APA teacher will call a patient once a week for follow-up.~Answer questionnaires and scales on the digital platform will be done :~* Motivational factors~* Self-evaluation of nutrition~* Self-assessment of fatigue~Part C : End of interventional phase(during 7 days)~* measuring physical activity~* complete questionnaires and numerical scales :~  * Motivational factors~ * Self-evaluation of nutrition~ * Self-assessment of fatigue"
223938473|NCT05885620|DEVICE|drinking reminder and cognitive task (smartwatch-based application)|task A: prompt to drink some water task B: prompt to circle bells on a sheet
223938474|NCT00105170|DRUG|hCBE-11|
223938475|NCT01737398|DRUG|Inotersen|
223938476|NCT01737398|DRUG|Placebo|
223938477|NCT02963571|PROCEDURE|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
223938478|NCT06585124|DIAGNOSTIC_TEST|Flow Cytometry|Study of t cell population in flow cytometry
223938479|NCT06012240|DRUG|Upadacitinib|Oral Tablets
223938480|NCT06012240|DRUG|Placebo|Oral Tablets
223938481|NCT03607175|DRUG|Triamcinolone-impregnated CMC foam|same information as included in the arm/group descriptions
223938482|NCT03607175|DEVICE|Propel Stent|same information as included in the arm/group descriptions
223938483|NCT03284359|BEHAVIORAL|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
223938484|NCT06065930|DEVICE|Subcutaneous microdialysis|"Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1."
223938485|NCT05794841|DIAGNOSTIC_TEST|Tongue coating sample collection and multi-omics analysis|Tongue coating sample collection and multi-omics analysis for building a diagnostic model
223938486|NCT03772132|BIOLOGICAL|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
223938487|NCT04126577|BIOLOGICAL|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
223938488|NCT00111631|DRUG|DPP-IV Inhibitor|Escalating doses po bid
223938489|NCT00111631|DRUG|Metformin|As prescribed
223938490|NCT00111631|DRUG|Placebo|po bid
223718797|NCT05540457|DEVICE|Intermittent Non-InvasiveBlood Pressure Monitor|"Brachial cuff integrated with theTablo Hemodialysis System. Cuffwill be placed contralateral to theaccess arm, with measurementscollected pre-dialysis, every 30minutes during dialysis, and post-dialysis.~Device: Continuous Non-InvasiveBlood Pressure Monitor VitalStream Monitor. Finger cuffwill be placed ipsilateral to theaccess arm, with measurementscollected pre-dialysis,continuously during dialysis, andpost-dialysis."
223718798|NCT04733404|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
224286854|NCT04973813|BEHAVIORAL|Guideline + Active Choice (GA)|Web-based intervention consisting of information and several assignments, including: completing a decision balance sheet; indicating the importance of personal values and the time, effort and energy spent on these personal values; identifying barriers to physical activity.
224286855|NCT04973813|BEHAVIORAL|Guideline + information (GI)|Web-based information about the national physical activity guideline, pros and cons of physical activity, and possible barriers to physical activity.
224286856|NCT04973813|BEHAVIORAL|Guideline (G)|Web-based information about the national physical activity guideline.
224286857|NCT05893446|DIETARY_SUPPLEMENT|Nutrition care by RDN, medical nutrition therapy -stepped wedge cluster-randomized trial design. Everyone gets the intervention so no arms.|RDNs in the community will provide MNT and meals for three months post discharge from the hospital
224286858|NCT04073017|DIETARY_SUPPLEMENT|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
224286859|NCT04073017|OTHER|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
224286860|NCT02092337|OTHER|computer-assisted speech training|
224286861|NCT01054352|DRUG|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
224286862|NCT01054352|DRUG|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
223938491|NCT05320289|DEVICE|AblaCare System|"The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue."
223938492|NCT03166085|DRUG|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
223938493|NCT03166085|DRUG|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
223938494|NCT03948295|DIETARY_SUPPLEMENT|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
223938495|NCT01438034|DRUG|kisspeptin 112-121|0.24 nmol/kg
223938496|NCT01438034|DRUG|GnRH|75 ng/kg
223938497|NCT06002867|PROCEDURE|SAPB (Serratus Anterior Plan) Block|The patient will be in the supine position. The area where the procedure will be performed will be cleaned with povidone iodine. Using a 22-gauge, 80 mm insulated Quincke needle with a high frequency (10-18 MHz) ultrasound linear probe covered with a sterile sheath, the latissimus dorsi muscle and the serratus muscle will be visualized at the level of the 4th and 5th ribs. After determining the fascia between the two muscles, the block needle will be advanced from caudal to cranial and 40 ml of 0.25% bupivacaine (local anesthetic) will be injected on the serratus muscle between the two muscles.
223938498|NCT01627314|BIOLOGICAL|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
223938499|NCT01627314|BIOLOGICAL|Untreated CB|Cord Blood
223938500|NCT00982072|DRUG|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
223938501|NCT00982072|DRUG|prednisolone|Prednisolone 1mg/kg maximum 60mg od
223938502|NCT02821936|PROCEDURE|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
223938503|NCT00325000|BEHAVIORAL|Interpersonal Psychotherapy|
223938504|NCT00325000|DRUG|sertraline or amitriptyline|
223938505|NCT01437410|PROCEDURE|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
223938506|NCT04025255|DIETARY_SUPPLEMENT|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
223938507|NCT04025255|DIETARY_SUPPLEMENT|Placebo|Matched placebo
223938508|NCT01754051|DEVICE|PC 400 coils|
223938509|NCT03524755|OTHER|Exercise|
223938510|NCT02610608|OTHER|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
223938511|NCT00263159|PROCEDURE|Pharmaceutical care for asthma patients|
223938512|NCT00790569|DRUG|nicotine|Given transdermally and orally
223938513|NCT00790569|DRUG|varenicline|Given orally
223938514|NCT00790569|OTHER|placebo|Given orally
223938515|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection|Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.
223718799|NCT05482412|DEVICE|transcutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerve|Direct superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]
223938516|NCT05310968|DRUG|Tirofiban hydrochloride sodium chloride injection placebo|Day 1: Tirofiban placebo will be injected at the same rate with experimental group.
223938517|NCT05310968|DRUG|Aspirin|Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day
223938518|NCT04612868|DEVICE|AEYE Software Device|"Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops."
223938519|NCT01448941|PROCEDURE|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
223938520|NCT01448941|PROCEDURE|Primary arthrodesis|Primary arthrodesis
224286863|NCT01054352|DRUG|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
224286864|NCT01054352|DRUG|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
224286865|NCT03752398|BIOLOGICAL|XmAb®23104|Monoclonal bispecific antibody
224286866|NCT03752398|BIOLOGICAL|Yervoy® (ipilimumab)|Monoclonal antibody
223938521|NCT01448941|PROCEDURE|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
223938522|NCT05543005|OTHER|maternal voice intervention|maternal voice in terms of lullaby, music, and meaningful words plays near the head of premature infant in the incubator by 30 mins each time after routine care period
223938523|NCT03244800|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
223938524|NCT03244800|DRUG|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
223938525|NCT04718259|DRUG|intrathecal bupivacaine|The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
223938526|NCT04718259|DRUG|midazolam|midazolam
223938527|NCT01581216|OTHER|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
223938528|NCT01581216|OTHER|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
223938529|NCT01581216|OTHER|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
223938530|NCT04129372|BEHAVIORAL|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
223938531|NCT04727294|BEHAVIORAL|Questionnaire|Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
223938532|NCT03258398|DRUG|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
223938533|NCT03258398|DRUG|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
223938534|NCT03412266|DRUG|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
223938535|NCT06367387|DRUG|Patient-Oriented Dosing (POD)|"Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference."
223938536|NCT06367387|BEHAVIORAL|Pain Self-Management (PSM)|"Pain self-management (PSM) is a manualized behavioral intervention consisting of 12 sessions, comprising 6 group and 6 individual sessions. The first session will be individual, followed by a group session, and then alternating weekly for the remainder of the intervention.~Individual sessions will be led by a staff Interventionist trained in the pain self-management intervention. The interventionist will guide participants through a PSM study manual, providing education, teaching associated skills, and assisting with goal setting.~Group sessions will be led by a Peer Facilitator who has experience with chronic pain, opioid use disorder, and buprenorphine treatment. These sessions will not have specific content but will serve as supportive forums for participants to discuss their experiences with the intervention, share tips for managing chronic pain, and provide mutual support."
223938537|NCT06367387|BEHAVIORAL|Usual Care|"Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions."
223938538|NCT06367387|DRUG|Standard Buprenorphine Dosing Condition|Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
223938539|NCT05079984|BEHAVIORAL|Graded exposure treatment (GET)|Graded-exposure is a theory driven, individually tailored, and evidenced based behavioral intervention for individuals with chronic pain targeting pain-related impairment by exposing patients to previously feared and avoided activities.
223938540|NCT05375071|OTHER|Blood Flow Restriction (BFR) Therapy|BFR Cuff will be applied to the most proximal portion of the affected arm or leg, immediately before performing exercises during physical therapy. The cuff will remain on for the entire time while an exercise is performed and will be removed in between exercises while the subject rests.
223938541|NCT05375071|OTHER|Physical Therapy|Standard of care physical therapy consisting of a structured program progressing from range of motion to strength training and then functional tests
223938542|NCT02362035|DRUG|Acalabrutinib|Orally Administered (PO)
223718800|NCT00057889|BIOLOGICAL|ipilimumab|
223718801|NCT04790422|DIETARY_SUPPLEMENT|Dietary fiber supplement|Dietary fiber
223718802|NCT04790422|DIETARY_SUPPLEMENT|Caseine protein hydrolisate|Dietary supplement
223938543|NCT02362035|DRUG|Pembrolizumab|Intravenous Administered (IV)
223938544|NCT06520202|DRUG|rhPRG4 (450 µg/mL)|1-2 drops of rhPRG4 450 µg/mL solution in both eyes
223938545|NCT06520202|DRUG|Vehicle|Sterile isotonic aqueous solution for ocular administration containing 0.01% polysorbate 20.
223938546|NCT05985681|PROCEDURE|Biospecimen Collection|Undergo blood sample and vaginal swab collection
223938547|NCT05985681|BIOLOGICAL|HPV16 RG1 VLP Vaccine|Given IM
223938548|NCT05985681|OTHER|Questionnaire Administration|Ancillary studies
223938549|NCT05985681|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given via injection
223938550|NCT04103983|DEVICE|Sensory retraining device|All participants will be given a device to keep at home and will be asked to use it for 60 minutes each day, as one block, or as multiple shorter sessions of 20 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will be asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
223938551|NCT04497727|OTHER|Gene Expression|Gene expression analysis of biopsy specimens obtained during routine colonoscopy examination
223938552|NCT06003426|DRUG|BMS-986278|Specified dose on specified days
223938553|NCT06003426|DRUG|BMS-986278 Placebo|Specified dose on specified days
223938554|NCT06001788|DRUG|Ziftomenib|Oral administration
223938555|NCT06001788|DRUG|Fludarabine|Intravenous infusion
223938556|NCT06001788|DRUG|Idarubicin|Intravenous infusion
223938557|NCT06001788|DRUG|Cytarabine|Intravenous Infusion
223938558|NCT06001788|DRUG|Gilteritinib|Oral administration
223938559|NCT06001788|BIOLOGICAL|Granulocyte colony-stimulating factor|Subcutaneous injection
223938560|NCT06049953|DRUG|Antipsychotics|Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
223938561|NCT06049953|DRUG|Non-antipsychotic medication|Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
223938562|NCT06049953|OTHER|No Medication|Non-psychotropic medications
224098743|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
224098744|NCT01042379|DRUG|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|"For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle"
224098745|NCT01042379|DRUG|Amcenestrant|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
224098746|NCT01042379|DRUG|Amcenestrant + Abemaciclib|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
224098747|NCT01042379|DRUG|Amcenestrant + Letrozole|Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
224098748|NCT01042379|DRUG|ARX788|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
224098749|NCT01042379|DRUG|ARX788 + Cemiplimab|ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
224098750|NCT01042379|DRUG|VV1 + Cemiplimab|VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
224098751|NCT01042379|DRUG|Datopotamab deruxtecan|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
224098752|NCT01042379|DRUG|Datopotamab deruxtecan + Durvalumab|Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
223718803|NCT04790422|DIETARY_SUPPLEMENT|Maltrodextrine|Placebo comparator
223718804|NCT00820846|BIOLOGICAL|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
223718805|NCT00820846|BIOLOGICAL|Placebo|1 mL of sodium chloride for injection
223718806|NCT00820846|BIOLOGICAL|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
224098753|NCT01042379|DRUG|Zanidatamab|Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
224098754|NCT01042379|DRUG|Lasofoxifene|Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
224098755|NCT01042379|DRUG|Z-endoxifen|Z-endoxifen: 10 mg QD, p.o., for 24 weeks
224098756|NCT01042379|DRUG|ARV-471|ARV-471: 200 mg QD, p.o, for 24 weeks
224098757|NCT01042379|DRUG|ARV-471 + Letrozole|ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
224098758|NCT01042379|DRUG|ARV-471 + Abemaciclib|ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
223938563|NCT05460715|DEVICE|Quadra P anteverted|"* Assess clinical performance by Harris Hip score collected during preoperative and postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assess radiological performance by standard radiographic examination performed before surgery, after surgery before discharge and during postoperative visits at 3 months, 1, 2, 5, 7 and 10 years.~* Assessing the patient's perception of the prosthetic joint by means of FJS questionnaire collected during the preoperative visit and postoperative visits at 3 months and at 1, 2, 5, 7 and 10 years after surgery.~* Assessment of functional recovery by gait analysis study~* Collect the rate of complications throughout the course of the study"
223938564|NCT02245997|RADIATION|External beam radiotherapy|
223938565|NCT02245997|RADIATION|proton beam RT|
223938566|NCT04144335|BIOLOGICAL|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
223938567|NCT04144335|BIOLOGICAL|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
223938568|NCT00229658|DRUG|pramlintide acetate|Subcutaneous injection prior to each major meal
223718807|NCT04624646|DEVICE|Discontinuous monitoring|Discontinuous ECG monitoring by finger contact every day
223938569|NCT00249769|BIOLOGICAL|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)|Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
223938570|NCT00249769|BIOLOGICAL|Measles Vaccine (MV)|"The Serum Institute of India (SII) measles vaccine provided routinely in the Expanded Program on Immunization (EPI) of the Philippines was the measles vaccine provided to the study participants. The vaccine met the requirements of the World Health Organization (WHO).~SII measles vaccine contained live attenuated (freeze-dried) Edmonston-Zagreb strain measles virus propagated on human diploid cells (HDC). Each single human dose when reconstituted in a volume of 0.5 ml contains no less than 1000 Cell culture infectious dose 50% (CCID50) of live virus particles. SII measles vaccine is presented as a yellowish-white dry cake. The vaccine should be reconstituted with the diluent supplied (sterile water for injection). A sterile disposable syringe and needle are supplied separately. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 2979."
223938571|NCT06060119|DEVICE|microneedling|The operative sites will be anaesthetized with 2% lignocaine hydrochloride with adrenaline(1:80,000).Electric microneedling pen device model THAPPINKTM is used. Microneedling is carried out on the isolated site involving one tooth mesially and distally and 1.5mm apical to marginal gingiva each for 30-40 second intermittently. When pin point bleeding observed on the area of gingiva it is irrigated with sterile saline solution. Patient will be instructed to refrain from consuming hot beverage and brushing in that area for one day to avoid mechanical trauma. A total of 4 session of micro needling procedure will be carried out in one subject at 10 days intervals upto 40days
223938572|NCT01630226|DRUG|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
223938573|NCT04337944|PROCEDURE|Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy|Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
223938574|NCT06170619|DEVICE|Obsidio™ Conformable Embolic|Embolization with Obsidio™ Conformable Embolic.
223938575|NCT04859985|DEVICE|SELUTION SLR|Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
223938576|NCT04859985|DEVICE|DES|For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
223938577|NCT03389789|OTHER|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
223938578|NCT03389789|OTHER|Breastfeeding|Infants will be breastfed
223938579|NCT03389789|OTHER|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
223938580|NCT03389789|OTHER|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
223938581|NCT01862016|PROCEDURE|APRV|Pressure ventilation mode allowing early spontaneous breathing
223938582|NCT01862016|BIOLOGICAL|arterial blood gas measurement each morning|
223938583|NCT05055700|BEHAVIORAL|Mobile app with prenatal genetic testing information|In the intervention group, participants will be asked to download, register, and review a mobile app on their own mobile phones before their appointment with maternal-fetal medicine specialists. This mobile app includes prenatal genetic testing information about amniocentesis, chorionic villus sampling, nuchal translucency screening, cell-free DNA, triple/quad/penta screening, anatomy ultrasound, and carrier screening.
223938584|NCT04558723|OTHER|ICD/CRT-D implantation|ICD/CRT-D implantation (if indicated)
223938585|NCT05623982|DRUG|GNC-038|Administration by intravenous infusion
224098759|NCT01042379|DRUG|Endoxifen + Abemaciclib|Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
224098760|NCT01042379|DRUG|Rilvegostomig + TDXd|Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
223938586|NCT01953224|BEHAVIORAL|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
223938587|NCT01953224|DEVICE|Smartphone|
223938588|NCT03277404|PROCEDURE|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
223938589|NCT03277404|PROCEDURE|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
223938590|NCT00210275|BEHAVIORAL|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
223938591|NCT04886349|BIOLOGICAL|Platelet-rich plasma|Platelet-rich plasma injection for first CMC OA
223718808|NCT04624646|DEVICE|Continuous single-lead ECG Patch|Continuous 72hr ECG monitoring by a single-lead patch at 3, 6, 9, 12 months after stroke
223718809|NCT04624646|DEVICE|24-hour Holter monitoring|Continuous 24-hour monitoring by Holter monitor at 1, 6, 12 month after stroke
223718810|NCT06199817|BEHAVIORAL|occupational therapies|music, garden-soil and sports practices for individuals diagnosed with schizophrenic disorder
223938592|NCT04104672|DRUG|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
223938593|NCT04104672|DRUG|Zimberelimab|Zimberelimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
223938594|NCT04104672|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
223938595|NCT04104672|DRUG|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
223938596|NCT01895582|OTHER|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
223938597|NCT04817059|DEVICE|Caseforge headcase|We used a custom-fitted styrofoam head mold designed to reduce head motion during MRI scanning.
223938598|NCT05515146|DIAGNOSTIC_TEST|near infra red fluorescence lymphatic imaging|ICG (0.2 ml from 25mg of ICG diluted by 5.0 ml of aqua ad injectabilia) was injected intradermally at the basis of the tattooed cutaneous area and at one point chosen so that the tracer had to flow under this area directly towards the root of the limb
223938599|NCT05303467|DEVICE|TheraSphere GBM|Single treatment of TheraSphere GBM device
223938600|NCT06680817|DRUG|Faricimab|Faricimab will be administered as per local clinical practice and local labeling.
223938601|NCT05930158|OTHER|Dual Task Exercises|Cognitive exercises to be added during walking and balance exercises will be given as a dual task. Cognitive exercises will consist of exercises for memory, executive functions, calculation, information processing speed (reaction time) and working memory areas. Cognitive exercises such as grouping the words given, giving appropriate answers to the simple situations described, simple addition, subtraction, multiplication, and asking the words that the patient is asked to remember before the exercise will be used. Cognitive exercises will be performed simultaneously with walking and balance exercises.
223938602|NCT05930158|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation content; relaxation exercises, stretching exercises, strengthening exercises, walking exercises, cycling exercises, balance exercises. Exercise intensity will be planned as moderate intensity. Walking and cycling exercises will have warm-up and cool-down periods.
223938603|NCT02450708|GENETIC|KIR genotyping|
223938604|NCT02450708|GENETIC|HLA genotyping|
223938605|NCT00858650|OTHER|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
223938606|NCT02420431|BEHAVIORAL|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
223938607|NCT02420431|BEHAVIORAL|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
223938608|NCT02172560|DRUG|Tiotropium|
223718811|NCT05869266|DEVICE|professional fitting vs. self fitting|Licensed professional fits the hearing aid fitting using professional programing tools and thresholds obtained from the traditional audiometry vs. subject performs self-fitting of the hearing aids using the Tuned App.
223718812|NCT03166384|DEVICE|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
223938609|NCT03041233|OTHER|Observation / Data Collection|"The following data will be reviewed / collected:~Baseline Visit: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~Ablation Procedure: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6- and 12-month follow-up (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
223938610|NCT01937494|DRUG|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
223938611|NCT03809949|DRUG|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
223938612|NCT03809949|DRUG|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
223938613|NCT04565691|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment that is accepted to cause bacteremia in about 40% of the cases.
224286867|NCT04394338|OTHER|self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia|to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
223938614|NCT05805202|OTHER|Blood sampling and urine analysis|A blood sample of 10- 20 ml from pediatric patients, 30-50 ml from adult patients will be collected for each patient and healthy voluntarees
223938615|NCT06387082|DRUG|HMPL-506|HMPL-506 will be administered orally in 28-day cycles, until disease progression/relapse , death, intolerable toxicity, receipt of another anti-tumor therapy (including HSCT), failure to further benefit , patient withdrawal, loss to follow-up or end of the study, whichever comes first.
223938616|NCT04003324|BEHAVIORAL|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
223938617|NCT04825626|BIOLOGICAL|HB-adMSCs|Hope Biosciences adipose derived Mesenchymal Stem Cells.
223938618|NCT05523453|BEHAVIORAL|Processing of Positive Memories Technique (PPMT)|PPMT comprises of 5 sessions focused on identifying and processing positive memories. In Session 1-5, participants narrate details of one positive memory, and process the positive memory to elicit positive values, affect, strengths, and thoughts.
223938619|NCT05523453|BEHAVIORAL|Supportive Counseling (SC)|SC is a 5-session, active and non-specific treatment administered weekly, which includes a discussion of the daily monitoring diary and exploration of current issues and concerns.
223938620|NCT04904367|PROCEDURE|Deep tissue massage|The amount of pressure during the massage was adjusted by the physiotherapist with reference to muscle tissue palpation in the patients. During the massage, olecranon, pisiform bone protrusion, metacarpophalangeal and proximal interphalangeal joint faces forearm, wrist and fingers were used during the massage to reach deep tissue. As a massage technique, compression and stretching techniques are used in combination.
223938621|NCT04904367|PROCEDURE|Conventional physiotherapy|For 4 weeks 20 session, this group were applied hot pack with 20 minutes of conventional TENS to back and neck region, followed by 4 minutes of ultrasound at a frequency of 3 MHz and at a dosage of 1 w / cm2.
223938622|NCT01130285|GENETIC|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
223938623|NCT05740540|DEVICE|IRS-8|Implanted Receiver Stimulator (IRS) delivering 8 channels of stimulation. Appropriate for muscle-based (intramuscular or epimysial) electrodes only
224098761|NCT01042379|DRUG|Dan222 + Niraparib|DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks
224286868|NCT06326177|PROCEDURE|Spine Posture Assessment|Spine posture will be assessed with double inclinometer method. After determining landmarks for each assessment, inclinometers will be placed and degree will be noted. Both degree which are obtained with different inclinometers will be used to summed up for determining postural alteration degree. Cervical, thoracal, thoracolumbar and lumbar spinal postures will be used. Spine postures are going to be expressed as, cervical lordosis degree, thoracal kyphosis degree, thoracolumbar posture degree and lumbar lordosis degree. Landmarks for cervical lordosis are C2 and C7, for thoracal kyphosis are T1 and T12, for lumbar lordosis are T12 and S1, for thoracolumbar posture C7 and S1.
224286869|NCT06326177|PROCEDURE|Spine Movement Assessment|Spine movement will be assessed via using bubble inclinometer in terms of degree. Bony landmarks will be spotted like done in spine posture assessment after that full spinal flexion and extension wanted in order to record degrees in inclinometers at the end range. As a result the difference between two inclinometer will give the motion of that segment. Lumbar and thoracolumbar spinal movement will be assessed with this method. For thoracal and cervical range of motion values will be recorded separately without substruction from both inclinometer. Thoracal rotation range of motion will be assessed with two landmarks and will be recorded separately according to landmark. Thoracolumbar range of motion will be assessed with two substruction of degrees. Landmarks for cervical range of motion are vertex and C7, for thoracal range of motion are T1 and T12, for lumbar range of motion are T12 and S1, for thoracolumbar range of motion C7 and S1.
224286870|NCT06326177|PROCEDURE|Core Muscle Endurance Assessment|Core muscle endurance is divided into three components. Trunk anterior flexion test will be used to assess anterior core region endurance. Lateral plank test will be used to determine lateral core muscle endurance. Trunk posterior extensor test will be used to determine endurance of the posterior core musculature. All of these test are calculated in predetermined positions according to literature with static contractions. Maximum duration of maintaining that position is needed. In trunk anterior flexion test participant will sit with 60 degree inclination from the ground while making contact with their feet when hips and knees are flexed. In lateral plank test participants should place their elbow to ground and lift their hip while feet are in contact with ground in side lying position. In trunk extensor endurance test participants will lie prone to the bed while maintaining contact with their ASIS and lower extremity. The upper body should stay outside of the bed.
224286871|NCT06326177|PROCEDURE|Scapular Dyskinesia|Scapular dyskinesia will be assessed with scapular dyskinesia test. Dumbbells which are 1,5kg will be used in the testing setting. Participant will perform full shoulder abduction for 5 times while examiner assesses the movement quality by ranking it as subtle dyskinesis, obvious dyskinesis and no dyskinesis according to the movement of the scapula. After that participant will perform 5 repetitions of shoulder flexion.
224286872|NCT06326177|PROCEDURE|Shoulder Strength|Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.
224286873|NCT02581878|DRUG|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
224286874|NCT04155827|OTHER|SIT|Sprint interval training of 4\*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
224286875|NCT01030094|DRUG|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
224286876|NCT01030094|DRUG|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
224286877|NCT01030094|DRUG|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
224286878|NCT01030094|DRUG|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
224286879|NCT05108844|PROCEDURE|Videocapsule endoscopy|Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
224286880|NCT04783194|DRUG|Dexamethasone+ Bupivacaine|Dexamethasone plus bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
223938624|NCT05740540|DEVICE|IST 12 & IST 16|Implantable Stimulator Telemeter (IST) that provides 12 independent channels of stimulation with the option of 2 channels of bipolar myoelectric signal recording, or 16 independent stimulus channels. Suitable for muscle-based or nerve cuff electrodes such as the CWRU Spiral, Flat Interface Nerve Electrode (FINE) or Composite-Flat Interface Nerve Electrode (C-FINE).
223938625|NCT05002335|DEVICE|Medacta Shoulder System|Performance of Total Shoulder Arthroplasty (anatomic/reverse) with Medacta Shoulder System
223938626|NCT03229408|DRUG|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
223938627|NCT03229408|OTHER|Placebo|Appears identical to experimental drug
223938628|NCT04330833|OTHER|Novel Communication Intervention|The intervention is a series of 3 guided discussions (using visual aids) between the child's primary oncology physician/nurse team and the child's parent(s) with the purpose of improving parental comprehension of the options for goals of treatment, along with the benefits and burdens of each option.
224098762|NCT01042379|DRUG|Sarilumab + Cemiplimab + Paclitaxel|Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
224286881|NCT04783194|DRUG|Bupivacaine|Bupivacaine in bilateral trans-incisional paravertebral block in lumbar spine surgery.
224286882|NCT01265667|DRUG|CF101|orally q12h
224286883|NCT01265667|DRUG|Placebo|orally q12h
224286884|NCT02674386|DRUG|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
224286885|NCT05103917|DRUG|X4P-001|CXCR4 inhibitor
223534480|NCT05578066|OTHER|Analysis of Internal Policies, Procedures and Protocols|This component involves evaluating CESFAM policies, procedures, and protocols using an anti-stigma/pro-recovery approach to identify strengths and areas for improvement in service delivery for individuals affected by MISUI. This will be completed using a policy analysis tool based on existing frameworks, such as the Health Equity Impact Assessment Tool (PHO \& OMHLTC, 2012) and the QualityRights Toolkit (WHO, 2012). At least 5 policies, procedures, or protocols to be analyzed will be selected by the local leaders at intervention CESFAM during months 3-6 of the intervention. Recommendations concerning health equity, prevention of stigma, and promotion of recoveryoriented practices for individuals with MISUI will be developed and shared following analysis. Each intervention CESFAM will be expected to implement at least one recommendation and make the necessary efforts to educate PHC providers about the policy change in months 7-18 of the intervention.
223718813|NCT03166384|PROCEDURE|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
223938629|NCT04330833|OTHER|Enhanced Usual Care Parent Education|The Enhanced Usual Care Parent Education is a series of 3 discussions between the child's primary oncology nurse and the child's parent(s) designed to control for time and attention. These discussions are focused on answering parents' questions and reviewing routine disease and treatment related information. Parents will receive a 1-hour face-to-face session every 3-4 months for a total of 3 sessions. At each session, parents choose 2-3 topics to review with the nurse.
223938630|NCT04853251|DEVICE|PDS Implant With Ranibizumab 100 mg/ml|Ranibizumab 100 mg/mL will be delivered via PDS
223938631|NCT04853251|DRUG|LUCENTIS (Ranibizumab Injection)|Ranibizumab (0.5 mg intravitreal \[IVT\] injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving IVT ranibizumab injections in the study eye, per investigator's discretion.
223938632|NCT05150015|DEVICE|To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)|Single arm study
223938633|NCT04934943|DIAGNOSTIC_TEST|mini_FC|100 ml of Crystalloids infused over 1 minute - data recording and new baseline - FC 4 ml/kg in 10 minutes - data recording
223938634|NCT02392442|OTHER|Saline|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6 hours after 1800 of normal Saline installed in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total).
223938635|NCT02392442|BIOLOGICAL|Endotoxin|Investigate the changes in miRNA signatures found in BAL and lung cells from healthy volunteers at baseline and at 6, 24, or 48 hours after endotoxin segmental lung challenge.
223938636|NCT04029896|BIOLOGICAL|HB-adMSCs|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
223938637|NCT02579967|DRUG|Immunosuppression Only Conditioning -Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
224098763|NCT01042379|DRUG|GSK 5733584|Route: Intravenous infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection. Will receive a max of 12 weeks.
224098764|NCT01042379|DRUG|GSK 5733584 + Dostarlimab|"GSK 5733584 Route: Intravenous Infusion Dosage Form: 4.8 mg/kg intravenous Q3W for injection x 12 weeks max.~Dostarlimab Route: Intravenous Infusion Dosage Form: 500 mg fixed dose intravenous Q3W for infusion x 12 weeks max."
224098765|NCT05623670|PROCEDURE|minimally invasive cardiac surgery using a VJI cannula.|Observation of postinterventional internal jugular vein thrombus after minimally invasive cardiac surgery using VJI cannulation to achieve complete CPB.
224286886|NCT01413763|DRUG|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
224286887|NCT01413763|DRUG|Placebo cream|placebo cream applied daily for 2 weeks
224286888|NCT05568316|DIETARY_SUPPLEMENT|Preoperative Immunonutrition|"Participants consumed oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before surgery.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
223938638|NCT02579967|DRUG|Reduced Intensity Conditioning|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
223938639|NCT02579967|DRUG|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
223938640|NCT02579967|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
223938641|NCT02579967|PROCEDURE|Allo BMT|Allogeneic blood or marrow transplantation
223938642|NCT04821284|DRUG|Gemcitabine Hydrochloride|Given IV
223938643|NCT04821284|DRUG|Nab-paclitaxel|Given IV
223938644|NCT04821284|DRUG|Fluorouracil|Given IV
223718814|NCT04926428|DRUG|tPA|Selectively catheter thrombolysis with alteplase in each main pulmonary
223938645|NCT04821284|DRUG|Irinotecan Hydrochloride|Given IV
223938646|NCT04821284|DRUG|Leucovorin Calcium|Given IV
223938647|NCT04821284|DRUG|Oxaliplatin|Given IV
223938648|NCT04821284|OTHER|Perflubutane Microbubble|Oxaliplatin
223938649|NCT04821284|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
223938650|NCT04821284|OTHER|Quality-of-Life Assessment|Ancillary studies
223938651|NCT04821284|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223938652|NCT04821284|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223938653|NCT06514794|BIOLOGICAL|WU-CART-007|A single IV infusion of WU-CART-007
223938654|NCT05318729|DEVICE|Vibration tool|Therapeutic mini massager for scar management, desensitization, muscle stimulation, oral stimulation and sensory re-education. Seek pain relief for sore achy muscles, tendons or bones.
223938655|NCT02505750|RADIATION|3D conformal EBRT|External Beam Radiation Therapy
223938656|NCT02505750|DEVICE|Contact X-ray brachytherapy 50 kV|
224098766|NCT02078349|DRUG|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
224098767|NCT02912273|OTHER|Baseline Participant Assessment|"* Section 1 contains demographic questions~* Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~* Section 3 has the participant list all medication~* Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~* Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~* Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
224098768|NCT02912273|OTHER|Baseline Healthcare Provider Assessment|"* Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
223938657|NCT02505750|DRUG|Capecitabine|
223938658|NCT02586857|DRUG|ACP-196|Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
223938659|NCT03747458|DRUG|OPN-375|OPN-375, BID
223938660|NCT05459948|DEVICE|GMK SpheriKA|"The first objective is to study the FJS of patients who were implanted a GMK® SpheriKA knee prosthesis using the kinematic alignment technique"
223718815|NCT01264757|BEHAVIORAL|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
223718816|NCT01264757|BEHAVIORAL|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
223718817|NCT00033020|BEHAVIORAL|Behavior Therapy|
223718818|NCT04101877|DRUG|Bevacizumab Injection|25 mg/ml
223718819|NCT04101877|DRUG|Aflibercept Injection|40 mg/ml
223718820|NCT04486105|DIETARY_SUPPLEMENT|sucrose|pure sucrose in water in addition to habitual diet
223718821|NCT01844518|BIOLOGICAL|Abatacept|
223718822|NCT00008372|DRUG|chloroquinoxaline sulfonamide|
223938661|NCT06403280|DIETARY_SUPPLEMENT|Alcoholic drink|Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.
223938662|NCT06403280|DIETARY_SUPPLEMENT|Placebo drink|Participants will receive a non-alcoholic rum flavored orange juice.
223938663|NCT03288207|DEVICE|Step it Up mobile app|Step it Up mobile app
223938664|NCT03288207|DEVICE|Global Positioning System (GPS) Device|Global Positioning System (GPS) Device
223938665|NCT03288207|DEVICE|Bluetooth-enabled scale|Bluetooth-enabled scale
223938666|NCT03288207|DEVICE|Bluetooth-enabled glucometer|Bluetooth-enabled glucometer
223938667|NCT03288207|DEVICE|MRI: Image Reconstruction and Analysis Software (Device Manufacturer: NIH)|Image Reconstruction and Analysis Software
223938668|NCT03288207|DEVICE|MRI: Research pulse sequences (Device Manufacturer: NIH)|pulse sequences
223938669|NCT03288207|DEVICE|MRI: radiofrequency coils (Device Manufacturer: Siemens Medical Solutions USA, Inc.)|radiofrequency coils
223938670|NCT03288207|DEVICE|AMRA Researcher Image reconstruction software|Image reconstruction software
223938671|NCT02694783|BIOLOGICAL|PyVST|ex vivo generated polyomavirus-specific T cells from HLA-matched donor
223938672|NCT06467799|DRUG|Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1|Patients will first receive two cycles of FOLFOX-HAIC combined with tislelizumab as neoadjuvant therapy, with a 3-week interval between cycles. Two weeks after completing the neoadjuvant therapy, imaging assessments will be conducted to evaluate treatment efficacy and surgical feasibility. Surgical resection should be performed within two weeks following the imaging assessment. Four weeks post-resection, patients will undergo a follow-up evaluation to assess postoperative recovery and determine the presence of any residual tumor. If no residual or recurrent tumor is detected, adjuvant therapy with tislelizumab will commence (every three weeks, for a total of four cycles).
223938673|NCT06962930|OTHER|8-week personalized self-management program tailored to their individual needs using Engage-Qatar PD. participants will be invited to one face-to-face coaching session and 7 online sessions|The first session will lay the groundwork for the program, in which an orientation of the features of the online forum will be provided. In addition, goal setting, use of watches, and how to track progress will be discussed. During the remote sessions, the participant and coach will work through informational modules of how to overcome barriers to exercise engagement and how to manage PD symptoms. In addition, the coach will provide encouragement in relation to regular physical activity and exercise, and the participant will report on progress related to up to three realistic and individualized goals they developed. key elements: (1) participant-therapist interaction, (2) online forum featuring a physical activity guidebook and workbook, (3) an online platform with personal physical activity database, (4) a wearable smart watch for activity monitors, (5) a video exercise library, (6) online support group, and (7) incorporate adaptation to Arabic culture and available in Arabic
223938674|NCT06350903|OTHER|Fast + High-fat low-carbohydrate diet|Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
223938675|NCT06350903|COMBINATION_PRODUCT|Fast + Empagliflozin|Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.
223938676|NCT06558643|DRUG|MMV371 LAI|Single intra-muscular dose
223938677|NCT06558643|DRUG|Placebo for MMV371|Single intramuscular dose
223938678|NCT03147885|DRUG|Selinexor|Given PO
223938679|NCT05825287|OTHER|Trained by teaching back method|in chemotherapy symptom management training, 2 groups will be created and a group will be given normal symptom management training, and the other group will be trained by teaching back method to assess the symptom control and quality of life after the chemotherapy training that patients have received and evaluate the effect of the teaching back method
223938680|NCT05825287|OTHER|Management training|Management training
223938681|NCT03415828|DEVICE|Ethanol gel|Intradiscal injection of ethanol gel
223938682|NCT03415828|DRUG|Prednisolone acetate|Intradiscal infiltration of steroids
223938683|NCT04956081|DEVICE|Neuro-navigated Transcranial Magnetic Stimulation (TMS)|TMS delivered to a target within the left- dorsolateral prefrontal cortex (L-DLPFC)
223938684|NCT03516812|OTHER|Laboratory Biomarker Analysis|Correlative studies
223938685|NCT03516812|DRUG|Olaparib|Given PO
223938686|NCT03516812|OTHER|Quality-of-Life Assessment|Ancillary studies
223938687|NCT03516812|OTHER|Survey Administration|Ancillary studies
223938688|NCT03516812|DRUG|Testosterone Enanthate|Given IM
223938689|NCT03516812|DRUG|Testosterone Cypionate|Given IM
223938690|NCT04064957|BIOLOGICAL|HB-adMSCs|
223938691|NCT05100004|DEVICE|Accelerated Theta Burst Stimulation|"Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered using the Magventure Magpro X100 TMS system."
223938692|NCT05100004|DEVICE|Sham Stimulation|"Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC.~Sham stimulation will be delivered using the Magventure Magpro X100 TMS system."
223938693|NCT02867059|DRUG|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20\_SJ733\_Challenge Protocol\_v2.0\_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
223938694|NCT05251844|OTHER|receiving an email|The email informed that the employee has had been identified as having accessed a patient's electronic medical record without a known work-related purpose and that unauthorized access is a privacy violation.
223534481|NCT05578066|OTHER|Raising Awareness|Various forms of media will be used to raise awareness about stigma related to MISUI among PHC providers and users. Local leaders at intervention CESFAM will determine the type of media they would like to use; this may include images, film, music, or a combination of media. The research team will work with local leaders to develop messaging to include in the media and assist with showcasing these pieces within each intervention CESFAM. This component will be implemented throughout the intervention (intervention months 1-18). Depending on the type of media, instances of use will be tracked accordingly. For example with posters, data on the number of posters posted at a CESFAM over what time period and an estimation of the number of PHC providers and users who have viewed the posters will be collected.
223718823|NCT02557555|OTHER|educational information|patients will receive pamphlet on labor analgesia options.
223718824|NCT00012311|BIOLOGICAL|filgrastim|
223938695|NCT05273944|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, intravenous drip on Day 1 of each cycle. On Day 1 of Cycle 1 patients will receive either reference or test product. On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation. To measure pharmacokinetic paratemers of Caelyx® versus Lipodox®.
223718825|NCT00012311|DRUG|CMF regimen|
223718826|NCT00012311|DRUG|carboplatin|
223938696|NCT03389802|BIOLOGICAL|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the maximum tolerated dose (MTD) is reached or until dose level 3 (0.6 mg/kg) is complete without the MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
223534482|NCT05578066|OTHER|Innovative Contact-Based Education|Educational workshops will include anti-stigma and recovery principles, along with specific MISUI topics relevant to PHC providers. This will be determined by findings from the exploratory phase, current research, best practices, and the perspectives of local leaders. It may include (1) supporting CESFAM PHC providers in preventing stigma and promoting recovery in their practice and (2) enhancing the competencies of CESFAM PHC providers for discussing MISUI with their users, identifying MISUI signs and symptoms, and referring users to psychosocial centres for treatment. The key feature of these workshops is the contact-based educational element, where people with lived experience participate in developing and delivering the curriculum to CESFAM PHC providers. Four three-hour workshops will be held at each intervention CESFAM and will be facilitated by two academic/clinical trainers with expertise in stigma research and practice, and one person with lived experience.
223718827|NCT00012311|DRUG|cyclophosphamide|
223938697|NCT03389802|BIOLOGICAL|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the recommended phase II dose (RP2D) determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
224098769|NCT02912273|OTHER|Follow-up Participant Assessment|"* Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
224098770|NCT02912273|OTHER|Follow-up Healthcare Provider Assessment|"* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
224098771|NCT02912273|OTHER|End-of-study Participant Assessment|"* Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~* Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
224098772|NCT02912273|OTHER|End-of-study Healthcare Provider Assessment|"* Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
224098773|NCT02471690|DRUG|Oritavancin|IV - Single dose 1200 mg Oritavancin
224098774|NCT02471690|DRUG|Dextrose|D5W 5% in Water
224098775|NCT05368675|DRUG|medication for opioid use disorder|This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
224098776|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
224098777|NCT02919293|BIOLOGICAL|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
223718828|NCT00012311|DRUG|docetaxel|
223718829|NCT00012311|DRUG|doxorubicin hydrochloride|
223718830|NCT00012311|DRUG|etoposide|
223718831|NCT00012311|DRUG|fluorouracil|
223718832|NCT00012311|DRUG|ifosfamide|
223718833|NCT00012311|DRUG|methotrexate|
223718834|NCT00012311|DRUG|thiotepa|
223718835|NCT00012311|PROCEDURE|peripheral blood stem cell transplantation|
223718836|NCT01945528|DRUG|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
223938698|NCT05533775|DRUG|Obinutuzumab|Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)
223938699|NCT05533775|DRUG|Glofitamab|"Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)"
223938700|NCT05533775|DRUG|Rituximab|Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
223938701|NCT05533775|DRUG|Ifosfamide|Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
223938702|NCT05533775|DRUG|Carboplatin|Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
223938703|NCT05533775|DRUG|Etoposide|Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
223938704|NCT05533775|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
223938705|NCT05159453|BIOLOGICAL|Human Insulin|International Unit for International Unit exchange of transdermally delivered Human Insulin for injected Human Insulin or combinations of basal and fast-acting insulins.
223938706|NCT05159453|DEVICE|Finger-actuated, Metered Pump Sprayer|Stock, pharmaceutical grade High Density Polyethylene (HDPE) bottle and HDPE nylon and stainless steel finger-actuated pump sprayer delivering 0.2 mL per pump.
223938707|NCT00274261|DRUG|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
223938708|NCT00274261|DRUG|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
223938709|NCT02806674|DEVICE|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
223718837|NCT01945528|DRUG|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
223938710|NCT02806674|DEVICE|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
223938711|NCT02426138|OTHER|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
223938712|NCT02426138|OTHER|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
223938713|NCT00238901|DRUG|Basiliximab|
223938714|NCT03387189|OTHER|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
223938715|NCT06966778|DRUG|Oxybutynin chloride extended-release tablets 5mg/tab, 2 tab, PO, qd.|"The intervention being studied is oxybutynin chloride extended-release tablets (Oxbu), a muscarinic antagonist that is used to manage overactive bladder symptoms, including urinary incontinence. In this study, it is specifically evaluated for its potential to improve early continence recovery following robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.~This formulation is an extended-release version of oxybutynin, which allows for a slower, sustained release of the drug over time, ensuring more consistent therapeutic effects with reduced side effects compared to immediate-release formulations. The intervention involves a daily dose of 10 mg, administered as two 5 mg tablets, to assess its impact on postoperative continence recovery.~The key distinction of this intervention is its focus on improving continence recovery after prostate cancer surgery, specifically through its targeted use in early post-surgical recovery, making it different from othe"
223938716|NCT06966778|DRUG|Placebo (2 tab), PO, qd.|placebo, which is designed to look identical to the active drug but contains no therapeutic ingredient.
223938717|NCT06967597|PROCEDURE|Cholecystoscopy and gallbladder cleaning|"Upper gastrointestinal endoscopy and cholecystoscopy are performed 4 weeks after GB drainage. A standard gastroscope is used to inspect the gallbladder cavity with retrieval or lithotripsy of residual stones until complete cleaning of the GB is achieved. Several procedures may be required to achieve complete stone clearance.~Finally, the LAMS is retrieved and replaced with a double pigtail plastic stent."
223938718|NCT04071106|DRUG|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
223718838|NCT04739904|OTHER|Normoxia|48 hours experimental protocol conducted at sea level
223718839|NCT04739904|OTHER|Normobaric hypoxia|24 hours experimental protocol conducted in a normobaric hypoxic facility
223718840|NCT04739904|OTHER|Hypobaric hypoxia|72 hours experimental protocol conducted at terrestrial altitude
223718841|NCT02144415|DRUG|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
223718842|NCT02144415|DRUG|EB-1020 800 mg|8 x EB-1020 100-mg capsules
223718843|NCT02144415|DRUG|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
223718844|NCT02144415|DRUG|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
223718845|NCT02144415|DRUG|Placebo|8 x matching placebo capsules
223718846|NCT06524284|DEVICE|Releaf|10 days/35 minutes per day EVNS (non-invasive electrostimulation) treatment on lower legs and feet by the subject or its caregiver after instruction by the podiatrist.
223938719|NCT04071106|DRUG|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
223938720|NCT04071106|DRUG|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
223938721|NCT04071106|DEVICE|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
223938722|NCT04071106|DRUG|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
223938723|NCT00371670|DRUG|balicatib (AAE581)|
223938724|NCT00410254|DRUG|HCV-796|
223938725|NCT00410254|DRUG|midazolam|
223938726|NCT04674813|DRUG|CC-95266|Specified dose on specified days
223938727|NCT04674813|DRUG|Fludarabine|Specified dose on specified days
223938728|NCT04674813|DRUG|Cyclophosphamide|Specified dose on specified days
223938729|NCT04674813|DRUG|Bendamustine|Specified dose on specified days
223938730|NCT05549102|BEHAVIORAL|Cognitive Behavioural Therapy|In the Cognitive Behavioural Therapy group (N=87), patients will undergo CBT as part of their routine care in Step 3 of the IAPT programme. This will be administered by suitably trained clinicians. The specification of CBT is as recommended by the National Institute for Health and Care Excellence (NICE) guidelines (CG113 - Generalised anxiety disorder and panic disorder in adults: management). In these guidelines, patients are offered on average, 12-15 hourly, weekly sessions of CBT with a trained and competent practitioners. Therapy sessions involve discussions that identify patterns in thinking or behaviours which may be problematic, and therapists and patients work to set goals to reduce these using cognitive techniques. The principle is to teach the patient how to use CBT techniques in their day-to-day life to promote a lasting effect on mental health. We will test patients before (T1) and after (T2) a course of treatment.
223938731|NCT05549102|OTHER|Waiting List|In the control group (N=87), we will test patients who are currently seeking (but not undergoing) treatment before (T1) and after a wait (T2) of equivalent time (i.e. waiting list controls)
223938732|NCT05174351|OTHER|beta blocker discontinuation|beta blocker discontinuation
223938733|NCT03292133|DRUG|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
223938734|NCT03292133|DRUG|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
223938735|NCT02260024|OTHER|High fat, high caloric meal|
223938736|NCT02260024|DRUG|Pramipexole IR tablets|
223938737|NCT02260024|DRUG|Pramipexole SR C|
223938738|NCT02260024|DRUG|Pramipexole SR C2|
223938739|NCT02260024|DRUG|Pramipexole SR C2A|
223938740|NCT02260024|DRUG|Pramipexole SR C2B|
223938741|NCT04707001|OTHER|Catheterization based on ultrasound|Bladder volume ultrasound
224286889|NCT05568316|DIETARY_SUPPLEMENT|Perioperative Immunonutrition|"Participants received oral IMN supplementation containing arginine, omega-3 fatty acids, and dietary nucleotides for 5 days before and after surgery, in addition to their standard isocaloric diet.~The nutritional status of patients was evaluated according to the score determined from the NRS 2002 screening tool. Anthropometric measurements (height, body weight, BMI, and middle-upper arm circumference) were measured at the beginning (7 days before the operation) and seventh day after the operation. The biochemical parameters (albumin, prealbumin, C-reactive protein, fasting plasma glucose, alanine aminotransferase, and aspartate aminotransferase) of participants were recorded 7 days before, on the day, and 7 days after the operation from hospital patients forms.Infections (such as urinary tract, wound infections), complications, and the length of patients' hospital stay were recorded during the postoperative period."
223718847|NCT00143637|OTHER|Office dust|airborne office dust spiked with glucan
223718848|NCT00143637|OTHER|clean air|Clean air
223938742|NCT04707001|OTHER|Catheterization based on evaluation of symptoms|Ask for symptoms: Need to urinate, lower abdominal pain
223938743|NCT00281892|BIOLOGICAL|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
223938744|NCT00281892|DRUG|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
223938745|NCT04381949|PROCEDURE|positive pressure extubation|"Two arms:~the first with classic extubation with disconnection of the ventilator and the second with an extubation without disconnection of the respiratory positive pressure"
223938746|NCT06294756|OTHER|Inhalation of Sulfurous Thermal Water|Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.
223938747|NCT06294756|OTHER|Inhalation of Sterile Distilled non-pyrogenic Water|Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
223938748|NCT06511544|DEVICE|Transcranial magnetic stimulation|rTMS delivered at 1 Hz for 1800 pulses over 30 minutes for 20 daily sessions, 5 days/week. Treatment will be directed to the ventromedial prefrontal cortex using each participant's structural MRI.
223938749|NCT00231699|PROCEDURE|Plastic wrap (study group) and cotton (control group) wrap.|
224286890|NCT02462486|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
223718849|NCT03268369|RADIATION|MRI of the brain|to eliminate a structural intra-cerebral lesion
223718850|NCT03268369|RADIATION|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq \[18F\]F-A-85380
223718851|NCT03268369|RADIATION|PET scan [18F]FDG|exam performed after iv injection of 200 MBq \[18F\]FDG
223938750|NCT01273610|DRUG|Lapatinib|250 mg tablets
223938751|NCT01273610|DRUG|Trastuzumab|Intravenous injection
223938752|NCT01273610|OTHER|laboratory biomarker analysis|
224286891|NCT02462486|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
224286892|NCT02462486|OTHER|Sham Procedure|Sham injection.
224286893|NCT04560439|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo METFIT program
224286894|NCT06502210|PROCEDURE|Personalized surgical therapy of neuroblastoma|If the size of the tumor tissue is too large, the doctor gives the patient chemotherapy and then performs surgery to remove the tumor. In this study, the genotypes of children with neuroblastoma are screened by using Deep Sequencing Technology and Third Generation Sequencing Technology, and the treatment will be performed according to different therapeutic modalities.
224286895|NCT00275639|DRUG|Cozaar|
224286896|NCT02010294|GENETIC|DNA samples, GAS strains|DNA samples,GAS strains
224286897|NCT01402973|OTHER|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
224286898|NCT02245698|BIOLOGICAL|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
224286899|NCT05715476|PROCEDURE|cesarian surgery|The same anesthesia protocol will be applied to the patient group at each altitude. In the sitting position, the spinal space was entered with a 25 gauge Quincke-tipped needle from the L4-5 space and a drop of CSF will be dripped onto the pH paper. Immediately afterwards, 12 mg of 0.5% hyperbaric bupivacaine will be given. The color formed on the pH paper will be noted. Sensory block level will be tested with pinprick test and motor block level will be evaluated with Modified Bromage scale. The number and duration of spinal anesthesia applications, the time of occurrence of sensory block in the T6 dermatome, the time to reach each score of the MB scale, the duration of the operation, the highest level of sensory block and anesthetic complications will be recorded. Sensory block time and motor block time of the patients followed in the service will be recorded.
224286900|NCT02595827|OTHER|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
224286901|NCT01540292|BIOLOGICAL|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
224286902|NCT04467320|BEHAVIORAL|Teaching Recovery Techniques|Teaching Recovery Techniques is a 7-session group programme, with 5-sessions for the young person and 2-sessions for the carer. All sessions will be held online. The carer sessions are focused on psychoeducation around trauma and PTSD, as well as skills for supporting a young person through the intervention and with PTSD symptoms more broadly. The young person sessions are primarily focused on skill building and include: psychoeducation and understanding intrusive memories; intrusive images, worries and dreams; arousal, emotions, relaxation and coping; avoidance and triggers; and, memories.
224286903|NCT04467320|BEHAVIORAL|Care as usual|In the care as usual arm, social workers will follow their standard care protocol for young people experiencing psychological distress. A typical response may include a referral to either the specialist local CAMHS or general CAMHS.
224286904|NCT01613794|DRUG|Rosuvastatin|20 mg od
224286905|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
224286906|NCT01657526|BIOLOGICAL|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
224286907|NCT01657526|BIOLOGICAL|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
224286908|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
224286909|NCT03898531|PROCEDURE|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
224286910|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
224286911|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
224286912|NCT03898531|PROCEDURE|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
224286913|NCT03898531|PROCEDURE|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
223938753|NCT01273610|OTHER|pharmacological study|
223938754|NCT05469568|OTHER|Circuit training followed by telerehabilitation|Patients participate in an ambulatory rehabilitation program (12 weeks) and then gain access to mobile application to record their movement activities. This application will aslo inlude a library with exercise vidoes from the ambulatory program. These videos should inspire patients to do the exercises at home.
223938755|NCT05469568|OTHER|Usual care|Patients have usual information about importance of regular movement activities and recommendation of proper exercises
223938756|NCT06481774|BEHAVIORAL|CONNECT platform|CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.
223938757|NCT05879887|BEHAVIORAL|UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)|UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
223534483|NCT05578066|OTHER|Recovery-Based Arts|Local leaders at CESFAM will select one PHC provider member and recruit one artist to develop an arts curriculum and facilitate the art sessions. The facilitators will select an art form to use throughout the sessions, and in collaboration with local leaders they will determine themes related to MISUI to cover in each session (planning process will be completed in intervention months 7-8). Arts workshops will be held for 10 weeks, with each session lasting up to three hours (during intervention months 9-12). Ten users affected by MISUI and at least three CESFAM PHC providers will participate in the workshops each week. At the end of the 10-week program, each CESFAM will host an exhibition to showcase the artwork that has been produced (during intervention months 13-18). All PHC providers and users, as well as community members, will be invited to attend the exhibition. PHC providers and users will be invited to speak about their experiences learning and working together to create art.
223534484|NCT06032884|PROCEDURE|continuous renal replacement therapy (CRRT)|renal replacement therapy (RRT).
223534485|NCT06032884|PROCEDURE|Intermittent hemodialysis (IHD)|renal replacement therapy (RRT).
223534486|NCT01626742|OTHER|Ready to Drink Flavored Beverage|2 servings a day
223534487|NCT01626742|OTHER|Ready to drink flavored beverage w/ AN 777|2 servings a day
224098778|NCT04576442|BEHAVIORAL|Asthma-PASS|The investigator will collaborate with the student's primary care provider (PCP) by sending a letter via facsimile, and/or email to ensure appropriate medications are prescribed or adjusted and rescue medications are available at school. Community Health Workers (CHWs) will follow up with PCPs as needed to provide reminders about prescriptions for controlled medications and to ensure a MAF is provided to schools to allow rescue medication administration by nurses. CHWs will work with local pharmacies when possible to have prescribed medications delivered to schools and homes. For students without a PCP, we will refer families to one of Montefiore Medical Center's 20 practices throughout the Bronx. For students without medical insurance or who are unable to go to a Montefiore clinic, the NYC DOE physicians who routinely attend NYC schools will provide medical care and prescribe appropriate medications.
224098779|NCT04576442|BEHAVIORAL|Basic Asthma Management (AM)|PCPs and caregivers will be notified that children in the AM group have persistent/uncontrolled asthma that warrants use of guideline-based preventative medications.
224098780|NCT04576442|BEHAVIORAL|Child/Caregiver Education session|The investigator will provide in-school child asthma education sessions delivered by trained, bilingual (English-Spanish) Community Health Workers (CHWs) using an established manualized protocol from past and current studies designed to improve knowledge and self-efficacy. Each child will receive two 1-on 1, 20-minute developmentally appropriate educational sessions at school 3-4 weeks apart. Sessions will cover: 1) asthma basics, symptoms and triggers; and 2) medications and correct administration technique. Caregivers will be called after each child session to highlight key points reviewed with the child and answer questions.
224098781|NCT02867007|DRUG|KHK2455|oral dosing
223534488|NCT04533945|DEVICE|FreeStyle Libre|The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
223534489|NCT06563960|OTHER|carbonated water|Participants will drink carbonated water during videofluoroscopy.
223534490|NCT01585025|DRUG|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
223534491|NCT00890760|BIOLOGICAL|AdCh63 ME-TRAP|5 x 10\*10 vp IM
223534492|NCT00890760|BIOLOGICAL|MVA ME-TRAP|2 x 10\*8 pfu ID
223534493|NCT00890760|OTHER|Sporozoite challenge|Infected mosquito bite
223534494|NCT00890760|BIOLOGICAL|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10\*10 vp MVA ME-TRAP 2 x 10\*8 pfu
223938758|NCT05350501|DRUG|EO2040|"EO2040, is a therapeutic peptide vaccine composed of two microbial-derived peptides mimicking cytotoxic T cell (CD8+ T cell) epitopes from the Tumor Associated Antigens (TAAs) combined with the helper peptide (CD4+ T cell epitope) Universal Cancer Peptide 2 (UCP2).~The peptide mix EO2040, i.e. drug product (DP), will be emulsified with the adjuvant Montanide.~EO2040 will be given in combination with nivolumab, which is an anti-PD1. Nivolumab is approved for use for the treatment of multiple cancer types, including subtypes of CRC (mismatch repair deficient or microsatellite instability-high metastatic disease after prior treatment). However, it is not currently approved for ctDNA defined MRD of CRC."
224098782|NCT02867007|DRUG|Mogamulizumab|i.v. administration
224098783|NCT01667263|DRUG|All-trans retinoic acid|
223718852|NCT06301334|DRUG|Bupivacaine 0.25% Injectable Solution|Group CTB (n=30): patients included in this group will receive unilateral US-guided CTB after general anesthesia. The CTB will be performed by using 20 ml bupivacaine 0.25% Group ESPB (n=30): patients included in this group will receive unilateral US-guided ESPB after general anesthesia. The ESB will be performed by using 20 ml bupivacaine 0.25%
224098784|NCT01667263|DRUG|Danazol|
223718853|NCT00291577|DRUG|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
223718854|NCT00291577|DRUG|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
223938759|NCT06199557|DRUG|Hydroxyurea, Hydroxycarbamide|Hydroxyurea (HU/hydroxycarbamide) is a hydroxylated analogue of urea which prevents DNA synthesis by inhibiting the activity of ribonucleotide reductase (RNR). HU has been used to treat a variety of diseases. As an antineoplastic drug, HU has some advantages. It may be used by ambulatory patients and has relatively few side effects, which are relieved almost immediately after withdrawal of the drug. The drug is readily absorbed from the gastrointestinal tract following oral administration. At present, HU has an important role as standard of care for treating hyperleukocytosis in chronic and acute myeloid leukemia.
224098785|NCT01730248|DRUG|INC424|5 mg tablets administered orally twice daily
224098786|NCT01730248|DRUG|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
224098787|NCT05606172|BEHAVIORAL|Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11|This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.
224098788|NCT05606172|BEHAVIORAL|Waitlist Treatment as Usual|Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
224286914|NCT03898531|PROCEDURE|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
224286915|NCT03302572|OTHER|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
224286916|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 350mg|
224286917|NCT02930668|DIETARY_SUPPLEMENT|Glucosanol 500mg|
224286918|NCT02930668|DIETARY_SUPPLEMENT|Placebo|
224286919|NCT05140317|PROCEDURE|Transcatheter heart valve implantation with or withour predilatatation|long term up to 5 years echographic and clinical follow up
224286920|NCT05659134|OTHER|Alfredson protocol|Alfredson eccentric therapeutical protocol.
224286921|NCT05659134|OTHER|Silbernagel protocol|Silbernagel concentric-eccentric protocol.
224286922|NCT01261624|DRUG|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
224286923|NCT04744155|BEHAVIORAL|Multi-Level Intervention|Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
224286924|NCT04744155|BEHAVIORAL|Enhanced Standard of Care|Behavioral intervention that assesses uptake of contraception from follow-up care.
224286925|NCT01829815|BEHAVIORAL|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
224286926|NCT02094261|DRUG|AZD9291|Once daily tablet 80 mg
224286927|NCT03092882|BEHAVIORAL|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
224286928|NCT06295094|DRUG|Cisplatin|10.5 mg/m2 body surface in 150ml saline
224286929|NCT06295094|DRUG|Doxorubicin|2.1 mg/m2 body surface in 50ml saline
224286930|NCT03767062|DRUG|Topamax|An antiepileptic agent used for migraine prophylaxis.
224286931|NCT03767062|PROCEDURE|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
223938760|NCT06199557|DRUG|Valproic acid|Valproic acid (VPA) has been used clinically as an anticonvulsant and mood-stabilizing drug. During the last two decades, VPA has been described as a histone deacetylase (HDAC) inhibitor and gained increased interest for use in cancer therapy. VPA is administered orally with available routine measurements of serum levels and has a low toxicity profile.
223938761|NCT06199557|DRUG|6-Mercaptopurine (6-MP)|In 1953, 6-MP was an approved antileukemic agent resulting in remissions in children with acute lymphocytic leukemia (ALL). After adding 6-MP to methotrexate and prednisolone in the treatment regimen, the one-year mean survival of children with ALL was increased from 29% to 50%. 6-MP, even about 70 years after its discovery, remains the standard maintenance therapy once the children are in complete remission.
223938762|NCT03362190|DRUG|Avacincaptad Pegol|Avacincaptad Pegol in combination with Lucentis
223938763|NCT03362190|DRUG|Lucentis|Avacincaptad Pegol in combination with Lucentis
223938764|NCT05889130|OTHER|Resistant Exercise|"The exercises were planned to be performed in 3 sets, 10 repetitions in each set, with 3 minutes rest between sets. Before starting the main exercises, it was planned to do 1 set of the same exercises without weight as a warm-up and cool-down exercise.~Exercises were planned as lower extremity hip abduction, adduction, flexion and extension, straight leg raise, terminal knee extension, ankle flexion and bridge exercises. During the exercises, it was planned to be combined with breathing, paying attention to respiratory control."
223938765|NCT00687219|BIOLOGICAL|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
223938766|NCT00687219|DRUG|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks
223938767|NCT04047641|DRUG|Cladribine|Given Intravenous
223938768|NCT04047641|DRUG|Cytarabine|Given Intravenous
223938769|NCT04047641|DRUG|Idarubicin|Given Intravenous
223938770|NCT04047641|DRUG|Quizartinib|Given by mouth
223938771|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells|50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.
223938772|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells|150M cells delivered in a dose of 15M cells per injection over 10 injections
223938773|NCT05068674|DRUG|Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells|300M cells delivered in a dose of 30M per injection over 10 injections
223534495|NCT04801576|OTHER|Flouride in mouthrinses|Custom made toothpastes and mouthrinses that do or do not contain flouride as sodium fluoride in different concentrations.
223938774|NCT05086432|OTHER|Sputum-guided management|As previously described.
223938775|NCT05086432|OTHER|Standard of Care|As previously described.
223938776|NCT06971250|DRUG|Capsaicin only (7.6 ng)|Intradermal injection of 7.6 ng capsaicin (0.5 µM, 50 µL) in synthetic interstitial fluid (SIF) without Flupirtine. Used to induce experimental burning pain in the skin.
223938777|NCT06971250|DRUG|Capsaicin + Flupirtine 0.5 µg|Intradermal co-injection of 7.6 ng capsaicin (0.5 µM) and 0.5 µg Flupirtine in 50 µL SIF. Used to assess local analgesic effect of very low-dose Flupirtine on chemically induced pain.
223938778|NCT06971250|DRUG|Capsaicin + Flupirtine 1.2 µg|Intradermal co-injection of 7.6 ng capsaicin and 1.2 µg Flupirtine in 50 µL SIF. Part of dose-response evaluation for peripheral pain inhibition.
223938779|NCT06971250|DRUG|Capsaicin + Flupirtine 3.0 µg|Intradermal co-injection of 7.6 ng capsaicin and 3.0 µg Flupirtine in 50 µL SIF. Intermediate dose in microdose titration series.
223938780|NCT06971250|DRUG|Capsaicin + Flupirtine 7.6 µg|Intradermal co-injection of 7.6 ng capsaicin and 7.6 µg Flupirtine in 50 µL SIF. This is the highest Flupirtine microdose used in the capsaicin model.
223938781|NCT06971250|DRUG|Placebo (SIF only, no capsaicin or Flupirtine)|Intradermal injection of 50 µL synthetic interstitial fluid without capsaicin or Flupirtine. Used as negative control for capsaicin-Flupirtine co-injection conditions.
224098789|NCT06485128|DIAGNOSTIC_TEST|Optical coherence tomography(-angiography) OCT(A)|OCTA is a non-invasive diagnostic tool capable of generating cross-sectional coupes of the retina and choroid. Novel algorithms allow to render a 3-dimensional model of the ocular microcirculation based merely on the motion contrast of the circulating blood.
224098790|NCT06485128|DIAGNOSTIC_TEST|Fundus pictures|Visucam (Zeiss), Topcon NW8 fundus camera, NFC 600 (Crystalvue)
223534496|NCT04801576|OTHER|Placebo mouthrinse|Mouthrinses without flouride
223534497|NCT00503984|DRUG|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
223534498|NCT00503984|DRUG|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
223938782|NCT06971250|DRUG|Room Temperature Injection (Control)|Intradermal slow infusion of SIF at \~23°C using a programmable pump. No capsaicin or Flupirtine included. Used as baseline control in heat model.
223938783|NCT06971250|DRUG|Heated injection without Flupirtine|Intradermal slow infusion of synthetic interstitial fluid preheated up to \~52°C. No Flupirtine included. Used to induce thermal pain in human skin.
223938784|NCT06971250|DRUG|Heated Injection with Flupirtine 124 µg|Intradermal slow infusion of synthetic interstitial fluid up to \~52°C containing 124 µg Flupirtine. Used to test local analgesic effect of high-dose Flupirtine in heat pain model.
223534499|NCT00503984|DRUG|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
223534500|NCT00503984|GENETIC|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
224098791|NCT06485128|DIAGNOSTIC_TEST|DVA 3.0|IMEDOS GmbH
224098792|NCT06485128|DIAGNOSTIC_TEST|Hyperspectral retinal images|Ximea SNm4x4 hyperspectral snapshot camera
224098793|NCT06485128|DIAGNOSTIC_TEST|SphygmoCor|Sphygmocor Excell
224098794|NCT06485128|DIAGNOSTIC_TEST|Sphygmomanometer|For the measurement of the blood pressure.
224098795|NCT06485128|DIAGNOSTIC_TEST|Blood sample|For both routine cardiovascular health biomarkers as well as genetic markers (DNA, mRNA, miRNA).
224098796|NCT06485128|DIAGNOSTIC_TEST|Skin biopsy|Spatial proteomics and transcriptomics for endothelial function.
223938785|NCT04960813|BEHAVIORAL|Structured games|"Camp Kidpower - Structured Games is an interactive, child-friendly camp and is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 15 different exercises will be taught. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Playgroup intervention.~Parents will be asked to attend an approximately one-hour group meeting, during which information is presented regarding child anxiety, effortful control and the rationale for this treatment. Parents are asked to continue to utilize the intervention at home every day if possible with the child and will receive texts or emails to track the games that are played at home."
223938786|NCT04960813|BEHAVIORAL|Playgroup|"Camp Kidpower - Playgroup includes structured play activities. This will include art activities, dramatic play props, and a story time. Children will attend 5 three-hour playgroup sessions over a 4-week period (twice the first week, and then only once per week for the subsequent 3-week period) to match the Kidpower intervention.~During the first week parents will attend an approximately one-hour group meeting, during which information is presented regarding the positive benefits of child-led play and special time with caregivers.~Parents well be asked to complete homework with their children during the week between sessions, and are shown how to track time spent in this activity. Parents will receive a daily text (or email) to to measure frequency of homework practice between sessions."
223938787|NCT01596413|DRUG|Sancuso|granisetron transdermal system
223938788|NCT01596413|DRUG|IV granisetron|IV
223938789|NCT02350634|DRUG|Flortaucipir F18|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq) (10 millicurie \[mCi\]) of flortaucipir.
223938790|NCT04205487|BEHAVIORAL|Motivational Interviewing (MI)|Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
223938791|NCT04205487|BEHAVIORAL|Contingency Management (CM)|CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
223938792|NCT04241848|DEVICE|Keeogo|A new and novel type of robotic-device (Keeogo, B-temia, Inc.) was developed to provide powered assistance at the knee for persons with stroke. This device provides assistance for both knee extension and knee flexion during ambulation, transfers to standing and sitting, in addition to ascending and descending stairs. As this device isn't able to fully control the movement, it requires the ability of the patient to stand and initiate stepping. The approach the Keeogo uses to monitor the desired movement in order to appropriately provide assistance. This promotes intuitive learning for the user, minimizing the amount of instruction and practice needed to effectively ambulate allowing users to independently ambulate within one session. This device does not restrict leg movement, so the user can side-step and walk backwards. However, it does not provide assistance during these movements.
223938793|NCT04241848|OTHER|Ambulation training|Ambulation training will consist of mobility activities affecting daily life including: walking; squatting (or getting in and out of a chair); bending, kneeling or stooping (for picking an item up off of the floor); and ascending and descending stairs. Sessions will be monitored and tailored to the individual, based on their functional ability and to ensure their safety.
224098797|NCT06485128|DIAGNOSTIC_TEST|Neuropsychological examination|Moca, Stroop color word test, concept shifting test, COWAT, (R)AVLT, Beck depression inventory, GDS
224098798|NCT03521947|DIAGNOSTIC_TEST|Complete blood picture|Iaboratory investigation
224098799|NCT05522426|DEVICE|SyntrFuge System|Microsized Adipose Tissue
224098800|NCT01328457|DRUG|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
223938794|NCT03952598|DRUG|HP 13C Pyruvate|Contrast agent used with magnetic resonance spectroscopic imaging (MRSI)
224098801|NCT04807959|OTHER|20Lighter anti-obesity program|A customized expert supervised 3-phase program including non-invasive proprietary nutritional, behavioral, and physiological components.
224286932|NCT03321474|PROCEDURE|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
224286933|NCT00242229|DRUG|DVS-233 SR|
223938795|NCT03952598|DEVICE|3T MRI scanner|Research proton MRS (1H-MRS) followed by DW-MRI
223938796|NCT02484599|BEHAVIORAL|Computerized attention training (CAT)|Three sessions of active computerized attention training.
224098802|NCT03058744|DRUG|IDP-118 Lotion|Lotion
224098803|NCT03058744|DRUG|HP Monad Lotion|Lotion
224098804|NCT03058744|DRUG|Ultravate Cream|Cream
224098805|NCT03058744|DRUG|Tazorac Cream|Cream
224098806|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
224098807|NCT01731002|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
224286934|NCT03400436|OTHER|No intervention in observational studies|No intervention in observational studies
224286935|NCT02363439|DRUG|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
224286936|NCT02221063|OTHER|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
224286937|NCT02221063|OTHER|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
224286938|NCT02221063|OTHER|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
224286939|NCT05270486|PROCEDURE|Electromagnetic navigation system|The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
224286940|NCT04429841|PROCEDURE|Radical gastrectomy with D1 lymphadenectomy|
224286941|NCT04429841|PROCEDURE|Radical gastrectomy with D2 lymphadenectomy|
223534501|NCT00503984|DRUG|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
223534502|NCT00503984|DRUG|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
223938797|NCT02484599|BEHAVIORAL|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
223938798|NCT05051982|DEVICE|Sedline EEG in View|EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
223938799|NCT06515457|DIETARY_SUPPLEMENT|Eye Empower|Participants will take three capsules of the Eye Empower supplement daily for three weeks.
223534503|NCT02282748|OTHER|No intervention|
223534504|NCT00754884|DRUG|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
223534505|NCT00754884|DRUG|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
223534506|NCT01246960|BIOLOGICAL|Ramucirumab|Administered intravenously
223534507|NCT01246960|DRUG|Placebo|Administered intravenously
223534508|NCT01246960|DRUG|Oxaliplatin|Administered intravenously
223534509|NCT01246960|DRUG|Leucovorin|Administered intravenously
223534510|NCT01246960|DRUG|5-Fluorouracil|Administered intravenously
223534511|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 1|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 1 (S2/cre5/S15domV/rec1/hifi3).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* Two modifications in the polymerase 3D to further improve stability of the attenuation and reduce frequency of recombination events~* Relocation of a key replication element from the 2C coding region to the 5'-untranslated region, to inhibit recombination."
223534512|NCT03430349|BIOLOGICAL|Novel OPV2 candidate 2|"Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).~Modifications included the following:~* Changes to the viral nucleotide sequence in part of the 5'-untranslated region to improve the genetic stability of this major attenuating determinant of Sabin type-2 to avoid reversion by single nucleotide changes.~* silent non-coding modifications engineered within the capsid (VP1-4) designed to reduce replicative fitness and, potentially, to improve stability of the attenuated phenotype while also reducing transmission."
223938800|NCT04091178|DIETARY_SUPPLEMENT|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
223938801|NCT01400958|DRUG|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
223938802|NCT01400958|DRUG|Placebo|Placebo x 42 days; THEN, No More Placebo
223938803|NCT06499766|OTHER|Biodiversity intervention by inactivated microbial extract|Participants use the lotion including microbial extract on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
223938804|NCT06499766|OTHER|Placebo intervention by colored lotion|Participants use the lotion including safe, non-active coloring ingredient on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
223938805|NCT04219215|DEVICE|100% O2 in oxygen chamber|Application of 100% O2 in an hyperbaric oxygen chamber
223938806|NCT04219215|DEVICE|21% O2 in oxygen chamber|Application of ambient air (21% O2) in an hyperbaric oxygen chamber
223938807|NCT03925649|BIOLOGICAL|HB-adMSCs|single infusion of HB-adMSCs
223938808|NCT06404723|DIAGNOSTIC_TEST|Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio|to detect their relation to disease activity to use as predective and prognostic tools
223938809|NCT04775667|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
223938810|NCT04044781|DRUG|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
223938811|NCT00914966|BIOLOGICAL|C1 inhibitor (human) [C1 INH]|
223938812|NCT01161953|GENETIC|Genetic Analysis|Perform Genome Wide Association Studies.
223938813|NCT05556161|BEHAVIORAL|General Practitioners and Diabetes Specialists Co-management|"Self-monitoring of blood glucose: Participants will monitor blood glucose with a a free intelligent home blood glucose meter. Then, the intelligent blood glucose meter will upload data to the platform.~Glycosylated hemoglobin check:~Cooperative General Practitioner-Specialist Management: Based on the remote monitoring of blood glucose, general practitioners and specialists will jointly carry out management measures including health education, medication adjustment, outpatient consultation, referral, case discussion, etc. for participants."
223938814|NCT06197724|DEVICE|Magnetocardiography|Magnetocardiography
223938815|NCT05557006|PROCEDURE|left bundle branch pacing|In the procedure of left bundle branch pacing, various QRS morphologies are observed as penetrating the lead into the interventricular septum.
223938816|NCT06109454|DRUG|Huaier granule|The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.
223938817|NCT06109454|OTHER|Control|The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
223938818|NCT03643055|DIAGNOSTIC_TEST|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
223938819|NCT02460393|DRUG|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
223534513|NCT05809947|OTHER|Neuromuscular electrical stimulation|One bout of neuromuscular electrical stimulation in conjunction with forced lengthening contractions on one leg
223938820|NCT02460393|OTHER|placebo|Subcutaneous injection of different doses for healthy people
223938821|NCT04797468|DRUG|HLX23|administered IV.
223938822|NCT05946629|DEVICE|PCI with SELUTION SLR DCB|After target lesion pre-dilatation and preparation , a SELUTION SLR 014 PTCA DEB study device should be selected with nominal diameter equal to the RVD of the target lesion (1:1 ratio) and length that allows approximately 2.00 mm longer than the proximal and distal edges of the target lesion (defined as the proximal and distal extent of predilation). If IVUS is performed to assess RVD, and DEB upsizing is deemed clinically necessary for optimal results, a maximum nominal DEB diameter of 3.0 mm is permitted. The SELUTION SLR 014 PTCA DEB should then be delivered, positioned in and deployed per instructions per use. The balloon should be inflated for 60 seconds provided that the patient can tolerate this duration. The minimum inflation time is 30 seconds.
223534514|NCT00716820|DRUG|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
223938823|NCT05946629|DEVICE|"PCI with FDA approved -limus DES"|"For subjects randomized to the control group (DES), the treating physician will choose an FDA cleared DES and follow lesion preparation and stent deployment according to the Instructions per use (IFU) and institutional practices.~The DES should be sized per IFU with respect to the vessel RVD. The use of IVUS or OCT is encouraged to guide optimal stent placement and assess final results. After DES deployment, additional balloon inflations should be performed as needed to obtain \< 30% residual diameter stenosis and resolve proximal or distal edge dissections greater than or equal to NHLBI grade B."
223938824|NCT06806293|DRUG|Atogepant|Oral Tablet
223938825|NCT06806293|DRUG|Placebo for Atogepant|Oral Tablet
223938826|NCT04604288|BIOLOGICAL|HB-adMSC|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
223938827|NCT06985342|DRUG|Rimegepant|Rimegepant 75 mg orally disintegrating tablet (ODT), administered as a single dose
223938828|NCT06985342|DRUG|Zavegepant|Zavegepant 10 mg nasal spray, administered as a single dose
223938829|NCT06986226|BEHAVIORAL|Dose Calculations|Dose calculations either with or without performing ventilations during CPR (15:2)
223938830|NCT06986226|PROCEDURE|Ventilations|Performing ventilations during CPR in a 15:2 manner
223938831|NCT02544880|DRUG|Tadalafil|Tadalafil tablets administered by mouth. Dose will be between 10 to 20 mg adjusted depending on patient's body weight. On course 1, Tadalafil will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil will be administered daily for 14 consecutive days. No Tadalafil will be provided on Course 5.
223938832|NCT02544880|BIOLOGICAL|Anti-MUC1 Vaccine|300 uL Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
223938833|NCT02544880|BIOLOGICAL|Anti-Influenza Vaccine|300 uL Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
223938834|NCT02544880|OTHER|Tadalafil Placebo|Placebo tablets mimicking Tadalafil administered by mouth. On course 1, Tadalafil Placebo will be administered daily for 19 consecutive days. On Course 2 through 4, Tadalafil placebo will be administered daily for 14 consecutive days. No Tadalafil Placebo will be provided on Course 5.
223938835|NCT02544880|OTHER|Anti-MUC1 Vaccine Placebo|Placebo for Anti-MUC1 vaccine will be administered intramuscularly in the right upper limb. Placebo for Anti-MUC1 vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5..
223938836|NCT02544880|OTHER|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
224098808|NCT01731002|DRUG|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
223938837|NCT02544880|OTHER|Anti-Influenza Vaccine Placebo|Placebo for Anti-Influenza vaccine will be administered intramuscularly in the left upper limb. Placebo for Anti-Influenza vaccine will be administer on Day 7 on course 1, on Day 10 for courses 2 through 4 and on Day 1 on course 5.
223938838|NCT06109857|OTHER|Non-Interventional Study|Non-interventional study
224098809|NCT04820751|DRUG|Cyproheptadine Hydrochloride 4 MG|Cyproheptadine associated to standard care
224098810|NCT04423848|OTHER|Home Hospital for Lymphoma|Remote monitoring and home-based care designed for hospitalized patients with lymphoma
224098811|NCT01697345|DRUG|Testosterone|
224098812|NCT05141682|DRUG|Oral Azacitidine|Given PO
224286942|NCT04712084|PROCEDURE|Positive pressure|Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
224286943|NCT02154802|BEHAVIORAL|video: community member|
224286944|NCT02154802|BEHAVIORAL|video: physician|
224286945|NCT02154802|BEHAVIORAL|video: choice of video|
224286946|NCT06204575|OTHER|Data collection|Data collection
224286947|NCT06283121|BIOLOGICAL|BioTTT001 intraperitoneal infusion|Monotherapy lead-in phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3; Combination therapy phase: BioTTT01 1×10\^10 VP, i.p., D1 and D3, 3 weeks per cycle
224286948|NCT06283121|DRUG|SOX regimen|Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle
224286949|NCT06283121|DRUG|toripalimab|Combination therapy phase: toripalimab 160mg i.v. D1, 3 weeks per cycle.
224286950|NCT01719562|PROCEDURE|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
224286951|NCT01719562|OTHER|Physical Activity|Tailored aerobic exercise program onsite and at home.
223938839|NCT06856421|BEHAVIORAL|Auricular point compression|"Acupuncture Points: Endocrine, Sympathetic, Shenmen, Heart~Procedure Instructions:~Disinfect the areas with 75% alcohol as per standard precautions. Treatments use only ear patches without Vaccaria seeds applied to these specific acupuncture points.~Treatment sessions occur every Monday and Thursday. On Mondays, left ears are patched for three continuous days. Then on Thursdays, qualified medical personnel will remove the patches from the left ear and apply new patches to the right ear for four consecutive days. Any replacements must be performed at the hospital by qualified staff; patients should not attempt to do this themselves.~This procedure is repeated weekly over a span of four weeks, resulting in eight total applications. Importantly, patients in this group do not perform acupoint stimulation as part of their treatment."
223938840|NCT06856421|BEHAVIORAL|No pressure on the ear point|"Acupuncture Points: Endocrine, Sympathetic, Shenmen, Heart~Procedure Instructions:~Disinfect the areas with 75% alcohol as per standard precautions. Treatments use only ear patches without Vaccaria seeds applied to these specific acupuncture points.~Treatment sessions occur every Monday and Thursday. On Mondays, left ears are patched for three continuous days. Then on Thursdays, qualified medical personnel will remove the patches from the left ear and apply new patches to the right ear for four consecutive days. Any replacements must be performed at the hospital by qualified staff; patients should not attempt to do this themselves.~This procedure is repeated weekly over a span of four weeks, resulting in eight total applications. Importantly, patients in this group do not perform acupoint stimulation as part of their treatment."
223938841|NCT06540521|OTHER|No intervention|No intervention
223938842|NCT06994559|OTHER|Preferred Music|The self-selected preferred music intervention will expose participants to music chosen based on personal tastes. Patients will be instructed to compile a playlist lasting approximately 1 hour, but preferably over 1 hour (to avoid repetition or moments without music) of their favorite music. They will be instructed to select songs that they find extremely pleasurable to listen to. Participants will be instructed to select songs that will have a higher likelihood to facilitate relaxation and introspection. This does not need to be an all-time favorite selection, but rather the music that they currently enjoy listening to the most.
223938843|NCT06994559|OTHER|Therapist-selected Music|The therapist-selected music intervention will expose participants to a curated playlist specifically designed for psychedelic treatment by expert Music Therapists, which was used in a previous study to investigate the additive hemodynamic effects of music during ketamine infusions for depression. Patients will be randomly exposed to one of 9 available playlists, all containing songs without lyrics.
223938844|NCT06994559|OTHER|Silence|The silence intervention will expose patients to the same therapeutic procedures, in the same room and context, and with the same noise-cancelling headphones. The purpose is to cancel any potentially perturbing background noise, as no music will be played.
223938845|NCT06990542|RADIATION|Image-guided tumor-focused radiation therapy|Image-guided tumor-focused radiation therapy
224098813|NCT04357171|PROCEDURE|Low anterior resection with protective loop ileostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning ileostomy is performed.
224098814|NCT04357171|PROCEDURE|Low anterior resection with protective loop transverse colostomy|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta or right below left colic artery. Nerve-sparing total mesorectal excision is performed. Side-to-end sigmoido-rectal anastomosis is created. A loop defunctioning transverse colostomy is performed.
224098815|NCT01085188|BEHAVIORAL|ACC|Weekly community based behavioral counseling and case management
224098816|NCT01085188|BEHAVIORAL|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
224098817|NCT01085188|BEHAVIORAL|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
224098818|NCT03957915|DRUG|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.02 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.02 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
224098819|NCT03476239|DRUG|Blinatumomab|"Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator."
224098820|NCT03476239|DRUG|Dexamthasone|Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
224098821|NCT01835444|OTHER|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
224286952|NCT01719562|OTHER|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
224286953|NCT01719562|DEVICE|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
224286954|NCT01719562|OTHER|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
224286955|NCT00508027|DRUG|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
224098822|NCT04905862|DIAGNOSTIC_TEST|Immune response|"1. Venous blood samples will be collected at seven-time points: before dose 1 of vaccine, 21 days after dose 1, within 14-21 days after dose 2 and 3,6,9,12 months after vaccination. From the volume of about 8 ml of the patient's peripheral blood, a fraction of PBMC (peripheral blood mononuclear cells) will be isolated.~2. The level of antibodies against the SARS-CoV-2 nucleocapsid (N) antigen will be detected in serum using the Abbot Architect™SARS-CoV-2 IgG test.~3. The level of neutralizing IgG and IgA antibodies against the SARS-CoV (S1 and S2 subunits) (S) will be detected in serum using the DiaSorin LIAISON®SARS-CoV-2 S1/S2 IgG serology COVID-19 S-Protein (S1RBD) Human IgA ELISA Kit respectively.~4. The cellular component of the immune response will be tested using the ELISPOT method, which involves testing the amount of INF-γ and IL-2 released from leukocyte cells."
224098823|NCT04905862|OTHER|Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events|The grading scales for side effects used in this study will derive from the FDA Center for Biologics Evaluation and Research guidelines on toxicity grading scales for volunteers enrolled in preventive vaccine clinical trials. Solicited reactions will be obtained 7 days after the first and the second dose, and 30 days after the final vaccination. Unsolicited adverse events and serious adverse events will be observed recorded through 1 month after the second dose
223938846|NCT03334669|BEHAVIORAL|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.
224098824|NCT01999673|BIOLOGICAL|bavituximab|
224098825|NCT01999673|DRUG|Docetaxel|
223938847|NCT03334669|BEHAVIORAL|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.
223938848|NCT03334669|BEHAVIORAL|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
223938849|NCT06853782|DEVICE|High Frequency Linear Probe (GE Logic e R7 Ultrasonography Device, USA)|A high frequency linear probe (GE Logic e R7 Ultrasonography Device, USA) device will be used while blocking in both groups.
223534515|NCT00886730|BEHAVIORAL|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
223938850|NCT06853782|DEVICE|High Frequency Linear Probe (GE Logic e R7 Ultrasonography Device, USA)|A high frequency linear probe (GE Logic e R7 Ultrasonography Device, USA) device will be used while blocking in both groups.
223938851|NCT06545292|DIAGNOSTIC_TEST|Therapeutic drug monitoring with a dried blood spot and microatainer.|Patients who use an oral oncolytic will be asked to provide twelve microsamples obtained by finger prick (eight dried blood spots (DBS) and four wet blood samples in microtainer EDTA) and four paired whole blood (WB) samples obtained by venapuncture.
223938852|NCT06865677|DRUG|Sacituzumab govitecan|10mg/kg administered IV infusion on days 1 and 8 of each 21-day cycle.
223938853|NCT06615557|DRUG|Fasedienol Nasal Spray|Nasal spray delivered 20 minutes before the PSC
223938854|NCT06615557|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the PSC
223938855|NCT06010355|PROCEDURE|Discussion|Participate in focus groups
223938856|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
223938857|NCT06010355|OTHER|Interview|Undergo interview
223938858|NCT06010355|OTHER|Media Intervention|Watch culturally appropriate video
223938859|NCT06010355|OTHER|Test|Complete test
223938860|NCT05657548|RADIATION|spine and pelvis radiography|X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
224098826|NCT01999673|OTHER|Placebo (for bavituximab)|
224098827|NCT04836039|OTHER|A questionnaire and scales.|Participants will be evaluated by applying a questionnaire and scales created by the researcher physiotherapists based on the researches and examples in the literature.
224098828|NCT02278913|DRUG|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
224098829|NCT02278913|DRUG|Human Insulin|NPH twice a day + Regular insulin before meals
224098830|NCT03977246|BEHAVIORAL|Open-placebo|Application of the open-placebo intervention
224098831|NCT03977246|BEHAVIORAL|Control|Application of the control session
224098832|NCT02871479|DRUG|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
223938861|NCT05959434|BEHAVIORAL|Cognitive Processing Therapy + Relapse Prevention|Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol use disorder
223938862|NCT05959434|BEHAVIORAL|Relapse Prevention|Cognitive-Behavioral Therapy that targets alcohol use, specifically
223938863|NCT04088890|DRUG|Fludarabine|Fludarabine 30 mg/m2
223938864|NCT04088890|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2
223938865|NCT04088890|DRUG|CD22 CAR|Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D
223938866|NCT07009379|DEVICE|Intervention A|Intervention A means Pillow Brace
223938867|NCT07009379|DEVICE|Intervention B|Intervention B means standard management
224098833|NCT02871479|DRUG|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
224286956|NCT01337726|BEHAVIORAL|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
224286957|NCT01337726|BEHAVIORAL|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
223938868|NCT06869850|DIETARY_SUPPLEMENT|MFGM-RUTF (milk fat globule membrane ready-to-use therapeutic food)|MFGM whey protein/fat concentrate powder used in place of skim milk powder in peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications. There will be 10g of MFGM-containing whey protein/fat concentrate powder per 100g of MFGM-RUTF. Other ingredients and amounts per 100g: 9.5g rice flour, 5g whey permeate, 18.5g palm oil, 31g peanut paste, 22.1g sugar, 2.9g micronutrient mix, 1g fish oil.
223938869|NCT06869850|DIETARY_SUPPLEMENT|S-RUTF (standard ready-to-use therapeutic food)|Standard peanut paste-based ready-to-use therapeutic food made with skim milk powder meeting Codex Alimentarius specifications. This RUTF is modeled on the most widely used recipe worldwide, containing per 100g: 19.5g skim milk powder, 9.3g palm oil, 7g canola oil, 31.3g peanut paste, 28g sugar, 1g soy flakes, 1g hydrogenated vegetable oil, and 2.9g micronutrient mix.
223938870|NCT06869850|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
224098834|NCT02871479|DRUG|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
224098835|NCT02519660|DRUG|Lidocaine/Tetracaine patch|
224098836|NCT02519660|DRUG|Lidocaine/Prilocaine cream|
224098837|NCT01446809|DRUG|Doxorubicin Hydrochloride|Given IV
223938871|NCT06869850|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|Malaria chemoprophylaxis, dosed by weight, to be given every month during SAM treatment
224098838|NCT01446809|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
224098839|NCT01446809|DRUG|Ifosfamide|Given IV
224286958|NCT06615830|DRUG|Standard chemotherapy|Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
224286959|NCT06615830|DRUG|Organoid-guided treatment|Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
224286960|NCT05606952|DEVICE|Color Doppler|color Doppler with pulsed wave Doppler to accurately detect the position of epidural catheter
224286961|NCT04414033|DEVICE|Bubble: A New VR-AI Way of Treatment for Hot Flashes|Bubble Bubble is a virtual reality (VR) mobile application. Bubble offers a psychological intervention based upon cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR) protocols. The bubble mobile application offers the intervention in a virtual reality (VR) coaching environment and in a winter wonderland setting called Frosty. Frosty provides both a virtual reality winter wonderland experience as well as guided meditation. The cold, winter-like experience is designed to help patients calm down and feel cooler.
224286962|NCT03554317|DRUG|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
224286963|NCT03554317|DRUG|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
224286964|NCT02036801|OTHER|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
224286965|NCT03322020|RADIATION|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
224286966|NCT03322020|RADIATION|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
224098840|NCT01446809|OTHER|Laboratory Biomarker Analysis|Correlative studies
224098841|NCT01446809|DRUG|Pazopanib Hydrochloride|Given PO
224098842|NCT01446809|OTHER|Pharmacological Study|Correlative studies
224098843|NCT01446809|OTHER|Placebo|Given PO
224098844|NCT01446809|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224098845|NCT02157454|OTHER|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
224098846|NCT06316479|DEVICE|PTMC Dermal Filler|A total of 120 subjects will receive treatment with PTMC Dermal Filler. The volume of filler injected will vary depending on the severity of the nasolabial fold. Injections will be administered by the investigator at the beginning of the study, with the injection technique, plane, and volume recorded. Touch-up treatments are permitted at the 1-month follow-up visit, if necessary.
224098847|NCT00365755|DRUG|carboplatin|
224098848|NCT00365755|DRUG|cisplatin|
224098849|NCT00365755|DRUG|cyclophosphamide|
223938872|NCT06866171|OTHER|Modular child restraint|The participant will be asked to install two different child safety seats into a vehicle, presented to the participant one at a time (random order). The researcher will explain that the participant should install each seat to the best of his/her ability and may take as long as needed. When each installation is completed, the participant will be led away from the vehicle while their work is evaluated by a study-team approved researcher who is a certified Child Passenger Safety Technician (CPST). A data collection form will be used to document any installation errors. Following the installations, participants will complete a short survey with open-ended queries to describe facilitators or barriers they experienced while installing the seats, as well as what they liked or did not like about each seat. They will use a Likert scale to rate their self-efficacy in installing the seats, if they believed they were installed correctly, general ease-of-use, and which seat they preferred.
223938873|NCT04807842|DEVICE|vaginal gel|The placebo gel is a non-buffered gel. The active device is an acidic gel.
223938874|NCT04827732|RADIATION|Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy|When feasible it is strongly recommended that radiotherapy begin on a Monday
223938875|NCT04827732|DEVICE|MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine|-The device that will administer the IMPT
223938876|NCT07011030|OTHER|Measure of skeletal muscle mass|Bioimpedance analysis with integrated electrodes and osteodensitometry examination
223938877|NCT07010107|DRUG|Anaprazole + Rabeprazole placebo|Anaprazole 3 tablets (20 mg/tablet) + Rabeprazole placebo 1 tablet (0.16 g/tablet), administered orally 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
223718855|NCT02445092|OTHER|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
223938878|NCT07010107|DRUG|Rabeprazole + Anaprazole placebo|Rabeprazole 1 tablet (20 mg/tablet) + Anaprazole placebo 3 tablets (0.2 g/tablet), orally administered 30-60 minutes before breakfast once daily for up to 8 weeks. After 4 weeks of continuous treatment, if endoscopic evaluation confirms the cure of reflux esophagitis, treatment may be discontinued.
223938879|NCT07011615|BEHAVIORAL|Brief Motivational Mobile Health (mHealth) Intervention|Participants randomized to the mHealth intervention condition will receive a five-week online program that incorporates weekly text messages. The program will begin with prompting the young adult to reflect on their journey with cannabis and to reflect on their personal goals and how cannabis is reflected in these goals. Personalized feedback about their patterns of use, motivations, emotions, and social connections will be integrated throughout the program. Text messages will be sent throughout the week to prompt reflection and support any goals the participant indicates.
223938880|NCT07011615|OTHER|Psychoeducational Attention Control (AC)|Participants randomized to the control group will receive a program to learn more about psychoeducational information about cannabis. They can opt in to receive psychoeducational material via text messages.
223938881|NCT06873581|DEVICE|Voro Urologic Scaffold|The Voro Urologic Scaffold is placed during the prostatectomy procedure after prostate removal.
223941414|NCT03711084|DIETARY_SUPPLEMENT|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
223941415|NCT03711084|DIETARY_SUPPLEMENT|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
223941416|NCT03711084|DIETARY_SUPPLEMENT|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
224098850|NCT00365755|DRUG|etoposide|
224098851|NCT00365755|DRUG|melphalan|
224098852|NCT00365755|DRUG|vincristine sulfate|
224098853|NCT00365755|PROCEDURE|autologous bone marrow transplantation|
224286967|NCT03956589|DRUG|Orkambi|Open label of Orkambi treatment during 3 months
224286968|NCT06463717|DRUG|Transplant, Autologous|High-dose melphalan followed by autologous stem cell transplantation
224286969|NCT06463717|DRUG|Chemotherapy drug|Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone
224286970|NCT01954914|DRUG|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
224286971|NCT05420116|BEHAVIORAL|Cerdanya on Fitness|The intervention lasts 9 months. The participants will carry out group activities and will be followed individually by the different interdisciplinary professionals. Goals will be set for each visit. Before and after the training there will be an assessment of physical exercise, nutritional and positive mental health habits.
223718856|NCT05430932|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic resection of a part of the stomach to enable the patient to lose weight.
223718857|NCT04584645|OTHER|Targeted digital intervention|Messages that provide informational content on the influenza vaccine (sourced from the Centers for Disease Control and Prevention and the American Heart Association), specific information about influenza and cardiovascular disorders, and behavioral prompts (e.g., reminders) surrounding influenza vaccination behaviors.
223718858|NCT00390468|DRUG|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
223718859|NCT00830362|DRUG|Propranolol|40 mg administered once
223938882|NCT06681740|DEVICE|Inspiratory muscle training|The control group will perform a standard cardiac rehabilitation program, consisting of 16 multicomponent exercise sessions, health education, and a weekly group of psychological therapy session. The intervention group will do the same program with the addition of Inspiratory Muscle Training (IMT). The following device will be used: Power Breath model: Medic Classic. The training will be performed by adjusting the device load to 70% of the Maximum Inspiratory Pressure value, performing 1 daily training session 4 days a week of 3 sets of 10 repetitions, with a rest of 3 minutes between sets, during 8 weeks. A physical therapist will teach participants how to use the device on the first day and they will be instructed to perform it at home. They will be given a diary to record their compliance. In addition, once a week the physiotherapist will supervise the execution of the IMT by the participants.
223938883|NCT06681740|DEVICE|Sham Inspiratory muscle training|The control group will be given the same device as experimental group, but the load for all of the participants of the control group will be 5cm de H2O. This load is so low that it´s not able to induce improvement of the inspiratory musculature.
224286972|NCT02112279|BIOLOGICAL|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1\. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
224286973|NCT03945799|DRUG|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
224286974|NCT00537199|OTHER|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
224286975|NCT00537199|DRUG|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
224286976|NCT01376206|DRUG|Fluticasone|Collection of safety data
224286977|NCT00510315|OTHER|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
224286978|NCT02241109|OTHER|no intervention|progression monitoring by echocardiography
224286979|NCT03187028|BEHAVIORAL|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
223718860|NCT00830362|DRUG|Placebo|administered once
223718861|NCT01930864|DRUG|metformin|metformin up to 2500mg/d
223718862|NCT01930864|DRUG|irinotecan|Irinotecan 350 mg/m² IV q21d
223938884|NCT06873152|PROCEDURE|Control preoperative program|Patients will undergo a control preoperative program with no enhances preparation when undergoing bilateral third molar extraction
223938885|NCT06873152|PROCEDURE|Advanced preoperative program|Patients will undergo an comprehensive program including enhanced preoperative preparation and a dedicated operating room team when undergoing bilateral third molar extraction
223938886|NCT06626321|BEHAVIORAL|Pre-visit patient text messaging|Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming visit and encourage the patient to ask their provider about receiving the vaccine.
223938887|NCT06626321|BEHAVIORAL|Default pended order|A default pended order for the flu vaccine will be pended to the patients upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
223938888|NCT06626321|BEHAVIORAL|Monthly peer comparison feedback|Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention
224286980|NCT03187028|BEHAVIORAL|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
224286981|NCT02276768|DRUG|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
224286982|NCT02276768|DRUG|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
224286983|NCT02276768|DRUG|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
224286984|NCT02276768|DRUG|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
224286985|NCT02276768|OTHER|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
224286986|NCT03241316|BEHAVIORAL|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
224286987|NCT02740179|DRUG|Eplerenone|Eplerenone 50mg by mouth twice daily
223718863|NCT06009705|DRUG|toripalimab|JS001, the active ingredient of toripalimab injection, independently developed by Shanghai Junshi Biomedical Technology Co., Ltd, is an independently developed novel recombinant humanised (degree of 97%) anti-PD-1 monoclonal antibody (Chinese Patent License No. CN104250302B, PCT Patent Publication No. WO2014/206107A1), belonging to the human IgG4/Kappa subtype, and introducing a point mutation at the Serine to Proline (S228P) protein site 228 in the hinge region of the IgG4 heavy chain.
223718864|NCT00277498|DRUG|Xalacom|
223718865|NCT00277498|DRUG|Xalatan|
223718866|NCT00277498|DRUG|Timolol|
223938889|NCT06626321|BEHAVIORAL|High risk bidirectional pre-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
223938890|NCT07012096|BEHAVIORAL|counseling, leaflet and mhealth education for hypertension|Investigators will develop 6 leaflets and 24-SMSs containing messages on the burden of hypertension, consequences, and the benefits of preventing of hypertension, and the healthy practices for preventing hypertension, tobacco, physical inactivity, dietary salt intake, inadequate fruits and vegetables, overweight and obesity, and the use of trans fat. It will be written in plain and simple Bengali. Leaflets will be received by CG-1, CG-3, IG-1 and IG-3. 24-SMSs. Face-to-face counselling (approximately 20 min/session). A total of 20 sessions (1 cycle) will be provided. The session will be repeated if the cycle is over.
224286988|NCT02740179|DRUG|Placebo|Placebo by mouth twice daily
224286989|NCT02740179|BEHAVIORAL|Lifestyle Modification|Counseling regarding diet and healthy activity
224286990|NCT02388698|PROCEDURE|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
224286991|NCT02388698|RADIATION|PET-CT|PET-CT will be completed 3 month post chemoradiation.
224286992|NCT02388698|BIOLOGICAL|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
224286993|NCT03680976|DRUG|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
223938891|NCT07012096|BEHAVIORAL|Leaflets and mhealth education|"Participants will receive 6 leaflets containing messages on the burden of hypertension, consequences, and benefits of prevention of hypertension, and the healthy practices for preventing hypertension.~Participants will receive 24 SMSs containing the burden of hypertension, consequences, and benefits of prevention of hypertension, and the healthy practices for preventing hypertension.~And additionally receive a dummy counselling of 5 to 10 minutes informal discussion with the participants, which will not include any health messages that will be received by the participants of the intervention group."
223938892|NCT07012096|OTHER|Dummy Placebo|Participants will only receive a dummy counselling of 5 to 10 minutes informal discussion with the participants, which will not include any health messages that will be received by the participants of the intervention group.
223938893|NCT07012252|PROCEDURE|Optical coherence tomography|Infants underwent optical coherence tomography.
224098854|NCT00365755|PROCEDURE|conventional surgery|
224286994|NCT03680976|DRUG|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
223534516|NCT00886730|BEHAVIORAL|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
224286995|NCT01035476|BEHAVIORAL|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
224286996|NCT03259191|PROCEDURE|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
224286997|NCT04030663|DRUG|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
224286998|NCT04030663|DRUG|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
224286999|NCT04030663|DRUG|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
224287000|NCT01483014|DRUG|imatinib mesylate|
224287001|NCT05487560|DRUG|Esomezol Cap|Esomezol Cap, Once daily administered per the locally approved product information
223938894|NCT07013500|PROCEDURE|Conventional Gasserian Ganglion Radiofrequency|Conventional RFA was performed at the Gasserian ganglion under fluoroscopic guidance with thermal lesioning at 70-75°C for up to 90 seconds. Sensory and motor stimulation were used to verify needle placement.
223938895|NCT07013500|PROCEDURE|Peripheral Pulsed Radiofrequency|PRF was applied to the peripheral branch of the trigeminal nerve at 42°C for two cycles of 120 seconds using fluoroscopic guidance. This technique was preferred in our clinic to avoid thermal complications such as hypoesthesia or motor dysfunction.
223938896|NCT07012785|DRUG|Bismuth quadruple therapy|Bismuth quadruple therapy
223938897|NCT07012785|DRUG|Saccharomyces boulardii|Saccharomyces boulardii
223938898|NCT07015424|DEVICE|TORe with OverStitch|Transoral Outlet Reduction with OverStitch Endoscopic Suturing System
223938899|NCT07015424|BEHAVIORAL|Intensive lifestyle modification|Intensive lifestyle modification program consists of the following: well-balanced calorie-restrictive diet, incorporation of exercise and coaching on lifestyle changes. The program should include personal discussions and goals designed and overseen by the treating physician, obesity management professional or dietician.
223938900|NCT07011784|OTHER|Blood flow restriction in combination with dance classes|Blood flow restriction in combination with online ballet and modern-style dance classes to test if the balance of older women can be improved. Participants will wear 5 centimetre elasticized blood flow restriction bands on their proximal thighs throughout the online ballet-modern dance classes. Tightness levels will be set at a 7/10 of the perceived tightness scale used by Wilson et al. (2013), with a total restriction time of approximately 60 minutes, twice per week.
223938901|NCT07011784|OTHER|Dance classes alone|Online ballet and modern-dance inspired classes will be held on Zoom twice per week for 75 minutes. The sessions will span a 12 week time frame. All classes will begin with a warm-up, 1 plie exercise, 1 tendu exercise, a travelling ballet-inspired exercise, 1 travelling Graham or Limón modern dance exercise and a seated cool-down.
223938902|NCT06623240|BIOLOGICAL|allogeneic Hope Biosciences adipose-derived mesenchymal stem cells|"Product: Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)~Dose determined by body weight:~* 50 million cells in 50mL saline: ≥ 10 kg to \< 22 kg~* 100 million cells in 100mL saline: ≥ 22 kg to \< 45 kg~* 200 million cells in 250mL saline: ≥ 45 kg Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 1: Group A and Cohort 2: Group AB) or Weeks 20, 24, and 28 (Cohort 2: Group BA)"
223938903|NCT06623240|OTHER|Normal Saline Solution 0.9%|Product: Normal Saline Solution 0.9% Route: Intravenous Regimen: Weeks 0, 4, and 8 (Cohort 2: Group BA) or Weeks 20, 24, and 28 (Cohort 2: Group AB)
223938904|NCT05807074|DRUG|Tranexamic Acid|Applied intraoperatively
223938905|NCT05807074|OTHER|Saline|Applied intraoperatively
223938906|NCT04476563|DIAGNOSTIC_TEST|Obtaining biological samples|Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
223938907|NCT07020520|DEVICE|Optilume|Has pre-treatment (balloon dilation or ureterotomy) followed by paclitaxel-coated balloon (Optilume) treatment of the ureteric stricture.
223938908|NCT07020234|BEHAVIORAL|Epigenetics Video|Educational video about health and epigenetics.
223938909|NCT07020234|BEHAVIORAL|Nanotechnology Video|Educational video about nanotechnology
223938910|NCT07011719|DRUG|Casdatifan|Administered as specified in the treatment arm
223938911|NCT07011719|DRUG|Cabozantinib|Administered as specified in the treatment arm
223938912|NCT07011719|DRUG|Placebo|Administered as specified in the treatment arm
223938913|NCT07014098|DEVICE|Robot-Aided Off-Axis Neuromuscular Training|A novel custom-designed elliptical trainer is developed, and its footplates are robot-controlled to be moved in four off-axis directions (sliding in/out, pivoting in/out; corresponding to knee valgus/varus, internal rotation/external rotation). Before the training, off-axis neuromechanical assessments will be conducted to determine which specific off-axis direction (valgus, varus, internal rotation, external rotation, or combination of the off-axis directions) has neuromechanical deficits. During the evaluation-based and subject-specific neuromuscular training, the different training modes will be conducted progressively from regular stepping, footplate position control, spring mode, perturbation, to slippery mode.
223938914|NCT07014098|DEVICE|Traditional elliptical regular stepping|traditional elliptical regular stepping
223938915|NCT06618157|DEVICE|Cerebellothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the cerebellothalamic pathway on the patient-specific connectomic deep brain stimulation model
223938916|NCT06618157|DEVICE|Pallidothalamic optimized deep brain stimulation|A deep brain stimulation plan will be created by maximizing the Pallidothalamic pathway on the patient-specific connectomic deep brain stimulation model
223938917|NCT06618157|OTHER|No deep brain stimulation|Patients will also be tested without any deep brain stimulation
223938918|NCT06618157|DEVICE|Usual care deep brain stimulation|Patient will also be tested with the deep brain stimulation clinical settings that were previously established during usual care with their neurologist
224287002|NCT04625062|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, participants view a dynamic display of the speech signal in the form of a real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants were cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency.
224287003|NCT04625062|BEHAVIORAL|Motor-based treatment|Motor-based articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract were used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
223534517|NCT00886730|BEHAVIORAL|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
223534518|NCT04324281|OTHER|Investigation|cadaveric dissection
223534519|NCT02267434|BIOLOGICAL|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
223938919|NCT06328777|BIOLOGICAL|CABA-201|Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
223938920|NCT06691854|OTHER|The group that applied the Intrapartum Care Model|"Pregnant women who apply to the hospital for delivery, have cervical dilatation of 5 cm and above, agree to participate in the study and are assigned to the intervention group;~A Personal Information form will be applied at the first clinic admission. All primiparous pregnant women assigned to the intervention group will be applied the intrapartum care model by the research midwife during the labor process and after birth in line with the WHO positive birth recommendations.~The labor process of the pregnant woman will be recorded on the birth experience follow-up form.~After birth, the Respectful maternity care scale, Birth experience scale, Traumatic birth perception scale will be applied."
223938921|NCT06874621|DRUG|VY7523|VY7523 is a recombinant humanized immunoglobulin gamma 4 (IgG4) monoclonal antibody targeting human pathological tau
223938922|NCT06874621|DRUG|Placebo Comparator|Matching placebo to VY7523
223938923|NCT07026968|DRUG|Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR|Prusogliptin, Dapagliflozin(high dose) and Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose.
223938924|NCT07026968|DRUG|Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR|Prusogliptin placebo, Dapagliflozin (high dose), Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
223938925|NCT07026968|DRUG|Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XR|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
223938926|NCT07026968|DRUG|Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), plus metformin XR|Prusogliptin placebo, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose), once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
223938927|NCT07026968|DRUG|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin(low dose) placebo, plus metformin XR|Prusogliptin, Dapagliflozin (high dose) placebo, Dapagliflozin (low dose) placebo, once a day, 1 tablet per dose; Metformin XR, Once a day, the dosage remains the same as the pre-screening dose
223938928|NCT07024420|OTHER|Sigh Breaths|Sigh breaths were added by elevating PEEP, targeting a plateau pressure of 35 cmH2O (or 40 cmH2O for patients with a Body Mass Index \> 35 kg/m2). These sigh breaths were administered once every 6 minutes at predefined stages in the perioperative period from the time of anesthesia intubation until endotracheal extubation, postoperative day 7, or death, whichever occurred first, but not during transport. Each sigh consisted of the minimum number of respiratory cycles aimed to achieve a total duration of at least 5 seconds, based on the respiratory cycle duration preset on the ventilator.
223938929|NCT07024420|OTHER|Low Tidal Volume|6-8ml/kg predicted body weight
224098855|NCT02600299|BEHAVIORAL|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
224098856|NCT02600299|BEHAVIORAL|Usual Care|Usual Care
224098857|NCT06227403|BEHAVIORAL|Leadership, Engagement, and youth Action Program with Mindfulness|The Leadership, Engagement, and youth Action Program with Mindfulness intervention (LEAP) was designed and co-created with youth to improve youth well-being by enhancing leadership opportunities and by developing mindfulness in day-to-day life. LEAP seeks to foster these improvements in youth as a strategy to increase mental, emotional, and behavioral health. Youth voice is incorporated into the intervention, with facilitators leading the first 7 sessions, and youth leading the remainder.
224098858|NCT06227403|BEHAVIORAL|EnvisionIT|Participants in this arm will receive 14 sessions of EnvisionIT training, focused on preparing students with essential skills including digital literacy through competency in information technology, financial literacy, English language arts skills, and college and career readiness. All sessions will be delivered by facilitators trained in EnvisionIT.
224098859|NCT05792826|OTHER|BSZY Cream|The patients receive BSZY Cream twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
224287004|NCT05449782|DIETARY_SUPPLEMENT|Cocoa flavanol|Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)
224287005|NCT05449782|OTHER|Placebo|Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
224287006|NCT04726189|OTHER|Standard exercises|Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
224287007|NCT04726189|OTHER|Standard exercises plus Early progressive exercises|This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
224287008|NCT05890092|OTHER|Observation|Observing for disease prevalence - actual and self-reported
224287009|NCT02208752|OTHER|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
223534520|NCT02267434|BIOLOGICAL|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
223534521|NCT02267434|BIOLOGICAL|Adjuvant without active component|s.c. injection
224287010|NCT03439631|OTHER|Patient satisfaction questionnaire|Patient satisfaction questionnaire
224287011|NCT06193031|DRUG|C16TR|Administered as inhalation using a Philips Micro device inhaler.
224287012|NCT06193031|DRUG|Placebo|Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.
224287013|NCT06193031|DRUG|Tyvaso®|Administered as inhalation.
223938930|NCT07024420|OTHER|Moderate PEEP|PEEP set according to ARDSnet low PEEP- fraction of inspired oxygen table, FiO2 was set as the lowest fraction targeted to maintain SpO2 ≥ 96%
224098860|NCT05792826|OTHER|emulsion matrix|The patients receive emusion matrix twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
224098861|NCT00785577|DRUG|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
223534522|NCT02475421|BIOLOGICAL|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
223938931|NCT07028281|DRUG|SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin|SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
223938932|NCT07023341|DRUG|BAY3723113|Oral tablet
224098862|NCT00785577|DRUG|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
224098863|NCT00785577|DRUG|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
224098864|NCT00785577|DRUG|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
224098865|NCT00785577|DRUG|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
224098866|NCT06842199|DRUG|ICP-488 Tablets|Eligible patients will receive ICP-488 orally as per the protocol
224098867|NCT06842199|DRUG|ICP-488 Placebo|Eligible patients will receive ICP-488 Placebo orally as per the protocol
224098868|NCT01682044|BIOLOGICAL|pegfilgrastim|Given SC
224098869|NCT01682044|BIOLOGICAL|rituximab|Given IV
224098870|NCT01682044|OTHER|flow cytometry|Correlative studies
224098871|NCT01682044|PROCEDURE|biopsy|Correlative studies
224098872|NCT01682044|OTHER|immunohistochemistry staining method|Correlative studies
224098873|NCT01682044|GENETIC|western blotting|Correlative studies
223534523|NCT02022709|DRUG|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
223534524|NCT02022709|DRUG|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
223534525|NCT02022709|DRUG|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
223534526|NCT02022709|DRUG|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
223534527|NCT02022709|DRUG|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
223534528|NCT02022709|BEHAVIORAL|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
223938933|NCT07034638|BEHAVIORAL|WNG|In addition to the hospital's standard care protocol, patients in this group will listen to white noise through headphones before and during the colonoscopy procedure, as directed by the researcher.
223938934|NCT07034638|BEHAVIORAL|PNG|In addition to the standard care protocol, patients included in this group will listen to pink noise through headphones as directed by the researcher.
223938935|NCT07032506|PROCEDURE|Intraoperative placement of an inflated intrauterine pediatric foley catheter|Intraoperative placement of an inflated intrauterine pediatric foley catheter balloon to remain in place for 7-10 days following surgery.
223938936|NCT07032506|PROCEDURE|No Catheter placement|No Intraoperative placement of an inflated intrauterine pediatric foley catheter balloon
223938937|NCT07032506|DRUG|Hormonal Therapy Agent|2 weeks of oral estradiol (2 mg daily) or transdermal (two 0.1 mg patches changed twice weekly) estradiol supplementation followed by 1 week of oral or transdermal estradiol (same dosing as above) with oral medroxyprogesterone acetate (10 mg daily)
224098874|NCT00757315|DEVICE|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
224098875|NCT00757315|DRUG|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
224098876|NCT00083161|DRUG|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
224098877|NCT00083161|DRUG|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
224098878|NCT00083161|DRUG|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
224098879|NCT06979557|DEVICE|Odyssey IOL|Bilateral implantation with the Odyssey IOL
224098880|NCT06985758|DRUG|Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg|Intravenous administration of a first dose of Rezafungin 400mg followed by weekly doses of intravenous Rezafungin 200mg to study the pharmacokinetic parameters of the drug.
224098881|NCT06598787|DRUG|BL-B01D1 for Injection|Administration by intravenous infusion for a cycle of 3 weeks.
224098882|NCT03435978|BEHAVIORAL|MetS+|
224098883|NCT03435978|OTHER|MetS-|Data processing from Patient Medical Files
224287014|NCT01685658|DRUG|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
224287015|NCT01685658|DRUG|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
224287016|NCT03711916|DEVICE|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
224287017|NCT03466541|BEHAVIORAL|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
223938938|NCT07032506|DRUG|Oral antibiotics|100 mg of oral doxycycline twice daily or other appropriate antibiotic in allergic patients to be given while the intrauterine stent is in place
223938939|NCT06727604|DRUG|IMVT-1402|600 mg SC QW for 52 weeks
223938940|NCT06727604|DRUG|IMVT-1402|600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
223938941|NCT06727604|DRUG|Placebo|SC QW for 52 weeks
223938942|NCT04555161|DEVICE|Aria CV Pulmonary Hypertension System|The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
223938943|NCT03414684|DRUG|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
223938944|NCT03414684|DRUG|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
223938945|NCT04711811|BIOLOGICAL|HB-adMSC|Hope Biosciences adipose derived autologous mesenchymal stem cell product
223938946|NCT06753838|BIOLOGICAL|Sampling of 3 additional BAPA tubes|the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test
223938947|NCT03570801|OTHER|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
223938948|NCT06741618|BEHAVIORAL|MyPEEPS Mobile|An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence
223938949|NCT06741618|BEHAVIORAL|Electronic PrEP peer navigation|Electronic peer navigation to PreP services
223938950|NCT07060365|DRUG|Saruparib|Participants will receive saruparib via oral administration.
223938951|NCT07061288|DRUG|KarXT|Specified dose on specified days
223938952|NCT04038580|DEVICE|Laminated Socket|This is the currently prescribed socket the participant normally wears.
223938953|NCT04038580|DEVICE|Quatro|The Quatro (Quorum) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
223938954|NCT04038580|DEVICE|Infinite Socket|The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
223938955|NCT04038580|DEVICE|CJ Socket|The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
223938956|NCT01922440|OTHER|No intervention|This is a non-interventional study.
223938957|NCT06578390|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
223938958|NCT04907175|BIOLOGICAL|HB-adMSCs|Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year.
223938959|NCT06770855|PROCEDURE|Total consolidative MPDT|After stopping systemic anti-cancer therapy for metastatic RCC, participant will receive one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and/or radiotherapy (SAbR or other definitive radiotherapy).
223938960|NCT07062198|DRUG|Combined metabolic activators|A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.
223938961|NCT07062198|OTHER|Collagen and maltodextrin|As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.
223938962|NCT02954432|DEVICE|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
223938963|NCT02954432|DEVICE|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
223938964|NCT06208735|BIOLOGICAL|CLIC-2201|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-2201 CAR-T cells. All treatments will be delivered intravenously.
223938965|NCT06161545|BIOLOGICAL|PD-L1 t-haNK cells|Irradiated PD-L1 t-haNK cells at a dose of 2 x 10\^9 administered via IV infusion over 30 minutes on Days 1, 5, 8, 12, and 15
223938966|NCT06161545|DRUG|pembrolizumab|400 mg administered as a 30 minute IV infusion on Day 1
223938967|NCT06161545|DRUG|N-803|15 ug/kg via subcutaneous injection on Day 1
223938968|NCT05320692|DRUG|TACE+Camrelizumab+Apatinib mesylate|TACE. Camrelizumab，200mg，iv，once every 3 weeks. Apatinib mesylate, 250 mg, administered orally once daily，once every 3 weeks.
223938969|NCT05320692|PROCEDURE|TACE|TACE Alone.
223938970|NCT06828952|DRUG|ceftriaxone|ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly
223938971|NCT06828952|DRUG|ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly|Conservative management
223938972|NCT06832358|BEHAVIORAL|Routine nursing methods|According to their condition, they receive individualized drug treatment, including the main drugs of Parkinson's disease (such as dopamine replacement drugs) and combined antidepressant drugs. Secondly, regular follow-up evaluations will be conducted to monitor disease progression and drug side effects. At the same time, patients and their families will receive health education on Parkinson's disease and depression.The patients would receive basic psychological support. Medical staff will encourage patients to express their emotions and pay attention to their psychological state, which will help alleviate anxiety and depression. Medical staff will provide patients with information about local support organizations and social groups, and encourage patients to participate in related activities to increase social interaction and emotional support.
223938973|NCT06832358|BEHAVIORAL|PERMA positive psychological intervention mode|(1) Formation of an intervention team.(2) Development and execution of interventions.The study group participated in a series of positive psychology workshop involving interviews and exercises aligned with the PERMA model as part of their routine health education. Each participant took part in individualized interviews focused on two specific topics each week until all subjects were covered, with each session lasting between 30 to 50 minutes. This interview phase continued for one month, conducted in the hospital ward.
223938974|NCT04021862|DRUG|Bermekimab Monoclonal Antibody|Bermekimab 400 mg or 800 mg will be administered subcutaneously.
223938975|NCT04021862|DRUG|Placebo|Placebo will be administered subcutaneously.
223938976|NCT01574339|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a technical representative."
223938977|NCT06384521|BEHAVIORAL|Lifestyle MIND|Lifestyle MIND is implemented twice a week in the group format, including a physical activities class and a health class. The physical activity class lasts for 60 minutes. Participants engage in physical activities modified from the American College of Sports Medicine guidelines for diabetes. The health class lasts for about 2 hours and is delivered by occupational therapy faculty and students with light refreshments that are friendly for people with diabetes. The first hour of the health class involves psychoeducation and skills training for managing SMI and Type 2 Diabetes Mellitus (T2DM), including topics such as recognizing signs and symptoms of mental disorders and diabetes, goal setting, dealing with setbacks and resistance to change, celebrating culture and holidays, and establishing healthy habits and routines. The second hour of the health class is to address individual needs, social determinants of health, and any needed homework assistance.
223938978|NCT06420492|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug for four weeks.
223938979|NCT07088458|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice of BAY94-9027 to further define the treatment outcomes of damoctocog alfa pegol based on real-world use for regular prophylaxis in ages 7 to \<12 years, including a broader population and a real-world treatment patterns.
223938980|NCT04834154|BEHAVIORAL|Mindfulness|6 weekly 2.0 hour video-conferenced group sessions with the following components: 1) short grounding meditation, 2) check in/review of prior weeks practice and symptoms, 3) educational topic, 3) main meditation, 4) reflection on meditation, and 5) action plan formation
223938981|NCT04834154|BEHAVIORAL|Control group|Wait list control
223534529|NCT03789981|GENETIC|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
223534530|NCT00445094|DRUG|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
223534531|NCT00445094|DRUG|Comparator: amikacin / Duration of Treatment: 3 Days|
223718867|NCT01996852|BEHAVIORAL|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
223718868|NCT01996852|DRUG|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
223938982|NCT06411418|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments. The Pipeline™ Flex Embolization Device with Shield Technology™ is also indicated for use in the internal carotid artery up to the terminus for the endovascular treatment of adults (22 years of age or older) with small and medium wide-necked (neck width ≥ 4 mm or dome-to-neck ratio \< 2) saccular or fusiform intracranial aneurysm (IAs) arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 5.0 mm.
223938983|NCT05059223|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
223534532|NCT00445094|DRUG|Comparator: tazocin / Duration of Treatment: 3 Days|
223534533|NCT00445094|DRUG|Comparator: vancomycin / Duration of Treatment: 3 Days|
223534534|NCT00692887|DEVICE|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
223534535|NCT03583229|DRUG|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
223534536|NCT03583229|OTHER|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
223534537|NCT00003873|DRUG|fluorouracil|Given IV or orally
223534538|NCT00003873|DRUG|eniluracil|Given orally
223534539|NCT02466724|DEVICE|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
223534540|NCT05889325|PROCEDURE|DEB-TACE plus HAIC|the patients received HepaSphere DEB-TACE plus HAIC
223938984|NCT05059223|DRUG|Placebo|Placebo tablets, taken twice daily
223938985|NCT02802423|DRUG|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
223938986|NCT05440448|DEVICE|Patch-free occlusion therapy|Use of filters in glasses to provide occlusion therapy
223938987|NCT05440448|DEVICE|Adhesive patch|Standard-of-care occlusion therapy with an adhesive patch
223938988|NCT00136006|BEHAVIORAL|Study to determine the burden of disease|
224098884|NCT06817980|BEHAVIORAL|Physical activity|"\- Physical activity: We will compare the impact of 3 different environments (with no object in the environment, vs. with some objects but no hidden objects vs. with objects at the fore- and background) during (total of 9 sessions of 30 minutes + 3\*5 minutes of testing), on the measure of self (see below).~Visit 10: We will repeat a walking session. Participants will wear mixed-reality goggles, which allow them to visualize the environment and superimpose a continuous stream of light. This session is intended to test the idea that this flow would enable SZ patients to suffer less from the discontinuous appearance of information when moving around.~Measure of 'self' : the participants will decide whether the line presented on a computer screen is static or moving. They will be immobile, walking on the spot in front of the computer, or passively mobilized with a whole-body movement platform. The latter condition will be used only in the first phase of the protocol"
224098885|NCT06817005|DEVICE|Intervention arm|Prior to general anesthesia induction, a finger is inserted into the probe which is connected to the PMD200® to provide the NOL index. This output, a single dimensionless number from 0 to 100, correlated proportionally to nociception.
223534541|NCT06405386|BEHAVIORAL|ReCharge|ReCharge is an emotions-focused intervention that utilizes core components of Acceptance and Commitment Therapy (ACT) to address and minimize diabetes distress. This 5-week, group-based, virtual intervention will include a stepwise process to address diabetes distress and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
223938989|NCT03978962|DEVICE|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
223938990|NCT01690624|DRUG|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
223938991|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
223938992|NCT02980510|DRUG|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
223938993|NCT05349292|OTHER|ANH|one group will be managed with ANH and the other without (control group)
224287018|NCT03466541|BEHAVIORAL|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
224287019|NCT05248984|DRUG|Ketorolac|"Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg"
224287020|NCT05801302|DEVICE|Foam rolling (shorter volume)|A single intervention will be performed (3 sets of 30 seconds, with between-sets intervals of 30 seconds).
224287021|NCT05801302|DEVICE|Foam rolling (longer volume)|A single intervention will be performed (3 sets of 60 seconds, with between-sets intervals of 30 seconds).
224287022|NCT01748955|DRUG|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
224287023|NCT01748955|DRUG|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
223938994|NCT05153668|DRUG|Everolimus Oral Tablet|Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.
224287024|NCT04203121|RADIATION|low dose whole brain radiation to treat Alzheimer disease|"subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions"
224287025|NCT03827018|COMBINATION_PRODUCT|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
224287026|NCT03827018|COMBINATION_PRODUCT|placebo|1 mL of placebo in a pre-filled syringe
224287027|NCT03827018|DRUG|prednisone|Prednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
224287028|NCT00004079|DRUG|SarCNU|Given PO
224287029|NCT00004079|OTHER|pharmacological study|Correlative studies
223938995|NCT01341301|RADIATION|Total Body Irradiation|Undergo TBI
223938996|NCT01341301|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Undergo DLI
223938997|NCT01341301|DRUG|Cyclophosphamide|Given IV
223938998|NCT01341301|DRUG|Tacrolimus|Given IV or PO
223938999|NCT01341301|DRUG|Mycophenolate mofetil|Given IV or PO
223939000|NCT01341301|PROCEDURE|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
223939001|NCT01341301|OTHER|Laboratory biomarker analysis|Correlative studies
223939002|NCT03622021|DRUG|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
223939003|NCT06735300|DRUG|Nirmatrelvir/Ritonavir (Paxlovid)|After providing the potential benefits and associated risks of antiviral treatment with Paxlovid, patients made well-informed decisions about whether or not to receive Paxlovid (300/100 mg nirmatrelvir/ritonavir, Pfizer Inc., New York, NY, USA) twice daily for 5 days.
223939004|NCT06888284|BEHAVIORAL|Tui Jing therapy|Tui Jing therapy (Gua Sha + Meridian pressure) was utilized, a specialized form of Gua Sha that incorporates traditional techniques with targeted pressure on specific meridians.
224287030|NCT00004079|OTHER|laboratory biomarker analysis|Correlative studies
224287031|NCT04814784|RADIATION|Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum|Study the effect of neoadjuvent radiotherapy in treatment of locally advanced cancer rectum e higher possiblity of preservation of anal sphincter and decreased rate of locoregional recurrence compared to surgery alone
223718869|NCT01996852|DEVICE|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
224098886|NCT06657040|OTHER|MUSIC|The intervention group will receive a soundtrack through individual choice of anti-noise headphones. The music offer platform will be provided by an application developed by MusicCare (www.music.care/en/index.html) in two periods of the day (09:00 and 16:00), lasting 45 minutes each, for up to seven postoperative days or until discharge from the unit (whichever occurs first). MusicCare has been widely tested in several countries and there are a large number of publications in anesthesiology, ICU, cardiology and neurology, among other specialties, demonstrating its safety and efficacy69,70. Patients who were hospitalized for more than 48 hours, that is, who received a minimum of 4 intervention periods, will be considered as patients with effective intervention. Patients with less time will be evaluated in the form of intention to treat.
224098887|NCT06656871|DIETARY_SUPPLEMENT|iron supplementation|The iron tablet group received iron supplementation (30 mg, 1 tablet/day of iron) for 4 weeks
224098888|NCT06656871|DIETARY_SUPPLEMENT|Biostimulated lettuce supplementation|the intervention group SwE lettuce group received lettuce biostimulated with Ecklonia Maxima algae (SwE lettuce, 100 grams/day) daily for 4 weeks
223939005|NCT06888284|DEVICE|sham ultrasound intervention|Participants will receive a sham ultrasound intervention on the same meridians. To enhance comfort and prevent cold sensations from the metal probe, the ultrasound device will be pre-warmed to body temperature. A gel, mimicking the texture of the lubricant used in Tui Jing therapy, will be applied. The device will mimic the motion, direction, duration, and frequency of the Tui Jing therapy, but without activating the ultrasound's therapeutic mode. The participants will be informed that they are accepting low-intensity ultrasound mode, which will not produce any sensory perception, ensuring in distinguishing ability between active and sham interventions
223939006|NCT03260387|PROCEDURE|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
223939007|NCT03595917|DRUG|ABL001|•ABL001 is administered daily per 28 day cycle
224098889|NCT06657261|PROCEDURE|The patient group receiving deep and superficial serratus anterior plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
224098890|NCT06657261|PROCEDURE|The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block|The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
224287032|NCT01946984|PROCEDURE|ERCP|endoscopy, retrograde cholangio-pancreaticography.
224287033|NCT01946984|DRUG|Diclofenac hydroxyethylpyrrolidine|
224287034|NCT01946984|DRUG|Normal Saline|
223718870|NCT00067600|BEHAVIORAL|Diet with increased fruits, vegetables, and calcium|
224287035|NCT00855075|DEVICE|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
224287036|NCT00727077|BIOLOGICAL|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
224287037|NCT00727077|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
224287038|NCT03968497|OTHER|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
224287039|NCT03968497|OTHER|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
224287040|NCT05592353|OTHER|Brace|Brace following hip arthroscopy
223718871|NCT00067600|BEHAVIORAL|Increased high impact activity and resistance training|
223718872|NCT01587001|DIETARY_SUPPLEMENT|N-acetyl-cysteine|900mg three times daily for 8 weeks
223718873|NCT01587001|DRUG|Placebo|Matching placebo three times daily for 8 weeks.
223718874|NCT01458938|OTHER|treatment plan|Data Collection Study
224287041|NCT02930629|DEVICE|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~* Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~* The TOF force transducer will be placed on the volar aspect of the thumb.~* The TOF Watch leads will be attached to the ECG electrodes.~* A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~* Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
224287042|NCT01566526|DRUG|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
224287043|NCT04845646|DRUG|ASC41|5mg/tablet
223718875|NCT01781143|DEVICE|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
223939008|NCT03595917|DRUG|Dasatinib|Fixed doses oral once a day per 28 day cycle
223939009|NCT03595917|DRUG|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
223939010|NCT03595917|DRUG|Blinatumomab|By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
224287044|NCT04845646|DRUG|Itraconazole|200mg/capsule
224287045|NCT04845646|DRUG|Phenytoin|300mg/capsule
224287046|NCT00746291|OTHER|6 min walk test, Step climbing|walking for 6 minute and climbing steps
223939011|NCT06275750|DEVICE|Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)|The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
223939012|NCT02517268|PROCEDURE|Pancreaticoduodenectomy|
223939013|NCT05773365|OTHER|PENG block with or without local anaesthetic infiltration|As mentioned.
223534542|NCT06405386|BEHAVIORAL|TakeCharge|TakeCharge is a problem-solving focused intervention that empowers participants to identify and make meaningful changes in their blood glucose management and other diabetes-related behaviors. This 5-week, group-based, virtual intervention will include a stepwise process to analyze data and resolve challenging situations surrounding diabetes management and provide opportunities to practice new skills. Weekly assignments between the sessions will reinforce class material and give additional practice opportunities. Participants will be expected to interact in each session and will have opportunities to share their experiences and be engaged in discussion with the group and the facilitator.
223534543|NCT00693550|OTHER|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
223939014|NCT06103227|DRUG|Prednisone 5Mg|Prednisone administered for three weeks. If pregnant women weighs less than 90 kg , she will receive prednisone on altering days instead of every morning for pregnant women weighing more than 90 kg.
223939015|NCT04043117|OTHER|Body Image evaluation|"Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~1. Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~2. Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~3. Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves."
223939016|NCT04043117|OTHER|Self esteem evaluation|"Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false."
223939017|NCT06183619|PROCEDURE|Pulmonary vein isolation plus superior vena cava isolation|Pulmonary vein isolation plus superior vena cava isolation
223939018|NCT06183619|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation only
224098891|NCT06657118|PROCEDURE|Ultrasound guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* Transducer is placed over TMJ, parallel to the long axis of mandibular ramus. • Transducer is tilted until the optimal visualization is obtained.~* Disc is visualized as a thin homogenous, hypo-to-iso-echoic band lying adjacent to the inferior relation. The bony landmarks of the mandibular condyle and the articular eminence are visualized as hyperdense lines.~* Superior joint space located between the disc and articular eminence is the targeted point of the needle.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
224098892|NCT06657118|PROCEDURE|Conventional anatomically guided arthrocentesis of tempromandibular joint|"* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* Head turned to the affected side. • External auditory meatus will be blocked with a cotton plug.~* A line will be drawn from tragus of the ear to the outer canthus of the eye with ink.~* Double needled canula is inserted into superior compartment of the joint space 2mm below and 10 mm ahead of mid-tragal end of Holmund Hellsing's line.~Intra-operative procedures - continued in both groups:~* Lavage is performed with 100 ml of saline solution.~* 1 ml of Hyaluronic acid is injected into the superior joint space.~* Puncture point is covered with sterile dressing for 24 hours"
224098893|NCT06656468|DEVICE|Pacemaker and defibrillator|Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.
223534544|NCT06564662|DEVICE|Rapid Response EEG|The Ceribell(R) Rapid Response EEG is a relatively new device that is becoming standard of care in the adult critical care. In this pediatric study the device will be placed by trained ICU physicians
223534545|NCT04779099|BEHAVIORAL|Brief 4-session intervention for borderline personality disorder|Intervention consists of weekly 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support. This intervention is detailed in a published manual.
223534546|NCT04779099|BEHAVIORAL|Treatment as usual|TAU comprises access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
223718876|NCT04833543|OTHER|Robotic Mobility Device (REX)|A self supporting robotic mobility device (REX) will be utilized. It is a Class I device, and it is classified as powered exercise equipment meant for anyone that requires use of a wheelchair for mobility who has difficulty with standing and walking. The participant will be supported securely within the device using a pelvic harness, and thigh and calf cuffs. The device will be operated under the supervision of a device trained physical therapist and therapy technician. The participant will be transferred into the device in a seated position. Once aligned properly and strapped in, the participant will be passively moved by the device into standing and walking positions. To provide constant vestibular input, a variety of mobility functions will be performed including standing, sitting, walking, turning, shuffling (side-stepping), and backwards stepping.
223939019|NCT06753045|OTHER|Smartwatch|Sensors on the smartwatch will measure vitals such as heart rate, blood pressure, oxygen saturation, body composition, and electrocardio gram (ECG)
223939020|NCT03013946|BEHAVIORAL|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:~* Patient education:~  * Information on nature and severity of treatment emergent AEs~ * information about remedies for TEAEs~ * propagation and explanation of tests and treatment decisions~ * Patient instruction on self-care and preventive measures~* Preemptive AE treatment strategies~* Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
223939021|NCT06742905|DIAGNOSTIC_TEST|Robot-guided echo|This echo will be performed by a remote sonographer, though a robot
223939022|NCT06742905|DIAGNOSTIC_TEST|Standard echocardiogram|Echocardiogram acquired by a sonographer at the patient's bedside
223939023|NCT03391921|BIOLOGICAL|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
223939024|NCT06830915|OTHER|Observation only|No intervention made
223939025|NCT06389136|DRUG|Upadacitinib 15mg Dose|Oral tablet
224287047|NCT06142669|DEVICE|EVOLUTION® Revision Tibial System and EVOLUTION® Stemmed CS Femur with the EVOLUTION® MP CS Tibial Insert|Primary knee arthroplasty or a revision knee that requires a revision procedure.
223718877|NCT04833543|OTHER|Tilt Table|A tilt table is a table with a footplate that can be tilted at different angles. The participant will lie flat on the table and straps will be placed to stabilize the trunk and lower extremities. The inclination of the tilt table will be adjusted from a horizontal to a vertical position to allow the participant to attain and maintain a standing or partial-standing position. Sessions will be supervised by a physical therapist and therapy technician.
223718878|NCT01186471|OTHER|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
223718879|NCT01186471|OTHER|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
223718880|NCT01186471|DRUG|placebo|placebo - three times daily during each treatment period
223718881|NCT00828659|DRUG|Placebo|
223718882|NCT00828659|DRUG|Active Comparator #1|
223718883|NCT00828659|DRUG|Active Comparator #2|
223718884|NCT00828659|DRUG|Active Comparator #3|
223718885|NCT00828659|DRUG|Lorcaserin Dose #1|
223718886|NCT00828659|DRUG|Lorcaserin Dose #2|
223718887|NCT00828659|DRUG|Lorcaserin Dose #3|
223939026|NCT06389136|DRUG|Dupilumab 300mg Dose|Subcutaneous (SC) injection
223939027|NCT06389136|DRUG|Upadacitinib 30mg Dose|Oral tablet
223939028|NCT05203237|BIOLOGICAL|VK2735|Administered SC
223939029|NCT05203237|BIOLOGICAL|Placebo|Administered SC
223939030|NCT05203237|DRUG|VK2735 Placebo|Administered orally
223939031|NCT05203237|DRUG|VK2735 Drug|Administered orally
223939032|NCT06827756|DRUG|Norfloxacin 400 MG|Patients receiving Norfloxacin 400 Mg to prevent SBP
223939033|NCT06827756|DRUG|Nitazoxanide 500 MG|Patients receiving Nitazoxaide 500 Mg to prevent SBP
223939034|NCT06827756|DRUG|Colistin|Patients receiving Colistin 15ml three times/ day to prevent SBP
223939035|NCT06826456|PROCEDURE|sub-ablative Er,Cr:YSGG laser|The irradiations will be done with an Er,Cr:YSGG laser device Er,Cr:YSGG Laser (Waterlase iPlus 2011,Biolase,Germany). This equipment emits photons at a wavelength of 2.78 µm. The repetition rate will be fixed at 20 Hz. The pulse duration will be fixed on 140 µs. The beam diameter at the focal area for the handpiece will be 600 µm. The tip will be positioned 1.0 mm from the enamel surface (focused mode). The handpiece will be positioned perpendicularly to the enamel. Power =0.25 Watt; energy density per pulse will be 62.5 J/cm2, Time = 20 seconds; Frequency = 20 Hz; without air/water. To ensure that each spot of a fissure was irradiated, each fissure will be irradiated for 2 min with overlapping irradiation
223939036|NCT06826456|PROCEDURE|Fluoride varnish application|"The first permanent molar assigned for control group will receive fluoride varnish applications. Fluoride varnish will be applied to all teeth in the oral cavity, including the laser-treated as well as the control tooth at baseline and the 6-month recall.~Parents and children will be given age-appropriate oral hygiene instructions including proper teeth brushing with a 1100-ppm fluoride-containing dentifrice for at least 2 min twice daily especially before bedtime, as well as flossing if indicated."
223939037|NCT05858437|DIETARY_SUPPLEMENT|Sodium propionate|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
223939038|NCT05858437|OTHER|Placebo|"The patients will be randomized to PA or placebo intervention (2:1 randomization).~After the intervention of 28 days, we conduct an open-label study phase, where all patients are offered a dietary supplement of PA for overall 12 weeks (8 additional weeks for the intervention group and 12 weeks for the placebo group).~By doing so we are giving every patient the opportunity to take PA and benefit from the possible positive impact on immunsystem and intestinal barrier function."
224098894|NCT06656546|DIAGNOSTIC_TEST|Tracheal Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. A linear transducer will be placed perpendicular to the trachea at the level of the cricoid membrane. During ETI, visualization of the ETT moving within the trachea, specifically behind the cricothyroid membrane, indicates successful intubation. In contrast, if the ETT is mistakenly placed in the esophagus, a double-lumen appearance lateral to the trachea, created by the ETT within the esophagus, suggests esophageal intubation.
224098895|NCT06656546|DIAGNOSTIC_TEST|Lung Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Linear Probe (5-12 MHz) or the eSaote MyLab Seven Linear Probe (3-13 MHz), will be selected based on suitability for the procedure at the time. Following ETI, the presence of lung sliding will be evaluated using ultrasound with the aid of a linear probe.The transducer will be placed bilaterally along the mid-axillary line, between the second and fifth intercostal spaces, in a coronal orientation. After the ETT is placed and ventilation is initiated, the movement of the visceral and parietal pleura will be assessed. The presence of sliding motion between these pleural layers during ventilation indicates successful intubation, whereas the absence of this movement suggests a failed intubation.
224098896|NCT06656546|DIAGNOSTIC_TEST|Diaphragm Ultrasound|In the clinic, one of the routinely used ultrasound machines, either the HM70 EVO Curvilinear Probe (2-8 MHz) or the eSaote MyLab Seven Curvilinear Probe (1-8 MHz), will be selected based on suitability for the procedure at the time. Using a curvilinear transducer, the probe will be placed along the mid-axillary line, approximately at the seventh to ninth intercostal spaces, in a coronal orientation. The movement of the diaphragm during ventilation will be assessed over the spleen and liver. Diaphragmatic motion during ventilation indicates successful ETI, while the absence of bilateral diaphragmatic movement suggests esophageal intubation. If diaphragmatic movement is only observed on one side, it is indicative of endobronchial intubation.
224098897|NCT06092437|OTHER|Urine sodium guided diuretic algorithm|Loop diuretics are administered intravenously as soon as possible after diagnosis of ADHF and continued 3dd until recompensation. Spot urine sodium is measured 2 hours after administration of the first in-hospital IV diuretic dose and repeated until the target of 100mmol/L is reached in the first 72 hours of admission (after which, UrNa will be measured once daily). When target is not met, the next dosage of loop diuretic is doubled (max 3dd 250mg furosemide) and thereafter, other diuretics (thiazide, MRA) are added. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
224098898|NCT06092437|OTHER|Usual care|Treatment with IV loop diuretics left to the discretion of the treating physician. Acetazolamide in the first 72 hours is advised as background therapy in both treatment arms.
223939039|NCT06827015|BEHAVIORAL|Laughter-Based Anger Reduction Program|This intervention involves structured Laughter Yoga sessions lasting 40 minutes each, conducted twice a week. It specifically targets students with high anger levels. The program combines breathing exercises, playful laughter activities, and relaxation techniques to reduce stress and promote emotional regulation. Unlike other interventions, this program uniquely emphasizes laughter as a tool for managing anger and enhancing overall well-being.
224098899|NCT06679790|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics|All participants will receive 8 sessions of CBIT following a published treatment manual.
224098900|NCT03972488|DRUG|Lutathera|Lutathera is a sterile radiopharmaceutical supplied as a ready-to-use solution for infusion containing 177Lu-DOTA0-Tyr3-octreotate as a drug substance with a volumetric activity of 370 MBq/mL at reference date and time (calibration time). Each Lutathera infusion continued for 30 min.
224098901|NCT03972488|DRUG|30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
224287048|NCT02850172|BEHAVIORAL|Walk, Eat, & Breathe|"1. Walking exercise: 3 times per week, 20\~30 mins per section~2. Eat: nutritional assessment and advice weekly~3. Inspiratory muscle training: twice every day, 7 days a week, 6\~8 weeks before surgery"
224287049|NCT00980889|DEVICE|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
224287050|NCT00980889|DEVICE|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
223939040|NCT05104515|BIOLOGICAL|OVM-200|"The first part (Phase 1a) comprises a first-in-human (FIH) multiple-dose, sequential-cohort 3+3 design to establish a dose of OVM-200 that is safe and tolerable, and that elicits an immune response in humans.~This dose will be taken forward into the second part (Phase 1b) of the study. Phase 1b will further assess the safety and tolerability of the selected dose and investigate the immune and tumour response in 3 expansion cohorts of additional patients with NSCLC, ovarian cancer, and prostate cancer."
224287051|NCT01017939|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
224287052|NCT01017939|DRUG|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
224287053|NCT01017939|DRUG|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
224287054|NCT01017939|DRUG|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
224287055|NCT06304714|OTHER|Patients suffering from envenomation by Bothrops|"For research purposes, the investigator will collect six additional tubes of blood during a venipuncture. This additional volume of blood will be used for research analysis.~The total volume drawn will be within the maximum volume of blood that can be drawn based on body weight.~Venous sampling is planned as part of routine care and the additional blood volumes collected are not significant. This is a low risk procedure due to the small amount of extra blood taken (25,5 ml)."
224287056|NCT00975741|DEVICE|OXIMAX|
224287057|NCT00975741|DEVICE|ASMANEX TWISTHALER|
224287058|NCT02165514|PROCEDURE|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
223939041|NCT06823128|DEVICE|RIC|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure,last for 7 to 10 days.
223718888|NCT00730769|DRUG|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
223718889|NCT04931407|OTHER|A 12-week interdisciplinary complex intervention|"The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian."
223718890|NCT00133328|DRUG|valsartan|
223939042|NCT06823128|DEVICE|Sham|RIC is given twice a day with 60mmHg pressure, last for 7 to 10 days.
223939043|NCT06823128|OTHER|Guideline-based therapy|Guideline-based therapy
223939044|NCT04777084|DRUG|IBI318|IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued medication until disease progression, death, toxicity is intolerable, Withdrawal of informed consent, start a new anti-tumor treatment or terminate the treatment for other reasons specified in the plan, the maximum use time is 2 years.
223939045|NCT05605054|BEHAVIORAL|UCSD RELINK|UCSD RELINK coach-guided health literacy intervention and in-person service navigation assistance
223939046|NCT05605054|BEHAVIORAL|Self-study|Self-studying of programmatic information and list of service referrals
223939047|NCT05080777|BEHAVIORAL|Tele-Savvy|A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
223941417|NCT03711084|DIETARY_SUPPLEMENT|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
224098902|NCT03972488|DRUG|2.5% Lys-Arg sterile amino acid solution|Participants who received Lutathera were administered a concomitant 2.5% Lys-Arg solution for kidney protection, with each Lutathera dose. The 2.5% Lys-Arg solution was administered intravenously for 4 hours (infusion rate: 250 ml/h); the infusion was to start 30 minutes prior to the start of the Lutathera infusion and continue during (30 min) and up to at least 3 hours after the Lutathera infusion.
223718891|NCT04800744|OTHER|Lavender peppermint elequil aromatab|Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
223718892|NCT04800744|OTHER|Sweet almond oil elequil aromatab|Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
223718893|NCT02701400|BIOLOGICAL|Durvalumab|Given IV
223941418|NCT03611075|OTHER|No Intervention|No interventions are administered in this study
224098903|NCT03972488|DRUG|High dose 60 mg octreotide long-acting repeatable|"Sandostatin® LAR Depot (octreotide LAR) is a pharmaceutical that was available in single-use kits containing a 6-mL vial of 10 mg, 20 mg, or 30 mg strength for intramuscular injection, a syringe containing 2.5 mL of diluent, two sterile 1½ 19-gauge needles, and two alcohol wipes."
224098904|NCT04812860|DRUG|HR18042|Tablet, Dosing frequency: once daily, Route of administration: oral
224098905|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
224098906|NCT04812860|DRUG|HR18042|Tablet,Dosing frequency: once daily, Route of administration: oral
224098907|NCT04812860|DRUG|Tramadol hydrochloride ER|Tablet,Dosing frequency: once daily, Route of administration: oral
224098908|NCT04812860|DRUG|Placebo|Tablet,Dosing frequency: once daily, Route of administration: oral
224287059|NCT01625481|DEVICE|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
223718894|NCT02701400|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223718895|NCT02701400|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223718896|NCT02701400|BIOLOGICAL|Tremelimumab|Given IV
223718897|NCT02756013|DRUG|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
224287060|NCT02910414|DRUG|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
224287061|NCT02910414|DEVICE|Peregrine System Kit (Sham Procedure)|Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization
224287062|NCT00992212|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
224287063|NCT00128037|DRUG|mitomycin C, vindesine, cisplatin and radiotherapy|
224287064|NCT02523937|OTHER|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
224287065|NCT02501551|DRUG|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
223939048|NCT05080777|BEHAVIORAL|Caregiving During Crisis (Educational Program)|The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
223939051|NCT03922256|OTHER|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
223939052|NCT05606341|DRUG|CpG1018|"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
223939053|NCT05606341|DRUG|CpG1018|"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
223939054|NCT05606341|DRUG|CpG1018|"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."
223939055|NCT05606341|DRUG|Placebo|Sterile saline injection supplied by the NYU Investigational Pharmacy.
223939056|NCT06034353|BEHAVIORAL|Pharmacist-led Cognitive Behavioral therapy|Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
223939057|NCT06910033|DEVICE|Craniomaxillofacial (CMF) porous titanium implant|All patients were treated, between 2016 and 2023, with patient-specific CMF Porous Titanium Implants for facial and/or cranial reconstruction or restoration of bone defects.
223939058|NCT07106632|DRUG|test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone|In this experimental arm, the treatment is driven by the score of the Prosigna test. If the score is superior to 60, the patient is considered at hight risk so the patient will receive chemo-endocrine therapy. If the result is under or equal to 60, only endocrine therapy will be prescribed to the patient.
223939059|NCT07106632|DRUG|In the control arm, the treatment will be as standard of care : chemo-endocrine therapy|Standard treatment: Chemotherapy followed by endocrine therapy
223939060|NCT03031483|DRUG|clarithromycin and lenalidomide|"Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total."
223939061|NCT05682300|PROCEDURE|peripheral nerve block|After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
223939062|NCT06809972|OTHER|Ultrasound imaging|Ultrasound, MRI and elastography to screen for and follow subclinical synovial changes in ankle, elbow and knee.
224287066|NCT01362426|DRUG|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
224287067|NCT06616922|DRUG|RD03/2016 eye drops|1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.
223718898|NCT02756013|DRUG|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
223718899|NCT00608686|DIETARY_SUPPLEMENT|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
223718900|NCT00592930|DRUG|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
224287068|NCT06616922|DRUG|Levofloxacin 0.5% eye drops solution (Oftaquix®)|1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
224287069|NCT06415214|DRUG|Placebo|Placebo
224287070|NCT06415214|DRUG|HRS-7535|HRS-7535
224287071|NCT00775528|DRUG|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
224287072|NCT02087176|DRUG|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
224287073|NCT02087176|DRUG|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
224287074|NCT02087176|DRUG|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
223718901|NCT00592930|DRUG|placebo|
223718902|NCT00002588|DRUG|etoposide|
223718903|NCT00002588|DRUG|topotecan hydrochloride|
223718904|NCT00552565|DRUG|Rezular 15mg|Oral Tablets
223718905|NCT00552565|DRUG|Placebo|placebo
223939063|NCT06887764|DEVICE|RKO-assisted walking in children with CP|The investigators will assess walking in each of the following conditions: shod (shoes or shoes + AFO) and RKO-assisted (shoes + RKO), to achieve the following: (1) Evaluate the effect of RKO, compared to shod upon endurance in children with CP at GMFCS level II, and (2) Evaluate the effect of RKO, compared to shod, upon temporal-spatial parameters, lower limb sagittal joint kinematics, and muscle EMG in children with CP at GMFCS level II.
223939064|NCT06773390|PROCEDURE|Percutaneous liver biposy|Percutaneous liver biopsy in pediatric patient diagnostic significance and pattern of liver diseases
223939065|NCT05809856|DEVICE|GrOwnValve - novel heart valve replacement approach|The autologous GrOwnValve is implanted into a stent before it is implanted via minimal-invasive transcatheter technique into the patients with high-grade pulmonary valve insufficiency and right ventricular dilatation. Control intervention/Reference test: Since the study is designed for investigating the safety of the procedure, there will not be a control group. However, the outcomes will be compared as a non-inferiority analysis with the standard of current medical care (Edwards SAPIEN 3 or Medtronic's Melody, both bioprosthetic transcatheter pulmonary valves).
223939066|NCT06529848|OTHER|Exercise training|"The training sessions are consist of cycling and as follows: a 10 min warm-up at a light intensity, 20-35 min of cycling exercise in intervals at varying intensities from light (\~60% of max heart rate) to more intensive (80-90% of max heart rate) and ending with 5 min of warm-down at a light intensity. The training intensity will be progressive during the course of the intervention period. The cycling training sessions are supervised .~Home training is allowed up to once a week if participants are able to adhere to the prescribed intensity levels.~Training sessions are closely monitored to ensure effectiveness and safety. This includes heart rate monitoring, perceived exertion assessment."
223939067|NCT05793034|DIAGNOSTIC_TEST|Biological biomarker assessment|IHC, PCR, NGS, methylome
223939068|NCT04279158|BEHAVIORAL|"experience 1 The negative priming task"|The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.
223939069|NCT04279158|BEHAVIORAL|"experience 2 Stop signal task"|The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
223939070|NCT04279158|BEHAVIORAL|"experience 3 Anti-saccades"|The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
223939071|NCT06363578|DRUG|Dexmedetomidine 0.5 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg diluted in saline.
223939072|NCT06363578|DRUG|Dexmedetomidine 1 μg/kg|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 1 μg/kg diluted in saline.
224098909|NCT03086850|BEHAVIORAL|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~* \<6000 steps/day: increase by 3000 steps/day~* 6000 - 10000 steps/day: reach 10000 steps/day~* \> 10000 steps/day: maintain or increase steps"
224098910|NCT03086850|OTHER|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
224098911|NCT01191593|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
224098912|NCT01191593|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
224098913|NCT06558344|DRUG|BI 1569912|BI 1569912
224098914|NCT06558344|DRUG|Placebo matching BI 1569912|Placebo matching BI 1569912
224098915|NCT06988761|BEHAVIORAL|Standard of care treatment for Fibromyalgia|Patients will receive standard of care as decided by treating physician which may include patient education, physical therapy, occupational therapy, cognitive behavioral therapy, biofeedback therapy, massage, acupuncture, graded activity therapy, sleep hygiene therapy, relaxation therapies, and meditative movement therapies.
223534547|NCT05345483|DEVICE|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter|Rescue stenting with CREDO heal Stent together with NeuroSpeed PTA Balloon Catheter
223534548|NCT03326245|DRUG|Methylphenidate Pill|Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride
223534549|NCT03326245|DRUG|Oral Placebo|Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
223534550|NCT03326245|DRUG|Intravenous Placebo|Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
223534551|NCT03326245|DRUG|Intravenous methylphenidate|Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.
223534552|NCT01144000|DRUG|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
223534553|NCT01792167|BEHAVIORAL|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
223718906|NCT00552565|DRUG|Rezular|Rezular 37.5mg 3xday up to 12 weeks
223939073|NCT06118138|COMBINATION_PRODUCT|Hyperbaric oxygen therapy (HBOT)|"HBOT is a medical treatment employed for various conditions. It entails breathing 100% oxygen within a pressurized chamber known as a hyperbaric chamber. This oxygen-rich environment promotes healing and aids in combating specific infections.~In this study, the investigators will administer HBOT using a hyperbaric chamber set to 2 times the normal atmospheric pressure, indicated as 2 atmosphere absolute (ATA). This pressure surge enhances oxygen dissolution into the bloodstream, surpassing levels achievable at sea level. The pressure will be raised incrementally, followed by HBOT sessions lasting for a total of 90 minutes. The 90-minute sessions include brief 5-minute intervals for ambient air every 20 minutes to ensure safety and comfort. Treatment will be conducted five days a week over eight weeks.~Supervised by competent healthcare professionals, HBOT is considered safe, with potential side effects primarily stemming from heightened pressure and, in rare cases, oxygen toxicity."
224098916|NCT06988761|BEHAVIORAL|Longitudinal Behavioral Health Techniques|Patients will receive standard of care as decided by treating physician, along with the integration of longitudinal behavioral health techniques provided by Lin Health. Patients have 24/7 access to digital content and will be able to interact directly with care team members on average three times per week.
224098917|NCT03320629|COMBINATION_PRODUCT|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
223939074|NCT06357468|OTHER|midwife-led births in low risk women in pregnancy|Pregnant women in the low-risk collective are cared for in a midwife-led delivery room if they wish to have a natural birth
223534554|NCT06426979|DRUG|Methotrexate|Methotrexate 25 mg/ml was given as single-dose of intramuscular (IM) injection in a dose of 50 mg/m2.
223534555|NCT06426979|DRUG|Letrozole|FEMARA 2.5 mg tablets two tablets daily
223534556|NCT00140140|DRUG|ABI-007|Weekly intravenous infusions over 30 minutes.
223534557|NCT00140140|DRUG|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
223939075|NCT06137768|DRUG|HRS-5965|HRS-5965
223534558|NCT00140140|DRUG|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
223718907|NCT00552565|DRUG|Rezular|Rezular 75mg 3xday up to 12 weeks
223718908|NCT02521545|DRUG|BIIB061|Capsule
223718909|NCT03256643|BEHAVIORAL|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
223718910|NCT03256643|BEHAVIORAL|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
223718911|NCT03256643|BEHAVIORAL|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
223718912|NCT03217331|DRUG|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
224098918|NCT03320629|COMBINATION_PRODUCT|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
224098919|NCT06860750|DRUG|SHR-1314 Injection|SHR-1314 injection.
224098920|NCT06860750|DRUG|SHR-1314 Placebo Injection|SHR-1314 placebo injection.
224098921|NCT07004699|PROCEDURE|Laryngoscopy|Introduction of the laryngoscope to maintain spontaneous ventilation in order to observe, in real conditions, the evolution and movements of the otorhinolaryngology sphere.
224098922|NCT07004699|PROCEDURE|High-flow oxygen therapy|Introduction of High-flow oxygen therapy to maintain spontaneous ventilation in order to observe, in real conditions, the evolution and movements of the otorhinolaryngology sphere.
223718913|NCT01475357|OTHER|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
223939076|NCT06137768|DRUG|Placebo|Placebo.
223939077|NCT06921590|DRUG|AL001|Crystalized Lithium
223939078|NCT06921590|DRUG|Lithium Carbonate Capsule|Lithium Carbonate
223939079|NCT02473276|DRUG|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
223939080|NCT02473276|DRUG|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
224098923|NCT02971592|DEVICE|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
224098924|NCT02971592|OTHER|Mock Device|reception of device that does not apply the electromagnetic field
223939081|NCT06474598|DRUG|MTX228|Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete
223939082|NCT06474598|DEVICE|DEXCOM G6|To monitor participants blood glucose levels continuously
223939083|NCT05418491|OTHER|No intervention is used in the current study. Interventions were given in the original A.R.T. study|The current study is a post-intervention study; interventions were given in the original A.R.T. study
223939084|NCT04721548|DRUG|Minoxidil Topical Foam|Apply 1 mL of solution twice a day.
223939085|NCT04721548|DRUG|Placebo|1 mL of solution twice a day.
223939086|NCT05256797|DRUG|Rivaroxaban|Any rivaroxaban dispensing claim is used as the reference group
223939087|NCT05256797|DRUG|Apixaban|Any apixaban dispensing claim is used as the exposure group
223939088|NCT01535430|DIAGNOSTIC_TEST|Brain mapping|Brain mapping will be employed pre-, intra-, and post-operatively to evaluate specific functions.
223939089|NCT05758285|OTHER|AI-Based Prediction of Treatment Engagement and Outcomes|AI-based algorithms and prediction models of treatment engagement and outcomes based on data from the Online Therapy Unit by Prof. Heather Hadjistavropoulos will be trained to predict symptom improvement of patients from pre- to post-digital psychotherapy intervention and to predict patients' engagement with the digital psychotherapy intervention and to predict patient drop out probability. For prediction model estimation, state of the art AI-based algorithms, such as XGBoost, is used . XGBoost is a machine learning method developed by refining previously established decision-tree-based methodologies. Data is split into training and testing sets (e.g., 80/20 split).
223939090|NCT06936410|DRUG|Lidocaine 2% Injectable Solution|patients received Lidocaine 2%, 1 mg/kg, IV bolus over 10 mins after the induction of anaesthesia , followed by Lidocaine infusion (2 mg/kg/h) diluted in 50 ml of normal saline with a maximum dose of 200 mg/h. The tourniquet was inflated 10 minutes after the start of the Lidocaine infusion then the Lidocaine infusion stopped at the time of tourniquet deflation
223939091|NCT06936410|DRUG|Dexmedetomidine HCL Injection|patients received a loading dose of Dexmedetomidine-Pfizer (0.8 μg·kg-1 over 10 min) followed by continuous infusion of Dexmedetomidine (0.4 μg·kg-1.h-1) diluted in 50 ml of normal saline. The tourniquet was inflated 10 mins after the start of Dexmedetomidine infusion then the Dexmedetomidine infusion stopped at the time of the tourniquet deflation.
223939092|NCT05233072|OTHER|Blood sample|Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
223939093|NCT06285123|BEHAVIORAL|REP|"REP is a bundle of strategies designed to help hospitals implement an evidence-based clinical practice. REP's core components include 1) user-friendly packaging of the clinical guidance, 2) structured clinician training, 3) performance feedback, and 4) brief technical assistance."
223939094|NCT06285123|BEHAVIORAL|Facilitation|Facilitation is a process of interactive problem-solving via a supportive consultation relationship. Facilitation is delivered by an expert who meets regularly with site quality improvement leaders to support interactive problem-solving to address local barriers and unanticipated implementation challenges. In contrast to the group-based, brief technical assistance in REP, facilitation is individualized consultation with the site clinical champion that generates highly customized, local solutions that can potentially be sustained by the local providers and champions.
223939095|NCT05245877|DRUG|enoxaparin/tinzaparin/dalteparin|Patients randomized to the preoperative thromboprophylaxis will have their thromboprophylaxis initiated approximately 2-14 hours prior to the planned pancreatic surgery skin incision (depending on the center's current practice and logistics). Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function according to the local standard of care. A center may reduce the dose 25-50% if the dose is given very close to the skin incision (i.e. at the morning of the operation instead of the evening before the operation).
223939096|NCT06768892|OTHER|Dietary Intervention|Each study participant will offer a tailored diet regimen according to age, sex, health status, physical activity and type of work either (office work or physical demanding work) after A 24-hour Dietary recall to calculate average calories requirements for each study participant separately. The participants' meals will be based on Mediterranean Diet and The Dietary Approaches to Stopping Hypertension (DASH Diet) as they proved effectiveness in lowering the risk of cardiovascular disease, insulin resistance, hypertension, obesity and Metabolic Syndrome. Dietary intervention aimed to the extent that 5-10% reduction in body weight, following the guideline of prevention and treatment of obesity.
223941419|NCT05395234|BEHAVIORAL|Cook Like A Boss Online - virtual week long cooking camp|The original Cook Like A Boss camp style intervention, was based on the Cook-Ed Model (Asher et al., 2020) and underpinned by SLT and ELT (Bandura \& McClelland, 1977; Kolb, 1984). The content was developed to ensure it was age-appropriate in line with the guidelines (Dean et al., 2021a) and included co-creation. The camp was designed to introduce the children to a range of food and skills and to nurture an initial interest in cooking. The adapted online version of the camp included five daily videos of the original chef performing the recipes. Minor adaptions included the removal of cooking pasta from scratch due to equipment concerns, reordering the days, and chef suggestions around alternative equipment/ingredients to use. The five daily videos were: 1) Introduction \& flatbreads; 2) Chicken Chowder; 3) Baking day; 4) Chilli non Carne; 5) Honey Chilli Chicken
224287075|NCT02087176|DRUG|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
223718914|NCT01475357|OTHER|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
223941420|NCT00676091|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
224098925|NCT06765122|BEHAVIORAL|Program for Alleviating Relationship Trauma and Stress through New Behaviors (PARTS-NB)|"PARTS-NB (Program For Alleviating Relationship Trauma and Stress through New Behaviors) is a group-based program for people who use violence and aggression in intimate relationships. Phase I is 4-weeks of 120 minutes of weekly group-based sessions focused on clarifying the way parts work in the mind, increasing inner compassion and emotion regulation, and explaining the role of trauma and stress in substance use and the use of violence in relationships. Phase II lasts 8-weeks, maintaining the 120 minutes of weekly group-based sessions. This phase introduces the model and focuses on practicing unblending, helping individuals gain awareness and acceptance of internal and external experiences. The final phase, Phase III runs 8 weeks and consists of weekly 120-minute group sessions which addresses and releases trauma-based beliefs and experiences through a process called unburdening."
224098926|NCT06524297|OTHER|Metaverse system (Patients)|The experimental group will undergo preoperative training using the metaverse surgical simulation system for 15 minutes before selecting the surgical incision site (this refers to residents receiving the assisted training). The trial process requires participants' consent to provide high-resolution CT images as the basis for reconstructing digital twin organs. Except for the intervention training, the surgery, postoperative care, follow-up, and other treatment processes the participants receive will be the same as those for typical patients.
224098927|NCT06524297|OTHER|Metaverse system (Resident Physician)|The participants (residents) will receive 15 minutes of preoperative training using the Metaverse surgical simulation system. They will superimpose the digital twin model onto the patient on the operating table and use the CT cross-sectional matching function within the Metaverse system to locate the lesion. The participants (residents) can use the system to repeatedly simulate incision sites and mark planned entry points on the patient by overlaying the virtual model onto the real patient. Except for the intervention training with the system, the subsequent surgery, postoperative care, follow-up, and other treatment processes the patients receive will be the same as usual.
224098928|NCT06305182|DRUG|Metreleptin|"Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection."
223941421|NCT00676091|BIOLOGICAL|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
223941422|NCT05063045|BEHAVIORAL|smart-cloth assisted home nursing care|Older persons with dementia or hip fracture were asked to wear a smart vest, which contained a coin-size monitor in a hidden inner pocket. Sensors were installed in bedrooms and living areas to receive signals from the smart clothing. The home care nurses then gave feedback from the sensor signals to family caregivers.
223941423|NCT03160521|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
223939097|NCT06768892|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT method will be adapted and customized to facilitate a transition towards a heightened level of physical activity and to address the emotional and practical difficulties associated with weight loss. This encompassed assisting the participants in establishing attainable weight loss goals, identifying individualized approaches to manage appetite, sustaining healthy habits, and navigating social environments and circumstances related to food. The aforementioned factors were deliberated upon within the context of both group-based and individual settings, adhering to a meticulously customized guideline. This guideline encompassed the incorporation of positive thinking tactics, accompanied by assigned tasks to be completed between each session. The Cognitive Behavioral Therapy (CBT) intervention was administered as a 20-minute component within the weekly therapy sessions. cognitive-behavioral therapy (CBT) in conjunction with lif
223939098|NCT06768892|OTHER|Physical exercise training|A weekly session of physical exercise training lasting 10 to 20 minutes will be incorporated at the workplace. The primary objective of the sessions was to increase muscle mass in the lower limbs for the purpose of sustaining physical capacity and boosting quiescent metabolism. The exercises comprised squats involving one or two legs, performed with or without dumbbells and core balls, as well as lunges performed while strolling forward and to each side. Additional exercises that emphasized overall strength encompassed shoulder and arm movements, as well as abdominal and back extension exercises. Participants were encouraged to execute the strength training exercises depicted in the program's takeout pamphlets twice per week. Furthermore, participants will be motivated to engage in aerobic leisure activities for a duration of two hours per week, including bicycling, walking, running, swimming, or participating in various sports.
223939099|NCT06127810|DEVICE|CE MRI on 0.064T Scanner|Pt will undergo contrast enhanced images using Gadopiclenol on Hyperfine MRI
223939100|NCT06127810|DRUG|Gadopiclenol|Subjects will receive Gadopiclenol instead of standard of care contrast
223534559|NCT00140140|BIOLOGICAL|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was \>20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
223939101|NCT06943846|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet-rich fibrin added to extraction socket
223939102|NCT06944951|DEVICE|Hydrophilic emulsion for the relief of haemorroidal symptoms|Administration for 2 weeks of PROCTOeze® PLUS - a soft and light hydrophilic emulsion able to provide symptomatic relief of haemorrhoids and anal irritation.
223939103|NCT06946758|OTHER|Core stabilization exercises|Patients in the core stabilisation exercise group underwent a total of 24 sessions of core stabilisation exercise programme 3 days a week (with at least 1 day of rest between each session) for a total of 8 weeks. Each exercise session was performed under the supervision of a physician in the Department of Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine. Each session was arranged as 35-minute programmes with an average of 8-10 patients, 5 minutes of which was warm-up. Before starting the exercise, patients were taught to reduce lumbar lordosis by contracting and drawing in the abdominal muscles and to find a lumbar and pelvic neutral position by moving the pelvis forwards and backwards. In each session, the neutral position was found first and attention was paid to maintain the neutral position throughout the exercise. The exercises consisted of 3 levels. The exercise level was completed gradually
223939104|NCT06946758|OTHER|Aerobic Exercises|The aerobic exercise group underwent core stabilisation exercises applied to the control group. After the core stabilisation exercises, aerobic exercise was performed with a stationary bicycle at a speed of 50 rpm for approximately 40 minutes.
223939105|NCT06952192|DEVICE|Virtual reality|VR application via a head-mounted display one minute before and throughout the SPT procedure. The VR intervention utilized a Samsung Gear VR headset (Samsung, Seoul, South Korea) in conjunction with a Samsung S7 or S8 mobile device to provide an immersive and engaging experience. Children were allowed to choose from a range of age-appropriate VR content designed to enhance engagement and relaxation. Prior to the procedure, children were trained on how to use the headset by study staff to ensure a smooth experience.
223939106|NCT06951360|PROCEDURE|ENERGY questionnaire|Questionnaire including NASA Task Load Index, difficulty level of operation, patient and operation factors
223939107|NCT04985539|DEVICE|Verily Study Watch|Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.
224098929|NCT06305182|DRUG|Sodium chloride|The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.
224098930|NCT02464150|DIETARY_SUPPLEMENT|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily, or up to four slices of regular bread daily.
224098931|NCT02639676|OTHER|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
224098932|NCT03665155|DRUG|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
223534560|NCT00772759|DRUG|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
223534561|NCT00772759|DRUG|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
223534562|NCT01761578|DEVICE|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
224098933|NCT03665155|DEVICE|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
223939108|NCT07148232|DRUG|Nicotine Replacement Therapy (NRT)|NRT will be administered as patch (transdermal), gum, or lozenge
223534563|NCT03376516|DRUG|Wilate|von Willebrand factor / Factor VIII (plasma derived)
223534564|NCT02235324|BIOLOGICAL|ziv-aflibercept|Given IV
223534565|NCT02235324|DRUG|leucovorin calcium|Given IV
223534566|NCT02235324|DRUG|fluorouracil|Given IV
223718915|NCT01162460|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
223718916|NCT00547482|DEVICE|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
223718917|NCT02771912|DRUG|Propofol|Propofol and excipients
223939109|NCT07148232|BEHAVIORAL|Wellness Coaching|Delivered via phone call
223939110|NCT07152652|BEHAVIORAL|Groups 4 health|Groups 4 Health (G4H) at the University of Helsinki is a manualized group intervention for the students that focuses on social connectedness and aims at improving general health and life satisfaction. G4H groups are facilitated by two psychology master's students (or licensed psychologists) carefully trained for the intervention and mentored by experienced clinical psychologists. G4H consists of five 90 minutes sessions that aim to give participants the knowledge and skills they need to effectively manage their social group memberships and identities. Each session contains exercises and discussions described in the G4H workbook that target different aspects of group life identified within the social identity model of identity change and put the Social Identity Approach to Health -model to practice. Students earn 2 European Credit Transfer and Accumulation System (ECTS) credits for completing the intervention.
223939111|NCT07152821|OTHER|Best Supportive Care|Measures designed to provide palliation of symptoms and improve quality of life as much as possible
223939112|NCT07152821|DRUG|Balstilimab|450mg IV every 3 weeks
223534567|NCT02235324|OTHER|laboratory biomarker analysis|Correlative studies
223534568|NCT01216488|DRUG|Xylocaine|40 ml or 25 ml of Xylocaine injection
223534569|NCT01359956|DRUG|Dacarbazine|900 mg / m2 every 3 weeks
223534570|NCT01359956|DRUG|Fotemustine|100 mg / m2 every 3 weeks
223534571|NCT01359956|DRUG|Interferon Alfa-2b|5 M units every 3 weeks
223718918|NCT02771912|DRUG|Placebo|Qualitative composition of Propofol lipuro 2% excipients
223718919|NCT03533543|DEVICE|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
223939113|NCT07152821|DRUG|Botensilimab|75mg IV every 6 weeks x 4 doses
223939114|NCT06280885|BEHAVIORAL|Exercise|Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription
223939115|NCT06280885|BEHAVIORAL|Health Behaviour Change (Pedometer)|Participants in both arms will be provided with a pedometer as a health behaviour change intervention
223939116|NCT02843191|DRUG|Chemotherapy|5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)
223939117|NCT06544291|DRUG|CBD 300mg|3 Nantheia™ (100mg) softgel capsules and 3 placebo (0mg) softgel capsules will be administered to participants on one of the three test session days.
223939118|NCT06544291|DRUG|CBD 600mg|6 Nantheia™ (100mg) softgel capsules will be administered to participants on one of the three test session days.
223939119|NCT06544291|DRUG|Placebo 0mg|6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
223939120|NCT07156084|BIOLOGICAL|HPV nonavalent vaccine (Gardasil-9)|One dose HPV nonavalent vaccine
223939121|NCT07151235|OTHER|Simulated wildfire smoke exposure|1 hour exposure to simulated wildfire smoke (300 ug/m3 PM)
223939122|NCT07151235|OTHER|Clean Air exposure|1 hour exposure to clean (HEPA-filtered) air (0 ug/m3 PM)
223939123|NCT04577651|DEVICE|16-contact Directional Deep Brain Stimulation|Deep Brain Stimulation with 16-contact Directional Lead
223939124|NCT05480709|BEHAVIORAL|Psychocardiological Rehabilitation|Psychocardiological Rehabilitation: Regular cardiac rehabilitation with in-depth psychological and psychotherapeutic care, individual and group counseling, relaxation training, and interdisciplinary specialist psychiatric and psychosomatic visits.
223939125|NCT07162948|DEVICE|The ICU-Recover Box: using smart technology for monitoring health status after ICU admission Pilot 2.0|The Corsano CardioWatch 287-2 measures blood pressure, heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature and their daily activity.This devices is used for personal management, never to directly base a diagnosis or treatment on. The patient has to download the Corsano App on his/her mobile phone.
223941424|NCT03160521|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
223941425|NCT03160521|DRUG|Placebo of Risperidone ISM|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
223941426|NCT02213146|DRUG|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
223941427|NCT02213146|DRUG|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
223941428|NCT02213146|DRUG|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
223941429|NCT00459524|BEHAVIORAL|Questionnaire|Questionnaires taking about 30 minutes to complete.
223941430|NCT00459524|BEHAVIORAL|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
223941431|NCT01701401|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
223718920|NCT03706456|BIOLOGICAL|Darvadstrocel|Darvadstrocel cell suspension for intralesional injection.
223939126|NCT07163806|DIAGNOSTIC_TEST|PET/CT with 18-FDG|"Patients will fast for at least four hours before imaging with blood glucose level \<200 mg /dL before intravenous administration of about 3.7 MBq/kg (0.1 mCi/kg). Imaging will be performed approximately 45 to 60 min after 18F-FDG injection , an imaging field of view from the base of skull to mid thighs with the arms above the head whenever possible is used or otherwise the arms are positioned beside the body.~The semiquantitative analysis will be done using standardized uptake values (SUV). The SUV calculation will be done via the default method by body weight \[(SUV = mean ROI activity (MBq/g)/injected activity (MBq)/body weight (g)\]. For measurement of SUVs of lesion, multiple circular ROIs will be drawn covering the lesion over its entire length. For healthy organs, a circular ROI of 10 mm diameter will be drawn"
224098934|NCT03665155|OTHER|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
223718921|NCT00866385|DRUG|AZD8566|Single 6 mg oral solution dose
223939127|NCT02076906|DEVICE|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
223939128|NCT07155057|DEVICE|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|Prospective, single-site, single-arm study enrolling 60 patients who have elected advanced IOL implantation at the time of cataract surgery and have a diagnosis of dry eye disease. The study will consist of 5 study visits, over a 3-5 month time period. Patients will receive bilateral lacrimal occlusion of crosslinked hyaluronate canalicular gel pre-operatively
223939129|NCT06271330|DRUG|Faricimab|switch from previous anti-VEGF agents to faricimab
223939130|NCT07164105|DEVICE|Low intensity focused ultrasound|Low intensity focused ultrasound neuromodulation of the ventral anterior cingulate cortex
223939131|NCT07164105|DEVICE|Sham modulation|Low intensity focused ultrasound with a Sorbothane membrane cover to prevent acoustic energy transmission
223939132|NCT07170709|DEVICE|Whole-Body Vibration|Participants will receive whole-body vibration (WBV) at 30-36 Hz under different mechanical loading conditions (e.g., standing on one foot, both feet,). Vibration-induced reflex responses will be recorded from the soleus muscle using surface electromyography. The intervention is designed to evaluate latency differences between tonic vibration reflex (TVR) and bone myoregulation reflex (BMR) under controlled biomechanical scenarios.
223939133|NCT06023043|DRUG|Dexamethasone|Three (3) post operative intravenous dexamethasone injections at 8-hour intervals post-operatively. Dosing will be determined as 0.15 mg/kg per dose (WS)
223939134|NCT07181408|OTHER|Wheat flour-based control snack|Consumption of a single 50-gram portion of a wheat flour-based control snack.
223939135|NCT07181408|OTHER|Snack enriched with 15% cricket flour|Consumption of a single 50-gram portion of a snack enriched with 15% cricket flour (Acheta domesticus).
223939136|NCT07181408|OTHER|Snack enriched with 15% pea flour.|Consumption of a single 50-gram portion of a snack enriched with 15% pea flour.
223939137|NCT07175506|DRUG|Placebo|Placebo injection administered IV, once.
223939138|NCT07175506|BIOLOGICAL|CM559|CM559 injection administered IV, once.
223939139|NCT07183592|PROCEDURE|7-day Infusion set replacement|7-day infusion set replacement (Experimental arm) In this group, the infusion sets (the tubes and connectors used to deliver medications through the central venous catheter) will be changed once a week, every 7 days. During each replacement, all sets will be disconnected and replaced with new sterile ones.
223939140|NCT07183592|PROCEDURE|4-day infusion set replacement|4-day infusion set replacement (Active comparator arm) In this group, the infusion sets will be changed every 4 days, which reflects the most common international recommendation. The procedure is the same: all sets connected to the central venous catheter will be replaced with new sterile ones. This strategy represents the current standard of care and will serve as the comparison for the 7-day approach.
224287076|NCT05553782|COMBINATION_PRODUCT|Implantable Microdevice (IMD)|"* Percutaneous CT image-guided placement of the microdevice(s). At least one, and up to 3, devices will be placed in each tumor.~* Drugs will be released from the microdevice into local tumor tissues. The duration of drug release will be for a period of 3-5 days while the microdevice is in the tumor prior to retrieval. The local tissue is retrieved along with the microdevice and no residual drug will remain.~* Each microdevice harbors up to 20 drugs and/or drug combinations relevant to the treatment of salivary cancer. The drugs used will include some standard agents approved by the Food and Drug Administration (FDA) for treatment of different types of cancers, or drugs classes under investigational.~  * Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations: Lenvatinib, Axitinib, All trans retinoic acid (ATRA), Venetoclax, Pembrolizumab, Cisplatin, Carboplatin, Vinorelbine"
224287077|NCT03329976|OTHER|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
224287078|NCT04081441|DEVICE|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
223939141|NCT07197112|DRUG|Gecacitinib|Administer 50 mg twice daily for a minimum of 28 days.
223939142|NCT06505759|DRUG|Bromelain gel|bromelain gel is prepared from bromelain capsules in laboratory
223939143|NCT06505759|DRUG|chlorhexidine gel|chlorhexidine gel is prepared from mouth wash
223939144|NCT06505759|PROCEDURE|SRP|Scaling and root planing was done with ultra sonic and hand scaling
223939145|NCT04202133|BEHAVIORAL|WW (formerly Weight Watchers)|The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
223939146|NCT04202133|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
224098935|NCT05277012|DRUG|Etrumadenant|Etrumadenant capsule and tablet formulations
224287079|NCT04081441|BEHAVIORAL|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
224287080|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (Low dose)|Pumpkin seed extract standardized with specific peptides (300 mg/day)
223718922|NCT00866385|DRUG|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
223718923|NCT02784431|DEVICE|Contour Neurovascular System placement|Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
223939147|NCT04300270|DEVICE|Smartphone PPG recordings|Smartphone camera PPG recordings using a novel software application.
223939148|NCT04300270|DEVICE|Smartphone ECG|Smartphone connected one-lead ECG recordings.
223939149|NCT04318028|PROCEDURE|7 Tesla Magnetic Resonance Imaging|Undergo 7 Tesla MRI
224287081|NCT05738655|DIETARY_SUPPLEMENT|Pumpkin seed extract (High dose)|Pumpkin seed extract standardized with specific peptides (600 mg/day)
224287082|NCT05738655|DIETARY_SUPPLEMENT|Placebo|Placeo (300 mg/day)
223939150|NCT05108558|DRUG|CCH administration|Patients will be randomized 3:1 into the CCH administration arm. After undergoing baseline assessments, this arm will receive up to 8 CCH injections, followed by final assessments 6 weeks later.
223939151|NCT05108558|DRUG|Control - Crossover to CCH|Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
223939152|NCT05108558|DEVICE|RestoreX|Both treatment arms will incorporate the use of RestoreX for 30-60 minutes daily during CCH administration and continued until 6 weeks after final injection administration.
224287083|NCT02230618|DRUG|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
223939153|NCT05662345|DIAGNOSTIC_TEST|CellSearch Circulating Tumor Cells|Serial CTC enumeration
223939154|NCT05901766|DIETARY_SUPPLEMENT|UNIMAP Multiple Micronutrient Supplement|Iodine Containing Multiple Micronutrient Supplement once daily
223939155|NCT05459298|DIETARY_SUPPLEMENT|Placebo|Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.
223939156|NCT05459298|DIETARY_SUPPLEMENT|800 IU/day vitamin D supplementation with feedings in the first 28 days after birth|800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.
223939157|NCT05459298|OTHER|Usual Care|Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
223939158|NCT05627362|DRUG|Elafibranor 80 mg|Oral Tablet
223939159|NCT05627362|DRUG|Elafibranor 120 mg|Oral Tablet
223939160|NCT05627362|DRUG|Placebo Matched to Elafibranor 80 mg|Oral Tablet
223939161|NCT05627362|DRUG|Placebo Matched to Elafibranor 120 mg|Oral Tablet
223939162|NCT02328014|DRUG|Acalabrutinib|Oral
223939163|NCT02328014|DRUG|ACP-319|Oral
223534572|NCT04108650|OTHER|Fit & Strong! group|Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
223939164|NCT01274338|BIOLOGICAL|Ipilimumab|Given IV
223939165|NCT01274338|OTHER|Quality-of-Life Assessment|Ancillary studies
223939166|NCT01274338|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV and SC
223939167|NCT06373146|DRUG|Tirzepatide|Administered SC
223939168|NCT06373146|DRUG|Mibavademab|Administered SC
223939169|NCT06373146|DRUG|Tirzepatide-Placebo|Administered SC
223939170|NCT06373146|DRUG|Mibavademab-Placebo|Administered SC
223939171|NCT03959891|DRUG|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
223939172|NCT03959891|DRUG|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
223939173|NCT03959891|DRUG|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
223939174|NCT03959891|DRUG|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
223939175|NCT06005493|DRUG|AZD5863|T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
223939176|NCT06342544|DRUG|immediate treatment with corticosteroids|Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
223939177|NCT06342544|DRUG|addition of rituximab if recurrence|rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.
223939178|NCT04651504|OTHER|Colorectal Cancer Toolkit|The intervention toolkit will include patient education materials and supportive materials for providers. Tracking systems and supports will be jointly developed with participating clinic and providers, in order to maximize their existing systems and develop processes that meet their needs and preferences, and training will be offered to help providers/teams efficiently use the tracking system and clinic resources. The study team will provide technical assistance and support through email, phone and zoom to support the clinic in their implementation process.
223939179|NCT05422339|DEVICE|The MapHabit system (MHS)|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available to families through compatible smartphones and tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified content and structure.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device."
223939180|NCT05527834|DRUG|VNRX-7145|Single oral dose
223939181|NCT05527834|DRUG|Ceftibuten|Single oral dose
223939182|NCT05979272|BEHAVIORAL|Treatment as usual|Treatment as Usual at the local family court, which includes a brief, computerized motivation enhancement intervention. All CINI youth will receive TAU, regardless of condition.
223939183|NCT05979272|BEHAVIORAL|Teen Empowerment through Computerized Health (TECH) app|An adjunct smartphone app (i.e., TECH) developed to support TAU. All participants randomly assigned to TAU+TECH will receive the TECH app.
223939184|NCT05455814|BEHAVIORAL|Shambhavi Madamudra Kriya|The intervention is taught at the Inner Engineering program offered by non-profit Isha Foundation as online as well as in-person formats. It incorporates a combination of different breathing patterns and meditative components. The intervention training provides precise, step by step and easy to follow instructions on how to perform this practice. Performed in a seated posture, this is a simple, safe and accessible intervention that requires no previous experience of meditation. The intervention selected for this study was shown to significantly reduce perceived stress, enhance self-reported general well-being, improve positive emotions, mindfulness, sleep, engagement, relationships, and may promote enhanced Heart Rate Variability and Sympathovagal balance.
223939185|NCT03837483|GENETIC|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
224287084|NCT01058551|DEVICE|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
224287085|NCT04776954|DEVICE|Forced Air Warming System|"The forced air warming system has a heater unit that blows air through a conduit to an air blanket that inflates with forced air that circulates throughout the blanket, and exits through tiny perforations on the patient-side of that blanket. The heat primarily warms the subject through convective means. As the warmed air escapes through the perforations in the blanket, it creates an environment of continuously circulating warm air that is in contact with the skin."
223534573|NCT03968874|DEVICE|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
223534574|NCT03968874|DEVICE|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
223718924|NCT03589560|DRUG|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
224098936|NCT01826214|DRUG|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
223939186|NCT06044259|PROCEDURE|AMDS; Artivion, Atlanta, Georgia, US|Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, US) hybrid prosthesis which comprises a proximal sewing collar and a distal self-expanding nitinol un-covered stent.
223939187|NCT06044259|PROCEDURE|Conventional hemiarch replacement|Coventional open hemiarch replacement
223939188|NCT03648905|DRUG|13N-Ammonia|a perfusion imaging agent
223939189|NCT03648905|DRUG|18F-DOPA|is a positron-emitting analog of the catechol amino acid, levodopa
223939190|NCT03648905|DRUG|11C-Methylreboxetine (11C-MRB)|11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.
223939191|NCT03648905|DRUG|18F-Dopamine|is a positron-emitting analog of the catecholamine, dopamine
223939192|NCT06338917|BEHAVIORAL|Moderate-to-vigorous intensity physical activity program (+moviMENT)|The intervention comprises 16 weeks of group based High Intensity Interval Training (HIIT), with transition to individual community based Vigorous Intermittent Lifestyle Physical Activity (VILPA) over the next 12 weeks - for a total intervention period of 28 weeks.
223939193|NCT04594902|BEHAVIORAL|Infant Behavior Program (IBP)|Infant Behavior Program (IBP) is a home-based adaptation of the Child-Directed Interaction (CDI) phase of Parent-Child Interaction Therapy (PCIT), an evidence-based intervention for early externalizing problems. Consistent with recommendations we maintained core features of CDI and addressed the unique developmental needs of infants. All IBP sessions will completed remotely.
223939194|NCT04594902|OTHER|Enhanced Pediatric Primary Care (EPPC)|Families in EPPC will receive six one-hour home visits where they will receive information about normative developmental and health expectations for their infant. Specifically, therapists will provide education on six topics: (1) cognitive and emotional development; (2) language and social development; (3) safety; (4) feeding and nutrition; (5) sleep; and (6) fitness and activity. All EPPC sessions will completed remotely.
223939195|NCT05556512|DRUG|Tirzepatide|Administered SC
224287086|NCT04776954|DEVICE|Resistive Blanket Warming System|This blanket is equivalent to an operating-room-safe electric blanket. Through a power cord, a separate power source powers a semiconductor layer within the resistive blanket to generate heat. The heat primarily warms the subject by conductive warming through direct skin contact, and, secondarily, by warming the air around the participant in areas where there is no direct skin contact.
224287087|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
224287088|NCT03793530|OTHER|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
224287089|NCT03153826|OTHER|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
224287090|NCT04099641|DRUG|Bavituximab|Bavituximab IV infusion
224287091|NCT04099641|DRUG|Pembrolizumab Injection|Pembrolizumab IV Infusion
224287092|NCT00668447|DIETARY_SUPPLEMENT|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
224287093|NCT00668447|DIETARY_SUPPLEMENT|Control protein|20 grams of powder mixed in beverages or food daily for one year
224287094|NCT00668447|DIETARY_SUPPLEMENT|Novasoy isoflavones|3 tablets daily for one year
224287095|NCT00668447|DIETARY_SUPPLEMENT|Placebo tablets|3 tablets daily for one year
224287096|NCT02965664|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
224287097|NCT02965664|DRUG|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
223718925|NCT03589560|DRUG|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
223718926|NCT02829697|DRUG|Ropivacaine|Perineural injection.
223939196|NCT05556512|DRUG|Placebo|Administered SC
223939197|NCT03632343|OTHER|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
223939198|NCT03632343|OTHER|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
224098937|NCT00525291|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
223939199|NCT05035030|DRUG|Odevixibat|Odevixibat is a small molecule and selective inhibitor of IBAT.
223939200|NCT06798649|OTHER|The intervention in the GESTACOR study involves providing detailed feedback from vascular imaging to women who have experienced adverse pregnancy outcomes (APOs).|"This is aimed at assessing whether such feedback can encourage the adoption of healthier lifestyles and enhance adherence to preventive treatments, thereby potentially reducing the incidence of postpartum hypertension and other cardiovascular diseases.~Components of the Intervention:~Vascular Imaging:~Women in the intervention group undergo advanced vascular imaging using ultrasound technology to detect the presence of arterial plaques vs. no information about vascular images in the standard manag group.~The images are analyzed to assess the extent of vascular health, focusing on areas typically affected by cardiovascular risks such as the carotid arteries.~Feedback Delivery:~Detailed results from the vascular imaging are provided to the participants in a comprehensible format by healthcare professionals specialized in cardiovascular health.~This feedback session includes a thorough explanation of the findings, highlighting areas of concern and potential risks."
223939201|NCT05564247|BEHAVIORAL|Wheelchair Skills Training Program (WSTP)|Participants will complete customized MWC skills training based on the evidence-based wheelchair skills program. Lessons plans will be created by the clinicians, children and parents participants based on goals, age, skills and interests, and used to customize the training.
223939202|NCT04463979|OTHER|Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia|"Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.~Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire."
223939203|NCT06520514|DRUG|Spesolimab|Spesolimab
223939204|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C antibody (anti-HCV) test|Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
223939205|NCT06431945|DIAGNOSTIC_TEST|Hepatitis C RNA test and genotype test|RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
223939206|NCT06072170|DRUG|Kratom|Single administration thirty minutes after the start of a high-fat breakfast
223939207|NCT06072170|DRUG|Placebo|Single administration thirty minutes after the start of a high-fat breakfast
224287098|NCT03544359|DEVICE|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
223718927|NCT04903990|OTHER|Blood sample|As part of the treatment, 2 EDTA tubes of 10mL will be taken during a scheduled venipuncture as part of the preoperative assessment.
223939214|NCT03852186|BEHAVIORAL|Cognitive behavioral therapy|Group based psychotherapy
223939215|NCT03852186|BEHAVIORAL|Acceptance and commitment therapy|Group based psychotherapy
223939216|NCT00001160|DRUG|68-Gallium Dotatate|For evaluation risk/benefit evaluation
223718928|NCT02228200|BEHAVIORAL|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
223939217|NCT05951777|BIOLOGICAL|Autologous HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
223939218|NCT05951777|DRUG|Normal Saline|Sterile Saline Solution 0.9%
223939219|NCT02329704|PROCEDURE|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
223939220|NCT02329704|PROCEDURE|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
223939221|NCT02329704|PROCEDURE|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
223939222|NCT02329704|PROCEDURE|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
223939223|NCT02329704|PROCEDURE|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
223534575|NCT06544044|BEHAVIORAL|Brief Mindfulness' Self compassion|session includes mindfulness exercises like breath awareness and body scans, self-compassion practices like self-kindness meditations, and emotional regulation strategies such as cognitive reappraisal and response modulation. Discussions focus on applying mindfulness and self-compassion to manage difficult emotions, improve interpersonal interactions, and reduce aggression. Home practice assignments encourage students to integrate mindfulness and self-compassion into their daily lives. The program curriculum is based on existing evidence-based interventions, including mindfulness-based stress reduction for teens.
223939224|NCT02329704|PROCEDURE|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
223939225|NCT02329704|BIOLOGICAL|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
223939226|NCT05632887|OTHER|no intervention|no intervention
223939227|NCT06552351|DEVICE|Needle-Free Jet Injection of 1 % lidocaine|The needle-free jet injection device delivers 1% lidocaine through high-pressure fluid without the use of a needle. This method aims to reduce the pain associated with needle-based anesthesia during infant lumbar punctures.
224287099|NCT06490575|OTHER|Educational Intervention Based on Protection Motivation Theory to Improve Knowledge and Promote Nonpharmacological Approaches to Prevent and Manage Hypertension among Adults|Participants in the intervention group attended four face-to-face workshops (one session per week). Each session took about 30 minutes and consisted of lectures with PowerPoint presentations, discussion, questions and answers, and the distribution of educational pamphlets and booklets.
224287100|NCT01293552|BIOLOGICAL|ANT-1207|single dose application
224287101|NCT01293552|BIOLOGICAL|Vehicle|
224287102|NCT02592759|DEVICE|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
224287103|NCT02505152|PROCEDURE|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
224287104|NCT04101695|DEVICE|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
224287105|NCT00834899|DRUG|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
224287106|NCT00834899|DRUG|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
224287107|NCT06227520|OTHER|decellularized dermal matrix|Application of Wound bed
224287108|NCT01534637|DRUG|aprepitant|Given PO
224287109|NCT01534637|DRUG|gemcitabine hydrochloride|Given IV
224287110|NCT01534637|DRUG|capecitabine|Given PO
224287111|NCT01534637|DRUG|fluorouracil|Given IV
224287112|NCT01534637|PROCEDURE|radiation therapy|Undergo radiation therapy
224287113|NCT01534637|OTHER|questionnaire administration|Ancillary studies
224287114|NCT01534637|PROCEDURE|quality-of-life assessment|Ancillary studies
224287115|NCT01534637|PROCEDURE|nausea and vomiting therapy|Receive aprepitant
223534576|NCT05123326|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM/ Sonoclot tests will be done in all patients at enrolment and after initiating anticoagulation in those who are eligible for the same.
223534577|NCT05123326|DIAGNOSTIC_TEST|Genetic tests for Thrombophilia|Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
223534578|NCT05123326|DIAGNOSTIC_TEST|ELISA tests/ Functional assays|Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
223534579|NCT05544253|PROCEDURE|mitomycin C-based hyperthermic intraperitoneal chemotherapy|The patients with srHCC or PM of HCC were randomly allocated to either the HIPEC group or the control group. All of them have received open liver resection and perfusion tubes had been set in the operation. For patients with PM of HCC served operation, we are subject to reach CC score at 0-1 to creating sufficient conditions for HIPEC. Finally, place the HIPEC tubes. Implementation of HIPEC was administered 3times on the 1st, 3rd, 5th days within one week after operation. We used intraperitoneal hyperthermic perfusion device (BR-TRG-IITM, Bao Rui medical corporation, Guangdong, China) to achieve HIPEC. The abdominal temperature was maintained at 43°C (109°F) by circulating heated saline. The perfusion volume was 3000ml of normal saline, and the chemotherapeutic agent of mitomycin C was 10mg for a 1-hour perfusion period.
223534580|NCT00626080|DRUG|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
224287116|NCT01534637|PROCEDURE|management of therapy complications|Receive aprepitant
224287117|NCT06412042|DIETARY_SUPPLEMENT|Probiotic BLa80|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
223939228|NCT06552351|OTHER|traditional needle infiltration of 1% lidocaine|Traditional needle infiltration involves injecting 1% lidocaine with a needle to provide local anesthesia before an infant lumbar puncture. This method is the standard practice for pain management in such procedures.
223939229|NCT03592888|DRUG|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
223939230|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose A U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections."
223939231|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections."
223718929|NCT02228200|BEHAVIORAL|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
223939232|NCT06047457|OTHER|Placebo|"0 U/I, IM on Day 1 and Week 12 with a total of 2 injections."
223939233|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose A U/I, IM on Week 24 and Week 36 with a total of 2 injections."
223939234|NCT06047457|BIOLOGICAL|Botulinum toxin type A|"Dose B U/I, IM on Week 24 and Week 36 with a total of 2 injections."
223939235|NCT05456841|BEHAVIORAL|Empathic Communication Skills (ECS) training|"The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others"
223939236|NCT05456841|OTHER|Standard of Care participant interaction|Standard of Care participant interaction
223939237|NCT06578897|DEVICE|3D Metal Tibial and Femoral cones|"* To collect retrospective clinical outcomes and data on revision TKAs using Medacta GMK Revision with 3D metal tibial and femoral cones~* Evaluate the patient reported functionality of the operated knee~* Evaluate the clinical and radiological performance~* Evaluate safety of the cones~* Evaluate survivorship of revisions using tibial and femoral cones"
223939238|NCT06248619|BIOLOGICAL|Teprotumumab|SC injection
223939239|NCT06248619|OTHER|Placebo|SC injection
223939240|NCT02541305|OTHER|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
223939241|NCT02541305|OTHER|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
223939242|NCT03678688|DRUG|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
223939243|NCT03678688|DRUG|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
223939244|NCT03678688|DRUG|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
223939245|NCT03678688|DRUG|3 mg OPC-167832|Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
223939246|NCT03678688|DRUG|RHEZ|"RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day"
223939247|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
223939248|NCT03678688|DRUG|30 mg OPC-167832 + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
224287118|NCT06412042|OTHER|Placebo Maltodextrin|Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
224287119|NCT04596124|DEVICE|fitostimoline plus|randomized controlled multicentric study
224287120|NCT00605917|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
224287121|NCT01476228|DEVICE|EEG recording|EEG recording
224287122|NCT00757614|GENETIC|DNA analysis|
224287123|NCT00757614|GENETIC|polymorphism analysis|
224287124|NCT00757614|OTHER|laboratory biomarker analysis|
224287125|NCT00757614|OTHER|questionnaire administration|
224287126|NCT00881413|DRUG|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
224287127|NCT00881413|DRUG|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
224287128|NCT00890552|DRUG|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
224287129|NCT00890552|DRUG|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
223939249|NCT03678688|DRUG|30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ|Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
223939250|NCT03560323|DRUG|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (26 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
223939251|NCT06546189|DIETARY_SUPPLEMENT|OMNi BiOTiC® 41167|"The product OMNi BiOTiC® 41167 contains lactobacillus strains"
223939252|NCT06546189|OTHER|Placebo|Placebo
223939253|NCT02343094|DRUG|PBA 7,5g/d|Treatment for 14 days with PBA
223939254|NCT02343094|DRUG|PBA 15g/d|Treatment for 14 days with PBA
223939255|NCT01427517|DRUG|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
223939256|NCT05689606|BEHAVIORAL|Exercise|Exercise includes acute high-intensity interval training.
223939257|NCT06462092|DRUG|Sacituzumab Govitecan|Patients receive Sacituzumab Govitecan 10mg/kg by intravenous infusion on days 1 and 8. Treatment cycles are every 21 days.
223939258|NCT06462092|DRUG|Pemetrexed|Intrathecal pemetrexed chemotherapy, administered via intracerebroventricular or lumbar puncture, consists of three phases: induction therapy (15 mg twice weekly for 2 weeks), consolidation therapy (once weekly for 4 consecutive weeks), and maintenance therapy (once monthly).
223939259|NCT00360191|DRUG|Buspirone|
223939260|NCT00360191|PROCEDURE|Motivational enhancement therapy|
223939261|NCT06049095|DRUG|LTG-001|Oral doses
223939262|NCT06049095|DRUG|Placebo|Oral doses
223939263|NCT02162394|DEVICE|Observational ambulatory ECG monitoring|
223939264|NCT03033667|DIETARY_SUPPLEMENT|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
223939265|NCT03033667|DIETARY_SUPPLEMENT|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
224287130|NCT00890552|DRUG|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
224287131|NCT00789113|DRUG|Extended Release Lamotrigine|
223534581|NCT00626080|DRUG|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
223534582|NCT03344341|DRUG|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
223534583|NCT03344341|DRUG|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
223939266|NCT03033667|DIETARY_SUPPLEMENT|Group C|Over night fasting with no supplementation
224287132|NCT00240617|DRUG|sumatriptan succinate/naproxen sodium|comparator
224287133|NCT00240617|DRUG|placebo|placebo to match
224287134|NCT06247501|GENETIC|SNUH-CD19-CAR-T|CD19 CAR-T is a gene therapy that uses genetically modified autologous peripheral blood T-cells to target CD19 on the surface of B-cells. In this approach using CARs, lymphocytes are genetically manipulated, introducing the chimeric antigen receptor gene into the lymphocytes to combine the function of effector T-cells with antibody-like abilities. The chimeric antigen receptor can recognize cell surface antigens without the need for antigen processing. By using a single-chain variable fragment (scFv) antibody, which combines the variable regions of the heavy chain (VH) and light chain (VL) through a peptide linker of approximately 15 amino acids in length, the CAR gains the ability to bind to tumor antigens.
223939267|NCT06492148|OTHER|Myofascial Release|The myofascial release technique is a widely used manual therapy method characterized by low-load, prolonged mechanical forces applied to manipulate the myofascial complex, aiming to restore optimal length, alleviate pain, and improve function.
223939268|NCT06492148|OTHER|Sham-Myofascial Release|The hands of the researcher applying the technique will be placed in the same areas as the myofascial release technique, with only the palms in light contact for the same duration. However, no intervention will be made to create any pressure or open the tissue barrier.
223939269|NCT01278030|PROCEDURE|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
223939270|NCT00885625|BIOLOGICAL|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
223939271|NCT05646407|DEVICE|Honeywell HT-900 Turbo Force Air Circulator|This is a basic, portable, household fan with a single cost of CDN$21.99.
223939272|NCT02133625|DRUG|carboplatin|
223939273|NCT02133625|DRUG|pioglitazone|
223939274|NCT04093115|DRUG|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
223939275|NCT02949297|DEVICE|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
223939276|NCT00458783|BIOLOGICAL|Prolonged RBC storage|Transfusion with oldest available matching RBCs
223939277|NCT00458783|BIOLOGICAL|Short RBC storage|Transfusion with youngest available matching RBCs
223939278|NCT05708599|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
223939279|NCT05800990|BEHAVIORAL|dietary intervention|Research participants will be assigned to two dietary conditions.
223939280|NCT06307457|DRUG|Palbociclib in combination with AI|Patients with HR+/HER2- locally advanced or metastatic breast cancer treated with palbociclib in combination with AI as first-line treatment, in Denmark.
223939281|NCT06549764|BEHAVIORAL|Youth Aware of Mental Health|Help-seeking and literacy increasing intervention
223534584|NCT00582907|DRUG|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
223534585|NCT00582907|DRUG|Placebo|placebo by subcutaneous injection weekly for 3 months
223534586|NCT01701882|DRUG|tenofovir/emtricitabine/rilpivirine|
223534587|NCT02024412|DRUG|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
223534588|NCT02024412|OTHER|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
223534589|NCT01737866|DRUG|AMG 423|omecamtiv mecarbil
223534590|NCT04129307|BEHAVIORAL|Motor imagery|This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
223534591|NCT04129307|BEHAVIORAL|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
223534592|NCT04129307|BEHAVIORAL|Action observation|This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
223534593|NCT01149746|DRUG|Tamsulosin|Test 0.4 mg Capsule
223534594|NCT01149746|DRUG|Tamsulosin|Reference Listed 0.4 mg Capsule
223534595|NCT01150292|DIETARY_SUPPLEMENT|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
223534596|NCT01150292|DIETARY_SUPPLEMENT|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
223534597|NCT02823002|PROCEDURE|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
223534598|NCT02823002|PROCEDURE|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
223939282|NCT06294795|PROCEDURE|congenital/pediatric cataract surgery|All procedures are performed under general anesthesia according to the standard technique of congenital/pediatric cataract surgery with an intraocular lens (IOL) implantation. Paracentesis is performed at 2.30 o\&#39;clock using a 20-gauge straight microvitreoretinal (MVR) knife; a high molecular weight ophthalmic viscosurgical devices (OVD) is injected into the anterior chamber. Then a 2.4 mm corneal tunnel incision is made at 11 o'clock with a disposable keratome knife 2.2 mm. Circular continuous capsulorhexis (≈ 5.5 mm). Сortical cleaving hydrodissection is followed by bimanual phacoaspiration in irrigation-aspiration mode. OVD is injected in the anterior chamber and an IOL is implanted in the capsular bag. Residual OVD is aspirated from the anterior chamber and behind the IOL and followed by IOL alignment. The surgery is completed with corneal hydration at the tunnel incision site.
223939283|NCT06294795|DEVICE|Non-Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ SN60WF and Clareon SY60WF for the non-toric group (Alcon Laboratories, Inc.) ARE implanted.
223534599|NCT02823002|PROCEDURE|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
223534600|NCT02823002|PROCEDURE|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
223939284|NCT06294795|DEVICE|Toric IOLs|A folding hydrophobic acrylic IOLs AcrySof IQ Toric SN6ATx and Clareon Toric CNW0Tx for the toric group (Alcon Laboratories, Inc.) were implanted.
224287135|NCT05235659|BEHAVIORAL|Basic modules|Caregivers will only have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child.
223534601|NCT02823002|PROCEDURE|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
223534602|NCT02823002|PROCEDURE|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
223534603|NCT02823002|DRUG|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
223534604|NCT02823002|DRUG|Buffer|Sodium Bicarbonate
223534605|NCT01482858|DIETARY_SUPPLEMENT|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
223534606|NCT01482858|OTHER|Placebo|Gelatin capsules, each containing 500 mg \[comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose\] for oral use as placebo
223718930|NCT04123600|DEVICE|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
223718931|NCT00598988|PROCEDURE|traditional Chinese acupuncture|10 treatments over 6 weeks
223718932|NCT00598988|OTHER|standard medical care|standard care as provided by primary physician
223534607|NCT00003614|DRUG|estramustine phosphate sodium|
223534608|NCT00003614|DRUG|paclitaxel|
223534609|NCT00370292|DRUG|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
223534610|NCT00370292|DRUG|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
223534611|NCT06049914|BEHAVIORAL|Experimental group|"1. Exercise interventions~   * Measuring blood pressure and weight: before starting exercise~  * Flexibility exercises: 5-10 minutes of stretching~  * Strength exercises: Consists of 4 upper body exercises (Biceps Curl, Dips, Front raise, Chest press) and 5 lower body exercises (Leg lateral rotation, Leg extension, Hip abduction, Squat, Heel raise). The intensity of the band starts according to the subject's muscle strength.~  * Aerobic exercise: 5 times a week, home-based, 30 minutes or more each time~2. Nutritional interventions~   * Well nourished: Overall diet check and correction~  * at risk: Correction of diet and intake of up to 2 packs of supplemental protein products per day~  * Malnourished: Correction of diet and intake of up to 3 packs of supplemental protein products per day~  * Nutrition counseling is provided at the beginning of the intervention and high-protein diet composition education is provided~  * Confirm compliance and provide feedback once every 2 weeks"
223534612|NCT00193024|DRUG|Docetaxel|
223534613|NCT00193024|DRUG|Epirubicin|
223534614|NCT04714593|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
223534615|NCT04627129|DRUG|SHR2554 and Itraconazole|Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
223534616|NCT01171911|DRUG|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
223939285|NCT03447509|DEVICE|iTMS|Small magnetic pulse will be given to the brain in a non invasive manner.
223939286|NCT03447509|OTHER|Motor Task|Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
223718933|NCT05488730|DIAGNOSTIC_TEST|passive leg raising test and fluid challenge|"Shocked patients were subjected to echocardiographic examination if (EF \<52%) .baseline LVOT VTI was obtained Then IVC scanning was done through subcostal Window and using M-mode the minimum and the maximum diameters were measured then the collapsibility index was calculated~Then passive leg raising test was done Patients who tolerated the PLR test and did not develop clinical or lung ultrasound signs of fluid overload (lung congestion) were given IV fluid bolus (250 ml normal saline) over 10 minutes followed by measurement of LVOT VTI.~Patients who did not tolerate PLR test or developed clinical or lung ultrasound signs of fluid overload (lung congestion) during PLR test were excluded from the third step (fluid challenge).~The differentiating factor used to allocate patient in which group (non-responder or responder) was LVOT VTI variability after fluid challenge (our gold standard to assess fluid responsiveness)."
223939287|NCT03447509|DEVICE|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner.
223718934|NCT05979558|DRUG|ropivacaine with dexmedetomidine|this group received with ropivacaine with dexmedetomidine
223534617|NCT06073522|OTHER|Artificial Intelligence for combining multi-domain data acquisition|Artificial Intelligence and machine learning techniques to combine data coming from multidomains data collection (such as clinical multiaxial assessments and questionnaires, Neuroimaging, Upper limb movement analysis during clinical assessment and daily life )
223718935|NCT05979558|DRUG|Ropivacaine with placebo|this group received with ropivacaine with normal saline
223718936|NCT04774315|DRUG|Omalizumab|omalizumab 300mg SQ every 4 weeks as part of standard of care
223718937|NCT05699031|DEVICE|APP|Patients allocated in the app-group will use the newly developed smartphone app te rehabilitate. 5 exercises are provided daily. Daily questionnaires will monitor exercise performance, VAS pain, household activities. Information modules will be sent at specific times.
223718938|NCT05699031|OTHER|PHYSICAL THERAPY|Patients allocated in the physio-group will go, twice a week, to a physical therapist of their choice to rehabilitate. The physical therapist will follow the general guidelines provided by the hospital (surgeon).
223718939|NCT01102959|DEVICE|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
223718940|NCT03692130|BEHAVIORAL|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
223718941|NCT03692130|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson
223939288|NCT03447509|OTHER|Training|The participant will be instructed to do repetitive motor movements with their arm or hand.
223939289|NCT04794972|DRUG|GNC-039|Administration by intravenous infusion.
223939290|NCT03410589|OTHER|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
223718942|NCT02605824|DRUG|n-acetylcystine|NAC is a mucolytic drug.
223939291|NCT04401267|DRUG|Intensive Antihypertensive Therapy|Receives intensive antihypertensive therapy
223939292|NCT04401267|DRUG|Conventional Antihypertensive Therapy|Receives conventional antihypertensive therapy
223939293|NCT04401267|OTHER|Symptom Survey|The symptom survey is comprised of the PROMIS Ped 25 profile, PROMIS pain interference 8a, PROMIS physical activity 8a, and PROMIS mobility 8a during induction (day 23-28), during week 17 of continuation (+/- 2 weeks), and continuation week 49 (+/- 3 weeks).
223939294|NCT04401267|OTHER|Semi-structured interview|Patients will be interviewed by a trained examiner about their treatment and symptom burden on Week 49 of TOT17 Continuation Therapy. The interview will be recorded and will take about 30-45 minutes.
223534618|NCT00240851|DRUG|acetaminophen extended release|
223534619|NCT02704208|BEHAVIORAL|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
223718943|NCT02605824|DRUG|0.9% saline|Normal saline is a placebo agent.
223718944|NCT00000297|DRUG|Labetalol|
223939295|NCT05462704|DRUG|Ferric derisomaltose|Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.
223939296|NCT05462704|DRUG|Ferrous sulfate|325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.
223939297|NCT05418764|OTHER|Miyamodel Training|standardized training by performing five hysterectomies on the Miyamodel with a trainer who is a sub-PI at each institution
223939298|NCT05440851|OTHER|Ultra-Protective Ventilation Facilitated by Extracorporeal Support|Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
223939299|NCT05440851|OTHER|Lung-Protective Ventilation (LPV)|Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
223939300|NCT05440851|OTHER|Driving Pressure-Limited Ventilation (DPL)|Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
224098938|NCT00525291|DEVICE|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
224098939|NCT06051630|DRUG|Lidocaine intravenous|Perioperative lidocaine intravenous administration
224098940|NCT06051630|DRUG|Serum saline intravenous|Perioperative serum saline intravenous administration
224098941|NCT00664170|DRUG|ANX-514|75 mg/m\^2
224098942|NCT00664170|DRUG|docetaxel|75 mg/m\^2
224098943|NCT03176290|DIAGNOSTIC_TEST|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml-1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 - platelet count (×109 l-1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
223534620|NCT02704208|BEHAVIORAL|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
223939301|NCT05440851|OTHER|Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)|Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
223939302|NCT05440851|DRUG|Early Cohort corticosteroid dose|Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
223939303|NCT05440851|DRUG|Extended Cohort corticosteroid dose|Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
223939304|NCT05440851|DRUG|Usual care without routine corticosteroids|Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
223939305|NCT05440851|DRUG|Usual care without extending corticosteroids|Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
223939306|NCT05440851|DRUG|Usual care with fludrocortisone|Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
224098944|NCT04865848|PROCEDURE|Dental local anesthesia|Dental local anesthesia
224098945|NCT06543992|DRUG|Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir|Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
224287136|NCT05235659|BEHAVIORAL|"Basic modules and experimental condition My coach"|Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Professional support of the caregiver will be provided. Caregivers will receive one phone call (50 minutes) to support processing of information from module 1 and 2. Finally, they will receive text messages or emails with the core message of the modules.
224287137|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
223534621|NCT05117814|DRUG|Zanubrutinib|as long as 24 months or consolidated with ASCT or WBRT after achieving PR or CR
223718945|NCT01938456|DRUG|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
223718946|NCT01938456|DRUG|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
223939307|NCT05440851|DRUG|Usual care without fludrocortisone|Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
223939308|NCT05440851|DRUG|4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.|4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
224098946|NCT03067220|OTHER|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
224098947|NCT03067220|OTHER|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
224098948|NCT04792229|OTHER|Whole Body Viberation|WBV device (frequency of 40 Hz), 3 Minute vibration with 3 minute rest
224098949|NCT04484909|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
224098950|NCT04484909|RADIATION|Radiation Therapy|Undergo radiation therapy
223718947|NCT01938456|DRUG|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter\^2 or 75 mcg/body
223718948|NCT02592252|BEHAVIORAL|Participatory gender training|10 sessions of participatory gender training
223939309|NCT05440851|DRUG|40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours|40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
223939310|NCT05440851|OTHER|PEEP-20|fixed high positive end-expiratory pressure at 20 cmH2O
223939311|NCT05440851|OTHER|PEEP-AOP|positive end-expiratory pressure set according to airway opening pressure
223939312|NCT05440851|OTHER|PEEP-10|fixed lower positive end-expiratory pressure at 10 cmH2O
223939313|NCT05440851|OTHER|VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation|Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
223939314|NCT05440851|OTHER|Electrical impedance tomography (EIT)|Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
223939315|NCT06375278|DEVICE|Intra-Ear Canal Cooling Catheter|Mild therapeutic hypothermia will be applied via the catheter device installed inside the ear canal by an experienced surgeon during cochlear implantation (CI) surgery.
223939316|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo CARE
224098951|NCT04622852|DEVICE|Open reduction internal fixation (ORIF) with an angular stable plate|Operative treatment of proximal humeral fracture
224098952|NCT01710761|DIETARY_SUPPLEMENT|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
223718949|NCT02592252|OTHER|Microfinance|Microfinance loan
223718950|NCT06075862|PROCEDURE|Decompressive surgery|Decompressive lumbar spinal surgery
223718951|NCT03207230|DEVICE|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
223939317|NCT03284346|BEHAVIORAL|Exercise Intervention|Undergo standard stretching program
223939318|NCT03284346|OTHER|Laboratory Biomarker Analysis|Correlative studies
223939319|NCT03284346|OTHER|Polar heart rate monitor|Receive Polar heart rate monitor
223939320|NCT03284346|OTHER|Quality-of-Life Assessment|Ancillary studies
223939321|NCT03284346|OTHER|Questionnaire Administration|Ancillary studies
223939322|NCT02875548|DRUG|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of enhancer of Zeste homolog 2 (EZH2), a histone-lysine N-methyltransferase enzyme.
224098953|NCT01710761|DIETARY_SUPPLEMENT|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
224098954|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
223718952|NCT03207230|DEVICE|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
223939323|NCT05120804|BEHAVIORAL|Standard behavioral treatment|Nutrition and physical activity education along with behavior modification techniques
223939324|NCT05120804|BEHAVIORAL|Standard behavioral treatment plus relationship skills training|Nutrition and physical activity education along with behavior modification techniques plus relationship skills training
223939325|NCT05799274|DRUG|RAD301 ([68Ga]-RAD301)|A single dose of 68Ga-RAD301 of 150 +/- 50 MBq (\~4mCi) administered as a slow bolus injection over 2-5 minutes
223939326|NCT04936542|BIOLOGICAL|AboBoNT-A|AbobotulinumtoxinA for injection: 500 Unit vial. Dose: 900 Units (3.6 mL)
223939327|NCT04936542|BIOLOGICAL|OnaBoNT-A|OnabotulinumtoxinA for injection: 200 Unit vial. Dose: 360 Units (3.6 mL)
223939328|NCT06304441|DRUG|Osimertinib|Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
223939329|NCT06304441|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
223939330|NCT05108233|OTHER|Survey Administration|Complete survey
223939331|NCT03293264|BEHAVIORAL|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
224098955|NCT04034615|BIOLOGICAL|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1\*10\^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
223939332|NCT05873543|OTHER|smartphone-assisted hybrid cardiac rehabilitation (SHCR)|"The 12-week case manager-led SHCR program includes:~* Customized exercise prescriptions following ACSM's heart failure guidelines.~* A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app.~* Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms."
223939333|NCT06393439|DIAGNOSTIC_TEST|Virtual reality motor task|After a short practice task, participants perform motor tasks in a virtual reality environment. Reaction time is used to assess task performance.
223939334|NCT06353386|DRUG|Opevesostat|Oral Tablet
223939335|NCT06353386|DRUG|Olaparib|Oral Tablet
223939336|NCT06353386|DRUG|Docetaxel|IV Infusion
223939337|NCT06353386|DRUG|Cabazitaxel|IV Infusion
223939338|NCT06353386|DRUG|Fludrocortisone acetate|Oral Tablet
223939339|NCT06353386|DRUG|Dexamethasone|Oral Tablet
223939340|NCT06353386|DRUG|Prednisone|Oral Tablet
223939341|NCT05769582|BIOLOGICAL|Anti-BK polyomavirus (AntiBKV)|"Participants in the study arm will each receive four doses (1,000 mg; 1,000 mg or 500 mg in the dose comparison part) of IMP administered at four-week intervals.~IMP will be administered on Days 1, 29, 57 and 85."
223939342|NCT03214081|DRUG|Vonoprazan|Vonoprazan tablets
223939343|NCT04580043|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
223939344|NCT04580043|DEVICE|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
223939345|NCT04580043|BEHAVIORAL|Sham Training|Computer-based task practice in a non-active/inert task.
223939346|NCT04580043|DEVICE|Sham Transcranial Magnetic Stimulation|Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
223939347|NCT04842929|DEVICE|Transcranial magnetic stimulation|The coil will be positioned in the prefrontal dorsolateral cortex, with intermintent TBS (TBSi) mode on the left and continuous TBS (TBSc) on the right. 1800 pulses will be used on each side, totaling 10 minutes of total duration. There will be 20 consecutive sessions, one per day, except on weekends and holidays, totaling around 4 weeks. A day of stimulation with the same technique will be done in the 6th week, 8th week and 12th week.
224098956|NCT04034615|BIOLOGICAL|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
223939348|NCT06344377|DIETARY_SUPPLEMENT|Betaine|Betaine supplemented for 8 weeks
223939349|NCT06344377|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
223939350|NCT06012656|DEVICE|MiniMAX|Total or Partial Hip Arthroplasty
223939351|NCT02962284|DRUG|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
224098957|NCT02350543|DRUG|Aspirin|
224098958|NCT01158183|DRUG|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
224098959|NCT01317849|DRUG|Folic Acid|0.8mg
223939352|NCT05211154|DRUG|Diclofenac Potassium 50Mg/Pkt Oral Pwdr|Treatment for an acute, moderate to severe migraine attack
223939353|NCT05211154|DRUG|Rimegepant 75 MG|Treatment for an acute, moderate to severe migraine attack
223939354|NCT06049797|DRUG|Fezolinetant|Oral
223939355|NCT06049797|DRUG|Paroxetine|Oral
223939356|NCT06049797|DRUG|Citalopram|Oral
223939357|NCT06049797|DRUG|Escitalopram|Oral
223939358|NCT06049797|DRUG|Desvenlafaxine|Oral
223939359|NCT06049797|DRUG|Venlafaxine|Oral
223939360|NCT06049797|DRUG|Gabapentin|Oral
223939361|NCT06049797|DRUG|Clonidine|Oral
223939362|NCT06049797|DRUG|Pregabalin|Oral
223939363|NCT06049797|DRUG|Oxybutynin|Oral
223939364|NCT06049797|DRUG|Any other SSRI/SNRI not already specified|Oral
223939365|NCT06049797|DRUG|Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above|Oral
223939366|NCT03294863|DEVICE|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
223939367|NCT03294863|OTHER|Standard of Care|Without the embrace Scar Therapy Device
223939368|NCT03811769|OTHER|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
223939369|NCT03811769|PROCEDURE|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
223939370|NCT05312879|DRUG|VX-147|Tablets for oral administration.
224098960|NCT01317849|DRUG|Vitamin B6|10mg
223939371|NCT05312879|DRUG|Placebo|Tablets for oral administration.
223939372|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
223939373|NCT04671433|BIOLOGICAL|Genetic: AAV5-hRKp.RPGR|No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study)
223939374|NCT06640231|OTHER|sealer activation after cleaning and shaping with XP-Endo Finisher|activation of sealer before the obturation of root canals
223939375|NCT06640231|OTHER|negative control where canals are obturated directly without sealer activation|sealer after cleaning and shaping before the obturation without using activation method
223939376|NCT06188741|DRUG|Selumetinib|Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
224098961|NCT01317849|DRUG|Vitamin B12|500ug
224098962|NCT01317849|DRUG|placebo|0.8 mg
223534622|NCT02208219|BEHAVIORAL|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
223534623|NCT02208219|BEHAVIORAL|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
223718953|NCT03207230|DEVICE|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
223939377|NCT05329766|DRUG|Domvanalimab|Administered as specified in the treatment arm
223939378|NCT05329766|DRUG|Quemliclustat|Administered as specified in the treatment arm
223939379|NCT05329766|DRUG|Zimberelimab|Administered as specified in the treatment arm
224098963|NCT01317849|DRUG|placebo|10mg
224098964|NCT01317849|DRUG|placebo|500ug
223939380|NCT05329766|DRUG|Fluorouracil|Administered as specified in the treatment arm
223939381|NCT05329766|DRUG|Leucovorin|Administered as specified in the treatment arm
223939382|NCT05329766|DRUG|Oxaliplatin|Administered as specified in the treatment arm
223939383|NCT05815342|DEVICE|Omnipod 5 Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
223941432|NCT01701401|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223941433|NCT02481466|BEHAVIORAL|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
223534624|NCT02208219|BEHAVIORAL|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~* Passive mobilization: controlled manipulation of movements to release a joint.~* Stretch and progressive resistance training.~* Task-specific training: reaching and manipulation of different objects.~* Intense physical training: repetition of sequence of movements."
223534625|NCT01042314|DRUG|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
223534626|NCT01042314|DRUG|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
223534627|NCT01819740|OTHER|"determine the levels of the HEM substance in seminal plasma"|
223534628|NCT03545672|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
223534629|NCT00598650|DRUG|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
223534630|NCT01628913|DRUG|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
223718954|NCT05888766|DRUG|Rimegepant 75 milligrams|At the screening visit patients with episodic migraine, which will be prescribed Rimegepant 75 mg as abortive treatment, will be asked to participate in the study.
223718955|NCT06382259|OTHER|Movement breaks|Stretching and mobility-based exercises lasting 1-minute each performed 4 times per day on two consecutive days.
223939384|NCT05779605|DEVICE|Home-based training|Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.
223939385|NCT05779605|DEVICE|Center-based training|Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.
223939386|NCT06814171|OTHER|Low-carbohydrate breakfast|Daily low-carbohydrate breakfasts for one year.
223718956|NCT01048177|DRUG|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
223939387|NCT06814171|OTHER|Low-fat Control breakfast|Low-fat breakfasts for one year.
223939388|NCT05503446|OTHER|Peanut in common foods or supermarket-sourced cow's milk (CM)|Participants will be given a set dose of peanut (e.g. peanut-containing cereal, whole peanuts) or cow's milk to take on a daily basis, as per protocol
223939389|NCT03015896|OTHER|Laboratory Biomarker Analysis|Correlative studies
223939390|NCT03015896|DRUG|Lenalidomide|Given PO
223939391|NCT03015896|BIOLOGICAL|Nivolumab|Given IV
223939392|NCT00061906|DRUG|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
223939393|NCT00677209|BIOLOGICAL|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
223939394|NCT04244942|DEVICE|CERAMENT BVF|CERAMENT BONE VOID FILLER is a synthetic biphasic bone graft substitute.
223939395|NCT04809025|DEVICE|endoscopy|gastroscope
223939396|NCT04809025|PROCEDURE|Surgery|radical gastrectomy
223939397|NCT02198417|DRUG|Metformin ER|Treatment with metformin ER for 12 weeks
223939398|NCT00259142|DRUG|Chloroquine, sulphadoxine-pyrimethamine|
223534631|NCT01628913|DRUG|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
223534632|NCT00508521|DEVICE|Functional Electrical Stimulation|commercially available surface electrical stimulator
223534633|NCT00508521|OTHER|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
223534634|NCT01731795|DRUG|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
223718957|NCT06233617|DRUG|0.9% Sodium Chloride Injection|biliteral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
223534635|NCT03070093|DRUG|gilteritinib|oral
223534636|NCT00057161|BEHAVIORAL|Coordinated Representative Payeeship with Case Management|
223534637|NCT02176915|BEHAVIORAL|Group program|
223534638|NCT02176915|BEHAVIORAL|Print Materials|
223534639|NCT02935192|BIOLOGICAL|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
223534640|NCT02935192|OTHER|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
223534641|NCT03665259|PROCEDURE|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
223534642|NCT03665259|PROCEDURE|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
223718958|NCT06233617|DRUG|Dexamethasone 4 Mg/mL Injectable Solution|biliteral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
223718959|NCT06233617|DRUG|Dexmedetomidine injection|biliteral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
223939399|NCT04756648|DRUG|CT0180 Cells|Five dose levels were tentatively determined.
223939400|NCT01119651|DRUG|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
223939401|NCT04169776|DEVICE|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
223939402|NCT03211988|DRUG|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
223939403|NCT01698541|DRUG|Tacrolimus|Tested generic
223534643|NCT06400667|DEVICE|Upper limb Kinematic Assessment with Optoelectronic system|All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 60 Hz. The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film, 10 mm in diameter). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of body landmarks. During the data acquisition protocol, the subject perform five trial for each upper limb of a determinate functional task for each session. Every subject repeat this operations 2 times with 2 different operators.
223939404|NCT01698541|DRUG|Tacrolimus|Original formulation used as comparator
223939405|NCT02919748|OTHER|Choral Singing|Weekly sessions at 1 hour of choral singing.
223939406|NCT02919748|OTHER|Health Education Program|Weekly session at 1 hour of health education talk and group activities
223939407|NCT03130894|OTHER|Plasma TMAO concentration|Plasma TMAO concentration
223939408|NCT05739370|OTHER|Problem-Solving Therapy for Older Adults|"Problem-Solving Therapy for Older Adults (Ger-iPST) is an 8-week online psychotherapy program with online therapist support delivered through the Online Psycho Therapy Tool (OPTT). Ger-iPST has several evidence-based elements tailored to the specific needs of older adults, including relevant content (e.g. aging-related examples); process adaptations (e.g. more repetition); and digital usability modifications (e.g. high-contrast text).~Ger-iPST contains therapy modules assigned weekly and accessible at any time during the week. Modules begin with a brief, guided mindfulness relaxation exercise, followed by approximately 20 slides taking, on an average 1 hour to complete. Each module highlights a different step of Psychotherapy (PST) and includes an overview of a new skill, interactive activities and examples. A homework exercise designed to guide participants in applying a new PST skill exercise is submitted through the platform, and a clinician will provide personalized feedback."
223939409|NCT05697835|BEHAVIORAL|Behavioral activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
223939410|NCT05697835|OTHER|Medication optimzation|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
223939411|NCT05697835|OTHER|Care as usual|Care as usual, with written resources provided
223939412|NCT01354444|DRUG|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
223939413|NCT01354444|DRUG|Placebo|a pill that will look like the active drug but will not contain any carvedilol
223939414|NCT06184321|BIOLOGICAL|Alteplase|Instilled into IPC
223939415|NCT06184321|DRUG|Placebo Administration|Instilled into IPC
223939416|NCT00345046|DRUG|Pred Forte|Four drops daily decreasing to once daily over four weeks.
223939417|NCT00345046|DRUG|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
223939418|NCT00345046|DRUG|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
223939419|NCT00732849|DRUG|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
223939420|NCT00309036|BIOLOGICAL|Recombinant grass pollen|
223939421|NCT06336382|DIAGNOSTIC_TEST|Tau PET imaging scan|Subjects will be scanned with novel tau PET tracer \[18F\] PI-2620 to determine whether neurofibrillary tangle pathology is present.
223718960|NCT05367622|BEHAVIORAL|Self-regulation health education|"1. Insert the continuous blood glucose monitor~2. Give self-regulation model of health education to assist patients in making a judgmental decision on how to modify health promotion behaviors to reach a good glucose control~3. Use Telecommunications on the modifications of health promotion behaviors for 7 days"
223939422|NCT05099419|DEVICE|Repetitive Transcranial Magnetic Stimulation|"rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles."
223939423|NCT06030960|DEVICE|Virtual Reality (VR)|Virtual Reality (VR) Stabilization Exercises
223939424|NCT06030960|OTHER|Regular Exercises|Regular Stabilization Exercises
223939425|NCT06030960|OTHER|patient instructions and education|a unified form of patient instructions and education in regards of LBP
223939426|NCT03107169|OTHER|FMT|Patients in the FMT group received FMT-FURM
223939427|NCT03107169|DRUG|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
223939428|NCT04926519|OTHER|Type of periodontal treatment|Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
223939429|NCT01227746|PROCEDURE|Tumor biopsies|
223939430|NCT01613417|DRUG|gadoteridol|ProHance 0.1 mmol/kg
223939431|NCT01613417|DRUG|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
223939432|NCT04365959|PROCEDURE|Prone position|The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
223939433|NCT06547125|DEVICE|JUVÉDERM® VOLITE™|Injection, intradermal
223939434|NCT06547125|OTHER|Control|No-treatment control
223939435|NCT00077935|DRUG|Civamide|Cream 0.075%, TID for 52 weeks
223939436|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
223939437|NCT00532116|DRUG|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
223939438|NCT03676569|BIOLOGICAL|ADRC transplantation in autoimmune refractory epilepsy|
223939439|NCT02622698|DIETARY_SUPPLEMENT|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
223939440|NCT02622698|OTHER|Placebo|Placebo- Patients did not take any protein supplementation after surgery
223939441|NCT02861820|DEVICE|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
223939442|NCT02413138|DRUG|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
223939443|NCT01687920|DRUG|BAY94-8862 (1.25mg)|
223939444|NCT01687920|DRUG|BAY94-8862 (2.5mg)|
223939445|NCT01687920|DRUG|BAY94-8862 (5mg)|
223939446|NCT01687920|DRUG|BAY94-8862 (7.5mg)|
223939447|NCT01687920|DRUG|BAY94-8862 (10mg)|
223939448|NCT03041961|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
223939449|NCT03041961|DIETARY_SUPPLEMENT|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
223939450|NCT03041961|DIETARY_SUPPLEMENT|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
223939451|NCT02663804|DEVICE|Total Knee Arthroplasty|
223939452|NCT05485116|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223939453|NCT03185793|DRUG|Placebo|Placebo once daily for 5 weeks
223939454|NCT03185793|DRUG|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
223939455|NCT03185793|DRUG|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
223939456|NCT02168998|BEHAVIORAL|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
223939457|NCT03955926|DIETARY_SUPPLEMENT|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
223939458|NCT04612465|BIOLOGICAL|ASC|"Injection of ASC(Autologous Adipose-derived Mesenchymal Stem Cells) to Crohn's Fistula.~The ASC injection dose is about 1x10\^7 cells of ASC per 1cm\^2 of the surface area of the fistula, and the additional injection dose is 1.5 times the initial injection dose. and up to 30% of the ASC injection dose is administered in combination with Fibringlu."
223718961|NCT05367622|BEHAVIORAL|Usual diabetes health education|"1. Practice self-monitoring of blood glucose~2. Give usual diabetes health education"
223939459|NCT04612465|DRUG|Fibringlue|Injection of Fibringlue to Crohn's Fistula. The Fibringlu injection dose is given the size of the fistula that is fill the entire fistula, and the additional injection dose is the same.
223939460|NCT03339466|DEVICE|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
223939461|NCT03473717|DEVICE|classic method|"* Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~* Insert the hysterometer to measure the uterus depth.~* Locate the uterine depth on the inserter tube."
223939462|NCT03473717|DEVICE|direct method|"* Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~* Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
223939463|NCT03415412|DEVICE|Clearfil Univesal Bond|Adhesive systems
223939464|NCT03415412|DEVICE|IBond Universal|Adhesive systems
223939465|NCT03415412|DEVICE|G-Premio Bond|Adhesive systems
223939466|NCT05786872|DEVICE|dual-target deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat alcohol use disorder and to evaluate the efficacy and safety of DBS system.
223534644|NCT00527228|DRUG|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
223939467|NCT04121715|DEVICE|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
223534645|NCT00527228|DRUG|placebo|
223534646|NCT00560508|DRUG|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
223939468|NCT04121715|DRUG|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
223939469|NCT00491296|DEVICE|SYNERGO|
223939470|NCT00491296|DEVICE|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
223939471|NCT00512252|DRUG|AMD3100|
223939472|NCT00512252|DRUG|Mitoxantrone|
223939473|NCT00512252|DRUG|Etoposide|
223939474|NCT00512252|DRUG|Cytarabine|
223939475|NCT00001752|DRUG|L-arginine|
223939476|NCT00001752|DRUG|Estrogen|
223939477|NCT01703546|PROCEDURE|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band \& Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
223939478|NCT01100151|DRUG|RDC-1036 (ALKS 37)|Capsules for oral administration
223534647|NCT00560508|DRUG|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
223939479|NCT01100151|DRUG|Placebo|Capsules for oral administration
223939480|NCT02941094|DEVICE|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
223939481|NCT02941094|DEVICE|Ultrasound|Xario, Toshiba Tokyo Japan
223939482|NCT06180226|DIAGNOSTIC_TEST|PET CT with 18 FDG .|Impact exerted by the use of 18FDG PET in the process of functional monitoring of the patient undergoing radiotherapy treatment.
223939483|NCT02357966|BIOLOGICAL|514G3 (2 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
223939484|NCT02357966|BIOLOGICAL|514G3 (10 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
223939485|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment|True Human Monoclonal Antibody
223939486|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment|Sterile isotonic formulation buffered at pH 6.2 - 6.5 plus standard IV antibiotic treatment
223939487|NCT02357966|BIOLOGICAL|514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II|A single dose of 514G3 plus standard IV antibiotic therapy
223939488|NCT02357966|OTHER|Placebo plus standard IV antibiotic treatment: Phase II|A single dose of placebo plus standard IV antibiotic therapy
223939489|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
223939490|NCT00573105|PROCEDURE|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
223939491|NCT00705406|DRUG|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
223939492|NCT00705406|DRUG|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
223939493|NCT06509022|DIAGNOSTIC_TEST|PEPTEST test|Quantitative determination of gastric salivary amylase。
223939494|NCT06526286|OTHER|Medications for Opioid Use Disorder Pathway Clinical Decision Support (CDS)|Clinical decision support (CDS) in the form of an electronic health record (EHR)-integrated, provider-facing notification suggesting (a) the patient may be at risk for opioid use disorder and could benefit from screening, (b) patients with opioid use disorder would benefit from treatment with buprenorphine and (c) utilization of a clinical care pathway to help treat patients with opioid use disorder with buprenorphine as suggested by the Center for Disease Control and Prevention (CDC) guidelines.
223939495|NCT04456569|DEVICE|Geniculate Artery Embolization|All patients within the embolization group will undergo unilateral angiography and embolization of the appropriate treatment limb geniculate arteries. For patients with bilateral disease the more clinically symptomatic side will be chosen as the treatment/control knee.
223534648|NCT04513782|DIAGNOSTIC_TEST|Audiological Assessments|Participants will all undergo routine audiological assessments. The results from these assessments will be evaluated in order to advance understanding of central hearing loss.
223534649|NCT05952050|DRUG|Dexmedetomidine|Different Administration Routes of Dexmedetomidine
223534650|NCT01115907|DEVICE|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
223534651|NCT04102007|DRUG|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
223534652|NCT00818090|DRUG|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
223534653|NCT03669796|DIETARY_SUPPLEMENT|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
223534654|NCT03669796|DIETARY_SUPPLEMENT|Control|Maltodextrin/Casein
223534655|NCT00537043|DRUG|SK&F-105517 (COREG CR FDC)|
223534656|NCT01126073|DRUG|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
223939496|NCT06521086|DIETARY_SUPPLEMENT|Nutrition Supplements - Fresubin KCAL Drinks|Fresubin drinks will be taken up to 3 times a day throughout hospitalization and for 4 weeks after discharge.
223939497|NCT02378376|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|
223534657|NCT01126073|DRUG|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
223534658|NCT04156139|DEVICE|HFNC|The gas flow rate was set at 45\~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
223534659|NCT04156139|DEVICE|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
223534660|NCT05834049|BEHAVIORAL|Virtual Parental Presence on Induction of Anesthesia|Apple Inc's FaceTime™ video application will be used when the child is taken to the operating room
223534661|NCT05834049|BEHAVIORAL|Midazolam|Preoperative midazolam (0.5 mg/kg of oral midazolam with a maximum dose of 20mg) will be given unless medically contraindicated.
223534662|NCT06414083|DEVICE|Diathermy|Diathermy will be used to ablate the randomized sample.
223534663|NCT06414083|DEVICE|CO2 Laser|CO2 Laser will be used to ablate the randomized sample.
223534664|NCT06414083|DEVICE|Argon Beam Coagulator|Argon Beam Coagulator will be used to ablate the randomized sample.
223939498|NCT02378376|DIETARY_SUPPLEMENT|Dietary fiber enriched bran|
223939499|NCT04518709|PROCEDURE|Posterior Mitral Annulus Elevation Technique|Posterior mitral annulus elevation technique is performed using a large pledget and non-absorbable braided suture starting from the subvalvular section of the posterior mitral valve sutured to the ring annuloplasty (if in the process of repairing the mitral valve, ring implantation is performed; if without the use of ring annuloplasty, the suture is placed in the left atrial wall / supravalvular of PML), so that the posterior annulus is slightly attracted upward toward the cranial and the PML moves toward the center.
223939500|NCT04518709|PROCEDURE|Conventional Mitral Valve Repair|Conventional mitral valve repair in the pediatric patient using annuloplasty, leaflet resection and plication, sliding-plasty of chordae technique
224098965|NCT01403298|BEHAVIORAL|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
224098966|NCT01403298|OTHER|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
224098967|NCT06132568|DEVICE|VITALYST System|The VITALYST System is a temporary ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively in hemodynamically stable subjects with severe coronary artery disease.
224098968|NCT06070363|OTHER|Manual Acupuncture|Acupuncture Needle Insertion
224098969|NCT02801175|PROCEDURE|Pulmonary vein isolation|
223534665|NCT00638729|DRUG|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
223534666|NCT00638729|DRUG|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
223939501|NCT02268708|PROCEDURE|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
223939502|NCT04082507|DIAGNOSTIC_TEST|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
223534667|NCT00638729|DRUG|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
223534668|NCT00686673|BEHAVIORAL|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
223534669|NCT00686673|BEHAVIORAL|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
223534670|NCT06117007|DIETARY_SUPPLEMENT|Betalains|"Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)"
223534671|NCT06117007|OTHER|Placebo|Placebo capsules containing rice hulls. (0 mg betalains per capsule)
223534672|NCT01453166|OTHER|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
223939503|NCT05768282|DRUG|Oral prednisolone (30mg/day) for 28 days|Oral prednisolone was started at a dose of 30 mg/day on the third day after RFA, and continued for 4 weeks.
224098970|NCT00849550|DRUG|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
224098971|NCT04314687|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.
224098972|NCT04314687|BIOLOGICAL|Conditioned Medium|Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.
224098973|NCT04314687|OTHER|Standard Therapy|Standard therapy for cerebral palsy such as physiotherapy
224098974|NCT03409302|BEHAVIORAL|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
223939504|NCT04860999|PROCEDURE|Osteopathic Manipulative Treatment|The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
223534673|NCT01453166|OTHER|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
223534674|NCT01453166|OTHER|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
223534675|NCT04636996|OTHER|artificial intelligence assisted follow-up|We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process
223534676|NCT02429817|DRUG|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
223534677|NCT02429817|DEVICE|Aeroneb Solo|
223534678|NCT02429817|DEVICE|Jet Nebulizer|
223534679|NCT02429817|OTHER|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
223534680|NCT02429817|OTHER|Spirometry|FEV1, FVC assessment
223534681|NCT00284180|DRUG|Vinflunine|Novel second generation vinca alkaloid
223534682|NCT00284180|DRUG|Trastuzumab|Anti-HER2 monoclonal antibody
223534683|NCT00892008|DRUG|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
223534684|NCT05140356|DEVICE|Applied high amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(100%RMT) for 20 minutes each time, 5 times a week
223534685|NCT05140356|DEVICE|Applied low amplitude repeated transcranial magnetic stimulation|Each mode required 20 stimuli(15%RMT) for 20 minutes each time, 5 times a week
223534686|NCT04944771|DRUG|Capivasertib|Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
223534687|NCT04944771|DRUG|Rabeprazole|Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
223534688|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
223534689|NCT00614133|OTHER|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
223534690|NCT03004885|DEVICE|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
223534691|NCT05007964|DEVICE|Spatz4 Adjustable Balloon System|The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
223534692|NCT06244589|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy: Cholecystectomy that performed with laparoscopic method
223939505|NCT01903902|DEVICE|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length \< 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
223534693|NCT06244589|PROCEDURE|Open-conversion cholecystectomy|Open-conversion cholecystectomy: Cases in which laparotomy (Generally right subcostal incision) was performed based on intraoperative findings.
223534694|NCT04934267|OTHER|Eccentric Exercise for subjects with JHS|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
223939506|NCT04929470|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
223939507|NCT05250063|DRUG|LUM-201|Administered orally once daily
223939508|NCT06012500|DRUG|Xenon-129|Inhaled contrast for MRI
223939509|NCT04087889|BIOLOGICAL|HB-adMSCs|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
223939510|NCT02927249|OTHER|Placebo|Given PO
224098975|NCT03409302|BEHAVIORAL|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
223939511|NCT02927249|DRUG|Aspirin|Given PO
223939512|NCT04566861|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) for anxiety during pregnancy|Women who are randomized to the intervention group will receive six core Cognitive Behavioral Therapy (CBT) sessions for anxiety during pregnancy (and possible booster sessions) to treat symptoms of anxiety.
223939513|NCT05596994|DEVICE|Lighting Intervention Therapy|The LIT will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The TLI intervention will remain in place and will be delivered to participants for 10 weeks each in a counterbalanced manner. Combining spectrum and light level, LIT will allow the research team to: (a) use a light source that will stimulate the circadian system, and (b) provide the participants with options as to how the light treatment will be delivered. The research team will deliver at least 300-400 lux at the eye of the bluish-white light during the day (CS of 0.4 or greater) and about 50 lux at the eye during the evening hours (CS of less than 0.1) and when the control lighting intervention is used.
223939514|NCT05596994|DEVICE|Sham LIT|A placebo comparison lighting intervention will be used. The comparison lighting intervention will remain in place and will be delivered to participants for 10 weeks.
223939515|NCT00504023|DRUG|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
223939516|NCT00504023|PROCEDURE|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
223939517|NCT00504023|PROCEDURE|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
223939518|NCT01562834|DRUG|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
224098976|NCT03607370|PROCEDURE|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
224098977|NCT06176703|DEVICE|mobile application|using mobile application along with standard treatment of diabetes mellitus
223939519|NCT01562834|DRUG|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
224098978|NCT06049316|OTHER|Scapular stabilization exercises|"In Scapular stabilization exercise, following treatment protocol will involve.~* In supine position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree. After this patient will raise his hand overhead with 90 degree flexion and elbow extension and also perform scapular retraction. (10 sec hold, 10 reps, 20 sec break).~* In quadrupled position with 120 degree flexion and shoulder abduction patient will lifted his hands. (10 sec hold, 10 reps, 20 sec break) TYI exercises will be administered~* T shape: Place both arms horizontal with thumbs up. (10 times, 5 sec hold, 3 sets)~* Y-shape: In prone lying place arms in 45 degree. (10 times, 5 sec hold, 3 sets)~* I-shape: In prone position patients will place his both arms overhead. (10 times, 5 sec hold, 3 sets).~These above exercises will perform 3 times a week for eight weeks."
224098979|NCT06049316|OTHER|Scapular functional exercises|"In Scapular functional exercises, following treatment protocol will involve~* Press-up (in a chair).~* Push-up plus, Grade 1, in oblique position exercise will be performed with the support of a table. After progression perform this in horizontal plane.~* Lateral pull down~* Horizontal pull apart~* Prone flexion: in prone position on plinth. Both arms placed overhead, and then raise arms towards ceiling.~* Prone rows: in prone position, with elbow straight, slowly raise arms towards ceiling while bending the elbows.~These all above exercises will perform by holding dumbbells in hands (20RM at first week, 10RM at last week) with 3 sets, 3 times a week for eight weeks."
224098980|NCT00459927|DEVICE|Floseal tonsillectomy|
224098981|NCT00459927|DEVICE|Coblation tonsillectomy|
224098982|NCT00934895|DRUG|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
224098983|NCT00934895|DRUG|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
224098984|NCT04183101|DRUG|Aliskiren|Patients will be randomized to start treatment with aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight. After 6 months switch to enalapril 2.5-20 mg daily and continue with that 2.5 years.
224287138|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Who am I and where do I belong? and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 5. Finally, they will receive text messages or emails with the core message of the modules."
223718962|NCT02272062|OTHER|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
223718963|NCT06248632|OTHER|Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)|Expression of inflammatory markers obtained from circulating monocytic cells of XLH
223718964|NCT05840991|DEVICE|elastic bandage|3M™ Coban™ elastic bandage
223939520|NCT04652726|DRUG|Inclisiran|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL solution for subcutaneous injection
223939521|NCT04652726|DRUG|Placebo|Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
223939522|NCT02157116|DRUG|cisplatin|
223939523|NCT02157116|DRUG|Docetaxel|
223939524|NCT02157116|DRUG|Pegfilgrastim|
223939525|NCT04739137|DIAGNOSTIC_TEST|DDiVAT Testing|Participants will self examine his/her distance visual acuity via application in a simulation room of our department with certain predetermined environmental lighting conditions using the same smart devices.
223939526|NCT04739137|DIAGNOSTIC_TEST|Distance visual acuity assessment via ETDRS chart|The distance visual acuity of each participant will be measured with the conventional method via ETDRS chart
224098985|NCT04183101|DRUG|Enalapril|Patients will be randomized to start with enalapril 2.5-20 mg daily depending on weight. After 6 months switch to aliskiren tablet 150 mg every other day up to 300 mg daily depending on weight and continue with this treatment for 2.5 years.
224098986|NCT01614457|DRUG|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
224098987|NCT01614457|DRUG|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
223939527|NCT00370383|DRUG|Erlotinib|erlotinib 150 mg/day once daily
223534695|NCT04934267|OTHER|Eccentric Exercise for Controls|There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
223534696|NCT03421184|OTHER|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223534697|NCT03421184|OTHER|urine sample|10 ml
223534698|NCT03421184|OTHER|food questionnaire|dietary habit enquiry and a 48h dietary
223534699|NCT03421184|OTHER|hair|lock of hair
223534700|NCT03564886|DRUG|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
223534701|NCT03564886|DRUG|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
223534702|NCT00785720|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
223534703|NCT02005744|DRUG|CKD-501|CKD-501 0.5mg, PO(per oral), once
223534704|NCT03610048|DRUG|ALKS 5461|samidorphan + buprenorphine administered sublingually
223534705|NCT03773809|OTHER|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape \& appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
223534706|NCT03773809|OTHER|placebo|oral administration of placebo
223534707|NCT00006384|BIOLOGICAL|recombinant interferon alfa|
223534708|NCT00006384|DRUG|semaxanib|
223534709|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
223939528|NCT00370383|DRUG|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
223939529|NCT00093496|DRUG|gemcitabine hydrochloride|Given IV
223939530|NCT00093496|DRUG|tanespimycin|Given IV
223939531|NCT01370928|DEVICE|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
223534710|NCT04510207|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell)|The inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by BIBP
223534711|NCT04510207|BIOLOGICAL|Placebo|The placebo of inactivated SARS-CoV-2 Vaccine (Vero cell) manufactured by WIBP
223534712|NCT01155050|DEVICE|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
223534713|NCT01155050|BEHAVIORAL|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
223534714|NCT01155050|DEVICE|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
223534715|NCT01340456|DRUG|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
223534716|NCT03070678|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223939532|NCT01370928|DEVICE|Standard colonoscope|Screening colonoscopy
223939533|NCT03936192|DRUG|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
223939534|NCT03936192|DRUG|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
223939535|NCT03936192|DRUG|Placebos|Placebo administered once daily for 12 weeks.
223939536|NCT05610787|DEVICE|EXCOR Active Driving System for Pediatric VAD|The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
223939537|NCT02036112|PROCEDURE|conventional ELAPE|device
223939538|NCT02036112|PROCEDURE|Individual ELAPE|device
223939539|NCT03264547|DRUG|Pertuzumab|Every 3 weeks
223939540|NCT03264547|DRUG|Trastuzumab|Every 3 weeks
223939541|NCT03264547|DRUG|Docetaxel|Every 3 weeks
223939542|NCT03264547|DRUG|Paclitaxel|Every week
223939543|NCT03264547|DRUG|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
223939544|NCT01085513|DEVICE|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
223939545|NCT05316766|OTHER|Physical rehabilitation|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on conventional therapy
223939546|NCT05316766|OTHER|Physical rehabilitation interactive table|Exercises to rehabilitate upper limb strength, coordination and range of movement, based on multi-user touch surface
223939547|NCT05588453|BIOLOGICAL|Natural Killer Cell Therapy|Given UD TGFbi NK cell IV
223939548|NCT05588453|DRUG|Temozolomide|Given PO
223939549|NCT00903110|DRUG|Increlex®|Increlex® (mecasermin \[rDNA origin\] injection), 10 mg/ml solution for injection, 40-120mcg/kg BID or 0,04 to 0,12 mg/kg BID, as prescribed by physician
223939550|NCT03770429|DRUG|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
223939551|NCT06545916|DRUG|Sunobinop|1 tablet taken orally at bedtime
223939552|NCT06545916|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
223939553|NCT03653897|DEVICE|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
223939554|NCT03653897|DEVICE|Wearable Sensor|Subjects will wear an ID-Reader
223939555|NCT04187443|DRUG|MS-553|MS-553
224098988|NCT06128512|OTHER|Auricular acupuncture|Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch containing the needle will remain in place until the student completes the examination.
224098989|NCT06128512|OTHER|Sham Auricular acupuncture|Sham Auricular acupuncture is administered 24 hours before the examination using patches, each possessing a square shape with a side length of 10 mm, without a needle. Four acupoints are selected on one ear, including the Master cerebral point, Tranquilizer point, Relaxation point, and Heart point (CO15). The patch will remain in place until the student completes the examination.
224098990|NCT04577768|DEVICE|HD-tDCS 2 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
224098991|NCT04577768|DEVICE|HD-tDCS 1.5 mA|anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
223939557|NCT04360395|BEHAVIORAL|Gait Therapy|The therapeutic gait training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints.
223939558|NCT06016842|DRUG|Elafibranor|Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily
223939559|NCT06016842|OTHER|Matched 80 mg placebo|Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily
223939560|NCT04475939|DRUG|Niraparib|Niraparib will be administered.
223939561|NCT04475939|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered
223939562|NCT04475939|DRUG|Placebo|Matching placebo will be administered
223939563|NCT04595266|DRUG|FOLFOX regimen|"Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.~Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1"
224098992|NCT04577768|DEVICE|HD-tDCS sham|sham stimulation of the right primary motor cortex
224098993|NCT05863429|BIOLOGICAL|Taking biological samples (blood) and keeping records with phone calls|Within the scope of the study, no intervention will be made to the participants. According to the vaccination program implemented in Turkey, subjects who apply to the study centers for TURKOVAC vaccine will be invited to the study.
224098994|NCT02950623|OTHER|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
224098995|NCT02950623|OTHER|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
224098996|NCT05604105|OTHER|Questionnaire|The questionnaire includes a section for socio-demographic data, a section to detect their general awareness of oral cancer as a disease, a section about their awareness of its signs and symptoms and lastly, a section about its risk factors and habits.
224098997|NCT02795910|BEHAVIORAL|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
223534717|NCT03070678|DRUG|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
223534718|NCT04120207|BEHAVIORAL|Home-based Pilates|The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
223534719|NCT04120207|OTHER|Delayed-start Pilates|The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
223534720|NCT04612426|DEVICE|Brain-computer Interface-Pedaling Training System|The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
223718965|NCT05840991|DEVICE|compression stocking|Class 2 compression full-length stocking (23-32mm Hg)
223939564|NCT04595266|BIOLOGICAL|Anti-EGFR or Bevacizumab|"In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.~Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications."
223939565|NCT04595266|DRUG|LIVERPEARLS-Irinotecan|Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
223939566|NCT05980949|DRUG|KarXT|KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
223939567|NCT05980949|DRUG|KarX-EC|Specified dose on specified days
223939568|NCT02101775|DRUG|Adavosertib|Given PO
223939569|NCT02101775|DRUG|Gemcitabine Hydrochloride|Given IV
223939570|NCT02101775|OTHER|Laboratory Biomarker Analysis|Correlative studies
223939571|NCT02101775|OTHER|Pharmacological Study|Correlative studies
223939572|NCT02101775|OTHER|Placebo Administration|Given PO
224098998|NCT02795910|BEHAVIORAL|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
223939573|NCT02101775|OTHER|Questionnaire Administration|Ancillary studies
223939574|NCT03502447|DEVICE|TearCare|TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
224098999|NCT00381316|DRUG|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
223534721|NCT04612426|DEVICE|Traditional Pedaling Training System|The patient will wear the same EEG equipment that will only collect data, but not guide training.
223534722|NCT01186757|DRUG|PF-03715455|PF-03715455 1.6 mg BID
223534723|NCT01186757|DRUG|PF-03715455|PF-03715455 4mg BID
223534724|NCT01186757|DRUG|PF-03715455|PF-03715455 10 mg BID
223534725|NCT01186757|DRUG|Placebo|Placebo
223534726|NCT03792516|DRUG|artesunate ointment 40%|artesunate formulated as an ointment to be applied topically to the vulva
223534727|NCT00652834|PROCEDURE|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
223534728|NCT00652834|DRUG|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
223718966|NCT03067961|OTHER|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
223718967|NCT01324908|PROCEDURE|extracorporeal photopheresis|Undergo ECP
223718968|NCT01324908|OTHER|laboratory biomarker analysis|Correlative studies
223939575|NCT03502447|DEVICE|Warm Compress and Lid Massage|Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
223939576|NCT04956978|OTHER|Patient Decision Support Tool|Patient decision support tool is a web based educational material that informs a patient on the risk and benefits of oral anticoagulation. In addition, such a tool aims to assess patient values and preferences in the decision making process for oral anticoagulation for stroke reduction.
223939577|NCT05523817|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|iTBS is a form of non-invasive brain stimulation used to treat depression. It works on the principles of electromagnetic induction.
223939578|NCT00494949|DRUG|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
223939579|NCT00494949|DRUG|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
223939580|NCT03414645|BIOLOGICAL|CAM-101 10%|fibrinogen-depleted human platelet lysate
223939581|NCT03414645|BIOLOGICAL|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
223939582|NCT03414645|BIOLOGICAL|CAM-101 30%|fibrinogen-depleted human platelet lysate
223939583|NCT06349538|DIAGNOSTIC_TEST|Clinical examination, blood draw, cerebral MRI, sonography, tremor analysis, OCT, olfactory mucosa swab.|see previous descriptions
224099000|NCT00381316|DRUG|Thallous Chloride T1-201|Myoview SPECT Imaging
224099001|NCT01341873|OTHER|educational intervention|Undergo APN FCI
224099002|NCT01341873|OTHER|psychosocial support for caregiver|Undergo APN FCI
224099003|NCT01341873|PROCEDURE|quality-of-life assessment|Ancillary studies
224099004|NCT01341873|OTHER|questionnaire administration|Ancillary studies
224099005|NCT03397420|OTHER|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
224099006|NCT01854567|BIOLOGICAL|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
223939584|NCT04024943|DEVICE|Quadripolar LV Lead|The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
223939585|NCT05999682|OTHER|apigenin|Intragastric tube injection of ground apigenin tablet 50 mg with 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
223939586|NCT05999682|OTHER|sterilized water|Intragastric tube injection of 5 ml of sterilized water + conventional standardized treatment, for 4 consecutive days.
223939587|NCT06100198|OTHER|nutrition and exercise program|Nutrition courses include understanding malnutrition and sarcopenia; understanding the six major food categories and their requirements; and understanding protein-rich food sources. Exercise courses include understanding exercise types, flexibility exercises, and muscle strength training exercises.
223939588|NCT06541886|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I was developed as a treatment for adults with insomnia. There are more than 100 studies showing that CBT-I is effective in treating insomnia in adults, and several studies suggest it is also effective in treating insomnia in teens.
223939589|NCT05158218|BEHAVIORAL|Robotic Exoskeleton Gait Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will be completed in a 60-minute sessions with rests as needed. The key components of the therapy will include: 1) optimally challenging activities of variable intensity that emphasize motor planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints, 2) task specific overground movements that promote building a repertoire of mobility strategies that can be utilized in the community, and 3) motor tasks requiring active control that increase participant therapeutic engagement. An overhead body weight support system or a gait-belt may be used for some individuals during the robotic exoskeleton gait training blocks.
223939590|NCT05158218|BEHAVIORAL|Physical Therapy|The training protocol will consist of 24-treatment sessions that will be performed 3 times-a-week for an 8-week period. All therapeutic exercises will be performed under the direction of a licensed pediatric physical therapist. Any sessions missed will be added on to the 8-week period. Each intervention session will consist of over-ground gait activities that will be completed in a 60 minute session with rests as needed. The key ingredients of the therapy will include: 1) activities of adequate intensity that promote gait adaptation and gait speed sustainment, 2) exploratory activities that enhance the somatosensory experience through rich/novel movement, and 3) optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. An overhead body weight support system or a gait-belt may be used for some individuals during the gait training blocks
223939591|NCT04479267|DRUG|Prednisone|Given PO
223939592|NCT04479267|DRUG|Prednisolone|Given IV
223939593|NCT04479267|DRUG|Methylprednisolone|Given IV
223939594|NCT04479267|BIOLOGICAL|Rituximab|Given IV
223939595|NCT04479267|DRUG|Polatuzumab Vedotin|Given IV
223939596|NCT04479267|DRUG|Cyclophosphamide|Given IV
223939597|NCT04479267|DRUG|Doxorubicin Hydrochloride|Given IV
223939598|NCT01779245|DIETARY_SUPPLEMENT|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
224099007|NCT01854567|BIOLOGICAL|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
224099008|NCT04296136|OTHER|Advance Care Planning Discussion|Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
224099009|NCT06069687|BIOLOGICAL|MELPIDA|A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
224099010|NCT04985708|OTHER|data collection of clinically available procedures|when to place Impella related to PCI in patients with AMICS
223534729|NCT00320606|DRUG|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
223939599|NCT01779245|DIETARY_SUPPLEMENT|Placebo|
224099011|NCT05955742|DEVICE|Control|The operator prepared the glide path using a #15K-type stainless-steel hand file.
224099012|NCT05955742|DEVICE|ProGlider|The operator prepared the glide path using the ProGlider file.
224099013|NCT05955742|DEVICE|WaveOne Gold Glider|The operator prepared the glide path using the WaveOne Gold Glider file.
224099014|NCT01166269|BIOLOGICAL|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
224099015|NCT01166269|BIOLOGICAL|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
223534730|NCT05957042|DRUG|Lumason|Up to 4.8mL administered intravenously
223534731|NCT03297658|DEVICE|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
224099016|NCT01166269|OTHER|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
224099017|NCT01186653|DRUG|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
224099018|NCT01186653|DRUG|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
224099019|NCT05762705|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Information-Motivation-Behavior based mobile gaming application tailored for those taking PrEP and adherence-based text messages
224099020|NCT05762705|BEHAVIORAL|Treatment as Usual +|non-PrEP related mobile gaming application
224099021|NCT03707093|DRUG|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
224099022|NCT03903055|DIAGNOSTIC_TEST|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
224099023|NCT02857465|DRUG|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
224099024|NCT02857465|DRUG|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
224099025|NCT02857465|DRUG|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
224099026|NCT02857465|DRUG|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
224099027|NCT04599790|DRUG|TACE combined with lenvatinib and sintilimab|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
223939600|NCT06423365|OTHER|Virtual Statin Management (VSM)|"VSM is a web-based decision aid to help manage statin therapy after experiencing muscle pain perceived to be caused or worsened by their statin therapy. The introduction will feature a brief explanation of the tool and what they can expect. The modules are:~1. General education (lipids, heart disease, medications)~2. Side effects (causes, diagnosis).~3. Statin modifications. VSM will guide patients to understand their lipid-lowering options, particularly their statin options that may best match patients' stated preferences.~4. ASCVD risk \& statin benefit. Finally, the VSM experience will end by providing the patient with a summary of the results of their use of the tool, which can be used during discussions with their healthcare provider. The information gathered from the VSM will remain confidential and will not be disclosed to anyone other than the patient."
223939601|NCT06357403|DIAGNOSTIC_TEST|Anti-factor Xa activity calibrated for enoxaparin|Anti-factor Xa activity calibrated for enoxaparin
224099028|NCT01183962|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 3000 IU daily
224099029|NCT01183962|OTHER|No medication|No intervention
224099030|NCT01512524|OTHER|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
224099031|NCT05424692|DRUG|5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
224099032|NCT06443073|OTHER|Patient-reported outcomes for speech disorders: positive|The Communicative Participation Item Bank (CPIB) aims to assess communication participation in all kinds of communication disorders. The Voice Self-Efficacy Questionnaire (VSEQ) monitors self-efficacy in individuals with self-declared voice problems before and after interventions. The Vocal Fatigue Handicap Questionnaire (VFHQ) and the Vocal Fatigue Index (VFI) aim at reflecting vocal fatigue. Both have been adapted to reflect purely positive wording.
224099033|NCT04570579|DEVICE|Vivity Extended Depth of Focus Intraocular Lens|Patients selected to have bilateral sequential cataract surgery using the Vivity (spherical and/or toric where applicable) intraocular lens implant will subsequently be offered enrollment into this observational study. Visual outcomes will be recorded at postoperative day 1, week 1, month 1 and month 3.
224099034|NCT01225263|DRUG|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
224099035|NCT01225263|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
224099036|NCT01225263|OTHER|Placebo|Two placebo pills, taken twice daily for 6 months
223939602|NCT04597866|BEHAVIORAL|Multimodal rehabilitation|A combination of exposure in vivo and interventions directly targeting the cortical reorganization for treating CRPS.
223939603|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)|Patients will be treated with a single eco-guided injection of Autologous LR-PRP in the elbow affected by epicondylitis.
224099037|NCT03804541|DRUG|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
224099038|NCT05804162|DRUG|Cagrilintide|Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period.
224099039|NCT05804162|DRUG|Cagrilintide Placebo|Participants will receive cagrilintide placebo subcutaneously once weekly.
224099040|NCT05804162|DRUG|Moxifloxacin|Partcipants will receive a single dose of moxifloxacin orally.
223534732|NCT03297658|DEVICE|sham|Micro electrodes will be placed but there will be no stimulation
224099041|NCT05804162|DRUG|Moxifloxacin Placebo|Partcipants will receive a single dose of moxifloxacin orally.
223534733|NCT01426802|DRUG|vildagliptin|Drug 50mg vildagliptin bid
224287139|NCT05235659|BEHAVIORAL|"Basic modules and experimental module You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
223718969|NCT06467474|BEHAVIORAL|PEG-D program|PEG-D will be carried out in person, open format, for six consecutive weeks lasting 90 minutes each. An approximate group of 6 to 10 participants will be led by a team of experienced psychologists and psychiatrists. Each group will have a main therapist and a co-therapist to ensure effective support and guidance for participants. Before the start of the group, participants received a booklet containing the content of the sessions.
223939604|NCT06040203|BIOLOGICAL|Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)|Patients will be treated with a single eco-guided injection of Autologous LP-PRP in the elbow affected by epicondylitis.
224099042|NCT00374556|DRUG|Placebo|3mg placebo capsule, once daily at bedtime
224287140|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 4. Finally, they will receive text messages or emails with the core message of the modules."
223534734|NCT03690245|PROCEDURE|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
223534735|NCT01127919|BEHAVIORAL|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
223534736|NCT01127919|OTHER|Cognitive Component|Provide general information about health and fitness
223534737|NCT00744744|OTHER|informational intervention|Patient educational information
223534738|NCT00744744|OTHER|questionnaire administration|Survey
223534739|NCT00744744|PROCEDURE|management of therapy complications|Survey
223534740|NCT00744744|PROCEDURE|psychosocial assessment and care|Survey
223534741|NCT00744744|PROCEDURE|quality-of-life assessment|Survey
223534742|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
223534743|NCT01697644|DRUG|somatropin|3 IU/m\^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
223534744|NCT00146744|BIOLOGICAL|Mtb72F/AS02A|
223939605|NCT06040203|DRUG|Placebo (saline solution)|Patients will be treated with a single injections of saline solution in the elbow affected by epicondylitis.
223939606|NCT04132414|DIAGNOSTIC_TEST|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
223939607|NCT02509442|PROCEDURE|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
224099043|NCT00374556|DRUG|Eszopiclone|3mg capsule, once daily at bedtime
223939608|NCT00734877|DRUG|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
223939609|NCT00734877|DRUG|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
223939610|NCT03722303|OTHER|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
223939611|NCT03722303|DRUG|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
223939612|NCT06062875|DRUG|Adalimumab|Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
223939613|NCT02457936|BEHAVIORAL|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
223939614|NCT05348733|DRUG|Kerendia (Finerenone, BAY94-8862)|Decision will taken by the treating physician to initiate treatment with finerenone.
223939615|NCT05688982|BEHAVIORAL|General information provision|Patients will receive information with general oral health and aSDoH resources.
224099044|NCT05349955|OTHER|Intensive guideline algorithm implementation|Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
224099045|NCT05349955|OTHER|Conventional guideline algorithm implementation|The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
224099046|NCT01380899|PROCEDURE|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
223718970|NCT06467474|DRUG|TAU|The treatment will start with Sertraline (SSRI) - doses of 50 mg and adjusting as necessary according to the patient\&#39;s profile. After 8 weeks, if the patient experiences remission, they will continue on monotherapy with Sertraline. In case of relapse Bupropion, Quetiapine, Lithium or Aripiprazole might be add-on. In this case, add-on medications will be determined according to the patient profile, by the clinician. If there is a response above 25% of the symptoms, but without remission, the patient will proceed to augmentation with the aforementioned medications and if there is no improvement of at least 25%, the patient will be considered drop-out. Associations with Lorazepam if necessary will be allowed in any phase of the study.
223718971|NCT00160628|DRUG|Levetiracetam|
223718972|NCT01390805|DRUG|Valaciclovir Hydrochloride.|
223718973|NCT03123718|DRUG|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
223718974|NCT03123718|DRUG|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years."
223939616|NCT05688982|BEHAVIORAL|Geographic information provision|Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.
223939617|NCT05688982|BEHAVIORAL|Navigational assistance|Patients will receive phone-based navigational assistance from the study navigator.
223939618|NCT04130269|OTHER|No intervention|Questionnaires, lab-run
223939619|NCT05191030|BEHAVIORAL|High-Stress Intervention|Those undergoing the High-Stress will be exposed to a gold-standard laboratory stressor, the Trier Social Stress Test (Kirschbaum et al., 1993), which reliably induces cortisol reactivity in most individuals.
223939620|NCT06030037|BIOLOGICAL|Healthy Donor Fecal Microbiota Transplantation (hdFMT)|hdFMT (induction) via colonoscopy or oral capsule on C1D1 and C3D1. hdFMT (maintenance) via sigmoidoscopy or oral capsules will be repeated every 9 weeks.
223939621|NCT06030037|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg every 3 weeks (Q3W) as a 30-minute IV infusion (treatment intervals may be increased due to toxicity)
223939622|NCT06030037|DRUG|Lenvatinib|Lenvatinib will be administered at 20 mg daily
223939623|NCT04995081|BIOLOGICAL|Biological/Vaccine: Allogeneic HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
223939624|NCT04995081|OTHER|Placebo|Sterile Saline Solution 0.9%
224099047|NCT01568723|GENETIC|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
224099048|NCT04345185|OTHER|Infant egg consumption (i.e., age of introduction and frequency of intake)|
224099049|NCT01355406|DEVICE|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
223939625|NCT06259851|BEHAVIORAL|Dialectical behavioral therapy program|Dialectical behavioral therapy (DBT) program with all the standard DBT modules (individual therapy 1 hour per week, skills group 3 hours per week, phone coaching, and therapist consultation team 1,5 hour per week). The program takes 24 weeks in total comprising two 12-week runs of skills training. The program will be precluded with 4 individual sessions of pretreatment before the start of the main program part.
223534745|NCT04116255|OTHER|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
223939626|NCT06259851|DEVICE|Prefrontal rTMS treatment|rTMS will be performed by DuoMag XT with 70BF cool coil. Patients will undergo 15 daily stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds. Gradual titration of the individual resting motor threshold (RMT) will apply, meaning probands will undergo first session with 90% RMT intensity, second session with 100% RMT intensity, third session with 110% RMT intensity. All the following sessions will use the final 120% RMT intensity. In case a session is left out because of any reason, the total duration of treatment will be prolonged by one day, so that the total number of sessions underwent is the same in all patients. Patients will receive 2000 pulses during one session (total 30000 pulses during the whole procedure) with 10 Hz frequency.
223939627|NCT06259851|DEVICE|Sham rTMS sessions|Sham TMS will be performed by sham coil that looks identical to DuoMag XT in the active group. Patients will undergo 15 daily sham stimulation sessions during a period of three weeks with one session each working day. Each session consists of 20 trains with 100 pulses (10 seconds for train). Inter-train interval will be 30 seconds.
223939628|NCT02581085|DRUG|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
223939629|NCT02581085|OTHER|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
223939630|NCT04200664|DIAGNOSTIC_TEST|Hearing assessment|All study participants will undergo hearing tests, including hearing-specific questionnaires
223939631|NCT04200664|DIAGNOSTIC_TEST|Vestibular/balance assessment|Siderosis group participants will undergo vestibular/balance tests, including gait assessment and balance-specific questionnaires
224099050|NCT05352191|DRUG|Beclomethasone|inhaled 800ug
223718975|NCT01425996|DRUG|Lipotecan® (TLC388)|"* Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
223718976|NCT05637866|OTHER|Soy milk|Soya milk or soymilk, a plant-based beverage that can be sweetened or unsweetened.
223718977|NCT05682898|PROCEDURE|Timing of colorectal cancer surgery|The timing of colorectal cancer surgery is different according patients' different conditions which is difined as more than 7 weeks or less than 7 weeks.
223534746|NCT04116255|OTHER|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
224099051|NCT04207398|PROCEDURE|Transjugular intrahepatic portosystemic shunts|Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that uses imaging guidance to connect the portal vein to the hepatic vein in the liver. A small metal device called a stent is placed to keep the connection open and allow it to bring blood draining from the bowel back to the heart. TIPS may successfully reduce internal bleeding in the stomach and esophagus in patients with cirrhosis and may also reduce the accumulation of fluid in the abdomen (ascites).
223534747|NCT02487511|OTHER|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
223939632|NCT04200664|OTHER|Quality of life assessment|All study participants will be asked to complete a set of quality of life questionnaires
223939633|NCT04200664|DIAGNOSTIC_TEST|Olfactory (smell) function testing|Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents
223939634|NCT04200664|GENETIC|DNA bio-banking|Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
224099052|NCT04207398|OTHER|Nonselective β-blocker (NSBB)+ endoscopic band ligation (EBL)|Combination therapy of nonselective β-blocker (NSBB) and endoscopic variceal ligation (EBL) will be used for participants in this group. NSBB, which will be titrated to the maximum tolerated dose aiming to decrease the heart rate by 25%, with a lower limit of 50 beats per minute, was started at day 5 after the index bleeding, unless a contraindication was present (severe arrhythmia, severe obstructive chronic obstructive pulmonary disease, or known intolerance). Endoscopic variceal ligation sessions started 2 weeks after the index bleeding and were performed every 2-4 weeks thereafter until eradication of varices, followed by endoscopic surveillance and retreatment, if indicated, every 6-12 months.
223534748|NCT01935388|OTHER|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
223939635|NCT04907188|BIOLOGICAL|HB-adMSCs|The subject will receive 6 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10\^8 cells) cells approximately every 28 days.
223939638|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Semestrial administration
224099053|NCT01938859|DRUG|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
223534749|NCT00338637|DEVICE|APOS shoe kit|
223534750|NCT01914588|PROCEDURE|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
223534751|NCT01914588|OTHER|Standard care|"* Detailed instruction about medical therapy and lifestyle counseling~* Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~* Follow-up visits"
224099054|NCT01938859|DRUG|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
223718978|NCT03255798|DEVICE|G2 and G3|Two iStent inject devices and one iStent supra device
224099055|NCT01938859|DRUG|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
224099056|NCT00648986|DRUG|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
223718979|NCT01965587|PROCEDURE|novasure mirena IUS combined|novasure mirena IUS combined
224099057|NCT05268848|OTHER|Thermographic photo|Barefoot patient, thermographic photo of the sole of the feet is taken
223939639|NCT05999604|DRUG|Ocrelizumab Injection [Ocrevus]|Annual administration
223939640|NCT05949619|DRUG|BL-M02D1|Administration by intravenous infusion
223939641|NCT06778187|DRUG|Oral arsenic trioxide|"Patients will be treated in 28-day cycles.~Each cycles will comprise:~Oral arsenic trixoide (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14~PLUS:~* Oral ascorbic acid (1000mg/day) from Days 1-14~* Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (20mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5.~* Venetoclax (100mg-400mg/day) from Days 1-14 (if used)"
223939642|NCT06433115|OTHER|Lean (≥90%) Grass-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
223939643|NCT06433115|OTHER|Lean (≥90%) Grain-Fed Beef|The specified amount will be 4 oz. per day or 28 ounces per week for participants with an energy requirement of 2000 kcal.
223939644|NCT06433115|OTHER|Plant-Based Meat|Plant-based meat would be macronutrient matched to the same quantities of meat prescribed for a given energy level.
223939645|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Clarithromycin tablets|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
223939646|NCT06005714|DRUG|Mindeudesivir hydrobromide tablets and Cyclosporine softgels|Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
223939647|NCT05312671|DRUG|Atezolizumab|Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)
223939648|NCT05312671|DRUG|Carboplatin|Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
223939649|NCT05312671|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).
223939650|NCT05312671|DRUG|Etoposide|Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)
224099058|NCT00673855|OTHER|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
224099059|NCT00673855|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
224099060|NCT03932955|BIOLOGICAL|MC-19PD1 CAR-T cells|T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
224099061|NCT03941444|DRUG|ANAVEX2-73|Liquid oral solution
223939651|NCT05312671|PROCEDURE|Cystectomy|Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
224099062|NCT03941444|DRUG|Placebo|Liquid oral solution
224099063|NCT06214728|PROCEDURE|Hyaluronic acid gel application|HA gel was applied to the periodontal pockets where the intraosseous defect was located using a sterile injector with a plastic needle. The gel was applied until it overflowed from the gingival sulcus. Patients were instructed not to eat, drink or brush their teeth for at least one hour. Subgingival application of HA was repeated 4 weeks after the first session.
224099064|NCT06214728|PROCEDURE|Placebo gel application|The control group received placebo HA gel probe without rinsing. Placebo application was repeated 4 weeks after the first session.
224099065|NCT04057443|OTHER|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
223939652|NCT05477524|BIOLOGICAL|VLA15|Shot in the deltoid muscle (preferable in the nondominant arm)
224099066|NCT04057443|OTHER|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
224099067|NCT04057443|DRUG|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
224099068|NCT06453694|DRUG|Efgartigimod Alfa|"2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
223939653|NCT05477524|OTHER|Saline|Shot in the deltoid muscle (preferable in the nondominant arm)
223939654|NCT06456190|BEHAVIORAL|Skills Training in Active Recovery (STAR) Video|a 12-15 minute video that includes psychoeducation about ptsd and substance misuse plus tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
223939655|NCT06456190|BEHAVIORAL|Text Skills Training in Active Recovery (TextSTAR) program|a 3-week daily text program that includes supportive/empowering messages along with brief coping tips to not avoid safe but scary situations, cope with distress and urges to use, and engage with social support to aid recovery
223939656|NCT06634277|BEHAVIORAL|NavSTAR (Philly adaptation)|Patient Navigation
223939657|NCT01488968|RADIATION|Standard Radiation Treatment|39 radiation treatments
223939658|NCT01488968|RADIATION|Hypofractionated radiation treatment|25 radiation treatments
223939659|NCT06534437|DRUG|MEN1703|MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
223939660|NCT06534437|DRUG|Glofitamab|Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
223939661|NCT06223542|PROCEDURE|Biopsy Procedure|Undergo biopsy
224099069|NCT06453694|DRUG|Placebo|"Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."
224099070|NCT01046149|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
224099071|NCT01046149|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
224099072|NCT02153840|DRUG|PSORI-CM01（YXBCM01） granule|
224099073|NCT02153840|DRUG|placebo|
224099074|NCT00509886|DRUG|Drysol|20% aluminum chloride hexahydrate
224099075|NCT00509886|DRUG|Drioff|1% aluminum acetate
224099076|NCT01670201|DEVICE|Mepilex Transfer Ag|Silver dressing
224099077|NCT04619407|DIAGNOSTIC_TEST|Nasopharyngeal swab|SARS-CoV-2 PCR
223939662|NCT06223542|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223939663|NCT06223542|PROCEDURE|Computed Tomography|Undergo CT
223939664|NCT06223542|PROCEDURE|Echocardiography Test|Undergo ECHO
223939665|NCT06223542|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224099078|NCT04619407|DIAGNOSTIC_TEST|Serum testing|Anti-SARS-CoV-2 antibody testing (IgA and IgG ELISA)
224099079|NCT02265328|DIETARY_SUPPLEMENT|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
224099080|NCT02265328|DIETARY_SUPPLEMENT|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
223939666|NCT06223542|DRUG|UAE Inhibitor TAK-243|Given IV
223939667|NCT04825743|DRUG|zalunfiban|zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
223939668|NCT04825743|DRUG|Placebo|A placebo will be prepared to those subjects assigned to placebo. Less than 1 mL (depending on subject's weight) will be administered by subcutaneous injection.
223939669|NCT04541589|DRUG|Iscalimab|Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).
223939670|NCT04541589|OTHER|Placebo|Placebo (1 injection of 2 ml) administered to participants in the iscalimab 300 mg arm to maintain blinding until the final database lock of the core study
223939671|NCT04280289|DRUG|cannabidiol extract|"The test article CBD Cannabis Extract Oral Solution will be manufactured by the University of Mississippi National Center for Natural Products Research (NCNPR) at the Coy Waller Laboratory under FDA Current Good Manufacturing Practices. The drug product, derived from hemp and containing less than 0.3% of Δ9-tetrahydrocannabinol, is no longer a Drug Enforcement Agency (DEA) controlled substance. DEA registrations are not required for the manufacturing, handling or dispensing of these clinical test materials"
224099081|NCT02265328|OTHER|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to \<40mg/day for next 4 weeks. (If Lilli score \> 0.45 after 7 days, then prednisolone would be stopped)
224099082|NCT00775164|DRUG|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
224099083|NCT00775164|DRUG|Metformin|Metformin XR; 1000 mg once daily
223939672|NCT04026776|DRUG|Allopurinol|Study Part 2- Preterm group only: After Visit 5 preterm born participants will start allopurinol 200 mg daily PO for 6 weeks. The 1 week high and low salt diets and assessments will be repeated while on allopurinol.
223939673|NCT04026776|OTHER|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the Clinical Research Unit Metabolic Kitchen. Part 2 preterm only- the diets will be repeated while the participant is taking allopurinol.
223939674|NCT05902013|DEVICE|laryngoscopy|laryngoscopy for nasotracheal intubation
223939675|NCT06181435|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
224099084|NCT03560362|DRUG|Bupivacaine liposome|
224099085|NCT03560362|DRUG|Bupivacaine / Epinephrine|
224099086|NCT06476080|PROCEDURE|ultrasound guided erector spine block|Ultrasound guided thoracic erector spinae block
224099087|NCT06476080|PROCEDURE|Serratus anterior block|Ultrasound guided serratus anterior block
223939676|NCT06181435|DRUG|Placebo|"Pharmaceutical form:~Injection solution Route of administration: SC injection"
224099088|NCT02486068|DEVICE|ABSORB scaffold|
223939677|NCT06546553|DRUG|PF-07826390|PF-07826390 is a novel, fully humanized bispecific IgG1 that targets the leukocyte immunoglobulin-like receptor, LILRB1 and LILRB2 (B1 and B2) cell-surface receptors
223939678|NCT06546553|BIOLOGICAL|sasanlimab|A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2
223939679|NCT06546553|OTHER|SOC (anti-PD-1 + platinum -based chemo)|Standard of Care (anti-PD-1 + platinum -based chemo)
223939680|NCT03745313|DEVICE|Edwards PASCAL Transcatheter Valve Repair System|Repair of the tricuspid valve through a transcatheter approach
223939681|NCT04567784|DRUG|Cannabidiol (CBD)|CBD 800 mg Cannabidiol - oral CBD solution
223939682|NCT04567784|DRUG|Placebo|inactive solution
223939683|NCT02748408|DEVICE|SMS femoral stem|
223939684|NCT05460676|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
223939685|NCT05460676|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
224099089|NCT02486068|DEVICE|Xience|
224099090|NCT03560440|OTHER|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
224099091|NCT00388089|DRUG|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
224099092|NCT00388089|DRUG|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
224099093|NCT00388089|OTHER|flow cytometry|No description
224099094|NCT00388089|OTHER|immunoenzyme technique|No description
224099095|NCT00388089|OTHER|immunohistochemistry staining method|No description
224099096|NCT00388089|OTHER|laboratory biomarker analysis|No description
224099097|NCT05080829|DIAGNOSTIC_TEST|Myeloid mutations measurement|Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done
224099098|NCT01587963|DRUG|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
224099099|NCT01587963|OTHER|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
224099100|NCT00430040|DRUG|Carvedilol Controlled Release (CR)|"lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80"
224099101|NCT00430040|DRUG|lisinopril|lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
224099102|NCT00679107|DEVICE|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
223939686|NCT05460676|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
223939687|NCT04753190|BEHAVIORAL|Baseline Sleep Satiation and Phase Stabilization|All participants will be assigned a 9-h sleep opportunity for the first week of the 2-week study. This will ensure that adolescents are not sleep restricted before living in the laboratory during the second week of the study. The 9-h sleep schedule will be individually timed from his/her averaged wake time (± 15 mins) before the study begins. Assigned bedtime will be 9 h before wake.
223939688|NCT04753190|BEHAVIORAL|Gradually Shifted Sleep|For all participants, their assigned baseline sleep/wake schedule will gradually shift earlier over 3 days in the laboratory to facilitate the phase advance shift of the circadian system.
223939689|NCT06852664|BEHAVIORAL|Motivational Interviewing|The participants will meet with the research staff three times a week during the eight weeks of wearing the activity monitor via video or Webex call with a duration ideally not exceeding one hour. All staff involved in these coaching sessions have been MINT trained and certified and have mastered the skills of motivational interviewing. Their goal will be to discuss with the participant about how successful they have been or not been in increasing their daily step count and movement and discussing the barriers preventing them from achieving that goal. Open-ended questions, affirmations, reflections, summaries, balancing change and sustain talk, and eliciting change behavior will all be used accordingly during the sessions. Coaching is tied to the overall results in investigating if motivational interviewing and coaching are effective in increasing movement in populations with cerebral palsy.
223939690|NCT03901755|DRUG|Alprolix|Extended half-life factor IX product
223939691|NCT05154851|BIOLOGICAL|HB-adMSCs|HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) is manufactured by Hope Biosciences, L.L.C., a biotechnology company headquartered in Sugar Land, Texas.
223939692|NCT04248322|BEHAVIORAL|Semi-structured interview|Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
224099103|NCT00825071|DRUG|Dexamethasone|8 mg, Intravenous
224099104|NCT00825071|DRUG|Ondansetron|4 mg, intravenously
224099105|NCT00825071|DRUG|normal saline|2 ml, intravenously
224099106|NCT06001580|DRUG|BR101|BR101 injection was administered once for 28 days observation period and then weekly until the subject experienced unacceptable toxicity, disease progression, poor compliance, pregnancy, informed withdrawal, death, study interruption, and withdrawal from the study
224287141|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
223939693|NCT06557850|DRUG|Lu AG22515|Solution for infusion
223939694|NCT05988645|DEVICE|MiWEndo System|"All colonoscopies will be performed with high-definition technology. The MiWEndo System will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System. The MiWEndo Analyzer will be managed by the assistant.~At the beginning of the extubation, the MiWEndo System will be turned on and the endoscopist will put music headphones on (blind to the results of MiWEndo).~In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
223939695|NCT05516992|DRUG|SB-01 For Injection|Intradiscal injection
223939696|NCT05516992|DRUG|Sham Needle|Sham needle placement
223939697|NCT03887936|DRUG|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
223939698|NCT03887936|DRUG|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
223939699|NCT04235777|RADIATION|Stereotactic body radiation therapy (SBRT)|A fixed dose of 8 Gy x 3 fractions sequential or concurrent with M7824 and PDS01ADC
223939700|NCT04235777|DRUG|PDS01ADC|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks while on M7824 and with or without SBRT
223939701|NCT04235777|DRUG|M7824|1200 mg administered IV every two weeks while on PDS01ADC and with or without SBRT
223939702|NCT05208567|DIAGNOSTIC_TEST|Echocardiogram|Cardiac Ultrasound Scan - using an abbreviated protocol
223939703|NCT06188910|OTHER|Neurofeedback|Conducting neurofeedback sessions guided by a researcher
224099107|NCT01358110|OTHER|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
224099108|NCT01358110|OTHER|Care as usual|Standard care as usual which may or may not include palliative care consultation
224099109|NCT00583401|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
224099110|NCT01175928|DEVICE|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
223939704|NCT06188910|OTHER|Health education|Health education on mobile phone addiction
223939705|NCT03945721|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
223939706|NCT03945721|RADIATION|Radiation Therapy|radiation therapy
224287142|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 4, and 5. Finally, they will receive text messages or emails with the core message of the modules."
224287143|NCT05235659|BEHAVIORAL|"Basic modules and experimental module Watch out!"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior."
224287144|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Professional support of the caregiver will be provided. Caregivers will receive two phone calls (each 50 minutes) to support processing of information from module 1, 2, and 3. Finally, they will receive text messages or emails with the core message of the modules."
224287145|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
223939707|NCT05963984|DRUG|Samuraciclib|Samuraciclib tablet by mouth once a day
223939708|NCT05963984|DRUG|Fulvestrant|Injection administered monthly (i.e., every 4 weeks), plus additional dose at Cycle 1 Day 15
223939709|NCT06564194|BIOLOGICAL|JCXH-108|IM injection
223939710|NCT06564194|OTHER|Placebo|IM injection
223939711|NCT04239989|DRUG|Itacitinib|Given PO
223939712|NCT04239989|DRUG|Itacitinib Adipate|Given PO
223939713|NCT06413498|DRUG|Anitocabtagene Autoleucel|A single infusion of CAR+ transduced autologous T cells
223939714|NCT06413498|DRUG|Cyclophosphamide|Administered intravenously
224099111|NCT01175928|DEVICE|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
224099112|NCT02514538|DRUG|Non- effervescent Paracetamol kern|1g
224099113|NCT02514538|DRUG|Effervescent paracetamol termalgin|1 g
224099114|NCT02189382|DEVICE|Potassium Oxalate|
224099115|NCT02189382|OTHER|Water|
223939715|NCT06413498|DRUG|Fludarabine|Administered intravenously
223939716|NCT06413498|DRUG|Pomalidomide|Tablet administered orally
223939717|NCT06413498|DRUG|Bortezomib|Administered intravenously or subcutaneously
223939718|NCT06413498|DRUG|Dexamethasone|Tablet administered orally
223939719|NCT06413498|DRUG|Daratumumab|Administered intravenously or subcutaneously
223939720|NCT06413498|DRUG|Carfilzomib|Administered intravenously
223939721|NCT06569082|DEVICE|CD34+ Selected Donor Cell Boost|The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.
223939722|NCT06569082|PROCEDURE|Blood Stem Cell Infusion|The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
224099116|NCT03868722|DRUG|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
224099117|NCT03868722|DRUG|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
224099118|NCT01351662|BEHAVIORAL|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
223939723|NCT06062628|DRUG|Ketamine Hydrochloride|Administration of ketamine with subsequent measurement of intracranial pressure and brain tissue oxygenation
223939724|NCT05237960|PROCEDURE|Biopsy|Undergo biopsy
224099119|NCT03016234|DRUG|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
224099120|NCT03016234|DRUG|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
224099121|NCT01756157|BIOLOGICAL|CINRYZE with rHuPH20|
224287146|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 5. Finally, they will receive text messages or emails with the core message of the modules."
224287147|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out! and You are safe here"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers."
223718980|NCT04635462|OTHER|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
223718981|NCT04635462|OTHER|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
223718982|NCT02554500|PROCEDURE|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
223939725|NCT05237960|PROCEDURE|Biospecimen Collection|Correlative studies
223939726|NCT05237960|DRUG|Extended Release Metformin Hydrochloride|Given PO
223939727|NCT05237960|DRUG|Placebo Administration|Given PO
223939728|NCT04706429|DRUG|Trientine|Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
223939729|NCT04706429|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
223939730|NCT04929795|BEHAVIORAL|Rhythmic auditory stimulation (RAS)|"The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions."
223718983|NCT01352910|DEVICE|rTMS|120 pulses 0.2 Hz
223718984|NCT01352910|DEVICE|Sham rTMS|120 pulses 0.2 Hz
223534752|NCT05245903|DEVICE|Emerald Device Monitoring|The study participants will have the Emerald device deployed in their home for up to 12 weeks as they participate in the parent study (ClinicalTrials.gov identifier NCT04430517). The device will be deployed in the bedroom of each subject to capture behavior continuously. The Emerald device is a radio-wave sensor that will use signal processing and machine learning algorithms to track the gait, movement, respiration, and sleep of these subjects via low-powered radio signals. Reflections of the radio signals are processed using algorithms to convert them into movement data, sleep stages, and key sleep parameters. These data will supplement bioenergetic, imaging, and biochemical data with digital biomarkers and phenotyping using this device.
223534753|NCT00806585|DRUG|MK-0736|
223534754|NCT00806585|DRUG|Comparator: Placebo|
223534755|NCT00806585|DRUG|Comparator: HCTZ|
223534756|NCT04345055|OTHER|Treatment of the lumbar fasciae|Treat the lumbar facial with a manual technique
223534757|NCT04345055|OTHER|Placebo intervention|Introduce in a machine off
223534758|NCT03985735|DRUG|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
223534759|NCT00474903|DRUG|acetylsalicylic acid|Given orally
223534760|NCT00474903|DRUG|esomeprazole magnesium|Given orally
223534761|NCT00474903|OTHER|placebo|Given orally
223534762|NCT04863742|DRUG|Dextenza 0.4Mg Ophthalmic Insert|sustained released dexamethasone, 0.4mg
223534763|NCT04863742|DRUG|Prednisolone Acetate|Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.
223939731|NCT04929795|BEHAVIORAL|no RAS|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
223939732|NCT05878717|BIOLOGICAL|Belimumab|Belimumab will be administered.
223939733|NCT05878717|OTHER|Placebo|.Placebo will be administered.
223939734|NCT04270734|PROCEDURE|EEG|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Resolution Electroencephalography will be performed
224099122|NCT02812680|OTHER|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
224099123|NCT02308280|DRUG|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
224099124|NCT00267241|OTHER|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
223534764|NCT02847403|DRUG|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
223534765|NCT02847403|OTHER|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
223534766|NCT02599116|OTHER|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
223534767|NCT02599116|OTHER|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
223534768|NCT04843280|PROCEDURE|FORCE therapeutics (physical therapy)|6 weeks of internet based physical therapy following arthroscopic knee surgery
223534769|NCT04843280|PROCEDURE|Traditional Outpatient Physical Therapy|6 weeks of outpatient physical therapy following arthroscopic knee surgery
223534770|NCT00399529|BIOLOGICAL|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
223534771|NCT00399529|DRUG|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
223718985|NCT01699906|OTHER|Diet regimen to induce weight loss|Diet regimen to induce weight loss
223939735|NCT04270734|PROCEDURE|NIRS|Response of the cortical network in premature aged between 25 and 36 wGA in response to auditory stimuli using High Density Near Infrared Spectroscopy will be performed
223939736|NCT06370988|DEVICE|iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
223939737|NCT06370988|DEVICE|Sham iTBS Stimulation|Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30
223939738|NCT01226316|DRUG|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
223939739|NCT01226316|DRUG|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
223939740|NCT01226316|DRUG|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
223939741|NCT01226316|DRUG|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
224099125|NCT00181298|DRUG|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
223939742|NCT02227134|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
223939743|NCT04968587|PROCEDURE|Sustained Low-Efficiency Dialysis|All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional anticoagulation with Citrate or Regional anticoagulation by Decalcification without Citrate
223939744|NCT05052099|DRUG|mFOLFOX6, Atezolizumab and Bevacizumab|"All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg"
223939745|NCT04785950|DRUG|Low-dose levonorgestrel intrauterine systems (LNG-IUS)|Any low-dose intrauterine system (IUS) marketed in Spain
223939746|NCT01367236|DRUG|standard care|"* atazanavir 300 mg daily~* ritonavir 100 mg daily~* tenofovir 245 mg daily\*~* emtricitabine 200 mg daily\*"
224099126|NCT00181298|DRUG|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
224287148|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Professional support of the caregiver will be provided. Caregivers will receive three phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, and 4. Finally, they will receive text messages or emails with the core message of the modules."
224287149|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, and Who am I and where do I belong?"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation of caregiver and child. Caregivers will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Caregivers will have access to module 4 You are safe here to improve children´s relationship-related safety and facilitate solid relationships with family and peers. Caregivers will have access to the module 5 Who am I and where do I belong? This module will support caregivers in helping their child developing an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers."
224287150|NCT05235659|BEHAVIORAL|"Basic modules and experimental modules Watch out!, You are safe here, Who am I and where do I belong?, and My coach"|"Caregivers will have access to the two basic modules (1\&2) in order to increase knowledge on parental self-care and facilitating the self-worth of the child as well as emotional regulation. They will have access to module 3 Watch out! on improving children´s relationship-related risk detection and self-protective behavior. Further access will be provided to module 4 You are safe here on improving children´s relationship-related safety and facilitating solid relationships. Access to module 5 Who am I and where do I belong? will support caregivers in helping their child develop an identity of their choice, while providing the freedom to consider potential contributing influences of the family of origin, foster family, and peers. Professional support will be provided. They will receive four phone calls (each 50 minutes) to support processing of information from module 1, 2, 3, 4, and 5. Text messages or emails with the core message of the modules will be provided."
224287151|NCT05262192|OTHER|nutrition education|Nutrition education will be given to the patients in the experimental group.
224287152|NCT01909128|DIETARY_SUPPLEMENT|fermented milk|fermented milk with Lactobacillus CBA-L74
223939747|NCT01367236|DRUG|novel treatment|"* darunavir 800 mg daily~* ritonavir 100 mg daily~* lamivudine 300 mg daily\*\* and abacavir 600mgs daily\*\*~* maraviroc 150 mg once daily"
223939748|NCT04008316|DRUG|Colchicine|colchicine 1mg/day
223939749|NCT05536141|DRUG|casdatifan|Administered as specified in the treatment arm
223939750|NCT05536141|DRUG|Cabozantinib|Administered as specified in the treatment arm
223939751|NCT05536141|DRUG|Zimberelimab|Administered as specified in the treatment arm
223939752|NCT00406887|DRUG|Difluprednate Ophthalmic Emulsion|
223939753|NCT03637296|OTHER|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
223939754|NCT03134300|DIAGNOSTIC_TEST|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
223939755|NCT05639010|DEVICE|regular hemodialysis|Routine blood purification therapy (including hemodialysis, hemofiltration) 3 times a week
223939756|NCT05639010|DEVICE|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once a week. The hemoperfusion apparatus will use type KHA80 hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
223939757|NCT03074656|OTHER|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
224099127|NCT03388970|DRUG|Vitamin K 1|Research group use Vitamin K1
224099128|NCT03388970|DRUG|normal saline|Placebo group use normal saline
224099129|NCT03103399|DRUG|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
224099130|NCT03103399|DRUG|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
223534772|NCT00399529|DRUG|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
223534773|NCT04457024|OTHER|classification statistics|Without any intervention
223534774|NCT01936831|DRUG|Isoniazid|INH was available in 100 mg tablets. INH was administered orally daily in the morning on an empty stomach. Doses of INH were given according to the weight bands and by cohort.
223534775|NCT01936831|DIETARY_SUPPLEMENT|Vitamin B6|Vitamin B6 was administered at \>= 25 mg daily and was obtained locally for use by study participants.
223718986|NCT03280498|PROCEDURE|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
223718987|NCT04637230|DIAGNOSTIC_TEST|Electrocardiogram analysis by Artificial Intelligence|1-channel electrocardiograms are collected to train an Artificial Intelligence in the automatic diagnosis of regular and irregular heart rhythms
223718988|NCT02412605|PROCEDURE|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
224287153|NCT01909128|DIETARY_SUPPLEMENT|fermented rice|fermented rice wit Lactobacillus CBA-L74
224287154|NCT04714151|DRUG|K-877 ER 0.2 mg/day (once daily)|K-877 ER 0.2 mg tablet
224287155|NCT04714151|DRUG|K-877 ER 0.4 mg/day (once daily)|K-877 ER 0.4 mg tablet
224287156|NCT04714151|DRUG|K-877 IR 0.2 mg/day (twice daily)|K-877 IR 0.1 mg tablet
224287157|NCT00078507|BEHAVIORAL|Sensory Re-training|
224287158|NCT00078507|BEHAVIORAL|Sensory Retraining|Facial Exercises
224287159|NCT00078507|BEHAVIORAL|Opening Exercises|
224287160|NCT03135652|RADIATION|adjuvant SBRT|adjuvant SBRT of liver lesions
224287161|NCT03135652|DRUG|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
224287162|NCT05814991|DRUG|Nitroglycerin solution|Controlled hypotension will be induced (intravenous administration of nitroglycerin 2-10 µg/kg/min) 15 minutes prior to the start of mucosal detachment, and will be sustained for the osteotomy stage.
224287163|NCT05814991|DEVICE|monitoring of cerebral oxygen saturation|NIRS-based monitoring of rSO2 has unique advantages: directly or indirectly detecting physiological changes and metabolic processes, it is easy to realize, and involves simple procedures.
224287164|NCT04079491|OTHER|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
224287165|NCT02356991|DRUG|Famitinib|
224287166|NCT02356991|DRUG|Placebo|
224287167|NCT03417791|OTHER|no intervention|no intervention
224287168|NCT04965389|DRUG|BMS-986177 Oral Solution|Specified dose on specified days
224287169|NCT04965389|DRUG|[14C]BMS-986177 Solution for Infusion|Specified dose on specified days
224287170|NCT04965389|DRUG|BMS-986177 Spray-dried Dispersion Capsules|Specified dose on specified days
224287171|NCT01872702|DRUG|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
224287172|NCT02562417|DRUG|Normal saline|
224287173|NCT02562417|DRUG|IV dexamethasone|
224287174|NCT03060759|DEVICE|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
224287175|NCT03903159|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
224287176|NCT02443545|DRUG|Deferiprone|
224287177|NCT02401477|DRUG|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
224287178|NCT00724373|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
224287179|NCT00724373|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
224287180|NCT03589248|DIAGNOSTIC_TEST|GIF score|assessment by GIF score
224287181|NCT03589248|DIAGNOSTIC_TEST|US score|assessment by ultrasonography score
224287182|NCT03041168|DEVICE|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
224287183|NCT00553592|DRUG|Bicifadine|600mg/day
224287184|NCT00553592|DRUG|Bicifadine|placebo tablet
224287185|NCT00553592|DRUG|Bicifadine|1200 mg
224287186|NCT03399240|DEVICE|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
224287187|NCT01923584|DRUG|EPI-743 400mg|
224287188|NCT01923584|DRUG|EPI-743 200mg|
224287189|NCT05037786|BEHAVIORAL|Infographic|Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
224287190|NCT05037786|BEHAVIORAL|Powerpoint|Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
224287191|NCT03821363|BIOLOGICAL|SCT-I10A|Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
223939758|NCT03074656|OTHER|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
223939759|NCT00845364|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
223939760|NCT00845364|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
223939761|NCT02463994|DRUG|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
224287192|NCT00536484|DRUG|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
224287193|NCT00536484|DRUG|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
223718989|NCT05374369|DIAGNOSTIC_TEST|SDC2 Gene Methylation Test and Q-FIT Test|Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test
223718990|NCT05374369|PROCEDURE|Colonoscopy and/or pathological examination|Subjects underwent colonoscopy and/or pathological examination.
223939762|NCT02463994|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
223939763|NCT03784105|DRUG|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
223939764|NCT03784105|DRUG|Siripus simplex|Sugar syrup
223939765|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
223939766|NCT04041219|DRUG|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses
223939767|NCT00000127|PROCEDURE|Optic Nerve Sheath Decompression Surgery|
223939768|NCT03058757|DRUG|intravesical mitomycin-C 40mg/20ml instillation|"neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery"
224287194|NCT05616403|OTHER|No intervention|This is an observational study without any intervention
224287195|NCT02303314|DRUG|Trigonella Foenum-graecum Seed Extract|
224287196|NCT02303314|DRUG|Drug: Placebo|
224099131|NCT03103399|DRUG|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
224287197|NCT01653795|DEVICE|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
224287198|NCT01653795|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
223718991|NCT02900196|OTHER|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
223939769|NCT02940249|DIETARY_SUPPLEMENT|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
223939770|NCT02940249|DIETARY_SUPPLEMENT|Placebo|
223939771|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Electrostimulation+Kegel|Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)
223939772|NCT05026970|DEVICE|Biofeedback+Tibial Neuromodulation+Kegel|Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)
223939773|NCT05026970|COMBINATION_PRODUCT|Biofeedback+Kegel|Biofeedback+Kegel exercises
223939774|NCT07039916|DRUG|IMVT-1402|• Dose 1 subcutaneous (SC) once weekly (QW) for 12 weeks (Period 1)
223939775|NCT07039916|DRUG|IMVT-1402|"* Dose 2 SC QW for 12 weeks (Period 1)~* Dose 2 SC QW for 14 weeks (Period 2)"
223939776|NCT07039916|DRUG|Placebo|• Placebo SC QW for 12 weeks (Period 1)
223939777|NCT07039916|DRUG|IMVT-1402|• Dose 1 SC QW for 14 weeks (Period 2)
223939778|NCT06881602|PROCEDURE|Remote clinical monitoring|Patients after a distal pancreatectomy will be discharged faster from the hospital and will be remote monitored
223939779|NCT07036874|DIAGNOSTIC_TEST|transient elastography and oesophagogastroduodenoscopy|Liver and spleen stiffness will be measured by transient elastography. Varices will be identified by oesophagogastroduodenoscopy.
223939780|NCT05785832|DEVICE|t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM|The t:slim X2 insulin pump with Control-IQ+ technology, used with the Dexcom G6 CGM.
223939781|NCT05785832|DEVICE|Standard Therapy plus continuous glucose monitoring (CGM)|Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.
223939782|NCT07043283|DRUG|Ebronucimab|Ebronucimab subcutaneous injection.
223939783|NCT07042698|OTHER|Glomerular Filtration Rate measurement with iohexol clearance|After performing a 4-phase CT urography (or 3-phase CT scan, with the addition of a 4th phase for research purposes), performed for clinical indications as part of the patient's care, and using iohexol as a contrast agent, patients will undergo a biological measurement of iohexol clearance, based on serum and urine samples taken over 4 periods of 1 hour, between 3 and 7 hours after the CT scan. No iohexol will be reinjected to measure GFR. The CT scan images will be segmented by the investigator to determine the CT-measured GFR.
223939784|NCT07041164|DIAGNOSTIC_TEST|Bitewing radiograph|Digital radiograph, proximal caries, initial caries
223939785|NCT07041164|DIAGNOSTIC_TEST|Near-infrared light transillumination|DIAGNOcam, proximal caries, initial caries
223939786|NCT07050563|DRUG|Compound Ciwujia Granules|In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, Compound Ciwujia Granules were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.
224287199|NCT01506908|DRUG|oral nicotine|oral nicotine replacement product
224287200|NCT01506908|DRUG|Placebo|no active
224287201|NCT06331117|DIAGNOSTIC_TEST|Diagnostic test|Multiomics profiling
223939787|NCT07050563|DRUG|Placebo granules|In addition to standard treatment protocol for ovarian cancer combined with psychological intervention, placebo granules which containing 10% of Compound Ciwujia Granules drug were administered at a dosage of one sachet twice daily for a treatment duration of 3 months.
223939788|NCT07050563|COMBINATION_PRODUCT|Standard treatment protocol for ovarian cancer combined with psychological intervention.|Standard treatment protocol for ovarian cancer: In accordance with the 2024 NCCN International Guidelines, patients opt for chemotherapy regimens containing platinum-based drugs and/or targeted therapy, anti-angiogenic therapy, hormonal therapy, etc. Psychological intervention is conducted once a week in the form of online and offline patient education sessions for psychological intervention, continuing until the end of the study period. Both the intervention group and the control group use this as the baseline treatment plan.
223939789|NCT07051148|BEHAVIORAL|UJI Online Transdiagnostic Protocol|Is a manualized treatment for emotional disorders delivered through an interactive multimedia platform. The self applied format consists of 12 self applied modules (psychoeducation, emotional processing, cognitive flexibility training, exposure, coping strategies, maladaptive behaviors, avoidance, etc)
223939790|NCT07051148|BEHAVIORAL|UJI On Line Transdiagnostic Hibrid Protocol|Hybrid format: 12 self applied modules with two synchronous sessions with a trained therapist
223939791|NCT06733675|DRUG|Ledaborbactam etzadroxil|capsules
224099132|NCT03103399|DRUG|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
224099133|NCT02638181|PROCEDURE|trabeculectomy|
224099134|NCT01623466|DRUG|levonorgestrel|transdermal contraceptive delivery system
224099135|NCT01701700|PROCEDURE|portable electronic magnifier|
224099136|NCT01701700|PROCEDURE|optical aids|
224287202|NCT03749954|DIAGNOSTIC_TEST|Detachable string magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
224287203|NCT02155374|DRUG|Sliding scale insulin|
224287204|NCT02155374|DRUG|Intermediate acting insulin|
223941435|NCT02481466|BEHAVIORAL|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
223941436|NCT02481466|BEHAVIORAL|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
223941437|NCT06666543|OTHER|Questionary|"The questionnaire will address the following topics for each child who is not infected with HIV and was born to an infected mother at the time of birth:~* Pregnancy progression~* Immediate postpartum course~* Medical development of the child from 0 to 3 years~* Medical development of the child from 3 to a maximum of 15 years"
223941438|NCT02223923|DRUG|AZD6738|
223941439|NCT02223923|RADIATION|Palliative radiotherapy|
223941440|NCT03685071|OTHER|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~* patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~* correlation between the outcome and CBC will be done."
223941441|NCT05519852|BEHAVIORAL|Pilates training|the pilates group (20 patients) will be trained 30 minutes of pilates exercise (before it there will be warm up period and after it there will be cooldown period , each will be 5 minutes). the pilates will be repeated five sessions per the week for 3 months
223941442|NCT05950672|BEHAVIORAL|CAT Intervention Group|The experimental group will take part in the CAT intervention after baseline assessments. All cat-training methods will be positive reinforcement based, using owner-approved food, toys and social reinforcers (e.g. petting).
223941443|NCT04927494|BEHAVIORAL|Health is Wealth: A Cervical Health Program|Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
223941444|NCT06602999|OTHER|Nutritional Intervention|Receive a booklet on nutrition and physical activity for cancer survivors
223941445|NCT06602999|OTHER|Instacart Voucher|Receive Instacart grocery delivery voucher
223941446|NCT06602999|BEHAVIORAL|Telephone-Based Intervention|Receive nutrition navigation phone calls
223941447|NCT06841289|COMBINATION_PRODUCT|Pediatric Invasive Pictorial Shield (PIPS)|It is a device used to distract children during clinical procedures (blood sampling, invasive procedures, etc.) by making them feel less pain, stress and fear. It is an 18x15 cm 3D printed device designed to be worn around the upper arm, above the elbow, and used to hide the procedure from view and attract the child's attention with stickers printed on one side. The device is fixed on the child's arm by means of a tourniquet that can be interchangeably attached. The child asked questions about the pictures related to the stickers to distract his/her attention from the procedure. While answering these questions, the child will not see the procedures and will pay attention to the pictures, while the procedural procedure (such as blood sampling, intravenous intervention) will be performed. For the children in this group, the pain, fear will be scored 1 minute before, during and 1 minute after the blood collection procedure.
223941448|NCT06841289|BEHAVIORAL|Distraction cards|Distraction cards consist of picture cards with various hidden pictures and patterns. These hidden pictures and patterns can only seen by the child if he/she looks carefully. During the procedure, the child is expected to focus on the cards and answerabout the pictures and shapes on the cards. In this study, 5X8 cm cards with various pictures and shapes will be used.
223941449|NCT06841172|RADIATION|radiotherapy|Radiotherapy (Biologically Equivalent Dose \[BED\]≥60Gy)
223941450|NCT06841172|DRUG|Systemic therapy (Continuation of current first-line systemic therapy)|Continuation of current first-line systemic therapy, which may include, but is not limited to, combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at the discretion of the treating physician.
224122617|NCT04438746|BEHAVIORAL|Emotion discussion|General discussion of emotions; no therapy or training is offered
224122618|NCT04438746|BEHAVIORAL|Cognitive Behavioral Affective Therapy|Active training in regulating anger
223941451|NCT06841172|DRUG|Systemic therapy (Early switch to second-line systemic therapy)|For patients who received sorafenib as FLST, regorafenib will be the preferred second-line option. For patients who received other FLST regimens, the SLST selection will be determined through an MDT discussion led by the treating physician based on the patient's overall condition, prior therapies, drug indications, and potential adverse effects, ensuring an individualized treatment approach. The specific dosing regimen, administration frequency, and dose adjustments will strictly follow the same prescribing information for each drug.
223941452|NCT06842121|DRUG|Sodium Glycerophosphate Injection|Organic phosphate (SGP) will be diluted with 500mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 60 mmol over 4 hours (h)
223941453|NCT06842121|DRUG|Sodium Phosphates Injection|Inorganic phosphate (NaP) will be diluted with 500mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 60 mmol over 4 h
223941454|NCT03620500|BEHAVIORAL|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
223941455|NCT06515301|BEHAVIORAL|Intervention 1: Structured nurse-led telephone call reminders. Intervention 2: Home-visit reminders by health extension workers. Intervention 3: Application-based automated SMS text reminders.|Information already available
223941456|NCT05678231|DEVICE|Zero Degree Knee Positioner|The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
223941457|NCT06609187|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
223941458|NCT07015619|OTHER|Task Specific Balance Training|Group A participants will undergo Task Specific Balance Training. It is a rehabilitation approach that focus on improving balance by practicing specific balance related tasks.
223941459|NCT07015619|OTHER|Task-oriented Basketball Training|Group B participants will undergo Task-oriented Basketball Training. It is a rehabilitation approach that focuses on balance, coordination and gross motor skills through specific basketball related tasks.
223941460|NCT07012564|DIETARY_SUPPLEMENT|Vitamin C|1000 mg oral vitamin C tablet taken daily from one day before surgery to postoperative day 7.
223941461|NCT07012564|OTHER|Placebo|Identical-appearing oral tablet taken on the same schedule as the vitamin C group.
223941462|NCT07009782|PROCEDURE|QIP block|The Quadroiliac Plane (QIP) block is a novel ultrasound-guided fascial plane block. In this study, it will be performed postoperatively under spinal anesthesia in the prone position. A low-frequency convex transducer will be used to visualize the quadratus lumborum muscle at its attachment to the inner iliac crest. Using an in-plane technique with a 22G x 100 mm needle, 40 mL of 0.25% bupivacaine will be injected into the fascial plane beneath the quadratus lumborum muscle. The block will be performed unilaterally on the surgical side. The aim is to provide postoperative analgesia in patients undergoing femur fracture surgery.
223941463|NCT03936478|RADIATION|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
223941464|NCT07012824|BEHAVIORAL|Crisis Response Planning|Crisis Response Planning (CRP) is a brief, one-time intervention that teaches individuals to notice warning signs of an impending crisis (e.g., suicidal crisis) and provide them with skills to help reduce suicide risk.
223941465|NCT07012824|BEHAVIORAL|Couples-based Crisis Response Planning|This intervention expands on traditional CRP by integrating the intimate partner into the intervention. Among service members, intimate partners are the group most likely to be told about suicidal thoughts prior to a suicide attempt.
223941466|NCT07016399|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223941467|NCT07016399|PROCEDURE|Breast Biopsy Procedure|Undergo breast biopsies
223941468|NCT07016399|DRUG|Carboplatin|Given IV
223941469|NCT07016399|DRUG|Cyclophosphamide|Given IV
223941470|NCT07016399|DRUG|Darolutamide|Given PO
223941471|NCT07016399|DRUG|Doxorubicin|Given IV
223941472|NCT07016399|DRUG|Epirubicin|Given IV
223941473|NCT07016399|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223941474|NCT07016399|DRUG|Paclitaxel|Given IV
223941475|NCT07016399|BIOLOGICAL|Pembrolizumab|Given IV
223941476|NCT07016399|PROCEDURE|Surgical Procedure|Undergo breast surgery
223941477|NCT07016399|PROCEDURE|Ultrasound Imaging|Undergo US
223941478|NCT07011953|DRUG|Antipsychotics plus Levothyroxine Sodium|Maintain the original antipsychotic regimen combined with levothyroxine sodium tablets (Euthyrox), 50 μg/day for 8 weeks. Manufacturer: Merck Serono Ltd. Levothyroxine Sodium Tablets should be administered as a single daily dose on an empty stomach, 30 minutes before breakfast, with sufficient liquid (e.g., half a glass of water).
223941479|NCT07011953|DRUG|Antipsychotics plus Placebo|"All participants maintain pre-study antipsychotic medication at stable doses. ADDITIONALLY, they receive a visually identical placebo tablet.~Placebo characteristics \& Blinding guaranteet: Matches levothyroxine in appearance (size/color/coating), taste, and packaging.~Active ingredien : starch tablet with no biological activity. Administration: Once daily in the morning under identical fasting conditions."
223941480|NCT05366751|DRUG|SAGE-324|SAGE-324 oral tablets
223941481|NCT04894591|DRUG|Zepzelca|Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.
223941482|NCT06697106|DRUG|Nonsteroidal anti-inflammatory drugs|Patients will undergo direct vision internal urethrotomy (DVIU) plus nonsteroidal anti-inflammatory drugs (NSAID) for 3 weeks.
223941483|NCT06697106|DRUG|Placebo|Patients will undergo direct vision internal urethrotomy (DVIU) plus a placebo for 3 weeks.
223941484|NCT06699784|BEHAVIORAL|Progressive lenses intervention|Progressive lenses intervention group will receive 1-month progressive lens correction in daily life.
223941485|NCT06699784|BEHAVIORAL|Single-vision lenses intervention|Single-vision lenses intervention group will use near-vision spectacles during near work and use their original habitual distant glasses for distance tasks for 1 month.
223941486|NCT04884035|DRUG|CC-220|CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
223941487|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
223941488|NCT04884035|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
223941489|NCT04884035|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
223941490|NCT04884035|DRUG|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
223941491|NCT04884035|DRUG|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
223941492|NCT04884035|DRUG|CC-99282|CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
223941493|NCT04884035|DRUG|Polatuzumab vedotin|Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
223941494|NCT04884035|DRUG|Rituximab|Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
223941495|NCT07029035|BIOLOGICAL|İnjectable platelet-rich fibrin|Repeated application of I-PRF to the periodontal pockets in the test sites was performed twice: once immediately following scaling and root planing (SRP), and once at the third week.
223941496|NCT07029035|OTHER|Sterile saline (0.9%)|Control sites received a sham intervention consisting of sterile saline solution irrigation into the periodontal pockets, to mimic the procedural aspects of PRF placement without delivering any biologically active material.
223941497|NCT07028632|BIOLOGICAL|Human Dopaminergic Progenitor Cells|Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.
223941498|NCT07022106|OTHER|Myofascial Release Therapy (MRT) Group|"Myofascial Release Therapy (MRT) involves hands-on palpation to detect fascial restrictions, followed by 60-90 seconds of sustained pressure to release tension. In the supine position, the target areas include the superficial fascia, transversalis fascia, and extraperitoneal fascia, while in the prone position, the focus shifts to the thoracolumbar fascia and the erector spinae complex. This technique aims to restore mobility and reduce restrictions within the fascial system.~Frequency: Each patient will recieve a single session at their most painful day from this intervention."
223941499|NCT07022106|OTHER|Kinesiotape (KT) Group|"Kinesio Taping (KT) Intervention~Description:~Participants will receive a standardized 3-tape sensory modulation technique using Kinesiotape, applied to the abdomen and sacrum to target fascial tension and visceral pain in primary dysmenorrhea.~Procedure:~Abdominal Application (Two Tapes, 0% Stretch):~Horizontal Tape: Placed between the iliac crests (lower abdomen) to reduce fascial tension.~Vertical Tape: Applied from the navel to the pubic symphysis to modulate visceral pain signaling.~Sacral Application (One Tape, 15-25% Stretch):~Horizontal Tape: Anchored across the S2-S4 vertebrae (at PSIS level) to activate the pain-gating mechanism via cutaneous-visceral reflexes.~Frequency/Duration:~Each participant will receive a single session at their most painful day from this intervention"
223941500|NCT07036744|BEHAVIORAL|MIND-over-MIRROR|An eight session (plus one follow-up booster session) on Acceptance and Commitment Therapy (ACT) with compassion developed specifically for BDD, in a group setting and applied remotely or in hybrid format.
223941501|NCT07043517|OTHER|RDC/TMD|TMJ functions were assessed using the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).
223941502|NCT07042750|OTHER|Eccentric cycling exercise|Patients perform eccentric cycling exercise instead of normal cycling exercise in addition to standard car during a cardiopulmonary rehabilitation
223941503|NCT07042750|OTHER|Standard Care Arm|Patients perform cardiopulmonary rehabilitation according to standard care
223941504|NCT07042581|DRUG|Revaree Plus|Revaree Plus is a hyaluronic acid vaginal suppository
223941505|NCT07043010|DEVICE|Near-Infrared Parathyroid Tissue Sensor Imaging (PTS)|FDA-cleared imager (e.g., Fluobeam LX/PTeye) providing real-time autofluorescence to identify parathyroid tissue during surgery; no dye or radiation.
223941506|NCT07043010|PROCEDURE|Rim-Preservation Technique|Surgical excision of adenoma while leaving the NIRAF-positive rim of normal parathyroid tissue in situ; minimal defatting to ensure perfusion.
223941507|NCT07043010|PROCEDURE|En-bloc Resection Technique|Surgical excision of adenoma together with the surrounding NIRAF-positive rim; autotransplant fragment if \< 2 normal glands remain in neck.
223941508|NCT07043413|DIAGNOSTIC_TEST|thrombus analysis|Detailed expression pattern of RNA and histological characteristics will be investigated.
223941509|NCT07044154|OTHER|Tai Chi (Sun Style)|The Sun Tai Chi intervention will be conducted by a Sun Tai Chi instructor with 7 years of teaching experience and will take place in an exercise room at the Catholic University of Maule. The intervention will last for 12 weeks, with a frequency of twice per week, and each class will last 60 minutes. Each session will begin with 10 minutes of warm-up exercises, followed by 20 minutes of basic Sun Tai Chi exercises, including lower limb movements, overall body mobility at a slow pace, precise movements of the hands and feet, and proper body alignment. This will be followed by 20 minutes of practice of the basic movement sequence of Sun Tai Chi (Taolú), and will conclude with 5 minutes of meditation and 5 minutes of relaxation exercises.
223941510|NCT07044154|BEHAVIORAL|Health lifestyle education|The control group will receive guidance on a healthy physical and mental lifestyle.
223941511|NCT07043439|OTHER|Mobilization|"Participants receiving this intervention will undergo Grade 3 joint mobilization targeting the first metatarsophalangeal (1st MTP) joint. The technique will be administered by a licensed physiotherapist with the participant lying in the prone position and the foot in a neutral position.~Mobilization will be performed according to the Maitland concept, which defines Grade 3 as large-amplitude, rhythmic oscillatory movements applied within the range of motion but up to the limit of tissue resistance, without entering the paraphysiological space.~The goal of this technique will be to increase joint play and mobility, reduce stiffness, and potentially improve biomechanical alignment. The mobilization will last approximately 5 minutes, and outcome measures will be collected before and immediately after the session."
223994356|NCT05974683|DRUG|mycophenolate mofetil|Use low dose mycophenolate mofetil (0.5g per day) as an add-on therapy of current basic maintenance treatment of IgG4-RD, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
223994357|NCT03229486|DRUG|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
224122619|NCT03186404|DRUG|Atorvastatin|Atorvastatin 40mg OD
224122620|NCT03186404|DRUG|Placebo oral tablet|Placebo
223941512|NCT07043439|OTHER|High-Velocity Low-Amplitude (HVLA) Manipulation|"This intervention will involve the application of a high-velocity, low-amplitude (HVLA) thrust manipulation to the first metatarsophalangeal (1st MTP) joint. A licensed physiotherapist will perform the procedure with the participant positioned prone and the foot placed in a neutral alignment.~The therapist will stabilize the 1st metatarsal bone with one hand and apply a quick, controlled thrust to the proximal phalanx of the hallux in a dorsal direction using the other hand. The technique will be delivered with minimal amplitude and maximal speed, aiming to restore joint motion, reduce soft tissue tension, and stimulate neuromechanical reflexes.~The manipulation procedure will take approximately 2-3 minutes, including setup and execution. Pre- and post-intervention outcome measures will be used to assess its immediate effects."
223941513|NCT07043439|OTHER|Sham Manipulation|"Participants in the control group will receive a sham (placebo) intervention designed to mimic the real treatment in setup and duration, without applying any therapeutic mechanical stimulus. The sham procedure will be conducted by the same physiotherapist with participants lying prone and their foot in a neutral position.~The physiotherapist will place their hands around the 1st MTP joint as if a manipulation were to be performed and will maintain static contact for the same duration as in the experimental group. However, no thrust, traction, or mobilization force will be applied.~The sham intervention will also last approximately 10 minutes, ensuring consistency across groups. All assessments will be conducted immediately before and after the intervention to evaluate potential placebo effects."
223941514|NCT06890208|OTHER|No intervention|No intervention
223941515|NCT07042308|DIAGNOSTIC_TEST|Transient elastography|Liver stiffness and spleen stiffness from transient elastography
223941516|NCT06737354|GENETIC|IVB103 Injection（Low dose）|Single intravitreal injection
223941517|NCT06737354|GENETIC|IVB103 Injection（Intermediate dose）|Single intravitreal injection
223941518|NCT06737354|GENETIC|IVB103 Injection（High dose）|Single intravitreal injection
223941519|NCT02136654|BEHAVIORAL|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
223941520|NCT02773225|DRUG|Eltrombopag|"* CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> partial or complete remission Eltrombopag and slow tapering of CSA~* 12 month after therapy start --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
223941521|NCT02773225|DRUG|Placebo (for Eltrombopag)|"* CSA + Placebo, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --\> dose escalation~* 12 month after start of eltrombopag --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment"
223941522|NCT06469554|BEHAVIORAL|MEP-only group|Participants in this group will receive a Multicomponent Exercise Program (MEP) consisting of: Supervised aerobic training on a stationary bike Progressive resistance/strength training using weight machines Balance training exercises The MEP sessions will be 30-40 minutes long and conducted over 4 consecutive days.
223941523|NCT06469554|BEHAVIORAL|MEP-VR group|"Participants in this group will receive the same MEP intervention as the MEP-only group.~Additionally, they will use an immersive virtual reality (IVR) system during the exercise program"
223941524|NCT06894498|OTHER|No Intervention: Observational Cohort|No Intervention, Observational Cohort
223941525|NCT06749119|PROCEDURE|Free gingival graft operation|Free gingival graft was harvested from palatal region and stabilized on the maxillary anterior recipient bed with sutures .
223941526|NCT06782009|OTHER|Calorie restriction|Participants will be provided with a food menu guide for fifteen days with a 30% energy restriction (kcal) according to their usual diet, with a macronutrient distribution of 20-30% protein, 50-60% carbohydrates and 20-30% fat.
223941527|NCT06782009|OTHER|Intermittent fasting 16/8|Participants will be provided with a food menu guide for fifteen days with an energy intake according to the energy expenditure determined by indirect calorimetry with normal distribution of macronutrients. Intermittent fasting will be used with a time-restricted model of 16:8. For 16 hours, they will not be able to eat or drink calories. In the other 8 hours, they need to adhere to the energy-restricted diet.
223941528|NCT06782009|OTHER|Ketogenic diet|Participants will be provided with a food menu guide for 15 days with an energy intake according to the energy expenditure determined by indirect calorimetry, with the following distribution of macronutrients: 20-25% protein, 5-10% carbohydrates, 70-80% fat.
223941529|NCT05381480|BEHAVIORAL|In-home Preventive Health Visits by Advanced Practice Nurse|Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
223941530|NCT05381480|BEHAVIORAL|On-site Evidence-based Physical Activity, Health and Wellness Classes|Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
223941531|NCT06751186|BEHAVIORAL|Teté Dance Guided Support|A culturally tailored behavioral intervention combining physical activity and community engagement to support breastfeeding practices.
223941532|NCT06066619|DIETARY_SUPPLEMENT|Cranberry Juice A|Cranberry juices will be provided by Ocean Spray Company.
223941533|NCT06066619|DIETARY_SUPPLEMENT|Cranberry Juice B|Cranberry juices will be provided from Ocean Spray Company.
223941534|NCT06066619|DIETARY_SUPPLEMENT|Placebo Juice|Placebo juice will be provided from Ocean Spray Company to match the appearance, taste, and calories of the cranberry juice.
223941535|NCT04252677|BEHAVIORAL|Obesity Prevention|This intervention includes content specific to obesity behaviors-related health information, motivation, and behavioral skills.
223941536|NCT04252677|BEHAVIORAL|Health Literacy|This intervention includes content specific to improving health literacy.
223941537|NCT06647979|BIOLOGICAL|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein|autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein
223941538|NCT06647979|DEVICE|Sequencing Assay for Variant rs114518452|Device used to carry out the diagnostic testing for exclusion criteria number 12
223994358|NCT03229486|DRUG|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
223941539|NCT06823440|DEVICE|Compression using surgical gloves and compression knee socks|Compression therapy will be applied using surgical gloves and compression knee socks. The compression itself will take place on the principle of compressing the limbs, which will narrow the blood vessels and thereby limit the flow of cytostatics to the peripheral parts of the body. This is believed to reduce damage to nerve fibers. Special knee socks with compression of 20-30 mm Hg and latex/nitrile surgical gloves will be used for pressure therapy. The size of the compression aids will be determined by the nursing staff (gloves will be a tight-fitting size; they will not cause discomfort). The patients will wear the compression aids for a specific amount of time before administering paclitaxel, throughout paclitaxel infusion, and after the infusion.
223941540|NCT03713879|DEVICE|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
223941541|NCT03713879|DRUG|Indomethacin|rectally administered indomethacin before or after ERCP
223941542|NCT04162873|DRUG|Celecoxib|Given PO or via feeding tube
223941543|NCT04162873|OTHER|Placebo|Given PO or via feeding tube
223941544|NCT04162873|OTHER|Quality-of-Life Assessment|Ancillary studies
223941545|NCT04162873|OTHER|Questionnaire Administration|Ancillary studies
223941546|NCT03915106|DEVICE|Brace|Wear a rigid brace
223941547|NCT03915106|PROCEDURE|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
223941548|NCT03909347|BEHAVIORAL|PLAN|The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
223941549|NCT03909347|BEHAVIORAL|Standard of Care|The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
223941550|NCT05878405|OTHER|Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Given PO
223941551|NCT05878405|OTHER|Methylene Blue Oral Rinse|Given PO
223941552|NCT06444516|OTHER|FID123300 ocular lubricant|Investigational ocular lubricant
223941553|NCT06799351|DRUG|Ozone therapy|Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
223941554|NCT06799351|DRUG|Oxygen (placebo)|Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
223941555|NCT06929286|DRUG|Nadofaragene Firadenovec|For patients randomized to receive nadofaragene firadenovec, the patient will receive nadofaragene firadenovec as of normal saline instilled intravesically every 3 months for up to 12 months.
223941556|NCT06929286|DRUG|Gemcitabine|gemcitabine instilled intravesically for 1 h, then drained completely out of the bladder
223941557|NCT06929286|DRUG|Docetaxel|followed by docetaxel instilled intravesically for 1 h. This is given once weekly for 6 weeks for induction. Those who have a complete response typically proceed with once-monthly instillations of GemDoce for up to 24 months as maintenance therapy
223941558|NCT07087145|DIAGNOSTIC_TEST|Mail-based Saliva Sample Kit|Sent via United States Postal Service and returned via FedEx
223941559|NCT07087145|OTHER|Study-related Surveys|Online surveys will be administered
223941560|NCT06743568|DEVICE|Transcatheter aortic valve replacement|Eligible patients will be randomized 1:1 to self-expandable valve group or balloon-expandable valve group.
223941561|NCT06890117|DEVICE|Ultrasonic Scalers with EMS PI tip and Saline Irrigation|Control Group: Non-surgical peri-implantitis treatment using ultrasonic scalers and EMS PI tips designed for implants, combined with saline irrigation to remove plaque and biofilm from implant surfaces.
223941562|NCT06890117|DEVICE|Er:YAG (2940nm) and Diode (808nm) Laser|Experimental Group: Non-surgical peri-implantitis treatment using Er:YAG laser (2940nm) and Diode laser (808nm) for decontamination of the implant surface and surrounding tissues. The Er:YAG laser is used for mechanical debridement and biofilm removal, while the Diode laser has biostimulatory effects.
223941563|NCT03641664|BEHAVIORAL|Family Centered Treatment|Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
223941564|NCT03641664|BEHAVIORAL|Level II or Level III Out of Home Placement|Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
223941565|NCT04564547|DRUG|Islatravir|ISL capsule taken by mouth.
223941566|NCT04564547|DRUG|Ulonivirine|Ulonivirine tablet taken by mouth.
223941567|NCT04564547|DRUG|BIC/FTC/TAF|BIC/FTC/TAF tablet taken by mouth.
223941568|NCT04564547|DRUG|Placebo to ISL|Placebo capsule matched to ISL taken by mouth.
223941569|NCT04564547|DRUG|Placebo to Ulonivirine|Placebo tablet matched to ulonivirine taken by mouth.
223941570|NCT04564547|DRUG|Placebo to BIC/FTC/TAF|Placebo tablet matched to BIC/FTC/TAF taken by mouth.
223941571|NCT06619977|DEVICE|Analgesia nociception monitoring (ANI)|Analgesia nociception index (ANI; MetroDoloris Medical Systems, Lille, France) is a noninvasive tool for monitoring the intraoperative state of the autonomic nervous system, in particular - the parasympathetic nervous system. The ANI algorithm uses data from one lead ECG trace. Heart rate variability, or the beat-to-beat alterations in heart rate, is a well-known and recognised noninvasive indicator of autonomic nervous system activity.
223994359|NCT03828188|DIETARY_SUPPLEMENT|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
223994360|NCT03828188|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
224122621|NCT02805868|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223941572|NCT06163625|DEVICE|Repetitive Transcranial Magnetic Stimulation|For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD.
223941573|NCT06163625|BEHAVIORAL|Research Interview, Questionnaires|"Research Interview: A study team member will meet the participant to ask questions regarding the degree of depression at the beginning of the study. This interview will take approximately 30 minutes.~Research Questionnaires: A study team member will ask the participant to complete questionnaires assessing the severity of the participant's depression, daily activities, personality/traits, and quality of life. Questionnaires will be completed via pen and paper at each visit. These questionnaires will take approximately 90 minutes to complete."
223941574|NCT06163625|BEHAVIORAL|Brain Scan|The participant will be asked to undergo a magnetic resonance imaging (MRI) scan to look at the structure and function of their brain. The functional MRI measures the level of blood flow to areas of the brain associated with mood and behaviour, and the participant will be asked to complete two behavioural games while they are in the scanner. During the scan, the participant will be required to lie on a table within the cylindrical tube of the MRI scanner in order to complete the scan. This will result in limited movement for the duration of the scan. The scan will take approximately 60 minutes, and there will be a recovery period for 40 minutes. The participant will be given instructions about these tasks outside of the scanner. This brain scan will happen at St. Michael's Hospital.
223941575|NCT06163625|BIOLOGICAL|Saliva Samples|The participant will be asked to provide six 1mL saliva samples during the MRI scan and recovery period so that the investigators can measure molecular markers associated with depression. In order to provide the sample, the investigators will collect their saliva using a cotton swab and test tube. Each sample should take no more than 5 minutes.
223941576|NCT06883149|BIOLOGICAL|PIN +anti-PD1|"1. Initial treatment phase:~   PIN injection frequency: day0 and day 3, per 3 weeks for 8 cycles;~   PIN injection dosage:~   Cycle1: 4e9 or 8e9 viral particles of PIN based on the number of injectable lesions, their longest diameter, and the tumor volume capacity .~   Cycle 2\~8: 4e9 or 8e9 viral particles of PIN based on the tumor volume's capacity.~   Anti-PD1: day -3, per 3 weeks for 8 cycles;~2. Maintenance treatment phase:~   No injection lesion: Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~   Have injection lesion:~   PIN: 4e9 or 8e9 viral particles based on the tumor volume's capacity, per 6 weeks (within first 24 weeks), then per 8 weeks till 2 years unless unavailability of injection lesion, PD or serious intolerable AEs.~   Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~3. Salvage treatment phase:~Dosage and frequency of administration refer to the initial treatment phase and maintenance treatment phase."
223941577|NCT05667805|DRUG|Platelet Concentrate|Liberal use (standard treatment)
223941578|NCT05667805|DRUG|Prothrombin Complex Concentrate|Liberal use (standard treatment)
223941579|NCT05667805|OTHER|Restricitve Use|Restrictive use of human prothrombin complex and platelet concentrates. No prophylactic substitution.
223941580|NCT03728335|DRUG|Enasidenib Mesylate|Given PO
223941581|NCT05373017|OTHER|DANE Recovery Program|Virtual visits with care coordinator to carry out an individualized recovery plan
223941582|NCT05373017|OTHER|Questionnaires|Physical, cognitive, and psychological assessments
223941583|NCT05886530|OTHER|No intervention|Observational data collection only.
223941584|NCT05496686|DRUG|4.7 microCi 225Ac-MTI-201|4.7 microCi intravenous solution
223941585|NCT05496686|DRUG|9.5 microCi of 225Ac-MTI-201|9.5 microCi intravenous solution
223941586|NCT05496686|DRUG|19 microCi of 225Ac-MTI-201|19 microCi intravenous solution
223941587|NCT05496686|DRUG|38 microCi of 225Ac-MTI-201|38 microCi intravenous solution
223941588|NCT05496686|DRUG|76 microCi of 225Ac-MTI-201|76 microCi intravenous solution
223941589|NCT05496686|DRUG|152 microCi of 225Ac-MTI-201|152 microCi intravenous solution
223941590|NCT05496686|DRUG|254 microCi of 225Ac-MTI-201|254 microCi intravenous solution
223941591|NCT05496686|DRUG|424 microCi of 225Ac-MTI-201|424 microCi intravenous solution
223941592|NCT05496686|DRUG|564 microCi of 225Ac-MTI-201|564 microCi intravenous solution
223941593|NCT05496686|DRUG|750 microCi of 225Ac-MTI-201|750 microCi intravenous solution
223941594|NCT05496686|DRUG|998 microCi of 225Ac-MTI-201|998 microCi intravenous solution
223941595|NCT05496686|DRUG|1327 microCi of 225Ac-MTI-201|1327 microCi intravenous solution
223941596|NCT06910020|OTHER|Active Cycle of Breathing Technique|"* Patients will assume the sitting position and relax their shoulders, then perform the following:~  1. Breathing control (abdominal breathing)~ 2. Chest expansion (thoracic breathing)~ 3. Huff cough (forced expiratory technique)~* After completing the above actions, patients will be asked to cough up the residual deep sputum to promote pulmonary expansion.~* The ACBT intervention will be performed for three days, each day two sessions, each session three courses, with 10 minutes of rest between them as needed."
223941597|NCT06191302|PROCEDURE|blood sample|Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.
223941598|NCT06191302|OTHER|Online questionaire|The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.
223941599|NCT05826977|BEHAVIORAL|CASI-Plus|See arm description
223941600|NCT06909799|DRUG|N-Acetyl Cysteine (NAC)|NAC will be provided as 600 mg capsules from NOW Healthgroup. Standard TB treatment will be provided as fixed dose combination tablets.
223941601|NCT06909799|DRUG|Standard TB treatment|Standard TB treatment will be provided as fixed dose combination tablets.
223941602|NCT04932577|BIOLOGICAL|Faecal microbiota transplantation|All participant will receive three applications of either FMT or placebo and afterwards followed for 1 year.
223941603|NCT04932577|BIOLOGICAL|Placebo|Placebo
223729352|NCT02669381|DIETARY_SUPPLEMENT|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
223941604|NCT06347432|OTHER|Power wheelchair skills training using the IndieTrainer system|The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.
223941605|NCT05261581|PROCEDURE|Erector Spinae Plane Block|Erector spinae block (ESB) is an ultrasound-guided interfascial plane block. The local anesthetic is injected using ultrasound guidance superficial to transverse process and deep to erector spinae muscle group
223941606|NCT05261581|DRUG|NSAID|Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation.
223941607|NCT05261581|BEHAVIORAL|Home Exercise Programme|Home exercise programme will include some stretches that aid in pain relief by helping take stress off the low back and hips, core stabilization exercises and postural exercises.
223941608|NCT04651010|OTHER|Multimodal MRI|Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
223941609|NCT06215144|DRUG|NRCT-101SR|NRCT-101SR is a sustained release formulation.
223941610|NCT06161285|OTHER|Sampling|Single-time sampling of respiratory virus-infected children
223941611|NCT06054854|BIOLOGICAL|Extra blood sampling, Non-invasive or leftover samples or medical waste|"Extra blood sampling, Urine, Saliva, Stool, Superficial nasal swamp sampling. Bronchoalveolar lavage fluid, Mediastinal node or mass, Peripheral nodule aspiration supernatant, Pleural fluid, Cerebrospinal fluid collection (leftover samples or medical waste).~Blood will be collected in larger quantity during a blood test planned as part of the patient's care.~Non-invasive or leftover samples or medical waste will be collected on top of the usual diagnosis and during follow-up, depending on the case."
223941612|NCT06909942|DIAGNOSTIC_TEST|Psoas Muscle Index|The PMI is typically calculated using cross-sectional imaging (CT or MRI) at the level of the third lumbar vertebra (L3).The total psoas area is normalized to patient height: PMI = Total psoas muscle area (cm²) / height² (m²).The PMI is particularly valuable in hospital settings where patients may have difficulty performing functional tests like handgrip strength measurements, offering an objective assessment of muscle status from readily available imaging data.
223941613|NCT06909942|DEVICE|Handgrip Dynamometer|Handgrip strength (HGS) is one of the key diagnostic criteria for sarcopenia according to several international consensus guidelines, including those from the European Working Group on Sarcopenia in Older People (EWGSOP2) and the Asian Working Group for Sarcopenia (AWGS).Men: \<27 kg and women: \<16 kg values indicates sarcopenia for each patient.Handgrip strength measurement with a dynamometer provides a standardized, reliable, and clinically relevant assessment that helps identify individuals with sarcopenia who may benefit from early intervention strategies.
223941614|NCT06909942|OTHER|SARC-F Score|"The SARC-F is a simple screening tool used to identify individuals at risk for sarcopenia, which is the progressive loss of muscle mass and strength typically associated with aging.~The SARC-F questionnaire consists of 5 components that assess key aspects related to muscle function:~Strength: Difficulty lifting and carrying 10 pounds Assistance with walking: Difficulty walking across a room Rising from a chair: Difficulty transferring from a chair or bed Climbing stairs: Difficulty climbing a flight of 10 stairs Falls: Frequency of falls in the past year~Each component is scored from 0-2 points:~0 = No difficulty~1. = Some difficulty~2. = A lot of difficulty or unable to do~The total score ranges from 0-10, with higher scores indicating higher risk:~A score of 4 or greater suggests risk of sarcopenia A score of less than 4 suggests low risk"
223941615|NCT06909942|DEVICE|Train-of-Four(TOF)|"A Train of Four (TOF) device is a specialized neuromuscular monitoring tool used primarily in anesthesiology and critical care to assess the degree of neuromuscular blockade in patients who have received neuromuscular blocking agents (NMBAs).The device delivers four sequential electrical stimuli (hence train of four) at 0.5-second intervals to a peripheral nerve, typically the ulnar nerve at the wrist. It then measures the resulting muscle contractions, usually of the adductor pollicis muscle (thumb).Modern TOF devices provide a numerical value called the TOF ratio or count, which compares the strength of the fourth twitch to the first twitch.~Ratio of fourth twitch to first twitch amplitude \<0.7: Significant residual blockade 0.7-0.9: Moderate recovery 0.9: Adequate recovery for extubation"
223941616|NCT06909942|DEVICE|Bispectral Index(BIS)|"A Bispectral Index (BIS) device is a specialized monitoring system used primarily in anesthesiology and critical care to assess a patient's level of consciousness during sedation and general anesthesia.Uses a sensor placed on the patient's forehead to capture electroencephalogram (EEG) signals from the brain.Employs advanced algorithms to analyze the raw EEG data, examining frequency, power, and phase relationships.Processes the EEG information into a dimensionless number (the BIS value) ranging from 0 to 100.~BIS Scale:~100-80: Awake, normal consciousness 80-60: Light to moderate sedation 60-40: General anesthesia (surgical level of hypnosis) 40-20: Deep hypnotic state 20-0: Burst suppression to flatline EEG (very deep anesthesia)"
223941617|NCT05695027|DRUG|Dietary supplements - Nicotinamide and Pyruvate|Nutritional supplements
223941618|NCT05695027|DRUG|Placebo|Placebo
223941619|NCT06758076|DEVICE|Lens 1 (ocufilcon D)|15 minutes of daily wear
223941620|NCT06758076|DEVICE|Lens 2 (somofilcon A)|15 minutes of daily wear
223994361|NCT00288223|DRUG|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
223994362|NCT00808002|DRUG|Raltegravir|Raltegravir 400 mg every 12 hours
223729353|NCT00217386|BIOLOGICAL|anti-thymocyte globulin|
223729354|NCT00217386|BIOLOGICAL|etanercept|
223729355|NCT05763550|DRUG|HSK16149 20mg BID|HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
223729356|NCT05763550|DRUG|HSK16149 40mg BID|HSK16149 40mg, orally twice a day, treatment period; 4-weeks fixed dose.
223729357|NCT05763550|DRUG|Pregabalin 150mg|pregabalin, orally twice a day, treatment period; 150 mg (75 mg twice daily) for 1 week；300 mg (150 mg twice daily) daily for 3 week
223729358|NCT02664441|DRUG|Exenatide|Weekly injections of active drug.
223729359|NCT02664441|DRUG|placebo|Weekly placebo injections
223941621|NCT06830460|OTHER|Training|"The training will consist of a four-hour session, including a 30-minute lecture on ocular anatomy and ultrasound techniques, a real-time demonstration, and supervised hands-on practice with at least 20 measurements.~Participants must achieve a score of at least 70% on a multiple-choice test to proceed to practical verification, where they will measure the ONSD in five healthy volunteers. These measurements will be compared to those taken by an expert tutor."
223941622|NCT06828276|BEHAVIORAL|Culturally adapted i-CBT|A culturally and language adapted i-CBT intervention for Farsi/Dari speaking youth migrants and refugees. The intervention targets mild to moderate common mental health problems.
223941623|NCT04230395|BEHAVIORAL|HATHI Intervention|4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
223941624|NCT04230395|OTHER|Usual Care|Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
223941625|NCT06628674|BEHAVIORAL|core muscle exercise|Patients in experiment group will do core muscle exercise with online interactive videos
223941626|NCT06628674|BEHAVIORAL|pelvic muscle exercise|Patients in experiment group will do pelvic muscle exercise without online interactive videos
224287396|NCT04553835|BEHAVIORAL|Rhythmic auditory stimulation (RAS) for schizophrenia patients|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday."
224287397|NCT04553835|BEHAVIORAL|No RAS for schizophrenia patients|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
224287398|NCT04553835|BEHAVIORAL|RAS for at-risk individuals|"A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day."
224287399|NCT04553835|BEHAVIORAL|No RAS for at-risk individuals|The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
224287400|NCT05637853|DRUG|GDMT|Predifined fast uptitration of GDMT for HFrEF with support of home monitoring.
224287401|NCT00146380|DRUG|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
224287402|NCT00146380|BEHAVIORAL|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
224287403|NCT05984602|DRUG|Canakinumab|250 mg subcutaneous injection in prefilled syringes on day 1 of every 28-day cycle
224287404|NCT05984602|DRUG|Tislelizumab|300 mg in a liquid vial (concentrate for intravenous (i.v.) solution) on day 1 of every 28-day cycle
224287405|NCT05984602|DRUG|Nab-Paclitaxel|125 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
224287406|NCT05984602|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion on days 1, 8, 15 of every 28-day cycle
224287407|NCT02753517|DEVICE|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
224287408|NCT05745441|BEHAVIORAL|Early Dinner|Dinner before DLMO
224287409|NCT05745441|BEHAVIORAL|Late Dinner|Dinner after DLMO
223729360|NCT01602874|DRUG|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
223941627|NCT06828731|DRUG|Empagliflozin 10mg daily|This intervention will assess recruitment and retention (feasibility trial).
223941628|NCT06828731|OTHER|Lifestyle education|This intervention is considered standard care for prediabetes.
223941629|NCT06381622|DRUG|Ropivacaine 0.5% Injectable Solution|30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
223994363|NCT00808002|DRUG|Maraviroc|Maraviroc 300 mg every 12 hours
224287410|NCT05745441|DRUG|Early Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
224287411|NCT05745441|DRUG|Late Dinner tracer|Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner after DLMO
224287412|NCT06689592|DEVICE|Transcranial Magnetic Stimulation|Intermittent theta burst stimulation
224287413|NCT05857631|RADIATION|Hypofractionated Image guided External Beam Radiation Therapy (EBRT)|"External beam radiotherapy to pelvis:~Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks."
223941630|NCT06381622|DRUG|Lidocaine epinephrine|20 mL Ropivacaine 5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg) / ml (= 100 mg Ropivacaine + 200 mg Lidocaine)
223941631|NCT06381622|DRUG|Ropivacaine 0.75% Injectable Solution|20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
223941632|NCT06784830|OTHER|Effects on Image Quality and Patient Satisfaction|Effect of nursing intervention on image quality and patient satisfaction during PET/CT imaging in Alzheimer's patients
223941633|NCT06784830|OTHER|Anxiety degree of patients after nursing|Self Rating Anxiety will be used Scale (SAS) to assess the degree of anxiety after care
223941634|NCT06098040|DEVICE|flash glucose monitoring continuous|Group 2 (FGM continuous): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion continuously for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
223941635|NCT06098040|DIAGNOSTIC_TEST|capillary blood test|Group 1 (SMBG): will be asked to test capillary blood glucose as recommended by subjects' usual provider for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
223941636|NCT06098040|DEVICE|flash glucose monitoring intermittent|Group 3 (FGM intermittent): will be asked to wear the sensor FreeStyle Libre2 for the FGM with the following frequency fashion 1 week off/2 weeks on for the first 12 weeks and followed by 12 weeks testing as recommended by their usual provider.
223941637|NCT06636773|BEHAVIORAL|Diet|A reduced energy diet ranging from 1200-2100 kilocalories per day will be recommended for participants.
223941638|NCT06636773|BEHAVIORAL|Aerobic Exercise|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress from an initial amount of 100 minutes per week to 300 minutes per week across the initial 6 months of the intervention, with this level of physical activity continuing to be recommended between months 7-12.
223941639|NCT06636773|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly group-based behavioral session for months 1-6, with these sessions being offered twice per month during months 7-12 to assist in supporting recommended changes in energy intake (diet) and physical activity.
223941640|NCT06636773|BEHAVIORAL|Aerobic + Yoga Exercise|Physical activity will be recommended in the form of a combination of aerobic types of activity, such as brisk walking, and yoga. Aerobic activity will progress from 60 minutes per week to 180 minutes per week across the initial 6 months of the intervention. Yoga will progress from 40 minutes per week to 120 minutes per week across the initial 6 months of the intervention. When combined this will progress from a total of 100 minutes per week to 300 minutes per week across the initial 6 months of treatment. This level of physical activity will continue to be recommended between months 7-12.
223941641|NCT04800367|DRUG|Romosozumab Prefilled Syringe [Evenity]|2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
223941642|NCT04800367|DRUG|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
223941643|NCT05140967|OTHER|High Intensity Interval Training (HIIT)|High Intensity Interval Training
223941644|NCT05140967|OTHER|Moderate Continuous Intensity Training (MICT)|Moderate Intensity Continuous Training
223941645|NCT06828640|DEVICE|vaginal dilators|Evaluate the efficacy of vaginal dilators as an addition to Standard of Care in premenopausal or menopausal women, including breast cancer survivors
223941646|NCT06204250|DRUG|GS1-144|Oral tablets.
223941647|NCT06204250|DRUG|Placebo|Matching placebo tablets.
223941648|NCT05819619|DRUG|Prophylactic use of ibuprofen and ondansetron post misoprostol administration|Prophylactic use of ibuprofen and ondansetron post misoprostol administration
223941649|NCT05819619|DRUG|Use of ibuprofen and ondansetron at symptom onset post misoprostol administration|Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
223941650|NCT03804372|DRUG|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
223941651|NCT03804372|DRUG|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
223941652|NCT03804372|DRUG|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
223941653|NCT06153693|DRUG|Placebo|Placebo once daily (QD) for 12 weeks
223941654|NCT06153693|DRUG|lorundrostat Dose 1|50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
224287414|NCT05857631|DRUG|Cisplatin|Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.
224287415|NCT05857631|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.
224287416|NCT05529511|OTHER|Phase 1 - semi-structured interviews|Semi-structured face-to-face or virtual interviews.
224287417|NCT05529511|OTHER|Phase 2 - consensus meeting|Face-to-face or virtual meeting(s)
224287418|NCT06142929|PROCEDURE|Microfasciectomy|Using the microscope in Dupuytren's surgery
223941655|NCT06153693|DRUG|lorundrostat Dose 2|50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
223941656|NCT06813131|OTHER|Dietary counseling|This intervention uniquely focuses on the frequency of dietitian-led follow-up visits and their impact on metabolic syndrome-related parameters. The study includes three distinct groups with varying levels of follow-up intensity (control, intervention, and intensive intervention).
223994364|NCT00808002|DRUG|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
224287419|NCT05617625|DRUG|Busulfan|0.8 mg/kg q6h x 12 doses via IV injection on Days -9, -8, and -7 prior to transplant
224287420|NCT05617625|DRUG|Melphalan|70 mg/m\^2/day x 2 days via IV infusion over 30 minutes on Days -6 and -5 prior to transplant
223941657|NCT06813131|OTHER|calling via telephone|"The intensive intervention group involves weekly diet adherence assessments via phone calls, setting it apart from other studies that typically rely on less frequent or standardized follow-up schedules. This design allows for the evaluation of how consultation frequency influences outcomes such as weight loss, blood sugar levels, lipid profile, and metabolic syndrome components."
223729361|NCT01602874|DRUG|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
223941658|NCT06892769|OTHER|telehealth counseling|Patients in the intervention group will be called every week (for 4 weeks) and will be trained in line with the determined guide and scales will be filled.
223941659|NCT06775405|DRUG|AK0529|Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
223941660|NCT06775405|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
223941661|NCT06488274|DIETARY_SUPPLEMENT|New infant formula|The new formula will be given to infants during the 4-month study period.
223941662|NCT04268277|DRUG|Rituximab|100 mg concentrate for solution for infusion
223941663|NCT04268277|DRUG|Pembrolizumab|100 mg/ 4mL concentrate for solution for infusion
223941664|NCT06825377|DIETARY_SUPPLEMENT|Whey protein|Whey protein powder will be provided with nutritional support in both groups if needed to meet the target protein intake.
223941665|NCT06169800|DEVICE|MPFL repair with Biobrace augmentation|MPFL repair with Biobrace augmentation
223941666|NCT03036462|DRUG|Iron|i.v. iron administration
223941667|NCT03036462|DRUG|Saline|i.v. NaCl administration
223941668|NCT06893523|OTHER|Concentrated Growth Factor|Bilaterally impacted third molar of the patients areremoved surgically and concentrated growth factor isplaced in one of the extraction sockets.
223941669|NCT06893523|OTHER|Non-CGF|The other extraction socket is left empty for control purposes.
223941670|NCT06759129|BEHAVIORAL|Immediate-use of a mobile health application until completion|"Participants will use the RomSi app for approximately 14 days, completing all scheduled activities. Throughout the intervention, they will respond to ecological momentary assessments (EMA) designed to evaluate stigma, help-seeking intentions, and suicidal ideation.~The activities within the app will include interactive games aimed at fostering empathy and emotional understanding. Participants will also have continuous access to specialized help contacts to ensure their well-being during the study.~The protocol involves two groups that will receive tailored information based on their specific needs:~1. Individuals with low suicidal ideation and/or self-stigma, who will engage in activities focused on reducing personal stigma.~2. Individuals experiencing suicide bereavement, who will receive support tailored to address their loss and foster resilience.~A follow-up will be carried out one month and three months after the end of the intervention."
223941671|NCT06759129|BEHAVIORAL|Delayed use of a mobile health application until completion|"Participants assigned to the dApp group (delayed use) will not have access to the RomSi app during the first two weeks of the study. During this period, they will complete ecological momentary assessments (EMA) to evaluate stigma, help-seeking intentions, and suicidal ideation, without engaging in the intervention activities associated with the app.~After completing this initial control phase, participants in the dAPP group will begin using the RomSi app, following the same protocol as the iAPP group. This includes interactive activities, such as games designed to foster empathy and understanding, along with continuous access to specialized help contacts.~This crossover design allows for the immediate effects of the intervention to be compared between groups, while also evaluating changes in pre- and post-intervention measures across both conditions.~A follow-up will be carried out one month and three months after the end of the intervention."
223941672|NCT06113536|DIAGNOSTIC_TEST|Ultrasonographic evaluation|Ultrasonographic evaluation for assessment of possible meniscal extrusion
223941673|NCT06516887|DRUG|bemcentinib|Bemcentinib has been investigated in a phase I/II clinical trials for solid tumors. Phase I and II clinical studies of BGB324 are ongoing in non-small cell carcinoma, in which combinations with other agents such as Phase I study of docetaxel (NCT02922777), erlotinib (NCT02424617), and pembrolizumab (NCT03184571) are also being investigated. In a phase I dose escalation study of bemcentinib in combination with docetaxel study, patients with treatment naïve, advanced lung adenocarcinoma receive docetaxel 75 mg/m2 given IV every 21 days in combination with bemcentinib. Bemcentinib dose will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
223941674|NCT06516887|DRUG|pacritinib|For use in clinical studies as an oral agent, pacritinib is supplied as size #0 hard gelatin capsules with gray bodies and scarlet caps. Capsules contain 100 mg pacritinib (free base) and the following inactive ingredients: microcrystalline cellulose NF, polyethylene glycol 8000 NF, and magnesium stearate NF. The capsule gelatin is bovine derived. Pharmacies at investigational sites will receive subject-specific bottles containing 120 capsules packaged in 200 mL high-density polyethylene bottles with child-resistant closures.
223941675|NCT06715514|DRUG|GLP-1 Receptor Agonist|Wegovy®
223941676|NCT06715514|DRUG|Menopausal Hormone Therapy|Estradot® and Utrogestan®\* (in women with intact uterus\*)
223941677|NCT03633604|BIOLOGICAL|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
223941678|NCT05325294|DEVICE|MiniMed 780G System|MiniMed™ 780G Insulin Pump, Guardian™ 4 Glucose Sensor, and Guardian 4 Transmitter; used with Insulin Lyumjev® insulin lispro-aabc
223941679|NCT02520544|DEVICE|Accolade stem|Total hip replacement
223941680|NCT02520544|DEVICE|Accolade II stem|Total hip replacement
223941681|NCT02520544|DEVICE|Trident/Tritanium cup|Total hip replacement
223941682|NCT05799794|BEHAVIORAL|Supervisor-led Implementation Coaching|Implementation coaching, support, or facilitation includes the support provided to supervisors and their organizations for successfully delivering an evidence-based practice (EBP). Implementation support can include consultation, supervision, and coaching.
223941683|NCT06938230|BEHAVIORAL|Health Education Initiative|Participants will receive a one time 45 minute intervention session. During the session participants will receive information regarding COVID-19 disease process and behavioral effects and had the opportunity to ask questions.
223941684|NCT06344156|DRUG|Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy|Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines
223941685|NCT06944197|OTHER|Standard Care Guidance Group|"Participants in this group will receive an individual, face-to-face consultation with a physiotherapist from the primary and community care service at the Primary Care Center. During the session, participants will be provided with an informational guide focused on the management of post-stroke conditions, as well as health promotion and secondary prevention strategies relevant to stroke recovery.~The document provided is titled Guide for People Affected by Cerebrovascular Disease, Their Families, and Caregivers, published in 2022 by the Department of Health of the Generalitat de Catalunya in collaboration with the Stroke Foundation. This group serves as the control group, as the intervention closely resembles the standard care currently implemented across Primary Care Centers in Catalonia for individuals in the chronic phase of stroke recovery."
223941686|NCT06944197|OTHER|Home-Based Therapeutic Exercise - Document Group|"Participants in this group will receive an individual, face-to-face consultation with a physiotherapist at the Primary Care Center. During the session, the Home-Based Therapeutic Exercise Program document will be explained and provided. This document outlines an exercise program to be followed over a 10-week period, with a frequency of three sessions per week.~The explanatory document includes three weekly exercise charts covering a total of 30 sessions. Each session is clearly described with detailed instructions to ensure proper execution, including dosage specifications such as repetitions, sets, and load. A checklist template is also included to help participants track their progress and completed activities.~The exercise program consists of strength exercises targeting the major muscle groups of the lower extremities (LE), upper extremities (UE), and trunk; stretching exercises focused on the most relevant flexor muscles of the lower and upper extremities; and exercises aimed"
223941687|NCT06944197|OTHER|Home-Based Therapeutic Exercise - Telerehabilitation Group|"Participants will have an individual consultation with a physiotherapist at the Primary Care Center, where an individualized therapeutic exercise program will be explained. The program spans 10 weeks with three sessions per week (totaling 30 sessions) and is delivered through the Physitrack telerehabilitation platform.~They will receive the Guide for the Use of the Physitrack Telerehabilitation Platform, which provides all necessary information for effective platform use. A brief tutorial will be given during the consultation to ensure familiarity with the tool.~The program mirrors the Therapeutic Exercise Document Group program, but with weekly progress monitoring via the platform. This allows the physiotherapist to adjust exercises or load based on progress. The platform also enables direct communication between participants and the physiotherapist, offering continuous support throughout the intervention."
223941688|NCT06951763|OTHER|stretching exrcise|The participants will receive stretching exercises program for 45 minutes, 3 days/week for 4 weeks.
223941689|NCT06951763|OTHER|myofascial release|The participants will receive the same stretching exercises program in addition to myofascial release of cesarean scar, abdominal fascia, diaphragm and psoas muscle for 30 minutes session twice a week for two weeks.
223941690|NCT06036316|BEHAVIORAL|Language assessment|"The proposed speech and language therapy assessment will consist of a battery of standardized tests that speech and language therapists can use to assess the language skills in reception and expression of adult patients.~Concerning the assessment of the interactions between working memory and semantic abilities, a complete protocol has been developed."
223941691|NCT06036316|BEHAVIORAL|TLC - Scale for the Assessment of Thought, Language, and Communication|This scale is frequently used in psychiatry and is used to measure formal thought disorders in patients suffering from psychosis. As part of this study, it will be intended for patients suffering from schizophrenia
223941692|NCT06036316|BEHAVIORAL|MINI - Mini International Neuropsychiatric Interview|This scale corresponds to a rapid assessment of the psychiatric and psychological state of patients. It helps detect any psychiatric disorders. Here, it will be offered to volunteers who are part of the control group.
223941693|NCT06036316|COMBINATION_PRODUCT|CAST - Cannabis Abuse Screening Test|The purpose of this questionnaire is to approximate participants' cannabis consumption and to assess any disorders associated with cannabis consumption. It will be offered to all participants, patients and healthy controls
223941694|NCT06371534|DRUG|QL2109|subcutaneous injection 3-5 min D1 (Day 1, single dose)
223941695|NCT06371534|DRUG|DARZALEX FASPRO®|subcutaneous injection 3-5 min D1 (Day 1, single dose)
223941696|NCT03896815|DRUG|INCB054329|
223941697|NCT05937594|GENETIC|Buccal swab saliva for further genetic testing|Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
223941698|NCT07158242|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
223941699|NCT07170592|DRUG|OTS-412|3×10E8 pfu, once q3 weeks, 3 cycles, IT
223941700|NCT07170592|DRUG|Hydroxyurea (HU)|15 mg/kg/day, 14 days, 1 cycle, PO
223941701|NCT07170592|DRUG|Atezolizumab|1,200 mg, once q3 weeks, 2 cycles, IV
223941702|NCT07170592|DRUG|OTS-412|3×10E8 pfu, once q3 weeks, 2 cycles, IT
223941703|NCT07170592|DRUG|OTS-412|1×10E8 pfu, once q3 weeks, 2 cycles, IT
223941704|NCT07170592|DRUG|Hydroxyurea (HU)|20 mg/kg/day, 14 days, 1 cycle, PO
223941705|NCT07170592|DRUG|Hydroxyurea (HU)|25 mg/kg/day, 14 days, 1 cycle, PO
223941706|NCT07170592|DRUG|Hydroxyurea (HU)|30 mg/kg/day, 14 days, 1 cycle, PO
223941707|NCT07170592|DRUG|Hydroxyurea (HU)|35 mg/kg/day, 14 days q3 weeks, 2 cycles, PO
223941708|NCT07170592|DRUG|OTS-412|optimal dose, once q3 weeks, 2 cycles, IT
223941709|NCT07170592|DRUG|Hydroxyurea (HU)|optimal dose, 14 days q3 weeks, 2 cycles, PO
223941710|NCT05357144|BEHAVIORAL|Loyalty card program at drug shops & supply of HIVST and SRH products|"Consenting drug shops will receive:~* training on Malkia Klabu implementation;~* HIVST training (same as comparison drug shops);~* procedures for referring to youth-friendly HIV/SRH services;~* a monthly supply of HIVST reserved for free distribution to AGYW, with free price stickers and pre-packaged with referral information; and~* reimbursement for SRH products given to AGYW (e.g., birth control pills)."
224122622|NCT02805868|OTHER|Laboratory Biomarker Analysis|Correlative studies
224122623|NCT02805868|BIOLOGICAL|Siltuximab|Given IV
224122624|NCT00398619|DRUG|INCB13739|
223941711|NCT05357144|BEHAVIORAL|Comparison drug shops|Consenting drug shops in the comparison arm catchment areas will have access to the Maisha Meds inventory management application system for offline digital recording of HIVST, HIVST kits earmarked for free to AGYW, guidance on HIV care referral plan to facilitate linkage to nearby health facilities for AGYW. These control drug shops will not participate in Malkia Klabu (Queen Club) program implementation.
223941712|NCT05387564|BEHAVIORAL|SCT Documentation and Disclosure Toolkit (SCT-DD)|A toolkit of implementation strategies
223941713|NCT05941013|DEVICE|Ultrasound detectable cuffed endotracheal tube (USD-ETT)|Intubation with a novel ultrasound-detectable endotracheal tube
223941714|NCT00647387|DEVICE|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
223941715|NCT07190534|DRUG|Hydroxychloroquine (HCQ)|400 mg orally once daily
223941716|NCT07190534|DRUG|Methotrexate (MTX)|15 mg weekly, orally or subcutaneously (+ concomitant medication: Folic acid 10 mg once weekly, taken 24 hours after MTX)
223941717|NCT05876338|OTHER|CRCaSSM|The intervention group will receive face-to-face training, giving patient education booklet and telephone counseling based on the symptom management model. After the training, it is planned to provide telephone counseling for a total of 6 times, once every 2 weeks for 3 months.
223941718|NCT07191561|DIAGNOSTIC_TEST|Liver biopsy|Biopsy of the liver
223941719|NCT07195747|DIAGNOSTIC_TEST|Creatinine|Renal Function Follow-Up for 5 years
223941720|NCT07196709|DEVICE|high-power laser acupuncture and the exercise program|The experimental group will receive high-power lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises
223941721|NCT07196709|DEVICE|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
223941722|NCT07196761|OTHER|Bowel care advice|"It includes: - Encourage adequate fiber intake (20 to 35 grams) each day.~* Avoid caffeine - containing foods and beverages~* Drink at least 1.5 to 2 liters of water/day~* Proper defecation position such as, sitting with knees higher than hips (use a foot stool or other flat, stable object if necessary) , lean forward and put elbows on knees, relax and bulge out the stomach and straighten the spine"
223941723|NCT07196761|DEVICE|Whole-body vibration|Crazy fit massager (made in China ) with platform surface size (65 cm X 35 cm ) base height 20 cm, heavy-duty motor wattage: 200 - 500 watts, will be used to provide whole body vibration for the participants in the experimental group, for 25 minutes, 3 times per week for 6 weeks.
223941724|NCT07196358|OTHER|Standard dressing|Intervention Description: Donor site of STSG treated with standard dressing. Wound is cleaned, paraffin gauze applied, covered with gauze pieces and bandaged. Dressing is removed on the 10th post-operative day, or earlier if excessive exudate is present. Pain and wound healing monitored per standard care protoco
223941725|NCT07196358|OTHER|Topical Heparin Dressing|Intervention Description: Donor site of STSG treated with heparin dressing. 5 ml of 5000 IU/ml heparin is diluted in 50 ml normal saline to produce 500 IU/ml concentration. Gauze is soaked in this solution and applied to donor site immediately after graft harvest. Dressing remains in place until 10th post-operative day unless clinical indication requires earlier change. Pain, wound healing, and hypertrophic scarring assessed during follow-up.
223941726|NCT07196059|DIETARY_SUPPLEMENT|Delphinol|Contains maqui berry powder
223941727|NCT07196059|DIETARY_SUPPLEMENT|Placebo|Contains cellulose
223941728|NCT07195669|DRUG|Suzetrigine (SUZ)|Used in the course of acute post-operative pain following oral and maxillofacial surgeries
223941729|NCT07195669|DRUG|Norco|Its standard of care
223941730|NCT07197840|DEVICE|Numen SILK coil embolization system|The Numen SILK coil embolization system is designed to be used in conjunction with the NumenFR detachment system. It consists of two main parts: • Introducer Sheath: The purpose of this sheath is to facilitate the introduction of the coil into the microcatheter. • Coil System: Composed of the pusher and coil implant. The coil is a permanent implant intended to occlude blood flow in vascular abnormalities. The pusher is used to deliver the coil implant to the target lesion. The NumenFR detachment system is a sterile, handheld, single-patient use device designed for use with the Numen SILK coil embolization system and is operated by two pre-loaded batteries
223941731|NCT07196410|BIOLOGICAL|KAN-004|Each dose of KAN-004 contains a consortium of bacteria isolated from the stool of healthy donors formulated as a powder in a capsule intended for oral administration
223941732|NCT07195851|OTHER|1.Bare Anatomy Expert Advanced Hair Growth Serum 2.Bare Anatomy Expert Ultra-Smoothing Shampoo 3.Bare Anatomy Expert Ultra-Smoothing Hair Serum 4.Bare Anatomy Expert Ultra-Smoothing Hair Mask|Dose: 0.1 ml of sample solution Route of administration: Topical Mode of usage: Products will be evaluated through the complete occlusion for 48 hours.
223941733|NCT07189390|DRUG|Probiotic|Probiotic capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. Probiotic Infloran® Hard capsules (Bifidobacterium bifidum \& Lactobacillus acidophilus) are a listed medicine on the Australian Register of Therapeutic Goods (ARTG). Infloran® has been previously used in infants including pre-term infants for other indications including supporting healthy digestion or improving digestive system flora. Infloran® is manufactured by Laboratorio Farmaceutico SIT S.r.l., Via Cavour 70 - 27035 Mede (PV) Italy.
223941734|NCT07189390|DRUG|Matching placebo|Placebo contains the same excipients as Infloran, it is also made from the same capsule, but it does not contain any bacterial strains. Placebo capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. The placebo is manufactured by Syntro Health, 558-562 Swan St, Richmond, VIC 3121.
223941735|NCT07197658|PROCEDURE|endodontic microsurgery / rotary bur osteotomy|Endodontic microsurgery will be executed by use of a rotary bur
224122625|NCT04473443|OTHER|FEops HEARTguideTM|A patient-specific computer simulation that aims to improve the outcomes after TAVI by suggesting THV platform, THV size and implantation depth with the use of the pre-procedural CT-scan.
224122626|NCT00206115|DRUG|Seroquel Sustained Release (SR)|
224122627|NCT00206115|DRUG|Seroquel Immediate Release (IR)|
224122628|NCT00206115|DRUG|Placebo|
223941736|NCT07197658|PROCEDURE|Endodontic microsurgery / piezo osteotomy|Endodontic microsurgery will be performed by use of a piezosurgery unit
223941737|NCT07197658|PROCEDURE|Endodontic microsurgery / bone window|'Bone window' technique will be performed by use of piezoelectric surgery
223941738|NCT07197203|PROCEDURE|Sacral ESP Block|"* Position: Prone with a pillow under the pelvis.~* Ultrasound: High-frequency linear probe placed parasagittal, 1-1.5 cm lateral to the midline at S2-S3. Structure identified: skin → subcutaneous tissue → erector spinae muscle → sacral lamina.~* Technique: An echogenic 22G needle will be advanced in-plane until contact with the sacral lamina under the erector spinae muscle. After hydro dissection with saline, the study drug will be injected with visible spread along the fascial plane. The same procedure will be repeated contralaterally.~* Dose: Bupivacaine 0.25% total 1 mL/kg divided equally on both sides, dexmedetomidine 1 μ g/kg divided equally."
223941739|NCT07197203|PROCEDURE|Caudal epidural block|"* Position: Prone with a pillow under the pelvis.~* Ultrasound: High-frequency linear probe placed parasagittal, 1-1.5 cm lateral to the midline at S2-S3. Structure identified: skin → subcutaneous tissue → erector spinae muscle → sacral lamina.~* Technique: An echogenic 22G needle will be advanced in-plane until contact with the sacral lamina under the erector spinae muscle. After hydro dissection with saline, the study drug will be injected with visible spread along the fascial plane. The same procedure will be repeated contralaterally.~* Dose: Bupivacaine 0.25% total 1 mL/kg divided equally on both sides, dexmedetomidine 1 μ g/kg divided equally."
223941740|NCT07197606|DRUG|Placebo|Intravenous injection of placebo
223941741|NCT07197606|DRUG|IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells)|Intravenous injection of IxCell hUC-MSC-S
223941742|NCT07196475|PROCEDURE|FOCAL LASER ABLATION OF PROSTATE|All monopolar TURP procedures were performed under spinal anaesthesia, whereas all TU-FLAP procedures were conducted under local anaesthesia with intravenous sedation. A single experienced surgical team performed all operations, with each surgeon having completed over 100 similar procedures prior to the study's initiation. Prophylactic antibiotic coverage with a third-generation cephalosporin has been administered at the time of anaesthesia induction. Cases were placed in the lithotomy position, followed by diagnostic urethrocystoscopy. In the TU-FLAP group, a 980 nm diode laser fig(1) by applying end-firing fiber fig(2) was introduced via the side working channel of a 22 Fr cystoscope under local anesthesia. Laser energy was applied at 15 watts for two minutes at multiple sites within the right and left prostatic lobes, approximately 1.5 cm distal to the bladder neck, with 1 cm spacing between punctures. In cases with an enlarged median lobe, one or two additional laser punctures were
224122629|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension|topical suspension
224122630|NCT00804193|DRUG|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
223941743|NCT07196878|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|An ultrasound-guided puncture is performed to place one needle near the sciatic nerve and another near the peroneal nerve. Then, an electrical stimulus at 10 Hz is applied for 10 seconds, repeated 10 times.
223941744|NCT07196111|BIOLOGICAL|BAFFR CAR-T|A single infusion of BAFFR CAR-T Injection administered intravenously.
223941745|NCT07195825|GENETIC|Injecting BBM-P002 into the bilateral putamen|BBM-P002 is an AAV-based gene therapy that delivers a therapeutic gene cassette into putamen for the treatment of Parkinson's Disease
223941746|NCT07197008|DRUG|Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab|Eligible patients will receive Sacituzumab tirumotecan at a dose of 4 mg/kg in combination with bevacizumab 5mg/kg by intravenous infusion on day 1 and day 15 of each 28-day cycle.
223994365|NCT02080546|PROCEDURE|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
223994366|NCT02080546|PROCEDURE|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
223994367|NCT02080546|DEVICE|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
223994368|NCT01666093|PROCEDURE|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
223994369|NCT01403649|BEHAVIORAL|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
223994370|NCT01403649|OTHER|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
223994371|NCT00983112|DRUG|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
223994372|NCT00983112|DRUG|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
223994373|NCT00844597|DRUG|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
223994374|NCT04811144|DEVICE|Er:YAG dental laser|To treat Cavity, Sensitive Teeth, Abnormal Frenum Attachment and Peri-implantitis by using Er:YAG Dental Laser system which manufactured by LightMed Dental Technology Corp
223994375|NCT03702387|PROCEDURE|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
223994376|NCT03999632|OTHER|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
223994377|NCT05360628|DRUG|D-0120 in combination with Allopurinol|noted above
223941747|NCT07197697|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy|The dosage of Iparomlimab and Tuvonralimab Injection is 5mg/kg, administered intravenously, with each treatment cycle lasting every 3 weeks. The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles. A total of 8 cycles of neoadjuvant chemotherapy combined with immunotherapy were performed before the surgery. It is recommended that the surgery be conducted within 4 weeks after the completion of neoadjuvant treatment. The postoperative adjuvant treatment can be continued with postoperative adjuvant chemotherapy and the treatment of the etolo combination antibody according to the decision of the researcher and/or the willingness of the subject.
223941748|NCT07196631|DRUG|Liposomal Bupivicaine|patients randomized to the intervention arm received 133mg of liposomal bupivacaine
223941749|NCT07196631|DRUG|ropivacaine|those in the control group received 80mg of ropivacaine
223941750|NCT07196865|PROCEDURE|Open Hemorrhoidectomy|Patients in this group undergo a hemorrhoidectomy procedure where, after external stripping and internal ligation, the surgical wound is left entirely open without sutures to heal by secondary intention. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
223941751|NCT07196865|PROCEDURE|Closed Hemorrhoidectomy (Ferguson Technique)|Patients in this group undergo a hemorrhoidectomy procedure where, after achieving hemostasis, the entire surgical wound is closed primarily using interrupted non-absorbable sutures. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
223941752|NCT07196865|PROCEDURE|Semi-Closed Hemorrhoidectomy|Patients in this group undergo a hemorrhoidectomy procedure where, after achieving hemostasis, the distal half of the incision (away from the anal canal) is closed with interrupted sutures, while the proximal half remains open. All patients receive standard postoperative care including potassium permanganate rinses and povidone-iodine disinfection.
223941753|NCT07196293|PROCEDURE|Customized Healing Abutment - bulk fill composite|instead of standard healing abutments , customization was done using bulk fill composite
223941754|NCT07196293|PROCEDURE|customized healing abutments - Bis acryl composite materials|customized healing abutments with bis acryl composite material was used instead of standard healing abutments
223941755|NCT07196644|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
223941756|NCT07196852|DIETARY_SUPPLEMENT|N Acetyl L Cysteine|Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 1200 mg N-acetylcysteine (2 pills x 600 mg/day ).
223941757|NCT07196852|DIETARY_SUPPLEMENT|Placebo|Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 2 placebo pills/day.
223941758|NCT07197593|OTHER|Calf Raise Test|The study participants perform three single-leg CRTs (tracked by the CRT App) in a fixed sequence: concentric power, eccentric-concentric power and endurance. ATRC/LAS Individuals start with the affected leg, healthy participants with the dominant leg.
223941759|NCT07197073|OTHER|Ozonated olive oil|Ozonated olive oil mouthwash will be prepared by Smart Ozone Marvel using by company's ozone. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
223941760|NCT07197073|OTHER|Propolis|Propolis mouthwash will be prepared by using 2% raw propolis, 40 ml flavouring and 0.1 gm coloring agents, 150 ml propylene glycol, and 60 gm sorbitol. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
223941761|NCT07197073|OTHER|Chlorhexidine|The patients were given 0.12% Chlorhexidine. Children will be instructed to use 10 ml of mouthwash for 1 minute twice daily after 1 hour after tooth brushing
223941762|NCT07195656|DEVICE|Device Group|non-implanted, vaginal electrical stimulation device
223941763|NCT07195656|DRUG|Medication Group|OAB Medication
223941764|NCT07195890|OTHER|A course of teen Mental Health First Aid to be provided to participants|The teen Mental Health First Aid course consists of three sessions developed in Mental Health First Aid in Australia. It has been translated and attuned to the Chinese in Hong Kong.
223941765|NCT07197814|OTHER|Rice formula (New formula based on hydrolysed rice proteins)|Infant formula based on hydrolysed rice proteins.
223941766|NCT07197814|OTHER|Placebo formula|The placebo formula will be the formula the subject is currently successfully fed with as part of his/her diet to eliminate cow's milk proteins.
223941767|NCT07196163|DRUG|Golidocitinib|Golidocitinib will be administered orally as capsules in a 28-day cycle.
223941768|NCT07196163|DRUG|Placebo|Placebo will be administered orally as capsules in a 28-day cycle.
223941769|NCT02969356|BIOLOGICAL|Botulinum toxin type A|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
223941770|NCT02969356|OTHER|GSC|The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
223941771|NCT06035068|DRUG|Indocyanine green|Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.
223941772|NCT07196345|DRUG|TAS-102|Administered orally at 35 mg/m²/dose twice daily (morning and evening), in a bi-weekly regimen on Days 1-5.
224122631|NCT00804193|DRUG|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
223941773|NCT07196345|RADIATION|Radiotherapy|Total dose of 50-60 Gy, delivered in 25-28 fractions, administered Monday through Friday (daily) until the full prescribed dose is achieved.
223941774|NCT05562609|DRUG|Tranexamic acid|Ampoules and packaging for all arms will be identical in appearance.
223941775|NCT05562609|OTHER|Placebo|Ampoules and packaging for all arms will be identical in appearance.
223941776|NCT07196891|OTHER|frontal-QRST angle|The frontal QRS/T angle represents the angle between the ventricular depolarization (QRS) and repolarization (T) vectors on the ECG and serves as a parameter for assessing cardiac electrical heterogeneity. In this study, the frontal QRS/T angle was calculated using data obtained from standard 12-lead surface ECGs. The QRS and T axes in the frontal plane were derived from the automated ECG device reports.
223994378|NCT05253599|DEVICE|Isokinetic training|The knees were flexed slightly at 15 degrees, and the fixation straps were tied around the popliteus, thigh, pelvis, chest and scapula to prevent the tricky movements.
223941777|NCT07196891|OTHER|Hunt-Hess scale|The Hunt-Hess scale was used to assess SAH severity according to the clinical presentation and the visible neurological deficits. The Grades run from 1 to 5: - Grade 1: Asymptomatic or minimal headache, slight neck stiffness. - Grade 2: Moderate to severe headache, and neck stiffness, but no neurological deficit except cranial nerve palsy. - Grade 3: Drowsiness, confusion, or a mild focal deficit. - Grade 4: Stupor, moderate to severe hemiparesis, early decerebrate rigidity, and vegetative disturbance. - Grade 5: Deep coma, decerebrate rigidity, and a moribund appearance.
223941778|NCT07196891|OTHER|modified Fisher scale|The modified Fisher scale was used to evaluate SAH severity by reference to the extent of hemorrhage as revealed by CT of the brain. Four grades are depending on the degree of bleeding observed: - Grade 0: No hemorrhage apparent in CT. - Grade 1: Minimal hemorrhage without intraventricular hemorrhage (IVH). - Grade 2: Thin or diffusely thin (\<1mm) hemorrhage with bilateral IVH. - Grade 3: Thick (\> 1 mm) hemorrhage without bilateral IVH. - Grade 4: Thick (\> 1 mm) hemorrhage with bilateral IVH.
223941779|NCT07197827|DRUG|YL242|The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.
223941780|NCT07197827|DRUG|YL242; Pembrolizumab|The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes. Pembrolizumab will be administered subsequent to YL242.
223941781|NCT07197827|DRUG|YL242; 5-FU; LV|"The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.~LV and 5-FU will be sequentially administered following YL242."
223941782|NCT07197827|DRUG|YL242; Pembrolizumab; 5-FU|"The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. YL242 will be administered via Intravenous (IV) Infusion.~Pembrolizumab and 5-FU will be administered in sequence after YL242."
223941783|NCT07197268|DRUG|nL-ASXL3-001|Personalized antisense oligonucleotide
223941784|NCT07196514|DIETARY_SUPPLEMENT|Raw turmeric shots|This group will take one 60 mL commercially-available shot (containing 30% turmeric) twice per day for 8 weeks.
223941785|NCT07196514|OTHER|Placebo|This group will take one placebo shot (containing a small amount of turmeric for taste-matching purposes) twice per day for 8 weeks.
223941786|NCT07196800|RADIATION|High intensity laser therapy (low dose) combined with conventional physiotherapy program|840 joules delivered during each session combined with conventional physiotherapy program Participants
223941787|NCT07196800|PROCEDURE|High intensity laser therapy (High dose) combined with conventional physiotherapy program|2632 joules delivered during each session combined with conventional physiotherapy program
223941788|NCT07196254|PROCEDURE|sandwich mesh technique|the hernia repair include using double mesh onlay and sublay
223941789|NCT07196579|DRUG|KXV01 TCR Lentinvivo Injection|KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reactive TCR.
223941790|NCT07196527|DEVICE|Puressentiel Allergy Protection Nasal Spray|Crossover study after nasal provocation test (Dermatophagoides pteronyssinus)
223941791|NCT07196527|DEVICE|Saline spray (0.65%)|Crossover study after nasal provocation test (Dermatophagoides pteronyssinus)
223941792|NCT07197034|DRUG|ARD-101|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 50 weeks
223941793|NCT07196280|DRUG|5-Alpha Reductase Inhibitors|Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.
223941794|NCT07197528|BEHAVIORAL|Experimental Arm：Smart-assisted rehabilitation exercise system Control Arm：Usual care or routine physical activity|"Interventions~Behavioral: Smart-assisted rehabilitation exercise system (KNEESUP) A wearable smart-assisted rehabilitation system providing personalized, progressive lower limb resistance training for elderly residents with sarcopenia in long-term care institutions. The system includes real-time monitoring, feedback, and remote adjustment by rehabilitation specialists. Unlike traditional programs, it integrates sensor technology to track knee joint angles and exercise performance, enabling precise and adaptive training.~Other: Usual care / routine physical activity Participants follow standard daily activities and rehabilitation provided by the long-term care facility, without the smart-assisted rehabilitation system."
223941795|NCT07196943|DEVICE|Fully guided static computer-assisted implant surgery (CAIS) for mandibular overdentures using Equator® attachments|Mandibular edentulism will be rehabilitated with implant-supported overdentures using a fully guided static computer-assisted implant surgery (CAIS) protocol. Each patient will receive four implants placed in a quadrilateral configuration (lateral incisor and first premolar regions) under a stereolithographically manufactured surgical guide. Following 3-4 months of osseointegration, definitive mandibular overdentures will be fabricated and retained exclusively with Equator® attachment systems (Rhein 83, Bologna, Italy). Patients will be followed for 3 years to assess implant survival, peri-implant soft tissue health, and marginal bone changes.
223941796|NCT05915026|DRUG|Gadoquatrane (BAY1747846)|0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
223941797|NCT04675294|DRUG|evorpacept|IV Q3W
223941798|NCT04675294|DRUG|pembrolizumab|IV Q3W
223941799|NCT06267729|BIOLOGICAL|AZD0754|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
223941800|NCT02976961|OTHER|Supportive care|Information, guidance, supportive care, and psychological intervention
223941801|NCT02972034|DRUG|MK-8353|PO capsule
223941802|NCT02972034|BIOLOGICAL|Pembrolizumab|IV infusion
223941803|NCT04378205|PROCEDURE|0.014-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.014-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
223941804|NCT04378205|PROCEDURE|0.016-inch NiTi on one side /0.018-inch NiTi on the other side|Where each patient received 2 archwire sizes (0.016-inch and 0.018-inch) at one time joined in the midline by crimpable hook and applied in the lower arch.
223941805|NCT00378898|DEVICE|BRAVO capsule|
223941806|NCT00378898|PROCEDURE|Fluoroscopy|"one time xray to determine evacuation of bravo"
223941807|NCT00378898|OTHER|sham BRAVO capsule placement|
223941808|NCT03136159|DEVICE|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
223941809|NCT00916110|DRUG|ATN-103|1.5 mg solution, single subcutaneous injection
223941810|NCT00916110|DRUG|ATN-103|4 mg solution, single subcutaneous injection
223941811|NCT00916110|DRUG|ATN-103|10 mg solution, single subcutaneous injection
223941812|NCT00916110|DRUG|ATN-103|25 mg solution, single subcutaneous injection
224287421|NCT05617625|DRUG|Fludarabine|25 mg/m\^2/days x 5 days via IV infusion over 30 minutes on Days -6, -5, -4, -3, and -2 prior to transplant
223941813|NCT00916110|DRUG|ATN-103|25 mg solution, single intravenous injection
223941814|NCT00916110|DRUG|ATN-103|50 mg solution, single subcutaneous injection
223941815|NCT00916110|DRUG|ATN-103|100 mg solution, single subcutaneous injection
223941816|NCT00916110|DRUG|ATN-103|200 mg solution, single subcutaneous injection
223941817|NCT00916110|DRUG|ATN-103|200 mg solution, single intravenous injection
223941818|NCT04557566|BEHAVIORAL|EBT yoga-based eating disorder course|Yoga for Eating Disorder Recovery online course. This course will be led by certified facilitators via Zoom and offered over the course of four weeks, comprising one two-hour session per week. The course will continue to recruit and enroll participants until sufficient power is reached for the study.
223941819|NCT06301048|PROCEDURE|Stent Placement in Pancreatic and Bile Ducts|Post-resection, endoscopic retrograde cholangiopancreatography (ERCP) was performed for stent placement in pancreatic or bile ducts as needed, with X-ray confirmation of stent positioning.
223941820|NCT04632290|DEVICE|STIMO-BSI system implantation|Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
223941821|NCT04632290|DEVICE|ARC-BSI Lumbar System|ARC-BSI Lumbar System for participants entering the optional extension with system upgrade: replacement of the neurostimulator, and upgrade of the WIMAGINE system and STIMO system wearable devices.
223941822|NCT05554159|BEHAVIORAL|Standard Fitbit Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
223941823|NCT05554159|BEHAVIORAL|Virtual Exercise Program|Participants will be given a Fitbit to wear during their participation in this program. Participants will need to wear the Fitbit at least 5 days per week and for at least 10 hours a day. Participants will take part in video calls (through the video conferencing platform Zoom) 1 time a week.
223941824|NCT03845699|DEVICE|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
223941825|NCT06543797|DEVICE|wearable rTMS|Application of inhibitory low-frequency rTMS on unaffected primary motor cortex by wearable rTMS
223941826|NCT00846222|PROCEDURE|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
223941827|NCT01681563|DRUG|Pentostatin|Lyophilized powder for intravenous administration.
223941828|NCT01681563|DRUG|Cyclophosphamide|IV
223941829|NCT01681563|DRUG|Ofatumumab|Liquid concentrate for solution for infusion.
223941830|NCT03353285|PROCEDURE|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
223941831|NCT04909333|DRUG|Exenatide|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive Exenatide study medication according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of Exenatide, a 10ml 0.9% saline solution will be administered intravenously."
223941832|NCT04909333|DRUG|0.9% saline solution|"Day1: After a standardized night meal (Maizena 40g plus dessert) at 22 p.m. on the day before, patients receive 0.9% saline solution according to the randomization list (injection done slowly over 2 min.). Regular clinical examination of vegetative and neurological state will be done as well as continuous blood sugar measurements and blood withdrawals will be performed.~Day2:~The procedure is equal to study day 1. Instead of 0.9% saline solution, Exenatide will be administered intravenously."
223941833|NCT01096472|DRUG|LAS41003|Once daily
223941834|NCT01096472|DRUG|LAS189961|Once daily
223941835|NCT01096472|DRUG|LAS189962|Once daily
223941836|NCT00745875|DRUG|ZD4054|10mg oral tablet, once daily
223941837|NCT00745875|DRUG|Pemetrexed|500mg2/m IV infusion
223941838|NCT00745875|DRUG|Placebo|10mg oral tablet, once daily
223941839|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941840|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941841|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941842|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941843|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941844|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941845|NCT05112913|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
223941846|NCT01256359|DRUG|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
223941847|NCT01256359|DRUG|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
223941848|NCT01653652|DIETARY_SUPPLEMENT|Probiotic|
223941849|NCT01653652|DIETARY_SUPPLEMENT|Maltodextrin|
223941850|NCT01429454|DRUG|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
223941851|NCT01429454|DRUG|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
223941852|NCT00252382|DRUG|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
223941853|NCT04097509|BIOLOGICAL|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
223941854|NCT04097509|BIOLOGICAL|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
223941855|NCT04097509|OTHER|control|no application
223535349|NCT06078826|OTHER|foot massage|Massage will be applied by the researcher in the research. Towel, sponge, etc. under the foot to be worked on. The foot will be held at a 45 degree angle While applying, 1-2 drops of liquid Vaseline will be used to moisten the hand. A total of 30 minutes of foot massage will be made for each individual, 15 minutes per foot. Foot massage will start 30 minutes before the start of aspiration and massage will continue throughout the aspiration period. Since the speed of the massage movements and the number of repetitions should be at the normal frequency, the massage will be done at a speed that does not disturb the individual, has a non-stimulating and calming effect and does not tire the practitioner. In the massage, efflorescence (stroking), petrissage and friction (circular rubbing) movements that support circulation and relax the tissues will be used. Evaluations will be made before the foot massage, at the end of the foot massage and 30 minutes after the foot massage.
223535350|NCT02403544|RADIATION|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
223535351|NCT02403544|DRUG|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
223941856|NCT02522104|DRUG|Siklos|
223941857|NCT01545583|DRUG|LY3016859 intravenous|Administered intravenously
223941858|NCT01545583|DRUG|Placebo intravenous|Administered intravenously
223941859|NCT01545583|DRUG|LY3016859 subcutaneous|Administered subcutaneously
223941860|NCT01545583|DRUG|Placebo subcutaneous|Administered subcutaneously
223941861|NCT03489811|OTHER|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
223941862|NCT03489811|OTHER|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
223941863|NCT03489811|OTHER|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
223941864|NCT04839809|DRUG|CC-92480|Oral
223941865|NCT04839809|OTHER|Placebo|Oral
223941866|NCT01989052|DRUG|CTO|
223941867|NCT01989052|DRUG|Lomustine|
223941868|NCT01747538|DRUG|Placebo|Solution for subcutaneous injection
223941869|NCT01747538|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
223941870|NCT01747538|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
224122632|NCT02352051|DRUG|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
223941871|NCT03314259|DRUG|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
223941872|NCT03314259|DRUG|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
223941873|NCT04497415|OTHER|Video-Based intervention|Three minutes video of a nurse that shares her personal story
223941874|NCT03944200|DRUG|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229\_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
223941875|NCT03944200|DRUG|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229\_01(A)) together with 150 mL of water containing 30 g sugar."
223941876|NCT04926259|DRUG|18F-T807|Intravenous injection of one dose of 10mCi (370MBq, ±5%) 18F-T807. Each subject receive a single intravenous injection of 18F-T807, and undergo PET/CT imaging within the specificed time.
223941877|NCT01231178|DIETARY_SUPPLEMENT|Alginate beverage|The dosage is 3x500ml daily
223941878|NCT01231178|DIETARY_SUPPLEMENT|Control beverage|The dosage is 3x500ml daily
223941879|NCT04186377|OTHER|Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers|Optimization of glycemic control, off-loading, local debridement as needed, atraumatic surface scrubbing, saline washing and sterile dressing
223941880|NCT04186377|DRUG|S26E|Daily application of S26E extract on wound site
223941881|NCT04514653|BIOLOGICAL|Ranibizumab|Ranibizumab (anti-VEGF agent)
223941882|NCT04514653|GENETIC|RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)
223941883|NCT04514653|GENETIC|RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)
223941884|NCT04514653|GENETIC|RGX-314 Dose 3|AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)
223941885|NCT04514653|DRUG|Local Steroid|Local steroid
223941886|NCT04514653|DRUG|Topical Steroid|Topical steroid
223941887|NCT04693637|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion
223941888|NCT02322489|DEVICE|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
223941889|NCT02322489|DEVICE|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
223941890|NCT00807079|DRUG|carboplatin|
223941891|NCT00807079|DRUG|topotecan hydrochloride|
223941892|NCT04716517|OTHER|Alkasite bioactive restorative material.|"Alkasite restorative is a category of filling material, like compomer, and is essentially a subgroup~of the composite resin. Cention N is a urethane dimethacrylate (UDMA)-based, self-curing powder/liquid restorative with optional additional light curing. The liquid comprises of dimethacrylates and initiators, while the powder contains various glass fillers, initiators, and pigments. It is radio opaque and contains alkaline glass fillers capable of releasing fluoride, calcium, and hydroxide ions. Due to the sole use of cross-linking methacrylate monomers in combination with a stable, efficient self-cure initiator, Cention N displays a high polymer network density and degree of polymerization over the complete depth of the restoration."
223941893|NCT04716517|OTHER|Resin Modified Glass Ionomer|The resin-modified glass ionomer materials are hybrid materials of traditional glass ionomer cement with a small addition of light-curing resin, and hence exhibit properties intermediate to the two, with some characteristics superior to conventional glass ionomer materials
223941894|NCT00003167|BIOLOGICAL|Ad5CMV-p53 gene|Given intravesically
223941895|NCT03542747|DEVICE|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
224122633|NCT02352051|DRUG|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
223535352|NCT02403544|DRUG|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
223941896|NCT03542747|DEVICE|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
223941897|NCT00330499|DRUG|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
223941898|NCT00330499|RADIATION|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
223941899|NCT04091347|BEHAVIORAL|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
223941900|NCT05346094|OTHER|No intervention|No intervention
224122634|NCT01831557|OTHER|Blood samples will be taken for gene sequencing|
223941901|NCT03071354|DIETARY_SUPPLEMENT|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
223941902|NCT03071354|DIETARY_SUPPLEMENT|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
223941903|NCT02596919|OTHER|photography|photography of meibomian glands
223941904|NCT01578941|OTHER|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (\>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
223941905|NCT04160741|OTHER|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
223941906|NCT04160741|OTHER|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
223941907|NCT04160741|RADIATION|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
223941908|NCT04160741|OTHER|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~* rest (two hours)~* work (cycling) at 100 W (one hour)~* recovery (twenty minutes)"
223941909|NCT03615612|OTHER|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
223941910|NCT00806767|BIOLOGICAL|therapeutic immune globulin|
223941911|NCT00806767|DRUG|busulfan|
223941912|NCT00806767|DRUG|fludarabine phosphate|
223941913|NCT00806767|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223941914|NCT05390905|DRUG|HSK21542 Injection|1μg/kg/dose
223941915|NCT05390905|DRUG|Tramadol hydrochloride|50mg/dose
223941916|NCT05390905|DRUG|placebo|placebo
223941917|NCT00344916|DRUG|Ng-monomethyl-L-arginine (drug)|
223941918|NCT03760913|DRUG|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
223941919|NCT03760913|DRUG|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
223941920|NCT03760913|OTHER|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
223941921|NCT03760913|OTHER|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
223941922|NCT02974322|DRUG|GED-0301|GED-0301
223941923|NCT02974322|DRUG|Placebo|Placebo
223941924|NCT05800236|PROCEDURE|Gastrectomy|Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
223941925|NCT01798667|DRUG|DA-8031|
223941926|NCT01798667|DRUG|Placebo|Placebo of DA-8031, undistinguishable
224122635|NCT06261138|DRUG|Transarterial chemoembolization|A 5-French RH catheter was then introduced to the celiac artery, superior mesenteric and artery common hepatic artery for angiography to determine tumor location, quantity, size, and vascularity. After confirmation by C-arm cone-beam computed tomography (CBCT), chemoembolization was administered by superselective catheterization of the branches of the tumor-feeding arteries using a 2.8-French coaxial microcatheter. For cTACE, oxaliplatin, raltitrexed and an emulsion containing idarubicin and ethiodized oil were infused for over 20 minutes, followed by combined embolization with blank embolic microspheres. For DEB-TACE, DC/LC Beads® (Biocompatibles, Farnham, Surrey, UK), as drug carriers and embolic materials, were loaded with doxorubicin hydrochloride and mixed with nonionic contrast medium. Real-time assessment of embolization was performed with the assistance of CBCT.
223941927|NCT00229970|DRUG|montelukast sodium|7 mg or 14 mg single injection
223941928|NCT00229970|DRUG|Comparator: Placebo|Placebo single injection
223941929|NCT05502094|OTHER|Heart Rate Variability Measurement|The heart rate variability of the participants will be measured with the Polar H10 device with a measurement time of 5 minutes.
223941930|NCT06038695|DEVICE|Xenogeneic Volume-Stable Collagen (VCMX) graft with growth factor-BB|"* Fibro-Gide is the Volume-Stable Collagen Matrix.~* Recombinant human platelet-derived growth factor-BB will be found within the device of GEM21S."
223941931|NCT03387254|DEVICE|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
223941932|NCT03387254|DEVICE|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
223941933|NCT04389385|BIOLOGICAL|COVID-19 Specific T Cell derived exosomes (CSTC-Exo)|The virus-specific T-cells (VSTs) are body's natural immune defense against various disease-causing viruses. Donor originated COVID-19 specific T-cells (CSTC) are in vitro activated and expanded by exposing to viral peptide fragments in the presence of natural immune stimulant proteins called cytokines. These Covid-19 specific fragment peptides activate specific T-cells and stimulate the secretion of potent mediators including IFN gamma in forms of exosomes. We propose treatment of Covid-19 patients -who are at early stages of pulmonary disease- with CSTC-exomes to control disease progression.
223941934|NCT02238041|DEVICE|GlucoClear System|
223941935|NCT03213145|DRUG|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
223941936|NCT03213145|DRUG|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
223941937|NCT03213145|DRUG|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
223941938|NCT05926674|OTHER|Myofascial Release|Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.
223941939|NCT05926674|OTHER|Light Touch Contact|The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
223941940|NCT00964236|DRUG|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
223941941|NCT02398487|DEVICE|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
223941942|NCT02398487|DEVICE|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
223941943|NCT05860504|DIAGNOSTIC_TEST|Echocardiography|All patients in the study will be examined with echocardiography
223941944|NCT05860504|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Sub-group of patients with left ventricular systolic dysfunction will be examined with cMRI
223941945|NCT05860504|DIAGNOSTIC_TEST|Coronary CT|Sub-group of patients with left ventricular systolic dysfunction will be examined with CCT
223941946|NCT00853580|DRUG|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
223941947|NCT00853580|DEVICE|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
223941948|NCT01503372|DRUG|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
223941949|NCT01503372|DRUG|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
223941950|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit # 1
223941951|NCT01224613|BIOLOGICAL|Intanza|0.1 mL of Intanza intradermally at visit #1
223941952|NCT01700205|OTHER|Type of Formula|infant formula
223941953|NCT05011955|BEHAVIORAL|Mindfulness, compassion and intercare based Intervention|"The mindfulness based intervention was a short version of the Mindfulness based intercare program (IBAP). The intervention consists of four synchronic group sessions via ZOOM of one hour each, one peer week and home practice. A total of four groups were conducted of 15 students each.~The IBAP program was inspired by first and second generation mindfulness based interventions, such as Mindfulness based cognitive training, Self-Compassion and Cognitive based Compassion training. Also compassionate communication, conservation of resource theory and habits theory.~Each module consists in meditation practices, inquiry and self or group reflections on different topics such as mindfulness, automatic pilot, mind wandering , acceptance, gratitude and compassion, care resources and intercare."
223941954|NCT05011955|BEHAVIORAL|Psychoeducational based intervention|Four week, one hour peer week, online group intervention plus home work base on psychoeducation about stress, anxiety, selfcare and effective communication. Plus general curricular intervention. Delivered by psychologist.
223941955|NCT05011955|OTHER|General curricular intervention|"All participants were offered psychological sessions if a high score on depression or anxiety symptoms were detected. Psychological sessions consists of 4 to 8 sessions with specific objectives and then referral to continue the mental health process according to the student's welfare system.~Participants also have academic breaks of two week per semester, apart from holidays, and academic flexibility in submitting work, attending practical activities and taking exams."
223941956|NCT02629224|DRUG|ASP8825|Oral
223941957|NCT05866575|OTHER|escitalopram|Patients will receive an antidepressant strategy : escitalopram. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
223941958|NCT05866575|OTHER|vortioxetine|Patients will receive an antidepressant strategy : vortioxetine. The strategy will not be modified for a period of 4 weeks. Dosage adjustment and co-prescriptions will be at the discretion of the refeering psychiatrist. After 4 weeks, the treatment strategy can be adapted by the refeering psychiatrist exactly as if the patient had not been included in the trial.
223941959|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
223941960|NCT02714075|OTHER|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
223941961|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
223941962|NCT02714075|OTHER|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
223941963|NCT02714075|OTHER|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
223941964|NCT02714075|OTHER|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
223941965|NCT01728324|DRUG|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
223941966|NCT01728324|DRUG|Ribavirin: 24-week treatment|24 weeks of active treatment
223941967|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
223941968|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
223941969|NCT01728324|DRUG|Faldaprevir: 24-week treatment|24 weeks of active treatment
223941970|NCT01728324|DRUG|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
223941971|NCT01728324|DRUG|BI 207127: 24-week treatment|24 weeks of active treatment
223941972|NCT01728324|DRUG|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
223941973|NCT01728324|DRUG|Faldaprevir: 16-week treatment|16 weeks of active treatment
223941974|NCT01728324|DRUG|Ribavirin: 16-week treatment|16 weeks of active treatment
223941975|NCT01728324|DRUG|RBV: 24-week treatment|24 weeks of active treatment
223941976|NCT01728324|DRUG|BI 207127: 16-week treatment|16 weeks of active treatment
223941977|NCT02884245|DRUG|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
223941978|NCT02732990|BEHAVIORAL|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
224295106|NCT02592772|OTHER|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
223941979|NCT02604251|DEVICE|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
223941980|NCT02604251|DEVICE|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
223941981|NCT03712150|DEVICE|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
223941982|NCT05642806|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
224295107|NCT02592772|OTHER|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
224295108|NCT05212441|DEVICE|Light emitting diode therapy (LED therapy)|The patient's forearm is positioned on table with palm facuing upward during the therapy. For LEDT, the center of the light spot located at approximately 50% of landmark line from the medial epicondyle to the styloid process of the ulna, which is the center belly of ﬂexor digitorum superﬁcialis. The subject's forearm maintained in the rest state without moving during the therapy. LED is performed before exercise.
224295109|NCT05212441|BEHAVIORAL|Patient/family education program (Home program)|Patients and their families will instructed to learn the anti contracture positioning/splinting, scar massage and exercises program, application of the custom garments and inserts, and functional training to perform them on their own at home. Written and illustrative instructions and reciprocal demonstration sessions will be provided to the children and their families to ensure successful acquisition and delivery of rehabilitation skills at home program. The therapist will be reported about compliance with the home program every couple of days
224295110|NCT05212441|PROCEDURE|Positioning & Splinting|"The wrist joint is splinted at 30 hyperextension, the MCP joint in 90 of flexion, the IP joints in extension, and the thumb in abduction. The webs of fingers kept in abduction. The hands are elevated above the level of the heart to minimize post-burn edema.~Splinting: Splints are tailored to help to maintain the functional or anti-contracture position of the injured body parts.The intervals for monitoring vary from once every hour to once every 4-6 hours, depending on types of splints and skin conditions. It is described as 10 hours on and two hours off. When the splint is taken off, active and/or passive ROM should be carried out."
224295111|NCT05212441|OTHER|Therapeutic Exercises|"1. Passive ROM (PROM).~2. Active ROM (AROM) \& Active-assistive ROM (AAROM): The exercise will focus on extending the wrist to 45 degrees, flexing the MCP joints to 90 degrees and keeping the IP joints in full extension, while maintaining a thumb web space. The exercises will performed in the following sequences; (1) MCP joints flexion and extension with the wrist in neutral or slight extension and the IP joints in neutral position. (2) IP joints flexion to only 30-40 degrees with the wrist stabilized in the neutral or slight extension, while the MCP joints held in full extension, (3) thumb and fingers abduction and adduction, and (4) thumb opposition (tip of the thumb to tip of the small finger). Each exercise was performed for 8-10 repetition, daily, for 6 days/week.~3. Stretching exercises: A low-load (low-intensity), long-duration stretch~4. Strengthening exercises: done in static mode initially and progress to dynamic strengthening using elastic bands."
224295112|NCT05637476|OTHER|Functional strength training of hip abductors|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Pelvic drop.~2. Single leg -bridge.~3. Side-lying hip abduction with hip internal rotation.~4. Lateral step-up.~5. Standing hip abduction on stance or swing leg with extra resistance ."
224295113|NCT05637476|OTHER|A selected physical therapy exercise program|"Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)"
224295114|NCT00215449|DRUG|Formoterol Fumarate|
224295115|NCT05528861|DRUG|Lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
224295116|NCT05528861|OTHER|Placebo|Placebo
224295117|NCT02669160|DEVICE|PC Innowalk|
224295118|NCT02669160|DEVICE|Conventional passive stander|
223535353|NCT00639457|DRUG|Pioglitazone|Oral 30mg/day for 16 weeks
223941983|NCT05642806|OTHER|Placebo|Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks
223941984|NCT04288167|DIAGNOSTIC_TEST|Sample collection|Samples of urine and saliva will be collected from participants using customary sample collection means.
223941985|NCT02438007|DRUG|Galeterone|2550 mg galeterone tablets once daily PO
223941986|NCT02438007|DRUG|Enzalutamide|160 mg enzalutamide capsules once daily PO
223941987|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
223941988|NCT03642366|OTHER|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
223941989|NCT03642366|OTHER|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
223941990|NCT00000215|DRUG|Pergolide|
223941991|NCT00144235|DRUG|Pharmaton PHL 00749|
223941992|NCT00144235|DRUG|Placebo|
223941993|NCT00023400|DRUG|Nelfinavir|
223941994|NCT00023400|DRUG|Rifabutin|
223941995|NCT02535221|DRUG|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
223941996|NCT02535221|DRUG|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
223941997|NCT01351376|DEVICE|Low Level Laser Therapy|Placebo LLL combined with CDT
223941998|NCT01351376|DEVICE|Low Level Laser|Active LLL combined with CDT
223941999|NCT05340452|DRUG|Klaribact 125mg/5ml Suspension|one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
223942000|NCT05340452|DRUG|Klaricid 125mg/5ml Suspension|one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
223942001|NCT01170208|DEVICE|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
223942002|NCT05268991|OTHER|Geriatric Assessments and Frailty Indices|Eligible and consented subjects will undergo a baseline assessment prior to chemotherapy initiation inclusive of geriatric/frailty assessments, patient reported outcomes and blood samples for biomarkers of aging. Assessment measures and blood samples will be repeated post cycle 1 and 2 of chemotherapy. Toxicity will be recorded from the medical record
223942003|NCT02322372|DRUG|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
223942004|NCT02322372|DRUG|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
223942005|NCT00766909|DRUG|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
223942006|NCT00766909|DRUG|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
223942007|NCT00766909|OTHER|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
223942008|NCT01116206|DRUG|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
223942009|NCT01116206|DRUG|Placebo|1 tablet, orally once dailyfor 12 weeks
223942010|NCT06510569|DEVICE|U lab aligners|Aligner group change the aligner every 10 days
223942011|NCT06510569|DEVICE|oramco bracket|changing orthodontic wire every one month
223942012|NCT04154007|DIAGNOSTIC_TEST|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output \<0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output \<0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of \<0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
223942013|NCT04181099|OTHER|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
223942014|NCT04273672|DIAGNOSTIC_TEST|Cognitive Battery|Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
223942015|NCT04273672|BEHAVIORAL|Voice, Speech and Language Analysis|Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
223942016|NCT04273672|BEHAVIORAL|Questionnaires and Clinical Assessments|Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
223942017|NCT04273672|GENETIC|DNA Analysis|Participants will have their blood drawn for DNA analysis.
223942018|NCT03937765|PROCEDURE|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
223942019|NCT02432898|DEVICE|3D OCT-1|Spectral Domain OCT Device
223942020|NCT02432898|DEVICE|3D OCT-2000|Spectral Domain OCT Device
223942021|NCT02432898|DEVICE|DRI OCT-1|Swept Source OCT Device
223942022|NCT02432898|DEVICE|NW-300|Fundus Camera
223942023|NCT02432898|DEVICE|CT-1P|Tonometry
223942024|NCT02432898|DEVICE|TRK-2P|Tonometry, Corneal Topography
223942025|NCT02432898|DEVICE|SP-1P|Specular Microscopy
223942026|NCT02432898|DEVICE|SL-D701|Slit Lamp Imaging
223942027|NCT02432898|DEVICE|MC-4S|Visual Acuity Testing
223942028|NCT02168309|DRUG|Labetalol|Titrate up for blood pressure control
223942029|NCT02168309|DRUG|Nifedipine|Titrate up to achieve blood pressure control
223942030|NCT02233556|DRUG|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~1. Mismatch negativity(MMN)~2. P50"
223942031|NCT05230966|DEVICE|Remote Ischemic Conditioning (RIC)|RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
223942032|NCT04422392|DRUG|Carboplatin|(IV, Q3W)
223942033|NCT04422392|DRUG|Pemetrexed or Nab-paclitaxel|Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
223942034|NCT04422392|DRUG|PD-1 antibody|(IV, Q3W)
223942035|NCT05538572|DRUG|PRT3645|PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
223942036|NCT03989310|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
223942037|NCT03989310|DRUG|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
223942038|NCT03989310|DRUG|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
223729362|NCT01602874|DRUG|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
223942039|NCT03989310|DRUG|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
223942040|NCT05146635|DRUG|Intravesical Bcg|Patients will receive induction and maintenance BCG after complete TURBT.
223942041|NCT05146635|DRUG|Intravesical chemotherapy (epirubicin)|Patients will receive induction and maintenance epirubicin after complete TURBT.
223942042|NCT00592891|DRUG|Hyperbaric oxygen therapy|Total body pressurized oxygen
223942043|NCT05925335|DEVICE|Transseptal Transcatheter Mitral valve-in-valve Replacement|Transcatheter transfemoral mitral valve-in-valve replacement is an alternative surgery in patients with severe dysfunction of a degenerated mitral bioprosthesis and high surgical risk for repeat operation. The procedure is performed via femoral vein access. All procedures were carried out using intra-procedural TEE guidance to aid in transseptal puncture. After balloon septostomy, the bioprosthetic valve is introduced through the degenerative valve into the left ventricle and expanded in the mitral position during rapid ventricle pacing.
223942044|NCT04419207|DIAGNOSTIC_TEST|Breath test|Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
223942045|NCT06630325|DRUG|Abemaciclib|Given PO
223942046|NCT06630325|PROCEDURE|Biopsy|Undergo tumor biopsy
223942047|NCT06630325|PROCEDURE|Bone Scan|Undergo bone scan
223942048|NCT06630325|DRUG|Carboplatin|Given IV
223942049|NCT06630325|PROCEDURE|Echocardiography|Undergo echocardiography
223942050|NCT06630325|DRUG|Exemestane|Given PO
223942051|NCT06630325|DRUG|Fulvestrant|Given IM
223942052|NCT06630325|DRUG|Gefitinib|Given PO
223942053|NCT06630325|DRUG|Gemcitabine|Given IV
223942054|NCT06630325|DRUG|Letrozole|Given PO
223942055|NCT06630325|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223942056|NCT06630325|DRUG|Olaparib|Given PO
223942057|NCT06630325|DRUG|Osimertinib|Given PO
223942058|NCT06630325|DRUG|Paclitaxel|Given IV
223942059|NCT06630325|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223942060|NCT06630325|DRUG|Pemetrexed|Given IV
223942061|NCT06630325|OTHER|Survey Administration|Ancillary studies
223942062|NCT06630325|DRUG|Tamoxifen|Given PO
223942063|NCT06630325|DRUG|Temozolomide|Given PO
223942064|NCT06630325|PROCEDURE|Biospecimen Collection|Biological Sample Collection, Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection
223942065|NCT02423642|PROCEDURE|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
223942066|NCT02423642|PROCEDURE|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
223942067|NCT01722409|DRUG|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
223942068|NCT01722409|DRUG|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
223942069|NCT02483468|BEHAVIORAL|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
223942070|NCT02483468|DEVICE|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
223942071|NCT02483468|DEVICE|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
223942072|NCT03677037|OTHER|Short-term MBT|Short-term mentalization-based therapy
223942073|NCT03677037|OTHER|Long-term MBT|Long-term mentalization-based therapy
223942074|NCT06495970|DEVICE|Gradient Denervation System|The Gradient Denervation System delivers ultrasound ablation to planned locations in the pulmonary artery to down-regulate the sympathetic nervous drive. The system includes a sterile, single-use catheter that is designed to centrally position the transducer within the arterial target zone for consistency of ablation.
223942075|NCT03335488|DRUG|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
223942076|NCT03335488|DRUG|NaPBA|"* NaPBA in patients weighing \< 20 Kg - 600 mg/Kg, maximum total daily dose~* NaPBA in patients weighing \> 20 Kg - 13 g/m2, maximum total daily dose"
223942077|NCT03771066|BEHAVIORAL|bisphenol A|Vanilla wafer cookie with bisphenol A administered
223942078|NCT03771066|BEHAVIORAL|Placebo|Vanilla wafer cookie with no bisphenol A
223942079|NCT05328466|DEVICE|The engineer-built system, video-game based Kinect sensor|The games were developed by the researcher team.
223942080|NCT03183804|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
223942081|NCT03183804|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
223942082|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
223942083|NCT01003366|DEVICE|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
223942084|NCT00856362|DRUG|Moxidectin|
223942085|NCT00856362|DRUG|Midazolam|
223535354|NCT00639457|BEHAVIORAL|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
223942086|NCT06174948|DEVICE|CUE1 non-invasive device|This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.
223942087|NCT06174948|DEVICE|CUE1+ device active vs sham CUE1+ device|30-40 participants with idiopathic Parkinson's disease only will be randomly allocated to one of two interventions groups: one group will use the active CUE1+ device while the other group will use the CUE1+ at silent settings (e.g., sham device). All participants will use their device in the same way which is starting the usage from the morning, within an hour once they took their medications for Parkinson's (if any) and continue using the device for 8 hours, once a day, every day for 12 weeks
223942088|NCT04346914|BIOLOGICAL|recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide|ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
223942089|NCT03741023|PROCEDURE|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture and/or by fingerstick. Finger sticks will not be collected in the pediatric population.
223942090|NCT05038839|DRUG|Cabozantinib|Given PO
223942091|NCT05038839|DRUG|Pamiparib|Given PO
223942092|NCT06336590|BEHAVIORAL|Morning Exercise|Exercise is changed from normal (6pm-11pm) exercise to morning (6am-11am) exercise.
223942093|NCT02022670|DRUG|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
223942094|NCT02022670|DRUG|Sodium Nitrite|80 mg/d or 160 mg/d
223942095|NCT02113449|DRUG|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
223942096|NCT02792738|BEHAVIORAL|hypnosis|
223942097|NCT00324948|DRUG|Topical alprostadil (PGE-1)|
223942098|NCT00868894|DRUG|DE-104 medium concentration|Topical ocular application
223942099|NCT00868894|DRUG|DE-104 high concentration|Topical ocular application
223942100|NCT00868894|DRUG|Placebo|Topical ocular application
223942101|NCT00868894|DRUG|0.005% latanoprost|Topical ocular application
223942102|NCT03336892|BEHAVIORAL|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
223942103|NCT05841342|OTHER|No intervention|No intervention
223942104|NCT04931966|PROCEDURE|block|Adductor canal block
223942105|NCT04931966|PROCEDURE|adductor canal block|adductor canal block bupivacain
223942106|NCT04931966|PROCEDURE|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using bupivacaine
223942107|NCT04931966|PROCEDURE|adductor Canal Block plus PAI Block|Adductor Canal Block plus PAI Block using bupivacaine
223942108|NCT06013124|OTHER|Work environment, well-being, customer satisfaction|Evaluation hospital work environment, staff well-being features and patients/caregivers satisfaction and perceived quality of care
223942109|NCT04316494|DRUG|Hydroxychloroquine|"White, round, film-coated tablets marked 'HCQ' on one side and 200' on the other side.~Excipients:~Lactose monohydrate Maize Starch Magnesium Stearate Polyvidone Opadry OY-L-28900"
223942110|NCT04316494|DRUG|Placebo|"Placebo to match Hydroxychloroquine.~Excipients:~Microcrystalline cellulose Lactose Magnesium Stearate"
223942111|NCT01347294|DRUG|Bleomycin|Intralesional
223942112|NCT01347294|DRUG|Fibrovein|Intralesional
223942113|NCT01347294|DRUG|Bleomycin + Fibrovein|Intralesional
223942114|NCT02590198|OTHER|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
224122636|NCT06261138|OTHER|Systemic treatment|"sorafenib (Bayer HealthCare, Berlin, Germany), lenvatinib (Eisai, Tokyo, Japan), apatinib (Hengrui Pharmaceuticals, Lianyungang, China) and donafenib (Zelgen Biopharmaceuticals, Suzhou, China), while a minority of patients received bevacizumab (Innovent Biologics, Suzhou, China).~sintilimab (Innovent Biologics, Suzhou, China), toripalimab (Junshi Biosciences, Suzhou, China), camrelizumab (Hengrui Pharmaceuticals, Lianyungang, China), tislelizumab (BeiGene, Shanghai, China), pembrolizumab (Merck Sharp \& Dohme, NewJersey, USA), nivolumab (Bristol Myers Squibb, New York, USA), atezolizumab (Roche, Basel, Switzerland) and envafolimab (Alphamab Biopharmaceuticals, Suzhou, China)."
224122637|NCT04072146|DRUG|Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg|Cross over bioavailability study
223942115|NCT02590198|OTHER|PCT algorithm|care based on PCT algorithm
223942116|NCT03208465|DRUG|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
223942117|NCT03208465|DRUG|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
223942118|NCT04409392|OTHER|Prothestic joint infection due to Staphylococcus lugdunensis|description of prosthetic joint infection with Staphylococcus lugdunensis
223942119|NCT04008953|DEVICE|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
223942120|NCT02042092|DEVICE|Ultrasound|
223942121|NCT02042092|DEVICE|MRA|
223942122|NCT03917186|DRUG|Sevoflurane|administration of sevoflurane
223942123|NCT03917186|DRUG|Desflurane|administration of Desflurane
223942124|NCT05749120|PROCEDURE|Recipient vessel selected for microanastomosis|Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
223942125|NCT04374981|DRUG|Celecoxib 100mg|Tablets
223942126|NCT04374981|DRUG|Montelukast 10mg|Tablets
223942127|NCT03441009|OTHER|Physio-/occupational therapy|Physio-/occupational therapy, ADL
223942128|NCT04964037|OTHER|No intervention|No intervention
223942129|NCT05912218|BIOLOGICAL|MEI6570|Saline Control
223942130|NCT04638816|DEVICE|Restylane Volyme|Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).
223942131|NCT04638816|DEVICE|Restylane Lyft Lidocaine|Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).
223942132|NCT04309552|DRUG|18F-FMISO PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
223942133|NCT04309552|DRUG|18F-FLT PET|Suspected HGG subjects will undergo combined FMISO/FLT dyn-PET at baseline as part of surgical planning. Dyn-PET images will be acquired with staggered FMISO/FLT injections using a lag time of 50 minutes. Preoperatively FMISO/FLT dyn-PET data will be used for intraoperative neuro-navigation and targeted sampling of PET avid tumor subregions prior to tumor excision. Paraffin blocks will be analyzed with immuno-histochemistry and in situ hybridization for HIF-1α, Ki-67, VEGF, EGFR, IDH, and pimonidazole, as well as TERT. FMISO-PET uptake rate, k3, (surrogate for hypoxia) and FLT-PET influx rate, Ki (surrogate for proliferation) will be correlated with time to progression, progression-free survival at 9 months, and overall survival (OS) at 1 year.
223942134|NCT06315985|OTHER|Experimental group: Listenning to the Turkish Classical Music to pregnant women diagnosed with preeclampsia|The music to be used in the research will be applied together with midwifery practices and is not a treatment option, tool or treatment option for any disease. Although listening to Classical Turkish music has no effect on treatment and care, it does not have a harmful effect on pregnant women. The participant can withdraw from the study at any time without giving any reason. The Personal Information Form, Perceived Stress Scale, and Pittsburgh Sleep Quality Index (PSQI) will be administered to the pregnant women in both groups participating in the study by face-to-face interviews with the individuals on the first day of their admission to the clinic. At the end of the third day, the Perceived Stress Scale and Pittsburgh Sleep Quality Index (PSQI) scales will be re-administered to both groups.
223942135|NCT02400931|PROCEDURE|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
223942136|NCT02400931|PROCEDURE|no mask ventilation|
223942137|NCT02400931|DRUG|Rocuronium|
223942138|NCT06303869|DEVICE|Deep Brain Stimulation (DBS) of the Motor Thalamus|All participants enrolled in this group will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days.
223942139|NCT02251652|DRUG|Ingenol Mebutate|Ingenol mebutate 0.05% gel
223942140|NCT02251652|PROCEDURE|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
223942141|NCT00087022|BIOLOGICAL|girentuximab|Given IV
223942142|NCT00087022|OTHER|placebo|Given IV
223942143|NCT05212272|PROCEDURE|PET-MRI Brain Scan|Before starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
223942144|NCT05212272|DIAGNOSTIC_TEST|Blood draw|Blood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
223942145|NCT05212272|BEHAVIORAL|Memory testing|3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
223942146|NCT05212272|PROCEDURE|Optional lumbar puncture for cerebrospinal fluid collection|Participants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
223942147|NCT04207424|PROCEDURE|Emblization of the gastro-epiploic arcade|Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
223942148|NCT01280513|DIETARY_SUPPLEMENT|High protein intake|30% of energy intake coming from proteins
223942149|NCT01280513|DIETARY_SUPPLEMENT|Low Protein intake|9% of energy intake coming from proteins
223942150|NCT05951036|PROCEDURE|Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 70% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
223535355|NCT03324789|OTHER|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
223535356|NCT03324789|OTHER|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
224122638|NCT04072146|DRUG|OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg|Cross over bioavailability study
223535357|NCT04628130|OTHER|Yoga Therapy|Yoga based self managed practices personalised to chronic pain patients
223942151|NCT05951036|PROCEDURE|Sham Low-load Blood Flow Restriction training|Physical therapist will apply the BFR cuffs with 10% of arterial occlusion pressure on the both legs of participants. Then, participants will be asked to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 30% of repetition maximum.
223942152|NCT05951036|PROCEDURE|High-load Eccentric training|Physical therapist will ask participants to perform eccentric trainings (including, double leg squats, split squats, deadlifts, and monster walks) with 70% of repetition maximum.
223942153|NCT04543812|DRUG|Ferric citrate|Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
223942154|NCT04543812|DRUG|Placebo|Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.
223942155|NCT03885245|DRUG|L-ctirulline|7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
223942156|NCT03885245|DRUG|Matching Placebo|7 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
223942157|NCT06394947|OTHER|Fluid administration (any type)|The fluid challenge (FC) (bolus) is defined as the administration of any bolus of fluid (crystalloid or colloid) which is expected to affect pressure/flow/perfusion variables. The FC is expected to be completed within 30 min.
223942158|NCT06230731|OTHER|Oxygen saturation|Measure oxygen levels in 5 proximal colon mucosa locations.
223942159|NCT02873559|DRUG|testosterone|Testosterone supplemented in 5 months
223942160|NCT02873559|OTHER|Progressive muscle training|Progressive muscle training during 4 months
223942161|NCT04366024|OTHER|other|clinical diagnosis
223942162|NCT04989296|DIAGNOSTIC_TEST|Peripheral blood samples were obtained following the standard procedures.|Taking 4 ml of peripheral blood from patients on an empty stomach.
223942163|NCT04514718|DEVICE|Holmium laser|low energy holmium laser
223942164|NCT01160354|DRUG|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
223535358|NCT05287750|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
223942165|NCT01160354|DRUG|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
223942166|NCT01822756|DRUG|ruxolitinib|
223942167|NCT01822756|DRUG|gemcitabine|Other names: Gemzar®
223942168|NCT01822756|DRUG|nab-paclitaxel|Other names: Abraxane®
223942169|NCT01822756|DRUG|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
223942170|NCT04738656|DIETARY_SUPPLEMENT|Diet plan|Mediterranean style is a non-restricted diet plan compared with the open protein diet plan
223942171|NCT04876495|DIETARY_SUPPLEMENT|Whey protein isolate|"Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the whey protein shake:~* Tropicana Trop50 Orange Juice 207mL~* Water 43 mL~* Sucralose 0.5g~The total energy 233.47Kcal.~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
223942172|NCT04876495|DIETARY_SUPPLEMENT|Potato protein isolate|"Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.~Other ingredients in the potato protein shake:~* Tropicana Trop50 Orange Juice 250mL~* Sucralose 0.5g~The total energy 233.46Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
223942173|NCT04876495|DIETARY_SUPPLEMENT|Rice protein isolate|"Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.~Other ingredients in the rice protein shake:~* Tropicana Trop50 Orange Juice 183mL~* Water 67mL~* Sucralose 0.5g~The total energy 233.43Kcal~Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study."
223942174|NCT01918176|DRUG|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
223942175|NCT01918176|DRUG|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
223942176|NCT03636854|OTHER|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
223942177|NCT03636854|OTHER|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
223942178|NCT05783843|BEHAVIORAL|Pictorial Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different pictorial warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
223942179|NCT05783843|BEHAVIORAL|Text Warnings|Participants will be shown 6 waterpipe tobacco packages with 6 different text-only warnings about the health harms of waterpipe smoking. The order of the 6 packages within this trial arm will be randomized. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study and designed the warnings for this arm.
223942180|NCT05783843|BEHAVIORAL|No Warnings (Control)|Participants will be shown a single package without a warning. Study investigators developed a fictitious waterpipe tobacco brand to be used in this study.
223942181|NCT02419300|DEVICE|ultrasoungraphy|pelvic ultrasonography and Doppler
223942182|NCT05035329|OTHER|Outcome measurements|Outcome measurements were applied.
223942183|NCT01025128|DRUG|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
224099753|NCT07018518|BIOLOGICAL|PIN +anti-PD1|"1. Initial treatment phase:~   PIN injection frequency:~   day 0 and day 3, per 3 weeks for 8 cycles; PIN injection dosage: Cycle1: 4e9 or 8e9 viral particles of PIN based on the number of injectable lesions, their longest diameter, and the tumor volume capacity .~   Cycle 2\~8: 4e9 or 8e9 viral particles of PIN based on the tumor volume's capacity.~   Anti-PD1: day -3, per 3 weeks for 8 cycles;~2. Maintenance treatment phase:~   No injection lesion: Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~   Have injection lesion: PIN: 4e9 or 8e9 viral particles based on the tumor volume's capacity, per 6 weeks (within first 24 weeks), then per 8 weeks till 2 years unless unavailability of injection lesion, PD or serious intolerable AEs.~   Anti-PD1: day 1, per 3 weeks till 2 years unless PD or serious intolerable AEs.~3. Salvage treatment phase: Dosage and frequency of administration refer to the initial treatment phase and maintenance treatment phase."
224099754|NCT06127472|OTHER|Training in detection and diagnosis of ASD|To improve detection and diagnosis of ASD the participating mental health institutes will be trained by the research group on how to detect and diagnose autism in older adults. The basis of the ASD training involves two separate training sessions. Part one focuses on recognition and detection of ASD, specifically in older adults, and will be offered to the entire teams of the participating centres. The second part of the training focuses on the diagnosis of ASD and as such is offered primarily to diagnosticians. Follow up will consist of monthly recurring options for online consultation during the entire project to discuss clinical cases by experts in ASD in older adults from PersonaCura, clinical centre of excellence for personality and developmental disorders in older adults (dr. A. Videler and R. Wilting).
224099755|NCT06127472|OTHER|PE program|An adapted PE program for older adults with a (probability) diagnosis of ASD. The PE program consists of eight, two-hour group meetings on a weekly basis.
224099756|NCT07022184|DEVICE|Personalized Lifestyle Intervention|"The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse.~The Patient Journey App integrates four digital health tools within a single smartphone application:~1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity.~2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals.~3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals.~4. Monitoring of depression symptoms over time to support measurement-based care.~General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes."
224099757|NCT04008524|BIOLOGICAL|CAR-T cells|Chimeric Antigen Receptor-T cells
224099758|NCT02656472|DRUG|Tranexamic acid|TXA Loading dose: 31 mg/kg diluted to 2 ml/kg Normal saline (NS) -in syringe
224099759|NCT02656472|DRUG|Epsilon Aminocaproic Acid|Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
223535359|NCT03235050|DRUG|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
223942184|NCT03849066|OTHER|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 28 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 28 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
223942185|NCT04439500|BEHAVIORAL|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
223942186|NCT04439500|BEHAVIORAL|Brain Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
223942187|NCT00297349|DRUG|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
223942188|NCT00367874|DRUG|Buprenorphine|
223942189|NCT00367874|DRUG|Valproate|
223942190|NCT03243006|DRUG|Paracetamol|2 tablets of 500mg of paracetamol
223942191|NCT03243006|DRUG|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
223942192|NCT03243006|DRUG|Placebo Oral Tablet|2 tablets of placebo
223942193|NCT01543893|BEHAVIORAL|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
223942194|NCT01543893|BEHAVIORAL|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
223942195|NCT06210152|DEVICE|Radial Extracorporeal Shockwave Therapy|Radial Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. Each session involved the delivery of 1000 pulses at a frequency of 10Hz and an air pressure setting of 1.0 bar.
223942196|NCT06210152|DEVICE|Sham Extracorporeal Shockwave Therapy|Sham Extracorporeal Shockwave Therapy (rESWT) was administered using the Masterpuls® MP200 device (Storz Medical AG, Tägerwilen, Switzerland). Participants were seated with their calves exposed. A coupling gel was applied to the Achilles tendon area and, adhering to the 90° application rule, a 15-mm applicator was used in both transverse and diagonal patterns at the myotendinous junction, extending across the muscle belly using a smoothing motion. In each session, the device was held against the achilles tendon without being powered on.
223942197|NCT04318483|OTHER|survey|parents' telephone interview to collect medical history
223942198|NCT06508749|DRUG|PGDM1400LS|IV Antibody Infusion based on subject's weight
223942199|NCT06508749|DRUG|VRC07-523LS|IV Antibody Infusion based on subject's weight
223942200|NCT06508749|DRUG|PGT121.414.LS|IV Antibody Infusion based on subject's weight
223942201|NCT06508749|DRUG|ART Regimen prior to enrolling in Step 1a|Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.
223942202|NCT06508749|DRUG|ART Regimen prior to enrolling in Step 1b|Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.
223942203|NCT06508749|OTHER|Analytic Treatment Interruption|(all anti-HIV agents are discontinued)
223942204|NCT01708278|DRUG|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
223942205|NCT01708278|OTHER|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
223942206|NCT01122914|DRUG|Anakinra|
223942207|NCT03693807|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
223942208|NCT03693807|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
223942209|NCT03693807|DRUG|Gemcitabine|Please see Detailed Description.
223942210|NCT03693807|DRUG|Oxaliplatin|Please see Detailed Description.
223942211|NCT03693807|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
223942212|NCT03693807|DRUG|Fluorouracil|Please see Detailed Description.
223942213|NCT03693807|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
223942214|NCT06195345|DIAGNOSTIC_TEST|MR Imaging|MR imaging pertaining to the patient and project (ICHOR 1)
223942215|NCT00191542|DRUG|Atomoxetine|
223942216|NCT00191542|DRUG|Placebo|
223942217|NCT04251923|DEVICE|Retro pubic sling|patient after hysterectomy will undergo retropubic sling surgery in the same setting. Retropubic sling will be inserted vaginally in the retropubic area following standard protocol.
223942218|NCT01524497|DRUG|Trazodone|75mg tablet/150 mg tablet
223942219|NCT01524497|DRUG|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
223942220|NCT04139304|DRUG|Cyclophosphamide|Given IV
223942221|NCT04139304|BIOLOGICAL|Daratumumab|Given IV
223942222|NCT04139304|DRUG|Doxorubicin|Given IV
223942223|NCT04139304|DRUG|Doxorubicin Hydrochloride|Given IV
223942224|NCT04139304|DRUG|Etoposide|Given IV
223942225|NCT04139304|DRUG|Prednisone|Given PO
223942226|NCT04139304|DRUG|Vincristine|Given IV
223942227|NCT04139304|DRUG|Vincristine Sulfate|Given IV
223942228|NCT03067948|BEHAVIORAL|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
223942229|NCT02138123|PROCEDURE|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
223942230|NCT02138123|PROCEDURE|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
223942231|NCT04468412|DIAGNOSTIC_TEST|Carotid Artery Reactivity Testing|The carotid artery reactivity (CAR) test assesses macrovascular endothelial function by measuring the carotid artery diameter in response to sympathetic stimulation. Participants are in the supine position with the neck extended for assessment of the carotid artery. Left carotid artery diameter is recorded continuously during baseline (30 seconds) and during immersion of the right hand up to the wrist in icy water (4°C) for 3 minutes. CAR can either represent a dilatory response (normal endothelial function) or a constrictive response (endothelial dysfunction) of the carotid artery.
223942232|NCT06294249|DEVICE|Laser-induced Incision|On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.
223942233|NCT06294249|PROCEDURE|Punch Incision|On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.
223942234|NCT06294249|PROCEDURE|Implant Placement|Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
223942235|NCT03758742|BEHAVIORAL|High-Fruit Diet|In this supervised controlled feeding study, participants will consume a diet rich in whole fruit. During the Ramp-Up Phase (Weeks 1-4), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In the Main Phase (Weeks 5-12), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable throughout the intervention.
223942236|NCT05886920|DRUG|D3S-002|Oral
223942237|NCT05682950|RADIATION|online adaptive radiotherapy|CTV covers pelvis.
223942238|NCT00597636|BEHAVIORAL|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
223942239|NCT00597636|BEHAVIORAL|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
223942240|NCT06623773|DRUG|Chondroitin sulfate|Chondroitin sulfate (CS) is a natural biomacromolecule belonging to the class of glycosaminoglycans and is an unbranched complex polysaccharide consisting of a repeating disaccharide structure of glucuronic acid and N-acetyl-D-glucosamine \[18\]. It is a major component of the extracellular matrix (ECM), where it constitutes an essential component of proteoglycans. Oral bioavailability of CS has been demonstrated \[19\], and its use for the treatment of OA has been established in animal models \[20\], as well as in clinical trials \[21, 22\]. CS, is available as a pharmaceutical grade drug (Structum®), meaning that the product is manufactured under Good Manufacturing Practices (GMP) conditions, and is in excess of 99% purity with no binders, fillers, excipients, dyes, or unknown substances. According to the Instructions for Use (IFU), the recommended posology for Structum® is 500 mg twice daily.
223942241|NCT03565484|DRUG|susceptibility guided therapy|Patients will take a gastroscopy and 2 biopsies will be attained from antrum and gastric body for H.pylori culture and antimicrobial susceptibility testing (AST). The susceptibility of amoxicillin, clarithromycin, metronidazole, levofloxacin, furazolidone and tetracycline will be tested.Then patients with positive culture will be treated with a 14-day quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST. Dose of two sensitive antibiotics are listed as follows : amoxicillin 1000mg bid, clarithromycin 500mg bid, tinidazole 500mg tid, levofloxacin 500mg qd, furazolidone 100mg bid, tetracycline 500mg qid.
224099760|NCT07031076|DIETARY_SUPPLEMENT|Ready-to-eat lean pork in frozen, 5-oz packages|The dietary intervention lasts 16 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 4 portions of ready-to eat lean pork in frozen packages per week; each portion of ready-to-eat lean pork in this intervention will weigh 5 ounces.
223942242|NCT03565484|DRUG|personal medication history guided therapy|Patients will be treated with a 14-day emprical tailored quadruple therapy for the H.pylori eradication. The regimen contains rabeprazole 20mg bid， colloidal bismuth pectin 200mg bid and two antibiotics based on personal medication history. If the patient doesn't have levofloxacin history, he will be treated with amoxicillin 1000mg bid plus levofloxacin 500mg bid. Otherwise, he will be treated with amoxicillin 1000mg bid and furazolidone 100mg bid.
223942243|NCT03565484|DRUG|salvage treatment for failed eradication|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, tetracycline 500mg qid and furazolidone 100mg bid.
223942244|NCT03874169|DEVICE|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
223942245|NCT04874259|PROCEDURE|Living donor liver transplantation|Living donor liver transplantation
223942246|NCT01827839|BIOLOGICAL|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
223942247|NCT03987646|PROCEDURE|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
223942248|NCT01536366|DRUG|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
223942249|NCT01536366|DRUG|Repaglinide|0.5 mg repaglinide (single-dose)
223942250|NCT06110546|DRUG|Methadone group|Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).
223942251|NCT06110546|DRUG|Usual care|Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
223942252|NCT04366193|DIAGNOSTIC_TEST|Oximetry|Validation of a high-resolution wireless oximeter for OSA diagnosis comparing with a well established and validated method (home sleep test).
223942253|NCT01484743|PROCEDURE|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
223942254|NCT06515210|DIETARY_SUPPLEMENT|Acacia Gum|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
223942255|NCT06515210|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|Participants (n=23) incorporate the fibre supplement into their usual diet daily.
223942256|NCT06515210|DIETARY_SUPPLEMENT|Placebo|Participants (n=23) incorporate the placebo into their usual diet daily.
223942257|NCT06051799|OTHER|Myofascial trigger points pressure release|Patient lying down in the supine position, Therapist do a first and second finger pincer grasp is performed on the myofascial trigger points located on the upper trapezius muscle and sternocleidomastoid muscle, this pressure will be increased as the therapist perceives a reduction in soft tissue resistance under the finger over a period of 90 seconds. Previous studies indicate no difference between 60 and 90 seconds of pressure. It will be performed on as many trigger points as we find in each muscle associated with the study.
223942258|NCT06051799|OTHER|Therapeutic exercise and postural hygiene|"Therapeutic exercise and postural hygiene: A progression of exercises with contraction of the deep neck flexor muscles will be included in the first session. Subjects will be taught to perform a slow and controlled craniocervical flexion. Subjects will then be trained to be able to progressively maintain craniocervical flexion through feedback from an air device (Stabilizer™, Chattanooga Group Inc., Chattanooga, TN) placed behind the neck. This sensor monitors the slight flattening of the cervical curve that occurs with contraction of the craniocervical deep flexor musculature. It should be performed at least once a day during the treatment regimen.~Also Postural correction exercises carried out regularly throughout the day, especially when seated. Indications are given to avoid pelvic retroversion and maintain a natural lumbar lordosis while performing retraction and adduction of the scapulae and gently lengthening the spine."
223942259|NCT04705649|OTHER|Treatment de-escalation|De-escalation from standard treatment based on molecular profile
223942260|NCT04350619|OTHER|Genetic screening. No therapeutic intervention|Genetic screening using NGS technique. No therapeutic intervention
224099761|NCT07031011|BIOLOGICAL|PD-1-M1-NK Cells|At dose escalation stage, four dose groups were initially determined: 5×106CAR NK cells/kg, 1×107CARNK cells/kg, 2×107CARNK cells/kg, and 5×107 CARNK cells/kg. Administration cycle: In Cycle 1 (C1), the drug was administered once on days 1, 4, 7, 10 and 13 respectively. A complete cycle was formed by five consecutive administrations. For subjects with stable, partial response or complete response in the tumor assessment at the first time in week 4, the treatment in Cycle 2 will continue subsequently. In Cycle 2, the drug was administered once every two weeks (Q2W: D14±7 days and D28±7 days).
223942261|NCT01695291|DRUG|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
223942262|NCT01695291|OTHER|Placebo|A placebo pill will be administered twice a day (BID) for 12 weeks.
223942263|NCT03988283|BIOLOGICAL|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive one injection of the neoantigen DNA vaccine, one injection into the vastus lateralis.
223942264|NCT03988283|DEVICE|Papivax Biotech TDS-IM v2.0|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM v2.0 device - Papivax Biotech).
224099762|NCT07030816|DEVICE|Guardner Belt|The Guardner Belt is a commercially available elastic lumbar support belt designed to reduce low-back pain and improve posture. Participants wore the belt sized according to waist circumference for at least 8 hours per day during working hours for 4 weeks.
224287422|NCT05617625|DEVICE|CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)|CliniMACS system will be used to derive CD34+ enriched, T-cell depleted (T-cells limited to 1.0 x 10\^5 CD3+ cells/kg) PBSC for transplant, which will occur on Day 0. PBSC (5 x 10\^6 CD34+ cells/kg) are suspended in a volume of approximately 20-50 mL and delivered via IV infusion over 15 minutes.
223942265|NCT03988283|PROCEDURE|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); no more than 2 weeks after the 3rd vaccine dose; no more than 2 weeks after the 6th vaccine dose; two weeks after the last dose; time of progression or discontinuation (optional)
223942266|NCT06354985|DRUG|Modafinil 200mg|Modafinil 200mg daily for 8 weeks.
223942267|NCT06354985|DRUG|Placebo|Placebo daily for 8 weeks.
223942268|NCT06354985|BEHAVIORAL|Exercise|Exercise three times per week for 8 weeks.
223942269|NCT06670651|DEVICE|total knee arthroplasty device|total knee arthroplasty device with ultracongruent bearing surface
223942270|NCT04177498|DRUG|Rigosertib Sodium|given PO or 72 hour continuous infusion
223942271|NCT04177498|OTHER|Quality-of-Life Assessment|Ancillary studies
223942272|NCT05044312|OTHER|Sleeping Disturbances|most common complaints of patients after surgery and may affect the ability to carry out daily activities, quality of life, and post-surgery recovery.
223942273|NCT05014516|DRUG|129Xenon gas|Observational
223942274|NCT05175898|DEVICE|VA-ECMO|Treatment with veno-arterial extracorporeal membrane oxygenation
223942275|NCT05175898|DEVICE|ECMELLA|Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
223942276|NCT01421836|PROCEDURE|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
223942277|NCT01421836|PROCEDURE|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
223942278|NCT02147717|DEVICE|Laser stimulation|"Infants will be divided in 2 groups:~* Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~* Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
223942279|NCT02147717|DEVICE|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
223942280|NCT03005119|DRUG|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
223942281|NCT03005119|DRUG|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
223942282|NCT03382470|OTHER|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
223942283|NCT05927220|DIAGNOSTIC_TEST|Biopsy Specimens Histopathology|paraffin-embedded blocks with sections from the tumor will be selected. Patterns of invasion will be recorded by for all cases by histopathologists
223942284|NCT00405158|PROCEDURE|Acupuncture treatment|
223942285|NCT00405158|PROCEDURE|Administration of oxytocin nasal spray|
223942286|NCT00405158|PROCEDURE|Improved breast milk removal|
223942287|NCT00405158|PROCEDURE|Warmth applied to breasts|
223942288|NCT00405158|PROCEDURE|Breast massage|
223942289|NCT00405158|DRUG|Anti-pyretic medication, paracetamol|
223942290|NCT00405158|DRUG|cefadroxil|
224295119|NCT01602172|BEHAVIORAL|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
223535360|NCT03235050|DRUG|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
223942291|NCT00405158|DRUG|penicillin|
223942292|NCT00405158|DRUG|flucloxacillin|
223942293|NCT01125124|DRUG|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
223942294|NCT01724996|OTHER|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
223942295|NCT05048758|OTHER|No intervention|No intervention
223942296|NCT00160498|DRUG|Lercanidipine|
223942297|NCT02071043|DRUG|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3
223942298|NCT02071043|DRUG|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
223942299|NCT03608293|DIAGNOSTIC_TEST|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
223942300|NCT00533494|BEHAVIORAL|physician feedback (A)|Feedback information to physicians
223942301|NCT02736851|OTHER|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
223942302|NCT00933270|DEVICE|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
223942303|NCT00755144|DEVICE|LCS Knee|Cementless total knee arthroplasty with LCS Knee
223942304|NCT00755144|DEVICE|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
223942305|NCT00266448|DRUG|Chlorhexidine solution 4%|
223994379|NCT05253599|DEVICE|Virtual reality training|"Training was given in the sitting position which provides challenges to the balance activities of the participant. The game which was used in the current study was a shooting game, which consists of the subject sitting on the virtual platform and visualizing the game on the display screen. The game was executed and controlled by moving the trunk back and forth and left and right according to the signs. Participants can perform all the six movements of their spine within their pain limits.~The level of difficulty of the exercises was increased by graded activity, in which the activities were gradually getting difficult and harder as participants required more muscle activity and movement."
223942306|NCT05753176|BEHAVIORAL|Online 1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained facilitators (i.e., psychotherapists, social workers, nurses, and/or a psychiatrist) consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. Participants are also given a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD.
223942307|NCT05250206|OTHER|Myopia control lens|Evaluation of the efficacy in decreasing myopia progression of the proposed ophthalmic lens prototypes.
223942308|NCT03476798|DRUG|Rucaparib|Rucaparib 600mg PO BID daily
223942309|NCT03476798|DRUG|Bevacizumab|Bevacizumab 15mg/kg IV on day 1 of each cycle
223942310|NCT03532477|DRUG|Venlafaxine|Patients are tested for their normal prescription metaprolol medication
223942311|NCT00592345|RADIATION|Proton Beam Radiation|Administered over a period of 12 weeks.
223942312|NCT00592345|RADIATION|Photon Beam Radiation|Administered over a period of 12 weeks.
223942313|NCT00592345|RADIATION|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
223942314|NCT06151782|DIETARY_SUPPLEMENT|Wheat gluten 1000 mg|Nothing to add here
223942315|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 1000 mg|Nothing to add here
223942316|NCT06151782|DIETARY_SUPPLEMENT|Barley gluten 50 mg|Nothing to add here
223942317|NCT06151782|DIETARY_SUPPLEMENT|Barley hydrolyzed gluten 50 mg|Nothing to add here
223942318|NCT06151782|DIETARY_SUPPLEMENT|Placebo slurry|In slurry, measurement of immune activation (Interleukin-2) four hours after intake
223942319|NCT05882695|DRUG|SPG302|synthetic small molecule
223942320|NCT05882695|DRUG|Placebo|Placebo
223942321|NCT06594445|DRUG|GTB-360|"GTB-3650 is administered by a continuous infusion (CI). A patient's dose of GTB-3650 is calculated using their assigned Dose Level and their actual body weight (ABW) obtained within 5 days prior to or on Cycle 1, Day 1.~Dose Level 1: 1.25 ug/kg/day Dose Level 2: 2.5 ug/kg/day Dose Level 3: 5 ug/kg/day Dose Level 4: 10 ug/kg/day Dose Level 5: 25 ug/kg/day Dose Level 6: 50 ug/kg/day Dose Level 7: 100 ug/kg/day"
223942322|NCT06988059|DRUG|CAR-T cells Infusion chimeric antigen receptor T cells|CAR-T cells Infusion
223942323|NCT06857968|BEHAVIORAL|Mobile Mindfulness Training|Participants will be instructed to complete a mobile application-based mindfulness training daily for 30 days.
223942324|NCT05824559|DRUG|ME-344|ME-344 will be administered intravenously (IV)
223942325|NCT05824559|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV)
223942326|NCT05282706|DRUG|Lavender Oil|A hydrogel lavender oil infused aromatherapy patch
223942327|NCT05282706|DRUG|Mandarin Oil|A hydrogel mandarin oil infused aromatherapy patch
223942328|NCT05282706|DRUG|Peppermint oil|A hydrogel peppermint oil infused aromatherapy patch
223942329|NCT05282706|OTHER|Placebo|A placebo patch containing no aromatherapy oil
223942330|NCT03737409|OTHER|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
223942331|NCT03737409|OTHER|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
223942332|NCT06993415|OTHER|data collection|"The ORACLE program is a prospective, deep phenotyping, study based on multimodal information and artificial intelligence computation. We will prospectively collect in-hospital and out-of-hospital data of a large cohort of patients presenting with MI, including data from wearable devices recording continuous ECG, interstitial-fluids, non-invasive blood pressure and mobility, behavioural patterns from a dedicated mobile application, blood and urine biomarkers and non-invasive imaging. We will leverage on AI, using statistical learning methods and neural networks, to explore patterns and higher order interactions within the data to provide novel computational biomarkers of ischemic and bleeding risk."
223942333|NCT06665022|DEVICE|Active tDCS|A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
223942334|NCT06665022|DEVICE|Sham tDCS|Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
223942335|NCT06668142|DEVICE|Beacon Platform|The Beacon Platform is a robotically assisted surgical (RAS) device. It enables the urologist, through software, to control and move surgical instruments for a variety of transurethral, endoscopic procedures
223535361|NCT03235050|DRUG|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
223535362|NCT03235050|DRUG|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
223942336|NCT06994975|DRUG|0.25mg/kg TNK|Patients in the tenecteplase group were administered a 0.25mg/kg dose as a bolus over 5-10 seconds, followed by a 2 mL saline flush.
223942337|NCT06994975|DRUG|Standard medical treatment|Patients in the standard medical treatment group will receive the standard treatment selected by local doctors, including antithrombotic agents, lipid-lowering agents, antihypertensive drugs, and hypoglycemic agents. Patients would be ineligible if bridging endovascular treatment is planned at the time of randomization.
223942338|NCT05346224|DRUG|HLX11|Neoadjuvant(q3w/cycle，total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
223942339|NCT05346224|DRUG|EU-Perjeta®|Neoadjuvant(q3w/cycle，total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle
223942340|NCT02823028|DRUG|NRT|8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
223942341|NCT02823028|BEHAVIORAL|Web Guide|"A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules."
223942342|NCT02823028|BEHAVIORAL|Tweet2Quit|"A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group."
223942343|NCT03765567|DRUG|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
223942344|NCT02409680|DRUG|Low dose aspirin|Daily administration of low dose (81 mg) aspirin \[also known as acetylsalicylic acid (ASA\], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
223942345|NCT02409680|DRUG|Placebo|Placebo
223942346|NCT06536504|OTHER|Steinway Spirio M recording/player piano|Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.
223942347|NCT06857981|OTHER|Clinical data collection|Patient's data will be collected, including: date of birth, age, gender/sex, pathology for admission, comorbidities, treatment received, and proposed interventions based on initial assessment.
223942348|NCT04411199|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
223942349|NCT04411199|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
223942350|NCT02761616|OTHER|eBC treated participants|No intervention administered in this retrospective observational study.
223942351|NCT06871228|DEVICE|PPG/ECG dual mode based smartwatch|The intervention initiates anticoagulation when AF is detected as either a single episode ≥1 hour or cumulative ≥2 hours/24h (adjusted for monitoring compliance), triggering a 30-day NOAC therapy cycle that restarts if AF recurs during treatment. Participants are required to wear the device ≥12 hours daily, supported by automated reminders (vibration/SMS/phone alerts) and a reward system to reinforce adherence.
223942352|NCT06871228|DRUG|Continuous DOAC therapy|Continuous standard-dose DOAC therapy with dose adjustments per the drug labels.
223942353|NCT06867705|DEVICE|Resilience PRO|The patient will use Resilience PRO remote symptoms monitoring.
223942354|NCT07011966|DEVICE|ASV therapy|Adaptive servo ventilation (ASV) therapy using ResMed AirCurve 11 device will be used to target potential upper airway resistance and respiratory related arousals in patients with insomnia. The ASV device is approved for the treatment of obstructive sleep apnea, and this will be designated as the investigational device for this study with appropriate labelling.
223942355|NCT07012850|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|To reduce radiation exposure while simultaneously allowing for the visualization of soft tissues, newer imaging methods, including magnetic resonance imaging (MRI), as well as Black Bone and CT-like MRI protocols (ZTE, UTE), are being explored. These MRI techniques offer high-resolution, non-ionizing alternatives, showing promise for diagnosing soft tissue injuries and fractures without radiation risks.
223942356|NCT07012369|OTHER|Experimental group: sanitary pads with messages about family planning on them|"Sanitary pads with messages about family planning on them.~Signing the Informed Consent Form, Filling in the first section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, Obtaining contact information, Giving 2 packages of sanitary pads (14 in each package, 28 in total) with messages about family planning methods, Notifying that contact will be made three months after the end of the first menstrual bleeding, Filling in the second section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, three months after the sanitary pads are given, Expressing gratitude for participating in the study and saying goodbye."
223942357|NCT07012369|OTHER|Control group: not be given any materials|"Not be given any materials~Signing the Informed Consent Form, Filling in the first section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, Obtaining contact information, Notifying that contact will be established three months after the end of the first menstrual bleeding, Filling in the second section of the data collection form, the Family Planning Information Form and the Family Planning Attitude Scale, three months after the sanitary pads are given, Expressing gratitude for participation in the study and saying goodbye,"
223942358|NCT07013565|DRUG|Vinblastine (Velban)|Low risk cohort patients will receive 2 cycles of Induction therapy with single-drug vinBLAStine (VBL), then undergo disease assessment. If complete remission (CR) and MRD -, LR patients will continue single-drug VBL for a total of 24 months (if absent disease progression or unacceptable toxicity).
223942359|NCT07013565|DRUG|Brentuximab vedotin (Adcetris)|HR cohort patients with no previous exposure to BV will receive 2 cycles of Induction therapy with BV and NIVO \[BV + NIVO\] one every 21 days, then undergo disease assessment. Patients in CR will proceed with consolidation with RTC allogeneic SCT (SCT)\*. If patient has any response other than CR and MRD-, they will receive 2 cycles of BV, VBL, and NIVO \[BV + VBL + NIVO\] once every 21 days
223942360|NCT07013565|DRUG|Nivolumab (Opdivo)|High risk cohort patients with previous exposure to Brentuximab vedotin (BV) will receive 2 cycles of Induction therapy with VBL and NIVO \[VBL + NIVO\] on day 1 and 15, then undergo disease assessment. If response is not CR, or patient has PR/SD/PD, patient will receive \[BV+VBL+NIVO\] and subsequent therapy as defined for the HR2 cohort.
223942361|NCT07013058|DIETARY_SUPPLEMENT|Nigella sativa extract (Nisatol®)|Participants will take 2 softgel capsules daily of Nigella sativa oil standardized to 10% thymoquinone (Nisatol®), one capsule with lunch and one with dinner, for 4 months.
223942362|NCT07013058|BEHAVIORAL|Mediterranean Diet|Participants will follow a Mediterranean diet for 4 months under dietary guidance, without receiving any Nigella sativa supplementation.
223942363|NCT07012746|DRUG|TJ0113 capsules|Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .
223942364|NCT07012746|DRUG|Placebo capsules|Oral intake on an empty stomach in the morning, 200 mg each time, fasting within half an hour after taking. It is recommended to keep the drug at the same time (± 1 h ) of a day .
223942365|NCT07013604|DEVICE|Neuromuscular Electrical Stimulation (NMES) Group,Resistance + BFR Group|"NMES Group: Receives neuromuscular electrical stimulation to the thigh muscles for 30 minutes, three times per week, over 8 weeks.~Resistance + BFR Group: Performs low-load resistance exercises with blood flow restriction applied to the thighs, also for 30 minutes per session, three times per week, over 8 weeks.~Control Group: Receives placebo treatment using a turned-off stimulation device with no active intervention during the 8-week period."
223942366|NCT07014319|DRUG|Maribavir|Participants will receive maribavir 400 mg twice daily starting from Week 1 and continuing until clearance of CMV. CMV clearance is defined as either an unquantifiable plasma CMV DNA titer (i.e., below the lower limit of quantification \[LLOQ\]) as assessed by the local laboratory, or a CMV DNA level below 500 IU/mL in plasma without evidence of CMV disease.
223942367|NCT07012512|DRUG|Use of phentolamine eye drops to reverse cycloplegia|Use of phentolamine 0.75% eye drops to reverse cycloplegia
223942368|NCT07012512|DRUG|Pilocarpine 0.1%|Use of pilocarpine 0.1% to reverse cycloplegia
223719585|NCT03612505|BEHAVIORAL|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
223942369|NCT07012512|DRUG|Combination of pilocarpine 0.1% and phentolamine 0.75%|Combination of pilocarpine 0.1% and phentolamine 0.75%
223942370|NCT07013526|PROCEDURE|Ropivacaine|Administration of ropivacaine in a Suprazygomatic maxillary nerve block
223942371|NCT07011823|RADIATION|Partial breast-irradiation|"First, 8Gy partial breast irradiation will be delivered in immune-cold triple-negative breast cancer (TNBC) confirmed by PD-L1 and TILs.~Sequentially, standard neoadjuvant chemotherapy for triple-negative breast cancer including pembrolizumab, paclitaxel, carboplatin, doxorubicin, and cyclophosphamide (KeyNote-522 regimen) will be administered, followed by surgical treatment."
223942372|NCT07013838|DRUG|Deucravacitinib|Deucravacitinib is a new, oral, selective, allosteric inhibitor of TYK2. It was first approved in the United States on 09-Sep-2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
223942373|NCT07013838|DRUG|Adalimumab|TNFα inhibitors have already been used in TAK treatment. Several retrospective studies have demonstrated the treatment effects of these agents in patients with TAK, including disease remission, GC tapering and vascular inflammation control. According to the ACR and EULAR guidelines, TNFis are recommended to be considered in cases of relapsing or refractory TAK. These agents (including adalimumab) are the most frequently analyzed therapeutic modalities in recent studies of TAK.
223719586|NCT00865696|DRUG|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223942374|NCT07014293|OTHER|Enhanced Usual Care|Participants will receive a singleevaluation with a site social worker along with a list of mental health, social or community resources . This most closely resembles the real-world care available to survivors on an outpatient basis, however, we call this enhanced usual care since proactive identification and referral of posttreatment survivors is not routinely done.
223942375|NCT07014293|OTHER|SMART3RP-Lymphoma|The intervention components include: 1. Eliciting the relaxation response (RR) involves sustained mental focus with an attitude of open receptive awareness. 2. CBT to improve stress management involves increasing awareness and identification of the components of one's stress response (negative thoughts, emotions, physical reactions, behaviors, and relational) and learning skills at each session to alter these components (e.g., cognitive restructuring). 3. Positive psychology strategies to achieve growth enhancement focus on utilizing techniques and skills to promote positive growth. Skills focus on increasing social support, positive affect, and compassion.
223942376|NCT07012993|DRUG|18F-Florbetapir or 18F-Flutemetamol|Participants will be injected with 18F-Florbetapir or 18F-Flutemetamol and imaged for up to 3 hours on a PET scanner
223942377|NCT07012811|DRUG|Topical tretinoin 0.05%|Topical tretinoin cream 0.05% applied once daily at night
223942378|NCT07012811|DRUG|Topical tretinoin 0.05% + oral isotretinoin (0.5 mg/kg/day)|Topical tretinoin cream 0.05% once daily at night + oral isotretinoin capsule in the dose of 0.5 mg/kg/day
223942379|NCT07014059|DRUG|Autologous Serum 20%|The collection of autologous serum in a closed blood processing system for ocular use
223942380|NCT07012759|OTHER|biomarkers|pleural effusion biomarkers in lung adenocarcinoma
223942381|NCT07014215|DRUG|Sintilimab combined with Bevacizumab and tafolecimab|Patients who met the inclusion criteria were treated with sintilimab(200mg Q3W) combined with Bevacizumab(7.5mg/kg Q3W) and tafolecimab(600mg Q6W) until disease progression or intolerable adverse reactions or death(up to 24 months)
223942382|NCT07014254|DRUG|177Lu-CTR-FAPI nuclide-targeted therapy|Fasting, special diets, or other specific preparations are not required on the day of 177Lu-CTR-FAPI administration. Patients were given 4 mg ondansetron 30 minutes before treatment to prevent nausea and vomiting. The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi) was diluted with 100 mL of 0.9% saline and given slowly by intravenous infusion over 20-30 minutes (flow rate 200 ml/h). Symptoms and vital signs were monitored before and after treatment. The treatment regimen was planned for a maximum of 3 courses of treatment, with 4-8 weeks between each cycle
223942383|NCT05861258|DRUG|Minocycline|Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
223942384|NCT07017192|PROCEDURE|SIFI Block|Infiltration of local anesthetics in the suprainguinal iliac fascia (Ropivacaine 0.375 40 mls)
223942385|NCT07017192|PROCEDURE|ESP block|Infiltration of local anesthetics in the fascial plane underneath the erector spoinae mulscle at lumbar level (Ropivacaine 0.375 40 mls)
223942386|NCT07017829|BIOLOGICAL|Anti-CFH Monoclonal Antibody GT103|Given IV
223942387|NCT07017829|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223942388|NCT07017829|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223942389|NCT07017829|PROCEDURE|Computed Tomography|Undergo CT
223942390|NCT07017829|PROCEDURE|Echocardiography Test|Undergo ECHO
223942391|NCT07017829|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223942392|NCT07017829|BIOLOGICAL|Pembrolizumab|Given IV
223942393|NCT07012070|BEHAVIORAL|supervised exercise therapy (SET)|Supervised exercise therapy (SET) is a structured program of exercise designed for individuals with peripheral artery disease (PAD) and intermittent claudication (IC). It consists of 12 weeks of intermittent treadmill walking to moderate to severe claudication pain at a speed of ≈2 mph and at a grade equal to 40% of the highest workload achieved during the baseline maximal treadmill test, with intermittent period of rest, for at least 3 times per week with a minimum of 30-45 minutes per session
223942394|NCT07012070|DEVICE|Wearable activities monitor (WAM)|The WAM use in this study is the FitBit Inspire 3 Advanced Activity Tracker (FitBit Inc. San Francisco, CA, USA), which is a commercially available tri-axis accelerometer and heart rate monitor capable of continuous monitoring of heart rate using LED sensor, and activities including daily steps count and derived daily activity level, detection of arrythmia and measuring peripheral capillary oxygen saturation. Fitbit devices connect with HOBBIT-PAD platform which was developed specifically for patients with PAD based on user-centred design. It contains patient education information, instruction for exercise, activity record, and embedded messaging function between the patient and the research team about any technical and clinical issue. Important and thorough customizations will be made to tailor this mobile health platform for this study, which includes the addition of patient education materials on PAD and its management, tips on health eating and lifestyle, and tips on exercise.
223942395|NCT07012070|BEHAVIORAL|enhanced HBET|Instructions for HBET are programmed according to the AHA recommendation on the exercise programs for patients with PAD and are automatically generated by the mobile apps. Patients will be prompted to use the exercise function on the mobile apps at least 3 times per week. Once the exercise function is activated, it will extract the steps counts and the walking pace from the WAM during exercise. Patients will be instructed to walk to maximal claudication symptom before stopping, at which point they will press pause on the WAM which will mark the claudication onset time. After the claudication subside, they can resume walking and resume recording on their WAM. Each exercise session will last for 45 minutes excluding rest periods, but the subject can terminate the exercise before the session ends.
223994380|NCT05253599|OTHER|Exercises|They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
223719587|NCT00865696|DRUG|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
223942396|NCT07012070|BEHAVIORAL|Mobile application|The mobile apps and mobile platform are adopted from the HOBBIT-PAD platform prototype that was developed specifically for patients with PAD based on user-centred design. This platform contains patient education information, instruction for exercise, activity record, and embedded messaging function between the patient and the research team about any technical and clinical issue. The source code for this platform is publicly available. Important customization will be made to tailor this mobile health platform for this study, which includes addition of patient education materials on PAD and its management, tips on health eating and lifestyle, and tips on exercise. These materials are adopted from the patient education materials available on the Hospital Authority and the AHA website. This information will be periodically sent to the subject's mobile device as a push notification to help them better understand their disease and to promote independent self-care and healthy lifestyle.
223942397|NCT07011836|BEHAVIORAL|mNav Interactive Video + Navigator|A personalized, video-based tool paired with navigator support to address individual screening barriers.
223942398|NCT07011836|BEHAVIORAL|Educational Video|A culturally tailored cervical cancer education video without additional support or tailoring.
223942399|NCT07012629|DRUG|acetylsalicyclic acid (ASA)|Daily dose 75 mg to 100 mg p.o.
223942400|NCT07012629|DRUG|Clopidogrel|Daily dose 75 mg p.o.
223942401|NCT07012629|DRUG|Rosuvastatin|"Daily dose 20 mg p.o. (10 mg once daily for the first 4 weeks, then 20 mg once daily for the remainder of the study period if tolerated).~If Rosuvastatin 20 mg is not tolerated, a dose reduction to 10 mg is allowed."
223942402|NCT07012629|DRUG|Atorvastatin|Daily dose 40 mg p.o. If Atorvastatin 40 mg is not tolerated, a dose reduction to 20 mg is allowed.
223942403|NCT07014072|PROCEDURE|intensive toe pressure evaluation|This measurement is non-invasive, painless and is also carried out as part of the care in the follow-up of critical limb ischemia. It takes place like a blood pressure measurement except that it is carried out at the level of a toe.
223942404|NCT07014072|OTHER|data collection|retrospective data
223942405|NCT06698861|DRUG|PEG-MetHuG-CSF|Single dose of PEG-MetHuG-CSF will be given SC injection at 2 mg in Cohort 1 and 6 mg in Cohort 2
223942406|NCT06698861|DRUG|Neulasta (Amgen)|Single dose of Neulasta will be given SC injection at 6 mg in Cohort 2b.
223942407|NCT07033962|COMBINATION_PRODUCT|"Fractional CO2 laser and topical fluconazole microemulsion"|four sessions of fractional CO2 at 3weeks interval with a laser device (multixel, Daeshin enterprise co., LTD. (D.S.E) 105, 271, digital -ro, Guro-gu, Seoul, Koreaa) at a pulse energy of 140 mJ, a density of 150 spots/ cm2 and a depth of 1 cm combined with twice daily topical fluconazole microemulsion.
223942408|NCT07033962|COMBINATION_PRODUCT|"Urea 40% and topical fluconazole microemulsion"|urea 40% paste under occlusion once daily over 4 weeks followed by topical fluconazole microemulsion twice daily for 8 weeks.
223942409|NCT07033455|DRUG|HRS-1893|Single dose of HRS-1893 orally administered
223942410|NCT07032363|OTHER|Core Implementation Strategies|"* Task Sharing/Revise Professional Roles~* Distribute educational materials/Dynamic Training/Address Stigma~* Clinician Implementation Team Meetings~* Partner with CoCT DoH~* Champion~* Audit and Feedback~* Stage Scale Up/Tailoring"
223942411|NCT07032363|OTHER|Enhanced Implementation Strategies|"* Train the trainer~* Ongoing supervision and consultation"
223942412|NCT07034404|BEHAVIORAL|Digital Adapted Physical Activity|"The digital Adapted Physical Activity (APA) program will be delivered via a digital platform and participants will be guided by an APA teacher to meet the WHO recommendations (i.e. 150 minutes of moderate intensity aerobic PA per week and muscle-strengthening activities that involve all major muscle groups twice weekly).~Participants will benefit from 10 visits with the APA teacher: an initial assessment to define personalized goals and familiarize participants with the digital platform, eight sessions to monitor progress and adapt the exercise program, and a final evaluation aimed at assessing outcomes and encouraging long-term adherence to physical activity. Daily physical activity will be objectively monitored using a Withings connected watch to provide feedback and track metrics such as step count."
223942413|NCT07034404|BEHAVIORAL|Control (Standard treatment)|Participants will receive standard care and advice on physical activity (based on the recommendations of the World Health Organization, WHO, and the European Alliance of Associations for Rheumatology, EULAR) through a document provided to them.
223942414|NCT07031271|BEHAVIORAL|Tangram game|Tangram game; It is a very old intelligence and attention game of Chinese origin. This game stands out with its both entertaining and educational aspects. Tangram consists of seven geometric pieces formed from a square shape. These 7 pieces; 2 large right triangles, 1 medium right triangle, 2 small right triangles, 1 square and 1 parallelogram. The aim is to create various shapes (animals, people, objects, letters, etc.) with these pieces. The aim of the Tangram game is to recreate the same appearance with a given shape (silhouette) using the pieces. All 7 pieces must be used in the game, the pieces must not be overlapped, the pieces must not be cut or divided, the pieces can be rotated or turned according to the selected shape. For example, the person is asked to create a cat figure with these 7 pieces in accordance with the rules. This game is one of the non-pharmacological pain management techniques by diverting the attention of the patients. It is easy to apply and cheap.
223994381|NCT03941899|OTHER|Levobupivacaine in QLB II|Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
223994382|NCT00219479|DRUG|Phenytoin (Dilantin) levels during change in enteral feeding|
223994383|NCT02670122|DEVICE|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
223994384|NCT03035669|BEHAVIORAL|Mindfulness group|8 week program
223994385|NCT03035669|BEHAVIORAL|Reading group|8 week program
223994386|NCT00565071|DEVICE|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
223994387|NCT03321253|DEVICE|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
223994388|NCT01262547|DEVICE|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
223994389|NCT01262547|PROCEDURE|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
223942415|NCT07035470|OTHER|PhenoAge-Based Biological Age Assessment|Biological age was retrospectively calculated using the PhenoAge algorithm, based on nine routine laboratory parameters and chronological age. This model estimates phenotypic aging and was used to predict short-term outcomes including mortality, functional status, comorbidity burden, and hospital length of stay. No new intervention was administered; all data were collected from existing medical records.
223942416|NCT07035171|OTHER|Multimodal prehabilitation intervention|"Multimodal prehabilitation interventions (CABGpreHAB):~* Home-based exercise intervention delivered by a skilled physiotherapist via a web-based application.~* Nutritional intervention~* Psycho-educative intervention~* Smoking cessation~* Alcohol cessation"
223942417|NCT07035171|OTHER|Control (Standard treatment)|This includes standard information about CABG surgery, pre- and postoperative care, and postoperative physical activity advice. Patients are either admitted days before or on the day before surgery. They receive written materials and links to animated videos about preparing for surgery. This preparation includes counseling with a multidisciplinary team, including a department nurse, a physiotherapist, a cardiac anesthesiologist, and a surgeon.
223942418|NCT07038135|DIETARY_SUPPLEMENT|Novel Natural Supplement (NNS)|Multi-ingredient formula including whey protein, pea protein, oats, sweet potato, flaxseed, chia seeds, spinach powder, cardamom, green tea extract, beetroot powder, and stevia. Administered daily for 8 weeks.
223942419|NCT07038135|DIETARY_SUPPLEMENT|Placebo|A placebo containing maltodextrin, microcrystalline cellulose, and beetroot powder, matched in appearance, flavor, and texture to the NNS. Administered daily for 8 weeks.
223942420|NCT06718127|BIOLOGICAL|blood samples collection|blood samples collected at D0 ,W1, W5, M3 and M6
223942421|NCT03562741|PROCEDURE|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
223942422|NCT07040605|OTHER|Deep cervical flexors muscle training and sensorimotor training|"deep cervical flexor muscle training will be performed according to the protocol of Jull and Falla using a pressure biofeedback unit. Participants will be positioned in a supine crook-lying posture with the neck in a neutral position, and the air bag of the pressure biofeedback unit will be placed beneath the cervical lordosis and inflated to a baseline of 20 mmHg. Patients will be instructed to perform a gentle nodding action, increasing the pressure by 2 mmHg increments up to 30 mmHg. Each increment will be held for ten seconds, repeated in three sets of ten repetitions, with a two-minute rest between sets. To enhance activation of the deep flexors, patients will be instructed to keep their mouth open during the exercise.~Proprioception training will include head relocation practice, oculomotor exercises, and eye-head coordination exercises."
223942423|NCT07040605|OTHER|conventional physical therapy exercise|"will include stretching exercises targeting the sternocleidomastoid, upper trapezius, levator scapulae, scalene, Rhomboids and pectoralis muscles, performed in three repetitions, holding each stretch for thirty seconds, strengthening exercises will be provided Isometrically for the cervical flexors, extensors and at sides using a prescription of three sets of ten repetitions with a ten-second hold and two minutes of rest between sets.~TENS and Hot back."
223942424|NCT06724471|DEVICE|Human ovarian tissue cryopreservation using thermosoldered or screwed cryovials|Human ovarian tissue Cryopreservation: immediately after cyst resection, pericystic ovarian cortex will be cut into 1mm3 fragments and cryopreserved in screwed or thermosoldered cryovials using a slow programmable freezing device (Nano Digitcool, Cryo Bio System).
224099763|NCT07030335|OTHER|Mobile-Atrial Fibrillation Training Program|Patient Information Form, Atrial Fibrillation Information Scale, Atrial Fibrillation Severity Scale and Atrial Fibrillation Impact on Quality of Life Questionnaire will be administered face-to-face by the researcher using Mobile Atrial Fibrillation Education Program (M-AFEP). The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants and the application will be added to the main screens by entering the relevant address from their phones. Participants will be asked to use M-AFEP for twelve weeks / at least ten minutes a week and the frequency and duration of use will be recorded on the mobile application. Participants in the intervention group will be followed up by phone once a week in the first, fourth and eighth weeks and a reminder message (sms) will be sent for the use of M-AFEP. At the end of the twelfth week, the scales will be filled in again through the application.
223535363|NCT03235050|DRUG|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
223942425|NCT07042620|DEVICE|SonoClear(R) System|The SonoClear(R) System is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
223719588|NCT04950998|BEHAVIORAL|Moving Up - A|Moving Up - A is a physical activity smartphone app for persons with mild cognitive impairment or mild forms of dementia. The app includes a personally tailored set of messages, tips, strategies, and tasks designed to increase physical activity levels and disrupt extended periods of sedentary time. Users also have the ability to track their steps and and sedentary behavior time as well as their progress towards activity goals.
223942426|NCT07042282|DEVICE|Nighttime Splinting|Nighttime splinting for 6 weeks.
223942427|NCT07042282|DRUG|Corticosteroid Injection|Local corticosteroid injection (triamcinolone acetonide 40mg). A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered. The injection is performed under ultrasound guidance and anatomical landmarks to target the proximal carpal tunnel. With the wrist extended, the needle is typically inserted on the ulnar side of the palmaris longus tendon, approximately 1 cm proximal to the wrist crease. If blood is aspirated or the patient reports paresthesia (which usually indicates nerve irritation), the injection site should be adjusted.
223942428|NCT07042282|OTHER|Evaluation and Dynamic Adjustment|6 weeks later, all patients will undergo evaluation of their initial treatment. Further therapeutic decisions will be made based on physician assessment, including: continuing nighttime splinting, administering corticosteroid injections to patients who initially received only the splint, adding nighttime splinting for patients initially received only corticosteroid injections, and transitioning from nighttime splint use to continuous wear. Subsequently, evaluations will be conducted every 6 weeks, with dynamic adjustments to the treatment plan. Throughout the study period, physicians will perform electrophysiological examinations according to changes in patients' clinical status.
223994390|NCT03659331|DIETARY_SUPPLEMENT|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
223719589|NCT03198117|DRUG|Huaier Granule|a Chinese traditional medicine
223942429|NCT07042360|DIAGNOSTIC_TEST|ReDs Pro|"The basic principle invovles emitting low-power electromagnetic sgnals into the lungs and measuring the dielectric properties of lung tissue~The varing dielectric constants of these components result in differences in the impedance values for electromagnetic waves. Therefore, using the impedance method allows the estimation of the dielectric properties of lung tissue, which can be further converted into lung fluid content data through calculations."
223942430|NCT07042360|DIAGNOSTIC_TEST|Fibroscan|Using external ultrasound scanner to check fo rliver stiffness using acoustic energy
223942431|NCT07043231|OTHER|Creative materials|This intervention provides professionals with co-created creative materials specifically designed to facilitate structured, safe conversations about suicidality with children and adolescents. Unlike standard tools, it offers three flexible pathways-Conversation, Drawing, and Walking-allowing a personalized approach tailored to the young person's preferences and context. The materials guide professionals through the assessment of suicidal intent, risk and protective factors, and help formulate a risk assessment and Safety Plan. The content is aligned with national clinical guidelines but uniquely integrates experiential insights from youth with lived experience, ensuring both theoretical grounding and practical applicability.
223942432|NCT07043829|DIETARY_SUPPLEMENT|SAEP (Solution of Cimarrón Bean Extrudate in Water)|A single oral dose of 10 grams of Cimarrón bean (Phaseolus vulgaris, variety Cimarrón) extrudate dissolved in 500 mL of water, consumed once under fasting conditions. Used to evaluate acute effects on platelet function and postprandial glycemia.
223942433|NCT07043894|DRUG|Romiplostim N01|Participants receive weekly subcutaneous injections of romiplostim N01 (250 μg/vial; Qilu Pharmaceutical) starting at 2 μg/kg. Doses are adjusted weekly based on platelet counts: increased by 2 μg/kg if platelets are \<50 × 10⁹/L, by 1 μg/kg if 50-99 × 10⁹/L, up to a maximum of 10 μg/kg. Treatment continues for up to 2 weeks but stops early if platelets reach ≥100 × 10⁹/L or increase by ≥30 × 10⁹/L from baseline.
223994391|NCT00098397|DRUG|romidepsin|Given IV
223994392|NCT00098397|OTHER|laboratory biomarker analysis|Optional correlative studies
223994393|NCT00303706|PROCEDURE|Endoscopic Radial Artery Harvest|
223719590|NCT03198117|OTHER|placebo|placebo
223719591|NCT04332562|OTHER|dietary restriction (salt restriction)|salt restriction for one week after being diagnosed with hypertension
223719592|NCT05823961|DEVICE|Cross-linked hyaluronic acid eye drops|Cross-linked hyaluronic acid (CLHA)-based eyedrops
223719593|NCT00169598|PROCEDURE|positron emission tomography|
223994394|NCT06222242|BEHAVIORAL|mychoiceTM|mychoiceTM is an online, educational tool designed to help prepare patients for a conversation with their provider about clinical trials as a treatment option. It consists of text, animations, and videos of real cancer patients sharing their experience with clinical trials. It is not meant to be a recruitment tool, but rather a preparatory tool to promote shared decision making between patients and providers.
223994395|NCT02781649|DRUG|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
223994396|NCT02781649|DRUG|Ribavirin|Ribavirin 1200 mg/d (\> 75 kg) or 1000 mg/d (\< 75 kg) by mouth daily in two divided doses
223994397|NCT02781649|DRUG|Sofosbuvir|Sofosbuvir 400 mg daily
223994398|NCT02901847|OTHER|PAD tailored care|PAD tailored care
223994399|NCT01722747|BEHAVIORAL|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year \& included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
223994400|NCT03714568|DRUG|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
223994401|NCT03714568|DRUG|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
223994402|NCT04099654|OTHER|Core-Stabilization Exercise|A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
223994403|NCT04099654|OTHER|Counseling of physical activity|Only physical activity counseling will be given to the subjects in this group.
223994404|NCT02690844|DRUG|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
223535364|NCT03852030|BEHAVIORAL|Text or email message|Text or email messages sent to research participants
223535365|NCT02870465|PROCEDURE|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
223942434|NCT07044284|DEVICE|Fractal mindfulness recombination|Immersive virtual reality using fractal mindfulness software
223942435|NCT07044076|OTHER|Quality of life|The four questionnaires (MQOL, EQ-5D, Karnofsky, and FACT-Br) will be sent to patients online using the secure online platform Redcap.
223942436|NCT07043127|OTHER|Sham-BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
223942437|NCT07043127|OTHER|BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
223942438|NCT07042477|BEHAVIORAL|Integrated Telemedicine Program|The integrated telemedicine program is short-term bridge support provided by a virtually accessible team, including a behavioral health provider (Health Psychologist or Licensed Clinical Social Worker \[LCSW\]) and Community Health Worker (CHW). Once stabilized, members transition from bridge support to ongoing care with a Geisinger Health System Primary Care Provider and Behavioral Health Provider.
223535366|NCT03089060|DEVICE|Silicone Finger cap|Treatment with silicone finger cap
223535367|NCT03089060|DEVICE|Film Dressing|Treatment with conventional film dressing
223535368|NCT04707092|DRUG|Antibiotic|Antibiotic in case of now allergies will be Cefazolin at induction and Amoxicillin plus Clavulanic acid for the oral treatment week
223535369|NCT05412992|DRUG|DMTS Patch|DMTS applied before surgery and worn for 96 hours
223942439|NCT07043179|DEVICE|Nighttime Splinting|Nighttime splinting for 6 weeks.
223535370|NCT05412992|DRUG|Placebo Patch|Matching patches that have no active drug applied before surgery and worn for 96 hours
223535371|NCT01843530|DRUG|Berinert|
223535372|NCT01843530|DRUG|Clemastin|
223535373|NCT01843530|DRUG|Cortisone acetate|
223535374|NCT01843530|DRUG|NaCl|
223535375|NCT03825627|DEVICE|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
223994405|NCT02690844|DRUG|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
223994406|NCT02690844|DRUG|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
223994407|NCT00781495|DEVICE|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
223994408|NCT01299311|BEHAVIORAL|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
223994409|NCT01299311|BEHAVIORAL|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
223994410|NCT01066715|DRUG|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
223994411|NCT01066715|DRUG|Placebo|Sterile solution subcutaneously administered monthly for 6 months
223994412|NCT02762903|PROCEDURE|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
223994413|NCT02762903|PROCEDURE|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
223994414|NCT02762903|DEVICE|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
223994415|NCT03774147|DEVICE|24-hour Ambulatory Blood Pressure Monitoring (ABPM)|
223994416|NCT02421536|OTHER|Vibrogent Smartphone Application|
224099764|NCT07030335|OTHER|Routine Outpatient Clinic Care|"* Participants in the control group will be given M-AFEP application usage training by the researchers.~* The application link, individual e-mail and user passwords will be sent to the mobile phones of the participants in the control group.~* Participants in the control group will enter the relevant address of the mobile application from their phones and the application will be added to their home screens.~* In the M-AFEP application of the participants in the control group, there will be a short general information section containing information specific to AF, different from the intervention group content.~Participants in the control group will continue only routine outpatient follow-up throughout the process and no intervention will be applied."
224099765|NCT07031167|BEHAVIORAL|Cognitive and functional stimulation using digital platforms|Participants in the intervention group receive personalized cognitive and functional stimulation over one year through digital platforms developed by the COMFORTage project. These include Eligence, a brain-training tool featuring interactive games targeting memory, attention, and language; Language Games, which assess and train linguistic and cognitive skills in realistic scenarios; and Healthentia, a platform that monitors daily health metrics and provides virtual coaching. Sessions are conducted both in person and remotely, and are adapted to each participant's abilities and level of digital literacy. The intervention aims to support cognitive health and daily functioning in individuals with MCI or mild AD.
224295120|NCT01602172|OTHER|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
224295121|NCT04448496|DRUG|Dexamethasone implant|Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
223942440|NCT07043179|DRUG|Corticosteroid Injection|Local corticosteroid injection (triamcinolone acetonide 40mg). A single injection of triamcinolone acetonide 40mg mixed with an equal volume of 1% lidocaine is administered. The injection is performed under ultrasound guidance and anatomical landmarks to target the proximal carpal tunnel. With the wrist extended, the needle is typically inserted on the ulnar side of the palmaris longus tendon, approximately 1 cm proximal to the wrist crease. If blood is aspirated or the patient reports paresthesia (which usually indicates nerve irritation), the injection site should be adjusted.
223942441|NCT07043179|OTHER|Evaluation and Dynamic Adjustment|6 weeks later, all patients will undergo evaluation of their initial treatment. Further therapeutic decisions will be made based on physician assessment, including: continuing nighttime splinting, administering corticosteroid injections to patients who initially received only the splint, adding nighttime splinting for patients initially received only corticosteroid injections, and transitioning from nighttime splint use to continuous wear. Subsequently, evaluations will be conducted every 6 weeks, with dynamic adjustments to the treatment plan. Corticosteroid injections will be administered at least 24 weeks apart, and the second injection dosage may be adjusted based on the patient's condition, with a maximum dose of 80mg. Throughout the study period, physicians will perform electrophysiological examinations according to changes in patients' clinical status.
223942442|NCT07042919|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223942443|NCT07042919|PROCEDURE|Computed Tomography|Undergo CT
223942444|NCT07042919|PROCEDURE|Echocardiography Test|Undergo ECHO
223942445|NCT07042919|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223942446|NCT07042919|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223942447|NCT07042919|DRUG|Zanzalintinib|Given PO
223942448|NCT07043218|DRUG|Chimeric Antigen Receptor T Cells (CAR-T)|chimeric antigen receptor T cells
223942449|NCT07044206|DEVICE|Use of bone substitute during intervertebral fusion surgery|Participants randomized will receive bone substitute during intervertebral fusion surgery. Routine postoperative follow-up procedure (identical for both groups) with two postoperative visits at 3 months and 12 months.
223942450|NCT07042438|BIOLOGICAL|Axicabtagene Ciloleucel|Given CAR-T cells
223942451|NCT07042438|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223942452|NCT07042438|DRUG|Chemotherapy|Receive chemotherapy
223942453|NCT07042438|PROCEDURE|Fecal Microbiota Transplantation|Given PO
223942454|NCT07042438|PROCEDURE|Leukapheresis|Undergo leukapheresis
223942455|NCT07042438|DRUG|Placebo Administration|Given PO
223942456|NCT07043530|BEHAVIORAL|In-person sleep hygiene-based intervention|The in-person sleep hygiene-based intervention will be delivered in 8 sessions by an sleep expert using digital resources, previously designed and expert validated. During the intervention, the following topics will be covered: (1) sleep hygiene generalities, (2) sleep and environment, (3) sleep and technology, (4) sleep and diet, (5) sleep and excercise, (6) sleep and stimulus control, (7) breathing techniques, (8) mindfulness. The sessions will be delivered twice a week with an approximated duration of 45 minutes each, until completed.
223942457|NCT07043530|BEHAVIORAL|Online sleep hygiene-based intervention|The online sleep hygiene-based intervention will be delivered in 8 sessions through a self-paced educational platform; the content will be the same as in the in-person intervention, but tailored for use in digital learning platforms. The suggest completion time for each session will be 45 minutes. Although its self-paced nature, participants are required to complete it within one month, following the same timeline as the face-to-face arm.
223942458|NCT07044024|COMBINATION_PRODUCT|CeraVe|"Patients with GEA classification 1 will be assigned to use CeraVe Blemish Control Cleanser in combination with CeraVe Blemish Control Gel.~Patients in GEA Class 2 will be assigned to use CeraVe Blemish Control Cleanser in combination with CeraVe Facial Moisturising Lotion in combination with topical medications.~Patients with GEA classification 3 will be assigned to use CeraVe Foaming Facial Cleanser in combination with CeraVe Facial Moisturising Lotion in combination with topical medications.~Patients with a GEA classification of 4 and above will be assigned to use CeraVe Hydrating Facial Cleanser in combination with CeraVe Moisturising Cream in conjunction with a commonly used sunscreen product in combination with an oral medication."
223942459|NCT07043062|PROCEDURE|Open surgical Interference|to compare the outcomes of Laparoscopic repair versus Open surgical repair of Genitovesical fistula in females.
223942460|NCT06745362|OTHER|self-monitoring of breath acetone|Participants perform self-monitoring of braeth acetone in order to get information about their ketosis state.
223942461|NCT06745362|OTHER|lifestyle-intervention via LIM-App|Participants are offered a lifestyle intervention via LIM-App.
223942462|NCT05829629|BIOLOGICAL|FluBHPVE6E7|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule
223942463|NCT05829629|DRUG|Placebo|Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
223942464|NCT05835219|DRUG|REBYOTA™|REBYOTA™ is administered in the rectum
223942465|NCT04578938|DRUG|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
223942466|NCT04578938|BEHAVIORAL|Cognitive training|8 sessions of computer-based cognitive training
223942467|NCT04578938|BEHAVIORAL|Sham Training|8 sessions of computer-based sham training
223942468|NCT06061107|BEHAVIORAL|"The cartoon version of the ACP for Seniors brochure"|"The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention."
223942469|NCT06463366|DEVICE|3D-MRE,MRI-PDFF|3D-MRE(storage modulus, ., loss modulus and damping ratio \[DR\] for liver inflammation and fibrosis) MRI-PDFF(liver fat content)
223942470|NCT06492083|OTHER|traditional Chinese medicine hot bag|traditional Chinese medicine hot bag
223942471|NCT06826898|DEVICE|DEFEHERE Absorbable Adhesion Barrier|DEFEHERE Absorbable Adhesion Barrier, 1.0 mL/syringe
223942472|NCT06826898|DEVICE|Sham (No Treatment)|conventional therapy without using any antiadhesion product
223942473|NCT04104022|BEHAVIORAL|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
223942474|NCT04104022|BEHAVIORAL|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
223942475|NCT06939491|DEVICE|Ultrasound guided electrolysis therapy|"Ultrasound-guided galvanic electrolysis (USGET) is a technique most commonly used on chronically affected tissue. A galvanic current flows through an acupuncture needle producing an inflammatory reaction in the tissue. The inflammatory reaction will trigger a host of biological processes in the body. These will ultimately start the generation of new immature collagen fibres. The fibres become mature by means of training stimulus.~The technique shows good results on tendons in the chronic phase, and may be used for injuries, such as long-standing muscle injury and treatment of myofascial pain syndrome and trigger points."
223942476|NCT06939491|DEVICE|Sham Electrolysis|The same intervention as the electrolysis group with the device turned on but the current intensity turned to 0 mA (e.g., no galvanic current).
223942477|NCT05529472|DEVICE|Peripheral Orbital Atherectomy System (OAS)|Treatment with Orbital Atherectomy System (OAS) followed by Percutaneous Old Balloon Angioplasty (POBA), pre-dilation and Drug Coated Balloon (DCB) - Medtronic IN.PACT™ Admiral™
223942478|NCT06951282|DIETARY_SUPPLEMENT|Selenium|200 microgram selenium was given daily for 3 months
223942479|NCT06951282|DRUG|Methotrexate|0.4 mg/kg/week sub cutaneous methotrexate for 3 months
223942480|NCT06947876|OTHER|Enrolment 3T MRI research scan|Enrolment research scan performed with 3T magnetic resonance imaging scanner.
223942481|NCT06947876|OTHER|Enrolment Field-cycling Imaging research scan|Enrolment research scan performed with Field-Cycling Imaging scanner.
223942482|NCT06947876|OTHER|Enrolment ultra-low field MRI research scan|Enrolment research scan performed with ultra-low field MRI scanner
223942483|NCT06947876|OTHER|Follow up 3T MRI research scan|Follow up research scan performed with 3T magnetic resonance imaging scanner, 18-months after baseline scans.
223942484|NCT06947876|OTHER|Follow up Field-cycling Imaging research scan|Follow up research scan performed with Field-Cycling Imaging scanner, 18-months after baseline scans.
223942485|NCT06947876|OTHER|Follow up ultra-low field MRI research scan|Follow up research scan performed with Ultra-low field MRI scanner, 18-months after baseline scans.
223942486|NCT06947876|OTHER|Enrolment cognitive assessment interview|Enrolment interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test.
223942487|NCT06947876|OTHER|Follow up cognitive assessment interview|Follow up interview performed to complete cognitive assessment scoring of Montreal Cognitive Assessment, EQ-5D, Trail making test, Animal naming test, controlled oral word association test, and Hopkins Verbal Learning Test. Performed 18-months after baseline interview.
223942488|NCT05787106|OTHER|Cyberball task|"The game consists of ball throws between animated characters lasting about 50 throws. In the rejection condition, after 2 or 3 throws, the participant no longer receives the ball (no more passes). In the control conditions (all included), the participant receives the ball as often as the others."
223942489|NCT06950567|OTHER|psycho-educational intervention and therapeutic activity|"The objective is to provide knowledge and skills to tolerate/reduce discomfort so that they can begin to reduce or discontinue medication (BZD).~The focus is on the effect of combined care, but the implementation of this approach is also evaluated, which will provide valuable knowledge for further health developments in Primary Care."
223942490|NCT06950567|OTHER|Control|"Sending a Benzocarta to each person's postal address-a personalized letter signed by their Family Doctor, an explanatory sheet on how to gradually reduce medication, and infographics on sleep hygiene, stress, or anxiety."
223942491|NCT06951061|PROCEDURE|IVF/ICSI|In vitro fertilization with or without ICSI with ejaculated and surgically retrieved sperm.
223942492|NCT00491894|DRUG|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
223942493|NCT06952205|OTHER|Experimental group|McKenzie exercises, Transcutaneous Electrical Nerve Stimulation (TENS), Hot Pack (HP) and pulsed ultrasound treatments were applied.To experimental group, functional taping were applied in addition of these treatments.
223942494|NCT06952205|OTHER|only exercises|McKenzie exercises, Transcutaneous Electrical Nerve Stimulation (TENS), Hot Pack (HP) and pulsed ultrasound treatments
223942495|NCT06950918|OTHER|Experimental|"This study is a quasi-experimental parallel group design comparing Flipped Classroom (FC) and Flip-Jigsaw models in a theoretically-oriented public health course. Both groups used the same pre-prepared video lectures to standardize content, but differentiated in-class strategies: The FC group used instructor-led discussions, while the Flip-Jigsaw group used Jigsaw technique and peer teaching (students learning subtopics in expert groups and teaching them in master groups). Unlike traditional FC, this hybrid model includes systematic peer collaboration and role-based accountability mechanisms. Theoretical knowledge acquisition, motivation and engagement outcomes were assessed through quantitative tests (pre-post-retention tests) and qualitative interviews, and objectivity was ensured in practical exams with single-blinded assessors. The study brings innovation to the literature as it is the first study to demonstrate the unique effect of Flip-Jigsaw in theoretical courses in the fie"
223942496|NCT05434598|DEVICE|ChromoSeq|Novel, streamlined whole genome sequencing approach
223942497|NCT03496766|DRUG|Tipifarnib|Tipifarnib 600 mg will be administered until progression
223942498|NCT05454826|OTHER|Exercise|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
224295122|NCT04526652|DRUG|Dexmedetomidine|Evaluating anxiety score in both arms
223729363|NCT01602874|DRUG|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
224295123|NCT04526652|DRUG|Placebo|Evaluating anxiety score in both arms
224295124|NCT03223454|BIOLOGICAL|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
223942499|NCT05454826|OTHER|Cold Application|1st group (n=15) relaxation exercises, 2nd group (n=15) relaxation exercises+cold compression. The exercise program will be applied for 6 weeks, 3 days a week \* 45 minutes. Relaxation exercises will be applied to the patients 3 days a week using web-based methods (Zoom).
223942500|NCT03427463|DRUG|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
223942501|NCT03427463|DRUG|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
223942502|NCT06341023|BEHAVIORAL|Functional Balance Intervention|Participants in the intervention group will undergo a multi-component FBI exercise program, both in a lab setting (Study 1) and at home (Study 2), for 2 days/week over 4 months. This evidence-based protocol, previously piloted with chronic stroke patients, older adults with mild cognitive impairment, and pre-frail older adults, focuses on improving physical (endurance, strength, balance, and gait) and cognitive function (processing speed, attention, and memory). The program consists of functional agility, functional strength, dual-task, and vestibular exercises, with each 1-hour session including 10 minutes dedicated to each component. The exercise order will be randomized for each session, preceded by a warm-up with gentle self-stretching exercises.
223942503|NCT06341023|BEHAVIORAL|Stretching|Participants in the control group will undergo a 4-month lab-based stretching program, with the same frequency and session length as the intervention group (1 hour/session for 2 days/week). The stretching regimen will include progressive stretches targeting upper and lower-limb muscles, core, and back muscles, followed by a 10-minute cool-down comprising relaxation and breathing exercises. These stretches are designed to improve performance in daily living activities. In Study 2, stretching participants will receive a detailed printed exercise manual for home-based training, ensuring consistency with the lab-based program. No additional equipment, such as computers or tablets, is required for the home stretching program.
223942504|NCT05393024|DRUG|Belantamab mafodotin|MMRR patients included in Named Patient Program e Expanded Access Program
223942505|NCT07197502|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
223942506|NCT07196462|DEVICE|3 Minute iTBS to the L DLPFC|Five daily sessions of TMS (iTBS) to the L DLPFC target.
223942507|NCT07196462|DEVICE|One-Minute, Personalized, DMN Targeted CTBS|Personalized, DMN Targeted CTBS to the DMN for one minute, five daily sessions.
223942508|NCT07195968|DIAGNOSTIC_TEST|NTG-Pd/Pa measurement|The coronary artery with intermediate stenosis will sequentially undergo NTG-Pd/Pa, saline-Pd/Pa, and FFR assessments. Intracoronary NTG dosage will follow the protocol based on blood pressure.
223942509|NCT07195968|DIAGNOSTIC_TEST|Saline-Pd/Pa measurement|The coronary artery with intermediate stenosis will sequentially undergo NTG-Pd/Pa, saline-Pd/Pa, and FFR assessments. Ten millilitres of intracoronary saline will be given over five seconds.
223942510|NCT07196397|PROCEDURE|cardioneuroablation|Cardioneuroablation and related autonomic interventions aim to modulate parasympathetic and/or sympathetic inputs to the heart in order to treat functional bradycardia, inappropriate sinus tachycardia, vasovagal syncope, and other reflex arrhythmias. Techniques include catheter-based ablation of ganglionated plexi, thoracoscopic sinus node-sparing ablation, cardiac sympathetic denervation, and percutaneous stellate ganglion blockade. These procedures are tailored to each patient's autonomic profile and diagnosis.
223942511|NCT07196397|PROCEDURE|SN sparing hybrid ablation|Sinus node-sparing hybrid ablation is a minimally invasive surgical procedure that modulates autonomic inputs to the sinoatrial node while preserving its intrinsic function. The intervention is performed via video-assisted thoracoscopic surgery (VATS) and targets the epicardial autonomic ganglia and neural connections responsible for inappropriate sinus tachycardia or autonomic dysfunction. Unlike traditional sinus node modification, this approach avoids direct ablation of the sinus node and focuses on surrounding autonomic structures. The goal is to reduce pathologic chronotropic activity and improve symptom control without inducing iatrogenic bradycardia.
223942512|NCT07196397|PROCEDURE|Cardiac sympathetic denervation|Cardiac sympathetic denervation is an interventional procedure aimed at reducing excessive sympathetic drive to the heart by ablating or removing components of the sympathetic nervous system. It is typically performed via a thoracoscopic approach and involves bilateral or left-sided denervation of the stellate ganglion and thoracic sympathetic chain (usually T2-T4). CSD is used in patients with arrhythmias associated with sympathetic overactivity, such as long QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), or autonomic dysfunction-related tachyarrhythmias. The procedure helps reduce arrhythmic burden, modulate autonomic tone, and improve symptom control.
223942513|NCT07196397|BEHAVIORAL|Hybrid Cardiac Rehabilitation Program|A two-phase program combining supervised inpatient exercise, respiratory training, psychological support, and education with a home-based telerehabilitation phase (Nordic walking, remote ECG and vital sign monitoring). The aim is to restore functional capacity, reduce symptoms, and improve autonomic balance.
223942514|NCT07196397|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive neuromodulation technique in which the vagus nerve is stimulated via surface electrodes placed on the skin, most commonly in the auricular region (e.g., tragus or cymba conchae). The intervention is performed using a certified external stimulation device that delivers mild electrical impulses to activate afferent vagal fibers. tVNS is used in the treatment of various conditions, including depression, epilepsy, migraine, chronic pain, and disorders of the autonomic nervous system such as postural orthostatic tachycardia syndrome (POTS) and inappropriate sinus tachycardia (IST). In this study, tVNS is applied as a supportive neuromodulatory therapy with individualized stimulation parameters and session duration based on clinical response and patient tolerance.
223942515|NCT07196488|OTHER|Dyadic Co-learning Intervention|Participants in the experimental group will receive routine care plus an 8-week Dyadic Co-learning Intervention, which will consist of three components: (1) a co-learning handbook, (2) a co-learning mobile app, and (3) professional support.
223942516|NCT07197411|DIAGNOSTIC_TEST|Evaluating the Consistency and Accuracy of Two Devices in Monitoring Hemodynamic Parameters|This portable patch-type carotid ultrasound has not yet been used in clinical settings.
223942517|NCT07197411|DEVICE|Hemodynamic monitoring|Whether the parameters monitored by portable patch-based ultrasound devices agree with the gold standard has not yet been thoroughly validated
223942518|NCT07196215|PROCEDURE|passive ultrasonic activation|passive ultrasonic irrigant activation will be performed by using a stainless steel ultrasonic Irrisafe file of size 20 (IRRI S 21/25; VDW, Germany) mounted on ultrasonic unit (Woodpecker Ultrasonic Scaler UDS-J). The file will be kept 2 mm short of working length loosely without binding to the canal. 2.5% NaOCl will be activated for 30 seconds by using a power setting of five
223942519|NCT07196215|PROCEDURE|sonic activation|root canals will be filled with 2.5% sodium hypochlorite and medium size tip (red, 25/04) of EndoAcivator (YAHOPE A3, China) will be used keeping it 2 mm short of working length. The activation of irrigant will be done in 2-3 mm vertical strokes for 30 seconds in between each instrumentation
223942520|NCT07197164|DRUG|Remdesivir (RDV)|Participants will receive their first dose of remdesivir also within the 24 (+/-12) hours prior to going to the operating room. Remdesivir doses will be 200 mg on day 1, followed by 100 mg daily from days 2 to 10, for a total of 10 days.
223942521|NCT07196007|BEHAVIORAL|Community-Clinical Intervention|The intervention involves enhancing usual care for screening patients with diabetes for unmet social needs and referring those who screen positive to a Community Health Worker. Patients who screen positive for unmet social needs will work with CHWs to be connected to community organizations.
223942522|NCT07197385|PROCEDURE|Laparoscopic Ureterolithotomy|Keyhole laparoscopic approach to remove proximal ureteral stones by direct ureteral incision and closure.
223942523|NCT07197385|PROCEDURE|Ureteroscopic Lithotripsy|Semirigid ureteroscopic fragmentation of upper ureteral stones using pneumatic lithotripsy.
223942524|NCT07197801|BEHAVIORAL|Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment|The intervention adds a peer recovery support (PRS) program to standard outpatient medication for opioid use disorder treatment and medical care. The PRS program will entail meeting one-on-one with a peer recovery specialist over a 6-month period, who will utilize their lived experience with substance use and recovery to provide emotional, informational, instrumental, and aﬃliational support to participants.
223942525|NCT03187223|DRUG|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
223942526|NCT03187223|DRUG|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
223942527|NCT00302211|DRUG|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
223942528|NCT00302211|DRUG|Inhaled Placebo|inhaled placebo
223942529|NCT00302211|DRUG|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
223942530|NCT00302211|DRUG|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
223942531|NCT04302233|OTHER|New pharmaceutical support (NPS)|The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
223942532|NCT07196306|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution|At the time of enrollment, the intervention arm subjects are administered single or double dose of study drug while the placebo arm subjects are administered the placebo drug (normal saline). Subjects will be assigned to the intervention or placebo arm in random order.
223942533|NCT07196306|DRUG|Placebo|Normal saline 0.9% 1.14 mL Subcutaneous x 1 or 2 dose(s)
223942534|NCT07196618|DRUG|dimethyl sulfoxide|dentin pretreated using dimethyl sulfoxide and follow up of patients at 2 weeks, 3 months and 6 months
223942535|NCT07196618|DRUG|Cholorhexidine|dentin pretreated using chlorhexidine and follow up of patients at 2 weeks, 3months and 6 months
223942536|NCT07197554|DRUG|ST-01156|ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer
223942537|NCT07195981|DEVICE|virtual reality|The virtual reality (VR) technology is defined as a system that allows users to interact with images and sounds in a virtual environment, which can stimulate responses and provide real-time feedback concerning their performance.
223942538|NCT07195981|OTHER|selected physical therapy|selected physical therapy program only included: (Therapeutic Ultrasound device, Transcutaneous Electrical Nerve Stimulation (TENS) and Hot packs)
223942539|NCT07197151|OTHER|Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens|Perform surgery on patients with colorectal cancer and collect cancer and adjacent tissue specimens
223942541|NCT07197346|DEVICE|rTMS - cTBS (Continuous Theta-Burst Stimulation)|Continuous theta-burst stimulation (cTBS) is a patterned form of rTMS consisting of bursts of three pulses at 50Hz, repeated every 200ms (5Hz), administered continuously without breaks. In this study, cTBS is delivered over the target cortical area according to established safety guidelines (e.g., a continuous 40s train for a total of 600 pulses) at an intensity set as a percentage of the resting motor threshold. The procedure is used to induce a transient reduction in cortical excitability as a priming intervention prior to motor practice.
223942542|NCT07197346|BEHAVIORAL|Self-controlled (autonomy)|Self-controlled practice is a motor learning intervention in which participants are granted autonomy to make choices about key aspects of their practice sessions (e.g., when to receive feedback, the sequence/timing of trials, or selection of specific practice parameters). This design allows participants to actively control elements of the training experience according to their preference, thereby fostering intrinsic motivation and engagement. The intervention is grounded in the OPTIMAL theory of motor learning, which highlights the role of autonomy support in enhancing learning outcomes and motivation. In this study, participants in the self-controlled practice group make their own decisions regarding practice conditions, in contrast to yoked controls who follow externally assigned parameters.
223942543|NCT07197346|DEVICE|Sham|Sham TBS involves the application of a sham theta-burst stimulation protocol designed to mimic the sensory experience of active TBS without delivering effective magnetic pulses to the brain. This is typically achieved by angling the coil to prevent cortical stimulation. The procedure controls for placebo effects and participant expectations while ensuring blinding. The sham stimulation session matches the timing and setup of active TBS interventions but does not induce cortical excitability changes.
223994417|NCT00544232|DRUG|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
223729364|NCT04857242|DIAGNOSTIC_TEST|Apnea test, alveolar recruitment|Alveolar recruitment following the phase of apnea testing
223729365|NCT04023786|PROCEDURE|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
223729366|NCT03942627|BEHAVIORAL|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
223942544|NCT07197346|BEHAVIORAL|Yoked Practice|Yoked practice refers to a motor learning protocol in which participants perform tasks under externally controlled practice conditions, matched to the parameters (e.g., feedback) of a paired participant from a self-controlled practice group. This design removes participant autonomy over practice choices, allowing comparison between self-controlled and externally controlled practice to evaluate the effects of autonomy on motor learning and motivation.
223942545|NCT07197346|DEVICE|rTMS- iTBS (Intermittent Theta-Burst Stimulation)|Intermittent theta-burst stimulation (iTBS) is a patterned form of repetitive transcranial magnetic stimulation (rTMS) consisting of bursts of three pulses at 50Hz, repeated every 200ms (5Hz). In this study, iTBS is delivered over the target cortical area using standard protocols (e.g., 2s trains of TBS repeated every 10s for a total of 600 pulses) at an intensity set as a percentage of the resting motor threshold. The procedure aims to facilitate cortical excitability as a priming intervention prior to motor practice.
223942546|NCT07196670|DRUG|intralesional vitamin D3 versus intralesional acyclovir|injecting intralesional vitamin D in group A versus injecting intralesional acyclovir in group B in treatment of plantar warts
223942547|NCT07197580|RADIATION|177Lu-TLX250|3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals
223942548|NCT07197632|PROCEDURE|Surgery with intraoperative MRI|In this clinical study, we have the unique opportunity to utilize a 3 Tesla MRI intraoperatively during the surgical resection of brain metastases. This approach is distinctly different from standard procedures and offers several advantages. The use of a 3 Tesla MRI provides high-resolution imaging during surgery, offering unparalleled detail of brain structures and tumor boundaries. This level of imaging precision is typically not available in standard surgical procedures. Through real-time visualization, surgeons can better differentiate between tumor tissue and healthy brain tissue, potentially increasing the accuracy of tumor removal and minimizing damage to surrounding areas. Unlike conventional methods, this procedure allows for immediate intraoperative imaging feedback, enabling surgical teams to adjust their techniques dynamically
223942549|NCT07195877|DEVICE|Insertion/placement of tension threads|"* Standard preoperative anti-staphylococcal antibiotic prophylaxis by intramuscular injection.~* Disinfection of the surgical area.~* Marking of the paths of the threads to be implanted according to the physician's choice.~* Placement of sterile surgical drapes.~* Local anesthesia of the paths.~* Implantation of a needle (manufactured by Thread \& Lift) and pulling of the threads into the subcutaneous tissue. Adjustment of the tension of all the implanted threads. Cutting of the ends of the threads."
223942550|NCT07197021|DEVICE|TEER|TEER
223942551|NCT07197021|DRUG|GDMT|GDMT
223942552|NCT07197853|DRUG|Huaier Granule|Patients in this arm will undergo CT-guided percutaneous microwave ablation using a standard protocol (2450 MHz, 30-50 W, 5-10 minutes per lesion, multi-probe as needed based on tumor size). Seven days post-ablation, patients will start oral administration of Huaier granules at a dose of 10g, three times daily (TID), for 72 consecutive weeks. The combined therapy aims to improve local tumor control and modulate anti-tumor immunity.
223942553|NCT07197294|DRUG|nL-MAPK8-001|Personalized antisense oligonucleotide
223942554|NCT07196982|OTHER|No intervention (observational study)|This is an observational retrospective case-control study. No experimental intervention is administered. All participants received standard surgical management for intertrochanteric femoral fractures according to clinical practice, including proximal femoral nail antirotation (PFNA) with or without additional lateral wall plate fixation. The study only compares clinical and radiological data between patients with isolated intertrochanteric fractures and those with concomitant lateral wall involvement.
223942555|NCT06413979|BEHAVIORAL|Family Support Protocol for Adolescent Internalizing Disorders (Fam-AID)|(1) Family Engagement of caregivers and primary supports in treatment planning and services; (2) Relational Reframing of family constraints, resiliencies, and social capital connected to the youth's ID symptoms; (3) Functional Analysis of the youth's ID symptoms and related behaviors; (4) Cognitive-behavioral therapy (CBT) core techniques to address the youth's ID symptoms and functional needs, featuring three transdiagnostic interventions (emotion acceptance, emotional exposure, behavioral activation) to address negative affect and emotional dysregulation underlying both depression and anxiety; and (5) Family Psychoeducation and Safety Planning focused on education about comorbid SUD/ID and prevention of youth self-harm. All interventions featured in each module have strong empirical support.
223942556|NCT07196787|OTHER|Exercise|"The 18-Week Program Structure This program is divided into three 6-week phases. Each week consists of 5 sessions, mixing different focuses to ensure balanced development.~Day 1: Foundational Strength \& Stability~Day 2: Low-Impact Cardio \& Active Recovery~Day 3: Core Focus \& Hip Stability~Day 4: Low-Impact Cardio \& Mobility~Day 5: Full Body Integration \& Strength"
223942557|NCT07197424|DIAGNOSTIC_TEST|Robot assisted magnetically controlled capsule endoscopy|Examination of the upper GI tract (oesophagus and stomach) with robot assisted magnetically controlled capsule endoscopy. Examination of the small bowel will be completed using the same capsule, however it will not be robot assisted.
223942558|NCT04716101|OTHER|Massage therapy technique|The massage therapy technique consists of manual deep and slow compression and shearing forces applied on the lumbar spine muscles and thoracolumbar fascia in a distal to proximal direction.
223942559|NCT04716101|OTHER|Sham massage technique|For the sham massage technique the massage therapist will put the right palm at the participant's right lower back along erector spinae and likewise left palm at left lower back without applying force, holding the palm during 2 minutes and half.
223942560|NCT06414577|DRUG|Irinotecan Liposomal combined With Nituzumab|Irinotecan liposomal: 70mg/m2, ivgtt, d1; Nituzumab: 400 mg, igvtt, d1 One treatment cycle every two weeks for up to 8 cycles, or until disease progression, intolerable toxicity, death, and investigator judgment of no further benefit
223942561|NCT02921711|DEVICE|LVIS®|Low-profile Visualized Intraluminal Support device
223729367|NCT03942627|BEHAVIORAL|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
223729368|NCT01413191|BIOLOGICAL|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
223729369|NCT01413191|OTHER|Laboratory biomarker analysis|Correlative studies
223942562|NCT04200196|PROCEDURE|"fabrique à histoire"|"Fabrique à histoire is a participatory entertainment method. Children of this arm going to create and listening a story before and during the venous puncture."
223942563|NCT04200196|PROCEDURE|Usual care|It is a passive entertainment method. Children of this arm going to do habitual activities before and during the venous puncture, like to sing, blow up a balloon, to play with recreational thing, etc.
223942564|NCT01850355|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
223942565|NCT04692532|OTHER|8-hour Time restricted eating|Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
223942566|NCT04692532|OTHER|Calorie restriction|25% energy restriction every day
223942567|NCT04994301|DIAGNOSTIC_TEST|Lung T1 MRI|Evaluation of lung T1 MRI to Assess Lung Disease
223942568|NCT05475015|DEVICE|3D-MRE|All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.
223942569|NCT05475015|DEVICE|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
223942570|NCT06256393|OTHER|Collection of biological samples|Collection of blood samples and intestinal biopsies during a surgery or colonoscopy for disease relapse
223942571|NCT06075966|OTHER|Non-fusion group|Patients who have undergone the INTRA-Spine dynamic stabilization system insertion surgery for lumbar spondylosis and have complete follow-up data and meet the standards completed at the First Affiliated Hospital of Shandong First Medical University.
223942572|NCT06075966|OTHER|Fusion group|Patients who have undergone lumbar spine fusion surgery due to lumbar spondylosis and meet the standards and have complete follow-up data completed at the First Affiliated Hospital of Shandong First Medical University
223942573|NCT04858412|DIETARY_SUPPLEMENT|β-hydroxy β-methyl butyrate (HMB) enriched amino acid|β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
223942574|NCT04858412|DIETARY_SUPPLEMENT|Balanced amino acid|Balanced amino acid is the balanced mixture of the various essential amino acids.
223942575|NCT04148742|DRUG|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
223942576|NCT05396638|BEHAVIORAL|Contingency Management|Participants will be paid for abstinence at each study visit.
223942577|NCT06217588|OTHER|Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence.|The study will collect extensive historical health data (retrospective), and at baseline will conduct an extensive characterization of the disease progression using the parameters described above.
223942578|NCT06282913|BEHAVIORAL|Mindfulness Meditation|Mindfulness Meditation application will be implemented online by the researcher in 20-minute group sessions once a week for 8 weeks. Participants will be asked to provide a quiet, ventilated, dimly lit environment for the practice. The researcher will start the application when the participants take their places as they feel comfortable. In the first stage, the researcher will teach physicians and nurses to take deep diaphragmatic breaths through the nose and out through the mouth.
223942579|NCT02808468|BEHAVIORAL|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
223942580|NCT05405140|OTHER|Shock wave therapy with multiphasic neuroplasticity based training protocol|Interventions program will be based on Activity dependent neuroplasticity targeting relevant impairments included: task specific practice, motor learning, strengthening, postural awareness, Balance training, aerobic and conditioning exercises, range of movement with Shock wave therapy for most of time of the day .
223729370|NCT04416503|OTHER|Foot reflexology|Foot reflexology was performed for 12 week in the study group,whereas the control group continued their routine treatment and follow-up.
223942581|NCT05405140|OTHER|Conventional physical therapy|The CP program focused on the facilitation of movements on the paretic side, range of motion, stretching exercises, upper and lower limb strengthening exercises, and improving balance, standing, sitting, transferring, patients received a program for at least 30 sessions, 5 times per week for 6 or more weeks.
223942582|NCT05887531|OTHER|Prehabilitation|Patients will be included in a prehabilitation program
223942583|NCT03869476|DIAGNOSTIC_TEST|Non-invasive diagnosis score|"* spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells"
223942584|NCT06518486|OTHER|Foot-ankle exercise|Foot-ankle exercise group will receive usual care provide by public health center and intervention through health education, leaflets, and videos about foot-ankle exercise. At the first meeting, participants will be taught how to do foot exercises and practice them in front of the instructor. Afterwards, participants will practice foot exercises independently without supervision for 12 weeks. One foot exercise session takes 10-15 minutes, while the physical activity target is for participants to fulfil a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do foot exercises for 2-3 sessions every day. The minimum duration of each session is 10 minutes, and two consecutive days without foot exercise are not allowed. Participants are asked to document all foot exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for ±5 minutes/week.
223994418|NCT00544232|DRUG|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
223994419|NCT01228175|DRUG|Placebo|25mg look alike riboflavin tablets to match active study medication.
223729371|NCT02319746|BEHAVIORAL|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
223942585|NCT06518486|OTHER|Walking exercise|Participants in the walking exercise group will receive usual care provide by public health center and intervention through health education and leaflets about walking exercise. Participants will practice walking exercises independently without supervision for 12 weeks. Participants walked at the same speed as they did every day. The physical activity target to be achieved is for participants to be able to engage in a moderate level of physical activity (150 minutes/week). For this reason, participants are advised to do walking exercises with a minimum duration of 10 minutes for each session. Two consecutive days without walking exercise are not allowed, and a minimum of 150 minutes/week is allowed. Participants are asked to document all walking exercise practices in the logbook given at the first meeting. To monitor the intervention, we will contact participants by telephone for ±5 minutes/week.
223942586|NCT06518486|OTHER|Usual care and health education|Participants in the control group will receive the usual care provided by the community health center and intervention in the form of health education about DM in general.
223942587|NCT01434251|OTHER|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
223942588|NCT05253781|DRUG|Low-dose aspirin|Low dose aspirin (LDA) group will receive 100mg aspirin daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
223942589|NCT05253781|OTHER|Placebo|Placebo group will receive one tablet of the placebo which has same shape, size, thickness and colour as the LDA daily taken at once just before bedtime from 12 weeks gestational age or enrollment till 36 weeks gestational age.
223942590|NCT06017505|DIAGNOSTIC_TEST|electronic self administered gerocognitive examination (eSAGE)|A self-administered digital assessment that evaluates multiple cognitive domains: orientation, language, memory, executive function, calculations, abstraction, and visuospatial abilities, through multiple questions. Additionally, it includes the collection of six clinical variables: education, gender, race, family history of dementia, stroke, and emotion.
223942591|NCT04906057|BEHAVIORAL|Forced Aerobic Exercise (FE)|High-rate aerobic exercise on a semi-recumbent custom-designed stationary cycle ergometer
223942592|NCT04906057|BEHAVIORAL|Voluntary Aerobic Exercise (VE)|Voluntary-rate aerobic exercise on a semi-recumbent stationary cycle ergometer
223942593|NCT02294461|DRUG|Enzalutamide|Oral
223942594|NCT02294461|DRUG|Placebo|Oral
223942595|NCT02632994|DRUG|LY2503029|Administered orally.
223942596|NCT02632994|DRUG|LY3023414|Administered orally.
223942597|NCT02632994|DRUG|LY3838915|Administered orally.
223729372|NCT02319746|BEHAVIORAL|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
223729373|NCT01280916|BEHAVIORAL|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
223729374|NCT03051035|DRUG|KO-947|Intravenous administration
223942598|NCT02632994|DRUG|LY3847429|Administered orally.
223942599|NCT04266236|PROCEDURE|L3 LPB|ultrasound-guided L3 lumbar plexus block
223942600|NCT04266236|PROCEDURE|L4 LPB|ultrasound-guided L4 lumbar plexus block
223942601|NCT04266236|PROCEDURE|T12 block|ultrasound-guided thoracic 12th segment nerve block
223942602|NCT04266236|PROCEDURE|L3 QLB|ultrasound-guided quadratus lumborum block at L3 level
223942603|NCT04266236|DRUG|0.375%ropivacaine 25 ml (Raropin)|0.375%ropivacaine (Raropin) 25ml will be given
223942604|NCT04266236|DRUG|0.375%ropivacaine 40 ml (Raropin)|0.375%ropivacaine (Raropin) 40ml will be given
223942605|NCT04266236|PROCEDURE|General anesthesia with tracheal intubation|General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
223942606|NCT00237016|DRUG|doxycycline treatment|
223942607|NCT06464016|DEVICE|Ventricular Assist Device with Berlin Heart EXCOR|"The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body."
223942608|NCT06470503|BEHAVIORAL|Exercise Program|8-week program and four-week short maintenance period.
223942609|NCT05326646|DIETARY_SUPPLEMENT|Low FODMAP diet|After the realisation of a wireless motility capsule, patients will underwent 6 weeks of low FODMAP diet after dietician education. Symptomatic scores (IBS-SSS, GIQLI, HAD) and stools samples (metabolomic and lipidomic) will be performed before and after the low FODMAP diet.
223942610|NCT03469791|PROCEDURE|Surgical treatment of Degenerative Spondylolisthesis|
223942611|NCT06247904|DEVICE|Active rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be determined from individual MRI-modeled e-field, to achieve approximately motor threshold in the target area.
223942612|NCT06247904|DEVICE|sham rTMS|The stimulation protocol will comprise 15Hz pulse trains, each 50 pulses, repeated 10x, with a 60s inter-train interval. Stimulation intensity will be close to zero (negligible) since sham coil will be used for the intervention
223942613|NCT03508232|DRUG|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
223942614|NCT03508232|DRUG|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
223942615|NCT06429449|DRUG|Venetoclax|Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
223942616|NCT06429449|DRUG|Azacitidine|An analog of the pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
223942617|NCT06429449|DRUG|Mitoxantrone|Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use.
223994420|NCT01228175|DRUG|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
223994421|NCT01888549|DRUG|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
223729375|NCT05456464|OTHER|Reiki|Reiki is applied touching the energy centers of the body (chakras). There are seven main and many small chakras on a body. Chakras are located on the front and back sides of the body in a vertical line that runs along the middle of the body in humans. A complete Reiki therapy includes all the chakras and organs.
223729376|NCT01308346|DEVICE|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
223942618|NCT06075121|OTHER|Abdominal massage|Patients in the massage group will receive an abdominal massage twice a day for 5 days, between 10.00 in the morning and 22.00 in the evening. Enteral nutrition will be interrupted twice a day for 5 days, between 09.30-10.00 in the morning and 21.30-22.00 in the evening, and patients will receive an abdominal massage for 15 minutes.
223942619|NCT05432986|DEVICE|Thermal Anisotropy Measurement Device|A wireless device for non-invasively assessing CSF shunt flow.
223942620|NCT05791227|DIAGNOSTIC_TEST|Sonographer Evaluation|A sonographer will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
223942621|NCT05791227|DIAGNOSTIC_TEST|AI Evaluation|An AI model will assess measurements of left ventricular diameter during diastole (LVIDd), intraventricular septum thickness during diastole (IVSd) and left ventricular posterior wall thickness during diastole (LVPWd).
223942622|NCT05581953|OTHER|Omnivorous|Pork-added plant-forward diet
223942623|NCT05581953|OTHER|No meat|Plant-forward no meat
223942624|NCT03753555|DRUG|Atorvastatin Calcium|20mg Qd for 12 months
223942625|NCT03753555|DRUG|Atorvastatin Calcium|40-80mg Qd for 6 months
223942626|NCT03753555|DRUG|Probucol|0.5g Bid for 6 months
223942627|NCT03753555|DRUG|PCSK9 inhibitor|Evolocumab 140mg subcutaneously injected, twice each month
223942628|NCT03357562|DEVICE|lung MRI|lung MRI without contrast injection
223942629|NCT02200276|BIOLOGICAL|Influenza|
223942630|NCT06027996|DEVICE|Absorbable Antibacterial Matrix|Soft tissue support coated with antibiotics
223942631|NCT05006482|OTHER|Best Practice|Receive usual follow-up survivorship care
223942632|NCT05006482|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
223942633|NCT05006482|OTHER|Educational Intervention|Participate in survivorship health education sessions
223942634|NCT05006482|OTHER|Exercise Intervention|Participate in EXCAP program
223942635|NCT05006482|OTHER|Questionnaire Administration|Ancillary studies
223942636|NCT05006482|PROCEDURE|Tailored Intervention|Participate in GEM consultation
223942637|NCT06269263|BEHAVIORAL|Home-based cardiac rehabilitation|Guided by physiotherapists, patients will receive different trainings regrading endurance/balance/resistance,/coordination at home
223942638|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
223942639|NCT05649137|DRUG|Semaglutide|Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
223942640|NCT05649137|DRUG|Placebo|Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
223942641|NCT03997786|DRUG|Tildrakizumab|Week 0 (Day 1), Week 4 (Day 28) and week 16 (Day 112)
223942642|NCT03997786|DRUG|Placebo|(Weeks 0 to 16)
223942643|NCT03997786|DRUG|Tildrakizumab|(Weeks 16 to 52)
223942644|NCT03997786|DRUG|Tildrakizumab|at every 12 weeks in open label fashion till 5 years (240 weeks).
223942645|NCT03997786|DRUG|Tildrakizumab|(Weeks 0 to 16)
223942646|NCT03997786|DRUG|Etanercept|(Weeks 0 to 16)
223942647|NCT03997786|DRUG|Placebo|(Weeks 16 to 52)
223942648|NCT05355792|DEVICE|OmniTaper EV implants|Partially edentulous subjects in need of one implant in the maxilla or mandible (2nd and 3rd molars excluded) will receive an OmniTaper EV implant system. The study will be done in accordance with standard dental practice using a one- or two-stage surgical protocol and immediate or delayed placement and/or loading.
223942649|NCT05098171|BIOLOGICAL|Signal Switch Receptor Modified TIL|Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
223942650|NCT06082518|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device).|"40 hyperbaric oxygen therapy (HBOT) treatments (90 minute exposures at 2 atmospheres (ATM) per treatment), scheduled daily from Monday to Friday (i.e., 5 treatments per week) until treatments are completed (approximately 8 weeks). Treatments will be delivered in a medical grade, Health Canada-approved monoplace hyperbaric chamber and overseen by specialist hyperbaric physicians and a Certified Hyperbaric Technologist.~Device is being used in manner consistent with approved usage in Canada."
223942651|NCT05405101|PROCEDURE|Thermal ablation of aldosterone producing adenoma.|"On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.~On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance."
223942652|NCT05405101|PROCEDURE|Unilateral adrenalectomy|Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in \>1-2 patients)
223942653|NCT06453681|OTHER|bilateral PECS|ectoralis nerve (Pecs) block, which is novel, less invasive regional analgesic technique.
223942654|NCT06453681|DRUG|Dexmedetomidine|Dexmedetomidine is a potent α2 agonist. In our practice, dexmedetomidine is administered as an additive to regional anesthesia to improve the duration and quality of analgesia
223942655|NCT04680481|DEVICE|Transcranial alternating current stimulation|Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
223942656|NCT05683457|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with 0.9% sodium chloride (normal saline).
223942657|NCT05683457|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223942658|NCT05830825|PROCEDURE|Vertebral Body Tethering (VBT)|Vertebral Body Tethering surgery with the Tether™ in UK
223942659|NCT05392556|DIETARY_SUPPLEMENT|Probiotic|Cerebiome (Lallemand Health Solutions): probiotic supplement containing Bifidobacterium longum R0175, Lactobacillus helveticus R0052, and maltodextrin. Dosing: Oral, 3.6 g/d containing 3x10\^9 CFU/d (powder form)
223942660|NCT05392556|DIETARY_SUPPLEMENT|Prebiotic|Bimuno-GOS (Clasado Biosciences): Dosing: Oral; 3.6 g/d containing 2.75 g active GOS/d (powder form)
223942661|NCT05392556|OTHER|Placebo|Maltodextrin 3.6 g/d (powder form)
223942662|NCT06023927|OTHER|Clinical observation, diagnostic testing|Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months
223942663|NCT05689502|DEVICE|Treatment|Subjects will participate in 6 hours of therapy a day, 5 days a week, for 3 consecutive weeks. These sessions will include 2 hours of occupational therapy, 2 hours of physical therapy, and 2 hours of guided individual work. Some of these sessions will be in a group setting. The therapy sessions will be individualized to the subject's personal goals and will focus on improving the function of the arm most affected by the stroke. Sessions may include electrical stimulation of the muscles, if it is determined to be safe. At the end of each week, the therapists will recommend exercises for the subjects to continue to work on at home on the weekend.
223942664|NCT04572451|DRUG|nivolumab|"Nivolumab (BMS-936558-01), 480 mg intravenous (every 4 weeks)~Treatment must be within 7 days of the last dose of radiation."
223942665|NCT04572451|DRUG|BMS-986253|"BMS-986253 (Anti-IL-8), 2,400 mg intravenous (every 2 weeks)~Treatment must be within 7 days of the last dose of radiation."
223942666|NCT04572451|RADIATION|Stereotactic Body Radiotherapy (SBRT)|"Stereotactic Body Radiotherapy (SBRT) (varying doses)~SBRT: Initial Dose fractionation of 3 or 5 fractions of radiation as determined by the location of the metastases to be irradiated, to at least 1 but no more than 4 metastatic lesions. There will be a minimum of 40 hours between treatments for an individual metastasis.~SBRT must be completed within a 14-day window, separate from the screening phase. Treatment with nivolumab and BMS-986253 must be within 7 days of the last dose of radiation."
223942667|NCT03383302|RADIATION|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions, 55 Gy if delivered in 5 fractions or 60 Gy if delivered in 8 fractions.
223942668|NCT03383302|DRUG|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be administered intravenously at a flat dose of 240 mg q2w over 30 minutes for 13 cycles followed by 480mg q4w over 60 minutes for 7 cycles, until 20 cycles in total to complete (a minimum of 1 year of treatment if no delays are encountered).
223942669|NCT06449521|BEHAVIORAL|BECOME intervention|The intervention, BECOME, includes: a) Evidence-based stress reduction (EBSR): as recommended in the WHO mhGAP guidelines, diaphragmatic breathing and body scan will be used to manage stress and anxiety. b) Behavioral activation (BA): as recommended in the mhGAP guidelines, this evidence-based strategy will increase the time that patients spend engaging in pleasurable activities to both treat depression and increase physical activity, depending on their cognitive and physical capabilities (e.g., going to a neighbor's house for tea or walking to the local market). c) Motivational interviewing (MI): an evidence-based patient-interaction strategy that increases the patient's internal motivation to engage in healthy behaviors (e.g., quit tobacco) both to prompt change (if they are not engaging in healthy behaviors) and maintain them (if they are already engaged in healthy behaviors), as recommended by Package of Essential Noncommunicable disease interventions) PEN protocols.
223942670|NCT06118086|DRUG|REM-422|"* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily"
223942671|NCT05741229|DRUG|Nebulized nitroglycerine as adjunctive therapy|Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
223942672|NCT05741229|DRUG|conventional therapy for PPHN|patients will receive sildenafil which is used routinely in management of PPHN in our unit, in addition to appropriate oxygenation and ventilation.
223942673|NCT05763953|DRUG|Etripamil NS|"Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A."
223942674|NCT05064306|DRUG|131I-omburtamab|50 mCi 131I-omburtamab
223942675|NCT03295227|BIOLOGICAL|Pembrolizumab|Given IV
223942676|NCT05018624|BEHAVIORAL|Alcohol brief intervention|At baseline, subjects will receive face-to-face or online alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
223942677|NCT05018624|BEHAVIORAL|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
223942678|NCT05018624|BEHAVIORAL|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
223729377|NCT01308346|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
223994422|NCT01888549|DRUG|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
223994423|NCT01888549|DRUG|placebo|
223942679|NCT05018624|BEHAVIORAL|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
223942680|NCT05018624|BEHAVIORAL|AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong|"a diagram explaining drinking behaviour and potential health risks, definitions of alcohol unit and binge drinking, and advise on limiting daily drinking to 2 alcohol units for men and 1 unit for women"
223942681|NCT04172675|DRUG|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
223942682|NCT04172675|DRUG|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
223942683|NCT04172675|DRUG|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
223942684|NCT05641766|DRUG|THC|Participants will receive THC into a rapidly flowing IV infusion.
223942685|NCT05641766|OTHER|Placebo|Participants will receive an equivalent amount (about 1-2 ml) of placebo (sterile 190 proof USP ethanol). The placebo does not produce any measurable blood alcohol levels or subjective/behavioral effects.
223942686|NCT05943054|OTHER|Temporal perception tasks|"A long temporal perception task in which the duration of the stimulus, around 2 min, is materialized by a video. For each trial, two videos are displayed to the participants, and then the task of the participant is to indicate the longest video and to give his level of confidence in his answer. A short temporal perception task which will take place in the same way as the long task except that the duration of the stimulus, around 2 seconds, is materialized by still frames from the videos used in the previous task."
223942687|NCT03013218|DRUG|Evorpacept (ALX148)|Evorpacept (ALX148)
223942688|NCT03013218|DRUG|Pembrolizumab|Keytruda
223942689|NCT03013218|DRUG|Trastuzumab|Herceptin
223942690|NCT03013218|DRUG|Rituximab|Rituxan
223729378|NCT05713721|DEVICE|Transcranial magnetic stimulation (TMS)|TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
223729379|NCT05713721|OTHER|Video-based clinical examination|A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
223729380|NCT05713721|OTHER|24 hours drug withdrawal of dopaminergic medication|Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
223942691|NCT03013218|DRUG|Ramucirumab + Paclitaxel|Standard of care chemotherapy
223942692|NCT03013218|DRUG|5-FU + Cisplatin|Standard of care chemotherapy
224099766|NCT07032064|PROCEDURE|Sequential ventricular pacing at five sites|"This intervention involves sequential temporary pacing at five distinct ventricular sites within the same patient during a single electrophysiological study. The pacing sites include:His bundle pacing (HBP),Deep septal pacing (DSP),Left ventricular septal pacing (LVSP),Non-selective left bundle branch pacing (NS-LBBP),Selective left bundle branch pacing (SLBBP).~Each pacing modality is tested under identical hemodynamic and electrophysiological conditions using a fixed output and AV delay. Electrical parameters and acute hemodynamic responses are recorded for each site. The study uses a within-subject crossover design, allowing direct intra-individual comparison of different pacing strategies in patients meeting standard CRT indications. No long-term device implantation is involved during this phase of the study."
224099767|NCT06744816|DRUG|Qutenza Patch|Given topical
223942693|NCT04400188|DRUG|Fluzoparib|Given PO
223942694|NCT04400188|DRUG|temozolomide|Given PO
223942695|NCT04400188|BIOLOGICAL|SHR-1316|Given injection
223942696|NCT06830681|DIETARY_SUPPLEMENT|New generation eHF|New generation of a whey-based eHF formula intended for the dietary management of infants with CMPA.
223942697|NCT06830681|DIETARY_SUPPLEMENT|Commercial eHF|Commercial whey-based eHF formula intended for the dietary management of infants with CMPA.
223942698|NCT06786351|PROCEDURE|Right atrial balloon occlusion|Thoracic endovascular aortic repair with right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
223942699|NCT06786351|PROCEDURE|Non right atrial balloon occlusion|Thoracic endovascular aortic repair not using right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
223942700|NCT04786262|BIOLOGICAL|VX-880|Infused into the hepatic portal vein.
223942701|NCT06242015|OTHER|Carbohydrate-first meal|Rice (150 grams) eaten first, followed by broccoli (150 grams) and chicken (100 grams)
223942702|NCT06242015|OTHER|Carbohydrate-last meal|Broccoli (150 grams) and chicken (100 grams) eaten first, followed by rice (150 grams)
223942703|NCT05317689|DRUG|Psilocin|17.5mg oral psilocin with psychological support and physiological monitoring
223942704|NCT05317689|DRUG|Psilocybin|25mg oral psilocybin with psychological support and physiological monitoring
223942705|NCT05317689|DRUG|Sublingual Psilocin|2.18mg - 4.36mg sublingual psilocin with psychological support and physiological monitoring
223942706|NCT04228991|RADIATION|Locoregional radiation treatment - Conventional fractionation|40 Gray in 15 daily fractions over 3 weeks
223942707|NCT04228991|RADIATION|Locoregional radiation treatment - Hypofractionation|26 Gray in 5 daily fractions over 1 week
223942708|NCT04948645|DRUG|Fosigotifator|Oral
223942709|NCT04948645|DRUG|Placebo|Oral
223942710|NCT06963437|OTHER|Diet|A four-stage dietary program will be implemented in accordance with ASMBS guidelines. To the best of our knowledge, there is currently no study comparing the dietary approach following revisional bariatric surgery with ketogenic and intermittent fasting diets
223942711|NCT06963437|OTHER|Ketogenic diet|A high-protein Very Low-Calorie Ketogenic Diet (VLCKD) will be implemented as the nutritional intervention. In line with previous studies, the daily energy intake of the ketogenic diet will be planned as 600-800 kcal, with approximately 10% of energy from carbohydrates (\<30 g/day), 40-45% from protein, and 40-50% from fat. Total carbohydrate intake will be restricted to less than 30 g per day, primarily from vegetables, while fat intake will derive from natural protein sources and 10 g of olive oil per day.
223942712|NCT06963437|OTHER|Fasting|Patients in this group will follow a time-restricted eating pattern (16/8) for a duration of 6 weeks, with food intake limited to an 8-hour window each day. Intermittent fasting will preferably be observed between 6:00 PM and 10:00 AM; however, patients may choose alternative 16-hour fasting periods such as 7:00 PM-11:00 AM or 8:00 PM-12:00 PM, depending on their individual routines. During the 8-hour feeding window, patients will adhere to the stage 4 post-bariatric dietary guidelines in accordance with ASMBS recommendations
223942713|NCT06963437|OTHER|Control|No individualized diet will be planned
223942714|NCT06230783|OTHER|TalkTracker|Participants will be asked to complete the speech collection procedures remotely/at home once per week for 8 weeks. The 8-week period of weekly remote speech collection will take place yearly for a total of 3 years. At the end of each 8-week study period for years 1-3, participants will complete a survey that asks questions about how easy/difficult the application was to use, how frustrated they felt using the application, and other usability questions.
223942715|NCT04182646|DEVICE|Spartz Balloon|The Spatz Adjustable intragastric balloon (AIGB) was developed to extend implantation to 1 year, decrease balloon volume for intolerance and increase volume for diminishing weight loss effect. The concept of an adjustable balloon came from the fact that around 10% of patients are intolerant to the balloon, requiring early extraction and also gastric balloons lose their effectiveness by approximately the 4th month post-implantation, and studies have shown that patients actually regain weight while the balloon is still implanted. AIGB balloon can mitigate this effect by adjustment of balloon volumes as required
223942716|NCT06484751|DEVICE|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
223942717|NCT06432881|DEVICE|RD SET Sensor|All subjects are enrolled into this arm and will have Sp02 measurements obtained.
223942718|NCT05635643|DRUG|CHS-114|CHS-114
223942719|NCT05635643|DRUG|toripalimab|toripalimab-tpzi
223942720|NCT00570999|DRUG|Palifermin|60 mg/kg/day
223942721|NCT00570999|OTHER|Placebo|1,2 mL once daily
223942722|NCT04907617|OTHER|FAW|After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.
223942723|NCT04907617|OTHER|Warmed fluids|In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.
223942724|NCT04907617|OTHER|Combination|"After the induction of anaesthesia, for patients assigned to groups 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.~In patients assigned to groups 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet."
223942725|NCT04907617|OTHER|Control|The patients assigned to group 4 will only receive 'routine care'. They will not be given intraoperative forced-air warming or heated IV and irrigation fluids.
223942726|NCT02873897|DIETARY_SUPPLEMENT|Session A: Experimental products (selected enriched products)|
223942727|NCT02873897|DIETARY_SUPPLEMENT|Experimental session: to select enriched products|
223942728|NCT02873897|DIETARY_SUPPLEMENT|Session B: Control (standard products without enrichment)|
223942729|NCT02873897|DIETARY_SUPPLEMENT|Control session|
223942730|NCT03008785|OTHER|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
223942731|NCT03008785|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
223942732|NCT03008785|OTHER|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
223942733|NCT06369714|DRUG|Concerta|Methylphenidate Hydrochloride Extended-Release Tablets with the following specifications: 18mg dosage, oral administration, once a day for a duration of 8 weeks.
223942734|NCT06369714|DEVICE|Digital therapeutics|30 sessions of digital therapeutics, each lasting 30 minutes, will be conducted with a frequency of once every 1-2 days over an 8-week period.
223942735|NCT06364280|DEVICE|BVM|Bag-Valve-Mask Ventilation
223942736|NCT06364280|DEVICE|SGA|Supraglottic Airway
223942737|NCT06364280|DEVICE|ETI|Endotracheal Intubation
223994424|NCT03352154|DIAGNOSTIC_TEST|P300 - Auditory long latency potential|Perform the P300 exams.
223994425|NCT02683499|PROCEDURE|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
223942738|NCT06794138|PROCEDURE|dental implant placement|The fit of the surgical guide was checked and a flapless procedure was performed under local anesthesia. However, in cases where the width of keratinized mucosa was insufficient a limited full-thickness flap was elevated. The surgical template was fixed on the remaining dentition and mucosa using template fixation pins. Fully guided implant bed preparation was performed. Osteotomies were carried out with external cooling at a drill rotation speed of 800 rpm. Implant placement was performed using a manual torque wrench Dental implants were placed non-submerged. In cases of flap elevation, wound margins were stabilized with single interrupted sutures. Sutures were removed at 7 days postop.
223942739|NCT06465017|DIAGNOSTIC_TEST|standard-of-care imaging (18F-FDG and 68Ga-FAPI PET/CT), 68Ga-THP-Trop2 VHH PET/CT|Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG and 68Ga-FAPI) and 68Ga-THP-Trop2 VHH, and undergoes PET/CT imaging within the specified time.
223729381|NCT05713721|OTHER|Evaluation of deep brain stimulation|Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)
223942740|NCT04432584|DRUG|Crovalimab|"Dosing depends on body weight. Participants will be dosed as follows:~* 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study~* 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study~* 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study~* 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study~* 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study~* 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study."
223942741|NCT04432584|DRUG|Eculizumab|Eculizumab will be administered at a dose of 900 mg Q2W, as per the dosing schedule described above.
223942742|NCT05349721|DRUG|PTC857|PTC8657 will be administered as an oral solution twice a day.
223942743|NCT05349721|DRUG|Placebo|Matching placebo will be administered as an oral solution twice a day.
223942744|NCT03070392|BIOLOGICAL|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
223942745|NCT03070392|DRUG|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
223942746|NCT03070392|BIOLOGICAL|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
223942747|NCT03070392|BIOLOGICAL|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
223942748|NCT02276443|DRUG|Chemotherapy|Receive standard chemotherapy
223942749|NCT02276443|OTHER|Immunotherapy|Receive standard immunotherapy
223942750|NCT02276443|OTHER|Laboratory Biomarker Analysis|Correlative studies
223942751|NCT02276443|PROCEDURE|Lymph Node Biopsy|Undergo baseline lymph node evaluation
223942752|NCT02276443|PROCEDURE|Ultrasonography|Undergo standard ultrasound
223942753|NCT06006455|DEVICE|Erchonia LunulaLaser|405nm violet and 635nm red laser light therapy.
223942754|NCT05718245|DEVICE|HEPA filter|HEPA filters with the capacity to reduce PM2.5 levels
223942755|NCT05718245|DEVICE|Sham filter|sham filters without the capacity to reduce PM2.5 levels
223942756|NCT04762758|DRUG|(RS)-baclofen, naltrexone hydrochloride and D-sorbitol|oral fixed dose combination
223942757|NCT04762758|DRUG|Placebo|liquid oral solution
223942758|NCT05994014|DIAGNOSTIC_TEST|PET/CT|Experimental test for detecting atherosclerosis
223942759|NCT05812976|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery.
223942760|NCT05812976|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
223942761|NCT05327608|OTHER|Time Restricted Eating|Undergo intermittent fasting
223942762|NCT00466869|DRUG|Betahistine|
223942763|NCT05424666|PROCEDURE|Harvesting method and Fat graft preparation method|"The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection."
223942764|NCT03861052|DRUG|Tirzepatide|Administered SC
223942765|NCT03861052|DRUG|Dulaglutide|Administered SC
223942766|NCT02357654|DRUG|GnRH|single shot of GnRH agonist
223942767|NCT02357654|DRUG|placebo|placebo
223942768|NCT04329598|OTHER|Whole-Body Electromyostimulation Group|Whole-Body Electromyostimulation group includes exercises with electric stimulation. Whole-Body Electromyostimulation group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
223942769|NCT04329598|OTHER|Exercise Group|Exercise group includes exercises without electric stimulation. Exercise group will have 45 minutes of exercises which are specific exercises for Lumbar Disc Herniation.
223942770|NCT03009344|DRUG|Tazemetostat|Tazemetostat tablets.
223942771|NCT04180943|DRUG|interscalene nerve block|intra and post-operative analgesia
223942772|NCT02794428|DRUG|Eflornithine|Eflornithine\*, 2 tablets, Oral, Daily for 18 months
223942773|NCT02794428|OTHER|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
223942774|NCT02534233|DEVICE|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
223942775|NCT05867381|DEVICE|HEPA filtration|HEPA filters with the capacity to reduce PM2.5 levels
223942776|NCT05867381|DEVICE|Sham filtration|Sham filtration use the same appearance of air purifier but with HEPA filter removed.
223942777|NCT00369460|OTHER|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
223942778|NCT03393559|PROCEDURE|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
223942779|NCT05905549|PROCEDURE|extended pancreatic transection during laparoscopic pancreaticoduodenectomy|the pancreatic transection was performed at the pancreatic neck beyond the left side of the mesenterico-portal axis during laparoscopic pancreaticoduodenectomy
223942780|NCT03823703|DRUG|Miricorilant|Tablets taken orally
223942781|NCT03823703|DRUG|Placebo|Placebo tablets
223942782|NCT03265756|DEVICE|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
223942783|NCT03072810|BEHAVIORAL|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
223942784|NCT03617575|DIETARY_SUPPLEMENT|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)
223942785|NCT03617575|DIETARY_SUPPLEMENT|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
223942786|NCT03617575|DIETARY_SUPPLEMENT|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
223942787|NCT03617575|DIETARY_SUPPLEMENT|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
223942788|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
223942789|NCT03617575|DIETARY_SUPPLEMENT|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
223942790|NCT01451359|DEVICE|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
223942791|NCT00151866|PROCEDURE|platelet transfusion|
223942792|NCT00664599|DRUG|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
223942793|NCT00664599|DRUG|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
223942794|NCT01491815|DRUG|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
223942795|NCT01491815|BIOLOGICAL|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
223942796|NCT01491815|BIOLOGICAL|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
223942797|NCT01491815|BIOLOGICAL|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
223942798|NCT03137459|BEHAVIORAL|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
223942799|NCT03137459|OTHER|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
223942800|NCT04918719|DRUG|Acetylcysteine|The dosing of Acetylcysteine will be similar to the standard intravenous acetaminophen toxicity dosing: 150mg/kg in 200 milliliters of 5% Dextrose (D5W) infused over 1 hour, immediately followed by 50mg/kg in 500mL D5W infused over 4 hours, then 100mg/kg in 1000 milliliters D5W infused over 16 hours. (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
223942801|NCT04918719|DRUG|Dextrose in Water|The placebo will consist of a 5% Dextrose in Water instead of NAC (dosage and timigs are the same as the NAC arm). (Any patient receiving t-PA who enrolls in the study will have their study drug infusion delayed by 24 hours after the completion of the t-PA infusion. )
223942802|NCT03770715|DEVICE|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
223942803|NCT03888807|DRUG|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
223942804|NCT03888807|DRUG|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
223942805|NCT01732757|DRUG|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
223942806|NCT01732757|DRUG|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
223942807|NCT01732757|DRUG|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
223942808|NCT00925548|BIOLOGICAL|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)\* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~\*calculated as mass of lipopeptide (antigen)"
223942809|NCT00925548|BIOLOGICAL|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
223942810|NCT00925548|DRUG|cyclophosphamide|300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
223942811|NCT00925548|DRUG|sodium chloride (NaCl)|NaCl 9 g/L infusion
223942812|NCT06086548|OTHER|metabolomic on plasma sample|metabolic phenotyping by plasma metabolomic and mitochondrial biomarker profiling
223942813|NCT01619007|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
223942814|NCT01619007|DRUG|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
223942815|NCT00374998|BIOLOGICAL|FP9-PP (FP9 polyprotein)|
223942816|NCT00374998|BIOLOGICAL|MVA-PP (Modified Virus Ankara polyprotein)|
223942817|NCT02781519|DRUG|THC|Active THC (0.015mg/kg) administered over 10 minutes
223942818|NCT02781519|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
223942819|NCT01858649|PROCEDURE|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
223942820|NCT01858649|DRUG|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
223942821|NCT01858649|DRUG|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
223942822|NCT01858649|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
223942823|NCT01858649|DRUG|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
224099768|NCT06757348|DIAGNOSTIC_TEST|Fecal elastase|\*\*Stool Samples\*\* To investigate exocrine pancreatic insufficiency (EPI), a stool sample will be requested from all patients for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be stored refrigerated at 4-8 °C for no more than 48 hours. The concentrations of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), and fecal elastase will be extracted and analyzed according to the manufacturer's instructions.
224099769|NCT06757348|DIAGNOSTIC_TEST|Ecoendoscopy|\*\*Diagnosis of Pancreatic Steatosis\*\* The diagnosis of pancreatic steatosis will be performed using endoscopic ultrasound. A Pentax EG-3870UTK endoscope will be used in conjunction with Hitachi Avius ultrasound equipment. The procedure is performed under anesthesia using propofol.
223729382|NCT02093754|PROCEDURE|MRI and biopsy|
223729383|NCT01702454|BIOLOGICAL|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
223729384|NCT00710710|DRUG|BI 2536|Intravenous Infusion
223729385|NCT01365325|OTHER|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
223942824|NCT02400060|BEHAVIORAL|Telephone-Based Intervention|Receive text messaging
223942825|NCT02400060|OTHER|Survey Administration|Ancillary studies
223942826|NCT02400060|OTHER|Laboratory Biomarker Analysis|Correlative studies
223942827|NCT04921358|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks
223942828|NCT04921358|DRUG|Docetaxel|75 mg/m\^2 intravenously once every 3 weeks
223942829|NCT04921358|DRUG|Sitravatinib|100 mg orally once daily
223942830|NCT03546829|DRUG|Vancomycin|125 mg, 4x daily for 5 weeks
223942831|NCT03546829|RADIATION|Precision hypofractionated radiation|Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
223942832|NCT06130046|BIOLOGICAL|MR-proADM dosage|Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
223942833|NCT04350502|PROCEDURE|chest tube drainage|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day).
223942834|NCT04350502|BIOLOGICAL|antibiotic concentration in pleural fluid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
223942835|NCT04350502|DRUG|Amoxicillin + clavulanic acid|Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
223942836|NCT05305365|DRUG|QBS72S|QBS72S 18mg/m2 injection given intravenous once a month.
223942837|NCT01205633|PROCEDURE|venous angioplasty|catheter venous angioplasty via femoral vein approach
223942838|NCT03543059|DRUG|GnRH analogue|gonadotrophin releasing hormone analogue
223942839|NCT05773235|DIAGNOSTIC_TEST|Combined 3- and 7 Tesla-MRI|7 Tesla-MRI including the following sequences: susceptibility weighted imaging (SWI), T1, T2, FLAIR, quantitative mapping sequences (T1mapping, qSM)
223942840|NCT02395497|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
223942841|NCT02395497|DRUG|Tacrolimus|
223942842|NCT02395497|PROCEDURE|Penile Allotransplantation|
223942843|NCT02372799|DRUG|Vilazodone|
223942844|NCT02372799|DRUG|Placebo|
223942845|NCT02372799|DRUG|Fluoxetine|
223942846|NCT03799588|DEVICE|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
223942847|NCT03455868|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
223942848|NCT05284643|RADIATION|Intensity Modulated Proton Therapy (IMPT)|Participants will receive radiation therapy delivered via intensity modulated proton therapy (IMPT) simultaneous integrated boost technique over a period of 10 days, 5 days per week for approximately 2 weeks.
223942849|NCT05284643|DRUG|Bevacizumab|Bevacizumab will be administered intravenously (IV), beginning at a dose of 10 mg/kg every 2-3 weeks until disease progression.
223942850|NCT04376788|BIOLOGICAL|exchange blood transfusion from normal donor|IV method
223942851|NCT04376788|BIOLOGICAL|plasma from convalescent patients with COVID-19|IV method
223942852|NCT04376788|DRUG|Methylene Blue 5 MG/ML|IV method
223942853|NCT06549725|DEVICE|software Lipidica|"The investigational in vitro diagnostic medical device-software (IVDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device."
223942854|NCT06549725|PROCEDURE|endoscopic ultrasonography|Endoscopic ultrasonography - maximum frequency: 3 times during the participation
223942855|NCT06549725|PROCEDURE|magnetic resonance|Magnetic resonance - maximum frequency: 3 times during the participation
223942856|NCT06549725|DIAGNOSTIC_TEST|laboratory examination|Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
223942857|NCT06549725|PROCEDURE|computed tomography|computed tomography - maximum frequency: 3 times during the participation
223942858|NCT05989542|DRUG|PLB1001|200mg BID Oral
223942859|NCT03116464|BEHAVIORAL|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
223942860|NCT00447837|DRUG|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
223942861|NCT03324724|BEHAVIORAL|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
223942862|NCT03464955|BEHAVIORAL|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
223942863|NCT00353691|DRUG|glimepiride|
223942864|NCT00353691|DRUG|metformin|
223942865|NCT01084525|DRUG|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
223942866|NCT01084525|DRUG|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
223942867|NCT01084525|DRUG|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
223942868|NCT00491400|DRUG|Fenofibrate|140 mg/day for 8 weeks
223942869|NCT00491400|DRUG|Atorvastatin|20 mg/day for 8 weeks
223942870|NCT06341959|PROCEDURE|Oral screening|The participants in the intervention group will receive an oral examination. Subsequently, information about any identified problem will be given. Lastly, participants will receive a referral letter for their dentist and a report for the general practitioner. If the participants don't have a regular dentist, they will also be given a list with contact information of dentists in the area.
223942871|NCT05912374|BEHAVIORAL|standard Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|CHRP-BB is an evidence-informed behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. CHRP-BB consists of 4 weekly 50- minute sessions.
223942872|NCT05912374|BEHAVIORAL|enhanced Community-Friendly Health Recovery Program- Biobehavioral (CHRP-BB)|The enhanced version of CHRP-BB is an adapted behavioral intervention for HIV prevention among high-risk drug users in treatment on PrEP. This intervention consists of 4 weekly 50- minute sessions that include cognitive dysfunction accommodation strategies.
223942873|NCT03929471|OTHER|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
223942874|NCT00597376|OTHER|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
223942875|NCT00597376|OTHER|Cerefolin NAC placebo|Placebo tablet once a day
223942876|NCT03261466|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
223942877|NCT03261466|DRUG|Placebos|
223942878|NCT04726657|DRUG|Premixed Human Isophane Insulin Suspension + Human Insulin Injection|premixed human insulin
223942879|NCT04726657|DRUG|Premixed Insulin|Premixed Insulin Analog Biphasic Aspart 30
223942880|NCT05033327|BEHAVIORAL|Nutrition and Exercise app|Personalized, home-based, interactive therapy app
223942881|NCT02304614|OTHER|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
223942882|NCT02304614|OTHER|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
223942883|NCT02304614|OTHER|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
223942884|NCT02304614|OTHER|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
223942885|NCT01030237|OTHER|FID 114657|1 drop both eyes four times a day for 6 weeks
223942886|NCT01030237|OTHER|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
223942887|NCT05033522|BIOLOGICAL|AlloStim® immunotherapy|3 cycles of intradermal and intravenous administrations
223942888|NCT05033522|DRUG|FOLFOX regimen|Comparative arm: Physician Choice of FOLFOX4 chemotherapy
223942889|NCT05033522|DRUG|Sorafenib|Comparative arm: Physician Choice of Sorafenib
223942890|NCT05033522|DRUG|Lenvatinib|Comparative Arm: Physician's Choice of Levantinib
223942891|NCT02344680|DRUG|Anti-HIV Agents|
223942892|NCT01655563|DRUG|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
223942893|NCT05125224|DRUG|Dihydropyridine calcium channel blocker|Dihydropyridine calcium channel blocker claim is used as the exposure group.
223942894|NCT05125224|DRUG|Hydrochlorothiazide|Hydrochlorothiazide claim is used as the reference group.
223942895|NCT00156507|BEHAVIORAL|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
223942896|NCT01898585|DRUG|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
223729386|NCT01365325|OTHER|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
223942897|NCT04415775|OTHER|Game based treadmill Program|Participants will be expected to play several cognitive computer games while standing on a sponge pad (10-min warm-up and while walking on the treadmill at your self-selected comfortable speed. (Dual-task treadmill training). This would be done in intervals of 2-4 min with rest periods for a total time of 35 minutes Treadmill speed and the difficulty level of the cognitive games will progress depending on participant performance and comfort level.
223942898|NCT04415775|OTHER|Conventional Gait Rehabilitation|Participants will undergo a mixture of current gait training programs available for people with Parkinson's Disease. The protocol will be a Warm-up exercise consisting of rhythmical large movements (10 minutes), as well as video game practice while standing (i.e., single-task; 10 minutes). Treadmill walking in intervals of 2-4 minutes with rest periods. Walking over the ground while negotiating through obstacles. (10 minutes) The speed of the treadmill will be progressed gradually and as tolerated.
223942899|NCT05136794|OTHER|Data collection|complications: cardiac, neurological, renal, respiratory, red blood transfusion Hospital stays: ICU stays and hospital stay
223942900|NCT01487460|DRUG|TAP311|
223942901|NCT05691842|OTHER|HIIT intervention|Patients will perform a muscle strength training circuit interspersed with resistance training circuit. The strength training circuit will consist of 10 strength exercises and resistance training circuit will consist of walking, jogging and running exercises. Each exercise will be performed for one minute, trying to reach maximum intensities adapted to each individual's condition.
223942902|NCT05691842|OTHER|Dual task intervention|Dual task training will consist of the progressive and specific assignment of primary motor tasks and secondary motor or cognitive tasks focused on: i) Primary tasks: static, dynamic balance and gait exercises; ii) Secondary tasks (motor or cognitive): verbal fluency, mathematical calculation, memory, visual-spatial planning, auditory discrimination, fine motor task, motor transport task.
223942903|NCT01602913|DRUG|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
223942904|NCT01602913|DRUG|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
223942905|NCT01602913|DRUG|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
223942906|NCT03486574|DIAGNOSTIC_TEST|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
223942907|NCT02955199|BEHAVIORAL|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
223942908|NCT02955199|BEHAVIORAL|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
223942909|NCT01532648|DRUG|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
223942910|NCT01532648|DRUG|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
223994426|NCT04905368|OTHER|SS-POR11|Topical composition containing probiotic strains derived from human skin (SS-POR11). Participants will be instructed to apply it topically to face, twice weekly for the duration of the trial.
223942911|NCT01532648|DRUG|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
223942912|NCT05603182|DRUG|PRA052|PRA052
223942913|NCT05603182|OTHER|Placebo|Placebo
223942914|NCT02929420|DRUG|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
223942915|NCT02929420|DRUG|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
223942916|NCT03637036|OTHER|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
223942917|NCT00479375|PROCEDURE|Adding Human Papillomavirus testing to organised cervical screening|
223942918|NCT03983759|DRUG|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
223942919|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
223942920|NCT02753998|COMBINATION_PRODUCT|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
223942921|NCT02753998|PROCEDURE|Conventional angioplasty|
223942922|NCT00031720|DIETARY_SUPPLEMENT|soy protein|Given orally
223942923|NCT00031720|DIETARY_SUPPLEMENT|isoflavones|Given orally
223942924|NCT00031720|DRUG|Tamoxifen|
223942925|NCT00031720|OTHER|Placebo|Oral
223942926|NCT00047125|RADIATION|radiation therapy|
223942927|NCT01990508|BEHAVIORAL|Targeted beverage education and financial incentives|
223942928|NCT01990508|BEHAVIORAL|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
223942929|NCT01035372|DIETARY_SUPPLEMENT|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
223942930|NCT01583166|DRUG|Bupivacaine|10ml 0.5% bupivacaine
223729387|NCT03510884|DRUG|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
223942931|NCT01583166|DRUG|Saline|10ml 0.9% sodium chloride
223942932|NCT01583166|DRUG|Epinephrine|1:200,000 epinephrine
223942933|NCT01160588|DRUG|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
223942934|NCT00352131|DRUG|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
223942935|NCT00794807|DRUG|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
223942936|NCT00808834|DEVICE|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
223942937|NCT00808834|DEVICE|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
223942938|NCT04778670|DIAGNOSTIC_TEST|AI CAD|The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
223942939|NCT04778670|DIAGNOSTIC_TEST|Radiologist reading|Standard of care, each radiologist will assess the mammography examination, making a binary flagging decision (flag the examination to continue to consensus discussion, or not)
223942940|NCT00010049|DRUG|imatinib mesylate|
223942941|NCT03667833|OTHER|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
223942942|NCT03559205|OTHER|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring."
223942943|NCT05948774|DRUG|MT200605 for Injection|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
223942944|NCT05948774|DRUG|MT200605 Placebo|Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
223942945|NCT04652869|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation targeting the dorsolateral prefrontal cortex
223942946|NCT04652869|BEHAVIORAL|Mindfulness|Mindfulness is a type of meditation in which you focus on being intensely aware of what you're sensing and feeling in the moment, without interpretation or judgment.
223942947|NCT01833455|DRUG|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
223942948|NCT01833455|DRUG|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
223994427|NCT04621461|DIETARY_SUPPLEMENT|Zinc Sulfate 220 MG|220mg once daily for 5 days
223994428|NCT04621461|DRUG|Placebo|Once daily for 5 days
223942949|NCT04301206|BEHAVIORAL|Intervention Group|Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
223942950|NCT05964426|OTHER|Turkey Health Literacy Scale (TSOY-32)|A survey will be conducted.
223942951|NCT00247351|PROCEDURE|Cryoablation|
223942952|NCT02206867|BIOLOGICAL|LBAL|Anti-inflammatory agents
223942953|NCT02206867|BIOLOGICAL|Humira|Anti-inflammatory agents
223942954|NCT00562094|DRUG|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
223942955|NCT03900585|BEHAVIORAL|Interval walking|Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
223942956|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
223942957|NCT00887224|DRUG|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
223942958|NCT00887224|DRUG|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
223942959|NCT03944694|DIAGNOSTIC_TEST|Delirium assessment.|Full blood count analysis.
223942960|NCT01144559|PROCEDURE|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
223942961|NCT01144559|PROCEDURE|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
223942962|NCT01600482|DEVICE|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
223942963|NCT01555138|DRUG|Indacaterol|Indacaterol is delivered via a SDDPI.
223942964|NCT01555138|DRUG|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
223942965|NCT05381519|BIOLOGICAL|DXP604|1800mg，IVgtt
223942966|NCT03883828|DRUG|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
223942967|NCT03883828|DRUG|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
223942968|NCT05902936|PROCEDURE|Pulpotomy for mature permanent mandibular molars|Performing pulpotomy for mature teeth that involves removal of the coronal pulp tissue that is diseased or inflammed followed by placement of a biocompatible material with the intent of maintaining the vitality of the remaining radicular pulp tissue.
223942969|NCT02915211|DIETARY_SUPPLEMENT|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
223942970|NCT00943969|PROCEDURE|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
224099770|NCT06757348|DIAGNOSTIC_TEST|Fibroscan|\*\*Fibroscan Procedure:\*\* This is a new technique based on the evaluation of liver elasticity or stiffness that allows for the measurement of liver hardness and quantification of liver fibrosis in a simple and completely painless manner using ultrasound. The results are obtained immediately and can be safely repeated periodically.
224099771|NCT06757348|DIAGNOSTIC_TEST|Serum cytokines|Peripheral blood will be drawn from all participants in the Gastroenterology Division of the Hospital de Clínicas. Samples will be collected in EDTA tubes, centrifuged, and the serum will be frozen at -80 °C until processing. Serum cytokine levels will be measured using a commercial kit (Bio-Plex Pro human cytokine, Bio-Rad Lab., Inc.), which includes a panel of 27 cytokines: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, MIP-1α, IL-12 (p70), MIP-1β, IL-13, PDGF-BB, IL-15, RANTES, IL-17, TNF-α, IP-10, VEGF, MCP-1 (MCAF).
223942971|NCT02291406|PROCEDURE|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
223942972|NCT02291406|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
223942973|NCT01399450|DRUG|paliperidone|paliperidone augmenting on ongoing medication
223942974|NCT00135018|DRUG|celecoxib and chemotherapy|
223942975|NCT01439906|PROCEDURE|Surgical correction of the deformity|"Three different surgical techniques are used:~* lumbar fusion vs thoraco-lumbar fusion~* iliac fixation vs fixation to the sacrum~* posterior + interbody fusion vs posterior interbody fusion"
223942976|NCT02860949|DRUG|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
223942977|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
223942978|NCT02860949|PROCEDURE|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
223942979|NCT02386332|PROCEDURE|transplantation|
223942980|NCT00418119|DRUG|erythropoietin|
223942981|NCT01279694|DRUG|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
223942982|NCT01279694|DRUG|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
223942983|NCT01279694|DRUG|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
223942984|NCT00310609|DRUG|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
223942985|NCT02000752|DEVICE|Acupuncture|
223942986|NCT02000752|DEVICE|Sham acupuncture|Sham point acupuncture
223942987|NCT01933100|OTHER|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55\~70%, protein 7\~20%, fat 15\~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
223942988|NCT03646266|DRUG|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
223942989|NCT03903692|DEVICE|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
223535376|NCT05361460|OTHER|Cognitive decline|This is an observation study with the aim of explore patients' experiences of their early and late postoperative cognition after major orthopaedic surgery in relation to postoperative cognitive function assessed with validated neuropsychological tests, inflammatory signalling molecules and quality of postoperative recovery as well as to describe the relative's view of early postoperative cognition.
223942990|NCT03903692|DEVICE|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
223942991|NCT05108363|BEHAVIORAL|Lifestyle modification program|Participants will attend dietary consultation sessions weekly in the first 4 months during the intensive phase , and monthly in the subsequent 8 months in the maintenance phase of LMP either face-to-face or via telephone. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The diet will aim for a calorie reduction of 10-20%, at least 10% body weight reduction or body mass index less than 23 kg/m2.Participants will see an exercise instructor a minimum of four times starting at the 2nd month. The exercise instructor will design a suitable exercise regime. Participants will first be advised to increase daily physical activities or to do moderate intensity aerobic exercise, with the goal of 30 minutes for 3 to 5 days a week.
223942992|NCT06132009|PROCEDURE|Surgery of endometriosis|Cystectomy or unilateral oophorectomy due to endometriosis
223942993|NCT01209156|DRUG|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.
223942994|NCT03444415|OTHER|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
223942995|NCT03444415|OTHER|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
223942996|NCT02431741|DEVICE|Mepilex Transfer Ag|
223942997|NCT02052687|DRUG|LFX453 H1|LFX453 high dose cream 1
223942998|NCT02052687|DRUG|LFX453 L1|LFX453 low dose cream 1
223942999|NCT02052687|DRUG|LFX453 H2|LFX453 high dose cream 2
223943000|NCT02052687|DRUG|LFX453 L2|LFX453 low dose cream 2
223943001|NCT02052687|DRUG|Imiquimod|Imiquimod cream
223943002|NCT02052687|DRUG|Placebo 1|Placebo cream 1
223943003|NCT02052687|DRUG|Placebo 2|Placebo cream 2
223943004|NCT01945372|OTHER|EEG NeuroFeedback|
223943005|NCT06353620|DIAGNOSTIC_TEST|High Density EEG recording|Recording of resting state high density EEG (128 channels)
223943006|NCT06353620|DIAGNOSTIC_TEST|Rey Complex Figure Test|Memeory functioning evaluation
223943007|NCT05451589|BEHAVIORAL|RESET|RESET consists of 7 weekly group phone sessions led by Community Health Workers, along with an accompanying podcast series.Topics will include positive psychology, physical activity, social connection, eating well, relaxation, and more. There will be one individual session with the Community Health Worker to screen for unmet social needs and to offer connections to resources as needed. In the group sessions, participants will set goals incorporating positive activities and strategies to improve daily functioning. Up-to-date information related to COVID-19 prevention and treatment will be provided.
223943008|NCT05451589|BEHAVIORAL|Wellness Check Control|"After completing the baseline survey, control group participants will be mailed an educational packet consisting of information about COVID-19 prevention and treatment, as well as essential community resources. Control group participants will also be invited to take part in a wellness check telephone session with a Community Health Worker, about a half-hour long, at which a social needs screener will be administered, and any needed referrals will be made. After completing the 8-month follow up, they will have the opportunity to participate in the full intervention."
223943009|NCT03408028|OTHER|Medical File consultation|Medical File consultation
223943010|NCT01685268|DRUG|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
223943011|NCT01685268|DRUG|abiraterone acetate|1000 mg PO daily.
223535377|NCT01518790|DRUG|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
223535378|NCT04971928|DRUG|GSK3228836|GSK3228836 will be administered
223943012|NCT01685268|DRUG|Prednisone|5 mg PO twice daily.
223535379|NCT01853709|BEHAVIORAL|Education|
223535380|NCT01853709|OTHER|Fiber free diet|
223943013|NCT02124252|BEHAVIORAL|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
223994429|NCT01079910|DRUG|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
223994430|NCT01079910|DRUG|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
223535381|NCT01853709|DIETARY_SUPPLEMENT|Adjuvants|
223535382|NCT01853709|DRUG|Polyethylene glycol (PEG)|
224099772|NCT06900634|BEHAVIORAL|Kisoboka Amaka|"KISOBOKA AMAKA intervention adapts and combines a behavioral intervention with a structural component. The behavioral intervention component includes, alcohol screening, financial literacy training, and counseling and goal setting related to savings, alcohol use, and HIV care engagement. The structural intervention component focuses on depositing earnings into mobile savings programs. Kisoboka Amaka content will be finalized in aims 1 and 2. However, we expect core intervention components to remain unchanged including: 4 counseling sessions (2 individual, 2 group), 2x weekly text message reminders of goals and mobile money set up. Potential additional components include: 1 family focused couples session, self monitoring of alcohol use (via mobile breathalyzer) and PEth (an objective biomarker measure of alcohol use) boosted alcohol counseling."
224099773|NCT06900634|BEHAVIORAL|Screening and Referral|Alcohol screening and referral and emphasizing the importance of HIV care engagement and ART adherence
224099774|NCT06899191|DIAGNOSTIC_TEST|Hemoglobin A1c|Prompt to order A1c
224099775|NCT06899191|BEHAVIORAL|Observation Unit|Electronic prompt nudging ED provider to consider admitting patient to the Observation Unit for care coordination and more aggressive glycemic control
223943014|NCT02124252|BEHAVIORAL|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
223943015|NCT04921709|OTHER|Medical tests|Blood tests
223943016|NCT00042965|DRUG|capecitabine|
223943017|NCT00042965|DRUG|gemcitabine hydrochloride|
223943018|NCT04996225|OTHER|Aerobics exercises, Balance exercises|Aerobic exercise, or endurance exercise, is a subdivision of physical exercise that improves cardiovascular and respiratory health. Additionally, it is generally assumed to increase well-being and reduce negative mood states such as anxiety and depression.
223943019|NCT04497545|DEVICE|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
223943020|NCT04497545|DEVICE|lower limb rotor|The duration of the overall therapeutic intervention in both groups will be the same.
223943021|NCT01052766|PROCEDURE|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (\~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
223943022|NCT06475079|OTHER|• FHP app (Pyeongtaek, South Korea) mobile application|FHP app (Pyeongtaek, South Korea) mobile application ,is mobile application to asses cranio vertebral angle
223943023|NCT01065532|DEVICE|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
223943024|NCT01065532|DEVICE|Xience V everolimus eluting stent|Xience V everolimus eluting stent
224099776|NCT03900598|DRUG|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
224099777|NCT06904105|DRUG|HRS-7535 Tablets|HRS-7535 tablets.
224099778|NCT06904105|DRUG|HRS-7535 Placebo Tablets|HRS-7535 placebo tablets.
224099779|NCT07100145|OTHER|Coconut oil|The composition per 100 g of virgin coconut oil 50% in oral mucoadhesive gel will be coconut oil (50 ml), tween 20 (surfactant-2.5 g) or span 60 (surfactant-2.5 g), Carbopol 940 (gelling agent-1 g), triethanolamine (viscous organic compound-0.2 g) and vanillin (0.001 g)
224099780|NCT07100145|DRUG|Triamcinolone Acetonide|topical corticosteroid
224099781|NCT07108257|DEVICE|ExAblate Neuro 4000|ExAblate Neuro 4000 is an MR-guided focused ultrasound (MRgFUS) device used to perform noninvasive thermal ablation of targeted brain tissue. In this study, ExAblate Neuro 4000 will be used to ablate the anterior limb of the internal capsule (capsulotomy) in patients with treatment-resistant bipolar depression (TRBD). The procedure is conducted under real-time MRI guidance and thermometry to assess safety and initial effectiveness in improving clinical symptoms and quality of life.
223943025|NCT02509715|PROCEDURE|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
224099782|NCT07108036|DRUG|N-803 (IL-15 Superagonist)|N-803 administered subcutaneously.
223535383|NCT01853709|DRUG|Bisacodyl|
223943026|NCT05069038|DRUG|Palbociclib 125mg|Palbociclib at a dose of 125 mg should be taken by mouth with food on 21 days on 7 days off schedule (meaning: on Days 1-21of each 28-day cycle). If a subject misses a day's dose entirely, she must be instructed not to make it up the next day but just take her regular dose at the next assigned time. If a subject vomits any time after taking a dose, she must be instructed not to retake the dose but resume subsequent dosing at the next assigned time. If a subject inadvertently takes an extra dose during a day, she must be instructed to not take the next day's dose.
223943027|NCT04938453|DRUG|nintedanib 25 mg|soft gelatin capsule
223943028|NCT04938453|DRUG|nintedanib 100 mg|soft gelatin capsule
223943029|NCT02966652|DRUG|DITEST|Lipid formulation of native oral testosterone.
223943030|NCT02966652|DRUG|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
223943031|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety normal nebulizer and mask+ distraction|Children in group 2 will receive their inhaler treatment with a normal nebulizer and mask, while at the same time one of the distraction techniques of their choice (drawing a picture, reading a story or watching an age-appropriate cartoon) will be applied.
223943032|NCT06510166|BEHAVIORAL|Children's Fear and Anxiety a toy nebulizer and a toy mask|Children in Group 3 will receive their inhaler treatment using a toy nebulizer and a toy mask.
224099783|NCT07106905|OTHER|Measurements|These measurements are used in other clinical applications. However, the effectiveness of these measurements in discriminating the presence of low back pain in mothers of children with disabilities over the past year has been identified.
224099784|NCT07107893|DEVICE|double lumen tube with video|Methods used to confirm tube placement in one-lung ventilation: auscultation, fiberoptic bronchoscopy, and video to evaluate double-lumen tube use
224099785|NCT07106489|OTHER|beetroot juice - Placebo|Participants receive the beetroot and placebo in the form of waffles to ensure the study is blinded, as the 6 mmol of nitrates used require a high concentration of beetroot, which is masked by the waffle ingredients and food coloring.
223943033|NCT03169933|RADIATION|Combined, intensified and modulated adjuvant radiotherapy|
223729388|NCT03510884|DRUG|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
223535384|NCT03995160|PROCEDURE|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
223729389|NCT03510884|DRUG|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
223729390|NCT03510884|DRUG|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
223943034|NCT02978066|OTHER|Spinal anaesthesia|
223943035|NCT00075998|DRUG|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
223943036|NCT01232166|OTHER|Auscultation|
223943037|NCT01232166|OTHER|Observation of symmetric chest movements|
223943038|NCT01232166|OTHER|Tube depth|
223943039|NCT01232166|OTHER|All three|
223943040|NCT00284466|PROCEDURE|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
223729391|NCT03510884|DRUG|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
223943041|NCT04620252|DRUG|Inactive supplement|Chewable candy (negative control), chewed for 30 seconds.
223943042|NCT04620252|DRUG|Tricalcium phosphate supplement|Chewable tricalcium phosphate supplement, chewed for 30 seconds.
223943043|NCT04620252|DRUG|Calcium carbonate supplement|Chewable calcium carbonate supplement, chewed for 30 seconds.
223943044|NCT04620252|DRUG|Calcium citrate supplement|Chewable calcium citrate supplement, chewed for 30 seconds.
223943045|NCT04620252|DRUG|Inactive supplement and fluoride mouthwash|A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
223943046|NCT04620252|DRUG|Calcium carbonate supplement and fluoride mouthwash|A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
223943047|NCT04620252|DRUG|Calcium citrate supplement and fluoride mouthwash|A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
223943048|NCT01583868|DEVICE|B&L RD2135-01 lens C|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
223943049|NCT01583868|DEVICE|B&L RD2135-01 lens D|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
223994431|NCT05790070|DIETARY_SUPPLEMENT|Betaine|3g/ twice daily (separated by \~12 hours) betaine anhydrous
223994432|NCT05790070|OTHER|Placebo|3g/ twice daily (separated by \~12 hours) cellulose placebo
223994433|NCT03510767|DRUG|TQ-B3525|TQ-B3525 p.o. qd
223994434|NCT00984191|RADIATION|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
223994435|NCT00243074|DRUG|cediranib maleate|Given orally
223994436|NCT00243074|OTHER|laboratory biomarker analysis|Correlative studies
223994437|NCT06442124|DIAGNOSTIC_TEST|Electromyography (EMG)|The present study will be conducted to add a new information to the body of knowledge of physical therapy profession as it will investigate the effect of BMI on gluteus maximum activity recorded by EMG in adulthood with sacroiliac dysfunction
223994438|NCT04033965|GENETIC|Corellation of Mutations, TILs and Age in Breast Cancer|
223994439|NCT05962190|BEHAVIORAL|Diet|High fat (\~60% of total energy intake) diet enriched with either SFA or UFA
223994440|NCT03570762|PROCEDURE|hybrid percutaneous intervention|
223994441|NCT02909933|DRUG|liraglutide|
223994442|NCT02909933|DRUG|metformin and liraglutide|
223994443|NCT05321849|OTHER|Echocardiography guide|Patients with PDA are percutaneously closed with echocardiography guide, without fluoroscopy like classical procedures
223994444|NCT04288349|PROCEDURE|perineal block with usage of one of solutions|Perineal block using solution of ropivocaine and epinephrine for the first group was performed. Anococcygeal ligament is infiltrated with 10 ml of the solution after the intracutaneous infiltration in 2 cm from the anus. Ten ml of the solution is injected in ischiorectal fat on each side. The needle is orienteered at the angle of 45 degrees cranially and laterally, and to the surface what allows the surgeon to anesthetize the deep branches of the pudendal nerve. In addition, 10 ml of solution is injected transdermal on the front edge of the anus with further subcutaneous infiltration on each side of the anus to provide anesthesia to the nerve branches laying more superficial. The total amount of the injected solution is 50 ml.
223994445|NCT04288349|DRUG|epinephrine + ropivacaine +saline|epinephrine + ropivacaine +saline
223994446|NCT04288349|DRUG|epinephrine + saline|epinephrine + saline
223994447|NCT06012981|BEHAVIORAL|ACT|"The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions.~The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree."
223994448|NCT03742375|DIAGNOSTIC_TEST|HPV genotyping|Quantitative HPV genotyping on anal swab
223994449|NCT00664534|DRUG|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
223994450|NCT00664534|DRUG|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
223994451|NCT00542204|BEHAVIORAL|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
223994452|NCT02481570|OTHER|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
223943050|NCT01583868|DEVICE|PureVision2|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
223943051|NCT01583868|DEVICE|Air Optix Aqua|Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
223943052|NCT00362219|OTHER|Placebo|Gel with no active ingredient.
223943053|NCT00362219|DRUG|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
223943054|NCT00362219|DRUG|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
223943055|NCT00362219|DRUG|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
223943056|NCT00797550|BIOLOGICAL|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
223943057|NCT00797550|PROCEDURE|Autologous bone graft|
223943058|NCT00474799|DRUG|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
223943059|NCT00307216|BEHAVIORAL|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
223943060|NCT00307216|BEHAVIORAL|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
223943061|NCT04115553|DIAGNOSTIC_TEST|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
223943062|NCT04115553|DIAGNOSTIC_TEST|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
223943063|NCT03866824|DRUG|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
223943064|NCT03866824|DRUG|injection of corticosteroids|intra-articular injection
223943065|NCT03866824|DEVICE|RMI|A CONTROL RMI at 1 year follow-up.
223943066|NCT02997410|DEVICE|Ozone|
223943067|NCT02997410|DEVICE|Placebo (for Ozone)|
223943068|NCT02997410|DEVICE|Dental treatment with occlusal splint|
223943069|NCT05059106|BIOLOGICAL|Half dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.
223943070|NCT05059106|BIOLOGICAL|Standard dose of ChAdOx1 nCoV-19 (AZD1222)|Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.
223943071|NCT02205515|DRUG|Everolimus|Everolimus is a novel derivative of rapamycin.
223943072|NCT01883193|DIETARY_SUPPLEMENT|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
223943073|NCT06959771|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|The study cell product is base edited autologous HSPCs which will be administered as a one-time infusion following myeloid conditioning.
223943074|NCT06959771|DRUG|Alemtuzumab|Serotherapy agent, 10 mg/m\^2 on days -21, -20 and -19
223943075|NCT06959771|DRUG|Sirolimus|Immunophilin drug, will start on day -1, targeting a trough level between 4-12 ng/mL.
223943076|NCT06959771|DRUG|Palifermin|Mucositis prophylaxis agent, will be administered at 60 mcg/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
223943077|NCT06959771|DRUG|Busulfan|Myeloid conditioning agent, administered once daily (3 mg/kg) x 2 days, targeting a daily AUC of 4500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L for the 2 days of therapy, if levels are available
223535385|NCT03995160|PROCEDURE|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
223943078|NCT06959771|BIOLOGICAL|Base-edited T lymphocyte cells|The secondary study cell product is base edited autologous which will be administered as a one-time infusion two weeks following the infusion of the base-edited autologous HSPCs.
223943079|NCT02840045|DEVICE|high-density electroencephalography|Musical stimulation during electroencephalography recording
223943080|NCT06488742|OTHER|3% kanuka oil|To assess the efficacy in patients with mild atopic dermatitis, 3% kanuka oil will be applied twice a day for 28 days. 3% kanuka oil is a naturally occurring extract from the kanuka tree and is considered an over-the-counter agent.
223943081|NCT01289600|DEVICE|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
223943082|NCT06259032|OTHER|Mechanical alignment|Goal alignment in TKA with mechanical alignment, resection bone in perpendicular to mechanical axis of femur and tibia.
223943083|NCT06259032|OTHER|Functional alignment|Goal alignment in TKA with functional alignment, resection of bone base on native joint line obliquity.
223943084|NCT06369532|DEVICE|Active tDCS|During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.
223943085|NCT06369532|DEVICE|Sham tDCS|The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
223943086|NCT01271244|DRUG|Escitalopram|10-20mg daily for 12 weeks
223943087|NCT05469165|DRUG|Cyproheptadine 4 Mg Oral Tablet|Cyproheptadine treatment for 3 months
223943088|NCT05469165|OTHER|Placebo|Placebo administration for 3months
223994453|NCT05879237|DRUG|Vitamin D3|Vitamin D3 ,1000 unit ,once daily, oral, for 1 month plus triple therapy
223943089|NCT05227898|DEVICE|Device: Attune™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
223943090|NCT05227898|DEVICE|Device: Cerena™|People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
223943091|NCT02539576|DRUG|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
223943092|NCT04160559|OTHER|green tea|The investigators require patients to regularly drink green tea during the trial period.
223943093|NCT05493488|BIOLOGICAL|DBI-001 Gel|Topical application of DBI-001 gel on foot/feet affected with tinea pedis
223943094|NCT05493488|BIOLOGICAL|DBI-002 Gel|Topical application of DBI-002 gel on foot/feet affected with tinea pedis
223943095|NCT05493488|BIOLOGICAL|Aqueous Gel|Topical application of Aqueous gel on foot/feet affected with tinea pedis
223943096|NCT05907070|OTHER|Mandala group|Mandala group will participate in 2 sessions of individual mandala drawing art activity with the theme of 'Emotions' accompanied by classical or instrumental music. In each session, a mandala will be created.
223943097|NCT05907070|OTHER|Value clarification group|Value clarification groups will participate in the value clarification activity by writing 2 sessions individually with the theme of 'Emotions' accompanied by classical or instrumental music.
223943098|NCT04019067|DIAGNOSTIC_TEST|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
223943099|NCT06134557|PROCEDURE|conventional stents|performed the study to compare the safety and efficacy between flow diverters and conventional stents in IVADA patients undergoing endovascular therapy. Stent-assisted coiling is the preferred option for most surgeons. In addition,It is believed that dense packing is not necessary as long as the aneurysm neck is covered to isolate the dissection. How ever,whether it is really necessary to adjunct coil,and if it is necesary, what is the ideal packing density of coils, there is no clear conclusion at present.This study aimed to compare the safety and efficacy between flow diverter and conventional stents in patients with IVADA, determine the ideal packing density of coils after FD stent placement,and to observe the hemodynamic changes before and after the treatment of FD stent.
223943100|NCT02095145|OTHER|Laboratory Biomarker Analysis|Correlative studies
223943101|NCT02095145|OTHER|Pharmacological Study|Correlative studies
223943102|NCT02095145|OTHER|Placebo|Given PO
223943103|NCT02095145|DRUG|Pomegranate-Extract Pill|Given PO
223943104|NCT04148885|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223943105|NCT04148885|DRUG|carboplatin|Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223943106|NCT04413526|PROCEDURE|radiofrequency|radiofrequency combined with liver resection
223943107|NCT04413526|PROCEDURE|TACE|only TACE treatment
223943108|NCT04413526|PROCEDURE|TACE+radiofrequency|TACE followed by radiofrequency
223943109|NCT01703598|DEVICE|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
223943110|NCT01703598|PROCEDURE|DBS surgery|Placement of DBS electrodes
223943111|NCT03063021|DRUG|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
223943112|NCT05260866|OTHER|national population-based study|No intervention
223943113|NCT01542255|DRUG|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
223943114|NCT01542255|DRUG|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
223943115|NCT01542255|DRUG|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
223943116|NCT05771857|DEVICE|Obesity|the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19
223943117|NCT00355745|DEVICE|Ultrasound breast scanning|breast scanning
223943118|NCT00540956|DRUG|cytarabine|
223943119|NCT00540956|OTHER|laboratory biomarker analysis|
223943120|NCT00239967|DRUG|Rimonabant (SR141716)|
223943121|NCT00239967|DRUG|Placebo|
223943122|NCT04241640|DRUG|Nefopam 20 MG/ML|Nefopam group nefopam 20 mg during surgery and follow by 80 mg in 24 hours postoperative
223943123|NCT04241640|DRUG|Placebo|Placebo
223535386|NCT00276419|DRUG|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
223943124|NCT02489357|PROCEDURE|Cryosurgery|Undergo whole gland cryoablation
223943125|NCT02489357|DRUG|Degarelix|Given SC
223943126|NCT02489357|OTHER|Laboratory Biomarker Analysis|Correlative studies
223943127|NCT02489357|BIOLOGICAL|Pembrolizumab|Given IV
223943128|NCT05703659|DIETARY_SUPPLEMENT|B. longum subsp. infantis|Infants will receive 1 dose of a B. infantis probiotic daily for 4 weeks
223943129|NCT05703659|DIETARY_SUPPLEMENT|L. reuteri probiotic|Infants will receive 1 dose of an L. reuteri probiotic daily for 4 weeks
223943130|NCT02166632|PROCEDURE|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
223943131|NCT02166632|PROCEDURE|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
223943132|NCT04237792|DRUG|dexmedetomidine|dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
223943133|NCT04237792|DRUG|propofol|propofol IV administration will be given if needed to maintain sedation
223943134|NCT04272385|OTHER|Observational|Observational
223943135|NCT02625025|PROCEDURE|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
223729392|NCT03510884|DRUG|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
223943136|NCT02625025|PROCEDURE|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
223943137|NCT02625025|PROCEDURE|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
223943138|NCT03177707|OTHER|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
223943139|NCT05155046|DRUG|18F-DCFPyL|18F-DCFPyL imaging will be performed at baseline, 8 weeks after ADT initiation, 6 months post SBRT and at recurrence. The target administered activity will be 6.5 mCi with a lower limit of 6 mCi.
223943140|NCT03181100|DRUG|Atezolizumab|Given IV
223943141|NCT03181100|BIOLOGICAL|Bevacizumab|Given IV
223943142|NCT03181100|DRUG|Cobimetinib|Given PO
223943143|NCT03181100|DRUG|Nab-paclitaxel|Given IV
223943144|NCT03181100|DRUG|Paclitaxel|Given IV
223943145|NCT03181100|DRUG|Vemurafenib|Given PO
223943146|NCT05243056|OTHER|Best Practice|Receive enhanced usual care
223943147|NCT05243056|OTHER|Educational Intervention|Receive Y-AMBIENT
223943148|NCT05243056|OTHER|Quality-of-Life Assessment|Ancillary studies
223943149|NCT05243056|OTHER|Questionnaire Administration|Ancillary studies
223943150|NCT00456339|DRUG|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
223943151|NCT05371483|DIAGNOSTIC_TEST|24-hour Ambulatory Blood Pressure Monitoring|Arm blood pressure cuff that will automatically inflate every 15-30 minutes to check blood pressure while awake and asleep over 24 hours. Patient will also complete a sleep diary and wear an actigraphy watch during this test.
223943152|NCT05371483|DIAGNOSTIC_TEST|Oculo-Cognitive Addition Test (OCAT)|Tracks users' eye movements as they complete a simple mental addition test.
223943153|NCT05636111|DRUG|Paclitaxel|Given by (IV) vein
223943154|NCT05636111|DRUG|Bevacizumab|Given by (IV) vein
223943155|NCT05636111|DRUG|Lurbinectedin|Given by (IV) vein
223943156|NCT05660473|DRUG|Vincristine|Anti-tumor alkaloids
223943157|NCT05660473|DRUG|Daunorubicin|Anthracycline
223943158|NCT05660473|DRUG|Cyclophosphamide|Alkylating agent
223943159|NCT05660473|DRUG|Pegaspargase|Polyethylene glycol (PEG) conjugated to L-asparaginase
223943160|NCT05660473|DRUG|Prednisone|Glucocorticoids
223943161|NCT05660473|DRUG|Cytarabine|Pyrimidine antimetabolites
223943162|NCT05660473|DRUG|6-mercaptopurine|Cell cycle-specific antitumor drug
223943163|NCT05660473|DRUG|Dexamethasone|Glucocorticoids
223943164|NCT05660473|DRUG|Methotrexate|Antifolate antineoplastic drug
223943165|NCT05660473|DRUG|Venetoclax|Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
223943166|NCT01477177|DEVICE|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
223943167|NCT06951295|PROCEDURE|Thyroidectomy operation is a surgical removal of thyroid, injury of recurrent laryngeal nerve one of common complications of thyroidectomy Which can affect Vocal cords mobility|Assessment of vocal cords mobility at thyroidectomy operation is very important and life saving for patient, during thyroidectomy one of common complications, injury of recurrent laryngeal nerve unilateral or bilateral, unilateral injury may complicate to dysphonia, bilateral injury may complicate to dyspnea
223943168|NCT02304809|DRUG|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
223943169|NCT05716100|DRUG|XEN1101|XEN1101 Capsules
223943170|NCT05716100|DRUG|Placebo|Placebo Capsules
223943171|NCT05414201|DRUG|Adalimumab|Subcutaneous Injection
223943172|NCT00515060|OTHER|Sensory Tests|Tests to find the threshold at which perceive stimuli.
223943173|NCT06229418|OTHER|DFR AED Pilot Program|Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
223943174|NCT06113692|BIOLOGICAL|mRNA-1273|intramuscular injection
223943175|NCT05553366|DRUG|SUZ|Tablets for oral administration.
223943176|NCT05553366|DRUG|HB/APAP|Capsules for oral administration.
223729393|NCT03510884|DRUG|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
223729394|NCT03510884|DRUG|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
223729395|NCT03510884|DRUG|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
223943177|NCT05553366|DRUG|Placebo (matched to SUZ)|Placebo matched to SUZ for oral administration.
223943178|NCT05553366|DRUG|Placebo (matched to HB/APAP)|Placebo matched to HB/APAP for oral administration.
223943179|NCT02915432|BIOLOGICAL|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
223943180|NCT02915432|BIOLOGICAL|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
223943181|NCT02915432|BIOLOGICAL|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
223943182|NCT05808595|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
223943183|NCT05808595|OTHER|Placebo|One capsule of Placebo will be taken twice daily for 28 days.
223943184|NCT03877575|OTHER|No specific intervention. Collection of clinical data|
223943185|NCT01505166|BIOLOGICAL|Vigil™ Vaccine|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
223943186|NCT01505166|DRUG|Placebo|Patients will receive 1 x 10\^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
223943187|NCT06020352|DRUG|KN046 plus Axitinib|KN046 combined with axitinib as a neoadjuvant treatment regimen
223943188|NCT02022657|DRUG|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
223943189|NCT06434064|PROCEDURE|Biopsy|Undergo tumor biopsy
223943190|NCT06434064|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223943191|NCT06434064|PROCEDURE|Computed Tomography|Undergo CT scan
223943192|NCT06434064|PROCEDURE|Echocardiography|Undergo echocardiography
223943193|NCT06434064|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223943194|NCT06434064|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223943195|NCT06434064|DRUG|Tamoxifen|Given PO
223943196|NCT06108635|PROCEDURE|McKenzie Exercises|"These can be performed in sitting and the protocol includes,~1. Retraction and extension~2. Retraction and extension with rotation~3. Postural correction~There will be 2 sets of 5 repetitions in week 1 and 3 sets of 10 repetitions in week 2 followed by alternative days in a week. Each set is 30 seconds and each repetition is given in 2 seconds."
224099786|NCT07106489|OTHER|40 meters sprint|The participant performs a race at maximum speed with two attempts, times are taken at 10, 30 and 40 meters, to evaluate acceleration and speed, the attempt with the shortest times is the one taken for the research.
223943197|NCT06108635|PROCEDURE|Maitland mobilization|The grade I and II Maitland mobilizations are given in week 1 and then progressed to grade III and IV in week 2
223943198|NCT06108635|PROCEDURE|Heat Therapy|Moist heat therapy with hot pack.
223943199|NCT06079242|DEVICE|Resin microspheres containing yttrium-90 (Y-90)|SIR-Spheres Y-90 resin microspheres are permanent implant and for single use only
223943200|NCT03813472|DEVICE|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
223943201|NCT06075017|PROCEDURE|dental implant placement|Comparing the amount and type of biofilm on zirconia vs. titanium implants
223943202|NCT03363984|DRUG|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
223943203|NCT03363984|DRUG|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
223943204|NCT01515241|DRUG|CER-001|Weekly injection
223943205|NCT01979276|DRUG|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
223943206|NCT01979276|DRUG|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
223943207|NCT01979276|DRUG|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
223943208|NCT02546531|BIOLOGICAL|Defactinib|
223943209|NCT02546531|BIOLOGICAL|Pembrolizumab|
223943210|NCT02546531|DRUG|Gemcitabine|
223943211|NCT06180070|DRUG|Ibuprofen/ Paracetamol tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
223943212|NCT06180070|DRUG|Nuromol® tablets|1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
223943213|NCT03739866|DRUG|Lenacapavir|Administered subcutaneously in the abdomen
223943214|NCT03739866|DRUG|Placebo|Administered subcutaneously in the abdomen
223943215|NCT03739866|DRUG|B/F/TAF|50/200/25 mg tablets administered orally once daily
223943216|NCT03739866|DRUG|TAF|Tablets administered orally
223943217|NCT05123079|DRUG|Darigabat|Tablets
223994454|NCT05879237|DRUG|Helicobacter pylori triple therapy|"Triple therapy which is: amoxcillin on 50 mg/kg/day for 2 weeks, Clarithromycin 20mg/kg/day for 2 weeks and proton pump inhibitor~3.ppi 1mg/kg/day for 1month"
223994455|NCT05421468|OTHER|L-Thyroxine time B (5-15 minutes Before dawn)|Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.
223943218|NCT03090711|DEVICE|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
223943219|NCT03090711|DEVICE|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
223943220|NCT03090711|DEVICE|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
223943221|NCT03090711|DEVICE|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
223943222|NCT01034306|DRUG|CF101|orally q12h
223943223|NCT01034306|DRUG|Placebo control|orally q12 hours
223943224|NCT01939249|DEVICE|Abbott Laboratories Xience|
223943225|NCT01939249|DEVICE|Biotronik Orsiro|
223943226|NCT02195856|DIETARY_SUPPLEMENT|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
223943227|NCT02195856|DIETARY_SUPPLEMENT|Placebo|
223943228|NCT01619059|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
223943229|NCT01619059|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
223943230|NCT01619059|DRUG|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
223943231|NCT01619059|DRUG|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
223943232|NCT01335867|DRUG|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
223943233|NCT01335867|DRUG|Placebo|Placebo pills
223943234|NCT03080805|DRUG|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m\^2 daily, 1000 mg/ m\^2 BID)
223943235|NCT03080805|DRUG|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m\^2 daily, 1000 mg/m\^2 BID)
223943236|NCT02381132|DRUG|Norco 7.5mg/325|
223943237|NCT02381132|DRUG|MNK155|
223943238|NCT02024217|RADIATION|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
223943239|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
223943240|NCT00831506|DRUG|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
223943241|NCT00831506|DRUG|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
223943242|NCT02520674|OTHER|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
223943243|NCT03057600|DRUG|Paclitaxel|standard weekly paclitaxel in 28-day cycles
223943244|NCT03057600|DRUG|CB-839|CB-839 administered as oral tablets twice daily (BID)
223535387|NCT00276419|DRUG|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
223729396|NCT03510884|DRUG|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
223943245|NCT00748982|DRUG|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
223943246|NCT00748982|DRUG|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
223943247|NCT01793779|PROCEDURE|cold water immersion|
223943248|NCT01793779|DIETARY_SUPPLEMENT|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
223943249|NCT01793779|DIETARY_SUPPLEMENT|Placebo|
223943250|NCT01431118|OTHER|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
223943251|NCT01431118|OTHER|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
223943252|NCT03500523|DIAGNOSTIC_TEST|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
223943253|NCT04305197|DRUG|ICP-022|Tablet, 50mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
223943254|NCT04305197|DRUG|ICP-022|Tablet, 80mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
224099787|NCT07106489|OTHER|Fitness test by bronco test|The participant runs a distance of 20, 40, and 60 meters, back and forth, 5 times at maximum speed. The variable to be measured is the total time taken to complete the test.
223943255|NCT04305197|DRUG|ICP-022|Tablet, 100mg, once a day, oral, will be administered for 12 weeks in double-blind treatment period
223943256|NCT04305197|DRUG|Placebos|Tablet, matched to ICP-022, once a day, oral, will be administered for 12 weeks in double-blind treatment period
223943257|NCT02108704|DRUG|Helicobacter pylori eradication therapy|
223943258|NCT02108704|DRUG|Placebo|
223943259|NCT01595269|OTHER|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
223943260|NCT03044457|PROCEDURE|TKA|"femoral and tibial positioning using the reversed gap technique"
223943261|NCT03627637|DIETARY_SUPPLEMENT|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
223943262|NCT03489369|DRUG|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
223943263|NCT02408913|BIOLOGICAL|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
223943264|NCT02408913|BIOLOGICAL|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
223943265|NCT01968967|DRUG|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
223943266|NCT01968967|OTHER|Placebo|subcutaneous injection every 2 weeks for 12 months
223943267|NCT04255225|BEHAVIORAL|Walking for 10 minutes|Participants will walk on a treadmill for 10 minutes at a moderate intensity.
223943268|NCT04255225|BEHAVIORAL|Walking for 20 minutes|Participants will walk on a treadmill for 20 minutes at a moderate intensity.
223943269|NCT04255225|BEHAVIORAL|Walking for 30 minutes|Participants will walk on a treadmill for 30 minutes at a moderate intensity.
223943270|NCT00002437|DRUG|Cidofovir|
223943271|NCT00002437|DRUG|Probenecid|
223943272|NCT04715815|OTHER|No intervention (only interview)|Interview
223943273|NCT05558072|GENETIC|Toll-like receptor 4|Toll-like receptor 4
223943274|NCT03074032|DRUG|ONC1-0013B|ONC1-0013B per os daily
223943275|NCT03411382|OTHER|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
223943276|NCT03411382|OTHER|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
223943277|NCT03411382|OTHER|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
223943278|NCT03411382|OTHER|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
223943279|NCT06343727|DIETARY_SUPPLEMENT|Egg white protein pudding|Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks
224099788|NCT07106489|OTHER|Maximal strength|Each participant performs squats and bench press to evaluate lower-body and upper-body maximal strength, thus identifying their maximum strength taken per kilogram lifted.
224099789|NCT07106489|OTHER|Borg scale|At the end of the tests, each participant is asked to evaluate their perception of fatigue by giving a number between 1 and 10, with 1 being the lowest level of fatigue and 10 being the highest.
223943280|NCT06343727|DIETARY_SUPPLEMENT|: Ensure Plus|Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks
223943281|NCT06104618|DRUG|Enfortumab Vedotin|Given IV
223943282|NCT06104618|PROCEDURE|Computed Tomography|Undergo CT
223943283|NCT06104618|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223943284|NCT00545311|DRUG|NVA237|
223943285|NCT00545311|DRUG|NVA237|
223943286|NCT00545311|DRUG|NVA237|
223943287|NCT00545311|DRUG|NVA237|
223943288|NCT00545311|DRUG|Placebo|
223943289|NCT04007705|BEHAVIORAL|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
224099790|NCT07106151|BEHAVIORAL|Transmission of additional AKI-D recovery information|Measuring residual kidney function at the time of hospital discharge by timed urine collection (6-24 hours in duration), transmitting the results (urine volume, urea clearance, and creatinine clearance) to the accepting nephrologist and to the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.
223535388|NCT02483364|OTHER|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
223943290|NCT04007705|BEHAVIORAL|General healthy eating|Healthy eating counseling according to the World Health Organization
223943291|NCT03133299|DRUG|Glucocorticoids|Oral prednisolone for four months
223943292|NCT03133299|DRUG|Vitamin D|Oral vitamin D for two months
223943293|NCT05522309|DRUG|ET0111|Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
223943294|NCT05380115|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|weekly one on one video or telephone interviews with a study coach
223943295|NCT00850915|OTHER|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
223943296|NCT00001930|DRUG|Amantadine|
224099791|NCT07106151|OTHER|No additional AKI-D recovery information|The same timed urine collection will be collected at the time of hospital discharge as in the intervention arm, but in the control arm the results will not be transmitted to the accepting nephrologist or to the patient and no information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule will be transmitted. Instead, the research team will call the accepting nephrologist to alert them that this is an AKI-D patient that is being followed by the research team for recovery for up to 60 days.
224099792|NCT07108153|DRUG|SION-719|All participants receive SION-719, as specified by their treatment sequence assignment
224099793|NCT07108153|DRUG|Placebo-to-match SION-719|All participants receive placebo to match SION-719, as specified by their treatment sequence assignment
224099794|NCT07107035|OTHER|No Intervention: Observational Cohort|No intervention
224099795|NCT07105683|OTHER|hot pack therapy|Application of a commercial hot pack to the lumbar region for 20-30 minutes per session, twice daily, for 6 weeks.
224287423|NCT03632135|DIAGNOSTIC_TEST|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses a patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
224287424|NCT03632135|DRUG|Chemotherapy|Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent high-grade glioma
224287425|NCT06467292|DEVICE|continuous theta-burst stimulation (cTBS)|cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.
224287426|NCT06467292|BEHAVIORAL|Adaptation|Auditory adaptation in speech
224287427|NCT06467292|DEVICE|Single pulse Transcranial magnetic stimulation (TMS)|TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.
223943297|NCT03690804|DEVICE|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
224287428|NCT06467292|DEVICE|fMRI|To assess functional connectivity patterns between regions that predict learning.
224287429|NCT04379635|DRUG|Tislelizumab|administered via Intravenous (IV) injection
224287430|NCT04379635|DRUG|Cisplatin injection|administered via IV infusion
224287431|NCT04379635|DRUG|Paclitaxel injection|administered via IV infusion
223943298|NCT03316690|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
224287432|NCT04379635|DRUG|Pemetrexed Disodium|administered via IV infusion
224287433|NCT04379635|DRUG|Placebos|Placebo to match tislelizumab IV infusion
224287434|NCT04379635|DRUG|Carboplatin|administered via IV infusion
224287435|NCT05213169|DRUG|Apomorphine Hydrochloride 5mg/ml|Product administered using an external continuous subcutaneous infusion pump.
224287436|NCT05213169|OTHER|Sodium chloride 9mg/ml|Product administered using an external continuous subcutaneous infusion pump.
223943299|NCT03316690|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
223943300|NCT03316690|BEHAVIORAL|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
223943301|NCT02604693|OTHER|Nothing|No interventions will be administered.
223943302|NCT00490789|DRUG|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
223943303|NCT02662205|OTHER|Psychotherapy Group|Traditional process group
223943304|NCT02662205|OTHER|Yoga class|Yin yoga class
223943305|NCT02662205|OTHER|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
223943306|NCT03049332|BEHAVIORAL|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
223943307|NCT05939505|OTHER|Su Jok therapy|Sujok therapy will be applied with Mexican bean seeds 14 times with an interval of one day.
223943308|NCT05939505|OTHER|placebo|Instead of the Mexican bean seed applied in sujok therapy, plastic beans will be applied 14 times with an interval of one day.
223943309|NCT05939505|OTHER|routine interventions|routine applications in the hemodialysis unit
223943310|NCT02865785|DRUG|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
223943311|NCT02865785|DRUG|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
223943312|NCT01607320|DRUG|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
223943313|NCT01607320|DRUG|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
223943314|NCT03852082|PROCEDURE|percutaneous coronary intervention|Patients with coronary heart disease co-morbid depression post percutaneous coronary intervention.
223943315|NCT00984048|OTHER|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
223943316|NCT00824642|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
223943317|NCT00824642|DEVICE|placebo|placebo TENS applied prior to exercise
223943318|NCT03496883|BIOLOGICAL|Recombinant Activated Factor VII (rFVIIa)|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
223729397|NCT03510884|DRUG|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
223535389|NCT01706484|DRUG|BNO 1016|comparison of different dosages of drug and placebo
223943319|NCT03496883|BIOLOGICAL|Placebo|Participants will be randomized in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Participants in both arms will receive best standard therapy as per published AHA Guidelines for ICH, including a target systolic blood pressure of 140 mm Hg.
223729398|NCT03510884|DRUG|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
223943320|NCT00826995|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
223943321|NCT05483088|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected for analysis with the NEPHROCLEAR CCL14 Test
223943322|NCT03440086|DEVICE|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
223943323|NCT05364697|DEVICE|IoNIR Ridaforolimus-Eluting Coronary Stent System|The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
223943324|NCT06476015|OTHER|Therapeutic exercise|Duration: 30 minutes. Frequency: Once a week. Type of excercise: Cardiovascular, strengthening and balance. Supervised by a health professional.
223943325|NCT03018067|DRUG|RDX227675|
223943326|NCT03018067|DRUG|Placebo|
223943327|NCT03051568|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
223943328|NCT00614614|BIOLOGICAL|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
223943329|NCT00614614|BIOLOGICAL|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
223943330|NCT00614614|BIOLOGICAL|Infanrix®|One dose as intramuscular injection
223943331|NCT00614614|BIOLOGICAL|ActHIB®|Three doses in the priming phase as intramuscular injection
223943332|NCT00614614|BIOLOGICAL|Pediarix®|Three doses in the priming phase as intramuscular injection
223943333|NCT02577926|DRUG|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
223943334|NCT02577926|DRUG|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
223943335|NCT06266611|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
223943336|NCT06266611|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
223943337|NCT06266611|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
223943338|NCT04537403|DRUG|Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
223943339|NCT04537403|DRUG|Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine)|Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart
223943340|NCT05089461|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV), 20 mg/m\^2. Solid tumors: every 3 weeks (q3w, 1 cycle), Lymphoma: every 4 weeks (q4w, 1 cycle).
223943341|NCT00989196|BIOLOGICAL|Human-cl rhFVIII|50 IU/kg for PK dose
223943342|NCT00989196|BIOLOGICAL|Kogenate FS|50 IU/kg for PK dose
223943343|NCT01000805|DRUG|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
223943344|NCT01000805|DRUG|Placebo|Participants received placebo QD, po for 8 weeks.
223943345|NCT06106100|PROCEDURE|Antireflux mucosal ablation|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed, followed by mucosa markings with straight-fire APC catheter (ERBE Electromedizin, Tübingen, Germany) in forced coagulation mode (VIO300D, ERBE Electromedizin, Tübingen, Germany, 20W). The marking site at 1-cm and 2-cm distal to squamocolumnar junction at anterior-posterior and lesser curvature site, respectively, sparing the greater curvature site of cardia, is done. After marking, mucosal ablation (forced coagulation mode, 1L/min, 80W) is performed at marking site in a hoarse-shoe shape. Adequate ablation depth is defined as reaching the submucosal layer with blackish discolored tissue with carbonization
223943346|NCT06106100|PROCEDURE|Sham procedure|Patients are instructed to fast for 6 hours pre-procedurally, which are performed under intravenous propofol sedation. Retroflexion endoscopy to visualize the cardia is performed. Using the straight-fire APC catheter to touch the marking sites similar to the treatment group without electrocauterization is performed.
223943347|NCT00005974|DRUG|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
223729399|NCT03510884|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
223943348|NCT04986475|OTHER|Music Therapy|Music therapy was performed by listening to the ney sound during the non-stress test procedure.
223943349|NCT06587919|DEVICE|Neurofeedback|EEG-based neurofeedback, administered with the Neuroguide software.
223943350|NCT06605053|BEHAVIORAL|Co-produced intervention to optimize PMTCT care engagement|While the specific interventions package will developed earlier in the project, it may include evidence-based approaches such as peer mentor mothers, male partner involvement, flexible hours for girls/young women and mobile phone reminders. Overall, the interventions should be brief and easy to integrate into standard care, aiming to 'nudge' or motivate participants (towards improved engagement, retention, and outcomes) as well as health care providers or community stakeholders to better understand and support girls/young women\&#39;s specific needs. A focal team of 2-3 persons will be trained and engaged to drive the implementation of the interventions at randomized faciltiies. The focal team will orient and engage other staff and stakeholders to deliver the interventions, identify and address gaps, and monitor implementation fidelity and quality using standard operating procedures.
223943351|NCT06586398|DEVICE|rTMS|Participants will be randomized to 15 sessions of double-blind multi-target rTMS treatment (active vs sham) and then will receive only open-label active stimulation for another 15 sessions. Each session will include rTMS to the left dorsolateral prefrontal cortex (DLPFC), followed by rTMS to left primary motor cortex (M1).
223943352|NCT06816927|DRUG|Nivolumab|For Neoadjuvant treatment, on both Arms 1 and 2, all 92 patients will receive single dose of 480 mg by IV infusion on Day 1 followed by surgery. Post-resection, in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Nivolumab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.
223943353|NCT06816927|DRUG|Relatlimab|For Neoadjuvant treatment, only on Arm 2, 69 patients will receive a single dose of 480 mg of nivolumab and 480 mg of relatimab by IV infusions on Day 1 followed by surgery. Post resection in Part 1 Adjuvant treatment, all patients will receive two doses of 480 mg of nivolumab and relatlimab by IV infusion on Days 1 and 29. In Part 2 Adjuvant Treatment of Relatimab dosing will continue for up to 12 cycles. Each cycle is 28 Days long.
223943354|NCT06816927|DRUG|TMZ|All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment setting will receive 75 mg/m2 TMZ from Day 1 to Day 42 orally. In Part 2 Adjuvant Treatment of TMZ dosing with TMZ will continue for up to 6 cycles with 150 mg/m2 for cycle 3 and escalating to 200 mg/m2 for cycles 4 to 8 day 1 to 5 for these 6 cycles.
223943355|NCT06816927|RADIATION|Radiation Therapy|All patients in safety lead-in, Arm 1 and Arm 2 post resection in Part 1 Adjuvant Treatment will receive External Beam Radiation 2 Gy/day (60 Gy in total) Once daily, 5 days per week, for 6 weeks Starting on Day 1
223943356|NCT06061978|PROCEDURE|left bundle branch of His pacing|left bundle branch of His pacing
223943357|NCT06061978|PROCEDURE|right ventricular pacing|right ventricular pacing
223943358|NCT06855706|BEHAVIORAL|Behavioral Intervention|Receive personalized PA goals and positive feedback
223943359|NCT06855706|OTHER|Best Practice|Receive general PA counseling
223943360|NCT06855706|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223943361|NCT06855706|OTHER|Electronic Health Record Review|Ancillary studies
223943362|NCT06855706|OTHER|Exercise Intervention|Participate in MVPA
223943363|NCT06855706|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit Sense 2 and CGM device
223943364|NCT06855706|OTHER|Questionnaire Administration|Ancillary studies
223943365|NCT06855706|OTHER|Supportive Care|Receive ongoing support
223943366|NCT06016088|DRUG|RSP-1502|RSP-1502 is a sterile, preservative free solution to be administered by inhalation via a nebulizer. Each dose of RSP-1502 contains the active components tobramycin (300 mg) and CaEDTA in a 5 mL solution.
223943367|NCT06016088|DRUG|Tobramycin inhalation solution|Tobramycin inhalation solution is 300 mg tobramycin in 5 mL solution.
223943368|NCT06386744|DRUG|Dusquetide|1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks
223943369|NCT05460741|OTHER|integrated exercise approach|Integrated exercise plan will be given for 16 weeks with frequency of 3 times per week, with duration of session to be 50 minutes being 30 minutes of exercise in total and 10 minutes of rest and 10 min of warm up and cool down exercises.
223943370|NCT05460741|OTHER|educational program|educational program related to menstrual cycle will be given to females.
224287437|NCT06323551|OTHER|Mother's Smell|The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). one).
224287438|NCT06323551|OTHER|Mother's Breast Milk Smell|In the study group that will be made to smell the scent of breast milk, the procedures for the scent of the mother will be carried out in the same way, and 20 drops of each baby's own mother's milk will be dropped onto the diaper.
223729400|NCT01030939|DRUG|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
223729401|NCT02374554|DEVICE|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
223729402|NCT02374554|DEVICE|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
224287439|NCT03363464|DRUG|Empagliflozin|Empagliflozin
223729403|NCT01036035|DRUG|Tolterodine|Comparison of different dosages of drug
223943371|NCT04827810|DRUG|Gamitrinib|This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
223943372|NCT06670313|OTHER|postop Erector spinae plane block|Postoperative ESP block was performed as the control group
223943373|NCT06196840|GENETIC|LX102 subretinal injection|LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
223943374|NCT06196840|BIOLOGICAL|Aflibercept intravitreal injection|Commercially available Active Comparator
223943375|NCT06612840|DRUG|GNC-077|Administration by intravenous infusion for a cycle of 3 weeks.
223943376|NCT06587789|DRUG|Ribociclib|Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
223943377|NCT06592859|DIETARY_SUPPLEMENT|NMN|NMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
223943378|NCT06592859|DIETARY_SUPPLEMENT|placebo|Placebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
223943379|NCT04025164|RADIATION|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
223943380|NCT04025164|RADIATION|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
223943381|NCT06994377|BEHAVIORAL|ED and quality of life assessment|Patients will undergo ED and quality of life assessments through specific questionnaires completion
223943382|NCT06863051|PROCEDURE|Immediate Implant Placement and Alb-PRF|Immediate Implant Placement in lower molar region, Grafted with Xenograft and Albumin PRF Gel
223943383|NCT06863051|PROCEDURE|Immediate Implant Placement and L-PRF|Immediate Implant Placement in lower molar region, Grafted with Xenograft and L-PRF
223943384|NCT05355428|OTHER|offering of breast milk feed 3 hours prior to planned surgery start|parents will be asked to offer a breast milk feed (from breast or expressed in bottle) at a given time 3 hours prior to planned induction time
223943385|NCT06020274|BEHAVIORAL|Internet-delivered Cystic Fibrosis Mental Health Prevention, Wellness, and Resource (iCF-PWR) program|The iCF-PWR program is a self-guided mental health prevention program designed for families with CF. Upon logging on to the iCF-PWR, the viewer will see two paths (i.e., child with CF or sibling) and will be encouraged by program narrator to choose the appropriate path. Each pathway (i.e., child with CF or sibling) is comprised of five text/voice-delivered, animated, interactive modules: (1) CF education, (2) CF health, (3) emotions and CF, (4) cognitive behaviour model of emotions, and (5) coping strategies. Each module takes 15-20 minutes to complete.
223943386|NCT06156410|DRUG|Cabozantinib|Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.
223943387|NCT06995625|DRUG|SNE-101|Experimental: Cohort 1 - SNE-101 4.8 × 10e10 particles (n=3 to 6) Experimental: Cohort 2 - SNE-101 9.6 × 10e10 particles (n=3 to 6) Experimental: Cohort 3 - SNE-101 19.2 × 10e10 particles (n=3 to 6)
223729404|NCT01036035|DRUG|Pilocarpine|Comparison of different dosages of drug
223729405|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
223729406|NCT01036035|DRUG|THVD-201|Comparison of different dosages of drug
223729407|NCT01036035|DRUG|placebo capsule|Comparison of different dosages of drug
223943388|NCT06211530|DEVICE|SpO2 Sensor Testing|Participants participating in this study will be connected sensors.The participants are exposed to a desaturation protocol. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.
223943389|NCT07006532|DRUG|Tocilizumab|The trial is an open-labeled randomized clinical trial that evaluates the safety and efficacy of Tocilizumab as an add-on therapy to standard of care treatment of Plasmapheresis, IVIG, and Rituximab in treatment of CAMR in kidney transplant recipients.
223729408|NCT02390401|DEVICE|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
223729409|NCT02390401|DEVICE|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
223943390|NCT06397937|BEHAVIORAL|SHIFT team intervention|The SHIFT team, comprising a community health worker (CHW), community social worker (CHW), and community nurse (CN) will visit the participant starting within 72 hours of hospital discharge and provide social service referrals related to food insecurity, housing, immigration, and employment, and assist with medical appointment preparation (CHW), deliver individualized counseling focused on coping skills, reducing caregiver strain, and the psychological distress associated with experiences of racism and SDOH (CSW), and address health literacy and review of treatment goals and medications (CN).
223943391|NCT07007052|DRUG|Venetoclax|Single interventional arm
223943392|NCT07007052|DRUG|Tagraxofusp|Single interventional arm
223943393|NCT07003061|PROCEDURE|Standard Anesthesia Management|All patients will receive standard anesthesia care as per institutional protocols. No experimental intervention will be applied.
223943394|NCT06069297|OTHER|Multimodal Prehabilitation|Preoperative multimodal intervention including exercise training, nutritional therapy and psychosocial counseling, aimed at preventing or attenuating surgery-driven functional decline. A personalized intervention program will be prescribed based on specific physical, nutritional and psychological conditions recognized during the multimodal assessment. Patients will follow a 2 to 3-day per week exercise program for 4-6 weeks including endurance, resistance, and inspiratory muscle training, tailored to individual preferences and clinical conditions. Based on dietary habits and nutritional status, a certified nutritionist will provide a comprehensive diet management program. A food-based intervention with a balanced macronutrient composition coupled with oral nutritional supplements will be prescribed to achieve the estimated daily energy and protein requirements. Patients will meet with a psychologist to explore their emotional and psychosocial needs related to their current situation.
223943395|NCT06683105|OTHER|MyIBDDiet app|Participants in the Standard of Care arm will be administered the intervention (using the app) for 30 days, and participants in the MYIBDDiet arm will use the app for 60 days.
223943396|NCT07007247|OTHER|Mind-WIN self-help only|The program lets participants work through the module content at their own speed. Part of the program involves keeping an online diary every two weeks to track symptoms. The results are categorized as mild, moderate, or severe depression. If participants have severe symptoms, the recommendation is to get professional help. If participants are taking medication to improve their depression, they can also use the online diary to track their mood and medication
223943397|NCT07007247|OTHER|Mind-WIN blended care|The program lets participants work through the module content at their own speed. Part of the program involves keeping an online diary every two weeks to track symptoms. The results are categorized as mild, moderate, or severe depression. If participants have severe symptoms, the recommendation is to get professional help. If participants are taking medication to improve their depression, they can also use the online diary to track their mood and medication. In addition to the content provided by the Mind-WIN aftercare module participants get six digital contacts with a psychotherapist.
223943398|NCT06873204|DIETARY_SUPPLEMENT|Soluble Arabinoxylan|10 grams of soluble arabinoxylan diluted in 200 mL of water, twice daily for 3 consecutive weeks.
223943399|NCT06873204|DIETARY_SUPPLEMENT|Rice Bran|10 grams of rice bran fiber diluted in 200 mL of water, twice daily for 3 consecutive weeks.
223943400|NCT06873204|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10 grams of maltodextrin diluted in 200 mL of water, twice daily for 3 consecutive weeks.
223943401|NCT07014280|DRUG|Bevacizumab|anti-VEGF
223943402|NCT07014280|DRUG|Triamcinolone Acetonide|corticosteroid
223943403|NCT07012330|DRUG|Capecitabine (Xeloda)|Capecitabine (1650 mg/m2/day) was administered for two weeks from the start of each PRRT cycle.
223943404|NCT07012330|DRUG|177Lu-DOTATATE|Patients with advanced somatostatin receptor positive GEP NET or bronchopulmonary NET were included to receive four cycles of 7.4 GBq 177Lu-Dotatate.
223943405|NCT07014150|DRUG|Lenvatinib|daily,8mg/ day for less than 60kg, 12mg/ day for more than 60kg, for 9 weeks
223943406|NCT07014150|DRUG|Iparomlimab and Tuvonralimab|7.5mg/kg, every 3 weeks, for 3cycles.
223943407|NCT07012317|OTHER|High Fiber Bar with Inulin|Bar with Inulin - high fiber
223943408|NCT07012317|OTHER|High Fiber bar with Fiber Blend|Bar with a fiber blend of psyllium husk and bran fibers - high fiber
223943409|NCT07012317|OTHER|High Fiber Bar with Resistant Starch type 4|Bar with Resistant Starch type 4 - High Fiber
223943410|NCT07012317|OTHER|Low Fiber Bar|Snack Bar - Low Fiber
223943411|NCT07014163|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|0.1 mL or 0.15 mL of a 10 mg/mL deoxycholic acid solution will be injected into every 1\*1 cm2 of the lipoma using an insulin syringe with a 1cm needle attached (the max volume of injection is 2 cc in each treatment session).
223943412|NCT07012447|DRUG|Venetoclax|Orally by mouth
223943413|NCT07012447|DRUG|Azacitidine|Subcutaneous injection
223943414|NCT07012447|DRUG|Cytarabine|Intravenous infusion
223943415|NCT07013279|BIOLOGICAL|DWP712 inj.|Clostridium botulinum Toxin
223943416|NCT07013279|BIOLOGICAL|Botox® 100 Units|Clostridium botulinum Toxin
223994477|NCT04996433|DRUG|algorithm-based study medication|"All patients will receive an optimized, algorithm-based antidepressant medication following the current S3-Guidelines on Unipolar Depression. In case of nonresponse:~* 1st line dose escalation (if appropriate)~* 2nd line lithium augmentation~* 3rd line augmentation with 2nd generation antipsychotics or evidence-based combinations of antidepressants~* 4th line change of antidepressant."
223994478|NCT01857336|OTHER|infusion of G-CSF mobilized peripheral harvest|
223943417|NCT07013721|PROCEDURE|Transversus Abdominis Plane Block, TAPB|The procedure was performed by anesthesiologists with extensive expertise in nerve blockade techniques. For upper abdominal surgical incisions, a subcostal approach transversus abdominis plane block (TAPB) was implemented under ultrasound guidance to identify the transversus abdominis plane. A total of 20 mL of 0.33% ropivacaine hydrochloride injection (Naropin®) was incrementally administered, followed by contralateral application using identical techniques, with ultrasonographic confirmation of fusiform drug distribution within the transversus abdominis plane to achieve upper abdominal incision analgesia. For lower abdominal incisions, a lateral approach was employed, with the same dosage of local anesthetic injected at the target site and bilateral blocks performed after confirming fluid dispersion patterns under real-time ultrasound visualization.
223943418|NCT07012798|DRUG|Durvalumab|1120mg, iv, q3w
223943419|NCT07012798|DRUG|Bevacizumab|15mg/kg, iv, q3w
223943420|NCT07012798|DRUG|HAIC of FOLFOX|"HAIC (FOLFOX): oxaliplatin 100mg/m2, 4h, day 1 + leucovorin 300mg/m2, 2h, day~1 + fluorouracil 500mg/m2, 20min, day 1 + fluorouracil 1500mg/m2, 20h, q3w"
223943421|NCT06700083|DRUG|SHR-6934 injection|SHR-6934 injection
223943422|NCT06700083|DRUG|SHR-6934 placebo|SHR-6934 placebo
223943423|NCT07030842|PROCEDURE|liver resection|"This is a retrospective observational study analyzing existing clinical data; no experimental interventions were administered. The study evaluates the predictive performance of two deep learning models (preoperative and postoperative) using standard-of-care medical data collected during routine clinical practice, including:~Preoperative contrast-enhanced MRI scans Postoperative hematoxylin and eosin (H\&E)-stained whole slide images Clinical variables (laboratory results, pathology reports, and demographic data)~All data were collected as part of standard diagnostic and treatment protocols for hepatocellular carcinoma (HCC) patients undergoing liver resection. No additional interventions or modifications to clinical care were implemented for study purposes. The artificial intelligence models were applied to previously acquired, de-identified data to predict aggressive recurrence patterns"
223943424|NCT07032584|OTHER|Telerehabilitation Intervention|TheTelerehabilitation Intervention (TR) group utilizes a touchscreen tablet equipped with a computer-guided rehabilitation program that provides ongoing support and feedback for home-based rehabilitation.
223943425|NCT07039214|OTHER|Observation of low-back pain symptoms|No intervention was applied.
223943426|NCT07039214|OTHER|Observation of healthy comparators|No intervention was applied.
223943427|NCT07036224|DEVICE|Exergaming Training using Kinect sensor device|A 6-week standardized training program was carried out with the use of the game rehabilitation platform with Kinect sensor device. The subjects exercised under the supervision of an instructor for at least 30 minutes twice a week.
223943428|NCT07043985|DIAGNOSTIC_TEST|biopsy|Diagnosis of the HGF and healthy tissues depends on pre-described criteria; gingival overgrowth covering one third of the crown length as a minimum, systemically free, no history of drug uptake causing gingival overgrowth (nifedipine, phenytoin, cyclosporine, oral contraceptive pills). Before sampling, written consents were obtained from all patients. Using light microscope, haematoxylin and eosin (H\&E) stained sections were precisely examined and histopathological features were reported. All specimens were assessed semi-quantitatively, on a graded scale, under ×100 magnification power and a fixed grid for the following parameters. Three to four fields of each gingival specimen were randomly selected. A blinded evaluation was done by two independent observers. If a debate was reported regarding a specimen, a consensus was reached following re-evaluation. The most representative areas were selected to be morphometrically analyzed using Leica QWin 500 analyzer computer system (Germany).
223943429|NCT07042269|BEHAVIORAL|Aerobic Exercise|Performed daily 10,000-step walking (5 days/week)
223943430|NCT07042269|BEHAVIORAL|Respiratory Muscle Training|Performed 12-week progressive resistance training using the Lung Fitness® breathing trainer (initial/moderate/high resistance levels)
223943431|NCT07043660|BEHAVIORAL|AdoptMindful2Care|AdoptMindful2Care is a mindful parenting post-adoption intervention with eight weekly group sessions (approximately 90 minutes each), delivered in person by trained psychologists, plus one follow-up session held two months after completion. The intervention integrates psychoeducation, mindfulness-based exercises, mindful parenting and self-compassion practices, as well as strategies informed by Cognitive Behavioral Therapy (CBT). The program is designed to help adoptive parents reduce parenting stress and promote positive parenting practices.
223943432|NCT06538077|DRUG|Oral Branched chain Amino acid|The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 12 weeks
223943433|NCT06538077|DRUG|Rifaximin 550 MG|Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 12 weeks
223943434|NCT06538077|DRUG|Lactulose|Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
223943435|NCT06538077|DRUG|Placebo for BCAA|A placebo comparator of 15 gm of skimmed milk powder will be used.
223943436|NCT06538077|DRUG|Placebo for Rifaximin 550mg|Identical placebo sugar pills will be used as a placebo.
223943437|NCT06812507|PROCEDURE|intact umbilical milking|"Umbilical cord milking will be performed by holding the newborn at or~∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team."
223943438|NCT06812507|PROCEDURE|cut umbilical milking|Another technique, used more often in Asia, involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM
224287440|NCT03363464|DRUG|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
224287441|NCT03363464|DRUG|GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist
224287442|NCT06231563|DRUG|Ketamine|intravenous ketamine infusion 0.5 mg/kg
224287443|NCT06231563|DRUG|Remimazolam|intravenous remimazolam infusion 0.25 mg/kg
224287444|NCT05645471|BEHAVIORAL|Together After Cancer|This is an online couples intervention for Latina breast cancer survivors and their intimate partners.
224287445|NCT01730040|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
223943439|NCT06812507|PROCEDURE|Delayed cord clamping|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60-second before clamping the cord.
223943440|NCT06876194|OTHER|Music intervention|A previously defined list of songs will be administered to these patients during the procedure.
223943441|NCT04033224|DEVICE|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
223943442|NCT06898073|BEHAVIORAL|cognitive dual-task group|Cognitive tasks as the second task in addition to walking
223943443|NCT06898073|BEHAVIORAL|Single-task group|walking without performing a second task during the walking training
223943444|NCT06768411|DRUG|PEG-rhGH|1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH
223943445|NCT06768411|DRUG|GnRHa|"1. pubertal children of short stature without GnRHa treatment~2. pubertal children of short stature with GnRHa treatment"
223943446|NCT06803615|DEVICE|Electrocardiographic imaging|Electrocardiographic imaging is an electrophysiological mapping technique which is used to noninvasively map cardiac arrhythmias.
223943447|NCT06759441|BEHAVIORAL|Reframe-It+|Reframe-IT+ is an individual intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, which is carried out at the Educational Establishment with a trained psychologist. It consists of 13 weekly sessions of 25 minutes each, of which 5 sessions have a face-to-face component and 8 sessions have a face-to-face-digital component where students use a computer always in the company of a psychologist facilitating the program.
223943448|NCT06056206|RADIATION|Balloon Angioplasty|Revascularisation procedures will be performed according to randomised list.
223943449|NCT04278833|DRUG|Triamcinolone or Betamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
223943450|NCT04278833|DRUG|Dexamethasone|Image guided intra-articular, peri-tendinous, or intra-bursal corticosteroid injection
223943451|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 1|Step 1 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 25% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
223943452|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 2|Step 2 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 50% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
223943453|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 3|Step 3 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 75% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
223943454|NCT06489964|OTHER|Transitional Stepped Co-payment Model - Step 4|Step 4 of the transitional stepped co-payment model will have participants (e.g., eligible patients) receive an estimated 100% cost reduction in the vaccine. The vaccines will include FluMist Quadrivalent and Shingrix.
223943455|NCT06821373|BEHAVIORAL|Chatbot|The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.
223943456|NCT06821373|BEHAVIORAL|Control|The intervention includes five modules based on the five stages of Stages of change. Chatbots will build up a rapport with the participants, monitor their stage with a few simple questions based on previous Stages of Change studies, and provide stage-tailored packages of response, advice, and feedback (one of the five modules) accordingly to enhance their motivation and self-efficacy each week. For those who click 'yes' to a question assessing the first stage of change (PC), Chatbot will make a record and automatically ask questions assessing the next stage; for those who click 'no', Chatbot will automatically send them the module corresponding to their SoC via WhatsApp. Each module will take 10-15 minutes. In total, it will take 1 hour to complete all the modules.
223943457|NCT02864550|DRUG|Doxycycline|doxycycline 100mg orally daily
223943458|NCT02864550|OTHER|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
223943459|NCT03343704|DRUG|Idarucizumab|Intravenous
223943460|NCT06754059|DRUG|Pyrotinib|In this study, after at least 4 cycles of taxoid chemotherapy combined with trastuzumab ± pertuzumab, the evaluation result reached SD, CR or PR, and capecitabine combined with pyrotinib + trastuzumab was given successively in the later period (capecitabine was used for 4-6 cycles
223943461|NCT06757686|DEVICE|Mousetrap appliance|two mini-implant will be inserted in the palate. then, the mousetrap appliance will be inserted on the mini-implant and activated with power chain.
223943462|NCT06750653|OTHER|CeraVe Moisturizing Cream|CeraVe is a formulation of Purified Water, Glycerin, Cetareth-20 and Cetearyl Alcohol, Caprylic/Capric Triglyceride, Behentrimonium Methosulfate and Cetearyl Alcohol, Cetyl Alcohol, Petrolatum, Dimethicone, Hyaluronic Acid, Ceramide 1, Ceramide 3, Ceramide 6-II, Cholesterol, Phytosphingosine, Potassium Phosphate, Dipotassium phosphate, Phenoxyethanol, Methylparaben, Propylparaben, Disodium EDTA, Sodium Lauroyl Lactylate, Carbomer, Xanthan Gum, manufactured by L'Oréal, for topical skin use.
223943463|NCT06750653|DRUG|Vaseline|Vaseline is a formulation of active ingredient white petrolatum, USP (100%), manufactured by Unilever, for topical skin use.
224287446|NCT01730040|DRUG|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
224287447|NCT01730040|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
224287448|NCT01730040|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
223943464|NCT06771661|OTHER|Workshops|The investigators will conduct workshops with parents to get closer to the main topic.
223943465|NCT06771661|OTHER|Focus group interviews|The investigators will conduct focus group interviews with parents on their needs before and during child loss.
223943466|NCT06771661|OTHER|Narrative interviews|The investigators will conduct narrative interviews with parents to gain an in-depth understanding of their lived experience before and during the intrauterine or perinatal child loss.
223943467|NCT06771661|OTHER|Delphi approach|The investigators will carry out a Delphi approach with parents to translate and confirm or revise the findings into treatment recommendations for healthcare professionals.
223943468|NCT06410001|DEVICE|Epidural Spinal Cord Stimulation (eSCS)|"The spinal cord stimulator system (Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead) will be used for this study which is manufactured by Abbott Laboratories. The The stimulators will be surgically inserted above the dura in the spinal canal and administer an electrical signal from the neurostimulator to specific sections of the spinal cord underlying the electrodes. The duration of implantation will be 10 years (the longevity of the device battery). The device will not be removed unless it causes complications such as malfunction, illness, or other harm.~The device can also be removed electively for any reason."
223943469|NCT06901648|DRUG|HS-20094|Administrated by subcutaneous injection once a week
223943470|NCT06901648|DRUG|Dulaglutide|Administrated by subcutaneous injection once a week
223943471|NCT06901648|DRUG|Palcebo|Administrated by subcutaneous injection once a week
223943472|NCT06906887|DRUG|Induction Chemotherapy (modified FLOT or modified FOLFOX-6)|Subjects are expected to receive 2-4 months of induction chemotherapy; the interval and dosages will be determined and can be modified at the discretion of their medical oncologist. The preferred induction chemotherapies are modified FLOT or FOLFOX-6. Subjects can enroll if they receive less than 2 months of induction chemotherapy as long as they are deemed to be a candidate for concurrent chemoradiation therapy.
223943473|NCT06906887|DRUG|Chemotherapy|The preferred concurrent chemoradiation is carboplatin/paclitaxel weekly.
223943474|NCT06906887|RADIATION|Conventional Radiation|For both standard conventional radiation therapy and PLDR radiation therapy, the standard dose (5000cGy/25fx default, 4140-5040 in 23-28 fractions) should be given. Fractions should consist of 180-200 cGy per treatment.
223943475|NCT06906887|RADIATION|Pulsed Low-Dose-Rate (PLDR) Radiation|"For both standard conventional radiation therapy and PLDR radiation therapy, the standard dose (5000cGy/25fx default, 4140-5040 in 23-28 fractions) should be given. Fractions should consist of 180-200 cGy per treatment.~For PLDR radiation therapy, each fraction will be delivered as a series of 20 cGy (or 0.2 Gy) pulses that are separated by 3-minute time intervals."
223943476|NCT06906887|PROCEDURE|Surgery|Esophagectomy is not required for trial and will be administered per medical judgement of the treating physicians. Surgery will take place at the time directed by the surgeon. This typically will take place approximately 6-13 weeks after chemoradiation therapy.
223943477|NCT05226364|PROCEDURE|Rubber tourniquet|The blood sample is taken with a rubber tourniquet
223943478|NCT05226364|PROCEDURE|Fabric tourniquet|The blood sample is taken with a fabric tourniquet
223943479|NCT05226364|PROCEDURE|Without tourniquet|The blood sample is taken without tourniquet
223943480|NCT07098962|OTHER|Kinesiotaping|In this group, KinesioTaping will be applied around the thoracic drain sites alongside standard analgesic therapy. This physical therapy technique uses elastic tapes placed on the skin to support healing, reduce pain, and improve patient comfort. The tapes will remain in place for 2-3 days and will be removed together with the drains.
223943481|NCT07098962|DRUG|Dexketoprofen, tramadol|Patients in this group will be treated with painkillers consisting of tramadol and dexketoprofen.
223943482|NCT06892600|DRUG|Combined Spinal anesthesia (heavy bupivacaine 0.5%) and General anesthesia|Combined spinal and general anesthesia Spinal anesthesia with Bupivacaine heavy 0.5% 10 mg General anesthesia with Lidocaine 1.5mg/kg, Fentanyl 2 mcg/kg, propofol 2 mg/kg, Rocuronium 0.6 mg/kg
223943483|NCT06892600|DRUG|General Anesthesia (control group)|Lidocaine 1.5mg/kg, fentanyl 2 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg
223943484|NCT03789656|DRUG|Paltusotine|Paltusotine, capsules, once daily by mouth
223943485|NCT04287647|DEVICE|Transpyloric stent|See arm/group descriptions
223943486|NCT04287647|OTHER|Sham|Sham
223943487|NCT04069247|BEHAVIORAL|e-CBT-I|The e-CBT-I will be delivered through a mobile application (eSleep) with a personal password.
224287449|NCT01730040|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
223943488|NCT04069247|BEHAVIORAL|e-HE|The e-HE will be delivered in control though a mobile application (eSleep) with a personal password.
223943489|NCT04604197|OTHER|Angiography and Clinical Follow up|Angiography and Clinical Follow up
223943490|NCT04604197|OTHER|Clinical Follow up|Clinical Follow up
223943491|NCT06035744|DRUG|CLN-617|Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences
223943492|NCT06035744|DRUG|Pembrolizumab|Humanized IgG4 anti-PD-1 monoclonal antibody
223943493|NCT06172946|DEVICE|powerbreath|Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise. (Gandullo et al., 2022)
223943494|NCT06172946|DEVICE|TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION|Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness. A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS. (Hsin et al., 2022)
223943495|NCT01086241|PROCEDURE|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
224287450|NCT04474431|OTHER|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.|Evaluation of VEGF-A levels in patients with septic shock is positively correlated with a positive fluid balance.
223943496|NCT01086241|PROCEDURE|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
223943497|NCT01054287|OTHER|Multifactorial falls prevention program|
223943498|NCT01054287|OTHER|No falls prevention intervention|
223943499|NCT06214052|DRUG|VH4524184|VH4524184 was administered as tablets orally at Day 1.
223943500|NCT06214052|DRUG|Matching Placebo|VH4524184 Matching Placebo was administered as tablets orally at Day 1.
223943501|NCT06214052|DRUG|Antiretroviral therapy|Antiretroviral therapy was administered as available and as per investigator's recommendation.
223943502|NCT06387199|DRUG|Semaglutide with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
223943503|NCT06387199|DRUG|Placebo with 4 meal strategies|The blinded drug will be used in addition to the participants routine closed-loop insulin pump therapy. It will be administered through subcutaneous injection on a weekly basis. The first 12 weeks will include progressively increasing doses of the drug whereby, the dose increases every 4 weeks. Once the maximum tolerated dose is achieved after 12 weeks, participants will undergo 4 meal strategies in a randomized order. These include (in no particular order); full carbohydrate counting with rapid-acting insulin, SMA with rapid-acting insulin, SMA with Lyumjev and fully closed-loop system with Lyumjev. Each meal strategy will be 3 weeks in duration and will occur sequentially in the designated order.
223943504|NCT06940960|DRUG|JY231 Injection|This is an open-label, single-arm study to evaluate the efficacy and safety of in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy in patients with relapsed refractory B-cell lymphoma/ leukemia. Upon enrollment, subjects will receive an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be hospitalized for one month for observation, and subjects will be evaluated for safety and efficacy. Subjects will be followed for up to 2 years to determine if the disease is under control.
223943505|NCT01804166|DRUG|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
223943506|NCT01804166|DRUG|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
223943507|NCT02434328|DRUG|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
223943508|NCT02434328|DRUG|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
223943509|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 8mA|Phrenic nerve stimulation (PNS) at 8mA is applied.
223943510|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 15mA|Phrenic nerve stimulation (PNS) at 15mA is applied.
223943511|NCT06952335|PROCEDURE|Phrenic nerve stimulation at 15mA combined with phrenic-abdominal stimulation at 15mA|Phrenic nerve stimulation (PNS) at 15mA combined with phrenic-abdominal stimulation at 15mA is applied.
223943512|NCT06951243|DRUG|MHB088C for Injection (B7-H3 ADC)|MHB088C for Injection, an antibody drug-conjugated molecule (ADC), is conjugated from a humanized monoclonal antibody targeting the B7-H3 molecule and a DNA topoisomerase I inhibitor (TOP1i) via protease-hydrolyzable linkers.The intervention will be administered intravenously at a dose of 2.0 mg/kg every 2 weeks (Q2W) until disease progression, withdrawal from the study, or death.
224099796|NCT07105683|GENETIC|Kinetic control training|is an evidence-based rehabilitation approach, focused on retraining movement patterns by addressing and improving motor control of the lumbar spine and pelvis, correcting faulty movement strategies, enhancing stability in functional tasks. The principles of KCT entail the identification of direction-specific motor control deficit, uncontrolled extension, followed by focused retraining of movement control through specific exercises designed to improve the coordination and activation of deep stabilizing muscle systems, including the transversus abdominis, multifidus, and pelvic floor muscles. This approach is especially relevant in postpartum women, where motor control deficits and poor load transfer capabilities are commonly observed . Based on the clinical presentation of patients with postnatal low back pain, demonstrated symptoms that were aggravated during lumbar extension movements or when maintaining prolonged upright postures. The
224099797|NCT05428176|OTHER|Best Practice|Receive usual care
224099798|NCT05428176|OTHER|Internet-Based Intervention|Undergo eHealth intervention
224099799|NCT05428176|OTHER|Quality-of-Life Assessment|Ancillary studies
223943513|NCT06952088|OTHER|Training on Neonatal Resuscitation|Improve training of health care personnel (physicians, nurses and midwives) on neonatal resuscitation through manikin simulation using two different devices: a face mask and a laryngeal mask. Before the simulations begin, each participant will receive a brief introduction on the technical characteristics of the manikin and how to use the two masks. A stopwatch will be used to record the time required to achieve effective ventilation, defined by the expansion of one-third of the newborn manikin's rib cage. Consideration will also be given to whether corrective maneuvers will need to be performed during the use of each mask and the timing with which these maneuvers will be applied. Finally, a pseudonymous questionnaire will be administered to participants to assess their perceptions of the ease of use of each mask.
224099800|NCT05428176|OTHER|Questionnaire Administration|Ancillary studies
224099801|NCT06515587|DIAGNOSTIC_TEST|Lewis genotype detection reagent|By evaluating the results of the Lewis gene test combined with the CA19-9 test, different subtypes of pancreatic cancer patients were differentiated to evaluate the prognosis
224099802|NCT04259359|DRUG|Insect Venom|Patients will be treated with bee venom immunotherapy (protocol can be selected by patient). Blood samples are taken before starting VIT to determine specific immunoglobulin E (sIgE) Levels for bee venom components. Patients are sting challenged and the outcome will be recorded.
223943514|NCT06951854|DRUG|Drug: NV01-A02|NV01-A02 will be administered orally at a different dose once daily for 8 weeks. The formulation is a white, film-coated tablet, designed for use in patients with mild to moderate cognitive impairment.
223943515|NCT06951854|DRUG|Drug: Placebo (ZP8396)|ZP8396 is a matching placebo tablet administered orally once daily for 8 weeks. The placebo is identical in appearance to NV01-A02 but contains no active ingredient.
223943516|NCT05436665|PROCEDURE|UT-DSAEK|"The main incision (3.5-5mm) is created at the corneal limbus or via a cornea-scleral tunnel with 2-3 smaller (approx. 1mm) paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber, according to the surgeon's preference. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed. Once the anterior chamber is prepared, OVD or air has been removed, then the eye is ready for the new corneal graft.~The pre-cut corneal tissue delivered by the bank is then gently rinsed and may be stained with 0.06% trypan blue if required. The tissue is loaded into a glide or injector, and pulled into the anterior chamber using a smooth-tipped micro-forceps (e.g., Busin forceps). Once the graft enters the eye, it is lifted to the posterior cornea. The graft is further centred using air (or SF6 Gas) in the anterior chamber."
223943517|NCT05436665|PROCEDURE|DMEK|"The main incision (2.8-3mm) is created superior or temporally at the corneal limbus and is accompanied by 2-3 smaller paracentesis incisions. An ophthalmic viscosurgical device (OVD) or a continuous infusion of water or air can be used to maintain the stability of the anterior chamber. The corneal endothelium is scored using a scoring instrument and the central diseased corneal endothelium is removed.~The DMEK roll is poured into a basin and rinsed. The graft is then stained with 0.06% trypan blue to aid in graft visualization. The graft is loaded into an injector and introduced into the anterior chamber. The graft is unrolled using external manoeuvres and once unrolled, it is lifted to the back of the cornea. The eye is then pressurised with a full air fill from 10 to 120 minutes. The pressure is then reduced and the case is completed by suturing any incisions required."
223943518|NCT05825885|DRUG|E2|micronized E2 at a daily dose of 4-6mg,
223943519|NCT05231018|OTHER|Psychotherapy|8-sessions psychotherapy
223943520|NCT02370797|RADIATION|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
223943521|NCT00604890|DRUG|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
223943522|NCT00604890|DRUG|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
223943523|NCT00604890|OTHER|Placebo|Topical treatment placebo applied to the lesion
223943524|NCT06532136|DRUG|Deucravacitinib|Deucravacitinib 6 mg orally once daily.
223943525|NCT06532136|DRUG|Placebo|Matching placebo orally once daily.
223943526|NCT06117124|RADIATION|Digital X-Ray Radiogrammetry|An x-ray of the left hand will be taken by a Radiographer. This will be uploaded to PACS and analysed using BoneXpert software. This calculates bone density as a 'Bone Health Index', and provides a standard deviation score for age, gender and bone age.
223943527|NCT06117124|DIAGNOSTIC_TEST|Quantitative Ultrasound (QUS)|The MiniOmni Bone Densitometer will be used to measure bone density at three peripheral sites on both sides of the body (left and right): the distal radius (lower arm), mid-tibia (lower leg) and phalynx (hand). The speed of ultrasound (speed of sound) through the bone will be measured and converted to a standard deviation score.
223943528|NCT07197463|OTHER|drug therapy （Aspirin, Atorvastatin, Nitroglycerin）+ general treatment（quit smoking）|The experimental group received Phase I cardiac rehabilitation intervention + medication treatment + general treatment, while the control group only received medication treatment + general treatment.
223943529|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
223943530|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
223943531|NCT06289452|GENETIC|IVB102 Injection|Gene transfer by intravitreal injection of the RS1 AAV vector
223943532|NCT04153682|DIAGNOSTIC_TEST|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
223943533|NCT04153682|DIAGNOSTIC_TEST|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
223943534|NCT06703476|PROCEDURE|Stent placement|Surgeon may choose to use a single or double J ureteral stent (6- to 8.5-fr in size) or an alternative ureteral stent of the surgeon's choice.
223943535|NCT06703476|DRUG|Alvimopan|Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).
223943536|NCT00457119|DRUG|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
223943537|NCT05543109|DRUG|Fentanyl|1 mic/kg during induction of anesthesia
223943538|NCT05543109|DRUG|Propofol|3mg/kg during induction of anesthesia
223943539|NCT05543109|DRUG|Rocuronium|0.9 mg/kg during induction of anesthesia
223943540|NCT05543109|DRUG|Sevoflurane|2-3% during maintanance of anesthesia
223943541|NCT05543109|DRUG|Ropivacaine|0.25% Ropivacaine will be used at 1 ml/kg will be injected Ultrasound guided after induction of general anesthesia.
223943542|NCT02310581|DRUG|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
223943543|NCT02310581|DRUG|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
223943544|NCT00650169|DRUG|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
223943545|NCT00650169|DRUG|Plavix® Tablets 75 mg|75mg, single dose fed
223943546|NCT00192959|DRUG|Xenon vs propofol|
223943547|NCT06269029|OTHER|Chest mobility exercises|exercises were repeated 6 times on each side with rest of period for 30 seconds in between. The intervention will be carried out for one week with total of 7 sessions. Each Exercise will be accompanied by breathing pattern. In neutral position of exercises, subjects will be asked to exhale during flexion, turning or extension subject will be asked to do inhale.
223943548|NCT06269029|OTHER|proprioceptive neuromuscular facilitation|The technique used in this study Proprioceptive neuromuscular facilitation technique of hold and relax stretching for isolated clavicular head of the pectoralis major muscle. The subjects sitting on a chair with back support to keep spine in a neutral position and both their arms are extended and hands are placed behind the occipital region. His both arms will be positioned in glenohumeral horizontal extension, and glenohumeral abduction and external rotation with elbow bent to perform stretch position of pectoral muscle. Then ask him to contract the pectoral muscles .This isometric contraction is held for 6 seconds. The patient then relaxed and passive stretch in the opposite direction . and it was repeated 6 times with rest period 30 seconds. The session will be given every day for one week
223943549|NCT06071052|PROCEDURE|TACE and HAIC Combined With Regorafenib|TACE and HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer who failed the second line treatment regimens
223943550|NCT03543332|DIAGNOSTIC_TEST|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
223943551|NCT00486304|OTHER|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
223943552|NCT00486304|OTHER|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
223943553|NCT04313699|DRUG|Antiretroviral treatment|The cohort will recruit HIV infected participants who are on antiretroviral treatment
223943554|NCT00615368|DRUG|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
223535390|NCT05162690|DRUG|Dapagliflozin 10 milligram|10mg per day of Dapagliflozin will be given to the patients
223535391|NCT05162690|OTHER|Placebo|Metformin DPP4 inhibitors
223535392|NCT00639951|BIOLOGICAL|A|20 vials up front in a Single Dose of Antivipmyn
223943555|NCT00615368|DRUG|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
223943556|NCT06522139|PROCEDURE|Implantation of Episealer Talus Implant|Subjects will be on study for up to 60 months after their talus implant surgery. Treatment: Implantation of Episealer Talus Implant Follow-up: 60 months The total duration of the study is expected to be 75 months. 12 months for subject recruitment, 60 for final subject follow-up and 3 for data analysis and production of the final report.
223943557|NCT04658784|DEVICE|2-0 dioxanone, glycolide and trimethylene carbonate|delayed absorbable, monofilament barbed suture
223943558|NCT04658784|DEVICE|2-0 polydioxanone|delayed absorbable, monofilament non-barbed suture
223943559|NCT05018156|BEHAVIORAL|Default Genetics Referral Process|Patients and their oncology providers will be notified of their eligibility for a cancer genetics referral, with an option to opt out if they are not interested in proceeding. Everyone else will be automatically referred to their local hospital's cancer genetics program for contact and scheduling. Standard genetic counseling, testing, and results disclosure will take place, including usual methods of payment and insurance coverage for testing.
223943560|NCT05030415|DRUG|Ixekizumab Auto-Injector|160 mg week 0 followed by 80 mg every two weeks
223943561|NCT03260998|DIAGNOSTIC_TEST|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
223943562|NCT02224469|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
223943563|NCT03387826|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
223943564|NCT03387826|DRUG|Prasugrel 5mg|Prasugrel 5 mg once daily
223943565|NCT01349998|DRUG|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
223943566|NCT03783936|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2
223943567|NCT03783936|DRUG|Leucovorin|Leucovorin 400 mg/m2
223943568|NCT03783936|DRUG|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
223943569|NCT03783936|DRUG|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
223943570|NCT03783936|DRUG|Avelumab|Avelumab 800 mg
223943571|NCT00454194|DRUG|pemetrexed disodium|given IV
223943572|NCT00454194|DRUG|sorafenib tosylate|given orally
223943573|NCT05388045|OTHER|Patient Reported Outcome Measure|A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
224099803|NCT03116529|COMBINATION_PRODUCT|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as \>10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
224099804|NCT04164667|BEHAVIORAL|Mental and physical (MAP) training intervention|"In this study, the MAP intervention consisted of two MAP training sessions and one health coaching session per week for eight weeks. Both groups received the same MAP intervention with the exception of the delivery format (directed versus self-guided).~Each MAP training session included 30 minutes of guided meditation and 30 minutes of moderate-to-vigorous aerobic exercise."
224099805|NCT06082401|DEVICE|hemodiafiltration (HDF)|Hemodiafiltration (HDF) is a variation of conventional HD. By the addition of a substitution solution, convection forces are significantly increased. This substitution solution is added to the blood and is completely removed again in the dialyzer. This increases the negative pressure on the dialysate side and the removal of toxins through convection. The substitution solution can be added in a pre-dilution (before the dialyzer) or post-dilution (after the dialyzer) manner. Pre-dilution is associated with longer run times, less filter clotting, but is also less effective in removing toxins. Post-dilution offers a better toxin clearance capacity, but is associated with an increased risk of filter clotting. Several studies have shown that HDF provides higher clearance rates for both small and middle molecule solutes. Moreover, effective cytokine removal has been shown in HDF both in acute and chronic renal disease patients.
224099806|NCT06082401|DEVICE|Ex vivo lung perfusion (EVLP)|"Lung transplantation has become a standard treatment for patients suffering from end-stage lung diseases. One of the major obstacles in the modern transplant era is the fact that the need for organs by far exceeds availability. This leads to growing waiting lists with mortality rates ranging between 10-30%. On the other hand, up to 80% of offered lungs from brain dead donors are rejected because they do not meet predefined donor selection criteria.~Recently, ex vivo lung perfusion (EVLP) has become available as a tool to expand the donor pool. Based on experimental work by Stig Steen, the Toronto lung transplant group developed an EVLP system with the purpose to evaluate lungs with uncertain quality. Consequently, Aigner et al. have expanded the indications for EVLP by showing that primarily unacceptable donor lungs can be reconditioned and then become suitable for transplantation. This concept of organ repair by EVLP has recently been highlighted by a number of publications."
224099807|NCT04633343|OTHER|Small volume breath and fast breathing rate for 5 minutes|Small volume breath and fast breathing rate delivered via mechanical ventilator.
224099808|NCT04633343|OTHER|Large volume breath and slow breathing rate for 5 minutes|Large volume breath and slow breathing rate delivered via mechanical ventilator.
224099809|NCT06084806|DRUG|[18F]F-ARAG PET|Two imaging sessions
224099810|NCT01163422|DEVICE|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
224099811|NCT06782906|BEHAVIORAL|≥10,000 daily steps (≥5 days/week) and stopping evening snacking|Participants in the intervention arm will be asked to perform ≥10,000 daily steps (≥5 days/week) and omit evening snacking after 8:00 p.m.
224099812|NCT04568330|OTHER|best support care|Best support care
224099813|NCT04568330|OTHER|moisture cream|BSC plus moisture cream
224099814|NCT04568330|OTHER|10% urea-based cream|BSC plus 10% urea-based cream.
224099815|NCT03609164|PROCEDURE|Suture-bridge augmentation of single-row repair|
224099816|NCT02172118|DRUG|BI 1774 CL|
224099817|NCT00001446|DRUG|thalidomide|
224099818|NCT05415280|BEHAVIORAL|Mindfulness Based stress reduction|The aim of the psychological intervention to reduce the mental health problems of the participants.
224099819|NCT03974919|OTHER|NO intervention required|NO intervention required
224099820|NCT04007484|DEVICE|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
224099821|NCT03552783|BEHAVIORAL|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
224287451|NCT06473402|DIAGNOSTIC_TEST|Muscle Strength Test|Hamstring muscle strength of the participants was measured with a dynamometer (Microfet 2, Hoggan Health Industries, HHD) with the knee flexed at 90 degrees. After the physiotherapist fixes and positions the dynamometer 5 cm proximal to the calcaneus with a belt, the participant will be asked to accelerate to maximum isometric strength by trying to bring his heel closer to his hip against this resistance. The isometric strength of the hamstring muscle will be measured in Newtons (N) by being asked to wait at maximum force level for three seconds. Measurements were made in 2 repetitions and the highest value was noted. There will be a 30-second rest period between attempts.
224295125|NCT03223454|BIOLOGICAL|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
223943574|NCT06227988|PROCEDURE|patients with liver disease who undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
223943575|NCT06227988|PROCEDURE|patients with liver disease who do not undergoing surgery|"For each patient and surgery, we will be collecting detailed pre-operative data regarding demographics (age, sex, body mass index, surgery category, comorbidities (diabetes mellitus, hypertension), and pertinent laboratory values (sodium, creatinine, total bilirubin, the international normalized ratio \[INR\], albumin, platelet count.) The etiology of liver disease will be classified.~To ensure that laboratory data accurately reflected the pre-operative state, only those from within 30 days prior to surgery will be considered For each patient VOCAL PENN score, MELD score, and Mayo score will be calculated using an online calculator."
223943576|NCT03946956|BEHAVIORAL|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
223943577|NCT03946956|BEHAVIORAL|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
223943578|NCT02827201|DRUG|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
223943579|NCT02827201|DRUG|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
223943580|NCT00620854|DRUG|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
223943581|NCT00620854|DRUG|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
223943582|NCT00620854|DRUG|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
223943583|NCT00620854|DRUG|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
223943584|NCT01586416|BEHAVIORAL|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
223943585|NCT02279485|DRUG|Perampanel|
224099822|NCT03552783|BEHAVIORAL|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~1. Personal responsibility~2. Personal responsibility to your child~3. Responsibility to your family and community"
224099823|NCT01959360|PROCEDURE|Direct lateral|Total hip replacement; direct lateral approach
224099824|NCT01959360|PROCEDURE|minimal invasive|Total hip replacement; minimal invasive approach
224099825|NCT01959360|PROCEDURE|modified minimal invasive|Total hip replacement; modified minimal invasive approach
223943586|NCT01705366|PROCEDURE|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
223943587|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
223943588|NCT01705366|PROCEDURE|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
223943589|NCT01705366|DEVICE|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
223943590|NCT01705366|DEVICE|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
223943591|NCT01705366|DEVICE|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
223943592|NCT03829553|RADIATION|Hypofractionated radiotherapy|4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
223943593|NCT03829553|RADIATION|Conventional radiotherapy|5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
223943594|NCT02353507|DEVICE|Opticell Ag+|
224099826|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fed state
224099827|NCT05902728|DRUG|HLX208|Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ，then receive treatment HLX208 900 mg in the fast state.
224099828|NCT05902728|DRUG|HLX208|450 mg
224099829|NCT05902728|DRUG|HLX208|900 mg
224099830|NCT05902728|DRUG|Itraconazole 200 mg|200 mg
224099831|NCT05902728|DRUG|Rifampicin|600mg
224099832|NCT01309126|BIOLOGICAL|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
224295126|NCT05308680|BIOLOGICAL|BNT162b2|Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19
223943595|NCT02353507|DEVICE|Aquacel Ag+|
223943596|NCT04094207|DRUG|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
223943597|NCT04094207|DRUG|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
223943598|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
223943599|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
223943600|NCT00637858|DIETARY_SUPPLEMENT|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
223943601|NCT00637858|DIETARY_SUPPLEMENT|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
223943602|NCT00637858|OTHER|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
223943603|NCT00010959|DRUG|Cimicifuga racemosa|
223943604|NCT00010959|DRUG|Trifolium pratense|
223943605|NCT01229384|DEVICE|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
223943606|NCT01229384|DEVICE|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
223943607|NCT01244997|PROCEDURE|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
223943608|NCT05197452|BEHAVIORAL|COVID-19 Testing|"For in-person PCR testing, a nasal swab will be inserted shallowly into the participant's nose and rotated in each nostril. The swab will be broken off into a designated test tube and placed into a specimen bag along with a label. All specimens will be stored in a cooler until they are transported the Rush Laboratory for COVID-19 analysis.~For at home antigen testing, participants will download an app to their mobile phone and watch an informational video. The test will be self-administered by inserting a nasal swab into the nostril until a cap containing the swab touches the nose; rubbing the swab tip around the nose cavity 3 times; removing the swab and repeating in the other nostril. The nasal swab, a dropper, processing fluid, and a blue tooth connected analyzer are provided with the testing kit to analyze the sample for COVID-19. COVID-19 home test results are displayed on the participants smart phone after 15 minutes."
223943609|NCT02323945|OTHER|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
223943610|NCT02323945|OTHER|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
223943611|NCT02323945|OTHER|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
223943612|NCT02823340|DEVICE|Fractional microneedle RF(United, Peninsula Medical, China)|
223943613|NCT01760005|DRUG|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
223943614|NCT01760005|DRUG|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
223943615|NCT01760005|DRUG|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
223943616|NCT01760005|DRUG|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
223943617|NCT01760005|DRUG|Gantenerumab|Open-label administered Subcutaneously every 4 weeks at escalating doses
223943618|NCT01760005|DRUG|E2814|Administered intravenously in a blinded fashion
223943619|NCT01760005|DRUG|Lecanemab|Administered intravenously
223943620|NCT01760005|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
223943621|NCT04482556|DEVICE|Q-NRG+ Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
223943622|NCT04482556|DEVICE|V(max) Encore Indirect Calorimetry Device|The two indirect calorimetry devices will be tested in an alternating fashion for each enrolled patient. Each enrolled patient subsequently will alternate in which device is tested first.
224295127|NCT00161681|DRUG|Levonorgestrel/Ethinyl Estradiol|
224295128|NCT02983032|BEHAVIORAL|BBTI|3 group sessions over 4 weeks
224295129|NCT00036647|DRUG|Tarceva (erlotinib HCl, OSI-774 )|
224295130|NCT04659551|DRUG|Epirubicin|Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles
224295131|NCT04659551|DRUG|Cyclophosphamide|Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
224295132|NCT04659551|DRUG|Triptorelin|Triptorelin 3.75 mg i.m. every 4 weeks until surgery
224295133|NCT04659551|DRUG|Exemestane|Exemestane 25 mg oral continuous daily dose until surgery
224295134|NCT04659551|DRUG|Nivolumab|Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles
224295135|NCT00469053|DRUG|Buprenorphine|
224295136|NCT05331183|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablets for oral administration.
224295137|NCT05331183|DRUG|IVA|Tablets for oral administration.
224295138|NCT06768580|DRUG|Melatonin|Patients will receive one capsule of melatonin (5mg) orally the night before surgery at 9 pm, the night of the operation, and two nights after the surgical operation at 9 pm, also the patients will receive 10 ml bolus of saline intravenous (IV) over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) until the end of surgery.
224295139|NCT06768580|DRUG|Lidocaine|Patients will receive a bolus (10 ml) of intravenous lidocaine (1mg/kg) diluted with saline over 10 min before induction of anesthesia. Continuous infusion of 1.5 mg/kg/hr of intravenous lidocaine diluted with saline (20 ml/hr) will be administered until the end of the surgery, also will receive placebo capsule the night before surgery at 9 pm, the night of operation and two nights after the surgical operation at 9 pm.
224295140|NCT06768580|DRUG|Placebo|Patients will receive a bolus (10 ml) of saline over 10 min before induction of anesthesia, then continuous infusion of saline (20 ml/hr) and placebo capsule the night before surgery at 9 pm, the night of the operation and two nights after the surgical operation at 9 pm.
223943623|NCT03447912|BEHAVIORAL|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in public indoor and and outdoor spaces.
223943624|NCT00108589|DRUG|S-adenosylmethionine|
223943625|NCT05600439|BEHAVIORAL|CareME|"CareME program was planned to integrate 12 group session (90 minutes), implemented fortnightly during a 6-month period, and facilitated by two psychologists and expert researchers on attachment framework. Components included psychoeducation (description of core concepts such as attachment, secure base, safe haven, emotion regulation, mentalization, trauma, and discussion of research on professional caregiving in YRC); experiential and relational exercises (roleplay; cases discussion, film script discussion).~The program has 7 moduli: (i) adolescents' pain-based behaviors and attachment theoretical lens; (ii) adolescence and main developmental challenges (iii) setting rules and limits; (iv) trust \& secure base (figures and environment); (v) professionals' stories of attachment \& caregiving (vi) personal and structural characteristics that prevent a secure caregiving environment and (vii) professional impairment and strategies promoting healthy secure base provision."
223943626|NCT05271045|DIETARY_SUPPLEMENT|fortified canola oil with vitamins A and D and γ-oryzanol|30 g fortified canola oil with vitamins A and D and γ-oryzanol
223943627|NCT05271045|DIETARY_SUPPLEMENT|Active comparator|30 g fortified canola oil with vitamins A and D
223943628|NCT05271045|DIETARY_SUPPLEMENT|Placebo|30 g fortified sunflower oil with vitamins A and D
223943629|NCT04022421|DRUG|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
223943630|NCT04530370|BIOLOGICAL|recovered covid 19 patients plasma|we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
223943631|NCT03466216|DRUG|AlphaMedix|There is only a single treatment intervention.
223943632|NCT00221065|DEVICE|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
223943633|NCT05804357|BEHAVIORAL|Manual Therapy|Mobilization applications are passive movements that do not involve pushing or stimuli, applied within the range of motion or up to the physiological range of motion
223943634|NCT05804357|BEHAVIORAL|Exercise|It is an approach that is combined with diaphragmatic breathing, activating the passive-active musculoskeletal and neural systems. In this approach, transversus abdominis and multifudus muscles are activated as deep core muscles.
224099833|NCT01309126|DRUG|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
224099834|NCT03176849|DIETARY_SUPPLEMENT|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
224099835|NCT03176849|DIETARY_SUPPLEMENT|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
224099836|NCT02851654|DEVICE|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
224099837|NCT00022932|DRUG|Iodine-131 Anti-B1 Antibody|
223535393|NCT00639951|BIOLOGICAL|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
223943635|NCT01427816|DRUG|KCT-0809|
223943636|NCT01427816|DRUG|KCT-0809|
223943637|NCT01427816|DRUG|Placebo|
223943638|NCT06346652|OTHER|Routine Physical Therapy|Routine physical therapy involving muscle strengthening exercises, range of motion exercises and stretching exercises up to patient's tolerance. Other exercises were pelvic bridging, rolling, sitting and standing exercises, walking practice and balancing in parallel bars, wobble board exercises. Each session was of 60 minutes 5 times weekly for 6 weeks.
223943639|NCT06346652|OTHER|Routine Physical Therapy+ PNF and Core Stregthening|Routine physical therapy for 20 minutes and additionally PNF technique (rhythmic initiation, and then agonistic reversals were performed in lower extremity in D1 flexion pattern and D1 extension pattern up to patient's tolerance and core strengthening for 20 minutes 5 times weekly for 6 weeks.
224099838|NCT03101072|OTHER|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
224099839|NCT03101072|OTHER|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
223535394|NCT04101097|OTHER||
223535395|NCT01808378|DRUG|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
223535396|NCT03015493|OTHER|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
223943640|NCT06055491|DRUG|Vitamin D3 or Saline injection at ipsilateral deltoid muscle|study group: 1.0mL Vitamin D3 injection control group: 1.0mL saline injection
223943641|NCT05193175|BEHAVIORAL|Prolonged sitting|Cross over design, where participants will take part in all three interventions listed above: 1) uninterrupted sitting, 2) sitting interrupted with standing and 3) sitting interrupted with light stepping
223943642|NCT03367416|BEHAVIORAL|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~1. educating executives on how to promote effective process change techniques~2. training staff teams in the theory and practice of organizational change techniques~3. training staff to develop and implement a process improvement intervention~4. implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
223943643|NCT01355809|DRUG|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
223943644|NCT01355809|DRUG|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
223943645|NCT01355809|DRUG|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
223943646|NCT02782000|OTHER|lessons,long-term supervision and message|
223943647|NCT02782000|OTHER|lessons,short-term supervision and message|
223943648|NCT03717207|OTHER|ecg Holter,|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
223943649|NCT03717207|DIAGNOSTIC_TEST|cardiac scintigraphy|all patients before to perform an head up tilt test for syncope evaluation will receive a the 123I-MIBG, which is a norepinephrine analogous, to calculate the late heart-to-mediastinum ratio (H/Mlate) and washout rate (WR). Thus, we evaluated the H/Mlate as the index of global neuronal function due to norepinephrine uptake and the WR as the index of sympathetic tone.
223943650|NCT04263714|BEHAVIORAL|Exercise|Aerobic exercise and resistance exercise
223943651|NCT00074646|DRUG|CC-8490|
223943652|NCT03516877|BEHAVIORAL|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
223943653|NCT05738434|DRUG|Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib|camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
223943654|NCT05738434|DRUG|Camrelizumab+Chemotherapy→Camrelizumab|camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
223943655|NCT02797743|OTHER|Whole blood|"* Adults ≥18 yrs of age: up to 50 mL (5 tubes)~* Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~* Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
223943656|NCT02331485|DEVICE|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
223943657|NCT01124045|DRUG|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
223943658|NCT01124045|DRUG|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
223943659|NCT00729547|BEHAVIORAL|Neurofeedback|enhance relative activity level of left frontal activity
223943660|NCT00729547|BEHAVIORAL|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
223943661|NCT03939416|OTHER|Experimental|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~1. Rhythmic transversal muscle mobilization in posterior chain musculature.~2. General vertebral decompression from the sacrum and pelvis~3. Metameric subcutaneous mobilization~4. Rhythmic vertebral mobilization from the spinous processes."
223943662|NCT03939416|OTHER|Control|"STANDART~1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~2. Sophrology: mental control of insomnia and painful perception~3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
223943663|NCT06029842|OTHER|Collaborative approach of clinical pharmacist with physicians in a medical center|For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
223943664|NCT05298423|BIOLOGICAL|pembrolizumab/vibostolimab|Administered as an intravenous (IV) infusion
223943665|NCT05298423|BIOLOGICAL|durvalumab|Administered as an IV infusion
223943666|NCT05298423|DRUG|cisplatin|Cisplatin 75 mg/m\^2 administered as an IV infusion in combination with pemetrexed on Day 1 of Cycles 1-3 for non-squamous histology only; In combination with etoposide, cisplatin 50 mg/m\^2 is administered on Days 1, 8 of Cycles 1-2 and Days 8, 15 of Cycle 3
223943667|NCT05298423|DRUG|pemetrexed|Pemetrexed 500 mg/m\^2 administered as an IV infusion on Day 1 of Cycles 1-3 for non-squamous histology only
223943668|NCT05298423|DRUG|etoposide|Etoposide 50 mg/m\^2 is administered as an IV infusion on Days 1-5 of Cycles 1-2 and Days 8-12 of Cycle 3;
223943669|NCT05298423|DRUG|carboplatin|Carboplatin area under the curve (AUC) 6 mg/ml/min on Day 1 of Cycle 1 and AUC 2 mg/ml/min on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
223943670|NCT05298423|DRUG|paclitaxel|Paclitaxel 200 mg/m\^2 on Day 1 of Cycle 1 and 45 mg/m\^2 on Days 1, 8, 15 of Cycles 2-3, administered as an IV infusion
223943671|NCT05298423|RADIATION|thoracic radiotherapy|60 Gray \[Gy\] in 2 Gy fractions for 30 days total administered as an external beam radiation
223943672|NCT04289571|DIAGNOSTIC_TEST|VR Mobility Tool|Participant wears VR goggles and interacts with a visual avatar via a control unit to navigate four courses. Derived parameters automatically recorded by the VR system include number and type of collisions, walking speed, task time, and distance walked.
223943673|NCT03177824|DRUG|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
223943674|NCT03177824|DRUG|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
223943675|NCT04122885|COMBINATION_PRODUCT|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
223943676|NCT04122885|PROCEDURE|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
223943677|NCT05618951|OTHER|Lower Trapezius Strengthening Exercises|"Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra"
223943678|NCT05208034|DRUG|Methotrexate|Two-doses of intramuscular methotrexate as 50mg/m2.. One at at day-zero and 2nd at day 7.
223943679|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
223943680|NCT01286064|DEVICE|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
223943681|NCT03220334|DRUG|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
223943682|NCT03220334|DRUG|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
223943683|NCT06375759|PROCEDURE|Subarachnoid-Subarachnoid (S-S) Bypass|"The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation.~After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long."
223943684|NCT06375759|PROCEDURE|Intradural Adhesion Lysis|Intradural spinal cord Adhesion Lysis
223943685|NCT02108171|DRUG|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
223943686|NCT02108171|DRUG|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
224099840|NCT03101072|OTHER|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
224099841|NCT02463942|DRUG|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
224295141|NCT00518882|DRUG|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
223535397|NCT03015493|OTHER|Traction|Traction techniques for the cervical spine
223535398|NCT04032821|DRUG|Alkotinib（300mg)|1\. First empty stomach, after the meal.2. After eating first, after fasting.
223535399|NCT02015247|PROCEDURE|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
223943687|NCT01428206|OTHER|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
223943688|NCT04734600|DEVICE|Electronic Treadmill device|"group A:PN-7001M Panasonic Treadmill 130 kg, frequency 50 HZ, input voltage AC220 V, input power 100W+\_ 10 will usefor aerobic training program ,start by 1pbm grading to 2pbm speed and increase according to patient abilities during sessions ,0% treadmill inclination angle for two month as a total treatment period for study group patients.~Patients in this group will participate in aerobic training as march walking on treadmill for 45 mints duration for session 3 times per week, start with 5 mints warm up beginning and 5 mints cooling down at end session, in addition to their medical program and burger exercises"
223535400|NCT02315222|DIETARY_SUPPLEMENT|Regenium|
223943689|NCT04734600|OTHER|myofascial release technique|"group B:The myofascial release technique group will receive a 45 mints session time, for3 times per week for two months in addition to their medical program and burger exercises. Before the MF will starte, patient will rested in a relaxed prone position for 15 to 30 mints and also after end session time, MF protocol will applied as follow sequence over all period of total treatment sessions (8) week.:~thoracolumbar cross hand facial release technique for at least 5 mints for every barrier depth area, started by one hand will place on high thoracic area with pressure applied cephalic, the other hand was placed directly on the lower lumbo -sacrum area pushing caudal and arms are crossed to maximize as leverage as the barrier sense of softening will occurre and release sense on fascia under hand (release done at transverse alternative with longitudinal direction)alternation same methods to affected leg"
223943690|NCT02616276|OTHER|Control breakfast|It consists of 350 ml of water at room temperature.
223943691|NCT02616276|OTHER|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
223943692|NCT02616276|OTHER|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
223943693|NCT03680638|OTHER|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
223943694|NCT03680638|DRUG|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
223943695|NCT03680638|DRUG|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
223943696|NCT03680638|DRUG|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
223943697|NCT00031941|DRUG|lenalidomide|
223943698|NCT00843050|DRUG|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
223943699|NCT03205566|DRUG|Raltegravir 400Mg Tab|bd for 7 days
223943700|NCT03205566|DRUG|Lamivudine 150Mg Tablet|\+ Raltegravir 400Mg tablet bd for 7 days
223943701|NCT05623033|OTHER|The study is an observational study without intervention|The study is an observational study without intervention
223943702|NCT01744808|DRUG|EB-1020 IR|Immediate release
223943703|NCT01744808|DRUG|EB-1020 SR1|sustained release
223943704|NCT01744808|DRUG|EB-1020 SR2|Sustained release
223943705|NCT01744808|DRUG|EB-1020 SR3|Sustained release
223943706|NCT01744808|OTHER|Placebo|Placebo formulation
223943707|NCT02973594|DRUG|Ivabradine|
223535401|NCT02315222|DIETARY_SUPPLEMENT|Placebo|
223535402|NCT02315222|PROCEDURE|Full Mouth Disinfection|
223943708|NCT02973594|DRUG|Placebo|
223943709|NCT05340231|DRUG|TACE protocol|"Transarterial infusion chemotherapy: Oxaliplatin(85mg/m\^2)+Raltitrexed(3mg) Chemoembolization: Lipiodol emulsion (lipiodol 10ml+ Oxaliplatin 85mg +Lidocaine 1ml)，The endpoint for embolization was defined as stagnation of blood flow of the posterior mesenteric artery.~Intervention cycle：4W; Treatment times: 2. followed by mFOLFOX6"
223943710|NCT05340231|DRUG|Neoadjuvant Chemotherapy|mFOLFOX6, Q2W
223943711|NCT04378894|BEHAVIORAL|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
223943712|NCT04701372|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.
223943713|NCT02328144|DRUG|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
223943714|NCT02328144|DRUG|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
223943715|NCT06014372|DRUG|Envafolimab|Upon confirming eligibility based on inclusion criteria and obtaining signed informed consent, the patient will be administered Envafolimab at a dose of 300mg every 3 weeks (Q3W) for a total of 4 cycles, starting on Day 1.
223943716|NCT06014372|DRUG|CAPEOX|The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and Capecitabine at a dose of 1000mg/m2, orally, twice daily from Day 1 to Day 14, every 3 weeks, for a total of 4 cycles.
223535403|NCT05365100|DRUG|BN102|oral tablets: BN102, BID
223535404|NCT05790447|DRUG|Thymalfasin|loading dose with thymalfasin based on the amounts of T lymphocyte
223535405|NCT05790447|RADIATION|Radiotherapy|hypofractionated radiotherapy/SBRT
224295142|NCT00518882|DRUG|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
224295143|NCT01295086|DRUG|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
223535406|NCT05790447|DRUG|PD-1/PD-L1 inhibitor|The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
223943717|NCT04559074|DRUG|Amlodipine|Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry; starting dose equivalent to current dose for patients on amlodipine at entry or at next 1-2mg dose step (according to clinical need based on the Investigator's judgement). Investigation of whether gradually increasing the dose of liquid amlodipine (can be an add-on to existing amlodipine tablets) in small increments (e.g. 1-2mg) will enable blood pressure control within the sequence 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg to a maximum of 10mg amlodipine per day.
223943718|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|2 capsules - 200 mg total CoQ10
223943719|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP1)|2 softgels - 200 mg total CoQ10
223943720|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP2)|2 softgels - 200 mg total CoQ10
223943721|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP3)|2 softgels - 200 mg total CoQ10
223943722|NCT04780074|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP4)|2 capsules - 200 mg total CoQ10
223943723|NCT00836498|BIOLOGICAL|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
223943724|NCT00836498|BIOLOGICAL|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
223943725|NCT00836498|BIOLOGICAL|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
223943726|NCT02082652|DRUG|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
223943727|NCT02821299|OTHER|Laryngeal transplantation|Laryngeal transplantation
223943728|NCT02923479|DEVICE|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
223943729|NCT02923479|OTHER|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
223943730|NCT02923479|OTHER|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
223943731|NCT02923479|DEVICE|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
223943732|NCT02923479|DEVICE|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
223943733|NCT00255372|DRUG|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
223943734|NCT00255372|DRUG|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
223943735|NCT02944123|DRUG|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
223943736|NCT02944123|DRUG|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
223943737|NCT02944123|DRUG|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
223943738|NCT04624139|BEHAVIORAL|Internet-based cognitive behavioral therapy + physiotherapy|"Combined intervention of stress reducing I-CBT and physiotherapy. The intervention consists of two components; I-CBT and physiotherapy aiming to reduce symptoms of stress.~I-CBT: Designed to reduce stress, during 8 weeks. Physiotherapy: A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
223943739|NCT04624139|BEHAVIORAL|Physiotherapy only|"A total of three visits with a physiotherapist (at start, after 4 weeks and after 12 weeks). Visit 1 (at start): The participant and the physiotherapist design together an individual plan of physical activity, based on the recommendations for stress as suggested in the Physical Activity in the Prevention and Treatment of Disease (FYSS in Swedish): Physical activity on moderate intensity 150 min/week and a strengthening exercise program performed at twice a week.~The physical activity is performed outside health care - in the participant´s home or in other exercise premises outside health care Visit 2 and 3 (after 4 and 12 weeks): Follow up and revision of the Physical activity plan."
223943740|NCT03418545|DEVICE|JUVÉDERM VOLBELLA® XC injectable gel|JUVÉDERM® VOLBELLA™ XC dermal filler injected into the infraorbital and adjacent area.
223943741|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
223943742|NCT01630668|DIETARY_SUPPLEMENT|One-a-Day placebo capsule|Once per day, 12 weeks
223943743|NCT03333824|DRUG|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
224295144|NCT01295086|DRUG|Oxaliplatin|100 mg/m² day 1 every 3. week
223943744|NCT03333824|DRUG|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
223943745|NCT03333824|DRUG|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
223943746|NCT03333824|DRUG|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
223943747|NCT03333824|DRUG|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
223943748|NCT05486494|OTHER|Treatment (non- surgical/surgical)|Treatment Outcome based on different aspects
223943749|NCT01824849|PROCEDURE|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
223943750|NCT01824849|PROCEDURE|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
223943751|NCT01953679|DRUG|Ulipristal Acetate|
223943752|NCT00003654|DRUG|patent blue V dye|
223943753|NCT00003654|PROCEDURE|lymphangiography|
223943754|NCT00003654|PROCEDURE|radionuclide imaging|
223943755|NCT00003654|PROCEDURE|sentinel lymph node biopsy|
223943756|NCT00003654|RADIATION|technetium Tc 99m sulfur colloid|
223943757|NCT03672032|DEVICE|Fork-tip Needle|Fork-tip Needle will be used to obtain biopsy
223943758|NCT03672032|DEVICE|Franseen Needle|Franseen Needle will be used to obtain biopsy
223943759|NCT04440540|BEHAVIORAL|Dietitian led life style modification intervention|lifestyle changes supervised by dietitians
223943760|NCT04440540|BEHAVIORAL|Conventional care (control)|receive routine care
223943761|NCT02134626|DRUG|Simvastatin|40mg / pill, one pill orally once a day for three months
223943762|NCT02134626|DRUG|Placebo pill|
223943763|NCT01080404|PROCEDURE|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
223943764|NCT01080404|DEVICE|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
223943765|NCT06285812|DEVICE|OtoSight Middle Ear Scope|Subjects will be evaluated with the OtoSight Middle Ear Scope
223943766|NCT03170050|DEVICE|YYD701-2|HA Filler
223943767|NCT03170050|DEVICE|Restylane Perlane Lidocaine|HA Filler
223943768|NCT00462072|DRUG|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
223943769|NCT05199506|DEVICE|RAP|Treatment of cellulite with RAP device
223943770|NCT05847452|DRUG|Benralizumab|30mcg ever month for 3 months
223943771|NCT04190485|OTHER|Placebo|Subjects will be randomized to one of two groups, using placebo toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite treatment for 4 weeks.
223943772|NCT04190485|OTHER|GMNL-143 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-143 probiotic toothpastes toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
223943773|NCT04190485|OTHER|GMNL-464 Probiotic Toothpastes|Subjects will be randomized to one of two groups, using GMNL-464 probiotic toothpastes for 4 weeks, and then will enter a 1 week-washout and afterward will be crossed over to the opposite placebo for 4 weeks.
223943774|NCT02384382|DRUG|Enzalutamide|
223943775|NCT05036434|DRUG|Pembrolizumab / Lenvatinib|Pembrolizumab Plus Lenvatinib administration.
223943776|NCT03695549|PROCEDURE|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
223943777|NCT03695549|PROCEDURE|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
223943778|NCT04284085|OTHER|Psychoeducational intervention|Psycho-educational groups of 10 to 12 people, led by two professionals, one of them will always be a psychologist and an educator. In some sessions, other collaborators will be invited to participate, such as psychiatrists, educators, social workers, etc. who may act as external observers or implement the session. The number of sessions will be 13, one or two sessions a week and duration of 90 minutes.
223943779|NCT03338166|OTHER|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
223943780|NCT00630500|DRUG|Memantine|Tablets, 5 or 10 mg, twice daily
223943781|NCT00630500|DRUG|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
223943782|NCT06263673|DRUG|Sitagliptin|100 mg once daily, oral
223943783|NCT06263673|DRUG|Dapagliflozin|10 mg once daily, oral
223943784|NCT06263673|DRUG|Placebo|Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
223943785|NCT00407888|DRUG|doxorubicin hydrochloride|Given IV
223943786|NCT00407888|DRUG|cyclophosphamide|Given orally
223943787|NCT00407888|BIOLOGICAL|filgrastim|Given SC
223943788|NCT00407888|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223943789|NCT00407888|BIOLOGICAL|trastuzumab|Given IV
223943790|NCT00407888|OTHER|laboratory biomarker analysis|Correlative studies
223943791|NCT00407888|PROCEDURE|quality-of-life assessment|Ancillary studies
223943792|NCT03187548|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
223943793|NCT04970732|PROCEDURE|Gum chewing|The patients in the experimental group returned to the ward for general anesthesia, started to wake up for 2 hours, chewed xylitol gum, and the professional nurses distributed it on time every 2 hours on the operation day, then 3 times / day, 15-20 minutes / time, 2 tablets / time. Body position: lateral position. The first anal exhaust stop chewing, normal sleep at night (8 p.m.), do not chew gum. Gum waste must be identified
223943794|NCT05654285|OTHER|Cola beverage with aspartame and acesulfame K|"Before starting the study: Subjects were asked to avoid non-nutritive sweetener consumption for 48 hours prior to the study sessions. A standardized menu of 346 Kcal was prescribed for dinner and fasting for at least 8 hours prior to each study session. A 7-day washout period was left between each study session.~Session 1: Weight, height, and waist circumference were measured, the BMI was calculated, and sociodemographic data of the participants and information on the habitual consumption of soft drinks were collected.~In each session: The beverages were offered at approximately 4°C, in standardized disposable cups, and the participants were asked to drink them in a maximum time of 10 minutes. Heart rate, respiratory rate, and blood pressure were measured before the intervention and every 30 minutes during the observation period. The subjects who manifested adverse sensations were referred to receive medical attention and withdrawn from the session."
223943795|NCT05654285|OTHER|Cola beverage with sucrose and stevia|
223943796|NCT00861991|BEHAVIORAL|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
223943797|NCT04353856|OTHER|quality of life assessment|quality of life assessment using the EQ5D questionnaire once a month
223943798|NCT01098409|DRUG|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
223943799|NCT01098409|DRUG|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
223943800|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
223943801|NCT00070642|DRUG|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
223943802|NCT00070642|DRUG|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
223943803|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
223943804|NCT00070642|DRUG|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
223943805|NCT03784898|OTHER|Blood draw for future biomarker analysis|Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
223943806|NCT02320097|OTHER|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
223943807|NCT01198314|PROCEDURE|immunosuppression withdrawal|tapering off immunosuppressant
223943808|NCT01198314|PROCEDURE|continue of taking immunosuppressant|maintain immunosuppression
223943809|NCT04870788|BEHAVIORAL|Mindfulness Relaxation|Participate in mindfulness program
223943810|NCT04870788|OTHER|Quality-of-Life Assessment|Ancillary studies
223943811|NCT04870788|OTHER|Questionnaire Administration|Ancillary studies
223943812|NCT04870788|OTHER|Group II (mindfulness waitlist)|Patients and their partners participate in mindfulness program together or separately, depending on their preference, as in Group I beginning 12 weeks after starting the study and completing the third study visit.
223943813|NCT01263522|OTHER|different training programs|two different endurance programs and one strength endurance program
223943814|NCT01263522|OTHER|control condition|unchanged lifestyle
223943815|NCT01031056|PROCEDURE|Blood Draw|
224099842|NCT02463942|DRUG|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
223729410|NCT02338414|DRUG|Romiplostim|Subcutaneous Romiplostim (weekly injection) -\> if titrated with maintaining PLT count between 50-200 x 10\^9/L -\> Subcutaneous Romiplostim (biweekly injection)
223535407|NCT05790447|DRUG|GM-CSF|subcutaneous injection daily for 7 consecutive days
223943816|NCT01031056|PROCEDURE|Frozen Tumor Specimens|
223943817|NCT06425289|OTHER|Macrohemodynamic parameters|"Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)"
223943818|NCT01784744|OTHER|Hydroworx Pool at 98 degrees Fahrenheit|
223943819|NCT01784744|OTHER|Hydroworx Pool at 102 degrees Fahrenheit|
223943820|NCT03475264|DIAGNOSTIC_TEST|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
224099843|NCT02463942|OTHER|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
224295145|NCT01295086|DRUG|Capecitabine|1250 mg/² continuously
224295146|NCT01295086|DRUG|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
224295147|NCT03395639|DRUG|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to \<18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
224295148|NCT03395639|DRUG|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
223943821|NCT04826211|DIAGNOSTIC_TEST|PET/MRI|All included patients will undergo PET/MRI both prior to PST and prior to surgery. In order to analyze results the population will be divided into two groups: women with positive axillary lymph nodes after PST (Group 1) and women with negative axillary lymph nodes after PST (Group 2).
223943822|NCT04527874|BEHAVIORAL|VITAL model|"The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening."
223943823|NCT06218745|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
223943824|NCT04180683|OTHER|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
223943825|NCT04180683|OTHER|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
223943826|NCT00951132|DRUG|rosuvastatin|10mg tablets, once daily in three months
223943827|NCT00951132|DRUG|Placebo|tablet, once daily, three months
223943828|NCT02035046|PROCEDURE|Samplings of blood|
223943829|NCT02035046|PROCEDURE|Sampling of urine|
223943830|NCT02035046|PROCEDURE|Measure of the blood pressure|
223943831|NCT02035046|PROCEDURE|glycemia test|
223943832|NCT03700554|DEVICE|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
223943833|NCT03700554|PROCEDURE|Chest tube|Chest tube insertion
223943834|NCT02520219|DRUG|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
223943835|NCT02520219|BIOLOGICAL|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
223943836|NCT02161354|DRUG|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
223943837|NCT02161354|DRUG|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
223943838|NCT02161354|DRUG|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
223943839|NCT03665532|BEHAVIORAL|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
223943840|NCT04352517|OTHER|Online Survey|Online survey completion through google app.
223943841|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
223943842|NCT00361907|PROCEDURE|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
223943843|NCT00361907|PROCEDURE|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
223943844|NCT01989793|DRUG|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
223943845|NCT01989793|DRUG|Placebo|Placebo will be given to those in placebo arm
223943846|NCT06090513|COMBINATION_PRODUCT|Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation|TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)
223535408|NCT05874089|DIETARY_SUPPLEMENT|VSL#3®|VSL#3® 450 billions/sachets
223535409|NCT05874089|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
223535410|NCT04937725|DIAGNOSTIC_TEST|eye tracking|Eye tracker will be used to evaluate study parameters
223535411|NCT03528317|OTHER|Alternate day fasting|Alternate day fasting with a high protein diet
223729411|NCT02034279|DRUG|Albumin|Intravenous infusion of 20% albumin
223943847|NCT06090513|DIAGNOSTIC_TEST|limited genetic testing or no testing|Minimal genetic testing for eligible patients or treatment without testing
223943848|NCT00035100|DRUG|epothilone b|
223943849|NCT00817154|BEHAVIORAL|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
223943850|NCT05422846|OTHER|standard treatment|The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
223943851|NCT05422846|OTHER|aerobic exercise|The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
223943852|NCT05422846|OTHER|exercise protocol|The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
223943853|NCT00973505|DRUG|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
223943854|NCT00332319|DRUG|GW679769|
223943855|NCT01291212|DRUG|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
223943856|NCT01291212|DRUG|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
223943857|NCT03232398|DRUG|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
223943858|NCT03232398|DRUG|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
223943859|NCT05313412|DEVICE|Lens A (comfilcon A lens)|6 hours
223943860|NCT05313412|DEVICE|Lens B (lehfilcon A lens)|6 hours
223943861|NCT01253213|DRUG|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
223943862|NCT03567616|DRUG|Venetoclax|Tablet; oral
223943863|NCT03567616|DRUG|Pomalidomide|Capsule; oral
223943864|NCT03567616|DRUG|Dexamethasone|Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
223943865|NCT03141918|DIETARY_SUPPLEMENT|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
223943866|NCT03141918|OTHER|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
223943867|NCT00109031|DRUG|palifermin|Administered as one daily intravenous bolus.
223943868|NCT00109031|RADIATION|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
223943869|NCT00109031|DRUG|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
223943870|NCT00109031|DRUG|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
223943871|NCT00109031|DRUG|Placebo|Administered as one daily intravenous bolus.
223943872|NCT02426229|DRUG|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
223943873|NCT05966012|DRUG|Tranexamic acid|Recent data suggests that antifibrinolytics like tranexamic acid (TXA) might be able to lessen the inflammation of the nervous system caused by surgery and CPB through the inhibition of plasmin production, thereby stabilising the blood brain barrier.
223943874|NCT04613713|OTHER|Somatocognitive physiotherapy|"The main intervention areas include:~1. education about the PVD, healthy vulvo-vaginal and sexual behaviors, nature of chronic pain and factors influencing pain intensity~2. bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension and respiration pattern in different situations~3. techniques to cope with emotions and thoughts related to bodily experiences and to PVD~4. structured homework assignments promoting application of the learned techniques in daily situations and gradual exposure of the patient to activities associated with pain.~Participants will be offered maximally 15 treatment sessions. No minimal number of sessions is set. Treatment will be conducted by female physiotherapists experienced in treating long-standing pain conditions."
223943875|NCT04613713|OTHER|Treatment as usual|The participants will follow the current treatment advice as recommended by the Vulva Clinic at OUH, a tertiary health care center specialized in treatment of vulvar disorders. Advice include guidance about the management of PVD as a condition, use of medication, physiotherapy, sexologist and psychological counseling, usage of internet resources (vulva.no) and others. Participants will be free to pursue treatment options of their choice. The type of treatment, number of treatments and medication usage will be monitored by bi-weekly electronic forms during the whole study period.
223943876|NCT06028308|DEVICE|Smartphone playing a sound|A sound will be played from a portable device (smartphone mounted with earphones) during movement
223943877|NCT03972046|DRUG|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
223943878|NCT03972046|DRUG|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
223943879|NCT03972046|DRUG|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
223943880|NCT00894894|DRUG|MP-470|escalating daily doses of amuvatinib
223943881|NCT00894894|DRUG|amuvatinib (MP-470)|escalating doses of daily amuvatinib
223943882|NCT01006538|DEVICE|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
223943883|NCT01006538|DRUG|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
223943884|NCT03777566|DIAGNOSTIC_TEST|sonohysterography|sonohysterography with measuring the uterine cavity volume
223943885|NCT06452069|OTHER|IMMUNO19|"280 participants will be divided into 2 groups. There will be 140 participants in the groups.~The 1st group will receive IMMUNO19 10 mL one time, The 2nd group will receive Placebo 10 mL for one time."
223943886|NCT06218758|OTHER|General anesthesia|General anesthesia using 2% propofol, and remifentanil for lung transplantation
223943887|NCT05075421|PROCEDURE|Gastrectomy|Any type of gastrectomy for gastric cancer
223943888|NCT04070963|OTHER|HbA1C|To take additional blood test of HbA1C once patient consented to the study
223943889|NCT00562614|DRUG|SLx-2101|
223943890|NCT01203943|DRUG|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
223943891|NCT01203943|OTHER|Placebo|Placebo
223943892|NCT01203943|DRUG|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
223943893|NCT01203943|DRUG|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
223943894|NCT02139813|PROCEDURE|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~* a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~* a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~* an Omega loop of 200 cm~* a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
224099844|NCT02455115|OTHER|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
223943895|NCT02139813|PROCEDURE|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
223943896|NCT00004805|BEHAVIORAL|CPR instruction|
223943897|NCT04547764|DRUG|triple antibiotic paste (TAP)|root canal treatment of pulpally involved teeth.
223943898|NCT04547764|DRUG|Vitapex (calcium hydroxide/iodoform paste)|root canal treatment of pulpally involved teeth.
223943899|NCT04897633|DEVICE|transcranial electric stimulation|Simon's task assessment when under tDCS
223943900|NCT03110536|DIAGNOSTIC_TEST|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
223943901|NCT03110536|OTHER|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
223943902|NCT02233998|OTHER|Mouth Rinse 1|
223943903|NCT02233998|OTHER|Mouth Rinse 2|
223943904|NCT02233998|OTHER|Mouth Rinse 3|
223943905|NCT01957163|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
223943906|NCT01957163|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
223943907|NCT01957163|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
223943908|NCT01957163|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
223943909|NCT02498145|OTHER|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
223943910|NCT02498145|OTHER|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
223943911|NCT01307254|PROCEDURE|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
223943912|NCT01982994|BEHAVIORAL|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
223943913|NCT01920126|DRUG|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
224099845|NCT02455115|DRUG|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
224099846|NCT02455115|DRUG|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
224099847|NCT03783156|PROCEDURE|hot snare|polypectomy with hot snare
224099848|NCT03783156|PROCEDURE|cold snare|polypectomy with cold snare
223943914|NCT01920126|DRUG|Saline|
223943915|NCT03776760|DEVICE|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
223943916|NCT03776760|DRUG|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
223943917|NCT03776760|DRUG|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
223943918|NCT06428656|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule of postbiotics supplement per day
223943919|NCT06428656|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule of placebo per day
223943920|NCT02131922|PROCEDURE|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
223943921|NCT02131922|PROCEDURE|Dental Hygienization Treatment|
223943922|NCT02131922|DRUG|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
223943923|NCT05014607|BIOLOGICAL|Personalized multi-peptide vaccine|"Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 1-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.~Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.~Treatment schedule:~Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses."
223943924|NCT01939509|DRUG|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
223943925|NCT01939509|DRUG|Bisoprolol|
223943926|NCT03735381|DEVICE|Pedometer watch 'Xiomi mi band2'|"1. They receive information on the use of the pedometer.~2. Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~3. Prescription of benefits of walking in pregnancy:~   * Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~  * Receive information on the adequacy of walking with moderate intensity.~4. They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
223943927|NCT03011047|PROCEDURE|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
223943928|NCT03011047|PROCEDURE|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
223943929|NCT04675268|DIAGNOSTIC_TEST|oximetry|A CE medical approved polygraphy device (Dreamscan 2 - Medatec) will be used to obtain oximetry (and PPG) data
223943930|NCT00953355|DRUG|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
223943931|NCT00953355|DRUG|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
223943932|NCT01065779|DRUG|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
223943933|NCT01065779|DRUG|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
223943934|NCT06317623|DIAGNOSTIC_TEST|Prenatal and postnatal ultrasound examination|Prenatal ultrasound examination of fetus with urinary tract dilation in second trimester and next in third trimester and when the dilation is persist, the child is managed after birth by pediatric nephrologist.
223943935|NCT04816006|BEHAVIORAL|Aerobic Exercise Training|Breast cancer survivors in the intervention group will participate in a 24-week moderate intensity exercise program led by community-based fitness center personal trainers. Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Treadmill walking is the primary mode of exercise. However, participants will be permitted to use other cardiovascular equipment (e.g., elliptical machines, stationary bicycles) as prescribed by their exercise trainer. The trainer will supervise three weekly exercise sessions in Weeks 1-2, two in Weeks 3-4, one in Weeks 5-8, biweekly across weeks 9-16, and monthly in Weeks 17-24 (N=20 supervised sessions).
223943936|NCT04816006|OTHER|Health Education (Active comparator)|Breast cancer survivors in the Health Education group will participate in education sessions with a health educator and receive monthly newsletters/webinars (N=20 total contacts) across 24 weeks. The program will include cancer support and discussion of cancer-related wellness topics (e.g., stress management, coping). Control group participants will be offered a 6-month fitness center membership upon study completion.
223943937|NCT06453590|PROCEDURE|Randomization to uncovered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
223943938|NCT06453590|PROCEDURE|Randomization to partially covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
223943939|NCT06453590|PROCEDURE|Randomization to fully covered SEMS treating jaundice due to distal malignant biliary obstruction.|Patients with jaundice due to distal malignant biliary obstruction in whom surgical resection is not possible are treated at ERCP with metal stents, SEMS. The study is comparing three types of commercially available SEMS, Patients are randomized and allocated to either of three stent types (SEMS), uncovered, partially covered , or fully covered.
223943940|NCT03055559|DIETARY_SUPPLEMENT|Globifer Forte|
223943941|NCT01012063|DRUG|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
223943942|NCT01012063|DRUG|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
223943943|NCT03543631|OTHER|Survey|Online survey
224099849|NCT01672892|RADIATION|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
223943944|NCT03559959|BEHAVIORAL|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
223943945|NCT02093169|DRUG|Part A: Lu AF35700|One 30 mg single dose for one day; orally
223943946|NCT02093169|DRUG|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
223943947|NCT02630966|DRUG|Vedolizumab|Vedolizumab 300 mg IV infusion
223943948|NCT02630966|DRUG|Placebo|0.9% sodium chloride IV infusion
223943949|NCT03590899|DEVICE|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
223943950|NCT01334840|DIETARY_SUPPLEMENT|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
223943951|NCT01334840|DIETARY_SUPPLEMENT|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
223943952|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
223943953|NCT00641537|DRUG|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
223943954|NCT00641537|DRUG|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
223943955|NCT00641537|DRUG|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
223943956|NCT00641537|DRUG|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
223729412|NCT00951990|BEHAVIORAL|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
223729413|NCT00951990|BEHAVIORAL|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
223943957|NCT02704416|PROCEDURE|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
223943958|NCT04486703|OTHER|Exercise with music|physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
223943959|NCT01801007|DEVICE|Flow Re-Direction Endoluminal Device (FRED)|
223943960|NCT03298295|DEVICE|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
223943961|NCT05027633|DRUG|Pembrolizumab|given by IV
223943962|NCT05027633|DRUG|Docetaxel|given by IV
223943963|NCT05027633|DRUG|Cisplatin|given by IV
223943964|NCT05027633|DRUG|Carboplatin|given by IV
223943965|NCT00665392|DRUG|cisplatin|75 mg/m², day 1. 3 cycles
223943966|NCT00665392|DRUG|docetaxel|75 mg/m² Day 1. 3 cycles
223943967|NCT00665392|DRUG|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
223943968|NCT00665392|DRUG|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
223943969|NCT02024854|BEHAVIORAL|skin-to-skin|
223943970|NCT02024854|BEHAVIORAL|standard care|
223943971|NCT03431129|DIAGNOSTIC_TEST|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
223943972|NCT06041386|DRUG|Mepolizumab|Mepolizumab will be prescribed based on physician decision.
223943973|NCT06041386|OTHER|Spirometry|Lung function via spirometry will be collected.
223535412|NCT04601129|PROCEDURE|enhanced recovery after surgery program|practice of an enhanced recovery after surgery program, according to the international reviews of literature and national recommendation
223943974|NCT06524648|DIAGNOSTIC_TEST|niPGT-A|"Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.~Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).~Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active."
223943975|NCT02159716|BIOLOGICAL|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
223943976|NCT06566690|DEVICE|Addition of ORi monitoring to SpO2 monitoring|Integration of Oxygen Reserve Index (ORi) monitoring into standard SpO2 monitoring
223943977|NCT02798341|OTHER|Biospecimen Collection|
223943978|NCT05843552|OTHER|no intervention|no intervention, this is an observational study
223943979|NCT06040294|OTHER|DDS program|dementia virtual reality and disability simulation of activity design for seniors
223943980|NCT06040294|OTHER|dementia course with no DDS|Regular dementia course and group discussions of activity design for seniors with no DDS
223943981|NCT06461286|DRUG|PYC-001|Single Group Assignment
223943982|NCT05508464|RADIATION|Arm 2: SABR|SABR to all tumors 6 Gy x 5 over three weeks
223943983|NCT05508464|RADIATION|Arm 1: Standard of Care|Standard of care palliative radiotherapy
223943984|NCT05643430|DEVICE|BioFreedom Ultra|The BioFreedom Ultra CoCr DCS is a combination product consisting of two key components: the cobalt chromium stent platform coated abluminally with the active ingredient BA9TM (polymer and carrier free) and the delivery system.
223943985|NCT03742414|COMBINATION_PRODUCT|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
223943986|NCT03742414|COMBINATION_PRODUCT|Fluticasone propionate Cream 0.05%|Proactive use of fluticasone proprionate cream for inflammation of the skin, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
223943987|NCT03742414|OTHER|Standard of Care|Participants' eczema will be managed by their primary physician, i.e. standard of care with routine reactive topical products for atopic dermatitis flares.
223943988|NCT06463340|DRUG|SGR-3515|SGR-3515 will be administered orally with an intermittent schedule.
223943989|NCT06501001|BEHAVIORAL|High-Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 45 minutes. The intervention period will be sixteen weeks.
223943990|NCT06501001|BEHAVIORAL|Experimental: Time-Restricted Eating|Restricted daily window of caloric intake to a maximum 10 hours. The intervention period will be sixteen weeks.
223943991|NCT06335173|DRUG|sabirnetug|Intravenous sabirnetug
223943992|NCT06335173|DRUG|Placebo|Intravenous Placebo
223943993|NCT05699174|DRUG|Standard of Care PO (oral) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to PO (oral) antibiotics for up to 6 weeks post hospitalization. The exact type of oral antibiotic will be depended on the patient's infection diagnosis.
223943994|NCT05699174|DRUG|Standard of Care Intravenous (IV) antibiotics|An intervention in this study includes randomization of patients with an infected nonunion to intravenous (IV) antibiotics for up to 6 weeks post hospitalization. The exact type of IV antibiotic will be depended on the patient's infection diagnosis.
223943995|NCT04111510|DRUG|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
223943996|NCT04810546|DIETARY_SUPPLEMENT|Jarrow Formulas Oral Bovine Lactoferrin Supplement|Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
223943997|NCT05525455|DRUG|TT-816|TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors
223943998|NCT05525455|DRUG|A PD-1 inhibitor|Programmed death receptor-1 (PD 1)-blocking antibody
223943999|NCT06143709|OTHER|DNA sample collection|Patients will be asked to provide a blood or mouth wash sample for DNA extraction
223944000|NCT02422524|DRUG|PA-824|Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
223944001|NCT01321073|DEVICE|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
224099850|NCT01672892|RADIATION|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
223729414|NCT02560584|DRUG|Hexaminolevulinate hydrochloride|Instillation in bladder
223944002|NCT05594524|BEHAVIORAL|Body Confident Athletes|The Body Confident Athletes program is a three-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10-20 girls. The sports organizations will work with the community partner and researchers on how to schedule the intervention over a three-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sports organization. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Knowledge (20 mins), The Skills (20 mins), and The Final Score (15 mins). A variety of activity modalities will be utilized to convey learning outcomes, including group and individual activities and discussion-, writing-, and movement-based activities.
223944003|NCT03395080|DRUG|Paclitaxel|Administered by IV infusion
223944004|NCT03395080|DRUG|300mg DKN-01|Administered by IV infusion
223944005|NCT03395080|DRUG|600mg DKN-01|Administered by IV infusion
223944006|NCT05206942|DIAGNOSTIC_TEST|Doppler ultrasound|Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
223944007|NCT05206942|DIAGNOSTIC_TEST|Long Ensemble Angular-coherence Doppler [LEAD] ultrasound|Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
223944008|NCT05206942|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound (CEUS)|Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
223944009|NCT04799301|BEHAVIORAL|Diet with no soda|Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
223944010|NCT04799301|BEHAVIORAL|Diet with 50% of carb intake from soda|Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
223944011|NCT04799301|BEHAVIORAL|Diet with 20% of carb intake from soda|Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
223944012|NCT05824871|DRUG|Sudapyridine|Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.
223944013|NCT05824871|DRUG|Bedaquiline|Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
223944014|NCT03901807|DEVICE|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
223944015|NCT06097091|OTHER|Self-management education|A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).
223944016|NCT06097091|BEHAVIORAL|pain neuroscience education|"Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content."
223944017|NCT05958017|BEHAVIORAL|reSET|Participants in this group will use a mobile application that delivers treatment for substance use disorder. 31 required and 30 optional modules. Among many topics covered in the modules, some are substance use management, communication, emotion management, relationship skills, HIV/Sexually Transmitted Infections and triggers for risky sex. In the reSET app you will get the chance to earn rewards for two activities: (1) completing a module and (2) providing a negative urine drug screen in exchange for a motivational or monetary prize. You will have 12 weeks to complete as many modules as you like, about 4 modules per week. Each module takes approximately 10-15 min. Every 3-4 days you will meet with the same study team member to provide a urine drug screen from a place comfortable for you (e.g. home) which will be observed and read via Zoom.
223944018|NCT05958017|OTHER|Standard of care|Participants in this group will receive assistance connecting to an in person community-based outpatient treatment program.
223944019|NCT06579092|DRUG|AZD5004|AZD5004 film-coated tablet once daily during 36 weeks
223535413|NCT02764411|DRUG|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
223535414|NCT00905229|DRUG|Phytonadione|2.5 mg po
223729415|NCT02560584|DEVICE|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
223944020|NCT06579092|DRUG|Placebo|Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
223944021|NCT03099356|DRUG|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
223944022|NCT03099356|DRUG|Sirolimus|Sirolimus 4 mg, PO, days 1-28
223944023|NCT05352230|DEVICE|Free style libre-2|A cross-over design will allow estimation of feasibility and acceptability of patients using CGM vs patients using blood glucose meter monitoring (conventional therapy). The study will consist on two phases, the first will last three months, then it will be a two months of washout period followed by the crossover, then the second phase will last another three months. Patients in the conventional therapy group will also use masked CGM (CGM professional) during the first two and last two weeks of their study phase with the purpose of collecting CGM-parameters information. The cross over randomization will be stratified by donor type (live vs deceased) using a web-based randomization tool. During the washout period the patients will continue using blood glucose meter monitoring
223944024|NCT03991234|BEHAVIORAL|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, \& contextualized reading.
223944025|NCT03991234|BEHAVIORAL|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge \& counting strategies to build arithmetic skill.
223944026|NCT03991234|BEHAVIORAL|Coordinated Intervention|Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm \& similar objectives as the math intervention arm.
223944027|NCT03396107|DRUG|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
223944028|NCT03396107|DRUG|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
223944029|NCT05683990|DRUG|Diamyd|4 μg (0.1 mL) of Diamyd administered 1 month apart.
223944030|NCT02010957|OTHER|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
223944031|NCT02010957|OTHER|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
223944032|NCT03697603|DRUG|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
223944033|NCT03697603|DRUG|Placebo|Tablets, Oral, once daily, 14 weeks
223944034|NCT00828126|PROCEDURE|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
223944035|NCT06971861|BEHAVIORAL|Acceptance and Commitment Therapy|The current program is based on ACT and consists of four one-hour sessions covering the six core components of psychological flexibility. The four sessions respectively focus on Cognitive Defusion, Being Present and Acceptance, Self-as-Context and Values, and Committed Action. All sessions involve experiential learning activities and reflective discussions. Each participant also receives a workbook to facilitate post-session home practice.
223944036|NCT06965348|DEVICE|Application of kinesio tape|"The facilitating taping technique for the quadriceps and hamstring muscle group described by Kase et al. will be applied to the kinesio tape group. The tape will be applied from the muscle origin to the insertion (proximal to distal) for facilitation.~The application for the hamstring muscle group will be applied from the proximal to the distal of the muscle up to the lateral and medial heads of the gastrocnemius muscle. The tape will be applied to the quadriceps muscle from the proximal to the distal of the muscle, ending on the undersurface of the patella.~The physiotherapist places the tape base without tension in the first 5 centimeters of the starting point of the hamstring muscles and quadriceps muscle. Light to moderate tension (25-50%) is applied for facilitation. The tail parts of the tape are placed on the skin without tension at a distance of 2 to 5."
223944037|NCT06965348|OTHER|Placebo Group|The application for the hamstring muscle group will be applied from the proximal to the distal of the muscle up to the lateral and medial heads of the gastrocnemius muscle. The tape will also be applied to the quadriceps muscle from the proximal to the distal of the muscle, ending at the lower surface of the patella.The placebo group will have tape applied to the quadriceps and hamstring muscle groups without any tension.
223944038|NCT03749187|DRUG|PARP Inhibitor BGB-290|Given PO
223535415|NCT00905229|DRUG|Phytonadione|0.5 mg IV
223535416|NCT06306001|DRUG|Methylene Blue|Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
223729416|NCT03249766|OTHER|Observational|Observational study
223944039|NCT03749187|DRUG|Temozolomide (TMZ)|Given PO
223944040|NCT04560946|BEHAVIORAL|Personalized Augmented Cognitive Training (PACT)|Personalized Augmented Cognitive Training (PACT) group. Intervention: Behavioral: The study neuropsychologist will use a portion of the TBI education session to describe available treatment modules and make recommendations for module selection based on results from baseline assessment. After discussion, five 60-minute CogSMART modules will be selected. PACT participants will receive guidance to complete 2 modules per week of the CogSMART app. PACT participants will also receive guidance to complete BrainHQ exercises of their choice for 30 minutes a day, 5 days per week, for a total training time of 15 hours.
223944041|NCT04560946|BEHAVIORAL|Enhanced Treatment As Usual|"Enhanced Treatment As Usual (ETAU) group. Intervention: Behavioral: The ETAU condition was designed to replicate treatment as usual following neuropsychological assessment of post-TBI cognitive problems. Treatment as usual for mTBI patients at the VA hospital usually consists of: 1) A general evaluation by the polytrauma clinic, 2) Possible neuropsychological assessment evaluation by the TBI Cognitive Rehabilitation Clinic, and 3) If impairments are present, cognitive rehabilitation is offered. The current study's condition is considered enhanced treatment as usual because standard of care for chronic mTBI does not always involve neuropsychological assessment with feedback and psychoeducation or the provision of self-directed tools such as the CogSMART app or BrainHQ cognitive training software."
223944042|NCT02686658|DRUG|Avacincaptad Pegol|Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection
223944043|NCT02686658|OTHER|Sham|The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
223944044|NCT00485693|DRUG|Bupivacaine HCl|150 mg Bupivacaine HCl
223944045|NCT00485693|DRUG|SKY0402|600 mg SKY0402 (study drug)
223944046|NCT02348866|OTHER|method of laundering and donning scrubs|
223944047|NCT01565187|BEHAVIORAL|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
223944048|NCT00881296|DRUG|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
223944049|NCT00881296|DRUG|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
223944050|NCT03413085|DEVICE|soft contact lens|"Group A~Group B"
223944051|NCT02309294|DEVICE|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
223944052|NCT02309294|DEVICE|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
223944053|NCT02309294|DEVICE|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
223944054|NCT02309294|DEVICE|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
223944055|NCT02309294|DEVICE|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
223944056|NCT04068272|DRUG|Bosentan|Eyedrop
223944057|NCT04068272|DRUG|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
223944058|NCT03520036|DRUG|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
223944059|NCT03520036|DRUG|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
223944060|NCT03520036|DRUG|Placebo|Placebo QD, oral, 16 weeks
223944061|NCT06682143|BEHAVIORAL|Virtual Reality (VR)|Participants will engage in a virtual reality greenspace activity for a period of 5 minutes
223944062|NCT06682143|BEHAVIORAL|Control|Participants will sit quietly for a period of 5 minutes
223944063|NCT01878305|DEVICE|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
223944064|NCT00012259|DRUG|troxacitabine|
223944065|NCT03981588|OTHER|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
223944066|NCT04448652|DRUG|NSAID|no other intervention than described in the groups.
223944067|NCT00758550|DEVICE|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
223944068|NCT00758550|DEVICE|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
223944069|NCT02424474|DEVICE|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
223944070|NCT02424474|BIOLOGICAL|Regular serum screening|
223944071|NCT01588093|DRUG|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
223944072|NCT01588093|DRUG|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
223944073|NCT06406426|DRUG|Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin|Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
223944074|NCT01989416|DRUG|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
223944075|NCT01989416|DRUG|Soap|The ICU patients will be bathing with Soap
223944076|NCT03936023|DRUG|Saxagliptin|Saxagliptin dispensing claim is the exposure
223944077|NCT03936023|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
223944078|NCT00869934|OTHER|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
223944079|NCT00869934|OTHER|Behavior Therapy|Sleep restriction and stimulus control
223944080|NCT00869934|OTHER|Cognitive Therapy|Cognitive restructuring therapy
223944081|NCT02278666|PROCEDURE|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
223944082|NCT02278666|DEVICE|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
223944083|NCT02278666|DEVICE|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
223944084|NCT04565977|OTHER|Observational|Retrospective chart review
223944085|NCT02617693|BEHAVIORAL|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
223944086|NCT02617693|OTHER|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
223944087|NCT02574806|PROCEDURE|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
223944088|NCT00467272|DRUG|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria. Treatment expected to be at least 14 days for SA and at least 7 days for enterococci and CNS, Corynebacterium, and Propionibacterium.
223944089|NCT05094011|BIOLOGICAL|Aadipose-Derived Mesenchymal Stem Cells|Stereotactic intrastriatal implantation of 3×10\^7 per hemisphere (total 6×10\^7 cells) or 1×10\^8 per hemisphere (total 2×10\^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).
223944090|NCT04198467|BIOLOGICAL|Platelet rich plasma|Platelet rich plasma : 100 billion platelets in 10 ml of plasma(PRP) administered intra-articular
223535417|NCT06306001|OTHER|Placebo|Subjects in the placebo arm will receive normal saline in the same volumetric dose as methylene blue in the intervention arm
223944091|NCT04198467|DRUG|Hyaluronic Acid|Hyaluronic acid :Four ml of high-molecular-weight hyaluronic acid with a concentration of 22mg/ml injected intra-articular
223944092|NCT04275167|DEVICE|Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope|Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.
223944093|NCT01572805|DRUG|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
223944094|NCT01572805|DRUG|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
223944095|NCT01572805|DRUG|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
223944096|NCT01841515|DRUG|Desmopressin administration|
223944097|NCT00570505|DEVICE|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
223944098|NCT04990856|PROCEDURE|Exercise|Tumor blood flow after acute exercise
223944099|NCT05426109|OTHER|Peanut snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal peanut-containing (whole peanuts or peanut butter) snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
223944100|NCT05426109|OTHER|No peanut-containing snacks|Participants will undergo a 10-week diet and weight training regimen to promote healthy weight gain. These participants will receive seven 500 kcal non-peanut-containing high carbohydrate snacks each week and consume one snack per day throughout the study. They will also perform a series of weight training exercises supervised by a personal trainer on 3 days per week.
223944101|NCT05793996|DRUG|Ferinject|The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.
223944102|NCT05793996|OTHER|Diet therapy|Patients will receive diet therapy to correct latent iron deficiency
223944103|NCT04302740|BEHAVIORAL|LEAP|The LEAP is a comprehensive, multidimensional, community-level intervention offered in Housing First settings that was developed using a CBPR framework. The LEAP principles, process, and components were conceptualized and operationalized by the CAB in the pilot study, and are outlined in a recently published articles in the American Psychologist and Journal of Community Psychology. Briefly, LEAP principles include recognizing and respecting community as a key unit of identity versus solely as individuals in a traditional research hierarchy; embracing cultural humility; practicing pragmatism and compassion; aiming to build equitable research partnerships with communities; acknowledging and promoting community strengths; and supporting relevant, sustainable, positive and community-led change.
223944104|NCT05212285|DEVICE|Inbody 570|Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up
223944105|NCT05212285|DEVICE|JAMAR Dynamometer|Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up
223944106|NCT05212285|RADIATION|CT scan|Chest and abdominal CT scan during each follow-up
223944107|NCT06346886|BEHAVIORAL|FAITH! HTN app|Participants will remain in the intervention for 11 weeks. The app-based intervention is a tailored program to promote HTN self-management and knowledge through an 11-module educational video series with a focus on HTN. Participants will also be provided with at home Blood Pressure (BP) monitoring system to allow for self-tracking of BP measurements(automatically synchronized with the app). The app will include pre-post module quizzes, a tracking component for participants to input self-monitored measures (medication adherence, diet, physical activity, etc.). The app sharing board will be a moderated discussion platform and feed for participant interaction by posting healthy lifestyle practices through text, photographs and video to foster discussion on HTN management barriers/facilitators. The project team will post weekly to the sharing board on HTN-related topics to generate discussion among patients.
223944108|NCT05591534|RADIATION|Endorectal brachytherapy|Endorectal brachytherapy : 30 Gy in 3 sessions of 10 Gy delivered weekly
223944109|NCT06305962|DRUG|177Lu-RAD204|177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
223944110|NCT04313816|OTHER|questionnaire|no intervention at all apart from filling a brief questionnaire
223944111|NCT06215391|DEVICE|3d printed mask|"* Concurrent, prospective, non-randomized inclusion, cross-over design. A minimum of 6 patients will be included for each group, COPD, and ALS.~* T0: Patient enrollment (informed consent signing), retrospective review of the respirator log (1 month prior), variable extraction (extracting EDF files from the respirator log and data obtained from ResScan).~* During the first week, a 3D scan of the patient's face will be conducted, and the personalized 3D-printed mask (M3D) will be manufactured.~* Once ready, the mask will be fitted, and the 1-month evaluation period will begin (T1: after 1 month of M3D use). The respirator card will be downloaded in the same manner as at T0, and a respiratory polygraphy (RP) will be scheduled.~* T2: At the end of the study month, the patient will resume using a similar MC, which is new and well-fitted. After one month of MC use, the respirator log will be reviewed, and a new RP will be conducted."
223944112|NCT04354389|DRUG|DAS181|4.5 mg b.i.d
223944113|NCT04354389|DRUG|Placebo|q.d. or b.i.d.
223535418|NCT05247203|BIOLOGICAL|Telitacicept|subcutaneous injection
223944114|NCT04354389|DRUG|DAS181|4.5 mg q.d.
223944115|NCT02933294|PROCEDURE|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
223944116|NCT02933294|PROCEDURE|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
223944117|NCT04810390|DRUG|Bilastine|Ophthalmic solution 0.6%
223944118|NCT04810390|DRUG|Placebo|Ophthalmic solution
223944119|NCT02222493|BIOLOGICAL|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
223944120|NCT02222493|BIOLOGICAL|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
223944121|NCT06046196|DRUG|Sarpogrelate SR|Sarpogrelate SR 300mg, once a daily, for 24weeks
223944122|NCT06046196|DRUG|Sarpogrelate|Sarpogrelate 100mg, 3 times a day, for 24weeks
223944123|NCT05987774|DEVICE|AI Modules for Improving Social Conversation|"The application if the modules will be delivered using software. These modules have been developed to provide feedback on specific areas following voice or text input (user preference will be recorded in case this effects the results).~The investigators currently have developed AI modules for common social communication challenges exhibited by individuals with ASD. Examples include:~Empathy (general and in the work setting), Asking Relevant Questions, Listen and Respond, Talking the right amount, giving the right amount of personal information, Tactful Responses, Giving compliments, and Staying on topic during Conversation. These are all areas that can be challenging for individuals diagnosed with autism spectrum disorder.~AI modules consist of thousands of total training examples. Participants may access the modules on their phones or computers."
223944124|NCT00900341|GENETIC|DNA analysis|
223944125|NCT00900341|GENETIC|gene expression analysis|
223944126|NCT00900341|GENETIC|protein expression analysis|
223944127|NCT00900341|GENETIC|reverse transcriptase-polymerase chain reaction|
223944128|NCT00900341|GENETIC|western blotting|
223944129|NCT00900341|OTHER|immunohistochemistry staining method|
223944130|NCT00900341|OTHER|laboratory biomarker analysis|
223944131|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
223944132|NCT00185276|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
223944133|NCT02627391|OTHER|Early surgical aortic valve replacement|
223944134|NCT02627391|OTHER|Delayed Surgical aortic valve replacement|
223944135|NCT00219466|OTHER|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
223944136|NCT00219466|OTHER|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
223944137|NCT01584752|PROCEDURE|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
223944138|NCT03665792|DEVICE|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
223944139|NCT00476905|DEVICE|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
223944140|NCT03951259|DRUG|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
223944141|NCT03951259|DRUG|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
223944142|NCT01548703|DRUG|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
223944143|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
223944144|NCT01548703|DRUG|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
223944145|NCT06179875|DRUG|Intervention/Treatment|VRDN-001 10 mg/kg (5 infusions of VRDN-001 10 mg/kg)
223944146|NCT03975400|BEHAVIORAL|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
223944147|NCT03454256|DEVICE|Virtual Reality|Virtual Reality Rehabilitation System
223944148|NCT02433444|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
223944149|NCT03924869|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT will be administered once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks.
223944150|NCT03924869|BIOLOGICAL|Pembrolizumab|Pembrolizumab will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
223944151|NCT03924869|DRUG|Placebo|Placebo (normal saline solution) will be administered at 200 mg via IV infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year).
223944152|NCT02401503|DRUG|Bendamustine|Debulking: Cycles 1-2, d1 \& 2: 70mg/m² i.v.
223944153|NCT02401503|DRUG|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
223944154|NCT02401503|DRUG|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
223944155|NCT06569771|DIAGNOSTIC_TEST|Functional assessments|"* Computer Adaptive Test for Fugl-Meyer (CAT-FM)~* Action Research Arm Test (ARAT)~* Measurement of Functional Independence~* Star cancellation test~* Stroke Impact Scale~* ACTIVLIM (assesses the ability to perform activities of daily living requiring the use of the upper limbs)"
223944156|NCT05131685|PROCEDURE|Reduction|closed reduction under conscious sedation followed by casting
223944157|NCT05131685|PROCEDURE|Immobilization|immobilization in cast without reduction
223944158|NCT02542943|DEVICE|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
223944159|NCT02542943|DEVICE|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
223944160|NCT02542943|OTHER|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
223944161|NCT02542943|DRUG|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
223944162|NCT03126604|DIAGNOSTIC_TEST|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
224099851|NCT06091501|BEHAVIORAL|Lev Livet|"The program consists of a total of 9 sessions with a duration of two and a half to three hours for each session. In the first four sessions coping skills are taught across different chronic diseases. In this part of the program citizens suffering from different chronic diseases can participate. Citizens living with T2D then move on to four diabetes-specific sessions, followed by a ninth follow up session. The sessions are held consecutively over eight weeks. The ninth session is held three weeks after the eighth session.~The 8 weeks supervised HIIT-protocol will be comprised of blocks of 5 x 1 min high-intensity intervals interrupted by 1 min active recovery. The HIIT intervention will progress continuously, from two weekly training sessions with two training blocks (22 minutes of training) in the first two weeks, to two weekly training sessions with four training blocks in the last four weeks of the intervention."
224099852|NCT05374343|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule orally (by mouth) on Day 1
224099853|NCT06116383|DEVICE|NIRS|Renal perfusion will be evaluated with NIRS
223719594|NCT04478539|DEVICE|Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter|"Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition.~The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia.~Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h.~The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF)."
224099854|NCT01861197|DRUG|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
223944163|NCT01522014|DEVICE|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
223944164|NCT01522014|DEVICE|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
223944165|NCT05527808|DRUG|Tislelizumab|200 mg ,intravenous injection ,Q3W 2-4 cycles
223944166|NCT05527808|DRUG|pemetrexed|500 mg/m2,intravenous injection ,Q3W 2-4 cycles
223944167|NCT05527808|DRUG|cis-platemum|60-75mg/m2 ,intravenous injection ,Q3W 2-4 cycles
223944168|NCT05527808|DRUG|or carboplatin|AUC(4-5) ,intravenous injection ,Q3W 2-4 cycles
223944169|NCT02734355|DRUG|Telmisartan 80 mg and amlodipine 5 mg|
223944170|NCT02734355|DRUG|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
223944171|NCT03315299|DRUG|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
223944172|NCT05558683|OTHER|Randomized clinical trial.|Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
223944173|NCT04976764|OTHER||
223944174|NCT05097105|DEVICE|MRI|MRI sequences: TI. T2 and diffusion weighted
223944175|NCT06153745|DEVICE|Tecnis Eyhance ICB00 intraocular lens (Johnson&Johnson Vision, Santa Ana, California USA)|pediatric cataract surgery
223944176|NCT04814108|DRUG|ZN-c3|ZN-c3 is an investigational drug.
223944177|NCT05731440|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan.
223944178|NCT03848143|DRUG|onabotulinum toxin A|Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
223944179|NCT06242535|BIOLOGICAL|GLY-LOW|This supplement is available for over-the-counter purchase. Each capsule is a combination of vitamins and natural products: Vitamin B1 (100mg); Vitamin B6 (50mg); Niacin (200mg); Alpha Lipoic Acid (150mg); and Piperine (15mg). The supplement, GLY-LOW, is FDA approved for use as a dietary supplement (IND 162006)
223944180|NCT06227130|BEHAVIORAL|MindYou|A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
223944181|NCT04190550|DRUG|Cytarabine|Given IV
223944182|NCT04190550|DRUG|Idarubicin Hydrochloride|Given IV
223944183|NCT04190550|DRUG|Navtemadlin|Given PO
223944184|NCT05728840|OTHER|Immersive virtual reality gamified cognitive activities|This intervention will include 20 sessions of training with the experimental rehabilitation program using immersive VR cognitive gamified activities, in addition to the standard of care.
223944185|NCT05728840|OTHER|Double neuropsychological standard activities|This intervention will include 20 sessions of training using a standard neuropsychological rehabilitation program, in addition to the standard of care.
223944186|NCT00644514|BIOLOGICAL|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
223944187|NCT05510310|PROCEDURE|Breast stimulation|By breast pump
223944188|NCT05510310|BIOLOGICAL|Oxytocin|Oxytocin will be administered intravenously and titrated
223944189|NCT06236802|DEVICE|ProVee device|ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
223944190|NCT06521619|PROCEDURE|Femoral and sciatic nerve blocks|Patients receiving Adductor canal block and infiltration of posterior capsule of knee
223944191|NCT02335554|BEHAVIORAL|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
223944192|NCT02335554|BEHAVIORAL|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
223944193|NCT00893555|DRUG|voriconazole|TDM (through level of 2-5mg/L).
223944194|NCT00893555|DRUG|voriconazole (dosing according to the SPC)|No serum concentrations are determined
223944195|NCT06979323|BIOLOGICAL|Depemokimab|Depemokimab will be administered.
223944196|NCT04267588|OTHER|Navio Mobile App|Participants will use the Navio Mobile App to track participants' pain and pain treatment
223944197|NCT06854640|DRUG|BAY3389934|Solution for IV infusion
224099855|NCT02976506|BEHAVIORAL|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
223944198|NCT04644575|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:Solution for Injection Route of administration: Intravenous
223535419|NCT05247203|DRUG|standard therapy|A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
223535420|NCT01265485|DRUG|coated suppository|Dose escalating study
223944199|NCT06585865|BEHAVIORAL|Resistance training|After pre-testing, participants will perform full-body strength training three times per week for two 6-week blocks. The acute program variables (sets, repetitions, training frequency) will follow a non-linear periodized, progressive design consisting of muti-joint and single-joint exercises. Exercise stress will be varied by using different exercises and loads. The two training blocks will be separated by a mid-intervention testing week, allowing for the study team to monitor participants' progress, communicate progress to participants to promote adherence, and adjust target loads as appropriate for the second half of the intervention. An additional testing week will follow the second 6-week block.
223944200|NCT06585865|DIETARY_SUPPLEMENT|Resveratrol 500 mg oral once daily.|Participants will be randomized to consume resveratrol (500 mg) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
223944201|NCT06585865|DIETARY_SUPPLEMENT|Placebo|Participants will be randomized to consume placebo capsules (cellulose, visually identical to resveratrol capsules) daily for 14 weeks (two 6-week blocks of resistance training \[supervised, full-body, 3 days/week\] + one testing week \[3 days\] following each block) after the pre-testing period. Participants will be provided with 7 days' worth of supplements at a time in pre-filled pill boxes. Pill boxes will be refilled weekly and adherence monitored.
223944202|NCT06592794|BIOLOGICAL|mRNA-1403|Intramuscular (IM) injection.
223944203|NCT06592794|BIOLOGICAL|Placebo|0.9% sodium chloride solution by IM injection.
223944204|NCT02581137|OTHER|Laboratory Biomarker Analysis|Correlative studies
223944205|NCT02581137|DRUG|Metformin Hydrochloride|Given PO
223944206|NCT04463446|BEHAVIORAL|Use of the CHD app|Use of the CHD app
223944207|NCT04463446|BEHAVIORAL|Nurse-led intervention|Teaching session with clinic nurse
223944208|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive clinically-optimized open loop stimulation to the pallidum/subthalmaic nucleus.
223944209|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive increased adaptive stimulation to the pallidum/subthalmaic nucleus.
223944210|NCT06819020|DEVICE|Percept RC|Using the Percept RC pulse generator, patients receive decreased adaptive stimulation to the pallidum/subthalmaic nucleus.
223944211|NCT06855745|DRUG|zabalafin|Active IP
223944212|NCT03615352|PROCEDURE|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
223944213|NCT03615352|PROCEDURE|ovarian cyst aspiration and coagulation|laparoscopic ovarian cyst aspiration and coagulation in endometrioma
223944214|NCT06677203|DRUG|ASN51|Oral capsules
223944215|NCT06677203|DRUG|Placebo|Oral capsules
223944216|NCT07002593|OTHER|Myofascial release (MFR)|A 10-minute manual myofascial release (MFR) technique targeting active upper trapezius trigger points (MTrPs), applying sustained pressure until tissue release was achieved.
223944217|NCT07002593|OTHER|Muscle Stretching|Three 30-second static muscle stretches were performed for the upper trapezius by placing neck side flexion with contralateral rotation.
223944218|NCT07002593|OTHER|High-powered pulsed therapeutic ultrasound (HPPT-US)|A 5-minute high-powered pulsed therapeutic ultrasound (HPPT) was delivered subcutaneously with specific parameters of 1.5 W/cm², 1 MHz, and pulsed mode.
223944219|NCT03559413|BIOLOGICAL|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
223944220|NCT01836445|BEHAVIORAL|Keep It Up!|
223944221|NCT01836445|BEHAVIORAL|HIV Knowledge Control|
223944222|NCT04580745|DRUG|MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057.~Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057."
223944223|NCT04580745|DRUG|Placebo for MORF-057|"SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo.~MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo."
223944224|NCT07003906|DEVICE|Negative pressure wound therapy|"Avance Solo Negative Pressure Wound Therapy (NPWT) System is a portable battery powered single use negative pressure system, suitable for use in closed incision and chronic wound indications.~The system consists of Avance Solo Pump, Avance Solo Canister 50 mL, Avance Solo Border Dressing and Avance Solo Foam."
223944225|NCT07003906|DEVICE|Standard postoperative dressing|Mepilex Border Post-Op is a self-adhesive absorbent surgical dressing designed for exuding wounds. It is intended for acute wounds, such as surgical wounds, cuts and abrasions.
223944226|NCT07004634|PROCEDURE|Chest mediastinal tube|Transthoracic mediastinal drainage was performed for postoperative management of the patient.
223944227|NCT07004634|PROCEDURE|Abdominal mediastinal tube|Transperitoneal mediastinal drainage was performed for postoperative management of the patient.
223944228|NCT07004634|PROCEDURE|Chest tube + chest mediastinal tube|Chest tube insertion combined with transthoracic mediastinal drainage was performed for postoperative management of the patient.
223944229|NCT06674889|OTHER|Rehabilitation-based intervention|Assessment of the subject by a specialty consultation and exercise program development.
223944230|NCT07002502|DRUG|PRaG-1(cordycepin tablet)|"The PRaG-1 cordycepin tablet involved in this clinical study is produced by Shengmingyuan Company, a subsidiary of the National Biochemical Engineering Research Center at Nanjing Tech University. It is an oral tablet, with each tablet containing 200 mg of cordycepin. The product has obtained a national food production license, and the production license number is SC11332019200201."
223944231|NCT07000851|DIAGNOSTIC_TEST|C-11 ER176 Radiotracer|PET scan looking for inflammation
223944232|NCT07000851|DIAGNOSTIC_TEST|C-11 PiB|PET scan looking for amyloid protein
223535421|NCT00456573|PROCEDURE|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
223535422|NCT01622296|DRUG|Sodium bicarbonate|8.4% neutralizing solution
223944233|NCT07000851|DIAGNOSTIC_TEST|AV1451 Tau|Pet scan looking for Tau protein
223944234|NCT06092970|DRUG|RBT-1|Intravenous administration
223944235|NCT06092970|DRUG|Placebo|Intravenous administration
223944236|NCT02037126|DRUG|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
223944237|NCT02037126|DRUG|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
223535423|NCT01622296|DRUG|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
223535424|NCT04946058|PROCEDURE|hyebrid Mathieu Urethroplasty|incision of the urethral plate during the procedure
223535425|NCT00023335|DRUG|Rifapentine|
223535426|NCT00023335|DRUG|Isoniazid|
223535427|NCT05017623|DRUG|YH003|All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
223944238|NCT05865392|BEHAVIORAL|Move physical activity support program|The Move program includes four intervention components: 1) 3, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) access to an online fitness membership, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week. They will receive an online fitness center membership during this entire 12-week program.
223944239|NCT07012655|DEVICE|Colour Doppler Ultrasound|All study participants will undergo abdominal Ultrasound and Colour doppler ultrasound study of the superior and inferior mesenteric arteries and the resistance index and peak systolic velocity (cm/s) of radial and ulnar arteries measured by ultrasonography color Doppler with spectral wave analysis.
223944240|NCT07012941|DEVICE|Superpulse Thulium Fiber laser (SPTFL) ureteroscopy for treatment of upper urinary tract stone or renal stone|RIRS procedure for upper ureteral or renal stone lithotripsy with Superpulsed Thulium Laser
223944241|NCT07012941|DEVICE|Holmium: YAG laser ureteroscopy for treatment of upper urinary tract stone or renal stone|RIRS procedure for upper ureteral or renal stone lithotripsy with Holmium: YAG Laser
223944242|NCT07012200|OTHER|Immersive Interactive Nursing Instruction|360-degree introduction to the environment of the cardiac catheterization laboratory, cardiac catheterization procedures (including preoperative, intraoperative, and postoperative), wound care, and precautions for home care (including diet, medication, and exercise)
223944243|NCT07012200|OTHER|Routine Nursing Instructions|Health education by talking and leaflets and key explanations, and providing talks and consultations
223944244|NCT03816163|DRUG|zolbetuximab|Administered as an intravenous infusion.
223944245|NCT03816163|DRUG|nab-paclitaxel|Administered as an intravenous infusion
223944246|NCT03816163|DRUG|gemcitabine|Administered as an intravenous infusion
223944247|NCT07013331|OTHER|[18F]MPPF PET-MRI|"Patients will be seen during an first inclusion visit during which a review of eligibility criteria, medical history and a clinical examination will be done. Participants will be scheduled for a PET-MRI scan within 2 to 8 weeks. For all women of childbearing age a urine pregnancy test will be performed before the PET-MRI.~Anatomical MR imaging will be first acquired for anatomical co-registration and morphometry analyses (Neuromelanin sensitive images and 3D anatomical T1-weighted covering the whole brain volume with 1mm3 cubic voxels) After i.v. injection of a bolus of 180 MBq ± 10%, with a maximum of 198 MBq MBq, of \[18F\]-MPPF, a dynamic emission scan consisting of 35 frames of increasing duration (20s to 5min) will be acquired over 90-min post-injection"
223944248|NCT07012382|PROCEDURE|Inferior Alveolar Nerve Block|Administration of standard IANB with 2% lidocaine containing 1:80,000 epinephrine
223944249|NCT07012382|PROCEDURE|Inferior-Alveolar-Nerve-Block|Administration of IANB with 2% lidocaine containing 1:80,000 epinephrine
223944250|NCT07013084|BEHAVIORAL|3D VR smoking cessation program|Participants in the experimental group engaged with the VR system using a head-mounted display, allowing for full immersion in the virtual environment.
223944251|NCT07012902|DRUG|Etomidate|Group A was induced with etomidate, the initial dose was 0.120mg/kg, and the ratio of adjacent doses was 1:0.6
223944252|NCT07012902|DRUG|Remimazolam|Group B was induced with remimazolam, the initial dose was 0.20mg/kg, and the ratio of adjacent doses was 1:0.8
223944253|NCT07012902|DRUG|Remimazolam-etomidate|In group C, 0.25ED50 remimazolam +0.75ED50 etomidate was used as the initial measurement In group D, 0.5ED50 remimazolam +0.5ED50 etomidate was used as the initial measurement In group E, 0.75ED50 of remimazolam +0.25ED50 of etomidate was used as the initial measurement
223944254|NCT07014553|BEHAVIORAL|web based nursing navigator programme|health education guidance surveillance case management
223944255|NCT07014241|OTHER|Family psychoeducation|The study intervention, tagged SPARKED (Supportive Program for Advancing Recovery, Knowledge, and Empowerment in Depression), is a co-designed family-based psychoeducational intervention for individuals with MDD and their family members or caregivers. The intervention will cover structured modules to enhance participants' understanding of MDD and its treatment, coping strategies, and self-efficacy skills. It will also focus on recognising early signs of relapse and empowering participants to engage actively in treatment decision-making.
223944258|NCT07020390|PROCEDURE|Anesthesia method|Patients will be divided into subgroups according to different anesthesia methods (general, spinal, and combined spinal-epidural anesthesia) and compared in terms of recovery quality (QoR-40) and other parameters.
223944259|NCT00504322|GENETIC|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10\^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
223944260|NCT00504322|GENETIC|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
223944261|NCT07012161|DRUG|Colecalciferol (Vitamin D3) 50000 UI|Participants will received vit d upto 6 months
223944262|NCT00179933|BEHAVIORAL|Newborn Individualized Assessment Program|
223944263|NCT04506567|DRUG|225Ac-J591|Single cycle of fractionated dose of 225Ac-J591
223944264|NCT04506567|DIAGNOSTIC_TEST|68Ga-PSMA-HBED-CC injection|68Ga-PSMA-HBED-CC PET/CT before and after treatment
223944265|NCT04506567|DRUG|225Ac-J591|Single dose of 225Ac-J591 every 6 weeks x 4
223944266|NCT07013357|BEHAVIORAL|Virtual Community Intervention|Modules of community building, civic participation, and achieving personal goals
223944267|NCT07013357|BEHAVIORAL|Control|Civic participation websites and educational information on civic and social connection provided to participants
223944268|NCT06691113|DRUG|Itepekimab (SAR440340)|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
223944269|NCT06691113|DRUG|Placebo|Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
223944270|NCT06691113|DRUG|Mometasone furoate nasal spray (MFNS)|Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
223944271|NCT05502523|PROCEDURE|Pulmonary Artery-First Surgical Technique|Undergo pulmonary artery first surgical technique
223944272|NCT05502523|PROCEDURE|Biospecimen Collection|Correlative studies
223944273|NCT07042659|DEVICE|Photobiomodulation|Accelerated photobiomodulation therapy using EmoLED™, a portable blue LED device (415 nm, 120 mW/cm², 7.2 J/cm²). The device delivers continuous blue light at 4 cm from the wound surface, 60 seconds per 25 cm² sub-area (120 seconds for diabetic wounds), administered twice weekly for 4 consecutive weeks. The protocol is combined with standard wound care (cleansing, dressings, compression as indicated). The intervention is designed to promote wound healing in hard-to-heal wounds by modulating inflammation, enhancing angiogenesis, fibroblast activation, and re-epithelialization. This accelerated protocol (twice weekly vs. standard weekly regimens) aims to optimize clinical outcomes in a nurse-led outpatient setting and distinguishes this intervention from lower-frequency or red/infrared-based photobiomodulation approaches.
223944274|NCT07042906|DEVICE|anesthesia depth monitorizing, awareness|Investigation of BIS and PSI Monitoring Methods for Anesthetic Depth and the Factors Affecting These Methods in Open-Heart Surgery
223944275|NCT07043491|DIAGNOSTIC_TEST|Endoscopy|We first observed the residual esophagus to evaluate the mucosal color. We then reached the top of the anastomosis to obtain a full view of the anastomosis to exclude obvious leakage around that site. We next conducted a more detailed endoscopic examination at a close focal distance, circumferentially around the anastomosis. During this process, we utilized saline solution to meticulously remove white fibrin coverings and bloodstains to the greatest extent possible to ensure a thorough evaluation of anastomotic integrity. Finally, we inspected the staple line of the tubularized stomach to exclude gastric fistula and assessed the perfusion of the gastric graft. Endoscopic findings were assessed by an additional endoscopist and 3 esophageal surgeons during the examination, as well as by reviewing captured images or videos after endoscopy.
223944276|NCT07042568|BEHAVIORAL|Nursing education aimed at preventing oral mucositis|The intervention group was trained on the use of the Oral Mucositis Prevention Patient Education Handbook, which was prepared by the researchers based on literature information and expert opinions. Participants in the intervention group received telephone consultations on days 7 and 14. The control group continued to receive routine nursing care. The second interview was completed on day 21, when both the intervention and control group patients returned for their next treatment cycle, using the WHO Oral Toxicity Criteria, ADR, and EORTC QLQ-C30 Version 3.0 Quality of Life Scale.
223944277|NCT07043114|OTHER|BFR-Walking|The training consists of the patients walking on a treadmill twice a week for a total of six weeks until their pain becomes too severe and they have to take a break. After a one-minute break, this is increased again until the pain reaches its maximum. This is done a total of three times per appointment. Additionally, patients will receive a individual BFR intervention bilaterally with a exercise pressure corresponding to 60% of their LOP.
223944278|NCT07042646|BEHAVIORAL|Sexual and Reproductive Health Training program|'The Sexual and Reproductive Health education program was prepared by researchers who are experts in the field of public health and public health nursing. The program was implemented once a week for 3 weeks (why 3 weeks) in 50-60 minute sessions (Table 1). The content and duration of the application were prepared in accordance with the Ministry of Health Sexual and Reproductive Health: National Strategic Action Plan for the Health Sector (2005-2015) and the Turkey Reproductive Health Program Sexual and Reproductive Health Service Standards (2007). Each program session was two education sessions, and all the questions of the disabled woman were answered .
223944279|NCT07043465|DIAGNOSTIC_TEST|14 days ambulatory rhythm monitoring|14 days ambulatory rhythm monitoring using Byteflies
223944280|NCT07043101|OTHER|Extended Reality based Gait Rehabilitation|XR headset augmenting traditional Vector based gait rehabilitation.
223944281|NCT07044245|PROCEDURE|immediate maxillary premolar implant placement with no subsequent laser Biostimulation|Sham laser application
223944282|NCT07044245|PROCEDURE|immediate maxillary premolar implant placement with subsequent laser Biostimulation|low lever biostimulation was performed on two consecutive sessions each of 100 s. First session was carried out immediately on surgery time after implant placement, using a diode laser Photo-biomodulation tip in a continuous wave and non-contact mode
223944283|NCT07044128|DEVICE|Digital stethoscope using MEMS sensor and mobile application for cardiac auscultation|The intervention is a digital stethoscope system comprising a handheld device with a micro-electromechanical system (MEMS) sensor and a Bluetooth Low Energy (BLE) connection to a mobile application (Keikku Mobile App) installed on an iOS or Android smartphone. The device captures auscultation sounds from standard precordial locations (mitral, tricuspid, aortic, and pulmonary), transmits them in real time to the mobile application, and stores the recordings on a secure, GDPR-compliant cloud server. The device does not interpret sounds. Each auscultation lasts 15 seconds per site. Physicians use Bluetooth headphones to listen during recording. The application allows for annotation and review of sound data. The intervention is administered once per participant during a single study visit, immediately followed by a comparator auscultation using a conventional analog stethoscope by a second blinded physician.
223944284|NCT07043998|OTHER|Self-adhesive resin cement in SELF-CURED mode|PFM crowns veneered with porcelain system cemented using self-adhesive resin cement in SELF-CURED mode
223944285|NCT07043998|OTHER|Self-adhesive resin cement in DUAL-CURED mode|PFM crowns veneered with porcelain system cemented using self-adhesive resin cement in DUAL-CURED mode
224295149|NCT05373381|DIETARY_SUPPLEMENT|Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt|Following a screening period, subjects will adhere to the sHFLC + KetoPhyt diet for six 4-week cycles. Patients will receive dietary advice from a Registered Dietitian (RD) to allow for the design of personalized meal plans maintaining carbohydrates up to 33% of total caloric intake, and be asked to maintain a daily dietary log. To assist patients in understanding, monitoring and controlling their dietary choices to maintain a low carbohydrate diet, they will be trained and receive assistance on the use of an online tool for tracking nutrition \[Healthtrac\].
224295150|NCT05271136|OTHER|Anti-aging Serum|Serum composed of a patent-pending botanical extract, bioavailable peptides, antioxidants, post-biotics, and short and long-term moisturizers
224295151|NCT05271136|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after serum
224295152|NCT05271136|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants
224295153|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of serum in the morning. Participants were asked to reapply every 2 hours
223719595|NCT01795209|DRUG|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
223719596|NCT01795209|DEVICE|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
223719597|NCT01795209|PROCEDURE|Rescue laser|"In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3"
224295154|NCT05271136|OTHER|Sunscreen|Sunscreen to be applied after application of facial moisturizer in the morning. Participants were asked to reapply every 2 hours
224295155|NCT00186823|DEVICE|Miltenyi Biotec CliniMACS|A stem cell selection device.
223944286|NCT07044271|DRUG|Olomorasib|Single dose
223944287|NCT07042932|OTHER|Exercise|26 weeks online high intensity functional training, performed 1-2 times per week + access to a LIFESTYLE PHYSICAL ACTIVITY WEBSITE including 8 modules; 1) Welcome, information about the intervention and the aims of the study, 2) Living a physically active lifestyle, 3) Sedentary behavior, 4) General exercise recommendations, 5) How to stay motivated, 6) Strength training, 7) flexibility, balance, and coordination, and 8) Healthy eating + weekly motivational counseling
223944288|NCT06754956|DEVICE|The patient will receive two intravenous injections of the same gadoterate meglumine contrast agent.|Each patient will undergo two different field strength HR-VWIs with enhancement, and on each occasion the patient will be injected with contrast DOTAREM (gadoterate meglumine) .
223944289|NCT05206513|DRUG|Placebo|Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
223944290|NCT05206513|DRUG|Valbenazine|Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
223944291|NCT07066657|DRUG|MRG007|MRG007 will be administrated as specified in the protocol.
223944292|NCT06771115|DRUG|VTX3232 Dose A|VTX3232 Dose A
223944293|NCT06771115|DRUG|Placebo|Placebo
223944294|NCT06771115|DRUG|VTX3232 Dose A in combination with semaglutide|VTX3232 Dose A in combination with semaglutide
223944295|NCT06771115|DRUG|Placebo in combination with semaglutide|Placebo in combination with semaglutide
223944296|NCT06749327|BEHAVIORAL|High UPF, high hPDI diet|High ultra-processed foods (UPFs) and healthy plant based diet
223944297|NCT06749327|BEHAVIORAL|Low UPF, high hPDI diet|Low ultra-processed foods (UPFs) and high healthy plant-based diet
223944298|NCT06778278|BEHAVIORAL|Transition Health and Resilience through Valued Experiences (THRiVE) Program|Six (6) total weekly, 90-minute, small-group, peer-led sessions delivered virtually
223944299|NCT06683989|OTHER|Pilates training|One hour of Pilates training was conducted for eight weeks, two days a week. Every training session was carried out by a certified and experienced physiotherapist from the Australian Institute of Pilates and Physiotherapy. The one-hour session was structured as a warm-up, a cool-down, and Pilates exercises.
223944300|NCT06683989|OTHER|Prenatal care|Regular prenatal care for participants in the CG included standard nursing and medical treatments.
223944301|NCT05292989|OTHER|Frailty Assessment|Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer
223944302|NCT05292989|OTHER|Standard Care|Standard care practice
223944303|NCT05200416|DEVICE|Heylo|Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.
223944304|NCT05200416|DEVICE|Standard of Care|Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses
223944305|NCT06508437|BIOLOGICAL|Influenza Vaccination|Standard Dose QIV (15µg Hemagglutinin) - VaxigripTetra Suspension for injection, 0,5ml prefilled syringe
223944306|NCT04185363|DRUG|Maralixibat|All subjects will receive Maralixibat oral solution (up to 600 microgram per kilogram \[mcg/kg\]) twice daily
223944307|NCT06756386|DEVICE|extra corporeal shock wave therapy (ESWT )|Using wound area measurements and histological/immunohistochemical analysis of wound biopsies, we show ESWT enhanced healing of chronic ulcers associated with improved wound angiogenesis ), significantly decreased-positive macrophages per biopsy area and generally increased macrophage activity ,this activity prevent bacterial infection which delay healing
223944308|NCT06756386|DEVICE|Low Level Laser Therapy|"Low-level laser therapy (LLLT) has been used as an adjuvant to conventional therapy with promising results,improve healing by delivering nutrient substances , especially in patients with acute and bloody ulcers.~Positive effects include acceleration of tissue repair, increased formation of granulation tissue, wound contraction, inflammation modulation, and pain reduction The biochemical effects of LLLT are associated with the release of preformed substances (histamine, serotonin, and bradykinin), which stimulate the production of ATP and inhibit the production of prostaglandins."
223944309|NCT06756386|OTHER|conservative treatments|( compression pandaging, lifestyle changes, physical activities)
223944310|NCT03505905|DRUG|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
223944311|NCT03505905|DRUG|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
223944312|NCT06037850|DEVICE|Test orthokeratology lens|Randomized to test orthokeratology lens worn during sleep every night
223944313|NCT06037850|DEVICE|Control orthokeratology lens|Randomized to control orthokeratology lens worn during sleep every night
223944314|NCT05847257|DRUG|Letrozole tablets|letrozole 2.5mg twice weekly for 3 months
223944315|NCT05847257|DIETARY_SUPPLEMENT|Coenzyme Q10 table|Coenzyme Q10 400 mg per day for 3 months
223944316|NCT07099729|OTHER|Volume-Controlled Ventilation (VCV) with inspiratory-to-expiratory (I:E) ratio of 1:2.|Patients received volume-controlled ventilation (VCV) with an inspiratory-to-expiratory (I:E) ratio of 1:2. Mechanical power was calculated geometrically (MPgeo) using ventilator screenshots, and results were compared with dynamic mechanical power (MPdyn) values.
223944317|NCT07099729|OTHER|Volume-Controlled Ventilation (VCV) with inspiratory-to-expiratory (I:E) ratio of 1:1.|Patients received volume-controlled ventilation (VCV) with an inspiratory-to-expiratory (I:E) ratio of 1:1. MPgeo was computed from ventilator screenshots and compared to MPdyn values to assess agreement.
223944318|NCT07099729|OTHER|Pressure-Controlled Ventilation (PCV) with inspiratory-to-expiratory (I:E) ratio of 1:2.|Patients received pressure-controlled ventilation (PCV) with an I:E ratio of 1:2. Mechanical power was measured using both geometric (MPgeo) and dynamic (MPdyn) methods for validation purposes.
223944319|NCT07099729|OTHER|Pressure-Controlled Ventilation (PCV) with inspiratory-to-expiratory (I:E) ratio of 1:1.|Patients received pressure-controlled ventilation (PCV) with an I:E ratio of 1:1. Geometric mechanical power calculations from ventilator screenshots were compared with MPdyn values for accuracy assessment.
223944320|NCT05986617|DEVICE|InBody Band 2|Wearable bioimpediance monitor similar to a fitness watch.
223944321|NCT05909995|DRUG|INCB 99280 with Ipilimumab|Dose Escalation and expansion of INCB 99280 with Ipilimumab
223944322|NCT06486051|DRUG|Fludarabine|30 mg/m\^2/day IV for three consecutive days
223944323|NCT06486051|DRUG|Cyclophosphamide|500 mg/m\^2/day IV for three consecutive days
223944324|NCT06486051|BIOLOGICAL|WZTL-002 CAR T-cells|"WZTL-002 comprises autologous T-cells transduced to express the third-generation 1928T2z chimeric antigen receptor, which recognises the CD19 antigen present on malignant and normal B-cells. The chimeric antigen receptor (CAR) incorporates an extracellular scFv specific for CD19, the intracellular signalling domains of CD28 and CD3ζ, and an intracellular co-stimulatory domain derived from TLR2 interposed between CD28 and CD3ζ.~On Day 0, the WZTL-002 CAR T-cell product is administered intravenously two days after completing lymphodepleting chemotherapy."
223944325|NCT05833724|DRUG|Chidamide|Subjects will receive a single dose of 30 mg chidamide. Twice a week.
223944326|NCT02882620|BEHAVIORAL|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
223719598|NCT04849598|OTHER|Oxygen therapy|Oxygen therapy during ESWTs and Stair Walking Test: one test using the prescribed constant oxygen flow and one using an automatic oxygen titration system. SpO2 target range: 90 - 94%
223944327|NCT02882620|BEHAVIORAL|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
223944328|NCT02882620|BEHAVIORAL|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
223944329|NCT05173415|DEVICE|Sirius Pintution|The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.
223944330|NCT05173415|DEVICE|HydroMARK (C) Clip|The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
223944331|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice combined with caffeine (COM)|"* 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session~* 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session"
223944332|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice placebo with caffeine (CAF)|\- 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - 200 mg caffeine capsule from the IO.GENIX Nutrition brand (Toledo, Spain) 60 minutes before experimental session
223944333|NCT06758323|DIETARY_SUPPLEMENT|Beetroot juice with caffeine placebo (BRJ)|\- 70 mL of beetroot juice (400 mg NO3-, BEET It Sport; James White Drinks Ltd) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
223944334|NCT06758323|OTHER|Beetroot placebo with caffeine placebo (PLA)|\- 70 mL of a blackcurrant beverage, which depletes NO3- (Capri-Sun) 120 minutes before experimental session - Multivitamin capsule from NaturrTierra (Leganés, Spain) 60 minutes before experimental session
224099856|NCT02976506|BEHAVIORAL|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
224099857|NCT05714371|DRUG|Nivolumab|Patients receiving nivolumab
223944335|NCT06942806|OTHER|HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V|HF-SCS parameter settings: Frequency 1000 Hz, pulse width 60-180 μs, amplitude 0.5-3.0 V
223535428|NCT01652781|DRUG|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
223535429|NCT05935956|DEVICE|Magnetic Peripheral Nerve Stimulation|Magnetic Peripheral Nerve Stimulation
223944336|NCT06942806|OTHER|LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V|LH-SCS parameter settings: Frequency 30-100 Hz, pulse width 100-300 μs, amplitude 0.5-5.0 V
224099858|NCT05714371|DRUG|Ipilimumab + nivolumab|Patients receiving ipilimumab + nivolumab
224099859|NCT05714371|DRUG|Pembrolizumab|Patients receiving pembrolizumab
224099860|NCT05714371|DRUG|Dabrafenib + trametinib|Dabrafenib + trametinib
224099861|NCT01491958|DRUG|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
224099862|NCT01491958|DRUG|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
223944337|NCT06951373|PROCEDURE|Multiple Percutaneous Needle Aspiration (MPNA)|A minimally invasive technique involving repeated needle aspiration of breast abscess fluid without making an incision.
223944338|NCT06951373|PROCEDURE|Incision and Drainage (ID)|A surgical procedure involving an incision in the abscess to allow drainage of pus, followed by wound care.
223944339|NCT06950827|PROCEDURE|laparoscopic right hemihepatectomy|Laparoscopic surgery has many advantages, such as small surgical incision and fast postoperative recovery. In recent years, more and more centers have gradually transitioned to performing right hemihepatectomy through laparoscopy as much as possible.
223944340|NCT06953206|PROCEDURE|Transcatheter aortic valve (S3UR) replacement (TAVR)|Elective transfemoral TAVi procedure with S3UR valve.
223944341|NCT06950216|OTHER|IONM|The probe needle electrodes were inserted into the corpus cavernosum penis, ischiocavernosus muscle, bulbocavernosus muscle, anal sphincter, etc., and each monitoring electrode was connected to the nerve monitor. The changes of electromyography of each effector during the operation were monitored in real time. The stimulation electrode was placed in the abdominal cavity during the operation. During the resection of the prostate, electrical stimulation was performed on the possible running area of the NVB, and the stimulation site where the signal was monitored was protected from resection and burning under the premise of safe surgery.
223944342|NCT06132737|DRUG|[90Y]Y-PentixaTher|\[90Y\]Y-PTT i.v. injection
223944343|NCT03715946|DRUG|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
223944344|NCT03715946|RADIATION|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
223944345|NCT06525077|DRUG|FT218|Sodium oxybate for extended-release oral suspension
224099863|NCT01491958|DRUG|methotrexate|Day +1, +3, and +6 and +11
224099864|NCT01954290|DRUG|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
223535430|NCT00415090|DRUG|Nevirapine|Switch one of ARV drugs to Nevirapine
223535431|NCT03567889|DRUG|Daromun|Patients will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
223535432|NCT03567889|PROCEDURE|Surgery|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
223535433|NCT03567889|DRUG|Adjuvant therapy|Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
223535434|NCT05003193|DEVICE|pedometer|2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
223535435|NCT01281111|DRUG|Dimethyl Fumarate (BG00012)|
223535436|NCT01281111|DRUG|Aspirin|
223535437|NCT01281111|DRUG|BG00012 matching placebo|
223535438|NCT01281111|DRUG|ASA matching placebo|
223535439|NCT00712387|BEHAVIORAL|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
223535440|NCT05351528|OTHER|Questionnaire|Caregiver burden and healthy lifestyle behaviors were evaluated.
223944346|NCT06525077|OTHER|Placebo|Matched placebo equivalent for oral suspension
223944347|NCT05587764|DIAGNOSTIC_TEST|Standard of Care|Standard of care for emergency events per local guidelines.
223944348|NCT06134193|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil, leucovorin (FOLFOX) treatment (Q3W) Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.
223944349|NCT06134193|DRUG|Surufatinib|250mg PO d1, Q3W
223944350|NCT06134193|DRUG|Tislelizumab|200mg IV d1, Q3W
223944351|NCT00076115|DRUG|Risperidone|
223944352|NCT06272110|OTHER|System level Language Access (LA) intervention|Culturally and linguistically appropriate and HL informed strategies and materials/toolkit for community members, patients, and health care providers and staff. Findings from the preparatory work and pre-implementation phase and discussions with key partners will inform the co-design of intervention strategies.
223944353|NCT06397235|DRUG|DEB-TACE+HAIC|"CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.~RALOX-based regimen for hepatic arterial infusion chemotherapy: oxaliplatin, 85 mg/m2 infusion for 2 hours; Raltitrexed, 3 mg/m2 infusion for 0.5 hour."
223944354|NCT06397235|DRUG|DEB-TACE|CalliSpheres (100-300 µm) loaded with pirarubicin for transarterial chemombolization: Typically, one vial of the beads was loaded with 60 mg pirarubicin. If blushed tumors is still visible after the embolization with one vial of beads, regular microspheres (8spheres) with diameters of 100-700 μm are additionally injected.
223944355|NCT01961063|DRUG|busulfan|Given IV
224099865|NCT01954290|DRUG|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
224099866|NCT01954290|DRUG|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
224099867|NCT04181281|DIAGNOSTIC_TEST|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
224099868|NCT04181281|DIAGNOSTIC_TEST|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
224099869|NCT06959199|PROCEDURE|Endovascular Treatment|EVT procedures may include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, or stenting, or other intra-arterial procedures as deemed appropriate by the treating physician.
224099870|NCT06959199|DRUG|Best Medical Treatment|Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.
224099871|NCT02101437|PROCEDURE|miRNA within 24hr|miRNA within 24hr
223944356|NCT01961063|BIOLOGICAL|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
224099872|NCT02101437|PROCEDURE|miRNA after 1 week|miRNA after 1 week
224099873|NCT02101437|PROCEDURE|miRNA after 1 month|miRNA after 1 month
223944357|NCT01961063|OTHER|pharmacological study|Correlative studies
224099874|NCT04553887|DRUG|Almonertinib|single agent, 110mg p.o once daily until disease progressed
224099875|NCT01106638|BEHAVIORAL|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
223944358|NCT01961063|OTHER|laboratory biomarker analysis|Correlative studies
223944359|NCT05621174|DRUG|Dexamfetamine|Magisterial Dexamfetamine
223944360|NCT05621174|DRUG|Dexamfetamine|Tentin
223944361|NCT03445689|OTHER|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
223944362|NCT03445689|OTHER|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
223944363|NCT03445689|OTHER|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
223535441|NCT03606577|DRUG|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
223944364|NCT03445689|OTHER|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
223944365|NCT03445689|OTHER|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
223944366|NCT03445689|OTHER|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
223944367|NCT05655949|DRUG|Gemcitabine|Intravenous infusion
223944368|NCT05655949|DRUG|Cisplatin|Intravenous infusion
223944369|NCT05655949|DRUG|Durvalumab|Intravenous infusion
223944370|NCT05655949|RADIATION|Yttrium-90|Injection of radiation microsphere beads
223944371|NCT05908773|DRUG|TTX-MC138-NODAGA-Cu64|TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging.
223944372|NCT04380805|BIOLOGICAL|AK104|All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.
223944373|NCT04725266|BEHAVIORAL|Family-based intervention|The intervention aims to motivate drug abusers to stay drug abstinence and improve family functioning with the support of their own families. In the component of engagement, we will use effective and appropriate skills to engage clients, understand their concerns, and provide necessary resources to them. In the component of role identification, we will help drug abusers identify their family roles through providing education on family roles and responsibilities. The component of affection is designed to learn affective responsiveness and enhance their emotional bonds with each other, while in the component of competence, we will enhance their competency to take care of the family. The intervention will be conducted in group sessions with 4-6 families per group. A total of 17 sessions will be delivered with 1.5-2 hour for each session (6 sessions for Engagement, 3 sessions for Role identification, 3 sessions for Affection, and 3 sessions for Competence).
223944374|NCT04725266|OTHER|routine care|Routine care includes individual-session components of engagement, case assessment, drug education, service referral, family support, and etc.
223944375|NCT04374474|OTHER|Olfactory retraining|Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
223944376|NCT04374474|DRUG|corticosteroid nasal irrigation|Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
223944377|NCT04374474|OTHER|smell household Items|Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items
223944378|NCT04374474|OTHER|Nasal Irrigation|Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
223944379|NCT04920253|DEVICE|Study Device Debridement|debritom+ water jet debridement
223944380|NCT04920253|DEVICE|SOC Debridement|Sharp Scalpel
223944381|NCT06014671|BEHAVIORAL|Interpersonal Psychotherapy|Intervention Group were took interpersonal psychotherapy
223944382|NCT02637063|BEHAVIORAL|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
223944383|NCT02637063|BEHAVIORAL|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
223944384|NCT02637063|OTHER|Usual care|No intervention beyond participants' own medical care.
223944385|NCT00663611|DRUG|Norditropin|Norditropin (somatropin, rDNA origin) is a polypeptide hormone of recombinant DNA origin. The amino acid sequence of the product is identical to that of the human growth hormone of pituitary origin.
223944386|NCT00663611|DRUG|Placebo|0.9% normal saline
223944387|NCT01850342|PROCEDURE|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
223944388|NCT05996900|DEVICE|Intracranial electrodes|Intracranial electrodes will be used for the delivery of invasive brain stimulation.
223944389|NCT05996900|DEVICE|TMS|TMS will be used for the delivery of noninvasive brain stimulation both before and after implantation electrode surgery.
223944390|NCT05856682|PROCEDURE|Laparoscopic-assisted TAP block(LATAP) and Rectus Sheath block|Laparoscopic -assisted TAP and rectus sheath block will be performed after insertion of optical port By Surgeon /surgery trainee. • Site of rectus block will be Bilaterally 3 cm lateral to Umblicus and 3cm lateral to midpoint between xiphisternum and umbilicus . Site of TAP block will be anterior to the midaxillary line between the costal margin and iliac crest bilaterally.
223944391|NCT02596061|BEHAVIORAL|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
223944392|NCT02596061|OTHER|Incentives|Patients receive incentives for completing smoking cessation activities.
223944393|NCT04529928|DEVICE|Carillon Mitral Contour System|Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
223944394|NCT03605082|DRUG|UCB0107|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
223944395|NCT03605082|OTHER|Placebo|"* Pharmaceutical form: solution for infusion~* Route of administration: intravenous use"
223944396|NCT04468191|DEVICE|Experimental expiratory muscle strength training (EMST)|The experimental EMST will involve blowing into a device with a spring-loaded valve set to 50% of the patient with ALS' maximum expiratory pressure.
223944397|NCT04468191|DEVICE|Sham expiratory muscle strength training (EMST)|The sham EMST will involve blowing into a device without a spring-loaded valve (0% resistance).
223944398|NCT05819294|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
223944399|NCT02640703|BIOLOGICAL|Infanrix + Prevenar 13|Different time of application
223944400|NCT01748864|DRUG|Etarfolatide (EC20)|
223944401|NCT01767688|DRUG|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
223944402|NCT00686257|DEVICE|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
223944403|NCT00686257|DEVICE|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
223944404|NCT01579799|DRUG|L-lysine|Dose finding study for L-lysine
223944405|NCT03066921|DIETARY_SUPPLEMENT|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
223944406|NCT03066921|DIETARY_SUPPLEMENT|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
223944407|NCT05732727|DRUG|Antihypertensive algorithm|Antihypertensive algorithm based on diuretics agents
223944408|NCT05732727|DRUG|Standard of care|standard of care management for antihypertensive therapy intensification
223944409|NCT04320914|OTHER|High Intensity LASER Therapy|"The total energy will be delivered to the patient during one session will be 1,250 J through three phases of treatment.~1. Initial phase (710 and 810 mJ/cm2 for a total of 500 J)~2. Intermediate phase (handpiece will be applied on the joint line just proximal to the medial and lateral tibial condyles with 25 J, a fluency of 610 mJ/cm2, and a time of 14 s for each point and a total of 250 J)~3. Final phase (same as the initial phase (500 J) except that scanning will be slow manual scanning ) The application time for all three phases will be approximately 15 min with the total energy delivered to the patient during one session of 1,250 J Duration of the treatment will be 8 minutes in one session/knee joint for each day for 3 days/week for 8 weeks."
223944410|NCT04320914|OTHER|Ibuprofen gel phonophoresis|Continuous ultrasound set at a frequency of 1 MHz and an intensity of 1 W/cm2 was applied on a circular basis. Each treatment session will last for 8 min with one session each day for 3 days/week for 8 weeks.
223944411|NCT02634307|DRUG|ALKS 8700|Administered as specified in the treatment arm.
223944412|NCT02698475|DRUG|Ustekinumab 0.75 mg/kg|Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
223944413|NCT02698475|DRUG|Ustekinumab 45 mg|Participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
223944414|NCT02698475|DRUG|Ustekinumab 90 mg|Participants weighing \>100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
223944415|NCT03876184|OTHER|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
223944416|NCT03876184|OTHER|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
223944417|NCT03263611|DRUG|Placebo|single intradiscal injection
223944418|NCT03263611|DRUG|AMG0103|single intradiscal injection
223944419|NCT01942954|OTHER|Mobile health cognitive stimulation|
223944420|NCT06360276|BEHAVIORAL|Seated Exercises|A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises
223944421|NCT06360276|BEHAVIORAL|Psychoeducational Rehabilitation|Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.
223944422|NCT06360276|BEHAVIORAL|Routine Care|Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
223944423|NCT01444365|DRUG|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
223944424|NCT01444365|DRUG|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
224099876|NCT01106638|BEHAVIORAL|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
224099877|NCT03401606|DRUG|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
224099878|NCT03401606|DRUG|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
224099879|NCT06958679|DRUG|SYS6005|SYS6005 administered via IV infusion on , Day 1 of each 21-day cycle
224099880|NCT01538771|DRUG|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
224099881|NCT01538771|DRUG|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
224099882|NCT02993237|DRUG|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
224099883|NCT02993237|DRUG|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
224099884|NCT03312855|DRUG|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
224099885|NCT03312855|DRUG|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
224099886|NCT03312855|DRUG|Placebo|single dose, intravenous application of Placebo solution
224099887|NCT01385696|DEVICE|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
224099888|NCT01385696|DEVICE|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
224099889|NCT04359966|DRUG|Esomeprazole 40mg, Clarithromycin 500 mg, Metronidazole 400 mg,|First line therapy
224099890|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|First line therapy second arm
224099891|NCT04359966|DRUG|Esomeprazole 40mg, Bismuth subcitrate 120 mg, Amoxicillin 500 mg, Metronidazole 400 mg|Second line therapy for Helicobacter pylori infection
223944425|NCT03528915|OTHER|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
223944426|NCT03528915|OTHER|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
223944427|NCT02795741|DEVICE|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
224099892|NCT04359966|DRUG|Esomeprazole 40mg, Amoxicillin 500 mg, Levofloxacin 500 mg|Second line therapy for Helicobacter pylori infection second arm
224099893|NCT02652429|DRUG|Inhaled Nitric Oxide|
224099894|NCT03551028|DEVICE|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
224099895|NCT04188158|COMBINATION_PRODUCT|CAPECITABINE AND OXALIPLATIN|Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
224099896|NCT04264104|OTHER|neural mobilization|This is a type of mobilization that uses a specific combination of joint movements
224295156|NCT00186823|PROCEDURE|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
223944428|NCT03528213|DRUG|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
223944429|NCT03528213|DRUG|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
223944430|NCT03528213|DRUG|Normal saline|normal saline at physician discretion
223944431|NCT02042703|DEVICE|anterior segment OCT|
223944432|NCT01158248|BIOLOGICAL|panitumumab|
223944433|NCT01158248|DRUG|cisplatin|
223944434|NCT01158248|RADIATION|brachytherapy|
223944435|NCT01158248|RADIATION|external beam radiation therapy|
223944436|NCT02132949|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m\^2 IV on Day 1 of each cycle q3w.
223944437|NCT02132949|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m\^2) intravenous (IV) given on Day 1 of each cycle q2w.
223944438|NCT02132949|DRUG|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m\^2 IV for the first cycle and the dose may be escalated to 100 mg/m\^2 for subsequent cycles q3w.
223944439|NCT02132949|DRUG|Doxorubicin|Participants will receive doxorubicin 60 mg/m\^2 IV on Day 1 of each cycle q2w.
224295157|NCT00186823|DRUG|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
223944440|NCT02132949|DRUG|Epirubicin|Participants will receive epirubicin 100 mg/m\^2 IV on Day 1 of each cycle q3w.
223944441|NCT02132949|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV given weekly.
223944442|NCT02132949|DRUG|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
223944443|NCT02132949|DRUG|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
223944444|NCT00549666|DRUG|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
223944445|NCT00549666|DRUG|Placebo 40 mg|Placebo 40 mg once daily during treatment period
223944446|NCT00549666|DRUG|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
223944447|NCT06340191|OTHER|Pilates with cueing|"The Pilates with a cueing component of the intervention involved a specialized approach to Pilates training. Participants in this group underwent an initial phase of training before the main sessions began, which consisted of two smaller group sessions focused on learning explicit verbal and tactile cues. These cues were designed to assist participants in maintaining proper body alignment, engaging specific muscle groups more effectively, and refining their movement techniques to enhance the overall efficacy of the Pilates exercises.~During the actual Pilates sessions, the instructors, who were certified and brought extensive experience to the program, provided real-time feedback to the participants. This feedback was based on the cueing instructions, aiming to optimize the execution of the Pilates exercises."
223944448|NCT06340191|OTHER|Pilates without cueing|"The Pilates without cueing portion of the study involved participants following the same comprehensive Pilates program as the Pilates with cueing group, with a significant distinction: they did not receive any additional training on cueing. This group engaged in 60-minute Pilates sessions twice a week for 8 weeks, under the supervision of certified and highly experienced Pilates instructors. The program included a variety of exercises, both mat-based and utilizing props, designed to improve participants\&#39; physical condition and wellness.~However, unlike their counterparts in the first group, these participants were not given explicit instructions on how to enhance their body alignment, muscle engagement, or movement techniques through verbal and tactile cues. They performed the Pilates exercises following the standard regimen, without the nuanced guidance and real-time feedback focused on optimizing exercise execution through cueing."
223944449|NCT06488794|DRUG|colistimethate sodium|100 000 IU/kg of colistimethate sodium (equivalent to 0.96 mg/kg of colistin base) ,maximum 750000 IU, will be nebulized daily, divided into two doses for a maximum of 7 days for eligible ventilated children starting from day 3 of mechanical ventilation.
223944450|NCT06488794|DRUG|0.9% Saline|Nebulization of 3 ml of 0.9% saline twice a day for a maximum of 7 days from day 3 of invasive mechanical ventilation for eligibile ventilated children
223944451|NCT05741450|DEVICE|Lens 1 (monthly replacement)|Monthly replacement spherical silicone hydrogel contact lens for 15 minutes
223944452|NCT05741450|DEVICE|Lens 2 (daily disposable)|Daily disposable spherical silicone hydrogel contact lens for 15 minutes
223944453|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
223944454|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
223944455|NCT02957396|DRUG|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
223535442|NCT03606577|DRUG|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 \& D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
223944456|NCT03360513|OTHER|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
223944457|NCT02132039|OTHER|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
223944458|NCT02132039|OTHER|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
223944459|NCT03926702|DRUG|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
223944460|NCT05377918|OTHER|Diary|spiritual diary group and diary gruop will write a diary
223944461|NCT01673594|DRUG|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
223944462|NCT01673594|DRUG|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
224295158|NCT05540873|DRUG|YYB-103|Biological: IL13Rα2 CAR-T cells Administration method: intravenous infusion YYB-103 is manufactured according to the subject's assigned dose group and body weight.
224295159|NCT00942331|BIOLOGICAL|Bevacizumab|Given IV
224295160|NCT00942331|DRUG|Cisplatin|Given IV
224295161|NCT00942331|DRUG|Gemcitabine Hydrochloride|Given IV
224295162|NCT00942331|OTHER|Laboratory Biomarker Analysis|Correlative studies
224295163|NCT00942331|OTHER|Placebo Administration|Given IV
224295164|NCT00006263|BIOLOGICAL|filgrastim|
224295165|NCT00006263|DRUG|carboplatin|
224295166|NCT00006263|DRUG|temozolomide|
224295167|NCT01397617|DEVICE|NobelActive Internal implant|Dental implant
224295168|NCT01397617|DEVICE|NobelActive External implant|Dental implant
224295169|NCT01397617|DEVICE|NobelReplace Tapered Groovy implant|Dental implant
224295170|NCT01849016|DRUG|N-Acetylcysteine|
224295171|NCT01849016|DRUG|Placebo|
224295172|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
224295173|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
224295174|NCT03699241|BIOLOGICAL|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
224295175|NCT03699241|BIOLOGICAL|Placebo|Tris-NaCl Diluent
223944463|NCT04178213|DEVICE|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
223944464|NCT03069391|BEHAVIORAL|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
223944465|NCT03069391|DEVICE|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
223944466|NCT03069391|DEVICE|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
223944467|NCT04627896|DEVICE|Katty focal therapy|Microwave ablation with TATO3 generator (Katty system) under guidance of ultrasound/mpMRI fusion image device Trinity
223944468|NCT04464031|OTHER|electronic alert|The e-alert system was developed by the divisions of Nephrology and Information Management of Guangdong Provincial People's Hospital (Patent Application 201610001950.5). The alert system made a diagnosis of acute kidney injury according to Kidney Disease: Improving Global Outcomes criteria. Then, the doctor receives an alert of acute kidney injury.
223535443|NCT03606577|DRUG|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
223535444|NCT03606577|DRUG|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
223944469|NCT03183349|PROCEDURE|deprotienized bovine bone (tutogen)|
223944470|NCT03183349|PROCEDURE|platelet rich fibrin|
223944471|NCT04843449|DRUG|ASC40|Oral tablets
223944472|NCT04843449|DRUG|Itraconazole|Oral capsules
223944473|NCT04843449|DRUG|rifampicin|Oral capsules
223944474|NCT04681794|OTHER|exercise-based intervention|MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
223944475|NCT03272412|DIAGNOSTIC_TEST|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
223944476|NCT03768466|DRUG|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
223944477|NCT04295642|DRUG|CVL-751|Oral tablet
223944478|NCT03622710|OTHER|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
223944479|NCT02323776|OTHER|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
223944480|NCT00987324|DEVICE|Taxus stent|Implantation of paclitaxel-eluting stent
223944481|NCT00987324|DEVICE|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
223944482|NCT00987324|DEVICE|Conventional Balloon Catheter|Ryuijin, Trek
223944483|NCT01849107|BIOLOGICAL|Plasma citrulline|
223944484|NCT04288388|BEHAVIORAL|massage group|In recent years, in the literature, it is known that many non-pharmacological techniques are applied to reduce the pain of birth in addition to local anesthesia. One of these nonpharmacological methods is the application of pressure to LI4 point on hand with ice.
223535445|NCT00090376|DRUG|GPI 1485|
223944485|NCT02976272|OTHER|bortezomib|
223944486|NCT00006350|BIOLOGICAL|daclizumab|
223944487|NCT00006350|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223944488|NCT00006350|DRUG|mycophenolate mofetil|
223944489|NCT00006350|DRUG|tacrolimus|
223944490|NCT00006350|PROCEDURE|peripheral blood stem cell transplantation|
223944491|NCT02964793|OTHER|intervention group|"The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
223944492|NCT01707303|OTHER|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
223944493|NCT01707303|OTHER|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
223944494|NCT04989842|BEHAVIORAL|Curriculum Hannover|The methodology uses a natural variation design within the Dr. Becker Clinical Group. The interventions consist of a face-to-face or a digital psychosomatic aftercare basing upon the concept of the Curriculum Hanover. A control group is included that does not receive these two interventions (but receives a similar rehabilitation treatment to the intervention groups).
223944495|NCT00293761|DRUG|Travoprost, Investigational|One drop in study eye once daily for 13 days
223944496|NCT00293761|DRUG|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
223944497|NCT00532350|DRUG|QAT370|
223944498|NCT00532350|DRUG|Placebo|
223944499|NCT00532350|DRUG|Tiotropium|
223944500|NCT06368999|DIAGNOSTIC_TEST|EEG|registration of 8 minutes of EEG
223535446|NCT02415556|DRUG|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
223535447|NCT02415556|DRUG|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
223535448|NCT04885101|PROCEDURE|LISWT Group|The treatment consists of a weekly session and 4,000 pulses will be emitted each of the eight sessions totaling 32,000 pulses with a frequency of 18Hz and 100mJ of energy.
223535449|NCT04885101|PROCEDURE|NARFT Group|The device used will be with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. Eight radio frequency sessions will be held with an interval of seven days between them.
223944501|NCT04460066|DRUG|anti-PD-L1 antibody|Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
223944502|NCT04460066|DRUG|albumin bound paclitaxel|Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .
223944503|NCT04460066|DRUG|cisplatin|Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.
223944504|NCT04460066|DRUG|placebo|Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
223944505|NCT04460066|PROCEDURE|radical resection of esophageal carcinoma|Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.
223944506|NCT03510195|OTHER|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
223944507|NCT00927706|DEVICE|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
223944508|NCT06509204|DIETARY_SUPPLEMENT|Glucotrojan|"Day 1: Start wearing the CGM sensor and let it self-calibrate for 24 h Day 2: Consume 1 serving of Test Meal for breakfast. Log the meal in the app. Day 3: Consume 1 serving of Test Meal with GlucoTrojan for breakfast. Log the meal in the app.~Days 4-8: Participants will be instructed to take GlucoTrojan twice per day. Once during their typical breakfast meal and once during their typical dinner meal. Each breakfast and dinner will be logged in the app.~Days 9-13: Participants will continue with their typical lives but continue to log meals - breakfast and dinner - in the app.~Day 14: end"
223944509|NCT05376982|DIAGNOSTIC_TEST|Neurodevelopmental Treatment|Using Neurodevelopmental Treatment Method
223944510|NCT05376982|DIAGNOSTIC_TEST|Body weight supported treadmill training along with conventional therapy|Using Body weight supported treadmill training along with conventional therapy Method
223535450|NCT04885101|PROCEDURE|Sham Group|In the RNA group, radiofrequency will be applied, the device used will be the Nèartek Esthetic Ibramed - Tecarterapia e Radiofrequency Apparatus, with an intensity of 350 Wpp; 75% pulsed operation mode; frequency of 640 kHz, 1200 kHz and 2400 kHz. The radiofrequency will be applied with the patient in the supine position on both sides of the penis with an opposite dispersion plate against the radiofrequency emitter. To perform the procedure, the therapist will use a glove. Eight radio frequency sessions will be held with an interval of seven days between them.
223535451|NCT04699344|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by PROUD to determine the level of CNV.
223944511|NCT05701579|PROCEDURE|"ACL decompression"|"The technique of ACL decompression by the means of longitudinal incisions and evacuation of extrafibrous mucoid tissue."
223944512|NCT05407051|BEHAVIORAL|Family Centered Treatment|In the Family-Centered Treatment Arm, parents would be given the same list of mental health referrals and crisis numbers, but in this condition, they would authorize researchers to share their contact information with the partner agency, Catholic Charities, and would then be linked directly to bilingual adult mental health services there with a behavioral health provider who would provide collateral therapy to parents via telehealth. Although parents will be referred to the community partner for therapy as a part of the research intervention, the behavioral health providers at the community partner will be providing therapy as they usually do for these participants in line with their usual job duties.
223944513|NCT05407051|BEHAVIORAL|Treatment as Usual|"All participants (parents) would receive follow-up calls from a MetroHealth research personnel at 3 months and 6 months to measure changes in parent mental health outcomes, as well as satisfaction.~Children of parents in both conditions will receive treatment as usual which includes brief consultation for 3-5 sessions with an integrated MetroHealth behavioral health provider which is already standard practice in the clinic. Sessions typically occur monthly. Teens will be re-administered the Patient Health Questionnaire -9 by the integrated behavioral health provider as a part of clinical practice to measure treatment progress and this information will be obtained at the end of 6 months of treatment via chart review (see data sheet). Repeated measurement of patient's symptoms over the course of several months of treatment is common in clinical practice to measure patient's symptom improvement."
223944514|NCT05697536|OTHER|Pilates training|"It consists of patients who will receive pilates exercise training sessions 3 times per week for 8 weeks. Every session will be of 45 minutes. Exercise programs follow the basic principles of pilates method but particularly movements with low and medium difficulty levels will be chosen to adapt the program to the physical capacity of the patients.~Protocol will be compromise of 9 modules: postural education, search for neutral position, sitting exercise, antalgic exercise, stretching exercises, proprioceptively improvement exercises and breathing exercises."
223944515|NCT05697536|OTHER|Aerobic Exercise|"It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 45 minutes.~It will include warm up phase, active phase and"
223944516|NCT04696016|PROCEDURE|Skin conductance guided antinociception|The value of skin conductance guides the titration of sufentanil
223944517|NCT04696016|PROCEDURE|Standard care antinociception|The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
223944518|NCT03087890|DRUG|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
223944519|NCT03087890|DRUG|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
223944520|NCT01776320|DRUG|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
224099897|NCT02012816|OTHER|Peer-referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
224099898|NCT05307471|OTHER|Thoracotomy/scopy|
224099899|NCT05089565|DIAGNOSTIC_TEST|Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation|Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination
224099900|NCT01695369|DEVICE|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
224099901|NCT01695369|DEVICE|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
224099902|NCT00656214|DRUG|Lycopene|08 mg/day in two divided dosage
224099903|NCT00656214|DRUG|Placebo|Two divided dosage
224099904|NCT01826669|PROCEDURE|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
224099905|NCT05926206|DRUG|Devimistat|Escalation: Assigned dose level (mg/m2), IV over 120 minutes, Days 1 and 3 Cohort A: 500 mg/m2, IV over 120 minutes, Days 1 and 3 Cohort B: MTD mg/m2, IV over 240 minutes, Days 1 and 3
224099906|NCT05926206|DRUG|Modified FOLFIRINOX|Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
223944521|NCT06412094|OTHER|Standard care|Recommendation of standard treatment plan, according to the clinical severity of the AD, and. are instruction to contact the doctor via messenger for any questions related to treatment recommendations.
223944522|NCT06412094|BEHAVIORAL|"Access to the AtopicApp mobile application"|"Access to the AtopicApp mobile application with 1 day after enrollment."
223944523|NCT06412094|BEHAVIORAL|Virtual oversight through the AtopicApp|Notification of doctor's virtual oversight through the AtopicApp mobile application.
223944524|NCT03642834|DRUG|ICP-105|25mg, 100mg capsule
223944525|NCT04270032|DIAGNOSTIC_TEST|ABUS and HHUS|Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
224099907|NCT02589587|PROCEDURE|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
224099908|NCT02589587|OTHER|no intervention|lean control group
224099909|NCT02813538|DRUG|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
224099910|NCT02813538|OTHER|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
224099911|NCT03160144|PROCEDURE|open lung approach|
224099912|NCT04676243|DRUG|Quizartinib|20 mg coated tablets, orally administered
224099913|NCT04676243|DRUG|Treatment according to Physician's Choice|Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
223944526|NCT02234999|DRUG|CC-122|3mg \[14C\]-CC-122 will be administered as a single dose
223944527|NCT05532553|DEVICE|Carotid Doppler U/S|Measurement of carotid intima media thickness by carotid doppler ultrasound
223944528|NCT04130490|DEVICE|ANTERION|3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
223944529|NCT01087710|OTHER|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
223944530|NCT01087710|OTHER|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
223944531|NCT01404000|DRUG|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
223944532|NCT02697968|DEVICE|Electroacupuncture|
223944533|NCT06509230|OTHER||The fibrosis grades were grouped without drug intervention
223944534|NCT04574206|BEHAVIORAL|Elaborative Reminiscence (ER)|Parents will be trained to use elaborative communication techniques in conversations with their child.
223944535|NCT04574206|BEHAVIORAL|Present Tense Talk (PTT)|Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
223944536|NCT03624283|DRUG|Betahistine|Betahistine is used in the treatment of and vertigo.
223944537|NCT03624283|BEHAVIORAL|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
223944538|NCT01189552|BEHAVIORAL|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
223944539|NCT01189552|BEHAVIORAL|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
223719599|NCT02073552|DRUG|Polyethylene glycol 4000|\- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
223729417|NCT00731289|DRUG|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
223944540|NCT04192357|BEHAVIORAL|WLM3P|18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
223944541|NCT04192357|BEHAVIORAL|Low-carb diet|18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
223944542|NCT04751981|PROCEDURE|Patient Specific Guide|For lumbar fusion pedicle screws will be placed with the aid of patient specific guides.
223944543|NCT04751981|PROCEDURE|Navigation|Conventional navigation will be used to place pedicle screws.
223944544|NCT05722626|PROCEDURE|PRP|2 ml of platelet rich plasma intraarticular injection twice in one week interval
223944545|NCT05722626|OTHER|Normal Saline|NaCl 0.9%
223944546|NCT02930317|DRUG|Recombinant Factor VIII (50 IU/kg)|
223944547|NCT02930317|DRUG|Recombinant Factor VIII (On-demand treatment)|
223944548|NCT01083706|DRUG|azacitidine|Given SC or IV
223944549|NCT01083706|OTHER|laboratory biomarker analysis|Correlative studies
223944550|NCT02269852|BIOLOGICAL|trivalent seasonal influenza vaccine|"* Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;"
223944551|NCT01833598|PROCEDURE|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
223944552|NCT01833598|PROCEDURE|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
223944553|NCT03890653|BEHAVIORAL|Performance-Based Financing|Incentive-based payments
223944554|NCT03890653|BEHAVIORAL|Decentralized Facility Financing|Financing not linked to service delivery.
223944555|NCT03028805|OTHER|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
223944556|NCT03028805|OTHER|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
223944557|NCT03392194|BEHAVIORAL|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
223944558|NCT03392194|BEHAVIORAL|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
223944559|NCT03865732|DRUG|Ganaxolone|active drug
223944560|NCT03865732|DRUG|Placebo|inactive
223944561|NCT01928875|DEVICE|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
223944562|NCT01928875|DEVICE|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
223944563|NCT04233905|BEHAVIORAL|Psychometric questionnaire study|Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
223944564|NCT04661774|OTHER|reflexology massage|reflexology massage of the foot zone implicated in diaphragm stimulation
223944565|NCT04661774|OTHER|sham massage|traditional massage of the foot
223944566|NCT02345551|BEHAVIORAL|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
223944567|NCT03863405|DRUG|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
223944568|NCT03863405|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
223944569|NCT03863405|DRUG|Placebo Oral Tablet|oral tablet
224099914|NCT04676243|DRUG|Standard of Care Chemotherapy|Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
224099915|NCT01519843|DEVICE|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
224099916|NCT01519843|DEVICE|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
223944570|NCT01170845|DRUG|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
223944571|NCT05361356|RADIATION|Spectral CT scanning|Volunteer accept spectral CT scanning
223944572|NCT00797056|DRUG|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
223944573|NCT00797056|DRUG|Placebo|Saline SQ daily for 10 days
223944574|NCT00797056|DRUG|Aspirin|Aspirin 75 mg/day for 14 days
223944575|NCT00797056|DRUG|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
223944576|NCT02517385|DRUG|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
223944577|NCT04069806|DIETARY_SUPPLEMENT|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
223719600|NCT02073552|DRUG|Macrogol 3350 plus ascorbic acid|\- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
223719601|NCT01829373|BIOLOGICAL|vaccine 1650-G|
223719602|NCT03782792|DRUG|Spesolimab|Solution for infusion
223719603|NCT03782792|DRUG|Placebo|Solution for infusion
223719604|NCT05273918|OTHER|cognitivo-comportmental therapy|15 workshops once a week during 90 minutes
223944578|NCT01386372|DRUG|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
223944579|NCT01386372|OTHER|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
223944580|NCT04634851|BEHAVIORAL|Virtual home visits|These participants will have a tailored evaluation of dietary choices based on their home dietary environment (refrigerator, pantry, etc). This will be conducted over video exchange.
223944581|NCT03210324|DRUG|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
223944582|NCT01509183|DEVICE|Propeller Health System (formerly Asthmapolis System)|The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
223944583|NCT03075683|BEHAVIORAL|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
223944584|NCT03075683|BEHAVIORAL|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
223944585|NCT03466983|DRUG|Iron Isomaltoside|administered IV
223944586|NCT03466983|DRUG|Ferric Carboxymaltose|administered IV
223719605|NCT05273918|OTHER|body mediation|15 workshops once a week during 90 minutes
223719606|NCT00919919|DRUG|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
224099917|NCT05978869|OTHER|physical fitness training|Through a three-step process, gamified physical fitness training was developed by a multidisciplinary team.
224099918|NCT00597558|DRUG|Egg white protein|Egg white protein powder
224099919|NCT00798512|DEVICE|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
224295176|NCT04142619|BIOLOGICAL|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
224295177|NCT02994251|DRUG|gemcitabine|1000 mg/m\^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
224295178|NCT02994251|DRUG|Cisplatin|25 mg/m\^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
224295179|NCT02994251|DRUG|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
223944587|NCT00343083|DRUG|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
223944588|NCT00343083|RADIATION|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
223944589|NCT03043443|DRUG|Melatonin|Natural health product for sleep problems treatment
223944590|NCT03043443|DRUG|Placebo|Lactose containing pills
223944591|NCT04187482|OTHER|Exercise training|All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
223944592|NCT03086226|DRUG|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
223944593|NCT03086226|DRUG|Itraconazole|This will be the active comparator
223944594|NCT05085704|DEVICE|Magnetic resonance imaging|Medical imaging technique used in radiology to form pictures of the anatomy.
223944595|NCT02808832|BEHAVIORAL|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
223944596|NCT05785325|DRUG|RC48-ADC plus Bevacizumab|Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.
223944597|NCT00396487|DRUG|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
223944598|NCT05672485|DIAGNOSTIC_TEST|SPECT/CT imaging with 99mTc-P137 nuclide probe|inject the tracer 99mTc-P137 to subjects and perform SPECT/CT scans
223944599|NCT00407706|PROCEDURE|blood test|
223944600|NCT05400759|OTHER|IOP monitoring data|
223944601|NCT00005799|DRUG|fludarabine phosphate|Given IV
223944602|NCT00005799|RADIATION|total-body irradiation|Undergo low-dose TBI
223944603|NCT00005799|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
223944604|NCT00005799|PROCEDURE|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
223719607|NCT00919919|DRUG|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
223944605|NCT00005799|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
223944606|NCT00005799|BIOLOGICAL|therapeutic allogeneic lymphocytes|Undergo DLI
223944607|NCT00005799|DRUG|cyclosporine|Given PO
223944608|NCT00005799|DRUG|mycophenolate mofetil|Given PO
223944609|NCT00005799|OTHER|pharmacological study|Correlative studies
223944610|NCT00005799|OTHER|laboratory biomarker analysis|Correlative studies
223944611|NCT00141232|DRUG|Atorvastatin and Omega-3 fatty acids|
223944612|NCT04689932|DRUG|Triferic AVNU|Ferric Pyrophosphate Citrate
223944613|NCT04927078|OTHER|Observation of breathing pattern|Observations will be collected using a remote vision based patient monitoring and management system.
223944614|NCT03345979|COMBINATION_PRODUCT|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
223944615|NCT03345979|DRUG|Paliperidone Palmitate|Intramuscular injection
223944616|NCT02407899|DRUG|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
223719608|NCT03105895|PROCEDURE|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
223944617|NCT02407899|DRUG|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
223944618|NCT02407899|DRUG|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
223944619|NCT02407899|DRUG|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
223944620|NCT05499767|BEHAVIORAL|HEPPI|Homebound Elderly People Psychotherapeutic Intervention
223944621|NCT05478096|BEHAVIORAL|GetStarted|Guided internet-based intervention for procrastination.
223944622|NCT04968509|DRUG|PCSK9 inhibitors and statins with or without ezetimibe|Patients in experimental group are treated with PCSK9 inhibitors (140mg with Evolocumab or 75mg with Alirocumab or 150mg with Tafolecimab subcutaneously every two weeks) and conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
223944623|NCT04968509|DRUG|Statins with or without ezetimibe|Patients in control group are only treated with conventional lipid-lowering therapy based on statins (atorvastatin 20-40mg qd with or without ezetimibe 10mg qd, or rosuvastatin 10-20mg qd with or without ezetimibe 10mg qd).
223944624|NCT03918005|OTHER|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
223944625|NCT05533905|DIAGNOSTIC_TEST|Lumbar puncture|A thin needle is inserted between the bones in the spine.
223944626|NCT05533905|DIAGNOSTIC_TEST|MRI|A scan of the head.
223944627|NCT01962597|OTHER|aerobic exercise|
223944628|NCT01962597|OTHER|resistance training|
223944629|NCT02673359|DRUG|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
223944630|NCT02673359|PROCEDURE|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
223944631|NCT00487240|DRUG|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
223944632|NCT00487240|DRUG|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
223944633|NCT01487954|DIETARY_SUPPLEMENT|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
223944634|NCT01487954|DIETARY_SUPPLEMENT|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
223944635|NCT01487954|RADIATION|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
223944636|NCT02223728|BEHAVIORAL|Lifestyle|
223944637|NCT02223728|BEHAVIORAL|Health Education|
223944638|NCT02560961|OTHER|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
223944639|NCT02560961|OTHER|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
223944640|NCT02773862|DEVICE|HS-1000|
223944641|NCT01814605|PROCEDURE|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
223944642|NCT01814605|PROCEDURE|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
223944643|NCT05072002|OTHER|no intervention / observational study|no intervention / observational study
223944644|NCT02318628|DEVICE|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
223729418|NCT00731289|DRUG|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
223944645|NCT01958385|DEVICE|placement of g-Cath EZ suture anchors|
223944646|NCT01958385|PROCEDURE|Sham procedure|
223944647|NCT01958385|BEHAVIORAL|Diet and Exercise|A structured diet and exercise plan
223944648|NCT05494658|DIETARY_SUPPLEMENT|BCAA|600ml drink which contains 18g BCAA was consumed by patients 2-4h before surgery.
223944649|NCT05494658|DIETARY_SUPPLEMENT|water|600ml water was consumed by patients 2-4h before suegery.
223944650|NCT03755115|DRUG|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
223944651|NCT05210309|PROCEDURE|Stem Cell Therapy|Application of Darvadstrocel locally, after fistula tract curettage and internal opening closure.
223944652|NCT04027985|OTHER|Kinesiotaping|inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
223944653|NCT04027985|OTHER|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
223944654|NCT04027985|OTHER|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
223944655|NCT01698918|DRUG|Everolimus|Everolimus was self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously until progression of disease, unacceptable toxicity or withdrawal of consent.
223944656|NCT01698918|DRUG|Letrozole|1st line study treatment: Letrozole was self administered as a daily dose of 2.5mg continuously until disease progression or any other reason for which the patient might be discontinued
223944657|NCT01698918|DRUG|Exemestane|2nd Line Study Treatment: Exemestane was self administered as a daily dose of 25mg taken orally continuously until disease progression or any other reason for which the patient might be discontinued
223944658|NCT01698918|DRUG|Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study)|Alcohol-free 0.5mg/5ml dexamethasone oral solution was self-administered at a daily dose of 10ml 3 times per day (participants with confirmed stomatitis who entered the stomatitis sub-study).
223944659|NCT01698918|DRUG|Standard of care to treat stomatitis (Stomatitis sub-study)|Standard of care used to treat stomatitis at the patient's center (participants with confirmed stomatitis who entered the stomatitis sub-study).
223944660|NCT03730688|DEVICE|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
223944661|NCT03730688|DEVICE|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
223944662|NCT02630186|DRUG|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
223944663|NCT02630186|DRUG|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
223944664|NCT03192501|DRUG|inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.|Choose appropriate targeted drugs according to NGS/IHC results.
223944665|NCT05851157|DRUG|VX-548|Tablets for oral administration.
223944666|NCT03690466|DEVICE|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
223944667|NCT03690466|DEVICE|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
223944668|NCT03492853|GENETIC|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
223944669|NCT02916576|DEVICE|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
223944670|NCT01019135|BEHAVIORAL|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
223944671|NCT05087407|PROCEDURE|Decomprssion and drainage seton|Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
223944672|NCT05087407|PROCEDURE|Cutting seton|Cutting seton is introduced from outside openning to internal openning and encircling the internal and external anal sphincter.
223535452|NCT06434558|PROCEDURE|Cryosa Procedure|The Cryosa Procedure is part of the ARCTIC-3 protocol (IRB #854182). Therefore, all patients enrolled in this study are expected to undergo the Cryosa Procedure. Undergoing the Cryosa Procedure is not a part of this protocol.
223535453|NCT00105534|DRUG|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
224099920|NCT02687308|PROCEDURE|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
224099921|NCT02687308|PROCEDURE|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
224099922|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
224099923|NCT03380949|PROCEDURE|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
223729419|NCT05725720|OTHER|Gut microbiome analysis|Characterization of the compositional and functional modifications of gut microbiome in patients affected by lymphoma undergoing therapy with CAR-T cells from baseline until the restaging after 18 months from the CAR-T cell infusion
223729420|NCT00227435|DRUG|val-mCyd|
223944673|NCT02027584|OTHER|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
223944674|NCT01263132|DRUG|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
223944675|NCT01263132|DRUG|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
223944676|NCT06470386|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
224099924|NCT01809236|BIOLOGICAL|Conbercept|intravitreal injection of 0.5 mg Conbercept
223535454|NCT00105534|OTHER|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
223944677|NCT06470386|DRUG|Carvedilol|taken orally, starting dose of 6.25 mg once a day, gradually adjusted according to heart rate to 6.25 mg twice a day, 12.5 mg in the morning and 6.25 mg in the evening, 12.5 mg twice a day, or adjusted to the maximum tolerated dose (heart rate greater than 55 beats/min and systolic blood pressure greater than 90 mmHg), taken continuously for 24 weeks.
223944678|NCT04179526|BEHAVIORAL|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
223944679|NCT05738785|OTHER|Document review and scanning|Osteoporosis risk and osteoporotic fracture risk will be calculated by examining the patients' files.
223944680|NCT00786344|BEHAVIORAL|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
223944681|NCT02558543|DRUG|Stromal Vascular fraction|
223944682|NCT02558543|DRUG|Ringer lactate|
223944683|NCT00439218|DRUG|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
223944684|NCT05154955|DRUG|10XB-101 Solution for Injection|One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.
223944685|NCT05154955|DRUG|10XB-101 Vehicle Solution for Injection|This is the placebo control
223944686|NCT03903978|BEHAVIORAL|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
223944687|NCT03903978|BEHAVIORAL|Healthy lifestyle|"1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
223944688|NCT02064283|PROCEDURE|Diffusion MRI|
223944689|NCT03971552|PROCEDURE|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
223944690|NCT05073822|DRUG|Tacrolimus|reduction of both standard Tacrolimus \& Mycophenolate mofetil does in one arm
223944691|NCT03176407|DIAGNOSTIC_TEST|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
223944692|NCT03339544|DRUG|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
223944693|NCT03339544|DRUG|Placebo|placebo is given as a tablet before initiation of endodontic treatment
223944694|NCT03342261|DRUG|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
223944695|NCT02142595|DRUG|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
223944696|NCT02142595|DRUG|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)\*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)\*0.15 ml/h through syringe pump to the end of surgery
223944697|NCT02052167|DEVICE|methotrexate prefilled pen|
223944698|NCT05579184|DRUG|[177Lu]Ludotadipep|"Patients will receive 100 mCi of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (up to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
223944699|NCT02263105|DRUG|CDDP|
223944700|NCT02263105|DRUG|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
223944701|NCT01482325|DEVICE|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
223944702|NCT04301713|OTHER|Evaluation of rik of falls|An evaluation of the risk of falls will be carried out in the elderly in the province of Salamanca. This will attempt to identify the risk of falling as well as to be able to establish protocols for action of a preventive and rehabilitative nature.
223944703|NCT04817826|DRUG|Durvalumab|durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
223944704|NCT04817826|DRUG|Tremelimumab|tremelimumab 300 mg single administration (day 1)
223535455|NCT02258802|BEHAVIORAL|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
223944705|NCT03591588|OTHER|diet|The study includes 2 types of diets, i.e., high-saturated fat diet and low-fat high-protein diet, which are provided to each participant in a randomized crossover design.
223944706|NCT02596737|BEHAVIORAL|wittyFit concept|
223944707|NCT01428583|DRUG|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
223944708|NCT01375699|DRUG|Doxorubicin|As prescribed by treating provider.
223944709|NCT01375699|DRUG|Sildenafil|Given PO, by mouth
223944710|NCT02983721|PROCEDURE|transradial|transradial route for coronary angiography and PCI
223944711|NCT02983721|PROCEDURE|Transfemoral|transfemoral route for coronary angiography and PCI
223944712|NCT00033748|BIOLOGICAL|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
223944713|NCT00033748|BIOLOGICAL|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
223944714|NCT00529009|DRUG|UDCA|
224099925|NCT00252850|GENETIC|CERE-120: AAV2-NTN|
224099926|NCT00918723|DRUG|Fludarabine Phosphate|Given IV
223535456|NCT01041430|OTHER|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
223535457|NCT01041430|OTHER|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
223535458|NCT01621178|DRUG|Dulaglutide|Administered SC
223944715|NCT05360537|DRUG|Insulin Degludec / Liraglutide Injectable Product|administration of Insulin Degludec/Liraglutide
223944716|NCT05360537|DRUG|Insulin Glargine|Administration of glargine insulin
223944717|NCT00655213|DEVICE|Symphony D 2450|
223944718|NCT00655213|DEVICE|Symphony DR 2550|
223944719|NCT00670488|DRUG|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
223944720|NCT00523900|DIETARY_SUPPLEMENT|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
223944721|NCT06554184|DRUG|HR20013 + dexamethasone + palonosetron placebo|HR20013 + dexamethasone + palonosetron placebo
223944722|NCT06554184|DRUG|Palonosetron + dexamethasone + HR20013 placebo|Palonosetron + dexamethasone + HR20013 placebo
223944723|NCT06836479|OTHER|NOURISH Diet|NOURISH meals will be prepared by NOURISH chefs for seven days. Both South Asian and Filipino meal plans will be prepared, vegetarian, vegan and non-vegetarian options available for all. Participants will pick-up NOURISH meals at a Stanford facility and consume three meals (breakfast, lunch, and dinner) and two snacks over one week. There will be no caloric restriction, the calories in each meal will be informed by the average intake for the participants gender and BMI.
223944724|NCT06836479|OTHER|Self-Selected Diet (Control)|The participants will eat their routine meals without any involvement of the investigators. Participants will be required to wear the CGM during this time and keep a detailed food log through Tastermonial.
224099927|NCT00918723|DRUG|Cyclophosphamide|Given IV
224099928|NCT00918723|BIOLOGICAL|Rituximab|Given IV
224099929|NCT00918723|DRUG|Vorinostat|Given PO
224099930|NCT00051844|DRUG|Capravirine|
224099931|NCT04072042|DRUG|Apatinib monotherapy|patients will receive Apatinib 250mg tablet by mouth, bid.
224099932|NCT03513380|BEHAVIORAL|Exergaming|free access to the exergame PedalTanks during 6 months
224099933|NCT05617092|OTHER|Physiotherapy treatment|physiotherapy individualized treatment according to the needs of the patient and clinical findings and symptoms
223944725|NCT06835985|OTHER|Chatbot Intervention|Participants screened for suicidality during the ETUDES Center Primary Care Study and who disclose experiencing online victimization will be onboarded by a research clinician on how to use SMILEY, the web-based intervention that delivers psychoeducation, basic concepts of social media self-efficiency, and guidance on how to respond to and cope with online victimization. The chatbot and/or research clinician will send out periodic reminders to users to remind them to engage with the chatbot over four weeks. Technical troubleshooting concerns will be carried out by research clinician and chatbot developer team.
223944726|NCT06835985|OTHER|Brief Psychoeducation|When youth onboard the study, a research clinician will deliver psychoeducation for youth and caregivers supported by web-based resources. Content will introduce basic concepts of social media self-efficacy (screen time guidance, technological coping skills, and encouragement of positive online interactions) and guidance on how to respond to and cope with online victimization.
223944727|NCT01020097|DRUG|fluorine F18 EF5|Given IV
223944728|NCT01020097|PROCEDURE|immunohistochemistry staining method|Correlative study
223944729|NCT01020097|PROCEDURE|biopsy|Correlative study
223944730|NCT01020097|PROCEDURE|Positron Emission tomography|Undergo scan
223944731|NCT01218048|DRUG|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
223944732|NCT01218048|PROCEDURE|Surgery|Surgery for tumor
223944733|NCT01218048|RADIATION|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
223944734|NCT01218048|DRUG|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
223944735|NCT01455779|DEVICE|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
223944736|NCT00505024|BEHAVIORAL|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
223944737|NCT00505024|OTHER|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
223944738|NCT02743039|BEHAVIORAL|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
223944739|NCT00301054|DRUG|Ferrous sulphate|
223944740|NCT00301054|DRUG|Sulphadoxine-Pyrimethamine|
223944741|NCT02232997|OTHER|Standard Hydration|Sodium chloride hydration was set between 12 hours before coronary intervention (before contrast exposure during coronary angiography), continued during procedure, and 12 hours after procedure at 1 ml/kg/h (0.5 ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \< 35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to calculated values for patients weighing 80 kg
223944742|NCT02232997|OTHER|Simplified Hydration|Hydration with sodium chloride was set 1 hour before procedure (before contrast exposure during coronary angiography), continued during procedure, and 4 hours after procedure at 3ml/kg/h (1.5ml/kg/h For patients with congestive heart failure, New York Heart Association class\>II, or LVEF \<35%). For patients weighing more than 80 kg, bolus and infusion rates are limited to those calculated for patients weighing 80 kg.
223944743|NCT03677167|OTHER|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
223944744|NCT02294994|DRUG|tirofiban|
223944745|NCT01037868|OTHER|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
223944746|NCT02110914|BEHAVIORAL|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
223944747|NCT00000178|DRUG|Prednisone|
223944748|NCT05227092|DEVICE|3D OPTIMIZED WMN MPRAGE|"* At the cervical level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 2D Sagittal PSIR / 3D MPRAGE and the 3D OPTIMIZED MPRAGE WMN data set with sagittal and axial acquisition.~* At the thoracic level the conventional data set: 2D Sagittal T2 FSE/ 2D Sagittal STIR / 3D MPRAGE and the 3D Sagittal OPTIMIZED MPRAGE WMN data set."
223944749|NCT00797212|DEVICE|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
223944750|NCT00649857|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
223944751|NCT00649857|DRUG|Zyrtec® 10 mg|10mg, single dose fed
223944752|NCT04781868|DRUG|Multi-nutrient supplement|Multi-nutrient supplement containing a combination of vitamins, minerals and antioxidants
223944753|NCT04781868|DRUG|Placebo|Placebo
223944754|NCT01249638|DRUG|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
223944755|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
223944756|NCT01249638|DRUG|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
223944757|NCT01249638|DRUG|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
223944758|NCT01249638|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
223944759|NCT01279707|BIOLOGICAL|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
223944760|NCT01279707|BIOLOGICAL|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
223944761|NCT01279707|BIOLOGICAL|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
223944762|NCT04945538|OTHER|Scatter radiation exposure measurement|Scatter radiation exposure of the operator and sterile assistant is recorded with digital live dosimeters at 3 locations of the operator (frontal head at eye level, left lateral head, below the left shoulder) and at 2 locations of the sterile assistant (left neck and below the left shoulder)
223944763|NCT02333318|DRUG|VVZ-149 injection|Colorless, transparent liquid in water for injection
223944764|NCT02333318|OTHER|Placebo|water for injection
223944765|NCT03096470|PROCEDURE|anesthesia|no anesthesia
223944766|NCT00516399|DRUG|povidone-iodine 1.25% ophthalmic solution|
223944767|NCT00516399|DRUG|natamycin ophthalmic suspension, USP 5%|
223944768|NCT04017104|DIAGNOSTIC_TEST|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
223944769|NCT04017104|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
223944770|NCT04017104|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
223944771|NCT02336802|BEHAVIORAL|Avoidance experiment|Participants complete an avoidance task
223944772|NCT02447666|DRUG|Azacitidine|
223944773|NCT01030263|OTHER|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
223944774|NCT01030263|OTHER|Random four-quadrant biopsies.|Random four-quadrant biopsies.
223944775|NCT01455948|DEVICE|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
223944776|NCT01455948|PROCEDURE|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
223944777|NCT02941692|DRUG|Oxytocin|
223944778|NCT02941692|DRUG|Placebo|Placebo for Oxytocin
223944779|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol 2.5 grams
224099934|NCT06247150|BIOLOGICAL|Additional blood sample|The procedure will consist of an additional blood sample for 3 ETDA tubes collection (NGS analysis) and citrate tube collection (NETose analysis)
224099935|NCT06247150|BIOLOGICAL|cGVHD target tissue biopsy|For chronic GVH patients only, cGVHD target tissue biopsy
224099936|NCT00942162|BIOLOGICAL|Immunotherapeutic GSK2132231A|Intramuscular administration
223944780|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
223944781|NCT01324089|DIETARY_SUPPLEMENT|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
223944782|NCT03385031|OTHER|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
223944783|NCT04675684|BEHAVIORAL|Recovery-group|The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
224099937|NCT03739970|DIETARY_SUPPLEMENT|Investigational Product (Silk Peptide)|"* Ingredient: Silk Peptide~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 9g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
224099938|NCT03739970|DIETARY_SUPPLEMENT|Control Group - Placebo Product|"* Ingredient: Microcrystalline Cellulose~* Type: Yellow granule stick~* Storage: Room temperature~* Weight: Silk Peptide 0g/day~* Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~* Duration of use: 8 weeks"
223944784|NCT03177941|OTHER|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
223944785|NCT03492021|OTHER|Diet Intervention_AP-CPT|Adequate Protein\_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
223944786|NCT03492021|OTHER|Diet Intervention_PP-PPT|Optimal Protein\_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
223944787|NCT06282354|OTHER|Type of post-operative appointment|remote post-operative appointment for small or medium urooncology procedures
223944788|NCT03914885|GENETIC|ATLCAR.CD30|Administered at a dose of 2 x 10\^8 cells/m2
223944789|NCT03914885|DRUG|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
223944790|NCT03914885|DRUG|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
223944791|NCT02245529|DRUG|Tamsulosin|
223944792|NCT03960957|BIOLOGICAL|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
223944793|NCT03960957|OTHER|Placebo|Treatment of glabellar facial lines with placebo
223944794|NCT01296230|PROCEDURE|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
223944795|NCT01264172|PROCEDURE|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
223944796|NCT01264172|PROCEDURE|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
223944797|NCT01264172|PROCEDURE|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
223944798|NCT02317172|OTHER|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
223535459|NCT01621178|DRUG|Insulin glargine|Administered SC
223535460|NCT01621178|DRUG|Insulin lispro|Administered SC
223944799|NCT04528914|OTHER|Low-FODMAP diet|The low-FODMAP diet will contain the amount of FODMAPs that will not exceed the cut-offs for each FODMAP sugar per serving of food per sitting. Diets will be individually tailored by dietitian and delivered by a catering company (five meals each day).
223944800|NCT04730726|DEVICE|MSOT Acuity Echo|Hybrid optoacoustic and ultrasonography imaging
223535461|NCT03005730|OTHER|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
223535462|NCT03005730|OTHER|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
223535463|NCT05863455|DRUG|mild sedation and analgesia|Intravenous injection of 0.1ug/kg sufentanil and 0.03mg/kg midazolam for sedation and analgesia before radial artery cannulation
223535464|NCT05863455|DRUG|control|ntravenous injection of an equivalent volume of saline before radial artery cannulation.
223944801|NCT06002087|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The current researchers adapted the Unified Protocol (UP) treatment and used the adapted version in this study. UP outlines two complimentary modules for goal setting and psychoeducation followed by five core treatment modules: mindful emotion awareness, cognitive flexibility, countering emotional behaviors, awareness and tolerance of physical sensations, and emotion exposures, and an optional relapse prevention module to help people maintain their gains after treatment.
223944802|NCT03176056|DIETARY_SUPPLEMENT|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
223944803|NCT03176056|DIETARY_SUPPLEMENT|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI \> 24 and 30 kcal/day for underweight subjects with a BMI \<18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
223944804|NCT02581904|DEVICE|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
223944805|NCT02581904|DEVICE|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
223535465|NCT03502564|BEHAVIORAL|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
223535466|NCT03502564|BEHAVIORAL|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
223535467|NCT01606579|DRUG|PRI-724|PRI-724
223535468|NCT01606579|DRUG|PRI-724|PRI-724 in combination with dasatinib
223944806|NCT03948438|PROCEDURE|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
223944807|NCT04496388|BEHAVIORAL|exercise|different type of exercise
223944808|NCT04496388|BEHAVIORAL|No exercise intervention|No exercise intervention
223944809|NCT02736422|OTHER|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
223944810|NCT01138384|DRUG|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
223944811|NCT01138384|DRUG|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
223944812|NCT04333485|OTHER|Home-based Active Case Finding (HACF)|Existing healthcare workers at the participating NTEP TB units will visit all patient homes at 6 and 12 months post-treatment completion. They will administer a standardized TB symptom screen questionnaire to treated TB cases and their household contacts (HHC). All those who screen positive will have a spot sputum taken at the home for microbiological testing at the TB unit.
223944813|NCT04333485|OTHER|Telephonic Active Case Finding (TACF)|Existing healthcare workers at the participating NTEP TB Units will administer a standardized TB symptom screen questionnaire to the index patient via telephone calls at 6 and 12 months post-treatment completion. The index patient will also be asked about any TB symptoms among household contacts (HHCs). If TB is suspected among any HH members, a home visit will be conducted and spot sputum specimens will be collected for microbiological testing at the TB unit.
223944814|NCT04250545|DRUG|Sapanisertib|Given PO
223944815|NCT04250545|DRUG|Telaglenastat Hydrochloride|Given PO
223944816|NCT06025344|DRUG|PanCytoVir™ 100 mg/mL oral suspension|Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
223944817|NCT06025344|DRUG|Probenecid 500 mg|Single oral dose of 1000 mg under fasted conditions
223944818|NCT06527755|DRUG|Eplontersen Solution for Injection|an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.
223944819|NCT03235245|DRUG|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
223944820|NCT03235245|DRUG|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
223944821|NCT06176443|PROCEDURE|One anastomosis gastric bypass with combined fundoplication|FundoRingOAGB
223944822|NCT06176443|PROCEDURE|One anastomosis gastric bypass without combined fundoplication|OAGB
223944823|NCT06965595|OTHER|Routine care|This group will be the control group. Routine care practices carried out in the hospital (vital sign monitoring, administration of analgesics, anti-inflammatory and antibiotics when necessary, and mobilization starting from the 6th hour) will be applied and the data will be recorded.
223944824|NCT06965595|OTHER|Routine care + Physiotherapy|"In addition to routine care practices, this group will receive physiotherapy and rehabilitation. During the postoperative period, the intervention will be applied twice a day.~Posture training: Information about posture will be provided in different positions and training will be conducted.~Breathing training (Diaphragmatic breathing, thoracic expansion exercises)~In-bed mobilization (Lower and upper extremity exercises, foot-ankle exercises (dorsiflexion-plantar flexion / inversion-eversion), hip and knee flexion-extension exercises, cervical region joint range of motion and stretching exercises, upper extremity exercises (shoulder elevation, circumduction, elbow and wrist flexion-extension exercises), pelvic floor training and exercises)~Out-of-bed mobilization (Sitting, standing, walking training after the 6th hour)"
223535469|NCT01606579|DRUG|PRI-724|PRI-724 in combination with low dose ara-C therapy
223535470|NCT02896257|OTHER|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
223944825|NCT06965595|OTHER|Routine care + Vagal stimulation|In addition to routine care practices, this group will receive vagal stimulation. The stimulation will be applied to the cervical region at 10 Hz, 200 μs for 20 minutes, twice a day.
223944826|NCT06965595|OTHER|Routine care + Physiotherapy + Vagal stimulation|In addition to routine care practices, this group will receive physiotherapy and rehabilitation, along with vagal stimulation.
223944827|NCT05143957|DRUG|sapablursen|Sapablursen will be administered by SC injection.
223944828|NCT06769685|DRUG|Basal therapy|Group A was treated with basal therapy including drugs such as interleukin-11, Ricocin, and Epsilon, and was administered until the PLT was ≥75×109/L.
223944829|NCT06769685|DRUG|rhTPO combined with Heptabopa treatment(group B)|In group B, they were treated with rhTPO and Heptabopa, and were medicated until their PLT was ≥75×109/L.
223944830|NCT06769685|DRUG|rhTPO combined with Heptabopa treatment(group C)|Ctit patients with platelet counts \<50×109/L were included in group C. All were treated with rhTPO and hypertrombopa and medicated until PLT ≥75×109/L.
223944831|NCT06507189|OTHER|Combined endurance and resistance training|ET will consist of 3x/wk training (MWF) with MF being steady state cycling, treadmill, or elliptical at 70-75% HRR for 30 min and the W session being a 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) targeting 85-90% HRR. The treadmill and elliptical on M or F will be provided for variety but the mainstay will be cycle ergometry. On MF participants will complete 3 sets x 8-12 repetitions for leg press, knee extension, hamstring curl, chest press, seated row, overhead press, lat pulldown, triceps push-down, and biceps curl in superset fashion \[i.e., alternate between opposing muscle groups without rest (chest press followed by seated row)\] with a 60 s rest between supersets. Sets will be performed with load progression to ensure volitional fatigue in the 8-12 rep range. Core exercises (trunk flexion and extension) will also be included using bodyweight only for 3 sets.
223944832|NCT02224105|DRUG|BI 653048 BS|
223535471|NCT01528579|OTHER|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
223944833|NCT02224105|DRUG|Prednisolone low|
223944834|NCT02224105|DRUG|Prednisolone high|
223944835|NCT02224105|DRUG|Placebo|
223944836|NCT02224105|DRUG|sodium chloride infusion|
223944837|NCT02224105|DRUG|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
223944838|NCT06461234|BEHAVIORAL|Pelvic floor muscle training|A therapist will instruct the patient to contract the anus, perineum as well as the urethra, until the patient masters the correct method.
223944839|NCT06461234|OTHER|Biofeedback electrical stimulation|The therapist will place the electrodes of the instrument into the vagina, adjust the current value until the woman feels obvious contraction of the pelvic floor muscles but no pain, and instructs the patient to refer to the biofeedback mode for vaginal and anal contraction and relaxation.
223944840|NCT06461234|OTHER|Magnetic Stimulation|The therapist will use the magnetic stimulator to intermittently stimulate the and adjust the stimulation intensity at any time according to the patient\&amp;amp;amp;#39;s condition, adjusting it until there is a clear sense of contraction and feel comfortable.
223944841|NCT06461234|OTHER|Magnetic stimulation combined with biofeedback electrical stimulation|Pelvic floor magnetic stimulation for 30 minutes followed by biofeedback electrical stimulation.
223944842|NCT02983266|DEVICE|InTENsity MicroCombo|An electrotherapy device.
223944843|NCT03340415|OTHER|Accelerated Rehabilitation plan|early weight bearing after surgery
223944844|NCT03593785|DRUG|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
223944845|NCT00346320|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
223944846|NCT04493359|DRUG|Renin-angiotensin system inhibitors|switch anti-hypertensive class
223944847|NCT01683409|DRUG|Baricitinib|Administered orally
223944848|NCT01683409|DRUG|Placebo|Administered orally
223944849|NCT04728841|GENETIC|Injection of GS001|"Patients will be enrolled sequentially every 3 weeks or more between cohorts. Dose escalation may occur after a single patient has been safely dosed if the resulting FVIII activity at Week 3 is \< 5 IU/dL.The dose levels are as follows:~1. 2×10\^12 vg/kg~2. 6×10\^12vg/kg or other recommended doses~3. 2×10\^13 vg/kg or other recommended doses"
223944850|NCT00912171|DRUG|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
223944851|NCT00912171|DRUG|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
223944852|NCT00076674|DRUG|Intravenous Levodopa|
223944853|NCT00451711|DRUG|Liposomal amphotericin B|
223944854|NCT03118206|DEVICE|lumbar traction|
223944855|NCT03118206|PROCEDURE|spinal manipulation|
223944856|NCT03118206|PROCEDURE|surgery|
223944857|NCT05652868|DRUG|MYTX-011|MYTX-011 will be administered as an intravenous infusion every 21 days.
223535472|NCT01528579|BEHAVIORAL|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
223535473|NCT01528579|OTHER|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
223535474|NCT01561833|DRUG|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
223535475|NCT05384314|DEVICE|RespiraSense|The use of continuous electronic monitoring of respiratory rate
223535476|NCT00372957|DRUG|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
223944858|NCT06225570|DRUG|Isotretinoin|This arm aims to study the effectiveness, side effects and patient satisfaction of taking isotretinoin on a weekly basis as opposed to current standard daily dosing.
223944859|NCT06225570|DRUG|Tetracycline|This arm aims to serve as the comparison group. Tetracycline antibiotics are the current standard of care for the treatment of moderate acne.
223944860|NCT04823468|DIETARY_SUPPLEMENT|Abbott®Ensure|Abbott®Ensure: 55.8 g each time, three times a day, from the beginning to the end of radiotherapy
223944861|NCT04823468|RADIATION|Intensity Modulated Radiation Therapy|The prescribed dose was 68-76 Gy to Planning target volume of the primary tumor (PTVnx), 66-70 Gy to Planning target volume of the cervical lymph node (PTVnd), 60-64 Gy to planning target volume 1 (PTV1), and 50-54 Gy to planning target volume 2 (PTV2) in 30-33 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
223944862|NCT04823468|DRUG|cisplatin|80-100 mg/m² cisplatin given intravenously every 3 weeks concurrently with radiotherapy.
223944863|NCT06969833|OTHER|Constitution of a biological collection|"* Left-over tissue samples (tumor tissue of different nature) frozen and secured in paraffin, and derived from standard care, are collected at study entrance until the end of oncologic treatment.~* One blood sample of 28mL is collected at time of inclusion"
223944864|NCT06969833|OTHER|Assessment of Quality of Life and level of anxiety/depression|Questionnaires QLQ-C30, OV-28 and HADS are completed by the patients at inclusion, after 3 and 6 cycles of systemic treatment, and every 3 months up to 2 years after inclusion
223944865|NCT06647498|DRUG|Remternetug|Administered subcutaneously every 12 weeks
223944866|NCT06647498|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
223944867|NCT04218864|BEHAVIORAL|Strength for U in Relationship Empowerment (SURE)|A brief computer-based intervention (one session plus one booster session) based on motivational interviewing.
223944868|NCT04218864|BEHAVIORAL|Attention, time, and information matched control|A brief computer based intervention (one session plus booster session) that involves viewing of popular television shows
223944869|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
223944870|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
223944871|NCT01634789|DRUG|bazedoxifene|20 mg oral tablet, single dose
223944872|NCT01634789|DRUG|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
223944873|NCT03506945|BEHAVIORAL|mPEP|Behavioral Activation Therapy
223944874|NCT03506945|BEHAVIORAL|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
223944875|NCT01852006|DEVICE|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
223944876|NCT01800305|DRUG|Pegylated rhEPO|
223944877|NCT01800305|DRUG|EPIAO®|
223944878|NCT03000257|DRUG|Venetoclax|Tablet taken orally
223944879|NCT03000257|DRUG|Rovalpituzumab Tesirine|Intravenous infusion
223944880|NCT03000257|DRUG|ABBV-181|Intravenous infusion
223944881|NCT02804815|DRUG|Aspirin 100mg|Aspirin 100mg
223944882|NCT02804815|DRUG|Aspirin 300mg|Aspirin 300mg
223944883|NCT02804815|DRUG|Placebo 100mg|Placebo 100mg
223944884|NCT02804815|DRUG|Placebo 300mg|Placebo 300mg
223944885|NCT03692845|PROCEDURE|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
223535477|NCT00372957|DRUG|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
223944886|NCT03511612|DIAGNOSTIC_TEST|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
223944887|NCT06626919|BIOLOGICAL|anito-cel|Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain
223944888|NCT06626919|DRUG|Standard Lymphodepletion regimen|Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion
223944889|NCT06772246|DRUG|Quizartinib|Participants will receive a single oral dose of 90 mg
223535478|NCT00372957|DRUG|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
223535479|NCT04778592|DRUG|ETX-018810|Study Drug
223535480|NCT04778592|DRUG|Placebo|Placebo
223535481|NCT03568747|DEVICE|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
223944890|NCT06772246|OTHER|Placebo|Participants will receive a single oral dose of 90 mg
223944891|NCT02568553|BIOLOGICAL|Blinatumomab|Given IV
223944892|NCT02568553|DRUG|Lenalidomide|Given PO
223944893|NCT05993754|OTHER|Non-pharmacological intervention|"The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs"
223944894|NCT01690416|PROCEDURE|Traditional palpation technique|
223944895|NCT01690416|PROCEDURE|Ultrasound DNTP|
223944896|NCT02831816|DRUG|ZuraPrep|Apply topically.
223944897|NCT02831816|DRUG|ChloraPrep|Apply topically.
223944898|NCT02831816|DRUG|ZP Vehicle|Apply topically.
223944899|NCT01227421|DRUG|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
223944900|NCT01227421|DRUG|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
223944901|NCT01227421|DRUG|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
223944902|NCT02847520|BEHAVIORAL|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
223944903|NCT03395600|DRUG|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
223944904|NCT03395600|DRUG|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
223944905|NCT03395600|DRUG|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
223944906|NCT06233552|PROCEDURE|conventional denture conversion|conventional workflow usually done to do immediate loading for full arch implant cases
223944907|NCT06233552|PROCEDURE|digital denture conversion|An alternative workflow for construction of the fixed interim requires impressions, model production, and jaw relation records then digitizing all these data then designing and milling the restoration.
223944908|NCT02045498|DEVICE|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
223944909|NCT06435169|DIAGNOSTIC_TEST|Lasegue's, Freiberg's and, FAIR (Flexion Adduction Internal Rotation) tests.|The Straight Leg Raise test or Lasegue test, is also crucial in detecting disc herniation and neural compression. Lasègue's sign is said to be positive if the angle to which the leg can be raised (upon straight leg raising) before eliciting pain is \<45°.The presence of Piriformis syndrome was investigated in these patients with Freiberg and FAIR tests. Freiberg's test elicits pain by passively internal rotation of the extended hip, when the patient is in supine. The purpose of this test is on the one hand stretching of the irritated Piriformis Muscle (PM), on the other hand provoking sciatic nerve compression. The FAIR test is a sensitive and specific test for detection if irritation of the sciatic nerve by the piriformis. FAIR stands for flexion, adduction and internal rotation. Also known as piriformis test.
223944910|NCT00934817|DRUG|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
223944911|NCT00934817|DRUG|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
223944912|NCT00558454|DRUG|Iron|Ferrous succinate mixture
223944913|NCT06328868|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223944914|NCT06328868|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223944915|NCT06328868|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223944916|NCT03150446|DEVICE|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
223944917|NCT04554108|OTHER|therapeutic strategy|Outpatient management strategy of acute non-severe osteomyelitis in children with oral antibiotic therapy compared to a standard strategy with conventional hospitalization and intravenous antibiotic therapy
223944918|NCT00468156|BEHAVIORAL|written materials only|related to fruit/vegetable servings/day
223944919|NCT00468156|BEHAVIORAL|written materials|related to fruit/vegetable servings/day
223944920|NCT00468156|BEHAVIORAL|telephone support|related to fruit/vegetable servings/day
223944921|NCT05224557|OTHER|No intervention|No intervention
223944922|NCT03759249|OTHER|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
223944923|NCT03563690|OTHER|treatment1|"1. Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~2. operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
223944924|NCT03563690|OTHER|treatment2|"1. Acupoints：Needling points are the same to the above group~2. operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
223535482|NCT03568747|DEVICE|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
223944925|NCT03563690|OTHER|treatment3|"1. Acupoints：treating points are the same to the above group~2. Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
223944926|NCT03563690|OTHER|treatment4|"1. Acupoints：Needling points are the same to the above group~2. Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
223944927|NCT03563690|OTHER|treatment5|"1. points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~2. Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 \* 25mm single-use needle with the depth of 1-2mm."
223944928|NCT03563690|DRUG|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
223944929|NCT00145470|DRUG|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
223944930|NCT00145470|DRUG|Placebo|Placebo fast dissolving SL tablets, BID
223944931|NCT02540525|DEVICE|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
223944932|NCT02540525|DEVICE|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
223944933|NCT04800042|DIAGNOSTIC_TEST|Diagnostic test|Blood iron status : ferritin and transferrin saturation factor
223944934|NCT03355534|DRUG|Intravenous dexmedetomidine|drug is intravenously infused to patients
223944935|NCT03355534|DRUG|nasal dexmedetomidine|drug is nasally given to patients
223944936|NCT03355534|DRUG|intravenous saline|saline is given to patients intravenously
223944937|NCT03355534|DRUG|nasal saline|normal saline is given to patients nasally
223944938|NCT02628106|DRUG|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
223944939|NCT00073255|DRUG|hokt3g1 (ALA-ALA)|
223944940|NCT06396975|PROCEDURE|robotic surgery|robotic surgery
223944941|NCT04185961|DEVICE|EVERA-RAPHA with 60mmHG|Apply EVERA-RAPHA with 60mmHG for 4weeks
223944942|NCT04185961|DEVICE|EVERA-RAPHA with 100mmHG|Apply EVERA-RAPHA with 100mmHG for 4weeks
223944943|NCT02499601|DEVICE|CORolla™ TAA device|
223944944|NCT04402736|BEHAVIORAL|The modified Barthel Index-based rehabilitation nursing program|The intervention with the program based on the MBI classified function of patients into five levels, with every 20 points as a level, Each level corresponds to different training items. Training items included self-care training and training in transfer activities, sitting balance, walking, and sit-to-stand, etc. Each training session lasting at least 30 minutes, two sessions per day, for seven continuous days. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
223944945|NCT04402736|BEHAVIORAL|Usual care|Patients in the control group received clinical usual care including the activities of daily living assessment, early mobilization guide and health education. During the intervention, the rehabilitation therapist's conventional treatment is not interfered.
223944946|NCT01183598|DRUG|tocilizumab [RoActemra/Actemra]|maintenance dose
223944947|NCT04773431|DRUG|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation|LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
223944948|NCT01237496|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
223944949|NCT04379869|DRUG|NNZ-2591|Single dose of NNZ-2591
223944950|NCT04379869|DRUG|Placebo|Comparator for double-blind MAD
223944951|NCT04931524|DRUG|carbon-14-[14C]-ANG-3777|Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
223944952|NCT05750043|DRUG|bi-annual CDTI|"bi-annual community directed treatment with ivermectin (CDTI) and community-based slash and clear vector control intervention"
223944953|NCT05194696|BEHAVIORAL|Questionnaire|Patients have to answer a questionnaire about their caffeine consumption habits during lifetime
223944954|NCT04851743|OTHER|Dry needling|The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
223944955|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+200% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
223944956|NCT05545306|DIETARY_SUPPLEMENT|fasting|Fasting for at least 24 hours
223944957|NCT05545306|DIETARY_SUPPLEMENT|-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-50% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
223944958|NCT05545306|DIETARY_SUPPLEMENT|+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|+150% of energy balance requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
223944959|NCT05545306|DIETARY_SUPPLEMENT|+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+200% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
223944960|NCT05545306|DIETARY_SUPPLEMENT|-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat|-25% of energy balance (EB) requirements with standard macronutrient balance of 50% of calories from carbohydrates, 20% from protein, and 30% from fat
223535483|NCT04670861|PROCEDURE|Upper extremity Biodex balance training|"The person assumes the prone plank posture with both hands poisoned in the area assigned for foot placement on the tilting balance platform. Using the four keypads, the person's left hand, left wrist, right hand and right wrist positions are entered into the system using the midline of the hand and the platform grid as reference points. The dot that appears on the position patient screen represents the person's segmental center of gravity.~During each trial test, the person should shift his weight to move the cursor from the center along a target path and back as quickly and with a little deviation as possible. The same process is repeated for each of the targets. Target paths activate in a random order."
223535484|NCT03173014|DEVICE|EEG|EEG monitoring
223944961|NCT05545306|DIETARY_SUPPLEMENT|+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein|+150% of energy balance requirements with low protein macronutrient balance of 51% of the calories from carbohydrates, 46%, from fat and 3% from protein.
223944962|NCT02697305|DIETARY_SUPPLEMENT|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
223944963|NCT02697305|DIETARY_SUPPLEMENT|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
223944964|NCT02697305|OTHER|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
223944965|NCT03440645|OTHER|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
223944966|NCT05656066|BEHAVIORAL|The Vibration Intervention|The vibration frequency of the massager, which accelerates blood circulation, is 6000 / min, it works with a 1.5 volt battery. Can be used easily with one hand. The vibration simulator design is based on the gate-control theory, which allows for a reduction in the perceived amount of pain experienced during injection by closing the pain gate in the spinal cord in creating a stimulus on the skin.
223944967|NCT05656066|BEHAVIORAL|The Pressure Intervention|Pressure was placed in the ıntramuscular area properly 30 seconds before injection. Then the injection process was completed.
223944968|NCT06477679|PROCEDURE|• Furlow with buccinators myomucosal flap|• Furlow with buccinators myomucosal flap. Two opposing Z-plasties were designed on the oral and nasal mucosal surface. The posterior based flap on each surface was composed of muscle and mucosa, and the anterior surface was composed of mucosa only. BMFs were raised from the donor site, and immediately transferred to the recipient site to repair the defect. The flaps were sutured to the recipient site. The donor site was also closed primarily
223944969|NCT06477679|PROCEDURE|• Two flap palatoplasty as von langenbeck technique|• Two flap palatoplasty as von langenbeck technique, Upper left: Medial incisions design. Upper right: Lateral relaxing incisions and nasal mucosa closure using the anterior triangular flap and lateral nasal mucosa flaps. Release of the abnormal muscular insertion is performed. But two flap palatoplasty can lengthen the soft palate by push-back
223944970|NCT06190132|DRUG|Omega 3 fatty acid, gabapentin|To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin
223944971|NCT06426966|DIETARY_SUPPLEMENT|Berberine|Berberine is an alkaloid derived from plants native to China called Rhizoma coptidis, Cortex phellodendrine and Hydrastis canadensis. These plants are used in the treatment of infectious diarrhea, inflammation, DM2, non-alcoholic fatty liver disease, dyslipidemias, cardiovascular diseases, and obesity. They have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)
223944972|NCT06426966|DIETARY_SUPPLEMENT|Gymnema sylvestre|"Gymnema sylvestre also known as meshashringi, is a plant from central and southern India. The leaf extract has been used as a laxative, diuretic, and cough suppressant; Likewise, it has antimicrobial, antihypercholesterolemic, and hepatoprotective activities. It is associated with antioxidant properties . Its adjuvant effect has been reported in the therapy of type 2 diabetes, revealing how its active compounds can influence glucose regulation and improve insulin sensitivity."
223944973|NCT05851495|PROCEDURE|physiotherapist-led groups, home-based follow up groups|The group involved in physiotherapists-led groups was shown the exercises in practice and under the supervision of the physiotherapist, the patients applied their exercises throughout their treatment. Home-based follow up groups, after the exercise training was given to the patients with a physiotherapist, daily text messages (SMS) were sent to the patients and the patients were reminded to do the exercises
223944974|NCT04378036|OTHER|Neurodevelopmental Therapy|The Neurodevelopmental Therapy rehabilitation program was determined according to the children's level of gross motor function, age, gender, mental state, and preferences. Neurodevelopmental Therapy program consists of the rehabilitation of muscle tone disorders, increasing sensory-perception-motor integrity, exercises to increase limb functions and body control, stretching and strengthening exercises for muscle shortness and weakness, exercises that include movements in daily life and training activities such as standing, walking, body care.
223944975|NCT04378036|DEVICE|Hippotherapy Simulator|Horse Riding Simulator (HRS) device was used as a hippotherapy simulator device. HRS is a device that moves forward, backward, backward-to-back, right-to-left swing and up-and-down swing in 3 dimensions, similar to the movements of a real horse, forming an 8-shaped movement on five axes. After the children sat in the saddle section, they were first taken to the warm-up speed program for 5 minutes, then to another one of the other speed levels (gradually moved to other speed levels as appropriate for the development and tolerance of children) and finally to the warm-up speed program for 5 minutes.
223944976|NCT04336618|DEVICE|Liver MultiScan|The LiverMultiscan is a quick 15 minute, contrast free, non-invasive MRI scan that provides 3 liver metrics
223944977|NCT06100744|DRUG|Adalimumab|SC Injection
223944978|NCT06100744|DRUG|Risankizumab|Subcutaneous (SC) Injection
223944979|NCT01866800|DEVICE|Renal Guard|Renal Guard
223944980|NCT01866800|DRUG|Conventional Treatment|Saline and N-acetylcysteine
223944981|NCT05604547|DIAGNOSTIC_TEST|Non-Invasive Infrared Spectroscopy|NIRS is a non-Invasive optical technique for characterizing microvascular hemodynamics.
223535485|NCT03917030|PROCEDURE|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the toot.
223944982|NCT00910832|DRUG|Eductyl suppository|one suppository every morning during 21 days
224099939|NCT05581043|DIETARY_SUPPLEMENT|3-hydroxybutyrate (3-OHB)|The aim of this study was therefore to i) investigate the dose/response relationship between 3-OHB servings of 0, 10, 20 and 40 grams 30 minutes before an OGTT and, ii) investigate the role of timing by serving 25 grams of 3-OHB at different timepoints ahead of an OGTT (0, 30 and 60 minutes).
224099940|NCT00203567|DRUG|carbamazepine ER|Active study drug, no comparator
223944983|NCT00910832|DRUG|Placebo suppository|placebo suppository every morning during 21 days
223944984|NCT00276276|DRUG|topotecan|
223944985|NCT06975410|DRUG|YH32364|"Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose.~Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be randomized 1:1 ratio to each dose. (Cohort 1: Participants with locally advanced or metastatic EGFR overexpressing HNSCC other than NPC, whose disease progressed after or who are intolerable to all the available standard treatment)"
223944986|NCT06981195|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the study drug. During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed
223944987|NCT06981195|DRUG|Lemborexant 10 MG|During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed
224099941|NCT02293109|DRUG|carfilzomib|Given IV
224099942|NCT02293109|DRUG|cyclophosphamide|Given IV
224099943|NCT02293109|DRUG|vincristine sulfate|Given IV
224099944|NCT02293109|DRUG|doxorubicin hydrochloride|Given IV
224099945|NCT02293109|DRUG|dexamethasone|Given PO
224099946|NCT02293109|DRUG|methotrexate|Given IV
224099947|NCT02293109|DRUG|cytarabine|Given IV
223535486|NCT03917030|PROCEDURE|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
223535487|NCT03243565|BIOLOGICAL|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
224099948|NCT02293109|DRUG|leucovorin calcium|Given IV or PO
224099949|NCT02293109|DRUG|methylprednisolone|Given IV
223535488|NCT03243565|BIOLOGICAL|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
223944988|NCT03988101|DRUG|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
223944989|NCT03988101|DRUG|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
223944990|NCT06607146|BEHAVIORAL|Sound Success|Subjects will be instructed to perform auditory training with the Sound Success computer-based auditory training program. This is a free program that requires a brief account registration. Subjects will be instructed to perform auditory training on a personal device and will be recommended a target usage of at least 30 minutes 5 times per week.
223944991|NCT06607146|BEHAVIORAL|Standard of Care|Subjects will be provided a list of common exercises for auditory training. This is the current standard of care at our institution.
223944992|NCT06870630|DEVICE|Per oral endoscopy myotomy|Poem procedure is meant for cutting of circular and longitudinal muscle fibers in esophagus to reduce the symptoms of dysphagia, regurgitation and chestpain, weight loss.
224099950|NCT02293109|BIOLOGICAL|rituximab|
224099951|NCT02293109|OTHER|laboratory biomarker analysis|Correlative studies
224099952|NCT03265691|OTHER|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
224099953|NCT03265691|OTHER|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
224099954|NCT01006356|DRUG|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
224099955|NCT02833311|BEHAVIORAL|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
224099956|NCT02833311|BEHAVIORAL|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
224099957|NCT02833311|BEHAVIORAL|Contact Control Group|Participants are prescribed an exercise program and given information on healthy eating.
224099958|NCT00003554|BIOLOGICAL|rituximab|
224099959|NCT00003554|DRUG|melphalan|
224099960|NCT00003554|DRUG|prednisone|
224099961|NCT01773824|BEHAVIORAL|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
224099962|NCT01773824|BEHAVIORAL|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
223944993|NCT06390267|DEVICE|Sparrow Hawk (Active)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of active (prophylactic or acute) therapy according to the participant's randomization group.
223944994|NCT06390267|DEVICE|Sparrow Hawk (Sham)|Wearable, battery-operated, device designed to transcutaneously stimulate nerves on and/or around the auricle. The device will be used to deliver tAN sessions of sham (prophylactic or acute) therapy according to the participant's randomization group.
223944995|NCT07044219|PROCEDURE|Third molar surgery|During the operation, after local anaesthetics (LIDOCAIN-ADRENALIN 20 mg/0,01 mg/ml) the same mucoperiosteal (sulcular flap without vertical incision) is raised. Bone removal happens with physio-dispenser driven surgical handpiece (60ml/min irrigation; 8.000-16.000 rpm) and tungsten carbide round drills. Tooth section is made where indicated. After tooth removal wound is rinsed with 10-20ml physiologic salt, the wound is closed with 4.0 monofil non-resorbable suture material and then gel test or placebo is injected with syringe and applicator tip into the wound and on the surface of the wound. Patient bites a gauze for 20 minutes.
223944996|NCT06899607|OTHER|Fibre arm|Increasing daily fibre intake by 10 grams
223944997|NCT06461962|OTHER|Treatment as Usual|Peer-facilitated referral to a local primary care provider to follow-up their screening results.
223944998|NCT06461962|OTHER|Telehealth-Cardiology|"Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer~Referral for a locally performed testing including echocardiogram~Transitional care management facilitated by a remote nurse care manager and the peer"
223944999|NCT05711719|DRUG|Vericiguat|Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms
223945000|NCT05711719|DRUG|Placebo|Administered the same way
223945001|NCT06780553|DIAGNOSTIC_TEST|Proteomic profiling|Proteomic profiling as a diagnostic tool in the face of suspected extrahepatic cholangiocarcinoma stenosis
223945002|NCT07077395|DRUG|fezolinetant - reference formulation|fezolinetant 45 mg daily x 12 weeks
223945003|NCT07077395|DRUG|placebo|placebo daily x 12 weeks
223945004|NCT03671967|DRUG|Piperacillin/tazobactam|4.5 grams QID
223945005|NCT03671967|DRUG|Meropenem|1 gram TID
223945006|NCT06394323|BEHAVIORAL|Behavioral: My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice), is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
223945007|NCT06778538|DIAGNOSTIC_TEST|Immunohistochemistry; WB; PCR|The intervention will specifically focus on evaluating the role of HPGD in patients with clear cell renal cell carcinoma by classifying them into high-low expression groups based on median HPGD expression values by immunohistochemical scores for prognostic analysis. Protein and RNA were extracted from collected ccRCC tissues for expression verification.
223945008|NCT04039750|DRUG|antibiotic rinse with suction|antibiotic rinse with suction
223945009|NCT04039750|PROCEDURE|suction only|no irrigation, suction only
223945010|NCT05062980|BIOLOGICAL|quaratusugene ozeplasmid|Quaratusugene ozeplasmid is an experimental non-viral therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, re-establishing pathways that promote cancer cell death and modulating the immune system response against cancer cells.
223945011|NCT05062980|DRUG|pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for treatment of patients with metastatic NSCLC.
224099963|NCT00702624|DRUG|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
224099964|NCT00702624|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
224099965|NCT00702624|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
223535489|NCT03059784|OTHER|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
223535490|NCT03323684|OTHER|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
223535491|NCT03323684|OTHER|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
223535492|NCT03323684|OTHER|Control group (C)|No intervention will be done
223945012|NCT05062980|DRUG|docetaxel|Docetaxel is a microtubule inhibitor indicated for locally advanced or metastatic NSCLC after platinum-based chemotherapy failure.
224099966|NCT00702624|BIOLOGICAL|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
224099967|NCT00702624|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
224099968|NCT00702624|DRUG|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
223535493|NCT03323684|DRUG|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
224099969|NCT00702624|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
224099970|NCT00702624|BIOLOGICAL|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
224099971|NCT06312306|DEVICE|transcranial direct current stimulation|Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)
224099972|NCT06312306|OTHER|Pilates based core training|The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.
223945013|NCT05062980|DRUG|ramucirumab|Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with docetaxel for treatment of NSCLC with disease progression after platinum-based chemotherapy.
223945014|NCT05062980|DRUG|Investigator's Treatment of Choice|Treatment will be administered during 21-day treatment cycles. The investigator's treatment must not include investigational drugs or therapies.
223945015|NCT06903052|DEVICE|Nurse parental support using a proactive mobile App|Nurse parental support using a proactive mobile App in symptom management for child with mechanical ventilation
223945016|NCT07084337|BEHAVIORAL|Bodypump Training Program|Participants in this group performed a structured 8-week Bodypump program consisting of three sessions per week (Monday, Wednesday, and Friday), each lasting 45 minutes. The sessions followed the official Les Mills format, incorporating choreographed resistance exercises using barbells, weight plates, and a step platform. All movements were synchronized with music and led by certified instructors. Participants completed high-repetition, low-load exercises (\~20% of 1RM) targeting major muscle groups. Exercises were adapted to individual capabilities to ensure safety and promote adherence.
223945017|NCT06876623|DRUG|dabigatran etexilate mesylate capsules 150mg|Oral dabigatran etexilate mesylate capsules，150mg Once every seven days，two cycle T drug, two cycles R drug
224099973|NCT06312306|OTHER|conventional physiotherapy program|"Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs"
224099974|NCT01962454|DRUG|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
224099975|NCT01962454|DRUG|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
224099976|NCT01962454|DRUG|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
224099977|NCT05429814|OTHER|Menthol Application|During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
223535494|NCT03323684|DRUG|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
224099978|NCT03057444|DIETARY_SUPPLEMENT|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
224099979|NCT04549987|DEVICE|Space closure without changing working archwire monthly|Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
224099980|NCT04549987|DEVICE|Space closure withchanging working archwire monthly|Upper premolar space closure using new 0.019X0.025 stainless steel archwire every month
224099981|NCT00002669|BIOLOGICAL|aldesleukin|
224099982|NCT00002669|BIOLOGICAL|recombinant interferon alfa|
224099983|NCT00002669|DRUG|cisplatin|
223535495|NCT03323684|DRUG|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
223535496|NCT01192126|DEVICE|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
223945018|NCT06826703|OTHER|Experimental Group|Individuals will receive diabetes education with motivational interviewing technique based on health belief model.
223945019|NCT06476509|DRUG|LV232 40mg|oral
223945020|NCT06476509|DRUG|Escitalopram 20 mg|oral
223945021|NCT06476509|DRUG|LV232 60mg|oral
223945022|NCT06476509|DRUG|LV232 20mg|oral
223945023|NCT04224272|DRUG|ZW25 (Zanidatamab)|Administered intravenously
223945024|NCT04224272|DRUG|Palbociclib|Administered orally
223945025|NCT04224272|DRUG|Fulvestrant|Administered as an intramuscular injection
223945026|NCT07091981|DEVICE|OneCurve Rotary File|A single-file NiTi system (25/.04) operated at 300 rpm and 2.5 Ncm torque. Applied directly to the MB2 canal without prior hand instrumentation.
223945027|NCT07091981|DEVICE|Perfect Minimally Invasive Kit|Two-file system using 10/.06 Shaper for coronal/middle thirds and 25/.04 Finisher for apical third. Operated at 300 rpm and 2.0-2.5 Ncm torque.
224099984|NCT00002669|DRUG|dacarbazine|
224099985|NCT02424539|DRUG|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
224099986|NCT02424539|OTHER|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
224099987|NCT01137630|DRUG|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
224099988|NCT01137630|DRUG|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
223729421|NCT04090840|BEHAVIORAL|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
223945028|NCT07091981|DEVICE|VDW Rotate|Three-file NiTi rotary system (15/.04, 20/.05, 25/.04) used sequentially for coronal, middle, and apical thirds. Applied with brushing-pecking motion in 2-3 mm increments under continuous irrigation. Operated at 300 rpm and 1.8 Ncm torque.
223945029|NCT07091981|DEVICE|Perfect Advanced Kit|NiTi rotary file system including 10/.07 Opener, 10/.04, 17/.05, and 25/.04 files. Used in crown-down sequence with rpm and torque settings ranging from 250-300 rpm and 2.0-2.5 Ncm. Brushing-pecking motion and continuous irrigation were applied during instrumentation.
223945030|NCT04425473|DRUG|Esketamine|Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.
223945031|NCT04425473|DRUG|Normal saline|Equivalent amount of normal saline will be administrated intravenously suturing incision.
223945032|NCT06821451|DEVICE|Bronchoscopic navigation robot|Preoperative CT data creates a 3D image of the lung anatomy to plan the navigation path. The surgeon controls the robotic arm in real-time to reach staining marker points for pulmonary nodule localization. After placing the staining catheter in the working channel, 1 ml of indocyanine green is injected at the site. Then the patient is positioned laterally for video-assisted thoracoscopic surgery for nodule resection, initially focusing on sub-lobar resection. More extensive resection is determined based on intraoperative frozen section results.
223945033|NCT06821451|DEVICE|Conventional electromagnetic navigation bronchoscope|Based on preoperative CT data, a three-dimensional image of the virtual bronchi is created to plan the navigation path, and manual registration is completed by selecting registration points using a conventional electromagnetic bronchoscope. After registration, the target position is reached under the guidance of the magnetic navigation positioning system, and when the positioning sensor indicates that it has arrived at the staining marker point, a staining catheter is inserted through the working channel to inject 1 ml of indocyanine green at the marker site, followed by thoracoscopic resection of the pulmonary nodule.
223945034|NCT06766838|PROCEDURE|1. Conventional dissection technique (group A) :|In this group, circumcision is performed by the dorsal slit technique. A slit is made dorsally to the level of about 5 mm from the coronal sulcus, and the redundant foreskin and mucosa were excised circumferentially. Hemostasis is secured with ligation , and the cut edges are sutured with absorbable suture. Then, dressing is applied.
223945035|NCT06766838|PROCEDURE|2. Bone cutting forceps technique (Group B)|Two mosquito forceps are used to grasp the foreskin. The glans penis is squeezed back to avoid its injury. After that, bone cutting forceps is applied to the foreskin for 3 minutes, at the level of the mark, then the foreskin is excised by scalpel at the same level. Bleeding points are ligated and the cut edges are sutured with absorbable suture. Then, a dressing is applied
223945036|NCT06766838|PROCEDURE|3. Electro-cauterization (bipolar) assisted circumcision (Group C)|"The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by scissor with hemostasis by bipolar cauterization.~The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane."
223945037|NCT06766838|PROCEDURE|4. Thermal cauterization assisted circumcision (Group D)|The skin is held by two hemostats to elevate the foreskin, and then the kocher clamp applied at the level of the skin to be removed for circumcision. Excess foreskin will be cut by thermal cauterization. The skin retracted proximally after that to expose the glans. Sutures are made if there is separation between the skin and the mucous membrane.
223945038|NCT06766838|PROCEDURE|5. Gomco clamp technique (Group E):|The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
223945039|NCT06766838|PROCEDURE|6. Plastibell device technique (Group F):|The prepuce is grasped using two hemostats applied at 2 and 10 o'clock. A dorsal slit at 12 o'clock is made, appropriate-sized bell is placed over the glans, and the foreskin is brought over its top. The string is placed around the foreskin and the Plastibell device at the level of the mark in a groove that acted as the string placement guide. The string is then tightened and tied in a simple square knot. The excess foreskin is trimmed from around the bell using iris scissors. The handle is then broken off the device
223945040|NCT07089641|PROCEDURE|Biospecimen Collection|Undergo urine, blood, and CSF sample collection
223945041|NCT07089641|PROCEDURE|Echocardiography Test|Undergo ECHO
223945042|NCT07089641|DRUG|EGFR Inhibitor ERAS-801|Given PO
223945043|NCT07089641|OTHER|Fludeoxyglucose F-18|Given FDG
223945044|NCT07089641|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
223945045|NCT07089641|PROCEDURE|Positron Emission Tomography|Undergo FDG PET
223945046|NCT07089641|PROCEDURE|Surgical Procedure|Undergo surgical resection
223945047|NCT02609048|DRUG|Placebo Comparator|Placebo Capsule
223945048|NCT02609048|DRUG|Experimental: Seladelpar 50 mg|Seladelpar 50 mg capsule
223945049|NCT02609048|DRUG|Experimental: Seladelpar / MBX-8025 200 mg|Seladelpar 100 mg capsules
223945050|NCT03571373|OTHER|No intervention|No intervention due to the observational set-up of this study.
223945051|NCT05388838|BIOLOGICAL|Blood sample|Blood sample will be taken at D0: 63 ml (7 tubes of 9 ml),
223945052|NCT07094893|DRUG|Cetuximab (EGFR inhibitor)|Administration according to the labels of each IMP.
223945053|NCT07094893|DRUG|Bevacizumab|Administration according to the labels of each IMP.
223945054|NCT07094893|DRUG|Irinotecan (CPT-11)|Administration according to the labels of each IMP.
223945055|NCT07094893|DRUG|Oxaliplatin|Administration according to the labels of each IMP.
223945056|NCT07094893|DRUG|Leucovorin and 5-FU|Administration according to the labels of each IMP.
224099989|NCT01137630|DRUG|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
224099990|NCT04581187|OTHER|Quality of life assessment|Quality of life questionnaires
223945057|NCT07094893|DRUG|Capecitabine|Administration according to the labels of each IMP.
223945058|NCT06524570|DEVICE|HIFU-HT|High-Intensify Focused Ultrasound Histotripsy
223945059|NCT06524570|DRUG|ICI|Ipilimumab and nivolumab
223945060|NCT05008484|DEVICE|NMES|Subjects will undergo 4.5 months of open kinematic chain resistance training followed by 4.5 months of closed kinematic chain using simple rowing approach
223945061|NCT05008484|DRUG|Vitamin D|2000IU oral vitamin D supplementation daily for 9 months
223945062|NCT05008484|PROCEDURE|Passive movement|Subjects will perform simple passive movement exercise for their legs while sitting in their wheelchairs at their home. The frequency of the training will be twice weekly. .
223945063|NCT02485925|DEVICE|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
223945064|NCT07099235|DRUG|ketamine hydrochloride|Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.
223945065|NCT07098039|OTHER|Semi-presential or hybrid group|The hybrid format will consist of 4 in-person sessions (every two weeks) complemented by a home program until completing 3 sessions of the full program at home.
223945066|NCT07098039|OTHER|Hospital Cardiac Rehabilitation|The hospital cardiac rehabilitation group will attend the hospital 3 days a week for the same, for eight weeks.
223945067|NCT07099196|DEVICE|Headset-based Virtual Reality Simulation|The device used was a HEALTHY-MIND© PICO G2 Virtual Reality headset, which is medically graded and suited for distraction and relaxation in clinical settings.
223945068|NCT07098624|OTHER|ACV Moringa Effervescent Tablets 4.3 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral"
223945069|NCT07098624|OTHER|Placebo Effervescent Tablets 4.3 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Twice daily, once before lunch and once before dinner Storage condition: Room temperature (15°C to 30°C) Route of Administration: Oral"
223945070|NCT07097896|DEVICE|ESV|This study arm will undergo ESV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
223945071|NCT07097896|DEVICE|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
223945072|NCT07098455|PROCEDURE|GNRFT- genicular nerve radiofrequency ablation|Ultrasound-guided genicular nerve radiofrequency ablation will be performed
223945073|NCT07098455|PROCEDURE|IAPRF- Intraarticular pulsed radiofrequency|Intra-articular pulsed radiofrequency will be applied under fluoroscopy guidance.
223945074|NCT07099040|BEHAVIORAL|Social support|Psychoeducation will be provided for enrolled participants and their caregivers by Community Resource, Engagement \& Support Team (CREST). Visits from CREST teams will be provided on an ad hoc basis, based on older adult participants' needs and circumstances.
223945075|NCT07099040|BEHAVIORAL|Health coaching|"Health coaching aims to control risk factors of dementia by community nurses (CMNs) and wellbeing coordinators (WBCs). These include addressing chronic conditions and lifestyle aspects (diet, exercise, habits stress management, and sleep). Care recipients are encouraged to proactively manage their health journey and establish Specific, Measurable, Achievable, Relevant, and Time-bound (SMART) goals with the support of WBCs and CMNs. This multi-faceted approach has the potential to not only address older individuals' immediate health concerns but also foster long-term lifestyle changes. The frequency of visits are once or twice a month, depending on recipients' health status and cognitive functions.~Flexible scheduling is based on individual needs and community nurses' usual practice at the Community Health Post at AACs."
223945076|NCT07099040|BEHAVIORAL|Physical Activity|Physical Activity that focuses on improving resistance and balance for care recipients. Physical activity will be conducted 2 times/week at the Active Ageing Centres (AACs) with care recipients for a duration of 1-hour and 1-2 times/week at home.
223945077|NCT07099040|BEHAVIORAL|Cognitive activity|"Cognitive activity will be delivered to enrolled care recipients by Community Resource, Engagement \& Support Team (CREST) and AAC staff. With the incorporation of using SilverPad as part of the cognitive activities, care recipients will undergo 1-hour weekly cognitive activity. Youth volunteers will also be engaged to help facilitate the sessions.~This will be augmented with additional 1-2 times weekly home-based training sessions supervised by caregivers."
223535497|NCT01192126|DEVICE|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
223535498|NCT03150381|BEHAVIORAL|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
223945078|NCT07099755|BEHAVIORAL|Intervention Group: Name: Dynamic Neuromuscular Stabilization (DNS) Exercises|"Distinguishing Description for DNS Intervention~This intervention consists of a structured Dynamic Neuromuscular Stabilization (DNS) exercise program specifically tailored for post-partum women with mechanical low back pain. DNS emphasizes restoring functional motor patterns through:~Breathing-based core activation techniques~Developmental positions mimicking infant motor milestones (e.g., supine 90/90, quadruped, side-lying)~Coordination of the diaphragm, pelvic floor, and transverse abdominis muscles~Progressive motor control retraining over 6 weeks, 3 sessions/week~What distinguishes this intervention:~It integrates developmental kinesiology principles with respiratory-pelvic-lumbar coordination.~DNS is performed under supervised sessions by a physiotherapist, ensuring precision and progression.~This protocol replaces standard strengthening/stretching exercises and focuses on neuromuscular re-patterning, not just symptom relief."
224099991|NCT01101074|OTHER|This is non-intervention observational study|This is non-intervention observational study
224099992|NCT01718314|DRUG|Sublingual Misoprostol|
224099993|NCT01718314|DRUG|Lidocaine pump spray|
224099994|NCT01718314|DRUG|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
223945079|NCT07099755|DEVICE|Control Group:Name: Conventional Physiotherapy (Ultrasound and Infrared Therapy)|"1-Therapeutic Ultrasonic: comparison group also received treatment through therapeutic ultrasound, which was applied three times per week. The ultrasound therapy was delivered to the paraspinal muscles of the lumbar region, using a stroking technique where each stroke overlapped by about 50% with the preceding stroke. The ultrasound used a frequency of 3 MHz and an intensity range of 1.0 to 1.5 W/cm²,The ultrasound head was placed over the L4 to L5 and L5 to S1 regions and moved in a circular motion for a total duration of 5 minutes per treatment session (Shobari et al., 2024).~infra red the infrared lamp was placed at 75 cm distance from the patient's back so that the radiation struck the surface at or near a right angle to achieve maximum penetration. The treatment duration was 15 minutes. Each woman with post-partum low back pain was treated by 20 minutes infrared irradiation 40 cm away from the low back region, from prone3 sessions per week for 6 weeks (El-Lassy and Madian, 2018"
223945080|NCT07099625|DEVICE|Adaptive Indoor Rowing Seat|Light weight adjustable indoor rowing seat for Veterans with limited trunk stability.
223945081|NCT07099625|DEVICE|Paddle Sport adaptive seating system|On market comparator (discontinued) adaptive indoor rowing seat for individuals with limited trunk stability.
223945082|NCT07097935|DRUG|HS-10516 + Lenvatinib|Administered orally.
223945083|NCT07098325|DEVICE|retainer with .5 mm thickness|direct 3d printed retainer with .5 mm thickness
223945084|NCT07098325|DEVICE|retainer with 1 mm thickness|direct 3d printed retainer with 1 mm thickness,
223945085|NCT07099586|OTHER|No Interventions|This is an observational study. No intervention will be administered. Participants will provide blood samples for micronutrient analysis.
223945086|NCT07098884|DIAGNOSTIC_TEST|AI model|AI model developed by smartphone photos of resected tumor specimens
223945087|NCT07099391|DRUG|Dara-RVd|This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
223945088|NCT07099391|DRUG|Tec-RVd|This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy
223945089|NCT07098897|DRUG|Telitacicept 160mg|Currently monoclonal antibodies, that may affect the main axis of pathogenesis of IgA nephropathy and biological therapy such as Telitacicept, provides a new treatment option and altering or depletion or modulation of Gd-IgA1 producing B cells and plasma cells. At present, Telitacicept are used for clinical treatment in IgA nephropathy patient inside China, but still clear data on safety and effect, and patient's complete remission, repeated relapse data are unclear.
223945090|NCT07098897|DRUG|Corticosteroid|Standard Supportive Care plus Corticosteroid(≤1mg/kg/d) without immunosuppressants
223945091|NCT07098897|DRUG|ACE Inhibitor or Angiotensin receptor antagonist|Drug: ACE Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization Drug: ARB Inhibitor (Treatment for proteinuria suppression and blood pressure regulation) - 2-3months before randomization
223945092|NCT07098052|DRUG|HDM2020|FGFR2b-ADC
223945093|NCT07096037|OTHER|Urtica dioica cataplasm|Participants will receive a warm Urtica dioica cataplasm applied topically on the affected knee, once daily for 60 minutes, three times per week (on alternate days) over a 6-week period.
223945094|NCT07096037|OTHER|Placebo|Participants will receive a placebo cataplasm, matched in texture, color, and odor to the active treatment. The placebo is inert and safe for pediatric topical use.
223535499|NCT03150381|BEHAVIORAL|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
223945095|NCT07096037|DRUG|Vitamin D|Participants will receive oral vitamin D.
223945096|NCT07096037|BEHAVIORAL|Resting conditions|Reduction in physical activity based on orthopedic advice.
223945097|NCT07099937|OTHER|Observational cross-sectional study with no intervention.|"This study does not involve any intervention. It is a cross-sectional observational study. The term intervention here refers to laboratory investigations and clinical assessments conducted as part of data collection only."
223945098|NCT07098065|BEHAVIORAL|Graphical health warnings|This group will receive only graphical health warnings (GHWs) featuring images proposed by the Bangladesh Tobacco Control Cell, explicitly illustrating smoking-related harms, such as mouth diseases, damaged teeth and gums, lung diseases and cancer, heart diseases and cardiovascular damage, and throat and oral cancer. Additionally, these warnings will clearly highlight the benefits of quitting smoking-including improved overall health, reduced disease risks, financial savings, and enhanced quality of life-as well as practical cessation techniques. Participants will receive these GHW materials at baseline and again at the six-month follow-up to reinforce these critical health messages; however, this intervention group will not receive any counselling services. Monthly SMS reminders will also be sent to participants, prompting them to review the GHW leaflet and reinforcing the negative health impacts of smoking and the benefits of quitting.
224099995|NCT01718314|DRUG|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
224099996|NCT03873207|DEVICE|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
224099997|NCT03873207|DEVICE|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
224099998|NCT04893265|BEHAVIORAL|Text Messaging Only|Active Comparator
223535500|NCT03150381|BEHAVIORAL|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
223945099|NCT07098065|BEHAVIORAL|Graphical health warnings plus pharmacist-led counselling|Participants in this group will receive graphical health warnings (GHWs) featuring Bangladesh Tobacco Control Cell-approved images clearly depicting smoking-related harms (e.g., mouth diseases, damaged teeth and gums, lung cancer, heart disease, and oral cancer). Additionally, they will receive personalized counselling from community pharmacists, focused on the specific health and financial benefits of quitting, practical cessation techniques, strategies for overcoming barriers, and relapse prevention. This combined intervention will be provided at baseline and reinforced at a six-month follow-up. Monthly SMS reminders will also be sent, reinforcing key messages on the harmful effects of smoking and benefits of cessation.
223945100|NCT07098065|OTHER|Routine pharmacy services (no intervention)|Participants in this group will receive only routine pharmacy services based on standard pharmacy practice guidelines applicable in each country. They will not receive any additional graphical health warnings or counselling interventions. Outcomes will be assessed at baseline, 6 months, and 12 months, consistent with the intervention groups.
223945101|NCT07098637|BEHAVIORAL|Self-Compassionate Mindfulness Psychoeducation Program|"The researcher completed the internationally accredited institutional and practical training program titled All About Compassion in 12 Weeks: A Thousand Faces of Compassion, offered by the School of Compassion. Expert opinions were sought from the planning phase of the study for the content of the program, which was designed by the researchers. In developing the content of the Self-Compassionate Mindfulness Psychoeducation Program for Delinquent Adolescents, the opinions of three academic faculty members were consulted. Based on the suggestions received, the session titles of the psychoeducation program were determined as follows:~1. Holding Our Own Hand: Discovering Self-Compassion~2. Discovering Awareness of Thought~3. Understanding Pain, Approaching with Compassion~4. Facing Reality: Acceptance~5. Calm Waters: Forgiveness~6. Moving Forward, Farewell, and a New Beginning."
223945102|NCT06910956|OTHER|CXR-LC|Alert to provider to discuss lung cancer screening CT eligibility, for patients considered at high risk of lung cancer based on CXR-LC AI tool.
223945103|NCT07098819|DEVICE|Vibrational Shear wave elastography algorithm|An algorithm that detects the propogation of shear waves in the head and neck.
223945104|NCT04523350|DEVICE|Instylla HES|Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)
223945105|NCT04523350|OTHER|TAE or cTACE|Bland TAE or cTACE
223945106|NCT05995977|BEHAVIORAL|Nursing interventions based on protection motivation theory in patients with hypertension|The intervention consists of two components and is planned to last 14 weeks. The first component consists of hypertension education based on the Protection Motivation Theory. The second component is the sending of regularly delivered Protection Motivation Theory-based SMS messages aimed at reminding, encouraging, and motivating patients to maintain medication adherence and healthy lifestyle changes.
223945107|NCT05523375|BEHAVIORAL|Intensive Lifestyle Intervention|"Trained health coaches deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
223945108|NCT04014387|DRUG|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
223945109|NCT04014387|DRUG|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
223945110|NCT04014387|DRUG|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
223945111|NCT04181788|DRUG|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
223945112|NCT05479929|OTHER|Canadian Triage Assessment Scale (CTAS)|The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
223945113|NCT06831227|DEVICE|High power Laser Therapy|"A total course protocol: 18 sessions, for 6 weeks ,3 sessions per week. Patients will receive High power Laser treatment. manually set to bio stimulation mode with high peak power (5 - 6 W), energy per impulse 150 mJ/c2, wavelength measuring 1064 nm, and spot beam diameter area of 1 cm2.~The hand piece was positioned in contact with and perpendicular to the treated area with the patient inside lying position with knee to chest. Scanning will perform transversely and longitudinally paravertebral region on the lower lumbar area at the level of the disc concerned. Each session included three phases (fast scan, sensitive trigger points, slow scan) and had a total duration of 20 minutes. During each session, a total energy of 3000 J was applied through three phases of treatment."
223945114|NCT06831227|DEVICE|physical therapy exercise program and hot pack|this group will receive the same selected physical therapy exercise program (45 minutes) and hot pack (10 min) for 18 session. All patients will attend the physical therapy clinic three times weekly for 6 weeks
223945115|NCT04886960|BIOLOGICAL|Amniotic Fluid Injection|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
223535501|NCT04556344|BEHAVIORAL|Emotional skills|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
223945116|NCT04886960|OTHER|Standard of Care|Comparison of Standard of Care (Corticosteroid) injection vs. Sterile Processed Amniotic Fluid Injection for Knee Osteoarthritis
223945117|NCT04256031|OTHER|Assessment|The structured questionnaire, Visual Analogue Scale, Copenhagen Neck Functional Disability Scale, Shoulder Disability Questionnaire, World Health Organization Quality of Life Instrument-Short Form, and Smartphone Addiction Scale-Short Version will be applied to all participants respectively. Lastly, posture analysis will be performed to all participants by using the New York Posture Rating Chart.
224099999|NCT04893265|BEHAVIORAL|INFORMED|Experimental
223535502|NCT04556344|BEHAVIORAL|Short free talk and relaxation|3 sessions of 1,5 hour each. The first session can be face to face or over the phone, the two last ones will be held over the phone.
223535503|NCT01490034|BEHAVIORAL|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
223535504|NCT01490034|BEHAVIORAL|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
223945118|NCT04937504|BEHAVIORAL|STAIR-PC Group|Skills Training in Affective and Interpersonal Regulation for Primary Care (STAIR-PC) is a face-to-face, individual, brief (5 session) therapy adapted from the STAIR program. STAIR-PC is an appropriate treatment for individuals who have experienced traumatic stressors, and addresses symptom targets by teaching skills to improve coping with emotions and strengthen interpersonal relationships.
223945119|NCT04937504|BEHAVIORAL|WebSTAIR Group|WebSTAIR is a web-based self-help program adapted from the STAIR program for individuals who have experienced traumatic stressors. WebSTAIR contains 10 self-guided interactive modules that teach skills to improve coping with emotions and strengthen interpersonal relationships.
223945120|NCT06832449|DEVICE|PNS|Retrospective study investigating PNS
223945121|NCT06087406|DRUG|Imvotamab|Administered intravenously
223945122|NCT06087406|DRUG|Placebo|0.9% sodium chloride administered intravenously
223945123|NCT06830252|BEHAVIORAL|Exercise|Exercise.
223945124|NCT05935085|DRUG|ANB032|BTLA agonist antibody
223945125|NCT05935085|DRUG|Placebo|Placebo
223945126|NCT06910709|DRUG|AMG 378|Oral tablet
223945127|NCT06910709|DRUG|Placebo|Oral tablet
223945128|NCT05182177|DEVICE|SurgiMend PRS|SurgiMend® PRS and SurgiMend® PRS Meshed are intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend® PRS and SurgiMend® PRS Meshed are specifically indicated for plastic and reconstructive surgery, including breast reconstruction.
223945129|NCT02881554|PROCEDURE|Computed Tomography|Undergo SC SPECT/CT
223945130|NCT02881554|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
223945131|NCT02881554|DRUG|Technetium Tc-99m Sulfur Colloid|Given IV
224100000|NCT02498223|OTHER|experiment protocol|"the subjects will undergo the following experiment protocol:~1. recruitment and medical examination day.~2. physiological evaluation day- the subjects will perform twice\* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~3. biomechanical valuation day- the subjects will perform twice\* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~   * once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
224100001|NCT02523586|OTHER|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
224100002|NCT02956889|DRUG|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
224100003|NCT02956889|RADIATION|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
224100004|NCT02599389|DEVICE|Drug-coated balloons|
224100005|NCT02599389|DEVICE|Excimer Laser|
224100006|NCT04066621|DRUG|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
224100007|NCT03033108|DRUG|Emixustat|Once daily, tablet for oral administration
224100008|NCT02900677|BEHAVIORAL|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
224100009|NCT02061995|DRUG|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
223945132|NCT04186247|DRUG|Azithromycin|Weeks 4-12: 7.5 mg/kg azithromycin once daily (500 mg/day maximum) for five consecutive days/ week for 4 weeks, and 3 times a week for the following 4 weeks
223945133|NCT04186247|DRUG|Metronidazole|Weeks 4-12: 20 mg/kg/day of metronidazole (10 mg/kg twice daily to a maximum of 1000 mg/day) for 8 weeks
223945134|NCT04186247|OTHER|Standard of Care|SOC induction therapy is nutritional therapy (Crohn's disease exclusion diet + partial enteral nutrition) for up to 12 weeks. Induction therapy is as assigned by the treating gastroenterologist prior to study entry.
223535505|NCT01490034|BEHAVIORAL|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
223535506|NCT01490034|BEHAVIORAL|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
223535507|NCT04734457|DRUG|Levothyroxin|We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
223535508|NCT03816189|DIAGNOSTIC_TEST|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
223729422|NCT04464512|DRUG|Sufentanil|IV buprenorphine plus IV sufentanil treatment group.
223945135|NCT02053662|PROCEDURE|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
223945136|NCT03504241|BIOLOGICAL|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
224100010|NCT00085969|DRUG|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
223945137|NCT03504241|DRUG|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
223945138|NCT03504241|DRUG|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
223945139|NCT03504241|DRUG|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
223945140|NCT03504241|DRUG|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
223945141|NCT03504241|DRUG|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
223945142|NCT03504241|DRUG|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
223945143|NCT03662659|BIOLOGICAL|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
223945144|NCT03662659|BIOLOGICAL|Nivolumab|Specified dose on specified days
223945145|NCT03662659|DRUG|XELOX|Oxaliplatin + capecitabine
223945146|NCT03662659|DRUG|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
223945147|NCT03662659|DRUG|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
223945148|NCT06922643|DRUG|Peginterferon Alfa-2A|180 mcg, subcutaneous injection, once weekly
223945149|NCT06922643|DRUG|Ribavirin Oral Product|15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)
223945150|NCT03695952|DRUG|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
223945151|NCT06247774|BEHAVIORAL|Cardiac Rehabilitation|Participation in a 12-week cardiac rehabilitation program
224100011|NCT00085969|DRUG|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
224100012|NCT00085969|DRUG|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
223945152|NCT06247774|BEHAVIORAL|Attention Control|Participants will receive regular phone calls in place of cardiac rehabilitation visits
223945153|NCT05246930|DEVICE|Impulse Oscillometer|The tremoFlo C-100 Airwave Oscillometry System is intended to measure respiratory system impedance using the Forced Oscillation Technique (FOT).
223945154|NCT05214989|BEHAVIORAL|Tailored intervention|Tailored intervention designed to address individual barriers to cardiac rehabilitation participation
223945155|NCT06762600|DRUG|HRS-4729 injection|HRS-4729 injection
223945156|NCT06762600|DRUG|HRS-4729 injection placebo|HRS-4729 injection placebo
223945157|NCT06762600|DRUG|HRS9531 injection|HRS9531 injection
223945158|NCT06762600|DRUG|HRS9531 injection placebo|HRS9531 injection placebo
223945159|NCT06762600|DRUG|Acetaminophen|Acetaminophen
224100013|NCT00085969|DRUG|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
224100014|NCT00085969|DRUG|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
224100015|NCT00085969|DRUG|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
223945160|NCT03426059|OTHER|No Intervention|No Intervention. This is an observational study.
223945161|NCT06354387|DRUG|Alectinib (Alecensa), Nivolumab (Opdivo)|Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)
223945162|NCT06932874|DRUG|Glucophage (Metformin Hydrochloride Tablets)|Metformin hydrochloride tablets combined with other oral hypoglycemic drugs for 24 weeks treatment.
223945163|NCT06932874|DRUG|New sustained-release metformin tablets (Ⅲ)|The experimental group received treatment with New Metformin Sustained-release Tablets (Ⅲ) combined with other oral hypoglycemic drugs for 24 weeks.
223945164|NCT05900570|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test with and without neurostimulation will be conducted. The external neurostimulator device settings will be adjusted to deliver acute nerve stimulation per the individual tolerance level to assess the effect on urethral pressure. A leak point pressure (LLP) during Valsalva maneuver will be assessed with and without acute nerve stimulation.
223945165|NCT06330610|OTHER|Intermittent enteral nutrition|Patients will receive intermittent enteral nutrition, defined as 3 60-minute administrations every 8 hours.
223945166|NCT02337985|DRUG|Prednisone|Given PO
223945167|NCT02337985|BIOLOGICAL|Rituximab|Given IV
223945168|NCT02337985|DRUG|Etoposide|Given IV
223945169|NCT02337985|DRUG|Doxorubicin Hydrochloride|Given IV
223945170|NCT02337985|DRUG|Vincristine Sulfate|Given IV
223945171|NCT02337985|DRUG|Cyclophosphamide|Given IV
223945172|NCT02337985|BIOLOGICAL|Filgrastim|Given SC
223945173|NCT02337985|BIOLOGICAL|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
223945174|NCT05414955|DEVICE|Neuromodulation|Neuromodulation
223945175|NCT06951035|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|"The repeated stimulations will be carried out using an eight-part probe detected by the infrared camera (eight shaped tracked coil), connected to a Rapid 2 stimulator (Magstim Company, Whitland, UK). The stimulation will be performed manually or with robotic assistance using TMS-Robot (Axilum Robotics, SCHILTIGHEIM, France)"
224100016|NCT00680732|DIETARY_SUPPLEMENT|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
224100017|NCT00680732|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
224100018|NCT00680732|DRUG|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
224100019|NCT00680732|DRUG|Sulphadoxyne-pyrimethamine (SP)|Tablets
224100020|NCT02221076|DEVICE|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
224100021|NCT03090191|BIOLOGICAL|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
224100022|NCT03090191|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
223535509|NCT03816189|DIAGNOSTIC_TEST|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
223535510|NCT03714607|DEVICE|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
223535511|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
223535512|NCT01458678|OTHER|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
223535513|NCT05494268|DRUG|Carbohydrate|Preoperative Carbohydrate Loading Drink
223535514|NCT02987608|DEVICE|Power Up|Smartphone phone app
223729423|NCT01503281|OTHER|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
223729424|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
223945176|NCT06951958|BEHAVIORAL|Cardiac Rehabilitation Program Based on Health Action Process Approach Model|The intervention program will start in the hospital setting and continue at home. A work schedule will be created with each individual in intervention group 1 by determining the times when they are available separately. Individuals are planned to receive 60-minute home visits once a week. In the following weeks, care interventions such as home visits, training, counseling and monitoring will be organized according to the specific needs and requirements of each individual. In the face-to-face preparation phase, the patient's health needs will be identified, health status will be assessed, daily activities will be reviewed, incompatibility between activity levels and recommended exercise guidelines will be examined, and individualized exercise goals and a behavior-specific exercise program will be created for behavioral changes. In the intervention phase, the parts that the patient lacks will be determined and the trainings needed will be given.
223945177|NCT06951139|DIAGNOSTIC_TEST|Ultrasound and Shear Wave Elastography|Non-invasive diagnostic imaging techniques used to assess the stomatognathic system. Ultrasound was performed to measure the thickness of the masseter, temporalis, and sternocleidomastoid muscles, as well as the articular disc of the temporomandibular joint. Shear Wave Elastography was used to evaluate the elasticity (stiffness) of the same muscles and joint structures in kilopascals. All evaluations were conducted at rest, using standardized positioning, and by the same experienced operator.
223945178|NCT05429632|DRUG|mocravimod|S1PR modulator
223945179|NCT06953986|DRUG|Vonoprazan|Vonaprazon is potassium competitive acid blockers
223945180|NCT06953986|DRUG|Esomeprazole 40mg|esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach
223945181|NCT03685305|BEHAVIORAL|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
223945182|NCT03685305|BEHAVIORAL|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
223945183|NCT02872532|PROCEDURE|Testicular tissue cryopreservation|Testicular tissue will be removed
223945184|NCT06299462|DRUG|ATG 5.0|ATG 2.5 mg/kg on days -3 and -2
223945185|NCT06299462|DRUG|Cyclophosphamide injection|Cyclophosphamide 50 mg/kg on days +3 and +4
223945186|NCT06299462|DRUG|ATG 4.0|ATG 2.5 mg/kg on day -2 + 1.5 mg/kg on day -3
223945187|NCT06520462|PROCEDURE|Pharmacopuncture|The physicians will decide the specific methods of pharmacopuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
223945188|NCT06520462|PROCEDURE|Acupuncture|The physicians will decide the specific methods of acupuncture based on the clinical judgment according to each participant's conditions. All applied treatment methods are documented in the case report forms.
223945189|NCT02678455|BIOLOGICAL|TV005 vaccine|Delivered by subcutaneous injection; contains 10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31, and 10\^3 PFU of rDEN4Δ30.
223945190|NCT02678455|BIOLOGICAL|Placebo|Delivered by subcutaneous injection
223945191|NCT03532139|DRUG|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
223945192|NCT03532139|DRUG|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
223945193|NCT03532139|OTHER|Thromboprophylaxis|standard of care therapy
223994479|NCT00851565|PROCEDURE|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~1. Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~2. Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~3. High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~4. High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
224100023|NCT01251575|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
224100024|NCT01251575|DRUG|Cyclosporine|Given PO or IV
223535515|NCT05444738|DRUG|oral lollipop with oxytocin (24IU)|Immediately before drug administration, a blood sample (5ml) is collected. For drug administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after drug administration.
223729425|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
223945194|NCT06524232|OTHER|Practice Facilitation (PF)|Practices will meet with practice facilitators monthly and apply tests of change using a Plan-Do-Study-Act approach, guided by the PF team. Facilitators will confirm that practices have established workflows for substance use disorder (SUD) screening and interventions and perform checks periodically to ensure progression. PF will entail: implementing protocols/algorithms for evidence-based screening and interventions, promoting decision support tools and templates to support practice workflow, optimizing electronic health record (EHR) use to pull clinical data monthly to guide the improvement process, developing patient registries (e.g., for those with SUD) to identify needed care and optimize delivery of evidence-based interventions, encouraging proactive, team-based care with assigned roles and responsibilities, and enhancing the understanding of evidence-based SUD interventions, including counseling and referral resources to ensure practices have appropriate intervention options.
223945195|NCT06524232|OTHER|Learning Collaborative (LC)|Virtual LC sessions will be held monthly and will include participants presenting anonymized cases to clinical experts, targeted brief didactics related to the content of the cases, and time for open discussion and Q\&A. Participant-generated ideas for topics to be covered during virtual LC sessions will be encouraged. Some specific topics will include optimal SUD screening approaches; prescribing medications for opioid use disorder (OUD) in primary care; pragmatic issues around integrated SUD care within primary care such as compliance with state and federal requirements, note templates/visit frequency, and when/how to escalate care for patients with severe or worsening SUD; medications for alcohol use disorder (AUD); and motivational interviewing.
223945196|NCT06524232|OTHER|Performance Incentives (PI)|We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.
223945197|NCT04922307|PROCEDURE|Blood Sparing Protocol|Acute Normovolemic Hemodilution, Cell Saver, and/or Veno-venous Bypass
223945198|NCT04922307|PROCEDURE|Standard Blood Replacement|Allogenic blood transfusion as determined intra-operatively
223945199|NCT03508700|DRUG|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
223945200|NCT02556918|DRUG|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
223945201|NCT02556918|DRUG|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
223945202|NCT02556918|DRUG|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
223945203|NCT02556918|DRUG|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate \>1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between \>180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG \>241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG \<100 mg/dl: stop basal"
223945204|NCT02556918|DRUG|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG greater than 400 mg/dL; 7-9 units of insulin lispro"
223994480|NCT00851565|PROCEDURE|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
223994481|NCT01337362|PROCEDURE|Insulin clamp|Patients will be exposed to low bloodsugar
223994482|NCT04978090|DEVICE|3D printed EAF management device|Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
223535516|NCT05444738|DRUG|oral lollipop with placebo|Immediately before drug administration, a blood sample (5ml) is collected. For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to taking another blood sample (5ml). Participants then start the anti-saccade attention task 45 minutes after placebo administration.
223535517|NCT01750853|DRUG|LY3045697|Administered orally
223535518|NCT01750853|DRUG|Placebo|Administered orally
223535519|NCT02660229|DRUG|Oxycodone Hydrochloride|Oxycodone injection
223535520|NCT02660229|DRUG|Morphine Sulphate|Morphine sulphate injection
223945205|NCT02556918|DRUG|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin aspart~* BG between 221-260 mg/dL; 3-5 units of insulin aspart~* BG between 261-300 mg/dL; 4-6 units of insulin aspart~* BG between 301-350 mg/dL; 5-7 units of insulin aspart~* BG between 351-400 mg/dL; 6-8 units of insulin aspart~* BG greater than 400 mg/dL; 7-9 units of insulin aspart"
224100025|NCT01251575|DRUG|Fludarabine Phosphate|Given IV
223535521|NCT01110057|DRUG|Placebo|Placebo to match GW856553
223945206|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Beginner]|Participants will be assigned a 'Caregiver vs. Patient' \[Beginner\] online negotiation exercise. All participants will complete this exercise, so it will serve as the constant.
223945207|NCT04837937|BEHAVIORAL|Caregiver vs. Caregiver|Participants will be assigned a 'Caregiver vs. Caregiver' online negotiation exercise.
223945208|NCT04837937|BEHAVIORAL|Caregiver vs. Physician|Participants will be assigned a 'Caregiver vs. Physician' online negotiation exercise.
223945209|NCT04837937|BEHAVIORAL|Caregiver vs. Patient [Advanced]|"Participants will be assigned a 'Caregiver vs. Patient \[Difficult\]' online negotiation exercise. This exercise is advanced compared to the constant since it involves negotiating more than one conflict."
223945210|NCT04128514|DEVICE|Panoptix Toric|Cataract surgery and IOL implantation
223945211|NCT05465954|PROCEDURE|Biospecimen Collection|Correlative studies
223945212|NCT05465954|BIOLOGICAL|Efineptakin alfa|Given IM
223945213|NCT05465954|BIOLOGICAL|Pembrolizumab|Given IV
223945214|NCT05465954|PROCEDURE|Biopsy|Undergo tumor biopsy
223945215|NCT02883361|BEHAVIORAL|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
223945216|NCT02883361|BEHAVIORAL|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
223945217|NCT03580629|BEHAVIORAL|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
223945218|NCT05281588|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations were performed only one time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations were performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations was controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations were aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation was performed between the two central incisors. The first perforation was performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
224100026|NCT01251575|OTHER|Laboratory Biomarker Analysis|Correlative studies
223945219|NCT03900286|DIETARY_SUPPLEMENT|Total Dietary Replacement|Total Dietary Replacement
223945220|NCT03736889|DRUG|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
223945221|NCT04640805|DIETARY_SUPPLEMENT|Protein supplementation|Liquid protein fortifier (Similac) will be added at 1ml per 25ml of PDHM at 130ml/kg/day of feed volume.
223945222|NCT04640805|OTHER|Analysis with Miris Human Milk Analyzer|PDHM macronutrient content will be analyzed using the Miris Human Milk Analyzer and PDHM with fat content of 3.8g/dL or higher will be selected and provided.
224100027|NCT01251575|DRUG|Mycophenolate Mofetil|Given PO
224100028|NCT01251575|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
224100029|NCT01251575|DRUG|Sirolimus|Given PO
224100030|NCT01251575|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
224100031|NCT06340594|PROCEDURE|Laproscopic cholecystectomy (LC)|Removal of gallbladder via laparoscopy
224100032|NCT06340594|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Removal of bile duct stones via endoscopy
224100033|NCT03340740|DRUG|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
224100034|NCT03340740|DRUG|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
223945223|NCT06449378|DEVICE|Transorb™ Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for repair of open ventral hernia.
223945224|NCT05910762|BEHAVIORAL|Associative inference|Participants will engage in an associative inference paradigm. Memory will be assessed behaviorally and neural representations will be assessed using functional magnetic resonance imaging.
223945225|NCT05910762|BEHAVIORAL|Category learning|Participants will engage in a category learning paradigm. Memory will be assessed behaviorally (Arms 2 and 3), and neural representations will be assessed using functional magnetic resonance imaging (Arm 2).
223535522|NCT01110057|DRUG|GS856553|GW586553 7.5mg bid
223945226|NCT05910762|BEHAVIORAL|Sleep|Participants will sleep after engaging in a category learning paradigm while electroencephalography data are collected, and memory will be assessed behaviorally after sleep.
223945227|NCT05980598|DRUG|TransCon TLR7/8 Agonist|TLR7/8 agonist prodrug
223945228|NCT05980598|DRUG|Pembrolizumab|A type of immunotherapy that works by blocking the PD-1 pathway to help prevent cancer cells from hiding
223945229|NCT05980598|DRUG|TransCon IL-2 β/γ|Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
223945230|NCT05714774|DEVICE|HIFU treatment of prostate cancer|HIFU treatment using Focal One (EDAP TMS) combined with the acquisition of additional ultrasound images before, between, and after HIFU shots will be performed.
224100035|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method A|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
224100036|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method B|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
223945231|NCT04939012|BEHAVIORAL|MyPath Intervention|MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.
223945232|NCT04939012|BEHAVIORAL|Usual care|Standard of Care
223945233|NCT03258866|DRUG|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
223945234|NCT03258866|DRUG|Rituximab|given with a single dose of 375mg/m2
223945235|NCT02423005|DEVICE|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
223945236|NCT02423005|DEVICE|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
223945238|NCT03954106|DRUG|Defibrotide|"* Part 1: Defibrotide 2.5 mg/kg/dose or 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7).~* Part 2 Recommended Phase 2 Dose: Defibrotide 6.25 mg/kg/dose once daily as a single dose on CAR-T Day -5, -4, and -3 before lymphodepletion, then every 6 hours daily for 8 days (CAR-T Day 0 to Day 7)."
223945239|NCT06132984|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance protocols include cine, non-contrast T1-mapping and T2-mapping.
223945240|NCT06280469|DEVICE|Single-Balloon Enteroscopy|The inflated balloon is supposed to fix the intestine to the endoscope system.Pushing the endoscope deeper into the small bowel with the balloon and enteroscope.
224100037|NCT04930250|OTHER|Beverage powder with 12% oat bran processed with method C|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
224100038|NCT04930250|OTHER|Placebo Comparator: Minimally-processed oat bran (Positive Control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
224100039|NCT04930250|OTHER|Placebo Comparator: Readily-digestible carbohydrate (negative control)|50g of beverage powder to be reconstituted with 330ml of water. Subjects will orally consume one of the five test products in a random order over the five test visits.
223945241|NCT06405451|OTHER|Conventional treatment|Conventional treatment to improve trunk control and stability for 30 minutes, twice a day, and six times per week.
224100040|NCT00687050|DIETARY_SUPPLEMENT|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
223535523|NCT00938262|DRUG|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
223535524|NCT01936233|DRUG|Aspirin|Aspirin 0.1 QD po
223535525|NCT01936233|DRUG|Lamivudine|LAminvudine 0.1 QD po
223535526|NCT04286152|DRUG|Mirabegron 50 MG|The experimental drug is administered to patients PO once a day for 7 days from stent insertion until removal
223535527|NCT04286152|DRUG|Placebo oral tablet|A sugar pill manufactured to mimic Mirabegron 50 mg tablet is administered to patients PO once a day for 7 days from stent insertion until removal
223994483|NCT02227992|BIOLOGICAL|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
223994484|NCT02227992|DEVICE|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
223994485|NCT04263987|PROCEDURE|Moses laser enucleation of prostate|Using the moses settings with the Lumenis laser system to evaluate outcomes for enucleation of the prostate; hypothesis is that it leads to faster operative time
223945242|NCT06405451|OTHER|Experimental treatment|"Respiratory muscle training will be conducted using the Threshold IMT-Philips inspiratory training device and the Threshold PEP expiratory training device, both from Respironics®. Participants will be comfortably seated in a chair with their feet on the ground, without back support, and with the trunk at a 90° angle to the hips. A conventional nasal clip will be used to prevent air leaks. During forced expiratory training, participants will use the ThresholdPEP® with a customized mouthpiece and perform forced expiration through the resistance device. Inspiratory muscle training will follow the same procedure using the Threshold IMT® (45).~Both inspiratory and expiratory trainings will be repeated 10-15 times, 5 sets for 20 minutes in one session, with a rest time of 30-60 seconds between each set."
223945243|NCT04458597|RADIATION|Image-guided adjuvant pelvic radiotherapy|Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.
223945244|NCT02064699|BIOLOGICAL|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
223945245|NCT06239012|DEVICE|Position measurement with BePow|14 measurements taken with the device
223945246|NCT06239012|OTHER|Position measurement with MCPAA scale|MCPAA : measurement of seated postural control in adults in French 12 measurements taken with the goniometer
223945247|NCT02610439|OTHER|Laboratory Biomarker Analysis|Correlative studies
223945248|NCT03702777|DRUG|ASP8302|Oral Capsule
223945249|NCT03702777|DRUG|Placebo|Oral Capsule
223945250|NCT00551421|BIOLOGICAL|pertuzumab|Given IV
223945251|NCT00551421|BIOLOGICAL|cetuximab|Given IV
223945252|NCT00551421|DRUG|irinotecan hydrochloride|Given IV
223945253|NCT00551421|OTHER|immunohistochemistry staining method|Correlative study
223945254|NCT00551421|OTHER|fluorescence in situ hybridization|Correlative study
223945255|NCT00551421|OTHER|gene expression analysis|Correlative study
223945256|NCT00551421|OTHER|mutation analysis|Correlative study
223945257|NCT00551421|OTHER|polymerase chain reaction|Correlative study
223945258|NCT00551421|OTHER|laboratory biomarker analysis|Correlative study
223945259|NCT02271906|DRUG|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
223945260|NCT05421572|DIAGNOSTIC_TEST|Fibrotouch|Fibrotouch will be performed showing the stiffness and fat content of liver
223945261|NCT00978718|DIETARY_SUPPLEMENT|high-selenium baker's yeast|Given orally
223945262|NCT00978718|DIETARY_SUPPLEMENT|selenium|Given orally
223945263|NCT00978718|OTHER|placebo|Given orally
223945264|NCT01039610|DRUG|GSK945237|Dose detailed in Arm description
223945265|NCT01039610|DRUG|Placebo|matching placebo tablet
223945266|NCT01039610|DRUG|Linezolid|600 mg BID, 14 Days
223945267|NCT01039610|DRUG|Moxifloxacin|40 mg single dose
223945268|NCT03919851|DRUG|Antibiotics|Administration of antibiotics
223945269|NCT03377049|DRUG|Acetazolamide|1 g acetazolamide through a peripheral IV line
223945270|NCT00455104|OTHER|No intervention|This is an observational, voluntary registry.
223945271|NCT05817513|OTHER|Myofascial release.|Myofascial release (MFR) is a therapeutic treatment that uses gentle pressure and stretching to facilitate the release of fascial restrictions caused by accidents, injury, stress, repetitive use, and traumatic or surgical scarring. The fascial restrictions are palpated by the practitioner and the techniques are applied directly to the skin of the patient without lotions or oils. The pressure is applied into the direction of the restriction just until resistance is felt or the tissue is perceived to stop moving. The pressure is sustained at this point of resistance, without sliding over the skin or forcing the tissue, for a minimum of 90-120s. As the tissue begins to release, the practitioner maintains the same amount of pressure and follows the release three dimensionally through multiple releases.
223945272|NCT05817513|OTHER|Traditional exercises for scoliosis treatment.|"The exercises are:~1. Pelvic tilt.~2. Arm and leg raises.~3. Cat-cow.~4. Bird dog.~5. Latismus dorsi stretch.~6. Abdominal press.~7. Practice a good posture.~8. Stretching and scapular exercises."
223945273|NCT04323800|BIOLOGICAL|Anti- SARS-CoV-2 Plasma|SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
223945274|NCT04323800|BIOLOGICAL|SARS-CoV-2 non-immune Plasma|Normal human plasma collected prior to December 2019
223945275|NCT00489554|BIOLOGICAL|Synflorix|Intramuscular injection, 3 doses.
223945276|NCT00489554|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses.
223945277|NCT00489554|BIOLOGICAL|Rotarix|Oral, 2 doses.
223945278|NCT05983939|DRUG|PIPE-791|Single and multiple ascending oral doses of PIPE-791 tablets.
223945279|NCT05983939|DRUG|Placebo|Single and multiple ascending oral doses of matching placebo tablets.
223945280|NCT01087346|BEHAVIORAL|Reading Information|Reading information about risk factors for obesity among children
223945281|NCT06563505|DRUG|Mosunetuzumab|Given by IV
223945282|NCT06563505|DRUG|Zanubrutinib|Given by IV
223945283|NCT06571695|PROCEDURE|Anatomic Long Head of Biceps Tensioning Technique|The standard mini-open subpectoral approach will be made. The myotendinous junction of the long head of the biceps tendon and its location within the intertubercular groove will be marked using electrocautery. The surgeon will then turn to the glenohumeral joint and perform the biceps tenotomy.The long head of the biceps tendon will be retrieved.The tendon is tagged with a running, locking number 2 fiberwire suture at the mid substance of the myotendinous junction using the previously made electrocautery marks to set the tension. The tendon is shortened. The sutures from the biceps are passed through the Arthrex cortical button.The pectoralis major tendon is retracted and 2 centimeters proximal to the distal insertion a unicortical bone tunnel is drilled in the bicipital groove with a 3.2 millimeter drill.The wound is irrigated and the biceps button is threaded into this tunnel and then flipped.The suture is tensioned, securing the biceps against the groove
223945284|NCT06571695|PROCEDURE|Traditional Long Head of Biceps Tensioning Technique|Diagnostic arthroscopic shoulder scope will occur to assess the long head of the biceps for tendinopathy. Tenotomy will occur at the junction of the supraglenoid tubercle with arthroscopic scissors. Subsequent tensioning and tenodesis will be based on surgeon's preference
223945285|NCT05453435|DRUG|Entecavir|All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
223945286|NCT06569836|OTHER|12-week intervention|"Rehabilitation Exercise Plan Week 1-4 For No Symptom Group: Therapeutic home exercise prescription(2 sessions, 60 minutes per session) For Mild \& Moderate Group: Rehabilitation Plan provided by Physiotherapist (4 sessions, 60 minutes per session)~Enhancement of Self-Management Capacity Week 5-8 For No Symptom Group: Educational Workshops provided by Physiotherapist (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Self-management group provided by Social Worker (4 sessions, 60 minutes per session)~Exercise Maintenance Week 9-12 For No Symptom Group: Mobilized Intervention (2 sessions, 60 minutes per session) For Mild \& Moderate Group: Exercise Maintenance provided by Exercise Mentor (4 sessions, 60 minutes per session)"
223945287|NCT06569836|OTHER|12-week attention control|The attention and waitlist control group will have weekly educational and virtual workshops for 12 weeks. Three topics will be covered, including online exercise class, cognitive training, leisure and recreational activities. Each session will be 30-45 minutes and each topic last for four weeks. Participants could access the virtual sessions by their electronic devices.
223945288|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with double-cone coil|Deep Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with double-cone coil
223945289|NCT06081985|DEVICE|Transcranial Magnetic Stimulation with sham coil|Transcranial Magnetic Stimulation to the Left Dorsolateral Prefrontal Cortex with sham coil
223945290|NCT06634927|DRUG|Ozempic®|Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.
223945291|NCT06634927|DRUG|HDG1901|Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.
223945292|NCT05616039|PROCEDURE|Standard Liver Surgery|Standard liver surgery using naked eye examination +/- palpation and intra-operative ultrasound scan (IOUS) examination to identify and remove liver tumours
223945293|NCT05616039|DIAGNOSTIC_TEST|Indocyanine Fluorescent Image Guided Surgery (I-FIGS)|Use of I-FIGS in accurate identification of tumours and their margins
223945294|NCT06073587|DIAGNOSTIC_TEST|Scintigraphy scan|Scans will be performed as specified in the arm description.
223945295|NCT05739136|DRUG|Relugolix + Estradiol + Norethindrone Acetate|Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
223945296|NCT05779631|DIAGNOSTIC_TEST|mpMRI plus a same-day cystoscopic bladder biopsy|mpMRI plus a same-day cystoscopic bladder biopsy
223945297|NCT05779631|PROCEDURE|TURBT|Transurethral resection of the bladder tumor
223945298|NCT03774849|DEVICE|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
223945299|NCT03774849|DEVICE|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
223945300|NCT03774849|DEVICE|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
223945301|NCT06092307|DIAGNOSTIC_TEST|Bioelectrical impedance|Resistance, reactance, phase angle,free-fat mass, body cell mass, body cell mass index and total body will be recorded
223945302|NCT06092307|DIAGNOSTIC_TEST|Handgrip strength test|Handgrip strength test using a hydraulic hand dynamometer and sit-to-stand test will be performed.
223945303|NCT06092307|DIAGNOSTIC_TEST|muscle ultrasound.|The following ultrasound parameters will be evaluated: radial, ulnar, rectus femoris, rectus abdominis and medial gastrocnemius muscle thickness and echo intensity with gray-scale-index; rectus femoris muscle cross sectional area; gastrocnemius muscle fiber length and pennation angle.
223945304|NCT00895596|DRUG|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
223945305|NCT00773344|DRUG|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
223945306|NCT01349270|DRUG|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
223945307|NCT01349270|DRUG|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
223945308|NCT00989742|DRUG|Doxycycline|50mg od
223945309|NCT00989742|DRUG|Placebo|50mg od
223945310|NCT05075200|DRUG|Tranexamic acid|Participants in both groups will be given single intravenous bolus of TXA 20 mg/kg over 15 min after induction of spinal (or other regional technique) or general anesthesia as per standard of care.
223945311|NCT06075641|PROCEDURE|Gingival depigmentation|Gingival depigmentation is the most widely used periodontal procedure to remove or reduce the melanotic areas. Various techniques can be employed to effectively carry out the depigmentation procedure, including surgical scraping, scalpel technique, bur abrasion, free gingival graft, gingivectomy, cryosurgery, electrosurgery, chemical therapies, and different types of lasers
223945312|NCT02118311|BIOLOGICAL|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
223945313|NCT02118311|DRUG|Fludarabine|Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
223945314|NCT02118311|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
223945315|NCT02118311|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
223945316|NCT01380145|BIOLOGICAL|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
223945317|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an intravenous (IV) infusion.
223945318|NCT05139615|DRUG|APD418|Participants will receive a single dose of APD418 as an IV infusion.
223945319|NCT05139615|DRUG|Placebo|Participants will receive a single dose of APD418 matching placebo as an IV infusion.
223945320|NCT00495066|DRUG|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
223945321|NCT02174146|PROCEDURE|non-surgical periodontal therapy|supra and subgingival debridement
223945322|NCT04918394|OTHER|Questionnaire of Mold / moisture exposure|"Mold / moisture exposure is assessed by the 5 following questions, whose positive response has been associated with the actual presence of mold in the household (according to data from the literature data), asked in the form of a parent-completed declarative questionnaire regarding the child's primary living home:~* Presence of visible mold~* Impression of dampness~* Apparent dampness~* Existence of recent water damage in the last year~* Presence of a moldy odor"
223945323|NCT04997798|DRUG|Trastuzumab Pyrotinib Exemestane Dalpiciclib|Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
223945324|NCT00724737|PROCEDURE|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
223945325|NCT00724737|PROCEDURE|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
223945326|NCT03848975|OTHER|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
223945327|NCT03848975|OTHER|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
223945328|NCT05213182|BEHAVIORAL|Young Women of Today|Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
223945329|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
223945330|NCT03833752|DIAGNOSTIC_TEST|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
223945331|NCT05687214|OTHER|Osteopathic manipulative treatment|"Each participant in the experimental group will receive eight osteopathic manipulative treatments. Each treatment will include the following manipulations:~* Pompage Cv4;~* Occipital-sternal technique;~* Relaxining manipulation of the diaphragmatic domes;~* Pelvic and abdominal diaphragm synchronization;~* Dynamogenic technique;~* Mesenteric traction;~* Release of colic angles;~* Manipulation and mobilization of the sacrum."
223945332|NCT04552457|BEHAVIORAL|No activity restrictions|"Patients in the No activity restrictions group will be allowed to return to their normal activity immediately."
224100041|NCT00687050|DIETARY_SUPPLEMENT|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
224100042|NCT03450772|DRUG|Creon® 25000|Experimental drug
224100043|NCT03450772|DRUG|Creon® 10000|Active comparator
224100044|NCT02506777|DRUG|metformin|
224100045|NCT02506777|DRUG|Fluoruracil|
223945333|NCT04552457|BEHAVIORAL|Activity restrictions|"Patients in the Activity restrictions group will not be allowed to perform strenuous exercise or lift anything greater than 10lbs. Strenuous exercise will be defined as is any activity that requires so much exertion that one cannot have a conversation comfortably while doing it."
223945334|NCT02038049|DRUG|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
223945335|NCT02038049|DRUG|Placebo|Placebo to VAY736
223945336|NCT03482102|DRUG|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
223945337|NCT03482102|DRUG|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
224100046|NCT02506777|DRUG|Doxorubicin|
224100047|NCT02506777|DRUG|Cyclophosphamide|
224100048|NCT02506777|DRUG|melatonin|
223945338|NCT03482102|RADIATION|Radiation|Radiation therapy is used to shrink cancer cells.
223945339|NCT05364840|DRUG|STI-1558|Orally available protease inhibitor capsule
223945340|NCT05364840|DRUG|Placebo|Placebo product capsule
223945341|NCT01691716|DRUG|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
223945342|NCT01691716|BEHAVIORAL|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
223945343|NCT02315014|OTHER|whey protein|whey protein.
223945344|NCT02315014|OTHER|placebo|placebo.
223945345|NCT02656147|BIOLOGICAL|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
223945346|NCT03540329|DEVICE|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
223945347|NCT03540329|DEVICE|External Osteogenesis distractor|External distraction osteogenesis in mandible
223945348|NCT02771366|DRUG|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
223945349|NCT02771366|OTHER|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
223945350|NCT00586755|PROCEDURE|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
223945351|NCT01378884|DRUG|Domperidone|Patient to receive treatment with Domperidone
223945352|NCT02454556|DRUG|FOLITIME®|
223945353|NCT02454556|DRUG|Gonal-F®|
223945354|NCT04540926|DRUG|Cyclosporin A|COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
223945355|NCT02905292|OTHER|evaluation and treatment maneuver for BPPV|
223945356|NCT01030315|DRUG|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
223945357|NCT04580004|OTHER|Med Optimization Arm|An evidence-based medication recommendation website that is provided to the patients.
224100049|NCT04427085|OTHER|Ultrasound assessment of optic nerve sheath diameter|Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
224100050|NCT05128617|DRUG|Epirubicin-cyclophosphamide|1 cycle of Epirubicin-cyclophosphamide
224100051|NCT05128617|DRUG|Paclitaxel|1 cycle of Paclitaxel
224100052|NCT04463394|DRUG|Vasopressin|Vasopressin administered intravenously
224100053|NCT04887298|DRUG|Liposomal Annamycin (L-Annamycin)|2-hour intravenous (IV) infusion of L-Annamycin on Day 1 followed by 20 days off of study drug (i.e., 1 treatment cycle= 21 days)
224100054|NCT05089630|BIOLOGICAL|Pentamer (low)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of low dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
224100055|NCT05089630|BIOLOGICAL|Pentamer (med)/gB(low)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and low dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
224100056|NCT05089630|BIOLOGICAL|Pentamer (med)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of medium dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
224100057|NCT05089630|BIOLOGICAL|Pentamer (high)/gB(med)/Adjuvant vaccine|Three doses of the candidate CMVsu vaccine consisting of a combination of high dose pentamer and medium dose gB antigens, adjuvanted are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
224100058|NCT05089630|COMBINATION_PRODUCT|Placebo (saline)|Three doses of placebo (saline) are administered intramuscularly in the deltoid region of the non-dominant arm in a 0, 2, 6-month schedule.
224100059|NCT05267028|OTHER|AD-TAR|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using a rehabilitation program named Training of Affect Recognition (TAR).
224100060|NCT05267028|OTHER|AD-Cognitive Stimulation|12 sessions in groups of 4 subject, over 6 weeks (2 sessions per week), using classic cognitive stimulation workshops.
224100061|NCT04062955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary counseling
223945358|NCT03917732|BEHAVIORAL|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
223945359|NCT03917732|BEHAVIORAL|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
223945360|NCT05537532|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
223945361|NCT05537532|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
223945362|NCT05537532|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
223945363|NCT04119947|DRUG|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
224100062|NCT04062955|PROCEDURE|Dual X-ray Absorptiometry|Undergo DXA scan
224100063|NCT04062955|OTHER|Questionnaire Administration|Ancillary studies
224100064|NCT03068962|OTHER|beetroot Juice|Beetroot Juice
224100065|NCT03068962|OTHER|Buxton water|natural mineral water
223719609|NCT03346915|BEHAVIORAL|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
223719610|NCT03948711|DEVICE|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
223719611|NCT03266965|DRUG|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
223719612|NCT03266965|DIETARY_SUPPLEMENT|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
223719613|NCT00257543|PROCEDURE|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
223719614|NCT01538043|OTHER|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
223719615|NCT03431428|PROCEDURE|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
223719616|NCT03431428|PROCEDURE|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
223719617|NCT03431428|DRUG|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
223945364|NCT05440240|PROCEDURE|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
223945365|NCT05440240|DRUG|Corticosteroid injection|Depo-Medrol
223945366|NCT05440240|OTHER|Saline injection|Isotonic saline
223945367|NCT01808534|DRUG|palifosfamide|Given IV
223535528|NCT03144167|OTHER|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
223535529|NCT04149665|DEVICE|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
223945368|NCT05186402|PROCEDURE|Total or subtotal gastrectomy|Gastric resection with digestive continuity according Roux or Bilroth
223945369|NCT00002599|BIOLOGICAL|filgrastim|
223945370|NCT00002599|BIOLOGICAL|recombinant interferon alfa|
223535530|NCT06460376|OTHER|Wurn Technique|"Treatment:~Site-specific pressures for 30 seconds across the restrictive bands of adhered tissues and structures, working progressively deeper from the most superficial tissues Traction: focusing on these adhered areas, engage the uterine fundus and sidewalls and traction them to the left.~To assist and improve the mobility of the soft tissues, release the traction tension either suddenly or gradually, depending on the desired effect to decrease spasms and adhesions between the uterus and the bladder. The baseline treatment was moist heat.~Each therapy session was 30 minutes for 6 weeks and 2 sessions per week. 10 minutes for baseline treatment."
223945371|NCT00002599|BIOLOGICAL|sargramostim|
223945372|NCT00002599|DRUG|carmustine|
223945373|NCT00002599|DRUG|cyclophosphamide|
223945374|NCT00002599|DRUG|doxorubicin hydrochloride|
223945375|NCT00002599|DRUG|melphalan|
223945376|NCT00002599|DRUG|methylprednisolone|
223945377|NCT00002599|DRUG|prednisone|
223945378|NCT00002599|DRUG|vincristine sulfate|
223945379|NCT00002599|RADIATION|low-LET cobalt-60 gamma ray therapy|
224295180|NCT05025280|OTHER|Adolescent/Adult Sensory Profile Questionnaire|"The Adolescent/Adult Sensory Profile Questionnaire (AASP), was developed based on Dunn's model of sensory processing. It is a 60-item self-assessment questionnaire that evaluates behavioral patterns related to sensory processing. The questionnaire consists of six different subsections such as taste/smell processing, movement processing, visual processing, touch processing, auditory processing, and activity level. According to the answers given, individuals are evaluated in 4 quartiles as low registration, sensory sensitivity, sensation avoiding, and sensation seeking."
223945380|NCT00002599|RADIATION|low-LET photon therapy|
223945381|NCT00063089|DRUG|S. aureus Immune Globulin Intravenous (Human) 5%|
223945382|NCT00505986|PROCEDURE|endometrial biopsy|
223945383|NCT05174520|OTHER|Routine Physical Therapy|Routine physical therapy will be provided to group A for 25 minutes thrice a week for 4 weeks.
223945384|NCT05174520|OTHER|Muscle Energy Technique|Muscle Energy technique along with Routine physical therapy will be provided to group B for40 minutes thrice a week for 4 weeks.
223945385|NCT03651934|DIETARY_SUPPLEMENT|Normal iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
223945386|NCT03651934|DIETARY_SUPPLEMENT|Weak iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
223945387|NCT03651934|DIETARY_SUPPLEMENT|Normal selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
223945388|NCT03651934|DIETARY_SUPPLEMENT|Weak selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
223945389|NCT00628706|DRUG|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
223945390|NCT06486610|BEHAVIORAL|Fish-shaped nebulizer and fish-shaped toy|In order to reduce the child's fear and anxiety, it is planned to apply inhalation therapy using a nebulizer with a red fish figure and an amigurumi toy with a red fish figure.
223945391|NCT06486610|DEVICE|Silent nebulizer|It is planned to apply inhalation therapy using a silent nebulizer to reduce the child's fear and anxiety.
223945392|NCT05302076|DEVICE|Low-intensity electrical current (LIEC)|Each patient in the electrical group will be asked to wear a removable device containing a small electrical circuit that will supply the required electric current for five hours a day until the completion the retraction of the upper anterior teeth.
223945393|NCT05302076|DEVICE|Traditional fixed orthodontic appliance|"The maxillary arch will be levelled and aligned. The rectangular stainless steel archwires (0.019 × 0.025) with anterior 8mm height soldered hooks distal to the canines will be inserted. (250-300) g force will be applied on each side using two NiTi springs attached between the mini-implants and the soldered hooks in a direction approximately parallel to the occlusal plane for conducting an en-masse retraction."
224295181|NCT00567476|DRUG|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
224100066|NCT03068962|OTHER|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
223945394|NCT01303796|DRUG|Sapacitabine|Oral sapacitabine capsules
223945395|NCT01303796|DRUG|Decitabine|Decitabine intravenous
223945396|NCT00326196|DEVICE|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
223945397|NCT00326196|PROCEDURE|Coronary artery bypass graft (CABG)|coronary bypass
223945398|NCT03863587|BIOLOGICAL|HLX12|healthy volunters receive HLX12 (8mg/kg) once
223945399|NCT03863587|BIOLOGICAL|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
223945400|NCT05532501|DRUG|Oral Oxytocin|Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
223945401|NCT05532501|DRUG|Intranasal Oxytocin|Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
223945402|NCT05532501|DRUG|Oral placebo|Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
223945403|NCT05532501|DRUG|Intranasal placebo|Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
223945404|NCT02890524|DEVICE|night guard|60 days before and after intervention with the night guard
223945405|NCT02890524|DEVICE|placebo night guard|60 days before and after intervention with the placebo night guard
224100067|NCT00193843|PROCEDURE|Post-operative chemoradiotherapy / accelerated radiotherapy|
223945406|NCT02148705|DRUG|NexoBrid|
223945407|NCT02148705|PROCEDURE|Standard of Care (SOC)|
223945408|NCT02148705|DRUG|Gel Vehicle|
224100068|NCT04503980|BIOLOGICAL|αPD1-MSLN-CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of αPD1-MSLN-CAR T cells. During αPD1-MSLN-CAR T cells production, subjects will receive cyclophosphamide for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection. The initial dose of 1×10\^5 CAR+ T cells/kg will be infused on day 0.
224100069|NCT01099345|PROCEDURE|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
224100070|NCT01099345|PROCEDURE|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
224100071|NCT05265351|DIAGNOSTIC_TEST|Transdiaphragmatic pressure measurement|Ultrafast ultrasound imaging of the diaphragm during artificially evoked responses
224100072|NCT05265351|DIAGNOSTIC_TEST|EMG|Surface electromyography of the diaphragm for phrenic nerve conduction study
223945409|NCT01462175|DRUG|RO5503781|
224100073|NCT03554512|OTHER|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
223719618|NCT01854710|DRUG|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
223945410|NCT00481572|DRUG|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
223945411|NCT00481572|DRUG|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
223945412|NCT00481572|DRUG|Norepinephrine|titrated norepinephrine over a period of 48 hrs
223945413|NCT00729794|DRUG|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
223945414|NCT00729794|DRUG|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
223945415|NCT01737021|OTHER|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
223945416|NCT05973773|DRUG|TAS6417|oral tablets
223945417|NCT04090476|OTHER|Exercise|During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
223945418|NCT01115036|DRUG|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
223945419|NCT00495144|DRUG|TH-302|
223945420|NCT03398980|RADIATION|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
223945421|NCT03739606|BIOLOGICAL|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
223945422|NCT01005615|DEVICE|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
224100074|NCT04723537|DRUG|Part A: Upamostat 200 mg|1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
224100075|NCT04723537|DRUG|Part A: Upamostat 400 mg|2 capsules, each capsule comprising 200 mg of upamostat
224100076|NCT04723537|DRUG|Part A and B: Placebo|1 or 2 capsules, each capsule a matching placebo
224100077|NCT04723537|DRUG|Part B: Upamostat 200 or 400 mg|"Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days."
224100078|NCT00502060|DRUG|AZD2171|
224100079|NCT00502060|DRUG|ZD1839|
223945423|NCT01005615|DEVICE|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
223945424|NCT05119699|DEVICE|MagPro X100/R30 stimulator equipped with the B70 fluid-cooled coil|Subjects will receive 5 consecutive days (always Monday to Friday) of TBS rTMS, administered 8 times daily at 1 hour intervals. Patients will undergo cTBS of the R DLPFC at 110-120% RMT using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for a total of 600 pulses over 40 seconds, followed by iTBS of the L DLPFC at 110-120% resting motor threshold (RMT) using bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz with a duty cycle of 2 s on, 8 s off for a total of 600 pulses over 3 min 9 s. Participants will be titrated to 110-120% RMT within the first four treatments to aid with tolerability. If patients tolerate the stimulation well, the target will be 120%. Assessments focused on depressive symptoms will be administered at baseline, after final treatment and four weeks post final treatment.
223945425|NCT06270732|BEHAVIORAL|iMentalize Program (iMentalize)|"This is a 30-hour group training involving 30 sessions lasting 45 minutes and 7.5 hours of inter-sessions work.~Session 1: Program presentation; Session 2: Reflective Parenting; Session 3: Cartoon's session I (baseline); Session 3: What is Mentalization; Session 4: Fundamentals of Human Interaction; Session 5: Cartoon's session II (the beginnings); Session 6: Mentalization and Mental Health; Session 7: MISC context and cultural components; Session 8: Cartoon's session III (practice with MISC context comp.); Session 9: The importance of emotions in human interaction; Session 10: MISC emotional components; Session 11: Cartoon's session IV (practice with emotional comp.); Session 11: How mentalization is developed; Session 12: MISC cognitive components; Session 13: Cartoon's session V (practice with cognitive comp.); Session 14: How to foster children mentalization skills. Sessions 15 to 30: Cartoon's sessions using MISC components to foster children mentalization."
223945426|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 30-hour individual training involving 30-weekly online, individual, self-administered 45' sessions (22.5h) + 7.5h of between sessions work (readings, supervision, video- recordings for later video-feedback, reﬂection exercises). BLOCK I: Session 1: Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC; Sessions 9-18 (MISC practice and video-feedback); Summer break: Recording daily life interactions; BLOCK II: Session 19: Recap; Sessions 20-30: guided reﬂection and video-feedback.
223945427|NCT06270732|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|"This is an equivalent 30-hour online self-administered training involving 30 x 45' individual online sessions (22.5h), mostly based on reﬂection exercises around brief readings, pills, and animated shorts, but not video- feedback and guided practice. This is complemented with 7.5h of between-sessions work based on looking for new information, adult-child (non-guided) activities (and not for later video- feedback) or out-of-line guided reﬂective exercises.~Session 1: Program presentation; Session 2-8: Theoretical bases of MISC and mentalization; Session 9-16: MISC and mentalization applied to mental health; 17-18: Benefits of MISC to improve children learning; 19-20: Benefits of MISC for self-esteem; 21-22: The importance of MISC to foster mentalization; 23-24: Mentalization and pro-social behavior; 25-26: The importance of MISC to promote secure attachment; 27: MISC impact in epistemic trust; 28-29: MISC and well-being; 30: MISC, mentalization and environmental enrichment."
223945428|NCT02290158|OTHER|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
223945429|NCT03851458|BEHAVIORAL|Initial in-person individual diet and exercise counseling (N vs. Y)|Individual counseling utilizing MI has been effective in promoting behavioral change.18 A SANOS interventionist (MRNY promotora) will deliver a 45-60 minute counseling session, utilizing MI techniques, on diet and exercise, and how to stretch one's food dollars (see description of 10 modules described above under COMIDA Pilot). The promotora will evaluate the participant's diet based on the 24-hour dietary recall132 conducted at intake (see below), will compare diet composition to the USDA's MyPlate guidelines, and will then personalize education to address identiﬁed knowledge gaps and unhealthy food choices. Promotoras will focus on goal-setting, problem solving, selfeﬃcacy enhancements, selfmonitoring skills (i.e., participants will be taught how to monitor their diet, weight, and physical activity (PA), with simple pencil-and-paper logs or with 'Self-monitoring tools' if randomized to also receive that component), and modeling of healthy behaviors.
223945430|NCT03851458|BEHAVIORAL|Thrice weekly diet and exercise text messages (N vs. Y)|Text message interventions have been demonstrated to be effective in increasing self-eﬃcacy, weight loss, and PA.65-67 Participants will receive thrice weekly healthy eating, PA, and health care access text message tips. Links to additional information and videos will also be sent via text (e.g. local farmers markets, healthy recipes, free exercise classes, workout videos, video demonstrations of how to prepare healthy meals, etc.). Texts were developed and piloted in the COMIDA Pilot, are designed to promote goal-setting, problem-solving, self-monitoring, modeling, and self-eﬃcacy, and will be further reﬁned during the formative research phase (see below). Texts will be sent via Mosio Text Messaging Solutions. Messages will be concise, as longer messages have shown no demonstrable impact. Based on each participant's status at intake, tailored text messages will also encourage regular follow-up with PCPs. Text messages will be interactive.
223945431|NCT03851458|BEHAVIORAL|Weekly telephone support (N vs. Y)|Several lifestyle interventions including Hispanics have successfully incorporated telephone support.134-138 Weekly telephone support (or more frequently if requested) will be delivered by the promotoras throughout the 6-month intervention. Frequent and prolonged contact in behavioral interventions is more effective than single sessions; most interventions leading to diet or PA changes persisting for \>12 months have follow-up contact sessions for at least 4 months.18 Greater numbers of follow-up sessions facilitate success of behavior change, and initial behavior change can decrease with decreased contact.18,139 Telephone sessions (10-15 minutes) will use MI principles, will focus on goal-setting, problem solving, reviewing/integrating new diet/PA knowledge/skills (including self-monitoring) into individuals' daily routines, self-eﬃcacy enhancements, encouraging participants to seek opportunities for modeling and encouraging regular follow-up with PCPs.
224295182|NCT00567476|DRUG|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent
224295183|NCT00567476|DRUG|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
223719619|NCT01854710|DRUG|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
223945432|NCT03851458|BEHAVIORAL|Self-monitoring tools (N vs. Y) (for diet and weight)|Self-monitoring is an important component in achieving behavioral change.18 Participants will be given a SANOS food diary (adapted for and pilot-tested at the VDS in our pilot work) and a digital scale. As part of VDS Mobile usual care, all participants will receive a pedometer to assess exercise behavior (secondary outcome), so additional self-monitoring tools for PA will not be included in this component.
223945433|NCT06435481|DRUG|3D printed chewable formulation of hydrocortisone|Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
223945434|NCT06435481|DRUG|Oral suspension of hydrocortisone|Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
223945435|NCT02431442|DRUG|RM-493|
223945436|NCT02431442|DRUG|Placebo|
223945437|NCT01738698|DRUG|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
223945438|NCT01738698|DRUG|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
223945439|NCT01738698|DRUG|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
223945440|NCT01738698|DRUG|Placebo|Oral administration once-daily for 12 weeks
223945441|NCT02575365|DRUG|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
223945442|NCT03438565|DEVICE|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
223945443|NCT04973306|PROCEDURE|Neoadjuvant Chemoradiotherapy|"Chemotherapy: carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. For each cycle, Carboplatin and paclitaxel were administered 30 minutes apart.~Radiotherapy: A total radiation dose of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 days per week (Radiotherapy was performed on the 2nd, 3rd, 4th, 5th, and 6th day in each cycle, and only 3 times in the 5th cycle)"
223945444|NCT04973306|DRUG|Tislelizumab|"Tislelizumab (200mg/time) was administered intravenously on the 1st and 22nd day.~The intravenous injection lasts about 30 minutes (micropump is recommended, intravenous bolus is prohibited, duration should be not less than 20 minutes and not more than 60 minutes);"
223945445|NCT04973306|PROCEDURE|Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)|After neoadjuvant therapy, patients in groups receive Ivor-Lewis or Mckeown Esophagectomy (Mckeown Esophagectomy recommended)
223945446|NCT01336842|DRUG|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
223945447|NCT02125292|DRUG|Mesalamine|
223945448|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
223945449|NCT00606216|PROCEDURE|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
223945450|NCT00606216|PROCEDURE|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
223945451|NCT04305340|DEVICE|Myant SKIIN Device|"1. Supine position: Participant lays on a bed on their back for 5 minutes~2. Sitting position: Participant sits on a chair for 5 minutes~3. Standing position: Participant stands for 5 minutes.~4. Exercise measurement: treadmill exercise test - the protocol entails increases of 0.5 mph every minute with zero change in the incline. Starting point would 1.5 mph. The test will be interrupted if the target heart rate of 190 beats per minute is reached or if symptoms and/or arrhythmias and ST depression would be observed. Patient will be monitor during recovery for 5 minutes.~5. Cool-down: Participants cool-down for 5 minutes"
223945452|NCT03620955|OTHER|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
223945453|NCT01009645|BEHAVIORAL|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
223945454|NCT01009645|BEHAVIORAL|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
224295184|NCT00567476|DRUG|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
224295185|NCT02696031|DRUG|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
224295186|NCT02696031|DRUG|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
224295187|NCT03758482|OTHER|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
223945455|NCT01009645|BEHAVIORAL|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
223945456|NCT01009645|BEHAVIORAL|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
223945457|NCT05461755|COMBINATION_PRODUCT|Fractional radiofrequency and topical Tretinoin|Treatment of striae with fractional radiofrequency and topical tretinoin in combination
223945458|NCT05461755|DRUG|Topical Tretinoin|Treatment of striae with topical tretinoin alone
223945459|NCT05461755|DEVICE|Fractional radiofrequency|Treatment of striae with fractional radiofrequency alone
223945460|NCT01255800|DRUG|IPI-926 and Cetuximab|"* Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
223945461|NCT05124210|BIOLOGICAL|Sotrovimab|Sotrovimab will be administered.
223945462|NCT05512299|DIAGNOSTIC_TEST|Transcranial Magnetic Stimulation|The CBI is recorded with two different TMS coils. The figure-of-eight coil (2X90 mm) is used for the motor cortex stimulation and the double cone coil (2X126 mm) is used for the cerebellar stimulation. The target recording muscle is first dorsal interosseous (FDI). The TMS intensity used to induce an average MEP amplitude of 0.5 mV is also determined. CBI is measured by a paired TMS with an inter-stimulus interval of 6 ms. That is, the test TMS at M1 is delivered 6 ms following the conditional TMS at contralateral cerebellum.
223945463|NCT01817491|OTHER|American Heart Association Diet|
223945464|NCT01817491|OTHER|Reduced Fat Vegan Diet|
223945465|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po
223945466|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
223945467|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
223945468|NCT00768755|DRUG|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
223945469|NCT00768755|DRUG|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
223945470|NCT02134782|BEHAVIORAL|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
223945471|NCT02134782|OTHER|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
224287452|NCT06473402|DIAGNOSTIC_TEST|Hamstring Flexibility|The Sit and Reach Test will be administered to evaluate flexibility. Measurements will be made with a test stand with a length of 35 cm, a width of 45 cm and a height of 32 cm. The measurement of the participant who cannot reach the zero point of the sole of the foot on this tripod will be recorded as minus (-), while the measurement of the participant who can pass the zero point will be recorded as plus (+). Participants will be seated in a long sitting position with the soles of their feet resting on the testing apparatus, and the measurement will begin with their knee joints fully extended. While leaning his body forward, he will be asked to lie forward as far as he can, with his hands in front of his body, without bending his knees. The test will be repeated 2 times and the best value will be recorded in cm.
223945472|NCT05785728|DRUG|DB-1202|Administered I.V.
223945473|NCT04037072|DRUG|Mitomycin C|Topical application of Mytomycin C (MMC)
223945474|NCT04037072|OTHER|Control|Topical application of Normal Saline
223945475|NCT00780793|DRUG|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop"
223945476|NCT00780793|DRUG|DMARD maintenance|DMARD maintenance
223945477|NCT00310037|DRUG|bortezomib|Given IV
223945478|NCT02222506|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
223945479|NCT04680598|DRUG|ICI|Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)
223945480|NCT04680598|DRUG|Antiviral Prophylaxis|Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
223945481|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 2 capsules
223945482|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch A Ultibro Breezhaler 85/43 μg 1 capsule
223945483|NCT04856098|DRUG|Indacaterol maleate and glycopyrronium bromide|Batch B Ultibro Breezhaler 85/43 μg 2 capsules
223945484|NCT04856098|DRUG|Ultibro Breezhaler with oral charcoal|Activated charcoal suspension, granules 50 g / bottle
223945485|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
223945486|NCT01157624|DRUG|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
223945487|NCT02198898|DEVICE|GUARDIX-SG|
223945488|NCT06244914|DEVICE|tDCS stimulation|tDCS 1mA will be applied for 20min. tDCS will be applied around the infract area. taVNS or sham taVNS wil be applied before tDCS. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
223945489|NCT06244914|DEVICE|taVNS stimulation|taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of taVNS will be adjusted under the patient's pain threshold. After taVNS, tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
223945490|NCT06244914|DEVICE|sham tDCS stimulation|sham tDCS 1mA will be applied for 20min. sham tDCS will be applied around the infract area. The stimulation will be applied for only 10 seconds and no stimulation afterward. taVNS or sham taVNS wil be applied before sham tDCS.The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
223945491|NCT06244914|DEVICE|sham taVNS stimulation|sham taVNS will be applied for 30 min. The electrode will be placed on the left ear of the patient. The amplitude of sham taVNS will be adjusted under the patient's pain threshold. The stimulation was only applied for 5 seconds and no stimulation afterward. After sham taVNS, tDCS or sham tDCS will be applied for 20 min. The intervention will be applied before physical therapy. A total of 10 sections are applied during the intervention period of 2 weeks.
223945492|NCT00643409|DRUG|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
223945493|NCT00643409|OTHER|placebo|placebo
223945494|NCT00643409|DRUG|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
223945495|NCT00643409|OTHER|placebo|placebo
223945496|NCT06412432|OTHER|Exercise training (ET1+ET2)|Exercise training will consist of continuous aerobic training of moderate intensity on cycle ergometer/treadmill, with a frequency of 2-3 weekly sessions lasting 12 weeks, with exercise intensity of VO2 peak of 40% gradually increasing up to 50-60% of VO2 peak based on individual tolerability and improvement; 55-65% of heart rate at peak; 40-59% of heart rate reserve; 4-6 Metabolic equivalents (METS); the duration of the session will gradually increase from 15-30 min to 45-60 min.
223945497|NCT06412432|BEHAVIORAL|Optimal Medical Therapy (No-ET)|Patients will be handled according to optimal medical therapy
223945498|NCT03279367|DIAGNOSTIC_TEST|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
223945499|NCT05160909|PROCEDURE|Beach Chair Position|Patients positioned in beach chair during arthroscopic shoulder stabilization
223945500|NCT05160909|PROCEDURE|Lateral Decubitus Position|Patients positioned in lateral decubitus position during arthroscopic shoulder stabilization
223945501|NCT05200286|DRUG|Olorofim|Single oral dose
223945502|NCT00188812|DRUG|donepezil hcl|
223719620|NCT01854710|DRUG|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
223719621|NCT01854710|DRUG|Oral placebo|Oral capsule identical in appearance to moxifloxacin
223945503|NCT03052517|DRUG|QAW039 150 mg|One tablet of QAW039 150 mg once daily
223945504|NCT03052517|DRUG|QAW039 450 mg|One tablet of QAW039 450 mg once daily
223945505|NCT03052517|DRUG|Placebo|One tablet of Placebo once daily
223945506|NCT06117891|DRUG|Atezolizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
223945507|NCT06117891|DRUG|Bevacizumab|Atezolizumab combined with Bevacizumab, immune checkpoint inhibitors combination.
223945508|NCT06117891|DRUG|Durvalumab|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
223945509|NCT06117891|DRUG|Tremelimumab,|Durvalumab combined with Tremelimumab, another immuno-oncology (IO) checkpoint inhibitors combination.
223945510|NCT04226118|DEVICE|Vein Illumintion System device|Spotting veins of a patient by use of a Vein Illumintion System device
223945511|NCT03790098|BEHAVIORAL|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
223945512|NCT02994524|PROCEDURE|Rerouting technique for transsphincteric perianal fistula|
223945513|NCT00996242|DRUG|L-lysine|6 g/day for four weeks
223945514|NCT05816707|BIOLOGICAL|PRF|"Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture"
223945515|NCT05816707|BIOLOGICAL|Curcuma Longa gel|Curcuma Longa gel
223945516|NCT05816707|OTHER|extraction socket|extraction socket
223945517|NCT03233997|OTHER|FT21018|An electronic cigarette
223945518|NCT03233997|OTHER|FT21033|An electronic cigarette
223945519|NCT03233997|OTHER|FT21034|An electronic cigarette
223719622|NCT05601284|BEHAVIORAL|Acceptance and commitment therapy|ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.
223729426|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
223719623|NCT05601284|BEHAVIORAL|Progressive relaxation training|PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
223719624|NCT05863832|DRUG|Ciprodiazole|Ciprofolxacin 500 mg / Metronidazole 500 mg
223945520|NCT03233997|OTHER|FT21035|An electronic cigarette
223719625|NCT05863832|DRUG|Ciprofloxacin Tablets & Metronidazole tablets|Ciprofolxacin 500 mg + Metronidazole 500 mg
223945521|NCT03843606|OTHER|Modified ketogenic diets|Different diet composition
223945522|NCT04266626|OTHER|kinesiotaping therapy|Kinesiotaping is a new therapeutic technique that gives support to the lip and tongue base muscles without restricting range of motion or blood flow.
223945523|NCT04266626|OTHER|oral motor manipulation therapy|Manipulation therapy include tapping and massage of oral motor muscles including orbicularis oris and base of tongue.
223945524|NCT00546156|DRUG|Doxorubicin|Standard chemotherapy regimen
223945525|NCT00546156|DRUG|Cyclophosphamide|Standard chemotherapy regimen
223945526|NCT00546156|DRUG|Paclitaxel|Standard chemotherapy regimen
223945527|NCT00546156|DRUG|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
223945528|NCT02580227|DRUG|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
223945529|NCT02580227|OTHER|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
223945530|NCT03579875|DRUG|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
223945531|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
223945532|NCT03579875|DRUG|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
224100080|NCT04984135|PROCEDURE|Percutaneous coronary intervention|All patients were treated with a loading dose of clopidogrel 300 or 600 mg before the procedure followed by maintenance clopidogrel 75 mg daily for 6 months. 100 U/ kg of unfractionated heparin was injected intravenously to maintain an activated clotting time ≥ 250 s during the procedure. For DCB treatment, the patient underwent predilation with an optimal-sized balloon (non-compliant balloon or cutting balloon) based on angiography (balloon-to-vessel ratio of 1.0), with the standard balloon shorter than the intended DCB size. The DCB was sized at 1:1 balloon-to-vessel ratio, delivered rapidly (median of 15 s) and inflated at nominal pressure for 60 s.
224100081|NCT01335646|PROCEDURE|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
224100082|NCT01335646|OTHER|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
224287453|NCT06473402|DIAGNOSTIC_TEST|Knee Range of Motion|Joint range of motion measurement of the participants was made with a universal goniometer. Degree was used as the measurement unit. The measurement was made in the prone position. The pivot point of the goniometer is placed on the lateral epicondyle of the femur, and the fixed arm is kept parallel to the lateral midline of the femur, while the movable arm will follow the fibula. The joint range of motion of the participants was measured before and after manual therapy. AAOS (American of Orthopedic Surgeons) was taken as the reference value.
223719626|NCT01929798|DEVICE|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
223719627|NCT04286243|OTHER|Community-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the community
223719628|NCT04286243|OTHER|Clinic-based HPV screening strategy|Offering HPV self-collection for cervical cancer screening in the clinic
223719629|NCT00038220|DRUG|Lopinavir/ritonavir|
223719630|NCT00038220|DRUG|Efavirenz|
223719631|NCT00038220|DRUG|Lamivudine|
223719632|NCT00038220|DRUG|Tenofovir DF|
223719633|NCT01949558|BEHAVIORAL|Dietary Intervention|
223719634|NCT03548259|PROCEDURE|Platelet-rich plasma|Platelet-rich plasma injection
223719635|NCT03548259|PROCEDURE|Platelet-poor plasma|Platelet-poor plasma injection
223719636|NCT03187106|DRUG|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
223719637|NCT03187106|DRUG|Placebo|Placebo representing standard of care
223719638|NCT03187106|DRUG|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
223719639|NCT02581514|OTHER|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
223945533|NCT03579875|DRUG|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
223945534|NCT03579875|DEVICE|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
223945535|NCT03579875|DRUG|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC \>2.5 x 10\^9/L for 3 consecutive days or single day ANC \>3000 Arm 1 and Arm 3)
223945536|NCT03579875|DRUG|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
223945537|NCT03579875|DRUG|Rituximab|200 mg/m2 IV once on day -1
223945538|NCT03579875|DRUG|Busulfan|Busulfan 0.6 mg/kg if \> 4 years old and/or \>12 kg (0.8 mg/kg IV if ≤ 4 years old and/or ≤ 12 kg) is given IV over 2 hours every 12 hours for 2 days.
223945539|NCT03579875|DRUG|Alemtuzumab|Alemtuzumab 0.2 mg/kg is given IV over 2 hours daily for 5 days (total dose 1 mg/kg)
223945540|NCT03579875|DRUG|Melphalan|If available, MEL dosing will be model-based using Bayesian methodology. If Bayesian methodology is unavailable, MEL dosing will be weight-based: MEL 70 mg/m2 for patients ≥10 kg (2.35 mg/kg for patients \<10 kg\^) IV for one dose over 30 minutes.
223945541|NCT03579875|DRUG|Rituximab|Rituximab will be given once on treatment plans 1-3 on day -1.
223945542|NCT03298087|PROCEDURE|radical prostatectomy|surgical removal of the prostate
223945543|NCT03298087|RADIATION|stereotactic body radiotherapy|Highly targeted radiation
224100083|NCT00746772|DRUG|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
223945544|NCT03298087|DRUG|Leuprolide|Lowers serum testosterone
224100084|NCT00746772|DRUG|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
224100085|NCT02195115|PROCEDURE|Laparoscopic Cholecystectomy|
224100086|NCT02195115|DRUG|amitriptyline|
224100087|NCT02195115|OTHER|low-fat and low cholesterol diet|
224100088|NCT05489068|BEHAVIORAL|Motivational Interviewing at Intake (MII)|The MII will involve a goal-oriented and collaborative conversation about why the client wants treatment now, and how treatment might fit with his/her most important values. The provider will use open questions, reflective listening and autonomy support in a flexible, non-authoritative manner. Rather than asking specific questions in different life domains, the provider will explore with the client their desires, abilities, reasons, and needs for treatment, how treatment fits with their values, and what successful treatment looks like to them. The client's language about change will be strategically reinforced to increase its frequency and strength across the session.
224100089|NCT05489068|BEHAVIORAL|Intake as Usual (IAU)|In line with the American Society of Addiction Medicine (ASAM) guidelines, the IAU condition involves a semi-structured interview of the client's psychosocial history and clients answer a series of questions in the following domains: support system, living situation, educational, occupational, family, and medical history.
224100090|NCT03751202|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
224100091|NCT03751202|DRUG|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
224100092|NCT02432807|DRUG|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
224100093|NCT02432807|DRUG|Placebo|Placebo
224100094|NCT00704470|OTHER|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
224100095|NCT00704470|OTHER|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
224100096|NCT01045954|DRUG|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
223719640|NCT03203304|DRUG|Nivolumab|240mg every two weeks by IV infusion
224100097|NCT00960271|PROCEDURE|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
224100098|NCT03115385|DIETARY_SUPPLEMENT|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
224100099|NCT03115385|DIETARY_SUPPLEMENT|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
224100100|NCT03530540|DEVICE|low-intensity extracorporeal shockwave therapy|Active shockwaves
224100101|NCT03530540|DEVICE|Placebo LI-ESWT|Placebo shockwaves
224100102|NCT03530540|DEVICE|Penile pump|both groups will be treated with a penile pump
224100103|NCT03888495|BEHAVIORAL|Gender Socialization Training workshop|Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
223719641|NCT03203304|DRUG|Ipilimumab|1mg/kg every six weeks by IV infusion
223945545|NCT03298087|DRUG|apalutamide|antiandrogen
223945546|NCT03298087|DRUG|abiraterone|Inhibits androgen synthesis
224100104|NCT03888495|BEHAVIORAL|Financial Literacy Training Intervention|Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
223719642|NCT02809937|DRUG|dexmedetomidine|low-dose dexmedetomidine infusion
223719643|NCT02809937|DRUG|placebo|normal saline infusion
223945547|NCT03089905|DRUG|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
223945548|NCT03089905|DRUG|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
223945549|NCT03089905|DRUG|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
223945550|NCT05107869|OTHER|High Saturated Fat|High saturated fat meal
223719644|NCT02004210|PROCEDURE|transarterial radioembolization (TARE)|transarterial radioembolization
223945551|NCT03935152|DRUG|Dydrogesterone|dydrogesterone capsule
223945552|NCT03935152|DRUG|placebo|placebo capsule
223945553|NCT04874493|OTHER|Electronic Health Record Review|Review of medical records
223945554|NCT04874493|OTHER|Questionnaire Administration|Complete questionnaire
223945555|NCT06130605|OTHER|Data collection|Data collection
223945556|NCT02124304|DEVICE|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
223719645|NCT02004210|PROCEDURE|transarterial chemoembolization (TACE)|transarterial chemoembolization
223719646|NCT00895167|DIETARY_SUPPLEMENT|curcumin|one oral dose of 12 caplets = 12 g curcumin
223719647|NCT00370032|DRUG|alosetron|
223719648|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
223945557|NCT05864625|DRUG|Remimazolam besylate|During induction, patients allocated to the remimazolam group will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combied with remifetanil.
223945558|NCT05864625|DRUG|Propofol/ Sevoflurane|During induction, patients allocated to the P/S group will receive propofol 1% 1-2mg/kg with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with sevoflurane and remifentanil.
223945559|NCT04781322|DRUG|Alirocumab|Alirocumab is a human monoclonal antibody (IgG1) that binds to and inhibits PCSK9 and was approved by the FDA in July of 2015. PCSK9 binds to and promotes degradation of low-density lipoprotein receptors (LDLR) on hepatocyte membranes.
223945560|NCT04781322|OTHER|Placebo|Heavy drinking healthy volunteers
223945561|NCT06489353|BEHAVIORAL|Video-watching|Participants will watch age-appropriate and engaging videos.
224100105|NCT03888495|BEHAVIORAL|Family Planning Counseling and Services|Family planning counseling sessions and linkage to services.
224100106|NCT03393351|OTHER|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~1. shared decision-making trainings for health care professionals,~2. individual coaching for physicians,~3. patient activation strategy,~4. provision of patient information material and decision aids,~5. revision of the clinics quality management documents, and~6. critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
223719649|NCT01772238|DRUG|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
223719650|NCT01109043|DRUG|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
223719651|NCT06120296|DEVICE|Acumen Hypotension prediction Index software|In the unblinded HPI group (the intervention group), the arterial waveform and pressure will be displayed on the anesthesia monitor and the HPI on the Hemosphere monitor of Edwards Lifesciences (the study monitor).
223719652|NCT04905485|BEHAVIORAL|VIOME Precision Nutrition Program|Precision diet and supplement recommendations based on participants' microbiome results.
223719653|NCT05890872|DEVICE|Aliya Pulsed Electric Fields (PEF)|Percutaneous or Endobronchial PEF
223719654|NCT06274918|DEVICE|Personalized Body-Worn Alcohol Dispenser|This is an alcohol dispenser that will be worn on the Anesthesia Providers scrub pants, near the hip. It will be worn by both the attending physician and the resident physician/CRNA/SRNA. The device is produced by Georgia-Pacific.
223719655|NCT03381482|DIAGNOSTIC_TEST|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
223945562|NCT06489353|BEHAVIORAL|Blowing Pinwheels|Participants will blow pinwheels during the venipuncture procedure
223945563|NCT05990933|DRUG|Adrenaline|Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
223945564|NCT02054000|DRUG|Tirofiban|Intracoronary administering of Tirofiban
224100107|NCT03393351|OTHER|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
224100108|NCT05352217|DEVICE|Mobile app ovarian cancer followup (ePRO)|The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
223719656|NCT03381482|DIAGNOSTIC_TEST|Fasting blood sample|6x5 mL of fasting blood sample
223719657|NCT03381482|DIAGNOSTIC_TEST|Lumbar puncture|10 mL of CSF by lumbar puncture
223719658|NCT03350581|PROCEDURE|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
223719659|NCT03350581|PROCEDURE|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
223719660|NCT06558565|PROCEDURE|stromal vascular fraction or platelet rich plasma|stromal vascular fraction will be injected in one half of the scalp \& PRP will be injected in the other half
223719661|NCT01217359|DRUG|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
223719662|NCT00082251|DRUG|Niacin extended release and simvastatin tablets|
223945565|NCT02054000|OTHER|Placebo|Intracoronary serum physiologic
223945566|NCT04228952|COMBINATION_PRODUCT|Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK|American Spirit cigarettes will be modified by adding 0.300 μg \[pyridine-D4\]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.
223945567|NCT05552157|DRUG|Remternetug (SC)|Administered subcutaneously every 12 weeks
223945568|NCT05552157|DRUG|Matching Placebo (Remternetug)|Administered as subcutaneous injection of placebo every 12 weeks
223945569|NCT04419519|DRUG|Venetoclax monotherapy|Venetoclax monotherapy
223719663|NCT01581645|DEVICE|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
223719664|NCT02590081|DRUG|Dextrose 5%|
223719665|NCT02590081|DRUG|normal saline|
223719666|NCT01452828|DRUG|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
223719667|NCT01452828|DRUG|TR-701 FA|Two separate infusions of 200 mg
223945570|NCT04419519|DRUG|Venetoclax with anti CD20 monoclonal antibody|Venetoclax with anti CD20 monoclonal antibody
223945571|NCT04645680|OTHER|Dietary Intervention|Consume isocaloric whole foods diet higher in fiber
223945572|NCT04645680|OTHER|Dietary Intervention|Whole foods diet
223535531|NCT06460376|OTHER|Mercier Therapy|"Treatment:~The patient lay face up on a massage or exam table. Feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles.~Manual poking, pressing, and massage actions do three things:~Reveals visceral adhesions. Find tender spots. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that make up fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Abdominal massage with pressing, deep strokes, and friction. The baseline treatment was moist heat. Each therapy session was 25 minutes for 6 weeks and 1 session per week. 10 minutes for baseline treatment"
223535532|NCT04949009|DRUG|Avatrombopag|Avatrombopag is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders.
223719668|NCT01452828|DRUG|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
223719669|NCT05229406|BEHAVIORAL|HMP app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
223719670|NCT03026400|PROCEDURE|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
223719671|NCT03026400|PROCEDURE|Subumbilical incision|Considered here as the ''control'' intervention.
223535533|NCT00998257|DRUG|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
223719672|NCT04873804|OTHER|Transcranial Direct Current Stimulation|The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
223719673|NCT00689234|PROCEDURE|diaphragm plication 6 months after inclusion|thoracotomy
223719674|NCT00689234|PROCEDURE|diaphragm plication at time of inclusion|thoracotomy
223719675|NCT02627105|BEHAVIORAL|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
223719676|NCT02627105|BEHAVIORAL|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
223719677|NCT04770662|OTHER|Questionnaires|"Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)"
223719678|NCT00158834|DRUG|Salmeterol/Fluticasone propionate combination product|
223719679|NCT00158834|DRUG|Fluticasone propionate|
223719680|NCT02978430|DEVICE|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
223719681|NCT02978430|OTHER|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
223535534|NCT02900430|OTHER|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
223719682|NCT02146898|OTHER|Position|
223719683|NCT05801250|BEHAVIORAL|AI Platform|AI platform can help patients evaluate the adequacy of bowel cleansing without the aid of caregivers.
223719684|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
223719685|NCT01537393|BIOLOGICAL|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
223719686|NCT05202652|DIETARY_SUPPLEMENT|HealthSpan|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the oral capsule containing the active ingredients, for three consecutive months.
223719687|NCT05202652|DIETARY_SUPPLEMENT|Placebo|The intervention was conducted on a group of healthy volunteers of age 29-85 with a once-daily administration of the placebo, for three consecutive months.
223729427|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
223729428|NCT01529346|DRUG|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
223945573|NCT04645680|OTHER|Quality-of-Life Assessment|Ancillary studies
223945574|NCT04645680|OTHER|Questionnaire Administration|Ancillary studies
223945575|NCT05925036|DRUG|Mesenchymal stem cells|Autologous bone marrow derived MSCs
223945576|NCT05925036|OTHER|Placebo|Controls
223945577|NCT01979393|DRUG|Cabozantinib|
223945578|NCT01979393|DRUG|Placebo|
223945579|NCT03416959|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
223719688|NCT01778218|RADIATION|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
223719689|NCT02655796|DEVICE|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
223945580|NCT04745156|DEVICE|RNS System Implantation|Following resection consistent with SoC, if there is evidence of residual tumor which cannot be resected due to invasion of hand-M1 but which is small enough to be covered by two four-electrode strips, these strips will be placed on the functional cortex of interest and secured to the dura. The location of the leads will be registered into the navigation software (either Medtronic Stealth or Brainlab). The dura will then be closed as watertight as possible, and the RNS System will be incorporated into the craniotomy on closure Prior to closure, four bone screws will be placed and registered to the intraoperative navigation system as internal fiducials to be retrieved for future procedures.
223945581|NCT06800404|DRUG|Autologous HB-adMSCs|Autologous HB-adMSCs
223945582|NCT03833440|DRUG|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
223945583|NCT03833440|DRUG|Monalizumab (IPH2201)|"1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
223945584|NCT03833440|DRUG|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
223945585|NCT03833440|DRUG|Ceralasertib (AZD6738)|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
223945586|NCT03833440|DRUG|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
223719690|NCT03036007|OTHER|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
223719691|NCT03036007|OTHER|Exercises with Internet support|Neck-specific exercise with Internet support
223719692|NCT04774796|OTHER|Cognitive Behavioural Therapy|Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
223719693|NCT01578187|DEVICE|Hair2Go|Treatment with the device once under observation
223719694|NCT05805410|BEHAVIORAL|robotic hippotherapy|A custom designed cable-driven robotic system that mimics horseback movement during walking was used in this study.
223719695|NCT05805410|BEHAVIORAL|Conventional physical therapy|Stretching of trunk and leg muscles, followed by sitting and standing balance training, and conventional treadmill walking.
223719696|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg|Single pill
223719697|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg|Single pill
223719698|NCT04518293|DRUG|Telmisartan 20 mg/amlodipine 2.5 mg|oral tablet
223719699|NCT04518293|DRUG|telmisartan 40 mg/amlodipine 5 mg|oral tablet
223719700|NCT04518293|DRUG|Telmisartan 20 mg/indapamide 1.25 mg|oral tablet
223719701|NCT04518293|DRUG|telmisartan 40 mg/indapamide 2.5 mg|oral tablet
223719702|NCT04518293|DRUG|Amlodipine 2.5 mg/indapamide 1.25 mg|oral tablet
223719703|NCT04518293|DRUG|amlodipine 5 mg/indapamide 2.5 mg|oral tablet
223719704|NCT01278979|DEVICE|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~1. Depth of tear, from the fourchette into the greatest depth of the perineal body.~2. Length of tear, from the fourchette to the apex of the vaginal tear.~3. Length of tear, from the fourchette along perineal skin towards the anus.~4. Length of the perineal body, from the fourchette to outer margin of anus."
223719705|NCT01278979|OTHER|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
223719706|NCT04837261|DRUG|Propranolol|3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
223719707|NCT04837261|DRUG|Flecainide|80 mg/m2/d
223719708|NCT04837261|DRUG|Amiodarone|Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
223719709|NCT01369758|DEVICE|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
223945587|NCT03833440|DRUG|Savolitinib|"600 mg QD~1 cycle = 28 days"
223945588|NCT04726449|OTHER|Screening for acute confusional state|The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted
223945589|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
223945590|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
223945591|NCT01768689|BEHAVIORAL|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
223945592|NCT05342246|PROCEDURE|Endodontic retreatment|retreatment of the patent root canal only without attempt to retrieve the separated instrument
223945593|NCT02967861|BEHAVIORAL|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
223945594|NCT02967861|PROCEDURE|Scaling and root planing|It is a mechanical debridement of dental plaque.
224100109|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
224100110|NCT01012661|DEVICE|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
224100111|NCT01023529|RADIATION|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
224100112|NCT06478836|OTHER|planter pressure|no intervention
223719710|NCT05043129|BIOLOGICAL|Biological/Vaccine: SARS-COV-2 VACCINE|The antibody titer and adverse reactions were observed.
224100113|NCT00378846|PROCEDURE|infrared thermography|
224100114|NCT04586712|DRUG|Active CBD|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
224100115|NCT04586712|DRUG|Vehicle Control (Placebo)|Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
224100116|NCT02132338|BEHAVIORAL|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
223945595|NCT04725136|BIOLOGICAL|FURESTEM-AD inj|Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.
223945596|NCT04905004|PROCEDURE|Canine retraction|Canines will be retracted using short elastomeric chains. Force applied to canines will be 150g.
223945597|NCT00081913|GENETIC|Cell Therapy - Autologous CD34 Positive Cells|
224100117|NCT06002022|DEVICE|REBECCA system (smartwatch + mobile app use)|Patients will be trained in the use of the REBECCA system, which will provide in-depth information about their lifestyle (including physical activity levels, dietary habits, sleep quality and social mobility), as well as of their online behaviour (with outcome indicators of anxiety, PTSD and depression development) and self- or companion-reported measures of emotional state and quality of life. Based on the additional information, exploiting the enhanced monitoring capabilities of the REBECCA system, the supervising clinicians will be given the opportunity to continuously evaluate the progress of the patients, allowing them to schedule up to 3 phone-based consultation sessions in the first 12 months of treatment
224100118|NCT05153408|DRUG|BLU-701|BLU-701 for oral administration
224100119|NCT05153408|DRUG|osimertinib|Osimertinib tablets for oral administration
224100120|NCT05153408|DRUG|carboplatin|IV infusion of carboplatin
224100121|NCT05153408|DRUG|pemetrexed|IV infusion of pemetrexed
224100122|NCT03648645|DEVICE|Self measurement of blood pressure|"Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
223719711|NCT06504706|PROCEDURE|Matcha Tea|Japanese tea rich in antioxidants and Catechins
223719712|NCT06504706|PROCEDURE|Green Tea|Green tea rich in catechins
223719713|NCT05012332|PROCEDURE|Erector Spinae Plane Block|All volunteers receive an Erector Spinae Plane Block and an MRI.
223729429|NCT01529346|OTHER|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
223945598|NCT01786876|DRUG|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
223945599|NCT00741650|BEHAVIORAL|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
223945600|NCT00741650|BEHAVIORAL|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
224100123|NCT01021007|DRUG|Iodine|Rinse 2 times per day for 6 weeks
224100124|NCT01021007|OTHER|water|Use 2 times per day for 6 weeks
224100125|NCT01477905|DEVICE|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
224100126|NCT01477905|DEVICE|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
224100127|NCT04287153|DEVICE|Cryotherapy on abdomen and saddlebags|Application of variable temperature (-10°c to -7°c) on the treated areas using the cryotherapy device FG660L-006 (Beijing ADSS Development CO., Ltd)
224100128|NCT01818349|OTHER|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
224100129|NCT01818349|OTHER|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
224100130|NCT03047005|DRUG|NB medication (Naltrexone Bupropion combination)|NB medication
224100131|NCT03047005|OTHER|Placebo|Placebo
224100132|NCT05075564|DRUG|Part 1 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
223945601|NCT05080036|OTHER|Medio-lateral imbalance|Thrust on the pelvis in the medio-lateral direction in order to create a balance perturbation
223945602|NCT05683834|DRUG|Matrix-M1 Adjuvant|Matrix-M1 is composed of 2 types of 40 nm-sized particles each with a different saponin fraction (fraction A and fraction B) combined with cholesterol and phospholipid.
223945603|NCT05683834|DRUG|EBV gp350-Ferritin Vaccine|The EBV gp350-Ferritin vaccine is composed of Helicobacter pylori non-heme ferritin fused to EBV gp350 which self-assembles to form a nanoparticle. The vaccine is supplied in single-use vials at a concentration of 250 micrograms/mL in 1.7 mM KH2PO4, 5 mM Na2HPO4, 150 mM NaCl, 5% sucrose, pH 7.4 (diluent).
223945604|NCT05683834|OTHER|Placebo Comparator|Normal Saline
223945605|NCT02282254|OTHER|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
223945606|NCT01530334|DRUG|Gefitinib 250mg|Gefitinib 250mg once daily
223535535|NCT02900430|DRUG|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
223729430|NCT01529346|DRUG|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
223729431|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
223729432|NCT01529346|OTHER|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
223945607|NCT03781375|DRUG|Etanercept|Administered by subcutaneous injection twice a week
223945608|NCT03781375|DRUG|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
223945609|NCT03781375|DRUG|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
223945610|NCT00262015|BIOLOGICAL|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
223945611|NCT01105988|OTHER|Radiologic exams|FLT PET scan x 2 MRI scan x 2
223945612|NCT01485887|DRUG|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
223945613|NCT03103048|DIAGNOSTIC_TEST|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
223945614|NCT03103048|DIAGNOSTIC_TEST|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
223945615|NCT03103048|DIAGNOSTIC_TEST|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
223945616|NCT03103048|DIAGNOSTIC_TEST|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
223945617|NCT01408394|DRUG|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
223945618|NCT01408394|DRUG|90 mg controlled release form|This is the 90 mg controlled release form
223945619|NCT01408394|DRUG|180 mg controlled release form|This is the 180 mg controlled release capsule
223945620|NCT00476736|DRUG|Effect on small airways (N-Acetylcystein)|
223945621|NCT02895659|PROCEDURE|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
223945622|NCT04332094|DRUG|Tocilizumab|162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)
223945623|NCT04332094|DRUG|Hydroxychloroquine|400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)
223945624|NCT04332094|DRUG|Azithromycin|500 mg / day v.o. for 3 days
223945625|NCT05879705|OTHER|Parent intervention|Family centered, strength-based, Occupational therapy intervention program
223945626|NCT00140725|DRUG|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
223945627|NCT00140725|DRUG|Lamivudine|
223945628|NCT05925699|OTHER|Collection of clinical, radiological, and biological data from patients' medical records|Collection of clinical, radiological, and biological data from patients' medical records
223945629|NCT04278755|DRUG|Drospirenone-Ethinyl Estradiol Oral Tablet|3 Mg-0.03 Mg continuous daily Drospirenone-Ethinyl Estradiol.
223945630|NCT04257799|OTHER|Structured Light Imaging (SLI) System|Investigation of SLI and Tomographic Imaging to see if they will identify cancer cells at the edge of tissue specimens removed during the operation.
223945631|NCT03154736|OTHER|Interview|Individual interview and group interview Socio-economic questionnaire
223535536|NCT00085748|DRUG|paliperidone ER|
223729433|NCT01529346|OTHER|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
223945632|NCT03340909|DRUG|Prednisolone|Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
223945633|NCT03340909|OTHER|Placebo|Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
223945634|NCT06438237|PROCEDURE|Bowel preparation before colonoscopy|Patients use purgative for bowel cleansing before colonoscopy.
223945635|NCT02013700|BIOLOGICAL|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
223945636|NCT02013700|BIOLOGICAL|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
223945637|NCT02541318|BEHAVIORAL|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
223945638|NCT02304757|DRUG|99Tc-MDP|99Tc-MDP, H20000218
223945639|NCT02304757|DRUG|Fosamax|H20080172
224100133|NCT05075564|DRUG|Part 2 ES002023|ES002023 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
223535537|NCT03526263|PROCEDURE|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
223729434|NCT06160960|OTHER|OCT Scan, Video of pupil movement, video of toric lens|A picture of the central macular area is taken, video of pupil movment, video of toric lens rotation.
223945640|NCT04437043|OTHER|quality of life questionnaires|pain will be recorded in rest and activity (VAS) and patients will complete the quality of life questionnaires (CCS, BIQ). Also, the intake of analgesic medication will be registered. A clinical examination is conducted to evaluate the occurrence of seroma and to evaluate recurrence, defined as a protrusion of the contents of the abdominal cavity or preperitoneal fat through the defect, which is no longer covered by the mesh.
223945641|NCT03184987|DRUG|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
223945642|NCT03184987|DRUG|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
223945643|NCT03184987|DRUG|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
223945644|NCT03184987|OTHER|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
223945645|NCT04758949|DRUG|FL-101|200 mg administered intravenously every 2 weeks prior to surgery.
223945646|NCT04758949|DRUG|Nivolumab|240 mg administered intravenously every 2 weeks prior to surgery.
223945647|NCT04758949|DRUG|Placebo|200 mg administered intravenously every 2 weeks prior to surgery.
223945648|NCT05054270|OTHER|Chest examination with Ultrasound device|Chest examination with Ultrasound device
223945649|NCT04826406|DRUG|Camrelizumab combined Apatinib regimen|Camrelizumab 200mg iv every 2 weeks; Apatinib,250 mg/day.
223945650|NCT03353961|BEHAVIORAL|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
223945651|NCT03353961|BEHAVIORAL|Treatment as usual|Treatment as usual as provided in the community.
224100134|NCT00525252|DRUG|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
224100135|NCT00525252|DRUG|placebo|Placebo will be orally administered for 12 consecutive weeks
224100136|NCT01571271|PROCEDURE|Laser Lithotripsy|Laser Lithotripsy
224100137|NCT01571271|PROCEDURE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
224100138|NCT00987415|DRUG|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
224100139|NCT00987415|DRUG|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
223535538|NCT01146613|DRUG|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
223535539|NCT01146613|DRUG|Placebo|identical matched placebo x 2, 2xday, 13 weeks
223535540|NCT02854163|DRUG|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
223535541|NCT02232360|DRUG|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
223535542|NCT02232360|DRUG|Rosuvastatin alone|Rosuvastatin 10mg per day
223535543|NCT04862754|OTHER|interval training exercise|interval training exercise
223535544|NCT00729950|BIOLOGICAL|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
223535545|NCT00506467|PROCEDURE|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
223535546|NCT01920490|DEVICE|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
223535547|NCT01920490|DEVICE|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
223535548|NCT02113319|DRUG|dasatinib|dasatinib 50 mg and 20 mg During one year
223535549|NCT06280248|PROCEDURE|Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst|"The technical success rates, clinical success rates, and potential complications of the different endoscopic ultrasound-guided techniques for the best drainage of pancreatic fluid collections (PFCs) as regard type, caliber, and number of plastic stents and the ideal timing for stent removal will be assessed.~Also compare early vs. late intervention for complete endoscopic necrosectomy of walled off pancreatic necrosis (WOPN ) as regard to technical success rates, clinical success rates, potential complications, and the number of sessions needed will be done.~In order to evaluate total resolution or a reduction in cyst diameters with clinically significant improvement in symptoms, patients will be monitored for one month and six months following the insertion of the stent."
223535550|NCT00329030|DRUG|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
223945652|NCT05500352|OTHER|Hyperglycemia with slow decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
223945653|NCT05500352|OTHER|Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes|Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
223945654|NCT05500352|OTHER|Rebound hyperglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
223945655|NCT05500352|OTHER|Rebound euglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
223945656|NCT05500352|OTHER|Hypoglycemia in type 1 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
223535551|NCT00329030|DRUG|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
223535552|NCT06199414|DEVICE|Venous Closure|Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
223535553|NCT02347592|DEVICE|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
223535554|NCT02347592|DEVICE|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
223535555|NCT05900752|DIETARY_SUPPLEMENT|QiMeiYan Probiotics|consume one sachet of the assigned product, once a day after meals.
223535556|NCT05900752|DIETARY_SUPPLEMENT|Placebo product|consume one sachet of the assigned product, once a day after meals.
223535557|NCT02892240|OTHER|No intervention. Observational study|
223535558|NCT05804721|DRUG|Apipe (Aripiprazole10 mg)|Test drug
223535559|NCT05804721|DRUG|Abilify (Aripiprazole10 mg)|Reference drug
223535560|NCT00314873|DRUG|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
223535561|NCT05839925|DIAGNOSTIC_TEST|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) Axis I and II|The presence of temporomandibular joint dysfunction was evaluated using the diagnostic criteria for temporomandibular disorders (DC/TMD).
223535562|NCT06370390|BEHAVIORAL|swallowing function training|"The group rehabilitation program comprised daily 60-minute sessions, five times per week for a duration of 4 weeks.~The group rehabilitation program included: Rehabilitation oral and facial exercises, Game-based surface electromyographic biofeedback training, Participants experience sharing, Individual direct feeding training"
223535563|NCT06230809|BEHAVIORAL|Web-based self-help|Web-based self-help with 5 modules, lasting 5 weeks.
223535564|NCT04340154|BIOLOGICAL|chimeric antigen receptor T cell|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
223535565|NCT00827957|DEVICE|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
223535566|NCT00827957|DEVICE|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
223729435|NCT02533830|BIOLOGICAL|sugarless gum|"One Stick of Sugarless Gum (Samara for food \& Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
223729436|NCT02533830|OTHER|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
223729437|NCT01725620|DRUG|LBEC0101 (Etanercept 25mg)|
223729438|NCT01725620|DRUG|Enbrel (Etanercept 25mg)|
223729439|NCT00106392|DRUG|Tacrolimus|oral
223729440|NCT00106392|DRUG|Placebo|oral
223729441|NCT01365234|DEVICE|Pacing Lead|Implant and follow up of Model 20066 lead
223719714|NCT04211623|OTHER|Constraint induced movement therapy|"Constrained on more affected side for three hours. To minimize the learned non use in hemiplegic CIMT is applied and criteria of applying CIMT is;~* 10 degrees active wrist extension on the affected hand,~* 10 degrees active thumb abduction,~* 10 º active extension of any two digits on the side or hand which is limited due to damage.~In order to gain the maximum good results from CIMT technique following points should also be considered attentively. Affected arm should move to 45 degrees shoulder flexion and abduction, and 90 degrees of elbow flexion and extension.~Constrained with cotton sling. 3 to 5 upper limb functional activities like~* using fork or a spoon,~* combing hair~* brushing teeth~* writing~* dressing all activities are performed for 10 t0 15 minutes in period of three hours on alternate days in a week"
223719715|NCT04211623|OTHER|Bimanual activities|"Bimanual activities of both hands are performed like~Set of bimanual activities is used to assess the bimanual hand function. Five bimanual activities are performed such as~* carrying a tray,~* cutting a fruit with a knife,~* holding and cutting the paper with scissor,~* buttoning and~* Carrying heavy objects with both hands.~Every activity was performed for 10 t0 15 minutes on alternate days for a period of 6 weeks session."
223719716|NCT02672878|DEVICE|Bioresorbable vascular scaffold|
223719717|NCT05581628|DIAGNOSTIC_TEST|Pain location inventory (PLI)|PLI is obtained by questioning the pain in 28 regions in the last 7 days. Total score is between 0-28
223719718|NCT05581628|DIAGNOSTIC_TEST|Symptom Impact Questionnaire (SIQR)|The SIQR score includes a total of 10 different evaluations in the last 7 days, including pain, energy, stiffness, sleep, depression, memory problems, anxiety, sensitivity to touch, balance problems, sensitivity to loud sounds-bright light-smells-cold. Each item is scored between 0-10 and the total score is obtained between 0-100. This total score is divided by 2 to get the SIQR score
223945657|NCT05500352|OTHER|Hypoglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
223945658|NCT05500352|OTHER|Hypoglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
223945659|NCT05500352|OTHER|Hyperglycemia in type 2 diabetes|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
223945660|NCT05500352|OTHER|Hyperglycemia in healthy controls|Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
223945661|NCT00275444|DRUG|Tipranavir|
223945662|NCT02851498|OTHER|Food product: high-protein pasta and cereal|
223719719|NCT05581628|DIAGNOSTIC_TEST|Fibromyalgia Impact Questionnaire (FIQ)|FIQ measures 10 different features, including physical function, well-being, absenteeism, difficulty at work, pain, fatigue, morning fatigue, stiffness, anxiety and depression. With the exception of the well-being trait, low scores indicate recovery or less affliction. The maximum possible score of each sub-title is 10. Thus, the total maximum score is 100.
223719720|NCT02066246|DEVICE|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
223719721|NCT02066246|DEVICE|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
223719722|NCT01022632|DIETARY_SUPPLEMENT|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
223719723|NCT01022632|DRUG|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
223719724|NCT01022632|DIETARY_SUPPLEMENT|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
223719725|NCT03208244|DRUG|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
223719726|NCT01974804|PROCEDURE|MRI|
223719727|NCT02398175|OTHER|reanimation/intubation|
223719728|NCT01221792|DRUG|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
223719729|NCT01221792|DRUG|Placebo|Non active comparator
223719730|NCT00894660|DRUG|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
223945663|NCT01727570|DIETARY_SUPPLEMENT|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
223945664|NCT06002035|DIETARY_SUPPLEMENT|Binom Vitamin D drops|Take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added
223945665|NCT05884567|OTHER|Isometric exercises|These exercises are used to increase muscle endurance, power and ROM
223945666|NCT05884567|OTHER|Mobilization|These exercises are used to increase ROM and used for pain reduction
223945667|NCT00826826|PROCEDURE|Catheter ablation|(Pulmonary vein isolation)
223719731|NCT00894660|DRUG|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
223719732|NCT01709162|BIOLOGICAL|Ipilimumab|
223719733|NCT01709162|DRUG|Chemotherapy|
223719734|NCT05057182|BIOLOGICAL|BNT162b2|BNT162b2 mRNA vaccine (Cominarty®, BioNTech/Fosun Pharma), one dose (0.3mL after dilution) contains 30 micrograms of COVID-19 mRNA Vaccine embedded in lipid nanoparticles.
223945668|NCT00826826|DRUG|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
223945669|NCT00826826|DRUG|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
223945670|NCT00259766|DRUG|Budesonide|
223945671|NCT00259766|DRUG|Formoterol|
223945672|NCT00259766|DRUG|Terbutaline|
223945673|NCT02003872|DEVICE|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
223719735|NCT02856035|OTHER|Neural feedback plus FES and motor training|We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
223719736|NCT03453008|OTHER|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
223719737|NCT02230800|DRUG|Tocovid SupraBio plus pentoxifylline|
223719738|NCT02230800|DRUG|Matching placebos|
223719739|NCT03737942|DEVICE|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
223719740|NCT01575587|DRUG|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
223719741|NCT01575587|DRUG|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
223719742|NCT01575587|DRUG|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
223719743|NCT01575587|DRUG|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
223719744|NCT02564237|BIOLOGICAL|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
223719745|NCT02564237|BIOLOGICAL|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
223945674|NCT05381090|DIAGNOSTIC_TEST|Venous blood collection|Participants will undergo venous blood collection following an overnight fast and 5, 60 and 180 minutes following food intake.
223945675|NCT02767674|DRUG|Rituximab|375 mg/m2 IVD day0
223719746|NCT02564237|BIOLOGICAL|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
223719747|NCT02564237|BIOLOGICAL|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
223719748|NCT03205332|BEHAVIORAL|Concreteness Training|
223719749|NCT06083285|OTHER|Implement the CRRT specialist nursing group management program on the basis of routine care|Training the department nurses on CRRT related theoretical knowledge and operation skills; guiding the process of CRRT different treatment modes, solving CRRT nursing problems, evidence-based nursing guidance; consulting CRRT treatment and nursing related treatment, timely understanding the new progress; responsible for CRRT nursing quality control, etc.
223719750|NCT06056713|BEHAVIORAL|Hand Massage|The hand massage application lasted 10 minutes, 5 minutes on each hand, before each brachytherapy (3 times in total in the 1st, 2nd and 3rd sessions).
223719751|NCT03129100|DRUG|Ixekizumab|Administered SC
223719752|NCT03129100|DRUG|Placebo|Administered SC
223719753|NCT00797030|DRUG|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
223719754|NCT00797030|DRUG|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
223719755|NCT02868775|PROCEDURE|cystoscopy, bladder hydrodistention and bladder biopsy|
223719756|NCT06557005|OTHER|Facilitated Transition to Primary Care|The intervention includes default PCP visit scheduling, tailored nudge messages to patients, ongoing care recommendations sent to the PCP, and a summary of recommendations after pregnancy given to the patient.
223719757|NCT04194034|BIOLOGICAL|TG6002|"Phase I part: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU. Phase II part: Established recommended Phase II dose (RP2D).~Intrahepatic arterial (IHA) administration on Day 1 within a 14-day cycle of TG6002/5-FC combination treatment.~A second cycle of TG6002/5-FC combination starting with TG6002 (IHA) administration at the same dose on Day43 can be initiated if no progressive disease or Dose Limiting Toxicity event in between; maximum 2 cycles of TG6002/5-FC combination treatment for each patient."
223945676|NCT02767674|DRUG|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
223945677|NCT02767674|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
223945678|NCT02767674|DRUG|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
223945679|NCT02767674|DRUG|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
223945680|NCT02767674|DRUG|Vindesine|Vindesine 2 mg IVP d1
223945681|NCT02767674|DRUG|Prednisone|Prednisone 40mg/m2 PO d1-5
223945682|NCT01750424|PROCEDURE|Autologous Fat Grafting|
223945683|NCT01750424|OTHER|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
223945684|NCT00853411|DRUG|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
223945685|NCT01553266|BEHAVIORAL|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
223945686|NCT02286869|PROCEDURE|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
223945687|NCT01756599|BIOLOGICAL|blood samples|
223945688|NCT03655366|OTHER|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
223945689|NCT03655366|OTHER|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
223945690|NCT02203799|BIOLOGICAL|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
223719758|NCT04194034|DRUG|Flucytosine (5-FC)|"Oral administration 4 times per day at the total dose of 200 mg/kg/day for 10 consecutive days per 14-day cycle of TG6002/5-FC combination.~A second cycle of TG6002/5-FC combination will be initiated if no progressive disease or Dose Limiting Toxicity event in between."
223719759|NCT04235985|COMBINATION_PRODUCT|Chlorhexidine Gluconate with HUBS|4% CHG soap will be applied to HUBS following manufacturers recommendation and applied to skin for different application times as dictated by the randomization of the marked sites on the forearm. Followed by a HUBS moistened with water.
223719760|NCT05658146|DRUG|Mavacamten Capsule 1|Specified dose on specified days
223719761|NCT05658146|DRUG|Mavacamten Capsule 2|Specified dose on specified days
223719762|NCT05658146|DRUG|Mavacamten Capsule 3|Specified dose on specified days
223719763|NCT01486667|DRUG|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
223719764|NCT01486667|DRUG|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
223719765|NCT03845985|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
223719766|NCT04459533|DEVICE|TOF protocol|"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."
223719767|NCT04642443|DEVICE|SENSE Device|The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
223719768|NCT00851370|DRUG|Omalizumab (Xolair)|Bi-weekly
223719769|NCT00851370|DRUG|Placebo|Bi-Weekly
223719770|NCT05501301|OTHER|IS weaning off|IS weaning off will be conducted in recipients with chronic virus infection or side effects of IS
223719771|NCT00492141|DRUG|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m\^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m\^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
223945691|NCT03658252|BEHAVIORAL|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
223945692|NCT03658252|BEHAVIORAL|Online disease specific forum|An invitation to join an online moderated disease specific social forum
223945693|NCT03556410|BEHAVIORAL|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
223945694|NCT03556410|BEHAVIORAL|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
223719772|NCT00492141|DRUG|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
223719773|NCT02818400|PROCEDURE|composite tissue allotransplantation|
223719774|NCT04141488|OTHER|experimantal group|Control Group
223719775|NCT00684346|OTHER|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
223719776|NCT06116760|DEVICE|Anodal or sham tDCS|"Anodal or sham tDCS (see Arms) is applied during the execution of an audio-visual training."
223719777|NCT06116760|BEHAVIORAL|Audio-visual training|"90 min/day x 10 days. Participants are seated in front of a 2 m × 2 m training board, at a distance of 1.2 m, in a dimly lit room. The board features 48 red light-emitting diodes (LED, diameter 1 cm, luminance 90 cd m2), distributed in six horizontal rows (eight lights per row). Forty-eight piezoelectric loudspeakers (0.4 W, 8Ω) are located above each light, producing a white-noise (80 dB, duration 100 ms).~Spatio-temporally congruent, cross-modal, audio-visual stimuli are presented at one out of 48 possible positions on the board. Participants are instructed to look at the fixation point - at the center of the apparatus - and to move their eyes to detect the presence of the visual stimulus (duration=100 ms) by pressing right button of a wireless mouse."
223719778|NCT02457260|DRUG|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
223719779|NCT05113017|OTHER|NO Intervention|NO Intervention
223719780|NCT05206578|DRUG|AGT2, AGZ|Tablet, q.d.
223719781|NCT05206578|DRUG|AGT2|Tablet, q.d.
223945695|NCT01178372|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
223945696|NCT01178372|DRUG|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
223945697|NCT02599025|DEVICE|Innowalk cycling system|Innowalk is a unique, motorized medical device
223719782|NCT05206578|DRUG|AGT4, AGZ|Tablet, q.d.
223719783|NCT05206578|DRUG|AGT4|Tablet, q.d.
223945698|NCT02599025|DEVICE|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
223945699|NCT02504801|DRUG|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
223945700|NCT04256395|OTHER|mobile internet survey on self-test|1\. make a questionnaire, the content of which refers to the new coronavirus diagnosis and treatment guidelines released by the National Health Commission; 2. develop the mobile applet and carry out internet propagation; 3. background data could be identified according to computer technology, de duplication and de privacy; 4. once registered, the applet can automatically remind the self-test twice a day, and encourage to adhere to 14 days; 5. automatically compare with the standards and highly suspected population could be given medical guidance and encouraged to go to the fever clinic of the designated hospital for definite diagnosis.
223945701|NCT00043589|DRUG|donepezil|
223945702|NCT00043589|PROCEDURE|Memory-training class|
223719784|NCT02250378|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
223719785|NCT02250378|PROCEDURE|therapeutic conventional surgery|Undergo wedge resection
223719786|NCT02250378|OTHER|laboratory biomarker analysis|Correlative studies
223719787|NCT02250378|OTHER|quality-of-life assessment|Ancillary studies
223719788|NCT01434030|BEHAVIORAL|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
223945703|NCT02106884|DRUG|Nab-paclitaxel|
223945704|NCT02106884|DRUG|Gemcitabine|
223945705|NCT05652907|DRUG|FSD201|Tablets for oral administration.
223945706|NCT05652907|DRUG|Placebo|Placebo tablets matched to FSD201 for oral administration.
223719789|NCT01332955|DRUG|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
223719790|NCT01332955|BIOLOGICAL|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
223719791|NCT01332955|DRUG|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
223945707|NCT00898521|DRUG|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
223719792|NCT05176730|BEHAVIORAL|Mindfulness meditation|Similar to the information included in arm/group descriptions
223719793|NCT02644135|DRUG|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
223719794|NCT02644135|DRUG|Halo Placebo|Three sprays per use, total = 9 sprays per day
223719795|NCT03302234|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
223719796|NCT03302234|BIOLOGICAL|Ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
223719797|NCT03302234|OTHER|Placebo|Normal saline solution administered as an IV infusion Q6W
223719798|NCT01901120|DRUG|Betanis|oral
223719799|NCT06199596|DIETARY_SUPPLEMENT|alpha-s1 casein hydrolysate|150mg of Prelactium per capsule
223719800|NCT06199596|DIETARY_SUPPLEMENT|Maltodextrin|150mg of Maltodextrin per capsule
223719801|NCT00200616|PROCEDURE|Antimicrobial prophylaxis|
223719802|NCT02795832|DRUG|ZPL-5212372 1% w/w Ointment BID|
223719803|NCT02795832|DRUG|Placebo Ointment BID|
223719804|NCT04523220|DRUG|BAY1213790 (Osocimab)|Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
223719805|NCT04523220|DRUG|Placebo|Subcutaneous administration in the same manner as Osocimab.
223719806|NCT01219569|DRUG|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
223719807|NCT01219569|DRUG|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
223719808|NCT00571948|OTHER|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
223719809|NCT00571948|OTHER|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
223719810|NCT05016999|DIETARY_SUPPLEMENT|Garlic and onion concentrate|Garlic extract concentrate (equivalent to 2 garlic cloves) and onion extract concentrate (equivalent to 1 onion)
223719811|NCT00483730|DRUG|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
223719812|NCT06292520|OTHER|Portage Guide Protocol|Portage Guide Protocol will be given to this group The study will follow the Randomized control trial study design and a purposive sampling technique will be used. Data will be collected from a special education centre BASES (Behaviour and special education services), Lahore. Children with autism spectrum disorder with mild to moderate severity level will be included in the study. The age range of the children will be from three years to seven years. Children with other neurological disorders or any comorbid conditions will be excluded from the study. The consent form will be filled out by parents of children who meet the inclusion criteria. The autism screening tool will apply by the speech and language pathologist. Half of the total number of children will receive therapeutic intervention under ABL
223719813|NCT06292520|OTHER|ABLLS-R protocol|ABLLS-R protocol will be given to this group
223719814|NCT05334966|OTHER|Maternal Hyperoxygenation|Oxygen is given to mothers at 8L through a non-rebreather mask.
223719815|NCT04112784|DEVICE|INVSENSOR00039|Noninvasive pulse oximeter sensor
223719816|NCT01989897|DRUG|saline with 1mg/ml Histamine base|
223719817|NCT01989897|DRUG|diluent, saline with HSA--phenol|
223729442|NCT03409406|BEHAVIORAL|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
223729443|NCT03409406|BEHAVIORAL|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
223729444|NCT03773679|PROCEDURE|Daily Exercise|Daily Exercise Programme
223719818|NCT04528108|DRUG|Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine|Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
223719819|NCT04528108|DRUG|Gong Xue Ning capsules|Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.
223535567|NCT01987414|BEHAVIORAL|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
223535568|NCT01987414|DEVICE|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
223535569|NCT01987414|OTHER|No treatment|Participants will maintain their daily routines during the no treatment period.
223535570|NCT02054637|DRUG|Lanreotide|
223535571|NCT00503490|DRUG|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
223535572|NCT00503490|DRUG|placebo|BID
223535573|NCT06179979|DIAGNOSTIC_TEST|PET/CT with 11C-PiB|Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
223535574|NCT01999192|DRUG|Tregalizumab|humanized anti-CD4 mAb
223535575|NCT01999192|DRUG|Placebo|identical end formulation buffer
223535576|NCT03419429|DRUG|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
223535577|NCT03419429|OTHER|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
223535578|NCT03419429|DEVICE|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
223535579|NCT03419429|DEVICE|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
223535580|NCT06441279|PROCEDURE|intra-articular injection with Platelet lysate (PL).|2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly
223535581|NCT06441279|PROCEDURE|intra-articular injection with Hyaluronic Acid.|2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
223535582|NCT00827229|DEVICE|Labor Monitor|
223535583|NCT02169648|DRUG|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
223535584|NCT06338111|DIAGNOSTIC_TEST|ELISA Sepsis Biomarkers dosage|Observational
223535585|NCT05309525|DRUG|Collagenase Clostridium Histolyticum-Aaes|subjects will be injected with up to 0.84 mg of QWO as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection), dependent on the amount of dimples (0.3 ml per dimple).
223535586|NCT05309525|DRUG|Lysteda 650 MG Oral Tablet|Subjects will be given the therapeutic dose of tranexamic acid for menorrhagia, which is 1300 mg PO TID for up to 5 days during menstruation
223535587|NCT03894085|DRUG|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
223535588|NCT06639789|DIETARY_SUPPLEMENT|Vitamin B12 (B12)|The new formulation of vitamin B12 will be ingested 3 days before and on the day of testing (3 hours before).
223535589|NCT06639789|DIETARY_SUPPLEMENT|PLACEBO (PLA)|The placebo will be ingested 3 days before and the same day of the tests (3 hours before).
223535590|NCT06564805|DRUG|Candida Albicans Antigen Injection|subcutaneous administration of Candida albicans antigen
223535591|NCT03410654|DRUG|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
223535592|NCT05961098|DRUG|RBD1016|RBD1016 with NAs background treatment will be explored.
223945708|NCT03315065|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
223945709|NCT04547660|BIOLOGICAL|Convalescent Plasma|Fresh frozen plasma collected by apheresis from recovered COVID-19 patients added to best supportive care.
223719820|NCT04889079|BEHAVIORAL|Contraceptive use (continuation/switching/discontinuation)|Assessing contraceptive continuation/switching/discontinuation over 12-months
223719821|NCT01796080|OTHER|Mueller manoeuvre|
223719822|NCT01796080|OTHER|Inspiratory threshold|
223719823|NCT01796080|OTHER|Expiratory apnoea|
223719824|NCT01796080|OTHER|Steady state normal breathing|
224100140|NCT05050240|OTHER|Cooling Vest Procedure|"A cold vest will be placed on the participant (consisting of a water-perfused CFA wearable vest, size S-M or M-L with adjustable straps Polar Products, Stow, OH; attached to a small 'cooler' reservoir to circulate cold water between the vest and the cooler; Product link: https://www.polarproducts.com/polarshop/pc/CoolOR-13-Quart-System-with-Arctic-Chiller-p24757.htm This product is safe and recommended by experimental guidelines and BARCIST criteria for human BAT studies. Note, the cooling vest will be cleaned between participants according to the manufacturer's guidelines found here: https://www.polarproducts.com/polarshop/pc/catalog/pdf/Polar\_CoolFlow\_Manual.pdf.~Briefly, the vest will be hand washed with a mild detergent and warm soapy water and air-dried. The vest will then be stored in a clean, dry environment with ventilation."
223719825|NCT05824793|COMBINATION_PRODUCT|A-PRF+|A-PRF+ contributes to accelerating the healing process, more rapid revascularization, and reducing the risk of inflammation at the graft site. It leads to a decrease in the severity of postoperative complications. Many authors have mentioned platelet concentrates as an effective adjunction that improves the healing of hard and soft tissue and decreases pain, swelling, and trismus. However, there are still some controversial results in the literature. Recently, it has been demonstrated that the production of PRF with lower centrifugal force and lower centrifugal time has more potential to release several growth factors and facilitate more favorable healing at the site of the application when compared to standard PRF. Promoting the healing process after tooth extraction using A-PRF+ aims to manage patient discomfort as well as postoperation complications.
223719826|NCT05947825|DRUG|Combination of sitagliptin+ gemcitabine + nab-paclitaxel|"Drug1: Sitagliptin will be administered orally once a day at a dose of 100 mg depending on cohort assignment.~Drug2: Gemcitabine will be intravenously administered on Days 1 and 8 of every 21-day cycle at a dose of 1000 mg/m2 depending on cohort assignment.~Drug3: Nab-Paclitaxel will be intravenously administered on Days 1 and 8 of every 28-day cycle at a dose of 125 mg/m2 depending on cohort assignment."
223719827|NCT04427566|RADIATION|Radiation therapy|Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
223719828|NCT04963335|BEHAVIORAL|Exergame Training|The individualized exergames were designed for a pressure sensitive plate connected to a personal computer and a frontal screen. The pressure-sensitive plate allows a precise analysis of the user's movements. This concurrent motor-cognitive training aims to improve motor and cognitive functions in an ecological valid setting. The cognitive functions are triggered by specific stimuli in the game scenarios. The video games are controlled via specific (whole body) movements as steps, weight shifting, jumps, and arm movements. The training focus is mainly on multi-tasking, balance and coordination as well as executive functions and attention. Furthermore, the meaningful games (colorful and appealing visuals) were designed to motivate the players to move. As the exergame will automatically adapt (individual progression) during play time, participants are challenged at their individual motor and cognitive level.
223719829|NCT04528381|PROCEDURE|Laparoscopy|Laparoscopic orchiopexy
223719830|NCT00065403|DEVICE|Acupuncture|
223719831|NCT03925883|BEHAVIORAL|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
223719832|NCT01475994|OTHER|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
223719833|NCT01475994|OTHER|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
223945710|NCT04547660|OTHER|Best Supportive Care|Any form of ventilatory support, extracorporeal membrane oxygenation, steroids, antibiotics and other supportive measures except for investigational interventions.
223945711|NCT00213278|DRUG|vinblastine sulphate injection|Vinblastine dose: 6 mg/m\^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
223945712|NCT03114215|DRUG|MD1003|capsules 100mg 3 times per day
223945713|NCT03114215|DRUG|Placebo oral capsule|capsules 100mg lactose 3 times per day
223945714|NCT00659373|DRUG|Tamoxifen|
223945715|NCT00659373|DRUG|triptorelin|
223945716|NCT00659373|DRUG|Exemestane|
223945717|NCT00060502|DRUG|Infliximab; Gemcitabine|
223945718|NCT04364230|DRUG|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
223945719|NCT04364230|DRUG|NeoAg-mBRAF|BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
223945720|NCT04364230|DRUG|PolyICLC|polyICLC, local adjuvant
223945721|NCT04364230|DRUG|CDX-1140|CDX-1140, local adjuvant
223945722|NCT00351026|DRUG|Methadone|short-term methadone maintenance
223945723|NCT02382640|DRUG|Febuxostat XR|Febuxostat extended-release (XR) capsules
223945724|NCT02382640|DRUG|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
223945725|NCT02356198|DRUG|EXPAREL|transversus abdominis plane injection
223945726|NCT02356198|DRUG|Intrathecal hydromorphone|Intrathecal opioid administration
223945727|NCT02697656|BEHAVIORAL|IPS|Individualized job support provided by an employment specialist
223945728|NCT02697656|BEHAVIORAL|Self-help|Self-help resources on obtaining employment and coping with chronic pain
223945729|NCT02697656|BEHAVIORAL|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
223945730|NCT02652845|BEHAVIORAL|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
223719834|NCT00256750|DRUG|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
223719835|NCT00256750|DRUG|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
223719836|NCT00256750|DRUG|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
223719837|NCT03072147|DRUG|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
223945731|NCT03471117|DRUG|Pioglitazone|Pioglitazone 15mg daily for 1 month
223945732|NCT03471117|OTHER|Placebo|Placebo pills for 1 month
223945733|NCT05850793|BEHAVIORAL|Sensorimotor Exercise|Balance, perturbation , aging and strengthing exercise will be performed for knee
223719838|NCT03072147|DRUG|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
223719839|NCT05781854|DRUG|Epidural analgesia with bupivacaine and dexmedetomidine|Epidural analgesia with bupivacaine and dexmedetomidine
223719840|NCT03017495|DRUG|Midazolam|2 mg/mL oral solution
223719841|NCT03017495|DRUG|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
223719842|NCT05019352|DEVICE|CytoSorb cytokine adsorber|device for extracorporeal hemoadsorption
223945734|NCT05850793|BEHAVIORAL|Conventional Exercise|Range of motion, strengthing and stretching exercise will be performed for knee
223945735|NCT05850793|BEHAVIORAL|Progressive Motor Imagery Exercise|Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
223945736|NCT01560429|PROCEDURE|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
223945737|NCT01560429|PROCEDURE|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
223945738|NCT00000892|DRUG|Ritonavir|
223945739|NCT00000892|DRUG|Nelfinavir mesylate|
223945740|NCT00000892|DRUG|Levocarnitine|
223945741|NCT00000892|DRUG|Adefovir dipivoxil|
223945742|NCT00000892|DRUG|Saquinavir|
223719843|NCT05019352|DEVICE|CRRT|continuous renal replacement therapy
223945743|NCT00000892|DRUG|Delavirdine mesylate|
223945744|NCT00917098|BEHAVIORAL|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
223945745|NCT00917098|BEHAVIORAL|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
223945746|NCT00647465|DRUG|vaccine|IFNalpha 2b
223719844|NCT05496530|DRUG|Suprachoroidal triamcinolone acetonide injection|Pars plana suprachoroidal injection of 4mg//0.1ml triamcinolone acetonide.
223719845|NCT02301000|BIOLOGICAL|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
223719846|NCT02301000|DRUG|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
223719847|NCT00211510|DEVICE|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
223719848|NCT00211510|DEVICE|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
223719849|NCT00000329|DRUG|Opioid-Related Disorders|
223719850|NCT01962896|DRUG|Erlotinib|
223719851|NCT01962896|DRUG|Sirolimus|
223945747|NCT00647465|DRUG|Placebo|Placebo
223945748|NCT05705245|OTHER|recruitment|Automated alveolar recruitment menouever applied during mechanical ventilation in the intraoperative period
223945749|NCT03162614|BIOLOGICAL|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
223945750|NCT03162614|BIOLOGICAL|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
223945751|NCT03162614|PROCEDURE|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
223945752|NCT01607697|BEHAVIORAL|Mindfulness Training|Mindfulness Training
223945753|NCT04188522|DIAGNOSTIC_TEST|Magnetoencephalography (MEG)|Participants will undergo MEG at the University of Maryland (College Park) to measure cerebral activity while performing a visual naming task. The Montreal Cognitive Assessment (MOCA) will also be administered.
223945754|NCT04127513|DRUG|Ammonium Lactate|12% ammonium lactate moisturizing cream
223945755|NCT04127513|DRUG|Urea|10% urea moisturizing cream
223945756|NCT01028976|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
223945757|NCT01028976|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
223945758|NCT06111014|DRUG|Latozinemab|All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
223945759|NCT01920191|BIOLOGICAL|IMA 950|
223719852|NCT01996501|DRUG|Olanzapine Orally Disintegrating 5mg Tablets|
223719853|NCT03781869|DRUG|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
223719854|NCT03781869|DRUG|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
223719855|NCT02400632|DEVICE|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
223719856|NCT03335098|DRUG|Bortezomib|Six 4-week cycles
223719857|NCT05089942|DRUG|Recombinant Human Insulin Patch ZJSRM2021|health subjects receive recombinant human insulin patch ZJSRM2021，diabetic patients receive recombinant human insulin patch ZJSRM2021（low-dosage or high dosage）
223719858|NCT05089942|DRUG|Placebo|health subjects receive placebo patch
223945760|NCT01920191|BIOLOGICAL|Poly ICLC|
223945761|NCT01920191|OTHER|Immunomonitoring|Blood samples, DTH analysis
223945762|NCT05353296|BEHAVIORAL|Digital cognitive behavioral therapy for insomnia (CBT-I) program|A self-guided digital program of CBT-I (Somryst) that has been culturally adapted for Spanish-language speakers. Somryst is an interactive and tailored mobile-based program modeled on the primary tenets of face-to-face CBT-I. Patients will be asked to complete six cores (main intervention content) during the 9-week intervention period. The cores provide key content across six domains including behavioral (sleep restriction, stimulus control), cognitive (cognitive restricting), educational (sleep hygiene), overview, and consolidation/relapse prevention.
223945763|NCT05353296|BEHAVIORAL|Minimally Enhanced Usual Care (mEUC)|A minimally enhanced usual care, which will include usual care by patients' Primary Care Provider and a sleep hygiene brochure.
223945764|NCT05353296|DEVICE|Somryst (culturally adapted)|FDA-authorized digital cognitive behavioral therapy for insomnia (CBT-I) trains your brain for better sleep.
223945765|NCT06576167|BEHAVIORAL|IMPROVE|IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.
223945766|NCT05681351|DRUG|Olezarsen|Administered as SC injection.
223945767|NCT05586243|OTHER|No intervention|This is an observational study looking at brain chemicals related to oxidative stress and inflammation using magnetic resonance spectroscopy (MRS).
223945768|NCT04349436|BIOLOGICAL|RP1, intra-tumoral injection, oncolytic virus|Genetically modified herpes simplex type 1 virus
223719859|NCT01925937|DRUG|Atorvastatin|
223945769|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).|Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. \[three video banks of RDE + Support\]).
223945770|NCT04484272|BEHAVIORAL|Self-monitoring of pain, stress, and opioid use + alerts/reminders.|Self-monitoring of pain, stress, and opioid use + alerts/reminders.
223945771|NCT06302439|OTHER|No Intervention for this observational study|No Intervention for this observational study
223719860|NCT01925937|DRUG|Coenzyme Q10|
223719861|NCT01925937|DRUG|placebo for coenzyme Q10|
223719862|NCT01362205|DRUG|Dexmedetomidine|
223945772|NCT02329639|GENETIC|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
223945773|NCT05703919|DRUG|Titrated Oxygen|Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%
223945774|NCT05703919|DRUG|Standard Oxygen|Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators
223719863|NCT01362205|DRUG|Placebos|Inactive placebo (normal saline)
223719864|NCT02131207|DEVICE|magnetic resonance imaging|Undergo pelvic MRI
223719865|NCT02131207|PROCEDURE|prostate biopsy|Undergo prostate biopsy
223719866|NCT04269252|OTHER|CHI-907|CHI-907 is a high CBD extract.
223719867|NCT04269252|OTHER|CHI-804|CHI-804 is the placebo formulation.
223719868|NCT00567294|BEHAVIORAL|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
223719869|NCT00567294|BEHAVIORAL|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
223719870|NCT00567294|BEHAVIORAL|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
223719871|NCT02640014|DIETARY_SUPPLEMENT|Milk|Milk Oral immunotherapy
223719872|NCT03224715|OTHER|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
223945775|NCT05698693|BEHAVIORAL|Sleep intervention|The sleep extension intervention is a 4-week intervention consisting of weekly one-on-one contact with the goal of increasing total sleep time by 60 minutes by the end of four weeks conducted by Dr. Wu or a trained counselor.
223719873|NCT01523535|BEHAVIORAL|repeated cycles of short sleep|\- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
223945776|NCT05698693|BEHAVIORAL|Contact Control|This is healthy homes intervention.The program provides education on healthy homes, provide advice on specific healthy homes problems, and recommend actions to be taken by families, landlords, and community members.
223719874|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
223719875|NCT04893538|DIAGNOSTIC_TEST|First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9|Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS
223719876|NCT06464068|DRUG|Durvalumab|"All drugs will be administered intravenously. Induction treatment will be administered on a 21-day cycle for four cycles and will consist of:~* etoposide 80-100 mg/m² (administered on days 1-3 of each 21-day cycle);~* investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m² (administered on day 1 of each cycle);~* durvalumab 1500 mg every 3 weeks in combination with chemotherapy (induction phase) followed by maintenance phase with durvalumab 1500 mg every 4 weeks. Patients will continue treatment until disease progression per investigator assessment, unacceptable toxicity, or other discontinuation criteria were met for a maximum of 24 months. Continuation of study treatment after disease progression will be permitted if there is evidence of clinical benefit for a maximum 24 months."
223719877|NCT01949506|RADIATION|SBRT|Stereotactic Body Radiation Therapy
223945777|NCT06159894|OTHER|DAY HOSPITAL ARM|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
224100141|NCT05050240|OTHER|Fasting overnight|Participants will be requested to refrain from food and caloric drinks overnight (starting at 10pm) prior to the hospital visit. Blood will then be drawn the following morning (between 8 and 9am) and 3hrs later (between 11am and noon). Participants will be sat in a room with ambient temperature (room temperature w/o cooling) between the two blood draws.
224100142|NCT06280625|OTHER|Replacement of wheat flour by soyflour|The intervention consist in replacing a fraction of wheat flour by soyflour
224100143|NCT05199870|DEVICE|RingLoc Bipolar Acetabular Cup|Patients that have been implanted with a RingLoc Bipolar acetabular cup.
223719878|NCT00130598|DRUG|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
223945778|NCT06159894|OTHER|Specialist-Care arm|"The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms.~The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored.~Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice."
223945779|NCT04539015|DEVICE|Prevena Plus|PREVENA Plus is a negative pressure wound therapy device intended for use on surgical incisions that continue to drain following sutured or stapled closures.
223719879|NCT01175252|OTHER|Database analysis|Review and collect data from database
223719880|NCT04812171|PROCEDURE|non-surgical endodontic treatment|standard non-surgical endodontic treatment performed by endodontic specialist
223719881|NCT03628794|DEVICE|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
223719882|NCT05332197|BIOLOGICAL|17D Yellow fever vaccine|This vaccine contains the Rockefeller17D-substrain 204 strain of Yellow fever virus. The exact potency of each batch is released with the certificate of analysis that accompanies each batch and the potency confirmed at time of release closest to internal minimum specification. This vaccine is the same vaccine used by the national EPI program
223945780|NCT02426255|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
223945781|NCT04693741|PROCEDURE|secondary alveolar bone graft|"Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps."
223945782|NCT04693741|PROCEDURE|Harvesting of the autogenous bone graft|Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
223945783|NCT04693741|PROCEDURE|Preparation of PRP|10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
223945784|NCT02276599|PROCEDURE|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
223945785|NCT00432016|DRUG|zidovudine|
223945786|NCT00432016|DRUG|amdoxovir|
223945787|NCT00432016|PROCEDURE|pharmacokinetic sampling|
223945788|NCT03175159|BEHAVIORAL|IMPACT|Ten counseling sessions
223945789|NCT03175159|BEHAVIORAL|Standard of Care|Two counseling sessions
223945790|NCT02251301|DIETARY_SUPPLEMENT|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
223945791|NCT02251301|BEHAVIORAL|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
223945792|NCT02251301|OTHER|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
223719883|NCT02915016|BIOLOGICAL|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
223719884|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
223719885|NCT02915016|BIOLOGICAL|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
223719886|NCT02915016|BIOLOGICAL|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
223719887|NCT03973710|DIETARY_SUPPLEMENT|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
223719888|NCT03973710|DIETARY_SUPPLEMENT|Placebo controls|placebo with a similar appearance to probiotics supplement
223719889|NCT00440713|DRUG|Aripiprazole|
223719890|NCT00440713|BEHAVIORAL|Interpersonal Therapy|
223719891|NCT03570021|PROCEDURE|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association \[American Thyroid Association Surgery Working Group, Thyroid 2009\]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery \[French Society of Otolaryngology Head and Neck Sugery\].~\- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection \[Hartl DM, Ann Surg 2012\], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons \[Hartl DM, World J Surg 2012\]."
223719892|NCT03570021|PROCEDURE|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
223719893|NCT05405309|DRUG|RP-3500|RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity.
223719894|NCT05405309|DRUG|Olaparib|Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate.
223719895|NCT06975878|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223719896|NCT06975878|BIOLOGICAL|Vaxneuvance vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223719897|NCT06975878|BIOLOGICAL|Hexyon vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223719898|NCT06975878|BIOLOGICAL|M-M-RvaxPro vaccine|Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
223719899|NCT06975878|BIOLOGICAL|Varivax vaccine|Pharmaceutical form:Powder and solvent for suspension for injection-Route of administration:Intramuscular or Subcutaneous
223719900|NCT05930483|BEHAVIORAL|¡Vida! program|Participate in ¡Vida! program
223945793|NCT02251301|DIETARY_SUPPLEMENT|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
223945794|NCT04810975|DEVICE|Muscle Strength Training|Strength training occurring specific exercise regimens using Exercise Equipment A or B
223719901|NCT05930483|BEHAVIORAL|¡Vida! Plus [¡Vida! + Experiential Learning (EL)]|Participate in ¡Vida! Plus program
223719902|NCT05930483|BEHAVIORAL|Health Coaching|Receive health coaching
223719903|NCT05930483|BEHAVIORAL|Mailed Toolkits|Receive a mailed toolkit of health items
223719904|NCT05913843|DEVICE|Take photo|We will use the camera to take 2 front and side images of the participant, and select one of the better images to upload to the facial analysis system (GestaltMatcher Database) for analysis.
223719905|NCT06272695|BIOLOGICAL|Volagidemab|Administered by SC injection once weekly for 6 weeks
223945795|NCT02111551|DRUG|DMXB-A 150 mg|
223945796|NCT02111551|OTHER|placebo|
223945797|NCT02111551|DRUG|DMXB-A 75 mg|
223945798|NCT04806100|DEVICE|Malleo-Lok|The Malleo-Lok is a novel, low-profile carbon fiber device with two laterally positioned struts aligned in the sagittal plane.
223945799|NCT00391170|DRUG|Topical Dexamethasone|dexamethasone 0.01%
223945800|NCT00391170|DRUG|Placebo|Placebo
224100144|NCT05199870|DEVICE|Endo II Femoral Head|Subjects that have been implanted with an Endo II Femoral Head
223945801|NCT02494336|PROCEDURE|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
223535593|NCT06564233|BEHAVIORAL|care.coach Avatar™|"care.coach Avatar™ (avatar) is a conversational relational agent that serves as a virtual companion and appears on a tablet device as an animated pet avatar. Each avatar is supervised by a 24x7 remote team of trained human staff whose abilities are augmented by artificial intelligence (AI) and software-driven health coaching and clinical protocols for consistency, automation, and scale. This unique human-in-the-loop design enables safe, empathic, natural conversations that form the basis for trusting relations and lasting behavior change. In addition to being a companion, the avatar educates patients about their condition, helps manage symptoms, and reinforces other healthy habits. Independent studies have demonstrated improved outcomes at a reduced cost of care. A pilot study demonstrated the feasibility of care.coach Avatar™ as a psychosocial support and health coach in hospitalized HCT patients. More research is needed to assess efficacy and applications in other HCT settings."
223535594|NCT06563843|PROCEDURE|Robotic-assisted TKA|Robotic-assisted Total Knee Arthroplasty or total knee replacement is a surgical procedure using a robot to resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
223535595|NCT06563843|PROCEDURE|Conventional TKA|Conventional Total Knee Arthroplasty or total knee replacement is a surgical procedure to manually resurface a knee joint damaged with arthritis, and where the knee joint of the patient is replaced with a prosthesis.
223535596|NCT06400082|DRUG|Insulin|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
223535597|NCT06400082|DRUG|Povidone-Iodine|Insulin is applied as a topical dressing for postoperative wounds and compared to the conventional povidone iodine treatment
223535598|NCT06565130|OTHER|Attention skills training|Attention skills program planned with occupational therapy principles
223535599|NCT05298930|OTHER|Physical activity program|"The supervised sessions will be offered 4 times a week in the participants' rooms by the APA teachers and will include moderate intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient will also be able to perform unsupervised sessions (on their own), following the advice given by the APA teacher. These unsupervised sessions can be done independently on the bike.~In order to encourage patients to perform these unsupervised sessions, patients and their relatives will be given a connected device and will have access to a mobile application developed by the Kiplin company, which offers connected physical activity games to be performed in teams (from 2 to 4 participants). These games, lasting from 1 to 3 weeks, use the participants' daily PA level as a unit of animation and are punctuated by challenges."
223535600|NCT03192436|DEVICE|Ultrasound|Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
223535601|NCT03952845|OTHER|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
223535602|NCT06560333|DRUG|N0892|1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg
223535603|NCT06560333|DRUG|Januvia® + Glifage XR® + Placebo|1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg
223535604|NCT06560333|DRUG|Forxiga® + Glifage XR® + Placebo|1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg
223535605|NCT05081830|BEHAVIORAL|Transdiagnostic online intervention|Based on the theoretical proposal of Barlow et al. (2011) a treatment applicable to all anxiety and mood disorders (unipolar depression) will be implemented. The unified protocol incorporates proven emotion-focused psychological techniques (Ellard et al., 2010). The main components are: (1) motivation for change, understanding emotions, and recognition and observation of emotional response; (2) learn to observe experiences, evaluate and reevaluate thoughts; (3) what is emotional avoidance, emotion and behavior, and awareness and tolerance of physical sensations; (4) emotional exposure to physical sensations and situations and achievements, maintenance and prevention of relapses.
223535606|NCT05081830|BEHAVIORAL|TCC online intervention|This program incorporates psychological techniques under the cognitive-behavioral model that have demonstrated their effectiveness in online mode (De la Rosa, 2019; Flores et al., 2014). The main components are: (1) psychoeducation, (2) cognitive restructuring, (3) identification and expression of emotions, (4) assertiveness training and (5) problem solving, and (6) relapse prevention. The order of application of each technique is established by the advisor derived from the formulation of treatment of each case to solve the problems raised, under supervision.
223945802|NCT02494336|PROCEDURE|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
224100145|NCT05780099|OTHER|Inpatient or Outpatient visit|Patients will be seen and treated at the clinics like in the usual care
223719906|NCT04519879|OTHER|Clinical Observation|Undergo clinical observation
223945803|NCT02494336|DRUG|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
223719907|NCT04519879|OTHER|Patient Observation|Undergo active surveillance
223719908|NCT04519879|OTHER|Questionnaire Administration|Ancillary studies
223719909|NCT04519879|DRUG|White Button Mushroom Extract|Given PO
223719910|NCT05735431|DRUG|Administration of investigation drug|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
223719911|NCT05735431|DRUG|Administration of comparator|Participants randomized to this group will receive 1 inhalation of the product, twice daily, for 12 weeks.
223719912|NCT05792709|OTHER|Oral Motor Therapy|In Traditional therapy we will give cognitive and articulation therapy to the patients.
223719913|NCT02592356|PROCEDURE|Computed Tomography|Correlative studies
223719914|NCT02592356|PROCEDURE|Dual X-ray Absorptiometry|Correlative studies
223719915|NCT02592356|PROCEDURE|Physical Examination|Correlative studies
223719916|NCT02592356|OTHER|Quality-of-Life Assessment|Ancillary studies
223719917|NCT02592356|OTHER|Questionnaire Administration|Ancillary studies
223719918|NCT02592356|DRUG|Cabozantinib|
223719919|NCT02592356|DRUG|Lenvatinib|
223719920|NCT01087138|BEHAVIORAL|exercise|exercise class 3x's/week
223719921|NCT01087138|BEHAVIORAL|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
223719922|NCT00580684|BIOLOGICAL|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
223719923|NCT01670240|DRUG|Adalimumab|
223719924|NCT01670240|DRUG|Placebo|
223719925|NCT03261050|BEHAVIORAL|Counter Attitudinal Therapy|8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.
223945804|NCT04644887|OTHER|Dietary intervention: Healthy diet|Dietary guidance in the intervention group is based on the Nordic and Finnish nutrition recommendations with an emphasis on the quality of dietary fat. The aims for the intake of fatty acids will be SFA \< 10 % of energy intake (E%) and mono- and polyunsaturated fatty acids (UFA) \>2/3 of the total fat intake. The key food products such as vegetable oil-based spread, liquid margarine and canola oil are provided to the participants. The participants are recommended to use fat free (e.g. milk, sourdough milk and yogurt) and low fat (e.g. cheese ≤ 17%) dairy products and low-fat meat, poultry, and fish as well as natural nuts and seeds.
223719926|NCT03261050|BEHAVIORAL|Interpersonal Therapy|8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.
223719927|NCT06667544|DRUG|RNK08954-01|Once daily oral treatment for a 3 week cycle
223719928|NCT06651437|OTHER|Experimental dietary educational intervention|At the end of the baseline examination, the Experimental group received a brief dietary education on the health damage due to excess salt consumption and on behavioural methods to gradually reduce dietary intake, for example at home, reduce the consumption of processed foods, do not bring salt shaker on the table, limit the use of condiments with a high sodium content; out of home, both when eating and when shopping, reduce the consumption of processed foods, check nutritional labels and choose products with lower salt content. In addition, written information was provided. All participants will be clinically followed every month, with potential titration of the antihypertensive therapy. After 3 months of follow-up, the baseline measurements will be carried out again. During the entire study period, subjects will be asked to maintain their lifestyle and report using additional medications.
223719929|NCT06650800|DRUG|Psilocybin|Single-dose psilocybin administration: oral ingestion of one 25 mg capsule
223719930|NCT06650800|OTHER|MRI|1.5 hour brain MRI before and after psilocybin administration
223719931|NCT06599996|DEVICE|Testing artificial intelligence algorithms for interpreting gestures|The effectiveness of artificial intelligence algorithms for detecting and interpreting body-based gestures by individuals who have motor/visual impairments will be evaluated.
223719932|NCT05505201|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
223719933|NCT05505201|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham Repetitive transcranial magnetic stimulation
223719934|NCT04921189|DRUG|The combined supplement of Ascorbic acid, Thiamine, and Cortisol|"The combined administration of 3 drugs will be mixed in a 50 mL 0.9% saline bag respectively and administered through intravenous infusion over 60 min every 12 h for 3 days.~1. Ascorbic acid (Ascorbic acid Inj \[500mg\]®): 50 mg/kg, maximum single dose 3 g, daily dose 6 g~2. Thiamine (Thiamine hcl inj \[50mg\]®): 200 mg~3. Cortisol (Cortisolu inj \[100mg\]®): 100mg (The main exposure was corticosteroid therapy, defined as the use of systemic corticosteroids. But if unavailable, it could be converted to hydrocortisone-equivalent doses (methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4).)"
223719935|NCT04921189|DRUG|Placebo|An identical volume of 0.9% saline (150mL) administered through intravenous infusion over 60 min every 12 h for 3 days.
223719936|NCT06577727|OTHER|Gold standard blood test|Blood test will measure haemoglobin and other parameters
223719937|NCT06577727|OTHER|Imaging and videography of anatomical sites|Images and videos of anatomical sites will be collected for AI to estimate iron status
223719938|NCT06535945|DRUG|Albumin administration|when albumin serum concentration is at 30 g/L or below
223719939|NCT06630728|DRUG|Reduced Nicotine Content Cigars|Participants will smoke a very low nicotine content filtered little cigar containing 0.50mg nicotine per gram of tobacco
223719940|NCT06630728|DRUG|Normal nicotine content cigar|Participants will smoke a normal nicotine content filtered little cigar containing 5.17mg nicotine per gram of tobacco
223719941|NCT06630728|DRUG|Usual brand cigar|Participants will smoke their usual brand filtered little cigar
223719942|NCT05977647|DRUG|Tamsulosin Oral Capsule|Patient will be enrolled in one of study arm through randomization.
223945805|NCT04644887|OTHER|Dietary intervention: Control diet|The control diet corresponds to the average nutrient intake in the Nordic countries, i.e. the intake of SFA about 15 E% and the proportion of UFA about 50 % of total fat intake. The participants of the control group will get butter-based spread for bread and cooking. They are recommended to use semi-skimmed milk (1,5 %), normal fat yogurt (\~2%), normal fat cheese (\~24-35 %) and avoid consumption of vegetable oils. They are allowed to eat a portion of fish and nuts once a week.
223945806|NCT02911961|DRUG|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
223945807|NCT02892591|DRUG|Cannabis|vaporized plant material
223945808|NCT02892591|DRUG|Oxycodone|oral capsule
223945809|NCT02892591|DRUG|Placebo for Cannabis|vaporized placebo plant material
223945810|NCT02892591|DRUG|Placebo for Oxycodone|oral placebo capsule
223945811|NCT02025504|DEVICE|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
223945812|NCT04572867|DEVICE|Aquapheresis|The Aquadex FlexFlow® Fluid Removal System (from CHF Solutions™, Minneapolis, MN) is an FDA approved device that provides mechanical isosmotic fluid removal in volume-overloaded CHF patients via veno-venous ultrafiltration, and has been used in patients with congestive heart failure refractory to diuretics, it should be considered standard of care also. This study is using it in a randomized, controlled study in the Outpatient setting. The Aquadex FlexFlow® Fluid Removal System is a dual rotary pump device used with a sterile, single-use UF 500 Blood Circuit Set. Blood withdrawal is usually from a peripheral arm vein (such as the antecubital vein), using a 16 or 18- gauge, 3.5 cm catheter (similar to a standard IV catheter). A similar IV catheter is used for blood return via a second peripheral vein (typically in the forearm).
223945813|NCT04572867|DRUG|IV Diuretics|Active Comparator: Intravenous Diuretics Per protocol (Fig 2), if randomized to IV diuretic therapy arm (IV), the patient will receive initial dose of IV diuretic based on base line renal function; then the dose will be doubled every 2 hrs if refractory, to a maximum of 8mg IV Bumex (or 320mg IV Lasix). Metolazone may be added at 2.5mg PO 30 minutes before loop diuretic if CR\< 2.0, or 5mg PO if Cr \> 2.0, if refractory to high dose loop diuretic. If the patient in IV arm is refractory to max 320 mg IV Lasix or 8 mg IV Bumex plus Metolazone then the patient may cross over to AQ arm.
223945814|NCT00958321|PROCEDURE|computed tomography|
223535607|NCT05119010|DIETARY_SUPPLEMENT|Continuous ketogenic diet|ARM A : continuous ketogenic diet
223945815|NCT00958321|RADIATION|3-dimensional conformal radiation therapy|
223535608|NCT05119010|DIETARY_SUPPLEMENT|Discontinuous ketogenic diet|ARM B : discontinuous ketogenic diet
223535609|NCT05119010|DIETARY_SUPPLEMENT|beta-hydroxybutyrate (BHB) supplementation|ARM C : BHB supplementation
223535610|NCT04049500|OTHER|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
223535611|NCT01889914|DRUG|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
223535612|NCT05390788|OTHER|Application Of Neuromuscular Bands; Kinesio Taping|"Kinesio tape is a specialized elastic and adherent adhesive tape that mimics the elasticity of skeletal muscle, in that it can be extended up to 140% of its original length, before application to the skin, without allowing restrictions in the range of motion. of structures. Subsequently, it provides a tensile (shear) force on the skin, consisting of a fabric with special characteristics, such as air permeability and water resistance, and can be used for repeated days. Kinesio will be applied from a point 10 cm below the anterior superior iliac spine and divided in a Y shape above the patella, ending at the tibial tuberosity; from the upper third of the medial thigh to the medial border of the patella; from the greater trochanter of the femur, ending at the lateral margin of the patella."
223535613|NCT04754490|DIAGNOSTIC_TEST|Speech Recognition|Speech Recognition
223535614|NCT03781674|DRUG|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
223535615|NCT03781674|DRUG|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
223535616|NCT03781674|DRUG|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
223535617|NCT03781674|DRUG|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
223535618|NCT02441218|DRUG|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
223535619|NCT02441218|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
223535620|NCT04454515|DRUG|Dexmedetomidine|Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
223535621|NCT04454515|DRUG|placebo|normal saline infusion
223535622|NCT01541371|DRUG|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
223535623|NCT02128087|BEHAVIORAL|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
223945816|NCT00958321|RADIATION|fludeoxyglucose F 18|
223945817|NCT00958321|RADIATION|radiation therapy treatment planning/simulation|
223945818|NCT02436694|DRUG|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
223945819|NCT02436694|DRUG|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
223945820|NCT01360918|DEVICE|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
223945821|NCT01360918|OTHER|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
224100146|NCT06118983|OTHER|I-TRANSFER-HF|"I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies (hospital-HHC agency dyads) across the US."
224100147|NCT06526312|BEHAVIORAL|SMS/Text (CAMPI)|Configurable Assessment Messaging Platform for Interventions (CAMPI) is a SMS text messaging platform to promote motivation and home practice.
224100148|NCT06526312|BEHAVIORAL|Fidelity Monitoring (Lyssn and COACH)|"Lyssn's HIPAA-compliant, cloud-based platform uses embedded speech-to-text transcription from audio recorded sessions for rapid assessment and easy session review for supervisors and interventionists.~The COACH fidelity rating system assesses clinical skills in five domains considered essential for the effective provision of the FCU and the EDP intervention sessions. The COACH rating form is used to assess the extent to which the provider is:~Conceptually accurate and adherent to the intervention model Observant and responsive to the family's needs Active in structuring the session Careful when teaching and providing feedback Helpful in building hope and motivation"
224100149|NCT06526312|BEHAVIORAL|Family Check-Up 4 Health (FCU4Health)|An evidence-based, data-driven, individually tailored parenting intervention with evidence of effectiveness on child and family health behaviors and psychosocial well-being. The program includes three components: 1) a comprehensive family assessment, 2) feedback and motivation session, and 3) individually tailored follow-up support (including parent training modules from the Everyday Parenting curriculum and connection with community resources). Dosage and content of these follow-up sessions are driven by the results of the assessment and family interest. The assessment, feedback and motivation session, and follow-up support are repeated annually.
224100150|NCT06550076|DRUG|TAK-279|TAK-279 oral tablet
223535624|NCT02128087|BEHAVIORAL|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
223535625|NCT03290352|OTHER|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
223535626|NCT03248323|RADIATION|dyna-pbv|
223535627|NCT06453031|PROCEDURE|Gastric Ischemic Preconditioning Before Esophagectomy|Does embolization of the left gastric artery prior oesophagectomy reduce postoperative complications, particularly anastomotic leaks and ischemia of the gastric conduit?
223535628|NCT04946604|BEHAVIORAL|Ashtangayoga|This is an active and intense type of yoga, focused on physical activity and breath control
223535629|NCT06325787|PROCEDURE|thyroid lobectomy|thyroid lobectomy
223535630|NCT06325787|PROCEDURE|image-guided thermal ablation|radiofrequency ablation or microwave ablation or laser ablation
223535631|NCT01131052|DRUG|Insulin Glargine|glargine once a day
223535632|NCT01131052|DRUG|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
223535633|NCT01131052|DRUG|Insulin glulisine|glulisine given as needed before meals
223535634|NCT03609424|DRUG|PDR001, Imatinib|"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested"
223535635|NCT02404714|DEVICE|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
223535636|NCT02497105|OTHER|Ketogenic Diet|Dietary
223535637|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Sevoflurane|Sevoflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
224100151|NCT02555163|DEVICE|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
223535638|NCT05024084|PROCEDURE|Minimal flow anesthesia (fresh gas flow <0.5 l/min) using Desflurane|Desflurane will be used for the maintenance of general anesthesia which will be carried out using a fresh gas flow of less than 0,5 l/min
223535639|NCT06250764|DIAGNOSTIC_TEST|Clinical periodontal measuremenets|The periodontal assessment was performed by a single trained examiner (S.D.). A graded periodontal probe (Williams, Hu-Friedy, Chicago, IL, USA) was used to measure probing depth (PD) which was determined as the depth from the gingival margin to the bottom of the gingival sulcus/periodontal pocket, clinical attachment loss (CAL) which was calculated as the distance from the cemento-enamel junction to the bottom of the periodontal pocket and dual recording (+/-) of bleeding on probing (BOP), gingival index (GI) and plaque index (PI) in total except third molars G
223535640|NCT06250764|DIAGNOSTIC_TEST|ELISA test from gingival crevicular fluid (GCF)|GCF sampled from the buccal aspects of non-contiguous proximal regions in maxillary single-rooted teeth. In the periodontitis groups, fluid samples were taken from the two deepest pockets. In the gingivitis and periodontal healthy groups, fluid samples were obtained from areas with and without visible inflammation, respectively
223535641|NCT00969423|DEVICE|5mm videoscope|use of 5mm videoscope
223535642|NCT00969423|DEVICE|10mm videoscope|use of 10mm videoscope
223535643|NCT02867137|OTHER|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
223535644|NCT02271880|OTHER|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
223719943|NCT06820021|OTHER|Strength-based Tailored-Exercise Program at Home (STEP@Home)|The 20-week STEP@Home is a multi-component exercise training program designed to recondition the functional status of older adults in the post-discharge period and to develop long-term exercise engagement. The content is developed based on the recommendations from a scope review and the Vivifrail exercise guideline on home-based exercise for older adults , with expert input from the research team including geriatricians in frailty management, exercise physiologist, nursing academicians in aged care research. Three design characteristics, including an empowerment approach (Funnell \& Anderson, 2004), lifestyle-integrated functional exercises (Weber et al., 2018), and an optimized tele-platform, are incorporated into the exercise program to enhance such therapeutic benefit.
223945822|NCT00556478|DRUG|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
223945823|NCT00556478|DRUG|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
223719944|NCT06820021|OTHER|Usual Care|The control group will receive the usual post-discharge care provided in the hospital setting, including general education on medication, basic knowledge of disease-related self-care, and/or attending regular medical follow-ups in the specialist outpatient clinics. The RA will review the client's post-discharge planning and record social and healthcare service referral information. The RA will only make home visits for data collection, and the controls will receive a HK$100 supermarket coupon as an incentive, which will be applied to the intervention group.
223719945|NCT05795439|BEHAVIORAL|Low-fat, vegan diet|The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
223719946|NCT06596655|DEVICE|Single use bronchoscope|Use of single use bronchoscopes for interventional pulmonology procedures instead of reusable bronchoscopes.
223719947|NCT06827418|OTHER|simulation|Students will practice the psychomotor steps of blood pressure measurement using a simulator.
223945824|NCT02733484|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
223945825|NCT02733484|DIETARY_SUPPLEMENT|Placebo|the patients in this arm will receive placebo intervention
223945826|NCT01228500|DEVICE|PriMatrix|Dermal Repair Scaffold
223945827|NCT05022615|DIAGNOSTIC_TEST|Topcon Camera|Standard 7 field imaging
223945828|NCT05022615|DIAGNOSTIC_TEST|Optos Camera|Ultrawide field imaging
223945829|NCT05022615|DIAGNOSTIC_TEST|Clarus Camera|Ultrawide field imaging
223945830|NCT04987528|DIAGNOSTIC_TEST|Aminoterminal type III peptide of procollagen|Serial Measurement of PIIINP in serum and/or BAL
223945831|NCT04987528|DIAGNOSTIC_TEST|Lung computed tomography|Screening for the presence of reticulation or bronchiectasia within lung parenchyma
223945832|NCT05270460|DRUG|PCS12852|PCS12852 oral tablet administered once daily
223945833|NCT05270460|DRUG|Placebo|Placebo comparator oral tablet administered once daily
223945834|NCT00380250|DRUG|Lubiprostone|
223945835|NCT00380250|DRUG|Placebo|
223945836|NCT02765126|BIOLOGICAL|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
223945837|NCT02765126|BIOLOGICAL|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
223945838|NCT04913103|DRUG|Polatuzumab vedotin|treatment by a study drug polatuzumab-vedotin, i.v.
223945839|NCT04913103|DRUG|Bendamustine Hydrochloride|treatment by a study drug bendamustin i.v.
223945840|NCT04913103|DRUG|Rituximab|treatment by a study drug rituximab, i.v.
223945841|NCT01350167|PROCEDURE|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
223945842|NCT05972252|DEVICE|Cerebrovascular Interventional Procedural Control System|The Cerebrovascular Interventional Procedural Control System is intended for use in the remote delivery and manipulation of guidewires and rapid deliver stent catheters, and remote manipulation of guide catheters during cerebrovascular intervention procedures.
223945843|NCT03156738|DRUG|MT-2990|Subjects will receive a single IV dose of MT-2990
223945844|NCT03156738|DRUG|Placebo|Subjects will receive a single IV dose of placebo
223535645|NCT02271880|OTHER|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
223535646|NCT00966108|DEVICE|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
223535647|NCT03423511|DEVICE|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
223535648|NCT03423511|DEVICE|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
223945845|NCT04863365|DRUG|Placebo ophthalmic solution|A matching placebo ophthalmic solution, 3 drops daily, 28 days
223945846|NCT04863365|DRUG|PHP-201 ophthalmic solution|PHP-201 0.5% ophthalmic solution, 3 drops daily, 28 days
223719948|NCT06827418|OTHER|peer teaching|Students will practice the psychomotor steps of blood pressure measurement through peer teaching. Third- and fourth-year nursing students will serve as peer educators. Students will apply the skill steps under the guidance of an upper-class peer instructor.
223719949|NCT04779554|DRUG|Mitomycin C, flat dose 40 mg|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two flat doses. Dose 1 will be 30mg at minute 0 and dose 2 will be 10 mg at minute 60.
223719950|NCT04779554|DRUG|Mitomycin C, weight-based dose 12.5 mg/m2|Mitomycin C will be delivered as heated intraperitoneal chemotherapy (HIPEC) in two weight-based doses of 9 mg/m2 at minute 0 and 3 mg/m2 at minute 60.
223719951|NCT06992063|PROCEDURE|Spinal anesthesia|In both groups patients will undergo spinal anesthesia and be followed intra- and postoperatively in the context of postdural puncture headache
223719952|NCT07000630|DRUG|Deucravacitinib|25 subjects with palmoplantar pustulosis will be allocated to receive oral Deucravacitinib 6mg everyday for 16 weeks.
223719953|NCT06081036|OTHER|Questionnaire|Questionnaire about children development
223719954|NCT07001592|BIOLOGICAL|vvDD-hIL-2-RG-1|"A single dose of the investigational agent will be injected intratumorally at one of the following three dose levels.~Level 1: 3 x 108 p.f.u. Level 2: 1 x 109 p.f.u. Level 3: 3 x 109 p.f.u. p.f.u = Plaque-forming unit(s)~Dose will be escalated in cohorts of 3, according to a standard 3+3 design."
223719955|NCT07002190|OTHER|Watching an animation video|education
223719956|NCT07002177|DRUG|FWD1802|orally QD with 28 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
223945847|NCT05647642|DRUG|Precedex and dormicum|Premedication
223945848|NCT04029090|DRUG|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
223945849|NCT04029090|DRUG|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
223945850|NCT04029090|DRUG|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
223945851|NCT02157948|DRUG|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
223945852|NCT02157948|DRUG|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
223945853|NCT04942288|OTHER|The first group is acupressure and massage, the second group is massage|In the study, acupressure + massage will be applied to one group during 3 menstrual cycles and in the first 3 of the menstrual cycles, and only to the other group by the researcher in the experiment groups with dysmenorrhea.
223945854|NCT06097260|DRUG|PLN-74809|PLN-74809
223945855|NCT06097260|DRUG|Placebo|Placebo
223945856|NCT04803799|OTHER|Training Programme|Cognitive-motor dual task exercises corresponding to associations between different motor tasks and different cognitive tasks.
223945857|NCT04069416|PROCEDURE|living donor liver transplantation|liver graft from a living donor
223945858|NCT05254392|DEVICE|Digital BP monitor (Chidalex®)|Interventions were provided in groups of 4 - 10 participants after data collection at baseline while reinforcing individualized interventions were provided during subsequent visits to the research clinic for follow-up at 6 months and 12 months. Medication reminder text messages were delivered to each participant biweekly.
223945859|NCT03707899|DRUG|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
223945860|NCT03707899|DRUG|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
223945861|NCT03470805|DRUG|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
223945862|NCT01604824|DRUG|Alirocumab|SC injection in the abdomen
223945863|NCT01604824|DRUG|Placebo|SC injection in the abdomen
223945864|NCT04197791|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
223945865|NCT04197791|OTHER|Core Stabilization Exercises|Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.
223945866|NCT02073500|OTHER|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
223945867|NCT03938987|BIOLOGICAL|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
223945868|NCT04899999|BEHAVIORAL|Financial reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping leads to nothing. Don't let your money vaporize away.
223945869|NCT04899999|BEHAVIORAL|Health reward graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Dying for a vape? It hurts more than you know.
223945870|NCT04899999|BEHAVIORAL|Self-efficacy graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Vaping companies are targeting Black and Latino teens. Your life matters. Don't let them take it away.
223945871|NCT04899999|BEHAVIORAL|Social norms graphic message|Graphic image will be shared with the participants online once in either English or Spanish depending on their language of preference. Image includes the following text: Just because vaping is common, doesn't mean it's cool. Stay woke. Don't smoke.
223945872|NCT03816839|DRUG|Amcenestrant (SAR439859)|"Pharmaceutical form: Capsules~Route of administration: Oral"
223719957|NCT07002177|DRUG|Palbociclib 125mg|Dose: 125 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break (3-weeks-on/1-week-off), constituting a 28-day cycle
223719958|NCT07002177|DRUG|Ribociclib 200Mg Oral Tablet|Dose: 600 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break, constituting a 28-day cycle
223719959|NCT07002177|DRUG|Abemaciclib 150 MG|Dose: 150 mg Route: Orally Frequency: BID Schedule: Everyday
223719960|NCT07002177|DRUG|Everolimus 10 mg|Dose: 10 mg Route: Orally Frequency: QD Schedule: Everyday
223719961|NCT06547918|DEVICE|Omnipod 5 SA2.0 System|The Omnipod 5 SA2.0 System provides automated insulin delivery based on Continuous Glucose Monitoring (CGM) values.
223719962|NCT07131930|OTHER|Caregiver Burden, Psychological Resilience, Sleep Quality|Informal caregivers who provide daily care for bedridden patients are evaluated in this study. The exposure involves physical, emotional, and financial caregiving responsibilities such as assistance with feeding, mobility, and emotional support. The impact of caregiving on sleep quality and psychological resilience is assessed using validated questionnaires (Zarit Burden Interview, Pittsburgh Sleep Quality Index, Resilience Scale).
223945873|NCT00243867|DRUG|Taxoprexin|Administered by intravenous infusion over 1 hour infusion
223945874|NCT00243867|DRUG|Carboplatin|Administered by intravenous infusion over 30 minutes. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate (GFR) + 25).
223945875|NCT00243867|DRUG|Paclitaxel|Administered by intravenous infusion over 3 hour infusion
223945876|NCT04712539|DRUG|Baloxavir Marboxil|Given PO
223945877|NCT04712539|DRUG|Oseltamivir|Given PO
223945878|NCT05269394|DRUG|E2814|Administered intravenously in a blinded fashion
223535649|NCT02449525|PROCEDURE|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
223719963|NCT06246578|DEVICE|Continuos glucose monitoring and blood glucose measurement|The individuals who use Dexcom G 7 sensors for continous glucose monitoring is in addition applied a Libre 2 sensor and asked to wear both sensors for 14 days. In case of a Dexcom glucose value \< 5 mmol/l, the participants is aked to measure a blood glucose as well uising fingerprick and Contour Next One
223719964|NCT04710056|DRUG|REGN4461|
223719965|NCT04316676|DIAGNOSTIC_TEST|PET-MPI Protocol|Patients with suspected CAD who are referred to a clinical PET-MPI will undergo the standard clinical protocol applied in the Emory Nuclear Medicine department.
223535650|NCT05165706|BEHAVIORAL|Dietary Intervention Mediterranean Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a diet that is high in unsaturated fats and low in carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
223719966|NCT04316676|DIAGNOSTIC_TEST|CT-MPI|"For the CT-MPI, dynamic volume CT myocardial perfusion applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium. The dynamic shuttle mode consists of an image acquisition during rapid, yet smooth back-and-forth movement of the CT scanner table, so that contrast media bolus passage can be evaluated within the entire left ventricle in a time-resolved fashion. This scan acquisition will be performed during pharmacologically induced stress and during rest conditions. CT-MPI studies will be contrast medium enhanced by 50-70 ml of iodinated contrast agent, administered at a flow rate of 5 mL/s. The CT examinations are scheduled within 90 days of the standard clinical PET examination."
223719967|NCT04316676|DIAGNOSTIC_TEST|CT-FFR|Coronary CT angiography (CCTA) will be performed for delineation of the coronary arteries, detection of potential coronary stenosis and FFR calculation. CCTA will be performed at rest following administration of intravenous contrast agent (50-70 mL of iodinated contrast material at a flow rate of 4-5 mL/s). A total radiation dose of approximately 8 millisievert (mSv) has expected to be administered with the stress/rest protocol to the patient. The total amount of contrast agent will not exceed 140 ml. The CT examinations are scheduled within 90 days of the standard clinical PET examination.
223719968|NCT04316676|DRUG|Regadenoson|Pharmacological stress testing for the CT-MPI scan will be performed with a single injection of 0.4 mg of regadenoson (Lexiscan).
223719969|NCT03734055|BEHAVIORAL|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
223719970|NCT03734055|BEHAVIORAL|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
223719971|NCT06526052|BEHAVIORAL|Mindfulness Program|Online, coached mindfulness training program
223719972|NCT06526052|BEHAVIORAL|Active Comparator|Remote meetings with a supportive coach
223945879|NCT05269394|DRUG|Lecanemab|Administered intravenously
223945880|NCT05269394|DRUG|Matching Placebo (E2814)|Placebo administered intravenously in a blinded fashion.
223945881|NCT06384573|DRUG|lecanemab|Administered intravenously
223945882|NCT05283512|OTHER|Preventive treatment with IV-hydration|IV hydration with isotonic 0.9% NaCl
223945883|NCT05283512|OTHER|Preventive treatment with oral hydration|Oral hydration with regular bottled water
223945884|NCT06798701|OTHER|Best Practice|Undergo standard care
223945885|NCT06798701|OTHER|Interview|Ancillary studies
223945886|NCT06798701|OTHER|Survey Administration|Ancillary studies
223945887|NCT06798701|PROCEDURE|Virtual Reality|Use VR device
223945888|NCT03651973|OTHER|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
223945889|NCT03651973|OTHER|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
224100152|NCT02555163|DEVICE|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
224100153|NCT00340431|DRUG|MSP1(42)-FVO & MSP1(42)-3D7|
223535651|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Carbohydrate Diet|Assigned participants will receive instruction by a registered dietitian on a low carbohydrate diet that is high in fats found in the typical American diet. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
223945890|NCT06613087|OTHER|Foot bath|In the foot bath application, the feet will be kept in water at a constant temperature of 38-40 °C for about 20 minutes. During this time, the water temperature will be checked with a thermometer at intervals. Foot bath applications will be performed for 3 days, on the 2nd, 3rd and 4th days of hospitalization.
223945891|NCT05847998|DEVICE|Standardized measurement of capillary refill time by second generation DICART prototype|"Capillary refill time is measured by two independent operators, each one blinded from the other, with second generation DICART prototype.~Each operator performs two series of three consecutive measurement on the finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax"
223945892|NCT05847998|DIAGNOSTIC_TEST|Clinical measurement of capillary refill time|"Capillary refill time is clinically measured by two independent operators, each one blinded from the other.~Each operator performs, two series of three consecutive measurement on the second finger.~Then, an operator performs a train of three measurements on the knee, and the other operator on the thorax, inverted relative to DICART measurements."
223945893|NCT05835895|GENETIC|GNSC-001|intra-articular injection
223945894|NCT05835895|DRUG|transient immune-modulation|oral
223945895|NCT05835895|DRUG|transient immune-modulation|intra-articular injection
223945896|NCT05835895|DRUG|Placebo|intra-articular injection
223945897|NCT05507723|OTHER|Treat-to-target|Treatment to achieve urate target using supported self-management approach
223945898|NCT05507723|OTHER|Usual Care|Treatment escalation by GP based on usual clinical practice
223945899|NCT06281496|BEHAVIORAL|AlloCare|Survivorship supportive care
223945900|NCT05541965|OTHER|Reflexology and kegel exercises|"Reflexology is specific to a foot massage, and ıt can use different symptoms for patients.~Kegel exercise is specific an activities and ıt can used for urinary incontinence"
223719973|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
223945901|NCT00544115|DRUG|busulfan|
223945902|NCT00544115|DRUG|cyclophosphamide|
223945903|NCT00544115|DRUG|cyclosporine|
223945904|NCT00544115|DRUG|etoposide|
223945905|NCT00544115|DRUG|fludarabine phosphate|
223945906|NCT00544115|DRUG|melphalan|
223945907|NCT00544115|DRUG|methotrexate|
223945908|NCT00544115|DRUG|mycophenolate mofetil|
223945909|NCT00544115|DRUG|sirolimus|
223945910|NCT00544115|DRUG|tacrolimus|
223945911|NCT00544115|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223945912|NCT00544115|PROCEDURE|peripheral blood stem cell transplantation|
223945913|NCT00544115|RADIATION|total-body irradiation|
223945914|NCT06505122|BEHAVIORAL|Dyadic Life Review|DLR is an intervention that will promote relationship closeness, communication, and psychological distress in both older adults and caregivers.
223945915|NCT01638000|DRUG|Mirabegron|oral tablet
223945916|NCT01638000|DRUG|Solifenacin succinate|oral tablet
223945917|NCT04220021|DRUG|Metformin|Metformin is a widely used, well-tolerated drug that has been used for decades as a first-line defense for treating type 2 diabetes. Its safety has been well established. Subjects will begin treatment with Metformin at a dosage of 500mg with an escalation of dosage by 500mg every week to a maximal dosage of 2000mg. Dosing will be twice daily.
223945918|NCT03141060|DRUG|Delamanid|Administered orally; dosing will be based on participants' age and weight.
223945919|NCT03141060|DRUG|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
223945920|NCT06071468|DEVICE|UltraGuideCTR (Device) with Ultrasound Guided Carpal Tunnel Release (CTR-US)|The UltraGuideCTR is a commercially available medical device specifically developed to facilitate CTR-US. The device is a single-use, hand-held device that is inserted into the carpal tunnel through a small (typically \< 5 mm) wrist incision using continuous US guidance. The working tip of the UltraGuideCTR consists of two inflatable balloons that border a centrally located, retractable retrograde cutting knife. When inflated with sterile saline, the balloons increase the diameter of the tip from 4 mm to 8 mm. After the tip is positioned within the transverse safe zone of the carpal tunnel, the balloons are inflated to create space in the carpal tunnel, the blade is activated, and the TCL is transected in a retrograde manner. Following TCL transection, the blade is recessed, the balloons deflated, and the device is removed. The TCL is probed to ensure a complete release. The entire procedure is performed using US guidance.
223945921|NCT06071468|PROCEDURE|Endocscopic CTR|"Endoscopic CTR makes one or two short incisions to introduce instruments for visualizing. The key procedural steps involved in Endoscopic CTR are listed below.~1. Following the delivery of anesthesia, the surgeon makes a small wrist incision (usually less than 1.5 cm), with or without a small palmar incision (usually less than 1.5 cm, depending on whether they are using a single portal or double portal technique, respectively.~2. A series of dilators and raspers are used to create space in the carpal tunnel and clear synovial tissue from the undersurface fo the TCL.~3. A camera attached to a narrow tube (endoscope) is inserted into the carpal tunnel.~4. The transverse carpal ligament (which forms the roof of the carpal tunnel) is identified.~5. Using specialized cutting instruments and endoscopic guidance, the surgeon transects the TCL.~6. Endoscopic visualization and/or probing are used to confirm a complete release.~7. The wound(s) is/are typically closed with sutures."
223945922|NCT06071468|PROCEDURE|Open CTR|"OCTR is the most commonly used CTR technique in the United States.The key procedural steps involved in OCTR are listed below.~1. Following the delivery of anesthesia, an incision is made in the palm directly over the carpal tunnel.~2. The surgeon cuts through the palmar fascia to identify the TCL.~3. The surgeon transects the TCL with a scalpel and/or similar cutting instruments.~4. The surgeon inspects the carpal tunnel to ensure proper decompression.~5. The wound is closed with sutures."
223945923|NCT05253846|DRUG|Irinotecan|chemotherapy treatment
223945924|NCT05253846|DRUG|Oxaliplatin|chemotherapy treatment
223945925|NCT05253846|DRUG|Lederfolin|treatment
223945926|NCT05253846|DRUG|5-Fluorouracil|chemotherapy treatment
223719974|NCT06259175|DRUG|Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
223719975|NCT06259175|DRUG|Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg|a triple fixed combination of Amlodipine , indapamide and perindopril combinations, was in a 3-month in accordance to the instruction for medical use approved in the Russian Federation
223719976|NCT02821013|DRUG|Intermittent PD-1 inhibitor therapy|
223719977|NCT02821013|DRUG|Continuous PD-1 inhibitor therapy|
223719978|NCT03997110|RADIATION|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
223719979|NCT03997110|RADIATION|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
223719980|NCT06318871|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer (CIML NK) Cells|Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.
223719981|NCT06318871|DRUG|Interleukin-2 (IL-2)|Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
223719982|NCT05425745|DRUG|Obicetrapib|10 mg Obicetrapib tablet
223719983|NCT05425745|DRUG|Placebo|placebo tablet made to resemble active
223945927|NCT05253846|RADIATION|Short-course radiotherapy|RT
223945928|NCT05253846|PROCEDURE|TME|surgery
223945929|NCT06849596|DEVICE|Ventilator derived positive pressure ventilation - V-PPV|The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. Ventilator delivered positive pressure ventilation (V-PPV) using a nasal interface will be delivered to the infant in the resuscitation room.
223945930|NCT06849596|DEVICE|T-piece resuscitator (TPR)|The clinical team will determine the need for PPV, as per local practice and Neonatal Resuscitation Program. Each site will be previously randomized to their method of providing PPV for preterm neonates during the first 10 minutes after birth. PPV will be provided with a T-piece resuscitator (Neopuff, Fisher \& Paykel Healthcare) connected to an appropriately sized face-mask.
223945931|NCT06853054|PROCEDURE|Personalized patch template|The personalized, sterilizable patch template will be used as the surgeon's guide in fashioning the precise size and shape of the surgical patch.
223945932|NCT05465109|OTHER|TBI-AD/ADRD Caregiver Support Intervention (TACSI)|The TBI-AD/ADRD Caregiver Support Intervention (TACSI) incorporates psychosocial and psychoeducational approaches with the objective of: a) identifying stressors associated with caregiving for family members who have the dual diagnosis of traumatic brain injury and dementia; and b) supporting caregivers in developing more effective coping and communication strategies as well as enhanced caregiving self-efficacy. This intervention offers individual and family coaching and knowledge and skills to help manage stress and reduce caregiver burden.
223945933|NCT03954782|DRUG|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
223945934|NCT03954782|DRUG|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
223719984|NCT06463210|DEVICE|Virtual reality as a distraction technique|A 360º relaxing video with music was displayed through a VR headset
223719985|NCT01479673|DIETARY_SUPPLEMENT|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
223719986|NCT01002703|DRUG|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
223719987|NCT01974583|PROCEDURE|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
223719988|NCT01974583|PROCEDURE|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith \& Nephew)
223945935|NCT04783038|OTHER|Distance Reiki|Reiki therapy session performed remotely over a Zoom® video conferencing platform led by Reiki Practitioners who are also Health Care Providers at the Mayo Clinic, and have at least 6 months of experience in Reiki.
223945936|NCT04783038|OTHER|Sham distance Reiki|Session performed remotely over a Zoom® video conferencing platform led by a Health Care Provider employed at the Mayo Clinic, but will have no experience in Reiki and will not be a certified Reiki Practitioner.
223945937|NCT05599191|DRUG|BLU-5937|Oral administration of BLU-5937 Tablets
223719989|NCT01974583|PROCEDURE|covered with paraffin gauze|Group C covered with paraffin gauze
223719990|NCT02129725|DRUG|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
223945938|NCT05599191|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 Tablets
223719991|NCT02129725|DRUG|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
223719992|NCT00215332|DEVICE|CHARITE|Lumbar Total Disc Replacement
223945939|NCT06268015|DRUG|Botensilimab|75 mg IV every 6 weeks for up to 4 doses
223945940|NCT06268015|DRUG|Balstilimab|240 mg IV every 2 weeks
224100154|NCT00036335|DRUG|Duloxetine Hydrochloride|
223719993|NCT06376279|GENETIC|IEM-EP|Data from IEM-inborn error of metabolism cohort of individuals
223719994|NCT01941121|BEHAVIORAL|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
223719995|NCT02452489|DEVICE|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
223719996|NCT02452489|DEVICE|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
224100155|NCT04908995|DRUG|EC5026 oral tablet|"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."
223719997|NCT02452489|DEVICE|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
223719998|NCT05104320|PROCEDURE|MICS-CABG|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
223719999|NCT05104320|PROCEDURE|sternotomy CABG|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
223945941|NCT06268015|DRUG|Oxaliplatin|85 mg/m2 IV every 2 weeks
223720000|NCT02075710|OTHER|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
223720001|NCT02075710|OTHER|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
223720002|NCT02075710|OTHER|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
223720003|NCT02075710|OTHER|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
223720004|NCT02075710|OTHER|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
223720005|NCT02075710|OTHER|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
223720006|NCT02820753|BEHAVIORAL|EHR + (Text or Portal)|"Per protocol analysis:~Patients who received the initial 6 weeks of SMS messaging continuously, or logged on to the patient portal and completed at least one survey."
223720007|NCT05588232|PROCEDURE|scheduled outpatient interventions in interventional cardiology|coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
223720008|NCT01332474|DRUG|BOTOX|BOTOX
223720009|NCT02878746|DEVICE|Robotic mirror therapy|2-dimensional
223720010|NCT02878746|DEVICE|Conventional mirror therapy|2- and 3-dimensional
223720011|NCT02161731|DRUG|Evacetrapib|Oral administration
223720012|NCT02161731|DRUG|Warfarin|Oral administration
223720013|NCT05742594|DRUG|Lazertinib|Lazertinib will be administered orally.
223720014|NCT04884477|BIOLOGICAL|Convalescent Plasma|Convalescent Plasma
223945942|NCT06268015|DRUG|Leucovorin|400 mg/m2 IV every 2 weeks
223945943|NCT06268015|DRUG|Fluorouracil|400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
223945944|NCT06268015|DRUG|Bevacizumab|5 mg/kg IV every 2 weeks
223945945|NCT06268015|DRUG|Panitumumab|6 mg/kg IV every 2 weeks
224100156|NCT04908995|OTHER|Placebo oral tablet|"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."
224100157|NCT02547727|BIOLOGICAL|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
224100158|NCT01929083|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
224100159|NCT01929083|DRUG|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
224100160|NCT01929083|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
224100161|NCT02386774|DEVICE|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
224100162|NCT02386774|DEVICE|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine"
223535652|NCT05165706|BEHAVIORAL|Dietary Intervention Standard Low Fat Diet|Assigned participants will receive instruction by a registered dietitian on a low fat diet that is high in complex carbohydrates. Total caloric intake will be adjusted to induce a supervised metabolic challenge defined as weight gain of approximately 2.5 kg over 5 weeks followed by 3-5kg weight loss over 8 weeks.
223945946|NCT05403658|BEHAVIORAL|Family Navigation|FN will be delivered by navigators who will provide support and services that complement obesity management care provided by multidisciplinary teams at the study clinical sites. With advanced training in motivational interviewing and patient- / family-centered care, navigators will access a bundle of logistical and relational strategies to help families derive the greatest possible benefit from their care, which will include working to reduce barriers to care, improve access, and optimize treatment outcomes related to obesity management that is part of their Usual Care. Navigators will provide various resources/supports to study participants including, but not limited to, offering communication via text message, flexible navigator appointments, parking/transit passes, community-based resources, and liaising with members of the multidisciplinary clinical teams at each site.
223535653|NCT06249464|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
223535654|NCT06249464|DRUG|Lidocaine hydrochloride|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
223535655|NCT01402310|OTHER|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
223535656|NCT06048458|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance with stress perfusion|Cardiac MRI scan to assess changes in left ventricular function, parametric mapping, strain and myocardial blood flow. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
223535657|NCT06048458|DIAGNOSTIC_TEST|CT coronary angiography|CT coronary angiogram at baseline only in both cohorts to assess for coronary artery disease
223535658|NCT06048458|DIAGNOSTIC_TEST|Retinal OCT angiography|Retinal OCTa to assess changes in retinal vasculature. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
223535659|NCT06048458|DIAGNOSTIC_TEST|Sublingual microscopy (GlycoCheck)|To determine changes in sublingual microvascular health. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
223535660|NCT06048458|DIAGNOSTIC_TEST|Serum cardiac biomarkers (High sensitivity troponin, NT pro BNP)|Performed to assess for myocardial injury. In cohort 1 this will be performed pre, during and on completion of treatment. In cohort 2 this will be performed during the acute presentation and on completion of treatment.
223535661|NCT02345239|DRUG|Pantoprazole|proton pump inhibitor
223535662|NCT06547736|DRUG|SHR-A2102 or/and HRS-4642|"Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
223535663|NCT06547736|DRUG|SHR-A1904 or/and HRS-4642|"Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
223535664|NCT06547736|DRUG|SHR-A1811 or/and HRS-4642|"Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned."
223535665|NCT00738296|DRUG|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
223535666|NCT00738296|DRUG|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
223535667|NCT00738296|DRUG|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
223535668|NCT02431325|DRUG|Teduglutide|
223535669|NCT02431325|DRUG|Placebo|
223535670|NCT05206903|OTHER|Questionnaires|Questionnaires about pandemia process
223535671|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
223535672|NCT00727116|BEHAVIORAL|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
223535673|NCT04931238|DRUG|JS016|Single Intravenous Injection of JS016 with a dose of 50mg/kg
223945947|NCT05403658|BEHAVIORAL|Usual Care|Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
223945948|NCT06966401|DRUG|NBI-1065845|NBI-1065845 tablets
223945949|NCT05676346|GENETIC|LUTS|Patients included in this group are subjects with lower urinary tracto symptoms. An oral mucosa swab will be used to extract a genetic specimen
223945950|NCT02502461|PROCEDURE|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
223945951|NCT04376775|OTHER|Transplant patient|Surveys will be distributed via an email sent by transplant centres or patient's associations. A link to a secure survey platform will be given. A questionnaire will completed by patients. Patients, who agreed to fill the survey, will be offered the possibility to be contacted for a second survey over a 6 months period.
223945952|NCT03275961|BEHAVIORAL|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
223945953|NCT02089295|DRUG|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
223945954|NCT02089295|DRUG|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
223945955|NCT02089295|DRUG|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
223945956|NCT03156816|DRUG|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
223945957|NCT03156816|DRUG|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
223945958|NCT04784715|DRUG|Trastuzumab deruxtecan|Administered by intravenous infusion
223945959|NCT04784715|DRUG|Placebo|Administered by intravenous infusion
223945960|NCT04784715|DRUG|Taxane|Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion
223535674|NCT05157087|DRUG|Omalizumab|"Omalizumab use was analyzed in two categories. First, initiators were defined as individuals with ≥ 1 omalizumab prescription. Responders were defined as individuals with at least 4 administrations of omalizumab."
223535675|NCT02185300|DRUG|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
223535676|NCT02185300|DRUG|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
223945961|NCT04784715|DRUG|Pertuzumab|Administered by intravenous infusion
223535677|NCT02901886|BEHAVIORAL|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
223535678|NCT06041321|DEVICE|Reparel Sleeve|For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.
223945962|NCT04784715|DRUG|Trastuzumab|Administered by intravenous infusion
223535679|NCT06041321|DEVICE|Placebo Sleeve|Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
223535680|NCT01641484|PROCEDURE|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
223535681|NCT03857776|OTHER|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
223535682|NCT03857776|OTHER|Standard care|Standard care including referral to a homepage about CAM
223535683|NCT02045602|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
223535684|NCT02045602|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
223535685|NCT02045602|DRUG|Abraxane®|125 mg/m2 intravenous administration
223535686|NCT01818687|DRUG|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
223535687|NCT00049361|DRUG|temozolomide|
223535688|NCT00049361|DRUG|thalidomide|
223535689|NCT00049361|RADIATION|radiation therapy|
223535690|NCT05524831|OTHER|KINESIOTAPE|kinesiotape will be applied on orbicularis oris muscle
223535691|NCT05524831|OTHER|oromotor training|selected oromotor training: Perioral sensory stimulation ,Tapping,Tongue pressure,Jaw exercises andIntraoral stimulation
223535692|NCT05185076|DEVICE|CureSight|watch CureSight treatment for 90 minutes per day, 5 days a week for 16 weeks
223535693|NCT00744861|DEVICE|Exospine sham|Inactive Exospine LIPUS device (dual transducers)
223535694|NCT00744861|DEVICE|Exospine|Active Exospine LIPUS device (dual transducers)
223535695|NCT00744861|DEVICE|Exogen 4000+|Active Exogen LIPUS device (single transducer)
223535696|NCT00744861|DEVICE|Exogen 4000+ sham|Inactive Exogen 4000+ LIPUS device (single transducer)
223535697|NCT01885988|DRUG|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
223535698|NCT01885988|DRUG|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
223535699|NCT02353962|OTHER|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
223720015|NCT05755048|BIOLOGICAL|Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.
223720016|NCT05755048|BIOLOGICAL|Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)|Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
223720017|NCT03935100|PROCEDURE|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
223720018|NCT03935100|OTHER|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
223720019|NCT04489680|OTHER|Educational|Teaching session
223720020|NCT03006497|OTHER|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
223720021|NCT02287272|DRUG|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
223720022|NCT02287272|DRUG|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
223720023|NCT01513161|DRUG|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
223720024|NCT01513161|DRUG|Placebo|
223720025|NCT00090480|BIOLOGICAL|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
223720026|NCT00059982|DRUG|perifosine|
223720027|NCT02716454|PROCEDURE|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
223945963|NCT00741546|PROCEDURE|Cardiac Surgery|Cardiac Surgery
223945964|NCT06623669|BEHAVIORAL|MORPH|A remote behavioral intervention combining coaching and digital health tools to improve diet and activity behaviors.
223945965|NCT06623669|BEHAVIORAL|Measurement Only|This intervention entails receipt of a body weight scale and wearable activity monitor.
223945966|NCT04587648|OTHER|NA, observational study|NA, observational study
223945967|NCT03185052|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
223945968|NCT00527267|DRUG|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
223945969|NCT00527267|DRUG|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
223945970|NCT02674841|OTHER|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
223535700|NCT05201651|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
223945971|NCT02674841|OTHER|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
223945972|NCT02674841|OTHER|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
223720028|NCT04822454|OTHER|Night shift shadowing program|Our population, made up of 70 students, was divided into two randomly randomized groups: 31 (44.3%) had five night shift shadowing duty prior to their first official night shifts, and 39 (55.7%) did not participate in the shadowing program.
223720029|NCT03880071|BEHAVIORAL|DBT+ACT|\- The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
223945973|NCT02499328|DRUG|AZD9150|AZD9150
223945974|NCT02499328|DRUG|MEDI4736|MEDI4736
223945975|NCT02499328|DRUG|AZD5069|AZD5069
223720030|NCT03880071|BEHAVIORAL|DBT|"The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)"
223720031|NCT01053884|DRUG|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC \> 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
223720032|NCT04201002|PROCEDURE|Resection plus intraoperative radiotherapy|En-bloc resection plus intraoperative radiotherapy
223945976|NCT02499328|DRUG|tremelimumab (treme)|tremelimumab
223720033|NCT05708287|DEVICE|HFNC|The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation \>90%, were commenced on HFNC therapy
223945977|NCT04847375|DRUG|exogenous surfactant|Nebulized Surfactant would be administered by face mask which has a nebulizer
223945978|NCT04603508|DRUG|BERLIM 25/10 association|Berlim 25/10 association coated tablet.
223945979|NCT04603508|DRUG|EMPAGLIFLOZIN|Empagliflozin 25 mg coated tablet.
223945980|NCT04603508|DRUG|ROSUVASTATIN CALCIUM|Rosuvastatin 10 mg coated tablet.
223945981|NCT04603508|OTHER|BERLIM 25/10 ASSOCIATION PLACEBO|Berlim 25/10 association placebo coated tablet.
223535701|NCT05201651|DIETARY_SUPPLEMENT|Maltodextrin Placebo|Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
223535702|NCT01252615|BEHAVIORAL|patient only|education, behavioral strategies, psychological interventions
223535703|NCT01252615|BEHAVIORAL|patient and partner intervention|education, psychological support, behavioral strategies
223535704|NCT03212352|DRUG|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
223535705|NCT03212352|DRUG|Misoprostol|Regular treatment with Misoprostol 800 mcg.
223535706|NCT01385592|DRUG|AFQ056|
223535707|NCT01385592|DRUG|Placebo|
223535708|NCT02746302|DRUG|HS-20004|
223535709|NCT02746302|DRUG|Placebo|
223535710|NCT06263036|OTHER|Men|Laryngeal cartilages
223535711|NCT06263036|OTHER|Women|Laryngeal cartilages
223535712|NCT03103854|BEHAVIORAL|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
223535713|NCT03103854|BEHAVIORAL|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
223535714|NCT03103854|BEHAVIORAL|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
223535715|NCT04653974|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-11 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 70 patients were evaluated in accordance with the exclusion criteria and 56 children (31 girls and 25 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the Wong-Baker Pain Scale at three time points: immediately after injection (Pain 1), during treatment (Pain 2), and at the end of the treatment (Pain 3)."
223535716|NCT02126163|BEHAVIORAL|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
223535717|NCT03736148|OTHER|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
223535718|NCT03736148|OTHER|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
223535719|NCT03736148|OTHER|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
223535720|NCT04763434|DRUG|dexamethasone; dexmedetomidine; ropivacaine|Ultrasound-guided multilevelTPVB is performed at the end of lobectomy
223535721|NCT03939585|BIOLOGICAL|Cellular therapy product|"Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.~* Infused using venous catheter on post-transplant Day 28 (+ 7 days).~* Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized)."
223720034|NCT01975753|DRUG|Morphine|
223720035|NCT01975753|DRUG|Fentanyl|
223945982|NCT04603508|OTHER|EMPAGLIFLOZIN PLACEBO|Empagliflozin placebo coated tablet.
223945983|NCT04603508|OTHER|ROSUVASTATIN CALCIUM PLACEBO|Rosuvastatin placebo coated tablet.
223945984|NCT03350698|BIOLOGICAL|Gardasil-9|3 vaccine series
223720036|NCT03761277|DEVICE|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
223945985|NCT05631808|OTHER|Epicardial adipose tissue volume and attenuation|Epicardial adipose tissue volume and attenuation assessed by CT are the exposure factors in this study.
223945986|NCT02036177|DEVICE|SCu300A IUB intrauterine device|Spherical copper IUD
223945987|NCT02036177|DEVICE|T380A IUD|T-shaped copper IUD
223945988|NCT05328570|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Subjects will complete an Oral Glucose Tolerance Test in which glucose is given and blood samples are taken every 15 minutes over a 2 hour period to determine how quickly the glucose is cleared from the blood.
223945989|NCT04740580|DIETARY_SUPPLEMENT|Glycine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
223945990|NCT04740580|DIETARY_SUPPLEMENT|N-acetylcysteine|The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)
223945991|NCT04740580|DIETARY_SUPPLEMENT|Alanine|The placebo arm will supplement Alanine
223945992|NCT06980090|BEHAVIORAL|Session A: Positive Placebo + Active tTIS|Participants receive active tTIS, with two signals set at 2000 Hz and 2080 Hz, creating an 80 Hz interference beat targeting the anterior/mid-cingulate cortex (aMCC). Stimulation is delivered at 2 mA for 20 minutes. The stimulation is combined with a positive social placebo intervention delivered by the care provider. Participants complete three multimodal negative affect tasks (MNAT) before and after the stimulation.
223945993|NCT06980090|BEHAVIORAL|Session B: Positive Placebo + Sham tTIS|Participants receive sham tTIS, using two identical 2000 Hz signals that produce no low-frequency interference. The device mimics active parameters (2 mA, 20 minutes) without delivering effective stimulation. The sham stimulation is paired with a positive social placebo intervention. Participants complete three MNAT tasks before and after the session.
224100163|NCT02386774|PROCEDURE|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
224100164|NCT04390685|DRUG|Tacrolimus ointment|Treatment with tacrolimus ointment once daily for one year following axillary lymph node dissection
224100165|NCT00250393|DRUG|Istradefylline (KW-6002)|
224100166|NCT01057277|DRUG|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
224100167|NCT04258618|BEHAVIORAL|CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS|Cognitive Behavioral Therapy for insomnia (CBT-I) with rTMS (repetitive Transcranial Magnetic Stimulation) will be performed as part of this study by the PI. This includes weekly, one hour sessions addressing sleep for 6 weeks.
223535722|NCT06043336|DRUG|Dexamethasone, granisetron & palonosetron|. Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
223535723|NCT02957630|DRUG|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
223535724|NCT02957630|DRUG|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
223535725|NCT02957630|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
223535726|NCT04524988|PROCEDURE|Laparoscopic Simulation Training|All participants underwent 2.5h of training with one of two laparoscopic simulation trainers (FLS or EMIG).
223535727|NCT01361659|PROCEDURE|shockwave treatment|9 treatments in 3 months
223535728|NCT05047042|BEHAVIORAL|Advanced Cancer Support in Virtual Rehabilitation and Exercise|The study intervention will consist of an individualized 8-week program of online exercise modules, supervised interactive group class and one-to-one consultations with an exercise or rehabilitation specialist and a pain and symptom physician, delivered via secure live Zoom sessions.
223535729|NCT02099396|DRUG|Docetaxel+lobaplatin|
223535730|NCT02099396|DRUG|Gemcitabine+lobaplatin|
223535731|NCT00198471|DRUG|Vitrase|
223535732|NCT00219089|DRUG|aliskiren|
223535733|NCT00089622|DRUG|Intravenous Levodopa|
223535734|NCT00089622|DRUG|Lisuride Transdermal System|
223535735|NCT04741906|PROCEDURE|Dental implant surgery|Dental surgery in patients treated with antiresorptive medication
223535736|NCT04741906|PROCEDURE|Prosthetic treatment|Prosthetic treatment and loading of the dental implants
223535737|NCT02149459|RADIATION|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
223535738|NCT02149459|DRUG|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
223535739|NCT02149459|BEHAVIORAL|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
223535740|NCT05483959|OTHER|BIPAP mode/SIMV PC mode|BIPAP is a mode of ventilation recently used in ARDS
223535741|NCT03847584|OTHER|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
223535742|NCT02307630|BIOLOGICAL|124I-Humanized 3F8|
223535743|NCT05551468|BEHAVIORAL|StayFine guided app-based personalised intervention modules|Participants work on guided app-based personalised intervention modules in the StayFine app over the course of three months. The modules are selected by the participant based on shared decision making and a personalized advice. The intervention is based on Preventive Cognitive Therapy (PCT) with elements of Cognitive Behavioral Therapy (CBT) and Positive Psychology. Modules are: psycho education (mandatory), cognitive restructuring (mandatory), positive affect, behavioral activation, exposure, wellness, sleep and a relapse prevention plan (mandatory).
223535744|NCT05551468|BEHAVIORAL|StayFine app-based monitoring|Monitoring six times per day for two weeks in the StayFine app.
223535745|NCT00181844|DRUG|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children \<12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
223535746|NCT05855018|DRUG|Atropine sulfate eye drops|One drop once daily
223535747|NCT04416113|PROCEDURE|photobiomodulation and photodynamic therapy|antiviral treatment
223720037|NCT03761277|DRUG|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
223720038|NCT05123768|DIAGNOSTIC_TEST|NGS|A genetic panel of more than 100 genes, associated with CP spectrum disorders, will be assessed using NGS
223945994|NCT06980090|BEHAVIORAL|Session C: Negative Placebo + Active tTIS|Participants receive active tTIS (2000 Hz and 2080 Hz signals, 2 mA, 20 minutes) combined with a negative social placebo intervention (neutral or skeptical messaging about treatment efficacy). Participants complete three MNAT tasks before and after the stimulation.
223945995|NCT06980090|BEHAVIORAL|Session D: Negative Placebo + Sham tTIS|Participants receive sham tTIS (identical 2000 Hz signals, mimicking active stimulation) combined with a negative social placebo intervention. Participants complete three MNAT tasks before and after the session.
223945996|NCT06980090|BEHAVIORAL|Session E: On-Placebo + Sham tTIS|Participants receive sham tTIS (brief 15-second stimulation followed by no current) paired with a positive social placebo intervention. Participants complete three MNAT tasks before and after the session.
223945997|NCT06980090|BEHAVIORAL|Session F: Off-Placebo + Sham tTIS|Participants receive sham tTIS (brief 15-second stimulation, then no current) without any placebo intervention. Participants complete three MNAT tasks before and after the session.
223535748|NCT00678730|DRUG|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
223535749|NCT04507906|DRUG|Nivolumab Combined with Anlotinib|In combination dose finding phase, Phase 1b will begin with Dose Level 1; anlotinib 12 mg/day orally (from days 1 to 14 in a 21-day cycle) and nivolumab (360mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (anlotinib 10 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously) and Dose Level 3 (anlotinib 8 mg/day orally, from days 1 to 14 in a 21-day cycle) and nivolumab 360mg q3w, intravenously).If RP2D was reached in Part A, eligible patients would be enrolled and receive nivolumab (360mg q3w, intravenously) plus anlotinib (RP2D, QD from day 1 to 14 of a 21-day cycle) .
223535750|NCT03763734|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
223535751|NCT06211712|DRUG|Experimental: Human Urinary Kallidinogenase|Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
223535752|NCT06211712|DRUG|Placebo Comparator: Placebo|Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
223535753|NCT04513808|DRUG|Propofol-based total intravenous anesthesia|Propofol-based total intravenous anesthesia, titrated to clinical need.
223535754|NCT04513808|DRUG|Sevoflurane intravenous anesthesia|Sevoflurane intravenous anesthesia, titrated to clinical need.
223535755|NCT04802603|RADIATION|Spine stereotactic body radiotherapy|"Cohort 1 - De novo: Spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions.~Cohort 2 - Prior radiotherapy: Risk-adapted spinal cord tolerance based on prior spine stereotactic body radiotherapy to a dose of 40 Gy in 5 fractions."
223535756|NCT05592548|DEVICE|cold atmospheric plasma|Cold atmospheric plasma will be generated on the skin surface using an electric device
223535757|NCT06012851|BEHAVIORAL|Mobile behavioral parent training (mBPT)|The mobile phone application includes behavioral parent training content (for example, praise, effective commands, reward systems) delivered in videos, examples, and quizzes that parents/caregivers access.
223535758|NCT06012851|BEHAVIORAL|In the moment feedback|In-the-moment feedback will include parenting feedback.
223535759|NCT06012851|BEHAVIORAL|In the moment suggestions|In-the-moment feedback will include suggestions for parenting strategies.
223535760|NCT05023460|DEVICE|Paresthesia-free (burst) ONS|Stimulation intensity target of 60% of paresthesia threshold.
223535761|NCT05023460|DEVICE|Placebo|ONS system deactivated
223535762|NCT03407768|BEHAVIORAL|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
223535763|NCT04678258|PROCEDURE|HR electroanatomic mapping and MVG catheter ablation|High resolution CTI mapping using the mini-electrodes at the 8 mm catheter tip followed by voltage guided ablation
223535764|NCT04678258|PROCEDURE|Conventional bipolar mapping and linear catheter ablation|Bipolar mapping and conventional anatomic linear catheter ablation
223535765|NCT05162586|DRUG|Enpatoran low dose|Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
223535766|NCT05162586|DRUG|Enpatoran medium dose|Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
223535767|NCT05162586|DRUG|Enpatoran high dose|Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
223535768|NCT05162586|DRUG|Placebo|Participants will receive placebo matched to Enpatoran up to 24 weeks.
223535769|NCT05373472|BIOLOGICAL|COVID-19 mRNA vaccine|2 doses of vaccine on Day 0 and Day 21
223535770|NCT05373472|BIOLOGICAL|Placebo|2 doses of placebo on Day 0 and Day 21
223535771|NCT04815564|DEVICE|Invisalign|Invisalign clear aligner system
223535772|NCT06637657|OTHER|No intervention (observational study)|No intervention, only guideline implementation (observational study)
223535773|NCT04661033|DRUG|Isatuximab SAR650984|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
223535774|NCT05943262|DEVICE|mesoscale nonlinear optical microscope|The mesoscale nonlinear optical microscope based on the principles of nonlinear optics and computed-algorithms can acquire large-area image within few minutes.
223535775|NCT02603757|DIETARY_SUPPLEMENT|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
223535776|NCT06165991|DRUG|Liposomal bupivacaine, Bupivacaine|"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"
223720039|NCT01525537|DRUG|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
223720040|NCT01525537|DRUG|sufentanil|sufentanil was given at standard practise
223720041|NCT04153240|DEVICE|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
223945998|NCT06602089|DEVICE|Arterial pressure monitoring|We will record intraarterial arterial pressure, finger-sensor arterial pressure and oscillometric arterial pressure in all included patients.
223945999|NCT05563181|BEHAVIORAL|Control bar code label|Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages
223720042|NCT02177305|DRUG|0.02 mcg tiotropium solution|
223720043|NCT02177305|DRUG|0.04 mcg tiotropium solution|
223720044|NCT02177305|DRUG|0.08 mcg tiotropium solution|
223720045|NCT02177305|DRUG|0.16 mcg tiotropium solution|
223720046|NCT02177305|DRUG|0.28 mcg tiotropium solution|
223720047|NCT02177305|DRUG|0.40 mcg tiotropium solution|
223720048|NCT02177305|DRUG|Placebo solution|
223720049|NCT03591198|BEHAVIORAL|Qigong Training|Eight-Section Brocades
223720050|NCT03591198|BEHAVIORAL|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
223720051|NCT01118702|DRUG|Ritalin-SR|3-20mg tablets, once
223720052|NCT01118702|DRUG|Concerta|one 54mg tablet, once
223946000|NCT05563181|BEHAVIORAL|Warning label|"Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages"
223720053|NCT01118702|DRUG|Novo-Methylphenidate ER-C|one 54mg tablet, once
223720054|NCT05770791|DIETARY_SUPPLEMENT|Black Seed ( Nigella Sativa)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
223946001|NCT05563181|BEHAVIORAL|Informational campaign poster about added-sugar warning labels|Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
223720055|NCT05770791|DIETARY_SUPPLEMENT|Cumin Seed (Cuminum Cyminum)|Intervention will be given once a day for 1 month, total 30 days Data will be collected at baseline and at the end of the intervention at 30th day
223720056|NCT02254993|DRUG|C16G2|antimicrobial peptide
223720057|NCT05604092|DIAGNOSTIC_TEST|VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)|VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.
223720058|NCT05604092|OTHER|Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)|It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR
223720059|NCT01331915|BIOLOGICAL|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
223720060|NCT01896544|DIETARY_SUPPLEMENT|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
223720061|NCT01896544|DIETARY_SUPPLEMENT|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
223946002|NCT04961762|OTHER|Navigator Program|The main role of the Homeless Outreach Counsellor is to support continuity and comprehensiveness of care by helping participants follow their post-discharge plans and facilitating strong links with community-based health and social services. The Homeless Outreach Counsellor also helps address specific needs of participants, develop comprehensive care plans with members of patient's multidisciplinary circle of care, and facilitate the transition of clients to long-term community-based health and social services.
223946003|NCT06825715|OTHER|Multilevel intervention|3 components: patient education video, provider audit/feedback, and EMR ordering change
223946004|NCT06214923|DEVICE|RelieVRx|Participants will use RelieVRx daily for 20min/day for 3 weeks
223946005|NCT06214923|DEVICE|Sham-VR|"Participants will use Sham-VR, consisting of video, images, and sound in a head-mounted display but lack the sense of presence and immersive features of Active-VR (for example, scene changes with head movement). Participants will use the Sham-VR daily for 20min/day for 3 weeks"
223946006|NCT06214923|OTHER|No-VR (natural history control)|Participants will continue regular/usual care without any VR devices (goggles or audiovisual input)
223946007|NCT04984213|DEVICE|Karma Posterior Fixation Device|Posterior Fixation
224100168|NCT04258618|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants in this study will be undergoing repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder as part of their clinical treatment. This involves magnetic stimulation with specific settings to a specific region of the brain to help treat depression. Treatment time ranges, but is around 30 minutes per session and occurs 5 days a week for 6 weeks.
224100169|NCT05283993|OTHER|No intervention|No intervention
223720062|NCT04044235|BEHAVIORAL|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
223535777|NCT06246305|OTHER|conventional physical therapy training|conventional therapy rehabilitation program is divided into three phases: on-brace, off-brace, and active mobilization. The on-brace phase (post-op 0-6 weeks) mainly consists of low-intensity whole-body exercises with shoulder girdle, elbow, and hand mobilization exercises on the affected side. The off-brace phase (post-op 6-9 weeks) consists of passive shoulder ROM exercises using an exercise stick and an early scapular stabilization exercise. The active mobilization phase (post-op 9-12 weeks) consists of both active and passive shoulder ROM , strengthening exercise with progressive resistance, and scapular stabilization exercises. The intervention is done 3 times per week for 12 weeks.
223720063|NCT03062683|OTHER|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
223720064|NCT06959472|BEHAVIORAL|Hyperarch Fascia Training|A 12-week behavioral intervention involving Hyperarch Fascia Training (HFT), which includes one weekly 1-hour virtual session with a certified coach and two 1-hour independent training sessions. The protocol combines meditation, mental imagery, foot and toe strengthening exercises, myofascial rolling, balance drills, and low-impact plyometrics.
223720065|NCT03425123|OTHER|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
223535778|NCT06246305|DEVICE|Virtual Reality (VR) training|During the on-brace phase (0-6 weeks), participants in this group will use the program as performed in the control group. During the off-brace (6-9 weeks post-op) and active mobilization phases (9-12 weeks post-op), participants will use the Virtual Reality machine. this program involves warming up and down stretching exercises and exercise training that includes bilateral shoulder elevation, boxing, bowling and tennis games accompanied by avatar. The intervention is done 3 times per week for 12 weeks.
223720066|NCT01823523|DRUG|Cefazolin, Cephalexin, Clindamycin|
223720067|NCT00429273|DRUG|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
223720068|NCT00429273|DRUG|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
223720069|NCT02618889|BEHAVIORAL|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
223720070|NCT04165434|OTHER|Concurrent Training|Strength training and interval aerobic training in the same training session
223535779|NCT04064905|BIOLOGICAL|mRNA-1893|Zika vaccine
223535780|NCT04064905|OTHER|Placebo|0.9% sodium chloride
223535781|NCT06505226|BEHAVIORAL|in person meditation|in person guided meditation
223535782|NCT06505226|BEHAVIORAL|in person meditation using headphones|in person meditation using headphones
223535783|NCT06505226|BEHAVIORAL|virtual meditation|virtually guided meditation via Zoom
223535784|NCT06274957|OTHER|CONTROL|Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education
223720071|NCT06628791|DIETARY_SUPPLEMENT|BK329|Lactococcus lactics. subsp. lactis CAB701(KCCM13360P) 400 mg/day for 12 weeks
223720072|NCT06628791|DIETARY_SUPPLEMENT|Placebo|Placebo 400 mg/day for 12 weeks
223720073|NCT00374790|DRUG|Ferrous sulfate|
223720074|NCT01438957|DRUG|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
223720075|NCT01438957|DRUG|Placebo|
223720076|NCT01186679|PROCEDURE|laminectomy|surgical laminectomy with glial scar resection
223720077|NCT01186679|PROCEDURE|Intrathecal|direct into the CSF through lumbar puncture
223720078|NCT02760199|DRUG|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
223720079|NCT02760199|DEVICE|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
223720080|NCT03095014|PROCEDURE|Cesarean Myomectomy|Myomectomy was done during Cesarean section
223720081|NCT03095014|PROCEDURE|Cesarean section|Cesarean delivery
223720082|NCT01682057|DEVICE|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
223720083|NCT01682057|DEVICE|ROX Anastomotic Coupler System (ACS)|
223720084|NCT02115789|BEHAVIORAL|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
223720085|NCT06055647|GENETIC|immunohistochemical approach|Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
223720086|NCT02854735|OTHER|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
223720087|NCT01506167|DRUG|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
223720088|NCT01506167|DRUG|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
223720089|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
223720090|NCT01506167|DRUG|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
223720091|NCT01506167|DRUG|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
223720092|NCT01506167|DRUG|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
223720093|NCT05240053|OTHER|enhanced recovery programe|Early postoperative analgesia , early oral intake , early mobilization , early removal of nasogastric tube \& drains if any. The patients in this group started clear fluid once they awaked from anesthesia , a full liquid diet on first postoperative day , normal diet on second day provided that there was no vomiting or abdominal distension. The patients in this group were instructed for early ambulation \& encouraged to stay out of the bed for 4 hours on first day postoperative , 6 hours in following day , 8 hours on subsequent days. Also they were encouraged to walk the length of 3 meters once on first day postoperative , twice on day 2 \& three times on subsequent days. Regarding analgesia in this group postoperatively , they were received fentanyl via an epidural catheter.
223720094|NCT02603614|DRUG|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
223720095|NCT02603614|DRUG|Placebo|Placebo control
223720096|NCT01793675|PROCEDURE|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
223720097|NCT04897932|DEVICE|RS - WP06|Ad hoc use of handheld urinal
223946008|NCT04602728|BEHAVIORAL|Back2Life|The Back2Life intervention uses an adaptive treatment approach with module-based treatment sessions selected on the basis of baseline assessment (rather than a fixed treatment approach) to allow flexibility in tailoring treatment components to meet individual family needs. All youth participants will receive the standard 6-session pain coping skills training program, consisting of learning ways to cope with and manage chronic sickle cell pain. The standard program includes topics that were identified by young people with chronic sickle cell pain and their parents as important skills for all youth with chronic pain and sickle cell disease. In addition to the standard 6-session program, youth participants may receive an additional 1 to 4 sessions that may help with specific problems and/or co-morbidities related to pain. At least one parent or guardian is required to attend the sessions with their child.
223946009|NCT07012486|DRUG|Oral DHA + Topical minoxidil 5%|DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
224100170|NCT01357213|DRUG|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
224100171|NCT01357213|OTHER|Placebo|Normal saline 100 ml
223720098|NCT00398892|DRUG|Lipoic acid|Lipoic acid capsules
223720099|NCT02150096|OTHER|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
223720100|NCT02150096|OTHER|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
223720101|NCT02150096|OTHER|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
223720102|NCT01074866|DEVICE|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
224100172|NCT02436109|DEVICE|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
223720103|NCT04561661|PROCEDURE|Percutaneous pinning|Closed reduction, percutaneous pinning and plaster
223720104|NCT04561661|PROCEDURE|Conservative treatment|Closed reduction, custom made orthosis and early mobilization
223720105|NCT03513731|DEVICE|Adipose-derived stem cell injection|ADRC injection into the facet joint
223720106|NCT03513731|DRUG|Corticosteroid injection|Corticosteroid injection into the facet joint
223720107|NCT04404374|PROCEDURE|A-PRF/EMD|Comparing healing effect of an autologous and a xenogenic product
223720108|NCT03323112|BIOLOGICAL|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
223720109|NCT03052725|DRUG|reslizumab|Reslizumab was provided in a pre-filled syringe.
223720110|NCT00314093|DRUG|RFT5pdgA|
224100173|NCT03698734|DRUG|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
224100174|NCT03698734|DRUG|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
224100175|NCT00087438|RADIATION|stereotactic body radiation therapy|
223946010|NCT07012486|DRUG|Topical Minoxidil 5%|Topical minoxidil 5% daily for 180 days
223946011|NCT03365622|DRUG|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
223946012|NCT03365622|DRUG|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
224100176|NCT03766243|BEHAVIORAL|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
223535785|NCT06274957|DEVICE|PEP DEVICE|"Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~PEP training was applied using the Acapella device.~In addition, participants were subjected to two sessions of 10 minutes each with the Acapella device. In the study, the Acapella device, capable of sustaining expiratory flow of at least 15 L/min for 3 seconds, was activated by taking a deep breath, holding the breath for 2-3 seconds, and then exhaling into the device."
224100177|NCT03766243|BEHAVIORAL|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
224100178|NCT00466505|BIOLOGICAL|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
223720111|NCT03809117|DIAGNOSTIC_TEST|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
223720112|NCT05921305|DRUG|MTX|MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR
223720113|NCT05921305|DRUG|Corticosteroid|Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).
223720114|NCT06378255|DEVICE|Polycation-based new dentinal desensitizer|Dental desensitization treatment
223720115|NCT06378255|DEVICE|GLUMA desensitizer|Dental desensitization treatment
223720116|NCT00289965|BEHAVIORAL|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
223720117|NCT00289965|BEHAVIORAL|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
223720118|NCT00289965|BEHAVIORAL|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
223720119|NCT01448486|DRUG|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
223720120|NCT00934830|DRUG|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
223720121|NCT00934830|OTHER|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
223720122|NCT00415662|DEVICE|Pulsed Signal Therapy (PST)|
223720123|NCT04277416|DEVICE|Total Hip Arthroplasty|To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
223720124|NCT03047694|OTHER|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
223720125|NCT03047694|OTHER|usual care|speech therapy
223729445|NCT03454581|PROCEDURE|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
223946013|NCT03365622|DRUG|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
223946014|NCT03365622|DRUG|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
223946015|NCT07038694|OTHER|Qualitative semi structured interview|60 minute, virtually performed via Microsoft Teams, semi-structured interview
223946016|NCT07038382|DRUG|HLX79 10mg/kg/Placebo+HLX01|Subjects with MN will receive HLX79 10mg/kg or placebo, combine with HLX01 375 mg/m2
223720126|NCT03294902|DEVICE|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
223720127|NCT03192111|DRUG|Entinostat|HDAC (histone deacetylase) inhibitor
223946017|NCT07038382|DRUG|HLX79 20mg/kg/Placebo + HLX01|Subjects with MN will receive HLX79 20mg/kg or placebo combined with HLX01 375 mg/m2
223946018|NCT07038382|DRUG|HLX79 30mg/kg/placebo+HLX01|Subjects with MN will receive HLX79 30mg/kg or placebo combined with HLX01 375 mg/m2
223946019|NCT07035548|OTHER|Educative: Peer-learning|Peer learning, also known as peer-to-peer learning, is a collaborative educational strategy where students actively learn from one another. It involves interaction among peers to share knowledge, solve problems, and develop skills. This methodology can take various forms, from peer tutoring, where a more advanced student assists a less experienced one, to study groups where everyone contributes equally. The process fosters critical thinking, effective communication, and the co-construction of knowledge. By explaining concepts to others or discussing ideas, students solidify their own understanding and discover new perspectives. Moreover, it promotes individual and collective responsibility, as each participant plays an active role in their own learning and that of their peers. This approach not only improves academic performance but also develops crucial social and emotional skills, such as empathy, patience, and the ability to collaborate, preparing students for more cooperative work
223946020|NCT07033156|DIAGNOSTIC_TEST|This study does not require intervention trials|This study does not require intervention trials
223946021|NCT07039786|DIETARY_SUPPLEMENT|Placebo Control|Participants will use their Radicle Health Control Study Product as directed for a period of 6 weeks.
223946022|NCT07039786|DIETARY_SUPPLEMENT|Active Product|Participants will use their Radicle Health Active Study Product as directed for a period of 6 weeks.
223946023|NCT06887348|OTHER|Observational study with no interventions|This is an observational study and there will be no clinical interventions.
223946024|NCT07043140|OTHER|mobile application|mobile application for lymphedema information and exercise
223720128|NCT01142349|BEHAVIORAL|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
223946025|NCT07043257|BEHAVIORAL|Escape Room-Based Bladder Catheterization Training|This intervention involves an escape room-based educational strategy designed to teach bladder catheterization to nursing students. The method includes interactive puzzles, clinical problem-solving tasks, and scenario-based simulations. The training promotes engagement, teamwork, and application of theoretical knowledge in a gamified learning environment.
223946026|NCT07043257|BEHAVIORAL|Traditional Bladder Catheterization Training|This intervention includes standard bladder catheterization training based on traditional teaching methods. The students will receive theoretical instruction through lectures and demonstration-based simulation without interactive or gamified components.
223946027|NCT07042815|DEVICE|Epidural Stimulation Programs|Epidural stimulations will accompany stimulation programs that have been established during research visits in the prior study and have been recommended by the clinical research team for use in the home and community. Stimulation programs will be given for activities (such as standing or walking) and/or responses that were completed in the previous study. This will be continued until the device is removed or approved for commercial use.
224100179|NCT00466505|DRUG|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
224100180|NCT00466505|GENETIC|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
223720129|NCT01142349|BEHAVIORAL|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
224100181|NCT00466505|OTHER|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
224100182|NCT00466505|OTHER|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
224100183|NCT00466505|OTHER|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
223720130|NCT01142349|BEHAVIORAL|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
223720131|NCT00727025|DEVICE|wound closure device (Steri-Strip™)|wound closure with steri-strip S
223720132|NCT04231864|BIOLOGICAL|Durvalumab|Given intravenously (IV)
223720133|NCT04231864|DRUG|Epacadostat|Given orally (PO)
223720134|NCT03645369|DEVICE|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
223720135|NCT03645369|DEVICE|Ice pack|Ice pack containing gel
223729446|NCT03454581|PROCEDURE|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
223720136|NCT01785927|OTHER|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
223720137|NCT04144205|OTHER|Change of the fraction of inspired oxygen|"After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2)."
223720138|NCT00751270|BIOLOGICAL|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
223720139|NCT00751270|DRUG|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
223720140|NCT05447715|DRUG|Fruquintinib|Fruquintinib sequential BEV+FOLFIRI vs. BEV+FOLFIRI sequential fruquintinib in the treatment of metastatic colorectal cancer that has failed previous fluorouracil/oxaliplatin therapy
223946028|NCT07042711|DIETARY_SUPPLEMENT|Placebo|Patients are given capsules that can contain either a placebo or Vitamin D.
223946029|NCT07042711|DIETARY_SUPPLEMENT|Vitamin D 5,000IU Oral Tablet|Patients are given capsules that can contain either a placebo or Vitamin D.
223946030|NCT07042984|DIAGNOSTIC_TEST|AI-Ultrasound RET Prediction|Deep-learning algorithm that analyses thyroid ultrasound DICOM images and outputs a probability score for RET gene alteration and lateral-neck lymph-node metastasis; run offline, results blinded to treating surgeons.
224100184|NCT06041750|PROCEDURE|Elective surgical procedure under general anesthesia|The incidence of postoperative pulmonary complications in OSAS patients undergoing elective surgery under general anesthesia will be determined.
224100185|NCT00811252|DRUG|Placebo|capsules; daily; orally
224100186|NCT00811252|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
224100187|NCT00811252|DRUG|Duloxetine|encapsulated tablets; daily; orally
224100188|NCT03420638|DRUG|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
224100189|NCT03420638|OTHER|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
223946031|NCT07042555|BEHAVIORAL|CBT-cp|The participants in CBT-cp arm will receive weekly sessions of Cognitive Behavior Therapy for Chronic Pain.
223720141|NCT04106960|OTHER|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
223720142|NCT00728871|PROCEDURE|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
223720143|NCT04976751|DRUG|Percutaneous electrical nerve stimulation treatment|Using the percutaneous electrical nerve stimulation instrument to different points of the body
223720144|NCT06258356|DRUG|Remimazolam|novel ultra-short-acting benzodiazepine-like anesthetic.
223720145|NCT06258356|DRUG|placebo|normal saline (compared to Remimazolam)
223946032|NCT07042555|OTHER|Pelvic Floor Therapy|The participants in PFT arm will receive weekly sessions of pelvic floor therapy.
224100190|NCT05293418|OTHER|data collection|data collection from medical records and the microbiological surveillance system of the enrolled patients
224100191|NCT01543750|DRUG|4-Aminopyridine|
224100192|NCT01543750|DRUG|Placebo|Placebo
223720146|NCT06102759|DRUG|Adebrelimab，Fruquintinib|Adebrelimab，Fruquintinib combined with chemotherapy
223720147|NCT05935293|DRUG|Dexmedetomidine|iv administration dexmedetomidine
223720148|NCT00136656|DRUG|antibiotic|cephalosporine by oral route : cefixime
223720149|NCT00136656|DRUG|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
223720150|NCT01996293|DRUG|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
223946033|NCT07042555|DRUG|Pharmacotherapy|The participants in Pharmacotherapy arm will receive prescription and non prescription pain medication.
224100193|NCT03456011|OTHER|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
223720151|NCT03018821|DRUG|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
223720152|NCT03018821|DRUG|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
223720153|NCT03018821|DRUG|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
223946034|NCT07042555|COMBINATION_PRODUCT|CBT-cp+PFT|The participants in integrated arm will receive weekly sessions of both CBT-cp and PFT.
223946035|NCT07042555|OTHER|Placebo|The participants in placebo arm will receive sham drug.
223946036|NCT07042490|PROCEDURE|Plasma adsorption|Plasma adsorption was initiated after endovascular thrombectomy once daily for 3 days.
223946037|NCT07042490|PROCEDURE|Endovascular Thrombectomy|The patients will be treated with endovascular thrombectomy.
223720154|NCT03018821|DRUG|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
223720155|NCT03018821|DRUG|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
223720156|NCT03018821|DRUG|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
224100194|NCT03848819|DEVICE|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
224100195|NCT04872725|BEHAVIORAL|Time management & participation & the leisure time activity|evaluated in terms of leisure time activities, time management and participation
224100196|NCT02978014|DEVICE|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
223720157|NCT03018821|DRUG|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
223720158|NCT03018821|DRUG|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
223946038|NCT07042724|BEHAVIORAL|Physical exercise and nutrition intervention for the neoadjuvant setting|"* Physical exercise: 3 sessions/week. It will comprise high-intensity interval training consisting of 2 minutes of high-intensity intervals interspersed with 2 minutes of active recovery completed at mild intensity. The number of intervals will start with five and progress based on the patient's exercise response. Resistance training will include 3-4 exercises involving major muscle groups, performed with body weight or using elastic bands, at moderate to vigorous intensity.~* Nutrition: will be directed to achieve estimated protein-calorie requirements. Total daily energy requirements will be calculated using the data obtained in the baseline assessment, while daily protein requirements will be set at 1.5 g/kg of body weight. Oral nutritional supplements, particularly a high-calorie, high-protein nutritional blend containing arginine, nucleotides \[RNA\], and omega-3 fatty acids, will be proposed."
223946039|NCT07042724|BEHAVIORAL|Physical exercise and nutrition for the adjuvant setting|"* Physical exercise: 2-3 sessions/week. Each session will be composed of: i) resistance training, including 6-8 exercises for major muscle groups performed in 2-4 sets of 8-12 repetitions; ii) aerobic component, starting at 10-20 minutes, based on the patient's baseline assessments, with monthly progressions up to 40-45 minutes at the end of the program. The insentisy will be set from moderate to vigorous.~* Nutrition: will be directed to achieve estimated protein-calorie requirements. Total daily energy requirements will be calculated using the data obtained in the baseline assessment, while daily protein requirements will be set at 1.5 g/kg of body weight. Oral nutritional supplements, particularly whey protein, will be proposed."
223720159|NCT03018821|DRUG|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
223720160|NCT03018821|DRUG|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
224100197|NCT04247048|OTHER|infusion of tracer [5,5,5-2H3] -L-leucine|A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
223720161|NCT03018821|DRUG|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
223720162|NCT03018821|DRUG|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
224100198|NCT05459597|DRUG|antiepileptic drugs|phenytoin, carbamazepine, lamotrigine, levetiracetam, perampanel, etc. as part of routine treatment.
224100199|NCT03250741|DRUG|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
224100200|NCT03250741|OTHER|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
223720163|NCT03018821|DRUG|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
223720164|NCT01694030|OTHER|Attachment security priming|
223720165|NCT01125683|DRUG|AZD1446|Capsule, oral single and multiple dose
224100201|NCT04328480|DRUG|Colchicine|"The colchicine dosage schedule will vary according to the following scenarios:~1. In patients not receiving Lopinavir/Ritonavir~   * Loading dose of 1.5 mg followed by 0.5 mg after two hours (day 1)~  * The next day 0.5 mg bid for 14 days or until discharge.~2. In patients receiving Lopinavir/Ritonavir~   * Loading dose of 0.5 mg (day 1)~  * After 72 hours from the loading dose, 0.5 mg every 72 hours for 14 days or until discharge.~3. Patients under treatment with Colchicine that are starting with Lopinavir/Ritonavir~   * Dose of 0.5 mg 72 hours after starting Lopinavir/Ritonavir.~  * Continue with 0.5 mg every 72 hours for 14 days or until discharge.~Only the oral route will be used except in the case of patients associated with mechanical ventilation or with contraindications to the oral route, in whom it will be administered by nasogastric tube."
223720166|NCT01125683|DRUG|Donepezil|Capsule, oral and single dose
223720167|NCT01125683|DRUG|Placebo|Capsule, oral and single dose
223720168|NCT05392010|OTHER|no intervention|no intervention
223946040|NCT07042724|BEHAVIORAL|Health educational material|Health educational materials, including the benefits of exercise and nutrition during cancer care, the current recommendations and information on how to pursue them, as well as strategies to achieve and maintain a healthy psychological status
223946041|NCT07042958|PROCEDURE|zirconia membrane|Patients with atrophic maxilla will undergo a direct sinus lift procedure, utilizing a customized zirconia membrane for tenting, along with simultaneous implant placement.
224100202|NCT04328480|OTHER|Local standard of care|Local standard of care for COVID-19 SARS moderate /high-risk patients
223535786|NCT06274957|DEVICE|HFCWO DEVICE|"Patients were provided with conventional exercises including Pursed Lips breathing exercise, Active Respiratory Techniques Cycle, Postural Drainage, Mobilization, Calisthenic Exercises, and Patient Education. Relaxation positions and energy conservation techniques were taught in Patient Education~In addition, participants will receive High-Frequency Chest Wall Oscillation (HFCWO) therapy twice a day for 10 minutes each.~HFCWO training was applıed using the WEST device"
223535787|NCT02587910|DIETARY_SUPPLEMENT|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
223535788|NCT02587910|DIETARY_SUPPLEMENT|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
223535789|NCT03332030|DIAGNOSTIC_TEST|Collection of Stem Cells|One time collection of a 20 ml blood sample
223946042|NCT07042958|PROCEDURE|control group|Patients with atrophic maxilla will undergo a direct sinus lift procedure, using tenting with simultaneous implant placement.
223946043|NCT07043036|DEVICE|GutyCare|Device : GutyCare The participants will use GutyCare remote patient monitoring.
223946044|NCT07043699|OTHER|Phonophoresis|Each woman in the first group received phonophoresis treatment. The procedure was performed using diclofenac sodium gel. Treatment was administered three times per week over a period of eight weeks. Ultrasound was applied at an intensity of 1 W/cm² for 8 minutes using a pulsed mode at a frequency of 1 MHz.
223946045|NCT07043699|OTHER|Iontophoresis|Each woman in the second group received iontophoresis treatment using a diclofenac sodium solution (Voltaren ampoules). The solution was applied under the cathode (drug delivery electrode). The iontophoresis leads were connected, and the current intensity was adjusted based on individual tolerance, ranging between 1 and 4 mA, for a duration of 20 minutes. The negative electrode was placed on the medial side of the calcaneal tubercle (origin), while the positive electrode was positioned on the forefoot. Treatment was administered three times per week over a period of eight weeks.
223946046|NCT07044167|DIETARY_SUPPLEMENT|Polyphenol-enriched functional product|Polyphenol-enriched functional product
223946047|NCT07044167|DIETARY_SUPPLEMENT|Control without active polyphenols|Product with identical characteristics to the experimental product, but without active polyphenols.
223946048|NCT07047040|DRUG|Ketorolac Tromethamine 30 MG/ML Prefilled Syringe|a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
223946049|NCT07047040|DRUG|Gabapentin|a pre-operative dose of ketorolac and gabapentin is given to the patients undergoing unilateral TKA one hour prior to surgery, then a post-operative pain scores will be recorded
223946050|NCT07047040|DRUG|Empty Medication Capsules|two empty capsules of gabapentin
223946051|NCT07042971|DEVICE|Pre-operative BiPAP Training|Seven consecutive nights (≥ 4 h/night) of BiPAP use at home or on ward, pressure ladder EPAP 6→8 cmH₂O / IPAP 12→16 cmH₂O, recorded on SD card; devices: ResMed AirCurve 10 ST or Philips A40.
223946052|NCT07042971|DEVICE|Post-extubation BiPAP Support|Same BiPAP device started immediately after tracheal extubation; EPAP 8 cmH₂O / IPAP 14 cmH₂O (or patient's final training setting) maintained ≥ 48 h, then weaned when SpO₂ ≥ 94 % off-BiPAP for 24 h.
223946053|NCT07042971|OTHER|Standard Peri-operative Care|Routine oxygen, nebulized steroids, airway monitoring; rescue re-intubation or tracheostomy per institutional protocol; no planned BiPAP unless crossover criteria met.
223535790|NCT04629742|OTHER|Seawater Pizza|A seawater pizza administered to 12 healthy subjects
223535791|NCT04629742|OTHER|Standard pizza|A standard pizza administered to 12 healthy subjects
223535792|NCT02256995|DEVICE|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
223535793|NCT06645795|COMBINATION_PRODUCT|Robot assisted gait training plus conventional physical therapy|Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.
223535794|NCT06645795|OTHER|Conventional pjysical therapy|Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
224100203|NCT01931865|DRUG|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
223720169|NCT00292266|DRUG|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
223720170|NCT00292266|DRUG|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
223720171|NCT05261074|OTHER|No intervention|No intervention (retrospective study)
223946054|NCT07043569|OTHER|Resistance Training with Sham-BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
223946055|NCT07043569|OTHER|Resistance Exercise with BFR|"The exercise protocol provides for units of approx. 25 minutes of BFR training five times a week as part of medical training therapy. Based on the initial strength measurements prior to rehabilitation, the training phase of the intervention group starts with 30% of the 1RM (calculated from the force-velocity profile) and 70% LOP in the operated leg and 75% of the 1RM (calculated from the force-velocity profile) in the unoperated leg. The patients are randomized into 2 groups: 1) intervention group, which receives a daily intervention with an occlusion pressure and the 2) control group, which receives a daily Sham-BFR intervention with an occlusion pressure of 20mmHg."
223946056|NCT04412616|BIOLOGICAL|ZZ06|"The phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of ZZ06 : 0.03mg/kg,0.06mg/kg,0.12mg/kg,0.22mg/kg,0.39mg/kg,0.70mg/kg,1 mg/kg."
223946057|NCT07063914|BEHAVIORAL|Reframe-IT and CARIBOU|"Reframe-IT+ An individual intervention based on cognitive-behavioral therapy (CBT) focused on developing skills in behavioral activation, cognitive restructuring, emotion regulation, stress tolerance, and problem-solving. It is delivered in the school setting by a trained psychologist from the research team. The program consists of 13 weekly sessions of 45 minutes each: 5 face-to-face sessions and 8 combined digital/in-person sessions where students use a computer under the supervision of a psychologist facilitator.~CARIBOU An individual CBT-based intervention focused on behavioral activation, cognitive restructuring, problem-solving, and communication skills. It is conducted in the school setting by a trained psychologist and consists of 16 weekly sessions of 45 minutes each."
224100204|NCT01050621|DIETARY_SUPPLEMENT|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
223720172|NCT00859053|DRUG|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
223720173|NCT01679860|PROCEDURE|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~* CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~* HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~* Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
223720174|NCT01679860|DRUG|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
223720175|NCT02130973|DRUG|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
224100205|NCT00047411|OTHER|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
223720176|NCT02130973|DRUG|Experimental Cyclic Regimen|Experimental Cyclic Regimen
224100206|NCT00047411|DEVICE|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
224100207|NCT03425708|DRUG|20mg Febuxostat|Participants take 20mg febuxostat pill once a day for at least six months.
223720177|NCT02302820|OTHER|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
223720178|NCT00157534|DRUG|Celgosivir|
223720179|NCT02459353|DRUG|Dapagliflozin|
223720180|NCT02459353|DRUG|Placebo|
224100208|NCT03425708|DRUG|40mg Febuxostat|Participants take 40mg febuxostat pill once a day for at least six months.
224100209|NCT00904254|RADIATION|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
223720181|NCT04028700|BIOLOGICAL|G6PD Deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
223720182|NCT04028700|BIOLOGICAL|Non-G6PD deficient Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50 mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
223946058|NCT06773208|DRUG|Azacitidine (AZC)|75 mg/m2 daily, on days 1-7, given IV or SC
223946059|NCT06773208|DRUG|Venetoclax|Venetoclax 400 mg orally daily on days 1-28
223946060|NCT06827080|DRUG|30 mCi NYMO32|The initial dose is set at 30 mCi.
223720183|NCT03674749|OTHER|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
223720184|NCT02548650|DRUG|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
223720185|NCT02548650|DRUG|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
223720186|NCT02548650|DRUG|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
223720187|NCT02766699|DRUG|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
223720188|NCT02060123|BEHAVIORAL|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
223946061|NCT06827080|DRUG|50 mCi NYMO32|The dose will be escalated to 50 mCi.
223946062|NCT06827080|DRUG|80 mCi NYMO32|The dose will be escalated to 80 mCi.
223946063|NCT06827080|DRUG|130 mCi NYMO32|The dose will be escalated to 130 mCi.
223946064|NCT06827080|DRUG|200 mCi NYMO32|The maximum dose is set at 200 mCi.
223946065|NCT06864494|PROCEDURE|Endometrial ablation|Performed using a transfer catheter (used for embryo transfers) positioned at the level of the internal cervical orifice in the uterine cavity. Five ml of saline will be injected and collected in a dry tube
223946066|NCT06577662|BEHAVIORAL|individual and family self-management (IFSM) fall prevention program|"The IFSM program will last for ten weeks, two weeks in the hospital, and follow up at eight weeks after patients discharge to home. It will include 11 sessions, including ten sessions developed in the inpatient department within two weeks and one online booster session developed in the first month (week 4) after discharge in home. There will be also one session just for caregivers.~Session 1 : PRST combined with GRI (one) Session 2 : Environment safety Session 3 : Assistant technology Session 4 : PRST combined with GRI (two) Session 5 : Medication review Session 6 : Safety in daily activities Session 7 : How to keep loved one safety Session 8 : Review of PRST combined with GRI Session 9 : Review of other five fall prevention skills Session 10 : Summary of the program and setting goals Session 11 : Booster session Week 10: Evaluation"
223720189|NCT02060123|OTHER|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
223729447|NCT03171792|OTHER|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
223946067|NCT04447027|DRUG|Romidepsin|Romidepsin (12mg/ m\^2) will be administered on days 1 and 10 of each cycle through a peripheral or central intravenous catheter for 6 cycles.
224100210|NCT02774590|DRUG|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
224100211|NCT02515240|BIOLOGICAL|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
224100212|NCT01033994|BIOLOGICAL|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
224100213|NCT05157633|OTHER|Controls|questionnaire food scale: HME data collection of food survey
224100214|NCT03689218|DIETARY_SUPPLEMENT|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
224100215|NCT03689218|DIETARY_SUPPLEMENT|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
224100216|NCT01162525|PROCEDURE|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
224100217|NCT04295187|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
223946068|NCT04447027|DRUG|Lenalidomide|Lenalidomide will be administered by oral intake in a dose-escalation with a starting dose of 5mg daily, a second dose level of 10mg daily, a third dose level at 15mg daily, and a fourth dose level at 20mg daily on days -7 to day 10 of first cycle. After the second cycle, lenalidomide will be given from day 1 to day 10 in each cycle for up to 6 cycles.
223535795|NCT02051192|BEHAVIORAL|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
223720190|NCT02983474|PROCEDURE|cholecystectomy|"Laparoscopic surgery~1. Reverse Trendelenburg position~2. Skin incision and trocar insertion~3. CO2 gas insufflation~4. Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction~6. Calot triangle exposure~7. Cystic artery and cystic duct isolation~8. Gallbladder bed dissection~9. Bleeding control~10. Gallbladder extraction~11. Trocar removal and wound closure~Open surgery~1. Supine position~2. Skin incision~3. Intra-abdominal inspection and gallbladder exposure~5\. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
223720191|NCT05988970|OTHER|Blood samples will be collected at two times before the treatment initiation:|"* at 4:00 a.m.~* at 10:00 a.m.~Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable)."
223946069|NCT04447027|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.
223946070|NCT04447027|DRUG|Dexamethasone|Dexamethasone, 40mg, by mouth (PO), will be given on days 1 and 10 of each cycle.
223720192|NCT03909841|BEHAVIORAL|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
223946071|NCT04447027|DIAGNOSTIC_TEST|EKG|Screening
223946072|NCT04447027|PROCEDURE|Bone Marrow Aspiration/Biopsy|Baseline, end of treatment and disease progression, and Day 30 (+7).
223946073|NCT04447027|DIAGNOSTIC_TEST|MRI|Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.
223946074|NCT04447027|PROCEDURE|Lumbar Puncture|Baseline, every 2 cycles, end of treatment and disease progression, and follow-up.
223946075|NCT04447027|DIAGNOSTIC_TEST|TTE|Screening
223946076|NCT02227927|DRUG|Domperidone|10-30mg oral dose, four times daily.
223946077|NCT06850259|DEVICE|PureWick™ System|The PureWick™ System consists of the PureWick™ Urine Collection System used with the PureWick™ Male External Catheter (MEC), which is intended for non-invasive urine output management in male patients. The PureWick™ MEC is a single-use, non-sterile, commercially available device, which is Class I, 510(K) exempt.
223946078|NCT06850259|DEVICE|UltraFlex™ Self-Adhering Male External Catheter|UltraFlex™ is a self-adhering male external catheter used for the drainage of urine. The catheter is applied by the patient or caregiver. The self-adhering male external catheter is designed for the management of adult male urinary incontinence.
223946079|NCT06809842|DRUG|Vastus lateralis nerve block|Patients received vastus lateralis nerve block with 5 ml of bupivacaine 0.5%.
223946080|NCT06809842|DRUG|Lateral femoral cutaneous nerve block|Patients received lateral femoral cutaneous nerve block with 5 ml of bupivacaine 0.5%.
223946081|NCT06745986|DRUG|ultrasound guided fascia iliaca compartment block ( bupivacaine 0.25% )|Fascia iliaca compartment block by bupivacaine 0.25% in a total volume of 40 ml.
223946082|NCT06745986|DRUG|Spinal Anesthesia (bupivacaine)|spinal anesthesia by 2.5 ml bupivacaine 0.5%
223946083|NCT06147063|BIOLOGICAL|AZD9838|Intramuscular (IM) injection.
224100218|NCT04295187|OTHER|Physical development and General Health|Physical development and General health examination
224100219|NCT04295187|OTHER|Developmental Red flags|Developmental Red flags Questionnaires
224100220|NCT02453399|DEVICE|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
223946084|NCT06147063|BIOLOGICAL|Licensed mRNA vaccine|Intramuscular (IM) injection.
223946085|NCT06147063|BIOLOGICAL|AZD6563|Intramuscular (IM) injection.
223946086|NCT06931028|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
223946087|NCT06931028|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362
223946088|NCT06192927|DRUG|TenoMiR|Single intralesional injection
223946089|NCT06192927|DRUG|0.9% Sodium Chloride Injection|Single subcutaneous injection
223946090|NCT06825091|RADIATION|SBRT|Standard of care SBRT (36.25 Gy in 5 fractions or 42.7 Gy in 7 fractions) for localized prostate cancer, delivered either via an adaptive or a non-adaptive image-guided treatment. Androgen deprivation therapy use and duration is at the discretion of the treating physician and patient, in accordance with standard practice based on patients' prostate cancer risk group.
223946091|NCT05511207|DEVICE|RECOM - hBCI training|The RECOM device is a h-BCI system that controls FES of upper limb muscles: the patient is asked to attempt simple upper limb movements (eg extension of fingers); the device recognizes (in correct trials) close-to-normal EEG-EMG activation and initiates FES of extensor muscles in the forearm. RECOM training consists in a set of trial repetition for a total duration per session of approximately 20-30 minutes (excluding set up time and calibration). FES parameters will be set specifically for each patients according to standard guidelines to achieve full movement and so as to avoid any kind of discomfort for the patients. The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
223720193|NCT03909841|OTHER|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
224100221|NCT03979729|OTHER|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
224100222|NCT03979729|OTHER|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
223946092|NCT05511207|OTHER|CTRL - upper limb training with FES|An expert physiotherapist will define a set of active exercises focused on upper limb function; the exercises will be combined with FES of forearm muscles. FES parameters will be set specifically for each patients according to standard guidelines to achieve the full required movement and so as to avoid any kind of discomfort for the patients. Session duration will be approximately 20-30 minutes (excluding FES calibration time). The intervention regimen will be 2-3 times per week for 4 consecutive weeks.
223946093|NCT03999138|DIAGNOSTIC_TEST|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
223946094|NCT02831049|BEHAVIORAL|Retrieval-extinction|Memory retrieval-extinction is a novel behavioral procedure for reduction of craving and drinking in problem drinkers.
223946095|NCT02831049|BEHAVIORAL|Alcohol-related cues|Alcohol related cues
223946096|NCT02831049|BEHAVIORAL|Soft-drink related cues|Soft drink related cues
224100223|NCT03979729|OTHER|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
223946097|NCT06907823|DRUG|propofol|propofol anesthesia
224100224|NCT04219371|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224100225|NCT03752905|DRUG|PTR-01|Recombinant human collagen 7 (rC7)
224100226|NCT03752905|DRUG|Normal saline|Saline control
224100227|NCT00013884|DRUG|T-20|
224100228|NCT00716443|DRUG|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
224100229|NCT00716443|DRUG|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
224100230|NCT00002523|DRUG|fluorouracil|
223946098|NCT06907823|DRUG|Sevoflurane|sevoflurane anesthesia
223946099|NCT04434092|DRUG|Crovalimab|"Dosing depends on body weight. Participants will be dosed as follows:~* 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study~* 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study~* 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study~* 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study~* 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study~* 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study."
223946100|NCT04434092|DRUG|Eculizumab|Eculizumab will be administered as specified in the respective arm.
224100231|NCT00002523|DRUG|leucovorin calcium|
223946101|NCT07090252|OTHER|Group I zinc oxide Neem|preperation: 1\\ A standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove coronal pulpal tissues then will remove radicular pulp by barbed broach then will be used K files for chemo mechanical preparation (size 15,20,25) with saline (2%) irrigation to remove necrotic pulp tissues then all the canals will be dried using paper points. 2\\ After complete excavation of all pulp tissue, saline irrigation is done then the canals will be obturated zinc-oxide with Neem ( Zinc oxide powder(Prime Dental Pvt. Ltd.Thane, Maharashtra, India) and 100% Neem oil with mixing ratio of 1:3 will be mixed on a glass slab with a stainless- steel spatula) and then the rest of the pulp chamber will be filled with Zinconol. (reinforced zinc oxide eugenol)3\\ Tooth will be restored with stainless steel crown.
224100232|NCT00002523|PROCEDURE|conventional surgery|
224100233|NCT00002523|RADIATION|radiation therapy|
224100234|NCT05385562|DRUG|Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfate|formulated with sodium hyaluronate and chondroitin sulfate
224100235|NCT05385562|DRUG|Triamcinolone Acetonide alone|Triamcinolone Acetonide alone
223946102|NCT07090252|OTHER|Group II zinc oxide eugenol|preperation: 1\\ A standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove coronal pulpal tissues then will remove radicular pulp by barbed broach then will be used K files for chemo mechanical preparation (size 15,20,25) with saline (2%) irrigation to remove necrotic pulp tissues then all the canals will be dried using paper points 2\\ After complete removed of coronal and radicular pulp zinc oxide eugenol will be manipulated in the ratio of 3:1 (powder: liquid) to obtain semisolid mix.This mix will be placed in the canals. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of Zinconol.3\\ Tooth will be restored with stainless steel crown.
224100236|NCT00009672|DRUG|Nortriptyline|
224100237|NCT00009672|DRUG|Morphine|
224100238|NCT00035893|DRUG|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
224100239|NCT03876587|DRUG|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
224100240|NCT03645291|DIAGNOSTIC_TEST|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
224100241|NCT01590329|DEVICE|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
223720194|NCT01909674|DEVICE|Switch CPAP mask type|
223720195|NCT00873197|DRUG|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
223720196|NCT04604223|DRUG|Pioglitazone 45 mg|Pioglitazone will be started at 45 mg/day dose for 10 days, after 10 days, the dose will be reduced to 30 mg/day to minimize possible adverse events. The treatment will be continued for 4 weeks (28 days) total
223720197|NCT04858243|OTHER|Home-Based ART|Community-based male-specific counseling followed by home-based ART initiation (or at any location that is convenient for participants) and home-based ART continuation for a 3-month period, followed by linkage to a local health facility for further ART continuation.
223946103|NCT06482814|BEHAVIORAL|Partial sleep deprivation (sleep restriction)|During the experimental segment the sleep opportunity will be restricted to 5 hours/night. During the acclimation and recovery phases a 9-hour/night sleep opportunity will be provided.
223946104|NCT06482814|BEHAVIORAL|Normal sleep|During the normal sleep condition a 9-hour/night sleep opportunity will be provided throughout the 10-day inpatient visit.
223946105|NCT07098429|DRUG|Bupivacain (Postoperative)|20ml of 0.25% bupivacaine instillation in gallbladder fossa after removal of gallbladder in laparoscopic cholecystectomy this study used less amount of drug
223946106|NCT07098429|DRUG|Normal (0.9%) saline|In 30 patients who underwent Laparoscopic Cholecystectomy , 20ml of 0.9% normal saline instillation in gallbladder fossa after removal of gallbladder.
223946107|NCT07100028|OTHER|SSC crown with Hall technique|SSC crown placement using Hall technique
223720198|NCT04858243|OTHER|Facility-Based ART|Community-based male-specific counseling followed by linkage to a local health facility for ART initiation and continuation.
223720199|NCT02969369|DRUG|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
223720200|NCT02969369|DRUG|Placebo capsule|Placebo once daily
223720201|NCT00521014|BIOLOGICAL|filgrastim|
223720202|NCT00521014|BIOLOGICAL|rituximab|
223720203|NCT00521014|BIOLOGICAL|sargramostim|
223720204|NCT00521014|DRUG|carmustine|
223946108|NCT07100028|OTHER|SSC with conventional technique|SSC placement using conventional technique
223946109|NCT07099807|BEHAVIORAL|Carbohydrate Mouth Rinse|A 6.4% maltodextrin solution (64 g/L) was prepared using Nutricost Maltodextrin Powder. Participants performed five mouth rinses per trial, each using 25 mL of the solution for 10 seconds before expectorating. Each rinse was followed by a 30-second rest. Participants were instructed not to swallow the solution. Rinsing procedure was standardized across all sessions.
223946110|NCT07099807|BEHAVIORAL|Placebo Mouth Rinse|A placebo solution containing 0.05 g/L of non-caloric sucralose in distilled water was used to match sweetness and viscosity of the CHO-MR. Participants performed five rinses of 25 mL for 10 seconds each, spitting out the solution after each rinse. 30-second rest intervals followed each rinse. Swallowing was not allowed. Rinse frequency, volume, and duration were standardized.
224100242|NCT00497224|DRUG|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
224100243|NCT06103110|DEVICE|Photobiomodulation|Laser therapy using low level laser
224100244|NCT04776343|OTHER|telemedecine follow-up|weekly home-based follow-up of visual acuity on electronic tablet
223720205|NCT00521014|DRUG|cytarabine|
223720206|NCT00521014|DRUG|etoposide|
223720207|NCT00521014|DRUG|melphalan|
223720208|NCT00521014|PROCEDURE|autologous hematopoietic stem cell transplantation|
223720209|NCT04645927|DIETARY_SUPPLEMENT|flaxseed beverage|"Pizzey Ingredients Inc. introduced a flax beverage product that is a plant-based beverage product that is designed as an alternative to non-diary milks (almond milk \& soy milk). Each 330 ml serving of flax beverage contains 15 g flaxseed, which amounts to 3.75 gm of omega-3 fatty acid. Preventing MCI or even AD may be within reach, if appropriate measures are taken early enough using strategies such as dietary supplementation."
223720210|NCT04645927|DIETARY_SUPPLEMENT|control beverage|Oat fibre control. For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
223720211|NCT00120731|DRUG|Potassium Citrate|
223720212|NCT00120731|DRUG|Acetazolamide|
223720213|NCT00120731|BEHAVIORAL|Diet low in oxalate and purines|
223720214|NCT01695187|DRUG|NB-001 (0.3%)|Topical administration at least five times throughout the day
223720215|NCT01695187|DRUG|Placebo|
223720216|NCT01780077|DRUG|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
223720217|NCT01780077|DRUG|Placebo|Multiple intradermal injections of placebo at incision sites
223720218|NCT04890769|DEVICE|Moisture sensor wound dressing|Clinical procedure for change of wound dressing
223720219|NCT04027426|BEHAVIORAL|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
223720220|NCT04027426|BEHAVIORAL|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
223729448|NCT05053789|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
223729449|NCT05053789|DEVICE|Hylo-Vision|Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).
223729450|NCT03725696|DIAGNOSTIC_TEST|Semen Analysis|Sperm counts will be determined by semen analysis.
223729451|NCT03725696|DIAGNOSTIC_TEST|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
224100245|NCT00744289|OTHER|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
223720221|NCT03641859|DEVICE|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
223720222|NCT04390191|DEVICE|Continuous Positive Airway Pressure|CPAP at fixed pressure (8-10cm H20) for 72 hours continuously (except for daily activities such as eating, personal activities and breaks for ambulation etc).
223720223|NCT02321878|DRUG|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
223720224|NCT00942253|OTHER|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
223720225|NCT01867437|DRUG|Placebo|Sterile solution (vehicle) for subcutaneous infusion
224100246|NCT03777514|DRUG|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
224100247|NCT03777514|DRUG|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
224100248|NCT03777514|OTHER|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
224100249|NCT03777514|OTHER|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
224100250|NCT00759577|DRUG|Solifenacin|5mg and 10 mg, oral once daily
224100251|NCT04249882|DRUG|Placebo|Matched to active medication
224100252|NCT04249882|DRUG|Naltrexone|50 mg once a day
224100253|NCT04249882|DRUG|Varenicline|1 mg twice a day
224100254|NCT00608088|BEHAVIORAL|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
224100255|NCT00608088|BEHAVIORAL|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
224100256|NCT06379334|DIAGNOSTIC_TEST|Urine test|Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
223720226|NCT01867437|DRUG|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
223720227|NCT00735410|BIOLOGICAL|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
223720228|NCT05576870|OTHER|Plant based toddler nutrition|Plant based toddler nutrition fed daily ad libitum
223720229|NCT05576870|DIETARY_SUPPLEMENT|Dairy based toddler nutrition|Commercially available toddler nutrition fed daily ad libitum
223720230|NCT05214885|DIAGNOSTIC_TEST|No intervention was required for patients or control group in this study|The patient was treated normally and no intervention was required in this study
223720231|NCT02794883|BIOLOGICAL|Durvalumab|Given IV
223720232|NCT02794883|OTHER|Laboratory Biomarker Analysis|Correlative Studies
223720233|NCT02794883|PROCEDURE|Surgical Procedure|Undergo surgical tumor resection
223720234|NCT02794883|BIOLOGICAL|Tremelimumab|Given IV
223729452|NCT03725696|PROCEDURE|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
223729453|NCT03725696|DIAGNOSTIC_TEST|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
224100257|NCT01696812|PROCEDURE|electrode position|
224100258|NCT02566512|OTHER|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
224100259|NCT02566512|OTHER|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
224100260|NCT05600127|DRUG|Avelumab|3 cycles of avelumab (800mg, every 2 weeks)
224100261|NCT02304003|OTHER|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
223946111|NCT07099807|BEHAVIORAL|Music Listening|"Participants listened to high-tempo music (120 bpm) for 15 minutes before exercise using standardized earbuds. Music was selected from a public YouTube playlist titled 120 BPM Best Dance Music for Running and Working Out. Volume was calibrated at 65 dB (50% of max device volume). Auditory conditions were standardized across all participants."
223946112|NCT06947434|OTHER|Laughter Yoga|Laughter yoga is a behavioral intervention that combines intentional laughter exercises with yogic breathing techniques. In this study, the intervention consisted of 10 sessions delivered over five weeks (two sessions per week), each lasting approximately 40 minutes. Sessions were conducted live via Zoom and included components such as rhythmic clapping, deep breathing (pranayama), playful movements, and guided laughter exercises. The aim was to promote relaxation, reduce stress, and enhance psychological well-being in individuals with multiple sclerosis.
223946113|NCT06950242|DEVICE|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.
223946114|NCT06950242|DEVICE|Boston Scientific Corporation|Balloon dilation treatment for intracranial arterial stenosis in order to improve intracranial blood supply.
223946115|NCT04118894|DEVICE|Foot and Ankle Devices|Wright devices used in foot and ankle procedures
223720235|NCT03336671|PROCEDURE|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
223720236|NCT03336671|PROCEDURE|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
223720237|NCT02781597|DRUG|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
223720238|NCT02781597|DRUG|Placebo|Patients will receive 0.9% normal saline
223720239|NCT05700097|DRUG|Dengzhanxixin Injection|Experimental arms for low, and high dose for the standard protocol
223720240|NCT05700097|DRUG|Placebo injection|placebo control arm for the standard protocol
223720241|NCT05566912|OTHER|filling out a survey|This research is a descriptive study
223720242|NCT02954731|BEHAVIORAL|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
223720243|NCT02954731|BEHAVIORAL|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
224100262|NCT02304003|OTHER|Standard Care|Standard follow up in primary care.
224100263|NCT03506503|PROCEDURE|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
224100264|NCT01244737|DRUG|[18F] FLT|\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
224100265|NCT05830383|BEHAVIORAL|PDCA circular management|"PDCA circular management means PlanDoCheckAction four steps"
224100266|NCT02204865|DEVICE|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
224100267|NCT00874380|OTHER|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
223729454|NCT02859779|BEHAVIORAL|education programs|Four audio-recorded discussion groups will be organized in each of the 10 clinical settings
223729455|NCT02311010|DRUG|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
223946116|NCT06325280|DIAGNOSTIC_TEST|Exercise cardiac MRI Assessment|Participants will undergo a standard cardiac MRI to assess resting ventricular structure and function then complete an exercise cardiac MRI assessment using an MRI-compatible stepping ergometer.
223946117|NCT06325280|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Cardiopulmonary exercise testing will be performed using a cycle ergometer. Consistent with standard guidelines, workload will progressively increase (10W ramp protocol) such that peak oxygen consumption (VO2peak) is achieved within 8-12 minutes. VO2peak, VO2 at anaerobic threshold, peak power output (PPO), ventilation/carbon dioxide production (VE/VCO2) slope, peak heart rate (HR), and HR recovery at 1- and 3-minutes will be recorded. VO2peak will be converted to age-, weight, and sex-specific norms and a %predicted value.
223946118|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~4. Trilaciclib: 240mg/m2, d1, d2, d8 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
223946119|NCT06364904|DRUG|Tislelizumab, Cisplatin, Gemcitabine|"Chemoimmunotherapy:~1. Tislelizumab: 200mg, 1x time at d1 each cycle~2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle~3. Cisplatin: 70 mg/m2, in d2 each cycle~Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W."
223946122|NCT06350097|DRUG|Osimertinib|"Arm 1: Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.~Arm 2: Osimertinib 80 mg QD as oral tablet ."
223946123|NCT06350097|DRUG|Datopotamab Deruxtecan|Osimertinib 80 mg QD as oral tablet with Datopotamab Deruxtecan 6mg/kg as i.v. infusion.
223946124|NCT05680259|OTHER|Maela connected follow-up|Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
223946125|NCT05680259|OTHER|traditional follow-up|medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
223720244|NCT02034214|BEHAVIORAL|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
223720245|NCT02034214|OTHER|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
223720246|NCT02034214|BEHAVIORAL|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
223720247|NCT03978832|DRUG|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
223946126|NCT04560049|DRUG|Silver Nitrate|application of silver nitrate to sinus tract
223946127|NCT04560049|DRUG|Phenol|phenolisation of sinus tract
223946128|NCT05606185|PROCEDURE|retraction method|Three dimensional evaluation of root resorption using cone beam computed tomography
223946129|NCT03792061|BEHAVIORAL|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
223946130|NCT01219153|DRUG|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
223946131|NCT01219153|DRUG|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
223946132|NCT03462771|DRUG|Fish oil|4g of fish oil daily for 14 weeks
223946133|NCT03462771|DRUG|sunflower oil|4g of sunflower oil daily for 14 weeks
223946134|NCT04421534|DRUG|Lactoferrin|adding lactoferrin to standard of care treatment regimens
223946135|NCT02713594|BEHAVIORAL|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
224100268|NCT01243931|DRUG|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
224100269|NCT01144754|DRUG|Rituximab|Calculated per patient
224100270|NCT00730236|DRUG|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
223720248|NCT03978832|DRUG|Risperidone|Oral risperidone
223720249|NCT04281810|DEVICE|transcutaneous electric diaphragm stimulation|The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
223720250|NCT01752998|BEHAVIORAL|Treating Opioid Patients' Pain and Sadness (TOPPS)|
223720251|NCT01752998|BEHAVIORAL|Health Education|
223720252|NCT02563405|DRUG|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
223946136|NCT02713594|OTHER|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
223946137|NCT01058694|BEHAVIORAL|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
224100271|NCT06075303|BEHAVIORAL|Modified Cycles|
224100272|NCT02317731|OTHER|Straw|Bowel preparation ingestion with a straw
224100273|NCT02160418|BEHAVIORAL|Financial Incentives|
224100274|NCT02160418|BEHAVIORAL|Cognitive Incentives|
224100275|NCT02160418|BEHAVIORAL|Financial and Cognitive Incentives|
224100276|NCT04224623|BEHAVIORAL|Raising Well at Home|The Raising Well at Home intervention was delivered via 3 core home visits designed to be delivered every 4-6 weeks, with additional support via text or phone over 6 months. The home visits were designed to engage the whole family, build skills, and promote changes in the home environment to support lifestyle behavior change. These essential behaviors focused on reducing sugary beverage intake, promoting appropriate portion sizes, improving fruit and vegetable intake, increasing walking and reducing screen time/sedentary activity.
224100277|NCT03364218|DRUG|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
224100278|NCT03486314|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
224100279|NCT03486314|DRUG|Rifampin|Rifampin capsules.
224100280|NCT03486314|DRUG|Docetaxel|Docetaxel intravenous infusion.
224100281|NCT03486314|DRUG|Carboplatin|Carboplatin intravenous infusion.
224100282|NCT03486314|DRUG|Paclitaxel|Paclitaxel intravenous infusion.
224100283|NCT01047410|OTHER|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
224100284|NCT01047410|OTHER|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
224100285|NCT03928873|DEVICE|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
223720253|NCT02563405|DRUG|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
223720254|NCT05772000|DIAGNOSTIC_TEST|cerebrospinal fluids exams|cerebrospinal fluids will be examined by conventional cytology and flow cytometry
224100286|NCT03928873|DEVICE|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
224100287|NCT03928873|DEVICE|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
224100288|NCT02354950|DRUG|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
224100289|NCT05259475|OTHER|Lifestyle Advice|Maintain a weekly healthy diet and regular exercise.
224100290|NCT05259475|OTHER|Diet Intervention|Calorie-restricted meals (lunch and dinner)
223720255|NCT01744574|OTHER|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
223720256|NCT01744574|DRUG|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
223720257|NCT01744574|OTHER|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
223946138|NCT05080257|DEVICE|Lung Ultrasonography|"The ultrasonography will be done using the curved probe of the SONOACE R3 SAMSUNG ultrasonography machine, SN: S0GYM3HCC00016M, manufacture date: 12-2012.~Assessment of lung condition using the Lung Ultrasonography Score (total score calculated from the 12 standard examined areas, from 0 to 3 in each area, with a minimum of 0 up to 36)"
223946139|NCT06211998|DEVICE|Group 1|Salbutamol inhaler, Omron® CompAIR Pro NE-C900 Compressor Nebulizer (Omron Healthcare Co., Ltd., Kyoto, Japan) was used in Group 1
223720258|NCT02027896|OTHER|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
223720259|NCT02256189|DRUG|Sitagliptin|Sitagliptin 100 mg daily
223720260|NCT02256189|DRUG|Placebo|Placebo one tablet daily
223720261|NCT00263601|BIOLOGICAL|Allergovit 6-grasses|Subcutaneous injections
223720262|NCT00263601|OTHER|Placebo|Subcutaneous injections
223720263|NCT05698030|OTHER|Food allergy|Oral immunotherapy to pistachio
223720264|NCT03312270|BEHAVIORAL|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
223720265|NCT04902794|DEVICE|Light Emitting Diode|Blue light-emitting diode applied to the female genital region for eight minutes, for five sessions, one per week
223720266|NCT04902794|DEVICE|Sham Light Emitting Diode|Sham Blue light-emitting diode turned off applied to the female genital region for eight minutes, for five sessions, one per week
223946140|NCT06211998|DEVICE|Group 2|Salbutamol inhaler, Mesh nebulizer (Aerogen Solo®, Aerogen Ltd, Galway, Ireland) was used in Group 2
223946141|NCT01672684|PROCEDURE|support group therapy|Complete at-home group video calling support sessions
223946142|NCT01672684|OTHER|educational intervention|Receive an educational workbook journal
223946143|NCT03531242|BIOLOGICAL|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (\< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
223946144|NCT04746404|BEHAVIORAL|Emotional Skills Development Program|Emotional Skills Development Program (positive psychology)
223946145|NCT00217152|DRUG|CellCept|
223946146|NCT01181115|DRUG|Avonex|Interferon treatment for MS
223946147|NCT05082688|BIOLOGICAL|Herpes zoster vaccination (Shingrix, GSK)|Shingrix is an ASO1-adjuvanted herpes zoster vaccination used to prevent shingles and its associated complications in at-risk populations
223946148|NCT05082688|BIOLOGICAL|Influenza Vaccine (Fluarix Tetra Northern Hemisphere 2021 or 2022, GSK)|Fluarix Tetra is a quadrivalent inactivated influenza vaccine
223946149|NCT05082688|BIOLOGICAL|Placebo|0.9% NaCl
223946150|NCT01503450|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
223946151|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
223946152|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
223946153|NCT02443909|PROCEDURE|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
223946154|NCT02443909|DEVICE|Holmium laser device|
223946155|NCT02068157|OTHER|Laboratory Biomarker Analysis|Correlative studies
223946156|NCT02068157|DRUG|Photodynamic Therapy|Undergo image-guided I-PDT
223946157|NCT02068157|DRUG|Porfimer Sodium|Given IV
223946158|NCT01363128|DRUG|Cyclophosphamide|Given IV
223946159|NCT01363128|DRUG|Cytarabine|Given IV
223946160|NCT01363128|DRUG|Dexamethasone|Given IV or PO
223946161|NCT01363128|DRUG|Doxorubicin Hydrochloride|Given IV
223946162|NCT01363128|OTHER|Laboratory Biomarker Analysis|Correlative studies
223946163|NCT01363128|DRUG|Methotrexate|Given IV
223946164|NCT01363128|BIOLOGICAL|Ofatumumab|Given IV
223946165|NCT01363128|DRUG|Vincristine Sulfate|Given IV
224100291|NCT05259475|OTHER|OCFA Meal-Based Diet-Intervention|OCFA-containing food product
224100292|NCT01966510|OTHER|Cord Blood Transplantation|
223946166|NCT02155868|OTHER|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (\< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood \< 35 mmHg; mean arterial pressure \< 60 mmHg; central venous pressure \> 10 mmHg; cardiac index \< 2.0 l/min/m2; mixed venous oxygen saturation \< 60%; hemoglobin \< 65 g/L during cardiopulmonary bypass or hemoglobin \< 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
223946167|NCT02155868|OTHER|Standard treatment|Standard treatment
223946168|NCT06499116|DRUG|Topiramate|Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.
223720267|NCT01013376|DRUG|MC-1101|MC-1101 1.0%
223720268|NCT01013376|DRUG|Vehicle|Vehicle
223720269|NCT00407797|DRUG|Pregabalin|150 to 600 mg/day during 21 weeks
223720270|NCT01084369|DRUG|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
223720271|NCT03485339|DIAGNOSTIC_TEST|genome testing|blood sampling via venipuncture
223720272|NCT01812174|DEVICE|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
223720273|NCT01812174|DEVICE|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
223720274|NCT04481932|DRUG|Trastuzumab combined with Pyrotinib and chemotherapy|"Pyrotinib is a small molecule, irreversible tyrosine kinase inhibitor with targets of epidermal growth factor receptor 1 (EGFR/HER1/ErbB1), human epidermal factor receptor 2 (HER2/ErbB2/Neu) and human epidermis Factor Receptor 4 (HER4/ErbB4).~As a new generation of anti-HER2 therapeutic targeted drugs, pirotinib covalently binds to the ATP binding sites of the kinase regions of EGFR, HER2 and HER4 in cells to prevent homogeneity and heterogeneity of EGFR, HER2 and HER4 in tumor cells Dimer formation, inhibiting its own phosphorylation, blocking the activation of downstream signaling pathways, thereby inhibiting tumor cell growth"
223720275|NCT00016185|DRUG|alvocidib|
223946169|NCT06499116|DRUG|Flunarizine|Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.
223946170|NCT06499116|DRUG|Amitriptyline|Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.
224100293|NCT04392986|OTHER|Sunlight exposure|The weather was sunny and found suitable for outside activity and sunlight exposure program, with a mean temperature of 27.0-28.5 °C, the humidity of 64-80%, and global solar exposure of 1.28 to 2.99 MJ/m2 during treatment.\[15\] Participants were asked to lie on the beach for 45 minutes per day between 2 to 3 pm to avoid extreme skin irritation and sunburn from direct sunlight exposure.
224100294|NCT01872351|DRUG|Nutraceuticals|
224100295|NCT06028815|BEHAVIORAL|Group music therapy|Music therapy intervention using active and receptive techniques, focusing on the technique of songwriting.
224100296|NCT05863936|DRUG|Methylprednisolone Injectable Suspension|Methylprednisolone pulse therapy, total dose from 1500mg to 3000mg.
224100297|NCT05863936|DRUG|Belimumab Injection|Belimumab at a dose of 10mg per kilogram at weeks 2, 4, and 6, and every 4 weeks for 24 weeks.
224100298|NCT05863936|DRUG|Immunosuppressive Agents|"1. Mycophenolate Mofetil, oral, 1.0-1.5g per day;~2. Tacrolimus, oral, 2-4mg per day."
223720276|NCT00016185|DRUG|docetaxel|
223720277|NCT00428311|DRUG|Metformin|
223720278|NCT00428311|DRUG|Ethynyl-estradiol plus cyproterone acetate|
223720279|NCT01437072|OTHER|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
223720280|NCT01783301|DRUG|FSH|
223720281|NCT04987346|OTHER|Walking on an instrumented treadmill|Participants will be asked to walk at different gait velocities for 1 minute. The treadmill speed will be increased incrementally at 0.1m/s intervals until just before running.
223720282|NCT04987346|OTHER|Walking on an instrumented treadmill while dual-tasking|Participants aged between 6 and 17 years will be asked to walk at comfortable walking speed while playing either a cognitive (Stroop Color and Word Test) or motor (requiring arm swing) game.
223720283|NCT01333254|PROCEDURE|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
223720284|NCT05776498|PROCEDURE|immediate implant placement with particulate bone graft using the dual zone technique.|Tooth extraction and immediate implant placement as mentioned, then particulate bone graft will be packed in the gap between the implant and the buccal plate of bone and the tissue (dual zone), then will be covered by a customized healing abutment.
223720285|NCT05776498|PROCEDURE|immediate implant placement with connective tissue grafting|Tooth extraction and immediate implant placement as mentioned. Connective tissue grafts will be harvested from the hard palate and placed at the implant sites in a supraperiosteal partial dissection pouch prepared at the buccal aspect without using vertical incisions and without flap elevation. Sutures will be used to stabilize the graft in its desired place. Followed by customized healing abutment.
223946171|NCT06499116|DRUG|Propranolol|Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
223946172|NCT05013398|BEHAVIORAL|The Together Webinar Programme|"The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT)."
224100299|NCT03203629|DEVICE|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
224100300|NCT00763893|DRUG|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
223720286|NCT03137290|DRUG|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
223720287|NCT03137290|DRUG|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
223720288|NCT04964375|DRUG|ABSK043 oral capsule|ABSK043 is a novel, oral small molecule inhibitor of PD-L1
223720289|NCT00807378|OTHER|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
223720290|NCT04883931|DRUG|Normal Saline|0.5 ml 0.9% normal saline will drop on both eyes twice in a day.
223720291|NCT04883931|BIOLOGICAL|Breast milk|0.5 ml breast milk from all infant's own mother will drop both eyes twice in a day
223720292|NCT04866225|DRUG|Oral [14C]PF-06865571|Oral radiolabeled PF-06865571
223720293|NCT04866225|DRUG|Oral PF-06865571|Oral PF-06865571
223720294|NCT04866225|DRUG|IV [14C]PF-06865571|IV radiolabeled PF-06865571
223720295|NCT05509920|OTHER|S-PRG barrier coat|S-PRG filler was the best composition of compressive strength and F- and B release acid buffering capacity. It was found to be the most promising for use as a novel cement.
223720296|NCT00425295|BEHAVIORAL|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
223946173|NCT01868555|DRUG|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
223946174|NCT01868555|DRUG|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
223946175|NCT01868555|DRUG|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
223720297|NCT02837601|DEVICE|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
223720298|NCT02396485|OTHER|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
223946176|NCT01868555|DRUG|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
223946177|NCT06500546|PROCEDURE|Treatment of cervical lesions|"Four non-carious cervical lesions from patients will be separated into four groups according to according to the adhesion trategies described below:~1. adhesive material will be applied in total-etch mode,~2. adhesive material will be applied in self-etch,~3. universal adhesive material will be applied for 10 sec. in total-etch mode, which includes rubbing,~4. universal adhesive material will be applied for 10 sec. in self-etch mode, which includes rubbing,"
223946178|NCT01890278|RADIATION|Whole Brain IMRT|
223946179|NCT01890278|RADIATION|Conventional Whole Brain RT|
223946180|NCT00016042|BIOLOGICAL|lymphokine-activated killer cells|
223946181|NCT00016042|BIOLOGICAL|recombinant interferon alfa|
223946182|NCT00016042|BIOLOGICAL|sargramostim|
223946183|NCT00016042|DRUG|fluorouracil|
223946184|NCT05726097|DRUG|polyethylene glycol|colonic preparation
223946185|NCT05726097|DRUG|sodium phosphate|colonic preparation
223946186|NCT05726097|DRUG|polyethylene glycol + ascorbic acid|colonic preparation
223946187|NCT05726097|DRUG|gastrografin|colonic preparation
223946188|NCT05726097|DRUG|magnesiumoxid + sodium picosulfate|colonic preparation
223946189|NCT05726097|DRUG|prucalopride|colonic preparation
224100301|NCT00763893|DRUG|Losartan|50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
224100302|NCT03133715|PROCEDURE|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
224100303|NCT03133715|PROCEDURE|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
224100304|NCT00410891|DRUG|gatifloxacin|
224100305|NCT01595217|DEVICE|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
223720299|NCT06413563|DIAGNOSTIC_TEST|Complete blood count|"Complete blood count will be done for all patients and then will search about CD4, CD8 T lymphocyte cells surface markers~* CD56 Natural killer cells surface marker~* CD19 Lymphocyte cells surface marker"
223720300|NCT05336812|DRUG|Acalabrutinib|Given PO
223720301|NCT05336812|BIOLOGICAL|Obinutuzumab|Given IV
223720302|NCT05336812|DRUG|Venetoclax|Given PO
223720303|NCT06199895|DRUG|Paclitaxel Polymeric Micelles for Injection|300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
223946190|NCT01000935|OTHER|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
223720304|NCT05084378|DRUG|Povidone-Iodine Lavage Solution|0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.
223720305|NCT05084378|DRUG|Chlorhexidine Lavage Solution|0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.
223720306|NCT05084378|DRUG|Topical Antibiotic|2 grams Vancomycin powder
223720307|NCT05084378|DRUG|Saline Lavage Solution|1 litre of sterile isotonic saline
223720308|NCT04269096|OTHER|Protocol Compliance|Compliance with the Prisma Health-Upstate Laparoscopic Cholecystectomy Perioperative Protocol
223720309|NCT06113809|DRUG|Palbociclib|"Palbociclib is a CDK4/6 inhibitor.~Palbociclib, 125 mg, (pediatric dose 75mg/m2 up to 125mg) daily for 21 days out of every 28 days, PO (orally) starting 14 days prior to Pembrolizumab"
223720310|NCT06113809|DRUG|Pembrolizumab|"Pembrolizumab is a PD-1 blocking antibody.~Given 14 days following Palbociclib: Pembrolizumab, 200 mg, once every three weeks, intravenously (IV)"
223946191|NCT01355445|DRUG|Vincristine, Irinotecan|"* D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
224100306|NCT00155402|DRUG|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
224100307|NCT00579904|DIETARY_SUPPLEMENT|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
224100308|NCT00579904|DIETARY_SUPPLEMENT|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
224100309|NCT06065722|DRUG|Akynzeo|OLANZAPINE
224100310|NCT01177215|PROCEDURE|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
224100311|NCT00929630|PROCEDURE|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
223720311|NCT00543504|DRUG|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
224100312|NCT00929630|PROCEDURE|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
224100313|NCT00929630|PROCEDURE|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
223720312|NCT00543504|DRUG|Sorafenib|200 mg By Mouth Daily for 28 Days
223720313|NCT00543504|DRUG|Erlotinib|50 mg By Mouth Daily for 28 Days.
223720314|NCT00543504|DRUG|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
223720315|NCT00543504|DRUG|Lapatinib|250 mg By Mouth Daily for 21 Days.
223720316|NCT00543504|DRUG|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
223720317|NCT00543504|DRUG|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
223720318|NCT05521789|DRUG|ESB Thoracic|Erector spinae thoracic block with bupivacaine
223720319|NCT02407353|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
223720320|NCT02407353|DRUG|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
223720321|NCT03132220|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
223720322|NCT03132220|BEHAVIORAL|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
223720323|NCT03837197|DEVICE|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
223720324|NCT03837197|DEVICE|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
223720325|NCT03824613|DIAGNOSTIC_TEST|Urinary miRNA|MiRNA detection in urine
223720326|NCT00935571|DRUG|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
223720327|NCT04884854|DEVICE|Efferon LPS|Efferon LPS is a single-use therapeutic device for extracorporeal blood purification using direct hemoperfusion. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and non-selective removal of cytokines by internal porous structure. It is a cylindrical polycarbonate casing filled with spherical granules of LPS-selective polymeric adsorbent mesoporous beads and isotonic sodium chloride solution. The device is registered in Russia as a medical device RZN 2019/8886.
223720328|NCT06506786|OTHER|Garden-fresh Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.
223720329|NCT06506786|OTHER|Supermarket Produce|Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
223720330|NCT00702611|DEVICE|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
223720331|NCT01969968|OTHER|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
223720332|NCT03365830|DIAGNOSTIC_TEST|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
223720333|NCT00373152|PROCEDURE|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
223720334|NCT00373152|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
223946192|NCT01355445|DRUG|Vincristine, Irinotecan, Temozolomide|"* D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days"
223946193|NCT02008214|DRUG|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
223946194|NCT02008214|DRUG|Placebo|Placebo matching pentoxifylline dosage
224100314|NCT00929630|PROCEDURE|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
224100315|NCT01119040|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
224100316|NCT03124069|DEVICE|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
224100317|NCT02604264|DEVICE|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
224100318|NCT00623571|OTHER|Treatment of elderly patients in a GMW|
223720335|NCT00373152|PROCEDURE|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
223720336|NCT00373152|RADIATION|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
223720337|NCT02024815|RADIATION|External Beam radiotherapy|External Beam radiotherapy
223720338|NCT06498492|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy (LC) has been established as the gold standard of treatment for acute mild biliary pancreatitis.
223720339|NCT00790985|DIETARY_SUPPLEMENT|flavocoxid|medical food
223946195|NCT00470756|OTHER|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
223946196|NCT05338567|DIAGNOSTIC_TEST|Small intestine length measurement method|Accuracy of digital 3D reconstruction for predicting small bowel length
223946197|NCT01214200|DEVICE|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
223946198|NCT01823224|DRUG|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
224100319|NCT00623571|OTHER|Treatment of elderly patients in GHHS|
224100320|NCT04003610|DRUG|Pemigatinib|13.5 mg once a day orally
223946199|NCT01823224|DRUG|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
223946200|NCT00188747|PROCEDURE|Thromboelastograph, Point of Care|
223946201|NCT00038636|DRUG|Lopinavir/ritonavir|
223720340|NCT00790985|DRUG|Naproxen|antiinflammatory drug
223720341|NCT05251974|DIAGNOSTIC_TEST|Quest beta blocker assay|Blood assay to detect presence of beta blocker medications
223720342|NCT02458040|DRUG|Drug selected in the study|
224100321|NCT04003610|DRUG|Pembrolizumab|200 mg Q3W intravenously
224100322|NCT04003610|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
224100323|NCT04003610|DRUG|Carboplatin|Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
224100324|NCT03502122|OTHER|VR rehabilitation for motor function|rehabilitation for motor function
224100325|NCT00872222|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
224100326|NCT00629395|BEHAVIORAL|Captain's Log Computer Program|12 Computer Program
223720343|NCT00039975|DRUG|Indinavir sulfate|
223720344|NCT00039975|DRUG|Ritonavir|
223720345|NCT00039975|DRUG|Amlodipine|
223720346|NCT00039975|DRUG|Diltiazem HCl|
223720347|NCT01111097|DRUG|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
223946202|NCT00038636|DRUG|Ritonavir|
223946203|NCT05353062|PROCEDURE|Hemostatic therapy|Bipolar hemostatic forceps
223946204|NCT05353062|PROCEDURE|Endoscopic therapy with hemoclip +/- injection of epinephrine solution|Endoscopic therapy with hemoclip +/- injection of epinephrine solution
223946205|NCT06436105|OTHER|FICB|FICB is applied to the patients after spinal anesthesia.
223946206|NCT06436105|OTHER|4 in 1 block|4 in 1 block is applied to the patients after spinal anesthesia.
223946207|NCT06436105|OTHER|Control|Peripheral nerve block will not be performed on Group Control patients.
224100327|NCT00908284|BEHAVIORAL|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
224100328|NCT00908284|BEHAVIORAL|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
224100329|NCT05230147|PROCEDURE|Spinal cord stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord.
224100330|NCT05230147|PROCEDURE|Sham stimulation|Single stimuli are delivered to define the stimulation threshold. High-frequency stimulation is not delivered.
224100331|NCT05668221|BEHAVIORAL|Prehabilitation|Prehabilitation includes exercise prescription, cognitive function assessment and training, nutritional optimisation at least 4 weeks prior to surgery
224100332|NCT05413330|DRUG|Triamcinolone Acetonide|Intravitreal injection of 4 mg/0.1 mL preservative-free triamcinolone acetonide at the end of phacoemulsification surgery will be injected at 3.5 mm inferolateral and posterior to the limbus.
223946208|NCT01419210|OTHER|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
223946209|NCT01419210|OTHER|Educational Presentations|Attend a two-hour presentation each week for four weeks
223946210|NCT01419210|OTHER|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
223946211|NCT01419210|OTHER|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
223946212|NCT01337141|OTHER|Control|7 face-to-face visits.
223946213|NCT01337141|DEVICE|Telecare system|5 telematic visits and 2 face-to-face visits.
223946214|NCT05566249|DEVICE|ArtiSential|Articulating laparoscopic instrument
224100333|NCT00976755|DRUG|everolimus|"Everolimus:~10mg daily"
224100334|NCT03271710|DEVICE|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
224100335|NCT03032744|OTHER|Asthma Assessment & Management|Asthma Assessment \& Management based on NAEPP-EPR3 guidelines
224100336|NCT03032744|OTHER|Asthma Education|Asthma education on medications
224100337|NCT03032744|OTHER|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
224100338|NCT03664726|BEHAVIORAL|Episodic Future Thinking|Participants will be instructed to use their episodic future cues as they engage in different decision making tasks.
223720348|NCT00903591|OTHER|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
223720349|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
223720350|NCT03956732|DIETARY_SUPPLEMENT|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
223720351|NCT03956732|DIETARY_SUPPLEMENT|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
223720352|NCT01051323|DRUG|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
223946215|NCT05040828|BEHAVIORAL|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.|Start taking Montelukast Sodium Tablets 10mg quaque die orally two weeks before peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
223946216|NCT05040828|BEHAVIORAL|Montelukast Sodium Tablets 10mg quaque die orally was administered after peak pollen count.|10mg quaque die orally was administered after peak pollen count.Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
223720353|NCT02533739|BEHAVIORAL|Cognitive and neuropsychological assesment|
223720354|NCT00888368|PROCEDURE|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
223720355|NCT00888368|PROCEDURE|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
223720356|NCT02596308|BIOLOGICAL|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
223720357|NCT03181334|BEHAVIORAL|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
223720358|NCT03181334|BEHAVIORAL|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
223720359|NCT03181334|BEHAVIORAL|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
223720360|NCT03181334|BEHAVIORAL|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
223720361|NCT03181334|BEHAVIORAL|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
223720362|NCT05477810|DRUG|Treatment A (investigational drug) followed by Treatment B (reference drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
223720363|NCT05477810|DRUG|Treatment B (reference drug) followed by Treatment A (investigational drug)|Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
223720364|NCT00601458|DRUG|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
223946217|NCT05040828|DRUG|No oral drug therapy throughout the pollen period|Intranasal corticosteroids (mometasone furoate) 100μg was used in the group after peak pollen count.
223946218|NCT01475266|DRUG|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
223946219|NCT01475266|DRUG|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
224100339|NCT03664726|BEHAVIORAL|Episodic Recent Thinking|Participants will be instructed to use their episodic recent cues as they engage in different decision making tasks.
223946220|NCT05764057|DRUG|Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)|"Dapagliflozin (10 mg per day; per os) on top of standard of care as recommended in current guidelines\* for 6 months (experimental group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
223720365|NCT00601458|DRUG|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
223946221|NCT05764057|DRUG|Placebo comparator|"Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended."
223946222|NCT02094534|BIOLOGICAL|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
224100340|NCT03664726|BEHAVIORAL|Scarcity Narrative|Participants will read a narrative to induce a scarcity mindset, in which they are asked to imagine a scenario in which they have lost their job and have no current secondary income.
224100341|NCT03664726|BEHAVIORAL|Neutral Narrative|Participants will read a narrative in which they are asked to imagine a scenario in which they have been transferred between departmental jobs, with little change in salary/commute.
223720366|NCT00601458|DRUG|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
223720367|NCT04564937|DRUG|SCT510A|SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
223720368|NCT03445208|DRUG|BMS-986036|Crossover administration to abdomen then upper arm
223720369|NCT00518986|DRUG|armodafinil|200 mg/day
223720370|NCT00518986|DRUG|placebo|placebo
224100342|NCT03301857|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
224100343|NCT04614818|OTHER|Non-intervention research|Non-intervention research
223720371|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
223946223|NCT02094534|OTHER|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
224100344|NCT00298714|DRUG|Losartan|
224100345|NCT03140319|BIOLOGICAL|Fibroblast|Transplantation of 20 million cell by three injection
223720372|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
223720373|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
223720374|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
224100346|NCT03140319|BIOLOGICAL|Placebo|Injection of Placebo
224100347|NCT01726361|BEHAVIORAL|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
223720375|NCT00819806|BIOLOGICAL|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
223720376|NCT00819806|BIOLOGICAL|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
223720377|NCT04258384|OTHER|survey application|Data collection tools used in the study; Demographic Data Form, Mcgill and Melzack Pain Questionnaire, Short Form-36 (SF-36), Vanderbilt Multidimensional Pain Coping Inventory (VMPCI), Pain Coping Inventory (PCI), Pain Coping Scale were used.
223720378|NCT01116011|DRUG|AZD7268|Capsule, Oral, BID
223720379|NCT01116011|DRUG|Placebo|Capsule, Oral, BID
223720380|NCT05540652|BEHAVIORAL|Mindfulness-Based Queer Resilience (MBQR)|"Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community."
223720381|NCT05707910|BIOLOGICAL|EBV immunological agent|Low-dose group:2\*10\^7 Medium-dose group:5\*10\^7 High-dose group:2\*10\^8
223720382|NCT05683249|DRUG|NRCT-101-SR|NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.
223720383|NCT05683249|DRUG|Placebo|Matching placebo
223720384|NCT04741828|DRUG|Vi-DT Typhoid Conjugate Vaccine|Typhoid Conjugate Vaccine
223720385|NCT03503305|DEVICE|adipose-derived stem cell injection|5 ml injection of adipose derived stem cells
223720386|NCT03503305|DRUG|Corticosteroid injection|5 ml injection of corticosteroid
223946224|NCT02139241|DRUG|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
223946225|NCT02139241|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
223946226|NCT03155100|DRUG|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
223946227|NCT03155100|DRUG|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
223720387|NCT01804283|PROCEDURE|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
223720388|NCT01804283|PROCEDURE|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
223720389|NCT01804283|DEVICE|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
223720390|NCT01804283|DEVICE|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
223720391|NCT00880828|OTHER|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
223720392|NCT00880828|OTHER|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
223720393|NCT00880828|DRUG|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
223720394|NCT05873387|DEVICE|Use of Eko DUO stethoscope (paired ECG/PCG)|Auscultation of heart sounds using electronic stethoscope
223720395|NCT01486732|BIOLOGICAL|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
223720396|NCT01486732|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
223946228|NCT03155100|DRUG|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
223946229|NCT03081013|BEHAVIORAL|Social information|Social comparison information will be provided to the study participants weekly via SMS
223946230|NCT03081013|DEVICE|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
223946231|NCT03733275|DRUG|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
223946232|NCT03398668|DEVICE|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
223946233|NCT03398668|DEVICE|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
223946234|NCT02522598|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
223946235|NCT02522598|DRUG|Placebo|water for injection
223946236|NCT00236652|DRUG|levofloxacin|
223946237|NCT05114993|DEVICE|wearing a disposable surgical mask|Physiologic vital signs will be monitored every minute for 5 minutes without a mask, followed by every minute for 15 minutes with a surgical mask.
223946238|NCT03540524|DRUG|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
223946239|NCT03540524|DRUG|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
223946240|NCT03540524|DRUG|GLPG2222|GLPG2222 tablet for oral use, daily.
223946241|NCT03540524|DRUG|GLPG2737|GLPG2737 capsules for oral use, daily.
223720397|NCT01486732|OTHER|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
223720398|NCT00574132|DRUG|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
223720399|NCT00574132|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
223946242|NCT05372224|DRUG|Cholecalciferol|4000 IU were administrated once a day for 3 months.
223720400|NCT00574132|DRUG|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
223720401|NCT00821353|PROCEDURE|RF catheter ablation|RF catheter ablation
223720402|NCT00821353|DRUG|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
223946243|NCT05563571|DRUG|Methylprednisolon, Lidocaine|Intra-articular cortisone injection
223946244|NCT05563571|OTHER|Pulsed radiofrequency, Lidocaine|pulsed radiofrequency of shoulder joint and suprascapular nerve
223946245|NCT02459860|BEHAVIORAL|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
223720403|NCT04443270|DRUG|Chloroquine phosphate|"Drug: Chloroquine phosphate~Dosage form, frequency and duration: 300 mg per day during initial 30 days and 150 mg per day during the next 30 days."
223946246|NCT02459860|BEHAVIORAL|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
223946247|NCT05927259|DRUG|n acetyl cysteine|A patients received NAC 140 mg/Kg IV infusion (as a loading dose), then 70 mg/KgIV infusion every 4 hours up to 17 doses
223946248|NCT05927259|DRUG|standard treatment|stabilization and antidotes
223946249|NCT00681941|DRUG|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
223946250|NCT01481974|DRUG|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
223535796|NCT02051192|OTHER|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
223535797|NCT01567722|GENETIC|DNA analysis|This sample will be used for germline DNA analysis.
223946251|NCT00315848|DRUG|Buprenorphine transdermal delivery system|
223535798|NCT01567722|GENETIC|RNA analysis|RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
224100348|NCT01726361|BEHAVIORAL|Treatment as usual|Other kinds of out of home placement
224100349|NCT03295305|BEHAVIORAL|Action-Based Cognitive Remediation|
224100350|NCT03295305|BEHAVIORAL|Unstructured support group|
224100351|NCT02210338|DEVICE|Karl Storz C-MAC|
224100352|NCT02210338|DEVICE|Bonfils Intubation Fibrescope|
224100353|NCT03471026|DIAGNOSTIC_TEST|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
223535799|NCT01567722|GENETIC|gene expression analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
223535800|NCT01567722|GENETIC|polymorphism analysis|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
223535801|NCT01567722|OTHER|biologic sample preservation procedure|Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
223535802|NCT01567722|OTHER|flow cytometry|Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
223535803|NCT01567722|OTHER|medical chart review|Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
223535804|NCT06176209|DIAGNOSTIC_TEST|screening tool with biomarkers for prediction of chronic post traumatic neck pain|Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
223535805|NCT00344981|DRUG|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
223535806|NCT00344981|DRUG|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches \>400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
223946252|NCT01888991|OTHER|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
223946253|NCT04714346|OTHER|no interventions|there is no intervention
223946254|NCT01130298|DRUG|Testosterone Gel 1.62%|5 grams
223946255|NCT06234020|OTHER|To see the frequency of vertebrospinal anomalies in patients presenting with Anorectal Malformation|The patients presenting with anorectal malformation go through x-ray. We will get the reporting of x-ray done to see the vertebral anomalies and the patients presenting with fecal/urinary incontinence will go through MRI for spinal anomalies.
223946256|NCT05922124|DRUG|Cefiderocol|Test drug regimen
223946257|NCT05922124|DRUG|Ampicillin-sulbactam|Synergistic combination
223946258|NCT05922124|DRUG|Colistin|Historical comparator
223946259|NCT05922124|DRUG|Meropenem|Historical comparator synergistic combination
223946260|NCT03087318|BEHAVIORAL|Physical activity|"Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months."
223946261|NCT03372252|DEVICE|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
223946262|NCT01014299|OTHER|Recruitment maneuver|"Assigned interventions:~* No intervention after tracheal intubation (control group)~* Alveolar recruitment maneuver (RM group) immediately after intubation"
223946263|NCT02151084|DRUG|Selumetinib|
223535807|NCT03234634|PROCEDURE|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
223535808|NCT03991585|BEHAVIORAL|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
223946264|NCT02151084|DRUG|Cisplatin|
223535809|NCT00382174|DRUG|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
223946265|NCT02151084|DRUG|Gemcitabine|
223946266|NCT04224415|DRUG|C225+CPT-11|"Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1"
223946267|NCT02085512|PROCEDURE|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
223946268|NCT02085512|OTHER|Control, web-based tasks|No training modules
223946269|NCT00259116|DRUG|Relaxin|
223946270|NCT05781932|PROCEDURE|Dermal barb suture combined with medical glue|In the experimental group, after tension reduction and suture were completed, the wound and surrounding skin were wiped clean with normal saline and clean gauze, and the blood accumulated in the wound was squeezed out. Histoacryl medical tissue glue (specification:0.5 ml/piece, main components: n-butyl 2-cyanoacrylate (embutate), pigment (1-hydroxy-4\[(toluene)amino\]-9,10-anthraquinone), and stabilizers (p-diphenol, sulfur dioxide, phosphoric acid)) were evenly spread on the surgical incision and kept in the butt state for 4 to 6 seconds. After it got solidify and dry, a sterile gauze covered the surgical incision. There was no need to disinfect and change the dressings after the operation. Patients can shower normally on the day after the operation by just avoiding rubbing the incision covered with glue. Patients can move normally 1-2 days after the operation, and the glue film falls off on its own within 5-10 days.
223946271|NCT05206058|PROCEDURE|venipuncture|Plan to enroll 240 health people who are 20-35 years of age. People with received veinpuncture. Blood will be collected at time and drawn into Heparin-coated tube.
223946272|NCT06390449|OTHER|Kahoot intervention|Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.
223535810|NCT00382174|DRUG|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
223535811|NCT01918189|BEHAVIORAL|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
223535812|NCT02566863|DRUG|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
223535813|NCT02160288|DRUG|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
223535814|NCT02160288|DRUG|Normal Saline|Dispensed in a 5 cc syringe
223535815|NCT04301648|OTHER|STAR Nurse|"This intervention will consist in that the nurse who is in the hemodynamic nurse's office will do the STAR Nurse's tasks and competences.~Although the intervention will be detailed through phase 1 (integrative review) and 2 (Delphy methodology).~It is expected that the main STAR nurse's competencies and tasks in the nurse's office will be:~1. To guarantee a comprehensive evaluation and appropriate triage to candidates for an interventional procedure of structural heart disease, coordinating the request for complementary tests and previous visits.~2. Make education to the patient and family.~3. Make communication bridge with cardiologists.~4. Establish specific patient-centered care processes.~5. Promote continuity of care after discharge, follow up after discharge, and reevaluate quality of life and fragility."
223535816|NCT04301648|OTHER|Common Practice|Common practice will consist in that the nurse who is in the hemodynamic nurse's office will do her usual task that is exclusively health education.
223535817|NCT02144467|DEVICE|MRI|fMRI, sMRI, ASL and DTI
224100354|NCT06544109|DRUG|venetoclax|patients in whom the WBC counts increased to more than 2 × 109/L received Venetoclax
223946273|NCT03292406|DRUG|Placebo|Non active ingredients of CD11301
223946274|NCT03292406|DRUG|CD11301 0.03%|Topical Gel
223720404|NCT03385512|BEHAVIORAL|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
223720405|NCT03385512|BEHAVIORAL|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
223720406|NCT03385512|BEHAVIORAL|ASK Poster in Exam Rooms|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
223720407|NCT00823095|DRUG|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
223720408|NCT01764672|DRUG|Methylphenidate|Oral dose 40mg (2 x 20mg)
223720409|NCT01764672|OTHER|Placebo|Oral intake of 2 placebo tablets
223720410|NCT04789135|DRUG|Ozone|Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.
223720411|NCT05123820|DRUG|Treatment period A|Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
223720412|NCT05123820|DRUG|Treatment period B|ACT-1014-6470 soft capsule for oral administration. Midazolam solution for oral administration. Omeprazole hard capsule for oral administration.
223720413|NCT00436839|DRUG|Docetaxel|75mg/m² intravenously (day 1) every 21 days
223720414|NCT00436839|DRUG|Mitoxantrone|12mg/m² intravenously every 21 days
223720415|NCT00436839|DRUG|Prednisone|10mg orally given daily
223720416|NCT04904562|DRUG|Angiotensin II|Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
223946275|NCT03292406|DRUG|CD11301 0.06%|Topical Gel
224100355|NCT00264407|DRUG|Hormone Replacement Therapy - HRT|
223720417|NCT04904562|DRUG|Placebo|Placebo
223535818|NCT04756830|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
223535819|NCT05408780|DRUG|AC-OLE-01-VA|formulation of tricaprilin or matching placebo
223535820|NCT05791214|OTHER|score|Creation and validation of new nurse' score in ICU
223535821|NCT03794973|BIOLOGICAL|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
223535822|NCT03794973|OTHER|TOL-3021 Placebo|TOL-3021 Placebo
223720418|NCT00016887|BIOLOGICAL|filgrastim|
223946276|NCT00706888|DIETARY_SUPPLEMENT|Vitamins B6, B9 and B12 and polyphenols|
223946277|NCT00706888|DIETARY_SUPPLEMENT|placebo|
223946278|NCT04638049|OTHER|Collection of human biofluids|Feces, blood and urine: (1) shortly before, (2) during and (3) shortly after RT treatment, as well as (4) one-month post-RT
223946279|NCT04638049|OTHER|Patient reported outcome measures|EORTC QLQ-C30, PR25: (1) shortly before and (2) shortly after RT treatment, as well as (3) one-month post-RT
223946280|NCT00647075|DIETARY_SUPPLEMENT|Yunzhi extract|3.5 g/day
223535823|NCT04397380|DEVICE|Thermography|Measure Temperature using Thermal Camera
223535824|NCT04397380|DEVICE|Tympanic Temperature|Measure Temperature using Tympanic Temperature
223720419|NCT00016887|BIOLOGICAL|recombinant interferon alfa|
223720420|NCT00016887|DRUG|carmustine|
223720421|NCT00016887|DRUG|cyclophosphamide|
223720422|NCT00016887|DRUG|cytarabine|
223720423|NCT00016887|DRUG|dexamethasone|
223720424|NCT00016887|DRUG|etoposide|
223720425|NCT00016887|DRUG|melphalan|
223720426|NCT00016887|PROCEDURE|bone marrow ablation with stem cell support|
223720427|NCT00016887|PROCEDURE|peripheral blood stem cell transplantation|
223720428|NCT00016887|RADIATION|radiation therapy|
223720429|NCT03571425|OTHER|Oral Placebo|A placebo beverage will be consumed orally
223720430|NCT03571425|OTHER|Oral Protein|A protein beverage will be consumed orally
223720431|NCT03571425|OTHER|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
223720432|NCT05964205|OTHER|Electronic clinical decision support tool|Electronic clinical decision support tool
223946281|NCT00647075|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
223946282|NCT03720249|DIETARY_SUPPLEMENT|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
223946283|NCT03720249|DIETARY_SUPPLEMENT|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
223946284|NCT03438409|OTHER|Robotic gait training|Robotic gait training
223946285|NCT01293292|DRUG|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
223946286|NCT02056847|DRUG|Pitavastatin calcium 4mg|taking once a day
223946287|NCT02056847|DRUG|Pitavastatin calcium 2mg|Taking once a day
223946288|NCT03737110|DRUG|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
223946289|NCT03737110|DRUG|Placebo|Placebo SC injections once weekly
223946290|NCT02409043|OTHER|Blood draw|Blood drawn for comparison with other groups
223720433|NCT03972332|DIAGNOSTIC_TEST|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
223946291|NCT02409043|OTHER|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
223946292|NCT01619319|OTHER|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
223946293|NCT01619319|OTHER|computer games|computer games that that consist of word puzzles
223946294|NCT05647759|BEHAVIORAL|HEART Camp Connect|Once eligible and enrolled, participants will aim to complete 150 minutes of moderate-intensity exercise a week with the help of a virtual exercise coach
223946295|NCT01235520|DRUG|Placebo|Oral doses, once a day for 52 weeks
223946296|NCT01235520|DRUG|RO4917838|Oral dose level 1, once a day for 52 weeks
223946297|NCT01235520|DRUG|RO4917838|Oral dose level 2, once a day for 52 weeks
223946298|NCT06293066|DIAGNOSTIC_TEST|Ultrasound|Usefulness of transvaginal ultrasound
223946299|NCT02434276|BIOLOGICAL|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
223946300|NCT02434276|BIOLOGICAL|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
223946301|NCT03263117|DRUG|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
223946302|NCT03263117|DRUG|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
224100356|NCT00855439|DRUG|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
224100357|NCT00855439|DRUG|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
224100358|NCT02792868|OTHER|24 h urines analyses|patient collects urines during 24h
224100359|NCT02485392|DEVICE|Da Vinci Single Site Robot-Assisted Cholecystectomy|
223946303|NCT03263117|PROCEDURE|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
224100360|NCT02485392|DEVICE|Single Incision Laparoscopic Cholecystectomy|
224100361|NCT03639740|DRUG|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
224100362|NCT06037876|DRUG|IVM (200 µg/kg) + ALB (400 mg)|World Health Organization Pre-Qualification (WHO PQ) recommended ivermectin 3mg tablets will be used together with albendazole 400mg tablets as provided by WHO for Neglected Tropical Disease (NTD) programs.
223720434|NCT01637272|DRUG|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
223720435|NCT05196204|OTHER|Trunk-oriented task training combined with functional electrical stimulation|Training will consist to perform one hour of trunk task-oriented training combined with functional electrical stimulation (FES/T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. FES will be combined with functional and non-functional tasks to work functionality and muscle strengthening. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises.
223720436|NCT05196204|OTHER|Trunk-oriented task training alone|"The SCI participants who will perform T-TOT training alone will have to perform the same exercises as explained in the previous section (two functional tasks and two non-functional tasks) but they will not receive any functional electrical stimulation.~Training will consist to perform one hour of trunk task-oriented training (T-TOT) specific for muscle strength and motor control. All training will be done seated without support with knees and hips flexed to 90 degrees. Each training session will consist on the fulfilment of two functional tasks (as reaching) and two non-functional tasks (as push-up movement) from a battery of postural control exercises."
223720437|NCT04141592|PROCEDURE|Bariatric Surgery|Already clinically indicated surgical procedures
223720438|NCT02493140|DIETARY_SUPPLEMENT|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
223720439|NCT02493140|DIETARY_SUPPLEMENT|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
223720440|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrencePrognosticScore|Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling
223720441|NCT05866783|DIAGNOSTIC_TEST|HCCRecurrenceDiagnosticScore|Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling
223720442|NCT03024060|DRUG|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
223720443|NCT03024060|DRUG|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
223720444|NCT03024060|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
223946304|NCT02867579|BEHAVIORAL|"evaluation of the child quality attachment (Strange situation)"|
224100363|NCT06037876|DRUG|ALB (400mg)|Albendazole 400mg manufactured and donated by GlaxoSmithKline (GSK) to WHO
224100364|NCT01246492|DIETARY_SUPPLEMENT|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
223720445|NCT03024060|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
223720446|NCT06487585|DRUG|Angiotensin II|Angiotensin II: Starting dose of 20 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
223720447|NCT02968797|DEVICE|SafeSed|Monitor respiratory parameters
223720448|NCT01399515|DRUG|Valproic Acid|One 500mg tablet by mouth daily
223720449|NCT00681005|DRUG|rabeprazole|20 mg bid for 14 days
223720450|NCT00681005|DRUG|pantoprazole|pantoprazole 40 mg bid
223720451|NCT05866796|DIAGNOSTIC_TEST|GlycoTransplantTest|Determination of serum glycomics in the early posttransplant stage, using an optimal cutoff based on statistic modeling.
223946305|NCT05967130|BIOLOGICAL|Phage|Inserting specific specimen of phages in to the bladder
223946306|NCT04397185|DEVICE|Breast Cancer Locator (BCL) guided partial mastectomy|The BCL is a patient-specific, plastic, bra-like form which is placed on the breast to localize the tumor during surgery.
223946307|NCT04397185|DEVICE|Wire Localized (WL) partial mastectomy|Standard of care procedure
224100365|NCT01089192|DRUG|Metformin|
224100366|NCT04538404|PROCEDURE|Colon Surgery|Right, left colon surgery, transverse colon surgery, multiple colon surgery in open and minimally invasive surgert
224100367|NCT04454411|DRUG|Brixadi|Extended release injectable Buprenorphine
224100368|NCT04454411|DRUG|Vivitrol|Extended release injectable Naltrexone
224100369|NCT05904587|DEVICE|SureSmile® VPro™|the pain is recorded when the patient is biting on the mouthpiece of the device during the debonding procedure
224100370|NCT05904587|OTHER|ortho technology, sports advantage, thermal forming soft EVA 3mm|the pain is recorded when the patient is biting on the EVA sheet during the debonding procedure
224100371|NCT05904587|OTHER|cotton roll|the pain is recorded when the patient is biting on the cotton roll during the debonding procedure
224287454|NCT06473402|DEVICE|Percussion Therapy|A percussion massage device was used in the study. Massage application was applied to the Hamstring muscle, adhering to optimal standards. During the application, a wide round head, which is the most preferred by clinical professionals, was used and 30 Hz, which is considered as the average application speed, was used. The application was applied for a total of 6 minutes, 2 minutes for each part of the muscle. Applications have been made many times on every part of the muscle, from the starting point to the ending point.
223946308|NCT04039646|COMBINATION_PRODUCT|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
223946309|NCT05984667|BEHAVIORAL|C-SMART|The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.
223946310|NCT04171674|DRUG|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
223946311|NCT00639418|BIOLOGICAL|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
223946312|NCT02693288|PROCEDURE|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
223946313|NCT03744026|DEVICE|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
223946314|NCT03744026|DRUG|Carboplatin|Dose of carboplatin infusion is AUC4-6
223946315|NCT02614157|PROCEDURE|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
223946316|NCT02614157|DEVICE|labeled line|
223946317|NCT00269815|DRUG|methylphenidate HCl|
223946318|NCT04648215|OTHER|lavender oil|aromatherapy--two drops applied to a 2x2 gauze and pinned to subject's gown
223946319|NCT04648215|OTHER|Grapeseed Oil|aromatherapy--two drops applied to a 2 X 2 gauze and pinned to subject's gown
223946320|NCT02731066|OTHER|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
223946321|NCT02731066|OTHER|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
223946322|NCT02731066|OTHER|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
223946323|NCT02731066|OTHER|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
223535825|NCT02213029|DRUG|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or \>150mg
223535826|NCT02213029|DRUG|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
223535827|NCT02213029|DRUG|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
223535828|NCT02213029|DRUG|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
223535829|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
223535830|NCT02072954|DRUG|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
223535831|NCT03144284|OTHER|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
223535832|NCT06254066|DRUG|Adebrelimab plus Fluzoparib|Adebrelimab combined with Fluzoparib in HRD-positive HR +/HER2- advanced breast cancer
223535833|NCT03130686|DEVICE|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
223535834|NCT04442893|BEHAVIORAL|Rumination-Focused Cognitive Behaviour Therapy|Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
223535835|NCT04442893|OTHER|Health Education programme|Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
223535836|NCT00814255|DRUG|Adalimumab|Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
223535837|NCT00814255|DRUG|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
223946324|NCT00444743|DRUG|MM-093|60 mg, administered subcutaneously, weekly
223946325|NCT00444743|OTHER|Placebo|Placebo
223946326|NCT01784809|BEHAVIORAL|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
223720452|NCT04534361|OTHER|CBCT measurements|No intervention will be performed on patients for this study. Based on the CBCTs already done previously of the patients in the sample, linear measurements will be taken in order to assess dimensional changes of the alveolar ridge at 1, 3, 5 and 7 mm from the bone crest in the CBCTs taken before and after implant explantation, 4-6 months apart.
223946327|NCT01784809|BEHAVIORAL|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
223946328|NCT01784809|BEHAVIORAL|Wellness Promotion|
223946329|NCT05159271|DEVICE|Azeol spray nasal|Azeol Spray Nasal is a nasal spray intended to reduce the nasal congestion due to rhinitis, rhinosinusitis and colds which is marketed. The ID is conforming to the European Union (EU) legislation and is bearing the CE-mark. The ID is manufactured by PILEJE S.A.S (France).
223946330|NCT05159271|DEVICE|Placebo nasal spray|with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
223946331|NCT02734706|DIETARY_SUPPLEMENT|LRC™ capsule|Twice per day (BID), 9 weeks
223535838|NCT00814255|DRUG|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
223535839|NCT02526784|DRUG|degarelix|
223535840|NCT04734314|OTHER|conventional physical therapy|conventional physical therapy in the form of transcutaneous electrical stimulation (TENS) for 20 min and hot pack for 10 min Each patient received 12 sessions three session per week.
223535841|NCT04734314|OTHER|vojta therapy|"Vojta Dynamic Neuromuscular Stabilization (DNS) is a therapy used to manage neurological and musculoskeletal conditions each patient in the study group (group B) was instructed to lie prone on an examination table with the participant's shoulders abducted, elbows flexed approximately 80-90°, and the forearms hanging off the edge of the table. Pressure-like stimulation of the calcaneus and ASIS were performed in the postural position named by Vojta as reflex creeping.~Each patient received 12 sessions three session per week."
223535842|NCT03738722|DRUG|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher\&Paykel.
223535843|NCT00529360|DRUG|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
223535844|NCT00529360|DRUG|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
223535845|NCT05298475|DRUG|Statin|Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)
223946332|NCT02734706|OTHER|Placebo capsule|Twice per day (BID), 9 weeks
223946333|NCT00005826|DRUG|rubitecan|
223535846|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor once a month SC
223535847|NCT05298475|DRUG|PCSK9 inhibitor|1 injection of PCSK9 inhibitor twice a month SC
223535848|NCT03060902|BEHAVIORAL|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
223535849|NCT04858581|DIAGNOSTIC_TEST|Virological and serological tests|Survey, RT-PCR test and blood test
223535850|NCT01465841|DEVICE|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
223720453|NCT01350297|PROCEDURE|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
223720454|NCT02600572|OTHER|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
223720455|NCT02600572|OTHER|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
223720456|NCT01496612|DRUG|Buspirone|
223720457|NCT01496612|DRUG|Placebo|
223720458|NCT02554448|OTHER|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
223946334|NCT04541199|DEVICE|closed loop|RR and VT will be selected according to the respiratory mechanics by closed loop algorithm
223946335|NCT04541199|DEVICE|conventional|RR, VT, Ti will be selected by the clinician according to the respiratory mechanics
223946336|NCT06509867|PROCEDURE|DGG+PRF|de-epithelialized subepithelial connective tissue grafts+ L-Platelet Rich Fibrin + Coronally advanced flap
223946337|NCT06509867|PROCEDURE|DGG|de-epithelialized subepithelial connective tissue grafts+ Coronally advanced flap
223946338|NCT00047385|DEVICE|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
223946339|NCT00047385|DEVICE|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
223946340|NCT01179100|DRUG|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
223946341|NCT00057499|BIOLOGICAL|IBC-VS01|IBC-VS01
223946342|NCT00057499|BIOLOGICAL|IBC-VS01 placebo|IBC-VS01 placebo
223720459|NCT05032560|DRUG|ABX464|Drug: ABX464 ABX464 is a new anti-inflammatory drug
223946343|NCT00669474|PROCEDURE|Suction curettage|Suction curettage
223946344|NCT00669474|DRUG|Treatment with Botox|Treatment with Botox
223946345|NCT02123953|DRUG|TAK-438|TAK-438 tablets
223720460|NCT05032560|DRUG|Placebo|Drug: Matching Placebo placebo matching with ABX464
223946346|NCT02123953|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
223946347|NCT05109598|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell)|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person /dose Recombinant new coronavirus vaccine (CHO cells).
223946348|NCT05329519|BEHAVIORAL|Listening music|Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
223946349|NCT04217252|DIAGNOSTIC_TEST|PMseqTM high-throughput sequencing technology|high throughput sequencing of infectious pathogens
223946350|NCT00776139|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
223946351|NCT03068312|DRUG|Ivacaftor|IVA 150 mg tablet.
223946352|NCT03068312|DRUG|Placebo|Placebo matched to IVA tablet.
223720461|NCT00358371|DRUG|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
223720462|NCT00358371|DRUG|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
223720463|NCT03675100|PROCEDURE|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
223720464|NCT01146418|BIOLOGICAL|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
223720465|NCT01146418|BIOLOGICAL|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
223720466|NCT06201741|RADIATION|[131I]/[18F]/[68Ga]ZT-111|\[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
223720467|NCT02885103|DEVICE|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
223720468|NCT02885103|DEVICE|Nebulizer|Inhalation will be done will Nebulizer and via mouth
223720469|NCT00358852|OTHER|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
223946353|NCT06140888|DRUG|Ginkgo Biloba Extract|Ginkgo biloba extract 8 pills three times per day is administrated.
223946354|NCT03166605|DRUG|Simethicone|Giving simethicone before and after capsule ingestion.
223946355|NCT02551224|OTHER|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
223946356|NCT00986869|PROCEDURE|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
223946357|NCT00608699|DRUG|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
223946358|NCT01070537|DEVICE|Bonfils fiberscope intubation|
223946359|NCT02110407|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
223946360|NCT02110407|BEHAVIORAL|training|intensive training of visual-spatial abilities (in LOCATO task)
223946361|NCT04455204|DIAGNOSTIC_TEST|Serum asymmetteric dimethyl arginine|Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay
223946362|NCT04455204|DIAGNOSTIC_TEST|serum lipid profiles|serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits
223946363|NCT04455204|DIAGNOSTIC_TEST|Serum vaspin|vaspin concentrations will be assayed using commercially available ELISA kits
223946364|NCT04455204|DIAGNOSTIC_TEST|Serum resistin|resistin concentrations will be assayed using commercially available ELISA kits
223946365|NCT00273052|DRUG|Carvedilol Phosphate modified release formulation|
223946366|NCT00273052|DRUG|metoprolol succinate|
223946367|NCT05099562|DEVICE|Acupuncture|Patients received standardized acupuncture treatment. A blood sample of genomic DNA storage was taken from the back of the hand between the first and second metacarpals. Genotypes were obtained by oligonucleotide ligation/polymerase chain reaction and capillary electrophoresis of peripheral neuropathy-associated SNPs.
223946368|NCT05005351|DEVICE|Digital ACT|Participants in Digital ACT arm complete daily ACT lessons and activities and continue their non-pharmacological and pharmacological treatment as usual.
223946369|NCT05005351|DEVICE|Digital Symptom Tracker|Participants in the Digital Symptom Tracker arm complete daily symptom and function tracking, have access to digital fibromyalgia and health education, and continue their non-pharmacological and pharmacological treatment as usual.
223946370|NCT01951703|DEVICE|senofilcon A|Control, senfilcon A
223946371|NCT01951703|DEVICE|senofilcon A|Test, senofilcon A
223946372|NCT03773432|OTHER|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
223720470|NCT00356291|BEHAVIORAL|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
223720471|NCT00356291|BEHAVIORAL|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
223720472|NCT04489563|DEVICE|i-ACT|Performing exercises with an adapted motion detection device (i.ACT) for 20-30 minutes.
223946373|NCT05350670|BEHAVIORAL|Perineal massage and cold compress|Using perineal massage and cold compress during the second stage of labor to observe the effect
223720473|NCT05856032|DEVICE|Acapella device|Acapella is one of the Oscillatory Positive Expiratory Pressure (OPEP) device used in mobilization of peripheral secretions to the central trachea. It consists of a mouth piece and metal strip that is attached to a magnet which oscillates upon exhalation of the patient into the device results in oscillations. This helps in generating positive expiratory pressure (PEP) and oscillations of the magnetic ball assist in mucus collection and expectoration. Pulmonary functions are greatly reduced in patients undergone CABG surgery due to prolong effects of anaesthesia and muscle relaxants administered prior to surgery.
223720474|NCT05856032|OTHER|Conventional Treatment|Conventional chest physiotherapy techniques
223720475|NCT02828696|DEVICE|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
223946374|NCT04383392|DEVICE|Rate adaptive pacing|Rate-adaptive pacing is a function of permanent pacemaker to accelerate patients' heart rate when they are walking, stair climbing, running or carrying on intensive physical activity. Appropriately, the function is similar to human's electrophysiology of sinus node but it may be difficult to replace sinus node's function totally. For example, the acceleration or deceleration slope when exercise beginning or cessation is not always the same or consistent in different patients and different time.
223946375|NCT02708498|BEHAVIORAL|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
223720476|NCT05106283|PROCEDURE|Deep block and Combined Block|Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
223946376|NCT02803866|BEHAVIORAL|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
223946377|NCT04312425|PROCEDURE|Modified rapid sequence induction|Modified RSI was put into use in day shift emergency surgery since March 1, 2018. In this scheme, dorsal elevated position and apneic oxygenation technic are applied. Positive pressure mask ventilation is avoided unless necessary. Sellick's technic is not used in this scheme.
223720477|NCT05865067|OTHER|Yoga Therapy|The intervention sessions will consist of 12 yoga therapy sessions, each one approximately 30 to 45 minutes long, it will be given once a week (on Saturdays) in a room in the building of the School of Health Professions in the Campus of Medical Sciences from the University of Puerto Rico.
223720478|NCT05865067|OTHER|Exercise|The wait-list control group will be motivated to exercise at home (except for Yoga).
223720479|NCT05191771|DEVICE|Neovis Total Multi|1 drop in each eye, 4 times per day
223720480|NCT05191771|DEVICE|Systane Balance|1 drop in each eye, 4 times per day
223946378|NCT04312425|PROCEDURE|Classic rapid sequence induction|In classic RSI scheme, patients are in supine position during induction and intubation. Sellick's technic is applied after sedatives and muscle relaxant are given.
223946379|NCT05501340|DRUG|Serplulimab|PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
223946380|NCT05501340|DRUG|Molgramostim|200ug qd subcutaneous injection for 7 days
223720481|NCT01117831|OTHER|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
223720482|NCT01499056|BIOLOGICAL|stem cell injection|intra articular inection of mesenchymal stem cell
223720483|NCT03789474|DEVICE|HUNTLEIGH FLOWTRON ACS900|
223720484|NCT02171520|DRUG|Dabigatran etexilate generation I|
223946381|NCT05501340|RADIATION|Hypofractionated radiotherapy/Sterotactic body radiotherapy|8Gy\*3f
223946382|NCT03683641|DEVICE|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
223946383|NCT03683641|DEVICE|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
223720485|NCT02171520|DRUG|Dabigatran etexilate generation II|
223720486|NCT01332903|DRUG|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
223946384|NCT03945084|DRUG|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
223535851|NCT06098326|DRUG|cyclophosphamide, fludarabine, and antithymocyte globulin|"1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)"
223720487|NCT02544360|BEHAVIORAL|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
223720488|NCT05344170|DRUG|30 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (1.5%), an oral formulation of CBN (15 mg/mL) suspended in medium chain triglycerides (MCT) oil.
223946385|NCT03945084|OTHER|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
223946386|NCT02330900|OTHER|Study group|Exposure to cell phone interference of the ICD
223946387|NCT03305705|DRUG|Iron Carboxymaltose|Single intravenous infusion within 20 min
223946388|NCT03305705|DRUG|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
223946389|NCT02718339|BEHAVIORAL|Intensive counseling|
223946390|NCT01890954|DEVICE|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
223946391|NCT02039999|OTHER|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
223535852|NCT00956293|DRUG|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
223720489|NCT05344170|DRUG|300 mg Cannabinol (CBN)|Participants will receive a 2 mL oral dose of 'ECS 310' (15%), an oral formulation of CBN (150 mg/mL) suspended in medium chain triglycerides (MCT) oil.
223720490|NCT05344170|DRUG|Placebo|Participants will receive a 2 mL oral dose of placebo. Placebo contains the same excipient, medium chain triglycerides (MCT) oil, as the investigational products but does not contain cannabinoids.
223720491|NCT03889444|DRUG|Dexamethasone intravitreal implant|Dexamethasone intravitreal implant 0.7 mg injection, as per routine clinical practice.
223720492|NCT03708328|DRUG|Lomvastomig|Lomvastomig will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
223720493|NCT00753467|DRUG|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
223720494|NCT00753467|DRUG|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
223720495|NCT00753467|DRUG|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
223720496|NCT02955160|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
223720497|NCT02955160|BIOLOGICAL|Tdap|Tetanus, diphtheria, and pertussis vaccine
223720498|NCT00066885|DRUG|calcitriol + docetaxel|
223720499|NCT00283452|BEHAVIORAL|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
223946392|NCT02039999|OTHER|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
223946393|NCT02039999|OTHER|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
223946394|NCT02730091|DRUG|Letrozole|Letrozole 2.5 mg daily
223946395|NCT02730091|DRUG|Anastrozole|anastrozole 1 mg daily
223946396|NCT02730091|DRUG|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
223946397|NCT04803734|DRUG|Albuterol Sulfate inhalation aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
223946398|NCT04803734|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation|MDI, 2 puffs, single dose, fasting
223946399|NCT05570227|OTHER|[U-13C]Glucose Infusion|Peri-operative infusion of \[U-13C\]glucose
223946400|NCT01640288|DRUG|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
223946401|NCT01640288|OTHER|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
223946402|NCT03949478|DRUG|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
223946403|NCT03949478|DRUG|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
223946404|NCT03949478|DRUG|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
223946405|NCT04755907|PROCEDURE|surgical resection|Surgical resection will be performed for locoregional lesions or liver metastases.
223946406|NCT04755907|OTHER|adjuvant chemotherapy|Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
223946407|NCT04755907|OTHER|neoadjuvant therapy|Regimens of neoadjuvant chemotherapy are directed by clinical guidance and experience.
223946408|NCT04555057|PROCEDURE|Music therapy|Music selected according to the patient's individual preferences.
223535853|NCT00956293|DRUG|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
223535854|NCT00956293|DRUG|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
223535855|NCT00956293|DRUG|Cyclosporin A (CsA)|Dosage was based according to blood level
223535856|NCT00956293|DRUG|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
223535857|NCT04405817|DEVICE|ECMO|ECMO for circulatory and/or respiratory support
223535858|NCT03383666|DEVICE|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
223535859|NCT04655157|DRUG|encorafenib|A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
223535860|NCT04655157|DRUG|nivolumab|A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
223535861|NCT04655157|DRUG|ipilimumab|A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
223535862|NCT04655157|DRUG|binimetinib|A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
223535863|NCT02728024|OTHER|Missing items, Errors in Completion, Difficulties|
223535864|NCT03507127|DRUG|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
223535865|NCT03507127|DRUG|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
223535866|NCT03508050|DEVICE|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
223535867|NCT01240863|DRUG|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
223946409|NCT06506357|DIETARY_SUPPLEMENT|Good Girl Probiotics|Participants will take one capsule of the Good Girl Probiotics supplement daily in the morning for eight weeks.
223946410|NCT05210985|BEHAVIORAL|Affordances in the Home Environment for Motor Development-Infant Scale|Affordances in the Home Environment for Motor Development-Infant Scale is a parent-filled assessment to determine the nature and amount of factors affecting infant motor skill development in the home environment, including the availability of toys, materials, and the availability of spaces.
223946411|NCT05210985|BEHAVIORAL|Peabody Developmental Motor Scales-2|"Peabody Developmental Motor Scales \| Second Edition (PDMS-2) combines in-depth assessment with training or remediation of gross and fine motor skills of children from birth through 5 years."
223720500|NCT01944592|BEHAVIORAL|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
223946412|NCT05210985|BEHAVIORAL|Test Of Sensory Functions In Infants (Tsfı)|This test helps you identify infants with sensory integrative dysfunction-including those at risk for developing learning disabilities as they grow older. The TSFI provides objective criteria that allow you to determine whether, and to what extent, an infant has deficits in sensory functioning. Designed for use with children from 4 months to 18 months old, the TSFI provides an overall measure of sensory processing and reactivity, as well as scores on the following subdomains: Reactivity to Tactile Deep Pressure Visual Tactile Integration Adaptive Motor Function Ocular Motor Control Reactivity to Vestibular Stimulation
223946413|NCT01124552|DRUG|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
223946414|NCT01124552|DRUG|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
223946415|NCT01124552|OTHER|Vehicle|Vehicle Control
223946416|NCT01124552|DRUG|Placebo|Placebo Comparator
223946417|NCT02174978|BIOLOGICAL|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
223946418|NCT02174978|OTHER|P falciparum Controlled Human Malaria Infection (CHMI)|
223535868|NCT01240863|DRUG|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
223535869|NCT05873088|DIAGNOSTIC_TEST|Isometric|Effects of Isometric Exercise in Female Patients With Osteoarthritis
223535870|NCT05873088|DIAGNOSTIC_TEST|Isotonic Exercise|Effects of Isotonic Exercise in Female Patients With Osteoarthritis
223535871|NCT00240266|DRUG|Rosuvastatin|
223535872|NCT05495581|DRUG|pudexacianinium chloride|Intravenous
223946419|NCT06176014|PROCEDURE|implant placement|5 implant were placed in intraforaminal area using surgical guide
223946420|NCT06437158|DRUG|Bleomycin|To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
223535873|NCT02133079|BIOLOGICAL|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
223946421|NCT05837689|DRUG|Blinatumomab|IV
223946422|NCT00338325|BEHAVIORAL|Reading program|Reading of children's story/picture books preoperatively
223946423|NCT05076825|OTHER|Neurodynamic Sliding|Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.
223946424|NCT05076825|OTHER|Static Stretching|Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.
223946425|NCT03883724|BEHAVIORAL|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
223946426|NCT03883724|BEHAVIORAL|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
223946427|NCT00911391|DEVICE|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
223946428|NCT00911391|PROCEDURE|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
223946429|NCT03810300|OTHER|Cash transfer|1500 taka ($18.75) per household distributed monthly
223946430|NCT03810300|OTHER|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
223946431|NCT03810300|OTHER|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
223946432|NCT03810300|BEHAVIORAL|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
223946433|NCT03810300|OTHER|Control|No transfer, no behavior change communication
223946434|NCT00195819|BIOLOGICAL|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
223946435|NCT00195819|BIOLOGICAL|placebo|Placebo every other week (eow)
223946436|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
223946437|NCT01629589|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
223946438|NCT03973515|DRUG|glucokinase activator|PB-201 is a kind of dual and partial GKA
223946439|NCT03973515|DRUG|Placebo|Placebo oral tablet
223946440|NCT01218841|DIETARY_SUPPLEMENT|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
223535874|NCT05993741|DEVICE|AR Dental Care Training System|AR dental care training system is the first training system used in tooth clean skill learning (including Bass method of brushing and inter-dental toothbrush brushing technique) the world, it has been used to training elementary school children and dental hygiene student. And we are the first study to use this system to learn oral cleaning skill in hospital for patient with T2DM.
223535875|NCT05994352|OTHER|virtual reality simulation|The effect of virtual reality simulation on therapeutic communication skill levels
223535876|NCT02081586|BEHAVIORAL|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
223535877|NCT02081586|DEVICE|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
223535878|NCT02081586|OTHER|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
223535879|NCT02460276|DRUG|Lenalidomide|
223535880|NCT02460276|DRUG|Ibrutinib|
223535881|NCT02460276|DRUG|Rituximab|
223946441|NCT01218841|DIETARY_SUPPLEMENT|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
223946442|NCT01303510|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
223946443|NCT06161259|DRUG|Leritrelvir(Ray1216)|Participants receive Leritrelvir orally.
223946444|NCT03770520|PROCEDURE|QFR-guided CABG|CABG surgery based on CAG and QFR
223946445|NCT03770520|PROCEDURE|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
223946446|NCT03877354|OTHER|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
223946447|NCT03877354|OTHER|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
223946448|NCT00891631|BEHAVIORAL|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
223946449|NCT00891631|BEHAVIORAL|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
223946450|NCT02797587|DRUG|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
223535882|NCT02118155|PROCEDURE|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
223535883|NCT04017234|OTHER|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
223946451|NCT02797587|DRUG|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
223946452|NCT02797587|DRUG|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
223946453|NCT02797587|DRUG|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
223946454|NCT02797587|DRUG|Cytisine Placebo|Multi-daily dosing for 25 days.
223946455|NCT02797587|DRUG|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
223946456|NCT00822900|DRUG|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
223535884|NCT05513963|BEHAVIORAL|Clairity|Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.
223535885|NCT03904160|BEHAVIORAL|Weight management|Please see the arm descriptions.
223535886|NCT03393104|BEHAVIORAL|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
223535887|NCT03393104|BEHAVIORAL|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
223720501|NCT01944592|BEHAVIORAL|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
223946457|NCT00822900|DRUG|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
223946458|NCT00177619|DRUG|Alendronate|
223946459|NCT04874649|OTHER|Balloon-blowing breathing|Participant sit on a chair. Inhale fully through their nose and hold for a full 3 second inhalation, then exhale through their mouth into the balloon fully. By having the balloon inflate until their touch the balloon size control device and hold the exhalation period for 1 second, cover the balloon immediately with your fingers count as 1 breath cycle, then replace the balloon immediately. Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
223946460|NCT04874649|OTHER|Sustained maximal inspiration breathing|Participant sit on a chair. Inhale through their nose fully and hold for 3 seconds for a full breath, Do this for 3 consecutive rounds, counted as 1 set, in each training, do a total of 3 sets, rest between sets for 1 minute, which takes about 15 minutes, 5 times per week for 8 weeks
223946461|NCT03254472|DIAGNOSTIC_TEST|Measured concentrations of biomarkers|
223535888|NCT05064228|BEHAVIORAL|Mobile Rewarding Activity Centered Treatment (m-ReACT)|Participants will utilize m-ReACT for 12-weeks, reporting daily on substance-free activity engagement and enjoyment (EMA). m-ReACT will utilize these EMA reports to generate brief, automated, and personalized feedback about enjoyed categories of substance-free activities as well as make suggestions for increasing engagement in those rewarding, goal-oriented substance-free activities, and provide personalized suggestions of activities of interest.
223535889|NCT03722810|OTHER|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
223720502|NCT00496808|DRUG|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
223535890|NCT03722810|OTHER|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
223535891|NCT05802901|PROCEDURE|Spinal manipulation|Spinal manipulation of the lumbar spine only to be performed in the spinal manipulation arm/group.
223720503|NCT01691209|DEVICE|Phoenix (BAY81-2996)|Topical formulation applied to the skin
223535892|NCT05802901|PROCEDURE|Dry needling|Dry needling of the lumbar erector spinae, multifidus, and gluteus medius on the symptomatic side performed in the dry needling arm/group.
223535893|NCT05802901|PROCEDURE|Spinal manipulation and dry needling|The spinal manipulation and dry needling arm/group receive both spinal manipulation and dry needling as outlined in the other groups.
223720504|NCT01691209|DRUG|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
223720505|NCT01256801|BIOLOGICAL|cytokine|interleukin 2 2 million unit every week
223720506|NCT04345809|PROCEDURE|MESH WHIT OMEGA-3|Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
223946462|NCT06177561|PROCEDURE|Lymphoplasma exchange|The LPE treatment regimen is: LPE\*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2\*2 times, gamma globulin 0.4g/kg/d\*5d.
223946463|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
223946464|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
223946465|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
223946466|NCT01142063|DRUG|Neratinib|Tablet, a 240 mg single oral dose
223946467|NCT03764020|DRUG|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
223946468|NCT03764020|DRUG|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
223946469|NCT03569774|PROCEDURE|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
223946470|NCT03569774|PROCEDURE|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
223946471|NCT01802424|BEHAVIORAL|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
223946472|NCT01629420|DRUG|KLH-2109|
223946473|NCT01629420|DRUG|KLH-2109|
223946474|NCT01433185|OTHER|Text message|Text messages sent to women before and after delivery
223946475|NCT00349232|BEHAVIORAL|lifestyle intervention (diet and physical activity)|
223946476|NCT01847768|BIOLOGICAL|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
223946477|NCT01847768|PROCEDURE|Bronchoalveolar Lavage|
223946478|NCT01847768|DRUG|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
223946479|NCT01847768|PROCEDURE|Nasal Lavage|
223946480|NCT01847768|PROCEDURE|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
223946481|NCT01847768|PROCEDURE|Bronchial Brushings|
223946482|NCT01847768|PROCEDURE|Lung Mucosal Biopsy|
223946483|NCT01847768|PROCEDURE|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer \& glycerol negative control.
223946484|NCT01847768|PROCEDURE|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
223946485|NCT01847768|PROCEDURE|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
223946486|NCT01847768|PROCEDURE|Spirometry|
223946487|NCT01581099|PROCEDURE|Digestive Adaptations III surgery|
223946488|NCT04105751|DEVICE|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
223946489|NCT02562612|DRUG|SM-88|Daily SM-88 in multiple ascending doses over 6 months
223946490|NCT03346733|DIETARY_SUPPLEMENT|Psyllium Fibre|Viscous soluble psyllium fibre
223946491|NCT04377191|OTHER|exergame|Microsoft Xbox 360 Kinect The exercises were advanced from simple to complex. The program started with exercises in a sitting position. In the next stage, the games requiring weight transfer and use of upper limbs in standing position were continued. The program ended with games that require more complex movements such as lunge and mini squats.
223946492|NCT04377191|OTHER|exergame|ALDA In the training, games that could be controlled by balance swing, trunk movements and weight transfer in sitting or standing position were used.
224100372|NCT06371339|DEVICE|"Additional acquisitions with the investigational gamma-camera  MoTI ."|"The gamma-camera MoTI will be used for the study to carry out 3 or 4 additional acquisitions (depending on the therapeutic indication) compared with those provided for in standard practice with a conventional gamma camera (Syngula).~Patients will receive their treatment as usual in two stages:~* 1/ Pre-therapy phase:~  1. Administration of a tracer dose of 131I (Day 0).~ 2. Assessment of 131I uptake/fixation rate at Day 0, Day 1, Day 5.~ 3. Determination of the therapeutic dose of 131I to be administered to the patient after collegial discussion.~* 2/ Therapy phase:~  1. Administration of the therapeutic dose (Day 0).~ 2. Thyroid scintigraphy within 4 hours of treatment before the patient returns home (Day 0).~For the study, scintigraphic acquisitions will be carried out respectively using both the standard gamma camera Syngula and the gamma camera MoTI."
223535894|NCT03601299|OTHER|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
223535895|NCT04146155|DRUG|Liraglutide+standard-of-care treatment|"Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines."
223535896|NCT04146155|OTHER|standard-of-care treatment|Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
223535897|NCT05671250|COMBINATION_PRODUCT|PRP gel and SOC-treatment|Platelet-lysate loaded sustained release thermo-gelling formulation
223535898|NCT05671250|COMBINATION_PRODUCT|EPO/ISDN/UFH cryogel dressing|Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
223535899|NCT05671250|PROCEDURE|Standard of Care|Sharp debridement, saline washing and regular saline dressing
223535900|NCT00951392|DRUG|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
223535901|NCT00951392|PROCEDURE|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~* Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~* Global transcriptome analysis by DNA Chip"
223535902|NCT00951392|DEVICE|indirect calorimetry|energy expenditure measurement
223535903|NCT04613388|OTHER|Assesment of Effectiveness and side effects|Case Report forms, Quality of life questionaire
223535904|NCT05296161|DRUG|Ocrelizumab|Personalized B cell tailored ocrelizumab treatment
223535905|NCT04033692|DEVICE|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
223535906|NCT05390684|OTHER|audit of complications, prospective data collection|Prospective colecction of data will be performed to create a predictive model of leak and major complication
223535907|NCT01677988|DRUG|Neo-adjuvant Chemotherapy|"1. Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~2. Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~   1. Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~  2. Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
223535908|NCT01677988|RADIATION|Chemoradiation|"1. Chemoradiation may be administered at selected approved CTN sites.~2. Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~   1. Unresectable → Off study. Subsequent treatment per patient's primary MD.~  2. Resectable → Continue to Registration #3 for Surgical Resection"
223535909|NCT01677988|PROCEDURE|Surgical Resection|"1. Meets criteria for resectable\* →pancreaticoduodenectomy (POD)~2. At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
223535910|NCT00928772|DEVICE|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
223535911|NCT00928772|DRUG|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
223535912|NCT00928772|OTHER|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
223535913|NCT00544206|OTHER|standard enteral feeding product|16 hrs daily x 5 days
223535914|NCT00544206|OTHER|Diabetes specific feeding product|16 hrs daily for 5 days
223946493|NCT04377191|OTHER|exercise|Standard Exercise Program The program included warm-up, main exercise and cooling. Warm-up and cooling included neck, trunk, upper-lower extremity range of movement (ROM) exercises and stretching exercises. Main exercise included postural alignment, strengthening for trunk and lower extremity, balance and walking exercises.
223946494|NCT00681109|DRUG|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
223946495|NCT00681109|DRUG|Placebo|custom eye drop to be applied three times a day in both eyes for three months
223946496|NCT00681109|DRUG|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
223946497|NCT05017909|BEHAVIORAL|Face to face education|Face to face education techniques on the acquisition of the mothering Role
223946498|NCT05017909|BEHAVIORAL|Web based education|web based education techniques on the acquisition of the mothering Role
223946499|NCT05017909|BEHAVIORAL|No education|Control group will not be educated
223946500|NCT04016207|DRUG|Guanfacine|regular treatment
224100373|NCT02531815|BIOLOGICAL|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
223535915|NCT04955184|DEVICE|non-invasive monitoring|non-invasive measurements of cardiac output
223535916|NCT00499837|DRUG|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
223720507|NCT04345809|PROCEDURE|MESH WITHOUT OMEGA-3|Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
223720508|NCT00453622|DEVICE|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
223720509|NCT05780229|PROCEDURE|Conservative treatment|The rehabilitation is based on restoring the balance of the shoulder joint. Aiming to diminish pain and restore function, pain control and inflammation are addressed during the firsts 3-6 weeks. Before week 3, pendulum movements are allowed to initiate mobilization of the shoulder joint. Aiming to gain (almost) complete shoulder joint mobility, a passive and active mobility exercise program is carried out. Lastly, the focus is on muscle reinforcement, performing a series of active exercises with weights or bands to exercise different muscles of the shoulder or the shoulder girdle.
224100374|NCT02531815|DRUG|Placebo|Placebo for PF-06741086, single dose
224100375|NCT02497703|DEVICE|Knee robot|
224100376|NCT05405829|OTHER|Health education|theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
224100377|NCT01402219|DRUG|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
224100378|NCT01402219|DRUG|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
223720510|NCT05780229|PROCEDURE|Arthroscopic Decompression Surgery|Arthroscopic decompression surgery of the rotator cuff tear consists of cleaning the subacromial space. The procedures that are sometimes performed to diminish pain may include, removing the inflamed bursa, releasing the long head of the biceps (if injured), or lightly burring the acromion bone under which the tendons slide.
223720511|NCT05780229|PROCEDURE|Reverse Prosthesis|The reverse prosthesis consists of shoulder articular joint replacement. The humeral head is sectioned, and, on the scapular side, a metal tray is placed, which is fixed with screws, and a metal half-sphere fixed to the metal tray. On the humeral side, a metal stem with a concave plastic component is placed to articulate with the metal half-sphere, allowing shoulder mobility without the need of rotator cuff muscles.
223720512|NCT05780229|DRUG|Pain-Relief Medication|In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
224100379|NCT00477087|DRUG|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
224100380|NCT00477087|DRUG|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
224100381|NCT05110066|PROCEDURE|Pulmonary endarterectomy|Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
224100382|NCT05110066|PROCEDURE|Balloon pulmonary angioplasty|Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
224100383|NCT05639764|DEVICE|Oculus Quest 2|A specific immersive virtual reality software designed to address chronic shoulder pain on the Oculus Quest 2 device.
224100384|NCT05639764|DEVICE|Oculus Quest 2|"a VRi placebo intervention with the game Tsuro, which consists of a puzzle-based strategy game where the patient will have to solve a maze by placing pieces."
223535917|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535918|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535919|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
224100385|NCT01442298|PROCEDURE|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
224100386|NCT01442298|PROCEDURE|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
224100387|NCT01397851|DEVICE|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
224100388|NCT03119649|DRUG|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
224100389|NCT03119649|DRUG|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
224100390|NCT03119649|DRUG|Placebo|Matching oral tablet(s) containing placebo
224100391|NCT03119649|DRUG|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
224100392|NCT03119649|DRUG|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
223720513|NCT05780229|DEVICE|Reverse Prosthesis Device|In the reverse prosthesis procedure, a Delta III reverse shoulder prosthesis is applied. The original design was developed by Grammont in 1980's, and has 2 components: 1) a metal tray fixed with screws, and a metal half-sphere fixed to the metal tray, and 2) a concave polyethylene component.
223946501|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously through Cycle 1-8 at a standard dose of 375 mg/m\^2 (milligram per square meter).
223720514|NCT01802931|DRUG|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
223946502|NCT04660799|DRUG|Rituximab SC|Rituximab will be administered subcutaneously through Cycle 2-8 at a dose of 1400 milligram (mg).
223946503|NCT04660799|DRUG|Rituximab IV|Rituximab will be administered intravenously in Cycle 1 at a standard dose of 375 mg/m\^2.
223946504|NCT04660799|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dose of 750 mg/m\^2
223946505|NCT04660799|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dose of 50 mg/m\^2
224100393|NCT05822856|OTHER|Blood sampling and others interventions|Blood sampling, faeces collection, questionnaires, tactile sensitivity, sensorial tests
224100394|NCT03529487|DRUG|Oxymetazoline|Oxymetazoline gel applied intra-analy
223535920|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535921|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535922|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535923|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535924|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
223535925|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
223535926|NCT00659425|DRUG|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
223535927|NCT01332656|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
223720515|NCT01802931|DRUG|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
223720516|NCT02716428|DRUG|Faldaprevir|
223720517|NCT02716428|DRUG|TD-6450|
223720518|NCT02716428|DRUG|Ribavirin|
223720519|NCT01347944|DRUG|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
223720520|NCT00779285|DRUG|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
223946506|NCT04660799|DRUG|Vincristine|Vincristine will be administered IV at a dose of 1.4 mg/m\^2
223946507|NCT04660799|DRUG|Prednisone|Prednisone will be administered orally at a dose of 100 mg/day
223946508|NCT04660799|DRUG|Paracetamol|All participants are required to receive 1000 mg oral paracetamol as premedication prior to starting each infusion of rituximab
223946509|NCT04660799|DRUG|Diphenhydramine hydrochloride or alternative antihistamine|All participants are required to receive 50-100 mg oral diphenhydramine hydrochloride or alternative antihistamine as premedication prior to starting each infusion of rituximab
223946510|NCT05995691|DRUG|ABP 501|SC injection
223946511|NCT05995691|DRUG|Adalimumab|SC injection
223946512|NCT03941509|BEHAVIORAL|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
223946513|NCT00134186|DRUG|motexafin gadolinium|
223720521|NCT03209596|DIETARY_SUPPLEMENT|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
223720522|NCT03209596|DIETARY_SUPPLEMENT|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
223720523|NCT06237998|DEVICE|Telemedicine|Patients receive equipment for report of vital signs and patient reported experience measures (PREMS), automatically transmitted via smartphone/bluetooth for six months (possible extension to 12 months in case of instability). A digital smartphone application is used for registration and transmission of data, including modes for asynchronous (chat) communication with the healthcare provider. Planned titration to OMT or diuretic adjustments may be done remotely depending on clinical assessment. The digital sensors include an electronic scale, pulse and blood pressure monitor for daily measurements by the patient.
223720524|NCT04891952|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|Functional precision medicine test to predict response to candidate chemotherapeutic agents
223720525|NCT01623583|OTHER|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~* The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~* Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
223946514|NCT04262115|BEHAVIORAL|AM-EX|AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
223946515|NCT04262115|BEHAVIORAL|PM-EX|PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
223946516|NCT05850624|OTHER|ice massage|active phase when cervical dilatation was 6-8 cm. Ice will apply to the huko point (LI4 area) which is located on the dorsum of the hand, between the first and second metacarpal bones, between the thumb and the index finger for 20 minutes with an ice pack
223946517|NCT05850624|OTHER|virtual reality animation|cervical dilatation was 6-8 cm. Immediately after the second VAS application, the women will be asked about the video they wanted to watch of the sound of waves in the Ocean, rain falling or blooming trees with virtual reality glass. animation will show for a total of 20 min.
223946518|NCT02858115|OTHER|Fluid challenge|100 ml of crystalloid was infused over 1-min
223946519|NCT02858115|OTHER|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
223946520|NCT00774059|DEVICE|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
223946521|NCT01737749|DEVICE|Neurokeeper stroke detector|Electrophisoloigcal monitoring
223946522|NCT02446275|OTHER|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
223946523|NCT02446275|OTHER|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
223946524|NCT03616015|BIOLOGICAL|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
223946525|NCT03616015|BIOLOGICAL|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
223946526|NCT03616015|BEHAVIORAL|Anxiety test|Test of Spielberger
223946527|NCT03616015|BEHAVIORAL|Stress test|Test of Cohen
223946528|NCT02449785|DEVICE|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
223946529|NCT02449785|DEVICE|CT measurements of lung morphological changes in cystic fibrosis|
223946530|NCT02376309|BEHAVIORAL|Inactivity|Inactivity
223946531|NCT02376309|DRUG|ND|1 nandrolone decanoate injection
223946532|NCT02376309|DIETARY_SUPPLEMENT|Leu|Leucine supplements
223946533|NCT04406532|BEHAVIORAL|PT-Pal|"Participants will be guided through an exercise program in the PT-Pal app. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
223720526|NCT01623583|OTHER|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~1. Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~2. Basic training on relaxation breathing~3. Brief video of a patient overcoming needle phobia~4. Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
223720527|NCT04729270|PROCEDURE|Physiotherapy treatment with physium device.|The intervention for this group consisted of 10 sessions with Transcranial Direct Current Stimulation for a month.
223720528|NCT04729270|PROCEDURE|Conventional physiotherapy treatment.|The intervention for this group consisted of 10 sessions with Electrical Nerve Stimulation (TENS) for a month.
223535928|NCT01332656|DRUG|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
223535929|NCT01332656|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
223535930|NCT01332656|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
223535931|NCT05687370|PROCEDURE|Modified dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using modified dynamic short-axis view.
223535932|NCT05687370|PROCEDURE|Long-axis technique|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
223535933|NCT02361892|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
223535934|NCT03888560|DEVICE|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
223535935|NCT05364450|BEHAVIORAL|Enhanced Usual Care|"Interventionists will provide a brief explanation of the intervention and coaching to the group on how to utilize the resources provided. Prior to the single session group, EUC participants will have received a workbook with the National Cancer Institute's Facing Forward: Life After Cancer Treatment booklet on maximizing quality of life during cancer survivorship and the American Society of Clinical Oncology's Guide to Cancer Survivorship."
223946534|NCT04406532|BEHAVIORAL|Self-guided exercises|"Participants will use the exercise manual to guide the exercise program. The program is stratified into 3 levels. Participants begin with Level 1 exercises to prevent atelectasis, strengthen inspiratory and expiratory muscles. Gradually exercises to stretch limb and chest wall muscles, build sitting tolerance and to improve transfer ability are added. These exercises can improve respiratory vital capacity. Level 2 focuses on sitting tolerance, strengthening limb and accessory muscles of breathing. Level 3 focuses on standing balance, large muscle strengthening, and building cardiopulmonary endurance.~Each exercise is done 2-3 times, and gradually increased to a complete set of 8. Each set is then repeated 2-3 per day, building up tolerance and fitness. Duration of session varies from 10 min initially up to 45 min later depending on fitness."
223946535|NCT01714076|OTHER|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
223946536|NCT03120026|DIETARY_SUPPLEMENT|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
223535936|NCT05364450|BEHAVIORAL|Acceptance Commitment Therapy|Interventionists will support participants in adopting a psychologically flexible posture toward FCR through six interdependent processes of change - acceptance, cognitive defusion, mindfulness, perspective taking, values, and committed action. During ACT sessions, participants will learn to respond adaptively to FCR by being more fully aware of thoughts, feelings, and bodily sensations without judging or attempting to control or avoid them. Participants will also clarify their deeply-held values and set action goals in alignment with their values.
223535937|NCT05364450|BEHAVIORAL|Cognitive Behavioral Therapy|Interventionists will provide psycho-education on the cognitive behavioral model of FCR and assist participants in changing unhelpful thinking patterns and maladaptive behaviors linked to FCR. Session topics will include FCR triggers, behavioral experiments to reduce FCR-perpetuating safety behaviors, and pleasant events scheduling. Interventionists will also provide evidence-based information on behaviors that may reduce recurrence risk (e.g., achieving a healthy weight, physical activity, cancer surveillance).
223535938|NCT03634956|DRUG|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
223535939|NCT05663684|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
223946537|NCT03120026|DIETARY_SUPPLEMENT|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
223946538|NCT03192709|DRUG|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
223946539|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
223946540|NCT03192709|OTHER|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
223946541|NCT05815420|DEVICE|Non invasive ventilation|Treatment by non invasive ventilation
223535940|NCT05663684|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
223535941|NCT05754866|PROCEDURE|Transbronchial lung cryobiopsy|Lung tissue was obtained by transbronchial lung cryobiopsy for subsequent pathology and clinical diagnosis.
223535942|NCT05754866|PROCEDURE|Transbronchial lung biopsy|Lung tissue was obtained by transbronchial lung biopsy for subsequent pathology and clinical diagnosis.
223720529|NCT03036696|OTHER|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
223946542|NCT02161458|DRUG|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
223946543|NCT02161458|DRUG|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
223946544|NCT02161458|DRUG|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
223535943|NCT00271544|DEVICE|Pacing Lead|implant and follow-up of study device
223946545|NCT02161458|DRUG|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
223946546|NCT03567278|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
223535944|NCT05700409|BEHAVIORAL|Intensive lifestyle consultations|detailed above
223535945|NCT06564064|DEVICE|abdominal binder|study group will be abdominal binders and control group will be control group , 12 hrs and one week later VAS and QOR 40 will assess patient,s wellbeing
223535946|NCT02445209|OTHER|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
223535947|NCT02445209|OTHER|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
223535948|NCT05215002|OTHER|Telephone Call|Patient will be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
223535949|NCT05215002|OTHER|No telephone call|Patient will not be called in the evening of the day of the surgery or one day after surgery and asked about any complaints
223535950|NCT03358030|DRUG|ISIS 416858|Subcutaneous injection
223535951|NCT03358030|DRUG|Placebo|Subcutaneous injection
223946547|NCT01078272|OTHER|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
223720530|NCT03036696|OTHER|Breastfeeding Mothers Interview|"Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
223720531|NCT02695329|DEVICE|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
223946548|NCT01078272|OTHER|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
223535952|NCT05730842|DRUG|EDG-5506 Tablet|Single Oral Dose - Tablet
223535953|NCT05730842|DRUG|Radiolabeled EDG-5506 Suspension|Single Oral Dose
223535954|NCT05730842|DRUG|Radiolabeled EDG-5506 Intravenous|Single Intravenous Dose
223535955|NCT06324032|PROCEDURE|EUS Elastography (EUS-E)|All procedures will be performed with Olympus echoendoscopes (Olympus Europa SE \& CO. KG, Hamburg, Germany) or Pentax echoendoscopes in combination with dedicated elastography software
223535956|NCT00652171|DRUG|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
223535957|NCT00652171|DIETARY_SUPPLEMENT|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
223720532|NCT04324775|OTHER|Exercise + Manual Lymphatic Drainage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, manual lymphatic drainage applied to rectus femoris for 5 minutes
223535958|NCT04314622|DRUG|Supaglutide|Administered SC
223535959|NCT04314622|DRUG|Placebo|Administered SC
223535960|NCT00158093|DRUG|Nebivolol|
223535961|NCT00158093|DRUG|Atenolol|
223535962|NCT00158093|DRUG|Moxifloxacin|
223535963|NCT03973957|DEVICE|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
223535964|NCT03973957|DRUG|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
223535965|NCT03973957|DRUG|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
223720533|NCT04324775|OTHER|Exercise + Swedish massage|Quadriceps exercises with weight of 75%1 Max repetition and 8 repetionX3 sets Following exercises, swedish massage applied to rectus femoris for 5 minutes
223720534|NCT03198247|OTHER|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
223946549|NCT04047407|DEVICE|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
223946550|NCT03046706|BEHAVIORAL|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
223946551|NCT03046706|BEHAVIORAL|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
223946552|NCT02476929|DEVICE|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
223946553|NCT02476929|DEVICE|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
223946554|NCT01354288|OTHER|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
223946555|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
223946556|NCT01934452|DRUG|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
223946557|NCT05589415|DEVICE|High-definition Transcranial Direct Current Stimulation|"High-definition Transcranial Direct Current Stimulation (HD-tDCS) delivers current through five small electrodes (0.8 cm2) placed in an X-shaped configuration via a simple cap. This configuration leads to an 80% greater concentration or focusing of the electric field within the targeted region compared to conventional, non-focal Transcranial Direct Current Stimulation (tDCS). The participant will undergo 30 minutes of treatment at 2 milliamps."
223946558|NCT05589415|DEVICE|Conventional Transcranial Direct Current Stimulation|Surface electrodes will be placed in saline-soaked sponges (5 x 7 cm2) and applied to different regions of the scalp. The participant will undergo 30 minutes of treatment at 2 milliamps.
223946559|NCT02253966|DRUG|Methylprednisoloneacetate|
223946560|NCT02253966|DRUG|Lidocaine|
223946561|NCT02253966|OTHER|sodium chloride|
223946562|NCT03837015|DRUG|Estring Vaginal Ring|Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
223946563|NCT03837015|OTHER|RepHresh Pro-B|Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
223720535|NCT03198247|OTHER|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
223946564|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
223720536|NCT05446805|DRUG|F 18 AV-1451 (Flortaucipir)|A dosage range between 6.5 - 10.0 mCi (240-370MBq) is planned for \[18F\] AV-1451. A PET-certified medical professional will prepare and administer the \[18F\] AV-1451tracer. Prior to the administration, the dosage will be assayed in a dose calibrator. The volume of 18F-AV-1451 dose should not be adjusted by adding normal saline to the syringe. Participants will receive a maximum intravenous bolus injection of 10.0 mCi of \[18F\] AV-1451 followed by a 10 mL flush of 0.9% sodium chloride (normal saline).
223946565|NCT04028518|DRUG|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
223720537|NCT05446805|DRUG|[11C]-Pittsburgh Compound B ([11C]PiB)|A dosage range between 6.0 - 20.0 mCi (222-740 MBq) is planned for \[11C\] PIB. A PET-certified medical professional will prepare and administer the \[11C\] PIB tracer. Prior to the administration, the dosage will be assayed in a dose calibrator and diluted with 0.9% sodium chloride (normal saline) up to a total 20 mL syringe volume. Participants will receive a maximum intravenous bolus injection of 20.0 mCi of \[11C\] PIB followed by a 10 mL 0.9% sodium chloride (normal saline) flush.
223720538|NCT00978198|DRUG|ASP1517|oral
223720539|NCT00978198|DRUG|Placebo|oral
223720540|NCT01351922|OTHER|No treatment given|Patients will fill out a questionaire by interview.
223720541|NCT06085612|DIAGNOSTIC_TEST|Automated retinal oximetry|Non invasive standard examination on automated retinal oximetry.
223946566|NCT04028518|DRUG|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
223946567|NCT00461656|DRUG|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
223535966|NCT03973957|DEVICE|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
223720542|NCT04786145|PROCEDURE|Cryoneurolysis|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways by freezing it. Small probe is inserted in order to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve.
223720543|NCT04786145|PROCEDURE|Radiofrequency ablation|This is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. Small needle with an active heating tip is inserted, to destroy the functionality of the target nerve using heat from radiofrequency energy.
223720544|NCT04786145|PROCEDURE|Placebo|No active treatment is given.
223535967|NCT02009579|DRUG|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
223535968|NCT02009579|DRUG|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
223535969|NCT01298336|DRUG|Clarithromycin|500 mg twice a day seven days a week
223535970|NCT01298336|DRUG|Moxifloxacin|400 mg per day seven days a week
223535971|NCT04597749|DIAGNOSTIC_TEST|PSG|In-lab sleep polysomnography test
223535972|NCT04597749|DIAGNOSTIC_TEST|Home Sleep Apnea Test with FDA cleared devices|In-lab HST test
223946568|NCT05732142|OTHER|Postpartum Integration of Vaccines and Contraception Through Gender-Transformative Programming(PIVoT)|The PIVoT intervention is a 30-minute focused information exchange that supports shared contraceptive decision making. The program includes a gender-equity and family planning curriculum covering basic family planning information as well as gender norms and son preference and interactive family planning method index cards (detailing method characteristics, use, duration of action, efficacy, side effects, and contraindications for each method). The program is designed to support person-centered contraceptive choice and encourages women to consider joint family planning decision-making with male partners. If a contraceptive method is desired, it will be provided by nurses who are trained to provide comprehensive family planning care.
223946569|NCT01053793|OTHER|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
223946570|NCT06157554|OTHER|Breathing Exercises|During the exercise sessions, participants will be seated in a chair. In the first five and last five minutes of the session, they will be instructed to focus on their breathing and the sensations produced in the body while sitting comfortably in a relaxed position with all joints in the chairs with their eyes closed. After the initial 5 minutes of relaxed breathing, participants will be instructed to perform diaphragmatic and costal breathing for 10 minutes. After 5 minutes of diaphragmatic breathing, the patient will be rested for 1 minute and then 5 minutes of costal breathing will be performed. While doing coastal breathing, patients will be asked to place their hands on their costas, take a deep breath and inflate the bottom of their hands; then they will be asked to exhale the breath they take in a longer (1:2) time.
223946571|NCT06157554|OTHER|Conventional treatment|Ultrasound, hotpack and TENS will be applied to both control and study groups as physical therapy modality. Then 15 sessions of Codman exercises, normal range of motion exercises and stretching exercises will be applied to both groups.
223946572|NCT00849485|DRUG|Levetiracetam|750 mg Tablet
223946573|NCT00849485|DRUG|Keppra®|750 mg Tablet
223720545|NCT06270667|BEHAVIORAL|Aerobic Exercise|Participants receive twice weekly supervised aerobic treadmill-based exercise sessions for five months. Session duration varies from 20 to 60 minutes, including warm-up, with exercise intensity ranging from 60 to 95% of peak heart rate. Maximal exercise capacity (VO2peak and peak heart rate) will be determined by the CPET performed by certified exercise physiologists at baseline.The exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. This intervention is also given to the Active Comparator group (i.e. non-cancer reference group)
223946574|NCT00528216|DRUG|Capsaicin Dermal Liquid|
223946575|NCT00186446|DRUG|bupropion and smoking cessation behavioral intervention|
223946576|NCT01576796|RADIATION|Radiotherapy|"No additional dose (patients negative F-miso)~* Radiation therapy is conducted under standard conditions of conformal radiotherapy:~* The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
223720546|NCT06270667|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Twice weekly, supervised combined aerobic and resistance exercise sessions will be offered to participants. Participants randomized to the combined aerobic and resistance training group will follow the same aerobic exercise prescription as described for the Aerobic Exercise arm. In addition, participants in this group will perform five resistance exercises after the aerobic sessions. The resistance exercises will be leg press, knee extension, and calf rise, followed by seated row and chest press. Following familiarization, the training load will progressively increase following a linear periodization model throughout the intervention. exercise prescription will be sequenced so that the exercise intensity and -duration of each exercise varies within each week, leading to an accumulative increase in weekly exercise volume throughout the intervention. Only Lymphoma participants can be randomized to this arm.
223720547|NCT02023606|DRUG|SPN-810M|
223535973|NCT04597749|OTHER|Non-Contact Screening App|Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
223535974|NCT03571490|DRUG|Ropivacaine|Single shot of ropivacaine 0.325%
223946577|NCT06030817|DIAGNOSTIC_TEST|99mTc-CNDG SPECT/CT|Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.
223535975|NCT03571490|DRUG|Saline|Single shot of saline 0.9%
223535976|NCT02505425|BEHAVIORAL|Behavioral Support|"ENABLE CHF-PC includes:~1. In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~2. Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
223946578|NCT05215249|PROCEDURE|Transnasal humidified high-flow oxygen delivery|The Optiflow system consists of an apparatus that is capable of delivering humidified oxygen, room air, or a mixture of variable oxygen concentration. The oxygen concentration can be precisely varied from 21-100% (or 0.21 - 1.00 FiO2). The gas is warmed to 37°C with a 100% relative humidity. The humidified and warmed gas can be delivered to the patient at high-flows (up to 70 L/min) using various delivery mechanisms. The investigators will be using a nasal cannula to deliver high flow oxygen (2-3 L/kg/min) to the patient.
223946579|NCT00158483|DRUG|Acyclovir (ACV)|
223946580|NCT04924296|DRUG|SHR-1314|SHR-1314 s.c. + Steroids
223946581|NCT04924296|DRUG|Placebo|Placebo s.c. + Steroids
223535977|NCT02505425|BEHAVIORAL|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
223535978|NCT06645197|DRUG|SNUG01|Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
223535979|NCT06395558|BEHAVIORAL|Lifestyle intervention|Multimodal web-based intervention programme on anxiety, depression and cognitive impairment consisting of knowledge development sessions and practical/gaming sessions focused on different domains: cognitive competence, socio-relational competence and emotions/affectivity, and physical activity-nutrition
223535980|NCT02383784|DIETARY_SUPPLEMENT|Low GI index diet|Low glycemic index diet
223535981|NCT02383784|DIETARY_SUPPLEMENT|High GI diet|High glycemic index diet
223535982|NCT00000621|DRUG|all trans retinoic acid|
223535983|NCT00000621|DRUG|13 cis retinoic acid|
223535984|NCT00000621|DRUG|placebo|
223535985|NCT03150264|DEVICE|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
223535986|NCT03150264|DEVICE|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
223535987|NCT05432609|DIAGNOSTIC_TEST|Weight bearing CT|Weight bearing CT in loaded and unloaded positions
223535988|NCT04329767|DEVICE|IRIS 1.0|Intuitive's IRIS 1.0 system is a software only device and service intended to create and deliver segmented image studies (3D anatomical models) based on patients computed tomography (CT) scans. It is intended as software for preoperative surgical planning, and as software for the intraoperative display of the aforementioned multidimensional digital images.
223535989|NCT05175014|BIOLOGICAL|PCV10 full dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a full dose.
223535990|NCT05175014|BIOLOGICAL|PCV10 fractional dose|Mass vaccination campaign with one single dose PCV10 vaccine administered as a fractional dose.
223535991|NCT05470166|DRUG|Lidocaine IV|lidocaine infusion as bolus 1.5mg/kg then 2mg/kg/hr
223535992|NCT05470166|OTHER|saline IV|saline infusion same volume as lidocaine
223535993|NCT05465655|OTHER|ECG monitoring for Conduction Disturbances|Continuous ECG monitoring of Conduction Disturbances in patients undergoing TAVR procedure
223535994|NCT04337151|DEVICE|MAGEC Spine Rod|Magnetically controlled growing spine rod used for the surgical treatment of scoliosis.
223535995|NCT04337151|DIAGNOSTIC_TEST|Titanium blood test|A blood test captured to measure the level of titanium
223535996|NCT03699865|OTHER|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
223946582|NCT02285218|OTHER|serum blood sampling|
223946583|NCT05032716|OTHER|Balance exrcises|the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights
223946584|NCT05032716|OTHER|Balance exrcises and Treadmill training|the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
223946585|NCT04125901|OTHER|Pain Neuroscience Education and Exercise|The incorporation of the exercise in this group will be gradual, in order to decrease the education component and increase the exercise component (up to 45/60 minutes). The 1st session will be only PNE and will last approximately 45 minutes. In the 2nd session, there will be 30 minutes of PNE and the remaining 15 minutes of exercise. In the following 4th and 6th sessions, 15 minutes of each session will be used to clarify doubts and emphasize PNE concepts and strategies. The 8th session will include exercises only. In WhatsApp sessions, in addition to the video with the exercises, participants will receive activities about the PNE.
223946586|NCT04125901|OTHER|Exercise|The exercise group will perform exercises in all sessions (45 minutes of exercise in face-to-face sessions). In WhatsApp sessions, participants will receive a video with exercises to perform at home.
223946587|NCT03942575|DEVICE|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
223946588|NCT00188305|BEHAVIORAL|General health counselling and risk information|General health counselling and risk information
223946589|NCT00705159|DRUG|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
223946590|NCT00705159|DRUG|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
223946591|NCT00705159|DRUG|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
223946592|NCT00705159|DRUG|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
223535997|NCT05154734|DRUG|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
223535998|NCT05036135|DRUG|AV-101|AV-101 (imatinib) administered via dry powder inhalation
223535999|NCT05036135|DRUG|Placebo|Placebo administered via dry powder inhalation
223536000|NCT05456087|DRUG|incobotulinumtoxin A|Up to 150 units of incobotulinumtoxin A will be injected at up to 30 injection sites within the hair loss area
223536001|NCT05869747|BEHAVIORAL|Blood Donation|Participants asked to donate whole blood at a donation facility from a list provided by the study.
223536002|NCT05869747|BEHAVIORAL|Plasma Donation|Participants asked to donate plasma at a donation facility from a list provided by the study.
223536003|NCT05869747|BEHAVIORAL|Zone 2 Training|Participants asked to work out in their custom Zone 2 heart range 4 times a week for 45 to 60 minutes.
223536004|NCT05869747|BEHAVIORAL|Intermittent Fasting|Participants asked to engage in an intermittent fasting routine of a 16 hour fast followed by an 8 hour eating period at least 4 times a week.
223536005|NCT05869747|BEHAVIORAL|Surveys|Participants were asked to complete surveys throughout the study to monitor intervention progress and to collect baseline and end-of-study data.
223536006|NCT04411992|DEVICE|Vibrating Device|The device used for the vibration application was produced to control pain and distract attention by providing vibration of 150 at 183 Hz (9000-11,000/min). The device is used again by being cleaned with 70% alcohol. The device was placed put 3 cm above the injection site. It should be ensured to completely contact with skin. Vibration was applied on the site for 3 minutes before injection
223536007|NCT04173169|DRUG|Elagolix 200 MG|Elagolix tablet
223536008|NCT04173169|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
223536009|NCT01442987|DRUG|Irbesartan/Atorvastatin A|once daily, P.O. 8week
223536010|NCT01442987|DRUG|Irbesartan|once daily, P.O. 8week
223536011|NCT01442987|DRUG|Atorvastatin A|once daily, P.O. 8week
223536012|NCT01442987|DRUG|Placebo|once daily, P.O. 8week
223536013|NCT01442987|DRUG|Irbesartan/Atorvastatin B|once daily, P.O. 8week
223536014|NCT01442987|DRUG|Atorvastatin B|once daily, P.O. 8week
223536015|NCT04194554|DRUG|Niraparib|given PO per dose escalation schedule
223536016|NCT04194554|DRUG|Leuprolide|22.5 mg q3 month
223536017|NCT04194554|DRUG|Abiraterone Acetate|1000 mg daily
223536018|NCT04194554|RADIATION|Stereotactic body radiotherapy (SBRT)|5-6 fraction SBRT (total dose: 37.5-40 Gy)
223536019|NCT06490367|BEHAVIORAL|Time-Restricted Eating Diet|Participants engage in a time-restricted eating diet, specifically maintaining a 6-8-hour eating window every day for 12 weeks. Participants are allowed to self-select the timing of the eating window, but once selected, they are asked to maintain that schedule daily. Outside of that window, for the remaining 16-18 hours of day/night, participants are asked not to consume calorie-containing food or drink. Beverages without calories are allowed.
223536020|NCT00949039|DRUG|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
223720548|NCT06037447|PROCEDURE|3-steps standardized repair-oriented strategy|3-steps standardized repair-oriented strategy, including subvalvular apparatus rehabilitation (leaflet plication if chordae absent on leaflet margin, mal-connected chordae resection if chordae mal-connected to leaflet body, papillary muscle splitting if short chordae or dysplastic or fused papillary muscle etc.), leaflets repair (leaflets plication if functional leaflet prolapse, leaflet cleft closure and patch augmentation for anatomical leaflet defect, etc.) and annuloplasty (posterior annuloplasty for annular dilatation and shallow leaflet coaptation, etc.)
223720549|NCT05309642|BEHAVIORAL|Intermittent calorie restriction|Recipes will be provided with suggestions of meals that would not exceed the calorie restriction. For the remaining 5 days of the week, they will receive instructions and recipes that follows the Korean Dietary Reference Intakes (KDRIs), with an intake limit of 2,000 kcal/day for women and 2,500 kcal/day for men. The percentage of energy (E%) from different macronutrients in the recipes will be 45-60 E% carbohydrates, 25 E% fat and 10-20 E% protein.
223536021|NCT00949039|RADIATION|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
223536022|NCT00949039|PROCEDURE|Surgery|
223536023|NCT06570252|DEVICE|activated Light Source (aPDT)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~Activation of SW4000 Light Source (Class 1 Laser Device) that generates red light consisting of 2 channels of 700 mW, 664 nm light (continuous wave) used to activate the disinfecting formulation.~Duration of illumination 2 minutes"
223946593|NCT02564536|DRUG|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
223946594|NCT02564536|DRUG|Decitabine|-From commercial stock
223946595|NCT04864782|DRUG|QL1604|Intravenous Infusion
223946596|NCT04864782|DRUG|Paclitaxel injection|Intravenous Infusion
223946597|NCT04864782|DRUG|Cisplatin/Carboplatin|Intravenous Infusion
223946598|NCT04440800|DEVICE|Wearable activity tracker - FitBit|Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
223946599|NCT01570894|DRUG|Quetiapine Fumarate|25 mg tablet
223946600|NCT03736980|DRUG|Placebo|100% lactose
223946601|NCT03736980|DRUG|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
223946602|NCT01190852|DRUG|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
223946603|NCT01190852|DRUG|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
223946604|NCT01190852|DRUG|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
223946605|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
223946606|NCT01057082|DIETARY_SUPPLEMENT|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
223946607|NCT00065000|BEHAVIORAL|Water, Cafeteria and Staff Health Promotion|
223946608|NCT04002349|DRUG|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
223946609|NCT04002349|DRUG|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
223946610|NCT04002349|DRUG|0.9% natural saline|Detailed in arm descriptions
223946611|NCT03606551|DEVICE|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
223946612|NCT03385759|PROCEDURE|Unicompartmental knee arthroplasty|Implant to replace the medial compartment of a patient with knee osteoarthritis
223946613|NCT03385759|PROCEDURE|Total knee arthroplasty|Implant to replace the knee joint of a patient with knee osteoarthritis
223946614|NCT00349206|DRUG|sorafenib tosylate|Given orally
223946615|NCT00349206|DRUG|temsirolimus|Given IV
223946616|NCT01896843|DRUG|STX107|
223946617|NCT04275960|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered orally as liquid suspension (20 mg/mL) on Day 1 of each period. Each period lasts 4 days, both periods of each arm are separated by at least 3 days.
223946618|NCT02399241|DEVICE|Bluetooth enabled nebuliser device (I-neb)|
223720550|NCT05309642|BEHAVIORAL|Standard of care|They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
223946619|NCT05878106|DIETARY_SUPPLEMENT|Creatine supplementation|"5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention.~The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily."
223946620|NCT05878106|OTHER|Resistance training|They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.
223946621|NCT03224806|OTHER|Wholegrain bread|156.8g wholegrain bread
223946622|NCT03224806|OTHER|White bread|122.6g white bread
223946623|NCT03224806|OTHER|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
223720551|NCT00115102|DRUG|fentanyl|
223946624|NCT03224806|OTHER|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
223946625|NCT00794300|DEVICE|second magnetic resonance imaging scan|
223946626|NCT03196869|DEVICE|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
223720552|NCT00115102|DRUG|S-ketamine|
223946627|NCT03196869|DEVICE|Routine intravenous drip|Routine intravenous drip-chemotherap
223946628|NCT03196869|DRUG|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
223946629|NCT03196869|DRUG|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
223946630|NCT03196869|DRUG|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
224100395|NCT05002309|BEHAVIORAL|Cognitive-Behavioural Therapy|"20 sessions of individual CBT are offered over 16 weeks, conducted 1-on-1, with a trained and supervised therapist. Participants will learn about the cognitive, behavioural, emotional, and environmental factors which contribute to maintaining their depression. They will apply skills to interrupt unhelpful cognitive and behavioural patterns and engage in guided exploration to improve self-understanding. CBT is a structured and collaborative treatment. Weekly homework will be used to maximize opportunities for practice and consolidation of new skills. The individual sessions can be combined with optional family/parent/partner sessions, depending on the situation and preferences of the participant. All sessions will be video-recorded to allow high-quality supervision, fidelity- and quality-assurance. This corresponds to evidence available for CBT for adolescents and young adults that is established as the best practice through rigorous trials."
223946631|NCT03196869|DRUG|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
223536024|NCT06570252|DEVICE|non activated Light Source (Control)|"Application of SW3100 Formulation (0.2% chlorhexidine gluconate and methylene blue) in both nostrils followed by placing the SW3200 Nasal Light Illuminator with one channel per nostril.~No activation of SW4000 Light Source~Waiting for 2 minutes"
223536025|NCT06569823|BIOLOGICAL|Z-1018|Formulation for injection
223536026|NCT06569823|BIOLOGICAL|Shingrix|Formulation for injection
223536027|NCT06570200|PROCEDURE|PMPR+iPRF|locally applied iPRF in the periodontal pocket
223536028|NCT06570200|DRUG|PMPR+iPRF+Vit.D|locally applied iPRF plus vitamin D in the periodontal pocket
223536029|NCT06570200|PROCEDURE|PMPR only|scaling and root planing only will be done for the periodontal pocket for the control group
223536030|NCT05007158|OTHER|procalcitonin blood test|blood samples of all participants were analyzed for procalitonin levels, using a commercially available procalitonin testing kit
223536031|NCT01064726|DRUG|Ibuprofen|800 mg oral
223536032|NCT01064726|DRUG|Fluticasone propionate|200 mcg intra-nasal
223536033|NCT01064726|DRUG|Placebo|Placebo
223536034|NCT01356368|DRUG|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
223536035|NCT02781558|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
223536036|NCT02781558|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223536037|NCT00380146|DRUG|sulfadoxine-pyrimethamine|
223536038|NCT06539481|DRUG|fluocinolone acetonide 190 micrograms|ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
223536039|NCT00557037|DRUG|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
223536040|NCT02987738|DRUG|Dapagliflozin|two administrations in the evening and 12 hours later
223536041|NCT02987738|DRUG|Placebo Oral Tablet|two administrations in the evening and 12 hours later
223536042|NCT00001066|DRUG|Lamivudine|
223536043|NCT00001066|DRUG|Zidovudine|
223536044|NCT00001066|DRUG|Didanosine|
223536045|NCT01627886|DRUG|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
223946632|NCT03196869|RADIATION|intensity-modulated radiation therapy|control group is similar to Experimental group
223946633|NCT00262366|DEVICE|Comparison of automatic CPAP versus fixed CPAP|
223946634|NCT03026166|DRUG|Ipilimumab|Administered by intravenous infusion
223946635|NCT03026166|DRUG|Nivolumab|Administered by intravenous infusion
223946636|NCT03026166|DRUG|Rovalpituzumab tesirine|Administered by intravenous infusion
223946637|NCT03897699|DEVICE|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
223946638|NCT03897699|BEHAVIORAL|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
223720553|NCT02792725|DRUG|Abemaciclib|Administered orally
223720554|NCT06504940|DRUG|Orelabrutinib combined with bendamustine and rituximab|they will receive three cycles of Orelabrutinib combined with bendamustine and rituximab (BR: bendamustine 70mg/m\^2 on days 1-2; rituximab 375mg/m\^2 on day 0). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 21 cycles, each cycle 28 days).
223720555|NCT06504940|DRUG|Orelabrutinib combined with obinutuzumab|they will receive six cycles of Orelabrutinib combined with obinutuzumab (G 1000mg iv on days 1, 8, 15 of cycle 1, and day 1 of cycles 2-6; Orelabrutinib 150mg once daily). Patients achieving PR or better will enter the Orelabrutinib monotherapy maintenance phase (up to 18 cycles, each cycle 28 days ).
223720556|NCT04874298|OTHER|Ginger|Patients who meet the inclusion criteria and agree to participate in the study will be assigned to the experimental group. In the postoperative period at the 2nd, 4th, 6th, 12th and 24th hours, the patient will use Ginger and Peppermint oil as inhalation. The structure of the inhaler tube is explained. The back cover of the inhaler tube is opened and absorbent cotton swab is inserted into it. Cotton swab 1 ml of essential oil is added by dropping on it. The back cover of the inhaler tube is closed. It is waited for 10-15 minutes. The front cover of the inhaler tube is opened at the time intervals specified in the study procedure (at the 2nd, 4th, 6th, 12th and 24th hours after the operation, and the patient is allowed to smell essential oil from the tube. With the end of the sniffing process, the front cover of the tube is closed and the essential oil remains in the tube. The essential oil tubes to be applied will be prepared separately for each patient and that day.
223946639|NCT03897699|OTHER|Sham|Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
223946640|NCT06082115|OTHER|Selected Physical and Occupational Therapy Program|"The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands."
223946641|NCT06082115|OTHER|Mirror Therapy|The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
223946642|NCT06082115|OTHER|Task-Oriented Training|The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
223536046|NCT06645418|DIAGNOSTIC_TEST|relative Hand grip strength|To perform this study the relative handgrip strength (rHGS) index was used. The rHGSi is defined as the sum of the handgrip strength of both hands divided by body mass index (BMI), and it is considered a better prognostic tool than handgrip strength. rHGS was measured by Jamar hand dynamometer. The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
223536047|NCT06645418|DIAGNOSTIC_TEST|senior fitness test|The Functional Performance was determined by using 3 tests of the Senior Fitness Test (The 30-second chair stand test, the 8-feet Up-and-Go test, and the 2 minutes' Walk Test).
223536048|NCT04171895|OTHER|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
223720557|NCT04874298|OTHER|Peppermint|Peppermint
223720558|NCT02871700|BEHAVIORAL|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
223720559|NCT02871700|BEHAVIORAL|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
223946643|NCT05522023|PROCEDURE|group treated with aromatic solution|The aromatic solution applied in the experimental group will be obtained by mixing lavender oil and ginger oil into cold drinking water. For this, lavender and ginger oil approved by the Ministry of Agriculture will be used. 3 drops of lavender oil and 3 drops of ginger oil will be mixed into each 100 ml of drinking water, and it will be applied by spraying 4 times in the oral cavity and throat by shaking to ensure homogeneous distribution before each use. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
223946644|NCT05522023|PROCEDURE|group treated with drinking water|In the placebo group, drinking water will be sprayed 4 times in the oral cavity and throat of the patients after the surgery. The aromatic solution to be applied in the study will be applied with spray bottles with mouth caps and caps that will be specially provided for each patient.
223946645|NCT03035942|DRUG|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
223946646|NCT03035942|DRUG|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
223946647|NCT03035942|DRUG|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
223946648|NCT01911559|DEVICE|standing-frame|
224100396|NCT05002309|DRUG|Antidepressant medication|The choice of antidepressants follows best-established evidence for treating depression in adolescents and young adults. We will offer treatment with fluoxetine, starting at 10mg a day, increasing to 20mg a day after 1 week if tolerated; a protocol established as safe and effective in adolescents and adults in multiple trials. Additional increases to 40 or 60mg will be possible based on positive effects and side-effects and clinical judgement, as recommended in this age group. In cases of intolerance or adverse reaction to fluoxetine, we will switch to sertraline (25-200mg) or escitalopram (5-20mg), two antidepressants licensed by the FDA for major depressive disorder in adolescents. Treatment will be optimized over 16 weeks, a time-frame comparable to the CBT arm. Pharmacotherapy will be managed and prescribed by qualified psychiatrists when starting treatment and reviewed after 1 week, 2 weeks and then in 2-weekly intervals for the remainder of the 16 weeks acute treatment period.
224100397|NCT02031094|OTHER|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
223720560|NCT02871700|BEHAVIORAL|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
223720561|NCT02385513|BIOLOGICAL|10-valent pneumococcal conjugate vaccine|
223720562|NCT02901405|DEVICE|Negative Pressure Wound Therapy (ActivVAC, KCI)|
223720563|NCT02901405|DEVICE|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
223720564|NCT00099008|DIETARY_SUPPLEMENT|Genistein|oral Genistein twice daily on days 1-84
223720565|NCT00099008|DIETARY_SUPPLEMENT|Placebo|oral Placebo twice daily on days 1-84
223720566|NCT02726152|PROCEDURE|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
223720567|NCT02726152|PROCEDURE|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
223720568|NCT04645082|DIAGNOSTIC_TEST|x-ray examination|A total of 40 individuals who underwent an axial x-ray examination of the lower extremity following ankle sprain were included.
223720569|NCT00074204|DRUG|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
223720570|NCT00074204|DRUG|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
223720571|NCT00074204|DRUG|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
223720572|NCT01172431|DRUG|Indapamide|Indapamide SR 1.5mg qd
223720573|NCT01172431|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
223720574|NCT03648983|PROCEDURE|arm circumference measurement|Undergo arm circumference measurement
223720575|NCT03648983|DEVICE|Bioimpedance spectroscopy|bioimpedance spectroscopy
223720576|NCT04972695|DIAGNOSTIC_TEST|Fundus Photographs (retinographies)|Fundus photographs under mydriasis
223720577|NCT05892120|BEHAVIORAL|the MedAdhere app|The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
223720578|NCT05119452|OTHER|Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)|The biological/targeted synthetic disease modifying anti-rheumatic drug will be discontinued in both arms at baseline
223720579|NCT05677581|OTHER|iodine nutrition status|iodine nutrition status
223720580|NCT01269463|DRUG|Methylphenidate Hydrochloride Extended Release Capsule|An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
223720581|NCT01269463|DRUG|Placebo|Capsule without active drug
223720582|NCT01435200|DRUG|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
223720583|NCT02803632|BEHAVIORAL|questionnaires|
223720584|NCT02803632|DEVICE|actigraphic recording|
223720585|NCT02288897|DRUG|PV-10 (10% rose bengal disodium)|
223720586|NCT02288897|DRUG|Dacarbazine, temozolomide or talimogene laherparepvec|
223720587|NCT00270868|PROCEDURE|Double guide wire technique|
223720588|NCT00270868|PROCEDURE|Standard bile duct cannulation|
223720589|NCT05745571|OTHER|Blood sample|The study foresees a phase of patient recruitment, in which, in the hours immediately following the blood sampling, the isolation of the PBMCs, their incubation and cytofluorimetric analysis will be carried out and the conservation of the material to be analyzed subsequently by molecular biology and immunochemistry.
223720590|NCT03428724|DRUG|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
223720591|NCT03428724|DRUG|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age\>65, neurologic comorbidities)
223720592|NCT00456014|DRUG|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
223946649|NCT05387863|OTHER|Decision Aid (DA) Web Tool|The DA web tool provides information on kidney masses and available treatment options. It uses risk communication, directed teaching, and interactive benefit-harm assessment to present information.
223946650|NCT05387863|OTHER|Institutional Pamphlet|The institutional pamphlet provides information on kidney masses, but does not use risk communication, directed teaching, or interactive benefit-harm assessment.
223720593|NCT00456014|DRUG|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
223720594|NCT02499822|DRUG|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
223720595|NCT02499822|DRUG|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
223720596|NCT03121638|BIOLOGICAL|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
223720597|NCT03121638|BIOLOGICAL|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
223720598|NCT03121638|BIOLOGICAL|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
223946651|NCT06009666|DIAGNOSTIC_TEST|Shear Wave Elastography and B Mode Ultrasonography|We evaluated the both upper extremities of the patient and control group with elastography and B mode ultrasonography. Shear wave elastography evaluates tissue deformation caused by acoustic radiation force. A highly focused ultrasound radiation is produced; The propagation speed of the shear wave depends on the stiffness of the tissue. It is a simple, inexpensive, bedside, widely available, non-invasive technique. B mode USG can be used to assess skin and subcutaneous tissue thickness and echogenicity. Skin and subcutaneous thickness were measured with b mode ultrasound. Skin and subcutaneous tissue stiffness was measured by shear wave ultrasonography
223720599|NCT03121638|BIOLOGICAL|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
223720600|NCT03121638|BIOLOGICAL|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
223946652|NCT06009666|DIAGNOSTIC_TEST|Quick Dash Questionnare|Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. In the questionnaire, the difficulties of the patients during their daily living activities are questioned with 11 questions. Each answer is scored from 1 to 5 on a Likert scale, from best to worst.
223720601|NCT03886805|OTHER|Dual task with variable- and fixed-priority instructions|The participants were asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
223720602|NCT03886805|OTHER|Dual-task with variable-priority instructions|The participants were asked to spend half the session focused on balance (motor tasks) and half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
223720603|NCT04404361|DRUG|Pacritinib|100 mg capsules
223720604|NCT04404361|DRUG|Placebo|Placebo capsules matching pacritinib 100 mg capsules
223720605|NCT04008576|BEHAVIORAL|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
223720606|NCT03534960|DEVICE|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
223720607|NCT03534960|DEVICE|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
223720608|NCT02657291|DRUG|Ropivacaine|Local anesthetic
223720609|NCT02657291|DEVICE|Ultrasound|Ultrasound guided block
223720610|NCT02862171|DRUG|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
223720611|NCT03324308|DIAGNOSTIC_TEST|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
223720612|NCT02849431|BEHAVIORAL|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
223720613|NCT04132258|OTHER|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
223720614|NCT00245115|BIOLOGICAL|filgrastim|
223720615|NCT00245115|DRUG|busulfan|
223720616|NCT00245115|DRUG|cyclophosphamide|
223720617|NCT00245115|PROCEDURE|in vitro-treated bone marrow transplantation|
223720618|NCT00245115|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223720619|NCT05282862|PROCEDURE|Horizontal bone augmentation|Horizontal bone augmentation of a limited span (1-2 teeth) edentulous ridge with neighboring teeth present.
223720620|NCT02549937|DRUG|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
223946653|NCT06009666|DIAGNOSTIC_TEST|The Lymphedema Life Impact Scale|The Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 functional subgroups. Each question is scored from 1 to 5, with higher scores indicating increased seriousness.
223720621|NCT02798601|OTHER|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
223720622|NCT03930797|BEHAVIORAL|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
223946654|NCT06009666|DIAGNOSTIC_TEST|Questioning lymphedema-related symptoms|Arm pain and feeling of tension, heaviness and stiffness in the arm were evaluated separately by numerical scale. This scale is a 10 cm ruler that writes no pain, no tension, no heaviness, no stiffness on one side, and unbearable pain, tension and heaviness on the other side. Patients were asked to rate their associated symptoms on this scale between 0 and 10.
223720623|NCT03930797|BEHAVIORAL|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
223720624|NCT00662012|DRUG|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
223720625|NCT04199910|OTHER|There is no intervention, only research blood samples are collected|Research blood samples collected
223720626|NCT01322139|DRUG|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
223720627|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
223720628|NCT01322139|DRUG|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
223720629|NCT01322139|DRUG|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
223720630|NCT00217594|DRUG|Alemtuzumab (Campath)|
223720631|NCT00000208|DRUG|Buprenorphine|
223720632|NCT02764060|DEVICE|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
223720633|NCT02764060|DEVICE|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
223720634|NCT03594721|OTHER|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
223720635|NCT00980382|DRUG|S-1, Docetaxel|"* Phase I study~  * S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~* Phase II study~  * S-1 (80mg/m2/day) q 12 hours po Days 1-14~ * Docetaxel (35 mg/m2) iv : Days 1, 8"
223720636|NCT06451094|DEVICE|US therapy|3 MHz probe with a BTL brand device at a dose of 1.5 watts/cm2 for 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions.
223720637|NCT06451094|DEVICE|TECAR|Transfer Energy Capacitative and Resistive Therapy
223720638|NCT05853185|DRUG|Pro Root MTA®|Patients in this group will receive the pulpotomy with Pro Root MTA®.
223720639|NCT05853185|DRUG|EBRRM®|Patients in this group will receive the pulpotomy with Endo Sequence Bioceramic Root Repair (EBRRM)®.
223720640|NCT01205906|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
223720641|NCT01205906|BEHAVIORAL|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
223946655|NCT06009666|OTHER|Extremity circumference and volume measurement|For the diagnosis of lymphedema, a detailed physical examination and extremity circumference were measured. This measurement was taken from both wrists to arm height with 4 cm intervals. Those with a circumference difference greater than 2 cm and/or no 10% volume difference were considered preclinical (latent) and those with clinical lymphedema.
223946656|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
223536049|NCT04171895|OTHER|Communication training Part 1 (no longer recruiting)|1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.
223536050|NCT04171895|OTHER|Enhanced usual care|"Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants."
223536051|NCT04171895|OTHER|Communication training Part II|Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
223536052|NCT04704193|OTHER|Survey of Decision Aid|The decision aid will be evaluated by a survey administered to those who have used the tool.
223536053|NCT01202084|DRUG|Formoterol/Fluticasone|
223536054|NCT01202084|DRUG|Foraseq®|
223536055|NCT01202084|DRUG|Fluticasone|
223536056|NCT04667156|DRUG|SHR6390|SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles
223536057|NCT05181228|BEHAVIORAL|Web-Based Education Based on Family-Centered Empowerment Model|Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
223536058|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
223720642|NCT01205906|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
223720643|NCT01744197|DRUG|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
223720644|NCT02872194|DRUG|BAY987516, Y55-170|10 uL in one eye
223946657|NCT01054859|OTHER|alcohol|0.5 g/kg alcohol
223946658|NCT01054859|DRUG|avanafil|200 mg avanafil tablet QD
223946659|NCT01595867|DRUG|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
223946660|NCT01595867|DRUG|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
223946661|NCT01595867|DRUG|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
223946662|NCT04338451|OTHER|Music during the first part of ESWL|Music listening during first part of ESWL
223720645|NCT02872194|DRUG|BAY987516, X72-151|10 uL in one eye
223946663|NCT04338451|OTHER|Music during the second part of ESWL|Music listening during second part of ESWL
223946664|NCT02231970|PROCEDURE|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
223946665|NCT04707820|DIAGNOSTIC_TEST|ELISPOT|"The evolution of the number of gamma interferon (IFN) producing T lymphocytes in response to Spike glycoprotein (Spike glycoprotein) will be assessed by enumeration in ELISPOT method at 4 measurement times: D0 (confirmation of infection by PCR), D+7, D+14 or at hospital departure (D+Departure) and D+56±14 days.~The ELISPOT method consists in stimulating peripheral blood mononuclear cells (isolated by density gradient and containing a known CD3+ T lymphocyte count) over a short period of time (16 to 20 hours) with a pool of 15 amino acid peptides (overlapping on 11 amino acids) representative of the S protein."
223720646|NCT02872194|DRUG|BAY987516, Y49-034|10 uL in one eye
223720647|NCT02872194|DRUG|Standard shampoo mixture (control)|10 uL in one eye
223720648|NCT00216632|DRUG|risperidone|
223720649|NCT01156870|DRUG|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
223946666|NCT05757674|OTHER|Sample examination|No intervention will be performed
223946667|NCT06497920|DEVICE|Active rTMS to the motor cortex|Active bilateral repetitive transcranial magnetic stimulation to the motor cortex
223720650|NCT01893632|DRUG|gabapentin|
223720651|NCT01893632|DRUG|Placebo|
223720652|NCT05450952|DIETARY_SUPPLEMENT|Theanine Formulation|Theanine Formulation Tablet
223720653|NCT05450952|DIETARY_SUPPLEMENT|Placebo|Placebo Tablet
223720654|NCT03863054|DEVICE|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
223720655|NCT05190237|DIETARY_SUPPLEMENT|TMD21-16 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
223720656|NCT05190237|DIETARY_SUPPLEMENT|TCD21-55 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
223946668|NCT06497920|DEVICE|Sham rTMS to the motor cortex|Sham bilateral repetitive transcranial magnetic stimulation to the motor cortex
223946669|NCT03482999|DEVICE|TissuGlu Surgical Adhesive|
223946670|NCT03673605|DRUG|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
223946671|NCT03673605|DRUG|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
223946672|NCT02091752|DRUG|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
223946673|NCT06510413|DRUG|Loxoprofen Sodium Patches(reference product)|Single dose of one patch in each period; Apply for 24 hours each time
223720657|NCT05190237|DIETARY_SUPPLEMENT|TFD21-1 group|2 times a day, 1 pack for 1 time, after breakfast/dinner meal(6 g/day, Soybean paste 6 g/day) for 4 weeks
223946674|NCT06510413|DRUG|Loxoprofen Sodium Patches(test product )|Single dose of one patch in each period; Apply for 24 hours each time
223946675|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
223946676|NCT00876005|OTHER|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
223946677|NCT04888052|DEVICE|Acute ACL injury|Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits \> 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
223946678|NCT03929198|OTHER|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
223946679|NCT05406947|OTHER|Prospective observational study, no intervention|Prospective observational study, no intervention
223946680|NCT03579407|PROCEDURE|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
223720658|NCT01965301|DRUG|BP1.5375 suspension|single oral dose
223720659|NCT01965301|DRUG|Diphenhydramine|single oral dose of Diphenhydramine 50mg
223720660|NCT01965301|DRUG|Placebo|Single oral dose
223720661|NCT00477256|BEHAVIORAL|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
223720662|NCT04186728|DIETARY_SUPPLEMENT|Magnesium glycinate|Daily magnesium capsule.
223720663|NCT04186728|OTHER|Placebo|Daily placebo capsule.
223946681|NCT03719352|PROCEDURE|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
223946682|NCT03719352|PROCEDURE|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
223946683|NCT03719352|PROCEDURE|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
223946684|NCT04703907|OTHER|Auricular stimulation|"Auricular acupuncture-like stimulation (percutaneous sensory stimulation of cranial nerves)"
223946685|NCT05544305|OTHER|Digital Home Based Care pathway|The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.
223946686|NCT02180932|BIOLOGICAL|periodontal pocket samples|
223946687|NCT01420757|PROCEDURE|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
223946688|NCT00729209|DRUG|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
223946689|NCT00729209|DRUG|Placebo; oral|matching placebo
223946690|NCT02390778|BEHAVIORAL|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
223946691|NCT02390778|BEHAVIORAL|leisure activity (film showing)|
223946692|NCT02268240|BEHAVIORAL|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
223946693|NCT05344742|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle)
223946694|NCT05344742|DRUG|Capecitabine|The fixed dose of oral capecitabine will be administered 1000mg/m\^2, twice daily, from day 1 to day 14.
223946695|NCT05344742|DRUG|Albumin-paclitaxel|The fixed dose of albumin-paclitaxel will be set as 260 mg/m\^2, once every three weeks.
223946696|NCT05101317|DRUG|HMI-115|HMI-115 is human monoclonal antibody
223946697|NCT05101317|DRUG|Placebo|Placebo
223946698|NCT06398210|OTHER|Cognitive Exercise Therapy Approach (BETY)|Cognitive Exercise Therapy Approach (BETY) BETY includes mind-body interaction information management, pain management strategies, mood information management through dance therapy/authentic movement, and sexuality information management. BETY first session; After meeting the patient and completing the evaluations, it consists of the steps of analysis of the person's problem, selection of exercise for this problem, replacement of the exercise in function, pain management, and recovery agreement. The basic exercise model used in BETY is function-oriented trunk stabilization exercises. Patients are given information about the 5 features of trunk stabilization (neck, shoulder, rib cage, lumbopelvic region postures, and respiratory control), visual imagery, and their control.
223946699|NCT00783952|DEVICE|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
223946700|NCT00783952|DEVICE|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
223946701|NCT01910194|DRUG|Luyxumia versus Lantus|
223946702|NCT03064906|DEVICE|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
223720664|NCT05686811|OTHER|Myofascial release therapy therapy|Group A was treated with myofascial release therapy and routine physical therapy. For routine physical therapy subjects will first applied TENS, hot pack and neck isometric exercises then myofascial release therapy will be given. For myofascial release therapy subjects was in the supine or possibly sitting position, the examiner was seated at the head of the table, the examiner was used his right thumb to palpate (using flat palpation) the upper trapezius muscles from medial to lateral to establish if any MTrPs are present. The entire mass of the upper trapezius muscle is lifted by the supraspinatus muscle and grasped with a pincer grasp. The muscles at this point rotate between the thumb and forefinger to detect the delicate location of the trigger point. Treatment session longs for 10 minutes of myofascial release on each side
223720665|NCT05686811|OTHER|Post isometric relaxation technique|This group will receive routine physical therapy with myofascial release therapy.This protocol will be given for 3 alternative days per week. Each session will be of 40 minutes. Data will be calculated at baseline , at 2nd and at 4th week.
223720666|NCT02144012|DRUG|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
223720667|NCT02144012|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
223720668|NCT02144012|DRUG|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m\^2) or 100 mg/m\^2 Q3W.
223536059|NCT00995852|DEVICE|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
223536060|NCT04171960|DIAGNOSTIC_TEST|Blood draw|Venous whole blood collection within 12 hours and 12-24 hours following injury.
223536061|NCT04171960|OTHER|Outcome assessments|Administered at baseline.
223720669|NCT01412515|DRUG|everolimus|everolimus per os 10mg per day
223720670|NCT02412475|DRUG|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
223720671|NCT02412475|DRUG|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
223946703|NCT02170532|DRUG|levalbuterol|0.5 ml. levalbuterol
223946704|NCT02170532|DRUG|saline|0.5ml saline
223946705|NCT02170532|OTHER|levalbuterol MDI|
223946706|NCT02170532|DEVICE|breath actuated nebulizer|
223946707|NCT02170532|DEVICE|aerochamber max|
223946708|NCT02170532|DRUG|ipratroprium|
223946709|NCT03658603|PROCEDURE|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
223946710|NCT03658603|PROCEDURE|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
223536062|NCT06988748|OTHER|Assigned Interventions (diet training)|"Pain and bleeding will be evaluated at 4 hours, 8 hours, 24 hours and 7 days after adenotonsillectomy by using Wong-Baker Faces Pain Rating Scale and Follow-up and Evaluation Form for Children After Adenotonsillectomy in Children."
223720672|NCT02412475|DRUG|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
223720673|NCT02412475|DRUG|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
223946711|NCT01381341|DRUG|linifanib|QD on Day 1 of Periods 1 and 2
223946712|NCT02833948|DRUG|Acetylsalicylic acid|"Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)"
223946713|NCT02833948|DRUG|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
223946714|NCT02833948|DRUG|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)"
223946715|NCT05071677|PROCEDURE|Discussion|Participate in treatment planning meeting
223946716|NCT05071677|OTHER|Interview|Participate in interview
223946717|NCT05071677|OTHER|Survey Administration|Complete survey
223946718|NCT03034278|OTHER|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
223946719|NCT03511144|DEVICE|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
223946720|NCT03511144|DEVICE|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
223946721|NCT00493688|OTHER|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
223946722|NCT02397707|DRUG|Voxilaprevir|100 mg tablet administered orally
223720674|NCT02412475|DRUG|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
223720675|NCT02412475|DRUG|Cytarabine|"Patient Age (years) IT Cytarabine Dose \> 1 30 mg~* 2 and \< 3 50 mg~* 3 and ≤ 18 70 mg \> 18 100 mg~given IT on day 0 or -1"
223946723|NCT00142246|DRUG|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
223946724|NCT00142246|OTHER|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
223946725|NCT04123795|DRUG|Certolizumab pegol|"Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use"
223946726|NCT04123795|DRUG|Placebo|"Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Route of Administration: Subcutaneous use"
223720676|NCT02412475|DRUG|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
223720677|NCT02567916|DRUG|Fresofol|
223536063|NCT07004907|DEVICE|Treatment with the pedriatic mode of the APD cycler|Patients weighing less than 20 kg will be treated for 4 weeks with APD using the PAED mode of the Silencia PD cycler
223536064|NCT06675760|DEVICE|The intervention group|The intervention group received training through a mobile augmented reality application in the laboratory.
223536065|NCT04612140|PROCEDURE|Radiosurgery|The study subjects randomized in this study arm will undergo a radiosurgery procedure.
223536066|NCT04612140|PROCEDURE|Repeated catheter ablation|The study subjects randomized in this study arm will undergo repeated catheter ablation.
223536067|NCT07004582|PROCEDURE|HDR brachytherapy|High dose rate (HDR) brachytherapy for the treatment of high-risk or recurrent prostate cancer
223720678|NCT02567916|DRUG|Propofol|
223720679|NCT03602144|OTHER|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
223720680|NCT03602144|OTHER|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
223720681|NCT01375556|DRUG|Ethanol|
223720682|NCT01831050|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
223946727|NCT05173987|BIOLOGICAL|pembrolizumab|Intravenous (IV) infusion
223946728|NCT05173987|DRUG|carboplatin|IV infusion
223946729|NCT05173987|DRUG|paclitaxel|IV infusion
223946730|NCT05173987|DRUG|docetaxel|IV infusion
223946731|NCT05173987|DRUG|cisplatin|IV infusion
223946732|NCT05369000|BIOLOGICAL|LAVA-1207|"In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion."
223720683|NCT01831050|BIOLOGICAL|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
223720684|NCT01831050|BIOLOGICAL|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
223720685|NCT01831050|BIOLOGICAL|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
223720686|NCT01831050|BIOLOGICAL|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
223946733|NCT05369000|BIOLOGICAL|LAVA-1207 plus Pembrolizumab|Pembrolizumab will be administered via intravenous infusion
223946734|NCT05440760|DEVICE|The Oculus Quest 2 Virtual Reality Headset|"The hardware includes the wireless headset with integrated headphones which will block the sight and sounds of the clinical setting as well as the hand controllers for the interactive VR experience, which will be delivered through any of three VR software options (subject may choose one or more from the following options):~* Titans of Space® PLUS developed by Drash VR, LLC (Murrieta, CA, USA)~* TRIPP® developed by TRIPP, Inc. (Los Angeles, CA, USA)~* Nature Treks VR published by Greener Games (Ironbridge, England, UK)"
223946735|NCT05658497|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
223946736|NCT05658497|DRUG|Avonex|Administered as specified in the treatment arm.
223946737|NCT05658497|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
223946738|NCT05658497|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
223946739|NCT02102113|DRUG|Placebo|placebo
223946740|NCT02102113|DRUG|Very Low Dose THC|Subjects will receive 0.010mg/kg.
223946741|NCT02102113|DRUG|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
223946742|NCT04670640|DEVICE|Vibration|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. There will be no explicit tasks or direction given in this intervention. Participants will experience smooth slowly varying breath-like vibration on their sternum. They will receive their assigned intervention for approximately 18 minutes.
223536068|NCT07004582|DIAGNOSTIC_TEST|Diagnostic biopsy|Transperineal prostate biopsies guided with transrectal ultrasound for the diagnosis of (recurrent) prostate cancer
223536069|NCT06225206|BEHAVIORAL|donor-derived cell free DNA in liver|Determine the difference in age, gender, LFTs, IS regimen (tacrolimus/sirolimus/cyclosporin with mycophenolate mofetil (MMF) and /or prednisone) between patients who underwent liver transplant \<1 year PTX and \>1 year PTX
223720687|NCT01831050|BIOLOGICAL|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India \[SII\]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
223946743|NCT04670640|BEHAVIORAL|Breath Focus|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. The participant will be asked to focus on their breathing during this intervention. They will receive their assigned intervention for approximately 18 minutes.
223946744|NCT04670640|BEHAVIORAL|No Distractions|Participants will attend two intervention sessions per week for a total of 8 sessions. Participants will sit in a chair in a sound-proof booth monitored by a researcher in front of a computer screen (which delivers instructions) and will be fitted with psychophysiology leads and a device strapped around the chest. Participants will engage in a period of no-screen time; during this time there will be no outside visual or auditory distractions. There will be no explicit tasks or direction given in this intervention. They will receive their assigned intervention for approximately 18 minutes.
223946745|NCT03237780|DRUG|Atezolizumab|Given IV
223536070|NCT07002931|PROCEDURE|khoury block graft|Bone blocks will be harvested from the retromolar area after measuring of the size required and measuring of the donor site anatomy. Piezoelectric device will be used to perform the graft osteotomy. The osteotomy lines will be connected and the graft will be mobilized using a bibeveled chisel and mallet. Sharp bony edges will be smoothened and the donor defect was packed with gelatin sponges. The bone block margins will be smoothened and separated into two thinner bone shells using titanium disk with copious saline irrigation. The blocks will be fixed into the recipient site buccally using at least two microscrews leaving a gap to be filled with bone graft. Particulate xenogenic bone graft will be mixed with the autogenous bone chips (50% Xenograft: 50% Autogenous graft) to fill the gap.
223720688|NCT05665478|OTHER|Dose prediction using population pharmacokinetic models|Dose prediction using population pharmacokinetic models.
223720689|NCT04166175|PROCEDURE|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
223720690|NCT04166175|PROCEDURE|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
223720691|NCT04433221|BIOLOGICAL|Multiple sarcoma-specific CAR-T cells and sarcoma vaccines|1 infusion, CART 1x10\^6\~1x10\^7 cells/kg via IV and vaccines 1-5x10\^6 irradiated cells via subcutaneous injection
223720692|NCT05457764|DEVICE|Virtual reality headset|"The VR headset was a Pico G2, Pico Interactive, San Fransisco, USA, offering a choice from 60 erotic videos each of 10-30 minutes duration. The men were allowed to watch any and as many of these video clips as they wished. The No VR arm, donors used the computer monitor available in the donation rooms."
223720693|NCT06197750|OTHER|Vestibular stimulation|Vestibular stimulation by swing
223720694|NCT06197750|OTHER|General strengthening exercises|General strengthening exercises
223720695|NCT01190774|BEHAVIORAL|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
223720696|NCT01190774|BEHAVIORAL|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
223720697|NCT02784808|DRUG|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
223720698|NCT02784808|DRUG|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
223720699|NCT06170970|DRUG|Solriamfetol|solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)
223720700|NCT06170970|DRUG|Placebo|Four weeks of oral placebo
223720701|NCT06979141|DRUG|Dexmedetomidine|Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
223720702|NCT06979141|DRUG|Magnesium sulfate|Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
223720703|NCT06979141|DRUG|Lidocaine|Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
223720704|NCT06979141|DRUG|normal saline|Patients will receive 10 ml normal saline 10 min before the end of surgery.
223720705|NCT06977256|OTHER|Sensory-Based Exercises|Participants in the Sensory-Based Intervention Group received weekly 40-minute face-to-face sessions for 8 weeks, involving structured exercise and sensory-based activities tailored to individual needs, with caregiver feedback and home programs provided after each session.
223720706|NCT06977256|OTHER|Telerehabilitation and Based Sensory Intervention|Participants in the Telerehabilitation-Based Sensory Intervention Group received 8 weeks of in-person sessions followed by 8 weeks of weekly 30-minute telerehabilitation sessions, combining individualized sensory-based activities with caregiver coaching and home-based implementation via Zoom. Sessions were personalized, progressively structured, and conducted in a stable virtual environment to support continuity and engagement.
223720707|NCT07133165|OTHER|standard biometric ultrasound|In this study, biometric measurements were systematically performed for each patient using both manual methods and an artificial intelligence (AI) system (Live View Assist, Samsung). The AI system provided real-time guidance by identifying anatomical landmarks and assisting in the measurement of key biometric parameters, including Femur Length (FL), Abdominal Circumference (AC), Head Circumference (HC), and Biparietal Diameter (BPD). This dual approach ensured that both manual and AI-assisted methods were applied uniformly as part of routine clinical care.
223720708|NCT07132515|DRUG|Enoxaparin, warfarrin, or apixaban|Enoxaparin, warfarrin, or apixaban
223720709|NCT07131683|BIOLOGICAL|Human umbilical cord mesenchymal stem cell derived exosomes|Nasal spray of hUC-MSC-Exo (low dose: 2.5×10\^10 particles, mid-dose: 5.0×10\^10 particles, high-dose: 1.0×10\^11 particles), once per day for 7 days, then once per week for 3 weeks
223946746|NCT03237780|PROCEDURE|Biopsy Procedure|Undergo biopsy
223946747|NCT03237780|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223946748|NCT03237780|PROCEDURE|Computed Tomography with Contrast|Undergo CT scan
223946749|NCT03237780|DRUG|Eribulin Mesylate|Given IV
223946750|NCT06416397|DIAGNOSTIC_TEST|Proteomic profile|"Proteomic analysis of bile samples will be performed every 5 bile samples. Bile samples will be taken during endoscopy with retrograde papillary catheterization or radiological procedures in selected patients. In clinical practice, bile samples are taken for bacteriological purposes. An average of 10 mL is taken.~Five mL are required for bacteriological analysis. The remaining millilitres, which are usually discarded, will be kept for storage and to form the bile bank at the Biological Resources Centre before to be analyzed in proteomics."
223946751|NCT02646774|DRUG|Micafungin|Injection
223946752|NCT00892541|DRUG|ER OROS paliperidone|
223720710|NCT07131683|OTHER|Placebo Control|Nasal spray of placebo control, once per day for 7 days, then once per week for 3 weeks
223720711|NCT07131306|DRUG|ucMSC and Standard medical treatment|umbilical cord Mesenchymal stem cell1 million/kg will be given once a week for 4 week . 250 ml normal saline will be infused 30 minutes prior to ucMSCs infusion. All patients will receive the standard medical treatment.
223946753|NCT00293410|DRUG|clofarabine|
223946754|NCT00293410|DRUG|cyclophosphamide|
223536071|NCT07002931|PROCEDURE|urban sausage technique|: A resorbable pericardium membrane will be fixed with titanium pins on the lingual bone plate (2-3mm from the bone crest) and on the buccal bone plate allowing for packing of particulate mix of bone graft (50% Xenograft: 50% Autogenous graft). Overfilling of the graft will be respected to compensate for future resorption. The membrane will be stretched over the graft ensuring maximum immobilization of the graft.
223720712|NCT07131306|OTHER|Standard medical treatment|Standard medical treatment
223720713|NCT04415008|DRUG|HAD induction with intermediate dose cytarabine|daunorubicin,cytarabine,homoharringtonine
223720714|NCT05284656|DRUG|combination of Pentoxifylline 400 MG and Folic Acid|drugs used to delay progression of chronic kidney disease
223720715|NCT05284656|DRUG|folic acid|drugs used to delay progression of chronic kidney disease
223720716|NCT05284656|DRUG|Pentoxifylline 400 MG|drugs used to delay progression of chronic kidney disease
223720717|NCT06164418|PROCEDURE|Dental restoration|Each patient will receive a cervical restoration using the corresponding group adhesive and restorative material
223946755|NCT06133075|DRUG|Mirabegron 50 MG|10 patients will receive drug for 8 weeks
223720718|NCT05766852|BEHAVIORAL|Somatic Psychoeducational Intervention|Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
223946756|NCT06133075|DRUG|Mirabegron 25 MG|10 patients will receive drug for 8 weeks
223946757|NCT05383989|BEHAVIORAL|UniVenture Hopelessness manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
223946758|NCT05383989|BEHAVIORAL|UniVenture Anxiety Sensitivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
223946759|NCT05383989|BEHAVIORAL|UniVenture Sensation Seeking manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
223946760|NCT05383989|BEHAVIORAL|UniVenture Impulsivity manual|Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Impulsivity (IMP) personality traits on the Substance Use Risk Profile Scale (SURPS).
223946761|NCT05383989|BEHAVIORAL|Service as usual provided by the University|It is the regular university-provided well-being services.
223946762|NCT06968351|BEHAVIORAL|Animal-Assisted Intervention|A brief animal-assisted intervention is offered on a group basis across four sessions. Each session lasts approximately 60 minutes and covers the same themes but through different exercises. These themes include effective communication, behavioral principles, problem-solving, and teamwork. The first part of a session involves learning to give effective single-component commands to a rehabilitative dog under the guidance of a professional dog handler. The second part of a session involves the applications of two or more of these single-component commands to an interactive group activity. Project staff are present at each session to facilitate discussions among participants on any challenges encountered, learning, and intra- as well as inter-personal experiences during the session.
223946763|NCT00462475|DRUG|Recombinant Growth Hormone, Genotropin (Pfizer)|
223946764|NCT04634682|DIETARY_SUPPLEMENT|MYODM|Formulated composition containing Theobroma cacao supplemented with caffeine
223946765|NCT03936777|DRUG|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
223946766|NCT04914702|DEVICE|Everion®|The Everion® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
223946767|NCT04914702|DEVICE|CORE®|The CORE® is an on-skin wearable devices measuring vital signs. It will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear all the time, with exception of the time needed for the patients' hygiene.
223946768|NCT03507179|OTHER|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
223946769|NCT03507179|OTHER|conventional dentures|conventional dentures
223946770|NCT04821271|OTHER|Placebo|Participants received Placebo capsule orally once daily for three weeks.
223946771|NCT04821271|DRUG|TS-161|Participants received TS-161 50-100 mg capsule orally once daily for three weeks. TS-161 is a mGlu2/3 receptor antagonist prodrug.
223946772|NCT02414178|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223946773|NCT04076059|DRUG|Enzalutamide|Oral
223946774|NCT04076059|DRUG|Placebo|Oral
223946775|NCT04076059|DRUG|Androgen deprivation therapy (ADT)|All participants were required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
223720719|NCT06994962|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the mobile technologies as they choose while drinking for a four-week period.
223720720|NCT06994962|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
223720721|NCT06994962|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
223720722|NCT06994962|BEHAVIORAL|Higher tech facilitation|Participants will use an app developed during the study, SmartSip, that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
223946776|NCT05640167|BEHAVIORAL|Interdisciplinary Clinic|Interdisciplinary Clinic - assessment and recommendations by Nutrition, Pharmacy, Physical Therapy, and Speech Therapy and Educational Seminar - Parkinson's specific education and resources in group format
223946777|NCT06326996|DRUG|Thiamine|Participants will be given an infusion of thiamine.
223946778|NCT06326996|DRUG|Placebo|Participants will be given an infusion of the placebo treatment.
223946779|NCT03830788|RADIATION|Radiation by brachytherapy|Brachytherapy by Iodine 125 delivering 144 Gy to the prostate
223720723|NCT06994962|BEHAVIORAL|Alcohol Education|Brief 25/30-minute psychoeducation on generalized alcohol use providing information about alcohol and its effects, adapted from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Rethinking Drinking resources
223720724|NCT06994962|DEVICE|Alcohol Education Technology|Participants will be able to prompt text messages which will provide them one-off trivia facts using information provided during the attention control psychoeducation session
223720725|NCT06674499|OTHER|Self-help rehabilitation model|The intervention measures followed the principles and processes of cognitive-behavioral therapy. Three intervention sessions were conducted over a period of eight weeks. The first session lasted 90 minutes, while the subsequent sessions (in weeks 4 and 8) lasted 45 minutes each and were conducted face-to-face by the therapist.
223720726|NCT06674499|OTHER|Conventional rehabilitation model|The control group, which follows the conventional rehabilitation model, operates under the current standard of cancer treatment and follow-up. In this model, oncology healthcare professionals provide recommendations based on the specific circumstances of the patients. However, the choice of the rehabilitation model is primarily decided by the patients themselves, aligning with current clinical practice.
223720727|NCT07001527|DEVICE|Chlorhexidine|dressing impregnated
223720728|NCT07001527|DEVICE|Chlorhexidine|COmmon dressing
223946780|NCT03830788|RADIATION|Radiation by SBRT|SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
223946781|NCT02678182|DRUG|Capecitabine|1250 mg/m2/day, 21 day cycle
223720729|NCT07000565|OTHER|Eye Care with Artificial Tears|Every 2 hours, the artificial tear solution was gently applied to the designated eye for 5 days. The artificial tear product (REFRESH®) contains 5.6 mg of polyvinyl alcohol and 2.4 mg of povidone per mL and is used to maintain ocular surface moisture and reduce irritation.
223720730|NCT07000565|OTHER|Eye Care with Normal Saline|Every 2 hours, the saline solution(Bio-Fleks brand) was gently applied to the designated eye for 5 days.
223720731|NCT07002372|BEHAVIORAL|Procedure video viewing|Patients who have never had an intravitreal injection before will be randomly assigned to watch an educational video about the procedure prior to treatment.
223946782|NCT02678182|DRUG|MEDI4736 (Durvalumab)|IV treatment on days 1\&15 of 28 day cycle
223946783|NCT02678182|DRUG|Trastuzumab|6mg/kg on day 1 cycle every 21 days
223946784|NCT02678182|DRUG|Rucaparib|600mg PO twice daily
223946785|NCT02678182|DRUG|Ramucirumab|ramucirumab 8mg/kg IV day 1 and day 8
223946786|NCT05452681|OTHER|Educational Intervention|Receive Y-AMBIENT
223946787|NCT05452681|OTHER|Quality-of-Life Assessment|Ancillary studies
223946788|NCT05452681|OTHER|Questionnaire Administration|Ancillary studies
223946789|NCT05452681|OTHER|Control Intervention|Receive cookbook and socialization calls
223946790|NCT05630807|DRUG|Bepirovirsen|Bepirovirsen will be administered.
223946791|NCT05630807|OTHER|Placebo|Matching placebo will be administered.
223946792|NCT00684242|DRUG|Lenalidomide|10 mg by mouth daily
223946793|NCT03085407|PROCEDURE|early cholecystectomy|cholecystectomy was done within 48 after admission
223946794|NCT03085407|PROCEDURE|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
223946795|NCT04823754|OTHER|Hospitalized patient with advanced hepatocellular carcinoma receiving systemic therapy.|"Administation of two surveys to included patients, about the perception of the disease and the expectations related to the treatment.~The physician will be asked to complete a survey on his or her perception of the prognosis and information received by the patient."
223946796|NCT00692185|DRUG|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
223946797|NCT00692185|DRUG|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
223536072|NCT07002931|PROCEDURE|non resorbable membrane|A non-resorbable polytetrafluoroethylene (PTFE) membrane (Permamem membrane, Botiss Biomaterials, Germany) will be fixed with titanium tacks on the lingual bone plate (2-3mm from the bone crest) and on the buccal bone plate allowing for packing of particulate mix of bone graft (50% Xenograft: 50% Autogenous graft). Overfilling of the graft will be respected to compensate for future resorption.
223536073|NCT06625372|DIETARY_SUPPLEMENT|SMOF lipid|The SMOF lipid is given to the patient as a fat component of total parenteral nutrition.
223536074|NCT06625372|DIETARY_SUPPLEMENT|INTRALIPIDS|The Intralipid will be given to the patient as fat component of total parenteral nutrition.
223720732|NCT06993545|BEHAVIORAL|Video-based educational program on physical activity for migraine management|The intervention consisted of a series of seven short, pre-recorded educational videos delivered over a 3-month period. The videos focused on the benefits of regular physical activity for individuals with migraine and included practical strategies to increase daily activity levels. The content was evidence-based, developed with input from healthcare professionals, and tailored to migraine management. Participants received access to one video approximately every two weeks via email or online platform. The videos aimed to improve awareness, motivation, and self-efficacy regarding physical activity without prescribing a specific exercise program. No direct interaction with healthcare providers occurred during the intervention period.
223720733|NCT07001254|DRUG|Romiplostim|The investigational drug, Romiplostim, is a thrombopoietin receptor agonist (TPO-RA) that has been granted orphan drug designation by the FDA.
223946798|NCT03510169|DEVICE|NeoVest|Negative pressure ventilation with NeoVest
223536075|NCT06621277|OTHER|No intervention|No intervention
223536076|NCT06621277|OTHER|Tailored counseling programs (Phase 2)|Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
223946799|NCT05137600|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
223536077|NCT06945523|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
223536078|NCT06945523|BIOLOGICAL|Targeted CEA CAR-T|Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
223946800|NCT05137600|DRUG|Midazolam|Midazolam is a sensitive CYP3A index substrate
223946801|NCT05137600|DRUG|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)
223536079|NCT04860466|DRUG|CC-96673|IV Infusion
223536080|NCT04111354|DEVICE|Pacemaker implantation|Pacemaker implantation
223720734|NCT07001254|DRUG|Immunosuppressive therapy (IST)|Standard of Care immunosuppressive therapy (IST) includes HORSE ANTI-THYMOCYTE GLOBULIN (H-ATG) and Cyclosporine (CSA)
223946802|NCT00281905|DRUG|carboplatin|
223946803|NCT00281905|DRUG|cisplatin|
223946804|NCT00281905|DRUG|cyclophosphamide|
223536081|NCT04826237|DRUG|Statin|Oral dose to be taken with methylprednisolone
223946805|NCT00281905|DRUG|methotrexate|
223536082|NCT04826237|DRUG|methylprednisolone|oral dose, standard of care
223946806|NCT00281905|DRUG|vincristine sulfate|
223946807|NCT00281905|RADIATION|radiation therapy|
223946808|NCT06595160|OTHER|Non-Interventional Study|Non-interventional study
223946809|NCT06586125|OTHER|Powered Mobility Training|The study procedure aims to observe the partecipants' behaviour while using the Virtual Reality - Power Mobility Program (VR-PMP) simulator applied during Power Mobility Training in clinical practice for 15 sessions. Participants use either semi-immersive mode (laptop screen with VR-PMP simulator) or immersive mode (head-mounted display with VR-PMP simulator). Five out of ten children unable to use conventional VR controllers or alternative access technologies available on the market, use brain-computer interface (BCI) developed specifically for these children to control the VR-PMP simulator.
223946810|NCT06141499|BEHAVIORAL|Provider educational materials|Dialysis providers will receive educational material about the kidney transplantation and waitlisting process.
223536083|NCT04826237|DRUG|dexamethasone|Drug for intratympanic administration
223536084|NCT04826237|DRUG|Placebo|Capsule the same as for statins but without statin
223536085|NCT02622035|BEHAVIORAL|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
223946811|NCT06141499|BEHAVIORAL|Patient letters|Dialysis patients will receive letters with information about their status within the kidney transplantation and waitlisting process. Letters will describe kidney waitlist status, living donor transplantation, Hepatitis C positive kidney transplants, and high Kidney Donor Profile Index (KDPI) transplants.
223946812|NCT05181618|DRUG|Emicizumab|The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
223536086|NCT02622035|BEHAVIORAL|Emotion induction|Film clip designed to induce anger or fear
223536087|NCT02622035|BEHAVIORAL|visual perceptual load|visual and interactivity-based load of virtual reality buffet environment
223536088|NCT01566240|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 162mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 \& 36.
223536089|NCT01566240|DRUG|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, \& 36.
223946813|NCT06980766|DEVICE|Non Invasive Blood Pressure|"Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor"
223946814|NCT06982677|BEHAVIORAL|Nurse Navigator Intervention|The intervention will integrate education, decision support, patient activation strategies, and cognitive-behavioral menopause symptom management skills. Participants will receive video and audio-recorded materials and a written manual.
223946815|NCT06982677|OTHER|Education Control|"The control arm will receive the National Cancer Institute booklet, Facing Forward: Life After Cancer Treatment, which provides basic strategies for navigating cancer survivorship."
223720735|NCT07001436|DRUG|Azvudine tablets|On the first day of the study, a single oral dose of 3 mg ( 3 tablets ) of Azvudine tablets is taken orally on an empty stomach.
223720736|NCT06997263|DRUG|Melatonin 3 mg Sublingual|A single 3 mg dose of sublingual melatonin will be administered the night before surgery and repeated 1 hour before anesthesia induction in participants randomized to the Low-Dose Melatonin Group.
223720737|NCT06997263|DRUG|Melatonin 6 mg Sublingual|A single 6 mg dose of sublingual melatonin will be administered the night before surgery and repeated 1 hour before anesthesia induction in participants randomized to the High-Dose Melatonin Group.
223720738|NCT07000786|PROCEDURE|Endometrial biopsy or menstrual cup and blood sample|Enrolled patients will give their menstrual effluent either via a menstrual cup or via a pipelle biopsy. They will also undergo a blood draw.
223720739|NCT07004010|DEVICE|Deoxycholic Acid Injection|The intervention include Deoxycholic acid, SC, 0.15 ml each injection, up to 2-4 ml in each site (2 ml at visit 1 for everyone, and 2 ml at visit 2 unless the patient does not agree)
223720740|NCT07001566|OTHER|There was no intervention. Only assessment procedure will be performed.|There was no intervention. Only assessment procedure will be performed.
223720741|NCT07001033|BEHAVIORAL|Dance Movement Therapy (DMT)|All participants will be invited to five group meetings at weekly intervals. Each of these therapy sessions will take place with a specific theme. In weeks 1 and 5, data important for the study will be collected once before the short-term DMT and once again at the end of the study. This includes different assessments, laboratory blood tests as well as immunophenotyping. Additionally, patients are requested to complete a questionnaire that addresses QoL. Specific examinations, such as testing the maximal handgrip strength, a BIA and recording Eastern Cooperative Oncology Group (ECOG) performance status are implemented in each of the five meetings.
223946816|NCT06800989|BEHAVIORAL|sophrology sessions|Two sophrology sessions will be conducted in the experimental group. The first session (S1) should take place on Cycle 1 Day 1 or within a maximum of 3 weeks following Cycle 1 Day 1. The second session (S2) should be conducted within 3 to 4 weeks after the first session.
223946817|NCT06800989|DEVICE|Morphee Device|Patients will be encouraged to perform at least one daily ambulatory sophrology session with the Morphée® device, according to a support plan defined with the sophrologist.
223946818|NCT06978920|DRUG|Allogeneic dopaminergic neural precursor cell(NCR201)|Bilateral implantation
223946819|NCT06116968|DRUG|Aficamten|5-20mg
223946820|NCT06027268|DRUG|Trilaciclib|IV infusion Day 1 and Day 8 every 21 days, at dose of 240 mg/m2
223946821|NCT06027268|DRUG|Pembrolizumab|IV infusion Day 1 every 21 days, at dose of 200 mg
223946822|NCT06027268|DRUG|Gemcitabine|IV infusion Day 1 and Day 8 every 21 days, at dose 1000 mg/m2
223946823|NCT06027268|DRUG|Carboplatin|IV infusion Day 1 and Day 8 every 21 days, at dose area under curve (AUC) 2 (maximum of 300 mg)
223946824|NCT06986759|OTHER|Laser|The therapy system will be used the Thor DD Laser Therapy Unit. This will be a class 3B laser with an 810-nm, 100-mW infrared probe. Laser or placebo laser treatment protocols will be identical and will be delivered with the patients lying prone, with their foot over the end of the treatment plinth and the ankle plantar-grade. The contact method will be used to apply the laser treatment probe to 3 standardized points on both sides of the Achilles' tendon (6 in all: at the site of the lesion, 2cm proximal, and 2cm distal) for 30 seconds, giving a dose of 3J per point and 18J per session for the active probe(23). The treating physiotherapist, without any knowledge of which position on the switch will be the active laser, will select position 1 or 2 on the switch according to group allocation.
223946825|NCT06986759|OTHER|Extracorporeal shock wave therapy protocol|When treating Achilles tendinopathy, most researchers will be used 3 sessions of extracorporeal shock wave therapy (ESWT) with a one-week break in between. There will also be shorter breaks of 3 to 4 days or longer 2-week breaks. The number of pulses per session will range from 800 to 3000, and the pulse frequency will be between 4 and 50 Hz.
223720742|NCT04118114|DRUG|PRL3-zumab|IV administration every 2 weeks
223720743|NCT06679270|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
223720744|NCT07132203|DEVICE|Laser interstitial thermal therapy|The LITT procedure was performed using the LS1 laser ablation system and SR1 stereotactic robotic system (Sinovation, Beijing, China). The ablation system was equipped with a 980-nm laser with a maximum of 15 W of power, a core silica fiber optic with a 1.8-mm diameter cooling catheter, and a cooling pump to make saline flow into and out through the catheter. The optic and catheter approaches were planned with the preoperative simulation software (Sinovation, Beijing, China) using the preoperative T1-weighted MRI scan, and passing through important cerebral vascular and functional zones was avoided。. The catheter was implanted by neurosurgeons under stereotactic guidance, and a laser probe was inserted through the catheter. After LITT, a T1-weighted intraoperative MRI scan was performed to confirm the effect of ablation. The ablation rate was calculated by another neurosurgeon who did not participate in the study.
223720745|NCT07007832|PROCEDURE|Endoscopic retrograde cholangiopancreatography|Since patients with biliary strictures almost universally require endoscopic biliary interventions for both diagnostic and drainage purposes, bile aspiration can be readily obtained during these procedures, facilitating subsequent analyses. However, proteomic and metabolomic profiling of bile in malignant biliary strictures remains unreported to date. This study aims to evaluate the diagnostic value of combining bile proteomics/metabolomics with biliary brush cytology/biopsy for malignant biliary strictures, while also providing evidence for identifying potential biomarkers.
223720746|NCT07133152|OTHER|Adverse events|During patient follow-up (hospitalisation + 6 months post-hospitalisation), adverse events will be collected from the patient's computerised medical record (available at the hospital) and by means of a questionnaire carried out by telephone with the patient at 3- and 6-months post-hospitalisation.
223720747|NCT06865560|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|A validated, 8-week, group-based telehealth-based behavioral intervention for chronic pain. Session content will include pain neuroscience education, emotion-focused expressive writing, in-vivo emotional expression practices, self-compassion and forgiveness exercises, and assertive communication strategies. Participants will also be provided handouts and pre-recorded guided imagery and cognitive exercises that they can use to facilitate between-session practices.
223720748|NCT07016191|OTHER|Ingestion of Water|Ingestion of Super-Oxygenated or Normal water
224100398|NCT01151072|DRUG|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
223946826|NCT06269003|OTHER|Expert, one-sided|Participants will view a brief description of an expert source and see one-sided e-cigarette education messages.
223946827|NCT06269003|OTHER|Expert, two-sided|Participants will view a brief description of an expert source and see two-sided e-cigarette education messages.
223946828|NCT06269003|OTHER|Peer, one-sided|Participants will view a brief description of a peer source and see one-sided e-cigarette education messages.
223946829|NCT06269003|OTHER|Peer, two-sided|Participants will view a brief description of a peer source and see two-sided e-cigarette education messages.
224100399|NCT01416129|DEVICE|Standard of care socket|Amputees' preferred socket.
224100400|NCT01416129|DEVICE|Prosthetic brimless socket|Study socket
224100401|NCT01639183|DEVICE|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
224100402|NCT01639183|OTHER|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
223536090|NCT01566240|RADIATION|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
223536091|NCT01566240|DRUG|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
223536092|NCT03243864|DRUG|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
223536093|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine pattern diagnosis.
223536094|NCT04747288|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) and non AIDDES Healthy Controls subjects will take the Traditional Chinese Medicine tongue diagnosis.
223536095|NCT04747288|DIAGNOSTIC_TEST|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
223536096|NCT04747288|DIAGNOSTIC_TEST|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
223536097|NCT04747288|DIAGNOSTIC_TEST|Ocular Surface Diseast Index (OSDI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the Ocular Surface Diseast Index (OSDI).
223536098|NCT04747288|DIAGNOSTIC_TEST|EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI).
223536099|NCT04747288|DIAGNOSTIC_TEST|36-Item Short Form Survey (SF-36)|Autoimmune disease (AID) as Sjögren's syndrome (SJS) and Systemic lupus erythematosus (SLE) for comparing with the Dry eye syndrome (DES) subjects will take the 36-Item Short Form Survey (SF-36).
223536100|NCT06715228|BEHAVIORAL|shitali pranayama respiratory rehabilitation training|in this group, patients (n=20) with obstructive sleep apnea will participate and will administer six cycles of 5-min shitali respiratory pranayama exercise rehabilitation training (the rehabilitation will be repeated or applied at morning, afternoon, and also at evening) for 12 week as a daily performance
223536101|NCT05812352|BEHAVIORAL|Audio kit|MP3 audio files for each of 6 steps and instructional flashcard with pictures corresponding to each of the 6 steps of tourniquet application
223536102|NCT05812352|BEHAVIORAL|Instructional flashcard|Single page (instructional flashcard) with pictures corresponding to each of the 6 steps of tourniquet application
223536103|NCT05812352|BEHAVIORAL|In-person training|Stop the Bleed bleeding control (B-Con) course is used for instruction for tourniquet application attempt
223536104|NCT02562781|DRUG|Oxygen|Oxygen in sufficient quantity to maintain SpO2 \> 98%
223536105|NCT02562781|OTHER|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%
223536106|NCT01492426|DRUG|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
223536107|NCT01492426|DRUG|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
223720749|NCT07015294|DIETARY_SUPPLEMENT|Fruits and chaya infusion|Increased fruit consumption and daily intake of chaya infusion (prepared from Cnidoscolus chayamansa leaves),
223720750|NCT07015294|DIETARY_SUPPLEMENT|Conventional diet|Usual dietary habits, with no specific modifications
223720751|NCT07014917|DRUG|Venetoclax|intermittent venetoclax (7days administration per cycle) + acalabrutinib
223720752|NCT07014917|DRUG|Acalabrutinib|intermittent venetoclax (7days administration per cycle) + acalabrutinib
223946830|NCT06605872|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. Insulin therapy prescription for the next 24 hours is suggested once daily by the GlucoTab system taking previous insulin doses, glucose readings, patient age, renal function and insulin sensitivity into account. The goal of the algorithm is to maintain fasting and premeal glucose concentrations between 100-140 mg/dl, (5.6 to 7.8 mmol/l).
223946831|NCT06605872|OTHER|Diabetes Treatment|Diabetes Standard Care
223946832|NCT06607549|DRUG|Loncastuximab tesirine and rituximab (Lonca-R)|Patients will receive stereotactic radiosurgery (SRS) followed by a brain MRI approx. 4 weeks after SRS. This will be followed by loncastuximab tesirine and rituximab administered intravenously for a total of 6 cycles (every 21 days).
223946833|NCT04060758|DRUG|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
223946834|NCT07006181|DRUG|cyproheptadine hydrochloride|Giving Cyproheptadine hydrochloride 0.25 mg/kg/day divided by 2 dose every 12 hours for 4 weeks.
223946835|NCT07006181|OTHER|Giving placebo divided by 2 dose every 12 hours for 4 weeks.|Giving placebo divided by 2 dose every 12 hours for 4 weeks.
223946836|NCT06831994|OTHER|gp-multitool.de|"The intervention is based on the digital tool gp-multitool.de. The GPs can send questionnaires by email to patients and patients can fill out questionnaires at their home or in the waiting room of the practice using any digital device with browser and access to the internet. The digital tool also includes instructions for conducting a medication review. Results will be available from the computers of attending GPs. Decisions from talks between GPs and patients can be documented in the tool. The tool includes ten questionnaires:~1. patient preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. social life (including a. activities and participation, and b. social support);~3. treatment situation (including a. problems with medication, and b. treatment burden);~4. health complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~5. resilience and protective behavior against heat."
223720753|NCT07014917|DRUG|Venetoclax|continuous venetoclax (28 days administrations per cycle) + acalabrutinib
223720754|NCT07014917|DRUG|Acalabrutinib|continuous venetoclax (28 days administrations per cycle) + acalabrutinib
223720755|NCT07014878|BIOLOGICAL|TCR-T cells|"Dose escalation will follow the standard 3+3 design. Patients will receive a single infusion of DCTY1102 injection. Exploration of higher, lower, or intermediate dose levels may be considered based on emerging safety and tolerability data. Dose escalation will proceed sequentially."
223720756|NCT07016360|DRUG|Topical Adapalene Gel 0.1%|Topical adapalene is a retinoid that helps in epidermal changes. Cryotherapy is a liquid nitrogen applied to affected parts for 6 months
223720757|NCT07016360|PROCEDURE|Topical Liquid Nitrogen application|Liquid Nitrogen will be applied to affected parts.
223720758|NCT07015788|OTHER|EARLY GRAND|Participants will consume a standardized portion of peach variety A containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
223720759|NCT07015788|OTHER|SPRING CREST PEACH|Participants will consume a standardized portion of peach variety B containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
223720760|NCT07015788|OTHER|INDIAN BLOOD|Participants will consume a standardized portion of peach variety C containing 50 grams of available carbohydrates. Capillary blood glucose levels will be measured at multiple time points post-consumption to assess glycemic response.
223946837|NCT07013344|DIAGNOSTIC_TEST|BNP|Measurement of plasma NT-proBNP level.
223946838|NCT07012239|DRUG|Azathioprine (AZA)|"Patient fulfilled indication of AZA Maintenance of remission of lupus nephritis, Neuro-psychiatric lupus, vasculitis, intolerance to steroid, associate with Defuse Parenchymal Lung Disease (DPLD) Starting AZA at a dose of 1 mg/kg/ body weight~First follow-up at 2nd week and change dose of AZA 2 mg /kg/ BW/day~Then Follow-up 4 weekly for total 12 week~Not adverse effect of Azathioprine"
223946839|NCT07012239|DRUG|TPMT|Adverse effect of azathioprine in SLE
223946840|NCT07012278|OTHER|Caesarean section scar dressing with St. John's wort oil|Dressing the incision site with St. John's wort oil once a day every day
223946841|NCT07012681|OTHER|discharge training (oral and written brochure)|The group that received oral and written brochure training during discharge training
223946842|NCT07012681|OTHER|discharge education (oral education)|group receiving oral training in discharge training
223946843|NCT07025018|DRUG|HMPL-306|IDH small molecule inhibitor
223720761|NCT06235203|PROCEDURE|endoscopic surgery|The tumor was resected by endoscopic nasopharyngectomy.
223720762|NCT06235203|DRUG|Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy|Two courses of Toripalimab Injection and two courses of Toripalimab Injection and Gemcitabine based chemotherapy were given before endoscopic surgery.
223720763|NCT06235203|DRUG|Adjuvant therapy in experimental group,Toripalimab Injection and Gemcitabine based therapy|Eight courses of Toripalimab Injection and two to four courses of chemotherapy, or until unacceptable side effects.
223720764|NCT06235203|DRUG|Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy|Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
223720765|NCT07014475|DEVICE|drug-coated balloon|Drug-coated balloon was used during the index procedure.
223720766|NCT07014683|BEHAVIORAL|INCREM|This is a specifically designed program to improve psychosocial functioning which targets cognitive symptoms.
224100403|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|"Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patients success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2)."
224100404|NCT01275404|BEHAVIORAL|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
223946844|NCT06699472|DRUG|Chemotherapy|Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
223946845|NCT06699472|DRUG|Trilaciclib Injection [Cosela]|Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
223946846|NCT06699992|DIAGNOSTIC_TEST|Blood biomarkers quantification|Blood biomarkers quantification
223946847|NCT06698653|DEVICE|SAM device (experimental): a removable structure, fixed to the horizontal frame of the medical bed, equipped with a handle to assist the sitting-up process|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
223946848|NCT06698653|DEVICE|Over bed pole hoist (control device)|The patients will use the experimental device during 7 days straight as well as the comparator during 7 days straight. The order in which they will use each device will depend on the groupe they have been randomized in : - Groupe 1 : Experimental device during 7 days then control device during 7 days - Groupe 2 : Control device during 7 days then experimental device during 7 days
223946849|NCT06632691|DEVICE|Virtual reality headset|Use of a virtual reality headset during rectosigmoidoscopy
223536108|NCT01492426|DRUG|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
223536109|NCT01492426|DRUG|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
223536110|NCT01978145|DRUG|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
223536111|NCT01978145|DRUG|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
223536112|NCT01658059|OTHER|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
223536113|NCT01658059|OTHER|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
223536114|NCT01597739|DRUG|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
223536115|NCT01597739|DRUG|Placebo|Form=capsule; route=oral use; twice daily.
223536116|NCT02916264|PROCEDURE|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
223946850|NCT07025850|DRUG|Digoxin|p.o. 0.5mg q.d.
223946851|NCT07025850|DRUG|Fuquinitinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
223946852|NCT07025850|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
223946853|NCT06692608|OTHER|strength training|Comparison between isometric and dynamic strength training in soccer players
223946854|NCT06688539|DRUG|Varenicline Pill|In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
223946855|NCT06688539|BEHAVIORAL|Contingency management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
223946856|NCT06688539|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.
223946857|NCT06698991|BIOLOGICAL|Plasma Exchange|"• Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours"
223946858|NCT06698991|OTHER|Standard Medical Treatment|Standard Medical Treatment
223946859|NCT06698341|PROCEDURE|Blood Draw|3X 6mL K2-EDTA tubes, 1X 3mL K2-EDTA tubes and 1X 3.5mL SST tube - 24.5ml of blood will be collected from patient
223946860|NCT06698952|OTHER|Intervention Group|The intervention group will engage with SPI-Bot, a conversational agent designed to deliver cognitive and behavioral strategies for managing psychological symptoms through fully automated interactions. SPI-Bot operates on a template-based platform with predefined dialogue options, utilizing natural language processing technology. The intervention spans eight weeks and includes key components such as psychoeducation, cognitive restructuring, relaxation training, activity scheduling, problem-solving skills training, and social skills training. Participants will complete one session per week over the eight-week period. Participants will receive weekly contact from the research team to report AIS symptoms, receive homework reminders, and address any intervention-related questions.
223720767|NCT07014683|BEHAVIORAL|Psychoeducation|This is a 12-session psychoeducation program designed as an active comparator for the current trial
223946861|NCT06698952|OTHER|control group|Participants in the control group will interact with a different generative chatbot, engaging in casual conversations at a similar dosage to ensure balanced attention and interaction effects.
223946862|NCT06711640|DRUG|LUCEMYRA (lofexidine) tablets|Tablets. Participants weighing ≥45 kg: three 0.18 mg tablets (0.54 mg) four times per day (QID). Participants weighing ≥30 to \<45 kg: two 0.18 mg tablets (0.36 mg) QID.
223946863|NCT06716632|DEVICE|Using Ligasure for heamostasis|Ligasure is a bipolar vascular sealing system utilized to achieve effective control of bleeding and create a bloodless surgical environment. It operates by utilizing an electrical current within the frequency range of 2-4 MHz It induces denaturation of collagen and elastin within the vessels and surrounding tissues. The localized tissue temperatures typically range between 60-100°C, facilitating the fusion of collagen and elastin in the vessel walls. This fusion process creates a durable sealed zone without any carbonization and enables hemostasis in vessels with diameters of up to 7 mm.
223946864|NCT06716632|PROCEDURE|Use of conventional knot tying technique for heamostasis|Conventional methods of vessel ligation, which involve the use of ties and suture ligatures, have long been employed in most medical centers. While these techniques effectively control bleeding from vessels, they are time-consuming and carry the risk of harming adjacent structures like the recurrent and superior laryngeal nerves.
223946865|NCT06699173|OTHER|Heat ped|The hot ped was used during ricig cystoscopy
223946866|NCT07032350|OTHER|Web-based pain management support tool|The Pain Control Enhancement App (PACE-app) is a web-based tool designed to help family caregivers manage pain in persons with dementia. The app provides a brief screening to identify caregiver challenges and delivers tailored strategies, communication prompts for providers, and an educational resource library. It includes a digital pain diary for tracking daily pain, treatments, and urgent care use, with weekly reports that can be shared with healthcare providers. The app is accessible on any internet-connected device and designed for caregivers with varying levels of digital literacy.
223946867|NCT07032350|BEHAVIORAL|Usual Pain Management Care|Caregivers receive no new intervention; they manage their care recipient's pain according to standard practices. No access to the PACE-app is given during the study period.
223946868|NCT06691776|DEVICE|online CBCT-guided adaptive radiation therapy using a new software|Patients are treated in the NKI with CBCT-guided online adaptive radiotherapy. While in the clinical workflow one planning CT is used to make the radiotherapy plan, this study treatment creates a new radiotherapy plan on the day of every treatment fraction. Instead of directly irradiating, the radiotherapy plan is adjusted to the anatomy of the day.
223946869|NCT06706310|DRUG|Placebo|Placebo contains no active substance.
223946870|NCT06706310|DRUG|TQA3334 Tablet|Inhibit viral replication.
223946871|NCT06706310|DRUG|Nucleoside (acid) analogs (NAs)|Inhibit viral replication.
223946872|NCT07039071|DEVICE|Laceback|"Lacebacks are a kind of orthodontic auxilliaries used during the initial phase of orthodontic fixed appliance treatment, especially in premolar extraction cases. They are 0.010 stainless steel ligatures tied in figure-of-8 fashion beneath the main archwires, from the canine bracket till the first molar hook of one quadrant. For this study, on the side that is randomly allocated to receive laceback, laceback will be put on both upper and lower arches (from canine bracket to 1st molar hook)."
223946873|NCT06704009|DRUG|NT-101 0.05 mM|Low concentration of NT-101 (0.05 mM)
223946874|NCT06704009|DRUG|NT-101 0.2 mM|High concentration of NT-101 (0.2 mM)
223946875|NCT06883032|OTHER|AR Eyeglasses first, SR Eyeglasses second|First Eyeglasses based on Automated Refraction, Second Eyeglasses based on Subjective Refraction
223946876|NCT06883032|OTHER|SR Eyeglasses first, AR Eyeglasses second|First Eyeglasses based on Subjective Refraction, Second Eyeglasses based on Automated Refraction
223946877|NCT06712719|OTHER|LP then HP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~LP then HP"
223946878|NCT06712719|OTHER|HP then LP|"Each cross-over phase will be 21 days and consist of a 7-day outpatient, controlled diet period, followed by a 7-day inpatient, controlled diet, balance, and kinetic study period, followed by a second 7-day outpatient, controlled diet period.~HP then LP"
223946879|NCT07043153|DIAGNOSTIC_TEST|Albumin to globulin ratio and prognostic nutritional index model|Measurement of albumin to globulin ratio and prognostic nutritional index in participants to assess disease activity in systemic lupus erythematosus patients
223946880|NCT07044050|BIOLOGICAL|allogenic natural killer cells|OT-C001 will be administered by IV infusion weekly for at least 3 doses.
223946881|NCT07043712|DIETARY_SUPPLEMENT|High pulse consumption|Subjects are provided a high pulse diet for 4 weeks.collection, and anthropometrics measured.
223946882|NCT06716606|DRUG|Belimumab|Belimumab will be administered.
223536117|NCT03198871|DRUG|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
223536118|NCT03198871|DRUG|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
223536119|NCT01173679|DRUG|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
223536120|NCT01173679|DRUG|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
223536121|NCT01173679|DRUG|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
223536122|NCT00332618|DEVICE|OXYGENATED GLYCEROL TRIESTERS|
223536123|NCT02552797|BEHAVIORAL|Shared Decision Making tool|
223536124|NCT06259357|OTHER|Protocolized protective mechanical ventilation in prone position|Prone Position: Study subjects randomized to the intervention group will be placed and maintained in prone position for at least 16 hours/day until the time of organ procurement or decline (typically 24-48 hours after donation consent) or the time that the lungs are declined for transplant.
223536125|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
223536126|NCT00984503|DRUG|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
223536127|NCT00984503|DRUG|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
223536128|NCT00984503|DRUG|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
223536129|NCT01254448|DRUG|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
223536130|NCT01254448|DRUG|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
223536131|NCT06154018|DRUG|Protamin|ACT and Clot- Pro test will be ran after initial and possible next protamine administrations
223536132|NCT05174585|BIOLOGICAL|JAB-BX102 (anti-CD73 monoclonal antibody)|Administered by intravenous infusion (IV)
223536133|NCT05174585|BIOLOGICAL|pembrolizumab (anti-PD-1 monoclonal antibody)|Administered by intravenous infusion (IV)
223536134|NCT01250054|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
223536135|NCT01250054|DEVICE|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
223536136|NCT02559648|DRUG|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
223536137|NCT02559648|DRUG|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
223536138|NCT03886467|OTHER|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
223536139|NCT04815798|COMBINATION_PRODUCT|Bacteriophage-loaded Microcapsule Spray|Study intervention consists of a dosage-metered airless spray containing a cocktail of 14 bacteriophages encapsulated in a biodegradable polymer. This bacteriophage product will be delivered topically every 3 days for 56 days or until wound has healed.
223536140|NCT04815798|COMBINATION_PRODUCT|Placebo|Placebo intervention consists of a dosage-metered airless spray containing a buffer solution analogous to the study intervention. This placebo will be delivered topically every 3 days for 56 days or until wound has healed.
223946883|NCT06717165|COMBINATION_PRODUCT|ERP combined with high-definition active tACS|The active tACS +ERP referred to a period of tACS applied in the first 20 minutes of the ERP treatment (the tACS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tACS+ERP treatment. Based on the EEG parameters, individualized modeling was conducted to determine specific stimulation parameter schemes (stimulation frequency). Anode electrode will be localized in front of the mPFC on the Fz point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AFz, Fcz, F1, F2).
223946884|NCT06717165|COMBINATION_PRODUCT|ERP combined with sham tACS|Patients will get the same CBT setting as the active tACS group and they were applied the sham tACS cocurrently with ERP. The sham tACS device is the same as the active comparator's except that the sham tACS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tACS.
223946885|NCT07052773|DEVICE|Lung Cancer Detection System (LCDS)|An AI-based decision support software designed to detect solid pulmonary nodules on LDCT chest scans. In this study, the LCDS is applied retrospectively to 100 previously acquired LDCT scans, and its performance is compared to a ground truth established by double-read radiologist reports with arbitration.
223720768|NCT05761561|BEHAVIORAL|Exercise and medical nutrition|"The study dietitian and exercise trainer will each conduct weekly counseling sessions via telephone or zoom throughout the course of chemotherapy (approximately 18 weeks) to assist the participants in achieving the diet and exercise study goals. Participants will be provided written informational material, exercise bands for strength training and a Fitbit to record activity.~Participant goals are to: 1) participate in 150 min/week of moderate-intensity physical activity 2) participate in two weekly strength training sessions; 3) eat a combination of 5 or more servings of vegetables and/or fruits per day 4) consume 25 grams or more of fiber/day; 5) consume adequate amounts of protein to prevent muscle wasting (1.2g/kg body weight)."
223720769|NCT03793127|OTHER|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
223946886|NCT06829303|DEVICE|Emotional Facial Expression Paradigm (EFP)|The experimental intervention is a social cognition gamified training, through a software that implements communication between a participant and a computer, using a detection and classification algorithm based on EEG signal. The training consists of a visual stimulation model, specifically an emotional facial paradigm, where the subject is asked to observe the movements of a facial expression (referred to as cue image) expressing either happiness or sadness and to adapt the visual gaze according the cue image.
224100405|NCT00816036|BEHAVIORAL|Smoking Cessation Guideline Implementation|"1\. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
224100406|NCT03212261|BEHAVIORAL|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
224100407|NCT00388466|DEVICE|GALILEO|
224100408|NCT02739412|BIOLOGICAL|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
223720770|NCT03793127|OTHER|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2\* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
223720771|NCT03793127|OTHER|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
223720772|NCT06548581|DEVICE|SpeedPlate™ Rapid Compression Implants|MTP and/or TMT joint fixation with SpeedPlate™ Rapid Compression Implants
223720773|NCT06752980|OTHER|Eye mask|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
223720774|NCT06752980|OTHER|Earplugs|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
223720775|NCT06752980|OTHER|Eye Mask and Earplugs|The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
223946887|NCT06829303|DEVICE|Speller task|The control intervention is a executive function gamified training, through a software that implements communication between a participant and a computer, using a detection and classification algorithm based on the P300 EEG signal. The task consists of a speller, in which the participant is asked to write a word, by sequentially focusing the attention on the necessary letters.
223946888|NCT06808048|BEHAVIORAL|Cognitive testing|Participants will complete a cognitive testing battery that includes measures of attention, learning, memory, problem-solving and executive function.
224100409|NCT05893134|OTHER|Risk Assessment|A probabilistic risk model will be generated based on the variables of different natures used and maps will be built to identify the areas of greatest risk for dengue transmission in the study area
224100410|NCT02032628|BEHAVIORAL|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
224100411|NCT04255134|DRUG|Abatacept Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
224100412|NCT04255134|DRUG|Adalimumab Injection|Subjects will be randomized to treatment with either abatacept or adalimumab
223536141|NCT04815798|PROCEDURE|Standard of Care|Standard of care consists of but is not limited to offloading, positioning, cleansing, debridement, and wound dressing. A topical antimicrobial hydrogel will applied to wounds with signs of localized infection.
223946889|NCT06808048|BEHAVIORAL|Task-based fMRI measure of inhibitory control|All participants will complete a task-based fMRI measure of inhibitory control. This Go/No-Go task provides a contrast of BOLD signals when response conflict is low (execution of motor responses on frequent Go trials) vs high (inhibiting the prepotent response on infrequent NoGo trials). It will provide an assessment of the effects of cannabis use on the frontostriatal implicit motor learning and cognitive control systems. Participants view shapes and press a button quickly (Go trials) to every shape except circles and squares (NoGo Trials). To increase response prepotency, Go trials are frequent (75%). Button presses must be rapid to be considered correct. The task uses an event-related design with each stimulus presented for 600 ms, followed by a 1.0-4.5 second jittered ISI during which a white fixation crosshair is displayed. Trial type is pseudo-randomized with the constraint of equal frequencies of consecutive Go trials (2, 3, or 4) between NoGo trials.
223946890|NCT06808048|BEHAVIORAL|Task-based fMRI measure of face-name learning|"This task is ideally suited to assess cannabis effects on explicit associative learning and memory as mediated by frontohippocampal networks. Participants memorize names corresponding to faces (encoding phase), and then recall the names after a short delay. The first encoding block begins with a 2-second cue (MEMORIZE) followed by 5 face-name pairs, each shown for 4 seconds; participants press a button when they encode each face-name pair. A distractor block follows. Next, a retrieval block begins with a cue to RECALL followed by presentations of each of the same 5 faces, now paired with ??? (i.e., prompting recall of previously paired names), with a 4 second stimulus duration and no ISI. On recall trials, participants press a button to indicate that they have recalled the name for the displayed face. Participants engage in silent uncued recall of face-name pairs. Immediately following the scan, participants are tested for accuracy of name retrieval."
223946891|NCT06776146|DIAGNOSTIC_TEST|proteomic profiling|proteomic profiling
223536142|NCT04470388|DRUG|EDP-514|Oral Capsule
223536143|NCT04470388|DRUG|Placebo|Placebo to match EDP-514
223536144|NCT01577602|OTHER|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
223536145|NCT01577602|OTHER|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
223536146|NCT01577602|OTHER|Combined intervention|Combines the printed medication list with the open ended question
223536147|NCT02777086|BEHAVIORAL|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
223536148|NCT02982629|BEHAVIORAL|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
223536149|NCT00403325|DRUG|rhuFab V2 [ranibizumab] ( Lucentis )|
223536150|NCT06353477|DRUG|EPs® 7630|EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
223536151|NCT03372161|DRUG|SP-102|injection
223536152|NCT03372161|DRUG|Placebo|injection
223536153|NCT00626535|DRUG|Esomeprazole|20mg Oral Once Daily
223536154|NCT00626535|DRUG|Matching placebo|Oral Once Daily
223536155|NCT03395496|DRUG|Biodentine|Biodentine pulpotomy agent
223536156|NCT03395496|DRUG|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
223536157|NCT04054336|BEHAVIORAL|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
223536158|NCT04054336|BEHAVIORAL|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
223536159|NCT04054336|BEHAVIORAL|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
223536160|NCT01294852|OTHER|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
223536161|NCT03954912|PROCEDURE|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
223536162|NCT03954912|PROCEDURE|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
223536163|NCT01133665|DRUG|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
223536164|NCT05529407|DEVICE|Simple Vaginal Tampon|Use of single use vaginal tampons
223536165|NCT05529407|DEVICE|Glass Vaginal Trainer|Use of glass vaginal trainers
223536166|NCT01464645|DEVICE|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
223536167|NCT00918606|DRUG|LIPO-102|LIPO-102
223536168|NCT05812885|DEVICE|TENS|Active TENS
223536169|NCT05912621|DRUG|Tirzepatide|Tirzepatide dose is titrated up by 2.5 mg every four weeks as per below, starting with 2.5 mg weekly and maxing out at 15 mg.
223536170|NCT03547427|OTHER|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
224100413|NCT01663441|DRUG|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
223946892|NCT05197998|BEHAVIORAL|ColorBRAVE|The intervention is a multi-module program delivered via a mobile app for parents of children in K-2nd grade. Each module in the program will take approximately 30 minutes to complete, with lessons facilitated through interactive storytelling, videos, and games.
223946893|NCT07094230|DIAGNOSTIC_TEST|biomarkers analyses|blood analyses
223536171|NCT03547427|OTHER|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at \~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
223720776|NCT06895538|DRUG|Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG)|Patients in the ATLG arm receive ATLG instead of ATG as part of the routine conditioning regimen before allo-HSCT; ATLG is given intravenously by infusion for 4 consecutive days, after which they undergo routine transplantation.
223946894|NCT07099014|DRUG|Inahled Isoflurane|treatment administration
223946895|NCT07099014|DRUG|Propofol, midazolam|treatment administration
223946896|NCT07099144|DRUG|Inhaled nitric oxide (NO)|"The starting dose of INOmax is 20 ppm, which is controlled by the INOmax DSIR Plus delivery system in the respiratory circuit during mechanical ventilation. The dose will be maintained at 20 ppm for 4 hours after the start of administration, then the dose can be weaned to 5 ppm provided that the arterial oxygenation is adequate, as determined by the investigator within 4-24 hours of therapy, and the therapy should be maintained at 5 ppm until the fraction of inspired oxygen (FiO2) \< 0.60.~The treatment will be maintained until the potential hypoxia is resolved, or the investigator determines that the neonate no longer needs to use this drug. The maintenance treatment time is usually less than 4 days (96 hours). If the oxygenation level has not improved significantly after 4 days of maintenance treatment, the suitability of the treatment plan should be reassessed."
224100414|NCT01663441|DRUG|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
224100415|NCT01663441|DRUG|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
224100416|NCT01663441|DRUG|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
224100417|NCT04686890|PROCEDURE|erector spinea plane block administered preoperative open nephrectomy|erector spinae plane block applied in this group before open nephrectomy
223536172|NCT03547427|OTHER|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
223536173|NCT03547427|OTHER|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
223536174|NCT03547427|OTHER|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
223536175|NCT03547427|OTHER|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
223536176|NCT02122380|DRUG|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
223536177|NCT02122380|DRUG|Placebo|1 placebo pill by mouth per day for 30 days
223536178|NCT04127318|BEHAVIORAL|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
223536179|NCT00786162|OTHER|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
223536180|NCT00786162|OTHER|BP cuff at workplace|Provided BP cuff for communal use at the worksite
223536181|NCT02710539|DRUG|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
223536182|NCT02710539|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
223536183|NCT02212665|BEHAVIORAL|High intense interval training|
224100418|NCT04686890|PROCEDURE|intravenous analgesic ( 1 mg/kg tramadol + non-steroid antiinflamatuar paracetamol )drug + 10 mg.kg|intarvenous analgesic administered in this group for analgesia end of the open nephrectomy
223536184|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer|
223536185|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+HIIT|
223536186|NCT02212665|BEHAVIORAL|Increased daily activity detected by the pedometer+group intervention|
223720777|NCT05159492|DEVICE|PVI using PEF|PVI using PEF
223720778|NCT05159492|DEVICE|PVI using CFRF|PVI using CFRF
223720779|NCT06916533|BEHAVIORAL|ENBORTH-TR Intervention|This intervention program is structured with a multifaceted and holistic approach, starting with the definition of pain and covering topics such as basic body anatomy, functions and pain mechanisms, ergonomics training, environmental regulations, psychosocial factors such as stress, relaxation techniques, sleep and time management.
223946897|NCT07098923|BEHAVIORAL|combination of aerobic and resistance exercise|"Aerobic exercise: The main form is walking(gait), which includes three parts: warm-up, walking, and relaxation. Exercise time and frequency: 30-60 minutes of exercise per day, 3-5 times per week.~Resistance exercise: Mainly uses elastic bands to enhance resistance exercise, since the risks of increased intra-abdominal pressure and fluid leakage in peritoneal dialysis patients is high, Investigator considered selective resistance exercise especially for limb and shoulder joint exercises. Patients can choose 3-5 muscle groups based on individual conditions, with each action 10-15 times and maintained for 10 seconds. Start with 2 sets of resistance exercise and then gradually increase to 3-5 sets, with 2-3 minutes of rest between each sets. Exercise frequency and duration: 2 times a week (non-consecutive days), 20 minutes each time."
223946898|NCT07098780|DRUG|Tranexamic Acid|At the time of incision, 1000mg of the drug would be given intravenous, followed by two postoperative doses of 1000mg eight hours apart.
223946899|NCT07098780|OTHER|Normal Saline (Placebo)|At the time of incision, 10ml of the drug would be given intravenous, followed by two postoperative doses of 10ml eight hours apart.
223946900|NCT07098117|DRUG|SHR0302 Base Gel|Part I: once daily. Part 2:, twice daily.
223946901|NCT07098117|DRUG|SHR0302 Base Gel Placebo|Part I: once daily. Part II: twice daily.
223720780|NCT06916533|BEHAVIORAL|Client-centred Occupational Therapy Intervention Group|Client-centered occupational therapy intervention consists of 5 stages: (1) Client-centered goal setting, (2) creation of the therapy plan, (3) implementation of interventions, (4) evaluation of results, and (5) obtaining feedback.
223946902|NCT07098806|DRUG|186RNL|Multiple Doses of 186RNL
223946903|NCT07099599|DIAGNOSTIC_TEST|CT Perfusion|CT perfusion within 90 minutes of complete angiographic reperfusion
223720781|NCT07111858|OTHER|Watchful waiting with supportive care|Usual care is Pavlik Harness Treatment. Watchful waiting with ongoing ultrasound scans is the intervention in this study to determine whether the hip matures without the use of the Pavlik Harness
223720782|NCT06781255|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 24 weeks
223720783|NCT06918795|BEHAVIORAL|Digital Exercise Intervention|Subjects randomized to the intervention arm will receive the same as the enhanced usual care arm but will be additionally exposed to: (1) personalized plans for aerobic-based PA, (2) personalized resistance exercise sessions, and (3) financial and non-financial engagement strategies. These intervention components will be delivered continuously using an advanced digital health informatics platform during the 6 months of the intervention. The intervention will be overseen and supplemented by the exercise physiologist, who will meet with participants on a weekly, then biweekly and finally monthly basis over 6 months.
223720784|NCT07125976|BEHAVIORAL|peer support|This intervention is a one-week, structured peer support program for patients in the first six months of hemodialysis treatment.
223720785|NCT04774471|DIAGNOSTIC_TEST|Evaluation of BIT-Motion software|Software program to discern benign versus malignant breast lesions.
223720786|NCT07131904|OTHER|non-alcoholic, fiber-enriched beer (FEB)|500 ml FEB consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
223720787|NCT07131904|OTHER|conventional, non-alcoholic beer|500 ml conventional non-alcoholic beer consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
223720788|NCT07131904|OTHER|glucose solution|Glucose solution containing 12.5 g glucose in 500 ml water, consumed once during a test day in a randomized crossover design. Postprandial blood glucose is monitored for 120 minutes using a continuous glucose monitor (FreeStyle Libre 3).
223720789|NCT07132944|OTHER|CTraC-FIT|"The intervention is designed to support Veterans at high risk of readmission with comprehensive transitional care that includes:~Structured Follow-Ups: Regularly scheduled follow-up calls to monitor the patient's progress, address any issues, and provide ongoing support.~Health Coaching: Personalized coaching to help Veterans manage their health conditions, adhere to treatment plans, and make lifestyle changes that can improve their overall health.~Care Coordination: Assistance with navigating the healthcare system, facilitating appointments, and ensuring that the Veteran receives all necessary post-discharge services.~The intervention arm aims to improve functional abilities and reduce hospital readmissions by providing tailored support based on the unique needs of each participant. The CTraC NCM will follow a standardized protocol to ensure consistent and effective delivery of the intervention across all participants in this group."
223720790|NCT07132944|OTHER|Enhanced Usual Care|"The Enhanced Usual Care (EUC) arm involves participants receiving the standard care provided by their assigned Veterans Affairs Boston Healthcare System (VABHS) inpatient and outpatient teams. This includes routine medical evaluations, treatments, and follow-up appointments as typically recommended by their healthcare providers. In addition to receiving standard care, participants in the EUC group will undergo baseline, endpoint, and 3-month follow-up assessments as part of the study protocol.~For participants with intermediate functional ability (SPPB score of 7-9), no additional intervention will be provided after randomization to the control group. However, for participants with low functional ability (SPPB score of 0-6), a safety protocol will be activated to notify their assigned inpatient medical team (e.g., hospitalist, social worker) about the participant's risk of functional decline, ensuring that appropriate support and referrals are provided if needed."
223720791|NCT07132931|BEHAVIORAL|Mindful Leadership Intervention|Mindful leadership training program focusing on contemplative practices, mindfulness exercises, and leadership skill development.
223536187|NCT03753048|PROCEDURE|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
223720792|NCT07132931|BEHAVIORAL|Management Skills Training|Standard management skills training including organizational techniques, communication skills, and leadership fundamentals.
223720793|NCT07132125|BEHAVIORAL|Default-style LLM chatbot|A large language model chatbot (GPT-4o) that delivers tailored persuasive messages to parents about HPV vaccination, using the model's default style with longer, structured responses. Participants engage in a three-minute, multi-turn conversation, with responses personalized to their top-rated vaccine concern identified in a pre-intervention survey.
223946904|NCT07100041|OTHER|Breathing Exercise Group|Before the dressing procedure, patients who volunteer to participate in the study will be given a patient information form, a burn-specific pain anxiety scale, and their pain level before dressing will be recorded using the GAS. After their vital signs are checked, they will be given a practical demonstration of breathing exercises. The breathing exercise will first be explained verbally by the project coordinator in the burn centre's training room, followed by a practical demonstration. The patient will then be asked to perform the exercise. Once the project coordinator is confident that the patient has learned how to perform the breathing exercise, the patient will be taken to the dressing room. During the standard dressing procedure, the patient will be instructed to continue performing the breathing exercise. Immediately before the dressing change, the patient will be positioned comfortably, and they will be instructed to use the breathing
223536188|NCT03753048|PROCEDURE|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
223536189|NCT02359006|DRUG|Minocycline|Minocycline will be compared with placebo
223536190|NCT02359006|DRUG|Placebo|Placebo will be compared with minocycline
223536191|NCT06088173|OTHER|exercises|Patients in both group will use Kleinert splint. Sessions will start with ice application if there is edema and continue with scar tissue massage. After general hand massage, passive flexion, active extension exercises; tenodesis exercise and passive punch will be performed for the postoperative (postop) first two weeks. In postop 3-4 weeks, four finger sliding exercises, active half fist and NMES (Neuromuscular electrical stimulation) will be performed. In postop 5-6 weeks, blocking exercises, full punch, grappling hooks and small on-digits holding and releasing exercises will be performed additionally.
223536192|NCT06088173|OTHER|Exercises and Education|In addition to the same treatment as the patients in the first group, in the first postoperative (postop) two weeks, the gmi will be explained to the patients and lateralization will be started. lateralization refers to right-left discrimination and the patients will be presented with visuals with the help of the noi recognise app and they will have to decide whether the visual is right or left hand. In the postop 3-4th weeks, the motor imagery stage will be started and imagery will be practiced with the help of the same app. In postop 5-6 weeks, mirror therapy will be practiced with the help of a mirror box.
223536193|NCT05390164|DIAGNOSTIC_TEST|skin biopsy|skin biopsy to be analyzed by ELISA
223720794|NCT07132125|BEHAVIORAL|Conversational-style LLM chatbot|A large language model chatbot (GPT-4o) that delivers tailored persuasive messages to parents about HPV vaccination in a conversational style, with short responses. Participants engage in a three-minute, multi-turn conversation, with responses personalized to their top-rated vaccine concern identified in a pre-intervention survey.
223720795|NCT07132125|BEHAVIORAL|Public health informational materials|Official public health informational materials on HPV vaccination from the Centers for Disease Control and Prevention (U.S.), National Health Service (U.K.), or Public Health Agency of Canada, matched to the participant's country of residence. Materials are 589-680 words in length, cover HPV risks and benefits of vaccination, and are presented for three minutes before participants proceed.
223946905|NCT07100041|OTHER|Stress Ball Group|The stress ball is made of a medium-hard plastic material that can be easily held in the hand. Before the dressing procedure, patients who volunteer to participate in the study will be given information about the use of the stress ball after the patient information form, the burn-specific pain and anxiety scale, and the pain level before dressing have been recorded using the GAS, and their vital signs have been checked. During the standard dressing procedure, patients will be instructed to squeeze and release the stress ball periodically until the dressing procedure is complete, focusing solely on the stress ball during this time (Ozen et al., 2023) (Kasar et al., 2020). A separate stress ball will be used for each patient in the stress ball group to ensure that the effectiveness of the stress ball remains consistent. To support patients' relaxation during the dressing procedure, a stress ball usage guide prepared by the project team will be provided
223946906|NCT07100041|OTHER|Control (Standard Treatment) Group|The standard dressing procedure in the control group is as follows: The protective covering over the wound is removed, and the wound is washed with an irrigation solution. Appropriate medications (decontamination and moisturising gel, debridement gel, alginate, antibiotics, and medications that promote cell regeneration) are applied based on the condition of the wound. A non-adhesive wound care dressing is then placed over the wound, and gauze is applied on top to cover it. Analgesia is not routinely administered in standard wound care. The dressing procedure takes an average of 5 minutes, depending on the size of the burn wound. In the control group, before the dressing procedure, the patient who volunteered to participate in the study will be given a patient information form, a burn-specific pain anxiety scale, and the pain level before dressing will be recorded using the Visual Analogue Scale (VAS) and vital signs will be checked,
223946907|NCT07099521|DEVICE|Active High-definition transcranial direct current stimulation|Participants completed 10 sessions of anodal HD-tDCS stimulation over 5 consecutive days (two 20-minute sessions per day, with a 3-hour interval between sessions). Stimulation was delivered using an HD-tES device (Soterix Medical, Inc, Woodbridge, NJ, USA), targeting the left dorsolateral prefrontal context (DLPFC). In the active HD-tDCS condition, current was ramped up to 2mA over 30 seconds, maintained for 20 minutes, then ramped down to 0mA at the end.
223946908|NCT07099521|DEVICE|Sham high-definition transcranial direct current stimulation|Participants completed 10 sessions of sham HD-tDCS stimulation over 5 consecutive days (two 20-minute sessions per day, with a 3-hour interval between sessions). Stimulation was delivered using an HD-tES device (Soterix Medical, Inc, Woodbridge, NJ, USA), targeting the left dorsolateral prefrontal context (DLPFC). In the sham condition, the current was ramped up to 2mA within the first and last 30 seconds to mimic the sensation of stimulation, but then ramped down, with no current maintained at other times.
223946909|NCT07098949|OTHER|Acupuncture|The patient takes a sitting or lateral position. The following acupoints are selected Baihui (GV20), Yintang (EX-HN3), Zhongwan (CV12), Bilateral Neiguan (PC6), Bilateral Zusanli (ST36), Bilateral Sanyinjiao (SP6), Bilateral Gongsun (SP4), Bilateral Pishu (BL20). Electroacupuncture is applied at bilateral Sanyinjiao (SP6) and bilateral Zusanli (ST36) by connecting them to an electroacupuncture device. The needles are retained for 30 minutes.
223946910|NCT07098949|OTHER|Sham Acupuncture|sham acupuncture procedure that mirrors the acupuncture treatment in terms of acupoint selection and treatment schedule. However, instead of actual needle insertion, a blunt-tipped sham needle will be used to apply superficial pressure at the designated acupoints. The design of the sham needle includes a base that allows for simulated insertion, providing patients with a mild sensation of pressure and a visual cue as the needle appears to move toward the skin. This innovative approach ensures that while participants experience a similar tactile sensation, there is no penetration of the skin, distinguishing it clearly from the actual acupuncture treatment.
223946911|NCT07098949|DRUG|Chemotherapy|Adjuvant chemotherapy with either the XELOX (capecitabine + oxaliplatin) or SOX (S-1 + oxaliplatin) regimen
223720796|NCT06932757|DRUG|Quisinostat|Participants will receive 12 mg of Quisinostat via capsule to be taken orally three times per week of each 21 day cycle.
223946912|NCT07097987|DIETARY_SUPPLEMENT|WM formula Group|Participants in the intervention group will consume a single dose of WM formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol.
223946913|NCT07097987|OTHER|Control group|Participants in the control group will consume 50 mL water
223946914|NCT07098754|OTHER|Dry Needling|"will use dry needles of different recommended sizes to intercept the trigger points~will add on myofascial release technique manually."
223946915|NCT07098754|OTHER|Trigger point therapy|"will release trigger points by manual pressure using trigger point therapy technique protocols~will ad on stretching techniques"
223946916|NCT07098754|OTHER|Maitlands' Mobilizations|"Maitlands' Mobilizations Grade-1\& Grade-2 will be applied to upper thoracic and cervical regions~dry cupping therapy will be applied as ad on therapy"
223946917|NCT07098754|OTHER|Tens and ultrasound|TENS and ultrasound will be applied according to recommended dosages followed by stretching and Range of motion activities
223720797|NCT05799729|DRUG|Ketamine|CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
223720798|NCT02371551|OTHER|Blood/urine sampling|Routine chemistry profile
224100419|NCT06802159|BEHAVIORAL|Conventional therapy|"The methods of traditional neuropsychological rehabilitation used in the classes included:~* attention tasks: proofreading tests, Schulte's Table;~* spatial thinking tasks: copying, drawing, tasks using Nikitin cubes;~* text reading tasks: texts from the Luria album. Each session began with oculomotor exercises. The correction programs differed by the type of feedback given to the patient in the course of correction.~Feedback in this type of intervention is in the form of prompts from a specialist."
224100420|NCT06802159|BEHAVIORAL|Eye tracking based therapy|"Rehabilitation in this group was carried out using an alternative communication device - oculograph C-Eye Pro (Assistech). The use of the device is characterized by a number of features: the presence of the eye movement biofeedback function (the patient and the specialist can see where the patient's gaze is directed by the movement of the red dot on the screen), the device needs to be pre-calibrated before the beginning of the session. To implement rehabilitation activities such tasks were used as:~* Visual field training;~* Word composing;~* Vowel insertion;~* Reading;~* etc. The peculiarity of correction on the apparatus of alternative communication - oculograph - was the use of visual biological communication, visual biological communication, also in case of wrong answer a sound signal followed."
223720799|NCT02371551|OTHER|Conventional routine CT examination|Standard diagnostic examination
223720800|NCT02371551|OTHER|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
224100421|NCT06802159|BEHAVIORAL|Cognitive therapy|"Rehabilitation of patients in the second experimental group was carried out on the RehaCom modular therapeutic system. The modular system includes a dedicated keyboard that has: numbers 1-9, 4 ok buttons, 4 arrow buttons, 2 pause/tip buttons and 2 exit/cancel buttons. Most of the tasks are performed using the keyboard, some of the tasks involved touch screen control. Tasks with stimulus images in the left screen space were used for rehabilitation activities:~* Saccades;~* Attention and Concentration;~* Planar Imagination;~* General Presentation and Reading;~* Shopping;~* Daily routine. A feature of the correction on the modular therapy system was the involvement of a motor component, playing a sound cue or visual cue when an error occurred."
224100422|NCT05534724|OTHER|Partial weight-bearing (10 - 15kg)|Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks
223720801|NCT02371551|OTHER|Functional MRI|Study-specific diagnostic examination
223720802|NCT03019822|DRUG|LSD|100ug per os, single dose
223720803|NCT03019822|DRUG|MDMA|125mg per os, single dose
223720804|NCT03019822|DRUG|Amphetamine|40.3mg per os, single dose
223720805|NCT03019822|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs
223720806|NCT05035953|DRUG|Edaravone Dexborneol|Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
223946918|NCT07098845|BEHAVIORAL|Learning to BREATHE|L2B is a group MBI designed for adolescents (Broderick \& Metz, 2009) and teaches three families of practices: focused attention (e.g., breath awareness), open awareness (i.e., awareness of sensations, thoughts, and feelings as they occur), and compassion. Each letter in BREATHE corresponds to a theme: Body, Reflections, Emotions, Attention, Tenderness, and Habits, building to the overall goal of Empowerment. Each session involves guided discussions, activities, and mindfulness practices.
223946919|NCT07098845|BEHAVIORAL|Learning to BREATHE Plus|"The in-person, group program portion of L2B PLUS and L2B are identical. But, L2B PLUS (Lucas-Thompson et al., 2020) builds on the standard L2B program with 3 additional supplements: 1) Extensive on-demand library designed by the team to be integrated with the group program and specifically to allow participants to independently practice skills that have already been introduced in the group program. 2) Intervention messages sent across the day. The team developed intervention messages to be sent 5 times a day to participants (Lucas-Thompson et al., 2020). Each week, participants receive intervention content tailored to what they have just learned in the group program. 3) JIT support. When participants indicate high stress via EMAs completed during the intervention period, tailored intervention content is delivered just-in-time during a moment of high need. These JIT messages were developed specifically to support applying or using mindfulness during periods of high stress."
223946920|NCT07098845|BEHAVIORAL|HealthEd|Hey-Durham is a health education program that the team has extensive experience implementing (Lucas-Thompson et al., 2019; Shomaker, Berman, et al., 2019; Shomaker et al., 2016; Tanofsky-Kraff et al., 2014) and covers topics such as domestic violence, substance use, depression/signs of suicide, and conflict resolution. Mental health components focus only on prevalence and identification. There is no content overlap with L2B, but it is matched to L2B in format, time, frequency, in-person contact, and facilitator expertise. Inclusion of HealthEd in a future efficacy trial will allow us to test the extent to which the active ingredients of MBI (i.e,. a top-down and bottom-up focus on emotion and stress regulation(Zelazo \& Carlson, 2012)), with and without the between-session support L2B, improve mental health and stress responding, relative to an active control matched for critical characteristics but that does not include these active ingredients.
224100423|NCT05534724|OTHER|Complete weight-bearing|Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
224100424|NCT04111588|OTHER|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
223720807|NCT05035953|DRUG|Placebo|Edaravone Dexborneol matching injection, addition to thrombolysis
223720808|NCT05659095|OTHER|autologous hair follicle derived mesenchymal stem cell suspension|Healthy hair follicles were extracted from the occipital area and treated to obtain hair follicle mesenchymal stem cells suspensions. The recipient sites were divided into two groups. Nine points were injected in a 1 cm2 area, and 100 μl of solution containing either 1 × 105 cells or normal saline was injected at each point. The follow-up duration was 9 months.
223720809|NCT04492202|OTHER|Survey|The survey will be sent to health professionals via online link.
223720810|NCT02976428|PROCEDURE|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
223720811|NCT02976428|PROCEDURE|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
223720812|NCT06001424|OTHER|physical therapy|Frenkel's exercises for lower limb, Proprioceptive neuromuscular facilitation for upper limb in the form of rhythmic stabilization
223720813|NCT06001424|OTHER|life kinetic exercises|A multimodal training that combines coordinative, cognitive and visual tasks.
223946921|NCT07094542|DRUG|Temporo-masseteric Nerve Block Injection|The TMNB injection/placebo will be administered by the Principal Investigator. The injection will only be delivered on Day 2 on the side/s of significant jaw muscle pain. Following disinfection of skin overlying the suprazygomatic injection site, a single carpule of 1.8 ml 2% lidocaine with 1:100,000 epinephrine will be delivered using a 25- or 27- gauge 30 mm needle). The injection site will be approximately a centimeter above the zygomatic arch, and a centimeter behind the palpable posterior border of the frontal process of the zygomatic bone. The needle will be directed at a 45-degree downward angle, directed medially along the coronal plane. At the depth of insertion of the needle, the local anesthetic/placebo will be delivered.
223720814|NCT02674529|DRUG|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
223720815|NCT02674529|DRUG|Placebo|Placebo
223720816|NCT02674529|BEHAVIORAL|Real-time Neurofeedback fMRI task pre- and post-RCT|Placebo experiment during an fMRI scanning session
223720817|NCT02891850|DRUG|Riociguat (Adempas, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
223720818|NCT02891850|DRUG|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
223720819|NCT02891850|DRUG|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
223720820|NCT06069245|DIETARY_SUPPLEMENT|MitoQ|80mg of MitoQ taken in one dose on one occasion.
223720821|NCT06069245|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules
223720822|NCT04349670|PROCEDURE|GPOEM - gastric per-oral endoscopic myotomy|Endoscopic section of the pyloric muscle with submucosal tunnel technique.
223720823|NCT06141590|DRUG|administration of UI068|Test
223720824|NCT06141590|DRUG|administration of UIC202205, UIC202206|Reference
224100425|NCT03192579|DRUG|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
224100426|NCT03192579|DRUG|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
224100427|NCT03040154|OTHER|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
224100428|NCT03040154|OTHER|Usual Care Video that is publicly available|
223946922|NCT07094542|DRUG|Oral Pain Medications only|For participants with jaw muscle pain to palpation \<5 NRS score, no additional injection will be given. The participant will take the recommended pain medications as described.
223946923|NCT07098871|DIAGNOSTIC_TEST|Ultrasonography (Rectus and diaphragma muscle thickness measurement)|Rectus and diaphragma muscle thickness will be measured by ultrasonography preoperatively.
223946924|NCT07099924|DRUG|Ropivacaine 0.2%|2x30ml (bilateral) ropivacaine 0.2% every 8 hours via rectus sheath catheter
223946925|NCT07099924|DRUG|Saline 0.9%|2x30ml saline 0.9% every 8 hours via rectus sheath catheter
223946926|NCT07098533|BEHAVIORAL|Cognicise Training|The Cognicise program included 16 sessions over 8 weeks (twice weekly, 60 minutes each). This dual-task training combined motor activities with cognitive exercises. During basic gymnastic movements, participants responded to real-time changes in live music and visual stimuli while also solving simple verbal and math tasks. Sessions were divided into 15 minutes of warm-up, 30 minutes of dual-task activity, and 15 minutes of breathing and relaxation exercises.
223720825|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
223946927|NCT07098533|BEHAVIORAL|Yoga Training|The yoga intervention consisted of 16 instructor-led sessions over 8 weeks (twice weekly, 60 minutes each). Each session included a warm-up (15 minutes), a main phase (30 minutes) focused on exercises targeting the spine, pelvis, and hips, and a relaxation period (15 minutes), including 10 minutes of deep relaxation techniques.
223946928|NCT07098520|OTHER|No intervention, just observation|no intervention, study investigates biomarkers associated with a disease
224100429|NCT01140087|PROCEDURE|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
224100430|NCT04756544|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell®-52, Bifidobacterium longum Rosell®-175|probiotic
224100431|NCT04756544|OTHER|placebo|placebo
223720826|NCT00766337|DRUG|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
223720827|NCT00766337|DRUG|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
223720828|NCT06111300|DRUG|Dexmedetomidine|Group D (dexmedetomidine group): Patients in this group will receive loading dose of dexmedetomidine 0.7 ug/kg over 10 min. then maintenance dose 0.2 - 1 ug/kg/hr till end of surgery. Group C (control group): Patients in this group will receive volum- matched normal saline infusion (NaCL 0.9%) as a placebo.
223720829|NCT02532491|DRUG|Aripiprazole|Initial dose: 10 mg.
224100432|NCT00628355|DRUG|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
223946929|NCT03938792|DRUG|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
223946930|NCT07099131|DRUG|Anesthetic spray|will be applied to back of the throat for 10 seconds; their chin will also be concealed from the GSI examiner using a small cup and masking tape.
223946931|NCT07099131|DEVICE|Acupuncture|"A 6C file (endodontic instrumentation file) will be placed on the patient's mentolabial fold (CV24). This file will be concealed by a small paper cup; A clean alcohol wipe will be used to clean the mentolabial area prior to placing the acupuncture needle (6 C-File)."
223720830|NCT02532491|DRUG|Risperidone|Initial dose: 2 mg.
223720831|NCT05385731|OTHER|Nordic Walking (NWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
223720832|NCT05385731|OTHER|Free Walking (FWG)|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
223946932|NCT07099131|GENETIC|Masking Tape|A piece of commercially available masking tape will be adhered to the patient's mentolabial fold and concealed by the small paper cup
223946933|NCT07097948|DRUG|Etoposide|Specified dose on specified days.
223946934|NCT07097948|DRUG|Platinum|Specified dose on specified days.
224100433|NCT00628355|PROCEDURE|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
223946935|NCT07097948|DRUG|Toripalimab|Specified dose on specified days.
224100434|NCT04567563|DEVICE|Remote Ischemic conditioning (RIC)|Intervention Group: Patients will self-administer RIC treatment with the LifeCuff device 3 times a week. Treatment will be delivered at the patient's home and compliance will be monitored by the LifeCuff device. Control Group: Patients undergo typical standard of care treatment. Assessment of Ulcer Closure: Ulcers will be assessed as completely closed by the Principal Investigator through clinical judgement and photographic support. Patients that completely heal their ulcer during the healing period will complete the study and no further blood or tissue measurements will be taken
224100435|NCT04975802|OTHER|Placebo|10 oz (296 ml) cherry flavored still beverage
224100436|NCT04975802|DIETARY_SUPPLEMENT|Coffeeberry|10 oz (296 ml) cherry flavored still beverage
224100437|NCT04975802|DIETARY_SUPPLEMENT|Caffeine|10 oz (296 ml) cherry flavored still beverage
224100438|NCT00433888|DRUG|R744|100μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
224100439|NCT00433888|DRUG|R744|150μg/4 weeks for 8 weeks,then 25\~400μg/4 weeks for 40 weeks
224100440|NCT01466244|BIOLOGICAL|cetuximab|
224100441|NCT01466244|DRUG|cisplatin|
224100442|NCT01466244|GENETIC|gene expression analysis|
224100443|NCT01466244|GENETIC|microarray analysis|
224100444|NCT01466244|OTHER|immunohistochemistry staining method|
223720833|NCT05385731|OTHER|Health Education (HEG)|"The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months."
224100445|NCT01466244|OTHER|laboratory biomarker analysis|
224100446|NCT04532788|PROCEDURE|Customized crosslinking|"In the customized corneal cross-linking protocol (cCXL) a patient-specific treatment pattern, based on the patient's Pentacam images, will be used to treat the cornea. The CXL pattern exists out of 3 concentric circles and is centered on the cone. To estimate the cone location a combination of the thinnest corneal point, maximum anterior elevation and maximum posterior elevation is used. The epithelium is debrided with alcohol within the marked zone. After the application of riboflavin each circle receives a different amount of energy, which gradually decreases with increasing circle size.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
223720834|NCT00854477|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
223720835|NCT04388709|DRUG|Peginterferon Lambda-1A|Peginterferon lambda-1a (Lambda) 180mcg subcutaneous injection once
223720836|NCT05131698|COMBINATION_PRODUCT|Tislelizumab and Lenvatinib|"TACE therapy: For transarterial infusion chemotherapy before or after TACE embolization, each drug will generally be diluted with 0.9% sodium chloride solution or 5% dextrose solution 150-250 mL and injected slowly into the target artery for ≥20 min. Subsequent TACE therapy will be administered on an as-needed basis as assessed by the clinician, with each treatment interval exceeding 6 weeks and no more than 6 treatments in total.~Lenvatinib: The starting dose of lenvatinib will depend on the patient's baseline weight: if baseline weight ≥ 60 kg, patients will receive 12 mg of lenvatinib administered once daily; if baseline weight \< 60 kg, patients will receive 8 mg of lenvatinib once daily. TACE therapy will be given 3 days apart.~Tirelizumab: Tirelizumab 200 mg , intravenous infusion on the same day as the first dose of lenvatinib, once every three weeks.~Translated with www.DeepL.com/Translator (free version)"
223720837|NCT04655391|DRUG|Bosutinib Monohydrate|Given PO
223720838|NCT04655391|DRUG|Decitabine|Given IV
223720839|NCT04655391|DRUG|Enasidenib Mesylate|Given IV
224100447|NCT04532788|PROCEDURE|Standard crosslinking|"In the standard corneal cross-linking protocol (sCXL) the epithelium is debrided with alcohol over a region with a diameter of 9.0 mm. After the application of riboflavin the cornea is irradiated with UVA with a fluence of 10 mW/cm2 during 9 minutes with a diameter of 9.0 mm, resulting in a total energy of 5.4 J/cm2.~The procedure is done with the Avedro Mosaic CXL device (Avedro, Inc. Waltham, Massachusetts, United States)."
223720840|NCT04655391|DRUG|Gilteritinib Fumarate|Given PO
223946936|NCT07099495|DEVICE|Low Frequency Neuromuscular Electrical Stimulation|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 10 Hz, duration of 10 seconds (ON time: 10s), interspersed with a 20-second rest period (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
223946937|NCT07099495|DEVICE|Medium Frequency Neuromuscular Electrical Stimulation|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. Each electrically stimulated contraction will have a frequency of 50 Hz, duration of 10 seconds (ON time: 10s), interspersed by a period of 20 seconds of rest (OFF time: 20s), with a pulse width of 400 µs. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
224100448|NCT03935516|OTHER|Cast|The use of plaster and/or fiberglass for casting of subject arm.
224100449|NCT00319514|DRUG|Docetaxel|
224100450|NCT03392766|DEVICE|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
224100451|NCT03392766|DEVICE|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
224100452|NCT05636280|OTHER|schroth exercise|In this study, Schroth exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist trained in schroth.
224100453|NCT05636280|OTHER|traditional scoliosis exercise|In this study, traditional scoliosis exercise training applied 3 days a week for 6 weeks in people with Adolescent Idiopathic Scoliosis will be applied by a physiotherapist.
224100454|NCT00342368|PROCEDURE|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
224100455|NCT00108329|BEHAVIORAL|Weight Loss|
224100456|NCT03202693|DRUG|PA-824|
224100457|NCT05295628|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
224100458|NCT05295628|DEVICE|SENTINEL™ Cerebral Protection System|The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
224100459|NCT03542682|DEVICE|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
224100460|NCT03542682|DEVICE|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
224100461|NCT00303550|DRUG|Intravenous iclaprim|
224100462|NCT00303550|DRUG|Intravenous linezolid|
224100463|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology.
224100464|NCT05643664|PROCEDURE|prosthetics of the abdominal aorta after determining the safe zones of clamping|aneurysmectomy is performed with prosthetics of the abdominal aorta using the standard technology. Before surgery, multispiral computed tomography data is evaluated using artificial intelligence and safe zones of aortic and arterial clampings are determined. Intraoperatively, clamping is performed in the settlement zones.
223720841|NCT04655391|DRUG|Glasdegib Maleate|Given PO
224100465|NCT04747405|OTHER|therapy group|therapy group of maximum 8 people repeated twice
224100466|NCT01312194|PROCEDURE|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
224100467|NCT01312194|PROCEDURE|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
223720842|NCT04655391|DRUG|Ivosidenib|Given PO
223720843|NCT04655391|DRUG|Venetoclax|Given PO
223720844|NCT03304743|DIAGNOSTIC_TEST|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
223720845|NCT02937909|OTHER|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
223720846|NCT04700371|DEVICE|Interwoven stent|Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
223720847|NCT04700371|DEVICE|Laser-cut stent|Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
223720848|NCT00318110|PROCEDURE|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
223946938|NCT07099495|DEVICE|Neuromuscular Electrical Stimulation without generating contractility|The surface electrodes will be placed on the upper lateral side of the quadriceps, 5 cm below the inguinal fold and 3 cm above the upper edge of the patella of both lower extremities, bilaterally and with a slight flexion of the knees. They will be fixed with bandages or adhesive tape, and conductive gel will be used below the electrodes. No muscle contractions will be generated. The protocol will last a total of 8 weeks, being performed 3 times a week, with application of the equipment for 30 minutes each day.
223536194|NCT02896946|RADIATION|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
224100468|NCT03793543|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
223536195|NCT05810519|BEHAVIORAL|Active break with the proposed lumbar and hip extension exercises|Participants assigned to the experimental group will receive recommendation to take an active break with the proposed lumbar and hip extension exercises for every 30 minutes of sitting. In the experimental intervention, the exercise program include exercises and will be based on patient education. The participants will also explain the importance of regular training and receive a booklet with photographed and described exercises.
223536196|NCT05810519|BEHAVIORAL|Self-care recommendations|Participants assigned to the control group will receive an educational self-care book containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. The control group will perform their regular baseline activities.
223536197|NCT02912819|OTHER|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
223536198|NCT03590886|OTHER|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
223720849|NCT04773483|DIETARY_SUPPLEMENT|Quorn Foods products|180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
223720850|NCT04773483|DIETARY_SUPPLEMENT|Meat/fish products|Standard meat/fish products matched to Quorn group for protein intake
223720851|NCT02531906|DRUG|Gabapentin|Given PO
223946939|NCT07098507|PROCEDURE|sentinel lymph node biopsy|As sentinel lymph node biopsy is still a standard of care in early-stage breast cancer surgery, it represents the intervention in the standard of care arm
223946940|NCT07098507|PROCEDURE|omission of sentinel lymph node biopsy|omission of sentinel lymph node biopsy is the intervention in the experimental arm
223946941|NCT06827691|OTHER|Heat Therapy Intervention|Heat Therapy Intervention of shoulder depth submersion in a 40°C hot tub.
223946942|NCT06831695|PROCEDURE|Craniotomy|Intervention: Bone flap replaced after dural closure Additional Information: This procedure involves creating a single free bone flap using high-speed drills. The bone is repositioned and secured using mini plates or sutures after the surgical intervention is completed. Post-operative monitoring will include assessment for CSF leakage, wound healing, and neurological recovery.
223946943|NCT06831695|PROCEDURE|Craniectomy|Intervention: Bone permanently removed Additional Information: In this approach, the bone is removed in pieces using rongeurs, leaving an open dural surface without replacement of the bone. The dura is closed with sutures, and dural augmentation may be performed as needed. Post-operative assessment will focus on complications such as pseudomeningocele, CSF leakage, and extended hospital stays.
223946944|NCT05440110|DEVICE|active and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
224100469|NCT01212445|DRUG|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
224100470|NCT06656585|OTHER|Individual food selectivity protocol|"Children in the experimental group wear Oculus headsets and interact with virtual foods for 20 minutes. In the Pairing in the Kitchen phase, Oculus is removed. Two identical plates with 6 foods are placed in front of the child. The operator, seated next to the child, interacts with the food without eating it, maintaining a positive expression, and discussing non-food topics. No prompts to eat are given, and the child can leave at any time. Progress to the next phase if the child sits calmly for 30 seconds across 3 sessions.~Shaping Phase: Two identical plates are prepared. The operator comments on the food and keeps a small container of the child's favorite food visible but out of reach. Any food-related behavior is reinforced with praise and the favorite food. Target behaviors are adjusted if no response occurs for 15 seconds or if negative emotions are observed. Differential reinforcement is used."
223536199|NCT02781441|BEHAVIORAL|Question prompt list (QPL)|
223946945|NCT05440110|DEVICE|sham and active TBS|The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
223946946|NCT07098702|OTHER|educational sessions and booklet|educational sessions and booklet about ergonomic practices during breastfeeding which include appropriate body mechanics , breastfeeding positions, and use of breastfeeding pillows.
223946947|NCT07098702|OTHER|No Interventions|In this group, the mothers will breastfeed their newborns according to the routine hospital postpartum instructions only.
223946948|NCT04779853|DIAGNOSTIC_TEST|Blood samples for pertussis antibody testing|Blood samples will be sent to the laboratories of the National Centers of Expertise within 24-48 hours of blood collection. The samples will be transferred to the reference laboratory of SPCSEEM in Almaty, Kazakhstan. Serum samples will be stored in the reference laboratory at a temperature of -20 C.
223946949|NCT06830161|DIAGNOSTIC_TEST|Gingival Thermal Images|The degree of inflammation was evaluated using the Gingival Index
223946950|NCT03821623|DRUG|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
223946951|NCT03821623|OTHER|Placebo|Subjects will take placebo pills twice a day for 3 months
223946952|NCT06917352|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of pulse rate.
223946953|NCT04535414|DEVICE|Cellvizio (Registered trademark) Real-Time In Vivo Cellular Imaging Platform with Confocal Miniprobes|Participants of both study arms will undergo confocal endomicroscopy of the gastric mucosa until sufficient data for statistically accurate and reliable application of machine learning (i.e., computer models), currently believed to total the first 50 enrolled participants.
223946954|NCT04535414|DEVICE|Olympus Graphics Interchange Format (GIF) 190 endoscope|Participants will undergo white light endoscopy. The mucosa of the stomach may be thoroughly washed before examination, as medically indicated, and inspection will include repeated inflation and deflation to check distensibility and any abnormal appearing areas will additionally be biopsied. Nontargeted biopsies will be obtained as indicated per the assigned Arm.
223946955|NCT04535414|PROCEDURE|Gastric mucosal biopsy|As clinically indicated.
223946956|NCT06914492|BEHAVIORAL|AWARD advice|AWARD advice include Ask about smoking history, Warn about the high risk, Advise to quit, Refer smokers to smoking cessation services (with a referral card), and Do it again.
223536200|NCT02781441|BEHAVIORAL|Education brochure of Groupe Français des Myélodysplasies|
223536201|NCT03239457|BIOLOGICAL|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
223536202|NCT04464239|DRUG|TS-142|TS-142 tablets
223536203|NCT04464239|DRUG|TS-142 Placebo|TS-142 matching placebo tablets
223536204|NCT02465931|OTHER|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
223536205|NCT02465931|OTHER|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
223536206|NCT01160809|OTHER|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
223536207|NCT00403156|DRUG|Imatinib Mesylate /Ranibizumab|
223536208|NCT02394821|DRUG|Polihexanide 2%|
223536209|NCT02394821|DRUG|Metronidazole 0.8%|
223536210|NCT02441842|DRUG|atenolol|administered 60 minutes pre procedure
223536211|NCT02441842|DRUG|lisinopril|administered 60 minutes pre procedure
223536212|NCT02441842|OTHER|glucose|administered 60 minutes pre procedure
223536213|NCT03730584|DRUG|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
223536214|NCT03730584|BIOLOGICAL|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
223536215|NCT01574144|DEVICE|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
223536216|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic CGRP|Immunoassay kit for the evaluation of CGRP in blood
223536217|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic SP|Immunoassay kit for the evaluation of SP in blood
223536218|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic enkephalins|Immunoassay kit for the evaluation of enkephalins in blood
223536219|NCT05958914|DIAGNOSTIC_TEST|Dosage of ematic VIP|Immunoassay kit for the evaluation of VIP in blood
223536220|NCT05958914|DIAGNOSTIC_TEST|Dosage of CGRP in follicolar fluid|Immunoassay kit for the evaluation of CGRP in follicolar fluid
223946957|NCT06914492|BEHAVIORAL|Brief leaflet on health warning and smoking cessation|The contents of the leaflet include (1) highlights of the absolute risk of death due to smoking; (2) the whole list of diseases caused by active and second-hand smoking; (3) ten horrible pictorial warnings of health consequences of smoking and second-hand smoking in one page to maximize the impacts; (4) benefits of SC and (5) simple messages to encourage participants to quit smoking.
223946958|NCT06914492|BEHAVIORAL|Referral card|The contents consist of brief information and a highlight of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans.
223946959|NCT06914492|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
223536221|NCT05958914|DIAGNOSTIC_TEST|Dosage of SP in follicolar fluid|Immunoassay kit for the evaluation of SP in follicolar fluid
223536222|NCT05958914|DIAGNOSTIC_TEST|Dosage of enkephalins in follicolar fluid|Immunoassay kit for the evaluation of enkephalins in follicolar fluid
223536223|NCT05958914|DIAGNOSTIC_TEST|Dosage of VIP in follicolar fluid|Immunoassay kit for the evaluation of VIP in follicolar fluid
223536224|NCT02399644|BEHAVIORAL|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
223536225|NCT02399644|OTHER|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
223536226|NCT00371371|PROCEDURE|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
223536227|NCT00371371|PROCEDURE|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
223536228|NCT00371371|PROCEDURE|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
223536229|NCT05816824|OTHER|Symptom monitoring software via visual feedback|With PhysioAnalyst software, individuals are evaluated using clinical tools (questionnaire, scale). These evaluations provide visual feedback to individuals in the form of tables and graphs. In this way, patients can observe the changes in their clinical status.
223536230|NCT04067089|PROCEDURE|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
223720852|NCT02531906|DRUG|Methadone Hydrochloride|Given PO
223720853|NCT02531906|DRUG|Oxycodone Hydrochloride|Given PO
223720854|NCT02531906|OTHER|Quality-of-Life Assessment|Ancillary studies
223720855|NCT02531906|OTHER|Questionnaire Administration|Ancillary studies
223946960|NCT06914492|BEHAVIORAL|Personalized active referral|Smokers will be introduced to various SC services in Hong Kong (using the referral card) and be motivated to use these services. Well-trained SC ambassadors will assist smoker to choose favourite/most convenient or preferred type of services. Research staff will assist participants in booking or re-booking the SC services at the 1- and 2-month follow-ups (after very brief questionnaire surveys). Participants' contact information will be forwarded to SC services providers within seven days, and providers are expected to contact the participants within 1-2 weeks. Research staff will also monitor SC services use of the participants at each follow-up (1-, 2-, 3- and 6- month) and assist participants to book or re-book the appointments if necessary at 1- and 2- month follow-up. We shall liaise with the existing service providers and seek their assistance in helping our smokers in helping our smokers in a timely manner.
223946961|NCT06914492|BEHAVIORAL|12 weeks of chatbot-based instant messaging support|Participants in the intervention group will receive 12 weeks of instant messaging support delivered by the LLM-based chatbot accessible via WhatsApp platform. The chatbot, powered by GPT-4o model (or more advanced model available) using prompt-engineering and agent-based techniques, will deliver brief theory-based, structured SC intervention alongside freeform, on-demand support. The structured intervention session deploys the 5As model (Ask, Advise, Assess, Assist, and Arrange follow-up) and 5Rs model (Relevance, Risks, Rewards, Roadblocks, Repetition), as used in our previous telephone-counselling trials and recommended by WHO for brief SC intervention.
224100471|NCT06656585|OTHER|Traditional food selectivity protocol|"Step 1:Pairing in the Kitchen Propose enjoyable activities in the kitchen. Move to Step 2 when the child plays in the kitchen for 5 minutes over 3 consecutive sessions.~Step 2:Transition to Kitchen Two plates with 6 identical foods are placed in the kitchen. The operator engages the child in a welcome game, waiting 30 seconds for spontaneous interaction. If no response, the operator prompts the child to go to the kitchen. If the child doesn't follow within 30 seconds, the session is postponed. The operator sits next to the child and interacts with the food, without encouraging the child to eat. Progress when the child stays seated for 30 seconds without problem behavior for 3 sessions.~Step 3:Shaping Two plates are prepared, and the operator comments on the food. A visible container with the child's favorite food is used for reinforcement. Target behaviors are reinforced with praise and the favorite food. Adjust behaviors if there's no response for 15 seconds or negative emotions occur"
223946962|NCT06914492|BEHAVIORAL|Reminder messages|WhatsApp messages on follow-up survey reminders.
223946963|NCT06914297|DRUG|TQB2450 injection + oral progestin|TQB2450 (1200 mg q3w ivgtt) + megestrol acetate (MA, 160 mg qd po)/megestrol acetate (MPA, 500 mg qd po)
223946964|NCT07099872|OTHER|Control|Wear normal attire (shorts/t-shirt) during exercise sessions in a gym-like environment.
223946965|NCT07099872|OTHER|Overdressing|Wear standardized overdressing ensemble during exercise sessions in a gym-like environment.
223946967|NCT06472869|OTHER|NJOY ACE e-cigarette|Patients will be provided with NJOY ACE electronic cigarettes and 5% nicotine e-liquid cartridges in tobacco flavor for 4 weeks and asked to use the electronic cigarette as a substitute for smoking combustible cigarettes during the 4 weeks
223946968|NCT06400732|DEVICE|Fitbone Transport and Lengthening System|Implantation of the intramedullary Fitbone Transport Nail and subsequent bone segment transport and, optionally, lengthening.
223946969|NCT04576689|DRUG|IBE-814 70ug|At least 10 and up to 33 participants will receive one (1) IBE-814. Route of administration: intravitreal injection.
223946970|NCT04576689|DRUG|IBE-814 140ug|Up to 27 participants will receive two (2) IBE-814. Route of administration: intravitreal injection.
223946971|NCT06934265|BEHAVIORAL|exuberant voice therapy|exuberant voice therapy validated for patients with age-related voice changes (i.e., vocal fold atrophy, presbyphonia)
223946972|NCT05119140|DRUG|Hydroxychloroquine|400mg of hydroxychloroquine per oral daily
223946973|NCT05119140|DRUG|Mesalamine|the participant will maintain their current standard of care dose which can range from 1.5g to 4.8g of mesalamine per oral daily
223946974|NCT05972837|DEVICE|Surface electrical stimulation (SES)|Participants will undergo 3 weeks (20 minutes/ time, three times/ week) of SES intervention.
224100472|NCT06819696|PROCEDURE|ACL reconstruction with a dual-flow arthroscopy sheath|ACL reconstruction will be performed by the surgeon without a tourniquet but using a dual-flow arthroscopy sheath.
223536231|NCT04067089|PROCEDURE|Surgical aortic valve replacement|Surgical aortic valve replacement
223536232|NCT04286178|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.
223536233|NCT04286178|DIETARY_SUPPLEMENT|ubiquinol|Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.
223536234|NCT04286178|DIETARY_SUPPLEMENT|glucose tablet|Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.
223720856|NCT00630396|DRUG|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
223720857|NCT04467060|DRUG|Anaprazole Sodium|2.5mg, 5mg, 10mg, 20mg, 40mg, 80mg, 120mg, 160mg，fasting oral administration.
223720858|NCT04467060|DRUG|Placebo|single dose, fasting oral administration
223720859|NCT05611398|PROCEDURE|Orthopedic Surgery|A complete retrospective chart review was performed for all the patients' records and included all patients aged 18 years or higher who presented to Arrowhead Regional Medical Center with long bone fractures with Injury Severity Score \<16 and their repair and lactate levels at the time of surgery
223720860|NCT01456247|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
223946975|NCT05972837|OTHER|Remote medical support|The remote medical support includes a session of video call with a rehabilitation doctor in the first week and weekly telehealth visits with a live physical therapist or physician. The contents of the video calls contain patient education, stretching exercises teaching and instructions of using SES for MPS.
223946976|NCT01818063|DRUG|Paclitaxel|Given IV
223720861|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
223720862|NCT01456247|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
223720863|NCT01456247|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
223720864|NCT01456247|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
223720865|NCT01456247|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
223720866|NCT01748032|BEHAVIORAL|Cognitive training|20 minutes/day for 5 sequential working days
223720867|NCT01087190|DRUG|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
223720868|NCT05000060|OTHER|Timing/1 week|Time of restart of antiplatelet therapy is one week after injury
223536235|NCT04286178|DIETARY_SUPPLEMENT|gel capsule|Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.
223536236|NCT04286178|BEHAVIORAL|Exercise|"Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)"
223536237|NCT01720030|DRUG|Levosimendan|Verum therapy
223536238|NCT01720030|DRUG|Conventional therapy|Placebo therapy to safeguard blinding
223536239|NCT05465525|PROCEDURE|Quadratus Lumborum Block Type III|Patients will receive ultrasound-guided quadratus lumborum block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
223720869|NCT05000060|OTHER|Timing/3 weeks|Time of restart of antiplatelet therapy is left to treating clinician discretion
223946977|NCT01818063|DRUG|Carboplatin|Given IV
223720870|NCT02741024|DRUG|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
223720871|NCT02741024|DRUG|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
223720872|NCT00635596|BIOLOGICAL|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
223720873|NCT04143321|DRUG|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
223720874|NCT01446900|DRUG|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
223720875|NCT01446900|DRUG|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
223946978|NCT01818063|DRUG|Doxorubicin|Given IV
223720876|NCT00413127|DRUG|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
223720877|NCT00413127|DRUG|NaCl 0,9%|Administration of placebo i.v.
223720878|NCT04617509|DRUG|Formulation A GS-248|Formulation A of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
223720879|NCT04617509|DRUG|Formulation B GS-248|Formulation B of GS-248 in a capsule, dose 120 mg given as a single-dose of 3 capsules a´40 mg.
223720880|NCT02521636|OTHER|Antibiotic therapy randomization|
223720881|NCT02521636|OTHER|Serum PCT dosage|
223946979|NCT01818063|DRUG|Cyclophosphamide|Given IV
223946980|NCT01818063|DRUG|Veliparib|Given PO
223946981|NCT04353778|DRUG|Pyridostigmine|Eight weeks of low-dose pyridostigmine
223946982|NCT04353778|DRUG|Placebos|matching placebo x 8 weeks
223946983|NCT04353778|PROCEDURE|non-invasive vagal nerve stimulation|stimulation of the vagus nerve
223946984|NCT03411421|DRUG|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
223946985|NCT03411421|DRUG|Placebo|Matching placebo tablets will be administered.
223946986|NCT05643534|DRUG|Tenapanor 50 MG|Participants will receive tenapanor 50 mg BID (total of 100 mg daily)
223946987|NCT05643534|DRUG|Tenapanor 25 mg bid|Participants will receive tenapanor 25 mg BID (total of 50 mg daily)
223946988|NCT05643534|DRUG|Placebo|Participants will be randomized to receive matching placebo
223946989|NCT06463860|DEVICE|DermDx|DermDx is a computer-aided diagnosis (CADx) software product that uses an AI-based algorithm to evaluate non-invasively captured images of skin lesions obtained from any commercially available dermoscopes. DermDx uses state-of-the-art deep neural network models that have been trained on a large database of dermoscopy images. DermDx analyzes the image of a new skin lesion and provides an output.
223946990|NCT06021457|DRUG|RBT-1|Intravenous administration
223946991|NCT06021457|DRUG|Placebo|Intravenous administration
223946992|NCT00768716|DRUG|Acetaminophen|2 x 500 mg by mouth once
223536240|NCT05465525|PROCEDURE|Erector Spinae Plane Block|Patients will receive ultrasound-guided erector spinae plane block type III with 60 ml of bupivacaine 0.25% followed by general anesthesia.
223946993|NCT03559452|PROCEDURE|Eccentric exercise|300 eccentric contractions of the knee extensors
223946994|NCT06001593|DEVICE|YPS-201b|electrical stimulation device.
223946995|NCT06001593|DRUG|betahistine|Relieve symptoms of balance disorders or dizziness
223946996|NCT06001593|DEVICE|YPS-201b|sham electrical stimulation device.
223946997|NCT06237465|DRUG|Normal saline|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
223946998|NCT06237465|DRUG|Botulinum toxin type A|Thirty subjects with active bilateral axillary hidradenitis suppurativa will be consecutively enrolled and randomly stratified into two groups (Group 1 and Group 2). Both groups will contain five subjects each with mild, moderate, and severe disease. All participants will have 50-units of Botulinum Toxin-A (BTX-A) injected intradermally in one axilla and normal saline (NS) placebo administered in the other in a randomized, double-blinded fashion. At three months, Group 1 will receive 50-units BTX-A and NS in the same axillae as before while Group 2 will receive NS in both axillae.
223946999|NCT03753256|DEVICE|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
223947000|NCT03753256|DEVICE|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
223947001|NCT03753256|DEVICE|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
223947002|NCT03753256|DEVICE|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
223536241|NCT05465525|OTHER|No Block|The patients will receive general anesthesia.
223536242|NCT04467814|BEHAVIORAL|Better Together|"Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.~Caregiver participants in the intervention group will receive up to six telephone or video calls with the research assistant or Clinical Resource Therapist. Sessions will review the knowledge translation (KT) product with family members (\~15 minutes), art goals, brainstorm strategies, and discuss setbacks. The calls with the caregiver may occur 1 to 2 times in the hospital, within one week of going home, and then in Months 2 and 3."
223536243|NCT04467814|BEHAVIORAL|Usual Care|Patient and caregiver dyads from both groups will receive usual care during hospitalization and following discharge. This will include a handout on strategies for safely remaining active.
223536244|NCT03423602|DEVICE|PerQseal®|Large hole closure system
223536245|NCT04444089|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
223536246|NCT03249363|PROCEDURE|Group A - Pulsed PVP-I Irrigation|
223536247|NCT04618029|OTHER|Home Modification|"Home Modification Intervention~Floor~Provide recommendations to:~* Fix the back of the rugs and mats with adhesive/heavy duty tape~* Buy non-slip mats~* Tie all cables with a proper cable tie~Lighting~Provide recommendations to:~* Buy a torch light~* To replace worn light bulbs~* Buy a light switch~Bathroom~Provide recommendations to:~* Buy a non-slip mat~* Install a grab rail~* Buy a commode chair for showering~Stairways~Provide recommendations to:~• Fix an adhesive tape for stair contrast"
223947003|NCT05676541|OTHER|Complex intervention to enhance care for patients with multimorbidity in general practice consisting of an extended overview consultation and supporting elements|The intervention consists of 1) an extended overview consultation lasting 30-45 minutes in general practice, 2) access to cross-sectoral video conferences with secondary care specialists and 3) an instruction material for GPs on how to organize the intervention and 4) an adaptive toolbox to support elements in the intervention (not yet developed)
223947004|NCT01867879|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
223947005|NCT01867879|DRUG|Placebo|Placebo tablets, orally, single dose.
223947006|NCT04820088|OTHER|Computer based role play trianing|Participants will train with a computer-based role-play simulation. They will interact with a lifelike video character on screen. They will interact with the character in one of four scenarios (i.e., patient intake, traditional needs, high-risk needs,and social and physical transition). They will receive real-time and after-action feedback in a safe, non-stressful environment. Their usage of the system will be monitored and transcripts will be collected.
224100473|NCT06819696|PROCEDURE|ACL reconstruction with a thigh tourniquet|ACL reconstruction will be performed by the surgeon using a thight tourniquet
224100474|NCT05988385|DEVICE|Positive airway pressure|Positive airway pressure (PAP) therapy is a sleep apnea treatment that uses a stream of compressed air to support the airway during sleep. With PAP therapy, a mask is worn during sleep and a portable machine gently blows pressurized room air from into your upper airway through a tube connected to the mask. This positive airflow helps keep the airway open, preventing the collapse that occurs during apnea, thus allowing normal breathing.
224100475|NCT05988385|DEVICE|Oral appliance therapy|Oral appliance therapy involves the use of a dental appliance or oral mandibular advancement device that prevents the tongue from blocking the throat and/or advances the lower jaw forward. These devices help keep the airway open during sleep.
224100476|NCT05988385|DEVICE|Positional therapy|A NightShift Sleep Positioner (Advanced Brain Monitoring) is a neck vibration device, FDA approved to treat positional sleep apnea. The device detects patient supine position and delivers a small vibratory signal to the back of the neck to prompt position change.
223947007|NCT01267188|DRUG|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
223947008|NCT05052151|OTHER|Low dialysate temperature|35°C
223536248|NCT04618029|OTHER|Education|"Techniques Description Energy Conservation~* Take your time~* Go to the toilet more often, so you don't have to rush~* Use a nearby toilet: commode, different bathroom~* Prepare ahead (e.g., toilet paper near, other items for toileting, etc.)~* Adjust equipment before changing position~* Avoid transfers when tired~* Ask for help if you feel sick or especially tired~* Allow time for eyes to adjust to change in lighting~Task Simplification~* Plan and organise workspaces to eliminate unnecessary steps, save time, energy and reduce fatigue.~* Prioritise and plan activities, alternating between active and quiet jobs and include rest periods.~Ergonomics~* Proper positioning while doing tasks~* Safe mobility around the home"
223536249|NCT03423121|DRUG|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
223947009|NCT05052151|OTHER|High dialysate temperature|37°C
223947010|NCT05052151|OTHER|Low dialysate bicarbonate concentration|30 mmol/L
223947011|NCT05052151|OTHER|High dialysate bicarbonate concentration|38 mmol/L
224100477|NCT00777543|OTHER|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
224100478|NCT00777543|DIETARY_SUPPLEMENT|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
223536250|NCT03423121|DRUG|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
223720882|NCT04051723|DRUG|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
224100479|NCT00777543|DIETARY_SUPPLEMENT|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
224100480|NCT06991855|DIETARY_SUPPLEMENT|Animal-Based Oil Group|Participants in animal-based oil group will follow a diet in which the primary fat source is animal-based oil. The diet will supplement for 12 weeks.
224100481|NCT06991855|DIETARY_SUPPLEMENT|Plant-Based Oil Group|Participants in plant-based oil group will follow a diet in which the primary fat source is plant-based oil. The diet will supplement for 12 weeks.
224100482|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Tumor Ablation and Liquid Biopsy Acquisition|Partial ablation of tumor using ExAblate Neuro 4000 device (InSightec Ltd, Tirat Carmel, Israel) and blood and CSF draws for liquid biopsy
224100483|NCT04940507|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound Thalamotomy|Ablation of VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel) and blood draws.
224100485|NCT03463070|DRUG|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
223947012|NCT01064778|OTHER|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
223947013|NCT01064778|OTHER|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
223720883|NCT04051723|DRUG|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
223720884|NCT04775459|DRUG|Surfactant administration until 2020|Surfactant is administrated if Fi02 \>30% among the Guidelines of 2019
223947014|NCT06720272|OTHER|School nurse program|The intervention consists in the introduction of a school-nurse program providing health care through education about rheumatic heart disease, assessment, intervention, and follow-up of group A beta-hemolytic streptococcal pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with rheumatic heart disease.
223947015|NCT06359574|OTHER|Core Competency Model for Corrections (CCM-C) Self-Directed Violence Prevention Training|The Core Competency Model (CCM; Cramer et al., 2013, 2019) is an evidence-based educational training program for BHCs in suicide prevention core suicide prevention skills. The ten core competencies are: (1) Manage personal attitudes and reactions to suicide; (2) Maintain a collaborative stance toward the client; (3) Elicit evidence-based risk and protective factors; (4) Focus on current suicide plan and intent of suicidal ideation; (5) Determine risk level; (6) Enact a collaborative evidence-based treatment plan; (7) Notify and involve other persons; (8) Document risk, plan, and reasoning for clinical decisions; (9) Know the law concerning suicide, and; (10) Engage in debriefing and self-care. The CCM will be adapted for this pilot trial. In light of the SDV problem in carceral settings, the CCM for Corrections (CCM-C; Cramer, Kaniuka, \& Peiper, 2022) was adapted to address both suicide and self-injury assessment, treatment, and prevention.
223720885|NCT04775459|DRUG|Surfactant administration since 2021|Surfactant is administrated if Fi02 \>30% OR if score LUS \>8/18 among the literature
223720886|NCT05832385|RADIATION|IMRT|anal cancer: chemoradiotherapy, radiation dose\>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
223720887|NCT00109798|DRUG|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
223720888|NCT00109798|DRUG|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
223720889|NCT01786798|DEVICE|Transvaginal sonography|"Transvaginal sonography will be performed to:~* measure the endometrial thickness~* detect the endometrial pattern"
223720890|NCT00903695|DRUG|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, \& acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
223720891|NCT00903695|DRUG|placebo|placebo comparator
223720892|NCT00573911|PROCEDURE|Endoscopy and pH study|endoscopy and PH study done one time
223720893|NCT03983291|BEHAVIORAL|FaReWell Depression|Facial massage and force exercise
223720894|NCT01785732|PROCEDURE|Renal Denervation|Sympathetic renal denervation via renal arteries
223720895|NCT02817191|DRUG|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
223720896|NCT02817191|DRUG|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
223720897|NCT02466360|BEHAVIORAL|Back Belief questionnaire|
223720898|NCT02466360|BEHAVIORAL|QUEBEC scale|
223947016|NCT03385291|DEVICE|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
223947017|NCT05586178|BEHAVIORAL|Reminder that facilitates action|Patients will receive a text message reminding them that they can now get the bivalent COVID-19 booster and facilitating action. The message will contain a link to schedule a booster appointment at UCLA Health and a link to vaccine.gov (where people can find local pharmacies that carry the bivalent booster).
223947018|NCT05586178|BEHAVIORAL|Consistency framing|The message will leverage the psychological principle of consistency. It will highlight to patients that based on medical records, they have completed a COVID-19 vaccine primary series, have done a great job protecting their health, and can now get the bivalent booster.
223947019|NCT05586178|BEHAVIORAL|Information provision about the uniqueness of the bivalent booster|The message will contain information about how the bivalent booster differs from previous doses patients have received and why it is valuable.
223947020|NCT05586178|BEHAVIORAL|Information provision about bivalent booster eligibility|The message will clarify to patients that regardless of whether they are at high risk, received the original boosters, or previously got COVID-19, they are eligible for the bivalent booster based on their medical records, and the updated booster will be valuable for them.
224100486|NCT07015216|OTHER|VR-Assisted Dual Task Training|Virtual reality-based training will be conducted at ISÜFİZYOTEM in a custom-designed augmented VR environment. A 3D avatar and interactive scene (a 1 km crowded street) will be developed using Blender and Adobe Mixamo, with audio components from the Unity Asset Store. Participants will follow the avatar and perform exercises via a VR headset. After 1 minute of self-paced walking, a three-stage Stroop test will be introduced as a dual-task challenge. Sessions will be 20 minutes, supervised by a physiotherapist, with optional breaks. The intervention will be performed 3 times per week for 6 weeks.
224100487|NCT07015216|OTHER|Conventional Therapy Program|A pulmonary rehabilitation program will be administered to individuals with COPD once daily, three days per week for six weeks. The program will include diaphragmatic, chest, and bilateral segmental breathing exercises, breathing control training, relaxation positioning, peripheral muscle strengthening, and airway clearance techniques. Exercises will be explained and prescribed as a home-based program, to be performed twice daily with 10 repetitions. Patients will be given a daily log sheet to record adherence, which will be regularly monitored.
223536251|NCT06447909|BEHAVIORAL|Treatment App|"The behavioral treatment app content consists of tasks that caregivers can assign to their children in the app (e.g., finish homework, make bed, etc.). These tasks are completed offline, and then caregivers approve the child's completion of those tasks through the app, administering a token reward (coins) in-app. In the child version of the app, children take care of a virtual pet by feeding, cleaning, buying various accessories (using in-game coins), and exploring different lands with the virtual pet. The caregiver-assigned token coins can be used to redeem items needed to raise their pet, and access virtual lands. Caregivers can also choose to have their child redeem virtual tokens for real-life rewards. Ultimately, the app combines a video game with evidence-based principles to help children practice important tasks and behaviors as administered by caregivers."
223536252|NCT06447909|BEHAVIORAL|Sham app|As described above, the child will access a virtual pet that they can feed, clean and buy various accessories by redeeming virtual coins. They will not be able to explore different lands with that pet. Coins in the placebo version will be rewarded non-contingently. Additionally, children will not be able to redeem coins for real-life rewards as above in the treatment app. Caregivers will not need to review and approve tasks in order to redeem coins. The caregiver-version of the app will not contain the Assigned or Review tabs as assigned above, since the child will earn coins regardless of whether or not they complete tasks, so caregivers will not be able to review nor assign tasks. Instead, caregivers in this group will only have access to the guide tab which will contain helpful articles the parent can read about disruptive behavior problems in children.
223720899|NCT02466360|BEHAVIORAL|Fear Avoidance beliefs questionnaire|
223720900|NCT02466360|BEHAVIORAL|Visual analog scale|
223720901|NCT02466360|BEHAVIORAL|individual interviews|
223720902|NCT02466360|BEHAVIORAL|Focus groups|
223720903|NCT05420077|BIOLOGICAL|RVM-V001 10 µg|Low Dose
223720904|NCT05420077|BIOLOGICAL|RVM-V001 30 µg|Mid Dose
223720905|NCT05420077|BIOLOGICAL|RVM-V001 60 µg|High Dose
223947021|NCT05586178|BEHAVIORAL|Information provision about the severity of COVID-19 symptoms|The message will contain information about the often underestimated chances of people developing severe or long-lasting COVID-19 symptoms. The message will also mention that the bivalent booster can reduce such chances.
223947022|NCT05460910|OTHER|core stability exercises with treadmill|swiss ball use patient is lying in supine position with 15 repitations and 3 sets.
223720906|NCT01285674|DRUG|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
223947023|NCT05460910|OTHER|core stability exercise without treadmill|technique used to improve stability
223947024|NCT04596488|DRUG|Efavirenz 400mg|HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.
224100488|NCT07024693|DRUG|DT-168|Active
223720907|NCT05404295|OTHER|Umbilical cord blood platelel lysate gel|For the treatment group, a gel from Umbilical cord blood platelel lysat will be applied in the ulcer, and then a few layers of sterile gauze, and non-compressible bandage will be used to cover the wound/ulcer area.
223720908|NCT00543140|DEVICE|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
224100489|NCT07031648|OTHER|Laughter Yoga Group|iving information about the yoga of meeting and laughter, Obtaining written consent through the informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school, P
223947025|NCT05750719|GENETIC|BRCA1/2 genetic testing|All patients will undergo genetic testing for BRCA 1 and BRCA 2 germline mutations, employing next generation sequencing (NGS) techniques.
224100490|NCT07031648|OTHER|Pilates Group|Providing information about meetings and Pilates, Obtaining written consent through an informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school, Doing a total of 8 sessions of pregnant pilates exercises for 4 weeks, 2 times a week, Sessions should consist of a maximum of 10 people, A total of 45 minutes of pilates exercise for pregnant women, At the end of the fourth week, the final test will be administered
223947026|NCT03795688|OTHER|Pregnancy|Peripartum transition from pregnant to postpartum state
223947027|NCT03560271|DRUG|Cyclo-Z|Cyclo (His-Pro) and zinc
223947028|NCT03560271|OTHER|Placebo|Matching placebo
224100491|NCT07031648|OTHER|Education Group|Providing information about the research, Obtaining written consent through the informed consent form, Pre-test will be applied in the first week Providing routine pregnancy school trainings by midwife trainers in the pregnancy school (pregnancy, postpartum care, baby care, breastfeeding, etc.) At the end of the fourth week, the final test will be administered
224100492|NCT07030296|BEHAVIORAL|Sprint Training With Weighted Vest|Participants performed a sprint training program wearing a weighted vest equal to approximately 10% of their body weight. The program lasted 6 weeks and included 16 sessions of linear and change-of-direction sprint drills. The goal was to examine whether the added external load improved running speed over 30 and 60 yards.
224100493|NCT07030296|BEHAVIORAL|Sprint Training Without Weighted Vest|Participants completed the same sprint training program as the experimental group but without the use of a weighted vest. The intervention lasted 6 weeks and consisted of 16 sessions including sprint and agility exercises. This group served as the control condition to assess the effect of external resistance.
224100494|NCT07030114|DIAGNOSTIC_TEST|complete blood tests|"Complete Blood Count (CBC): Using automated hematology analyzers to measure various blood cell parameters.~* C-Reactive Protein (CRP): Quantitative analysis using immunoturbidimetric assay.~* Erythrocyte Sedimentation Rate (ESR): Measured using the Westergren method.~* Coagulation profile:~* Prothrombin Time (PT): Using thromboplastin reagents and automated coagulation analyzers.~* Activated Partial Thromboplastin Time (aPTT): Using phospholipid-based reagents and automated analyzers.~* International Normalized Ratio (INR): Calculated from PT results.~* Bleeding Time: Ivy method or template bleeding time.~* Liver function tests: Including ALT, AST, ALP, bilirubin using spectrophotometric methods.~* Kidney function tests: Creatinine and BUN using enzymatic methods."
224122639|NCT04000672|PROCEDURE|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
223947029|NCT06358599|DRUG|Cisplatin|Neoadjuvant cisplatin-containing combination chemotherapy was defined as the receipt of multiagent systemic chemotherapy initiated within 6 months prior to the date of radical cystectomy
223947030|NCT05277454|DRUG|HMPL-653|"Dose-escalation Stage:~Several dose levels will be evaluated for HMPL-653. The participants will receive oral HMPL-653 single-dose evaluation and oral HMPL-653 QD continuously treatment in a therapeutic cycle of 28 days until reaching the criteria for the end of treatment.~Dose-expansion Stage:~The participants will receive HMPL-653 treatment （RP2D）until reaching the criteria for the end of treatment."
223947031|NCT04304378|BEHAVIORAL|Stabilization Techniques (ST)|The Stabilization Techniques intervention provides an opportunity to improve emotion/affect regulation and coping skills. The overarching goal of these sessions is to introduce different ways of managing emotional distress through imagery and stress reduction techniques. ST sessions focus on providing coping mechanisms for managing important symptoms of PTSD (i.e., hyperarousal, negative emotions, and physical symptoms).
223536253|NCT00149786|BEHAVIORAL|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
223536254|NCT00149786|BEHAVIORAL|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
223536255|NCT02474979|DEVICE|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
223536256|NCT02474979|OTHER|Control|
223536257|NCT03246087|DEVICE|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
223536258|NCT03246087|OTHER|Standard of care|standard of care home exercise program
223536259|NCT00586794|DRUG|Sildenafil|3x per day 20 mg TID
223536260|NCT00586794|DRUG|Placebo|3x per day, 20 mg TID
223536261|NCT01082627|DRUG|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
223536262|NCT01082627|OTHER|common daily practice|common daily practice
223536263|NCT06206863|OTHER|Exercise Intervention|Participate in virtual exercise classes
223536264|NCT06206863|OTHER|Questionnaire Administration|Ancillary studies
223536265|NCT04188132|OTHER|EEG -BCI based Feedback for rehabilitation|Subjects will undergo EEG based BCI as feedback for rehabilitation
223536266|NCT06319404|OTHER||
223536267|NCT01973868|DRUG|Regorafenib (Stivarga, BAY73-4506)|
223536268|NCT01973868|DRUG|Cetuximab (ERBITUX)|
223720909|NCT00578812|DEVICE|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
223947032|NCT04304378|BEHAVIORAL|Stabilization Techniques with Behavioral Activation (ST+BA)|The Stabilization Techniques with Behavioral Activation intervention includes stabilization techniques as well as sessions targeted at increasing time engaged in physical activities during times outside of the intervention session. Preferred activities are selected by the participant. Strategies to foster engagement in the selected activities will include self-monitoring, structuring and scheduling daily activities, rating the degree of pleasure and accomplishment experienced during engagement in specific daily activities, exploring alternative behaviors related to achieving goals, and using role-play to address specific barriers. Establishing/maintaining routines and behavioral strategies to reduce avoidance and mange negative emotions are emphasized.
223947033|NCT04304378|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|EMDR is an exposure-based treatment that is the standard of care for PTSD delivered by the research team in Phnom Penh. EMDR utilizes sensory stimulation when participants are engaged in mental processing of traumatic material. EMDR follows a sequential framework targeting 1) past memories, 2) present symptoms, and 3) future actions.
223947034|NCT01372475|DEVICE|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
223720910|NCT00578812|DEVICE|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
223720911|NCT05329974|OTHER|Computer guided buccal cortical plate separation|Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
223536269|NCT06487299|DRUG|Ferrous Lactate|The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.
223720912|NCT04978740|OTHER|Ophthalmological examination|"Eye examination :~Ocular tonometry to determine intraocular pressure Refraction assessment Retina examination Slit lamp examination Visual acuity Schirmer's test Corneal topography Funduscopic examination Optical coherence tomography"
223720913|NCT02663323|DEVICE|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
223720914|NCT01186510|PROCEDURE|lung perfusion|see literature of proceeding
223720915|NCT01186510|PROCEDURE|no lung perfusion|see literature of proceeding
223720916|NCT02584673|DEVICE|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
223720917|NCT00873223|DRUG|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
223720918|NCT00873223|DRUG|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
223720919|NCT06000098|OTHER|Restrictive fluid therapy|"0,5 ml/hour fluid administration during prostatic anastomosis.~After general anesthesia induction, the patients were placed in the deep Trendelenburg position (at least 25°-45° upside down)."
223536270|NCT06487299|DRUG|Iron sucrose|The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.
223536271|NCT06487299|DRUG|0.9% NaCl solution|The same volume and color as Iron sucrose.
223536272|NCT02481193|DRUG|Cisatracurium|Different doses of cisatracurium pretreatment
223536273|NCT00362492|PROCEDURE|Bilateral ultrasound examination 7+/- 2 after surgery|
223536274|NCT05130593|DIETARY_SUPPLEMENT|Nutrasorb bar|250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
223947035|NCT01372475|PROCEDURE|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
223947036|NCT00949117|DIETARY_SUPPLEMENT|Ensure|Given orally
223947037|NCT00949117|DIETARY_SUPPLEMENT|PediaSure|Given orally
223536275|NCT05171153|OTHER|Densitometry with Trabecular Bone Score|"Conventional bone densitometry at the level of the proximal femur and lumbar spine (L1-L4) (anteroposterior and lateral) measured with a General Electric Prodigy Advance Full enCORE version 11.x equipment. With the data from the lateral densitometry, and using the VFA Dual Vertebral Assessment H8650DA/DM software, a quantitative morphometric analysis of the thoracolumbar vertebrae (T4-L4) will be carried out. Additionally, microarchitectural parameters of the lumbar spine will be evaluated with TBS (iNsight v3.0) and bone quality in the proximal femur with the DEXA-3D 3D-SHAPER v2.10.1 software. Vertebral fracture will be excluded from the DXA and TBS analysis of the spine."
223536276|NCT05171153|OTHER|Quantitative Ultrasound of Calcaneus|Quantitative bone ultrasound of calcaneus evaluated with a SONOST 3000, (OsteoSys Co, Korea).
223536277|NCT05171153|OTHER|Laboratory test|Analysis of general biochemical parameters and serum phospho-calcium metabolism, including: total calcium, albumin, phosphorus, 25-OH-vitamin D, intact PTH (iPTH), creatinine, estimated glomerular filtration rate, carboxy-terminal telopeptide of type I collagen ß-CTx (Crosslaps) and N-terminal propeptide of type I procollagen (P1NP).
223536278|NCT01340222|BIOLOGICAL|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
223536279|NCT00080574|PROCEDURE|Skin Biopsy|
223536280|NCT04313738|OTHER|Assigned Interventions|Home visit, health education
223536281|NCT04195490|PROCEDURE|feminizing genitoplasty|feminizing genitoplasty including vaginoplasty,clitroplasty, labioplasty and urethroplasty
223536282|NCT02343848|DEVICE|smart bracelet.|Physical activity will be evaluated using smart bracelet.
223536283|NCT03280693|DIAGNOSTIC_TEST|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
223536284|NCT05674227|PROCEDURE|Robotic surgery|Surgical treatment of operable lung cancers using robotic systems
223729456|NCT05856201|PROCEDURE|Laparoscopic cervicosacropexy|The first step consists of a supracervical hysterectomy with morcellation. Anterior and posterior dissection of the vesicovaginal and rectovaginal space. Placing a flexible blade or a Breisky blade in the vagina which is manipulated by the assistant in order to improve exposure of the tissue planes. The retroperitoneum will then be opened from sacral promontory to cervix with the incision just medial to the uterosacral ligament. A low-weight preshaped Y-shaped polypropylene mesh will be secured to the anterior and posterior vagina with four to six separated absorbable 2.0 polyglactin sutures and two nonabsorbable 2.0 prolene sutures can be placed at the level of the remaining cervix. The mesh will be attached to the sacral promontory using two or three nonabsorbable monofilament 2.0 prolene suture. The retroperitoneal space will be closed with continuous 2.0 polyglactin suture or barbed 2.0 absorbable suture material.
223947038|NCT00949117|DRUG|cyproheptadine hydrochloride|Given orally
223947039|NCT05867992|OTHER|Type of trauma|Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
223947040|NCT03926806|OTHER|Plain yoghurt|cups of 200 g yoghurt
223947041|NCT03926806|OTHER|Vitamin B yoghurt|cups of 200 g yoghurt
223947042|NCT04024982|OTHER|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
223947043|NCT04024982|OTHER|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
223536285|NCT05674227|PROCEDURE|Video-assisted thoracoscopy|Surgical treatment of operable lung cancers using a video-assisted thoracoscopy approach (VAT)
223536286|NCT05674227|PROCEDURE|Open surgery|Surgical treatment of operable lung cancers using open surgery
223536287|NCT01673776|DEVICE|PulsioFlex® Monitoring|"* goal directed therapy according to PulsioFlex® Monitoring- measurements~* femoral catheter~* extended perioperative monitoring~* nutritional supplementation, (if necessary)"
223536288|NCT01092884|DIETARY_SUPPLEMENT|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
223536289|NCT01092884|OTHER|Placebo|This placebo capsule will be taken orally three times daily
223720920|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Induction Phase|To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.
223947044|NCT02393976|DIETARY_SUPPLEMENT|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
223947045|NCT02393976|DIETARY_SUPPLEMENT|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
224100495|NCT07030114|DEVICE|mechanical ventilation (MV)|"Mechanical Ventilation Parameters~* \- Ventilation Mode: Ventilator settings will record modes such as volume-controlled ventilation or synchronized intermittent mandatory ventilation (SIMV), which deliver breaths based on patient needs.~* Tidal Volume: Measured in milliliters per kilogram of predicted body weight. Tidal volume settings aim to optimize oxygenation while minimizing lung injury risks by adhering to evidence-based limits (\<6 mL/kg).~* Positive End-Expiratory Pressure (PEEP): PEEP levels will be recorded in cmH₂O to prevent alveolar collapse and improve oxygenation. Adjustments will balance oxygenation benefits with potential risks like reduced venous return or lung overdistension.~* Fraction of Inspired Oxygen (FiO₂): FiO₂ values will be documented as decimals, starting at 1.0 (100% oxygen) and adjusted downward based on patient oxygenation needs."
224100496|NCT07030829|DEVICE|Laser Lithotripsy|Laser Lithotripsy
224100497|NCT07030829|DEVICE|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
224100498|NCT07031492|DEVICE|FLEX-AP system will be implemented to T1D patients|A FLEX-AP system will be implemented to T1D patients after they have been given a Minimed 780G hybrid closed-loop system
223536290|NCT05021939|OTHER|2-Dimensional Group|In the 2-Dimensional Group, 2D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device will be played in 2D for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
223536291|NCT05021939|OTHER|3-Dimensional Group|In the 3-Dimensional Group, 3D VR gaming training in addition to traditional vestibular rehabilitation will be employed. In this group, the 'Verti-Go' game from the Playstation 4 VR gaming device with 3D glasses will be played for 20-25 minutes, as well as vestibular therapy for 20-25 minutes. A total of 45-50 minutes will be given over the course of 8 weeks, 3 sessions per week. The intensity of treatment will rise with each session, depending on how well the patient cooperates. Evaluation will be done at the beginning and in the 8th week.
223536292|NCT01229683|PROCEDURE|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
223947046|NCT00749827|DRUG|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
223947047|NCT00749827|DRUG|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
223947048|NCT00006200|DRUG|thalidomide|
223947049|NCT00006200|DRUG|dacarbazine|
223947050|NCT02930265|DRUG|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
223947051|NCT04531007|DIAGNOSTIC_TEST|iFR/ FFR/ IVUS/ OCT|intermediate lesion evaluation with intracoronary physiology and imaging
223536293|NCT02136914|DRUG|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
223947052|NCT01246635|DEVICE|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
223947053|NCT01246635|PROCEDURE|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
224100499|NCT07030192|BEHAVIORAL|Peer support service|"Peers approach identified patients who could potentially benefit from peer support services. Peers offer a range of supports tailored to individual patients' needs, which include referrals to clinical and social support services (e.g., social work, addictions specialist, Indigenous patient navigator, community-based addictions resources), resources (e.g., blankets, food, naloxone kit, sterile drug use supplies, information brochures), providing emotional support, and liaising between patients and healthcare providers to communicate information about patients' condition and ED trajectory.~Peer support workers share their personal experiences to guide patients through their ED visit and to facilitate awareness and understanding of available resources."
224100500|NCT07031583|PROCEDURE|Delayed Umbilical Cord Clamping (DCC)|The umbilical cord was clamped between 60 and 180 seconds after birth or after the cessation of cord pulsation, in accordance with WHO recommendations. This procedure allows for additional placental transfusion and potential enhancement of neonatal antioxidant capacity.
223536294|NCT02136914|OTHER|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
223947054|NCT02980432|OTHER|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
223947055|NCT04711291|COMBINATION_PRODUCT|Conversion to Envarsus-XR and use of smart phone app, TransMedAx|"Convert to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours used in combination with the smart phone application, TransMedAx.~Patients in this arm will be trained to use the app along with conversion to Envarsus-XR. Once patient scan the code on medicine bottle and the app will remind them about the time and dose of the medication in their native language."
224100501|NCT07031583|PROCEDURE|Early Umbilical Cord Clamping (ECC)|The umbilical cord was clamped within the first 60 seconds after birth. This represents the standard or traditional approach used for comparison with delayed clamping in terms of oxidative stress outcomes.
224100502|NCT07031505|DEVICE|Active Photobiomodulation|Local photobiomodulation using a high-power superpulsed diode laser (GeminiEvo, Ultradent, USA) with dual infrared wavelengths (810 nm and 980 nm). Eight sessions will be conducted (twice a week for 4 weeks). Application will be at one point each on the masseter, temporal, trapezius, and temporomandibular joint regions. Each point will be irradiated for 13 seconds with 4 J of energy (10.52 J/cm²), in contact mode. The procedure includes safety measures such as protective eyewear and disinfection of the laser tip.
224100503|NCT07031505|DEVICE|Sham Photobiomodulation|The same application protocol as the experimental group will be followed, using the same laser device (GeminiEvo, Ultradent, USA), but with the laser emission deactivated. The guide light and sound will remain active to preserve participant blinding. Application points, duration, frequency, and session environment will be identical to the active group.
224100504|NCT07031960|DEVICE|3D Eyeball Movement Simulator Group|"A physical, interactive 3D-printed educational model that replicates human eyeball movements and demonstrates the biomechanical action of extraocular muscles. The simulator allows hands-on manipulation to demonstrate all cardinal eye movements (adduction, abduction, elevation, depression, intorsion, and extorsion) through mechanical actuation of synthetic muscle analogues."
224100505|NCT07031960|OTHER|Conventional Teaching Methods Group|Standard medical education methods for teaching eye anatomy and movements, including: (1) didactic classroom lectures with 2D illustrations, (2) static anatomical models of the orbit and eyeball, and (3) textbook-based learning materials. This represents the current conventional approach to teaching this content in medical curricula
224100506|NCT07031778|DRUG|Simvastatin|Simvastatin gel with 1.2% simvastatin
224100507|NCT07031778|DRUG|Simvastatin 10 mg|sponge of collagen impregned in saline solution with 10 mg of simvastatin
224100508|NCT07031778|DRUG|Simvastatin Placebo|Collagen sponge impregned in simvastatin placebo gel without simvastatin
224100509|NCT07030621|DRUG|Semaglutide 0.5 mg|Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) analog, which has been found to have neuroprotective effects.
224100510|NCT07030621|DRUG|Normal Saline|Normal saline is the placebo drug.
224100511|NCT07031115|DRUG|Linperlisib|Linperlisib 40 mg, orally, once daily. Following 2 weeks of treatment, efficacy was assessed. If the reticulocyte count remained \<20×10⁹/L, the dose was escalated to 60 mg, once daily. After an additional 2 weeks of therapy, a second efficacy assessment was performed. Patients failing to achieve partial response (PR) underwent further dose escalation to 80 mg, once daily. Treatment was discontinued if PR was not attained after 8 weeks at the maximum dose. Responding patients maintained therapy at their effective dose level. The core study period comprised 12 weeks, with responders continuing treatment at the investigator's discretion.
223536295|NCT02312648|OTHER|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
223536296|NCT02312648|OTHER|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
223536297|NCT04136145|DRUG|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
223536298|NCT04136145|DRUG|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
223536299|NCT00004466|DRUG|Atorvastatin|
223536300|NCT00004466|DRUG|Placebo|
223536301|NCT02915627|DEVICE|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
223536302|NCT01148667|DIETARY_SUPPLEMENT|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
223536303|NCT01148667|DIETARY_SUPPLEMENT|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
223947056|NCT04711291|DRUG|Convert to Envarsus XR once daily|Convert from tacrolimus immediate release to tacrolimus extended release (Envarsus XR) prescribed dose every 24 hours
223947057|NCT00799409|DRUG|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
223947058|NCT00799409|DRUG|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
223947059|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 1|Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
224100512|NCT07030400|DRUG|Bruton's tyrosine kinase inhibitor|BTKi
224100513|NCT07030400|DRUG|B-Cell Lymphoma 2 Protein Inhibitor|BCL2i
224100514|NCT07030374|OTHER|conscious connected breathing exercises|conscious connected mouth breathing session where the diaphragm is activated
224100515|NCT07031154|DRUG|Adebrelimab|Adebrelimab 1200mg, iv, D1，Q3W
224100516|NCT07031154|DRUG|Apatinib|Apatinib 250mg，P.O，qd，Q3W
223947060|NCT05488990|DRUG|AKVANO-Calcipotriol formulation 2|Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)
223947061|NCT05488990|DRUG|AKVANO vehicle formulation 1|Novel lipid based formulation (AKVANO) vehicle 1
223947062|NCT05488990|DRUG|AKVANO vehicle formulation 2|Novel lipid based formulation (AKVANO) vehicle 2
223947063|NCT05488990|DRUG|Daivonex solution|Daivonex solution containing Calcipotriol (50 μg/g)
223536304|NCT03249324|BEHAVIORAL|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
223536305|NCT03249324|OTHER|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
223536306|NCT00147992|PROCEDURE|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
223536307|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
223536308|NCT03838614|BEHAVIORAL|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
223536309|NCT03838614|BEHAVIORAL|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
223536310|NCT03838614|OTHER|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
223536311|NCT03492502|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
223536312|NCT02673983|PROCEDURE|Endoscopic full-thickness biopsy|
223536313|NCT03552107|DRUG|Lorcaserin|Treatment initiation with Lorcaserin
223536314|NCT06395116|OTHER|Denture base material|Denture base material constructed with different techniques for completely edentulous populations
223536315|NCT03497273|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
223536316|NCT03497273|DRUG|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
223536317|NCT04389697|DIETARY_SUPPLEMENT|Clear fluids and food up to up to 1 hour before the procedure|Clear fluids and food up to up to 1 hour before the start of the procedure
223536318|NCT02665325|DRUG|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
223536319|NCT01493089|DRUG|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
223947064|NCT05488990|DRUG|Daivonex cream|Daivonex cream containing Calcipotriol (50 μg/g)
223947065|NCT05825105|BIOLOGICAL|Platelet-Rich Plasma|The PRP will be prepared using a single centrifugation process. Approximately 30 ml of peripheral blood will be drawn and collected into a vacutainer tubes with sodium citrate anticoagulant 0.129 mol/l (3.8%). The tubes will then be centrifuged at 900 RPM for 12 minutes at room temperature in a benchtop centrifuge. We will separate the lower third of the plasma fraction from all tubes with a syringe and needle, taking care to avoid the leukocyte layer. The PRP will be refrigerated at 4°C for no less than 1 hour. We will not use any exogenous factors to stimulate the platelet activation process. The periauricular skin surface will be disinfected with a povidone iodine solution, and an intra-articular local anesthetic with 1% lidocaine will be applied. A 21-gauge needle will be placed at the point of application. Finally, PRP will be injected into the joint, and the needle will be removed.
223947066|NCT05979766|OTHER|Manual lymphatic drainage versus marian clark drainage|Manual lymphatic drainage versus marian clark drainage
223947067|NCT04427124|OTHER|Multidisciplinary Team Based Care Model|All prospective patients admitted into the study will receive care based on multidisciplinary team collaboration and an institutional protocol for critical limb ischemia.
223947068|NCT03072745|DIAGNOSTIC_TEST|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
223947069|NCT05861232|BEHAVIORAL|Behavioral|fear and anxiety during inhalation therapy
223947070|NCT06341309|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
223947071|NCT06341309|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
223947072|NCT02776124|DIETARY_SUPPLEMENT|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
223947073|NCT05233904|DIAGNOSTIC_TEST|Diagnostic-CT-enabled Planning|Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease
223947074|NCT05233904|DIAGNOSTIC_TEST|Standard of Care|Patients will be booked for CT simulation and treatment as per the local institution's standard practice
224100517|NCT07030634|OTHER|conventional physical therapy|"consist of Strengthening exercise: will begin with isometric exercises performed against an immovable object in four directions of ankle movement (dorsiflexion, planter flexion, inversion, and eversion) and will be progressed to dynamic resistive exercises (isotonic exercises) using ankle weights.~and Bracing: The participants will receive instructions from the therapist about using and applying the soft brace. The soft brace will be based on the principles of the functional tape bandage"
224100518|NCT07030634|OTHER|Low load blood flow restriction|Patients in blood flow restriction training groups will receive low load resistance exercise (20-40 % 1RM) using tourniquet around thigh proximally to knee joint to occlude arterial blood flow by 50-80 %.
223536320|NCT01493089|DRUG|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
223536321|NCT05276336|PROCEDURE|Radiofrequency turbinate reduction|Before the radiofrequency turbinate reduction procedure, local anaesthesia will be given by applying a cotton tamponade soaked in lidocaine adrenaline 1:5000 titration and added with xylocaine gel for 10 minutes in both nostrils. Then, a mixture of 1 mL of lidocaine 2% and 2 mL of sodium chloride 0,9% will be infiltrated to both nostrils using 3 mL and 1 mL needles until the inferior turbinates are pale. The radiofrequency probe (made by Sutter, both in monopolar and bipolar modes) will be inserted to the distal inferior turbinate until the black line from the probe is inside the inferior turbinate (approximately 10-12 mm). The procedure will be done for 10 seconds and the insertion of the probe can be done in 2-3 sites. After this, subjects from this group will be treated with pharmacology treatment using intranasal steroid and AH-1 according to ARIA WHO guideline 2008, similar to the pharmacology treatment received by the control group.
223536322|NCT05276336|DRUG|Pharmacology treatment|Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
223536323|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
223536324|NCT03951285|DIETARY_SUPPLEMENT|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
223536325|NCT03202394|DRUG|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
223536326|NCT03202394|DRUG|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
223536327|NCT03012334|DRUG|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
223536328|NCT03012334|DRUG|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
223536329|NCT03012334|OTHER|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
223536330|NCT00368524|BEHAVIORAL|contingency management and behavioral day treatment|
223536331|NCT02167789|DEVICE|Paradym CRT 8770|
223536332|NCT00325143|BIOLOGICAL|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
223536333|NCT00325143|BIOLOGICAL|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
223536334|NCT02791464|BEHAVIORAL|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
223536335|NCT01073293|BIOLOGICAL|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
223536336|NCT01073293|BIOLOGICAL|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
223536337|NCT01073293|BIOLOGICAL|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
223536338|NCT00639288|OTHER|modified CPT-C|modified CPT-C
223536339|NCT01926132|DRUG|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
223536340|NCT01926132|DRUG|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
223536341|NCT04435743|DRUG|Lenalidomide|"Lenalidomide is given as any following dosage:~1. 25mg, PO QD, Day 1-10 in every 21 days for 6 cycles;~2. 15mg, PO QD, Day 1-14 in every 21 days for 6 cycles;~3. 25mg, PO QD, Day 1-10 in every 21 days for 1 year;~4. 25mg, PO QD, Day 1-21 in every 28 days for 1 year;~5. 25mg, PO QD, Day 1-10 in every 28 days for 12 cycles;~6. 20mg, PO QD, Day 1-21 in every 28 days for 12 cycles."
223536342|NCT05317130|OTHER|Athlete health monitoring|Observational study
223947075|NCT03470597|OTHER|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
223947076|NCT03964974|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia in Cannabis Users (CBTi-CB)|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
224100519|NCT07030634|OTHER|proprioception training|Patients will receive proprioception exercises in duration of 30 minutes per session, frequencies will be 3 times per week, and lengths for 4 weeks (Matthew et al., 2017). Progression of the proprioceptive training should be static to dynamic (such as lateral movements, backward movements, jumping, cutting, twisting, pivoting), slow speeds to faster speeds with balance and control, two legs to one leg, and with visual control to no visual control.
224122640|NCT04000672|PROCEDURE|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
223536343|NCT02725333|PROCEDURE|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
223536344|NCT04224519|BIOLOGICAL|sIPV batch 1|Type I 30 DU, Type II 32 DU, Type III 45 DU
223536345|NCT04224519|BIOLOGICAL|sIPV batch 2|Type I 30 DU, Type II 32 DU, Type III 45 DU
223536346|NCT04224519|BIOLOGICAL|sIPV batch 3|Type I 30 DU, Type II 32 DU, Type III 45 DU
223536347|NCT00256126|DRUG|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
223536348|NCT00256126|DRUG|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
223536349|NCT03674983|BEHAVIORAL|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
223536350|NCT02141009|BIOLOGICAL|Prevnar 13|
223536351|NCT02250417|OTHER|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
223536352|NCT00899912|GENETIC|microarray analysis|
223536353|NCT00899912|OTHER|diagnostic laboratory biomarker analysis|
223536354|NCT05579652|DIAGNOSTIC_TEST|Abdominal tension measurement|A tensiometer scale will be used to measure the tension needed to pull each side of the abdominal wall to midline
223536355|NCT01711528|DRUG|Bortezomib|Given SC
223536356|NCT01711528|DRUG|Dexamethasone|Given PO
223536357|NCT01711528|DRUG|Dinaciclib|Given IV
223536358|NCT01711528|OTHER|Laboratory Biomarker Analysis|Correlative studies
223536359|NCT01752218|DEVICE|arcuate incision|
223536360|NCT02640300|DRUG|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
223536361|NCT00468091|DRUG|exendin(9-39)amide|
223536362|NCT00468091|DRUG|atropine|
223536363|NCT02320188|OTHER|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
223536364|NCT02320188|OTHER|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
223536365|NCT03838835|BEHAVIORAL|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
223536366|NCT03838835|BEHAVIORAL|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
223536367|NCT03838835|OTHER|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
223536368|NCT03423407|DEVICE|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
223536369|NCT00454116|DRUG|Vandetanib|once daily oral tablet two doses
224122641|NCT01987986|BIOLOGICAL|Collagenase Clostridium Histolyticum|injectible intervention
224122642|NCT01987986|BIOLOGICAL|Placebo|
224122643|NCT05646303|DRUG|Psilocybin|Psilocybin and psychotherapy
223536370|NCT00454116|DRUG|FOLFIRI|Intravenous infusion
223536371|NCT01021800|BIOLOGICAL|MIS|Cell infusion
224100520|NCT07031440|BEHAVIORAL|digital LWWCOPD|LWWCOPD (Living well with COPD) contains six modules conventionally delivered by trained LWWCOPD Coaches. For the digital delivery the six modules are as closely adapted to the conventional LWWCOPD program as possible to make the two approaches comparable. Participants can access the digital LWWCOPD application by a weblink using a smartphone, tablet or desktop computer. Since the program duration of the conventional LWWCOPD is 6 weeks (one module per week), patients will be instructed to complete the digital LWWCOPD also within 6 weeks at their own pace, although completion within 12 weeks (3 months) is still possible. Modules can be repeated as chosen by the user. In contrast to the conventional delivery, the online delivery of LWWCOPD does not preview face-to-face contact between participants and healthcare providers, however if needed additional phone calls or meetings are still possible.
224100521|NCT07030387|BEHAVIORAL|Smoking cessation counselling group|3A-OR very brief intervention for smoking cessation
224100522|NCT07030387|BEHAVIORAL|Control group patients were those who had not received the 3A-OR intervention|Control Group (Patients of the other family physicians in the same family health centers)
224100523|NCT07030582|BEHAVIORAL|Internet-delivered cognitive behavioral therapy|The intervention group received a comprehensive core muscle training protocol delivered through a digital rehabilitation platform from hospital admission to 6 months post-surgery. The protocol began with initial screening, including online assessments of cognitive misconceptions, kinesiophobia, and posture analysis. Pain-related cognitive restructuring was addressed through virtual reality sessions, educational videos, and mindfulness breathing guidance. Behavioral activation incorporated graded exposure therapy with EMG biofeedback, interactive knowledge quizzes, and peer modeling. Exercise skills were developed through personalized progressive training with real-time video guidance, and protocols were adjusted based on mid-term assessments. Behavioral reinforcement strategies included recovery support groups, compliance tracking, and integration of exercises into daily activities. A three-tier warning system (Red/Yellow/Green) was implemented to monitor safety and compliance, trigger
224100524|NCT07030582|BEHAVIORAL|Basic Postoperative Care|All participants were instructed to maintain their usual daily activities and abstain from additional treatments throughout the 6-month study period.
224100525|NCT07030582|BEHAVIORAL|Conventional Postoperative Care|The control group received conventional postoperative care, which included the establishment of a WeChat support group and provision of a rehabilitation manual focusing on core muscle training on the first postoperative day. Physical therapists provided individualized bedside instruction to ensure proper exercise techniques. Structured follow-up was conducted via telephone or social media (weekly during the first month, then monthly from months 2-6, with each session lasting at least 15 minutes) to provide psychological support and exercise guidance through relaxation techniques and individualized core muscle training progression.
224100526|NCT07032025|PROCEDURE|Innovative Device Group|Catheter-based thrombectomy is performed within 4 hours after baseline CTPA acquisition. Pre-procedural anticoagulation with either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) is administered prior to thrombectomy. Post-procedural oral anticoagulation is transitioned to rivaroxaban 20 mg once daily (QD).
223536372|NCT00516282|DRUG|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
223536373|NCT00516282|DRUG|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
223536374|NCT03085680|DRUG|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
223536375|NCT03085680|DRUG|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
223536376|NCT06005909|OTHER|Cawthorne-Cooksey Exercises|"A- Head and Eye Movements While Lying and Sitting:~1. While keeping your head still, look up and then down again.~2. Look from side to side while keeping your head still.~3. Extend your hand at arm's length, draw your fingers towards your nose while focusing your eyes on your fingers.~4. With eyes open, slowly turn your head from side to side.~5. Turn your head from side to side quickly.~6. With eyes open, slowly move your head up and down.~7. Move your head up and down quickly.~8. Repeat items 4,5,6 and 7 with your eyes closed.~B-Head and Body Movements While Sitting:~1. Place an object on the floor in front of your feet, reach out to pick it up, then upright return to your position. Looking down while picking up the item, then Remind you to look up when trying to fix it.~2. Lean forward and move the object forward and back under your knees. C- Standing Exercises~1-Get from a sitting position to a standing position and sit down again. 2-Repeat this with your eyes closed."
223536377|NCT06005909|OTHER|Mechanical Hippotherapy Exercises|"From the patient on the mechanical hippotherapy device;~* Maintaining trunk balance while raising both hands above head,~* Maintaining trunk balance while opening the arms next to the trunk,~* Maintaining trunk balance while extending the arms back and forth with successive movements,~* Maintaining trunk balance with hands clasped behind the waist,~* The arms are open to both sides, while transferring the weight ball from one hand to the other, it is requested to maintain the body balance."
223536378|NCT06108570|OTHER|Cosmetic Product TOPIALYSE Baume Protect+|One or two application.s of TOPIALYSE Baume Protect+ daily on one side for 28±3 days and the Neutral Product daily on the other side for 28±3 days. The side will be decided before by randomisation.
223536379|NCT03333603|DRUG|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
223536380|NCT02748681|DEVICE|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
223947077|NCT03964974|BEHAVIORAL|Sleep Hygiene Education (SHE)|The SHE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
223947078|NCT01702103|DRUG|Mometasone furoate|
223947079|NCT06236204|PROCEDURE|Arthroscopic Scapholunate Ligament Reconstruction|reconstruction of the SL ligament with palmaris tendon graft tunneled through the scaphoid and lunate as described by Corella et al.
223720921|NCT04532164|DRUG|Butenafine HCl 1% (BAY1896425) - Challenge Phase|5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
223720922|NCT04353076|OTHER|Simulated heatwave exposure|Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.
223720923|NCT04353076|OTHER|Simulated heatwave exposure with mid-day cooling|Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
223720924|NCT01541124|DRUG|Opioid|10 mg/pill, po, each 6h, during 6m
223947080|NCT01729793|DIETARY_SUPPLEMENT|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
223947081|NCT01729793|OTHER|Placebo|Capsule containing microcrystalline cellulose
223947082|NCT01698567|DRUG|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
223720925|NCT02515058|DEVICE|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
223720926|NCT02515058|DEVICE|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
223720927|NCT01975545|DRUG|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
223720928|NCT01975545|DRUG|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
223720929|NCT06146452|OTHER|Not|Not
224100527|NCT07032025|DRUG|Standard Pharmacological Therapy Group|Following thrombolytic agent administration, anticoagulation with rivaroxaban is initiated and maintained at 15 mg twice daily (BID) for the initial 3 weeks, then switched to 20 mg once daily (QD) thereafter.
224100528|NCT00002884|DRUG|chemotherapy|
224100529|NCT00002884|DRUG|cisplatin|
223720930|NCT05711940|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
223720931|NCT02743559|DEVICE|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
223720932|NCT00846430|DRUG|Peg-Interferon alpha-2b|age and weight dependant
223720933|NCT00846430|DRUG|Celecoxib (Celebrex)|age and weight dependant
223720934|NCT00846430|DRUG|Temozolomide (temodar)|age and weight dependant
223720935|NCT00846430|DRUG|Vincristine Sulfate (Oncovin)|age and weight dependant
223720936|NCT05571540|BIOLOGICAL|U-CAR-T Cells (LstCAR019)|"LstCAR019 will be administered by vein. The trial includes two portions. The first portion is a3+3dose escalation study, in which three dose groups are set:Dose level one: 1×10\^6 cells/kg;Dose level two: 2×10\^6 cells/kg;Dose level three: 5×10\^6 cells/kg. Each dose group requires at least three subjects. The trial will start from dose level one. The second portion includes a dosage extended cohort and will start after the finish of the3+3dose escalation study. Twelve subjects will get infusion of LstCAR019 at the best dose verified in the first portion."
223720937|NCT00661882|OTHER|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
223947083|NCT01698567|DRUG|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
223947084|NCT05148949|BIOLOGICAL|Standard dosage inactivated vaccine|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
223947085|NCT05148949|BIOLOGICAL|Double dosage inactivated vaccine|This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
223947086|NCT05942664|BEHAVIORAL|Sleep|Sleep will be restricted to 60% normal sleep duration
223947087|NCT00513123|PROCEDURE|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
223947088|NCT00511316|DRUG|Montelukast/ Singulair|20 mg daily for six months
223947089|NCT00511316|DRUG|Placebo|Placebo 20 mg daily for 6 months
224100530|NCT00002884|DRUG|fluorouracil|
224100531|NCT00002884|RADIATION|brachytherapy|
224100532|NCT00002884|RADIATION|radiation therapy|
223720938|NCT00661882|OTHER|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
223720939|NCT00661882|OTHER|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
223947090|NCT04917185|OTHER|Electro-Acupuncture|Acupuncture used for thousands years is part of traditional Chinese medicine. We use electro-acupuncture to treat our patients because it is more sufficient than traditional acupuncture and proved effectively treating protracted withdrawal syndrome of opioid use disorder. Paired alligator clips of the EA apparatus will be attached to the needle holders of Shenmen and Neiguan points on both sides. EA stimulation will last for 30 min with a continuous wave of 2/100Hz and intensity of 10-15 mA which patients can stand. All needles will be removed in 30 min and use a dry sterilised cotton ball to press the points in case of bleeding.
223720940|NCT00661882|PROCEDURE|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
224100533|NCT06843499|OTHER|The VeriSee AI-assisted diagnostic system|VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-based medical software devices designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, respectively. These systems utilize advanced AI algorithms to analyze color fundus photography images for disease assessment. By installing the software on a computer, the system can evaluate image quality, predict disease conditions, and instantly provide results to clinical physicians, serving as a diagnostic aid.
224100534|NCT06843499|OTHER|Data collection from the patient's clinical history|Data collection from the patient's clinical history was conducted because the VeriSee AI-assisted diagnostic system was not used.
223720941|NCT02113592|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
223720942|NCT00115050|DRUG|TMC114|
223720943|NCT05864001|BEHAVIORAL|STAR-C mobile app|Digital coaching intervention for healthy lifestyle
223720944|NCT05500586|DRUG|Glucagon response study|Please see information in group descriptions
223720945|NCT02689388|PROCEDURE|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
223720946|NCT04648956|OTHER|Standard treatment|Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
223720947|NCT05219084|DRUG|hip denervation|Lidocaine 2% 2ml was injected into each genicular nerve
223720948|NCT05219084|DRUG|intra-articular hydration|10 ml; of normal; saline were injected inside the hip joint
223720949|NCT05219084|DRUG|Combined group|hip denervation and intra-articular hydration were conducted together
223720950|NCT05219084|DRUG|Control group|Normal; saline was injected subcutaneously
223720951|NCT04752150|OTHER|Analgesia management; group ESPB and RIB|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
223720952|NCT02632955|DRUG|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
223947091|NCT01567852|DRUG|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
223947092|NCT01567852|DRUG|Methohexital|Methohexital (1.5mg/kg) will be given for induction
223947093|NCT00620230|DRUG|NVP-VAK694|
223947094|NCT00620230|DRUG|NVP-VAK694|
223947095|NCT03188978|DRUG|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
223947096|NCT03188978|OTHER|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
223947097|NCT04004520|BEHAVIORAL|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
223947098|NCT04004520|BEHAVIORAL|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
223947099|NCT04004520|BEHAVIORAL|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
224100535|NCT03232073|DRUG|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
224100536|NCT07075341|OTHER|None - Observational study|None - Observational study
224100537|NCT05225324|DRUG|Equfina 50 mg|Equfina 50 mg tablets.
224100538|NCT03856216|PROCEDURE|Allogeneic Bone Marrow Transplantation|Given IV
224100539|NCT03856216|DRUG|Bendamustine|Given IV
223720953|NCT02632955|PROCEDURE|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
223720954|NCT00144963|DRUG|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
223720955|NCT00144963|DRUG|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
223720956|NCT02615587|DRUG|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
223720957|NCT01892202|OTHER|Cohort|
223720958|NCT02198066|OTHER|Dry Sterile Dressing|Described in Arm Description.
223720959|NCT02198066|OTHER|Metallic Silver Dressing|Described in Arm Description.
223720960|NCT02198066|OTHER|Ionic Silver Dressing|Described in Arm Description.
223720961|NCT04390178|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
223720962|NCT06433869|DRUG|serplulimab|Additional intraperitoneal injection of bevacizumab or rmhTNF-NC is added to the PD-1 inhibitor.
223720963|NCT06433869|DRUG|Bevacizumab|Intraperitoneal injection of bevacizumab is added to PD-1 inhibitor or rmhTNF-NC.
223947100|NCT03306329|DRUG|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
223720964|NCT06433869|DRUG|rmhTNF-NC|Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
223720965|NCT06178939|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
223720966|NCT06178939|PROCEDURE|intervention group|For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
223720967|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
223720968|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
223947101|NCT03306329|DRUG|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
224100540|NCT03856216|BIOLOGICAL|Filgrastim-sndz|Given IV
224100541|NCT03856216|DRUG|Fludarabine|Given IV
224100542|NCT03856216|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223720969|NCT02438332|DEVICE|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
223947102|NCT03306329|DRUG|Placebo|Placebo tablets administered once daily
223947103|NCT02976363|RADIATION|Radiotherapy breast cancer|
223947104|NCT02976363|OTHER|Evaluation Maximal Respiratory Pressures|
224100543|NCT03856216|DRUG|Melphalan|Given IV
224100544|NCT03856216|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Given IV
224100545|NCT03856216|BIOLOGICAL|Rituximab|Given IV
223947105|NCT01505699|GENETIC|RNA analysis|
223947106|NCT01505699|GENETIC|cytogenetic analysis|
223947107|NCT01505699|GENETIC|microarray analysis|
223947108|NCT01505699|OTHER|laboratory biomarker analysis|
223720970|NCT02438332|DEVICE|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
223720971|NCT03651921|BEHAVIORAL|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
223720972|NCT04013334|DRUG|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
223720973|NCT04013334|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
223720974|NCT00679315|DRUG|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
223720975|NCT00679315|DRUG|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
223720976|NCT02468115|DRUG|VIS410|Single fixed IV dose of VIS410
223947109|NCT02211508|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
223947110|NCT05010499|DRUG|Levobupivacaine|femoral nerve block receives 20 ml of levobupivacaine 0.25%
223947111|NCT05010499|DRUG|Levobupivacaine|Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
224100546|NCT03856216|DRUG|Tacrolimus|Given IV and PO
224100547|NCT07108244|DIAGNOSTIC_TEST|[18F]FET PET-MRI|All participants will undergo both \[18F\]fluoroethyltyrosine positron emission tomography-magnetic resonance imaging (\[18F\]FET-PET-MRI) and inferior petrosal sinus sampling (IPSS) as part of the diagnostic work-up for ACTH-dependent hypercortisolism. The purpose is to compare the diagnostic accuracy of these two modalities in distinguishing Cushing's disease from ectopic ACTH secretion. The results from both diagnostic tests will be communicated to the treating medical team and the participant to guide further clinical management.
223720977|NCT02468115|DRUG|Placebo|Single IV dose of placebo
223720978|NCT00812864|DRUG|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
223720979|NCT02269241|DRUG|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
223947112|NCT00705172|DRUG|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
223947113|NCT04870905|DRUG|Tis-U-Sol|Tislelizumab 200mg will be given every 3 weeks for 12 cycles
223947114|NCT02125409|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
223947115|NCT02125409|PROCEDURE|Screening colonoscopy|
223947116|NCT05459974|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg once daily for 30 days after the atrial fibrillation ablation
223947117|NCT05459974|DRUG|Placebo|Placebo pill once daily for 30 days after the atrial fibrillation ablation
223947118|NCT03337022|DRUG|CC-90006|CC-90006
224100548|NCT07106281|DIETARY_SUPPLEMENT|Grape Seed Extract|600mg of Grape Seed Extract
224100549|NCT07106281|DIETARY_SUPPLEMENT|Placebo|Placebo
224100550|NCT07107828|OTHER|Ambient air|Standard ambient air will be breathed during endurance training.
224100551|NCT07107828|OTHER|Oxygen|SSOT will be applied during endurance training
223720980|NCT01487551|DRUG|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
224100552|NCT07107828|OTHER|Altitude|Training will be performed at moderate altitude
224100553|NCT07108075|DRUG|Carvedilol|Carvedilol 12. 5mg
224100554|NCT07108075|DRUG|Metformin|Metformin 1000 mg
224100555|NCT07105579|DRUG|BITE and DLI|"Blinatumomab dosage:~Cycle 1 (starting at day 60 post-transplant):Days 1-3: 9 μg/day，Days 4-14: 28 μg/day Cycles 2-4:Days 1-14: 28 μg/day Administration method: Continuous 24-hour intravenous infusion, one cycle every 3 months.~DLI eligibility criteria:No history of grade III-IV acute GVHD (aGVHD).No active aGVHD or chronic GVHD (cGVHD) at the time of infusion~DLI dosage:Administered at day 120 post-HSCT, CD3+ cell dose: 1 × 10⁷/kg"
224100556|NCT07106983|OTHER|No intervention (observational study)|Observational survey only
224100557|NCT05936359|DRUG|INCA033989|INCA033989 will be administered at protocol defined dose.
224100558|NCT05936359|DRUG|Ruxolitinib|Rux will be administered according to Prescribing Information/SmPC.
224100559|NCT07107074|DRUG|AD04|Each patient will receive 6 single s.c. injections of IMP at monthly intervals over a 5-month treatment period.
224100560|NCT07107074|DRUG|Placebo|Each patient will receive 6 single s.c. injections of Placebo at monthly intervals over a 5-month treatment period.
223536381|NCT03557866|DIAGNOSTIC_TEST|running|individuals will be asked to run for 5 km in self selected speed
223536382|NCT01760070|DEVICE|Hybrid knife|Use Hybrid knife in ESD procedure
223947119|NCT03337022|OTHER|Placebo|Placebo
223536383|NCT01760070|DEVICE|IT knife|Use IT knife in ESD procedure.
223536384|NCT04868344|DRUG|MRG003|Administered intravenously
223947120|NCT02734784|PROCEDURE|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
223947121|NCT02734784|PROCEDURE|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
223947122|NCT00670449|DRUG|Fingolimod|Fingolimod was supplied in capsules.
223947123|NCT01452867|DEVICE|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
223720981|NCT03604380|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
223720982|NCT03604380|OTHER|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
223947124|NCT01452867|DEVICE|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
223536385|NCT03410069|DEVICE|IKORUS UP system|Continuous assessment of the urethral microcirculation
223536386|NCT01008618|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
223536387|NCT01008618|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
223720983|NCT02270957|BIOLOGICAL|Abatacept|
223720984|NCT02270957|OTHER|Placebo|
223720985|NCT04305262|DEVICE|Wireless continuous vital parameter monitoring|The patients included in this study will have continuous, wireless monitoring of vital parameters during the first four days of acute admission
223720986|NCT05033353|DIAGNOSTIC_TEST|Monitoring of regional cerebral oxygenation|Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
223947125|NCT01452867|DEVICE|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
223947126|NCT03030651|BEHAVIORAL|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
223947127|NCT04728191|OTHER|Physiotherapy|physiotherapeutical instructions and training as described.
223947128|NCT04728191|OTHER|standard care|Standard care as described.
223947129|NCT00709605|DRUG|VRC-HIVADV014-00-VP|
223947130|NCT04809623|DRUG|Edecesertib|Tablets administered orally
223947131|NCT04809623|DRUG|Placebo|Placebo to match edecesertib tablets administered orally
224100561|NCT07107282|DEVICE|MyHip Verifier|Numerical information on the position of the implant is provided to the surgeon.
224100562|NCT07107542|OTHER|Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities (EPAs) Assessment|Participants undergo standard fieldwork assessments using Mini-CEX and EPAs during their internship to evaluate fieldwork competence and readiness for independent practice. These are observational assessments without additional experimental interventions.
224100563|NCT07107087|OTHER|Multi-Modal Integrated Intervention Combining Exercise, Anti-inflammatory & Dietary Advice (MMIEAD)|In addition to their standard care, the intervention group will receive MMIEAD - an individualised exercise programme, oral omega-3 supplementation and dietary advice.
224100564|NCT07106359|BEHAVIORAL|booklet|a clinical letter with a booklet for at-risk families highlighting implications of family history, testing motivators, steps for genetic testing, and potential costs.
224122644|NCT05646303|DRUG|Placebo|Placebo and psychotherapy
223947132|NCT04809623|DRUG|Standard of Care|Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)
224100565|NCT07106359|BEHAVIORAL|control clinical letter|a clinical letter with basic information about LS and implications of counseling and testing of LS, and a few websites for more information and locating genetic counselors.
224100566|NCT07106892|DRUG|HLX43 Dose 1;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 1 is 2.0mg/kg
224100567|NCT07106892|DRUG|HLX43 Dose 2;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 2 is 2.5mg/kg
224100568|NCT07106892|DRUG|HLX43 Dose 3;|HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8. DOSE 2 is 3.0mg/kg
224100569|NCT07107854|OTHER|cosmetic: EFFACLAR ULTRA CONCENTRATED SERUM|Transparent solution (gel)
224100570|NCT07106944|OTHER|Community pregnant women: rectal and throat swab|Community pregnant women: rectal and throat swab
224100571|NCT07105566|DIAGNOSTIC_TEST|serum TPI|serum TPI level
224100572|NCT07106099|BEHAVIORAL|Training given with the tell-what-you-learned method|Students in the intervention group will be given training on diagnosing the symptoms and risks of child abuse and neglect, given by the tell-what-you-learned method, and will be given a practice in which its effectiveness will be evaluated.
224100573|NCT07107126|DRUG|RPT1G|RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.
224100574|NCT07106866|PROCEDURE|sacrospinous ligament fixation|A longitudinal incision was made at the midline of the posterior vaginal wall, extending approximately 2-3 cm from the perineal body to the vaginal apex to form a tunnel. The incised vaginal epithelium was dissected from the underlying muscularis layer. Dissection was continued to the level of the ischial spine. The rectum was medialized to access the perirectal space. Upon palpating the ischial spine, the sacrospinous ligament was identified medial to it. Long retractors were placed over the ischial spine to protect the pudendal neurovascular structures. The bladder was retracted superiorly, and the rectum medially, for optimal visualization. Two separate or a loop 1-0 polypropylene suture(s) were placed approximately 1.5 fingerbreadths medial to the ischial spine on the ligament using a needle holder. These sutures were passed through the posterior vaginal tunnel to the apex and tied to secure the vaginal apex to the ligament
224100575|NCT07105839|DRUG|Intraoperative rescue analgesia|If signs of inadequate analgesia occur (e.g., \>20% increase in heart rate or blood pressure), IV remifentanil infusion rate will be titrated upward within the safety margin.
224100576|NCT07105839|DRUG|Intraoperative rescue analgesia:|If signs of inadequate analgesia occur (e.g., \>20% increase in heart rate or blood pressure), IV dexmedetomidine infusion rate will be titrated upward (up to maximum safe dose).
224100577|NCT07107958|PROCEDURE|Electroacupuncture|Electroacupuncture is applied using standardized stroke rehabilitation protocols. Needles are inserted at acupoints including LI15 (Jianyu), LI11 (Quchi), TE5 (Waiguan), LI4 (Hegu), GB30 (Huantiao), ST36 (Zusanli), and GB34 (Yanglingquan), and connected to an electroacupuncture device delivering alternating current stimulation at 10-20 Hz. Each session lasts 15-20 minutes, performed once daily, 5 days per week, for 4 weeks. The intervention follows Vietnam's national traditional medicine guidelines for post-stroke recovery.
224100578|NCT07106320|DEVICE|VDW Ultra Ultrasonic Irrigation Activation|Irrigation will be activated using an ultrasonic tip (IRRI S 21/25) connected to the VDW Ultra device (VDW GmbH, Munich, Germany), 2 mm short of working length. NaOCl and EDTA will each be activated for 20 seconds, repeated three times.
223947133|NCT00201045|OTHER|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
223947134|NCT00237926|BEHAVIORAL|Exercise|aerobic or resistance training
223947135|NCT05770115|PROCEDURE|Vicryl 1|Double layer closure with split thickness with vicryl 1, in continuous, non-locked, 1 cm apart sutures.
223947136|NCT05770115|PROCEDURE|Vicryl 2/0|Double layer closure with split thickness with vicryl 2/0, in continuous, non-locked, 1 cm apart sutures.
223947137|NCT05559697|DEVICE|Sponsor incisional negative pressure wound therapy device and dressing|A sponsor incisional dressing placed on the knee and connected to a sponsor disposable negative pressure therapy device
223947138|NCT05559697|DEVICE|Standard of Care incisional negative pressure wound therapy system|The control incisional negative pressure wound therapy system represents the standard of care system and market leader. It consists of a disposable negative pressure therapy device and incisional dressing.
223947139|NCT04518397|BEHAVIORAL|Theatre|6-week participatory arts culturally-informed theatre program
223947140|NCT02144883|BEHAVIORAL|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
223947141|NCT02144883|BEHAVIORAL|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
224100579|NCT07106320|DEVICE|EDDY Sonic Irrigation Activation|Irrigation solution will be activated using the EDDY sonic tip (VDW GmbH, Munich, Germany), positioned 2 mm short of the working length. NaOCl and EDTA will each be activated for 20 seconds, repeated three times.
223720987|NCT01880398|OTHER|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
224100580|NCT07106320|PROCEDURE|Conventional Needle Irrigation|Irrigation will be performed using a syringe and needle without activation. A total of 6 ml NaOCl, 2 ml EDTA and 5 mL of sterile saline will be used during final irrigation.
224100581|NCT07107191|OTHER|Assessment|Data will be collected from all participants in assessmnet group.
224100582|NCT07106021|BIOLOGICAL|RNDP-001|Stem cells
224100583|NCT07106021|DEVICE|Syringe Front-Loading Device|Delivers the stem cells
224100584|NCT07106957|OTHER|CICAPLAST BAUME B5+|Twice a day (morning and evening) on face
224100585|NCT07106957|OTHER|Standard cream|Twice a day (morning and evening) on face
223720988|NCT00859404|DRUG|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
224100586|NCT07107919|OTHER|18F PET/MR|"Tracer: \^18F FAPI 04 is used in this study. A single intravenous bolus dose of 3.70-4.44 MBq/kg is administered.~• Simultaneous PET/MR Acquisition: During PET imaging, cardiac MR (CMR) is performed in the supine position. All images are acquired with ECG gating and respiratory gating, during end expiratory breath holds.~1. Cardiac Morphology and Function (Localization \& Cine):Assess cardiac structure and global/regional function~2. T2 Weighted Fat Suppressed Imaging:Evaluate myocardial edema~3. First Pass Perfusion Imaging:Quantitatively assess the extent and severity of myocardial perfusion defects~4. Late Gadolinium Enhancement (LGE): Detect and quantify myocardial necrosis and fibrosis~5. T1 Mapping (Pre and Post Contrast): Quantify myocardial interstitial fibrosis~6. T2 Mapping (Pre Contrast):Quantify myocardial edema~7. Cardiac PET Imaging:Evaluate myocardial fibrosis characteristics using \^18F FAPI PET data"
224100587|NCT07105930|DEVICE|Debulging approach using the orbital atherectomy system|A uniform approach using only the orbital atherectomy system (Diamondback 360®), which sands away the calcium with a rotating crown
224100588|NCT07105930|PROCEDURE|Debulging using rotational atherectomy, scoring or cutting balloons, or shockwave therapy|A tailored approach, where the operator chooses from various available methods based on the patient's specific type of calcium
223947142|NCT00778609|DRUG|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
223947143|NCT00778609|DRUG|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
223947144|NCT02660086|BEHAVIORAL|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
223947145|NCT03266432|OTHER|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
224100589|NCT07105475|DEVICE|Paired Associative Transcranial Magnetic Stimulation (TMS)|"Transcranial Magnetic Stimulation (TMS) is a non-invasive technique that uses magnetic fields to stimulate nerve cells in the brain. By placing a coil on the scalp, TMS generates magnetic pulses that induce electrical currents in specific brain regions. This can alter brain activity and potentially influence behavior and symptoms of various neurological and psychiatric conditions.~PAS involves the use of transcranial magnetic stimulation (TMS) at a low and high frequency to stimulate the prefrontal cortex at different areas of the brain. The goal is to assess its effects on cortical arousal and ADHD symptoms. Participants will receive daily sessions of this stimulation for three weeks, with the stimulation designed to influence brain activity and potentially alleviate symptoms of ADHD."
224122645|NCT02930655|DRUG|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
223720989|NCT05325554|BEHAVIORAL|Multimodal rehabilitation|Multimodal rehabilitation
223947146|NCT00407732|BEHAVIORAL|psychosocial intervention|motivational enhancing case management intervention
223947147|NCT00644501|DRUG|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
223947148|NCT01653509|DEVICE|Acyclovir patch|Patch containing acyclovir
223947149|NCT01653509|DEVICE|Placebo patch|Patch without acyclovir
223947150|NCT00785798|DRUG|Vorinostat|200mg to 400 mg twice daily on days 1-7
223947151|NCT00785798|DRUG|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
223720990|NCT04246008|OTHER|Neuromuscular training|The exercise training was developed based on assuring the correct performance of the exercise focusing in motor control.
223720991|NCT04246008|OTHER|Conventional strength training|The exercise training was developed based on standard strength training used in cardiac rehabiliation programmes
223720992|NCT02931487|BEHAVIORAL|Attentional Bias Modification|Computerized
223947152|NCT04809701|PROCEDURE|Temporary implantation of defibrillation coils and pulse generator|Each subject will undergo temporary implantation of defibrillation coils and pulse generator according to the NV-ICD electrode configurations.
223720993|NCT02931487|BEHAVIORAL|Sham Comparator|Computerized
223720994|NCT02031107|DEVICE|cTBS|
223720995|NCT02031107|DEVICE|cathodal tDCS|
223720996|NCT02031107|DEVICE|sham stimulation|
223720997|NCT00637481|DRUG|atorvastatin calcium|Given orally
223720998|NCT00637481|OTHER|laboratory biomarker analysis|Correlative studies
223720999|NCT04380168|PROCEDURE|Modified pec11 trunk block|Ultrasound guided modified pec 11 block injecting local anesthetic with or without adjuvant between pectoralis minor and serratus anterior muscles
223721000|NCT04077983|DRUG|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses."
223947153|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration A first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration A. Then up to two defibrillation energies will be tested for Configuration B.
223721001|NCT02093832|OTHER|There are no specific Intervention|are no specific Intervention
223947154|NCT04809701|PROCEDURE|Defibrillation following induction of VA (Configuration B first)|Ventricular arrhythmia (VA) will be induced via an EP catheter placed in the right ventricle. After VA is confirmed, a defibrillation shock will be attempted to terminate the arrhythmia. Up to two defibrillation energies will be tested for Configuration B. Then up to two defibrillation energies will be tested for Configuration A.
223721002|NCT02335294|DRUG|TRV130|Rescue: Ibuprofen, oxycodone
223721003|NCT02335294|DRUG|Morphine|Rescue: Ibuprofen, oxycodone
223947155|NCT04809701|PROCEDURE|Removal of defibrillation coils and pulse generator|Defibrillation coils and pulse generator will be removed from the subject after the defibrillation tests are completed.
223947156|NCT01256242|DEVICE|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
223947157|NCT01256242|PROCEDURE|Standard Suture Repair|standard suture repair
223947158|NCT01648049|BEHAVIORAL|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein \& Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, \& Dick, 1995).
223721004|NCT02335294|DRUG|Placebo|Rescue: Ibuprofen, oxycodone
223721005|NCT01218204|DRUG|10mg atorvastatin|10mg
223721006|NCT01218204|DRUG|80mg atorvastatin|80mg
223721007|NCT01218204|DRUG|GSK1292263 Placebo|Placebo
223721008|NCT01218204|DRUG|100mg GSK1292263|100mg
223947159|NCT01648049|BEHAVIORAL|Treatment as usual|Standard Care - Treatment as usual
223721009|NCT01218204|DRUG|300mg GSK1292263|300mg
223721010|NCT01218204|DRUG|800mg GSK1292263|800mg
223721011|NCT01218204|DRUG|10mg ezetimibe|10mg
223721012|NCT01218204|OTHER|Washout|No interventions - washout period
223721013|NCT00545168|DRUG|Spinosad|10 minute topical application of product, followed by a complete rinse off.
223721014|NCT00545168|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
223721015|NCT00545168|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
223721016|NCT05615272|BIOLOGICAL|Bio-PRF|Intervention group
223721017|NCT05615272|DRUG|Alveogyl|Control group
223721018|NCT03516994|BEHAVIORAL|Respecting Choices First Steps|Advance Care Planning Approach
223721019|NCT03516994|BEHAVIORAL|Five Wishes Form|Advance Care Planning Approach
223721020|NCT02302001|DEVICE|Silicone Implant|
223721021|NCT06436482|DEVICE|Optical Coherence Tomography|Placing the probe of OCT in RB10c through the working channel of bronchoscope for real time dynamic scanning and collecting OCT parameters from participants in different groups.
223721022|NCT02216188|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
223721023|NCT02216188|OTHER|Control|Untreated control group
223721024|NCT04554667|BEHAVIORAL|Exercise Intervention|Heavy Lifting Strength Training
223721025|NCT03251768|DRUG|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
223721026|NCT03251768|DRUG|GCSF|GCSF 5 mcg/kg/day
223721027|NCT01221571|DRUG|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
223721028|NCT02685085|DRUG|Misoprostol ( Prostaglandin E2)|
223947160|NCT04089930|DIAGNOSTIC_TEST|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
223947161|NCT00667017|BIOLOGICAL|RFT5-dgA immunotoxin|
223947162|NCT00667017|OTHER|fluorescence activated cell sorting|
223947163|NCT00667017|OTHER|immunohistochemistry staining method|
223947164|NCT05168345|OTHER|Course and web information|"The interventional phase of the study will be conducted on IBD patients only. Patients will undergo two interventional periods which will include:~1. Self-selected information from the internet - patients will be asked to independently search the web for information regarding the categories of information which are discussed in the online course.~2. An online, interactive IBD course. Lectures will be passed by the multidisciplinary team of the IBD Center which includes IBD gastroenterologists, an IBD nurse, an IBD dietitian, and a social worker."
223721029|NCT02685085|DEVICE|Foley's catheter|
223721030|NCT00775424|BIOLOGICAL|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
223721031|NCT00775424|BIOLOGICAL|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
223721032|NCT00775424|BIOLOGICAL|PLACEBO|PLACEBO
223721033|NCT00775424|BIOLOGICAL|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
223721034|NCT01919125|DRUG|IDX719|IDX719 supplied as 50 mg tablets.
223721035|NCT02427893|DRUG|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
223947165|NCT04617145|OTHER|Aerobic exercise|resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.
223947166|NCT04122820|DIAGNOSTIC_TEST|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
223721036|NCT02427893|DRUG|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
223721037|NCT01987505|DRUG|Rituximab|1400 mg will be injected subcutaneously (SC).
223721038|NCT03763214|DEVICE|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
223947167|NCT02876653|OTHER|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
223947168|NCT03937089|OTHER|Data collection|Data collection from medical file
223947169|NCT00721097|OTHER|spirometry, and blood taken|each month during one year
223721039|NCT00035334|DRUG|NC-503 (Anti-amyloidotic (AA) Agent)|
223721040|NCT04829396|OTHER|placebo|Powder consisting of 13 g of digestible carbohydrates with similar appearance as the investigational fibre mixture.
223721041|NCT04829396|DIETARY_SUPPLEMENT|Fibre mixture|The study product is a fibre mixture consisting of a mix of 10 g of Acacia Gum and 3 g of carrot fibre taken p.o. o.d. in powder form for a total of approximately 10 g of dietary fibre per day.
223721042|NCT04224649|DEVICE|HARA Filler(Hyaluronic acid Filler)|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
223721043|NCT04224649|DEVICE|Restylane® Lidocaine|The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
223721044|NCT05506891|BEHAVIORAL|Physical therapy group|Limit water and sodium intake. Raise the head of the bed. Standardized amount of exercise. Low temperature diet and small meals. Avoid alcohol, coffee and dehydration. The treatment lasted for 3 months.
223721045|NCT05506891|DRUG|Astragalus|After a 2-week washout period, astragalus granules 15g, drunk with warm water, once a day, will be taken for 3 months.
223947170|NCT03723902|OTHER|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
223947171|NCT03723902|DIETARY_SUPPLEMENT|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
223947172|NCT06173622|BEHAVIORAL|Fetal Positioning|In the study, venipuncture was applied to the intervention and control groups. While the procedure was performed by an experienced neonatal nurse, the neonates' pain score, crying duration and physiological parameters were monitored by another researcher (observer).
223947173|NCT05390515|DRUG|Tildrakizumab Prefilled Syringe|IL-23 inhibitor
223721046|NCT04617002|DRUG|ONC201 (dordaviprone)|ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.
223721047|NCT04930016|BEHAVIORAL|Quality of life diagnosis and therapy during the completed RCT DIQOL|Quality of life measurement, diagnosis, and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
223721048|NCT02098759|DEVICE|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
223721049|NCT00489541|DEVICE|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
223947174|NCT04012359|DIAGNOSTIC_TEST|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
223721050|NCT05131646|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101
223721051|NCT01186354|BEHAVIORAL|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
223947175|NCT04012359|DIAGNOSTIC_TEST|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
223947176|NCT04012359|DIAGNOSTIC_TEST|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
223721052|NCT03132207|OTHER|Non interventionel study|Only one questionnaire will be done for women and professional
223721053|NCT06299826|DRUG|AZD5462|Participants will receive low, medium \& high doses of film-coated tablets of AZD5462 OD orally.
223721054|NCT06299826|DRUG|Placebo|Participants will receive matching doses of film-coated tablets of Placebo OD orally.
223721055|NCT02823301|BEHAVIORAL|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
223947177|NCT04012359|OTHER|Clinical examination|Standard clinical examination performed by investigating physician
223721056|NCT01176084|BEHAVIORAL|low carbohydrate diet|
223947178|NCT01711294|DEVICE|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
224100590|NCT04292717|BEHAVIORAL|Gait training|All participants will receive training three times a week for 6 weeks (18 training sessions) at the University Hospital Balgrist, Spinal Cord Injury Centre. Each exercise session will last for 1 hour and will be conducted and supervised by an experienced physical therapist.
223721057|NCT01176084|BEHAVIORAL|low carbohydrate diet and exercise|
223721058|NCT03266107|DEVICE|Intracept|Radiofrequency ablation of the basivertebral nerve using the Intracept System
223721059|NCT01503151|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
223721060|NCT01503151|BEHAVIORAL|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
223721061|NCT01503151|BEHAVIORAL|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
223721062|NCT01503151|BEHAVIORAL|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
223721063|NCT01898611|DRUG|Ghrelin|Ghrelin
223721064|NCT01898611|DRUG|Placebo|Saline will be used as a placebo
223947179|NCT01711294|DEVICE|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
223947180|NCT01711294|DEVICE|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
223947181|NCT02605174|DRUG|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
223947182|NCT02605174|DRUG|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
223947183|NCT02605174|DRUG|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
223947184|NCT02605174|DRUG|Placebo|Two placebo tablets to match lasmiditan doses.
223947185|NCT06195449|OTHER|ALKASITE RESTORATIVE MATERIAL|Restorative material for primary teeth
223947186|NCT06195449|OTHER|Glass Ionomer Cement|Restorative material for primary teeth
223947187|NCT01010945|DRUG|erlotinib|administered orally
223947188|NCT01010945|DRUG|gemcitabine|administered intravenously
223947189|NCT01010945|DRUG|nab-paclitaxel|administered intravenously
223947190|NCT01730456|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
223947191|NCT00005962|BIOLOGICAL|sargramostim|
223947192|NCT00005962|DRUG|cyclophosphamide|
223947193|NCT00005962|DRUG|cytarabine|
223947194|NCT00005962|DRUG|gemtuzumab ozogamicin|
223947195|NCT00005962|DRUG|liposomal daunorubicin citrate|
223947196|NCT00005962|DRUG|topotecan hydrochloride|
223947197|NCT03041090|DEVICE|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
223947198|NCT01779050|DRUG|Doxorubicin|
223947199|NCT01779050|BIOLOGICAL|Trastuzumab|
223947200|NCT01779050|DRUG|Cyclophosphamide|
223947201|NCT01779050|DRUG|Paclitaxel|
223947202|NCT01779050|DRUG|Epirubicin|
223947203|NCT01779050|DRUG|Docetaxel|
224100591|NCT06936605|DRUG|RGD Peptide|RGD peptide is an integrin binding site
224100592|NCT06936150|OTHER|Electrocardiography|Electrocardiography (ECG) is a non-invasive test used to measure the electrical activity of the heart. It involves placing electrodes on all four extremities and the chest area of the person and measuring the derivation between these electrodes. This procedure is painless and does not contain any elements that will disrupt the integrity of the body.
224100593|NCT06936423|PROCEDURE|Open herniotomy|Open inguinal herniotomy through inguinal incision then dissection and separation/ligation of the hernial sac
223721065|NCT06089291|DEVICE|Persona IQ|"Persona IQ is a system comprised of the following subsystems:~1. RTM utilizing mymobility® patient application and care team dashboard,~2. PPK System with~3. CTE Extension Implant and Instrumentation,~   1. Surgical Base Station System,~  2. Home Base Station System,~  3. Canary CDMP,~  4. Canary CMGP software module, and~4. The ZBEdgeTM Connected Artificial Intelligence data platform.~The system combines physical components, electronics, software, and user interfaces to collect, store, analyze, transmit, and display patient data for use by both physicians and patients."
223947204|NCT01779050|DRUG|Carboplatin|
223947205|NCT01779050|DRUG|Fluorouracil|
223721066|NCT01708733|DRUG|KSY|Chinese herbal formula
223721067|NCT03784729|OTHER|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
223721068|NCT03784729|OTHER|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
223721069|NCT01191801|DRUG|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
223721070|NCT01191801|DRUG|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
223721071|NCT02506140|DRUG|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
223721072|NCT02506140|DRUG|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
223721073|NCT00740805|DRUG|Cyclophosphamide|Given IV
223947206|NCT01782105|BEHAVIORAL|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
223947207|NCT01782105|BEHAVIORAL|Control group|Evaluation of nutritional and physcial activity habits
223721074|NCT00740805|DRUG|Doxorubicin Hydrochloride|Given IV
224100594|NCT06936423|PROCEDURE|Needlescopic percutaneous Internal ring suturing|Laparoscopic extracorporeal percutaneous Internal ring suturing using epidural needle and prolene/ethibond suture
224100595|NCT06955975|DIETARY_SUPPLEMENT|Pectin|10g of pectin with 10g of whey protein and 10g of cocoa powder added as flavour were randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.
224100596|NCT06955975|OTHER|Whey protein|10g of whey protein with 10g of cocoa powder added as flavour served as the control/ placebo to compare the effects observed with pectin.
223721075|NCT00740805|OTHER|Laboratory Biomarker Analysis|Correlative studies
223947208|NCT00864006|DRUG|Divalproex Sodium|
223947209|NCT00864006|DRUG|Depakote DR Tablets|
223947210|NCT01087437|DIETARY_SUPPLEMENT|gastrolith calcium|
223947211|NCT03585400|OTHER|Observational Study|Observational Study: Not Applicable for Observational Studies
223947212|NCT02202317|DEVICE|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
223947213|NCT00977249|BEHAVIORAL|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
223947214|NCT00977249|DRUG|varenicline|
223947215|NCT00977249|DRUG|placebo|
223947216|NCT02718196|BEHAVIORAL|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
223947217|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
223947218|NCT00859300|GENETIC|Blood sample|Blood sample Determination of genetic background
223947219|NCT01353274|DRUG|Micamlo|Telmisartan plus Amlodipine T40/A5
223947220|NCT04185818|OTHER|Reading a book|"Participants requested to specify usual genre of book they read.~1. Fiction~2. Non-Fiction~3. Other~4. Don't usually read a book in bed"
223947221|NCT05374694|DIAGNOSTIC_TEST|Physiological invasive coronary evaluation|Performance of FFR, IMR and acetylcholine test (Only patients in groups 3 and 4 will undergo the acetylcholine test)
223947222|NCT04514562|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
223947223|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
223947224|NCT04235205|DRUG|Elobixibat 10mg + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
223947225|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
223947226|NCT04235205|DRUG|Elobixibat placebo + cholestyramine powder placebo|Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
223721076|NCT00740805|OTHER|Pharmacological Study|Correlative studies
223721077|NCT00740805|DRUG|Veliparib|Given PO
223947227|NCT05820763|DRUG|Selinexor|Selinexor is administered by mouth on Days 1, 8, 15, and 22 at a dose of 60 mg during the four cycles of consolidation. Selinexor is then decreased to 40 mg and administered by mouth on Days 1, 8, 15, and 22 for up to 8 cycles of maintenance therapy.
223947228|NCT05820763|DRUG|Lenalidomide|"Lenalidomide is administered by mouth daily on Days 1 to 21 at a dose of 10 mg during the first three cycles of consolidation, and then titrated up to 15 mg on Days 1 to 21 for the fourth cycle of consolidation. Lenalidomide 15 mg by mouth daily on Days 1 to 21 can be continued for up to 8 cycles of maintenance therapy.~For patients with baseline renal dysfunction, the starting dose of lenalidomide will be 2.5 mg or 5 mg by mouth daily on Days 1 to 21. Patients may titrate up per physician discretion."
223947229|NCT05820763|DRUG|Dexamethasone|Dexamethasone is administered by mouth on Days 1, 8, 15, and 22 at a dose of 20 mg during all four cycles of consolidation only.
223947230|NCT05868304|DEVICE|BFR|Exercises may involve warm up on a stationary bike for 5 minutes, application of a BFR cuff (a cuff that often uses air to inflate around a limb) on the selected extremity, and exercise sets (e.g. banded squats, step ups, Romanian dead lifts). We will record metrics on an iPad. Testing will be done with ForceDecks and ForceFrames (system for measuring muscle strength and imbalance).
223947231|NCT05868304|OTHER|Stanard strengthening program.|"The exercise program will be completed 3 times per week Participants will warm up on a stationary bike for 5 minutes~The program will consist of the following exercises using a 30,15,15,15 rep scheme:~Banded squats Step ups (8 inch) Romanian dead lifts (RDL)"
223947232|NCT00386685|DRUG|larotaxel (XRP9881)|intravenous administration
223947233|NCT00386685|DRUG|trastuzumab|intravenous administration
223947234|NCT01603108|DRUG|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
223947235|NCT01603108|DRUG|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
223947236|NCT00764166|DRUG|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~* To D1 of every cycle in the dose of 70 mg/m²,~* Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
223947237|NCT00764166|DRUG|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
223947238|NCT04886466|PROCEDURE|core stability in a sitting position and while walking in one place|The intervention consisted of checking how the active tension of the multisection and transverse abdominal muscles affects the pattern of the trunk movement (in the sitting position) and the work of the lower limbs and the speed of movement while walking in a place.
223947239|NCT05075499|BIOLOGICAL|COVID-19 vaccination|Blood sample obtained before, 1 , 3 and 6 months after the intervention
223721078|NCT03348956|DIAGNOSTIC_TEST|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
223721079|NCT03731780|OTHER|Personalized Treatment|Targeting individual caries risk factors
223721080|NCT03731780|OTHER|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
223721081|NCT03731780|OTHER|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
223721082|NCT00934973|DRUG|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
223947240|NCT06031818|OTHER|The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework.
223947241|NCT06031818|OTHER|The model prediction|The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction.
223947242|NCT06031818|OTHER|The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation|The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction.
223947243|NCT01580436|PROCEDURE|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
223947244|NCT02431767|BIOLOGICAL|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
223947245|NCT02431767|BIOLOGICAL|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
223947246|NCT02431767|BIOLOGICAL|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
223947247|NCT00944541|DRUG|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
223947248|NCT05501652|DEVICE|ALV1System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
223721083|NCT00934973|DRUG|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
223721084|NCT00934973|DRUG|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
223721085|NCT00934973|BEHAVIORAL|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
223721086|NCT00934973|BEHAVIORAL|No website|No CBT website
223721087|NCT00934973|BEHAVIORAL|CBT website with minimal support|
223947249|NCT01052974|DRUG|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
223721088|NCT00328757|BEHAVIORAL|Regular diet as the first postoperative meal|
223721089|NCT02221947|DRUG|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
223721090|NCT02221947|DRUG|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
223721091|NCT03017547|DRUG|IC14|Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
223721092|NCT03017547|OTHER|Placebo|sterile normal saline for infusion
223721093|NCT00114101|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
223721094|NCT00114101|OTHER|Laboratory Biomarker Analysis|Correlative studies
223721095|NCT00114101|DRUG|Lenalidomide|Given PO
223947250|NCT03649191|OTHER|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
223947251|NCT03649191|OTHER|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
223947252|NCT02808234|PROCEDURE|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
223947253|NCT02808234|OTHER|Nucel|Allograft derived from human amnion and amniotic fluid
223721096|NCT00114101|DRUG|Melphalan|Given IV
223721097|NCT00114101|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
223721098|NCT00114101|OTHER|Placebo Administration|Given PO
223721099|NCT06517693|DRUG|PGT121.414.LS|Administered SC in the thigh
223721100|NCT06517693|DRUG|VRC07-523LS|Administered SC in the thigh
223721101|NCT03210376|DRUG|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
224100597|NCT03809624|DRUG|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
223721102|NCT03210376|DRUG|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
223721103|NCT03210376|DRUG|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
223721104|NCT03210376|DRUG|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
223721105|NCT03210376|BEHAVIORAL|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
223721106|NCT06421428|OTHER|LEI Interview|"In accordance with the IPA (Interpretative phenomenological analysis) methodology, a semi-structured interview outline will be defined, aimed at understanding the lived experiences of women (lived experience) during their coexistence with urinary incontinence and during the treatment process.~The screwdriver questions were formulated starting from the scientific literature and with reference to the Theoretical Domains Framework (TDF), created and validated by Michie et al. (2005) and later updated by Cane et al. (2012). The interview questions will be discussed in a focus group composed of a uro-gynecologist, two midwives, a nurse, an expert in qualitative methodology. The final screwdriver questions resulting from the focus group will be tested on a small group of women."
223721107|NCT06421428|OTHER|LEI Survey|Some sociodemographic data identified from the reference literature will be collected in paper form immediately at the end of each interview, for the description of the sample. The data will concern: age, nationality, marital status, level of education, number of children, menopause, social relationships, level of information, period of onset of symptoms, type of symptomatology, frequency of episodes of urinary incontinence, quantity of urinary leakage, uro-gynecological pathological history.
223721108|NCT05802121|DRUG|Apple Cider Vinegar|"Each patient will be instructed to take 1 caplet (equivalent of 143 mg/caplet containing 36% acetic acid) per day for 3 months (NPN: 80078433)~https://www.jamiesonvitamins.com/products/apple-cider-vinegar-chromium?srsltid=AfmBOoqdVBFe83\_5JM9BmkomQM1LqsJYSFTiP\_78cnmehfzVg-4T4Z6o"
223721109|NCT03569514|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
224100598|NCT03809624|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
223947254|NCT01318850|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
223947255|NCT01318850|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
223947256|NCT01318850|OTHER|Healthy controls|No intervention
223947257|NCT00978159|DRUG|esomeprazole|esomeprazole 20 mg po for 4 weeks
223947258|NCT00978159|DRUG|Famotidine|Famotidine 40 mg po for 4 weeks
223947259|NCT00237120|DRUG|Imatinib|
223947260|NCT00856687|DRUG|PF-03893787|Oral, two doses 12 hours apart
223947261|NCT00856687|DRUG|Placebo|Oral, two doses 12 hours apart
223947262|NCT00856687|DRUG|Montelukast|Oral, two doses 12 hours apart
223947263|NCT01409837|DRUG|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
223947264|NCT02177825|DRUG|Imatinib Mesylate|oral administration
223947265|NCT03960645|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
223947266|NCT02638506|DRUG|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
223947267|NCT02638506|OTHER|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
223947268|NCT05610566|DEVICE|the HighLife Trans-Septal Transcatheter Mitral Valve Replacement System|The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a subannular implant (SAI), and their delivery systems and accessories. The TMV is a 28mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI), comprising a ring (made of polycarbonate urethane (PCU), nitinol, gold markers and polyester (Dacron) to be placed around the mitral valve apparatus to stabilize the position of the mitral valve implant.
223947269|NCT02808403|OTHER|No intervention|No intervention; observation of routine medical care
223721110|NCT05147350|DRUG|RP-6306 (oral PKMYT1 inhibitor)|RP-6306 (Oral) in combination with FOLFIRI (IV)
223721111|NCT01539538|DRUG|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
223721112|NCT01539538|DRUG|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
223947270|NCT02605850|OTHER|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
223947271|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
223947272|NCT02605850|DIETARY_SUPPLEMENT|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
223947273|NCT01058018|DRUG|RVX000222|RVX000222 twice a day for 12 weeks
223947274|NCT01058018|DRUG|Placebo|Placebo twice a day for 12 weeks
223947275|NCT04951791|DRUG|SMOFlipid|will receive intravenous infusion of 2ml\\kg of smoflipid 20%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed
223947276|NCT04951791|OTHER|Normal saline 0.9%|will receive intravenous infusion of 2ml\\kg of normal saline 0.9%, in the internal jugular vein 10 minutes before removal of aortic cross clamp in a constant speed.
223721113|NCT05947396|DIETARY_SUPPLEMENT|SMARTO ONE|The SMARTO ONE® small molecule natural flavonoid compound product is provided by Beijing Jiafurui Biological Technology Co., Ltd. The intervention agent formula consists of extracts from Polygonum cuspidatum leaves, Fructus ligustri lucidi, Prunus mume, Semen ziziphi spinosae, celery, resistant maltodextrin, and steviol glycoside. Each package of the test product (3g) contains a total flavonoid content of 150mg.
223721114|NCT05947396|OTHER|placebo|The placebo is provided by Beijing Jiafurui Biological Technology Co., Ltd. The formula consists of maltodextrin, grapefruit powder, and food coloring. The manufacturing facility has adjusted the appearance, color, solubility, and taste of the placebo to match the intervention agent. There is no risk of unblinding.
223947277|NCT02746107|OTHER|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
223947278|NCT05818852|DRUG|VX-548|Tablets for oral administration.
223947279|NCT05818852|DRUG|Moxifloxacin|Capsules for oral administration.
223947280|NCT05818852|DRUG|Moxifloxacin Placebo|Capsules for oral administration.
223947281|NCT05818852|DRUG|VX-548 Placebo|Tablets for oral administration.
223947282|NCT03031509|BIOLOGICAL|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
223947283|NCT03031509|PROCEDURE|debridement|debridement
223947284|NCT01992965|OTHER|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
223947285|NCT00022672|DRUG|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
223947286|NCT00022672|DRUG|anastrazole (Arimidex®)|1 mg tablet taken orally daily
223947287|NCT06050941|DRUG|idarubicin|Idarubicin 6mg/m2 d5-7
223947288|NCT06050941|DRUG|Cytarabine|Cytarabine 60mg/m2 d5-9
223947289|NCT00403494|OTHER|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
223947290|NCT00403494|DRUG|Sapropterin Dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
223947291|NCT06462781|DRUG|Lidocaine hydrochloride|Intra-arterial injection of 40mg lidocaine per middle meningeal artery (total 2 arteries) administered one time
224100599|NCT05987527|DIAGNOSTIC_TEST|Blood sample|Routine procedures
223947292|NCT06462781|DRUG|Methylprednisolone sodium succinate|Intra-arterial injection of 20mg methylprednisolone per middle meningeal artery (total 2 arteries) administered one time
223947293|NCT03490032|DRUG|[68Ga]-PSMA-R2|radio-labelled PSMA ligand
223947294|NCT05593107|DRUG|[68Ga]N188|68Ga-N188 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
223947295|NCT01453959|DRUG|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
223947296|NCT01453959|OTHER|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
223947297|NCT01459952|DIETARY_SUPPLEMENT|Rose hip Liquid|Rose hip Liquid, 20 ml BID
223721115|NCT06567054|DEVICE|Measurements with the POROUS R3C ultrasound device at the midshaft tibia|The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
223947298|NCT02343666|BIOLOGICAL|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
223947299|NCT02343666|DRUG|Carmustine|Given IV
223947300|NCT02343666|BIOLOGICAL|Filgrastim|Given SC
223947301|NCT02343666|OTHER|Laboratory Biomarker Analysis|Correlative studies
223947302|NCT02343666|DRUG|O6-Benzylguanine|Given IV
223947303|NCT02343666|DRUG|Plerixafor|Given SC
223947304|NCT01040312|DRUG|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
223947305|NCT01040312|DRUG|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
223947306|NCT00416975|OTHER|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
223947307|NCT00416975|OTHER|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
223947308|NCT00416975|PROCEDURE|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
223947309|NCT03950726|PROCEDURE|ileocolic resection|Ileocolic resection through McBurney incision
223947310|NCT05583656|PROCEDURE|Pulmonary valve replacement|Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.
223947311|NCT05371951|DEVICE|Erchonia HLS|84 procedure administrations with the Erchonia® HLS™ administered by the subject at home: twice daily procedure administrations for 6 weeks.
223947312|NCT04336709|DRUG|Calcipex II|Water based intracanal medicament
223947313|NCT04336709|DRUG|Metapex|Oil based intracanal medicament
223947314|NCT03028285|DRUG|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
223947315|NCT04648670|BEHAVIORAL|Cognitive stimulation|The intervention was applied to the experimental group and consisted in 10 sessions of 45 minutes/week during 10 weeks. Each session included four parts: (a) Reality orientation therapy, (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises..
224100600|NCT00248729|DRUG|Etomidate (20mg) or Midazolam (7mg)|
224100601|NCT06459687|DRUG|Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of Socazolimab (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with Socazolimab (5 mg/kg), Q3w."
223721116|NCT06567054|DEVICE|DXA measurement of the hip and lumbar spine|"The following DXA measurements are to be performed:~* Spine L1-4~* Hip left~* Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan."
223721117|NCT06567054|DEVICE|DXA-based Vertebral Fracture Assessment (VFA)|DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
223721118|NCT06567054|DEVICE|Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)|Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
223947316|NCT03160976|OTHER|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
223947317|NCT02404844|DRUG|BKM120|daily oral
223947318|NCT02404844|DRUG|Tamoxifen|daily oral
223947319|NCT02224755|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
223947320|NCT02224755|DEVICE|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
223947321|NCT01852045|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
223947322|NCT02736188|DRUG|Aceneuramic Acid Extended-Release Tablets|
223947323|NCT04220983|RADIATION|MR-Guided Prostate SBRT|Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
223947324|NCT02584426|DEVICE|Ultrasonic Distribution of Cefazolin|
223947325|NCT03274648|DIETARY_SUPPLEMENT|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
223947326|NCT03274648|DIETARY_SUPPLEMENT|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
223947327|NCT03274648|DIETARY_SUPPLEMENT|Habitual diet|Patients follow the habitual diet
223947328|NCT00012688|DRUG|Doxycycline HCI 10mg po for 2 weeks|
223947329|NCT00012688|PROCEDURE|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
223947330|NCT02799537|OTHER|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
223947331|NCT02487680|DIETARY_SUPPLEMENT|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
223947332|NCT02487680|DIETARY_SUPPLEMENT|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
223947333|NCT03019432|BEHAVIORAL|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
223947334|NCT03738592|OTHER|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
223947335|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
223947336|NCT03738592|OTHER|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
223947337|NCT04081532|PROCEDURE|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
223947338|NCT01772199|DRUG|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
223947339|NCT01772199|DRUG|Placebo|White to almost white, round tablets. Once daily orally.
223947340|NCT05352737|DIAGNOSTIC_TEST|methylmalonic acid testing|
223947341|NCT04753450|OTHER|No intervention|No intervention
223947342|NCT05413993|RADIATION|photobiomodulation|Laser application intraorals and extraoral points in the region of the salivary glands bilaterally
223947343|NCT04017364|DEVICE|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
223947344|NCT04017364|DEVICE|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
223947345|NCT02560155|DRUG|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
223947346|NCT02560155|DRUG|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
223947347|NCT05391867|DRUG|Lenvatinib|Tyrosine kinase inhibitor
223947348|NCT02028390|DEVICE|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
223947349|NCT02028390|DEVICE|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
223947350|NCT02028390|DEVICE|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
223947351|NCT02028390|DEVICE|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
223947352|NCT02028390|DEVICE|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
223947353|NCT02007070|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223947354|NCT06374407|BEHAVIORAL|Dietary intervention based on the MIND diet|A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.
223947355|NCT00693836|GENETIC|genetic linkage analysis|
223947356|NCT00693836|GENETIC|loss of heterozygosity analysis|
223947357|NCT00693836|GENETIC|mutation analysis|
223947358|NCT00693836|GENETIC|polymerase chain reaction|
223947359|NCT00693836|GENETIC|polymorphism analysis|
223947360|NCT00693836|OTHER|biologic sample preservation procedure|
223947361|NCT00693836|OTHER|medical chart review|
223947362|NCT00693836|OTHER|questionnaire administration|
223947363|NCT00693836|PROCEDURE|evaluation of cancer risk factors|
223947364|NCT01473069|DRUG|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
223947365|NCT01473069|DRUG|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
223947366|NCT06452121|OTHER|triglyceride glucose index|"The TyG index was calculated using the following equation: Ln \[TG (mg/dL)×FPG (mg/dL) / 2\].~CAD was referred to as at least one major coronary artery with≥50% stenosis evaluated by CAG"
223947367|NCT03556852|DRUG|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
223947368|NCT03556852|DRUG|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
223947369|NCT05004909|DRUG|0.05% Tretinoin|Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
223947370|NCT04476524|OTHER|Quality improvement|All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER. Patients will be followed up and outcomes will be compared between two groups at 1, 3, 6 and 12 months.
223947371|NCT00114452|BIOLOGICAL|Provacel|ex vivo cultured adult mesenchymal stem cells
223947372|NCT00114452|BIOLOGICAL|Placebo|Placebo
223947373|NCT01622049|DEVICE|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
223536388|NCT06405126|DIAGNOSTIC_TEST|Optiek predictive model|Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.
223536389|NCT03338400|DRUG|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
223536390|NCT03338400|DRUG|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
223536391|NCT01603017|DEVICE|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
223536392|NCT01603017|DEVICE|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
223536393|NCT00363571|DRUG|GTN, Diamox|
223536394|NCT03454789|DRUG|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
223536395|NCT03454789|DRUG|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
223536396|NCT03454789|DRUG|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
223536397|NCT03454789|DRUG|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
223536398|NCT04945486|OTHER|Peer-mentor intervention|Peer-mentor support for up to 6 months
223536399|NCT01627691|DEVICE|Lotus Valve System|"* bioprosthetic bovine pericardial aortic valve~* delivery system"
223947374|NCT02979678|OTHER|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
223721119|NCT06298500|DEVICE|hernia repair surgery|In recent years, atraumatic mesh fixation with tissue adhesive has increasingly become the method of choice. It is the recommended mesh fixation method by the International Hernia Society Guidelines. In this study patients with inguinal hernia are treated by placing a prosthetic mesh in one of the layers of the abdominal wall to cover the weakness, the mesh is fixed by Histoacryl LapFix,
223721120|NCT06576674|DIETARY_SUPPLEMENT|Dietary Fiber + Green Tea Extract|10g fiber + 750mg green tea supplement will be administered at experimental arm
224100602|NCT06459687|DRUG|Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab|"6\~8 cycles of placebo (5 mg/kg) + cisplatin (50 mg/m2) /carboplatin (AUC5) + paclitaxel (175 mg/m2) ± Bevacizumab (15 mg/kg), Q3w.~Followed with placebo (5 mg/kg), Q3w."
223721121|NCT06576674|OTHER|Alcohol|alcohol administered up to a target BAC 60mg% during lab sessions
224100603|NCT04980703|DEVICE|Grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
224100604|NCT04980703|DEVICE|Sham grain moxibustion|Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half （the patient hasn't feel hot or feel a little hot）, take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).
224100605|NCT04980703|OTHER|Standard care|Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.
224100606|NCT06060938|OTHER|Risk stratified arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every 1-4 years according to the risk-group)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~* Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~* Receive a screening schedule recommendation."
223536400|NCT03758261|DRUG|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
223536401|NCT03758261|DRUG|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
223536402|NCT00795028|OTHER|Standard Care for people after hip fracture|
224122646|NCT02930655|DRUG|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
223721122|NCT06576674|OTHER|Aspartame Placebo Supplement|Aspartame sweetener mixed with water + aspartame capsule
223947375|NCT05260437|BIOLOGICAL|CV2CoV (2 µg)|Study vaccine was administered as a single intramuscular injection.
223947376|NCT05260437|BIOLOGICAL|CV2CoV (4 µg)|Study vaccine was administered as a single intramuscular injection.
223947377|NCT05260437|BIOLOGICAL|CV2CoV (8 µg)|Study vaccine was administered as a single intramuscular injection.
223947378|NCT05260437|BIOLOGICAL|CV2CoV (12 µg)|Study vaccine was administered as a single intramuscular injection.
223947379|NCT05260437|BIOLOGICAL|CV2CoV (16 µg)|Study vaccine was administered as a single intramuscular injection.
223536403|NCT00795028|OTHER|Standard Care + exercise intervention|
223536404|NCT00988793|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
223536405|NCT00988793|PROCEDURE|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
223536406|NCT04130412|PROCEDURE|open release|Open release of lateral retinaculae
223536407|NCT02035514|BIOLOGICAL|Bone marrow autologous mesenchymal stem cells transplantation|
223536408|NCT06454656|OTHER|MOBILE|"Intensive motor learning based intervention to target specific walking goals as identified using the Gait Outcome Assessment List.~Full Protocol outlining strategies available on request.~Three key principles underpin the intervention:~Principle 1: The type of task~Principle 2: The type of practice~Principle 3: The type of Feedback"
223536409|NCT04054362|DRUG|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
223536410|NCT04054362|DRUG|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
223721123|NCT05862480|OTHER|Spray with Hypochlorous Acid Group|For Each Patient included . A prescription of a nasal spray in each nostril/3 hours and two oral sprays/3 hours by a solution of hypochlorous acid (NEED DEFENDER) for 5 days
223721124|NCT05862480|OTHER|Spray with Placebo Group|For Each Patient included , A prescription of an identical to the intervention nasal spray in each nostril/3 hours and two oral sprays/3 hours by Placebo for 5 days.
223721125|NCT04105101|DEVICE|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
223721126|NCT02359760|PROCEDURE|Piezocision|Flapless corticotomies
223721127|NCT00723983|DRUG|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
223947380|NCT05260437|BIOLOGICAL|CV2CoV (20 µg)|Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
223947381|NCT00910962|DRUG|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
223947382|NCT00910962|DRUG|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
223721128|NCT00723983|DRUG|NP101 Study Patch|NP101 study patch 4 hour application
223721129|NCT04673422|DRUG|Montelukast|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
223721130|NCT04673422|DRUG|Placebo|A 10-mg tablet will be given orally immediately and every day thereafter for 10 days or until recovery, defined as the discontinuation of the follow up appointment by the attending physicians, whichever is shorter
223721131|NCT04669652|DEVICE|Piezo-ICSI|During piezo-ICSI, a piezo-electric effect is generated through the conversion of electric energy to mechanical energy. This causes a smooth movement of the injection pipette, which allows for steady, controlled microinjection of a sperm with less psychical stress applied on the oocytes than by the conventional technique.
223721132|NCT04927260|DRUG|Patient treated by Avapritinib in real life|"The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA."
223947383|NCT00910962|DRUG|Placebo|Placebo
223947384|NCT02677688|BIOLOGICAL|Autologous EBV specific CTL infusion|
223947385|NCT04434872|PROCEDURE|Colonoscopy|Fecal microbiota transplantation through colonoscopy
223947386|NCT04434872|PROCEDURE|Gastroscopy|Fecal microbiota transplantation through gastroscopy
223947387|NCT04434872|DRUG|Fecal Microbiota|
223947388|NCT04434872|PROCEDURE|Enema|Fecal microbiota transplantation through enema
223947389|NCT03788707|OTHER|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
223947390|NCT03222232|BEHAVIORAL|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
223947391|NCT00001998|DRUG|Nystatin|
223947392|NCT03732456|PROCEDURE|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
223947393|NCT00787176|DRUG|Group A Intravenous bolus of 1000 ml lactated ringers solution|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
223947394|NCT00787176|DRUG|Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
223536411|NCT04054362|DRUG|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
223536412|NCT04054362|DRUG|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
223947395|NCT00787176|DRUG|Group C 125 mL/hr of lactated ringers|The maintenance infusion of 125 mL/hr of Lactated Ringers will be given with no additional fluid bolus. Oxytocin management continued per protocol.
223947396|NCT00787176|DRUG|Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement will be halved and not increased for 60 minutes until after placement.
223947397|NCT03037736|DRUG|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
223947398|NCT03037736|DRUG|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
223947399|NCT03037736|DRUG|Normal saline|Normal saline will be used as the placebo.
223947400|NCT04463654|DEVICE|Zero Self-Harm app|Safety plan app for smartphones
223947401|NCT02556697|DEVICE|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
223947402|NCT01190995|DRUG|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
223947403|NCT01190995|DRUG|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
223947404|NCT00884806|DEVICE|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
223947405|NCT00884806|DEVICE|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
223536413|NCT02626169|DRUG|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
223536414|NCT02626169|DRUG|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
223536415|NCT02637986|DIETARY_SUPPLEMENT|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
223536416|NCT02637986|OTHER|Placebo - capsule with no active ingredient|2 capsules will be given per day
223536417|NCT06452693|DRUG|TQA3038 injection/placebo|TQA3038 is a Anti-Hepatitis B virus (HBV) drugs.
223536418|NCT06452693|DRUG|Nucleotide drugs Control group|Nucleotide drugs are nucleoside reverse transcriptase inhibitors.
223536419|NCT03461471|BEHAVIORAL|Exercise Intervention|Exercise intervention
223536420|NCT02266563|DRUG|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
223536421|NCT02266563|DRUG|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
223536422|NCT00888537|OTHER|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
223536423|NCT00888537|OTHER|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
223536424|NCT03018158|DEVICE|denture wear.|MR Imaging was collected with or without denture wear.
223536425|NCT00002907|DRUG|bryostatin 1|
223536426|NCT01482130|BEHAVIORAL|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
223536427|NCT01482130|BEHAVIORAL|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~* Weight bearing activities (walking, jogging or strength training)~* 30 - 60 minutes, 3 - 5 times each week~* A total of 2 - 3 hours each week should be achieved"
223536428|NCT05129956|DEVICE|"Covidien Emprint Ablation System with Thermosphere Technology"|The ablation time and wattage are determined according to the size of the tumor. The wattages are respectively 45W, 75W, and 100W, and the maximum time is 10 minutes
223536429|NCT03037970|DRUG|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
223536430|NCT03037970|OTHER|Placebo|Collagen Wound Dressing wetted with buffer.
223947406|NCT00884806|DEVICE|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
223947407|NCT00884806|DEVICE|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
223947408|NCT00884806|DEVICE|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
223947409|NCT00559572|BEHAVIORAL|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
223947410|NCT00559572|OTHER|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
224100607|NCT06060938|OTHER|Control arm|"* Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every second year)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)"
224100608|NCT06288594|BEHAVIORAL|Application Plus Online Therapist Support Group|Participants in the therapist-supported group will receive weekly 20-30 minute online sessions for five weeks, with content based on a semi-structured manual. After 80% completion of the psychoeducation module, the coping module becomes available, and similarly, the exposure module follows. These sessions will be conducted in adherence to a structured manual, with the therapist introducing the module of the week, guiding through exercises, assigning homework, and reviewing the previous assignments. Sessions include module introductions, exercises, homework assignments, and application use review. Feedback and PCL-5 scores guide post-session recommendations. A random 40% of sessions will undergo fidelity checks by doctoral-level psychologists.
224100609|NCT06288594|BEHAVIORAL|Application Only Group|"Participants allocated to this group will have access to the TraumaRelief mobile application over a five-week period, with the exception of the online module component. The application's deployment strategy ensures a structured progression through its features: participants will gain access to the subsequent modules only after completing 80% of the preceding module. Initially, they will engage with the psychoeducation module; upon completion of at least 80% of this module, the coping with symptoms module will become available. Similarly, successful engagement with 80% of the coping module will unlock the imaginary exposure module. This sequential module access is designed to reinforce the acquisition of knowledge and skills in a stepwise manner, paralleling the structure provided to the TraumaRelief Mobile Application with Therapist Support group, yet without the additional therapist interaction."
224100610|NCT04909463|DEVICE|Chest Splint|Those receiving intervention will be given the Duracore chest splint for use throughout the trial.
224100611|NCT02047955|DEVICE|Shoulder Arthroplasty|"Data will be collected for commercially available Sponsor devices. These systems treat both the humeral and glenoid side of the shoulder joint. The following products will be included in the study in the geographies where they are commercially available.~* Aequalis Ascend Flex Convertible Shoulder System~* Pyrocarbon Humeral Head (used with Aequalis Ascend Flex)~* Simpliciti Shoulder Prosthesis~* Aequalis Reversed Fracture Prosthesis~* Aequalis PerFORM Glenoid~* Aequalis PerFORM+ Glenoid~* Aequalis PerFORM Reversed Glenoid~Devices previously included, but discontinued under clinical investigation plan (CIP) version 4.0:~* Aequalis Resurfacing Head~* Aequalis Ascend Anatomic Shoulder System~* Aequalis IM Humeral Nail - Short and Long~* ORTHOLOC™ SPS (Shoulder Plating System)~* Aequalis Reversed II Shoulder System~* Aequalis Adjustable Reversed Prosthesis~* Aequalis Flex Revive Shoulder System"
224100612|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid|The control group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF.
223536431|NCT02604459|DEVICE|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
223536432|NCT02604459|DEVICE|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
223536433|NCT02604459|PROCEDURE|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
223536434|NCT02604459|PROCEDURE|General anesthesia|General anesthesia will be used in both groups
223536435|NCT02604459|DRUG|propofol|propofol per protocol
223947411|NCT01817894|DRUG|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
223947412|NCT00059527|BEHAVIORAL|Healthy Youth Places: a behavior change model|
223947413|NCT02486939|DRUG|CHS-0214|Open label
223947414|NCT02649725|BEHAVIORAL|patient's satisfaction|Questionnaire based measurement.
223536436|NCT02604459|DRUG|fentanyl|fentanyl per protocol
223536437|NCT02604459|DRUG|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
223536438|NCT00186628|PROCEDURE|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
223947415|NCT00006084|BIOLOGICAL|lintuzumab|
223947416|NCT00328666|BEHAVIORAL|Iyengar yoga|
223536439|NCT00186628|DRUG|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
223536440|NCT00186628|DRUG|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
223536441|NCT00186628|DRUG|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates \> 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
223947417|NCT00328666|BEHAVIORAL|Enhanced nutritional care classes|
223947418|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture without skin adhesive
223721133|NCT00577681|DRUG|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
223721134|NCT00923338|DEVICE|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
223721135|NCT04955197|DIAGNOSTIC_TEST|exfoliated cytology|Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division. They are considered as a sensitive indicators of genetic damage. They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation. Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions. Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
223721136|NCT01616667|PROCEDURE|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
223721137|NCT01774604|DRUG|Indomethacin|100 mg Indomethacin PR x 1
223947419|NCT06006572|PROCEDURE|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive|wound closure subcuticular running stitch using 3-0 monocryl suture with two layers of skin adhesive
223947420|NCT02095678|PROCEDURE|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
223947421|NCT02095678|DEVICE|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to \<8 seconds and validate quantifiable techniques which improve liver image quality
223947422|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: BGM|measurement of blood glucose concentration using different BGM
223947423|NCT05219526|DIAGNOSTIC_TEST|blood glucose measurement: reference method|measurement of blood glucose concentration using reference Method
223947424|NCT05467566|DEVICE|Transcranial direct current stimulation|Exercise protocol + application of active direct current stimulation for 30 minutes.
223947425|NCT05467566|DEVICE|Sham Transcranial direct current stimulation|Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
223947426|NCT00000418|PROCEDURE|Psychosocial intervention|
223947427|NCT01663454|BEHAVIORAL|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
223947428|NCT01758549|OTHER|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
223947429|NCT01758549|OTHER|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
223721138|NCT01774604|DRUG|Placebo|
223721139|NCT00509015|DRUG|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S\&25mg P/20 kg, 1 day, single dose
223721140|NCT00509015|DRUG|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
223721141|NCT00509015|DRUG|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
223721142|NCT00509015|DRUG|placebo tablets|3 days of lactose tablets (160mg) albochin
223721143|NCT04052347|BEHAVIORAL|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
223721144|NCT04052347|BEHAVIORAL|routine shared decision-making|control group
223721145|NCT03384095|DRUG|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
223721146|NCT03384095|OTHER|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
223947430|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
223947431|NCT00701415|BIOLOGICAL|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
223947432|NCT04864834|BIOLOGICAL|SOK583A1 (40 mg/mL)|IVT administration of 2 mg of SOK583A1 in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
223947433|NCT04864834|BIOLOGICAL|Eylea EU (40 mg/mL)|IVT administration of 2 mg of Eylea EU in the study eye, every 4 weeks (q4w) at Baseline, Week 4 and Week 8, and thereafter every 8 weeks (q8w) at week 16, 24, 32, 40 and 48.
223947434|NCT00944359|DIETARY_SUPPLEMENT|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
223947435|NCT00944359|DIETARY_SUPPLEMENT|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
223947436|NCT00944359|DIETARY_SUPPLEMENT|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
223947437|NCT00944359|OTHER|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
223947438|NCT03592407|DRUG|Epacadostat|Given PO
223947439|NCT03592407|OTHER|Laboratory Biomarker Analysis|Correlative studies
223947440|NCT03592407|BIOLOGICAL|Pembrolizumab|Given IV
223947441|NCT03592407|OTHER|Pharmacodynamic Study|Correlative studies
223947442|NCT01849523|BEHAVIORAL|Web-based information and support|
223947443|NCT02067689|DEVICE|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
223947444|NCT04597931|DRUG|Romosozumab|SC Romosozumab 210 mg/monthly
223947445|NCT04597931|DRUG|Zoledronic Acid|IV Zoledronic acid 5 mg
223947446|NCT05178706|OTHER|upper extremity rehabilitation program|Patients with FSHD who have undergone and have not undergone surgery will be given activity training by the same physiotherapist after they agree to participate in the study. Both groups will be given the same exercises, the same number of repetitions and the same frequency. A two-phase exercise protocol will be established and progression will be performed after 4 weeks. The exercises will be based on the upper extremity and will include various types of exercises and the primary affected November muscles in the upper extremity. It is planned that the exercises will be accompanied by a physiotherapist 2 days a week, with a total of 16 sessions for 8 weeks. It is planned that there will be a total of 8-10 exercises in 10 repetitions in the exercise program. The total length of the exercise session will be 30 minutes. It is planned that the same physiotherapist will be one-on-one with the patient from the beginning to the end of the exercises.
223947447|NCT05178706|DIAGNOSTIC_TEST|Results of assessment|The total follow-up period of participants included in intervention programs will be 8 weeks. Evaluations will be evaluated by physiotherapist before and at the end of treatment.
223947448|NCT03177226|DEVICE|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
223947449|NCT03177226|DEVICE|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
223947450|NCT04129099|BIOLOGICAL|GC022F|GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.
223947451|NCT02879942|OTHER|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
224100613|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
223947452|NCT02879942|OTHER|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
223947453|NCT01005693|OTHER|questionnaire administration|
223947454|NCT01005693|PROCEDURE|cognitive assessment|
224100614|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU. The standard dose is 1 ml per 30 ml of breast milk.
224100615|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb|For participants in the control group, additional fortification can be added to the milk for patients in this group in response to poor growth, as is standard of care in the NICU.
223536442|NCT00186628|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
223536443|NCT00186628|DRUG|Filgrastim|Filgrastim provided as needed for neutrophil support
223536444|NCT00186628|DRUG|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
223536445|NCT00186628|DRUG|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
223536446|NCT00186628|DRUG|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
223536447|NCT00186628|DRUG|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
223536448|NCT00186628|DRUG|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
223536449|NCT05822310|PROCEDURE|radiofrequency thermocoagulation to the articular branches of the femoral and obturatory nerves|Patients are operated under sedation in the operating room. C-arm fluoroscopy device is used for imaging purposes for radiofrequency thermocoagulation process. In order to prevent vascular injury, the needle is advanced under the guidance of ultrasonography. There are target points determined in fluoroscopy for the femoral nerve and the obturatory nerve. Before the thermocoagulation procedure, local anesthetic and steroid are injected into each of the target points.
223536450|NCT05822310|PROCEDURE|intraairticular steroid injection|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The femoral neck was detected under ultrasonography and the joint capsule was entered with a 22G 9 cm spinal needle. Then, 5 cc bupivacaine and 5 mg betamethasone were given and the procedure was terminated.
223721147|NCT05806281|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
223721148|NCT00564772|DRUG|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
224100616|NCT04294368|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid (Targeted Fortification)|The experimental group will receive mother's breast milk when it is available. Mother's breast milk will be fortified with 4 packets of Similac Human Milk Fortifier (HMF) per 100 mL. When mother's breast milk is not available, participants will be fed donor breast milk with 4 packets of HMF. For participants in the experimental group, the investigators will continue to add fortification. Two packets of HMF per day will be added until goal fortification is reached.
223947455|NCT01005693|PROCEDURE|examination|
224100617|NCT04294368|DIETARY_SUPPLEMENT|Similac Liquid Protein Fortifier (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base protein content in the donor breast milk for each particular batch of donor breast milk.
224100618|NCT04294368|DIETARY_SUPPLEMENT|Nestle Microlipid (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base fat content in the donor breast milk for each particular batch of donor breast milk
224100619|NCT04294368|DIETARY_SUPPLEMENT|Medica Nutrition SolCarb (Targeted Fortification)|Participants in the experimental group will receive a dose that will vary depending on the base carbohydrate content in the donor breast milk for each particular batch of donor breast milk
223947456|NCT01005693|PROCEDURE|management of therapy complications|
223721149|NCT01312272|DRUG|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
223721150|NCT01312272|DRUG|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
223947457|NCT05804825|BEHAVIORAL|Argument inoculation messages|Participants will then be presented with arguments randomly selected by the Qualtrics software algorithm from the full set of messages.
223721151|NCT05927506|BEHAVIORAL|Other|Observational study of behavior cognitive and motor control
223721152|NCT01615185|DRUG|full-dose amisulpride|amisulpride 800mg/d
223947458|NCT05804825|BEHAVIORAL|Simple forewarning message|Participants will be presented with a simple forewarning message.
223947459|NCT01061580|DEVICE|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
224100620|NCT04294368|OTHER|Analysis with Miris (AB) Human Milk Analyzer|For participants in both the control and the experimental arms, each batch of donor milk will be analyzed using the Miris Human Milk Analyzer. Manufacturer recommendations for milk analysis will be strictly followed.
224100621|NCT06469970|DRUG|Glucose 30% Intravenous Solution|"Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.~The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients."
223536451|NCT05822310|PROCEDURE|pericapsular nerve group (PENG) block|The patients were placed in the supine position in the operating room. The patient was stained sterile with povidone iodide. The high-frequency linear ultrasonography probe was placed on the anterior superior iliacspina (ASIS). Later, the anterior inferior iliac spine (AIIS) was detected by descending caudally. Afterwards, the probe was brought to the oblique position and AIIS, iliopubikeminence, psoas muscle and tendon were seen. Using a 22G 90-mm Quinckespinal needle, the tendon of the iliopsoas muscle was entered in the lateral-medial direction in the in-plane plane and bone contact was achieved. After negative aspiration, 15 ml of 0.5% bupivacaine were administered by seeing the appropriate drug distribution.
223536452|NCT01585727|PROCEDURE|TME|Total mesorectal excision
223536453|NCT01585727|PROCEDURE|TME|Total mesorectal excision
223536454|NCT01585727|PROCEDURE|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
223536455|NCT01448538|DRUG|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
223721153|NCT03609632|OTHER|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
223721154|NCT05574790|OTHER|annual follow up|Collection of the following information during the year following discharge from the initial episode (initial cohort): readmissions, dates and causes of readmission, mortality
223721155|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
223721156|NCT06324539|DIAGNOSTIC_TEST|Diagnostic Test: Rapid Intestinal anti-TG2 Assay|"Evaluation of the reliability of the Rapid Intestinal anti-TG2 Assay for revealing anti-TG2 antibodies in duodenal biopsy specimens of patients suffering from CD, especially potential CD in which the diagnosis may be challenging.~Intestinal anti-TG2 will be investigated also in patients suffering from other non-CD related gastrointestinal disorders. Sensitivity, specificity and likelihood ratios of the Rapid Intestinal anti-TG2 assay will be calculated and compared to the reference standard (serology + histopathology) of CD diagnosis."
223947460|NCT01562964|BEHAVIORAL|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
223947461|NCT01562964|BEHAVIORAL|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
223947462|NCT03491566|OTHER|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
223947463|NCT03491566|OTHER|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
223721157|NCT01192516|BEHAVIORAL|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
223721158|NCT01192516|BEHAVIORAL|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
223947464|NCT03056378|BIOLOGICAL|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
223536456|NCT01076010|DRUG|Tivozanib|Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
223536457|NCT01076010|DRUG|Sorafenib|Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
224122647|NCT00668434|DRUG|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
223536458|NCT03259295|DEVICE|Digiclamp (Skin tag removal initial plus follow-up)|Skin tag will be assessed for size, location, and overall appearance. After assessment and confirmation that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site. Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
223536459|NCT06470516|DEVICE|high-frequency transcranial alternating current stimulation|The experimental group received real stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 77.5Hz and 15mA.
223536460|NCT06470516|DEVICE|sham high-frequency transcranial alternating current stimulation|The the control group received sham stimulation of high-frequency transcranial alternating current stimulation (Hi-tACS).The treatment duration is 30 days, with two sessions per day, each lasting 40 minutes.The experimental group received Hi-tACS with parameters set at 0mA
223721159|NCT01256008|BEHAVIORAL|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
223721160|NCT01256008|BEHAVIORAL|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
223721161|NCT03874247|DRUG|pelubiprofen 45mg|bid for 3 days after meal
223721162|NCT03874247|DRUG|pelubiprofen placebo|bid for 3 days after meal
223721163|NCT03641430|OTHER|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
223947465|NCT02436070|BEHAVIORAL|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
223947466|NCT02436070|BEHAVIORAL|General text messages|Subjects received text messages generalized to children with asthma
223947467|NCT02345603|PROCEDURE|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
223947468|NCT03901781|COMBINATION_PRODUCT|ST266 via Intranasal Delivery|ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
223947469|NCT02798016|PROCEDURE|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
224122648|NCT00668434|DRUG|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
224122649|NCT03960710|OTHER|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
223721164|NCT02846311|DEVICE|Flu Test|
223947470|NCT02798016|PROCEDURE|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
223947471|NCT02066636|DRUG|Nivolumab|
223947472|NCT06021613|BEHAVIORAL|Randomized instructions|"Behavioral: Start: On Cannabis- In this two-day block, participants will be instructed to consume cannabis for one day and avoid cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis.~Behavioral: Start: Off Cannabis- In this two-day block, participants will be instructed to avoid cannabis for one day and consume cannabis the next day. Participants will be asked to smoke or vape cannabis at least once on days they are instructed to consume cannabis."
223947473|NCT02878616|DRUG|LFG316|LFG316 single dose
223947474|NCT02878616|DRUG|IVIG|IVIG single dose
223947475|NCT00405184|DRUG|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
223947476|NCT00405184|DRUG|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
223947477|NCT03139331|DRUG|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
223536461|NCT05669222|DIAGNOSTIC_TEST|FAST Technique|The next-generation QFR (μQFR) introduces a more intelligent algorithm and supports single-projection rapid calculation with a diagnostic accuracy of 93.0% compared with FFR; Computational RWS technique facilitates the assessment of lesion vulnerability.
223947478|NCT03139331|DRUG|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
223721165|NCT05458843|PROCEDURE|Fluid replacement|Participants will drink Gatorade Zero ad libitum, up to 1 cup every 15 minutes.
223721166|NCT05458843|PROCEDURE|No fluid replacement|Participants will not be permitted to drink.
223947479|NCT03139331|DRUG|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
223947480|NCT06032689|COMBINATION_PRODUCT|Xtra-fill|the material was placed in bulk.
223721167|NCT02248103|PROCEDURE|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
223721168|NCT02248103|BIOLOGICAL|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
223536462|NCT05669222|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries.
223721169|NCT00119626|DRUG|NXY-059|
223721170|NCT00036712|PROCEDURE|management of therapy complications|
223721171|NCT00036712|PROCEDURE|pain therapy|
223721172|NCT01685034|BIOLOGICAL|"Allergy immunotherapy (allergy shots)"|
223721173|NCT05527340|DRUG|Iberdomide|Iberdomide on days 1 to 21 at 1.6 mg, every 4 weeks, orally (PO)
223721174|NCT05527340|DRUG|Dexamethasone|Dexamethasone 40 mg (PO) (or 20 mg (PO) if patient ≥ 75 years old) should be administered on the days 1, 8, 15 and 22 of every 4-week cycle.
223721175|NCT05527340|DRUG|Daratumumab|Daratumumab will be given at 1800 mg, every 4 weeks, subcutaneously (SC). Cycles 1 and 2 (C1 and C2): Days 1, 8, 15, and 22 C3-6: Days 1 and 15 From C7 onwards: Day 1 of each cycle Cycles will be of 4 weeks of duration (28 days).
223947481|NCT06032689|COMBINATION_PRODUCT|x-base|The x-base liner was placed and then veneered with Xtra-fill.
223947482|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-tra|bulk placement of the restoration Admira fusion -xtra.
223947483|NCT06032689|COMBINATION_PRODUCT|Admira fusion x-base|Admira fusion x-base liner was used and then veneered by Admira fusion x-tra.
223536463|NCT03545048|OTHER|Internet based exercises|Exercises for knee OA (online- digital health)
223536464|NCT05320484|OTHER|Clinical Pilates Exercises|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
223536465|NCT05320484|OTHER|Classic Posture exercise|clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
223721176|NCT05722483|OTHER|Virtual Intensive Outpatient Program|Components of the intervention include a cognitive behavioral therapy for alcohol use disorder group (12 sessions), a DBT skills group (12 sessions), a Health and Wellness group (8 sessions), weekly individual therapy, weekly medication management appointments, and abstinence monitoring multiple times per day using breathalyzers equipped with facial recognition and internet connectivity.
223721177|NCT02205112|DRUG|Nemonoxacin|
223721178|NCT02205112|DRUG|Levofloxacin|
223721179|NCT01250275|OTHER|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
223721180|NCT01250275|OTHER|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
223721181|NCT01250275|OTHER|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
223721182|NCT01250275|OTHER|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
223721183|NCT01250275|OTHER|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
223721184|NCT01250275|OTHER|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
223721185|NCT01250275|OTHER|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
223721186|NCT02321800|DRUG|Cefiderocol|2000 mg intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
223947484|NCT01849536|DEVICE|SENSIMED Triggerfish®|
223947485|NCT04556773|DRUG|Trastuzumab deruxtecan|T-DXd: administered as an IV infusion
223947486|NCT04556773|DRUG|Durvalumab|Durvalumab: administered as an IV infusion
223947487|NCT04556773|DRUG|Paclitaxel|Paclitaxel: administered as an IV infusion
223721187|NCT02321800|DRUG|Imipenem/cilastatin|1000 mg of each intravenously every 8 hours for 7 to 14 days; dose adjustments for participants with reduced renal function (estimated CrCl ≤ 70 mL/minute) and/or body weight (\< 70 kg) included every 6-hour dosing intervals and/or reduced doses.
223721188|NCT06558032|DRUG|Tamsulosin 0.4 mg Sustained Release Tablet (produced by PT Dexa Medica, Indonesia)|One tablet of the test drug was given orally under fasting condition
223721189|NCT06558032|DRUG|Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)|One tablet of the test drug was given orally under fasting condition
223721190|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
223721191|NCT03012165|DRUG|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
223721192|NCT03012165|DRUG|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
223721193|NCT02454491|DRUG|Heparin|intraradial administration of heparin 5000 ui
223721194|NCT02454491|DRUG|Verapamil|intraradial administration of verapamil 5 mg
223721195|NCT00064116|BIOLOGICAL|rituximab|Rituximab 375 mg/m² i.v. day 1
223721196|NCT00064116|DRUG|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
223721197|NCT05536986|OTHER|Stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
223721198|NCT05228132|DEVICE|Pristine™ Long-Term Hemodialysis Catheter|Placement of the Pristine™ Long-Term Hemodialysis Catheter Placement.
223721199|NCT02362061|RADIATION|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
223721200|NCT02770560|DEVICE|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
223947488|NCT04556773|DRUG|Capivasertib|Capivasertib: administered orally
223947489|NCT04556773|DRUG|Anastrozole|Anastrozole: administered orally
223947490|NCT04556773|DRUG|Fulvestrant|Fulvestrant: administered as an IM injection
223721201|NCT01753271|OTHER|thoracic mobilization & shoulder mobilization & exercise|
223721202|NCT01753271|OTHER|shoulder mobilization & exercise|
223721203|NCT02277756|DEVICE|thermode|thermal stimulation with test thermode
223721204|NCT05230303|DIETARY_SUPPLEMENT|Caffeine supplementation|Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
223721205|NCT05230303|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
223721206|NCT01131754|OTHER|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
223947491|NCT04556773|DRUG|Capecitabine|Capecitabine: administered orally
223947492|NCT04402073|DRUG|Sonidegib|Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
223536466|NCT05993793|DEVICE|Fototherapy|The Antares brand Laser device was used for 3 sessions with an interval of 24 hours. The Visual Analogue Scale (VAS) was used before starting treatment, after the first and second sessions, and 1 week after the third session. In addition, at the end of the treatment, the closure, or not, of the lesion was verified, and the questionnaires performed prior to phototherapy were reapplied. The VAS assesses the patient's level of pain, which can be divided into mild pain (1-2), moderate pain (3-7), and severe pain (8-10). The Bristol Scale is based on the identification of the patient's consistency of stools, while types 1-2 correspond to constipation, 3-4 indicate normal intestinal rhythm, 5 indicate lack of fiber, and 6-7 correspond to diarrhea
223536467|NCT06389175|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|"Participants receive tVNS during the neuroimaging sessions and the extended stimulation period. To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established, conventional stimulation protocol (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany). To improve blinding, the stimulations intensities will be adjusted to correspond to a mild pricking sensation for tVNS and sham.~The extended stimulation period in the experimental group involves six sessions with at least 1.5h of stimulation (stimulation in the lab or at home with home device using the same stimulation protocol as during the neuroimaging sessions; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany)."
223947493|NCT04402073|DRUG|Cisplatin|Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
223947494|NCT04402073|DRUG|Lomustine|Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
223947495|NCT04402073|DRUG|Vincristine|Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
223947496|NCT04402073|RADIATION|radiotherapy|Radiotherapy to the cranio-spinal axis of 35.2 Gy in 22 daily fractions of 1.6 Gy, followed by an additional boost to the tumour site of 19.8 Gy in 11 daily fractions of 1.8 Gy, summing up to a total dose of 55.0 Gy in 33 daily fractions of 1.6/1.8 Gy.
223947497|NCT03539055|DRUG|Dabigatran Etexilate Oral Capsule|Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
223721207|NCT01336764|BEHAVIORAL|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
223721208|NCT01336764|BEHAVIORAL|Control|Unguided listening to radio/music.
223721209|NCT01357733|OTHER|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
223721210|NCT02294591|DRUG|N-acetylcysteine|Add-on treatment of NAC
223721211|NCT02294591|DRUG|Placebo|Add-on treatment of placebo
223947498|NCT05148988|DIAGNOSTIC_TEST|EchoPIV|All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
223947499|NCT05148988|DIAGNOSTIC_TEST|4D flow MRI|A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
223721212|NCT04873505|DIETARY_SUPPLEMENT|troches|Take one troche after each meal.
223947500|NCT06542562|PROCEDURE|guided implant placement|The key difference is that in Group 1, the guide is only used for the drilling sequence, while in Group 2 the guide is used for both the drilling and the actual implant placement.
223947501|NCT05343741|OTHER|Psychological Intervention|The CPA provides outpatient psychological services to individuals: children, adolescents and adults, couples and families. At the CPA, care is carried out through the co-therapy model, which involves the participation of a professional clinical psychologist and a trainee. Psychotherapists with diverse theoretical and clinical backgrounds (mainly psychodynamic, cognitive, systemic and integrative), but a common constructivist approach, work in the center. The following elements are transversal in their practice: therapeutic alliance, healing environment, and a collaborative procedure between the client, the psychotherapist and the trainee co-therapist.
223947502|NCT02278627|OTHER|manual lymphatic drainage|
223947503|NCT00552253|DRUG|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
223947504|NCT06152900|DEVICE|Accufit|"Magnet-based and Direct muscle stimulation devices are commonly used to generate current flow through the muscles in order to activate the muscle. The Accufit Electrical Muscle Stimulation device is an FDA cleared device having a two-channel stimulator that provides up to 8 electrodes with waveforms of interferential and biphasic for muscle stimulation. The Accufit system is indicated for relaxation of muscles, muscle re-education, reduction of pain and increased local blood circulation.~Muscle stimulation technology has been around for many decades and has been shown to be safe and effective for a variety of clinical applications. The foundational basis for the technology revolves around electrical current flowing through the muscle can be used to activate the muscle."
224122650|NCT03960710|OTHER|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~\- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
223721213|NCT01888237|DRUG|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
223721214|NCT01888237|DRUG|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
224100622|NCT05614219|OTHER|Biochemistry interpretive comment on elevated LDL-C levels|The interpretive comment on LDL-C will encourage for excluding secondary dyslipidemia (measuring Hba1C, TSH and checking current drugs and talk about diet). If secondary dyslipidemia ca be excluded we encourage to referral to lipid clinic. Familial hypercholesterolemia should be suspected if LDL-C \> 4 mmol/L in persons under the age of 40, or LDL-C \> 5 mmol/L in persons over the age of 40. The biochemistry interpretive comment will thus be released to the referring physician if the blood sample meet the criteria above. We advice that in pregnant women to control elevated LDL-C after childbirth.
224100623|NCT06963229|PROCEDURE|Spinal Anesthesia (bupivacaine)|L3-L4 or L4-L5 3cc of 2% bupivacaine
224100624|NCT06963229|PROCEDURE|Peripheral Nerve Block|"Sciatic Nerve Block 20ml of Anesthetic Mixture, Paravertebral Nerve Block (L3-L4 and L4-L5) 20ml of Anesthetic Mixture~Mixture Details:~* 5ml Lidocaine 2%~* 5ml Lidocaine 1% with Adrenaline (1-200000)~* 10ml Bupivacaine 0.5%"
223536468|NCT06389175|DEVICE|Sham stimulation|"The control intervention consists of a sham stimulation. In the neuroimaging session the electrode will be placed upside down to stimulate the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation.~During the extended stimulation period, the electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA). To ensure blinding, participants will be instructed that the extended stimulation period will examine the effects of a low- vs. high-intensity tVNS protocol. Each repeated stimulation period will involve six sessions with at least 1.5h of low-intensity stimulation (stimulation in the lab or at home with home device; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany)."
223721215|NCT01033968|PROCEDURE|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
224100625|NCT05218213|OTHER|No intervention|"Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)"
224100626|NCT03226197|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone ester drink
224100627|NCT05200351|BEHAVIORAL|Equine assisted Therapy (EAT)|15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.
224100628|NCT00853632|DEVICE|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
224100629|NCT06244082|DRUG|AOC 1044|AOC 1044 will be administered via intravenous (IV) infusion
224122651|NCT03960710|OTHER|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~\- Use of computer data to drive the artificial intelligence network."
223947505|NCT01401790|DEVICE|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~* Automatic download of blood glucose levels~* Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~* Changes in treatment plan by the diabetes professionals~* E mail exchanges between families and health care professionals~* Reinforcement of teaching program"
223947506|NCT01401790|OTHER|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
223536469|NCT03388892|DEVICE|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
223536470|NCT03388892|DEVICE|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
223536471|NCT06127433|DRUG|Insulin Glargine|Insulin Glargine
223536472|NCT06127433|DRUG|Metformin|Metformin
223536473|NCT06127433|DRUG|Dapagliflozin|Dapagliflozin
223536474|NCT06127433|DRUG|Insulin aspart|Insulin aspart
223536475|NCT03814928|BEHAVIORAL|Caregivers eCourse|Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
223536476|NCT04470297|DRUG|Ramelteon 8mg|Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
223536477|NCT02918669|RADIATION|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
223536478|NCT06642415|PROCEDURE|Surgery under loupes|surgery performed under loupes
223536479|NCT06642415|PROCEDURE|surgery performed under microscope|surgery performed under microscope
223536480|NCT06637098|BEHAVIORAL|routine rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training."
223536481|NCT06637098|BEHAVIORAL|Oral tube feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223721216|NCT06133205|OTHER|Catgut Embedding at acupoints|Supplemented by auricular point therapy, can increase the effect of catgut embedding therapy.
223721217|NCT00730132|DRUG|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
223721218|NCT00730132|DRUG|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
223947507|NCT05913791|DIETARY_SUPPLEMENT|Nutrients-fortified egg|Consumption of 2 cooked nutrients fortified eggs (half-boiled, hard-boiled, or steamed)
223947508|NCT05913791|OTHER|Regular egg|Consumption of 2 regular eggs, prepared in the same manner as nutrients-fortified egg, which serves as a placebo comparison.
223947509|NCT05113134|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder will undergo Transvaginal NOSE
223947510|NCT01719874|BIOLOGICAL|TCN-032|
223947511|NCT01719874|BIOLOGICAL|Placebo (saline)|
223947512|NCT00258115|DRUG|salsalate|
223947513|NCT01963598|DRUG|REGN1033 (SAR391786)|
223947514|NCT01963598|DRUG|placebo|
223947515|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
223947516|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
223947517|NCT01537497|DRUG|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
223947518|NCT01537497|DRUG|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
223947519|NCT06458036|DRUG|Selpercatinib Monotherapy|Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.
223947520|NCT06458036|RADIATION|131I Therapy|Patients will receive 131I therapy after 6 months of selpercatinib.
223947521|NCT06305312|BEHAVIORAL|Community Service Navigation|Patients randomized to the intervention will be directly referred to the United Way of Salt Lake's 211 community referral service for additional outreach.
223947522|NCT06305312|OTHER|Usual Care|Standard referral to community resources.
223947523|NCT02124356|OTHER|Evaluation of functional performance|
223947524|NCT02521493|DRUG|Asparaginase|Given IM or IV
223947525|NCT02521493|DRUG|Asparaginase Erwinia chrysanthemi|Given IM or IV
223947526|NCT02521493|DRUG|Cytarabine|Given IT and IV
223947527|NCT02521493|DRUG|Daunorubicin Hydrochloride|Given IV
223947528|NCT02521493|DRUG|Etoposide|Given IV
223947529|NCT02521493|OTHER|Laboratory Biomarker Analysis|Correlative studies
223947530|NCT02521493|DRUG|Mitoxantrone Hydrochloride|Given IV
223947531|NCT02521493|DRUG|Thioguanine|Given PO
223947532|NCT06060353|BEHAVIORAL|Regulation Focused Psychotherapy (RFP-C)|Regulation-focused psychotherapy for children (RFP-C; Hoffman, Rice, \& Prout, 2016) is a manualized, psychodynamic play therapy. Through 20 sessions (16 with the child and four parent meetings), RFP-C allows the child to understand the ways distressing affects are avoided and to explore alternative ways of coping with unpleasant affect. The clinician works to increase the child's understanding that all behavior, especially oppositional and disruptive behavior, has meaning in the service of emotional and behavioral regulation. This work is also done with the parents to better support the child in achieving symptom reduction and increased emotion regulation.
223947533|NCT06060353|BEHAVIORAL|Parental Awareness and Child Social Skills Group|Parental awareness and child social skills group is a manualized group psychotherapy that involves twelve parallel sessions conducted separately with parents and children. The parent group involves modules related to psycho-education, role-play and awareness building activities on child needs \& rights, child temperament, praise \& acceptance, child play, limit setting, anger management, transmission of parenting styles through genograms and family trees. With children, the groups involve psycho-education and play based activities to build awareness on children's rights, temperament, feelings, play \& relationship skills, empathy \& praise, anger management.
223947534|NCT06439329|BEHAVIORAL|Standard PN|Standard of care
223947535|NCT06439329|BEHAVIORAL|Patient Choice|Participants can select from a menu of options including brick and mortar services, Mobile Health Unit (MHU) or telehealth services.
223947536|NCT01470300|OTHER|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
223947537|NCT05527613|OTHER|whatsapp application with oral hygiene reminder for orthodontic patients|Participants with orthodontics will be randomly assigned to receive the WhatsApp application, through which oral hygiene reminders will be sent using images and videos containing necessary information, and at the same time they will receive verbal instructions on oral hygiene
223947538|NCT00951691|BEHAVIORAL|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
223721219|NCT05168527|DRUG|Fruquintinib,Albumin Paclitaxel,Gemcitabine|The study will mainly explore the safety and tolerability of fixed-dose level of Fruquintinib (4 mg, continuous medication for 3 weeks and withdrawal for 1 week) combined with fixed-dose level of albumin paclitaxel and gemcitabine. The fixed dose of Fruquintinib is 4 mg, with a treatment cycle every 28 days. A 28-day observation window was used to explore the side effects of fruquintinib in the combined treatment of pancreatic cancer patients with liver metastases. Evaluable patients will be assessed for DLT within 28 days after the first administration of the study drug. The 24 patients enrolled in the follow-up group will mainly evaluate the initial efficacy of furquintinib combined with albumin paclitaxel and gemcitabine as the first-line standard treatment for patients with metastatic pancreatic cancer.
223721220|NCT04007718|BEHAVIORAL|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
223947539|NCT00951691|BEHAVIORAL|Treatment as usual|Standard treatment with physical and occupational therapies
223947540|NCT01194011|BEHAVIORAL|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
223947541|NCT00352599|DRUG|Lovastatin|
223947542|NCT00352599|DRUG|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
223947543|NCT00352599|DRUG|placebo pill|
223947544|NCT02727205|DRUG|Rotigotine Transdermal System|
223947545|NCT04334005|DIETARY_SUPPLEMENT|Vitamin D|The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
223947546|NCT02848105|DRUG|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
223947547|NCT05070559|OTHER|Active Release Technique|"Patients in this group will receive Active Release Technique along with conventional therapy. ART will be given with patient seated, elbow flexed and resting on the treatment table, forearm in midprone \& wrist in neutral position and then the therapist will work on the common extensor tendon by applying pressure to the tendon distal to their attachment at the elbow. The patient will start with the elbow bent and wrist straight. As the therapist hold the muscles, the patient will extend the elbow and pronate and flex the wrist while the therapist move the pressure proximally, attempting to release adhesions around and between muscle planes. Total of 15 repetitions for of 10 minutes.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
223947548|NCT05070559|OTHER|Graston Technique Group|"Patients in this group will receive IASTM along with conventional therapy. In graston technique proper application of GT3 which include application of a cream to the common extensor tendon. The GT3will be then used to common extensor tendon. In areas of increased tissue restriction, more required pressure with GT3 is applied using increased force and shorter strokes over the areas of restriction. Ice will be offered as needed for pain management after each session.~The study includes interventional protocol of 4 weeks. The sessions will be given 3 times a week for 4 weeks.~CONVENTIONAL THERAPY:~* Hot pack for 15 minutes~* TENS for 15 minutes~* Ultrasound (pulsed mode, 1MHz at 1.5 W/cm2 for 5 minutes)"
223947549|NCT03449771|OTHER|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
223947550|NCT05734690|DRUG|SGLT2i, beta blocker, ARNI, MRA, MTD|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
223947551|NCT05734690|BEHAVIORAL|Education-First|For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
223947552|NCT00140400|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
223947553|NCT03483649|DRUG|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
223947554|NCT03483649|DRUG|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
223947555|NCT03483649|DRUG|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
223947556|NCT03483649|DRUG|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
223947557|NCT04142255|BIOLOGICAL|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
223947558|NCT00968903|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
223947559|NCT00973999|DRUG|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
223947560|NCT02337114|BEHAVIORAL|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
223947561|NCT02337114|BEHAVIORAL|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
223947562|NCT02101138|DRUG|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
223947563|NCT00968695|DRUG|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
223947564|NCT01670474|DRUG|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
223721221|NCT03059602|OTHER|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
223721222|NCT01626391|DRUG|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
223721223|NCT01626391|DRUG|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
223721224|NCT02624908|DRUG|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
223721225|NCT02624908|DRUG|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
223947565|NCT01670474|DRUG|rt-PA|At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
223947566|NCT04841057|PROCEDURE|50 cm BP limb length|50 cm biliopancreatic limb length
224100630|NCT04098601|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
224100631|NCT04163809|DEVICE|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
223947567|NCT04841057|PROCEDURE|100 cm BP limb length|100 cm biliopancreatic limb length
223947568|NCT04841057|PROCEDURE|150 cm BP limb length|150 cm BP limb length
223947569|NCT00446368|DRUG|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
223947570|NCT05912049|DRUG|9MW3811 Injection|Single dose intravenously infused on day 1
223536482|NCT06637098|BEHAVIORAL|Gastrostomy feeding|Feeding begins through the gastrostomy tube. A registered dietitian will develop a tailored feeding plan, specifying the type and amount of nutrition. Healthcare providers regularly monitor the patient's tolerance to feeding, checking for any signs of complications. Adjustments to the feeding regimen may be made based on the patient's progress and nutritional needs.
223536483|NCT02304159|DRUG|daclatasvir|
223536484|NCT02304159|DRUG|Sofosbuvir, Sovaldi|
223536485|NCT02304159|DRUG|Ribavirin|
223536486|NCT00584857|DRUG|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
223536487|NCT02789982|DRUG|β-adrenergic blocker propranolol|
223536488|NCT02789982|BEHAVIORAL|Treatment as usual|
223536489|NCT03767881|DEVICE|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
223536490|NCT04201535|DIAGNOSTIC_TEST|Protein arrays on plasma samples|Protein arrays on plasma samples obtained from RA, OA patients and controls will be performed to identify a panel of acute phase proteins, cytokines and chemokines present at systemic levels and to highlight analogies and differences in the systemic protein profile.The synovial fluid will be used to identify through high-throughput MudPIT the proteins present in the synovial fluid of RA and OA patients.
223536491|NCT03278522|DRUG|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
223536492|NCT04366856|BEHAVIORAL|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
223947571|NCT05912049|DRUG|Placebo|Single dose of matching placebo intravenously infused on day 1
223947572|NCT01412606|PROCEDURE|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
223947573|NCT03295409|BEHAVIORAL|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
223947574|NCT05605132|OTHER|Proprioceptive Training Exercise|"oculomotor exercises will be applied to the participants three times a week for four weeks.~oculomotor exercises:~* head relocation~* gaze stability~* eye follow~* saccadic eye movement~* head and eye coordination"
223947575|NCT05605132|OTHER|Tactile Acuity Training|Participants will be requested to lie face down. Five points will be marked in the painful areas on the right and left sides of the neck. The distance between the points will equal the two-point discrimination value. A photograph of the neck will be taken. The patient will not see his/her own neck during the application but see the photograph of his/her neck. The points will be touched lightly with two different stimuli (a pen with a 2 mm diameter and a mushroom probe with an 11 mm diameter). Participants will be asked about the location and type of the stimuli. The interstimulus interval will be 15 seconds. If more than 90% of correct answers are obtained, the distance between the points will be reduced by 10%. The training will be performed in three separate blocks, a total of 72 stimuli (block duration = 6 minutes, rest time between blocks = 3 minutes, number of stimuli applied in each block = 24 stimuli). The treatment time will be 24 minutes.
223947576|NCT05605132|OTHER|Control Group|The participants will be evaluated two times at 4-week intervals. No intervention will be applied during the time frame.
223947577|NCT06152718|OTHER|Karisma|Use of regenerative capabilities of a new medical device focused on dermal redensification, induced by injections of single-strand alpha 1 collagen
223947578|NCT03932214|DEVICE|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
223947579|NCT01218594|DRUG|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
223947580|NCT02305498|OTHER|Vigorous yoga practice|
223947581|NCT02305498|OTHER|Restorative (gentle) yoga practice|
224122652|NCT03960710|OTHER|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~\- Carried out by an intern at the Lyon hospitals"
223536493|NCT04366856|BEHAVIORAL|2: No instruction regarding positioning|group with no instruction regarding positioning (control group)
223536494|NCT00766519|OTHER|volume optimization|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  \+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is \> 10%"
223536495|NCT00766519|OTHER|standard volume administration|"Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
223536496|NCT05747248|DEVICE|Ultrasonography|Tracheal, diaphragmatic and lung ultrasonography
223536497|NCT06010680|DRUG|[14C]SHR2554|Patients will receive single dose of orally \[14C\]SHR2554 on Day 1.
223536498|NCT04548206|OTHER|Pilates training|The program consisted of core-based Pilates exercises on the mat for 60 minutes.
223536499|NCT04548206|OTHER|control|The program consisted of progressive relaxation exercises at home.
223536500|NCT05884372|DRUG|Eldecalcitol|the same as arm descriptions.
223536501|NCT05884372|DRUG|Native Vitamin D|the same as arm descriptions.
223536502|NCT05884372|DRUG|Denosumab|the same as arm descriptions.
223536503|NCT05884372|DRUG|Calcium|the same as arm descriptions.
223536504|NCT01384318|OTHER|Manometer|Measuring cuff pressure
223536505|NCT01158859|DRUG|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
223536506|NCT01484652|DRUG|COV795|2 tablets taken every 12 hours
223536507|NCT01484652|DRUG|Placebo|2 tablets taken every 12 hours
223536508|NCT05973162|OTHER|Virtual Realty Training|"They would be receiving treatment as follow:~Virtual Reality is a technology that aims to completely immerse the user inside the computer generated world, giving the impression to the user that they have stepped inside the synthetic world. RA mobile phone , head mounted display (HMD) will be used and videos of patient's interest will be played on phone which will create a 3D world around the patient.~And while watching conventional physical therapy will be performed side by side.~Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
223536509|NCT05973162|OTHER|Transverse friction massage (TFM)|"They would be receiving treatment as follow:~Transverse friction massage (Soft tissue mobilization technique) on the surrounding burn region for 5-10min in intervals. Frequency: 3 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 10 mins Conventional PT including range of motion exercises of elbow region including flexion, extension, supination, pronation, stretching and strengthening exercises of elbow muscles. Frequency: 10 reps with 5 sec hold for 3 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins Type: Strengthening Exercises"
223536510|NCT00654537|DRUG|Rosuvastatin|
223536511|NCT00654537|DRUG|Atorvastatin|
223536512|NCT00654537|DRUG|Pravastatin|
223536513|NCT00654537|DRUG|Simvastatin|
223536514|NCT02552576|BIOLOGICAL|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
223536515|NCT03134326|DEVICE|R1-25 and R2-25 Pulse Oximeter Sensor|
223536516|NCT04750161|OTHER|No intervention|No intervention will be given to participants. It is purely observational.
223536517|NCT04207320|DEVICE|αβ+ T-cell depletion with Miltenyi CliniMACS system|Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.
223947582|NCT02955966|DEVICE|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
223947583|NCT02955966|BIOLOGICAL|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
223947584|NCT01597674|DRUG|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
223947585|NCT02562274|DIETARY_SUPPLEMENT|Placebo|Subjects are received placebo treatments once daily for 8 weeks
223947586|NCT02562274|DIETARY_SUPPLEMENT|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
223947587|NCT02562274|DIETARY_SUPPLEMENT|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
223947588|NCT06151340|OTHER|Data collection|Data collection
223947589|NCT02516709|RADIATION|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
223947590|NCT05594732|BEHAVIORAL|Weak outdoor light|Stay and stare far on the balcony or under the tree
223947591|NCT05594732|BEHAVIORAL|Strong outdoor light|Stay and stare far in the sunlight
224100632|NCT06044285|OTHER|Low UP (meals provided)|"This study incorporates within- and between-subject comparisons. All participants complete a series of three in-lab visits with remote data collection:~Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Food is provided by the study team for 7 days in accordance with a low UP diet.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
224100633|NCT06044285|OTHER|Low UP (self-guided)|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat a low UP diet according to study provided nutritional guidance.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
224100634|NCT06044285|OTHER|Active Control|"Visit 1 and the following week comprise the baseline assessment period.~Visit 2 and the following week comprise the dietary intervention period. Participants are asked to eat as they normally do.~Visit 3 assesses post-dietary intervention outcomes. All participants will complete remote assessments at 1 month and 3 month follow-up."
224100635|NCT03020186|OTHER|Physical activity|
224100636|NCT03020186|OTHER|Physical activity+ MED diet|
223536518|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
223536519|NCT01644435|BIOLOGICAL|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
223947592|NCT01959958|OTHER|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
223947593|NCT06287957|PROCEDURE|Labrida BioClean|Debriding the tissue around the implant with Labrida Bioclean
223536520|NCT06256055|BIOLOGICAL|UCMYM802 Injection|1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
223536521|NCT02915497|BEHAVIORAL|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
223536522|NCT06396936|OTHER|Calisthenic exercise program|Calisthenic exercises to be applied in our study; These are exercises that are performed by creating resistance only with your body weight, without the need for any equipment or gym.
223536523|NCT05321563|BEHAVIORAL|iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment)|iDECIDE is a 4 session curriculum that addresses topics such as the neurobiology of substance use, adolescent brain development, industry tactics, motivations for using substances, risk and protective factors, triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. Facilitators are selected by schools and community agencies to receive free trainings conducted by the iDECIDE team, which includes personnel from the Massachusetts Department of Public Health, Massachusetts General Hospital (MGH) Center for Addiction Medicine, and the Institute for Health and Recovery.
223536524|NCT06384170|DEVICE|Spinal Cord Stimulation- Closed loop|This is a percutaneously placed epidural electrode that is connected to a battery-powered impulse generator for power. The electrical delivery is monitored in real-time with the measurement of evoked compound action potentials and adjusted to provide titration of therapeutic stimulation delivery.
223947594|NCT06287957|PROCEDURE|EMS Handy 3.0 Perio Premium|Debriding the tissue around the implant with Air-Flow Device
224100637|NCT03020186|OTHER|Physical activity+green MED diet|\*\*\*\*Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
224100638|NCT00452621|PROCEDURE|blood draw|
224100639|NCT05076422|DRUG|BI 3006337|BI 3006337
224100640|NCT05076422|DRUG|Placebo|Placebo
224100641|NCT03008551|DRUG|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
224100642|NCT03008551|DRUG|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
224100643|NCT00188448|DEVICE|MRI|
223536525|NCT05622578|OTHER|QST, CPM and Paisudoscan|Quantified pain tests
223536526|NCT01006395|DRUG|Zoledronic acid|yearly infusion
223536527|NCT01006395|DRUG|Placebo|yearly infusion
224122653|NCT03960710|OTHER|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~\- Carried out by the neural network"
223721226|NCT04394260|BEHAVIORAL|Savvy Caregiver Program via Remote Learning|The SCP program is comprised of four pre-recorded Savvy Caregiver videos (each 1 hour and 45 minutes in length). Course material was designed to provide informal caregivers with the knowledge, skills, and attitude needed to carry out their role as a caregiver for a person living with dementia (PLWD). Course learning objectives include: 1) introduction to dementing disorder; 2) caregiver self-care; 3) the anchors of enjoyable involvement; 4) levels of thinking and performance; 5) strengthening the family as a resource for caregiving; and 6) review and integration of the previous sections.
223721227|NCT04394260|BEHAVIORAL|Focus group|After watching the Savvy Caregiver videos participants will take part in a focus group to discuss their experience with the SCP and how the course material applies to them as a LGBT caregiver. The semi-structured discussion will include, but not be limited to the following questions: 1) Can you tell me about your role as a caregiver? (Probes: living situation, experiences, challenges). 2) What went well with the SCP, and what could be improved? 3) How relevant to your situation as an LGBT caregiver were the course materials? 4) How well did the questionnaire reflect your experiences with discrimination due to sexual orientation and/or gender identity? (Probe about when working with your care recipient's health care providers, in-home aides/visiting nurses, adult day care staff, respite, etc? 5) What are some of the additional caregiver challenges that should be considered in these questionnaires? (Probes: mental health, physical health, and social life strain, Quality of life, stress).
223721228|NCT06279962|OTHER|Survey questionnaire|The intervention is being assigned to one of the 8 different versions of the survey vignette.
223721229|NCT00420927|BIOLOGICAL|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
223947595|NCT04748341|OTHER|Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)|"The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed."
223721230|NCT00420927|DRUG|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
223721231|NCT00420927|BIOLOGICAL|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
223721232|NCT03032146|PROCEDURE|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
223721233|NCT00320411|DRUG|lapatinib|Lapatinib 1500mg QD
223947596|NCT04748341|OTHER|Traditional Method|"The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins"
223947597|NCT00258609|DRUG|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
223947598|NCT03530631|DRUG|Adderall|Participants will be administered Adderall
223947599|NCT03530631|DRUG|Placebo|Participants will be administered placebo
223947600|NCT05407272|OTHER|Health Education Manual|A health education manual based on a shared model
223947601|NCT05407272|OTHER|manual|routine care
223947602|NCT05913349|BEHAVIORAL|Group Cognitive Behavioral Therapy (GCBT)|Group cognitive behavioral therapy can achieve its therapeutic effect by enhancing emotion regulation and cognitive control, and by improving the activation patterns of the brain's internal networks to promote self-regulation. This can help individuals better manage emotional fluctuations in daily life, resulting in further improvement of depressive and anxious symptoms.
223947603|NCT05895578|DIETARY_SUPPLEMENT|Probiotic|1 capsule of probiotic (Lactobacillus CECT 9422 + Bifidobacterium CECT 30257) every 12 hours for 6-months.
223947604|NCT05895578|DIETARY_SUPPLEMENT|Probiotic + placebo|1 capsule of probiotic + 1 capsule of placebo per day for 6-months.
223947605|NCT05895578|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo every 12 hours for 6-months.
223947606|NCT00708266|DEVICE|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
223947607|NCT00708266|DIETARY_SUPPLEMENT|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
223947608|NCT00708266|OTHER|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
223947609|NCT00452114|DEVICE|In-Exsufflator Cough Assist Device|
223947610|NCT00452114|DEVICE|Active Comparator: Flutter Valve Device|Active Comparator
223947611|NCT06156176|OTHER|COVIDEx|The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
223947612|NCT02334215|DRUG|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
223947613|NCT02334215|BEHAVIORAL|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
223947614|NCT02334215|BEHAVIORAL|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
223721234|NCT01348503|DRUG|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
223721235|NCT01348503|DRUG|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
223721236|NCT03233503|DIAGNOSTIC_TEST|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
223721237|NCT00081640|DRUG|PRO 2000/5 Gel (P)|
223721238|NCT01094223|BEHAVIORAL|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
223947615|NCT00848289|BEHAVIORAL|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
223721239|NCT01094223|BEHAVIORAL|Health Education|Psychoeducation group focused on various topics pertaining to physical health
223721240|NCT01786044|BEHAVIORAL|MasterMed|An online interactive educational program
223721241|NCT01786044|BEHAVIORAL|Usual Care|
223721242|NCT05484622|DRUG|Vorasidenib|Administered orally as tablets.
223947616|NCT06988774|PROCEDURE|chromopertubation|Pre- and post-myomectomy chromopertubation procedure using dilute methylene blue dye solution for evaluation of tubal occlusion
223947617|NCT06992076|DRUG|Marstacimab|the first visit (V1) is scheduled on the day of the first administration of marstacimab. The recommended dosing frequency for the patient should follow the instructions provided, which are as follows: On Day 1, administer 300 mg subcutaneously (divided into two injections, each 150 mg) (loading dose); starting from Day 8, administer 150 mg subcutaneously once a week. Record the patient's prescription recommendations, actual treatment records (administration time, dosage, frequency), and adherence rates. Visit 2 (V2) and visit 3 (V3) are defined as 30 days (±7 days) and 180 days (±30 days) after the initiation of marstacimab treatment, respectively.
223721243|NCT05484622|DRUG|Pembrolizumab|Administered as IV infusion.
223721244|NCT01220622|DRUG|Nimodipine|Administration of nimodipine 30mg tid for 6 months
223721245|NCT01220622|DRUG|Placebo|Administration of placebo 30mg tid for 6 months
223721246|NCT00089154|BIOLOGICAL|apolizumab|Given IV
223721247|NCT00089154|OTHER|laboratory biomarker analysis|Correlative studies
223721248|NCT00089154|OTHER|pharmacological study|Correlative studies
223947618|NCT05324085|BEHAVIORAL|High-intensity interval training|Supervised exercise intervention, three times a week for eight weeks.
223721249|NCT02088047|DEVICE|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
223721250|NCT04287816|OTHER|Zero hard-boiled egg at 0 h|No eggs will be consumed on test day along with spinach consumption
223721251|NCT04287816|OTHER|One hard-boiled egg at 0 h|One egg will be consumed on test day along with spinach consumption
223721252|NCT04287816|OTHER|Two hard-boiled eggs at 0 h|Two eggs will be consumed on test day along with spinach consumption
223721253|NCT04287816|OTHER|Three hard-boiled eggs at 0 h|Three eggs will be consumed on test day along with spinach consumption
223721254|NCT04287816|OTHER|One hard-boiled egg at 3 h|One egg will be consumed on test day three hours after spinach consumption
223721255|NCT04287816|OTHER|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Two eggs will be consumed on test day: one along with spinach consumption and the other one three hours after spinach consumption
223721256|NCT04287816|OTHER|Two egg whites at 0 h|Two egg whites will be consumed on test day along with spinach consumption
223721257|NCT04287816|OTHER|Vegetable oil at 0 h|9.6 grams of Vegetable oil will be consumed on test day along with spinach consumption
223721258|NCT01010490|PROCEDURE|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
223721259|NCT01010490|PROCEDURE|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
224100644|NCT00292773|PROCEDURE|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
223721260|NCT01010490|PROCEDURE|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
223721261|NCT05660551|OTHER|Demostration|This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.
223947619|NCT05324085|BEHAVIORAL|Treatment as usual|The content of TAU is broadly individualized but most often includes various forms of group therapy, psychotherapy, psychoeducation and physical activity. The physical activity schedule for the patients typically includes gym-based exercises, individualized by preference of each patient, and various outdoors activities, four times per week all together.
224100645|NCT01936246|DIETARY_SUPPLEMENT|Increased protein|
223536528|NCT03350464|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
223536529|NCT02287779|DRUG|SHP626|
223721262|NCT05660551|OTHER|Telesimulation|After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.
223721263|NCT05660551|OTHER|Kahoot Game|Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
223721264|NCT04089384|OTHER|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
223721265|NCT04089384|OTHER|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
224100646|NCT00886821|BIOLOGICAL|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
224100647|NCT04177654|DRUG|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
223721266|NCT04089384|OTHER|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
223721267|NCT04774640|DEVICE|MaterniT GENOME|
223721268|NCT05148052|DEVICE|Virtual reality exergames|Twelve sessions of virtual reality exergames involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
223721269|NCT05148052|BEHAVIORAL|Conventional occupational therapy|Conventional occupational therapy involving upper extremities will be conducted. Each session is 30 minutes and will be held 3 times a week. The washout period between the two types of interventions is 2 weeks.
223721270|NCT04704921|GENETIC|ABBV-RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
223721271|NCT04704921|GENETIC|ABBV-RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
223721272|NCT04704921|BIOLOGICAL|Ranibizumab (LUCENTIS®)|0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
223721273|NCT00265798|DRUG|Sorafenib Tosylate|
223721274|NCT05517083|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject with NSCLC will undergo bronchooscopic procedure. First, ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Then, intratumoral washing is performed. Subsequently, transbronchial lung biopsy is performed under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance.
223721275|NCT05637710|DRUG|Administration of investigation of Eurofarma drug|Participants randomized to this group will receive one (01) film-coated tablet of the investigational drug + one (01) levocetirizine placebo tablet, once a day, for seven (07) days.
223536530|NCT02287779|DRUG|Placebo|
223536531|NCT01936558|OTHER|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
223536532|NCT01958749|PROCEDURE|Fat graft with Platelet Rich Plasma|
223536533|NCT01150032|OTHER|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~* hip and wrist Dual energy X-ray Absorptiometry (DXA)~* wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~* hip Quantitative Computed Tomography (QCT)~* High Resolution Digital X-Ray of calcaneum using BMA(tm) system~* low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
223721276|NCT05637710|DRUG|Administration of Comparator|Participants randomized to this group will receive one (01) levocetirizine 5mg tablet (Zina® 5mg) + one (01) FDC placebo tablet, once daily, for seven (07) days.
223721277|NCT04015622|DRUG|Enzalutamide|Enzalutamide 160 mg PO OD
223721278|NCT04015622|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks
223721279|NCT05618652|BEHAVIORAL|Equity Focused and Trauma-Informed Communication Intervention|Clinician communication intervention that includes didactic training and real-time feedback on communication behaviors during clinical encounters.
223721280|NCT05765266|DEVICE|ACP Max™|Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
223721281|NCT05765266|DEVICE|Depo-Medrol®|Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
224100648|NCT06097936|DIAGNOSTIC_TEST|HPV-ASSOCIATED OROPHARYNGEAL CANCER|The study involves the coexistence of a retrospective part, in which a group of patients with HPV-associated OPC for whom follow-up data of at least 2 years after diagnosis are available, designed in order to evaluate the expression of HPV16-specific E5 transcript as well as that of pEGFR and HLA, and a multicenter prospective part, involving the enrollment of a control group, enrolled at the ENT outpatient clinic of the IRE and the outpatient clinics of the relevant LILT provincial committees, to better elucidate the role of HPV16-E5 in identifying potentially transforming infections due to the presence of HPV.
223536534|NCT06266546|DRUG|Tranexamic acid|Prophylactic tranexamic acid will be instilled via endobronchial route in all patients undergoing transbronchial cryobiopsy. The medication will be administered through the bronchoscope one minute prior to the cryobiopsy. 500 mg of TXA diluted in 10 ml of saline and the procedure would be carried out as usual.
223536535|NCT04900298|DEVICE|SafeHaven Automated Hand Hygiene Device|Anesthesia providers in the intervention arm will be given a personal hand hygiene device, containing 64% ethyl alcohol, which provides actionable real-time performance feedback. The personalized device will be affixed to the provider's waist and will remain there for use throughout the perioperative period. Performance feedback is given to the anesthesia provider in real time with the number of personal hand hygiene events and an hourly hand hygiene rate, which is displayed on the device. Devices will be handed out to participating providers in the preoperative bay and retrieved in the post-anesthesia care unit upon case completion.
224100649|NCT05872425|DRUG|DingKunDan(GuangYuYuan)|"The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.~Subjects in the control group only needed to take COC. Both groups take medicine for 3 months consecutively as a course of treatment."
223536536|NCT05886478|DRUG|No intervention|As this is an observational study, no intervention will be administered.
223721282|NCT00725569|DRUG|Bellis perennis and Staphysagria (C6)|homeopathic remedy
223721283|NCT00725569|DRUG|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
223721284|NCT00725569|DRUG|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
223721285|NCT00316849|OTHER|pharmacological study|
223536537|NCT06564558|OTHER|Spinal Strengthening Exercises|Individuals in the experimental group will carry out 3 sets of 10 repetitions or what is tolerated within a Borg scale intensity of 4-5 with 70-80% of perceived exertion with appropriately picked elastic bands. The exercises include: Shoulder horizontal abduction; Shoulder elevation; Back Extensions over a plinth; Shoulder extension exercises; One arm and opposite leg lifts from quadruped; and finally bilateral arm lifts with upper thoracic extension from prone (superman exercise).
223536538|NCT06564558|OTHER|Thoracic Spine Stretching|Participants will be instructed to do two exercises: Firstly, to lay supine with and hinge the thoracic spine over a roller placed in a way that would ensure the patient is forward lying and not completely supine. The participant will be instructed to maintain hinging until a stretch or pressure feeling is felt in the midback and hold this position for 3 sets of 30 seconds. Secondly, the patient was asked to be in a seated position, clasp the hands together and behind the head while arching backward over the chair and looking up. This exercise will be done for 3 sets of 20-30 repetitions with a slight hold time at the end of the movement. All interventions will be carried out for 45 minute sessions 3 times per week.
223721286|NCT00316849|PROCEDURE|adjuvant therapy|
223721287|NCT00316849|RADIATION|3-dimensional conformal radiation therapy|
223947620|NCT06538090|BEHAVIORAL|Early Movers|The intervention includes: 1) an educational resource (i.e., hard-copy handout) developed for this study on the 24-Hour Movement Guidelines provided to parents at 2-month immunization appointments by public health nurses, who will answer any questions, followed by a discussion with research staff. 2) Follow-up support via access to a digital app with evidence-based information and support through an online toolkit, an anonymous forum, as well as weekly text messages that include tips and supportive messaging related to the guidelines.
223721288|NCT00316849|RADIATION|intensity-modulated radiation therapy|
223721289|NCT00316849|DRUG|temsirolimus|Given IV
223721290|NCT00316849|DRUG|temozolomide|Given orally
223721291|NCT01862900|BIOLOGICAL|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
223721292|NCT05810883|DIAGNOSTIC_TEST|Blood Tests; Serum Fasting Insulin and Glucose|"Laboratory results of blood samples, for high-density lipoprotein (HDL), low-density protein (LDL), triglycerides, and total cholesterol (TC) will be evaluated for this study. Fasting Insulin and fasting glucose levels will be used to calculate IR.~Insulin Resistance will be calculated using Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) (FPG (mmol/L) × FPI (mU/L)/22.5) \[21\] and defined as HOMA-IR ≥ 3.4"
223721293|NCT01666496|BEHAVIORAL|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
223721294|NCT01666496|BEHAVIORAL|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
223721295|NCT05680896|BIOLOGICAL|inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV|the protection of COVID-19 vaccines on breakthrough infection
223721296|NCT03721744|DRUG|GB201|GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
223721297|NCT03721744|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 will be administered intravenously starting on Day 1 of Cycle 1. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle
223947621|NCT06860295|DIAGNOSTIC_TEST|Single Cell RNA Sequencing|"Reprocessing~Data normalization, dimensionality reduction, and clustering will be performed using the Seurat package (based on R).~Cell types will be identified based on canonical marker gene expression. Cell Subpopulation Identification~Clusters will be annotated based on signatures of known cell types (e.g., endothelial cells, smooth muscle cells, macrophages, etc.).~Differential gene expression analysis will be conducted to identify disease-associated genes.~Pathway and Function Enrichment~Gene Set Enrichment Analysis (GSEA) and pathway analyses (e.g., KEGG, Reactome) will be carried out to investigate the biological processes and pathways driving atherosclerosis.~Quality Control~Sequencing reads will be assessed for quality using FASTQC, and low-quality reads will be filtered out.~The Cell Ranger software (10x Genomics) will be used to align reads to the human genome and quantify gene expression at the single-cell level."
224100650|NCT05872425|DRUG|Drospirenone and Ethinylestradiol Tablets (Ⅱ)|The experimental group and the control group would be given oral Drospirenone and Ethinylestradiol Tablets (Ⅱ). According to the packaging instructions, on the first day of menstruation, according to the packaging instructions, the subjects should take the tablet, then take the rest sequential at the same time every day for 28 consecutive days, menstruation would happen after drug withdrawal (or after 7 days of drug withdrawal), and the next medication cycle begin on the first day of menstruation.
223721298|NCT03721744|DRUG|Gemcitabine|Low-dose gemcitabine 600 mg/m\^2 will be administered intravenously following completion of paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle.
223721299|NCT03721744|OTHER|Standard of care treatment options|Patients will receive one of the standard of care treatment options assigned by the Investigator for each patient prior to starting protocol treatment, including Gemcitabine, capecitabine, 5-FU/LV, Onivyde plus 5-FU/LV (if Onivyde is available in the country/region) or best supportive care (BSC).
223947622|NCT06616779|DEVICE|GlucoTab|Insulin therapy will be started and adjusted according to the GlucoTab system with incorporated software algorithm. The goal of the basal insulin algorithm is to maintain blood glucose (BG) within acceptable targets according to the predefined health status. For a limited time period after therapy start, three BG measurements per day are suggested by the algorithm to determine blood glucose. Insulin dosage titration will be performed according to the algorithm in GlucoTab under supervision of the nurses of domiciliary nursing care. Correctional bolus insulin will be administered at defined time-points according to BG targets in the predefined health status. Nurses and nursing assistants will be trained in the use of the GlucoTab system.
223947623|NCT06616779|OTHER|Diabetes Treatment|Diabetes Standard Care
223947624|NCT06993155|DRUG|Leflutrozole, Dose 1|Leflutrozole, Dose 1 once weekly for 16 weeks
223721300|NCT00384566|DRUG|Carvedilol|anit hypertensive medication
223947625|NCT06993155|DRUG|Leflutrozole, Dose 2|Leflutrozole, Dose 2 once weekly for 16 weeks
223947626|NCT06993155|DRUG|Leflutrozole, Dose 3|Leflutrozole, Dose 3 once weekly for 16 weeks
223947627|NCT06993155|DRUG|Placebo|Placebo once weekly for 16 weeks
223947628|NCT06861660|BEHAVIORAL|Digitally Prompted Parenting|Parents will receive an email invitation to sign up for Digitally Prompted Parenting, a text message-delivered PBI. Parents set up an account and input information about themselves and their student, which will customize the text messages they receive. Parents will receive at least two text prompts per week for the first 10 weeks of their student's first semester in college. These texts will (1) prompt parents to call their student to discuss the past week and week ahead, and (2) prompt parents to send an alcohol-specific risk reducing text to their student.
224122654|NCT04372329|BEHAVIORAL|CPAP4HealthySleep system|Tailored multimedia messages and tailored feedback messages delivered via web-based system to participants' phones to motivate them to use their CPAP therapy
223721301|NCT00384566|DRUG|Metoprolol|Anti hypertensive medication
223721302|NCT02213367|DRUG|Bilastine|20mg (8 weeks)
223721303|NCT02213367|DRUG|Bilastine|40mg
223721304|NCT02213367|DRUG|Bilastin|80mg
223721305|NCT02366052|BEHAVIORAL|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
223721306|NCT02366052|DIETARY_SUPPLEMENT|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
223947629|NCT06861660|BEHAVIORAL|Active Control|Parents will receive an email that explains the Parent Handbook intervention and includes a link to a website where the Handbook is embedded. They will also receive three booster emails summarizing the key points of the intervention. Parents can review both the Parent Handbook and the booster emails at their own pace.
223721307|NCT02366052|OTHER|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
223947630|NCT07004179|BEHAVIORAL|Implementation strategy developed using the Implementation Mapping model to enhance the effective integration of the Protocol for Assistance to People with Diabetic Foot|"The intervention will be based on the Implementation Mapping methodology (IM). This model is based on the Intervention Mapping. IM consists of several specific tasks:~1. Conduct an assessment of needs and identification of programme adopters and implementers through a review of qualitative or mixed studies assessing the perceptions of both patients and professionals regarding DF prevention as well as individual semi-structured interviews with patients, health professionals and management staff~2. Indicate adoption and implementation outcomes and action objectives, identifying determinants and create matrices of change; this process will allow for the identification of determinants, which are those factors that influence the actions will be implemented~3. Select theoretical methods and select or design implementation strategies using the ERIC model (Expert Recommendations for Implementing Change)~4. Produce implementation protocols and materials~5. Evaluate implementation results"
223947631|NCT07004179|OTHER|Sham Comparator|Usual care: No systematic implementation of the protocol based on the prevention of foot at risk, ulcer treatment and screening of the risk of diabetic foot ulcer for referral to hospital care.
223947632|NCT07008014|OTHER|Magnetic Resonance Imaging|Participants will receive an additional MRI image in addition to standard of care to investigate if it was a useful imaging modality for their condition
223947633|NCT06067763|BEHAVIORAL|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
223947634|NCT06067763|BEHAVIORAL|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
223947635|NCT06067763|OTHER|The Weight of the Nation|This 2012 documentary discusses the facts and myths about obesity and the impacts of obesity on individuals and the health care system in the United States.
223947636|NCT07012460|DEVICE|CTI ablation|CTI ablation will be performed with PFA. Before ablation, The RA geometry will be created with a multipolar catheter. Coronary angiogram will be performed at baseline in LAO 45 degree before and after each set of ablations. After ablation, a 15-minute waiting period will be mandated. The CTI block will be rechecked with 3D mapping system and multipolar catheter. If there is persistent CTI conduction, ablation will be repeated until CTI block is achieved. This will be followed by another 15 minutes of waiting period before rechecking the block across CTI, and so on. TNG will be prepared. It will be given via intracoronary route in 100-200mcg bolus if severe spasm is observed. If CTI block cannot be achieved with repeated PFA ablation, ablation with radiofrequency will be allowed to achieve block. Patient will come back for follow up at 3 months for a remapping procedure. During the remapping procedure, a RCA coronary angiogram will be performed to exclude late coronary damage.
223947637|NCT07012980|DRUG|Glofitamab|Glofitamab will be administered i.v. on a step-up dosing schedule starting on Day 8 of Cycle 1 (2.5 mg), Day 15 of Cycle 1 (10 mg), followed by 30 mg on Day 1 of Cycles 2-6, with each cycle being 21 days. A single dose of obinutuzumab 1000 mg will be administered intravenously on Day 1 of Cycle 1.
223947638|NCT07012980|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin (1.8 mg/kg) will be administered intravenously on Day 2 of Cycle 1 and on Day 1 of the subsequent Cycle 2-6 (each Q3W).
223947639|NCT07012980|DRUG|Zanubrutinib|Zanubrutinib (160mg bid p.o.) will be administered for 7 days as pretreatment and from D1 to D21 through all 12 cycles Q3W.
223947640|NCT07012304|DRUG|Gecacitinib Hydrochloride Tablets|Gecacitinib hydrochloride tablets are taken orally on an empty stomach. The starting dose is 50 mg once daily (QD). The maximum dose is 100 mg twice daily (BID), and the minimum dose is 50 mg every other day (QOD). Dose adjustments should be made in 50-mg increments or decrements.
223947641|NCT07013695|DEVICE|Virtual reality headset|Patients in the intervention group receive a virtual reality session with a hypnotic purpose during surgery under regional anesthesia. The device consists of a virtual reality headset providing visual and auditory immersion in a calming environment, freely chosen by the patient. The session begins before the regional anesthesia is administered and may continue throughout the entire surgical procedure
223947642|NCT07013695|OTHER|Standard Care (in control arm)|Participants in this group receive standard anesthetic and surgical care without the use of virtual reality
223947643|NCT07013955|DRUG|Saline|Group I (Group C): (control group) Patients in this group will receive only 5 ml of intranasal saline.
223947644|NCT07013955|DRUG|Dexmedetomidine|Group II (Group D): Patients in this group will receive only intranasal Dexmedetomidine (1 mcg/kg) made up to 5 ml in normal saline.
223947645|NCT07013955|DRUG|Midazolam|Group III (Group M): Patients in this group will receive only intranasal midazolam (0.2 mg/kg) made up to 5 ml in normal saline.
223947646|NCT07013955|DRUG|Bupivacaine|Group IV (Group B): Patients in this group will receive only intranasal bupivacaine (0.5% solution) 5 ml.
223947647|NCT07013981|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
223947648|NCT07013981|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|
223947649|NCT07012720|DIAGNOSTIC_TEST|Single-cell sequencing and spatial transcriptome|Tumor tissue samples of all enrolled patients before and after neoadjuvant therapy were collected. Based on single-cell sequencing and spatial transcriptome technology, the transcriptomic differences in neoadjuvant therapy response or treatment resistance under the same treatment regimen, as well as the transcriptomic changes of tumor tissues before and after treatment were explored.
223947650|NCT07012837|DRUG|Placebo|Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Saline will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
223721308|NCT04425915|BIOLOGICAL|Convalescent Plasma|Dose-250 ml Frequency - 2 doses on consecutive days Duration -Start by day 3 of symptom onset (of severe COVID-19 as in inclusion criteria) in eligible patients
223721309|NCT04425915|OTHER|Standard of Care|The Ministry of Health and Family Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity which may be periodically updated. For the management of ARDS or sepsis the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented. (Ref: Guidelines on Clinical Management of COVID-19. MoHFW, GoI.2020.)
223721310|NCT01032837|DRUG|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
223721311|NCT01032837|DRUG|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
223721312|NCT01032837|DRUG|Placebo|Matching placebo provided as capsules and as a suspension.
223947651|NCT07012837|DRUG|Desmopresin|Before induction of anesthesia, patients will receive identical and similar clear study solutions in similar size transparent 50-cc bags, including Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr. The local pharmacists who will not be involved in patients' care or data collection will prepare the study solution.
223947652|NCT07013370|BIOLOGICAL|Anti-CMV immunoglobulins [Megalotect (R)]|Children received an anti-CMV immunoglobulin to prevent viral infections
223947653|NCT02359565|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
224100651|NCT00914628|GENETIC|HSV-Tk|Infusion of approximately 1±0.2 x 10\^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
224100652|NCT00914628|OTHER|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10\^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
223947654|NCT02359565|PROCEDURE|Conventional Magnetic Resonance Imaging|Undergo standard MRI
223721313|NCT00674245|DRUG|Pantoprazole|40 mg once daily for 4 weeks
223721314|NCT00674245|DRUG|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
223721315|NCT00674245|DRUG|placebo|40 mg once daily for 4 weeks
223721316|NCT00843024|DRUG|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
223947655|NCT02359565|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
223721317|NCT00843024|DRUG|Placebo|Placebo to match
223721318|NCT01741597|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
223721319|NCT01741597|OTHER|pharmacological study|Correlative studies
223721320|NCT01741597|BIOLOGICAL|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
223947656|NCT02359565|PROCEDURE|Diffusion Weighted Imaging|Undergo MR diffusion imaging
223947657|NCT02359565|PROCEDURE|Dynamic Contrast-enhanced MR Perfusion|Undergo DCE permeability MRI
223947658|NCT02359565|PROCEDURE|Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|Undergo DSC perfusion MRI
223947659|NCT02359565|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
223947660|NCT02359565|BIOLOGICAL|Pembrolizumab|Given IV
223947661|NCT07014124|BEHAVIORAL|Nicotine Replacement Therapy (NRT) Sampling|Participants will be advised to choose the NRT according to their preferences and daily cigarette consumption. Cigarette consumption of ≤20 daily will receive the 14mg patch or 2mg gum and participants consume \>20 cigarettes daily will receive the 21mg patch. An NRT use card (Appendix 6 draft) containing the instructions and potential side effects were given with a brief oral explanation. Full course of pharmacological treatment for 12-week are available in smoking cessation services. Participants requesting for additional or full course of NRT will be actively refer to the respective services as part of the Referral step in the AWARD model (Ask, Warn, Advise, Refer, and Do-it-again).
223947662|NCT07014124|BEHAVIORAL|mHealth-based motivational counselling|The mHealth intervention will be delivered via the most popular instant messaging app in Hong Kong (WhatsApp). A total of 24 messages with contents including the harms of smoking and smoke exposure for children, encouragement, benefits of quitting for children, methods of quitting, dealing with craving, and measures to reduce cigarette smoke exposure at home will be provided. The messages will be scheduled in a tapering schedule that participants will receive 5 messages in the first week, then cut down to 3 messages/week for the next 4 weeks and 1 message/week for the last 7 weeks. Using a more personalized approach, the messages will be tailored to the participants' motivation, intention to quit and other quitting patterns collected at baseline. Real-time conversations could be initiated by participants themselves, triggered by regular messages, or through prompt inquires (e.g., asking about the quitting progress).
223721321|NCT05948397|DIAGNOSTIC_TEST|Combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and quality of life scale|A combined version of International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) and quality of life scale would be given to all patients. The sum of the responses for the third, fourth and fifth questions and quality of life scale scores will be recorded.
223721322|NCT05948397|DIAGNOSTIC_TEST|Bladder diary|Bladder diary is an online application. Frequency, nocturia, functional bladder capacities will be reported. More than 8 urination during daytime will be recorded as overactive bladder. More than 1 interruption of sleep for urination at night is nocturia. Functional bladder capacity below 100 ml will be defined as decreased bladder capacity, while capacity over 400 ml will be reported as increased bladder capacity and compliance
223721323|NCT05948397|DIAGNOSTIC_TEST|Pad test|"One-hour pad test.~* the test is started by putting one pre-weighted pad without patient voiding, -patient drinks 500 ml of sodium-free liquid in \<15 min- then sits or rests,~* patient walks for 30 min, including climbing one flight of stairs (up and down),~* patient performs the following activities: standing up from sitting (10 ), coughing vigorously (10 ), running on the spot for 1 min, bending to pick up an object from the floor (5 ), and washing hands in running water for 1 min (this activity program may be modified according to the patient's physical fitness),~* the total amount of urine leaked is determined by weighing the pad. In the analysis of 1-hr pad test, an increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and \>50 g severe incontinence. The values for 24-hr pad test are classified as follows: Mild (4-20 g/ 24 hr), moderate (21-74 g/24 hr), and severe (\>75 g/24 hr) incontinence"
223947663|NCT07014124|BEHAVIORAL|Brief cessation advice and self-help material|At baseline, participants will receive brief face-to-face advice on quitting smoking for the health of the children using the validated AWARD model (Ask, Warn, Advise, Refer, Do-it-again) with a print-based self-help material providing detailed information on health hazards of SHS exposure on children, methods to deal with craving and withdrawal symptoms, and measures on preventing SHS exposure for children at home.
223947664|NCT06869915|DIAGNOSTIC_TEST|Prevalence (percentage) of ASD, ADHD and IDD in the studied population (homeless people sheltered in accommodation and social rehabilitation centers).|This study is an observational prospective multi-centric non interventional study. The focus of the study is a homeless population sheltered in accommodation and social rehabilitation centres. The prevalence of neurodevelopmental disorders in this population will be studied.
223947665|NCT03731221|DRUG|Bupi HCI and lipo bupi|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
223947666|NCT03731221|DRUG|Bupi HCI|The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
223947667|NCT03778554|DRUG|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
223947668|NCT03778554|DRUG|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
223721324|NCT02840500|OTHER|No intervention|No intervention
223947669|NCT03778554|DRUG|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
223947670|NCT03778554|DRUG|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
223947671|NCT07014306|DIAGNOSTIC_TEST|MRI|Cohort 2
223947672|NCT07014306|DIAGNOSTIC_TEST|Computed tomography|Quantitative computed tomography
223947673|NCT03905642|DRUG|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
223947674|NCT06164743|DRUG|VVN461 Ophthalmic Solution 1.0%|Topical ocular drug
223947675|NCT06164743|DRUG|VVN461 Ophthalmic Solution 0.5%|Topical ocular drug
223947676|NCT06164743|DRUG|Vehicle|Topical ocular drug
223947677|NCT06698419|DEVICE|RADA16 gel application into mastoid cavity|A single application of RADA16 gel will be applied along the surface of the mastoid cavity intraoperatively prior to insertion of gelatin sponge packing. Application will involve a thin layer of gel just enough to cover the entire surface of the cavity.
223947678|NCT06699368|PROCEDURE|The ultra-high-power ablation group|The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
223947679|NCT06699368|PROCEDURE|The high-power ablation group|The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.
223947680|NCT06698523|BEHAVIORAL|Breathing exercise|bubble blower used as play toys to facilitate the breathing exercise
223947681|NCT06698523|BEHAVIORAL|Deep breathing|pin wheel used as a play toy for achievement of breathing exercise
223947682|NCT06699108|DRUG|VGR-R01|Subretinal injection of VGR-R01 (0.1 mL)
223947683|NCT06699160|DEVICE|Revision arthroplasty|Hip or knee revision surgery resulting from aseptic loosening of the prosthesis and/or infection of the prosthesis by gentamicin and/or clindamycin sensitive strains.
223947684|NCT07042867|BIOLOGICAL|biobanking|blood draw at each time point
223947685|NCT07042867|RADIATION|low dose scan|low dose lung scan will be performed at each timepoint
223947686|NCT07042828|DRUG|Bilastine oral dispersible tablets|Bilastine 20 mg oral dispersible tablets
223947687|NCT07042828|DRUG|Bilaxten oral dispersible tablets|Bilaxten 20 mg oral dispersible tablets
223947688|NCT07043244|BEHAVIORAL|virtual reality simulation|no description, work attempt completed
223947689|NCT07044141|DRUG|Azathioprine|azathioprine 50mg twice daily will be given
224100653|NCT03624660|RADIATION|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
223947690|NCT07044141|DRUG|Tofacitinib|It is a janus kinase inhibitor
223721325|NCT04113005|DRUG|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
223947691|NCT05675059|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation and then biweekly follow-up visits (in-person or virtually) with a study dietician for 12 weeks.
223947692|NCT05675059|BEHAVIORAL|Daily Food Intake Diary with Fitbit Smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone app and wearing a Fitbit for 12 weeks.
223721326|NCT02643680|DEVICE|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
223947693|NCT05675059|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at 4, 8, 12 and 16 weeks.
223947694|NCT06410846|DEVICE|TopSpin360|Neck strength and conditioning device used during neck strengthening program.
223721327|NCT02643680|DEVICE|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
223721328|NCT03839979|DIAGNOSTIC_TEST|BIOLINE HCV kits|We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
223721329|NCT03839979|DIAGNOSTIC_TEST|ACCU-CHEK kits|For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
223721330|NCT03839979|DIAGNOSTIC_TEST|ErKameter 3000 mercury manometer|For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
223947695|NCT06410846|OTHER|Neck Strengthening Exercise Plan|Physical therapist designed neck strengthening program.
223947696|NCT06500988|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement a comprehensive digital atrial fibrilation guideline-recommended toolkit
223947697|NCT06547515|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
223947698|NCT06737809|DEVICE|IP Plasmafit® Revision cup (and stem) system|Revision total hip arthroplasty (THA) due to periprosthetic joint infection
223947699|NCT06736769|DRUG|Ketamine infusion|Ketamine will be delivered intravenously at 0.5 mg/kg over 40 minutes.
223947700|NCT07052799|DRUG|Aspirin 80mg|8-day (-5, +3) supply of aspirin 80mg before and after colonoscopy
223947701|NCT07052799|DRUG|Placebo Oral Tablet|8-day (-5, +3) supply of placebo before and after colonoscopy
223947702|NCT06754644|DRUG|QL2107|200mg on day 1 of each 21-day cycle of the study
223947703|NCT06754644|DRUG|Pemetrexed|500 mg/m2 on Day 1 of each 21-day cycle of the study
223947704|NCT06754644|DRUG|Carboplatin|Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles
223947705|NCT06754644|DRUG|Keytruda®|200mg on day 1 of each 21-day cycle of the study
223947706|NCT06897683|DRUG|PF-07220060|Single dose PF-07220060 tablet administered with a moderate-fat standard calorie meal
223947707|NCT06897683|DRUG|Carbamazepine ER Tablet|Carbamazepine dosing titration regimen in Period 2 from Day 1 to 18
223947708|NCT05004662|BEHAVIORAL|Smartphone-delivered automated treatment|An interactive smartphone-based intervention that comprises content delivered via audio/video clips and text content automatically each week to the participant
223947709|NCT05004662|DRUG|Nicotine patch|Participants will be provided with a 10-week supply of nicotine patches
223947710|NCT05004662|BEHAVIORAL|Counceling|Phone counseling with the Florida Quitline
223947711|NCT05004662|DRUG|Nicotine lozenge|Participants will be provided with a 10-week supply of nicotine lozenges
223947712|NCT06897046|DRUG|QL1706|PD-1/CTLA-4
223947713|NCT06897046|DRUG|QL1706+Carboplatin+Paclitaxel（Albumin-bound ）/ Pemetrexed|PD-1/CTLA4 combined chemotherapy drugs
223947714|NCT07063056|DIETARY_SUPPLEMENT|Curcumin (Longvida™)|1 capsule per day at a usual curcumin dose for this particular product (80 mg curcumin)
223947715|NCT07063056|DIETARY_SUPPLEMENT|Half Dose Curcumin (Longvida™)|1 capsule per day at half the usual curcumin dose for this particular product (40 mg curcumin as the half dose)
223947716|NCT07063056|DIETARY_SUPPLEMENT|Astaxanthin|1 capsule per day at a usual astaxanthin dose (12 mg)
223947717|NCT07063056|OTHER|Placebo Control|Subject will get 1 capsule per day of a small amount of cellulose
223721331|NCT01008488|DRUG|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
223721332|NCT00804544|DEVICE|SPECT/CT|SPECT/Low-Dose MultiSclice CT
223721333|NCT01218711|DRUG|Losartan Potassium and Hydrochlorothiazide Tablets|
223721334|NCT02801383|DRUG|Yallaferon®， the recombinant human interferon α-2b gel|
223947718|NCT05735496|DRUG|TQB2102 injection|TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
223947719|NCT05831605|PROCEDURE|venipuncture with near-infrared light|with near-infrared light to locate the veins
223947720|NCT07064226|OTHER|RICORDO|"During the RICORDO intervention, participants will engage in a multidomain cognitive telerehabilitation program using a digital platform (\[http://www.ricordo-dtx.com/\]), which allows for personalized interventions through an adaptive algorithm allowing an increment in task difficulties according to patients' needs. The treatment can be self-administered by the patient at home. The program lasts five weeks, with three treatment sessions per week, each lasting approximately 45 minutes.~The active control group (TAU) will undergo the same type of treatment with the following differences: the digital platform will not be used, as the treatment will consist solely of paper-and-pencil exercises; and there will be no personalization of the exercises, since automatic adaptation is not possible."
223947721|NCT07064226|OTHER|Treatment as Usual (TAU)|As described above, this type of intervention will consist in a multidomain cognitive rehabilitation treatment to be self administered by the participants at home with pencil paper excercises. Treatment will last 5 weeks, 3 sessions per week, each lasting approximately 45 minutes. The treatment will follow a predefined incremental difficulty structure since no personalization is available.
223947722|NCT06841640|DRUG|AERO-001|Open-label
223947723|NCT06841640|DRUG|AERO-002|Open-label
223947724|NCT06841640|DRUG|AERO-007|Double-blind
223947725|NCT03173950|DRUG|Nivolumab|Individuals will receive nivolumab at standard dose of 240 mg IV every 2 weeks for cycles 1 through 2, then doses of 480 mg every 4 weeks for a total of 14 additional doses
223947726|NCT05656248|DRUG|CPX-351|Given Intraveneously (IV)
223947727|NCT05656248|DRUG|MHA|Given Intrathecal (IT)
223947728|NCT05656248|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223721335|NCT02801383|OTHER|gel without active ingredient|
223721336|NCT01523262|PROCEDURE|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
223947729|NCT06416436|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1680 mg IV route every 4 weeks (1680 mg on Day 1 of each 28-day cycle), which is an approved dosage for atezolizumab, as outlined in the prescribing information.
223947730|NCT06416436|RADIATION|Stereotactic Ablative Radiotherapy (SBRT)|"Ultra-High Doses of Ablative Radiosurgery~SBRT is delivered to metastases over 3-5 fractions within 1-2 weeks"
223947731|NCT07090447|BEHAVIORAL|Nutrition in Cirrhosis guide|"Patients in the intervention group received a paper copy of the Nutrition in Cirrhosis guide and were instructed to read and use it over the 6 months study period. The Nutrition in Cirrhosis guide consists 7 chapters, namely:~Chapter 1: Malnutrition - What is it and why is it so important?; Chapter 2: What should patients eat and what to avoid?; Chapter 3: Tips for when patients do not feel like eating; Chapter 4: Recipe list; Chapter 5: Using meal supplements; Chapter 6: Managing weight loss and cirrhosis; Chapter 7: What to expect in the hospital."
223947732|NCT07098494|DIETARY_SUPPLEMENT|Saccharomyces Boulardii Probiotic Supplement|• Saccharomyces boulardii (strain CNCM I-745): 250 mg per day (5 billion colony-forming units (CFU)
223947733|NCT07099794|DRUG|Liposomal irinotecan+5-FU/LV+Lenvatinib|Liposomal irinotecan II: calculated as free base, 56.5 mg/m2, IV, d1q2w Renvastinib: ≥60kg, 12mg; \<60kg, 8mg, PO, once daily 5-FU: 1200 mg/ (m2·d) x2d continuous intravenous infusion for 46-48h, q2w LV: 400 mg/m2 intravenously, d1 q2w
223947734|NCT07099794|DRUG|NALIRI|Liposomal irinotecan II: calculated as free base, 56.5 mg/m2, IV, d1q2w 5-FU: 1200 mg/ (m2·d) x2d continuous intravenous infusion for 46-48h, q2w LV: 400 mg/m2 intravenously, d1 q2w
224100654|NCT03624660|RADIATION|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
224100655|NCT03359291|DRUG|Rosuvastatin|Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
223721337|NCT01523262|PROCEDURE|Normal surgery, with sham intervention without inflating arm cuff|
223721338|NCT00394368|DRUG|beclomethasone dipropionate plus formoterol fumarate combination|
223721339|NCT00394368|DRUG|fluticasone propionate plus salmeterol xinafoate combination|
223947735|NCT07099703|OTHER|Experimental|At Kırşehir Ahi Evran University, which is part of the Intervention Group, Ahilik education is a compulsory course within the current curriculum and will be taught over a period of 14 weeks. Ahilik education covers topics such as morality, etiquette, ethics, values, and professional ethics.
223947736|NCT07099703|OTHER|Routine education|They will continue with their current curriculum and will not receive any Ahilik training.
223947737|NCT07098208|BEHAVIORAL|Twin Heart Meditation|"Participants in this group receive the Twin Heart Meditation intervention, a guided meditative technique based on the principles of loving-kindness and spiritual energy. The intervention is designed to reduce exam-related anxiety by promoting inner peace and emotional regulation. The meditation protocol follows the steps conceptualized by Master Choa Kok Sui and includes the following components:~* Physical warm-up exercises~* Activation of the heart chakra~* Activation of the crown chakra~* Blessing the Earth with loving-kindness~* Silent meditation using the phrase Amen~* Expression of gratitude~* Closing exercises~Participants practice the meditation in three guided sessions over one week, each lasting 30 minutes, under the supervision of a trained instructor. Sessions are conducted in a quiet room with audio guidance and follow-up support."
223947738|NCT07100002|DEVICE|Control Group|Patients in this group did not receive any treatment to improve pain and sleep quality during the study period. Routine postoperative care was applied in the clinic.
223947739|NCT07100002|DEVICE|Earplug Group|Patients who met the inclusion criteria were fitted with standard earplug of the same brand by the researcher at night. The researcher applied the earplug from 01:00 AM to 05:00 AM. The reason for this is that the procedures performed on the patients within the clinical routine ended at 01:00 AM and the patients' uninterrupted sleep hours coincided with these hours.
223947740|NCT07100002|DEVICE|Eye mask Group|Patients who met the inclusion criteria were fitted with standard eye masks of the same brand by the researcher at night. The researcher applied the eye mask from 01:00 AM to 05:00 AM. The reason for this is that the procedures performed on the patients within the clinical routine ended at 01:00 AM and the patients' uninterrupted sleep hours coincided with these hours.
224100656|NCT03359291|DRUG|Macitentan|Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
224100657|NCT05581576|DRUG|Pitolisant|Pitolisant initial dose 8.9 mg, titrated depending on symptomatic response.
223721340|NCT04234178|DRUG|Epidural|2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
223947741|NCT07098975|DRUG|Pravastatin 40 mg|This study proposes administering a daily dose of 40 mg of pravastatin between 24 and 29.6 weeks of gestation to mothers diagnosed with preeclampsia and/or fetal growth restriction.
223947742|NCT07098975|OTHER|Placebo|A visually identical but inactive pill (a placebo),
223947743|NCT07098299|DRUG|Metformin|Metformin will be given for 14 days alone as a run in and then added to any standard of care chemotherapy or immunotherapy for solid tumors.
223947744|NCT07098442|BEHAVIORAL|Control Group|On the first clinical day, students had a 30-45 minute meeting with the patient they were responsible for, which included the instructor.
223947745|NCT07098442|BEHAVIORAL|Online Interview Group|"Before the Interview~* Preliminary briefings were given by providing a scenario for the standard patient to be interviewed.~* Students were given the Interview Guide, Nursing Process Case Example, and Tips for Conducting a Successful Interview documents and were asked to read them before the interview.~Interview~• Students conducted a 30-45 minute interview with a pre-determined standard patient.~After the Interview~* The instructor, who monitored the interview, debriefed the students.~* On the first clinical day after the intervention, students conducted a 30-45 minute interview with the patient they were responsible for, which included the instructor."
223947746|NCT07098442|BEHAVIORAL|Clinical Real Patient Group|"Before the Interview~* Patients who were willing to be interviewed in the clinic, stable, and physically and psychologically competent were selected, and the faculty member who would monitor the interview provided preliminary information about the interview.~* Students were provided with the Interview Guide, Nursing Process Case Example, and Tips for Conducting a Successful Interview documents and were asked to read them before the interview.~Interview~• Students conducted a 30-45 minute interview with a real patient in the pre-determined clinic.~After the Interview~* The faculty member who monitored the interview debriefed the students.~* On the first clinical day after the intervention, students had a 30-45 minute interview with the patient for whom they were responsible, which included the faculty member."
223947747|NCT07099859|DRUG|Losartan 50 mg|Losartan 50 mg per day
223947748|NCT07099859|DRUG|Placebo|Placebo 1 pill per day
223721341|NCT04234178|DRUG|Intrathecal+Epidural|10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
223721342|NCT01003288|BIOLOGICAL|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~\* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
223947749|NCT07098598|DEVICE|PET/CT|PET/CT with FAPI-74 tracer is performed.
223947750|NCT06668428|DEVICE|Virtual Reality Glasses|Pharmacological and non-pharmacological methods are applied in the management of pain and anxiety after cesarean section (Tetik \& Tekinemre, 2017). In addition to medical treatment during the post-cesarean care process, complementary and supportive non-pharmacological approaches can be used to address the woman holistically and provide multi-faceted contributions to the health of the mother and baby (Ali, 2022; Bayraktar, 2023). One of the non-pharmacological approaches, virtual reality glasses, is a device that provides two or three-dimensional environments to stimulate our senses by creating illusions of images (Appel et al., 2021). SGG creates a therapeutic effect by diverting attention, provides relaxation, and can thus be used in the management of pain and anxiety (Ayed et al., 2019). It has been determined that virtual reality glasses are an effective method in the management of pain and anxiety in the field of nursing (Akıncı \& Aydın Özkan, 2024).
224100658|NCT04720729|BIOLOGICAL|Chemotherapy monitoring by circulating tumor DNA analysis|"During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 \& L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2.~For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (\> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed."
224100659|NCT02823522|OTHER|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
223947751|NCT07100015|DEVICE|Control Group|in which patients did not receive any treatment and received routine postoperative care in the clinic
223947752|NCT07100015|DEVICE|therapeutic touch|Therapeutic touch applications
223947753|NCT07100015|DEVICE|Shoulder massage|shoulder massage was applied
223947754|NCT07098078|DRUG|Domperidone (drug)|The primary exposure of interest will be oral domperidone at a dose of 30 mg or more per day, which represents the median dose found in high-throughput computing analyses. For the primary comparison, oral domperidone at doses below 30 mg per day will be chosen to reduce the influence of indication bias.
223721343|NCT06321783|OTHER|Assessment|Evaluation of cervical proprioception, hand-eye coordination, postural control and endurance of cervical muscles
223721344|NCT00002105|DRUG|Doxorubicin hydrochloride (liposomal)|
223721345|NCT00002105|DRUG|Bleomycin sulfate|
223721346|NCT00002105|DRUG|Vincristine sulfate|
223721347|NCT01926236|OTHER|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
223721348|NCT01926236|DRUG|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
223721349|NCT01926236|DRUG|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
223721350|NCT01926236|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
223721351|NCT02941198|DEVICE|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
223721352|NCT02941198|DEVICE|Cu T380 A|Cu T380 A will be inserted into the uterus
223721353|NCT00450281|GENETIC|chromogenic in situ hybridization|
223947755|NCT07099261|OTHER|Crowns|"1. Tooth Preparation: Prepare the teeth to receive a zirconia crown.~2. Impression Taking: Obtain impressions using silicone.~3. Digital Conversion: Convert impressions into a digital model using a laboratory scanner.~4. Design Submission: Send the digital model to selected crown design program.~5. Crown Fabrication: crowns designed will be produced from PMMA using a milling unit.~6. Clinical Evaluation: Conduct a clinical assessment of the crowns~7. the best crown design will be milled from zirconia and delivered~Evaluation of Crowns designed by following metrics:~1. Marginal fit~2. proximal contact~3. Occlusion"
223947756|NCT07098936|DRUG|Momelotinib treatment|Patients included will receive momelotinib continuously until disease progression or loss of response, at physician's discretion.
223947757|NCT07097974|DIETARY_SUPPLEMENT|WM formula liquid drink|One glass jar (50 g) of the WM formula liquid drink was administered once daily, 1 hour prior to the first meal of the day.
223947758|NCT07097974|DIETARY_SUPPLEMENT|Placebo|One glass jar (50 g) of the placebo liquid drink was administered once daily, 1 hour prior to the first meal of the day.
223947759|NCT07099547|DRUG|ZG005|ZG005 20 mg/kg IV Q3W
223947760|NCT07099547|DRUG|Tislelizumab|Tislelizumab 200mg IV Q3W
223947761|NCT07099547|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 Q3W. Gemcitabine will be administered on D1/D8 in every three weeks cycle.
223947762|NCT07099547|DRUG|Cisplatin|Cisplatin 25mg/m\^2 Q3W. Cisplatin will be administered on D1/D8 in every three weeks cycle.
223947763|NCT07099833|OTHER|Azita Sadeghzade|Azita Sadeghzade
223947764|NCT07099287|BEHAVIORAL|TRANSform your health|A culturally adapted smoking cessation intervention for transgender and gender diverse individuals living in Argentina
223947765|NCT07099066|OTHER|sampling blood|3 types of sampling : urine, skin and blood.
223947766|NCT07098013|BEHAVIORAL|Relaxation Self-Coach|This intervention is a fully automated, unguided internet-based relaxation program in English. Unlike many digital mental health programs, it required no therapist involvement or incentives and was structured for real-world use. It combined evidence-based techniques-mindfulness, deep breathing, progressive muscle relaxation, guided imagery, and acceptance practices-delivered via audio modules. The program was tested in two formats: a 4-week daily format (28 sessions) and a revised 3-week modular format (21 sessions) with enhanced usability and adherence features, such as a simplified multimedia interface, reminder emails, and optional reflection prompts.
223947767|NCT06812975|OTHER|No intervention|This is an observational study
223947768|NCT07099417|DIAGNOSTIC_TEST|No intervention (observational study)|No intervention (observational study)
223947769|NCT07098195|DEVICE|Coronary Stent|RisoR Crest Everolimus Eluting Coronary Stent System
223721354|NCT00450281|GENETIC|gene expression analysis|
223721355|NCT00450281|GENETIC|mutation analysis|
223721356|NCT00450281|GENETIC|polymerase chain reaction|
223721357|NCT00450281|GENETIC|polymorphism analysis|
223721358|NCT00450281|OTHER|fluorescent antibody technique|
223721359|NCT00450281|OTHER|immunohistochemistry staining method|
223721360|NCT00450281|OTHER|laboratory biomarker analysis|
223721361|NCT00450281|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
223721362|NCT00450281|OTHER|study of socioeconomic and demographic variables|
223721363|NCT00450281|PROCEDURE|study of high risk factors|
223721364|NCT02920372|DRUG|EPOETIN ALFA|
223721365|NCT03727347|DEVICE|InSeca Stylus|Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
223721366|NCT05096897|OTHER|Self-administrated questionnaires|GOHAI, IBD-Q, IBD-disk
223721367|NCT03295812|OTHER|standard therapy|standard therapy,non-interventional study
223721368|NCT00585247|DRUG|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
223721369|NCT00585247|OTHER|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
223721370|NCT05829304|OTHER|MTA based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
223721371|NCT05829304|OTHER|Collagen based pulpotomy|The principal investigator will carry out all treatment procedures, and the patients will be assigned. It will be as split mouth, both groups A\&B will be at the same patient.
223721372|NCT04821115|DEVICE|Low intensity choc waves therapy (active applicator)|At each of the 4 sessions, 4000 shockwaves will be delivered at level 8 (EFD = 0.133 mJ/mm2), over a period of 15 to 20 minutes. The probe will be applied directly to the plaque, on the flaccid penis. The device will stop automatically after the 4000 shock waves.
223947770|NCT07098104|DRUG|Immunotherapy|The nICT group received PD-1 inhibitors (sintilimab 200mg, tislelizumab 200mg, or nivolumab 240mg, all iv q3w) combined with two-drug chemotherapy (SOX: oxaliplatin 130mg/m² d1 + S-1 40-60mg bid d1-14; or XELOX: oxaliplatin 130mg/m² d1 + capecitabine 1000mg/m² bid d1-14, both q3w). The nCT group included two subgroups: nCT2 (SOX/XELOX) and nCT3 (FLOT: docetaxel 50mg/m² + oxaliplatin 85mg/m² + leucovorin 200mg/m² d1 + fluorouracil 2600mg/m² 48h CIV q2w; or DCF: docetaxel 75mg/m² + cisplatin 75mg/m² d1 + fluorouracil 750mg/m² d1-5 q3w).
223947771|NCT07099573|RADIATION|Hyperthermia|Hyperthermia will be applied for a period of 15 to 20 minutes in the area to be treated, maintaining a thermal sensation of gentle heat for the patient and accompanied by active-assisted or passive mobilization of the structures adjacent to the bursa.
223947772|NCT07099573|OTHER|Physical Exercise|The therapeutic physical exercise will consist of 3 periods of isometric contraction of 30 seconds, with a rest period of 1 minute, varying the number of repetitions from 3 to 5 depending on the patient's symptoms.
223721373|NCT04821115|DEVICE|Sham (sham applicator)|At each of the 4 sessions, a sham applicator will be used. The sham applicator has an internal foam pad that disperses the shockwave energy, but is not visible from the outside. The sham applicator will look, feel and sound the same as the active, but no measurable energy is emitted.
223721374|NCT04835532|PROCEDURE|guided bone gereration|"guided bone generation: GBR is a procedure that uses barrier membranes with or without particulate bone grafts or/and bone substitutes.~tenting screws: Screws are implanted in the surgical area to prevent the barrier membrane from collapsing.~A-PRF/I-PRF: Obtained by autologous blood centrifugation."
223947773|NCT07099573|OTHER|Stretching|Stretching of the involved muscles will involve 3 periods of maximum tolerable stretching without pain, lasting 20 seconds and resting for 30 seconds.
223721375|NCT03290092|DRUG|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
223721376|NCT03290092|DRUG|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
223721377|NCT05654220|BEHAVIORAL|Text Messaging Intervention|A text messaging intervention will be conducted that includes prompts to call trained BenePhilly enrollment specialists to submit applications for benefits programs. Text message prompts will be sent on days 2, 4, 7, 14, and 21 post-discharge from a Penn Medicine emergency department.
223721378|NCT06268002|DIETARY_SUPPLEMENT|Vernonia cinerea|Vernonia cinerea is an herb that is claimed in many Thai medicinal formulas. In traditional medicines, they use this herbal to treat diseases such as hypertension, asthma, fever, hepatitis, gallstones, including use to help smoker quit smoking.
223947774|NCT03649724|DRUG|Placebo|Placebo (0.25 ml normal saline) will be administered subcutaneously once every twelve weeks for 48 weeks.
223947775|NCT03649724|DRUG|Eligard 22.5Mg Suspension for Injection|Eligard 22.5Mg Suspension for Injection will be administered subcutaneously, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
223947776|NCT06941337|BEHAVIORAL|HealthySteps (HS)|Evidence-based program that focuses on addressing Adverse Childhood Experiences (ACEs) and family stressors. The program provides parenting guidance, mental health support, and care coordination. The program is delivered during well-child visits by an HS specialist.
223947777|NCT06941337|BEHAVIORAL|PlayReadVIP|Evidence-based program that promotes Positive Childhood Experiences (PCEs) and strengthens parent-child interactions. The program involves recording and reviewing videos of parents engaging with their child to provide feedback and encourage positive practices. Families receive toys, books, and guides to extend activities at home.
223947778|NCT06945796|OTHER|ACT based eating disorder prevention program|"This intervention protocol was developed specifically for women who have body dissatisfaction and disordered eating behaviors. Based on the psychological flexibility model (hexaflex), it is designed to improve people's body image flexibility using Acceptance and Commitment Therapy techniques.~Interventions related to the dimensions of the hexaflex were made during each session. The first session covers values and goal setting. The second session includes creative hopelessness, acceptance, and self-compassion. The third session covers defusion and mindfulness. The last session focuses on self-as-context exercises and the combined use of skills for committed action."
223947779|NCT06147921|DRUG|Verasone|Administered by sinonasal irrigation.
223947780|NCT06943638|OTHER|Mild Exercise and stretches|For 15 minutes the patient received an individualized mild workout program intending to relax and relieve some of his stress. The workout includes deep breaths, easy-to-do exercises, and stretches from lying on the bed, sitting in a chair, or standing. I always followed the patient's tempo and provided him with as many breaks as he needed.
223947781|NCT04253457|DRUG|1ml of triamcinolone (40mg/1ml)|Single injection of 1ml of triamcinolone (40mg/1ml)
223721379|NCT06268002|DIETARY_SUPPLEMENT|Placebo|Sweetener
223721380|NCT00533598|DRUG|MK0557|
223947782|NCT06955286|DIAGNOSTIC_TEST|complete ACTH stimulation test the day after surgery|patients complete ACTH stimulation test on the one day after surgery
223947783|NCT06952023|PROCEDURE|Modified Maze ablation with PFA|Modified Maze ablation with PFA
223721381|NCT02837783|DRUG|Linaclotide|Oral, once daily
223721382|NCT02837783|DRUG|Placebo|Oral, one daily
223721383|NCT03409835|DRUG|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
223721384|NCT03409835|DRUG|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
223721385|NCT05759247|DEVICE|BORA Band (wristband)|Wristband collecting patient vital signs and activity
223947784|NCT06952023|PROCEDURE|PVI only with PFA|PVI only with PFA
223947785|NCT06951984|DIAGNOSTIC_TEST|11C/18F-HED|Each subject receive a single intravenous injection of 11C/18F-HED and undergo PET/CT or MRI imaging within the specificed time.
223947786|NCT06951568|OTHER|Physical Exercise Program|The physiotherapy protocol has been developed using the GMFCS scale as a reference. Based on this assessment, each patient's level is determined according to their functional motor abilities, limitations, and use of assistive or mobility devices. Each protocol consists of a total of five exercises: two general exercises and three specific exercises focused on the phases of the corresponding transfer and on skills common to all transfers. Rest periods of 2 minutes and 30 seconds are provided between exercises to ensure adequate recovery and a safe progression. The somatosensory stimulation will consist of intermittent mechanical pressure applied to the skin over the neuromuscular motor points of the quadriceps and gastrocnemius muscles. T
223947787|NCT06952231|DRUG|Sitagliptin + Metformin|Self administration of Sitagliptin (as phosphate monohydrate) 50 mg twice daily plus metformin HCl 1000 mg twice daily
223947788|NCT06952231|DRUG|Empagliflozin + Metformin|Self administration of Empagliflozin 12.5 mg twice daily plus metformin HCl 1000 mg twice daily.
223947789|NCT05552066|OTHER|Standard follow up|Patients enrolled into front phase will be followed in a standard way without any additional procedure except satisfaction questionnaire
223947790|NCT05552066|OTHER|short circuit|"Patients included in the post phase will have to complete the cem@santé application. If no contraindications are identified by the plateform with the remote PRO collection, patients will undergo chemotherapy directly the next day (without any medical validation)."
223721386|NCT06306781|DRUG|HCL001 cell (homologous allogeneic hepatocytes) injection|The patient will undergo a DSA procedure in the hospital's operating room before infusion. A catheter will be inserted into the femoral artery and guided to the hepatic artery. Upon confirmation through imaging, HCL001 cell injection will be slowly infused through the catheter. During the infusion, the cells should be continuously agitated to prevent clumping. The infusion can be administered as a single dose or multiple doses, and after infusion, the patient will be closely monitored for at least one week.
223721387|NCT03638297|DRUG|PD-1 antibody + cox inhibitor|"BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
224100660|NCT05117970|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
224100661|NCT04585685|BEHAVIORAL|Cognitive Processing Therapy|A 12-session cognitive behavioral therapy for posttraumatic stress disorder
223947791|NCT03895658|DEVICE|MRI|Structural and functional neuroimaging pre and post ECT treatment
223947792|NCT03895658|DEVICE|MagPro TMS stimulator and coil|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
223947793|NCT03895658|DEVICE|Thymatron (R) System IV paired with 4X1 HDECT|Multi-Channel Stimulation Interface (Model 4X1 HDECT)
224100662|NCT04585685|BEHAVIORAL|Self-Compassion Therapy|A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
224100663|NCT03311126|DRUG|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of chronic lymphocytic leukemia (CLL) and for indolent B cell non-Hodgkin lymphomas (NHLs) progressing during or within 6 months of rituximab or a rituximab - containing regimen.
223947794|NCT04313114|BEHAVIORAL|health literacy appropriate education and demonstration|If a patient chooses the Fecal Immunochemical Test (FIT), the Screening Coordinator (SC) will give the FIT kit, emphasize the necessity of annual completion, and distribute an additional plain language, literacy appropriate, actionable handout with simplified illustrated instructions on how to complete the test and mail to the central lab. The SC will review the handout and instructions with the patient and use the 'teach back' method to confirm understanding.
224100664|NCT03311126|DRUG|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 monoclonal antibody (mAb).
224100665|NCT00885443|DRUG|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
224100666|NCT00885443|DRUG|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
224100667|NCT00014742|DRUG|collagenase|
223721388|NCT01487200|DRUG|FX006 10 mg|single 3 mL IA injection
223721389|NCT01487200|DRUG|FX006 40 mg|single 3 mL IA injection
224100668|NCT03335124|DRUG|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
224100669|NCT03335124|DRUG|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
223721390|NCT01487200|DRUG|FX006 60 mg|single 3 mL IA injection
223721391|NCT01487200|DRUG|TCA IR 40|single 1 mL IA injection
223721392|NCT00920712|DRUG|Weiqi decotion|Decoction ,two times a day
223721393|NCT02158403|OTHER|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
223721394|NCT02186990|DRUG|propofol|2,5 mg/kg
223721395|NCT02186990|DRUG|etomidate|0,3 mg/kg
223721396|NCT02186990|DRUG|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
223947795|NCT04313114|BEHAVIORAL|shared decision making|Screening Coordinator (SC) will give patients a plain language, literacy appropriate, actionable printed CRC screening handout emphasizing the benefits of CRC screening and screening options; using the low literacy handout as a teaching tool, the SC will briefly counsel patients on CRC screening options prior to seeing their healthcare provider, reviewing the benefits of each, as well as applicable costs. After reviewing the CRC screening pamphlets with a patient, the SC will use shared decision-making techniques using the study CRC materials to aid patients in selecting the test they prefer and that meets their needs - colonoscopy or FIT.
223947796|NCT04313114|BEHAVIORAL|automated call reminders or automated texts|"Colonoscopy year 1: Will receive an automated call recording by PCP 48 hours after the clinic visit to remind them of their choice of colonoscopy; then, one week before the test reminding them to pick up the preparation kit. Those who chose SMS will receive a text message from their PCP with content similar to the voice call. A 3rd reminder call/text will be sent 2 days prior to the test. If no colonoscopy with 3 months, the clinical manager (CCM) will call to determine if they want to switch screening options. The CCM will discuss barriers and option of choosing FIT for 3 years. If they opt to change, they will be mailed a FIT with simplified instructions and then follow the FIT follow-up protocol.~FIT year 1: Motivational reminders recorded by their PCP will be sent by automated call or text within 48 hours after the visit and again at 4, 8 and 12 weeks for those who have NOT completed the test. FIT will be mailed year 2 \& 3 - follow-up will follow same procedure as year 1."
223947797|NCT03124212|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
223947798|NCT02421679|DRUG|TNX-102 SL|1x 2.8mg TNX-102 SL Sublingual tablet
223947799|NCT05133700|OTHER|Interview or focus group discussion|There is no intervention. This is a qualitative piece of work only
223947800|NCT05133700|OTHER|Review of submitted medicines audit tools|There is no intervention. This is a qualitative piece of work only
223947801|NCT04476199|COMBINATION_PRODUCT|Venetoclax and Decitabine|The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
223947802|NCT01458015|DRUG|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
223947803|NCT03616886|DRUG|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
223947804|NCT03616886|DRUG|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
223947805|NCT03616886|DRUG|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
223947806|NCT03616886|DRUG|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
223947807|NCT01953900|GENETIC|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10\^6 cells/m\^2~Dose Level 2: 1x10\^7 cells/m\^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10\^7 cells/m2~Dose Level 8: 1 x 10\^8 cells/m\^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10\^8 cells/m\^2~Dose Level 10: 5 x 10\^8 cells/m\^2~Dose Level 11: 1 x 10\^9 cells/m\^2~The previously planned dose levels 3-6 will not be studied."
223947808|NCT01953900|BIOLOGICAL|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
223947809|NCT01953900|DRUG|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
224100670|NCT03335124|DRUG|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
224100671|NCT03335124|DRUG|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
224100672|NCT01717846|DRUG|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
223721397|NCT03641443|DEVICE|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
223721398|NCT00040482|DRUG|Cyclophosphamide|
223721399|NCT00040482|DRUG|ATG|
223721400|NCT00040482|DRUG|MESNA|
223721401|NCT00040482|PROCEDURE|Radiation therapy|
223721402|NCT04013204|OTHER|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
223721403|NCT03072992|DRUG|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
223947810|NCT01953900|DRUG|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m\^2/day followed by Fludarabine 30 mg/m\^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
223947811|NCT02589106|DEVICE|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
223721404|NCT03072992|DRUG|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
223721405|NCT03072992|DRUG|Placebo|Placebo i.v. solution, once weekly for 12 weeks
223947812|NCT05509569|DRUG|Icatibant|Icatibant, 10 to 30 mg, Subcutaneous injection
223947813|NCT04180904|OTHER|Diet 1|Diet 1 will focus on which foods are eaten and the impact on disease outcomes.
223721406|NCT06505876|BEHAVIORAL|Basic treatment|including anti-infection therapy, blood pressure and blood glucose control
223721407|NCT06505876|DEVICE|Oral Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223947814|NCT04180904|OTHER|Diet 2|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
223947815|NCT05230784|OTHER|AirOk Air Purifier|The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.
223947816|NCT05230784|OTHER|Placebo Air Filter|Participants in the placebo arm will receive an air purifier with only the EGAPA filter.
223947817|NCT06434246|BEHAVIORAL|pulley system exercise regimen|The warm-up consists of gentle stretching and basic mobility exercises to prepare the muscles and joints for the activity. Following this, the main segment of the session involves specific exercises using the pulley system, designed to target and improve motor function, strength, and coordination of the upper limbs. The therapist will adjust the exercises according to each child's individual abilities and progression over time. The session concludes with a cool-down period involving light activities and relaxation techniques to ensure a gradual return to baseline physiological states.
223721408|NCT06505876|DEVICE|Nasogastric Tube Feeding|The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223721409|NCT00867724|DEVICE|Aer-O-Scope Colonoscopy|Screening Colonoscopy
223947818|NCT06434246|BIOLOGICAL|physical therapy program for CP|Participants in the control group will attend physical therapy sessions twice per week. These sessions aim to maintain or improve physical functioning and manage the symptoms of cerebral palsy. Each session lasts approximately 45 to 60 minutes, These sessions include a variety of therapeutic exercises tailored to each child's needs but do not include the use of the pulley system. Typical activities might involve stretching, strengthening exercises, and manual therapy techniques to enhance joint mobility and muscle function.
223947819|NCT02553616|BEHAVIORAL|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
223947820|NCT04596358|OTHER|Observational|Evaluation of adherence to the Mediterranean diet through the administration of the Med Diet Score questionnaire.
223947821|NCT04528147|BEHAVIORAL|Yi Jin Jing Tiger Roaring Speech Rehabilitation|A traditional Chinese medicine treatment
223947822|NCT04528147|BEHAVIORAL|Conventional Speech Rehabilitation|A active speech rehabilitation method recommended by the Parkinson's Foundation of America
223947823|NCT04614688|BEHAVIORAL|Patient Education Platform|The patient education platform for hysteroscopy surgery is a website platform which has patient education materials regarding hysteroscopy procedures in the format of pictures, videos, and text. Information on this platform includes anatomy of the surgery area, what to expect, reasons for the surgery, ways to prepare for the surgery, and recovering from the surgery.
223947824|NCT03477266|DRUG|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
223947825|NCT03477266|DRUG|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
223947826|NCT04751097|OTHER|CUSH Health Digital platform|Remote mobility monitoring and physiotherapy video app
223721410|NCT06242158|PROCEDURE|arthroscopic assisted mini-open 5 step repair|"First step Identifying the tear size , quality and if reducible on the foot print . minimal removal of the bursa and pulling of the tendon with a grasper to reach the foot print area with gentle mobilization of the tendon .~Step two Acromioplasty Using a probe, the LHBT was palpated and mobilized, looking for any signs of degeneration and fraying or instability . The LHBT was inspected either through the tear by the subacrominal portal or through the glenohumeral portal .~Step three Antero-lateral mini-open approach was used through a longitudinal 4 cm skin incision Step four Transosseous repair using the giant needle was used. 3 to 4 number two fiber wire sutures was passed equidistance through the tendon Step five The subarominal bursa was used for biological augmentation of the repair"
223721411|NCT01201005|DIETARY_SUPPLEMENT|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
223721412|NCT01201005|DIETARY_SUPPLEMENT|Sham injection|needle injection without any substance given
223721413|NCT01316796|DRUG|Sodium Nitrite Cream|
223721414|NCT02313792|DRUG|Palifermin|
224100673|NCT01717846|OTHER|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
224100674|NCT02641899|DRUG|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
224100675|NCT02641899|DRUG|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
223721415|NCT01239004|DRUG|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
223721416|NCT01239004|DRUG|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
223947827|NCT01160159|OTHER|Tests|Arterial parameters
223947828|NCT01160159|OTHER|Healthy volunteers|Arterial parameters and blood test
223947829|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
223947830|NCT03769090|COMBINATION_PRODUCT|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
223721417|NCT01910025|DRUG|ADI-PEG 20|
223721418|NCT02275468|DRUG|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
223721419|NCT00003997|DRUG|irofulven|
223947831|NCT03769090|DRUG|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
223947832|NCT03030365|DEVICE|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
223947833|NCT00837291|DRUG|CF101|CF101 tablets 1 mg BID
223947834|NCT00837291|DRUG|Placebo|Placebo tablets BID
223947835|NCT02806752|DRUG|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
223947836|NCT02806752|DRUG|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
223947837|NCT00329914|DRUG|Progesterone|Vaginal pessaries, 200 mg/day
223947838|NCT00329914|DRUG|Placebo|Placebo pessaries containing peanut oil
223947839|NCT01921985|DRUG|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
223947840|NCT01921985|DRUG|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
224100676|NCT02641899|DRUG|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
223721420|NCT02216591|DEVICE|Active Cognitive Training (ACT)|
223721421|NCT02216591|DEVICE|Control (CON)|
223721422|NCT04298801|PROCEDURE|Nurse-driven HIV screening for key populations combined with usual physician-directed diagnostic testing|"A self-administered questionnaire on HIV exposure factors will be offered to all patients of ages 18-64 able to complete it. This questionnaire will be available in a paper-based format, electronic format on the patient phone or can be conducted verbally by the nurse. According to the answers, the nurses will suggest performing a rapid test to patients belonging to key populations. A finger-stick rapid HIV test will be performed and results will be disclosed by the nurse assisted by a physician if necessary.~If needed, a follow-up visit with an infectious disease specialist will be scheduled within 72 hours."
223947841|NCT03878394|OTHER|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
224100677|NCT02641899|DRUG|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
224100678|NCT02641899|DRUG|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
224100679|NCT02641899|DRUG|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
224100680|NCT06387056|DRUG|Rezvilutamide|240mg by mouth once a day for 24 weeks.
224100681|NCT06387056|DRUG|Goserelin Microspheres for Injection|3.6mg by intramuscular injection once 4 weeks for 24 weeks.
224100682|NCT06387056|DRUG|Docetaxel|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
224100683|NCT06387056|DRUG|Pamiparib|60mg by mouth twice a day for 20 weeks.
223947842|NCT03878394|OTHER|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
223947843|NCT04808024|PROCEDURE|SelfMyofascial Release|Myofascial auto-release consisted of rolling the roller on a group of knee flexors for 3.5 minutes between the sciatic tumor and the knee joint in both directions, omitting the popliteal fossa. Before and after the intervention, sEMG of the biceps and gluteal muscles will be performed.
223947844|NCT05057819|DRUG|Empagliflozin 25 MG|Treatment naive patients with bariatric bypass surgery will be given oral empagliflozin 25mg once daily for 20 days
223947845|NCT05057819|DRUG|Placebo|Treatment naive patients with bariatric bypass surgery will be given oral placebo once daily for 20 days
223947846|NCT01643122|OTHER|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
224100684|NCT06387056|DRUG|Cisplatin|70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
224100685|NCT06387056|DRUG|Tislelizumab|200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).
224100686|NCT02579603|DRUG|Nintedanib|Nintedanib 150mg bid
224100687|NCT02579603|DRUG|Pirfenidone|
224100688|NCT05281315|OTHER|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.|Patients were retrospectively enrolled. This was a retrospective study and no intervention was performed.
224100689|NCT03540823|BIOLOGICAL|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
224100690|NCT01836315|OTHER|Observational Study|
224100691|NCT00469079|DRUG|Nicotine gum and lozenge|Nicotine replacement
224100692|NCT00469079|OTHER|Taboka|smokeless tobacco product
224100693|NCT00469079|OTHER|Camel Snus|smokeless tobacco product
224100694|NCT03028493|BEHAVIORAL|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
224100695|NCT03028493|BEHAVIORAL|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
224100696|NCT05645094|DRUG|Envafolimab|Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.
224100697|NCT00577187|DEVICE|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
224100698|NCT04209738|OTHER|This is an observational study being conducted as a substudy of another trial.|This is an observational study being conducted as a substudy of another trial. No intervention is planned for Substudy.
224100699|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
224100700|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
224100701|NCT03931837|DEVICE|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
223947847|NCT01643122|OTHER|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
223947848|NCT00864188|DIETARY_SUPPLEMENT|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
223947849|NCT00864188|DIETARY_SUPPLEMENT|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
223947850|NCT00864188|DIETARY_SUPPLEMENT|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
223947851|NCT00864188|DIETARY_SUPPLEMENT|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
223947852|NCT01838707|DRUG|0.125% Bupivacaine HCL @ 4-5 ml/h|
223721423|NCT04298801|OTHER|Physician-directed diagnostic testing|Throughout the intervention, physicians will prescribe HIV tests to patients with HIV-related symptoms, following usual practice.
223721424|NCT04356391|PROCEDURE|Connective Tissue Graft Technique|For the sites receiving the control technique (Connective Tissue Graft), the technique described by Langer B. and Langer L. will be started with a sulcular incision followed by a partial thickness flap. A CTG is then harvested according to the technique described by Bruno, the first incision is perpendicular to the 2nd premolar and 1st molar and is 2-3mm apical to their gingival margin as wide as the recipient site, followed by a second incision parallel to the for mentioned teeth, 1-2mm apical to the first incision, then the CTG is raised by periosteal elevator and released from apical and lateral attachments by sharp incision when needed. The graft is then prepared to have a homogenous thickness of 1.5-2mm. The donor CTG is stabilized to the underlying connective tissue interproximally using 4-0 Vicryl sutures. The recipient flap is repositioned coronally, to cover as much as possible of the graft with no tension, 2mm coronal to the CEJ, then sutured with 4-0 Vicryl sutures.
223947853|NCT01838707|DRUG|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
223947854|NCT01838707|DRUG|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
223947855|NCT04214093|DRUG|AZD0466|"In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort."
224122655|NCT06672835|BEHAVIORAL|eBASIS|eBASIS is an online, optimized, and evidence-based practice agnostic implementation strategy that addresses the behavioral component often missing from standard evidence-based practice training and consultation. It relates to motivation before and volition after the evidence-based practice training and targets behavioral intentions by improving attitudes, subjective norms, and self-efficacy. The implementation strategy is designed to be designed to be delivered within the Preparation/Adoption phase immediately prior to the Action implementation in the EPIS model.
223721425|NCT04356391|PROCEDURE|Pinhole Surgical Technique|For the sites receiving the test technique (Chao Pinhole Surgical Technique) the surgery starts with a small pinhole opening in the alveolar mucosa apical to the mucogingival junction of the affected tooth, the flap is then undermined using special instruments to create a full thickness pouch, followed by extending the pouch horizontally and coronally to undermined the adjacent papilla without incising it and free the flap for its coronal displacement. Then multiple 2x12mm strips of collagen resorbable membrane material (Bio-Gide, Geistlich Pharma AG) are packed under the papilla to secure the flap in a coronal direction. Gentle pressure is applied for 5 minutes to minimize the thickness of the blood clot after each of the procedures. The patients are advised to brush all teeth and sites except the buccal surfaces of the operated-on teeth, which are to be cleaned with 0.12% Chlorhexidine mouth rinse.
223947856|NCT04845542|BEHAVIORAL|ReStoreD|ReStoreD is a remotely-administered behavioral intervention in which couples coping with stroke learn and practice goal-setting, communication strategies, and positive psychology activities, such as expressing gratitude, finding meaning, and fostering connections. Participants are provided with 8 weekly modules, each featuring two components: 1) psychoeducational materials, such as an informational video and resources/links about a general topic related to resilience, coping, and/or overall well-being of the individual and couple, and 2) examples of positive psychology activities that relate to the week's theme or topic. Participants are asked to complete at least two positive psychology activities alone and two together each week.
223947857|NCT04737993|DRUG|licocain|pulsed radiofrequency stimulation
223947858|NCT04737993|OTHER|pulsed radiofrequency stimulation|pulsed radiofrequency stimulation of joint capsel
223721426|NCT00563498|DRUG|Glutamine|
223947859|NCT05201625|DIAGNOSTIC_TEST|real time PCR|real time PCR
223947860|NCT06306937|DIAGNOSTIC_TEST|Evalution of serum levels of vitamin D and IL8|"Group 1 (Periodontitis Group): The intervention involves observing and analyzing individuals diagnosed with periodontitis based on established clinical criteria. The focus is on assessing vitamin D and IL8 levels in the serum and correlating these levels with the severity of periodontitis, determined by clinical indices such as probing depth, clinical attachment loss, and bleeding on probing.~Group 2 (Control Group): The intervention involves observing and analyzing individuals without any signs or history of periodontal disease. The focus is on assessing vitamin D and IL8 levels in the serum for comparison with the periodontitis group. This group serves as the healthy control for the study."
223721427|NCT02256020|OTHER|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
223721428|NCT02256020|OTHER|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
223721429|NCT01184300|GENETIC|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
224100702|NCT05813821|BEHAVIORAL|Antimicrobial stewardship in surgery|"Hospitals were invited to form a surgical antibiotic stewardship program (ASP) with surgeons, pharmacists and infectious disease specialists. The interventional ASP relied on an audit and feedback strategy to issue recommendations aimed at reducing the duration of antibiotic treatment and the use of drugs with a particular impact on microbial ecology.~All patients hospitalized in surgical departments were prospectively analyzed weekly. A computerized alert allowed the ASP team to identify patients with antibiotic treatment \>7 days. The team meet to discuss the appropriateness of each antibiotic treatment, issuing a written recommendation for each patient. The intervention was performed only once for each patient, except if they had a new focus of infection. The recommendations available for prolonged treatments were: withdraw, maintain, de-escalate, broaden, change route, optimize dose, no recommendation. Adherence to the recommendations was recorded 48 hours later by the ASP team."
224100703|NCT02655861|OTHER|Observation|
224100704|NCT01319955|BIOLOGICAL|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
223947861|NCT04634994|DRUG|[F-18]SDM-8|PET radiopharmaceutical. Subjects will undergo \[F-18\]SDM-8 PET Scanning to measure synaptic density.
224100705|NCT05794529|OTHER|There are no interventions in the present study|There are no interventions in the present study
224100706|NCT04807491|OTHER|Kabat Technique's|"As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises"
223721430|NCT02406716|OTHER|Biospecimen retention|
223721431|NCT00908713|DRUG|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
223721432|NCT00908713|DRUG|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
223947862|NCT03062488|DRUG|IV acetaminophen|multi-modal analgesia with IV acetaminophen
223947863|NCT03062488|DRUG|Fentanyl|single modal analgesia
223947864|NCT03062488|DRUG|PO acetaminophen|multi-modal analgesia with PO acetaminophen
223721433|NCT06505434|PROCEDURE|Cataract surgery|Phaco + IOL Implantation
223721434|NCT00745836|DRUG|statin|
223721435|NCT03147560|BIOLOGICAL|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
223947865|NCT02014402|BIOLOGICAL|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
223947866|NCT02014402|BIOLOGICAL|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
223947867|NCT03105024|OTHER|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
223947868|NCT03105024|OTHER|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
223947869|NCT05024396|DIAGNOSTIC_TEST|maximum jump height|Three single leg countermovement jumps were performed. The maximum jump height is measured with a sensor that is adapted at the subjects'leg and with a force plate.
223947870|NCT01985945|OTHER|Yoga|
223947871|NCT03684772|DRUG|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
223947872|NCT03684772|DRUG|Furosemide Topical Gel|Furosemide (0.125%)
223947873|NCT03684772|DRUG|Digoxin Topical Gel|Digoxin (0.125%)
223947874|NCT03684772|DRUG|Vehicle Topical Gel|Vehicle Gel
223947875|NCT05228964|DEVICE|Focused ultrasound|Focused ultrasound at a 10 Hz pulse repetition frequency, 5% duty cycle, and 720 mw/cm squared de-rated spatial peak temporal average intensity, delivered over 10 min.
223947876|NCT04156256|BIOLOGICAL|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
223947877|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
223947878|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 48 weeks
223947879|NCT00443820|DRUG|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
223947880|NCT00443820|DRUG|Placebo|Vehicle (placebo) once daily for 24 weeks
223947881|NCT04633200|OTHER|DOT mobile app|DOT is a mobile phone app that has daily pill reminders and supportive texts, as well as various features designed to support PrEP medication adherence.
223947882|NCT04768556|OTHER|EEG experimental sessions 1|An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.
223947883|NCT04768556|OTHER|EEG experimental sessions 2|An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action
223947884|NCT06113393|PROCEDURE|GRV thresholds|Hold enteral feeding when GRV reaches 200 mL(current standard)
223947885|NCT04674605|DEVICE|biomarkers|biomarkers
223947886|NCT02642640|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
223947887|NCT02642640|DRUG|placebo|
223947888|NCT04580732|DEVICE|MiniStim PNS|MiniStim PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
223947889|NCT03493282|DRUG|Active Treatment- CT1812 100 mg|CT1812
223721436|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
223947890|NCT03493282|DRUG|Active Treatment- CT1812 300 mg|CT1812
223947891|NCT03493282|DRUG|Placebo|Matching Placebo
223947892|NCT02333747|DEVICE|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
223947893|NCT04859465|DRUG|Abraxane combined with liposomal doxorubicin|Patients with advanced or unresectable angiogenic sarcoma who met the criteria of treatment failure received abraxane combined with liposomal doxorubicin regimen. Administration regimen: abraxane 220 mg / m2 D1 plus liposomal doxorubicin 35 mg / m2 D1, IV drip, 3 weeks as a cycle, until the disease progression or intolerable toxicity. Up to 8 cycles.
223947894|NCT04475874|OTHER|supervised stretching exercises|30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
223947895|NCT04475874|OTHER|non-supervised active stretching home program|non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
223947896|NCT06584955|OTHER|Weighted Blanket|Participants will be given a weighted blanket
223947897|NCT01523392|DRUG|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
223947898|NCT01523392|DRUG|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
223947899|NCT00893100|DRUG|Diltiazem|2%,3 times daily
223947900|NCT01685476|DEVICE|Echodia® hand-held equipment|
223947901|NCT03462966|DRUG|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
223947902|NCT00671853|DRUG|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
223947903|NCT00671853|DRUG|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
223947904|NCT05516745|DEVICE|AioCare spirometer|In the first part of the trial, all participants from arms 1 and 2 will receive the AioCare spirometer (Healtup, Poland) to home-based monitoring pulmonary function. Hospital spirometry examinations (Jaeger, Germany) evaluating disease progression will be performed periodically. There are to be follow-up visits after 3 months and after 6 months. The end-point visit is planned for 12 months.
224100707|NCT04807491|OTHER|Neuromuscular Re-Education|"After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises"
223947905|NCT05516745|OTHER|telerehabiliation of the respiratory system|A major component of respiratory dysfunction seems to be a decline of respiratory muscle weakness. The proposition is respiratory telerehabilitation to improve the function of respiratory muscles. Telerehabilitation includes breathing exercises for use at home. The participants will be trained in the hospital and will receive video presentations to support the exercises at home.
223947906|NCT03252210|PROCEDURE|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
223947907|NCT00907933|DRUG|SB-705498|0.5mg intranasal SB-705498
223947908|NCT00907933|DRUG|SB-705498|1.5mg intranasal SB-705498
223947909|NCT00907933|DRUG|SB-705498|3mg intranasal SB-705498
223947910|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498
223947911|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498
223947912|NCT00907933|DRUG|Placebo|Placebo '498
223947913|NCT00907933|DRUG|SB-705498|6mg intranasal SB-705498 for 14 days bid
223947914|NCT00907933|DRUG|SB-705498|12mg intranasal SB-705498 14 days bid
223947915|NCT00907933|DRUG|Placebo|Placebo
223947916|NCT01719172|DEVICE|Veriset™ Hemostatic Patch|Topical Hemostat
223947917|NCT02122484|DRUG|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
223947918|NCT04566276|BIOLOGICAL|ChulaCov19 vaccine|SARS-Cov2 Wild-type S-spike mRNA/ lipid nanoparticle (LNP) vaccine
223947919|NCT04566276|OTHER|Placebo|Saline
223947920|NCT05944666|PROCEDURE|Multimodal technology (MT)|"Only fo the patients of the Main group. It will be different programms depending on severety of UL or LL paresis. Patients will receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, in moderate paresis of the upper limb, the neurointerface Exokist-2 with EEG registration will be used. The program for IS patients includes 10 sessions in inpatient stage every day 15-30 min for the method, 15 sessions with the MT in outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
223947921|NCT05944666|PROCEDURE|Conventional rehabilitation|It will be different programms depending on severety of UL or LL paresis. Conventional rehabilitation (CR) includes physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients consists of 10 sessions of every day trainings for inpatients stage, 15 sessions with the CR for outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
223947922|NCT03015753|BEHAVIORAL|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
223947923|NCT03015753|OTHER|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
223947924|NCT01752816|BEHAVIORAL|exercise training|
223947925|NCT02027259|BEHAVIORAL|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
223947926|NCT05940805|PROCEDURE|Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|"1. Low-frequency transcranial electrical stimulation (2/100 Hz) applied through 0.3-mm-diameter and 40-mm-long needles placed subcutaneously on the scalp at the projection of Penfield's motor homunculus and sensory and frontal supplementary motor associative areas.~2. Paraspinous block at the levels of the C5, C6 and C7 vertebrae concordant with spasticity laterality.~3. Dry needling of spastic upper limb muscles, as identified through a thorough physical examination, using 0.3-mm-diameter and 40-mm-long needles.~4. Muscular functional electrical stimulation (FES) in the antagonists of the upper limb muscles with spasticity with the following parameters: 20-Hz frequency, 300-µs pulse width, zero-second ramp time, 5-second stimulation time, and 5-second resting time."
223947927|NCT05940805|PROCEDURE|SHAM Low-frequency transcranial electrical stimulation; Paraspinous block; Dry needling of spastic upper limb muscles; Muscular functional electrical stimulation (FES)|For simulation of transcranial electrical stimulation and FES, electrodes were placed on the scalp and in the upper extremity muscles and were connected to a device similar to the real electric current generator. This device did not transmit any electric current but had blinking lights and produced sound to provide the subjects visual and auditory feedback. To simulate dry needling and paraspinous block, retractile needles were used.
223947928|NCT04125342|DEVICE|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
223947929|NCT04125342|DEVICE|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
223947930|NCT00587171|DEVICE|Patching|2 hours daily patching
224100708|NCT02140125|DRUG|ASP2408|subcutaneous administration
224100709|NCT02140125|DRUG|Placebo|subcutaneous administration
224100710|NCT00725738|GENETIC|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
223947931|NCT00587171|PROCEDURE|Near activities|30 minutes daily near activities at home
223947932|NCT00587171|PROCEDURE|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
224100711|NCT02860793|OTHER|Bone marrow aspiration|
224100712|NCT02860793|OTHER|Blood sampling|
224100713|NCT04712175|DIAGNOSTIC_TEST|Nasopharyngeal sampling|Swabs will be taken of nasopharyngeal samples for RT-PCR
224100714|NCT04712175|DIAGNOSTIC_TEST|Saliva sampling|A 10ml saliva sample will collected in a sterile 60ml bottle for mass spectrometry and RT-PCR
224100715|NCT05631925|DRUG|propofol bolus|Propofol will be added in bolus doses of 0.5mg/kg.
224100716|NCT05631925|DRUG|propofol infusion|Propofol will be administered as 10mg/kg/hour infusion.
224100717|NCT03351673|DIAGNOSTIC_TEST|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
224100718|NCT02698410|DRUG|Lanreotide (Autogel formulation) and Temozolomide|
223721437|NCT03147560|BIOLOGICAL|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
223721438|NCT01866930|BIOLOGICAL|Pegylated Interferon Lambda-1a|
223721439|NCT01866930|DRUG|Daclatasvir (DCV)|
223721440|NCT01866930|DRUG|Ribasphere (RBV)|
223721441|NCT03834597|DEVICE|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
223721442|NCT03834597|DEVICE|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
223721443|NCT00750815|DRUG|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
223721444|NCT00750815|DRUG|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
223721445|NCT00279305|DRUG|Anti-CD20 (rituximab)|
223721446|NCT00279305|DRUG|Placebo Comparator|Placebo intravenous infusion
223721447|NCT01212315|DEVICE|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
223721448|NCT03081988|OTHER|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
223721449|NCT04380415|DIAGNOSTIC_TEST|Single lead ambulatory ECG patch|Single lead ambulatory ECG patch worn on the chest
223947933|NCT00587171|PROCEDURE|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
223947934|NCT04246905|DRUG|sulforaphane|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
223947935|NCT04246905|OTHER|placedo|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
223947936|NCT04246905|DRUG|selective 5 - HT reuptake inhibitors (SSRI)|To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
223721450|NCT05173805|DRUG|YL-15293|After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
223721451|NCT05165901|DEVICE|Scrambler Therapy|LG Medipain is a type of non-invasive neuromodulation.
223947937|NCT04389554|OTHER|Blood D-dimer assay|Blood samples will be taken from the patients and will be examined by the ELISA method.
223947938|NCT06102538|BEHAVIORAL|# The importance of service in the IDF # Physical activity # Healthy nutrition # Psychological support|\# Education for the importance of service in the IDF # Education and training for physical activity adapted to abilities # Training for a healthy diet # Psychological support
223947939|NCT00865033|DRUG|Metformin HCL Tablets, 1000 mg Sandoz|
223947940|NCT00865033|DRUG|Glucophage 1000 mg|
223947941|NCT01848483|BEHAVIORAL|AIDS EPC Package plus MI|"1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care."
224100719|NCT05285852|OTHER|Dry Needling|Dry needling technique is maneuvered by different skilled health practitioners aiming to reduce central sensitization, i.e., the hypersensitivity to pain of the central nervous system. It is also apprehended to reduce the local and referred pain, and improve the muscle activation patterns leading to improved range of motion.
223721452|NCT05106686|DIETARY_SUPPLEMENT|Aureobasidium pullulans produced β-glucan group|Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
224100720|NCT05285852|OTHER|Placebo Dry Needling|Placebo Dry Needling only causes a pricking sensation
224100721|NCT05325164|DRUG|Methadone|Methadone
223721453|NCT05106686|DIETARY_SUPPLEMENT|placebo group|Placebo 300 mg/day for 12 weeks
223721454|NCT04481854|PROCEDURE|cricoid pressure|cricoid pressure during laryngoscopy
223721455|NCT04481854|PROCEDURE|left paratracheal pressure|left paratracheal pressure during laryngoscopy
223721456|NCT03378232|DIETARY_SUPPLEMENT|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
223721457|NCT03378232|DIETARY_SUPPLEMENT|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
223721458|NCT03378232|DIETARY_SUPPLEMENT|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
223721459|NCT03303365|RADIATION|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~* 20 Gy to the 70%-isodose (lesions \< 2 cm max. diameter)~* 18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~* 6 x 5 Gy to the conformally surrounding isodose (lesions \> 3 cm max. diameter)"
223721460|NCT04956367|PROCEDURE|Ablative fractional carbon dioxide laser combined with autologous platelet-rich plasma|Carbon dioxide laser (Smaxel.878.4810) was FDA-approved device used in dermatology practice. PRP was described as having growth factors to be used to promote healing.
223721461|NCT04956367|DEVICE|CO2 laser with PRP|CO2 laser with PRP
223721462|NCT04956367|DEVICE|CO2 laser with placebo|CO2 laser with placebo
223721463|NCT03533764|BEHAVIORAL|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
223721464|NCT00171353|DRUG|valsartan|
223947942|NCT01848483|OTHER|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
223947943|NCT01148017|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
223947944|NCT01599078|DRUG|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
223947945|NCT01599078|DRUG|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
223947946|NCT02813954|DEVICE|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
224100722|NCT05325164|DRUG|Morphine|Morphine
224100723|NCT01733563|PROCEDURE|Soft drink consumption|
224100724|NCT04611477|OTHER|Rice Hulk|Placebo
223721465|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(High dose 2g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins \& vitamin C 500 mg (2 g-daily in 4 divided doses) started one day before operation till the end of hospital stay or development of post operative atrial fibrillation
223947947|NCT06304051|DEVICE|Intermittent Oro-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223721466|NCT06074367|DRUG|Vitamin C 500 MG Oral Capsule(Low-dose 1g daily)|A sixty CABG patients commenced on maximum tolerated dose of b-blocker, statins, vitamin C 500 mg (1 g-daily in 2 divided doses) and also received 2 capsules containing starch to be completely equivalent in frequency to the other groups. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
223721467|NCT06074367|DRUG|placebo capsules|A sixty CABG Patients commenced on maximum tolerated dose of b-blocker, statins and placebo capsules containing starch mimic vitamin C capsules was taken every 6 hrs. The placebo capsules were prepared in the same shape and size as the original ones manufactured by the same pharmaceutical company. the intervention started one day before operation till the end of hospital stay or development of post operative atrial fibrillation.
223721468|NCT04813198|BEHAVIORAL|TIPSTART|TIPSTART is a multimodal, cognitive behavior-based therapy integrating peer-sharing, technology, aerobic and resistance training.
223721469|NCT03615378|DIETARY_SUPPLEMENT|5000 IU D3|Daily
223721470|NCT03615378|DIETARY_SUPPLEMENT|1000 IU D3|Daily
223721471|NCT03615378|DIETARY_SUPPLEMENT|Placebo|lactose/sugar tablet
223721472|NCT04158115|OTHER|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
223721473|NCT04158115|OTHER|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~\- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
223721474|NCT03046004|OTHER|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
223721475|NCT03046004|OTHER|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
223721476|NCT01421004|DRUG|TKI258|
223721477|NCT00078442|DRUG|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
223721478|NCT04063930|DRUG|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
223947948|NCT06304051|DEVICE|Nasogastric Tube Feeding|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, the investigators made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223721479|NCT04063930|DRUG|Placebos|Matching placebo
223947949|NCT01605448|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
223947950|NCT03758391|OTHER|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
223721480|NCT02418364|OTHER|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
223721481|NCT02418364|OTHER|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
223721482|NCT05894083|PROCEDURE|Surgery|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
223721483|NCT05894083|COMBINATION_PRODUCT|Chemoradiation|Patients will receive an initial plan with a single prescription of 30 Gy in 15 fractions to PTV\_High and PTV\_Low with RT given once daily, 5 days a week (Monday through Friday). After analysis of mid-treatment PET/CT, the remaining radiation treatment will be delivered as a conedown to the gross disease only. Patients will be planned to receive a total dose of 70 Gy, 54 Gy, or 44 Gy to PTV\_High in 2 Gy per fraction.
223947951|NCT00678925|DIETARY_SUPPLEMENT|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
223947952|NCT00678925|DIETARY_SUPPLEMENT|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
223947953|NCT03100188|OTHER|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
223947954|NCT00143806|DRUG|Transitioning patients from cyclosporine to alefacept|
223947955|NCT05292066|DRUG|Duloxetine Tablets,|"Duloxetine is an FDA-approved medication used to treat the major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. It is taken by mouth. It is a serotonin-norepinephrine reuptake inhibitor.~Pregabalin is an FDA approved, sold under the brand name Lyrica. it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,"
223947956|NCT05292066|DRUG|Pregabalin Tablets|Pregabalin is an FDA approved, it is an anticonvulsant and anxiolytic medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome,
223947957|NCT00239512|DRUG|Indomethacin and Ibuprofen|
224100725|NCT04611477|OTHER|Synbiotic365 Ver 5|Active Comparator
224100726|NCT04611477|OTHER|Synbiotic365 Ver 7|Active Comparator
223721484|NCT05894083|OTHER|Observation|Cohort A will undergo initial surgical resection of the primary and neck dissection with pathologic features directing predetermined adjuvant treatment. Pathology of the primary and nodal specimens will then be reviewed as to determine the next intervention per protocol. Based on operative findings including degree of nodal involvement, extracapsular spread, perineural invasion, and lymphovascular involvement, patients will be designated to adjuvant treatment arms consisting of observation, adjuvant radiation, or adjuvant chemoradiation.
223947958|NCT00770874|DRUG|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
223947959|NCT00770874|DRUG|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
223721485|NCT05894083|RADIATION|Post-operative radiation|Patients will receive adjuvant radiation based on pathologic features.Total radiation treatment doses and prescriptions will include 36 Gy in 18 fractions, 50 Gy in 25 fractions and 60 Gy in 30 fractions.
223721486|NCT00232024|DRUG|Tegaserod|
223721487|NCT00701675|DRUG|sertraline 50 mg daily|50 mg daily
223721488|NCT00701675|DRUG|sertraline 100 mg daily|100 mg daily
223721489|NCT00701675|DRUG|Placebo 50 or 100 mg|50mg or 100mg matching placebo
223721490|NCT06049862|BEHAVIORAL|MaRiTensi App|"MaRiTensi is a mobile health-based hypertension self-management application used on Android smartphones.~MariTensi provides facilities for recording blood pressure, BMI, activity, examination results, education about hypertension, consultations, reminders and community chat."
223721491|NCT04644081|BEHAVIORAL|LTP|LTP is a low-literacy, sustainable programme that will provide depressed mothers with valuable skills on parenting, improve mother-child relation and mental health self-care. This is a research-based activity that enhances postpartum mental health while simultaneously promoting attachment security through building parents' ability to monitor and be sensitive to their children's cues, and thereby, actively involves in their children's mental and physical development.
223721492|NCT04644081|BEHAVIORAL|CaCBT|CaCBT adopts 'here and now' problem-solving approach, which involves collaborating with families, active listening techniques, changing negative thinking, and depressive symptoms associated with postnatal depression and other forms of parenting distress.
223721493|NCT04644081|DRUG|TAU|TAU is the routine care currently available for the treatment of postnatal depression at the primary health care sites of intervention (e.g. antidepressants and other forms of mental health care).
223947960|NCT05825274|DEVICE|Cathodal tDCS|We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
223947961|NCT04250636|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS at 30mg/kg
223947962|NCT04250636|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS at 30mg/kg
223947963|NCT04062396|DEVICE|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
223947964|NCT04062396|DEVICE|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
223947965|NCT00539812|BEHAVIORAL|Standard Care|Standard 40 hour state mandated batterer intervention program
223947966|NCT00539812|BEHAVIORAL|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
224100727|NCT03158584|DRUG|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
223947967|NCT04910204|OTHER|FES Therapy combined with task-specific training (FEST+TST)|The FEST+TST protocol consists of a 1-hour session, 3 to 5 days a week, for up to 12 weeks (40 sessions total) in addition to conventional occupational and physical therapies according to the standard of care.
223721494|NCT01261910|BEHAVIORAL|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
223721495|NCT05482724|BEHAVIORAL|Super Skills for Life|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.~The intervention was administered by a trained clinical psychologist in SSL. Sessions were held after school hours once a week for eight weeks, with each session lasting approximately one hour. The contents of the program were covered through playful activities in groups of 4 to 6 children"
223721496|NCT01939652|PROCEDURE|Restrictive VS Standard Fluid Regime|
223721497|NCT01939652|DRUG|Drag: Crystalloids and Colloids|
223947968|NCT02433587|DRUG|Aspirin|Patients will take Aspirin 81 mg
223947969|NCT02433587|DRUG|Clopidogrel|Patients will take Clopidogrel 75 mg
223947970|NCT04024176|OTHER|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
224100728|NCT05013840|BEHAVIORAL|Filling in an online survey|Physicians are asked to fill in an online survey regarding 1) goals to treat patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.
223947971|NCT04598594|DRUG|Patch, Nicotine|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
223721498|NCT03258437|DIETARY_SUPPLEMENT|DA-9401|
223721499|NCT03258437|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
223721500|NCT04193098|BIOLOGICAL|CTL|CTL injection
223721501|NCT04193098|BIOLOGICAL|Toripalimab|Toripalimab injection
223721502|NCT03331367|PROCEDURE|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
223721503|NCT03331367|PROCEDURE|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
223721504|NCT06266910|OTHER|Visual training video|"The video, designed according to the principles of pencil pushups, features a dynamic standard E and is presented on an autostereoscopic 3D display equipment."
223947972|NCT04598594|DRUG|Patch, Placebo|Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
223947973|NCT02326506|DEVICE|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
223721505|NCT02019329|OTHER|Placebo|Oral daily administration from Days 1-12
223721506|NCT02019329|DRUG|RO5545965|Oral daily administration from Days 1-12
223721507|NCT02019329|DRUG|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
223721508|NCT00317356|DRUG|OPC-6535(Tetomilast)|
223721509|NCT06504849|BEHAVIORAL|Receiving LSM messages.|"* LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications"
223721510|NCT06504849|BEHAVIORAL|Receiving brief pre-HTN messages.|"* A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications"
223721511|NCT02551965|OTHER|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
223721512|NCT00870792|BEHAVIORAL|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
223721513|NCT03844646|DEVICE|CGM|Intermittent use of a continuous glucose monitor (CGM)
223721514|NCT03844646|OTHER|Dietitian|Monthly meetings with a dietitian
223721515|NCT02154243|DRUG|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
223721516|NCT02154243|OTHER|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
224100729|NCT00189761|DRUG|Tacrolimus|
224100730|NCT01407120|BEHAVIORAL|New Beginnings Program|A preventive intervention for divorced families.
224100731|NCT03943381|DEVICE|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
224100733|NCT00753636|DRUG|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
223721517|NCT00176228|DRUG|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
223721518|NCT03931538|DIAGNOSTIC_TEST|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
223721519|NCT03931538|DIAGNOSTIC_TEST|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
223721520|NCT02223897|DRUG|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
223721521|NCT02223897|DRUG|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
223721522|NCT01833013|OTHER|live birth date and quality of life assessment|
223947974|NCT01874964|BEHAVIORAL|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
223947975|NCT01874964|BEHAVIORAL|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
223721523|NCT00323921|DEVICE|dermatological infrared laser|
223721524|NCT01378949|DRUG|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
223721525|NCT01378949|DRUG|Morphine|Morphine 1 mg/cc
223721526|NCT01270776|DRUG|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
223721527|NCT01270776|DRUG|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
223721528|NCT00112320|PROCEDURE|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
223721529|NCT00112320|PROCEDURE|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
223721530|NCT00694174|DRUG|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
223721531|NCT00694174|DRUG|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
223721532|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
223721533|NCT00621153|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
223721534|NCT00621153|DRUG|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
223721535|NCT00753415|BIOLOGICAL|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10\^9 vector genomes/mL) or a HD (1 x 10\^11 vector genomes/mL).
223947976|NCT00937014|OTHER|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
223947977|NCT00937014|OTHER|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
223721536|NCT00753415|BIOLOGICAL|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
223721537|NCT05221528|DIAGNOSTIC_TEST|Measurement of lipid profiles|Measured: total cholesterol, high-density lipoprotein cholesterol, and triglyceride Calculated: low-density lipoprotein
223721538|NCT04974385|DRUG|Liposomal bupivacaine|Validate the analgesic efficacy of admixed LB + bupivacaine compared with plain bupivacaine when injected for ISNB for total shoulder arthroplasty.
223721539|NCT04974385|DRUG|Bupivacaine|Active comparator as standard of care.
223721540|NCT00653575|BEHAVIORAL|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
223947978|NCT00002801|DRUG|leucovorin calcium|
223947979|NCT00002801|DRUG|tegafur-uracil|
223947980|NCT00002801|RADIATION|radiation therapy|
223947981|NCT00666419|OTHER|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
223721541|NCT00653575|BEHAVIORAL|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
223947982|NCT02199626|DEVICE|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
223721542|NCT06341842|DRUG|Dapagliflozin 10mg Tab|Dapaglifloziin 10 mg 1 tab daily
223721543|NCT04212650|DRUG|Losartan|Losartan will be administered to improve the quality of hip cartilage repair following arthroscopic microfracture. Losartan is a known anti-fibrotic agent via blocking of TGF-B1.
223721544|NCT04212650|OTHER|Placebo|Appearance-matched microcrystalline cellulose placebo
223947983|NCT03963466|DRUG|tranexamic acid|Oral tranexamic acid group(menstrual period\>2days) 250mg bid（exclude menstrual period ）
223947984|NCT03963466|RADIATION|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
223721545|NCT00003993|BIOLOGICAL|aldesleukin|
223721546|NCT00003993|DRUG|bryostatin 1|
223721547|NCT04235114|DRUG|50 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 50 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
223947985|NCT03963466|RADIATION|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
223947986|NCT01292213|PROCEDURE|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
223947987|NCT01292213|PROCEDURE|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
223947988|NCT01292213|PROCEDURE|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
223947989|NCT01292213|PROCEDURE|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
223947990|NCT01292213|PROCEDURE|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
223947991|NCT01292213|OTHER|Data collection|Questionnaire completion.
223947992|NCT05582824|OTHER|Blood and urine test|Daily blood and urine samples
223947993|NCT00163501|DRUG|Ciclesonide|
223947994|NCT03185936|PROCEDURE|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
223721548|NCT04235114|DRUG|1 mg 89Zr-DFO-Nimotuzumab|A maximum of 2 mCi (range 1 - 2 mCi) 1 mg of 89Zr-DFO-nimotuzumab will be injected intravenously over a period of at 2 - 3 minutes. Injection will be followed by a normal saline flush of 20-30 mL. PET/CT scan will be done at different time points post infusion.
223721549|NCT00634374|DEVICE|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
223721550|NCT02099994|BIOLOGICAL|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10\^10 vp or saline placebo
223721551|NCT02099994|BIOLOGICAL|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10\^8 pfu or saline placebo
223721552|NCT02099994|BIOLOGICAL|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
223721553|NCT02099994|BIOLOGICAL|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
223721554|NCT01530568|OTHER|Xpert|This arm receives the GeneXpert test
223721555|NCT01530568|OTHER|Smear|This arm receives smear microscopy
223721556|NCT03004027|OTHER|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
223721557|NCT00241215|DRUG|Botulinum toxin serotype A|
223721558|NCT04804475|OTHER|Exercise Trainig|SSE is performed on a thin exercise mat divided into 40 small squares in 250 cm x 100 cm of size (25 cm each part). Participants are given patterns of a few steps and asked to take steps that match them. Participants must, in principal, move ahead in line with the length forward with no contact on the lines forming the squares. Forward, backward, lateral and oblique stepping patterns are required. Stepping patterns get increasingly difficult. Each pattern consists of 2 to 16 steps; participants are asked to repeat step pattern till the end of exercise mat. Upon completing a pattern, another pattern in the same mirror-image is repeated. In essence each pattern is reiterated for 3-5 times and next its mirror-image pattern is repeated but if participants face challenge in performing the pattern it is repeated till the pattern is learnt
223947995|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 200mg
223947996|NCT05559645|DRUG|DZD9008|Daily dosing of DZD9008 300mg
223947997|NCT04012242|DIAGNOSTIC_TEST|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
223947998|NCT00082966|DRUG|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
223947999|NCT04880018|DEVICE|Capsular Tension Ring|Experimental group uses Capsular Tension Ring from Eyebright Medical Technology (Beijing) Co., Ltd;control group uses Capsular Tension Ring from Carl Zeiss Medical Technology Co., Ltd
223948000|NCT02117310|DRUG|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
223948001|NCT01792401|DRUG|Probiotics|
223948002|NCT01792401|DRUG|Placebo|
223948003|NCT01855165|BEHAVIORAL|Advice on DDIs|
223536539|NCT06564558|OTHER|Thoracic Spine Mobilization|The patient will be seated with both hands clasped at shoulder level. An experienced and blinded therapist standing homolateral to the patient supports the clasped hands with one arm while placing the other hand was placed at different thoracic regions until the thoracolumbar junction. Specifically, the dorsal aspect of the index finger and pad of the thumb were used to create a fixation point at the junction. Following that, gentle extension-directed glides (postero-anterior) will be done by the therapist for 3 sets of 10 repetitions or until tolerated by the patient.
223536540|NCT06564558|OTHER|Sham Postural Correction|comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
223536541|NCT06563908|PROCEDURE|Lipiodol® uterine treatment prior to IVF/ICSI|Lipiodol®, treatment will be performed by a HSG technique with X-ray screening on day 3 or day 5 after oocyte retrieval. The contrast medium will be Lipiodol Ultra Fluide® (Guerbet, France), an iodized poppy seed oil obtained by substitution of ethyl esters for the glyceryl esters of Lipiodol®. One millilitre of Lipiodol Ultra Fluide® contains 0.48g iodine. Women will lie in the left lateral or supine position. Radiologists will use a 'no touch' technique after applying antiseptic solution to the cervix. Uterine cannulation using the Cook HSG catheter will be applied to conduct Lipiodol® treatment. Prewarmed (37oC) Lipiodol® will be slowly instilled, with intermittent fluoroscopic X-ray guidance. Up to 10 ml of Lipiodol® will be slowly injected into the uterus and directly monitored by fluoroscopy. If intravasation was observed on X-ray (contrast apparent in the venous system), instillation will be stopped immediately.
223536542|NCT05140421|BEHAVIORAL|Data to Suppression (D2S)|Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
223536543|NCT06399224|DEVICE|Local Plantar vibrator|A vibrating device that applies 80 hz vibration waves applied on the sole of the foot
223536544|NCT06399224|OTHER|Otago exercise|Warm up Front Knee strength Back knee strength Side hip strength Calf raising Toe raising Sit to stand Heel walk Toe walk One leg standing Side way walk Cool down
223536545|NCT05554679|DRUG|Metformin|Metformin is an oral insulin-sensitising medication that acts to decrease blood glucose concentrations. It inhibits pathways in the liver that stimulate glucose production and also acts to increase glucose uptake into skeletal muscle and fat cells . Metformin is commonly used in the treatment of type 2 diabetes mellitus and polycystic ovarian syndrome , and is being used increasingly in the treatment of gestational diabetes, having been shown to result in decreased rates of neonatal hypoglycaemia and no increased risk of adverse maternal outcomes when compared with insulin.
223536546|NCT04849897|DEVICE|Experimental: Virtual Reality Guided Imagery|Platform and VR Goggles
223536547|NCT04849897|OTHER|Active Comparator: Audio Only Guided Imagery|Audio Recordings of Guided Imagery via an iPAD
223536548|NCT00114348|PROCEDURE|R-Blocks|
223536549|NCT00114348|PROCEDURE|Protocol II-Ida|
223536550|NCT04970914|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
223536551|NCT04970914|DRUG|Penpulimab|Penpulimab 200 mg administered intravenously every 3 weeks.
223536552|NCT06432465|DEVICE|active tDCS|The anode will be placed over the right DLPFC (F4 on the EEG 10-20 system) and the cathode over the left DLPFC65 (F3) using 25cm2 sponges at an intensity of 2mA. Stimulation will be delivered for 20 minutes via two saline-soaked surface sponge electrodes and a battery-driven, constant current stimulator (NeuroConn DC Stimulator Plus).
223536553|NCT06432465|DEVICE|sham tDCS|Same device and procedures as active tDCS with the exception that the device includes a study mode, in which subject-specific codes are entered to deliver active or sham stimulation, keeping the administrator blinded. Sham stimulation will use a method in which stimulation will be ramped up and back down over a 30-second period at the beginning and end of sham tDCS.
223536554|NCT00760552|OTHER|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
223721559|NCT06001840|BEHAVIORAL|Promotion factors|In the full nicotine conditions, participants' preferred cigarettes and NVP products will be available in the LETM and preferred cigarettes will be available in the iETM. In the low nicotine conditions, a ban will permit only VLNCs in the LETM and preferred cigarettes will be available in the iETM.
223948004|NCT00853528|OTHER|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
223948005|NCT00853528|PROCEDURE|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
223948006|NCT00853528|PROCEDURE|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
223948007|NCT00853528|RADIATION|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
223948008|NCT00853528|RADIATION|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
223948009|NCT04338919|PROCEDURE|Percutaneous coronary intervention|PCI with stent implantation
223948010|NCT04338919|DRUG|Ticagrelor plus aspirin|Ticagrelor plus aspirin
223948011|NCT00130182|DRUG|denufosol tetrasodium (INS37217)|
223948012|NCT04053699|DRUG|Von Willebrand Factor-Containing Product|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
223948013|NCT05704192|PROCEDURE|TACE ± Systemic therapy|TACE: conventional TACE (cTACE) or drug-eluting beads TACE (dTACE); Systemic therapy: programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, vascular endothelial growth factor -tyrosine kinase inhibitor (VEGF-TKI)/bevacizumab, PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, radiotherapy or chemotherapy.
223948014|NCT05020028|DRUG|Cannabidiol (CBD)|Patients will be dispensed enough 25mg cannabidiol (CBD) Orally Disintegrating Tablets (ODT) to take a standard dose of 50mg three times daily for 84 days.
223948015|NCT05020028|DRUG|Placebo|25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
223948016|NCT02542332|OTHER|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
223948017|NCT00712413|DRUG|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
223948018|NCT01332266|DRUG|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
223948019|NCT01332266|DRUG|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
223536555|NCT00760552|OTHER|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, \& possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
223536556|NCT00760552|OTHER|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
223536557|NCT03616821|DRUG|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
223536558|NCT03616821|DRUG|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
223948020|NCT02196610|OTHER|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
223948021|NCT03306498|DRUG|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
223948022|NCT03302091|DRUG|BI 1467335|28 day treatment period
223948023|NCT02086461|DEVICE|Pneumatic pyloric dilatation|
223948024|NCT02086461|OTHER|15 mm pyloric balloon dilatation|
223948025|NCT02680015|BEHAVIORAL|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
223948026|NCT02792855|DEVICE|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
223948027|NCT02792855|DEVICE|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
223948028|NCT00994851|DRUG|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
223948029|NCT00994851|DRUG|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
223948030|NCT03139526|OTHER|observational study so no intervention|observational study, so no intervention
223948031|NCT05556200|DRUG|Anti-PD-1 monoclonal antibody|Camrelizumab 200 mg, iv, d1, q3W (3 mg/kg if weight \<50 kg)
223948032|NCT05556200|DRUG|VEGFR2 Tyrosine Kinase Inhibitor|Apatinib 250 mg, po, qd
223948033|NCT02941744|DRUG|nivolumab|low fixed dose ipilimumab in combination with nivolumab
223948034|NCT02941744|DRUG|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
223948035|NCT00286039|PROCEDURE|Blood sampling|Blood sampling is used.
223948036|NCT06269068|DIAGNOSTIC_TEST|Central sensitization inventory|Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.
223948037|NCT06269068|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.
223948038|NCT06269068|OTHER|Oswestry Low Back Pain Disability Questionnaire|With this scale, it is questioned to what extent the patient is affected by low back pain in selected daily living activities under certain ten headings. In total scoring, disability is expressed as a percentage, and high scores are interpreted in favor of an increase in disability.
223948039|NCT06269068|OTHER|Douleur Neuropathique 4|The questionnaire consists of 10 items; while the nature of pain is questioned in 7 items, the other 3 items include brief sensory examination. Patients with a score of 4 or more out of 10 are considered to have neuropathic pain.
223948040|NCT06269068|OTHER|Visual analogue scale|global pain score on a 0 to 10
223948041|NCT06323369|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948042|NCT06323369|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948043|NCT06323369|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948044|NCT06323369|PROCEDURE|Surgical resection|Standard of care
223948045|NCT06323369|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948046|NCT06323369|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948047|NCT06323369|RADIATION|Radiation|Recommended, standard of care
223948048|NCT06323369|DRUG|Carboplatin（neoadjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948049|NCT06323369|DRUG|Carboplatin（adjuvant）|Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223948050|NCT01404637|DRUG|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
223948051|NCT01404637|DRUG|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
223948052|NCT05582226|PROCEDURE|ACL reconstruction|"Orthopedic surgical operation in which a ruptured anterior cruciate ligament is repaired and reattached to the muscle connection points with a graft, a fashioned ligament that is meant to serve as a replacement for the ruptured muscle tissue."
223948053|NCT05582226|PROCEDURE|Mesenchymal stem cell implantation|Stem cells are to be extracted from tissue at the stump of the ACL attachment point and inserted on the graft in the hopes of improving healing response
223536559|NCT04883944|OTHER|Intervention group|"Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice."
223536560|NCT04883944|OTHER|Standard care group|"A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding."
223536561|NCT04915716|OTHER|Peripheral blood glucose levels were monitored|Peripheral blood glucose levels were monitored
223536562|NCT04723719|BEHAVIORAL|SIESTA|SIESTA is a CBT sleep training for adolescents with ADHD with a focus on sleep hygiene, motivational interviewing and planning and organization.
223948054|NCT02504411|DEVICE|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
223948055|NCT02504411|DEVICE|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
223948056|NCT04613284|DRUG|Recombinant human endostatin (Endostar)|Continuous intravenous infusion of endostar (Simcere Pharma- ceutical, Nanjing, China) was made over 120 h before the begin- ning of radiotherapy, and then repeated every two weeks. The dose was 7.5 mg/m2/24 h 120 h, 14 days/cycle. ECG monitoring was performed during the first delivery of endostar.
223948057|NCT04613284|RADIATION|Thoracic irradiation of 50 Gy with 3DCRT or IMRT|Concurrent thoracic chemoradiotherapy with reduced irradiation dose of 50 Gy will be given to patients with unresectable stage III NSCLC who can not tolerate irradiation dose to 60 Gy.
223948058|NCT04630119|OTHER|Questionnaires on quality of life, emotional health and presenteeism|After obtaining informed consent, a pro forma consisting of the socio-demographic details and pre-treatment assessment questionnaire (including Visual analog scale The Medical Outcomes Study Short-Form Health Survey The hospital anxiety and depression scale Work functioning impairment scale) was filled for each subject.
223948059|NCT01375790|DEVICE|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
223948060|NCT01375790|OTHER|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
223948061|NCT02124044|DRUG|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
223948062|NCT02124044|DRUG|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
223536563|NCT04723719|OTHER|Treatment as usual for ADHD|Participants continue their treatment as usual for ADHD.
223536564|NCT01312831|OTHER|Vitamin B12 (cyanocobalamin)|
223536565|NCT02189109|DRUG|NVX-108|0.2% emulsion administered i.v.
223948063|NCT02815865|DEVICE|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
223948064|NCT02815865|DEVICE|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
223948065|NCT02815865|DRUG|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
223948066|NCT01835652|OTHER|Active Exercise|
223948067|NCT01835652|OTHER|Passive Exercise|
223948068|NCT02822599|DRUG|RiaStAP|To decrease post-operative bleeding volume.
223948069|NCT02822599|DRUG|Saline|Placebo consisting of normal saline 0.9%
223721560|NCT06001840|BEHAVIORAL|Mitigation strategies|"Health Communications. The first narrative describes a person unknown to the participant who purchases from the illegal market and experiences negative life outcomes (e.g., ill health from contaminants). The second narrative incorporates cognitive biases of social proof (i.e., portraying a choice as the opinion of the majority).~Availability of Nicotine Replacement Therapies (NRT): Transdermal NRT will be available in the LETM at two different prices. In one condition, transdermal NRT will be available at a 50% subsidy in the form of coupons. In the other condition, a five-day supply of NRT will be available for free.~Penalties: Penalties will be presented in different fine magnitudes along with a description of the consequences of illegal purchases (i.e., a criminal record)."
223948070|NCT02128269|BIOLOGICAL|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
223948071|NCT06026943|DEVICE|DaRT seeds insertion|An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
223948072|NCT00878189|DRUG|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
224100734|NCT01568944|DRUG|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
224100735|NCT01568944|PROCEDURE|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
223948073|NCT01623011|PROCEDURE|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
223721561|NCT05370365|PROCEDURE|Below elbow cast|Patients will be stay with a below elbow cast for 4 or 6 weeks
224100736|NCT02650310|DEVICE|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
223721562|NCT07131319|OTHER|Spatially Fractionated Radiotherapy (SFRT)|Several spherical volumes (with a diameter of 1 cm) are selected within the hypoxic area of the primary tumor. The distance between each spherical volume is 1.5 - 2 cm, and a high-dose radiotherapy of 12 Gy × 1F is delivered.
223721563|NCT07131319|DRUG|Tislelizumab, Carboplatin, Pemetrexed|For adenocarcinoma, pemetrexed (500 mg/m², day 1) + carboplatin (AUC 5, day 1) is used.
223721564|NCT07131319|DRUG|Tislelizumab, paclitaxel, Carboplatin|For NSCLC with pathological types other than adenocarcinoma, nab-paclitaxel (100 mg/m² on day 1 and day 8) + carboplatin (AUC 5, day 1) is used.
223721565|NCT04841590|OTHER|Intervention of the experimental group (EG)|Treatment through the use of manual physiotherapy techniques such as mobilization techniques in the spinal column, cranial techniques and visceral mobilization applied by gentle pressure, according to the therapist's diagnostic criteria after performing palpatory and mobility tests.
223721566|NCT04841590|OTHER|Control Group (CG)|Subjects in the control group (CG) will not receive any treatment
224100737|NCT06392490|OTHER|Technology Based Asthma Program|Evaluate the impact of peer-led and adult-based technology-based education on the quality of life, asthma control, asthma knowledge and self-efficacy in adolescents diagnosed with asthma.
224100738|NCT03139370|DRUG|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
223721567|NCT06985446|OTHER|Study Group:Black stain-positive|In children with black stains (BS+), we evaluated DMFT, dft, plaque index (Silness-Löe), gingival index (Löe-Silness), salivary pH, salivary flow rate, salivary buffering capacity, and body mass index (BMI).
223721568|NCT06985446|OTHER|Control Group: Black stain-negative|In healthy children without black stains (BS-), we assessed DMFT, dft, plaque index (Silness-Löe), gingival index (Löe-Silness), salivary pH, salivary flow rate, salivary buffering capacity, and body mass index (BMI).
223721569|NCT06992791|BEHAVIORAL|Prenatal Education on Childbirth|"Starting at 30 weeks, participants will be given access to Tinyhood, an online educational service aimed at perinatal education. Text reminders will be sent periodically throughout the third trimester to encourage interaction with educational videos and written materials, which will be tracked for number of interactions via the Tinyhyood interface. The videos include: Pregnancy Milestones, Physically and Mentally Preparing for Labor, Finding Support During Labor, Deciding Birth Preferences and Self-Advocacy, Signs Labor Is Approaching, Contractions, Signs of Preterm Labor, Going to the Hospital, Baby's Positioning, Stages of Labor, Induction of Labor, Managing Pain, Pain Options in Labor, Relaxation Techniques for Labor,  Breathing Techniques, Labor Positions and several handouts highlighting common obstetrical emergencies and possible interventions."
223948074|NCT01623011|PROCEDURE|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
223948075|NCT01623011|OTHER|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
223948076|NCT01750788|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
223948077|NCT00703092|DRUG|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
223948078|NCT05774262|PROCEDURE|Pacemaker implantation|Elective pacemaker implantation (DDDR) for functional AVB according to the 2021 ESC Guidelines for Cardiac Pacing
223948079|NCT05774262|PROCEDURE|Cardioneuroablation (CNA)|"Experimental method; elective implantable loop recorder (ILR) and biatrial, binodal, atomically and electroanatomically guided CNA with extracardiac vagal nerve stimulation (ECVS) prior and after procedure monitoring (disappearance of ECVS-induced AVB with the goal of achieving post-procedure and maintaining a target heart rate \> 50 beats per minute). CNA procedure is performed with radio-frequency generators and irrigated catheters and with support of 3D-electroanatomic mapping system.~CNA group will receive external ECG recorders. The major reason for external ECG recorders is to provide documentation of clinical AVB, as well as monitoring of patients before and after CNA (or PM implantation, if accepted). In case of severe AVB symptoms always the emergency system will be called."
223948080|NCT03165305|OTHER|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
223948081|NCT05396365|DIAGNOSTIC_TEST|Dynamometry|Hand grip dynamometer measure of strength and anthropometric measurements
223948082|NCT05255744|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
223948083|NCT04155372|PROCEDURE|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
223948084|NCT05173766|OTHER|ergonomic principls|Ergonomic principles for posture correction in office for computer users.
223948085|NCT00539955|BEHAVIORAL|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
223948086|NCT00539955|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
223948087|NCT01558726|BEHAVIORAL|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
223948088|NCT01558726|BEHAVIORAL|Usual Treatment|The usual treatment used for regular patients of CAPSad
223948089|NCT03748056|BEHAVIORAL|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
223948090|NCT03748056|BEHAVIORAL|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
223948091|NCT06215326|BEHAVIORAL|moderate-intensity continuous training|Participants in MICT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a warm-up of 5 minutes at 50% at peak WR, the patient start exercising at 60%-70% peak WR for 30-40 minutes (four 5-8 minutes sets, with a 2-min rest in between), and then the patients cooled down for 5 minutes at 50% peak WR. Moderate-intensity exercise training intensity control at 55-74% HRmax or 40-69% VO2peak or PRE12-13 as recommended by guidelines.
223948092|NCT06215326|BEHAVIORAL|high-intensity interval training|Participants in HIIT group will need to additional complete a total of 12 supervised training sessions in 2-3 weeks.After a 5-minute warm-up at 50% at peak WR, the patients complete 20 series of vigorous-intensity sprint (80%-100% peak WR for 30-60s) separated by a low-intensity recovery (30% peak WR or completely rest for 15s), and then the patients cooled down for 5 minutes at 50% peak WR. Participants will begin training at a relatively moderate intensity (60%-65% peak WR) for the first 3 sessions and gradually increase to the target intensity beginning on the 4th session. Intensity control of high-intensity exercise training at 75-90% HRmax or 70-85% VO2peak or PRE14-16 as recommended by guidelines.
223948093|NCT02520336|BEHAVIORAL|Reminder|
223536566|NCT03268564|BEHAVIORAL|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~1. Viewing a promotion video and a demonstration video~2. Brief motivational interviewing through telephone~3. Visiting the HIVST-online webpage~4. Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~1. Viewing a promotion video and a demonstration video~2. Visiting the HIVST-online webpage~3. Receiving a free self-testing kit and follow-up reminders"
223536567|NCT01306292|DRUG|SonoVue|dose of 4.8 mL administered intravenously one time
223536568|NCT01306292|DRUG|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
223536569|NCT01165034|OTHER|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
223536570|NCT03251521|OTHER|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
223536571|NCT02797821|DRUG|Asfotase alfa|
223536572|NCT01057979|BEHAVIORAL|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
223536573|NCT01057979|BEHAVIORAL|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
223536574|NCT00353002|DRUG|Ametop (4% Amethocaine cream )|
223536575|NCT00353002|DRUG|Maxilene (4% Liposomal Lidocaine)|
223721570|NCT06992310|DEVICE|Hearing Aid with standard noise reduction (NR_1)|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The active comparator condition is the state of the art Noise Reduction principle to mimic the natural directivity of the outer ear."
223721571|NCT06992310|DEVICE|Hearing Aid with NR_2|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
223536576|NCT04039932|BEHAVIORAL|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
223536577|NCT04391920|DEVICE|CytoSorb 300 mL device|CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.
223536578|NCT01249001|DRUG|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
223536579|NCT01249001|DRUG|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
223536580|NCT05595746|PROCEDURE|dental implant placement|In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
223536581|NCT04786054|DIAGNOSTIC_TEST|BED Questionnaire|BED Questionnaire
223536582|NCT02333448|BIOLOGICAL|Blood sample taken on the day the treatment is initiated|
223536583|NCT02333448|BIOLOGICAL|Blood sample taken on day 3 after initiation of treatment|
223536584|NCT02333448|BIOLOGICAL|Blood sample taken on day 5 after initiation of|
223536585|NCT02333448|BIOLOGICAL|Blood sample taken on day 7 after initiation of treatment|
223536586|NCT02333448|BIOLOGICAL|Blood sample taken on day 10 after initiation of treatment|
223721572|NCT06992310|DEVICE|Hearing Aid with NR_3|"Each participant will be fitted with the 3 different noise reduction (sound changing) principles on the same hearing aid, saved to 3 manual programs (ensures exact same hearing loss compensation for each intervention).~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort.~The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
223721573|NCT06856915|OTHER|Inspiratory muscle training|Participants will engage in inspiratory muscle training programme at home using an inspiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
223721574|NCT06856915|OTHER|Combined inspiratory and expiratory muscle training|Participants will engage in inspiratory+expiratory muscle training programme at home using an inspiratory+expiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
223721575|NCT06856915|OTHER|Sham inspiratory muscle training|Participants will engage in sham inspiratory muscle training programme at home using a sham inspiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
223721576|NCT06856915|OTHER|Sham combined inspiratory and expiratory muscle training|Participants will engage in sham inspiratory+expiratory muscle training programme at home using a sham inspiratory+expiratory muscle training threshold device . This training will be conducted twice daily, five days a week, for eight weeks, with physiotherapist supervision provided three times per week by telerehabilitation.
223721577|NCT06856915|OTHER|Conventional cardiac rehabilitation programme|Following the respiratory muscle training programme, participants will transition to a center-based cardiovascular exercise programme conducted twice weekly for eight weeks.
223721578|NCT04196842|DEVICE|Telemonitoring devices|Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
224100739|NCT03139370|DRUG|Cyclophosphamide|Administered intravenously
223721579|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 9 mg/kg/day
223721580|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 18 mg/kg/day
223721581|NCT06614894|DRUG|Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day|Ambroxol Hydrochloride 30 mg oral pill/tablet - 27 mg/kg/day
223948094|NCT05121285|OTHER|Delivery of contrast fluid by lower GI endoscopy|Each participant will receive one delivery of 440 ml contrast fluid by lower GI endoscopy to the cecum of the colon. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. An colon X-ray is obtained within 10 minutes after the contrast fluid is delivered. The participants is in a supine position fram delivery and until the colon x-ray is obtained.
223721582|NCT06997120|BEHAVIORAL|Bodhi AIM (intervention group)|"AIM (Action In Mindfulness) is a smartphone app that teaches users to establish a daily meditation practice via a 30-day path, with each day consisting of a brief audio- or video-guided file. In addition to the 30 daily path files, users have access to a menu of to go audio-guided meditation practices that they may access any time to prepare for particular situations."
224100740|NCT03139370|DRUG|Fludarabine|Administered intravenously
224100741|NCT03139370|DEVICE|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
224100742|NCT03926403|OTHER|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least lightly anxious about their management (score ≥ 36)."
223536587|NCT06564415|PROCEDURE|Transperineal Laser Ablation of Prostate|Transperineal Laser Ablation of the Prostate is an ultra minimally-invasive procedure that consists in the insertion trough the perineum skin of laser fibers into the prostatic adenoma, under US guidance. Laser energy generates an area of coagulative necrosis that will bring to a reduction of the prostatic volume.
223536588|NCT03848780|DRUG|Desflurane|
223536589|NCT03662061|OTHER|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
223721583|NCT06997120|BEHAVIORAL|HIB (control group)|"HIB (Health In Balance) is a smartphone app that is matched to AIM for time and structure, but includes health promotion content (e.g., educational information on substance use) in place of the meditation content featured in AIM. Like AIM, HIB includes a 30-day path of audio and video files, along with a menu of to go audio files that users may access any time to review key intervention concepts."
223536590|NCT06101810|BEHAVIORAL|COMET|information already included in arm/group descriptions.
223536591|NCT06101810|BEHAVIORAL|CBT|information already included in arm/group descriptions.
223536592|NCT05905562|OTHER|core stabilization exercises|Core muscles activation exercises will be performed on patients to target the abdominals.
223536593|NCT05905562|OTHER|Spinal mobilization techniques|lumbar spine joint mobilization techniques will be performed to patient in prone lying.
223536594|NCT00105664|PROCEDURE|Collaborative care model|
223536595|NCT00105664|PROCEDURE|Group interventions|
223536596|NCT00105664|PROCEDURE|Facilitated consultation|
223536597|NCT04780139|DIAGNOSTIC_TEST|Ultrasonographic Evaluation of Internal Jugular Vein Cross Sectional Area|Measuring the internal jugular vein cross section area and relate this to the incidence of hypotension after spinal anesthesia.
223536598|NCT00549159|DEVICE|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
223536599|NCT00549159|DEVICE|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
223536600|NCT04243148|COMBINATION_PRODUCT|Home exercise program for 12 months.|Physical exercise at home: At the beginning of the study, group sessions will be conducted with 5 patients of 1-hour duration, where they will be taught the individualized program according to their physical condition and they will be given the necessary material (pedaling, dumbbells and elastic bands) and paper support on the program, also using the Vivifrail method through infographics. The group session will be repeated every 3 months to check the compliance of the program by reviewing daily activity, evaluate possible problems and review the exercises. The program will consist of aerobic and anaerobic exercise by pedaling (cardiovascular resistance) and resistance exercises with dumbbells and elastic bands (muscular strength), flexibility training by stretching, and coordination and balance exercises. Patients will perform 3 sessions per week of 20-30 min. increasing progressively according to tolerance up to 45-60 min. each.
223536601|NCT04243148|COMBINATION_PRODUCT|Multispecies probiotic: Vivomixx®|"Multispecies probiotic: Vivomixx® is a probiotic mixture of 8 bacterial strains:~Streptococcus thermophilus DSM 24731® / NCIMB 30438, Bifidobacterium breve DSM 24732® / NCIMB 30441, Bifidobacterium longum DSM 24736® / NCIMB 30435\*, Bifidobacterium infantis DSM 24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM 24735® / NCIMB 30442, Lactobacillus plantarum DSM 24730® / NCIMB 30437, Lactobacillus paracasei DSM 24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM 24734® / NCIMB 30440\*\*~\* Re-classified as B. lactis \*\* Re-classified as L. helveticus The active agent will be supplied as an envelope of 4.4 g with a dose of 450x109 million live bacteria per envelope with maltose and silicon dioxide as excipients, administered 2 times/day throughout the study."
223729457|NCT05856201|PROCEDURE|Shull technique via V-NOTES|Using a cold-bladed scalpel, pericervical colpotomy and subsequent opening of the Douglas and vesico-uterine space is performed. The following step is forcipressure and section of uterosacral ligaments bilaterally with cold blade scissors and ligation in Polysorb 0. A v-PATH® wall retractor is placed, after insertion of three trocars. Total hysterectomy is then performed by standard V-NOTES technique. After transperitoneal visualization of the ureters bilaterally, the peritoneum is incised between the ureters and the uterosacral ligaments, which are thus bilaterally isolated, and three points in polydioxanone 2/0 are placed per side. The v-PATH wall retractor is then removed. Finally the suspension of the vaginal vault at the uterosacral ligaments is made according to Shull technique. Eventual fascial corrections of concomitant anterior or posterior defects will be associated if needed.
223948095|NCT05121285|OTHER|Delivery of contrast fluid by enema with and without positioning|"Each participant will receive one delivery of 440 ml contrast fluid by enema. The participants perform a bowel lavage using Sodiumpicosulphate/Magnesiumcitrate (Picoprep, Ferring) 24 hours before the delivery of contrast fluid. The enema procedure includes:~1. The participant lies on his/her left side in neutral position when the enema is delivered~2. X-ray of the colon is obtained with the participant lying on his/her back.~3. The participant is positioned back to his/her left sided position and tilted in a Trendelenburg position. The position is held for two minutes~4. The participant is turned to an abdominal position while the bed remains tilted in Trendelenburg position.~5. Participant turne to the right side. When positioned the bed is tilted the opposite way (anti-Trendelenburg.) The position is held for two minutes.~6. A second colon X-ray is obtained after the participants has rested for ten minutes in a supine neutral position"
223948096|NCT04347005|DRUG|Cohort 1: AR882|Single dose of AR882 or matching placebo
223948097|NCT04347005|DRUG|Cohort 2: AR882|Single dose of AR882 or matching placebo
223536602|NCT04243148|COMBINATION_PRODUCT|Branched-chain amino acids (BCAA)|Branched-chain amino acids (BCAA): In addition to the exercise program and the probiotic, patients in the intervention group will receive BCAA supplements (powder in 8:1:1 ratio in favor of L-leucine) 10 g 30-60 min. before the exercise session throughout the study, in order to enhance the effect of exercise on muscle mass and improve cognitive function. We have chosen this dose based on the literature data and the satisfactory results obtained with this dose in our previous study. BCAA supplements will be supplied by the Pharmacy Service of our center.
223948098|NCT04347005|DRUG|Cohort 3: AR882|Single dose of AR882 or matching placebo
223948099|NCT04347005|DRUG|Cohort 4: AR882|Single dose of AR882 or matching placebo
223948100|NCT04347005|DRUG|Cohort 5: AR882|Single dose of AR882 or matching placebo
223948101|NCT04347005|DRUG|Cohort 6: AR882 Food Effect|Single dose of AR882 or matching placebo in a fed state
223536603|NCT04243148|COMBINATION_PRODUCT|No specific intervention.|Follow up as a clinical practice
223536604|NCT02536664|DRUG|Rituximab|
223536605|NCT04063813|BEHAVIORAL|Experimental: 40 minute up trial|
223536606|NCT04063813|BEHAVIORAL|Experimental: 40 minute down trial|
223536607|NCT04063813|BEHAVIORAL|Experimental: Two 20 minute up trials|
223536608|NCT04063813|BEHAVIORAL|Experimental: Two 20 min down trials|
223536609|NCT04063813|BEHAVIORAL|Active Comparator: Sedentary trial|
223536610|NCT03807583|DRUG|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
223948102|NCT04347005|DRUG|Cohort 7: AR882 Solid Oral Formulation|Single dose of AR882 or matching placebo
223948103|NCT04347005|DRUG|Cohort 8: AR882 in combination with allopurinol|Single dose of allopurinol alone and a single dose of AR882 in combination with a single dose of allopurinol
223948104|NCT04347005|DRUG|Cohort 9: AR882 in combination with febuxostat|Single dose of febuxostat alone and a single dose of AR882 in combination with a single dose of febuxostat
223948105|NCT02382172|BEHAVIORAL|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
223536611|NCT03807583|DIETARY_SUPPLEMENT|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
223536612|NCT01790373|BEHAVIORAL|Suubi+Adherence|"* Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~* Financial education and workshops on asset-building, future planning, and protection from risks~* Mentorship from a young adult/near-peer~* Family-based microenterprise development training~* Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
223536613|NCT01790373|BEHAVIORAL|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
223948106|NCT02382172|OTHER|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
223948107|NCT05015842|OTHER|Conventional Physical Therapy|This is a combine protocol of different therapeutic exercises and heat therapy.
223948108|NCT05015842|OTHER|Kinesio Tapping|Kinesio Tapping is an adhesive and elastic fiber used for different outcomes like pain and swelling reduction among physical therapists.
223948109|NCT06509594|OTHER|Protocol of Scapular Stabilization Exercises;|"Exercise for the middle trapezius and rhomboid muscles: Participants were instructed to stand with their arms hanging beside their bodies. Then, they were instructed to flex their elbows 90◦ holding an elastic band and performing an external rotation of the shoulder, pulling both scapula together. Subsequently, they returned to a neutral shoulder position with elbow flexion.~Exercise for the lower trapezius muscle: Participants were instructed to lie down in a prone position while holding an elastic band attached at one end under a mattress. They were then instructed to raise their shoulder 140◦.~Exercise for the serratus anterior muscle: Participants were instructed to stand and flex their elbows 90◦ while holding an elastic band fixed behind the participants. Next, they were instructed to move the arm forward with a protracted scapula."
223721584|NCT06996431|BEHAVIORAL|EMA-based weight management intervention|"Participants will complete four 7-day EMA sessions, reporting their diet for 3 days and physical activity for 4 days by completing ﬁve brief daily mobile app surveys (under 2 minutes each), using a 5-digit case number for privacy. The app automatically retrieves Fitbit data-such as step count, moderate-to-vigorous physical activity (MVPA), sedentary behavior, and heart rate- and sends timely reminders if surveys are missed.~Within one week after the ﬁrst EMA session, participants will attend a nurse- led counseling session using the 5A Model (Assess, Advise, Agree, Assist, Arrange), providing tailored feedback based on EMA and Fitbit data, and addressing barriers to change. This is followed by risk-based coaching from a dietitian and ﬁtness instructor, with individualized diet and exercise plans. Between sessions, participants receive ongoing support, including instant reminder messaging and weekly motivational messages to encourage healthy behaviors."
223948110|NCT06509594|OTHER|Protocol of Muscle Energy technique;|"During upper trapezius stretching, the participants were in seated position by holding the chair with one arm, and laterally tilted the head to the opposite side with the other hand pushing the head to increase lateral stretch.~For pectoralis muscle stretch, participants were asked to stand in front of the Doorframe with elbow bent at 90 degree and was asked to lean forward without Taking a step forward. The stretch is felt across the anterior chest, which is held for 15-30 seconds with 2-3 repetitions. For levator scapulae stretch, the subjects were asked to take the seated position while holding the chair with one hand in order to maintain shoulder depression, then To flex and rotate neck to the opposite side by placing the other hand at the back of their head and to slowly pull it down toward the armpit."
223948111|NCT01273298|DRUG|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
223948112|NCT01273298|DRUG|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
223948113|NCT01021748|DRUG|MK-2206|Oral tablets
223948114|NCT01021748|DRUG|AZD6244|Oral capsules
223948115|NCT00958048|DEVICE|non-invasive ventilation|CPAP, BiPAP
223948116|NCT05020067|RADIATION|superficial parotid lobe-sparing intensity-modulated radiotherapy|The superficial parotid lobe was contoured as an OAR, and V26 (the percentage volume receiving 26 Gy or more) in the superficial parotid lobe was constrained to be less than 30%.
223948117|NCT01260883|DRUG|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
223948118|NCT01260883|DRUG|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
223948119|NCT01260883|DRUG|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
223948120|NCT03070548|DRUG|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
223948121|NCT02027350|DEVICE|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
223721585|NCT06996431|BEHAVIORAL|Minimal Intervention|Participants will not receive risk-stratified services but will be provided with informational leaflets offering general advice on maintaining a healthy diet, regular exercise, smoking cessation, and alcohol cessation.
223721586|NCT06999226|BEHAVIORAL|RENEW-AI|AI assisted health coaching using the LLM-driven chat functionality.
223721587|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
223721588|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days."
223729458|NCT05528679|DRUG|610 100mg|100mg administered subcutaneously Q4W
223729459|NCT05528679|DRUG|610 300mg|300mg administered subcutaneously Q4W
223948122|NCT04907383|OTHER|quality of life|QoL assessment
223948123|NCT02319707|DRUG|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
223948124|NCT02319707|DRUG|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
223948125|NCT01566383|PROCEDURE|24-hr pH monitoring|"Visit 1~The following will be done:~* A medical history including review of your current drugs;~* Collection of demographic information;~* A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~* 24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~* The catheter will be removed from your nose; and~* You will return the recording device"
223721589|NCT07002229|DRUG|Azvudine tablets(FNC) and Dolutegravir Sodium Tablets (DTG)|"This study consisted of 3 cycles, each cycle was administered orally for 5 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~DTG: 50 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days; FNC+ DTG: FNC 3 mg (1 tablet) + DTG 50 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 5 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 5 consecutive days."
223721590|NCT07000812|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants in the intervention arm receive 12 weekly sessions of individual CBT. Therapy includes exposure and response prevention, cognitive restructuring, psychoeducation, and relapse prevention strategies.
223721591|NCT07002281|DRUG|[14C]Azvudine suspension|A single oral dose of 3 mg/100 μCi of \[14C\]Azvudine suspension is given orally on an empty stomach.
223721592|NCT07000474|OTHER|Omics|Multiparametric analysis of clinical images, histopathological images, CT scans, and molecular analysis.
223948126|NCT01829711|DRUG|Moxetumomab pasudotox|
223948127|NCT01829711|DRUG|IV Bag Protectant for Moxetumomab pasudotox|
223948128|NCT01482091|DRUG|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
223948129|NCT01482091|DRUG|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
223948130|NCT01214070|OTHER|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
223948131|NCT01214070|BEHAVIORAL|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
223948132|NCT01214070|BEHAVIORAL|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
223948133|NCT01214070|BEHAVIORAL|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
223948134|NCT01480258|BIOLOGICAL|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis \[acellular, component\], hepatitis B \[recombinant DNA\], polio virus \[inactivated\], and Haemophilus influenza type b conjugate vaccine \[adsorbed\]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
223948135|NCT01480258|BIOLOGICAL|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
223948136|NCT01480258|BIOLOGICAL|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
223948137|NCT01480258|BIOLOGICAL|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis \[DTaP\], Hepatitis B \[HepB\], Poliovirus \[IPV\] and Haemophilus influenzae type b \[Hib\] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
223948138|NCT01000207|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
223948139|NCT05448222|DIAGNOSTIC_TEST|Diagnostic Test: gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
223948140|NCT01315977|DIETARY_SUPPLEMENT|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
223948141|NCT03477084|BIOLOGICAL|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
223948142|NCT03799809|DRUG|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
223948143|NCT02953756|RADIATION|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
223948144|NCT04089202|OTHER|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
223948145|NCT04089202|OTHER|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
223948146|NCT06092177|PROCEDURE|Periodontal surgery with virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
223948147|NCT06092177|PROCEDURE|Periodontal surgery without virtual reality distraction|Periodontal surgery to improve gingival contour and eliminate inflamed periodontal pockets
223948148|NCT05549466|DRUG|Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W."
223948149|NCT05549466|DRUG|Apatinib, Camrelizumab|Apatinib, po, 250mg, qd. Camrelizumab, iv, 200mg, D1, Q3W.
223948150|NCT05549466|DRUG|Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|"Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.~Camrelizumab, iv, 200mg, D1, Q3W."
223721593|NCT07002424|BEHAVIORAL|Therapeutic - Psychological|The intervention uses a transdiagnostic model that incorporates aspects of peer support, psychoeducation, trauma-informed cognitive behavioural therapy (CBT), Compassion focused therapy (CFT) models of distress. It also aligns itself to the Dual Processing Model of coping with bereavement (Stroebe \& Schut, 2010) and Tonkin's model of grief (Tonkin, 1996).
223948151|NCT05549466|DRUG|Chemotherapy (gemcitabine/ capecitabine/ docetaxel)|Gemcitabine, iv, 1000 mg/m\^2, D1+D8, Q3W, 6 cycles; or capecitabine, po, 1250 mg/\^2, D1-14, BID, Q3W; or docetaxel, iv, 75 mg/m\^2, D1, Q3W.
223948152|NCT03316170|BEHAVIORAL|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
223948153|NCT03316170|DRUG|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
223948154|NCT02636114|PROCEDURE|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
223948155|NCT00368602|DRUG|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
223948156|NCT00368602|OTHER|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
223948157|NCT02169414|DRUG|BIA 9-1067 5 mg|OPC, Opicapone
223948158|NCT02169414|DRUG|BIA 9-1067 25 mg|OPC, Opicapone
223948159|NCT02169414|DRUG|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
223948160|NCT02169414|DRUG|Placebo|PLC, Placebo
223948161|NCT02169414|DRUG|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
223721594|NCT07132827|DRUG|SHR-1905 Injection|SHR-1905 Injection
223721595|NCT07132827|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
223948162|NCT03688087|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
223948163|NCT03688087|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
223948164|NCT03874949|DEVICE|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
223536614|NCT01221506|DRUG|Pazopanib|800 mg PO QD x 28 days
223536615|NCT01221506|DEVICE|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
223536616|NCT03339596|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
223948165|NCT03874949|DEVICE|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
223948166|NCT03374254|BIOLOGICAL|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
223536617|NCT03339596|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
223536618|NCT01873105|OTHER|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
223948167|NCT03374254|DRUG|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
223948168|NCT03374254|DRUG|Oxaliplatin|85 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m\^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
223948169|NCT03374254|DRUG|Leucovorin|400 mg/m\^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
223948170|NCT03374254|DRUG|5-Fluorouracil [5-FU]|2400 mg/m\^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m\^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
223948171|NCT03374254|DRUG|Irinotecan|180 mg/m\^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m\^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
223721596|NCT07132320|BIOLOGICAL|Pressure Ulcer Nursing AI Application Training|Clinical nurses receive training and guidance via an AI application designed for pressure ulcer nursing based on a clinical judgment model.
223721597|NCT07132320|BIOLOGICAL|Traditional Pressure Ulcer Nursing Education|Clinical nurses receive conventional pressure ulcer nursing education not involving the developed AI application.
223721598|NCT07132190|RADIATION|Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV|Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
223721599|NCT07016438|PROCEDURE|Transplant surgery|One piece of PAL-222 is implanted into the ulcer area through the surgical procedure.
223948172|NCT06012409|DEVICE|Hall Technique Prefabricated Metal Crown|The Hall Technique is a type of minimally invasive dental treatment. Hall Technique involves sealing the carious lesion under a Prefabricated Metal Crown to stop its progression preventing pain and/or infection.This makes the technique less invasive and it can be more acceptable to children than a traditional filling involving injections and drilling.
223948173|NCT04288869|OTHER|Continuous monitoring of arterial blood pressure|For all patients, mean arterial pressure (unit mmHg) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation.
223948174|NCT04288869|OTHER|Transcranial Doppler|"Measurement of cerebral blood flow velocity (CFV) with use of Transcranial Doppler ultrasonography.~For all patients, CFV (unit cm/s) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
223721600|NCT07014774|DEVICE|Laser acupuncture|"Laser acupuncture is a modern, non-invasive approach to acupuncture that uses low-level laser therapy (LLLT) instead of traditional needles to stimulate acupuncture points. This technique combines the principles of traditional Chinese medicine with modern technology to provide pain relief and promote healing (Chon et al., 2019).~* Device: UNIPHY PHYACTION 740, made in EEC device.~* Laser type: Gallium aluminum arsenide laser.~* Wavelength: 808 nm.~* Power Output: 200 mW.~* Dose/energy density: 4J/point.~* Frequency of treatment: Three times weekly for 8 weeks.~* Duration: 12 min.~* Cumulative dose: 48J/point.~* Target Acupuncture Points: Key points for CTS: PC4 (Ximen), PC6 (Neiguan), PC7 (Daling), PC8 (Laogong), LI4 (Hegu), LI10 (Shousanli), LI11 (Quchi), HT-2 (Qingling), HT7 (Shenmen), HT-8 (Shaofu), LU9 (Taiyuan) and LU10 (Yuji)"
223721601|NCT07014774|OTHER|Traditional Therapy|"* Splinting/Bracing: Patients in the two groups will advised to wear a static wrist splint locked at 0\_ wrist flexion for at least 8 h at night throughout the entire length of the study as the primary management which reduce pressure on the median nerve.~* Physical Therapy: Engaging in specific exercises, such as nerve glide exercises and wrist stretches, can improve mobility and reduce symptoms. These exercises aim to restore normal movement of the median nerve and alleviate compression"
223948175|NCT04288869|OTHER|Bispectral Index (BIS)|"Continuous measurement of burst suppression (BS; %) with use of Bispectral Index (BIS).~For all patients, BS will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation"
223721602|NCT07015502|OTHER|Questionnaires|Patients will undergo socio-demographic and history of violence suffered interview, passation of the Montgomery-Asberg Depression Rating Scale (MADRS),Childhood Trauma Questionnaire, Deshumanization Measure within Romantic Relationships scale, self-esteem scale, violentometer and an implicit association test (IAT).
223721603|NCT06680050|DRUG|Durvalumab (MEDI4736)|Durvalumab will be administered via IV infusion at a dose of 1500 mg on day 8 Q4W until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
223721604|NCT06680050|DRUG|Ceralasertib|Ceralasertib dose will be administered orally, 240mg BID, approximately 12 ± 2 hours apart, days 1 to 7 q28 (Q4W), up to progression or unacceptable toxicity.
223721605|NCT06680050|RADIATION|radiotherapy|Loco-regional recurrences of the primary tumor and regional lymph node metastases will be treated with a total dose of 36 to 50 Gy in daily fractions with a dose of 2 to 3 Gy per fraction. Two weeks from the last dose of radiotherapy, a systemic treatment with durvalumab and ceralasertib will be started.
223721606|NCT07014540|DRUG|Irinotecan Hydrochloride Liposome Injection|Liposome irinotecan (70/50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week
223721607|NCT07014540|DRUG|5-FU|5-FU (2400mg/m\^2) will be administered by continuous infusion for 46 hours in a 2-week
223721608|NCT07014540|DRUG|LV|LV (400mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week
223948176|NCT04288869|OTHER|Near-infrared spectroscopy|"Continuous measurement of cerebral oxygen saturation (SO2) with Near-infrared spectroscopy (NIRS).~For all patients, SO2 (%) will be collected over three distinct periods: 1) baseline or during pre-oxygenation at FiO2 of 21% in awake patients, 2) before orotracheal intubation, and 3) just after mechanical ventilation."
223948177|NCT05637944|PROCEDURE|oro tracheal intubation|chest trauma requiring oro tracheal intubation
223948178|NCT01164176|DRUG|everolimus|
223729460|NCT05528679|DRUG|placebo|administered subcutaneously Q4W
223948179|NCT01164176|OTHER|laboratory biomarker analysis|
223948180|NCT03040453|DEVICE|Microwave ablation|
223948181|NCT03040453|DEVICE|Irreversible electroporation|
223948182|NCT04502459|PROCEDURE|Tourniquet|A tourniquet is often used in total knee arthroplasty to achieve better visualization, reduce intra-operative bleeding and facilitate cement interdigitation
223721609|NCT07015489|DRUG|induction chemotherapy and immunotherapy|"All patients will first receive 2 cycles of induction chemoimmunotherapy, followed by radiotherapy. During radiotherapy, 2 concurrent cycles of chemoimmunotherapy will be administered. Afterward, maintenance immunotherapy will continue for up to one year.~Chemotherapy regimen: Paclitaxel: 135 mg/m², Day 1, every 3 weeks (Q3W); Carboplatin: area under the curve (AUC) = 5, intravenous infusion over more than 30 minutes, Day 2, Q3W; Alternatively, Nedaplatin: 75 mg/m², Day 2, Q3W.~Immunotherapy regimen: programmed death-1 (PD-1) inhibitor (e.g., Camrelizumab): Day 0, intravenous infusion, Q3W; Continued until disease progression (PD) or unacceptable toxicity, for a maximum duration of one year.~Radiotherapy: Prescribed dose: 95% of the planning target volume (PTV) and planning target volume for nodal disease (PTV-nd) should receive 50-50.4 Gy over 25-28 fractions; Fraction dose range: 1.8-2.0 Gy per fraction, 5 days per week; External beam radiotherapy to the chest."
223721610|NCT06826989|DRUG|[14C]MK-8527|Oral Dose
223721611|NCT03989999|PROCEDURE|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 12 hours of the brain injury.~If TCD is normal (FVd\>25 cm/sec and PI \<1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (\< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
223721614|NCT06618586|BEHAVIORAL|TodaysBaby|The TodaysBaby intervention is comprised of: 1) Text message-delivered, short educational videos in the first 2 months after birth, with each video timed to match content addressing anticipated barriers and facilitators to adhering to guidelines (e.g. parental concerns that infant will choke while supine). Participants will also have access to a web portal where intervention videos will be maintained. 2) Text queries regarding safe sleep practices, which collect data on sleep practices in near real-time and provide reinforcement of adherence. Mothers will receive 1-2 text message questions weekly that assess sleep practices in near real-time .
223721615|NCT03618186|COMBINATION_PRODUCT|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
223721616|NCT04419714|DEVICE|TatchSleep|Wearable measurement device
223721617|NCT07127211|BEHAVIORAL|Suspension and Stable Push-Up Training at Multiple Angles|"Participants will perform push-ups under three suspension conditions: (1) no suspension (hands and feet on a stable surface), (2) hands suspended using TRX straps, and (3) feet suspended using TRX straps. Each condition will be performed at five different body angles relative to the floor: +30°, +15°, 0°, -15°, and -30° (0° defined as shoulder joints aligned with ankle joints when arms are extended).~For each angle, participants will complete five repetitions, with 3-5 minutes of rest between angles and at least 48 hours of rest between suspension conditions to minimize fatigue effects. All exercises will be conducted under supervision to ensure correct form and safety.~Surface electromyography (EMG) will record muscle activity from the pectoralis major, anterior deltoid, triceps brachii, upper trapezius, and serratus anterior. EMG data will be processed as root mean square (RMS) and normalized to maximal voluntary isometric contraction (%MVIC).~This intervention is designed to dete"
223721618|NCT07132008|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
223948183|NCT05409170|PROCEDURE|COVID|Each surgical procedure was considered an independent event. Moreover, the January 2016-December 2019 and January 2020-December 2021 intervals were defined as pre-COVID and COVID periods, respectively.
223948184|NCT02176694|BEHAVIORAL|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
223948185|NCT02309515|OTHER|Laboratory Biomarker Analysis|Correlative studies
223948186|NCT02309515|DRUG|Lenalidomide|Given PO
223948187|NCT02309515|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
223948188|NCT02369328|DEVICE|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
223948189|NCT02102698|DRUG|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
223948190|NCT03481153|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
223948191|NCT06321094|DRUG|Vericiguat|Investigators divide our participants into two groups ;one group is required to take vericiguat,and the other isnot required to take vericiguat.Expect this,no intervention is used in the research.
223948192|NCT03180476|DRUG|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
223948193|NCT02605876|DEVICE|Whole body vibration|
223948194|NCT02605876|DEVICE|Local muscle vibration|
223536619|NCT02343315|DEVICE|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~* Equipment- TENS (CEFAR Basic TENS Machine)~* Electrodes- Four channel electrode to cover the site of pain~* Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~* Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~* Frequency- 5 Hertz~* Duration- 30 minutes"
223536620|NCT02343315|OTHER|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
223536621|NCT02343315|OTHER|UHEP|"All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
223536622|NCT03576235|DRUG|PG102P|Daily dose of 1.5g
223536623|NCT03576235|DRUG|Placebo|Daily dose of placebo
223536624|NCT03055091|OTHER|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
223948195|NCT02205255|DRUG|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
223536625|NCT03055091|OTHER|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
223536626|NCT00098995|DRUG|cisplatin|
223721619|NCT07132008|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
223721620|NCT07132008|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
223721621|NCT07133204|OTHER|Investigator developed cream infused with HuangQin extract|A water in oil emulsion with consistency similar to cold cream. Infused with organic extract of scutellaria baicalensis.
223721622|NCT01297400|DRUG|Investigational Drug, MW-III|Topical application, twice a day
223721623|NCT01297400|DRUG|Silvadene® Cream 1% [Silver Sulfadiazine]|Topical application, twice a day
223721624|NCT06935227|OTHER|Use Steri-Strip in post-surgery + standard care|Steri-strip will be maintained for 8 days postoperatively.
223721625|NCT06935227|OTHER|Standard care|Postoperative care recommendations.
223948196|NCT02205255|DRUG|Placebo|
223948197|NCT05205083|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 3-9 months after the immunization with 2 doses of inactivated vaccine (BBIBP-CorV), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
223948198|NCT04070105|DEVICE|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to switch from a walking foot to a running foot with the push of a button
223948199|NCT04070105|DEVICE|AllPro|Participants will be fit with a high activity foot designed to be used for walking and running
223948200|NCT01942525|OTHER|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
223536627|NCT00098995|DRUG|tirapazamine|
223536628|NCT00098995|RADIATION|brachytherapy|
223536629|NCT00098995|RADIATION|radiation therapy|
223721626|NCT05179798|DEVICE|mobile app|Lifestyle modification, insulin therapy if needed, utilization of a mobile app with personalized recommendations.
223721627|NCT06943820|DRUG|AK129(dose 1)|IV infusion
223721628|NCT06943820|DRUG|Pemetrexed|IV infusion;500mg/m2
223948201|NCT03794388|DRUG|Capsaicin|Application of capsaicin patches at 8% on painful area
223948202|NCT03794388|DRUG|Pregabalin|Taking Pregabalin tablets
223721629|NCT06943820|DRUG|Paclitaxel|IV infusion;175mg/m2
223721630|NCT06943820|DRUG|Carboplatin|IV infusion;AUC 5
223721631|NCT06943820|DRUG|AK129(dose 2)|IV infusion
223948203|NCT04717687|PROCEDURE|Irreversible electroporation|Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
223948204|NCT05164926|OTHER|perineal massage with St. John's Wort oil|perineal massage with St. John's Wort oil during labor
223948205|NCT03665714|OTHER|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
223536630|NCT02522039|DRUG|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
223536631|NCT02522039|DRUG|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
223948206|NCT03665714|OTHER|Enteral Nutrition Emulsion(TPF-T)|TPF-T
223948207|NCT03237026|OTHER|No intervention required|No intervention required
223948208|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
223948209|NCT03626376|DRUG|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
223536632|NCT02522039|DRUG|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
223948210|NCT02399956|OTHER|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
223948211|NCT01903954|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
223948212|NCT01903954|DRUG|placebo|Orally b.i.d.
223948213|NCT01903954|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
223948214|NCT01903954|DRUG|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
223536633|NCT01455480|DRUG|RPh201, botanical drug product|topical
223721632|NCT06943820|DRUG|Docetaxel|IV infusion;75mg/m2
223721633|NCT06943820|DRUG|Cis-platinum|IV infusion;100 mg/m2
223948215|NCT00162409|DRUG|Folic acid|
223948216|NCT02820506|PROCEDURE|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
223948217|NCT04026256|DRUG|Teriparatide|teriparatide daily subcutaneous injection
223948218|NCT04026256|DRUG|Denosumab|denosumab subcutaneous injection
223948219|NCT05964309|OTHER|supine group|after pre-oxygenation in supine position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
223948220|NCT05964309|OTHER|sitting group|after pre-oxygenation in sitting position general anesthesia will be established then apnea alarm time will be recorded and compared with other group
223948221|NCT01864590|DEVICE|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
223948222|NCT01864590|DEVICE|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
223948223|NCT01941576|DRUG|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
223948224|NCT01941576|DRUG|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
223948225|NCT05576779|OTHER|Ofatunumab|All eligible patients with at least 1 claim for ofatumumab observed during the index period were included in the ofatumumab cohort
223948226|NCT01039909|DRUG|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
223948227|NCT01039909|DRUG|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
223948228|NCT02395692|OTHER|Treatment|Correlative studies
223948229|NCT02395692|DRUG|Methoxyamine|Given PO
223948230|NCT02395692|DRUG|Temozolomide|Given PO
223948231|NCT04221165|DRUG|Opioids|Opioids will be prescribed as per institutional standards.
223948232|NCT04221165|DRUG|PAiN - multimodal analgesia|PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
223948233|NCT00534677|DRUG|Terlipressin|2 mg stat \& then 1 mg q6h iv and Placebo of Octreotide
223948234|NCT00534677|DRUG|Octreotide|Octreotide 50mcg/hr infusion \& a placebo of Terlipressin
223948235|NCT06021002|DRUG|R848|Nasal R848 administration
223948236|NCT06021002|DRUG|Saline|Nasal saline administration
223948237|NCT05575687|OTHER|Water (reference)|Ingestion of 500 ml mineral water
223948238|NCT05575687|OTHER|Sucrose|Ingestion of 500 ml of a flavored mineral water sweetened with sucrose
223948239|NCT05575687|OTHER|Sucralose|Ingestion of 500 ml of a flavored mineral water sweetened with sucralose
223948240|NCT05575687|OTHER|Stevia|Ingestion of 500 ml of a flavored mineral water sweetened with stevia extract
223948241|NCT05575687|OTHER|Monk fruit|Ingestion of 500 ml of a flavored mineral water sweetened with monk fruit extract
223948242|NCT05575687|OTHER|Allulose + stevia|Ingestion of 500 ml of a flavored mineral water sweetened with allulose and stevia extract
223948243|NCT06092905|OTHER|Endoscopic clearance of common bile duct stones|Under general anesthesia, in left lateral decubitus, endoscopic clearance of common bile duct stones was done. Ultrasonography was used to ensure right positioning of the guide wire in the common bile duct, and ensure stone clearance.
223948244|NCT03958266|DEVICE|MyIBD Care|Novel mobile phone application
223536634|NCT05119530|DIAGNOSTIC_TEST|AcuVid COVID-19 Rapid Antigen Saliva Test|The AcuVid COVID-19 Rapid Antigen Saliva Test is a lateral flow immunoassay to detect SARS-CoV-2 nucleocapsid antigens in human saliva specimens
223948245|NCT06022653|OTHER|Treatment|EVAR,TEVAR,PTA
223948246|NCT02400645|PROCEDURE|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
223948247|NCT02400645|PROCEDURE|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
223948248|NCT02400645|DRUG|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
223948249|NCT02400645|DRUG|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
223948250|NCT02400645|DRUG|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
223948251|NCT03779945|BIOLOGICAL|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
223948252|NCT03779945|PROCEDURE|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
223948253|NCT03966456|DRUG|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
223948254|NCT03936725|OTHER|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
223948255|NCT03043339|OTHER|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
223721634|NCT06943820|DRUG|5-FU (5-fluorouracil)|IV infusion;1000 mg/m2
223721635|NCT06943820|DRUG|Cetuximab|IV infusion;400mg/m2/ 250mg/m2
223948256|NCT03043339|OTHER|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
223948257|NCT03043339|OTHER|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
223948258|NCT03043339|OTHER|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
223536635|NCT00790673|DRUG|CF 102|Oral capsules
223536636|NCT00790673|DRUG|Placebo|Matching placebo capsules
223536637|NCT05811325|OTHER|kinesiotaping without craniosacral therapy|The first treatment group will receive kinesio taping for 6 weeks atleast 4 times per week
223536638|NCT05811325|OTHER|kinesiotaping with craniosacral therapy|The second treatment group will receive kinesio taping with craniosacral therapy for 6 weeks atleast 4 times per week with each session lasting for 60 minutes
223536639|NCT02412150|DRUG|Desflurane|Anesthesia is maintained with desflurane
223536640|NCT02412150|DRUG|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
223536641|NCT02412150|PROCEDURE|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
223536642|NCT02412150|OTHER|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
223536643|NCT02412150|BEHAVIORAL|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. \[Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)\]
223536644|NCT02412150|BEHAVIORAL|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~1. Awake Patient anxious and agitated or restless or both!~2. Patient cooperative, oriented and tranquil!~3. Patient responds to commands only!~4. Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~5. A sluggish response to a light glabellar tap or loud auditory stimulus!~6. No response to a light glabellar tap or loud auditory stimulus"
223536645|NCT02412150|OTHER|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
223536646|NCT02412150|BEHAVIORAL|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
223536647|NCT02412150|OTHER|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
223536648|NCT02412150|OTHER|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
223536649|NCT02412150|OTHER|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
223536650|NCT02412150|DRUG|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
223536651|NCT02412150|DRUG|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
223721636|NCT06943820|DRUG|Paclitaxel|IV infusion;80mg/m2
223721637|NCT06943820|DRUG|Docetaxel|IV infusion;35mg/m2
223721638|NCT06943820|DRUG|Chemotherapy|IV infusion
223721639|NCT06943820|DRUG|AK129(RP2D)|IV infusion
223721640|NCT06943820|DRUG|Penpulimab|IV infusion;200mg
223721641|NCT01466647|DRUG|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
223721642|NCT03320954|BEHAVIORAL|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
223721643|NCT01839851|DRUG|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
223721644|NCT01839851|DRUG|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
223721645|NCT06955494|OTHER|Empowerment Network for Auditory-Cognitive Training (ENACT) Program|The ENACT Program is an overall 12-week training and comprises of three phases as follows: 1. Goal-oriented health counseling phase (1st - 2nd week) - A nurse consultation will be conducted in the center with the aim to identify the participants' experience of living with the hearing and cognitive impairment. 2. Peer-assisted group-based auditory-cognitive training phase (3rd-8th week) - This phase is led and conducted by the nurse with the focus to provide combined group-based auditory and cognitive training (group size = 6) with support from the trained peers. 3. Family engaged active-communication training phase (9th - 12th week) - This phase is to empower the PLwMCI and their primary caregivers on active communication strategies in the presence of hearing loss. In the 2nd and 3rd phase, the nurse will continue to monitor the goal attainment of the PLwMCI and make additional health counseling and goal adjustment accordingly.
223721646|NCT06955494|OTHER|Usual Care|Usual care will be provided to the control group which mainly covers the social activities offered by the affiliated center. The participants are requested not to join any activities relating to cognitive training or auditory training before the post-test data collection.
223721647|NCT06132191|DRUG|Cemiplimab|
223721648|NCT03395743|BIOLOGICAL|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
223721649|NCT05102006|DRUG|LBL-007 Injection|LBL-007 Injection; dose A or dose B; Q3W
223721650|NCT05102006|DRUG|Toripalimab Injection|Toripalimab Injection; dose C; Q3W
223721651|NCT04312126|DEVICE|MRI system|MRI system - GE Discovery MR750 3T
223721652|NCT04312126|DEVICE|MEG system|MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
223721653|NCT06362733|BEHAVIORAL|Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth|This is a 12-week intervention program (1 hour/week) of treatment to target insistence on sameness in youth with autism spectrum disorder (ASD). Treatment will be delivered via secure telemedicine platform and consist of combination of parent-training and parent-mediated intervention with the child.
223721654|NCT05947643|DRUG|theophylline|capsules dissolved in intranasal irrigation
223721655|NCT05947643|DRUG|Placebo|identical-appearing lactose capsules dissolved in intranasal irrigation
223721656|NCT04023526|DRUG|Azacitidine|Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.
223721657|NCT04023526|DRUG|Cusatuzumab|Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.
223721658|NCT02940977|OTHER|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
223721659|NCT05857735|OTHER|Observational registry with no intervention.|No intervention
223721660|NCT01373437|DEVICE|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
223948259|NCT00637559|DRUG|Esomeprazole Magnesium|
223948260|NCT06300294|OTHER|acupressure|After the CAG procedure, acupressure will be applied to individuals whose vital signs are within the normal range.
223948261|NCT01333449|DRUG|Decitabine|20mg/m\^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
223721661|NCT00015301|DRUG|Methylphenidate|
223721662|NCT00147810|PROCEDURE|Telephone outreach to enhance asthma care|
223721663|NCT05554705|BEHAVIORAL|Intensive Lifestyle intervention|12 week therapeutic lifestyle change program
223721664|NCT02194205|DRUG|COMBIVENT HFA|
223721665|NCT02194205|DRUG|Placebo HFA|
223721666|NCT02194205|DRUG|COMBIVENT CFC|
223721667|NCT02194205|DRUG|Placebo CFC|
223948262|NCT01964586|DRUG|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
223948263|NCT01964586|DRUG|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
223948264|NCT01964586|DRUG|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
223948265|NCT06019715|BEHAVIORAL|Postpartum Remote Physical Activity Intervention|Includes 8 remote health coaching session to promote physical activity, use of a Fitbit device, and use of a home based blood pressure monitor.
223948266|NCT01858688|DEVICE|Multiparametric MRI|an MRI of the prostate will be performed
223948267|NCT01858688|PROCEDURE|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
223948268|NCT04123119|BIOLOGICAL|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 \& 10 weeks.
223721668|NCT05871294|DEVICE|Acoustic stimulation|The sound used for treatment is selected based on the patient's tinnitus frequency and loudness. Patients receive 90 minutes of acoustic stimulation therapy every day (at least 5 days per week). The entire treatment period is 3 months.
223721669|NCT05871294|DEVICE|Repetitive transcranial magnetic stimulation|The course of repeated transcranial magnetic stimulation therapy is 4 weeks, with 5, 5, 4, and 3 treatments per week, each lasting 90 minutes (including rest time)
223729461|NCT03071627|OTHER|New items with spin|Interpretation of news items with spin
223729462|NCT03071627|OTHER|New items without spin|Interpretation of news items without spin
223948269|NCT02973932|BEHAVIORAL|Cognitive-bahavioral psychotherapy|
223948270|NCT02593552|DEVICE|DriveCam|Video event monitoring device
223948271|NCT05612009|COMBINATION_PRODUCT|Toothpastes|"Signal Expert Protection: Conventional toothpaste including Sodium Lauryl Sulphate and fluoride.~Colgate Hemp Seed Oil: Herbal toothpaste including hemp seed oil and also fluoride.~Gumgumix: Herbal toothpaste including ginger extract (no fluoride)."
223948272|NCT00833599|DRUG|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
223721670|NCT05990972|PROCEDURE|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
223721671|NCT04723745|BEHAVIORAL|V-TRACTS Assessment/Feedback|The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
223721672|NCT04723745|BEHAVIORAL|OPTIONAL Brief Assessment of Thinking|A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
223721673|NCT04723745|BEHAVIORAL|OPTIONAL STEP-Home-Brief|STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
223721674|NCT04723745|BEHAVIORAL|OPTIONAL At-home Exercise Program|This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
223721675|NCT04723745|BEHAVIORAL|OPTIONAL Referral to 12-week STEP-Home|Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
223721676|NCT04723745|BEHAVIORAL|OPTIONAL Clinical Referral|Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
223721677|NCT00785668|DRUG|AER 001|10 mg dry powder administered using a handheld device
223721678|NCT01929278|DRUG|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
223948273|NCT04883515|DIETARY_SUPPLEMENT|Oral glutamine supplementation|patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
223948274|NCT04883515|DIETARY_SUPPLEMENT|Oral protein powder supplementation|patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
223948275|NCT04883515|PROCEDURE|Insulin-resistance evaluation|Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
223948276|NCT04883515|PROCEDURE|Functional intestinal disorders evaluation|Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
223948277|NCT04372706|DRUG|RTX-240|Engineered red cells co-expressing 4-1BBL and IL-15TP
223948278|NCT04372706|DRUG|Pembrolizumab|Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody
223948279|NCT01999335|DRUG|Oprozomib|Extended release (ER) tablets administered orally
223948280|NCT01999335|DRUG|Pomalidomide|Capsules for oral administration
223948281|NCT01999335|DRUG|Dexamethasone|Tablets for oral administration
223948282|NCT02013804|DRUG|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
223948283|NCT01775657|DEVICE|Thopaz (Digital drainage)|
223948284|NCT01775657|DEVICE|Pleur Evac (Analogue drainage)|
223948285|NCT01753167|DRUG|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
223948286|NCT01753167|DRUG|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
223948287|NCT01753167|DRUG|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
223948288|NCT02909205|OTHER|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
223948289|NCT02909205|OTHER|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
223721679|NCT01929278|OTHER|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
223721680|NCT01929278|OTHER|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
223948290|NCT05584748|DEVICE|transcranial direct current stimulation|tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).
223721681|NCT00819611|BEHAVIORAL|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
223721682|NCT00819611|BEHAVIORAL|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
223721683|NCT00125294|DRUG|Methadone|
223721684|NCT00319865|DRUG|Velcade|
223721685|NCT00319865|DRUG|Thalidomide|
223721686|NCT00319865|DRUG|Adriamycin|
223721687|NCT00319865|DRUG|Dexamethasone|
223721688|NCT04540601|OTHER|Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)|"We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday."
223729463|NCT04087694|PROCEDURE|Microdecompression|comparative surgical treatment
223948291|NCT05049941|DIAGNOSTIC_TEST|lactat and blood gases|observational
223948292|NCT05671445|BIOLOGICAL|CM326|CM326 injection
223948293|NCT03421249|OTHER|Exercises|Muscle strengthening exercises of the hip and knee muscles
223948294|NCT03421249|OTHER|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
223948295|NCT05746741|BEHAVIORAL|Telehealth solution|Video conferencing
223948296|NCT02234141|DRUG|Placebo|Tablet administered orally once daily
223948297|NCT02234141|DRUG|Selonsertib|Tablets administered orally once daily
223948298|NCT04694066|BEHAVIORAL|Qigong|Qigong Baduanjin, comprising eight standardized movements, will be adopted in the study. It is practiced as a combination of body movements, breath control, and mindful meditation.
223948299|NCT04694066|BEHAVIORAL|Light flexibility exercise|The supervised sessions will include seated and standing stretches that target upper (neck, arms, upper back, shoulders, and chest) and lower body (quadriceps, hamstrings, calves, and hips), as well as trunk rotations.
223948300|NCT03849482|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
223948301|NCT03849482|DIAGNOSTIC_TEST|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
223948302|NCT03849482|DIAGNOSTIC_TEST|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
223948303|NCT03849482|DIAGNOSTIC_TEST|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
223948304|NCT02470169|DRUG|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
223948305|NCT02470169|PROCEDURE|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
223948306|NCT02470169|DRUG|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
223948307|NCT02470169|DEVICE|shepherd catheter|
223948308|NCT02470169|PROCEDURE|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
223948309|NCT02861456|OTHER|Standard Model of Care|
223948310|NCT02861456|OTHER|Alternative Model of Care|
223948311|NCT01788605|DRUG|ramosetron|
223948312|NCT01488084|PROCEDURE|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
223948313|NCT01488084|PROCEDURE|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
223948314|NCT00895245|DRUG|fosaprepitant dimeglumine|Given IV
223948315|NCT00895245|DRUG|cisplatin|Given IV
223948316|NCT00895245|DRUG|palonosetron hydrochloride|Given IV
223948317|NCT00895245|DRUG|dexamethasone|Given IV and orally
223948318|NCT00895245|OTHER|Functional Living Index-Emesis Questionnaire|Ancillary studies
223948319|NCT00895245|BEHAVIORAL|Emesis Diary|Ancillary studies
223948320|NCT00895245|RADIATION|Radiotherapy|Undergo radiotherapy
223948321|NCT01717066|DRUG|the ginsenoside Rg3|
223948322|NCT01717066|DRUG|Placebo|
223948323|NCT04653688|DEVICE|The FeetMe® Evaluation|The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
223948324|NCT04653688|DEVICE|the PKG® Watch,|The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
223948325|NCT04653688|RADIATION|MRI|"* an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis"
223948326|NCT04653688|RADIATION|DaTSCAN|"* quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease."
223721689|NCT05433805|OTHER|Fasting-mimicking diet (FMD) and physiotherapy|"FMD is a diet held monthly during five days with the restriction of calories to less than 1000 kcal, glucose and proteins.~Physiotherapy will be organized as home-based exercises explained by the physiotherapeutist at the beginning of the study."
223721690|NCT01304316|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
223721691|NCT01213745|OTHER|Intervention|
223721692|NCT01213745|OTHER|Attention|
223721693|NCT01213745|OTHER|Control|
223721694|NCT02403492|DEVICE|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
223721695|NCT02403492|DEVICE|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
223948327|NCT02764905|BEHAVIORAL|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
223948328|NCT04347941|PROCEDURE|Prone Positioning|Patient will be asked to remain for at least one hour and to a maximum total of 16 hours in prone position with 45 minutes breaks for meals. Immediately prior to proning, if spO2 \<94% on FiO2 0.4, start on 100% O2 to ensure stability during proning. A nurse or assistant will assist patient to turn on side and then face down with the support of pillows as required for comfort, ensure that they are predominantly on their chest rather than on their side. Arms can be at side, in swimmer position and can be moved to patients' comfort, pillows under knees and chest for comfort and call bell to be at patient's arm's length. Vitals and work of breathing score will be measured before and at 1 hour into each proning session and at the end of each session. Total length of time in prone position will be recorded. Intervention to continue daily until oxygen requirement to maintain spO2 \>94% is below FiO2 0.4 via venturi facemask or high flow nasal cannula
223948329|NCT04347941|PROCEDURE|Standard of care.|Standard of care. Prone positioning may be administered as a rescue therapy
223948330|NCT04248868|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
223948331|NCT04248868|DRUG|r-tPA|Pulse spray and infusion
223948332|NCT02418689|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
223948333|NCT02706483|DRUG|Plecanatide|
223948334|NCT03131713|DRUG|Acetaminophen|Acetaminophen 1000mg
223948335|NCT01504984|DRUG|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
223948336|NCT01504984|DRUG|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I\&II D1(crossover)
223948337|NCT02764970|DRUG|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
223948338|NCT00916409|DEVICE|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
224100743|NCT03926403|PROCEDURE|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
224100744|NCT03926403|PROCEDURE|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
224100745|NCT00284115|DEVICE|Gait trainer|Mechanical gait repetitive training
224100746|NCT00284115|DEVICE|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
223948339|NCT00916409|DRUG|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
223948340|NCT02208843|DRUG|Afatinib|Afatinib tablet once daily until progression
223536652|NCT02803905|BIOLOGICAL|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
223536653|NCT01918137|DIETARY_SUPPLEMENT|chocolate bar|
223536654|NCT01918137|DIETARY_SUPPLEMENT|Porridge|
223536655|NCT06050980|DRUG|HSK40118|Oral administration, QD
223536656|NCT02972996|OTHER|Blueberry|22 g freeze-dried whole blueberry powder
223536657|NCT02972996|OTHER|Placebo|22 g placebo blueberry powder
223721696|NCT02403492|DEVICE|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
223721697|NCT06102239|DIAGNOSTIC_TEST|Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium \&c-reactive protein as indicator of complicated appendicitis
223948341|NCT01976507|DRUG|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
223536658|NCT04265131|OTHER|art therapy|Art therapy is a form of psychotherapy that uses creative methods of expression through art media, such as pencils, clay, paint etc.
223721698|NCT00056316|BEHAVIORAL|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
223948342|NCT05657821|DIETARY_SUPPLEMENT|Pumpkin seeds extract capsules|the intervention group was given pumpkin seed capsules for 12 weeks, and the intervention group was given iron tablets for 12 weeks
223948343|NCT04996654|BEHAVIORAL|Exergame|According to the training concept, each participant is instructed to train 5x/week for 21 min per session resulting in a weekly exercise volume of 105 min. All training sessions are planned to take place at participant's homes using the exergame training system Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification).
223948344|NCT04996654|BEHAVIORAL|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
223948345|NCT02587052|DRUG|Generic tacrolimus|Generic tacrolimus
223948346|NCT02587052|DRUG|Prograf|Prograf, the original tacrolimus
223721699|NCT00056316|BEHAVIORAL|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
223948347|NCT03003104|DRUG|DMT210 Topical Gel 5%|
223721700|NCT05813951|DRUG|Linezolid|linezolid either continues infusion or standard intermittent dose
223948348|NCT03003104|OTHER|Vehicle Control|
223948349|NCT02799849|OTHER|Sleep and metabolism assessment|
223948350|NCT04514081|DRUG|Chidamide; Decitabine; Camrelizumab|"Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.~Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.~Camrelizumab is a humanized anti-PD-1 monoclonal antibody."
223948351|NCT04514081|DRUG|Decitabine+Camrelizumab|Decitabine+Camrelizumab
223948352|NCT02684032|DRUG|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
223948353|NCT02684032|DRUG|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
223948354|NCT02684032|DRUG|Letrozole|Letrozole at 2.5 mg daily
223948355|NCT02684032|DRUG|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
223948356|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
223948357|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
223948358|NCT01966705|BEHAVIORAL|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
223948359|NCT00569439|DRUG|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
223948360|NCT00569439|DRUG|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
223948361|NCT00569439|DRUG|NS|Normal Saline solution at 125 cc/hr
223948362|NCT03630549|OTHER|Standard of Care|Clinic-based HIV care
223948363|NCT03630549|OTHER|Village-based ART refill|Option to get ART refill and care by the village health worker
223948364|NCT00946972|DRUG|JNJ-38431055; Placebo|
223948365|NCT04453488|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
223948366|NCT04453488|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo
223948367|NCT03575507|DEVICE|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
223948368|NCT05474326|DEVICE|intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System)|application of intermittent pneumatic pressure device (Kendall SCD™ 700 Smart Compression™ System) on lower limbs and its effect on fetal and maternal doppler and amniotic fluid index in women with oligohydramnios. the compression system will be applicated on lower limbs for one hour in which it will produce intermittent compression on lower limbs. amniotic fluid amnout assessment will be done after this including doppler studies in order to detect any change in amniotic fluid amount or dopper.
223536659|NCT05812326|DRUG|AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells|AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
223536660|NCT03655067|BEHAVIORAL|CATCH-IT|The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).
223536661|NCT04534673|DRUG|Lambda 180 mcg S.C|Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7
223536662|NCT00335166|DRUG|Pardaprunox|12-42 mg
223721701|NCT04413396|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
223948369|NCT02144597|DIETARY_SUPPLEMENT|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
223948370|NCT02144597|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|Participant went through Roux-en-Y gastric bypass (RYGB) surgery
223948371|NCT02144597|OTHER|Control diet|
223948372|NCT02105571|BEHAVIORAL|Intervention|
223948373|NCT00383383|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
223948374|NCT00383383|BIOLOGICAL|Engerix-B|
223948375|NCT04317430|DRUG|Niclosamide|Niclosamide tablets 1 gram once daily
223948376|NCT04317430|DRUG|Placebo oral tablet|lactose tablets
223948377|NCT01246804|DRUG|raltegravir single dose|single dose 400mg raltegravir
223948378|NCT01246804|DRUG|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
223948379|NCT00655109|DRUG|Olopatadine|Ophthalmic solution
223948380|NCT00655109|DRUG|Fluticasone|Nasal spray
223948381|NCT00655109|DRUG|Saline|Nasal spray
223948382|NCT00655109|DRUG|Artificial tears|Ophthalmic Solution
223948383|NCT04166084|OTHER|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
223948384|NCT04166084|OTHER|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
223948385|NCT05928754|DIAGNOSTIC_TEST|care strategy|"Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7."
223536663|NCT00335166|DRUG|pramipexole|1.5-4.5 mg
223536664|NCT00335166|DRUG|Placebo Comparator|Placebo
223536665|NCT04051177|BEHAVIORAL|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
223536666|NCT04051177|BEHAVIORAL|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
223536667|NCT03017443|BEHAVIORAL|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
223948386|NCT03328637|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
223948387|NCT00105846|PROCEDURE|Home care telemedicine|
223948388|NCT00765544|DEVICE|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
223948389|NCT00765544|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
223948390|NCT01593644|DRUG|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
223536668|NCT03017443|BEHAVIORAL|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (\~50% kcal from carbohydrate, \~25% from protein, \~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
223721702|NCT05798650|BEHAVIORAL|facial dissatisfaction|"Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs."
223721703|NCT03150615|OTHER|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
223721704|NCT03150615|OTHER|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
223948391|NCT01388413|DRUG|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
223721705|NCT03150615|DEVICE|nasojejunal tube insertion|
223721706|NCT03150615|OTHER|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
223721707|NCT02329353|DRUG|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
223948392|NCT02969200|DRUG|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
223948393|NCT01496339|BIOLOGICAL|MenSCs transplantation|1×10\^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
223948394|NCT01496339|DRUG|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
223948395|NCT02427191|OTHER|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
223721708|NCT02338440|DRUG|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
223948396|NCT02427191|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
223948397|NCT02163148|BEHAVIORAL|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
223721709|NCT06159530|PROCEDURE|dental implants|4 dental implants placed in the mandible according to all-on 4 concept
223721710|NCT06159530|PROCEDURE|peek framework|peek framework screwed to multi-unit abutments of 4-implants
223948398|NCT01868230|BEHAVIORAL|Lifestyle Intervention|
223948399|NCT00077558|DRUG|fludarabine phosphate|
223948400|NCT00077558|DRUG|triapine|
223721711|NCT06159530|PROCEDURE|visio-lign nano composite|peek framework veneered with nano composite (visio-lign) as an occlusal material
223948401|NCT02733731|DRUG|Chinese Herbal Compound Ointment|
223948402|NCT02733731|DRUG|Estriol|
223721712|NCT06159530|PROCEDURE|zirconia crowns|peek framework covered with zirconia crowns as an occlusal material
223721713|NCT04882540|DRUG|brivaracetam|"* Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use"
223948403|NCT04999072|PROCEDURE|Colectomy for colon cancer|Segmental or total colectomy was performed for colorectal cancer.
223948404|NCT01217866|PROCEDURE|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
223721714|NCT02662296|DRUG|Ibrutinib|Given PO
223721715|NCT02662296|DRUG|Idelalisib|Given PO
223721716|NCT02097576|OTHER|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
223721717|NCT02097576|OTHER|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
223721718|NCT02487693|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
223948405|NCT01968824|PROCEDURE|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
223948406|NCT03760653|OTHER|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
223948407|NCT03760653|DIETARY_SUPPLEMENT|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
223948408|NCT03760653|DIETARY_SUPPLEMENT|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
223948409|NCT06466616|OTHER|Real stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks stretching of plantar fascia, gastrocnemius and hamstring muscle.
223948410|NCT06466616|OTHER|Placebo stretching|Aplying 3 sesions of ESWT in patients with plantar fasciitis in the zone of pain. Futhermore they are going to do a program of 8 weeks placebo stretching of plantar fascia, gastrocnemius and hamstring muscle.
223948411|NCT00089791|DRUG|placebo|Placebo administered by subcutaneous injection
223948412|NCT00089791|DRUG|Denosumab|Denosumab 60 mg administered by subcutaneous injection
223948413|NCT01594606|BEHAVIORAL|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
223948414|NCT05307952|DIAGNOSTIC_TEST|Tone Audiometry|Evaluation of the participants' audiometrical thresholds
223536669|NCT03017443|BEHAVIORAL|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included \< 30% fat (\< 7% saturated fat), \< 150 mg/d of cholesterol, and \< 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu \[7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week\], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
223536670|NCT03017443|BEHAVIORAL|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
223536671|NCT01497756|DEVICE|CAPP use|Any abdominal pelvic pressure
223536672|NCT06077877|DRUG|GSK4524101|GSK452101 will be administered.
223536673|NCT06077877|DRUG|Niraparib|Niraparib will be administered.
223536674|NCT01273571|DRUG|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
223536675|NCT03368066|DRUG|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
223536676|NCT00079313|DRUG|Imatinib|
223721719|NCT02487693|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
223721720|NCT02599129|DRUG|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
223721721|NCT02599129|DRUG|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
223721722|NCT05551559|PROCEDURE|bariatric surgery|bariatric surgery
223721723|NCT03489720|BEHAVIORAL|Prescribed Exercise Program|"Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing"
223948415|NCT05307952|DIAGNOSTIC_TEST|Spectrotemporal Assessment|Evaluation of the participants' promptness in detecting a modulation of a harmonic complex
223948416|NCT05307952|DIAGNOSTIC_TEST|Phoneme and Speech Perception|Evaluation of the participants' understanding of phonemes and short words, both in quiet and in noise
223948417|NCT05307952|DIAGNOSTIC_TEST|Digit Triplet Test|Evaluation of the participants' ability to discern speech in noise
223948418|NCT05307952|OTHER|Personalized fitting|Adjustment of the parameters of the participants' cochlear implants aimed at improving their speech perception
223948419|NCT05307952|BEHAVIORAL|Personalized training|Self-administered training exercises focused on the speech components the participants are experiencing difficulties into
223948420|NCT02446106|DIETARY_SUPPLEMENT|Soup with MSG|0.5% MSG + 0.48% salt
223948421|NCT02446106|DIETARY_SUPPLEMENT|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
223721724|NCT03489720|BEHAVIORAL|Usual Exercise Program|Usual exercise activity for 8 weeks
223721725|NCT03723759|DRUG|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
223721726|NCT03723759|DRUG|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
223721727|NCT00799240|DRUG|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
223948422|NCT06080087|BEHAVIORAL|I-TEAM|I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
223948423|NCT04176952|DRUG|FOLFOX-A|"* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
223948424|NCT04176952|DRUG|AG|"* nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
223948425|NCT01933997|DRUG|Metadoxine (MG01CI )|
223948426|NCT00148122|DRUG|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
223536677|NCT05407103|OTHER|Cold Acupressure|For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.
223536678|NCT05407103|OTHER|Warm Acupressure|For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
223536679|NCT02625181|PROCEDURE|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
223536680|NCT02625181|PROCEDURE|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
223536681|NCT02625181|PROCEDURE|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
223721728|NCT00799240|DRUG|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
223536682|NCT02625181|PROCEDURE|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
223536683|NCT02625181|DEVICE|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
223721729|NCT02801292|DRUG|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
223721730|NCT04190615|DIAGNOSTIC_TEST|thromboelastometry test (TEM test)|TEM test from the whole blood sample
223721731|NCT02845544|OTHER|Pilates-based exercises|
223721732|NCT01366690|BEHAVIORAL|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
223536684|NCT02625181|DEVICE|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
223536685|NCT02625181|PROCEDURE|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
223536686|NCT02625181|PROCEDURE|Elective surgery|Surgical procedures that are scheduled and not an emergency.
223536687|NCT02625181|DRUG|Propofol|Anesthetic drug used to maintain general anesthesia
223721733|NCT05790629|PROCEDURE|endo-sequence putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
223536688|NCT02625181|DRUG|Sevoflurane|Anesthetic drug used to maintain general anesthesia
223536689|NCT02625181|DRUG|Isoflurane|Anesthetic drug used to maintain general anesthesia
223536690|NCT02625181|DRUG|Desflurane|Anesthetic drug used to maintain general anesthesia
223536691|NCT02625181|DRUG|Scopolamine|Prophylactic antiemetic
223536692|NCT02625181|DRUG|Droperidol|Prophylactic antiemetic \& rescue antiemetic
223536693|NCT02625181|DRUG|Haloperidol|Prophylactic antiemetic \& rescue antiemetic
223536694|NCT02625181|DRUG|Dexamethasone|Prophylactic antiemetic \& rescue antiemetic
223536695|NCT02625181|DRUG|Promethazine|Prophylactic antiemetic \& rescue antiemetic
223536696|NCT02625181|DRUG|Meclizine|Prophylactic antiemetic \& rescue antiemetic
223536697|NCT02625181|DRUG|Aprepitant|Prophylactic antiemetic \& rescue antiemetic
223536698|NCT02625181|DRUG|Metoclopramide|Rescue antiemetic
223536699|NCT02625181|DRUG|Fentanyl|Analgesic drug / Opioid
223536700|NCT02625181|DRUG|Sufentanil|Analgesic drug / Opioid
223536701|NCT02625181|DRUG|Alfentanil|Analgesic drug / Opioid
223536702|NCT02625181|DRUG|Remifentanil|Analgesic drug / Opioid
223536703|NCT02625181|DRUG|Morphine|Analgesic drug / Opioid
223536704|NCT02625181|DRUG|Meperidine|Analgesic drug / Opioid
223536705|NCT02625181|DRUG|Hydromorphone|Analgesic drug / Opioid
223536706|NCT02625181|DRUG|Methadone|Analgesic drug / Opioid
223536707|NCT02625181|DRUG|Oxycodone|Analgesic drug / Opioid
223536708|NCT02625181|DRUG|Oxymorphone|Analgesic drug / Opioid
223721734|NCT05790629|PROCEDURE|neo-MTA putty|pupal medicament which is materials used in case of vital pulp therapy (VPT) procedure after opening access in the inflamed pulp to maintain it is vitality, inducing dentin bridge formation and encourage continued root maturation.
223948427|NCT00148122|DRUG|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
223948428|NCT04738149|DRUG|Bimatoprost|Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
223948429|NCT04738149|DEVICE|Excimer laser|Participants will be receiving excimer laser 2x a week for 12 weeks
223948430|NCT04738149|DEVICE|Microneedling with a dermaroller|Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
223948431|NCT00904085|DRUG|Oxymorphone IR|5 mg
223536709|NCT02625181|DRUG|Hydrocodone|Analgesic drug / Opioid
223536710|NCT02625181|DRUG|Ketamine|Analgetic / Analgesic drug
223536711|NCT02625181|DRUG|Ondansetron|Prophylactic antiemetic \& rescue antiemetic
223536712|NCT02625181|DRUG|Granisetron|Prophylactic antiemetic \& rescue antiemetic
223536713|NCT02625181|DRUG|Dolasetron mesylate|Prophylactic antiemetic \& rescue antiemetic
223536714|NCT02625181|DRUG|Palonosetron|Prophylactic antiemetic \& rescue antiemetic
223536715|NCT02625181|DRUG|Tropisetron|Prophylactic antiemetic \& rescue antiemetic
223948432|NCT00276679|DRUG|temozolomide|
223536716|NCT02625181|DRUG|Ramosetron|Prophylactic antiemetic \& rescue antiemetic
223536717|NCT03961308|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
223536718|NCT03537443|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Prenatal and postpartum supplementation with vitamin D3 and/or placebo.
223536719|NCT04561856|DRUG|Dexamethasone|Intravenous 4mg
223536720|NCT04561856|DRUG|Dexamethasone|Perineural 4mg
223721735|NCT05163600|OTHER|Blod flow restriction training|includes one strength and one endurance training
223721736|NCT06281600|DIETARY_SUPPLEMENT|Human milk oligosaccharide|5g daily dose of HMOs.
223721737|NCT06281600|DIETARY_SUPPLEMENT|Maltodextrin placebo|5g daily dose of maltodextrin.
223721738|NCT00786500|DIETARY_SUPPLEMENT|Gynostemma pentaphyllum tea|3 grams twice daily, orally
223948433|NCT01092715|PROCEDURE|Spinal mobilization|Non thrust mobilization to the cervical spine
223948434|NCT01092715|PROCEDURE|Massage|Sedative massage to cervical paraspinal muscles
223948435|NCT01092715|PROCEDURE|Neck exercises|Range of motion exercises to include foraminal opening
223948436|NCT05247307|BIOLOGICAL|convalescent plasma infusion covid 19|"Operating process~* A single dose of plasma (300 mL) immune anti-coronavirus or not, depending on what corresponds will be infused.~* The collaborating staff will enter the initial and follow-up data in Red Cap based on the information contained in the medical record, or by talking to the patient by telephone to clarify any doubts."
223948437|NCT04249440|PROCEDURE|Preoperative systemic treatment|neoadjuvant chemotherapy combined with trastuzumab as preoperative systemic treatment
223536721|NCT04561856|DRUG|Placebo|Normal Saline 2ml
223536722|NCT01542970|DIETARY_SUPPLEMENT|Placebo|Olive oil
223536723|NCT01542970|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
223536724|NCT01542970|DIETARY_SUPPLEMENT|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
223721739|NCT00786500|DIETARY_SUPPLEMENT|Placebo tea|3 grams twice daily, orally
223721740|NCT00549965|DRUG|Risedronate Sodium|
223948438|NCT05508477|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARS-CoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.
223948439|NCT05508477|BIOLOGICAL|CoronaVac Biofarma COVID-19 Vaccine|Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia
223948440|NCT04865744|DRUG|Semaglutide 7 MG Oral Tablet|Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.
223948441|NCT04865744|DRUG|Placebo|Placebo tablet is taken after an overnight fast with up to120 ml of water.
223536725|NCT01542970|DIETARY_SUPPLEMENT|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
223536726|NCT03710889|DRUG|Abaloparatide|Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
223536727|NCT00133445|BIOLOGICAL|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
223536728|NCT00133445|BIOLOGICAL|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
223536729|NCT00133445|DRUG|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
223536730|NCT05690425|DRUG|BC3402 Injection|Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
223536731|NCT02648945|OTHER|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
223536732|NCT01159093|BEHAVIORAL|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
223536733|NCT01159093|BEHAVIORAL|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
223536734|NCT01159093|OTHER|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
223948442|NCT04865744|DRUG|Semaglutide 14 MG Oral Tablet|Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.
223948443|NCT00519207|DRUG|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
223948444|NCT00519207|DRUG|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
223536735|NCT01159093|OTHER|Control|Usual care
223536736|NCT03700177|DRUG|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
223536737|NCT03700177|DRUG|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
223536738|NCT03700177|DRUG|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
223536739|NCT03037125|PROCEDURE|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
223536740|NCT03037125|PROCEDURE|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
223536741|NCT00000857|DRUG|Interleukin-12|
223536742|NCT00894595|BEHAVIORAL|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
223536743|NCT05725122|PROCEDURE|Extracorporeal shock wave lithotripsy|Extracorporeal shock wave lithotripsy will given to the patients
223536744|NCT05725122|PROCEDURE|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy.|Extracorporeal Shock Wave Lithotripsy combined with Tamsulosin Therapy will be given to the patients
223948445|NCT01785056|BIOLOGICAL|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
223948446|NCT04514978|PROCEDURE|Blood donation and blood transfusion|24 subjects (12 female, 12 male) is phlebotomized and four weeks later \~130 mL packed red blood cells are re-infused in the same subjects.
223536745|NCT03517670|OTHER|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
223536746|NCT03517670|OTHER|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
223536747|NCT03517670|OTHER|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
223536748|NCT03517670|OTHER|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
223721741|NCT01024634|BEHAVIORAL|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
223721742|NCT02352402|DRUG|Ticagrelor|
223948447|NCT02016365|DRUG|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
223536749|NCT02164344|DIETARY_SUPPLEMENT|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
223721743|NCT02352402|DRUG|Placebo|
223948448|NCT02016365|DRUG|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
223948449|NCT03763968|OTHER|treatment and outcome|
223948450|NCT03042767|BIOLOGICAL|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
223948451|NCT03042767|OTHER|Placebo|Matched Placebo
223948452|NCT04641715|PROCEDURE|OAGB-MGB|One Anastomosis Gastric Bypass - Mini Gastric Bypass as both restrictive and malabsorptive bariatric procedure
223948453|NCT01385800|BIOLOGICAL|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
223948454|NCT01385800|BIOLOGICAL|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
223948455|NCT04697615|DEVICE|Algometry|The evaluation with the algometer was carried out in the same way by the two examiners, who held the instrument with the dominant hand, in order to adjust and coordinate the movements, while the non-dominant hand was used to stabilize the participant's skin, providing more security, avoiding thus small deviations. The pressure was applied at an angle of 90 ° (between the tool surface and the evaluated point), the rate of pressure increase was approximately 2 kg / cm² / s (kilogram per centimeter squared per second), up to the level that the participant reported a change in the sensation of pressure to a sensation of discomfort and immediately the examiner removed the device from the positioned location.
223536750|NCT04098705|OTHER|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
223948456|NCT06092736|DRUG|Compound Danshen Dropping Pills|Dosage of Compound Danshen Dropping Pills: 20 capsules each time, 3 times a day, after meals. The follow-up period was 6 months.
223948457|NCT06092736|DRUG|Placebo|placebo (appearance is the same as Compound Danshen Dropping Pills, main ingredient: starch. Production unit: Tianjin Tasly Co., Ltd.), orally after meals, 3 times a day , 20 capsules each time.
223948458|NCT02216084|DRUG|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
223948459|NCT05963802|OTHER|Artificial Intelligence (ChatGPT) Group|Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
223948460|NCT05565898|DEVICE|positron emission tomography for exclusion of bone marrow infiltration in lymphoma|compare the diagnostic accuracy of PET/CT scan against Bone Marrow Biopsy in detection of bone marrow involvement for staging of lymphoma
223948461|NCT00330785|DRUG|Amlodipine/Atorvastatin|
223948462|NCT02782260|DRUG|Dipyridamole|
223948463|NCT02782260|DRUG|Placebo|
223948464|NCT03020433|DEVICE|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
223948465|NCT03020433|DEVICE|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
223948466|NCT03020433|DEVICE|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
223948467|NCT03020433|DEVICE|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
223948468|NCT00412178|DEVICE|telecommunication based glucose monitoring system|
223948469|NCT01984099|DRUG|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
223948470|NCT01984099|DRUG|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
223948471|NCT01501721|BEHAVIORAL|Exercise|Home-based exercise program
223948472|NCT01501721|BEHAVIORAL|Diet|Nutritional counseling aiming to reduce suggar intake
223948473|NCT01543204|DRUG|Etanercept|Administered by subcutaneous injection
223948474|NCT00995683|DRUG|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
223948475|NCT00995683|DRUG|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
223948476|NCT06505096|PROCEDURE|cataract surgery|Phaco+IOL implention
223948477|NCT01220999|DRUG|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
223948478|NCT00603018|DRUG|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
223948479|NCT05713136|DEVICE|Diagnostic Test: Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
223948480|NCT01854866|OTHER|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
223948481|NCT01820702|OTHER|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at \~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against \~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
223948482|NCT02527694|DEVICE|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
223948483|NCT02527694|DEVICE|mechanical CPR|
223948484|NCT05197088|DRUG|Tamsulosin|1 week of tamsulosin
223948485|NCT03742297|DRUG|Lenalidomide.|Lenalidomide
223948486|NCT03742297|DRUG|Carfilzomib|Carfilzomib
223948487|NCT03742297|DRUG|Bortezomib|Bortezomib
223948488|NCT03742297|DRUG|Daratumumab|Daratumumab
223948489|NCT03742297|DRUG|Dexamethasone|Dexamethasone
223948490|NCT03742297|DRUG|Prednisone|Prednisone
223948491|NCT03742297|DRUG|Melphalan|Melphalan
223948492|NCT01896609|BIOLOGICAL|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
223948493|NCT01896609|DRUG|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
223948494|NCT01896609|DRUG|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
223948495|NCT01896609|DRUG|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
223948496|NCT06451107|OTHER|specific strength training with static neck stretching|The intervention will consist of specific strength training composed of 5 exercises performed with dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. In addition to the following static stretches: stretching towards lateral flexion of the upper part of the trapezius muscle, the scalene muscles, and the sternocleidomastoid muscle on both sides; extension of the extensor muscles; flexion of the flexor muscles; and contralateral flexion and rotation combined with scapular depression of the scalene muscles and elevation of the scapula on both sides, holding each stretch for 10 seconds. This sequence of stretches will constitute one set, with 6 sets performed with a 30-second rest between sets, lasting 8 minutes. Therefore, the intervention will have a total duration of 28 minutes per session, conducting 3 sessions per week.
223948497|NCT06451107|OTHER|Specific Strength Training|The intervention will consist of specific strength training comprised of 5 exercises using dumbbells: front raises, lateral raises, reverse flies, shoulder shrugs, and wrist extensions. Four sets will be performed, with a 1-minute rest between sets. Each exercise will be executed for 30 seconds, followed by a 25-second rest between exercises. Three 20-minute sessions will be conducted per week.
223948498|NCT01688388|PROCEDURE|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
223948499|NCT02322645|DRUG|Eszopiclone Tablets 3 mg|
223948500|NCT01697826|DRUG|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
223948501|NCT01697826|DRUG|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
223948502|NCT02449902|DRUG|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
223948503|NCT02449902|DRUG|placebo|1 placebo capsule inserted vaginally for 14 days.
223948504|NCT02990494|BEHAVIORAL|STANDARD|Standard Internet-delivered behavioral weight loss
223948505|NCT02990494|BEHAVIORAL|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
223948506|NCT02990494|BEHAVIORAL|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
223948507|NCT00038597|DRUG|SCH66336|
223948508|NCT00465114|PROCEDURE|Hemodynamic Monitoring|
223948509|NCT02362789|BIOLOGICAL|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
223948510|NCT02362789|BIOLOGICAL|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
223948511|NCT01302106|DRUG|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
223948512|NCT01498614|BEHAVIORAL|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
223948513|NCT06455072|DRUG|Nituzumab|EGFR monoclonal antibody
223948514|NCT06455072|DRUG|Serplulimab|PD-1 (programmed death receptor 1) monoclonal antibody
223948515|NCT03326856|BIOLOGICAL|botulinum toxin, Type A|topical liniment
223948516|NCT03326856|BIOLOGICAL|Vehicle|Vehicle Formulation
223948517|NCT04058847|OTHER|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
223948518|NCT02967822|GENETIC|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
223948519|NCT02967822|GENETIC|Biological samples for healthy relatives|Blood samples.
223948520|NCT03861234|DRUG|BI 836880|Solution for Intravitreal (IVT) injection
223948521|NCT05914896|DRUG|HighOsmo|This group received a priming solution with high osmolality
223948522|NCT03883217|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
223948523|NCT02571868|DEVICE|Optimization CRT-D|
223948524|NCT04393571|OTHER|Mobile application|telemedicine is used to overcome distance when patients must travel to receive specialized care. We depend on the available, widely used smartphones via a mobile application to conduct follow up data as regard to patient quality of life and comparing this to conventional follow up visits and whether it help to obtain a complete follow up data
223948525|NCT00249405|DRUG|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
223948526|NCT00249405|BEHAVIORAL|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
223948527|NCT02789488|DIETARY_SUPPLEMENT|Fenugreek seeds extract 500 mg|Furocyst one caps BID
223948528|NCT05816317|BEHAVIORAL|Single-Session Mechanism-Focused Intervention (SSMFI)|A brief intervention for patients hospitalized for suicide risk that directly targets hopelessness and perceptions of social relatedness.
223948529|NCT05816317|BEHAVIORAL|Distress Tolerance Skills Review|Treatment as usual at the inpatient setting for this study.
223536751|NCT05758324|DIETARY_SUPPLEMENT|Nutri PNEA|4 sequences of 10 tablets (one intake)
223536752|NCT05758324|DIETARY_SUPPLEMENT|Placebo|4 sequences of 10 tablets (one intake)
223948530|NCT04810832|OTHER|Evoked related potentials|"Evoked related potentials are performed for each patient during each paradigm (neutral voice and expressive voices):~* with scalp electrodes in the department of neurophysiology~* with intracranial electrodes in the department of neurosurgery."
223948531|NCT04373772|OTHER|abdominal massage|the patients in the AM group were given a total of 30 minutes of AM by the nurses (HD, OM) everyday for 15 minutes in the morning and evening.In this study AM, which included effleurage, strokes, petrissage and vibration techniques, was applied to the patients for 15 minutes in each session at 9:00 am and 9:00 pm.
223948532|NCT00365885|OTHER|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
223948533|NCT05967845|PROCEDURE|cartilage tympanoplasty|cartilage tympanoplasty procedure entails repairing the tympanic membrane perforation by using a piece of cartilage harvested from the patient's auricle.
223948534|NCT05967845|PROCEDURE|platelet rich fibrin augmented tympanoplasty|platelet rich fibrin augmented tympanoplasty entails performing the traditional tympanoplasty using the tempralis fascia as a grafting material. However, platelet rich fibrin clot is obtained from the patient's own blood, and applied to the graft to enhance healing process.
223948535|NCT05907720|BEHAVIORAL|Human-centered design prototype solutions for vulnerable pregnant women|The intervention package will include various social and behavior change programs derived from a human-centered design approach. The intervention will be tailored to vulnerable pregnant women's needs and contexts. It may include but is not limited to health communication campaigns, including radio and print media.
223948536|NCT02852824|DRUG|BI 655130 (spesolimab)|
223948537|NCT02852824|DRUG|Placebo|
223948538|NCT02795884|DRUG|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
223948539|NCT02795884|DRUG|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
223948540|NCT03973021|BIOLOGICAL|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
223948541|NCT05729126|OTHER|Questionnare|A questionnaire form is emailed to radiologists to get their response of their practice with hemodialysis and chronic kidney disease patients
223948542|NCT02611869|PROCEDURE|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
223948543|NCT02611869|PROCEDURE|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
223948544|NCT00236509|DRUG|topiramate|
223948545|NCT06052722|OTHER|Correlation assessment|The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
223948546|NCT04896567|DIAGNOSTIC_TEST|Cell isolation|Tissue from kidney biopsy will be used to isolate Cluster Differentiation 34+ cells.
223948547|NCT02958566|DRUG|Acetaminophen|
223948548|NCT02958566|DRUG|Gabapentin|
223948549|NCT02958566|DRUG|Orphenadrine|
223948550|NCT02958566|DRUG|Lidocaine|
223948551|NCT02958566|DRUG|Marcaine|
223948552|NCT02958566|DRUG|Ketamine|
223948553|NCT02958566|DRUG|Methadone|
223948554|NCT02958566|DRUG|Tramadol|
223948555|NCT02958566|DRUG|Ketorolac|
223948556|NCT02958566|DRUG|Morphine Sulfate|
223948557|NCT02958566|DRUG|Fentanyl|
223948558|NCT02958566|DRUG|Dilaudid|
223948559|NCT02958566|DRUG|Hydrocodone-Acetaminophen Tab 5-325 MG|
223948560|NCT02958566|DRUG|Morphine Sulfate|PCA
223948561|NCT02958566|DRUG|Fentanyl|PCA
223948562|NCT02958566|DRUG|Dilaudid|PCA
223948563|NCT02958566|DRUG|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
224100747|NCT05321186|PROCEDURE|minimally invasive spinopelvic fixation|"Bilateral percutaneous L4 and L5 pedicle screws will be placed under fluoroscopic guidance with Jamshidi needles, and these were will also be used the iliac fixation via percutaneous S2 alar iliac screws.~Cases presenting with significant instability, minimally invasive Transforaminal lumbar interbody fusion (MIS-TLIF) will be performed. Additionally, in cases with neurological deficit, posterior decompression will be performed."
223721744|NCT03556150|OTHER|Manual Therapy protocol|"This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching."
223948564|NCT03775213|BEHAVIORAL|Decision Support Tool with Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including active monitoring and surgery options.
223948565|NCT03775213|BEHAVIORAL|Decision Support Tool without Active Monitoring|The decision support tool communicates trade-offs for different management strategies for DCIS, including surgery options only.
223536753|NCT04034888|BEHAVIORAL|HEX|HEX is a customized exercise program with components including: 1) controlled flexibility movements; 2) progressive ADL training focusing on bed mobility, bed to chair transfers, and indoor walking; 3) task-specific seated resistance training to improve ability to get out of bed and; 4) and balance exercises. Participants will be expected to perform their HEX program at least 2 times/week in their home and all individualized exercise sessions will be supervised by an Exercise Physiologist. Each exercise has four levels of difficulty, which will be progressed as tolerated throughout the 12-weeks. Seated resistance exercises were designed to target all the major muscle groups and will include the following: arm curls, shoulder raises (lateral/front), overhead arm raise, wrist curls, leg extensions, hip flexion, hip ab/adduction, sit-to-stands, torso rotation, and marching.
223536754|NCT03643081|DEVICE|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
223536755|NCT00180284|DEVICE|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
223721745|NCT03556150|OTHER|Effleurage|"The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
223536756|NCT03425955|DEVICE|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
223536757|NCT03425955|DEVICE|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
223536758|NCT03076684|OTHER|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to \<5% of energy and keeping their weight stable.
223536759|NCT03076684|DRUG|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
223536760|NCT03254784|DRUG|BMS-986165 Capsule|Oral capsule
223536761|NCT03254784|DRUG|BMS-986165 Tablet|Oral tablet
223536762|NCT00570713|DRUG|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
223536763|NCT00570713|DRUG|Placebo|As per package insert.
223948566|NCT01567007|BEHAVIORAL|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
223721746|NCT03291054|DRUG|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
224100748|NCT04331899|DRUG|Peginterferon Lambda-1a|Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
224100749|NCT04331899|OTHER|Placebo|Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
224100750|NCT02859701|DRUG|AK002|IV AK002
224100751|NCT02859701|OTHER|Placebo|
223948567|NCT01567007|BEHAVIORAL|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
223948568|NCT01567007|BEHAVIORAL|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
223948569|NCT00786188|DRUG|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
223948570|NCT00786188|DRUG|Sugar pill|Subjects will receive a sugar pill.
223948571|NCT00655785|BIOLOGICAL|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
223948572|NCT00655785|DRUG|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
223948573|NCT06970249|BEHAVIORAL|Music intervention|Patient-preferred music (e.g., classical, jazz, ambient) will be selected preoperatively from a standardized list and delivered via headphones at 40-60 dB, verified by a sound meter.
223536764|NCT00570713|DRUG|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
223948574|NCT06452576|DEVICE|Vibration|Watch vibrates.
223948575|NCT06452576|BEHAVIORAL|constraint-induced movement therapy|A splint or mitt is placed on the stronger, unaffected hand to encourage use of the affected upper limb in therapy.
223948576|NCT03950427|BEHAVIORAL|Videogame-based physical activity|videogame-based physical activity
223948577|NCT03950427|BEHAVIORAL|Sedentary videogame|sedentary videogame
223948578|NCT03950427|DRUG|Bupropion|Bupropion
223948579|NCT03950427|BEHAVIORAL|Counseling|Counseling for smoking cessation
223948580|NCT02790281|PROCEDURE|Blood sampling|Blood sample collected at a single visit
223948581|NCT05123144|BEHAVIORAL|BHS+ORCHID|"At the clinic level, sites randomized to implement BHS+ORCHID will receive training, materials, and other support to administer behavioral health screening and refer their clients with elevated depression symptoms to ORCHID.~At the individual level, those clients who are eligible and choose to enroll in ORCHID will receive self-guided training on 8 positive affect skills through weekly online sessions and daily practice exercises."
223948582|NCT03787628|DRUG|Cannabidiol (CBD) 600 mg|CBD (300 mg) will be administered orally twice daily in the morning and again in the afternoon. The active ingredient in the Ananda investigational new drug, ATL5, is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc. (California, USA) under cGMP conditions.
223536765|NCT04982952|BEHAVIORAL|Contingency Management - Increasing|Increasing incentive payment for abstinent participant
223536766|NCT04982952|BEHAVIORAL|Fixed payments|Fixed payments for attending study visits
223948583|NCT03787628|DRUG|Placebo|The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc. under cGMP conditions. The amount (number of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
223948584|NCT05288959|DEVICE|Session 2: Single-pulse TMS (spTMS)|Uni-focal TMS (MagVenture, Farum, Denmark) is delivered to one brain area while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The targeted brain areas and TMS intensities may vary across runs. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coil.
223948585|NCT05288959|DEVICE|Sessions 3 - 5: Paired associative stimulation (PAS)|During each PAS run, bi-focal TMS (MagVenture, Farum, Denmark) is delivered to two brain areas while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. The asynchronies between the two TMS coils are kept constant within each session but differ across sessions. Within each session, to observe PAS effects on connectivity, uni-focal spTMS is delivered to the stimulated areas before and after the PAS modulation while EEG/EMG (NeurOne, Bittium, Kuopio, Finland) are recorded. In addition, resting-state EEG/EMG and a behavioral measure (bimanual task coordination) are recorded before and after the PAS modulation. An MRI-based TMS navigation system (Localite, Bonn, Germany) is used to navigate the TMS coils.
223948586|NCT03784469|OTHER|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
223948587|NCT05962476|DEVICE|Transcutaneous vibro-acoustic device|Wearable device which sends low-frequency sound vibrations through the skin.
223948588|NCT06510088|PROCEDURE|3-week multimodal prehabilitation program|"This program included four components:~Aerobic and Resistance Exercises A designated physical therapist supervises the resistance exercises and offers corrective guidance. Training intensity was continuously monitored and fine-tuned based on Borg scale assessments.~Respiratory Training Respiratory training was conducted using a respiratory trainer. Patients were instructed to engage in respiratory training at least three times daily, with each session lasting 10 minutes.~Nutrition Intervention Those in the multimodal prehabilitation group received daily whey protein powder to ensure a recommended protein intake of 1.5 g/kg/d. Protein supplements were to be consumed within one hour of exercise to promote muscle synthesis.~Psychological Intervention Anxiety-coping interventions included relaxation techniques and deep breathing exercises, administered in a one-to-one format by a nurse trained in psychological care."
223948589|NCT05402566|DIAGNOSTIC_TEST|Deuterium metabolic imaging|MRI after oral administration of 75g of \[6,6'-2H2\]glucose.
223948590|NCT07052370|DRUG|Thymoglobulin|IV
223948591|NCT07052370|DRUG|Cyclophosphamide|IV
223536767|NCT02431156|OTHER|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
223536768|NCT01649713|DRUG|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
223948592|NCT07052370|DRUG|Fludarabine|IV
223948593|NCT07052370|DRUG|Thiotepa|IV
223948594|NCT07052370|DRUG|Melphalan|IV
223948595|NCT07052370|DRUG|Mesna|IV
223948596|NCT07052370|DRUG|Filgrastim|IV
223948597|NCT07052370|DRUG|Blinatumomab|IV
224100752|NCT00101361|DRUG|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
223536769|NCT00776360|DRUG|oxytocin|80mIE/min as continuous infusion for 70 minutes
223536770|NCT00776360|DRUG|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
223536771|NCT03150537|BIOLOGICAL|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
223536772|NCT06154603|PROCEDURE|Surgical treatment type|This observational design will study the clinical outcome for each type of upper gastrointestinal perforation in relation to surgical or non-surgery treatment and in relation to treatment centre.
223948598|NCT07052370|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
223948599|NCT07052812|BEHAVIORAL|MCT|Metacognitive Therapy (MCT) is a 12-week manualized treatment for OCD targeting maladaptive thought patterns. Clinicians deliver structured sessions including: (1) Attention Training to modify focus, (2) Detached Mindfulness to change responses to intrusive thoughts, and (3) behavioral experiments to reduce compulsions. Treatment progresses through psychoeducation, challenging perfectionism, addressing thought control, and relapse prevention. Primary outcome: Y-BOCS; secondary: MCQ-30 and TFI. Based on the evidence-based myMCT protocol.
223948600|NCT06842134|DRUG|Numeta G16%E|Numeta G16%E (1000mL) will be given intravenously via peripherally inserted central catheter and will provide an equimolar IV phosphate dose of 8.7 mmol over 9 h.
223536773|NCT04179422|OTHER|anthropometric measurement|weight, height, BMI
223536774|NCT04179422|OTHER|nutritional questionnaire|24hs food recall, presence of feeding disorders
223536775|NCT06008977|OTHER|Exercise Test|Supervised pedaling on an ergometer (stationary bike) at a moderate pace for a goal of 30 minutes. The exercise test will be scheduled at infusion visits 1, 6, and 12 or 1 and 3 over the treatment cycle, depending on the group assignment.
223536776|NCT05207384|PROCEDURE|Ozone (O2-O3) injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. 3 sessions (1 session/week) of 5 mL of ozone (O2-O3) will be injected (with a concentration of 10 μg/mL in the first session, 15 μg/mL in the second session, and 20 μg/mL in the third session).
223536777|NCT05207384|PROCEDURE|Corticosteroid injection|US-guided injections will be performed with a 5-12 MHz linear transducer (Logic e portable; GE Healthcare, China) by the same physiatrist and injections will be administered into the subacromial bursa with a posterolateral approach. A mixture of 1 mL corticosteroid (betamethasone 3 mg/mL) and 1 mL lidocaine (20 mg) will be injected (1 session).
223536778|NCT03498573|OTHER|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
223948601|NCT06842134|DRUG|Sodium Glycerophosphate Injection|Organic phosphate (SGP) will be diluted 1000mL of sodium chloride (0.9% normal saline) to achieve an equimolar IV phosphate dose of 8.7 mmol over 9 h.
223536779|NCT06168396|DEVICE|Somatosensation Device|The somatosensation device will be worn on the lower limb (either the residual limb for an amputee, or limb with decreased sensation for a participant with diabetic neuropathy) while performing outcome measures.
223536780|NCT06168396|OTHER|Baseline|Participants will perform outcome measures without wearing the somatosensation device.
223536781|NCT04881760|DRUG|LY3437943|Administered SC
223536782|NCT04881760|DRUG|Placebo|Administered SC
223536783|NCT06220084|BEHAVIORAL|Dance for PD®|The intervention consists of 16 60-min adapted to Greek culture DfPD® classes, which will be performed twice weekly for 8 weeks and instructed by a single researcher, who has the approval to use it for research reasons. The intervention will be delivered both live and online in separate periods for each participant.
223536784|NCT06513533|OTHER|Placebo|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
223536785|NCT06513533|DRUG|Dimethyl fumarate|1 tablet twice daily (one in the morning and one in the evening) for the first 7 days as a starter dose followed by 2 tablets (240 mg) twice daily
223721747|NCT03291054|DRUG|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
223721748|NCT01246401|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
223948602|NCT06762769|DRUG|Isatuximab|Subcutaneous isatuximab will be delivered using an unlicensed medical device (On Body Delivery System)
223948603|NCT06762769|DRUG|Iberdomide|Oral iberdomide
223948604|NCT06762769|DRUG|Dexamethasone|Oral dexamethasone
223948605|NCT03407079|OTHER|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
223948606|NCT03407079|OTHER|Placebo|Placebo capsules will be taken orally for 28 days
223948607|NCT06758804|DEVICE|Winterized Pistacia Lentiscus Oil Nasal Drops (Bactorinol®)|Participants will receive winterized Pistacia lentiscus oil nasal drops (Bactorinol®), administered as 3 drops per nostril, three times daily for six consecutive days.
223948608|NCT06758804|DEVICE|Saline Solution (0.9% NaCl)|Participants will receive a saline solution (0.9% NaCl) administered as 3 drops per nostril, three times daily for six consecutive days.
223948609|NCT05501054|DRUG|Ipilimumab|Given by IV (vein)
223948610|NCT05501054|DRUG|Nivolumab|Given by IV (vein)
223948611|NCT05501054|DRUG|Ciforadenant|Given by PO
223948612|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2)|"1. 12 years or older~   * Primary series: 2 doses, 30 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot~2. 5 to 11 years of age~   * Primary series: 2 doses, 10 μg each, administered 21 days apart~  * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot~3. 6 months to 4 years of age~   * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)"
223948613|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)|"1\. 12 years or older~\- Single booster dose, 15/15 μg, administered after ≥3 months after primary series"
223536786|NCT00135083|DRUG|insulin glulisine|"* Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
223536787|NCT00867139|DRUG|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
223948614|NCT06743334|BIOLOGICAL|Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)|"1\. 12 years or older~\- Single booster dose, 15/15 μg administered after ≥3 months after primary series"
223948615|NCT07098767|DIAGNOSTIC_TEST|ultrasound evaluation|Use high-frequency ultrasonography to assess the swallowing function in patients with dysphagia. The ultrasound examination focuses on visualization of the pharyngeal region to measure vocal cord movement, swallowing reflex, pharyngeal contraction, and the presence and location of pharyngeal residue.
223948616|NCT07098767|DIAGNOSTIC_TEST|Fiberoptic endoscopic evaluation of swallowing (FEES)|FEES involves the use of a flexible endoscope inserted through the nasal passage to observe the pharyngeal phase of swallowing directly. This procedure allows for the real-time assessment of key aspects of swallowing, including vocal cord function, swallowing reflex, pharyngeal contraction, and the detection of aspiration or penetration.
223948617|NCT07098741|OTHER|Core stability exercises with electrotherapy|electrotherapy modalities for pain control will be used and exercises strengthening abdominal core muscles will be applied in two phases.
223948618|NCT07098741|OTHER|Soft tissue release with manual therapy and stretching|Manual soft tissue release will be performed and then stretching of back muscles and thigh muscles will be added to treatemnet.
223948619|NCT07098741|OTHER|Postural correction exercises with contrast therapy|Hot and cold packs will be used one after other for 10-15mins and specific exercises which are designed to improve posture will be taught and performed
223948620|NCT07098741|OTHER|combination of electrotherapy with stretching and flexibility exercises|some pain reducing electrotherapy modality like TENS will be used and general stretching and flexibility exercises will be performed
223948621|NCT07098221|DIETARY_SUPPLEMENT|Molecular Hydrogen|Participants in this arm will consume a single 250 mL dose of hydrogen-rich water containing approximately 1.6-2.0 ppm of dissolved molecular hydrogen (H₂), The HRW will be ingested following an overnight fast, and resting metabolism will be measured approximately 30-60 minutes post-consumption using indirect calorimetry.
223948622|NCT07098221|DIETARY_SUPPLEMENT|Placebo Comparator|Non-hydrogen-producing tablets, identical in appearance and taste to the active supplement
223948623|NCT07098793|DEVICE|Cough monitoring|continuous recording of cough in patients sleeping area for 90-180 days
223948624|NCT07100054|GENETIC|Whole gene sequencing|Whole gene sequencing of CYP3A4 and PXR
223948625|NCT07100054|OTHER|Drug-drug interaction analysis|Evaluating potential drug interactions with CYP3A4 inhibitors and inducers
223536788|NCT00867139|DRUG|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
223536789|NCT00867139|OTHER|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
223536790|NCT01203397|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
223948626|NCT07100054|OTHER|Biomarker analysis|Determination of circulating CYP3A4 mRNA, and 4b-hydroxycholesterol
223948627|NCT06247553|OTHER|Gait Training|The gait training in the experimental group will use a treadmill with a partial body-weight support system and our gait training device. A gait training session will include 2-minute warming up at the beginning and 2-minute cooling down at the end, at a treadmill speed of 0.6 mph. After the warming up, the treadmill speed will increase at every two minutes by an increment of 0.2 mph. Participant's heart rate will be monitored throughout the training session by using a Polar OH1 optical HR sensor placed in the participant's left forearm. Researchers will stop the increase and maintain the same treadmill speed after the HR reaching the target heart rate zone of 50% - 60% of age-predicted heart rate reserve.
224100753|NCT00101361|DRUG|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
223536791|NCT03272555|OTHER|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
223536792|NCT02525198|DIETARY_SUPPLEMENT|fatty acid/flavonoid blend|see arm description
223536793|NCT02525198|DIETARY_SUPPLEMENT|Placebo|see arm description
223536794|NCT06327711|OTHER|Control: CHO Blend|2 servings as a snack or between meals morning and evening
223536795|NCT06327711|OTHER|Experimental: CHO Blend plus AN100|2 servings as a snack or between meals morning and evening
223536796|NCT01538199|DEVICE|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
223536797|NCT01538199|DEVICE|Sham device|The sham device does not emit near-infrared radiation.
223536798|NCT05965219|DRUG|Emraclidine|Emraclidine tablets.
223536799|NCT05965219|DRUG|Itraconazole|Itraconazole oral solution.
223536800|NCT05965219|DRUG|Carbamazepine|Carbamazepine tablets.
223536801|NCT05965219|DRUG|Metformin|Metformin tablets.
224100754|NCT02669563|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
224100755|NCT02669563|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
224100756|NCT02669563|DRUG|[13N]ammonia|IV injection of \[13N\]ammonia
224100757|NCT02669563|DRUG|[11C]HED|IV injection of \[11C\]HED
224100758|NCT02446639|OTHER|Blood collection|
224100759|NCT00719810|DRUG|delafloxacin|300 mg intravenous every 12 hours
224100760|NCT00719810|DRUG|delafloxacin|450 mg intravenous every 12 hours
223948628|NCT06247553|OTHER|Leg Cycling Exercise|The leg cycling exercise will use a stationary bicycle and the similar protocol as in the experimental group. The cycling exercise will include 2-minute warming up in the beginning and 2-minute cooling down at the end with a speed of 10 rpm and resistance of level 1 of 4. After warming up, the speed will increase at every two minutes by an increment of 5 rpm until reaching the target heart rate zone of 50% - 60% of age-predicted maximum heart rate. If the participant cannot tolerate any more increase in cycling speed before reaching the target heart rate, the resistance will be increased. The training duration will be individualized at the beginning and increase weekly by 5 minutes, depending on the tolerance of the participant, up to the maximum of 30 minutes. Both heart rate and blood pressure will be monitored before, during, and after each session to ensure safety. Each session including setting up will be about one hour.
223536802|NCT04844333|OTHER|Extubation under deep anesthesia|When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
223536803|NCT02951260|DRUG|Metformin|17 days treatment with metformin
223536804|NCT02951260|OTHER|Placebo|17 days treatment with placebo
223536805|NCT04845256|DEVICE|SOMAVAC 100 Sustained Vacuum System|Evaluate performance of sustained vacuum system compared to manual suction bulbs
223536806|NCT00571883|OTHER|questionnaire administration|
223536807|NCT00571883|PROCEDURE|psychosocial assessment and care|
223536808|NCT00571883|PROCEDURE|quality-of-life assessment|
223536809|NCT00571883|PROCEDURE|regional lymph node dissection|
223536810|NCT00571883|PROCEDURE|therapeutic conventional surgery|
223536811|NCT05290532|OTHER|Individualized exercise training|The intervention will consist of a multicomponent exercise training program, which will composed of supervised progressive resistance exercise training, aerobic and anaerobic exercises. This training period consist on 2 training sessions of 40 minutes (Warm up 5´+ aerobic exercise 15´+ anaerobic exercise 15´+ stretching 5´)per week during 4 weeks after one week of discharge
223948629|NCT07098585|DRUG|Lisdexamfetamine capsule|Lisdexamfetamine 70 mg capsule
223536812|NCT01533545|DRUG|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
223536813|NCT01533545|DRUG|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
223948630|NCT07098585|DRUG|Elvanse® (Lisdexamfetamine dimesylate capsules, hard)|Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard)
223536814|NCT01389687|BIOLOGICAL|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
223536815|NCT04052009|OTHER|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
223536816|NCT04052009|OTHER|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
223948631|NCT07099781|DEVICE|handheld dynamometer and hand grip dynamometer|using handheld dynamometer and hand grip dynamometer to test the strength of the hand grip and lateral rotators of the shoulder
223948632|NCT07099612|DEVICE|MEMS® Mobile smartphone application|The MEMS® Mobile app is a smartphone application that connects to the Cere®Pak smart blister pack via near-field communication (NFC). It allows participants to view their medication intake history, receive optional reminders, and manually edit or confirm recorded dosing events. The app is installed on the participant's own smartphone (iOS or Android) and used throughout the 8-week study period. Participants are encouraged to scan their blister at least once daily to synchronize data. This intervention is for the Arm 1 group only.
223948633|NCT07099612|DEVICE|Cere®Pak smart blister pack|The Cere®Pak is an electronic blister pack with 28 cavities containing placebo tablets. It automatically records the date and time when each cavity is opened, using embedded electronics. Participants are instructed to simulate a twice-daily medication schedule (morning and evening) for 8 weeks by pushing out tablets without ingesting them. The device functions independently in the control group and connects with the MEMS® Mobile app in the intervention group. Both arms work with this intervention.
223994486|NCT06239233|PROCEDURE|Laparoscopic cholecystectomy|"The surgeon makes small incisions in the abdominal wall, usually around the navel.~Trocars (hollow tubes) are inserted through these incisions to provide access for the laparoscope and specialized instruments.~A laparoscope, a thin tube with a light and camera, is inserted through one of the trocars. It allows the surgical team to visualize the abdominal cavity on a monitor.~The surgeon carefully identifies the gallbladder and the cystic duct, which connects the gallbladder to the common bile duct.~The cystic duct and artery are clipped and cut to disconnect the gallbladder from the biliary system. This step ensures the safe removal of the gallbladder.~The surgeon gently detaches the gallbladder from the liver bed and removes it through one of the small incisions.~Any bleeding vessels are sealed, and the small incisions are closed with stitches or surgical glue."
223536817|NCT04052009|OTHER|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
223536818|NCT01147302|BIOLOGICAL|Placebo|
223536819|NCT01147302|BIOLOGICAL|C1 Esterase Inhibitor (Human)|
223721749|NCT03466697|OTHER|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
223536820|NCT05899829|DRUG|Camlipixant|Camlipixant will be administered
223536821|NCT05899829|DRUG|Rabeprazole|Rabeprazole will be administered
223536822|NCT05899829|DRUG|Rifampin|Rifampin will be administered.
223536823|NCT00281593|DRUG|Telmisartan|
223536824|NCT00281593|DRUG|Ramipril|
223536825|NCT04174352|DRUG|Tamoxifen|estrogen modulator
223721750|NCT00925912|PROCEDURE|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
223721751|NCT00925912|PROCEDURE|Perianal block|0.25% bupivacaine injected at perianal region
223721752|NCT00166114|DRUG|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
223721753|NCT00166114|DRUG|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
223721754|NCT05496257|OTHER|direct pulp capping in primary molars|caries will be removed, and if the pulps are exposed, the material will be place directly over the exposed pulp.
223948634|NCT07099976|DIAGNOSTIC_TEST|The novel care pathway intervention|The pathway uses already-ascertained data, bioMérieux Spotfire testing, and POC CRP testing to stratify patients into risk categories. The first step in the pathway will be POC CRP testing; children with CRP \> 60 mg/L will be deemed 'appreciable risk', whereas those with CRP \< 20 mg/L will be deemed 'low risk'. The CRP cut-offs of 20mg/L (more sensitive) and 60mg/L (more specific) were selected after reviewing the literature, with particular emphasis on meta-analyses; other large recent studies have also used 60mg/L as an upper cut-off for bacterial infection. Participants with CRP between 20-60mg/L will be categorized further to identify children either more likely to have bacterial pneumonia or more intolerant of misclassification. 'If they have O2 saturation \<95% AND tachypnoea as per age-specific norms, they will be 'appreciable risk' (\>60 bpm for age \<1 y, \>50 bpm for 1-2 y, \>40 bpm for 2-4 y, and \>30 bpm for \>4 y).
223948635|NCT07099976|OTHER|Usual Care Alone|Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management.
223948636|NCT07098689|OTHER|The BEM (Body Emotional Maps) program|"The BEM method involves an intervention with the parents of children with diabetes, conducted in group settings, aimed at facilitating parents' adaptation to their child's diabetes condition. The BEM method involves an intervention with the parents of children with diabetes, conducted in group settings, aimed at facilitating parents' adaptation to their child's diabetes condition. The intervention is organized into three sessions.~The first session consists of an introduction and group formation. The second session involves sharing the onset of diabetes, identifying the most critical daily challenges, and the primary change the participants wish to implement. The third session features the BEM pathway, which includes guided visualization and the creation of a map with spatial anchors."
223948637|NCT07098689|OTHER|Control group|The control group will receive the same diabetes management information, accompanied by parent discussion sessions and recreational activities guided by the diabetes team staff. As with the BEM group, activities will take place over three days in an off-hospital location, in contact with nature.
223948638|NCT07099248|OTHER|Cervico-vestibular Home Exercise Program|Patients who consent to participate in this study will be given an informational handout by clinical athletic trainers that provides information about the study, the exercises in their cervico-vestibular home exercise program, and a detailed progression to higher HEP levels/intensities based on their symptoms. The handout will also provide the purpose of the program, definitions of unfamiliar terms, a planning section for frequency and success, how to monitor symptoms through program completion, and how to properly access their exercises, log their completion, and track their progression in the Medbridge Go app.
223948639|NCT07098156|OTHER|Single Research Visit 3T MRI Research Scan|Single research visit scan performed with a 3T magnetic resonance imaging scanner.
223536826|NCT04174352|DIAGNOSTIC_TEST|FES PET/CT|Radiolabeled estrogen \[18F\]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
223536827|NCT04482127|OTHER|SubEpithelial connective graft|Connective tissue graft harvested from hard palate, to be placed buccal to extraction sockets in the intervention group
223536828|NCT06272890|BEHAVIORAL|motivational interviewing|motivational interviewing
223721755|NCT02122250|BEHAVIORAL|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
223721756|NCT02122250|BEHAVIORAL|Static web-based materials|Static web-based materials
223948640|NCT07098156|OTHER|Demographic and Behavioural Questionnaires|A series of demographic and behavioural questionnaires to be completed by participants, either online or during the single study visit. Questionnaires include the Eating Disorder Examination Questionnaire, Autism Spectrum Quotient, Monotropism Questionnaire, Camouflaging Autistic Traits Questionnaire, Hospital Anxiety and Depression Scale, Adult Attention Deficit Hyperactivity Disorder Self-Report Scale, Work and Social Adjustment Scale, International Trauma Questionnaire and Leibowitz Social Anxiety Scale. These questionnaires will also include a demographic questionnaire to acquire measures such as age, BMI, co-occurring conditions, etc.
223536829|NCT03419182|PROCEDURE|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
223536830|NCT03419182|PROCEDURE|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
223536831|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
223948641|NCT07099118|DRUG|HEC169584 capsule|Each dose of HEC83518 will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
223948642|NCT07099118|DRUG|placebo|The placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.
223948643|NCT07099027|DIAGNOSTIC_TEST|Low dose CT|In this arm, participants will undergo a respiratory assessment, smoking cessation, low-dose CT and biospecimen for translational research.
223948644|NCT05318027|DEVICE|ChatBot|The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits. The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups. High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video. Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day. Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV). If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
223948645|NCT06946433|DEVICE|Transcranial Direct Current Stimulation - Active|"This intervention involves non-invasive brain stimulation using transcranial direct current stimulation (tDCS) delivered via saline-soaked sponge electrodes. The anode is placed at F3 (left dorsolateral prefrontal cortex) and the cathode at Fp2 (right frontopolar cortex), according to the international 10-20 EEG system. A 2 mA current is applied for 20 minutes per session, administered once daily on 10 consecutive workdays.~During stimulation, participants engage in cognitive training using the NeuronUP platform, which provides structured, interactive tasks designed to train executive function, attention, and working memory. This combination aims to enhance neural plasticity by pairing neuromodulation with cognitive engagement."
223948646|NCT06946433|DEVICE|Transcranial Direct Current Stimulation - Sham|The sham condition mimics the active setup but delivers only brief ramp-up/down stimulation, producing the initial sensation without sustained current.
223948647|NCT06946433|BEHAVIORAL|Cognitive Training|The cognitive training intervention in this study is delivered through NeuronUP, a digital platform offering evidence-based cognitive stimulation activities. This intervention targets core cognitive domains such as working memory, attention, and executive function through personalized, interactive tasks. What distinguishes this approach is NeuronUP's extensive library of over 10,000 activities, its ability to tailor difficulty levels in real time based on individual performance, and the inclusion of functional tasks that mirror real-life scenarios. Unlike other interventions, NeuronUP also enables therapist-guided customization, allowing for individualized treatment plans that evolve with participant progress, ensuring both relevance and ecological validity.
223948648|NCT05454124|BEHAVIORAL|Training visual sensitivity|Investigators adopt a standard PL approach to train early visual processes of discriminating the orientation of Gabor patches presented at threshold contrast. Across training blocks, Gabors will range in spatial frequency, where contrast is adapted with a 3/1 staircase. Whenever a specific contrast threshold is reached, spatial frequency will increase by 2 cycles per degree and contrast will be reset. Preliminary data from this method in normally seeing and MD participants show both feasibility and tentative evidence that this training gives rise to improvements in acuity.
223948649|NCT05454124|BEHAVIORAL|Combination training|Daily tasks involve a combination of being sensitive to basic visual features, being able to integrate these features, and directing attention and eye movements to better evaluate the information of potential interest. To address this integrative nature of real-world vision, this condition combines elements of training visual sensitivity, spatial integration, and spatial attention.
223536832|NCT03537703|COMBINATION_PRODUCT|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
223721757|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing=no|
223721758|NCT00127660|BEHAVIORAL|Menu: calories=yes, value pricing = yes|
223721759|NCT00127660|BEHAVIORAL|Menu: calories=no, value pricing = no|
223536833|NCT03537703|COMBINATION_PRODUCT|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
223536834|NCT04069988|BEHAVIORAL|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
223536835|NCT04445948|DRUG|Esomeprazole 40 milligrams Oral Tablet|Proton Pump inhibitor
223536836|NCT04445948|DRUG|Amoxicillin 1000 milligrams tablets|Penicillin derivative antibiotic
223536837|NCT04445948|DRUG|Clarithromycin 500 milligrams Tablets|Macrolide antibiotic
223536838|NCT04445948|DRUG|MetroNIDAZOLE 500 milligrams Oral Tablet|Antiprotozoal
223536839|NCT04445948|DRUG|Lactoferrin Bovine sachets 200 milligrams|a protein found naturally in milk from humans and cows
223536840|NCT06652295|OTHER|Complex decongestive physiotherapy (CDP)|CDP consists of patient education, manual lymph drainage, short traction bandaging, skin/nail care and exercise. The applications of all modalities of the CDP programme were performed by the physiotherapist.
223948650|NCT06123143|OTHER|Standardized/structured CPAP weaning protocol|Standardized/structured CPAP weaning protocol up to 32 or 34 weeks gestational age (GA) (based on GA at birth) for infants born at less than 30 weeks GA.
223948651|NCT04785261|DRUG|Methylhydroxypropylcellulose|1-2 drips each time, every 4 hours, for 12 weeks.
223948652|NCT04785261|DRUG|Carbomer|1 drip each time, at bedtime, for 12 weeks.
223948653|NCT04785261|DRUG|TCM Formula|6.0g Chi-Ju-Di-Huang-Wan plus 6.0g Jia-Wei-Xiao-Yao-San, 6.0g twice daily for 12 weeks.
223536841|NCT06652295|OTHER|Self-administered Complex Decongestive Physiotherapy (CDP)|The self-administered CDP programme consisted of patient education, self-manual lymph drainage, self-short traction bandage application, self-skin/nail care and exercise. Participants were given one session of patient education before the self-administered CDP programme and patients were given practical information about all applications. Additionally, each component of the self-administered CDP programme was presented to the participants with a patient booklet and a video prepared by the researchers. Patients in the self-CDP group were followed up once a week with a patient follow-up diary.
223536842|NCT04692389|DEVICE|Jalosome soothing gel|This study has not got other intervention
223536843|NCT02181920|DRUG|Metamizole|
223536844|NCT02181920|DRUG|Diclofenac|
223536845|NCT02181920|DRUG|Diclofenac placebo|
223536846|NCT02181920|DRUG|Metamizole placebo|
223536847|NCT01280968|BIOLOGICAL|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
223536848|NCT01280968|BIOLOGICAL|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
223536849|NCT03688971|DRUG|Omiganan|Omiganan Topical Gel
223536850|NCT03688971|DRUG|Ketoconazole|Ketoconazole Cream
223721760|NCT05735015|DRUG|encaleret|Oral administration, twice a day
223948654|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
223948655|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
223948656|NCT02643368|BIOLOGICAL|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
223948657|NCT02643368|BIOLOGICAL|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
223948658|NCT02572986|DRUG|Permethrin|
223721761|NCT06127953|PROCEDURE|intermediate cleft rhinoplasty|intermediate cleft rhinoplasty using open approach and combined techniques of Tajima, Dibbell and Potter's Rhinoplasty
223721762|NCT05499312|DRUG|HKIIM-KU formula|Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
223721763|NCT05499312|DRUG|Placebo|Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
223721764|NCT01264900|BEHAVIORAL|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
223721765|NCT00113620|DRUG|Neurodex|
223721766|NCT04019574|DRUG|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
223721767|NCT04019574|DRUG|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
223536851|NCT03688971|DRUG|Placebo|Vehicle
223536852|NCT03507725|BEHAVIORAL|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
223536853|NCT03507725|PROCEDURE|Prostate Biopsy|Prostate needle biopsy under local anesthesia
223536854|NCT03507725|BEHAVIORAL|Questionnaires|Questionnaires completion will be by telephone interview or manual completion of paper or online REDCap instruments, depending on participant preference.
223536855|NCT05262569|OTHER|ileus|retrospectively allocation according to a postoperative outcome-ileus
223536856|NCT05231863|DRUG|TKIs|tyrosine kinase inhibitors based therapy
223536857|NCT00451230|DRUG|cocaine|
223536858|NCT00451230|DRUG|hydrocortisone|
223536859|NCT00087217|DRUG|tanespimycin|Given IV
223536860|NCT00087217|DRUG|paclitaxel|Given IV
223536861|NCT00087217|OTHER|laboratory biomarker analysis|Correlative studies
223536862|NCT00087217|OTHER|pharmacological study|Correlative studies
223536863|NCT06643273|OTHER|Robotic rehabilitation|"Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
223721768|NCT04019574|DRUG|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
223536864|NCT06643273|OTHER|Conventional rehabilitation|"Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions."
223536865|NCT02247128|DRUG|Aspirin + clopidogrel|
223536866|NCT02247128|DRUG|Aspirin monotherapy|
223536867|NCT02247128|DRUG|OAC + clopicogrel|
223536868|NCT02247128|DRUG|OAC monotherapy|
223536869|NCT05411497|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
223536870|NCT05411497|DRUG|Cyclophosphamide|Given IV
223536871|NCT00542178|DRUG|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
223721769|NCT04019574|OTHER|Placebo|IV Placebo as a bolus injection
223721770|NCT02088710|BEHAVIORAL|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
223721771|NCT03118258|BEHAVIORAL|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
223721772|NCT03118258|BEHAVIORAL|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
223721773|NCT04357132|OTHER|VR-Biofeedback|Participants will be instructed to use the Mindful Aurora Application
223536872|NCT00542178|DRUG|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
223536873|NCT00542178|DRUG|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
223536874|NCT00542178|DRUG|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
223536875|NCT00542178|DRUG|Fenofibrate|Blinded fenofibrate
223721774|NCT04357132|OTHER|VR-Distraction|Participants will be instructed to use one of four applications
223721775|NCT06379412|OTHER|observational study, no intervention|observational study, no intervention
223536876|NCT00542178|DRUG|Simvastatin|Simvastatin 20-40 mg/d
223721776|NCT05817825|BEHAVIORAL|Smart IOP Intervention|Smart IOP is a remotely delivered IOP program in operation since 2016, allowing patients to complete addiction treatment entirely online. The original program, consisting of 72 video modules across 8 different topics, will be adapted and tailored to hospitalized patients with serious infections from injection drug use. Participants will watch video content asynchronously, and will be required to correctly answer knowledge questions to proceed to the next module. The whole treatment program will require approximately 4 weeks to complete. Participants are also asked to answer questions about how to apply the knowledge to their own personal circumstances. The answers to these are reviewed by the peer recovery coach during weekly encounters. Videos can be viewed at a time that is most convenient to the participants. T
223948659|NCT01331278|PROCEDURE|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
223948660|NCT01331278|PROCEDURE|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
223948661|NCT05190224|OTHER|Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.|In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
223948662|NCT05673616|OTHER|Mckenzie Extension Exercises|"After two weeks of initial consultation, the patient will be taught to perform slouch-overcorrect on day 1 followed by flexion on day 2 in lying position and accompanied by flexion for 5 days in sitting position and finally flexion in standing will be performed.~The exercises will be repeated for 10 times and followed by extension in standing exercises."
223948663|NCT03928743|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223948664|NCT03928743|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
223948665|NCT01212822|BIOLOGICAL|bevacizumab|Given IV
223948666|NCT01212822|DRUG|oxaliplatin|Given IV
223948667|NCT01212822|DRUG|leucovorin calcium|Given IV
223948668|NCT01212822|DRUG|fluorouracil|Given IV
223948669|NCT01212822|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223948670|NCT01212822|OTHER|laboratory biomarker analysis|Correlative studies
223948671|NCT04195789|OTHER|Lung sonography|"Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist."
223948672|NCT01493882|DRUG|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
223948673|NCT01493882|DRUG|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
223536877|NCT00542178|DRUG|Placebo|Placebo
223536878|NCT02281045|DEVICE|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
223536879|NCT02281045|DEVICE|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
223948674|NCT01493882|DRUG|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
223948675|NCT01493882|DRUG|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
223948676|NCT02236611|DRUG|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
223536880|NCT01099488|PROCEDURE|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
223536881|NCT01916473|OTHER|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
223536882|NCT01916473|OTHER|Continuous wound infusion|Continuous wound infusion via catheter
223536883|NCT03449576|OTHER|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
223948677|NCT02236611|DRUG|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
224100761|NCT00719810|DRUG|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
224100762|NCT02303080|OTHER|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
223536884|NCT03449576|OTHER|Exposure Therapy with Psychotherapy group|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
223536885|NCT06058416|BIOLOGICAL|Healive (hepatitis A vacine(human diploid cell), inactivated)|"The hepatitis A vaccine contains 500 SU inactivated hepatitis A virus per dose in 1mL of aluminum hydroxide solution.~For anti-HAV antibody-negative participants, two dose of hepatitis A vaccine will be given with vaccination interval of 6 month, 18 months, 36 months, and 60 months, respectively."
223536886|NCT03518151|OTHER|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
223536887|NCT03518151|OTHER|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
223721777|NCT05817825|BEHAVIORAL|Peer Recovery Coach|Peer recovery coach, an individual in sustained recovery (\>5 years) and certified to be a coach, will meet weekly with the participant to review progress, answer questions about the videos, review answers to questions, and encourage continuation of treatment after discharge. These meetings will occur in-person or remotely.
223721778|NCT00094744|DEVICE|Eye patch|adhesive eye patch used to cover the sound eye
223721779|NCT05820685|DRUG|Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol)|Participants will receive acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, and gabapentin 300 mg every eight hours. Participants will also receive Oxycodone 5 mg or Tramadol 50 mg every six hours as needed for breakthrough pain. Providers will have the ability to adjust this pain regimen based on clinical judgement.
223721780|NCT05820685|DRUG|Dronabinol|Participants will receive Dronabinol 10 mg every 12 hours scheduled. Providers will have the ability to adjust this pain regimen based on clinical judgement.
223721781|NCT00772343|BIOLOGICAL|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
223721782|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
223721783|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
223948678|NCT04131257|BEHAVIORAL|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
223948679|NCT01056159|DRUG|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
223948680|NCT01056159|DRUG|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
223948681|NCT05085418|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
224100763|NCT02303080|OTHER|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
224100764|NCT02303080|OTHER|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
223721784|NCT00772343|BIOLOGICAL|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
223721785|NCT01218568|DRUG|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
223721786|NCT01218568|DRUG|Lactulose|Lactulose 30-60 ml in two or three divided doses.
223721787|NCT05786820|DIETARY_SUPPLEMENT|Pycnogenol|daily consumption of a pycnogenol-containing capsule
223948682|NCT00004474|DRUG|Anti-thymocyte globulin|Given via IV over 4 hours
223948683|NCT00004474|DRUG|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
223948684|NCT00004474|PROCEDURE|Bone marrow transplantation|Given on Day 0
223948685|NCT02311062|OTHER|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
223948686|NCT02311062|OTHER|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
223948687|NCT02311062|OTHER|Control|Only soccer training
224100765|NCT02303080|OTHER|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
224100766|NCT03083912|DIETARY_SUPPLEMENT|Fortimel Complete|The residents included receive 2 bottle por day.
224100767|NCT02536482|DIETARY_SUPPLEMENT|Amix|Treat the children with cow's milk allergy for 5 months.
224100768|NCT00450463|DRUG|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
223721788|NCT05786820|DIETARY_SUPPLEMENT|Placebo|Daily consumption of a placebo capsule
223721789|NCT03018704|DRUG|Topiramate|anticonvulsant medication. The medication was dosed twice per day with a starting dose of 25 mg, increasing the dose as tolerated to 200mg daily in divided doses. Patient were titrated to the highest dose tolerable.
223721790|NCT03018704|DRUG|placebo|inactive medication. the doses of placebo were titrated the same as the active intervention.
224100769|NCT00450463|DRUG|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
224100770|NCT00450463|BIOLOGICAL|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
224100771|NCT00450463|BIOLOGICAL|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
223948688|NCT00808496|OTHER|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
223536888|NCT05896202|OTHER|taVNS Video|One third of the participants will see the taVNS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
223948689|NCT00808496|OTHER|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
223948690|NCT00808496|OTHER|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
223948691|NCT05193799|DEVICE|Investigational devices must be used 8 hours per day|During 3 consecutive days
223948692|NCT03175406|DIAGNOSTIC_TEST|Manipal cervical scoring system|
223948693|NCT00002235|DRUG|Indinavir sulfate|
223948694|NCT00002235|DRUG|Nelfinavir mesylate|
223948695|NCT00002235|DRUG|Efavirenz|
223536889|NCT05896202|OTHER|Educational materials|Participants will receive sample consent forms and brochures for taVNS and TMS. These materials will be reviewed with each participant once on site, and they will have the opportunity to ask questions. participants will take these materials home and have the opportunity to review further at their leisure.
223721791|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Teachers' version (MISC-T)|"This is a 36-hour group training involving 4 theoretical + 11 practice online sessions using video-feedback, the core component of MISC original trainings.~Session 1: MISC presentation; Session 2: Bases of the interaction and MISC culture-context components; Session 3: The emotions in the interaction and MISC emotional components; Session 4: MISC cognitive components and implications for learning; Session 5: Practice with you-tube examples of interaction; Session 6: Practice with trainer's examples of video-feedback. Sessions 7 to 14: Practice with participants' video-recordings. Session 15: End of the intervention, last video-feedback training and preparing for post-assessment."
223948696|NCT02666404|OTHER|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
223536890|NCT05896202|OTHER|TMS Video|One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
223948697|NCT04390516|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mechanical ventilation and mortality within 24 hours after hospital admission.
223948698|NCT02430454|BEHAVIORAL|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
223948699|NCT05569343|OTHER|No intervention|This is an observational study without any intervention
223948700|NCT05474950|DRUG|minocycline|minocycline capsule (100mg) per day orally
223948701|NCT05545800|DRUG|metformin+empagliflozin+insulin glargine|Randomization was performed with the use of a computer-generated system provided by the sponsor. The dose of metformin will be initiated at 0.5 grams three times a day (the maximum dose is 2g/day); the dose of empagliflozin will be 10 milligrams once a day; insulin glargine will be received once daily at bedtime and the dose will be initiated at the 50% of 0.4-0.5 units/kg/day. All groups received counseling on lifestyle modification.
223948702|NCT05545800|DRUG|IDegLira|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will be initiated on 16 units (16 units degludec/0.58 mg liraglutide) and titrated twice weekly. The maximum dose of IDegLira was 50 units (50 units degludec/1.8 mg liraglutide). All groups received counseling on lifestyle modification.
223948703|NCT05545800|DRUG|premixed insulin analogues|Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients will received twice a day. The total daily insulin dose will be initiated at 0.4-0.5 units/kg/day and adjusted according to the plasma glucose. All groups received counseling on lifestyle modification.
223948704|NCT01450007|DRUG|Ropivacaine|25 ml ropivacaine 0.5%
223948705|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (perineural)
223948706|NCT01450007|DRUG|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
223948707|NCT01450007|DRUG|Normal saline|5 ml normal saline (intravenous)
223948708|NCT01450007|DRUG|Normal saline|0.8 ml normal saline (perineural)
223948709|NCT00204399|BEHAVIORAL|Telephone counseling support|
223948710|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
223948711|NCT01335061|BIOLOGICAL|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
223948712|NCT02501369|BEHAVIORAL|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
223948713|NCT00357019|DRUG|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
223948714|NCT03851094|BEHAVIORAL|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
223948715|NCT06020300|DRUG|Oral Colchicine 0.6 mg|Anti-Inflammatory Effects
223948716|NCT06020300|DRUG|Oral Pyridoxine 10 mg|Colchicine look alike placebo
223948717|NCT02022293|DRUG|Atorvastatin|Patients in this group will take 20mg per night.
223948718|NCT02022293|OTHER|Placebo|
223948719|NCT01536704|DRUG|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
223948720|NCT01536704|DRUG|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
223948721|NCT04301999|PROCEDURE|Photodynamic therapy|The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.
223536891|NCT03313999|DEVICE|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
223948722|NCT04301999|PROCEDURE|radiofrequency ablation|an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
223948723|NCT05581251|BEHAVIORAL|Food and cooking skills|The researchers collected the study data using the face-to-face interview method through a questionnaire including the Descriptive Information Form, Cooking Skills and Food Skills Scale, and Three-Factor Eating Questionnaire-R21.
223948724|NCT05904652|DEVICE|"Fisher and Paykel HealthCare Airvo™ 3 high flow system"|High Flow Nasal Oxygen Delivery Device
223948725|NCT05904652|DEVICE|Conventional Oxygen Therapy|Low flow oxygen delivery device (Flow rate between 2 litres per minute and 15 litres per minute)
223948726|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
223948727|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
223948728|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
223948729|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
223948730|NCT01208506|DRUG|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
223948731|NCT01208506|DRUG|placebo|A single dose of NNC0114-0000-0005 placebo.
223536892|NCT06669871|OTHER|Shirt-A|A dress shirt of a specific design will be provided to the participants, in which weight of the front side will be double than the back side.
223536893|NCT06669871|OTHER|Shirt-B|A dress shirt of a simple design will be provided to the participants, in which weight of the front side will be equal to the back side.
223536894|NCT06995469|PROCEDURE|Chairless Chair® 2.0 Passive Lower-Limb Exoskeleton|"Participants used a passive lower-limb exoskeleton (Chairless Chair® 2.0) during their regular work tasks involving prolonged standing. The device enables a semi-seated posture without the need for external power, aiming to reduce lower limb strain.~The intervention involved each participant performing their typical standing tasks once with the exoskeleton and once without it, in a within-subject repeated-measures design. Each participant served as their own control.~Objective data were collected using a plantar pressure platform (Podoprint S4, Namrol) to measure:~Plantar pressure distribution~Postural stability~Body sway"
223536895|NCT06995612|BEHAVIORAL|SMART-CPT|SMART-CPT T is a psychotherapy that combines Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) and Cognitive Symptom Management and Rehabilitation Training (CogSMART) for neurobehavioral and neurocognitive symptoms to simultaneously target persistent postconcussive symptoms and PTSD
223536896|NCT06995612|BEHAVIORAL|CPT|CPT is a cognitive behavioral treatment specifically targeting PTSD and other corollary symptoms following traumatic events (Resick \& Schnicke, 1992). Based on a social cognitive theory of PTSD and trauma, CPT focuses on identifying the content of trauma-related thoughts, examining whether these thoughts are consistent or inconsistent with a patient's prior beliefs about the world, and addressing the impact these thoughts have on emotions and behaviors. Patients are taught to recognize and challenge thought patterns such as, assimilation (distorting the memory of the traumatic event to fit prior world beliefs), over-accommodation (excessively altering world beliefs to be consistent with the trauma), or the reinforcement of previously held distorted world beliefs.
223948732|NCT03233152|DRUG|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
223948733|NCT03233152|DRUG|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
223948734|NCT00986752|DEVICE|Stenting (Smart Stent)|Nitinol stent
223948735|NCT00986752|DEVICE|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
223948736|NCT00986752|PROCEDURE|Atherectomy (SilverHawk device)|Atherectomy
223948737|NCT03765385|OTHER|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
223948738|NCT03765385|OTHER|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
223948739|NCT01539252|PROCEDURE|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
223948740|NCT01539252|PROCEDURE|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
224100772|NCT02985346|BIOLOGICAL|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
224100773|NCT03787433|DEVICE|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
223536897|NCT06994715|OTHER|Acupressure|The patient will be placed in a suitable position (supine) or alternatively in a side-lying position, and the patient's privacy will be taken into account to determine the pressure points. The patient's own finger measurement will be taken into account when determining the pressure points. Acupressure points will be marked using a surgical marking pen. The pressure will be applied manually. The thumb will be used for this. Before applying direct pressure to the point, a light rubbing movement will be made for approximately 15 seconds on the point area to reduce tension and tissue sensitivity, to warm, relax and prepare. Approximately 2 minutes of pressure will be applied to each point in a circular manner. Each application will last approximately 18 minutes. The patient will be measured 9 times in total during 4 sessions.
223536898|NCT06994715|OTHER|pseudo acupressure|A pseudo acupressure will be applied to the patients in the supine or side-lying position. The researcher will perform this application by wearing gloves. Wearing gloves will reduce the therapeutic interaction with the patient. Since applying pressure or circular rubbing movements to patients may enter the area where other meridians pass and create a different effect, it will be waited for 2 minutes without applying any pressure or rubbing movements on the bone protrusions where the meridian does not pass and where there are no active pressure points. The application will be determined to be approximately 2 cm away from the acupressure points. The application will again be done manually with the thumb. Each application will take approximately 18 minutes. 4 sessions of application and a total of 9 measurements will be made to the patients.
223536899|NCT06996366|OTHER|Outreach to encourage Annual Wellness Visit completion|Mailed and telephone outreach to patient.
223536900|NCT06997276|DRUG|Mirdametinib (MEK Inhibitor)|Mirdametinib will be administered as a single, oral, 4 mg dose in the morning on Day 1 for each study participant enrolled in the study.
223948741|NCT03105960|DRUG|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
223948742|NCT03105960|DRUG|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
223948743|NCT02392507|DRUG|Necitumumab|Administered IV
223948744|NCT02392507|DRUG|Nab-Paclitaxel|Administered IV
223948745|NCT02392507|DRUG|Carboplatin|Administered IV
223948746|NCT04686617|DIAGNOSTIC_TEST|Mechanical Vibration|Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
223948747|NCT00240994|DRUG|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
223948748|NCT00240994|DRUG|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
223948749|NCT00240994|DRUG|Mycophenolate mofetil|Per recommendation
223948750|NCT00240994|DRUG|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
223948751|NCT00851513|DRUG|Lidocaine|local anesthetics
224100774|NCT00072722|DRUG|CC-4047|
223948752|NCT00851513|DRUG|Depmedrol|local steroids
223948753|NCT00851513|OTHER|physiological serum|important volumes of physiological serum
223948754|NCT05689177|BIOLOGICAL|Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)|Booster dose administration
223948755|NCT04191863|OTHER|Clinical, EEG and laboratory assessment at presentation|"* The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG."
223948756|NCT04191863|DRUG|Valproate|valproate monotherapy
223948757|NCT00854594|BEHAVIORAL|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
223948758|NCT04293718|OTHER|papillary gum biopsies|1 or 2 papillary gum biopsies were performed simultaneously, 1 for histological examination and 1 for immunohistochemistry
224100775|NCT06132490|DEVICE|Valveless Insufflator with 12 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under low intra-abdominal pressure throughout the surgery.
224100776|NCT06132490|DEVICE|Valveless Insufflator with 8 mmHg intra-abdominal pressure|In this group valveless insufflators, which are relatively new in clinical practice, will be used under ultra-low intra-abdominal pressure throughout the surgery.
223721792|NCT06150313|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers, Self-Administered version (MISC-SA)|This is a 36-hour individual training involving 25-weekly online, individual, self-administered 50' sessions (21h) + 4 online 1.5-hour group meetings with a supervisor (6h) and 9h of between sessions work (readings, video-recordings for later video-feedback, reflection exercises). Session 1 (Supervisor): Presentation of the MISC program; Sessions 2 to 8 (Self-Administered or SA): Theoretical bases of the MISC: Session 9 (Supervisor): Summary, online group exercises and keys for forward recordings; Sessions 10-11 (Christmas Homework): Recording daily life interactions; Sessions 12-17 (SA): guided reflection with video-feedback; Session 18 (Supervisor): Control session for doubts and video-feedback group training. Sessions 19-28 (SA): guided reflection with video-feedback. Session 29 (Supervisor): Final online video-feedback group training.
223536901|NCT06624800|PROCEDURE|Shoulder chuna treatment(posterior displacement, anterior displacement, or lateral displacement)|The Shoulder Chuna therapy for the shoulder joint will be performed on the affected shoulder from the second day of hospitalization until the day before discharge.
223536902|NCT06624800|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
223536903|NCT05992376|BEHAVIORAL|Food system and demand generation|The Vegetables for All program will create FitFood Zones (FFZs) in low-income estates in urban and peri-urban areas with a minimum of 1,000 households and 10 mama mbogas. FFZs are the last mile/point of purchase for delivering a variety of fresh, safe, and accessible vegetables to BoP households. The program will support mama mbogas to source vegetables from Good Agricultural Practices (GAP)-compliant suppliers, support the uptake of digital solutions for mama mbogas to access vegetables, create business-to-business mentorship opportunities, and support county governments to improve market infrastructure. To encourage BoP parents of children 3-11 years to buy and consume more vegetables, the program will include a demand generation component. This will be implemented through a communication campaign, including above-the-line (ATL) activities (mass media such as radio and television), below-the-line (BTL) activities (market activations and others), and FFZ branding.
223536904|NCT04586075|DIAGNOSTIC_TEST|Trio Whole Genome Sequencing and Participant-Specific Research|"The initial evaluation begins with short-read genome sequencing of DNA extracted from blood of affected individual(s) and participating family members (The most common approach will be trio whole genome sequencing, which involves the affected child + their parents).~Additional evaluation may include: functional assessments, animal modeling, reverse phenotyping (may require an interim visit), epigenetic profiling, or clinical database matching through selective sharing of coded patient data with external collaborators (e.g., via Matchmaker Exchange and Phenome Central), long read genome sequencing, de novo genome assembly, RNA sequencing, and novel bioinformatics analyses"
223721793|NCT06150313|OTHER|Mediational Intervention for Sensitizing Caregivers - Readings version (MISC-R): Treatment as Usual (TAU)|This is an equivalent 36-hour online self-administered training involving 27 x 45' individual online sessions (20.25h), mostly based on reflection exercises around brief readings, animated shorts, or pills, but not video-feedback. This is complemented with 2 x 1.5h online group face-to-face sessions with a supervisor (3h) and 13h of between-sessions work based on looking for new information, adult-child activities (but not for video-feedback) or out-of-line guided reflective exercises. Session 1 (Supervisor): group meeting for program presentation; Sessions 2-28 (Self-Administered): Online self-administered sessions doing readings or watching pills; Session 29 (Supervisor): Final doubts session to close de course.
223721794|NCT00327249|DRUG|imexon|
223536905|NCT06699251|BEHAVIORAL|Chat|Chat is a brief motivational interviewing intervention for partner clinic participants with an alcohol or cannabis use condition.
223536906|NCT06699251|BEHAVIORAL|Enhanced Usual Care|An informational brochure will be give to partner clinic participants with an alcohol or cannabis use condition.
223536907|NCT06701461|DEVICE|Electrodermal Activity signal|Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.
223536908|NCT04928547|DIAGNOSTIC_TEST|Test|Different test
223536909|NCT04809233|DRUG|Tipifarnib|
223536910|NCT06764615|DRUG|Zasocitinib|Zasocitinib capsules.
223536911|NCT06766968|DEVICE|Graduated Compression Stocking: 1 month using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
223536912|NCT06766968|DEVICE|Graduated Compression Stocking: 1 week using|Class 2 (RAL-GZ 387 standard: 23-32 mm Hg at the ankle level) above-knee graduated compression stockings
223536913|NCT03424733|DRUG|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
223536914|NCT03424733|DRUG|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
223536915|NCT03424733|DRUG|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
223536916|NCT04925427|BEHAVIORAL|Case Management and Peer Recovery|A blend between a Critical Time Intervention (CTI) case management model and a peer recovery coaching approach. CORI will employ peer-based case management/recovery coaching and other transitional services (e.g., peer navigation) to provide support and service linkages to medication-assisted treatment (MAT) and harm reduction interventions to reduce subsequent opioid use and related harms.
223536917|NCT04925427|BEHAVIORAL|Naloxone-Only|Participants will be trained on naloxone administration, and upon re-entry, they will be given a naloxone kit and information on local resources for harm reduction, SUD treatment, and additional supportive services.
223536918|NCT02618941|BIOLOGICAL|AFFITOPE® PD01A|s.c. injection
223536919|NCT00208338|DEVICE|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
223536920|NCT00208338|PROCEDURE|Rotator cuff repair|Standard surgical repair of torn rotator cuff
223536921|NCT04133415|RADIATION|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
223721795|NCT04383795|DRUG|Antithyroid Drug|Administration of antithyroid Drug for 6 months
223536922|NCT04133415|PROCEDURE|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
223536923|NCT04549467|DRUG|Lamivudine 300 MG|Experimental arm
223536924|NCT04549467|DRUG|Emtricitabine / Tenofovir Disoproxil Pill|Active Comparator
223536925|NCT00399022|DRUG|Duloxetine|
223536926|NCT02501421|BIOLOGICAL|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
223536927|NCT02501421|BIOLOGICAL|Placebo|Buffer
223536928|NCT06819475|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Non-invasive MRI will be used to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort and healthy controls and measure how muscle mitochondria produce energy to function.
223536929|NCT06819475|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy|Non-invasive MRS will be used to measure the major muscle groups in the calf muscle mtOXPHOS in childhood survivors of Acute Lymphoblastic Leukemia (ALL) in SJLIFE cohort and healthy controls and measure how muscle mitochondria produce energy to function.
223536930|NCT06819475|OTHER|Physical function assessment|As part of the SJLIFE visit in the Human Performance Lab, the participant's physical health will be assessed by testing muscle strength, physical function, and lean muscle mass.
223721796|NCT02397785|DEVICE|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
223536931|NCT06819475|OTHER|Peripheral blood sample|Peripheral blood sample will be used to evaluate muscle morphology, mitochondrial health and epigenetic differences in the muscles of survivors and age/sex-matched healthy controls.
223536932|NCT06819475|OTHER|Skeletal muscle biopsy|Muscle biopsy will be used to evaluate muscle morphology, mitochondrial health and epigenetic differences in muscles of survivors and age/sex-matched healthy controls.
223536933|NCT06819475|DIAGNOSTIC_TEST|Muscle Ultrasound|Bilateral quadriceps and calf muscle ultrasound will be used to measure muscle volume by calculating the cross-sectional area using the Cavalieri method.
223536934|NCT00630617|BEHAVIORAL|Diet, Physical activity, Physical inactivity|Community based participatory research design
223536935|NCT02051426|OTHER|D-serine|single P.O. administration of D-serine (2.1g)
223721797|NCT02397785|DEVICE|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
223721798|NCT00642460|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg (patients\>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
223536936|NCT02051426|OTHER|Placebo|single P.O. administration of Placebo
223536937|NCT00946595|DRUG|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
223536938|NCT00946595|DRUG|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
223536939|NCT06047938|RADIATION|ultrasound on carotid|CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
223536940|NCT00916448|DRUG|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
223536941|NCT00916448|DRUG|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
223536942|NCT05679063|OTHER|Physiotherapy|A program of therapeutic exercise and education in the neurophysiology of pain will be applied to the participants of the experimental group
223721799|NCT00642460|DRUG|Placebo|iv every 2 weeks for 12 weeks
223721800|NCT00642460|DRUG|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
223721801|NCT00642460|DRUG|methotrexate|as prescribed
223721802|NCT00642460|DRUG|corticosteroids|orally, as prescribed
223721803|NCT01947205|DRUG|paracetamol|
223721804|NCT01947205|DRUG|dexketoprofen trometamol|
223536943|NCT05679063|OTHER|Sham, Control|Talks about healthy habits
223536944|NCT03238053|PROCEDURE|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
223721805|NCT01947205|DRUG|suction curettage|
223721806|NCT01947205|DRUG|suction curettage|
223721807|NCT01947205|OTHER|without drug|
223721808|NCT04580953|DEVICE|CardiaCareTM RR2|Treatment with CardiaCareTM RR2
223721809|NCT00937625|BIOLOGICAL|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
223721810|NCT01110434|DRUG|Topiramate|Topiramate (200 mg daily)
223721811|NCT01110434|DRUG|Placebo|Placebo (daily)
223721812|NCT02317185|DEVICE|genex bone graft with bone graft|
223721813|NCT02317185|OTHER|autogenous bone graft|
223721814|NCT00439842|BEHAVIORAL|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
223721815|NCT03085420|DIAGNOSTIC_TEST|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
223536945|NCT03238053|DEVICE|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
223721816|NCT05260788|PROCEDURE|Cystoscopy|Standard of care cystoscopy procedure
223721817|NCT06471452|DEVICE|Interaktor|"In the app (Interaktor), the patients will report frequency and distress on common symptoms and concerns.~Free text comments will also be possible to make to cover the patients' other potential needs. Information about the concerns will be included in the app containing; a) general information about why they have the side effects and what it means b) evidence-based advice about self-management; c) when they should contact health care providers, and d) further information linked to reliable documents, web pages or YouTube videos.~Supportive Care delivered from a study-specific nurse. During the health dialogues with a nurse, the patient-reported assessments in the app will be used to discuss the individual's current situation and needs and to plan eventual additional actions needed such as support from a physiotherapist, social worker, dietitian or if a visit to the physician if needed. This is documented in the patient's journal."
223721818|NCT06072729|OTHER|comparison of magnesium sulphate versus cold compression|This study will involve a total of 70 participants who will be divided into two groups. One group will receive magnesium sulphate, while the other group will receive cold compression. The severity of phlebitis will be assessed in both groups using a visual phlebitis (VIP) rating scale.
223721819|NCT02557646|BIOLOGICAL|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
223721820|NCT02557646|DRUG|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
223721821|NCT04013139|DIAGNOSTIC_TEST|CPET|CPET
223721822|NCT01703949|DRUG|Brentuximab Vedotin|Given IV
223721823|NCT01703949|OTHER|Laboratory Biomarker Analysis|Correlative studies
223721824|NCT01703949|BIOLOGICAL|Nivolumab|Given IV
223721825|NCT00856154|BIOLOGICAL|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~1. Gag150 RLLNAWVKV~2. Gag433 FLGKIWPV~3. Env 67 NIWATHACV~4. Pol606 KLGKAGYVV~5. Vpu66 ALVEMGHHV~6. Vif101 GLADQLIHL~7. Vif23 SLVKHHMYV~8. Gag298 KRWIILGLNKIVRMY~9. gp41 VWGIKQLQARVLAVERYLKD~10. Padre AKXVAAWTLKAAA"
224100777|NCT00573131|DRUG|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
223721826|NCT05157854|BEHAVIORAL|Active in My Home (AiMH)|"AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity."
223721827|NCT04448171|DEVICE|Active TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an active setting.
223948759|NCT05918549|DEVICE|Motion Analysis in Musculoskeletal Oncology|Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
223721828|NCT04448171|DEVICE|Sham TENS|Standard TENS unit with four pads affixed to the lower back area, will be used in this arm. The TENS device will be set to an inactive setting.
223721829|NCT01115101|DRUG|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
223721830|NCT01115101|DRUG|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
223948760|NCT03162835|OTHER|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
223721831|NCT03740711|PROCEDURE|Left atrial venting|The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
223948761|NCT06038747|OTHER|Self-Monitoring|The post-session battery consists of two self-report scales measuring both positive and negative affective reactions of the participants toward their therapist during the therapy session. The general feedback is a brief text that encourages participants to share and discuss their feelings and reflections with their therapist.
223948762|NCT06038747|OTHER|Individual Psychotherapy|Individual psychotherapy sessions
223948763|NCT03471442|PROCEDURE|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
223721832|NCT05788081|DRUG|golcadomide|BMS-986369 is an orally administered Cereblon-modulating compound
223721833|NCT05788081|DRUG|Nivolumab 10 MG/ML|Nivolumab is a fully humanised IgG4 blocking monoclonal antibody against PD-1.
223721834|NCT05788081|DRUG|Rituximab|Rituximab is a chimeric anti-CD20 antibody containing human IgG lambda and kappa constant regions with murine variable regions
223721835|NCT06578338|OTHER|Physical height measurement|Physical height will be measured and images will be collected for AI to estimate the height
223721836|NCT00002916|BIOLOGICAL|human papillomavirus 16 E7 peptide|
223721837|NCT00002916|BIOLOGICAL|synthetic human papillomavirus 16 E6 peptide|
223721838|NCT00002916|PROCEDURE|adjuvant therapy|
223721839|NCT00002916|PROCEDURE|surgical procedure|
223721840|NCT00002916|RADIATION|radiation therapy|
223948764|NCT03471442|PROCEDURE|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
223948765|NCT03471442|DRUG|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
224100778|NCT00573131|DRUG|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
223721841|NCT04605484|BIOLOGICAL|Posoleucel (formerly known as ALVR105) cells|Infusion
223721842|NCT04605484|BIOLOGICAL|Placebo (visually identical to Posoleucel)|Infusion
223721843|NCT05290415|DIAGNOSTIC_TEST|DNA methylation testing|DNA CDO1 and CELF4 methylation testing
223721844|NCT00006097|DRUG|CC-1088|
223721845|NCT02761278|PROCEDURE|Endometrial biopsy|
223721846|NCT04603183|DRUG|Abemaciclib|Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
223721847|NCT04603183|DRUG|Paclitaxel|Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
223721848|NCT04603183|DRUG|Letrozole|Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
223721849|NCT04603183|DRUG|Fulvestrant|Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
223721850|NCT06628128|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
223721851|NCT04038502|DRUG|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
223721852|NCT04038502|DRUG|Olaparib|Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.
223721853|NCT03286335|RADIATION|Proton Radiation|Radiation treatment
223721854|NCT03886480|DEVICE|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
223721855|NCT00896571|DRUG|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
223536946|NCT03238053|DEVICE|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
223536947|NCT06907407|OTHER|Diaphragmatic Myofascial Release|six technique will be applied; 1-Diaphragmatic transverse plane, 2-Anteroposterior equilibrium technique, 3-Supra and infrahyoid fascial induction, 4-Psoas fascial induction,5-Diaphragm stretching technique and 6-Phrenic centre inhibition. diaphragmatic breathing, Mobilization of the ascending colon, descending colon, sigmoid colon, and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual plus medication
223536948|NCT06907407|OTHER|visceral mobilization techniques|Mobilization of the ascending colon, descending colon, sigmoid colon, and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual plus medication
223536949|NCT06907407|OTHER|irritable bowel syndrome medication|the patients will receive irritable bowel syndrome medication
223536950|NCT06534775|OTHER|Questionnary|"The patients were included in a previous study (PABLOS) - These patients received locoregional anesthesia (LRA) by deep parasternal intercostal block (Deep-PIP) or bilateral superficial parasternal intercostal block (Superficial-PIP), compared with standard management (general anesthesia without LRA) for chronic postoperative pain after cardiac surgery by sternotomy.~In PABLOS 2.0 study, the evaluation focuses on the presence of chronic pain between 12 and 24 months postoperatively. There is no intervention in PABLOS 2.0 study but only a questionnary."
223536951|NCT06505460|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
223536952|NCT04473833|PROCEDURE|Serial Transvaginal Ultrasonography|Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
223536953|NCT05229614|RADIATION|Carbon Ion Therapy|After confirming the disease stability and upon patient inclusion in the study, hypofractionated carbon ion boost will be administered to one site of disease previously untreated. Patient will be irradiated to a single lesion with a total dose of 24 Gy\[RBE\], 8 Gy\[RBE\]/fraction, one fraction/day, for 3 days.
223721856|NCT00247897|DRUG|Skin antisepsis|See Detailed Description
223721857|NCT03342183|OTHER|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
223721858|NCT03342183|OTHER|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
223721859|NCT04505462|OTHER|Therapeutic diet|A special healthy diet for dialysis patients
223721860|NCT03201835|DRUG|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
223536954|NCT05229614|DRUG|Immunotherapy (Pembrolizumab)|Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
223721861|NCT03201835|DRUG|Sativex|spray X 4 actuations
223721862|NCT03201835|DRUG|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
224100779|NCT00573131|DRUG|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
223536955|NCT06148311|DRUG|Matching placebo|One matching placebo will be given under the tongue on a thin dissolvable film.
223721863|NCT03201835|DRUG|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
223721864|NCT03201835|DRUG|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
223721865|NCT05379738|OTHER|6 sessions of adapted physical activity after stem cell transplant|"physical assessement before and after stem cell transplant:~* weight loss~* brachial muscle circumference~* grip strength evaluation~* short physical battery test~psychometric assessment before and after stem cell transplant:~* quality of life questionary~* physical activities questionary"
223721866|NCT03849196|DRUG|2L PEG-Asc|PEG-Asc powder
223721867|NCT03849196|DRUG|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
223721868|NCT03849196|DRUG|1L PEG-Asc|PEG-Asc powder
224100780|NCT00573131|RADIATION|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
224100781|NCT00573131|PROCEDURE|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
223536956|NCT06148311|DRUG|Dexmedetomidine|Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
223536957|NCT06904313|DRUG|Piflufolastat F18|Participants will be injected with Piflufolastat F18 and imaged for up to 3 hours on a PET scanner
223536958|NCT06927674|BEHAVIORAL|Consumption of vegetables|DELIVER is designed to address challenges of low consumption of vegetables in both variety and quantity by working with smallholder farmers to increase production and promoting healthier diets through greater vegetable consumption. The project will build the capacity of smallholder farmers in vegetable production through collaborating with lead farmers to establish demonstration plots that showcase advanced agricultural techniques and technologies. These plots will serve as training hubs for other farmers in vegetable production, postharvest handling, as well as business and market planning. DELIVER aims to increase consumption among neighbors of the smallholder farmers by asking the farmers to recruit at least one neighbor family to whom they will regularly sell vegetables. The project also includes a livelihood component that will increase market connections and access to finance for smallholder farmers.
223536959|NCT06507540|OTHER|No intervention (observational study)|Retrospective description of diagnostics and treatements of dental emergencies
223536960|NCT06943209|OTHER|Creation of a contraception education program and post on social networks for high school students|Training of peer influencers and program design.
223536961|NCT06943209|OTHER|Education program|View videos/messages created by peer influencers on social networks
223536962|NCT06943209|OTHER|Survey and questionnaires|Respond to the sexual health and contraception knowledge survey and the education program satisfaction survey
223536963|NCT06421649|RADIATION|Proton Beam Therapy|All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
223536964|NCT06954454|OTHER|prenatal physical exercise intervention|Multicomponent prenatal exercise program including aerobic, coordination, strength, stretching, balance, postural, and pelvic floor muscle training exercises. Delivered either in person or online by qualified exercise physiologists. Duration and frequency: two sessions of 60 minutes per week for 12 weeks. Moderate intensity: According to the Borg scale of perceived exertion, from six to 20, moderate exercise is rated between 13 and 14. Each pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. Settings: home or healthcare, university, or fitness centers. Following international guidelines for physical activity during pregnancy (ACOG-USA, ACSM-USA, CSEP-Canada, PSOG-Poland, SEGO-Spain).
223536965|NCT05722223|COMBINATION_PRODUCT|Trimodal prehabilitation|Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
223536966|NCT03984188|DRUG|Theophylline ER|200 mg extended release (ER) low-dose theophylline taken orally daily
223536967|NCT03984188|DRUG|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
223536968|NCT03984188|OTHER|Standard of Care Treatment|Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment
223536969|NCT03508674|DEVICE|Levita Magnetic Surgical System|use of surgical tool
223536970|NCT00652743|BIOLOGICAL|Pandemic influenza vaccine GSK1562902A|IM administration
223721869|NCT02973698|OTHER|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
223536971|NCT01978483|DRUG|Denosumab|
223536972|NCT01978483|RADIATION|UVB exposure|
223536973|NCT01978483|DRUG|Diphenylcyclopropenone|
223536974|NCT01978483|DRUG|Normal Saline|
223536975|NCT01312519|DEVICE|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
223536976|NCT01312519|DEVICE|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
223536977|NCT00157963|DRUG|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
223536978|NCT05389748|OTHER|Placebo|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to placebo in association with standard of care
223536979|NCT05389748|BIOLOGICAL|dodecafluoropentane emulsion (DDFPe)|Subjects with large vessel occlusion stroke eligible for mechanical thrombectomy are randomized to DDFPe in association with standard of care
223536980|NCT06473298|OTHER|Visual Light Tracking|visual light tracking program consists of 10 tasks every task lasts for 6 minutes and may be repeated for the child especially in the first sessions to give him trials to him/her to understand the exercise.
223536981|NCT02377843|BEHAVIORAL|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
223536982|NCT02377843|BEHAVIORAL|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~1. Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~2. Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~3. Practice using the communication strategy via role play~4. Discussion on applying the communication strategy to medical practice"
223536983|NCT03233828|BIOLOGICAL|Aldesleukin|500,000 IU in 0.1mL
223536984|NCT03233828|OTHER|Saline|0.1 mL of sterile saline solution (0.9% m/v)
223536985|NCT02151929|DEVICE|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
223721870|NCT02973698|OTHER|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
223536986|NCT02151929|DEVICE|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
223721871|NCT02973698|OTHER|Control|No intervention will do
223721872|NCT02742610|BEHAVIORAL|Mindfulness with Contingency Management|
223721873|NCT02742610|BEHAVIORAL|Active Control|
223536987|NCT04505761|DEVICE|Virtual Reality|Participants will use a Virtual Reality headset with a range of applications applicable for rehabilitation after COVID-19. Applications target physical, psychological, and cognitive rehabilitation. VR headset will be used for six weeks first at the physiotherapist's practice, and when possible, at home.
223536988|NCT03345277|OTHER|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
223536989|NCT00165828|DRUG|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
223536990|NCT06354673|PROCEDURE|Stellate ganglion block|Sympathectomy by using combination of regional nerve block and systemic drugs
223536991|NCT06354673|DRUG|Dexmedetomidine|intravenous Dexmedetomidine infusion
223536992|NCT06354673|DRUG|Ketamine|intravenous ketamine infusion
223536993|NCT06255405|BEHAVIORAL|Self-compassion|The dyadic parent-child self-compassion program is designed by the research team and validated by a panel of experts. It includes 5 weekly sessions. Each session lasts for 60 minutes. The dyads will be guided to do self-compassion practices (e.g. affectionate breathing, compassionate letters to oneself etc). Didactic topics, inquiry, and home practices are also involved.
223536994|NCT00272792|DRUG|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
223536995|NCT00272792|DRUG|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
223536996|NCT06447766|BEHAVIORAL|Feeding Families Your Way Program|Feeding Families Your Way is a video-based education program delivered by the University of Rhode Island Supplemental Nutrition Assistance Program - Education (SNAP-Ed).
223536997|NCT00530881|DRUG|PHX1149|
223536998|NCT04937634|DRUG|Melphalan|The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
223536999|NCT00558818|DRUG|Clevudine|clevudine 30 mg qd
223537000|NCT04930315|DRUG|Apatinib Mesylate|250mg, po, qd, q2w in neoadjuvant and adjuvant group, before surgery
223537001|NCT04930315|DRUG|Camrelizumab|200mg, iv, d1, q2w, both in two groups
223537002|NCT05987124|DRUG|Defibrotide|HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
223537003|NCT01231789|PROCEDURE|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
223537004|NCT01231789|PROCEDURE|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
223721874|NCT05015244|PROCEDURE|3T (Tesla) Magnetic Resonance Imaging (MRI)|Neurological evaluation using MRI and neuropsychological tests
223721875|NCT00885430|DRUG|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
223721876|NCT05292846|DRUG|Direct-acting oral anticoagulation|Apixaban Dabigatran Edoxaban Rivaroxaban
223721877|NCT04318795|PROCEDURE|minimally invasive spinal decompression (MIS-D)|lumbar spinal decompression alone using minimally invasive approach, without any fusion or implantation
223721878|NCT04318795|PROCEDURE|minimally invasive spinal decompression and fusion (MIS-TLIF)|lumbar spinal decompression plus interbody fusion with implantation using minimally invasive approach
223721879|NCT03863249|PROCEDURE|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
224100782|NCT03500107|DEVICE|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
224100783|NCT01827501|DEVICE|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
224100784|NCT00400387|DRUG|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
224100785|NCT00400387|DIETARY_SUPPLEMENT|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
223721880|NCT03863249|DRUG|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
223721881|NCT03863249|DIAGNOSTIC_TEST|MICROBIAL SAMPLING|"1. Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~2. The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
223721882|NCT02912910|OTHER|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
223721883|NCT02912910|OTHER|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
224100786|NCT05948878|DEVICE|Novel Taping Method|Subjects will be asked to have the novel taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
224100787|NCT05948878|DEVICE|BCH Emergency Department Taping Method|Subjects will be asked to have the BCH emergency department taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
223721884|NCT00905697|PROCEDURE|Living donor lung transplantation|Living donor lung transplantation
223721885|NCT04103853|DRUG|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
223721886|NCT06407167|DIAGNOSTIC_TEST|DN4 (Douleur Neuropathique 4 Questions) questionnaire|DN4 includes a series of ten questions consisting of both sensory descriptors and signs related to bedside sensory examination
223721887|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 1. Group 1 receives treatment A\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment B\*\* was applied to group 1 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
223721888|NCT05037708|PROCEDURE|Manual lymphatic drainage|"Subjects are randomly assigned to group 2. Group 2 receives treatment B\*\* for 4 weeks.~Afterwards, a period of washing or bleaching should be allowed in order to be sure that the effects of the intervention have disappeared. This period will last 2 months during which the usual treatment for LGA patients will be carried out, which consists of 2 monthly physiotherapy sessions, in this way it is intended that the subjects are in the initial state (as before the start of the first intervention). After this washout period, treatment A\* was applied to group 2 for 4 weeks.~\*Treatment A consists of manual lymphatic drainage.~\*\*Treatment B consists of no treatment"
223721889|NCT05812898|OTHER|exercises|strengthening of the gluteus maximus and medius, calf muscles stretching for calf and hamstring muscles
223721890|NCT05812898|OTHER|myofascial release|myofascial release using instrument assisted soft tissue mobilization
223721891|NCT06384768|OTHER|Video training|A 4 week support program consist of videos for fear of childbirth
223721892|NCT03624894|OTHER|impression|common polyvinylsiloxane oral impression
223721893|NCT05292040|DRUG|LY3857210|Administered orally.
223721894|NCT02337257|DRUG|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
223721895|NCT02337257|DRUG|Placebo|subjects will receive placebo one pill per day for 16 weeks
224100788|NCT05948878|DEVICE|Chevron Taping Method|Subjects will be asked to have the Chevron taping method placed on their left and right antecubital fossa region, superficially taping an IV catheter.
223721896|NCT01057342|DRUG|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
223721897|NCT01057342|DRUG|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
223721898|NCT01057342|DRUG|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
223948766|NCT03471442|DRUG|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
223721899|NCT00459953|DRUG|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
223721900|NCT02579044|DRUG|Everolimus and lonafarnib|
223721901|NCT04512716|DRUG|131-I Apamistamab|Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
223721902|NCT04512716|BIOLOGICAL|CAR T-cell|19-28z CAR T-cells will be administered inpatient as a single infusion of 1x10\^6 19-28z CAR T-cells/kg, for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL cohort. Patients will be observed inpatient for a minimum of 7 days (longer as clinically indicated and at the discretion of the treating physician).
223721903|NCT06251648|DRUG|Lenalidomide|Patients exposed to LEN
223721904|NCT06332781|DRUG|Gentamicin|administered via bladder
223721905|NCT06332781|DRUG|Nitrofurantoin|administered PO
223721906|NCT02054260|DRUG|Surgicel|
223721907|NCT04242303|PROCEDURE|Total knee replacement|"Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts."
223721908|NCT04556695|OTHER|Questionnaire survey|Online questionnaire, based on the International Sedentary Assessment Tool (ISAT)
223721909|NCT04556695|DEVICE|Accelerometer study|Consenting participants will be asked to wear an accelerometer on the lateral aspect of the middle of the right thigh (over the midpoint of the iliotibial band), continuously over a seven-day period.
223948767|NCT03471442|DRUG|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
223948768|NCT02892318|DRUG|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
223948769|NCT02892318|DRUG|Guadecitabine|Guadecitabine 60 mg/m\^2 SC on Days 1-5 of every 28-day cycle.
223948770|NCT00749944|DRUG|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
223948771|NCT00749944|DRUG|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
223948772|NCT00913445|PROCEDURE|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
223948773|NCT00201656|PROCEDURE|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
223948774|NCT00201656|PROCEDURE|Removal of Cerclage|Immediate removal of Cerclage following randomization
223948775|NCT00201656|PROCEDURE|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
223948776|NCT00006214|DRUG|flutamide|
223948777|NCT00006214|OTHER|placebo|
224100789|NCT03393962|BIOLOGICAL|OC-EIEs|2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
223721910|NCT04556695|OTHER|Semi-structured interview study|Semi-structured interviews will take place via telephone or webcam. Participants will be given feedback regarding their accelerometer data relating to their levels of physical activity and sedentary behaviour. Questions will examine participants' thoughts and opinions regarding sedentary behaviour and physical activity in the General Practice setting. Further questions will explore participants' experiences of wearing accelerometers, their knowledge of and attitudes towards physical activity and sedentary behaviour and their thoughts or suggestions on interventions to reduce sedentary behaviour among GPs and GPSTs.
223537005|NCT05367869|PROCEDURE|Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy|General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
223721911|NCT06331416|DEVICE|Telemonitoring|Patients will be asked to carry out one measurement (arterial pressure, oxygen saturation, body temperature, heart rate, spirometry) every 24 hours for 90 days. The system will be supplied by the company Vivisol. The telemonitoring data will be read once a day and the principal investigator will be alerted in case of alteration of any parameter. If vital parameters remain stable, a phone call will be performed every 5 days. In case of compromise of any parameter, the patient will be offered a phone call within the same day. In case of new occurrence of any respiratory or non-respiratory symptoms, the patient must contact the principal investigator and he will be offered a phone call or a video-assisted call within the same day. If the alterations or symptoms persist for 24 hours, or in any case upon decision of the investigator in charge, the patient will be offered an in-person evaluation in the same day. If deemed necessary according to usual care, the patient will be hospitalized.
223721912|NCT00499577|BIOLOGICAL|CMV pp65 peptide|Given intramuscularly
223721913|NCT00499577|BIOLOGICAL|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
223721914|NCT00499577|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
223721915|NCT00499577|BIOLOGICAL|survivin Sur1M2 peptide vaccine|Given subcutaneously
224100790|NCT02990884|DRUG|ketamine|
223537006|NCT05111145|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablets for oral administration.
223721916|NCT00040664|DRUG|ritonavir|ritonavir oral capsules or oral solution
223721917|NCT00040664|DRUG|fosamprenavir|fosamprenavir oral suspension or tablet
223721918|NCT02275871|OTHER|MRI|High risk screening MRI will be performed as part of the patient's routine care.
224100791|NCT02482220|BEHAVIORAL|Physical activity intervention|
223721919|NCT02275871|OTHER|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
223721920|NCT04006574|OTHER|Exercises|Core stabilization
223721921|NCT06182059|PROCEDURE|continuous peripheral nerve block|continuous regional anesthesia in total knee replacement
223721922|NCT06072313|OTHER|Monopolar electrical diathermy plus therapeutic exercise|The Experimental Group will undergo two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device and one session of therapeutic neck exercise per week.
223721923|NCT06072313|OTHER|Therapeutic Exercise|The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Participants will be asked to focus on their posture, joint positions and muscle tension in each exercise posture.
223721924|NCT02672826|PROCEDURE|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
223721925|NCT06562751|OTHER|Questionnaire|Online questionnaire designed by the investigatory team.
223721926|NCT06562751|OTHER|Focus group|Online focus group
223721927|NCT06562751|OTHER|Interview|Online semi-structured interview
223721928|NCT06562751|OTHER|Workshop|Online and face to face co-production workshops
223948778|NCT04235920|DIAGNOSTIC_TEST|Montreal Cognitive Assessment (MoCA)|This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a thirty point test with a score of 25 or less considered as abnormal impaired cognition
223948779|NCT00000617|DRUG|azithromycin|
223948780|NCT01995734|DRUG|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
223948781|NCT02629575|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
223948782|NCT03556267|DEVICE|spinal needle|It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
223537007|NCT05111145|DRUG|IVA|Tablets for oral administration.
223537008|NCT01510873|OTHER|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
224100792|NCT05013060|DIETARY_SUPPLEMENT|Probiotics and microcapsulated sodium butyrate|The patients who give their consent to take part in this study, will receive an oral microencapsulated sodium butyrate and a mixture of probiotics formulation 2 times a day for a period of 12 weeks.
224100793|NCT05013060|DIETARY_SUPPLEMENT|Maltodextrin|The patients who give their consent to take part in this study will receive an oral maltodextrin as placebo 2 times a day for a period of 12 weeks.
224100794|NCT00841724|DRUG|Fludarabine, Busulfan, Thymoglobuline|
223537009|NCT00888225|PROCEDURE|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
223537010|NCT00888225|PROCEDURE|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
223537011|NCT01836289|DRUG|High-dose Cyclophosphamide|
223537012|NCT02854995|PROCEDURE|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
223721929|NCT05451225|BEHAVIORAL|Targeted Educational Campaign|"Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC."
224100795|NCT00893789|DRUG|Armodafinil|Armodafinil 50 mg/day
224100796|NCT00893789|DRUG|Armodafinil|Armodafinil 150 mg/day
223721930|NCT00654680|DRUG|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
223721931|NCT00654680|DRUG|Placebo|Matching placebo
223721932|NCT01086085|DRUG|Adefovir|Adefovir 10 mg po once daily for 36 weeks
223721933|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
223721934|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
223721935|NCT01086085|DRUG|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
223948783|NCT03152214|OTHER|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at \> 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
224100797|NCT00893789|DRUG|Armodafinil|Armodafinil 250 mg/day
223721936|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
223721937|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
223721938|NCT01233258|BIOLOGICAL|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
223721939|NCT04966039|OTHER|No intervention.|There was no intervention.
223721940|NCT03875651|DEVICE|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
223721941|NCT04173585|DRUG|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitinated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
224100798|NCT00893789|OTHER|Placebo|Placebo
224100799|NCT01174914|OTHER|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
224100800|NCT01174914|DRUG|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
223721942|NCT04173585|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
223721943|NCT01185756|RADIATION|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
223721944|NCT00437307|DRUG|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
223721945|NCT05806073|PROCEDURE|Elective neck dissection|patient underwent elective neck dissection(level I-III) as initial treatment, along with the excision of the primary tumor
224100801|NCT01174914|DRUG|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
224100802|NCT04127136|BEHAVIORAL|Multi-disciplinary obesity management therapy|In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
224100803|NCT02316444|BIOLOGICAL|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
223721946|NCT05806073|PROCEDURE|Therapeutic neck dissection|patient underwent Therapeutic neck dissection(level I-V) as initial treatment, along with the excision of the primary tumor
223721947|NCT00386178|DRUG|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
223721948|NCT05978804|OTHER|Computerized Cognitive Training|Computerized Cognitive training (BrainHQ or Constant Therapy)
223721949|NCT05978804|DEVICE|Active tDCS (tDCS) on DLPFC|Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
223721950|NCT05027100|DRUG|Anlotinib Tislelizumab Irinotecan|Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
224100804|NCT02545374|OTHER|Telemedicine|
224100805|NCT02545374|OTHER|Control|
223948784|NCT03152214|OTHER|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
223948785|NCT02400528|BEHAVIORAL|quality of life questionnaires|
223948786|NCT04236297|DEVICE|bite block|Physicians performing transesophageal echocardiogram in patients under sedation or general anesthesia will use either standard or modified bite block.
223948787|NCT03046394|DEVICE|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
223948788|NCT03046394|DEVICE|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
223948789|NCT03046394|DEVICE|A-DER|Triton by Otto Bock, advertised for activity category 3-4
223948790|NCT00000250|DRUG|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
223948791|NCT00000250|DRUG|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
223948792|NCT06500195|PROCEDURE|implantation of the hybrid instrumentation system|Surgery corrections were performed using the hybrid instrumentation system (screws and bands).
223948793|NCT03775915|OTHER|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
223948794|NCT03775915|OTHER|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
223948795|NCT05667909|DRUG|Rituximab|375mg/m2 once a week, 4 times in total, or 1g intravenous drip, once again after 2 weeks, twice in total.
223948796|NCT00624377|DRUG|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
223948797|NCT05064566|DEVICE|caries assessment|clinical visual examination (ICDAS II), digital io radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), and micro-CT images.
223948798|NCT04669119|DIETARY_SUPPLEMENT|Bromelain/Boswellia Serrata Casperome|Dietary supplement already commercialized based on Bromelain/Boswellia Serrata Casperome (Arm A and B), called Siben by Agaton
223948799|NCT04669119|DIETARY_SUPPLEMENT|Centella Asiatica/Vitamins|Dietary supplement already commercialized based on Centella Asiatica/Vitamins (Arm B), called Kardinal V by Agaton
223948800|NCT04669119|DIETARY_SUPPLEMENT|Placebo|Placebo
223948801|NCT02525185|OTHER|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
223948802|NCT03979937|PROCEDURE|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
223948803|NCT03054506|DEVICE|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
223948804|NCT03054506|DEVICE|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
223948805|NCT03054506|DEVICE|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
223948806|NCT00923078|BEHAVIORAL|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
223948807|NCT00923078|BEHAVIORAL|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
223948808|NCT01950689|DRUG|Nimorazole|
223948809|NCT01950689|RADIATION|Radiotherapy|
223948810|NCT04518865|DEVICE|Herbst appliance|The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.
223948811|NCT01274156|DEVICE|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
223948812|NCT01274156|DEVICE|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
223948813|NCT01274156|DEVICE|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
223948814|NCT01274156|DEVICE|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
223948815|NCT00992745|DRUG|123-I-MIP-1072|Single 10 mCi intravenous injection
223948816|NCT00992745|DRUG|111-In capromab pendetide|Single 5 mCi intravenous injection
223948817|NCT00992745|DRUG|123-I-MIP-1072|Single 5 mCi intravenous injection
223948818|NCT05220813|DRUG|Lidocaine|local infiltration by lidocaine in the surgical site
223948819|NCT05220813|DRUG|Bupivacain|44patients will receive bupivacaine in ilioinguinal \& iliohypogastric nerve blocks
223948820|NCT02028650|BIOLOGICAL|the first donor's stem cell|HLA-matched stem cell infusion
223948821|NCT02028650|BIOLOGICAL|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
223948822|NCT05228834|DRUG|Voxelotor Only Product in Oral Dose Form|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
223948823|NCT05228834|DRUG|Placebo|During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
223948824|NCT06469931|OTHER|range of motion exercises|In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
223948825|NCT06469931|DEVICE|Extracorporeal shock wave therapy|Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
223948826|NCT06469931|OTHER|ozone therapy|ozone therapy
223948827|NCT04044885|BEHAVIORAL|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
223948828|NCT02936401|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
223948829|NCT03431649|DRUG|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
223948830|NCT03431649|DRUG|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
223948831|NCT00825318|PROCEDURE|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
223948832|NCT01948557|BEHAVIORAL|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
223948833|NCT01631409|OTHER|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
223948834|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
223948835|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
223948836|NCT01631409|PROCEDURE|PCA|Percutaneous coronary angioplasty
223948837|NCT01631409|PROCEDURE|CABG|Coronary artery bypass grafting
223948838|NCT01631409|DEVICE|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
223948839|NCT01631409|DRUG|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
223948840|NCT00564447|DRUG|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
223948841|NCT00564447|DRUG|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
223948842|NCT01762397|DRUG|PMK-S005|
223948843|NCT00502359|DEVICE|capillary blood glucose measurement|
223948844|NCT00988845|DIETARY_SUPPLEMENT|Indole-3-carbinol|200 mg bid po X 8 weeks
223948845|NCT06495463|DRUG|Trifluridine/tipiracil|"Trifluridine/tipiracil 35 mg/m2 PO twice daily on days 1-5 and day 6-14 off~(choose one combination) : oxalipatin 85mg/m2 IV on day 1 every 14 days or irinotecan 100mg/m2 IV on day 1 every 14 days."
223948846|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 1|SBTs with T-piece breathing for one hour during odd-numbered months and SBTs with inspiratory pressure augmentation for one hour during even-numbered months.
223948847|NCT04222205|DIAGNOSTIC_TEST|Spontaneous breathing trial (SBT) crossover sequence 2|SBTs with inspiratory pressure augmentation for one hour during odd-numbered months and SBTs with T-piece breathing for one hour during even-numbered months.
223948848|NCT06962969|DRUG|Ibrance|Patients who received at least one initial prescription of Ibrance following a diagnosis of advanced/metastatic breast cancer
223948849|NCT01291810|BIOLOGICAL|TNF Kinoid|TNF Kinoid
223948850|NCT01291810|BIOLOGICAL|WFI|WFI
223948851|NCT04719026|OTHER|Full-mouth periodontal examination using computerised Florida probe|It is an observational study to investigate the prevalence of periodontitis in cases and controls.
223948852|NCT04241952|OTHER|Exercise|Bedcycling
223948853|NCT05380089|OTHER|Increasing water intake|Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
223948854|NCT04751799|DEVICE|Virtual reality headset before colposcopy|Patients wear a virtual headset presenting 360° 3D views of relaxing environments
223948855|NCT04751799|DEVICE|Virtual reality headset during colposcopy|Patients wear a virtual headset presenting 360° 3D views of distracting environments
223948856|NCT05723666|OTHER|Group watching virtual reality glasses|A nature video will be watched with virtual reality glasses.
223948857|NCT03807596|PROCEDURE|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
223948858|NCT03807596|PROCEDURE|Scaling & root planning alone|Patients received full-mouth supra- \& sub-gingival SRP with the use of ultrasonic device \& periodontal universal \& Gracey curettes under local anesthesia.
223948859|NCT01837602|BIOLOGICAL|cMet RNA CAR T cells|
224100806|NCT05065021|DRUG|Niraparib|Niraparib works by blocking poly(ADP-ribose) polymerases (PARP) 1 and PARP 2 from working. PARP 1 and PARP 2 are proteins that are involved in cell growth, cell survival, and cell death, including cancer cells. It is believed that blocking PARP1 and PARP 2 from working will slow or stop the growth of cancer cells.
223537013|NCT02854995|PROCEDURE|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.\[5\] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
223537014|NCT04927481|DRUG|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
223948860|NCT01141972|DIETARY_SUPPLEMENT|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml \[≥75 nmol/L\]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
223948861|NCT01141972|OTHER|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
223948862|NCT03597087|PROCEDURE|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
223948863|NCT03597087|DRUG|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
223537015|NCT03201640|BEHAVIORAL|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
223537016|NCT03201640|BEHAVIORAL|virtual|Participants will be shown an immersive virtual reality preparation for surgery
223537017|NCT00112892|DIETARY_SUPPLEMENT|selenium|
223537018|NCT00112892|DRUG|irinotecan hydrochloride|
223537019|NCT02718235|OTHER|Overall survival|Observation of overall and disease free survival
223721951|NCT00810030|DRUG|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
223948864|NCT01769716|PROCEDURE|Umbilical cord blood transplantation|
223537020|NCT05558488|OTHER|Meatless, restrictive ketogenic diet|"Each participant received a nutritional plan that was the same qualitatively but differed quantitatively - a 500 kcal reduction based on Estimated Energy Requirement (EER) was assumed. Before the start of the study, each participant obtained information about the basic principles of the ketogenic diet. Diet was designed to be isoproteic (1.8gxKg-1xbody weight-1xday-1) with three meals a day. The distribution of macronutrients during the very low carbohydrate ketogenic diet (KD) was: protein 1.8 gxKg-1xbody weight-1xday-1(\~25-30%), fats (\~65-70%,with a strong emphasis on the content of omega 3 fatty acids) and carbohydrate (\<30gxday-1;\<10%).~The food lists encouraged the consumption of fish,raw and cooked vegetables, eggs,fruits with the lowest glycemic index (blueberry, raspberry), plant oils and fats from avocado,olives.Drinks permitted were tea, coffee without sugar and the foods and drinks to be avoided were alcohol,meat (any kind of meat),bread,pasta,rice,milk,dairy and potatoes."
223537021|NCT02255539|DEVICE|Geelong Prototype Mask|A nasal pillows prototype mask to be trialled with a PAP therapy device for a period of 6 weeks. Participants will wear the mask in place of their current mask for the duration of the trial.
223537022|NCT06513000|DIAGNOSTIC_TEST|Dry eye diagnostic system|"following tests:~1. Non-invasive tear film break up time (TBUT), a parameter of tear film stability.~2. Non-invasive tear meniscus height.~3. Evaluation of Meibomian glands function.~4. Lipid layer thickness.~5. Eyelid margin.~6. Analysis of conjunctival hyperemia.~7. Cornea sodium fluorescein staining.~8. Schirmer I test"
223537023|NCT02126046|GENETIC|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
223537024|NCT00297869|PROCEDURE|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
223537025|NCT04389905|BEHAVIORAL|Dental education - Motivational Interviewing|Motivational Interviewing - Focusing on oral/dental health
224100807|NCT05065021|DRUG|Dostarlimab|Dostarlimab is a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. A monoclonal antibody is a special kind of antibody that is created in a laboratory that seeks out specific proteins in the body that may be involved in cancers to stop tumor growth. Dostarlimab attaches to PD-1 and inhibits the interaction of PD-L1 and PD-L2 with PD-1.
224100808|NCT05065021|DRUG|Bevacizumab|Bevacizumab is a chemotherapy drug commonly used for the treatment of various cancers.
224100809|NCT05065021|DRUG|Paclitaxel|Paclitaxel is a chemotherapy drug commonly used for the treatment of various cancers.
224100810|NCT00723658|BIOLOGICAL|rituximab|
224100811|NCT00723658|DRUG|bortezomib|
224100812|NCT00723658|DRUG|carmustine|
224100813|NCT00723658|DRUG|cisplatin|
223537026|NCT01024348|DRUG|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
223537027|NCT01024348|DRUG|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
223537028|NCT04973358|OTHER|buccotherm mouthwash|twice a day for 14 weeks
223537029|NCT04973358|OTHER|placebo mouthwash|twice a day for 14 weeks
223537030|NCT00553566|PROCEDURE|medical chart review|
223537031|NCT00553566|PROCEDURE|questionnaire administration|
223537032|NCT00553566|PROCEDURE|study of socioeconomic and demographic variables|
224100814|NCT00723658|DRUG|cyclophosphamide|
224100815|NCT00723658|DRUG|cytarabine|
224100816|NCT00723658|DRUG|dexamethasone|
224100817|NCT00723658|DRUG|doxorubicin hydrochloride|
224100818|NCT00723658|DRUG|etoposide|
224100819|NCT00723658|DRUG|melphalan|
224100820|NCT00723658|DRUG|thalidomide|
224100821|NCT00723658|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
224100822|NCT00723658|PROCEDURE|peripheral blood stem cell transplantation|
224100823|NCT02024464|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
224100824|NCT02024464|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
223948865|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
224100825|NCT02024464|PROCEDURE|Cataract removal and intraocular lens (IOL) implantation|Cataract removal with phacoemulsification using standard techniques, followed by implantation with a posterior-chamber IOL suitable for glaucoma subjects
224100826|NCT02551172|DRUG|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
224100827|NCT02551172|DRUG|HGP0816|Rosuvastatin
224100828|NCT02551172|DRUG|Placebo of HCP1105|Soybean Oil
224100829|NCT02551172|DRUG|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
224100830|NCT01479725|PROCEDURE|HBOT|HBOT
224100831|NCT01223248|RADIATION|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
224100832|NCT01223248|RADIATION|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& within 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
224100833|NCT06145230|OTHER||
224100834|NCT05439031|RADIATION|Stereotactic Arrhythmia Radiotherapy|Single radiation treatment of 25 Gy with external beam radiation therapy to the pro-arrhythmic region as determined by the cardiologist-electrophysiologist and radiation-oncologist combined
224100835|NCT00691548|DRUG|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
224100836|NCT04382261|PROCEDURE|Scaling and root planing|Full mouth or quadrant SRP
224100837|NCT06085066|PROCEDURE|Conventional Ultrafiltration alone on Cardiopulmonary bypass|Conventional Ultrafiltration was used on Cardiopulmonary bypass for patients who underwent open heart surgery
224100838|NCT06085066|PROCEDURE|Conventional Ultrafiltration followed by Modified Ultrafitration on Cardiopulmonary bypass|Modified Ultrafiltration was used following the Conventional Ultrafiltration on Cardiopulmonary bypass for patients who underwent open heart surgery
224100839|NCT00499707|DRUG|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
224100840|NCT03818815|COMBINATION_PRODUCT|OP0201|OP0201 20mg per day in two divided doses for 10 days
224100841|NCT03818815|COMBINATION_PRODUCT|Placebo|Placebo 0mg per day in two divided doses for 10 days
224100842|NCT03818815|DRUG|Amoxicillin-clavulanate|Oral Amoxicillin-clavulanate in two divided doses for 10 days
224100843|NCT02466256|PROCEDURE|Intraocular lens implantation|Intraocular lens implantation
223948866|NCT01028287|DRUG|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
223948867|NCT01835639|DIETARY_SUPPLEMENT|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
223948868|NCT02336958|DRUG|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
223948869|NCT02336958|DRUG|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
224100844|NCT02466256|DEVICE|Autosert Injector|Motorised injection device for intraocular lens implantation
224100845|NCT02466256|DEVICE|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
224100846|NCT02466256|DEVICE|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
224100847|NCT00242879|DRUG|Physician determined comparator PI + ritonavir|
224100848|NCT00242879|DRUG|GW640385 + ritonavir|
224100849|NCT03514147|OTHER|Experimental|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
223537033|NCT02002507|OTHER|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
223729464|NCT02510859|OTHER|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
223948870|NCT02336958|DRUG|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
223948871|NCT02336958|DRUG|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
223948872|NCT02374736|DRUG|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
224100850|NCT03514147|OTHER|Control|"1. Profile of participants: an anamnesis file was used to collect personal data;~2. To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~3. To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
223948873|NCT03372694|BEHAVIORAL|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
223948874|NCT03372694|DRUG|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
223948875|NCT03372694|OTHER|Rehabilitation Education|General health education
223948876|NCT03372694|DRUG|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
223948877|NCT05127967|OTHER|Skin biopsy|A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
223948878|NCT02322424|PROCEDURE|pancreaticoduodenectomy|
223948879|NCT02404441|BIOLOGICAL|PDR001|anti-PD1 antibody
223948880|NCT02725138|DIETARY_SUPPLEMENT|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
223948881|NCT02725138|OTHER|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
223948882|NCT04471441|DRUG|Everolimus Tab.|After first dose 1mg BID(total 2mg daily PO), check the blood concentration of everolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3\~8ng/mL.
223948883|NCT04471441|DRUG|Mycophenolate mofetil Tab./Cap.|Up to 1.5g BID(total 3g daily), PO
223948884|NCT00989755|OTHER|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
223948885|NCT02417285|DRUG|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
223948886|NCT02417285|DRUG|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
223948887|NCT04976556|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
223948888|NCT01861015|DRUG|Epinephrine|
223948889|NCT01861015|DRUG|Vasopressin|
223948890|NCT01676298|DEVICE|Spartan FRX CYP2C19 Test System|
223948891|NCT01972776|DRUG|QBM076|Supplied in 25 mg and 75 mg capsules
223948892|NCT01972776|DRUG|Placebo|Matching placebo capsules
223948893|NCT02912247|DRUG|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
223948894|NCT02912247|DRUG|adalimumab|adalimumab, 40mg,subcutaneous injection,once
223948895|NCT02364856|DEVICE|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
223948896|NCT05640505|BEHAVIORAL|School based Gratitude Interventions|Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
223948897|NCT01784107|DRUG|Belotecan and Ifosfamide|
223948898|NCT00831948|GENETIC|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
223721952|NCT00810030|DRUG|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
223948899|NCT04179565|BEHAVIORAL|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
223948900|NCT01470209|DRUG|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
223948901|NCT01470209|DRUG|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
223948902|NCT05052398|DRUG|PSP NEURO SERUM|PSP NEURO SERUM is a topical product that contains a concentration of Paralytic Shellfish Toxins of 10 micrograms/mL of equivalent of Gonyautoxin 2/3. Each patient will apply 1 g of PSP NEURO SERUM in their hands, three times a day.
223948903|NCT05052398|DRUG|Placebo PSP NEURO SERUM|Placebo PSP NEURO SERUM is the same topical product as PSP NEURO SERUM without the active ingredient. Each patient will apply 1 g of Placebo PSP NEURO SERUM in their hands, three times a day.
223948904|NCT02589613|DIETARY_SUPPLEMENT|tap water|300ml tap water via nasogastric tube
223948905|NCT02589613|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g Glucose via nasogastric tube
223721953|NCT02250781|DRUG|Oral ONC201|Given PO
223721954|NCT04658953|OTHER|Ultrasound guided infiltration|In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
223948906|NCT02589613|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g Fructose via nasogastric tube
223948907|NCT04243772|OTHER|Data extraction|Data extraction from medical files
224100851|NCT06807996|DIETARY_SUPPLEMENT|Zinc-enriched yeast capsule|Daily zinc supplementation: zinc-enriched yeast capsules (15 mg) for a total of 6 months.
224100852|NCT06807996|DIETARY_SUPPLEMENT|Edible yeast placebo capsule|Daily edible yeast placebo capsules (not zinc-enriched) (15 mg) for a total of 6 months.
223948908|NCT02037568|BEHAVIORAL|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
223948909|NCT02684136|DRUG|suvorexant|suvorexant 20 mg taken before sleep
223948910|NCT02684136|DRUG|placebo|placebo taken before sleep
223948911|NCT00407485|BIOLOGICAL|ziv-aflibercept|Given IV
223948912|NCT00407485|OTHER|pharmacological study|Correlative studies
223948913|NCT05064072|DEVICE|Water-based barrier tape|"The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure."
223948914|NCT05064072|DEVICE|Hydrocolloid barrier tape|"As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the pain felt by the infants evaluated with Neonatal Infant Pain Scale and the score recorded in the chart. Since the hydrocolloid barrier tape can stay on the skin for 7 days and the assessment of the pain realized in 7th day and noted down to the chart. Pain score evaluated in 7th day 3 min. before procedure, during and 3 min after procedure"
223948915|NCT05064072|DEVICE|Silk tape|"The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape on the silk tape, the pain felt by the infants evaluated through Neonatal Infant Pain Scale and the score recorded in the chart. This procedure actualized 3 min. before procedure, during and 3 min after procedure"
223948916|NCT00721734|DRUG|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
223948917|NCT04001582|OTHER|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
223948918|NCT06186063|OTHER|Pramlintide|At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.
223948919|NCT06186063|OTHER|Placebo (saline) infusion|At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.
223948920|NCT00621842|DRUG|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
223948921|NCT00621842|DRUG|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
224100853|NCT02458976|DEVICE|PDL|
223537034|NCT03564574|COMBINATION_PRODUCT|Lipid Emulsion|All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
223537035|NCT02336815|DRUG|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
223537036|NCT02336815|DRUG|Dexamethasone|20 mg was given with each dose of Selinexor.
224100854|NCT04169568|PROCEDURE|Manual cuff blood pressure|Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
223537037|NCT05821452|DRUG|Camrelizumab|200mgQ3w
223537038|NCT05821452|DRUG|Paclitaxel|175mg/m2，D1，Q3w
223537039|NCT05821452|DRUG|Cisplatin|75mg/m2，D1，Q3w
223537040|NCT05821452|RADIATION|Radiotherapy|41.4Gy, 1.8Gy each time, 5 times a week
223537041|NCT00578851|DEVICE|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
223537042|NCT01444820|RADIATION|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
223948922|NCT03655704|DRUG|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
223948923|NCT05786768|DRUG|single infusion of Rituximab|single infusion of Rituximab 375 mg/m2
223948924|NCT05786768|DRUG|single infusion of Obinutuzumab|single infusion of Obinutuzumab 300mg/1.73 m2
223948925|NCT00432445|RADIATION|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
223948926|NCT00432445|PROCEDURE|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
223948927|NCT06311266|DEVICE|Robotic endoscopic neurosurgical intervention|Robotic guidance device for intraoperative trajectory alignment in endoscopic neurosurgical procedures
223948928|NCT00004831|DRUG|cysteine hydrochloride|
223948929|NCT03620474|DRUG|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
223948930|NCT04580433|BEHAVIORAL|Time-Restricted Feeding|"The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day."
223537043|NCT01444820|RADIATION|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."
223537044|NCT04038879|DIAGNOSTIC_TEST|MRI|MRI of the heart
223948931|NCT02136641|DRUG|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
223537045|NCT04445909|DEVICE|VA-ECMO|Deployment of extracorporeal membrane oxygenation cardiac assist device.
223537046|NCT02031614|PROCEDURE|Phlebotomy|Withdrawal of 500 mL of whole blood.
223537047|NCT04490798|PROCEDURE|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat the different painful syndromes. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation.
223537048|NCT00873925|BIOLOGICAL|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
223537049|NCT00873925|DIETARY_SUPPLEMENT|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
223537050|NCT00873925|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
223537051|NCT04099277|DRUG|LY3435151|Administered IV
223537052|NCT04099277|DRUG|Pembrolizumab|Administered IV
223537053|NCT04995172|PROCEDURE|Computed Tomography|Undergo mobile CT-assisted bronchoscopy
223537054|NCT04995172|OTHER|Electronic Health Record Review|Patients' medical records are reviewed
223537055|NCT04995172|PROCEDURE|Endobronchial Ultrasound Bronchoscopy|Undergo radial probe EBUS
223537056|NCT06379828|OTHER|Please note that this is an observational study; not applicable|Please note that this is an observational study; not applicable
223537057|NCT06361134|BEHAVIORAL|SAFE Early İntervention|As part of the intervention, sensory-based intervention was applied in an enriched environment. In the home setting, physiotherapists collaborated with the family to advance the intervention. The intervention was revised by making monthly home visits to infants with a corrected age of 42 weeks.
223948932|NCT02136641|DRUG|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
223537058|NCT06361134|BEHAVIORAL|NDT based therapy|Neuromotor evaluations of the babies were performed in a clinical setting. The rehabilitation program to be implemented was given to the family as a booklet. The programs of the children examined in the clinic every month were revised.
223537059|NCT01697111|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
223537060|NCT01697111|DRUG|Placebo|One tablet (no active ingredient) / day and one tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day, for the first 24 weeks and the later 28 weeks, respectively
223537061|NCT01697111|DRUG|Dienogest|Dienogest 1mg twice a day (bid)
223537062|NCT04391712|DEVICE|MLS Laser|Treatments will be delivered to the participants days 1-4, in a prone position using a 10 by 25 cm laser field across each lung with 7j/cm2 at 1500 Hz.
223537063|NCT04391712|OTHER|Regular Inpatient Medical Care|Regular inpatient medical care
223537064|NCT02886130|DIETARY_SUPPLEMENT|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
223948933|NCT02136641|DRUG|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
223537065|NCT02886130|DIETARY_SUPPLEMENT|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
223537066|NCT01426061|OTHER|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
223537067|NCT01426061|OTHER|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
223537068|NCT01426061|OTHER|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
223537069|NCT03997032|DIETARY_SUPPLEMENT|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
223537070|NCT04259216|BEHAVIORAL|IMPACT Intervention|Brief remote session + tailored, daily 8-week mobile application facilitated messaging secondary prevention intervention.
223537071|NCT04259216|OTHER|Control: Enhanced Online Resources (EOR)|EOR group participants will receive standardized information on cyberbullying.
223537072|NCT00492557|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
223537073|NCT00492557|BIOLOGICAL|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
223537074|NCT06048211|OTHER|Stool color scale|observationnal trial about the use of the stool color scale by the health professionnals
223537075|NCT06086743|OTHER|Experimental Group|This group will perform 10 minutes of same warm up exercises. After warm up participants will perform 4 resistance exercises with induced EMS. The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises. the intensity of EMS would be 100A and it would remain same throughout training session. The current administered would be galvanic current. Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
223721955|NCT04658953|OTHER|Fluoroscopy guided infiltration|In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
223721956|NCT03937011|DEVICE|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"1. Robotic Bariatric Sleeve gastrectomy~2. Robotic Hysterectomy with or without oophorectomy;"
223948934|NCT02506270|DEVICE|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
223721957|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
223721958|NCT01087645|DRUG|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
223721959|NCT01087645|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
223721960|NCT01087645|DRUG|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
223721961|NCT01087645|DRUG|placebo|Subjects will be randomised to receive a single dose of placebo
223721962|NCT03725098|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
223721963|NCT03725098|DEVICE|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
223721964|NCT00545662|DRUG|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
223721965|NCT00545662|DRUG|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
223948935|NCT02506270|DEVICE|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
223948936|NCT04813224|BEHAVIORAL|TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT|Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
223948937|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet and exercise advice
223721966|NCT04664166|OTHER|Alpena Otago Telehealth Program|"A physical therapist will use video visits to evaluate the participants and provide exercise instructions from Week 1 to Week 4. Each participant will use the Blue Marble Health in Motion app from a mobile tablet to complete the exercise guided by an avatar at their own pace after receiving the exercise instructions from the physical therapist. Participants are encouraged to exercise three days a week and 30 minutes each day using the app for 6 months. The exercise protocol based on the evidence-based Otago program includes warm up, strengthening, and balance exercise.~3.5. Research Study Design and Data Analyses:"
223948938|NCT01025323|BEHAVIORAL|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
223537076|NCT06086743|OTHER|Control Group|Group B (Control group)will perform 10 minutes of same warm up exercises (Arm swings, jogging on the spot, Walks on treadmill). Group B will perform same 4 resistance exercises without EMS. These 4 exercises include Bicep curls, Triceps dips, Quadriceps chair and squats.The assessment of muscle strength, muscle bulk and muscle fat of the participants will be carried out at baseline before resistance exercises and the participants will be instructed, not to perform any kind of exercise during this period.Initially the weight will be adjusted according to 1 repetition maximum, and it will increase 2kg after 3 week. 3 sets of every exercise would be performed; every set will have 12 repetitions. These exercises will be performed 3 days a week for 6 weeks. Readings of both the groups will be taken at baseline and at the end of last week.
223537077|NCT03454230|PROCEDURE|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
223948939|NCT02926118|DIETARY_SUPPLEMENT|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
223948940|NCT02926118|DIETARY_SUPPLEMENT|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
223948941|NCT01989689|DRUG|Etanercept|Etanercept 50mg twice weekly
223537078|NCT02487953|DRUG|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
223537079|NCT02487953|OTHER|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
223537080|NCT02487953|OTHER|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
223537081|NCT02487953|OTHER|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
223721967|NCT01600469|DRUG|DAOI-B|250-1500 mg/day, oral, for 24 weeks
223721968|NCT01600469|OTHER|Placebo|placebo, oral, for 24 weeks
223721969|NCT01734356|OTHER|Skin biopsies|
223948942|NCT01989689|DRUG|Placebo|
223948943|NCT00491101|OTHER|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
223721970|NCT05751902|OTHER|Arabic version of OHIP questionnaire|Translated Arabic version of Oral Health Impact Profile questionnaire
223721971|NCT05050604|DRUG|Choline Alfoscerate 400mg|Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
223721972|NCT05050604|DRUG|Placebo of Choline Alfoscerate 400mg|Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entrie treatment period
223721973|NCT03474770|DRUG|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
223721974|NCT03926169|DRUG|Risankizumab|Risankizumab is administered as a SC injection in pre-filled syringe (PFS)
223721975|NCT03926169|DRUG|Placebo for risankizumab|Placebo for risankizumab is administered as a SC injection in PFS
223721976|NCT03556774|BEHAVIORAL|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
223948944|NCT00491101|OTHER|spirometry|spirometry
223948945|NCT00857077|DRUG|Sulfadoxine-pyrimethamine|
223948946|NCT00857077|DRUG|Placebo|
223948947|NCT03154775|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
223948948|NCT02570100|PROCEDURE|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles"
223948949|NCT02160600|OTHER|Standard multiphase CT|
223948950|NCT02160600|OTHER|split bolus Dual energy CT|
223948951|NCT01051869|PROCEDURE|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
223948952|NCT01051869|PROCEDURE|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
223537082|NCT00419692|DRUG|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
223537083|NCT04841954|DIAGNOSTIC_TEST|hemp prick-test|hemp seed and flower prick-test
223948953|NCT01825720|DRUG|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
223948954|NCT01825720|DRUG|normal saline group|same rate of normal saline
223948955|NCT00526994|OTHER|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
223948956|NCT00526994|BEHAVIORAL|universal education|receives referral information
223948957|NCT03805243|DEVICE|test of sensors for somnonaute device|test of sensors
223948958|NCT03805243|DEVICE|test of sensors for uronaute device|test of sensors
223948959|NCT03805243|DEVICE|test of sensors for toconaute device|test of sensors
223948960|NCT03805243|DEVICE|test of sensors for neuronaute device|test of sensors
223948961|NCT03805243|DEVICE|test of sensors for cardioskin device|test of sensors
223948962|NCT01034488|BIOLOGICAL|Suine|5000UI /mL
223948963|NCT01034488|BIOLOGICAL|Suine|5000UI/mL
223537084|NCT00272220|BEHAVIORAL|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
223537085|NCT01322256|PROCEDURE|Bone scintigraphy|Bone scintigraphy of the affected area
223537086|NCT01322256|PROCEDURE|Leukoscan|Scintigraphy with labeled neutrophils
223948964|NCT04402476|DEVICE|Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
223948965|NCT03938272|BIOLOGICAL|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
223948966|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
223948967|NCT04466137|DRUG|YPEG-rhG-CSF|YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
223948968|NCT04466137|DRUG|rhG-CSF/PEG-rhG-CSF|rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
223948969|NCT03062072|DRUG|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
223948970|NCT04604652|DRUG|HTD1801 (BUDCA)|HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.
223948971|NCT03052998|DRUG|Ivermectin|Effect of Ivermectin on frequency of seizures
223948972|NCT01874366|DRUG|P11187|"* Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
223948973|NCT01874366|DRUG|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
223537087|NCT01322256|PROCEDURE|PET / CT|PET / CT of the affected area
223948974|NCT02906137|OTHER|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
223537088|NCT01322256|PROCEDURE|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
223537089|NCT01322256|BIOLOGICAL|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
223537090|NCT01781884|DRUG|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
223537091|NCT01781884|DRUG|Placebo|
223537092|NCT01354223|DEVICE|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
223537093|NCT01354223|DEVICE|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
223721977|NCT02392143|OTHER|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test \[18\]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
223948975|NCT05118100|DRUG|Clearfil Protect Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive containing an antibacterial monomer (MDPB)
223537094|NCT00569322|PROCEDURE|BG Test|
223537095|NCT01035502|DRUG|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
223721978|NCT02392143|OTHER|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
223948976|NCT05118100|DRUG|Clearfil SE Bond|An adhesive is used routinely when placing resin composite restorations. This group receives a commercially available adhesive.
223948977|NCT02500082|DRUG|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
223721979|NCT02392143|OTHER|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
223948978|NCT05198219|DEVICE|Ambu® aScope™ 4 Rhinolaryngo|Patient indication following a rhinolaryngoscopy
223948979|NCT05198219|DEVICE|Conventional reusable rhinolaryngoscope|Patient indication following a rhinolaryngoscopy
223948980|NCT05749237|OTHER|respiratory exercises|respiratory exercises
223948981|NCT05749237|OTHER|relaxation exercises|relaxation exercises
224100855|NCT04272307|BIOLOGICAL|Blood samples|"At inclusion, at day 5, day 42 and at 3 months, one 2 ml EDTA blood tube will be collected for metabolomics.~Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method.~At inclusion, one 2 ml EDTA tube will be stored as a DNA collection."
224100856|NCT04272307|PROCEDURE|Stool samples|"One stool sample will be taken at baseline, day 5, day 42 and at 3 months and frozen at -80°C and divided in 2 aliquots.~One stool aliquot will be used for metabolomics. Polar metabolites, lipids, free fatty acids and bile acids will be identified and quantitated using ultra high-performance liquid chromatography/tandem accurate mass spectrometry method. The other one will be used for microbiota analysis. Samples will be sent to the McGill University (Prof. SALEH's lab) for extraction and then, Génome Québec Innovation Centre (McGill University, Montréal, Canada) for sequencing of the V4 region of the 16S rRNA gene on Illumina MiSeq in paired-end mode."
224100857|NCT04272307|PROCEDURE|Colorectal biopsies|During routine flexible sigmoidoscopy, 6 biopsies will be collected with a 5 mm biopsy forceps at baseline and at 3 months. Biopsies will be placed into a sterile vial containing RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Two biopsies will be used for mucosal microbiome analysis in the same way as the stool sample. Four biopsies will be used for RNAseq. Samples will be shipped to Prof. SALEH's lab in Montréal for nucleic acid extraction. The McGill University and Génome Québec Innovation Centre (McGill University, Montréal, Canada) will provide library preparation and next generation sequencing. The average number of uniquely mapped reads per sequencing run will be 30 million reads per sample.
224100858|NCT05408858|BEHAVIORAL|LGBTQ-affirmative cognitive behavioral group therapy|10 sessions of supportive, LGBTQ-affirmative psychotherapy
224100859|NCT03618641|DRUG|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
224100860|NCT03618641|BIOLOGICAL|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
224100861|NCT01613092|DRUG|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
224100862|NCT01613092|DRUG|Cefazolin|Preoperative antibiotic
224100863|NCT00920543|DRUG|Placebo|Twice daily dosing
224100864|NCT00920543|DRUG|FP 100mcg|Twice daily dosing
223948982|NCT00661206|DRUG|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
223948983|NCT00661206|DRUG|Placebo|Patients randomized in this group will receive placebo for 6 months.
224100865|NCT00920543|DRUG|FP 500mcg|Twice daily dosing
224100866|NCT00920543|DRUG|FP 250mcg|Twice daily dosing
224100867|NCT00920543|DRUG|FSC 100/50mcg|Twice daily dosing
224100868|NCT00920543|DRUG|FSC 250/50mcg|Twice daily dosing
224100869|NCT00920543|DRUG|FSC 500/50mcg|Twice daily dosing
224100870|NCT03950323|RADIATION|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
223537096|NCT05794607|OTHER|Rehabilitation group|The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
224100871|NCT01657123|OTHER|ergometry|ergometry measurements
224100872|NCT01657123|OTHER|ergometry|Ergometry measurements
223948984|NCT03788226|DRUG|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
223537097|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab|Administration of Lilly Bamlanivimab to COVID positive patients
223537098|NCT04790786|BIOLOGICAL|Regeneron Casirivimab + Imdevimab|Administration of Regeneron Casirivimab + Imdevimab to COVID positive patients
223537099|NCT04790786|BIOLOGICAL|Lilly Bamlanivimab + Etesevimab|Administration of Lilly Bamlanivimab + Etesevimab to COVID positive patients
223537100|NCT04790786|BIOLOGICAL|Sotrovimab|Administration of Sotrovimab to COVID positive patients
223537101|NCT04790786|BIOLOGICAL|Bebtelovimab|Administration of Bebtelovimab to COVID positive patients
223537102|NCT03317743|DRUG|NOV140101 (IDX-1197)|The dose levels will be escalated following a 3+3 dose escalation scheme.
223537103|NCT02098304|DEVICE|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
223537104|NCT01891929|BEHAVIORAL|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
223537105|NCT01891929|BEHAVIORAL|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
223721980|NCT06153329|DRUG|THDB0206 injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
223721981|NCT06153329|DRUG|Humalog®|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
223721982|NCT06153329|DRUG|BC222insulin lispro injection|0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
223721983|NCT02216734|BEHAVIORAL|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
223721984|NCT03265769|OTHER|radial access site|radial route
223721985|NCT03265769|OTHER|femoral access site|femoral route
223721986|NCT03123913|DRUG|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
223721987|NCT03123913|DRUG|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
223721988|NCT03108183|DIAGNOSTIC_TEST|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
223721989|NCT02517567|DEVICE|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
223721990|NCT02517567|DEVICE|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
223948985|NCT03788226|DRUG|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
223721991|NCT02517567|DEVICE|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
223948986|NCT00695188|DRUG|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
223948987|NCT00695188|DRUG|methotrexate|25 mg oral administration
223948988|NCT00487045|DEVICE|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
223948989|NCT06075030|DRUG|AND017|Oral administration of AND017 capsules three times per week
223948990|NCT01419184|DRUG|Daptomycin|
223948991|NCT01419184|DRUG|Vancomycin|
223948992|NCT05918107|DRUG|PM8002|IV infusion
223948993|NCT05918107|DRUG|Pemetrexed|IV infusion
223948994|NCT05918107|DRUG|Cisplatin|IV infusion
223948995|NCT05918107|DRUG|Carboplatin|IV infusion
223948996|NCT05751733|DRUG|Apatinib Mesylate|Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.
223948997|NCT05751733|DRUG|Sunitinib, Imatinib dosage, Dasatinib, Reveratinib|Second-line TKI drugs
223948998|NCT01110096|BEHAVIORAL|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
223948999|NCT01110096|BEHAVIORAL|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
223949000|NCT01110096|BEHAVIORAL|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
223949001|NCT04242797|DEVICE|Calmare|Skin is stimulated with an electrical voltage via electrode pads, variably distorted sine wave at \~47 Hz.
223949002|NCT04242797|DEVICE|TENS|Skin is stimulated with an electrical voltage via electrode pads, 300 micro-second rectangle pulse at 47 Hz.
223949003|NCT03794232|DIETARY_SUPPLEMENT|NIUCHANG|
223949004|NCT03794232|DIETARY_SUPPLEMENT|Placebo|
223949005|NCT01542983|BEHAVIORAL|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
223949006|NCT01542983|BEHAVIORAL|treatment as usual|Standard treatment for fatigue and insomnia
223949007|NCT01469585|DRUG|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
223949008|NCT00821288|BEHAVIORAL|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
223949009|NCT00821288|BEHAVIORAL|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
223949010|NCT03692871|BIOLOGICAL|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
223949011|NCT03692871|BIOLOGICAL|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 ml dose
223949012|NCT00734682|DRUG|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
223949013|NCT04417075|BEHAVIORAL|Impacto (Mobile App)|This is the mobile app to be developed and evaluated in this project. It is designed for Spanish-speaking, Latinx smokers with high anxiety sensitivity and will be built for the Android platform. The app will include components to address and remediate anxiety sensitivity, as well as having smoking cessation components.
223721992|NCT02439138|DRUG|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
223721993|NCT00837642|DIAGNOSTIC_TEST|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
223949014|NCT04417075|BEHAVIORAL|Dejar de Fumar Asistente (Mobile App)|Dejar de Fumar Asistente (English version called: Quit Tracker: Stop Smoking) is a popular, free third party mobile application aimed at helping smokers quit smoking. This is the mobile app that will serve as the control condition in evaluating the efficacy of Impacto. This mobile app is well established as a smoking cessation app for Spanish-speaking, Latinx smokers. The app includes smoking cessation components but does not have a specific emphasis on anxiety sensitivity.
223949015|NCT04658888|DEVICE|Evalyn Self-Sampling Brush|A self-sampling brush to collect cervical cancer cells for screening purposes.
223949016|NCT03989232|DRUG|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
223949017|NCT03989232|DRUG|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
223949018|NCT00515242|BEHAVIORAL|massage|therapeutic massage
223949019|NCT00515242|BEHAVIORAL|thermotherapy|heat therapy
223537106|NCT01774773|DRUG|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
223949020|NCT00515242|BEHAVIORAL|relaxing environment|time in a relaxing environment
223949021|NCT05923788|DIAGNOSTIC_TEST|T1 mapping measurement|T1 mapping values to test the ability of the MRI sequence to detect Gb3 in kidney
223949022|NCT01042132|PROCEDURE|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
223949023|NCT01042132|PROCEDURE|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
223949024|NCT03400579|DEVICE|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
223949025|NCT00898313|GENETIC|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
223949026|NCT00898313|GENETIC|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
223949027|NCT00898313|GENETIC|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
223949028|NCT00898313|OTHER|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
223949029|NCT00898313|PROCEDURE|nasal brushing|Using a brush, superficial cells are removed from the nose.
223949030|NCT00898313|PROCEDURE|Blood draw|Venous blood will be collected
223949031|NCT00898313|PROCEDURE|Urine collection|Subjects will be asked to provide a urine specimen.
223949032|NCT00898313|PROCEDURE|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
223949033|NCT00898313|PROCEDURE|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
223949034|NCT00898313|PROCEDURE|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
223949035|NCT00898313|PROCEDURE|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
223949036|NCT02644122|DRUG|SF1126|
223949037|NCT00162253|DRUG|BMS 587101|
223949038|NCT06003244|OTHER|6-minute walk distance (6MWD) test|6-minute walk distance (6MWD) test will be performed according to clinical standards
223949039|NCT06003244|OTHER|6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)|6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
223949040|NCT01187888|DRUG|Rasagiline|tablet once daily 1 mg 1 year
223949041|NCT01187888|DRUG|Sugar pill|tablet once daily one year
223949042|NCT04901416|BIOLOGICAL|DVX201|"Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included."
223949043|NCT03192189|OTHER|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
223949044|NCT03868878|OTHER|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
223949045|NCT04976946|OTHER|Comprehensive questionnaire|Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
223721994|NCT00615511|DIETARY_SUPPLEMENT|placebo pregnenolone|Sugar pill, taken twice a day
223949046|NCT06178380|OTHER|rehabilitation|"For the experimental group:~Isokinetic training Antigravity treadmill Posturography~For the control group:~Patients will receive a standard rehabilitation prescription comprising:~Physiotherapy , muscle stretching and strengthening , proprioceptive exercises, and self-programmed"
223949047|NCT03690557|BEHAVIORAL|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
223949048|NCT00539084|DEVICE|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
223721995|NCT00615511|DIETARY_SUPPLEMENT|pregnenolone|500mg in tablet form taken orally twice a day
223949049|NCT00209885|DRUG|Gabapentin|
223949050|NCT00209885|DRUG|S-ketamine|
223949051|NCT00209885|DRUG|Lidocaine|
223949052|NCT00209885|DRUG|Droperidol|
223949053|NCT02450084|PROCEDURE|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
223949054|NCT02450084|DRUG|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
223949055|NCT02450084|OTHER|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
223949056|NCT02450084|DRUG|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
223949057|NCT02053714|BEHAVIORAL|Diabetes self-management and education|
223949058|NCT00399685|DRUG|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
223949059|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
223949060|NCT00399685|DRUG|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
223949061|NCT00399685|DRUG|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
223949062|NCT00297297|OTHER|No intervention. Applying gene profiling on needle aspirates|
223949063|NCT05851014|DRUG|GB491 combined with Letrozole|Patients were randomized to receive GB491 150 mg orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
223949064|NCT05851014|DRUG|Placebo combined with Letrozole|Patients were randomized to receive placebo orally twice daily, depending on their assignment. Letrozole 2.5 mg orally once a day from the first day of cycle 1 (one cycle every 28 days)
223949065|NCT03778788|OTHER|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
223949066|NCT03778788|OTHER|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
223949067|NCT03778788|OTHER|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
223949068|NCT04269044|DIAGNOSTIC_TEST|non-contact EKG|ultra-sensitive, non-contact EKG pad will be placed beneath the infant
223949069|NCT04738214|OTHER|Neoadjuvant CCRT+operation +/- adjuvant treatment|Patients receive neoadjuvant CCRT and operation. Adjuvant treatment after operation is performed depending on pathologic response. The patients showing pathologic complete response after neoadjuvant CCRT are not treated with any adjuvant treatment.
223949070|NCT03182244|DRUG|Gilteritinib|Tablet administered orally once daily.
223949071|NCT03182244|DRUG|Cytarabine|Once/twice daily Intravenously (IV)/subcutaneously (SC).
223949072|NCT03182244|DRUG|Mitoxantrone|Once daily IV injection.
223949073|NCT03182244|DRUG|Etoposide|Once daily IV injection.
223949074|NCT03182244|DRUG|G-CSF|Once daily IV/SC injection.
223721996|NCT05108155|PROCEDURE|Cemented THA|THA with cement fixation
223721997|NCT05108155|PROCEDURE|Unemented THA|THA with uncemented / pressfit fixation
223722000|NCT02147236|BEHAVIORAL|Social Skills Training|
223722001|NCT06968195|BIOLOGICAL|Anti-GPC3-CAR Autologous T Lymphocytes|Given IV
223949075|NCT03182244|DRUG|Fludarabine|Once daily IV injection.
223949076|NCT05253092|OTHER|Virtual mindfulness meditation|Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
223949077|NCT01552083|OTHER|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
223949078|NCT02383797|BIOLOGICAL|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
223949079|NCT02074384|DEVICE|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
223949080|NCT02074384|DEVICE|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
223949081|NCT02074384|OTHER|Clinician|Survey of clinicians after study visits
223949082|NCT02135315|DRUG|Isosorbide Dinitrate|administration of continuous intravenous isosorbide dinitrate to obtain a SBP between 110 and 120 mmHg. After 2 hours from the start of treatment and if the blood pressure goal is not achieved, labetalol is used
223722002|NCT06968195|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223722003|NCT06968195|PROCEDURE|Computed Tomography|Undergo CT
223949083|NCT02266927|DRUG|Flovent HFA|
223537107|NCT01774773|DRUG|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
223537108|NCT01774773|DRUG|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
223722004|NCT06968195|DRUG|Cyclophosphamide|Given IV
223537109|NCT02547103|OTHER|Chlorhexidine gluconate-soaked cloths|
223537110|NCT02547103|OTHER|Normal saline|
223722005|NCT06968195|PROCEDURE|Echocardiography Test|Undergo ECHO
223722006|NCT06968195|DRUG|Fludarabine|Given IV
223722007|NCT06968195|PROCEDURE|Leukapheresis|Undergo leukapheresis
223722008|NCT06968195|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223722009|NCT06968195|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223722010|NCT00592943|DRUG|armodafinil|tablet, taken by mouth, once each study day
223722011|NCT00006237|BIOLOGICAL|interleukin-2|Given IV
223537111|NCT02547103|OTHER|mupirocin ointment|
223537112|NCT00948688|RADIATION|Radiation therapy|Once per day, 5 days a week for 6 weeks
223537113|NCT00948688|DRUG|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
223537114|NCT00948688|DRUG|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
223537115|NCT04093232|DRUG|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
223537116|NCT00563758|DRUG|tegaserod|
223537117|NCT02480088|DRUG|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
223537118|NCT02480088|DRUG|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
223537119|NCT02629926|OTHER|GH Replacement (NutropinAq®)|GH Replacement continued.
223537120|NCT02629926|OTHER|No additional treatment|GH Replacement not continued.
223537121|NCT03571932|BEHAVIORAL|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
223537122|NCT01963988|PROCEDURE|Transurethral Coagulation (TUC)|
223537123|NCT01963988|PROCEDURE|Transurethral Resection(TUR)|
223537124|NCT03180229|DRUG|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
223537125|NCT03991910|DRUG|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking). Placebo will be given until 5 days prior to Mitral valve replacement surgery.
223722012|NCT00006237|BIOLOGICAL|filgrastim|Given subcutaneously
223722013|NCT00006237|BIOLOGICAL|interferon alfa|Given IV and subcutaneously
223722014|NCT00006237|DRUG|cisplatin|Given IV
223722015|NCT00006237|DRUG|dacarbazine|Given IV
223722016|NCT00006237|DRUG|vinblastine|Given IV
223722017|NCT00820560|DRUG|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
223722018|NCT01846416|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
223722019|NCT01130012|BEHAVIORAL|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
223949084|NCT02266927|DRUG|OPTINOSE™ FLUTICASONE|
223949085|NCT00223769|DRUG|Oxandrolone|
223949086|NCT01297088|DRUG|BAY86-9596|One single dose administration of a diagnostic agent
223949087|NCT00869609|BEHAVIORAL|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
223722020|NCT01130012|BEHAVIORAL|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
223949088|NCT00869609|BEHAVIORAL|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
223722021|NCT01257087|DRUG|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
223722022|NCT01065285|BIOLOGICAL|Evaluation of vaccines against flu|evaluate efficacy and tolerance
223722023|NCT02200562|DRUG|ipilimumab and dabrafenib|
223722024|NCT03794271|PROCEDURE|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
223722025|NCT03794271|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
223722026|NCT05173662|PROCEDURE|Providing education and brochures on non-pharmacological methods that can be applied during the heel blood collection process|Theeduvation initiative was implemented by the researcher at least 12 hours ago in the mothers' room and a brochure was given about the education.
223722027|NCT03258268|DEVICE|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
223722028|NCT03258268|OTHER|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
223722029|NCT05325671|PROCEDURE|transarticular multimodal drug infiltration|as described previously
223722030|NCT05375370|OTHER|circulating tumor DNA dosage|blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
223722031|NCT02634671|OTHER|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
223722032|NCT02634671|OTHER|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
223722033|NCT02634671|OTHER|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
223722034|NCT03980002|DRUG|FCR and Ibrutinib|"Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d"
223722035|NCT03980002|DRUG|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
223722036|NCT03980002|DRUG|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
223722037|NCT03601975|DRUG|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
223722038|NCT01190345|DRUG|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
223722039|NCT01190345|DRUG|no bevacizumab|no bevacizumab
223722040|NCT00843947|PROCEDURE|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
223722041|NCT02714582|BEHAVIORAL|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson \& Mangino 2006).
223722042|NCT04933877|PROCEDURE|Fascial plane block|Serratus anterior plane block
223949089|NCT02721407|DRUG|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
223949090|NCT01652014|DRUG|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
223949091|NCT01652014|DRUG|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
223722043|NCT06237829|BEHAVIORAL|Single bump acuity|Investigators will design bumps of varying heights, spacings, diameters, and bump shapes (rounded top, flat top, angled top) which give a precise amount of mechanical stimulus to the finger. Subjects will be asked if they could notice a bump on the surface and instructed to make the judgment quickly (\<2 seconds). A psychometric curve, with a standard braille bump serving as the positive, \~100% success rate control, will be constructed
223722044|NCT06237829|BEHAVIORAL|Optimal spacing between bumps|Investigators will fabricate and characterize two bumps of varying widths (ranging from 150 μm to 3 times the bump width, based on fabrication resolution available in commercial tactile aid machines). Subjects will be asked to run their finger across the two bumps (two bumps always form a line, so investigators do not need to ask subjects to orient their fingers) quickly and asked if they felt one bump or two.
223722045|NCT06237829|BEHAVIORAL|Improving signal from a single bump with designer materials|"Investigators will coat single bumps with our designer materials (with alkyl and amino functional groups) to improve the mechanical stimuli from a single bump. Subjects will then be asked to perform a similar experiment as the single bump acuity test and the optimal spacing between bumps test. (can you notice the bump? or did you feel one or two bumps)."
223722046|NCT02207244|DRUG|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
223722047|NCT02207244|DRUG|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
223722048|NCT02207244|DRUG|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
223722049|NCT02207244|DRUG|Placebo for adalimumab|Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
223722050|NCT04938804|DEVICE|Low-dose computed tomography|The Low-dose computed tomography is conducted according to the guideline suggested by American College of Radiology.
223949092|NCT01652014|DRUG|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
223722051|NCT04039698|OTHER|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
223722052|NCT04039698|DRUG|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
223949093|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
223949094|NCT01652014|PROCEDURE|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
223949095|NCT01652014|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
223949096|NCT01652014|RADIATION|total-body irradiation|Undergo TBI
223949097|NCT01652014|DRUG|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
223949098|NCT01652014|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
223949099|NCT01652014|PROCEDURE|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
223722053|NCT04920019|PROCEDURE|Thoracic continuous epidural analgesia|"Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)"
223722054|NCT00039130|BIOLOGICAL|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC\>5000/ul courses II-VII
223722055|NCT00039130|BIOLOGICAL|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
223722056|NCT00039130|DRUG|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
223722057|NCT00039130|DRUG|cytarabine|1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
223722058|NCT00039130|DRUG|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
223949100|NCT00257894|DRUG|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
223949101|NCT00257894|DRUG|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
223949102|NCT06204653|DEVICE|HFNO group|100% oxygen supplied in proportion to body weight using the Optiflow THRIVETM system while maintaining jaw thrust. (0-12 kg; 2 L/kg/min, 13-15 kg; 30 L/min, 16-30 kg; 35 L/min, 31-50 kg; 40 L/min)
223949103|NCT06204653|DEVICE|MV group|Mask ventilation using the one-hand E-C clamp technique and oropharyngeal airway (fresh gas flow 3 l/min, 100% O2, tidal volume 8-10 ml/kg, respiratory rate 20/min, I:E ratio 1:2, pop-off valve 13 cmH2O).
223949104|NCT01276275|DRUG|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
223949105|NCT06452173|DIAGNOSTIC_TEST|Plasma|Plasma levels of metabolites and some proteins will be further determined
223949106|NCT06452173|DIAGNOSTIC_TEST|carotid high-resolution magnetic resonance imaging|Define plaque composition and morphological characteristics
223722059|NCT00039130|DRUG|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
223722060|NCT00039130|DRUG|etoposide|80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
223722061|NCT00039130|DRUG|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
223722062|NCT00039130|DRUG|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
223722063|NCT00039130|DRUG|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
223722064|NCT00039130|DRUG|prednisone|60 mg/sq m PO/day Days 1-7 course I
223722065|NCT00039130|DRUG|vincristine sulfate|2 mg IV push Day 1 courses II-VII
223722066|NCT00039130|DRUG|Allopurinol|300 mg/day PO Days 1-14, course I
223722067|NCT00810238|BIOLOGICAL|C-Cure|Intraventricular injection
223722068|NCT00139698|DRUG|olmesartan alone or in combination with hydrochlorothiazide|
223722069|NCT05079282|DRUG|ONO-4685|ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
223722070|NCT01950741|DRUG|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
223949107|NCT03791736|PROCEDURE|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
223949108|NCT04564365|DRUG|beta-blocker|To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction
223949109|NCT04343898|OTHER|No intervention|Observational
223949110|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
223949111|NCT00299507|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
223949112|NCT00299507|OTHER|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
223949113|NCT04243915|OTHER|Percutaneous neuromuscular electrical stimulation (PNMES) plus motor control exercise program|The technique consists of a muscular stimulation of the deep lumbar multifidus by means of a TENS current applied through four dry needling or acupuncture needles introduced by ultrasound guidance in said muscle 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
223949114|NCT04243915|OTHER|Sham PNMES (introducing the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
223949115|NCT04243915|OTHER|TENS plus motor control exercise program|Transcutaneous electrical nerve stimulation will be applied through 4 patches / adhesives placed in your lower back for 30 minutes. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
223949116|NCT04243915|OTHER|Sham PNMES (without inserting the needle) plus motor control exercise program|The same procedure will be performed as in the experimental treatment, but in this case, the needle will not be inserted and the electric current will be placebo and only the first 15 seconds will slightly notice it. This will add to a protocol of motor control exercises for deep abdominal and lumbar muscles.
223949117|NCT01316913|DRUG|GSK573719/GW642444 125/25|125/25 mcg once-daily
223949118|NCT01316913|DRUG|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
223949119|NCT01316913|DRUG|GSK573719|125 mcg once-daily
223949120|NCT01316913|DRUG|tiotropium bromide|18 mcg once-daily
223949121|NCT03267797|OTHER|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
223949122|NCT03267797|OTHER|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
223949123|NCT00872248|PROCEDURE|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
223949124|NCT00872248|PROCEDURE|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
223949125|NCT03564106|DRUG|intraarticular radiofrequency + intraarticular methylprednisolone|intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
223949126|NCT03564106|DRUG|intraarticular methylprednisolone|intraarticular methylprednisolone (30 mg)
223949127|NCT05716438|RADIATION|Forearm anteroposterior and lateral plain radiograph|2 view plain film of forearm after valving a short arm cast.
223949128|NCT01861041|DRUG|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
223949129|NCT01861041|DRUG|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
223949130|NCT03528304|BEHAVIORAL|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
223949131|NCT00541996|DRUG|vabicaserin|
223949132|NCT06510985|DEVICE|transcutaneous vagus nerve stimulation|The study employs a CE-certified tVNS® E device, ensuring European safety standards (EU regulation 2017/745 on medical devices). This device features a stimulation cycle of 28 seconds on and 32 seconds off, with a 25 Hz impulse frequency. For the high-intensity group, the stimulation intensity will be individually adjusted in the session before starting the high-intensity tVNS stimulation at home. Recommended daily usage is max. 4 hours, after which it automatically shuts off.
223949133|NCT06510985|BEHAVIORAL|Monitoring|Participants are monitored over 12 weeks using a combination of questionnaires and ecological momentary assessment. This approach allows for a comprehensive assessment of the patient's health and well-being.
223722071|NCT05651997|PROCEDURE|MACT|"* A biopsy of healthy cartilage is taken from a non-weight bearing area of the knee joint during an arthroscopic procedure.~* The biopsy is processed in the GMP accredited laboratory to isolate and amplify chondrocytes.~* The cells are seeded and cultured on a collagen matrix (Chondro-Gide®, Geistlich Pharma)~* The membrane is implanted and sutured onto the injured site."
223722072|NCT05651997|PROCEDURE|AMT|This treatment combines the microfracture procedure with the application of a bilayer matrix of porcine type I/III collagen (Chondro-Gide, Geistlich Pharma) and the supplementation of autologous bone.
223949134|NCT06510985|DEVICE|cardiowatch bracelet|The study employs the medically certified cardiowatch bracelet from Corsano (CE-MDR medical certification, FDA 510 (k) cleared) for continuous monitoring of vital signals, such as heart rate, heart rate variability, breathing rate, SpO2, physical activity and sleep.
223537126|NCT03991910|DRUG|Ramipril 5Mg Oral Capsule|the treatment group will be given each Ramipril 2,5 mg inside a capsule as an initial dose, for 2 weeks. If there is no serious adverse effect in the observation period of 2 weeks, Ramipril 5 mg inside a capsule will be given for the next weeks until 5 days before the mitral valve surgery date. Study participant won't be able to know the drug and doses inside the capsule (for masking)
223949135|NCT05081726|DIAGNOSTIC_TEST|Functional MRI|Series of MRI scans of the brain
223537127|NCT00776529|OTHER|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
223537128|NCT00776529|OTHER|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
223537129|NCT02878083|DRUG|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
223949136|NCT00004085|BIOLOGICAL|filgrastim|as prescribed by physician
223949137|NCT00004085|PROCEDURE|autologous bone marrow transplantation|1-2 weeks prior to treatment
223949138|NCT00004085|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
223537130|NCT02878083|DRUG|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
223537131|NCT01135992|DRUG|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
223537132|NCT01135992|DRUG|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
223537133|NCT03601390|DEVICE|PET/CT and EBV DNA|PET/CT and EBV DNA will be proformed after the IMRT treatment
223537134|NCT03407092|OTHER|ADAPT cohort|Thrombectomy with distal aspiration technique
223537135|NCT03407092|OTHER|Stentriever Cohort|Thrombectomy with stent retriever
223537136|NCT04420858|BEHAVIORAL|Enhanced (experimental) education|See arm description.
223537137|NCT04420858|BEHAVIORAL|Standard (control) education.|See arm description.
223537138|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water|
223949139|NCT00004085|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
223949140|NCT02461979|OTHER|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
223537139|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate|
223537140|NCT02535897|DIETARY_SUPPLEMENT|Flavoured water + carbohydrate + protein|
223537141|NCT00006004|DRUG|carboplatin|
223537142|NCT00006004|DRUG|cisplatin|
223537143|NCT00006004|DRUG|gemcitabine hydrochloride|
223537144|NCT00006004|DRUG|paclitaxel|
223537145|NCT02859974|BEHAVIORAL|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
223537146|NCT04242706|DEVICE|ETTEvac|Endotracheal tube with evacuation lumen without noble metal coating
223537147|NCT04242706|DEVICE|BIP ETTEvac|Endotracheal tube with evacuation lumen with noble metal coating
223537148|NCT03218280|DRUG|Vitamin C|
223537149|NCT06453382|BEHAVIORAL|Behavioural change modification, Screening, NCD related knowledge practice and attitude|The investigators will provide periodic training regarding the control and prevention of NCDs to the stakeholders. The investigators will provide WHO-Package of Essential Non-Communicable Diseases (PEN) protocol training to the stakeholders involved in healthcare service delivery. The investigators will equip the government healthcare facilities with the equipment needed for the screening of NCDs. For the stakeholders who are not directly involved with healthcare service delivery, the investigators will train them about the 5 NCDs (diabetes, hypertension, chronic respiratory disease, cancer, and mental illness) and the 5 NCD risk factors (unhealthy diet, inadequate physical activity, tobacco cessation, alcohol cessation, and air pollution). The investigators will also share information, education, and communication (IEC) materials with the stakeholders, and then they will share the information with the community.
223537150|NCT02852967|DRUG|Belumosudil|
223537151|NCT02852967|DRUG|Placebo|Placebo tablets matching belumosudil
223537152|NCT05556486|DEVICE|GlioStem|GlioStem is an oligothiophene derivative which can penetrate physiological cell membranes and selectively binds to structures inside the GSCs. GlioStem is conveniently administered ex-vivo onto the investigated tissue or cell culture by a pipette. After only a few minutes, the GSCs will emit green light from GlioStem molecules under blue illumination.
223537153|NCT02898922|BIOLOGICAL|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
223537154|NCT03853044|DRUG|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
223537155|NCT03853044|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
223537156|NCT03853044|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
223537157|NCT03853044|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
223537158|NCT03853044|DRUG|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
223537159|NCT01774812|DIETARY_SUPPLEMENT|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
223537160|NCT01774812|DIETARY_SUPPLEMENT|Ergocalciferol|50,000IU 1x per week for 6 weeks
223537161|NCT01078948|DEVICE|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
223537162|NCT00003312|RADIATION|iodine I 125|
223537163|NCT05069727|PROCEDURE|Regular Protocol with advanced carbohydrate counting|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use)."
223722073|NCT06266169|OTHER|making artificial intelligence based decisions of gamete, embryo and endometrial potential|The method of Raman spectroscopy is based on the registration of inelastic scattering of photons. Each compound has its own spectral pattern when using a certain type of monochromatic radiation (laser). With this method, it is possible to obtain metabolic fingerprints from the objects being studied. Luminescent spectroscopy is a type of spectroscopy used to register emission from objects that occurred after absorbing the exciting (primary) radiation. Spectrophotometry is the detection of radiation in the visible area of the spectrum. Raman spectroscopy is used for the spent medium and semen to build artificial intelligence model and make prognosis of function for each object. For endometrium, luminescent spectroscopy and spectrophotometry are used to build the model and test its clinical relevance
223949141|NCT02516085|DRUG|Metformin|
223722074|NCT02521870|DRUG|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses).
223722075|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).
223722076|NCT02521870|DRUG|SD-101(2)|Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
223722077|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
223949142|NCT02516085|DRUG|L-Arginine|
223949143|NCT00002086|DRUG|Zidovudine|
223949144|NCT00002086|DRUG|Zalcitabine|
223949145|NCT00002086|DRUG|Interferon alfa-n1|
223949146|NCT00911638|BEHAVIORAL|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
223722078|NCT02521870|BIOLOGICAL|SD-101(3)|Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).
223722079|NCT02521870|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
223722080|NCT04336085|PROCEDURE|caudal block|Caudal block will be performed using ultrasound guidance, the sacral hiatus will be visualized at the level of the sacral cornus by employing the linear transducer of ultrasound machine the ultrasound transducer will be rotated to 90 degree to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the two cornua. The needle advancement will be terminated immediately after penetrating the sacrococcygeal ligament.
223722081|NCT04336085|PROCEDURE|pericapsular nerve group block|In PENG group, the patient will be placed in supine position. The ilio-pubic eminence (IPE), the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be visualized using a linear ultrasound probe. A 22-gauge, 50-mm needle will be introduced in a lateral to medial fashion in an in-plane approach to place the tip of the needle in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, a total volume of 0.5 mL/kg local anesthetic solution will be injected.
223949147|NCT00911638|BEHAVIORAL|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
223949148|NCT04565717|DRUG|ALN-HSD|ALN-HSD will be administered by subcutaneous (SC) injection.
223949149|NCT04565717|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
223949150|NCT05149963|OTHER|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
223537164|NCT05069727|PROCEDURE|Simplified Protocol with fixed carbohydrate content|"* Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits."
223537165|NCT01693367|DEVICE|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
223537166|NCT01693367|DEVICE|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
223722082|NCT02877381|PROCEDURE|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
223949151|NCT03942094|DRUG|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
223537167|NCT00579423|BIOLOGICAL|QS21|"* Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~* Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~* Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
223722083|NCT02877381|PROCEDURE|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
223722084|NCT00920998|DRUG|Z-338|oral
223722085|NCT04400591|BIOLOGICAL|Nonconforming Lisocabtagene Maraleucel|Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
223722086|NCT00519831|BIOLOGICAL|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
223722087|NCT00519831|DRUG|vinflunine|Vinflunine 320 mg/m² every 21 days
223722088|NCT02150317|PROCEDURE|TACE+Sorafenib|TACE followed by Sorafenib
223722089|NCT02150317|PROCEDURE|TACE|TACE alone
223722090|NCT02854631|DRUG|Selonsertib|18 mg tablet administered orally once daily
223722091|NCT02854631|DRUG|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
223949152|NCT05141409|DEVICE|Artificial Intelligence|Artificial Intelligence
223949153|NCT02567591|OTHER|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
223949154|NCT02691702|DRUG|BIIB118|Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
223949155|NCT02691702|DRUG|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
223949156|NCT01694147|DEVICE|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
223949157|NCT04876846|DEVICE|GEN 3 Monitoring of Fetus|"Measurement of tissue light scatter in the body in body during late term pregnancy and evaluation of signal integrity"
223949158|NCT06389877|DRUG|BEAM-302|BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
223722092|NCT02854631|DRUG|Placebo|Selonsertib placebo tablet administered orally once daily
223722093|NCT04232995|OTHER|Balance Training|Balance enhancing exercises
223949159|NCT05847114|OTHER|Stres ball|Stress ball compression for 15 minutes during surgery
223949160|NCT05169684|BIOLOGICAL|BMS-986218|Specified dose on specified days
223949161|NCT05169684|DRUG|Docetaxel|Specified dose on specified days
223949162|NCT05169684|BIOLOGICAL|Nivolumab|Specified dose on specified days
223949163|NCT01668719|DRUG|Bortezomib|Given SC or IV
223949164|NCT01668719|DRUG|Dexamethasone|Given PO or IV
223949165|NCT01668719|BIOLOGICAL|Elotuzumab|Given IV
223949166|NCT01668719|OTHER|Laboratory Biomarker Analysis|Correlative studies
223949167|NCT01668719|DRUG|Lenalidomide|Given PO
223949168|NCT06352619|OTHER|Conservative SBP Control|No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg
223949169|NCT06352619|OTHER|Moderate SBP Control|If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated
223949170|NCT06352619|OTHER|Intensive SBP Control|SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
223949171|NCT05147675|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223949172|NCT04922242|BEHAVIORAL|Welch Emotional Connection Screen for Neonatal Intensive Care Unit|The Welch Emotional Connection Screen (WECS) is an investigational developmental screening tool, developed to rate the quality of the emotional connection that formed between mother and child. The screen is administered in 2-3 minutes by observing a mother and child interact, and requires the rater to critically assess 4 sub-domains of emotional connection. The NICU WECS is a clinical tool adapted for use with neonates in the NICU. Reliability of NICU staff WECS scoring will be calculated via intra-class correlations with key scores. The WECS is scored on intervals of 0.5, with a minimum of 1 (rarely--low level of connection) and maximum of 3 (mostly--high connection). Scores are used to determine the level of need for intervention.
223949173|NCT04922242|OTHER|NICU WECS Training|"WECS Training is an educational module consisting of an introduction of the concepts of emotional connection and autonomic co-regulation as studied by The Nurture Science Program, as well as an illustration of how these experiential constructs differ from traditional care plans that focus on educating parents to encourage bonding as opposed to autonomic emotional connection within the NICU. An introduction to the domains of the WECS screen as well as illustrations of these domains through video will augment the training designed for NICU staff."
223949174|NCT04489355|PROCEDURE|coronary artery bypass graft (CABG) with surgical ventricular restoration (SVR) and mitral repair (MR)|
223949175|NCT06186960|DEVICE|Tandem Virtual Reality|Hospice patients and their primary caregiver will each wear virtual reality headsets and will experience a customized and synchronized 5-15min virtual reality experience.
223949176|NCT02732171|OTHER|Research Blood Collection|Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)
223949177|NCT06533722|DRUG|Gemcitabine, Vinorelbine, or Eribulin|Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
223949178|NCT04923256|BEHAVIORAL|AAT-APP: A novel smart-phone approach-avoidance bias modification intervention|Participants allocated to the intervention group will be required to upload photos of drinks they wish to avoid, as well as activities they wish to engage in more, and be trained to avoid and approach by repeatedly 'swiping' images away from and towards themselves, respectively.
223949179|NCT04923256|BEHAVIORAL|Sham training control|Complete an AAT on a weekly basis for four weeks
223949180|NCT03497052|OTHER|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
223949181|NCT03497052|OTHER|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
223949182|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
223949183|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
223949184|NCT02060487|DRUG|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
223949185|NCT06498609|BIOLOGICAL|iprf|i-PRF with leveling and alignment
223949186|NCT06498609|PROCEDURE|MOPs with leveling and alignment|mop
223949187|NCT03307044|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
223949188|NCT03307044|OTHER|Questionnaire Administration|Ancillary studies
223949189|NCT05484661|DIETARY_SUPPLEMENT|BCAA|Participants will participate in high-volume, moderate-intensity exercise 3x/week and consume either a placebo or BCAA (\~7-10 g of BCAAs (100 mg/kg) daily for eight weeks.
223949190|NCT03212638|DRUG|Baricitinib suspension|Administered orally
223949191|NCT03212638|DRUG|Baricitinib tablet|Administered orally
223949192|NCT03670121|DEVICE|Bronchoscopic Thermal Vapor Ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
223949193|NCT00005820|DRUG|nitrocamptothecin|
223949194|NCT04786275|DRUG|Fentanyl|Standard dose of 2 ug/kg after tetanic stimulation.
223537168|NCT04368013|PROCEDURE|Extended sampling and procedures|The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
223722094|NCT04232995|OTHER|General Exercises|General Exercises
223949195|NCT04786275|OTHER|Tetanic stimulation|Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.
223949196|NCT00152672|DEVICE|nCPAP vs oral appliance|
223949197|NCT01286636|OTHER|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
223722095|NCT04653961|DEVICE|DreaMed Advisor Pro DSS-MDI algorithm|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
223949198|NCT01286636|OTHER|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
223949199|NCT03789357|DIAGNOSTIC_TEST|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
223537169|NCT05850767|OTHER|Sleep deprivation|Participants will stay fully awake for 24 hours
223537170|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
223537171|NCT00724659|PROCEDURE|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
223537172|NCT02286895|BIOLOGICAL|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
223537173|NCT02286895|BIOLOGICAL|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
223537174|NCT02286895|BIOLOGICAL|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
223722096|NCT04662125|DRUG|caffeine, paracetamol tablet|oral fluid intake, recumbent positioning, combination of paracetamol and caffeine tablet three times per day for three days (2 tablets of Panadol-Extra tablet, film coated, GlaxoSmithKline Consumer Healthcare Holdings (US) LLC were given every 8hours) and stool softener and to maintain blinding a tablet of vitamins was given twice per day for three days.
223722097|NCT04662125|DRUG|Oral prednisolone|patients who received conservative treatment as control group together with oral tablet prednisolone 20 mg once daily plus one tablet of vitamins to maintain blinding for three days. .
223722098|NCT04662125|DRUG|oral pregabalin|patients who received conservative treatment as control group together with oral tablet pregabalin 150 mg twice per day for three days.
223722099|NCT03544658|PROCEDURE|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
223722100|NCT03544658|PROCEDURE|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
223722101|NCT03544658|PROCEDURE|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
223722102|NCT03544658|PROCEDURE|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
223722103|NCT04945005|PROCEDURE|Transesophageal guidance of lead implantation|In patients undergoing lead implantation including transesophageal echocardiography for clinical reasons (e.g. intraprocedural cardioversion), echocardiography was also used for guidance of lead implantation to reduce lead-leaflet interactions
223949200|NCT01981746|PROCEDURE|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
223949201|NCT00875706|BEHAVIORAL|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
223722104|NCT02473432|PROCEDURE|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
223722105|NCT02473432|PROCEDURE|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
223722106|NCT02473432|PROCEDURE|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
223722107|NCT03200860|DRUG|Empagliflozin 10 MG|10 mg daily, oral, 30 days
223722108|NCT03200860|DRUG|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
223722109|NCT03129984|DEVICE|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
223722110|NCT02129400|DRUG|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
223722111|NCT02129400|DRUG|Aer medicinalis Linde 100%|
223722112|NCT05148598|DEVICE|ADRCs|Adipose Derived Regenerative Cells (ADRCs) processed with Celution System
223722113|NCT05148598|OTHER|Standard Care|Standard care
223722114|NCT05148598|OTHER|Placebo|Placebo visually indistinguishable from ADRCs
223722115|NCT00686933|DRUG|ABT-089|Subjects will take up to 80 mg daily for 24 months
223722116|NCT02174250|DRUG|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
223949202|NCT03096132|BEHAVIORAL|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
223722117|NCT02174250|DRUG|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
223722118|NCT00350909|BEHAVIORAL|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
223722119|NCT05367401|DRUG|Sabatolimab|Solution for intravenous infusion
223722120|NCT05367401|DRUG|Magrolimab|Solution for intravenous infusion
223722121|NCT05367401|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous infusion
223949203|NCT03096132|BEHAVIORAL|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
223949204|NCT02950883|DRUG|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
223722122|NCT05337228|DRUG|IN-C006 Peri inj.|IN-C006 peri inj. will be injected continuously for 3 days.
223722123|NCT05337228|DRUG|RPN301|RPN301 will be injected continuously for 3 days.
223722124|NCT03570645|DRUG|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
223722125|NCT03570645|DRUG|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
223722126|NCT03570645|DRUG|control group|block with only ropivacaine
223722127|NCT00603668|BIOLOGICAL|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
223722128|NCT03808532|OTHER|Cura+ Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily for six months.
223722129|NCT03992001|BIOLOGICAL|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
223949205|NCT02950883|DRUG|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
223949206|NCT02804256|OTHER|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
223949207|NCT04037033|BEHAVIORAL|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
223949208|NCT03615833|DRUG|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
223949209|NCT01904097|DRUG|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
223949210|NCT01904097|OTHER|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
223722130|NCT03992001|BIOLOGICAL|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
223722131|NCT03699098|DIAGNOSTIC_TEST|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
223722132|NCT02817256|DIETARY_SUPPLEMENT|Vitamins and Minerals|Multivitamins and Minerals supplementation
223722133|NCT01814514|DRUG|Timolol-trusopt|
223722134|NCT01814514|DRUG|placebo|
223722135|NCT02080949|RADIATION|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
223722136|NCT04333797|OTHER|Risk and Protective Factors Assessment|First assessment at baseline (T0) - 17 y.o. Follow-up 2 years later (T1) - 19 y.o.
223722137|NCT00401453|BEHAVIORAL|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
223949211|NCT01904097|OTHER|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
223949212|NCT01828671|OTHER|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
223949213|NCT01828671|OTHER|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
223722138|NCT01031927|DRUG|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
223722139|NCT00130936|DRUG|Epirubicin|
223949214|NCT01828671|OTHER|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
223949215|NCT01828671|OTHER|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
223722140|NCT00130936|DRUG|Carboplatin|
223722141|NCT00130936|DRUG|Capecitabine|
223722142|NCT02091492|DRUG|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
223722143|NCT02091492|DRUG|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
223722144|NCT04342897|DRUG|LY3127804|Administered IV
223722145|NCT04342897|DRUG|Placebo|Administered IV
223722146|NCT03792698|OTHER|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
223722147|NCT00273871|DRUG|Cyclosporin or tacrolimus|
223537175|NCT02286895|BIOLOGICAL|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
223949216|NCT01828671|OTHER|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
223949217|NCT01578629|OTHER|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
223949218|NCT01578629|OTHER|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
223949219|NCT04711200|DRUG|Adipose derived stromal cells intravenously injected|2×10\^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).
223949220|NCT06580275|DEVICE|CLAAS|All eligible subjects will have an LAA closure attempt using the CLAAS device guided by ICE technology.
223949221|NCT02970318|DRUG|Acalabrutinib (ACP-196)|Acalabrutinib monotherapy
223949222|NCT02970318|DRUG|Rituximab|Rituximab in combination with idelalisib or bendamustine
223949223|NCT02970318|DRUG|Idelalisib|Idelalisib in combination with rituximab
223949224|NCT02970318|DRUG|Bendamustine|Bendamustine in combination with rituximab
223537176|NCT03849105|RADIATION|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-\[131I\]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
223537177|NCT00002366|DRUG|Ritonavir|
223949225|NCT05498155|DRUG|Neoadjuvant Olaparib monotherapy group|Neoadjuvant olaparib monotherapy (300 mg BID) for four to six 28-day cycles.
223949226|NCT05498155|COMBINATION_PRODUCT|Neoadjuvant combination therapy with olaparib plus durvalumab|Neoadjuvant combination therapy with olaparib (300 mg BID) plus durvalumab (1500 mg IV Q4W) for four to six 28-day cycles.
223949227|NCT00221559|PROCEDURE|Blood sampling for determination of serum Zn|
223949228|NCT05470231|DIETARY_SUPPLEMENT|Beetroot Juice|The swimmers drank 3 hours before the test, mL70 of BJ (containing mmol6.4 of NO-3) (Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) or PLA (0.04 mmol of NO-3)
223949229|NCT03476772|DRUG|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
223949230|NCT03584074|DRUG|Pregabalin 75mg|Orally taken twice daily for 8 weeks
223949231|NCT03584074|DRUG|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
223949232|NCT01179802|OTHER|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
223949233|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
223949234|NCT00824408|DRUG|pemetrexed|500 mg/m\^2 i.v. on day 1 of 21 day cycle
223949235|NCT00824408|DRUG|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
223949236|NCT01088841|DIETARY_SUPPLEMENT|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
224100873|NCT00847340|PROCEDURE|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
223949237|NCT00125905|BEHAVIORAL|Advice|
223949238|NCT00125905|BEHAVIORAL|Motivational Interviewing|
224100874|NCT05632172|PROCEDURE|implant insertion|bone level dental implant insertion
224100875|NCT03980093|BEHAVIORAL|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
224100876|NCT03980093|BEHAVIORAL|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
223949239|NCT00125905|DRUG|Nicotine Gum and Patch|
223949240|NCT00125905|DRUG|Bupropion|
223949241|NCT00718120|BIOLOGICAL|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
223949242|NCT03292692|BEHAVIORAL|OurRelationship|Online intervention with coach support
223949243|NCT00040105|DRUG|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
223949244|NCT00040105|DRUG|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
224100877|NCT04074993|DRUG|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
223537178|NCT02405299|OTHER|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
223537179|NCT03376932|DRUG|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
223537180|NCT03376932|DRUG|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
223537181|NCT03376932|DRUG|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
223537182|NCT03376932|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
223537183|NCT03376932|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
223537184|NCT03376932|DEVICE|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
223537185|NCT03376932|DEVICE|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
223537186|NCT03376932|DEVICE|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
223537187|NCT03376932|DEVICE|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
223537188|NCT02949011|DRUG|Baloxavir Marboxil|Tablets taken orally
223537189|NCT02949011|DRUG|Placebo to Baloxavir Marboxil|Matching tablets taken orally
224100878|NCT00989326|OTHER|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
223537190|NCT02949011|DRUG|Oseltamivir|Capsules taken orally
223537191|NCT02949011|DRUG|Placebo to Oseltamivir|Matching placebo capsules taken orally
223537192|NCT05829876|OTHER|High Frequency ECG Mapping|A high frequency ECG map will be performed to assess the optimum left ventricular pacing site.
223537193|NCT05829876|OTHER|Q-LV Measurement|Measurement of Q wave on 12 lead ECG to LV stimulus to assess optimum left ventricular pacing site.
223537194|NCT05014152|DEVICE|Q-temp-w1|Q-temp-w1 is a contact type body temperature patch developed by Quanta Computer Co., Ltd. It is mainly used to measure the body temperature of the human body. It can be used for general body temperature measurement, home temperature measurement records and medical tracking.
223537195|NCT05014152|DEVICE|Omron thermometer(MC-171W)|Omron thermometer(MC-171W) is mainly used to measure the body temperature of the human body. The reference temperature patch used in this study is the OMRON thermometer, model: MC-171W.
223537196|NCT02523287|BIOLOGICAL|Fluad|Randomized assignment
223537197|NCT02523287|BIOLOGICAL|Saline|Randomized assignment
223537198|NCT02489084|OTHER|Blood sampling|
223722148|NCT03910374|PROCEDURE|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
223722149|NCT05142943|OTHER|Visual illusion|the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes.
223949245|NCT02110381|DEVICE|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
223949246|NCT02110381|DEVICE|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
223949247|NCT02971215|DEVICE|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~\+ Physical Therapy protocol."
223949248|NCT02971215|DEVICE|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
223949249|NCT02695004|DRUG|DKF-310|
223949250|NCT02695004|DRUG|Placebo|
223949251|NCT01915888|OTHER|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
223949252|NCT03241810|DRUG|Seribantumab|Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
223949253|NCT03241810|DRUG|Fulvestrant|Fulvestrant is an estrogen receptor antagonist with no agonist effects
223949254|NCT03241810|DRUG|Placebo|Placebo
223949255|NCT06584734|OTHER|Not exercise|Patients were withdrawn from the exercise they had previously been doing during their hemodiafiltration sessions.
223949256|NCT06584734|OTHER|Exercise during hemodiafiltration session|Exercise with cycle ergometers during hemodiafiltration session, intensity was measure with power meters in Watts units.
223949257|NCT04566263|DEVICE|Neuroform EZ Stent System|The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
223949258|NCT04255251|DRUG|Silver Diammine Fluoride|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
223949259|NCT04255251|DRUG|Fluoride Varnishes|Subjects will receive SDF around their crown margins every 6 months for next 3 years.
224100879|NCT03014869|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
224100880|NCT00334750|OTHER|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
224100881|NCT01381523|DRUG|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
224100882|NCT01381523|DRUG|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
224100883|NCT05965570|DRUG|Brensocatib|Oral tablets.
224100884|NCT05965570|DRUG|Clarithromycin|Oral tablets.
224100885|NCT03928470|DRUG|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
223949260|NCT01189929|DRUG|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
224100886|NCT03168061|DRUG|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
224100887|NCT00602628|OTHER|questionnaire administration|
224100888|NCT00602628|PROCEDURE|adjuvant therapy|
224100889|NCT00602628|PROCEDURE|biopsy|
224100890|NCT00602628|PROCEDURE|computed tomography|
224100891|NCT00602628|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
224100892|NCT00602628|PROCEDURE|magnetic resonance imaging|
224100893|NCT00602628|PROCEDURE|therapeutic conventional surgery|
224100894|NCT00602628|PROCEDURE|ultrasound imaging|
224100895|NCT00602628|RADIATION|radiation therapy|
223949261|NCT01189929|DRUG|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
223949262|NCT01189929|DRUG|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
224100896|NCT05186532|RADIATION|Dry Heat Application|50 postnatal women they were encouraged to place an infrared lamp at distance of 45 cm from the perineum and the heat produced with 230 volts for ten minutes. But the mother is checked after the first five minutes to make sure that she was not being burned. The researchers were demonstrated for each woman how to use infrared lamp, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days. The researcher gives the infrared lamp device for each woman then restore it after completion of the study.
224100897|NCT05186532|OTHER|Moist Heat Application|included 50 postnatal women they were encouraged to sit in a basin (tub) of warm water (45 o C -59 o C) without pressure on the perineum and with the feet flat on the floor for 10 minutes. The researchers were demonstrated for each woman how to do warm sitz bath, and it was followed by re demonstrations and discussions. After 12 hours of episiotomy this procedure was carried out in the morning and evening for ten consecutive days.
224100898|NCT05839132|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
224100899|NCT04086940|DRUG|Esmolol|preventive
224100900|NCT02207387|DRUG|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
224100901|NCT02207387|BEHAVIORAL|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
223537199|NCT00163189|DRUG|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
224100902|NCT02207387|OTHER|Music|
224100903|NCT04369339|OTHER|Colposcopy|
224100904|NCT05325112|DIAGNOSTIC_TEST|FFRCT|FFRCT is a diagnostic test following a CCTA to help diagnose and treat coronary artery disease.
224100905|NCT05951127|PROCEDURE|Esophagectomy|Esophagectomy for esophageal cancer and regional lymph nodes dissection.
224100906|NCT01519115|OTHER|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
224100907|NCT01519115|OTHER|usual care|one physical therapy visit in hospital following ACF surgery
224100908|NCT04059809|DEVICE|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 \~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
224100909|NCT04777955|OTHER|core stabilization exercises|"Core is at the center of almost all kinetic chains in the body. Core force, balance, and motion control maximize all kinetic chains of upper and lower limb function. A stable and strong core can contribute to more efficient use of the lower extremities. Core stability is defined as the ability of the lumbo-pelvic hip complex to prevent bending of the vertebral column and return to balance after perturbation.~Neuromuscular electrical stimulation (NMES) is a technique in which muscle contraction is electrically stimulated in the area where the surface electrodes are connected. It improves secondary muscle atrophy and weakness in immobilization by preventing a decrease in muscle protein synthesis.~Kinesiological banding (CT) is a treatment method used in the treatment of various musculoskeletal and neuromuscular deficits. The mechanism of action of CT is to facilitate muscle activation, increase blood and lymph circulation and reduce pain due to neurological suppression."
223537200|NCT06348095|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
223537201|NCT06348095|DIETARY_SUPPLEMENT|Placebo|The experimental phase of this study had last 14 days, and each patient will make 4 visits (d0, d3, d7, d14).
223537202|NCT01995097|BEHAVIORAL|Scheduled Gradual Reduction Text Messages|
223537203|NCT01995097|BEHAVIORAL|Support Text Messages|
223537204|NCT05035888|DRUG|Phenylephrine|An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
223537205|NCT05035888|DRUG|Norepinephrine|An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
224100910|NCT05983302|DRUG|Platelet-Rich Plasma-Fibrin Glue|The first intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone PRP-FG intervention for 8 weeks.
224100911|NCT05983302|DRUG|Repairing Gel|The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.
224100912|NCT05983302|DRUG|Repairing Gel and Platelet-Rich Plasma-Fibrin Glue|The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
224100913|NCT05983302|OTHER|Classical wound irrigation (control)|For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
223722150|NCT05142943|OTHER|Physical exercise|"* General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~* Gross mobility and coordination: ball games.~* Fine mobility and coordination: writing tasks, puzzles, abacus ...~* Strength exercises: shoulder, elbow, wrist, fingers.~* Stretching."
223722151|NCT05142943|OTHER|Sham Visual illusion|only the placebo visual illusion
223722152|NCT00079898|PROCEDURE|Acupuncture|
223537206|NCT04955288|PROCEDURE|Aortic balloon assisted resuscitation|On the basis of the traditional resuscitation mode, the aortic balloon occlusion technology is used, that is, at the same time when the cardiopulmonary resuscitation starts, the aortic balloon catheter is quickly punctured to the distal end of the aortic zone I (septum level) through ultrasound assistance, and then Continue to inflate the balloon to block the aortic blood flow until the end of the cardiopulmonary resuscitation to deflate the balloon and remove the balloon catheter.
223722153|NCT01154790|DRUG|CG100649|6 subjects: study drug 2 subjects: placebo
223537207|NCT04955288|PROCEDURE|Traditional cardiopulmonary resuscitation|"Use the traditional manual chest compression mode, that is, refer to the latest version of the CPR Guidelines.~Artificial chest compressions are performed under the monitoring of the pressure quality feedback device to ensure that the compression depth is 5-6cm, the frequency is 100-120 times/min, the compression position is fixed, and the chest wall fully rebounds."
223722154|NCT01154790|DRUG|Placebo|6 subjects: study drug 2 subjects: placebo
223722155|NCT01154790|DRUG|Naproxen|6 subjects: study drug 2 subjects: placebo
223537208|NCT04955288|PROCEDURE|Esophageal cooling|The new transesophageal cooling method is adopted, that is, the esophageal cooling catheter is indwelled after resuscitation in patients with cardiac arrest, and then connected to a small temperature-controlled water circulation system to continuously infuse 4℃ cold water. After the patient's body temperature reaches the target temperature of 33℃, the temperature-controlled water circulation system is adjusted Maintain the target body temperature of (33±0.5)°C for 24 hours, and then rewarm to (37±0.5)°C normal body temperature at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
223537209|NCT04955288|PROCEDURE|traditional cooling|The traditional body surface ice blanket cooling method is adopted, that is, the patient with cardiac arrest lies on the temperature control blanket after resuscitation, and then uses the ice blanket host to continuously infuse the temperature control blanket with 4℃ cold water, and wait until the patient's body temperature reaches the target temperature of 33℃. The temperature of the circulating water is controlled by adjusting the ice blanket host to maintain the target body temperature of (33±0.5)°C for 24 hours, and then reheat to the normal body temperature of (37±0.5)°C at a rate of 0.25-0.5°C/h and maintain it for 24 hours.
223537210|NCT02154061|DRUG|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
223537211|NCT02154061|DRUG|Metronidazole|This is a standard antibiotic
223537212|NCT02154061|DRUG|Neomycin|This is a standard antibiotic.
223537213|NCT02154061|DRUG|Vancomycin|This is a standard antibiotic.
223537214|NCT00506142|DRUG|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
223537215|NCT00477984|DRUG|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
223537216|NCT02946203|OTHER|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
223537217|NCT02946203|OTHER|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
223537218|NCT00346723|BIOLOGICAL|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
223537219|NCT04106245|BEHAVIORAL|Behavioral Intervention|Participate in PACK Health
223537220|NCT04106245|OTHER|Survey Administration|Complete survey
223722156|NCT05914298|DIAGNOSTIC_TEST|blood and buccal swab genetic test|blood samples and buccal swabs will be obtained from patients with HME in order to analyze the genotype (EXT1 or EXT2 mutations) and correlate the genotypic pattern with the phenotypic presentation
223537221|NCT02862119|PROCEDURE|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
223537222|NCT02862119|OTHER|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
223537223|NCT05443529|OTHER|Adaptive sports|Participation in community adaptive sports programs
223537224|NCT03319576|OTHER|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
223537225|NCT01399853|BIOLOGICAL|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
223537226|NCT01399853|BIOLOGICAL|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
223537227|NCT01399853|BIOLOGICAL|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
223537228|NCT01399853|BIOLOGICAL|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
223722157|NCT05914298|DIAGNOSTIC_TEST|PUL|measurement of ulnar length with anthropometer and patient's height
223722158|NCT05914298|DIAGNOSTIC_TEST|Range of motion|measurement of range of motion of elbow, forearm and wrist
223722159|NCT01699204|DIETARY_SUPPLEMENT|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
223722160|NCT01699204|OTHER|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
223537229|NCT01399853|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
223537230|NCT02213250|DRUG|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
223537231|NCT03186339|PROCEDURE|TAVI|transfemoral transcatheter aortic valve implantation
223537232|NCT03186339|PROCEDURE|SAVR|isolated surgical valve replacement
223537233|NCT03186339|OTHER|MM|management of aortic stenosis by medical treatment only
223537234|NCT01917318|DRUG|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
223537235|NCT01917318|DRUG|Placebo|During 8 weeks subjects will receive oral placebo
223537236|NCT00151450|DRUG|Pregabalin|
223537237|NCT00151450|DRUG|Venlafaxine XR|
223537238|NCT01306747|BEHAVIORAL|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
223537239|NCT00742625|DRUG|daunorubicin hydrochloride|Given IV
223537240|NCT00742625|DRUG|cytarabine|Given IV
223537241|NCT00742625|DRUG|bortezomib|Given IV
223537242|NCT05357833|DRUG|Ferumoxytol infusion|Subjects will receive a single, weighted dose of intravenous ferumoxytol (4 mg/kg) diluted in 50 mL of saline.
223537243|NCT05357833|DRUG|Gadoteridol|Subjects will receive a single, weighted dose of intravenous gadoteridol (0.2 mL/kg).
223722161|NCT01699204|OTHER|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
223537244|NCT05357833|DIAGNOSTIC_TEST|MRI Brain and Cervical Spine|3T MR imaging of the brain and cervical spine pre- and post-administration of gadolinium, then pre- and 96 hours (±24 hours) post-administration of ferumoxytol
223537245|NCT01291966|BEHAVIORAL|Motivational interview|
223537246|NCT02432430|BEHAVIORAL|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
223537247|NCT02432430|BEHAVIORAL|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
223537248|NCT04256187|OTHER|Qualitative interview|Qualitative interviews to sample the patient's feelings, experiences and thoughts risen by the treatments in the program.
223722162|NCT00691418|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
223722163|NCT00691418|DIETARY_SUPPLEMENT|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
223537249|NCT00891150|DRUG|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
223537250|NCT05245539|DRUG|CVL-231|CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.
223537251|NCT01084889|DEVICE|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
223537252|NCT04429464|DEVICE|AcQBlate Force Sensing Ablation Catheter|Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
223537253|NCT03984721|DIAGNOSTIC_TEST|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
223537254|NCT00800800|DRUG|Rosuvastatin|40 mg, oral, single dose
223537255|NCT00800800|DRUG|Placebo|oral, single dose
223537256|NCT01012284|DRUG|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
223537257|NCT02941614|BEHAVIORAL|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire-9 (PHQ-9), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm.
223537258|NCT02012803|PROCEDURE|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
223537259|NCT02012803|OTHER|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
223537260|NCT00093509|DRUG|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
223537261|NCT00093509|DRUG|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
223537262|NCT00093509|PROCEDURE|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
223537263|NCT00093509|RADIATION|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of \> 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
223537264|NCT06345885|BIOLOGICAL|HPV vaccine|Participants in the group A will be administrated with bivalent HPV vaccine Cecolin. The immunization schedule is 0, 6 months; Participants in the group B will be administrated with quadrivalent HPV vaccine Gardssil. The immunization schedule is 0, 2, 6 months
223537265|NCT02227303|BEHAVIORAL|lifestyle modification instructional and motivational sessions|
223537266|NCT04179110|DRUG|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg \& Ramucirumab 10 mg/kg every 3 weeks.
223537267|NCT05009095|DEVICE|The Listening Program® with bone conduction headphones|The Listening Program method of Music-Based Auditory Stimulation is enhanced with the addition of bone conduction technology with the ABT Bone Conduction System. Bone Conduction combines the experience of listening to music through modified headphones adding subtle, synchronized acoustic vibration of the skin and skeletal system, engaging the whole body and brain in the listening process. This multi-sensory approach accelerates and expands the benefits of The Listening Program.
223537268|NCT06465784|PROCEDURE|Retrograde and Antegrade Ureteroscopic Laser Lithotripsy|Comparison Between Retrograde and Antegrade Ureteroscopic Laser Lithotripsy for Management of Medium Sized Proximal Ureteral Stones: A Randomized Prospective Study
223537269|NCT05046392|BEHAVIORAL|Face-to-Face ART Adherence Intervention|All participants will receive a one hour face-to-face session with an adherence coach, based on LifeSteps. The session will cover behavioral skills that are important for maintaining adherence to ART and will explore potential barriers for managing each skill. Cognitive-behavioral therapy, problem solving, and motivational interviewing techniques are used to explore barriers and create health goals.
223537270|NCT05046392|BEHAVIORAL|Carium Mobile Health Platform|Participants assigned to the experimental condition will receive access to a mobile health app, called Carium, for 12 months. The app will be used to facilitate continued coaching from the adherence coach. The app incorporates automated medications reminders with interactive adherence coaching via a secure messaging feature. Participants will receive custom medication reminders as push notifications that will ask them to indicate if they have taken their medication or not. This will allow adherence coaches to monitor self-reported adherence in the app. Adherence coaches will use the secure messaging feature to check-in with participants and reach out to participants who appear to be struggling with adherence and offer assistance.
223537271|NCT05962021|DRUG|Toripalimab plus Chemotherapy|Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
223537272|NCT03759990|DEVICE|lean|Videolaryngoscope used in intubation
223537273|NCT03759990|DEVICE|obese|Videolaryngoscope used in intubation
223537274|NCT03906643|DRUG|HS-201|HS-201 will be administered intravenously as a single dose
223537275|NCT01865487|BIOLOGICAL|H56ug/IC31nmol|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
223722164|NCT04552847|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
223722165|NCT04552847|DEVICE|PET/CT|Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
223537276|NCT01865487|BIOLOGICAL|Placebo|Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
223537277|NCT01441388|DRUG|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
223537278|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
223537279|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
223537280|NCT01441388|DRUG|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
223537281|NCT01441388|DRUG|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
223537282|NCT01441388|DRUG|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
223537283|NCT01441388|DRUG|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
223537284|NCT02821325|OTHER|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
223537285|NCT04008914|OTHER|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
223537286|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
223537287|NCT02572375|DRUG|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
223537288|NCT03218839|DEVICE|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
223537289|NCT00129285|DRUG|Low Dose Modafinil|modafinil 200 mg/day
223537290|NCT00129285|DRUG|High Dose Modafinil|modafinil 400 mg/day
223537291|NCT00129285|DRUG|Placebo|placebo 400 mg/day
223537292|NCT01213082|DRUG|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
223949263|NCT04290533|DEVICE|Active High Definition transcranial Direct Current Stimulation (HD-tDCS)|TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
224100914|NCT04372589|DRUG|Heparin|"Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement."
223537293|NCT01213082|DRUG|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
224122656|NCT06672835|BEHAVIORAL|eAttention Control|eAC is an online control for eBASIS. Providers assigned to eAttention Control (eAC) will receive pre- and post-training experiences designed to mirror those received in eBASIS. These training experiences will be delivered on the same platform and be approximately the same length as the eBASIS but will not contain any eBASIS content or mechanisms of change. The eAC pre-training experience will define, describe, and advocate for evidence-based practice implementation in schools. Content in eAC will be didactic similar to a typical professional development training for providers.
223537294|NCT01213082|DRUG|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
223537295|NCT03848416|BIOLOGICAL|Ixekizumab|Administered SC
223537296|NCT01883024|OTHER|A decision support software|
223537297|NCT01883024|OTHER|Insulin Pump|
223537298|NCT01883024|OTHER|Continuous glucose monitoring|
223537299|NCT02639390|DEVICE|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
223722166|NCT04552847|DEVICE|PET/MR|Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.
223722167|NCT04061213|DIAGNOSTIC_TEST|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
223722168|NCT06266000|DRUG|Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
223722169|NCT06266000|DRUG|Commercial Saw palmetto extract 320mg per day|Saw palmetto extract 160mg per capsule
223722170|NCT06266000|DRUG|Palm Oil capsule|Palm oil capsule
223722171|NCT04334070|DRUG|Lamprene®/Clofazimine|All participants will receive Lamprene/clofazimine 50 mg capsules. The recommended dose of clofazimine for this program is 100 mg once daily, administered orally, preferably with meals. Duration of treatment will be decided by the treating physician. When considering clofazimine for the treatment of NTM infection, clofazimine is to be administered as part of a multi-drug regimen.
223949264|NCT04290533|DEVICE|Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)|For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
223949265|NCT06454929|PROCEDURE|operative|open reduction : fixation by k-wires or screws
223949266|NCT06454929|PROCEDURE|non-operative|close reduction : by cast Immobilization
223949267|NCT03445364|OTHER|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
223949268|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
223949269|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
223949270|NCT01507935|OTHER|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
223949271|NCT02252822|BEHAVIORAL|Overcoming Bulimia Online Programme|
223949272|NCT04434651|PROCEDURE|SPGB|Sphenopalatine Ganglion Block using 2% lidocaine in block group. Sphenopalatine Ganglion Block is performed by a hollow culture swab that is connected with a 21-gauge a syringe filled with three ml 2% lidocaine, inserted parallel to the floor of the nose until resistance is felt. The swab is at the posterior pharyngeal wall superior to the middle turbinate. The applicator was kept in the nostril for five to ten mins. The same procedure is done also in the second nostril SPGB using normal saline is performed in the control group
223949273|NCT03592524|BEHAVIORAL|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
223949274|NCT02954289|BEHAVIORAL|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
223949275|NCT00514306|DRUG|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
223949276|NCT03347851|OTHER|MRI|Enrolled patients will complete a non-contrast cardiac MRI
223949277|NCT03347851|OTHER|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
223949278|NCT04114019|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
223949279|NCT02676011|DRUG|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
223949280|NCT02676011|DRUG|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
223949281|NCT02676011|DRUG|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
223949282|NCT02676011|DRUG|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
223949283|NCT02676011|DRUG|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
223949284|NCT02676011|DRUG|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
223949285|NCT04802681|DEVICE|FFR-measurement with different pressure guidewires|Measuring FFR with different pressure guidewires
223949286|NCT01263496|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
223949287|NCT01263496|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
223949288|NCT01263496|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
223949289|NCT01263496|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
223949290|NCT01263496|DRUG|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
223949291|NCT02842957|BEHAVIORAL|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
223949292|NCT00780806|BIOLOGICAL|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
223949293|NCT00780806|PROCEDURE|Blood draw|Blood draw
223537300|NCT02639390|OTHER|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
223537301|NCT06271824|BEHAVIORAL|Self-Compassion Based Resilient Caregiving Course|The Resilience Habits for Caregivers Course is a live, online, weekly 6 session program lasting 1.5 hours per session. The structure contains didactics, group discussions, guided exercises, and practices facilitated by a certified self-compassion instructor. Topics covered include: (1) noticing and accepting emotions (including conflicting emotions); (2) cultivating curiosity and self-compassion; (3) relating skillfully to difficult thoughts; (4) savoring and gratitude practices.
223537302|NCT05257928|BEHAVIORAL|CARE-CITE Gait|The CARE-CITE intervention content modified to address gait rehabilitation, and test 4-weeks of CARE-CITE-Gait in 15 CP/SS dyads.It will occur in the dyad's home.CP will complete 6 online CARE-CITE modules. Modules will include demonstration videos and instructive content covering the following areas:principles of functional task practice, the adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity. Examples are provided to address potential SS frustration and improve adherence.Underpinning the content is the concept of autonomy support,with examples of fostering empathy, problem-solving, instruction in the use of non-controlling language with role-playing situations and the importance of creating choice in activities. During the two home therapy sessions, the physical therapist will work with the CP and stroke survivor to collaboratively develop goals and an exercise program to improve mobility, gait and balance.
223537303|NCT01908140|DRUG|Aclidinium Bromide / Formoterol Fumarate|
223537304|NCT01908140|DRUG|Salmeterol / Fluticasone|
223722172|NCT05200091|OTHER|Combined explosive strength and specific balance training group|"Training will consist to perform one hour of combined ankle explosive strength training and specific balance training using randomized perturbations.~Explosive strength training: Participants will perform only 2 sets of 3 min (12 contractions for each set) for both lower limbs and both ankle plantar- and dorsiflexion movements.~Balance specific training: Participants will be standing, secured by an adjusted harness, which do not support the weight but is strictly there to prevent a fall. They will have online visual feedback of their CoP via an avatar on the screen in front of them. Each training session will consist of 10 sequences of 3 min, including the 5 different conditions:~* Forward tilt of base of support;~* Backward tilt of base of support;~* Translation forward;~* Translation backward;~* Without moving their feet, participants will have to move their avatar to reach different targets placed around them on the screen, at different distance from the center."
224100915|NCT06485544|DRUG|Adebrelimab + Etoposide + Platinum-based Therapy|"Intervention Description for Treatment Group:~This intervention includes Adebrelimab in combination with Etoposide and Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Adebrelimab is administered intravenously at a fixed dose of 1200 mg over 30 minutes on Day 1 of each 3-week cycle, followed by Etoposide at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
224122657|NCT01568905|OTHER|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
223537305|NCT05822154|OTHER|comprehensive geriatric assessment|The clinical, biological and functional characteristics will be collected in elderly subjects attending the hospitals of participating centers.
223722173|NCT05985577|OTHER|Without any intervention|There were no special interventions for the two groups.
223722174|NCT03568734|OTHER|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
223537306|NCT01809886|DRUG|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC\<2).
223537307|NCT01809886|DRUG|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC\<2).
223537308|NCT03256721|DRUG|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
223537309|NCT03256721|DRUG|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
223537310|NCT02700672|OTHER|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
223537311|NCT04451759|OTHER|MRI exploration|ultra high field (7T) magnetic resonance imaging
223537312|NCT02013609|DRUG|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
223537313|NCT01135225|DEVICE|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
223949294|NCT02070809|PROCEDURE|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
223949295|NCT02070809|PROCEDURE|split-thickness skin graft method|This method is traditional split-thickness skin graft
223949296|NCT03576092|DIAGNOSTIC_TEST|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
223949297|NCT02959385|RADIATION|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
223537314|NCT01135225|DEVICE|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
223537315|NCT00533130|PROCEDURE|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
223537316|NCT00533130|PROCEDURE|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
223537317|NCT05730881|PROCEDURE|ECMO|VA-ECMO is a life support measures, we need to estimate the survival by different techniques to allocate therapeutic interventions properly
223537318|NCT02136043|DEVICE|PBASE system 1.1 (active treatment)|
223537319|NCT03346525|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children \<30kg, 1.2 million IU for children ≥30kg), every 28 days.
223537320|NCT00783432|DRUG|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
223949298|NCT02959385|PROCEDURE|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
223949299|NCT01324076|DRUG|doxorubicin-eluting beads|
223537321|NCT00783432|DRUG|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
223537322|NCT00852410|DRUG|1% lidocaine with 1:100,000 adrenaline|high dose
223722175|NCT06129071|PROCEDURE|US guided block of maxillary nerve|Extraoral ultrasound-guided block of the maxillary nerve will be performed in the examined group using an ultrasound device and local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL).
223537323|NCT00852410|DRUG|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
223537324|NCT02546882|BIOLOGICAL|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
223537325|NCT02546882|DRUG|saline|1 ml saline was injected for 1 cm2 area.
223537326|NCT01923766|DRUG|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
223537327|NCT01436110|DRUG|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
223537328|NCT01436110|DRUG|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
223537329|NCT01436110|DRUG|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
223537330|NCT03912610|DIAGNOSTIC_TEST|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
223537331|NCT04321616|DRUG|Hydroxychloroquine|Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
223722176|NCT00257101|BEHAVIORAL|self-medication monitoring|
223722177|NCT02426437|OTHER|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
223722178|NCT02426437|OTHER|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
223722179|NCT04374773|DRUG|Dronabinol|2.5 mg PO administered once prior to and once after 1 week of hormone therapy
223949300|NCT01324076|DRUG|sorafenib tosylate|
223949301|NCT01324076|OTHER|laboratory biomarker analysis|
223949302|NCT01324076|OTHER|pharmacogenomic studies|
223949303|NCT01324076|OTHER|pharmacological study|
223949304|NCT01324076|PROCEDURE|quality-of-life assessment|
223949305|NCT05088200|PROCEDURE|surgery|Our study is observational and we use secondary data
223949306|NCT00640588|DRUG|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
223949307|NCT00640588|DRUG|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
223949308|NCT04063124|DRUG|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
223722180|NCT03158116|DRUG|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
223722181|NCT04655898|DRUG|[14C]CC-90001|Oral
223722182|NCT00886574|DRUG|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
223722183|NCT00886574|DRUG|Aspirin|100 mg once a day
223722184|NCT02634320|DRUG|Aripiprazole Lauroxil|Monthly IM injection
223722185|NCT06123845|BEHAVIORAL|static CPAP 8 cmH2O|Set static CPAP or PEEP pressure level at 8 cmH2O
223949309|NCT00524797|DIETARY_SUPPLEMENT|Profonycia|
223722186|NCT06123845|BEHAVIORAL|static CPAP 5 cmH2O|Set static CPAP or PEEP pressure level at 5 cmH2O
223722187|NCT01952275|PROCEDURE|Collection of biological samples|
223722188|NCT01900704|DRUG|SER120 750 ng|SER120 750 ng
223722189|NCT01900704|DRUG|SER120 1500 ng|SER120 1500 ng
223722190|NCT01900704|DRUG|Placebo|Placebo
223949310|NCT02950961|BEHAVIORAL|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
223949311|NCT02709200|DRUG|Dexmedetomidine|
223949312|NCT04158206|OTHER|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
223537332|NCT04321616|DRUG|Remdesivir|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
223722191|NCT03274505|OTHER|Questionnaires|"* Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)"
223722192|NCT00197132|DRUG|Avandia|
224122658|NCT01568905|OTHER|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
224122659|NCT01568905|OTHER|High level nicotine cigarette|smoke the study cigarette exclusively for one week
223537333|NCT04321616|OTHER|(Standard of Care) SoC|The standard of care will be supplied to all patients not receiving a drug intervention.
223537334|NCT00124930|DRUG|Olanzapine|
223537335|NCT00124930|DRUG|Haldol|
223537336|NCT00537472|DRUG|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
223537337|NCT00537472|DRUG|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
223537338|NCT03461939|OTHER|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
223722193|NCT00359060|BEHAVIORAL|Physical activity|
223722194|NCT01849198|DEVICE|accelerometry m. trapezius and m. adductor pollicis|
223722195|NCT03919799|DRUG|Belumosudil (KD025)|ROCK-2 Inhibitor
223722196|NCT03919799|DRUG|Placebo|Inactive substance
223722197|NCT04736420|DRUG|Rivaroxaban|Rivaroxaban dispensing claim is used as the exposure group
223722198|NCT04736420|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
223722199|NCT02970422|OTHER|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
223722200|NCT04936256|DEVICE|Clareon|Clareon monofocal intraocular lens (IOL)
223722201|NCT06254703|DIAGNOSTIC_TEST|VexLUS (venous excess lung ultrasound)|IVC, hepatic veins (HVs), portal veins (PVs) and intrarenal veins (IRVs), and lung ultrasound
223722202|NCT04255602|DRUG|Ticagrelor 60mg|Ticagrelor 60mg plus Aspirin 100mg for experimental group
223537339|NCT01175343|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223537340|NCT01175343|OTHER|Laboratory Biomarker Analysis|Correlative studies
223537341|NCT06169618|OTHER|cervical radiculopathy|this group will have patients with cervical radiculopathy
223537342|NCT06169618|OTHER|normal group|this group will have normal subjects
223537343|NCT03940807|DRUG|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
223537344|NCT03940807|DRUG|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
223537345|NCT03940807|DRUG|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
223537346|NCT03273907|DEVICE|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
223537347|NCT03273907|PROCEDURE|Cataract surgery|Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit
223537348|NCT02491281|DRUG|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
223537349|NCT02491281|DRUG|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
224100916|NCT06485544|DRUG|Etoposide + Platinum-based Therapy|"Intervention Description for Control Group:~This intervention includes Etoposide in combination with Platinum-based therapy as neoadjuvant treatment for resectable small cell lung cancer (SCLC). Etoposide is administered at a dose of 100 mg/m2 via intravenous infusion over 30 minutes on Days 1 to 3 of each 3-week cycle. Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) is administered via intravenous infusion on Day 1 of each cycle. The treatment regimen consists of 3-4 cycles, with a 4-6 week drug-free interval before surgical treatment."
223722203|NCT04255602|DRUG|Ticagrelor 90mg|Ticagrelor 90mg plus Aspirin 100mg for active comparator group
223722204|NCT03951402|DRUG|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
223722205|NCT03951402|DRUG|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
223722206|NCT03951402|DRUG|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
224100917|NCT00354068|DRUG|imatinib mesylate|
224100918|NCT00354068|DRUG|temozolomide|
224100919|NCT00354068|OTHER|pharmacological study|
224100920|NCT01599351|RADIATION|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
224100921|NCT00875771|DRUG|Capecitabine+Irinotecan+Bevacizumab|"* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~* Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~* Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
223537350|NCT01074073|DRUG|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
223722207|NCT03951402|DRUG|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
223722208|NCT02812160|DEVICE|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
223722209|NCT06177600|BEHAVIORAL|Interactive educational digital platform for transgender and gender-diverse (TGD) young adults and caregivers|"Investigators will develop a free mobile- and web-enabled platform for TGD young adults and their caregivers that combines educational modules with high-quality, evidence-based information and interactive features. At the time of account creation, users will complete an intake survey that will be used to personalize platform features. Young adults will be asked about their goals; mental health; access to health care; degree of caregiver support; and sociodemographic characteristics. Caregivers will be asked about their goals and self-assessed level of supportiveness of their young adults.~Users will be assigned educational modules that build knowledge and skills related to improving mental health and navigating relationships and communication with others. Both exposure to and completion of modules will be tracked."
223722210|NCT00465205|DRUG|Valacyclovir|500mg oral twice daily
223722211|NCT00465205|DRUG|Matching Placebo|500 mg oral twice daily
223722212|NCT04423237|DRUG|Deferasirox|DEFERASIROX administered as per clinical practice and according to technical note
223537351|NCT01389986|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
223537352|NCT03983447|BEHAVIORAL|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers"
223537353|NCT01531998|DRUG|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
223722213|NCT04656691|DRUG|bamlanivimab|Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
223722214|NCT00282594|DRUG|Novolin R (human recombinant Insulin)|
223722215|NCT03199274|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
223722216|NCT03199274|DRUG|Perflutren Protein-Type A Microspheres|Given IV.
224100922|NCT05823493|BEHAVIORAL|Schroth exercise therapy|The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis.
223722217|NCT03199274|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
223722218|NCT00766480|DRUG|cisplatin|Given IV
223722219|NCT00766480|DRUG|fluorouracil|Given IV
223722220|NCT00766480|RADIATION|radiation therapy|Patients undergo radiotherapy
223722221|NCT05948696|BEHAVIORAL|Horticultural group therapy.|Estimated 10 persons with schizophrenia who attend to a 12-week horticultural group therapy will be assessed for their experience about the program.
223722222|NCT03779724|OTHER|exercises|
224100923|NCT05823493|DEVICE|laser therapy|Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
223537354|NCT01531998|DRUG|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
223537355|NCT01531998|DRUG|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
223537356|NCT01531998|DRUG|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
223537357|NCT01531998|BEHAVIORAL|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
223722223|NCT03548909|DIAGNOSTIC_TEST|VITROS Immunodiagnostic Products|NT-proBNP II assay
223949313|NCT04958837|OTHER|FIFA 11+ protocol with additional Core training exercises|Slow paced running exercises of 8 minutes' duration (2 rounds each), followed by Strength, plyometric and balance exercises including 3 sets of 20-30 sec of The Bench, Sideways Bench each side, Nordic Hamstring strengthening, single leg stance balance training, squatting and high speed running. The protocol will end with additional core training exercises including leg raises, crunches, superman, plank hip twist, and supine bridge. Each exercise plan will be progressively increased. Core training will be followed by 30 sec stretch of major muscle groups.
224100924|NCT02037919|OTHER|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
223722224|NCT00602342|DRUG|Terbinafine|
223949314|NCT04958837|OTHER|FIFA 11+ protocol|Slow paced running exercises of 8 minutes' duration including running straight, running with hip out, running hip in, running circling partner, running shoulder contact and running quickly forward and backwards (2 rounds each), followed by Strength, plyometric and balance exercises including The Bench, Sideways Bench each side, Nordic Hamstring strengthening and single leg stance balance training, squatting and jumping. All exercises will be progressively increased as per established protocol. The final phase of the study includes fast running for 2 minutes.
223949315|NCT02241785|DRUG|natalizumab|Administered as specified in the treatment arm
223949316|NCT01640340|DRUG|aprepitant|Given by mouth
223949317|NCT01640340|DRUG|palonosetron hydrochloride|Given IV(intervenous infusion)
223949318|NCT01640340|DRUG|ondansetron|Given PO
223949319|NCT01640340|DRUG|dexamethasone|Given PO
223949320|NCT03055988|DRUG|Tiotropium|Fixed Dose Combination
223949321|NCT03055988|DRUG|Olodaterol|Fixed Dose Combination
223949322|NCT03055988|DRUG|Fluticasone propionate|Fixed Dose Combination
223949323|NCT03055988|DRUG|Salmeterol|Fixed Dose Combination
223949324|NCT06131957|COMBINATION_PRODUCT|Fluoride varnish with SBGC|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA) mixed with 7.5% SBGC (Dencare (Chongqing) Oral Care Co., Ltd).
223949325|NCT06131957|DRUG|Fluoride varnish|The Fluoride varnish (containing 5% NaF, Duraphat®, Colgate-Palmolive Company, NY, USA)
223949326|NCT02541292|OTHER|No intervention, observational|
223949327|NCT05664776|DEVICE|Dynamic office chair|The dynamic office chair has a typical office chair design (e.g. seat pan and a lumbar support). The seat pan is mounted on a flexible mechanic construction that allows hip movements in the frontal plane while sitting.
223949328|NCT02918045|DEVICE|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
223949329|NCT02918045|DEVICE|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
223949330|NCT05591937|BEHAVIORAL|Self-Guided Online Prevention|An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
223949331|NCT05591937|BEHAVIORAL|Coach-Guided Online Cognitive Behavioral Therapy|An online digital therapy program that consists of online CBT modules supported by coaches through video chats. The modules are evidence-based and formatted into a unified approach for depression, anxiety and worry, panic, social anxiety, trauma and sleep dysregulation (developed as part of the University of California, Los Angeles (UCLA) Depression Grand Challenge). Lessons are designed to respond to participants' specific symptoms. Participants can access the system through any personal device (phone, tablet or computer) and speak to a certified student coach through remote video chat.
223949332|NCT05591937|BEHAVIORAL|Clinician-Delivered Psychological and Psychiatric Care|Evidence-based clinician-delivered CBT modules. Participants are connected to a team of clinicians who will evaluate participants' specific symptoms and create an individualized and tailored treatment plan. Treatment will include weekly sessions delivered through telehealth, and if deemed appropriate, participants may also have medication appointments.
223949333|NCT01733862|OTHER|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
223949334|NCT06085989|BEHAVIORAL|Infant directed singing|In every known human culture and historical period, infant-directed singing exists as a natural feature of parental care for newborn infants. Infant-directed singing is effective in regulating infant affect and in capturing an infant's attention for a longer period than infant-directed speech. Parental stress significantly decreases when parents are encouraged to use their own voices to soothe their infants with a song or a lullaby of their choice.
223949335|NCT06085989|BEHAVIORAL|Standard care|Standard breastfeeding support to mothers with breastfeeding difficulties provided by health care professionals.
223949336|NCT05695469|DEVICE|Smart resuscitation glove (ResuGlove)|Participants will be randomly assigned into two equal groups using the online-based random number generator (https://www.random.org). Participants in the ResuGlove group will perform hand-only CPR wearing the ResuGlove with a running feedback program for 2 minutes.
223949337|NCT05695469|OTHER|Traditional CPR|Participants in the traditional CPR group will perform hand-only CPR without the ResuGlove and feedback guidance for 2 minutes.
223949338|NCT03307694|DIAGNOSTIC_TEST|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
223949339|NCT03307694|DIAGNOSTIC_TEST|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
223949340|NCT03307694|DIAGNOSTIC_TEST|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
223949341|NCT03389919|BIOLOGICAL|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
223949342|NCT05089487|PROCEDURE|Nocturnal rest (sleep study)|Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .
223949343|NCT02507869|BEHAVIORAL|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
223949344|NCT02507869|BEHAVIORAL|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
223949345|NCT00845520|DEVICE|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
223722225|NCT04239144|PROCEDURE|Bilateral sympathectomy|Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason. The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion. Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
223949346|NCT00845520|DEVICE|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
223949347|NCT00845520|DEVICE|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
223949348|NCT01357694|BEHAVIORAL|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
223722226|NCT04239144|PROCEDURE|Catheter ablation|Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
223722227|NCT00227695|BIOLOGICAL|rituximab|comparing two maintenance schedules of Rituximab
223949349|NCT00860236|OTHER|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
223949350|NCT00860236|BEHAVIORAL|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
223949351|NCT01181232|DRUG|Zolpidem MR|oral
224100925|NCT02037919|OTHER|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
224100926|NCT03102736|DRUG|Placebos|Placebo saline
224100927|NCT03102736|DRUG|Ketamine|0.5 mg/kg ketamine
224100928|NCT03102736|DRUG|Nitroprusside|0.5 mcg/kg nitroprusside
224100929|NCT00242177|DRUG|ACTOS (Pioglitazone)|
224100930|NCT04110249|PROCEDURE|Photoacoustic Imaging|Undergo PAI
224100931|NCT04110249|PROCEDURE|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
224100932|NCT00247481|DRUG|Gefitinib|
223949352|NCT01181232|DRUG|Zolpidem IR|oral
223949353|NCT01736475|BIOLOGICAL|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
223949354|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
223949355|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|Prophylaxis treatment
223949356|NCT01736475|BIOLOGICAL|PEGylated Recombinant Factor VIII|On-demand treatment
224100933|NCT00247481|DRUG|Docetaxel|
224100934|NCT06170658|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, silicone hydrogel investigational lenses for one week
224100935|NCT06170658|DEVICE|Control Lenses (omafilcon A)|Daily disposable, hydrogel commercially available lenses for one week
224100936|NCT06240598|PROCEDURE|Second Look Laparoscopy|Second Look Laparoscopy (SLL)
224100937|NCT00430807|DRUG|hydroxychloroquine/placebo|
224100938|NCT02912663|DRUG|Verapamil and Magnesium Sulfate|Single dose strategy will be used
224100939|NCT02912663|OTHER|Placebo|Single matching dosing strategy will be used
224100940|NCT04518384|PROCEDURE|colon or rectum resection|surgical procedure to resect the colon or rectum
224100941|NCT02079727|DRUG|chondroitin sulfate|
224100942|NCT02079727|DRUG|celecoxib|
224100943|NCT02079727|DRUG|placebo|
224100944|NCT01973283|DRUG|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
223949357|NCT00127582|PROCEDURE|Electrophysiological study|
223949358|NCT00127582|DEVICE|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
223949359|NCT02807857|PROCEDURE|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
223949360|NCT01876966|DRUG|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
223949361|NCT01876966|DRUG|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
223949362|NCT01876966|DRUG|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
223949363|NCT03632876|DIETARY_SUPPLEMENT|retinyl palmitate|The intervention is a daily vitamin A supplement.
224100945|NCT03023748|DRUG|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
224100946|NCT05549388|OTHER|Front-of-pack labeling|The intervention being tested is the effect of front-of-package labeling on consumers' intent to purchase foods which are high in one or more nutrients of public health concern. Participants randomized to the control group will view images of packaged foods and beverages and answer a series of questions about those products. In the intervention arms, participants will view images of the same packaged foods and beverages, but with different front-of-package labels displayed that provide nutrition information about the product. Participants in each arm will be asked the same series of questions about the products shown.
224100947|NCT01475955|DRUG|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
224100948|NCT01475955|DRUG|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
224100949|NCT01475955|DRUG|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
224100950|NCT01475955|DRUG|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
223722228|NCT02180152|BEHAVIORAL|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
223722229|NCT06968624|DRUG|Intravenous Ketamine Infusions|The patients received a single intravenous infusion of esketamine (0.2 mg/kg), which was added to 50 ml of normal saline and administered via a micro-infusion pump over 40 minutes.
223949364|NCT02509858|DRUG|thyroxine|treatment with 50μg of thyroxine once daily for two months.
223949365|NCT02509858|DRUG|Placebo|treatment with 50μg of placebo, once daily, for two months.
223949366|NCT02509858|OTHER|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
223949367|NCT00482742|DEVICE|CiTop(TM) Guidewire|
223949368|NCT01137916|DRUG|Imatinib|800 mg
223949369|NCT05001126|BEHAVIORAL|HIFT 1x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 1x/week represents a dose of one HIFT workout per week.
223949370|NCT05001126|BEHAVIORAL|HIFT 2x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 2x/week represents a dose of two HIFT workouts per week.
223949371|NCT05001126|BEHAVIORAL|HIFT 3x/week|HIFT is a time-efficient modality of exercise combining high-intensity aerobic and resistance training using minimal equipment. HIFT 3x/week represents a dose of three HIFT workouts per week.
223949372|NCT02515123|DEVICE|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
223949373|NCT02515123|DEVICE|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
223949374|NCT04237909|BIOLOGICAL|PRP injection into at least one ovary|The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into at least one ovary using a 35 cm 17 G single lumen needle. The injection will be done underneath the ovarian cortex to the subcortical and stromal areas. Approximately 2-4cc of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30-40 minutes and also be discharged home on the same day.
223949375|NCT06143007|DRUG|BB3008 tablet|BB3008 tablets will be administered orally once daily (QD).
223949376|NCT00056654|DRUG|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
223949377|NCT00746759|DEVICE|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
223949378|NCT05554549|OTHER|Dietary pattern observed|Dietary pattern: regular meat-eater, occasional meat-eater, pescatarian, and vegetarian. There are no interventions in this observational cohort.
223949379|NCT04205799|DRUG|Cabozantinib|Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.
223949380|NCT01827982|DRUG|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
223949381|NCT01827982|DRUG|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
223949382|NCT01827982|DRUG|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
224100951|NCT01475955|DRUG|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
223722230|NCT06968624|DRUG|Intravenous normal saline|The patients received a single intravenous infusion of 50 ml normal saline via a micro-infusion pump over 40 minutes
223722231|NCT06968624|DRUG|Oral Duloxetine 60mg|Patients received 60 mg/day of oral duloxetine as maintenance therapy for depression.
223722232|NCT00042900|DRUG|pyroxamide|
223722233|NCT06971731|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
223722234|NCT06971731|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
223722235|NCT06971731|DRUG|Placebo Tablet: BID|Placebo Tablet: BID
223722236|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
223722237|NCT00330746|DRUG|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
223722238|NCT00330746|DRUG|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
223722239|NCT00330746|DRUG|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
223722240|NCT02458820|PROCEDURE|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
223949383|NCT01827982|DRUG|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
223949384|NCT01827982|DRUG|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
224100952|NCT01475955|DEVICE|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
223949385|NCT01827982|DRUG|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
223949386|NCT01827982|DRUG|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
223949387|NCT01827982|DRUG|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
223949388|NCT01827982|DRUG|Placebo|Matching placebo will be given as a single oral dose.
223949389|NCT01042184|DRUG|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
223949390|NCT01042184|DRUG|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
223949391|NCT01042184|DRUG|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
223722241|NCT06969963|DRUG|Lepsiramp, 0.5 Mg/mL Oral Suspension|Test product
223722242|NCT06969963|DRUG|Fycompa, 0.5 Mg/mL Oral Suspension|Reference product
223722243|NCT06969638|BEHAVIORAL|Black Ads|Food ads that feature Black individuals
223949392|NCT01472406|DEVICE|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
223949393|NCT01472406|DEVICE|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
223949394|NCT01472406|DEVICE|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
223949395|NCT01472406|DEVICE|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
223949396|NCT01472406|DEVICE|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
223949397|NCT02457806|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
223949398|NCT02457806|DRUG|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
223949399|NCT00354237|OTHER|Conventional antidiabetic treatment|No intensive treatment
223949400|NCT00354237|OTHER|Intensive insulin treatment|Intensive insulin treatment
223949401|NCT05679479|BIOLOGICAL|Meplazumab for injection|Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
223949402|NCT05679479|OTHER|Normal saline|0.9% normal saline
223949403|NCT06272032|PROCEDURE|High-intensity focused ultrasound (HIFU)|Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
223949404|NCT06272032|DRUG|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines|intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
223949405|NCT03186248|PROCEDURE|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
223949406|NCT01479010|DRUG|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
223949407|NCT01409772|DRUG|Ethanol Lock|Ethanol Lock
223949408|NCT02481804|OTHER|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
223949409|NCT02481804|OTHER|Standard treatment|Standard treatment will be continued
223949410|NCT04851665|OTHER|No Intervention - this was a qualitative analysis|No Intervention - this was a qualitative analysis
223949411|NCT00297466|DRUG|transdermal nicotine patches|
223949412|NCT00297466|BEHAVIORAL|Motivational interview|
223949413|NCT00703391|DRUG|AZD9668|30mg oral tablets twice daily (bid) for 14 days
223949414|NCT00703391|DRUG|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
223722244|NCT06969638|BEHAVIORAL|White Ads|Food ads that feature White individuals.
223949415|NCT02994004|OTHER|no intervention|
223949416|NCT01583959|DRUG|Folic Acid|Folic acid tablets 5 mg
223949417|NCT01583959|DRUG|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
223949418|NCT04396938|DRUG|Lamotrigine|Active Drug Capsule
223949419|NCT04396938|DRUG|Placebos|Placebo Capsule
223949420|NCT03681366|DEVICE|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
223949421|NCT03695757|BIOLOGICAL|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
223949422|NCT03695757|BIOLOGICAL|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
223949423|NCT01075152|DRUG|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
223949424|NCT01075152|BIOLOGICAL|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
224100953|NCT06487052|COMBINATION_PRODUCT|Standard Catheter-Directed Low Dose Thrombolysis|Using femoral or jugular vein access the mechanical blood clots fragmentation by PigTail 6F catheter circular rotational movements. For unilateral thromboembolism, the PigTail catheter is positioned in the obstructed branch of the pulmonary artery, 1 mg of alteplase is injected as a bolus, followed by a micro-jet injection of 1 mg/hour. For bilateral thromboembolism, the PigTail catheter is positioned in the pulmonary trunk with a bolus of 2 mg alteplase followed by an infusion of 2 mg/hour. The total duration of infusion will be 9 hours, the total dose of alteplase will be 10 mg for unilateral lesions and 20 mg for bilateral lesions. During the alteplase infusion, unfractionated heparin is continued with a target activated partial thromboplastin time (aPTT) of 50 to 60 seconds. After completion of the procedure, UFH therapy is continued for 24 hours, followed by a change to oral anticoagulants.
224100954|NCT06487052|DRUG|Standard Anticoagulation|Therapy with UFH with targeted аPTT lasts for 24 hours (no more than 48 hours in total). Then the change to oral anticoagulants is performed
224100955|NCT02872103|DRUG|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
224100956|NCT02872103|DRUG|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
224100957|NCT00294151|PROCEDURE|Vertebroplasty|
224100958|NCT01867489|OTHER|No intervention|
224100959|NCT01855230|DRUG|ASM-024|ASM-024 b.i.d for 14 days
224100960|NCT01855230|DRUG|Placebo|Placebo b.i.d. for 14 days
223722245|NCT06969638|BEHAVIORAL|Many Likes|"Food ads that have many likes"
224100961|NCT01160731|DRUG|cisplatin|
224100962|NCT01160731|DRUG|etoposide phosphate|
224100963|NCT01160731|DRUG|panobinostat|
224100964|NCT01160731|OTHER|laboratory biomarker analysis|
224100965|NCT01160731|OTHER|pharmacological study|
224100966|NCT04940923|DIAGNOSTIC_TEST|MRI|"T2 weighted and DTI MRI images of brachial plexus and wrist. Quantitative sensory tests include warm and cold detection and pain thresholds, paradoxical heat sensation, mechanical detection thresholds, mechanical pain sensation and thresholds, wind up ratios, vibration thresholds and pressure pain thresholds.~Clinical tests include standard neurological tests and test for heightened nerve mechanosensitivity.~Blood serum to analyse inflammatory proteins. Questionnaires include neck disability index, painDETECT, PTSD8, pain catastrophising scale, eq-5D-5L, DASS 42 and global perceived recovery"
224100967|NCT03369847|DRUG|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
224100968|NCT05611138|DIETARY_SUPPLEMENT|Protein supplementation|Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
224100969|NCT03444337|DEVICE|Catheter Ablation|
224100970|NCT03795350|DRUG|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
223949425|NCT03700034|OTHER|mHealth Integrated Model of Antenatal Care|"In the intervention facilities, antenatal care (ANC) will be provided to all pregnant women using the mIRA electronic decision support system (EDSS) by ANMs (Auxiliary Nurse Midwife), Staff nurses, or Medical Officers (MOs). These frontline healthcare workers (FHWs) will be trained to use the EDSS and will also be provided refresher training on the guideline-recommended processes of ANC. This training will enable them to use the mIRA EDSS in the provision of ANC. Non-physician FHWs (ANMs and staff nurses) will screen, detect, and refer PIH, GDM, and severe anemia cases. They will not prescribe treatments, but will carry out all other duties including diagnosis, referral to the MO to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans."
224100971|NCT00861185|DRUG|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
224100972|NCT00861185|DRUG|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
224100973|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Amygdala|Low intensity focused ultrasound pulsation will be administered to the amygdala in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 10Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the amygdala and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
223537358|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
224100974|NCT03717922|DEVICE|Low Intensity Focused Ultrasound Pulsation to Entorhinal Cortex|Low intensity focused ultrasound pulsation will be administered to the entorhinal cortex in 10 sonications at 650kHz, ispta 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5% duration 30s, with 30s spacing between sonications. Prior to receiving LIFUP sonication, the LIFUP transducer will be aimed at the entorhinal cortex and gently strapped in place to their head. Participants will then return to the scanner where a T1 image will verify the position of the LIFUP transducer and allow for estimation of the spatial location of the sonication beam focus. If needed, adjustments to transducer placement will be made to ensure that the beam focus is correctly aimed; an additional T1 will be collected after adjustment. Once correct placement of the transducer has been confirmed, LIFUP will be administered.
224100975|NCT01671410|DRUG|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
224100976|NCT01671410|DRUG|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
224100977|NCT01563601|DRUG|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
224100978|NCT01563601|DRUG|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
224100979|NCT05565924|OTHER|Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (100% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
224100980|NCT05565924|OTHER|Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (70% weight-bearing) plus medications plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
224100981|NCT05565924|OTHER|Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (50% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)"
224100982|NCT05565924|OTHER|Group- D (30% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks.|"Moderate-intensity aerobic exercise training on the antigravity treadmill (30% weight-bearing) plus medications (Biguanide alone or Sulfonylureas plus Biguanide combination)."
224100983|NCT05565924|OTHER|Group- E; Control group|"Control: No aerobic exercise training on the antigravity treadmill, but only medications (Biguanide alone or Sulfonylureas plus Biguanide combination) throughout the study."
224100984|NCT00290472|DRUG|temsirolimus|
224100985|NCT04112758|OTHER|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
224100986|NCT04223089|DIAGNOSTIC_TEST|Near Infrared Spectroscopy|"The Kent Camera is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports an approximate value of the following in superficial tissue:~* oxygen saturation (StO2),~* relative oxyhemoglobin level (HbO2), and~* relative deoxyhemoglobin (Hb) level~The Kent Camera displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. The Kent Camera is indicated for use to determine oxygenation levels in superficial tissues."
224100987|NCT04194931|BIOLOGICAL|Autologous BCMA CAR-T cells and CD19 CAR-T cells|Autologous BCMA CAR-T cells and CD19 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
224100988|NCT06380998|DIETARY_SUPPLEMENT|whey protien|Whey, the supernatant of yogurt and a byproduct of cheese, is rich in protein and consists of β-lactalbumin, α-lactoglobulin, immunogloblin, bovine serum albumin, and other minor proteins. Whey protein is a globally consumed food material and is well known for its health benefits
224100989|NCT03767738|DRUG|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
224100990|NCT01718717|OTHER|Thoracic Epidural Analgesia (TEA)|
223722246|NCT06969638|BEHAVIORAL|Few Likes|"Food ads that have few likes"
224100991|NCT01718717|OTHER|TEA followed by Intravenous morphine|
224100992|NCT04250805|DRUG|Lidocaine|Patients will receive Lidocaine during percutaneous gastrostomy under radiological guidance.
224100993|NCT04250805|DRUG|Ropivacaine|Patients will receive Ropivacaine during percutaneous gastrostomy under radiological guidance.
224100994|NCT01837082|DRUG|ferric carboxymaltose|
224100995|NCT01837082|DRUG|Placebo|
223949426|NCT04263740|PROCEDURE|Kinesio Taping|Taping for 3 days every week and two sessions of PT twice a week. The PI also instructed the patient to inform him if the tape gets off or become loose. KT was removed after 72 hours, and then reapplied after a few days rest to allow the skin to recover and to avoid skin irritation. The patient was instructed to refrain from getting the tape wet for 30 to 45 minutes after application to allow for better adherence. Patients were also instructed to be careful during dressing and undressing so the tape does not get caught with their clothes if the edges of the tape get slightly loose. No physical therapy treatment or taping was provided during the rest period except for the prescribed home exercise program. Patients in both groups received the same traditional physical therapy treatment two times a week.
223722247|NCT01503918|DRUG|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
223722248|NCT01503918|DRUG|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
223949427|NCT04263740|PROCEDURE|Traditional Physical therapy|Traditional physical therapy was in the form of patient education, manual therapy and therapeutic exercises. Patient education focused on the natural history of the condition and its favorable prognosis, positive thinking, and encouragement of activity participation. Patient education was delivered through one-on-one discussion by the principal investigator.
223949428|NCT05696405|PROCEDURE|VATS resection of MEPA|VATS resection of mediastinal parathyroid adenoma
223949429|NCT03846037|OTHER|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
223722249|NCT01794884|DRUG|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
223949430|NCT03846037|OTHER|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
223949431|NCT03080350|DRUG|Fentanyl sublingual|Fentanyl sublingual
224100996|NCT00427661|OTHER|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
224100997|NCT06468202|DRUG|Aspirin 81 mg|Participants will be assigned to 81mg Aspirin
224100998|NCT06468202|DRUG|Aspirin 162 mg|Participants will be assigned to 162mg Aspirin
224100999|NCT03624998|OTHER|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
224101000|NCT02417415|OTHER|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at \~44ºC continuously for 2 hr.
224101001|NCT02417415|OTHER|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
224101002|NCT01982110|BEHAVIORAL|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
224101003|NCT01982110|BEHAVIORAL|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
224101004|NCT06553781|DRUG|Temozolomide、Fruquintinib、Cadonilimab|"Combination treatment period:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; Temozolomide: 150\~200mg/m2, poqd, d1-5, q4W; The combined treatment lasted 6 cycles.~Maintenance treatment:~Fruquintinib: 4mg d1-21, po qd q4w; Cadonilimab 6mg/kg, ivgtt q2w; The maximum duration of maintenance treatment is not more than 2 years."
224101005|NCT06962475|OTHER|Podiatric advice|A podiatrist with 11 years of clinical experience will take the negative foot impressions using a semi-weightbearing method with a foam box for both groups to ensure adequate blinding of participants. Then, the foam boxes of the experimental group will be scanned so that the FOs can be 3D printed. Both groups will receive identical clinical guideline-based information and support at the beginning of the trial. The instructions will be as follows: (1) undertake a familiarization protocol of 14 consecutive full days (2) wear the FOs (customized or sham) at all time when they are standing (targeted minimum of 5 hours per day), (3) avoid positions that cause the metatarsophalangeal joints to dorsiflex (e.g., squatting or tiptoeing), (4) mechanical stress load management according to the tissue stress model, (5) do not walk barefoot and (6) wear shoes with good cushioning in which the FOs will be properly placed.
223722250|NCT01794884|DRUG|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
223949432|NCT03080350|DRUG|Fentanyl ev|Fentanyl ev
223949433|NCT03080350|DRUG|Placebo sublingual|Placebo sublingual
223949434|NCT03080350|DRUG|Placebo ev|Placebo - NaCL 0,9% ev
223949435|NCT02339519|DEVICE|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
223949436|NCT02339519|DEVICE|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
223949437|NCT02339519|DEVICE|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
223949438|NCT04885166|OTHER|Web-based placebo presentation|This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
223949439|NCT04885166|BEHAVIORAL|Web-based simulation active intervention|This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
223949440|NCT03182816|BIOLOGICAL|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
223949441|NCT07011862|BEHAVIORAL|Cancer, Older adults, Balance and Resistance Activities|The COBRA intervention is delivered as a web-based application through an iPad configured to allow access only to the study application and Zoom videoconferencing icons during the trial.
223949442|NCT07014189|DRUG|Neviparine (NVP)/ Lamivudine (3TC)|Treatment with nevirapine (400mg retard) and lamivudine (300mg) once daily
223949443|NCT07013448|OTHER|Foot scan|This does not constitute a intervention but all participants will undergo image scans of their ulcer
223949444|NCT07013188|OTHER|Neuromuscular function|Assessing their neuromuscular abilities using some functional and electromyography assessments
223949445|NCT06683209|DIAGNOSTIC_TEST|Schocket scleral depressor|Use of this instrument to examine one eye
223949446|NCT06683209|DIAGNOSTIC_TEST|Josephberg-Besser|Use of this instrument to examine one eye
223949447|NCT06683209|DIAGNOSTIC_TEST|Cotton tip applicator|Use of this instrument to examine one eye
223949448|NCT07012109|DRUG|BEBT-507 Injection|The initial dose of BEBT-507 injection is 1.25mg/kg, administered subcutaneously at 1.25mg/kg, 2.5mg/kg, 5mg/kg, 10mg/kg or 15mg/kg every 12 weeks for two doses in total.
223949449|NCT07013942|PROCEDURE|Dry Needling Group|Group A, which will be considered the interventional group. This group will be receiving the dry needling along with the PNF techniques for spasticity and functional performance.
223949450|NCT07013942|PROCEDURE|Sham Needling Group|Group B, which will be considered the control group. This group will be receiving sham needling in addition to the PNF techniques for spasticity and the functional performance
223949451|NCT07012473|BEHAVIORAL|Nutrition education on green leafy vegetables and legumes|The nutrition education intervention will be based on the Theory of Reasoned Action, Social Cognitive Theory, and the Health Belief Model to influence key behaviour change factors such as knowledge, attitudes, practices, and beliefs. Educational materials will include stickers featuring indigenous green leafy vegetables, legumes, and vitamin C-rich fruits, with information on their benefits, storage, preparation, and the importance of combining them for enhanced iron absorption. Other materials include videos, messages, and affirmative words on iron deficiency and its prevention. The intervention will be delivered to selected households in the intervention community through biweekly meetings and phone calls over six months. The control community will not receive any intervention from the researcher.
224101006|NCT06962475|OTHER|Customized foot orthoses|The customized foot orthoses will be manufactured with a Nylon-11 shell with 6° medially wedged forefoot-rearfoot posts (2.6 mm if the participants' weight (PW) is inferior or equal to 45 kg; 3.2 mm if 45\<PW\<100 kg; 4.0 mm if PW\>100 kg), a full-length 3 mm Poron top cover and a metatarsal pad (15 shore A) located 5 mm proximal to the metatarsal heads.
223537359|NCT02581891|DRUG|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
223537360|NCT03767543|DRUG|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
223537361|NCT02507154|DRUG|Cetuximab + NK cells|
223537362|NCT03313830|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
223537363|NCT03313830|DIETARY_SUPPLEMENT|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
223537364|NCT00364247|DRUG|CG5503 IR;tapentadol|
223537365|NCT05029310|DRUG|Patiromer Oral Product|interaction study
223537366|NCT04698304|PROCEDURE|endovascular treatment|All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
223537367|NCT06174740|BEHAVIORAL|Music-cued audiovisual motor training|In addition to visual cues, music stimuli guide finger sequence movement both rhythmically (temporal component) and sonically (pitch-finger alignment).
223537368|NCT06174740|BEHAVIORAL|Visually-cued motor training|Visual cues guide finger sequence movement by indicating which finger to move in alignment with the position and of the visual cue.
223949452|NCT07013552|DRUG|Administration of a single or repeated dose of a long half-life antibiotic - oritavancin|"Intravenous administration of a single or repeated dose of lipoglycopeptide antibiotic - oritavancin.~In superficial ABSSSI or PI: Single dose of 1,200 mg (3 vials) administered as a 3-hour intravenous infusion in 5% glucose solution.~In LRIE: First dose of 1,200 mg (3 vials) administered as a 3-hour intravenous infusion in 5% glucose solution, subsequent doses of 800 mg (2 vials) administered as a 2-3 hour intravenous infusion at 7-day intervals, to achieve the required duration of drug therapy of 2-6 weeks (counted from the day of transvenous lead extraction)."
223949453|NCT07013552|DRUG|Administration of a repeated dose of a short half-life antibiotic - vancomycin|"Intravenous administration of repeated doses of glycopeptide antibiotic - vancomycin.~Repeated doses of 15-20 mg/kg body weight every 8-12 hours administered as an hourly intravenous infusion in 0.9% sodium chloride solution, under monitoring the drug concentration in serum, for 7-10 days in ABSSSI, for 10-14 days in PI, and for 2-6 weeks in LRIE (counted from the day of transvenous lead extraction)."
223949454|NCT06866678|PROCEDURE|Observational Data Collection|No intervention will be performed as part of this study. This is an observational study; all patients will receive standard perioperative care according to current clinical practice. The study will only observe and record data related to frailty status and postoperative outcomes in patients undergoing elective colorectal cancer surgery. No experimental procedures, drugs, or additional interventions will be administered.
223949455|NCT06874504|DEVICE|Norbert Device|The Norbert Device (ND) is a contactless, noninvasive device that provides measurements of pulse rate.
223537369|NCT06121895|OTHER|Video Laryngeal Mask|Patients who are intubated using Video Laryngeal Mask for intubation purposes will be included.
223537370|NCT06121895|OTHER|Fastrack Laryngeal Mask|Patients who are intubated using Fastrack Laryngeal Mask for intubation purposes will be included.
223537371|NCT03856866|DRUG|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
223537372|NCT03856866|DRUG|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
223537373|NCT01425476|DRUG|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
223537374|NCT01425476|DRUG|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
223537375|NCT01425476|DRUG|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
223537376|NCT01808469|BIOLOGICAL|Monoclonal antibody|
223537377|NCT02249403|DRUG|Talsaclidine 6 mg|
223537378|NCT02249403|DRUG|Talsaclidine 12 mg|
223537379|NCT02249403|DRUG|Talsaclidine 24 mg|
223537380|NCT02249403|DRUG|Talsaclidine 36 mg|
223537381|NCT02249403|DRUG|Placebo|
223537382|NCT01726374|DRUG|BEP(500)|"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
223537383|NCT05819762|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab LS screening panel on a specified Flow Cytometry
223537384|NCT03440008|OTHER|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
223949456|NCT07013097|DRUG|PG-033|Oral tablets (2mg， 10mg)
223949457|NCT07013097|DRUG|PG-033 placebo comparator|Oral tablets (2 mg, 10 mg) (matching corresponding study medication)
223949458|NCT07012551|PROCEDURE|Common iliac artery stenting|Stenting of common iliac artery by balloon mounted stent
223949459|NCT07013123|DRUG|Tezepelumab|"Patients will take Tezepelumab for 3 to 6 months (M-3/-6) to control asthma symptoms.~Once asthma symptoms are controlled (D0), patients will take an additionnal of 18 months of Tezepelumab"
223949460|NCT07013123|DRUG|Acarizax|Once asthma symptoms are controlled (D0), patients will take 18 months of Acarizax.
223949461|NCT07013123|DRUG|Placebo|Once asthma symptoms are controlled (D0), patients will take 18 months of Placebo.
223949462|NCT06223633|DEVICE|PK Papyrus Covered Coronary Stent System|PK Papyrus Covered Coronary Stent System has been approved for use in the treatment of free perforations, defined as free contrast extravasation into the pericardium, in native coronary vessels or saphenous vein bypass grafts greater than or equal to 2.75mm in diameter.
223949463|NCT05430841|DIAGNOSTIC_TEST|18F-FDG, 18F-AlF-FAPI PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 18F-AlF-FAPI, and undergo PET/CT imaging within the specified time.
223949464|NCT06698354|DEVICE|Virtual Reality-Assisted Hypnotherapy|Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic low back pain.
223949465|NCT06698354|OTHER|Standard Physical Therapy|Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
223949466|NCT07034365|OTHER|No intervention|No intervention
223949467|NCT06883110|DRUG|Z11020076|Beijing Tongrentang Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.
223537385|NCT03440008|DEVICE|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
223537386|NCT04700423|DRUG|moxidectin (8 mg) / albendazole (400 mg)|Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
223537387|NCT04700423|DRUG|ivermectin (200 µg/kg) / albendazole (400 mg)|Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
223537388|NCT04700423|DRUG|ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]|Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
223537389|NCT04700423|DRUG|ivermectin (200 µg/kg)|Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
223949468|NCT06883110|DRUG|Z20063878|Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd. Angong Niuhuang Pills (3g once daily as a single dose) for 7 consecutive days.
223537390|NCT04700423|DRUG|moxidectin (8 mg)|Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
223537391|NCT02958345|BIOLOGICAL|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
223949469|NCT07044193|DRUG|pipecuronium bromide|Investigation of muscle relaxation with pipecuronium bromide
223537392|NCT02958345|OTHER|Placebo|Injection of 0.65 mL of sterile normal saline
223537393|NCT03735732|BEHAVIORAL|prime|groups be confronted with health or palatability aspects of food items
223537394|NCT05450211|DEVICE|Low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy)|A low frequency convex probe (ESAOTE Fixed Color Doppler Ultrasonography Device, Italy) device will be used while blocking in group SFI.
223537395|NCT05450211|DEVICE|Patient controlled analgesia|Patient-controlled analgesia will be used for pain control after surgery in both groups.
223537396|NCT03419494|DRUG|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
223537397|NCT03419494|DRUG|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
223537398|NCT03132987|OTHER|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
223949470|NCT07044193|DRUG|Rocuronium bromide|Muscle relaxation with rocuronium as a control
223949471|NCT07045909|DRUG|Daratumumab|Daratumumab will be administered by subcutaneous (SC) injection.
223949472|NCT07045909|DRUG|Isatuximab|Isatuximab will be administered IV.
223722251|NCT02717585|DEVICE|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
223949473|NCT07045909|DRUG|Bortezomib|Bortezomib dose will be calculated using the patient's actual body surface area at baseline and will be administered by SC injection.
223949474|NCT07045909|DRUG|Lenalidomide|Lenalidomide will be administered by oral route (all cohorts at induction, and cohorts A and B at maintenance).
223949475|NCT07045909|DRUG|Cyclophosphamide|As part of lymphodepleting therapy before CAR-T manufacture, administered IV.
223949476|NCT07045909|DRUG|Fludarabine|As part of lymphodepleting therapy before CAR-T manufacture, administered IV
223949477|NCT07045909|DRUG|Anitocabtagene Autoleucel|Single infusion IV
223722252|NCT06584552|DIETARY_SUPPLEMENT|Lactobacillus Paracasei LPB27|Probiotic
223722253|NCT06584552|OTHER|Maltodextrin|Placebo
223722254|NCT04170153|DRUG|M1774|M1774 will be administered orally throughout the study.
223722255|NCT04170153|DRUG|Niraparib|Niraparib will be administered orally throughout the study.
223949478|NCT07050732|BIOLOGICAL|Arexvy (2 doses total)|Arexvy at enrollment, Arexvy at Day 365
223949479|NCT07050732|BIOLOGICAL|Arexvy (3 doses total)|Arexvy at enrollment, Day 60, and Day 365
223949480|NCT07050732|BIOLOGICAL|Arexvy (1 dose total)|Arexvy at enrollment
223949481|NCT07050732|OTHER|Placebo|Placebo vaccine at day 60
223949482|NCT07052747|OTHER|Clinical periodontal assessment|Comprehensive site-level and full-mouth evaluations of periodontal parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), recession depth (RD), bleeding on probing (BOP), keratinized tissue width (KTW), mucosal phenotype, mucosal redness (MR), mucosal discomfort (MD), and torque gauge (TG) measurements.
223949483|NCT07052838|DRUG|HSK39297 tablets|200mg QD
223949484|NCT07052851|DEVICE|CCoat, Liposphere Ltd|a single IA injection of 4 ml CCoat
223949485|NCT07052851|DEVICE|Synvisc-One® (hylan G-F 20)|Group 2 (Active Comparator): a single IA Synvisc-One® (hylan G-F 20) of 6 mL, Genzyme Corporation
224101007|NCT06962475|OTHER|Sham foot orthoses|The molded sham FOs will be manufactured from 3 mm ethylene vinyl acetate. They will have an identical top cover material, color and a similar shape than the customized FOs, however, they will provide negligible mechanical support, considering the very low stiffness of their medial arch. The only impact of these FOs on plantar pressure is under the heel. These devices have been used as a sham condition in previous trials and a study has validated them as being credible.
223949486|NCT06782178|PROCEDURE|Arthroscopic lysis and lavage|Arthroscopic lysis and lavage refers to an arthroscopic procedure where the temporomandibular joint is rinsed with saline solution and where the joint capsule is distended and where adhesions are lysated bluntly.
223949487|NCT06782178|PROCEDURE|Arthrocentesis/Saline|Arthrocentesis refers to a blind irrigation of the temproromandibular joint with saline solution
223949488|NCT07052721|DEVICE|Experimental Treatment|Percutaneous peripheral nerve stimulation with a frequency of 100 Hz, a pulse duration of 100 µs, and a current amplitude of 0.001-10 mA (1-10,000 µA). Participants will adjust the amplitude, as needed.
223949489|NCT07052721|DEVICE|Sham Comparator|SHAM percutaneous peripheral nerve stimulation with a frequency of 100 Hz, a pulse duration of 100 µs, and a current amplitude of 0.001-10 mA (1-10,000 µA). Participants can adjust the amplitude, as needed; but no electrical current will ever reach the patient's body.
223949490|NCT07099950|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, administered as a single dose (1-epoch), or in multiple doses (3-epoch).
223949491|NCT07097922|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops were instilled into the inferior conjunctival vault of both eyes
223949492|NCT07097922|DRUG|0.1% hyaluronic acid|0.1% sodium hyaluronate eye drops were instillation into the inferior conjunctival vault of both eyes
223949493|NCT07099664|DIAGNOSTIC_TEST|Measurement of aortic Vmax and VTI with suprasternal doppler.|Measurement of aortic Vmax and VTI with suprasternal doppler. Measurement of VTI variation and cardiac output after general anaesthesia. After preoperative fasting compensation, measurement of cardiac output (CO). Search of a difference in the suprasternale VTI variability between the patients who have increased their CO after fasting compensation and the patient who haven't.
223949494|NCT07098728|DRUG|Levetiracetam IV|Leveget injection 500mg/5ml
223949495|NCT07098728|DRUG|Phenobarbital|Phenobarbital injection 200mg/ml (BPI Insein)
223537399|NCT05338073|DIAGNOSTIC_TEST|Known 3Dx Test|Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
223949496|NCT07099378|OTHER|Saliva and Serum|Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes. Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff from each participant.Saliva and serum were then stored at -80 °C until analysis.
223949497|NCT07099378|OTHER|Saliva and Serum|ELISA method will be used to measure TNF-α values in collected saliva and serum samples.RT-qPCR based miRNA gene expression analyses will be performed with 2-step qRT-PCR Kits (Thermofisher Scientific, MA, USA).
223949498|NCT05523505|DEVICE|Sham intervention|Use of the non-invasive brain stimulation device to simulate peripheral experience of stimulation without actually stimulating the brain.
223949499|NCT05523505|DEVICE|RLN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left angular gyrus using transcranial alternating current stimulation (tACS).
223949500|NCT05523505|DEVICE|RLN and CCN real non-invasive brain stimulation intervention|Real non-invasive brain stimulation to the left dorsolateral prefrontal cortex and left angular gyrus using transcranial alternating current stimulation (tACS).
223949501|NCT04094675|DRUG|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
223537400|NCT01775384|DIETARY_SUPPLEMENT|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
223537401|NCT01775384|DIETARY_SUPPLEMENT|Placebo|
223537402|NCT04605666|BIOLOGICAL|CD19-CAR-T2 Cells|CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
223537403|NCT03360994|OTHER|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
223537404|NCT03360994|OTHER|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
223537405|NCT03498716|DRUG|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
223537406|NCT03498716|DRUG|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.
223537407|NCT03498716|DRUG|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses"
223537408|NCT03498716|DRUG|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
223537409|NCT05337566|DRUG|Azithromycin Pill + Cefuroxime|Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
223537410|NCT05337566|DRUG|Placebo + Cefuroxime|Placebo (2 tablets) per orally in the evening when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
223949502|NCT06941792|DRUG|inclisiran sodium injection|After randomization, patients in the inclisiran group will receive inclisiran sodium injection
223949503|NCT06941792|COMBINATION_PRODUCT|Standard of Care|After randomization switching to or adding on another/other lipid-lowering therapies
223949504|NCT04742894|BEHAVIORAL|Visual Feedback Training|Participants will be trained to work with a computer setup to control the position of a visual cursor on the screen using their speech while their auditory feedback is altered. The goal of the training is to help improve speech production and motor control ability.
223537411|NCT05613816|PROCEDURE|Senhance Surgical System|100 patients affected by uterine diseases with indication for hysterectomy undergo treatment with robotically assisted laparoscopic procedures using the Senhance Surgical System
223949505|NCT03425461|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
223949506|NCT03425461|BIOLOGICAL|Ipilimumab|Given IV
223949507|NCT03425461|OTHER|Laboratory Biomarker Analysis|Correlative studies
223949508|NCT03425461|BIOLOGICAL|Nivolumab|Given IV
223949509|NCT03425461|OTHER|Pharmacological Study|Correlative studies
223949510|NCT06170983|DRUG|Azithromycin|500 mg once daily for 3 days
223949511|NCT06170983|DIAGNOSTIC_TEST|Biopsy|Skin punch biopsy
223949512|NCT06170983|OTHER|Skin inflammation model|LPS- or imiquimod induced skin inflammation
223949513|NCT02316821|DRUG|RTA 402|
223949514|NCT02316821|DRUG|Placebo|
223949515|NCT03297593|DRUG|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
223537412|NCT06029790|OTHER|gum chewing|For the patients in the experimental group, sugar-free xylitol gum containing 1.2-1.37 grams of xylitol per piece, available in the market, will be used. Participants in the experimental group will start chewing gum on the first postoperative day and will be allowed to chew a single piece of gum 3 times a day at 9:00, 14:00 and 19:00, respectively, for 15 minutes. The gum will be given to the participants regularly by a researcher until the first reported flatulence.
223722256|NCT06444464|OTHER|Aerobic exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of aerobic exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
223722257|NCT06444464|OTHER|Isometric exercise|After baseline 24-hour blood pressure measurements are taken at visit 2, participants will attend a final study visit where they will engage in a single session of isometric exercise. The exercise routines will include 5 to 10-minute warm-up and cool-down periods, along with a 30-minute workout. Twenty-four hour blood pressure measurements will be taken after the exercise bout.
223722258|NCT05542576|DRUG|AMDX2011P|AMDX2011P single bolus injection intravenous for diagnostic review
223722259|NCT05076630|OTHER|Air pollutants|Particulate matter and gaseous pollutants
223722260|NCT00704054|DRUG|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
223722261|NCT06360562|BEHAVIORAL|Resilience Training|Behavioral group-based intervention delivering mindfulness, metallization, and self-compassion skills.
224101008|NCT06091423|DRUG|XELOX combined with Fruquintinib and Sintilimab|XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
224101009|NCT00450606|PROCEDURE|Balneotherapy and hydrotherapy|
223537413|NCT02702050|OTHER|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
223722262|NCT05733221|DEVICE|3D Printed Model|3D Printed Model generated pre-operatively of the patients mandible.
223722263|NCT05980182|BEHAVIORAL|mHealth Application|Self-directed application (app) that is downloaded to the participant's personal device. The app contains five informational videos, that provide an orientation to the content on the app, and discuss what colorectal cancer is, and the type of CRC screening tests that are available as well as a video with a personal history. There is a a National Cancer Institute (NCI) risk calculation tool, and a family history infographic. Once the videos have been viewed participants have the option to indicate if they wish to receive a call from the healthcare clinic to discuss scheduling an appointment for screening.
223722264|NCT03076697|DIAGNOSTIC_TEST|Fundus photography|Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
223722265|NCT06436547|DEVICE|Subiculum-DBS ON|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral subiculum.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
223722266|NCT03107780|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223722267|NCT03107780|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223722268|NCT03107780|DRUG|Navtemadlin|Given PO
223722269|NCT03107780|RADIATION|Radiation Therapy|Undergo radiation therapy
223722270|NCT05226117|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 7.5 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
223722271|NCT03752827|DEVICE|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
223722272|NCT03752827|DRUG|Corticosteroid|Corticosteroid injection into subacrominal space
223949516|NCT03297593|DRUG|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
224101010|NCT03567577|DRUG|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
224101011|NCT03567577|DRUG|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
223722273|NCT03730181|DRUG|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
223537414|NCT02702050|OTHER|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
223537415|NCT00212602|DRUG|ONO-7436|
223537416|NCT04588142|DIETARY_SUPPLEMENT|Probiotic|Non-elite athletes receive probiotic for 6 weeks
223722274|NCT03730181|DRUG|Isoniazid|Isoniazid. 25mg/kg
223537417|NCT04588142|DIETARY_SUPPLEMENT|Placebo|Non-elite athletes receive placebo for 6 weeks
223722275|NCT03385993|DEVICE|Technology based guided meditation and relaxation|Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
223722276|NCT05403450|DRUG|Tolinapant|Capsule for oral administration
223722277|NCT05403450|DRUG|Decitabine + Cedazuridine|Tablet for oral administration
223722278|NCT04375033|DRUG|Sublingual buprenorphine with naloxone|The combination SL-containing buprenorphine contains naloxone in a ratio of 4:1 buprenorphine:naloxone. Participants will be given a 28-prescription at each 28-day visit through Week 48.
223722279|NCT04375033|DRUG|Injectable subcutaneous buprenorphine|Injectable buprenorphine consists of a depot injectable formulation in polymeric solution and releases buprenorphine over a 28-day (4-week) period by diffusion as the polymer biodegrades. The injection will be administered subcutaneously in the abdomen at each 28-day visit through Week 48.
223722280|NCT04566380|DRUG|ONO-4538|IV infusion over 30 minutes
223722281|NCT04566380|DRUG|oxaliplatin|IV infusion over 2 hours
223722282|NCT04566380|DRUG|S-1|Administered orally twice daily
223722283|NCT04566380|DRUG|capecitabine|Administered orally twice daily
223537418|NCT00265850|BIOLOGICAL|bevacizumab|Given IV
223537419|NCT00265850|BIOLOGICAL|cetuximab|Given IV
223537420|NCT00265850|DRUG|FOLFOX or|Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours
223722284|NCT04566380|DRUG|bevacizumab|IV infusion over 30 minutes
223722285|NCT04566380|DRUG|temozolomide|Administered orally once daily for 5 days every 28 days
223722286|NCT00659997|DRUG|Albendazole|Single oral dose of 400mg
223722287|NCT00659997|DRUG|Levamisole|Single oral dose of 2.5mg/kg
223722288|NCT03291730|BEHAVIORAL|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
223722289|NCT03291730|OTHER|Art-therapy|May help reduce anxiety of receiving chemotherapy
223722290|NCT05491109|DEVICE|Venous Assistance and Contracture Management System (VACOM)|Mimic therapist-assisted on bed passive ankle exercises to preclude the development of ankle joint contracture and facilitate venous flow in lower extremities to reduce DVT risk. Using soft pneumatic extension actuators, which is capable of providing robot-assisted ankle exercises, specifically dorsiflexion-plantarflexion and inversion-eversion movements. Through these natural movements to improve blood flow and venous return and maintain ankle joint flexibility. Furthermore, it can facilitate and stimulate the neurologic recovery in walking by early mobilization.
223722291|NCT03996252|DRUG|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
223722292|NCT03996252|DRUG|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
223949517|NCT04276740|DIETARY_SUPPLEMENT|MitoQ|"MitoQ in inflammation: In the experimental setting, MitoQ has been extensively studied with clear mode of action on inflammatory mechanisms relevant to IBD:~* MitoQ can limit the damage to mitochondria caused by mitochondrial ROS and thereby reducing the leak and oxidisation of mtDNA that are critical to its pro-inflammatory actions within the cell.~* MitoQ reduces the inflammatory potential of mitochondrial DNA which have escaped or released from dying inflammatory cells.~* MitoQ can influence how the immune cells generate their energy, diverting it away from a more inflammatory type of metabolism (glycolysis)~* MitoQ can induce autophagy, a cellular recycling mechanism that removes damaged mitochondria. Defective autophagy is heavily implicated in the pathogenesis of IBD.~* Hence collectively, MitoQ acts upstream of several pro-inflammatory mechanisms with the net effect to promote resolution of inflammation and mucosal healing."
223949518|NCT04276740|OTHER|Placebo|Placebo
223722293|NCT07131410|OTHER|Group hialuronyc|Patients will receive the container with cream for application on both feet after thoroughly washing and drying them. It is recommended to use an amount the size of a hazelnut for each foot, spreading it in a thin layer over the entire foot, excluding the interdigital area. The application will be done every night for twelve months. The product will be massaged into the foot for 15 seconds. During the study, participants will not be allowed to use any other topical product (cream, emulsion, gel, lotion, or oil) on their feet and/or nails.
223722294|NCT07131631|DIAGNOSTIC_TEST|Cardiac MRI|Clinically indicated baseline CMR study with contrast up to 90 days before TEER procedure, including KCCQ questionnaire. At 6 months, participants will return for repeat of KCCQ, CMR study and a transthoracic echocardiogram. Blood samples, done as standard clinical care for hemotocrit for ECV calculation, will be obtained.
223722295|NCT05475236|BEHAVIORAL|Experimental: Locomotor Learning|Participants will undergo four sessions of locomotor and turn learning. Locomotor learning will involve practicing walking over different terrains (i.e., soft and firm mats) and obstacles at different walking speeds (slow or fast) and turning practice at each end of the walking course. The full cohort will undergo either transcranial direct current stimulation or sham stimulation.
223949519|NCT01346826|DRUG|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
223949520|NCT01346826|DRUG|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
223949521|NCT01346826|DRUG|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
224101012|NCT06392919|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS intervention timing: rTMS is applied after the tracheal tube is removed in the PACU. Stimulation site: DLPFC (left dorsolateral prefrontal cortex); Stimulation intensity: 100% RMT; Stimulation frequency: 10Hz; Total number of stimulation pulses: 2000. Pulse characteristics: Each duration lasts 5 seconds, with a 25-second interval.
224101013|NCT05809687|DRUG|DKP21102_C|Placebo
224101014|NCT05809687|DRUG|DKP21102_B|Treatment
224101015|NCT05809687|DRUG|DKP21102_A|Active Control
224101016|NCT01599559|OTHER|observation|observation
223537421|NCT00265850|DRUG|FOLFIRI|Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
223537422|NCT01287299|OTHER|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
223537423|NCT01287299|OTHER|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
223537424|NCT01188967|DRUG|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
223537425|NCT01188967|DRUG|Placebo|Placebo
223537426|NCT03939390|DRUG|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
223537427|NCT04826380|PROCEDURE|Trapeziectomy|Simple trapeziectomy (without LRTI)
223537428|NCT04149743|DIAGNOSTIC_TEST|Standard of Care with Hemotag|Comparison of outcomes
223722296|NCT07131761|OTHER|Tai chi|Yang style of Tai Chi (24 form)
223722297|NCT07131761|OTHER|Moderate-Intensity Combined Exercise (MICE)|start from warm up (5 minute )repetitions in circuit in the exercises bent row with elastic band, bodyweight squats, adapted push-ups (on the wall or on the counter), deadlifts with an elastic band, presses with an elastic band and an abdominal band on the floor or adapted on the chair and cool down in the end
223722298|NCT07131761|OTHER|Control ( No Exercise )|The CON session will last 60 minutes and will be conducted only sitting. Participants will be told not to sleep and will not be allowed to use reading materials or any electrical gadgets during the CON session.
223722299|NCT07131475|DRUG|PBR28 TSPO PET|Each SEAL participant will undergo brain imaging with PBR28 translocator protein (TSPO) positron emission tomography (PET) at study enrollment and at 1-year follow up.
224101017|NCT01599559|RADIATION|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
223722300|NCT07131670|OTHER|Electronic Patient-Reported Outcome Monitoring|Participants complete the MDASI-LC and EQ-5D questionnaires electronically on a weekly basis during CRT and for 12 weeks after CRT. The data are used to evaluate symptom burden, symptom clusters, and symptom trajectories.
223722301|NCT07132359|OTHER|The Body Understanding Measure for Pregnancy Scale|During the study, the purpose of the study was explained to the pregnant women, and it was stated that participation in the study was completely voluntary and that they could leave the study at any time, and their written and verbal consent was obtained (Informed Consent Form). Pregnant women who agreed to participate in the study filled out the data collection forms individually.
223722302|NCT07132242|DRUG|SHR-A1811 4.0mg/kg|SHR-A1811 4.0mg/kg, IV, Day 1, Q3W
223722303|NCT07132242|DRUG|Pyrotinib 240mg|Pyrotinib 240mg, po, QD, from Day 8 to Day 21,Q3W
223722304|NCT07132242|DRUG|SHR-A1811 4.8mg/kg|SHR-A1811 4.8mg/kg, IV, D1, Q3W
223722305|NCT07132242|DRUG|Pyrotinib 320mg|Pyrotinib 320mg, po, QD, from Day 8 to Day 21, Q3W
223722306|NCT07131059|DRUG|Ivosidenib|500mg d1-28
223722307|NCT07131059|DRUG|Gilteritinib|120mg d1-28
223722308|NCT07131059|DRUG|Venetoclax|400mg d1-21 ; 400mg d1-7;400mg d1-28; 600mg d1-21
223722309|NCT07131059|DRUG|Avapritinib|200mg d1-28.
223722310|NCT07131059|DRUG|Daunorubicin|45mg/m2/d d1-2;
223722311|NCT07131059|DRUG|Cytarabine|100mg/m2/d d1-5
224101018|NCT02607527|DEVICE|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
223722312|NCT07131059|DRUG|Idarubicin|10mg/m2/d d1-2
223722313|NCT07131059|DRUG|MTZ|8mg/m2/d d1-2
223722314|NCT07131059|DRUG|HHT|2mg/m2/d d1-5
223722315|NCT07131059|DRUG|Azacitidine|75mgd/m2 d1-7.
223722316|NCT07132099|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|This is a brief, structured, patient-centered therapy consisting of three to four face-to-face sessions. Each session typically lasts between 60 to 90 minutes. A fourth session may be added if clinically necessary.
223722317|NCT07132099|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"This intervention uses the ACT for Life protocol, which is designed to maximize recovery after suicidal crises. It consists of three components delivered over three to six individual sessions. The average number of sessions is four to five, with each session lasting approximately 60 minutes."
223722318|NCT07132099|OTHER|Treatment as Usual (TAU)|Treatment as usual (TAU) is not a structured intervention within this study. It may include standard outpatient or inpatient services, pharmacotherapy, or no structured treatment, depending on individual circumstances.
223722319|NCT06813092|OTHER|Whole-Body Electromyostimulation|20 min of WB-EMS (bipolar, 85 Hz, 350 µs, 6s impulse - 4s impulse break)
223722320|NCT06813092|OTHER|Resistance exercise|High-intensity/high velocity multiple set resistance exercise
223722321|NCT05011422|DEVICE|Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus|Once pheresed, the product will be washed to remove platelets and the cell concentration will be adjusted per laboratory and ClinicMACS technology recommendations. It is then labeled using the CliniMACS αβ-TCR Biotin Kit and CD19+ immunomagnetic microbeads. After labeling, the cells are washed to remove unbound microbeads. The partially processed product is loaded on the CliniMACS device where labeled cells are depleted and the negative fraction is eluted off the device. The negative fraction is centrifuged and volume reconstituted to obtain the final product
223722322|NCT06983041|DEVICE|vaginal cooling device|medical grade polymer capsule filled with inert fluid (15 cc's)
223722323|NCT06443359|RADIATION|hypofractionated radiation|All patients will receive a dose of 42.56 Gy in 16 daily fractions to the whole breast or chest wall and regional lymph nodes. A boost dose of 10 or 12.5 Gy in 4 or 5 daily fractions of 2.5 Gy, respectively, will be administered to either the lumpectomy cavity or mastectomy scar, as appropriate.
223722324|NCT06985108|PROCEDURE|nazotracheal intubation|intubation tube will be placed from nasal orifice through nazopharyngeal pathway to place into trachea
223722325|NCT04309604|BIOLOGICAL|IC14|monoclonal antibody directed against CD14
224287455|NCT06473402|OTHER|Manual Therapy Technique|Anterior and posterior innominate muscle energy techniques were performed on patients. In the anterior technique, the patient lay on their back with their leg on the diagonal shoulder. The clinician flexed the hip and knee, placed their hand on the back thigh, and instructed the patient to push, resulting in hip extension. After eight seconds, the patient inhaled and exhaled. The clinician then increased hip flexion and applied pressure against a new barrier. In the posterior technique, the patient lay on their side in the modified sims position. The clinician held the leg with their caudal hand and placed the hypothenar edge of their cranial hand on the right SIPS. The patient then pulled the leg towards themselves, applying equal counterforce for eight seconds before inhaling and exhaling. Finally, the clinician extended the leg and pushed it against a new barrier.
224287456|NCT06615700|DRUG|NA-931|NA-931 is a quadruple receptor agonist for weight loss
224287457|NCT06615700|DRUG|Placebo|Placebo of NA-931
224287458|NCT00245817|BEHAVIORAL|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
224287459|NCT04328870|OTHER|oxytocin and spinal anesthesia|start oxytocin 10 IU/200 ml saline at the insertion of the spinal anesthesia
224287460|NCT04328870|OTHER|General anesthsia|General anesthesia alone.
224287461|NCT01552369|DRUG|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
224287462|NCT02329119|OTHER|electrophysiological recordings|
223722326|NCT01844440|PROCEDURE|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
223722327|NCT05479474|BIOLOGICAL|Platelet rich plasma|"Patients will undergo a blood draw (12 tsp) to prepare the PRP infusion. The use of a centrifuge and an Arteriocyte Magellan kit are necessary for the PRP preparation. After injection of local anesthesia, PRP will be injected into each testicle.~* On the third month after the testicular PRP procedure, a TESE will be performed~* If the procedure is successful a new IVF cycle using the sperm procured from the procedure will be done."
223722328|NCT06089473|OTHER|Intervention Group: Exercise and education.|"* Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session.~* Education: Prior to each zoom session with the kinesiologist (starting on week 2), participants will watch short educational videos. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress."
224287463|NCT00522990|DRUG|AT9283|Three weekly intravenous administration of AT9283
224287464|NCT00000334|DRUG|Buprenorphine|
224287465|NCT03150355|PROCEDURE|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
224287466|NCT01543555|DRUG|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
224287467|NCT01543555|DRUG|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
224287468|NCT01914523|DEVICE|Macintosh|Laryngeal exposure and tracheal intubation using that device
224287469|NCT01914523|DEVICE|King Vision|Laryngeal exposure and tracheal intubation using that device
224287470|NCT01914523|DEVICE|Glidescope|Laryngeal exposure and tracheal intubation using that device
224287471|NCT01914523|DEVICE|AirTraq|Laryngeal exposure and tracheal intubation using that device
224287472|NCT04174716|DRUG|IDX-1197|Until progression or unacceptable toxicity develops
224287473|NCT00621920|DRUG|FM-601|Dose-escalation, split dosage, liquid
224287474|NCT00110188|DRUG|ridaforolimus|
223722329|NCT06089473|OTHER|Usual Care Only|Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.
223722330|NCT05923866|DRUG|ONO-2808|Oral administration of ONO-2808 at low, middle or high doses once a daily for 24 weeks
224287475|NCT02631837|PROCEDURE|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
224287476|NCT02631837|PROCEDURE|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
223722331|NCT05923866|DRUG|Placebo|Oral administration of placebo once a daily for 24 weeks
223722332|NCT06607432|DEVICE|Transcranial Interference Stimulation (tIS)|Field strength dose of 0.30 - 0.40 V/m
223722333|NCT06607432|OTHER|Sham tIS|Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
223729465|NCT05931159|OTHER|Abdominal Hypopressive Training|"Week 1 and 2 - Patient education , Hypopressive Maneuvers in Standing, Sitting and Supine 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week.~Week 3 and 4, Hypopressive breathing in with varying arm movements along with Week 1 and 2 protocols.~Week 5 to 8 - Hypopressive breathing in kneeling, Four-point kneeling and sitting, and supine positions with varying arm movements 5-7 repetitions x 5 sets, with a 10-second hold each time, rest for 30 seconds between each set, 2 days/week."
224287477|NCT05569330|OTHER|Air purification|Aerosol particles are removed from room air by several methods
224287478|NCT06026852|DEVICE|Prediction of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.
224287479|NCT06026852|DIAGNOSTIC_TEST|Determination of plasma concentration of piperacillin-tazobactam or meropenem|For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
224287480|NCT06026852|OTHER|Daily short questionnaire|Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
223722334|NCT06590285|BEHAVIORAL|App-based Educational Intervention|"The program's educational content is designed to engage patients in the science of sleep and recovery. Segments like The Sleep Adventure demystify complex neurobiological processes in an accessible format, aligning with emerging trends in patient education that focus on engagement and knowledge empowerment. Concurrently, the program's physical activity component is meticulously crafted, offering safe, supportive exercises that correspond with the treatment stages of alloHSCT patients. This aspect draws upon evidence highlighting the importance of sustained physical activity during intensive treatments to enhance overall recovery and quality of life. Additionally, the program comprehensively addresses sleep disturbances, prevalent in HSCT patients, through in-depth exploration and evidence-based, non-pharmacologic management strategies, reflecting the significant impact of sleep quality on patient recovery and long-term health outcomes."
224101019|NCT05511961|BEHAVIORAL|Healthier Wealthier Families|Budget and debt counselling will involve at least one meeting with a counsellor. Examples of assistance the counsellors can offer include: suggestions on ways to improve a participant's financial situation; checking eligibility and helping to apply for social welfare support; helping to organise finances and develop a budget; and assistance with debt management, threatening letters or harassment by debt collectors, or imminent house eviction. The municipal budget and debt counselling services involved in the trial will receive guidance on how to work preventatively with families, which will align with the content of the 'Your child, your money'. The book covers topics such as planning finances, consumer rights, private insurance, family law, parental leave, pensions, saving, and budgeting.
224101020|NCT05796661|OTHER|Effects of increased blood flow during regional anticoagulation with 4% trisodium citrate in patients undergoing continuous venovenous hemodiafiltration|"Patients will be exposed to continuous venovenous renal therapy with distinct blood flows in 2 periods, to be defined by draw. The control group will have a flow of 150ml/min and the intervention group 250ml/min. Therapy is intended for a period of 72 hours (maximum defined by the manufacturer); with a 6-hour washout and, after that, the arm is changed to be exposed to the other blood flow."
223722335|NCT05513859|PROCEDURE|Craniotomy|Undergo craniotomy
224287481|NCT06093087|PROCEDURE|SAIF|The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height
224287482|NCT06093087|PROCEDURE|BKP|The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
224287483|NCT03008239|DEVICE|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
224287484|NCT03008239|DEVICE|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
223722336|NCT05513859|DEVICE|Quantitative Oblique Back-Illumination Microscopy|Undergo intraoperative microscopy utilizing qOBM
223722337|NCT06587399|OTHER|Manual therapy treatment|"Joint mobilization techniques will be applied to the shoulder joint complex, adapted to the subjects' degree of irritability.~The muscular trigger points of the shoulder muscles will be treated using a pressure release technique applied for 60 seconds.~In addition, the subjects will carry out a 12-week home-based therapeutic exercise program."
223729466|NCT05931159|OTHER|Conventional Physical therapy for DrA|"Week 1 to 4, Draw-in maneuver in supine, Quadruped and Prone lying, Bent knee Fallouts and Curl ups. (8 to 12 repetitions x 3 sets, 2 days/week)~Week 5 to 8, Front and side planks added to week 1 to 4 exercises. (12 to 20 repetitions x e sets, 2 days/week)"
224101021|NCT06042049|DRUG|Nirsevimab|Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
224101022|NCT02132390|DRUG|Goserelin|
224101023|NCT02132390|DRUG|Toremifene|
224101024|NCT05206110|DRUG|10 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 10 mg ketorolac (IV). Also, 10 mg IV ketorolac will be given 8h and 16h after the surgery
224101025|NCT05206110|DRUG|30 mg IV ketorolac|Patients undergoing LAVH, RARP or TLH will receive half an hour before the end of surgery, 30 mg ketorolac (IV). Also, 30 mg ketorolac will be given 8h and 16h after the surgery
224101026|NCT01735110|PROCEDURE|transfemoral intervention (TFI)|
224101027|NCT01735110|PROCEDURE|Transradial intervention|
224101028|NCT06407375|DIAGNOSTIC_TEST|mpMRI|mpMRI
224101029|NCT06428630|DRUG|dexamethasone oral rinse|"The study drug is FDA approved (NDC- 0054-3177) and will be used as it would be used in a standard of care setting. The rinse will be administered on the same therapeutic dose to OLP/OLR (0.5 mg/5ml of dexamethasone oral rinse once (rinse for 2 minutes or 5 minutes), then spit the excess into a cup.~The oral rinse dexamethasone 0.5 mg/5ml will be used only on the subjects who participated in the study."
224101030|NCT06353711|BEHAVIORAL|CA-LINC Intervention|Participants received the CA-LINC intervention.
223722338|NCT06587399|OTHER|Radial shock wave treatment|"The treatment will be carried out with 1 session per week for 6 weeks. For this purpose, a radial shock wave generator will be used, at a frequency of 8 to 12 Hz, 2000 pulses/session and with a pressure of 2.5 to 4.0 bar.~Between 3 and 5 points will be treated per session: insertion of the supraspinatus muscle, dorsolateral area under the acromion and a maximum of 3 trigger points of the rotator cuff muscles.~In addition, the subjects will carry out a 12-week home therapeutic exercise program."
224287485|NCT03970265|DIAGNOSTIC_TEST|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
224101031|NCT06353711|BEHAVIORAL|Treatment as Usual|Participants received Treatment as Usual
224101032|NCT05379504|BEHAVIORAL|Standard Health Education|Participants randomized to the standard health education arm will receive the intervention at month 1 and then months 3, 6, 9, and 12 (coinciding with the quarterly interviews). The participant will use the tablet and telehealth platform to complete the interview and education session with research staff. The content of these sessions will be focused on helping the participant (and family member/caregiver as appropriate) understand their health data, assisting them with any technology issues and providing the participant with education on their condition(s) and any requested resources. Research staff will will also provide any additional health education if there are changes to conditions or new diagnoses after an outside provider visit.
224287486|NCT00692146|DRUG|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
224287487|NCT00692146|DRUG|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
224287488|NCT02608970|DRUG|BMS-986177|
224287489|NCT02608970|OTHER|Placebo|
224101033|NCT05379504|BEHAVIORAL|Self Management|"The self-management intervention will be delivered over the course of a year. There will be a minimum of four intervention sessions with each healthcare profession (OT, RN and SW) for 12 visits per participant. The team (OT, RN and SW) will meet twice during the first 2 months to determine a lead interventionist based on the participant's SMART goals and areas of concern. The lead interventionist will have three additional sessions with the participant and will be the point-person for sensor system alerts and messages. Goal Attainment Scaling \[83\] will be administered during the quarterly interview to assess participant progress on SMART goals. This measure is administered collectively with the participant, provides further accountability, offers opportunities to the participant for reflection on progress, and is a concrete measure of success of the self-management intervention."
224101034|NCT06154291|DRUG|XON7|The trial intervention (XON7) is a glyco-humanized polyclonal antibody drug which is formulated for intravenous (IV) administration
223722339|NCT07001969|PROCEDURE|Massoud-Goel Technique and Theory|Percutaneous Trans-facet Fixation Massoud-Goel Technique and Theory for Treatment of Degenerative Spine
224101035|NCT05357690|PROCEDURE|Stellate ganglion block|Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
224101036|NCT05357690|DRUG|Bupivacaine|10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion
224287490|NCT01167517|OTHER|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
224287491|NCT04733209|OTHER|TENS, US, exercise|Physiotherapy
224287492|NCT01208428|BEHAVIORAL|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
224287493|NCT01208428|BEHAVIORAL|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
224287494|NCT03050697|DEVICE|HARMONI® Modular Toric Intraocular Lens|Two-component system consisting of a base and a separate toric optic
224287495|NCT03050697|PROCEDURE|Cataract extraction with intraocular lens (IOL) implantation|Cataract removal via manual phacoemulsification, followed by HMTIOL implantation
224287496|NCT02597582|PROCEDURE|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
224101037|NCT05357690|DRUG|Placebo|10 mL of saline injected in the plane of the right stellate ganglion
224101038|NCT06419439|DRUG|Ketamine hydrochloride|Participants in Arms 1, 2, and 3 will receive four twice-weekly ketamine hydrochloride intravenous infusions dosed at 0.5mg/kg.
223722340|NCT07001969|PROCEDURE|Percutaneous Trans-facet Fixation for Treatment of Degenerative Spine|Percutaneous Trans-facet Fixation (Developmental of Dr Atul goel technique of transfacet fixation by open surgery using Magrel technique) Massoud-Goel Technique and Theory for Treatment of Degenerative Spine
223722341|NCT07001904|OTHER|Enzyme-linked immunosorbent assay (ELISA)|The enzyme-linked immunosorbent assay (ELISA) was utilized in order to determine the levels of IL-6 in the serum
223722342|NCT07002463|DEVICE|Luna EMG|Participants receive additional upper limb rehabilitation using the Luna EMG robotic system. Each session includes 4 EMG-triggered exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program.
223722343|NCT07002463|BEHAVIORAL|Therapist-assisted upper limb training|Participants receive additional upper limb rehabilitation with a physiotherapist performing assisted movements equivalent to the robotic training protocol. Each session includes 4 assisted exercises (shoulder flexion, external rotation, elbow extension, and forearm supination), with 50 repetitions per movement. The intervention is delivered 5 days per week for 6 weeks alongside a standard rehabilitation program.
223729467|NCT00255450|DRUG|ferumoxytol or placebo|
224287497|NCT06147531|BIOLOGICAL|Delayed Cold-Stored Buffy Coat Platelets|To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
224287498|NCT06147531|BIOLOGICAL|Room Temperature Buffy Coat Platelets|Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
224287499|NCT00389220|DEVICE|Coronary stent placement|Coronary stent placement
223722344|NCT07001163|DIETARY_SUPPLEMENT|Probiotic|Probiotic sachets contained 1× 109 colony-forming unit of Bifidobacterium Animalis subsp.lactis BB-12), were given via orogastric tube twice daily.
224287500|NCT04815382|OTHER|Dynamic Upper Limb Orthosis|"The dynamic upper limb orthosis extends from subdeltoid level to 10 mm distal to the metacarpal-phalangeal joints. The orthosis will be tailored to include 20 degrees of wrist extension and to abduct the thumb. They made from nylon and lycra.~The orthosis will be used throughout the day, being removed when the patient lies down.~The orthosis will be used during 3 months"
224287501|NCT03136874|OTHER|Interview and questionaires|"* Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~* Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
224287502|NCT04776746|DRUG|trofinetide|Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
224287503|NCT00707564|DEVICE|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
223949522|NCT05104450|BEHAVIORAL|lifestyle intervention|Intervention Arm: Usual Care plus a lifestyle behavior change intervention aimed at improving eating habits and increasing physical activity. The lifestyle behavior change intervention encourages participants to gradually achieve and maintain a 5-10% loss of baseline body weight and at least 150 minutes of moderate-intensity physical activity, such as brisk walking, each week. The lifestyle intervention program consists of watching one video, completing corresponding written self-guided learning materials, and tracking food intake and physical activity each week for the first 12 weeks, then working through 10 additional written handouts and continued food and activity tracking for the next nine months. Intervention participants will have access to a lifestyle coach as desired for the full 12-month intervention period.
223722345|NCT07001072|DEVICE|Smartshoes with haptic vibration feedback|wearable smartshoe with capability‬ to deliver haptic/vibration feedback to assess effect on freezing of gait
223949523|NCT04995601|DEVICE|RF Health MAC|The RF Health MAC is a novel device that is applied to the lower legs of patients that provides intermittent active compressions to the calf muscles which results in increased blood flow in the veins, moving blood towards the direction of the heart and reducing the risk of clot formation.
223949524|NCT00000111|PROCEDURE|Oral mucosal graft|
223949525|NCT03596697|DRUG|CRV431|Single or multiple dose(s) of CRV431
223949526|NCT03596697|DRUG|Placebo|Single Placebo dose
223722346|NCT07001202|BEHAVIORAL|Indicated Prevention for suicidality|The Reframe-IT+U program is an individualized preventive intervention based on cognitive behavioral therapy, with a problem-solving and help-seeking approach, delivered within the University with psychologists and supervision. The program consists of six weekly sessions of 60-90 minutes each.
223722347|NCT07001995|DRUG|limertinib|limertinib 80 mg
223722348|NCT07001995|DRUG|etoposide and carboplatin|etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV
224287504|NCT00707564|DEVICE|Gauze with pressure|Gauze with pressure
224287505|NCT03392740|DRUG|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
223722349|NCT07000903|OTHER|Exposure and immune profiles|The exposure and immune profiles will be determined in HBM blood and urine samples collected prospectively during the first SOC visit.
223722350|NCT07001787|DRUG|Drug：HS-10510；|Drug：HS-10510 Description：Subjects will receive HS-10510 orally as a single and multiple ascending dose.
223949527|NCT03596697|DRUG|TDF|Single or multiple dose(s) of TDF
223949528|NCT04832724|GENETIC|RGX-314|RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
223949529|NCT06067958|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
223949530|NCT06067958|DRUG|Saline|Intranasal administration of saline 0.9% will be done using MAD Nasal atomization device (Teleflex Medical, 3015 Carrington Mill Blvd, Morrisville, NC 27560, USA). Administration will be given to both nares at a similar volume.
223949531|NCT06720181|DIAGNOSTIC_TEST|MRI|Resting-state Functional Magnetic Resonance Imaging and Diffusion Tensor Magnetic Resonance Imaging of the brain
223949532|NCT05179109|PROCEDURE|Minimally invasive surgery|Minimally invasive surgery for severe deep endometriosis
223722351|NCT07001787|DRUG|Drug：Placebo|Drug：Placebo Description：Subjects will receive placebo matching the HS-10510 dose orally as a single and multiple ascending dose.
223722352|NCT07001787|DRUG|Drug： Rosuvastatin|Drug：Rosuvastatin Description：Subjects will receive rosuvastatin orally.
223722353|NCT07000292|DRUG|Injection of MSC303|Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.
223722354|NCT06676904|PROCEDURE|Higher Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 50 x 10\^9/L during postnatal days 1-7, and then for a platelet transfusion threshold of 35 x 10\^9/L at 8 or more postnatal days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
223722355|NCT06676904|PROCEDURE|Lower Platelet Transfusion Threshold|Infants randomized to this arm will be monitored for a platelet transfusion threshold of 25 x 10\^9/L during postnatal days 1-7, and then for a platelet transfusion threshold of 20 x 10\^9/L at 8 or more postnatal days of life. Infants will remain on this protocol-driven threshold through 40 0/7 weeks postmenstrual age. The platelet dose will be 10 ml/kg administered over 60-120 minutes.
223722356|NCT07002450|DIAGNOSTIC_TEST|Cardiac computed tomography angiography|Patients will undergo CCT according to the following protocol. A non-contrast enhanced prospective ECG-triggered image will be acquired followed by a contrast-enhanced prospective ECG-triggered image using a tri-phasic contrast protocol. Delayed CT images 60 seconds after the initial contrast-enhanced CT scan will be obtained. Cardiac CT image interpretation will be performed according to routine clinical practices in a pragmatic fashion. The LA will be assessed for filling defects and characterized based upon attenuation values. If LA thrombus cannot be excluded, filling defects will be assessed on the delay images. Increases in attenuation would be consistent with pseudo-thrombus from 'slow flow' and 'incomplete opacification'. Areas where attenuation does not change significantly (persistent filling defect) will be diagnosed as thrombus. If the CCT shows no LA thrombus then the ED physician will be able to perform electrical and/or chemical cardioversion at their discretion.
223722357|NCT07002450|OTHER|Standard of care management|"Patients in the standard of care arm may undergo any combination of the following management strategies in the emergency department (ED) at the discretion of their treating physician:~1\. Transesophageal echocardiogram (TEE) facilitated cardioversion; 2. Rate control; 3. Consultation with inpatient cardiac specialist for assessment/management and consideration of hospital admission; 4. cardioversion after 3 weeks of anticoagulation; and/or 5. Outpatient referral to cardiac specialist or general practitioner for further management."
223949533|NCT05693272|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
223949534|NCT05693272|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
223949535|NCT06415357|BEHAVIORAL|Mobile Healthy Choices (mHC)|mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.
223949536|NCT06415357|BEHAVIORAL|Motivational Text Messaging (MTM)|Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.
223949537|NCT06415357|BEHAVIORAL|Standard ART Counseling|All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.
223949538|NCT05700279|PROCEDURE|Stellate Ganglion Block|Stellate Ganglion Block (SGB) procedure involves an injection of a local anesthetic (0.5% ropivacaine) around the stellate ganglion (a bundle of nerves located at the base of the neck) to block the transmission of pain signals. The SGB injection is administered by an anesthesiologist.
223949539|NCT05700279|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a form of trauma-based talk therapy that will be conducted by clinical therapists. CPT can help people identify and challenge unhelpful trauma-related beliefs about themselves, others, and the world.
223949540|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
223949541|NCT03644082|BEHAVIORAL|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
223949542|NCT03644082|BEHAVIORAL|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
223949543|NCT03644082|BEHAVIORAL|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
223949544|NCT03644082|BEHAVIORAL|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
223949545|NCT03644082|BEHAVIORAL|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
223729468|NCT03280914|DEVICE|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
223722358|NCT07000643|RADIATION|Intensity-Modulated Proton Therapy (IMPT)|"This is the experimental arm intervention. Patients receive Intensity-Modulated Proton Therapy (IMPT) for primary nasopharyngeal carcinoma.~The subjects are patients with histologically confirmed, previously untreated, non-metastatic (M0) nasopharyngeal carcinoma.~Radiotherapy target volumes and doses: GTV (gross tumor volume of primary tumor and metastatic lymph nodes); CTV70Gy (GTVp + 0-5mm margin, GTVn + 0-3mm margin, reducible near organs at risk) at a dose of 69.6-70Gy; CTV50-54Gy (GTVp + 8-10mm margin + entire nasopharyngeal mucosa + adjacent high/intermediate risk structures and intermediate-risk subclinical lymph node regions) at a dose of 50-54Gy, delivered at 2Gy/(RBE) per fraction. The protocol notes that proton therapy does not use a PTV (Planning Target Volume).~The systemic therapy plan is formulated according to clinical guidelines."
223729469|NCT06186011|PROCEDURE|Wire-guided surgery|If assigned to the WGS, the marking will be performed by the radiologist on the day prior to the intervention.
223729470|NCT06186011|PROCEDURE|Radioactive seed localization|If assigned to the RSL, the marking will be performed by the radiologist on the day prior to the intervention. The handling and traceability will be done by the nuclear medicine physician.
223729471|NCT06186011|PROCEDURE|Intraoperative ultrasound localization|If the patient is assigned to the Intraoperative ultrasound localization (IOUS), no further procedures will be necessary until surgery. Subsenquently, the primary surgery will be performed.
223722359|NCT07000643|RADIATION|Intensity-Modulated Radiotherapy (IMRT)|"This is the control arm intervention. Patients receive Intensity-Modulated Radiotherapy (IMRT) for primary nasopharyngeal carcinoma; IMRT is one of the current standard and widely used treatment techniques.~The subjects are patients with histologically confirmed, previously untreated, non-metastatic (M0) nasopharyngeal carcinoma.~Radiotherapy target volumes and doses: GTV (gross tumor volume of primary tumor and metastatic lymph nodes); CTV70Gy (GTVp + 0-5mm margin, GTVn + 0-3mm margin); PTV70 (CTV70 + 3-5mm margin, reducible near organs at risk) at a dose of 70Gy; CTV50-54Gy (GTVp + 8-10mm margin + entire nasopharyngeal mucosa + adjacent high/intermediate risk structures and intermediate-risk subclinical lymph node regions); PTV50-54 (CTV50-54 + 3-5mm margin, reducible near organs at risk) at a dose of 50-54Gy, delivered at 2Gy/(RBE) per fraction.~The systemic therapy plan is formulated according to clinical guidelines."
223722360|NCT07000695|DRUG|Pelacarsen|Patients receive Pelacarsen
223722361|NCT07000539|DIAGNOSTIC_TEST|Indocyanine Green Angiogram|Three different doses of indocyanin green will be compared (5 mg, 7.5 mg, and 10 mg). These doses are within the range of currently recommended doses by the International Society for Fluorescence Guided Surgery (ISFGS) for bariatric surgery.
223722362|NCT07002099|DRUG|Selinexor + High-dose Methotrexate + Rituximab + WBRT|"Rituximab 375 mg/m² intravenously on Day 0 of each 21-day cycle~High-dose Methotrexate (HD-MTX) 3.5 g/m² intravenously over 4 hours on Day 1 of each cycle~Selinexor 80 mg orally once weekly (on Days 1, 8, and 15) during each cycle~Treatment is administered every 21 days for up to 6 cycles. Tumor response will be evaluated every 3 cycles.~Patients who achieve a partial response (PR) or better will undergo consolidative low-dose whole-brain radiotherapy (WBRT) at 23.4 Gy in 13 fractions."
223722363|NCT07000942|OTHER|Electrical cardioversion (ECV)|Electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure
223722364|NCT07001007|DIAGNOSTIC_TEST|Coronary Computer Tomography (CCTA)|Use of standard equipment for usual care
223722365|NCT07001007|OTHER|Laser Doppler Vibrometry and single-lead ECG|Physiological data acquisition equipment
223722366|NCT07001007|DEVICE|Echocardiography|GE Vivid E95
223949546|NCT03644082|BEHAVIORAL|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
223722367|NCT07001007|DEVICE|Pulse Wave Velocity|Arteriograph, Tensiomed, Hungary
223722368|NCT07001683|DEVICE|VR SHINECON VIRTUAL REALITY GLASES|"Unity program; It is a game engine that is used for the development of 2D, 3D, virtual reality and augmented reality applications and also has mobile support. 3D objects and animations necessary to develop the application have been prepared. These objects and animations; It was developed in the Autodesk 3ds Max program, where 3D modeling and animations are made.~The virtual reality aspect of the application is integrated into the Google VR SDK (Google Virtual Reality Software Development Kit). Interactions in the virtual environment and 360° viewing operations in the virtual world are provided through this Google VR SDK. The development process was completed by writing application codes in C#, one of the languages supported by the Unity program, using the methods included in the SDK."
223722369|NCT07000461|PROCEDURE|Group Non-pulsatile perfusion|Non-pulsatile group in pump blood flow
223722370|NCT07001397|DRUG|EPAG-pfos|The initial dose of EPAG-pfos is 150mg/d orally. The dose is adjusted according to hematological indicators, with a maximum dose of 150mg/d until hematological remission is achieved
223722371|NCT07001839|DRUG|QLS4131 for Injection.|Eligible participants will be assigned to 1 of the 9 dose groups ranging from 0.06 μg/kg to 600 μg/kg.
223722372|NCT07001514|BEHAVIORAL|Calming digital content|Participants watch a curated selection of soothing documentaries narrated by Sir David Attenborough for 30-60 minutes each evening during one hour before bedtime.
223722373|NCT07001514|BEHAVIORAL|Exciting Digital Content|Participants engage with the interactive word-based game Ruzzle for 30-60 minutes each evening during one hour before bedtime, designed to provide mental stimulation.
223722374|NCT07001514|BEHAVIORAL|Non-digital book reading|Participants read a non-fiction book of their choice for the same duration, avoiding all digital screens during one hour before bedtime before bedtime.
223729472|NCT00589914|DRUG|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
223722375|NCT07002151|OTHER|educational kinesiology training program intervention for study group|The Educational kinesiology program were included : (Cross crawl) Sit or stand and with the right-hand elbow touch the left knee and vice versa. (The owl) Bring one hand up to the opposite shoulder and hold a pinch around the trapezius muscle between the neck and shoulder. the thumb should be on one side of the muscle and the other fingers clasping around the other side. Turn the head to the same side as thehand is gripping and take a deep breath. Slowly exhale as bringing the head gently around to the other side. Repeat this movement one more time. (The arm activation) Hold one arm next to the ear. Exhale gently while activating the muscles by pushing the arm against the other hand in four directions (front, back, in and away). (The Energizer) Place the head on the desk in front exhale and inhale while coming up and try to hyperextend the neck carefully. (cook's hook-up) put the left ankle over your right knee. Next, hook the right hand around the left ankle.
223722376|NCT07002151|OTHER|conventional upper extremities coordination training for both arms experimental and comparator (study and control) groups|Bimanual coordination,Hand-arm coordination ,Drinking \& Strength training
223722377|NCT07000877|DRUG|Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))|Decongestant nasal spray containing active ingredient.
223949547|NCT03644082|BEHAVIORAL|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
223537429|NCT04641832|OTHER|Soccer heading|A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
223537430|NCT02783833|DRUG|MMV390048 40mg|
223949548|NCT03644082|BEHAVIORAL|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
223537431|NCT02783833|DRUG|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
223949549|NCT03644082|BEHAVIORAL|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
223949550|NCT03644082|BEHAVIORAL|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
223949551|NCT03909074|BIOLOGICAL|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
223949552|NCT03909074|BIOLOGICAL|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
223949553|NCT03909074|BIOLOGICAL|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
223949554|NCT04173000|OTHER|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
223949555|NCT04173000|OTHER|Mehealth for ADHD software without medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
223949556|NCT00353106|BEHAVIORAL|Interview|30-minute interviews of participating patients and their caregiver(s).
223949557|NCT00353106|BEHAVIORAL|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
223949558|NCT01668355|OTHER|Patient Aligned Care Team (PACT)|An integrated healthcare model to coordinate and address physical health needs of people with serious mental illness. This specialized PACT medical home model is designed for individuals with serious mental illness.
223949559|NCT00162006|DRUG|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
223949560|NCT01578304|DRUG|Imidafenacin|Tablet, 12 weeks twice daily
223949561|NCT01578304|DRUG|Fesoterodine|Tablet, 12 weeks once daily
223949562|NCT06012799|DIAGNOSTIC_TEST|continuous glucose monitoring|FreeStyle Libre Flash Glucose Monitoring System
223949563|NCT06193915|DEVICE|Ultrasound guided hematoma block.|Patients with a dislocated fracture of the distal radius will receive ultrasound guided hematoma block with 10mL lidocaine 2% to get real-time guidance of the given anesthesia into the fracture site before closed reduction of a distal radius fracture.
223949564|NCT06193915|PROCEDURE|Blind hematoma block|Patients with a distal radius fracture will receive standard treatment; hematoma block with 10mL 2% lidocaine performed with palpation of the fracture site (blind hematoma block) before closed reduction of dislocated distal radius fractures.
223949565|NCT03054766|PROCEDURE|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
223949566|NCT03054766|DRUG|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
223949567|NCT01439399|DRUG|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
223949568|NCT01439399|DRUG|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
223722378|NCT07000877|DRUG|PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%|Control nasal spray containing no active ingredient.
223722379|NCT07001085|DIAGNOSTIC_TEST|Tumor Tissue Collection and NGS|Tumor tissue is collected during surgery and used for DNA extraction. Next-Generation Sequencing (NGS) is performed to identify oncogenic mutations.
224101039|NCT06419439|BEHAVIORAL|Minimally Enhanced Usual Care|Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression and will be provided to participants in arms 2 and 3 (pilot RCT).
223722380|NCT07001085|OTHER|Blood Collection for Plasma ctDNA|Blood is collected at three time points: one day before surgery, one month, and six months after surgery. Plasma is separated and used for further molecular analysis or storage.
223722381|NCT07001085|DIAGNOSTIC_TEST|ctDNA Mutation Analysis via ddPCR|Circulating tumor DNA (ctDNA) is isolated from plasma samples. Mutations previously identified by NGS are quantitatively analyzed using droplet digital PCR (ddPCR).
223722382|NCT06603844|DRUG|CRB-601 monoclonal antibody|CRB-601
224101040|NCT06419439|BEHAVIORAL|Brief narrative intervention|"Participants in Arm 1 (open label pilot) will receive the brief narrative intervention after four ketamine infusions.~Participants in Arm 2 (those randomized after ketamine infusions are complete to the active arm of the pilot RCT) will receive the brief narrative intervention."
224101041|NCT03031210|DRUG|Amoxicillin|(90 mg/kg/day) twice daily
223722383|NCT06603844|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD(L)-1 used as per label
224101042|NCT01464697|DRUG|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
224101043|NCT01464697|DRUG|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
224101044|NCT04896853|BIOLOGICAL|ProTrans®|Allogeneic Wharton's jelly (WJ) Mesenchymal Stromal Cells
223722384|NCT05782361|DRUG|Tepotinib|Tepotinib hydrochloride hydrate will be supplied as film coated tablets. The 250 mg oval, white-pink film-coated tablets contain the excipients mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and Opadry II pink. All formulations are intended for oral administration. Refer to pharmacy manual for formulation and strength information.
223729473|NCT00589914|DRUG|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
224101045|NCT06533384|DRUG|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.|As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
224101046|NCT06533384|DRUG|9 cycles of Camrelizumab as adjuvant therapy.|9 cycles of Camrelizumab as adjuvant therapy.
224101047|NCT03184935|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
223537432|NCT01276951|DIETARY_SUPPLEMENT|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
223537433|NCT01276951|PROCEDURE|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
223537434|NCT01276951|PROCEDURE|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
223537435|NCT01276951|PROCEDURE|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
223537436|NCT01276951|PROCEDURE|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
223537437|NCT01276951|PROCEDURE|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
223537438|NCT00475098|DRUG|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
223537439|NCT04384614|DIAGNOSTIC_TEST|Test PCR|Viral load (COVID+) testing by PCR
223537440|NCT04384614|GENETIC|TDR|IDR and blood sampling for testing DNA Cheque
223537441|NCT04384614|OTHER|Clinical Examination|COVID 19 symptoms and Physical Examination
223537442|NCT03400423|DRUG|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
223537443|NCT03400423|BEHAVIORAL|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)\*0.6.
223537444|NCT04293198|DEVICE|KODEX-EPD System|The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 3D images of the human heart. The KODEX occlusion viewer provides an indication of the occlusion status of the PV during cryoballoon PVI procedure
223537445|NCT04293198|DEVICE|Fluoroscopy with contrast dye|Fluoroscopy with contrast dye is used to determine occlusion status during cryoballoon PVI procedures
223537446|NCT04450732|DRUG|GQ1001|anti-HER2 antibody drug conjugate
223537447|NCT05081362|OTHER|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity|Non invasive cardiovascular monitoring with CNAP device of arterial pressure, ECG and respiratory activity during ten minutes in rest and ten minutes in orthostatic position
223537448|NCT01738243|DRUG|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
223722385|NCT05782361|DRUG|Pembrolizumab|"Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material."
223722386|NCT07000825|DIETARY_SUPPLEMENT|Intervention with yerba mate extract or placebo|The standardized extract of yerba mate (Ilex paraguariensis) will be supplied by Sustentec. It is a dry extract of the plant's green, powdered leaves, obtained through aqueous extraction. The extract was obtained by infusing the dried leaves of the plant and the drying process was carried out using a spray-dryer (ratio 6/1 leaves/extract). The extract will be encapsulated containing 250 mg each. Administration Intervention group: 2,250 mg of standardized yerba mate extract will be administered in 9 capsules, 3 times a day, just before the main meals. This amount will provide approximately 980 mg of caffeoylquinic acids/day, which was defined based on the estimated usual intake of caffeoylquinic acids by individuals in a municipality in the southern region of the country, from traditional drinks made with yerba mate (chimarrão and tereré) (Gebara et al., 2017). Placebo group: 9 capsules containing maltodextrin will be administered 3 times a day, just before the main meals.
223722387|NCT05342467|DRUG|Gemeprost 1 Mg Vaginal Pessary|Intravaginal gemeprost 1 mg inserted 3 hourly for maximum of 5 doses in 24 hours
223722388|NCT05342467|DRUG|Dinoprostone 3 mg|Intravaginal dinoprostone 3 mg inserted 4 hourly for maximum of 3 doses in 24 hours
223722389|NCT07131254|BIOLOGICAL|GT719 Injection|GT719 Injection
223722390|NCT07131124|BEHAVIORAL|Mindful Self-Compassion program|"The MSC self-compassion program will be delivered by instructors trained by the LBCM Organization, certified Qualiopi and affiliated to the ADM (accredited training organization).~The MSC program consists of 8 weekly sessions, each 2.5 hours long, plus an additional half-day of supplementary practice ."
223722391|NCT07131124|BEHAVIORAL|Treatment As Usual (TAU) program|"Current treatment strategies for Alcohol Use Disorders (AUD) rely on a combination of pharmacological and psychotherapeutic treatments (Schuckit, 2009). The three specialized outpatient centers participating in our study provide comprehensive and up-to-date addiction care that meets international and national recommendations (HAS, 2023; SFA, 2023).~The services offered, in addition to standard care, include:~Brief interventions, Psychoeducation sessions, Motivational interview, Individual and group therapies for patients (cognitive-behavioral therapies, cognitive remediation, relaxation techniques), Individual and group therapies for families, Psychosocial interventions, including social support and strengthening of psychosocial skills, Peer support groups (peer helpers, expert patients, former user groups)"
223722392|NCT07133061|DIAGNOSTIC_TEST|Wingate test|During the test, 1s power, 5s power, 30s power, speed, heart rate, the value of lactate and other parameters are determined.
223722393|NCT07133061|DIAGNOSTIC_TEST|Dynamometry|The test determines the strength of the handshake by right and left hand separately.
223722394|NCT07133061|DIAGNOSTIC_TEST|Rebound plate|The test determines the height of the jump from the right lower limb and from the left lower limb separately.
223722395|NCT07133061|DIAGNOSTIC_TEST|Blood lactate test|Measurement of volume of lactate in the blood.
223722396|NCT06681480|DEVICE|figure-of-eight active rTMS coil device|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains with a total of 15000 pulses during 5 weekdays at low frequency 0,5Hz Device: figure-of-eight active rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil, optic navigation system
223722397|NCT06681480|DEVICE|figure-of-eight sham rTMS coil device|rTMS is administered using the figure-of-eight sham coil, in trains with a total of 15000 pulses during 5 weekdays Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
223729474|NCT01488539|BEHAVIORAL|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
223729475|NCT01488539|BEHAVIORAL|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
224101048|NCT03184935|DRUG|Decitabine|Decitabine，20mg/m\^2/d
224101049|NCT05751369|BEHAVIORAL|Education plus Support|Brief behavioral support for using TECW Tracker
224101050|NCT04164212|DRUG|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
224287506|NCT03392740|DRUG|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
224287507|NCT02507440|DRUG|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
224287508|NCT02507440|DRUG|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
224287509|NCT02507440|DRUG|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
224287510|NCT00025740|DRUG|clonazepam and paroxetine|
224287511|NCT00860366|DRUG|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
224287512|NCT00860366|OTHER|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
224287513|NCT00717496|OTHER|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
223722398|NCT07001631|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The Dutch version of the standard EMDR protocol with age-specific adaptations for children and adolescents will be used. The eight phases consist of history taking, preparation, assessment, desensitization, installation, body scan, closure, and re-evaluation. During an EMDR session, the child focuses on emotionally disturbing memories (images, thoughts, emotions, and sensations) while simultaneously focusing on an external distracting stimulus (e.g., eye movements). This process facilitates accessing and desensitizing the traumatic memory network, so information processing is enhanced, and new associations can be made between the traumatic memory and more adaptive memories and information. As a result, the traumatic memory representation will be less intense and emotionally disturbing. After the intake session (week 1), including case conceptualization and treatment plan, a maximum of 6 weekly EMDR sessions with a duration of 1 hour per session will be offered.
223722399|NCT06870812|PROCEDURE|Surgical management|"Following randomization into the surgical arm, a competency-trained neurosurgeon will perform the MIPS for clot evacuation with strict adherence to the Surgical Manual of the CSG. Image interpretation, patient position, anesthetic plan, stereotactic navigation registration, exoscopic positioning, access, optics, resection, and hemostasis are detailed in the Surgical Manual of the CSG.~The OR arrival time should occur \<24 hours from the last known normal (LKN) with a goal of arrival in less than 8 hours from the last known normal."
223949569|NCT01439399|DRUG|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
223722400|NCT06870812|OTHER|Medical Management|"Following randomization into the medical arm patients will be treated following the Medical Manual of the CSG. The Medical Manual has been adapted by the REACH Executive Committee (REC) from the current American Heart Association (AHA) and American Stroke Association (ASA) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Whenever clinically feasible, the CSG should be followed as it represents a template for the care of these subjects.~The Medical Manual details specialty level of care, including intensive care placement, blood pressure control, hemostasis and coagulopathy, anemia, deep venous thrombosis and pulmonary embolism prophylaxis/treatment, glucose management, temperature management, seizure prophylaxis, intracranial pressure monitoring and management, intraventricular hemorrhage (IVH)/obstructive hydrocephalus management, cerebral edema, decompressive hemicraniectomy, nutritional support, respiratory support, and comfort care."
223722401|NCT03905668|OTHER|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
223722402|NCT03905668|OTHER|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
223722403|NCT03905668|OTHER|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
223722404|NCT03905668|OTHER|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
223722405|NCT03905668|OTHER|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
223722406|NCT07010302|DRUG|Rituximab (R)|1000 mg at weeks 0 and 2 followed by 1000 mg every 6 months
223722407|NCT07010302|DRUG|Eculizumab (Soliris®)|900 mg weekly for 4 weeks, followed by 1200 mg every 2 weeks
223722408|NCT07010302|DRUG|Ravulizumab|"* 40 to \< 60 kg: 2400 mg~* 60 to \< 100 kg: 2700 mg~* 100 kg: 3000 mg as an induction dose, followed by~* 40 to \< 60 kg: 3000 mg~* 60 to \< 100 kg: 3300 mg~* 100 kg: 3600 mg Every 8 weeks starting 15 days after loading dose"
223722409|NCT07010302|DRUG|Satralizumab|120 mg at Weeks 0, 2, 4, followed by 120 mg every 4 weeks
223722410|NCT07010302|DRUG|Inebilizumab|300 mg on Day 1 and Day 15, followed by 300 mg every 6 months
223722411|NCT07015710|PROCEDURE|Gamma Knife Radiosurgery|Patients underwent gamma knife radiosurgery (GKRS) for tectal plate gliomas (TPGs).
223722412|NCT07015333|DRUG|pembrolizumab and cetuximab|Treatment of betel nut-induced oral cancer with pembrolizumab and cetuximab
223722413|NCT07015060|PROCEDURE|cutaneous biospy|cutaneous biospy
223722414|NCT07015320|BEHAVIORAL|urotherapy|prompted and scheduled voiding, regular sleep timing, fluid and caffeine restriction and avoiding the cellular phones 2 hours before bedtime. If the child had constipation, it should be treated. In addition, alarm therapy was performed in the form of awaking the child every night by his parents after 1-2 hours from deep sleep to void then continue the sleep. The parents should be informed about the importance of their psychological support to their child by avoiding any punishment or embarrassment. Furthermore, the parents were asked to monitor their child's response by documenting the number of wet nights within the last month
223949570|NCT01439399|DRUG|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
223949571|NCT05636306|DRUG|NoNO-42|A single intravenous infusion weight-based dose of NoNO-42 administered over 10±1 minute
223949572|NCT05636306|DRUG|Placebo|A volume of 0.9% normal saline matching the volume required for a weight-based dosing of NoNO-42, administered as a single 10±1 minute intravenous infusion.
223949573|NCT00003599|DIETARY_SUPPLEMENT|Vitamin E (AT)|Orally daily
223949574|NCT00003599|DRUG|Isotretinoin|Orally daily
223722415|NCT07015320|BEHAVIORAL|no intervention|no intervention
223722416|NCT07015073|DEVICE|Pulsed dye laser (PDL)|Treatment with a pulsed dye laser (PDL) at 595 nm using the VBeam Prima® system (Candela Medical). Parameters: 10 mm spot size, 7-9 J/cm² fluence, 0.5-3 ms pulse duration. Cryogen spray cooling is applied. No anesthesia is used. This intervention will be applied to one of the three defined regions of each participant's port-wine stain.
223722417|NCT07015073|DEVICE|Potassium titanyl phosphate (KTP) laser|Treatment with a KTP laser at 532 nm using the DermaV® system (Lutronic Medical Systems). Parameters: 10 mm spot size, 8-11 J/cm² fluence, 10 ms pulse duration. Cryogen spray cooling is applied. No anesthesia is used. This intervention will be applied to a second anatomically comparable region of the port-wine stain.
223722418|NCT07015073|DEVICE|Sequential KTP + PDL laser treatment|Sequential treatment of the same region with two lasers: first with KTP (532 nm, DermaV® system), then with PDL (595 nm, VBeam Prima® system). Each laser will be applied using its standard parameters: KTP (10 mm spot, 8-11 J/cm², 10 ms), followed by PDL (10 mm spot, 7-9 J/cm², 0.5-3 ms). Cryogen spray cooling is used before each pass. No anesthesia is applied. This treatment is administered to a third region of the port-wine stain.
223949575|NCT06049199|OTHER|Speech Enhancer|Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention
223949576|NCT00539604|PROCEDURE|MDCT and Coronary Angiography|
223949577|NCT01190488|BEHAVIORAL|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
223949578|NCT01190488|BEHAVIORAL|Active Comparator|TAU
224101051|NCT05036278|BIOLOGICAL|Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).|"Dosage Levels:~* 40 IU/kg/dose two times per week~* 50 IU/kg/dose every 5 days~* 60 IU/kg/dose, Less frequent dosing (e.g. every 7 days), the total recommended maximum dose/infusion is 6000 IU."
224101052|NCT01697215|OTHER|AirWave|
224101053|NCT05748379|PROCEDURE|Kompozite closure|Immediate implant placement and temporary closure of tapered implants with a custom-made composite shaper.
224101054|NCT05748379|PROCEDURE|Individual abutment|Immediate implant placement and temporary closure of tapered implant with a custom-made zirconium oxide abutment.
224101055|NCT05320367|DRUG|Cannabis, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
224101056|NCT02406846|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
224101057|NCT02406846|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
224101058|NCT03106233|PROCEDURE|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
224101059|NCT00167479|DRUG|risperidone (Risperdal)|
224101060|NCT01315574|DRUG|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
224101061|NCT01315574|DRUG|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
224101062|NCT05225155|DRUG|Enoxaparin|Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation
224101063|NCT00900796|OTHER|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
224101064|NCT00332904|DRUG|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
224101065|NCT00332904|DRUG|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
224101066|NCT02233842|BEHAVIORAL|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
224287514|NCT06468696|PROCEDURE|Suturing the cervical linea alba during endoscopic thyroid surgery.|Suturing the cervical linea alba during endoscopic thyroid surgery.
224287515|NCT06468696|GENETIC|Performing transcriptome sequencing|Performing transcriptome sequencing
224287516|NCT00918918|DIETARY_SUPPLEMENT|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
224287517|NCT00918918|DIETARY_SUPPLEMENT|Orange juice|200 mL orange juice
224287518|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
224287519|NCT05742919|DRUG|NNC0194-0499|Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
224287520|NCT05742919|DRUG|NC0194-0499|Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
224287521|NCT02759341|OTHER|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
224287522|NCT02759341|OTHER|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
224287523|NCT02759341|OTHER|State-Trait Anxiety Inventory form Y (STAI-Y)|
224287524|NCT02759341|OTHER|SF-36 Health-Related Quality of Life|
224287525|NCT02759341|OTHER|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
224287526|NCT04085536|PROCEDURE|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
224287527|NCT06427902|OTHER|Periodontal clinical measurements, Saliva sampling|Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque
223722419|NCT07015931|DRUG|retinoic acid cream 0.025%|half finger tip unit
223722420|NCT07015931|DRUG|adapalene cream 0.1%|half finger tip unit
223722421|NCT07016503|OTHER|Professional values education|At this stage, a comprehensive literature review was conducted and professional values education was prepared. The prepared education content was transferred to a website for which a domain was purchased within the scope of the research. The developed website was presented to the opinion of a group of 7 experts in terms of content: Child Health and Diseases Nursing Department Faculty Members (4), Nursing Fundamentals Department Faculty Members (1), Public Health Nursing Department Faculty Members (2). Expert opinions were evaluated with the measurement tool prepared by the researchers in line with the literature.
223722422|NCT07016061|OTHER|Motor İmagery Group|Participants will engage in a motor imagery exercise program consisting of 5 minutes of warm-up, 20 minutes of motor imagery, and 5 minutes of cool-down, totaling 30 minutes. The intervention will be administered in three sessions per week for one week.
223537449|NCT01738243|DRUG|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
223537450|NCT06571344|DRUG|Cholecalciferol|"The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm."
223722423|NCT07016061|OTHER|Action Observation Group|Participants will receive an action observation training program delivered by researchers, including 5 minutes of warm-up, 20 minutes of action observation, and 5 minutes of cool-down, totaling 30 minutes. The intervention will be administered in three sessions per week for one week.
223722424|NCT07016061|OTHER|Exercise Group|Participants will perform a standard physical exercise program. The session will last 30 minutes, including warm-up, exercise, and cool-down phases. The intervention will be administered in three sessions per week for one week.
223722425|NCT07016061|OTHER|Combined Group (Motor Imagery + Action Observation+Exercise)|articipants will engage in a combined motor imagery and action observation program for a total of 30 minutes, incorporating elements of both interventions. The intervention will be administered in three sessions per week for one week.
223722426|NCT07015970|OTHER|No Intervention: Observational Cohort|No intervention
223722427|NCT07014358|DEVICE|Fastening systems by placing two steel pins|Fixation of the osteotomized bone with a stable fixation system, in this case, the placement of two steel pins.
223722428|NCT07014358|DEVICE|Fastening systems by a wire in an obenque configuration|Fixation of the osteotomized bone with a stable fixation system, in this case, an obenque configuration
223722429|NCT07014358|DEVICE|Fastening systems by the placement of a bolted plate or the placement of a compression screw|Fixation of the osteotomized bone with a stable fixation system, in this case, the placement of a bolted plate or the placement of a compression screw.
223722430|NCT07014735|DRUG|glucose|Participants will receive treatments with glucose or matching placebo (please see study design section).
224101067|NCT02207114|OTHER|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
223722431|NCT07014735|DRUG|moxifloxacin|Participants will receive moxifloxacin or matching placebo (please see study design section).
223722432|NCT07016217|BEHAVIORAL|Early Plain Portrait and Letter|"In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns.~The Portraits provide data of individual prescribing along with evidence-based benchmarks or targets. The plain Portrait includes the main message, prescriber's data (compare to optimal prescribing, with or without information on BC mean/median). Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a standalone publication that details the evidence for the recommended practice in a brief and practical manner, with references."
223722433|NCT07016217|BEHAVIORAL|Early Complete Portrait and Letter|"In the context of audit and feedback interventions, the prescribing Portrait is a document produced by the Therapeutics Initiative that provides personalized prescribing feedback for clinicians in British Columbia. Portraits are used as a practice resource tool for reflection on prescribing or test-ordering patterns.~The Portraits provide data of individual prescribing along with evidence-based benchmarks or targets. The complete Portrait includes the main message, prescriber's data (compare to optimal prescribing, with or without information on BC mean/median) and a series of self-reflection questions. Prescribers are also given access to a succinct review of the best available evidence on the topic and recommendations for future action in the Therapeutics Letter, a standalone publication that details the evidence for the recommended practice in a brief and practical manner, with references."
223722434|NCT07016217|BEHAVIORAL|No intervention|To measure the impact of the interventions, Arm C (Group 3) will receive no intervention in the Early mailing and Arm B (Group 2) will receive no intervention in the Delayed mailing.
223722435|NCT07016217|BEHAVIORAL|Delayed Plain Portrait and Letter|"Delayed plain Portrait and Letter (as described)"
223722436|NCT07016217|BEHAVIORAL|Delayed Complete Portrait|"Delayed complete Portrait and Letter (as described)"
223722437|NCT07015567|BEHAVIORAL|Emotion regulation module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about emotion regulation. This module contains exercises for emotional awareness and emotion regulation with different focuses (on body, thoughts and behaviour).
223729476|NCT01732250|DRUG|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
224101068|NCT04082221|OTHER|no intervention|no intervention
224101069|NCT04117750|DIETARY_SUPPLEMENT|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
224101070|NCT06030934|DRUG|envafolimab and lenvatinib combined with paclitaxel-albumin|envafolimab: 200mg d1,15 s.c. Q4W; lenvatinib: 8mg (\<60kg) or 12mg (≥60kg) p.o. Q.d.; paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
223722438|NCT07015567|BEHAVIORAL|Negative self-concept module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about negative self-concept. In this module, we tackle topics such as what is the self, thinking about the self through cognitive restructuring, criticism and compassion and the self in relation to others.
223722439|NCT07015567|BEHAVIORAL|Interpersonal relationships module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. The manual was adapted to our target population. It contains 24 sessions which are organised in four modules, including a module about interpersonal relationships. This module includes exercises to understand relationship patterns, increasing assertiveness, practicing assertiveness, and managing power.
223722440|NCT07015567|BEHAVIORAL|Narrative exposure therapy module of Enhanced Skills Training in Affective and Interpersonal Regulation combined with Narrative Exposure Therapy (ESTAIR/NET)|"ESTAIR is a psychotherapeutic manual for the treatment of CPTSD. It contains 24 sessions which are organised in four modules. The manual was adapted to our target population. In this context, the module modified prolonged exposure was replaced with Narrative Exposure Therapy (NET). NET is a standardised approach for the treatment of PTSD that has been tested across diverse social and cultural contexts. In this intervention, patients and therapists elaborate together a chronological timeline (called the lifeline) of patient's life and the traumatic events, using a rope, stones for traumatic events, and flowers for positive events. Thereafter, the traumatic events are discussed in detail, one in each session. At the end of each session, patients receive a written form of these narrations, co-signed by patient and the therapist."
223722441|NCT07014943|DRUG|High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy|Gemcitabine (2.5 g/m²) (Days -9 and -3), Busulfan (3.2 mg/kg) (Days -9 to -7), and Thiotepa (5 mg/kg) (Days -5, -4, and -3) were all administered intravenously. Peripheral stem cells were infused on Day 0.
223722442|NCT06396741|OTHER|The quadriceps muscle will be punctured with ultrasound control|With the subject in the supine position, the quadriceps muscle will be shown by ultrasound. Subsequently, a dry needling technique will be performed at the most hyperalgesic point using ultrasound control.
223949579|NCT05839743|OTHER|Aerobic Exercise|The aerobic exercise program will be specially prepared for the participants and will aim to rhythmically exercise large muscle groups. The exercise will be performed twice a week for 6 weeks at 50-75% of maximum heart rate for 20-50 minutes per session. Each exercise will last 30-60 minutes in total, after adding 5 minutes of warm-up and 5 minutes of cool-down before and after the exercise. The participant's pulse will be monitored continuously during the exercise.
223949580|NCT05839743|OTHER|Balance Exercise|Balance exercises belonging to the Otago Exercise Program and other balance exercises used in the elderly will be prepared specifically for the participant and will be applied 2 days a week for 6 weeks in combination. Before and after the exercise, a 5-minute warm-up and 5-minute cool-down exercise will be performed.
223949581|NCT05839743|OTHER|Combined Exercise|In the combined exercise program, first balance exercises and then aerobic exercise program will be applied 2 days a week for 6 weeks.
223949582|NCT00535626|DEVICE|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
224287528|NCT04703621|DRUG|Daratumumab Injection|subcutaneious daratumumab administration
224287529|NCT05887219|DRUG|Group A 4 % Hydroquinone Cream Topically and Oral Tranexamic Acid|Group A was managed with 4% hydroquinone cream as an adjuvant to oral tranexamic acid (250 mg twice daily) for 6 months
224287530|NCT05887219|DRUG|Group B Azelaic Acid 20 % Cream for 6 months|Group B was managed with topical 20% azelaic acid (daily at night) for six months.
224287531|NCT04727684|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
224287532|NCT04727684|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
224287533|NCT04727684|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
224287534|NCT04727684|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
224287535|NCT00956787|DRUG|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
224287536|NCT02681744|BEHAVIORAL|Resistance Training|24-weeks of progressive strength training
224287537|NCT02950142|OTHER|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
224287538|NCT02950142|OTHER|CPOE without order sets for lab testing|CPOE only
224287539|NCT02563587|OTHER|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
224287540|NCT02563587|OTHER|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
224287541|NCT02563587|DRUG|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
224287542|NCT01891305|DRUG|VT-1161|
224287543|NCT01891305|DRUG|placebo|
224101071|NCT02595034|DRUG|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
224101072|NCT02595034|DRUG|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
224101073|NCT02595034|DRUG|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
224101074|NCT04452643|BIOLOGICAL|BACMUNE (MV130)|BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)
224101075|NCT04452643|OTHER|Placebo|Placebo is a solution on sodium chloride at 0.9%
224287544|NCT01957345|OTHER|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
224287545|NCT01956448|DEVICE|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
224287546|NCT02997657|BEHAVIORAL|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
223537451|NCT00467441|DRUG|VSF-173|
223537452|NCT00133133|DRUG|ALGRX 4975|
223537453|NCT05539651|DRUG|RBD5044|Subcutaneously Administered RBD5044 in Healthy Subjects
223537454|NCT05539651|DRUG|Placebo|Subcutaneously Administered Placebo in Healthy Subjects
223537455|NCT00929266|BIOLOGICAL|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
223537456|NCT00396617|DEVICE|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
223537457|NCT00396617|PROCEDURE|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
223537458|NCT05030584|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
223537459|NCT05030584|DRUG|Placebo|Matching placebo orally once daily.
223537460|NCT03481348|DEVICE|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
223537461|NCT04001400|DRUG|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
223537462|NCT04001400|DRUG|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
223537463|NCT05882396|OTHER|Rood's approach|Patients will receive Rood's approach includes various facilitatory and inhibitory techniques.
223537464|NCT05882396|OTHER|Traditional physical therapy program|Participants will be engaged in aerobic exercises and balance training, three times per week for twelve weeks.
223537465|NCT05291754|DEVICE|PEEK Cranioplasty|3D printed PEEK skull implant
223537466|NCT01657305|DRUG|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
223537467|NCT01657305|DEVICE|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
223537468|NCT00578097|BIOLOGICAL|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
223537469|NCT00578097|DRUG|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
223537470|NCT03841409|OTHER|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
223537471|NCT02588885|BEHAVIORAL|Trauma-sensitive Care|"Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills"
223537472|NCT04103450|DRUG|Vibegron|oral administration
223949583|NCT01277302|DRUG|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
224101076|NCT03981029|OTHER|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
224101077|NCT03981029|OTHER|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
224101078|NCT05102565|BEHAVIORAL|sleep education program|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
224101079|NCT03160729|DRUG|Dexamethasone|pre-operative, single-shot injection
224101080|NCT00235521|DRUG|aerosolized iloprost|
224101081|NCT02549950|PROCEDURE|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
224101082|NCT02549950|PROCEDURE|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
224101083|NCT01621932|PROCEDURE|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
224101084|NCT01621932|PROCEDURE|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
224101085|NCT02945982|DRUG|Entecavir+Carvedilol|The subjects will be taking half a Carvedilol per day at first week and one Carvedilol per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day for 96 weeks.
223537473|NCT01390623|DRUG|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
223537474|NCT01101607|PROCEDURE|Distal Forearm Fracture Reduction|Fracture reduction
224101086|NCT02945982|DRUG|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking half a Carvedilol tablet per day at first week and one Carvedilol tablets per day from second week. At the same time,the subjects will be taking one Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
224101087|NCT04893668|OTHER|Depression|Any participants who develop depression symptoms according to DSM 5 criteria
224101088|NCT04893668|OTHER|Anxiety|Any participants who develop anxiety symptoms according to DSM 5 criteria
224101089|NCT02952716|BIOLOGICAL|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
224101090|NCT02952716|OTHER|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
224101091|NCT00634673|OTHER|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
224101092|NCT03971981|DIETARY_SUPPLEMENT|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
224287547|NCT02997657|BEHAVIORAL|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
223949584|NCT03814226|OTHER|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
223949585|NCT02710669|DRUG|(R)-propafenone|
224287548|NCT02190448|DIETARY_SUPPLEMENT|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
224287549|NCT02190448|DIETARY_SUPPLEMENT|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
223537475|NCT04342247|DRUG|external testosteron|external testosteron
223722443|NCT03921047|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223722444|NCT03921047|OTHER|Laboratory Biomarker Analysis|Correlative studies
223949586|NCT02710669|DRUG|(S)-Propafenone|
223949587|NCT02710669|DRUG|Placebo|
223949588|NCT01386632|DRUG|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
224101093|NCT03971981|DIETARY_SUPPLEMENT|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
224101094|NCT01175512|DRUG|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
224101095|NCT01175512|DRUG|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
224101096|NCT00365781|DRUG|ISIS 113715|
224101097|NCT00719199|DRUG|IMO-2055|SC weekly injections
224101098|NCT00719199|DRUG|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
224101099|NCT00719199|DRUG|FOLFIRI|Given day 1 of each cycle
224101100|NCT02560454|BEHAVIORAL|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance's"
224287550|NCT01583257|BEHAVIORAL|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
224287551|NCT04756596|DIAGNOSTIC_TEST|DDVIT testing|One randomly selected eye will be included for each study participant. Participants respond to the DDVIT test in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
223722445|NCT06622941|DRUG|ONO-4538|every 2 weeks
224101101|NCT02560454|BEHAVIORAL|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
224101102|NCT02904226|DRUG|JTX-2011|Specified dose on specified days
223722446|NCT06693687|BEHAVIORAL|Metastatic Cancer|Participants will be asked to to take part in a research study because you have metastatic cancer (meaning that your cancer has spread to other parts of the body) and will be starting systemic therapy.
223722447|NCT02155790|DEVICE|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
223722448|NCT06701617|BEHAVIORAL|restorative visual rehabitation|black-and-white checkerboard patterns, visual stimulation program, restorative visual rehabitation
223722449|NCT05910242|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
223949589|NCT01386632|DRUG|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
223949590|NCT04894136|PROCEDURE|ICSI-TESE; embryo-transfer|The sperm injected into the cytoplasm of an oocyte (Intracytoplasmatic Sperm Injection) is obtained by testicular extraction. Ultrasound guided transvaginal embryo transfer.
223722450|NCT05910242|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
223722451|NCT06719531|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
223722452|NCT04109183|DRUG|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
223722453|NCT02041078|PROCEDURE|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
223722454|NCT02041078|PROCEDURE|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
223722455|NCT02856178|DRUG|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
223722456|NCT02856178|DRUG|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
223722457|NCT06634095|BEHAVIORAL|Moulage group|The experimental group is trained with a moulage-supported standardized patient simulation. Participants in the experimental group practice during the specified moulage-supported standardized patient simulation. Moulage-supported simulations regarding pressure ulcers will be created and training will be provided.
223722458|NCT06762561|PROCEDURE|Prophylactic retromuscular mesh reinforcement|Prophylactic retromuscular mesh placement involves reinforcing the abdominal wall during closure after open abdominal aortic aneurysm (AAA) repair to prevent incisional hernias. This technique creates a retro-muscular space by carefully dissecting the rectus abdominis muscles from the posterior rectus sheath. A self-gripping polyester mesh or composite mesh is placed in this space, extending 4 cm beyond the midline on each side, ensuring tension-free coverage. The mesh is secured at key points, and the rectus sheaths are closed with continuous sutures. This approach leverages the anatomical integrity of the abdominal wall to reduce hernia risk without increasing postoperative complications.
223722459|NCT06895096|DEVICE|Pit Fissure Sealant|Flowable composite is being used for the purpose of sealing pits and fissures which require etching and bonding before application whereas self etch sealants are self adhesive and do not require etching and sealing.
223949591|NCT00001895|DRUG|FDG|
223949592|NCT00001895|DRUG|NH(3)|
223949593|NCT03243838|DRUG|Apatinib|All enrolled patients were administered oral apatinib at a dose of 250 mg once daily and intravenously docetaxel (100 mg/m2) every three weeks for four cycles, followed by epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2) every three weeks for four cycles. All the treatments were continued until disease progression, patient withdrawal, or unacceptable toxic effects.
223949594|NCT06470347|DRUG|A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy|During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
223949595|NCT00055068|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
223949596|NCT00055068|BEHAVIORAL|Relaxation Training|
223949597|NCT03463291|DEVICE|MRI|"* T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
224101103|NCT02904226|DRUG|Nivolumab|Specified dose on specified days
224101104|NCT02904226|DRUG|Ipilimumab|Specified dose on specified days
224101105|NCT02904226|DRUG|Pembrolizumab|Specified dose on specified days
224101106|NCT05983393|PROCEDURE|Erector spinae plane block|Erector spinae plane block was performed
224101107|NCT05983393|PROCEDURE|Control|Erector spinae plane block was not applied.
224101108|NCT04329026|DEVICE|Smart glasses|The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
224101109|NCT04329026|DEVICE|Control|The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
224101110|NCT00527449|DRUG|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
224101111|NCT02152969|DRUG|Telmisartan|
223537476|NCT06055751|DEVICE|TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473)|No intervention will be done as part of this prospective registry. Implantation of Boston Scientific Loop Recorder (LUX-Dx) will be performed regardless of this research and outside this research protocol per standard of care
223537477|NCT02027792|OTHER|Cabbage leave wraps|
224101112|NCT02152969|DRUG|Amlodipine|
223722460|NCT05618704|DIETARY_SUPPLEMENT|Hydrolyzed protein infant formula|The subjects will take the formula for 16 weeks
224101113|NCT02152969|DRUG|Chlorthalidone|
224101114|NCT06021743|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
224101115|NCT06021743|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
224101116|NCT06021743|DIAGNOSTIC_TEST|Measurement of serum semaphorin concentrations|Semaphorin concentration will be measured in patient sera by ELISA.
224101117|NCT06021743|DIAGNOSTIC_TEST|Measurement of inflammatory cytokines|A panel of pro- and anti-inflammatory markers will be determined by flow cytometer microsphere-based assay.
224101118|NCT04457921|OTHER|deep tissue massage|DTM was applied to participants in the experimental group twice (at the 10th and 22nd h) after cesarean
224101119|NCT03669705|PROCEDURE|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
224101120|NCT02389881|DRUG|TAK-058|TAK-058 Solution
224101121|NCT02389881|DRUG|TAK-058 Placebo|TAK-058 placebo-matching solution
224101122|NCT02456220|DEVICE|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
224101123|NCT03679221|OTHER|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
224101124|NCT02013219|DRUG|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
223537478|NCT02027792|DRUG|Diclofenac Gel|
223537479|NCT04426474|DRUG|LY3502970|Administered orally.
223537480|NCT04426474|DRUG|Placebo|Administered orally.
223537481|NCT00487916|DRUG|AMA1-C1/ISA 720|
223537482|NCT06009302|PROCEDURE|US guided block of mandibular nerve|Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
223537483|NCT06009302|PROCEDURE|Intraoral block of lower alveolar nerve|Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
223537484|NCT06184802|BEHAVIORAL|TAU+Multisensory room|Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
223537485|NCT06184802|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
223537486|NCT05388578|DEVICE|Blood pressure monitor|Participants will receive the Withings BPM connect monitor and do weekly self-measurements of blood pressure.
223537487|NCT05388578|DEVICE|Weighting scale|Participants will receive the Withings Body scale and do weekly self-measurements of their body weight and BMI.
223537488|NCT05388578|DEVICE|Activity tracker|Participants will receive the Withings Move to automatically keep track of their number of steps and activity type.
223537489|NCT05388578|DEVICE|ECG device|Participants will receive the Withings Move ECG to make daily measurements of heart rhythm, an algorithm will detect abnormalities in heart rhythm such as atrial fibrillation.
223537490|NCT01180127|DIETARY_SUPPLEMENT|Flavanol containing food product|12 weeks, 2X/day, 20g serving
223537491|NCT01180127|BEHAVIORAL|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
223537492|NCT01180127|DIETARY_SUPPLEMENT|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
223537493|NCT01180127|BEHAVIORAL|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
223537494|NCT02298621|OTHER|pomegranate juice|Randomized clinical trial or RCT
223537495|NCT02298621|OTHER|placebo|Randomized clinical trial or RCT
223537496|NCT00879489|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
223537497|NCT03663192|DEVICE|strain echocardiography|strain echocardiography during septic shock
223537498|NCT01696643|DRUG|CB-5945|
223537499|NCT01696643|DRUG|Placebo|
223537500|NCT00160953|PROCEDURE|Endorectal Coil Magnetic Resonance Images|
223537501|NCT05833711|DRUG|Froniglutide|SC Weekly Injection
223537502|NCT05833711|DRUG|Placebo|SC Weekly Injection
223537503|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
223537504|NCT00039013|DRUG|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
223537505|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
224101125|NCT02013219|DRUG|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
224101126|NCT02013219|DRUG|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
224101127|NCT02931448|DEVICE|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
224101128|NCT03879291|OTHER|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
224101129|NCT03984409|DIETARY_SUPPLEMENT|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
224101130|NCT05363917|DRUG|Natrunix with MTX placebo (+folate)|True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α
223722461|NCT01594983|DRUG|LCQ908|
224101131|NCT05363917|DRUG|Natrunix placebo with MTX (+folate)|Natrunix placebo with MTX (+folate)
224101132|NCT02059824|DEVICE|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
224101133|NCT04579861|OTHER|Prospective data collection following gynaecological oncology surgery|Prospective data collection and entry on database following gynaecological oncology surgery
224101134|NCT06116305|OTHER|No intervention|No intervention
224101135|NCT00343902|DRUG|Crataegus Special Extract WS 1442|
224101136|NCT04352829|OTHER|VIDEO-TRAINING-SESSION ABOUT MDI USE|The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
224101137|NCT05152212|BIOLOGICAL|LVGN7409|Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits.
224101138|NCT01596491|PROCEDURE|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
223722462|NCT01594983|DRUG|Fenofibrate|Fenofibrate once daily 12 weeks
224101139|NCT05219812|DRUG|BAY2395840|Tablet, intake orally.
224101140|NCT05219812|DRUG|Placebo for BAY2395840|Tablet, intake orally.
224101141|NCT03457298|DEVICE|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
224101142|NCT03457298|DEVICE|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
223537506|NCT00039013|DRUG|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
223537507|NCT04414293|RADIATION|Lung Low Dose Radiation|The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.
223722463|NCT01594983|DRUG|Fish Oil|Fish Oil once daily for 12 weeks
223537508|NCT04804527|OTHER|Intensified physiotherapy|Physiotherapy x2
223949598|NCT02297464|OTHER|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
223949599|NCT02297464|OTHER|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
223949600|NCT03650972|OTHER|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL \> 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
223949601|NCT05313477|DRUG|Ergocalciferol Capsules|Depend on initial 25(OH) vitamin D level If \<10ng/mL, 60000U of Ergocalciferol capsules per week If 10-19.9ng/mL, 40000U of Ergocalciferol capsules per week If \>20 ng/mL, 20000U of Ergocalciferol capsule per week
223949602|NCT05313477|DRUG|Calcium carbonate|1000mg of Calcium carbonate daily
223537509|NCT04804527|OTHER|Usual care physiotherapy|Physiotherapy x1
223537510|NCT03279926|BEHAVIORAL|PLAY|Activity trackers + curriculum information
223537511|NCT03279926|BEHAVIORAL|PLAY Parents|Enhanced parental engagement
223949603|NCT02312544|DRUG|OTX-TP|OTX-TP and placebo drops
223949604|NCT02312544|DRUG|Timolol|Timolol drops and placebo punctum plug
223949605|NCT06046807|OTHER|Phone call|This follow-up will be conducted over the phone and by mail (some questionnaire may be sent by patient, as per his/her preference)
223949606|NCT04529824|DEVICE|Dexcom G6 Continuous Glucose Monitor (CGM) System|Participants wear a blinded Dexcom G6 CGM and a Fitbit Charge 3 activity tracker for 10 days.
223949607|NCT04582994|BEHAVIORAL|Beta tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)
223949608|NCT04582994|BEHAVIORAL|Alfa tACS|participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)
223949609|NCT04582994|BEHAVIORAL|Sham|participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
223949610|NCT01043614|BEHAVIORAL|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
223949611|NCT01184027|BEHAVIORAL|nutrition /swallowing counseling|general nutrition and swalling information
223949612|NCT01184027|BEHAVIORAL|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
223949613|NCT01184027|BEHAVIORAL|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
223949614|NCT03776604|DRUG|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were \<45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
223949615|NCT06152497|DRUG|Placebo|Oral placebo
223949616|NCT06152497|DRUG|H1 blockade: Telfast: 180mg Fexofenadine|H1 blockade: oral blockade with 180mg Fexofenadine
223949617|NCT06152497|BEHAVIORAL|Resistance training|Resistance training: lower body exercise
223949618|NCT06060847|PROCEDURE|Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome|Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.
223949619|NCT06060847|PROCEDURE|Liver resection for HCC induced by metabolic syndrome|Patients in the active comparator arm will undergo liver resection for HCC
224101143|NCT03398772|BEHAVIORAL|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
224101144|NCT03785080|OTHER|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
224101145|NCT03785080|OTHER|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
224101146|NCT00816803|PROCEDURE|Autologous bone marrow transplant|
224101147|NCT00816803|PROCEDURE|Physical therapy|
224101148|NCT04767425|RADIATION|Brachytherapy|• 3D image-based cervical cancer brachytherapy will be delivered as 4 sessions x 7 Gy High Dose Rate (HDR) brachytherapy
224287552|NCT04756596|DIAGNOSTIC_TEST|ETDRS testing|The same eye is included for each study participant. Participants respond to the standard ETDRS chart of our Ophthalmology Department in standard environmental lighting conditions at 4 m viewing distance. Visual acuity will be evaluated.
224287553|NCT03051139|BEHAVIORAL|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
224101149|NCT03834948|DRUG|AO-176|Humanized monoclonal antibody (mAb) targeting CD47
224101150|NCT03834948|DRUG|AO-176 + Paclitaxel|Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel
224101151|NCT03834948|DRUG|AO-176 + Pembrolizumab|Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab
224101152|NCT01876589|DEVICE|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
224101153|NCT01876589|DEVICE|Xience Prime|Drug eluting metallic stent
224101154|NCT03797287|DEVICE|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
224101155|NCT03797287|PROCEDURE|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
224287554|NCT05115526|OTHER|PEEP setting|PEEP setting according to various methods
224287555|NCT00908557|OTHER|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
224287556|NCT00908557|OTHER|Control|information based on the classic informed consent document
224101156|NCT01663649|BEHAVIORAL|Deprexis|web-based treatment program for depression
224101157|NCT01663649|BEHAVIORAL|Wait-list|the wait-list group receives Deprexis after 6 month
224101158|NCT02201810|BEHAVIORAL|Rate reduction intervention|
224101159|NCT02201810|BEHAVIORAL|Recycling Group|
224101160|NCT02201810|BEHAVIORAL|Choice Group|
224101161|NCT02201810|BEHAVIORAL|Proactive QL|
224101162|NCT00226642|DRUG|Sertralin|
223537512|NCT03279926|BEHAVIORAL|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
224101163|NCT00226642|BEHAVIORAL|Cognitive-behavioral therapy|
224101164|NCT00226642|DRUG|Placebo|
224101165|NCT00226642|BEHAVIORAL|Non-specific supporting group therapy|
224101166|NCT05453799|DRUG|Vudalimab|Given IV
224101167|NCT01567436|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
224101168|NCT04184648|OTHER|no interventions|no intervention
224101169|NCT05434546|DRUG|Sepranolone|Treatment with 10 mg Sepranolone s.c. twice weekly for 12 weeks alongside patient's standard of care Tourette treatment.
224101170|NCT02039947|DRUG|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
224101171|NCT02039947|DRUG|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
224101172|NCT06024252|DRUG|TACE|TACE in combination with atezolizumab + bevacizumab for at least one interval of no more than eight weeks.
224101173|NCT05251545|OTHER|Pulmonary vein isolation|Comparison of power levels in catheter ablation in regard of single procedure success rate (freedom of any atrial arrhythmia with a duration of more than 30 sec. 45 Watts versus standard power levels (30 Watts).
224101174|NCT00644267|BEHAVIORAL|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
224101175|NCT05939284|DRUG|Injection of Cetrorelix|Patients received Cetrorelix subcutaneous injection on the day-6 in a dose of 0.25 daily till the trigger day.
224101176|NCT05939284|DRUG|Oral insertion of dydrogeserone|Patients received dydrogesterone in an oral dose of 20 mg/day in parallel with gonadotropin injection from day-2 of the menstrual cycle till the trigger day
224101177|NCT01772134|DRUG|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
224101178|NCT01772134|DRUG|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
224101179|NCT01772134|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
224101180|NCT01772134|DRUG|Placebo|Inhalation Powder, Placebo
224101181|NCT06404190|COMBINATION_PRODUCT|Diode laser and 3% hydrogen peroxide|"Hydrogen peroxide due to its super radicals has a local antimicrobial effect. Since hydrogen peroxide can be easily available in a clinical setting and is cost-effective. It could be used for photo disinfection along with lasers.~The diode lasers that belong to the 655-980 nm spectrum could represent a safer alternative. Because of the transmission or scattering effect on hydroxyapatite, diode lasers have no effect on hard tissues and deposits. The photoactivation procedure uses photolysis of hydrogen peroxide with 810nm laser.~Hydrogen peroxide acts as an endogenous dye, which can increase the laser effect at this level and also generate ROS. Thus the combination of 3% H2O2 and laser light generate hydroxyl radicals as a result of photoactivation.~Therefore, the diode laser stimulation of 3%hydrogen peroxide has been utilized adjunctive to SRP to optimize clinical outcomes."
224287557|NCT05918757|OTHER|Protein dose 1.5 g/kg/day|Administration of 1.5 g of protein/kg/day via enteral/parenteral nutrition
223722464|NCT01594983|DRUG|Placebo of LCQ908|Matching placebo of LCQ908
223537513|NCT01227057|BEHAVIORAL|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
223537514|NCT01227057|BEHAVIORAL|Case Management|Case management
223537515|NCT04549480|DRUG|Bosutinib capsule|100 mg dose of bosutinib pediatric capsule
223537516|NCT04549480|DRUG|Bosutinib tablet|100 mg dose of bosutinib tablet
223722465|NCT01594983|DRUG|Placebo of fenofibrate|Matching placebo of fenofibrate
223722466|NCT01594983|DRUG|Placebo of fish oil|Matching placebo of fish oil capsule
223722467|NCT07073365|OTHER|Local Therapy (Surgery or Radiotherapy)|Patients will receive local therapy, either surgical resection or radiotherapy, to the primary lung tumor following disease control after first-line treatment with osimertinib plus platinum-based chemotherapy (FLAURA2 regimen). The specific modality (surgery or radiotherapy) will be determined based on tumor characteristics, patient condition, and multidisciplinary team assessment.
223722468|NCT07014969|PROCEDURE|En-bloc HoLEP|Removal of the whole adenoma in one piece using laser energy
223722469|NCT06879639|OTHER|Exercise|The workout routine for the Land Exercise (LE) group will be segmented as follows: A cardio segment (15-20 minutes) involving treadmill walking/running or cycling on the stationary bike; A strength training segment (35 minutes) comprising bench press, seated row, leg extension, squats, pull down, peck-deck, hamstring curls, curl-ups, and back extensions; and a cool-down phase (5-10 minutes) featuring stretching exercises.
223722470|NCT06879639|OTHER|Control|The control group will not receive any formal indication or support to perform structured exercise training but will be allowed to engage in physical activity ad libitum.
224101182|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
224101183|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
224101184|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
223537517|NCT01840033|DEVICE|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
223537518|NCT01840033|DEVICE|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
223537519|NCT02752347|DEVICE|Surface EMG device|measuring the muscles activity using surface EMG device
223537520|NCT00300014|PROCEDURE|Intravitreal triamcinolone injection|
223537521|NCT00300014|PROCEDURE|Air-fluid exchange|
223537522|NCT05562505|OTHER|Venovenous ECMO|ECMO therapy for patients with hypoxic respiratory failure.
223722471|NCT06879639|OTHER|Exercise|The activities for the Water Exercise (WE) group will be divided into segments: An aerobic portion (15-20 minutes) involving water walking and jogging combined with arm movements; A resistance portion (35 minutes) including chest/upper back guidance, chest back press, behind-the-back press, pivoted shoulder press (upper body), and calf lifts, supported squats, outer/inner thigh scissors, and forward and back leg glide (lower body), and finally, a cool-down period (5-10 minutes) comprising stretching exercises.
223722472|NCT06751927|BEHAVIORAL|Educational Video|Education video on smoking, nicotine receptor involvement in addiction, craving, withdrawal and mechanisms of action for nicotine replacement and varenicline.
223722473|NCT05610072|DRUG|n-acetylcysteine|Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.
224101185|NCT01740362|DRUG|CP-690,550|10 mg (2 x 5 mg tablets), single dose
223722474|NCT05610072|DRUG|Hydromorphone|Subjects will receive up to 192 mg oral hydromorphone daily.
223722475|NCT05610072|DRUG|Placebo n-acetylcystine|Subjects will be randomized to receive placebo n-acetylcysteine daily.
223722476|NCT05610072|DRUG|Placebo hydromorphone|Prior to some experimental sessions, subjects will receive placebo hydromorphone
223722477|NCT06930534|DEVICE|Swoop Plus Mk2.0|portable brain MRI scanner
223722478|NCT07124429|OTHER|Reformer Pilates|Reformer pilates is a form of exercise that uses a specialized machine with a sliding carriage and springs to provide resistance. It is highly effective for improving core strength, flexibility, and muscle tone while also promoting better posture and balance.
223729477|NCT01732250|DRUG|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
223729478|NCT04688762|OTHER|e-consult application (tool)|A numeric application used as a support in consultation to explain the surgical management of the patient.
224101186|NCT05749588|DRUG|A1: SHR-A1811|A1: an anti-HER2 antibody-drug conjugate (ADC)
224101187|NCT05749588|DRUG|A2: SHR-A1811 with Camrelizumab|"A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
224101188|NCT05749588|DRUG|B1: TROP2 ADC|B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
224101189|NCT05749588|DRUG|B2: TROP2 ADC with Camrelizumab|"B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody"
224101190|NCT05749588|DRUG|C1: SHR-A1811|C1: an anti-HER2 antibody-drug conjugate (ADC)
224101191|NCT05749588|DRUG|C2: SHR-A1811 with BP102|"C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
224101192|NCT05749588|DRUG|D1: TROP2 ADC|D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
224101193|NCT05749588|DRUG|D2: TROP2 ADC with BP102|"D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)"
224101194|NCT05749588|DRUG|E1: SHR-A1811|E1: an anti-HER2 antibody-drug conjugate (ADC)
224101195|NCT05749588|DRUG|F1: TROP2 ADC|F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
224101196|NCT05749588|DRUG|G1: SHR-A1811|G1: an anti-HER2 antibody-drug conjugate (ADC)
224101197|NCT05749588|DRUG|H1: TROP2 ADC|H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
224101198|NCT04702230|DIAGNOSTIC_TEST|MRI|Baseline and follow-up MRI at 1 and 3 months post-TAE or post-TARE
223537523|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
224287558|NCT05918757|OTHER|Protein dose 1.0 g/kg/day|Administration of 1.0 g of protein/kg/day via enteral/parenteral nutrition
223537524|NCT02878876|DIETARY_SUPPLEMENT|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
223537525|NCT00363584|DRUG|capecitabine|
223537526|NCT00363584|OTHER|clinical observation|
223722479|NCT07124429|OTHER|conservative treatment|Conservative physiotherapy is a treatment approach that aims to manage pain and improve function using non-surgical methods. This treatment often includes methods like applying hot packs to relax muscles and increase circulation, and using a TENS (Transcutaneous Electrical Nerve Stimulation) device to help relieve pain.
224101199|NCT03728244|DRUG|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
224101200|NCT03728244|DRUG|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
224101201|NCT06002464|PROCEDURE|Acupuncture|Patient will have session of 30 minutes of acupuncture every day during 3 days
224101202|NCT06002464|PROCEDURE|Bilateral ESP catheter|Analgesia by Bilateral Continuous erector spine plane block catheter at T9 level for 2 days
224101203|NCT05502289|DEVICE|TEST LENS|DAILIES TOTAL1® for Astigmatism Contact Lenses (DT1fA)
224101204|NCT05502289|DEVICE|CONTROL LENS|PRECISION1™ for Astigmatism Contact Lenses (P1fA)
223537527|NCT00363584|PROCEDURE|adjuvant therapy|
223537528|NCT02271529|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
223722480|NCT07133009|OTHER|Intentional Relationship Model (IRM) Training|"1 Theory: Brief introduction to the Intentional Relationship Model, therapeutic self-awareness, and explanation of therapeutic styles.~1. Practice: Students share their existing knowledge and thoughts about therapeutic styles, and discuss the practical implications of therapeutic styles that may be relevant to them.~2. Theory: Information about defining interpersonal characteristics and getting to know our clients~2 Practice: Sources of differences in client profiles in the client-therapist relationship, structuring questions appropriately, and practices for getting to know our clients better 3 Theory: Information about potential difficulties that may arise in the therapeutic process 3 Practice: Scenarios are played out about what can be done to address difficulties that may arise in the client-therapist relationship 4 Theory: Information about interpersonal reasoning skills and coping with difficulties 4 Practice: Strategies that can be used to create an appropriat"
224101205|NCT00968734|DIETARY_SUPPLEMENT|colecalciferol|50.000UI single oral dose
223537529|NCT03942224|DRUG|Bortezomib|Given SC
223537530|NCT03942224|BIOLOGICAL|Daratumumab|Given IV
224287559|NCT01706016|PROCEDURE|Thermic destruction of tissue by Laser using the Novilase device|
224101206|NCT04658069|OTHER|no specific interventions|no specific interventions
223722481|NCT06096857|DRUG|Roseomonas mucosa (RSM2015) and Cardamom seeds|Freeze dried packet to be reconstituted in water
223722482|NCT06096857|DRUG|Placebo (sucrose)|Freeze dried packet to be reconstituted in water
224101207|NCT04756934|DRUG|HX008|HX008: 200mg, Q3W
224101208|NCT04756934|DRUG|LP002|LP002: 1mg/kg, or 3mg/kg, or 5mg/kg, Q3W
223537531|NCT03942224|DRUG|Dexamethasone|Given IV and PO
223537532|NCT03942224|DRUG|Ixazomib|Given PO
224101209|NCT05523934|DRUG|Capsaïcine patch|Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.
224101210|NCT03369795|DRUG|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
224101211|NCT03369795|OTHER|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
224287560|NCT00455416|DRUG|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
224287561|NCT00455416|DRUG|Selenium (L-Selenomethionine),|100mcgx2 daily
224287562|NCT00455416|DRUG|Garlic extract (Allicin)|6 garlic pearls daily
224287563|NCT00455416|DRUG|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
224287564|NCT00455416|DRUG|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
224287565|NCT00455416|DRUG|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
224287566|NCT02440516|OTHER|Early treatment group|Physical- and occupational Therapy
224287567|NCT02440516|OTHER|Late treatment group|Waiting list - then Physical- and occupational Therapy
224287568|NCT04049916|DRUG|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
223722483|NCT06347484|BEHAVIORAL|EHR-informed Recruitment Method of Contact|The intervention being studied here is the method of contact (patient portal vs. email vs. postal mail) after being identified in the EHR
223722484|NCT06347484|BEHAVIORAL|Educational Text-Messages and Connection to Cardiovascular Research Opportunities|All participants who enroll in CONNECT, regardless of method of contact, will receive educational text messages and connection to cardiovascular research opportunities. Text messages will be tailored and include content on cardiovascular health promotion and research participation.
223722485|NCT04106856|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224101212|NCT01250821|DRUG|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
224101213|NCT00123084|BEHAVIORAL|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
223722486|NCT04106856|DRUG|Losartan|Given PO
223722487|NCT04106856|DRUG|Losartan Potassium|Given PO
224101214|NCT00123084|BEHAVIORAL|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
224101215|NCT06062719|DRUG|PPI group|80-mg bolus of PPI alone (control group= A), followed by continuous intravenous (IV) infusion at 8 mg/h for a total of 72 hours
224101216|NCT06062719|DRUG|PPI plus octreotide|octreotide adjunctive group, in addition to the pantoprazole (Study group= B) for 72 h, received a 100-μg bolus of octreotide, followed by continuous IV infusion of 50 μg/h for a total of 72 hours
224101217|NCT01179529|DRUG|Omalizumab (Xolair®)|
223722488|NCT04106856|OTHER|Quality-of-Life Assessment|Ancillary studies
224101218|NCT01349348|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
224101219|NCT01349348|DRUG|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
223722489|NCT04106856|OTHER|Questionnaire Administration|Ancillary studies
223949620|NCT06093451|DRUG|Dexmedetomidine|Moderate agitation: 120 mcg Severe agitation: 180 mcg
224101220|NCT01349348|DRUG|placebo|tablet, 7.5/15mg , Qd, 7days.
224101221|NCT04078750|BEHAVIORAL|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
224101222|NCT05531357|DIAGNOSTIC_TEST|Transvaginal ultrasound scans|"Transvaginal ultrasound scans to map ovarian follicle growth and ovulation, finger-prick blood sampling for dried blood spot (DBS) hormonal assays and urine sampling for hormone metabolites, every consecutive day for an interovulatory interval.~Weekly venipuncture samples will be taken for standard ELISA hormonal assays. The hormones of interest are FSH, LH, estradiol, progesterone, AMH, inhibins A and B, GDF-9 and BMP-15."
224101223|NCT02016807|DEVICE|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
223722490|NCT05346471|DEVICE|Multimodal neuromonitoring|Multimodal neuromonitoring accounts for intraparenchymatous ICP probe, brain tissue oxygen probe and/or cerebral microdialysis device
223722491|NCT03631472|DEVICE|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
223722492|NCT05952063|DIAGNOSTIC_TEST|Digital Psychological Test: Schema Scale|Thirty-five questionnaire, 5-point likert scale
223722493|NCT02197715|BEHAVIORAL|Computer-adaptive SAFE|
223722494|NCT02197715|BEHAVIORAL|Face-to-face SAFE|
223722495|NCT02197715|BEHAVIORAL|Usual Care|
223722496|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 10 mg administered once daily in the morning
223722497|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 15 mg administered once daily in the morning
223722498|NCT02470234|DRUG|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended-Release Capsules, 20 mg administered once daily in the morning
223722499|NCT00122668|DRUG|non-nucleoside reverse transcriptase inhibitors|
223722500|NCT00122668|DRUG|nucleoside reverse transcriptase inhibitors|
223722501|NCT00122668|DRUG|protease inhibitor|
223722502|NCT02289040|PROCEDURE|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
223722503|NCT00352560|DRUG|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
223722504|NCT00352560|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
223722505|NCT05463575|DRUG|Ketohexokinase inhibition|participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
223949621|NCT06093451|DRUG|Lorazepam 2 MG/ML|2 mg
223949622|NCT02915003|BEHAVIORAL|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
224101224|NCT04259502|PROCEDURE|Rhomboid intercostal block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
224101225|NCT04259502|PROCEDURE|Erector spinae plane block|The block is regional anesthesia injection techniques performed under ultrasound guidance.
224101226|NCT00133926|PROCEDURE|Treatment of periodontal disease|
224101227|NCT01605474|OTHER|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
224101228|NCT01605474|OTHER|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
224101229|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
224101230|NCT00706732|BIOLOGICAL|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
224101231|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
224101232|NCT00706732|BIOLOGICAL|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
224101233|NCT01137214|DEVICE|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
224101234|NCT00257751|PROCEDURE|Aprotinine|
224101235|NCT04626622|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
223537533|NCT01011114|DRUG|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
223537534|NCT01011114|DRUG|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
223537535|NCT02209467|OTHER|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
223537536|NCT03931226|DRUG|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
223537537|NCT02953912|PROCEDURE|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
223537538|NCT02953912|PROCEDURE|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
223537539|NCT05059886|OTHER|completion of a questionnaire on the practice of sports and possible injuries|completion of a questionnaire on the practice of sports and possible injuries
224101236|NCT04626622|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
224101237|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
224101238|NCT01523444|BEHAVIORAL|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
224101239|NCT05095389|DEVICE|ADRCs|Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer
224101240|NCT05095389|OTHER|standard care|standard care
224101241|NCT05095389|OTHER|Placebo|placebo
224101242|NCT06468371|DRUG|Dopamine Agonist (Ropinirole)|Ropinirole administration will start at 0.25 mg orally once daily, two hours before bedtime. The dose will be adjusted weekly based on symptoms, increasing by 0.5 mg increments, up to a maximum of 2.0 mg, which will be maintained for the remaining 12 weeks.
223537540|NCT03224039|DRUG|Sufentanil|Intranasal for one dose (experimental)
224101243|NCT06468371|OTHER|Excercise training|Exercise sessions will involve using a pedal bicycle twice a week for 12 weeks, integrated into the patients' hemodialysis schedule. Each session will last 20 minutes, scheduled between the second and third hours of dialysis. The first 5 minutes will be for warm-up with slow pedaling, followed by 10 minutes of intense pedaling, and concluding with a 5-minute cool-down period of slow pedaling to gradually reduce the heart rate.
224101244|NCT04751500|PROCEDURE|Outpatient hysteroscopy|Direct visualisation and careful extraction of retained pregnancy tissue using a specific hysteroscopic technology known as a hysteroscopic tissue retrieval system.
224101245|NCT04751500|BEHAVIORAL|Expectant management|Leaving the retained pregnancy tissue alone to pass by itself
224101246|NCT04751500|DRUG|Medical management|Giving medications to contract the womb to pass the retained pregnancy tissue
224101247|NCT04751500|DRUG|Antibiotic|Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
224287569|NCT04049916|DRUG|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
223722506|NCT05463575|OTHER|Placebo|participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
223722507|NCT05184140|PROCEDURE|Sentinel node detection|"Injection of the radiotracer to infundibulo-pelvic and utero-ovarian ligament in patients with high suspicion of malignancy adnexal mass. Injection of green indocyanine r to infundibulo-pelvic and utero-ovarian stumps only in case of malignancy after the adnexectomy.~Sentinel node exeresis and a complete staging surgery (including pelvic and para-aortic lymphadenectomy) will be performed in patients with ovarian cancer diagnosis."
223949623|NCT06102278|OTHER|Peritoneal Metastasis|Patients experiencing postoperative peritoneal metastasis
224101248|NCT04751500|PROCEDURE|Surgical management|Passing a small cannula/catheter/currette into the womb and mechanically scraping the womb lining to remove the retained pregnancy tissue
224101249|NCT03206502|DEVICE|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
224101250|NCT04848805|PROCEDURE|liver transplantation|total hepatectomy material was examined by pathology laboratory
224101251|NCT03022461|OTHER|Long term follow-up|
224287570|NCT04049916|DRUG|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
224287571|NCT02128555|PROCEDURE|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
224287572|NCT02128555|PROCEDURE|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
223537541|NCT03224039|DRUG|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
223537542|NCT03224039|DRUG|Morphine|intravenous push for one dose (active comparator)
223537543|NCT02866812|OTHER|questionnaires assessing the state of fatigue, depression and anxiety|
223537544|NCT02588469|OTHER|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
223537545|NCT02588469|OTHER|Control group|Standard obesity care with physical activity program
223537546|NCT03358602|RADIATION|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
223722508|NCT05778747|OTHER|Heart to Heart Yoga|The Heart to Heart Yoga intervention is a therapeutic and standardized form of yoga intervention that is adapted from MediYoga designed to fit the needs of patients with HF and family caregivers who have physical limitations and depressive symptoms and to fit cultural and social norms in Kentucky. The intervention will use a gradual, physical/ psychological yoga adaptation approach, and it will be delivered two times per week (40 -60 minutes per session) via videoconference technology for 12 weeks (total 24 sessions). Real-time, face-to-face, video conferencing technology is used.
223722509|NCT06226753|PROCEDURE|Type of anaesthesia used|Spinal anaesthesia will be used for closure of loop ileostomy
223949624|NCT03833765|PROCEDURE|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
223949625|NCT03833765|PROCEDURE|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
223949626|NCT01718223|DRUG|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
223949627|NCT01718223|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223949628|NCT01718223|OTHER|laboratory biomarker analysis|Correlative studies
224101252|NCT04863716|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be administered before the surgery.
224287573|NCT00643214|DEVICE|Tetrix|Twice daily topical application
224287574|NCT00643214|DEVICE|Tetrix|Twice daily topical application
224287575|NCT03505814|DEVICE|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
223722510|NCT04719754|DIAGNOSTIC_TEST|Vaginal swab|The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
223722511|NCT04182360|DRUG|Carbetocin|Carbetocin administered intravenously, over 1 minute following delivery of the fetal head.
223722512|NCT05605314|OTHER|Cyclosporine|eye drop
223722513|NCT00638378|DRUG|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
223722514|NCT01652898|DRUG|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
223722515|NCT01652898|DRUG|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
223949629|NCT01718223|DRUG|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
223949630|NCT02757456|BEHAVIORAL|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
223949631|NCT02757456|OTHER|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
224101253|NCT04863716|PROCEDURE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
223722516|NCT01652898|DRUG|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
223949632|NCT00070707|DRUG|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
223949633|NCT00070707|DRUG|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
223722517|NCT02559245|OTHER|Descurainia Sophia|
223722518|NCT02559245|OTHER|Ficus carica|
223722519|NCT06289608|OTHER|No intervention|No dental intervention was made. Only a clinical examination
223722520|NCT05519540|DRUG|Xevinapant (Debio 1143)|All participants (Japanese and non-Japanese) received a single oral dose of 200mg xevinapant (Debio 1143) on Day 1 under fasted condition.
223722521|NCT06259266|OTHER|Anti-reflux valve for dialysis catheter|
223722522|NCT04755803|PROCEDURE|Penoplasty|"Modified penoplasty technique:~1. Degloved the penile skin and excise the inner prepuce.~2. Advanced penoscrotal skin to cover penile shaft~3. Fixed the penis base and reconstructed the penoscrotal angle"
223722523|NCT00079118|DRUG|docetaxel|
223722524|NCT00079118|DRUG|irinotecan hydrochloride|
223722525|NCT02114814|BEHAVIORAL|Diabetes self-management program for Hispanics and their families|The intervention group received an 8-weekly culturally tailored diabetes self-management and family support education program delivered in Spanish
223722526|NCT02114814|BEHAVIORAL|General health educational program for Hispanics and their families|The attention control group received 8-weekly education program on general health information
223949634|NCT00070707|DRUG|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
223949635|NCT02462447|DRUG|11C-sarcosine|Radiotracer injection for PET/CT scan
223949636|NCT02462447|DRUG|11C-choline|Radiotracer injection for PET/CT scan
223949637|NCT04113226|DRUG|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
223949638|NCT04113226|DRUG|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
223949639|NCT04113226|OTHER|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,…) on which treatment may impact.
224101254|NCT05829057|BIOLOGICAL|Intravenous injection of P-IL-2|Ia :Single dose intravenous injection of P-IL-2；
224101255|NCT05829057|BIOLOGICAL|P-IL-2 plus Anti-PD-1 Monoclonal Antibody|Ib：P-IL-2 plus Anti-PD-1 Monoclonal Antibody；
224101256|NCT01978561|BIOLOGICAL|Post dosing with NT100|
224101257|NCT01978561|OTHER|Post dosing with Placebo|
223722527|NCT01927237|OTHER|HLR|
223722528|NCT01927237|OTHER|EHR|
223722529|NCT03825315|BIOLOGICAL|DAXI 80 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) with 80 U (Low Dose Group)
223729479|NCT01737944|DRUG|Methotrexate (MTX)|Vibex MTX Device
224101258|NCT04396587|DRUG|Sufentanil|Sufentanil(0.1μg/kg) was administered before anesthesia induction.
224101259|NCT04396587|DRUG|Hydromorphone|Hydromorphone(20μg/kg)was administered before anesthesia induction.
224101260|NCT04396587|DRUG|Oxycodone|Oxycodone(60μg/kg) was administered before anesthesia induction.
224101261|NCT04396587|DRUG|normal Saline|normal saline 10ml
224101262|NCT01059149|DEVICE|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
224101263|NCT00499551|DEVICE|Iontophoresis second generation Eyegate II device|
224101264|NCT04439786|DRUG|placebo|the control group will be given the same volume of saline.
223949640|NCT04113226|OTHER|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
224101265|NCT04439786|DRUG|lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
224101266|NCT04990076|PROCEDURE|Hysterectomy|Surgery includes different types of hysterectomy: vaginal hysterectomy, total abdominal hysterectomy and laparoscopic or Robotic hysterectomy. The type of hysterectomy does not influence histological outcome, as long as the uterus is removed in one part (no power morcellation). Indications for surgery and the type of surgery are according to the departments' protocols. If the patient is deemed to be inoperable due to the extent of the disease, a representive biopsy (e.g. trucut biopsy) will be accepted if sufficiently motivated by the oncology team.
223949641|NCT01415206|BEHAVIORAL|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
223949642|NCT01415206|BEHAVIORAL|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
223949643|NCT05995730|OTHER|Lavender oil inhalation|Lavender inhalation will be administered to this group. Participants will be asked to drop three drops of lavender oil solution on a small piece of cotton on the 1st, 2nd, and 3rd days of their first menstrual bleeding after enrollment in the study, hold it 7-10 cm from their noses, and sniff for 5 minutes. Participants will be asked to apply this application immediately after the onset of dysmenorrhea pain on the first day of their menstruation and to continue regularly every 8 hours for the first three days of menstrual bleeding. Participants will be asked to apply this application in the same way in two consecutive menstrual cycles and the participants will be followed in this process.
223949644|NCT05995730|OTHER|Placebo|Olive oil will be administered to the placebo group. The application will be similar to the experimental group.
224101267|NCT03165396|DRUG|Propofol|Propofol is the most common clinical anesthetics.
224101268|NCT03165396|DRUG|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
224101269|NCT02270567|DEVICE|NETest|Non-invasive blood test
224101270|NCT02237027|BIOLOGICAL|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
224101271|NCT02237027|BIOLOGICAL|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
224101272|NCT00070447|BIOLOGICAL|rituximab|
223949645|NCT04669366|DRUG|sunitinib|As provided in real world
223949646|NCT04669366|DRUG|axitinib|As provided in real world
223949647|NCT02239991|PROCEDURE|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
223949648|NCT02474004|PROCEDURE|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis \& knee scores 6 mo after the procedures
224101273|NCT00070447|DRUG|cyclophosphamide|
224101274|NCT00070447|DRUG|doxorubicin hydrochloride|
224101275|NCT00070447|DRUG|prednisone|
224101276|NCT00070447|DRUG|vincristine sulfate|
224101277|NCT00070447|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
224101278|NCT00274430|DRUG|dexamethasone 8 mg bid|
224101279|NCT00274430|DRUG|tadalafil 10mg bid|
224101280|NCT05194319|OTHER|All assessments of children (Demographic information, upper extremity skills, quality of life and participation levels)|The researcher will fill out the personal information form containing the descriptive characteristics of the parents and children. GMFCS to assess children's functional levels, Manual Ability Classification System (MACS) to assess hand skills, Modified Ashworth Scale for upper extremity muscle spasticity, for upper extremity functional skills; Jebson Taylor Test, Abilhand Kids scale, for Quality of Life; The Quality of Life Scale for Children (PedsQL), PODCI criterion for participation levels will be administered by a physiotherapist who has 2 years of experience in the profession and works in the field of pediatric rehabilitation. The Jebson Taylor test and spasticity classification will be applied directly to the child by the physiotherapist, but other scales will be filled in by the parents under the supervision of the physiotherapist. .
224101281|NCT06367322|DRUG|Statin|"The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy."
224101282|NCT05596981|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
224287576|NCT03505814|DEVICE|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
223722530|NCT03825315|BIOLOGICAL|DAXI 120 U|DaxibotulinumtoxinA for injection for the treatment of unilateral plantar fasciitis (PF) 120 U (High Dose Group)
223729480|NCT04630418|OTHER|NanoSilk Cosmo|Participant will receive 30 mL of NanoSilk Cosmo jar.
224101283|NCT03459040|DRUG|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
224101284|NCT02765841|DRUG|Lomitapide|
224101285|NCT04847986|BEHAVIORAL|acceptance and commitment therapy (ACT)|Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 8 weeks through Zoom videoconferencing with psychoeducation materials provided.
224101286|NCT04847986|BEHAVIORAL|Control group|The control group will receive care as usual with psychoeducation materials provided.
224101287|NCT00986349|DEVICE|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
224101288|NCT01585649|DRUG|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
224101289|NCT02299934|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
224101290|NCT02299934|DIAGNOSTIC_TEST|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
224101291|NCT05367661|DRUG|CHK336|Tablet
224287577|NCT02504723|DRUG|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure \>90 mm Hg.
224101292|NCT05367661|DRUG|Placebo|Tablet
224101293|NCT00561353|DRUG|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
224101294|NCT00561353|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
224101295|NCT00561353|DRUG|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
224101296|NCT00561353|DRUG|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
224101297|NCT05015712|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
224101298|NCT03142100|DEVICE|cochlear implants and hearing aids|speech perception tests and bimodal fitting
223949649|NCT02301507|BEHAVIORAL|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
224101299|NCT04205552|DRUG|Nivolumab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min
224101300|NCT04205552|DRUG|Relatlimab 10 MG/ML Intravenous Solution|Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
224101301|NCT02511210|BEHAVIORAL|regional anesthesia|preoperative anxiety
224101302|NCT02511210|BEHAVIORAL|general anesthesia|preoperative anxiety
224101303|NCT06372977|DIAGNOSTIC_TEST|kappa index|CSF albumin /serum albumin ratio (Qalb) k-index = (CSF kFLC/serum kFLC)/Qalb
224287578|NCT02504723|DRUG|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
224287579|NCT05927181|PROCEDURE|TAOM|In the TAOM group, the gap between the implant and the facial bone wall was grafted with inorganic bovine bone (Geistlich Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and, in addition, a connective tissue graft (CTG) was placed submucosally on the labial bone plate by means of an envelope technique.
224287580|NCT01111214|OTHER|no intervention|There is no intervention. This is a non interventional study.
223722531|NCT03825315|OTHER|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
223722532|NCT04758780|DRUG|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
224101304|NCT03728673|DRUG|Escitalopram Oral Capsules|Active capsules will contain 10 mg escitalopram oxalate.
224101305|NCT03732924|DIAGNOSTIC_TEST|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
224287581|NCT04692025|DRUG|ASC41 tablet|Oral tablet
224287582|NCT00799916|DRUG|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
224287583|NCT00799916|DRUG|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
224287584|NCT04385524|BIOLOGICAL|Adjuvanted Hepatitis B Vaccine|Adjuvanted Hepatitis B vaccine will be provided to healthcare workers previously vaccinated with the standard 3-dose series of Hepatitis B vaccine but who have failed to respond to two complete 3-dose series
224287585|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Placebo|Colored water
224287586|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
224287587|NCT03512496|DIETARY_SUPPLEMENT|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
223729481|NCT01052051|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 2000 IU/daily
223729482|NCT01052051|DIETARY_SUPPLEMENT|Calcium carbonate|Calcium carbonate 1500mg / daily
224287588|NCT06108258|DRUG|IV iron administration|IV iron administration during pregnancy
224287589|NCT01304758|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
224287590|NCT02244749|OTHER|skin specimen|skin specimen
223729483|NCT01252017|DRUG|nilotinib|nilotinib (200mg/tab) 1 tab everyday
223729484|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
223722533|NCT04654130|OTHER|Neurofeedback|"NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks."
223949650|NCT00488605|DRUG|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
223949651|NCT00488605|DRUG|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
223949652|NCT02169609|DRUG|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
223949653|NCT02002689|DRUG|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
223949654|NCT04524676|PROCEDURE|Individualized Treatment|Patients under evaluation including hepatic venous pressure gradient (HVPG) and contrast-enhanced computed tomography of portal venous. For those patients with a HVPG ≥12mmHg or with extraluminal para-gastric vein will under transjugular intrahepatic portosystemic shunt and others receive endoscopic treatment.
223949655|NCT01626833|DRUG|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE\* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
223949656|NCT01626833|BIOLOGICAL|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
223949657|NCT00009763|BIOLOGICAL|filgrastim|
223949658|NCT00009763|BIOLOGICAL|monoclonal antibody m170|
223949659|NCT00009763|DRUG|cyclosporine|
223949660|NCT00009763|DRUG|paclitaxel|
223949661|NCT00009763|PROCEDURE|peripheral blood stem cell transplantation|
223949662|NCT00009763|RADIATION|yttrium Y 90 monoclonal antibody m170|
223949663|NCT00087516|DRUG|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
223949664|NCT00087516|DRUG|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
223949665|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
223949666|NCT00087516|DRUG|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
223949667|NCT00087516|DRUG|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
224101306|NCT02601144|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation
224101307|NCT00540540|DEVICE|Diffuse Optical Spectroscopy|Breast properties scanning
224101308|NCT03431948|DRUG|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
224101309|NCT03431948|DRUG|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
223722534|NCT01693653|DRUG|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
223722535|NCT01204853|DRUG|Sitaxentan|sitaxentan sodium 100 mg
224101310|NCT03431948|DRUG|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
224101311|NCT03431948|RADIATION|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
224101312|NCT05954039|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex|The study foresees the intake of 2 capsules per day during 84 days
224101313|NCT05954039|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
224101314|NCT06380244|OTHER|anesthesia without opioids|Opioid free general anesthesia
224101315|NCT01273818|DRUG|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
224287591|NCT04109313|DRUG|LOU064|Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.
224287592|NCT02011919|DEVICE|Echopulse|HIFU Under ultrasound guidance
224287593|NCT04119219|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
224287594|NCT01574664|DEVICE|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
224287595|NCT06357949|DEVICE|High-intensity laser|"All patients will receive a rehabilitation program consisting of stretching, strengthening, balance, and walking exercises targeting the lower extremities for 45 minutes, 5 days a week, for 6 weeks. Walking training will initially begin on level ground and gradually progress to different levels and surfaces.~High-intensity laser will be applied continuously in biostimulation mode 3 days a week, once a day, for a total of 9 sessions over 3 weeks"
224287596|NCT06357949|DEVICE|Sham laser|The same procedure will be followed, but sham laser will be applied at 0 j/cm2 for 10 minutes.
223537547|NCT03358602|PROCEDURE|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
223537548|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
223537549|NCT03768427|COMBINATION_PRODUCT|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
223537550|NCT03768427|DRUG|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
223537551|NCT03768427|DRUG|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
223949668|NCT00612521|DRUG|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
223949669|NCT00972036|DEVICE|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
223949670|NCT01765699|DEVICE|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
223949671|NCT02638558|OTHER|written + oral explanation|
223949672|NCT02638558|OTHER|written explanation|
223949673|NCT03185143|DRUG|Naltrexone and Acetaminophen Combination|Treat a single Qualified Migraine attack.
223949674|NCT03185143|DRUG|Sumatriptan 100 mg|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
223949675|NCT03185143|DRUG|Placebo|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
223949676|NCT01093690|DRUG|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
223949677|NCT01093690|DRUG|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
223949678|NCT06086067|OTHER|Aerobic session|This session will consist of an aerobic training session performed on a cycle ergometer.
223949679|NCT01281436|OTHER|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
223949680|NCT01281436|OTHER|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
223949681|NCT01052935|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
223949682|NCT03999788|PROCEDURE|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
223949683|NCT03999788|PROCEDURE|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
223949684|NCT05658094|DEVICE|Exosome|Each patients will receive 4 injection with an interval of 14 days during two months
223949685|NCT01959776|PROCEDURE|Vitrectomy|
224287597|NCT06468423|DRUG|Deferasirox (DFX)|Oral DFX at a dose of 30mg/kg daily advised for a duration of 6 months.
224287598|NCT06468423|DRUG|Deferoxamine (DFO)|DFO group (n=71) included children who were given DFO at a dose of 50 mg/kg through the subcutaneous route by infusion pump five days a week for a duration of 6 months.
223949686|NCT01229904|BEHAVIORAL|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
223949687|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
223949688|NCT01049516|BEHAVIORAL|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
223949689|NCT01049516|BEHAVIORAL|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
223949690|NCT01049516|BEHAVIORAL|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
223949691|NCT04870775|BEHAVIORAL|Mindfulness Training Program|Mindfulness training program to reduce psychotropathological symptoms in hospital workers
223949692|NCT02399605|OTHER|Stimulation|Subcutaneous abdominal electrical stimulation
223949693|NCT00156845|PROCEDURE|AI-700 contrast-enhanced echocardiography|
223949694|NCT00113308|DRUG|GW406381|
223949695|NCT04349319|DEVICE|Digital preoperative planning|Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
223949696|NCT00568087|DRUG|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
223949697|NCT00568087|DRUG|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
223949698|NCT00815100|DRUG|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
223949699|NCT00815100|DRUG|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
224101316|NCT01273818|DRUG|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
223949700|NCT03830320|DRUG|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
223949701|NCT03830320|DEVICE|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
223949702|NCT03830320|PROCEDURE|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
223949703|NCT03830320|PROCEDURE|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
223949704|NCT01128959|DRUG|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
223949705|NCT02338999|RADIATION|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
224101317|NCT01273818|DRUG|Gentamicin|80 mg gentamicin application intraoperatively
223537552|NCT03768427|DRUG|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
223537553|NCT02583347|DEVICE|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
223537554|NCT01440361|DRUG|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
223537555|NCT01440361|DRUG|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
223537556|NCT00499668|DRUG|aprepitant|125 mg orally for 7 days
223949706|NCT02338999|DRUG|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
223949707|NCT02338999|DRUG|Placebo|
223949708|NCT02701296|DRUG|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
223949709|NCT02701296|DRUG|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
224101318|NCT05295277|OTHER|Standard of care genetic testing group|N/A - no intervention as this is an observational study.
224101319|NCT03815175|DEVICE|XIENCE|Subjects who received XIENCE family stent systems will be included.
224101320|NCT03815175|DRUG|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
224101321|NCT05833880|BEHAVIORAL|Self-administered questionnaire|Self-administered questionnaire regarding complementary and alternative medicine use
224101322|NCT06316427|DRUG|Autologous CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from patients.
223537557|NCT00499668|DRUG|ondansetron hydrochloride|24 mg orally for 7 days
223537558|NCT02710877|DEVICE|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
223537559|NCT02710877|OTHER|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
224101323|NCT06316427|DRUG|Prior-HSCT donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from prior-HSCT donors.
224101324|NCT06316427|DRUG|New donor-derived CD7 CAR T-cell|Peripheral blood mononuclear cells for the production of CD7 CAR T cells are collected from new donors.
224101325|NCT06244927|PROCEDURE|Replantation surgery|Surgery
224101326|NCT05817201|DRUG|Toripalimab|Toripalimab 240mg day7 and day 28，every 3 weeks 1month after radiotherapy，until progression or 1 years or intolerant.
224101327|NCT05817201|DRUG|Tegafur|Tegafur 70mg/m2/day day 1 to day 14，and day 29 to day42.
224101328|NCT05817201|RADIATION|IMRT|PGTV 54Gy/2.16Gy/25F/5W, PTV 45Gy/1.8Gy/25F/5W
223949710|NCT05483166|BEHAVIORAL|ImPACT|"During the ImPACT program, the childhood cancer survivor and at least one parent collaborates on:~1. Becoming aware of the child's core strengths and difficulties~2. Helping the child to be optimally responsive to the guidance of the parent(s), and~3. Creating compensatory strategies to respond to real-world manifestations of the child's difficulties and helping the child implement these strategies at home."
223949711|NCT05077670|PROCEDURE|Pulmonary vein electrical isolation|Electrical isolation of the pulmonary veins from the left atrium with cryoablation therapy.
223949712|NCT05077670|DEVICE|Atrial substrate mapping|Electro-anatomical maps will be performed with CARTO navigation system with multi-electrode catheters.
223949713|NCT03142867|OTHER|non-applicable|non-applicable
223949714|NCT01683669|OTHER|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
224101329|NCT05498298|DEVICE|Biopotentials measurement with gtec device|A measurement of 40 minutes is performed with the gtec g.Hlamp to collect biopotential signals. 32 electrodes are attached to the body (abdomen, thorax and back).
224101330|NCT04813510|DEVICE|electroacupuncture treatment|"Participants in the treatment group underwent 60 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. AfterDeqi, electroacupuncture stimulation apparatus(HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of treatment."
223537560|NCT02710877|DRUG|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
223949715|NCT01683669|OTHER|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
223949716|NCT05044416|DEVICE|VieScope|intubation with VieScope laryngoscope
223949717|NCT05044416|DEVICE|Videolaryngoscopy|intubation with videolaryngoscope
223949718|NCT01044446|DRUG|Icodextrin|one exchange daily
224101331|NCT04813510|DEVICE|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints).. Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle for the same time as treatment group"
224101332|NCT05124938|DIAGNOSTIC_TEST|Laboratory investigations for control: a-Complete blood count. b-Liver function test. c-kidney function test. d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.|a-Complete blood count. b-Liver function test. c-kidney function test d-thyroid-stimulating hormone,T3 and T4. e-Assessment of levels of CA19-9.
224101333|NCT05000801|BIOLOGICAL|DC vaccine|Autologous/or HLA-matched donors' DCs loaded with WT1/TERT/survivin
224101334|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention|This intervention is an abbreviated version of the Diabetes Prevention Program, which has been shown to be effective in reducing the risk of developing type 2 diabetes.
224287599|NCT01132664|DRUG|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
223537561|NCT02710877|DRUG|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
223537562|NCT02710877|DRUG|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
223729485|NCT01594125|DRUG|Nintedanib low dose|twice daily oral dosing
223949719|NCT01044446|DRUG|glucose-based peritoneal dialysate|original exchange frequency
223949720|NCT02441374|DEVICE|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
223949721|NCT02441374|OTHER|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
223949722|NCT04334252|OTHER|Questionnaire|Questionnaire
223949723|NCT05019859|BEHAVIORAL|low carb diet|low carb diet
223949724|NCT01844401|DRUG|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
223949725|NCT01844401|DRUG|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
224101335|NCT04457440|BEHAVIORAL|Intensive Lifestyle Intervention enhanced with Cognitive Behavioral Sleep Intervention|This intervention will consist of the same 8 sessions of ILI with additions of sleep components in each session. The additional sleep components will include (a) psychoeducation about the importance of sleep in weight control and glycemic control, (b) sleep hygiene, (c) stimulus control, (d) modifying maladaptive beliefs about sleep, (e) and, setting individualized sleep schedule and reviewing sleep schedule.
224101336|NCT00002700|DRUG|asparaginase|
224101337|NCT00002700|DRUG|cyclophosphamide|
224101338|NCT00002700|DRUG|cytarabine|
224101339|NCT00002700|DRUG|daunorubicin hydrochloride|
224101340|NCT00002700|DRUG|dexamethasone|
224101341|NCT00002700|DRUG|doxorubicin hydrochloride|
223949726|NCT05848856|BEHAVIORAL|Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up|Study of different types of risk-informed screening approaches and the measurement of patient compliance with screening recommendations based on different approaches to patient engagement
223949727|NCT02082990|BEHAVIORAL|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
223949728|NCT02082990|BEHAVIORAL|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
223949729|NCT03605420|OTHER|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
224101342|NCT00002700|DRUG|leucovorin calcium|
224101343|NCT00002700|DRUG|mercaptopurine|
224101344|NCT00002700|DRUG|methotrexate|
224101345|NCT00002700|DRUG|mitoxantrone hydrochloride|
224101346|NCT00002700|DRUG|prednisolone|
224101347|NCT00002700|DRUG|prednisone|
224101348|NCT00002700|DRUG|therapeutic hydrocortisone|
224101349|NCT00002700|DRUG|vincristine sulfate|
224101350|NCT00002700|PROCEDURE|allogeneic bone marrow transplantation|
224101351|NCT00002700|PROCEDURE|autologous bone marrow transplantation|
224101352|NCT00002700|RADIATION|radiation therapy|
224101353|NCT01020331|DRUG|Memantine|
223949730|NCT05498051|PROCEDURE|Sentinel lymph node identification|Therefore this prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using peritumoral submucosal injections.
223949731|NCT03682003|DIAGNOSTIC_TEST|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
223949732|NCT04276506|OTHER|music group|to reduce anxiety, some selected music pieces will have patients listened by headset.
223949733|NCT04276506|OTHER|information group|A visual information booklet which is prepared by the researchers will be used
223949734|NCT03940339|OTHER|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
223949735|NCT03940339|OTHER|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
223949736|NCT00569166|BEHAVIORAL|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
223949737|NCT00569166|BEHAVIORAL|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
223949738|NCT00569166|BEHAVIORAL|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
223949739|NCT06027970|DRUG|Terlipressin|After successful Endoscopic variceal ligation (EVL) The treatment group will receive injection Terlipressin (1 mg IV bolus q 4 hourly) for 2 days
223949740|NCT06027970|OTHER|0.9% normal saline (NS)|After successful Endoscopic variceal ligation (EVL) the control group will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly instead of Terlipressin for 2 days
223949741|NCT05103891|DRUG|Binimetinib Oral Tablet|two-period, crossover study
223949742|NCT03360617|DEVICE|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
224101354|NCT04934735|PROCEDURE|Rehabilitation program group|"The case-management rehabilitation program was conducted by a clinical social worker within the occupational medicine clinic and included several components:~1. Intake by a case manager~2. Referral to an occupational physician was within one week of the intake.~3. Charting an occupational rehabilitation program and timing the RTW date~4. Coordinating between the patients and their family, treating physicians, the employer, community services, and meeting with the patient's family - all on a needful basis.~5. Provision of a guidance booklet for employers on the RTW of cardiac patients.~6. The psychosocial intervention was tailored to the patient's emotional state, occupational needs, and specific requests.~7. Intensive follow-up sessions aimed to ensure that the rehabilitation program was carried out as planned."
224101355|NCT04853797|DRUG|Levcromakalim|20 min infusion of 1 mg Levcromakalim followed by either oral Ivabradine or Placebo.
224101356|NCT04853797|DRUG|Ivabradine|15 mg oral Ivabradine.
224101357|NCT04853797|DRUG|Placebo|Oral placebo (calcium supplements).
224101358|NCT03304457|DRUG|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
224101359|NCT03304457|DRUG|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
224101360|NCT03420677|DEVICE|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
224101361|NCT03420677|DEVICE|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
223949743|NCT03360617|DEVICE|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
224101362|NCT03945279|DRUG|BIIB100|Administered as specified in the treatment arm.
223722536|NCT05524038|DRUG|Bupivacaine Hydrochloride|20mg of Bupivacaine hydrochloride as local anesthetic will be used in (QL) group and (ESB) group
224101363|NCT03945279|DRUG|Placebo|Administered as specified in the treatment arm.
224101364|NCT00457639|DRUG|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
224101365|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"
224101366|NCT03638830|DRUG|Ftortiazinon (tablets 300 mg) full dose + Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"
224101367|NCT03638830|OTHER|placebo+Maxipim|placebo
224101368|NCT04057378|DEVICE|Electroconvulsive therapy|Electrically induced convulsion under anesthesia
224101369|NCT05066984|OTHER|structured, multidisciplinary and personalized post-ICU care|Structured, personalized and multidisciplinary post-ICU care tailored to patients' health problems initiated by ICU clinicians and coordinated by GPs.
224101370|NCT01579695|DRUG|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
223949744|NCT03803150|PROCEDURE|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
223949745|NCT03803150|PROCEDURE|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
224101371|NCT00000584|DRUG|immunoglobulins|
224101372|NCT03980314|DRUG|Nivolumab|Specified dose on specified days
223949746|NCT05005247|BIOLOGICAL|GBS-NN/NN2|GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
224101373|NCT01586845|DRUG|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
224101374|NCT01586845|DRUG|tacrolimus|tacrolimus as per labeled dose
224101375|NCT03419858|BEHAVIORAL|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice mindfulness meditation.
224101376|NCT03419858|BEHAVIORAL|Placebo Meditation|A well-validated brief meditation-based mental training regimen \[four sessions; 20 min/session\] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
224101377|NCT03419858|BEHAVIORAL|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
223722537|NCT05524038|DEVICE|Ultrasound device|high-frequency linear probe covered with sterile sheath Active Array L12-4 (8-13MHz) of an ultrasound machine (Philips clear vue350, Philips Healthcare, Andover MA01810, USA) for performing the blocks .
223949747|NCT06169566|DIETARY_SUPPLEMENT|synbiotics|synbiotics
223949748|NCT06169566|COMBINATION_PRODUCT|placebo|placebo
223949749|NCT05491291|OTHER|Patients with chronic wound of the lower limbs|The rating scale will be passed at three different times, day 1, day 15 and day 75.
223949750|NCT04778813|DRUG|Artemether-lumefantrine|In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
223949751|NCT02748200|RADIATION|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
223949752|NCT06200090|OTHER|No intervention|No intervention
224101378|NCT03419858|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
224101379|NCT03419858|OTHER|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
223722538|NCT05524038|DRUG|Dexamethasone|injection of 4mg dexamethasone in each block
223722539|NCT05524038|DEVICE|echogenic needle|22- gauge, 50 mm echogenic needle (Stimuplex D; B Braun, Germany) for performing the blocks .
223722540|NCT04397107|DRUG|IL-2|Patients were received low dose recombinant human Interleukin-2
223722541|NCT05625087|DRUG|Alpelisib|Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days
223722542|NCT05625087|DRUG|Ribociclib|Ribocilcib 600 mg once daily 3 weeks on/1 week off + fulvestrant 500 mg every 28 days
223949753|NCT04082598|DRUG|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
224101380|NCT02117687|DRUG|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
224101381|NCT02117687|DRUG|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
224101382|NCT04223466|PROCEDURE|Subxiphoid surgery procedure|Subxiphoid procedure for thymectomy
224101383|NCT04223466|PROCEDURE|VATS surgery procedure|VATS procedure for thymectomy
224101384|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
224101385|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
223722543|NCT02563444|DEVICE|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
224101386|NCT00782249|PROCEDURE|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
224101387|NCT01390168|BEHAVIORAL|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
224101388|NCT01390168|BEHAVIORAL|Waitlist|active waitlist
224287600|NCT01132664|DRUG|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
224287601|NCT01132664|DRUG|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
224287602|NCT04818437|OTHER|BALANCE TRAINING|Trunk, head, and upper limbs rotation from kneeling. 2- Upper limbs flexion and extension with simultaneous head movement from kneeling. 3-Pelvic bridging followed by raising one lower limb and extending knee. 4-Lifting opposite upper and lower limbs from Quadruped position. 6-Heel and toe raises, alternate rising of he right and left feet above the floor, and tandem standing. 7-Weight shifting forward. backward, sideward, and diagonally with eyes opened and eyes closed
224287603|NCT04818437|OTHER|CORE STABILITY EXERCISES|"1. Abdominal bracing while lying in supine position.~2. Abdominal bracing with heel slide while lying in supine position.~3. Abdominal bracing with Leg lifts while lying in supine position.~4. Abdominal bracing with bridging while lying in supine position.~5. Abdominal bracing while Standing.-Abdominal bracing while walking.~7-Quadra pod arm lifts with bracings while Quadra pod position. 8-Quadra pod alternate arm and leg lifts with bracing while Quadra pod position. 9-Side plank with knee flexion while side lying. 10-Side plank with knee extension while side lying"
223949754|NCT04082598|DIETARY_SUPPLEMENT|Bifidobacterium longum and Lactoferrin|
223949755|NCT01883063|DEVICE|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
223949756|NCT01883063|DEVICE|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
223949757|NCT04213768|PROCEDURE|Lateral rectus plication|The technique is the same as resection up to the muscle suturing, in the next step, the sutures is passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle is folded anteriorly by Stevens muscle hook during tightening and fixing the sutures. At the end, conjunctiva is repaired by Vicryl 8-0.
223949758|NCT04213768|PROCEDURE|Lateral rectus Resection|Following conjunctiva and tendon capsule incision, lateral rectus is hooked and dissected from its surrounding tissues. Then, the muscle is sutured according to the amount of supposed resection from lateral rectus insertion by Vicryl 6-0 (polyglation 910, coated Vicryl®, Ethicon, Blue Ash, OH). Afterwards, the muscle is cut at 1mm anterior to these sutures and the residual muscle is re-sutured to the sclera at its primary insertion. Finally the conjunctiva is repaired using Vicryl 8-0.
224287604|NCT00027742|BIOLOGICAL|pegylated interferon alfa|
224287605|NCT00027742|DRUG|temozolomide|
223722544|NCT02936570|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
223722545|NCT04109794|PROCEDURE|E-CTG|Envelope connective tissue graft
223729486|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
223729487|NCT01594125|DRUG|Nintedanib medium dose|twice daily oral dosing
223729488|NCT01594125|DRUG|Nintedanib high dose|twice daily oral dosing
223949759|NCT01535898|OTHER|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
223949760|NCT00644306|DRUG|Thalidomide|100 mg/day continuously for 18 months
223949761|NCT00644306|DRUG|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
224101389|NCT05846633|DEVICE|C mell treadmill|C Mell treadmill provides Virtual Reality environment for rehabilitation with obstacles and motivational assistance
224101390|NCT04176861|DEVICE|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
224101391|NCT05599958|DIAGNOSTIC_TEST|sweat chloride test|assessing chloride (Cl-) concentration in sweat of the patient
224287606|NCT04594915|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).
224101392|NCT05599958|GENETIC|genetic testing|detection of CFTR mutation
224101393|NCT05772364|OTHER|Loading of low-calcium water first, then high-calcium water|All cohort subjects are asked to consume water with less than 5 mg/L of calcium first, then are asked to consume water with at least 400 mg/L of calcium
224101394|NCT01360125|GENETIC|proteomic profiling|
223949762|NCT00644306|DRUG|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
224101395|NCT01360125|OTHER|flow cytometry|
224101396|NCT01360125|OTHER|laboratory biomarker analysis|
224101397|NCT04817540|DRUG|Herzuma|8mg/kg IVF loading dose at first cycle -\> 6mg/kg IVF at 2,3,4th cycle of each 21 day cycle
224101398|NCT06479603|DRUG|Nintedanib|The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
224101399|NCT06479603|DRUG|Standard of care|The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
224101400|NCT00843986|DRUG|conivaptan|Premix bag
224101401|NCT00843986|DRUG|placebo|Premix bag
224101402|NCT06989788|BIOLOGICAL|AVX70371|AstriVax Therapeutics' HBV immunotherapeutic
224101403|NCT06989788|OTHER|Placebo|Placebo
224101404|NCT07106333|OTHER|Topical Ozone Therapy|"The intervention involves local application of ozone in two forms:~Ozonated Water - used for irrigation of the extraction socket.~Ozonated Gel - applied topically inside the socket to promote healing and reduce pain.~Both are used after socket debridement and bleeding provocation, followed by standard analgesic administration (Diclofenac potassium)."
224101405|NCT07106333|OTHER|Irrigation with saline|The intervention involves irrigation with saline
224101406|NCT06994260|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|"MSOT is an advanced imaging technology that combines laser-induced ultrasound and light absorption to visualize biological tissues. By detecting ultrasound waves generated from tissue absorption of multispectral light, MSOT provides high-resolution, real-time images with functional and molecular information. One of its use is in biomedical research and clinical applications to study blood oxygenation and tissue composition, making it valuable for areas such as vascular research.~In this study, we aim to utilize MSOT to differentiate between venous, arteriovenous and lymphatic malformations."
224101407|NCT06994260|DIAGNOSTIC_TEST|Ultrasound Localization Microscopy|"ULM is a cutting-edge imaging technique that significantly enhances the resolution of traditional ultrasound by tracking the movement of microbubble contrast agents within blood vessels. This approach enables the visualization of microvascular structures and blood flow dynamics at a super-resolution scale, beyond the diffraction limit of conventional ultrasound.~In this study, we aim to utilize ULM to differentiate between venous, arteriovenous and lymphatic malformations."
224101408|NCT06994819|DEVICE|niostem headset (Active)|The niostem headset is a non-invasive electronic stimulation device designed to reduce hair loss and improve hair growth. It delivers low-level electrical stimulation through brush electrodes that contact the scalp. Used once daily for 30 minutes for 6 months. Sessions are guided via a smartphone app.
224101409|NCT06994819|DEVICE|Sham niostem headset (Placebo)|he sham niostem headset is visually identical to the active device but does not deliver electrical stimulation. Used once daily for 30 minutes for 6 months. Allows for blinding and placebo-controlled comparison.
224287607|NCT02936687|DRUG|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure \~8-15 mmHg that is within the range observed during exercise.
224287608|NCT02936687|DRUG|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
224287609|NCT02936687|DRUG|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
224287610|NCT02936687|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
224287611|NCT02936687|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
223949763|NCT06510959|OTHER|Digital course|The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
223949764|NCT04865718|DIAGNOSTIC_TEST|ICGA imaging|subjects undergoing intraoperative ICGA imaging
223949765|NCT03451461|OTHER|No intervention|Observational study. Clinical data recorded
224101410|NCT01725880|OTHER|Observation|
224101411|NCT03132077|PROCEDURE|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
224101412|NCT07022015|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
224287612|NCT02936687|OTHER|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
224287613|NCT02936687|DRUG|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
223949766|NCT01596686|DRUG|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
223949767|NCT00197444|DRUG|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
224287614|NCT04691375|DRUG|PY314|Dose of PY314 as a single agent given in a standard 3+3 design.
223722546|NCT04334031|GENETIC|Biobanking with genetic analysis|Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
223722547|NCT04334031|OTHER|SF-12 questionnaire|Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.
223949768|NCT00197444|RADIATION|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
223949769|NCT03142932|DEVICE|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
223949770|NCT03142932|OTHER|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
223949771|NCT03142932|BEHAVIORAL|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
223949772|NCT01229332|DRUG|Saline|Continuous 24 h administration
223949773|NCT01229332|DRUG|Carbidopa|Continuous 24 h administration
223949774|NCT00929526|PROCEDURE|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
223949775|NCT00929526|PROCEDURE|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
223949776|NCT00519844|DRUG|somatropin|
223949777|NCT01934322|OTHER|Case Management|"Furnish specific assistance and to provide referrals for the patients:~* If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~* If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~* If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~* In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
223949778|NCT06121765|OTHER|Tyrosine kinase inhibitor|Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI
223949779|NCT04062383|BEHAVIORAL|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
223949780|NCT01428609|PROCEDURE|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
223949781|NCT01984216|PROCEDURE|Roux-en-Y for the gastrojejunostomy reconstruction|
223949782|NCT01984216|PROCEDURE|Billroth II for the gastrojejunostomy reconstruction|
223949783|NCT05513729|DRUG|Canagliflozin|According to the guideline of type 2 diabetes，canagliflozin will be given to 40 patients with type 2 diabetes combined with NAFLD as first-line choice if accompanied with indicators of high risk or established atherosclerotic cardiovascular disease, chronic kidney disease or heart failure, independently of HbA1c level. It can be also given to T2DM combined with NAFLD if their HbA1c above target.
223949784|NCT05513729|DRUG|Pioglitazone|According to the newest guideline of Diabetes，pioglitazone will be given to 40 patients with T2DM combined with NAFLD if their HbA1c above target.
223949785|NCT01049698|BEHAVIORAL|Resistance Training|3 d/wk resistance training
223949786|NCT01049698|BEHAVIORAL|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
223949787|NCT02064686|OTHER|Exhaled breath temperature|
223949788|NCT05832970|OTHER|Brief skin cooling|Brief skin cooling will be applied to the hand using the cold-bath immersion
223949789|NCT01236898|DRUG|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
223949790|NCT00091728|DRUG|Depo Medroxyprogesterone acetate|
223949791|NCT00091728|DRUG|Combined oral contraceptives|
224287615|NCT04691375|DRUG|Combination Therapy: PY314 + Pembrolizumab|Dose of PY314 alone and given in combination with pembrolizumab
224287616|NCT01164306|BEHAVIORAL|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
224287617|NCT01164306|BEHAVIORAL|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
224101413|NCT07023042|OTHER|Abdominal Kinesio taping|Application of medical-grade Kinesio tape (NKH-50R) to the abdomen using a standardized circular technique, in addition to standard care for malignant bowel obstruction and ascites. Tape is applied by trained professionals after a skin sensitivity test and changed every three days or as needed. The procedure avoids open wounds and tumor sites. Participants and caregivers are educated on tape care and removal.
224101414|NCT07023042|OTHER|Standard Care Arm|Standard palliative care for malignant bowel obstruction and ascites, including symptom management, nutritional support, and medical treatment according to institutional protocols.
224101415|NCT00805415|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
224101416|NCT00805415|DRUG|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
224101417|NCT07032103|DRUG|Immunochemotherapy|Systemic chemotherapy with curative intent
224101418|NCT07030153|GENETIC|Oral swab DNA analyzed for myopia-related gene variants|Beyond detecting links between gene variants and myopia development, the testing analyzes how these variants influence treatment effectiveness. The aim is to enable early risk prediction and personalized treatment guidance for children through oral DNA testing.
224101419|NCT07031362|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|All patients who participated in the pulmonary rehabilitation and physiotherapy program underwent sessions lasting approximately two hours, conducted twice weekly over a period of eight weeks. The exercise program included breathing exercises, relaxation and stretching exercises, peripheral muscle strengthening exercises, and aerobic training.
224101420|NCT07031258|DRUG|Dose of docetaxel|According to the relative dose intensity of docetaxel (RDI; Defined as the ratio of the dose received to the full planned dose of 75mg/m2 per 6 cycles specified in the protocol) were divided into cohort 1 (patients receiving docetaxel dose intensity ≤80%) and cohort 2 (patients receiving docetaxel dose intensity ≤80%). A total of 50 patients who received docetaxel dose intensity \> 80% were planned to be enrolled, including 25 patients in the docetaxel dose intensity ≤80% group and 25 patients in the docetaxel dose intensity \> 80% group
224101421|NCT07031986|DEVICE|One-Lung ventilation with Double-Lumen Tube|To achieve the required one-lung ventilation during lung resection, patients will be managed with a double-lumen tube.
224101422|NCT07031986|DEVICE|One-Lung Ventilation with Bronchial Blocker|To achieve the required one-lung ventilation during lung resection, patients will be managed with a bronchial blocker.
224101423|NCT06710184|DRUG|Aspirin|Aspirin bolus of 300 mg followed by 75 mg daily until CAG
224101424|NCT06710184|DRUG|Fondaparinux Sodium|Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)
224101425|NCT06781294|DEVICE|Extracorporeal Cytokine hemadsorption therapy|Extracorporeal blood purification with oXiris set connected to cardiopulmonary bypass during all CPB time. Ultrafiltration was permitted.
224101426|NCT05592847|OTHER|Nurse Navigator Program|Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.
224287618|NCT01164306|BEHAVIORAL|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
224287619|NCT01322971|DRUG|Metronidazole|Metronidazole 500mg orally twice daily for seven days
224287620|NCT01322971|DRUG|Placebo|Placebo will be administered orally twice daily for seven days
223949792|NCT04277494|OTHER|Clorethyl cold spray® (Vapocoolant spray)|From the anterior superior of the dominant legs to the spinal iliac, the upper part of the patella will be measured and the center point will be marked. Cold spray will be applied to this point and its surroundings. The ethyl chloride spray bottle will be kept approximately 30 cm from the skin. An ethyl chloride stream will be applied at a 45 ° angle for 15 seconds (Shadgan et al., 2015). Skin temperature and mechanical properties of muscle; will be measured before, immediately after, 2 minutes, 5 minutes and 15 minutes after cold application.
224287621|NCT04977609|BEHAVIORAL|VR+MUSIC|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
223949793|NCT03880981|DRUG|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
223949794|NCT03880981|DRUG|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
223949795|NCT04188457|OTHER|Usual follow-up|2 medical consultations (nurse and doctor) over 24 months
223949796|NCT04188457|OTHER|Intensive follow-up|10 medical visits (nurse, doctor, pharmacist) over 24 months
224287622|NCT04977609|BEHAVIORAL|VR|A novel VR intervention designed for upper limb motor rehabilitation in post-stroke hemiparetic patients consisting in 10 daily sessions of 30 minutes, over 2 weeks, supervised by a physical therapist.
224287623|NCT04977609|BEHAVIORAL|TAU|Traditional post-stroke upper limb motor rehabilitation under the supervision of a physical therapist, for 0 daily sessions of 30 minutes, over 2 weeks.
224287624|NCT03717493|BEHAVIORAL|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking \& Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
224287625|NCT04539626|DRUG|Estrogen Therapy|EVRA skin patches with norelgesetromin 6mg / ethinyl estradiol 0.60mg, (1 patch will be placed every week during 21 days)
224287626|NCT01633294|DRUG|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
223949797|NCT04131036|OTHER|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
223949798|NCT00259363|DRUG|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
223949799|NCT00973414|DRUG|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
223949800|NCT00973414|DRUG|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
223949801|NCT00244452|DRUG|Cetrorelix|
223949802|NCT05928494|OTHER|Scenario-based high-fidelity simulation method|Postpartum care applications were carried out with the high-reality Gaumard Scientific brand, product code: S550.100 Noella simulator in the simulation laboratory of the midwifery department to the students in the intervention group.
223949803|NCT02547974|BIOLOGICAL|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
223949804|NCT02547974|BIOLOGICAL|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
223949805|NCT02547974|BIOLOGICAL|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
223949806|NCT02547974|DRUG|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
223949807|NCT04766996|BEHAVIORAL|Guided mindfulness exercises|Guided Meditation twice daily
223949808|NCT04766996|OTHER|Self-administered aromatherapy|Self-administered aromatherapy every 6 hours and at bedtime
223949809|NCT04766996|DRUG|Baby aspirin|Baby aspirin 81mg: Twice daily for 6 weeks after surgery
223949810|NCT04766996|DRUG|Tylenol/Acetaminophen|Tylenol/Acetaminophen 1000mg: Pre-operative one dose; Every 8 hours for three weeks after surgery
223949811|NCT04766996|DRUG|Pregabalin|"Pregabalin 25mg:~Twice a day for two weeks before surgery; Pre-operative 25-100 mg; Twice a day for two weeks after surgery"
223949812|NCT04766996|DRUG|Prednisone|Prednisone 5mg: Daily for three weeks after surgery
223949813|NCT04766996|DRUG|Meloxicam|"Meloxicam 7.5mg:~Twice a day, with food, for two weeks before surgery; Twice a day, with food, for two weeks after surgery"
223949814|NCT04766996|DRUG|Prilosec|"Prilosec 20mg:~Daily for two weeks before surgery; Daily for for two weeks after surgery"
223949815|NCT04766996|DRUG|Tramadol|Rescue pain medicine Tramadol 50mg up to three times a day as needed will be provided for rescue pain
223949816|NCT04766996|DRUG|Voltaren|Voltaren 1% topical arthritis gel up to 4 times daily pre-operative only
223949817|NCT04766996|DRUG|Zofran|Zofran 4 mg pre-operative
223949818|NCT04766996|DRUG|Pepcid|Pepcid 20 mg pre-operative
223949819|NCT04766996|DRUG|Reglan|Reglan 10 mg pre-operative
223949820|NCT04766996|DRUG|Versed|Versed 2 mg pre-operative
223949821|NCT04766996|DRUG|Lidocaine|Lidocaine (preservative free) height based dosing for subarachnoid block intraoperatively
223949822|NCT04766996|DRUG|Propofol|Propofol 10-125 mcg/kg/min intraoperative
223949823|NCT04766996|DRUG|Ancef|Ancef 2-3 gm weight-based dosing intraoperative
223949824|NCT04766996|DRUG|Tranexamic Acid (TXA)|Tranexamic Acid (TXA) 2 gm intraoperative
223949825|NCT04766996|DRUG|Decadron|Decadron 10 mg intraoperative
223949826|NCT04766996|DRUG|Bupivacaine hydrochloride|Local anaesthetic 0.5% bupivacaine hydrochloride intraoperative
223949827|NCT04766996|DRUG|Toradol|Toradol nonsteroidal anti-inflammatory drug max 30 mg intraoperative
223949828|NCT05656456|OTHER|Y-BOCS or FAS online survey, interview|Y-BOCS or FAS and online survey will be administered interview will be conducted
223949829|NCT00005635|BIOLOGICAL|trastuzumab|
223949830|NCT00005635|DRUG|paclitaxel|
223949831|NCT05624814|DEVICE|Spinal Cord Stimulation|Spinal Cord Stimulation consists of the transcutaneous or surgical implantation of different types of electrodes in the epidural space; electrodes are then connected to an Implanted Pulse Generator that generates stimulating currents.
223949832|NCT05624814|OTHER|Standard therapies|Standard therapies for chronic low back pain are pharmacological, psychological, physical and occupational therapies or surgery.
223949833|NCT00508183|PROCEDURE|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
223949834|NCT00508183|PROCEDURE|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
223949835|NCT01613456|DIETARY_SUPPLEMENT|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
223949836|NCT01613456|DIETARY_SUPPLEMENT|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
223949837|NCT01554332|DEVICE|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
223949838|NCT04211194|PROCEDURE|Upper GI Endoscopy|Patients with upper gastrointestinal bleeding undergoing endoscopic therapy. Information regarding the need for interventional radiology procedures or surgical interventions will also be collected in patients in whom endoscopic therapy is not successful.
223949839|NCT02405000|OTHER|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
224101427|NCT07107334|DRUG|Glucagon-like peptide 1 receptor agonist|Subjects will receive a glucagon-like peptide 1 receptor agonist by self-injection for as long as clinically indicated by the treating physician or until the subject receives clearance for staging hysterectomy or for pregnancy pursuit. The choice of glucagon-like peptide 1 receptor agonist for each subject will be at the treating physician's discretion. Subjects will discontinue the glucagon-like peptide 1 receptor agonist 2 weeks before any elective surgical procedure.
224101428|NCT07106645|DEVICE|Active iTBS|Patients in this condition will undergo 20 sessions of iTBS, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Intermittent theta burst stimulation will involve the delivery of triplets of pulses at 50 Hz, repeated at 5 Hz, at 100% of the individual motor threshold.
223722548|NCT03284944|DEVICE|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
223722549|NCT03284944|DEVICE|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
223722550|NCT05276401|DRUG|5% Bisphosphocin Topical Gel|Topical Gel
223722551|NCT05276401|DRUG|Placebo Topical Gel|Topical Gel
223949840|NCT03161665|OTHER|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
223949841|NCT05121376|GENETIC|Dose 1 of BMN 331|BMN 331 AAV Gene Therapy
223949842|NCT05121376|GENETIC|Dose 2 of BMN 331|BMN 331 AAV Gene Therapy
224101429|NCT07106645|DEVICE|Sham stimulation|Patients in this condition will undergo 20 sessions of sham stimulation, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Sham stimulation will be identical to active stimulation, with the only difference being the use of a sham coil, which produces the same sound as the real coil without generating a magnetic field
224101430|NCT07105787|OTHER|SDTT + VR triggered adaptations|The SDTT+ VR triggered adaptations program will trigger reactive gait adaptations by presenting obstacles in VR.
224101431|NCT07105787|OTHER|Speed-dependent treadmill training (SDTT)|This training methodology focuses on adjusting the treadmill's speed according to the individual's walking pace, creating a more dynamic and adaptive exercise environment. SDTT is designed to mimic real-world walking conditions and challenges, promoting neuromuscular coordination, balance, and overall mobility. By tailoring the treadmill speed to match the user's gait, SDTT encourages the development of natural and efficient walking patterns. This training technique has shown promise in various clinical settings, aiding individuals with gait impairments caused by neurological conditions, musculoskeletal disorders, or post-injury rehabilitation. Its adaptability allows for progressive adjustments as a person's walking abilities improve, making it a versatile tool for optimizing gait mechanics and functional mobility. To ensure continued progress and integration into daily life, home-based walking training, supported by a phone application, will be included between T1 and T2.
224101432|NCT07105995|OTHER|Examination and questionnaire|Participants will be enrolled in the study and will complete the Temporomandibular Disorders/Diagnostic Criteria (TMD/DC) questionnaire. Subsequently, the investigator will conduct a clinical examination to assess each participant's eligibility based on the predefined inclusion criteria.
223722552|NCT05276401|DRUG|10% Bisphosphocin Topical Gel|Topical Gel
223949843|NCT05121376|GENETIC|Dose 3 of BMN 331|BMN 331 AAV Gene Therapy
223949844|NCT05121376|GENETIC|Dose 4 of BMN 331|BMN 331 AAV Gene Therapy
223949845|NCT05121376|GENETIC|Dose 5 of BMN 331|BMN 331 AAV Gene Therapy
223949846|NCT05121376|GENETIC|Dose 6 of BMN 331|BMN 331 AAV Gene Therapy
223949847|NCT05121376|GENETIC|Dose 7 of BMN 331|BMN 331 AAV Gene Therapy
223949848|NCT01070199|BEHAVIORAL|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
223949849|NCT01070199|BEHAVIORAL|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
224101433|NCT07105995|OTHER|Intraoral scanning|The investigator will perform intraoral scanning of the participants' maxillary and mandibular dentitions, as well as record the bite registration.
224101434|NCT07105995|OTHER|Facebow registrations|The investigator will perform facebow registrations on the participants utilizing an optoelectronic tracking device.
223537563|NCT03160625|DEVICE|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
223537564|NCT00613431|DRUG|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
223537565|NCT00613431|DRUG|Placebo|Some subjects will receive matching placebo instead of CS-8080.
223949850|NCT01070199|BEHAVIORAL|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
223949851|NCT01070199|BEHAVIORAL|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
223949852|NCT05187520|DEVICE|Patient-controlled epidural analgesia (PCEA)|Epidural analgesia is a technique of neuraxial block by placement of a 20G polyether epidural catheter into the epidural lumen and fixed at the desired depth, and analgesic effect is usually achieved by administration of mixture of local anesthetics and opioids using a programmed pump.
223949853|NCT05187520|DRUG|Naldebain®|Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
223949854|NCT04300764|BEHAVIORAL|Gamification Intervention|Intervention participants will receive daily text messages to help them set goals, receive feedback and support on their progress towards daily goals, and receive points for daily goals achieved. Each participant will be given a Fitbit watch that will transmit data to the Way to Health study platform. Data will be passively collected during the inpatient stay and for 30 days after hospital discharge.
223949855|NCT06122818|OTHER|Immobile patients receiving home health care|Demographic characteristics, duration of immobility, sarcopenia presence, thigh circumference , Hand grip strength , bioelectrical impedance analysis
224101435|NCT07105995|OTHER|Mandibular border movement registrations|The investigator will perform mandibular border movement registrations utilizing an optoelectronic mandibular movement tracking device.
224101436|NCT07105995|OTHER|Chewing registrations|The investigator will perform 5 chewing registrations with different test foods utilizing an optoelectronic mandibular movement tracking device.
223537566|NCT00002372|DRUG|Indinavir sulfate|
223537567|NCT00002372|DRUG|Amprenavir|
223537568|NCT00002372|DRUG|Nelfinavir mesylate|
223537569|NCT00002372|DRUG|Saquinavir|
223537570|NCT02775266|OTHER|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
223537571|NCT02775266|PROCEDURE|Scaling and Root planing|Scaling and root planing will be done at baseline.
223537572|NCT01628523|OTHER|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
223537573|NCT05249686|OTHER|Manual Therapy + Dry Needling|"Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ)."
223537574|NCT05249686|OTHER|Manual Therapy|Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
223949856|NCT03082313|BEHAVIORAL|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will be based upon the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
223949857|NCT03109080|DRUG|Olaparib|five levels of dose, per os administration, twice daily each day
224101437|NCT07107932|DRUG|Siltartoxatug Injection (Brand name: Sintetol®)|The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
223949858|NCT03109080|RADIATION|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
223949859|NCT05765331|DEVICE|Chatbot|The AI chatbot is a kind of artificial intelligence technology that can help increase knowledge and understanding of men's health issues. That interacts with subjects through literal text and provides educational resources, advice, and assistance related to lifestyle changes. The chatbot is a valuable aid to increase men's health by providing information about enlarged prostate with urination problems and erectile dysfunction.
224101438|NCT07106242|DEVICE|Adaptive DBS|Subjects will receive Dual or Single Threshold aDBS which are acceptable
224287627|NCT02379780|PROCEDURE|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71\*50 mm 22G\*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
224287628|NCT02379780|PROCEDURE|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71\*50 mm 22 G\* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
224101439|NCT07106242|DEVICE|cDBS|cDBS
223949860|NCT03547154|BIOLOGICAL|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
223949861|NCT03547154|BIOLOGICAL|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m\^2
223949862|NCT01113736|BIOLOGICAL|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
223949863|NCT02988713|DEVICE|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
223949864|NCT01918033|DRUG|Desloratadine 5 mg|Desloratadine 5 mg tablets
224101440|NCT07107269|OTHER|Low plant diversity beverage|Blended drink made from 3 organic vegetables (Power Greens mix)
224101441|NCT07107269|OTHER|Functional Food intervention|This is a 4oz shot made from 30 different organic vegetables and packaged in mylar pouches.
224101442|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with two sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 2 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
224101443|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with four sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 4 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
224101444|NCT06924060|BEHAVIORAL|Flywheel Resistance Training with six sets|For each training session, 4 generic exercises will be performed, involving small and large muscle groups (leg extension, leg flexion, biceps curl, triceps french press). They will perform 6 sets of 8 repetitions, with a 2-minute break between exercises and sets. They will perform these exercises at a high intensity (always 10 on the OMNI-RES Scale).
223537575|NCT03115372|OTHER|Educational Intervention|Attend CRC education session
223537576|NCT03115372|OTHER|Educational Intervention|Attend healthy nutrition session
223537577|NCT03115372|OTHER|Informational Intervention|Receive CRC screening brochure
223537578|NCT03115372|OTHER|Survey Administration|Ancillary studies
223949865|NCT01918033|DRUG|Placebo|Matching placebo to desloratadine 5 mg tablets
223949866|NCT04679675|OTHER|Usual Care|Subjects will receive Kaiser Permanente Washington standard of care.
223949867|NCT04679675|BEHAVIORAL|Education|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening.
223949868|NCT04679675|BEHAVIORAL|Direct Mail|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will also receive an insert describing the home-based cervical cancer screening option and that a kit will be sent within 1 week. An HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
223949869|NCT04679675|BEHAVIORAL|Opt-in|Participants will receive an Educational Brochure describing why screening for cervical cancer is important, information about HPV and its role in cervical cancer, and different strategies for cervical cancer screening. Participants will receive an Opt-in Insert describing the home-based cervical cancer screening option and how to request a kit. Individuals can request a kit by phone or through a webpage. Individuals who request a kit will receive the HPV self-collection kit with instructions and a pre-paid return envelope (to Kaiser Permanente Washington's laboratory) will be sent to individuals with instructions on how to complete the kit.
223949870|NCT04852471|BEHAVIORAL|Standard Post-Operative Counseling + FACT-G|Counseling at discharge + FACT-G at enrollment, at 15-18 and at 30-32 days post-operative.
223949871|NCT04852471|BEHAVIORAL|PROM symptom tracker|A 12-item symptom tracker adopted from the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE), delivered via text, on days 4, 6, 8, 12, 18, 24, and 30 post surgery.
223949872|NCT05279066|DEVICE|Biostrap Wristband|The Biostrap Wristband device is a non-invasive optical sensor that monitors changes in arterial pulse volume using Photoplethysmography (PPG). PPG is frequently used in wearable sensors to detect heart rate as well as other metrics such as heart rate variability (HRV) and respiratory rate. The raw biosignals recorded by the wristband device will be further processed to estimate the ejection fraction and cardiac output.
223949873|NCT00529204|DRUG|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
223949874|NCT03810170|BEHAVIORAL|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
223949875|NCT03810170|OTHER|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
224287629|NCT00024648|DRUG|LErafAON|
223537579|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about CRC screening
223949876|NCT03072303|OTHER|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
223949877|NCT02695199|PROCEDURE|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
223949878|NCT02695199|PROCEDURE|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
223949879|NCT06172036|DRUG|irinotecan liposome + oxaliplatin + 5-FU / LV|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
223949880|NCT06172036|DRUG|Adebellizumab|Efficacy and safety of irinotecan liposome combined with oxaliplatin, 5-fluorouracil (5-FU) / leucovorin calcium (LV) with or without adbellizumab for resectable pancreatic cancer
223949881|NCT03878966|DEVICE|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
223949882|NCT01857999|DRUG|Losartan|
223949883|NCT01857999|DRUG|Placebo|
223949884|NCT01402518|PROCEDURE|Per-oral enodscopic myotomy|
223949885|NCT02424968|BIOLOGICAL|Anti-Thymocyte Globulin|Given per standard institutional practice
223949886|NCT02424968|DRUG|Cyclosporine|Given PO
223949887|NCT02424968|DRUG|Mycophenolate Mofetil|Given PO
223949888|NCT02424968|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|Undergo nonmyeloablative allogeneic HSCT
223537580|NCT03115372|BEHAVIORAL|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
223949889|NCT02424968|BIOLOGICAL|Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|Receive CD8+ memory T-cells via IV
223949890|NCT02424968|RADIATION|Total Nodal Irradiation|Undergo TLI
223949891|NCT06510244|DEVICE|EEG EMOTIV|The teeth will be dried with 2x2 gauze; then, Endo Ice will be applied. The patient response will be written on a sheet numbering to choose from 0 to 10, and at the same time, the brain waves will be recorded through EEG.
223949892|NCT06144437|DIAGNOSTIC_TEST|Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Gastroscopy will be completed and reported by experienced endoscopists, requiring no more than 1 month between gastroscopy and ultrasound examination, and patients should fast for at least 8 hours before gastroscopy."
223949893|NCT00644566|OTHER|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
224287630|NCT01394848|DEVICE|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
224287631|NCT01394848|DEVICE|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
224287632|NCT01394848|DRUG|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
224287633|NCT01394848|DRUG|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
224101445|NCT07105592|DRUG|Nimotuzumab+Adebrelimab+Chemotherapy|"Phase Ib Treatment Regimen:~Nimotuzumab: Three dose groups (200 mg, 400 mg, 600 mg), administered via intravenous infusion over at least 60 minutes, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Adebrelimab: Fixed dose of 1200 mg, administered via intravenous infusion, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Albumin-bound Paclitaxel: 100 mg/m², administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles.~Carboplatin: AUC=2 (calculated using the Calvert formula), administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles.~Phase II Treatment Regimen:~Nimotuzumab: Recommended Phase II dose (RP2D) as determined from Phase Ib, administered via intravenous infusion on Day 1, once every 3 weeks, until disease progression, intolerable toxicity, or subject withdrawal from the trial.~Adebrelimab: Fixed dose of 1200 mg, administered via"
224101446|NCT06935734|DIAGNOSTIC_TEST|Diagnostic Colonoscopy|Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies, and Phase B will evaluate the safety and efficacy of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies.
224101447|NCT04067661|BEHAVIORAL|CHIP|The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
224101448|NCT04067661|BEHAVIORAL|Control|Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
224101449|NCT01719575|DRUG|Motilitone|
224101450|NCT01719575|DRUG|Placebo|
224101451|NCT04237883|BEHAVIORAL|Standard communication email|This is the base communication that all physicians will receive.
224101452|NCT04237883|BEHAVIORAL|Social comparison Intervention|The social comparison is added onto the standard communication email to provide some peer comparison between the physicians.
223537581|NCT02008643|OTHER|filling questionnary to quality of life|filling questionnary to quality of life
223537582|NCT04898478|BEHAVIORAL|Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders|The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
223537583|NCT02374125|DEVICE|Diacutaneous Fibrolysis|Applied only around teres major muscle.
224287634|NCT03676166|DRUG|Cannabis|Inhaled cannabis
224287635|NCT03537157|DRUG|Rifaximin delayed release tablets|Active intervention
223949894|NCT06088576|OTHER|Together|"Tchat : limited to 20-30 minutes per day. With a member of the team Together. For teleconsultations : First teleconsultation, during the first month (1 to 4 sessions/month), are made by nurse and/or educator. After that, it is psychologists who do the teleconsultations (2 to 4 sessions/month). It's during 30 to 45 minutes.~Home visits, individual or group interviews on site are possible after 4 month."
223949895|NCT03610620|PROCEDURE|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
223949896|NCT02065609|DRUG|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
223949897|NCT02065609|DRUG|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
223949898|NCT01846715|BIOLOGICAL|Implantation of SRC|
223949899|NCT05028465|PROCEDURE|Endoscopic Papillectomy|A snare devicewas inserted via the working channel, and the endoscopist adjusted the snare to securely grasp the lesion, which was then excised by using standard electrocautery.
224101453|NCT04237883|BEHAVIORAL|Leadership Training|Clinic and Physician leads will be provided with a clinic leadership training seminars in leadership, quality improvement, and support from the Quality Improvement team at UCLA Health.
224101454|NCT04377529|BEHAVIORAL|Local Champion|Local champions (physiotherapists) will co-develop the champion training support based on a comprehensive behavioural analysis, previous implementation work and evidence-based theory. The study team will provide this training and support to the champions, who will then provide additional support to their peers participating in the study.
224101455|NCT00676039|DRUG|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
224101456|NCT00676039|DRUG|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
224101457|NCT00676039|DRUG|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
224101458|NCT00676039|DRUG|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
224101459|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
224287636|NCT03537157|OTHER|Placebo|Comparator placebo
224287637|NCT04677855|DRUG|PCUR-101|50 mg capsules
224287638|NCT04677855|DRUG|Dutasteride 0.5 mg|0.5 mg capsules
224287639|NCT04677855|DRUG|Abiraterone and Prednisone|500 mg tablets Abiraterone with 5 mg Prednisone Tablets
224287640|NCT04745208|BEHAVIORAL|Simulation based education|high fidelity simulation with moulage
224287641|NCT00655850|DRUG|Paclitaxel|"* Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~* Dexamethasone 20mg, intravenously (IV)~* Diphenhydramine 50 mg IV~* Ranitidine 50 mg IV~* Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~* The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~* Dose Level 1 \_\_\_\_\_\_\_\_80 mg/m2/weekly~* Dose Level -1 \_\_\_\_\_\_\_\_70 mg/m2/weekly"
224287642|NCT00655850|DRUG|Gemcitabine|"Premedication~* Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~* Prior to receiving paclitaxel chemotherapy~* Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~* The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~* Dose Level 2 \_\_\_\_\_\_\_\_300 mg/m2/weekly~* Dose Level 1 \_\_\_\_\_\_\_\_200 mg/m2/weekly~* Dose Level -1 \_\_\_\_\_\_\_\_150 mg/m2/weekly"
224287643|NCT00655850|BIOLOGICAL|Avastin|"* The dose of Avastin is 10 mg/kg IV every 2 weeks~* It will be administered following the administration of chemotherapy~* The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~* It should not be administered or mixed with dextrose solutions."
224287644|NCT02231424|DRUG|Drug: Berodual®|
223949900|NCT05028465|PROCEDURE|Endobiliary Radiofrequency Ablation|The RFA catheter was then placed under fluoroscopic guidance across the distal common bile duct. An ERBE VIO200D generator (ERBE Elktromedizin, Tubingen, Germany) was connected for RFA at 10 W for 90 seconds.
223949901|NCT04947709|BEHAVIORAL|Physical Activity|The main structure of the physical activity program will focus on increasing physical activity. Physical activity will initially start at a duration of 15-30 minute bouts, and at rate of perceived exertion levels of 5-6 (somewhat hard). Over the course of the intervention, goals will be set to progress to 60 minutes of continuous physical activity, at a rate of perceived exertion level of 5-6 (somewhat hard). Participants will be instructed on the use of the ratings of the perceived exertion scale (Borg's RPE 1-10 scale). Participants will be instructed to walk, or engage in other forms of leisure-time physical activity to achieve these goals (cycling, running, swimming, etc). As the adolescent and young adults' health and fitness status improve, frequency, intensity, and session duration will be modified accordingly during weekly support calls. Moreover, goals will be responsive to the most recent week's achieved minutes and rate of perceived exertion.
223949902|NCT05958966|OTHER|E-cigarette e-liquid self-administration|Participant will self-administer an experimenter-provided e-cigarette.
223949903|NCT04775537|DEVICE|OssiMend™ Bioactive Moldable|Lumbar Spine fusion with OssiMend™ Bioactive Moldable
223949904|NCT03259568|DEVICE|Repetitive TMS|1-10 Hertz rTMS will be administered
223949905|NCT01762982|DRUG|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
224101460|NCT03528681|DRUG|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
223537584|NCT02374125|OTHER|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
223537585|NCT02374125|OTHER|Protocolized physiotherapy|Exercises, TENS and cryotherapy
223537586|NCT04240691|BEHAVIORAL|60-Minutes-For-Health|Refer to description under Groups
223537587|NCT04240691|OTHER|Time-and-Attention Control Session|Refer to description under Groups
223537588|NCT05701553|DRUG|Anti-PD-1/PD-L1|Intravenous injection at indicated dose for at least 6 months
223537589|NCT05701553|DRUG|S-Adenosyl-Methionine|Taken orally at indicated dose for at least 6 months
223949906|NCT01762982|DRUG|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
223949907|NCT01762982|DRUG|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
223949908|NCT01762982|OTHER|Empty Finn Chamber|Empty Finn Chamber
223949909|NCT02160301|DRUG|Gabapentin|PO
223949910|NCT02160301|DRUG|Acetaminophen|PO
223949911|NCT02160301|DRUG|Acetaminophen|IV
223949912|NCT02160301|DRUG|Celecoxib|PO
223949913|NCT02160301|DRUG|Dexamethasone|IV
223949914|NCT02160301|DRUG|Oxycodone|PO
223949915|NCT01794299|BIOLOGICAL|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
223949916|NCT01029704|DRUG|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
223949917|NCT01029704|DRUG|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
223949918|NCT00234000|DRUG|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
223949919|NCT00234000|DRUG|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
223949920|NCT06177821|DEVICE|Rezum®|Rezum® Water vaporization device
223949921|NCT01230970|DRUG|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
223949922|NCT03006393|DRUG|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
223949923|NCT03006393|OTHER|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
223949924|NCT04226456|DRUG|N-acetyl cysteine|Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears
223949925|NCT01596465|OTHER|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
223949926|NCT01596465|OTHER|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
223949927|NCT03032757|DIETARY_SUPPLEMENT|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
223949928|NCT01774240|OTHER|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
223949929|NCT00458185|DRUG|etanercept|
224101461|NCT03528681|DRUG|Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day for at most 2 days.
223949930|NCT02817360|DRUG|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
224101462|NCT01195025|DRUG|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
223949931|NCT02817360|OTHER|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
223949932|NCT02333565|DRUG|Everolimus|
223949933|NCT02333565|DRUG|Octreotide|
223949934|NCT04749329|DEVICE|Mesh Group|"All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients."
223949935|NCT05856409|DIAGNOSTIC_TEST|68Ga-FAPI|\[68Ga\]-FAPI is tumor imaging agent for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF)
223949936|NCT01266837|DRUG|Everolimus|10 mg p.o once daily
223949937|NCT02203656|DRUG|Placebo|placebo supplement
223949938|NCT02203656|DIETARY_SUPPLEMENT|Nutritional Supplement|protein supplement
224101463|NCT01195025|DRUG|colloid|Infusion of starch 10 ml/kg over 30 min
224101464|NCT01195025|DRUG|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
224101465|NCT01195025|DEVICE|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
224101466|NCT03927976|BEHAVIORAL|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
224101467|NCT06103552|BEHAVIORAL|Building Lifestyle Options for Orthopedic Mobility (BLOOM)|This intervention is a lifestyle program with includes dietary coaching from a dietitian and regular doctor appointments with a bariatric medicine specialist over the course of 24 weeks.
224101468|NCT00920309|DRUG|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
224101469|NCT00920309|OTHER|Standard of Care-Placebo|
224101470|NCT06298097|DEVICE|Connectivity measures|Electroencephalography connectivity measures will be collected and compared in both stroke patients and healthy participants. Connectivity measures will be extracted using these devices: high-density electroencephalography (using either a 128-channel or a 256-channel system) and magnetic resonance imaging.
224101471|NCT01673880|DRUG|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
224287645|NCT03469817|DIAGNOSTIC_TEST|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
224287646|NCT04429334|DRUG|nangibotide|nangibotide 1.0 mg/kg/h
223949939|NCT02203656|BEHAVIORAL|In-home exercise|In-home exercise program
224287647|NCT04429334|DRUG|placebo|matching placebo
224287648|NCT06013917|DEVICE|Cardiac Monitoring|FDA cleared ECG monitoring device that will be used to obtain ECG recordings and capture cardiac arrhythmias/events from participants
223949940|NCT02203656|DRUG|Testosterone|Testosterone injection
224287649|NCT04507035|DRUG|Anlotinib hydrochloride capsules|Using anlotinib of 2 cycles as the first-line therapy.
224287650|NCT01307839|DRUG|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
223949941|NCT03999294|OTHER|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
223949942|NCT00838045|DEVICE|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch \& Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
224101472|NCT05004467|OTHER|Mobilization With Movement Technique|The researcher explains cervical movements to the patient to be done while the technique is performed. This movements will be the painful and limited movements detected in goniometric intervention before the treatment and movements done actively and in all range of motion.
224101473|NCT04512885|OTHER|Survey|Survey via questionnaire
224101474|NCT02975869|OTHER|Standard Leukemia Care|
224101475|NCT02975869|OTHER|Palliative Care|
223949943|NCT06284356|PROCEDURE|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
224101476|NCT04907604|DEVICE|A multi-modal and integrative e-health platform aimed at promoting health and reducing the negative impact of mental problems in the workplace|It addresses six main domains: improving awareness of mental health problems and reducing stigma; reducing psychosocial risk factors in the workplace; improving wellbeing and reducing psychological symptoms; ensuring early detection of mental disorders; promoting healthy behaviours and lifestyles; and facilitating early return to work.
224101477|NCT02725255|DIETARY_SUPPLEMENT|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
224287651|NCT01307839|DRUG|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
223949944|NCT04515550|DIAGNOSTIC_TEST|lumbar puncture|Some participants will have an optional lumbar puncture
224287652|NCT02165618|OTHER|Medication review, based on but not limited to the RASP list|"Systematic approach:~1. Medication reconciliation~2. Applying the RASP list~3. Expert review (not based on the RASP list)~4. Multidisciplinary discussion"
223949945|NCT05234489|BIOLOGICAL|Signature Cord Prime|"Low dose - Subjects will receive SIG001 (75 mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate.~High dose - Subjects will receive SIG001 (150mg) which will be diluted to a total of 4 ml volume with Ringer's Lactate."
223949946|NCT01289834|DEVICE|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH \& Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
223949947|NCT01289834|DEVICE|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
223949948|NCT01365546|BIOLOGICAL|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
223949949|NCT03033056|BEHAVIORAL|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
223949950|NCT00861315|DRUG|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
223949951|NCT00861315|DRUG|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
224101478|NCT02725255|DRUG|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
224101479|NCT02725255|DIETARY_SUPPLEMENT|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
224101480|NCT00005592|BIOLOGICAL|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
224101481|NCT00005592|BIOLOGICAL|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
224287653|NCT04289454|OTHER|Flavor additive|Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
223537590|NCT02873078|BEHAVIORAL|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
224287654|NCT03919487|PROCEDURE|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
224287655|NCT01005706|DRUG|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
223949952|NCT00861315|DRUG|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
223949953|NCT00861315|DRUG|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
223537591|NCT03225404|OTHER|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
223537592|NCT03225404|OTHER|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
223537593|NCT03582579|BEHAVIORAL|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
223949954|NCT02594267|DRUG|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone"
223949955|NCT06418919|PROCEDURE|Radiofrequency ablation treatment|RFA is used to ablate the entire thyroid gland
223949956|NCT04217798|DRUG|Niraparib|Subjects will receive niraparib combined with oral etoposide (on day 1-20, every 30 days). After 6-8 cycles, oral etoposide will be terminated. Niraparib will be still given to subjects until disease progression, intolerable toxicity or withdrawal of informed consent.
223949957|NCT00472082|DRUG|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
224101482|NCT00005592|RADIATION|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
224101483|NCT06035497|DRUG|BMS-986369|Specified dose on specified days
224101484|NCT04277572|PROCEDURE|Aortic valve replacement|Aortic valve surgery
224101485|NCT06411795|DRUG|Bupivacaine|Given via epidural and injection
224101486|NCT06411795|DRUG|Hydromorphone|Given via epidural
224101487|NCT06411795|DRUG|Iopamidol|Given via epidural
224101488|NCT06411795|DRUG|Liposomal Bupivacaine|Given injection
224101489|NCT06411795|OTHER|Medical Chart Review|Ancillary studies
224101490|NCT06411795|OTHER|Questionnaire Administration|Ancillary studies
224101491|NCT06411795|DRUG|Thoracic Epidural Analgesia|Undergo thoracic epidural placement
224101492|NCT06411795|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
224101493|NCT06411795|PROCEDURE|X-Ray Imaging|Undergo x-ray
224101494|NCT06267482|PROCEDURE|ROSA PSA Parapatellar Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be the same as the standard of care (medial parapatellar approach).
223722553|NCT00607971|DRUG|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
223949958|NCT04037592|DEVICE|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
223722554|NCT05415839|DEVICE|Laser|Laser
224101495|NCT06267482|PROCEDURE|ROSA PSA Subvastus Approach|This intervention will consist of using the ROSA alongside patient-specific alignment. The knee incision will be an alternative, quad-sparring, subvastus approach.
224101496|NCT04746326|PROCEDURE|Failure conservative treatment|Surgery was performed in patients who failed conservative treatment.
224101497|NCT04746326|PROCEDURE|Surgery|Surgery was performed in patients who had generalized peritonitis and perforation.
224101498|NCT04746326|OTHER|Conservative treatment|Conservative treatment was performed in patients who had no generalized peritonitis and perforation.
224101499|NCT00159484|DRUG|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
224101500|NCT01733706|DEVICE|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
224101501|NCT01733706|OTHER|Standard counseling|standard counseling
224101502|NCT04680884|DRUG|Experimental for steroid|2 mg/kg/day of IV methylprednisolone for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0,5 mg/kg/day from day 8 to day 14 + IV placebo of isavuconazole
224101503|NCT04680884|DRUG|Experimental for antifungals|IV placebo of methylprednisolone + IV isavuconazole (200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
223949959|NCT04037592|DEVICE|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
223949960|NCT04037592|DEVICE|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
223949961|NCT01274000|DRUG|YM060|oral
223949962|NCT01274000|DRUG|placebo|oral
223949963|NCT02762786|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
223949964|NCT05196958|OTHER|GLP1 analogues|This cohort study has 2 phases: an observation phase to collect all initial clinical and biological parameters and an intervention phase (prescription of GLP1 analogues) of 6 months including a visit at 3 and 6 months.
223949965|NCT04252794|PROCEDURE|Splenic artery ligation|Splenic artery will be ligated just after takeoff from coeliac trunk at the level of body of pancreas
223949966|NCT04252794|OTHER|No intervention|Splenic artery is not ligated despite the presence of portal hyperperfusion
223949967|NCT00296686|DRUG|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
223949968|NCT00296686|DRUG|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
223949969|NCT00296686|DRUG|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
223949970|NCT05634161|OTHER|Cognitive improvement software|Cognitive improvement software
223949971|NCT06301867|DIAGNOSTIC_TEST|Plateau Pressure|Plateau pressure will be measured on all patients in the participating intensive care units prior to extubation.
223949972|NCT00761267|DRUG|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
223949973|NCT00761267|DRUG|Fluconazole|Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
223949974|NCT03795532|PROCEDURE|SWL|Shock wave lithotripsy
224101504|NCT04680884|DRUG|Experimental for steroids and antifungals|IV methylprednisolone 2 mg/kg/day for three days. As of day 4, the daily dose will be tapered to 1 mg/kg/day until day 7, followed by 0.5 mg/kg/day from day 8 to day 14 + IV isavuconazole 200 mg every 8 hours for 2 days followed by 200 mg per day until ICU discharge or for a total duration of 14 days)
223949975|NCT02696200|DEVICE|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
224101505|NCT04680884|OTHER|Standard of care|IV placebo of methylprednisolone + IV placebo of isavuconazole. This group receives the treatment that is currently recommended.
224101506|NCT01416181|DRUG|natalizumab|Administered as specified in the treatment arm
223949976|NCT05394636|OTHER|None, pure observational study|None, pure observational study
224101507|NCT01416181|DRUG|Placebo|Matched placebo in part 1
223722555|NCT02255604|DRUG|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
223722556|NCT02255604|DRUG|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
223722557|NCT02255604|DRUG|0.1 ml Isoton saline|4 injection into a lymphnode
223949977|NCT01235936|DRUG|AKB-6548|Different dose levels
223949978|NCT02359916|OTHER|Time delays on delivery of less healthy snacks|
223949979|NCT02359916|OTHER|25%/$0.25 discount on healthy snacks|
223949980|NCT02359916|OTHER|25%/$0.25 tax on less healthy snacks|
223949981|NCT02148575|BEHAVIORAL|Self-Management Group|
223949982|NCT02148575|BEHAVIORAL|Symptom Management Group|
223949983|NCT04454476|DRUG|Trametinib treatment|1 mg taken by mouth once a day for 14 days
223949984|NCT04454476|PROCEDURE|Endoscopy|A tiny camera on the end of a long, flexible tube will be used to examine the stomach and take biopsies.
223949985|NCT03398798|DEVICE|".014"|".014 CuNiTi orthodontic arch wire"
223949986|NCT03398798|DEVICE|".016"|".016 CuNiTi orthodontic arch wire"
223949987|NCT03398798|DEVICE|Twin brackets|Ormco Insignia Metal Twin brackets
223949988|NCT03398798|DEVICE|Self-ligating brackets|Ormco Insignia SL brackets
223949989|NCT01847859|PROCEDURE|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
223949990|NCT04913506|OTHER|Group Mirror|For 30 minutes, ROM exercises will be applied to the solid upper extremity in all directions in front of a real mirror by the practitioner. (3 weeks, 5 days a week, 15 sessions in total)
223949991|NCT04913506|DEVICE|Group NMES|NMES will be applied to the hemiplegic arm(deltoid, elbow extensors and forearm) for 30 minutes by the practitioner (3 weeks, 5 days a week, 15 sessions in total)
224101508|NCT06146114|DIAGNOSTIC_TEST|Collect HER2 expression in prostate cancer patients|HER2 testing and disease information collection for patients diagnosed with prostate cancer and able to obtain tumor tissue in our hospital from January 2018 to July 2023
224101509|NCT02981472|DRUG|Apixaban|Specified dose on specified days
224101510|NCT02981472|DRUG|Vitamin K Antagonist (VKA)|Specified dose on specified days
224101511|NCT02981472|DRUG|Low Molecular Weight Heparin (LMWH)|Specified dose on specified days
224101512|NCT00335712|DRUG|ONO-5129|
224101513|NCT05446675|PROCEDURE|Endoscopic eTEP|Endoscopic extended view totally extraperitoneal prosthesis repair.
224101514|NCT05446675|PROCEDURE|Open Rives-Stoppa|Open Rives-Stoppa repair with retromuscular mesh placement.
224101515|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
224101516|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
224101517|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
224101518|NCT00839163|DRUG|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
224101519|NCT00839163|DRUG|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
224101520|NCT00001515|DEVICE|virtual bronchoscopy|
224101521|NCT04191668|DEVICE|NightOwl|The NightOwl is a finger-mounted home sleep apnea testing device
224101522|NCT04154540|OTHER|Motion analysis|Gait and posture recording
224101523|NCT02267928|OTHER|Check Symptoms|"Symptoms are Checked"
223729489|NCT03206645|DRUG|Unesbulin|Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
224101524|NCT02267928|OTHER|Uncheck Symptoms|"Symptoms are Un-checked"
224101525|NCT02267928|OTHER|Experienced|Focus of instructions is on symptoms the participant has experienced
224101526|NCT02267928|OTHER|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
224101527|NCT04878783|DIAGNOSTIC_TEST|CT scan|Patients undergoing CT scan staging for gastric and EJ junction cancer + perioperative chemotherapy (FLOT regimen) , CT scan re-staging and radical gastrectomy or esophagogastrectomy will be enrolled in the study
224101528|NCT06058234|DRUG|Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease|FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
224101529|NCT05133596|OTHER|Clinical examination|The investigator will conduct a clinical examination to rule out other causes of olfactory impairment independent of COVID-19. The investigator will also collect the following information: socio-demographic data (age, sex, blood type, weight, height, etc.), history of olfaction disorder symptoms, past or current treatments received and tobacco/alcohol consumption.
224101530|NCT05133596|OTHER|Blood collection|12ml-blood sample
224101531|NCT05133596|OTHER|Olfactory evoked potentials|Olfactory evoked potentials will be recorded during olfactory tests.
224101532|NCT05133596|OTHER|Brushing of olfactory slits|collection of olfactory slits cells.
224101533|NCT05133596|OTHER|Neurological examination and neuropsychological assessment|"* MOCA, BREF~* CVLT~* WAIS IV, MEM III~* Right-side and left-side empan, Trail Making Test A and B (TMT), verbal fluency tests, PASAT, Attention Assessment Test~* Benton's Line Judgement, VOSP~* Assessment of psychological status, fatigue and screening for psychiatric comorbidities: depression \& anxiety scales (HAD scale, mADRS depression scale, STAI anxiety scale), Fatigue Severity Scale."
224101534|NCT05133596|OTHER|Nasal endoscopy|Nasal endoscopy
224101535|NCT05133596|OTHER|Assessment of olfactory and taste functions|"* scales: VAS and TSS~* Sniffin Stick test"
223729490|NCT06495164|DRUG|Palbociclib|CDK4/6 inhibitor
224101536|NCT03864354|PROCEDURE|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
224101537|NCT01789879|DRUG|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
224101538|NCT01789879|DRUG|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
224101539|NCT01789879|DRUG|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
223729491|NCT06495164|DRUG|Aromatase inhibitor|Aromatase inhibitor
223729492|NCT06495164|DRUG|Ribociclib|CDK4/6 inhibitor
223729493|NCT06495164|DRUG|Abemaciclib|CDK4/6 inhibitor
223729494|NCT02461355|BEHAVIORAL|Aphasia therapy|Aphasia therapy using a computerized scripting program
224101540|NCT00834548|PROCEDURE|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
224101541|NCT03636828|DIAGNOSTIC_TEST|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
224101542|NCT02693977|PROCEDURE|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
224287656|NCT01005706|DRUG|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
224287657|NCT01567826|DRUG|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]"
224287658|NCT01567826|DRUG|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
224287659|NCT00040430|DRUG|111In-DAC|
223949992|NCT04913506|OTHER|Group Mirror+NMES|The practitioner will be synchronized with visual or auditory stimuli, and ROM exercises in all directions in front of the real mirror for 30 minutes, and NMES therapy for 30 minutes on the paretic upper extremity will be applied together. (3 weeks, 5 days a week, 15 sessions in total)
223949993|NCT03200574|DIAGNOSTIC_TEST|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
223949994|NCT03200574|DEVICE|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
223949995|NCT04266496|OTHER|Questionnaires|ICIQ FLUTS (women) or MLUTS (mannen) CIVIQ 2 PSQI
223949996|NCT04266496|DIAGNOSTIC_TEST|Frequency Volume Chart|Collect a frequency volume chart for 3 days: measure the amount of voids and volume urinated.
223949997|NCT04266496|DIAGNOSTIC_TEST|Collect urine during 1 day|Volunteers are asked to collected their urine during the last day of the frequency volume chart. Volunteers get 2 jars: One for collection during the day, and 1 for overnight collection of urine. Osmolality and sodium of urine is tested
223949998|NCT04266496|DIAGNOSTIC_TEST|Blood sample|Blood collection to measure plasma sodium and osmolality.
223949999|NCT04266496|DIAGNOSTIC_TEST|Measurement of the circumference of the lower legs|"Circumference of the lower legs wil be measured twice:~* After awakening, when still laying dowing in bed~* Before goin to sleep~Circumference should be measured 2 cm above the medial malleolus"
223950000|NCT00838994|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
223950001|NCT01758068|PROCEDURE|Coconut Oil Application|Coconut oil - 4 ml
224287660|NCT00040430|PROCEDURE|Diagnostic|
224287661|NCT02062801|DRUG|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (\<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
224287662|NCT02062801|DRUG|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
224287663|NCT01612884|DRUG|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
224287664|NCT01612884|DRUG|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
224287665|NCT04671537|DRUG|Preloading with crystalloid fluid|crystalloid fluid at 10 ml/kg of ideal body weight was administered intravenously in 30 min before the BCP for patients
224287666|NCT01680783|DEVICE|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
224287667|NCT01680783|OTHER|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
224287668|NCT05513287|OTHER|On the period of covid 19|In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
224287669|NCT04457453|OTHER|Macintosh in sniffing position|Macintosh direct intubation in sniffing position
224287670|NCT04457453|OTHER|Macintosh in Trendelenburg position and Sellick position|Macintosh direct laryngoscopic intubation in Trendelenburg position and Sellick position
224287671|NCT04457453|OTHER|AceScope in Trendelenburg position and Sellick position|AceScope videolaryngoscopic intubation in Trendelenburg position and Sellick position
224287672|NCT01007474|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
224287673|NCT01007474|DEVICE|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
224287674|NCT01007474|DEVICE|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
224287675|NCT01007474|DEVICE|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
224287676|NCT01007474|DEVICE|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
223729495|NCT02461355|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
223950002|NCT04698694|DEVICE|Electroporation with voltage amplitude of 40 V (corresponding to an electric field strength of 100 V/cm)|The physician will select the voltage amplitude of 40 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
223950003|NCT04698694|DEVICE|Electroporation with voltage amplitude of 60 V (corresponding to an electric field strength of 150 V/cm)|The physician will select the voltage amplitude of 60 V to be given to the subject based on a randomization list, while the subject will remain blind to the voltage he/she is assigned to. The electroporation will be performed with a EPS electrode gun.
223950004|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 7.5 µg administered IM
223950005|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 15 µg administered IM
224101543|NCT01498991|DEVICE|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
223950006|NCT04183491|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a 30 µg administered IM
223950007|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 31.25 µg administered SC
223950008|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 62.5 µg administered SC
223950009|NCT04183491|BIOLOGICAL|Peginterferon beta-1a|Peginterferon beta-1a 125 µg administered SC
224287677|NCT03623620|BEHAVIORAL|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
223950010|NCT04183491|BIOLOGICAL|Placebo|Placebo (administered either IM or SC)
223950011|NCT01331772|OTHER|Control arm|Dietetic follow-up only
223950012|NCT01331772|OTHER|Intervention arm|Dietetic follow up + adapted physical activity
223950013|NCT04003792|DRUG|oxaliplatin|intra-arterial oxaliplatin administration
223950014|NCT04003792|DRUG|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
223950015|NCT04003792|DRUG|Bevacizumab|systemic bevacuzimab therapy
224287678|NCT00811434|DRUG|Lactulose|1.5cc/kg/day po for three months
224287679|NCT00811434|DRUG|placebo|1.5 ml sugar water/kg day for three months
224287680|NCT00197522|BIOLOGICAL|CD34+ derived DCs|
224287681|NCT02790034|DRUG|Sarizotan low dose|2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
223537594|NCT03582579|BEHAVIORAL|Training on a computer screen|Action Video Game Based Training on a computer screen
223950016|NCT03251456|OTHER|Tertiary care|"1. Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~2. The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~3. Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
224287682|NCT02790034|DRUG|Sarizotan high dose|5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
224287683|NCT02790034|DRUG|Placebo|Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
224287684|NCT01084434|DIETARY_SUPPLEMENT|probiotic|Bifidobacterium lactis HN019 10\^9 CFU/day 1 sachet once a day for 7 weeks
224287685|NCT01084434|DIETARY_SUPPLEMENT|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
224287686|NCT01084434|DIETARY_SUPPLEMENT|Synbiotic|(Bifidobacterium lactis 10\^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
223537595|NCT02874092|DRUG|Ticagrelor|
223537596|NCT02874092|DRUG|MTX therapy|
224287687|NCT01084434|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
223729496|NCT02461355|DEVICE|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
223729497|NCT03430596|DRUG|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
223729498|NCT03430596|DRUG|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
223950017|NCT03251456|OTHER|Usual Care|"1. Inform the parents that there are abnormalities after eye disease screening of their children~2. Inform the parents that they should take their children to the hospital for further consultation~3. Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
223537597|NCT06187857|BEHAVIORAL|Ecologically Oriented Neurorehabilitation of Memory (EON-Mem)|Feasibility study of a virtually-delivered adaptation of an ecologically oriented neurorehabilitation of memory (EON-Mem) in improving memory for healthy older adults
223950018|NCT06142838|BEHAVIORAL|community pharmacist intervention|The community pharmacist intervention comprises 2 parts: (1) first prescription counseling (oral and written information), and (2) a follow-up consultation (by telephone or in person) 7-14 days later, to identify problems with adherence/treatment
224101544|NCT00621023|DRUG|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
224101545|NCT01759303|DRUG|pazopanib|"For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
223537598|NCT02286063|DRUG|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
224287688|NCT02135120|DRUG|Combined spinal epidural anesthesia technique with intrathecal morphine|
224287689|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
223537599|NCT02382354|DRUG|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
223537600|NCT02382354|DEVICE|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
223537601|NCT02382354|DEVICE|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
224287690|NCT02135120|DRUG|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
224287691|NCT00793026|DRUG|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
224287692|NCT04747704|BEHAVIORAL|Three Principles Counseling|A 10-week insight-based program offered in prisons in a group setting for 2 hours each week. Approximately 15 - 20 adults or youth in custody participate at a time, led by two trained teachers. The curriculum is designed to teach an understanding of the mind and human experience for the purpose of reducing risk factors, uncovering resiliency and to promote emotional and psychological well-being for adults and youth in the criminal justice system. This is taught through a compilation of sessions that speak to the potential, ability and resilience inherent in every individual. Sessions include a mix of lessons, experiential learning, and group conversations.
224287693|NCT01360866|DRUG|OPC-34712|Tablet
224287694|NCT01360866|DRUG|Escitalopram|Tablet
224287695|NCT01360866|DRUG|Fluoxetine|Capsule
224287696|NCT01360866|DRUG|Paroxetine CR|Controlled-release tablets
224287697|NCT01360866|DRUG|Sertraline|Tablets
224287698|NCT01360866|DRUG|Duloxetine|Delayed-release capsules
224287699|NCT01360866|DRUG|Venlafaxine XR|Extended-release capsules
224287700|NCT02499224|DRUG|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
224287701|NCT04102241|DRUG|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
224287702|NCT04102241|DRUG|Placebos|Placebos are the same as drugs, but contain no Hemay005.
224287703|NCT03440424|DRUG|Lemborexant|oral tablet
224287704|NCT02110017|OTHER|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
223537602|NCT02382354|DRUG|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
223537603|NCT03499756|BEHAVIORAL|Couple-based interpersonal psychotherapy|The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
223950019|NCT02875704|OTHER|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
224101546|NCT01418872|OTHER|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
224101547|NCT01712360|DRUG|NAFT500 (pediatric)|Applied to both feet and groin area
224101548|NCT01712360|DRUG|NAFT600 (pediatric)|Applied to both feet only
224101549|NCT01712360|DRUG|NAFT500 (adult)|Applied to both feet and groin area
224101550|NCT01712360|DRUG|NAFT600 (adult)|Applied to both feet
224101551|NCT00003323|DRUG|finasteride|5 mg/d PO
224101552|NCT00003323|DRUG|flutamide|250 mg PO tid
224101553|NCT00003323|OTHER|quality-of-life assessment|Assessment survey administered at baseline, and 3 \& 6 months post initiation of treatment
224101554|NCT02983058|RADIATION|PET/SPECT Scan|PET scan will be performed on a mCT scanner
224101555|NCT02983058|DEVICE|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
224101556|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Patients will receive 20 sessions of active HD-tDCS for a duration of 20min. Sessions will be delivered twice-daily over 2 weeks on the 5 consecutive working days. The number of electrodes used, electrode placement on the scalp (based on EEG 10/10), and the individual currents that need to be injected from each electrode will be determined based on the brain networks identified as involved in their hallucinations during a fMRI acquisition performed at baseline, and computed using a neurotargeting software that allows determining optimal electrode montages for achieving maximal brain current flow in the targeted brain region.
223537604|NCT03810976|DRUG|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1\& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1\& Day 8 every 3 weeks
223537605|NCT03780257|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
223537606|NCT03780257|OTHER|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
223537607|NCT02693756|OTHER|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
223537608|NCT05663060|DRUG|Probiotic Formula|Probiotic Formula
223950020|NCT00069706|DRUG|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
223950021|NCT00069706|OTHER|AL-12182 Ophthalmic Solution Vehicle|Placebo
223950022|NCT00069706|DRUG|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
223950023|NCT00069706|DRUG|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
223950024|NCT00069706|DRUG|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
223950025|NCT02053506|DIETARY_SUPPLEMENT|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
224101557|NCT06208176|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|Participants will receive 20 sessions of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS. However, stimulation will only be administered in the initial 30 seconds of the 20-minute period, with no further stimulation during the remaining duration. This approach aims to replicate the tingling sensation commonly associated with active stimulation.
223950026|NCT02053506|DIETARY_SUPPLEMENT|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
223950027|NCT02053506|DIETARY_SUPPLEMENT|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
224101558|NCT05906446|OTHER|Multicomponent (Exercise + Protein Supplementation)|"* Exercises selected from a pre-specified list, reassessed weekly~* Participants will receive individualized exercise sessions, (e.g. 15-30 minutes per session, one session per day, offered five times a week)~* Participants will also be offered a protein supplement within 30 min of exercise.~* Sessions will be supervised"
224101559|NCT02357277|DRUG|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
224101560|NCT02357277|OTHER|Placebo Inhaler|inhaled placebo
224101561|NCT06513468|OTHER|Group education session by DESMOND Program|is a validated structured education program for people with type 2 diabetes and their family members or carers (as appropriate)' This management approach was advised by the National Institute for Health and Care Excellence (NICE) in the UK since 2008. The program consists of a 6-hour face-to-face education session delivered by two trained educators over one day or two half-days to a group of 8-12 people with newly-diagnosed or ongoing type 2 diabetes. Annual reinforcement and review are part of the program , it is delivered as a business and usual in the secondary healthcare system of Qatar. The program is culturally adapted for Qatar considering beliefs and other health festivities.
224101562|NCT02123329|BEHAVIORAL|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
224101563|NCT02123329|OTHER|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
224101564|NCT01728259|DRUG|pomalidomide|Given PO
224101565|NCT01728259|DRUG|bortezomib|Given IV
224101566|NCT01728259|DRUG|dexamethasone|Given PO
223537609|NCT01974284|DRUG|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
223950028|NCT04085952|PROCEDURE|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
223950029|NCT04085952|PROCEDURE|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
223537610|NCT00685061|DRUG|Thymoglobulin|Induction
223537611|NCT00685061|DRUG|Campath-1H|Induction
223537612|NCT00685061|DRUG|Daclizumab|Induction
223950030|NCT04396210|OTHER|Questionnaire|Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.
223950031|NCT01494766|DIETARY_SUPPLEMENT|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
223537613|NCT02441894|DRUG|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
223537614|NCT02441894|DRUG|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
223537615|NCT02441894|DRUG|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
223537616|NCT02441894|DRUG|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
223537617|NCT02441894|DRUG|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
224101567|NCT01728259|OTHER|Laboratory Biomarker Analysis|Correlative studies
224101568|NCT04311905|DEVICE|Diode laser|Diode laser activated irrigation
224101569|NCT04311905|OTHER|Placebo|mock Laser activated irrigation
224101570|NCT02907944|BEHAVIORAL|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~* External Facilitator: Outside content expert who assists site~* Local Champion: Site stakeholder who promotes change~* Provider Education and Academic Detailing: Provision of unbiased peer education~* Stakeholder Engagement: Aligning goals of implementation and those impacted~* Tailor Program to Site: Addressing site specific needs based on Aim 1~* Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~* Formative Evaluation: Quant. and qual. determination of impact~* Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~* Program Marketing: Increase attention to availability of on-site addiction treatment services"
224101571|NCT03255278|BIOLOGICAL|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
224287705|NCT03702049|BEHAVIORAL|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
224287706|NCT06094907|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in an ascending fixed-order of 15mg and 60mg.
223537618|NCT02441894|DRUG|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
223537619|NCT02441894|DRUG|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
223537620|NCT03722979|PROCEDURE|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
223537621|NCT01090947|DEVICE|ProtoCAD|Aquiring acoustic signals from heart patients.
223537622|NCT01685684|DRUG|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
223950032|NCT03936699|DEVICE|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet \& Exercise Subjects to be instructed on a healthy 1200 calorie diet."
223950033|NCT03936699|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
223950034|NCT03269500|OTHER|use of nutrition education tools|"Use of different nutrition education tools :~* General advice: feeding seniors~* Oral supplementation: instructions for use~* Information about enriched food~* Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~* How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~* Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
224101572|NCT03255278|BIOLOGICAL|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
223950035|NCT05143125|BIOLOGICAL|Decitabine combined with NK cell infusion|Decitabine combined with NK cell infusion
224101573|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
224101574|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
224101575|NCT03255278|BIOLOGICAL|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
223537623|NCT01685684|DRUG|Placebo|Placebo, divided into 2 doses, q12h
223729499|NCT03590041|BEHAVIORAL|Standardized SMA|Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
223950036|NCT00053118|BIOLOGICAL|filgrastim|IV
223950037|NCT00053118|DRUG|carboplatin|IV
223950038|NCT00053118|DRUG|etoposide|IV
223950039|NCT00053118|PROCEDURE|bone marrow ablation with stem cell support|IV
223950040|NCT00053118|PROCEDURE|peripheral blood stem cell transplantation|IV
223950041|NCT03393390|DIAGNOSTIC_TEST|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
223950042|NCT03393390|OTHER|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
224101576|NCT02347358|DEVICE|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
224101577|NCT02347358|DRUG|IV r-tPA|intravenous recombinant human tissue plasminogen activator
224101578|NCT00275379|DRUG|ERB-041|
224287707|NCT06023849|DEVICE|IUD insertion|Trans Caesarean Intra Uterine Contraceptive Device Insertion and Conventional Postpartum 6 Weeks Insertion
224287708|NCT02598258|OTHER|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
223950043|NCT05983861|DIAGNOSTIC_TEST|Identification o Multi Drug Resistant Bacteria|Identification o Multi Drug Resistant Bacteria
223950044|NCT00068107|DRUG|Replagal|enzyme replacement therapy
224101579|NCT01411410|DRUG|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~* The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~* Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
224101580|NCT01411410|DRUG|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
224101581|NCT00003881|BIOLOGICAL|trastuzumab|
224101582|NCT00003881|DRUG|carboplatin|
224101583|NCT00003881|DRUG|paclitaxel|
224101584|NCT04630314|DEVICE|Percutaneus Coronary Intervention|Covered Stent
224101585|NCT06434740|RADIATION|Stereotactic Body Radiation Therapy，SBRT|The enrolled subjects will receive SBRT treatment for lung metastases.The dose segmentation is 10Gy/f, with a total dose of 50Gy/5f, once every other day.
224287709|NCT06094049|OTHER|Preference test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using flour fortified with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food.
224287710|NCT06094049|OTHER|Triangle test group|Standard meals will be prepared including the commonly consumed porridge and/or bread using unfortified flour and fortified-flour with folic acid and vitamin B12. The meals will be prepared in the same way, by a local person who is familiar with the selected food and who will be blinded to the flour type.
224287711|NCT00057486|DRUG|IL-12|
224287712|NCT01819324|BEHAVIORAL|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
224287713|NCT01819324|BEHAVIORAL|Standardized Lifestyle Management|SLM material (every other week for 4 months)
224287714|NCT02439203|DRUG|JM-010|
224287715|NCT02439203|DRUG|Placebo|
224287716|NCT03392675|BEHAVIORAL|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
224287717|NCT00049699|DRUG|laromustine|
224287718|NCT04528199|DRUG|[18F]FLOR (FC303) Injection|Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
224287719|NCT00006182|PROCEDURE|Blood Transfusion|
224287720|NCT03738176|DRUG|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
223950045|NCT03673618|DRUG|Soluble Corn Fiber|Fiber or placebo
223950046|NCT02025712|DRUG|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
223950047|NCT02025712|DRUG|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
223950048|NCT02321956|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound to determine the size of endotracheal tube
223950049|NCT02602691|OTHER|AlloMap®|
223950050|NCT02602691|PROCEDURE|Endomyocardial biopsies|
223950051|NCT03543904|PROCEDURE|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
223950052|NCT03543904|PROCEDURE|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~1. Deep breathing exercises~2. Pursed lip breathing exercises~3. Diaphragmatic breathing exercises~4. Leg ROM (active hip and knee flexion, extension and abduction exercises)~5. Ankle toe movements exercises"
223950053|NCT01838603|OTHER|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
223950054|NCT03189303|DEVICE|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit, Actis, or Corail femoral stem
223950055|NCT06466759|DEVICE|Mc Grath Videolaryngoscope|Use of Videolaryngoscope with Mc Grath versus direct laryngoscopy
223950056|NCT05302882|BEHAVIORAL|Myofascial release|The physiotherapist placed both palms on the two right and left ribs at the T12 level and applied continuous stretching to the superior for 2 minutes. After this application, the physiotherapist placed one hand on the sacrum with the other hand on T12 with his hands crossed, and applied rhythmically 2 seconds of stretching and 2 seconds of relaxation for a total of 2 minutes. Then, myofascial release was terminated by applying deep compression to the paraspinal muscles with palms for 2 minutes on the right and 2 minutes on the left side, respectively.
223950057|NCT05302882|BEHAVIORAL|Classical massage|Classical massage was applied to the lumbar region for 9 minutes. Classical massage was applied with the patient in the prone position. A small amount of solid vaseline was taken and a gentle stroke was applied for 1 minute to spread it sufficiently to the lumbar region. Then, superficial stroking was applied to the right paraspinal region for 1 minute from distal to proximal by the physiotherapist. After the same procedure was performed on the right paraspinal region for 1 minute. Then, both hands were placed on the right and left paraspinal region and friction was applied for 2 minutes. Afterwards, the patient's right paraspinal region was kneeding for 1 minute and then the same procedure was applied to the left paraspinal region for 1 minute. As the last procedure, the fingertips of both hands were placed on the right and left paraspinal region and the classical massage was completed by performing 2 minutes of deep euphlorage from the L5-S1 level to the T12 level.
223950058|NCT03205488|DRUG|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
224101586|NCT06434740|DRUG|Puterizumab|Within 7-14 days after SBRT, Puterizumab should be used (dosage: recommended dosage of 200mg, intravenous infusion, infusion time of 60 minutes (± 15 minutes), once every 3 weeks (Q3W), for 6-8 months or intolerable toxicity).
223950059|NCT03205488|DRUG|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
224101587|NCT04086303|OTHER|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
224101588|NCT05414968|DEVICE|Non-pharmacological Heat, Pressure, and Vibration|The innovation central to this approach is in the multifactorial combination of pressure, heat, and vibration stimuli to improve foot sensation. The heat stimuli will be provided with commercially available heating elements. The pressure stimuli will be provided via pneumatic garment. Lastly, the vibrotactile stimuli will be provided with commercially available vibrotactile motors. The non-pharmacological DPN device will be able to safely and consistently control temperature to 100-105°F within 1°F, control pressure to 50 mmHg within 5 mmHg at 0.25 Hz, and provide 5 distinguishable vibrational stimuli to 5 zones on the leg and foot.
224101589|NCT04945993|DEVICE|Endomethasone N|Endomethasone N is a powder intended to be mixed extemporaneously with a eugenol-based liquid (i.e, Endomethasone Liquid) to obtain a permanent root canal sealer. After selection of dentists, they will screen consecutively and systematically eligible patients, will send them the Patient Information Letter and will enroll them in the clinical investigation if non opposition from the patient. Patient clinical data will be recorded in an electronic Case Report Form. Pseudonymized retro-alveolar radiographies at baseline consultation and at 5 and 10 years post-obturation consultations will be recorded in the e-CRF. These radiographies will be examined by 2 independent endodontists and the results of these examinations will be recorded in the e-CRF. Site data will be collected on a Site Questionnaire with Visual Analog Scales.
224101590|NCT04038775|BEHAVIORAL|Volunteering|Subjects recommended volunteer by their provider.
224101591|NCT06512701|OTHER||This study is an observational study without any intervention measures.
224101592|NCT02559505|BIOLOGICAL|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
224101593|NCT02559505|OTHER|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
224101594|NCT02559505|BIOLOGICAL|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
223950060|NCT03205488|DRUG|Placebo|2 capsules taken once daily
224101595|NCT05347732|DIAGNOSTIC_TEST|Successfull thrombolysis|Biomarker levels will be compared between patients with successful and failed thrombolysis.
224101596|NCT01144546|PROCEDURE|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
224101597|NCT03341403|DIETARY_SUPPLEMENT|Probiotical®/Bactecal®|"Probiotical/Bactecal® is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
224101598|NCT03341403|OTHER|Placebo|pills containing placebo
224101599|NCT02933515|OTHER|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
223950061|NCT02186106|DRUG|Cholecalciferol|
224101600|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 100mg
224101601|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 200mg
224101602|NCT01557010|DRUG|DWP05195|Tablets, oral administration, 300mg
224101603|NCT01557010|DRUG|Control|Tablets, oral administration, Placebo
224101604|NCT02475460|PROCEDURE|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
224101605|NCT02475460|DEVICE|HeartMate 3™|HM 3 LIS
224101606|NCT00984789|DRUG|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
224101607|NCT00984789|DRUG|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
224101608|NCT03133897|DRUG|Dexamethasone|experimental group will receive 2 day treatment
224101609|NCT03133897|DRUG|Prednisone|control group will receive 4 day treatment
224101610|NCT05182333|OTHER|Examination|History taking, examination of upper limb
223950062|NCT00110669|DRUG|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
223950063|NCT04872296|DEVICE|Controlled Ankle Motion (CAM) boot|A CAM boot will be worn on the affected ankle to allow weight bearing
223950064|NCT04872296|PROCEDURE|Physical Therapy|Standard physical therapy protocol will be started at 6 weeks after surgery
223950065|NCT02525822|DRUG|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
223950066|NCT02525822|DRUG|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
223950067|NCT02525822|DRUG|Vehicle Cream|Comparator Product: Vehicle Cream
224101611|NCT06394219|PROCEDURE|traditional transperitoneal laparoscopic pyelolithotomy|Performing anterior Pyelotomy.
224101612|NCT06394219|PROCEDURE|modified transperitoneal laparoscopic pyelolithotomy|Performing posterior pyelotomy
224101613|NCT05442892|PROCEDURE|Multicomponent exercise training programme|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
224101614|NCT06379295|OTHER|Questionnaire|Self-administered questionnaire to assess the participants risk factors, history of heart disease and medications.
224101615|NCT00698516|DRUG|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
224101616|NCT04187820|OTHER|acupuncture|Patients receiving acupuncture and mild moxibustion, whom were treated 3 times per week for 12 weeks and followed up for 36 weeks. CV12 and Bilateral ST37, SP6, SP4, LR3, KI3, LI4 and LI11 were selected for acupuncture and bilateral ST25 and ST36 were selected for moxibustion. In the acupuncture group, Hwato acupuncture device was used to blind the subjects, and had the deqi sensation. The surface temperature of acupoints was maintained at 43℃± 1℃ for moxibustIon.
224101617|NCT02537860|OTHER|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
224101618|NCT02537860|OTHER|Placebo at T11 and L3|Two injections that contain saline are performed
224101619|NCT02537860|OTHER|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
224101620|NCT02537860|PROCEDURE|Herniorrhaphy|Unilateral inguinal hernia repair
224101621|NCT02537860|DRUG|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
224287721|NCT03738176|DRUG|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
224287722|NCT05408182|PROCEDURE|Robotic colorectal resection with ERAS (or eRCS) perioperative care|All patients will undergo robotic colorectal resections using the Da Vinci xi system. All common colorectal procedures will be included: right/left colectomy, sigmoid colectomy, anterior resection with PME/TME/TaTME. Patient will undergo an enhanced recovery pathway perioperatively ensuring prompt recovery and early discharge. Most ERAS guidelines will be followed including preoperative nutrition, behavioral training, avoidance of drains, NG tubes, catheters, opioids, patient based volume repletion, wound local anesthetic infiltration, early mobilization, early postoperative feeding, spirometry and physiotherapy.
223950068|NCT02525822|DRUG|Vehicle Lotion|Comparator Product: Vehicle Lotion
224101622|NCT02537860|DRUG|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
224101623|NCT01011257|DRUG|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
224101624|NCT01011257|DRUG|Clopidogrel|clopidogrel 75 mg bid
224101625|NCT01495988|DRUG|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
224101626|NCT01495988|DRUG|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
224101627|NCT01495988|DRUG|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
224101628|NCT05952414|BEHAVIORAL|self-efficacy-based interventions|The intervention aims at increasing self-efficacy and consists of Cognitive Behavioural Therapy (CBT)-based exercises related to sources of self-efficacy beliefs: 1) mastery experiences, 2) vicarious experiences, 3) verbal persuasions, and 4) emotional and physiological states.
224101629|NCT04880174|DIAGNOSTIC_TEST|serological testing|Antibody testing for Sars-COV-2 antibodies in blood.
224101630|NCT00738738|DRUG|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
224101631|NCT01218022|DRUG|Losartan Potassium Tablets|
224101632|NCT04079023|PROCEDURE|Sleeve Gastrectomy|Subtotal vertical gastrectomy
224101633|NCT05812508|DEVICE|corneal topography|corneal topography before and after pterygium surgery by two techniques bare scleral and conjunctival autograft
224101634|NCT01320228|DIETARY_SUPPLEMENT|Control|Alli treatment plus placebo (rice flour)
224101635|NCT01320228|DIETARY_SUPPLEMENT|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
224101636|NCT01320228|DIETARY_SUPPLEMENT|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
224101637|NCT01320228|DIETARY_SUPPLEMENT|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
224101638|NCT02384720|OTHER|Age: 20-40years|
224101639|NCT02384720|OTHER|Age: 41-64years|
223950069|NCT04431128|BEHAVIORAL|infant feeding position|correlation with allergy, GER or feeding position
223950070|NCT03516032|BEHAVIORAL|exercises|
223950071|NCT06439992|DRUG|18F-Fluselenamyl|Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer 18F-Fluselenamyl and will undergo an 18F-Fluselenamyl PET/CT scan of the head and neck.
223950072|NCT01856569|OTHER|no intervention|in real life of drug,dosage,frequency and duration
224101640|NCT02384720|OTHER|Age: ≥65years|
224287723|NCT00167128|DEVICE|hearing aid, Phonak EduLink-FM System|
224287724|NCT03444272|DRUG|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
224287725|NCT01715896|BIOLOGICAL|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
223950073|NCT04290741|PROCEDURE|Auricular (Battlefield) Acupuncture|Placement of needles based on battlefield acupuncture protocol which includes up to 5 sites on each ear to treat pain.
223950074|NCT04290741|PROCEDURE|Peripheral Acupuncture|Placement of needles in up to 30 specific sites in the head, neck, arms from the shoulders to the hands, and legs from the knees to the feet
223950075|NCT03515369|DRUG|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
223950076|NCT03515369|DRUG|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
223950077|NCT05077475|DRUG|C52R1H Tab. and C52R2 Tab.|Single oral dose C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
224101641|NCT04298411|DEVICE|Falcon|The Falcon contains a selection of 25+ games that require wrist extension and challenges children to grasp the controller with their affected hand. As children progress, they may advance to more difficult games that challenge the child to work against a resistance and/or apply greater grip forces. Therapists will be trained on the system, games, and given a guide summarizing the available games and the motor function areas targeted in the game. Using this guide, therapists can choose the games that are most suited to the child's abilities and goals. As multiple games will target many of the same motor function areas, children will have the option of choosing the games they like best to maximize motivational value. While this introduces some variability in the intervention, this flexibility is required to ensure that the therapy is targeting the specific interests, needs and goals of each individual child and is reflective of how ICP is used in a clinic setting.
224101642|NCT04008212|OTHER|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
224101643|NCT02314806|DRUG|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
224101644|NCT02314806|DRUG|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
224101645|NCT02314806|DRUG|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
224101646|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia|FDA022-BB05, intravenously infusion, q3w
224101647|NCT05564858|DRUG|FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib|FDA022-BB05, intravenously infusion, q3w
224101648|NCT00023348|DRUG|Isoniazid|
224101649|NCT00023348|DRUG|Rifabutin|
224101650|NCT03037216|OTHER|Exercise Intervention|10 Week aerobic exercise training
224101651|NCT03154138|DEVICE|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
224101652|NCT03154138|DEVICE|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
224101653|NCT06265896|OTHER|Kinesio taping|Tape will be applied on rectus abdominis muscles using muscles facilitation technique from origin to insertion of muscle with a tension between 15-35%. Band will start on symphysis pubis with no tension and then women make stretch on the abdominal region by deep abdominal inspiration and will end at xiphoid process. Tape will be applied on the right and left external oblique muscles; the procedure will start without tension from bottom and of 6-12 ribs, then the hip will be placed in flexion and rotation to opposite direction and the tape will be attached to pubic bone with tension between 15-35%. Finally, the tape will be performed on the right and left internal oblique muscles; the procedure will start without tension from anterior superior iliac spine and then the hip will be placed in extension position and the tape will be attached to lower 4 ribs and linea alba with tension between 15-35%.
224287726|NCT01715896|BIOLOGICAL|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
224287727|NCT04773717|DRUG|Ascorbic acid|200mg/kg/24h in four equal parts
224287728|NCT04773717|DRUG|Placebo|The same regimen as ascorbic acid.
224287729|NCT04226235|BEHAVIORAL|Yoga session|a 1-hour yoga session was completed by all participants following a DVD.
223950078|NCT05077475|DRUG|AJU-C52L|Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 80/5/12.5 mg FDC 2 tablet
223950079|NCT03652610|BIOLOGICAL|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
223950080|NCT03652610|BIOLOGICAL|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
223950081|NCT04841096|DRUG|A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
223950082|NCT04841096|DRUG|B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)|take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Initial dose for the first 45 days of intervention.
223950083|NCT04841096|DRUG|(A2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
223950084|NCT04841096|DRUG|(B2) Glimepiride/Vildagliptin/Metformin|Take one tablet of the prescribed dose of the investigational drug by mouth, preferably with food and in the morning. Escalation dose in cause the patient meets established criteria.
223950085|NCT03315338|DRUG|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
223950086|NCT03315338|DRUG|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
224101654|NCT06265896|OTHER|Pelvic floor exercise training|The intervention will be applied by a trained physical therapist. First of all, each participant will be instructed to relax thighs, bottom and abdomen musculature, then squeeze pelvic floor muscles 'focus on tightening without flexing abdomen, thighs or buttocks- avoid holding breath' 10 repetitions, 3 to 5 times a day (morning, afternoon, and night). Rest for 4 seconds and then repeat each contraction. Build up pelvic floor musculatures strength until each participant be able to do 10 slow contractions each time, holding them for 10 seconds each with rests of 4 seconds in between. Then do not hold your breath or tighten your stomach, bottom or thigh muscles at the same time. Will instruct participants to try holding each squeeze for a few seconds.
223950087|NCT03315338|DRUG|Glucose|75 g in 300 mL solution, orally administered
223950088|NCT03315338|DRUG|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
223950089|NCT03315338|DRUG|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
223950090|NCT03315338|DRUG|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
223950091|NCT03315338|DRUG|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
224101655|NCT06203808|OTHER|COMPLETION OF QUESTIONNAIRES|Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
223950092|NCT03315338|DRUG|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
223950093|NCT03315338|DRUG|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
224101656|NCT02262637|DRUG|Micardis®|
224101657|NCT02262637|DRUG|MicardisPlus®|
223950094|NCT03315338|DRUG|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
223950095|NCT03315338|DRUG|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
223950096|NCT03315338|DRUG|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
223950097|NCT03315338|DRUG|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
223950098|NCT03315338|DRUG|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
223950099|NCT03315338|DRUG|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
223950100|NCT03315338|DRUG|Placebo oral capsule|Placebo capsules, orally administered
223950101|NCT03315338|DRUG|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
223950102|NCT05611385|OTHER|Difference in development of Acute Lung Injury in Amphetamine positive and negative patients|No Intervention
223950103|NCT04693169|DRUG|11C-Choline|1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
224101658|NCT06251388|DRUG|AK104|AK104（10.0 mg/kg，intravenous (IV) infusion，Q3W）maintained with no more than 1 year.
224101659|NCT06346912|BIOLOGICAL|CD19-BAFF Targeted CAR T-cells|Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
224101660|NCT01817010|BEHAVIORAL|Multi-Component Rehabilitation (CMC)|
224101661|NCT01817010|BEHAVIORAL|Control (CON)|
224101662|NCT02424669|OTHER|ALS Functional rating Scale-revised (ALS FRS-R)|
224101663|NCT02424669|OTHER|slow vital capacity|
224101664|NCT02424669|OTHER|Blood sample|
223950104|NCT06122025|DEVICE|Patient Access|A 6-month pilot prospective interventional study with an independent groups design.
223950105|NCT06148636|DRUG|[212Pb] VMT-α-NET|Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
223950106|NCT06148636|DIAGNOSTIC_TEST|[203Pb] VMT-α-NET SPECT/CT|The \[203Pb\] VMT-α-NET SPECT/CT is performed for all participants to determine trial eligibility as well as for the calculations to determine the estimated radiation dose to kidneys. This involves three imaging sessions of about 2 hours each over 2 days. The participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage at the time they receive the injection of . \[203Pb\] VMT-α-NET, a radioactive tracer drug.
223950107|NCT02590094|DRUG|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
223950108|NCT03744052|OTHER|Motivational Messages|Messages regarding physical activity will be texted to participants.
223950109|NCT05596006|DRUG|ASIMOMMY®|ASIMOMMY 500 mg
224101665|NCT02424669|OTHER|Cerebrospinal Fluid (CSF) sample|
224101666|NCT03947541|OTHER|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
224101667|NCT03947541|OTHER|No Bracing|Participants will not wear a brace in the study.
224101668|NCT04376619|OTHER|remote ischemic preconditioning|inflation and deflation of cuff 5min each cycle repeated 3 times
224101669|NCT04376619|OTHER|KDIGO guidelines|KDIGO stands for Kidney disease Improving global outcomes guidelines, and have guidelines for prevention and treatment of AKI which is considered standard of care.
224101670|NCT02730559|OTHER|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
224101671|NCT02586805|DRUG|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
224101672|NCT02586805|DRUG|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
224101673|NCT02586805|DRUG|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
223537624|NCT06511583|PROCEDURE|Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department|For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
223950110|NCT05596006|DRUG|Domperidon|Domperidone capsule 10 mg
223950111|NCT05596006|DRUG|Placebo|Capsules of placebo 500mg.
224287730|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Sharp Dissection|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This is commonly performed both via scalpel (aka sharp medial peel) or electrocautery
223950112|NCT00434694|PROCEDURE|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
223950113|NCT01579071|PROCEDURE|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
224101674|NCT02586805|DRUG|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
224101675|NCT03094130|OTHER|News items with spin|Interpretation of news items with spin
224101676|NCT03094130|OTHER|News items without spin|Interpretation of news items without spin
224101677|NCT01859403|GENETIC|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
224101678|NCT01859403|GENETIC|Usual Care|Patients receive the same dietary recommendation regardless of their genetic information
224101679|NCT03917121|DEVICE|Jet injector|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
223950114|NCT04377542|PROCEDURE|LIFT|Ligation of the fistula tract in the intersphincteric plane
223950115|NCT04377542|PROCEDURE|Parks|Modified Parks fistulotomy with complete internal anal sphincterotomy
223950116|NCT04377542|PROCEDURE|Seton|Excision of the superficial part of fistula tract and tying loose seton around the remaining part and anal sphincter muscles
223950117|NCT00785499|BEHAVIORAL|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
223950118|NCT00326183|BIOLOGICAL|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
223950119|NCT00326183|BIOLOGICAL|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
223950120|NCT04923022|OTHER|Vegan Diet|Participants with chronic neck pain who will be on a vegan diet will follow a diet program prepared by an expert dietitian under the supervision of an endocrinologist. In this diet program, a diet that includes grains, fruits, vegetables, legumes, as well as dairy products and eggs, known as lacto-ovo vegetarian, will be applied. Consumption of meat, poultry, fish, seafood and processed food and beverages will not be allowed. There will be no calorie restriction in the diet, and the diet will be arranged according to the amount of calories calculated by the expert dietitian according to BMI. The diet will last eight weeks. Individuals who follow a diet will be constantly checked by the workers with the mobile device application (My Fitness Pal®).
223950121|NCT04923022|OTHER|Therapeutic exercise|Individuals in the therapeutic exercise group will perform therapeutic exercises for eight weeks, 3 days a week, accompanied by a specialist physiotherapist.
223950122|NCT00748891|DRUG|Recentin (Cediranib)|30mg once daily, oral dose
223950123|NCT01436214|DRUG|APC-100|Daily oral, dose escalation, 28-day cycle(s)
223950124|NCT04890626|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA]|Main randomization
223950125|NCT04890626|DRUG|Baricitinib + dexamethasone|Rescue randomization
223950126|NCT04890626|DRUG|Dexamethasone|Rescue randomization
223950127|NCT04329585|DRUG|flumazenil|EEG is observed in both groups to compare the difference between two groups.
223950128|NCT04329585|DRUG|Placebos|Placebo is the normal saline, which is given in the controlled group.
223950129|NCT03742622|BEHAVIORAL|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224101680|NCT03917121|DEVICE|Needle attached dental syringe|"* The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~* Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~* A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~* Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~* All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
224101681|NCT01926587|DRUG|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
224101682|NCT01926587|DRUG|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
224101683|NCT04982133|DIETARY_SUPPLEMENT|Protein supplementation based on plasma urea concentration every other week or human milk analysis on experiment|"At the time that the doctor decides to start fortification, it will be done according to urea levels in active comparator arm or human milk analysis on experimental group.~In Group A, fortification at 4% is started, and according to plasma urea control every 15 days the fortification is modified.~In Group B, fortification is adjusted based on the macronutrient analysis of breast or donated milk."
224101684|NCT04932889|OTHER|Survey|A detailed anamnesis was retrospectively recorded about age, gender, body mass index, education, working, the presence of any chronic disease (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, cardiac disease, cancer, rheumatological disease…), smoking, duration of symptoms, usage of supplementing vitamins such as vitamin D,C, zinc…, treatment place (home quarantine, hospital, intensive care unit), duration of home quarantine and hospital treatment, the number of months since the onset of Covid-19 symptoms, usage of anticoagulants, treatment drugs such as hydroxychloroquine, favipiravir. Also the symptoms during the period of Covid-19 infection were recorded from patient files; cough, fever, dyspnea, chest pain, loss of smell and taste, sore throat, headache, no symptom, musculoskeletal symptoms such as: muscle, low back, back, joint pain.
224101685|NCT04932889|OTHER|Laboratory parameters|The laboratory values of 182 patients, presence of chest computed tomography findings of 206 patients and symptoms of all patients during the period of Covid-19 infection, were retrospectively recorded. Laboratory values of hemoglobin, leucocyte, lymphocyte, platelet, C-reactive protein, erythrocyte sedimentation rate, ferritin, d-dimer, were recorded.
224101686|NCT04932889|OTHER|chest computed tomography|Typical findings of chest CT were; bilateral, multifocal, peripheral ground glass opacities with/without consolidation, including the fissures, close to visceral pleural surfaces. Covid-19 Reporting and Data System (CO-RADS) was used for chest CT. CO-RADS assigns scores from 1 (very low suspicion of Covid-19) to 5 (very high suspicion of Covid-19).
224101687|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, high-dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
224101688|NCT04544267|BIOLOGICAL|Quadrivalent influenza vaccine, standard dose|Pharmaceutical form: suspension for injection in a pre-filled syringe; route of administration: intramuscular
224101689|NCT03014648|DRUG|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
224101690|NCT00811226|DRUG|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
224101691|NCT00000851|DRUG|Stavudine|
224101692|NCT00000851|DRUG|Didanosine|
224101693|NCT02113657|DRUG|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
224101694|NCT04295902|DEVICE|C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.
224101695|NCT04295902|DEVICE|Direct laryngoscope with blades Miller nr 0 and Miller nr 1.|Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
224101696|NCT00367757|PROCEDURE|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
224101697|NCT00367757|PROCEDURE|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
224101698|NCT00367757|PROCEDURE|Combined approach for AF ablation|Combined trigger and substrate based approach
224101699|NCT00147927|BEHAVIORAL|Sequential emails and web support|
224101700|NCT05698186|DRUG|Thero2-01S22|Blinded recommended dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
224101701|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
224101702|NCT05698186|DRUG|Thero2-01S22|Blinded confirmed dose BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
224101703|NCT05698186|DRUG|Placebo|Blinded placebo BID for three (3) consecutive days starting the day before anti-HER2 targeted therapy containing regimen, at cycle 1 and cycle 2
224101704|NCT04373083|DRUG|Cemiplimab|Administered in 3-week intervals
224101705|NCT04373083|RADIATION|Involved-site radiotherapy (IS-RT)|Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
224101706|NCT00800072|DEVICE|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
224101707|NCT03884634|DEVICE|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
224101708|NCT01403129|PROCEDURE|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
224101709|NCT01403129|PROCEDURE|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
224101710|NCT01121406|DRUG|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
224101711|NCT01121406|DRUG|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
224101712|NCT01121406|DRUG|Topotecan|Patients receive topotecan in 3 or 4 week schedule
224101713|NCT01121406|DRUG|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
224101714|NCT01121406|DRUG|BI 6727|Patients receive BI 6727 infusion every 3 weeks
224101715|NCT00187083|DRUG|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
224101716|NCT00187083|DRUG|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
224101717|NCT00187083|DRUG|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
224101718|NCT00187083|DRUG|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
224101719|NCT00187083|DRUG|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
224287731|NCT05154058|PROCEDURE|Medial Subperiosteal Release with Electrocautery|Medial subperiosteal release - a routine step during primary total knee arthroplasty that will be conducted on every enrolled patient. This group will receive this procedure using electrocautery.
223537625|NCT06511583|PROCEDURE|Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department|"Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions."
224101720|NCT00187083|PROCEDURE|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
224101721|NCT04917874|BIOLOGICAL|Open Label Topical Beremagene Geperpavec (B-VEC)|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
224101722|NCT04996693|DIAGNOSTIC_TEST|Imaging on Scanner with Spectral Imaging Capabilities|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar in all three arms.
224101723|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (128 slice MDCT)|Patients will undergo imaging on a modern 128-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
224101724|NCT04996693|DIAGNOSTIC_TEST|CT Scan using an Energy-Integrating Detector CT (20-slice MDCT)|Patients will undergo imaging on a modern 20-slice CT scanner (Siemens Healthineers) with energy-integrating detector and without spectral acquisition mode. Contrast material protocol and scan ranges are similar in all three arms.
224101725|NCT01829048|DRUG|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
224101726|NCT01829048|DRUG|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
224101727|NCT01829048|DRUG|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
224101728|NCT01829048|DRUG|Placebo|Placebo Q12h
224101729|NCT03038022|DRUG|MGL-3196|Oral
224101730|NCT03038022|DRUG|Placebo|Oral
224287732|NCT02993692|DEVICE|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
224287733|NCT01565772|RADIATION|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
224287734|NCT01565772|DRUG|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
224287735|NCT01565772|DRUG|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
224287736|NCT01747122|DEVICE|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
224287737|NCT01747122|DEVICE|Epidural|
224101731|NCT03270722|DEVICE|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
224101732|NCT03270722|PROCEDURE|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
224101733|NCT00002103|DRUG|Trimetrexate glucuronate|
224101734|NCT00002103|DRUG|Leucovorin calcium|
224101735|NCT00504257|DRUG|Avastin|Day 1, every 21 day cycle
224101736|NCT00504257|DRUG|Docetaxel|Day 1, 8, every 21 day cycle
224101737|NCT01961531|DEVICE|Accuboost APBI|28Gy delivered in 5 daily fractions
224101738|NCT01606462|DRUG|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
223537626|NCT05815914|OTHER|app|The app will include a nutritional education programme through the APP throughout the study. At 2, 4, 6 and 8 months data will be collected through a telematics questionnaire
223537627|NCT05815914|OTHER|control group|Routine nutritional and dietary recommendations will be given.
224101739|NCT01945892|DRUG|Ozurdex|"\- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
224101740|NCT01183494|DRUG|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1\*1/\*1 and UGT1A1\*1/\*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
223537628|NCT00902330|PROCEDURE|energy-based therapy|Given once a day for 18 weeks
223537629|NCT00902330|PROCEDURE|sham intervention|Given once a day for 18 weeks
223537630|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
223537631|NCT00688857|DRUG|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
223537632|NCT01911455|DRUG|acamprosate|
223537633|NCT01911455|DRUG|Placebo|
223950130|NCT03742622|BEHAVIORAL|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
223950131|NCT03742622|BEHAVIORAL|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
223950132|NCT05116098|COMBINATION_PRODUCT|zinc 50 mg + Epigallocatechin gallate|ZINC 50 MG and EGCG 200mg oral daily for 1 month
223950133|NCT02279732|BIOLOGICAL|Paclitaxel|
223950134|NCT02279732|BIOLOGICAL|Carboplatin|
223950135|NCT02279732|BIOLOGICAL|Ipilimumab|
223950136|NCT02279732|OTHER|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
224101741|NCT02000843|PROCEDURE|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
224101742|NCT05326919|OTHER|Biobanking|For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
224101743|NCT01886664|DRUG|sevoflurane|
224101744|NCT01886664|DRUG|Desflurane|
224101745|NCT02750410|DRUG|Dulaglutide|Administered subcutaneously (SC)
224101746|NCT02750410|DRUG|Placebo|Administered SC
224101747|NCT02504541|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
224101748|NCT00940706|DEVICE|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
224101749|NCT00940706|OTHER|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
224101750|NCT00940706|BEHAVIORAL|Monitoring physical activity|Activity monitoring with accelerometers
224101751|NCT01349738|DRUG|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
224101752|NCT01531725|DEVICE|Percutaneous coronary intervention|Percutaneous coronary intervention
224101753|NCT02844790|DRUG|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
224101754|NCT03467178|DRUG|Decitabine|Nucleic Acid Synthesis Inhibitor
224101755|NCT03467178|DRUG|Carboplatin|Chemotherapy medication
224101756|NCT03467178|DRUG|Pegylated Liposomal Doxorubicin|Chemotherapy medication
224101757|NCT03467178|DRUG|Gemcitabine|Chemotherapy medication
224101758|NCT03467178|DRUG|Paclitaxel|Chemotherapy medication
224101759|NCT00481481|DRUG|tacrolimus|immunosuppression
224101760|NCT02440750|PROCEDURE|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
224101761|NCT02440750|DRUG|Dienogest|21 days administration of dienogest 2 mg/die
224101762|NCT02440750|DRUG|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
224101763|NCT04518371|OTHER|Reinforced composite for the fabrication of permanent, indirect restorations using a CAD/CAM grinding process.|Shock-absorbing effect due to the dentine-like modulus of elasticity makes BRILLIANT Crios extremely well suited for implant restorations.it is composed of dental glass (barium glass ˂ 1.0 μm), amorphous silica (Sio2 ˂ 20 nm), resin matrix (cross-linked methacrylates) and pigments
224101764|NCT05727774|OTHER|Water Biking in hot water condition|Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
223537634|NCT05271747|DIETARY_SUPPLEMENT|AB-Kolicare|Probiotic multi-strain formulation containing Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8830 for 21 days, 5 drops/day preferably during the first intake of milk
223537635|NCT05271747|DIETARY_SUPPLEMENT|Reuteri gotas|Probiotic single-strain formulation containing Lactobacillus reuteri DSM17938 for 21 days, 5 drops/day before or after any daily meal.
223537636|NCT03785184|DRUG|venetoclax|tablet; oral
223537637|NCT03785184|DRUG|lenalidomide|capsule; oral
223537638|NCT03785184|DRUG|dexamethasone|tablet; oral
224101765|NCT05727774|OTHER|Water Biking in neutral water condition|Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
224101766|NCT00986960|DRUG|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
224101767|NCT00986960|DRUG|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
224101768|NCT01608334|DRUG|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
224101769|NCT01608334|DRUG|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
224101770|NCT02252367|DRUG|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
224101771|NCT02252367|OTHER|Placebo|Placebo tablet once daily for 12 weeks.
224101772|NCT02317510|PROCEDURE|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
224101773|NCT02317510|PROCEDURE|general anesthesia|General anesthesia for laparoscopic cholecystectomy
224101774|NCT04937699|DRUG|Standard-DAPT of Ticagrelor plus aspirin|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects continue for another 11 months
224101775|NCT04937699|DRUG|Sequential monotherapy of Ticagrelor and clopidogrel|Ticagrelor 90mg bid+Aspirin 100mg qd for 1 month after PCI, Randomized subjects switch to ticagrelor 90mg bid for 5 months; then clopidogrel 75mg qd, for another 6 months.
224101776|NCT05239104|OTHER|No intervention|This is an observational study with no intervention
224101777|NCT02375022|DRUG|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
224101778|NCT00787007|DRUG|S-equol|capsule, oral, single dose
224101779|NCT00787007|DRUG|Placebo|capsule, oral, single dose
224101780|NCT01412437|DIETARY_SUPPLEMENT|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
224101781|NCT01412437|DRUG|sapropterin dihydrochloride|20 mg/kg for 4 months
224101782|NCT01412437|DRUG|sapropterin dihydrochloride|
224101783|NCT01476930|PROCEDURE|cupping and serkangabin syrup|wet cupping serkangabin syrup
224101784|NCT01476930|DRUG|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
224101785|NCT00500071|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
224101786|NCT00472303|DRUG|Tapentadol Extended Release|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
224101787|NCT00472303|DRUG|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
223950137|NCT04910711|DRUG|Dolutegravir|Dolutegravir-based antiretroviral therapy
224101788|NCT00472303|DRUG|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
224101789|NCT02365428|BEHAVIORAL|Physical activity text messages|
224101790|NCT05782088|PROCEDURE|Single Piezocision|Piezocision will be performed only once before the onset of canine retraction (T0) on one side of the maxillary arch that will be randomly chosen.
224101791|NCT05782088|PROCEDURE|Repeated Piezocision|Piezocision will be repeated three times, on a monthly basis (T0, T1, and T2), over the 12-week study period.
224101792|NCT05170360|DIAGNOSTIC_TEST|Assessment of smoking ,heavy metal, organophosphorus exposure and d) Mutational analysis of the KRAS and BRAF genes:|"1. Assessment of smoking exposure:~   Serum cotinine will be measured by using serum cotinine ELISA kits~2. Assessment of heavy metal exposure:~   Lead and cadmium will be measured using Graphite Tube Atomizer.~3. Assessment of organophosphorus exposure:~   By measuring pseudocholinesterase level by spectrophotometer~4. Mutational analysis of the KRAS and BRAF genes:~the tissue samples will be used to determine the mutation in k-ras and BRAF genes by RCR"
224101793|NCT05212025|DRUG|Adavosertib|Taken Orally
223950138|NCT04910711|DRUG|Levonorgestrel implant|Women initiating the levonorgestrel implant
224287738|NCT04583748|BEHAVIORAL|Sahaj Samadhi Meditation|Sahaj Samadhi Meditation (SSM) is a form of automatic self-transcending meditation that involves relaxed attention to a precise sound (mantra), to allow stress reduction and deep relaxation. This technique is easy to learn and offers the support of a group and facilitator.
224287739|NCT04583748|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program (HEP) is a standardized program used to teach participants about health promotion, including the benefits of a lifestyle of healthy diet, music, recreation, and exercise. In HEP, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes.
224101794|NCT05212025|DRUG|Gemcitabine|Intravenous Infusion
224101795|NCT03182738|BEHAVIORAL|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
224101796|NCT03182738|BEHAVIORAL|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
224101797|NCT03934762|BIOLOGICAL|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
224101798|NCT03934762|BIOLOGICAL|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
223950139|NCT04910711|DRUG|Depo medroxyprogesterone acetate injection|Women initiating the depo medroxyprogesterone acetate injection
223950140|NCT04014452|PROCEDURE|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
223950141|NCT04014452|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
223950142|NCT05966480|DRUG|ESK-001|Oral tablet
224101799|NCT03934762|BIOLOGICAL|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
224101800|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using a vial and syringe.
224101801|NCT05533801|DRUG|Lecanemab|Lecanemab will be administered subcutaneously using AI.
224101802|NCT01043640|DRUG|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
224101803|NCT01043640|DRUG|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
224101804|NCT01043640|DRUG|Busulfan|Administered every 6 hours: If \< or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If \> 12 kg then 0.8 mg/kg/dose IV
224101805|NCT01043640|PROCEDURE|Allogeneic stem cell transplantation|Administered \> 24 hours after last dose of busulfan.
224101806|NCT01043640|DRUG|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV\_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~* If body weight is ≤ 40 kg dosing will be 3 times daily~* If body weight is \> 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
224101807|NCT01043640|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC\>500 x 10\^6 neutrophils/L x 3 days and chimerism \>90%), whichever is later.
224287740|NCT03696355|DRUG|GDC-0084|Given PO
224287741|NCT03696355|RADIATION|radiation therapy|Both photon and proton therapy modalities will be allowed.
223950143|NCT05966480|DRUG|Placebo|Oral tablet
223950144|NCT03230981|DEVICE|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
223950145|NCT05167318|OTHER|frequent standardized oral care|Standardized oral care will be provided every 3-4 hours
223950146|NCT05254067|DEVICE|Codman Enterprise 2 Vascular Reconstruction Device|a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
224287742|NCT05515016|PROCEDURE|chin enhancement with a fatty flap sculpted from the double chin|Under general anesthesia, an incision was made behind the submental crease followed by the excision of the skin excess. The preplatysmal fatty compartment was individualized through a subcutaneous dissection. Then, the lower part of the preplatysmal fat was cut to start its separation from the platysma muscle, thus obtaining a real vascularized fatty flap. This flap could be folded on itself, then easily turned over to be fixed on the muscular layer of the chin.
223950147|NCT00002840|DRUG|lomustine|
223950148|NCT00002840|DRUG|procarbazine hydrochloride|
224101808|NCT04696744|BIOLOGICAL|CTC detection|"The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles"
223950149|NCT00002840|DRUG|vincristine sulfate|
224101809|NCT04421651|BEHAVIORAL|Dance Movement Therapy group|DMT-intervention was facilitated by a dance movement therapist and included 20 x 75 mins sessions within 10 weeks.
223950150|NCT00002840|RADIATION|radiation therapy|
223950151|NCT02563119|PROCEDURE|Gastric Bypass or Sleeve gastrectomy|
223950152|NCT00982917|BEHAVIORAL|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
223950153|NCT00982917|BEHAVIORAL|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
224101810|NCT00304473|DRUG|Quetiapine fumarate|
224101811|NCT01912118|DRUG|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
224101812|NCT01912118|DRUG|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
224101813|NCT01251523|BEHAVIORAL|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
224101814|NCT01251523|BEHAVIORAL|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
224101815|NCT05669521|DRUG|TK-112690|TK112690 treatment Post 5-FU chemotherapy
223950154|NCT01658241|DRUG|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
224101816|NCT05669521|DRUG|Placebo|Placebo treatment Post 5-FU chemotherapy
224101817|NCT00864734|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
224101818|NCT00864734|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
224101819|NCT04599426|BIOLOGICAL|Allogeneic NK cell regimen group|"10 patients with refractory MDS-RAEB were treated with allogeneic NK cell regimen.~Allogeneic NK cell regimen ×3 cycle; Cyclophosphamide 300mg/m2.d d1to 3; G-CSF 150ug bid d4-11; Azacitidine 75mg/m2 d5-11; Allogeneic NK cell 10-30×10\^6/kg d13，d15 ."
223950155|NCT02589457|DRUG|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
223950156|NCT02589457|DRUG|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
223950157|NCT01943669|DEVICE|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
223950158|NCT00198185|PROCEDURE|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
223950159|NCT05063006|OTHER|Cardiopulmonary exercise tests with maintained baseline optimal pump speed settings.|Optimal resting LVAD speed settings is defined as periodic aortic valve opening while maintaining the central position of the intraventricular septum, minimizing mitral regurgitation, and preserving the mean systemic blood pressure above 65 mmHg. The aim is to achieve an aortic valve opening ratio of around 25-33% by changing the pump speed at resting conditions.
223950160|NCT05063006|OTHER|Cardiopulmonary exercise test with gradually increased pump speed depending on live echocardiographic imaging.|During the modified speed exercise, when the aortic valve opening ratio rises above 50%, the pump speed is increased by 100 revolutions per minute (RPM). As the aortic valve remains closed the RPM is lowered by 100. Speed increment is not greater than 100 RPM per 45 seconds to enable an echocardiographic analysis of resulting changes and prevent suction events. There is no determined target speed, neither per time period nor maximal.
223950161|NCT01668394|BEHAVIORAL|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
223950162|NCT01668394|OTHER|Control arm|Usual care. Teaching style: deductive.
223950163|NCT06413888|PROCEDURE|pancreaticoduodenectomy|Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
224101820|NCT02888626|DEVICE|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
224287743|NCT05089929|DEVICE|Endoflip 2.0|FLIP topography (Endoflip 2.0) analysis will be performed on all patients undergoing routine evaluation for gastroesophageal reflux disease at the time of their pre-operative EGD.
224287744|NCT05089929|PROCEDURE|High Resolution Manometry|All patients undergoing routine evaluation for gastroesophageal reflux disease will undergo high resolution manometry (HRM) testing.
224101821|NCT04937257|OTHER|Virtual Reality|The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.
224101822|NCT04937257|OTHER|E-module|The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
224101823|NCT03596164|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
224101824|NCT03596164|DEVICE|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
224101825|NCT03596164|DEVICE|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
224101826|NCT03596164|DEVICE|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
224101827|NCT01457248|DEVICE|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
224101828|NCT01457248|DEVICE|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
224101829|NCT04112914|BEHAVIORAL|Post-concussion education for families|An educational intervention for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents.
223950164|NCT01406106|DIETARY_SUPPLEMENT|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
224101830|NCT03427073|DRUG|ALM201|Drug: ALM201 administered subcutaneously
224101831|NCT01358383|DRUG|naproxen|250mg, oral dose
224101832|NCT01358383|DRUG|esomeprazole|20mg, oral dose
224101833|NCT04048577|DRUG|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
224101834|NCT00508729|DRUG|Qingyi granules|
224287745|NCT04628104|RADIATION|cardiac magnetic resonance|"o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation"
224287746|NCT04719104|DEVICE|Transcutaneous Bilirubin Meter - 'Bilimeter'|Taking a transcutaneous (TcB) measurement will involve using a 'biliflash'. This is a non-invasive measurement that involves flashing a light against the helix of the infant's ear and can be done at the cotside. This process takes approximately 1-2 minutes and does not cause the baby discomfort. The meter gives an immediate bilirubin level.
224287747|NCT01027741|BEHAVIORAL|Phone Referral|Participants receive phone referral to cancer control and prevention services.
224287748|NCT01027741|BEHAVIORAL|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
224287749|NCT01027741|BEHAVIORAL|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
224287750|NCT05748119|DRUG|MEB-1170|Depending on the dosage, either 20 mg, 40 mg capsules, or a combination of both
223950165|NCT03704519|DRUG|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
223950166|NCT03704519|DRUG|Enzalutamide|4 x 40 mg capsules, once orally
223950167|NCT03704519|OTHER|Placebo|4 placebo tablets, once orally
223950168|NCT05932303|DRUG|BMS-986278|Specified dose on specified days
223950169|NCT05932303|DRUG|Itraconazole|Specified dose on specified days
223950170|NCT05932303|DRUG|Gemfibrozil|Specified dose on specified days
223950171|NCT05932303|DRUG|Carbamazepine|Specified dose on specified days
223950172|NCT06145191|DRUG|Tranexamic acid|Prophylactic topical application (1x) of tranexamic acid (100mg, 2ml, room temperature) before sampling
223950173|NCT06145191|DRUG|Adrenaline|Prophylactic topical application (1x) of adrenaline (1:10.000, 2ml, room temperature) before sampling
223950174|NCT06145191|DRUG|Placebo|Prophylactic topical application (1x) of placebo (0.9% NaCl, 2ml, room temperature) applied before sampling
224287751|NCT05748119|DRUG|Placebo|Equivalent number and size of capsules containing placebo
224287752|NCT00472121|DEVICE|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
224287753|NCT04393090|OTHER|eHealth platform CANKADO|The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.
224287754|NCT02196519|DEVICE|Sylys Surgical Sealant|
224287755|NCT00772135|DRUG|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
224287756|NCT02993770|PROCEDURE|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
224287757|NCT02993770|PROCEDURE|External DCR|External DCR
223722558|NCT04184869|DRUG|Belinostat|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
223722559|NCT04184869|DRUG|Atazanavir|"Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up."
223722560|NCT02050529|DRUG|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
223722561|NCT02050529|DRUG|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
223950175|NCT03701906|DIETARY_SUPPLEMENT|Lactobacillus PS11603 & Bifidobacterium PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1\*10E9 CFU of L.salivarius PS11603 and 1\*10E8 CFU of B.longum PS10402.
223950176|NCT03701906|DIETARY_SUPPLEMENT|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
223950177|NCT01141257|DRUG|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
223950178|NCT02915783|DRUG|lenvatinib|4 mg and 10 mg capsules
223950179|NCT02915783|DRUG|everolimus|5 mg tablets
223950180|NCT02203032|DRUG|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
224101835|NCT05523492|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
224287758|NCT00302549|DRUG|FK506|FK506,0.1mg/kg/d
224287759|NCT00276549|DRUG|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
224287760|NCT00276549|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
223722562|NCT05607277|PROCEDURE|Endovascular Repair of abdominal aortic aneurysms|Femoral artery access
223722563|NCT00666627|DRUG|Ibandronate|once monthly
223722564|NCT00666627|DRUG|Risedronate|Risedronate 35mg once weekly
223722565|NCT00666627|DRUG|Alendronate|Alendronate 70mg once weekly
223950181|NCT02203032|DRUG|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
223950182|NCT02203032|DRUG|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
223950183|NCT02203032|DRUG|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
223950184|NCT03507244|DRUG|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
223950185|NCT03507244|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
223950186|NCT03507244|RADIATION|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
223950187|NCT06360224|DEVICE|MiraQ systems with Transit Time Flow Measurement (TTFM) and High Frequency Ultrasound (HFUS) probes|The objective of this study is to harvest a wide dataset of high quality to allow exploratory analysis and training of machine learning
223950188|NCT02258178|BIOLOGICAL|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
223950189|NCT06269497|PROCEDURE|Scaffold placement|The scaffold is placed in the alveola following extraction
223950190|NCT06269497|RADIATION|CBCT|A Cone Beam Computer Tomography (CBCT) is taken of the area of interest after surgery
224101836|NCT01660815|DRUG|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
224101837|NCT01748227|BEHAVIORAL|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
224101838|NCT01955616|DRUG|RM-131|
224101839|NCT01955616|DRUG|Placebo|
224101840|NCT01564979|DRUG|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
223950191|NCT01192555|BIOLOGICAL|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10\^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
223950192|NCT01192555|DRUG|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
223950193|NCT01915914|DRUG|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
223950194|NCT05038202|DRUG|Bencycloquidium Bromide Nasal Spray|"The content of this product is a colorless and clear liquid, press the sprayer, the liquid will be sprayed out in mist.~This product is suitable for improving the symptoms of runny nose, nasal congestion, nasal itching and sneezing caused by allergic rhinitis."
223950195|NCT05038202|DRUG|Mometasone Furoate Aqueous Nasal Spray|"Mometasone furoate nasal spray is a quantitative hand-press spray device, and the content is a white to off-white suspension.~This product is suitable for the treatment of seasonal or perennial rhinitis in adults, adolescents and children from 3 to 11 years old. For patients who have had moderate to severe seasonal allergic rhinitis symptoms, it is recommended to use this product 2-4 weeks before the start of the pollen season Preventive treatment."
224101841|NCT01564979|DRUG|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
224101842|NCT02955329|DRUG|Nicotine|Participants will vape tobacco leaves with nicotine out of the PAX device.
224101843|NCT02955329|DRUG|Cannabis|Participants will vape marijuana leaves with nicotine out of the PAX device.
224101844|NCT02955329|DEVICE|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
224101845|NCT01486238|DRUG|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
224101846|NCT00332787|DRUG|Fluoxetine|
224101847|NCT00759603|DRUG|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
224101848|NCT00759603|DRUG|Rituximab|Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
224101849|NCT03963973|DRUG|RDN-929 oral capsule|low, medium and high dose
224101850|NCT03963973|DRUG|Placebo oral capsule|matching placebo dose
224101851|NCT02835495|BEHAVIORAL|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
224101852|NCT02835495|BEHAVIORAL|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
224101853|NCT03384992|OTHER|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
224287761|NCT05223491|PROCEDURE|En Bloc resection|Tumour is resected and removed from the bladder in one piece, if possible.
224101854|NCT03384992|OTHER|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
224101855|NCT03384992|OTHER|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
224287762|NCT05223491|PROCEDURE|Conventional TURB|Tumour is resected piecemeal.
224287763|NCT01478737|DRUG|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
224287764|NCT01478737|PROCEDURE|Vitrectomy|Vitrectomy only
224287765|NCT01820351|OTHER|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
224287766|NCT05778955|GENETIC|detection and monitoring of cirulating tumor DNA|detection and monitoring of cirulating tumor DNA in pediatric soft tissue sarcoma
224287767|NCT02630836|DRUG|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
224287768|NCT02630836|PROCEDURE|Surgical treatment|Isolated endomedullary nailing
223950196|NCT04700202|OTHER|Observational|Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP
223950197|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Test product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India
223950198|NCT06233149|DRUG|Esomeprazole magnesium dihydrate-Reference product|Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: AstraZeneca AB, Kingdom of Sweden
224101856|NCT03384992|OTHER|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
223950199|NCT03278977|BIOLOGICAL|Blood sample for specific analyzes|"Standard management of ALTE~* Hospitalization in pediatric intensive care unit or pediatric emergencies~* Etiologic research~* Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
223950200|NCT05058157|DIETARY_SUPPLEMENT|different ketogenic formulae|The research product may be in a form of powder to reconstitute or in a ready-to-drink format.
223950201|NCT03450811|PROCEDURE|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
223950202|NCT00454922|BEHAVIORAL|standard of care|no intervention
223950203|NCT00454922|OTHER|education|meet with trained glaucoma educator 6 times over life of study
223950204|NCT00519935|BEHAVIORAL|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
223950205|NCT01528605|DIETARY_SUPPLEMENT|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
224287769|NCT02283164|BEHAVIORAL|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
223950206|NCT01528605|DIETARY_SUPPLEMENT|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
223950207|NCT01528605|DIETARY_SUPPLEMENT|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
223950208|NCT01528605|DIETARY_SUPPLEMENT|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
223950209|NCT01528605|DIETARY_SUPPLEMENT|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
223950210|NCT01528605|DIETARY_SUPPLEMENT|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
223950211|NCT01404338|DRUG|Halobetasol 0.05% ointment|
223950212|NCT01404338|DRUG|Placebo Ointment|
223950213|NCT01615770|BEHAVIORAL|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
223950214|NCT02432274|DRUG|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
223950215|NCT02432274|DRUG|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
223950216|NCT02432274|DRUG|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
223950217|NCT02432274|DRUG|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose). Lenvatinib dose can be escalated to the RD from Cohort 1 or de-escalated to 40 and 60% lower than the RD from Cohort 1.
223950218|NCT02432274|DRUG|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
223950219|NCT02432274|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Ifosfamide dose can be de-escalated to 2400 mg/m2/day and 1800 mg/m2/day.
223950220|NCT02432274|DRUG|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles. Etoposide dose can be de-escalated to 80 mg/m2/day and 60 mg/m2/day.
223950221|NCT02432274|DRUG|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
224287770|NCT00099710|DIETARY_SUPPLEMENT|Curcumin C3 Complex|
223950222|NCT02432274|DRUG|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
223950223|NCT06238934|BIOLOGICAL|Bone marrow aspirate matrix|Bone marrow aspirate \* Hyaluronic acid
223950224|NCT06238934|BIOLOGICAL|Bone marrow aspirate|Bone marrow aspirate
223950225|NCT06238934|DEVICE|Hyaluronic acid|Hyaluronic acid
223950226|NCT00116649|DRUG|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
224101857|NCT03384992|OTHER|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
224101858|NCT00669773|DRUG|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
224101859|NCT00669773|DRUG|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
224101860|NCT02712775|DRUG|Minocycline (yes/no)|
224101861|NCT02712775|DRUG|Placebo|Saline
223950227|NCT03869970|BEHAVIORAL|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
223950228|NCT03869970|BEHAVIORAL|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
223950229|NCT03869970|BEHAVIORAL|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
223950230|NCT05758584|OTHER|Intervention|Vibrating tourniquet
223950231|NCT05758584|OTHER|Distraction card|Distraction card
223950232|NCT04696900|PROCEDURE|Exercise training|exercise training in an approved rehabilitation program
223950233|NCT02176577|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
223950234|NCT04057261|DRUG|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
223950235|NCT04057261|DRUG|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
223950236|NCT05794659|BIOLOGICAL|AST-201|i.d. (3-week interval, 3 cycles in total)
223950237|NCT05794659|DRUG|Paclitaxel|3-week interval, 6 cycles in total
223950238|NCT05794659|DRUG|Carboplatin|3-week interval, 6 cycles in total
223950239|NCT05794659|DRUG|Placebo|i.d. (3-week interval, 3 cycles in total)
223950240|NCT05794659|DRUG|rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)|i.d. (3-week interval, 3 cycles in total)
223950241|NCT03428438|OTHER|Rehabilitation at home via SMS|Cardiac rehabilitation
223950242|NCT05305508|DRUG|Calcium Dobesilate|The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.
223950243|NCT05305508|DRUG|Mannitol|The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.
223950244|NCT06140550|DEVICE|Drug balloon dilated|Through the expansion after the balloon is in place,Release drugs on the surface of the balloon and improve the blood perfusion of nerve vessels to treat stenosis
223950245|NCT06140550|DEVICE|balloon dilated|Through the expansion after the balloon is in place, improve the blood perfusion of nerve vessels to treat stenosis.
223950246|NCT01728298|BIOLOGICAL|SLITone ULTRA HDM immunotherapy|
223950247|NCT00781118|DEVICE|Guardian System|There is no intervention in this study. The device is a diagnostic only.
223950248|NCT05086874|OTHER|butylphthalide|Observational only and no predesigned interventions in this study
223950249|NCT01486459|DRUG|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
223950250|NCT00005943|BIOLOGICAL|aldesleukin|
223950251|NCT00005943|BIOLOGICAL|staphylococcal enterotoxin B|
223950252|NCT00779194|DRUG|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
223950253|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
223950254|NCT01121328|BIOLOGICAL|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
224101862|NCT04551443|BIOLOGICAL|Intravenous infusion placebo|Intravenous infusion placebo or WJMSCs in patients with AMI
224101863|NCT04551443|BIOLOGICAL|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with AMI
224101864|NCT04073615|DRUG|Rivoceranib|Film-coated tablets
224101865|NCT04073615|DRUG|Trifluridine/Tipiracil|Film-coated tablets
224101866|NCT02087566|DRUG|600 mg linezolid|
224101867|NCT02180386|BEHAVIORAL|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
224101868|NCT06487156|DRUG|Nivolumab + ipilimumab|As per product label
224101869|NCT00674531|PROCEDURE|Artery resection|Artery resection
224101870|NCT01225354|DRUG|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
224101871|NCT01091129|DEVICE|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
224101872|NCT01627704|DRUG|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
224101873|NCT02318602|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
224101874|NCT03736044|DRUG|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
224101875|NCT04300348|DEVICE|Heel2Toe|Heel to Toe (Heel2Toe) is a device that clips on the shoe and provides an instant auditory feedback (a beep) for each correct step characterized by putting the heel first and it provides data on gait parameters
224101876|NCT04300348|OTHER|No-feedback control group|The control group will follow the same protocol as the Heel2Toe group but the device will not be in feedback mode just in data acquisition mode.
224101877|NCT04147949|DRUG|AV-101|Oral capsules taken twice daily for 14 days
224101878|NCT04147949|DRUG|Placebo|Oral capsules taken twice a day for 14 days
224101879|NCT00942006|DRUG|doxycycline|100 mg bid, 14 days
223950255|NCT03526406|DIETARY_SUPPLEMENT|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
223950256|NCT03526406|DIETARY_SUPPLEMENT|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD\&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
223950257|NCT00513071|DRUG|saracatinib|Given orally
223950258|NCT00513071|OTHER|laboratory biomarker analysis|Correlative studies
223950259|NCT05842382|DRUG|Active Ingredient|IV Vitamin C (12g/day)
223950260|NCT05842382|DRUG|Placebo|IV dextrose 5%
224101880|NCT00942006|DRUG|ceftriaxone|2g x 1 iv, 14 days
224101881|NCT00693706|BIOLOGICAL|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
224101882|NCT00693706|BIOLOGICAL|Fluarix|IM injection on Day 0
224101883|NCT05025943|OTHER|Diet intervention|The intervention group will receive diet counseling and information to implement a standard lifestyle intervention plus omega-3 fatty acid enriched foods Diet assessment and counseling provided throughout study.
224101884|NCT05025943|OTHER|Control group|The control group will receive diet counseling and information to implement a standard lifestyle intervention Diet assessment and counseling provided throughout study.
223950261|NCT02089529|DRUG|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
224101885|NCT06356740|BIOLOGICAL|Blood sample|"blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum."
224101886|NCT06356740|DRUG|Treatment :Abacavir 600 mg/lamivudine 300 mg|Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.
224101887|NCT06356740|OTHER|Lupus Impact Tracker questionnaire|Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
223950262|NCT02089529|DRUG|Placebo|Placebo with no information, positive information and neutral information
223950263|NCT02368652|DRUG|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
223950264|NCT02368652|DRUG|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
223950265|NCT03977805|DRUG|Hetrombopag Olamine|a single oral taking
224101888|NCT04242537|DEVICE|High flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
224101889|NCT04242537|DEVICE|Low flow nasal cannula oxygen delivery|It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
223950266|NCT01660659|DEVICE|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
223950267|NCT01573338|DRUG|Roniciclib (BAY1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
223950268|NCT01573338|DRUG|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
223950269|NCT01573338|DRUG|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
223950270|NCT01573338|DRUG|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
223950271|NCT05348603|OTHER|Traditional Letter|Patients receive a traditional letter.
223950272|NCT05348603|OTHER|Direct to Patient Message|Patients receive a direct to patient message via the portal.
223950273|NCT05348603|OTHER|Chatbot|Patients are contacted by a chatbot via the portal.
223950274|NCT05348603|OTHER|Banner|Patients are exposed to a banner ad via the portal.
223950275|NCT03056066|DEVICE|Plethysmograph|A full Body Plethysmography examination
224101890|NCT04425655|DRUG|Fludarabine|30mg/m2 days 1 through 5
224101891|NCT04425655|DRUG|Vyxeos|100U/m2 days 1, 3 5 in induction, 65U/m2 days 1 and 3 for consolidation
224101892|NCT06229509|DEVICE|Effective noninvasive ventilation|Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)
224101893|NCT06229509|DEVICE|Sham noninvasive ventilation|Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
224101894|NCT01873950|DRUG|Ranolazine|
224101895|NCT01873950|DRUG|Dofetilide|
224101896|NCT01873950|DRUG|Verapamil|
224101897|NCT01873950|DRUG|Quinidine sulfate|
224101898|NCT01873950|DRUG|Placebo|
224101899|NCT05786170|DIAGNOSTIC_TEST|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging
224101900|NCT03615027|BEHAVIORAL|Dementia-specific advance care planning|see detailed description
224101901|NCT02712502|DRUG|Levofloxacin|"* Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
223950276|NCT01177449|PROCEDURE|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
223950277|NCT03146026|BEHAVIORAL|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
223950278|NCT00667732|DRUG|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
223950279|NCT00667732|DRUG|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
223950280|NCT02659540|DRUG|Nivolumab|Nivolumab was administered as an intravenous (IV) infusion over approximately 30 or 90 minutes, with dosing calculated using body weight.
223950281|NCT02659540|DRUG|Ipilimumab|Ipilimumab was administered as an IV infusion over approximately 30 or 90 minutes, with dosing calculated using body weight. The ipilimumab infusion was initiated approximately 30 minutes after the end of the nivolumab infusion on applicable dosing days.
223950282|NCT02659540|RADIATION|Radiotherapy|RT was delivered in accordance with cohort assignment and institutional practices.
223950283|NCT02725372|DRUG|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
223950284|NCT02725372|DRUG|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
223950285|NCT01240590|DRUG|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
223950286|NCT01240590|DRUG|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
223950287|NCT01213940|BEHAVIORAL|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
223950288|NCT01213940|PROCEDURE|bariatric surgery|bariatric surgery for weight loss
223950289|NCT02123940|DEVICE|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
223950290|NCT01472159|BEHAVIORAL|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
223950291|NCT02106325|DRUG|Ketamine|IV of Ketamine (.25mg/kg)
223950292|NCT02106325|DRUG|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
223950293|NCT03890484|BEHAVIORAL|Peer Type - New Peer|Participants drink with 2 unfamiliar confederate peers
224101902|NCT02712502|DRUG|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
224101903|NCT04603248|DRUG|Nivolumab|Nivolumab 3mg/kg treatment will be given every 2 weeks up to progression or unacceptable toxicity
224101904|NCT02631161|OTHER|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
224101905|NCT02631161|OTHER|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
223950294|NCT03890484|BEHAVIORAL|Peer Type - Close Friends|Participants drink with 2 close friends
223950295|NCT00035048|DRUG|aprepitant|
223537639|NCT06328842|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223950296|NCT00035048|DRUG|Comparator: placebo (unspecified)|
223950297|NCT01600196|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
223950298|NCT06604481|BEHAVIORAL|eCoaching for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills. This program is designed to operate individually on an e-platform. It consists of 6 weekly sessions, each lasting for less than 90 minutes. The content of the sessions focuses on teaching caregivers CBT techniques, lifestyle modifications to improve caregiving experiences, and effective communication strategies. In between each session, participants are assigned home practices to reinforce the skills learned further. All content will be included.
223950299|NCT06604481|BEHAVIORAL|eCoaching (need specific) for Caregivers of Older Adults|The experimental group receives an online intervention based on Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, lifestyle intervention, and effective communication skills as in eCoaching I. However, eCoaching II will include content specified to carer's specific need.
224101906|NCT05421754|DEVICE|ANNE Sleep|ANNE Sleep system for 1 night with HST followed by 3 nights of ANNE Sleep system alone.
224101907|NCT05038761|DEVICE|CGM System|"Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days."
224101908|NCT05038761|PROCEDURE|Standard Venous Blood Glucose Test|Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
223950300|NCT06604481|BEHAVIORAL|Control Intervention for Caregivers of Older Adults|The control group attends 6 weekly online sessions that primarily provide educational information about lifestyle factors and communication. These sessions aim to enhance the control group's knowledge and understanding of the factors that impact caregiving. Each session in the control group also lasts for 90 minutes. The focus of these activities will be on building practical caregiving skills and promoting overall well-being, rather than targeting any particular psychological or mental health-related factors directly.
223950301|NCT00509756|DRUG|FXR-450|capsule, single oral doses from 10 mg to 450 mg
223950302|NCT00509756|DRUG|Placebo|capsule similar to active drug
223950303|NCT00563134|DRUG|GR270774|
224101909|NCT01318616|OTHER|Strength training of the hip adductors|Adductor strength training
224101910|NCT04687124|DIETARY_SUPPLEMENT|Fish oil|Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)
224101911|NCT04687124|OTHER|standard care|No specified intervention
224101912|NCT06448156|DIAGNOSTIC_TEST|"cardiac arrest and sudden death"|"Selection of cases with a secondary diagnosis containing the diagnostic keywords cardiac arrest and sudden death.cardiac arrest and sudden death.The incidence rate is then calculated"
224101913|NCT01994343|OTHER|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
223950304|NCT03263572|BIOLOGICAL|Blinatumomab|Given IV
223950305|NCT03263572|DRUG|Cytarabine|Given intrathecally via spinal tap
223950306|NCT03263572|DRUG|Methotrexate|Given intrathecally via spinal tap
224101914|NCT03880812|OTHER|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
224101915|NCT03593694|BEHAVIORAL|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
224101916|NCT03593694|BEHAVIORAL|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
224101917|NCT03593694|BEHAVIORAL|TECH DMBAT Other|Technology delivered diabetes education
224101918|NCT02580058|BIOLOGICAL|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
223950307|NCT03263572|DRUG|Ponatinib|Given PO
223950308|NCT06999577|DRUG|Omeprazole 40 MG|8 week double dose therapy of proton pump inhibitor or placebo.
224101919|NCT02580058|DRUG|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
224101920|NCT04758793|OTHER|blood samples|3 citrated tubes and 3 EDTA tubes
223950309|NCT06999577|BEHAVIORAL|Laryngeal Recalibration Therapy|LRT utilizes therapies that SLPs standardly utilize (mechanical and cognitive guidance) in combination specifically designed to treat laryngeal symptoms. Each session with the SLP will guide subjects through these therapies. The existing script-based LRT protocol consists of the following: 1) mechanical guidance (laryngeal suppression, voice production, breath coordination), 2) cognitive guidance (identification of thinking patterns, recalibration of thoughts about laryngeal sensations).
224101921|NCT04758793|OTHER|biopsy of abdominal paroie|a muscle biopsy will be performed on the incision area
223950310|NCT06999577|BEHAVIORAL|GERD Lifestyle Recommendations|This is the typical lifestyle recommendations for GERD used clinically.
224101922|NCT05125653|PROCEDURE|Indocyanine Green Fluorescent Laparoscopic Cholangiography|Indocyanine Green Fluorescent Cholangiography
224101923|NCT05125653|PROCEDURE|White Light|Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
224101924|NCT00117078|DRUG|Aranesp®|
224287771|NCT06062849|DEVICE|nephrostomy tube|we will investigate if a nephrostomy tube really necessary after PNL operations
224287772|NCT06062849|DEVICE|double J stent|we will investigate if a JJ stent really necessary after PNL operations
224287773|NCT06062849|PROCEDURE|totally tubless|we will not insert any device after the procedure and investigate if a nephrostomy tube or JJ stent really necessary after PNL operations
224287774|NCT04783974|DEVICE|Dental implants|Treatment of total or partial edentulism through the placement of osseointegrated dental implants
224287775|NCT03844958|OTHER|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
224287776|NCT03844958|OTHER|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
224287777|NCT05452135|OTHER|Observation of visual, audotory and motor reaction time|Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
224287778|NCT01247246|DRUG|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
224287779|NCT01247246|DRUG|Placebo|Placebo
224287780|NCT00207454|BEHAVIORAL|Social Cognitive Counseling|
224287781|NCT05633238|BEHAVIORAL|Visual Search Information Type (target or distractor information)|Participants will have information about targets, distractors, or neither in different blocks of the intervention.
224287782|NCT02193607|PROCEDURE|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
224287783|NCT02193607|PROCEDURE|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
224287784|NCT00666887|DRUG|Minocycline|100 mg twice daily to be taken for up to 2 years
224287785|NCT00666887|DRUG|Placebo|placebo twice daily for 2 years
224287786|NCT02588079|BEHAVIORAL|Internet-based cognitive behavioral therapy|
224287787|NCT03029117|PROCEDURE|correction of rheumatic valve lesions|
224287788|NCT04490226|DIETARY_SUPPLEMENT|Beta-Hydroxybutyrate as Ca-Mg-salt, active|24 hour intervention with ketone body supplements additional to a normal diet (isocaloric diet in total) to induce ketosis (exogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
224287789|NCT04490226|DIETARY_SUPPLEMENT|ketogenic diet (KetoCal® 4:1 Neutral, Nutricia GmbH, Erlangen, Germany), active|24 hour interventions with ketogenic isocaloric diet to induce ketosis (endogenous ketone bodies), in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
224101925|NCT05382481|DIAGNOSTIC_TEST|Peak value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the peak level of anti-Xa after 4 to 6 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the peak value of anti Xa.
224101926|NCT05382481|DIAGNOSTIC_TEST|Trough value anti-Xa|This group will receive low molecular weight heparins (LMWH) 40mg, once a day for the first 3 days. And detect the trough level of anti-Xa after 12 hours after injection of the third dose of LMWH. Adjust the dose of LMWH according to the trough value of anti Xa.
224101927|NCT05382481|DIAGNOSTIC_TEST|Control Group|This group will receive fixed dose of low molecular weight heparins (LMWH) 40mg, once a day. And will not detect the level of anti-Xa
224101928|NCT04837911|DEVICE|Spirobank Smart|Patients using the Spirobank Smart
224101929|NCT01152138|DEVICE|Open cells stent|Cobalt Chromium Stent with open cell design
224101930|NCT01152138|DEVICE|Closed Cells Stent|Cobalt Chromium stent with closed cell design
224101931|NCT04299529|DIAGNOSTIC_TEST|In-vitro urinary diagnostic test|Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).
224101932|NCT01697332|DRUG|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
224101933|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
223950311|NCT06820177|DRUG|Tranexamic Acid|1g tranexamic acid
224101934|NCT01193335|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
224101935|NCT04554368|PROCEDURE|intra-arterial contrast enhanced Flat Detector CT|After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
223537640|NCT06328842|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223950312|NCT06820177|DRUG|Placebo|10 mL 0.9% normal saline
223950313|NCT04557176|DEVICE|CRP, point-of-care assay|CRP is a non-specific marker of inflammation whose levels rise in the setting of interleukin 6 (IL-6)-mediated inflammation, such as active TB. In clinical settings, CRP is used to identify patients with systemic inflammation from infection or non-infectious cases. In settings with high TB prevalence, the investigators hypothesize that CRP can be used to accurately screen individuals for active TB (i.e., distinguish individuals with high likelihood of having active TB from those individuals unlikely to have active TB).
223950314|NCT07006493|DEVICE|Transcatheter Intramyocardial Septal Radiofrequency Ablation System|The device system includes a single-use RF ablation catheter, sheath, RF generator, and irrigation pump. Ablation is guided by intracardiac echocardiography (ICE).
223950315|NCT07013994|PROCEDURE|peripheral venous cannulation with ultrasound-guided technique|Peripheral venous cannulation with short peripheral vascular access device, performed by ultrasound technique.
224101936|NCT01187225|DRUG|Fibrinogen concentrate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
224101937|NCT01187225|DRUG|Cryoprecipitate|In this arm, children (\< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (\< 1g/L) or TEG \< 7 mm
224101938|NCT00683943|DRUG|Lithium Carbonate|
224101939|NCT05942690|PROCEDURE|manual osteopathic intervention|The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
224101940|NCT03436589|BEHAVIORAL|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
224101941|NCT03642561|DEVICE|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
224101942|NCT03642561|DEVICE|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
224101943|NCT00071773|PROCEDURE|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
224101944|NCT00071773|PROCEDURE|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
223722566|NCT04410211|DRUG|Sevoflurane|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator"
223950316|NCT07013994|PROCEDURE|Arterial gas puncture using ultrasound-guided technique|Arterial puncture using a needle and heparinised syringe to extract a sample for arterial blood gas analysis, using the ultrasound-guided technique.
223950317|NCT07013994|PROCEDURE|Peripheral venous cannulation with traditional technique|Cannulation of a short peripheral vascular access device using the traditional visualisation and palpation technique.
223950318|NCT07013994|PROCEDURE|Arterial puncture by traditional technique|Arterial puncture using a needle and heparinised syringe to extract an arterial blood sample for arterial gamosetry analysis, performed using the traditional arterial pulse palpation technique.
223950319|NCT07013591|DRUG|MIB-626|An orally-administered stable crystalline tablet formulation of NMN
223950320|NCT07013591|OTHER|Placebo|matching placebo tablets
223950321|NCT07013786|DIAGNOSTIC_TEST|Pressure biofeedback assessment|Participants will be assessed for lumbar motor control using a pressure biofeedback unit (PBU) during the Abdominal Draw-In Maneuver (ADIM) in both crock lying and prone positions. This is a non-invasive test to evaluate deep core muscle function (TrA and MF) in patients with NSCLBP. No therapeutic intervention will be administered.
223950322|NCT07012733|OTHER|Thoracic mobilization|Participants in this group will receive thoracic mobilization techniques in addition to conventional respiratory therapy. Thoracic mobilization will be delivered by a licensed physical therapist using passive manual techniques targeting the thoracic spine and rib cage to improve chest wall mobility and respiratory function.
224101945|NCT01723306|GENETIC|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
224101946|NCT01733329|DRUG|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
224101947|NCT01733329|DRUG|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
223950323|NCT07012733|OTHER|conventional therapy|Participants in this group will receive conventional respiratory therapy, including diaphragmatic breathing, pursed-lip breathing, and chest expansion exercises. The therapy will be administered by a licensed physical therapist following standard pulmonary rehabilitation protocols.
223722567|NCT04410211|DRUG|Midazolam injection|"Incidence of side effects such as excitation, headache, apnea, airway obstructions are recorded. Patients who experiences severe excitation disinhibition as defined in the investigator's opinion as agitation. Uncontrollable patient movements that causes unsafe procedural conditions and conversion to general anaesthesia is needed~Post procedural recovery scoring are taken which includes:~1. Time taken from the point that the procedure ended to the first OAAS score of 5~2. Time taken from (a) to meeting discharge eligilibility~Pre and post procedure pyschometric test (delayed and immediate memory test, posting box test and Stroop test) will be done and compared by the blinded observer/investigator."
223722568|NCT05954013|BEHAVIORAL|PD_Pal intervention|The PD\_Pal intervention will be delivered by a nurse that is specifically trained to deliver the PD\_Pal intervention, i.e. the PD\_Pal nurse. In the PD\_Pal intervention, the patient, family caregiver and PD\_Pal nurse complete four steps wherein they discuss and compose a: 1) Individual care plan; 2) Proactive care plan; 3) Quality of life and end-of-life plan and; 4) Coordination and revision plan. Together these steps lead to the Parkinson Support Plan. To facilitate patients in taking these steps, all patients receive a Parkinson Support Plan workbook. This workbook consists of information and questions aligned with the four steps. Patients can utilize this workbook before, during, or after the conversations with the PD\_Pal nurse.
223950324|NCT07012642|DRUG|GLP-1 Receptor Agonists|GLP-1 RAs in lymphedema
223950325|NCT07013773|DRUG|Y-4 tablet|The enrolled subjects will be randomly divided into group AB and group BA, with a total of 10 subjects in each group, all subjects will take one Y-4 tablet (pregabalin 112.5 mg, riluzole 28.125 mg) at each period. Subjects of group AB will take Y-4 tablet under fasted condition in period 1, and take Y-4 tablet under fed condition in period 2. In contrast, subjects of group BA will take Y-4 tablet under fed condition in period 1, and take Y-4 tablet under fasted condition in period 2. There will be 7 days of wash-out between the two periods.
224101948|NCT03950986|OTHER|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
224101949|NCT05510986|DRUG|Fentanyl group|Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
224101950|NCT05510986|DRUG|Oxycodone Hydrochloride group|"Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes."
223950326|NCT07011693|DRUG|Sertraline|Commonly used oral antipsychotics intervention therapy.
223950327|NCT07011693|DRUG|Agomelatine|Commonly used oral antipsychotics intervention therapy.
223950328|NCT07011693|DRUG|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
223950329|NCT07014228|PROCEDURE|single visit re-endo|In this group, a single visit re-endodontic treatment will be performed and completed in the same visit, including all the steps.
224287790|NCT04490226|DIETARY_SUPPLEMENT|fasting, active|36 hours of fasting, in a metabolic chamber at physical activity level of 1.6, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.6.
223537641|NCT03732989|DEVICE|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
223537642|NCT03732989|DEVICE|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
223537643|NCT02001129|BEHAVIORAL|Automated Telephone System|Participants receive automated reminder phone calls.
223537644|NCT02001129|BEHAVIORAL|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
223950330|NCT07014228|PROCEDURE|multi visit re-endo|In this group, a multi-visit re-endodontic treatment will be performed and completed over different visits, including all the steps.
223950331|NCT06875362|DIETARY_SUPPLEMENT|Probiotic|The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
223950332|NCT06875362|DIETARY_SUPPLEMENT|Placebo|The trial period of this study lasts for 2 months(8weeks), during which each participant will have 3 visits (at month 0, month 1, andmonth 2).
223950333|NCT06625515|DRUG|ATX-559|DHX9 tablets will be taken orally
223950334|NCT07012538|DRUG|Renin-angiotensin system inhibitors (RASi)|Using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or inappropriate use of RASi.
223950335|NCT07012538|DRUG|No renin-angiotensin system inhibitors (No RASi)|Not using RASi after radical resection of stage II/III colon cancer for at least 3 years or till recurrence or death or needing RASi.
223950336|NCT07012499|DEVICE|Automated peritoneal dialysis with Sharesource device|Patients receive APD with an FMC device that contains sharesource software which can communicate with the medical team.
224287791|NCT04490226|DIETARY_SUPPLEMENT|fasting, inactive|"36 hours of fasting, in a metabolic chamber at physical activity level of 1.3, after one day of isocaloric diet in a metabolic chamber at physical activity level of 1.3.~The same intervention is reproduced one week later."
224287792|NCT04067388|OTHER|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
224287793|NCT03083977|OTHER|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
224287794|NCT01048502|DRUG|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
224287795|NCT01048502|DRUG|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
224287796|NCT01048502|DRUG|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
224287797|NCT03861663|DEVICE|Ultrasound|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
224287798|NCT03365544|OTHER|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
224287799|NCT03507478|DEVICE|BPI1000013|Foam insole
224287800|NCT06387680|OTHER|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial|The Effect of Peanut Ball Use on Labor Memory, Labor Satisfaction, Delivery Length, and Neonatal APGAR Score: A Randomized Controlled Trial
224287801|NCT06123182|BEHAVIORAL|Episodic Future Thinking|During the audio recorded guided imagery exercise participants will be asked to think in detail of a future (6 months to a year) where they have made healthy choices regarding physical activity and are physically active.
223537645|NCT02001129|BEHAVIORAL|Usual Care|Participants receive a standard reminder letter in the mail.
223537646|NCT05930080|DRUG|SKCPT|the randomly assigned subjects took the study drug for 12 weeks
223537647|NCT05930080|DRUG|Celebrex|the randomly assigned subjects took the study drug for 12 weeks
223537648|NCT02406222|DRUG|Pomalidomide|Chemotherapy
223537649|NCT02406222|DRUG|Dexamethasone|Chemotherapy
223537650|NCT02406222|DRUG|Cyclophosphamide|Chemotherapy
223537651|NCT04068805|BEHAVIORAL|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
223537652|NCT03703505|DRUG|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.
223537653|NCT03703505|DRUG|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
223537654|NCT02598037|DIETARY_SUPPLEMENT|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
224287802|NCT06123182|BEHAVIORAL|Episodic Recent Thinking|During the audio recorded guided imagery exercise participants will be asked to think about a routine weekly activity.
224287803|NCT06123182|BEHAVIORAL|Positive Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the positive outcomes and sensations associated with an exercise bout.
223950337|NCT07012499|DEVICE|APD without sharesource|Patients received APD with Same machine but this patients dose not using sharesource software
223950338|NCT05628363|DEVICE|Ethos Varian treatment system|Device that will be used to administer radiotherapy
223950339|NCT05628363|RADIATION|Adaptive stereotactic body radiotherapy|Radiotherapy interruptions are acceptable as long as treatments are no more than 16 days apart.
223950340|NCT05628363|DRUG|Androgen deprivation therapy|"Androgen deprivation therapy (ADT) will be administered to study patients according to institutional standard. Patients should initiate ADT beginning no sooner than 60 days prior to start of radiation. ADT is defined as a GnRH agonist/antagonist (leuprolide, goserelin, degarelix, or relugolix). Patients treated with leuprolide, goserelin, or degarelix should also receive an androgen receptor antagonist (flutamide or bicalutamide) for 30 days from the start of GnRH agonist/antagonist or until the end of radiation, depending on institutional standard and physician preference.~Agent selection is per treating physician discretion and will be administered per institutional standard and FDA-approved labeling."
223950341|NCT06699082|OTHER|KinesioTaping and Keltonborn Mobilization|Experimental group was treated with kinesiotape and kaltenborn mobilization while the non experimental group was treated with conventional therapy along with kaltenborn mobilization.
223950342|NCT06699238|OTHER|Home Exercise|Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
223950343|NCT06699238|OTHER|Aerobic exercise|The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.The aerobic exercise group performed on a treadmill under the supervision of a physician.
223950344|NCT06728982|DRUG|Metformin|1000mg of metformin twice daily by mouth
224101951|NCT00488527|DRUG|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
224101952|NCT04207710|DRUG|Gebauer's Pain Ease Top Aerosol Mist Spray|Topical refrigerant spray
224287804|NCT06123182|BEHAVIORAL|Neutral Affective Imagery|During the audio recorded guided imagery exercise participants will be asked to think in detail about the physical sensations associated with an exercise bout.
223537655|NCT03872115|DEVICE|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
223537656|NCT02999009|DEVICE|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
223950345|NCT06890767|DEVICE|Wearable mobile device|Patients admitted due to an acute COPD exacerbation will be asked to wear the wearable mobile device for a period of 3 months. An app linked to the device will be installed on their phone, and be used to send vital parameter data to the investigators.
223950346|NCT06890767|OTHER|CAT Questionnaire|During the time of hospital admission and at the end of study, a COPD Assessment Test questionnaire will be taken.
223950347|NCT06890767|OTHER|DHRQ Questionnaire|During the time of hospital admission, the patient will be asked to fill in the Digital Health Readiness Questionnaire
224101953|NCT04207710|DRUG|Gebauer's Ethyl Chloride|Topical refrigerant spray
224101954|NCT02028949|DRUG|Zavedos®|
224101955|NCT02028949|OTHER|Blood samples|
224101956|NCT06392815|DIAGNOSTIC_TEST|Cu DOTATATE PET|The primary endpoint of the study is diagnostic performance for detecting LNB by 64Cu-DOTATATE-PET/CT/MRI measured as the difference in uptake between patients with definite LNB and patients without LNB. The primary read-out from 64Cu-DOTATATE-PET/CT/MRI is SUV in CNS and reference organs
224101957|NCT03724708|DEVICE|IUD|IUD insertion
224101958|NCT04718064|DRUG|Fingolimod|fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days
224101959|NCT04718064|DRUG|placebo|placebo once daily, for three consecutive days,
224101960|NCT04706572|OTHER|Stimulation with external auditory bio-feedback|Administration of an external cue based on a personalized Golden Ratio -rhythm or a metronome-rhythm through an ad-hoc App for Smartphone
224101961|NCT04516681|DRUG|Ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
224101962|NCT04516681|DRUG|FOLFOX Protocol|Oxaliplatin 130 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks
224101963|NCT04516681|DRUG|Adebrelimab|20mg/Kg intravenously every 3 weeks
224287805|NCT06123182|BEHAVIORAL|HIIT Exercise Intervention|"The high intensity interval training (HIIT) will be conducted 2 times per week for 6 weeks. The duration of each individual exercise session will last about 45 minutes. After the 5-minute warm-up at 30% peak workload, HIIT will consist of repeated 1-minute high intensity bursts (on interval) alternated with 1-minute interval recovery (off interval) for 25 minutes. The on interval will begin at 80% of peak watts (range: 75%-85%) followed by the off interval at 10% of peak watts. The session will end with up to 10 minute cool-down at 20% peak workload."
224287806|NCT03921060|DRUG|Denosumab|treatment with denosumab every 6 months for up to 5 years
224287807|NCT06700122|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D|non-surgical periodontal therapy (SRP) and Photodynamic therapy (PDT) with systemic vitamin D
224101964|NCT05387590|BEHAVIORAL|Preventiometer device with wellness coaching|Four wellness coaching sessions with a certified wellness coach to develop and implement your own personalized wellness plan will be included in this study.
224101965|NCT02388776|DEVICE|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
224101966|NCT04950738|OTHER|pess tack acupuncture|Patients enrolled will receive intervention in a form of either press tack acupuncture needles or press tack placebos. Three total intervention sessions will be taken place on day 1,3,5 from patient's enrolment. Needles/placebos skin withdrawal will be done 48 hours after treatment by an acupuncture doctor or by a trained ICU nurne. In cases when a patient will be transferred from the ICU, the 3 study interventions will be continued in the new ward.
224101967|NCT04950738|OTHER|pess tack placebo|pess tack stickers without a needle
224101968|NCT02464631|DRUG|Sofosbuvir + Ribavirin 1|
224101969|NCT02464631|DRUG|Sofosbuvir + Ribavirin 2|
224101970|NCT02464631|DRUG|Sofosbuvir + Ribavirin 3|
224101971|NCT01946009|DRUG|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
224101972|NCT03210844|PROCEDURE|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
224101973|NCT03826914|DIETARY_SUPPLEMENT|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
224101974|NCT03826914|DIETARY_SUPPLEMENT|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
223537657|NCT05085132|BEHAVIORAL|MindFi app: Standard content|Digital wellness training in this study will be delivered via the MindFi app, designed by Jaedye Labs. Content includes learning, assesesment, and practice tracks A core component of the exercises in this app is mindfulness training; however, the app also incorporates other exercises drawn from positive psychology such as journaling and diaphragmatic breathing. The app goes beyond traditional guided meditation through content that reinforces the principles and attitudes taught during in-person training, and also seeks to maximize user experience by using interactive tasks and progress charts.
223950348|NCT07098481|DRUG|ACCESS+ strategy Epclusa 400/100 Oral Tablet|The ACCESS+ strategy will rely on four components: (1) same-day on-site rapid anti-HCV and HCV RNA testing (rapid diagnostic test and GeneXpert), (2) same-day on-site pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg once daily for 12 weeks), (3) minimal clinical and biological monitoring, and (4) management of patients in non-specialist services by trained general medical doctors and counselors (community health workers, nurses or social workers).
223950349|NCT07098481|DRUG|ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet|The ACCESS+ strategy will rely on four components: (1) same-day on-site rapid anti-HCV and HCV RNA testing (rapid diagnostic test and GeneXpert), (2) same-day on-site pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg) once daily for 12 weeks, (3) minimal clinical and biological monitoring, and (4) management of patients in non-specialist services by trained general medical doctors and counselors (community health workers, nurses or social workers).
224101975|NCT05981950|DIAGNOSTIC_TEST|artificial intelligence algorithm|Retinal diseases diagnosed by artificial intelligence algorithm
224101976|NCT04252378|PROCEDURE|Deep Serratus Anterior Plane Block|Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
224101977|NCT04252378|PROCEDURE|Superficial Serratus Anterior Plane Block|Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
224101978|NCT05174715|OTHER|BIA|nutritional status was evaluated using BIA
224101979|NCT02379858|DRUG|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
224101980|NCT02379858|DRUG|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
224101981|NCT05218629|DRUG|Anlotinib, PD-1 inhibitor|Anlotinib, 8-12 mg/day, orally, day 1-14; PD-1 inhibitor 200 mg iv, every 21 days one cycle
224101982|NCT00288210|PROCEDURE|Primary angioplasty in acute myocardial infarction|
224101983|NCT05689060|OTHER|mulling Straight leg raising technique|Subject was in supine lying, therapist stood at the side of limited, therapist placed subjects flexed knee over therapists shoulder and subject was asked to push therapist away with his leg and then relax. At this point therapist pushed subjects bent knee up as far as in the direction of shoulder.
224287808|NCT04862884|DRUG|HRS4800 tablets|"1. Drug: HRS4800 tablets Low-dose group, single oral administration~2. Drug: HRS4800 tablets Low-medium dose group, single oral administration~3. Drug: HRS4800 tablets medium -dose group, single oral administration~4. Drug: HRS4800 tablets Medium and high dose group, single oral administration~5. Drug: HRS4800 tablets High-dose group, single oral administration"
224287809|NCT04862884|DRUG|placebo|"1. Drug: placebo Low-dose group, single oral administration~2. Drug: placebo Low-medium dose group, single oral administration~3. Drug: placebo medium -dose group, single oral administration~4. Drug: placebo Medium and high dose group, single oral administration~5. Drug: placebo High-dose group, single oral administration"
223950350|NCT07098481|DRUG|Standard Strategy Vosevi 400/100/100 Oral Tablet|In the standard strategy based on routine medical practice in Cameroon, anti-HCV positive participants will be referred to and managed by gastroenterologists who will initiate pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100mg) once daily for 12 weeks, and the patients' management will be closer. However, the process for screening and treatment initiation will be longer.
223950351|NCT07098481|DRUG|Standard Strategy Epclusa 400/100 Oral Tablet|In the standard strategy based on routine medical practice in Cameroon, anti-HCV positive participants will be referred to and managed by gastroenterologists who will initiate pan-genotypic DAA treatment initiation (sofosbuvir 400 mg/velpatasvir 100 mg) once daily for 12 weeks, and the patients' management will be closer. However, the process for screening and treatment initiation will be longer.
223950352|NCT07098026|DRUG|Shenqi Fuwei Mixture|Shenqi Fuwei Mixture
223950353|NCT07098026|DRUG|Shenqi Fuwei Mixture Placebo|Shenqi Fuwei Mixture Placebo
223950354|NCT06944821|PROCEDURE|In-situ simulation|Each simulation session takes place over one day, with 4 scenarios recreating life-threatening emergency situations (cardiorespiratory arrest, hemorrhagic shock, etc.). Each scenario is designed to meet specific pedagogical objectives, which will be debriefed by simulation trainers: crisis resource management (communication, alerting, etc.) or organization of multi-professional teamwork
223950355|NCT06944821|OTHER|Role-playing using a simulation scenario|Team performance in critical situations, assessed during a simulation scenario for all participants. The assessment will be carried out blind by 1 examiner, trained in CRM (Crisis Resource Management) analysis in simulation and debriefing.
223950356|NCT06944821|OTHER|Questionnaires|Quality of lige questionnaire Pro-QOL, Karasek questionnaire, Satisfaction questionnaire at work : WRQoL, Work Life Balance scale, Mayo Hight Team Performance scale will be completed at baseline and at 6 months
223950357|NCT06948604|BEHAVIORAL|Exercise|this exercise used to improve urine complication post TURP
223950358|NCT06951997|DRUG|QL1706|5mg/kg, q3w
223950359|NCT06951997|DRUG|Chidamide|20mg, biw, q3w
223950360|NCT06951997|DRUG|Gemcitabine|1000mg/m2 Q3W
223950361|NCT06951997|DRUG|Nab-paclitaxel|125mg/m2 Q3W
223950362|NCT06951945|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
223950363|NCT06951945|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
223950364|NCT00682318|DRUG|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
224101984|NCT05689060|OTHER|post facilitation stretch|Muscle energy technique was applied using post facilitation stretch While the participant lying in supine position, the pelvis was strapped down to the table for stabilization and control on accessory movement and the contralateral limb was securely strapped down to the table to prevent excessive hip and pelvic rotations during procedures.The participant's hip was passively flexed and the leg extended until tension was sensed and the participant reported a moderate stretching sensation.
224101985|NCT04233424|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.
224101986|NCT04233424|OTHER|Standard of Care (SoC)|prophylactic, pre-operation per institution guidelines
224101987|NCT05320939|DRUG|Mepolizumab 100 MG|30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
224101988|NCT02698189|DRUG|Birabresib Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
224101989|NCT04378426|DRUG|Nitrous Oxide|PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
223950365|NCT00682318|DIETARY_SUPPLEMENT|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
223950366|NCT00682318|DIETARY_SUPPLEMENT|Ethanol|"Part 1 \& Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
224101990|NCT04378426|DRUG|Midazolam|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
224101991|NCT04378426|DRUG|Nitrogen|PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
224101992|NCT04378426|DRUG|Oxygen|inhaled gas
224101993|NCT04378426|DRUG|Saline|Placebo infusion
224101994|NCT00109421|BEHAVIORAL|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
224101995|NCT05068856|DRUG|HRS2543|"Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC."
223950367|NCT00682318|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
224101996|NCT00157300|DRUG|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
223950368|NCT00682318|DIETARY_SUPPLEMENT|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (\<130 mg/day EPA/DHA)"
223950369|NCT05561244|DEVICE|Weekly monitoring using the capillary International Normalised Ratio strategy|Patients in the interventional group will be monitored using the capillary International Normalised Ratio strategy every week, and more often if the International Normalised Ratio is not in the therapeutic target. Venous International Normalised Ratio punctures will also be performed as described for the control group in order to calculate the Time in Therapeutic Range equivalently in both groups. Specific training in handling the device and the dose adjustment protocol will be provided to nurses and prescribers.
223950370|NCT04738370|OTHER|Sample collection|Bloods +/- urine +/- vaginal swabs taken
224287810|NCT02914249|OTHER|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
224287811|NCT06301087|DEVICE|Web Application|web application for monitoring children's development and postnatal depression of mothers
223950371|NCT05646602|DRUG|Collagenase Clostridium Histolyticum|Intralesional injection
223950372|NCT05646602|DEVICE|Duolith SD1 T-TOP|Delivers low-intensity shockwave therapy, six sessions (once/week) of 2000 shockwaves per session with a constant energy flux density of 0.29 mJ/mm2 and frequency of 3 Hz
223950373|NCT01404702|DRUG|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
223950374|NCT01404702|BIOLOGICAL|Aldesleukin|"Dose Level 1: 3 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10\^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
223950375|NCT00972686|DRUG|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
223950376|NCT00731692|DRUG|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
223950377|NCT00731692|DRUG|Placebo|Matching placebo capsules were administered orally once daily
223950378|NCT05293691|BEHAVIORAL|Body, Breath & Mind|"The program Body, Breath \& Mind is a minimally guided self-help program to improve mood. It contains a total of eight modules, which are to be completed in a weekly rhythm. Each module includes Qi Gong exercises, and instructions and exercises for value-based behavioral activation used in behavioral therapy for depression (Hofheinz, Heidenreich \& Michalak, 2017). If possible, the entire program should be completed within a period of 8 weeks."
223950379|NCT05293691|BEHAVIORAL|Moodgym|Moodgym is an interactive training program for the prevention and reduction of depressive symptoms. It is based on the methods and techniques of cognitive behavioral therapy and includes five modules: feelings, thoughts, developing alternative thoughts, deal with stress and relationship. In addition to the modules, there is a workbook section where personal results and responses are stored. The effectiveness of the programme has been proven in clinical trials (Loebner et al., 2018).
223950380|NCT02709265|DRUG|amikacin/fosfomycin|single aerosolized dose
223950381|NCT01666171|DRUG|metformin hydrochloride|
223950382|NCT01666171|OTHER|clinical observation|
223950383|NCT01666171|OTHER|diagnostic laboratory biomarker analysis|
223950384|NCT01666171|OTHER|imaging biomarker analysis|
223950385|NCT01666171|OTHER|medical chart review|
223950386|NCT01666171|PROCEDURE|digital mammography|
223950387|NCT05652452|OTHER|Neurodynamics|Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
223950388|NCT05652452|OTHER|Static stretch|Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
224101997|NCT03580330|OTHER|mHealth intervention|Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
224101998|NCT00001325|DRUG|18 FDG|
224101999|NCT01122329|DIETARY_SUPPLEMENT|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
224102000|NCT01122329|DIETARY_SUPPLEMENT|Placebo|
224102001|NCT01851837|OTHER|Exercise time|Continuous training, Interval training
224102002|NCT04903860|DEVICE|total hip replacement with single use ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
224102003|NCT04903860|DEVICE|total hip replacement with conventional ancillary|Comparison of the use of conventional ancillary reaming and single-use ancillary reaming material in total hip replacement
224102004|NCT05752448|BEHAVIORAL|POSTCare Survivorship transition process|Survivorship coaching intervention
224102005|NCT05647993|DRUG|Azithromycin Injection [Zithromax]|Intervention group patient will receive standard antimicrobial prophylaxis(cefazolin intravenously weight dependent) and azithromycin 500 mg intravenously before the incision
224102006|NCT05647993|DRUG|Cefazolin|All the participants will receive the cefazolin intravenously. The dosage of the cefazolin is depend on participant's weight. The participant with weight less than 80kg will receive cefazolin 1 gm and between 80-120kg will receive cefazolin 2 gm and for the participant with more than 120kg will receive cefazolin 3 gm before the incision.
224102007|NCT05647993|DRUG|Sodium Chloride 0.9% Intravenous Solution|For the placebo group will receive the cefazolin intravenously and 0.9% NaCl 100ml before the incision
224102008|NCT03467906|OTHER|In-laboratory assessment|Participants will stay in the laboratory for two days and one night during which they will complete questionnaires, have blood drawn, and have other measurements taken.
224287812|NCT05655156|DEVICE|OrthoPure XT|"Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  \- Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)"
224102009|NCT04032366|DRUG|inhaled nitric oxide|using of inhaled nitric oxide
224102010|NCT04032366|DEVICE|PEEP|increasing PEEP or decreasing PEEP
224102011|NCT04654507|DRUG|Dexamethasone Oral|Drug: Dexamethasone 0.3mg/kg/dose twice daily for 3 days
224102012|NCT04654507|DRUG|Placebo|Placebo
224102013|NCT04837560|DEVICE|ElastiMed's SACS 2.0|A wearable medical device that improve circulation using smart materials
224102014|NCT03845530|DIAGNOSTIC_TEST|Blood Test|Blood test taken and sent for laboratory analysis
224102015|NCT04728945|PROCEDURE|lung recruitment|Automatic lung recruitment using the anesthetic machines (with PEEP 15 cmH2O for 30 seconds) will be performed every 30 minutes during laparoscopy.
224102016|NCT04728945|PROCEDURE|Standard ventilatory management|"After tracheal intubation, standard ventilatory management (metered ventilation) should be performed with the following initial settings, and rescue should be performed when hypoxemia occurs, if necessary.~\[initial setting\] PEEP 4cmH2O, FIO2 0.3 Ventilation rate: 6-8 ml/kg predicted body weight (PBW)"
224287813|NCT04977661|DRUG|Vitamin E|Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.
224287814|NCT04977661|DRUG|Ursodeoxycholic acid|is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)
224287815|NCT04977661|DRUG|Pentoxifylline|"it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription"
224287816|NCT05391711|BEHAVIORAL|Culturally Smart Relationships|"Mentors assigned to the intervention will receive the following trainings and support:~1. Online Justice, Equity, Diversity, and Inclusion (JEDI) trainings (self-paced)~2. Culturally Smart Relationships Training (live, virtual)~3. JEDI enhanced monthly supervision from case managers~4. Monthly emails with activity suggestions for mentors and youth"
223537658|NCT05085132|BEHAVIORAL|Mindfi app: Standard content without practice|In this condition, participants will receive a version of the MindFi app that does NOT contain the practice tracks, only the learning and assessment tracks.
224102017|NCT02375776|OTHER|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
224102018|NCT02219230|DEVICE|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
224102019|NCT02219230|DEVICE|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
224102020|NCT02219230|DEVICE|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
224102021|NCT03862456|OTHER|Azithromycin|azithromycin (500 mg/24h/3 days)
224102022|NCT03862456|OTHER|Metronidazole|metronidazole (500 mg/8h/7 days)
224102023|NCT05356793|DRUG|SCH-1|Novel anti-infective eyedrop
224102024|NCT05356793|DRUG|Placebo|SCH-1 vehicle minus active components eyedrop
223950389|NCT06213363|DRUG|TCR1672 tablet|All potential participants proceed to the screening period (7-14 days) after voluntarily signing the informed consent form, and the investigators conduct eligibility assessment for the participants as per the inclusion and exclusion criteria. 72patients with RCC are planned to be enrolled in this study. All participants will firstly be randomized at a ratio of 1:1:1 to receive one of the three oral doses of three times a day TCR1672 (20mg, 40mg, 60mg). Then patients will further be randomized to two treatment sequences, Dosing Sequence 1 and Dosing Sequence 2. Participants in Dosing Sequence 1 will be given TCR1672 Tablets for 1 weeks, followed by a 1-week washout period, and then crossover to 1-week placebo treatment. Participants in Dosing Sequence 2 will be firstly administered 1-week placebo treatment, followed by a 1-week washout period, and then crossover to TCR1672 tablets for 1-week treatment.
223950390|NCT04565873|DIAGNOSTIC_TEST|TSH|retrospective TSH level
224102025|NCT06056284|BEHAVIORAL|Progressive relaxation exercises and sleep hygiene training|Voluntary Consent Form, Personal Information Form, Pittsburgh Sleep Quality Index (PSQI), Sleep Hygiene Index (SHI) and Beck Anxiety Scale (BAS) will be applied to the patients in the experimental group in the first week of the 7-week study. Data will be collected by face-to-face interviews with the patients. After seven weeks, an appointment will be given for the post-test. In the second week, those in the experimental group will be taught progressive relaxation exercise using a compact disc (CD) prepared by the Turkish Psychological Association in the hospital and after the sleep hygiene training, progressive relaxation exercise brochure and sleep hygiene training brochure will be distributed. Starting from the second week, the individuals in the experimental group will be expected to apply the trainings given in the hospital accompanied by the researcher two days a week for six weeks and to apply the trainings given to the individuals at home on the other days of the week.
224102026|NCT03436264|OTHER|MRI|fMRI
224102027|NCT01211691|DRUG|KB004, Monoclonal Antibody|
224102028|NCT01044355|DEVICE|CPAP|6 weeks treatment with fixed CPAP
224102029|NCT01044355|DEVICE|APAP|6 weeks of treatment with auto-titrating positive airway pressure
224102030|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
224102031|NCT00831051|DRUG|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
224102032|NCT00831051|DRUG|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
224102033|NCT00831051|DRUG|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
224102034|NCT00831051|DRUG|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
224102035|NCT00831051|DRUG|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
224102036|NCT05435521|BEHAVIORAL|Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)|"Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation."
224102037|NCT05435521|OTHER|Body composition|Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device
224287817|NCT00957619|DRUG|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
224287818|NCT00957619|DRUG|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
224287819|NCT00384293|DRUG|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
224287820|NCT00384293|DRUG|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
224287821|NCT06364254|DIETARY_SUPPLEMENT|Cannabidiol Capsules|300 mg of cannabidiol administered 2 hours before 2 mile run
224287822|NCT01911806|DEVICE|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
224287823|NCT01911806|PROCEDURE|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
224287824|NCT04702763|OTHER|Eye-Tracker®T2 + e-VOG|"* 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
224287825|NCT04702763|OTHER|e-VOG + Eye-Tracker®T2|"* 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care"
224287826|NCT00457210|PROCEDURE|Brain Radiotherapy/Stereotactic Radiosurgery|
224287827|NCT02988869|DRUG|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
224287828|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
224287829|NCT02988869|DRUG|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
224287830|NCT02988869|DRUG|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
224287831|NCT03541239|DEVICE|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
224287832|NCT01367938|DEVICE|OMNI Apex Ultracongruent Knee Device|
224287833|NCT05701618|OTHER|Psychologically Informed Education Video Series|A short three video series (5-8.5 minutes each) provides psychologically-informed education at an age-appropriate level to address kinesiophobia, pain catastrophizing, and fear-avoidance beliefs.30 Participants will view the three-part education video series on an iPad at their first visit (video 1), one week (video 2), and three weeks (video 3).
223950391|NCT05935072|BEHAVIORAL|Exercice and meal|The participants will carry out four experimental visits in a randomized order: CON\_Calibré: control condition with a calibrated test meal; CON\_AdLib: control condition with an ad libium test meal; EX\_Calibré: exercise condition with a calibrated test meal; EX\_AdLib: exercise condition with an ad libitm test meal. During each of the conditions, the participants will join the laboratory at 8:00 a.m. and will receive a calibrated breakfast. They will be asked at 11:00 a.m. either to rest in a semi-recumbent position for 30 minutes (CON conditions) or to perform a pedaling exercise on an ergocycle at 65% of their estimated aerobic capacity for 30 minutes. A test meal will be served to participants at 12:00 p.m., either ad libitum or calibrated. Appetite sensations will be assessed at regular intervals during each condition and their food reward preferences and ratio assessed 15 minutes before and 15 minutes after the test meals.
224287834|NCT05701618|OTHER|Anatomy and biomedical education videos|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
224287835|NCT06015113|DRUG|Disitamab Vedotin plus pyrotinib or naratinib|"Trastuzumab Injection: Intravenous infusion, initial loading dose of 2 mg/kg, administered via intravenous infusion over 30-90 minutes (usually recommended around 60 minutes), administered on day 1 of each cycle, with each cycle lasting 14 days.~Pyrotinib Maleate Tablets: 400 mg, taken orally once daily, within 30 minutes after a meal, at the same time every day. Taken continuously, with each cycle lasting 14 days.~Neratinib Maleate Tablets: 240 mg, taken orally once daily with a meal, at the same time every day. The neratinib tablet should be swallowed whole (it should not be chewed, crushed, or split before swallowing). Taken continuously, with each cycle lasting 14 days."
224287836|NCT00992563|DRUG|AL-39324 ophthalmic suspension|
223950392|NCT02596178|DEVICE|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
223950393|NCT03332589|DRUG|E6201|E6201 formulated in cyclodextrin for IV administration.
223950394|NCT03332589|DRUG|E6201 plus dabrafenib|E6201 formulated in cyclodextrin for IV administration. Dabrafenib capsules for oral administration.
223950395|NCT04823078|OTHER|Activity base therapy|"activity based therapy~Weight bearing activities of daily living like vertical lifting, bilateral body weight shifting, lifting and shifting, forward reaching and sideways reaching."
224102038|NCT05435521|OTHER|Musculoskeletal and visceral Ultrasound|Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
224102039|NCT05888116|DEVICE|Hidrante HA|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
223537659|NCT04476992|DRUG|Nitric Oxide-Sessions|Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
224287837|NCT00992563|DRUG|Ranibizumab 10 mg/mL|
224102040|NCT05888116|DEVICE|Cumlaude Hidrante Interno®|Apply the 5 ml single dose three times a week, every other day, preferably at night before going to bed for 4 weeks.
224102041|NCT01254344|DRUG|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
224102042|NCT01254344|DRUG|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
224102043|NCT01254344|DRUG|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
224102044|NCT01254344|DRUG|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
224102045|NCT00789126|DRUG|VX-509|
224102046|NCT05947019|DEVICE|Myopic amblyopia comprehensive treatment instrument|Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.
224287838|NCT02584088|OTHER|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
223722569|NCT01411774|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
224102047|NCT05947019|DEVICE|Glasses|Optometry with glasses as a routine treatment
224102048|NCT02341612|OTHER|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
223950396|NCT04823078|OTHER|Strength training|Strengthening exercises of upper limb involved muscles (elbow extensors, shoulder adductors, abductors, wrist extensors, shoulder protractors and retractors
223950397|NCT03990376|OTHER|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
224102049|NCT02341612|OTHER|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
223950398|NCT00279409|DRUG|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
224102050|NCT02341612|OTHER|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
224102051|NCT02341612|OTHER|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
224102052|NCT02341612|OTHER|passive recovery|The control group was exposed to treatment after the EIMD protocol.
224102053|NCT01982630|DRUG|MK-8521|
224102054|NCT01982630|DRUG|Liraglutide|
224102055|NCT01982630|DRUG|Placebo|
224102056|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
224102057|NCT00786240|DRUG|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
224102058|NCT03433625|BEHAVIORAL|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
224102059|NCT00444184|DRUG|Travoprost/timolol fixed combination, travoprost|
224102060|NCT02812511|PROCEDURE|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
224102061|NCT06085157|OTHER|electronic diary|a smartphone application for self-documentation of drinking pattern
224102062|NCT02070432|DRUG|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
224102063|NCT02981290|DRUG|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
223950399|NCT00279409|DRUG|Sugar pill|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
224102064|NCT02981290|DRUG|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
224287839|NCT04829760|DIETARY_SUPPLEMENT|Psyllium|Participants will consume 10 grams of fiber from psyllium in two doses each day for 8 weeks
224287840|NCT04829760|DIETARY_SUPPLEMENT|Coarse wheat bran|Participants will consume 10 grams of fiber from coarse wheat bran in two doses each day for 8 weeks
224287841|NCT04829760|DIETARY_SUPPLEMENT|Maltodextrin|Participants will consume maltodextrin in a volume equivalent to the psyllium intervention (\~2 tablespoons) in two doses each day for 8 weeks
223950400|NCT02542202|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
223950401|NCT05653609|DEVICE|Cureety TechCare|Weekly adverse event questionnaires completed by the patients using a digital tool called Cureety
223950402|NCT03161509|DRUG|Paracetamol|single dose of 1 gr paracetamol
223950403|NCT03161509|DRUG|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
223950404|NCT03957759|DIAGNOSTIC_TEST|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
224102065|NCT02981290|DRUG|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
224102066|NCT02981290|DRUG|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
224102067|NCT03451448|DIAGNOSTIC_TEST|PET/MRI|PET/MRI with USPIO contrast
224102068|NCT03451448|DIAGNOSTIC_TEST|MRI|MRI with USPIO contrast
224102069|NCT03310125|DRUG|Colchicine|Over-encapsulated 0.5mg tablet twice daily
224102070|NCT03310125|DRUG|Placebo|Matching placebo capsule twice daily
224102071|NCT05821543|DRUG|metformin+sibutramine|1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)
224102072|NCT05821543|DRUG|sibutramine+ microcrystalline cellulose|1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)
224102073|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
224102074|NCT00213239|DRUG|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
224102075|NCT04636918|DRUG|Cyclosporine Ophthalmic|Prospective interventional study (single arm)
224102076|NCT02659449|DEVICE|made to measure compression gloves|Patients achieve tests with compression glove
224102077|NCT02659449|DEVICE|Compression bandaging|Patients achieve tests with compression bandaging
224102078|NCT02659449|OTHER|Free Hands|Patients achieve tests without device
224102079|NCT01203488|DRUG|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
224287842|NCT00203541|DEVICE|TELFA™ A.M.D. Island dressing|
224287843|NCT00363402|PROCEDURE|PET-CT|
223950405|NCT04745455|OTHER|Infant formula containing prebiotics, probiotics and postbiotics|Infant formula containing prebiotics, probiotics and postbiotics
223950406|NCT03627299|DRUG|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
223950407|NCT00108355|DRUG|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
223950408|NCT00108355|DRUG|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
224102080|NCT01203488|OTHER|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
224102081|NCT03425383|DIAGNOSTIC_TEST|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
224102082|NCT02974244|DRUG|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
224287844|NCT04792879|DIAGNOSTIC_TEST|Peripheral veins Doppler ultrasound|Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
224102083|NCT02974244|DRUG|basal insulin|basal insulin treatment in the customary clinical care in USA
223722570|NCT01411774|DRUG|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (\~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (\~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
223950409|NCT00108355|DRUG|Midodrine|Midodrine oral tablet at 10 mg three times a day.
223950410|NCT00108355|DRUG|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
223950411|NCT00108355|DRUG|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
223722571|NCT01411774|DRUG|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
223722572|NCT02466178|DEVICE|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
224102084|NCT00877838|DRUG|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
223722573|NCT03602183|DEVICE|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
223950412|NCT00108355|DRUG|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
223950413|NCT00108355|PROCEDURE|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
223950414|NCT00961597|PROCEDURE|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
224102085|NCT00877838|DRUG|Placebo|Gelatin capsules resembling the ones containing the active substance
224102086|NCT01636037|DRUG|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
223722574|NCT03602183|DEVICE|Miller laryngoscope|intubation will be performed using Miller laryngoscope
223722575|NCT03602183|DEVICE|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
223722576|NCT03602183|DEVICE|GlideScope|intubation will be performed using GlideScope video - laryngoscope
223950415|NCT00961597|PROCEDURE|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
223950416|NCT00386399|DRUG|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
223950417|NCT00674037|OTHER|monetary incentive|75 euros for each patient included
224102087|NCT05324215|PROCEDURE|Transversalis fascia plane block and rectus sheath block|Transversalis fascia plane block and rectus sheath block will be administered after the surgery.
224102088|NCT05324215|DEVICE|Intravenous fentanyl patient control device|24-hour fentanyl consumption will be recorded.
224102089|NCT05207462|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
224287845|NCT00617370|DRUG|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
224287846|NCT00553449|DRUG|rabeprazole|
224287847|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
224287848|NCT05681754|PROCEDURE|Experimental: RCT using conventional sealer and L-PRF + GTR|Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
224287849|NCT05681754|PROCEDURE|Experimental: RCT using hydraulic calcium silicate sealer and GTR|Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
224287850|NCT05681754|PROCEDURE|Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)|Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
224287851|NCT05212883|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionnaires
224287852|NCT00132054|DRUG|amrubicin hydrochloride|
224287853|NCT00132054|DRUG|irinotecan hydrochloride|
224287854|NCT02502734|DRUG|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
224287855|NCT02502734|DRUG|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
224287856|NCT02502734|DRUG|Salbutamol|Salbutamol will be provided as a inhaler.
224287857|NCT03338348|DRUG|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
224287858|NCT03338348|DRUG|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
224287859|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
223722577|NCT00279591|DEVICE|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
223950418|NCT06121739|BEHAVIORAL|Child Mental Health Literacy Program|The workshop has a participant-oriented character, seeking to apply the more theoretical contents to the local school context. It has four units and a total of nine modules, each lasting 90 or 120 minutes, with reference material on an educational platform. The topics are : 1) the person behind the role of educator; 2) the school community and its influence on the healthy development of students; 3) the expected development and its alterations in the different evolutionary stages; 4) common and differential factors of child and adolescent mental health disorders; 5) Stigma in Mental Health; 6) screening, the first care, and use of devices for the prevention and treatment of mental health disorders in children and adolescents.
224287860|NCT01430819|BIOLOGICAL|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
224287861|NCT04745715|PROCEDURE|craniectomy|craniectomy outcomes and survival
224287862|NCT04854252|DRUG|Fentanyl|TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
224287863|NCT03071328|DRUG|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
224287864|NCT04531995|DEVICE|CANKADO PRO-React Onco|CANKADO PRO-React Onco is approved as class I medical device within the European Union (registration number DE /CA59 /371/2020-R/Hd) and is compliant with the FDA classification for Mobile Medical Devices (2015) Appendix B. The purpose of CANKADO PRO-React Onco is to be an automated digital support for patients to help them decide how urgent it is to contact the attending physician based on the symptoms they independently record in the system. It supports patients with cancer under systemic, anti-tumor or anti-hormonal therapy in adjuvant, neoadjuvant, post-neoadjuvant or palliative situations. It is unsuitable for patients undergoing radiotherapy, cell and gene therapy, surgical procedures or alternative healing methods.
223537660|NCT04476992|DRUG|Nitric Oxide-Continuous and Sessions|"Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm."
223537661|NCT04708522|BEHAVIORAL|Breath Control - Equal Breathing Technique|The equal breathing (EB) exercise also known as square or box breathing will follow the four-part breathing cycle of inhalation, hold, exhalation, hold, repeat. Each part of the cycle will be a 4 second count repeated for 20 minutes.
223537662|NCT04708522|BEHAVIORAL|Guided Mindfulness Exercise|The guided seated mindfulness (GSM) exercise will lead the participant through a 20 minute mindfulness meditation exercise using an audio recording.
223537663|NCT04708522|BEHAVIORAL|Control|The control intervention will utilize a sham exercise. The participant will be asked to rest in a comfortable seated position for the duration of the 20 minute session.
223537664|NCT00425620|DRUG|SinuNase|Lavage
223537665|NCT03950856|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
223537666|NCT03950856|DRUG|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
223537667|NCT02020161|DRUG|Atra|
223537668|NCT02020161|DRUG|Idarubicin|
223537669|NCT02020161|DRUG|methotrexate|
223537670|NCT04829513|PROCEDURE|Home Exercise|This is a home exercise programme that involves flexibility and strengthening of the waist, hip girdle and sacroiliac region. These exercises are first shown by the physiotherapist in hospital, and then they are asked to do the exercises at home using illustrated forms. Patients continue the exercises as a home programme once a day for 1 month.
223722578|NCT00279591|DEVICE|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
223722579|NCT00002876|DRUG|cisplatin|
223722580|NCT00002876|DRUG|etoposide|
224102090|NCT05033210|BEHAVIORAL|Psychological First Aid (PFA)|PFA is a WHO developed support strategy that involves humane, supportive and practical help for individuals living in a serious humanitarian crisis. PFA does not necessarily involve a discussion of the event(s) that cause the distress but aims particularly at five basic elements that are crucial to promote in the aftermath of crises, i.e. a sense of safety, calm, self- and community efficacy, connectedness, and hope (Hobfoll et al., 2007). It consists of a conversation (approximately 30-45 minutes) that a helper has with a participant which can be provided remotely (e.g. videoconferencing or telephone). It has various themes; the helper provides non-intruding practical care and support, listen to needs and concerns, helps people to address basic needs (e.g. information), listens to people without pressuring them to talk, comforts people and helps them to feel calm, helps people to connect to information, services, and social support, and protects people from further harm (WHO, 2011).
224102091|NCT05033210|BEHAVIORAL|Care as Usual (CAU)|In addition to PFA, both arms will be allowed to receive any usual care (CAU). CAU ranges from community care to specialised psychological treatments.
224102092|NCT05033210|BEHAVIORAL|Doing What Matters in Times of Stress (DWM)|DWM is based on the acceptance and commitment therapy (ACT), a form of cognitive-behavioural therapy, with distinct features (Hayes, Levin, Plumb-Vilardaga, Villatte \& Pistorello, 2013). ACT is based on the concept that ongoing attempts to suppress unwanted thoughts and feelings can make these problems worse, so instead it emphasises on learning new ways to accommodate these thoughts and feelings without letting them dominate. ACT has been shown to be useful for a range of mental health issues (Tjak et al., 2015) and has been used successfully in a guided self-help format (Hayes et al., 2013). DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, will be adapted for use on a smartphone or other device with internet access.
224102093|NCT05033210|BEHAVIORAL|Problem Management Plus (PM+)|PM+ is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011). The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. In these 90-minute sessions participants may talk to trained non-professional helpers (who are supervised by registered (clinical) psychologists). PM+ has four core features: it is brief (five sessions); delivered by non-specialist helpers; transdiagnostic thereby addressing depression, anxiety, PTSD, stress and problems as defined by people themselves; and originally designed for people in low-income country communities but easily adaptable to different (vulnerable) populations, cultures and languages.
224102094|NCT00820040|DEVICE|acellular porcine dermal collagen mesh|porcine mesh for hernia repair/ abdominal wall reconstruction
223537671|NCT04829513|PROCEDURE|Ligament Correction Kinesiotaping|Ligament correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
223950419|NCT03811665|PROCEDURE|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
223537672|NCT04829513|PROCEDURE|Lymphatic Correction Kinesiotaping|Lymphatic correction kinesiotaping will be applied to the patients' sacroiliac region. Taping will be done once a week. It will be kept for 5 days. This application will be repeated 3 times.
223537673|NCT00678522|DRUG|Atorvastatin|80 mg atorvastatin daily on two following days
223537674|NCT03953807|DRUG|Dexamethasone Intravitreal Implant|Implant 700 μg
223537675|NCT05958602|BEHAVIORAL|Technology|See previous response.
223537676|NCT05958602|BEHAVIORAL|Standard DSMES Only|See previous response.
223537677|NCT05958602|BEHAVIORAL|Traditional Recruitment Methods|See previous response.
223537678|NCT05958602|BEHAVIORAL|CHW-Led Recruitment Methods|See previous response.
223537679|NCT06157073|DEVICE|Closed-loop ventilator|Fully automated closed-loop ventilator using the INTELLIVENT software
223722581|NCT04766580|BEHAVIORAL|Placebo and nocebo effect|The intervention focuses on the speech and instructions given with each placebo (positive for the placebo effect and negative for the nocebo effect)
223950420|NCT03811665|RADIATION|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
223537680|NCT06157073|DEVICE|Open-loop ventilator|Conventional closed-loop ventilator with manual adjustments by the physician in charge
223537681|NCT01816984|DRUG|PI3K inhibitor BKM120|Given PO
223537682|NCT01816984|BIOLOGICAL|cetuximab|Given IV
223537683|NCT00188214|PROCEDURE|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
223537684|NCT01321814|BEHAVIORAL|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
223537685|NCT01170351|DRUG|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
223537686|NCT02121509|DRUG|Linagliptin|1 x Linagliptin tablet
223537687|NCT02121509|DRUG|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
223537688|NCT02121509|DRUG|Metformin ER|3 x Metformin ER tablets
223722582|NCT00231075|DRUG|Paraplatin|
223722583|NCT00231075|DRUG|Paclitaxel|
223950421|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
223950422|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
223950423|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
223950424|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
223950425|NCT01006057|DRUG|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
223950426|NCT01411657|DRUG|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
223950427|NCT03862898|OTHER|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
224102095|NCT06217991|PROCEDURE|PTST(parachute-tunnel-style technique)for esophagogastrostomy|Suture the gastric remnant at the mark on the back wall of the esophagus.(Don't tighten the suture); Pull the esophageal stump out of the tunnel meanwhile tighten the suture and the gastric stump to close the back wall of the esophagus and the gastric stump together;Cut the back esophageal wall close to the esophageal stump,cut the front gastric wall along line B. Suture the back esophageal wall and the upper edge of the front gastric wall incision from right to left;Remove residual esophageal nail, and suture the back esophageal wall and the lower edge of the gastric incision from right to left. Suture the anterior wall of the stomach at the lower edge of the tunnel with the serosa layer at the lower edge of the front wall of the esophagus stomach anastomosis;Suture the upper edge of the tunnel with the front wall of the esophagus and the left and right lateral walls at the gastric stump suture of the original posterior wall of the esophagus. (all use 3-0 barbed suture continuously)
223537689|NCT04713189|DRUG|Inhaled fentanyl aerosol|Participants in the stage I were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhale fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
223950428|NCT01630304|BEHAVIORAL|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
223950429|NCT02751710|OTHER|Whole-body FDG PET-CT alone|FDG PET-CT imaging
223950430|NCT06509321|PROCEDURE|subinguinal loupe-assisted varicocelectomy (LV)|to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy
223950431|NCT06509321|PROCEDURE|subinguinal microscopic varicocelectomy (MV)|we are using surgical microscope to perform varicocelectomy as control group
223950432|NCT00009191|DRUG|Sertraline [Zoloft]|
223950433|NCT04224597|DIAGNOSTIC_TEST|ultrasonography|all participants will be determined by ultrasonography.
224287865|NCT05820867|PROCEDURE|Single-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
224287866|NCT05820867|PROCEDURE|Two-Session Bilateral Mandibular Third Molar Extraction|Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
224287867|NCT06240689|DRUG|Sintilimab|Sintilimab is administered intravenously on the first day of each cycle. 21 days per cycle.
224287868|NCT06240689|DRUG|Placebo|Placebo is administered intravenously on the first day of each cycle. 21 days per cycle.
223537690|NCT04713189|DRUG|Placebo|Participants in the stage Ⅰ were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence. I
224102096|NCT00749632|DRUG|oxybutynin|low dose oxybutynin administered daily
224102097|NCT00749632|DRUG|oxybutynin|middle dose oxybutynin administered daily
224102098|NCT00749632|DRUG|oxybutynin|high dose oxybutynin administered daily
223950434|NCT05519306|BEHAVIORAL|Mental Practice|Each patient will perform the following two activity-based tasks via MP: wiping a table and picking up a cup. Prior to a scheduled OT session patients will perform MP of the assigned motor task. Following MP, a research therapist will facilitate repetitive task practice of the same motor task. MP sessions will be completed 5x/week for 2 weeks, (3x/week in combination with RTP, and 2x/week independently). The MP will be completed at an MP station equipped with a tablet and noise-canceling headphones. The audio recording will be from a first-person view as if they are performing it with their own UE. Each task will consist of 20 repetitions and will be facilitated by the use of multisensory cues (visual, tactile, auditory, and kinesthetic). For example, the task of picking up a cup will include describing how the drink looks (water with ice) and the temperature and feel of the cup (cold/moist).
224102099|NCT01666132|OTHER|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
223722584|NCT02038023|DRUG|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
223722585|NCT04847362|BEHAVIORAL|Experimental|education group
224102100|NCT01666132|OTHER|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
224102101|NCT01666132|OTHER|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
224102102|NCT00772395|DRUG|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
224102103|NCT00772395|DRUG|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
224287869|NCT05021887|DRUG|Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
224287870|NCT05021887|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
224287871|NCT04645940|DRUG|fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole|"fruquintinib 5 mg with food on Day 1 and fruquintinib 5 mg without food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
224287872|NCT04645940|DRUG|fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole|"fruquintinib 5 mg without food on Day 1 and fruquintinib 5 mg with food on Day 15.~40 mg rabeprazole from Day 23 to Day 28. 40 mg rabeprazole one hour before 5 mg fruquintinib Day 29."
224287873|NCT02438982|DRUG|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
223537691|NCT01578161|DRUG|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
223537692|NCT01578161|DRUG|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
223537693|NCT01855893|OTHER|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
223537694|NCT01855893|OTHER|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
223537695|NCT01061528|DRUG|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
223537696|NCT02070653|DRUG|Ticagrelor|
223722586|NCT00712127|OTHER|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
223537697|NCT02070653|DRUG|Placebo|
223722587|NCT00712127|OTHER|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
223722588|NCT06334510|BIOLOGICAL|One dose of quadrivalent influenza virus split vaccine was administered|"Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection."
224102104|NCT04898452|OTHER|A new model of interaction across health services with use of welfare technology and telemedicine|Instead of admitted to the hospital, patients are followed up at home by the municipal regional response center and nurses in the response team according to the individual treatment plan. Hospital physicians are medically responsible throughout the course.
224102105|NCT00789204|OTHER|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
224102106|NCT00789204|OTHER|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
224102107|NCT03959189|DRUG|ERX-963|Active medicine
224102108|NCT03959189|DRUG|Placebo|Comparator
223950435|NCT03656198|BIOLOGICAL|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
223950436|NCT03656198|DRUG|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
223950437|NCT00236470|DRUG|risperidone|
224102109|NCT04350515|OTHER|Cyberball: Other Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
224102110|NCT04350515|OTHER|Cyberball: Player Exclusion|A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
224102111|NCT04350515|OTHER|Mindfulness: Emotion Regulation Task|In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.
224102112|NCT04350515|OTHER|Mindfulness: Word Recognition Task|"In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task."
224102113|NCT03267355|DEVICE|Endoscopic Ultrasound|Indication of EUS
224102114|NCT01420185|GENETIC|RNA analysis|
224102115|NCT01420185|GENETIC|gene expression analysis|
224102116|NCT01420185|GENETIC|microarray analysis|
224102117|NCT01420185|GENETIC|reverse transcriptase-polymerase chain reaction|
224102118|NCT01420185|OTHER|laboratory biomarker analysis|
224102119|NCT04432428|DRUG|Sufentanil Sublingual Tablet|"all patients will receive tablets for sublingual use, containing 15 microgram of sufentanil. The sufentanil tablets come in a cartridge (40 tablets) and are administered with a special patient-controlled device that uses thumb tag recognition.~max dose per hour : 3 tablets of 15µg sufentanil"
224102120|NCT01815684|DRUG|ASP3652|Oral
224102121|NCT01815684|DRUG|Placebo|Oral
223537698|NCT01172028|DRUG|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
223950438|NCT06509685|OTHER|Ladder Training|9 participants will perform only Ladder training exercise protocol. The training schedule included exercises such as Two foot run, Ladder traps, Lateral angle leg hops, Single leg forward hop, two-foot lateral run, Fight shuffle, Skiers, Carioca, Lateral in out, two in two out, Intermediate high knee run, Straddle squat hops, two foot laterals hop in \& out, Two-foot lateral hop, Ali shuffle, 180 Degree rotation, jumping jacks' variation, Advanced in in out, Quick hops cotch, Icky shuffle etc. For each session, ten stations were used and participants change the partner after every end of steps jumping exercise and continued each exercise at least 3 set, depending on the class design(22).
224102122|NCT02252978|DRUG|ciprofloxacin|Given PO
224102123|NCT02252978|OTHER|placebo|Given PO
224102124|NCT02252978|OTHER|quality-of-life assessment|Ancillary studies
224102125|NCT02252978|OTHER|laboratory biomarker analysis|Correlative studies
224102126|NCT02916446|BIOLOGICAL|Viaskin Peanut 250 mcg|
224102127|NCT02916446|BIOLOGICAL|Placebo|
224102128|NCT03195140|DEVICE|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
224102129|NCT04374994|DRUG|Avanafil 50 MG|Oral phosphodiesterase type 5 inhibitors
224102130|NCT04374994|DRUG|Placebo oral tablet|lactose and maize starch, Egypt
224102131|NCT00204386|DRUG|Topiramate|
224102132|NCT06449625|DRUG|Semaglutide Pen Injector [Ozempic]|Semaglutide active drug
224102133|NCT06449625|DRUG|Placebo|semaglutide placebo
224102134|NCT05232825|DRUG|Ocrelizumab IV|IV Injection
224102135|NCT05232825|DRUG|Ocrelizumab SC|SC Injection
224102136|NCT05232825|DRUG|Methylprednisolone IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
224102137|NCT05232825|DRUG|Diphenhydramine IV|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
223950439|NCT06509685|OTHER|balance training|9 participants will perform balance training protocol. The balance training program includes exercises based around balance development in unilateral dynamic balancing positions. The program included balance and landing activities incorporating wobble boards and change of direction activities.
224102138|NCT05232825|DRUG|Dexamethasone given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
224102139|NCT05232825|DRUG|Desloratadine given orally|Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
224102140|NCT01310530|RADIATION|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
224102141|NCT03767010|OTHER|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
224102142|NCT03767010|OTHER|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
224102143|NCT03987750|DRUG|Safinamide Methanesulfonate 150mg|150 mg (free base)
224102144|NCT03987750|DRUG|Safinamide Methanesulfonate 100mg|100 mg (free base)
224102145|NCT03987750|DRUG|Safinamide Methanesulfonate matching placebo|placebo
224102146|NCT02024256|OTHER|Cold pads soaked in Magnesium sulfate solution|
224102147|NCT02024256|OTHER|Cold pads soaked in water|
224102148|NCT05452070|DEVICE|HArmonyCa Lidocaine Injectable Gel|Subdermal or deep dermal injection
223950440|NCT03950206|OTHER|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung\&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
223950441|NCT04546451|BEHAVIORAL|Music practice|Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.
223950442|NCT04546451|BEHAVIORAL|Psychomotor therapy|Patients will be trained in body awareness and a wide range of of movement activities.
224102149|NCT05660161|PROCEDURE|Nanofracture|"The planned study intervention consists of nanofracture surgical procedure for the treatment of cartilage lesions of the knee.~Nanofractures will be standardized 9 mm deep perforations in the subchondral bone.~Under arthroscopic view, the cartilage lesion is shaved to expose the margins of the lesion and remove damaged tissue. After a satisfactory lesion debridement is performed, a nanofracture device (Plasmaconcept NanoFx®) is placed through the arthroscopic portal. The awl is repeatedly penetrated through the bone until marrow elements are seen in the joint. The flow of arthroscopic fluid is interrupted to better observe the marrow elements emanating from the nanofracture holes. The distance between two consecutive perforations will be approximately 2-3 mm, and the number of perforations will depend on the cartilage lesion extension. All post-operative procedures, including the rehabilitation protocol, will be carried out according to the usual standard of care."
224102150|NCT00448461|DRUG|heparin|comparison between heparin and bivalirudin
224102151|NCT00448461|DRUG|bivalirudin|comparison between heparin and bivalirudin
224102152|NCT02568904|OTHER|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
224102153|NCT02568904|OTHER|Glucose|oral Glucose tolerance test
224102154|NCT02568904|OTHER|Fructose|oral fructose tolerance test
224102155|NCT02568904|OTHER|vehicle|control (water)
224102156|NCT03822468|DRUG|Ribociclib|Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib was supplied as 200 mg tablets as individual patient supply packaged bottles.
224102157|NCT03822468|DRUG|Anastrozole|Anastrozole 1 mg tablets for oral use QD continuously
224102158|NCT03822468|DRUG|Letrozole|Letrozole 2.5 mg tablets for oral use QD continuously
224102159|NCT03822468|DRUG|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
224102160|NCT00460928|DRUG|intravenous immune globulin (IVIG)|
223722589|NCT06081257|DIETARY_SUPPLEMENT|"KB-120 small molecular nutrient and vitamin E"|"The experimental group was given oral KB-120 small molecular nutrients, once a day, once a bag (30ml), and vitamin E100mg orally twice a day for a total of 3 menstrual cycles"
223950443|NCT02670408|PROCEDURE|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
223950444|NCT01197924|OTHER|IRMf Bold|IRMf BOLD of the working memory
223950445|NCT05710614|DIETARY_SUPPLEMENT|Animal protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) animal-based protein (i.e.; whey protein) in drink form as a supplementary source of protein in their main meals of the day.
224102161|NCT00604578|DRUG|Pioglitazone Hydrochloride|
224102162|NCT02826057|OTHER|Targeted temperature management (33 degree Celsius)|
223537699|NCT01172028|DRUG|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
223537700|NCT03479983|DIETARY_SUPPLEMENT|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
223722590|NCT06081257|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E100mg is taken orally twice a day for a total of 3 menstrual cycles
223950446|NCT05710614|DIETARY_SUPPLEMENT|Plant Protein|Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) mixed plant protein (i.e.; soy and pea) in drink form as a supplementary source of protein in their main meals of the day.
223950447|NCT04437004|DRUG|Fenfluramine|The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.
223950448|NCT05731206|OTHER|Hydrolyzed protein infant formula|Hydrolyzed protein infant formula
223950449|NCT05731206|OTHER|commercially available hypoallergenic infant formula|commercially available hypoallergenic infant formula
223950450|NCT01337752|DRUG|BHQ880|
223950451|NCT01337752|DRUG|BHQ880 Placebo|Intravenous infusion
223537701|NCT03479983|DIETARY_SUPPLEMENT|Placebo|500 mg roasted rice powder in visually identical capsules
223722591|NCT03021122|DEVICE|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
224102163|NCT05422300|BEHAVIORAL|Fed|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine.
224102164|NCT05422300|BEHAVIORAL|Ex-Fed|"Participants will be subjected to a full-body resistance exercise protocol, consisting of an upper and lower body circuit. The upper body circuit will be a chest press and dumbbell row superset, whereas the lower body circuit will be leg press and leg extension (4 sets of 10 repetitions @ 75% of their 1 repetition max, respectively). The inter-set rest period will be 90 seconds.~Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.25g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13C\]-leucine."
224102165|NCT03742804|BIOLOGICAL|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
223537702|NCT04487405|DEVICE|OVAnex|OVAnex is a multivarite index assay assessing ovarian cancer risk
223722592|NCT03021122|DEVICE|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
223722593|NCT04370405|DRUG|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
223950452|NCT01337752|DRUG|bortezomib|intravenous injection
223950453|NCT01337752|DRUG|dexamethasone|Oral
223537703|NCT05556434|DIAGNOSTIC_TEST|radiological evaluation|"All patients undergoing hepatectomy receive imaging evaluation and laboratory test before and after surgery to define clinical parameters.~diseases"
223950454|NCT02958553|DEVICE|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
223950455|NCT02958553|DEVICE|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
223950456|NCT00001615|DRUG|Corticosteroid|
223950457|NCT03014791|OTHER|Brief lifestyle/medical history questionnaire|Core Measurement
223950458|NCT03014791|OTHER|Anthropometric measures|Core Measurement
223950459|NCT03014791|OTHER|Blood pressure and arterial stiffness|Core Measurement
223950460|NCT03014791|OTHER|Cardiac output and lung function|Core Measurement
223950461|NCT03014791|OTHER|Heart rate variability|Core Measurement
223950462|NCT03014791|OTHER|Blood sample & spot urine sample|Core Measurement
224102166|NCT00377650|DEVICE|Percutaneous thrombectomy|
224102167|NCT03248128|DRUG|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
224102168|NCT03248128|DRUG|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
224102169|NCT01914679|DEVICE|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
224102170|NCT04026789|OTHER|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
224102171|NCT04026789|OTHER|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
224287874|NCT02438982|DRUG|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If \>5 B cells per mm3, it will be measured again after 1 week. If count is still \>5 B cells per mm3, third \& fourth doses of rituximab will be given.
224287875|NCT04217148|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
223537704|NCT01520181|DRUG|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
224287876|NCT04217148|DRUG|ATRA|ATRA, po,10mg bid, for 12 weeks
224287877|NCT03324217|OTHER|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
224287878|NCT01483625|DRUG|tiotropium|18mcg
224287879|NCT01483625|DRUG|Placebo|placebo
224287880|NCT04625673|DEVICE|OsciPulse|OsciPulse device and standard IPC device
223537705|NCT02515318|OTHER|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
223537706|NCT02515318|DRUG|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~\- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones."
223537707|NCT04811690|BEHAVIORAL|front-of-package modification|testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
223537708|NCT00619996|DRUG|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
223537709|NCT00619996|DRUG|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
223537710|NCT03062943|DRUG|Nintedanib|
223950463|NCT03014791|OTHER|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
223950464|NCT03014791|OTHER|24 hour urine collection|Detailed Measurement (Optional for participants).
224287881|NCT05864924|BIOLOGICAL|Cohort A: 3.0x10^6 CAR-T cells/kg|Intravenous infusion
223537711|NCT02350218|DRUG|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
223537712|NCT04021290|DRUG|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.
223537713|NCT04021290|DRUG|CAR|Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
223537714|NCT00636181|DEVICE|Auto AFlex|Positive pressure therapy treatment
223950465|NCT03014791|OTHER|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
223950466|NCT03014791|OTHER|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
223950467|NCT03014791|OTHER|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
223950468|NCT03014791|OTHER|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
223950469|NCT03014791|OTHER|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
223950470|NCT03014791|OTHER|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
223950471|NCT03014791|OTHER|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
223950472|NCT03014791|OTHER|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
223950473|NCT03014791|OTHER|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
223950474|NCT03014791|OTHER|Small artery dilatory function: Forearm blood flow|Detailed Measurement (Optional for participants).
223950475|NCT03111368|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
223950476|NCT01247077|OTHER|selenium|200 ug selenium once daily
223950477|NCT01247077|OTHER|placebo|
223950478|NCT03340961|DRUG|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
223950479|NCT03340961|DRUG|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
223950480|NCT03340961|DRUG|Oraycea® (doxycycline) Capsules|Oral Treatment
223950481|NCT03340961|DRUG|Placebo Capsules|Oral Treatment
223950482|NCT03004989|BEHAVIORAL|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
223950483|NCT00407498|DRUG|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
223950484|NCT00308308|DRUG|Technosphere Insulin|Inhalation, 15U/30U
223950485|NCT00308308|DRUG|Active comparator|sc injectable insulin
223950486|NCT00120549|PROCEDURE|Assisted embryo hatching|
223950487|NCT03090698|DRUG|Hylan G-F 20|intra-articular administration
223950488|NCT03090698|DRUG|Triamcinolone|Intra-articular administration
223950489|NCT04009772|DRUG|Cefepime|Antibiotic prophylaxis
223950490|NCT04009772|DRUG|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
223950491|NCT01319032|OTHER|Extraction of whole blood|Extraction of DNA from whole blood
223950492|NCT01116609|DRUG|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
223950493|NCT03682614|DRUG|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
224102172|NCT02722044|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
224102173|NCT02722044|DEVICE|Autoinjector|Subcutaneous administration
224102174|NCT01158612|DRUG|Growth Hormone|infusion of Growth hormone in the patella tendon.
223537715|NCT00636181|DEVICE|Auto CPAP|Positive pressure therapy treatment
223950494|NCT03682614|OTHER|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
223950495|NCT05659394|OTHER|Standard Wound Care Alone|gold standard compression therapy
223950496|NCT05659394|DEVICE|Stand Wound Care plus IPC|gold standard compression therapy plus IPC (WoundExpress)
223950497|NCT01686152|DRUG|Imiquimod Cream, 3.75%|
223950498|NCT01686152|DRUG|Zyclara®|
223950499|NCT01686152|OTHER|Vehicle of Test Product|
223950500|NCT04784988|DRUG|EHL-FVIII|prophylaxis with EHL-FVIII targeting a 12% FVIII through level based on PK assessment with WAPPS-Hemo
223950501|NCT04784988|DRUG|FVIII concentrate|standard prophylaxis with FVIII concentrate according to current guidelines
223950502|NCT05093894|DEVICE|Group 1|Microlyte will be cut into strips and placed on the subcutaneous space
224102175|NCT02051101|OTHER|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
224102176|NCT00215254|DRUG|quetiapine|
224102177|NCT01363050|DRUG|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
224102178|NCT05195632|DRUG|Encorafenib|Hard capsule
224102179|NCT05195632|DRUG|Binimetinib|Film-coated tablet
224102180|NCT03180463|DRUG|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2\*10\^7 cells,
224102181|NCT03180463|PROCEDURE|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
224102182|NCT00927641|DRUG|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
224287882|NCT05864924|BIOLOGICAL|Cohort B: 9.0x10^6CAR-T cells/kg|Intravenous infusion
224287883|NCT05864924|BIOLOGICAL|Cohort C:1.5x10^7 CAR-T cells /kg|Intravenous infusion
224287884|NCT02574338|DEVICE|Foley's Catheter|intracervical extraamniotic Foley's catheter
223950503|NCT01095848|BIOLOGICAL|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
223950504|NCT00332852|DRUG|Letrozole|2.5 mg/day - oraly
223950505|NCT01853384|BIOLOGICAL|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
223950506|NCT01853384|OTHER|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
223950507|NCT01802333|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
223950508|NCT01802333|DRUG|Cytarabine|Given IV
224102183|NCT00927641|OTHER|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
223950509|NCT01802333|DRUG|Daunorubicin Hydrochloride|Given IV
224102184|NCT02848547|BEHAVIORAL|Text Messaging via Short Message Service|
223950510|NCT01802333|DRUG|Idarubicin|Given IV
224102185|NCT00002850|DRUG|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
224102186|NCT00002850|DRUG|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
224102187|NCT00002850|DRUG|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet \[TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole\] every 12 hours for two months..
224102188|NCT00049764|DRUG|Drotrecogin alfa (activated)|
224102189|NCT00049764|DRUG|Placebo|
224102190|NCT01729689|OTHER|counseling intervention|Undergo cognitive behavioral therapy
224102191|NCT01729689|OTHER|questionnaire administration|Ancillary studies
224102192|NCT01729689|PROCEDURE|quality-of-life assessment|Ancillary studies
224102193|NCT02412865|BEHAVIORAL|Quit4Baby|
224102194|NCT02412865|BEHAVIORAL|Text4Baby|
224102195|NCT05347654|OTHER|Local treatment with silver sulphadiazine only|Local treatment with silver sulphadiazine and tulle from day 0 to day 8 (included). From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
224102196|NCT05347654|OTHER|Local treatment with silver sulphadiazine followed by URGOCLEAN® dressing|Local treatment of silver sulphadiazine with tulle from day 0 to day 4, then with URGOCLEAN® dressing every 48h from day 5 to day 8. From the 9th day and until healing, the dressings are made with tulle, every 48 hours.
224287885|NCT02574338|DRUG|prostaglandin E1 analogue|intravaginal misoprostol
224287886|NCT03080376|OTHER|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
223537716|NCT00636181|DEVICE|CPAP|Positive pressure therapy treatment
223950511|NCT01802333|OTHER|Laboratory Biomarker Analysis|Correlative studies
223950512|NCT01802333|DRUG|Vorinostat|Given PO
223950513|NCT00154609|DRUG|Gu-Sui-Bu (Davallia Divaricata)|
223950514|NCT03709797|PROCEDURE|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
223950515|NCT00861874|DRUG|Decitabine|20 mg/m2 IV, Days 1-5
223950516|NCT00861874|DRUG|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
223950517|NCT01755559|DRUG|Artesunate-amodiaquine|antimalarial ACT
223950518|NCT01755559|DRUG|Dihydroartemisinin-piperaquine|antimalarial ACT
223950519|NCT01755559|DRUG|Artemether-lumefantrine|antimalarial ACT
224102197|NCT02297789|DEVICE|Investigative Full Face Mask with Headgear|
224102198|NCT02049502|BIOLOGICAL|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
224102199|NCT02049502|PROCEDURE|sigmoidoscopy|
224102200|NCT06154070|DRUG|DaxibotulinumtoxinA|"Patients enrolled who meet eligibility will receive a total of 344 units of DAXI Injections in divided doses over 19 landmarks, including the face, head and shoulders, as identified per the EEG paradigm, at visit 2.~Follow-up visits via combination of phone and in office will occur at V3, week 8 thru V9, week 24."
224102201|NCT00004829|DRUG|tobramycin|
224102202|NCT01447693|PROCEDURE|application of ointment (olive-omega 3 ointment)|
224287887|NCT03080376|OTHER|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
224287888|NCT03080376|OTHER|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
223722594|NCT05377983|OTHER|Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes|During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
223722595|NCT00585728|PROCEDURE|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
223722596|NCT04673162|DRUG|Methylprednisolone, Placebo|iv administration
223722597|NCT02893514|OTHER|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
223950520|NCT02488798|PROCEDURE|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
223950521|NCT02488798|PROCEDURE|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
224287889|NCT05990231|DRUG|Cadonilimab combined Anlotinib|Cadonilimab: intravenous administration at a dose of 10mg/kg on day 1 of each cycle, every 3 weeks (Q3W) Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle
224287890|NCT05708482|OTHER|Sling-Swing Position|The device is hammock which look likes a rope
224287891|NCT02497131|DRUG|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
223722598|NCT02893514|OTHER|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
223722599|NCT04014712|DRUG|Tetrahydrobiopterin|Oral, Single dose
223722600|NCT04014712|DRUG|Placebo oral tablet|Single dose
223950522|NCT02488798|PROCEDURE|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
223950523|NCT01947491|DRUG|DFD01 Spray|
223950524|NCT01947491|DRUG|Comp01 Lotion|
223950525|NCT01947491|DRUG|Vehicle Lotion|
223950526|NCT01947491|DRUG|Vehicle Spray|
223722601|NCT02990910|DRUG|Individualized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
223722602|NCT02990910|DEVICE|conventional opioid analgesia|(b) all received 25μg/kg morphine
223722603|NCT05272020|DIAGNOSTIC_TEST|CPET, 6MWT, QOL assessment|Preoperative and postoperative (6 months + 18 months) assessment
223950527|NCT00724009|DRUG|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
223950528|NCT04598646|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
223950529|NCT04598646|BEHAVIORAL|Support|Behavioural support via professionals and peer support and recommended physical activity guidelines for cancer survivors, to encourage physical activity.
223950530|NCT00001628|DRUG|Angiotensin II type 1 receptor antagonists|
223950531|NCT03879265|DIAGNOSTIC_TEST|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
223950532|NCT00606788|DEVICE|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
223950533|NCT00606788|PROCEDURE|Conventional weaning|Patients received physician-directed non-protocolized weaning
223950534|NCT05158426|DRUG|Propofol|anesthesia induction is initiated with intravenous infusion propofol at 1.5µg/ml, and increased 0.5µg/ml every 3min until OAA/S score 0.
224102203|NCT01904487|RADIATION|[11C]flumazenil|\[11C\]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
224102204|NCT01904487|DRUG|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
224102205|NCT02421393|OTHER|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
224102206|NCT01058603|OTHER|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
224102207|NCT01058603|OTHER|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
224102208|NCT01561131|DIETARY_SUPPLEMENT|Whey protein|45g protein/d; Dosage 3x15g protein daily
224102209|NCT01561131|DIETARY_SUPPLEMENT|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
223722604|NCT00851500|DRUG|K-604|K-604 is given for 26 weeks
223722605|NCT00851500|OTHER|Placebo|placebo tablets are given for 26 weeks
223722606|NCT00583778|DRUG|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
223722607|NCT00179114|DRUG|Botulinum Toxin Type A|
223950535|NCT02067663|DEVICE|Paragard|The IUD will be placed as part of standard clinical care.
223950536|NCT02067663|DRUG|Mirena|The IUD will be placed as part of standard clinical care.
223950537|NCT04103164|DEVICE|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
224102210|NCT01561131|DIETARY_SUPPLEMENT|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
224102211|NCT01561131|DIETARY_SUPPLEMENT|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
224102212|NCT00246168|DRUG|tramadol hydrochloride + acetaminophen|
224102213|NCT04054310|DIAGNOSTIC_TEST|Liver Multi Scan|MRI to create cT1, T2\* and PDFF images of patients liver.
224102214|NCT03260647|OTHER|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
224102215|NCT00787436|DRUG|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
224102216|NCT06600906|DRUG|Hyperpolarized 13C-Pyruvate|Given intravenously (IV)
223950538|NCT04130932|OTHER|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
223950539|NCT03124472|PROCEDURE|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
224102217|NCT06600906|PROCEDURE|Computed tomography (CT)|Undergo CT imaging
224102218|NCT06600906|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
224102219|NCT03528525|OTHER||observation
224102220|NCT00345891|BEHAVIORAL|Coping-focused counseling telephone calls|
224287892|NCT02402491|DRUG|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
223722608|NCT00179114|DRUG|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
223722609|NCT01937728|DRUG|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA \< 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
223722610|NCT01937728|DRUG|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
223722611|NCT01937728|DRUG|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
224102221|NCT03531099|PROCEDURE|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
224102222|NCT03531099|BIOLOGICAL|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
224102223|NCT03531099|DEVICE|MRI|MRI exam will be regularly performed during patient follow up.
224287893|NCT02402491|DRUG|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
224287894|NCT02402491|DRUG|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
224287895|NCT05444543|DRUG|Fluticasone Propionate|Participants will cycle topical steroid in a three-months on three-months off fashion
224287896|NCT05444543|DRUG|Budesonide|Participants will cycle topical steroid in a three-months on three-months off fashion
223537717|NCT04818905|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
223537718|NCT04818905|OTHER|Hot water|Active beverage or control beverage consumption after overnight fasting and calorimetry measurement on a single subject. After seven days washout period follows the consumption of the alternate beverage and measurements.
223537719|NCT03820011|OTHER|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
223950540|NCT03124472|PROCEDURE|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~\- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers"
223950541|NCT00163358|DRUG|Ciclesonide|
223950542|NCT01154504|OTHER|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
223950543|NCT01154504|PROCEDURE|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
223950544|NCT01154504|PROCEDURE|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
224287897|NCT02301858|GENETIC|Genome analysis of tissue samples.|Genome analysis of tissue samples.
223950545|NCT00905294|OTHER|Blood draws|Observational: blood draws only
223950546|NCT05814809|DRUG|JP-1366 20mg tablet|T : JP-1366 20mg tablet
224287898|NCT01872624|PROCEDURE|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
224287899|NCT02280187|PROCEDURE|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
224287900|NCT05661461|DRUG|nab-sirolimus|This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
224287901|NCT04668274|DRUG|200 mg resveratrol as JOTROL|Low (first) dose of single ascending dose study
224287902|NCT04668274|DRUG|500 mg resveratrol as JOTROL|Second (intermediate) dose of single ascending dose study
224287903|NCT04668274|DRUG|700 mg resveratrol as JOTROL|Third (highest) dose of single ascending dose study
224287904|NCT04668274|DRUG|500 mg resveratrol as JOTROL administered to assess influence of food|500 mg resveratrol as JOTROL administered to assess influence of food
224287905|NCT04159194|OTHER|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (\~55% CHO) and the type and amount of ingested food will be recorded.
224287906|NCT04159194|OTHER|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
224287907|NCT05110131|DEVICE|Device for performing biopsy via electromagnetic navigation bronchoscopy|Device for performing biopsy via electromagnetic navigation bronchoscopy (needle and forceps)
224287908|NCT01047891|DRUG|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
224287909|NCT03328429|OTHER|Excision|Bartholin gland will be excised
224287910|NCT03328429|OTHER|Marsupialization|Bartholin gland will be marsupialised
224287911|NCT05644886|BEHAVIORAL|FP Training and Technical Support|Same as in Intervention arm description
224287912|NCT05352724|DIETARY_SUPPLEMENT|Hydration drink|Intake of the different hydrating drinks for 4 weeks 3 times a week during sports practice
224287913|NCT02863549|DEVICE|MitraClip in tricuspid valve|MitraClip in tricuspid valve
224287914|NCT05190523|DRUG|ASC42 5 mg|5 mg of ASC42 tablets orally once daily for 12 weeks.
224287915|NCT05190523|DRUG|ASC42 10 mg|2 x 5 mg of ASC42 tablets orally once daily for 12 weeks.
224287916|NCT05190523|DRUG|ASC42 15 mg|15 mg of ASC42 tablets orally once daily for 12 weeks.
224287917|NCT05190523|DRUG|Placebo|Placebo tablets orally once daily for 12 weeks.
224287918|NCT01854255|DRUG|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
224287919|NCT00707447|BEHAVIORAL|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
224287920|NCT00707447|BEHAVIORAL|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
224287921|NCT05791747|OTHER|semi-structured interviews|This is an observational study Patients included in the study will conduct semi-structured interviews to discuss their knowledge and/or experience with supportive care, particularly hypnosis
224102224|NCT03531099|OTHER|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
224102225|NCT03531099|PROCEDURE|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
224102226|NCT04256928|PROCEDURE|Preoperative electrical clipping|Body hair in the operative field will be clipped with an electrical clipper by hospital personnel during preparation to planned surgery.
224102227|NCT05940597|DEVICE|Pulse field ablation|ablation of paroxysmal atrial fibrillation by Pulse field ablation
224102228|NCT05940597|DEVICE|Cryoballoon pulmonary vein isolation|ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
224102229|NCT06620107|DEVICE|noninvasive high frequency oscillation ventilation|"cases of group A extubated on NHFOV, and it will be provided by CNO, Medin device, Germany) via binasal prongs with the following parameters:~* MAP of 6 cmH2O and will be titrated targeting a FiO2 ≤ 25-30%, maximum FiO2 will be 40% and target oxygen saturation will be 90-95%.~* Frequency of 8 Hz and can be changed within the range of 8-12 Hz.~* Amplitude of 7 cmH2O and can be titrated within the range of 7-10 cmH2O according to PaCO2."
224102230|NCT06620107|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be provided by any type of neonatal ventilator available in the unit via binasal prongs starting with the following parameters:~* Positive end expiratory pressure (PEEP) of 5 cmH2O and can be titrated to 8 cmH2O according to the oxygenation .~* Peak inspiratory pressure (PIP) of 15 cmH2O and can be titrated to 25 cmH2O ,according to oxygenation , PaCO2 level and the chest expansion .~* FiO2 ≤ 25-30% and can be increased to 40 % maximally targeting oxygen saturation of 90-95% .~* Inspiratory time of 0.40-0.50 s .~* Rate of 30 bpm and can be increased to maximum 50 bpm .~* Synchronization will not be applied."
224102231|NCT07026435|PROCEDURE|LSTR|Lesion Sterilization and Tissue Repair (LSTR) is a minimally invasive pulp therapy using ciprofloxacin and metronidazole mixed with iodoform-calcium hydroxide, without canal instrumentation. The access cavity is sealed and restored with SSC or compomer.
224102232|NCT07026435|PROCEDURE|Pulpectomy|Pulpectomy includes mechanical canal preparation, irrigation, and obturation using iodoform-calcium hydroxide paste, followed by final restoration with stainless steel crown or compomer.
224102233|NCT07030946|BEHAVIORAL|Multimedia Health Education|A 10-minute multimedia video is provided to the intervention group during their final preoperative clinic visit. All participants receive standard verbal and printed education from the ophthalmologist. The video includes visual and auditory content on cataract surgery, preoperative instructions, postoperative care, and common concerns. Baseline data (T0) are collected before the intervention, including demographics, visual acuity, physiological indicators, BAI, and self-care knowledge. Follow-ups occur at T1 (surgery day), T2 (1 week postop), and T3 (1 month postop), assessing anxiety, physiology, vision, and self-care.
224102234|NCT07030881|DRUG|pMDI Triple Inhaler and Spacer|Participants in this group will use a valved mouthpiece spacer in combination with standard triple inhaled therapy delivered by a pressurized metered-dose inhaler (ICS/LABA/LAMA). The spacer device helps reduce the need for hand-breath coordination, prolongs aerosol suspension time, and improves drug delivery to the lungs. Participants will be trained in proper spacer use, including device attachment, timing of actuation and inhalation, mouth seal technique, cleaning, and daily maintenance. This intervention aims to optimize inhalation technique, improve treatment adherence, and potentially reduce the incidence of moderate-to-severe exacerbations.
224102235|NCT07030881|DRUG|pMDI Triple Inhaler Only|Participants in the control group will receive a standard fixed-dose combination of inhaled corticosteroid (ICS), long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA) administered via pressurized metered-dose inhaler (pMDI). No spacer will be used. All participants will receive standardized inhalation technique training at baseline, including hand-held device usage, actuation-inhalation timing, breath-hold, and mouth rinsing. This group represents the current standard-of-care for stable, high-risk COPD or asthma patients as per GOLD and GINA guidelines.
223950547|NCT05814809|DRUG|JP-1366 20mg capsule|R : JP-1366 20mg capsule
223950548|NCT05999448|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
223950549|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Individual|CICBT-Individual will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
223950550|NCT05999448|BEHAVIORAL|Culturally Informed Cognitive Behavioral Therapy (CICBT), Group|CICBT-Group will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
223950551|NCT05999448|BEHAVIORAL|Dialectical Behavioral Therapy (DBT)|DBT will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist.
223950552|NCT05999448|BEHAVIORAL|Durand Sleep Intervention|Durand Sleep Intervention will be deployed weekly for 12 weeks, alternating between individual and group formats, via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed psychologist or behavioral analyst.
224102236|NCT07031206|DRUG|Paracervical block- Lidocaine without epinephrine|1-2 cc of Lidocaine at the tenaculum site on the cervix at 12 o-clock will be injected after pain scale #1 is completed. Pain scale #2 will be done then 3 cc of 1% lidocaine at 4 and 8 o'clock position of the cervix will be administered. The IUD insertion or EMB will be performed nd pain scale #3 will be done.
224102237|NCT07031206|DRUG|Benzocaine Gel applied to the cervix|After pain scale #1 is performed , topical benzocaine will be applied to the cervix with Procto swabs and this will be allowed to remain on cervix for 203 minutes. Then Betadine will be applied to the cervix and surrounding vaginal tissue followed by pain scale #2. IUD insertion or EMB will be done followed by pain scale #3.
224287922|NCT03485846|DRUG|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
224287923|NCT03485846|DRUG|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
224287924|NCT03485846|DRUG|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
224102238|NCT07031206|DRUG|Hydroxyzine Hydrochloride|Preprocedure, a GAD 7 scoring will be performed to determine level of anxiety. If \> 10 indicating Moderate anxiety, participants will be offered pretreatment with Anxiolytic (Hydroxyzine 25mg) approximately 15-20 mins before procedure. If this is done at the preceding visit, participants will be sent home with a prescription for hydroxyzine to be taken 10-15 mins before the procedure when participants are brought back for procedure visit.
224102239|NCT07031999|COMBINATION_PRODUCT|PLA spacer|This is a phase 1/2 prospective, interventional, non-randomized, single-arm clinical study designed to evaluate the safety of using temporary articular spacers printed in PLA (polylactic acid) impregnated with vancomycin in patients with periprosthetic infections of the hip, knee, or shoulder.
224102240|NCT07030556|OTHER|Healthy Sleep Intervention|This intervention has a duration of nine weeks and starts with a kick-off event where the students of the action group provide explanations to fellow students. Furthermore, the intervention is structured in five themes of approximately two weeks each: 1) importance of healthy sleep, 2) sleep and wake cycle, 3) screen time, 4) exercise and nutrition and 5) screen use and mental well-being. Three posters are provided for each theme, five to seven Instagram posts and a class discussion. In addition, healthy sleep is explained during the biology lesson. Furthermore, a competition between classes is organized to sleep as well as possible with the help of an app, classes are given a planner to visualize the workload of school tasks, exercise snacks will be introduced during the lessons and students are given a notebook to write things down in case of worrying. Finally, a closing moment is provided. Flyers with information about healthy sleep in young people are distributed to parents.
224102241|NCT07030556|OTHER|Co-creation process|co-creation process with students and teachers: to adapt the existing intervention to the needs of the school. For this, schools can recruit 6 to 8 students via purposeful sampling to form an action group. They will be asked to participate in two sessions during the lunch break in which 1) the needs of the students at school in relation to healthy sleep are mapped out and the goals of the already developed intervention are supplemented or not based on the needs 2) a choice is made from the already developed intervention components 3) necessary adjustments are made to intervention components.
224287925|NCT06425367|DIAGNOSTIC_TEST|Antibiotic susceptibility testing|antibiotic susceptibility testing is performed on MHR-SIR or MH medium depending on randomization
224287926|NCT00175097|OTHER|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
224287927|NCT00175097|OTHER|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
224287928|NCT00175097|OTHER|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
224287929|NCT00175097|OTHER|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
223950553|NCT05999448|BEHAVIORAL|RUBI Intervention|RUBI will be deployed weekly for 12 weeks in small groups via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
223950554|NCT05999448|BEHAVIORAL|Naturalistic Communication Intervention (NCI)|NCI will be deployed weekly for 12 weeks on an individual basis via secure Zoom. Treatments will be deployed by supervised graduate student clinicians under the supervision of a licensed behavioral analyst.
223722612|NCT01937728|DRUG|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
223950555|NCT05999448|BEHAVIORAL|Self-Guided Resources|Participants will be provided a self-guided resource notebook that includes 12 weeks of content that parallels the topics examined in other support programs (child behavior management, child sleep, child communication, caregiver mental health, caregiver health behaviors, community connection)
223950556|NCT05999448|BEHAVIORAL|Participation Enhancement Intervention (PEI)|"A standardized PEI intervention will be conducted by trained peer coaches who are also rare disorder caregivers. Each peer coach will work with their clients to complete a Change Plan Worksheet and will complete two booster sessions at midpoint and end of treatment. Coaches will also meet with their clients after follow-up data are complete to support connection back to community resources and patient-specific rare disorder communities."
223950557|NCT00410748|DRUG|OROS hydromorphone HCI CR|
223950558|NCT03137784|DRUG|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
223950559|NCT03137784|DRUG|Placebo|In each treatment arm, patient will receive placebo
223950560|NCT04210830|DIAGNOSTIC_TEST|Quantra-Device|Point of Care Coagulation Monitoring System
223950561|NCT05578807|PROCEDURE|without reverse ureteral catheter insertion|In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
223950562|NCT01157195|BEHAVIORAL|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
224287930|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg|Administration: Inject intravenously single dose
224287931|NCT05276076|BIOLOGICAL|VM-001 3X10^6 cells/kg|Administration: Inject intravenously single dose
224287932|NCT05276076|BIOLOGICAL|VM-001 5X10^6 cells/kg|Administration: Inject intravenously single dose
224102242|NCT07030556|OTHER|Training for teachers|implementation of the implementation intervention for teachers. The implementation intervention consists of a one-off training for all teachers of the 1st and 2nd year of secondary school in which the importance of sleep and the intervention and its materials are explained. A manual per theme is then provided to the teachers who will implement components (see also appendix 'Manual Sleep Project'). Consultation moments will be planned in consultation to discuss the progress of the implementation.
224102243|NCT07030803|OTHER|Oxybutynin|oxybutynin
224102244|NCT07030803|DEVICE|medical device Urostim|medical device used to deliver posterior tibial nerve stimulation (PTNS)
224102245|NCT07032246|DEVICE|quantitative brain MRI (icobrain mr)|"Quantitative brain MRI refers to using a specialised software to compute volumes of brain structures and of MS lesions from brain MRI scans, and to measures differences between a previous brain MRI scan and the current brain MRI scan.~The quantitative brain MRI solution being investigated in the PROCLAIM study is icobrain mr, a software solution that uses artificial intelligence (AI) to help with tracking of MS disease progression by measuring brain structures and lesions on magnetic resonance imaging (MRI)."
224102246|NCT07032246|OTHER|Standard of Care (SOC)|Standard of Care practices at each participating site for management of multiple sclerosis.
224102247|NCT07030205|OTHER|Blood sample|A blood sample (fasting), for biobanking purposes to measure certain bone biological markers known to be indicators of bone remodeling (osteocalcin, sclerostin, periostin, irisin, procollagen type 1 N-terminal propeptide (P1NP), Dickkopf-related protein 1 (DKK1), and collagen type 1 C-terminal telopeptides (CTX)).
224102248|NCT07030205|OTHER|Bone density exam|A bone density exam will be performed in order to verify the non-osteoporotic status of the healthy volunteers group.
224102249|NCT07030205|OTHER|Tests and questionnaires of study|An assessment of cognitive functions will be realized using Montreal Cognitive Assessment (MoCA), Cantab® tests (MOT, MTS, RTI, DGS), the Trail Making Test (TMT), verbal fluency, the Stroop test, the Dubois 5-word test, and the oral picture naming test. Other questionnaires will be used, assessing: sleep quality (Pittsburgh Physical Activity Questionnaire (PSQI)), anxiety and depression (the anxiety/depression scale (HAD)), quality of life (Short Form-36 quality of life questionnaire (SF-36)), physical activity (International Physical Activity Questionnaire (IPAQ)), and pain with the Brief Pain Inventory questionnaire (BPI) and the numerical scale (EN).
224102250|NCT07030205|OTHER|Functional connectivity value of brain networks at rest|A Resting-State Functional Magnetic Resonance Imaging will be conducted in order to evaluate and compared functional connectivity value of brain networks at rest between three groups.
224102251|NCT06853418|DEVICE|Oocyte Cryopreservation|"The DaVitri System is intended to semi-automate vitrification preparation of human oocytes.~The Overture Semi-Automated Vitrification System (DaVitri) is a medical device that uses semi-automated oocyte vitrification.~The system comprises the DaVitri Station, and the DaVitri Dish. The DaVitri Station is a piece of capital equipment with touch screen control that manages the vitrification preparation. The DaVitri Dish is a cartridge-like device onto which oocytes and vitrification reagents are loaded. When the DaVitri Dish is loaded into the DaVitri Station, and the cryo process is initiated, a microfluidic pump controls the flow of reagents to and from the DaVitri Dish containing the oocytes."
224102252|NCT06903182|PROCEDURE|Preoperative TAP Block|Patients will receive preoperative TAP block
224287933|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg two dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, two dose in total, weekly"
223950563|NCT01157195|BEHAVIORAL|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
223950564|NCT02265107|OTHER|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
224102253|NCT06903182|PROCEDURE|Postoperative TAP block|Patients will receive postoperative TAP block
224102254|NCT06900595|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224102255|NCT06900595|DRUG|Cabozantinib|Given PO
224102256|NCT06900595|BIOLOGICAL|Cemiplimab|Given IV
224102257|NCT06900595|PROCEDURE|Computed Tomography|Undergo CT scan
224287934|NCT05276076|BIOLOGICAL|VM-001 1X10^6 cells/kg four dose|"Administration: Inject intravenously~1X10\^6 cells/kg per dose, four dose in total, weekly"
224287935|NCT00043576|DRUG|calcitriol|
224287936|NCT00043576|DRUG|docetaxel|
224287937|NCT01790230|DEVICE|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
224287938|NCT00338130|DRUG|AZD6244|Oral liquid or Capsule
224287939|NCT00338130|DRUG|Temozolomide|oral
224287940|NCT05799716|DRUG|IVIG|0.5g/Kg
224287941|NCT04823819|DEVICE|Magnetic Stimulator DuoMag|Stimulation of the left dorsolateral prefrontal cortex
224287942|NCT04823819|DEVICE|neuroConn DC-STIMULATOR|One electrode (anode) will be placed on the left dorsolateral prefrontal cortex, the other (cathode) on the right temporal lobe.
224287943|NCT01920984|DRUG|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
224287944|NCT06443255|DRUG|Cociane hydrochloride 4%|2 mL of 4% cocaine
224287945|NCT06443255|DRUG|Lidocaine 4%|1.5 mL of 4% lidocaine
224287946|NCT06443255|DRUG|Xylometazoline 0.1%|0.5 mL of xylometazoline 0.1%
224287947|NCT06443255|DRUG|Saline 0.9%|2 mL of saline 0.9%
224287948|NCT06208423|OTHER|GPT-4|OpenAI's GPT-4 large language model with chat interface.
224287949|NCT04082936|DRUG|imvotamab|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
224102258|NCT06900595|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224102259|NCT07087574|DEVICE|adapted cutlery handle printed with 3D printer|"The patient's autonomy will be assessed by the same ergotherapist, and the quantity of food ingested will be measured by a dietician at 3 similar lunch times:~* before using the adapted cutlery handles (Day0);~* when the adapted cutlery handles are used for the first time (Day1);~* after 3 days' use of the adapted cutlery handles (Day3) On Day0 and Day3, the ergotherapist will carry out an ecological assessment of the meals. Ecological assessment is used in occupational therapy to observe and analyze the patient's interactions with his environment and their repercussions on his ability to perform a task. The aim here is to assess whether the patient exhibits compensation of the upper limb (such as shoulder elevation or trunk inclination) during the meal performed without technical aids (Day0) and that performed after the learning phase of using the adapted handle (Day3).~The patient's participation will end at the end of the Day3 assessments."
224102260|NCT06456554|DEVICE|Acellular Dermal Matrix (Cortiva Tissue Matrix)|non-crosslinked dermis
224102261|NCT00036790|DRUG|doxorubicin hydrochloride|
224102262|NCT00036790|DRUG|motexafin gadolinium|
224102263|NCT07106073|OTHER|Collection of demographic, anthropometric and clinical data.|"Data collected is:~* demographic data: age, sex;~* anthropometric data: weight, height, body mass index;~* clinical data:~  * Palliative Performance Scale;~ * Palliative Prognostic Index;~ * comorbidities;~ * therapy;~ * presence of medical devices;~ * presence of pressure injuries;~ * time on waiting list;~ * place of care;~ * primary diagnosis;~ * length of stay;~ * symptom burden at admission (Edmonton Symptom Assessment System);~ * onset of fever and its characteristics (duration, intensity, treatment, etiology);~ * need for sedation (duration, refractory symptom(s));~ * outcome."
224102264|NCT07108231|DEVICE|Inspiratory muscle trainning|"The IMT protocol will involve the use of the Power Breath® linear resistor device, classic light model (Anvisa Registration: 81001390001). The IMT group will perform the protocol with a load ranging from 30% to 50% of maximal inspiratory pressure (MIP). Two daily sessions of 30 repetitions each will be conducted, starting with a minimum load of 30%, with a 10-minute interval between sessions, and a proposed weekly load increase based on patient tolerance.~For training load progression, patient effort will be taken into account, aiming to maintain a perceived exertion level between light and moderate fatigue (BORG scale less than 4).~Patients will remain seated at a 90° angle, using a nasal clip, and will be encouraged to perform consecutive inspirations with their mouth on the device's mouthpiece. Vital signs-including blood pressure (BP), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), respiratory rate (RR), heart rate (HR)-and dyspnea sensat"
224287950|NCT00663715|OTHER|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
224287951|NCT06842602|OTHER|gum|chewed gum within 2 hours before the procedure
224287952|NCT06842602|OTHER|candy|consumed candy within 2 hours before the procedure
224287953|NCT06842602|OTHER|strict fasting rules|followed strict fasting rules
224287954|NCT01868282|PROCEDURE|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
223950565|NCT01869465|OTHER|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
223950566|NCT01869465|BEHAVIORAL|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
223950567|NCT00714207|BEHAVIORAL|NOT program|Students in this arm of the study received the reformatted NOT intervention
224287955|NCT01868282|PROCEDURE|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
223950568|NCT00714207|BEHAVIORAL|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
223950569|NCT00714207|BEHAVIORAL|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
224102265|NCT07108231|DEVICE|Sham (No Treatment)|The control group (IMTsham) will perform two daily sessions of 30 repetitions each without any load, using the same resistor device.
224102266|NCT05881408|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
224102267|NCT05881408|GENETIC|placebo|Single IV infusion of matching placebo
224102268|NCT07106502|PROCEDURE|testicular palpation training on a mannequin|Study of testicular palpation training on a mannequin on the ability to perform a testicular examination and diagnose testicular positioning abnormalities
224102269|NCT07107867|BEHAVIORAL|breastfeding counseling|Pregnant women assigned to the intervention group then participated in a breastfeeding counseling training program held at the gynecology and obstetrics unit of an university training and research hospital. The training sessions lasted 60 to 90 minutes and included small groups of 5 to 6 participants, based on recommendations from the literature. The training was delivered through a slide presentation, and participants received a printed training booklet beforehand. Visual aids, including a baby model and breast model, were also used to enhance understanding. The training content was developed in line with infant feeding guidelines from UNICEF, the Turkish Ministry of Health, and relevant literature.
223537720|NCT04188951|DRUG|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
224287956|NCT01868282|PROCEDURE|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
224287957|NCT02555982|DRUG|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
223537721|NCT05248490|OTHER|pharmaceutical interview|Pharmaceutical interview with pharmacist: to be informed treatment taken and related SAE informations at the end of hospitalization
223537722|NCT02046018|OTHER|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
223537723|NCT02046018|OTHER|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
223537724|NCT02046018|OTHER|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
223722613|NCT01937728|DRUG|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
224102270|NCT07106086|OTHER|Scapulothoracic mobilization|"Scapulothoracic Mobilization and Buteyko Breathing Technique:~Subjects lay supine with arms crossed, hands on opposite scapulae. The interventionist stabilized elbows and applied pressure to shoulders, with one hand on the spine using a loose fist to mobilize vertebrae. Various spinal motions-rotation, flexion, lateral flexion, and translation-were assessed. In a lateral position, the subject bent both knees and placed the upper arm on a cushion. The interventionist stood close, placing fingers under the scapula's medial border."
224102271|NCT07106086|OTHER|Buteyko breathing|Buteyko Breathing: Subjects sat upright, relaxed respiratory muscles, and breathed gently through the nose. The sequence included calm nasal inhalation and exhalation using the diaphragm, followed by shallow inhalation and slow exhalation. A brief post-exhalation breath hold was added. The cycle was repeated for several minutes.
224102272|NCT07105735|BIOLOGICAL|allogeneic CAR-T|Fludarabine injection (30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before RN1201 infusion.
224102273|NCT07106177|OTHER|Scanning with verification jig|Comparing Relative Implant Positions of the 4 implants in each case obtained through desktop scanning of intraoral provisional verification jig. All-on-4 treatment for mandibular and maxillary edentulous cases were scanned using the Medit i700 intraoral scanner. Scan data were imported into Exocad software, where scan-body matching was performed using the Neodent library to determine the positions of multiunit abutment analogues.
224102274|NCT07106177|OTHER|Direct intraoral scanning|Comparing Relative Implant Positions of the 4 implants in each case obtained through direct intraoral scanning without jig. All-on-4 treatment for mandibular and maxillary edentulous cases were scanned using the Medit i700 intraoral scanner. Scan data were imported into Exocad software, where scan-body matching was performed using the Neodent library to determine the positions of multiunit abutment analogues.
224102275|NCT07106528|DRUG|Organoid Drug Sensitivity Testing-Guided Therapy|Personalized drug selection (chemotherapy/targeted therapy/immunotherapy) based on ex vivo organoid drug response testing
224102276|NCT07106528|DRUG|Topotecan|Intravenous topotecan 1.25 mg/m² daily on days 1-5 of each 21-day cycle
224102277|NCT07107711|PROCEDURE|One-Stop Hybrid Surgery|With the patient under moderate hypothermia (approx. 28°C) and cardiopulmonary bypass, surgeons perform a total arch replacement using a standard 4-branched graft. After the open repair is complete, a separate, distinct covered stent graft is deployed antegradely into the descending aorta through the open distal end of the arch graft. Completion angiography confirms correct placement.
224287958|NCT02555982|DRUG|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
224287959|NCT05305768|DRUG|IncobotulinumtoxinA|Injection of glabellar rhytids
224102278|NCT07107711|PROCEDURE|Conventional Total Arch Replacement with Frozen Elephant Trunk|With the patient under deep hypothermic circulatory arrest (23°C-25°C) and cardiopulmonary bypass, surgeons perform a total arch replacement using an integrated hybrid prosthesis (Frozen Elephant Trunk), which consists of a vascular graft sutured to a covered stent graft. This single device is deployed antegradely into the descending aorta, and the arch vessels are then reattached to the branches of the prosthetic graft.
224102279|NCT05393739|DEVICE|Theta burst transcranial magnetic stimulation (TBS) procedure|The procedure includes determining the specific occipital point at which place the stimulation coil; this corresponds to the area where magnetic stimulation is most capable of inducing phosphenes or transient visual phenomena. The phosphenes are directly induced by stimulation of the visual cortex and their presence indicates that the magnetic stimulation is in the correct location. The subjects would wear a personalized swimming cap with the determined area for stimulation marked on it. The major differences between iTBS and cTBS are the frequency and interval of stimulus.
224102280|NCT06152328|OTHER|Virtual reality applications based on mirror therapy|Mirror therapy-based games will be played for 30 minutes every day for eight weeks, three days a week, for the VR group.
224102281|NCT06152328|OTHER|Conventional treatment|Bobath therapy, walking exercises, upper extremity active exercises, and proprioceptive neuromuscular facilitation techniques will be applied three days a week for eight weeks.
224102282|NCT06152328|OTHER|Mirror therapy|In conventional mirror therapy, the unaffected extremities of the individuals will be positioned outside the mirror, while the affected extremities will be placed inside the mirror so that the patient cannot see them. In this way, the image of the intact hand will be transferred to the affected side and activities will be performed three days a week for eight weeks.
223537725|NCT05437419|DRUG|TCK-276|Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
223537726|NCT05437419|DRUG|TCK-276 Placebo|Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
224287960|NCT02931292|PROCEDURE|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
224287961|NCT01293266|DRUG|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
224287962|NCT06678204|OTHER|Optimized illustrated pamphlets|Participants in the control group received traditional text-based pamphlets covering similar self-care information for RT. Pretests were administered before the start of treatment, and posttests were conducted two weeks after the completion of RT.
224102283|NCT06152328|OTHER|Placebo virtual reality|For 8 weeks, watching the uninteractive virtual environment for 10 minutes
224102284|NCT06088836|DRUG|Retrolaminar block group|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency linear ultrasound probe (6-11 MHz) was placed into a longitudinal orientation in the paraspinous line 1 cm from the midline. Lamina appeared as a continuous line interrupted by the intra laminar spaces.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done Then, an 18-gauge Tuohy needle was inserted in plane 1 cm lateral to the spinous process using ultrasound imaging and advanced caudally or cranially until it contacts the lamina."
224102285|NCT06088836|DRUG|Erector spinae plane block group.|"Under complete aseptic precautions and sterilization and in sitting position, A high-frequency ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the midline midway between the uppermost and the lowest fractured rib to identify counting of ribs using ultrasound three muscles were identified as superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. However, when the rhomboid major muscle disappears this indicates that we are at the level of the seventh thoracic vertebra.~local infiltration of needle insertion site with 3ml of 2.0 % lidocaine was done. Then, an 18-gauge Tuohy needle was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles"
224102286|NCT00316875|DRUG|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
224102287|NCT00316875|DRUG|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
224287963|NCT01832402|DRUG|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
223950570|NCT00714207|BEHAVIORAL|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
223950571|NCT02832128|DRUG|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
224102288|NCT06938854|DEVICE|Peripheral Intravascular Lithotripsy (IVL)|For the Disrupt PAD Japan study, the Shockwave Medical Peripheral IVL System (SWM-831) is intended for lithotripsy enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the femoropopliteal arteries.
224102289|NCT06953687|BEHAVIORAL|Prolonged Exposure Therapy|PE is a cognitive-behavioral treatment for PTSD that is typically delivered in ten 90-minute sessions . For the current study using a variable length approach, participants may complete up to 24 sessions. Based on emotional processing theory PE addresses trauma-related avoidance of thoughts, behaviors, and situations, as well as unhelpful beliefs about oneself, others, and the world that were learned as a result of trauma.
223950572|NCT02832128|DRUG|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
224287964|NCT01832402|DRUG|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
223950573|NCT02074228|DRUG|Methylphenidate (Concerta)|
223950574|NCT01020266|PROCEDURE|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
223537727|NCT05076045|DEVICE|Personal sound amplification products|Participants will be tested with bilateral personal sound amplification products.
224102290|NCT06953687|BEHAVIORAL|Cognitive Processing Therapy|CPT is a 12-session, cognitive behavioral PTSD treatment typically delivered in 60-minute sessions that can be personalized to include fewer or additional sessions. For the current study using a variable length approach, participants may complete up to 24 sessions. CPT is based in cognitive theory and posits that impeded recovery following trauma occurs due to unhelpful and unrealistic beliefs that may develop after trauma, leading to chronic anger, guilt, shame, and avoidance of trauma reminders. During CPT, patients learn about PTSD symptoms, impeded recovery and cognitive theory, and the connection between trauma-based thoughts and feelings.
224287965|NCT01832402|OTHER|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
224287966|NCT01832402|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
224287967|NCT01832402|BEHAVIORAL|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
224287968|NCT01445418|DRUG|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
223537728|NCT03014804|BIOLOGICAL|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
223537729|NCT03014804|OTHER|Laboratory Biomarker Analysis|Correlative studies
223537730|NCT03014804|BIOLOGICAL|Nivolumab|Given IV
224287969|NCT03072654|PROCEDURE|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
224287970|NCT01353248|DRUG|GS-5885|tablet, 30 mg QD
224287971|NCT01353248|DRUG|Tegobuvir|capsule, 30 mg BID
224287972|NCT01353248|DRUG|GS-9451|tablet, 200 mg QD
223537731|NCT03014804|OTHER|Quality-of-Life Assessment|Ancillary studies
223537732|NCT03014804|OTHER|Questionnaire Administration|Ancillary studies
223537733|NCT06080555|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
223537734|NCT06080555|DRUG|Ferric Carboxymaltose Injection [Ferinject]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
223537735|NCT02128022|DRUG|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
223537736|NCT02128022|DRUG|Glibenclamide|Oral Glibenclamide 5mg
223537737|NCT04443088|DRUG|INV-1120|INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
223537738|NCT04443088|COMBINATION_PRODUCT|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
223537739|NCT05172297|BEHAVIORAL|Parent Web|Parent-Web (PW) is internet delivered and rooted in social learning and coercion theory, PW supports parenting practices and parent-child interactions encouraging prosocial behavior and emotion regulation, reduce coercive parenting, improve communication, problem solving, and warmth. PW has a universal and selective edition. Universal PW has 5 basic modules (1 module per week, 6-8 weeks) and bonus modules. Basic modules contain information, exercises, and videos of actors showing parenting practices. A family guide supports parents through modules.
223537740|NCT03659825|DIETARY_SUPPLEMENT|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
223537741|NCT03659825|DIETARY_SUPPLEMENT|Taste Matched Placebo|Placebo that tastes similar to active intervention
223537742|NCT03659825|OTHER|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
223537743|NCT00713193|DRUG|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
223537744|NCT00713193|DRUG|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
223537745|NCT04815174|OTHER|Standard of Care|(i) advanced clinical and biological monitoring system (ii) symptomatic treatment adapted to the patient's needs, such as antibiotic therapy, oxygen therapy and blood transfusion; (iii) dialysis or mechanical ventilation.
223537746|NCT01143636|DEVICE|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
223537747|NCT03131193|OTHER|Physician|Study primary health centers will be staffed with an additional physician
223537748|NCT03131193|OTHER|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
223537749|NCT03131193|BEHAVIORAL|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
223537750|NCT01044719|DRUG|Ceftazidime|Ceftazidime 2g TDS IV
223537751|NCT01044719|DRUG|Tobramycin|Tobramycin 7mg/kg/day OD IV
223537752|NCT01044719|DRUG|Meropenem|Meropenem 2g TDS IV
223537753|NCT02227745|DRUG|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
224102291|NCT06953687|BEHAVIORAL|Written Exposure Therapy|WET is a cognitive behavioral therapy for PTSD that typically consists of 5 weekly 50-minute sessions. For the current study using a variable length approach, participants may complete up to 7 sessions. WET is based on an extinction and emotional processing treatment model. First, patients learn about PTSD and the role of avoidance in maintaining PTSD symptoms. Next, patients are guided to write about their trauma for 30 minutes and afterwards, the therapist briefly checks in with the patient. This procedure is followed for the next 4 sessions, with guidance to first write about the trauma, and in later sessions to write about consequences of the trauma and the patient's current meaning of their lives. The goals of WET are to assist the patient in emotionally processing the event and reduce avoidance of trauma-related thoughts and memories, which facilities recovery.
224102292|NCT06953687|OTHER|Shared Decision Making (SHARE)|"The study will use the SHARE Approach to facilitate treatment planning and decision-making. SHARE stands for:~1. Seek the patient's participation~2. Help the patient explore and compare treatment options~3. Assess the patient's values and preferences~4. Reach a decision with the patient~5. Evaluate the patient's decision The Shared Decision Making Patient Preference Checklist will be used to determine the participant's preference for type of treatment, frequency of treatment sessions, and treatment delivery modality. Step 5 also includes following up with the patient and making changes if something it not working well for the patient."
224102293|NCT02446964|PROCEDURE|Bone Marrow Transplantation|Undergo bone marrow transplant
224102294|NCT02446964|DRUG|Cyclophosphamide|Given IV
223537754|NCT02227745|DRUG|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
223537755|NCT05773469|OTHER|Exercise|Ski traverse of Greenland polar Icecap
223537756|NCT05773469|OTHER|Nutrition|Maximising energy intake by consuming over the theoretical 2.4 x RMR
224102295|NCT02446964|DRUG|Fludarabine Phosphate|Given IV
224102296|NCT02446964|OTHER|Laboratory Biomarker Analysis|Correlative studies
224102297|NCT02446964|DRUG|Mycophenolate Mofetil|Given PO or IV
224102298|NCT02446964|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
223537757|NCT01174563|DRUG|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
223537758|NCT00020748|DRUG|epirubicin hydrochloride|
224102299|NCT02446964|DRUG|Tacrolimus|Given IV and PO
224102300|NCT02446964|RADIATION|Total Marrow Irradiation|Undergo TMLI
224102301|NCT04163783|DRUG|[14C]-BGB-3111|20-mg capsule containing \~200 μCi of \[14C\]-BGB-3111,
224102302|NCT04163783|DRUG|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
224102303|NCT04072640|DRUG|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
224102304|NCT04072640|DRUG|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
224102305|NCT04072640|DRUG|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
223537759|NCT00020748|DRUG|irinotecan hydrochloride|
223537760|NCT02427932|DRUG|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
223537761|NCT02427932|DRUG|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
223537762|NCT02427932|DRUG|Gentamicin|Prescribed to non-pregnant participants
223537763|NCT01761149|DRUG|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
223537764|NCT04670484|OTHER|Wearing Mask|Participants wearing masks as per federal guidelines to prevent Coronavirus spread
223722614|NCT01937728|DRUG|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
223722615|NCT03775655|DRUG|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
223537765|NCT01395745|DRUG|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
223537766|NCT01395745|DRUG|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
223537767|NCT03402841|DRUG|Olaparib|300 mg twice daily - oral
224102306|NCT00955110|DRUG|Oxymorphone ER|15mg or 30mg
224102307|NCT00955110|DRUG|Oxycodone CR|30mg or 60mg
224102308|NCT00955110|DRUG|Placebo|The placebo was a sugar pill.
224102309|NCT00955110|DRUG|Hydromorphone|8 mg
224102310|NCT03390231|COMBINATION_PRODUCT|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
224102311|NCT01756976|DEVICE|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
224102312|NCT06040177|DRUG|Cadonilimab|Cadonilimab will be administered within 2 weeks after the completion of the radiotherapy treatment once every 3 weeks (Q3W), for up to 2 years
224287973|NCT01353248|DRUG|ribavirin tablet|(weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
224287974|NCT01353248|DRUG|GS-5885|tablet, 90 mg QD
224287975|NCT00941720|DRUG|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
224287976|NCT00941720|DRUG|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
224287977|NCT00941720|PROCEDURE|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
224287978|NCT05299567|DRUG|Azithromycin|Placebo with the same color and size than azithromycin tree days a wek for 6 months
224287979|NCT01682148|BIOLOGICAL|Botulinum toxin type A|
224102313|NCT06040177|RADIATION|Stereotactic radiotherapy|Radiation therapy: Stereotactic radiotherapy (5-8Gy\*5F) for portal vein thrombus within 21 days after entry
224102314|NCT06040177|DRUG|Renvatinib|Renvatinib: 8mg (weight \<60kg) or 12mg (weight 60kg) once a day until disease progression, intolerable toxicity
223537768|NCT01198665|DRUG|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
223537769|NCT03174067|DRUG|Buprenorphine|The participant receives buprenorphine
224102315|NCT04430348|DRUG|PTX-35|Monoclonal antibody PTX-35
224102316|NCT05395169|OTHER|dietary supplement ,electronic treadmill ,DASH diet.|Control group Will be receive medical treatment for 12 weeks. Study group Will be receive the same medication as in control group in addition to DASH diet and aerobic exercise for 12 weeks.
224102317|NCT00368368|DRUG|GK Activator (2)|100mg po
224102318|NCT05574972|DEVICE|Timing Carotid Stent|all the participants in this group will be performed with Timing Carotid Stent
224102319|NCT05574972|DEVICE|Carotid Wallstent|all the participants in this group will be performed with Carotid Wallstent
224102320|NCT03623269|PROCEDURE|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
224102321|NCT05949125|OTHER|Cyclophosphamide (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
224102322|NCT05949125|OTHER|Fludarabine (Non-IMP, Lymphodepletion)|Intravenous infusion over 3 days (d-5 to d-3)
224102323|NCT05949125|DRUG|R-TM123|Intravenous infusion over 20 days
224102324|NCT05949125|DRUG|Allo-RevCAR01-T|Allo-RevCAR01-T will be administered as IV infusion on Treatment day 1.
223537770|NCT03174067|DRUG|Clonidine|The participant receives clonidine
223537771|NCT01347060|DRUG|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
223537772|NCT01347060|DRUG|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
223537773|NCT00178009|BEHAVIORAL|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
223722616|NCT06498999|BEHAVIORAL|4-STEP-Training Program for Social Media Addiction (4-STEP-TPS)|"4 Modules with 1 Module being delivered in 1 weekly session of approximately 90 minutes. The details of each module/step is described as follows:~Step 1 (Module 1): S = Screening, Assessment and Psychoeducation: Involves screening and assessment of the problem, interpretation of the results, feedback and psychoeducation, identifying and breaking the resistance, motivation, and conceptualization.~Step 2 (Module 2): T = Treatment Conceptualization and Planning: Involves pattern identification, distortion identification, as well as pattern and distortions modifications.~Step 3 (Module 3): E = Effective Management Strategies: Involves management strategies to treat the earlier identified patterns as well as the implementation and confirmation of activities via a Pattern Schedule Chart.~Step 4 (Module 4): P = Prevention (Lapse-Relapse): Involves self-reflection and support building, monitoring and dependency check and slip plans and support additions"
223722617|NCT05622084|DEVICE|Inperia Advance|Patients with infra-popliteal artery stenosis implanted with at least one Inperia Advance device
223722618|NCT03410550|DEVICE|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
223722619|NCT02314611|DEVICE|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
223722620|NCT00114036|BEHAVIORAL|Quality improvement strategies|
223722621|NCT00848705|BEHAVIORAL|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
224102325|NCT04260607|DRUG|Ketamine Hydrochloride|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect."
224102326|NCT04260607|DRUG|Normal saline|"Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion."
224102327|NCT05577754|DRUG|Alpelisib (BYL719)|Administration during open label and double-blind period of group B: alpelisib will be taken once a day each day over 24 mois During open label period of group A: alpelisib will be taken once a day each day over 24 months
224102328|NCT05577754|DRUG|Matching placebo|During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
224102329|NCT05577754|PROCEDURE|Optional lumbar puncture + blood sample|Between 6 and 24 months of treatment with Alpelisib
224102330|NCT03791970|DEVICE|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
224102331|NCT03791970|DEVICE|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
224287980|NCT06401967|BEHAVIORAL|Pivot Clear|A mobile app and program for alcohol reduction.
224287981|NCT06401967|DEVICE|BACtrack breathalyzer|Personal breathalyzer device that measures blood alcohol content.
223950575|NCT01020266|PROCEDURE|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
223950576|NCT05137366|DIAGNOSTIC_TEST|Transthoracic ultrasound scan|"An ultrasound scan of the thoracic aorta will be performed using an ultrasound machine with 2 MHz phased array transducer. The patient will lay supine on an ultrasound scan couch.The measurements will be taken in B-mode but colour Doppler imaging may be used to identify the thoracic aorta if it is obscured by artefacts. The measurement will be taken inner wall to inner wall and several images will be taken to check reliability.~Three different acoustic windows will be used to image the thoracic aorta:~1. Suprasternal window~2. Parasternal long axis window~3. Apical two chamber views~Ultrasound assessment will be considered satisfactory when at least two of the three regions of the descending thoracic aorta were visualised, partially satisfactory when a single view was obtained and inconclusive when none of the three windows could be obtained."
223950577|NCT03443206|OTHER|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
223950578|NCT03443206|OTHER|psychoeducation|educational materials related to mental health
223950579|NCT03443206|OTHER|online resources|links to online mental health resources
223950580|NCT00024245|DRUG|pralatrexate|
223950581|NCT00024245|DRUG|probenecid|
223950582|NCT01437540|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
223950583|NCT01437540|DRUG|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
223950584|NCT01039506|DRUG|CPT-11 based regimens|
223950585|NCT00130091|DRUG|clonidine|2 mcg clonidine added to local anesthetic
223950586|NCT04083209|BEHAVIORAL|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
223950587|NCT04417309|BEHAVIORAL|Experimental|Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
223950588|NCT04417309|BEHAVIORAL|Active Control|Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
223950589|NCT06470152|PROCEDURE|Correction strategy in reference to our PI-dependent clustering of sagittal alignment|For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI \> 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.
223950590|NCT06470152|PROCEDURE|Correction strategy in reference to the SAAS score|"This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1."
223950591|NCT05765526|DEVICE|A novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 10 minutes on the participant's scalp until half bottle (200ml) of water is used. Their scalp will then be rinsed and gently dried with a towel.
223950592|NCT01299285|DRUG|LY3009104|Administered orally
223537774|NCT00309283|DRUG|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
223950593|NCT03709225|BEHAVIORAL|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
223537775|NCT00309283|OTHER|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
223537776|NCT00100425|PROCEDURE|Viceral Perception Testing|
224287982|NCT05123781|DRUG|Metformin 1000 mg Prolonged Release Tablets (JSC Farmak, Ukraine)|One tablet of the test product was administered orally with 240 ml of water
223950594|NCT05147207|PROCEDURE|Superpath Approach|This is a minimally invasive surgical approach for THA.
223950595|NCT04059575|OTHER|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
224287983|NCT05123781|DRUG|Glucophage® XR 1000 mg Prolonged Release Tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orally with 240 ml of water
224287984|NCT06327217|RADIATION|Bilateral hip x-ray|Patients will be asked to visit the clinic for a bilateral hip x-ray, in order to evaluate the degree os osteoarthritis.
223537777|NCT02666560|DEVICE|Auditory Cueing|Auditory cueing set at different frequency rates
223537778|NCT05358002|PROCEDURE|Frontalis flap|Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
223537779|NCT00293176|DRUG|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
223537780|NCT00293176|DRUG|Placebo|Subjects will receive matching placebo tablets.
223537781|NCT01737892|DRUG|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
224102332|NCT03215914|DEVICE|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels \< 70 mg/dl.
224102333|NCT01737814|DRUG|Saline|
224102334|NCT01737814|DRUG|MST-188|
224102335|NCT00904124|DIETARY_SUPPLEMENT|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
224287985|NCT06327217|OTHER|Questionnaires|Patients will be asked to complete questionnaires on function, quality of life and pain (the modified Harris Hip Score (mHHS), Hip Outcome Score (HOS), the World Health Organisation Quality of Life Questionnaire (WHOWOL) and Visual Analogue Scale (VAS) for pain). One question will be asked: 'How satisfied are you with the results of the surgery?' on a 10-point scale.
224287986|NCT00688402|DRUG|AZD3355|Single dose
223537782|NCT01737892|DRUG|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
223537783|NCT00006379|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
223537784|NCT00006379|BIOLOGICAL|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
223537785|NCT00006379|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
223537786|NCT00006379|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
223537787|NCT00006379|PROCEDURE|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
223537788|NCT03732755|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
223537789|NCT00645502|DRUG|risperidone|
223537790|NCT01542788|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
223537791|NCT01542788|DRUG|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
223537792|NCT01542788|DRUG|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
223537793|NCT01542788|DRUG|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
223537794|NCT02112084|BEHAVIORAL|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
223537795|NCT05572294|BEHAVIORAL|Mindfulness meditation, breathing exercises (including incentive spirometry), and yoga therapy|Sickle cell patients admitted with a vaso-occlusive pain crisis over a consecutive 12-week period will be offered participation in the study. After providing informed consent, participants will have access to 4 videos containing guided mindfulness meditation, breathing exercises, and gentle yoga therapy. The videos are 5-12 minutes long and taught by a physical therapist who is also certified in yoga therapy. Participants may turn off the video at any time. Participants will have access to the videos for the duration of their hospitalization, and they may watch the videos as many times as they desire.
223537796|NCT03315585|DEVICE|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
223537797|NCT02972307|OTHER|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
223537798|NCT05781581|OTHER|no intervention|no intervention
223537799|NCT02092714|OTHER|laboratory biomarker analysis|Correlative studies
223537800|NCT05772871|DRUG|Huaiqihuang granule|Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
223537801|NCT05772871|DRUG|Prednisone|Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
223537802|NCT05772871|DRUG|Levamisole placebo|Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
223537803|NCT05772871|DRUG|Levamisole|Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
224102336|NCT06488196|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.
224102337|NCT06488196|OTHER|Treatment As Usual|TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
224102338|NCT04297644|OTHER|There is no intervention|There is no intervention
224102339|NCT02988648|RADIATION|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
224102340|NCT01671670|OTHER|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
223722622|NCT01672697|BEHAVIORAL|Physical Therapy (PT) and Behavioral Therapy (BT)|"1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
223722623|NCT01916213|PROCEDURE|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
223722624|NCT04949477|DRUG|Dexmedetomidine|the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.
223950596|NCT04059575|OTHER|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
223950597|NCT01205126|DRUG|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
223950598|NCT01205126|DRUG|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
224102341|NCT01671670|OTHER|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
224102342|NCT04902885|DRUG|Trilaciclib, carboplatin, etoposide，or Topotecan|Trilaciclib plus carboplatin, etoposide for first line patients ;Trilaciclib plus Topotecan for second or third line patients
224102343|NCT04902885|DRUG|placebo, carboplatin, etoposide，or Topotecan|placebo plus carboplatin, etoposide for first line patients ;placebo plus Topotecan for second or third line patients
224102344|NCT02652819|DRUG|FG-4592|
223537804|NCT05772871|DRUG|Huaiqihuang Granule placebo|Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
223537805|NCT00097279|DRUG|biphasic insulin aspart|
223537806|NCT00097279|DRUG|pioglitazone|
223537807|NCT00097279|DRUG|metformin|
223537808|NCT00946933|DIETARY_SUPPLEMENT|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
224102345|NCT02652819|DRUG|Placebo|
224102346|NCT01269567|PROCEDURE|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
224102347|NCT01269567|PROCEDURE|No pelvic drainage|no aspiration drain at the end of intervention
224102348|NCT00445783|GENETIC|gene expression analysis|
224102349|NCT00445783|GENETIC|mutation analysis|
224102350|NCT00445783|OTHER|immunohistochemistry staining method|
224102351|NCT00445783|OTHER|laboratory biomarker analysis|
224102352|NCT00445783|PROCEDURE|examination|
224102353|NCT00445783|PROCEDURE|mutation carrier screening|
224287987|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 5 minutes in the recovery room
224287988|NCT02898103|DEVICE|Sham stimulation|Sham (placebo) stimulation for 5 minutes in the recovery room
223537809|NCT00946933|DIETARY_SUPPLEMENT|placebo|0.025 g/kg/day of NaCl (sodium chloride)
224287989|NCT02898103|DEVICE|Percutaneous peripheral nerve stimulation|Active electrical stimulation for 2-4 weeks at home
223722625|NCT04949477|DRUG|paracetamol|the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
223722626|NCT00369616|BIOLOGICAL|CYT002-NicQb|
223722627|NCT03937310|DIAGNOSTIC_TEST|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
223950599|NCT01205126|DRUG|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
223950600|NCT03728452|PROCEDURE|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
224102354|NCT00445783|PROCEDURE|study of high risk factors|
224102355|NCT04648371|OTHER|Cognitive Remediation and Transcranial Direct Current Stimulation|"Cognitive Remediation (CR) is a well-established psychosocial group intervention that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.~Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation method that can be safely administered to awake outpatients. It does not require general anesthesia or surgical implantation. It utilizes low intensity electrical current (e.g., 2 mA) either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode."
224102356|NCT03940105|BEHAVIORAL|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
224102357|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)"
223537810|NCT04902209|PROCEDURE|postural stability measurements|"Static balance assessment on bi-module stabilometric platform CQStab2P. It registers the movement of centre of foot pressure (COP).~Harris hip score- disability assesment"
223537811|NCT02006108|DRUG|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
223950601|NCT05691400|DRUG|Palbociclib 125Mg Tab|125 mg single dose
223950602|NCT05691400|DRUG|Ribociclib 200Mg Oral Tablet|200 mg single dose
223950603|NCT05691400|DRUG|Abemaciclib 150 MG Oral Tablet|150 mg single dose
224102358|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg"
224287990|NCT03808584|OTHER|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
224287991|NCT03359915|BEHAVIORAL|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
224287992|NCT06287437|DRUG|HRS9531|HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
224287993|NCT06287437|DRUG|HRS9531 placebo|HRS9531 placebo low frequency injection for 12 weeks.
224287994|NCT05039476|DIETARY_SUPPLEMENT|Retinol face cream|Retinol face cream
223537812|NCT02006108|OTHER|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
223537813|NCT04253210|OTHER|psychological|Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
223537814|NCT05309967|OTHER|GLUMA DESINSITIZER|GLUTARALDEHYDE
223537815|NCT05309967|OTHER|PLACEBO|DESTILLED WATER
223537816|NCT00269113|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
224287995|NCT05039476|DIETARY_SUPPLEMENT|Placebo face cream|Placebo face cream
223537817|NCT00269113|DRUG|Standard chemotherapy|As prescribed
223537818|NCT05593354|DEVICE|Micropulse Transscleral laser therapy|Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine
224287996|NCT01803269|DRUG|topotecan hydrochloride|Given IV
224287997|NCT01803269|DRUG|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
224287998|NCT05839327|DIAGNOSTIC_TEST|Montreal cognitive assessment scale (MOCA)|Tests to evaluate cognitive disorders (MOCA), anxiety and depression (HADS) Pos-traumatic stress disorder (PCL-C) and quality of life (SF-36)
224287999|NCT01726127|OTHER|Broccoli and Brussels Sprouts|
224288000|NCT01726127|DIETARY_SUPPLEMENT|Cruciferous Complete|
224288001|NCT01726127|OTHER|Placebo|
224288002|NCT00006473|DRUG|oxaliplatin|Given IV
224102359|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)"
223950604|NCT01617811|PROCEDURE|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
223950605|NCT00486954|DRUG|Lapatinib|6 pills at 250 mg each once daily
223950606|NCT00486954|DRUG|Paclitaxel|Infusion at 80 mg/m2 weekly
223950607|NCT03230448|OTHER|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
223950608|NCT03340662|DRUG|CC-122|CC-122
223950609|NCT03340662|DRUG|Itraconazole|CYP3A Inhibitor
223950610|NCT03340662|DRUG|Fluvoxamine|CYP1A2 Inhibitor
224102360|NCT03019055|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
224102361|NCT02526849|DRUG|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
224102362|NCT02526849|BEHAVIORAL|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
224102363|NCT00410371|DRUG|Lamotrigine|Lamotrigine
224102364|NCT00410371|DRUG|GI267119|25 mg ODT
224102365|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
224102366|NCT04819672|OTHER|Low Intensity Training associated with Partial Blood Flow-Sham|16 treatment sessions in 8 weeks: warm-up, stretching of the lower limbs, strengthening of the quadriceps, hamstrings, sural triceps, abductors and adductors of the hip. The Partial blood flow restriction will be used during knee extension and squat exercises. During the exercises, a metronome will be used for the time under tension, 2 seconds for the eccentric and concentric phase.
224102367|NCT05733481|DEVICE|CapBuster System Medical Device for the Crossing of Chronic Total Occlusions in Coronary Arteries|The CapBuster System is a medical device intended to facilitate the intraluminal placement of conventional guidewires beyond chronic total occlusions prior to the utilization of interventional devices. The device system, manufactured by Praxis Medical, comprises the CapBuster support catheter and CapBuster penetrating wire which are mated together with a screw thread.
223537819|NCT00322049|BIOLOGICAL|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
223537820|NCT00322049|BIOLOGICAL|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
223537821|NCT04119752|DIETARY_SUPPLEMENT|Curcumin powder|10g of curcumin powder
223722628|NCT03733795|OTHER|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
223722629|NCT03912155|OTHER|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
223950611|NCT03340662|DRUG|Rifampin|CYP3A Inducer
223950612|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) implemented at the patient home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
223950613|NCT05727111|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living."
224102368|NCT02094469|DRUG|Cilostazol|Oral, Bid, 24 weeks
224102369|NCT04336150|OTHER|Hypopressive exercises|See information included in arm/group descriptions.
224102370|NCT04336150|OTHER|Hypopressive maneuver|See information included in arm/group descriptions.
224102371|NCT04336150|OTHER|Hypopressive exercises plus pelvic floor muscle contraction|See information included in arm/group descriptions.
223537822|NCT04119752|DIETARY_SUPPLEMENT|Placebo|1g of sucralose
224102372|NCT04336150|OTHER|Hypopressive maneuver plus pelvic floor muscle contraction|See information included in arm/group descriptions.
224288003|NCT05699291|OTHER|Sentinel node detection technique|Patients cared for by a surgeon for histologically proven breast cancer and for whom an indication for detection of the sentinel lymph node is posed.
223537823|NCT01283438|DEVICE|Barricaid|Annular closure device
223537824|NCT01283438|DEVICE|Standard of Care|Standard Limited discectomy
223537825|NCT01031888|DRUG|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
223722630|NCT01011634|DRUG|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
223722631|NCT05544357|OTHER|Short set configuration resistance training|Resistance training protocol with the lowest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
224102373|NCT03356847|DEVICE|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
223722632|NCT05544357|OTHER|Long set configuration resistance training|Resistance training protocol with the highest cardiovascular stress identified in the first study of the project. It can be expected to be a short set configuration protocol
223722633|NCT03147014|BIOLOGICAL|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
224102374|NCT06330753|OTHER|Trauma-informed Care Plan-|Per our IRB protocol patient participates will be consented for this study. A member of the healthcare team ( licensed nurse, social worker or doctor) will conduct the TICP with the patient. The TICP will be placed in the electronic medical record right below the patients name. The workflow is such is that if any plan of care placed on the Storyboard (under the patient's name) should be read first before engaging with a patient.
224102375|NCT01380756|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
223537826|NCT01031888|DRUG|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
223722634|NCT01357187|OTHER|Scheduled removal of posterior instrumentation with AmnioFix|
223722635|NCT01357187|OTHER|Scheduled removal of posterior instrumentation without AmnioFix|
223722636|NCT00309387|DIETARY_SUPPLEMENT|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
224102376|NCT01380756|DRUG|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
224102377|NCT00082823|BIOLOGICAL|ziv-aflibercept|
224288004|NCT05032326|DRUG|Follow-up study of the treated cohort|follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
224288005|NCT05032326|OTHER|Follow-up study of the untreated cohort|follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
224288006|NCT03793920|OTHER|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
224288007|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops|
224288008|NCT01869426|DIETARY_SUPPLEMENT|VSL#3 drops placebo|
223537827|NCT04832347|OTHER|Exercise|Exercise Group will be given stabilization exercises for a total of 24 sessions, 3 times a week for 8 weeks, each session for 45 minutes.
223537828|NCT04832347|OTHER|Vagus Nerve Stimulation|Vagus therapy will be applied for 8 weeks, 3 times a week for a total of 24 sessions, each session for 30 minutes.
223537829|NCT00848263|PROCEDURE|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
223722637|NCT00309387|OTHER|Placebo|placebo tablets manufactured to mimic Centrum tablets.
224288009|NCT00627081|DRUG|remifentanil|dosage
224288010|NCT01202877|DRUG|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
224288011|NCT01202877|DRUG|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
223722638|NCT04498013|DRUG|Cyclodynon|Cyclodynon 1 tablet a day during 6 menthes period.
223537830|NCT00848263|PROCEDURE|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
224102378|NCT04642144|OTHER|Yerba mate infusion|"Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate."
224102379|NCT04642144|OTHER|Carbohydrate meal|Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
223950614|NCT05727111|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) at the patient's home|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 1 hour per day (4 hours per week in autonomy and 1 hour per week under supervision).
223950615|NCT05727111|BEHAVIORAL|Usual care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
224102380|NCT00440323|DRUG|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
224102381|NCT00440323|DRUG|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
224102382|NCT00440323|DRUG|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
223537831|NCT04106115|DRUG|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
223950616|NCT01751295|DRUG|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
223950617|NCT00903214|DRUG|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
223950618|NCT00903214|GENETIC|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
223950619|NCT00903214|PROCEDURE|axillary lymph node biopsy|
223950620|NCT00903214|PROCEDURE|digital image analysis|
223950621|NCT00903214|PROCEDURE|needle biopsy|
223950622|NCT00903214|PROCEDURE|sentinel lymph node biopsy|
223950623|NCT00903214|PROCEDURE|therapeutic conventional surgery|
223950624|NCT06169345|OTHER|Echocardiographic evaluation|Echocardiographic follow-up
223950625|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (60 perturbations)|The intervention involves exposing participants to a series of 60 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by 5 epochs to assess motor flexibility. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
223950626|NCT06076525|BEHAVIORAL|Multidirectional Perturbations for Balance Control Assessment (150 perturbations)|The intervention involves exposing participants to a series of 150 controlled multidirectional perturbations while walking on a treadmill. These perturbations are delivered in varying directions and magnitudes to simulate real-world conditions that might lead to a loss of balance, such as slips or trips. Participants will undergo this series during multiple experimental sessions referred to as epochs. The complete intervention consists of a treadmill familiarization period followed by seven epochs. The first five epochs will deliver multidirectional perturbations to assess modifiability of motor flexibility, followed by a sixth epoch to test generalization to novel perturbation directions while walking. Finally there will be a seventh epoch of perturbations while standing to test generalization from walking balance control to standing balance control. Each epoch is followed by a rest period to ensure participant safety and minimize fatigue.
223950627|NCT02445404|DRUG|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
223950628|NCT02445404|DRUG|fractionated ICED|ifosfamide, 1.67 g/m² IV day1\~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1\~3 dexamethasone 40 mg PO or IV day1\~4 every 3 weeks
223950629|NCT05889832|DIAGNOSTIC_TEST|measurement of physiological parameters wih Shen.AI Vitals software on various camera-equipped devices (smartphones, tablets, laptops)|"Resting heart rate (HR), heart rate variability (HRV) and breathing rate (BR) will be measured (estimated) with the use of remote photoplethysmography (1-minute face video analysis with Shen.AI Vitals software).~Reference measurements will be taken simultaneously (chest ECG for the calculation of HR and HRV; impedance pneumography for BR)."
223950630|NCT01967394|OTHER|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
223950631|NCT01967394|OTHER|No use of social media|No social media ads will be available in these counties.
223950632|NCT04702594|BEHAVIORAL|Music therapy session via tools validated by MUSIC CARE|Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
223950633|NCT01765855|DRUG|Betrixaban single oral dose|
223950634|NCT03332316|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone injection
223950635|NCT03332316|DRUG|Ropivacaine Hydrochloride Inj 2 mg/ml|Ropivacaine injection
223950636|NCT03332316|DRUG|Sodium Chloride 9mg/mL|Sodium Chloride injection
223950637|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
224102383|NCT00308815|DEVICE|Automatic CPR machine|
224102384|NCT06338644|DRUG|Palbociclib|3 weeks on, 1 week off
224102385|NCT00756002|DRUG|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
224288012|NCT00396331|DRUG|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.
224102386|NCT00756002|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
224102387|NCT01928979|OTHER|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
224102388|NCT03040050|OTHER|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
224288013|NCT06617130|DIETARY_SUPPLEMENT|Corn soy bean blended flour porridge plus indispensable amino acid|"Protocol treatment will start within two weeks of enrollment to the study. Following the baseline study assessments, each participant will receive corn-soy bean blended flour porridge supplemented with IAAs (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine) dosed at 12g/d and providing 1.5 times the estimated average requirement (EAR) for a healthy child (Intervention group). The porridge will provide 30% daily energy requirement. The study foods will be taken once daily by the child with at least three observed feeding sessions per week over the 4 weeks of the study to assess compliance.~Children in the control arm will receive corn-soy blended flour porridge without added amino acids."
223722639|NCT04498013|BEHAVIORAL|Lifestyl modification|Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
224288014|NCT06605625|BIOLOGICAL|Influenza vaccination|one annual dose of inactivated influenza vaccine
224288015|NCT06605625|BIOLOGICAL|SARS-CoV-2 vaccine|dose of SARS CoV2 vaccine
224288016|NCT06605625|BIOLOGICAL|Zoster Vaccine Recombinant|first and/or second vaccination for shingles (Herpes zoster)
224288017|NCT01884584|DRUG|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
224288018|NCT02288208|DRUG|Antiviral Therapy (tenofovir or entecavir)|
223722640|NCT05360381|DRUG|HLX35|A Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody, HLX35 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
224288019|NCT02288208|DRUG|Birinapant|
223722641|NCT02483520|BEHAVIORAL|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
223722642|NCT00070278|DRUG|cyclophosphamide|
223722643|NCT00070278|DRUG|epirubicin hydrochloride|
223722644|NCT00070278|DRUG|gemcitabine hydrochloride|
224102389|NCT03040050|OTHER|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
224102390|NCT00666185|DRUG|Micafungin|IV
224102391|NCT00666185|DRUG|Fluconazole|IV
224102392|NCT02454114|OTHER|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
224102393|NCT02454114|OTHER|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
224102394|NCT04691258|BEHAVIORAL|Experimental: Complete Group|"The participants performed the squat and Stiff exercises with the maximum range of motion. In the squats, the knees were completely flirted, even if the participant could not perform the movement with neutral vertebral posture. The heels were also not supported to the ground in some participants due to lack of flexibility. It was instructed that the participants tried to perform the Squats and Stiff keeping the lumbar lordosis neutral, with the best posture they could in all training sessions, but all should perform the exercise with as much range of motion as possible.~The positioning of the feet was also carefully controlled, there was no hip rotation and the distance between the lateral edges of the heels was defined as the distance between the upper iliac spines (EIAS). The direction of the knees was oriented pointing in the direction of the tip of the feet parallel throughout the cycle of the movement."
224288020|NCT02288208|DRUG|Placebo (for birinapant)|
223722645|NCT00070278|DRUG|paclitaxel|
223722646|NCT00070278|GENETIC|comparative genomic hybridization|
223722647|NCT00070278|GENETIC|microarray analysis|
223722648|NCT00070278|GENETIC|mutation analysis|
223722649|NCT00070278|PROCEDURE|conventional surgery|
223722650|NCT00070278|PROCEDURE|neoadjuvant therapy|
224102395|NCT04691258|BEHAVIORAL|Active Comparator: Restricted Group|"The conventional movement technique of the squat exercise was used, in which the participants performed with the range of motion restricted to the neutral vertebral posture, approximately 90º of movement of the knee joint. may increase the range of motion if the lumbar posture did not rectify.~The positioning of the feet in this group was carefully controlled, the participants performed the exercise with the joints of the hips abducted and rotated laterally. Having markings on the ground as a reference, the feet went rotated at 21º and the lateral edge of the heels were moved away from each other, approximately with the biacromial distance. The direction of the knees was oriented pointing in the direction of the tip of the feet throughout the cycle of the movement, aligned to the lateral rotation of the hip. In the first training session, with the aid of a goniometer and metric tape, adhesive marks were placed on the floor to ensure this positioning of the support base."
223722651|NCT03141476|DRUG|Cefuroxime 1,5g|Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime
223537832|NCT04106115|BIOLOGICAL|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
223950638|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
223950639|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
223950640|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
223950641|NCT01836523|DRUG|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
223950642|NCT01836523|DRUG|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
223950643|NCT04728035|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection
223950644|NCT04169802|DIAGNOSTIC_TEST|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
223950645|NCT04169802|DIAGNOSTIC_TEST|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
223950646|NCT02462278|DEVICE|TempuRing|
223950647|NCT03914586|DEVICE|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
223950648|NCT00321971|BEHAVIORAL|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
223537833|NCT02026011|DRUG|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
223537834|NCT02026011|DRUG|Placebo|Sugar pill, matched to the active study medication in capsule size and color
223537835|NCT01400009|DRUG|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
223950649|NCT00321971|BEHAVIORAL|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
223950650|NCT05640245|DRUG|Sonelokimab|randomized treatment; parallel group
223950651|NCT05640245|DRUG|Placebo|randomized treatment; parallel-group
223537836|NCT01400009|DRUG|Placebo|Standard Placebo made of Lactose 100 mg
223950652|NCT05640245|DRUG|Adalimumab|randomized treatment; parallel-group
223950653|NCT05309057|DIETARY_SUPPLEMENT|Intermittent Fasting|Methods of intermittent fasting strategies, continuous energy restriction, and ad libitum diet.
223950654|NCT03898999|OTHER|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
223722652|NCT03141476|DRUG|Cefuroxime 3g|Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime
224102396|NCT00257127|BIOLOGICAL|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
224102397|NCT00257127|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
223722653|NCT03141476|DRUG|Cefuroxime 4,5g|Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime
223950655|NCT00304642|DRUG|dapivirine (TMC120) vaginal gel|
223950656|NCT02414594|DRUG|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
223950657|NCT02414594|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223950658|NCT02705885|DIETARY_SUPPLEMENT|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
223950659|NCT02705885|DIETARY_SUPPLEMENT|Placebo IgY|Placebo IgY
223950660|NCT01333709|DRUG|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
223950661|NCT01333709|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
224102398|NCT00257127|BIOLOGICAL|Hepatitis B vaccine|0.5 mL administered intramuscularly
224102399|NCT00257127|BIOLOGICAL|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
224102400|NCT05932433|BEHAVIORAL|Exercise|Each session (45 minutes aprox) is made by: mobility, endurance and final exercise to rest. The sesion is going to perform twice a week during 6 weeks.
224102401|NCT06497647|DRUG|Sulbutiamine|"sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C"
224102402|NCT06497647|DRUG|Imipramine|"imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C"
224102403|NCT02749487|OTHER|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
224102404|NCT06584279|DIAGNOSTIC_TEST|Biopsy of the prostate and pathological diagnosis|Whether the index-lesion-contralateral systematic biopsy was performed
224102405|NCT02416869|PROCEDURE|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
224288021|NCT05631821|PROCEDURE|differential rod bending with rod contours (MESA Spinal System)|differential rod bending with rod contours and Mesa Spinal system evaluate the correction of adolescent idiopathic scoliosis deformity achieved utilizing a technique of differential rod bending with rod contours pre-operatively determined from a best-fit measure utilizing a computer-based software tool
223950662|NCT01333709|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
223950663|NCT01333709|RADIATION|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
223950664|NCT01333709|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
223950665|NCT02290353|DEVICE|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer \[2\]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
223950666|NCT01721694|DRUG|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
224102406|NCT02416869|PROCEDURE|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
224102407|NCT02416869|DRUG|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
224102408|NCT02416869|DRUG|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
224102409|NCT02416869|PROCEDURE|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
224102410|NCT02416869|PROCEDURE|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
224288022|NCT02377180|PROCEDURE|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
224102411|NCT03511365|BIOLOGICAL|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
224102412|NCT00644592|DRUG|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
224102413|NCT00644592|DRUG|Fenofibrate|160 mg/day orally for 4 weeks
224102414|NCT01120639|DRUG|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
224102415|NCT01120639|PROCEDURE|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
224288023|NCT02377180|PROCEDURE|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
224102416|NCT01839474|DEVICE|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
224102417|NCT02939521|PROCEDURE|Surgery|
224102418|NCT02852226|OTHER|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
223950667|NCT01721694|DRUG|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
224102419|NCT02852226|BEHAVIORAL|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
224102420|NCT02852226|BEHAVIORAL|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
224102421|NCT01147783|OTHER|CT, MRI|
224102422|NCT04988230|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
224102423|NCT04988230|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/ d for men and 1200-1500kcal/d for women, without restriction on feeding time.
223950668|NCT04271865|OTHER|Nutritional Education|Provision of weekly awareness and educational sessions for 6 months. Sessions were conducted at the community based associations within the cases respective villages. Cases were subjected to 24 sessions for improving the patients' own nutrition situation through nutritional education about food rich in iron and counselling. The sessions focused on basic knowledge on iron deficiency anaemia, the most common presenting symptoms, iron rich dietary sources, factors that enhance and inhibit iron absorption, effects of anaemia on health and how to prevent it, Role of dates fruit in preventing and treating anaemia. Th e sessions also focused on the provision of a diverse range of local iron rich food. Special focus was on increasing patients' awareness for self-management of their status
223950669|NCT04271865|OTHER|model nutrition kitchen|Implementing model nutrition kitchen; once every month for six months with six sessions for each village (6 sessions/village) with cooking sessions was done to promote eating healthy and provide innovative ideas for feeding anaemic cases. 117 patients were reached by the nutritional kitchen activities with 6 sessions until the end of the project. Special focus was done on skills like sharing cooking, meal planning, and label reading that help support healthy eating patterns. Suggesting ways that individuals can model healthy eating behaviors for friends and family members that is based on Dates fruit was encouraged.
223950670|NCT04271865|OTHER|recipe book|3\) Development of recipe book that is based on the local food in the market to increase the number of nutritionally balanced meals and increase the frequency of iron-rich foods per day and improve current and risky nutritional habits
224102424|NCT00749606|BEHAVIORAL|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
224102425|NCT00749606|BEHAVIORAL|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
224102426|NCT04979884|DRUG|cyclosporine|Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
224102427|NCT03088579|DEVICE|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
224102428|NCT01879020|DRUG|TA-8995|Drug: TA-8995 1mg
224102429|NCT01879020|DRUG|TA-8995|Drug: TA-8995 2.5mg
224102430|NCT01879020|DRUG|TA-8995|Drug: TA-8995 5mg
224102431|NCT01879020|DRUG|TA-8995|Drug: TA-8995 10mg
224102432|NCT01879020|DRUG|TA-8995|Drug: TA-8995 25mg
224102433|NCT01879020|DRUG|Placebo|Placebo (TA-8995 1mg)
224102434|NCT01879020|DRUG|Placebo|Placebo (TA-8995 2.5mg)
224102435|NCT01879020|DRUG|Placebo|Placebo (TA-8995 5mg)
224102436|NCT01879020|DRUG|Placebo|Placebo (TA-8995 10mg)
224102437|NCT01879020|DRUG|Placebo|Placebo (TA-8995 25mg)
224102438|NCT00783640|DRUG|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
224102439|NCT05146908|BIOLOGICAL|2 Blood samples from arterial and/or central venous catheters|5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
224102440|NCT05146908|OTHER|Echography|"In 3 steps:~* before initiation of enteral nutrition~* 4h after initiation of enteral nutrition~* After 24 hours of enteral nutrition"
224102441|NCT05146908|OTHER|Data collection|"At inclusion:~Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.~Within the first 24 hours, collection of:~* echographic parameters at H0, H4 and H24~* venous congestion parameters~* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)~Within the first 7 days, collection of:~* the occurrence or not of the primary endpoint (and time to occurrence).~* symptoms of gastrointestinal dysfunction~Within 30 days, collection of:~* organ failure and replacement over the period, and mortality.~* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study."
224102442|NCT04748263|OTHER|No intervention. Only survey and normal use of eye-tracking|"The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE."
224102443|NCT00892437|DRUG|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
224102444|NCT00892437|DRUG|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
224288024|NCT02377180|PROCEDURE|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
224102445|NCT00892437|DRUG|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
224102446|NCT00892437|DRUG|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
224102447|NCT00892437|DRUG|COBI placebo|Placebo to match COBI administered orally once daily
224102448|NCT00892437|DRUG|RTV placebo|Placebo to match RTV administered orally once daily
224288025|NCT06050876|PROCEDURE|Laparoscopic cholecystectomy for gallbladder volvulus|Laparoscopic cholecystectomy for volvulus of gallbladder
224288026|NCT04373382|BEHAVIORAL|Peer Resilience Champion|PRC is supplied to everyone and provides support to hospital staff during the COVID-19 pandemic in a stepped-wedge design.
224288027|NCT04373382|BEHAVIORAL|Enriched Survey Feedback|This intervention provides feedback based on answers to questionnaires to those in the Enriched Feedback arm of the study.
224102449|NCT05187169|DRUG|VS-6766|Dual RAF/MEK inhibitor
224102450|NCT02950129|OTHER|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
223950671|NCT04271865|OTHER|Provision of Dates|"Dates fruit intake for all the anaemic patients was provided for 16 weeks (four months):~• Diagnosed anemic patients were given five to seven pieces of Dates (dependent on its weight) on daily basis for 16 weeks (each date fruits is about 10 -20 gm). Dates was taken as breakfast on daily base.~The Dates fruit that was used during the proposed trial is Saudi's Dates extract know as Barni which is organic Dates. The fruit is mentioned more than 20 times in the Quran, This Barni is known for its very high nutritive value (vitamins, minerals and antioxidants) compared with other Dates types. The nutritive value of Barni is shown in the below table, calculated per every 100 gram (range 5- 10 pieces) of dry weight (DW) :~The nutritive value of Barni calculated per every 100 gram (average 7-10 pieces) of dry weight (DW) of which iron constitutes 6.78 mg that represent 67.8 % of the recommended dietary allowance (RDA) of the males and 45.20 % of the RDA of the females"
224102451|NCT05057728|BEHAVIORAL|Social-Emotional Prevention Program enhanced version|The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
224102452|NCT03185130|DRUG|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
224102453|NCT03185130|DRUG|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
224102454|NCT03185130|DRUG|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will receive prochlorperazine 0.15 mg/kg up to 10mg IV slow push
223950672|NCT01648114|OTHER|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
223950673|NCT04181385|DRUG|Olanzapine 10 milligram|Oral olanzapine capsule
223950674|NCT04181385|DRUG|Bromocriptine 5 milligram|Oral bromocriptine capsule
223950675|NCT04181385|DRUG|Placebo oral tablet|oral placebo capsules
223950676|NCT01780272|OTHER|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
224102455|NCT03185130|DRUG|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
224102456|NCT05936086|DRUG|Cytoxan|Cytoxan 40mg/kg iv qd x 2days (day 1 and 2);
224102457|NCT05936086|DRUG|Etoposide|etoposide(VP16):150 mg/m2, twice a week, 1-2 weeks; 150mg/m2, once a week for the 3rd to 6th week.
224102458|NCT05936086|DRUG|Dexamethasone|Dexamethasone: 10 mg/m2/day, week 1 to 2; 5 mg/m2/d for the 3rd to 4th week; 2.5 mg/m2/ day at week 5-6.
224102459|NCT05936086|DRUG|Cyclosporine (CSA)|Cyclosporine (CSA) 100mg Bid, week 1 to 6 (dosed according to 2004 version).
224102460|NCT01925703|DRUG|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
224102461|NCT03392129|OTHER|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
224102462|NCT03392129|OTHER|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
224102463|NCT01860170|DRUG|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
224288028|NCT04010916|OTHER|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
223537837|NCT05626933|PROCEDURE|Buccinator myomucosal flap with Furlow palatoplasty|Anatomical restoration concept using Buccinator myomucosal flap with Furlow palatoplasty is an effective technique for lengthening the palate and improving speech outcomes
223537838|NCT01770743|BIOLOGICAL|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
223537839|NCT01770743|BIOLOGICAL|BioThrax|
223537840|NCT00000906|DRUG|Ritonavir|
223537841|NCT00000906|DRUG|Saquinavir|
223537842|NCT00000906|DRUG|Methadone hydrochloride|
223537843|NCT05067205|PROCEDURE|Carpal tunnel release surgery|Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
224102464|NCT01860170|DRUG|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
224102465|NCT01860170|DRUG|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
224102466|NCT03064282|OTHER|Placebo|observation of skin changes if any
224102467|NCT03064282|DRUG|papaverine|observation of symptoms
223722654|NCT03258489|DEVICE|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
223950677|NCT03264222|OTHER|Security screening procedure|Screening procedure with security device (model QPS 100)
223950678|NCT02212626|DEVICE|Rotarex S|
223950679|NCT06340984|DRUG|Montelukast 10 Mg Oral Tablet|group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group
224102468|NCT04168086|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
224102469|NCT04168086|OTHER|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
224102470|NCT02832089|DRUG|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
224102471|NCT03823729|DEVICE|Elosan Cabin|The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
223950680|NCT03308500|BEHAVIORAL|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
223950681|NCT03308500|BEHAVIORAL|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
223950682|NCT00037934|DEVICE|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
224102472|NCT03390829|OTHER|semi-directed interviews|semi-directed interviews
224102473|NCT02284724|PROCEDURE|Dry Needling|
224102474|NCT02284724|PROCEDURE|Sham Needling|
224102475|NCT04509089|DEVICE|Suremedix Device|Performing measurements using the Suremedix Device by applying gradually ascending air pressure to the subject lungs through a mouse piece while measuring respiratory chest motion, PPG and ECG.
224102476|NCT00540215|OTHER|Glucagonlike peptide|450 nmol native form, synthetic
224102477|NCT03851601|OTHER|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
224102478|NCT05343195|OTHER|Task-oriented exercise|Task-oriented exercise program for patients after total hip replacement.
224102479|NCT05343195|OTHER|Control|Control intervention: conventional physiotherapy after hip replacement
224102480|NCT01882725|DEVICE|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
223722655|NCT03258489|DEVICE|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
223722656|NCT03258489|DEVICE|TENS and IES Placebo|Same protocol without electrical output.
223950683|NCT00037934|OTHER|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
223950684|NCT00579839|PROCEDURE|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
223950685|NCT00579839|PROCEDURE|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
224102481|NCT04562337|DRUG|SHR1316|Anti-PD-L1 antibody
223950686|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
224102482|NCT04562337|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
224102483|NCT04562337|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
224102484|NCT04562337|RADIATION|Radiation therapy|Thoracic radiation therapy ,TRT
224102485|NCT04562337|DRUG|Cisplatin|Cisplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
224102486|NCT04236453|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
224102487|NCT04236453|DRUG|Darunavir|Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
224102488|NCT04236453|DRUG|Emtricitabine/Tenofovir Alafenamide|Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
223722657|NCT00084721|DRUG|celecoxib|
223722658|NCT00084721|DRUG|irinotecan hydrochloride|
223950687|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing \<40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
224102489|NCT04236453|DRUG|Cobicistat|Participant will receive a single dose of Cobicistat tablet orally on Day 1.
224102490|NCT01854177|DRUG|Aprepitant|
224102491|NCT01854177|DRUG|Placebo|
224102492|NCT03155451|DIAGNOSTIC_TEST|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
224102493|NCT00552266|DRUG|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
224102494|NCT05516329|DRUG|A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide|The patients will be intravenously injected with 18F-Thretide and undergo PET/CT scan at 60\~120 min after the injection.
224102495|NCT05352685|DRUG|Propofol Injection|1% propofol is used for target-controlled infusion, and gradually increase the effect concentration at 0.2ug/ml. Make the subject's sedation depth reach light sedation and deep sedation respectively. EEG data were collected during wakefulness, light sedation, deep sedation, and recovery.
224102496|NCT01519726|DRUG|Midazolam|
224102497|NCT01238120|DRUG|Ibuprofen|200 mg BID and 8 hours apart
224102498|NCT01238120|BEHAVIORAL|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
224102499|NCT01238120|DRUG|Placebo|200mg BID and 8 hours apart
224102500|NCT04386889|OTHER|Vasculitis In SLE|20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
224102501|NCT01661257|DRUG|Infliximab|
223950688|NCT01513902|DRUG|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing \<30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
223950689|NCT00251147|PROCEDURE|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
224102502|NCT01906437|DEVICE|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
224102503|NCT04558697|DRUG|Shepherd's Purse extractum oleosum vagitories|Shepherd's Purse extractum oleosum vagitories will be administered once daily for 5 days
224102504|NCT04558697|DRUG|Tea tree oil vagitories|Tea tree oil vagitories will be administered once daily for 5 days
224102505|NCT04558697|DRUG|Hyperici extractum oleosum vagitories|Hyperici extractum oleosum vagitories will be administered once daily for 5 days
224102506|NCT04558697|DRUG|Vagitories - Probiotic|Vagitories - Probiotic will be administered once daily for 5 days
224102507|NCT03835663|DIAGNOSTIC_TEST|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
224102508|NCT02167477|DEVICE|Macintosh laryngoscopy|Tracheal intubation
224102509|NCT02167477|DEVICE|Storz C-MAC, standard blade|Tracheal intubation
224102510|NCT02167477|DEVICE|Storz C-MAC, D-BLADE|Tracheal intubation
224102511|NCT02048514|DEVICE|The Nellix® EndoVascular Aneurysm Sealing System|
224102512|NCT06075940|DEVICE|MAGNITUDE BRS|Treatment with the MAGNITUDE Scaffold
224102513|NCT04896177|DEVICE|Sirolimus drug-eluting coronary balloon catheter|Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
224102514|NCT04896177|DEVICE|Paclitaxel drug-eluting coronary balloon catheter|Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
224102515|NCT00269763|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
224102516|NCT00699790|DRUG|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
224102517|NCT00699790|DRUG|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
224102518|NCT00019955|PROCEDURE|laparoscopic surgery|
224102519|NCT00019955|PROCEDURE|radiofrequency ablation|
224102520|NCT00019955|PROCEDURE|thermal ablation therapy|
224102521|NCT03338946|DEVICE|CIED interrogation|CareLink Express interrogation
224102522|NCT04881877|DEVICE|Synthetic nitrite Condom|The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
224102523|NCT04881877|DEVICE|Latex and graphene Condom|The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
224102524|NCT04881877|DEVICE|Standard latex condom|The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
224102525|NCT04273984|DRUG|Misoprostol|Tablets will be inserted digitally by an experienced gynecologist 3hours before IUD insertion with taking care not inserting the medication into the cervix.
224102526|NCT04733820|DRUG|Adjuvant chemotherapy|Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
224102527|NCT01415960|DRUG|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
224102528|NCT04520789|DIAGNOSTIC_TEST|RPE cell collection and single cell heterogeneity study|Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients, the percentage of which decides the risk of serious PVR occurring after surgery.
224102529|NCT04520789|PROCEDURE|Postoperative intervention|Early local steroids drug intervention in patients with severe postoperative PVR
224102530|NCT04520789|PROCEDURE|Conventional Surgery for Retinal Detachment|Conventional Surgery for Retinal Detachment
224102531|NCT02167061|DRUG|DA-1229_01|complex single administration
224102532|NCT02167061|DRUG|E+M|co-administration of 2 drugs
224102533|NCT02167061|DRUG|DA-1229_01 fast|
223950690|NCT00251147|PROCEDURE|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
223950691|NCT04570488|OTHER|EPIC risk score display|Display of risk score/ colored flag in Epic patient list column
223950692|NCT04323514|DIETARY_SUPPLEMENT|Vitamin C|10 gr of vitamin C intravenously in addition to conventional therapy.
223950693|NCT02254902|BEHAVIORAL|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
223950694|NCT01924117|OTHER|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
223950695|NCT00783185|BEHAVIORAL|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
223950696|NCT00783185|BEHAVIORAL|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
223950697|NCT01393600|DRUG|NBI-98854|12.5 mg powder in bottle once daily for 14 days
223950698|NCT01393600|DRUG|NBI-98854|50 mg powder in bottle once daily for 14 days
223950699|NCT01393600|DRUG|Placebo|Solution containing no active substance
223950700|NCT03848741|BEHAVIORAL|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
223950701|NCT03848741|BEHAVIORAL|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
223950702|NCT03848741|DIETARY_SUPPLEMENT|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
223950703|NCT03848741|DIETARY_SUPPLEMENT|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
223950704|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
224102534|NCT02167061|DRUG|DA-1229_01 fed|
224102535|NCT01901744|PROCEDURE|Cataract Surgery|
224102536|NCT04242030|OTHER|Moxibustion|"Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm."
224102537|NCT04242030|DEVICE|Laser doppler flowmetry|Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena for the Heart meridian and Lung meridians.
224102538|NCT00234949|DRUG|cefdinir|
224102539|NCT00234949|DRUG|cephalexin|
224102540|NCT00003565|DRUG|docetaxel|
224102541|NCT01382069|DRUG|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
224102542|NCT01382069|DRUG|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
224102543|NCT04278742|OTHER|Patient education|Using a collaborative approach to engage patients in their own care, allowing patients to continue to have full control of their treatment. The clinician and patient co-creates the treatment plan.
224288029|NCT04010916|OTHER|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
224288030|NCT04010916|OTHER|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
224288031|NCT04855448|DEVICE|Micro Hand S robot and da Vinci robot|The surgeries are performed with the Micro Hand S robot and da Vinci robot
224288032|NCT04855448|DEVICE|da Vinci robot|The surgeries are performed with the da Vinci robot
224288033|NCT05612282|DIAGNOSTIC_TEST|body composition analysis|A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
224288034|NCT05612282|OTHER|anthropometric measurements|An assessment of the status of nutrition based on anthropometric measurements was carried out.
224288035|NCT05612282|OTHER|Interview questionnaire|An interview questionnaire concerning the duration of obesity and past diseases was collected. Moreover, the diet and nutritional status were assessed.
223950705|NCT00603798|DRUG|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
223950706|NCT00603798|DRUG|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
223950707|NCT02374372|DEVICE|conventional hemodialysis|
223950708|NCT02374372|DEVICE|hemodiafiltration On-line|
223950709|NCT04996186|OTHER|Clinical interviews|Semi-qualitative interviews and questionnaire STAR-Q
223950710|NCT02687841|DRUG|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
223950711|NCT02687841|DRUG|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
223950712|NCT04195919|DRUG|Evogliptin 5mg|Participants receive Single oral administration of Evogliptin 5mg on day1
223950713|NCT04195919|DRUG|Evogliptin 5mg|"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"
223950714|NCT04326894|DRUG|25 mg/week oral methotrexate tablets|
223950715|NCT04326894|DRUG|25mg/week oral placebo tablets|
223950716|NCT03677271|BEHAVIORAL|Physical Activity|
224102544|NCT06023108|DEVICE|Orthokeratology|OK lenses will be used to evaluate the condition that causes dry eye in the treatment of myopia.
224102545|NCT06023108|DEVICE|Spectacles|Spectacles will be used to evaluate the condition that causes dry eye in the treatment of myopia.
224102546|NCT01449825|DRUG|Pazopanib use|Treatment with pazopanib
224102547|NCT01449825|DRUG|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
224102548|NCT05741203|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound
224102549|NCT01330290|DRUG|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
224102550|NCT02498652|DRUG|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
223722659|NCT04847492|PROCEDURE|Traditional corticotomy|A full-thickness mucoperiosteal flap will be elevated including the interdental papilla, and extended from the distal side of the second premolar on the right side to the same position on the left side without performing any vertical releasing incisions. Then, one vertical incision between the roots of upper anterior teeth and two vertical incisions in the site of first premolar extraction will be made by the piezosurgery knife.
224102551|NCT02498652|DRUG|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
224102552|NCT03306147|BEHAVIORAL|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
224102553|NCT00548912|DRUG|Spironolactone|
223722660|NCT04847492|PROCEDURE|Flapless corticotomy|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva by using a blade N.15. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
223722661|NCT01827397|BIOLOGICAL|EN41-UGR7C HIV vaccine|
223722662|NCT01827397|BIOLOGICAL|NaCl|
223722663|NCT01356472|DRUG|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
223722664|NCT01036841|DRUG|desmopressin tablet|Administration of desmopressine tablet
224102554|NCT05970887|BIOLOGICAL|bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine|The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.
223722665|NCT01036841|DRUG|desmopressin MELT formulation|Administration of desmopressine MELT formulation
224102555|NCT05970887|BIOLOGICAL|quadrivalent influenza vaccine|The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
224102556|NCT01153490|BEHAVIORAL|Behavioral Intervention|Substance-related
224102557|NCT05614011|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.
224102558|NCT05614011|DIAGNOSTIC_TEST|Real-time PCR Test|Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
224102559|NCT00661375|DRUG|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
223722666|NCT03684811|DRUG|FT-2102|FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
223722667|NCT03684811|DRUG|Azacitidine|Azacitidine will be administered per the site's standard of care.
223722668|NCT03684811|BIOLOGICAL|Nivolumab|Nivolumab will be administered per the site's standard of care.
223722669|NCT03684811|DRUG|Gemcitabine and Cisplatin|Gemcitabine and cisplatin will be administered per the site's standard of care.
223722670|NCT06231160|PROCEDURE|Systematic Therapy Combined With Microwave Ablation|Patients with unresectable pancreatic cancer were included for laboratory examination, and quality of life and pain scores were recorded. The experimental group underwent microwave ablation first, followed by chemotherapy according to the guidelines; The control group received the same chemotherapy. Record the use of chemotherapy drugs and the occurrence of adverse events. Follow up will be conducted at 30 days, 90 days, and 180 days after chemotherapy to evaluate pancreatic function and quality of life.
224102560|NCT04735029|DEVICE|Thermal gun|"Thermal gun used a heat-generating ceramic head to apply a dual effect called heat-and-light-pressure on the acupuncture points."
224102561|NCT04735029|OTHER|Heat pack|A hydrocollator heat pack used to simulate traditional thermal therapy
224102562|NCT00264277|DRUG|Vitamin K antagonist (Coumarin anticoagulants)|
224102563|NCT03216616|BEHAVIORAL|Cognitive Behavioural Therapy|
224102564|NCT01774942|PROCEDURE|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
224102565|NCT04210570|DEVICE|Memsorb|Memsorb uses a polymeric membrane (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system while maintaining the inhalational anesthetic in the anesthesia circuit
224102566|NCT04210570|DRUG|Chemical granulate absorber|Chemical granulate absorber trap CO2 chemically in granules that are later disposed of when absorption capacity is reached
224102567|NCT04057183|DIAGNOSTIC_TEST|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
224102568|NCT02137044|BEHAVIORAL|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
224102569|NCT04391764|DRUG|Naltrexone|Naltrexone at a dose of 50 mg per day
224102570|NCT04391764|DRUG|Placebo oral tablet|Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
224102571|NCT00302692|DRUG|Esmolol|
224102572|NCT00302692|DRUG|Metoprolol|
224102573|NCT02183389|DRUG|Warfarin|
223950717|NCT03555656|BEHAVIORAL|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
223950718|NCT03555656|BEHAVIORAL|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
223950719|NCT04006015|OTHER|No intervention being delivered.|No interventions are being delivered.
223950720|NCT01623609|DRUG|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
223950721|NCT01623609|DRUG|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
223950722|NCT02245620|DRUG|Elamipretide|Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
223950723|NCT02245620|DRUG|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
223950724|NCT04366895|OTHER|conventional single implant overdenture|conventional manufactured implant overdenture
223950725|NCT04366895|OTHER|3d printed single implant overdenture|CAD-CAM manufactured implant overdenture.
223950726|NCT01285167|DRUG|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
224102574|NCT02183389|DRUG|BI 1356|
223950727|NCT03039322|DIAGNOSTIC_TEST|Serum Golgi Protein 73|Serum test
223950728|NCT02327806|DEVICE|pulsed electromagnetic field therapy|
223950729|NCT01040299|DEVICE|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
223950730|NCT01040299|DEVICE|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
223950731|NCT01040299|OTHER|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
224102575|NCT01917331|DRUG|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
224102576|NCT01917331|DRUG|Beclometasone/Formoterol|Active comparator
223950732|NCT01765023|DRUG|Period I : atorvastatin, Period II : atorvastatin and metformin|
223950733|NCT01765023|DRUG|Period I : metformin, Period II : atorvastatin and metformin|
223950734|NCT02264847|DRUG|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
223950735|NCT02264847|DRUG|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
223950736|NCT00889473|DRUG|Larazotide acetate|gelatin capsule
223950737|NCT00889473|DRUG|Placebo|gelatin capsule
223950738|NCT00889473|DIETARY_SUPPLEMENT|Gluten 900 mg|gelatin capsule
224102577|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)|The COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)was manufactured by Sinovac Research\& Development Co., Ltd.1200SOU inactivated SARS-CoV-2 Omicron strain in 0.5ml of aluminium hydroxide solution per injection.
224102578|NCT05381350|BIOLOGICAL|COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
224102579|NCT01078753|DRUG|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
224102580|NCT01078753|DRUG|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
224102581|NCT00462423|DRUG|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
224102582|NCT00462423|DRUG|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
224102583|NCT03543371|DIAGNOSTIC_TEST|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
224102584|NCT04543500|OTHER|Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
224102585|NCT00349128|DRUG|fenofibrate and metformin combination (drug)|
224102586|NCT03193268|OTHER|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
224102587|NCT03193268|OTHER|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
224102588|NCT01565525|BEHAVIORAL|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
224102589|NCT01565525|BEHAVIORAL|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
224102590|NCT01576471|BIOLOGICAL|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
224102591|NCT01576471|BIOLOGICAL|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
224102592|NCT03982225|DRUG|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
224102593|NCT03982225|DRUG|Placebo|Phosphate buffered saline placebo for injection
223722671|NCT03902574|DRUG|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
223950739|NCT00312949|BEHAVIORAL|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
224102594|NCT06278636|DIAGNOSTIC_TEST|Laparoscopi ultrasound examination|Analysis of feasibility and fellow surgeons learning curve in minimally invasive gynecological procedures
223950740|NCT00312949|BEHAVIORAL|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
223950741|NCT04543188|DRUG|PF-07284890|PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
223722672|NCT03902574|DRUG|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
223950742|NCT04543188|DRUG|Binimetinib|Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
224102595|NCT05343910|OTHER|Aroma massage|The older adult participants in the experimental group were applied aroma massage through gentle movements with slight pressure for 15 min a day, five days a week for three weeks.
223722673|NCT03902574|DRUG|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
223722674|NCT00613249|DRUG|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
223722675|NCT00613249|DRUG|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
223722676|NCT00613249|DRUG|HEC-based Placebo Gel|intravaginal gel, dosed daily
223722677|NCT06243809|DRUG|Linagliptin 5 mg Oral Tablet|Linagliptin 5 mg Oral Tablet
223722678|NCT06243809|DRUG|Trajenta 5 MG Oral Tablet|Linagliptin 5 mg Oral Tablet (Trajenta )
224102596|NCT02913625|OTHER|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
224102597|NCT02913625|OTHER|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
224102598|NCT05742620|DRUG|anlotinib+CAPEOX/SOX|"Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1."
224102599|NCT04459962|DIAGNOSTIC_TEST|Breath Test & Cheek Swab|Breath Sample and Cheek Swab of participants will be used for machine learning (NBT - Nanobiotechnology Biomarkers Tagging) system to develop a profile which can be used later on for Covid-19 Diagnosis.
224288036|NCT05612282|DIAGNOSTIC_TEST|biochemical parameters|The concentrations of the following parameters were determined from the blood serum: fasting glucose, fasting insulin, total cholesterol, LDL cholesterol fraction, HDL cholesterol fraction, triglycerides, C-reactive protein (CRP), uric acid, creatinine, and aminotrasferases: alanine (ALT) and aspartate (AST). On the basis of fasting glucose and fasting insulin, the HOMA - IR insulin resistance index was calculated.
223722679|NCT06436508|BEHAVIORAL|Early mobilization protocol|"* Step 1 - Day 1: Bed rest, elevation of the head end to 30°~* Step 2 - Day 2: Bed rest, elevation of the head end to 60°~* Step 3 - Day 3: Bed rest, elevation of the head end to 80°~* Step 4 - Day 4: Sitting on the edge of the bed~* Step 5 - Day 5: Sitting in a chair, standing up~* Step 6 - Day 6: Walking with or without assistance~* Step 7 - Day 7: Walking with or without assistance from today"
223722680|NCT06436508|BEHAVIORAL|Standard care|During standard care, early mobilization does not take place in the intensive care unit; the patient receives only standard supportive care in bed rest.
223950743|NCT04543188|DRUG|Midazolam|Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15
223950744|NCT00811239|DRUG|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
223950745|NCT00811239|OTHER|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
223950746|NCT04891497|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
223950747|NCT04891497|DRUG|Placebo|Placebo 240mg orally twice daily for 3 consecutive days
223950748|NCT01102426|DRUG|Plitidepsin|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
223950749|NCT01102426|DRUG|Dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
223950750|NCT02899533|DRUG|[18F] FES|\[18F\] FES PET/CT scan, imaging tracer
223950751|NCT06315465|DIETARY_SUPPLEMENT|Modified Atkin's Diet with standard of care|children who have given their consent and are randomized into Group I arm receives Modified Atkins Diet along with standard of care after completion of baseline investigations. Modified Atkin's Diet will be started in ratio of 1:1 and compliance is monitored by urine ketones. Followup will be done telephonically to check for compliance , adverse events at every 4 week intervals till 24 weeks.
223950752|NCT06315465|OTHER|Standard of Care|Standard of care intervention plan will be devised for each subject which includes Behavioral therapy , Psychoeducation, Activity based interventions like attention enhancement exercises, self help skills, Occupational therapy, Pharmacotherapy, Sensory integration therapy. The parents of the children will be called telephonically every weekly to check for any issues and reinforcement to ensure appropriate regular behavioral intervention to be provided to the child. Physical follow up will be done every 4 weekly till 24 weeks.
224102600|NCT04925115|OTHER|Brisk walking|"* Warm up and cool down (10 minutes before physical activity)~* Brisk walking ( 30 minutes each session for 5 days in a week)"
224102601|NCT00408278|DRUG|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
224288037|NCT05612282|DIAGNOSTIC_TEST|cardiopulmonary fitness test|Cardiopulmonary fitness was assessed using the Modified Bruce protocol
224102602|NCT00408278|DRUG|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
223537844|NCT03293303|BEHAVIORAL|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
223537845|NCT00755807|DRUG|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
223950753|NCT03240471|PROCEDURE|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
223950754|NCT03240471|PROCEDURE|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
223950755|NCT03260270|DIAGNOSTIC_TEST|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
223950756|NCT04214808|DRUG|AD-208|Dutasteride 0.2mg
223950757|NCT04214808|DRUG|Avodart Soft Capsule 0.5mg|Dutasteride 0.5mg
223950758|NCT03199495|OTHER|electroacupuncture|acupuncture needle with TENS device
224102603|NCT00408278|DRUG|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
224102604|NCT00408278|DRUG|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
223950759|NCT05955885|DRUG|Flurbiprofen Oral Lozenge|This commercially available, over-the-counter lozenge manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years.
223722681|NCT01945957|DRUG|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
224102605|NCT02032953|DIETARY_SUPPLEMENT|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
224102606|NCT02032953|DRUG|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg\*min. Ten minuts after starting the insulin, and when the the blood glucose is\<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
224102607|NCT00336362|DRUG|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
224102608|NCT00283010|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
224102609|NCT00283010|OTHER|Educational DVDs|
224102610|NCT01668277|DRUG|7.2% NaCl|
223950760|NCT05955885|DRUG|Difflam|This is a non-medicated, control lozenge that is the same flavour as the experimental lozenge that is marketed to help soothe dry, tickly throats while supporting the body's immune health.
223950761|NCT05955885|DRUG|Flurbiprofen 8.75 MG|This commercially available, over-the-counter spray manufactured by Reckitt Benckiser contains flurbiprofen as the active ingredient and is registered for the short-term treatment of sore throat associated with upper respiratory tract infections in people over the age of 12 years. It requires 3 actuations of the spray to deliver the full 8.75 dose. Here, a low dose control can be delivered by only performing 1 actuation of the spray.
223950762|NCT05996315|OTHER|Hematoma block|A patient who presents to the emergency department with a suspected distal end radius fracture , will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give hematoma block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
223950763|NCT05996315|OTHER|Supracondylar radial nerve block|A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
224102611|NCT01668277|DRUG|0.9% NaCl|
224102612|NCT02333708|OTHER|Blood sample|
224102613|NCT02500550|BIOLOGICAL|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
224102614|NCT02500550|PROCEDURE|Haploidentical hematopoietic stem cell transplantation (HSCT)|"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)"
224102615|NCT02500550|PROCEDURE|TBI regime|"* Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
224102616|NCT02500550|PROCEDURE|Non-TBI regime|"* Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."
223537846|NCT00755807|DRUG|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams \[mg\] QD for 12 weeks).
223722682|NCT00786682|DRUG|docetaxel|
223722683|NCT00786682|DRUG|hydroxychloroquine|
223722684|NCT04492618|DRUG|Ruxolitinib|Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica
223722685|NCT03152851|PROCEDURE|Pressure stimulus group|
223722686|NCT00789139|DEVICE|ICM Implantation|Sub cutaneous implantation of the ICM
223950764|NCT02680262|BEHAVIORAL|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
224102617|NCT02852629|OTHER|observational study|
223722687|NCT01114178|OTHER|questionnaire|self completed questionnaire supervised by a technician
224288038|NCT05612282|OTHER|nutritional interview|A 7-day nutrition interview was collected. The supply of energy, protein (including amino acids), fat (including fatty acids), carbohydrates, dietary fiber, vitamins and minerals in the usual diet was assessed.
224288039|NCT04621916|DRUG|FVIII|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
224288040|NCT04621916|DRUG|Emicizumab|This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
224288041|NCT00350402|BEHAVIORAL|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
223722688|NCT03398681|DRUG|Ferric carboymaltose|Ferric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
223950765|NCT02680262|BEHAVIORAL|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
223950766|NCT02680262|BEHAVIORAL|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
223950767|NCT05454059|PROCEDURE|Non-surgical periodontal treatment|Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.
224102618|NCT06411184|DRUG|Regulator T Cells|Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs
224102619|NCT00930410|PROCEDURE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
224102620|NCT01626040|DRUG|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
223950768|NCT05454059|DIAGNOSTIC_TEST|ELISA Test|C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
223950769|NCT05454059|OTHER|Periodontal Examination|All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
223950770|NCT05454059|OTHER|Saliva Sample Collection|Saliva samples were collected from all subjects in the morning. Unstimulated saliva from each patient was collected by standard defined spitting method without stimulation.
223950771|NCT05454059|DIAGNOSTIC_TEST|HbA1c Level|Measurement of HbA1c levels from blood tests
223950772|NCT00427440|DRUG|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
223950773|NCT00427440|DRUG|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
223950774|NCT01702259|DEVICE|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
223950775|NCT01702259|DEVICE|Placebo device|Inactive Erchonia GLS.
224102621|NCT04143022|DEVICE|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
224102622|NCT02599012|DRUG|Ferinject®|intravenous Ferinject 1000mg injection
224102623|NCT04038333|OTHER|No intervention|This is an observational study without any interventions.
224288042|NCT00419887|DRUG|Vildagliptin (LAF237)|
224288043|NCT02331693|BIOLOGICAL|anti-EGFR CAR T|
224288044|NCT01884688|DRUG|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
224288045|NCT06236568|DEVICE|D-HOPE machine perfusion|use of the device
223722689|NCT03398681|DRUG|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
224288046|NCT06236568|PROCEDURE|Liver transplantation|Liver transplantation for HCC within Milan criteria
224288047|NCT02938013|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
224288048|NCT02938013|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
224102624|NCT02721862|DRUG|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
223950776|NCT05012462|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value.
223950777|NCT05012462|DEVICE|CM-1600|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors Bioelectrical Impedance, Photoplethysmography (PPG) Amplitude, ECG Amplitude and Skin Temperature. A combination of these parameters is represented by a single number known as the Relative Index value.
223950778|NCT04666181|BEHAVIORAL|Dual-task training|See descriptions under arm description. The dual-task training will occur across a total of 5 consecutive workday visits.
224102625|NCT02721862|DRUG|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
224102626|NCT02721862|RADIATION|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
224102627|NCT02729961|DRUG|Brentuximab Vedotin|Given IV
224102628|NCT02729961|DRUG|Ceritinib|Given PO
223722690|NCT03398681|DIAGNOSTIC_TEST|Cardiac magnetic resonance|Cardiac magnetic resonance including T2\* and T1-mapping sequences
223722691|NCT03862820|DIAGNOSTIC_TEST|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
223722692|NCT02181023|DRUG|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
223722693|NCT02181023|DRUG|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
223722694|NCT06160154|OTHER|no intervention|all patients undergoing minimally invasive distal pancreatectomy, no intervention, no randomization
223950779|NCT06499142|DEVICE|Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.|"The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample. The Parakeet is a point of care test completely controlled by the surgeon and operating team. It uses the scientific principle of Lateral Flow of antibody-antigen-conjugate complexes being arrested in a Test Line."
223950780|NCT03195803|BEHAVIORAL|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
223950781|NCT05760950|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for intracerebral hemorrhage.
223950782|NCT00605137|DRUG|insulin detemir|
223950783|NCT00605137|DRUG|insulin NPH|
223950784|NCT00017355|BIOLOGICAL|filgrastim|
224102629|NCT02729961|OTHER|Laboratory Biomarker Analysis|Correlative studies
224102630|NCT02729961|OTHER|Pharmacological Study|Correlative studies
224102631|NCT00954785|DEVICE|Ankle brace|Sports Stirrup ankle brace (Aircast)
224102632|NCT00954785|DRUG|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
224102633|NCT00954785|DRUG|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
224102634|NCT05123157|OTHER|NO intervention|"N/:~NO intervention"
224102635|NCT04334148|DRUG|Hydroxychloroquine|oral self administered tablet
224102636|NCT04334148|DRUG|Placebo oral tablet|oral self administered tablet
224102637|NCT00796783|DRUG|Cushing's syndrome confirmation|
224102638|NCT00922935|DEVICE|Cresco|Cresco components loading 10 days post surgery
224102639|NCT00922935|DEVICE|Cresco|Cresco loading at 6-8 weeks post surgery
224102640|NCT00922935|DEVICE|Straumann components|Straumann components loading 6-8 weeks post surgery
224102641|NCT02164565|DRUG|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
224102642|NCT02164565|DRUG|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
224102643|NCT00567931|DRUG|1-methyl-d-tryptophan|Given orally
224102644|NCT00567931|OTHER|pharmacological study|Correlative studies
224102645|NCT00567931|OTHER|laboratory biomarker analysis|Correlative studies
224102646|NCT01607723|OTHER|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
223950785|NCT00017355|BIOLOGICAL|therapeutic autologous dendritic cells|
223950786|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 supplement|
224102647|NCT01607723|OTHER|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
224102648|NCT01619618|GENETIC|mutation analysis|
224102649|NCT01619618|GENETIC|polymerase chain reaction|
224102650|NCT01619618|GENETIC|polymorphism analysis|
223950787|NCT01662193|DIETARY_SUPPLEMENT|calcium supplement|
224102651|NCT01619618|OTHER|laboratory biomarker analysis|
223722695|NCT03571269|PROCEDURE|Optical coherence tomography-guided reperfusion strategy|Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
224295188|NCT04762940|DEVICE|Robotic|"The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user."
223722696|NCT00399854|DEVICE|Dhermia® - Industra Mecânica Fina Ltda|
223950788|NCT01662193|DIETARY_SUPPLEMENT|vitamin D3 and calcium supplement|
223950789|NCT01662193|DIETARY_SUPPLEMENT|placebo|
223950790|NCT01827748|DEVICE|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
223950791|NCT01827748|DEVICE|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
223950792|NCT03608111|OTHER|single task balance training|single task balance training
223950793|NCT03608111|OTHER|dual task balance training|dual task balance training
224102652|NCT04952727|BIOLOGICAL|Recombinant SARS-CoV-2 Ad5 vectored vaccine|This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
223950794|NCT01738997|DEVICE|Dilation 10 sec|
223950795|NCT01738997|DEVICE|Dilation 2 min|
223950796|NCT03136861|BIOLOGICAL|AIN457|anti IL-17a monoclonal antibody
224102653|NCT04952727|BIOLOGICAL|Inactive SARS-CoV-2 vaccine (Vero cell)|This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
224102654|NCT03314168|OTHER|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
224102655|NCT03314168|OTHER|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
224102656|NCT04493749|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG
224102657|NCT05068804|PROCEDURE|Cooling|The participants in the cooling trial put cold towels on their forehead and neck for 3 min in the shaded dugout during their offensive half innings when they were not scheduled to hit or on base. Each participant received the cooling intervention 3 to 4 times in each game. After each use, the towels were kept in a cooler that contained water mixed with ice and salt to keep the temperature at approximately 0℃.
224102658|NCT05068804|OTHER|control|The participants in the control trial sat in the shaded dugout without any cooling intervention.
224102659|NCT03584802|OTHER|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
223950797|NCT03136861|DRUG|AIN457 Placebo|Placebo matching AIN457
223950798|NCT05185973|DIETARY_SUPPLEMENT|"For Baby supplements provided as powder"|One sachet daily
223950799|NCT05185973|DIETARY_SUPPLEMENT|Micronutrient powder provided as powder|One sachet daily
223950800|NCT02936544|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code:Z09-054)
223950801|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
223950802|NCT00728013|DRUG|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
223950803|NCT03125148|DEVICE|Enteral stenting|Enteral stent for malignant duodenal obstruction
224102660|NCT03584802|OTHER|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
224102661|NCT05335525|DEVICE|Closure of the femoral arterial puncture site|Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.
223950804|NCT06395207|BEHAVIORAL|Proactive community case management|Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.
223950805|NCT06395207|BEHAVIORAL|Strengthened SBCC and stock out mitigation|Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
224102662|NCT00542828|BIOLOGICAL|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
224102663|NCT04478422|OTHER|Muscle strengthening with vascular occlusion|The muscle strengthening group with partial vascular occlusion will perform the strengthening exercises: single leg squat on 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat. The equipment for vascular occlusion will be positioned over the proximal portion of the lower limb to be treated, just below the gluteal fold and inguinal ligament (Tennent et al. 2017). The pressure must be maintained during all series of exercises (approximately 5 minutes) (Bryk et al. 2016; Ferraz et al. 2018; Giles et al. 2017). If necessary, the pressure can be adjusted at intervals and after the end of the exercise, an interval of 5 minutes is suggested for blood reperfusion.
224102664|NCT04478422|OTHER|Conventional muscle strengthening|The conventional muscle strengthening group perform the same exercises as the intervention group: One-legged squat on a 25 ° inclined plane, eccentric + isometric + concentric quadriceps exercise and deep squat, however, without restriction on blood flow.
224102665|NCT01843556|DRUG|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
224102666|NCT00947102|OTHER|Observation|
224102667|NCT00722176|DRUG|BL-1020|10 mg
223950806|NCT04723979|DRUG|Eptacog alfa|Recombinant coagulation factor VII activated
223950807|NCT04723979|OTHER|Standard of care|Patients have been treated according to local routine clinical practice at the discretion of the treating physician.
223950808|NCT00161122|BIOLOGICAL|trivalent inactivated influenza vaccine|
223950809|NCT00161122|BIOLOGICAL|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
223950810|NCT00439686|DRUG|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
223950811|NCT05320133|DRUG|JWC containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.
223950812|NCT05320133|DRUG|Bismuth-containing quadruple therapy|Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and bismuth potassium citrate 220mg twice daily for 14 days.
223950813|NCT04970602|DRUG|Methylene Blue|Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
223950814|NCT03730038|DRUG|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
224102668|NCT00722176|DRUG|BL-1020 10-30 mg|BL-1020 10-30 mg
224102669|NCT00722176|DRUG|risperidone|risperidone
223950815|NCT03730038|BEHAVIORAL|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
223950816|NCT01319058|PROCEDURE|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
223950817|NCT04827849|OTHER|Structured education and follow-up|"The women in the intervention groups will administer a seven-session intervention program in addition to the routine care they will receive.~The training including preparation practices for the transition with the mother, which is planned to last for 7 weeks encompassed providing the women with an educational programme that were created to increasing women's adaptation to motherhood and perceptions of newborn baby~Nursing-recommended follow-up and physical examination of the pregnant woman will be performed at 28th and 34th week of pregnancy. In addition, postpartum and newborn follow-up, and mother-newborn physical examinations will be performed at the postpartum period."
223950818|NCT01672242|DEVICE|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
223950819|NCT01672242|DEVICE|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
223950820|NCT02613767|OTHER|Protein meal|Ingestion of protein
223950821|NCT02613767|OTHER|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
223950822|NCT04834830|DIAGNOSTIC_TEST|Pleural effusion will be examined for various cytokines and PD1-lymphocytes.|Examination of pleural effusion
223950823|NCT04709185|DRUG|Dexamethasone 1 MG Oral Tablet|oral 1 mg dexamethasone at 23:00-24:00 the night before AVS
223950824|NCT04709185|DRUG|Placebo|oral placebo at 23:00-24:00 the night before AVS
223950825|NCT05671549|PROCEDURE|Arthrocentesis of the temporomandibular joint|Arthrocentesis of the temporomandibular joint is a minimally invasive method performed under local anesthesia to irrigate the upper temporomandibular joint cavity with biocompatible substances. The procedure aims to wash out intra-articular inflammatory substances, reduce pain and restore the function of the related joint.
223950826|NCT02079259|PROCEDURE|Ultrafiltration|
223950827|NCT05376397|BEHAVIORAL|iTHRIVE 365|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) of interventions with mHealth features, THRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. THRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. THRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of BSMM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
223950828|NCT01328756|DRUG|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
223950829|NCT02757378|PROCEDURE|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
223950830|NCT02757378|PROCEDURE|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
223950831|NCT00652600|DRUG|Propranolol|ER Capsules, 160 mg, single-dose
223950832|NCT00652600|DRUG|Inderal-LA|ER Capsules, 160 mg, single-dose
223950833|NCT05575349|OTHER|Mandala coloring|Participants will be asked to choose the pages they want from 12 colored felt-tip pen paint sets and 12 mandala coloring pages given to each participant by the researcher for 6 weeks, 1 days a week, at any time of the day and for an average of 20-30 minutes each time, and paint them in the colors they want.
223950834|NCT00237705|DRUG|metoclopramide|
223950835|NCT02070276|PROCEDURE|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
223950836|NCT02070276|PROCEDURE|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
223950837|NCT02714244|OTHER|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
223950838|NCT02222649|DIETARY_SUPPLEMENT|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
223950839|NCT02222649|DIETARY_SUPPLEMENT|Placebo|Capsules of starch, no therapeutic action
223950840|NCT05094947|PROCEDURE|intermittent catheterization|clean intermittent catheterization with catheter Nelaton
223950841|NCT05094947|PROCEDURE|trial without catheter|catheter Foley
223950842|NCT05094947|DRUG|alpha-blockers|tamsulosin, alfuzosin, doxazosin, silodosin
223950843|NCT06248021|BEHAVIORAL|Ecological Footprint Awareness Program|The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature. The sessions were based on the principles of the Social Cognitive Learning Theory, developed by Bandura, which includes mutual determinism, symbolization, anticipatory capacity, vicarious learning, self-regulation capacity, and self-judgment capacity. During each session, various techniques such as animation, drawing, storytelling, memory cards, and games were employed. To ensure the program's content was appropriate for children's development, the opinions of two experts from the child development department of the university were obtained.
223950844|NCT06052943|BEHAVIORAL|Mindfulness-Based Intervention|Learning 2 BREATHE (L2B) is an evidence based curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
223950845|NCT06052943|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition and 3) physical activity. The parents set weekly goals to implement the parent education lessons into everyday living.
223950846|NCT06052943|BEHAVIORAL|Physical Activity|Combines aerobic and resistance training though game play.
223950847|NCT06052943|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education based on the Learning to BREATHE curriculum.
223950848|NCT06052943|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
223950849|NCT06052943|BEHAVIORAL|Cooking Matters|Nutrition education and hands-on cooking lessons for the whole family
223950850|NCT02189434|OTHER|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
223950851|NCT04136990|PROCEDURE|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
223950852|NCT04136990|PROCEDURE|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
224102670|NCT02558023|DRUG|Urapidil|"Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
224102671|NCT02558023|DRUG|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
223722697|NCT04183595|DRUG|(N1, N3-bis(2- mercaptoethyl)isophthalamide)|600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
224102672|NCT01486680|PROCEDURE|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
224102673|NCT01486680|PROCEDURE|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
224102674|NCT03759652|BEHAVIORAL|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
224102675|NCT05098288|BEHAVIORAL|Multicentre Pain Monitor + Unified Protocol|The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
224102676|NCT06382753|OTHER|Gingival inflammation|Patients were scored for their status of gingival inflammation using Gingival Index and Bleeding on Probing Scores
224295189|NCT04762940|DEVICE|Vibration|Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
224295190|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30)
223722698|NCT04183595|OTHER|Excipients microcrystalline cellulose, silica and magnesium stearate|6 Capsules will be administered every 24 hours for 14 days.
223722699|NCT01288495|DIETARY_SUPPLEMENT|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
223722700|NCT01288495|DIETARY_SUPPLEMENT|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
223722701|NCT01829334|OTHER|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
223722702|NCT01829334|OTHER|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
223722703|NCT01829334|OTHER|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
223950853|NCT04492475|DRUG|Interferon beta-1a|Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.
223950854|NCT04492475|OTHER|Placebo|The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.
224295191|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3-3´D4Δ30, 10\^3 PFU of rDEN4Δ30-200,201)
224295192|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30)
224295193|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10\^3 PFU of rDEN1Δ30, 10\^3 PFU of rDEN2/4Δ30\[ME\], 10\^3 PFU of rDEN3Δ30/31-7164, 10\^3 PFU of rDEN4Δ30-200,201)
224295194|NCT01072786|BIOLOGICAL|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
224102677|NCT01108991|BEHAVIORAL|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
224102678|NCT01108991|OTHER|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
224102679|NCT03426969|DRUG|Cyclophosphamide|Given IV
224102680|NCT03426969|BIOLOGICAL|Filgrastim|Given SC
224102681|NCT03426969|DRUG|Fludarabine Phosphate|Given IV
224102682|NCT03426969|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
224102683|NCT03426969|DRUG|Melphalan|Given IV
224102684|NCT03426969|DRUG|Mycophenolate Mofetil|Given PO
224102685|NCT03426969|DRUG|Tacrolimus|IV or PO
224102686|NCT03426969|RADIATION|Total-Body Irradiation|Undergo TBI
223950855|NCT04492475|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
223950856|NCT02417350|OTHER|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
223950857|NCT02417350|OTHER|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
223950858|NCT03451695|DRUG|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
224102687|NCT06266637|OTHER|Conventional Physical Therapy Program|"Conventional Physical Therapy program:~trunk muscles strengthening exercises, trunk muscles endurance exercises, trunk proprioception exercises . postural correction exercises. Core exercise Spinal mobility exercises"
224102688|NCT06266637|OTHER|Physiotherapeutic Scoliosis-Specific Exercise (Schroth)|It uses exercises customized for each patient to return the curved spine to a more natural position. The spine is addressed in all three anatomical planes - sagittal, frontal and transverse. The purpose of the method is to create spinal balance and stability by improving body mechanics and spinal stabilization to prevent further curve progression
224102689|NCT04950231|OTHER|The questionnaire survey|Questionnaires were issued and collected by 6 competent nurses with strict training, data entry by 2 researchers, statistical analysis by 1 researcher, and quality control by the other 2 researchers throughout the process.
224102690|NCT01773395|BIOLOGICAL|GVAX|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
223722704|NCT01829334|OTHER|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
223722705|NCT02396433|DRUG|Carboplatin|Carboplatin will be given on day 1 of each cycle.
223722706|NCT02396433|DRUG|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
223722707|NCT02396433|DRUG|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
223722708|NCT02818686|DRUG|TD-1473|
223950859|NCT03451695|DRUG|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
223950860|NCT06081608|DIAGNOSTIC_TEST|kidney function test|blood sample for kidney function test
223722709|NCT02818686|DRUG|Placebo|
223950861|NCT03150758|DEVICE|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
223950862|NCT03150758|DEVICE|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
223950863|NCT03150758|DEVICE|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
224102691|NCT01773395|BIOLOGICAL|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 60 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
224102692|NCT01773395|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
224102693|NCT01773395|DRUG|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
224102694|NCT01773395|DRUG|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
224295195|NCT01072786|BIOLOGICAL|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10\^3 PFU of rDEN1Δ30, 10\^4 PFU of rDEN2/4Δ30(ME), 10\^3 PFU of rDEN3Δ30/31-7164, and 10\^3 PFU of rDEN4Δ30)
224295196|NCT00183586|BEHAVIORAL|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
224295197|NCT00183586|BEHAVIORAL|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
224295198|NCT04948294|DEVICE|Channeled blade|In the present group, a tracheal tube was launched in the channel of the blade before tracheal intubation
224295199|NCT04948294|DEVICE|Non-channeled blade|In the present group, a tracheal tube was not launched in the videolaryngoscope blade before tracheal intubation
224295200|NCT02480231|DEVICE|Retropubic Midurethral Sling|
224102695|NCT01773395|DRUG|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
224102696|NCT01773395|DRUG|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~* Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~* Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
224102697|NCT01499576|PROCEDURE|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
224102698|NCT05537181|DEVICE|BTL-899; HPM-6000UF Treatments|The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
224102699|NCT03228186|DRUG|Pevonedistat|25mg/m2 days 1, 3, 5
224102700|NCT03228186|DRUG|Docetaxel|75mg/m2 day 1
224102701|NCT01548664|OTHER|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
224102702|NCT01548664|OTHER|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
224102703|NCT03784430|PROCEDURE|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
224102704|NCT03784430|PROCEDURE|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
224102705|NCT02016066|DRUG|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
224102706|NCT02016066|DRUG|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
224102707|NCT04283461|BIOLOGICAL|mRNA-1273|Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
224102708|NCT03671083|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
223722710|NCT04806854|DRUG|LUM-201|Administered orally once daily
223950864|NCT03150758|DEVICE|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
223950865|NCT05729386|DRUG|GC2129A(Period 1)|Linagliptin and Metformin Hydrochloride Tablet
224102709|NCT05227846|BIOLOGICAL|Human Umbilical Cord-derived Mesenchymal Stem Cells|Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously.
224102710|NCT02580539|BIOLOGICAL|Group A|Peptide-stimulated T cells 2 x 10\^7/m\^2
224102711|NCT02580539|BIOLOGICAL|Group B|Peptide-stimulated T cells per dose-escalation protocol
224102712|NCT00181077|DRUG|2% buffered hypertonic saline administration|
224102713|NCT04246047|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
224102714|NCT04246047|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
224102715|NCT04246047|DRUG|Bortezomib|Proteasome Inhibitor
224102716|NCT04246047|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
223537847|NCT01714323|BEHAVIORAL|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free \& Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
223537848|NCT01714323|BEHAVIORAL|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
223537849|NCT05938348|BEHAVIORAL|angiopuncture|we conducted acupuncture on perforators by using acupuncture needles.
223537850|NCT03704038|PROCEDURE|PEEP level|Patients will have variable PEEP levels and will be monitored
224102717|NCT02481505|DRUG|Chloroprocaine HCl 1%|Intrathecal Route
224102718|NCT04650633|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
224102719|NCT04768582|DIAGNOSTIC_TEST|P2Y12-reaction-units (PRU) by VerifyNow-P2Y12 assay|The efficacy endpoint was platelet reactivity, of which was serially assessed using the VerifyNow-P2Y12 assay and the results were expressed as P2Y12-reaction-units (PRU).
224102720|NCT03993015|OTHER|Help to diagnosis software|Help to diagnosis software
223537851|NCT03971175|PROCEDURE|Forceps biopsy|Endobronchial biopsy with the forceps
223537852|NCT03971175|PROCEDURE|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
223537853|NCT03531814|BEHAVIORAL|Medication Event Monitoring System (MEMS^TM)|A computerized method of tracking the dates and times of a pill bottle being opened.
223722711|NCT02322567|OTHER|medical records|review of medical records
223722712|NCT01410786|PROCEDURE|Conventional Instrumentation|Standard Oxford surgical instruments
223722713|NCT01410786|PROCEDURE|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
224102721|NCT05596266|BIOLOGICAL|CD5 CAR-T|CD5 CAR-T will be administered by I.V. infusion.
223950866|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
223950867|NCT05729386|DRUG|GC2129A(Period 2)|Linagliptin and Metformin Hydrochloride Tablet
223950868|NCT05729386|DRUG|Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)|Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
223950869|NCT05277285|DRUG|Sodium Thiosulfate 25% Solution for Injection|The drug will be administered via continuous infusion after being diluted to a concentration 12.5 gr/100ml
223950870|NCT05205213|OTHER|Surgical Technique (lateral retromuscular preperitoneal)|Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
224102722|NCT05888896|OTHER|methyldopa tablets 250mg|patients will be taken methyldopa tablets 250mg in the morning orally with a lot of water after breakfast daily and this medication continues for 8 weeks
224102723|NCT05888896|OTHER|methyldopa tablets 250mg + foot reflexology|patients will receive methyldopa tablets 250mg in oral way once daily per 8 weeks and patients will receive foot reflexology two sessions per week, every session will last for 30 minutes and sessions will last for 8 weeks.
224102724|NCT01559103|BIOLOGICAL|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
223950871|NCT04508777|BEHAVIORAL|Saliva-based testing|Participants will take part in a voluntary COVID-19 screening program that includes bi-weekly saliva-based testing.
223950872|NCT06405906|OTHER|Fat-free diet|The low-fat diet will consist of instructions to avoid fatty foods.
223950873|NCT06405906|OTHER|Balanced WHO diet|The balanced WHO diet will adhere to the recommendations of the World Health Organization (WHO) and the Dietary Guidelines for Americans 2020-2025
223950874|NCT00364988|DRUG|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
223950875|NCT00364988|DRUG|losartan|losartan (100 mg daily)
224102725|NCT01559103|BIOLOGICAL|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
223537854|NCT03531814|OTHER|Questionnaires|Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
224102726|NCT05139030|DRUG|bupivacaine liposome injectable suspension|Adductor canal block with EXPAREL
223537855|NCT02477488|DRUG|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
223537856|NCT00529243|DRUG|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
223537857|NCT03429738|DRUG|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
223537858|NCT03429738|DRUG|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
223722714|NCT05090137|OTHER|Diuretics|As per group descriptions
223722715|NCT05590013|DRUG|Pectointercostal and ESP block|Pectointercostal plane block will apply at the 4-5. intercostal space and ESP block will apply athe T6 level bilaterally
224288049|NCT05450484|DRUG|Fluorescence endoscopy using durvalumab-680LT|"Tracer administration: The PD-L1-targeted fluorescent tracer durvalumab-680LT will be administered intravenously 2-4 days prior to the endoscopy at the UMCG. Afterwards, patients will be monitored for half an hour by measurements of vital parameters for potential side-effects, such as infusion-related reactions.~Endoscopy procedure: Patients will undergo two endoscopies, before and after neoadjuvant therapy. First, routine high-definition white-light (HD-WL) inspection is used. Quantification of fluorescence using multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy will be performed both in vivo and ex vivo. Subsequently, fluorescence molecular endoscopy (FME) and endoscopic ultrasound (EUS) will be performed. EUS enables single fiber reflectance/single fiber fluorescence (SFR/SFF) spectroscopy measurements via fine needle aspiration (FNA) to gain insight in the drug distribution throughout the tumor. Additionally, biopsies will be obtained."
224288050|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy plus the fire dragon pot moxibustion therapy.|"Fire dragon pot moxibustion treatment The main acupuncture points are as follows: Fengchi, Jianjin, Dazhui, Feiyu, Xinyu, Ganyu, Piyu, Shenyu, etc (all acupuncture points are positioned according to the national standard: GB/T12346-2006).~Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
224288051|NCT05234814|OTHER|Traditional Chinese Medicine auricular acupuncture point buried seeds therapy|"Ear acupuncture seed burial method According to Ear Acupuncture Therapy \[6\], the main acupuncture points were Shenmen, subcortical, sympathetic, endocrine, kidney, heart, liver and spleen (all acupuncture points were positioned according to the national standard: GB/T12346-2006)."
223722716|NCT04613960|DRUG|Magnesium sulfate|MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
223950876|NCT03072706|DEVICE|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
223950877|NCT03072706|OTHER|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
223950878|NCT04296734|BEHAVIORAL|Mothers and Babies|Mothers \& Babies (MB) is a program that promotes healthy mood management by teaching pregnant women and new moms how to effectively respond to stress in their lives through increasing the frequency of thoughts and behaviors that lead to positive mood states. Designed as a perinatal depression prevention, the Mothers \& Babies targets three specific risk factors: limited social support, lack of pleasant activities, and harmful thought patterns.
223950879|NCT00972920|PROCEDURE|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
223950880|NCT04602949|DIAGNOSTIC_TEST|Breath Biopsy Analysis|Analysis of a single breath Biopsy
224102727|NCT05139030|DRUG|Bupivacaine Hydrochloride|Adductor Canal Block with bupivacaine HCl
224288052|NCT02268539|PROCEDURE|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
223722717|NCT04613960|DRUG|normal saline|Placebo treatment
223722718|NCT06497933|PROCEDURE|Atrial fibrillation ablation|Pulmonary veins isolation potentially associated with other atrial lesions, performed with the pentaspline PFA catheter
223722719|NCT05867745|OTHER|Interview|As previously specified
224102728|NCT03655444|DRUG|Abemaciclib|Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
223722720|NCT05867745|OTHER|Survey|As previously specified
224102729|NCT03655444|DRUG|Nivolumab|Nivolumab is commercially available
224102730|NCT03655444|PROCEDURE|Tumor biopsy|"* Phase II patients only~* If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab."
224102731|NCT03655444|PROCEDURE|Peripheral blood|"* Phase II patients only~* Peripheral blood will be collected at baseline, at the end of the Lead In (cycle 1 day 1 prior to treatment), during cycle 2 (between days 8-22), and during cycle 3 (between days 21-28). If patient does not have progression after cycle 3, patient will also have peripheral blood collected at time of progression."
224102732|NCT03655444|OTHER|EORTC QLQ-30|"* Phase II patients only~* Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)"
224102733|NCT01472484|OTHER|586/8x87 white|2 x 50 g
224102734|NCT01472484|OTHER|586/8x87 brown|2 x 50 g
224102735|NCT01472484|OTHER|BAT 881|2 x 50 g
224102736|NCT01472484|OTHER|586/8|2 x 50 g
224102737|NCT04216173|OTHER|Acupuncture|Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
224102738|NCT05585749|OTHER|Virtual Reality Based Relaxation Program|Virtual Reality Based Relaxation Program
223722721|NCT05867745|OTHER|Letter to a friend (autoethnography)|As previously specified
224102739|NCT00889096|DRUG|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
223950881|NCT02221778|RADIATION|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days"
223950882|NCT02673866|DRUG|DS-1971a|
223950883|NCT02673866|DRUG|placebo|
224102740|NCT00889096|DRUG|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
224102741|NCT06637540|DEVICE|RescueDoppler|Continous handsfree pulsed wave Doppler of the common carotid artery during cardiac surgery
223722722|NCT05225766|OTHER|bupivacaine|used for peripheral block
223722723|NCT06054698|DRUG|HRS9531 injection|HRS9531 injection , QW，36 weeks
223722724|NCT06054698|DRUG|HRS9531 injection Placebo|HRS9531 injection Placebo，QW，36 weeks
223722725|NCT01437462|DRUG|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
223722726|NCT01437462|DRUG|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
223722727|NCT01484847|DRUG|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
223722728|NCT01603056|BIOLOGICAL|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
223722729|NCT01603056|BIOLOGICAL|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
223950884|NCT02673866|DRUG|pregabalin|pregabalin
223950885|NCT03964779|DIAGNOSTIC_TEST|Hormonal assay|Measurement of Thyroid stimulating hormone
223950886|NCT03964779|DIAGNOSTIC_TEST|Antibody assay|antithyroglobulin and antithyroid peroxidase
223950887|NCT01122134|DRUG|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
223950888|NCT03407976|DRUG|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
224102742|NCT06637540|DEVICE|RescueDoppler|Continuous hands-free Doppler ultrasound of the common carotid artery during cardiac surgery
224102743|NCT01368796|BIOLOGICAL|Agriflu|0.5mL dose IM vaccination
224102744|NCT01368796|BIOLOGICAL|Fluad|0.5mL dose of vaccine given IM
224102745|NCT01368796|BIOLOGICAL|Intanza|0.5mL dose vaccine given IM
224102746|NCT01368796|BIOLOGICAL|Vaxigrip|0.5mL dose vaccine given IM
224102747|NCT05547945|BEHAVIORAL|Health Promotion Program|The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
224102748|NCT05547945|BEHAVIORAL|Control group|The control group received as usual care.
224102749|NCT01523821|DRUG|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
224102750|NCT02310373|OTHER|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
224102751|NCT00206167|DRUG|Budesonide/formoterol pMDI|
224102752|NCT00206167|DRUG|Formoterol Turbuhaler|
224102753|NCT01917123|DRUG|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
224288053|NCT00712244|DEVICE|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
224288054|NCT00712244|DEVICE|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
224288055|NCT00712244|DEVICE|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
224288056|NCT00712244|DEVICE|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
224102754|NCT01349309|BEHAVIORAL|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
224102755|NCT01798914|DRUG|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
224102756|NCT05740150|DEVICE|TauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL)|The TauroLock-Hep100 is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
224102757|NCT05740150|DEVICE|Heparin lock (heparin 100 IU/mL)|The Heparin lock is a lock solution that is instilled in the lumen of a central venous access device after a treatment cycle.
224102758|NCT02814721|DEVICE|Sonic Window ultrasound device|
224102759|NCT05937477|OTHER|Fitbit smartwatch|Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
224102760|NCT04410874|BIOLOGICAL|Imvamune|Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
224288057|NCT02063087|OTHER|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
223950889|NCT03407976|DRUG|Pembrolizumab|200 mg Q3 weeks IV
224102761|NCT04096534|PROCEDURE|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: mean blood pressure more or equal 65 mm Hg
224102762|NCT04096534|PROCEDURE|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: mean blood pressure less than 65 mmHg
224102763|NCT02502864|DRUG|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m\^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
224102764|NCT02502864|DRUG|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m\^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
224102765|NCT02502864|OTHER|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
224102766|NCT04522869|BIOLOGICAL|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation|Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
223950890|NCT04201314|DIETARY_SUPPLEMENT|InnoSlim®|Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
224102767|NCT01805271|DRUG|Everolimus|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
223722730|NCT04339439|DEVICE|Vessel loop (FDA product code FZZ)|The intervention will be a vessel loop placed below sutures to raise the sutures from the skin of the palm.
223950891|NCT04201314|DIETARY_SUPPLEMENT|Placebo|Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
223950892|NCT05935839|DEVICE|Multispectral optoacoustic tomography|Molecular Imaging of tissue changes using MSOT in macroangiopathy in diabetes. Dual imaging before and after physical stress.
223950893|NCT05935839|DIAGNOSTIC_TEST|Ankle Brachial Index|Dual measurement of ABI index before and after physical exercise.
223950894|NCT05935839|DIAGNOSTIC_TEST|Neuropathy Disability Score|Single measurement of the NSS
223950895|NCT01727193|DRUG|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
223950896|NCT01727193|DRUG|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
223950897|NCT01264874|DRUG|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
223950898|NCT01264874|OTHER|placebo|For 3 years IU every 50 days
224102768|NCT01805271|DRUG|Placebo|(5 or 10 mg/day, i.e. 1 or 2 tablets/day)
224102769|NCT06003959|OTHER|Routine nursing care|Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.
224288058|NCT02438696|DRUG|BI 1060469, iFF, Test|
224288059|NCT02438696|DRUG|BI 1060469, iFF, Test|
224288060|NCT02438696|DRUG|BI 1060469, TF1, Reference|
224288061|NCT02438696|DRUG|BI 1060469, TF2, Test|
224288062|NCT02438696|DRUG|BI 1060469, TF2, Test|
224288063|NCT02438696|DRUG|BI 1060469, iFF, Test|
224288064|NCT02438696|DRUG|BI 1060469, TF1, Reference|
224288065|NCT02438696|DRUG|BI 1060469, iFF, Test|
224288066|NCT02438696|DRUG|BI 1060469, iFF, Test|
224288067|NCT02438696|DRUG|BI 1060469, TF1, Reference|
224288068|NCT02438696|DRUG|BI 1060469, TF2, Test|
224288069|NCT02438696|DRUG|BI 1060469, TF1, Reference|
223950899|NCT05156606|DRUG|AndroGel|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
224102770|NCT06003959|OTHER|breastfeeding support system|The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
224102771|NCT03772327|DEVICE|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
224102772|NCT03772327|BEHAVIORAL|Routine adherence counseling|Participants will be provided with routine adherence counseling
224102773|NCT04576312|DRUG|UNI911 inhalation 1% and intranasal spray 1%|Niclosamide is a broad spectrum, host tageting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide 1% solution is administered as inhalation by nebulization and intranasal by a nasal spray.
224102774|NCT04576312|DRUG|Placebo|The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
224102775|NCT06491134|DRUG|Liposomal Irinotecan Hydrochloride|liposomal irinotecan With Cisplatin and Concurrent Radiotherapy
224102776|NCT05212051|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
224102777|NCT05212051|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
224102778|NCT03588689|PROCEDURE|Continuous fascia iliaca block|Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
224102779|NCT03588689|DRUG|Ropivacaine|Ropivacaine local anesthetic will be used for the fascia iliaca block
223722731|NCT02847832|OTHER|Standardized transvaginal ultrasound examination|
223950900|NCT02538094|DEVICE|Sham Transcranial direct current stimulation|Delivery of sham stimulation for 30 minutes using Neuro-Conn Direct Current (DC) Stimulator Plus.
223950901|NCT02538094|DEVICE|Anodal Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes.
223950902|NCT04027452|BEHAVIORAL|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
224102780|NCT03700957|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
224102781|NCT03700957|OTHER|placebo|placebo
224102782|NCT04324853|DIAGNOSTIC_TEST|Microscopy ( Urine filtration), UCAA test, qPCR,|Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
224102783|NCT04324853|DIAGNOSTIC_TEST|Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,|Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
224102784|NCT03441126|OTHER|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
224102785|NCT03643692|DEVICE|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
224102786|NCT03831087|DIAGNOSTIC_TEST|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
224288070|NCT02438696|DRUG|BI 1060469, TF1, Reference|
224288071|NCT02438696|DRUG|BI 1060469, TF2, Test|
224288072|NCT02438696|DRUG|BI 1060469, TF2, Test|
224288073|NCT02438696|DRUG|BI 1060469, iFF, Test|
224288074|NCT02438696|DRUG|BI 1060469, TF2, Test|
224102787|NCT03831087|DIAGNOSTIC_TEST|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
224102788|NCT05669742|DRUG|Empagliflozin|sodium-glucose transport protein two inhibitor
224102789|NCT05669742|DRUG|olanzapine|antipsychotics
224102790|NCT02495779|DRUG|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
224102791|NCT02495779|BEHAVIORAL|CBT-based counseling|Brief CBT-based counseling to promote adherence
224102792|NCT05623566|DEVICE|Picterus Jaundice Pro|In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
224102793|NCT06061445|COMBINATION_PRODUCT|Radiotherapy combined with TKI and Anti-PD-1 Antibody|After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
224102794|NCT01770340|BIOLOGICAL|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
224102795|NCT01770340|PROCEDURE|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
224102796|NCT06105138|DIETARY_SUPPLEMENT|200mg Cannabidiol oral solution|"200mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
223950903|NCT04027452|BEHAVIORAL|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
223950904|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance relaxometry|Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
224102797|NCT06105138|DIETARY_SUPPLEMENT|30mg Cannabidiol oral solution|"30mg cannabidiol administered in the laboratory prior to a standard dose of alcohol.~The water-soluble product is standardized to 5.0% cannabidiol, 0.0% THC and composed of reverse-osmosis water, gum arabic, cannabidiol, MCT (Medium Chain Triglyceride) oil and citric acid. The same lot of Caliper water soluble CBD was used for both the 30 mg and 200 mg test variable. All CBD was sourced from the same lot of CDB isolate. The Caliper commercial product conforms to all standards set forth by the CDPHE (Colorado Dept of Public Health and Environment)."
224102798|NCT06105138|DIETARY_SUPPLEMENT|Placebo|"Placebo administered in the laboratory prior to a standard dose of alcohol.~The placebo was made up for the study and contained reverse-osmosis water, gum arabic, MCT (Medium Chain Triglyceride) oil, citric acid, plus the addition of a natural food color, used at \<0.1%."
224288075|NCT02438696|DRUG|BI 1060469, TF1, Reference|
223537859|NCT05953298|DEVICE|Electrical impedance tomography (EIT)|Electrical impedance tomography (EIT) is a non-invasive evaluation tool, without radiation, simple to set up at the patient's bedside and validated, making it possible to monitor the distribution of ventilation and lung recruitment with high temporal resolution, dynamic way and at a regional level
224288076|NCT05416463|PROCEDURE|Intra-Operative Device for THA|The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
224288077|NCT06616792|COMBINATION_PRODUCT|Dexamethasone phonophoresis|Ultrasound therapeutic device with the use of 0.4% Dexamethasone sodium phosphate gel for phonophoresis.
224288078|NCT06616792|DEVICE|Laser Acupuncture|low level laser therapy placed in contact with the skin perpendicular over the body acupoints (LI 4) - (LI 20) - (EX- HN5) - (GV 20) - (GV 24) - (ST3) - (ST 7) in both sides and on (EX-HN3) acupoint,
224288079|NCT06616792|OTHER|Traditional medication|Each participant in this group receive the traditional medication.
224288080|NCT01029392|DRUG|Vitamin D|2000iu once a day
224288081|NCT02731963|DRUG|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
224288082|NCT05494216|OTHER|PICSI|Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
224288083|NCT05494216|OTHER|MACS|Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
224288084|NCT02822196|DRUG|Lidocaine|Local Anesthesia using 1% Lidocaine
224288085|NCT02822196|DRUG|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
224288086|NCT01779388|PROCEDURE|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
224288087|NCT00775788|PROCEDURE|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
224288088|NCT01588535|DRUG|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
224102799|NCT03632642|DRUG|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
224102800|NCT03632642|DRUG|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
223950905|NCT06216704|DIAGNOSTIC_TEST|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy. MRS will be performed within a 1 mL voxel situated in the medial aspect of the distal femoral metaphysis. A single voxel point resolved spectral acquisition (PRESS) technique will be used to acquire non-water suppressed spectra at multiple echo times. Spectral fits using JMRUI MRS processing software (www.jmrui.eu) to the water and methylene/methyl resonances will be used to quantify peak areas and establish T2 corrected fat/(fat + water) ratios.
224102801|NCT03517436|DEVICE|TAVR with CENTERA THV|TAVR with the Edwards CENTERA THV System
224102802|NCT00748657|BIOLOGICAL|Bevacizumab|Given IV
224102803|NCT00748657|OTHER|Laboratory Biomarker Analysis|Correlative studies
224102804|NCT04730895|DRUG|Oral 13 cis retinoic acid|Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days
224102805|NCT04730895|DRUG|Aerosolized 13 cis retinoic acid|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day
224102806|NCT04730895|COMBINATION_PRODUCT|13 cis retinoic acid doses orally in combination with spike protein based vaccine|Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
224102807|NCT04730895|COMBINATION_PRODUCT|Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine|Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart
224102808|NCT04730895|BIOLOGICAL|Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine|Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
224102809|NCT01213056|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
224288089|NCT01588535|DRUG|placebo|placebo solution, five drops in affected ear canal each hour as needed
224288090|NCT05249972|DRUG|AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)|Topical cutaneous spray
224288091|NCT05249972|DRUG|Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)|Topical foam
224288092|NCT05249972|OTHER|Placebo|Placebo cutaneous spray
224288093|NCT06207292|RADIATION|Stereotactic Ablative Radiotherapy|"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"
223950906|NCT06216704|DIAGNOSTIC_TEST|Blood Draw|Blood draw. Blood draws will be used to attain and assess markers of bone formation/resorption and inflammation. Specific markers of bone formation that will be assessed include osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP), and a marker of bone resorption, c-telopeptide (CTX). Additionally, in participants with CF, we will assess inflammation, with a c-reactive protein (CRP), and dysglycemia, with a continuous glucose monitor.
224288094|NCT06480604|DIETARY_SUPPLEMENT|Probiotic|Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
223950907|NCT06216704|DIAGNOSTIC_TEST|DXA|DXA will be utilized to obtain BMD of the total body, lumbar spine, and hip using a Hologic Horizon densitometer (Hologic Inc, Bedford, MA). Body composition will be obtained from total body scans.
224102810|NCT01113528|OTHER|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
224102811|NCT01113528|DRUG|Sugar pill|3 times daily
224102812|NCT02739464|OTHER|Exercise + SOC PT/OT|
224102813|NCT02739464|OTHER|SOC PT/OT|
224102814|NCT02279511|DRUG|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
224102815|NCT02279511|DRUG|PLACEBO|Infusion of 500 mL of saline solution. (IV)
224102816|NCT04549012|DRUG|Tranexamic acid|comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
224102817|NCT04549012|DRUG|Oxytocin|Oxytocin
224288095|NCT06480604|DIETARY_SUPPLEMENT|Placebo|Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
224288096|NCT00334256|DRUG|Tenofovir (TDF)|
224288097|NCT00334256|DRUG|Emtricitabine (FTC)|
224288098|NCT04131231|DRUG|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
224102818|NCT00397150|BEHAVIORAL|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
224102819|NCT05850377|DRUG|5-Aminolevulinic Acid (5-ALA) Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
224102820|NCT05850377|PROCEDURE|Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)|During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.
224102821|NCT04375878|DRUG|MS1819|MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
224102822|NCT04375878|DRUG|Porcine PERT|Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.
223950908|NCT06216704|DIAGNOSTIC_TEST|pQCT|pQCT will be utilized to obtain volumetric BMD (mg/cm3) of the left tibia. Measurements using a Stratec XCT 3000 device (Orthometrix, White Plains, NY) will be obtained at multiple locations, in relation to distal growth plate.
223950909|NCT03021616|OTHER|energy drink|32oz of commercially available energy drink
223950910|NCT03021616|OTHER|Moxifloxacin 400mg|400mg moxifloxacin active control drink
223950911|NCT03021616|OTHER|Placebo|Placebo drink
223950912|NCT00524069|BIOLOGICAL|bevacizumab|
223950913|NCT00524069|DRUG|capecitabine|
223950914|NCT00524069|DRUG|gemcitabine hydrochloride|
223950915|NCT00524069|OTHER|flow cytometry|
223950916|NCT00524069|OTHER|laboratory biomarker analysis|
223950917|NCT00524069|PROCEDURE|adjuvant therapy|
223950918|NCT00524069|PROCEDURE|computed tomography|
223950919|NCT00524069|PROCEDURE|neoadjuvant therapy|
223950920|NCT03877783|DIETARY_SUPPLEMENT|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
223950921|NCT03877783|BEHAVIORAL|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
223950922|NCT03877783|OTHER|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk \> 20% atorvastatin 40-80mg +ezetimib 10mg."
223950923|NCT03553225|DIETARY_SUPPLEMENT|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
223950924|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
223950925|NCT03553225|DIETARY_SUPPLEMENT|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
223950926|NCT03288506|BEHAVIORAL|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
223950927|NCT02676726|PROCEDURE|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
224102823|NCT03659435|DRUG|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
224102824|NCT03659435|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
224102825|NCT00428363|DEVICE|Cataract surgery with implantation of an intraocular lens|
224102826|NCT04382508|OTHER|Questionnaire|A weekly questionnaire will be filled in
224102827|NCT03280212|DRUG|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
224102828|NCT03759275|OTHER|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
224102829|NCT00194350|PROCEDURE|Test for Factor V Leiden gene mutation|
224288099|NCT04131231|DRUG|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
224102830|NCT05290220|DRUG|HLX07|1500 mg
224102831|NCT05290220|DRUG|HLX10|300 mg
223950928|NCT02676726|PROCEDURE|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
224102832|NCT05290220|DRUG|HLX04|15mg/kg
224102833|NCT05290220|DRUG|lenvatinib|12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
224102834|NCT05221190|PROCEDURE|Single buccal infiltration|injecting local anaesthetic solution into the soft tissues of the buccal sulcus adjacent to the target tooth.
224102835|NCT05221190|PROCEDURE|Inferior alveolar nerve block|Injection of local anesthetic solution into the pterygomandibular space to access the inferior alveolar nerve before it enters the mandible.
224102836|NCT01629849|DRUG|Placebo to BI 1021958 qd|tablet
224102837|NCT01629849|DRUG|BI 1021958 bid|tablets
224288100|NCT02405572|OTHER|infant formula|infant formulas
224288101|NCT01100450|BEHAVIORAL|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
224102838|NCT01629849|DRUG|Placebo to BI 1021958 bid|tablets
224288102|NCT04375995|DIAGNOSTIC_TEST|Impulse oscillometry|Impulse oscillometry test will be applied to all groups.
223537860|NCT03283488|DRUG|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
224288103|NCT04375995|DIAGNOSTIC_TEST|Spirometric pulmonary function test|Spirometric pulmonary function test will be applied to all groups.
224102839|NCT01629849|DRUG|BI 1021958 qd|tablet
224102840|NCT02441530|DIETARY_SUPPLEMENT|Vitamin D|
224102841|NCT02441530|DIETARY_SUPPLEMENT|Vitamin E|
224102842|NCT02441530|DRUG|Ibuprofen|
224102843|NCT03150940|DIAGNOSTIC_TEST|ECG|12 lead electrocardiogram used to demonstrate cardiac function
224102844|NCT03150940|DIAGNOSTIC_TEST|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
224102845|NCT01097902|DRUG|Ibuprofen|800 mg oral one time only
224288104|NCT04375995|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide (FENO) test|FeNO test will be applied to asthma group.
224288105|NCT04375995|DIAGNOSTIC_TEST|Thorax Computed Tomography|Thorax Computed Tomography will be taken to the asthma group.
224288106|NCT04375995|DIAGNOSTIC_TEST|Blood eosinophil level|The blood eosinophil level will be evaluated to determine the phenotype in the asthma group.
224288107|NCT04375995|OTHER|Asthma control test|Asthma control test questions will be applied to the asthma group.
224288108|NCT04375995|OTHER|Asthma quality of life scale|Asthma quality of life scale (AQLQ) will be applied to the asthma group.
224102846|NCT01097902|DRUG|Placebo tablet|Placebo tablet oral one time only
224102847|NCT04930939|OTHER|Aerobic training cardiac rehabilitation program|Moderate continuous training sessions and high intensity interval training sessiones were used to carried out aerobic training
223950929|NCT00164996|PROCEDURE|Local pharyngeal anaesthesia|
223950930|NCT00164996|DEVICE|Ultrathin endoscope|
223950931|NCT05914532|OTHER|lab testing|Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
223950932|NCT04389788|DEVICE|carboxy therapy|6 sessions of carboxy therapy every 2 weeks
223950933|NCT04389788|DEVICE|Dermapen with topical glutathione|6 sessions of Dermapen microneedling with topical glutathione every 2 weeks
224102848|NCT04512079|DRUG|Enoxaparin|Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
224102849|NCT04512079|DRUG|Apixaban|(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
224102850|NCT05641454|DIETARY_SUPPLEMENT|ElevATP supplement|ElevATP supplement containing apple and ancient peat extract
224102851|NCT05641454|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
224102852|NCT00866437|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
224102853|NCT00866437|DRUG|Skin test panel|"Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
224102854|NCT02058381|DRUG|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
224102855|NCT02058381|DRUG|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
224288109|NCT04375995|DIAGNOSTIC_TEST|Chest X Ray|Chest X Ray will be applied to the healthy control group.
224288110|NCT04530279|PROCEDURE|Clinical assessment|Clinical assessment of burn depth and the percentage of total body surface area (TBSA) burnt with any method
224288111|NCT04395248|PROCEDURE|Exploring potential risk factors of difficult intubation using ultrasound|Before surgery, ultrasound will be used to assess pretracheal soft tissue depth and height and width of tongue base. The distance from the skin to the anterior aspect of the trachea will be measured at three levels: vocal cords, thyroid isthmus, and suprasternal notch. With the patient in a seated position, the convex transducer of a portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be introduced to the skin of the neck in the submental region coronally, immediately cephalad to the body of the hyoid bone, and then in the area between the hyoid bone and the symphysis of the mandible. Maximal width of tongue base, tongue base height, and maximal height of mid-tongue will be measured. The laryngoscopy intubation will be performed using a size-3 or -4 Macintosh (Rüsch Inc., Duluth, GA, USA) blade and a styletted endotracheal tube. The laryngoscopic view will be graded according to Cormack and Lehane's classification with external laryngeal pressure applied.
224102856|NCT03381040|DEVICE|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
224102857|NCT03381040|DEVICE|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
224102858|NCT02715648|DRUG|Phenazopyridine|
224102859|NCT03460418|OTHER|Phone contact|Assessment of the different outcomes by means of a phone contact
224102860|NCT02493751|DRUG|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
224102861|NCT02493751|DRUG|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
224102862|NCT01132014|BIOLOGICAL|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
224102863|NCT00863668|DRUG|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
224102864|NCT00863668|DRUG|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
224102865|NCT00863668|PROCEDURE|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
224102866|NCT00863668|PROCEDURE|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
224102867|NCT06017323|DRUG|Gemcitabine|1000mg/m2 IV given days 1, 8, and 15every 28 days (1 cycle)
224102868|NCT06017323|DRUG|Nab paclitaxel|125 mg/m2 given days 1, 8, and 15every 28 days (1 cycle)
223537861|NCT03283488|DRUG|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
223537862|NCT01048398|DRUG|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
224102869|NCT06017323|DRUG|Proglumide Dose level 1|Daily dose of 1200 mg orally given as400 mg orally (PO), three times a day(TID) (dose level 1)
223537863|NCT01048398|DRUG|paracetamol|Control group: intravenous paracetamol 1g
224102870|NCT06017323|DRUG|Proglumide Dose level 2|Daily dose of 1600 mg orally given as800 mg orally (PO) twice a day (BID)(dose level 2).
224102871|NCT02367092|BEHAVIORAL|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
224102872|NCT01259466|DRUG|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
224102873|NCT03968510|PROCEDURE|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
224102874|NCT04282577|DIAGNOSTIC_TEST|urinary nephrin and alpha one microglobulin|urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
224102875|NCT04396457|DRUG|Pembrolizumab|Human PD-1 Monoclonal antibody
224102876|NCT04396457|DRUG|Pemetrexed|Antineoplastic antimetabolite
224102877|NCT01824602|DRUG|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
224102878|NCT01824602|DRUG|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
224102879|NCT01824602|DRUG|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
224102880|NCT01824602|DRUG|Placebo|Placebo sugar pills
224288112|NCT04395248|PROCEDURE|Radial artery catheterization using ultrasound guidance or blind palpation|For all patients, the wrist will be extended and taped to a board to maintain wrist extension. All patients will receive local skin anesthesia at the anticipated puncture site. All radial artery catheterizations will be performed by anesthesiology residents with similar levels of experience in both blind-palpation and ultrasound-guided radial arterial catheterization. In the ultrasound group, a linear vascular probe of portable ultrasound device (LOGIQTM, GE Healthcare, Chicago, IL, USA) will be applied to the skin to localize the radial artery and a 20-gauge catheter will be inserted distal to the transducer and directed according to the ultrasound image. In the palpation group, the radial artery will be identified by palpation, and the cannula will be directed by continuous or intermittent palpation of arterial pulsation. An attempt is defined as a new penetration of the skin with the needle, followed by an unlimited number of subcutaneous needle redirections.
224102881|NCT00291629|DRUG|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
224102882|NCT00291629|PROCEDURE|collection of mobilized peripheral blood stem cells|
224102883|NCT00291629|PROCEDURE|Intracoronary infusion of mobilized cells|
224102884|NCT00248950|BEHAVIORAL|Positive affect induction and /or self affirmation induction|
224102885|NCT02842814|OTHER|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
224102886|NCT02842814|DRUG|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
224102887|NCT02842814|DRUG|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
224102888|NCT03157557|BEHAVIORAL|Lifestyle treatment|Lifestyle treatment
224102889|NCT05555342|PROCEDURE|Irreversible electroporation (IRE) ablation|IRE will be performed using the NanoKnife or Aliya System. CT or cone-beam CT will be used to direct electrode placement.
224102890|NCT05555342|RADIATION|Radiation Therapy|Moderate-dose radiation therapy to the target tumor(s) in 1 fraction.
224102891|NCT06294028|OTHER|Adverse events collection|Collection of deaths from any cause, hospitalizations or emergency consultations for any event related to ventricular arrhythmia or its treatment (recurrence of ventricular tachycardia or complication linked to the defibrillator or crossover from one group to another)
224102892|NCT06294028|OTHER|Quality of life questionnaire EQ-5D-5L|"Questionnaire on the patient's quality of life and health in 6 questions: on mobility, the person's autonomy, current activities, pain, anxiety. Answers range from no problem to unable and 5 possible answers to each question.~The last question concerns the patient's health, the patient must rate his or her health on a scale of 0 to 100"
224102893|NCT06294028|OTHER|Medical-economic evaluation|"Collection of expenses incurred by the care of patients in each arm will be collected over a period of 36 months.~Direct medical and non-medical costs as well as costs related to absences from the workplace will be included in the analysis. Healthcare consumption will be collected using the National Health Data System (SNDS)."
223950934|NCT03885544|OTHER|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
223950935|NCT03885544|OTHER|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
223950936|NCT03885544|OTHER|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
223950937|NCT03845881|DRUG|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
224102894|NCT05036785|OTHER|Timing of suture removal|Patients will either be randomized to have their sutures removed at 7 or 10 days post skin surgery
224102895|NCT05207761|DRUG|D565|Q.D. in both eye
224102896|NCT05207761|DRUG|D930|T.I.D in both eye
223950938|NCT03845881|DRUG|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
223950939|NCT02662816|DEVICE|Proton magnetic resonance spectroscopy (1H MRS)|
223950940|NCT02662816|OTHER|a protein rich breakfast at home|
224102897|NCT04215679|OTHER|Three-dimensional immersive virtual reality application|In this group, individuals will be included in a game program that will last for 3 days a week for a total of 6 weeks and 45 minutes a day. Individuals will use the IVR to rehabilitate functions that are frequently used in daily life through task-oriented games. The IVR device will be placed on the head of the individual by closing the eyes of the individual and the Leap Motion device will be used to enable individuals to see their own hands in a virtual reality environment. In order to ensure the safety of individuals, practices shall be carried out with the individual sitting in the chair and leaning against the back. A total of 3 different games will be used for upper extremity function, each game will be 15 minutes and the total session time will be 45 minutes.
224102898|NCT04215679|OTHER|Motor imagery|Motor imagery will be performed with the eyes closed. In addition, for the safety of the individual, the individual will sit comfortably in a chair in a quiet environment and sit back. In the motor imagery group, individuals will be shown videos of the 3 games for 2 times in the IVR group and will be asked to imagine that they perform the same functions in the IVR games. The motor imagery will be 3 days a week for a total of 6 weeks and 45 minutes per day (including rest periods).
224102899|NCT04215679|OTHER|Conventional physiotherapy|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
223950941|NCT02662816|OTHER|a protein rich lunch at the Clinical Investigation Center|
223950942|NCT02486107|PROCEDURE|surgical procedure|
223537864|NCT01053507|DRUG|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
224102900|NCT06338891|OTHER|Main questionnaire|Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients
224102901|NCT06338891|OTHER|Secondary questionnaire|Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
224102902|NCT05300087|DRUG|Albuterol Sulfate Inhalation Aerosol 108mcg per actuation|MDI, 2 puffs, single dose, fasting
223950943|NCT01872104|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
223950944|NCT03654482|DEVICE|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
223537865|NCT01053507|DRUG|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
223950945|NCT03860129|DRUG|Isoflurane|Group A: Isoflurane (0.5 MAC)
223950946|NCT03860129|DRUG|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
223950947|NCT03860129|DRUG|Desflurane|Group C: Desflurane (0.5 MAC)
223950948|NCT02140879|DIETARY_SUPPLEMENT|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
223950949|NCT02140879|DIETARY_SUPPLEMENT|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
223537866|NCT03925571|OTHER|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music…).
223537867|NCT06397859|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
223950950|NCT03137849|OTHER|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
223950951|NCT03137849|OTHER|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
224102903|NCT05300087|DRUG|Proair HFA (albuterol sulfate) Inhalation Aerosol 90mcg per actuation|MDI, 2 puffs, single dose, fasting
224102904|NCT01390545|DRUG|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
224102905|NCT02725502|DRUG|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
223950952|NCT03137849|OTHER|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
224102906|NCT02725502|DRUG|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
223950953|NCT00070421|PROCEDURE|complementary or alternative medicine procedure|
223950954|NCT00070421|PROCEDURE|management of therapy complications|
223950955|NCT00070421|PROCEDURE|psychosocial assessment and care|
223950956|NCT04411771|BEHAVIORAL|Brief interventions|'Brief Interventions' (BI) is a generic term for a multitude of tools and interventions used in patient visits within PCBH. BI start immediately at the initial consultation, which ends with a personally tailored and evidence-informed plan adjusted to the patient's context. As such, there is no separation between assessment and intervention. The interventions within BI often have their foundation in CBT, ACT or MI. The common theme is that they are principle-based rather than manual-based and focus on behavioral change in relation to a problem that is perceived both possible to affect and relevant to the patient, rather than focusing on a specific diagnosis or condition. Follow-up appointments are scheduled flexibly depending on the patient's perceived need. Usually a BI treatment consists of 1-4 appointments with several weeks apart and ends when the patient feels that they are moving in the right direction.
223950957|NCT04411771|BEHAVIORAL|Guided self-help CBT|The patient receives a previously scientifically evaluated CBT-based self-help book for one of the following conditions: depression, generalized anxiety disorder, panic disorder, social anxiety, health anxiety, insomnia, or stress/burnout. The therapist support consists of 3-6 contacts throughout the 6-12 weeks long intervention period as decided by the clinician and patient together, as long as at least one and not more than three are physical visits at the center and the rest via phone, video conferencing, or secure internet messages. Clinicians delivering shCBT will need four days of reading and two days of training to be able to make initial assessments and problem profiling and use the self-help books.
223950958|NCT02365402|DRUG|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
223950959|NCT02262988|PROCEDURE|Total knee replacement|Total knee replacement (TKA)
224102907|NCT02246361|PROCEDURE|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
224102908|NCT00761215|DRUG|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
224102909|NCT00761215|DRUG|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
224102910|NCT00761215|DRUG|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
223537868|NCT03875638|DRUG|Levetiracetam|Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
223950960|NCT02773732|DRUG|Ciprofloxacin 750 MG|750 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
223950961|NCT02773732|DRUG|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
223950962|NCT02773732|DRUG|Ciprofloxacin 1000 MG|1000 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
223950963|NCT02773732|DRUG|Ciprofloxacin 500 mg|500 mg ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
223950964|NCT01860079|PROCEDURE|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
224102911|NCT02882607|BEHAVIORAL|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
224102912|NCT03992313|OTHER|Community-based HCV rapid test|HCV rapid tests will be done in the village
224102913|NCT03992313|OTHER|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
224102914|NCT03992313|OTHER|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
224102915|NCT03992313|OTHER|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
224102916|NCT06971458|PROCEDURE|Sclerotherapy|ultrasound (US)-guided sclerotherapy for the treatment of ovarian endometrioma
223537869|NCT03875638|DRUG|Placebo oral capsule|The placebo is a capsule that is identical in appearance to the levetiracetam
223537870|NCT04001842|OTHER|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
223537871|NCT02495285|DRUG|Gelofusine 4%|
224102917|NCT06970067|BEHAVIORAL|Active Middle School Communities|This intervention will engage multi-sectoral and multi-generational community members and middle school students to co-produce (co-design, co-implementation, and co-evaluation) contextually-responsive intervention strategies to improve access to active transport and leisure, resulting in increased physical activity and decreased risk for chronic disease in middle school communities. This intervention will use community-based participatory methods, with resources provided for changes in the built environment around the school catchment area.
224102918|NCT06970145|DRUG|Anlotinib|Anlotinib Hydrochloride Capsules (12mg),Chiatai Tianqing Pharma (China).
224102919|NCT06971822|DIETARY_SUPPLEMENT|Protein Supplementation|We are assessing the supplementation of a controlled diet with beta-lactoglobulin protein compared to regular isonitrogenous whey protein. We will make these comparisons over both the 24 hour rested and 24 hour post-exercise states. Beta-lactoglobulin has a higher leucine content than traditional whey protein, with this leucine amino acid thought to have a critical role as an anabolic stimulus to initiate muscle protein synthesis.
224102920|NCT06970938|OTHER|Cardiac rehabilitation program|The experimental group patients were included in the cardiac rehabilitation program. The cardiac rehabilitation program was implemented in the cardiopulmonary rehabilitation unit with bicycle ergometry devices by a team consisting of a physical medicine and rehabilitation physician, physiotherapist and nurse. The target heart rate that could be achieved during exercise was determined according to the patient's age and the medications he/she used. The exercise intensity was planned as low and moderate according to the target heart rate percentage. The program was organized as 30 sessions, 5 days a week, for 6 weeks. The sessions were implemented for half an hour while the patients were monitored from the bicycle ergometry device.
224102921|NCT06350383|BEHAVIORAL|WINGS+PM+|WINGS+PM+ is a safety, harm reduction, and brief psychological intervention combined and adapted by community members from informal settlements in Kenya (IPV survivors, health clinic staff, and CHVs) from two evidence-based interventions: Wings of Hope (WINGS) and Problem Management Plus (PM+). This intervention was designed to be facilitated by non-specialists (e.g., CHVs). It involves seven 90-minute weekly sessions. The intervention is informed by social cognitive theory.
224102922|NCT06350383|BEHAVIORAL|PM+-only|PM+: is a brief psychological intervention also designed to be facilitated by non-specialists (e.g. CHVs) and focused on problem management and evidence-based behavioral strategies to enhance one's capacity to adaptively manage psychological distress. It has been shown to be effective at reducing psychological distress among women who have experienced gender-based violence in informal settlements in Nairobi, Kenya. PM+ involves five 90-minute, weekly individual sessions.
224102923|NCT05662514|DIETARY_SUPPLEMENT|Bifidobacterium animalis subsp. lactis BLa80|"Test product contain 3 × 109 colony-forming units \[CFU\] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days."
224288113|NCT04395248|DEVICE|Comparing the effectiveness of preoxygenation between high-flow nasal cannula and facemask|In the HFNC group, preoxygenation will be performed using HFNC (Optiflow™, Fisher \& Paykel Healthcare, Auckland, NZ), nasal prongs set at 30 L/min flow of heated and humidified 100% oxygen. In the facemask group, patients will breath spontaneously with an anesthetic facemask and 100% oxygen 15 L/min. Gas flow for HFNC or facemask can be adjusted depending on patients' tolerance. During laryngoscopy intubation, HFNC will be left in place with the nasal flow escalated to 50 L/min of 100% oxygen in order to achieve apneic oxygenation. In the facemask group, the facemask will be removed when apnea occurs. After tracheal intubation, correct placement of the endotracheal tube will be confirmed by capnography and the nasal prongs of the HFNC group will be removed.
224288114|NCT04395248|DRUG|Type of volatile anesthetics and M-Entropy guidance of anesthesia depth|"At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge."
224288115|NCT00063882|RADIATION|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
224288116|NCT00063882|RADIATION|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
223950965|NCT04498780|DRUG|Sacubitril-Valsartan|Observational study during the clinically indicated treatment
223950966|NCT03116191|DRUG|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
223950967|NCT03116191|DRUG|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
223537872|NCT02495285|DRUG|Gelaspan 4%|
223537873|NCT04790500|OTHER|mobilization technique|Mobilization of sacroiliac joint which will increase the range of motion and reduction in pain and improvement in functional limitation.
223950968|NCT05174026|OTHER|Fludeoxyglucose F-18|Given IV
223950969|NCT05174026|PROCEDURE|Magnetic Resonance Imaging|Undergo 18F-FDG PET-MRI
223950970|NCT05174026|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET-MRI
223950971|NCT00336882|DRUG|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
223950972|NCT00336882|DRUG|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
224102924|NCT05662514|OTHER|Placebo|To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
224102925|NCT04201379|OTHER|quality of life assesment|The sociodemographic and clinical characteristics of the individuals who meet the study criteria will be recorded. Evaluations of the participants will be done only once
224102926|NCT01781949|OTHER|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
224102927|NCT01781949|OTHER|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
224102928|NCT01781949|OTHER|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
224288117|NCT00063882|RADIATION|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
224288118|NCT06231459|DRUG|Evolocumab|Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
223722732|NCT04430543|BEHAVIORAL|Cognitive Bias Modification|"CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%)."
223950973|NCT01341769|OTHER|Dietary Intervention|
223950974|NCT01341769|OTHER|Dietary Intervention|
224288119|NCT01103479|BEHAVIORAL|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
223950975|NCT01341769|OTHER|Dietary Intervention|
223950976|NCT01341769|OTHER|Dietary Intervention|
223950977|NCT01960972|OTHER|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
223950978|NCT03069209|BIOLOGICAL|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
223950979|NCT00006079|DRUG|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
223950980|NCT00006079|OTHER|Placebo|Patients receive oral placebo daily for 28 days.
223950981|NCT02181179|BEHAVIORAL|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
223950982|NCT01987518|OTHER|Procedure surgery behavioral and genetic diagnosis|Observational Study
223950983|NCT01987518|PROCEDURE|quality of life after different type of surgery|
224102929|NCT03050164|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
224102930|NCT03050164|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
224102931|NCT01561287|PROCEDURE|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
224102932|NCT01561287|PROCEDURE|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
224102933|NCT00867750|DEVICE|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
224102934|NCT00867750|DRUG|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
224102935|NCT03822910|DIAGNOSTIC_TEST|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
224102936|NCT03822910|DIAGNOSTIC_TEST|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
224102937|NCT03822910|DIAGNOSTIC_TEST|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
223537874|NCT04790500|OTHER|muscle energy technique|Muscle energy technique it is known as active muscular relaxation technique. It helps in lengthening the shorten muscle and increasing range of restricted muscles
224102938|NCT02302495|DRUG|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
224102939|NCT05057351|OTHER|Isopentenyltheophylline 0.44% + Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
224102940|NCT05057351|OTHER|Glycerin 4.56%|Application of topical cream twice a day on the area affected by Atopic Dermatitis
224102941|NCT00420914|PROCEDURE|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
224102942|NCT05508152|DRUG|Wound irrigation with amoxicillin-clavulanate in saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes."
224102943|NCT05508152|DRUG|Wound irrigation with a saline solution|"Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes."
224102944|NCT03008512|DRUG|Genexol-PM|
224102945|NCT03486730|DRUG|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
224102946|NCT04068597|DRUG|CCS1477|Oral capsule
224102947|NCT04068597|DRUG|Pomalidomide|oral capsule
224102948|NCT04068597|DRUG|Dexamethasone|oral tablet
223537875|NCT03957382|DEVICE|Accero® (heal) Stent|The Accero® (heal) Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
224102949|NCT04068597|DRUG|Azacitidine|Powder suspension for Injection
223950984|NCT04890899|PROCEDURE|Cystic enculation of spleen hydatid|Preoperative preparation did according to the general condition of the patient and fitness for anaesthesia. Laparotomy did under general anaesthesia, supine position, the abdomen opened either by midline or left subcostal incision. Identification of splenic hydatid cyst. Exploration of the peritoneal cavity for undetected hepatic or peritoneal hydatid preoperatively. Isolation of operative field by packs socked with hypertonic solution (20 -30 % hypertonic saline). Aspiration of the cyst fluid. Injection of suitable amount about 5 ml of (1 % of cetramid) solution and waiting for at least 5 minutes and then re-aspiration. The spleen is not needed to mobilize. Extraction of the endocyst and washing of the cavity with normal saline. Occupying the cystic cavity intracystic drain. Perioperative and postoperative close observation of the patient for an anaphylactic reaction or any other complication. Follow-up of the patient until discharge from hospital on (3th - 5th) days.
223950985|NCT03631966|DRUG|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
224102950|NCT04068597|DRUG|Venetoclax|Oral tablet
224102951|NCT02279316|DRUG|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
224102952|NCT02279316|OTHER|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
224102953|NCT02279316|OTHER|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
224102954|NCT06107829|DRUG|Valbenazine Oral Capsule|Open-label twenty-four-week treatment with valbenazine oral capsules (up to 80 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
224102955|NCT00297414|OTHER|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
223950986|NCT00989118|PROCEDURE|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
224102956|NCT00032929|DRUG|Selegiline|
224102957|NCT02830165|OTHER|Laboratory Biomarker Analysis|Correlative studies
223950987|NCT03731767|PROCEDURE|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
223950988|NCT01124942|DEVICE|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
224102958|NCT02830165|OTHER|Quality-of-Life Assessment|Ancillary studies
224102959|NCT02830165|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224102960|NCT05024994|DRUG|E7820|100mg of E7820 QD
223537876|NCT05160948|OTHER|Informational Report|All EcoMAPPE participants and their caregivers will be invited to complete a questionnaire to assess their understanding of air pollution and attitudes and beliefs about science and research before and after receiving their individual study air pollution monitoring results collected as part of their participation in EcoMAPPE.
223950989|NCT01124942|DEVICE|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
223950990|NCT04103099|DIETARY_SUPPLEMENT|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
224102961|NCT06358872|DRUG|Azithromycin for Oral Suspension|Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
224102962|NCT06159855|OTHER|Intervention group: nurse-led education for bowel preparation of colonoscopy|"1. PRE-TEST~   a) Patients will be evaluated using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~2. INTERVENTION~   1. Patients will be given face-to-face training in the clinic training room of the unit.~  2. After face-to-face training is given, an educational brochure will be given to the patient.~  3. If the patient is constipated, the bowel preparation diet is requested to be started 5 days in advance. If the patient is not constipated, the bowel preparation diet is started 3 days in advance.~  4. After the intervention group is given bowel preparation training, reminders about colonoscopy will be made via instant messaging 3 to 5 days before the day of the colonoscopy.~3. LAST TEST~   1. Data will be collected again using the Patient Information Survey, Procedure Compliance Survey and Beck Anxiety Scale.~  2. The cleanliness of the intestines will be evaluated by the physician using the Ottawa Bowel Preparation Scale."
224102963|NCT00484354|DRUG|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
224102964|NCT00484354|OTHER|Normal saline|IV Normal saline with volume given determined by patient weight
224102965|NCT00484354|OTHER|Bicarbonate|IV bicarbonate, dosed by weight
223537877|NCT04016857|PROCEDURE|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
223537878|NCT04016857|PROCEDURE|Control|deflated cuff placed on the left arm for 40 min
223537879|NCT02875470|DEVICE|Intensiv Perio Set|Diamond burs for root planing
223537880|NCT02875470|DEVICE|Gracey curette|
223950991|NCT05445557|DRUG|RZL-012|small synthetic molecule for submental fat reduction
223950992|NCT05445557|DRUG|Placebo|Placebo
223950993|NCT02482324|DRUG|ALZT-OP1a|Mast cell stabilizer
223950994|NCT02482324|DRUG|ALZT-OP1b|anti-inflammatory
223950995|NCT02482324|DEVICE|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
223950996|NCT02834559|DRUG|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
224102966|NCT00484354|OTHER|Placebo|Normal saline, with volume given based on patient weight
224102967|NCT01112709|BEHAVIORAL|SCT-based Resistance Training exercise program|Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
224102968|NCT01112709|OTHER|Standard Intervention with minimal contact|This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
224102969|NCT03024775|DIETARY_SUPPLEMENT|Wheat flour|Wheat flour will be administered three times per day for 15 days.
224102970|NCT03024775|DIETARY_SUPPLEMENT|Placebo|Placebo (xylose) will be administered three times per day for 15 days.
224102971|NCT01201499|DRUG|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
224102972|NCT01201499|DRUG|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
224102973|NCT01780233|DRUG|Fentanyl 400 µg sublingual spray|
224102974|NCT01780233|DRUG|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
224102975|NCT01780233|DRUG|Fentanyl citrate injection 100 µg intravenously|
224102976|NCT01780233|DRUG|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
224102977|NCT03530514|DRUG|REGN4461|REGN4461
224102978|NCT03530514|DRUG|Placebo|Placebo-matching REGN4461
224102979|NCT05676710|DRUG|Linperlisib|"Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation."
224102980|NCT01916395|DRUG|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
224102981|NCT00934609|BEHAVIORAL|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
224102982|NCT01747902|PROCEDURE|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
223537881|NCT01783210|BEHAVIORAL|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
223537882|NCT01783210|BEHAVIORAL|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
223537883|NCT03549741|DRUG|Clomiphene Citrate 50mg|oral tablets
223950997|NCT02834559|DRUG|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
223950998|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised CARE program
223950999|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo supervised TARE program
223951000|NCT03091842|BEHAVIORAL|Exercise Intervention|Undergo home-based stretching program
224102983|NCT01747902|PROCEDURE|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
223951001|NCT03091842|OTHER|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
223951002|NCT03091842|OTHER|Laboratory Biomarker Analysis|Correlative studies
224102984|NCT04377945|DRUG|Part 1, JM-010 component Group A|JM-010 component Group A
224102985|NCT04377945|DRUG|Part 1, JM-010 component Group B|JM-010 component Group B
224102986|NCT04377945|DRUG|Part 1, JM-010 component Group C|JM-010 component Group C
224102987|NCT04377945|DRUG|Part 1, Placebo Group|Placebo Group
224102988|NCT04377945|DRUG|Part 2, JM-010 combination Group A|JM-010 combination Group A
224102989|NCT04377945|DRUG|Part 2, JM-010 combination Group B|JM-010 combination Group B
224102990|NCT04377945|DRUG|Part 2, JM-010 component Group C|JM-010 component Group C
224102991|NCT04377945|DRUG|Part 2, Placebo Group|Placebo Group
224102992|NCT01450137|DRUG|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
224102993|NCT01450137|DRUG|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
224102994|NCT02544776|DRUG|Clomifene citrate ( clomid 50 mg )|
224102995|NCT02544776|DRUG|Amlodipine|
224102996|NCT03580447|DIETARY_SUPPLEMENT|Citrus extract|Citrus extract
223951003|NCT03091842|OTHER|Quality-of-Life Assessment|Ancillary studies
223951004|NCT03091842|OTHER|Questionnaire Administration|Ancillary studies
223951005|NCT00167999|DRUG|piperacillin-tazobactam|
224102997|NCT03580447|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224102998|NCT04232449|DRUG|PREDNISON Galepharm Tabl. 20 mg|5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
224102999|NCT04232449|DRUG|placebo tablets|5 daily- doses of placebo (2 tablets)
223537884|NCT03549741|DRUG|Cabergoline Oral Tablet|oral tablets
223537885|NCT03549741|DRUG|Placebo Oral Tablet|oral tablets
223537886|NCT05468281|OTHER|Checklist implementation|. Our strategies will include a) selection of local physician champions from the ED and cardiology; b) discussion of the goals of the study with the local physician groups; c) formal introduction of the CAEP Checklist to the physicians and nurses by means of presentations at staff meetings, emails, and an online video; d) development of an action plan to address local barriers to implementation; e) creation of a free smartphone application; f) regular reminders; and g) and distribution of charts of site compliance.
223537887|NCT05135598|OTHER|Partners for Life health behavior change program|A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
223537888|NCT00330369|DRUG|Darusentan|Darusentan administered orally once daily
223537889|NCT00330369|DRUG|Darusentan Placebo|Placebo to match darusentan administered orally once daily
223537890|NCT00952705|BIOLOGICAL|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
223537891|NCT00952705|BIOLOGICAL|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
223537892|NCT00952705|BIOLOGICAL|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
223537893|NCT04401774|DRUG|Nivolumab|Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
223537894|NCT06417671|DIETARY_SUPPLEMENT|Postbiotics supplementation|The participants will consume one capsule per day.
223951006|NCT06648785|DRUG|oxaliplatin|85 mg/m2 oxaliplatin
223951007|NCT06648785|DRUG|Fluoropyrimidine|oral fluoropyrimidine 1000mg/m2
223951008|NCT04672967|DIAGNOSTIC_TEST|BioROSA MAP test|The BioROSA MAP test is a blood test that is being developed to predict ASD risk
223951009|NCT03481751|DIAGNOSTIC_TEST|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
223951010|NCT03279406|DEVICE|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
223951011|NCT06047535|DRUG|Naxitamab|"Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles."
223951012|NCT04365205|PROCEDURE|Endobronchial biopsy|Endobronchial biopsies will be collected following a standardized procedure based on established guidelines. Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure. Anesthesia of the upper airways will be achieved with lidocaine 5% spray. The total amount of lidocaine per subject is limited to 225 mg. General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg). The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe. Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed. The duration of bronchoscopy is 15 minutes to 30 minutes. After the procedures, subjects will receive a short acting bronchodilator if required.
223951013|NCT01948024|DRUG|SAPHRIS|10 mg BID sublingual tablet
223951014|NCT01948024|DRUG|Asenapine|10 mg BID sublingual tablet
223951015|NCT03602950|BIOLOGICAL|PRP|autologous PRP will be injected subcutaneously before skin closure at time of elective CS
223951016|NCT01323790|DRUG|NKTR-118|12.5 mg oral tablet once daily
223951017|NCT01323790|DRUG|NKTR-118|25 mg oral tablet once daily
223951018|NCT01323790|DRUG|Placebo|Placebo to NKTR-118
223951019|NCT01351259|DEVICE|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
223951020|NCT03352726|DRUG|DBV712 IHRP|DBV712 Solution for Skin Prick Test
223951021|NCT06359548|PROCEDURE|Peeled ILM Reposition|"The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required."
224103000|NCT04037085|DRUG|Ketamine|Subjects in the intervention arm will receive infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Concentrations of ketamine and ketamine metabolites (nor-ketamine, NKET; and dehydro-nor-ketamine, DHNK) are measured in maternal plasma and urine as well as breastmilk. Maternal side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
224103001|NCT05191628|BIOLOGICAL|Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated amniotic membrane placed by the investigator during macular hole surgery
224103002|NCT02449330|DRUG|Teneligliptin|
223951022|NCT06359548|PROCEDURE|ILM Peeling|The ILM was stained using 0.1 mL of indocyanine green（ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.
223951023|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
223951024|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
224103003|NCT05077761|DEVICE|Active High-intensity laser therapy|"High-intensity laser therapy will be used in the contact method, with the laser beam irradiated over the hamstring muscle. Dosage and parameters for the laser will be calculated.~Parameters-~1. Wavelength- 980 nm~2. Intensity/Power density- 3W/cm2~3. Emission mode- Continuous Emission~4. Energy (Joules)- 490 J~5. Irradiation time- 70 Sec on each point~6. Peak power- 15 Watt~7. Irradiation points- 09"
224103004|NCT05077761|DEVICE|Sham High-intensity laser therapy|Sham High-intensity laser therapy will be used in the contact method, without the laser beam irradiation over the hamstring muscle.
224103005|NCT02001740|DRUG|Triamcinalone (steroid) and lidocaine|receive once
224103006|NCT02001740|OTHER|Lidocaine|receive once
223537895|NCT06417671|DIETARY_SUPPLEMENT|Placebo supplementation|The participants will consume one capsule per day.
223951025|NCT01880736|DRUG|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
223951026|NCT01706666|DRUG|bortezomib|Given SC
223951027|NCT01706666|DRUG|cyclophosphamide|Given PO
223951028|NCT01706666|DRUG|lenalidomide|Given PO
224103007|NCT01477450|DEVICE|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
224103008|NCT01477450|DEVICE|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
224103009|NCT06418542|DEVICE|use of florescein|Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
224103010|NCT04902287|BEHAVIORAL|Training Intervention for the Engagement of Families (TIES)|This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
223537896|NCT02502552|OTHER|blood specimen|blood specimen
223537897|NCT05378802|OTHER|different modes of mechanical ventilation|Four different ventilation modes were performed one by one and respiratory parameters were recorded.
223537898|NCT06632782|BEHAVIORAL|Breath Awareness using pyramid|Participants are provided 1-2 hr training for 6 weeks on bringing breath awareness to the present moment using a pyramid
223537899|NCT04615546|BEHAVIORAL|Use of Continuous Glucose Monitor (CGM)|Participants will wear CGM
223537900|NCT04615546|OTHER|"Use of Cardea Solo monitoring"|"Participants will wear a Cardea Solo patch during blinded CGM use"
223537901|NCT06180603|PROCEDURE|Gravity fluid drainage in the radiology department|Patients will be referred to the radiology department. Thoracentesis will be performed according to local guidelines.
223951029|NCT01706666|OTHER|laboratory biomarker analysis|Correlative studies
223951030|NCT01706666|DRUG|dexamethasone|Given PO
223951031|NCT01706666|PROCEDURE|quality-of-life assessment|Ancillary studies
223951032|NCT01249209|DEVICE|lifestyle advice|
223951033|NCT05011292|BEHAVIORAL|Educational Video about SCB|3-4 minutes video about SCB.
224103011|NCT04630054|DEVICE|Face mask|Intervention individuals will be given cloth or surgical face masks.
224103012|NCT04630054|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
224103013|NCT04632979|PROCEDURE|Backwards running on a Treadmil with a negative slope|Running backward on a treadmill with a negative slope
224103014|NCT02866344|PROCEDURE|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
223722733|NCT04430543|BEHAVIORAL|Sham Training|"Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)"
223722734|NCT00068471|DRUG|anidulafungin|
223722735|NCT06499077|DIAGNOSTIC_TEST|Sampling of exhaled breath|Exhaled breath of all participants is collected following our standardized procedure
223951034|NCT05011292|BEHAVIORAL|Survey on child feeding and related knowledge and practices|Short survey about infant feeding practices (3-4 minutes). No identifying information will be collected. The general scope of topics covered in the surveys will be attitudes toward the sugar-containing beverage reduction (SCB) videos played at the clinic as well as SCB knowledge and practices of parents and their children.
223951035|NCT05011292|BEHAVIORAL|Educational Video other than SCB|Educational video about a topic other than infant SCB consumption.
223951036|NCT03908164|BIOLOGICAL|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
223951037|NCT00046475|DRUG|Midodrine Hydrochloride|
223951038|NCT03375424|BIOLOGICAL|vedolizumab|duration of disease and kind of therapy
223951039|NCT02732132|DRUG|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
223951040|NCT02732132|DRUG|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
223951041|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
223951042|NCT00930475|DRUG|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
223951043|NCT00006045|BIOLOGICAL|lintuzumab|
223951044|NCT00006045|DRUG|cytarabine|
223951045|NCT00006045|DRUG|etoposide|
223951046|NCT00006045|DRUG|mitoxantrone hydrochloride|
223951047|NCT02441569|BEHAVIORAL|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
223951048|NCT02441569|BEHAVIORAL|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
223951049|NCT00266656|DRUG|Humatrope|According to investigator's clinical practice and guided by the approved package insert
223951050|NCT01720706|DEVICE|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
223951051|NCT00018512|PROCEDURE|Implant-supported denture|
223951052|NCT01990625|DEVICE|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
224103015|NCT02866344|PROCEDURE|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
224103016|NCT01167127|DRUG|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
224103017|NCT04002167|BEHAVIORAL|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
224103018|NCT04002167|BEHAVIORAL|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
224103019|NCT03200951|DRUG|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
223537902|NCT06180603|PROCEDURE|Manual drainage in the emergency department|Thoracentesis will be performed according to current guidelines in the emergency department. Fluid will manually be drained using a syringe connected to a three-way stopcock. Thoracentesis will be stopped early if:
223537903|NCT01510574|DRUG|Misoprostol|3 x 200mcg tablets of oral misoprostol
223951053|NCT01836159|OTHER|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~1. Popping a stationary balloon~2. Popping a moving balloon~3. Popping a pair of stationary balloons~4. Popping a pair of moving balloons~5. Stretching a balloon to pop~6. Balloon/Text distraction test"
223951054|NCT01836159|OTHER|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
223951055|NCT00532766|DRUG|Jusline|
223951056|NCT04255498|DRUG|Etanercept|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
223951057|NCT04255498|DRUG|Mifepristone|"Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies."
223951058|NCT03371316|BIOLOGICAL|ViaShield|Anti-adhesion scores using amnion patch
223951059|NCT01971255|BIOLOGICAL|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
223951060|NCT05364385|DRUG|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)|Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
223951061|NCT05364385|DRUG|Infants in the control group (S/P group) receive placebo (Normal saline 1mL)|Infants in the control group (S/P group) will receive surfactant 2.5 mls/kg and placebo (Normal saline 1mL)
224103020|NCT03200951|DRUG|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
224103021|NCT04820192|OTHER|Craniosacral Therapy|The Upledger method of applying both specific and non-specific manual therapy of gentle, sustained, non-invasive stretch to soft tissues of fascia, meninges and osseous attachments. Fluid exchange is also believed to be a resulting result of CST. Treatment is applied to myofascial and osseous sites over the entire body, tending to specific and unique constellation of tissue restrictions and osseous compressions of soft tissue.
224103022|NCT01253733|BEHAVIORAL|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
223537904|NCT01510574|DRUG|placebo|3 x placebo tablets resembling misoprostol taken orally
223537905|NCT03659578|DRUG|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
224103023|NCT04970667|DRUG|Flupentixol melitracen tablets|Patients were treated with Flupentixol and melitracen tablets for 12 weeks
224103024|NCT01321489|DRUG|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
224103025|NCT01321489|DRUG|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
224103026|NCT03781557|DIETARY_SUPPLEMENT|Docosahexaenoic acid|High-concentrated DHA
224103027|NCT03781557|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|High-concentrated EPA
224103028|NCT03781557|DIETARY_SUPPLEMENT|Olive oil|Olive Oil softgels
224103029|NCT00642330|DRUG|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
224103030|NCT00642330|DRUG|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
224103031|NCT01974791|BEHAVIORAL|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
224103032|NCT00003729|DRUG|cytarabine|
224103033|NCT00003729|DRUG|fludarabine phosphate|
224103034|NCT00003729|DRUG|idarubicin|
224103035|NCT01586091|DRUG|Levocetirizine Oral Tablet|
224103036|NCT01586091|DRUG|Fexofenadine 60 Mg Oral Tablet|
224103037|NCT01586091|DRUG|Placebo Oral Tablet|
224103038|NCT01935219|BEHAVIORAL|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
224103039|NCT01935219|BEHAVIORAL|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
224103040|NCT01935219|BEHAVIORAL|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
224103041|NCT00590161|DRUG|pentoxifylline (PTX)|400 mg PO tid
224103042|NCT00590161|DRUG|placebo|placebo tid
224103043|NCT03791632|OTHER|classical lecture style presentation|classical lecture style presentation
224103044|NCT03791632|OTHER|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
224103045|NCT03791632|OTHER|digital media intervention|digital media intervention
223951062|NCT06459544|DIAGNOSTIC_TEST|Bobath Technique with core stability|exercise to improve balance motor learning stretegy is basically used. Bobath in which we assess patient's posture, inhibit the abnormal muscle tone and facilitate normal patterns and posture through handling and posture. we also use sensory inputs like propioception to promote normal pattern. we take some exercise based on bobath technique with core stability like Bridging with core stability, quadroped with core stability, sitting and standing with core stablity, single leg standing , dynamic balance with core stability.treatment plan based on 45 minutes per day, 6 days a week for 4 week.
223951063|NCT06459544|OTHER|Conventional treatment for balance|like stretching, strenthening the Lower extremity muscles , PROMS, AAROMS,AROMS, RROMS,some balance exercise like sitting and standing
223951064|NCT01802619|OTHER|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
223951065|NCT01802619|OTHER|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
224103046|NCT02503891|DEVICE|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
224103047|NCT01687673|DRUG|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
224103048|NCT01687673|DRUG|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
224103049|NCT05012566|DEVICE|Juvederm|"* Juvederm Volbella: 15mg/ml, it is injected 1.5ml per patient per treatment (a total of 3ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Volifit: 17.5mg/ml, it is injected 3ml per patient per treatment (a total of 6ml per patient split in 2 treatment sessions at a 4 months interval);~* Juvederm Voluma: 20mg/ml, it is injected 5ml per patient per treatment (a total of 10ml per patient split in 2 treatment sessions at a 4 months interval)"
224288120|NCT01103479|BEHAVIORAL|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
223951066|NCT00145145|BIOLOGICAL|MAGE-3.A1 peptide and CpG 7909|
223951067|NCT05330000|DRUG|4 mg/kg Voriconazole|Low dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 4 mg / kg for 80 min.
223537906|NCT03659578|RADIATION|split-course radiotherapy|Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost
223537907|NCT03659578|DRUG|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
223951068|NCT05330000|DRUG|6 mg/kg Voriconazole|High dose group: 24 healthy adult subjects are planned to be enrolled. Intravenous drip Voriconazole for injection in fasting state per cycle. The dosage was 6 mg / kg for 120 min.
223951069|NCT02481011|DRUG|antithrombotic drugs|
224103050|NCT05012566|DRUG|Vistabex|Vistabex: 50U/vial, it is injected up to 80U per patient per treatment (2 treatment sessions at a 4 months interval)
224103051|NCT00618956|DRUG|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.
224103052|NCT00618956|DRUG|Placebo|Placebo
224103053|NCT02212418|OTHER|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
224103054|NCT03751384|DIETARY_SUPPLEMENT|Möllers Omega-3 Ekstra Sterk|
224103055|NCT03751384|DIETARY_SUPPLEMENT|Nutrifriend Cachexia|
224103056|NCT04150458|DRUG|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
224103057|NCT02006576|DRUG|600 mg ibuprofen three times daily for 48 weeks|
224103058|NCT02006576|OTHER|Placebo three times daily|
224103059|NCT00904787|DRUG|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
224103060|NCT03478683|DRUG|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
224103061|NCT03478683|DRUG|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
224103062|NCT03478683|DRUG|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
224103063|NCT03478683|DRUG|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
224103064|NCT03478683|DRUG|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
224103065|NCT03478683|DRUG|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
224103066|NCT03478683|DRUG|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
224103067|NCT03478683|DEVICE|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
224103068|NCT03478683|DEVICE|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
224103069|NCT03478683|DEVICE|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
224103070|NCT01999829|DRUG|citrate of caffeine|
224103071|NCT01999829|DRUG|placebo|
223951070|NCT03406390|PROCEDURE|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
224103072|NCT03483532|DIETARY_SUPPLEMENT|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
224103073|NCT03483532|DIETARY_SUPPLEMENT|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
224103074|NCT04152759|DRUG|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
224103075|NCT06596304|OTHER|Low intensity-resistance training with lower limb blood flow restriction|In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).
224288121|NCT02560428|BEHAVIORAL|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
223951071|NCT00428714|DRUG|enzastaurin|Administered orally
223951072|NCT04813133|OTHER|Synchronized Lifestyle Modification Program|Synchronization of dietary intake with circadian rhythm of the body.
223722736|NCT04517812|OTHER|Exercise-based games via the VirtualRehab platform|A 12-week exercise-based home rehabilitation intervention delivered via the VirtualRehab platform. A personalised exercise-based rehabilitation plan will be created for each participant.
223951073|NCT04813133|OTHER|Synchronized Lifestyle Modification Program and Physiotherapy|Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)
223951074|NCT04813133|OTHER|Physiotherapy|Only Physiotherapy training which includes ( Aerobics, flexibility, resistance and balance exercises.)
224103076|NCT06596304|OTHER|High Intensity Resistance Training|In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
224103077|NCT06602336|DEVICE|Continuous Lactate Monitoring Device|Continuous interstitial fluid lactate monitoring using the Abbott Investigational Lactate Device.
223537908|NCT04539171|OTHER|Pain Neuroscience Education and Physical Exercise|Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
224103078|NCT00735332|DRUG|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
224103079|NCT06444438|DIAGNOSTIC_TEST|subarachnoid hemorrhage|CT presented subarachnoid hemorrhage
224103080|NCT05175170|BEHAVIORAL|Decision-aid|The decision aid consists of domains related to human reproduction, fertility, and fertility preservation. The domains address priority learning objectives in each domain to increase knowledge on the impact of gender-affirming medical interventions on fertility and fertility preservation options.
224103081|NCT03153852|DRUG|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
224103082|NCT03153852|DRUG|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
224103083|NCT03153852|DRUG|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
224103084|NCT06656182|OTHER|Cervical and Thoracic SNAGs|cervical SNAGs (C3-C7) and thoracic SNAGs (T1-T12) with 6 repetitions of 1 set three times per week for 4 weeks along with scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
223951075|NCT02151994|DRUG|BIA 5-1058|oral administration
223951076|NCT02151994|DRUG|Placebo|oral administration
223951077|NCT04890457|DEVICE|Vagus nerve stimulation via tragus|The device will send stimulus intensity around 0.5mA via tragus in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
223722737|NCT02487602|DEVICE|Gelesis100|Gelesis100 capsules
223722738|NCT02487602|OTHER|Placebo|Sucrose (sugar) capsules
224103085|NCT06656182|OTHER|traditional physical therapy and scapular mobilizations|scapular mobilizations of 10 repetitions of 1 set and stretching of trapezius (upper, middle and lower fibers), levator scapulae and rhomboids (major and minor)
224288122|NCT03155737|OTHER|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
224288123|NCT03155737|OTHER|Knee health education|A course regarding knee health will be offered to the subjects in this group.
224288124|NCT03910660|DRUG|BXCL701 plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 mins. on Day 1 of each 21-day cycle."
224288125|NCT03910660|DRUG|BXCL701 monotherapy|"BXCL701 tablets dosage strengths include 0.05mg and 1mg tablets for oral administration.~BXCL701 will be administered orally as 0.05mg and 1mg tablets. Patients will take the prescribed number of tablets on Days 1 to 14 of each cycle, for a total daily dose of 0.4 mg, 0.6 mg, or an intermediate dose. BXCL701 will be continued until PD or unacceptable toxicity, or closure of the study by the sponsor; no maximum duration of therapy has been set.~BXCL701 should not be taken on an empty stomach.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day."
224103086|NCT06656897|BEHAVIORAL|FallScape for Persons with Alzheimer's disease or a related Dementia (FS-D)|FS-D is a multimedia behavioral intervention for use by family Caregivers (CG) of Persons with Alzheimer's disease or a related dementia (PwADRD) who are living at home and classified as at moderate to high risk for falls. FS-D will create, customize and support CG-provided daily multimedia sessions for PwADRD using structured learning techniques.
224103087|NCT05171387|DRUG|Darolutamide 600 mg twice daily|The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
224103088|NCT05171387|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
224103089|NCT02001012|DRUG|Artemether-lumefantrine combination|
224103090|NCT02001012|DRUG|Chloroquine|
224103091|NCT05651971|BEHAVIORAL|measurement group|Measurement of the distance between the origin of LCA (left colonic artery，LCA) and IMA (inferior mesenteric artery，IMA) root and the distance between IMA and IMV (inferior mesenteric vein，IMV) at the origin of LCA in rectal cancer patients
224103092|NCT06656611|OTHER|HPV self sampling|Selected women will perform a vaginal self-sampling using a swab
224103093|NCT06657287|OTHER|Mixed meal test|The biochemical parameters, blood pressure, and heart rates of participants undergoing the mixed meal test will be recorded over a 5-hour period.
224103094|NCT06655961|OTHER|Garden Activities Program|When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.
224103095|NCT06655961|OTHER|Clinical routine treatment and nursing care protocol|Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
224103096|NCT06657625|OTHER|Sepsis Performance Improvement Program|Training/awareness for medical and paramedical staff; creation of informational posters; development of an institutional pathway in the emergency department; creation of a protocol ; establishment of a sepsis team with a dedicated contact number.
224103097|NCT06657209|PROCEDURE|Insulin resistance testing|Steady state Plasma Glucose test
224103098|NCT06657209|PROCEDURE|OGTT|Will collect 5 blood draws during the test to measure insulin secretion
224103099|NCT06657209|PROCEDURE|Fat biopsy|Needle biopsy to gather a sample of abdominal subcutaneous fat
224103100|NCT06657209|RADIATION|DXA scan|Whole body DXA scan
224103101|NCT06657209|PROCEDURE|MRI|Abdominal MRI
224103102|NCT06657209|PROCEDURE|1H-MRS|Spectroscopy of the abdominal region
224103103|NCT06657209|DRUG|Tirzepatide|16 weeks started at 2.5mg/week and increased to 5mg/week dose
224103104|NCT06657209|DRUG|Pioglitazone|16 weeks at a 45mg/day dose
224103105|NCT06660693|DRUG|Upadacitinib Oral Product|Upadacitinib oral 45mg once daily.
224103106|NCT02625402|BEHAVIORAL|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
224103107|NCT02625402|BEHAVIORAL|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
224103108|NCT03849326|OTHER|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
224103109|NCT03849326|BIOLOGICAL|blood test|complete blood count and cytokine concentration
224103110|NCT03849326|OTHER|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
224103111|NCT03849326|DEVICE|actigraphy|assessment of sleep quality
224103112|NCT03849326|DEVICE|Neuromuscular evaluation|"* The maximum isometric force produced by the knee extensors will be measured on the ergometer~* the intensity of muscular electrical activity recorded by surface electromyography~* Peripheral nerve stimulation~* Transcranial magnetic stimulation~* Magnetic resonance imaging (optional)"
224103113|NCT05446844|OTHER|A nurse caring behavior protocol|"Nursing interventions based on caring behaviors protocol was provided as follows:~* Caring behaviors during ICU admission and orientation processes included orienting patients to time, place, and person.~* Caring behaviors during physical care informing patients regarding the purpose and expected duration of mechanical ventilator use.~* Caring behaviors during psychological care included offering religious sound meditation.~* Caring behaviors during social interaction included maintaining eye contact during nurse-patient interaction.~* Caring behaviors during health teaching included providing health teaching for patients.~* Caring behaviors during maintaining a safe healing environment included providing patients with an explanation regarding nursing activities."
224103114|NCT05446844|OTHER|Routine nursing care|Routine nursing care was concentrated mainly on hard skills of physically demanding care such as monitoring vital signs.
224288126|NCT01123317|DRUG|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
224288127|NCT03243929|BEHAVIORAL|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
224288128|NCT03243929|BEHAVIORAL|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
224288129|NCT06616129|DIAGNOSTIC_TEST|Geriatric assessment|At the clinic further information on the somatic, social, psychological and functional domain will be gathered by the nurse and two validated tests to map the vulnerability and resilience of the patient will be used; the Cognitive Impairment Test and the timed Up and Go Test.
224288130|NCT06616129|OTHER|Shared decision-making conversation|"The nurse and nurse practitioner together will talk with the patient and their partner about possible treatment options as well as patients' expectations, preferences and their life in general.~During the conversation the OPT (Outcome Prioritization Tool) will be used to clarify the most important goals of treatment for the patient. The OPT exists of four universal treatment goals rated on a visual analogue scale from 0 to 100. The goals represented are: life extension, maintaining independence, reducing pain and reducing other symptoms. The goals will be explained and the patient will be asked to rate each outcome according to the trade-off principle meaning that two outcomes cannot be rated equally."
224288131|NCT01057927|DRUG|OC000459|OC000459 capsules 2x100mg BID for 28 days
223722739|NCT02789709|PROCEDURE|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
224103115|NCT06825390|DEVICE|Cryo-auriculotherapy|The cryo-IQ device (containing compressed nitrous oxide) with a narrow-tip nozzle will be used. After disinfection of the device and both ears, 7 inter-related points in the auricular cartography will be treated with a 1-2 second application of cold gas, applied to both ears. Treatment points will be: mesoderm master, spine, reticular formation, sensory master point, thalamus, adrenocorticotropic hormone, and corpus callosum.
224103116|NCT06825390|DEVICE|Sham auriculotherapy|For the sham procedure, an empty gas canister will be used in the cryo-IQ device. This will make the same noise and temporary skin imprint on the ear, but does not deliver any cooling effect. The same 7 ear points will be sham-treated in a protocol that is imperceptibly different from the verum auriculotherapy treatment.
224103117|NCT06825390|OTHER|Experimental auricular stimulation|Three points on each ear will be repeatedly stimulated with a plastic (von Frey) filament. This will be felt, but not be painful and should not result in lasting irritation.
224288132|NCT01057927|DRUG|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
224288133|NCT01509521|DRUG|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
224288134|NCT01509521|DRUG|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
224288135|NCT04322578|DRUG|Crizotinib|Crizotinib 250mg po bid. Savolitinib 300mg po, qd.
224288136|NCT04322578|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, ivgtt erery 21day.
224288137|NCT06308172|PROCEDURE|Hysterotomy closure|Hysterotomy closure is done in either one of two ways. Single layer closure consists in a single layer, unlocked suture. Double layer closure consists in a double layer, unlocked suture.
224288138|NCT03968198|DRUG|Autologous ASC (for Adipose-derived Stem/Stroma Cell)|After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
224288139|NCT00027859|DRUG|docetaxel|
223722740|NCT02376361|DEVICE|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~1. Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~2. Recirculation, access flow will be performed according to HD03 Manual.~3. Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
223722741|NCT06379477|PROCEDURE|Refractive surgeries|after primary phacoemulsification surgery any resulting refractive error surprises will be corrected with different refractive surgery options
223722742|NCT02101060|OTHER|exercise|16-week progressive aerobic and resistance exercise training
223722743|NCT06166160|OTHER|Bulk fill flowable composite SDR Dentsply sirona|caries removal in class II cavities of primary molars and application of experminted restorations
223722744|NCT02302027|DEVICE|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 \* 67 \* 36 cm
223722745|NCT00736684|DEVICE|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
223951078|NCT04890457|DEVICE|Sham stimulation via earlobe|The device will send stimulus intensity around 0.5mA via earlobe in the left ear (based on participants' subjective report), delivered with a pulse width of 0.25 ms at 25 Hz. Stimulation will be active for 30 seconds, followed by a break of 30 seconds.
224103118|NCT04052737|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
224103119|NCT04052737|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
224288140|NCT00027859|DRUG|estramustine phosphate sodium|
224288141|NCT00027859|DRUG|ketoconazole|
224288142|NCT00027859|DRUG|therapeutic hydrocortisone|
224288143|NCT00209586|DRUG|fospropofol disodium|
224288144|NCT04588441|DRUG|Adenosine|Adenosine will be given like an inhaled asthma medication two times daily for one week (7 days). Treatment consists of 9 mg adenosine in 5ml normal saline (NS) administered over 5-10 min via an Aerogen™ nebulizer.
224288145|NCT02709486|DRUG|Tanezumab|2.5 mg
224103120|NCT04926155|DRUG|Metformin|The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
224103121|NCT02514057|OTHER|Questionnaire|Form filling only
224103122|NCT02332915|BEHAVIORAL|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
224103123|NCT01909492|PROCEDURE|Blood Draw|Patients will provide a serum sample for research.
224103124|NCT01909492|PROCEDURE|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
224103125|NCT07008404|DEVICE|online cognitive behavioral therapy|unguided online cognitive behavioral therapy app
224103126|NCT05563493|OTHER|Treatment group, Chair-Based Exercise Training|"The weights of the elastic bands to be used in the exercises will be determined by the physiotherapist according to the abilities and development of the participants.~The intensity of the exercise will be adjusted according to the dyspnea or fatigue patients feel according to the Modified Borg Scale.~During the exercises, heart rate and oxygen saturation will be measured with a pulse oximeter, and blood pressure will be measured with a sphygmomanometer.~Chair-based exercise training will be applied to the patients every day they are hospitalized."
224103127|NCT05563493|OTHER|Control group, Breathing exercise|Breathing exercise will be applied to the patients every day they are hospitalized.
224103128|NCT07032142|DRUG|I-01/23|The I-01/23 will be administered over a 5-day period, with dosing adjusted according to the patient's body surface area (BSA).
224103129|NCT07032155|DEVICE|Resynk VR session|The study will use hardware and software to achieve this immersive virtual reality. The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used. Immersive virtual reality (VR) is when technology makes you feel like you're inside a different world. You wear a virtual reality headset that covers your eyes and ears, showing you a 3D world and playing matching sounds. The headset's head tracking, changing the view in the VR world as you look around. You can then interact with this virtual reality world depending on the application or game you use. The Resynk VR software launches automatically, guiding them through therapist-designed games that make rehabilitation engaging. The system uses advanced hand-tracking technology, eliminating the need for physical controllers. It detects joint movements in the hands and fingers, allowing users to perform key rehabilitation exercises such as supination, pronation, grasping, and pinching.
224103130|NCT07032155|OTHER|Using Resynk VR on stroke survivors|The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used by Occupational therapy participants to treat the stroke survivor participants
224103131|NCT07030491|OTHER|Lactation Cookies|Participants will consume 2 cookies per day (approximately 40g daily) for 30 consecutive days. The lactation cookies contain ingredients commonly believed to enhance milk production, including moringa, fenugreek, and ginger.
224103132|NCT07030491|OTHER|Control Cookies|Participants in the control group will consume 2 cookies per day (approximately 40g total) for 30 consecutive days. These cookies are matched in taste, appearance, and caloric content but do not contain any known galactagogue ingredients.
224288146|NCT02709486|DRUG|Tanezumab|5 mg
224288147|NCT02709486|DRUG|Placebo|Placebo
224295201|NCT01163448|RADIATION|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
223722746|NCT00736684|DEVICE|Gamma Nail 3TM (Gamma3)|intramedullary nailing
223722747|NCT00949897|DEVICE|Biofoam|Device
223722748|NCT00949897|OTHER|Iliac Crest Allograft with locked plate|
223722749|NCT03829982|BEHAVIORAL|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
223951079|NCT04875767|DEVICE|HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)|General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
224288148|NCT05082363|COMBINATION_PRODUCT|C4d evaluation in lupus nephritis in serum and renal tissue|C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)
224288149|NCT00572117|DRUG|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
224103133|NCT07030660|OTHER|Model-Informed Precision Dosing (MIPD)|Model-Informed Precision Dosing (MIPD) of tacrolimus in kidney transplantation
224288150|NCT04267263|BEHAVIORAL|Self-guided lifestyle intervention|The intervention will consist of one 60-minute group based online session, adapted specifically for young men based previous work with young adults, followed by a self-guided program for 12-weeks. Participants will receive a tool kit that includes evidence-based resources (scale for self-weighing, handouts that will include free self-monitoring apps and strategies for no-cost exercise, sample meal plans and meal planning tips, and tips for healthy living that emphasize risk areas) to assist them during the self-guided phase, as well as weekly health risk text messages.
224288151|NCT04332016|OTHER|biological samples collection|collection of whole blood samples, urine and stool samples, upper respiratory samples, post-mortem biopsies
224103134|NCT06742125|DEVICE|Drug-coated balloon (DCB)|Drug-coated balloon treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
224103135|NCT06742125|DEVICE|Drug-eluting stent (DES)|Drug-eluting stent treatment of target lesions in patients with premature STEMI undergoing percutaneous coronary intervention.
224103136|NCT07107971|DEVICE|Paclitaxel-eluting balloon|Participants in the intervention group will receive local treatment of non-obstructive, lipid-rich coronary plaques using a paclitaxel-coated drug-eluting balloon (DCB) in addition to guideline-directed medical therapy (GDMT). The DCB will be applied to plaques identified as high-risk based on near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) imaging, defined by a maxLCBI4mm ≥325. The balloon catheter diameter will be sized 1:1 according to the true lumen diameter as derived from IVUS. Balloon length will be sized to the LRP length as measured with IVUS including a 5 mm margin on each side. The balloon will be inflated at nominal pressure (6-8 ATM) during a period of at least 60 seconds, but preferably for 90 seconds if tolerated. A 5 mm margin is taken into account to differentiate between single or multiple LRPs within the same coronary artery.
224288152|NCT00888784|PROCEDURE|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
224295202|NCT04699526|OTHER|Universal Prevention Curriculum Training for Schools|School administrators and teachers participated in UPC training and formed prevention leadership action teams
224295203|NCT00253981|DEVICE|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
223951080|NCT06356532|BEHAVIORAL|intensive care unit diary|The intensive care unit diary is a notebook provided to patients during their stay in the intensive care unit, allowing them to record all events that occur during this period. Patients are encouraged to freely write about their experiences, which may include details about their treatment progress, daily activities, visits from family members, and other relevant aspects of their stay.
223951081|NCT01072838|RADIATION|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
223951082|NCT01072838|DEVICE|Contura MLB Breast Brachytherapy Catheter|
223951083|NCT03153176|BEHAVIORAL|Training|Training program 30 hours accumulated before, during and after intervention
223951084|NCT03153176|BEHAVIORAL|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
223951085|NCT03153176|BEHAVIORAL|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
224103137|NCT05706129|DRUG|[68Ga]Ga-DPI-4452|\[68Ga\]Ga-DPI-4452, administered as IV injection.
224103138|NCT05706129|DRUG|[177Lu]Lu-DPI-4452|\[177Lu\]Lu-DPI-4452, administered as IV infusion.
223722750|NCT03829982|BEHAVIORAL|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
223722751|NCT03988985|OTHER|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
223722752|NCT03988985|OTHER|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
223722753|NCT06211478|DRUG|Vitamin E|Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
223722754|NCT02321644|DRUG|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
223722755|NCT06304194|OTHER|Analysis of biological samples|"The collected biological sample will be isolated and the specific nucleic acid (DNA/RNA/cfDNA) extracted for molecular analysis for understanding the reproducibility of the analysis and thus the feasibility of centralization:~* hot spot on DNa (ddPCR/Sanger)~* fusion genes on RNA (target resequencing)~* Known mutation analysis by liquid biopsy (cfDNA) for somatic mutations with a mutation frequency of less than 10%~* Tumor type-associated gene sequence analysis by Sanger sequencing and NGS"
224103139|NCT05847881|BEHAVIORAL|Self-guided at home activities|After the kick-off meeting participants will complete the cultural probe kit for 3 weeks. This kit is a design research tool, to prompt participants to document, map, journal, and reflect on various aspects of daily lives. Following this, participants will attend a facilitated workshop and then complete the next at-home kits.
224103140|NCT02610023|OTHER|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
224103141|NCT02610023|OTHER|Laboratory Biomarker Analysis|Correlative studies
224103142|NCT02610023|DEVICE|Spectroscopy|Undergo resonance Raman spectroscopy
224103143|NCT02951598|DRUG|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
224103144|NCT06299176|OTHER|Whole Heart Radiation Therapy|Radiation to the whole heart in one treatment with a prescribed dose of 5 Gy.
224103145|NCT05768789|DIETARY_SUPPLEMENT|Buoy Electrolyte|Each subject consumed Beverage 1 (Buoy Hydration Drops) at a dose containing 600 mg/L of Na+ over 4 hours while measuring urine output over 6 hours.
224103146|NCT05768789|OTHER|Water only|Each subjected ingested 1 L of Kirkland® bottled water at a rate of 6.25% of the total amount of water every 15 minutes for four hours
224103147|NCT05768789|DIETARY_SUPPLEMENT|Nuun Electrolyte|Each subject consumed 1 L of water with two dissolved Nuun® Sport Hydration tabs (Nuun, Seattle, WA), containing 600 mg of sodium, over 30 minutes (2 equal volumes every 15 minutes) while measuring urine output over 6 hours (
224103148|NCT04420793|OTHER|Questionnaire|3 voice recording tasks and 1 text entry task will be performed.
224295204|NCT04953416|DEVICE|1565nm non ablative fractional laser|The ResurFX module contains Erbium:Glass Fiber Laser Technology with wavelength of 1565 nm, which is transferred to the ResurFX handpiece via a fiber.
223951086|NCT04798534|BEHAVIORAL|Service decentralization facilitation intervention|The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
223951087|NCT02717819|DIETARY_SUPPLEMENT|Protein|Daily intake of supplement
224103149|NCT05207397|OTHER|Lactate infusion|The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions were made by a pharmacy and tested to be sterile and pyrogen free. Upon arriving to the KU Clinical and Translational Science Unit, a catheter will be placed in the subject's hand, which will be placed into a heated hand box for collection of arterialized blood. A second catheter will be placed in the opposing forearm vein for the infusion of lactate isotope solution and unlabeled lactate infusion cocktail. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. We will then administer priming doses of 57.5 mg \[13C3\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[13C3\]lactate at 10 mg/min and D2-glucose at 2 mg/min \[53\]. Along with the continuous isotope infusion we will begin infusion of the Na-lact
224103150|NCT06834009|DRUG|SUZ|Powder for oral administration.
224103151|NCT06489678|DIAGNOSTIC_TEST|Robotic Assisted Bronchoscopy|Cone-beam computed tomography (CBCT) technology and robotic-assisted bronchoscopy (RAB) present promising methods to enhance biopsy accuracy and procedural safety through 3-dimensional reconstructions and increased bronchoscope tip flexibility. Additionally, the transfer of navigational data between CBCT and RAB may further improve diagnostic yield. Given their distinct approaches to enhancing diagnostic outcomes, two separate study arms are warranted for CBCT and RAB.
224103152|NCT06226090|DRUG|TG103 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
223722756|NCT00048555|DRUG|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions
223951088|NCT02717819|DIETARY_SUPPLEMENT|Placebo|Daily intake of supplement
223951089|NCT02717819|OTHER|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
223951090|NCT02717819|DIETARY_SUPPLEMENT|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
223951091|NCT02326220|DRUG|Placebo|
223951092|NCT02326220|DRUG|Alirocumab|
223951093|NCT02114515|BEHAVIORAL|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
223951094|NCT02114515|BEHAVIORAL|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
224103153|NCT06226090|DRUG|Placebo 7.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.
224103154|NCT06226090|DRUG|TG103 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
224103155|NCT06226090|DRUG|Placebo 15 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
224103156|NCT06226090|DRUG|TG103 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
224103157|NCT06226090|DRUG|Placebo 22.5 mg|Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
224103158|NCT01084252|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224103159|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224103160|NCT01084252|DRUG|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
223722757|NCT04540224|DIAGNOSTIC_TEST|Flow-Cytometric analysis|Measuring the level of serum IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p (70), IL-17A, IL-18, IL-23 and IL-33
223951095|NCT02114515|BEHAVIORAL|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
223951096|NCT00286325|DRUG|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
223951097|NCT00002294|DRUG|Fluconazole|
223951098|NCT04565652|DEVICE|Device Wearers|The intervention arm will wear the LOIS ICD Smartband during routine ICD defibrillation following elective ICD implant.
223951099|NCT04568213|DRUG|Hypochlorous Acid Gel 0.02%|0.02% Hypochlorous Acid Gel (OCusoft Hypochlor GEL) will be sprayed onto the closed eyelid of the surgical eye while covering the fellow eye with palm of the hand, left for 60 seconds, then wiped off with a clean gauze, tissue, or cotton ball.
223951100|NCT02699099|DIETARY_SUPPLEMENT|Vitamin A|Oral administration of Vitamin A (1 dose)
223951101|NCT02699099|BIOLOGICAL|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
223722758|NCT01705639|DRUG|Melatonin|All subjects receive the same dose of melatonin
223722759|NCT00335673|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
223722760|NCT04012775|BIOLOGICAL|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
223722761|NCT04012775|BIOLOGICAL|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
223951102|NCT02699099|BIOLOGICAL|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
223951103|NCT02699099|BIOLOGICAL|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
223951104|NCT05443698|DEVICE|Transvaginal ultrasound|Adult women in the U.S. who are eligible for the ultrasound trial on the basis of the inclusion/exclusion criteria will complete an at home transvaginal ultrasound guided by real-time remote supervision from a qualified and specially trained ultrasound technologist.
223951105|NCT06143124|DRUG|Bismuth Subcitrate|shorter duration of therapy (7 instead of classical 14 days) with four dugs instead of three (adding Bismuth subcitrate).
223951106|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
223951107|NCT02284607|DRUG|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
223951108|NCT02284607|DRUG|Placebo|Matching placebo to MHAA4549A administration
223951109|NCT03572894|DEVICE|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~* T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~* T1 : Vt 8 mL/Kg of PBW during 5 minutes~* T2 : Vt 10 mL/kg of PBW during 5 minutes~* T3 : Vt 6 mL/kg of PBW during 5 minutes~* T4 : A single recruitment maneuver~Data will be recorded at each step."
223951110|NCT00241826|PROCEDURE|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
223951111|NCT00241826|PROCEDURE|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
223951112|NCT04216641|DIETARY_SUPPLEMENT|Adapted food intervention|Adapted food intervention
224103161|NCT05125081|DRUG|Liuwei Dihuang Pill (marketed product in China)|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
224295205|NCT05173870|DEVICE|Wearable device|The wearable devices has a biosensor able to daily collect,in a remote way, many biometric measurements such as: blood pressure, blood oxygenation, heart and respiratory rate
224295206|NCT01615042|DRUG|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
224295207|NCT00560027|OTHER|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
224295208|NCT01901874|DEVICE|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
224103162|NCT05125081|DRUG|Liuwei Dihuang Pill（placebo ）|LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
224103163|NCT05562193|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|CCS will participate in a 16-week physical activity program. CCS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize CCS' success. CCS will receive a Fitbit at the beginning of the intervention.
224103164|NCT05562193|OTHER|Standard post-cancer directed treatment care control|CCS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Children's Oncology Group Guidelines for Diet and Physical Activity recommendations and the International Pediatric Oncology Exercise Guidelines will be offered to CCS following completion of 16-week follow-up. Moreover, CCS will receive a Fitbit following completion of 16-week follow-up
224103165|NCT05519696|BEHAVIORAL|Intervention|Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.
224295209|NCT04352465|DRUG|Methotrexate|Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
224295210|NCT04352465|DRUG|Methotrexate|Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
223722762|NCT00799604|DRUG|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (\<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
223951113|NCT06369844|OTHER|Pressure injury education|Pressure injury education will be provided to participants in the intervention group in three separate sessions covering the topics of Pressure Injury Definition and Classification, Risk Assessment, Prevention, and Care.
223951114|NCT00420368|DIETARY_SUPPLEMENT|No food supplement|
223951115|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: fortified spread|
223951116|NCT00420368|DIETARY_SUPPLEMENT|Food supplement: maize-soy flour|
223951117|NCT00147667|DRUG|Erythromycin|
224295211|NCT04352465|DRUG|Methotrexate|Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
223722763|NCT00743340|DRUG|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
223722764|NCT04648072|PROCEDURE|Adductor Canal Block|As previously described.
223722765|NCT04648072|PROCEDURE|Periarticular Injection|As previously described.
223722766|NCT03817788|DRUG|polyethylene glycol|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
223722767|NCT03817788|DRUG|sodium phosphate|All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
223951118|NCT02656199|PROCEDURE|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
223951119|NCT03167008|DIAGNOSTIC_TEST|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
223951120|NCT03167008|DIAGNOSTIC_TEST|blood sample|blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
223951121|NCT04707599|OTHER|Reminder plus (telephone call from therapist)|Reminder plus (telephone call from therapist)
223951122|NCT00738959|DRUG|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
223951123|NCT00016107|DRUG|estramustine phosphate sodium|Given orally
223951124|NCT00016107|DRUG|docetaxel|Given IV
223951125|NCT00016107|BIOLOGICAL|bevacizumab|Given IV
223951126|NCT00016107|OTHER|laboratory biomarker analysis|Correlative studies
223951127|NCT05290090|DRUG|Rituximab, Lenalidomide, Zanubrutinib and RCHOP|"chemo free period (21 days as a cycle, a total of 2 cycles): rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-10, zanubrutinib 160mg bid.~Immunochemotherapy period: RCHOP regimen (21 days as 1 cycle, a total of 4 cycles): rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5."
223951128|NCT00036140|DRUG|Investigational drug|
223951129|NCT00774605|DRUG|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
224103166|NCT05519696|BEHAVIORAL|Comparison|Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
224103167|NCT02558946|BEHAVIORAL|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
224103168|NCT02558946|BEHAVIORAL|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
224103169|NCT05188235|DEVICE|Acoustical Resonance Device|"Infants will be studied for 15 min using an electronic tuning fork to transmit sound through the hip from a point on the skin while transmitted sounds FDA-approved stethoscope"
223722768|NCT03520803|OTHER|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
223722769|NCT06513949|BIOLOGICAL|Atibuclimab|monoclonal antibody against human CD14
224103170|NCT06194201|DRUG|HRS9432|Dosing frequency: intravenously once week
224288153|NCT00888784|DRUG|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was \>90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
224288154|NCT04916496|BEHAVIORAL|Acceptance and Commitment Therapy-based lifestyle counselling programme|"The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change."
223951130|NCT00774605|DRUG|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
223951131|NCT06402292|PROCEDURE|OSTEOMYELITIS SURGICAL TREATMENT WITH LOCAL ANTIBIOTICS AND PEROSSAL|25 PATIENTS WITH FRI WILL BE SURGICALLY TREAT WITH DESBRIDMENT AND PEROSSAL WITH ANTIBIOTCS
224103171|NCT06194201|DRUG|Caspofungin Acetate for Injection|Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
224103172|NCT05067777|PROCEDURE|Massage Therapy|Receive SMT
224103173|NCT05067777|OTHER|Questionnaire Administration|Ancillary studies
223722770|NCT06513949|OTHER|Placebo|Sterile normal saline for injection
224103174|NCT05067777|PROCEDURE|Sham Intervention|Receive light touch control procedure
224295212|NCT03463486|BEHAVIORAL|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
224295213|NCT05732896|DEVICE|Nociception Leve Indeks|During TIVA-TCI, propofol (Schnider) effect site concentration (Ce) was titrated to BIS score between 40-60 and remifentanil (Minto) Ce to standard hemodynamic parameters in the control group and NOL index value between 10-25 in the study group.
224295214|NCT05820386|PROCEDURE|Skin-to-skin Contact (SSC)|For the Skin-to-skin Contact (SSC) transfer, the bare-chested father will seat in a wheelchair. Newborns who will wear only a diaper and a cotton cap or noninvasive ventilation headgear will be placed in the kangaroo position against the father's chest to ensure direct contact with the father's skin. Preterm infants with gestational age less than 33 weeks will be wrapped with their father using plastic bags plus warmed cotton towels. More gestationally mature infants will be wrapped with only warmed cotton wraps. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
223951132|NCT00470483|DRUG|Placebo treatment during 8 weeks|comparator
223951133|NCT00470483|DRUG|Paroxetine treatment during 8 weeks|treatment drug
223951134|NCT03507998|DRUG|CGX1321|CGX1321 capsules for oral administration
223951135|NCT03305172|BEHAVIORAL|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
223951136|NCT01130870|DEVICE|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
223951137|NCT01130870|DEVICE|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
224103175|NCT05715190|OTHER|Education|Visiting the medical psoriasis outpatient clinic. Receiving a medical consultation, phototherapy and methotrexate treatment. Psoriasis plaque measurement, psoriasis care and questionnaires will be provided by the institute's nurses. After baseline data collection (T0) and random allocation to the intervention group, this usual care will be enhanced by a multidisciplinary nurse-led educational program
224295215|NCT05820386|PROCEDURE|Incubator|In the incubator group, infants will be transferred after resuscitation in an incubator with air temperature set to 36°C. The newborn will be laid on his/her back in a polyethylene bag with a cap. The newborn's heart rate, oxygen saturation and skin temperature will be monitored throughout the procedure.
224103176|NCT06964789|DEVICE|Mechatronic Remote Physiotherapy System (MRPS)|The MRPS is an Online Rehabilitation Platform for neurology patients. The platform has been designed to provide supervised and monitored remote rehabilitation therapy, initially focusing on patients who have suffered a stroke. The system comprises of a patent pending mirror therapy strengthening device, which is a neural therapy device using mirror therapy and exercise apparatus for upper limb rehabilitation. The platform also permits the addition of modules beneficial to the patients' recovery. A sensory substitution balance apparatus and motion detecting sensors are also being designed to connect to the system to allow for lower limb rehabilitation.
224103177|NCT06964789|OTHER|Early Supported Discharge|ESD is a multidisciplinary service providing medically stable patients continued therapy and healthcare in the community.
224103178|NCT06963684|DEVICE|Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)|This is the first clinical study to evaluate repeat bilateral Direct Selective Laser Trabeculoplasty (DSLT) in treatment-naïve patients, using a paired-eye design. Unlike prior SLT studies, which focused on monocular treatment or repeat treatment following IOP rebound, this study randomizes one eye to receive a second DSLT treatment three months after the first, while the fellow eye receives only a single treatment. This allows for a direct intra-subject comparison of efficacy and durability. Existing studies, including GLAUrious and LiGHT, suggest the potential benefits of repeat laser, but no data currently exist for early, scheduled repeat treatment with DSLT. This trial uniquely investigates whether proactively repeating the procedure in a controlled eye extends IOP reduction and delays or reduces the need for topical medications.
224103179|NCT06964802|OTHER|Cold salt water foot bath|The application of 175 grams of salt to cold water at a constant 22 degrees
224103180|NCT06964802|OTHER|Cold water foot bath|Constant 22 degree cold water application
224103181|NCT06964828|DEVICE|Flat-knitted compression garment|Flat knitted compression garments
224103182|NCT04677114|DRUG|Buprenorphine and Outpatient Parenteral Antibiotic Therapy|Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.
224103183|NCT04677114|DRUG|Buprenorphine and standard of care antibiotic treatment|All participants will receive treatment of OUD and the infection per usual clinical care.
224103184|NCT04933812|BEHAVIORAL|Facebook discussions and Virtual group meetings|Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
224288155|NCT04916496|BEHAVIORAL|Healthy lifestyle talk|"The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change."
224288156|NCT02214719|BEHAVIORAL|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
224103185|NCT05443399|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
224103186|NCT05443399|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
223537909|NCT06358495|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Digital CBT-I is an online, six-module, self-guided CBT-I intervention. It includes videos and read information on behavioral (e.g., stimulus control, relaxation) and cognitive (e.g., restructuring, reducing arousal, and problem-solving) techniques, as well as psychoeducation (e.g., sleep hygiene). Participants complete homework following each session and track their sleep using an online diary. Young people could choose to involve their parents, for example, through completing sessions together. However, we will add a virtual session for parents as their involvement may improve adolescent engagement with the intervention as well as outcomes for adolescent sleep problems (Gradisar et al., 2011). This module will include an overview of the program components (behavioural, cognitive, and educational), goals and homework, and addresses parents' beliefs about sleep.
223722776|NCT03332797|DRUG|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223722777|NCT03332797|DRUG|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223722778|NCT03332797|DRUG|LHRH Agonist|The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
224103187|NCT05443399|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 2D
224103188|NCT04493619|DRUG|PLX2853|PLX2853 tablets
224103189|NCT04493619|DRUG|Carboplatin|Carboplatin IV injection, 5 mg•min/mL
224103190|NCT06157242|DRUG|Xeruborbactam Oral Prodrug|Experimental
224103191|NCT06157242|DRUG|Ceftibuten|Experimental
224103192|NCT06623981|BEHAVIORAL|Enhanced Brief Interpersonal Psychotherapy|Enhanced IPT-B consists of a single, 45-60-minute pre-treatment engagement session followed by eight weekly, 45-minute individual sessions carried out within an 8-12-week timeframe.
224103193|NCT06623981|BEHAVIORAL|Supplemented Usual Care|Usual care for caregivers with PHQ-9 scores 10-27 involves the asthma clinic physician discussing the PHQ-9 results with the caregiver, providing brief psychoeducation on depression and giving the caregiver a written list of mental health resources. Usual care will be supplemented by providing short-term care coordination. Care coordination will involve assisting the participant in calling a mental health clinic to make an appointment and one follow-up phone call within two weeks.
224103194|NCT06219863|BEHAVIORAL|Body weight supported harness|A body weight supported harness will be provided to families for one month to set up in their home. Caregivers will be asked to use the harness for their infants for 30 min per day, 5 days a week. Caregivers will complete a daily log describing harness use. At the end of the month, they will complete feasibility and acceptability questionnaires.
224288157|NCT00589849|PROCEDURE|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
224288158|NCT05407506|DIAGNOSTIC_TEST|THYROID AI|thyroid artificial intelligence diagnosis system and fine needle puncture in the diagnosis of benign and malignant thyroid nodules
223722779|NCT05311618|DRUG|NGM438|NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
223951138|NCT01130870|DEVICE|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
223951139|NCT02120807|DRUG|Certolizumab|
223951140|NCT02120807|DRUG|cisplatin|
223951141|NCT02120807|DRUG|pemetrexed|
223722780|NCT05311618|DRUG|Pembrolizumab (KEYTRUDA ®)|Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
223951142|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
223951143|NCT00824850|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
223951144|NCT03824340|DRUG|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
223951145|NCT03864159|OTHER|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
224103195|NCT06511050|DIETARY_SUPPLEMENT|Lumbrokinase|Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.
224103196|NCT04296630|OTHER|Social media message #1|Social media message promoting colorectal cancer screening
224103197|NCT04296630|OTHER|Social media message #2|A different social media message promoting colorectal cancer screening
224103198|NCT04296630|OTHER|Social media message #3|A different social media message promoting colorectal cancer screening
224103199|NCT04296630|OTHER|Social Media Message #4|A different social media message promoting colorectal cancer screening.
224103200|NCT04296630|OTHER|Tailored Social Media Message|Tailored social media messages promoting colorectal cancer screening.
224103201|NCT05589493|DEVICE|Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis|A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
224103202|NCT05640908|DEVICE|iFuse Bedrock Granite Implant System|Surgical procedure of the spine with pelvic fixation/fusion using iFuse Bedrock Granite
224103203|NCT03913910|PROCEDURE|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
224103204|NCT04644900|OTHER|chewed mint gum|In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
224103205|NCT04644900|OTHER|Mouthwash|Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
224103206|NCT02257606|OTHER|I-TRAVLE training|
224288159|NCT01369602|DRUG|PF-04991532|single dose 300-mg
224288160|NCT01369602|DRUG|PF-04991532|single dose 300-mg
224288161|NCT01369602|DRUG|PF-04991532|single dose 300-mg
224288162|NCT01369602|DRUG|PF-04991532|single dose 300-mg
224103207|NCT05824208|BEHAVIORAL|PRENAYOGA - prenatal yoga|The intervention is a prenatal yoga module developed for prenatal women. Intervention details: bi-weekly yoga classes (60 minutes of duration) will be delivered in person in a yoga studio in London for 8 consecutive weeks. Participants will be provided with yoga mats, blocks, bolsters and yoga straps at the studio. The class will be adapted to pregnancy and for all levels of ability, focusing on slow movements and body awareness. The content of the class will include loosening exercises (warm up exercises), simple postures (standing, balancing, sitting, kneeling, supine and restorative poses), breathing exercises and meditation. Classes will be delivered by an internationally certified and trained yoga teacher and will be accompanied by soft instrumental music.
224103208|NCT01674764|PROCEDURE|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
224103209|NCT01674764|PROCEDURE|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
224103210|NCT06076746|BEHAVIORAL|NIC Psychotherapeutic Intervention(s) for İneffective Coping|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
224103211|NCT06076746|BEHAVIORAL|psychotherapeutic intervention|Patients will be treated by NIC psychotherapeutic intervention(s) for general anxiety (e.g. anxiety reduction, coping enhancement).
224103212|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
224103213|NCT03166800|DRUG|Mitoquinone|This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
224103214|NCT03166800|DRUG|Placebo|This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
224103215|NCT05888259|OTHER|foot insole|The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
224103216|NCT05879263|OTHER|INTERMITTENT ENTERAL NUTRITITION (IEN)|Administration of Enteral Nutriton (EN) by nasogastric tube in 4 bolus (24h): Duration of the infusion 1hour each shot, using an infusion pump.
224103217|NCT05879263|OTHER|CONTINUOS ENTERAL NUTRITITION (CEN)|Administration of Enteral Nutriton (EN) by nasogastric tube during 24 hours, using an infusion pump.
224103218|NCT00468715|DRUG|bicalutamide|
224288163|NCT05322902|DRUG|remimazolam group|Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
224288164|NCT05322902|DRUG|propofol group|Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
223722781|NCT04394286|GENETIC|SHP648|Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.
223951146|NCT03864159|OTHER|Foam roller|Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
223951147|NCT00364455|DRUG|Epoetin alfa|
223951148|NCT02118922|PROCEDURE|Brillouin imaging|
223951149|NCT02282215|BIOLOGICAL|CLT-008|Single intravenous infusion
223951150|NCT02282215|BIOLOGICAL|G-CSF|Daily subcutaneous injections
224103219|NCT00468715|OTHER|diagnostic laboratory biomarker analysis|
224103220|NCT00468715|OTHER|immunohistochemistry staining method|
224103221|NCT04704076|OTHER|ESVS|Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age
224103222|NCT04704076|OTHER|Exclusive breastfeeding|Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age
224103223|NCT03707717|DRUG|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
224103224|NCT06956833|OTHER|Ìmmersive virtual reality simulation with self-guided debriefing|"* Familiarization with immersive virtual reality simulation (1 hour)~* Video tutorial introducing paediatric Airway, Breathing, Circulation, Disability, Exposure (ABCDE) assessment, emergency teamwork and communication, and core elements in debriefing (1 hour)~* Three immersive virtual reality simulation-based pediatric emergency team training scenarios with self-guided debriefing (2 hours)"
224103225|NCT06956833|OTHER|Ìmmersive virtual reality simulation with facilitator-guided debriefing|"* Familiarization with immersive virtual reality simulation (1 hour)~* Video tutorial introducing paediatric ABCDE assessment, emergency teamwork and communication, and core elements in debriefing (1 hour)~* Three immersive virtual reality simulation-based pediatric emergency team training scenarios with facilitator-guided debriefing (2 hours)"
224103226|NCT00227461|DRUG|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
224103227|NCT00227461|DRUG|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
223537910|NCT06358495|OTHER|Active Control|Participants are encouraged to continue any care they are already receiving and will be placed on a wait-list for digital CBT-I after their final assessment. All activities participants try for improving their own sleep problems between assessments will be recorded and coded for.
223537911|NCT03399448|BIOLOGICAL|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
223537912|NCT03399448|DRUG|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
223537913|NCT03399448|DRUG|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
223537914|NCT03399448|DEVICE|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
223537915|NCT04781582|PROCEDURE|Lung volume reduction surgery|Surgical lung volume reduction
223537916|NCT04781582|PROCEDURE|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction by endobronchial valves
223537917|NCT05155982|BIOLOGICAL|COVAC-1|Intramuscular vaccine against SARS-CoV-2
223951151|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
223951152|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
223951153|NCT01412736|DRUG|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
223951154|NCT01412736|DRUG|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
223951155|NCT04987801|OTHER|Drug Toxicity|Patients who took over dose of Drugs
223951156|NCT04015505|BEHAVIORAL|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
223951157|NCT00105963|BEHAVIORAL|Education about infant crying|
223537918|NCT05155982|BIOLOGICAL|Saline Placebo|Intramuscular injection of saline placebo
223537919|NCT05833217|PROCEDURE|Adipose Tissue Biopsy|After an overnight fast, approximately 1-2 grams of subcutaneous fat will be removed by a needle. Participants will have a local anesthetic prior to the procedure. The needle fat biopsy will be repeated at quarterly intervals for one year (every 3 months). We will also draw 1 10mL tube of blood at each biopsy for measurement of inflammatory cytokines.
223951158|NCT03280511|DRUG|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
224103228|NCT01187368|DEVICE|EVAHEART Left Ventricular Assist System (LVAS)|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
224103229|NCT01187368|DEVICE|HeartMate 3|Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
224103230|NCT05394077|DIAGNOSTIC_TEST|Active Release Technique|Using Active Release Technique
223951159|NCT04820491|DIAGNOSTIC_TEST|X-Ray|Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
224103231|NCT05394077|DIAGNOSTIC_TEST|Abdominal Drawing-Maneuver|Using Abdominal Drawing-Maneuver Technique
224103232|NCT01419171|DEVICE|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
224103233|NCT01836601|BEHAVIORAL|Family-centered nighttime communication bundle|
224103234|NCT00775307|DRUG|PAZOPANIB|400 mg/day (24 weeks)
224103235|NCT00775307|DRUG|Placebo|Placebo 400 mg/day (24 weeks)
224103236|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day|Participants receive 3 EMA survey prompts daily for the duration of the study.
224103237|NCT04884087|BEHAVIORAL|Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day|Participants receive 6 EMA survey prompts daily for the duration of the study.
224103238|NCT04884087|BEHAVIORAL|Incentive Structure - fixed|"Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week."
224103239|NCT04884087|BEHAVIORAL|Incentive Structure - prize based|"Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90)."
224103240|NCT02125994|PROCEDURE|Interscalene nerve block|
224103241|NCT02045199|DEVICE|Tested product : V0111 cream|Application twice a day during 28 days
224103242|NCT02045199|DEVICE|Placebo|Application twice a day during 28 days
223537920|NCT05833217|DIAGNOSTIC_TEST|Steady State Plasma Glucose (SSPG) Test|An Insulin Sensitivity Test (SSPG: Steady State Plasma Glucose) is performed to determine if participants are insulin sensitive or insulin resistant. This test is approximately 5-6 hours in length. Participants will be asked to fast for 12 hours. The insulin sensitivity test is designed to measure how well your cells remove glucose from your blood in response to insulin. During this test participants will have two small catheters (tubing) placed in their veins (I.V. lines). The total amount of blood that will be drawn during this test will be 140 mL of blood (approximately 9.5 tablespoons). Insulin is a natural hormone, and octreotide (a synthetic hormone) is a drug that temporarily blocks the secretion of insulin from your pancreas. A member of the research team is present and monitoring the results along with the nursing staff.
223537921|NCT02921789|DRUG|Bleselumab|Intravenous infusion
223951160|NCT04820491|DIAGNOSTIC_TEST|Ultrasound|Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
223537922|NCT02921789|DRUG|Basiliximab|Bolus injection
223951161|NCT05997563|DRUG|Micronized progesterone|Vaginal micronized progesterone effervescent once daily until delivery
223951162|NCT03417700|DIETARY_SUPPLEMENT|NW training|NW training
223951163|NCT03417700|DIETARY_SUPPLEMENT|Placebo|training with placebo
223537923|NCT02921789|DRUG|Mycophenolate Mofetil (MMF)|Oral Intravenous
223537924|NCT02921789|DRUG|Tacrolimus Capsules|Oral Capsule
223537925|NCT02921789|DRUG|Methylprednisone|Oral or Intravenous
223537926|NCT02921789|DRUG|Prednisone|Oral Tablet
223537927|NCT03681756|BEHAVIORAL|WALK|Walking program
223537928|NCT02028845|DEVICE|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
223951164|NCT03417700|DIETARY_SUPPLEMENT|HICT|Training and vitamin D
223951165|NCT01840722|OTHER|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
223951166|NCT04033250|DRUG|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
223951167|NCT00937287|OTHER|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
223951168|NCT04337593|DRUG|Basiliximab|20mg d1,8, repeated every 3 weeks
224103243|NCT03149835|OTHER|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
224103244|NCT00216008|DRUG|docetaxel|
224103245|NCT00216008|DRUG|cisplatin|
224103246|NCT00216008|PROCEDURE|radiation|
224103247|NCT00216008|PROCEDURE|surgery|
224103248|NCT03719573|OTHER|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
223951169|NCT04337593|DRUG|Pegaspargase|2500IU/㎡, d1,repeated every 3 weeks
224103249|NCT02128490|DRUG|Febuxostat IR|Febuxostat IR over-encapsulated tablets
224103250|NCT02128490|DRUG|Febuxostat XR|Febuxostat over-encapsulated capsules
224103251|NCT02128490|DRUG|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
224103252|NCT02128490|DRUG|Colchicine|Colchicine tablets
224103253|NCT02128490|DRUG|Naproxen|Naproxen tablets
224103254|NCT02128490|DRUG|Lansoprazole|Lansoprazole capsules
224103255|NCT06425744|OTHER|self-myofascial release combined reformer Pilates|"The self-myofascial release combined reformer Pilates group performs 10 minutes of self-myofascial release using the BALLance© method before beginning 20 minutes of Reformer Pilates. The 6-week program includes warm-up and breathing, main supine exercises 1 and 2, and movements targeting the sacroiliac and hip joints.~All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants attend twice a week for 6 weeks, for a total of 12 sessions.~And all participants performed home exercise program follows the guidelines of Geroge et al (2021) and includes myofascial release and Pilates Reformer exercises, as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
224103256|NCT06425744|OTHER|Reformer Pilates|"The reformer Pilates group will do 30 minutes of Pilates on the Reformer. All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants also attend twice a week for 6 weeks, for a total of 12 sessions.~The home exercise program follows the guidelines of Geroge et al (2021) as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed."
224103257|NCT02243176|DRUG|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
224103258|NCT02243176|DRUG|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
224103259|NCT03533790|DRUG|DEP-Ru|"* Drug: ruxolitinib~* Drug: doxorubicin~* Drug: etoposide~* Drug: methylprednisolone"
224103260|NCT02040246|DRUG|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
224103261|NCT02040246|DRUG|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
223537929|NCT02028845|DEVICE|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
223951170|NCT01219127|OTHER|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
223951171|NCT03547206|DRUG|RPh201 Cohort A|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
223951172|NCT03547206|OTHER|Placebo Cohort A|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
224103262|NCT01620996|BEHAVIORAL|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
223537930|NCT04304560|DRUG|Dapagliflozin 10 MG|inhibitor of sodium-glucose cotransporter 2
223537931|NCT04304560|DRUG|Placebo oral tablet|Similar Placebo oral tablet
223537932|NCT02838667|PROCEDURE|Standard of Care plus Nephrology Care|
223951173|NCT03547206|DRUG|RPh201 Cohort B|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
223951174|NCT03547206|OTHER|Placebo Cohort B|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene \[BHT\]).
223951175|NCT04108104|DRUG|Cyproheptadine|3-month treatment
223951176|NCT04108104|DRUG|Alpress LP|3-month treatment
223951177|NCT02144285|DRUG|LY3113593|Administered IV
223537933|NCT01766102|PROCEDURE|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
223951178|NCT02144285|DRUG|LY3113593|Administered SC
223537934|NCT01766102|PROCEDURE|Standard Mammography|There is not an added device associated with this arm.
223537935|NCT04212663|PROCEDURE|The tendon release of musculi tibialis posterior|To release the tendon of musculi tibialis posterior.
223537936|NCT04212663|PROCEDURE|Anterior tibial tendon transfer(TATT)|To transfer the the tendon of anterior tibial from the navicular to the third cuneiform.
223537937|NCT04212663|PROCEDURE|Achilles tendon lengthing|To lengthen the achilles tendon by using two incisions.
223537938|NCT04212663|PROCEDURE|Fascial release|To cut off the metatarsal fascia in the middle part.
223951179|NCT02144285|DRUG|Placebo|Administered IV
223951180|NCT02144285|DRUG|Placebo|Administered SC
224103263|NCT01620996|BEHAVIORAL|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
224103264|NCT01620996|BEHAVIORAL|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
224103265|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, Q3W, 3 weeks a cycle
224103266|NCT06008379|DRUG|7MW3711 for injection|IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
224103267|NCT01810809|PROCEDURE|articular lavage with saline injection|Patients will receive articular lavage with saline injection
223537939|NCT05198401|OTHER|covid-19|viral infection
223951181|NCT03040856|DIETARY_SUPPLEMENT|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
223951182|NCT03040856|DIETARY_SUPPLEMENT|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
223951183|NCT03040856|OTHER|Placebo|Placebo capsules containing olive oil
223951184|NCT04998552|RADIATION|Cyberknife|5-10 Gy/fraction.Average of 45 minutes every other day for a total of 5 sessions (1.5-2 weeks).
223951185|NCT01942915|BIOLOGICAL|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
223951186|NCT00366470|DRUG|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
223537940|NCT01381367|BIOLOGICAL|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
223537941|NCT01381367|DRUG|Normal Saline|normal saline, 0.5ml given subcutaneously
223537942|NCT05353686|DRUG|Placebo|Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
223537943|NCT05353686|DRUG|XEN-D0501|Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
223537944|NCT03759600|DRUG|Niraparib|Niraparib capsule
223722782|NCT06266078|DEVICE|Innovative PPE|The healthcare workers will perform tasks using innovative personal protective equipments, such as LightWeight Powered Air-Purifying Respirator (PAPR) or other type of PAPR and a Sealed coverall
223722783|NCT06266078|DEVICE|Traditional PPE|The healthcare workers will perform tasks using usual personal protective equipments, such as N95 mask plus Faceshield and waterproof apron.
223722784|NCT06147362|DRUG|68Ga-NOTA-PEG2-RM26|Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.
223951187|NCT00366470|OTHER|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
223951188|NCT02759575|DRUG|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
223722785|NCT00116467|BIOLOGICAL|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
223722786|NCT02279537|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
223951189|NCT02759575|RADIATION|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
223951190|NCT02759575|DRUG|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
223722787|NCT02530593|BEHAVIORAL|There is no intervention, only observation|
223951191|NCT02410109|BEHAVIORAL|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
223537945|NCT05173974|DEVICE|Super Poligrip Free|A single application of 1 gram of Super Poligrip Free will be applied topically to oral tissues via the upper denture.
223537946|NCT05173974|DEVICE|Experimental Denture Adhesive 1|A single application of 1 gram of Experimental Denture Adhesive 1 will be applied topically to oral tissues via the upper denture.
223537947|NCT05173974|DEVICE|Experimental Denture Adhesive 2|A single application of 1 gram of Experimental Denture Adhesive 2 will be applied topically to oral tissues via the upper denture.
223951192|NCT01051271|DRUG|midazolam|midazolam 1.5 mg
223951193|NCT00937183|BIOLOGICAL|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
224103268|NCT01810809|DRUG|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
224103269|NCT01810809|DRUG|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
224103270|NCT01810809|DRUG|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
224103271|NCT03063385|BEHAVIORAL|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
224103272|NCT03063385|BEHAVIORAL|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
223537948|NCT01697085|DIETARY_SUPPLEMENT|Sea buckthorn oil|
223537949|NCT01697085|DIETARY_SUPPLEMENT|Placebo oil|
224103273|NCT04442581|DRUG|Cabozantinib S-malate|Given PO
223537950|NCT00050583|BEHAVIORAL|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
223537951|NCT00050583|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
223537952|NCT00733486|DEVICE|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
223537953|NCT04691921|BEHAVIORAL|Current clinical practices of participating physicians|Current clinical practice of participating physicians on choice of pharmacological agents for clinical management of Severe COVID-19
223537954|NCT03289143|DRUG|Semorinemab|Participants will receive Semorinemab intravenously (IV).
223537955|NCT03289143|DRUG|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
223537956|NCT03289143|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
223537957|NCT00328796|PROCEDURE|acupuncture in 6 specific points|
223951194|NCT00937183|BIOLOGICAL|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
223951195|NCT00937183|BIOLOGICAL|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
223951196|NCT04598139|OTHER|Study group|The study group uses a web-based medication error notification system
223951197|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
223951198|NCT00233714|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
224103274|NCT04442581|BIOLOGICAL|Pembrolizumab|Given IV
224103275|NCT02627846|DEVICE|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
223537958|NCT00328796|DRUG|lidocaine 10mg/ml|
224295216|NCT05796063|DIAGNOSTIC_TEST|gastric point of care ultrasound|Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
224295217|NCT01602016|DRUG|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
224295218|NCT01602016|DRUG|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
224295219|NCT01685541|OTHER|Maximum After Visit Summary Content|
224295220|NCT01685541|OTHER|Intermediate After Visit Summary Content|
224295221|NCT01685541|OTHER|Minimum After Visit Summary Content|
224295222|NCT01685541|OTHER|Usual AVS|
224295223|NCT03718741|RADIATION|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
224295224|NCT04328519|OTHER|observation|observation
224295225|NCT02591212|BEHAVIORAL|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
224103276|NCT02627846|DEVICE|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
224288165|NCT06233019|OTHER|Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart|Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
224288166|NCT05813938|DEVICE|LabTest Checker|A set of blood laboratory tests is ordered. Test results are recorded in the LabTest Checker. LabTest Checker's diagnostic engine automatically generates a personalized questionnaire that is filled out by the patient. After obtaining all necessary information, including the patient's chronic diseases, medications taken, and symptoms, the tool presents an interpretation of test results.
224288167|NCT05878379|BEHAVIORAL|Dietary Iron Program|"Teachers Lesson 1: Discuss about causes, prevention and effects of anemia and ID, dietary iron, dietary enhancers and inhibitors of iron absorption, and school lunch menu Lesson 2: Participate in and observe how to teach children in an iron curriculum~Caregivers Lesson 1: Presentation and group talk about causes, prevention, and effects of anemia and ID, dietary iron, and dietary enhancers and inhibitors of iron absorption Lesson 2: Discuss benefits and barriers of changing to an iron-rich meal at home Lesson 3: Cooking class for preparing an iron-rich meal at home (2 times) Lesson 4: Home visit~Children Lesson 1: Group talk about causes and effects of anemia and ID Games: Where are you from? Lesson 2: Presentation and group talk about dietary iron, and dietary enhancers and inhibitors of iron absorption, and iron-rich food Games: What is the winner? Assignment: Market assignment Lesson 3: Cooking class (2 times)"
224288168|NCT03658187|DIETARY_SUPPLEMENT|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
224288169|NCT03658187|DIETARY_SUPPLEMENT|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
224288170|NCT02377921|DRUG|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
224288171|NCT02377921|DRUG|Placebo|tablets for oral use
223722788|NCT02516345|DEVICE|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
223722789|NCT02516345|BEHAVIORAL|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
223722790|NCT02709733|BEHAVIORAL|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
224103277|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
224103278|NCT02627846|DRUG|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
224103279|NCT02627846|DRUG|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
224288172|NCT01615887|DRUG|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
224288173|NCT01615887|DRUG|placebo|sugar pill
224103280|NCT02627846|DRUG|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
224103281|NCT00181688|DRUG|Iressa (ZD1839)|
224103282|NCT00181688|DRUG|Arimidex (Anastrozole)|
223722791|NCT05009615|DIETARY_SUPPLEMENT|Green coffee extract|150 mg polyphenols from green coffee, twice daily
224103283|NCT02359123|OTHER|Cannabics capsules|Cannabis extract in an oil formulation
224288174|NCT04859036|DIAGNOSTIC_TEST|24 hours ambulatory Holter monitoring|
224288175|NCT00017459|DRUG|cisplatin|
224288176|NCT00017459|DRUG|tirapazamine|
223537959|NCT00730756|DRUG|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
223537960|NCT00730756|OTHER|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
223537961|NCT00305877|BIOLOGICAL|cetuximab|Given IV
223537962|NCT00305877|DRUG|gemcitabine hydrochloride|Given IV
223537963|NCT00305877|DRUG|capecitabine|Given orally
223537964|NCT00305877|RADIATION|radiation therapy|Undergo radiation therapy
223537965|NCT00305877|BIOLOGICAL|bevacizumab|Given IV
223537966|NCT00305877|OTHER|laboratory biomarker analysis|Correlative studies
223722792|NCT05009615|DIETARY_SUPPLEMENT|Beta glucan|2.5 g BG twice daily
223722793|NCT05009615|DIETARY_SUPPLEMENT|Green coffee + beta-glucan|150 mg polyphenols from green coffee + 2.5 g BG, twice daily
223722794|NCT06077318|OTHER|Keyhole repair|The keyhole technique involves placing a mesh with a slit in the central hole around the intestinal ring, allowing facilitating the passage of the intestine through the central slit.
223722795|NCT06077318|OTHER|Sugarbaker repair|The modified Sugarbaker technique uses a mesh to place a patch on the lateralized intestine, effectively preventing herniation of abdominal contents through the stoma.
223722796|NCT00645060|OTHER|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
224288177|NCT00017459|DRUG|vinorelbine tartrate|
223537967|NCT05504759|OTHER|splint|Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
223722797|NCT00645060|OTHER|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
223722798|NCT00645060|PROCEDURE|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
223722799|NCT00645060|PROCEDURE|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
223722800|NCT00645060|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
223722801|NCT04937673|DRUG|Camrelizumab+Albumin bound paclitaxel+Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Albumin bound paclitaxel: 130 mg / m2, intravenous drip for 30 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
223722802|NCT04937673|DRUG|Camrelizumab+ Paclitaxel+ Cisplatin|"Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.~Paclitaxel: 80 mg / m2, intravenous drip for 180 minutes, D1, D8, repeated every 3 weeks.~Cisplatin: 75 mg / m2, intravenous drip for 120 minutes, D1, repeated every 3 weeks."
223951199|NCT05356676|OTHER|Isometrics|"Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well."
224103284|NCT03345862|BEHAVIORAL|non-pharmacological multicomponent|Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
224103285|NCT00679562|DRUG|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
224103286|NCT00679562|OTHER|Distilled water|Application of patches containing distilled water for 24 hours
224103287|NCT02342171|OTHER|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
224103288|NCT00711451|BEHAVIORAL|Manual removal|Manual removal of placenta during cesarean delivery
224103289|NCT00711451|PROCEDURE|Expressed removal|Surgeon will perform an expressed delivery of the placenta
224103290|NCT03550339|PROCEDURE|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
224103291|NCT03550339|BEHAVIORAL|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
224103292|NCT03550339|BEHAVIORAL|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
224103293|NCT02062177|DRUG|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
224103294|NCT02062177|DRUG|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged \< 70, 0.03 mg/Kg if aged \> 70.
224103295|NCT04205591|PROCEDURE|split bone block technique|A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
224103296|NCT04309721|DRUG|Perampanel|Single-dose of Perampanel 12 mg film-coated tablet, will be given orally in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
224103297|NCT04309721|DRUG|Placebo|Single-dose of placebo of Perampanel, administered orally. Placebo of perampanel will be given orally, in patients with status epilepticus that do not involve the oral and pharyngeal musculatures. In alternative, Placebo of perampanel will be administered by a nasogastric feeding tube, a procedure which has been recently reported to be safe and tolerated in patients with generalised status epilepticus
224103298|NCT03708692|BEHAVIORAL|Group F|After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
224103299|NCT03518840|DEVICE|SIJ Belt|Support Belts
224103300|NCT01448551|BEHAVIORAL|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
224103301|NCT03110822|DRUG|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
224103302|NCT03110822|DRUG|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
223537968|NCT05504759|OTHER|steroid|Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
224288178|NCT05760352|DEVICE|Eccentric bike|Received eccentric cycling exercise
224288179|NCT05760352|DEVICE|Helmet ventilation|Using helmet ventilation during eccentric cycling exercise
224288180|NCT06617442|PROCEDURE|Pulmonary vein isolation|First pulmonary vein isolation performed for atrial fibrillation.
224288181|NCT00737737|DRUG|MS Contin|
224288182|NCT00737737|DRUG|Placebo|
224288183|NCT03099629|BEHAVIORAL|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
224288184|NCT02860182|OTHER|measure the elastic properties of aortic wall|
224288185|NCT00591331|DRUG|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
224288186|NCT00591331|DRUG|placebo|
223722803|NCT01095783|PROCEDURE|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
223722804|NCT01095783|PROCEDURE|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
223722805|NCT01201018|DRUG|Oshadi D, Oshadi R|Oral administration
223722806|NCT01402492|DRUG|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
223951200|NCT05356676|OTHER|Combination Therapy|"1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks."
223951201|NCT00278304|RADIATION|brachytherapy|
223951202|NCT00278304|RADIATION|radiation therapy|
223722807|NCT01402492|DRUG|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
224288187|NCT02549573|DRUG|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
224288188|NCT02549573|BEHAVIORAL|Physical Therapy|All subjects will participate in a standardized PT intervention
223951203|NCT06989359|DRUG|ADX-038|siRNA duplex oligonucleotide
223951204|NCT01553214|DRUG|Filgrastim|Donors shall receive G-CSF 480 mcg as a single 1.6-mL subcutaneous injection 12 to 24 hours prior to donation.
223951205|NCT01553214|DRUG|Dexamethasone|Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
223951206|NCT06919718|DIETARY_SUPPLEMENT|Vitamin D (Cholecalciferol )|2,000 IU Vitamin D
223951207|NCT06919718|OTHER|Placebo|Placebo
224103303|NCT03110822|DRUG|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
224103304|NCT06350162|DRUG|Serplulimab|4.5mg/kg,IV over 30 minutes +/- 10 minutes on day 1. Cycles repeat every 21 days.
224103305|NCT06350162|RADIATION|Chest Radiation|30Gy-45Gy/QD/3Gy
224103306|NCT02261480|OTHER|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
224103307|NCT02261480|OTHER|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
224288189|NCT05237440|BIOLOGICAL|Biological dosage|Metabolic, hormonal and psychometric evaluations will be carried out during inclusion inflammatory parameters, hormonal, capillary, saliva and urine assays will also be carried out at inclusion
224288190|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
224288191|NCT03827616|RADIATION|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
224103308|NCT03943667|DRUG|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
224103309|NCT03943667|DRUG|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
224103310|NCT02229994|OTHER|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~* From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~* From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
224103311|NCT00942201|DRUG|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
224103312|NCT00942201|DRUG|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
223722808|NCT04004715|DIETARY_SUPPLEMENT|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
223722809|NCT04004715|DIETARY_SUPPLEMENT|Whey Protein|commercially available whey protein isolate
224103313|NCT03068026|DEVICE|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
223722810|NCT04004715|DIETARY_SUPPLEMENT|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
223722811|NCT00772291|DRUG|pregabalin|pregabalin 150-600mg/day during 8 weeks
223722812|NCT00772291|DRUG|placebo|placebo drug during 8 weeks
223722813|NCT04254705|PROCEDURE|Rectal Biopsy|Suction biopsy or forceps biopsy
223722814|NCT00217295|DRUG|Avonex and Topamax|
223722815|NCT04022993|DRUG|Lantus Solostar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
223722816|NCT04022993|DRUG|Insulin RinGlar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
223722817|NCT00113984|BIOLOGICAL|PROSTVAC-V/TRICOM|
223951208|NCT06936280|BEHAVIORAL|ACTnow|"The group-based psychological intervention consists of six bi-weekly sessions, each lasting two hours, with 6-10 participants per group, led by a psychologist and nurse.~The intervention is based on Acceptance and Commitment Therapy (ACT), an evidence-based approach shown to be effective for chronic diseases, with additional elements from cognitive behavioral therapy and health education. It is manual-based, developed by experienced clinicians at SDCO, and includes tools from an existing diabetes distress intervention (REDUCE).~Each session includes a mindfulness exercise, a review of the previous session, a new topic, individual homework assignments, and a conclusion. Participants complete an online questionnaire to track diabetes distress after each session. The group process lasts about 3 months. Preliminary results from a feasibility study showed positive outcomes in recruitment, patient satisfaction, and reduction of diabetes distress (publication in progress)."
224103314|NCT03068026|OTHER|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
224103315|NCT05077189|OTHER|Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale|"4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.~1. Demographics Survey~2. DC/TMD Symptom Questionnaire (SQ)~3. Graded Chronic Pain Scale (GCPS)~4. Jaw Functional Limitation Scale-20 (JFLS-20)"
224103316|NCT01904461|DEVICE|Vacuum device|
224103317|NCT01904461|PROCEDURE|Conventional surgery|
224103318|NCT06512857|OTHER|Hand puppet method|Children in the experimental group were shown a hand puppet to distract them during the skin test for allergy.
224103319|NCT06512857|OTHER|Kaleidoscope method|Children in the other experimental group were look at kaleidoscope to distract them during the skin test for allergy.
224103320|NCT06468579|DRUG|GT20029|Stage 1: GT20029 gel single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
224103321|NCT06468579|DRUG|GT20029 matching placebo|Stage 1: GT20029 gel matching placebo single ascending dose (1mg, 2mg, 5mg, 10mg) with 14 days washout window; Multi ascending dose (2mg QD, 2mg Q12h, 5mg QD, 5mg Q12h,10mg QD) for 14 consecutive days; Stage 2: GT20029 solution matching placebo multi ascending dose (5mg QD, 10mg QD, 20mg QD) for 14 consecutive days;
224103322|NCT05640986|BEHAVIORAL|BART-EEG at V1 + V2|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 + V2 for Parkinsonian patients
224103323|NCT05640986|BEHAVIORAL|BART-EEG at V1 only|Balloon Analogue Risk Task coupled to Electroencephalogram (BART-EEG) at V1 only for healthy volunteers
224103324|NCT03704051|BEHAVIORAL|Mode of Feeding (breastfeeding versus bottle-feeding)|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
224288192|NCT06766721|DEVICE|Ultrasound (USG)|The intervention involves the use of a portable ultrasound (USG) device to assess costochondral joint separation in patients with blunt thoracic trauma. The ultrasound examination will focus on detecting disruptions in the connection between the ribs and cartilage, providing a non-invasive, radiation-free diagnostic method. A 12-MHz linear transducer will be used to scan the rib area for fractures or separations. The findings will be compared to those of computed tomography (CT), considered the gold standard. This intervention is designed to evaluate the accuracy, sensitivity, and specificity of ultrasound as a diagnostic tool in this context.
224288193|NCT03748355|GENETIC|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
224288194|NCT04824144|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
223722818|NCT00113984|BIOLOGICAL|PROSTVAC-F/TRICOM|
224288195|NCT06415279|DRUG|Winlevi (clascoterone) 1% cream|Twice daily (BID) dosing
224288196|NCT06029491|DEVICE|RapidPulseTM Aspiration System|The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.
224288197|NCT05555706|DRUG|B013+Nab-Paclitaxel|"B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle."
224288198|NCT05368012|DRUG|MIDCAB|Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
223951209|NCT05447286|DRUG|NYX-783|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
224103325|NCT03990662|OTHER|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
224103326|NCT06449599|DEVICE|ultrasound|"Local anesthesia 400 mg(20ml) prilocaine 2% to surgical field and additionally ultrasound-guided RIB with 0,25% bupivacaine 20 ml will be applied to the patients who will be inserted cardiac implantable electronic devices An additional 100 mg of prilocaine will be administered as the first-line rescue treatment if the intraoperative NRS-11 score was ≥4.If the patient has an NRS-11 score of ≥4 again during the procedure,100 mg of prilocaine will be administered again as the second rescue treatment.~In the postoperative follow-up of the patients,1 g of paracetamol will be administered IV as an infusion for 20 minutes as the first rescue treatment if the patients have an NRS-11 pain score of ≥4. Two hours after IV paracetamol,if the NRS-11 score≥4, 50 mg of tramadol HCL will be administered IV as the second rescue treatment.In addition, when the NRS score is ≥4 at follow-up, paracetamol 1 g, IV will be administered with dosing intervals not shorter than 6 hours."
224103327|NCT06449599|PROCEDURE|parenteral local anesthesia|"Only local anesthesia 400 mg(20ml) prilocaine 2% prilocaine to surgical field will be applied to the patients who will be inserted cardiac implantable electronic devices.~An additional 100 mg of prilocaine will be administered as the first-line rescue treatment if the intraoperative NRS-11 score was ≥4.If the patient has an NRS-11 score of ≥4 again during the procedure,100 mg of prilocaine will be administered again as the second rescue treatment.~In the postoperative follow-up of the patients,1 g of paracetamol will be administered IV as an infusion for 20 minutes as the first rescue treatment if the patients have an NRS-11 pain score of ≥4. Two hours after IV paracetamol,if the NRS-11 score≥4, 50 mg of tramadol HCL will be administered IV as the second rescue treatment.In addition, when the NRS score is ≥4 at follow-up, paracetamol (1 g, IV) will be administered with dosing intervals not shorter than 6 hours."
224103328|NCT06431542|PROCEDURE|physician-applied Triamcinolone Acetonide Econazole Cream|The doctor applies the Triamcinolone Acetonide Econazole Cream onto a thin cotton swab and gently inserts it deep into the ear canal, evenly spreading the cream around the sides of the ear canal and on the surface of the eardrum.
223951210|NCT05447286|DRUG|Placebo|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
223951211|NCT05447286|DRUG|Oxycodone|This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
223951212|NCT05640895|PROCEDURE|Intravitreal injection site|Intravitreal injections will be made at varying sites; patients will report on pain perception
224288199|NCT02403661|PROCEDURE|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
224288200|NCT02966184|DRUG|preservative free albuterol|Preservative free albuterol for nebulization
224288201|NCT03860207|BIOLOGICAL|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.
223722819|NCT00113984|DRUG|MDX-010|
223722820|NCT00113984|DRUG|Sargramostim|
223722821|NCT04639375|BIOLOGICAL|Vaccinated with polio vaccine (IPV)|poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
224103329|NCT06431542|PROCEDURE|patient-applied Triamcinolone Acetonide Econazole Cream|The patient applies Triamcinolone Acetonide Econazole Cream in the external auditory canal at home using a cotton swab.
224103330|NCT05624372|DIAGNOSTIC_TEST|hearing and cognitive assessment|psychiatric assessment, hearing assessment and brief cognitive assessment
224103331|NCT00304590|DRUG|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
224103332|NCT06097741|DEVICE|MRI sequences|Ultra short / zero TE sequence on MRI being tested on healthy patients and improved by manually fine tuning the sequence
224103333|NCT03478241|DEVICE|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
224103334|NCT03478241|DEVICE|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
224103335|NCT03478241|DEVICE|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
224103336|NCT03486236|DRUG|VX-440|VX-440 was administered in TC with TEZ and IVA.
224103337|NCT03486236|DRUG|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
224103338|NCT03486236|DRUG|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
224103339|NCT03486236|DRUG|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
224103340|NCT03715465|DRUG|Melatonin 0.5 MG|Melatonin tablet
223722822|NCT03533868|DIAGNOSTIC_TEST|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
224288202|NCT03860207|OTHER|Blood draw|In cycle 1, blood is drawn for PK studies.
224288203|NCT05477459|DRUG|LSD tartrate|LSD tartrate equivalent to 25 microgram LSD base
224103341|NCT03715465|OTHER|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
224103342|NCT05957640|COMBINATION_PRODUCT|Yttrium-90 carbon microspheres SIRT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
224288204|NCT05477459|DRUG|Placebo|Placebo with equal appearance
224103343|NCT03815292|DRUG|MMH-MAP|Oral administration
224103344|NCT03815292|DRUG|Placebo|Oral administration
224103345|NCT04988373|DEVICE|Modified aligner appliance|Patients will be treated using a single aligner appliance with NiTi Springs in order to align their crowding teeth.
224103346|NCT04988373|DEVICE|Traditional fixed appliance|Patients will undergo typical orthodontic treatment using an MBT-prescription of metallic brackets.
224103347|NCT02574221|DRUG|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
224103348|NCT02574221|DRUG|cavity protection toothpaste|0.243% sodium fluoride toothpaste
224103349|NCT06114654|BEHAVIORAL|Physical Therapy|Specific physical tests to assess muscle strength, ankle stability and activation of the lower extremity musculature: Single Leg Stance Test, Hurdle Step test and Single leg vertical jump.
224103350|NCT03963544|DRUG|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
224103351|NCT03361501|DRUG|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
224103352|NCT03361501|DRUG|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
224103353|NCT00638872|DRUG|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
224103354|NCT00638872|OTHER|0.9% NaCl|same as PDRN
224103355|NCT01733355|RADIATION|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
224103356|NCT01057264|DRUG|HAI Abraxane|Starting dose: 120 mg/m\^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
224103357|NCT01057264|DRUG|Gemcitabine|Starting dose: 600 mg/m\^2 by IV on Days 1 and 8 of 21 day cycle
224103358|NCT01057264|DRUG|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
224103359|NCT01057264|DRUG|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
224103360|NCT00003248|BIOLOGICAL|rituximab|
224103361|NCT00003248|DRUG|fludarabine phosphate|
224103362|NCT04943536|DRUG|bicalutamide|localized anti-androgen therapy
224103363|NCT04943536|RADIATION|Stereotactic body radiation therapy|localized radiation therapy
224103364|NCT02362607|BEHAVIORAL|Integrated Diabetes Management Protocol|
224103365|NCT02362607|BEHAVIORAL|Standard Diabetes Management Protocol|
224103366|NCT02758795|DIETARY_SUPPLEMENT|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
224288205|NCT04567576|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|"Within a non-experimental setting, the routine disease-modifying antirheumatic drugs (DMARDs) prescription will be evaluated as the exposure."
224288206|NCT01792414|DEVICE|Sham TES|Neuroconn Eldith device
224288207|NCT01792414|DEVICE|Active TES|Neuroconn Eldith device
224288208|NCT04685551|BEHAVIORAL|Change in knowledge, motivation, skills, and resources|Provide/enhance knowledge, modify attitudes, motivate and provide skills and resources to improve survivorship outcomes.
224288209|NCT01010126|BIOLOGICAL|Bevacizumab|Given IV
224288210|NCT01010126|DRUG|Temsirolimus|Given IV
223722823|NCT00814164|DRUG|clofarabine|IV
224103367|NCT02758795|DIETARY_SUPPLEMENT|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
224288211|NCT00635830|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
224288212|NCT04698772|DRUG|Ketamine|Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
224288213|NCT04698772|DRUG|Morphine|Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
224288214|NCT01150162|DRUG|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
224288215|NCT01150162|DRUG|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
224288216|NCT04060914|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
223722824|NCT00814164|DRUG|daunorubicin hydrochloride|IV
223537969|NCT05504759|OTHER|dry needling|The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
223951213|NCT06380127|BEHAVIORAL|Exercise training|The exercise intervention will take place at the nursing homes and consists of 12 weeks of supervised concurrent exercise training, performed thrice weekly on nonconsecutive days to avoid overtraining and fatigue. Each session will last 50-60 min and consist of a warm-up, resistance plus aerobic training, and a 5-min cool-down period. The resistance training will comprise 2-3 sets of 10 to 15 repetitions with a load equivalent to 40 to 70% of the 1-repetition maximum (1RM) for upper (i.e., bicep curl) and lower body exercises (i.e., seated knee extension). The sit-to-stand exercise will be performed as fast as possible according to each participant's capacity without external load. The recovery between sets is between 1 and 2 min. Afterwards, participants will perform walking exercises with changes in pace and direction. The duration of the aerobic training will progress from 5-10 min duration in the first weeks to 10-15 min. The sessions will end with stretching exercises.The exercise
223537970|NCT05017870|DRUG|KSR-001|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
223722825|NCT00814164|GENETIC|cytogenetic analysis|Correlative study
223722826|NCT00814164|GENETIC|protein expression analysis|Correlative Study
223722827|NCT00814164|OTHER|immunologic technique|Correlative Study
223722828|NCT00814164|OTHER|pharmacological study|Correlative Study
224103368|NCT00565500|DRUG|celecoxib|celecoxib capsules 200 mg bid for 1 week
223722829|NCT03537105|PROCEDURE|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
223722830|NCT00136799|DRUG|Fluvastatin|
223722831|NCT00675493|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
223722832|NCT03338374|DEVICE|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
223951214|NCT03659136|DRUG|Xentuzumab|Intravenous infusion
224103369|NCT00565500|DRUG|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
224103370|NCT00565500|DRUG|placebo|placebo capsules tid for 1 week
224103371|NCT06145919|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
224103372|NCT06145919|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
224103373|NCT02991651|DRUG|IRX4204|RXR agonist
224103374|NCT02991651|DRUG|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
224288217|NCT04060914|DRUG|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
224288218|NCT04060914|DRUG|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
224288219|NCT03883555|DEVICE|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
224288220|NCT03883555|DEVICE|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
224288221|NCT04238637|DRUG|Durvalumab|Durvalumab IV (intravenous Infusion)
224288222|NCT04238637|DRUG|Tremelimumab|Tremelimumab IV (intravenous Infusion)
224288223|NCT00595335|DRUG|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
224288224|NCT00595335|DRUG|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
224103375|NCT02163330|DRUG|Acetazolamide|
224103376|NCT02163330|DRUG|sugar pill|
224103377|NCT03085069|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
224288225|NCT00595335|DRUG|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
224288226|NCT01959490|BIOLOGICAL|trastuzumab|Given IV
224288227|NCT01959490|BIOLOGICAL|Pertuzumab|Given IV
224288228|NCT01959490|DRUG|docetaxel|Given IV
224103378|NCT06148610|DEVICE|NewSpringForMe digital solution|Follow-up of transplanted patients for hematological diseases using the NewSpringForMe device as support of quality of life
224288229|NCT01959490|DRUG|carboplatin|Given IV
224288230|NCT01959490|DRUG|doxorubicin|Given IV
224288231|NCT01959490|DRUG|cyclophosphamide|Given IV
224288232|NCT01959490|DRUG|paclitaxel|Given IV
224288233|NCT01959490|DRUG|Bevacizumab|
224288234|NCT04930666|OTHER|BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease|BREATHE-ALD utilizes the patient's nurse practitioner (NP) to deliver a brief intervention using motivational interviewing and shared decision making, in a one-time 9-minute intervention. The NP will follow a 4-step script tailored to specific ALD self-management discussed during the most recent visit with the patient's pulmonologist. Step 1: Raise the subject (1½ minute). Step 2: Provide feedback (1½ minutes). Step 3: Enhance engagement (3 minutes). Step 4: Shared decision-making (3 minutes).
223537971|NCT05017870|DRUG|KSR-004|(0 day) eye drops received one drop to both eyes once a day (1\~5 day) eyedrops recieved one drop to both eyes four times a day
223722833|NCT04395443|OTHER|medication reconciliation|the emergency clinical pharmacists will start medication reconciliation with the admitted patients and a full diseases and preadmission medications history will be taken.A comparison between the accuracy and completeness of drug history lists already presented in the profile and drug history taken by the clinical pharmacists to detect the medication discrepancies
224288235|NCT05671822|DRUG|SHR-A1811 and SHR-1701|(Arm 1A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion;
224288236|NCT05671822|DRUG|SHR-A1811 and capecitabine|(Arm 1B) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
223537972|NCT05017870|DRUG|KSR-001-02|KSR-001-02
223537973|NCT05017870|DRUG|KSR-001-03|KSR-001-03
223537974|NCT01152307|BEHAVIORAL|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
223537975|NCT01126190|BIOLOGICAL|Neugranin|Neugranin will be administered per dose and schedule specified in the arm description.
223537976|NCT01126190|BIOLOGICAL|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
223537977|NCT01126190|DRUG|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 in combination
223537978|NCT04817202|DRUG|hzVSF-v13 (intravenous, single dose)|Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)
223537979|NCT04817202|DRUG|hzVSF-v13 (subcutaneous, single dose)|Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
223537980|NCT04817202|DRUG|hzVSF-v13 (intravenous, multiple dose)|Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
223537981|NCT04817202|DRUG|Placebo (intravenous, single dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)
223537982|NCT04817202|DRUG|Placebo (subcutaneous, single dose)|Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)
223537983|NCT04817202|DRUG|Placebo (intravenous, multiple dose)|Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)
223722834|NCT03445104|OTHER|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
223722835|NCT03445104|OTHER|Placebo|During one of the two experimental sessions, participants will be given a placebo.
223722836|NCT01746745|DRUG|[^14C]-LY2940680|Administered as solution by mouth
223722837|NCT03722966|DRUG|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
224103379|NCT03445676|BEHAVIORAL|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
224103380|NCT02007239|DRUG|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
224103381|NCT04596657|DIETARY_SUPPLEMENT|Vitamin D supplementation|Daily vitamin D3 supplementation (5000 IU)
224103382|NCT03453060|DRUG|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
224103383|NCT03453060|DRUG|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
224103384|NCT03453060|DRUG|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
224103385|NCT03453060|DRUG|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
224103386|NCT03453060|OTHER|Placebo|Participants received a single intravenous dose of placebo.
224103387|NCT00292123|DRUG|Methadone|
224103388|NCT00292123|BEHAVIORAL|Contingency Management|
224103389|NCT04524975|DRUG|CD-008-0045|CD-008-0045 20 mg capsules
224103390|NCT04524975|DRUG|Placebo|Placebo capsules
224103391|NCT01095484|DRUG|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
224288237|NCT05671822|DRUG|SHR-A181, SHR-1701, and capecitabine|(Arm 1C) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1701, administered as an IV infusion Drug：capecitabine, administered orally；
224288238|NCT05671822|DRUG|SHR-A1811, SHR-1316, and capecitabine|(Arm 1D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally；
224103392|NCT00722059|PROCEDURE|Breast Tomosynthesis|3D breast imaging
224103393|NCT01142323|DRUG|fenofibrate|160 mg po daily
224103394|NCT04374903|DRUG|HCQ & AZ vs HCQ+SIR|Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus
224103395|NCT01959204|DRUG|Oxycodone|Pain
224103396|NCT00089180|DRUG|liposomal T4N5 lotion|Given topically
224103397|NCT00089180|OTHER|placebo|Given topically
224103398|NCT00089180|OTHER|laboratory biomarker analysis|Correlative studies
224103399|NCT00446394|BEHAVIORAL|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
224103400|NCT00446394|BEHAVIORAL|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
224103401|NCT00430781|DRUG|pazopanib (GW786034)|
224103402|NCT00430781|DRUG|lapatinib (GW572016)|
223537984|NCT04554303|DRUG|S-amlodipine 2.5mg|Oral administration, 1 tablet per day
224288239|NCT05671822|DRUG|SHR-A1811, SHR-1316, capecitabine,and oxaliplatin|(Arm 1F) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
224288240|NCT05671822|DRUG|SHR-A1811, SHR-1316, and 5-FU|(Arm 1G) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
223722838|NCT03722966|DRUG|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
224103403|NCT05946252|OTHER|Motor imagery|"Motor imagery will be performed according to the PETTLEP (Physical,Environment,Task,Time,Learn,Emotion,Perspective) model for 15 minutes.~1. To imagine walking activity in different environments (seaside, beach, walking path).~2. The rest activity will be imagined by sitting on a bench.~3. Upper extremity strengthening exercises with dumbbells, lower extremity strengthening exercises with elastic band and trunk-oriented bridging, posterior pelvic tilt and table top stabilization exercises will be visualized.~4. The rest activity will be imagined by sitting on a bench.~5. Imagination will end with homecoming and domestic activities."
224103404|NCT05946252|OTHER|Diaphragmatic breathing|Diaphragmatic breathing will be shown to pregnant women in the supine position, eyes closed, with one hand on the chest and the other hand on the abdomen. This practice will last for five minutes.
224103405|NCT01506791|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
224103406|NCT00622934|DRUG|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
224288241|NCT05671822|DRUG|SHR-A1811, SHR-1316, and capecitabine|(Arm 2A) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316 administered as an IV infusion; Drug：capecitabine, administered orally；
223537985|NCT04554303|DRUG|Amlodipine 5mg|Oral administration, 1 tablet per day
224288242|NCT05671822|DRUG|SHR-1316 and SHR-A1811|(Arm 2B) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion
224288243|NCT05671822|DRUG|SHR-A1811 and capecitabine|(Arm 2C) Drug: SHR-A1811, administered as an IV infusion Drug：capecitabine, administered orally；
224288244|NCT05671822|DRUG|SHR-A1811, SHR-1316, and 5-FU|(Arm 2D) Drug: SHR-A1811, administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：5-FU，administered as an IV infusion
223537986|NCT03334838|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
223537987|NCT00524121|DRUG|erlotinib hydrochloride|Oral
223537988|NCT00524121|OTHER|immunohistochemistry staining method|Correlative Study
223537989|NCT00524121|RADIATION|radiation therapy|Radiation Treatment
223722839|NCT03722966|BEHAVIORAL|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
223722840|NCT03722966|BEHAVIORAL|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
223722841|NCT01169493|DEVICE|VVI-40|Pacing mode set to VVI-40, RV only pacing
224103407|NCT00622934|DRUG|placebo|placebo
224103408|NCT00501319|BEHAVIORAL|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
224103409|NCT00501319|BEHAVIORAL|Questionnaire|Questionnaires taking 20 minutes to complete.
224103410|NCT00190463|DRUG|Amphotericin B|
224103411|NCT02580734|DIETARY_SUPPLEMENT|melatonin|Cross-over randomized clinical trials
224103412|NCT01576081|DEVICE|HEPHAISTOS|HEPHAISTOS unloading orthotic
224103413|NCT06478953|DIAGNOSTIC_TEST|FA Pneumonia Panel|A single BioFire® FilmArray® Pneumonia Panel assay will be performed on a respiratory clinical specimen.
224103414|NCT05000320|DIAGNOSTIC_TEST|Neuronal Injury Panel|A panel of neuronal and astroglial assays that may be a marker of brain injury.
224103415|NCT06369155|DRUG|Azenosertib|Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
224103416|NCT06510335|OTHER|Lavender essential oil-based product system|"Participants used the study products in a sequential, additive manner approximately 30-60 minutes before bedtime each night for 6 weeks. Usage consists of the following:~* 20 drops of essential oil blend in approximately 250 mL of water in a diffuser, which operated for 8 hours at nighttime.~* 3 x 6 swipes of the topical stick on the upper chest area, and 2 x 3 swipes on the inside of each wrist for topical application.~* 2 capsules of the dietary supplement.~Participants used the essential oil blend alone for 1 week, then added the topical stick for another 1 week. Finally, participants used the essential oil blend, the topical stick, and the dietary supplement for four weeks."
224103417|NCT05027269|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
224103418|NCT05027269|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
224103419|NCT06498908|DRUG|Nitrous oxide|Nitrous oxide, commonly known as laughing gas, is a colorless, non-flammable gas with a slightly sweet odor, used for its analgesic and anesthetic properties in medical and dental procedures to provide pain relief and sedation.
224103420|NCT06498908|DRUG|Oxygen|Oxygen is a colorless, odorless gas essential for human respiration and used medically to treat conditions resulting from low oxygen levels in the blood. In this trial Oxygen is being used as a placebo.
224103421|NCT03115645|OTHER|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
224288245|NCT05671822|DRUG|SHR-A1811and 5-FU|(Arm 2E) Drug: SHR-A1811, administered as an IV infusion Drug：5-FU，administered as an IV infusion
224288246|NCT05671822|DRUG|SHR-A1811, SHR-1316, capecitabine,and oxaliplatin|(Arm 2F) Drug: SHR-A1811,administered as an IV infusion Drug: SHR-1316, administered as an IV infusion Drug：capecitabine, administered orally； Drug：oxaliplatin，administered as an IV infusion
224288247|NCT04718545|PROCEDURE|Mucogingival surgery|The gingival recession at mandibular incisor site will be covered by a gingival graft harvested from the palate.
224288248|NCT04317872|DRUG|High dose of peri-operative intravenous dexamethasone|25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
224288249|NCT04317872|DRUG|Low dose of peri-operative intravenous dexamethasone|10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
224103422|NCT01950936|OTHER|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
224103423|NCT02158533|DRUG|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
224103424|NCT02158533|DRUG|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
224103425|NCT02158533|DRUG|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
224103426|NCT02801357|DRUG|lofexidine administration in subjects seeking buprenorphine dose reduction|
224103427|NCT04526522|OTHER|No intervention|No intervention
223537990|NCT00572182|DRUG|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
224103428|NCT04036760|BEHAVIORAL|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
224103429|NCT00548314|OTHER|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
224103430|NCT00548314|PROCEDURE|Split skin graft|
224103431|NCT00548314|DEVICE|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
224288250|NCT06456372|BEHAVIORAL|Digital Health Intervention Group|Our digital health intervention (DHI) uses Patient-Centered Digital Healthcare Technologies (PC-DHT) to promote co-regulation (child/parent), capture patient data, support efficient healthcare delivery, enhance patient engagement, and facilitate shared decision-making, thereby improving access to timely and targeted mental health intervention for children at great risk for poor outcomes. This system will integrate treatment across multiple points of care and will enable health care providers and caregivers to share reliable and targeted information that will facilitate collaborative decision-making (e.g., making decisions about changing or titrating medications/dosages or shifting behavioral therapy and educational intervention targets) and improve patient experiences and outcomes.
224288251|NCT06483282|DRUG|Adebrelimab|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
224103432|NCT01092442|PROCEDURE|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
224103433|NCT02642861|DRUG|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
224288252|NCT06483282|DRUG|Apatinib Mesylate|This product is an orally administered targeted therapy drug, with a recommended dosage of one tablet per day.
224288253|NCT06483282|DRUG|Etoposide|This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 100mg/m2, administered every 3 Weeks (Q3W).
224288254|NCT06483282|DRUG|Carboplatin|This product is administered by intravenously guttae. AUC=5, administered every 3 Weeks (Q3W).
224288255|NCT02658487|DRUG|Cytarabine|Given IV
224288256|NCT02658487|DRUG|Vosaroxin|Given IV
223537991|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
223722842|NCT01169493|DEVICE|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
224103434|NCT02642861|DRUG|Calcium Carbonate|Calcium carbonate for 2 weeks
224103435|NCT00598130|BIOLOGICAL|Fleece|Fibrin Patch
224103436|NCT03499054|OTHER|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
224103437|NCT05890391|OTHER|Time-Restricted Eating|They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
224103438|NCT05890391|OTHER|Energy-Restricted Diet|The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
224103439|NCT01691729|DEVICE|Ostomy accessory|Wearing each of the devices for 10 days each
224103440|NCT00236561|DRUG|topiramate, propranolol|
224103441|NCT00180115|DRUG|Cytarabine Dosage|
224103442|NCT04329949|DRUG|Relacorilant, 100 mg and 25 mg|Relacorilant is supplied as capsules for oral dosing.
224103443|NCT04329949|DRUG|Nab-paclitaxel|Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
224103444|NCT01825434|DIETARY_SUPPLEMENT|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
224103445|NCT06209697|DIETARY_SUPPLEMENT|red clover|Red clover (Promensil, PharmaCare Europe Ltd., UK) and placebo (starch capsules) were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
224103446|NCT03841877|PROCEDURE|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
223951215|NCT03659136|DRUG|Placebo|Intravenous infusion
224103447|NCT01744899|OTHER|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
224288257|NCT00688298|DEVICE|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
223537992|NCT03406208|BEHAVIORAL|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
223537993|NCT04758481|RADIATION|primary tumour radiotherapy|The study subjects will undergo primary tumour radiotherapy.
223537994|NCT04758481|RADIATION|stereotactic body radiotherapy|The study subjects will undergo stereotactic body radiotherapy.
223537995|NCT04758481|RADIATION|maintenance radiotherapy|The study subjects will undergo maintenance radiotherapy.
223537996|NCT01114737|DRUG|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
223722843|NCT01169493|DEVICE|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
223951216|NCT03659136|DRUG|Everolimus|Tablet
223951217|NCT03659136|DRUG|Exemestane|Tablet
223951218|NCT03786471|OTHER|Health System-based Dementia Care|Active comparator
223951219|NCT03786471|OTHER|Community-based Dementia Care|Active comparator
223951220|NCT03786471|OTHER|Usual Care|Control
223951221|NCT03346200|DRUG|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
223951222|NCT03346200|DRUG|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
223951223|NCT06402916|DIETARY_SUPPLEMENT|Blueberry drink|Blueberry drink equivalent to 240g fresh blueberries.
223951224|NCT06402916|DIETARY_SUPPLEMENT|Placebo drink|Drink containing no active ingredient.
223951225|NCT03265847|BEHAVIORAL|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
223951226|NCT01513447|DRUG|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
223951227|NCT00212862|OTHER|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
223951228|NCT06415552|BEHAVIORAL|Mindfulness-Based Stress Reduction|Eight iterations of the MBSR course will be delivered, over a total period of 24 months. Each iteration will take place over 8 weeks. Courses would consist of 8 weekly sessions, led by certified mindfulness instructors. Sessions will include core meditation practices, psychoeducation, and home practices.
223951229|NCT05620654|DRUG|Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin|The starting dose for paclitaxel was 175 mg/m2, with escalation in 25 mg/m2 increments until the MTD was determined or the maximum dose level of 225 mg/m2 was reached. The target dose-limiting toxicity (DLT) rate was 25%, and the total sample size was 30 patients. HIPEC was delivered immediately following the debulking surgery using the closed technique with a target temperature of 43 ℃ for 90 minutes.
223951230|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section.
223951231|NCT00762554|DRUG|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
223951232|NCT00762554|DRUG|Fentanyl|Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
223951233|NCT05001815|DEVICE|Continuous subcutaneous insulin infusion (CSII)|The CSII device used in this study has access to mobile phone, however, without CGM enhanced function
223951234|NCT05001815|DEVICE|Multiple daily insulin injection (MDI)|Patients with indication will receive MDI treatment with at least one basal insulin injection plus 2 to 3 prandial insulin injection.
223951235|NCT01276509|DRUG|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
223951236|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
223951237|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
223951238|NCT01276509|DRUG|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
223951239|NCT05560061|OTHER|Gait practice on an uneven terrain surface|Participants will walk back and forth on an uneven terrain surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
223951240|NCT05560061|OTHER|Gait practice on a flat terrain surface|Participants will walk back and forth on a level surface wearing an overhead harness (with zero bodyweight support), at their self-selected comfortable speed.
223951241|NCT03161652|DRUG|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
223951242|NCT03161652|DRUG|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
223951243|NCT03161652|DRUG|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
223951244|NCT03161652|DRUG|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
224103448|NCT02322307|OTHER|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
224288258|NCT00688298|DEVICE|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
224288259|NCT04734834|DIETARY_SUPPLEMENT|"Prodovite® VMP35"|"Efficacy of Prodovite® VMP35 will be Assessed as Compared to Placebo"
224103449|NCT02322307|OTHER|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
224288260|NCT03594825|DRUG|Valsartan|Different time of taking medicine
224288261|NCT05336435|DIAGNOSTIC_TEST|Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin|The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
224288262|NCT06239714|DRUG|SGB-3403|SGB-3403 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
224288263|NCT06239714|OTHER|Atorvastatin|The dosage of atorvastatin was determined by the investigator
224288264|NCT06239714|OTHER|Placebo|Normal saline 0.9%
224288265|NCT00804206|DRUG|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
224288266|NCT00804206|DRUG|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
224288267|NCT05477719|DEVICE|Wearing of specific compression stockings|The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body
223537997|NCT01114737|DRUG|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
223951245|NCT03161652|DRUG|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
223951246|NCT03161652|DRUG|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
223951247|NCT03161652|DRUG|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
224103450|NCT06094179|DRUG|Monoclonal antibody BAT6026|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
224103451|NCT06094179|DRUG|sodium chloride injection|300mg Q4W group, 600mg Q4W group (at week 0,4,8,12) and 600mg Q2W group (at week 0,2,4,6,8,10,12,14)
224103452|NCT03851744|OTHER|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
224103453|NCT03851744|OTHER|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
224103454|NCT05006807|DEVICE|Mechanomyograph Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
224103455|NCT05006807|DEVICE|Stimpod Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
223537998|NCT00706147|DRUG|Arimoclomol|Drug: Arimoclomol capsules given three times per day
223537999|NCT00706147|DRUG|Placebo|Drug: Placebo capsules given three times per day
223538000|NCT03637283|PROCEDURE|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
223538001|NCT03637283|PROCEDURE|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
223538002|NCT04955067|DIAGNOSTIC_TEST|Diagnositic test|The results of hip arthroscopy were taken as the gold standard, and MRI examination was taken as the research object
223538003|NCT02722005|BEHAVIORAL|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
223538004|NCT02722005|BEHAVIORAL|Access to referral to social services|Access to referral to a host of social services.
224288268|NCT02136303|DIETARY_SUPPLEMENT|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
224288269|NCT02136303|OTHER|S2: Kale extract versus kale purée|
224288270|NCT02136303|OTHER|S3: Kale extract: AMD-patients|
224288271|NCT02971722|DRUG|JY09|2mg/1ml/bottle
224288272|NCT02971722|DRUG|Placebo|1ml/bottle
224288273|NCT03800225|PROCEDURE|Repair|Anterior ligament repair with internal brace.
224103456|NCT05006807|DEVICE|TetraGraph Twitch Monitor|Measurement of train-of-four count and ratio and post titanic count
224103457|NCT05006807|DEVICE|TwitchView Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
224103458|NCT05006807|DEVICE|Nihon Kohden Twitch Monitor|Measurement of train-of-four count and ratio and post tetanic count
224103459|NCT05006807|OTHER|Palpation of twitch count|The train-of-four count is determined by manual palpation of the evoked twitch response
224103460|NCT05563532|BEHAVIORAL|dental anxiety and oral hygiene|Evaluation of the effect of mothers' dental anxiety and oral hygiene on children's dental anxiety and periodontal status.
224103461|NCT02494141|DRUG|Curcumin|Dietary Supplement
224103462|NCT02494141|OTHER|Placebo|
224103463|NCT06190314|DIAGNOSTIC_TEST|Measure serum vitamin b12 levels|Measure the vitamin b-12 levels in patients that are admitted for stroke of any kind
224103464|NCT01335971|DRUG|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
224103465|NCT01335971|DIETARY_SUPPLEMENT|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
224103466|NCT01335971|OTHER|Placebo|Microcrystalline cellulose once daily by mouth
224288274|NCT04204031|BEHAVIORAL|Presentation of the adherence record|Adherence record will be presented to participants with an actual time of use less than prescribed. The participant will also be asked about the presence of possible barriers concerning the use of oxygen therapy. The collaborator in charge of home visits will attempt to resolve these barriers as much as possible.
223722844|NCT00791856|DRUG|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
223951248|NCT03161652|DRUG|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
224103467|NCT00384956|DRUG|Azacitidine|
224103468|NCT06332443|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting or lateral position under sterile conditions. Spinal puncture will be performed at L2-L4 level using 50 mg of Clorotekal 1 or 2%. (intermediate-acting amide local anesthesia, commonly used) will be injected.
224103469|NCT06332443|PROCEDURE|Sedation epidural anesthesia|Sedation-EA will be performed in the sitting or lateral position under sterile conditions. Epidural puncture will be performed at the L2-L4 level and an epidural catheter will be inserted into the epidural space. 10 ml of 2% xylocaine without epinephrine will be injected through the catheter and the dose will be titrated (up to 20 mL) to achieve complete sensory block up to T12 dermatoma measured with a level to ice.
224103470|NCT03095092|DRUG|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
224103471|NCT01249170|BEHAVIORAL|First year program|Information on group that underwent new educational program
223951249|NCT05667012|OTHER|Educational videos|There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
223951250|NCT04985266|DRUG|Palbociclib 125Mg Tab|Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.
224103472|NCT01249170|OTHER|Control comparison|Information from group that did not undergo new first year program
223722845|NCT00791856|DRUG|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
223722846|NCT02744690|DRUG|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
224103473|NCT04075643|DRUG|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
224103474|NCT04075643|DRUG|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
224103475|NCT06234904|BIOLOGICAL|IBR733 Cell Injection|The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
224103476|NCT00917384|BIOLOGICAL|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
224103477|NCT00917384|DRUG|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
224103478|NCT00917384|OTHER|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
224103479|NCT02591992|OTHER|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
224103480|NCT02591992|OTHER|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
224103481|NCT02688569|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
224103482|NCT01095861|DEVICE|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
224103483|NCT01095861|DEVICE|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
224103484|NCT02636309|BEHAVIORAL|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
224288275|NCT01647958|DEVICE|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication using the EsophyX System with SerosaFuse fasteners
224288276|NCT01647958|DRUG|PPI|Control Arm participants will take maximum standard dose of PPI during Initial Study period
224103485|NCT00658229|BEHAVIORAL|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
224103486|NCT01518530|DEVICE|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
224103487|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose under fasted conditions
224103488|NCT00932464|DRUG|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
224103489|NCT00149214|DRUG|pemetrexed|500 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
224288277|NCT03190772|OTHER|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
224288278|NCT03190772|OTHER|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
224103490|NCT00149214|DRUG|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
224103491|NCT00149214|DRUG|doxorubicin|60 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (1-4)
224103492|NCT00149214|DRUG|docetaxel|100 mg/m\^2, intravenous (IV), every 21 days, 4 cycles (5-8)
224288279|NCT02440035|BIOLOGICAL|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10\^11) virus particles on Day 1 in Group 3.
224103493|NCT00262405|DRUG|zileuton|
224103494|NCT00262405|DRUG|azathioprine/prednisone|
223722847|NCT04144244|OTHER|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
223722848|NCT04144244|OTHER|Gradient-Density Centrifugation|sperm selection of IUI treatment
224103495|NCT00467844|DRUG|GTx-024|1 mg GTx 024
224103496|NCT00467844|DRUG|GTx-024|3 mg GTx-024
224103497|NCT00467844|DRUG|Placebo|Matching Placebo
224103498|NCT03433066|PROCEDURE|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
224103499|NCT03433066|PROCEDURE|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
224103500|NCT05877677|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
224103501|NCT05877677|DIETARY_SUPPLEMENT|Polygonatum kingianum extract drink|consume 1 bottle per day
224103502|NCT01655511|DRUG|Tafamidis|240 mg, solution, single dose
224103503|NCT01655511|DRUG|Tafamidis|480 mg, solution, single dose
224103504|NCT01655511|DRUG|Tafamidis|TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
224103505|NCT03010189|DEVICE|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
224103506|NCT03010189|DEVICE|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
224103507|NCT03010189|DEVICE|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
224103508|NCT03723096|DRUG|CC-4047|CC-4047 will be administered orally
224103509|NCT04320095|DEVICE|Bizact tonsillectomy device|Bizact tonsillectomy device is an advanced bipolar instrument that uses radiofrequency energy and pressure to ligate vessels interposed between its jaws. The energy produced by the device is automatically adjusted based on tissue impedance in an attempt to minimize thermal tissue damage.
224103510|NCT05952830|OTHER|ESWT group|subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
224103511|NCT05952830|OTHER|DN group|Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute
224103512|NCT01451515|DRUG|Prednisone|Given orally (PO).
224103513|NCT01451515|DRUG|Vincristine|Given intravenously (IV).
224103514|NCT01451515|DRUG|Daunorubicin|Given IV.
224103515|NCT01451515|DRUG|PEG-asparaginase|Given intramuscularly (IM) or IV.
224103516|NCT01451515|DRUG|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
224103517|NCT01451515|DRUG|Doxorubicin|Given IV.
224103518|NCT01451515|DRUG|Cyclophosphamide|Given IV.
224103519|NCT01451515|DRUG|Cytarabine|Given IV or IT.
224103520|NCT01451515|DRUG|Thioguanine|Given PO.
224103521|NCT01451515|DRUG|Clofarabine|Given IV.
224103522|NCT01451515|DRUG|Methotrexate|Given IV, IM or IT.
224103523|NCT01451515|DRUG|Mercaptopurine|Given PO.
224103524|NCT01451515|DRUG|Dexamethasone|Given PO or IV.
224103525|NCT01451515|DRUG|Hydrocortisone|Given IT.
224103526|NCT01451515|DRUG|Etoposide|Given IV.
224103527|NCT04590612|DRUG|Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet|25mg-100mg tablets to be taken orally three times a day on an empty stomach
224288280|NCT02440035|BIOLOGICAL|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10\^10 virus particles \[vp\]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10\^10) virus particles on Day 169 in Group 4.
224288281|NCT02440035|DRUG|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
224103528|NCT04590612|DRUG|Citalopram|20 mg tablet to be taken orally once and at the same time of the day, daily.
224103529|NCT05771571|OTHER|Functional olive oil, enhanced with orange peel extract|The functional olive oil was enriched with 10% w/w orange peel extract
224103530|NCT05771571|OTHER|Control|Refined olive oil
224103531|NCT05164328|OTHER|No intervention|No intervention
224103532|NCT01674426|BEHAVIORAL|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
224103533|NCT06067113|PROCEDURE|Supraaortic and transcranial duplex|Ecographic evaluation of supraaortic and transcranial arteries, including presence of plaques, flow velocities and pulsatility index
224103534|NCT04627545|OTHER|2h exposure to sperm for IVF|Oocytes will only be briefly (2h) exposed to progressive motile sperm for insemination
224103535|NCT04627545|OTHER|overnight exposure to sperm for IVF|Oocytes will be exposed for a longer duration (overnight, 16-20h) to progressive motile sperm for insemination
224103536|NCT00174941|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
224103537|NCT00174941|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
224103538|NCT00174941|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
224103539|NCT01594099|RADIATION|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
224103540|NCT01594099|DRUG|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
224103541|NCT01594099|DRUG|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
224103542|NCT00969722|BIOLOGICAL|MAb-3F8|
224103543|NCT00969722|BIOLOGICAL|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
224103544|NCT00969722|BIOLOGICAL|13-cis-Retinoic Acid|
224103545|NCT04230538|DEVICE|DJO Walker|
223722849|NCT02837445|DEVICE|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
224103546|NCT04230538|DEVICE|Traditional plaster cast|
224103547|NCT03127020|DRUG|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
224103548|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
224103549|NCT00849303|OTHER|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
224103550|NCT01025778|DRUG|Clofarabine for remission induction|
224103551|NCT01025778|DRUG|Etoposide for remission induction|
224103552|NCT01025778|DRUG|Cyclophosphamide for remission induction|
224103553|NCT01025778|DRUG|Clofarabine in conditioning before transplantation|
224103554|NCT01025778|DRUG|Thiotepa in conditioning before transplantation|
224103555|NCT01025778|DRUG|Melfalan in conditioning before transplantation|
224103556|NCT01025778|PROCEDURE|Haploidentical transplantation of T-cell depleted graft|
224288282|NCT03572842|OTHER|quantiferon monitor test|different blood test with quantiferon monitor
223722850|NCT02837445|DEVICE|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
223722851|NCT04799431|DRUG|Neoantigen Vaccine with Poly-ICLC adjuvant|"Neoantigen Vaccine with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22. 2 to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
224103557|NCT01025778|PROCEDURE|Donor lymphocyte infusion|
224103558|NCT06961071|BIOLOGICAL|Parathyroid Allotransplant|Parathyroid Allotransplant
224103559|NCT06205875|PROCEDURE|High dose serratus anterior plane block (2.4 mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% plus epinephrine solution will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% plus epinephrine solution will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound. In total a dose of 2.4mg/kg patient ideal body weight will be administered. There is a maximal dose of 200 mg adrenalized bupivacaine for patients with an ideal body weight of 83 kg or more.
224288283|NCT00544817|RADIATION|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
224288284|NCT00544817|DRUG|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
224288285|NCT00544817|DRUG|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
224288286|NCT01131299|OTHER|Placebo|2 tablets PO 3 times a day for 12-14 weeks
224288287|NCT01131299|DRUG|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
223951251|NCT04985266|DRUG|Fulvestrant injection|Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.
224103560|NCT06205875|PROCEDURE|Low dose serratus anterior plane block (1.2mg/kg patient ideal body weight)|The needle will be introduced in-plane from supero-anterior to postero-inferior until the needle tip is positioned in the plane underneath the serratus muscle (deep compartment). Under continuous ultrasound guidance, 3/4th of the bupivacaine 0.25% will be injected in the deep compartment. After the deep component of the serratus anterior plane block is completed, the needle will be withdrawn to the subcutaneous tissues. The needle will be flattened and advanced in-plane to the plane superficial to the serratus muscles. The remainder quarter of the bupivacaine 0.25% will be injected superficial to the serratus muscles after correct placement of the needle tip is confirmed on ultrasound.
224103561|NCT06205875|DRUG|PCIA with morphine|A patient controlled intravenous analgesia system (Bodyguard 595 Colorvision®) with morphine (Sterop®) using following settings: bolus 1.5 mg and lockout interval 7 min with maximal dose of 30mg per 4 hours.
224288288|NCT05765799|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
223722852|NCT04799431|DRUG|Retifanlimab|500 mg will be administered as a 30 minute IV. Infusion (-5 min/+15min) on Day 1 of each 28 day cycle every 4 weeks.
223722853|NCT01044771|DRUG|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
224288289|NCT00949728|PROCEDURE|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
224288290|NCT03012659|BEHAVIORAL|Contraceptive Counseling Training|"Intervention sites will receive:~1. In person training: All staff at an intervention health center will participate in a one-day counseling training.~2. On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~3. Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
223951252|NCT04985266|DRUG|Tamoxifen|As per clinical guidelines
223951253|NCT04985266|DRUG|Letrozole|As per clinical guidelines
223951254|NCT04985266|DRUG|Exemestane|As per clinical guidelines
223951255|NCT04985266|DRUG|Anastrozole|As per clinical guidelines
223951256|NCT05755178|BEHAVIORAL|Music, feelings and relationships - music group for children at shelters|"A music group intervention, offered to children 3-10 years who live or have lived at a shelter.~6 group sessions with musicians and music therapist and a group of 4-8 children.~Focus on improving recognition and regulation of emotions, and on relational capacity with adults and peers."
223951257|NCT06406049|OTHER|Control group|Participants will receive the standard of care (beginning of the study) which includes sexual health information once in-person for up to 15 minutes for the duration of the study.
223951258|NCT06406049|BEHAVIORAL|Social network intervention|Participants will come to the study location for up to 2 hours three times (beginning of the study, 6-month and 12-month follow-ups) during the duration of the study. During the study, participants will receive sexual health counseling for HIV prevention. Additionally participants will receive information and resources for PrEP usage. Participants will be encouraged to share sexual health information two times (three and nine months after the beginning of the study) during the duration of the study.
223951259|NCT03440177|DRUG|Ramipril|Patients are tested for their normal prescription ramipril medication
223951260|NCT06562972|OTHER|Occlusal equilibration of complete denture using articulating paper|Occlusal equilibration of complete dentures is vital for ensuring proper function, comfort, and longevity. The process aims to evenly distribute occlusal forces, eliminate premature contacts, improve stability, reduce wear, and minimize tissue trauma. It involves methods like the articulating paper technique, pressure indicator paste, T-Scan digital analysis, and clinical observation. The process includes evaluating centric and eccentric contacts, making fine adjustments, and achieving balanced articulation. Regular follow-ups are essential to monitor occlusion and make necessary adjustments, contributing to patient satisfaction and denture lifespan.
223951261|NCT06562972|OTHER|Occlusal equilibration of complete denture using occulosense|Occulosense denture equilibration is a digital occlusal analysis technique used to optimize denture fit and function. It employs a thin sensor placed between the dentures to measure bite force and timing. The system provides real-time data on occlusal contacts, allowing dentists to identify and adjust pressure points precisely. This process ensures even distribution of bite forces, enhancing denture stability, comfort, and longevity. T-Scan equilibration can significantly improve patient satisfaction by reducing pain, increasing chewing efficiency, and minimizing denture-related issues like sore spots and uneven wear.
223951262|NCT03329963|BEHAVIORAL|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
223951263|NCT03329963|BEHAVIORAL|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last \~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of \~90 min duration (\~15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
223951264|NCT03803423|OTHER|The Donor App|The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
223951265|NCT06005441|DRUG|CBL-514 injection|Provided as a ready for use injectable CBL-514 solution
223951266|NCT06005441|DRUG|CBL-A1 Injection|Provided as a ready for use injectable CBL-A1 solution
224288291|NCT05925244|OTHER|Control Condition|Control (no alteration to body mass).
223951267|NCT06005441|DRUG|CBL-A2 Injection|Provided as a ready for use injectable CBL-A2 solution
224103562|NCT06042179|BEHAVIORAL|Frequent PT|Physical therapy services twice a day Monday through Friday and daily Saturday and Sunday. Most sessions are geared toward bed mobility, transfers and gait training with therapeutic exercises provided to target any muscle weakness identified.
224103563|NCT06042179|BEHAVIORAL|Intense PT|Will receive error augmentation training 3-5x/wk while inpatient Standard of care PT with the addition of error augmentation principles (making hard tasks harder and increasing difficulty of tasks with added resistance to already weakened muscles) to address at least 2 stroke deficits or limitations.
224103564|NCT03186456|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 \*10\^6/kg. once a month, total 3 times.
224103565|NCT03186456|DRUG|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
223951268|NCT06005441|DRUG|0.9% Sodium Chloride|Sodium Chloride (0.9% NaCl) placebo for injection
223951269|NCT06373731|DRUG|Elamipretide|Subjects will receive once daily SC doses of 40 mg elamipretide for 96 weeks
223951270|NCT06373731|DRUG|Placebo|Subjects will receive once daily SC doses of Placebo 96 weeks
223951271|NCT06791551|DEVICE|active RIPC and tDCS|Preoperative use of a therapeutic device with sleeves fixed on the upper side of both arms, compressing the bilateral brachial arteries to 200mmHg for 5 minutes, resting for 5 minutes, repeating 5 times, recorded as 1 time, training once in the morning and afternoon each day, and continuing treatment for at least 3 days; Administer transcranial electrical stimulation, 2mA, 30min, for 3 days;
224103566|NCT05509257|DRUG|Naltrexone|Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.
224103567|NCT05509257|DRUG|Placebo|Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
224103568|NCT03806452|DRUG|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
224103569|NCT03806452|DRUG|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
224103570|NCT03669133|DRUG|Vitamin E|Vitamin E 800 IU/daily
224103571|NCT03669133|DRUG|Placebo|Matching placebo daily
224103572|NCT01601392|PROCEDURE|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
224103573|NCT01601392|PROCEDURE|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
224103574|NCT01601392|PROCEDURE|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
224103575|NCT05187533|OTHER|Osteopathic protocol of Sphenopalatine Ganglion Stimulation|Sphenopalatine Ganglion Stimulation to improve lacrimal and salivary gland secretion to improve ocular and oral dryness
224103576|NCT04819828|PROCEDURE|Extracorporeal shock wave lithotripsy|A single session of extracorporeal shock wave lithotripsy: the session will be finished upon reaching a maximum of 4,000 shocks or if a complete fragmentation of the kidney stone is observed.
224103577|NCT04819828|DRUG|Diclofenac|Standard treatment for analgesia: oral diclofenac (75 mg/12 h) as needed.
224103578|NCT04819828|DRUG|Tamsulosin|Oral tamsulosin (0.4 mg/day) for eight weeks.
224103579|NCT03389334|OTHER|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
224103580|NCT06272214|RADIATION|Adjuvant radiotherapy|"The start time for radiotherapy is 4-6 weeks after surgery, typically not exceeding 8 weeks. Intensity-modulated radiation therapy (IMRT) will be used, with a total dose of 45Gy administered in 25 fractions, five times per week.~The recommended target delineation for radiotherapy is based on the Chinese guidelines for radiation therapy of esophageal cancer, which mainly covers the high-risk lymph node area."
224103581|NCT06272214|OTHER|Observation|Patients receive surgery after neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer, followed by active survillance and maintenance therapy with PD1/PDL1 inhibitors for up to 1 year or until tumor progression.
224288292|NCT05925244|OTHER|+12% Body Mass|Loaded walking exercise (12% increase in body mass using a weighted vest).
223951272|NCT06791551|DEVICE|Sham (No Treatment)|received sham treatment with the same appearance instrument;
223951273|NCT06069544|BIOLOGICAL|BNT165e|Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
224103582|NCT05912816|DRUG|RC48 Combined With Tislelizumab|"In this trial, RC48 was scheduled to be administered at a dose of 2.0 mg/kg every 3 weeks, with the first dose on day 1 of the first cycle.~Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle. The drug is diluted with normal saline and administered by intravenous drip for one hour."
224103583|NCT04513418|DIETARY_SUPPLEMENT|Preoperative immunonutrition|Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
224103584|NCT03351244|DRUG|BI 409306|28 week treatment period
224103585|NCT03351244|DRUG|Placebo|28 week treatment period
224103586|NCT04998656|DEVICE|Werewolf FLOW 50|Use of Werewolf FLOW 50 electrocautery device during surgical treatment for ACL injury. This device is often used as standard of care when our other standard of care approach (use of no electrocautery device) is not used.
224288293|NCT05925244|OTHER|-12% Body Mass|Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
224103587|NCT04998656|OTHER|Control|Use of no electrocautery device during surgical treatment for ACL injury. This approach is often used as standard of care when our other standard of care approach (use of Werewolf FLOW 50 electrocautery device) is not used.
224103588|NCT04899271|DRUG|Ladarixin|400 mg b.i.d. for 13 cycles of 14 days on/14 days off
224288294|NCT04877587|DRUG|Ascorbate|"A patient-individualized pharmacokinetically-guided dose escalation design will be used for Ascorbate. The goal of the within-patient dose escalation is to achieve a target plasma ascorbate level between 20mM and 30mM. The administered dose levels under consideration are listed below.~Dose Level Ascorbate~* 2 60 g/m2 IV Days (1,2,8,9,15,16)~* 1 50 g/m2 IV Days (1,2,8,9,15,16) 0 (Starting dose) 40 g/m2 IV Days (1,2,8,9,15,16)~  * 1 30 g/m2 IV Days (1,2,8,9,15,16)"
224288295|NCT04877587|DRUG|Gemcitabine|Gemcitabine 900 mg/m2 given at a fixed dose rate of 10 mg/m2/min on D1, D8 and D15 to be given over 90 min every 28 days
224103589|NCT04899271|OTHER|Placebo|Placebo was administered orally with the same scheme of administration of LDX to preserve blinding
224103590|NCT04306042|DRUG|Nivolumab or Pembrolizumab|Nivolumab or Pembrolizumab
224288296|NCT01682629|OTHER|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
224288297|NCT01682629|OTHER|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
224288298|NCT00002194|DRUG|Erythromycin|
224288299|NCT00002194|DRUG|Nevirapine|
224288300|NCT00002194|DRUG|Clarithromycin|
224288301|NCT00686244|OTHER|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
224288302|NCT02105311|DEVICE|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
224288303|NCT02105311|DRUG|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
223951274|NCT06069544|OTHER|Placebo|Isotonic NaCl solution (0.9%)
223951275|NCT01534052|DRUG|Enzalutamide|Oral
223951276|NCT04906759|BEHAVIORAL|Meals plus exercise|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. Participants will also will receive an exercise kit from the MOW driver with their first meal delivery which will contain 2 tennis balls, 2 1-pound hand weights, and one towel. Every week, the driver will give the participants a handout containing 3 exercises from the NIA Go4Life Workout-to-Go book that are designed to help with strength/endurance, balance, and flexibility20. The participants will be asked to do the 3 exercises every day, if possible, on their own. Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
223951277|NCT04906759|BEHAVIORAL|Meals only|Participants will receive 12 weeks of a MOW delivery service that will include 2 meals per day during the weekdays with 4 shelf-stable meals at the end of the week. The MOW driver will visit the participants in-person to ask a series of 5 questions about change in health status, joint/muscle injuries, new pain, falls, and poor appetite twice a week. they will be asked to continue their usual level of activity.Every 4 weeks during the 12-week study period and at 6 months follow up patients will have blood drawn for frailty and inflammatory biomarkers.
223951278|NCT04172688|DIETARY_SUPPLEMENT|Prebiotic oligofructose-enriched inulin|Synergy1
223951279|NCT04172688|DIETARY_SUPPLEMENT|Placebo maltodextrin|Equicaloric dose of maltodextrin
223951280|NCT01523184|DRUG|Placebo Capsule|This is the placebo capsule
224103591|NCT00058370|DRUG|cisplatin|
224103592|NCT00058370|DRUG|lomustine|
224103593|NCT00058370|DRUG|vincristine sulfate|
224288304|NCT03050034|DEVICE|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
224288305|NCT03050034|OTHER|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
224103594|NCT00058370|PROCEDURE|adjuvant therapy|
224103595|NCT00058370|RADIATION|iodine I 131 monoclonal antibody 3F8|
224103596|NCT00058370|RADIATION|radiation therapy|
224103597|NCT03215277|DRUG|Bimekizumab|One bimekizumab dose will be administered.
224103598|NCT03215277|DRUG|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
223722854|NCT05780658|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
224103599|NCT03215277|OTHER|Placebo|Placebo will be provided to maintain the blinding.
224103600|NCT05232955|DEVICE|PET/MR scanner|Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
224103601|NCT02651610|BIOLOGICAL|Bavituximab|Biological: bavituximab
224103602|NCT02651610|DRUG|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
223538005|NCT04373304|OTHER|low FODMAP diet|A diet specifically developed for the management of IBS is the low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols (FODMAP) diet. FODMAP is a collective term that includes fructose in excess of glucose, oligosaccharides including fructans/fructo-oligosaccharides (FOS), galacto-oligosaccharides, sugar polyols such as sorbitol and mannitol, and lactose. Controlled studies have established efficacy of the low FODMAP in managing IBS symptoms, but this diet is complex, associated with low calorie intake, and requires individualized explanation and follow-up by an experienced dietician.
223538006|NCT00983034|DRUG|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
223538007|NCT00068289|DRUG|bortezomib|
223722855|NCT04964531|OTHER|speckle tracking echocardiography|before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
223722856|NCT03524898|DRUG|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
223538008|NCT01446874|DRUG|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
223538009|NCT06395701|RADIATION|radioteraphy and chemotherapy after RTU --trimodality therapy--|TMT ( trimodality treatment) consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent.
223722857|NCT03524898|DRUG|gemcitabine|1000 mg/m2
223722858|NCT01906008|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
223722859|NCT01906008|DRUG|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
223951281|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
223951282|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
223951283|NCT01523184|DRUG|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
223951284|NCT02283086|BEHAVIORAL|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
223951285|NCT05095077|DRUG|Tadalafil 40 MG|Single dose on study day 1/2
223951286|NCT05095077|DRUG|Placebo|Identical to active IMP
223951287|NCT02860702|OTHER|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
223951288|NCT02860702|OTHER|Human/Bovine Milk|Bovine milk derived fortification
223951289|NCT04128956|DRUG|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
223951290|NCT01128673|DEVICE|mRI|
223951291|NCT00005867|BIOLOGICAL|bleomycin sulfate|
223951292|NCT00005867|DRUG|CHOP regimen|
223951293|NCT00005867|DRUG|cyclophosphamide|
223951294|NCT00005867|DRUG|doxorubicin hydrochloride|
223951295|NCT00005867|DRUG|etoposide|
223951296|NCT00005867|DRUG|mitoxantrone hydrochloride|
223951297|NCT00005867|DRUG|prednisolone|
223951298|NCT00005867|DRUG|vincristine sulfate|
223951299|NCT00993434|BEHAVIORAL|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
223951300|NCT00993434|BEHAVIORAL|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
223951301|NCT06309641|DIAGNOSTIC_TEST|Blood sample after treatment|Blood samples for measurement of methemoglobin are obtained directly before and 30-120 minutes after drug administration.
223951302|NCT06309641|OTHER|Case reports|Description of clinical course and methemoglobin levels in patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
223951303|NCT04662320|DEVICE|Checkpoint BEST System|"Single use medical device, consisting of electric stimulator and intraoperative lead. Therapy consists of single, 10 minute dose delivered proximal to site of decompression/repair.~Other Name: Checkpoint BEST System"
223951304|NCT00647699|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
223951305|NCT00647699|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
223951306|NCT06585579|DEVICE|Mucogyne Ovule|In Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)
223951307|NCT03696563|DEVICE|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
223951308|NCT03696563|OTHER|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
224103603|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
224103604|NCT00982566|DRUG|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
224103605|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
224103606|NCT00982566|DRUG|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
224103607|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil|Split-scar fractional ablative erbium laser-assisted delivery of 50mg/mL of 5-fluorouracil solution to one half of the scar (4 treatments)
224103608|NCT04786210|COMBINATION_PRODUCT|Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide|Split-scar fractional ablative erbium laser-assisted delivery of 10 mg/mL of triamcinolone acetonide solution to the other half of the scar (4 treatments)
224103609|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
223538010|NCT02554994|OTHER|Multifactorial intervention|"There are six components of intervention in this study.~* For all participants:~  1. Group exercise~ 2. Nutritional supplement(commercial liquid formula will be provided every day).~* For selected participants:~  1. Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~ 2. At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~ 3. Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
224103610|NCT00668967|DRUG|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
224288306|NCT02309853|OTHER|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~1. Visual or tactile scanning in the personal space~2. Visual or tactile scanning and trunk rotation in the peripersonal space~3. Visual scanning and trunk rotation in the extrapersonal space"
224288307|NCT02309853|OTHER|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
224288308|NCT01398059|OTHER|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
224288309|NCT01398059|OTHER|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
223722860|NCT01906008|BEHAVIORAL|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
223722861|NCT01906008|BEHAVIORAL|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
223722862|NCT03469375|DRUG|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
223722863|NCT06236178|DRUG|Corticosteroid|1 ml of 40 mg methylprednisolone acetate
223722864|NCT06236178|DRUG|Autologous Blood|1 ml of autologous venous blood
224103611|NCT00158977|DEVICE|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
223722865|NCT06236178|DRUG|Local Anesthetic|1 ml of 2% prilocaine HCl
224103612|NCT04342065|DRUG|Celecoxib capsules|received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
224103613|NCT04342065|DRUG|Pregabalin 150mg|received Pregabalin 150mg 2 hours preoperative and the same dose 6 hours postoperative.
224103614|NCT01805648|DRUG|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
224103615|NCT04355286|DRUG|Bemotrizinol|Market-image topical sunscreen formulation containing BEMT (6%)
224103616|NCT04744558|OTHER|Low carb high fat ketogenic dieting|Macronutrient ratios for low carb high fat ketogenic diet were 20 %, 5 %, 75 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
224103617|NCT04744558|OTHER|Low carb high fat non-ketogenic dieting|Macronutrient ratios for low carb high fat non-ketogenic diet were 20 %, 15 %, 65 % of protein, carbohydrates and fat, respectively. Caloric intake for experimental phase was set to cover basal metabolism and sedentary activities (BMR times 1.2) for every participant using the Mifflin St Jeor equation.
224103618|NCT02512796|DRUG|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
224103619|NCT03677570|DIAGNOSTIC_TEST|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
224103620|NCT03550690|DEVICE|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
224103621|NCT03550690|DEVICE|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
224103622|NCT06189820|DIAGNOSTIC_TEST|FAPI PET/CT|"In the department of Nuclear Medicine:~* Installation in a relax chair after weight and height control~* Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started.~* Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46"
224103623|NCT02673281|OTHER|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
224103624|NCT02673281|OTHER|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
224103625|NCT03482661|OTHER|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
224103626|NCT00587223|DEVICE|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
224288310|NCT01398059|OTHER|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
224288311|NCT06332313|PROCEDURE|erector spina plane block|ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
223538011|NCT02554994|OTHER|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
223538012|NCT02681367|OTHER|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
223538013|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
223951309|NCT06160375|DIAGNOSTIC_TEST|pain assessment after video assisted thoracoscopic lung surgeries|a scalp needle with an extended tube will be inserted into the paravertebral space at the T4 level under thoracoscopic direct vision before closing the chest. One centimeter adjacent to the vertebrae will be inserted vertically 0.5 cm under the parietal pleura with the needle, and 20 ml 0.25% bupivacaine will be injected then the field will be observed for 5 min to make sure that there is no hemorrhage or hematoma.
223951310|NCT04532333|DRUG|Bivalirudin 250 MG Injection|Bivalirudin 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until end of the procedure
223951311|NCT04532333|DRUG|Heparin|Heparin should be administered each hour, 0.6mg/kg(75U/kg) as bolus dose, 0.3mg/kg 1h later, 10mg(1250U) every hour after.
223951312|NCT02430259|DRUG|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
223951313|NCT00413283|BIOLOGICAL|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
224103627|NCT00587223|OTHER|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
224103628|NCT02146846|DRUG|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
224103629|NCT00195351|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
223951314|NCT00413283|DRUG|Placebo|Placebo subcutaneous injection.
223951315|NCT00413283|DRUG|Gemcitabine|Intravenous infusion
223951316|NCT00413283|DRUG|Carboplatin|Intravenous infusion
224103630|NCT00195351|DRUG|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
224103631|NCT02783781|PROCEDURE|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
224103632|NCT03319199|DIETARY_SUPPLEMENT|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
224103633|NCT03319199|OTHER|Placebo - water|for a duration of 16 weeks
224103634|NCT05760495|OTHER|blood sampling|Blood sampling for evaluation of oxidative stress markers
224103635|NCT05167201|DEVICE|Nasal High Flow|High flow nasal cannula (NHF) is a device that delivers warmed and humid air through a high air flow rate, through the nose. It is used as a non-invasive ventilatory approach, which is relatively comfortable, in the management of respiratory failure and has been investigated in several studies evaluating the outcomes as domiciliary treatment in patients with COPD.
224103636|NCT02634515|DRUG|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
224103637|NCT02634515|DRUG|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
224288312|NCT05016934|BIOLOGICAL|A vaccine composed of a recombinant S1 antigen|Two applications of three different doses of a vaccine composed of a recombinant S1 antigen, a subunit of SARS-CoV-2 virus S protein
224288313|NCT00810862|DRUG|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
224103638|NCT01300143|OTHER|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
224103639|NCT01300143|OTHER|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
223538014|NCT00457392|DRUG|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
223538015|NCT00457392|DRUG|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
223538016|NCT00457392|DRUG|placebo|Placebo daily by oral capsules in a continuous regimen
224288314|NCT00810862|OTHER|placebo base cream|apply to affected study area twice daily for 21 days
223538017|NCT03925363|DEVICE|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
223538018|NCT05075889|DRUG|Indocyanine Green|Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
223538019|NCT01591265|PROCEDURE|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
224288315|NCT05981287|OTHER|Task-oriented activities based on NDT (TOA-NDT) principle and Conventional Physical Therapy|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
224288316|NCT05981287|OTHER|Gross motor task training and Conventional physical therapy (CPT)|This will be a randomized clinical trial. patients are divided into two groups. one of them will undergo task-oriented activities along with conventional physical therapy treatment, while the other will undergo gross motor task training along with conventional physical therapy treatment. Purpose is to determine that which of them has greater benefit in improving balance trunk control and functional mobility in children with cerebral palsy.
224288317|NCT02536469|DRUG|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
224288318|NCT00274885|DRUG|oxaliplatin|
224288319|NCT00274885|PROCEDURE|management of therapy complications|
224288320|NCT00642421|DRUG|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
224103640|NCT03180762|DRUG|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
224103641|NCT03180762|DRUG|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
224103642|NCT03180762|DRUG|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
224288321|NCT00642421|DRUG|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
224288322|NCT01215071|PROCEDURE|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
224103643|NCT03180762|DRUG|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
223538020|NCT01591265|PROCEDURE|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
223538021|NCT05886153|DEVICE|Vitaliti Continuous Vital Sign Monitor Model CVSM-1A|Measurements recorded by the Vitaliti CVSM device will be compared to the recordings from various standardized comparator devices.
223538022|NCT00399074|DRUG|sulfadoxine pyrimethamine|Monthly SP
223722866|NCT01230632|DIETARY_SUPPLEMENT|high fat overfeeding|Dietary Supplement:3 days overfeeding
223722867|NCT03332654|OTHER|Determine prevalence of stress urinary incontinence|
223722868|NCT04971122|OTHER|Trendeleburg -5 degree,-10 degree,-15 degree|Use a -5 or -10 or -15 degree trendelenburg position
224103644|NCT03180762|DRUG|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
224103645|NCT03180762|DRUG|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
224103646|NCT03180762|DRUG|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
224103647|NCT03180762|DRUG|Placebo|Matching placebo will be administered.
224103648|NCT02818010|OTHER|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
224103649|NCT02344940|DRUG|Toremifene|patients will take toremifene 60 mg qd.
224103650|NCT02344940|DRUG|Tamoxifen|patients will take tamoxifen 10 mg bid.
224103651|NCT05063370|DRUG|Levosimendan|Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
224103652|NCT05063370|DRUG|Standard Care|Patients will not receive Levosimendan and will receive standard care according to the institution protocol
224103653|NCT03832231|DEVICE|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
224103654|NCT05412329|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
224103655|NCT04606121|COMBINATION_PRODUCT|enhanced day care of TCM include acupuncture, massage, tai ji quan, TCM herbal medicine|acupuncture twice in enhanced day care of TCM massage twice in enhanced day care of TCM tai ji quan one time in enhanced day care of TCM TCM herbal powder three times a day
224103656|NCT02183454|DEVICE|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
224103657|NCT01600781|DIETARY_SUPPLEMENT|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
224103658|NCT02940964|BEHAVIORAL|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
224103659|NCT02940964|BEHAVIORAL|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
224103660|NCT02112968|PROCEDURE|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
224103661|NCT02112968|PROCEDURE|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
223538023|NCT02306811|DRUG|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
224288323|NCT01215071|PROCEDURE|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
224288324|NCT02647528|DEVICE|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
223951317|NCT00413283|DRUG|Cisplatin|Intravenous infusion
223538024|NCT01615783|OTHER|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
223951318|NCT01117402|RADIATION|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
223951319|NCT00680134|DRUG|AN2690|AN2690 1% Solution, once daily for 180 days
223951320|NCT00680134|DRUG|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
223951321|NCT04330612|OTHER|Perioperative Updates|In the intervention group, the families received additional standardized electronic updates via pagers at three pivotal moments: 1) Initial skin incision has been made; 2) Critical part of the case is completed and closure has begun; and, 3) Closure is complete, and patient will be transferred to the recovery room when ready.
224103662|NCT02112968|PROCEDURE|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
224103663|NCT00971321|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
223538025|NCT01615783|OTHER|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
224103664|NCT01968876|OTHER|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
224103665|NCT05233995|PROCEDURE|Damage Control Surgery|Delayed anastomosis
224288325|NCT02647528|DEVICE|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
224288326|NCT00982501|DRUG|WS® 1442 900 mg/d|
224103666|NCT03542552|DRUG|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
224103667|NCT03542552|DRUG|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
224103668|NCT01850810|OTHER|Experimental Study Product|
224103669|NCT01850810|OTHER|Control Study Product|
224103670|NCT05292677|DRUG|Steroid/Anesthesia Mixture|Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
223538026|NCT04563767|PROCEDURE|Infinitome|Added sequence of rs-fMRI.
223538027|NCT02184598|BEHAVIORAL|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
223538028|NCT02184598|BEHAVIORAL|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
223538029|NCT03446898|OTHER|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
223951322|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
223951323|NCT03430609|DIAGNOSTIC_TEST|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
223951324|NCT03430609|DIAGNOSTIC_TEST|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
223951325|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
224103671|NCT05292677|DRUG|Placebo|2 mL of Normal Saline
224103672|NCT03446924|DIETARY_SUPPLEMENT|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
224103673|NCT03446924|DIETARY_SUPPLEMENT|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
224103674|NCT00004046|DRUG|exatecan mesylate|
224103675|NCT06011070|BEHAVIORAL|Gambling Personalised Feedback|The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
223538030|NCT06259318|BEHAVIORAL|Kanasina Gulabi|Kanasina Gulabi is a theory-driven, educational-behavioral intervention designed to improve the quality of life and diabetes management among young adults living with type 2 diabetes in Mysore district, South India. In this intervention, young adults with type 2 diabetes were matched to non-specialist peer navigators -- trained young adult peers who were also managing type 2 diabetes -- and developed action plans to improve their physical and mental health outcomes. Intervention components included group education, mindfulness activities, self care activity tracking, and phone follow-ups to address knowledge gaps and misinformation about type 2 diabetes, build self-efficacy for type 2 diabetes-related self care activities, and provide emotional support for diabetes management.
223538031|NCT04844125|DRUG|SHR-1209|SHR-1209
224103676|NCT03322657|DRUG|Neostigmine|Neostigmine injection
224103677|NCT03322657|DRUG|Glycopyrrolate|Glycopyrrolate injection
224103678|NCT03322657|DRUG|Sugammadex|Sugammadex injection
224103679|NCT00519623|OTHER|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
224103680|NCT03541577|DEVICE|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
223538032|NCT04844125|DRUG|SHR-1209 Placebo|SHR-1209 Placebo
223538033|NCT04946630|DEVICE|PreciseInhale|Three different settings of the medical device PreciseInhale will be used in the study; PreciseInhale Whole Lung Exposure, PreciseInhale Bronchial Bolus/Breath hold Exposure and PreciseInhale Alveolar Bolus/Breath hold Exposure.
224103681|NCT03541577|DEVICE|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
224103682|NCT02596776|PROCEDURE|Fat biopsy|up to 16 biopsy samples will be taken from each subject
224103683|NCT02596776|DRUG|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
224288327|NCT00982501|DRUG|WS® 1442 1800 mg/d|
224103684|NCT02596776|OTHER|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
223722869|NCT04775875|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory wave form confirmation of cerebral arteries, and optical tracking technology (eg, AntNeuro Visor2 system) may be used in tandem with the Brainsonix Pulsar 1002 ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
224103685|NCT03679494|OTHER|Shared decision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
224103686|NCT02527304|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
224103687|NCT02527304|OTHER|Quality-of-Life Assessment|Ancillary studies
224103688|NCT02527304|OTHER|Questionnaire Administration|Ancillary studies
224103689|NCT02527304|RADIATION|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
224103690|NCT01750021|DIETARY_SUPPLEMENT|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
224103691|NCT01750021|DIETARY_SUPPLEMENT|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
224103692|NCT02433249|BEHAVIORAL|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
224103693|NCT02433249|BEHAVIORAL|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
224103694|NCT02433249|BEHAVIORAL|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
224103695|NCT05042245|DRUG|Ornithine aspartate granule|Ornithine aspartate granules in the experimental arm.
224103696|NCT05042245|DRUG|Silymarin capsule|Silymarin capsules in the active comparator arm.
224103697|NCT05042245|DRUG|Silymarin capsule simulant|Silymarin capsule simulant in the experimental arm.
224103698|NCT05042245|DRUG|Ornithine aspartate granule simulant|Ornithine aspartate granule simulant in the active comparator arm.
224103699|NCT04403867|PROCEDURE|Sentinel lymph node (SLN) biosy +/- lymphadenectomy|Evaluation of type and volume of lymph nodal disease
224288328|NCT00982501|BEHAVIORAL|Nordic walking training 2 x 30 min/week|
224288329|NCT00982501|BEHAVIORAL|Nordic walking training 4x45 min/week|
224288330|NCT02365948|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection"
223538034|NCT04946630|OTHER|Seretide Evohaler forte|Single dose of Seretide Evohaler forte (fluticasone propionate/salmeterol 250 µg/25 µg) administered according to SmPc or via the PreciseInhale system.
224288331|NCT02365948|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
224288332|NCT03554252|OTHER|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
223538035|NCT04458740|OTHER|biographical interviews|A sociologist trained in the sociology of cancer, to enable participants to talk about their experiences and clearly distinguish the experiences of each individual
223538036|NCT01136525|DRUG|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
223722870|NCT03911804|PROCEDURE|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
224103700|NCT00208468|DEVICE|European Hip|A cementless femoral component for use in total hip replacement
224103701|NCT00208468|DEVICE|Zweymüller|A cementless femoral component for use in total hip replacement
224103702|NCT00208468|DEVICE|CLS Spotorno|A cementless femoral component for use in total hip replacement
224103703|NCT05313230|OTHER|CITRASATE SLED|Applying of CITRASATE SLED
224103704|NCT02077322|DEVICE|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
224103705|NCT02077322|DEVICE|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
224288333|NCT03554252|OTHER|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
224288334|NCT00543452|OTHER|Oxygen|4 liters of oxygen a minute
224288335|NCT00543452|OTHER|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
224288336|NCT05665959|OTHER|Reiki|Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing.
224288337|NCT05887349|OTHER|Neck Stabilization Exercise|"1\. Control Group exercise program (Cervical Stabilization exercises group)~The patients in the control group will be given cervical stabilization exercises consisting of 3 levels and increasing difficulty. The exercises will be taught to the patients level by level by the physiotherapist for 6 weeks. The subjects will perform the exercises for a total of 6 weeks. Before each exercise session, stretching exercises will be performed on the subjects."
223951326|NCT03430609|PROCEDURE|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
223951327|NCT02354417|BIOLOGICAL|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
224103706|NCT02713750|OTHER|reversible contraceptive methods|"1. Consistent male condom use only~2. Consistent female condom use only~3. Hormonal contraception, combined oral contraceptive pills and male/female condom~4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~5. Hormonal contraception , progestin only hormonal implant and male/female condom~6. Intrauterine device and male/female condom"
224103707|NCT06559618|DRUG|Phage Therapy|A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
224103708|NCT06559618|OTHER|Placebo|Sterile 0.9% saline solution also 20 mL, followed with a 10 mL flush of the same solution.
224103709|NCT06513702|PROCEDURE|Transesophageal lung ultrasound (TELUS) guided recruitment maneuver|"1. Lung reinflation guided by transesophageal lung ultrasound (TELUS) after cardiopulmonary bypass weaning~2. TELUS guided recruitment maneuver with continuous positive pressure of 30cmh20 for 20 seconds and 40cmh20 for 20 seconds during sternal wiring"
224103710|NCT06513702|OTHER|Manual bag lung reinflation|"After weaning of CPB, Lung will be reinflated by 5 deep manual bag infaltion until full inflation observed by the anesthetist.~During sternal wiring, Lung ultrasound will be examine - LUNG ultrasound score will be taken- no recruitment maneuver will be done in this contro group (Basically this group of patient is a routine practice in cardiac surgery"
224103711|NCT04299269|OTHER|Questionnaire|Questionnaire including questions about Quality of life, symptoms and general informations
224103712|NCT02513446|DRUG|BI 1026706|Single dose of BI 1026706 on Day 1
224288338|NCT05887349|OTHER|Neck Stabilization Exercise + Rocabado Exercises|"2\. Intervention group exercise program (the group to which Robacado exercises will be added in addition to cervical stabilization exercises) The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. In addition, individuals in this group will be given Robacado exercises.~Robacado exercises:~1. Resting position for the tongue: The tip of the tongue is placed on the upper palate, just behind the front teeth (resting position for the tongue).~2. When the body is in an upright position, scapular retraction and depression movements are performed without disturbing the position of the cervical region.~3. When the body is in an upright position, at C2-C7 levels, hands are clamped on the neck and cranio-cervical flexion is studied."
224288339|NCT00053235|GENETIC|Comparative Genomic Hybridization|Correlative studies
224288340|NCT00053235|OTHER|Laboratory Biomarker Analysis|Correlative studies
224288341|NCT00053235|GENETIC|Polymerase Chain Reaction|Correlative studies
224288342|NCT03686150|DIETARY_SUPPLEMENT|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
223722871|NCT02008201|DIETARY_SUPPLEMENT|vitamin D|
223722872|NCT00802139|DRUG|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
224288343|NCT03421366|DRUG|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
223951328|NCT01169402|DRUG|Fluconazole|25mg/kg intravenously once weekly while on ECMO
224103713|NCT02513446|DRUG|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
224103714|NCT05394844|DEVICE|Dexcom G6|Dexcom G6 CGM device
224103715|NCT01898546|PROCEDURE|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
224103716|NCT01898546|PROCEDURE|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
224103717|NCT02296840|DRUG|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
224103718|NCT02296840|DRUG|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
224103719|NCT05707065|OTHER|core strengthening exercises|The core muscles training includes transverse abdominis, multifidus, paraspinals, quadratus lumborum, and obliques.
224103720|NCT05707065|OTHER|Proprioceptive Neuromuscular Facilitation|lower limb PNF technique along with conventional treatment i.e., Rhythmic initiation, slow reversal, stabilizing reversal, and combination of isotones.
224103721|NCT04641286|OTHER|Body motion categorisation|All patients will receive passive motion categorisation monitoring
224288344|NCT00614926|DRUG|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
224288345|NCT00614926|DRUG|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
224288346|NCT03694808|DRUG|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
224288347|NCT03694808|DRUG|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
224288348|NCT05409521|OTHER|Kinesio taping|Kinesio taping with the mechanical correction technique will be applied on the thoracic region
223722873|NCT00802139|DRUG|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
224103722|NCT01812161|OTHER|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
224103723|NCT01812161|OTHER|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of \<5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
224103724|NCT00104871|DRUG|Bortezomib|Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
224103725|NCT00843180|OTHER|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
224103726|NCT00385021|DRUG|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
224103727|NCT02485717|DRUG|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
224103728|NCT02485717|OTHER|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
224103729|NCT06533553|DRUG|Dexpramipexole Dihydrochloride|Administration of dexpramipexole tablet
224103730|NCT03808311|OTHER|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (\<120 mmHg in the intensive arm and \<140 mmHg in the standard arm).
224103731|NCT05903781|DIAGNOSTIC_TEST|Prostate MRI|MRI of the prostate
224103732|NCT01336101|DEVICE|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
224103733|NCT04373603|DRUG|Tranexamic acid|TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
223722874|NCT03618498|PROCEDURE|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
223722875|NCT02020330|DRUG|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
224103734|NCT04373603|OTHER|Saline|sodium chloride and water for use as control
224103735|NCT04373603|DRUG|Hyaluronic acid|Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
223722876|NCT02020330|DRUG|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
224103736|NCT02810990|DRUG|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 \> 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
224103737|NCT06970691|DIAGNOSTIC_TEST|panoramic radiograph|Panoramic radiographs for aggressive periodontitis previously diagnosed cases were interpreted by single examiner (NY). The included radiographs had to fulfill the following; 1) sufficient image quality; 2) All teeth with the surrounding alveolar bone had to be clear enough to facilitate alveolar bone tracing; 3) Only pre-operative radiographs were enrolled (before the surgical management of bony defects).
224103738|NCT06969937|DRUG|Ketamine|A single dose of ketamine 0.8 mg ketamine (i.v.) per kilogram bodyweight
224288349|NCT05409521|OTHER|Placebo taping|Placebo taping with no tension and technique will be applied on the arm
224288350|NCT00809237|DRUG|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
224288351|NCT02113371|BEHAVIORAL|Intervention|
223722877|NCT01193868|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223722878|NCT01193868|OTHER|laboratory biomarker analysis|Correlative studies
224288352|NCT06132633|DEVICE|Neospot vitals measurement|Vitals of participants in the intervention group will be measured using neospot alongside standard of care measurement.
223722879|NCT01193868|OTHER|pharmacological study|Correlative studies
224288353|NCT04520776|DEVICE|BAGUERA®C Cervical Disc Prosthesis|surgery
224288354|NCT04520776|DEVICE|Mobi-C® Cervical Disc|surgery
224288355|NCT05430945|BIOLOGICAL|BCMA Targeted CAR T-cells|Each subject receive BCMA Targeted CAR T-cells by intravenous infusion
224288356|NCT00320567|DRUG|norgestimate/ethinyl estradiol|
224288357|NCT03447886|OTHER|Phone interview|Collecting clinical and socio-demographic information.
224288358|NCT02544542|DEVICE|Rectum cooling system|
224288359|NCT02544542|DEVICE|Hyper-hypothermia blanket|
224103739|NCT06969937|BEHAVIORAL|Real-time fMRI Neurofeedback Training|Participants will undergo a closed-loop rt-fMRI paradigm over 25 minutes. Participants will be instructed to use strategies to downregulate cue-induced cravings. The Intensity of cues will adjust based on the participants neural activity in response to cues. This dynamic feedback mechanism allows for personalized training aimed at improving the participant's ability to manage cravings.
224103740|NCT06969937|DRUG|Placebo|Single dose of placebo (0.9% NaCl infusion)
224103741|NCT06969937|BEHAVIORAL|Sham Neurofeedback Training/ Ketamine|Participants get a real time neurofeedback based on a control regions' activity, which serves as a sham region and receive 0.8 mg ketamine (i.v.) per kilogram bodyweight. The use of sham-NFT allows for a rigorous assessment of the specific effects of combined rt-fMRI NFT and ketamine by controlling for non-specific factors such as expectancy effects or the therapeutic context.
224103742|NCT06970054|DEVICE|OPEP|-Patients are provided with a networked handheld respiratory training device. -Patients are provided with a wearable device for monitoring data. -Patients receive an OPEP training plan and instructions on using the respiratory training device. -Training on the OPEP device is conducted: -Inpatients: Twice daily training during hospitalization. -Outpatients: At least 3 training sessions in the clinic after enrollment. -Treatment compliance is monitored remotely via the IoT system for 8 weeks. -Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).
224103743|NCT06970054|BEHAVIORAL|Aerobic Exercise|-Patients are provided with a wearable device for monitoring data. -Patients receive an aerobic exercise training plan and instructions on using the device. -Exercise training is conducted: -Inpatients: Daily aerobic exercise during hospitalization. -Outpatients: At least 3 training sessions in the clinic after enrollment. -Treatment compliance is monitored remotely via the IoT system for 8 weeks. -Patients are scheduled for regular follow-up visits at 1 month, 2 months, 6 months, 12 months, and 24 months (with a window of ±7 days for each visit).
224103744|NCT03796403|OTHER|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
224103745|NCT02364817|BEHAVIORAL|cognitive and psychiatric assessment|"Administered at baseline:~* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~* hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~* psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~* cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~* impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~* alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~* administered at week 12: ASRS"
224103746|NCT04721314|DEVICE|Adjustment of lower rate limit|Patients with preserved ejection fraction (EF \>50%) and implanted pacemakers will have the lower rate limit adjusted to a personalized heart rate based on a heart rate algorithm.
224103747|NCT04721314|DEVICE|Maintenance of lower rate limit|Lower rate limit will be maintained at 60 beats-per-minute
223722880|NCT06076616|BEHAVIORAL|Prehabilitation and rehabilitation|A personalized lifestyle counseling programme.
223538037|NCT01466491|DRUG|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
223538038|NCT01001351|DRUG|PRT-201|Applied topically during surgery.
223722881|NCT06373991|BIOLOGICAL|ATHENA CAR-T|Phase 1 dose escalation (3+3): dose 1 and dose 2.
223722882|NCT06373991|DRUG|Fludarabine|Intravenous injection of fludarabine.
223722883|NCT06373991|DRUG|Cyclophosphamide|Intravenous injection of cyclophosphamide.
223951329|NCT04150016|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
223951330|NCT01377844|DRUG|EGT0001442|
223951331|NCT01377844|DRUG|Placebo|
223951332|NCT03680768|OTHER|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
224103748|NCT02732158|OTHER|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
224103749|NCT05899725|DRUG|Corticosteroids|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
224103750|NCT05899725|DRUG|Corticosteroids and Ruxolitinib|Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
224103751|NCT00921921|DRUG|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
224103752|NCT00921921|DRUG|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
224103753|NCT04795180|DRUG|Irrigations trough the efferent limb of loop ileostomy|Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
224103754|NCT06970730|PROCEDURE|virtual surgical planning and patient specific implants in craniomaxillofacial reconstruction|Image acquisition by computed tomography (CT slice thickness 1 mm or less) + laser scanning of patient models. Virtual surgical planning and design of patient specific implants. Patient specific implants manufacturing (milling technique) and 3D printing of surgical guides and fit models.
224103755|NCT02280811|DRUG|Fludarabine|Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.
224103756|NCT02280811|DRUG|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
224103757|NCT02280811|BIOLOGICAL|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
223538039|NCT01001351|DRUG|Placebo|Applied topically during surgery
223951333|NCT01928732|BEHAVIORAL|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
223951334|NCT01928732|BEHAVIORAL|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
223951335|NCT01185340|DRUG|LY2216684|
224103758|NCT02280811|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
224103759|NCT02437838|OTHER|No Intervention|No Intervention
223951336|NCT01185340|DRUG|Placebo|
223951337|NCT01185340|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
223951338|NCT01326624|DEVICE|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
223951339|NCT04554199|DEVICE|Flexible partial denture|removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
224103760|NCT02677584|DRUG|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
223538040|NCT02727322|DRUG|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
223538041|NCT02727322|DRUG|Placebo|Placebo
223951340|NCT01547689|BIOLOGICAL|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
223538042|NCT05745649|OTHER|Resistance exercises|Resistance exercises
223538043|NCT05745649|OTHER|Ankle weights|Ankle weights
224103761|NCT02677584|DRUG|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
224103762|NCT03746197|DEVICE|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
224103763|NCT04045210|OTHER|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1 to intervention by ICU doulas or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 3 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
224288360|NCT03341000|DEVICE|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system within the first 3-5 days of the current study.
224103764|NCT04333966|BEHAVIORAL|Interactive Social Networking Site Parent Based Intervention|Parents in the interactive PBI condition will receive an interactive web-based SNS PBI with text message prompts aimed to reduce adolescent alcohol use and risky cognitions related to alcohol displays on SNS.
224103765|NCT04333966|BEHAVIORAL|Active Control|Parents in the active control condition will receive an emailed copy of the Surgeon General's Call to Action: A Guide for Families.
224288361|NCT00601757|BEHAVIORAL|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
223538044|NCT04110106|OTHER|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H\&Y scale by a neurologist.
224103766|NCT00820638|DEVICE|myomo e100|use of the myomo e100 in home
223538045|NCT04457986|DRUG|Erector spina plane block (ESP)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
223951341|NCT05304221|OTHER|Shamir Resistance Calculator|"An on-line calculator which is free and accessible from all devices, which may predict the risk of MDRO infection upon admission, and the risk of nosocomial XDRO infection during the hospitalization.~The calculator contains only parameters that could be extracted bedside, at the first presentation of a septic patient, including the ability to conduct a complete assessment also among patients with reduced consciousness and/or cognition."
223951342|NCT02001649|GENETIC|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
223951343|NCT02001649|GENETIC|SNP genotyping|
223951344|NCT05411471|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain|The COVID-19 vaccine (Vero cell), Inactivated, Omicron Strain was developed by Sinovac Life Science Ltd.The product is a pre-filled syringe or a vial with an extractable volume of 0.5 mL. The antigen content is 1200 SOU/0.5 mL (6 µg/0.5 mL).
223951345|NCT02065895|DEVICE|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
224103767|NCT01476787|DRUG|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
224103768|NCT01476787|DRUG|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
224103769|NCT01476787|DRUG|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
224103770|NCT01476787|DRUG|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
224103771|NCT01476787|DRUG|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
224103772|NCT04626063|DRUG|Magnesium|Patients were treated with etodolac 400mg twice a day plus magnesium oral supplementation once a day for acute low back pain and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
224288362|NCT00601757|BEHAVIORAL|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
224288363|NCT00010166|DRUG|gemcitabine hydrochloride|
224288364|NCT00010166|PROCEDURE|adjuvant therapy|
224288365|NCT00010166|RADIATION|radiation therapy|
224288366|NCT00176540|DRUG|dextromethorphan hydrobromide|
223538046|NCT04457986|DRUG|Modified thoracolumbar interfacial plane block (MTI)|Patient will receive ultrasound guided regional anesthesia with bupivacaine and intravenous patient controlled analgesia with tramadol
223951346|NCT02065895|DEVICE|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
223951347|NCT02065895|DEVICE|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
224288367|NCT06154694|RADIATION|Stereo Radiographic EOS Measurements|"Healthy control will undergo a stereo radiographic EOS exam with their arm in various positions.~1. Relaxed standing (0 degree of abduction)~2. 45 degree of abduction in the coronal plane~3. 90 degree of abduction in the coronal plane~4. 120 degree of abduction in the coronal plane~5. 45 degree anterior flexion in the sagittal plane~6. 90 degree anterior flexion in the sagittal plane~7. 120 degree of anterior flexion in the sagittal plane~8. 45 degree extension in the sagittal plane"
224288368|NCT02242318|DRUG|Telmisartan|
224288369|NCT02242318|DRUG|Valsartan|
224288370|NCT02242318|DRUG|Placebo|
224288371|NCT04625192|PROCEDURE|Trephine osteotomy|"* Using a trephine on a straight implant handpiece (at approximately 1800 rpm) with copious irrigation to avoid overheating the bone, a round bone cut will be made 4 -5 mm above the crest of the alveolar ridge.~* The trephine is positioned perpendicular to the lateral wall, removing the outer cortex with a very gentle touch to avoid tearing the schneiderian membrane."
224288372|NCT01675024|DRUG|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
224288373|NCT01675024|DRUG|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
224288374|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 7 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
223951348|NCT03469258|DRUG|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
223951349|NCT06328725|DRUG|EN001|"Phase 1~* Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~* Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals.~Phase 2~* Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals.~* Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals."
223951350|NCT04205669|DRUG|Benzyl Benzoate 25% Topical Application Lotion|Applied to skin for the treatment of scabies
224103773|NCT04626063|DRUG|NSAID|Patients were treated with etodolac 400mg twice a day for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
224103774|NCT04626063|DRUG|paracetamol|Patients were treated with etodolac 400mg twice a day plus 500mg paracetamol twice a day paracetamol for acute low back pain and and clinical evaluation of participants was performed at first admission to emergency department, at 4th and 10th days after the initiation of designated treatment
224103775|NCT00315861|DRUG|pemetrexed|
224103776|NCT00315861|DRUG|topotecan|
224103777|NCT00368706|DRUG|solifenacin succinate|Oral
224103778|NCT00368706|DRUG|tolterodine|oral
224103779|NCT01936740|PROCEDURE|cataract surgery|
224103780|NCT05312502|OTHER|Birth Ball|During labour, the pregnant woman was positioned using a birth ball.
224103781|NCT05384301|OTHER|Urban Afforestation Program|An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
224103782|NCT05005884|DRUG|Oral intake of medication|Prescription of oral phenolics 250 mg two times daily
224103783|NCT05005884|DRUG|Placebo|Prescription of oral phenolics 250 mg two times daily
224103784|NCT02567695|DRUG|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
224103785|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head with smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone was activated in the PTB with the app group
224103786|NCT05150132|DEVICE|Oral-B Genius® 8000 power toothbrush with CrossAction brush head without smartphone app(Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. The installation and operation of the toothbrush application (app) on the smartphone were not activated in the PTB without the app group.
224103787|NCT05150132|DEVICE|Oral B ClinicLine Pro-FlexSoft (Procter&Gamble,Ohio, USA)|All the participants were asked to brush with fluoride toothpaste (Pro-Expert Professional Protection- Ipana, Gross-Gerau, Germany) with a pea-sized amount (0.25 g) of the toothbrushes, which were given oral and applied instructions for use, twice a day in the morning and evening. They were instructed to brush with the Modified Bass technique.
224103788|NCT01645761|DRUG|Endonase|PPI- based triple therapy with endonase
224288375|NCT04669717|DRUG|3/d 500 mg Amoxicilline Sandoz plus 500 mg Flagyl for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
223538047|NCT04457986|DRUG|Intravenous patient controlled analgesia (IV-PCA)|Patient will receive intravenous patient controlled analgesia with tramadol
224103789|NCT04990739|DRUG|MTB-9655|"MTB-9655 is an orally available investigational product that is highly potent as it exhibits selectivity as an ACSS2 inhibitor when tested against a panel of related enzymes. MTB-9655 is formulated as a powder blend in a hydroxypropyl methylcellulose (HPMC) capsule and is presented as 25 mg and 100 mg strengths for oral administration.~Patients will receive MTB-9655, by mouth daily in 21-day treatment cycles,either 1 hour before mealtime or 2 hours after mealtime."
224103790|NCT04946318|DRUG|CSJ117|CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
224288376|NCT04669717|DRUG|1/d 500 mg Azithromycine Pfizer for 3 days|Non-surgical periodontal therapy and radnomly administration of the antibiotics
224288377|NCT00312819|DRUG|chemotherapy +/- disulfiram|
224288378|NCT02619136|PROCEDURE|Transfusion|Red Blood Cell Transfusion
223538048|NCT00339040|BIOLOGICAL|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
223538049|NCT00339040|OTHER|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
223538050|NCT04009239|BEHAVIORAL|Time Restricted Feeding|Consuming energy during a short interval during the day
223951351|NCT02005172|DEVICE|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
223951352|NCT02132520|DEVICE|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
224103791|NCT04946318|DRUG|Placebo|Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
224103792|NCT01129752|OTHER|No intervention|there is no intervention for this study
224103793|NCT05187117|BEHAVIORAL|CAPABLE Family - Open Label Pilot|"As in CAPABLE (NA\_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW).~Adaptations for cognitive decline will be made on a per-client basis as part of the open-label pilot. Topics of adaptations include problem areas addresses, care partner involvement, length/frequency of visits, types of assessments and questions asked, and brainstorming/action planning structure."
224288379|NCT00118378|DRUG|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
224288380|NCT00118378|DRUG|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
224103794|NCT05187117|BEHAVIORAL|CAPABLE Family - Randomized Control Trial|As in CAPABLE (NA\_00031539), the delivery characteristics of CAPABLE Family consist of an assessment-driven, individually tailored package of interventions delivered over the course of 4 months by an occupational therapist (OT) (\~6 home visits for ≤ 1hour), a registered nurse (RN) (\~4 home visits for ≤ 1hour) and a handy worker (HW). Refinements based on the open label pilot results will be included.
224103795|NCT04653662|DEVICE|Earol|Treated with Earol on both ears and subsequent removal after 6 days of application
224103796|NCT03251547|DRUG|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
224103797|NCT05694598|GENETIC|VGR-R01|CYP4v2-coding gene delivered by AAV vector
224103798|NCT01106755|DEVICE|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
224103799|NCT01106755|DEVICE|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
224103800|NCT03426046|PROCEDURE|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
223951353|NCT02132520|BEHAVIORAL|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
223951354|NCT03403036|DRUG|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
223951355|NCT05413200|DRUG|Isotretinoin|oral isotretinoin with a standard dose regime for 90 days
223951356|NCT01008917|DRUG|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
223951357|NCT01682928|DRUG|IV/Oral Hydration and Bedrest|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs"
223951358|NCT01682928|OTHER|Hydrotherapy|"* Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
223951359|NCT02402270|DRUG|NuLYTELY® (PEG 3350)|
224103801|NCT03426046|DRUG|Pulp Capping Agents|Biocompatible materials
224103802|NCT03903471|DEVICE|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
224103803|NCT03903471|DEVICE|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
224103804|NCT04387279|OTHER|Interview|Surveys on medical use patterns and patient's perceptions about COVID-19
224103805|NCT02852369|BEHAVIORAL|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
224103806|NCT05430867|DRUG|Memantine Oral Tablet|Memantine 20mg once-daily
224103807|NCT05430867|DRUG|GV-971 capsule|GV-971 450mg twice a day
224103808|NCT05502588|BEHAVIORAL|Self-Guided Forest Bathing|Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.
224103809|NCT05502588|BEHAVIORAL|Guided Forest Bathing|Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
224103810|NCT04124367|DRUG|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
224103811|NCT04124367|DEVICE|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
224103812|NCT04124367|DRUG|Placebo|100 ml once daily 0.9% saline
224103813|NCT04124367|DEVICE|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
224103814|NCT00230763|PROCEDURE|GSS questionnaire|D0, D30 and D84
224103815|NCT00230763|PROCEDURE|IOP|D0, D30 and D84
223951360|NCT02402270|DRUG|ECP-019|
223951361|NCT02402270|DRUG|MoviPrep® (PEG 3350)|
223951362|NCT00327730|DRUG|Eperisone|
223951363|NCT03950661|OTHER|Walking|
224103816|NCT00230763|DRUG|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
224103817|NCT00230763|PROCEDURE|Visual acuity|D0 and D84
224103818|NCT05591833|PROCEDURE|SASI|Single-Anastomosis Sleeve ileal (SASI) Bypass
224103819|NCT05591833|PROCEDURE|SAS-J|Single-Anastomosis Sleeve Jejunal (SAS-J) Bypass
224103820|NCT01926886|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
224103821|NCT00083538|DRUG|Dexamethasone|
224103822|NCT00083538|DRUG|Thalidomide|
224103823|NCT00083538|DRUG|Cisplatinum|
224103824|NCT00083538|DRUG|Adriamycin|
224103825|NCT00083538|DRUG|Cyclophosphamide|
224103826|NCT00083538|DRUG|Etoposide|
224103827|NCT01450540|DEVICE|REMstar Auto A-Flex|Standard CPAP
224103828|NCT01450540|DEVICE|modified REMstar Auto A-Flex with AGPAP|Modified device -Software upgrade to GP 12
224103829|NCT03968146|PROCEDURE|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
223722884|NCT03749070|DIETARY_SUPPLEMENT|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment will be collected at the beginning and end of the trial for comparison purposes.
223722885|NCT05538702|DEVICE|IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
223722886|NCT05538702|DEVICE|IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)|Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.
223722887|NCT05538702|DEVICE|Marlboro Gold (Conventional cigarette)|Conventional cigarette
223951364|NCT04111159|DRUG|HSK3486|Subjects \< 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
223722888|NCT05538702|DEVICE|IQOS 3.0 DUO turned off with a bland taste unit|Placebo device
223951365|NCT04111159|DRUG|Propofol|Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
223951366|NCT00087256|DRUG|Celecoxib|
223951367|NCT00087256|OTHER|placebo|
223951368|NCT00003754|DRUG|cyclophosphamide|
223951369|NCT00003754|DRUG|thalidomide|
223951370|NCT00653185|DRUG|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
223951371|NCT00653185|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
223951372|NCT00653185|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
223951373|NCT00653185|DRUG|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
223951374|NCT00653185|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
223951375|NCT03840096|DEVICE|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
223951376|NCT01582321|BIOLOGICAL|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
223951377|NCT01582321|DRUG|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
223951378|NCT03340259|PROCEDURE|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
223951379|NCT03555812|OTHER|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
224103830|NCT03968146|DRUG|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
223951380|NCT00000872|DRUG|Abacavir sulfate|
223951381|NCT00000872|DRUG|Nelfinavir mesylate|
223951382|NCT00000872|DRUG|Nevirapine|
223951383|NCT00000872|DRUG|Lamivudine|
223951384|NCT00000872|DRUG|Stavudine|
223722889|NCT02444520|BEHAVIORAL|Integrated GP Care|"The overall aims of the intervention are to help the patient:~1. develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~2. understand factors that may be maintaining the problem;~3. learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~4. adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
223722890|NCT03706105|BEHAVIORAL|Cardiac Rehabilitation|3 x week \~1 hour of exercise + education
223951385|NCT00000872|DRUG|Zidovudine|
223951386|NCT04403178|DIAGNOSTIC_TEST|Radiographic examination with a Migration of > 40 %|Radiographic examination
223722891|NCT05351125|PROCEDURE|cardiac catheterization|catheterization in critical congenital heart disease requiring atrial septostomy or balloon valvuloplastyor PDA stenting
223722892|NCT03321123|DRUG|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
223722893|NCT02495805|PROCEDURE|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
223951387|NCT00484198|DRUG|Pioglitazone|45 mg over-encapsulated tablet administered orally, once daily
223951388|NCT00484198|DRUG|Placebo|Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule
223951389|NCT00484198|DRUG|Rivoglitazone|1.0 mg tablet administered orally, once daily
223951390|NCT00484198|DRUG|Rivoglitazone|1.5 mg tablet administered orally, once daily
223951391|NCT01965990|OTHER|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
223951392|NCT04371406|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
223951393|NCT04371406|DIETARY_SUPPLEMENT|Azinc|Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
223951394|NCT05122026|DRUG|Rifapentine|As included in arm/group description
223951395|NCT05122026|DRUG|Isoniazid|As included in arm/group description
223951396|NCT05300594|DIETARY_SUPPLEMENT|Plant extracts, vitamins and mineral|"Day tablet every day during 3 months : Magnesium (75 mg), Ginkgo Biloba extract (40 mg), hawthorn extract (37,5 mg), L-Theanin (50 mg) , Niacin (16mg), Quercetin (25mg), B12 Vitamin (2,5 µg), B6 Vitamin (1,4 mg), Thiamin (1,1 mg)~Night tablet every evening during 3 months : Magnesium (37,5 mg), Ginkgo Biloba extract (40 mg), Eschscholzia californica extract (40 mg), Zinc (10 mg), Melatonin (1mg), Lemon balm extract (80 mg), Tryptocetyn (65 mg)"
223951397|NCT05300594|DIETARY_SUPPLEMENT|Placebo|Day tablet every morning during 3 months : Excipients; Night tablet every evening during 3 months : Excipients
223951398|NCT02194907|BEHAVIORAL|Brain activity training - anterior insula|training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain
223951399|NCT02194907|BEHAVIORAL|Brain activity training - medial prefrontal cortex|training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
223951400|NCT04929509|OTHER|self-assembling peptide|each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators
223951401|NCT04929509|OTHER|nanosilver fluoride varnish|The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
223951402|NCT04929509|OTHER|sodium fluoride varnish|5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
223951403|NCT03077256|DEVICE|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
223951404|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
223951405|NCT01061658|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
223951406|NCT01061658|OTHER|Placebo|Placebo
223951407|NCT00704340|DEVICE|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
223951408|NCT00704340|OTHER|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
223951409|NCT00000284|DRUG|Cotinine fumarate|
224103831|NCT03968146|DRUG|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
224103832|NCT03968146|DRUG|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
224103833|NCT03968146|DRUG|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
224103834|NCT03968146|DRUG|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
223722894|NCT02495805|PROCEDURE|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
223722895|NCT01815515|DRUG|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push."
223722896|NCT02285790|DEVICE|Reflectance confocal microscopy|
223722897|NCT02285790|PROCEDURE|Punch biopsy|
223951410|NCT02586467|BEHAVIORAL|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
223951411|NCT02586467|BEHAVIORAL|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
223951412|NCT02586467|BEHAVIORAL|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
223951413|NCT02586467|BEHAVIORAL|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
223951414|NCT02586467|BEHAVIORAL|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
223951415|NCT00525616|DRUG|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
223951416|NCT01221402|DRUG|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
223951417|NCT04311983|BEHAVIORAL|Tobacco Quitline|"Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back)."
224103835|NCT03968146|DRUG|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
224103836|NCT03968146|DRUG|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
224103837|NCT04562363|PROCEDURE|Suturing of a laparotomic wound with modified methods|Suturing the white line of the abdomen with the help of developed techniques aimed at preventing hernias and eventrations
224103838|NCT03518515|OTHER|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
224103839|NCT03518515|OTHER|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (\~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
224103840|NCT03518515|OTHER|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (\~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
224103841|NCT02551848|DRUG|Botulinum toxin type A|
224103842|NCT01597869|DEVICE|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
224103843|NCT06428773|OTHER|Exercise|Participants were randomly divided into two groups: the exercise group and the control group. The exercise group performed moderate-intensity aerobic exercise on a stationary bicycle ergometer for 30 minutes during hemodialysis sessions, three days a week over 12 weeks. Additionally, the exercise group engaged in walking exercise for 30 minutes, three days a week outside of hemodialysis sessions, maintaining the heart rate between 50-60%. The exercise group also performed isolated exercises to expand wrist vessels, including wrist and elbow flexion, extension, and rotation, repeated 10 times, 2-3 days a week outside of hemodialysis sessions.
224103844|NCT04429932|OTHER|Myblu flavor A_2.4|Use of Myblu e-cigarette with flavor 1 at 2.4% nicotine
224103845|NCT04429932|OTHER|Myblu flavor B_2.4|Use of Myblu e-cigarette with flavor 2 at 2.4% nicotine
224103846|NCT04429932|OTHER|Myblu flavor C_2.4|Use of Myblu e-cigarette with flavor C at 2.4% nicotine
224103847|NCT04429932|OTHER|Myblu flavor D_2.4|Use of Myblu e-cigarette with flavor D at 2.4% nicotine
224103848|NCT04429932|OTHER|Myblu flavor E_1.2|Use of Myblu e-cigarette with flavor 1 at 1.2% nicotine
223722898|NCT02285790|PROCEDURE|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
223722899|NCT00171730|DRUG|Pasireotide|
223722900|NCT02220205|OTHER|PelvicSim|
223722901|NCT02220205|DEVICE|Manufacturer model|
223951418|NCT04311983|BEHAVIORAL|Smoke Free Home|The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
223722902|NCT00257478|DRUG|YM155|
223951419|NCT05484336|OTHER|Glucose as reference food|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose diluted in 250ml, tested two times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223951420|NCT05484336|OTHER|Beverage containing 4g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 4g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223951421|NCT05484336|OTHER|Beverage containing 6g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 6g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223951422|NCT05484336|OTHER|Beverage containing 8g spirulina|Thirteen healthy, with BMI between 18 and 29.9 kg/m2 (male: 3, female:10) after 10-14h fast, consumed 50g glucose and 8g spirulina diluted in 250ml, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223951423|NCT04794244|BEHAVIORAL|ASGE-FABES Program|In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
223951424|NCT00311545|BIOLOGICAL|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
223951425|NCT04986371|DRUG|Niraparib|Usage following drug insert is recommended
223951426|NCT02050815|DRUG|MEK162|
224103849|NCT04429932|OTHER|Myblu flavor F_1.2|Fse of Myblu e-cigarette with flavor F at 1.2% nicotine
223722903|NCT02266225|OTHER|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
223722904|NCT02600702|OTHER|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
223722905|NCT02600702|OTHER|Physical modalities|
223722906|NCT04620993|OTHER|Evaluation of biomechanics and viscoelastic properties of plantar fascia|"The biomechanical and viscoelastic properties of the plantar fascia will be measured in the side lying position.~Measurements will be made with the ankle in neutral position and maximum dorsi flexion position."
223722907|NCT04620993|OTHER|Evaluation of navıcular drop|The amount of navicular drop of both feet will be measured
223722908|NCT04620993|OTHER|Evaluation of plantar pressure distrubution|The distribution of foot plantar pressure and the amount of change in the center of gravity will be measured in the free standing position.
224103850|NCT04429932|OTHER|Myblu flavor G_2.4|Use of Myblu e-cigarette with flavor G at 2.4% nicotine
224103851|NCT04429932|OTHER|Myblu flavor H_2.4|Use of Myblu e-cigarette with flavor H at 2.4% nicotine
223722909|NCT01465997|DRUG|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
223722910|NCT01465997|DRUG|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
224103852|NCT04802746|DRUG|Alprazolam|Study participants will receive Staccato alprazolam Dose 1 and Staccato alprazolam Dose 2 at pre-specified time points in Part A. Study participants will receive single dose of Staccato alprazolam at pre-specified time points in Part B.
224103853|NCT04802746|OTHER|Placebo|Study participants will receive Staccato placebo at pre-specified time points in Part A and Part B matching the pre-specified Staccato alprazolam dosing.
224103854|NCT01381107|DRUG|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
223722911|NCT05152589|DIAGNOSTIC_TEST|hearing test|Auditory Brainstem Response (ABR) Test
223951427|NCT06144723|DRUG|HS-20105|Administered intravenously every 21 days.
223951428|NCT04130282|BIOLOGICAL|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
223951429|NCT04257500|DRUG|Etonogestrel/ethinyl estradiol vaginal ring|16 weeks of continuous use of contraceptive vaginal ring
223951430|NCT06430606|PROCEDURE|Tint Time|Arterial blood gas was obtained immediately after intubation(Tint) in supine position. Ventilator parameters and hemodynamic parameters were recorded.
223951431|NCT06430606|PROCEDURE|T0 Time|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
223951432|NCT06430606|PROCEDURE|T1|Arterial blood gas was obtained immediately after pneumoperitoneum in trendelenburg position. Ventilator parameters and hemodynamic parameters were recorded.
224103855|NCT01381107|DRUG|Placebo|Sublingual administration once daily for 7 consecutive days.
223538051|NCT04602143|DRUG|Testosterone gel|Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
223722912|NCT02246660|DRUG|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
223722913|NCT02246660|DRUG|Placebo|Placebo will be taken orally for 6 months.
223722914|NCT02656979|DRUG|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
223722915|NCT00700960|DRUG|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
223722916|NCT01021046|PROCEDURE|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
223951433|NCT03706872|OTHER|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
223951434|NCT05581394|DEVICE|BabySat V3|Evaluation of Accuracy of BabySat V3
224103856|NCT01662999|DRUG|Saxagliptin|
224103857|NCT01662999|DRUG|Dapagliflozin|
224103858|NCT03730896|PROCEDURE|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
224103859|NCT02234622|BEHAVIORAL|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
224103860|NCT02234622|BEHAVIORAL|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
224103861|NCT01199341|DRUG|AZD1981|100 mg per oral, twice daily for 14 days
224103862|NCT01199341|DRUG|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
224103863|NCT01199341|DRUG|AZD1981|4 x 100 mg per oral, twice daily for 14 days
224103864|NCT01574781|PROCEDURE|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
224288381|NCT04969042|DEVICE|Pins Medical G122 RS|G122RS model implanted spinal cord stimulation device, which could give closed-loop functional stimulation in the epidural space
224288382|NCT02969772|OTHER|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
224288383|NCT02969772|OTHER|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
224288384|NCT03442881|PROCEDURE|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
224288385|NCT01834781|DEVICE|Pulsed electromagnetic fields|
224288386|NCT01834781|DEVICE|w/o pulsed electromagnetic fields|
224288387|NCT00500552|DRUG|Perhexiline/Placebo|
224288388|NCT00207948|DRUG|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
224288389|NCT04194684|DRUG|nab-paclitaxel|nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
223951435|NCT03331978|BEHAVIORAL|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
224103865|NCT01574781|PROCEDURE|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
224103866|NCT05747404|DIAGNOSTIC_TEST|Echocardiography|\- Develop new parameters of FTR severity that take into account the lower momentum of the tricuspid regurgitant jet (compared with the mitral regurgitation jet), the complex anatomy of the regurgitant orifice, and both the intra-beat and respiratory variation of the regurgitant volume
224103867|NCT02291159|DEVICE|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
224103868|NCT02291159|DEVICE|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
224103869|NCT02388230|DEVICE|Ultrasound imaging|
223538052|NCT05399927|OTHER|Music Intervention|The objective of this study is to observe the effects that music produces on physiological parameters, in patients with Acute Cardiovascular Disease (ACVD), and to determine its influence on the types or doses of drugs administered during initial care. The intervention study is carried out in the ambulance cabin during the time of transfer to the destination Hospital.
224288390|NCT05877079|DRUG|Menthol|Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
224288391|NCT05877079|DRUG|Placebo|Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
223538053|NCT02135627|DRUG|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
223538054|NCT02135627|OTHER|Current standard therapy|
223951436|NCT02359071|OTHER|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
223951437|NCT00419172|DRUG|Deferasirox|
223951438|NCT00419172|DRUG|Rifampicin|
223951439|NCT03559777|OTHER|closed sinus lifting by Osteotome|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
223951440|NCT03559777|OTHER|closed sinus lifting by Densah bur|"* Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar."
224103870|NCT01658800|BIOLOGICAL|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
223538055|NCT05156437|DRUG|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin|Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin
223538056|NCT05156437|DRUG|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline|Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
224103871|NCT03643887|DRUG|FMT Capsule DE|30 capsule one-time oral dose
224103872|NCT03643887|DRUG|Placebo oral capsule|30 capsule one-time oral dose
224103873|NCT04882007|DRUG|OSE-127|mAb antagonist to CD127 receptor (or IL-7Rα)
224103874|NCT04882007|DRUG|Placebo|Normal saline
224103875|NCT05115084|OTHER|no intervention|no intervention
224103876|NCT04642235|OTHER|Nature Nook|The Nature Nook intervention will take place on lots that already have the standard greening intervention. In addition, design elements will be added such as a simple path and benches to explicitly invite people into the space. An additional difference is the exclusive use of larger, corner lots, rather than smaller mid-block spaces, to maximize visibility.
224288392|NCT01997294|DRUG|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
224288393|NCT04542850|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA + SFC)|"Moderately ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) two times daily (resulting in 500 mg 5-ALA-Phosphate and 286.8 mg SFC (30.4 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days~Severely ill hospitalized patients will receive:~250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) three times daily (resulting in 750 mg 5-ALA-Phosphate and 430.2 mg SFC (45.6 mg as Fe) daily) for 7 days, then 250 mg 5-ALA-Phosphate and 143.4 mg SFC (15.2 mg as Fe) once daily for 21 days"
224288394|NCT02632734|DEVICE|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
224288395|NCT02632734|DEVICE|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
224288396|NCT04082728|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
224288397|NCT04082728|DRUG|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
224288398|NCT05224284|OTHER|BPA levels|BPA (Bisfenol A) in blood and ejaculate samples
223538057|NCT02649920|DEVICE|Cervical ripening balloon|
223538058|NCT02649920|DRUG|Dinoprostone|
223722917|NCT01021046|PROCEDURE|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
223722918|NCT03647033|DEVICE|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
223951441|NCT00638456|DRUG|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
223951442|NCT00638456|DRUG|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
223951443|NCT03564184|BEHAVIORAL|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
223951444|NCT03564184|BEHAVIORAL|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
223951445|NCT03564184|OTHER|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
223951446|NCT04989023|OTHER|Blood flow restriction (BFR) with low load resistance training|Combination of low load resistance exercise in the upper or lower limb with the addition of blood flow restriction or sham-blood flow restriction.
223951447|NCT02204202|DRUG|[18F]FDG|10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
223951448|NCT02204202|DRUG|[18F]ISO-1|8 mCi of \[18F\]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
223951449|NCT04887857|DRUG|CC-486|Specified dose on specified days
223951450|NCT04887857|DRUG|Venetoclax|Specified dose on specified days
223951451|NCT00585793|DRUG|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
223951452|NCT00903981|DRUG|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
223951453|NCT00903981|DRUG|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
223951454|NCT00903981|DRUG|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
223951455|NCT02917148|OTHER|Peripheral Venipuncture or Blood draw from Central Line|
223951456|NCT03236779|OTHER|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
223951457|NCT03108430|OTHER|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
223951458|NCT02820909|PROCEDURE|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
224288399|NCT02813421|DEVICE|CGM Informed|
224288400|NCT01915719|PROCEDURE|Early non invasive ventilation|
223722919|NCT04332146|BEHAVIORAL|Mindfulness-based program (MBI-p-R)|The MBI-p-R was developed in line with the model of Mindfulness-based Stress Reducation (MBSR) proposed by Kabat-Zinn. It will be conducted for 1.5 hours for each session, once a week for 8 weeks. There are four key operational components to be included in each session: engagement and introduction, mindfulness practices, daily life application, and consolidation of learning.
223951459|NCT02820909|PROCEDURE|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (\> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than \> 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
223951460|NCT00824057|DRUG|AZD6280|oral
223951461|NCT00824057|DRUG|Midazolam|oral
223951462|NCT00824057|DRUG|Caffeine|oral
223951463|NCT06305910|DRUG|Treatment with CD200AR-L|Treatment with CD200AR-L (up to 3 dose levels of CD200AR-L with a Dose Level -1 in the event of toxicity) with fixed doses of GBM6-AD vaccine. Each patient will also be given topical imiquimod and a single dose of 300cGy re-irradiation.
223951464|NCT04776122|DEVICE|Therapy|Device-assisted breathing for relaxation
223951465|NCT04776122|OTHER|No device|Breathing platform without device
223951466|NCT00552461|DRUG|rituximab|IV, 1000 mg, two weeks, 2 times
223951467|NCT02751294|DRUG|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
223951468|NCT02751294|DRUG|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
223951469|NCT02751294|DRUG|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
223951470|NCT01061307|DIETARY_SUPPLEMENT|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
223951471|NCT04562883|OTHER|The way of Cumulus-oocyte complexes (COC) culture|Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
223951472|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms without self-affirmation|
223951473|NCT04813965|OTHER|Written information about potential chemotherapy-related cognitive symptoms with self-affirmation|
223951474|NCT00002409|DRUG|Lamivudine/Zidovudine|
223951475|NCT00002409|DRUG|Abacavir sulfate|
223951476|NCT02499809|OTHER|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
223951477|NCT02723799|BEHAVIORAL|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
223951478|NCT02723799|OTHER|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
223951479|NCT04221321|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg
223951480|NCT04221321|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
223951481|NCT04221321|DRUG|RAPA114|RAPA114 tablet
223951482|NCT05213585|DRUG|Ivermectin cream|Topical application of ivermectin cream to eyelashes of treatment eye.
223951483|NCT01583855|PROCEDURE|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
223951484|NCT01583855|DEVICE|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
223951485|NCT02807285|DRUG|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
223951486|NCT00753155|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
223951487|NCT04594876|OTHER|Flouroscopic guidance cervical epidural versus cervical facet injection|The patients are classified in two groups group P for cervical epidural and group F for facet injection. The skin will be prepared with an antiseptic solution. The midline of the selected interspace will be identified under fluroscopic guidance.
223951488|NCT00673088|DRUG|Ropinirole Hydrochloride|Restless Leg Syndrome
223951489|NCT02383693|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
223951490|NCT02183402|DRUG|Digoxin|
223951491|NCT02183402|DRUG|BI 1356|
223951492|NCT01271361|PROCEDURE|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
223951493|NCT01271361|PROCEDURE|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
224288401|NCT01915719|PROCEDURE|Oxygen therapy only|
224288402|NCT02759770|OTHER|no intervention|This is a clinical observational study, no intervention was included.
224288403|NCT04731402|OTHER|Acupressure, laughter yoga and mindfulness stress reduction program|Initiatives will be applied to the experimental group. only measurement tools will be applied to the control group
224288404|NCT05763706|DEVICE|Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)|MLS® Laser M6 is a PBM device that allows the patients to be treated in various positions, either sitting, lying down or at a distance, without risk of contamination. Treatment times are carefully calibrated to deliver the best possible energy dose to the tissue being treated.
224288405|NCT05457517|DRUG|YL-13027，Sintilimab|"YL-13027 combined with Sintilimab will be used as a cycle for 21 days. YLl-13027 is administered orally twice a day. Starting dose of YL-13027 is 240mg/d，with escalation to 360mg/d in phase Ib, and RP2D was administered orally twice a day in phase II.~Sindilizumab is administered intravenously 200mg every three weeks"
224288406|NCT00003517|DRUG|antineoplaston A10|
224103877|NCT04642235|BEHAVIORAL|Nature Coach|"The Nature Coach Intervention consists of 3 components - home visit, text message follow up, and goal feedback.~Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
224103878|NCT04642235|OTHER|Nature Nook + Nature Coach|The combined intervention will involve the installation of Nature Nooks to blighted vacant lots followed by the delivery of the Nature Coach intervention to people living in the immediate surrounding blocks. The intervention will be tailored to explicitly direct participants to use the Nature Nook.
224103879|NCT05559814|DRUG|Intraluminal peppermint oil|Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
224103880|NCT05559814|DRUG|Placebo|Intraluminal flushing of placebo solution through the scope during scope withdrawal
224103881|NCT02587494|PROCEDURE|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
224103882|NCT00986336|DRUG|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
224103883|NCT00986336|DRUG|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
224103884|NCT00986336|DRUG|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
224103885|NCT00986336|DRUG|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
224103886|NCT00337051|DRUG|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
224288407|NCT00003517|DRUG|antineoplaston AS2-1|
223538059|NCT05809323|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
223722920|NCT04332146|BEHAVIORAL|Booklet-based psychoeducation|The participants in the control group will be provided a booklet at baseline, including general information in handling every day stress by a new mother, as well as a record for their weekly activities. The contents covered a range of topics including work-stress, balanced diet, physical exercise, sleeping quality, bonding with baby and the treatment for depression. The participants will be contacted by phone call and/or whatsapp weekly for a short talk based on the record and content on the booklet. They will also be asked to record their daily life weekly for discussion.
223722921|NCT00660309|DRUG|Aliskiren|Aliskiren 300 mg tablets
223951494|NCT01282645|DEVICE|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
223951495|NCT00514670|OTHER|Alcohol-based hand sanitizer & quaternary ammonium wipes|
223951496|NCT01729767|DRUG|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
223722922|NCT00660309|DRUG|Irbesartan|Irbesartan 300 mg tablets
223722923|NCT00660309|DRUG|Captopril|Captopril 25 mg tablet
223722924|NCT04901468|OTHER|No Intervention|This is an observational study
223722925|NCT03005314|PROCEDURE|chemotherapy|chemotherapy before surgery
223722926|NCT03005314|PROCEDURE|Surgery|chemotherapy after surgery
223722927|NCT02454296|DRUG|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
224103887|NCT00337051|DRUG|Propofol|General anesthesia with propofol TCI
224103888|NCT02593370|DRUG|Lidocaine-epinephrine added gadoterate meglumine|
224103889|NCT03690791|DRUG|MediCabilis CBD Oil|50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
224103890|NCT03690791|DRUG|Placebo Oil|Placebo will contain only hemp seed oil.
224103891|NCT04965519|DRUG|RC48-ADC|2.0mg/kg IV every 2 weeks
224103892|NCT06656858|OTHER|Static stretching|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds
224103893|NCT06656858|OTHER|PNF stretching|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds.
224103894|NCT06656858|OTHER|Static stretching with BFR|Static stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
224103895|NCT06656858|OTHER|PNF stretching with BFR|PNF stretching exercises were performed on the dominant leg's hamstring muscle group for 3 sets of 15 seconds with BFR application.
224288408|NCT00003517|DRUG|bicalutamide|
224288409|NCT00003517|DRUG|flutamide|
224288410|NCT00003517|DRUG|leuprolide acetate|
224288411|NCT00003517|PROCEDURE|alternative product therapy|
224288412|NCT00003517|PROCEDURE|antiandrogen therapy|
224288413|NCT00003517|PROCEDURE|biological therapy|
224288414|NCT00003517|PROCEDURE|biologically based therapies|
224288415|NCT00003517|PROCEDURE|cancer prevention intervention|
224103896|NCT06656858|OTHER|Control|No stretching was applied to the control group. An information brochure about hamstring injuries was provided to the participants.
224103897|NCT06657742|OTHER|SCIM-SR|SCIM-SR was a self-reported scale that evaluated the independence of patients.
224103898|NCT06657014|OTHER|mind-mindedness|The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
224103899|NCT06657300|DRUG|PRP|A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
224103900|NCT06657300|DRUG|Corticosteroid|A single dose of 20 mg(1ml) of methyl-prednisolone (Depo-Medrol) (complemented to 1 ml by adding 0.5 ml of saline) was injected to the 1st CMC joint of the second group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
224103901|NCT06657469|OTHER|Attention Functions Training (AFT)|The AFT protocol included 18 group-based sessions, 75 minutes each, administered twice a week over a nine-week period. The training focused on improving sustained attention, selective-spatial attention, and executive attention through computerized tasks like the Conjunctive Continuous Performance Task and Go/No-Go tasks.
224103902|NCT06657469|OTHER|Executive Functions Training (EFT)|The EFT protocol included similar session structures with a focus on executive functions such as working memory, cognitive flexibility, and problem-solving. Tasks included computerized games such as visual puzzles.
224288416|NCT00003517|PROCEDURE|complementary and alternative therapy|
223951497|NCT01729767|DRUG|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
223951498|NCT01271894|DRUG|Efavirenz|600 mg once daily; given as 3 x 200 mg once
223951499|NCT01271894|DRUG|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
223951500|NCT02049684|PROCEDURE|Patch|
224288417|NCT00003517|PROCEDURE|differentiation therapy|
224288418|NCT00003517|PROCEDURE|endocrine therapy|
224288419|NCT00003517|PROCEDURE|hormone therapy|
223538060|NCT05809323|OTHER|Control Group|Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
223951501|NCT00635635|BEHAVIORAL|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
223951502|NCT00635635|BEHAVIORAL|Music Audio|Music only audio to be listened to 5x per week
223951503|NCT02935673|DRUG|lumicitabine|Oral administration of lumicitabine as tablet.
223951504|NCT02935673|DRUG|Placebo|Oral administration of matching placebo.
223951505|NCT01077440|GENETIC|DNA analysis|DNA analysis will be performed on samples collected.
223951506|NCT01077440|GENETIC|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
223951507|NCT01077440|OTHER|flow cytometry|Flow cytometry will be done on the samples collected.
223951508|NCT01077440|OTHER|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
223951509|NCT03060785|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|
223951510|NCT02772510|DEVICE|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
223951511|NCT02772510|DEVICE|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
223951512|NCT02635698|OTHER|Optifast|medically-supervised weight management program
223951513|NCT02635698|OTHER|Food-Based|low-energy, low-fat diet
223951514|NCT06220578|DEVICE|Oculus pentacam HR|Examination of corneal parameters by pentacam
223951515|NCT02684656|PROCEDURE|Hemodialysis|Hemodialysis \>/=4h
224288420|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid) and VILI (Visual Inspection with Lugol's Iodine)|A triage test that involved a gynaecological exam that applies acetic acid and then Lugol's iodine on the surface of the external os of the cervix.
224288421|NCT05125380|DIAGNOSTIC_TEST|VIA (Visual Inspection with Acetic acid)|A triage test that involved a gynaecological exam that applies acetic acid on the surface of the external os of the cervix.
224288422|NCT01530594|DRUG|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
224288423|NCT01530594|DRUG|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
224288424|NCT01530594|DRUG|Lenalidomide|Lenalidomide/Low dose Dex (LLD
224288425|NCT01452594|DRUG|Diphenylcyclopropenone|Topical administration
224288426|NCT01452594|DRUG|Placebo|Placebo
224103903|NCT06657066|DRUG|Beclomethasone 200mcg, salbutamol 100mcg , Beclomethasone 200 mcg/Formoterol 6 mcg, 250 mg of lyophilized saccharomyces boulardii|Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram plus Saccharomyces boulardii, available in sachet from employed in this research containing 250 mg of lyophilized saccharomyces boulardii. It was given daily for three months
224103904|NCT06657066|DRUG|Control (Standard treatment)|The control arm will receive only standard treatment for asthma i.e Daily low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram as needed Short acting beta 2 agonist (SABA)/salbutamol 100mcg ,OR as needed low dose inhaled corticosteroid (ICS)/ Beclomethasone 200 microgram -Long acting Beta2 Agonist (LABA)/Formeterol 6 microgram.
224103905|NCT06656624|DRUG|Ribociclib combined with AI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
224103906|NCT06656624|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS|Docetaxel: 100mg/m2 IV drip every 21 days; Paclitaxel: 175mg/m2 every 21 days, IV drip; Paclitaxel for Injection (Albumin Bound): 100\~150mg/m2 IV drip every 7 days; Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week; Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week; AI: Anastrozole 1mg, 1 time /d, oral; Letrozole: 2.5mg, 1 time /d, oral; Exemestane Tablets: 25mg, 1 time /d, oral Goserelin: 3.6 mg every 28 days, subcutaneous injection in the abdomen.
223951516|NCT02684656|PROCEDURE|Hemodiafiltration|Hemodiafiltration \>/=4h, \> 20l convection
223951517|NCT02894086|OTHER|database.|database
223951518|NCT02948309|DRUG|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
223951519|NCT02948309|DRUG|Placebo|1ml subcutaneous injection 3 times/week
224103907|NCT06656156|OTHER|Proprioceptive neuromuscular facilitation technique|"Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)"
224103908|NCT06656156|OTHER|Conventional treatment|"Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)"
223951520|NCT03093532|OTHER|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1\) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
224103909|NCT06657417|DEVICE|Video laryngoscopy|Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay
224103910|NCT06657417|DEVICE|Video larnygoscopy|Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
224103911|NCT06656130|OTHER|Pranayama|Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.
224103912|NCT06656130|OTHER|Jacobson's progressive muscle relaxation technique|Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
224103913|NCT06818422|OTHER|Home exercise and recommendations for nonspecific neck pain|The intervention involves neck exercises and recommendations for nonspecific neck pain. Patients will perform the exercises at home three times a day for 2 weeks and record their progress in an exercise diary. They will be monitored by a physician for pain levels and receive additional support at the 15th day, 30th day and 3rd months.
223951521|NCT03093532|OTHER|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
223951522|NCT01117285|OTHER|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
224288427|NCT02548312|OTHER|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
224288428|NCT01856036|PROCEDURE|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
224288429|NCT06411340|OTHER|Observation|Observation
224288430|NCT01006941|BIOLOGICAL|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
224288431|NCT04766541|OTHER|no intervention|There is no intervention.
224288432|NCT02109536|DEVICE|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
224288433|NCT03698266|PROCEDURE|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
224288434|NCT00117741|BEHAVIORAL|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
224288435|NCT00117741|BEHAVIORAL|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
224103914|NCT06819943|PROCEDURE|Automated Lateral Rotation Therapy|Platform-based automated lateral tilt system integrated into the Linet Multicare bed, which allows the entire bed platform to be tilted laterally up to 30 degrees along the axial axis, either manually or automatically. The system includes Continuous Low Pressure (CLP) mode, which automatically redistributes pressure to maintain low interface pressure, and Microclimate Management (MCM) to control moisture and heat at the skin interface. The intervention is designed to redistribute interface pressure as a preventive strategy against pressure injuries in critically ill patients.
224103915|NCT04905082|OTHER|Best Practice|Receive usual care
224103916|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics tool after genomic test results are available
223951523|NCT01117285|OTHER|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~* 3-day post-graduate course~* 2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~* Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~* Discussion platform~* Web-based registration system: Provides guidance in using the COTiD program for every individual client.~* Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~* Information on the COTiD program through a website and newsletters.~* Motivational reminders."
223951524|NCT03925909|DIETARY_SUPPLEMENT|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
223951525|NCT01558999|DRUG|High concentration SI-614|1 drop in each eye 4 times a day
223951526|NCT01558999|DRUG|Low concentration SI-614|1 drop in each eye 4 times a day
223951527|NCT01558999|DRUG|Vehicle|1 drop in each eye 4 times a day
223951528|NCT00520663|DRUG|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
223951529|NCT05308888|DIAGNOSTIC_TEST|18F-FDG PET-CT|The 18F-FDG PET-CT will be performed in the nuclear medicine department of the CHU of Brest. For this exam, the administration of 2-3 MBq/kg of 18F-FDG (\[18F\]F-fluorodeoxyglucose) will be performed to the patient in a single intravenous injection.
223951530|NCT00988130|OTHER|laboratory biomarker analysis|
223951531|NCT00988130|OTHER|questionnaire administration|
223951532|NCT00988130|PROCEDURE|assessment of therapy complications|
223951533|NCT00988130|PROCEDURE|high-intensity focused ultrasound ablation|
223951534|NCT00988130|PROCEDURE|quality-of-life assessment|
223951535|NCT06080945|OTHER|pharmacist-led patient-centered medication therapy management|The intervention group will receive a pharmacist-driven discharge counseling on budesonide, an inhaled glucocorticoid, from recruitment, until 12 months.
223951536|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
223951537|NCT00813709|DRUG|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
223951538|NCT00813709|DRUG|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
223951539|NCT00813709|DRUG|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
224103917|NCT04905082|OTHER|Educational Intervention|View HOPE-Genomics before sequencing results are available
224103918|NCT04905082|PROCEDURE|Genomic Profile|Receive genomics test results
224103919|NCT04905082|OTHER|Survey Administration|Ancillary studies
224103920|NCT06656091|DRUG|simmitinib|simmitinib 6mg,QD ,3 weeks on 1 week off
224103921|NCT06656091|DRUG|investigator's choice of chemotherapy,include docetaxel or irinotecan.|docetaxel injection 75mg/m\^2,d1,every 3 weeks or ilinotecan injection 180mg/m\^2,d1,every 2 weeks
224103922|NCT06655922|DIAGNOSTIC_TEST|FAPI Imaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPI) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPI imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
224103923|NCT06656533|OTHER|Repeated Transcranial magnetic stimulation (rTMS)|Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
224103924|NCT05750914|DEVICE|Broadband Light|Broadband Light treatment using standard protocol
224103925|NCT06388057|DIAGNOSTIC_TEST|Intraoperative Small Bowel Ultrasonography|An intraoperative ultrasound study will be performed on the intestinal segment identified as the resection site
224103926|NCT02173600|BEHAVIORAL|Group-level Intensive dietary Counselling|
224103927|NCT02173600|BEHAVIORAL|Individual-level Intensive Dietary Counselling|
224103928|NCT01200433|DRUG|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
224103929|NCT01200433|DRUG|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
224103930|NCT02053805|OTHER|PSA|PSA. Serum \& plasma will be stored for future investigations
224103931|NCT02053805|OTHER|IPSS questionnaire|the validated International Prostate Symptom Score
224103932|NCT02053805|OTHER|DRE (Digital Rectal Examination )|physical examination for the prostate gland
224103933|NCT02053805|OTHER|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
223951540|NCT06200909|OTHER|Mindfulness Meditation|8-week mindfulness meditation program, based on Kabat-Zinn's MBSR program and modified for caregivers. The intervention will be led by MBSR-trained facilitators.
223951541|NCT06200909|OTHER|Psychoeducation|"A lecture-style program based on the 10 KeysTM to Healthy Aging Course, an evidence-based program for older adults. The program will be delivered by a facilitator experienced in delivering similar content."
223951542|NCT06200909|OTHER|Wait list control|Participants will receive two hours of respite from their caregiving responsibilities per week, for eight weeks. They will be given the opportunity to participate in either the MM or the PSY condition following completion of testing.
223951543|NCT00708799|OTHER|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
223951544|NCT04577391|OTHER|Modified Constraint-Induced Movement Therapy|Children's less affected hand was restricted through a mitt with a material sewn shut on the palmar face to promote the involved side's use, and unimanual gross and fine motor activities were practiced with the more affected hand. Besides, if the participant attempted to use his/her less affected hand as an assistive, a bandage was also used to strap less affected upper limb to the trunk. Specific activities were selected according to the deficit of interest, participant preference (on the condition of having potential effects on hand skills) and parent/guardian, or their teacher's request (e.g., drawing, painting, and eating).
223951545|NCT04577391|OTHER|Bimanual Training|BIT was administrated without any restrictive material on the non-involved upper limb, but instead, children were engaged in age-appropriate gross and fine motor bimanual activities. All targeted deficits of interest were addressed within the context of the selected activity.
223951546|NCT05822791|DIAGNOSTIC_TEST|Prolonged cardiac monitoring|Prolonged cardiac monitoring
223951547|NCT05822791|DIAGNOSTIC_TEST|ECG|Electrocardiogram
223951548|NCT01237977|DRUG|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
223951549|NCT01237977|DRUG|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
223951550|NCT05730192|DEVICE|CADDIE|A colonoscopy is an examination of the bowels using a colonoscope, or a thin, flexible tube with a light and camera. It can help identify issues like colorectal cancer, polyps, and ulcers.
223951551|NCT05803122|OTHER|Uniform Data Set (UDS) neuropsychological battery|Uniform Data Set (UDS) neuropsychological battery was administered to patients with Mild Cognitive Impairment (MCI) and patients with Alzheimer's Disease
224103934|NCT02053805|PROCEDURE|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
224103935|NCT02053805|PROCEDURE|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
224103936|NCT03999970|OTHER|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
224103937|NCT01986530|DIETARY_SUPPLEMENT|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
224103938|NCT01986530|OTHER|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
224103939|NCT04321863|OTHER|Faecal calprotectin (FC)|FC is a surrogate marker of neutrophil influx into the gut lumen. It accurately predicts mucosal healing (MH) at colonoscopy, and thus is already widely used in clinical practice in disease monitoring in CD patients (standard of care).
224103940|NCT04321863|OTHER|quantitative Faecal Immunochemical Testing (qFIT)|Stool test for haemoglobin. It has been shown to predict mucosal healing in Crohn's disease and ulcerative colitis. This study will compare the ability of qFIT and FC to predict flare in CD (qFIT is a cheaper, more stable test with a quicker turn-around time than FC, and is also less labour intensive for the lab).
223951552|NCT00211042|OTHER|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
224103941|NCT04321863|OTHER|Serum and faecal zinc|Blood sample for serum zinc will be taken at same time as routine (standard of care) monitoring bloods which include CRP - no additional venipuncture will be required. A single stool sample will be sufficient to measure FC (as outlines above) and faecal zinc. This study will compare the ability of serum/faecal zinc and CRP at predicting relapse in patients with quiescent (inactive) luminal (affecting the small and/or large bowel) CD.
224103942|NCT00662155|DRUG|Zolpidem|sedative-hypnotic
223951553|NCT02010866|BEHAVIORAL|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
223951554|NCT00286013|DRUG|Association of gemcitabine, oxaliplatin and radiotherapy|
223951555|NCT02152384|DRUG|Insulin Peglispro|Administered SC
223951556|NCT02152384|DRUG|Insulin Lispro|Administered SC
223951557|NCT02152384|DRUG|Insulin Glargine|Administered SC
224103943|NCT00662155|DRUG|Placebos|Placebo
224103944|NCT06483893|PROCEDURE|US-guided thyroid cartilage plane block (group TCPB)|Participants in the (group TCPB) will receive US-guided thyroid cartilage plane block. Ultrasound-guided bilateral Thyroid Cartilage Plane Block is performed using the thyroid cartilage plate as an anatomical landmark. 3ml of 2% lidocaine is injected on the surface of the thyroid cartilage plate. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
224288436|NCT05698706|DEVICE|TOOsonix System ONE-M|Selected BCC sites will be treated using high intensity focused ultrasound
224103945|NCT06483893|PROCEDURE|US-guided traditional superior laryngeal nerve block (group traditional SLNB)|Participants in the (group traditional SLNB) will receive US-guided traditional superior laryngeal nerve block. Traditional Superior Laryngeal Nerve Block is performed using the thyrohyoid muscle and thyrohyoid membrane as an anatomical landmark. The thyroid cartilage and the greater horn of hyoid bone are hyperechoic signals on sonography. 3ml of 2% lidocaine is injected above the thyrohyoid membrane next to the superior laryngeal artery between two hyperechoic structures. Subsequently, perform fiberoptic bronchoscope-guided oropharyngeal, subglottic, and tracheal surface anesthesia. After completing surface anesthesia, perform fiberoptic bronchoscope-guided tracheal intubation, securing it properly.
224103946|NCT03358628|OTHER|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
223951558|NCT00942500|PROCEDURE|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade \<2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
223951559|NCT03483714|PROCEDURE|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
223951560|NCT00392652|DRUG|oral microencapsulated diindolylmethane|Given PO
224288437|NCT00441350|DRUG|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
224288438|NCT00441350|DRUG|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
223538061|NCT02435667|OTHER|Resistance Exercise Training|"1. Aerobic Exercise~   a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~2. Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~   a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~3. Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
223538062|NCT02435667|RADIATION|DEXA bone scan|A DEXA scan that provides bone density measures.
223538063|NCT02435667|OTHER|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
223538064|NCT02435667|OTHER|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
223951561|NCT00789971|DRUG|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
224288439|NCT01213836|DRUG|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
224288440|NCT01213836|DRUG|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
224288441|NCT01213836|DRUG|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
224288442|NCT01213836|DRUG|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
224288443|NCT05150756|DRUG|Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
224288444|NCT05150756|DRUG|morphine sulphate (10mg/ ml ampoule)|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
224288445|NCT02450877|DRUG|Azacitidine|
224288446|NCT02450877|OTHER|Control Arm|
224288447|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
224288448|NCT00255151|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
223951562|NCT00789971|DRUG|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
223951563|NCT01662232|DIETARY_SUPPLEMENT|Green tea beverage|
223951564|NCT01662232|DIETARY_SUPPLEMENT|Green tea extract|
223951565|NCT01662232|DIETARY_SUPPLEMENT|EGCG|
223951566|NCT01662232|OTHER|Placebo|
223951567|NCT05116306|DRUG|Hyaluronic acid|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with hyaluronic acid gel
224288449|NCT00255151|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
224288450|NCT00021060|DRUG|paclitaxel|Given IV
224288451|NCT00021060|DRUG|carboplatin|Given IV
224288452|NCT00021060|BIOLOGICAL|bevacizumab|Given IV
224288453|NCT00021060|OTHER|laboratory biomarker analysis|Correlative studies
224288454|NCT03574922|OTHER|Balance exercises|Balance Exercises
224103947|NCT03261869|OTHER|Cold application|
224103948|NCT02119130|DEVICE|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
223951568|NCT05116306|DRUG|Propylene glycol|lesion sterilization and tissue repair technique in non vital primary molars using double antibiotic paste mixed with Propylene glycol gel
223951569|NCT01613703|DRUG|ONO-2952|1 mg to 200 mg QD at a single descending dose
224103949|NCT01877655|BIOLOGICAL|ASP0113|Intramuscular injection
224103950|NCT01877655|DRUG|Placebo|Intramuscular injection
224103951|NCT01355432|OTHER|Observation|There is no intervention, this is an observational study.
224103952|NCT02798081|BEHAVIORAL|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
224103953|NCT03071432|DIAGNOSTIC_TEST|Paced breathing at 6, 10 and 15 breaths per minute|
223538065|NCT02435667|OTHER|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
224103954|NCT04282915|OTHER|Reducing Stigma among Healthcare Providers (RESHAPE)|Mental health service users are trained using Photo Voice to develop recovery story testimonials. They then participate in primary care providers mental health Gap Action Programme training. In addition, aspirational figures are trained to provider testimonials and conduct myth-busting.
224288455|NCT03574922|OTHER|Core Stabilization exercises|Core Stabilization exercises
224288456|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m\^2 for normal hepatic function.
224288457|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m\^2 for mild hepatic impairment (Child-Pugh A)
224288458|NCT00706095|DRUG|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m\^2 for moderate hepatic impairment (Child-Pugh B)
224288459|NCT05332834|BIOLOGICAL|SM17|Peripheral intravenous injection
223538066|NCT02435667|OTHER|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
223538067|NCT04807166|DRUG|Drug: Anlotinib|Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle
223951570|NCT02142218|DRUG|Nivolumab|
223951571|NCT04372732|DIAGNOSTIC_TEST|Serum tumor autoantibody detection|All enrolled patients will be tested for ten kinds of tumor autoantibodies using peripheral blood before PD-1 bloackade treatment.
223951572|NCT03153566|BIOLOGICAL|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
223951573|NCT03153566|DEVICE|cryotherapy|10 sec 1 cycle into all genital warts
223951574|NCT05982756|DRUG|DAG pre-excitation regimen with Bortezomib|Bortezomib+DAG pre-excitation regimen: Bortezomib (specification 3.5mg, intravenous injection, 4 times a course of treatment, 1.3mg/m2, d1, 4, 8, 11; doxorubicin liposome injection 5 mg/ m2, intravenous infusion, once every other day, 5 times in total; cytarabine 10 mg/m2 every 12 hours, subcutaneous injection, d1-14; G-CSF 200 μg/m2 daily, subcutaneous injection, d1-14 Days, WBC \>10×109/L during chemotherapy, postpone the use until it falls below this value;
224103955|NCT04282915|OTHER|mental health Gap Action Programme|The mental health Gap Action Programme is a training program for primary care providers in mental health services. The curriculum has been developed by the World Health Organization and was adapted in Nepal and certified by the Ministry of Health.
224103956|NCT05735054|PROCEDURE|endoscopic thyroidectomy|the patients who underwent endoscopic transaxillary thyroidectomy
224103957|NCT07031479|DRUG|Itopride HCI 50 mg|Enteral Itopride 50 mg enterally tid ac
224103958|NCT07031479|DRUG|Metoclopramide 10 mg ampoule|"Intravenous Metoclopramide (10 mg IV q 6 hours)~CrCl 15-60 ml/min: Metoclopramide 5 mg IV q 6 hours CrCl \<15 ml/min: Metoclopramide 5 mg IV q 12 hours Hepatic impairment/ cirrhosis: Metoclopramide 5 mg IV q 6 hours"
224103959|NCT07030361|BEHAVIORAL|suit group|elbise giydirme ve video izletme uygulaması
224103960|NCT07030361|BEHAVIORAL|training group|video izletme uygulaması
224103961|NCT07030361|BEHAVIORAL|control group|rutin hemş bakımı uygulaması, herhangi bir müdahale yok
224103962|NCT07030504|DRUG|SAL0133|once daily single dose or seven days multiple dose of SAL0133 tables
224103963|NCT07030504|DRUG|SAL0133 placebo|once daily single dose or seven days multiple dose of SAL0133 placebo
224103964|NCT07030478|DRUG|EP0089-101|EP0089 will be initially administered by intravenous (IV) infusion once every 2 weeks (Q2W)
224103965|NCT07030790|DRUG|KLA480 injection|Subcutaneous injection，Single dose
224103966|NCT07030790|DRUG|Placebo|Subcutaneous injection，Single dose
224288460|NCT05332834|OTHER|Placebo|Peripheral intravenous injection
224288461|NCT02676284|DEVICE|Durolane SJ|DUROLANE® is a clear, transparent, viscous gel of highly purified, stabilized, non-animal-derived sodium hyaluronate that is biosynthesized using bacterial fermentation. NASHA technology is used to stabilize naturally entangled hyaluronic acid (HA) chains to produce a gel. The gel is suspended in phosphate-buffered saline at a concentration of 20 mg/mL .
224288462|NCT00909584|DRUG|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
224288463|NCT05177159|OTHER|The regional cerebral oxygen saturation (rSO2)|Measurement of rSO2 with non-invasive near-infrared light spectrum monitor. The average, left and right frontal regions absolute rSO2 values will be collected every 30 seconds during the whole surgery until postoperative 2 hours, and the mean values will be calculated. Absolute rSO2 value and AUT (area under the threshold) send beneath the absolute threshold limits of 40%, 50% and 20%, 30% under the baseline. AUT will be calculated based on this formula: AUT (present)=AUT (past)+(rSO2 threshold-rSO2 value)×sample rate
224103967|NCT07030439|DRUG|Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.|A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) in second intervention period (after washout period: at least 7 days)
224103968|NCT07030439|DRUG|Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd.|A single oral dose of 100mg of Senaparib 10 mg strength capsules manufactured by WuXi STA (Shanghai) Co., Ltd. (reference product, manufactured at the original manufacturing site) administered in fasting state in first intervention period and then Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd. (test product, manufactured at the new manufacturing site) in second intervention period (after washout period: at least 7 days)
224103969|NCT06741111|OTHER|No treatment given|No treatment given
223538068|NCT04807166|DRUG|Drug: Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1
223538069|NCT01350050|DRUG|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
224288464|NCT05177159|OTHER|The glial fibrillary acidic protein (GFAP)|Venous blood sample will be collected and tested for plasma GFAP. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
224288465|NCT05177159|OTHER|The brain-derived-neurotrophic factor (BDNF)|Venous blood sample will be collected and tested for plasma BDNF. The blood will be collected 10 minutes before anesthesia, 30 minutes after intubation, every hour during operation, 15 minutes after extubation, and at 10:00 AM in postoperative 1,3,5 days.
223538070|NCT01350050|OTHER|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
223951575|NCT04528602|PROCEDURE|Control (Extended leg position) Group|"Common procedure steps -Legal representatives of the infants will sign an informed consent form. Materials (soap, napkin, non-sterile gloves, diaper, wet cotton towels for newborns, waste container, diaper change mat) will be prepared.~Hands will be washed and gloves will be worn. Tapes of the infant's dirty diaper will be opened.~For the Control Group~-The infant will be grasped on the legs, the legs will be given extension position and lifted up.~The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~The infant's feet will be freed. The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed.~The infant's legs will be given in extension position and a clean diaper will be placed under them.~Tapes of the clean diaper will be fastened. Hands will be washed after the procedure Data will be collected before, during, after and 3 minutes after application."
223951576|NCT04528602|PROCEDURE|Experimental (Legs are flexed toward abdomen) Group|"Procedure steps for the Experimental Group~* Common procedure steps~* The infant will be grasped on the legs; the legs will be kept in the flexion position and approached toward the abdomen.~* The dirty diaper will be folded in two and the perineum area will be wiped with a wet cotton towel from the front to the back.~* The infant's feet will be freed.~* The dirty diaper will be removed and thrown into the general waste bin. The used gloves will be removed and thrown into the medical waste bin.~* The infant's legs will be kept in the flexion position and a clean diaper will be placed under them. A bottom care plan will be applied in line with the treatment plan, if necessary.~* Tapes of the clean diaper will be fastened.~* Hands will be washed after the procedure.~* Data will be collected immediately before, during, immediately after and 3 minutes after the end of application."
223951577|NCT02745509|OTHER|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
223951578|NCT00101387|OTHER|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
224103970|NCT03497689|DRUG|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)
224103971|NCT04015557|DRUG|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
224103972|NCT04015557|DRUG|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
224103973|NCT06749054|DRUG|Oral Lenacapavir|Tablets administered without regard to food
224103974|NCT06749054|DRUG|Subcutaneous Lenacapavir|Administered via subcutaneous injections
224103975|NCT06749054|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
224103976|NCT03191786|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
224103977|NCT03191786|DRUG|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
224103978|NCT03191786|DRUG|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
224103979|NCT07106450|BEHAVIORAL|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
224288466|NCT01685073|DRUG|Zolpidem extended-release|nightly administration of zolpidem extended-release
224288467|NCT01685073|BEHAVIORAL|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
224288468|NCT01332578|DRUG|Paracetamol|Present in both test and active comparator
224288469|NCT01332578|DRUG|Phenylephrine|Test product
224103980|NCT06953310|OTHER|Shamba Maisha|"The Shamba Maisha Intervention intervention has three key parts:~Farming Equipment and Training: The study will provide families with water pumps, seeds, and other farming tools to improve their ability to grow food. Caregivers and girls will also get training on how to use these tools.~School-based Farming: Girls will participate in practical farming activities at school, where they can learn and practice the farming skills. This also benefits the entire school because the crops grown can be used to provide food for students.~Caregiver and Adolescent Relationship Strengthening: Families will take part in special sessions where they will learn how to improve their communication, reduce stress, and talk about important topics like sexual health."
224288470|NCT01332578|DRUG|Ascorbic Acid|Test product
224288471|NCT00934596|PROCEDURE|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
223538071|NCT03046446|DRUG|FX006 32 mg|Single intra-articular injection
223538072|NCT02871349|DRUG|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
223538073|NCT02871349|DRUG|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
223538074|NCT02871349|DEVICE|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
223538075|NCT01977196|BIOLOGICAL|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
223538076|NCT03917875|BEHAVIORAL|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
223538077|NCT06281743|OTHER|Survey|A web based survey is sent out to pediatric critical care physicians
223538078|NCT02808897|DEVICE|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (Fr) shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
223538079|NCT02808897|DEVICE|Active Tube Clearance drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 Fr shall be used. Use of silastic 19 Fr chest tubes were left at the discretion of the operating surgeon.
223538080|NCT02016391|DRUG|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
223538081|NCT00293163|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
223538082|NCT01017224|OTHER|18F-FAZA|PET scan
223538083|NCT02834455|DEVICE|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
223538084|NCT02834455|DEVICE|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
223538085|NCT01555060|DIETARY_SUPPLEMENT|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
223538086|NCT06000930|DIAGNOSTIC_TEST|Troponin fragmentation|laboratory test from blood sample
223951579|NCT00101387|OTHER|Lumbar PENS|As above
223951580|NCT00101387|OTHER|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
223951581|NCT00101387|OTHER|Control PENS + exercise|as above
223951582|NCT06240806|OTHER|Manuka Honey|Manuka honey will be topically applied to the oral mucosa as oral rinse based on the Biswal et al., 2003 administration protocol.
223951583|NCT06240806|OTHER|Saline mouthwash|Saline mouthwash will be used 3 times per day for one month
223951584|NCT02166723|DEVICE|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
223951585|NCT02166723|DEVICE|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
223951586|NCT04706442|OTHER|Supportive Parenting Application|The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
223951587|NCT05615506|PROCEDURE|Suction Diathermy Adenoidectomy|suction diathermy adenoidectomy
223951588|NCT05180175|DRUG|Top down treatment if patient at high risk|Patients with an increased risk of poor disease course (as defined by a serum protein signature at diagnosis), will be treated with a top down treatment strategy.
224103981|NCT06017869|BIOLOGICAL|MNV-201|Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.
223951589|NCT04389086|DRUG|Combination drug|"Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI."
223951590|NCT04389086|RADIATION|Chemoradiotherapy|"Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy."
224103982|NCT00528229|RADIATION|Computer Tomography|
224103983|NCT01689038|DRUG|F17464|Single dose
224103984|NCT04266574|DEVICE|Near Infrared Spectroscopy (NIRS)|"The anesthesiologist will apply optodes before induction of anesthesia and before preoxygenation, to detect baseline NIRS level, NIRS will be monitored continuously up to post-anaesthesia care unit (PACU) discharge, or up to three the investigator's after ICU admission.~When a decrease in NIRS value over 10% is detected, or if NIRS value is below 60%, patients will start hemodynamic optimization, to reverse the reduction in NIRS and return to baseline values, according to a predefined protocol."
224103985|NCT04266574|DEVICE|Standard Care|Controls will be treated according to standard of care, maintaining a MAP≥65 and an adequate cardiac output according to the hemodynamic monitoring chosen by the anesthesiologist (invasive blood pressure monitoring or pulse contour monitors). NIRS will be recorded also in controls, but caring anesthesiologists will be blinded to NIRS.
224103986|NCT00435552|PROCEDURE|Ease-It Spray|
224103987|NCT06046560|DRUG|SGLT2 inhibitor, GLP-1 RA|"Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention."
223951591|NCT04389086|PROCEDURE|Surgery locally recurrent rectal cancer|"Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional."
223951592|NCT04418609|OTHER|further processing of health data|further processing of biological materials and health related personal data for research
223951593|NCT05310292|BIOLOGICAL|Oral glucose tolerance test|Consumption of 75 grams of glucose, diluted in water, added 1,5 g of acetaminophen.
224103988|NCT06046560|BEHAVIORAL|Education-First|For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
224103989|NCT04513158|BIOLOGICAL|Convalescent Plasma|Plasma obtained from individuals previously diagnosed with SARS-CoV-2 (COVID-19) is administered to hospitalized patients meeting inclusion/exclusion criteria and have provided informed consent.
224103990|NCT02135640|DRUG|denosumab 60mg|solution
224103991|NCT02135640|DRUG|denosumab 120 mg|solution
224103992|NCT02135640|DRUG|placebo|solution
223951594|NCT05310292|BIOLOGICAL|Mixed meal test|Consumption of a standardized liquid meal, with caloric and dietary content equal to a standard meal.
224103993|NCT02935881|DEVICE|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
223951595|NCT03358485|DRUG|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
223951596|NCT03358485|OTHER|Placebo|Placebo
223951597|NCT02407288|DEVICE|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
223951598|NCT02407288|DEVICE|Sham tDCS|
223951599|NCT00002977|BIOLOGICAL|filgrastim|
223951600|NCT00002977|DRUG|melphalan|
223951601|NCT00002977|DRUG|thiotepa|
224103994|NCT02935881|PROCEDURE|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
224103995|NCT05202977|DEVICE|SinocrownTM Transcatheter Aortic Valve Replacement System|Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
224103996|NCT02517515|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
224103997|NCT02517515|DRUG|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
224103998|NCT04291300|DRUG|Lutetium-177-PSMA-I&T|4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
224103999|NCT04223167|DIETARY_SUPPLEMENT|Red Bull Energy Drink|473 ml Reb Bull Energy Drink
224104000|NCT04223167|DIETARY_SUPPLEMENT|Water|473 ml Water
224104001|NCT06287424|DIETARY_SUPPLEMENT|Aged Garlic Extract|Subjects will be instructed to continue using their regular home oral hygiene products until the Product Distribution Visit (Visit 2). They will also be instructed not to add or change any of their regular home oral hygiene products during that time.
224104002|NCT06287424|DIETARY_SUPPLEMENT|Placebo|Placebo
224104003|NCT03947879|DRUG|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
224104004|NCT03947879|OTHER|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
224104005|NCT04412603|OTHER|Conventional Mirror Therapy|The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
224288472|NCT00934596|DRUG|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
224288473|NCT01355718|DRUG|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
224288474|NCT00107042|BIOLOGICAL|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
224288475|NCT00107042|BIOLOGICAL|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
224288476|NCT01007747|OTHER|Geranium oil|Daily topical application over neuropathic pain
224288477|NCT01431352|DRUG|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
223538087|NCT03488329|DIETARY_SUPPLEMENT|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
223538088|NCT03946969|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for two cycles.
223538089|NCT03946969|DRUG|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel (135mg/m2), ivd, d1 + Cisplatin (25mg/m2), ivd, d1-3 + S-1 capsule (40mg), po, d1-14, repeated every 3 weeks for two cycles.
223538090|NCT04279743|DIETARY_SUPPLEMENT|omega-3 phospholipids|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
223722928|NCT02454296|DRUG|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
224288478|NCT01431352|DRUG|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
223951602|NCT00002977|PROCEDURE|peripheral blood stem cell transplantation|
223951603|NCT02491645|OTHER|Sensory interventions|"1. Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~2. Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~3. Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~4. Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~5. Auditory stimulation : Sound familiarisation and music time will be done."
224288479|NCT02848911|DRUG|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
224288480|NCT05210452|BIOLOGICAL|Follicular stem cells|Cultured autologous follicular stem cells
224288481|NCT05210452|OTHER|Standard treatment according to the clinical protocols|Standard treatment of alopecia according to the clinical protocols
224288482|NCT04294342|BEHAVIORAL|Active Comparator: Participants in 10 week Judo Inspired Exercise program|The intervention included 10 sessions, using a 10-week (45-50 minutes /week) pre-established program called Judo4Balance, a structured exercise program. Each session consisting of warm-up, balance, strength, power and break fall exercises. There is clear a progression within the 10 week program in three main blocks. Block 1: learning the exercises and principle movements, Block 2 more resistance and advance falling techniques, Block 3 Power training and falling strategies from stand up positions.
224288483|NCT04047537|OTHER|Medical Food Formulation 1|WBF-0011
223951604|NCT00889863|DRUG|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
224288484|NCT04047537|OTHER|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
223951605|NCT00889863|DRUG|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
223951606|NCT00475969|DRUG|duloxetine|
223951607|NCT00475969|DRUG|placebo|
223951608|NCT03656822|DIAGNOSTIC_TEST|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
223951609|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
223951610|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
224104006|NCT04745832|DRUG|Zandelisib|Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3
224104007|NCT04745832|DRUG|Rituximab|Rituximab IV 375 mg/m2 for 6 cycles
224104008|NCT04745832|DRUG|Bendamustine|Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles
224104009|NCT04745832|DRUG|CHOP|Cyclophosphamide, Vindcristine IV, and Prednisone daily orally
224104010|NCT03343821|OTHER|Balance and daily life questionnaire|Patients complete questionnaire
224104011|NCT03716726|BEHAVIORAL|WE CARE SDoH Screening Survey|The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
224104012|NCT03716726|BEHAVIORAL|Family Resource Book|The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
224104013|NCT03716726|OTHER|Standard of care|Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
224104014|NCT02752542|BEHAVIORAL|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
224104015|NCT02752542|DRUG|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
224288485|NCT04047537|OTHER|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
224288486|NCT00523328|DRUG|BG9924|dosage administered as per Biogen-idec protocol
224104016|NCT00337532|DRUG|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
224104017|NCT00337532|DRUG|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
224104018|NCT04935736|DEVICE|root canal sealer : CORTISOMOL SP|The participant will be treated with CORTISOMOL SP sealer in combination with gutta percha.
224104019|NCT04935736|DEVICE|root canal sealer : SEALITE REGULAR|The participant will be treated with SEALITE REGULAR sealer in combination with gutta percha.
224104020|NCT00065910|BEHAVIORAL|Caregiver joint attention intervention|
224104021|NCT00252863|DRUG|Symbicort, used twice daily (b.i.d) and as needed (prn)|
224104022|NCT00252863|DRUG|Budesonide Turbuhaler 200 µg|
224104023|NCT00252863|DRUG|Fluticasone Discus 250 µg|
224104024|NCT00252863|DRUG|Formoterol Turbuhaler 4.5 µg|
224104025|NCT00252863|DRUG|Terbutaline Turbuhaler 0.5 mg|
224104026|NCT00252863|DRUG|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
224104027|NCT00252863|DRUG|Salmeterol Discus 50 µg|
224104028|NCT00252863|DRUG|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
224104029|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 250/50 µg|
224104030|NCT00252863|DRUG|Fluticasone/Salmeterol Discus 500/50 µg|
224104031|NCT00252863|DRUG|Theophylline 200 mg|
224104032|NCT00252863|DRUG|Theophylline 300 mg|
224288487|NCT05865808|OTHER|cervical spine mobilization|headache SNAGs, 10 repetitions holding for 10 seconds in each glide with a rest time of 30 seconds in between. Eight weeks of treatment session will be provided and assessment of the improvement in cervicogenic headache will done at baseline, after 04, 06 and at the end of 8 week.
224288488|NCT05865808|OTHER|Rocabado 6x6|The Rocabado 6x6 program includes 6 types of exercises which are- rest position of the tongue, TMJ rotation control, upper cervical distraction, axial extension of cervical spine, shoulder girdle retraction, and rhythmic stabilization technique, which are to be performed 6 times in a day with 6 repetitions of each exercise in each session,
224104033|NCT00252863|DRUG|Singulair 10 mg|
223951611|NCT03656822|DIAGNOSTIC_TEST|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
224104034|NCT03638011|DRUG|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
224104035|NCT03715257|DEVICE|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
224104036|NCT03715257|DEVICE|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2\<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
224104037|NCT05528276|PROCEDURE|Repair surgery|"1. a circumscribing skin incision was made 2 mm below the hypospadias meatus,~2. penile degloving,~3. the para-urethral plate incision was made,~4. A vertical midline incision of the urethral plate was made from within the hypospadiac meatus and extended up to the mid-glans.~5. The urethral plate was tubularised, beginning proximally, and closed in two layers using 6/0 polyglactin 910 suture.~6. The neomeatus was formed on a catheter 2 F larger than the urethral stent.~7. A flap was harvested from the prepuce to cover the neourethra and finally glanuloplasty.~8. A suitable urethral stent was left in situ for 7-10 days, with a compressive dressing applied.~   * Grafted tubularised incised-plate .~1.Same steps but adding a graft (dorsal inlay) , 2. The graft will be taken from the inner preputial skin . 3. The graft will be sutured to overlying plate incision line from the old meatus to the tip of the glans."
224104038|NCT06319911|DEVICE|AETOS|The AETOS Shoulder System will be implanted into the right or left shoulder in the anatomic or reverse configuration
224104039|NCT01327430|DIETARY_SUPPLEMENT|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
224104040|NCT02786537|DRUG|SOF/LDV (sofosbuvir/ledipasvir)|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
224104041|NCT02786537|DRUG|PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)|Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)
224104042|NCT02786537|DRUG|EBR/GZR (elbasvir/grazoprevir)|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks
224288489|NCT01764867|DRUG|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
223951612|NCT03656822|DIAGNOSTIC_TEST|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
224104043|NCT02786537|DRUG|Ribavirin|200 mg pills (1-3 pills, 1-2 times per day)
224104044|NCT01981187|DRUG|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
224104045|NCT00929292|OTHER|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
224104046|NCT00929292|OTHER|Modilac 1|Infant formula used for non breastfed children
223951613|NCT03656822|DIAGNOSTIC_TEST|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
223951614|NCT00213317|PROCEDURE|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
223951615|NCT01118156|OTHER|Education|75-minute training teaching utilization of new standardized suicide nomenclature
223951616|NCT01532609|BEHAVIORAL|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
223951617|NCT02607176|DRUG|Heweizhixie capsule|3 #, Tid, Oral for 3 days
223951618|NCT01245998|DRUG|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
223951619|NCT01245998|DRUG|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
224104047|NCT03576872|OTHER|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
224288490|NCT01764867|DRUG|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
224288491|NCT01764867|OTHER|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
224288492|NCT01764867|OTHER|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
224288493|NCT01764867|DRUG|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224288494|NCT01764867|DRUG|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224104048|NCT02638012|DRUG|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
224104049|NCT02638012|OTHER|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
224104050|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
224104051|NCT00755001|DEVICE|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
224104052|NCT03440112|DRUG|Clarithromycin (Not used as of 4/2020)|Clarithromycin (generic) capsule 250mg each
223722929|NCT01308775|BEHAVIORAL|SIS.NET, Routine Follow-up|"* SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~* Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
223722930|NCT03103568|DRUG|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
223722931|NCT03103568|DRUG|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
223722932|NCT03103568|DRUG|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
223722933|NCT03103568|DRUG|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
223722934|NCT03103568|DRUG|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
223722935|NCT03103568|DRUG|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
223722936|NCT00160290|DRUG|Lactulose|15 mL / 12 hours
223722937|NCT00160290|DRUG|Plantago ovata|3,5 g / 12 hours
223722938|NCT02782975|DRUG|aducanumab|
223722939|NCT03712072|DEVICE|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
223722940|NCT03712072|DEVICE|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
223722941|NCT03712072|DEVICE|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on \>50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
223722942|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg）|
223722943|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg）|
223722944|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg）|
223722945|NCT02559921|BIOLOGICAL|rhRIG（20 IU/kg） and vaccine|
223722946|NCT02559921|BIOLOGICAL|rhRIG（40 IU/kg） and vaccine|
223722947|NCT02559921|BIOLOGICAL|HRIG（20 IU/kg） and vaccine|
224104053|NCT03440112|DRUG|Placebo (Not used as of 4/2020)|Lactose in a gel capsule
224104054|NCT03440112|DRUG|Transdermal flumazenil (Added 4/2020)|Transdermal flumazenil 24mg/mL
224104055|NCT03440112|DRUG|Placebo (Added 4/2020)|Transdermal placebo
223722948|NCT02559921|BIOLOGICAL|placebo and vaccine|
224104056|NCT00443560|OTHER|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
224104057|NCT04050748|PROCEDURE|Achilles tendon repair|Patients will be undergoing achilles tendon repair
224104058|NCT05829577|OTHER|Executive Function Strategies and Training|will be conducted by primary investigator and trained therapist ,EF strategies will be implemented during DLS and SI training and these strategies will target following area which proved by evidences within the context of functional training: Using monitoring system for each child , Improving sense of time, Externalize important information , Externalize Motivation, Provide consequences: Immediately, more frequently, Higher magnitude and more powerful, Richer degree of incentive, Rotated or changed more frequently, Personalize the command, praise, instruction, reprimanding, Process training, remediation and training on executive function skill
224104059|NCT05829577|OTHER|Daily Life skill training|each child will receive 25 minute of DLS training which will focus on training children on Grooming, feeding, dressing undressing, toileting and community reintegration tasks aligned with facilitation fine motor skills for children and Using several techniques for ADL training including : prompting, shaping, forward and backward chaining, and modeling ,training children based on level of independency identified by WeeFIM score
224104060|NCT05829577|OTHER|Sensory Integration /Processing training|each patient will receive 20 min of SI/SP training Manualized SI/SP intervention which will be used is based on the principles of sensory integration as outlined by Ayres ,such as deep pressure, brushing, weighted vests, and swinging will used , individually-tailored treatment activities might include activities such as using a carpeted scooter board while in the prone position to pull oneself up a ramp, then working to turn the scooter board around to ride down the ramp and land in a cushioned area of mats and pillows that are covered with various textures. Intervention is contextualized in play with active involvement of the child will be conducted in a large gym equipped with mats, a variety of suspended swings, large balls, a climbing wall, carpeted barrels, large inner tubes and foam blocks with opportunities for active, guided, sensory motor play.
224104061|NCT01943539|DEVICE|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
224104062|NCT05453253|BIOLOGICAL|Delayed second dose of oral cholera vaccine, Euvichol-Plus|The intervention arms (6 and 12 months) will modify the recommended interval for administration of the second vaccine dose, which will be extended to 6 and 12 months according to the intervention arm.
224104063|NCT05453253|BIOLOGICAL|Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice|"Euvichol-Plus, a WHO prequalified oral cholera vaccine, contains modified killed whole cell vaccine of formalin killed Vibrio cholerae strains of O1 Inaba, O1 Ogawa and O139.~In the control arm, participants will receive the Euvichol-Plus following the manufacturer recommendations: two doses administered orally 14 days apart for individuals aged ≥1 year."
224104064|NCT02413255|DRUG|TAK-020|TAK-020 oral solution
224104065|NCT02413255|DRUG|TAK-020 Placebo|TAK-020 placebo-matching oral solution
224104066|NCT03199911|DRUG|Topical Antibiotic Product|Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
224104067|NCT03199911|DRUG|Topical Non-Antibiotic Ointment|Mineral oil/petrolatum-based artificial tear ointment.
224104068|NCT01009463|DRUG|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
224104069|NCT01009463|DRUG|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
224104070|NCT03271827|DEVICE|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
223722949|NCT00754260|BEHAVIORAL|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
223951620|NCT05843526|DEVICE|Experimental healing abutment|"Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment"
223951621|NCT00375323|DRUG|NovoSeven|
223951622|NCT04180072|DRUG|Atezolizumab|Atezolizumab 1200 mg IV on day 1 every 3 weeks
223951623|NCT04180072|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV on day 1 every 3 weeks
223951624|NCT02714998|DRUG|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
223951625|NCT02714998|PROCEDURE|salpingectomy|Laparoscopic unilateral salpingectomy
223951626|NCT06288750|DEVICE|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
223951627|NCT06288750|DEVICE|No indocyanine green|Conventional means of identification and assessment of PGs are mainly based on surgeon-dependent identification of their anatomical location and appearance (color, shape, etc.) by the naked eye.
223722950|NCT06485167|DEVICE|HIFEM- chair|The intervention consists of pelvic floor training combined with high-intensity electromagnetic energy treatment (HIFEM®). This includes six HIFEM® treatments (each lasting 28 minutes) with one session per week over six weeks. The woman completes a voiding diary before treatment and one week (±7 days) after treatment. She sits fully clothed on the HIFEM chair.
223722951|NCT02573311|DRUG|tamsulosin hydrochloride|
223722952|NCT00603889|BIOLOGICAL|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
223722953|NCT00005589|BIOLOGICAL|filgrastim|
224104071|NCT04359953|DRUG|Hydroxychloroquine|Hydroxychloroquine 2 x per day during 14 days
224104072|NCT04359953|DRUG|Azithromycin|Azithromycin 2 x per day during 14 days
224104073|NCT04359953|DRUG|Telmisartan|Telmisartan 2 x per day during 14 days
224104074|NCT06282380|DEVICE|FibriCheck Mobile Application|PPG measurement with reference diagnosis
224288495|NCT01764867|DRUG|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224104075|NCT06507020|BEHAVIORAL|Fall prevention knowledge education|"Frequency of Intervention: 4 sessions, 60 mins each, weeks 1, 3, 5, 8.~Intervention format：group intervention, 12-15 participants in one group.~Intervention content: Elderly fall risks, home safety improvements, community hazard identification, behavior modification.~Intervention tools: digital teaching PPTs.~Intervention deliverers: 2 members per community, one as leader for organizing health ed. activities (lectures, discussions, exercises, Q\&A), the other as assistant for support and participant safety during exercises."
224104076|NCT06507020|BEHAVIORAL|Exercise education|"Frequency of intervention: 4 sessions Duration of intervention: 30 minutes/session, once in each of the 1st, 3rd, 5th and 8th weeks of the intervention period.~Intervention format: group intervention, 12 people in a group (in principle, no more than 15 people).~Intervention content: The content of health education included (1) basic knowledge of exercise safety, 4 methods of balance function exercise (2) review 4 methods of balance function exercise(3) methods of exercising muscle strength (4) 2 methods of endurance exercise.~Intervention tools: accompanying teaching materials Intervention deliverers: same as before."
223722954|NCT00005589|BIOLOGICAL|rituximab|
223722955|NCT00005589|DRUG|carmustine|
223722956|NCT00005589|DRUG|cyclophosphamide|
223722957|NCT00005589|DRUG|cytarabine|
223722958|NCT00005589|DRUG|etoposide|
223538091|NCT04279743|DIETARY_SUPPLEMENT|omega-3 Triglycerides|"The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele."
223538092|NCT00712517|DRUG|propofol|propofol anesthesia 3-5mg/kg
223538093|NCT00712517|DRUG|sevoflurane|sevoflurane anesthesia
223722959|NCT00005589|DRUG|melphalan|
223722960|NCT00005589|PROCEDURE|bone marrow ablation with stem cell support|
223722961|NCT00005589|PROCEDURE|peripheral blood stem cell transplantation|
223722962|NCT05022108|BIOLOGICAL|Alpha bisabolol gel|Using alpha bisabolol gel with a concentration of 0.5%, 2,5% or 5% to treat sensitized area with histamine.
224104077|NCT06507020|BEHAVIORAL|Home hazard reduction education|"Intervention Time:~One home fall risk assessment and modification instruction at week 6 of health education.~Frequency of Intervention:~Single session.~Intervention Format:~Project staff conduct in-home fall risk assessments by appointment.~Intervention Content:~1. Evaluate fall risks in elderly living areas.~2. Provide personal guidance, complete two written forms-one for records, one for the participants.~3. Supply night lights, anti-slip mats, warning signs, and carpet mats; more services encouraged where possible.~Intervention Tools:~Utilize Elderly Home Fall Risk and Retrofitting Guide for detailed assessments and suggestions. Include tools like night lights, mats, and signs.~Intervention Deliverers:~Skilled community social workers or community health center staff."
224104078|NCT02641704|BEHAVIORAL|Multidisciplinary program|Coordinated multidisciplinary program
224104079|NCT02333331|DRUG|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
224104080|NCT02333331|OTHER|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
224104081|NCT00003995|BIOLOGICAL|trastuzumab|
224104082|NCT00003995|DRUG|irinotecan hydrochloride|
224104083|NCT05170945|OTHER|Early bowel preparation for colonoscopy|Early (\<24 hours) bowel cleansing prior to colonoscopy.
224104084|NCT01688648|DRUG|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
224104085|NCT01688648|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 \~ 0.7 mcg/kg/hr during the surgery
224104086|NCT00643045|DRUG|Safinamide|
224104087|NCT00643045|DRUG|Safinamide|
224104088|NCT00643045|DRUG|Placebo|
224104089|NCT03644576|DRUG|ozanimod|ozanimod
224104090|NCT03644576|DRUG|Pseudoephedrine|Pseudoephedrine
223722963|NCT05494333|OTHER|no intervention|NO intervention
223722964|NCT02914899|BEHAVIORAL|Surveys|"Intake surveys recorded demographics, workplace profile, financial profile, health care access, cancer screening behavior, medical history, etc.~Exit surveys asked whether drivers received shared decision making (SDM) counseling, completed LCS (low-dose computed tomography \[LDCT\] scan), had barriers, felt satisfied, etc."
223722965|NCT02914899|BEHAVIORAL|Navigation|CHWs facilitated SDM and LCS for drivers, providing navigation ( finding a PCP, scheduling appointments, assisting with insurance, etc.), following up on results and next steps.
223722966|NCT02914899|BEHAVIORAL|Focus groups|Gained drivers' perspectives on adapting the community health worker (CHW) model to facilitate lung cancer screening (LCS).
224104091|NCT03644576|DRUG|ozanimod placebo|ozanimod placebo
224104092|NCT03016715|DRUG|Sirolimus 2%|
224104093|NCT03016715|DRUG|Vehicle|
224104094|NCT05542615|DRUG|Prolonged-Release Pirfenidone|1200 mg / day of Pirfenidone (KitosCell® LP)
224104095|NCT01494038|DRUG|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
224104096|NCT01494038|DRUG|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
224104097|NCT01827540|DRUG|Cenicriviroc|
224104098|NCT01827540|DRUG|Dolutegravir|
224104099|NCT01827540|DRUG|Midazolam|
224104100|NCT02874794|DRUG|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
224104101|NCT02874794|DRUG|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
224104102|NCT02874794|DRUG|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
224104103|NCT02874794|DRUG|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
224104104|NCT02199977|OTHER|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
223538094|NCT01870869|DEVICE|Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection|Surgical implant
223538095|NCT01093313|BEHAVIORAL|Cognitive therapy|
223538096|NCT01093313|BEHAVIORAL|attention training|
223951628|NCT04361617|BEHAVIORAL|Daily consumption of tree nuts and extra virgin olive oil|All participants will receive a 4-week supply of extra virgin olive oil and tree nuts, including unsalted English walnuts, almonds or pistachios (approximately 3-day supply of each type). Participants will be asked to include in their normal diets these products and will be provided recipes and other information that will allow them to replace other foods with the nuts and oil. We will ask participants to consume one ounce of tree nuts per day and two tablespoons of EVOO per day by incorporating these foods into their diet.
223951629|NCT05062226|DIETARY_SUPPLEMENT|PKU/TYR GMP Protein Substitute|After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
223951630|NCT01393964|DRUG|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
223951631|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
224104105|NCT02199977|OTHER|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
224104106|NCT02199977|OTHER|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
224104107|NCT04498858|OTHER|Patient interview|"Patient will be interviewed :~* tobacco consumption~* reported question asked by the dentist about his/her tobacco consumption~* presence and nature of reported advices given by the dentist~* presence and nature of actions proposed by dentists for patients reporting tobacco consumption, including prescription of NRT~* presence and nature of the actions carried out or envisaged by these patients, including - smoking cessation~* contact with the general practioner~* Fagerstrom score (2 questions)~* demographic variables, age, sex, level of education~* satisfaction"
224104108|NCT01556945|BIOLOGICAL|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
224288496|NCT01764867|DRUG|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224288497|NCT01764867|DRUG|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
223538097|NCT04747262|BEHAVIORAL|SPACE|SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
224288498|NCT01764867|DRUG|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224288499|NCT01764867|DRUG|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
223538098|NCT05302895|DEVICE|All-in-one health monitoring device|The staff will use the new monitoring device to carry out the health monitoring on every day during the 12-week period. After each round of health monitoring by the traditional and the new devices, the staff will need to fill in log sheets designed by HKU to document the time consumed for the entire process.
223538099|NCT06279611|DRUG|LY007|FC and LY007 infusion
223951632|NCT01393964|DRUG|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 \& 22 (cycle 1); days 8 \&22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
223951633|NCT01393964|DRUG|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
223951634|NCT01393964|BIOLOGICAL|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 \&15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
224288500|NCT01764867|DRUG|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224288501|NCT01764867|DRUG|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224288502|NCT01764867|DRUG|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224104109|NCT01556945|BIOLOGICAL|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
223722967|NCT02914899|BEHAVIORAL|In-depth interviews|"Interviews with Chinese livery bases elicited perspectives on adapting the CWH model for the drivers' occupational environment.~Interviews with PCPs, clinic directors, etc. serving Chinese communities provided insight into adapting the CHW model within the health care context."
223951635|NCT02416349|OTHER|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
223951636|NCT02416349|OTHER|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
223951637|NCT02125799|DEVICE|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
223951638|NCT04405180|DRUG|Placebos|Oral placebo capsule at a dose of 20 mg administered three times per day, during the day.
223951639|NCT04405180|DRUG|20mg sodium nitrite tid|Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
223951640|NCT06030739|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
223951641|NCT01193205|BEHAVIORAL|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
223951642|NCT01752959|DRUG|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
223951643|NCT01752959|DRUG|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
223951644|NCT05323032|DEVICE|Multifocal electroretinogram (mf-ERG) by electroretinogram device|Measurement of mf-ERG parameters with 61 stimulus elements to asses amplitude of waves in nano volt/degree square (nv/deg2) and latency in millisecond (msec) as measured by electroretinogram device.
223951645|NCT05224232|DEVICE|Access Socket|During a period of 4 weeks, patients will live in their usual environment with the soft socket (Access-Socket)
223951646|NCT05224232|DEVICE|Rigid socket|During a period of 4 weeks, patients will live in their usual environment with their usual rigid socket
223951647|NCT00687297|DRUG|vandetanib induction|100 mg daily by mouth
224104110|NCT01556945|OTHER|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
224104111|NCT01556945|OTHER|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
224104112|NCT00537940|DRUG|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
224104113|NCT00537940|DRUG|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
224104114|NCT00001933|DRUG|Nefiracetam|
224104115|NCT05741697|DRUG|bi-level ventillation|non-invasive mechanical ventilation
224104116|NCT06554990|OTHER|physical therapy excersies|1- selected physical therapy exercises
224104117|NCT06554990|OTHER|sensory perceptual motor exercises|selected sensory perceptual motor exercises
223951648|NCT00687297|DRUG|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
224104118|NCT05671094|BEHAVIORAL|Prehabilitation|Physical, mental, stress reducing and dietary prehabilitation programme, 4 to 2 weeks before surgery
224104119|NCT03549520|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
224288503|NCT01764867|DRUG|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
224288504|NCT00152191|DRUG|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
224288505|NCT00152191|DRUG|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
223722968|NCT04661384|BIOLOGICAL|IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Given ICV
224288506|NCT00000374|DRUG|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
224288507|NCT00000374|DRUG|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
224288508|NCT02712801|DRUG|Zidovudine|Dose will be adjusted according to the child's weight.
224288509|NCT02712801|DRUG|Nevirapine|Dose will be adjusted according to the child's weight.
223722969|NCT04171531|DRUG|Botox® injection|Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
223951649|NCT00687297|DRUG|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
223951650|NCT00687297|DRUG|Placebo|
223951651|NCT00687297|DRUG|Vandetanib maintenance|300 mg daily by mouth
224288510|NCT02712801|DRUG|Lamivudine|Dose will be adjusted according to the child's weight.
224288511|NCT02712801|DRUG|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
224104120|NCT06264726|OTHER|HealtheRx|CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support.
224288512|NCT00883623|DRUG|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
224288513|NCT00031850|DRUG|goserelin acetate|
224288514|NCT00031850|DRUG|raloxifene|
224288515|NCT04004117|DRUG|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
224288516|NCT04004117|DRUG|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
223722970|NCT04171531|DEVICE|Mid-urethral sling|"Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate."
223722971|NCT06629818|DRUG|Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)|qw cycle 1-2, q2w cycle 3-6, q4w cycle 7-12
223722972|NCT06629818|DRUG|Venetoclax|400mg po qd for 1 year
223722973|NCT06629818|DRUG|Dexamethasone|Dexamethasone 20mg po qw for the first 6 months, then 10mg po qw for the next 6 months
223722974|NCT06069102|DRUG|Usual care|The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
223722975|NCT06069102|DRUG|Tight blood pressure control|The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
223722976|NCT04947319|DRUG|Tirabrutinib|Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.
223722977|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
223951652|NCT04927468|PROCEDURE|supramaximal rectus recession|inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
224288517|NCT01221090|BEHAVIORAL|PDA|Technological assistance
224288518|NCT01221090|BEHAVIORAL|CDSMP|6-week classes
224288519|NCT01221090|BEHAVIORAL|PDA/CDSMP|Combined technology and education
224288520|NCT01758419|RADIATION|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
224288521|NCT01613664|DRUG|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
223722978|NCT04947319|DRUG|Tirabrutinib|"Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed.~For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment."
223722979|NCT05833152|PROCEDURE|total knee arthroplasty|To observe the postoperative functional outcome of patients with knee extension lag at different angles
223951653|NCT04927468|PROCEDURE|normal rectus recession|inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
223951654|NCT00688415|DRUG|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
223951655|NCT04370561|PROCEDURE|ORIF non-locking|Open reduction and internal fixation using 1/3 tubular plate
223951656|NCT04370561|PROCEDURE|ORIF locking|Open reduction and internal fixation using active ankle polyaxial locking plate
223951657|NCT01228734|DRUG|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
224288522|NCT01613664|OTHER|no tisseel|the surgeon does not applied tissucol during the surgery
224288523|NCT05246696|OTHER|BodyBabe questionnaire|assessment of young mothers' perceptions using self-questionnaires
224288524|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
224288525|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
224288526|NCT05856513|DRUG|ZSP1273|Participants receive ZSP1273 orally.
224288527|NCT04260321|DEVICE|AI|Artificial intelligence colonoscopy
224288528|NCT00708708|DRUG|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
224288529|NCT04417049|DRUG|Pentoxifylline 400 MG|All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
224288530|NCT04625075|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI with gadolinium and manganese contrast
223951658|NCT01228734|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
223951659|NCT01228734|DRUG|Folinic Acid|FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
223951660|NCT01228734|DRUG|5Fluorouracil|5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
223951661|NCT03498365|BEHAVIORAL|MCDA|Experimental decision support
223951662|NCT03498365|BEHAVIORAL|Delphi|Standard support
223951663|NCT06470633|DRUG|Adebrelimab|Adebrelimab 1200mg iv q3w
223951664|NCT06470633|PROCEDURE|High Intensity Focused Ultrasoun（HIFU）|HIFU treatment at lesion site
223951665|NCT06470633|DRUG|Cyclophosphamide|600mg/m2 iv q3w
223951666|NCT06470633|DRUG|Epirubicin|90mg/m2 iv q3w
223951667|NCT06470633|DRUG|Docetaxel|75mg/m2 iv q3w
224104121|NCT05309668|DRUG|Selumetinib granule formulation|"Selumetinib granule formulation will be administered using BSA-based dosing. The granule formulation dose schema to be used in the study will be established in the dose finding phase.~At enrolment participants must have a BSA within the range 0.40 to 1.09 m2; once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment."
224104122|NCT05309668|DRUG|Selumetinib capsule formulation|Selumetinib capsule formulation will be administered using BSA-based dosing. Once participants attain a BSA between 1.10 and 1.29 m2 they will be encouraged to transition to the capsule formulation, if feasible, although all participants must remain on the granule formulation until after they have completed their third cycle of treatment.
224104123|NCT06379256|RADIATION|Photon or proton radiotherapy|"* 39.6-72.6 Gy (or Cobalt Gray Equivalent, CGE) in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy (or CGE) in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-60 Gy (or CGE) in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
224104124|NCT03707340|DRUG|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.
223538100|NCT04167943|DRUG|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
224288531|NCT04625075|DIAGNOSTIC_TEST|Cardiac CT|Cardiac CT to assess coronaries
224288532|NCT04625075|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|ECG to assess rhythm
224288533|NCT04625075|DIAGNOSTIC_TEST|Blood samples|renal function liver function full blood count, hematocrit glucose
224288534|NCT02429375|DRUG|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
224288535|NCT03934749|DEVICE|Non Invasive Ventilation|NIV using standard mode or Lowenstein mode
223538101|NCT03036852|DRUG|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
223538102|NCT04221633|BEHAVIORAL|Enhancing Early Engagement (E3) webinar|Webinar-based training to provide information regarding evidence-based engagement strategies (e.g., motivational interviewing, McKay's engagement model), trauma, mental health screening, and identifying evidence-based mental health treatments for children.
223951668|NCT01997866|OTHER|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
223951669|NCT01997866|OTHER|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
223951670|NCT04301752|DIAGNOSTIC_TEST|MoCA|Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
223951671|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
223951672|NCT01114685|DIETARY_SUPPLEMENT|AlgaeCal-2|Taking 7 capsules a day for six months
224288536|NCT00873106|DEVICE|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
224288537|NCT04927026|BEHAVIORAL|Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)|The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
224295226|NCT02591212|BEHAVIORAL|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
224104125|NCT06408792|DEVICE|Deepithelized graft and protection technique|To obtain the graft in all cases, on the day of surgery, 4% articaine with epinephrine 1:100,000 will be administered to block the greater palatine nerve. Gingival grafts from all groups will be deepithelialized intraorally using a sterile 834 turbine diamond bur. This drill will go deeper into the palatal mucosa 0.5mm (half of the outermost active part of the drill). The gingival grafts will be obtained with the surgical technique described by Zucchelli et al. 2010.
224104126|NCT02014948|OTHER|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
224104127|NCT04392414|BIOLOGICAL|COVID-19 convalescent hyperimmune plasma|Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
224104128|NCT04392414|BIOLOGICAL|Non-convalescent fresh frozen plasma (Standard plasma)|Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
224104129|NCT04038346|DRUG|Naproxen|Patients will be randomized to an NSAID (naproxen)
224104130|NCT04038346|DRUG|Acetaminophen|Patients will be randomized to acetaminophen
224104131|NCT03437928|DEVICE|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
224288538|NCT03768726|DRUG|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
224295227|NCT01815112|OTHER|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
223951673|NCT03128099|BEHAVIORAL|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
223951674|NCT00001004|DRUG|Tumor Necrosis Factor|
223951675|NCT00001004|DRUG|Interferon gamma-1b|
223951676|NCT01485809|DRUG|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
224104132|NCT01401140|DRUG|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
224295228|NCT01815112|OTHER|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
223538103|NCT04221633|BEHAVIORAL|Consultation for E3 training|10 consultation calls with experts in engagement, child trauma, and mental health screening to support the webinar training
223538104|NCT03261895|BEHAVIORAL|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
224295229|NCT01269281|DRUG|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
224295230|NCT02595008|DRUG|DSXS|Active treatment
224295231|NCT05526859|OTHER|Kinsiotaping for wrist flexor muscles|The flexor muscles of the wrist area will be targeted.
223538105|NCT03866317|DRUG|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
223951677|NCT06248255|OTHER|Pads|Single arm design in which each participant act as its own control. Wet or Dry pads are applied to the participants forearms.
223951678|NCT01474382|DRUG|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
223951679|NCT01474382|OTHER|Sham injection|No drug administered, simulation of injection used in same manner as drug
223951680|NCT01606098|PROCEDURE|Surgery of the primary tumour|Surgical resection of the colon tumour
223951681|NCT01606098|DRUG|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
223951682|NCT00907959|DRUG|BZL101|Oral BZL101 20 grams/day (10 grams BID).
223951683|NCT06477549|DRUG|Bendamustine Hydrochloride|Days -7 through -6: Bendamustine 90 mg/m2 iv x 2 days
223951684|NCT06477549|DRUG|Ruxolitinib|Days -7 through -2: ruxolitinib 5 mg tid per os
223951685|NCT04885673|DEVICE|Vapotherm|flow rate 50 L/min with 100% humidified oxygen and the temperature adjusted to be 38℃
224104133|NCT01401140|DRUG|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
224104134|NCT05736549|DRUG|Bupivacaine-Liposomal Bupivacaine|A medication mixture of 40 ml (20 ml LB and 20 ml 0.25% plain bupivacaine) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
224295232|NCT05526859|OTHER|Kinesiotaping for wrist extensor muscles|The extensor muscles of the wrist area will be targeted.
224295233|NCT04632706|DRUG|Ivermectin|Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
224288539|NCT03768726|DRUG|Placebo|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
223722980|NCT05727215|BIOLOGICAL|SARS-CoV-2 subunit protein recombinant vaccine|SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma
223722981|NCT06398574|OTHER|Real dry needling|With the subject lying supine, a dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made
223722982|NCT06398574|OTHER|Sham dry needling|With the subject lying supine, a sham dry needling technique will be applied to the infraspinatus muscle. First, the most hyperalgesic point in the muscle will be located. Subsequently, Hong's fast-in and fast-out technique will be applied. Ten incisions will be made, simulating the real technique
223722983|NCT06249126|PROCEDURE|Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)|Definitive fixation by joint fusion
224104135|NCT05736549|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|A medication mixture of 40 ml (40 ml 0.25% plain bupivacaine, 10 mg DEX and 80 mg MPA) will be prepared, of which 20 ml will be used in Adductor canal block, 10 ml will be used in iPACK block and 5 ml each will be used in medial upper and lateral upper genicular nerve block, respectively.
224104136|NCT05093127|DEVICE|Carotid Artery Stenting|R-OneTM system is a tool available to physicians for performing CAS without changing the treatment of the pathology. R-OneTM system is designed to remotely deliver and manipulate guidewires and stent/balloon devices during Carotid Artery Stenting. The system is composed of the R-OneTM robotic platform used in combination with two accessories, the Mobile radioprotection screen and a sterile and single-use R-OneTM consumable kit. The physician, seated at the remote radio-protected control station, manipulates guidewires and/or balloon/stent catheters using joysticks on the Command unit.
223722984|NCT06249126|PROCEDURE|Open Reduction Internal Fixation (ORIF) only|Definitive fixation with plates and screws
223951686|NCT04885673|DEVICE|Apneic oxygenation|Standard apneic oxygenation through the side port of rigid bronchoscope during the procedure
223951687|NCT00201825|DRUG|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
223722985|NCT06188923|DRUG|Pregnenolone|Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial.
224104137|NCT00454597|PROCEDURE|omentectomy|surgery omentectomy
224104138|NCT02083276|DRUG|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
224104139|NCT05854134|DIAGNOSTIC_TEST|Closed Chain|Effectiveness of Closed Chain for Strengthening and Improving Quality of Life in Post Stroke Patients
224104140|NCT05854134|DIAGNOSTIC_TEST|Aerobic Exercise|Effectiveness of Aerobic Exercise for Strengthening and Improving Quality of Life in Post Stroke Patients
224104141|NCT02968030|OTHER|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
224104142|NCT00337636|PROCEDURE|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
224288540|NCT01766791|OTHER|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM
223951688|NCT00201825|DRUG|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
223951689|NCT05919732|DRUG|Bupivacaine, Dexmedetomidine, Caffeine, Tylenol|bupivacaine .3% + 1: 200,000 epinephrine (dose 3mg/kg). Dexmedetomidine 0.5mcg/kg, Caffeine 15mg/kg, rectal Tylenol 30mg/kg
223951690|NCT05919732|DRUG|Propofol, rocuronium, caffeine, Tylenol, bupivacaine|"propofol 3mg/kg and rocuronium 0.6mg/kg. Caffeine 15mg/kg and rectal Tylenol 30mg/kg.~single shot caudal with bupivacaine 0.25% + 1:200,000 epinephrine (total dose 2.5mg/kg)"
223951691|NCT01420198|BEHAVIORAL|Lifestyle intervention|Increased physical activity and improved food habits
224104143|NCT00337636|DRUG|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
224104144|NCT02401256|DRUG|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
224288541|NCT01766791|OTHER|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - \< 75 1RM
224288542|NCT01766791|OTHER|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, \> 75% 1RM and Protein Supplementation
224288543|NCT01766791|OTHER|Control|control group, no intervention, maintenance of physical activity
224288544|NCT03518892|DIAGNOSTIC_TEST|Resting Metabolic Rate|30 minute test to determine daily caloric needs
224295234|NCT04632706|DRUG|Placebo|Matching Placebo to the Active IMP.
224295235|NCT02341833|DRUG|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
224104145|NCT02401256|DRUG|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
224288545|NCT03518892|DIAGNOSTIC_TEST|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
224288546|NCT03518892|BEHAVIORAL|Dietary Assessment|Self administered dietary logs
224288547|NCT03382431|DRUG|PC786|Repeat doses
224288548|NCT03382431|DRUG|Placebo/vehicle|Repeat doses
224288549|NCT00444093|DRUG|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
224288550|NCT00444093|DRUG|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
224288551|NCT06495515|DRUG|Dalpiciclib，Toremifen|"1. Dalpiciclib : 150mg orally, once a day, taken for 3 weeks, stopped for 1 week, with a cycle of 4 weeks. It is recommended to take medication at the same time every day, with warm water for delivery. It is recommended to do so on an empty stomach and fast for at least 1 hour before and after taking the medication.~2. Toremifen: 60mg orally, once a day If it is a premenopausal or perimenopausal patient, it is necessary to combine with OFS (OFS includes bilateral ovariectomy or GnRHa drugs)."
224288552|NCT01286558|DRUG|40 mg telmisartan|once daily
224288553|NCT01286558|DRUG|5 mg amlodipine|once daily
224288554|NCT01286558|DRUG|5 mg amlodipine|once daily
224288555|NCT01286558|DRUG|80 mg telmisartan|once daily
224288556|NCT00872924|DRUG|sumatriptan 100mg|
224288557|NCT00362817|DRUG|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
224288558|NCT00362817|DRUG|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
224288559|NCT03037034|DEVICE|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
223538106|NCT02538120|OTHER|Microvascular assessment|Microvascular assessment
223538107|NCT00991809|DRUG|Alfentanil|15 mcg/kg IM
223538108|NCT00991809|DRUG|Diphenhydramine|25 mg IM
223538109|NCT05011136|OTHER|No intervention. This is a qualitative study|US nephrologists who care for dialysis patients will be asked to complete an internet based survey evaluating the time and effort required for home dialysis patient care.
223538110|NCT03569943|DEVICE|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
223538111|NCT02478151|DEVICE|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
223538112|NCT01561911|DRUG|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
223538113|NCT00416741|BEHAVIORAL|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting \[plasma flucose
223538114|NCT04591119|PROCEDURE|Transversus Thoracic Muscle Plane Block|40 ml %0.375 bupivacaine divided into 4 equal doses will be injected by the surgeon between internal intercostal muscle and transversus thoracis muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space
223538115|NCT04591119|PROCEDURE|Parasternal Intercostal Plane Block|40 ml %0.375 bupivacaine injection will be performed by ultrasound guidance after completion of surgery between pectoralis major muscle and external intercostal muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space bilaterally by anesthesiologist.
223538116|NCT02422329|BEHAVIORAL|Questionnaires|Participants complete questionnaires at baseline and after intervention.
223722986|NCT06188923|DRUG|Placebo|Same as active comparator, except placebo dispensed
224288560|NCT05650424|OTHER|Abdominal massage training|please refer to group description
224288561|NCT01787279|DRUG|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
224288562|NCT01471899|DRUG|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
224288563|NCT01471899|DRUG|Naproxen|2 tablets every 8 hours for 4 days
224288564|NCT03131622|BEHAVIORAL|Digital Therapeutics|
224288565|NCT01387425|DRUG|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
224288566|NCT01387425|DRUG|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
224288567|NCT03171441|DIAGNOSTIC_TEST|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
224288568|NCT03171441|DIAGNOSTIC_TEST|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
224288569|NCT04357613|DRUG|Experimental drug|Imatinib 800mg/d during 14days
224104146|NCT02401256|DRUG|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
224104147|NCT02401256|DRUG|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
224104148|NCT01403077|DEVICE|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
224104149|NCT04939896|OTHER|observation|Observed patients' compliance with rehabilitation at different time
224104150|NCT05491642|DRUG|BAY3283142|Oral administration
224104151|NCT05491642|DRUG|Placebo to BAY3283142|Oral administration
224104152|NCT00002042|DRUG|Epoetin alfa|
224104153|NCT02734732|DRUG|Trimethoprim/Sulfamethoxazole|
224104154|NCT02734732|DRUG|Ciprofloxacin|
224104155|NCT02066662|DRUG|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
224288570|NCT01430793|DRUG|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
224288571|NCT01430793|DRUG|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
224104156|NCT05099991|DEVICE|Single Foley Balloon|Foley Balloon will be placed through the cervix and inflated with 30mL of saline or water on the day prior to the procedure
223538117|NCT02422329|BEHAVIORAL|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
223538118|NCT02422329|BEHAVIORAL|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
223538119|NCT02918526|DEVICE|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
223722987|NCT06133270|DRUG|NNC0560-0004|NNC0560-0004, Oral administration (taken through the mouth)
223722988|NCT06133270|DRUG|Placebo (NNC0560-0004)|Placebo matching NNC0560-0004, Oral administration (taken through the mouth)
224104157|NCT05099991|DEVICE|Dilapan-S|Dilapan S will be placed through the cervix on the day prior to the procedure
224104158|NCT04889703|DRUG|15% Trichloroacetic acid peel|Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments at 4 week intervals.
224288572|NCT01430793|DRUG|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
224288573|NCT01430793|DRUG|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
224288574|NCT05012202|DEVICE|Hemi device|A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.
224288575|NCT01694017|DRUG|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
224288576|NCT01694017|DRUG|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
224288577|NCT01941888|DRUG|Propofol|
224288578|NCT01941888|DRUG|Midazolam|
224288579|NCT01941888|DEVICE|Target Controlled Infusion|
224288580|NCT01991288|PROCEDURE|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
223951692|NCT02334605|OTHER|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
224288581|NCT01991288|PROCEDURE|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
223951693|NCT02334605|DEVICE|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
224104159|NCT04889703|DRUG|30% Salicylic acid peel|Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4 week intervals.
223951694|NCT02334605|DEVICE|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
223951695|NCT03659942|OTHER|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
223951696|NCT03132909|OTHER|Feelings Determination|Determine the feelings of doctors caring for their colleagues
224104160|NCT02112266|OTHER|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
224104161|NCT02112266|OTHER|no mail support|follow-up without mail support
224104162|NCT04243369|DEVICE|Non-diagnostic software solution|Collaboration Live is a non-diagnostic software solution intended for use with Philips (Philips Ultrasound, 22100 Bothell Everett Highway, Bothell, Washington 98021) EPIQ and Affiniti Series Ultrasound Systems (software version 5.0.2) that allows users to communicate (by text, voice, screen share, webcam video and remote takeover) from an ultrasound system or workstation to a remote destination.
224104163|NCT03540121|BEHAVIORAL|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
224104164|NCT00029796|DRUG|soy isoflavones|
224104165|NCT02556086|DRUG|Daclatasvir|
224104166|NCT02556086|DRUG|Sofosbuvir|
224288582|NCT02857829|DIETARY_SUPPLEMENT|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
224288583|NCT02857829|DIETARY_SUPPLEMENT|Caffeine-alone|Caffeine (100 mg)
223951697|NCT01223014|DRUG|AZD2423|AZD2423
223951698|NCT05392972|BEHAVIORAL|Assessment of stress, resilience and associated factors in anesthesia professionals|Assessment of stress, resilience and associated factors in anesthesia professionals
223951699|NCT00558441|DEVICE|IVMRI|Intra Vascular Magnetic Resonance Imaging
223951700|NCT01864980|PROCEDURE|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
223951701|NCT01864980|PROCEDURE|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
224104167|NCT00599586|OTHER|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
224104168|NCT00215501|DRUG|Capecitabine|Orally twice a day for 14 days (dosage will vary)
224104169|NCT00215501|DRUG|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
224104170|NCT00215501|DRUG|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
224104171|NCT00215501|DRUG|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
224104172|NCT02234401|DEVICE|Bi level pressure support|
224104173|NCT02234401|OTHER|Standard Care|
224104174|NCT01516450|DRUG|GSK1550188 IV|Single IV dose of belimumab 200 mg
224104175|NCT01516450|DRUG|GSK1550188 SC|Single SC dose of belimumab 200mg
224104176|NCT06119698|BEHAVIORAL|GetActive+|This is a 10-week group mind body program focused on improving self-reported physical activity, performance-based physical activity, and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increase in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
224288584|NCT02857829|OTHER|Placebo|Rice flour
224288585|NCT04425889|DIAGNOSTIC_TEST|COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA)|a blood sample is drained for detection of IgG and IgM antibody
224288586|NCT04009889|DIETARY_SUPPLEMENT|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
223722989|NCT06647407|BIOLOGICAL|Pentavalent Meningococcal ABCYW vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)
223722990|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection in vial Route of administration: Intramuscular (IM)
223722991|NCT06647407|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Powder and solvent for injectable solution in a pre-filled syringe Route of administration: Intramuscular (IM)
224288587|NCT04009889|OTHER|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts before end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
223538120|NCT05348811|DRUG|HAIC combined with donafenib and sintilimab|"HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol."
223722992|NCT06647407|BIOLOGICAL|Meningococcal group B vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
223722993|NCT06647407|DRUG|Paracetamol|Pharmaceutical form:Suspension-Route of administration:oral
223722994|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
223722995|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
223722996|NCT06647407|BIOLOGICAL|DTap-HepB-IPV-Hib vaccine|Pharmaceutical form: Oral solution in tube Route of administration: oral
223722997|NCT06647407|BIOLOGICAL|Rotavirus vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
223951702|NCT03191448|PROCEDURE|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
223951703|NCT03191448|DEVICE|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
224104177|NCT04303390|DRUG|Cefuroxime|second generation cephalosporin
223722998|NCT06647407|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular (IM)
223722999|NCT06091748|DRUG|68Ga-DOTATOC|Detection of somatostatin positive lesions in GEP-NETs
223723000|NCT03569553|DRUG|AIGIV|Anthrax Immune Globulin Intravenous (Human)
223723001|NCT04545502|DEVICE|Gelsoft Plus Vascular Graft|Gelatin coated, knitted vascular prosthesis implanted to act as a conduit for channeling blood during repair of damaged or diseased vessels.
223723002|NCT04545502|DEVICE|Vascular Bypass Graft|Gelatin coated, knitted vascular prosthesis implanted to act as an extra-anatomical bypass for channeling blood during repair of damaged or diseased vessels.
223723003|NCT04545502|DEVICE|Cardiovascular Patch|Cardiovascular knitted polyester patches are frequently used to treat the carotid or femoral arteries to prevent stroke and repair damage to vessels.
223723004|NCT04545502|DEVICE|Gelweave Vascular Graft|The Gelweave woven polyester vascular graft allows replacement of large sections of arteries and, following anastomosis to the native blood vessel, provides a stable conduit for blood flow.
224104178|NCT04303390|DRUG|Cefazolin|First generation cephalosporin
223723005|NCT04545502|DEVICE|Gelweave Valsalva Vascular Graft|This woven polyester graft is designed to match the aortic root anatomy and is implanted to repair or replace a portion of the aorta in case of an aneurysm, dissection or coarctation at the level of the thoracic aorta.
223723006|NCT05854069|BEHAVIORAL|FAMS-T1D|"FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.~Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly."
223723007|NCT05854069|BEHAVIORAL|Digital resources for diabetes|Quality digital resources about diabetes management provided upon enrollment and during the study.
224104179|NCT04303390|OTHER|24 hours|Duration of antibiotic therapy
224104180|NCT04303390|OTHER|48 hours|Duration of antibiotic therapy
224104181|NCT03741543|OTHER|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
224288588|NCT04652544|DRUG|Cholecalciferol (Vitamin D3)|Vi-De 3® Monthly Dose from Dr. Wild \& Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.
224288589|NCT04652544|OTHER|Placebo|A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.
224288590|NCT00025129|DRUG|laromustine|
223951704|NCT03191448|DEVICE|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
224104182|NCT01382589|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
224104183|NCT01382589|DEVICE|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
224288591|NCT03651726|DRUG|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
224288592|NCT03651726|DRUG|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
224288593|NCT01587131|BIOLOGICAL|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
224288594|NCT02974491|OTHER|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
224288595|NCT01800526|DRUG|N-Acetylcysteine|Oral and Intravenous administration of NAC
224288596|NCT04377048|DRUG|Nivolumab|"as described in NGS Arm"
223951705|NCT02715388|DEVICE|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
223951706|NCT02689011|PROCEDURE|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
223951707|NCT02689011|PROCEDURE|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
223951708|NCT02377544|DIETARY_SUPPLEMENT|Probiotic|
223951709|NCT02377544|OTHER|Placebo|
223951710|NCT03390166|BIOLOGICAL|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
223951711|NCT03390166|BIOLOGICAL|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
224288597|NCT04377048|DRUG|Gemcitabine|"as described in NGS Arm"
224288598|NCT04377048|DRUG|Tegafur-Gimeracil-Oteracil|"as described in NGS Arm"
224288599|NCT03432065|DRUG|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
224288600|NCT01294566|DRUG|GSK1322888|1 mg, 5 mg or 25 mg capsule
224288601|NCT01294566|DRUG|Placebo|matching placebo capsules
224288602|NCT05443269|DIETARY_SUPPLEMENT|Jump Start Nutritional Program|Nutri-meal Active meal replacement shake and Metabolism pill at breakfast, lunch, and dinner, morning and evening Health Pak (multivitamin), 1 probiotic stick, and 300 calories fruits and vegetables daily
224288603|NCT03580564|DRUG|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
224288604|NCT01272921|DRUG|Bupivacaine|Varying doses to determine the duration of analgesia
224288605|NCT01272921|DRUG|Ropivacaine|Varying doses to determine the duration of analgesia
224288606|NCT00882206|DRUG|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
224288607|NCT00882206|DRUG|decitabine|Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour
224288608|NCT00882206|DRUG|doxorubicin hydrochloride|Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes
224288609|NCT00882206|DRUG|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for \>18 years on Days 5-33.
224288610|NCT00882206|DRUG|methotrexate|\*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
223538121|NCT00305448|DRUG|Fulvestrant|250 intramuscular injection
223538122|NCT00305448|DRUG|Fulvestrant|500 mg intramuscular injection
223538123|NCT00002766|BIOLOGICAL|dactinomycin|
223538124|NCT00002766|BIOLOGICAL|sargramostim|
223538125|NCT00002766|DRUG|carmustine|
223538126|NCT00002766|DRUG|cyclophosphamide|
223538127|NCT00002766|DRUG|cytarabine|
223538128|NCT00002766|DRUG|daunorubicin hydrochloride|
223538129|NCT00002766|DRUG|doxorubicin hydrochloride|
223538130|NCT00002766|DRUG|etoposide|
223951712|NCT03855384|DRUG|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
224104184|NCT05511389|OTHER|Anterolateral electrode position|As described previously
224104185|NCT05511389|OTHER|Anteroposterior electrode position|As described previously
224104186|NCT05511389|OTHER|Manual pressure|Manual pressure applied to the anterior electrode
224104187|NCT02266550|DRUG|[14C] BILL 284 BS|
224104188|NCT05418049|DRUG|Baclofen|30mg - Supplied as 10mg and 20mg tablets
224104189|NCT05418049|DRUG|Memantine|two 10 mg tablets
224104190|NCT05418049|DRUG|Roflumilast|250 mcg capsule
224104191|NCT05418049|DRUG|Placebo|Placebo pill
224104192|NCT00345605|DRUG|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
224104193|NCT00345605|DRUG|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
224104194|NCT04020432|BEHAVIORAL|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
224104195|NCT04942639|DEVICE|JOE|Audiovisual support by the robot when taking maintenance treatments at home.
224288611|NCT00882206|DRUG|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
224288612|NCT00882206|DRUG|prednisone|40mg/m2/day divided BID (days 5 - 33)
224288613|NCT00882206|DRUG|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
223951713|NCT03855384|DRUG|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m\^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m\^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
223951714|NCT00982527|DRUG|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
223951715|NCT00982527|DRUG|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
223951716|NCT00926107|DRUG|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
223951717|NCT03661398|DEVICE|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
224288614|NCT00882206|DRUG|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
224104196|NCT03180736|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
224104197|NCT03180736|DRUG|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
224104198|NCT03180736|DRUG|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
224288615|NCT01279252|DRUG|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
224288616|NCT04062149|OTHER|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
224288617|NCT04062149|OTHER|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
224288618|NCT04119999|DEVICE|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
223538131|NCT00002766|DRUG|mercaptopurine|
223538132|NCT00002766|DRUG|methotrexate|
223538133|NCT00002766|DRUG|mitoxantrone hydrochloride|
223538134|NCT00002766|DRUG|pegaspargase|
223538135|NCT00002766|DRUG|prednisone|
223538136|NCT00002766|DRUG|vincristine sulfate|
223538137|NCT00002766|RADIATION|radiation therapy|
223538138|NCT01451411|DRUG|Conivaptan hydrochloride|Intravenous
223538139|NCT01451411|DRUG|Placebo|Intravenous
223538140|NCT03483389|DRUG|Alcohol, Ethyl|Randomized within-subjects design
223538141|NCT03483389|OTHER|Alcohol, Ethyl - placebo|Randomized within-subjects design
223538142|NCT04194879|DIAGNOSTIC_TEST|multi-target FIT-DNA analysis|ColoClear® is intended for use as an adjunctive screening test for the detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It has the potential of increasing the sensitivity of detecting CRC as compared to FOBT or faecal immunochemical test (FIT), which detects the presence of hemoglobin in stool alone. A positive result may indicate the presence of colorectal cancer or pre-malignant colorectal neoplasia. ColoClear® is not intended as a replacement for diagnostic colonoscopy. A positive result in ColoClear®, as with any screening test, should be followed by colonoscopy. ColoClear® is intended for colorectal cancer screening in average risk individuals: adults of either sex, 40 years or older, who are at high risk for colorectal cancer.
223538143|NCT00020254|BIOLOGICAL|aldesleukin|
224288619|NCT04119999|DEVICE|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
224288620|NCT04986852|DRUG|Olinvacimab|Treatment with Olinvacimab and Pembrolizumab is to be continued until disease progression, the development of unacceptable toxicity or patient's withdrawal of consent. Maximum duration of treatment will be 35 cycles (approximately 2 years).
224288621|NCT06364332|BEHAVIORAL|Social Media campaign|Participants receive content three times a week; in total 24 pieces of content in 8 weeks. The content can consist of one or more photos or images with a caption (explanation in text).
224288622|NCT04869709|DRUG|Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
224288623|NCT00982891|DRUG|Opioid (morphine sulphate) in low dose|individualized titration
224288624|NCT02280720|PROCEDURE|Stenting using Optimax™|
224288625|NCT02280720|PROCEDURE|Stenting using PROMUS Element™ Plus|
224288626|NCT00932945|DRUG|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
224288627|NCT02668094|DRUG|Lidocaine|
224288628|NCT02668094|DRUG|Pregabalin|
224288629|NCT02668094|DRUG|propofol|
224288630|NCT03095898|DEVICE|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
224288631|NCT03046498|BEHAVIORAL|Evidence-Based Program|DSMP and DPP
224288632|NCT02215148|DRUG|Tolvaptan|
224288633|NCT01552967|DRUG|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
223538144|NCT00020254|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
224288634|NCT01152866|DRUG|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
223538145|NCT00020254|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
224288635|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
223538146|NCT00020254|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
224288636|NCT00892281|DRUG|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
224288637|NCT01976455|OTHER|20% fewer calories|
224288638|NCT01976455|OTHER|40% fewer calories|
224288639|NCT05628558|DRUG|Desmopressin|"The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care."
224288640|NCT05863624|PROCEDURE|Open hernioplasty|Inguinal hernia is operated using open surgery
223538147|NCT00020254|BIOLOGICAL|sargramostim|
223538148|NCT00020254|DRUG|nilutamide|
223538149|NCT00066872|DRUG|imiquimod|
224288641|NCT05863624|PROCEDURE|TEP hernioplasty|Inguinal hernia is operated using laparoendoscopic technique
224288642|NCT00140413|DRUG|Nutropin AQ|Daily injection. Dosage dependent on weight.
224288643|NCT04751539|DRUG|AND017 single dose|AND017 administrated as oral single-dose on Day 1 in Part A
224288644|NCT04751539|DRUG|AND017 multiple dose|AND017 administrated once daily from Day 1 to Day 10 in Part B
224288645|NCT04751539|DRUG|Placebo|Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
223951718|NCT00920985|DRUG|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
224288646|NCT03044236|PROCEDURE|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
223538150|NCT00066872|PROCEDURE|conventional surgery|
223538151|NCT02803385|OTHER|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
223951719|NCT00920985|DRUG|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
223951720|NCT04024709|PROCEDURE|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
223951721|NCT06404736|DRUG|Bispecific antibody (bsAb) targeting PD-1 and CLTA-4|QL1706 is a novel bispecific combination antibody composed of a recombinant humanized IgG4 monoclonal antibody targeting human PD-1 (programmed cell death protein 1) (PSB103) and a recombinant humanized IgG1 monoclonal antibody targeting human CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) (PSB105). Both antibodies have undergone engineering modifications to introduce mutations facilitating their correct assembly and preventing mispairing, and are expressed in the same cell line at a predetermined ratio (approximately 2:1).
223951722|NCT06404736|DRUG|Albumin-bound paclitaxel|Albumin-bound paclitaxel improves the solubility and delivery of paclitaxel to tumor cells by binding to human albumin, facilitating its transportation through the bloodstream and enhancing its uptake into tumor tissue. It works by binding to and stabilizing microtubules within cancer cells, thereby disrupting the normal process of cell division and leading to cell cycle arrest and apoptosis, ultimately resulting in the death of cancer cells.
224104199|NCT03421548|DEVICE|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
223951723|NCT06404736|DRUG|Carboplatin|Carboplatin is a chemotherapy medication belonging to the platinum-based class of drugs, commonly used in the treatment of various cancers, including ovarian cancer, lung cancer, and bladder cancer. It functions by forming DNA adducts, disrupting DNA replication and transcription processes in cancer cells, ultimately leading to cell death. Despite its efficacy, carboplatin can cause side effects such as nausea, vomiting, and bone marrow suppression.
223951724|NCT01989845|DRUG|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
223951725|NCT04803045|OTHER|Follow up email|Patients received an email 3 months after an initial consult asking why they had not returned to care. Patients were provided with 4 options and a space to write in comments. The email asked if the patient had any questions and offered support.
223951726|NCT02346357|PROCEDURE|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% \[local anesthetic\]) 30 minutes prior to induction of anesthesia.
223951727|NCT02346357|DRUG|Ropivacaine|
223951728|NCT02346357|DRUG|Placebo Saline|
223951729|NCT01584648|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily
224104200|NCT01059812|DRUG|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
224104201|NCT01059812|DRUG|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
224104202|NCT01389128|OTHER|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
224104203|NCT01389128|OTHER|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
224104204|NCT01521845|DRUG|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
224104205|NCT02682810|DEVICE|DNA PCR HIV diagnostic test|standard of care
224104206|NCT02682810|DEVICE|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
224104207|NCT06112925|OTHER|Medication Therapy Management|The medication therapy management intervention was delivered via the five (5) core components which include medication therapy review, personal medication record, medication-related action plan, intervention, and documentation and follow-up. The interventions was also given via educating patients about diabetes, hypertension, complications of diabetes and hypertension, impact of having diabetes and hypertension, antidiabetes and antihypertensive medications, goals of therapy for diabetes and hypertension, health promoting behaviours (healthy diet, regular exercise, salt reduction, \& smoking cessation), drug adherence, and self-monitoring of the diseases.
224104208|NCT03623750|DRUG|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
224104209|NCT03623750|BIOLOGICAL|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
223951730|NCT01584648|DRUG|Trametinib|Trametinib 2 mg once daily
223951731|NCT01584648|DRUG|Trametinib placebo|Dabrafenib 150 mg twice daily and trametinib placebo
223951732|NCT01500070|DEVICE|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
223951733|NCT03698383|DRUG|Trastuzumab biosimilars(Herzuma), Gedatolisib|"* Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~* Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
223951734|NCT06462378|RADIATION|Proton therapy|External beam proton therapy combined with standard cisplatin and brachytherapy
223538152|NCT02803385|OTHER|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
223538153|NCT00328172|DRUG|Placebo|Placebo matching BI 1356
224288647|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 24 hours s.c. post chemotherapy application.
224288648|NCT06616571|DRUG|QL0605(PEG-rhG-CSF)|Eligible patients are scheduled to receive 2 cycles of chemotherapy every three weeks. During each chemotherapy cycle QL0605 is injected 48 hours s.c. post chemotherapy application.
224288649|NCT04832048|OTHER|Therapeutic physical exercise|"The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF)."
223538154|NCT00328172|DRUG|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
223538155|NCT00328172|DRUG|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
223538156|NCT00328172|DRUG|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
223951735|NCT05684809|OTHER|Post Isometric relaxation Technique (PIR)|In PIR intervention, the patients were requested to lie down in a supine position and their neck was in a lateral flexion to the opposite side so that the target upper Trapezius muscle fibers would be in a lengthened position. The therapist performed a moderate isometric contraction (approximately 75% of maximal) of upper Trapezius muscles, held it for 5 seconds, then relaxed for 3 seconds before moving the cervical spine into the new barrier. In each session, this technique was repeated for four times, on alternate days for three weeks.
223951736|NCT05684809|OTHER|Cervical Mobilization (CM)|Cervical Mobilization was delivered in prone lying with their foreheads resting comfortably on his hands, and the chin was tucked in.The treatment session was done on alternate days (3 days a week) for 3 weeks, hence the total number of sessions were 9.
223951737|NCT05684809|OTHER|conventional treatment|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10-second relaxation) were given, and isometric exercise of the neck((10 repetitions of two sets with 10 seconds hold) alternate days for three weeks.
223951738|NCT03575494|OTHER|Intraoral and Radiographic Dental Examination|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
223951739|NCT01435720|BIOLOGICAL|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
223951740|NCT01435720|BIOLOGICAL|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
223951741|NCT01435720|BIOLOGICAL|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
223951742|NCT01435720|BIOLOGICAL|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
223951743|NCT04031794|DEVICE|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
223538157|NCT00328172|DRUG|Metformin|Metformin
223538158|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at morning
223538159|NCT05176158|DRUG|Dexketoprofen 25 MG|Pill at night
223538160|NCT00077974|DRUG|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
223951744|NCT00325845|PROCEDURE|Synvisc viscosupplementation|
223951745|NCT03975361|OTHER|Bliss-Believe|The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
223951746|NCT01137682|DRUG|Pasireotide|"* Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
223951747|NCT01137682|DRUG|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
223951748|NCT01137682|DRUG|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
223951749|NCT02970578|PROCEDURE|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
223951750|NCT00722865|DRUG|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
223951751|NCT00323778|DRUG|Hyalgan|
223951752|NCT03044756|DRUG|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
224288650|NCT04832048|OTHER|No physical exercise|No programmed physical exercise
224288651|NCT01046630|DRUG|AZD6765|single infusion
224288652|NCT01046630|DRUG|Ketamine|single infusion
224288653|NCT01046630|DRUG|Placebo|single infusion
224288654|NCT01466322|DRUG|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
224288655|NCT06389006|DRUG|Disitamab Vedotin for Injection|2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed
224288656|NCT06389006|DRUG|Toripalimab|3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.
223951753|NCT05756101|DEVICE|Research on the application of novel restraint devices in postoperative patient safety management in cardiac surgery|According to the individual characteristics of ICU patients and the needs of patients, a new type of restraint device was innovatively made and the effectiveness and safety of the new restraint device were studied, which provided clinical reference and theoretical basis for standardizing postoperative patient restraint.
224104210|NCT03623750|DRUG|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
224104211|NCT01538615|BEHAVIORAL|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
224104212|NCT02185469|PROCEDURE|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
224104213|NCT02185469|PROCEDURE|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
224104214|NCT02185469|DRUG|sulfur hexafluoride (SF6)|
224104215|NCT02185469|DEVICE|5/8-in 25-gauge needle|
224104216|NCT02185469|DEVICE|laser|intraoperative laser retinopexy
224104217|NCT05842798|DRUG|TNM002|TNM002, intramuscular injection
224104218|NCT05842798|DRUG|Placebo|Placebo, intramuscular injection
224104219|NCT04923373|OTHER|telerehabilitation|"Procedure for both groups:~I pre surgery evaluation~1. initial training in hospital~2. physiotherapeutic programme telerehabilitation versus standard 7 times a week~Therapy duration: 6 weeks post-surgery II 6weeks post-surgery evaluation"
224104220|NCT04923373|PROCEDURE|standard physiotherapy|standard physiotherapy
224104221|NCT00131443|DRUG|Topiramate|
224104222|NCT02621385|DRUG|tradipitant|test agent
224104223|NCT02621385|DRUG|Midazolam|substrate for drug-drug interaction assessment
224104224|NCT03918993|DRUG|Tadalafil 5mg tablet|Once-a-day 5 mg dose of tadalafil for 8 weeks
224104225|NCT05518786|OTHER|Exposure of interest: critical illness|Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
224104226|NCT05060042|OTHER|Whole body vibration group|WBV will be provided with a frequency of 6-26Hz with amplitude of 1-3mm 4-5 bouts(60 sec each) for 3 times a week
223951754|NCT06180109|DRUG|Empagliflozin film coated tablets|1 film coated tablet of 25 mg Empagliflozin
224104227|NCT05060042|OTHER|Bilateral proprioceptive training|"Static balance training will be provided in first week for 3-4 times for 10 mints of single session. 3 times a week In 2nd and 3rd week dynamic balance training for 3 times with a session of 10 mints.~In 4th week progressive balance training will be done with same frequency and duration.~Tai chai exercises will be given for 20 mints 3 times a week"
224104228|NCT01532453|DEVICE|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
224104229|NCT01532453|OTHER|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
224104230|NCT04954846|DIETARY_SUPPLEMENT|OMNi-BiOTiC SR-9|"The Probiotic contains the following ingredients:~Maize Starch, Maltodextrin, Inulin, Potassium Chloride, Hydrolysed rice protein, Magnesium Sulphate, Fructooligosaccharides, Amylase, Manganese Sulphate~Additionally, the following bacterial strains are included:~Lactobacillus Casei W56, Lactobacillus Acidophilus W22, Lactobacillus Paracasei W20, Bifidobacterium lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium lactis W52, Lactobacillus plantarum, Bifidobacterium bifidum W23"
224104231|NCT04954846|DIETARY_SUPPLEMENT|Placebo|The Placebo contains no bacterial strains, only the prebiotic ingredients found in OMNi-BiOTiC SR-9.
224288657|NCT06389006|DRUG|Epirubicin|According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.
224288658|NCT06389006|DRUG|Cyclophosphamide|According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
224288659|NCT00865098|DRUG|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m\^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m\^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
223723008|NCT01401582|OTHER|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
223723009|NCT05798897|DRUG|MT-601|Multi-antigen specific CD4+ andCD8+ T cells
223723010|NCT04862585|DRUG|Cimetidine|Given IV and/or PO
223723011|NCT04862585|DRUG|Dexamethasone|Given IV and/or PO
223951755|NCT06180109|DRUG|Jardiance film-coated tablets|1 film coated tablet of 25 mg Empagliflozin
223951756|NCT04421456|DRUG|GWP42003-P|oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring
223951757|NCT04421456|DRUG|Placebo|oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring
223951758|NCT00623844|BEHAVIORAL|physical activity|activity program at kindergarten 5 \* 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
224288660|NCT03634345|DRUG|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
224104232|NCT05117801|DEVICE|Petale|The child sits on the companion's lap between the two enclosures, and the investigator observes whether or not he is attracted to a familiar calibrated noise coming from one side or the other.
224104233|NCT01507194|DRUG|Ondansetron|Single IV dose
224104234|NCT01507194|DRUG|Vestipitant|Single IV dose
224104235|NCT01596829|DIETARY_SUPPLEMENT|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
224288661|NCT03634345|DRUG|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
223538161|NCT03293121|BEHAVIORAL|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength \& coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
223723012|NCT04862585|DRUG|Diphenhydramine|Given IV and/or PO
223723013|NCT04862585|DRUG|Famotidine|Given IV and/or PO
223951759|NCT00274287|DRUG|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
223951760|NCT05770206|DEVICE|Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03|Subjects in the experimental group will receive treatment by using Hydrogen-Oxygen Generator with Nebulizer (manufactured by Shanghai Asclepius Meditec Co., Ltd., flow rate: 3L/min) combined with conventional basic supportive treatment (symptomatic support treatment determined by the investigator based on the condition of the subjects);
223951761|NCT05770206|DEVICE|OLO-1 Medical Molecular Sieve Oxygen Generator|subjects in the control group will receive treatment by using Medical Molecular Sieve Oxygen Generator (manufactured by Shanghai Ouliang Medical Devices Co., Ltd., flow rate: 3L/min, provided by the sponsor) combined with conventional basic supportive treatment (same with that in the test group).
223951762|NCT01002586|OTHER|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
223723014|NCT04862585|DRUG|Paclitaxel|Weekly or every 14 day dosing
223723015|NCT04862585|OTHER|Quality-of-Life Assessment|Ancillary studies
223723016|NCT04862585|DRUG|Ranitidine|Given IV and/or PO
223723017|NCT03959839|PROCEDURE|ESD|Rectal Endoscopic Submucosal Dissection
223951763|NCT01002586|OTHER|Walking exercise program|walking exercise program
223951764|NCT06285058|DIAGNOSTIC_TEST|No interventions|The high-throughput extraction of large amounts of quantitative image features from medical images
223723018|NCT03959839|PROCEDURE|TAMIS|Transanal Minimally Invasive Surgery
223723019|NCT03959839|PROCEDURE|TEO|Transanal Endoscopic Operation
223723020|NCT05127265|OTHER|Video Monitoring|continuous video monitoring
223723021|NCT05127265|OTHER|Accelerometer Monitoring|continuous accelerometer monitoring of patient movements
223723022|NCT05127265|OTHER|Noise Level Monitoring|continuous environmental noise monitoring
224104236|NCT01596829|DIETARY_SUPPLEMENT|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
224104237|NCT01458340|DRUG|TD-9855|Once daily
224104238|NCT01458340|DRUG|TD-9855|Once daily
224104239|NCT01458340|DRUG|Placebo|Once daily
224104240|NCT03126227|BIOLOGICAL|AR101|AR101 powder provided in capsules
224104241|NCT03126227|BIOLOGICAL|Placebo|Placebo powder provided in capsules
224104242|NCT04277702|DRUG|Montelukast 10mg|Oral administration of 10mg of montelukast daily for 12 months
224104243|NCT04277702|PROCEDURE|Endovascular treatment|Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries
224104244|NCT04277702|DRUG|Standard anti-platelet treatment|Standard antithrombotic treatment for patients undergoing endovascular procedures
224104245|NCT03295422|PROCEDURE|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
224288662|NCT03634345|DRUG|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
224288663|NCT06070805|OTHER|depression|The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
224288664|NCT04092920|DEVICE|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
224288665|NCT02658916|DRUG|BIIB092|Same dose as corresponding CN002003 study panel.
224104246|NCT03295422|PROCEDURE|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
224104247|NCT04524741|DEVICE|intracardiac echocardiography|30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
224104248|NCT01569204|DRUG|Etoposide|
224104249|NCT01569204|DRUG|Cyclophosphamide|
224104250|NCT01569204|DRUG|Doxorubicin|
224104251|NCT01569204|DRUG|Prednisone|
224104252|NCT01569204|DRUG|Procarbazine|
224288666|NCT02126930|OTHER|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
224288667|NCT02126930|OTHER|Routine care|Patients randomized to this arm will receive care in the habitual manner.
224288668|NCT04702724|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be congruently related to the images in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
223723023|NCT05127265|OTHER|Light Level Monitoring|continuous environmental light monitoring
223951765|NCT05151016|DRUG|mifepristone|Mifepristone tablets, 10mg, 1 tablet daily, taken orally (beginning on the third day of Menstruation) for 24 weeks
223951766|NCT05151016|DRUG|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
224104253|NCT01569204|DRUG|Dexamethasone|
223538162|NCT03293121|BEHAVIORAL|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
223538163|NCT00030147|DRUG|Raloxifene|60 mg a day orally administered
223723024|NCT05127265|OTHER|Air Quality Monitoring|continuous environmental air quality monitoring
223951767|NCT01543945|DRUG|Dexamethasone|4 mg iv before induction for high and extremely high risk
223951768|NCT01543945|DRUG|Ondansetron|4 mg iv before ended surgery 30 min
223951769|NCT01543945|DRUG|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
223951770|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
223951771|NCT01330472|DRUG|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
223951772|NCT03624114|PROCEDURE|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
223951773|NCT04617847|DRUG|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
224104254|NCT01569204|DRUG|Dacarbazine|
224104255|NCT01569204|DRUG|Brentuximab Vedotin|
224104256|NCT06247540|PROCEDURE|Biopsy|Undergo tissue biopsy
223538164|NCT00030147|DRUG|Rimostil|1000 mg twice a day administered orally
223723025|NCT05127265|OTHER|EKG Monitoring|continuous EKG monitoring
224104257|NCT06247540|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224104258|NCT06247540|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224104259|NCT06247540|PROCEDURE|Computed Tomography|Undergo PET/CT, CT
224104260|NCT06247540|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224104261|NCT06247540|BIOLOGICAL|Nivolumab|Receive IV
224104262|NCT06247540|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224104263|NCT06247540|BIOLOGICAL|Rituximab|Receive IV
224104264|NCT06247540|DRUG|Venetoclax|Receive PO
224104265|NCT05847972|PROCEDURE|MWM (Mobilization with movement)|This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.
224104266|NCT05847972|DEVICE|Plantar orthoses|"Procedure: MWM All participants will undergo MWM. This manipulation is intended to improve ankle dorsiflexion. One session of 3 sets of 20 slow ankle dorsiflexion's separated by 10 seconds of rest will be performed.~Procedure: Plantar orthoses The moulds will be taken immediately after the manipulation. The PO will be made of resin (0.8mm +1.2mm), 2mm hard EVA heel stabiliser, 3mm semi-hard EVA cover. The PO should be worn for 3 months to obtain the results of the study."
224104267|NCT04727216|DEVICE|Dorsal Root Ganglion Stimulation (DRG-S)|Dorsal Root Ganglion stimulation will be delivered with continuous dosing and 2 different ON/OFF periods to compare effects for each patient.
224104268|NCT04929873|BEHAVIORAL|Closed transdyser|When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.
224104269|NCT04929873|BEHAVIORAL|Routine monitor|Obtain oxygen saturation, skin color, temperature, etc
224104270|NCT02237053|DRUG|Glucagon|
224104271|NCT02237053|DRUG|Octreotide|
224104272|NCT02237053|BEHAVIORAL|Placebo|
224104273|NCT02237053|DRUG|Insulin|
224104274|NCT00061308|DRUG|Topotecan|
224104275|NCT00061308|DRUG|Gemcitabine|
224104276|NCT06962943|OTHER|Auto-regulated Blood Flow Restriction Training|This group was recruited to conduct auto-regulated blood flow restriction exercise for 30-min, three times a week for six weeks by a trained physiotherapist, the subjects were asked to perform the following exercises: standing single leg calf raises with lateral resistance using a band, seated soleus raise, single leg balance on the edge of a step clearing the front foot with band on the big toe. SmartCuff 3.0 BFRT tool was used to automatically determine the individualized 50% arterial blood occlusion pressure for the BFRT group at the femoral artery, the cuff was connected to the smart tool device for the auto-regulated group to regulate the cuff pressure during muscle contraction and relaxation. The cuff was deflated in between exercises.
224104277|NCT06962943|OTHER|Non-regulated Blood Flow Restriction Training|This group was recruited to conduct a non-regulated blood flow restriction exercise for 30-min, three times a week for six weeks by a trained physiotherapist, the subjects were asked to perform the following exercises: standing single leg calf raises with lateral resistance using a band, seated soleus raise, single leg balance on the edge of a step clearing the front foot with band on the big toe. SmartCuff 3.0 BFRT tool was used, whilst the cuff was not connected to the device in the non-regulated blood flow restriction training group and the pressure was stabilized as the initial pressure determined by the device in the non-regulated group. The cuff was deflated in between exercises.
224288669|NCT01272115|BEHAVIORAL|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
223723026|NCT05127265|OTHER|Vitals Monitoring|continuous vitals monitoring (heart rate, oxygen saturation)
224104278|NCT06962943|OTHER|Control group|This group was recruited to conduct no blood flow restriction exercise 30 min, three times a week for 6 weeks. SmartCuff 3.0 BFRT tool was used, whilst the cuff was not connected to the device and the pressure was 0 (zero) in this group. The cuff was deflated in between exercises.
224104279|NCT03471754|DEVICE|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
224104280|NCT04144062|OTHER|CAD/CAM crowns|CAD/CAM crowns
224104281|NCT05485012|DRUG|Marijuana|Double-blind administration of marijuana
224104282|NCT05485012|DRUG|Opioid|Double-blind administration of an opioid agonist
224104283|NCT05174806|DRUG|Topical Pravibismane|Topical Pravibismane
224104284|NCT05174806|OTHER|Standard of Care|Standard of care treatment without investigational topical pravibismane (MBN-101) or other topical antibiotics.
224104285|NCT00428168|DRUG|Betahistine|Betahistine 24mg BID
223723027|NCT05127265|OTHER|Biosample Collection|blood and urine samples collected once on Day 1 and once on Day 2
223723028|NCT05127265|OTHER|Delirium Motor Subtyping Scale 4 (DMSS-4)|done daily on delirious patients to subtype delirium
223723029|NCT03366337|DRUG|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
223951774|NCT05323643|DEVICE|Ultrasound|"musculoskeletal US will be performed using commercially -available equipment, with high frequency linear -array transducers and a standard gel interface. The higher frequency transducers provide better spatial resolution, while the lower frequency transducers provide a greater depth of tissue penetrance. Colour Doppler US is also performed in most cases as it plays an important role in supporting and confirming diagnoses, by providing valuable information about the pathophysiology of the abnormality.~The patients will be seated with hands placed on a table, to permit examination of both volar and dorsal aspects, in longitudinal and transversal axis. Examination of the hands and fingers usually requires a large amount of transmission gel, in order to avoid compression and to permit dynamic evaluation. When acute trauma with skin lesions is investigated, sterile transmission gel, or sterile acoustic standoff pads can be used"
223951775|NCT00244751|DRUG|GI262570 0.5 mg|GI262570 0.5 mg
223951776|NCT00244751|DRUG|GI262570 1.0 mg|GI262570 1.0 mg
223951777|NCT00244751|DRUG|Placebo|Placebo
223951778|NCT04213235|BEHAVIORAL|Physical activity|The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
223951779|NCT05450159|BEHAVIORAL|ROADskills program|Participants in the intervention arm of the study will watch a 30-minute personalized video on their driving that uses information compiled from a GPS device that will be installed in their vehicle during their baseline visit.
223951780|NCT05450159|BEHAVIORAL|Healthy Aging|Participants in active comparator arm of the study will watch a 30-min video and receive a written brochure that provide tips for maintaining a healthy lifestyle in later life, including the importance of community mobility.
223951781|NCT02368288|DRUG|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
223951782|NCT06142799|PROCEDURE|root canal treatment|The root canal completedwill be completed. Then randomly it will be decided if the planned and milled overlay is placed the same day or delayed one week
223951783|NCT04120623|DRUG|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
223951784|NCT04120623|DRUG|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
223951785|NCT06091709|OTHER|Multimodal Exercises and Education delivered through tele rehabilitation|Participants will follow the MEET-R that will include stretching, strengthening and core stabilization exercises, and education material pertaining to the proper posture during work.
223951786|NCT06091709|OTHER|Selafcare|The control group is allowed to opt for self-care management of back pain in the form of medications, rest, conventional physiotherapy, and a home exercise plan. They are also allowed to change their self-care management during the study period; information about the use of the alternative management will be recorded. The information on self-care management will be gathered after 6 weeks at the end of the intervention
223951787|NCT01694199|DEVICE|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
223951788|NCT01694199|DEVICE|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
223951789|NCT00925327|OTHER|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
223951790|NCT04810104|DRUG|AZD0328|Active study drug
223951791|NCT04810104|DRUG|Placebo|Non-active study drug
223951792|NCT00729261|PROCEDURE|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
223951793|NCT00729261|PROCEDURE|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
224104286|NCT04230577|DEVICE|Real LED Intervention|A series of Real at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, 810nm (NIR), Vielight Neuro Alpha Head Frame Device (with NIR intranasal).
224104287|NCT04230577|DEVICE|Sham LED Intervention|A series of Sham at-home, transcranial LED treatments (3xWeek, 5 weeks), 20-minute treatment, Vielight Neuro Alpha Head Frame Device (with intranasal) with Sham LEDs that emit no photons. Sham and Real Devices look and feel identical.
224104288|NCT00480961|PROCEDURE|intramiocardiac autograft of autologous stem cells|
224104289|NCT04880811|DRUG|Afatinib|Afatinib is orally administered at 40mg Qd of each 21 day cycle.
224104290|NCT04880811|DRUG|Toripalimab|Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
224104291|NCT04282928|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Definitive Human umbilical cord mesenchymal stem cells selected by immunomodulatory assay through coculture with BV2 cell
224104292|NCT04282928|PROCEDURE|Routine treatment|"According toInfluenza diagnosis and treatment plan (2019 version)"
224104293|NCT04281537|DRUG|Enzyme Replacement Therapy (ERT)|ERT infusion every other week
224104294|NCT03230097|DRUG|BI 409306|50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
224104295|NCT03230097|DRUG|Placebo|placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
224104296|NCT03951571|DRUG|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
224288670|NCT01304693|BIOLOGICAL|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
224104297|NCT03951571|DRUG|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
223538165|NCT00030147|DRUG|Transdermal Estradiol|100 microgram per day transdermal estradiol
223538166|NCT00030147|DRUG|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
223538167|NCT03750019|BEHAVIORAL|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
223951794|NCT00741923|OTHER|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
223951795|NCT03722732|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
223951796|NCT02206607|DRUG|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
223951797|NCT02206607|DRUG|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
223951798|NCT02206607|DRUG|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
223951799|NCT02206607|DRUG|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
223951800|NCT03417479|OTHER|Gabapentin|
224104298|NCT06562816|DRUG|Trypsin-Chymotrypsin|100000 IU
224104299|NCT06562816|DRUG|Naproxen Sodium 550mg|550mg
224104300|NCT05058872|DRUG|Levonorgestrel/ethinyl estradiol|Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
224104301|NCT05058872|DRUG|Placebo|Placebo comparator
224104302|NCT03056287|BEHAVIORAL|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
224104303|NCT03056287|OTHER|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
224104304|NCT01481571|DEVICE|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
224104305|NCT02963467|PROCEDURE|cigarette|smoking 4 conventional cigarettes
224104306|NCT02963467|PROCEDURE|"dummy cigarette"|"smoking a dummy cigarette"
224104307|NCT05953662|PROCEDURE|Reduced-port laparoscopic surgery|compare different operational styles of colon and upper rectal cancer
224104308|NCT05953662|PROCEDURE|conventional laparoscopic surgery|conventional laparoscopic surgery
224104309|NCT00980083|DRUG|Saline|
224104310|NCT00980083|DRUG|Exendin(9-39)amide|
224104311|NCT00402350|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
224104312|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
224104313|NCT00402350|DRUG|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
224288671|NCT01304693|BIOLOGICAL|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
224288672|NCT02129647|DRUG|Axitinib|
224288673|NCT02164734|DEVICE|Endotracheal intubation|
224288674|NCT02164734|DEVICE|Laryngeal mask airway|
224288675|NCT02164734|DRUG|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
224288676|NCT06427525|OTHER|Mobile application-based adolecent obesity education|Mobile application-based adolecent obesity education
224288677|NCT02596321|DRUG|Mitizax|Allergen extract
224288678|NCT02596321|DRUG|Placebo|Placebo tablet
224288679|NCT00953108|DRUG|quetiapine|300 mg per day
224288680|NCT00953108|DRUG|escitalopram|escitalopram 10 mg per day
223951801|NCT00220649|DRUG|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
223951802|NCT05782894|DRUG|Remimazolam besylate|0\~2.0mg/kg/h
223951803|NCT05782894|DRUG|Propofol|0.3\~4.0mg/kg/h
223951804|NCT05782894|DRUG|Remifentanil|1.5\~12μg/kg/h
223538168|NCT03750019|BEHAVIORAL|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
223951805|NCT02730624|DRUG|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
223951806|NCT01262456|DRUG|Desmopressin|
223951807|NCT01262456|DRUG|Placebo|
223951808|NCT00120107|DRUG|Black Tea|
223951809|NCT02661958|DRUG|S6G5T-3|once a day topical cream
223951810|NCT02661958|DRUG|S6G5T-1|once a day topical cream
223951811|NCT02661958|DRUG|S6G5T-5|once a day topical cream
223951812|NCT02661958|DRUG|S6G5T-6|once a day topical cream
223951813|NCT02661958|DRUG|S6G5T-7|once a day topical cream
223951814|NCT02661958|DRUG|S6G5T-8|once a day topical cream
223951815|NCT05662930|BEHAVIORAL|First arithmetic problem solving|"In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation."
223951816|NCT05662930|BEHAVIORAL|Second arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the first subtraction process, patients were asked to subtract 7 from 6828 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
223951817|NCT05662930|BEHAVIORAL|Third arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 13 from 9561 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
223951818|NCT05662930|BEHAVIORAL|Fourth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 8 from 5113 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
223951819|NCT05662930|BEHAVIORAL|Fifth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 14 from 8318 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
223951820|NCT05662930|BEHAVIORAL|Sixth arithmetic problem solving|"In the same A4-sized white paper that was placed in front of each patient on a table, immediately after the previous subtraction process, patients were asked to subtract 17 from 9994 for another 100 seconds.~When the patient made a calculating error, the researcher stood in front of the patient and asked them to make corrections by issuing a warning."
223951821|NCT01368484|DIETARY_SUPPLEMENT|Sunflower oil|1500 mg sunflower/day for 10 weeks
223951822|NCT01368484|DIETARY_SUPPLEMENT|Docosahexanoic acid|1500mg/day for 10 weeks
223951823|NCT02718885|DIETARY_SUPPLEMENT|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
223951824|NCT02718885|DIETARY_SUPPLEMENT|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
223951825|NCT04546555|DEVICE|Dual chamber pacemaker|Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
223538169|NCT03750019|BEHAVIORAL|Neutral rehearsal|Participants rehearsed their journey to campus that day.
223951826|NCT04546555|OTHER|Accelerated Physiologic Pacing|The lower rate limit will be programmed to an individualized heart rate.
223951827|NCT04546555|OTHER|Nocturnal Pacing|In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
223951828|NCT03770897|PROCEDURE|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
223951829|NCT03770897|PROCEDURE|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
223951830|NCT05298540|BEHAVIORAL|Home-based computerised cognitive training with BrainHQ|Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
223951831|NCT05260944|DEVICE|Acapella device|patients will receive a two supervised sessions using acapella device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
224104314|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
224104315|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
223951832|NCT05260944|DEVICE|Power lung device|Group B. patients will receive a two supervised sessions using power lung device three sets for 10 repetitions from the first day postoperative until 7 days, in addition to routine physiotherapy program (phase I cardiac rehabilitation, breathing exercises, postural drainage, percussion and vibration.
223951833|NCT05260944|OTHER|routine Physical Therapy program|Group C. Thirty patients will receive only routine physical Therapy program
223951834|NCT00916656|BIOLOGICAL|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
223951835|NCT00916656|BIOLOGICAL|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
223951836|NCT00986505|DRUG|Lidocaine|Intravenous lidocaine once a week
223951837|NCT02500433|OTHER|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
223951838|NCT02500433|OTHER|Conventional therapy|
223951839|NCT05926557|PROCEDURE|Spermidine gel|First step: Non-surgical mechanical debridement (NSMD) Second step: application of spermidine gel
223951840|NCT05926557|PROCEDURE|NSMD|Only mechanical debridement with curettes and scaler peek tips
223951841|NCT03392844|OTHER|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
223951842|NCT04121234|OTHER|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
223951843|NCT06160453|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions
223951844|NCT06160453|DEVICE|Serious game with augmented reality|The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game will be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions
223951845|NCT04506047|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
223951846|NCT05033756|DRUG|Pembrolizumab Injection [Keytruda]|The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.
223951847|NCT05033756|DRUG|Olaparib Oral Tablet [Lynparza]|All patients will receive olaparib treatment as an addition to pembrolizumab. The dose of olaparib used in this study is 300 mg twice daily (total daily dose of 600 mg) which is the currently approved dose.
223951848|NCT00277277|BEHAVIORAL|Healthium|
223951849|NCT01531413|OTHER|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
223951850|NCT05659836|DEVICE|Abbott SCS Systems|Patients will be implanted with Abbott spinal cord stimulation (SCS) systems (both trial and permanently-implanted systems) and provided with wearable sensors, and software applications presented on a mobile device.
223951851|NCT00839085|DRUG|GSE|grape seed extract (100 mg/6h), PO
223951852|NCT00839085|DRUG|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
223951853|NCT02451072|DRUG|Placebo|Capsules containing mannitol looking identical to LSD per os
223951854|NCT02451072|DRUG|LSD|100µg per os, single dose
223538170|NCT02652221|DEVICE|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
223951855|NCT02451072|DRUG|Ketanserin|40mg per os, single dose looking identical to LSD per os
223951856|NCT01278914|BIOLOGICAL|Dendritic Cells (DC) prostate|
223951857|NCT00952640|DIETARY_SUPPLEMENT|vitamin A|high dose vitamin A, 200.000 IU
223951858|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
223723030|NCT05860647|DEVICE|Intermittent theta burst stimulation|MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
223723031|NCT06278779|DRUG|Esketamine group|"The recommended dosing for Spravato is:~Weeks 1-4:~Starting Day 1 dose:~\< 65 years: 56 mg~≥ 65 years: 28 mg~Subsequent doses:~28 mg (≥ 65 years), 56 mg or 84 mg twice weekly~Weeks 5-8:~28 mg (≥ 65 years), 56 mg or 84 mg once weekly~From Week 9:~28 mg (≥ 65 years), 56 mg or 84 mg every 2 weeks or once weekly"
223723032|NCT06278779|DRUG|Racemic ketamine|"Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted as needed using an ascending dose titration schedule:~1. 0.5 mg/kg~2. 0.6 mg/kg~3. 0.75 mg/kg~4. 0.9 mg/kg~5. Further increments by 0.1-0.2 mg/kg, up to max 1.5 mg/kg"
223723033|NCT05288062|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspirate/biopsy
223723034|NCT05288062|DRUG|Dexamethasone|Given orally
223723035|NCT05288062|DRUG|Lenalidomide|Given orally
223538171|NCT04161664|DRUG|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
223723036|NCT05288062|DRUG|Pomalidomide|Given orally
223723037|NCT06384209|DRUG|Fluoxetine|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 40mg Fluoxetine.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Fluoxetine will be increased to 60mg, reassured and encouraged that the goals they set can be achieved.
223723038|NCT06384209|DRUG|Sertraline Pill|The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 50mg Sertraline for all breastfeeding women instead of Fluoxetine. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 100mg Sertraline if breastfeeding.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study visit, Sertraline will be increased to 150mg.
223723039|NCT06384209|BEHAVIORAL|Friendship Bench Intervention- Problem Solving Therapy|The Friendship Bench Problem-solving therapy is an evidence-based intervention for depression delivered by Lay Health Workers according to an established manual. Patients are encouraged to come up with a list of their problems, to select one problem they want to tackle, brainstorm for solutions, identify the best solution, and develop an action plan to implement it until the next session. Each session consists of four stages, namely kuvhura pfungwa (opening the mind), kusimudzira (uplifting), kusimbisa (strengthening) and kusimbisisa (re-strengthening). The LHW helps patients to recognize potentially dysfunctional problem-solving and develop a realistic plan for the successful resolution of the prioritized problem. Participants are reassured and encouraged that the goals they set can be achieved. The sessions will be delivered approximately one week apart
223951859|NCT00884026|DEVICE|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
223951860|NCT04943640|OTHER|kinesio taping|Kinesio tape was developed by Kenzo Kase in the 1970s. It is an elastic tape, and its adhesive face is sinusoidal wavy. This feature has been shown to increase daily living activities and functions, as it supports the tissue while also allowing movement \[12\]. Kinesio tape lifts the skin and subcutaneous soft tissues of the fascia, which are painful and inflamed regions upon contractions seen in the tissue after tense adhesion to the skin. Therefore, it has been reported to reduce oedema and inflammation by creating more space and providing blood and lymphatic fluid flow.
223951861|NCT04943640|OTHER|rigid taping|The tape material used in rigid (athletic) tape application is hard. It is used to position and unite the soft tissue, to protect the tissue from impact and to prevent local swelling.There are studies in the literature supporting the sensorimotor and proprioceptive sensation-enhancing effect of the athletic band, which provides a very good sensory input through the skin.
223951862|NCT04943640|OTHER|placebo taping|Placebo taping was applied to the patients in this group, using betafix, an elastic fixation band, as the material. The patient was told that taping would be applied. A straight line betafix was applied to the non-painful scapular inferior level of the spine on the right and left sides of the standing patient.
223951863|NCT01277679|PROCEDURE|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
223951864|NCT04898582|OTHER|Mineral 89 Probiotic Fractions|The subjects applied the product M89 Probiotic Fractions on half a face, twice a day, in the morning and in the evening, for 30 days. They put two drops of the product in the palm of their hand and gently massage with their fingertips on half face. The face skin had to be cleaned and dried before the application of the product. The subjects used their standard skin care product on the side of the face not treated with M89 Probiotic Fractions
224104316|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
224104317|NCT00402350|DRUG|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
223538172|NCT01877304|DEVICE|AKITA|
223538173|NCT00003816|BIOLOGICAL|anti-thymocyte globulin|Given IV
223538174|NCT00003816|DRUG|busulfan|Given IV
223538175|NCT00003816|DRUG|carboplatin|Given IV
223538176|NCT00003816|DRUG|cyclophosphamide|Given IV
223538177|NCT00003816|DRUG|etoposide|Given IV
223538178|NCT00003816|DRUG|fludarabine phosphate|Given IV
223538179|NCT00003816|DRUG|melphalan|Given IV
223538180|NCT00003816|DRUG|thiotepa|Given IV
223538181|NCT00003816|RADIATION|total-body irradiation|Given twice daily for 3 days
224104318|NCT02659345|BEHAVIORAL|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
224104319|NCT02659345|BEHAVIORAL|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
224104320|NCT04456322|DRUG|RT plus Nimotuzumab|Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
224104321|NCT04456322|DRUG|RT plus Cisplatin|concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )
224104322|NCT05306678|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
224104323|NCT05306678|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
224288681|NCT03923699|DEVICE|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
224288682|NCT04031612|DRUG|Neoadjuvant therapy|Neoadjuvant therapy
224288683|NCT04107155|DIETARY_SUPPLEMENT|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
223538182|NCT00875914|PROCEDURE|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
223538183|NCT06068517|DEVICE|Closed incision negative pressure wound therapy|After the completion of abdominal surgery and standardised skin closure with staples, ciNPWT will be applied, using a commercially available device.
223538184|NCT06068517|DEVICE|Standard dressing|After the completion of abdominal surgery and standardised skin closure with staples, standard dressings will be applied.
223538185|NCT00312286|DRUG|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
223538186|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
223538187|NCT00312286|DRUG|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
223538188|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
223538189|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
223538190|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
223538191|NCT00312286|DRUG|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
223538192|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
223538193|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
223538194|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
223538195|NCT00312286|DRUG|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
223538196|NCT01404247|OTHER|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
223538197|NCT01404247|PROCEDURE|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
223538198|NCT00558636|DRUG|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), \[400 mg, (2 tablets x 200 mg each) orally, twice daily\] on Study Days 2-19 and paclitaxel (175 mg/m\^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
223538199|NCT00558636|DRUG|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m\^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
224288684|NCT04107155|DIETARY_SUPPLEMENT|Placebo|Placebo
224288685|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
224288686|NCT04107155|OTHER|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
224288687|NCT01276717|DRUG|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
224288688|NCT01276717|DRUG|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
224288689|NCT00209846|DRUG|Gaboxadol|
224288690|NCT06414239|DEVICE|Use of a VR mask|Virtual reality mask
224288691|NCT06414239|OTHER|Standard of care|Without any premedication or anesthesia
224288692|NCT05378919|RADIATION|Radiotherapy 50 Gy|Radiotherapy 50 Gy 5 radiations per week of 2 Gy for 5 weeks
224288693|NCT05378919|DRUG|Fluorouracil/folic acid|Fluorouracil 400 mg/m² D1-4 and folic acid 20mg/m2 D1-4 the first and fifth weeks of radiotherapy
223538200|NCT02874729|PROCEDURE|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
223538201|NCT02874729|PROCEDURE|Urine collection|Urine will be collected in appropriate sterile holders provided.
223538202|NCT02874729|PROCEDURE|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
223538203|NCT02874729|PROCEDURE|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
223538204|NCT00374114|PROCEDURE|cervical conization|
224288694|NCT05378919|DRUG|Chemotherapy in regimen with Oxaliplatin, fluorouracil, folinic acid (FOLFOX4)|oxaliplatin: 85 mg/m² in 2 hours at D1; folinic acid: 100 mg/m² simultaneously in 2 hours at D1 and D2 during the Oxaliplatin; bolus 5-fluorouracil (5-FU) 400mg/m² D1+D2; infusion 5-fluorouracil (5-FU): 600 mg/m² continuous infusion during 22hours at D1 and D2, every 14 days during 42 months (8 cycles).
223951865|NCT01123174|BEHAVIORAL|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
224288695|NCT05378919|RADIATION|Radiotherapy 50 Gy|"Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session; 25 fractions) + fluorouracil/leucovorin 400 mg/m² 1-4 day the first and fifth weeks of radiotherapy.~FOLOFX4 will be administrated for 8 cycles over a 16 week period. Patients will undergo re-staging within 6 weeks of their 8th cycle of FOLFOX. This will include MRI of the pelvis. If the reassessment reveals that there has been no disease progression compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection, the patient will proceed to definitive rectal cancer surgery within 8 weeks from the last chemotherapy dose. If the surgical oncologist's reassessment reveals that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous fluorouracil."
224288696|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
223538205|NCT00374114|PROCEDURE|ultrasonic surgical aspiration of the cervix|
223951866|NCT00000170|DRUG|Atropine|Atropine
223951867|NCT00000170|DEVICE|Eye Patch|Patching
223951868|NCT05953909|DRUG|Eribulin-Based Regimen|Eribulin Mesylate will be administered as a 1.4 mg/m\^2 intravenous (IV) injection over 2 to 5 minutes on day 1 and day 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared. Patients received up to two years of treatment.
223951869|NCT05953909|DRUG|nab-paclitaxel based regimen|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles.
223538206|NCT02133469|BIOLOGICAL|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
223538207|NCT02133469|BIOLOGICAL|Hib Vaccine|Single Dose
223538208|NCT06337448|DEVICE|Blue LED|The patient will remain naked, in a closed room, in the lithotomy position on a gynecological table, and he LED will be positioned in the direction of the patient's genitalia, keeping the internal and external vulvar lips open, so the LED can reach the largest possible region for therapeutic action.
223951870|NCT05953909|DRUG|Other Chemotherapy Regimen|"TX：Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m2 D1 Q3W)+Capecitabine 850-950mg/ m\^2, BID D1-14, Q3W.~GP:Gemcitabine 800-1000mg/ m\^2, D1,8 Q3W+Cisplatin 75mg/m\^2, D1-3, Q3W. AT:Epirubicin 75mg/ m 2, D1, Q3W+Docetaxel 75mg/ m\^2 D1 Q3W (or paclitaxel 175mg/ m\^2 D1 Q3W)~T:Docetaxel 75mg/ m ², D1 Q3W (or paclitaxel 80mg/ m ² QW)"
223538209|NCT04108273|BEHAVIORAL|Organizational Skills Training|OST targets three core organizational skills domains - Tracking Assignments, Managing Materials and Time Management - in a program consisting of sessions over 12 weeks, each training lasting about 1 hour, and corresponding 30-60 minute weekly review sessions with the parent and the child, 2-3 days following each training session.
223951871|NCT00869856|DRUG|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
223951872|NCT01275859|DRUG|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
223951873|NCT03541369|DRUG|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
223951874|NCT03204357|OTHER|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
223951875|NCT03204357|OTHER|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
223951876|NCT06377137|BEHAVIORAL|Small-sided soccer games groups (SSSG)|Physical exercise intervention
223951877|NCT06377137|BEHAVIORAL|Traditional soccer training groups (TSG)|Physical exercise intervention
223951878|NCT02583113|DEVICE|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
223951879|NCT04012970|OTHER|Manual spinal mobilisations|
223951880|NCT04724265|BIOLOGICAL|collection of sample of perilymphatic fluid during cochlear implantation|collection of sample of perilymphatic fluid during cochlear implantation and to analyse it with a CMV polymerised-chain-reaction to evaluate the involvement of CMV in hearing loss.
224288697|NCT03822221|OTHER|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
224288698|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
224288699|NCT03822221|OTHER|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
223538210|NCT05261659|BEHAVIORAL|Exposure Therapy and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound is associated with a waking experience (i.e., positive feedback in this study) and strengthening it during REM sleep, the investigators aim to accelerate the remission of social anxiety disorder.
224288700|NCT03863483|DRUG|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
224288701|NCT03863483|DRUG|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m\^2) will be administered intravenously on Day 1 of each 21-day cycle.
223538211|NCT05261659|BEHAVIORAL|Exposure Therapy|These patients will receive the classic treatment of Exposure Therapy (ET) for social anxiety disorder without any association with a sound.
223538212|NCT04357899|DRUG|thrombolysis therapy|
223538213|NCT04357899|PROCEDURE|endovascular therapy|
224288702|NCT03863483|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
224288703|NCT03863483|DRUG|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
224288704|NCT04761705|DRUG|JV-GL1|Experimental Treatment
224288705|NCT04761705|DRUG|Latanoprost 0.005% Ophthalmic Solution|Active Control
223538214|NCT04357899|PROCEDURE|decompressive surgery|
223538215|NCT04357899|DIAGNOSTIC_TEST|multimodal imaging in acute ischemic stroke|
223538216|NCT04357899|PROCEDURE|transfer of acute stroke patients to tertiary stroke centers|
223538217|NCT04357899|DRUG|initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention|
223538218|NCT03830879|OTHER|No intervention|This cohort study have any no intervention.
224288706|NCT03236142|PROCEDURE|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
224288707|NCT03236142|PROCEDURE|Standard Duodenal Switch Operation|
224288708|NCT01946776|DEVICE|implantable heart rate monitor|Implantation of Reveal XT
224288709|NCT01764295|DRUG|DWJ1276|
223951881|NCT04789174|DRUG|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
223951882|NCT04789174|DRUG|Placebo|Placebo
224288710|NCT01764295|DRUG|Olmesartan|
224288711|NCT01764295|DRUG|Rosuvastatin|
224288712|NCT01764295|DRUG|Placebo|
224288713|NCT01746264|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
224288714|NCT03566264|OTHER|Non-Interventional|Non-Interventional
224288715|NCT04841018|DRUG|High dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.5mg/kg of intravenous dexamethasone
224288716|NCT04841018|DRUG|Low dose dexamethasone|After caudal block with 1.2ml/kg of 0.15% ropivacaine, the patient receives 0.15mg/kg of intravenous dexamethasone
224288717|NCT04056871|DIAGNOSTIC_TEST|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
224288718|NCT02467608|DRUG|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
224288719|NCT02467608|DRUG|HRZE|the same as experimental group,without the excipient of HUEXC030 only
224288720|NCT06406660|OTHER|Chemotherapy and targeted-therapy guided by organoid drug sensitivity test|This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
223951883|NCT00090415|BEHAVIORAL|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
223951884|NCT04886674|DIETARY_SUPPLEMENT|bovine colostrum|The neonates will receive the colostrum in a dose of 2 g/dose for the 1000-1500 g stratum and 1.2 g/dose for \< 1000 g stratum, four times a day until discharge or death or day 21 of life, whichever is earlier.
224288721|NCT00476632|BEHAVIORAL|Questionnaire|50 Minute Interview
223951885|NCT06041438|DRUG|BI 1584862|BI 1584862
223951886|NCT06041438|DRUG|itraconazole|itraconazole
223951887|NCT05244967|OTHER|vaginal swab|self-sampling, vaginal swab
223951888|NCT06459128|DEVICE|Limbic Care|"Limbic Care is an AI-enabled smartphone application that delivers cognitive behavioral therapy (CBT) interventions and psychoeducation to users via an interactive, conversational interface using AI. Participants can choose from three courses (sleep, worry, and low mood) that sets the type of content they will see in the app. For each course, different interventions and psychoeducation material will appear in the to do list section of the app on a fixed schedule. The app also allows users to engage in open-ended conversation with the AI, which serves as an non-interventional, empathetic listener."
224288722|NCT05690087|DRUG|Lidocaine|intravenous lidocaine 2% bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively until desufflation
224288723|NCT05690087|DRUG|sodium chloride 0.9% solution|intravenous sodium chloride 0.9% solution volume matched bolus and infusion.
224288724|NCT01833533|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
224288725|NCT01833533|DRUG|Ribavirin|Capsule
223723040|NCT06459245|BEHAVIORAL|Resistance training|Bend the dumbbell, holding one dumbbell in each hand, on the side of the body, bend the arm to lift the dumbbell, front wall and upper arm as close as possible, pause for a moment, and then slowly lower the dumbbell until both arms are completely straight The second section of the dumbbell side flat, straight back, feet standing, arms perpendicular to the side of the body, hands grasp the dumbbell, to the side above the shoulder level, elbow slightly bent, and then put back in place The third section of the dumbbell rowing, feet stand straight, hold the dumbbell, the arm as far back as possible, can feel the upper arm and the waist back is stretched, and then straight back into the preparatory position Section 4: Lift the dumbbell flat in front of you, with your feet open, hold the dumbbell with both hands, extend your arms naturally in front of you, lift the dumbbell to the elbow above shoulder height, stay for 1-2 seconds.
223723041|NCT00390065|DRUG|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
223723042|NCT04755569|DEVICE|ODOCOR II CCM LEADS|ODOCOR II CCM LEADS Implantation
223723043|NCT00356473|DRUG|Atorvastatin|
223951889|NCT06459128|DEVICE|Digital Workbook|The digital workbook in PDF format will be provided to participants via the Internet. Participants can choose from three workbooks that each focus on a different topic: sleep, worry, and low mood. Each workbook contains psychoeducation material and CBT intervention worksheets, consisting of text, images, and response boxes to write in (if printed out).
223951890|NCT00003259|DRUG|vinorelbine tartrate|
223951891|NCT04828109|DEVICE|Virtual Reality|Use of any virtual reality experiences available
223951892|NCT04828109|DEVICE|Fitbit|Use of a Fitbit wearable activity device to track daily step goals.
223951893|NCT03791190|OTHER|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
224288726|NCT01833533|DRUG|Placebo for Ribavirin|Capsule
223538219|NCT03929692|BEHAVIORAL|Multi-layer health promotion program|
223951894|NCT03791190|OTHER|No-anticoagulation|Patients accepted CRRT without anticoagulant.
223538220|NCT03929692|OTHER|Standard health education|
224288727|NCT00704093|DEVICE|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
224288728|NCT02710097|DRUG|Active inhaled cannabis|"\~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
224288729|NCT02710097|DRUG|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
224288730|NCT02710097|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
224288731|NCT02710097|DRUG|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
223723044|NCT04578431|DIETARY_SUPPLEMENT|Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)|The intervention is found in light products ingested by millions of people on a daily basis worldwide
223951895|NCT05603949|DEVICE|3D deep learning neural network system|With the consent of the patient, we will assist in the production of images of 3D defect blocks for free (3D deep learning neural network system (3D DNN) system process planning), complete the repair and reconstruction under the clinical routine surgery, and track the repair results after surgery. meet medical needs.
223951896|NCT04214457|PROCEDURE|Biopsy and peripheral blood collection|"After obtaining informed consent, the samples (tumor tissue and peripheral blood) will be collected at the time of surgery, which the patient had already planned by medical indication according to the usual clinical practice. Part of the sample will be sent to histopathology for gold standard diagnosis while the rest of the sample will be sent to Igenomix for molecular analysis.~If samples are available from patients who underwent surgery prior to the study, after they sign the Informed Consent, the samples will be sent to Igenomix for molecular analysis and the results obtained by histopathology will be collected from the patient's medical record."
224288732|NCT04124666|BIOLOGICAL|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
224288733|NCT03192241|OTHER|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
224288734|NCT03192241|OTHER|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
223538221|NCT05173090|DRUG|Ropivacaïne 0,5% for appendectomy or cholecystectomy surgery|Visual analog scale 15 min after arrival in the recovery room, then H+4, H+6, H+12, H+24 and one week after the operation
223538222|NCT01196195|DRUG|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
223538223|NCT01196195|DRUG|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
223538224|NCT03715790|BEHAVIORAL|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
224288735|NCT05792124|PROCEDURE|Erector spina area block|After anesthesia and surgical intervention, bilateral ESP passage will be performed with ultrasonography from the T10 level 3 cm lateral to the midline. After cleaning the area with povidone iodine before the block, T10 transverse output will be determined using a linear ultrasound probe. Local anesthetic will be applied to the erector spina with the use of the needle used for peripheral block procedures and transverse access. With the serum treatment from the local anesthesia application, the location of the needle will be correct with the hydrodissection method. After the location of the needle is confirmed, a mixture containing 20 ml of LA and serum will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA is bupivacaine 0.5%, after 20 ml serum content.
223538225|NCT03715790|BEHAVIORAL|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
224288736|NCT05792124|PROCEDURE|Retrolaminar block|The patient is in the prone position and the high-frequency linear ultrasound transducer is in parasagittal orientation, but the entry point is determined more medial than the ESP block. The needle entry point is 1-1.5 cm lateral to the targeted spinos process. The echogenic needle is advanced until it contacts the lamina in the craniocaudal plane and 0.5-1 for control. By giving cc 0.9 nacl solution, it is observed that the fluid is distributed between the erector spina muscle and the lamina. After the location of the needle is confirmed, a mixture of 20 ml of LA and saline will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA will consist of bupivacaine 0.5% and 20 ml physiological saline.
224288737|NCT02844517|DEVICE|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
223538226|NCT02007629|DRUG|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
223723045|NCT04696315|DIAGNOSTIC_TEST|Multiple features extraction|"In the present study, the gold standard of preclinical AD is amyloid PET. SCD with positive amyloid is the target population for early AD intervention. The investigators aim to extract the diagnostic features from multiple parameter MRI, genetic, blood and clinical data using Max-Relevance and Min-Redundancy (mRMR) algorithm. Then, based on support vector machine (SVM), random forest (RF) and multi-kernel learning (MKL) classification methods, the investigators will construct predicted diagnostic model of preclinical AD."
223723046|NCT06498401|DIETARY_SUPPLEMENT|gut microbiota-targeted dietary intervention|The dietary intervention targeted at gut microbiota. Each participant's dietary habits,food preferences and economic level were taken into account. The dietary intervention was delivered by sending meals. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings. Meals will be delivered three times a week for a 12-week intervention period. Guided dietary follow-up was conducted through WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance every two weeks.
223951897|NCT06475248|OTHER|Placebo Technique|For the technique performed in the control group, the researcher will come into contact with the volunteers' chests. This contact will be maintained for the same period of time as the experimental group (6 minutes).
224104324|NCT00947154|DRUG|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
223951898|NCT06475248|OTHER|Stretching technique|"Stretching technique for the upper trapezius and sternocleidomastoid: the volunteer will be in supine position on the couch, the researcher will perform the technique from the contralateral side of the muscle to be treated, the hand will contact the ipsilateral shoulder to stabilize, meanwhile, with the other hand, contact the upper trapezius and perform a rhythmic pull in contralateral rotation. This technique is performed bilaterally."
223951899|NCT06475248|OTHER|Inhibition of the suboccipital|"Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions."
223951900|NCT04867382|BEHAVIORAL|Online training|This intervention consisted of two different interactive online trainings delivered through an online learning platform at HealthPartners.
223951901|NCT02548299|OTHER|Nutrition Education|Nutrition classes will be led by a registered dietician.
223951902|NCT02548299|OTHER|Cooking Lecture|
223951903|NCT02548299|OTHER|Cooking Demo|
223951904|NCT02548299|OTHER|Hands-on Cooking|
223951905|NCT02548299|OTHER|e-Coaching|
223951906|NCT03681132|OTHER|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
223951907|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First deflation of 3cc of air occurred 1 hour after inflation. Deflations occurred every 15 minutes unless bleeding was noted. If bleeding was noted, balloon was reinflated (1-3cc of air) until bleeding stopped. Next deflation occurred 30 minutes later, at which point regular 15 minutes deflations occurred if no bleeding noted. Band was removed 1 hour after final deflation."
224104325|NCT02260011|DRUG|Ipratropium bromide HFA-134a inhalation aerosol|
224104326|NCT02260011|DRUG|Atrovent® CFC inhalation aerosol|
224104327|NCT02260011|DRUG|Placebo|
224104328|NCT04186208|DRUG|NOVOCART 3D|Autologous Chondrocyte Implantation
224104329|NCT04069767|PROCEDURE|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~1. Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~2. Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~3. Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~4. Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~5. Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~6. Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
224288738|NCT04680234|PROCEDURE|DMEP kit|Superficial Cryotherapy using dimethyl ether and propane (DMEP) at -57C
223538227|NCT04161209|DRUG|Citalopram|Single dose administration of citalopram (20mg)
223538228|NCT04161209|OTHER|Placebo|Lactose placebo tablet
223723047|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
224104330|NCT04069767|PROCEDURE|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
224104331|NCT04363307|DEVICE|AF Ablation|Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
224288739|NCT04680234|DEVICE|Dermapen|Under aseptic precautions, the dermapen was moved on the alopecic patches diagonally, vertically and horizontally 4 to 5 times in each direction Pin point bleeding was taken as an end point
224288740|NCT02377635|DIETARY_SUPPLEMENT|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
223723048|NCT03785808|BEHAVIORAL|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
223723049|NCT03785808|BEHAVIORAL|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
223723050|NCT00211809|BEHAVIORAL|Cognitive Behavioral Therapy|standard psychiatric evaluation
223951908|NCT01326455|DEVICE|Terumo TR wristband|"A transparent unilateral compression device which is secured to the wrist via strap with velcro. The portion with the deflated 18cc balloon is placed directly over the puncture site. This balloon is inflated immediately after the catheter is removed and the balloon is inflated until bleeding visibly stops, with generally 9-18cc of air.~First balloon deflation of 3cc of air occurred 15 minutes after initial inflation. Deflations occurred every 15 minutes unless bleeding was noted. If active bleeding was noted, the balloon was re-inflated (1-3cc) until bleeding stopped. The next deflation occurred 15 minutes later. If no bleeding occurred, deflations continued every 15 minutes until the balloon was completely deflated. The band was removed 15 minutes after final deflation."
223951909|NCT01326455|DEVICE|Clo-Sur-P.A.D.|"A hydrophilic dressing has a high affinity for water, and absorbs and controls body fluid. The positively charged 4x4 centimetre pad reacts with the neuraminic acid residue on red blood cells causing agglutination of the cells. The Clo-Sur P.A.D. works outside of the clotting cascade.~The radial catheter was removed and occlusive pressure applied on the radial artery. Pressure was released just until bleeding noted \& the pad was applied with approximately 5 minutes of manual compression. The pad was assessed every 15 minutes for 90 minutes to ensure hemostasis. The pad was removed on post-CATH day 1."
223951910|NCT05778253|DIAGNOSTIC_TEST|WES and ctDNA detection|WES and ctDNA detection
223951911|NCT04140643|DEVICE|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
223951912|NCT04140643|BEHAVIORAL|Oral hygiene instructions|Oral Hygiene instructions
223951913|NCT04295382|DEVICE|Software Application|A software application targeting suicidal ideation via interactive exercises.
223951914|NCT03524131|OTHER|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
223951915|NCT03524131|OTHER|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
223951916|NCT03524131|OTHER|current national leaflet|4-sided leaflet
223951917|NCT03927651|DRUG|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
223951918|NCT00059384|BEHAVIORAL|Concentration-controlled therapy|
223951919|NCT03489356|BEHAVIORAL|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
223951920|NCT04728282|PROCEDURE|RTSA with subscapularis repair|Lateralized reverse total shoulder arthroplasty with repair of subscapularis
223951921|NCT04728282|PROCEDURE|RTSA without subscapularis repair|Lateralized reverse total shoulder arthroplasty without repair of subscapularis
223951922|NCT04535440|OTHER|No intervention|No intervention
223951923|NCT01681511|DEVICE|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
224104332|NCT04363307|DEVICE|MRI|Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
224104333|NCT04291157|OTHER|CVD risk estimation incorporating the PRS and guideline based preventive interventions.|Total CVD risk estimation using SCORE plus PRS and European Society of Cardiology (ESC) CVD prevention guideline based interventions.
224104334|NCT04291157|OTHER|Standard GP care|Usual GP care (opportunistic CVD prevention)
224104335|NCT02420886|OTHER|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
223723051|NCT00211809|DRUG|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
223951924|NCT01681511|DEVICE|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®\* silver alloy coating and BARD® hydrogel.
223951925|NCT04725032|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the propofol-based TIVA arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
223951926|NCT04725032|DRUG|Sevoflurane|Balanced general anesthesia with sevoflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study. In order to record the VEPs, standard spiral electrodes or subcutaneous electrodes will be inserted subcutaneously around the visual area and the Nicolet Viking IV System will be used to monitor VEP during surgery.
223951927|NCT01156675|DEVICE|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
223951928|NCT01156675|DEVICE|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
223951929|NCT00390845|DRUG|SB681323|15 milligrams (mg)/day
223951930|NCT00390845|DRUG|Placebo|
223951931|NCT04733417|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
223951932|NCT04733417|DRUG|famitinib|Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3.
223951933|NCT00278499|BEHAVIORAL|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
223951934|NCT00278499|BEHAVIORAL|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
223951935|NCT01463475|PROCEDURE|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
223951936|NCT03473041|PROCEDURE|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
223951937|NCT03473041|PROCEDURE|TVT-O|midurethral transobturator vaginal tape
223951938|NCT04074252|DEVICE|Lofstrand Crutches|Device: Set of Lofstrand Crutches
223951939|NCT04074252|DEVICE|Axillary Crutches|Device: Set of Axillary Crutches
223951940|NCT01319344|DRUG|Eplerenone|25 mg o.d. per os
223951941|NCT04084262|DEVICE|Intramedullary Nail|Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
223951942|NCT04718285|DRUG|Montelukast Oral Tablet|3x10 mg oral montelukast first day and other 13 days 1 x 10 mg montelukast
223951943|NCT04718285|DRUG|Montelukast plus Favicovir (Favipiravir)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5 and 3x10 mg oral montelukast first day and rest of 13 days 1 x 10mg, concurrently.
223951944|NCT04718285|DRUG|Favicovir (Standard Treatment)|200 mg oral favicovir for 5 days in a regimen of 2x1600 mg (oral) loading dose on day-1 (eight tablets in the morning and eight tablets in the evening) followed by 2x600 mg maintenance dose (three tablets in the morning and three tablets in the evening) on day-2 to day-5.
223951945|NCT01182532|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
224288741|NCT02377635|DIETARY_SUPPLEMENT|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
224288742|NCT04952077|DEVICE|MRI|Magnetic Resonance Imaging (MRI)
224288743|NCT03433144|DRUG|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
224288744|NCT03433144|OTHER|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
224288745|NCT04628520|PROCEDURE|Free gingival graft|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive a free gingival graft (FGG) harvested from the palate, that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
224288746|NCT04628520|PROCEDURE|Collagen matrix|After administration of local anesthesia, an intrasulcular incision will be made at the muco-gingival line and a partial thickness flap will be raised and sutured at the base of the newly created vestibule with resorbable mattress sutures. After the completion of the apically positioned flap, patients will receive either a collagen matrix (CM), that will be fixed with interrupted resorbable sutures to the recipient periosteal bed, free of any muscle attachment.
224288747|NCT04628520|PROCEDURE|Maintenance|Oral Hygiene Instruction, periodontal debridment and Supportive Periodontal Therapy
224288748|NCT05015881|DIETARY_SUPPLEMENT|"Ketone Ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate"|Drink a single dose of ketone ester 1.9 kcal/kg
224288749|NCT05015881|DRUG|FDG|Echocardiogram, and 2-Deoxy-2-\[18F\] fluoro-D-glucose (FDG) PET scan.
224288750|NCT03903926|BIOLOGICAL|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
223951946|NCT01182532|DRUG|TCM Syndrome Differentiation and Treatment|"1. Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~   Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~   Dosage: Adjusting by age and weight of patients. Decoction.~2. Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
223951947|NCT01182532|OTHER|Western therapy plus TCM treatment|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
224104336|NCT04621747|OTHER|Battery of neurophysiological explorations|"Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness."
224104337|NCT00288340|DEVICE|functional magnetic resonance imaging|
224104338|NCT02957708|OTHER|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
224104339|NCT02957708|OTHER|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
224104340|NCT03684083|PROCEDURE|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
224104341|NCT03794986|BEHAVIORAL|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
223951948|NCT05561491|BIOLOGICAL|ONCOS-102|Oncolytic virus
223951949|NCT05561491|BIOLOGICAL|Balstilimab|Anti PD-1
223951950|NCT05985200|DRUG|BI 3032950|BI 3032950
223951951|NCT05985200|DRUG|Placebo matching BI 3032950|Placebo matching BI 3032950
223951952|NCT03409159|DEVICE|LAAC|Left atrial appendage closure
223951953|NCT01079949|DRUG|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
224104342|NCT03794986|BEHAVIORAL|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
224104343|NCT05309083|BEHAVIORAL|Mindfulness Based Walking Therapy (MBWT)|MBWT will be a modified form of the typical Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking meditations and is acceptable for people with Parkinson disease and freezing of gait.
224104344|NCT06067477|DIETARY_SUPPLEMENT|Vitamin D Supplement|Vitamin D Supplement
223723052|NCT03740945|DRUG|Placebo|Daily administration of one placebo vaginal ovule at bedtime
224104345|NCT01050777|DRUG|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
224104346|NCT01050777|DRUG|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
224104347|NCT01050777|DRUG|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
224288751|NCT05850988|OTHER|%80 Oxygen concentration|Patients will be administered %80 Oxygen for 3 minutes during preoxygenation.
224288752|NCT05850988|OTHER|%100 Oxygen concentration|Patients will be administered %100 Oxygen for 3 minutes during preoxygenation.
224288753|NCT00259168|DRUG|Nateglinide|
223723053|NCT03740945|DRUG|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
223951954|NCT01079949|DRUG|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
223951955|NCT01079949|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
223723054|NCT06076265|PROCEDURE|Radical Gastric Cancer Surgery|Laparoscopic (robotic) radical surgery for gastric cancer
223951956|NCT01079949|DRUG|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (\>=) 14 mm, and maintained until at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
223951957|NCT02060084|DRUG|a control group|the same dose of luke warm water
223951958|NCT02060084|DRUG|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live\>0.5\*107CFU), twice per day, for 2 weeks
223951959|NCT01529632|DRUG|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
223951960|NCT01529632|DRUG|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
223951961|NCT01529632|DRUG|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
223951962|NCT01529632|DRUG|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
223951963|NCT01267552|PROCEDURE|Non drains will be placed during operation|Non drains will be placed during operation
224104348|NCT01050777|DRUG|Placebo|Placebo
224104349|NCT02424487|PROCEDURE|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
224104350|NCT01165229|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
223723055|NCT00496470|DRUG|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
224104351|NCT01165229|BIOLOGICAL|Placebo|Intramuscular injection.
224104352|NCT02951923|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
224104353|NCT02951923|DIETARY_SUPPLEMENT|Soy|
224104354|NCT01451333|DRUG|Efavirenz|600mg qd; 3 x 200mg qd
224104355|NCT01451333|DRUG|Efavirenz|400mg qd; 2 x 200mg
224104356|NCT01277575|DEVICE|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
224104357|NCT01277575|DEVICE|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
223723056|NCT00496470|DRUG|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
223723057|NCT06039930|BEHAVIORAL|Tele PROTECT|Tele-PROTECT is a behavioral intervention delivered virtually over nine 45-minute sessions for depressed elder abuse (EA) victims. It is designed to work in synergy with EA resolution services that provide safety planning, support services, and links to legal services.
223951964|NCT01267552|PROCEDURE|Closed suction drainage|Closed suction drainage will be placed during operation
223951965|NCT01653392|BIOLOGICAL|Observational Intervention|This is an observational study, therefore no interventions are specified.
223951966|NCT03674515|DEVICE|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
224104358|NCT01720251|DRUG|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
224104359|NCT01720251|DRUG|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
224104360|NCT01720251|DRUG|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
224288754|NCT00413686|DRUG|AZD7762|intravenous infusion
224288755|NCT00413686|DRUG|Gemcitabine|weekly intravenous infusion
224288756|NCT03853018|DEVICE|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
224288757|NCT03853018|DEVICE|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
224288758|NCT04706962|DRUG|TH1902|Intravenous infusion
224288759|NCT06617637|OTHER|Aerobic Based Virtual Reality Exercise Training|"With Aerobic Based Virtual Reality Exercise Training, participants will perform aerobic exercise training with the Xbox Kinect 360 game Your Shape Fitness Evolved 2012. Your Shape Fitness Evolved 2012 is a game that requires basic coordination and is designed to improve the fitness levels of individuals. The game is used as an entertaining aerobic training tool that includes many aerobic activities such as boxing, yoga, dancing, etc. with adjustable difficulty levels."
224104361|NCT04510259|PROCEDURE|Selective Brachial plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1: 200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
224104362|NCT02277886|DRUG|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
224104363|NCT02277886|DRUG|esomeprazole|40mg/tablet, one tablet once before breakfast
224104364|NCT01530490|DRUG|Cabergoline and Hydroxyethyl Starch|0.5mg
224288760|NCT06617637|OTHER|Traditional Aerobic Exercise Training|Using a treadmill, participants will be put through an exercise training consisting of a 10-minute warm-up at 0 degree incline, a 20-30-minute (by increasing the walking time by 5 minutes at the end of the first four weeks and the beginning of the last four weeks) walking at 40-80% of the heart rate reserve (moderate-vigorous intensity) and a 10-minute cool-down period. Treadmill walking levels will be changed if necessary to ensure the targeted exercise intensity.
224295236|NCT05772806|DEVICE|Electrocardiogram|"The electrocardiogram will help to diagnose atrial fibrillation and the electronic devices (App Fibricheck and Smart bracelet/watch) will help to detect an arrhythmic rhythm.~The echocardiography will be used for detecting criteria of atrial cardiomyopathy.~MRI may help to detect silent strokes."
223723058|NCT06039930|BEHAVIORAL|Depression Education|DepEd is designed as an intervention delivered virtually over nine 45-minute sessions with active therapeutic ingredients (education, support, empathy). It is designed to be what a good clinician providing education would do with an individual with depression.
223723059|NCT05704062|PROCEDURE|Diffusion Weighted Imaging|Undergo DW-MRI
223723060|NCT05704062|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
223723061|NCT01370356|DRUG|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
223723062|NCT01370356|DRUG|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
223723063|NCT03748186|DRUG|STRO-002|intravenous antibody drug conjugate
223723064|NCT06088953|DIAGNOSTIC_TEST|VRB test|"V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation."
223723065|NCT06317181|DEVICE|Collection of elastography data|patients who are scheduled for an elastography for clinical reasons usually receive an ultrasound scan in which the b-mode images of the liver tissue are collected. In this study additional radiofrequency data is collected through a software access.
223723066|NCT06317181|DEVICE|Collection of ultrasonic raw data|Patients who are transferred to the ultrasound departement due to suspicious focal lesions receive an ultrasonic investigation including the acquisition of raw data and extracting a definitive diagnose from the following clinical routine investigation, depending on the standards of the participating center
223723067|NCT00131118|DRUG|Zoledronic Acid|
223723068|NCT02837575|BIOLOGICAL|VCL-HB01|Investigational Product
223723069|NCT02837575|OTHER|Phosphate-buffered saline|Placebo
223723070|NCT05012488|OTHER|Comparison of gait and foot pressure|The spatio temporal gait parameters of the patients will be evaluated with Zebris (Zebris Medical Limited , Germany) FDM (Force Distribution Measurement ) treadmill system. The system has production of 3D motion analysis and force measurement technologies for biomechanics. When the treadmill is in static and dynamic condition, strong pressure distribution measurement will be taken.
223951967|NCT03674515|DEVICE|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
223951968|NCT05308589|DEVICE|CPPF|Continuous Postoperative Pericardial Flush
223951969|NCT06662630|DEVICE|High-Frequency Oscillatory Ventilation|Administer 10 minutes of high-frequency oscillatory ventilation in mechanically ventilated patients.
223951970|NCT05552924|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body.
223951971|NCT06203873|DEVICE|Biodegradable occluder|Patients assigned in this group will receive PFO occlusion with a biodegradable occluder.
223951972|NCT06203873|DEVICE|Metal occluder|Patients assigned in this group will receive metal occluder for PFO occlusion
223951973|NCT06452212|OTHER|No Intervention|No investigational drug will be administered to participants in this study.
223951974|NCT05184062|DRUG|600 mg AZD7442 IV|Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
223951975|NCT05184062|DRUG|600mg placebo IV|Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
223951976|NCT01558544|PROCEDURE|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
223951977|NCT04084522|DIETARY_SUPPLEMENT|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
223951978|NCT04084522|DIETARY_SUPPLEMENT|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
223951979|NCT04919395|DEVICE|Clip device for Nexplanon Removal|The clip device will be used to assist in the removal procedure to remove the Nexplanon implant from the subject.
223951980|NCT04919395|PROCEDURE|Standard of Care procedure|The participants Nexplanon will be removed per standard of care.
223951981|NCT04851197|OTHER|Flipped Learning Model|Students in the intervention group will be given training on testicular cancer and testicular self-examination in accordance with the Flipped Learning Model. The students in the control group will receive the same training with the traditional method. It was aimed to examine the effect of the training given with the Flipped Learning Model on the students' knowledge levels and health beliefs about testicular cancer and self-testicular examination.
223951982|NCT04865172|OTHER|Remote collection of passive and active data for 28 consecutive days|Passive sensor data: collected continuously for 28 days, from a multi-sensor wearable bracelet worn by each member of the dyad; Active questionnaire data: collected once a week during the four weeks of monitoring (and at the end of the 28 days for patient-caregiver dyads), from questionnaires filled by one partner of the dyad (for patient-caregiver dyads, this will be the caregiver) using a smartphone application.
224288761|NCT06494800|DIAGNOSTIC_TEST|True cut needle biobsy|The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.
224288762|NCT01039194|DRUG|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
224288763|NCT01039194|DRUG|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
223951983|NCT06597591|DEVICE|VR headset|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a VR Headset. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
223951984|NCT06597591|DEVICE|Tablet|8 sessions (2 times per week for 4 weeks) of 20 minutes playing the serious game with a tablet. The serious game is inspired by the GoNoGo task.The players' task is to throw objects in a basket matching the active rule. These objects can be of three different colors (red, yellow, and purple) with the presence or absence of stains on them. The objects' color is hidden until the player interacts with them. Example of rule: the active rule is to throw in the basket only the objects in red without stains, yellow with stains, and purple with stains. To earn points, the player must match the rule presented and throw the objects away if they do not match.
223951985|NCT06362291|PROCEDURE|MRI-AI guided cognitive prostate targeted biopsy|Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
223951986|NCT06362291|PROCEDURE|Routine cognitive prostate targeted biopsy|Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
223951987|NCT00598390|DRUG|[11C]MePPEP|
223951988|NCT02321137|PROCEDURE|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
223951989|NCT02321137|PROCEDURE|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
223951990|NCT03383848|DEVICE|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
224288764|NCT01039194|DRUG|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
224288765|NCT00733031|DRUG|AZD6918|liquid suspension, daily, oral dose
223951991|NCT06621771|OTHER|Music intervention|Participants will engage in a step-by-step piano training consisting in playing piano pieces designed to involve all 5 digits of the paretic hand and increasing in complexity. They will be using a Musical Instrument Digital Interface (MIDI) piano program called Synthesia to display musical pieces on a computer screen that is adapted for people with no music reading abilities and will be playing on a touch sensitive piano keyboard. The supervised session will also be complemented with a unsupervised home program consisting of piano sequence exercises comprising short excerpts of the same musical pieces practiced during the supervised sessions and they will receive a roll-up flexible piano
223951992|NCT06621771|OTHER|Occupational Therapy|Participants will receive conventional occupational therapy treatment (e.g., mobility, ADL, IALD, information session), excluding treatments focusing specifically on arm and hand motor recovery.The supervised session will also be complemented with an unsupervised home program consisting of assignments related to occupational therapy exercises and/or IALD/ADLs.
223951993|NCT07013227|OTHER|experimental group|Labor pain and comfort level will be measured by applying virtual reality glasses to the control group.
223951994|NCT04281017|DRUG|TIVA|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)
223951995|NCT04281017|DRUG|Balanced anesthesia|Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
223951996|NCT07013292|DRUG|SKYCLARYS (omaveloxolone)|"Skyclarys is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 and over. Opaque capsule with RTA 408 printed in white ink on the light green body and 50 printed in white ink on the blue cap. Capsules (size 0) measure 21.7 ± 0.3 mm in length and the outer diameter of the cap is 7.64 ± 0.06 mm. Omaveloxolone should be initiated and monitored by physicians experienced in treating patients with patients with Friedreich's ataxia. The recommended dose is 150 mg omaveloxolone (3 x 50 mg capsules) once daily."
224288766|NCT00733031|DRUG|gemcitabine|intravenous, doses are on an intermittent schedule
224288767|NCT00733031|DRUG|pemetrexed|intravenous, dose administered every 21-days
224288768|NCT00256776|DRUG|Velcade (Bortezomib)|
223951997|NCT07013240|DRUG|Botulinum toxin injection|"Intervention will be made immediately after surgery, still under general anesthesia, by the cardiac surgeon, after suture.~Each patient will receive (either in the lower part or the upper part of the scar according to randomization) 50 international units (IU) of type A botulinum toxin (Botox®, Allergan aesthetics) diluted in 1 mL of saline to enable injection of 5 IU at each point, every centimeter, at 1 cm of each scar side.~An equivalent volume of saline will be injected under the same modalities in the other part of the scar."
223951998|NCT07012889|DRUG|lidocaine infusion|The lidocaine group will receive initial intravenous bolus dose of 1.5mg/kg lidocaine over 10 min, followed by a continuous infusion of 1.5 mg/kg/h lidocaine until the end of surgery. The dose of lidocaine will be calculated according to ideal body weight. The placebo group will be administered normal saline at the same volume, infusion rate and timing.
224104365|NCT01530490|DRUG|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
224104366|NCT01243476|DRUG|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
224104367|NCT01243476|OTHER|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
224104368|NCT00881205|DRUG|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
224104369|NCT00881205|DRUG|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
224104370|NCT02569034|OTHER|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
224104371|NCT02569034|OTHER|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
224104372|NCT05742945|PROCEDURE|Immediate lymphatic reconstruction|Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
224288769|NCT00256776|DRUG|Thalidomide|
224104373|NCT03502135|DRUG|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
224288770|NCT00256776|DRUG|Dexamethasone|
224288771|NCT00911755|PROCEDURE|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
224288772|NCT00911755|PROCEDURE|Endotracheal Intubation|
224288773|NCT01555827|OTHER|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~* Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~* Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~* Wide-field colour and autofluorescence imaging (Optomap)~* Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~* Age, gender~* educational level~* smoking~* cardiovascular diseases, current medications~* scores at neuropsychological tests"
224288774|NCT03382249|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
224288775|NCT03382249|COMBINATION_PRODUCT|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
224288776|NCT04924374|DIETARY_SUPPLEMENT|Microbiota Transplant plus anti PD1 therapy|"Pooled fecal microbiota capsules of 1 donor selected based on their fecal abundance in Faecalibacterium prausnitzii, Bifidobacterium longum, Akkermansia muciniphila and Fusobacterium spp. after screening and metagenomic analysis of 10 donors with high-fiber diets (\>30g/day).~anti PD1 therapy every 2-3 weeks"
224288777|NCT04924374|DRUG|anti PD1 therapy|anti PD1 therapy every 2-3 weeks
224288778|NCT04966364|DEVICE|hypotension prediction index guided|patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension
224288779|NCT04966364|DEVICE|without hypotesion prediction index guided|patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
224288780|NCT01485484|DEVICE|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
224288781|NCT05797584|DRUG|Dobutamine|Dobutamine 5.0 - 10.0 mcg/Kg/min ev
224288782|NCT05797584|OTHER|Passive leg raising|Passive leg raising for acute volume load
224288783|NCT06390202|OTHER|no intervention|there is no intervention in this study
224288784|NCT00964288|DRUG|GSK1014802 low dose|oral tablet
224288785|NCT00964288|DRUG|Lidocaine|positive control
224104374|NCT02966457|DRUG|Colistimethate Sodium|Selective oral intestinal decolonization
224104375|NCT04543448|OTHER|Traditional Rehabilitation for multiple sclerosis|Traditional rehabilitation program include strengthening exercises for the muscles needed, balance and coordination exercises according to the individual's level, stretching for the lower limbs.
224104376|NCT04543448|OTHER|Cervical mobilization for multiple sclerosis|Cervical mobilization program include myofascial relaxation techniques and mobilization to cervical spine in addition to traditional program.
224288786|NCT00964288|DRUG|GSK1014802 high dose|oral tablet
223951999|NCT07012889|OTHER|Placebo|The placebo group will be administered normal saline 0.9% at the same volume, infusion rate and timing as lidocaine in the lidocaine group
223952000|NCT06683157|DIAGNOSTIC_TEST|not drug|"Patients presenting with symptomatic ICVT will be examined by CCUS for both legs. Inclusion/exclusion criteria will be checked. No anticoagulation therapy is given. Compression stockings at the calf length will be prescribed for 30 days.~CCUS will be repeated on day 5±2, day 10±2, and day 30±4. If the ICVT has propagated into the trifurcation area, the popliteal vein, or into more proximal veins therapy will be implemented according to current guidelines for proximal DVT. If no propagation to proximal veins has occurred anticoagulation will be withheld further on."
224288787|NCT00964288|DRUG|Placebo|To match GSK drug and positive control
224288788|NCT00514969|DRUG|Imatinib (STI571)|
224288789|NCT01017419|BEHAVIORAL|Counseling|Informational Counseling provided after hearing aid fitting
224288790|NCT04774341|DRUG|anticoagulation treatment|Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
224288791|NCT03494114|DRUG|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
224288792|NCT00251225|DRUG|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m\^2 administered IV
224288793|NCT00251225|DRUG|Docetaxel|60 mg/m\^2 administered IV on day 0
223952001|NCT03650166|OTHER|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
223538229|NCT02234726|BEHAVIORAL|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
224288794|NCT05511220|BEHAVIORAL|PRIMeR|Virtual PRIMeR intervention consists of coaching parents to use strategies derived from Social Routines (to boost positive affect) and Reciprocal Imitation Training (to boost toy play)
224288795|NCT05511220|BEHAVIORAL|PRT|Virtual PRT intervention consists of coaching parents to use key PRT strategies to enhance children's communication skills
224288796|NCT00003020|BIOLOGICAL|LMB-7 immunotoxin|
224288797|NCT00488930|OTHER|Observational|data collection ONLY
223538230|NCT00698828|DRUG|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
223538231|NCT00698828|DRUG|SUN11031 20 μg/kg|Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.
223952002|NCT03650166|OTHER|Personal BP monitor|Battery-powered BP monitor for personal use
223952003|NCT07013851|DRUG|Dostarlimab|"Patients will be treated in the neoadjuvant setting with dostarlima 500 mg (30') every 3 weeks for 4 cycles.All participants will undergo surgery within 6 weeks following the final dose of neoadjuvant dostarlimab. After surgery, adjuvant chemotherapy, including dostarlimab, will be administered as follows:~Stage II EC:~VBT/EBRT (completed within \>14 weeks after surgery) + Adjuvant dostarlimab 1000 mg Q6W x 9 cycles (54 weeks total).~Stage III EC:~1. Concurrent EBRT+cisplatin followed by carboplatin + paclitaxel OR~2. Sequential: EBRT followed by carboplatin + paclitaxel OR~3. Chemotherapy alone: carboplatin + paclitaxel~   * Adjuvant dostarlimab 500 mg Q3W x 4-6 cycles (in combination with chemotherapy) plus 1000 mg Q6W x 6-7 cycles (54 weeks total)."
223952004|NCT05931406|BEHAVIORAL|Control|A normal working day from of 12h
223538232|NCT00698828|DRUG|SUN11031 40 μg/kg|Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.
223538233|NCT00358111|DEVICE|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
223538234|NCT05983094|DRUG|Utidelone|Utidelone injection 30mg/m2, on days 1-5 of each cycle
223538235|NCT05983094|DRUG|Carboplatin|Carboplatin Area under curve(AUC)6, iv, was administered on day 1
223538236|NCT05983094|DRUG|Epirubicin|Epirubicin 75mg/m2 was administered on day 1
223952005|NCT05931406|BEHAVIORAL|Sit-and-stand desk|a working day during which the participants have to get up at least 5 min/hour
223952006|NCT05931406|BEHAVIORAL|Cycloergometer|a working day during which they can use a cycloergometer installed under the desk
223952007|NCT06696508|PROCEDURE|Insitu Spatulation with Pre-Dismembering Ureteropelvic Angle Suturing during laparoscopic pyeloplasty|"After proper dissection of the PUJ, the anterior wall of the renal pelvis was incised.~The incision continued downwards and laterally towards the PUJ and the lateral aspect of the ureter.~In cases where crossing vessels were present, the pelvis with the PUJ and the uppermost part of the ureter were properly dissected from these vessels. This gave a wide room for pulling the pelvis upwards and gentle retraction of the crossing vessels allowing incision of the anterior wall of the pelvis and starting the spatulation of the PUJ. Spatulation could then continue to the upper ureter behind the properly dissected and retracted vessels.~After complete spatulation and before dismembering the PUJ, we made benefit of splinting the ureter in place; a Maryland grasper opened the lumen of the ureter and the first stitch was precisely placed from outside inwards at the proper angle of the ureteric spatulation using 5/0 Vicryl sutures.~The posterior wall of the PUJ and the pelvis was then dismembered"
223952008|NCT06696508|PROCEDURE|Classic Laparoscopic Dismembered Pyeloplasty|the PUJ was dismembered after proper dissection, the lateral aspect of the ureter was spatulated and the first stich was also placed in the spatulation angle from outside inwards. All these steps were done after the discontinuation of the ureter and the pelvis, losing the benefit of ureteric splinting and orientation
223952009|NCT06698380|OTHER|Conventional Physical Therapy|The subjects of the control group received the CPT based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements
224104377|NCT01776125|OTHER|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
224104378|NCT04071665|PROCEDURE|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
224104379|NCT01870544|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
224104380|NCT01870544|DIETARY_SUPPLEMENT|Placebo|placebo will be administered daily for 44 days
224104381|NCT03219125|DEVICE|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
223723071|NCT05385952|DEVICE|GATT-Patch (currently named ETHIZIA)|"GATT-Patch (currently named ETHIZIA) is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
223723072|NCT05385952|DRUG|TachoSil|"TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge.~TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical."
224104382|NCT03219125|DEVICE|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
224104383|NCT02095561|OTHER|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
224104384|NCT03702257|PROCEDURE|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
224104385|NCT05011461|OTHER|Almond Oil|Almond Oil Pressed Cold
224104386|NCT05966701|DRUG|SSGJ-613|SSGJ-613 subcutaneous injection.
224104387|NCT05966701|DRUG|Placebo|Placebo subcutaneous injection.
224104388|NCT02278978|DRUG|BIBF1120|BIBF1120 200 mg two times per day orally
224104389|NCT03069638|DRUG|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
224104390|NCT03069638|DRUG|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
224104391|NCT02302911|BEHAVIORAL|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
224104392|NCT02302911|BEHAVIORAL|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
224104393|NCT02302911|OTHER|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
224104394|NCT03903328|OTHER|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
224104395|NCT06361459|BEHAVIORAL|Stop smoking|Sine fuma program is offered. nicotine is checked in urine
224104396|NCT00319163|DRUG|levonorgestrel/ethinyl estradiol|
224104397|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
224104398|NCT06270225|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|Subjects will receive one s.c. injection of SSGJ-613 on Day 1.
224104399|NCT06270225|DRUG|Colchicine 0.5 mg|Subjects will receive 0.5mg/d Colchicine for 12 weeks.
224104400|NCT03380858|DEVICE|colectomy|colectomy resection
224104401|NCT02988804|DEVICE|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
224104402|NCT02988804|DEVICE|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
224104403|NCT01561638|PROCEDURE|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
224104404|NCT01561638|PROCEDURE|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
224104405|NCT01561638|PROCEDURE|Sham|will receive puncture for 4 minutes
224104406|NCT02331264|OTHER|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
224104407|NCT03886077|DRUG|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
224104408|NCT03660501|DEVICE|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
224104409|NCT00465569|DRUG|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
224104410|NCT00465569|OTHER|Placebo|
224104411|NCT05959499|DRUG|BR6002A|One tablet administered alone
224104412|NCT05959499|DRUG|BR6002B|One tablet administered alone
224104413|NCT05959499|DRUG|BR6002|One capsule administered alone
224104414|NCT00163540|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
224104415|NCT01121016|DRUG|Montelukast|10mg, qn, 4 weeks
224104416|NCT01121016|OTHER|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
224104417|NCT02339298|OTHER|music application|music is applied during anaesthesia using headphones
224104418|NCT02339298|OTHER|only headphones|music is not applied, only headphones are placed
224104419|NCT02339298|DRUG|a caudal block|
224104420|NCT03564249|DEVICE|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
224288798|NCT06132620|DRUG|Femoston|"Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment."
223723073|NCT03659812|OTHER|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
223723074|NCT00729651|DRUG|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
223723075|NCT00729651|DRUG|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
223723076|NCT00729651|DIETARY_SUPPLEMENT|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
224288799|NCT06132620|DRUG|Qingxin Zishen Decoction|Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
224288800|NCT00104091|DRUG|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
223723077|NCT04418453|OTHER|Integration of telemedicine for MOUD in primary care|Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
223723078|NCT02611557|PROCEDURE|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
223723079|NCT00313391|DRUG|Risperdal Consta|
223723080|NCT02399826|DEVICE|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
223723081|NCT02399826|PROCEDURE|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
224288801|NCT03122340|DRUG|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
224288802|NCT03122340|OTHER|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
224288803|NCT01138826|DRUG|Amlodipine - reference|10 mg tablet, single dose, with water
224288804|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
224288805|NCT01138826|DRUG|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
224288806|NCT06337825|BEHAVIORAL|Activity Tracker (Fitbit)|Wearable, activity tracker
224288807|NCT06337825|DIAGNOSTIC_TEST|HbA1C|Average blood glucose (sugar) levels reported as a percentage
224288808|NCT06337825|BEHAVIORAL|The PROMPT Questionnaire|The PROMPT Questionnaire which is a 30-question previously validated assessment for non-specific symptoms in PHPT, will be administered to patients preoperatively and at 2-weeks and 6-months postoperatively
224288809|NCT05462730|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
224288810|NCT05462730|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
224104421|NCT03009695|DEVICE|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
224104422|NCT03009695|DEVICE|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
224104423|NCT03009695|DEVICE|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
224104424|NCT03501212|DRUG|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
224104425|NCT03501212|DRUG|Placebo|Placebo Cream 2.5gr applied to both wrist
224104426|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
224104427|NCT00834119|DRUG|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
224104428|NCT00004415|DEVICE|Medlink spinal cord electrode|
224104429|NCT00849212|DRUG|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
224104430|NCT01864135|DEVICE|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
224104431|NCT01864135|DEVICE|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
223538237|NCT05983094|DRUG|Trastuzumab|Trastuzumab 8mg/kg iv in first cycle on day 1, then 6mg/kg in the rest cycles
223538238|NCT05983094|DRUG|Pertuzumab|Pertuzumab 840mg/kg iv in first cycle on day 1, then 420mg/kg in the rest cycles
223538239|NCT00856609|DRUG|Byetta (exenatide)|Exenatide is an injectable medication
223538240|NCT00856609|BEHAVIORAL|Weight loss|Because response to weight loss
224104432|NCT00095303|BEHAVIORAL|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
224104433|NCT00095303|BEHAVIORAL|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
223538241|NCT00856609|OTHER|Metabolic Chamber|The subject stays in the small room
223538242|NCT00856609|DRUG|Placebo|
223538243|NCT01130181|DRUG|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
223538244|NCT01130181|DRUG|Placebo|Matching placebo
223538245|NCT02731287|DRUG|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
223538246|NCT02731287|DRUG|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
223538247|NCT00373607|DRUG|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
223538248|NCT00373607|DRUG|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
223538249|NCT05554458|BEHAVIORAL|ChildTaks+ intervention|The ChildTalks+ Intervention ChildTalks+ is a preventive intervention originally developed in the Netherlands, targeting children up to 18 years of age. It has been implemented in Norway, Italy, and Portugal. It has a clear and well-described theoretical basis focusing on psychoeducation. Its key strategy is to provide feasible and replicable interventions to improve the quality of life of families where parents are affected by a mental disorder.
223538250|NCT01738061|BEHAVIORAL|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
224288811|NCT02302521|DEVICE|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
224288812|NCT03360916|DRUG|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
224288813|NCT03360916|DRUG|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
224288814|NCT03360916|DRUG|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
224288815|NCT03360916|BEHAVIORAL|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
224288816|NCT01402180|BIOLOGICAL|Nimotuzumab|
224288817|NCT01402180|RADIATION|Radiation therapy|
224288818|NCT01402180|RADIATION|radiation therapy|
223538251|NCT01088503|DRUG|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
224288819|NCT01402180|DRUG|chemotherapy|
224288820|NCT01402180|DRUG|chemotherapy|
224288821|NCT01333072|DRUG|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
224288822|NCT01333072|DRUG|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
224288823|NCT03914768|BIOLOGICAL|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
224288824|NCT04441099|DRUG|NBE-002|NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
224288825|NCT01557842|DRUG|Drug Treatment|Class I and III antiarrhythmic drug treatment.
224288826|NCT01557842|DEVICE|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
224288827|NCT03121014|DRUG|Fludarabine|40 mg/m\^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
223538252|NCT00110214|DRUG|docetaxel|Given IV
223538253|NCT00110214|OTHER|placebo|Given IV
223538254|NCT00110214|DRUG|prednisone|Given orally
223538255|NCT00110214|BIOLOGICAL|bevacizumab|Given IV
223538256|NCT00110214|OTHER|laboratory biomarker analysis|Correlative studies
223538257|NCT01883921|OTHER|Immunoglobulin Therapy|
223538258|NCT02943694|DEVICE|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
223538259|NCT05412264|BEHAVIORAL|Website intervention|12 week motivational emails, recording pedometer steps and waist circumference
223538260|NCT03710265|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
223538261|NCT06288425|OTHER|Non interventional|Non interventional. Review of clinical, biopsy (histopathological and molecular) features associated with rejection and non-rejection pathology diagnosis
223538262|NCT01658553|DRUG|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
223538263|NCT04983771|DEVICE|Annotate ultrasound scans|Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
223538264|NCT01016067|DEVICE|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
224288828|NCT03121014|DRUG|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
224288829|NCT03121014|DRUG|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
224288830|NCT03121014|RADIATION|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
224288831|NCT03121014|PROCEDURE|Stem Cell Product Infusion|Day 0 according to BMT unit policy
224288832|NCT03121014|DRUG|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
224288833|NCT03121014|DRUG|Methotrexate|5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
224288834|NCT03053583|DEVICE|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
223723082|NCT02382393|OTHER|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
223723083|NCT02382393|OTHER|Computerized Assessment|a validated, computerized cognitive assessment tool
223723084|NCT06526650|OTHER|'Ai Pono|"Hands-on Cooking and Cultural Lessons These lessons will be widely advertised. Each 2-hour presentation will involve hands-on cooking demonstrations and tastings, accompanied by lessons on the cultural significance of featured food items. Demonstrations will link the consumption of vegetables (e.g., sweet potato, breadfruit, kalo) to Native Hawaiian (NH) history and traditional beliefs to help participants rediscover their heritage through the meals they prepare."
224104434|NCT01364467|DRUG|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
224288835|NCT06526507|OTHER|Implementation strategy package|Package includes a Community of Practice, a quality improvement (QI) practice, and a training \& delivery toolkit.
224288836|NCT01469507|DEVICE|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
224288837|NCT01469507|DRUG|Hyaluronan|3 weekly injections
223723085|NCT05594784|DRUG|Olverembatinib|a third-generation TKI
223723086|NCT05594784|DRUG|Venetoclax|a selective inhibitor of B-cell lymphoma 2 (Bcl-2)
223723087|NCT05594784|DRUG|prednisone|Glucocorticoids
223723088|NCT05594784|DRUG|Vincristine|Anti-tumor alkaloids
223723089|NCT06430528|DRUG|Osilodrostat|Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
223723090|NCT06174610|DIAGNOSTIC_TEST|Measurement of Renal Resistive Index|"The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally.~The investigators do not have access to previous measurements (each study is recorded on a separate card)."
223952010|NCT06698380|OTHER|Mirror Therapy|A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes followed by 30 minutes of CPT treatment. Each session lasted 45 minutes, held three times per week over six weeks.
223723091|NCT03530969|BEHAVIORAL|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
223723092|NCT03530969|BEHAVIORAL|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
223723093|NCT03530969|BEHAVIORAL|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
223723094|NCT03530969|BEHAVIORAL|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
223723095|NCT03530969|BEHAVIORAL|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|"Patients perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)"
223723096|NCT03530969|BEHAVIORAL|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
223723097|NCT00519402|OTHER|tonsillar examination and questionnaire completion|
223952011|NCT06699511|BEHAVIORAL|Exercise|Exercise
223952012|NCT06699576|DRUG|HS-20093|HS-20093: administered as an IV infusion
223952013|NCT06699576|DRUG|Anlotinib|Anlotinib: 12mg once daily (QD) orally
223952014|NCT06699576|DRUG|Epirubicin|Epirubicin: administered as an IV infusion
223952015|NCT06699576|DRUG|Adebrelimab|Adebrelimab: administered as an IV infusion
224104435|NCT01364467|DRUG|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
224104436|NCT03953560|DIAGNOSTIC_TEST|dyspnea grade ≥ II according NYHA-WHO|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~1. Pulsioximetry.~2. Electrocardiogram.~3. Blood sample with determination of NT-ProBNP.~4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~6. Right heart catheterization \& Pulmonary CT Scan are required for confirming the diagnosis"
224104437|NCT06295926|DRUG|Serplulimab|Undergo 4 cycles of synchronous radiotherapy and chemotherapy combined with Sintilimab immunotherapy, followed by Sintilimab monotherapy for maintenance treatment until disease progression or up to 1 year.
224104438|NCT04312997|DRUG|PUL-042 Inhalation Solution|20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
224104439|NCT04312997|DRUG|Placebo|Sterile saline for inhalation
224104440|NCT01634243|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
224104441|NCT03291327|DIETARY_SUPPLEMENT|Probiotics|Lozenges for Home use
224104442|NCT04548947|PROCEDURE|Cold snare polypectomy in conjunction with a submucosal injection|The cold snare polypectomy in conjunction with a submucosal injection is a procedure during which the endoscopist resects the colorectal polyps during a colonoscopy, without any electrocautery.
224104443|NCT01048229|DRUG|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
224104444|NCT01048229|DRUG|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
224104445|NCT03842137|DEVICE|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
224104446|NCT03842137|DEVICE|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
224104447|NCT01136239|DRUG|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
224104448|NCT01136239|DRUG|Placebo|Placebo (600mg twice daily)
224104449|NCT05920213|DRUG|Polyethylene Glycols|280g/ 24 hours for 5 days
224104450|NCT05920213|DRUG|Lactulose oral solution|60-120 ml per day for 5 days
224288838|NCT02457611|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
224288839|NCT04290234|OTHER|fMRI assessment of cognitive and reactive fear|An fMRI paradigm will be used to probe how childhood maltreatment may modulate the defensive survival circuitry that facilitates escape decisions when subjects encounter fast- or slow-attacking threats.
224288840|NCT00688428|DRUG|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
224288841|NCT00688428|DRUG|Esomeprazole|40mg capsule, administered as a single dose
224288842|NCT00688428|DRUG|ASA|325mg tablet, administered as a single oral dose
224104451|NCT05920213|DRUG|L-ornithine L-aspartate|30g/24 hours in 3 divided doses for 5 days
224104452|NCT01793987|DEVICE|Coblation polypectomy|
224104453|NCT04755374|OTHER|Discharged ≤ 21 days|Discharged from palliative care unit in equal less than 21 days
224104454|NCT04755374|OTHER|Prolonged discharge|Discharged from palliative care unit in longer than 21 days
224104455|NCT02755402|DEVICE|Xpert HCV Viral load|HCV viral load testing
224104456|NCT02755402|DEVICE|Transient elastography|Evaluation of liver fibrosis
224288843|NCT04553224|OTHER|Clinical evaluations|SCORAD and target SCORAD
224288844|NCT04553224|OTHER|Non-invasive instrumental measurements|TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index
224288845|NCT04553224|OTHER|Subject's evaluations|PO-SCORAD, target PO-SCORAD and subject's questionnaire
224288846|NCT03005067|DRUG|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
224288847|NCT03005067|OTHER|Placebo|Reference product containing vehicle without carbomer 980 gel
224288848|NCT02269644|DRUG|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
224288849|NCT02269644|DRUG|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
224288850|NCT02269644|DRUG|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
223538265|NCT01016067|PROCEDURE|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
223538266|NCT02103127|DEVICE|755nm Alexandrite laser with lens array|
223538267|NCT01960283|DRUG|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
223538268|NCT01960283|DRUG|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
224104457|NCT02228499|OTHER|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
224104458|NCT01558687|DRUG|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
224104459|NCT01558687|OTHER|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
224104460|NCT05269576|OTHER|Clinical practice|Period of 5 days where medical students carry out hospital clinical practices with real patients supervised by professionals who teach them at the same time.
224104461|NCT05269576|OTHER|Clinical simulation|Clinical simulation classes through 2 sessions of 5 simulated cases each day. All students actively participate in one or two of the simulation cases and observed and discussed all the cases in the debriefings of all of them.
224104462|NCT00693186|BIOLOGICAL|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
224104463|NCT00693186|BIOLOGICAL|Engerix B® 10 µg / 0.5 mL|10 µg
224288851|NCT02269644|DRUG|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
223538269|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Original doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
223538270|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Monkey doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush monkey doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
223952016|NCT06699186|OTHER|Sleep|A training programme was devised which involved the participants performing maximum squat repetitions with their own body weight as a workload, in order to induce delayed-onset muscle soreness in the quadriceps. Before the maximum squat repetition, all participants performed a warm-up programme including 5 minutes of walking. Participants were instructed to perform the maximum number of repetitions within the one minute allotted for each set of squats and, after a 10-second rest period, to continue the programme in the same cycle until exhaustion. In the initial 24-hour period following the intervention, participants were instructed to maintain their habitual sleep schedules. In consideration of the delayed-onset muscle soreness, which typically occurs between 24 to 48 hours following maximal squat intervention.The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period.
223952017|NCT06699186|OTHER|Non-sleep|A similar delayed-onset muscle soreness inducing protocol was applied to the sleep group.Participants in the non-sleep group were subjected to sleep restriction. The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
223952018|NCT06698484|DRUG|CAR-T cells|2×10\^6 CAR T cells/kg
224104464|NCT05574140|DIAGNOSTIC_TEST|Cardiac MRI|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths per minute) followed by a maximal breath-hold. This technique is used in Oxygenation Sensitive CMR, a type of MRI, and will induce a vasoactive response visible in cardiac and cerebral MRI images
224288852|NCT06115304|OTHER|Large liquid meal, spinal catheter and venous line|"Large liquid meal (e.g. Nutricia® Energy 500 ml (750 kcal) admixed paracetamol 1000 mg (for estimation of gastric emptying).~Spinal catheter for 4 hours, with samples taken at one hour interval.~2 venous lines, one for saline and one for venous sampling every half hour"
224288853|NCT02560779|DRUG|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
223952019|NCT06881966|DIETARY_SUPPLEMENT|Omega-3 Supplementation|Patients in the intervention group will consume 2 omega-3 capsules (Omevie) daily, which contain 36% and 24% of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, during a period of 3 months.
223952020|NCT06881966|OTHER|Placebo|The control group who will receive placebo supplementation, over a period of 3 months.The placebo capsules will be olive oil-based and will have the same visual as the omega-3 capsules. They will be developed by Vital Company.
224104465|NCT01543321|DRUG|Tetrabenazine|"Treatment with tetrabenazine consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
224288854|NCT02560779|DRUG|Sorafenib|400 mg of sorafenib will be given twice daily.
224104466|NCT01543321|DRUG|Placebo|"Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators"
224104467|NCT00364260|DRUG|epoetin alfa|
224288855|NCT02782091|BEHAVIORAL|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
224288856|NCT01176643|OTHER|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
224288857|NCT00619359|DRUG|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
224288858|NCT00619359|DRUG|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
224288859|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
224288860|NCT00619359|DRUG|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
224288861|NCT00619359|DRUG|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
224288862|NCT02296853|DRUG|TAF|25 mg tablet administered orally
224288863|NCT03128684|OTHER|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
224288864|NCT03128684|OTHER|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
224288865|NCT03128684|OTHER|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
224288866|NCT03128684|OTHER|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
224288867|NCT03128684|OTHER|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
224288868|NCT03128684|OTHER|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
223952021|NCT06724419|BEHAVIORAL|Nutrition education-based intervention|The nutrition education-based intervention program will span 6 weeks, providing participants with comprehensive nutrition education based on dietary guidelines and comprising 8 topics , each lasting approximately 60-120 minutes.The aim is to comprehensively promote participants' adoption of a healthy lifestyle through various educational interventions, and each participant will be provided with the PMS management booklet.
223952022|NCT00633633|OTHER|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
223952023|NCT00633633|BEHAVIORAL|Exercise Training|Exercise training 3 times a week.
223952024|NCT00633633|BEHAVIORAL|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
223952025|NCT07052825|PROCEDURE|CTR implantation|Phaco+IOL with CTR implantation
223952026|NCT06442748|DRUG|Levetiracetam|Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
223952027|NCT07099157|DRUG|Brivudine|brivudine 125 mg per dose, once daily, 7 days
223952028|NCT07099157|DRUG|Famciclovir|orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days
223952029|NCT07099989|DRUG|Zelquistinel 3 mg|Subjects will receive Zelquistinel 3 mg in fed and fasted state (high fat meal).
223952030|NCT07099989|DRUG|Zelquistinel 10 mg|Subjects will receive Zelquistinel 10 mg in fed and fasted state (high fat meal).
223952031|NCT06945549|DIAGNOSTIC_TEST|18F-FAPI PET Imaging|The ROI of the target lesions was delineated based on 18F-FAPI PET Imaging, and the lesions were divided on the cross section to obtain the lesions SUVmax, SUVmean, SUVpeak, FAPI metabolic volume (FAV), MTV, TBR, and TLG.
223952032|NCT06542289|DEVICE|BlinkER device.|Participants will use the BlinkER System for 8-16 hours daily (removed during sleep) at approximately 10 blinks/minute. The stimulation cycle will be ON and OFF to achieve the desired blink rate. Participants will receive training on device usage before starting the study.
223952033|NCT04343716|BEHAVIORAL|Low-carbohydrate diet|A diet low in daily carbohydrates (\<40 grams/day) provided as prepared meals.
223952034|NCT05522569|DRUG|Allogeneic human mesenchymal stem cells (Allo-hMSCs)|Participants will be treated with one intravenous (IV) infusion of 200 million allogeneic human mesenchymal stem cells (Allo-hMSCs), lasting from 40-90 minutes following an acute ischemic stroke within 9 days after stroke symptom onset.
223952035|NCT05597618|OTHER|Training Program to be Developed for Empowering New Graduated Nurses|"The training program, which will be prepared based on structural and psychological empowerment theories, will consist of two parts: face-to-face theoretical training and online training.~1. Theoretical Education Part In the theoretical part, empowerment based on structural and psychological empowerment theories, effective communication, problem-solving and decision-making, time management, stress management, and nursing legislation will occur. In addition, the subject related to the institution's promotion (organizational chart, vision, mission, values, etc.) will be included.~2. Online Education Part In the online part; Videos of theoretical education subjects, institutional information, and documents (institutional instructions and procedures, institution vision-mission-values, management chart, etc.), nursing-related legislation (nursing law, nursing regulation), nursing ethical codes and case studies of sample subjects are included."
223952036|NCT03083678|DRUG|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
223952037|NCT05792267|DEVICE|artificial intelligence system|Patients will undergo EUS examination with the assistance of artificial intelligence(AI) system.
223952038|NCT06415227|DRUG|Vericiguat|The target dose of vericiguat is 10 milligrams once daily, which will be started at 2.5mg once daily and uptitrated every two weeks to reach the target dose. Dose modification will depend on mean sitting systolic blood pressure and the absence of symptoms indicative of hypotension. The intention of the protocol is to reach and maintain the target study drug dose after completion of uptitration. If the dose is temporarily interrupted, then resumption of study drug treatment and continued uptitration will be considered at any subsequent visit when the investigator feels it is medically appropriate. Vericiguat will be taken orally once daily at about the same time.
224104468|NCT00997971|OTHER|Modilac Rose 1|Infant formula used for non-breastfed children
224104469|NCT01397019|DRUG|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
224104470|NCT04313946|DIAGNOSTIC_TEST|Scanning Chest X-rays and performing AI algorithms on images|Chest X-Rays; AI CNNs; Results
224104471|NCT06042686|DEVICE|RF Health MAC Device|Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
224104472|NCT02594592|OTHER|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
224104473|NCT02478684|OTHER|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
224104474|NCT02478684|OTHER|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
224104475|NCT05637450|DIETARY_SUPPLEMENT|Blue Whiting Protein Hydrolysate|25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
224295237|NCT00136578|DRUG|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
224295238|NCT00136578|DRUG|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
223723098|NCT01218243|DEVICE|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
223723099|NCT06297577|PROCEDURE|Albumin Platelet Rich Fibrin (Alb-PRF) combined with minimally invasive surgical technique (MIST)|Albumin-PRF will be placed into intrabony defect
223723100|NCT06297577|PROCEDURE|Minimally invasive surgical technique (MIST)|MIST will be the surgical access for treatment of Intrabony defect
223723101|NCT01114256|PROCEDURE|FNA Biopsy|
223723102|NCT05262127|BEHAVIORAL|Flash Version of EMDR|EMDR and the inclusion of a positive engaging focus generated autonomously by participant
223723103|NCT05071469|OTHER|Kinesiotaping|KT was applied.
223723104|NCT05071469|OTHER|Mulligan Mobilization Technique|MMT was applied
223723105|NCT04971408|OTHER|passive heat stress|as above
223952039|NCT04445337|DRUG|Stellate Ganglion Block|"An injection of local anesthetic into the front of the neck. SGB involves placing a small tube into the front of your neck, toward nerves at the back of your neck. This is done with the help of an x-ray machine or ultrasound device. The tube is left in place so you can get medication thru it for five days. Then the tube is taken out.~The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block. These medications are approved by the Food and Drug Administration (FDA)."
223952040|NCT04174378|DRUG|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
223952041|NCT04953793|BEHAVIORAL|TAY SUCCESS|TAY SUCCESS stands for transition age youth supported, comprehensive cognitive enhancement and social skills. The cognitive-behavioral intervention teaches a number of strategies for executive functioning, social cognitive functioning and social communication.
223952042|NCT04953793|OTHER|Usual Care|Usual care involved the typical vocational supportive education program delivered in the educational setting
223952043|NCT01510314|BIOLOGICAL|C-reactive protein and procalcitonin dosages|
223952044|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group one: The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, RNF180/Septin9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
223952045|NCT05996458|OTHER|Risk factor investigation;|Only the risk factors will be investigated, including previous disease history, drinking history, smoking history, drinking history, family history of malignant tumor, marriage and childbearing status, eating habits, etc.
223952046|NCT05996458|OTHER|Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test|group two: The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
223952047|NCT00747149|DRUG|Rosuvastatin|Oral
224104476|NCT05637450|DIETARY_SUPPLEMENT|Placebo|Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
224104477|NCT02234037|DRUG|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
223952048|NCT03322579|DEVICE|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
223952049|NCT04436484|DIAGNOSTIC_TEST|Peripheral blood sampling|Non-interventional study
223952050|NCT05361083|DRUG|F18CETO|Injection of F18CETO or O15water followed by PET/CT
223952051|NCT03412045|DEVICE|hyperbaric oxygen therapy|Participants in vaso-occlusive crisis from sickle cell anemia will receive 1-3 hyperbaric oxygen (HBO) sessions depending on response to the therapy. Each session will be approximately 2 hours in length at 2.5 ATM. Minimum time between HBO sessions of 4 hours.
223952052|NCT04117477|DRUG|Xylitol|Xylitol dental wipes
223952053|NCT04117477|OTHER|Placebo|Placebo dental wipes
223952054|NCT00212290|DRUG|pioglitazone|
223952055|NCT00212290|DRUG|nateglinide|
223952056|NCT00212290|DRUG|placebo|
223952057|NCT05987956|DRUG|Alectinib - Usual|"Usual Alectinib Chemotherapy (NDC...01)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
223952058|NCT05987956|DRUG|Alectinib - Study|"Study Alectinib Chemotherapy (NDC...86)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"
223952059|NCT05898789|BEHAVIORAL|CaRE@Home intervention|participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
223952060|NCT06313606|DIETARY_SUPPLEMENT|Dietary fat positive control|Dietary fat-containing meal plan with a specific supplement that may modify fat metabolism
223952061|NCT06313606|DIETARY_SUPPLEMENT|Dietary fat negative control|Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
223952062|NCT04831398|DIETARY_SUPPLEMENT|melatonin|A 5mg dose of melatonin spay will be delivered sublingually.
223952063|NCT04831398|OTHER|Placebo|10 sprays of diluted mint extract. This mimics the sensation and taste of the melatonin spray
223952064|NCT00334438|BIOLOGICAL|rituximab|250mg/m2, IV, Days 1 and 8
223952065|NCT00334438|DRUG|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
223952066|NCT00334438|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
223952067|NCT00334438|RADIATION|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
223952068|NCT00265252|DRUG|Alendronate|
223952069|NCT01362309|DRUG|d-cycloserine.|50 mg administered on two occasions.
223952070|NCT06633133|PROCEDURE|Virtual ileostomy|A pre-stage ileostomy, anchored under the abdominal wall by a vascular sling or rubber tape through the mesenteric window, is delivered to the outside of the abdomen, where the VI is pulled through the abdominal wall.
223952071|NCT05458271|DEVICE|VCMX|A flap will be raised and VCMX will be placed in order to increase the soft tissue volume
223952072|NCT05458271|PROCEDURE|CTG|A flap will be raised and a CTG will be harvested from the palate and placed in order to increase the soft tissue volume
224104478|NCT02234037|BEHAVIORAL|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise \> 10 minutes of muscle strengthening, \> 10 minutes of aerobic exercise (treadmill walking or cycling), \> 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
224104479|NCT03560076|OTHER|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
224104480|NCT01472276|BEHAVIORAL|Web-based program|Provided with the web-based program
224104481|NCT00903084|DRUG|Tenofovir Disoproxil Fumarate|300-mg tablet
223538271|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Dog without velcro doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush dog doll, without velcro in palms. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
224104482|NCT05855356|PROCEDURE|Rehabilitation|respiratory physiotherapy, personalized aerobic and strength training
224104483|NCT05855356|PROCEDURE|Standard of Care|Behavioural and Medical management
224104484|NCT03888625|PROCEDURE|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
224288869|NCT05992831|DEVICE|Accelerated iTBS|The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
224288870|NCT05992831|DEVICE|Sham Comparator|To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
224288871|NCT03233958|BEHAVIORAL|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation \[Hunger, Weinhold, Bornhäuser, Link, \& Schweitzer, 2015\].
223723106|NCT04971408|OTHER|control|participant engage in activity as usual
224288872|NCT06424106|OTHER|Glucagon|a variable rate glucagon infusion
224288873|NCT06424106|OTHER|Glucose|a variable rate glucose infusion
223538272|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Bear doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush smiling bear doll. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
223723107|NCT00172133|DRUG|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
223723108|NCT00268593|DRUG|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
223723109|NCT00268593|DRUG|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
223723110|NCT00268593|DRUG|prednisone|5 mg twice a day orally
223723111|NCT00004915|DRUG|raloxifene|
223723112|NCT03955744|OTHER|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
224104485|NCT03888625|PROCEDURE|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
224104486|NCT00780403|DRUG|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
224104487|NCT00780403|DRUG|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
224288874|NCT06475625|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
224288875|NCT06475625|DEVICE|Orsiro™ or Orsiro_Mission™ stent|Percutaneous coronary intervention with Orsiro™ or Orsiro\_Mission™ stents
223952073|NCT04564898|DRUG|Capecitabine|"Part 1 • Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days~Part 2~• Capecitabine, 1000 mg/sqm orally twice daily on days 1-14 each 28 days"
223952074|NCT04564898|DRUG|Bevacizumab|"Part 1 • Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days~Part 2~• Bevacizumab, 5 mg/kg IV dose over 30 minutes on days 1 and 15 each 28 days"
223952075|NCT04564898|DRUG|Trifluridine/Tipiracil|"Part 1 • Trifluridine/tipiracil, dose escalation from 25 mg/sqm to 35 mg/sqm orally twice daily on days 15-19 (and days 22-26) each 28 days~Part 2~• Trifluridine/tipiracil, at the recommanded dose established during part 1 orally twice daily on days 15-19 (and days 22-26) each 28 days"
223538273|NCT06155162|BEHAVIORAL|The HuggyPuppy Intervention: Rabbit doll|The HuggyPuppy Intervention, originally designed to alleviate war-related stress in children (Sadeh et al., 2006), is a concise psychosocial intervention featuring a soft plush toy, originally a puppy, accompanied by a 'cover story.' This narrative informs the child that 'Huggy' is seeking care, prompting the child to adopt and comfort the toy. In this version children receive a plush rabbit doll, with a neutral expression. In the parent-delivered version tested in this trial, parents will receive three instructional videos (each lasting 1.5-5 minutes), guiding them on introducing the doll to their child. These videos encourage parents to foster a strong bond between the child and the doll, emphasizing activities such as hugging and expressing emotions through this comforting companion.
224295239|NCT03522571|BEHAVIORAL|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
223538274|NCT01421966|BIOLOGICAL|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
223538275|NCT01421966|BIOLOGICAL|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
223723113|NCT00580190|DRUG|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
223723114|NCT00580190|OTHER|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
224104488|NCT05270603|OTHER|ICARUS intraoperative adverse events calculator|"The ICARUS calculator is a web-based tool that uses answers to Boolean, yes/no questions to determine the iAE grade (appendix I). The calculator providers iAE grade outputs for the 5 iAE classification systems.~https://garnmile.com/iaecalc/~Development of the ICARUS calculator was performed as follows: Referencing the 5 classification systems, we first assembled a list of Boolean questions based on the iAE grade descriptions. This list was distilled to the minimum number of questions necessary to represent all descriptions in the combined list of iAE grades. Next, these questions were used to independently establish the conditional logic required to determine iAE grade for each classification system. The questions and logic were translated into Hypertext Preprocessor (PHP), a server-side programming language, and JavaScript, a client-side scripting language."
223723115|NCT00580190|DRUG|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
223723116|NCT00844896|BEHAVIORAL|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
223723117|NCT00844896|BEHAVIORAL|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
223952076|NCT05159076|BEHAVIORAL|Behavioral Intervention to Increase Physical Activity|"The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active.~The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting until 90 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own physical activity (PA) data and the behavioural change stage, an individual action plan will be established to increase physical activity. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time."
224104489|NCT01416311|DRUG|Eltrombopag|
224104490|NCT06851013|DIAGNOSTIC_TEST|SpinChip hs-cTnI|SpinChip Platform, consisting of the SpinChip hs-cTnI test (self-contained cartridge) and SpinChip Analyzer (instrument)
224104491|NCT04327648|DEVICE|Social interaction treatment|Children in social interaction treatment group will have 30min social interaction each day for 3 months.
224104492|NCT04327648|DEVICE|Neuronal cognition treatment|Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months.
224104493|NCT04327648|OTHER|Routine treatment|Children in routine treatment group will keep the same initial treatment.
224104494|NCT02094599|DRUG|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
224104495|NCT02094599|DRUG|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
223538276|NCT02057965|DRUG|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
223538277|NCT06016322|DIETARY_SUPPLEMENT|Dried Chicory Root|"Subjects will receive 1 sachet of 10g WholeFiberTM for the first 2 weeks (equals 8.5 g fiber), and 2 sachets of 10g WholeFiberTM per day for the last two weeks (equals 17 g fiber).~WholeFiberTM is a fiber-rich dried vegetable made from the chicory root that contains four types of prebiotic fibers (inulin, pectin, cellulose, hemi-cellulose)."
224104496|NCT02094599|DRUG|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
224104497|NCT00002365|DRUG|LXR015-1|
224104498|NCT02585427|DIETARY_SUPPLEMENT|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
224104499|NCT04322708|OTHER|Placebo|Placebo
224104500|NCT04322708|DRUG|lirentelimab (AK002)|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
224104501|NCT00795730|DRUG|NSA-789|
224104502|NCT00795730|OTHER|placebo|
223952077|NCT06519955|COMBINATION_PRODUCT|Ropivacaine, Epinephrine, Ketorolac, NaCl (Saline)|"Weight 50-74.9 kg:~* ropivacaine 100mg/epinephrine 50 mcg/ketorolac 15mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total~Weight 75-99.9 kg:~* Ropivacaine 150mg/epinephrine 100 mcg/ketorolac 15mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total~Weight 100+ kg:~* Ropivacaine 200mg/epinephrine 150 mcg/ketorolac 15 mg in NaCl 0.9% 60mL~* 2 vials of this for 120mL total"
224288876|NCT02593396|DRUG|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
223952078|NCT03854734|BEHAVIORAL|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
223952079|NCT03854734|BEHAVIORAL|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
224104503|NCT02320578|PROCEDURE|3D Laparoscopy|3D Laparoscopy approach
224104504|NCT02320578|PROCEDURE|Standard Laparoscopy|Standard laparoscopy approach
224104505|NCT02509962|DIETARY_SUPPLEMENT|Slow sodium tablets|6 g sodium chloride per day over 14 days
224104506|NCT03603132|DRUG|Hetrombopag Olamine|7.5mg in each cycle
224104507|NCT04910217|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation
224104508|NCT04910217|PROCEDURE|Leg/lower body exerciser device intervention.|Patients will undergo leg/lower body exerciser device therapy.
224288877|NCT02593396|DRUG|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
223538278|NCT03961191|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
223538279|NCT03961191|DIAGNOSTIC_TEST|high-risk HPV|High-risk HPV testing for the cervical cytology
224104509|NCT04910217|PROCEDURE|Lokomat intervention|Patients will undergo therapy with Lokomat Pro FreeD device intervention.
224104510|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
224104511|NCT00845429|BIOLOGICAL|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
224104512|NCT00845429|BIOLOGICAL|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
224104513|NCT00746538|DEVICE|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
224104514|NCT01907685|DRUG|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
224104515|NCT01907685|DRUG|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
224104516|NCT05784090|OTHER|blood and saliva sample and lumbar puncture diagnostic for specific neurological diseases|"Saliva was collected using Salivettes (Sarsted, Newton, NC, USA) in dim light. CSF was obtained in the morning after overnight fasting by lumbar puncture at the L3/L4 or L4/L5 interspace.~Blood samples were drawn in fasting conditions. Plasma was separated by centrifugation."
224104517|NCT02090543|DRUG|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
224104518|NCT02090543|DRUG|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
224104519|NCT01715025|DRUG|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
224104520|NCT04512261|DRUG|Tucatinib|Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
224104521|NCT04512261|DRUG|Pembrolizumab|Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
224104522|NCT04512261|DRUG|Trastuzumab|Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
224104523|NCT01161225|BEHAVIORAL|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
224104524|NCT01161225|BEHAVIORAL|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
224104525|NCT00228371|DEVICE|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
224104526|NCT06221644|DIAGNOSTIC_TEST|[18F]SynVesT-1 PET/CT|60 MSA patients (30 MSA-P subtype and 30 MSA-C subtype) and 30 age-matched healthy controls (HCs) underwent \[18F\]SynVesT-1 PET/CT for synaptic density assessment
224104527|NCT00243737|DRUG|Artesunate-Mefloquine|
224104528|NCT03247400|DRUG|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
224104529|NCT03247400|DRUG|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
224104530|NCT05776537|DEVICE|Fibreoptic bronchoscopy|different endoscopies used for confirmation of diagnosis
223538280|NCT03961191|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
223538281|NCT02625350|OTHER|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
224104531|NCT01193764|DIETARY_SUPPLEMENT|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
224104532|NCT01193764|DIETARY_SUPPLEMENT|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
224288878|NCT03399578|BIOLOGICAL|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
224104533|NCT04632147|OTHER|Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama|Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
224104534|NCT06187818|DRUG|Crocin|According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
224104535|NCT03370146|BEHAVIORAL|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
224104536|NCT03370146|BEHAVIORAL|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
224104537|NCT03370146|BEHAVIORAL|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
224288879|NCT00913198|DRUG|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224288880|NCT02989298|OTHER|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
224104538|NCT00413751|DRUG|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
224104539|NCT05008887|DRUG|Methotrexate|Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
224104540|NCT05008887|DRUG|5-fluorouracil|Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
224104541|NCT05008887|DEVICE|Fractional CO2 laser|Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
224104542|NCT02999503|BEHAVIORAL|Nutritional education|Nutritional education trough a personal online nutritional consultant
224288881|NCT02433119|DRUG|OROSARTAN® 5/160mg|
224288882|NCT02433119|DRUG|CODIOVAN® 160/12.5mg|
224288883|NCT03964519|OTHER|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
224288884|NCT03964519|OTHER|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
224288885|NCT03964519|OTHER|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
224104543|NCT02111369|DRUG|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
224104544|NCT02111369|PROCEDURE|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
224104545|NCT04666883|OTHER|Review of records and follow up|Follow up to identify patients who developed splenic hilar nodal metastases
224104546|NCT06395272|DEVICE|SURA|The motor points are the site of penetration of the motor nerve fibres and the highest concentration of motor plates in the muscle, which when stimulated produce the maximum effective muscle contraction. For 15 minutes and in a comfortable seated position at 90° hip, knee and foot, sustained pressure of 30 seconds each shall be exerted through the output plunger of the proprioceptive stimulus device.
224104547|NCT01233726|DIETARY_SUPPLEMENT|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
224104548|NCT01233726|DIETARY_SUPPLEMENT|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
224104549|NCT01233726|DIETARY_SUPPLEMENT|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
224104550|NCT06432777|OTHER|Characteristics of patients and Campylobacter bacteraemia episodes|Variables: characteristics of the patients (demographic characteristics; characteristics of immunodeficiency: diagnosis, immunoglobulin dosage, white cells count etc.; chronic inflammatory bowel disease \[IBD\]), the bacteria (species, antimicrobial susceptibility) and the infection (clinical presentation, evolution, treatment received)
224104551|NCT05307744|DIETARY_SUPPLEMENT|PS128|Each PS128 capsule contained \>3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.
224104552|NCT05307744|OTHER|Placebo|The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
224104553|NCT04773769|DIETARY_SUPPLEMENT|Tea Made of Graviola Leaves|"Graviola leaves will be supplied to the patient with instructions on how to prepare the tea which will consist of 10 guanabana leaves which the patient will boil in 1 liter of water for 3 minutes. Once boiled, the formulation will be stores in the refrigerator and once cool enough the patient will start drinking 100 cc two times per day.~The Treatment Period begins with Cycle 1 Day 1 dosing. Patients will take the tea continuously during a 28-day cycles, until there is an indication for treatment change based on response assessment."
224104554|NCT03946267|DEVICE|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
224104555|NCT01813487|DRUG|HBsAg vaccine with Entecavir|
224104556|NCT02739139|DIETARY_SUPPLEMENT|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
224104557|NCT03240081|DRUG|50mcg estradiol cream|Use of study drug nightly applied to vulvar vestibule
224104558|NCT03240081|DRUG|100mcg estradiol cream|Use of study drug nightly
224104559|NCT05911997|DRUG|MTC 01|Slurry to be administered via colonoscopy
224104560|NCT05911997|DRUG|Fecal Microbiota Transplantation (FMT)|Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
224104561|NCT00944944|BEHAVIORAL|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
223952080|NCT02196259|DRUG|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
224295240|NCT03695705|DRUG|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
224295241|NCT04660305|DRUG|AT278|Concentrated rapid acting insulin aspart
223952081|NCT04889326|OTHER|Retrospective data and biological samples|Analysis of data and biological samples collected during hospitalization:
223952082|NCT03734432|DEVICE|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
223952083|NCT00286832|PROCEDURE|PET scan|One extra PET scan after 1 cycle of treatment.
223952084|NCT02830893|DEVICE|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
224295242|NCT04660305|DRUG|NovoRapid|Rapid acting insulin aspart
224295243|NCT02032251|DRUG|oral administration of ginger|Oral administration of ginger in patients with infertility.
224295244|NCT02032251|DRUG|Placebo|
224295245|NCT02214420|DRUG|Simeprevir|
224295246|NCT02214420|DRUG|Sofosbuvir|
224295247|NCT02214420|DRUG|Ribavirin|
224104562|NCT00944944|BEHAVIORAL|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
224104563|NCT00883753|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
224104564|NCT00648310|DRUG|Tolterodine 4 mg|
224104565|NCT00648310|DRUG|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
223952085|NCT02830893|BEHAVIORAL|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
224104566|NCT05426343|BIOLOGICAL|MVC-COV1901|Approximately 125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
224104567|NCT05426343|BIOLOGICAL|AZD1222|Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
224104568|NCT04720352|DEVICE|Active treatment|Active treatment delivers radiofrequency and cryogen
224104569|NCT04720352|DEVICE|Sham|Sham delivers non therapeutic levels of radiofrequency and cryogen
224104570|NCT00760175|BIOLOGICAL|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
224104571|NCT05401071|OTHER|Short Regimen with Rifapentine 10mg/kg|rifapentine 10mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
224104572|NCT05401071|COMBINATION_PRODUCT|Standardized Regimen|"During the intensive phase, rifampicin ≤55kg 450mg daily, 55-71kg 600mg daily, \>71kg 750mg daily; isoniazid ≤55kg 225mg daily, 55-71kg 300mg daily, \>71kg 375mg daily; pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol ≤55kg 825mg daily, 55-71kg 1100mg daily, \>71kg 1375mg daily; All treatment is taken orally.~During the continuation phase, rifampicin ≤50kg 450mg daily, \>50kg 600mg daily; isoniazid 300mg daily; All treatment is taken orally."
223952086|NCT00576485|PROCEDURE|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
224104573|NCT05401071|OTHER|Short Regimen with Rifapentine 15mg/kg|rifapentine 15mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
224104574|NCT05401071|OTHER|Short Regimen with Rifapentine 20mg/kg|rifapentine 20mg/kg daily; isoniazid 300mg daily; pyrazinamide ≤50kg 1000mg daily, 50-71kg 1200mg daily, \>71kg 1000mg daily; moxifloxacin 400mg daily. All treatment is taken orally.
224104575|NCT01370954|OTHER|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
224104576|NCT01731015|DRUG|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
224104577|NCT02256358|DRUG|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
224104578|NCT02256358|DRUG|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
224288886|NCT04390802|DRUG|5-aminolevulinic acid|Study participants who are deemed surgical candidates for management of their pituitary lesion will drink 20mg/kg 5-ALA 2-4 hours preoperatively. They will then be taken to the operation room and undergo general anesthesia. Intraoperative blood draw may occur from lines places for anesthesia purposes at any time during the operation. In alignment with the neurosurgeon's practice and discretion, the sella will be accessed and opened. During the surgical exploration of the sella, the surgeon will attempt to identify the pituitary mass. The location of the tumor will be assessed using the blue-light filtered microscope or endoscope. These steps will be documented photographically during the operation. A biopsy of the fluorescent region will be taken to confirm pituitary adenoma histopathology. The tumor will then be maximally resected. The tumor sample will be used for further clinical testing as part of the patient's routine care.
224288887|NCT03720769|BEHAVIORAL|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
224288888|NCT03720769|BEHAVIORAL|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
224104579|NCT00030758|BIOLOGICAL|filgrastim|
224104580|NCT00030758|BIOLOGICAL|pegfilgrastim|
224104581|NCT01302275|DRUG|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
224104582|NCT03867253|DRUG|ORY-2001 Low dose|0.6mg ORY-2001 capsule
224288889|NCT04982367|DEVICE|Sirolimus-eluting balloon catheter|Sirolimus-eluting balloon catheter designed and produced by Acotec
224104583|NCT03867253|DRUG|ORY-2001 High dose|1.2mg ORY-2001 capsule
224104584|NCT03867253|DRUG|Placebo|Placebo capsule
224104585|NCT02037945|PROCEDURE|18F-FCH PET Scan|
224104586|NCT05634564|DRUG|Tislelizumab|Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
224104587|NCT05634564|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
224104588|NCT05634564|DRUG|Nab paclitaxel|Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
224104589|NCT05634564|RADIATION|Hypofractionated radiotherapy with simultaneous integrated boost|Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions.
224104590|NCT02426606|OTHER|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~* white rice or white rice combined with 1 of 3 different lentil varieties or~* white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
224104591|NCT01771094|BEHAVIORAL|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
224104592|NCT04192604|OTHER|WMSDsQ|Work-related MusculoSkeletal Disorders Questionnaire
224104593|NCT04477122|OTHER|Manual therapy and extracorporeal radial shock waves therapy|25 minutes of manual therapy, 5 minutes of temporomandibular joint mobilization and 3 minutes of extracorporeal radial shock waves therapy (real or placebo)
224104594|NCT01480180|DRUG|turoctocog alfa pegol|Administered i.v.
224104595|NCT00202540|DRUG|S18986|
224104596|NCT06447792|OTHER|Loading protocol|The prosthetic restoration and functional loading of the dental implant.
224104597|NCT02334709|RADIATION|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
224104598|NCT00393822|DRUG|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
224104599|NCT00393822|DRUG|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
224104600|NCT02662439|DEVICE|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
224104601|NCT01341912|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
224288890|NCT04982367|DEVICE|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter (trade name:DHALIA)
224104602|NCT00424307|DEVICE|HiResolution Bionic Ear System|
224104603|NCT03721328|COMBINATION_PRODUCT|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
224104604|NCT03940885|PROCEDURE|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
224104605|NCT03940885|PROCEDURE|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
224104606|NCT03940885|PROCEDURE|Control group|this group will receive only standard general anesthesia
224104607|NCT03852225|DIAGNOSTIC_TEST|Intra-arrest echocardiography|Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
224104608|NCT05146622|BEHAVIORAL|Workplaces in the World|Formative research activities to better understand attitudes and behaviors of outdoor workers with respect to UV safety.
224104609|NCT00575679|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
224104610|NCT03429075|DRUG|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
224104611|NCT03429075|DRUG|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
224104612|NCT02670304|DRUG|letrozole|letrozole from the day of oocyte retrieval for 5 days
224104613|NCT02670304|DRUG|Aspirin|aspirin from the day of oocyte retrieval for 5 days
224104614|NCT06396208|DRUG|Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)|Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle
224104615|NCT06396208|DRUG|Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)|Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle
224288891|NCT00337974|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
224288892|NCT00337974|OTHER|Educational DVDs|
224104616|NCT05329792|DRUG|L19IL2/L19TNF|Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for 4 consecutive weeks
224288893|NCT01669031|OTHER|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
224288894|NCT02142231|DEVICE|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
224104617|NCT05907915|DEVICE|low level laser therapy|They recieved LLLT 1 session daily, 3 session per week for 3 weeks,with the following parameters( 650 nm wavelength, 150 mw power output, 0.25 cm2 radiation area, 0.6 W/cm2 power density, continuous mode, 2 j/ cm2, 90 seconds / cm2) in addition to the conventional medical treatment and traditional wound care (dressing)
224104618|NCT05907915|BEHAVIORAL|placebo|They received placebo laser 1 session daily, 3 session per week for 3 weeks in addition to the conventional medical treatment and traditional wound care (dressing)
224104619|NCT01955486|OTHER|flight simulation|
224295248|NCT01739920|OTHER|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
223952087|NCT03514667|DIETARY_SUPPLEMENT|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
223952088|NCT03514667|DIETARY_SUPPLEMENT|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
223952089|NCT02992496|DRUG|Ketamine|1mg/kg, 6 applications over 2 weeks
223952090|NCT02992496|DRUG|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
223952091|NCT05185674|OTHER|Exposure: Coronavirus disease 2019 (COVID-19)|Having presented Coronavirus disease 2019 (COVID-19) and stay in the Intensive Care Unit
223952092|NCT03627572|OTHER|No intervention|Not applicable (no intervention)
223729500|NCT03590041|BEHAVIORAL|Patient-driven SMA|Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
223952093|NCT04443556|DRUG|Tramadol|Before the closure of the thoracotomy, the surgeon will place two catheters through a Tuohy needle into fascial planes for continue the RISS block. First catheter tip will be placed towards the interfascial planes between the rhomboid major and intercostal muscles and the second catheter tip will be placed in subserratus fascial plane. Continue local anesthetics will be injected through the catheters for 48 hours. Also an IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
223952094|NCT04443556|OTHER|IV PCA|An IV patient-controlled analgesia device containing tramadol will be provided. Tramadol consumptions and postoperative numeric rating scale (NRS) scores for pain will be recorded.
223952095|NCT01394406|DRUG|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
223952096|NCT01394406|DRUG|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
223952097|NCT00215943|DRUG|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
223952098|NCT00215943|DRUG|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
224104620|NCT00839111|DRUG|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
224104621|NCT00839111|DRUG|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
224104622|NCT03533166|OTHER|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
223952099|NCT00215943|DRUG|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
223952100|NCT00215943|DRUG|vincristine|As outlined in VAD Treatment Arm
223952101|NCT00215943|DRUG|adriamycin|As outlined in VAD Treatment arm
223952102|NCT01581333|DRUG|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
223952103|NCT01581333|DRUG|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
223952104|NCT01275872|OTHER|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
223952105|NCT05283200|BEHAVIORAL|Yoga|Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction
223952106|NCT05283200|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills
223952107|NCT05283200|BEHAVIORAL|Music|Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
223952108|NCT02827851|PROCEDURE|Liposuction|
223952109|NCT02827851|OTHER|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
223952110|NCT02827851|OTHER|Intraarticular administration of autologous SVF|
223952111|NCT01250717|DRUG|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
223952112|NCT01250717|DRUG|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
223952113|NCT01250717|DRUG|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
224104623|NCT03533166|OTHER|Placebo|Placebo mouth rinse
224104624|NCT03490487|DRUG|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
224104625|NCT03490487|DRUG|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
224104626|NCT04580147|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection (2mg/0.05mL) at the conclusion of RRD repair surgery, at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
224104627|NCT04580147|OTHER|Sham control|Sham procedure at post-operative day 30 (+/-7 days), and at post-operative day 60 (+/-7 days)
224104628|NCT05609526|OTHER|Compression Therapy|6, 8, 10 and 12 cm short tension bandages multi-layered and will be applied specifically to the extremity. Starting with the finger bandage, the pressure will be reduced as it goes distally.
224104629|NCT05609526|OTHER|Inspiratory muscle training|Maximum inspiratory intraoral pressure (MIP) and expiratory intraoral pressure (MEP) will be measured before patients begin IMT. Total training time per day will be 30 minutes.
224104630|NCT05609526|OTHER|Calf muscle exercise training|A strengthening treatment program will be applied to the calf muscles.dorsiflexors and plantar flexors will consist of static stretching exercise, isotonic resistance exercise with elastic resistance bands, heel and toe raising in both feet, followed by toe raising and lowering without raising the heel.
224104631|NCT04876547|PROCEDURE|appendectomy|appendectomy performance
224288895|NCT02142231|DEVICE|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
224288896|NCT05231369|BIOLOGICAL|ChulaCov19 BNA159 mRNA vaccine|ChulaCov19 BNA159 mRNA vaccine is the lipid nanoparticles (LNPs)-encapsulated mRNA-based ChulaCov19 vaccine
223952114|NCT01250717|DRUG|Zoladex|Given subcutaneously for 4 doses every three months
224104632|NCT05863247|OTHER|Patient Reported Outcomes / Biometric data revision|Multivariate statistical analysis will be done to identify the reported biomarkers to characterize patients into the following categories: satisfied without dysphotopsias, unsatisfied with dysphotopsias, satisfied with dysphotopsias, unsatisfied without dysphotopsias.Main outcome measures will be photic phenomena at 6 months of follow-up in correlation with the following pre-surgical parameters: macular ganglion cell complex thickness and/or total ocular and corneal higher-order aberrations (coma, trefoil, spherical aberration). Patients with known contributing factors for the development of dysphotopsias (such as residual refractive error, IOL decentration, posterior capsular opacification) will be excluded from the analyzis.
224288897|NCT01110044|BIOLOGICAL|251154 vaccine|Intramuscular, single dose
224288898|NCT01110044|BIOLOGICAL|Infanrix hexa™|Intramuscular, four doses
224288899|NCT01110044|BIOLOGICAL|Synflorix™|Intramuscular, four doses
224288900|NCT01110044|BIOLOGICAL|Rotarix™|Oral, two doses
224104633|NCT02628587|DRUG|Generic clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
224104634|NCT02628587|DRUG|Patent clopidogrel|"Comparison of different brands of clopidogrel:~\*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
224104635|NCT03906682|BEHAVIORAL|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
224288901|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing placebo|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
224288902|NCT05735886|DIETARY_SUPPLEMENT|Softgel containing 250mg of Urolithin A (Mitopure)|Single oral dose administration (4 softgels) to be orally administered daily according to the randomization for 28 days
224288903|NCT02904538|DRUG|Dexamethasone|
224288904|NCT02904538|DRUG|isotonic saline|
224288905|NCT00056381|DRUG|Anidulafungin|
224288906|NCT02023008|PROCEDURE|yoga therapy|Undergo integral yoga intervention with videoconferencing
224288907|NCT02023008|OTHER|internet-based intervention|Undergo integral yoga intervention with videoconferencing
224288908|NCT02023008|OTHER|questionnaire administration|Ancillary studies
223538282|NCT02625350|OTHER|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
223952115|NCT01250717|DRUG|Casodex|Taken orally once a day for 6 months
223952116|NCT01250717|PROCEDURE|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
223952117|NCT00211276|DRUG|ONTAK (denileukin diftitox)|
223952118|NCT03527329|DEVICE|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
224288909|NCT01143649|DEVICE|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
224288910|NCT01143649|PROCEDURE|constraint induced movement therapy (CIMT)|
224288911|NCT01143649|DEVICE|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
224288912|NCT04061577|DEVICE|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
224288913|NCT01838382|DEVICE|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
224288914|NCT01434576|BIOLOGICAL|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
224288915|NCT01434576|BIOLOGICAL|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
224295249|NCT01739920|OTHER|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
224104636|NCT03906682|BEHAVIORAL|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
224104637|NCT01919411|DRUG|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
223952119|NCT01655199|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
224104638|NCT01919411|DRUG|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
224104639|NCT02007837|DRUG|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
224104640|NCT02007837|OTHER|Daily text reminder text messages|
224104641|NCT02986451|DRUG|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
223538283|NCT02625350|OTHER|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
223538284|NCT00634140|DRUG|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
223952120|NCT04683900|OTHER|Standard of care + Mediterranean diet (intervention)|"Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.~Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine."
223952121|NCT04683900|OTHER|Standard of care (control)|Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included.
223952122|NCT00360035|DRUG|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
223952123|NCT06571292|DEVICE|Intensive training with robotic exoskeleton for upper limbs|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
224104642|NCT02986451|DRUG|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
224104643|NCT02986451|DRUG|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
224104644|NCT03117933|DRUG|Olaparib|Tablet, 100mg and 150mg
223538285|NCT00634140|DRUG|Placebo|placebo for 4-6 weeks
223538286|NCT01452477|DRUG|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
223538287|NCT01452477|DRUG|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
223729501|NCT02964962|DEVICE|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
223729502|NCT02533427|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily
223729503|NCT02533427|DRUG|VOX|100 mg tablet administered orally once daily
224104645|NCT03117933|DRUG|Cediranib|Tablet 15mg and 20mg
224104646|NCT03117933|DRUG|Paclitaxel|Intravenous (IV)
224104647|NCT06657482|BEHAVIORAL|Delayed school start time|The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
224104648|NCT06656234|DRUG|Glofitamab|Glofitamab will be administered at the discretion of the physician per local clinical practice and local labeling.
224104649|NCT06656234|DRUG|Obinutuzumab|Obinutuzumab pre-treatment is given intravenously at a dose of 1g on Cycle 1 Day 1.
224104650|NCT06656806|DRUG|Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD|Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD
224104651|NCT06656806|DRUG|Determine the presence and concentration of CBD in subject's plasma with inhaled CBD|Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD
224104652|NCT06656559|DRUG|Envafolimab and Surufatinib|Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
224104653|NCT06656273|BEHAVIORAL|FT LCP|FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
224104654|NCT06656429|DRUG|Transforaminal Epidural Steroid Injections|Transforaminal Epidural Steroid Injections
224104655|NCT03373812|PROCEDURE|Blepharoptosis repair|levator advancement or mullerectomy
224104656|NCT06653751|DEVICE|Reminder App|The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
224104657|NCT00128687|BEHAVIORAL|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
224104658|NCT00323661|DEVICE|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
224104659|NCT00323661|DEVICE|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
224104660|NCT05240261|DRUG|Quetiapine|Quetiapine 25 mg / day
224104661|NCT04804215|PROCEDURE|Intraductal transanastomotic stent group|When bile duct anastomosis is performed, a intraductal transanastomotic stent is inserted into the bile duct.
224104662|NCT04804215|PROCEDURE|No stent group|Do not insert a stent into the bile duct during anastomosis of the bile duct.
224104663|NCT02421250|DEVICE|Radical-7 Noninvasive Hgb Monitor|
224104664|NCT04176510|BEHAVIORAL|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
224104665|NCT03820115|DEVICE|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
224104666|NCT04789824|BEHAVIORAL|eyelid hygiene|EH
224295250|NCT03078582|DRUG|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
223729504|NCT02533427|DRUG|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
223952124|NCT06571292|DEVICE|Task specific training|Both groups will be trained with robotic exoskeleton for upper limbs and task specific training.
223952125|NCT06580990|PROCEDURE|specific neck exercises with the Spinetrack|This group will receive an telerehabilitation exercise programme for the deep neck musculature using the spinetrack
223952126|NCT06580990|PROCEDURE|specific neck exercises|This group will receive a telerehabilitation programme with exercise for the deep neck musculature
223952127|NCT05483478|COMBINATION_PRODUCT|mobile health combined Multi-course Program|mobile health combined Multi-course Program
223952128|NCT03902327|DIETARY_SUPPLEMENT|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
223952129|NCT03902327|DIETARY_SUPPLEMENT|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
223952130|NCT04627168|DEVICE|Non-invasive, surface electrical stimulation device, DS5 Digitimer|Transcutaneous abdominal electrical stimulation will be delivered through the commercially available equipment, a DS5 Digitimer.
223952131|NCT04690309|DRUG|Treatment with human insulin preparations or treatment with insulin analogues|The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
223952132|NCT02499991|BEHAVIORAL|memory|keep track of social events in diary for memory recall. Used by treatment group
223952133|NCT03100851|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
223952134|NCT02639234|BIOLOGICAL|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10\^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
224104667|NCT03949777|DEVICE|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
224104668|NCT03505242|DEVICE|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
224288916|NCT01434576|DRUG|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
224288917|NCT03989531|BIOLOGICAL|Adrecizumab|Drip infusion over 60 minutes
224288918|NCT03989531|DRUG|Placebo|Drip infusion over 60 minutes
224288919|NCT02281682|DRUG|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
224288920|NCT02281682|DRUG|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
223538288|NCT06391892|PROCEDURE|Neoadjuvant chemotherapy instead of upfront surgery|"All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board.~If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.~* Apart from blood collection (within the scope of clinical routine), there is no additional diagnostic intervention performed on the patient.~* The respective neoadjuvant chemotherapeutical drug will be selected and applied by the treating medical oncologist at physicians choice (unaffected by study participation), usually mFOLFIRINOX or Gemcitabine/nabPaclitaxel at standardized dosage recommended by NCCN and local guidelines.~FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin."
223538289|NCT06391892|PROCEDURE|Upfront surgery|Standard of care as recommended by tumor board (not affected by study conditions).
223538290|NCT06438991|OTHER|Adjustment of spinal cord stimulation parameters for voluntary motor control|All patients will receive a spinal cord stimulator and undergo adjustment of stimulation parameters for optimal voluntary lower extremity motor control during research visits. Muscle strength will be assessed with the stimulation turned on and off.
223729505|NCT04800705|OTHER|ultrasound assessment|Zinc (Zn), copper (Cu), calcium (Ca), iron (Fe), manganese (Mn), selenium (Se), strontium (Sr), aluminum (Al), antimonium (Sb), phosphorus (P), magnesium (Mg), sodium (Na), potassium (K), barium (Ba) and thallium (Tl) measurements (µg/L,mean±SD)
223952135|NCT02639234|DRUG|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
223952136|NCT04135183|PROCEDURE|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
223952137|NCT01435499|BIOLOGICAL|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
223952138|NCT01435499|DRUG|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
224288921|NCT02281682|DRUG|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
224288922|NCT02281682|PROCEDURE|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
223952139|NCT02020200|DRUG|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight\<40 kg; 30 mg in case weight\>90 kg; otherwise 20 mg.
223952140|NCT02020200|DRUG|Placebo|
223952141|NCT06390176|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG powder|Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.
224288923|NCT01684527|OTHER|Respiratory secretions obtained|
223952142|NCT06390176|DIETARY_SUPPLEMENT|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus rhamnosus GG powder
223952143|NCT06390176|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
223952144|NCT03096496|OTHER|QoL questionnaires|Quality of life questionnaires
223952145|NCT04389684|OTHER|Psycho-Social Questionnaire|Patients, after enrollmenet in the study, receive a paper questionnaire during the month following COVID19 related confinement and all the material to send it back to the institution. They receive the same questionnaire 3 months later with all the material to send it back to the institution. The intervention is the same for all patients wether their treatment was modified or not.
223952146|NCT05530083|BEHAVIORAL|group education|Group education is one of strategies and behavioural interventions of smoking cessation. Lectures, group meeting for mutual support, discussion of coping skills and suggestions for prevention relapse can help smokers quit smoking by providing support and encouragement from people in same condition.
223952147|NCT05530083|BEHAVIORAL|conventional smoking cessation management|Including regular follow-up of smoking status and giving advice of smoking cessation
223952148|NCT00246129|DRUG|Campath|Monoclonal antibody induction therapy
223952149|NCT00246129|DRUG|Daclizumab|Monoclonal antibody induction therapy
223952150|NCT02704026|OTHER|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
224288924|NCT03208673|DEVICE|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
224288925|NCT01008514|PROCEDURE|adjuvant therapy|
224288926|NCT01008514|RADIATION|accelerated partial breast irradiation|
224288927|NCT01008514|RADIATION|intracavitary balloon brachytherapy|
224288928|NCT00768118|DIETARY_SUPPLEMENT|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
224104669|NCT03505242|DEVICE|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
224104670|NCT06377995|OTHER|Placebo technique|The patient is in a supine position with a 90° knees flexion. The osteopath lies cephalad to the patient and places their hands on their shoulders.
224104671|NCT06377995|OTHER|Diaphragm protocol|The patient is in a supine position with a 90° knees flexion.To stretch the diaphragm, the osteopath stands at the head of the bed and places his hands on the lower edge of the ribcage and accompanies the lifting of the ribs during inhalation and maintains it during deep exhalation for up to 2 sets of 10 deep breaths separated by 1 minute. For the neuromuscular technique, the osteopath is positioned contralateral to the side to be treated and slides with the thumb under the lower part of the thorax, applying a force in the opposite direction.To inhibit the phrenic centre, the osteopath places one hand on the sternum in a caudal direction and the other in the projection of the phrenic centre in a cephalic direction.The participant inhales deeply and the osteopath presses in both directions during the expiratory phase for 10 respiratory cycles.
224104672|NCT05059353|DEVICE|Digitally based multidomain intervention|"Education (5-10 mins). This session is to educate patients on instrumental activities of daily living such as the importance of companionship, medication, finance, home, travel, and kitchen safety. The content will be delivered using video and text-based material in English.~Physical Activity (10 mins). This session includes activities such as brisk walking and yoga. Participants will be allowed to choose their preferred exercise option from the menu.~Reminiscence Therapy (20 mins). This session includes recollection of events using directed questions, and a collection of photos from the past. Participants will be asked to share about any aspect related to the given topics using text or audio.~Cognitive Games (20 mins). Participants will be asked to play games using their fingers to control characters on the screen to achieve goals. These games are designed to train different cognitive abilities, including attention, memory, executive functioning, and processing speed."
224104673|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
224104674|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be \< 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
224104675|NCT00574977|BIOLOGICAL|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
223729506|NCT05288075|DRUG|Indacaterol/glycopyrronium|"In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration."
223952151|NCT01588847|PROCEDURE|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
223952152|NCT01588847|PROCEDURE|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
223952153|NCT02375243|DRUG|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
224104676|NCT06605664|DIAGNOSTIC_TEST|Hyperpolarized 13C pyruvate MRI|The subject enrolled in this trial will receive DNP-MRI scanning for two times through hyperpolarized \[1-13C\]pyruvate injection (\~250 mM, 0.43 mL/Kg) before and 2-5 weeks after radiotherapy.
224104677|NCT05426044|DRUG|Metformin|"To investigate whether metformin has a neuroprotective effect in patients with primary open-angle glaucoma by comparing the rates of change of average retinal nerve fiber layer ganglion cell inner plexiform layer (RNFL-GCIPL) thickness (primary outcome measure) between patients randomized to receive metformin versus those randomized to receive placebo.~To identify the risk factors associated with progressive RNFL-GCIPL thinning and progressive decline in visual field mean deviation in patients with glaucoma."
224104678|NCT05426044|DEVICE|Placebo|This study takes 24 months. Participants will have 12 visits within 24 months. All of the investigations will be carried out at Grantham Hospital and Hong Kong Eye Hospital. Patients will be randomly assigned in a 1:1 ratio to receive, twice daily, oral metformin 750mg (i.e. 1500mg/day) or identical-appearing oral placebo. The investigators and patients will be blinded to the treatment assignment. Participants will be followed up at 2-month intervals for 24 months.
224104679|NCT01650805|DRUG|ponatinib|45 mg tablet, taken orally once daily
223729507|NCT00022139|DRUG|carboplatin|
223729508|NCT00022139|DRUG|fluorouracil|
223729509|NCT00022139|DRUG|paclitaxel|
223729510|NCT00022139|PROCEDURE|conventional surgery|
223729511|NCT00022139|RADIATION|radiation therapy|
223952154|NCT05671211|OTHER|Task-Oriented Training|Participants in this group will receive 30 minutes of task-oriented training and 1 hour of conventional therapy for 6 weeks 5 times a week.
223952155|NCT05671211|OTHER|Conventional Therapy|Conventional therapy will be consisted of balance,upper and lower extremity strengthening exercises.
223952156|NCT03590496|DIETARY_SUPPLEMENT|Calcium-Propionate 500mg|Calcium-Propionate capsules
223952157|NCT03590496|OTHER|Placebo|Placebo capsules without any active ingredient
223952158|NCT04929600|DRUG|sacubitril/valsartan|Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.
223952159|NCT04929600|DRUG|Amlodipine|Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
223952160|NCT05217758|DRUG|Mifepristone|1200 mg/day, once daily, 7 days
223952161|NCT05217758|DRUG|Placebo|Placebo, once daily, 7 days
224104680|NCT01650805|DRUG|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
224104681|NCT03670576|PROCEDURE|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
224104682|NCT03670576|OTHER|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
224104683|NCT03670576|OTHER|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
224288929|NCT00768118|GENETIC|electrophoretic mobility shift assay|
224288930|NCT00768118|OTHER|laboratory biomarker analysis|
224288931|NCT03891329|DEVICE|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
224288932|NCT03891329|DEVICE|Plexa S DX|Implantation, measurements and follow-up schedule
223538291|NCT03999580|DRUG|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion \< 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion \< 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
223538292|NCT03509818|OTHER|plyometric exercise|acute plyometric exercise
223538293|NCT03509818|OTHER|Aerobic exercise|acute aerobic exercise
223538294|NCT00205764|DRUG|Melphalan|
223538295|NCT03192098|DEVICE|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
223538296|NCT03421886|DEVICE|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
223538297|NCT03421886|DEVICE|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
223538298|NCT05282875|DRUG|management of immunosuppressive therapy|"3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents"
223538299|NCT01138475|DRUG|Paricalcitol|1 microgram by mouth daily for 6 weeks
223538300|NCT01138475|DRUG|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
223538301|NCT01138475|DRUG|Placebo|Inactive substance, one capsule daily for 6 weeks
223952162|NCT06526442|DIAGNOSTIC_TEST|magnetic resonance imaging|all participants undergo novel MR sequences, including 3D-MRE，DCE-MRI，IVIM-DWI，T1/T2 mapping.
223952163|NCT02243449|PROCEDURE|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
223952164|NCT02243449|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
223952165|NCT02148120|DRUG|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
223952166|NCT02148120|DRUG|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
223952167|NCT02148120|DRUG|Placebo|
223952168|NCT01307306|DRUG|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
223952169|NCT01307306|DRUG|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
224288933|NCT00487929|DEVICE|nasal CPAP|Nocturnal
224288934|NCT00487929|DEVICE|Sham CPAP|Nocturnal
224288935|NCT04382430|PROCEDURE|Ultrasound guided venous access|Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.
224288936|NCT04382430|PROCEDURE|Conventional technique|Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
224288937|NCT06602492|DRUG|Lower nicotine e-liquid|A 3% nicotine concentration eliquid.
224288938|NCT06602492|DRUG|Higher nicotine eliquid|A 5% nicotine concentration eliquid.
224104684|NCT03670576|OTHER|Home Hand Held Spirometry|Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
224104685|NCT00289705|PROCEDURE|Surgery|Laparoscopic Roux-en-Y gastric bypass
223538302|NCT02169011|PROCEDURE|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
223538303|NCT02169011|PROCEDURE|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
224104686|NCT00222846|BEHAVIORAL|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
223538304|NCT01624935|BEHAVIORAL|interpersonal psychotherapy|interpersonal psychotherapy
223538305|NCT05636202|OTHER|No intervention|There was no intervention in the retrospective study
224288939|NCT03176784|DRUG|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
224288940|NCT03176784|DRUG|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
224288941|NCT03176784|OTHER|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
224288942|NCT03176784|OTHER|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
224288943|NCT01847365|DEVICE|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
224288944|NCT02414373|DRUG|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
224288945|NCT02414373|DRUG|Bupivacaine|local anesthetics, which will epidurally administered
224288946|NCT02414373|DEVICE|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
224288947|NCT02414373|DEVICE|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
224288948|NCT00823381|DIETARY_SUPPLEMENT|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
224288949|NCT00823381|OTHER|placebo|one placebo pill taken once a day with breakfast
223538306|NCT03968692|DIAGNOSTIC_TEST|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
223538307|NCT01871025|OTHER|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
223538308|NCT01871025|OTHER|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
223538309|NCT02125344|DRUG|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
224104687|NCT00222846|BEHAVIORAL|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
224104688|NCT05650827|BEHAVIORAL|Resistance training|10 weeks of resistance training 3 times pr. week.
224104689|NCT05650827|DIETARY_SUPPLEMENT|Protein supplement|A daily supplement of protein to ensure a daily intake of 1,6g protein/kg bodyweight
224104690|NCT05631028|DRUG|Dexmedetomidine|Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
224104691|NCT05631028|DRUG|Remimazolam tosilate|Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
224104692|NCT04770103|BEHAVIORAL|Balance recovery|"Balance recovery by stepping ascertains the capability of the participant to recover when subjected to a loss of balance in the forward direction.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
224104693|NCT04770103|BEHAVIORAL|Postural Sway|"Postural sway is a pseudo-static measure of postural control that evaluates a participants balance recovery ability when the perturbation does not require a dynamic step recovery.~Attitudes towards exercise, fear of falling and mental wellness a psychosocial measures to ascertain the relationship between perceptions and physical capability."
224104694|NCT01887210|BEHAVIORAL|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
224104695|NCT01887210|BEHAVIORAL|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
224104696|NCT00840463|DRUG|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
224104697|NCT00840463|OTHER|Placebo|Sugar pill
224104698|NCT03697239|DRUG|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
224104699|NCT03697239|DRUG|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
224104700|NCT03697239|DRUG|Cisplatin|25mg/m2 in 500\*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
224104701|NCT03697239|DRUG|Gemcitabine|1000mg/m2 in 500\*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
224288950|NCT00823381|BEHAVIORAL|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
224288951|NCT01526460|DRUG|Atorvastatin|80 mg
224288952|NCT01526460|DRUG|Rosuvastatin|40 mg
223952170|NCT06001515|DEVICE|Dual scan protocol|one CBCT scan for the patient while wearing the scan appliance and another scan for the appliance alone
223952171|NCT06001515|DEVICE|triple scan protocol|3D facial Scanning for the patients while wearing their dentures in addition to the dual scan protocol
223952172|NCT04475406|OTHER|PICF (Periopaper)|After the plaques and soft attachments around the implants were removed, the implants were isolated using cotton rolls and dried with an air spray. The PICF was collected from the mesio-buccal region of the implant using periopaper strips (Oraflow Inc, NY, USA). Paper strips were placed 1-2 mm inside the peri-implant sulcus and kept for 30 s. Paper strips were placed in sterile Eppendorf tubes containing 200 µL of phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. Paper strips contaminated with saliva or blood were excluded from the sampling.
223952173|NCT04475406|OTHER|Subgingival plaque, Gracey curette (Hu-Friedy)|After collecting the PICF, the supragingival plaque was carefully removed using a sterile scaler. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal region of the implant using a sterile plastic Gracey curette (Hu-Friedy, Switzerland) for 30 s. The samples collected were transferred to sterile Eppendorf tubes containing 200 µL of PBS. The tubes were kept at -80°C until the analysis day.
223952174|NCT04475406|OTHER|Clinical data, williams probe PCPNU (Hu-Friedy)|"A single calibrated examiner performed all (full-mouth and site-specific) clinical measurements (B.K.), including probing depth (PD), clinical attachment level (CAL), presence of bleeding on probing (BOP), 3-year survival rate (CSR), and bone loss (BL).~The values of PD and BOP were measured from four sites of each implant (mesial, distal, buccal, and lingual) with a Williams type (Hue Friedy, Switzerland) plastic periodontal probe. The PD was recorded as the distance from the base of the peri-implant to the side of the gum in millimeters. BOP was evaluated according to the presence (+) or absence (-) of bleeding within the first 30 s following the measurement of PD.17 Control panoramic films of all patients were taken, and differences in the marginal bone level between radiography images after implant placement and 3 years later were evaluated. Original films and images taken later were taken with the same angle for standardizaton."
223952175|NCT02994498|DRUG|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
223952176|NCT00409903|DRUG|Eprosartan|
223952177|NCT00750477|DIETARY_SUPPLEMENT|NEM|see Treatment Arms
223952178|NCT00750477|DIETARY_SUPPLEMENT|Placebo|Placebo comparator containing inactives
223952179|NCT01286311|BEHAVIORAL|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
223952180|NCT00265902|PROCEDURE|diagnostic imaging|
223952181|NCT05397509|OTHER|Olive leaf tea|250 mL of Olive leaf tea and a high-glycemic breakfast
223952182|NCT05397509|OTHER|Placebo tea|250 mL of placebo tea and a high-glycemic breakfast
223952183|NCT00248898|PROCEDURE|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
223952184|NCT01324648|BEHAVIORAL|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
223952185|NCT01324648|BEHAVIORAL|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
223952186|NCT01324648|OTHER|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
223952187|NCT00000532|BEHAVIORAL|diet, fat-restricted|
223952188|NCT00446576|DRUG|Epoetin Alfa|
223952189|NCT04022707|OTHER|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
224104702|NCT02452359|DEVICE|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
224104703|NCT00584350|OTHER|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
223723118|NCT05052762|OTHER|Group A: Elastic resisted training for Gluteus Maximus strength|"Subjects attended physical therapy two times per week for a total of 10 visits. In the first five sessions, subjects performed the following exercises to strengthen the gluteus maximus: bilateral bridge, unilateral bridge, and non-weight-bearing hip extension in prone with the knee flexed at 90 degrees. In the next five sessions, abduction and external rotation in a quadruped (fire hydrant exercise) and weight-bearing hip extension (known as deadlift exercise) are added. Each exercise was performed for 10 repetitions. Elastic resistance was Added to the fire hydrant, hip extension in prone and deadlift exercises to allow each subject to perform at a 10-repetition maximum. The resistance for each subject was adjusted weekly as needed. The exercise program was performed under direct supervision only during the physical therapy sessions."
224288953|NCT01526460|DRUG|Placebo|no statin loading dose
224288954|NCT04309526|DRUG|NCO-48 Fumarate|NCO-48 Fumarate
224288955|NCT04309526|DRUG|Placebo|Placebo
223729512|NCT01643655|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
223952190|NCT04022707|OTHER|Educational control|Lectures on health and fitness
224104704|NCT00584350|OTHER|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
224104705|NCT00584350|OTHER|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
224104706|NCT00500097|DEVICE|Digital retina image|
224288956|NCT04944082|DRUG|Ivermectin|(The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
223538310|NCT02125344|DRUG|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
223538311|NCT02125344|DRUG|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
223538312|NCT02125344|DRUG|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
223538313|NCT02125344|DRUG|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
223538314|NCT02125344|DRUG|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
223538315|NCT02125344|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
224288957|NCT05593731|BIOLOGICAL|dental implants with melatonin gel|platelet rich fibrin membrane around dental implants
223538316|NCT02125344|DRUG|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is \<70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is \<50 kg, both dosages will be reduced to 500 mg each.
224288958|NCT02729779|OTHER|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
223952191|NCT05214521|DEVICE|"digital interactive technology Smart glove SensoRehab"|"Participants will receive rehabilitation program including sessions on the Smart glove SensoRehab (SGSR) system. The program for IS patients includes 10 sessions with the SGSR: 15-30 minutes once a day for the affected hand, 2 weeks."
223952192|NCT06401590|DIAGNOSTIC_TEST|FROZEN SENTINEL LYMPH NODE BIOPSY|FROZEN SENTINEL LYMPH NODE BIOPSY
223952193|NCT00838448|BEHAVIORAL|Exercise|Exercise performed on a treadmill for 20-30 minutes
224104707|NCT00500097|DEVICE|direct ophthalmoscopy|
224288959|NCT02729779|OTHER|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
224288960|NCT01856387|BIOLOGICAL|high neutrophil to lymphocyte ratio|
224288961|NCT01856387|OTHER|normal neutrophil-to Lymphocyte ratio|
224288962|NCT06306092|BEHAVIORAL|Sleep on Schedule|Sleep education at school
224288963|NCT06306092|BEHAVIORAL|Technology restriction|Reduction of electronic media use before bedtime
223538317|NCT02373618|OTHER|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
223952194|NCT01632085|DEVICE|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
223952195|NCT06378281|OTHER|Modified teach-to-goal informed consent|Enhanced procedure to improve informed consent in vulnerable populations.
223952196|NCT04818476|PROCEDURE|diagnostic endoscopic resection|diagnostic endoscopic resection
223952197|NCT01759459|DRUG|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
224104708|NCT00500097|PROCEDURE|comprehensive eye exam|
224104709|NCT02043574|BEHAVIORAL|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
224104710|NCT02043574|BEHAVIORAL|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
224104711|NCT02287246|DRUG|Extended-Release liposomal bupivacaine (Exparel)|20mL
224104712|NCT02287246|DRUG|Normal saline|20mL
224288964|NCT05931120|DEVICE|Dry needling|"dry needling using 50mm or 60mm sized needles based on individual muscle bulk. Targeted dry needling will be performed on the muscles presenting with tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
224288965|NCT05931120|DEVICE|IASTM|"Instrument assisted soft tissue mobilization tools targeting tight hamstrings. hurdler Hamstring stretch, extended triangular pose 10 repetitions, 3 sets per session and 2 sessions per week for 4weeks.~total 8 sessions , each consisting of 40mins"
224288966|NCT04751474|OTHER|Motivational messages|Participants in the motivational group were sent to motivational messages to their mobile phones for 21 days.
224288967|NCT01351350|DRUG|MLN0128|MLN0128 capsules
224288968|NCT01351350|DRUG|paclitaxel|paclitaxel intravenous infusion
224288969|NCT01351350|DRUG|trastuzumab|trastuzumab intravenous infusion
224104713|NCT00770861|DRUG|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
224288970|NCT06011382|DEVICE|Advanced Molar Distalization Appliance (amda®)|AMDA is a prefabricated device anchored to the palate by miniscrews and it is a noncompliance appliance for maxillary molar distalization
224288971|NCT06011382|DEVICE|Buccal mini-implants|Buccal mini-implants for maxillary molar distalization
224288972|NCT00254020|DRUG|Citalopram|Patients who are found to have major depression will be referred to a psychologist
224288973|NCT06193447|OTHER|None intervention|None intervention
223729513|NCT01224067|DRUG|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
224104714|NCT00770861|DRUG|Placebo|Matching placebo tablets, oral administration
224104715|NCT02062086|DIETARY_SUPPLEMENT|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
223729514|NCT04094363|OTHER|Product A|Usual Brand, filtered combustible cigarette
224104716|NCT01468519|DRUG|Insulin|Insulin via continuous subcutaneous insulin infusion
224104717|NCT01468519|DRUG|Insulin|insulin via multiple daily injections
224104718|NCT04596813|DEVICE|CytoSorb 300 mL device|Intra-and postoperative CytoSorb hemoadsorption
224104719|NCT03237403|OTHER|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
224104720|NCT02515669|DRUG|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
224104721|NCT02515669|DRUG|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
224104722|NCT01259739|OTHER|Cocoa|dissolved in water twice-daily intervention
224288974|NCT01584531|DRUG|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake."
224288975|NCT01918579|PROCEDURE|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
224288976|NCT03379155|OTHER|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem \& Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
224288977|NCT01216657|DRUG|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
224288978|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
223538318|NCT02373618|OTHER|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
224288979|NCT01258101|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
224288980|NCT01258101|DRUG|ribavirin|800 mg orally daily
224288981|NCT01258101|DRUG|ribavirin|400 mg orally daily
224288982|NCT02610920|PROCEDURE|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
223538319|NCT04375527|DRUG|Binimetinib|Given PO
223538320|NCT04375527|BIOLOGICAL|Nivolumab|Given IV
223538321|NCT04375527|OTHER|Questionnaire Administration|Ancillary studies
223538322|NCT05120050|DEVICE|ASP Health instrument|The instrument is an integrated device with a short processing time (measured in 2 to 3 minutes) that distributes cells from limited volume samples (measured in microliters). The process involves a novel aerosolization technique that transfers liquid sample to a glass slide via a burst of air. After the sample is deposited on the glass slide, the automated system uses an integrated heating strip to heat the specimen slide. This process is similar to using a hair dryer to dry the specimen slide in the current ROSE setting. After drying the slide, the system uses series of pumps to dispense microliters of stain reagent onto the slide to stain the cells. Currently, the system is configured to perform DiffQuik staining, which is commonly used in the ROSE process. In the future, the staining capability will be broadened to include other staining processes such as Rapid PAP, H\&E staining etc.
223538323|NCT02117778|PROCEDURE|Continuous Nerve Block|
223729515|NCT04094363|OTHER|Product B|CSD1902-11, an electronic nicotine delivery system
224104723|NCT06080750|GENETIC|Quantitative Real Time Polymerase chain reaction (qRT-PCR)|to study gene expression of NLRP3 inflammasome and IL-1B in blood
224104724|NCT06080750|DIAGNOSTIC_TEST|ELISA and colorimeter|IL-6 and total LDH
224104725|NCT05032508|DRUG|Lidocaïne Aguettant 20 mg/ml|Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
224104726|NCT05032508|DRUG|NaCl 0,9%|Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
224104727|NCT02291341|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
224104728|NCT02291341|DRUG|Cymbalta®|60 mg capsule of Eli Lilly and Company
224104729|NCT00006061|DRUG|phosphatidylcholine|
224104730|NCT03942614|BEHAVIORAL|Nordic pole walking|
224104731|NCT03750838|BEHAVIORAL|Text Messaging Intervention|The content for the text messaging Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
224104732|NCT00994188|PROCEDURE|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
224104733|NCT04335825|PROCEDURE|phacotrabeculectomy|combined antiglaucoma procedure: trabeculectomy with phacoemulsification
224104734|NCT04335825|PROCEDURE|ExPress antiglaucoma surgery combined with phacoemulsification|combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
224104735|NCT02985801|DRUG|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
224104736|NCT02985801|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
224104737|NCT03738124|DEVICE|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
224104738|NCT02464319|DRUG|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
224104739|NCT02464319|DRUG|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
224104740|NCT01962662|OTHER|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
224104741|NCT01962662|OTHER|U/E exercise|strengthening and stretching
224104742|NCT03858582|DRUG|pembrolizumab|pembrolizumab 200mg
224104743|NCT03858582|RADIATION|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
223952198|NCT01759459|DRUG|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
224104744|NCT05387330|DIAGNOSTIC_TEST|ELISA kit|Sandwich ELISA kit for the accurate quantitative detection of sCD62L and SPARC in human plasma and serum samples.
223952199|NCT01759459|DRUG|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
224104745|NCT06510426|DRUG|Rebif 44 MCG Per 0.5 ML Prefilled Syringe|Rebif 44mcg per 0.5ml administered subcutaneously
224288983|NCT02610920|DRUG|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
224288984|NCT00414349|DRUG|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
223952200|NCT01572896|BEHAVIORAL|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
223952201|NCT01572896|BEHAVIORAL|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
223952202|NCT01711788|PROCEDURE|Intrabone infusion of umbilical cord blood stem cells|
224104746|NCT06510426|DRUG|Saline|0.5mL of saline administered subcutaneously
224104747|NCT01160367|OTHER|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
223729516|NCT04094363|OTHER|Product C|CSD1902-21, an electronic nicotine delivery system
223729517|NCT04094363|OTHER|Product D|4mg Nicotine gum
224104748|NCT01160367|OTHER|standard of care|Patient-family dyads will receive standard of care in health decision-making
224104749|NCT02236624|BEHAVIORAL|Aerobic exercise|
224104750|NCT01479972|BIOLOGICAL|VPM1002|Tuberculosis vaccine
224288985|NCT00414349|DRUG|oral intake|300 to 600 mg per day taken orally
224288986|NCT00414349|DRUG|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
224288987|NCT00958867|BEHAVIORAL|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
224288988|NCT00958867|BEHAVIORAL|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
224104751|NCT01479972|BIOLOGICAL|BCG|commercially available live vaccine BCG
224104752|NCT05581719|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
224104753|NCT05581719|DRUG|Nivolumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
224288989|NCT00958867|BEHAVIORAL|Exercise training (S & R; control)|Six-month, twice-weekly stretch \& relax (S \& R; control) program
223952203|NCT05670561|DRUG|Esketamine|PCIA formula#100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min.The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
224104754|NCT05581719|DRUG|Tislelizumab|Immune checkpoint inhibitor (anti-PD-1 antibody)
224104755|NCT02035943|DIETARY_SUPPLEMENT|Insulin separated|separate continuos infusion of insulin
224104756|NCT02035943|DIETARY_SUPPLEMENT|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
224104757|NCT00870493|DRUG|Aliskiren|Aliskiren 300 mg daily oral
224104758|NCT00870493|DRUG|Placebo|starch tablet, 300 mg/day
224104759|NCT00630032|DRUG|cyclophosphamide|500 mg/m² every 3 weeks
224104760|NCT00630032|DRUG|Docetaxel|100 mg/m² every 3 weeks
224104761|NCT00630032|DRUG|epirubicin hydrochloride|100 mg/m² every 3 weeks
224104762|NCT00630032|DRUG|fluorouracil|500 mg/m² every 3 weeks
224104763|NCT00630032|DRUG|ixabepilone|40 mg/m² every 3 weeks
224104764|NCT02798523|DRUG|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
224104765|NCT02798523|DRUG|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
224104766|NCT00385333|PROCEDURE|Feasibility Study - Imaging System|
224104767|NCT05459805|DRUG|traditional chinese medicine Xuanfei-Zhike formula|200ml, bid, for 8 weeks
223729518|NCT04593563|DRUG|Psilocybin|Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
224104768|NCT05459805|DRUG|inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)|one suction, q12h, for 8 weeks
224104769|NCT06342167|RADIATION|Radiotherapy|Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
224104770|NCT06342167|DRUG|Programmed Cell Death Protein 1 Inhibitor|200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
224104771|NCT06342167|DIETARY_SUPPLEMENT|Immunonutrition support|600-1600 ml of TPF-T per day according to the nutrition status evaluation
224104772|NCT01170156|DEVICE|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
224104773|NCT01236885|OTHER|computer-assisted intervention|Undergo blood glucose management using Glucommander
224104774|NCT00609440|OTHER|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
224104775|NCT04119908|DEVICE|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
224104776|NCT04119908|BIOLOGICAL|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
224104777|NCT02769871|BEHAVIORAL|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
224104778|NCT02769871|BEHAVIORAL|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
224104779|NCT04210713|DRUG|Minocycline|200 mg/day
224104780|NCT04210713|DRUG|Sugar pill|Matched placebo
224104781|NCT05370469|OTHER|Sensus Smartwatch Application|Sensus is capable of administering ecological momentary assessments (EMAs) on a schedule, randomly, or using sensor-triggers. In this way, Sensus will capture both active (patient-initiated) and passive data streams from native smartphone sensors. Passive streams may include, but are not limited to, GPS, accelerometer, gyroscope, and pedometer data. Participants will be able to log data such as their activity, symptoms and medication adherence via user-initiated surveys within the Sensus app. Sensus will also prompt users to record their medication adherence, symptoms, or activity. This will be done either at fixed intervals (e.g., three times daily) or whenever the onboard sensors detect potential changes in a user's physiological state (e.g., shaking / moving around).
224104782|NCT05370469|DEVICE|RX Cap|The RXCap medication event monitoring device will be used to collect data on participant adherence to their TKI medication. A small computer chip is included in the top of a pill bottle. When the cap is taken off of the pill bottle by turning it or unscrewing it, the cap records the time and date that it was removed.
224104783|NCT05370469|DEVICE|Fitbit Sense|The Fitbit Sense smartwatch will be used to collect data including steps, calories burned, total distance travelled, sleep (e.g. time spent sleeping and quality of sleep), flights of stairs climbed, active minutes, exercise (e.g. minutes spent exercising at various intensities), and average heart rate.
224104784|NCT05370469|OTHER|Surveys|Electronic and paper surveys will be administered throughout the study.
224104785|NCT02509338|DEVICE|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
224104786|NCT06870994|DEVICE|Targeted Hyperthermia Therapy|Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy
224104787|NCT04413799|COMBINATION_PRODUCT|lidocaine, ketamine intravenous infusion|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to lidocaine/ketamine group, the anesthesiologist led Acute Pain Service (APS) will prescribe lidocaine/ ketamine infusion, which will be monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
223723119|NCT05052762|OTHER|Group B: Weight resisted training for Gluteus Maximus strength|Subjects attended p two times per week for a total of 10 visits. The participants performed PHEKF in 90° knee flexion with 30° hip abduction and 10° hip extension to increase the muscle activity of the gluteus maximus. In the prone position, the participant performed 10° hip extension until the posterior knee reached the horizontal bar. The participants maintained 90° knee flexion with 30° hip abduction and 10° hip extension in the prone position against the resistance. Sandbags (3 kg) will be used to provide resistance on the ankle through a rope and pulley. Each subject performed three sets with three repetitions of five seconds each. 1-minute break is allowed between each set.
224104788|NCT04413799|DRUG|paravertebral block with ropivicaine|"Patients will be started with our standard analgesia regiment which is standing oral acetaminophen 1000mg every 8 hours, ibuprofen 600mg every 6 hours or celecoxib 200mg every 12 hours, and narcotics as needed. All patients who failed the standard analgesia regimen will be approached for the study. Failure of standard analgesia regimen will be determined by respirations \>20 minute, tidal volume ≤50% of predicted, numeric pain score ≥ 5, and a poor cough as determined by the trauma team.~Once the consent is obtained, the patients will be randomized to either PVB (control) or lidocaine/ketamine (study) groups. If the patient is randomized to PVB, the anesthesiologist led Acute Pain Service (APS) will place a paravertebral block catheter. Ropivacaine infusion will be started, monitored and titrated as necessary by APS. Standard analgesia will be continued on both study groups"
224104789|NCT02475200|DEVICE|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
224104790|NCT04561180|DRUG|EG-009A|Administered as an Intramuscular injection
224104791|NCT04561180|DRUG|EG-009A Placebo|Administered as an Intramuscular injection
224104792|NCT04561180|DRUG|Standard of Care|Standard of Care Treatment for COVID-19 Infection
224104793|NCT04561180|DRUG|Dexamethasone|The comparator, Administered as an Intravenous infusion
224104794|NCT07031128|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
224104795|NCT07031128|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
224104796|NCT06718751|DRUG|Tranexamic Acid 650 MG|PO administration of TXA tablet
224104797|NCT06718751|DRUG|Placebo|PO administration of placebo tablet
224104798|NCT02258412|DRUG|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
224104799|NCT02258412|DRUG|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
224104800|NCT03439345|DRUG|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
224104801|NCT03439345|DRUG|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
224104802|NCT04974307|DEVICE|OrCam MyEye 2|The OrCam MyEye 2 is a 22.5-g portable, eyeglass-mounted device that converts camera-captured inputs to auditory outputs. Its advertised functions include text reading, facial recognition, and product identification.
224288990|NCT01684059|DIETARY_SUPPLEMENT|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
224104803|NCT04806568|OTHER|Cognitive Training|The cognitive training treatment is a Greek adaptation of BrainHQ developed by Posit Science Corporation. The intervention will target speed, attention, working memory, and executive function through the visual and auditory domains via a set of 15 exercises. Each daily training session consists of four exercises chosen from an active set of six. Participants will be instructed to train for one hour per day, three days per week, over 12 weeks via a tablet. Each subject will receive at least 29 sessions of computerized cognitive training.
224104804|NCT04806568|DEVICE|Monitoring of daily activity|Monitoring of daily activity via Fitbit Charge 4 smartwatch.
224104805|NCT06173752|BEHAVIORAL|Exposure therapy|Participants will complete exposure therapy for up to 12 weeks, and coached exposure session will be approximately 50 minutes.
224104806|NCT05964738|DRUG|Diuretics withdrawal|Diuretics that not have been demonstrated improve survival in chronic HFrEF are withdrawn
224104807|NCT05964738|DRUG|Diuretics maintenance|Any diuretic could be used
224104808|NCT06025136|OTHER|Using a gel pillow|Within the scope of the study, gel pillows with a cold surface were used in the patients in the study group. It is produced by combining the obtained special liquid with elastic material with NASA approved molecule exchange technology and is made of OEKO-TEX CLASS 1 certified material.Thanks to the gel material on the pillow surface, the surface temperature is reduced from 37°C to 24°C in about 10 seconds. It gives a feeling of coolness with its thermal conductivity feature.
224104809|NCT05111210|OTHER|Blood sample|Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
224104810|NCT05111210|OTHER|Data collection|collection of socio-demographic, clinical and biological data.
224104811|NCT05111210|OTHER|skin biopsies|skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
224104812|NCT05733091|BEHAVIORAL|Standard of Care|Standard of care assessment of their function including pituitary hormone lab draws, audiogram hearing test, eye exam, teeth and jaw exam (in trismus clinic) and speech and swallowing evaluation
224104813|NCT03417765|DRUG|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
224104814|NCT05635838|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
224104815|NCT05635838|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
224104816|NCT05634512|DRUG|Laronidase therapy and a stem cell transplant|To identify key differences leading to variability in PK parameters for patients receiving IV laronidase therapy for the treatment of MPS-IH. There will be 12 samples per patient (6 pre-transplant and 6-post-transplant). Laronidase will be administered IV per protocol using standard dosing (0.58 mg/kg intravenously on a weekly basis), and six (n=6) blood samples will be collected over 24 hours for the determination of mononuclear cell lysates and plasma laronidase concentrations for a total of 18mL. The second PK monitoring will be obtained using the same PK design but following complete or near-completedonor derived myeloid engraftment which is evaluated at different time pointspost-HCT (day 30, day 42, day 60). The standard is to continue ERT through 8 weeks post-transplant.
223723120|NCT02590614|DIETARY_SUPPLEMENT|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
223723121|NCT02590614|DIETARY_SUPPLEMENT|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
223723122|NCT02233647|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
224104817|NCT06383520|DRUG|68Ga-aGPC3-scFv/Fab|"For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis."
224104818|NCT05955027|DRUG|ZX-7101A|a drug to treat influenza, oral
224104819|NCT05955027|DRUG|Placebo|placebo control, oral
224104820|NCT00717470|DRUG|Prograf®|oral
223723123|NCT02233647|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
224104821|NCT00717470|DRUG|Advagraf®|oral
224104822|NCT00717470|DRUG|Mycophenolate Mofetil|oral
224104823|NCT00717470|DRUG|Simulect|oral
223723124|NCT04774328|DRUG|CA-008 (vocacapsaicin)|Single administration of CA-008 (vocacapsaicin) versus placebo
223723125|NCT04774328|DRUG|Placebo|Single administration of CA-008 (vocacapsaicin) versus placebo
224104824|NCT00717470|DRUG|methylprednisolone / prednisone|oral
224104825|NCT06518161|OTHER|Voluntary|Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
224104826|NCT02082561|BEHAVIORAL|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
224104827|NCT03590457|DEVICE|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
224104828|NCT02459171|OTHER|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
224288991|NCT05724446|DRUG|Clobetasol Propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05 % is an oil-in-water (O/W), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w).
224288992|NCT05724446|DRUG|Prednisolone acetate ophthalmic suspension, 1%|Microfine sterile ophthalmic suspension of dense and whitish appearance.
223723126|NCT01858298|OTHER|Conservative treatment: pulpectomy and composite resin crown|
223723127|NCT01858298|OTHER|Non-conservative treatment: Tooth extraction|
223723128|NCT04906291|OTHER|Toothpaste use|Brushing three times a day
223723129|NCT01652612|OTHER|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
223729519|NCT05627960|DRUG|AG-01 Compound|"Phase 1A dose escalation study: enrolled subjects with advanced solid tumors will receive AG-01 compound at various doses.~Phase 1B patients will be treated with AG-01 at the RP2D."
223952204|NCT05670561|DRUG|Sufentanil|PCIA formula#100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline. 30min before TACE treatment, the first dose of 2ml was slowly injected intravenously.No obvious adverse reactions were observed for 10min. The PCIA pump was commenced at the beginning of TACE. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h. The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
223952205|NCT04401943|OTHER|online fatigue intervention|on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
223952206|NCT06123936|OTHER|Reminder|"At mid-campaign, GPs in the interventional arm will recall their patients to be vaccinated via the reminder module Eo software~* This recall will be carried out as follows: patients whose medical records include a number likely to receive telephone text messages will be recalled by this means Two generic messages that doctors can choose will be proposed by the call-back module integrated into the Eo medical software~* In addition, the recall module will offer to send a postal letter with the same content as the text message to patients who do not have a mobile phone number in the business software but do have a postal address~* The recall module will also provide the doctor with a list of patients who have neither a mobile phone number or a postal address, so that he can recall them to be vaccinated orally by landline telephone or in consultation when they next visit.~The type of recall and the date of it will be notified in the medical file of each patient."
223952207|NCT02565225|BEHAVIORAL|RheumaLive App use|
223952208|NCT02765984|DEVICE|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
223952209|NCT06231667|OTHER|Education|four training sessions were applied to the intervention group
223952210|NCT00264888|DRUG|PTC124|
223952211|NCT06139835|BIOLOGICAL|Tartarase|Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
223952212|NCT00827294|BEHAVIORAL|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
223952213|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
223952214|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
223952215|NCT02556606|DRUG|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
223952216|NCT02556606|DRUG|Midazolam|single 40 min infusion of MID 0.03mg/Kg
223952217|NCT00403845|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
223952218|NCT00403845|DRUG|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
223952219|NCT00403845|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
223952220|NCT03147586|DRUG|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
223952221|NCT03147586|DRUG|placebo|placebo
223994487|NCT05030051|DEVICE|SkinPen Precision System|Microneedling is a relatively new, minimally invasive technique originally developed for skin rejuvenation. Controlled micro-injury to the dermis via the application of several small needles connected to a motorized device stimulates the wound healing process, resulting in the formation of new tissue and blood vessels. The SkinPen by Crown Laboratories is an FDA-cleared microneedling device proven to improve the appearance of acne scars This study evaluates the clinical performance of the SkinPen device for the treatment of signs of aging on the back of the hand. We hypothesize that the SkinPen device will produce a significant improvement in dorsal hand appearance at 3 month post treatment visit, when compared with baseline scores. The assessments will be based on the Clinician's Global Aesthetic Improvement Scale, and the Subject's Global Aesthetic Improvement Scale at the 3 month post treatment visit.
224104829|NCT02459171|OTHER|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
224104830|NCT02459171|OTHER|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
224104831|NCT02459171|OTHER|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
224104832|NCT05282212|DIAGNOSTIC_TEST|Ultrasound Scan|Within 90 days before the revision surgery, a calibrated examiner will ultrasonically scan the implants. The ultrasound device has been validated for its usability and design on human subjects in our recent clinical study (the University of Michigan Institutional Review Board under the number HUM00139630 and was registered with the National Institutes of Health U.S. National Library of Medicine database for clinical trials (clinicaltrials.gov) under the following identifier: NCT03558282) Coupling will be achieved with commercially available sterilized US gel (Sterile Aquasonic, Fairfield, NJ). The US probe will be mounted on an adjustable arm attached to a fixed stand. The probe is navigated by a calibrated examiner at the implant of interest and then will execute a total ±5 mm linear mesio-distal and coronal-apical translations to create 3D cross-sectional and transverse volumes, respectively and stored as an imageframe series, i.e., a DICOM format cineloop.
224104833|NCT02574299|OTHER|E-learning|Management of auditory processing disorders with serious game (E-learning)
224104834|NCT02574299|DEVICE|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
224104835|NCT01956643|OTHER|gum chewing|gum chewing
224104836|NCT01956643|OTHER|Control|Routine care during NPO
223994488|NCT04565002|DEVICE|Transcutaneous Electrical Diaphragmatic Stimulation|The procedure consists of electrical stimulation in the region of the motor points of the diaphragm. Its configurations contribute to produce involuntary muscle contractions. There are four electrodes positioned superficially on the skin.
223994489|NCT00035386|PROCEDURE|trans-right ventricular alcohol septal ablation (TRVASA)|
224104837|NCT05738512|PROCEDURE|Medial Flap Coblation Turbinoplasty|Reduction of the inferior turbinate to manage inferior turbinate hypertrophy
224104838|NCT05738512|PROCEDURE|Submucous Resection|Submucous Resection
224104839|NCT00639067|DEVICE|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
224104840|NCT04832438|DRUG|9-ING-41|15 mg/kg as intravenous infusion on Days 1 and Day 4 of a 21-day cycle
224104841|NCT04832438|DRUG|Carboplatin|Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
224104842|NCT00001332|PROCEDURE|CHPP with cisplatin|
224104843|NCT03667651|DRUG|EpiCeram|Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
224104844|NCT02240498|DRUG|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
224104845|NCT02240498|DRUG|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
224104846|NCT02240498|DEVICE|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
224104847|NCT02240498|DEVICE|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
224104848|NCT02240498|DEVICE|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
224288993|NCT03418168|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
223723130|NCT03174834|OTHER|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
223994490|NCT03344068|RADIATION|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
223994491|NCT03344068|DRUG|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
223994492|NCT03344068|DIETARY_SUPPLEMENT|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
224288994|NCT02389101|OTHER|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
224288995|NCT00303667|BIOLOGICAL|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
224288996|NCT00303667|BIOLOGICAL|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.
224288997|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
224288998|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14
224288999|NCT00303667|PROCEDURE|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
224289000|NCT00303667|RADIATION|total body irradiation|Administered on Day -13, 200 cGy two times.
224289001|NCT00303667|BIOLOGICAL|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
224289002|NCT00303667|DRUG|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
224289003|NCT00303667|DRUG|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
224289004|NCT00303667|DRUG|fludarabine phosphate|Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
224289005|NCT06234319|DIAGNOSTIC_TEST|CXCR4|Patients with clinical suspected primary glioma will receive a CXCR4 PET imaging.
224289006|NCT01807117|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
223723131|NCT04587232|DIAGNOSTIC_TEST|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire|Turkish version of Mini Osteoarthritis Knee and Hip Quality of Life Questionnaire (Mini-OAKHQoL) was derived from the Turkish version of OAKHQoL questionnaire, which was developed to assess the quality of life (QoL) in subjects with lower limb osteoarthritis. It includes five subscales: physical activities, mental health, pain, social support, social functioning; with three additional independent items addressing sexual life, professional life, and fear of being dependent. The numerical rating scales in the items range from 0 (worst) to 10 (best). Scores were obtained by computing the means of the item scores in each subscale. The last three items' score (independent items) becomes the corresponding score.
223994493|NCT00373451|DRUG|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)
224289007|NCT01807117|PROCEDURE|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
224289008|NCT01807117|PROCEDURE|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
224289009|NCT01807117|RADIATION|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
223994494|NCT00373451|DRUG|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
223994495|NCT00373451|DRUG|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
223994496|NCT03138642|RADIATION|RT|All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
223994497|NCT01508663|DEVICE|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
223994498|NCT01508663|DRUG|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
223994499|NCT00735280|DRUG|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
223994500|NCT02786472|BEHAVIORAL|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
223994501|NCT02786472|BEHAVIORAL|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
223994502|NCT02786472|BEHAVIORAL|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
223994503|NCT02786472|BEHAVIORAL|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
223994504|NCT04051086|BIOLOGICAL|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~* Medical examination : birth, weight, gender, blood pressure, medical history~* Urine and blood samples"
223994505|NCT04051086|BIOLOGICAL|Urine and blood samples|"Only one visit for each participant~* Medical history~* Urine and blood samples"
223994506|NCT03862014|DEVICE|SDF+KI|Molar with MIH will be treated with SDF+KI
223994507|NCT03862014|DEVICE|SDF+KI+GIC(SMART)|Molar with MIH will be treated with SDF+KI+GIC(SMART)
223994508|NCT00439192|DRUG|ELB245|
223994509|NCT00439192|DRUG|Tolterodine|
223994510|NCT02727569|DEVICE|New visual field algorithm with DLS|Mathematical model (software based) to derive retinal sensitivity.
223994511|NCT02727569|DEVICE|SITA algorithm|Mathematical model (software based) to derive retinal sensitivity. Commercially available.
223994512|NCT02727569|DEVICE|New visual field algorithm with MMDT|Mathematical model (software based) to derive retinal sensitivity.
223994513|NCT02963662|PROCEDURE|laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
223994514|NCT02963662|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
223952222|NCT05130099|OTHER|Interdisciplinary complex intervention|"The interdisciplinary complex intervention lasts 12 weeks and includes the 4 following components;~Patient-education: a 2-hours group-based digital session, including information about fatigue, training theory, psychological strategies and nutrition, all in relation to chronic fatigue (CF).~Physical exercise program: two weekly sessions with aerobic exercise and resistance training. The participants are instructed to do the same program in the unsupervised sessions as in the supervised sessions. After the first 12 weeks exercise period, the participant and the physiotherapist makes an individually tailored plan for exercise and follow-up the next 12 weeks.~Cognitive behavioral program: 6 group-based online sessions lead by two psychologists, based on elements from cognitive behavioral therapy to reduce and/or manage CF. Each session lasts for 135 minutes.~Nutritional counselling: 3 individual sessions by a clinical dietitian. Each session lasts for 30-60 minutes."
224104849|NCT02240498|DEVICE|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
224104850|NCT02240498|DEVICE|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
224104851|NCT02240498|DEVICE|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
223952223|NCT03206398|DEVICE|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
224289010|NCT00577148|DRUG|Rimonabant|Tablet, oral administration
224289011|NCT00577148|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
224289012|NCT05396664|BEHAVIORAL|ATWA|The Adolescent Transition in West Africa (ATWA) program is an in-school (Niger, Mali, Burkina Faso) and out-of-school (Niger and Mali) educational intervention implemented by local staff members at Save the Children, local community members, and teachers. ATWA provides internationally-recognized life skills education (LSE) to adolescents ages 10-19 years, and seeks to improve adolescents' knowledge and behaviors regarding sexual and reproductive health and rights. Outcome indicators to assess knowledge, behavior and attitudes of adolescents will vary by adolescent demographics as well as by country context, as based on the final set of curriculum deemed appropriate by the respective Ministries of Education (MOE).
223538324|NCT03006588|PROCEDURE|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
223538325|NCT00547963|BEHAVIORAL|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
223538326|NCT04344730|DRUG|Dexamethasone injection|Box of 10 DEXAMETHASONE 20 mg / 5 ml, solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
223538327|NCT04344730|DRUG|placebo|Box of 10 NaCl 0,9% , solution for injection in ampoule of 5mL. Each allocated box contains complete treatment from D1 to D10 for one patient.
224289013|NCT05393063|DRUG|AK127|Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
223952224|NCT00805792|DRUG|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
224104852|NCT02240498|DEVICE|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
224104853|NCT02240498|DEVICE|Optical spectroscopy measurement|A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
224289014|NCT00603863|BIOLOGICAL|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
224289015|NCT04136418|DEVICE|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
224289016|NCT04136418|OTHER|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
223952225|NCT05044286|OTHER|no intervention|no intervention
223952226|NCT05779696|OTHER|No-intervention|This is a non-intervention study.
224289017|NCT03560687|DRUG|Sucrosomial Iron|CardioSideral 2 caps per day
224289018|NCT03349359|DRUG|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
224289019|NCT02375217|DRUG|Sugammadex|half dose
224289020|NCT02375217|DRUG|Sugammadex|full dose
224289021|NCT02375217|DRUG|Neostigmine|IV = 50mcg/kg
224289022|NCT02375217|DRUG|glycopyrrolate|
224289023|NCT02224066|DRUG|Ticagrelor 90 mg twice per day during three months following TAVI|
223538328|NCT04344730|PROCEDURE|conventional oxygen|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
223952227|NCT04874142|DRUG|YYC506-T|single administration
223952228|NCT04874142|DRUG|YYC506-A|single administration
223952229|NCT04874142|DRUG|YYC506-T + YYC506-A|concomotant administration
223952230|NCT04874142|DRUG|YYC506-A + YYC506-T|concomotant administration
224104854|NCT04002453|PROCEDURE|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
224104855|NCT00693212|DRUG|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
223952231|NCT03015688|RADIATION|x-ray images|
223952232|NCT00567606|OTHER|Strength/Weight Training & Drug/Supplement|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
223952233|NCT00567606|COMBINATION_PRODUCT|Drug/Supplement only|G2 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week, but do not participate in strength/weight training exercises.
223952234|NCT00169923|DRUG|rosiglitazone|
223952235|NCT03674788|DEVICE|Transcatheter valve intervention|
223952236|NCT00578344|DRUG|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
223952237|NCT00578344|BIOLOGICAL|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
223952238|NCT00578344|DRUG|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
224104856|NCT00693212|DRUG|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
224104857|NCT00693212|DRUG|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
224104858|NCT04776369|DRUG|Lidocaine IV|single-bolus of lidocaine IV 4 mg/kg
224104859|NCT04776369|DRUG|Magnesium Sulfate Injection|single-bolus of magnesium sulfate IV 30 mg / kg
224104860|NCT04776369|DRUG|IV saline|Saline IV 50 ml
224104861|NCT06340204|DRUG|Irinotecan Hydrochloride Liposome Injection|Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
224104862|NCT01893788|DRUG|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
224104863|NCT01893788|DRUG|Eplerenone|50 to 100 mg daily for 48 weeks
224104864|NCT03890276|OTHER|HMS EL&C training module|No additional information
224289024|NCT02224066|DRUG|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
223538329|NCT04344730|PROCEDURE|CPAP|Patients assigned to the CPAP plus oxygen group will receive periods of CPAP in addition to the standard treatment.The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
223538330|NCT04344730|PROCEDURE|HFNO|TIn the high-flow-nasal cannula group, oxygen will be delivered through a heated humidifier (Airvo-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 30 liters per minute and adjusted based on the clinical response. FiO2 will be adjusted for the target SpO2
223538331|NCT04344730|PROCEDURE|mechanical ventilation|The oxygen flow will be adjusted to maintain an oxygen saturation level of 92% or more, as measured by means of pulse oximetry (SpO2)
223538332|NCT05038696|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk B-ALL, refractory or relapsed B-ALL.
223952239|NCT04349709|BEHAVIORAL|Brief school-based DBT-A|The intervention is inspired to Dialectical Behavior Therapy for Adolescents (DBT-A) (Rathus \& Miller, 2015, Mazza et al, 2016; Cappelluccio, 2019). It consists in four monthly 2-hour sessions (for a total of 8 hours) scheduled during school-time. All the sessions are conducted by two psychotherapists trained about DBT. During the sessions, the model of emotions is described through a role-play between conductors. Subsequently, teens are trained about main emotional regulation skills. Moreover, basic elements of distress tolerance, mindfulness and interpersonal efficacy are introduced too.
223952240|NCT04257916|OTHER|Experimental|Myofascial technique intervention of the subastragalar joint, kinesiotape and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
224104865|NCT03890276|OTHER|Videos used to supplement live trainer|\[Cherrie to add\]
224104866|NCT04215549|OTHER|No intervention|cross sectional study，no intervention
224104867|NCT05346562|DIETARY_SUPPLEMENT|Cannabidiol|Cannabidiol tablets
224104868|NCT05346562|DIETARY_SUPPLEMENT|Placebo|Cannabidiol-matched placebo tablets
224104869|NCT02742389|OTHER|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
224104870|NCT06481189|BIOLOGICAL|GNR-086|The test drug GNR-086 was administered as a subcutaneous injection at a single dose of 150 mg.
224104871|NCT06481189|BIOLOGICAL|Ilaris®|The reference drug Ilaris® was administered as a subcutaneous injection at a single dose of 150 mg.
224104872|NCT00204893|DRUG|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
224104873|NCT01754896|OTHER|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
224104874|NCT01754896|OTHER|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
224104875|NCT01754896|OTHER|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
224104876|NCT01754896|OTHER|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
224104877|NCT01207544|BEHAVIORAL|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
224289025|NCT00399737|DRUG|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
224289026|NCT00261131|DRUG|Botulinum Toxin A|
224104878|NCT01207544|BEHAVIORAL|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
224104879|NCT03636594|OTHER|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
224104880|NCT05165394|DRUG|Placebo|Tablets for oral administration
224104881|NCT05165394|DRUG|NBI-1065846|Tablets for oral administration
224104882|NCT05652660|DRUG|ARV-471|Experimental
224104883|NCT05652660|DRUG|Rosuvastatin|Probe substrate
224104884|NCT04354025|BIOLOGICAL|Cytokine induced memory-like NK cells|-The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
224104885|NCT04354025|DRUG|Fludarabine|-Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
224104886|NCT04354025|DRUG|Ara-C|-Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
224104887|NCT04354025|DRUG|G-CSF|-Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
224104888|NCT04354025|DRUG|Interleukin-2|-IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
224104889|NCT04354025|PROCEDURE|Leukapheresis|-Donor only
224104890|NCT00875420|DRUG|RAD1901|10 mg Oral once a day for 28 days.
224104891|NCT00875420|DRUG|RAD1901|25 mg Oral once a day for 28 days
224104892|NCT00875420|DRUG|RAD1901|50 mg Oral once a day for 28 days.
224104893|NCT00875420|DRUG|RAD1901|100 mg Oral once a day for 28 days
224104894|NCT00875420|DRUG|Placebo|Placebo Oral once a day for 28 days
224104895|NCT03425565|DRUG|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
224104896|NCT02967120|OTHER|no intervention|
224104897|NCT01612793|DEVICE|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
224104898|NCT00001259|DRUG|Leuprolide|Eight to 12 weeks of GnRH agonist, Leuprolide Acetate 3.75 mg given intramuscularly monthly
224104899|NCT00001259|DRUG|Estradiol Patches|Transdermal Estradiol, 100mcg/day by skin patch
224104900|NCT00001259|DRUG|Progesterone|Progesterone suppository, 200mg vaginally twice/day
224104901|NCT00001259|DRUG|Placebo patch|Placebo by skin patch
224104902|NCT00001259|DRUG|Placebo injection|Placebo given intramuscularly monthly
224104903|NCT00001259|DRUG|Placebo suppository|Placebo vaginal suppository
224104904|NCT05336370|BEHAVIORAL|Hypnosis|The hypnosis will be conducted by clinical psychologists who have the formal competence and training in hypnosis. We will be using a tailored hypnosis script designed for this particular study, with a duration of 10-15 minutes. The script involves a hypnotic induction (relaxation-based), imagery (suggestions for pleasant visual imagery), a deepening procedure, and symptom-specific suggestions. The introduction begins by having the hypnotist debunk many of the common myths and misconceptions that patients may hold about hypnosis, and provide a description of hypnosis. Hypnosis is described as focused attention and concentration - like being so lost in a book or movie that it is easy to lose track of what is going on around you. Once the patient is deeply hypnotized, the therapist offers suggestions to reduce distress and improve pain tolerance.
224104905|NCT05336370|DEVICE|Vagus nerve stimulation|A CE approved tVNS device will be used to stimulate the afferent auricular branch of the vagus nerve located medial of the tragus at the entry of the acoustic meatus \[36\]. A standardized intensity of 10 mA with a pulse width of 250 μs and a consistent stimulation frequency of 25 Hz will be used for optimal stimulation. The stimulation will constantly alternate between active stimulation for 30 seconds, followed by a break of 30 seconds \[37\], and will have a duration of 15 minutes. Active tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing downward. The bipolar stimulation electrode is placed correctly within the concha of the left ear. Participants are instructed to breathe normally while not talking or making any movements during their session.
224104906|NCT05336370|DEVICE|Sham control|Sham tVNS is performed in a relaxed position, sitting back in a chair no more than 30 degrees from the horizontal, with both feet flat on the floor, and hands on thighs with palms facing upward. The bipolar stimulation electrode is placed correctly within the concha of the left ear, but no actual stimulation will be performed. The electrode will be left on for 15 minutes. Participants are instructed to breathe normally while not talking or making any movements during their session
224104907|NCT03142997|DIAGNOSTIC_TEST|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
224104908|NCT03633578|BEHAVIORAL|walk test|"The patient will have to walk on a treadmill in four different conditions:~* without distraction at preferential speed~* with distraction at preferential speed~* without distraction at the speed of 130% of the preferential speed~* with distraction at the speed of 130% of the preferential speed"
223538333|NCT05504512|OTHER|No intervention|No intervention
224104909|NCT04160403|OTHER|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
224104910|NCT03705494|OTHER|Home-based peer counselling (web-based) intervention|The intervention consists of 5-6 home based visits (web-based) over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
224104911|NCT03806569|BEHAVIORAL|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
224104912|NCT03806569|BEHAVIORAL|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
224104913|NCT03819283|DIAGNOSTIC_TEST|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
224104914|NCT02101606|DRUG|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
224104915|NCT00492622|DRUG|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
224104916|NCT00492622|DRUG|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
224104917|NCT01332435|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
224104918|NCT04510727|DEVICE|Optical Coherence Tomography (OCT)|VivoSight Dx OCT system from Michelson Diagnostics Ltd. OCT will be used to visualize the tumor and lesion in the skin.
224104919|NCT04510727|PROCEDURE|Curettage & Desiccation (C&D) Procedure|Standard of care C\&D where the basal cell carcinoma lesion will be scraped to its base using a Fox dermal curette and an electrodesiccation machine.
224289027|NCT02138292|DRUG|Trametinib (2mg)/Digoxin (.25mg)|"1. Trametinib (2mg) will be administered orally on a daily basis.~2. Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
224289028|NCT03938129|OTHER|Blood sample|1st trimester blood sample for bio-bank
224289029|NCT03938129|OTHER|Urine sample|1st trimester urine sample for bio-bank
224289030|NCT03938129|OTHER|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
223538334|NCT03950258|PROCEDURE|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
223538335|NCT05394610|DEVICE|Sana Device|Audio Visual Stimulation patterns intended to produce a therapeutic benefit.
223538336|NCT05394610|DRUG|Sana Device (Control)|A control device that mimics the physcial appearance of the Sana device.
224104920|NCT02199522|PROCEDURE|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
224104921|NCT05986344|DEVICE|Copper intrauterine contraceptive device|copper T-380 IUD
223538337|NCT01534481|BIOLOGICAL|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
223538338|NCT01534481|DIETARY_SUPPLEMENT|Preterm Formula|Preterm Formula determined by center practice.
223538339|NCT04468373|DEVICE|WA-NG (NG-IMT) Telescope Prothesis|The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
223538340|NCT01130337|DRUG|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
223538341|NCT01130337|DRUG|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
223538342|NCT01130337|DRUG|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
223538343|NCT06515015|DEVICE|Endobronchial Silicon Spigots|The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
224104922|NCT05986344|DEVICE|LNG-IUS|Levonorgestrel Intrauterine System
224104923|NCT03551418|BEHAVIORAL|Watching a video|Watching a video of an adult with DS washing his hands
224104924|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
224104925|NCT04795804|DIETARY_SUPPLEMENT|Maltodextrin|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
224104926|NCT04795804|DIETARY_SUPPLEMENT|Human Milk Oligossaccharide and resistant starch|The day before the CIDs, the participants receive the supplements 3x a day in randomized order
224289031|NCT05600205|BEHAVIORAL|GOAL!|GOAL! is a integrated support focused on a combination of lifestyle factors for achieving a healthier lifestyle for people with severe mental illness. The intervention consists of two year of guidance from a lifestyle coach and qualified professionals.
224289032|NCT03226119|DIAGNOSTIC_TEST|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
223538344|NCT02448199|DRUG|Meloxicam and Glucosamine|Experimental
223538345|NCT02448199|DRUG|Meloxicam|Active Comparator
223723132|NCT04587232|DIAGNOSTIC_TEST|Nottingham Health Profile|Standardized questionnaire to investigate the health-related quality of life. NHP is a general is used to measure health problems perceived by the patient. It comprises 6 sections. The sum of the items within each section ranges from 0 to 100, and the total score ranges from 0 to 600. The higher score shows a worse quality of life.
224104927|NCT01712386|DIETARY_SUPPLEMENT|Beetroot|
224104928|NCT01712386|DIETARY_SUPPLEMENT|Beetroot placebo|
224104929|NCT02385695|PROCEDURE|Posterior Dynamic Stabilization|
224104930|NCT02385695|PROCEDURE|Internal Fixation and Fusion|
224104931|NCT05409885|OTHER|General anesthesia|Evaluate the effects of general anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
224104932|NCT05409885|OTHER|Spinal anesthesia|Evaluate the effects of spinal anesthesia on NLR, PLR and MPV in patients undergoing cesarean section.
224104933|NCT03170336|DRUG|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
224104934|NCT03170336|DRUG|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
224104935|NCT05829720|DIETARY_SUPPLEMENT|a2 Full Cream Milk|Mothers in this arm will drink a2 Full Cream Milk twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
224289033|NCT00052416|DRUG|thalidomide|
224104936|NCT05829720|DIETARY_SUPPLEMENT|Conventional Milk (Weidendorf)|Mothers in this arm will drink Conventional Milk (Weidendorf) twice a day, 200ml each time, for 14 consecutive days. Infants in this arm will be fed with mather's breastmilk exclusively.
224104937|NCT06442709|DRUG|Tocilizumab Asprin|"Tocilizumab alone, Asprin alone, Tocilizumab combined with Asprin. Tocilizumab, an IL6R inhibitor, injected once a month at a dose of 4mg/kg in advanced NPC patients.~Asprin，an anticoagulant, taken orally once daily at a dose of 100mg in advanced NPC patients."
224104938|NCT06442709|OTHER|Placebo|Placebo replaces tocilizumab and asprin in advanced NPC patients.
224104939|NCT06047691|BEHAVIORAL|Abbreviated, Intensive, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy for PTSD|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format. Couples are provided with psychoeducation about PTSD and relationship functioning and are taught cognitive and behavioral skills to address the manifestation of PTSD in the couple relationship. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and once 1-2 weeks after the retreat.
224104940|NCT06047691|BEHAVIORAL|Prevention and Relationship Education Program|Approximately 12 hours of programming delivered over 2 consecutive days in a multi-couple group retreat format.The content of PREP and workshop experiences focuses on helping couples communicate effectively, manage conflict without harming their relationship, preserve and act on commitment, improve relationship decision-making, increase understanding of differences between partners, and protect positive connections between partners. Approximately 12 hours of PREP content will be delivered over 2 consecutive days in a multi-couple group retreat format. Couples will also meet once individually with one of the group leaders 1-2 weeks before the retreat and will check in with a member of the study staff 1-2 weeks after the retreat.
224104941|NCT04745442|DRUG|Antithrombin + best available treatment|The subject will be treated with Antithrombin (50 IU/Kg/12h) for 72 hours and the best available treatment for COVID-19.
224104942|NCT04745442|DRUG|Best available treatment|The subject will be treated with the best available treatment for COVID-19.
224104943|NCT02629393|DRUG|ORGN001 (formerly ALXN1101)|
224104944|NCT06513598|PROCEDURE|Major visceral surgery for gastrointestinal cancer|This is a longitudinal observational study of the patients undergoing major visceral surgery for gastrointestinal cancer. Biological samples will be collected to compare gastrointestinal and infection site metastases and develop biomarkers for postoperative infections.
224104945|NCT04640597|DEVICE|BioMimics 3D Vascular Stent System|Patients with BioMimics 3D Vascular Stent System
224104946|NCT02412007|OTHER|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~1. Standing up from squatting position to catch an object of interest.~2. Squatting from standing position to pick an object of interest.~3. Walking to reach an object of interest.~4. Climbing up steps to get an object of interest.~5. Climbing down steps to keep the above object of interest.~6. Cycling~7. Kicking a football~8. Dancing"
223538346|NCT02448199|DRUG|Glucosamine|Active Comparator
223952241|NCT04257916|OTHER|Manual therapy group|Myofascial technique of the subastragalar joint and eccentric training with isoinercial machine. The intervention lasted 4 weeks. Each treatment session lasted 50 minutes, with 2 sessions a week. Between training sessions, the indicated break was 48 hours.
223952242|NCT04159545|OTHER|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
223952243|NCT00667953|DRUG|Gleevec|Gleevec (600 mg) daily.
224289034|NCT03024047|DEVICE|Pacemaker|
223952244|NCT00667953|DRUG|Temodar|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle.
223952245|NCT05179772|DRUG|Olanzapine|Olanzapine (2.5 mg to 20 mg)
223952246|NCT00831194|BEHAVIORAL|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
223952247|NCT01303471|DRUG|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
223952248|NCT01596985|PROCEDURE|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
223538347|NCT01247623|BIOLOGICAL|GV1001|
223538348|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
223538349|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
223538350|NCT05525910|DRUG|Nirmatrelvir/ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
223538351|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
223538352|NCT05525910|DRUG|Nirmatrelvir/ ritonavir|Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
223723133|NCT04587232|DIAGNOSTIC_TEST|Short form 36|Standardized questionnaire to investigate the general health-related quality of life. The SF-36 questionnaire is a generic quality of life questionnaire and consists of 8 subscales, with 36 items. The scores ranges from 0 to 100 and the high score indicates good health.
224289035|NCT03517254|DIETARY_SUPPLEMENT|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
224289036|NCT03517254|OTHER|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
224289037|NCT03517254|OTHER|Placebo|Maltodextrin powder to mimic glutamine,
224104947|NCT01525511|DRUG|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
223952249|NCT01596985|PROCEDURE|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
224104948|NCT01525511|DRUG|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~* 1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~* Dosage: 2 tablets~DHA-PQP:~* 1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~* Dosage: 3 tablets"
224104949|NCT00534846|DRUG|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
224104950|NCT00534846|DRUG|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
224104951|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
224104952|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
224104953|NCT01525212|DRUG|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
224104954|NCT01525212|DRUG|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
224104955|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
223952250|NCT01444404|DRUG|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
224104956|NCT01525212|DRUG|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
224104957|NCT03000114|PROCEDURE|Percutaneous Needle Aponeurotomy|
224104958|NCT03000114|DRUG|XIAFLEX|
224104959|NCT02060825|DEVICE|Regional saturation monitor|
224104960|NCT02376439|OTHER|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
224104961|NCT02522910|DRUG|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
224104962|NCT05284110|BEHAVIORAL|Physical activity|Multiple bouts of 3-min brisk walking, every 30 min, for 4 hours.
224104963|NCT02097199|OTHER|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
223952251|NCT04328467|DRUG|Hydroxychloroquine|Hydroxychloroquine; 200mg tablet; oral
223952252|NCT04328467|OTHER|Placebo|Placebo; tablet; oral
223952253|NCT05817292|DIETARY_SUPPLEMENT|Probiotics|Assumption of commercial probiotics
223952254|NCT05817292|OTHER|No intervention|No assumption of probiotics
224104964|NCT04573777|DRUG|Repatha|140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor
224104965|NCT04354051|DRUG|Sodium Nitrite|Intravenous nitrite sodium infusion, dose 70μmol, of 5 minute duration (14μmol /min-1).
224104966|NCT03493503|DRUG|Salbutamol|Intravenous Salbutamol loading dose
224104967|NCT03493503|DRUG|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
224104968|NCT06407362|DIAGNOSTIC_TEST|Cerebral Oxygen Saturation|We have designed this study to evaluate the accuracy of PVI, PI and rSO2 in both ventilation modes in patients undergoing septorhinoplasty operation under general anaesthesia
223952255|NCT03204175|OTHER|FIT Plus|"* Group handwashing facilities~* Daily group handwashing and toothbrushing activities~* Sanitation operation and maintenance manuals for school officials~* Toilet cleaning consumable~* Toilet and handwashing station maintenance kits~* Soap, toothbrushes, and toothpaste"
224104969|NCT01226667|DRUG|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
224289038|NCT03517254|OTHER|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
224289039|NCT05336305|DIETARY_SUPPLEMENT|Polydextrose|Administration of 3g polydextrose per day, for 2 months
223952256|NCT03204175|OTHER|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
224289040|NCT00649727|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
224289041|NCT00649727|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
224104970|NCT01828125|PROCEDURE|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
224104971|NCT01828125|DRUG|Glucagon|
223538353|NCT03886493|DRUG|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
223538354|NCT02831660|DRUG|idarucizumab|
223538355|NCT03767439|DRUG|Vismodegib|150 mg PO daily
223538356|NCT03767439|DRUG|Nivolumab|480 mg IV every 4 weeks
223538357|NCT03767439|DRUG|Ipilimumab|1 mg/kg IV every 6 weeks
223538358|NCT00609752|DRUG|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
223538359|NCT00609752|DIETARY_SUPPLEMENT|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
223952257|NCT00689637|DRUG|AZD3480|AZD3480 capsules qd, 12 days
223952258|NCT00689637|DRUG|Placebo|Placebo capsules qd, 12 days
223952259|NCT00689637|DRUG|Warfarin|Warfarin: single dose on day 6
223952260|NCT02017509|PROCEDURE|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
223538360|NCT03901638|DRUG|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
223952261|NCT02017509|PROCEDURE|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
223952262|NCT02017509|PROCEDURE|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
223952263|NCT02017509|GENETIC|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
223952264|NCT02952170|OTHER|MRI|MRI to assess hepatic steatosis
223538361|NCT03901638|DRUG|Placebo|Placebo
223538362|NCT06146647|BEHAVIORAL|Positive body image TV show|This is a 15 minute (approximately) show that has positive body image content embedded in the storyline. It also showcases a diverse range of body sizes in the casting.
223538363|NCT06146647|BEHAVIORAL|Positive body image music video|This is a positive body image song with strong visual representation of diverse body sizes in the music video.
223538364|NCT06146647|BEHAVIORAL|Active control TV show about a visit to the dentist|14 minute tv show following a tv character as he visits the dentist.
223538365|NCT06146647|BEHAVIORAL|Active control music video about brushing teeth|Music video of a tv character singing about brushing teeth
223538366|NCT05792748|PROCEDURE|Pulp hemostasis with a dry cotton pellet|Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp
223538367|NCT05792748|PROCEDURE|Pulp hemostasis with a wet cotton pellet impregnated with FS|Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp
223538368|NCT05792748|PROCEDURE|Stainless steel crown|Stainless steel crown placed as a final restoration
223538369|NCT03330444|PROCEDURE|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
223538370|NCT06512506|OTHER|non-intervention|non-intervention
223538371|NCT03179761|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
224104972|NCT02047123|DIETARY_SUPPLEMENT|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
224104973|NCT06274359|BEHAVIORAL|Digital storytelling|Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
224104974|NCT02089737|DRUG|Panitumumab|Panitumumab for intravenous infusion
224104975|NCT04762355|DRUG|Palovarotene|ophthalmic solution in different concentrations: Dose 1, Dose 2 and Dose 3
224104976|NCT04762355|DRUG|Vehicle|Placebo-to-match palovarotene ophthalmic solution vials
224104977|NCT01887444|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
224104978|NCT01887444|OTHER|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
223538372|NCT03179761|OTHER|Laboratory Biomarker Analysis|Correlative studies
223538373|NCT03179761|BIOLOGICAL|Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine given intramuscularly
223538374|NCT05289752|PROCEDURE|dental implants in the mandible|placement of two interforaminal dental implants in the canine region in the mandible
223538375|NCT05289752|DEVICE|locator attachment and overdenture|placement of locator attachment and insertion of mandibular overdenture
223952265|NCT02903602|BEHAVIORAL|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
223952266|NCT02903602|BEHAVIORAL|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
223952267|NCT03402399|OTHER|Molecular analysis|Blood test
223952268|NCT03064256|BEHAVIORAL|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
224104979|NCT03177252|DRUG|Lidocaine|-2% lidocaine will be given
224104980|NCT03177252|DRUG|Sodium chloride|-Normal saline will be given
224104981|NCT03177252|DRUG|Bupivacaine|-0.5% bupivacaine will be given
223538376|NCT00448448|DEVICE|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
223538377|NCT00448448|OTHER|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
224104982|NCT02832271|DRUG|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
224104983|NCT02832271|DRUG|Placebo|Placebo
224104984|NCT01197573|DRUG|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
223538378|NCT02916316|DRUG|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
224104985|NCT01197573|OTHER|No TPA Treatment|Standard of Care
223538379|NCT02668289|OTHER|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
223538380|NCT02668289|OTHER|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
223538381|NCT02668289|OTHER|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
223952269|NCT03064256|BEHAVIORAL|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
223952270|NCT02769130|DRUG|Losartan|Losartan is given for 12 months
223952271|NCT01521702|DRUG|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
223952272|NCT01521702|PROCEDURE|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
224104986|NCT01009112|BEHAVIORAL|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
224104987|NCT01009112|BEHAVIORAL|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
224104988|NCT02964104|DRUG|Insulin icodec|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
224104989|NCT02964104|DRUG|placebo|Administered once daily subcutaneously for 35 days
224104990|NCT02964104|DRUG|insulin degludec|Administered once daily subcutaneously for 35 days
224104991|NCT02964104|DRUG|placebo|Administered once weekly subcutaneously for 35 days
224104992|NCT05744986|DEVICE|SYMPICITY Spyral RENAL DENERVATION (RDN) SYSTEMTM|The second generation SYMPLICITY RDN catheterTM has 4 times electrodes that are arranged in spirally in 90-degree intervals. Theoretically, the newer generation catheter can provide more efficient and extensive denervation in a shorter period of time16. Its efficacy was confirmed in SYMPLICITY HTN ON-MED and OFF-MED trial, which confirmed a consistent and durable BP reduction that lasted into 36 months with or without adjuvant anti-hypertensive drugs
224104993|NCT03456765|DIAGNOSTIC_TEST|Ultrasound|US will be made to assess kidneys
224104994|NCT05835258|DIETARY_SUPPLEMENT|Melatonin with phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement with phenyl capsaicin
224104995|NCT05835258|DIETARY_SUPPLEMENT|Melatonin without phenyl capsaicin|Blood samples will be collected at different time points following the oral administration of the melatonin supplement without phenyl capsaicin
224104996|NCT01362322|BIOLOGICAL|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
224104997|NCT01362322|BIOLOGICAL|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
224104998|NCT00405041|DIETARY_SUPPLEMENT|Dietary supplement GVG 2|2.670 g/day for 14 days
224104999|NCT05590299|OTHER|Fish oral immunotherapy (codfish)|Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses
224105000|NCT05590299|OTHER|Placebo oral immunotherapy|Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
223538382|NCT02668289|OTHER|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
223538383|NCT02668289|OTHER|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
223952273|NCT03284840|DIAGNOSTIC_TEST|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
223952274|NCT03284840|DIAGNOSTIC_TEST|Thyroid size|Thyroid size by ultrasound.
223952275|NCT05830032|DIETARY_SUPPLEMENT|Soluble corn fibre|As a powdered beverage
223952276|NCT05830032|DIETARY_SUPPLEMENT|Inulin|As a powdered beverage
223952277|NCT05830032|DIETARY_SUPPLEMENT|soluble corn fibre and inulin|As a powdered beverage
223952278|NCT05830032|DIETARY_SUPPLEMENT|Maltodextrin|As a powdered beverage
223952279|NCT04897347|DEVICE|Robotic Trunk-Support-Trainer (TruST)|"This will involve tailoring the level of postural assistance via force fields and systematically introduce postural task-progression across training sessions. Age-appropriate activities, including toys and games, will be used in training.~\- Twelve 2hr training sessions (3 times per week for 4 weeks)"
223952280|NCT04897347|DEVICE|Static Trunk Support|"This will involve static support for the trunk via a trained therapist. Age-appropriate activities, including toys and games, will be used in training.~\- Twelve 2hr training sessions (3 times per week for 4 weeks)"
224105001|NCT02447107|OTHER|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
224105002|NCT02447107|OTHER|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
224105003|NCT02097836|DEVICE|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
224105004|NCT05555030|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
224105005|NCT05555030|DIAGNOSTIC_TEST|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
224105006|NCT01566344|OTHER|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
224105007|NCT02102061|OTHER|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
224105008|NCT01469923|DRUG|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
223538384|NCT02668289|OTHER|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
223952281|NCT00299676|DRUG|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
223952282|NCT03835416|DIETARY_SUPPLEMENT|Foods rich in high quality protein|Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
223952283|NCT01792505|BIOLOGICAL|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
223952284|NCT02575014|DRUG|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
223952285|NCT02035852|OTHER|MRI|3T MRI vs. 7T MRI
223952286|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols and fish oil|4 weeks intervention, 3 times daily
224105009|NCT01469923|DRUG|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
224105010|NCT01099826|BEHAVIORAL|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
224105011|NCT01099826|BEHAVIORAL|Motivational Interview|motivational interview by trained MI counselors by phone
224105012|NCT04834986|DRUG|Tislelizumab combined with Lenvatinib|"Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year."
224105013|NCT00006669|BIOLOGICAL|rituximab|
224105014|NCT00006669|BIOLOGICAL|sargramostim|
224105015|NCT00006669|DRUG|EPOCH regimen|
224105016|NCT00006669|DRUG|cyclophosphamide|
224105017|NCT00006669|DRUG|doxorubicin hydrochloride|
224105018|NCT00006669|DRUG|etoposide|
224105019|NCT00006669|DRUG|prednisone|
224105020|NCT00006669|DRUG|vincristine sulfate|
224105021|NCT01205243|DRUG|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
224105022|NCT00479440|DRUG|SAM-315|
224105023|NCT04424498|PROCEDURE|Absorbable Rods and Kirschner Wires|A Boyd incision was applied in all patients; olecranon fractures were reduced first and fixed with Kirschner wires. Then, the displaced radial neck fractures were reduced and fixed using absorbable rods.
224105024|NCT00728507|DRUG|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those \>45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
224105025|NCT00728507|DRUG|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
224105026|NCT02413398|DRUG|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
224105027|NCT02413398|DRUG|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
224105028|NCT02690467|DEVICE|Insupen G34x3,5mm|
223538385|NCT02668289|OTHER|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
224105029|NCT02690467|DEVICE|Insupen G32x4mm|
223538386|NCT02668289|PROCEDURE|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
223538387|NCT02668289|OTHER|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
224105030|NCT01852864|DRUG|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
224105031|NCT00677963|DRUG|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
224105032|NCT03435029|BEHAVIORAL|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
224289042|NCT00110344|DRUG|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
224105033|NCT03435029|OTHER|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
224105034|NCT01893723|PROCEDURE|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
224105035|NCT01893723|PROCEDURE|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
224105036|NCT04576351|OTHER|Observation|The study is a multi-center Norwegian prospective observational clinical study of the occurence of neurological, neuropsychological and psychiatric manifestations and sequelae in patients with COVID-19 at 6- and 12-months follow-up.
224105037|NCT03119376|OTHER|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
224105038|NCT01147965|BIOLOGICAL|AD5 CEA Vaccine|AD5\[E1-, E2b-\]-CEA Vector Vaccine
224105039|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 10mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
224105040|NCT03451825|DRUG|Avelumab|Participants received an intravenous infusion of avelumab 20mg/kg intervention (IV) once every 2 weeks until confirmed progression, death, unacceptable toxicity, or any criterion for withdrawal occurred.
224105041|NCT01400334|RADIATION|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
224105042|NCT01496261|DRUG|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
224289043|NCT00110344|DRUG|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
224105043|NCT01496261|DRUG|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
224105044|NCT06528171|PROCEDURE|Brain MRI|non injected brain MRI
224289044|NCT01659164|BEHAVIORAL|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
224289045|NCT00706355|DRUG|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
224289046|NCT01784354|OTHER|Acupressure|
224289047|NCT01784354|OTHER|Acupressure dilatation|
223952287|NCT01313988|DIETARY_SUPPLEMENT|Plant sterols|4 weeks intervention, 3 times daily
223538388|NCT04549558|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal Ultrasound (Strain Ultrasound Elastography, Conventional Grey-Scale Ultrasound, Color-Doppler Ultrasound, and Ultrasound Guided Fine Needle Aspirate) on Axillary Lymph Nodes
223538389|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume whole-foods, fiber-rich diet
223538390|NCT03950635|DIETARY_SUPPLEMENT|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
223538391|NCT03950635|OTHER|Questionnaire Administration|Ancillary studies
223538392|NCT04231448|DRUG|R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)|R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
224105045|NCT06528171|BIOLOGICAL|Specific blood samples|blood samples to find immunological and inflammatory markers
224105046|NCT03874884|DRUG|Olaparib|"During dose escalation doses of olaparib that can be administered are 50mg BD D2-15, 100mg BD D2-15, 150mg BD D2-15, 200mg BD D2-15,250mg BD D2-15, 300mg BD D2-15, 200mg BD D4-14, 300mg BD D-4-14 or 400mg D-4-18 of a 42 day cycle for up to 6 cycles.~The recommended phase 2 dose of olaparib will be used in 2 consecutive dose expansion cohorts. The first cohort will received the recommended phase 2 dose of Olaparib on D4-14 of a 42 day cycle. Patients enrolled in the second dose expansion cohort will receive Olaparib continuously from cycle 1 day -4 to cycle 6 day 42."
224105047|NCT03874884|COMBINATION_PRODUCT|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for up to 6 cycles.
224105048|NCT05665335|DEVICE|Renuvion APR System|"The treatment area is defined as superior most not to exceed a horizontal line from the superior aspect of the axilla to the midline; inferior most not to cross the junction of the breast with the abdomen (inframammary fold). Lateral border to the outermost curvature of the breast or a vertical line drawn from the preaxillary line to the IMF; medial most to the innermost curvature of the breast up to 1 cm lateral to the sternal midline. The procedure will be in the intradermal and subdermal planes in the full breast area, without penetrating the breast gland.~Renuvion APR System settings will be 60-70% Power, 1.5 LPM, and up to 6 retrograde or 3 antegrade/retrograde passes, with a minimum of 2 incision sites."
224105049|NCT02660554|OTHER|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
224289048|NCT01784354|BEHAVIORAL|education|
224289049|NCT04179019|DRUG|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
223538393|NCT04231448|DRUG|Tucidinostat|Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
223952288|NCT01313988|DIETARY_SUPPLEMENT|Placebo|4 weeks, 3 times daily
223952289|NCT00483457|DRUG|enzyme inhibitor therapy|enzyme inhibitor therapy
223952290|NCT00483457|GENETIC|protein expression analysis|protein expression analysis
223952291|NCT00483457|OTHER|immunohistochemistry staining method|immunohistochemistry staining method
223952292|NCT00483457|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
223952293|NCT00483457|PROCEDURE|biopsy|biopsy
223994515|NCT01731223|BEHAVIORAL|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
224289050|NCT02382926|OTHER|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
224289051|NCT05684146|DEVICE|Emboliner Embolic Protection|Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
224289052|NCT05684146|DEVICE|Sentinel Cerebral Protection|The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
224289053|NCT05678855|BEHAVIORAL|A randomızed Controlled Study with pre-test and post-test|The intervention in this study is to apply multimedia-based instruction in distance education to the experimental group. control group students received distance education through traditional teaching. Experimental group students received distance education through interactive teaching prepared with multimedia tools. Experimental group, interactions were made using applications such as Icebreaker, Puzzle, QR code, Mentimeter, and Padlet. In addition, animation, infographics, animated slides (Multimedia tools) were used for the experimental group.In the control group, plain narration was given. Tests were administered to both groups before and after the intervention.
224105050|NCT05450055|PROCEDURE|intraperitoneal lidocaine analgesic or normal saline as control|Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
224105051|NCT05221125|BEHAVIORAL|Psychologically-Informed Physical Therapy (PIPT)|The PIPT group will receive evaluation and treatment based on the PT's assessment of the individual patient's clinical presentation and condition.
223952294|NCT01141985|DEVICE|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
224105052|NCT01691118|DRUG|Fimasartan|
224105053|NCT01691118|DRUG|Antihypertensive treatment|
223538394|NCT04231448|DRUG|Placebo|Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
223538395|NCT06154590|DRUG|Method(s)1 Attribution|"Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
224289054|NCT04765527|DIETARY_SUPPLEMENT|Turmeric Strength for Joint|Turmeric-based tablets
224289055|NCT04765527|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
224289056|NCT01704430|DIETARY_SUPPLEMENT|Glutamine|Enteric L-Glutamine
223538396|NCT06154590|DRUG|Method(s)2 Attribution,|"Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)"
223538397|NCT02284191|RADIATION|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
223538398|NCT05678140|DEVICE|soft tissue mobilization|soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
224289057|NCT01704430|DIETARY_SUPPLEMENT|Maltodextrin|Enteric Maltodextrin
223538399|NCT05678140|OTHER|conventional physical therapy|Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
224289058|NCT03465436|DRUG|Lasmiditan|100 mg administered orally (PO)
224289059|NCT03465436|DRUG|Lasmiditan|400 mg administered PO
224289060|NCT03465436|DRUG|Placebo|Placebo administered for lasmiditan or moxifloxacin
224289061|NCT03465436|DRUG|Moxifloxacin|400 mg moxifloxacin administered PO
224289062|NCT04867421|OTHER|No intervention|No intervention
224289063|NCT01995968|OTHER|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~* FGR was mentioned in medical charts~* OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~* OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~* OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~* OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
224289064|NCT05893316|DIAGNOSTIC_TEST|urine sample collection|The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
224289065|NCT00944112|BIOLOGICAL|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
224289066|NCT00944112|BIOLOGICAL|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
224289067|NCT03130114|DRUG|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
224289068|NCT03130114|OTHER|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
224289069|NCT02243293|DRUG|ABT-493|Tablet
224289070|NCT02243293|DRUG|ABT-530|Tablet
224289071|NCT02243293|DRUG|ribavirin (RBV)|Tablet
224289072|NCT02243293|DRUG|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
224289073|NCT05426616|DEVICE|collagen membrane (Creos Xenoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After having made multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied. An individualized collagen membrane is attached on top using membrane fixation pins. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved.
224105054|NCT02298244|PROCEDURE|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
223538400|NCT01859013|DRUG|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
224105055|NCT02298244|PROCEDURE|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
224105056|NCT04427592|DIAGNOSTIC_TEST|ultrasound|trans-vaginal and trans-abdominal ultrasound using different modalities such as grey-scale, Doppler, multi-planer mode
224105057|NCT04427592|PROCEDURE|closure of uterine wall defect|uterine incision above placental bulge by at least 5 mm then complete separation of the placenta starting from areas of least resistance to areas of high resistance leaving a clear defect which will be closed by non locked running sutures from inside the uterus starting from one edge, hitch the bed to the other edge of the defect and controlling placental bed hemorrhage then closing the uterine incision via running sutures in 2 layers with compressing the bed from outwards in the first layer. hemostasis of the abnormal pelvic vasculature if excessive bleeding internal iliac artery may be ligated then insertion of intra-peritoneal drain followed by closing the abdomen.
223538401|NCT01859013|OTHER|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
223538402|NCT01659060|OTHER|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
223538403|NCT01659060|OTHER|Placebo Chocolate|Placebo intervention
224105058|NCT02590679|DEVICE|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
224105059|NCT03626753|DRUG|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
224289074|NCT05426616|DEVICE|titanium reinforced d-PTFE membrane (Creos Syntoprotect , Nobel Biocare AB, Göteborg, Sweden)|A mucoperiosteal flap will be raised with two vertical releasing on each side of the edentulous space. Autogenous bone chips are harvested from the retromolar area with bone scrapers and/or from an edentulous site using ACM bone collector. DBBM particles soaked in blood are mixed with autogenous bone chips to a ratio of 1:1. After multiple bone perforations at the buccal aspect of the recipient site, the mixture of bone chips and DBBM is applied.A titanium reinforced d-PTFE membrane is attached on top using membrane fixation pins. Care is taken to leave a distance of at least 1 mm between the membrane and neighboring teeth. Prior to fixation of the final pin, bone grafting material is additionally applied from the lateral aspect to ensure that it is properly packed under the membrane and fully stable. Following release of the periosteum and muscle insertion, tension-free primary wound closure is achieved. The membrane is removed after 9 months, prior to implant placement.
224105060|NCT03626753|DRUG|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
224105061|NCT03626753|DRUG|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
224105062|NCT03626753|DRUG|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
224105063|NCT03626753|DRUG|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
224105064|NCT03626753|DRUG|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
224289075|NCT06269354|DEVICE|3D printed prostheses|3D printed prostheses
224289076|NCT03695055|DRUG|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
224289077|NCT01782287|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
224289078|NCT01782287|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
224289079|NCT03829007|DIAGNOSTIC_TEST|PD-L1 imaging|89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
223952295|NCT02464072|PROCEDURE|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
223952296|NCT02464072|PROCEDURE|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
223952297|NCT02464072|PROCEDURE|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
223952298|NCT03927963|DRUG|Dexmedetomidine|Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
223952299|NCT03927963|DRUG|Propofol|Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
223952300|NCT02167191|BEHAVIORAL|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
224289080|NCT03829007|DRUG|Durvalumab|Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
224289081|NCT06286657|DIETARY_SUPPLEMENT|Xanthohumol|Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
224289082|NCT06286657|DIETARY_SUPPLEMENT|Placebo|Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
224289083|NCT01983514|DRUG|8IU intranasal oxytocin|
224289084|NCT01983514|DRUG|24 IU intranasal oxytocin|
224289085|NCT01983514|DRUG|1 IU intravenous oxytocin|
224289086|NCT01983514|DRUG|Placebo|
224289087|NCT01475253|DRUG|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
223952301|NCT00587756|PROCEDURE|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
223952302|NCT01753440|PROCEDURE|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
223952303|NCT04470089|DRUG|Myramistin|Oromucosal application
223952304|NCT00755794|DRUG|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
223952305|NCT02797899|DEVICE|Platelet Rich Fibrin|Native growth factors
223994516|NCT02834299|BEHAVIORAL|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
223994517|NCT02834299|BEHAVIORAL|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
223994518|NCT02834299|BEHAVIORAL|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
223994519|NCT02715141|BEHAVIORAL|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
223994520|NCT03655743|DEVICE|LASIK, PRK, Phacoemulsification|"Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive\_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification"
223994521|NCT00996606|DRUG|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
223994522|NCT00996606|DRUG|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
223994523|NCT00223509|DRUG|Lamotrigine|
223994524|NCT03354468|BEHAVIORAL|fall prevention program|fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
223994525|NCT00532870|OTHER|laparoscopic|
223994526|NCT00305344|PROCEDURE|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
223994527|NCT00305344|BIOLOGICAL|Cord blood|Develop Cord blood vaccine
223994528|NCT05235282|DEVICE|IQoro|An acrylic mouth guard with a pulling loop. The mouth guard is placed in the mouth of the patient on the outside of the teeth. The therapist pulls the loop in different directions and the patient try to close his/her mouth on the mouth guard to keep it inside the mouth.
223994529|NCT05235282|OTHER|Usual care for swallowing function|Cuff deflation, speaking valve, masako exercises, shaker exercises, coughing, stimulation of the oral cavity, neuromuscular electrical stimulation, postural control
223994530|NCT00632502|DRUG|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
223994531|NCT00632502|DRUG|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
223994532|NCT00632502|DRUG|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
223994533|NCT05044676|OTHER|patients with hepatocellular carcinoma|The response of the hepatocellular carcinoma to treatment will be evaluated as part of the care
223994534|NCT06020950|OTHER|Control|Low-calorie diet with the use of placebo pearls (containing sunflower oil)
223994535|NCT06020950|DIETARY_SUPPLEMENT|Omega-3 supplementation|Low-calorie diet with the use of marine omega-3 pearls (containing 1200 mg eicosapentaenoic acid + 600 mg docosahexaenoic acid/day)
223994536|NCT06020950|OTHER|Chia seed|Low-calorie diet with the consumption of 30 grams of powdered chia seeds
223994537|NCT06289595|DEVICE|PBM Ortho device|Device emits light for photobiomodulation (light therapy).
223994538|NCT02038387|BEHAVIORAL|normocaloric low cholesterol diet|
223994539|NCT03075527|DRUG|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
223994540|NCT03075527|DRUG|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
223994541|NCT04108624|OTHER|Screening Phase|This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
223952306|NCT06510946|BEHAVIORAL|(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease|"The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:~Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.~Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.~Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.~Personalized Dosing Systems (PDS): Helping manage medication intake.~Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet."
224289088|NCT01475253|OTHER|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
224105065|NCT02803372|OTHER|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP \> 95 mmHg, SVV \< 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
224289089|NCT01475253|PROCEDURE|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
224289090|NCT05010824|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem. The second and third session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. Follow-up phone calls provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
224289091|NCT00005918|DRUG|Efavirenz|
224289092|NCT00005918|DRUG|Lamivudine|
224105066|NCT02803372|OTHER|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output \> 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
224105067|NCT04886830|PROCEDURE|laparoscopic appendectomy using a single endoloop for appendiceal stump closure|laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix
224105068|NCT04886830|PROCEDURE|laparoscopic appendectomy using two endoloops for appendiceal stump closure|laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
224105069|NCT04886830|PROCEDURE|laparoscopic appendectomy using a clip for appendiceal stump closure|laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
224105070|NCT00623012|DRUG|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
224289093|NCT00005918|DRUG|Stavudine|
224289094|NCT01328236|DRUG|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
223952307|NCT04078217|DEVICE|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
223952308|NCT04078217|OTHER|Booklet|Home-based exercise program using a paper booklet (not the technology).
223952309|NCT05758532|BIOLOGICAL|Measles-Mumps-Rubella vaccine (MMR)|0.5 ml of MMR vaccine injected intramuscularly in the deltoid region or in the anterolateral area of the thigh
223952310|NCT03627156|BEHAVIORAL|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
223952311|NCT04255823|OTHER|General practitioner and Patient receive informations related to PPI deprescribing.|"General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)"
224289095|NCT01328236|DRUG|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
224289096|NCT01328236|DRUG|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
223952312|NCT04255823|OTHER|Only General practitioner receive informations related to PPI deprescribing.|"General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations."
223952313|NCT03788278|DEVICE|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
223952314|NCT06257563|OTHER|Isle of TEND Intervention|"The Isle of TEND is an interactive videogame platform in which users navigate to different modules on a virtual island. The modules aim to create a pleasant, shared and error-free experience for persons with dementia and their caregivers."
223952315|NCT02753075|DEVICE|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
223952316|NCT02753075|DEVICE|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
223952317|NCT02753075|OTHER|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
224105071|NCT00623012|DRUG|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
224105072|NCT02227212|DRUG|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224105073|NCT00310245|PROCEDURE|STI (structured Treatment Interruption)|
224105074|NCT05405543|DRUG|MYK-224|Specified dose on specified days
224105075|NCT05405543|OTHER|Placebo|Specified dose on specified days
224105076|NCT06480929|OTHER|Contrast TTE procedure, the SonoVue ultrasound agent|The intervention involved using contrast-enhanced transthoracic echocardiography (TTE) to improve the detection of left ventricular thrombus in patients with anterior ST-elevation myocardial infarction (STEMI).
224105077|NCT03938662|DIETARY_SUPPLEMENT|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
224105078|NCT03938662|DIETARY_SUPPLEMENT|Placebo|Placebo of same appearance, colour and taste,
224105079|NCT00431860|PROCEDURE|Coronary computed tomographic angiography|
223723134|NCT04587232|DIAGNOSTIC_TEST|Western Ontario and McMaster|Standardized questionnaire to investigate the health status of patients with osteoarthritis. The WOMAC OA index assesses the symptomatic severity and disability with pain, stiffness, and physical function domains. Each subscale was summated to a maximum score of 20, 8, and 68, respectively, with the higher scores corresponding worst health status.
223952318|NCT02753075|DRUG|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
223952319|NCT05529485|PROCEDURE|Cataract surgery by phacoemulsification|Cataract surgery by phacoemulsification
223952320|NCT05658809|PROCEDURE|thyroidectomy|Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
223952321|NCT04151147|PROCEDURE|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
223952322|NCT04151147|PROCEDURE|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
223723135|NCT00795106|DRUG|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
223952323|NCT04867772|OTHER|Home based rehabilitation|
223952324|NCT00823966|DRUG|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
224105080|NCT03855072|PROCEDURE|customized fixation plate|"* All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
224105081|NCT03855072|PROCEDURE|maxillomandibular fixation|"* All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
224105082|NCT06127212|DRUG|Dapagliflozin 10 mg film-coated tablet|One tablet of the test drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
224105083|NCT06127212|DRUG|Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia|One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
224105084|NCT04527757|PROCEDURE|Inhalation induction|For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
224105085|NCT04527757|PROCEDURE|Intravenous induction|For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
224105086|NCT00524095|DRUG|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
224105087|NCT00524095|DRUG|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
224105088|NCT06963099|OTHER|INTACS implantation|intra corneal segments implantation
224105089|NCT00716937|PROCEDURE|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
224105090|NCT00716937|PROCEDURE|laying open|laying open the site of excision of sinus or cyst without any flap
224289097|NCT03418506|BEHAVIORAL|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
224289098|NCT03053336|BEHAVIORAL|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
223952325|NCT00941447|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
223952326|NCT00941447|BEHAVIORAL|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
224105091|NCT05154747|DRUG|Cabotegravir, Rilpivirine Drug Combination|"Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock."
224105092|NCT05154747|DRUG|TLD|Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
224105093|NCT05869643|DRUG|Low-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
224105094|NCT05869643|DRUG|Medium-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
224105095|NCT05869643|DRUG|High-dose STP0404 (Pirmitegravir)|Once daily, oral capsule taken after breakfast
224105096|NCT05869643|DRUG|Placebo|Matching placebo capsule, taken orally once daily after breakfast
223952327|NCT00941447|BEHAVIORAL|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
223952328|NCT04471805|DEVICE|Sham transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
224289099|NCT01790035|DRUG|LGG|
224289100|NCT01790035|DRUG|Placebo|
224105097|NCT05463601|DRUG|Mecapegfilgrastim|Mecapegfilgrastim
224105098|NCT05463601|DRUG|dalpiciclib|dalpiciclib
224289101|NCT03135899|DRUG|BI 443651|Three doses, each 12 hours apart
224289102|NCT03135899|DRUG|Placebo|Three doses, each 12 hours apart
224289103|NCT00212576|BEHAVIORAL|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
224105099|NCT05463601|DRUG|exemestane, fulvestrant, letrozole, tamoxifen|endocrine therapy
224105100|NCT06506279|DEVICE|CorTec Brain Interchange (BIC) System|Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
224105101|NCT00015249|DRUG|Amantadine|
224289104|NCT00212576|BEHAVIORAL|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
224289105|NCT03521063|DRUG|Budesonide|Drug: Budesonide inhalation suspension
224289106|NCT03521063|DRUG|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
224289107|NCT03521063|DRUG|Saline|Sodium chloride injection 0.9%
223723136|NCT00795106|DRUG|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
223723137|NCT04991415|OTHER|Manual Therapy|
223952329|NCT04471805|DEVICE|Transcranial direct current stimulation 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
223952330|NCT05746468|BEHAVIORAL|Ecological assessment and intervention|The MBI-EMI app will include five main parts, including virtual counselor, intervention library, weekly mindfulness practice, assessment bank and daily emotion log. In the eight weeks, the virtual counselor will initiate the conversation every day for three times (morning, afternoon and evening) to check the status of the participants. If the participants responded, the virtual counselor would invite the participants to rate their level of depression, stress and anxiety and then recommend appropriate mindfulness practice in the intervention library, such as 3-minute breathing space or mindful eating. The conversation between the virtual counselor and participants will be in the format of menu list and participants can easily choose from different options.
223952331|NCT05746468|BEHAVIORAL|Audio-based Mindfulness intervention|The control group will receive audio recordings of how to practice mindfulness at home.
223952332|NCT05371002|BEHAVIORAL|Online group nonviolent communication (NVC) interventions|"The primary purpose of NVC as defined by Dr. Marshall Rosenberg is to resolve interpersonal conflict using empathic communication skills. Nonviolence does not refer to the mere absence of physical harm. It is a way of life that helps us to transform old patterns of defensiveness and aggressiveness into compassion and empathy and to improve the quality of all types of relationships. The basic model of NVC consists of four key principles: the separation of observation from evaluation (observation), exploring and expressing the feelings that emerge from observations (feeling), taking responsibility for one's feelings (need), and telling others the need to enrich lives (request). A book on NVC specifically targets parents to improve communication and connection with their children. The NVC model emphasizes the importance of observation and has similarities with the concept of mindful parenting, which refers to a non-judgmental and open parenting style."
223952333|NCT05371002|OTHER|Waitlist control group|Waitlist control, but included a short active intervention during the 2nd and 3rd assessments.
223952334|NCT05063175|OTHER|Conventional Physical Therapy Protocol|The conventional physical therapy protocol was prescribed to correct the kyphotic posture of the dorsal spine, and improve postural balance stability during standing and walking. The conventional therapeutic protocol for every child was three sessions per week for 12 successive weeks. Every treatment session was applied for two hours with a few minutes rest in between them.
223952335|NCT05063175|OTHER|TheraTog orthotic undergarment with its strapping system|TheraTog orthotic undergarment with its strapping system was conducted for 8 hours daily for 12 successive weeks. It is made to be fitted directly on the skin as undergarments.
223952336|NCT01099878|DEVICE|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
223952337|NCT01099878|DEVICE|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
223952338|NCT00915629|DIETARY_SUPPLEMENT|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
223952339|NCT01558765|OTHER|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
223952340|NCT00035256|DRUG|teriparatide|
223952341|NCT00035256|DRUG|raloxifene HCl|
223952342|NCT00035256|DRUG|placebo|
223952343|NCT00896740|GENETIC|microarray analysis|
223952344|NCT00896740|PROCEDURE|biopsy|
223952345|NCT05534776|OTHER|Investigator Global Assessments (IGAs)|5-Point scale from 0-4 to score the severity of pemphigus, where 0=clear, 1=almost clear, 2=mild, 3=moderate and 4=severe.
223952346|NCT03200509|OTHER|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
223952347|NCT03200509|OTHER|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
223952348|NCT00623649|DRUG|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
223952349|NCT00623649|DRUG|Placebo|Dose escalation study with a full review of all safety data following each cohort.
223994542|NCT04108624|DEVICE|Discontinuation Phase|Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
223994543|NCT05053971|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223994544|NCT05053971|PROCEDURE|Core Biopsy|Undergo core needle biopsy
223994545|NCT05053971|DRUG|Entinostat|Given PO
224105102|NCT06472570|RADIATION|Stereotactic radiotherapy boost|"A stereotactic radiosurgery boost is given in two cases:~* Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy).~* Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy.~Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively~Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment~Prescribed doses of stereotactic boost are in the range of 10-18 Gy"
224289108|NCT01479257|BEHAVIORAL|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
223538404|NCT02308514|DEVICE|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
223538405|NCT02308514|OTHER|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
223538406|NCT00784121|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
223538407|NCT02930148|OTHER|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
223952350|NCT01079117|DRUG|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
223952351|NCT01079117|DRUG|Slow release oral morphine|
223952352|NCT01079117|DRUG|Methadone|
223952353|NCT05581108|DIETARY_SUPPLEMENT|Juice PLUS+® OMEGA|Daily dose of total Omega blend: 925 mg (2 capsules)
223952354|NCT05581108|DIETARY_SUPPLEMENT|Placebo|matched placebo (2 capsules)
224105103|NCT03987217|DIETARY_SUPPLEMENT|Creatine Monohydrate|Given orally
223952355|NCT03368274|DRUG|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
223952356|NCT03301597|BIOLOGICAL|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
224289109|NCT01479257|DEVICE|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
224105104|NCT03987217|BEHAVIORAL|Exercise Intervention|Complete POWER resistance training program
224105105|NCT03987217|OTHER|Questionnaire Administration|Ancillary studies
224289110|NCT01479257|DEVICE|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
224289111|NCT06125496|OTHER|Pain management|Investigation of relationship between kinesiophobia, physical activity and disability level and pain management in patients with CLBP
224289112|NCT03660241|DRUG|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
224289113|NCT00003034|DRUG|doxorubicin hydrochloride|Given IV
224289114|NCT00003034|DRUG|ranpirnase|Given IV
224289115|NCT03341546|OTHER|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
224289116|NCT05828355|OTHER|Knee Care@Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
224289117|NCT04156412|DEVICE|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
224289118|NCT01622608|BEHAVIORAL|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
223723138|NCT05363644|BIOLOGICAL|BioDFence G3|Placement of a sheet of BioDFence® G3 will be applied to the neurovascular bundle on participants undergoing an elective Full Nerve Sparing Radical Prostatectomy for primary treatment of prostate cancer.
223723139|NCT06260085|OTHER|Relatives vioce record|In the study, it was emphasized that the messages to be played to the patient should be 3-5 minutes and simple terms should be used in a way that can be understood by individuals with low education level. Written informed consent was obtained from the patient and the patient's relatives before the application. In the message recorded by a patient's relative decided by the patient's family members, the patient's relative said what he/she wanted to say to the patient and recorded it using a voice recorder. The researcher had a preliminary interview with the patient's relative before the voice recording was taken about the use of the voice recorder and the content of the message (Table 1) in order to prevent the messages from negatively affecting the patient. The voice recording created by the patient's relative was played to the patient by the researcher using a music pillow. After the patient listened to the audio recording, it was erased under the witness of the patient's relative.
224289119|NCT00856830|DRUG|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~* All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~* At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
223538408|NCT05358327|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
223538409|NCT01951053|DRUG|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
224289120|NCT03580174|OTHER|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
224289121|NCT03580174|OTHER|Routine physiotherapy group|Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
224289122|NCT01025674|BEHAVIORAL|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
224289123|NCT01922752|DRUG|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
223723140|NCT00119054|BEHAVIORAL|In Home Health Messaging Device|
224289124|NCT01914068|OTHER|Supervised exercise in hospital|
223723141|NCT06117657|DRUG|Low dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^11 vg/kg.
223723142|NCT06117657|DRUG|Middle dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 8.0x10\^11 vg/kg.
223723143|NCT06117657|DRUG|High dose KL-HIV-Tri01|Subjects will be dosed with single dose of KL-HIV-Tri01 at 2.4x10\^12 vg/kg.
223723144|NCT02108470|OTHER|Dental consultation using OHIP|The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
223723145|NCT04267198|BEHAVIORAL|Intention Treatment for Anomia|Word retrieval treatment for aphasia that engages right hemisphere intention mechanisms using a left-hand circular gesture.
223723146|NCT04943185|DEVICE|XEN gel microstent implantation|"Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention"
223538410|NCT01951053|DRUG|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
223538411|NCT01951053|DRUG|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
223538412|NCT05631444|BIOLOGICAL|Cell-based therapy|One dose of auto-BM-MNC, one dose of allo-WJ-MSCs, or one dose of placebo solution (saline solution with 2% of autologous serum), were periadventitial arteries administration in CTLI patients.
223538413|NCT01832727|DRUG|Oprozomib|Oprozomib tablets were supplied containing 60, 90, or 120 mg of oprozomib. Oprozomib extended release tablets were supplied containing 150, 180, 210, 240, or 270 mg of oprozomib. Both formulations were administered in a single dose on dosing days. The tablet formulation required multiple tablets to reach each dose on dosing days.
223538414|NCT01832727|DRUG|Dexamethasone|Dexamethasone was administered as 20 mg tablets in strengths of 4 and 6 mg taken orally. If a participant could not tolerate tablets or tablets were unavailable, 20 mg administered intravenously was substituted.
223538415|NCT02216526|OTHER|Cetaphil® Restoraderm|
223538416|NCT02216526|OTHER|Excipial|
223538417|NCT05918445|DRUG|PM8002|IV infusion
223538418|NCT04350684|DRUG|Umifenovir|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Umifenovir in COVID-19 patients.
223538419|NCT04350684|DRUG|Interferon-β 1a|This Drug will be used in all arms as we discovered its benefits in our previous randomized clinical trial.
223723147|NCT02059486|BEHAVIORAL|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
224105106|NCT00981435|DRUG|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
224105107|NCT00981435|DRUG|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
223538420|NCT04350684|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
224105108|NCT00981435|DRUG|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
224105109|NCT00602407|DRUG|Cilostazol|
224105110|NCT06445322|DIAGNOSTIC_TEST|Prescreening Assessments|Various genetic and visual assessments.
224105111|NCT05113004|DRUG|Hydroxychloroquine 400mg/d|Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
224105112|NCT05113004|DRUG|Leflunomide 20mg/d|Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation and consequently T cell-dependent B cell formation of autoantibodies.
224105113|NCT05113004|DRUG|Mycophenolate mofetil 2000mg/d|Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
224105114|NCT05113004|DRUG|Placebo of Hydroxychloroquine 400mg/d|Placebo of Hydroxychloroquine (HCQ) is a 4-aminoquinoline belonging to the group of antimalarial agents. Its immunomodulatory activity on B-cells has mainly been attributed to its inhibition of antigen presentation, cytokine production, and recently on Toll-like receptor signaling and IFN secretion that drives B cell activation.
224105115|NCT05113004|DRUG|Placebo of Leflunomide 20mg/d|Placebo of Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby inhibiting T cell proliferation
223723148|NCT01234298|DRUG|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
223723149|NCT01234298|DRUG|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
224105116|NCT05113004|DRUG|Placebo of Mycophenolate mofetil 2000mg/d|Placebo of Mycophenolate mofetil (MMF) is a morpholinoethyl ester of mycophenolic acid which blocks proliferation of lymphocytes by inhibiting the de novo pathway of purine biosynthesis (Allison, 2000).
223723150|NCT01234298|DRUG|Placebo|Placebo capsule taken once-daily for up to 26 weeks
223723151|NCT06049680|DRUG|SMOFlipid® (lipid injectable emulsion)|"SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated."
223723152|NCT02530489|DRUG|Atezolizumab|Given IV
223723153|NCT02530489|DRUG|Nab-paclitaxel|Given IV
224105117|NCT01247233|RADIATION|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
224105118|NCT01247233|RADIATION|Accelerated partial breast irradiation|Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
224105119|NCT00645242|DRUG|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
224105120|NCT04265534|DRUG|Telaglenastat|Oral Glutaminase Inhibitor
224105121|NCT04265534|DRUG|Carboplatin Chemotherapy|IV infusion
224105122|NCT04265534|DRUG|Pemetrexed Chemotherapy|IV infusion
224105123|NCT04265534|BIOLOGICAL|Pembrolizumab Immunotherapy|IV infusion
224105124|NCT04265534|DRUG|Placebo|Oral placebo
224105125|NCT04265534|DIETARY_SUPPLEMENT|Folic acid 400 -1000 μg|Orally, once daily beginning 7 days prior to the first dose of pemetrexed and continue until 21 days after the last dose of pemetrexed.
224105126|NCT04265534|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Vitamin B12 1000 μg Intramuscular injection one week prior to the first dose of pemetrexed and once every 3 cycles (9 weeks) thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
224105127|NCT04265534|DRUG|Dexamethasone 4 mg|For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
224105128|NCT02616653|PROCEDURE|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
223538421|NCT04350684|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
223723154|NCT02591589|OTHER|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 \> 70 mmHg or oxygen saturation greater than or equal to 92%.
224105129|NCT05089305|DRUG|Ozone plasma|Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
223538422|NCT04350684|DRUG|Standards of Care|This Drug will be used in all arms as mandated by our governmental guidelines.
223538423|NCT03083782|DRUG|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
223538424|NCT03083782|DRUG|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
223538425|NCT03083782|DRUG|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
223723155|NCT02591589|OTHER|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
224105130|NCT01726777|DIETARY_SUPPLEMENT|Control|Normal cheddar cheese
224105131|NCT01726777|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 supplemented cheddar cheese
224105132|NCT04097288|DRUG|Citalopram 40mg|Single dose
224105133|NCT04097288|DRUG|Reboxetine 8 mg|Single dose
223952357|NCT03301597|DRUG|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
224105134|NCT04097288|DRUG|Placebo oral tablet|Single dose
224105135|NCT04097288|DRUG|Placebo oral tablet|Single dose
224105136|NCT01570725|BEHAVIORAL|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
224105137|NCT01570725|BEHAVIORAL|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
224105138|NCT00884507|DRUG|Placebo|po daily for 24 weeks
223723156|NCT02846779|OTHER|Low intensity|Low intensity telepharmacy outreach
223952358|NCT00126620|DRUG|erlotinib hydrochloride|
224105139|NCT00884507|DRUG|RO5313534|1mg po daily for 24 weeks
224105140|NCT00884507|DRUG|RO5313534|5mg po daily for 24 weeks
224105141|NCT00884507|DRUG|RO5313534|15mg po daily for 24 weeks
224105142|NCT03778255|PROCEDURE|Sentinel Lymph Node Biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
224105143|NCT03607734|DRUG|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~* 50mg amoxicillin (10% total dose)~* 250mg amoxicillin (50% total dose)~* 200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
224105144|NCT04764032|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be undertaken by a range of appropriately competent practitioners including; intensive care clinicians, cardiologists and specialist echocardiographers. Imaging obtained will be in keeping with the protocol required for a Focused Intensive Care Echo (FICE) scan and should include ECG monitoring at all times. A focused dataset will be used to answer the primary outcome. If available and the echocardiographers competency and experience permit, further measures of RV function will be obtained at this time.
224105145|NCT03196050|DEVICE|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
224105146|NCT00609271|BEHAVIORAL|low carbohydrate diet|\<40 grams carbohydrate/day
223538426|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
223538427|NCT03083782|DRUG|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
223723157|NCT02846779|OTHER|Moderate intensity|Moderate intensity telepharmacy outreach
223723158|NCT02846779|OTHER|High intensity|High intensity telepharmacy outreach
223723159|NCT00803725|DRUG|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
223952359|NCT00126620|DRUG|sorafenib tosylate|
223952360|NCT03761199|OTHER|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
224105147|NCT00609271|BEHAVIORAL|low fat diet|\<30% fat, \<7% saturated fat
224105148|NCT01332032|BEHAVIORAL|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
224105149|NCT01332032|BEHAVIORAL|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
224289125|NCT05685277|DRUG|Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg|Ramipril/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
224289126|NCT05685277|DRUG|Tritace® Plus tablet 10 mg/25 mg|Tritace® Plus is manufactured by Sanofi S.p.A., Italy (holder of the registration certificate: Sanofi-Aventis Deutschland GmbH, Germany). Each tablet contains 10 mg of ramipril and 25 mg of hydrochlorothiazide.
224289127|NCT03604107|GENETIC|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
224105150|NCT01332032|BEHAVIORAL|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
224105151|NCT03650439|DIAGNOSTIC_TEST|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
224105152|NCT06477159|DRUG|Pancrelipase Capsules|Treatment with Pancreatic Enzyme Replacement Therapy
224105153|NCT03601026|BEHAVIORAL|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
224105154|NCT04788628|OTHER|Baseline|Hippocampal and scalp EEG monitoring during overnight sleep
224105155|NCT04788628|OTHER|Motor procedural memory task|Training on the finger tapping MST prior to monitored overnight sleep with MST testing the following morning
224105156|NCT04788628|OTHER|Motor procedural memory task plus auditory stimulation|Training on the finger tapping MST prior to monitored overnight sleep that includes auditory stimulation, with MST testing the following morning
224289128|NCT01744093|DRUG|Doxycycline|100 mg twice daily (BID orally) x 24 weeks
224289129|NCT01744093|DRUG|Placebo (sugar pill)|100 mg twice daily (BID orally) x 24 weeks
223952361|NCT05326685|OTHER|video with korotkoff sounds|The State-Trait Anxiety Inventory short version (STAIS-5, STAIT-5) and the student introduction form were applied at the beginning of the study. Then Intervention participants were shown and listened visual video with korotkoff sounds before blood presssure measurement. Afterwards, blood pressure was measured to the students 3 times and 3 measurements were recorded. After the application about 2 hours later, the students State Anxiety Inventory short version (STAIS-5) form was filled again by students.
223952362|NCT06121778|OTHER|Home|There is no intervention but evaluations of elderly persons living at home will be conducted every three years and for the next 12 years. If some people leave the home, as far as possible, the reason will be asked.
223952363|NCT01163214|DRUG|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
223952364|NCT01163214|DRUG|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
223952365|NCT06399939|BEHAVIORAL|Nap|Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging
224105157|NCT05772494|OTHER|Assessment of activity limitations, SDO and DOA|The assessment is made with two instruments (DOA, SDO), and finally the occupational therapist includes the analysis and summary of activity limitations to the sickness certificate. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
224105158|NCT05772494|OTHER|Control group|All assessments concerning activity limitations are made using usual routines, primarily by the sick-listing physician. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave
224105159|NCT06161415|DRUG|Laquinimod eye drops|n Laquinimod eye drops 10 mg/ml Dose: Dosing frequency will depend on the groups assigned
224105160|NCT04652258|DRUG|Actemra|Dosage: 8mg/kg (max. 800mg) Actemra administered intravenously as an infusion over 60 min.
224105161|NCT01627145|DRUG|Solifenacin|Solifenacin 5 mg qd,
224105162|NCT05212129|DEVICE|Percutaneous vagal nerve stimulation (pVNS) device|Subjects in Treatment Arm B will enter a six-week, prospective open label treatment trial with the FDA-approved and commercially available device IB-Stim. This is an ambulatory, neurostimulation device which consists of a battery powered, externally affixed generator with 4 wire leads attached to electrode/needle arrays affixed to the outer ear. The device delivers low voltage (3.2V) stimulation in alternating frequencies for a total of 5 days (around the clock).
224289130|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
223538428|NCT00749437|RADIATION|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
223538429|NCT03230188|OTHER|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
223538430|NCT03230188|OTHER|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
223538431|NCT03230188|OTHER|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
223952366|NCT06399939|BEHAVIORAL|Wake|Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
223952367|NCT04823156|DIETARY_SUPPLEMENT|Calcium|Daily calcium food supplement.
224289131|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
223952368|NCT03633318|DEVICE|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
223723160|NCT00803725|DRUG|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
223723161|NCT00404677|OTHER|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
223952369|NCT01506700|DEVICE|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
223952370|NCT01442207|PROCEDURE|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
223952371|NCT01442207|PROCEDURE|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~* Standard management for placenta previa.~* Hospital admission for vaginal bleeding/hemorrhage~* Antenatal corticosteroids \> 24w0d of gestation~* Tocolytic therapy per physician's discretion~* Magnesium sulfate for neuroprotection~* Fetal Heart Rate Monitoring~* Avoidance of digital examinations of the cervix~* Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM \> 34 wks, worsening maternal or fetal condition )~* Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
223994546|NCT00947947|BEHAVIORAL|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
223994547|NCT06032507|PROCEDURE|Bone lavage previous to cementation|Bone lavage previous to cementation in total knee arthroplasty
223994548|NCT00912145|DRUG|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
223994549|NCT01022411|DIETARY_SUPPLEMENT|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
223994550|NCT01103921|OTHER|Glucose|25% dose at 2-week intervention assigned to subjects.
223994551|NCT01103921|OTHER|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
223994552|NCT01103921|OTHER|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
223994553|NCT01103921|OTHER|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
223994554|NCT03496376|OTHER|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
223994555|NCT03496376|OTHER|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
223994556|NCT00391339|DRUG|Bryophyllum p.|
223994557|NCT01786304|PROCEDURE|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
223994558|NCT04714398|BEHAVIORAL|Opt-In Recruitment|Patients in the opt-in recruitment arm will receive a letter describing the program and inviting them to participate in the remote monitoring program. Along with the letter they will receive an informational brochure and a copy of the informed consent form. Patients in this arm will then receive a recruitment phone call explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will mail a blood pressure cuff and begin the remote monitoring program for the patient 6 days later.
223994559|NCT04714398|BEHAVIORAL|Opt-Out Recruitment|Patients assigned to opt-out recruitment will receive a blood pressure cuff with instructions in the mail along with a letter describing the program and opt-out framing regarding their participation, as well as a brochure and a copy of the informed consent form. Patients in this arm will receive a recruitment phone call similar to recruitment arm A, explaining the program and consenting the participant verbally. If the participant consents to participate in the remote monitoring program, to receive text messaging, and to connection to care, the research coordinator will begin the remote monitoring program for the patient immediately.
223994560|NCT03489876|DEVICE|Synthetic Cartilage Implant|The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.
223994561|NCT03489876|PROCEDURE|Osteochondral Autograft Transfer|The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
223994562|NCT00681668|DRUG|Quetiapine|150-800 mg, oral, twice a day (bid)
223994563|NCT02476942|DRUG|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
223994564|NCT02476942|DRUG|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
224289132|NCT01570283|BIOLOGICAL|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
224289133|NCT04051463|DRUG|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
223538432|NCT03551782|DRUG|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
223538433|NCT03551782|DRUG|Apalutamide 240 mg|Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
223538434|NCT01326442|OTHER|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
224105163|NCT05212129|OTHER|Acoustic vagal nerve stimulation (aVNS) treatment|All subjects receiving acoustic therapy via active VNS (aVNS; n=30) or sham VNS (sVNS; n=30) will enter a four-week, randomized, double-blind clinical trial during which they will listen to either computer altered/filtered vocal music (active treatment) that has been designed to stimulate vagal calming vs. regular non-filtered music (sham treatment). The stimuli will mirror the acoustic intervention known as the Safe and Sound Protocol. This protocol has been found to reduce auditory hypersensitivities and calming the autonomic nervous system by increasing vagal regulation of the heart via brainstem ventral vagal complex. The acoustic intervention may be played by an electronic device (i.e. smartphone, tablet, laptop, mp3) and delivered virtually with the help of trained coaches.
224105164|NCT03968965|DEVICE|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
223538435|NCT01326442|DIETARY_SUPPLEMENT|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
224289134|NCT04051463|DRUG|Placebo|Placebo eye drops instilled once daily
224289135|NCT04883970|OTHER|124I-18B10(10L) PET/CT|Study participants will undergo 124I-18B10(10L) PET/CT scans
224289136|NCT02756247|DRUG|Buparlisib|
223723162|NCT02288052|BEHAVIORAL|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
223952372|NCT05959902|OTHER|Forward Walking|During the 8-week treatment, the participants will undertake 10 minutes of forward walking, as well as a 5-minute warm-up and cool-down, three times a week on an even surface at their normal speed as a home exercise plan. During the warmup and cool down periods, the participants were advised to execute ankle toe motions, heel lift exercises, and hamstring and gastrocnemius-soleus stretches.
223952373|NCT05959902|OTHER|Physiotherapy Exercises|"Isometric quadriceps exercise. Straight leg raising (SLR) exercise. Isometric hip adduction exercise.~Terminal knee extension exercise:~Semi-wall squat exercise. Quadriceps drill exercise."
223952374|NCT03248076|DRUG|Fentanyl Citrate|1γ/Kg fentanyl
224105165|NCT03968965|OTHER|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
224105166|NCT03898934|DRUG|Vitamin D|receive 6000iu daily for 8 weeks
224105167|NCT03898934|DRUG|Placebo Oral Tablet|placebo for the same period
224105168|NCT03185676|OTHER|Bilberry|A bilberry based probiotic beverage
224105169|NCT03185676|OTHER|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
224105170|NCT02734563|OTHER|Collagen turnover|Type IV and V collagen synthesis and breakdown
224289137|NCT02756247|DRUG|Ibrutinib|
224289138|NCT02527499|BEHAVIORAL|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
223538436|NCT01554748|PROCEDURE|Total joint arthroplasty|
223538437|NCT03025126|OTHER|Multimedial Rehabilitation|
223538438|NCT03025126|OTHER|Usual care program|Usual care at home program according to healthcare professional's advice
223538439|NCT04017130|DRUG|MT-0169|MT-0169 intravenous infusion.
223538440|NCT02478489|DRUG|Oral naltrexone (PO-NTX)|oral naltrexone
223538441|NCT02478489|DRUG|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
223538442|NCT02455739|OTHER|chewing gum|postoperative gum chewing to improve gastrointestinal function
223538443|NCT04381247|DIAGNOSTIC_TEST|Molecular diagnostics in HAP and VAP|Airway samples will be analyzed both by standard and molecular based microbiological analysis.
223538444|NCT02455167|DRUG|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
223538445|NCT02455167|DRUG|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
223538446|NCT02455167|DRUG|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
223538447|NCT05504499|DEVICE|Interspinous Fusion|The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
223538448|NCT01133847|DRUG|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
223952375|NCT00847977|DRUG|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
224289139|NCT02527499|BEHAVIORAL|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
223952376|NCT00847977|DRUG|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
224105171|NCT03641300|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
224105172|NCT03641300|DEVICE|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
224105173|NCT06104683|DRUG|Placebo|Administered orally
223952377|NCT02084576|DRUG|Nepafenac|One drop in the study eye 3 times daily for 30 days
223952378|NCT02084576|DRUG|Ketorolac|One drop in the study eye 4 times daily for 30 days
223952379|NCT03800771|DEVICE|Cycléo BRAU|Practice dual-task tests.
224105174|NCT06104683|DRUG|Pirtobrutinib|Administered orally
224105175|NCT05483127|DEVICE|Verofilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
224105176|NCT05483127|DEVICE|Stenfilcon A toric soft contact lenses|Soft contact lenses for optical correction of ametropia and astigmatism
224105177|NCT06052462|DRUG|[14C]-LY3556050|Administered orally
224105178|NCT05299710|PROCEDURE|Laparoscopic surgery|Surgery used to remove your child's ovary tissue is called laparoscopic surgery. Laparoscopic surgery employs a telescope-like instrument called laparoscope. The laparoscope will be put into your child's belly through a small (about half an inch) cut just below the belly button. Two or three other cuts may be made to allow for other instruments to help remove one of the ovaries. The surgeon will then look at both ovaries before the removal of one. Both of your child's ovaries must appear normal and be free of any masses in order to complete the surgery. The surgeon will choose which ovary will be removed at the time of surgery. This type of surgery is likely to last for 30 to 65 minutes.
224105179|NCT01386671|DRUG|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
224105180|NCT01386671|DRUG|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
224105181|NCT01217775|DRUG|PH80|PH80 intranasal spray 800 nanograms
224105182|NCT01217775|DRUG|Placebo intranasal spray|Placebo intranasal spray
224105183|NCT00671151|DRUG|Theophylline|Theophylline 100 mg bid for 3 months
223952380|NCT03800771|DEVICE|GAITRITE®|Routine practice dual-task tests.
223952381|NCT03427645|BEHAVIORAL|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
223952382|NCT04255004|DEVICE|Pall Celeris System, point of care device for human cell therapy|Concentration of PB-MNCs autologous cell therapy was produced by a filtration-based point-of-care device. All the procedures were performed in operatory room with anaesthesiologic support (propofol and/or peripheral block). Blood withdrawal (120 ml) was collected through a peripheral venous access. Blood was loaded, and gravity filtration was allowed to proceed until the upstream side of the filter had no remaining blood; filtration last about 10 minutes. During filtration, MNCs were captured in the filter while plasma, platelets (PLTs) and red blood cells (RBCs) were not retained. Immediately concentrate solution is injected in the perilesional area and intramuscular in the foot and the leg (0.2-0.3cc in boluses) below the knee, at intervals of 1-2 cm and to a mean depth of 1.5-2 cm, using a 21G needle. This procedure is repeated on each patient for three times, at intervals of 30-45 days from each other.
223952383|NCT04824456|PROCEDURE|bilateral sagittal split osteotomy using separators.|The final split is completed with a thin osteotomes, splitting the entire ascending ramus from the anterior to the posterior border of the ramus.
224105184|NCT00396396|DRUG|Acetylcysteine|
224105185|NCT04252417|DRUG|MD1003|Single oral dose administration of MD1003 at Day 1
224105186|NCT00315302|DRUG|Atropine|Atropine 1% once each weekend day
224105187|NCT00315302|DEVICE|Plano Lens|Plano lens for the sound eye
224105188|NCT00217438|DRUG|melphalan|Given IV
224105189|NCT00217438|DRUG|amifostine trihydrate|Given IV
224105190|NCT00217438|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
224105191|NCT00217438|GENETIC|fluorescence in situ hybridization|Correlative study
224105192|NCT00217438|PROCEDURE|bone marrow ablation with stem cell support|Undergo transplant
224105193|NCT05635565|OTHER|Individualized goal training|This group will be submitted to individualized goal training, 3 hours/day, 5 times/week, over the course of two weeks, totaling 30 hours. Training will happen in a clinical setting. Adolescents will select their functional goals to be trained during the intervention period.
223952384|NCT02568202|OTHER|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
224105194|NCT05635565|OTHER|Individualized goal training with educational strategies|This group will be submitted to individualized goal training with their caregivers, for 2 weeks, with 5 face-to-face meetings lasting 3 hours a day at the rehabilitation center. The other 5 meetings will be held online with the adolescent and their caregiver at the same time, via video communication platform. Adolescents will select their functional goals to be trained during the intervention period.
224105195|NCT03939208|BEHAVIORAL|BRISC|
224105196|NCT03939208|BEHAVIORAL|SAU|
224105197|NCT02082691|DRUG|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
224105198|NCT00000249|DRUG|20% N2O|20% inhaled N2O
224105199|NCT00000249|DRUG|30% N2O|30% inhaled N2O
224105200|NCT00000249|DRUG|40% N2O|40% inhaled N2O
224105201|NCT05736315|OTHER|Placebo dairy beverage|Placebo dairy beverage (placebo) is a sweetened dairy beverage.
224105202|NCT00704106|DRUG|Entecavir|0.5 or 1 mg dose qd
224105203|NCT04297007|OTHER|PECS block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
224105204|NCT04297007|OTHER|Rhomboid intercostal block|A dose of ibuprofen 400 mgr and tramodol 100 mg will be performed intraoperatively. Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
224105205|NCT01241539|DRUG|Dabigatran etexilate|150 mg capsule
224105206|NCT01241539|DRUG|Dabigatran etexilate|75 mg capsule
224289140|NCT02527499|BEHAVIORAL|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
224289141|NCT06322394|DRUG|high-dose BXOS110|3.0 mg/kg, maximum dose not exceeding 300 mg，Participants received one administration by intravenous infusion.
224289142|NCT06322394|DRUG|low-dose BXOS110|2.0 mg/kg, maximum dose not exceeding 200 mg，Participants received one administration by intravenous infusion.
224289143|NCT06322394|DRUG|Placebo|Does not contain any test drug active ingredients，Participants received one administration by intravenous infusion.
224289144|NCT06290518|DIETARY_SUPPLEMENT|Ligilactobacillus salivarius CECT5713|Oral administration of a capsule containing 9.5 log10 cfu of the strain.
224289145|NCT06290518|DIETARY_SUPPLEMENT|Placebo|Oral administration of a capsule containing maltodextrin.
224289146|NCT05434377|OTHER|ergocalciferol supplementation|Participants in both groups will recieve ergocalciferol with different supplementation regimens for 6 months.
224289147|NCT05434377|OTHER|dialysis techniques|Both groups will have participants treated with maintenance hemodialysis and peritoneal dialysis.
223538449|NCT01133847|BEHAVIORAL|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
223952385|NCT05645445|DEVICE|virtual reality|patients who include intervention gruop during the ESWL process, patients will be shown videos with virtual reality glasses, which include nature and landscapes, giving people a feeling of comfort and peace, and making them feel like they are inside.
223952386|NCT01779492|DRUG|GL2907|once a day
223538450|NCT01133847|BEHAVIORAL|Parent Training|Nine sessions on parenting a child with ADHD
223538451|NCT01133847|DRUG|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
223952387|NCT01779492|DRUG|Oxycontine CR 10mg|twice a day
224105207|NCT01241539|DRUG|Dabigatran etexilate|110 mg capsule
224105208|NCT01400828|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
224105209|NCT01400828|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
224105210|NCT01400828|DRUG|Placebo|(encapsulated) Tablets QD/14 days
224105211|NCT02286960|DRUG|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
224105212|NCT02286960|DIETARY_SUPPLEMENT|Lactose Pills|4 day course 2 x 20mg per da
224105213|NCT00440401|DRUG|fibrinogen (human) + thrombin (human)|
224105214|NCT00440401|DRUG|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
224105215|NCT05064241|OTHER|Access to Genetic Counselor for answering questions|A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
224105216|NCT01288183|PROCEDURE|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
224105217|NCT01288183|PROCEDURE|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
224105218|NCT04616586|DRUG|Siltuximab|11 mg/kg IV administered over 1 hour
224105219|NCT04616586|OTHER|Normal Saline|IV administered over 1 hour
224105220|NCT04847115|PROCEDURE|Operative|Intramedullary screw fixation
224105221|NCT04847115|OTHER|Walking boot orthosis|Non-operative treatment with walking boot orthosis for six weeks. The non-operative study arm will use walking boot orthosis only. The operative study arm will use walking boot orthosis as adjuvant treatment.
224289148|NCT05434377|OTHER|sunlight exposure time|Both groups will be advised to receive similar hours of daily sunlight exposure time.
224289149|NCT02524587|DEVICE|standard polyethylene acetabular irradiated at 3 Mrad|
223952388|NCT03868774|PROCEDURE|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
223952389|NCT02197494|DRUG|Valsartan|320mg tablets
223952390|NCT00459849|PROCEDURE|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
223952391|NCT03883178|PROCEDURE|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
223952392|NCT04103333|PROCEDURE|Lumbar Puncture|Administered as specified in the treatment arm.
223952393|NCT04103333|PROCEDURE|Blood Collection|Administered as specified in the treatment arm.
223952394|NCT00880724|DEVICE|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
223952395|NCT03618888|OTHER|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
223952396|NCT03618888|OTHER|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
223952397|NCT00785031|OTHER|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
223952398|NCT05711589|PROCEDURE|CBA was performed under intracardiac echocardiography guidance without fluoroscopy|Zero-X group: Patients undergoing ICE-guided CBA
224105222|NCT00091793|DRUG|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
223952399|NCT05711589|PROCEDURE|cryoablation (CBA) was performed under fluoroscopic guidance|cryoablation (CBA) was performed under fluoroscopic guidance
224105223|NCT00091793|DRUG|Placebo|Placebo given at day 1, month 6, month 12 and month 18
224105224|NCT04120688|DEVICE|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
224105225|NCT05111314|RADIATION|Gallium Ga 68 Gozetotide|Given IA
224105226|NCT05111314|PROCEDURE|Hepatic Artery Embolization|Undergo hepatic artery embolization
224105227|NCT05111314|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
224105228|NCT03636815|OTHER|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
223538452|NCT01133847|DRUG|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
224105229|NCT01052064|DEVICE|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
224289150|NCT02524587|OTHER|radio stereometric analysis (RSA) of the acetabular|
224289151|NCT02524587|DEVICE|acetabular polyethylene vitamys®|
224105230|NCT00610636|PROCEDURE|Hepatic resection|Hepatic resection
224105231|NCT01370070|DRUG|MK-2206|200mg weekly repeated q 28 days
224105232|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
224105233|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
224105234|NCT00520598|DRUG|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
224105235|NCT00520598|BIOLOGICAL|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
224105236|NCT00520598|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
224289152|NCT05495035|DRUG|Olverembatinib, APG-2575, Dexamethasone|"* Period 1: Subjects will orally take olverembatinib 40mg adult equivalent dose alone QOD from Day 1 to Day 14 (D1 - D14) =. The investigator may start the combination therapy in advance based on medical conditions of the subjects, but not earlier than Day 5/the third dose (D5).~* Period 2: 1) Subjects will orally take olverembatinib 40mg adult equivalent dose QOD from Day 15 to Day 42 (D15 - D42)).~  2\) Subjects will orally take APG-2575 at a ramp up 200mg/400mg/600mg adult equivalent dos QD from D13 to D42 at a dose . In addition, a 3-day dose escalation from D13 to D15 will be needed, and the designated reference dose will be reached on D15.~  3\) Subjects will orally take dexamethasone 6 mg/m2/day, QD from D15 to D42 at 6 mg/m2/day."
224289153|NCT03487783|DRUG|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
224289154|NCT03487783|DRUG|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
224289155|NCT02908282|DEVICE|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
224105237|NCT00520598|BIOLOGICAL|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
224105238|NCT00550238|DRUG|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
224105239|NCT03669393|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
224105240|NCT02418494|OTHER|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
224289156|NCT02908282|DEVICE|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
224289157|NCT03028740|DRUG|Placebo|Cenicriviroc placebo-matching, tablet, orally, once daily for up to approximately 40 months.
224289158|NCT03028740|DRUG|Cenicriviroc|Cenicriviroc, 150 mg, tablet, orally, once daily for up to approximately 40 months.
224289159|NCT02583386|BEHAVIORAL|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
224105241|NCT02418494|OTHER|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
224105242|NCT00200681|DRUG|Velcade|
224105243|NCT03823638|DIETARY_SUPPLEMENT|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
223952400|NCT05917756|OTHER|Mobilization with Movement (MWM) and Tailored Therapeutic Exercise Program|The intervention consists of MWM techniques targeting the cervical and thoracic spine, and the first rib, applied by a certified physiotherapist for 8 weeks, 2 sessions per week, each session lasting 45 minutes. The intervention also includes a tailored therapeutic exercise program for the patients, comprising postural correction, stretching, and strengthening exercises. This intervention will be compared to conventional physiotherapy in the control group.
224105244|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein preservation|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
223952401|NCT05917756|OTHER|Conventional Physiotherapy|Conventional physiotherapy, including manual therapy (soft tissue mobilization, joint mobilization, and nerve gliding techniques) for 8 weeks, 2 sessions per week, each session lasting 45 minutes, combined with a tailored therapeutic exercise program (including postural correction, stretching, and strengthening exercises).
224105245|NCT05957562|PROCEDURE|EA/TOF primary repair with Azygos vein sacrifice (disconnection)|primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
223952402|NCT00930644|DRUG|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
224105246|NCT04350203|PROCEDURE|Laparoscopic right colectomy with intracorporeal anastomosis (IA)|First, the right colon dissection was completed by laparoscopy. An isoperistaltic side-to-side ileocolonic mechanical anastomosis was then performed by using a linear cutting stapler. The enterotomy used to enter the stapler was closed with a running suture (3-0 absorbable monofilament or a 3-0 barbed suture). Finally, the specimen was extracted through a Pfannenstiel mini-laparotomy (4-5 cm).
224105247|NCT04350203|PROCEDURE|Laparoscopic right colectomy with extracorporeal anastomosis (EA)|First, the right colon was widely mobilized. A small laparotomy was performed in the mid/upper abdomen to exteriorize the colon and to perform a side-to-side mechanical anastomosis, using a linear cutting stapler (GIA). The bowel opening was closed either with a manual suture or by a second firing of the GIA.
224105248|NCT05413447|COMBINATION_PRODUCT|Digital consult|Consultations will be prepared digitally using the Mychart patient portal, an elearning and questionnaires. The consultation takes place via Teams.
224105249|NCT06033443|OTHER|Collaborative Learning Group|The experimental group is the group that receives nursing education based on collaborative learning.
224105250|NCT05255614|DEVICE|Virtual reality Simulator|LapSim is a device designed by Surgical Science Device \& software at Swedan
224105251|NCT05255614|DEVICE|Pelvic trainer:|Video-box trainers include a box with a lid and holes cut on the lid for the trocar's insertion. A laparoscope inside the box is connected with a digital camera and provides video output to a monitor on which the trainees are watching their own movements, while performing the teaching task. Laparoscopic instruments, such as laparoscopic graspers and laparoscopic scissors are inserted through the trocars into the box, where the tasks are taught
224105252|NCT04341610|DRUG|Stem Cell Product|100 million allogeneic adipose-derived mesenchymal stromal cells diluted in 100 ml saline
224105253|NCT06554496|DEVICE|CPAP Treatment|Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
224105254|NCT01038492|BEHAVIORAL|p16 Methylation and Lung Cancer Education|"* patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~* patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~* a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~* patients are called again at three months and asked about any changes in their attitudes or smoking habits."
224105255|NCT03306771|DIAGNOSTIC_TEST|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
224105256|NCT03652454|DEVICE|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
224105257|NCT03652454|OTHER|conventional fixed appliance treatment|conventional fixed appliance treatment
224105258|NCT04956484|BIOLOGICAL|Belimumab|Belimumab 10 mg/kg
224105259|NCT04956484|DRUG|Standard of care|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
224105260|NCT05700747|BEHAVIORAL|Health Through Activity|Six, weekly, customized sessions with licensed physical and occupational therapists.
224105261|NCT02344810|DRUG|c-Met inhibitor AMG 337|Given PO
223952403|NCT05639166|BIOLOGICAL|IBIO123|IBIO123 10 mg
223952404|NCT05639166|OTHER|Placebo|Matching Placebo
223952405|NCT05923606|DEVICE|Active tACS|Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
223952406|NCT05923606|DEVICE|Placebo tACS|Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
224105262|NCT02344810|OTHER|placebo|Given PO
224105263|NCT02344810|DRUG|oxaliplatin|Given IV
224105264|NCT02344810|DRUG|leucovorin calcium|Given IV
224105265|NCT02344810|DRUG|fluorouracil|Given IV
224105266|NCT02344810|OTHER|pharmacological study|Correlative studies
224105267|NCT02344810|OTHER|laboratory biomarker analysis|Correlative studies
224105268|NCT01647763|PROCEDURE|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
224105269|NCT01647763|PROCEDURE|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
224105270|NCT04454814|OTHER|Protaper Universal instruments|Root canal treatment using Protaper Universal instruments
224105271|NCT04454814|OTHER|Reciproc Blue instruments|Root canal treatment using Reciproc Blue instruments
224105272|NCT04354454|OTHER|Fitbit|Participants will select a daily step goal and track their steps every day for 4.5 months.
224105273|NCT04354454|OTHER|Fitbit + Game + Support from a Teammate|"Daily Fitbit tracking for 4.5 months, divided into 2 parts.~* 3 months on active intervention with Fitbit, a Game, and Support from a self-selected Teammate and pre-designed game.~* 1.5 month follow-up period with Fitbit and social support teammate only"
224105274|NCT06849557|BEHAVIORAL|Exergaming|This intervention will last 12 weeks. Frail/ pre-frail participants will engage in supervised chair-bound exergaming.
224105275|NCT00396578|DRUG|aerosolized vancomycin or gentamicin|
224105276|NCT02882477|DRUG|Deferiprone|
224105277|NCT02882477|DRUG|Acetylcysteine|
224289160|NCT02583386|OTHER|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
224289161|NCT04060719|DRUG|BI 894416|tablet
224289162|NCT04060719|DRUG|Rifampicin|tablet
224289163|NCT02472535|OTHER|Run-In Period: Placebo|2 capsules, once a day for two weeks
224289164|NCT02472535|DRUG|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
224289165|NCT02472535|DRUG|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
224289166|NCT02472535|DRUG|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
224289167|NCT04578886|DRUG|Guanfacine|Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.
223952407|NCT05585827|BEHAVIORAL|Online cognitive behavioral therapy|"The e-CBT treatment manual is an adjusted version of a previously published treatment manuals for neuropsychiatric symptoms in PD, which is tailored to the preferences and needs for each participant. This manual encompass both modules from manuals for depression in PD and anxiety in PD. Individualization is ensures by including several interventions modules in the manual, wherein 5 sessions are considered core modules, and four modules that can be offered depending on the patients individual needs. The participant may include partners or caregivers. The treatment is schedules to be completed within 13 weeks, with maximum ten sessions during this period. Following each e-CBT session, the participant will be asked to complete a short survey evaluating the acceptability and relevance of the session, and evaluate the therapeutic alliance."
224289168|NCT04578886|DRUG|Placebo|Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
224289169|NCT04802408|COMBINATION_PRODUCT|Shampoo and saline|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with saline solution
223538453|NCT01133847|DRUG|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
223952408|NCT05798065|PROCEDURE|Inpatient gastrointestinal endoscopy|all inpatient endoscopy procedures (gastroscopy, colonoscopy, ERCP, sigmoidoscopy) during 2016-2022.
223952409|NCT01974258|DRUG|Cobimetinib|Escalating dose
223952410|NCT01974258|DRUG|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
223952411|NCT01974258|DRUG|Onartuzumab|Administered by IV infusion every 2 weeks
223952412|NCT01974258|DRUG|Vemurafenib|Orally administered twice daily
223952413|NCT03879538|DRUG|Nitrous Oxide|A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
223952414|NCT03879538|DRUG|Oxygen|A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
223952415|NCT00241618|DRUG|Pegylated interferon alpha 2|
223952416|NCT00241618|DRUG|Ribavirin|
223952417|NCT04756271|BIOLOGICAL|SARS-Cov-2 neutralizing antibody titer|Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
223952418|NCT02173288|DRUG|Standard medical therapy|
223952419|NCT02173288|DRUG|Tolvaptan|
223952420|NCT02173288|DRUG|Midodrine|
223952421|NCT01072045|DRUG|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
223952422|NCT01072045|DRUG|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
223952423|NCT02116075|PROCEDURE|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
224105278|NCT02882477|DRUG|Sitagliptin and Metformin|
224105279|NCT01122355|DRUG|lipid modification|1\) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
224105280|NCT00201799|DRUG|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
224105281|NCT00303810|DRUG|carboplatin|
224105282|NCT00303810|DRUG|cisplatin|
224105283|NCT00303810|DRUG|cyclophosphamide|
224105284|NCT00303810|DRUG|etoposide phosphate|
224105285|NCT00303810|DRUG|high-dose chemotherapy|
224105286|NCT00303810|DRUG|lomustine|
224105287|NCT00303810|DRUG|methotrexate|
224105288|NCT00303810|DRUG|thiotepa|
224105289|NCT00303810|DRUG|vincristine sulfate|
224105290|NCT00303810|RADIATION|radiation therapy|
224289170|NCT04802408|COMBINATION_PRODUCT|Saline and Listerine|Nasal washes with buffered saline solution and oropharyngeal gargles with Listerine Antiseptic® solution
224289171|NCT04802408|COMBINATION_PRODUCT|Shampoo and Listerine|Nasal washes with 1% baby shampoo solution and oropharyngeal gargles with Listerine Antiseptic® solution
224289172|NCT04802408|COMBINATION_PRODUCT|Saline and Saline|Nasal washes with buffered saline solution and oropharyngeal gargles with saline solution
224289173|NCT00894517|BIOLOGICAL|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
223723163|NCT02288052|BEHAVIORAL|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
223723164|NCT04076176|DIETARY_SUPPLEMENT|CGMP protein substitute|PKU sphere is a powdered, low phenylalanine protein substitute, containing a balanced mix of casein glycomacropeptide (CGMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals, trace elements and the omega-3 long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid.
223723165|NCT04076176|DIETARY_SUPPLEMENT|L-amino acid protein substitute|Patient may choose from a list of products, specified in the protocol, that are nutritionally comparable to PKU Sphere.
223952424|NCT02116075|PROCEDURE|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
224105291|NCT05279378|RADIATION|lung ultrasonography versus CT|"chest CT will be done before admission and LUS within first 24 h from admission into the quarantine sector. In addition to 2 weeks after admission.~CT images will be reviewed by chest radiologist expert, who will calculate a CT severity score based on extension and distribution of GGOs and consolidations.~All CT scans will be performed in supine position at end inspiration without intravenous administration of contrast media.~Within 24 h from admission and CT scanning, bedside LUS will be performed by clinician who will be blind to chest CT findings.~Examinations will be performed with the patient in the sitting position, systematically scanning the front and the back side of each hemithorax.~Blood sample will be collected into 4 mL Vacuette containing EDTA. Samples will be stored on ice, processed within 30 min and plasma will be isolated by centrifugation at 2000g for 20 min at 4 °C. Plasma will be immediately frozen at - 80 °C in several aliquots."
223723166|NCT02959307|DEVICE|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
224105292|NCT05962307|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
223723167|NCT02959307|DEVICE|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
224105293|NCT00677950|PROCEDURE|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
223723168|NCT06105554|DRUG|Belumosudil mesylate|Given by PO
224105294|NCT03243903|DEVICE|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
224289174|NCT00894517|DRUG|Placebo (saline)|Saline injected into the prostate on Day 1.
224289175|NCT05274672|DRUG|Nitrofurantoin|Prophylactic postoperative antibiotic use
223723169|NCT04849143|OTHER|Stingless bee honey ( Kelulut honey)|"The honey will be acquired from Brainey Sdn Bhd, a company that provides stingless bee honey certified with Good Manufacturing Practice (GMP), ISO 22000, and Halal.~As the honey used is not medical-grade honey, sterilization with 25kGy gamma-ray irradiation will be done for safety purposes to eradicate any potential life-threatening infection such as spores from Clostridium botulinum."
223723170|NCT04849143|OTHER|Gel dressing|Smith-Nephew's Intrasite gel
223723171|NCT03771677|DRUG|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
223723172|NCT03771677|DRUG|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
223723173|NCT05725902|DRUG|Etavopivat|The study intervention is etavopivat (400 mg), administered orally and once daily (QD)
223723174|NCT05044546|BEHAVIORAL|Behavioral Activation Therapy|Participate in BA counseling
223723175|NCT05044546|PROCEDURE|Discussion|Participate in focus group
224105295|NCT03243903|DEVICE|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
223723176|NCT05044546|BEHAVIORAL|Health Education|Participate in health and wellness education counseling
224289176|NCT05274672|DRUG|Cephalexin|Prophylactic postoperative antibiotic use
224289177|NCT05274672|DRUG|Sulfamethoxazole Trimethoprim Combination|Prophylactic postoperative antibiotic use
223723177|NCT05044546|OTHER|Questionnaire Administration|Ancillary studies
223723178|NCT05044546|OTHER|Tobacco Cessation Counseling|Participate in smoking cessation counseling
223952425|NCT05281081|DRUG|intraperitoneal levobupivacaine and morphine|istillation of the peritoneum with levobupivacaine mixture with morphine
223952426|NCT01159236|DRUG|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
223952427|NCT01159236|DRUG|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
223952428|NCT01159236|DRUG|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
223952429|NCT01159236|DRUG|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
223723179|NCT05615610|DEVICE|tSCS|The participants in Group A will receive tSCS (Burst mode, 9 pulses per burst, pulse frequency = 160 Hz, burst frequency = 2 Hz) with upper limb exercises. The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Two 7.5 × 12.6 cm electrodes will be attached between C6 and T5 level on each side of spinal column and with 2 cm from the spine. Intensity of TENS will be individually selected by the participants according to tolerance levels.
223952430|NCT01159236|DRUG|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
223952431|NCT01159236|DRUG|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
224289178|NCT05274672|DRUG|Ciprofloxacin|Prophylactic postoperative antibiotic use
224289179|NCT05274672|PROCEDURE|Holmium Laser Enucleation of prostate|Endoscopic transurethral Holmium Laser enucleation of enlarged prostate followed by morcellation of prostatic tissue
224289180|NCT06033157|BEHAVIORAL|Physiotherapist supervised training|"A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder."
224289181|NCT01826461|DRUG|PDI-192|
224289182|NCT01826461|DRUG|Vehicle|
224105296|NCT05372705|BEHAVIORAL|Short videos|Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
224105297|NCT06038448|PROCEDURE|Urinary catheter balloon size|The investigators will collect 120 participants divided into two groups ,in different procedure(stone procedure, herniarraphy, nephrectomy), and the investigators used different urinary catheter balloon size(10ml and 5ml), tp investigate the patient with the severity of catheter-related bladder discomfort.
224289183|NCT02327507|BEHAVIORAL|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
224289184|NCT03594409|DIAGNOSTIC_TEST|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
224289185|NCT01651611|BEHAVIORAL|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
224289186|NCT01651611|BEHAVIORAL|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
224289187|NCT01651611|BEHAVIORAL|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
224289188|NCT01651611|BEHAVIORAL|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
224289189|NCT02173652|DRUG|BI 1356, high dose|
224289190|NCT02173652|DRUG|BI 1356, low dose|
224289191|NCT00431782|DRUG|ATI-5923|
223723180|NCT05615610|DEVICE|tVNS|The participants in Group B will receive tVNS (pulse frequency = 25Hz, pulse duration = 0.3 ms) on the cymba conchae of left outer ear with upper limb exercises.The electrical stimulation will be generated by the neurostimulator (MH8000P; MEDIHIGHTEC MEDICAL CO., LTD., Taiwan). Intensity of tVNS will be individually selected by the participants according to tolerance levels. Previous studies showed that it was effective to improve the upper limb motor function in people with stroke and cognitive function in people with mild cognitive function.
223952432|NCT02311413|DRUG|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
223952433|NCT02311413|DRUG|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
223723181|NCT05615610|DEVICE|Control|The participants in Group C will receive placebo tSCS and tVNS with upper limb exercises, where the stimulation will be delivered by placebo-TENS device with disconnected electrical circuit.
223952434|NCT06041165|DRUG|JS401|Single dose of JS401 by subcutaneous (sc) injections
223952435|NCT06041165|DRUG|Placebo|Calculated volume to match active treatment
223952436|NCT06269731|BEHAVIORAL|Hamilton depression Rating Scale|also known as the Ham-D is the most widely used clinician-administered depression assessment scale. The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. Although the scale was designed for completion after an unstructured clinical interview, The scale has been translated into a number of languages including French, German, Italian, Thai , Turkish and Arabic version by Mostafa Lotfy.
223952437|NCT01338506|BEHAVIORAL|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
223952438|NCT01466569|DRUG|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
223952439|NCT01466569|DRUG|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
224105298|NCT00003789|DRUG|isolated limb perfusion|Undergo isolated limb perfusion
224105299|NCT00003789|DRUG|melphalan|Given via limb perfusion
224105300|NCT00003789|BIOLOGICAL|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
224105301|NCT00003789|OTHER|pharmacological study|Correlative studies
224105302|NCT00003789|OTHER|laboratory biomarker analysis|Correlative studies
224105303|NCT02906046|DEVICE|Weight in Lower Limbs|
224105304|NCT00294346|DRUG|AV608|
224105305|NCT00184054|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
224105306|NCT00184054|DRUG|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
224105307|NCT01274377|BIOLOGICAL|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
224105308|NCT05539053|DRUG|N Acetylcysteine A|paclitaxel + N-Acetylcysteine orally short course
223538454|NCT04436744|DRUG|Giredestrant|During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
223538455|NCT04436744|DRUG|Anastrozole|During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
223538456|NCT04436744|DRUG|Palbociclib|During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
223538457|NCT04436744|PROCEDURE|Surgery|Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
223538458|NCT04430998|DRUG|Zinc L-Carnosine|Undiluted 10 ml of Zinc L-Carnosine mouth rinse, retain for 3 minutes, 3 times daily
223952440|NCT02142725|DRUG|LT-02|four times per day
223952441|NCT02142725|DRUG|LT-02|two times per day
223952442|NCT02142725|DRUG|Placebo|four times per day
223952443|NCT04207372|DIETARY_SUPPLEMENT|whey protein isolate|whey protein isolate
223952444|NCT04207372|DIETARY_SUPPLEMENT|Zein|zein protein
223952445|NCT04207372|OTHER|protein-free|protein free
223952446|NCT03847545|DRUG|Fampridine|sustained-release tablet 10 mg morning and evening.
223952447|NCT02246699|DEVICE|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
223952448|NCT02246699|OTHER|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
223952449|NCT03265132|BIOLOGICAL|anakinra|sub cutaneous injection
224105309|NCT05539053|DRUG|N Acetylcysteine B|paclitaxel +N Acetylcysteine orally long course
224105310|NCT02247830|OTHER|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
224105311|NCT02247830|DRUG|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
224105312|NCT01429649|PROCEDURE|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
224105313|NCT03183635|PROCEDURE|Balance training|Improvement of balance ability in stroke patients
224105314|NCT04953455|OTHER|no intervention|no intervention
223538459|NCT04430998|DRUG|Chlorhexidine|Undiluted 10 ml of Chlorhexidine mouth rinse, retain for 3 minutes, 3 times daily
223538460|NCT04430998|OTHER|Water|Rinse mouth with 10 ml of water, retain for 3 minutes, 3 times daily
223538461|NCT03430167|OTHER|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
223538462|NCT03430167|OTHER|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
223538463|NCT03586947|DRUG|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
223952450|NCT03265132|DRUG|Placebo|sub cutaneous injection
223952451|NCT04723615|OTHER|Orebro Musculoskeletal Screening Questionnaire-12|It is a 12-item self-report questionnaire that aims to estimate the severity of the problem, functional impairment, reporting status, cost and recovery time in musculoskeletal problems.
224105315|NCT04047992|DEVICE|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
224105316|NCT00676507|BIOLOGICAL|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
224105317|NCT00676507|OTHER|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
224105318|NCT03569267|DRUG|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
224105319|NCT03569267|DRUG|Placebo|Placebo
224105320|NCT02604966|DRUG|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
224105321|NCT02604966|DRUG|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
224289192|NCT00751738|DRUG|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
224289193|NCT03815968|OTHER|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
224105322|NCT04045912|OTHER|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discreetly request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
224105323|NCT04045912|OTHER|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
224105324|NCT00364910|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
224105325|NCT00364910|BEHAVIORAL|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
224105326|NCT01041092|DRUG|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
224289194|NCT04259255|DRUG|Edaravone (Radicava®/Radicava ORS®)|"Participants will be followed from enrollment up to 24 weeks after treatment initiation (6 treatment cycles - 28 days per cycle, corresponding to a treatment period of approximately 24 weeks) or premature study discontinuation.~Biomarker testing and clinical assessments will be performed at baseline (at enrollment or before the start of cycle 1), and at cycles 1, 3, and 6. Dosing is 60 mg daily by intravenous infusion for 14 days for the initial treatment cycle, followed by daily dosing on 10 out of 14 days in subsequent treatment cycles."
224289195|NCT00685802|DRUG|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
224289196|NCT00685802|DRUG|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
224289197|NCT03204071|DRUG|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
224289198|NCT03204071|DRUG|Aloevera|Oral prophylaxis followed by placement of aloevera gel
224289199|NCT03204071|DRUG|Metformin|Oral prophylaxis followed by placement of metformin gel
223952452|NCT04723615|OTHER|Visual Analog Scale|A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.
223952453|NCT04723615|OTHER|The Tampa Scale of Kinesiophobia|The Tampa Scale of Kinesiophobia that was developed in 1990 is a 17 item scale originally developed to measure the fear of movement related to chronic lower back pain.
223952454|NCT04723615|OTHER|Short Form-12 (SF-12)|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
223952455|NCT01407874|DRUG|Placebo|Oral dose administered daily for 84 days.
223952456|NCT01407874|DRUG|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
223952457|NCT01407874|DRUG|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
223952458|NCT03909100|DEVICE|CoolSculpting® System|A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
223952459|NCT01669356|OTHER|Parenteral supplement with enteral nutrition for patients after esophagectomy|
223952460|NCT01669356|OTHER|Enteral Nutrition alone for patients after esophagectomy|
223952461|NCT01344980|PROCEDURE|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
223952462|NCT01344980|PROCEDURE|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
223952463|NCT01344980|BEHAVIORAL|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
223952464|NCT01344980|BEHAVIORAL|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
223952465|NCT00088166|DRUG|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
223952466|NCT00088166|DRUG|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
223952467|NCT02671266|DRUG|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
223952468|NCT02671266|DRUG|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
223952469|NCT01812330|DRUG|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
223952470|NCT01812330|DRUG|Ticagrelor|90mg Bid
223952471|NCT00666705|DRUG|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
223952472|NCT00666705|DRUG|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
223952473|NCT00666705|DRUG|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
223952474|NCT00666705|DRUG|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
223952475|NCT01540591|DRUG|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
223952476|NCT01540591|DRUG|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
224105327|NCT06971068|PROCEDURE|Procedure: EVLA|Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring fiber
224289200|NCT02708888|OTHER|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
224105328|NCT06971068|PROCEDURE|Procedure: VALA|Great or small saphenous vein occlusion with endovenous laser ablation using ELVeS Radial 2ring Pro fiber
224105329|NCT01591330|DRUG|LY2140023 Reference form|80-mg tablet administered orally
224105330|NCT01591330|DRUG|LY2140023 Test-Low|80-mg tablet administered orally
224105331|NCT01591330|DRUG|LY2140023 Test-Medium|80-mg tablet administered orally
224105332|NCT01591330|DRUG|LY2140023 Test-High|80-mg tablet administered orally
223538464|NCT01463033|DRUG|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
223952477|NCT05870085|BEHAVIORAL|Neuro-linguistic program|"Intervention: Neuro-linguistic program developed by three specialists (a clinical psychologist, a social worker, and one education specialist).~4 (45 minutes) sessions for teachers, and 2 for children (total of 6 sessions)"
224105333|NCT02520479|DRUG|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
223952478|NCT00053300|DRUG|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
223952479|NCT00053300|PROCEDURE|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
224105334|NCT02520479|RADIATION|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
224105335|NCT02520479|DRUG|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
224105336|NCT00175981|DRUG|sildenafil, fluvoxamine|
224105337|NCT03542214|COMBINATION_PRODUCT|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
224105338|NCT02912364|DRUG|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
224105339|NCT02912364|DRUG|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
224105340|NCT01525758|DRUG|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
224105341|NCT01525758|DRUG|microcrystalline cellulose|identical number of tablets to active drug groups
224105342|NCT04033289|DEVICE|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
224289201|NCT02708888|OTHER|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
223538465|NCT02539550|DRUG|Placebo|Placebo
223538466|NCT02539550|DRUG|PF-06266047|PF-06266047
223538467|NCT00335881|BIOLOGICAL|hepatitis B vaccine|
223538468|NCT02969135|BEHAVIORAL|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
223538469|NCT02969135|BEHAVIORAL|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
223538470|NCT02107534|BEHAVIORAL|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
223538471|NCT00658268|DRUG|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
223538472|NCT00658268|DRUG|Placebo|10 ml, single dose mixed in bone graft at operation
223538473|NCT03950232|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
223538474|NCT04812925|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
223538475|NCT03709901|OTHER|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
223538476|NCT03709901|OTHER|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
223538477|NCT04222192|OTHER|Epidural block|Epidural catheter insertions
223538478|NCT04284709|OTHER|cognitive-physical training|combined physical and cognitive training
223538479|NCT03361488|OTHER|Trained anesthesiogist|
223538480|NCT02332473|DRUG|Ypeginterferon alfa-2b|
223538481|NCT02332473|DRUG|Granulocyte-macrophage colony stimulating factor|
223538482|NCT01858727|OTHER|forced air warming group|30 minutes before the preoperative will use forced air warming
223538483|NCT01858727|OTHER|control group|do not heating group
223538484|NCT03573674|BEHAVIORAL|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
223538485|NCT03573674|BEHAVIORAL|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
223538486|NCT00967616|DRUG|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
224105345|NCT04980547|DEVICE|ACUMED® Scapholunate Repair System Group|To address the technical difficulties associated with the RASL procedure, Dr. Mel Rosenwasser developed an external over-the-top jig that in theory enables accurate and easy scapholunate-axis screw placement. The Acumed Scapholunate Repair System was designed treat patients with acute or chronic, static or dynamic scapholunate instability in the absence of significant capitolunate osteoarthritis, scapholunate ligament repair, scapholunate reduction, lunotriquetral ligament repair, lunotriquetral reduction, and carpal instability. This new Scapholunate Repair System features a targeting guide designed to enable the surgeon to reproducibly place the implant in optimal position. The implant allows physiologic intercarpal scapholunate rotation by means of a free rotation design. The procedure can forestall progressive osteoarthritis and the need for secondary salvage procedures.
224105346|NCT04708912|OTHER|Observation|The study parameters will be obtained at the time of recuirement (Basal)
224105347|NCT00121823|BIOLOGICAL|FP9 ME-TRAP|
224105348|NCT00121823|BIOLOGICAL|MVA ME-TRAP|
224105349|NCT01275638|DRUG|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
224105350|NCT01939795|OTHER|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
224289202|NCT03878888|DRUG|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
224289203|NCT03998436|DRUG|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
224289204|NCT03998436|OTHER|Only Standard of Care|Only Standard of Care treatment
224289205|NCT03998436|OTHER|Vehicle Gel|Vehicle gel application along with Standard of Care
224289206|NCT02447159|BEHAVIORAL|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
224289207|NCT03336242|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
223538487|NCT00967616|DRUG|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)"
223723182|NCT06526273|BEHAVIORAL|PILI 'Āina|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker. At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks).
223952480|NCT05404997|DEVICE|Shockwave Therapy|"Subjects in Group A will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes. After the conventional therapy, this group will be given shockwave therapy treatment twice a week for four weeks.~After exposing and cleaning the treated area with alcohol, adequate amount of gel will be placed on the lower back region, and the machine will be adjusted at (2000 shock per session, 8 sessions 2 per week for 4 weeks, energy flux density 0,18mJ per mm square, 2 bars of pressure, frequency 10hz), with using 20mm D-Actor head."
223952481|NCT05404997|OTHER|Maitland's lumbar mobilizations|"Subjects in Group B will receive conventional physical therapy treatment that involves lumbar stretching exercises (bridges, knee to chest, press-up back extensions, bird dogs) and core strengthening exercises (partial crunches, pelvic tilts, wall sits, hip stretches) for ten minutes.~After the conventional treatment, Group B will be given Maitland's lumbar postero-anterior glide mobilizations initiating from Grade 1, with 3-4 sets of oscillations of 40 counts in each set, 2 sets of oscillations will be given below and above the affected joint level.This whole mobilization treatment will also be given twice a week for 10 minutes."
223952482|NCT03949257|DEVICE|colonic transendoscopic enteral tubing|Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
223952483|NCT02481856|DRUG|SQ tree SLIT-tablet|
224289208|NCT03650959|OTHER|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
223952484|NCT02481856|DRUG|Placebo|
223538488|NCT05556889|PROCEDURE|a modified auriculotemporal nerve blockade|Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
223952485|NCT01109979|DRUG|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
223952486|NCT01109979|DRUG|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
223952487|NCT00893009|DRUG|Theophylline|100 mg twice a day
223952488|NCT00893009|DRUG|Placebo|Placebo
224105351|NCT04752787|OTHER|Online breastfeeding training|Online breastfeeding training will be provided to pregnant women expecting twin babies.
224105352|NCT04752787|OTHER|QR code supported online breastfeeding training|QR code supported online breastfeeding training will be given to pregnant women who are expecting twin babies.
224105353|NCT04554576|BEHAVIORAL|Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish|"The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)"
224105354|NCT04554576|BEHAVIORAL|Remote feedback active group|After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
224105355|NCT04554576|BEHAVIORAL|Remote feedback control group|After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
224105356|NCT04746040|DRUG|Test|2 inhalations of Test and Reference product in each study period
224105357|NCT04746040|DRUG|Reference|2 inhalations of Test and Reference product in each study period
224105358|NCT01748383|PROCEDURE|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
224105359|NCT01748383|PROCEDURE|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
224105360|NCT01748383|PROCEDURE|stenting of IRA|The only stent implantation
224105361|NCT03701503|BEHAVIORAL|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
224289209|NCT00971737|BIOLOGICAL|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
224289210|NCT00971737|BIOLOGICAL|trastuzumab|Given IV
224289211|NCT00971737|DRUG|cyclophosphamide|Given IV
224289212|NCT06027138|OTHER|blood flow resistance training|Muscle size and explosive power was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press ,vertical jump test and timed push ups and pull up tests .secondly treat the arm and thigh muscles to to blood flow resistance training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles.
223538489|NCT05556889|PROCEDURE|Traditional auriculotemporal nerve blockade|Traditional auriculotemporal nerve blockade
223538490|NCT04863794|DRUG|RO7248824|A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
223538491|NCT05489471|OTHER|Artificial intelligence review|The AI looks for ten different abnormalities on each chest X-ray and produces a heat map and percentage confidence score if it detects an abnormality.
223538492|NCT00575666|DRUG|Insulin or Placebo|intranasal, 40IU, 4 times daily
223538493|NCT01368614|DEVICE|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
223538494|NCT01368614|DEVICE|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
223538495|NCT01368614|DEVICE|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
223952489|NCT03587415|DIAGNOSTIC_TEST|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
223538496|NCT02951780|DRUG|LY3185643|Administered SC
223538497|NCT02951780|DRUG|rGlucagon|Administered SC
223538498|NCT03522961|DRUG|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
223538499|NCT03522961|DRUG|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
223538500|NCT01435161|DRUG|Nifedipine,|Nifedipine 30-60mg/day
223538501|NCT01435161|DRUG|Telmisartan|Telmisartan 80-160mg/day
223952490|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
224105362|NCT05300529|OTHER|Vestibular Rehabilitation Exercises|The Vestibular Rehabilitation program focuses on stabilizing the gaze and gaining the Vestibular Ocular Reflex (VOR). The general mechanisms of recovery from vestibular injuries are vestibular adaptation and replacement exercises, which are designed to improve gaze stability and the interaction between sight and the vestibular system during head movements. The exercises will be carried out progressively according to the tolerance of the patient, varying the stimulus in intensity and frequency.
224105363|NCT05300529|OTHER|Conventional Rehabilitation exercises|The conventional rehabilitation program in which exercises are performed to improve joint range, flexibility, and gait. It will always be done with the eyes open, on a firm surface and will not include training in sensory strategies
224105364|NCT01983865|OTHER|Exposure to birch pollen|
224105365|NCT02838030|DRUG|L-arginine|3 gr per day
224105366|NCT02838030|DRUG|Placebo (for L-arginine)|3 gr per day
224105367|NCT02838030|DRUG|acetylsalicylic acid|3 gr per day
224289213|NCT06027138|OTHER|slow motion strength training|We will use slow motion strength training method. Each exercise is performed by lifting weights for approximately 10 seconds, lowering the weight for another 10 seconds, and not resting between repetitions.before receiving treatment sample muscle size and explosive strength was determined by measuring the diameter of its arm and thigh muscles and performing 1RM testing in barbell parallel back squats and foot barbell Bench press (pre test).secondly treat the arm and thigh muscles to to slow motion weight training.weight training and is administered for approx 2 months a frequency of four times per week at an intensity of seventy five to eight five percent for 4 to 12 reps,1 to 5 sets, at interval of 30 to 40 sec.then determine the impact of treatmnt measurement was again carried out on the circumference and explosive strength of arm and thigh muscles. (Post test).
224289214|NCT05421793|OTHER|Fermented product of carrot derived rhamnogalacturonan I|Stimulation of human colonic biopsies with the fermented product of carrot derived rhamnogalacturonan I
224289215|NCT02964819|OTHER|exercise|
224289216|NCT02964819|DEVICE|Interferential current therapy|
224289217|NCT02964819|DEVICE|Therapeutic Ultrasound|
224289218|NCT03014193|DEVICE|Semiquantitative Multi-Level Pregnancy Test|
223952491|NCT03331536|PROCEDURE|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
224105368|NCT02319772|DRUG|BCX4430|
224105369|NCT02319772|DRUG|Placebo|
224105370|NCT01930071|DEVICE|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
224105371|NCT00631462|DRUG|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
224105372|NCT06156098|OTHER|No Intervention|No Intervention
224105373|NCT06457438|DIAGNOSTIC_TEST|Elecsys Anti-HEV IgG, IgM|Diagnostic test used to determine antibodies in blood and serum.
224289219|NCT02904668|OTHER|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
224289220|NCT03421782|BEHAVIORAL|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
224105374|NCT00055198|DRUG|daptomycin|
224105375|NCT00094120|DRUG|MSI-1256F (Squalamine Lactate)|
224105376|NCT05134623|DIAGNOSTIC_TEST|immunohistochemistry of tumors samples|routine resection of tumors, further analysis and immunohisochemical staining of the tissue slides.
224105377|NCT04800315|DRUG|CC-93538|Specified dosages on specified days
224289221|NCT03421782|BEHAVIORAL|Exercise Intervention|Undergo POWER exercise intervention
224289222|NCT02224573|DRUG|GWP42003-P|
223538502|NCT01374425|DRUG|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
223538503|NCT01374425|DRUG|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
223723183|NCT06526273|OTHER|Control|Participants will receive the 3-month adapted Diabetes Prevention Program's Lifestyle Intervention. These lessons will be delivered by a trained community health worker based on previously tested materials and protocols. At 3 months, participants randomized to the control group will receive monthly untailored health education information and links to community resources from the community health worker via United States Postal Service or electronic messaging. Examples include information on food assistance programs, farmers' markets, cultural events, and physical activity events.
224105378|NCT04800315|OTHER|Placebo|Specified dosages on specified days
224105379|NCT05261217|DEVICE|The motion 3D II appliance|The motion 3D II appliance treating class II malocclusion
224105380|NCT05707572|DRUG|methylprednisolone|a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
224105381|NCT05707572|PROCEDURE|manual manipulation|The lesser MTPJs of the affected foot will be manually manipulated using a high velocity, low amplitude thrust technique.
224289223|NCT05749679|OTHER|training and audit|"An evaluation of the practices with clinical audit before and after the management will be carried out.Every 3 months for 2 years, the investigating physicians of the intervention group will report for these patients the modifications or cessation of treatment, modification or implementation of interventions such as physical activity or implementation of nutritional modifications. Physician investigators will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers.10 possible actions to be deployed :~1. Hygienic and dietary measures~2. Physical activity~3. Smoking cessation~4. Avoidance of nephrotoxic substances~5. Treatment of hypertension~6. Proteinuria reduction~7. Oral antidiabetics; choice~8. Optimal HBA1c~9. Statin~10. Compliance"
223538504|NCT01374425|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
223538505|NCT01374425|DRUG|Leucovorin|Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
223538506|NCT01374425|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
223538507|NCT01374425|DRUG|Capecitabine|Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
224289224|NCT05749679|OTHER|Routine care|"Physicians in the control group will receive training on the study procedures. An evaluation of practices with a clinical audit before and after the treatments will be carried out. Every 3 months for 2 years, the investigating physicians in the control group will report for these patients the modifications or cessation of treatment, the modification or implementation of interventions such as physical activity or the implementation of modifications in terms of nutrition. The investigating physicians will be asked to report any occurrence of adverse events to their regional pharmacovigilance centers. Physician investigators in the control group will continue their care as usual."
224289225|NCT03177382|RADIATION|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
224289226|NCT03177382|RADIATION|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
224289227|NCT03177382|PROCEDURE|TME|The TME operation will be given after the end of the neoadjuvant treatment.
224289228|NCT03177382|DRUG|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
223538508|NCT01245725|DRUG|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
224289229|NCT03132194|DRUG|DPSG 7.5%|topical gel
224289230|NCT03132194|DRUG|Aczone|topical gel
224289231|NCT03132194|DRUG|Placebo|topical gel
224289232|NCT01456091|BEHAVIORAL|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
224289233|NCT05179694|DIAGNOSTIC_TEST|Prostate biopsy|Prostate biopsy via either the Transrectal route (comparator) or Transperineal route (experimental), each under local anaesthetic.
224289234|NCT02546362|DEVICE|Cefaly|
223538509|NCT01245725|DRUG|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
223538510|NCT02359903|DRUG|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
224289235|NCT05925504|DRUG|Luspatercept|The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
224289236|NCT01828944|DIETARY_SUPPLEMENT|olive oil|
224289237|NCT04529330|PROCEDURE|fasciotomy|if it was suspected with ACS, the fasciotomy was conducted. but if the blister observed, it means decreased conmpartment sydrome. therefore, the blister observed can avoid unnecessary fasciotomy to patients suspected with ACS
224289238|NCT00386126|DRUG|Iron Sucrose IV 200mg, once a week, for 5 weeks|
224289239|NCT00386126|DRUG|Ferrous sulfate 200mg PO TID, for 8 weeks|
224289240|NCT05036395|OTHER|The routine assessment protocol and AI-assisted cEEG Diagnostic tool|The AI-assisted cEEG diagnostic tool is an automated seizure reporting system, including a quantitively EEG neural signal processing pipeline to extract features from the original signal datasets, machine learning models based on gradient boosted model for prediction. The tool can report electrographic seizures in real time during cEEG monitoring. The neonatologists will evaluate the neonates by AI-assisted cEEG diagnostic tool, clinical conditions, real-time cEEG and amplitude-integrated EEG traces. The investigators will make a decision after review the neonates clinical conditions, AI-assisted cEEG diagnostic report, the cEEG and amplitude-integrated EEG.
224289241|NCT05036395|OTHER|The routine assessment protocol|The routine assessment protocol is that the neonatologists will evaluate the neonates by clinical conditions, real-time cEEG and amplitude-integrated EEG traces.
224289242|NCT02784782|DEVICE|Orthesis|
224289243|NCT02784782|BEHAVIORAL|No orthesis|
224289244|NCT05206448|DRUG|Letrozole|Letrozole tablet
224289245|NCT05206448|DRUG|Clomiphene Citrate|Clomiphene Citrate tablet
224289246|NCT01481857|OTHER|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
224105382|NCT00753922|DEVICE|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
224105383|NCT05078034|DEVICE|Helmet Non-Invasive Ventilation (HNIV)|HNIV will be connected to a ventilator by a conventional closed respiratory circuit. Sessions of HNIV will be delivered with PEEP targeting a minimum 12 hours/day. PEEP will be titrated according to patient comfort, work of breathing, and O2 saturation. Pressure support will be titrated to lowest level tolerated. Between HNIV sessions, patients will be supported with HFNO at the same required FiO2. Starting on study day 3, patients will be screened for discontinuation of HNIV. Once HNIV is stopped, patients will be transitioned to HFNO and then weaned from HFNO as tolerated.
224105384|NCT05078034|DEVICE|High Flow Nasal Oxygen|HFNO will be provided. FiO2 will be titrated to achieve a target O2 saturation of 92-97%, and flows will be initiated at 50 litres/minute and titrated as per usual practice for comfort and oxygenation. Once the target O2 saturation is achieved, the FiO2 will be titrated to the minimal value to maintain this target saturation. HFNO will be provided continuously over a minimum of 2 calendar days. Starting on study day 3, patients will be weaned from HFNO as tolerated.
224105385|NCT02016287|OTHER|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
224105386|NCT00543179|DRUG|Somatuline (Lanreotide Autogel®)|
224289247|NCT01481857|OTHER|Segmental trunk exercise|Segmental trunk exercise
224289248|NCT05748197|BIOLOGICAL|ADCLEC.syn1 CAR T cells|There are 4 planned flat-dose levels: 25 × 10\^6, 75 × 10\^6 , 225 × 10\^6 , and 450 × 10\^6 CAR T cells and 1 de-escalation dose: 10 × 10\^6 CAR T cells.
224289249|NCT05748197|DRUG|Conditioning chemotherapy|Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
224289250|NCT06513585|PROCEDURE|Superselective adrenal artery embolization or adrenalectomy|Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.
223952492|NCT03331536|PROCEDURE|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
224289251|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102
224289252|NCT05179239|DRUG|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102|SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
224289253|NCT05179239|DRUG|Placebo + paclitaxel + cisplatin/carboplatin ± BP102|Placebo + paclitaxel + cisplatin/carboplatin ± BP102
224289254|NCT02025010|DRUG|abiraterone acetate|Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.
224289255|NCT06260813|DIAGNOSTIC_TEST|Radiography|X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.
224289256|NCT06260813|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.
224289257|NCT06260813|DIAGNOSTIC_TEST|MRI|MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.
224289258|NCT06260813|DIAGNOSTIC_TEST|CT-scan|CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.
224289259|NCT06260813|DIAGNOSTIC_TEST|Gait analysis|This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
224289260|NCT03547973|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously.
224289261|NCT03547973|DRUG|Pembrolizumab|Administered per package insert
223538511|NCT02359903|DRUG|Infliximab (Remicade)|
223538512|NCT03026244|DIETARY_SUPPLEMENT|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
223538513|NCT03026244|DIETARY_SUPPLEMENT|Placebo product|3 periods of 3 weeks placebo product
223538514|NCT05309044|BEHAVIORAL|Planetary Health Diet Group|This group includes a diet proportional to the EAT-Lancet reference diet (2500 kcal), with a caloric intake of 1200 to 1800 kcal, in addition to a behavioral change protocol during the time of the study (4 months).
223538515|NCT05309044|OTHER|Low-fat diet group|This group includes a low-fat, low-calorie diet (1200-1800 kcal), in addition to a behavioral change protocol
223538516|NCT05309044|OTHER|Waiting list group|This group will only receive digital information with recommendations on healthy eating. When the study has finished, this group will receive a behavioral change protocol with a low-fat, low-calorie diet.
223538517|NCT00587041|DIETARY_SUPPLEMENT|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
223538518|NCT00587041|DIETARY_SUPPLEMENT|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
223538519|NCT00587041|OTHER|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
224105387|NCT05832762|PROCEDURE|Endovascular treatment (EVT) + Best medical treatment (BMT)|"Endovascular treatment (EVT) in the experimental arm can be performed with any recanalization strategy based on the operator's choice, and anatomical and radiological situation: MT using aspiration or stent retriever, with or without stenting (CE-labelled) or angioplasty. In case of acute stenting, the use of antiplatelet drugs will be based on the operator's preference, anatomical situation, and risk of hemorrhage.~Best medical treatment (BMT) : Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies."
224105388|NCT05832762|PROCEDURE|Best medical treatment (BMT)|Administration of drugs is at the treating physician's discretion (for example, intravenous fibrinolysis, anticoagulants, or antiplatelet agents) according to the local standards of care, but not intra-arterial therapies.
224105389|NCT02932267|DRUG|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
224105390|NCT03973450|OTHER|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
224105391|NCT02554305|DEVICE|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
224105392|NCT02554305|DEVICE|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
224105393|NCT01323296|OTHER|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
224105394|NCT04644718|DEVICE|Transcranial direct current stimulation (tDCS)|tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
224289262|NCT03547973|DRUG|Cisplatin|Administered per package insert
223952493|NCT03331536|PROCEDURE|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
223952494|NCT03954860|OTHER|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
224105395|NCT00337948|DRUG|Epoetin alfa|
224105396|NCT05056831|BEHAVIORAL|Behavioral Intervention|Attend face-to-face mind-body sessions
224105397|NCT05056831|OTHER|Best Practice|Receive usual care
224105398|NCT05056831|OTHER|Informational Intervention|Receive targeted text messages
224105399|NCT05056831|OTHER|Quality-of-Life Assessment|Ancillary studies
224289263|NCT03547973|DRUG|Avelumab|Administered per package insert
224289264|NCT03547973|DRUG|Zimberelimab|Administered intravenously
224105400|NCT05056831|OTHER|Questionnaire Administration|Ancillary studies
224105401|NCT00542984|DRUG|teriparatide 20 micrograms/day subcutaneous|
224105402|NCT00542984|DRUG|salmon calcitonin 100 IU/day subcutaneous|
224289265|NCT03547973|DRUG|Carboplatin|Administered per package insert
224289266|NCT03547973|DRUG|Gemcitabine|Administered per package insert
224289267|NCT03547973|DRUG|Domvanalimab|Administered intravenously
224289268|NCT03547973|DRUG|Enfortumab Vedotin|Administered intravenously
224289269|NCT06534320|DRUG|DA-302168S|SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 6 subjects receive DA-302168S tablets.
224289270|NCT06534320|DRUG|Placebo of DA-302168S|SAD study may cotain 7 cohorts at dosage of 2.5 mg, 7.5 mg, 15 mg, 30 mg, 50 mg, 75 mg, 100 mg. Each cohort enrolls 2 subjects receive placebo of DA-302168S tablets.
224289271|NCT06534320|DRUG|DA-302168S|MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 8 subjects receive study DA-302168S tablets.
224289272|NCT06534320|DRUG|Placebo of DA-302168S|MAD study may cotain 1-4 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive study placebo of DA-302168S tablets.
224289273|NCT05346354|DRUG|Ravulizumab|"Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight."
224289274|NCT04685655|OTHER|Therapeutic plasma exchange|Treatment with therapeutic plasma exchange. Plasma from healthy donors is used.
224289275|NCT01122316|DRUG|Metformin|3\. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
224289276|NCT06267794|DRUG|Pirfenidone 1200 mg|1200 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
224289277|NCT06267794|DRUG|Pirfenidone 1800 mg|1800 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
224289278|NCT06267794|DRUG|Placebo|0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
224289279|NCT02835963|OTHER|Data collection|Usual data collection
224289280|NCT01661881|DRUG|Rituximab|
224289281|NCT01661881|DRUG|Bendamustine|
224289282|NCT01661881|DRUG|Cytarabine|
224105403|NCT01563510|PROCEDURE|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
224105404|NCT01563510|PROCEDURE|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
224105405|NCT03977077|DRUG|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
224105406|NCT01530139|BEHAVIORAL|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
224105407|NCT01530139|BEHAVIORAL|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
224105408|NCT01530139|BEHAVIORAL|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
224289283|NCT06834568|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|t:slim X2 insulin pump with Tandem Freedom System consists of the Tandem t:slim X2 insulin pump and the Freedom algorithm embedded in the pump. Participants will also use the Dexcom G6 continuous glucose monitoring system.
223952495|NCT03954860|DRUG|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
223952496|NCT03954860|DRUG|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
223952497|NCT00807599|PROCEDURE|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
223952498|NCT00807599|DRUG|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
223952499|NCT01005030|OTHER|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
223952500|NCT04018300|DIETARY_SUPPLEMENT|Ferrous sulfate|65 mg Fe as ferrous sulfate
223952501|NCT04018300|DIETARY_SUPPLEMENT|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
223952502|NCT04018300|OTHER|Placebo|Contains maltodextrin.
224105409|NCT01530139|BEHAVIORAL|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
224105410|NCT04292938|DIETARY_SUPPLEMENT|Low carbohydrate ketogenic diet|Dietary modification, including the use of supplements, with the aim of reaching a lipid/carbohydrate-protein 3:1 ratio with a minimum 1g/Kg/die in protein
224105411|NCT00104507|DRUG|APD356|
223538520|NCT04996329|OTHER|early health warning intervention|early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
223952503|NCT05445050|DIAGNOSTIC_TEST|Application and measurement of tumor vascularization using diagnostic contrast enhanced ultrasound (CEUS)|"Part A: performing CEUS with the contrast agent SonoVue® at two different doses and two different injection speeds in participants with primary breast cancer~Part B: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants undergoing neoadjuvant chemotherapy~Part C: performing CEUS with the contrast agent SonoVue® using the established protocol from part A in participants with lesions of unknown dignity"
223952504|NCT00774592|BEHAVIORAL|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
223952505|NCT00774592|BEHAVIORAL|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
223952506|NCT00774592|BEHAVIORAL|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
224105412|NCT02858479|OTHER|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
224105413|NCT02858479|OTHER|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
224289284|NCT01560884|DRUG|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
224289285|NCT01560884|DRUG|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
224289286|NCT01560884|DRUG|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
224289287|NCT01560884|DRUG|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
223723184|NCT07132905|BEHAVIORAL|"Mpata Yathu (Our Space)"|Mpata Yathu is a church-based, lay counselor-delivered psychological intervention adapted from the Friendship Bench problem-solving therapy (PST) model. Designed for adolescent girls and young women in Zambia with a history of gender-based violence and elevated mental health symptoms, the intervention includes six weekly individual PST sessions delivered in private spaces within Catholic churches. Lay counselors are trained in trauma-informed, survivor-centered care and offer optional referrals to mental health, HIV, or GBV-related services. Mpata Yathu maintains the core structure of Friendship Bench but was adapted through community-partnered participatory research to meet the sociocultural needs of Zambian youth.
223952507|NCT00774592|BEHAVIORAL|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
223952508|NCT00774592|BEHAVIORAL|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
223952509|NCT00774592|BEHAVIORAL|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
223952510|NCT03293043|DEVICE|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
223952511|NCT00291941|BIOLOGICAL|Henogen HBV vaccine|20µg, Month 0, 2 and 6
223952512|NCT00291941|BIOLOGICAL|FENDRIX|20 µg,Months 0, 1, 2 and 6
223952513|NCT00774878|DRUG|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
223952514|NCT00774878|DRUG|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
223952515|NCT03711279|DRUG|SHR-1210 plus Apatinib|SHR-1210 200 mg q3w+ Apatinib 500 mg qd
223952516|NCT03711279|DRUG|ADM plus IFO or IFO alone|ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
223952517|NCT03456856|DRUG|Ivabradine|Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
223952518|NCT03608436|PROCEDURE|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
223952519|NCT03608436|DRUG|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
223952520|NCT03806205|OTHER|regular follow-up|we give a regular follow-up and supervision on the study group
223952521|NCT04534738|BEHAVIORAL|Mediterranean Diet|The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
223952522|NCT03481985|OTHER|Fenestration status|The exposure variable will be status of the Fontan fenestration
223952523|NCT05015699|DEVICE|HT Supreme|HT Supreme ( R\&D by Sinomed, Tianjin, China)
223952524|NCT00476294|OTHER|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
223952525|NCT06129981|BEHAVIORAL|Imaginary exposure therapy augmented by vocal feedback|"The procedure specific to the study~* adding inclusion procedures (explanation of the study, verification of inclusion and non-inclusion criteria, signature of informed consent)~* including, in the usual initial V0 visit, psychometric measures specific to the study (RSDI, CGI, PMI, GEW)~* including a single usual psychotherapy session (i.e. not augmented) S1, during which the psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study are used~* adding the VF device and using psychometric (RSDI, PMI, GEW) and psychophysiological (connected watch) measurements specific to the study during psychotherapy sessions S2 to Sn (minimum S6)~* adding, during the last usual end-of-treatment visit, psychometric measures specific to the study (CGI)~* adding psychometric measures specific to the study during the usual follow-up visit at 3 months~* adding a follow-up visit at 12 months (CGI, PCL-5), either by telephone or on-site."
223952526|NCT01655082|DRUG|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
224105414|NCT02858479|RADIATION|MRI scan|"2 sessions for 10 minutes :~* 11 controls stimulations for 6 s each spaced 20 s without stimulation.~* 11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
224105415|NCT04933630|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
224105416|NCT00758615|BEHAVIORAL|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
223952527|NCT01655082|DRUG|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
223952528|NCT02542696|DRUG|APL-130277|"Used to treat up to 5 OFF episodes per day"
223952529|NCT00738348|DRUG|sivelstat|sivelstat sodiumhydrate
223952530|NCT00738348|DRUG|glucose|glucose
223952531|NCT06432023|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diagnostic and research scanning using magnetic resonance imaging.
223952532|NCT02137785|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
223952533|NCT02137785|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
224105417|NCT04937270|DEVICE|High frequency therapy (5 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 5 minutes using a 500 kHz resistive electric transfer (RET).
224289288|NCT01958515|OTHER|research blood draw and tissue biopsy|research blood draw and tissue biopsy
223952534|NCT02137785|DEVICE|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
224105418|NCT04937270|DEVICE|High frequency therapy (7 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 7 minutes using a 500 kHz resistive electric transfer (RET).
224105419|NCT04937270|DEVICE|High frequency therapy (9 minutes)|The high-frequency therapy device (radio frequency therapy, WINBACK, Villeneuve Loubet France) used in this study was used to treat deep heat for 9 minutes using a 500 kHz resistive electric transfer (RET).
224289289|NCT01626651|DRUG|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
224289290|NCT01626651|DRUG|Ketoconazole|Ketoconazole (400 mg \[2 x 200 mg\] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
224289291|NCT01644487|DEVICE|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
223538521|NCT03152578|OTHER|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
223538522|NCT03152578|OTHER|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
224289292|NCT01644487|DEVICE|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
224289293|NCT06117943|OTHER|data collection|Pregnant women who smoke personally or are passively exposed to cigarette smoke
224289294|NCT05061914|PROCEDURE|pericardial effusion drainage|tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
224289295|NCT01359748|DEVICE|Reference sphygmomanometer|\* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
223952535|NCT02066155|BEHAVIORAL|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
224289296|NCT01359748|DEVICE|Sphygmomanometer under test|Electronic Oscillometric method.
223952536|NCT02066155|BEHAVIORAL|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
223952537|NCT03315195|DIETARY_SUPPLEMENT|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
223952538|NCT03001635|DRUG|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
223952539|NCT03001635|DRUG|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
223952540|NCT04478552|PROCEDURE|Fascia iliaca compartment block|It involves injecting local anaesthetic agent (levobupivacaine) into the fascia iliaca compartment of the patient, infiltrating three major nerves that supply the medial, anterior and lateral thigh, namely the femoral and lateral femoral cutaneous nerves. This procedure can be done with anatomical landmark approach or under image guidance.
224105420|NCT04937270|DEVICE|Superficial heat therapy|In the physical therapy used in this study, it was applied for 20 minutes using conventionally used superficial heat therapy.
224105421|NCT00583739|BEHAVIORAL|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
223538523|NCT03152578|OTHER|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
223538524|NCT05986266|DRUG|Carbetocin|To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
223538525|NCT04103021|DEVICE|Port-A-Cath|Totally implanted central venous access device
223538526|NCT01419119|DRUG|Cholecalciferol high dose at Vitamin D deficiency|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
223538527|NCT01419119|DRUG|Cholecalciferol median dose at Vitamin D insufficiency|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
223538528|NCT01419119|DRUG|Cholecalciferol low dose at Vitamin D deficiency|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
223538529|NCT01419119|DRUG|Cholecalciferol median dose at sufficient Vitamin D level|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
223538530|NCT03783780|DEVICE|INVSENSOR00031|Noninvasive pulse oximeter sensor
224289297|NCT00949988|DRUG|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
224289298|NCT00730951|DIETARY_SUPPLEMENT|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
224289299|NCT00730951|DIETARY_SUPPLEMENT|Corn Starch|500mg Capsulated Corn Starch
224289300|NCT02249221|BIOLOGICAL|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
224289301|NCT02249221|BIOLOGICAL|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
224289302|NCT01450241|OTHER|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
223538531|NCT02031406|OTHER|Post-discharge counseling on medication adherence & literacy|
223952541|NCT04478552|PROCEDURE|Placebo injection|same volume of normal saline, instead of levobupivacaine, will injected using the same technique.
224105422|NCT02429505|DRUG|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
224105423|NCT02514070|DRUG|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
223952542|NCT04184271|DRUG|38% silver diamine fluoride|Topical application of SDF to teeth
224105424|NCT02514070|DRUG|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
224105425|NCT05227573|PROCEDURE|Orthopedic surgery|Knee-, hip-, shoulder- and elbow surgery
224289303|NCT01450241|OTHER|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
224289304|NCT02651142|PROCEDURE|Patients receive SLNB|Patients receive sentinel lymph node biopsy
224289305|NCT00604084|DRUG|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
224105426|NCT00902837|DRUG|Oxycodone naloxone prolonged release tablets (OXN)|
223952543|NCT03605147|DIETARY_SUPPLEMENT|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
224105427|NCT00902837|DRUG|oxycodone prolonged release tablet|
224105428|NCT00902837|DRUG|oxycodone naloxone tablet|
224105429|NCT06970912|DRUG|Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy|"Patients receive 4 cycles of neoadjuvant dalpiciclib (125 mg orally, days 1-21 of 28-day cycles) combined with an aromatase inhibitor (letrozole/anastrozole/exemestane). Post-surgery treatment is guided by ctDNA status: （1）ctDNA-negative at baseline and post-neoadjuvant, with post-op Ki67 ≤10% :Continue dalpiciclib + endocrine therapy (ET) for 2 years； （2）ctDNA-positive → negative, or persistently ctDNA-negative with post-op Ki67 \>10% :Randomized 1:1 to:~* Arm B1: Dalpiciclib + ET for 2 years.~* Arm B2: Adjuvant chemotherapy (investigator's choice) → dalpiciclib + ET for 2 years；（3）Persistently ctDNA-positive or ctDNA-negative → positive:~Mandatory adjuvant chemotherapy → dalpiciclib + ET for 2 years. Premenopausal women undergo ovarian suppression with LHRH agonists."
224105430|NCT06970912|DRUG|Taxane-Based Neoadjuvant Chemotherapy|Patients receive 4 cycles of taxane-based neoadjuvant chemotherapy (e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly) before surgery. Post-surgery adjuvant chemotherapy (physician's choice) may be administered. This arm serves as the control group for comparing standard chemotherapy efficacy.
224105431|NCT02453841|DRUG|Oxymetazoline|
224105432|NCT00584662|DRUG|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
224105433|NCT06655077|OTHER|RA PRO Dashboard|The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
224105434|NCT06011486|COMBINATION_PRODUCT|Lymphocyte infusion (ImmuneCellVir-I)|Infusion of donor CMV specific cells into patients eligible to the trial
224289306|NCT00604084|DRUG|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
223538532|NCT04379154|DEVICE|Volatile Organic Compounds analysis|Volatile Organic Compounds analysis in exhaled air by electronic noses
223538533|NCT02742129|DRUG|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
223538534|NCT02742129|DRUG|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
223952544|NCT03605147|DIETARY_SUPPLEMENT|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
224105435|NCT06041347|DIAGNOSTIC_TEST|Transvaginal ultrasound|Preoperative detection with TVUS of proximity or the involvement of the sacral nerve roots in women diagnosed with deep endometriosis or other benign or malignant pelvic tumors would also contribute to the safety of surgical interventions (e.g laparoscopy, tru-cut biopsy) It aslo provides correct counseling and select the appropriate surgical team and assess the likely operative complexity of the surgery. Until now the diagnosis was based on MRI.
224105436|NCT04082247|BEHAVIORAL|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
224105437|NCT01430247|OTHER|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
224105438|NCT06498037|DRUG|Fentanyl|Administration of subcutaneously administered fentanyl loading boluses
224105439|NCT04248166|DEVICE|Photoacoustic imaging|"1. Photoacoustic image of thyroid nodule is obtained by using probe of photoacoustic imaging equipment and image data and data are stored in the device.~2. The patient's examination is the same as the general ultrasound, and the patient is asked to hold his breath for about 3-4 seconds to get the photoacoustic image."
224105440|NCT01944215|DIETARY_SUPPLEMENT|Meal|effect of meal
224105441|NCT01944215|OTHER|Exercise|effect of exercise
224105442|NCT01944215|RADIATION|Sestamibi|reduce radiation dose
223538535|NCT02747758|DEVICE|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
224105443|NCT01944215|DRUG|Caffeine Tablet|effect of caffeine
224289307|NCT03783988|COMBINATION_PRODUCT|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
223952545|NCT05739409|BIOLOGICAL|LILRB4 STAR-T cells injection|The study population was relapsed/refractory acute myeloid leukemia and chronic myelomonocytic leukemia.Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6#3E6#6E6#1E7 cells/kg
223952546|NCT02825550|DEVICE|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
224105444|NCT01944215|OTHER|External Heating|Heating Pad and warm blanket robe
224105445|NCT00191529|DRUG|somatropin|
224105446|NCT04494165|OTHER|massage with frankincense and myyrh essential oil|In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.
224289308|NCT06369649|DEVICE|Coolsense and Buzzy|Before the procedure, the independent observer, parent and child will be informed by the researcher about the method that will be used in the selected group and the scales that they will score. For children and parents in each group, a standard approach will be applied. Single blinding (participants) will be used in the research and the researchers will not have information about the other group. Cold application will be applied to children in group number one (Coolsense group). Coolsense, which does not contain any chemicals, provides cold application with the metal piece on its tip. In group number two (Buzzy group), vibration and cold application will be applied to the children. Buzzy is a handheld device with a bee-shaped motor that creates a small cold pad and vibration in the area in contact with the skin surface. Group number three (control group) will continue the standard procedure of the clinic and no different application or approach will be applied.
223952547|NCT03122444|DRUG|Imipramine|Imipramine will be given daily for 21-30 days.
224289309|NCT02506218|DIETARY_SUPPLEMENT|10 + 20 g protein consumption|whey isolate
224289310|NCT02506218|OTHER|30 g protein breakfast|30 g mixed meal breakfast
224289311|NCT02506218|OTHER|10 g protein breakfast|10 g mixed meal breakfast
224289312|NCT01956708|PROCEDURE|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
223952548|NCT01159314|PROCEDURE|Baerveldt Device surgical Procedure|Implant surgery
223952549|NCT03846817|OTHER|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
223952550|NCT02536534|OTHER|Correlation assessment|
223952551|NCT04417907|DRUG|Perampanel 1 week titration|Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.
223952552|NCT04417907|DRUG|Perampanel 2 week titration|Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.
224105447|NCT04494165|OTHER|massage with carrier oil|In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
224105448|NCT02190591|DEVICE|Peanut Labor Ball|Peanut Labor Ball
224105449|NCT04226352|DRUG|Dextromethorphan|Dextromethorphan will be administered and its tolerability evaluated.
224105450|NCT02495363|PROCEDURE|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
224105451|NCT02495363|DRUG|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
224289313|NCT01191528|DEVICE|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
224289314|NCT00719979|BEHAVIORAL|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
223538536|NCT02747758|DEVICE|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
223538537|NCT02747758|DEVICE|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
223538538|NCT03431597|DIETARY_SUPPLEMENT|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
223538539|NCT03431597|DIETARY_SUPPLEMENT|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
223538540|NCT05670327|OTHER|Diaphragmatic ultrasound assessment|TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
223538541|NCT03129542|DRUG|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
223538542|NCT03129542|DRUG|Placebo capsule|Three doses taken every 8 hours.
223538543|NCT04849273|DRUG|TPX-0131|Oral TPX-0131 tablets
223538544|NCT01604460|PROCEDURE|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
224105452|NCT03851510|DEVICE|Vector ventilator|The Vector ventilator is intended to provide non-invasive ventilatory support to treat adult patients with Obstructive Sleep Apnea (OSA), or Respiratory Insufficiency with the primary cause being COPD. This device is not intended for life support. It may be used to screened for the presence and abolishment of expiratory flow limitation. It is intended to be used within the home, institution/hospital, and diagnostic laboratory environments. The vector ventilator will titrate and treat EFL using non-invasive ventilatory support.
224105453|NCT03851510|DEVICE|Resmon Pro|The Resmon Pro uses the forced oscillation technique (FOT) which is a noninvasive method to measure the mechanical properties of the lung and airways during tidal breathing. In addition to measuring total impedance (resistance and reactance), the Resmon Pro can measure expiratory flow limitation which is a key index of respiratory obstruction
224105454|NCT03598777|BIOLOGICAL|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
224105455|NCT03598777|DRUG|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
224105456|NCT04820985|OTHER|Vaginal swab|Vaginal flora swab 3 months before stimulation, at oocyte puncture, embryo transfer and beta-human chorionic gonadotropin dosing
224105457|NCT04820985|OTHER|Blood test|Blood sample to measure plasma dose of progesterone
223538545|NCT01604460|PROCEDURE|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
223952553|NCT04417907|DRUG|Perampanel 4mg|Healthy adults will take 4mg perampanel PO QD for six weeks
224105458|NCT02908802|DIETARY_SUPPLEMENT|Probiotic|Probiotic
224105459|NCT02908802|DIETARY_SUPPLEMENT|Placebo|Probiotics capsules without the active ingredient
223538546|NCT02803684|OTHER|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
223538547|NCT00677794|DRUG|Clear fluids|Clear fluids only after lunch.
223538548|NCT00677794|DRUG|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
223952554|NCT04417907|DRUG|Placebo|Healthy adults will take 2mg placebo PO QD for six weeks
223538549|NCT00677794|DRUG|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
223952555|NCT00202228|DRUG|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
223952556|NCT06327997|BIOLOGICAL|Fast CAR T cells|This study designed three dose groups, each with a dosage of 5.0 × 10\^5/kg、1.0×10\^6/kg、5.0×10\^6/kg
223952557|NCT03522688|DRUG|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
223952558|NCT03522688|DRUG|Normal saline|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
224105460|NCT03488992|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
224105461|NCT03488992|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
224289315|NCT00719979|BEHAVIORAL|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
223538550|NCT02194413|PROCEDURE|therapeutic touch|receiving healing touch
224289316|NCT00719979|BEHAVIORAL|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
223538551|NCT02194413|OTHER|quality-of-life assessment|Ancillary studies
223538552|NCT02194413|OTHER|questionnaire administration|Ancillary studies
223538553|NCT03986957|OTHER|No interventions|No interventions - observational study
223538554|NCT01777867|PROCEDURE|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
223952559|NCT04722471|DRUG|Vaginally administered progesterone|The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
223952560|NCT05129722|DRUG|Low dose combination polydiuretic therapy|"Low dose combination polydiuretic therapy treatment consists of:~Loop diuretic bumetanide 0.5 mg Mineralocorticoid receptor antagonist eplerenone 25 mg Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg"
223952561|NCT05129722|DRUG|Comparator monotherapy empagliflozin|Sodium-glucose co-transporter 2 inhibitor (SGLT2i): empagliflozin 10mg
223952562|NCT04671875|DRUG|Recombinant Humanized Monoclonal Antibody MIL93|"PART I :The patients confirming to the eligibility criteria will be assigned to the 6 dose groups (0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg,respectively) based on the sequence of inclusion. Each patient will receive an intravenous infusion of MIL93 every 3 or 2 week on Day 1.~PART II:One recommended dose will be conducted from 6 dose groups based on results of PART I."
223952563|NCT03051074|BEHAVIORAL|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
223952564|NCT03051074|BEHAVIORAL|Comparison|Watching a relaxing film for up to 90 minutes
223952565|NCT04165018|PROCEDURE|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
224105462|NCT06454968|DRUG|Orelabrutinib, obinutuzumab, lenalidomide|Orelabrutinib: 150mg qd d1-d21/C1-C6 obinutuzumab: 1000mg iv d1,d8,d15/c1, 1000mg iv d1/C2-C6 lenalidomide：25mg po qd d1-14/C1-C6 Orelabrutinib: 150mg qd d1-d28/C7-C12
224105463|NCT03299023|OTHER|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
224105464|NCT02405312|BEHAVIORAL|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
224105465|NCT00072189|DRUG|7-hydroxystaurosporine|Given IV
224105466|NCT00072189|OTHER|laboratory biomarker analysis|Correlative studies
224105467|NCT00072189|OTHER|pharmacological study|Correlative studies
223952566|NCT02362386|DEVICE|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
224105468|NCT05998343|BEHAVIORAL|Intergenerational HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.
223952567|NCT05785650|DIAGNOSTIC_TEST|osteopathic palpation|comparaison of ultrasound caracteristics of areas with ad without TP
223952568|NCT02054208|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
224105469|NCT05998343|BEHAVIORAL|Same-Generation Peer Support HOW R U?|1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
224105470|NCT02438930|BEHAVIORAL|Motivational interviewing intervention during HIV testing|
224105471|NCT02438930|BEHAVIORAL|Standard-of-care counseling during HIV testing|
224105472|NCT00003937|DRUG|cisplatin|
224105473|NCT00003937|DRUG|dexrazoxane hydrochloride|
224105474|NCT00003937|DRUG|doxorubicin hydrochloride|
224289317|NCT01905059|DRUG|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
224289318|NCT01905059|DRUG|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
224289319|NCT05307406|BIOLOGICAL|Experimental|Participants will receive a single IV infusion in a double blind manner
223538555|NCT01777867|PROCEDURE|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
223538556|NCT02629861|DRUG|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
223538557|NCT02629861|DRUG|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
223538558|NCT05225909|DEVICE|Endoscopic retrograde Cholangio-pancreatography (ERCP) with aScope (Single use duodenoscope|ERCP Procedure will be done using aScope. We will assess the performance of the aScope.
223538559|NCT01272427|DIETARY_SUPPLEMENT|water with glucose|0.75 g/kg body weight of glucose added to water
224289320|NCT03207958|DRUG|Belimumab|-Given over 1 hour
224289321|NCT03988517|OTHER|timing of receiving the drug|each group took levothyroxine in different timing
223538560|NCT01272427|DIETARY_SUPPLEMENT|water and whey protein|0.75 g/kg body weight of whey protein added to water
223723185|NCT07131605|OTHER|Before bariatric surgery, both blood and biological samples (stool and urine) will be collected. Patients will also undergo a cardiology examination|This study includes a comprehensive set of laboratory and clinical investigations to evaluate the cardiovascular and metabolic impact of obesity and its modulation after bariatric surgery. Multiple biological samples (blood, urine, stool, and omental adipose tissue) will be collected at baseline and during follow-up.
224105475|NCT00003937|DRUG|etoposide|
223538561|NCT01272427|DIETARY_SUPPLEMENT|water with noncaloric sweetener|0.15 g of sucralose added to water
223538562|NCT03627702|RADIATION|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
223723186|NCT06977841|DRUG|Tegoprazan|50 mg twice daily (BID), d1-14, administered 30 minutes before morning and evening meals.
223723187|NCT06977841|DRUG|Amoxicillin 250Mg Cap|750 mg four times daily (QID), d1-14, administered immediately after breakfast, lunch, dinner, and bedtime snack.
223723188|NCT06977841|DRUG|Tetracycline 500 Mg|500 mg three times daily (TID), d1-14, postprandial after breakfast, lunch, and dinner.
223952569|NCT02054208|OTHER|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
224105476|NCT00003937|DRUG|ifosfamide|
224105477|NCT00003937|DRUG|methotrexate|
224105478|NCT00003937|PROCEDURE|conventional surgery|
224105479|NCT01656239|DRUG|fedovapagon 1 mg|
224105480|NCT01656239|DRUG|fedovapagon 2 mg|
224105481|NCT01656239|DRUG|fedovapagon 4 mg|
224105482|NCT01656239|DRUG|Placebo ( sugar pill)|
224105483|NCT02128568|BEHAVIORAL|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
224105484|NCT00144300|DRUG|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
224105485|NCT00144300|DRUG|Requip|Standard marketed product dispensed according to manufacturer's guidelines
224105486|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
224105487|NCT00739128|BIOLOGICAL|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
224105488|NCT00123201|DRUG|Dronabinol MDI|
224105489|NCT05243329|DRUG|Psilocybin|10 mg or 25 mg oral aqueous psilocybin solution
224105490|NCT01031095|OTHER|coronary intervention|elective coronary intervention
224105491|NCT01933672|DRUG|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
224105492|NCT01933672|DRUG|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
224105493|NCT01933672|DRUG|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
224105494|NCT04125745|DRUG|CXA-10|Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks
223538563|NCT00907621|PROCEDURE|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
224105495|NCT02426086|DRUG|Imetelstat 4.7 mg/kg|Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.
224105496|NCT02426086|DRUG|Imetelstat 9.4 mg/kg|Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
224105497|NCT00524303|DRUG|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
224105498|NCT00524303|DRUG|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
224105499|NCT00524303|DRUG|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
223538564|NCT00606489|DRUG|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
223538565|NCT00606489|DRUG|Placebo|Placebo
224289322|NCT00908219|DRUG|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
224289323|NCT04154358|DIAGNOSTIC_TEST|HPV testing|will perform HPV testing with self-collected specimen
223538566|NCT06543485|PROCEDURE|intramedullary screw fixation of metacarpal fractures|intramedullary screw fixation of metacarpal fractures through limited open approach
223723189|NCT06977841|DRUG|Bismuth|220 mg BID, d1-14, administered 2-3 hours after tetracycline doses at lunch and dinner
223952570|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
223952571|NCT04085614|DEVICE|Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap|Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
223952572|NCT02399449|DRUG|Brand sodium ferric gluconate|brand product
223952573|NCT02399449|DRUG|Generic sodium ferric gluconate|generic product
223952574|NCT05711433|PROCEDURE|pancreatic surgery|pancreaticoduodenectomy and distal pancreatectomy
223952575|NCT02993094|DRUG|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
223952576|NCT02993094|DRUG|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
223952577|NCT02516202|DRUG|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
223952578|NCT02516202|DEVICE|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
223952579|NCT02516202|OTHER|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
223952580|NCT02516202|OTHER|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
223952581|NCT03595670|OTHER|standardized questionnaires|standardized questionnaires concerning the perception
224105500|NCT00524303|DRUG|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
224105501|NCT04760548|OTHER|Observational study|
224105502|NCT04361110|RADIATION|Computerized tomography scan of the abdomen|Non-specific abdominal ct´s with different phases and contrast +/-.
224105503|NCT04453644|OTHER|Muscle static stretching|On day-I: Static Stretching done for 2 minutes (SS2), on day-II: Static Stretching done for 4 minutes (SS4), and on day-III: Static Stretching done for 8 minutes (SS8).
224105504|NCT00833859|DRUG|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
224105505|NCT00833859|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
224105506|NCT00887042|DRUG|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, \& -6)
224105507|NCT00499915|BEHAVIORAL|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
224105508|NCT00499915|BEHAVIORAL|Asthma Education|Asthma education will be provided at NICU discharge.
224289324|NCT00314431|PROCEDURE|Care coordination by telephone contacts with a nurse|
224289325|NCT04353024|DRUG|Dimethyltryptamine (DMT)|Intravenous DMT bolus and/or DMT maintenance perfusion over 90 min
224289326|NCT04353024|DRUG|Saline|Intravenous saline bolus and/or saline maintenance perfusion over 90 min
224289327|NCT00004150|DRUG|fluorouracil|
224289328|NCT00004150|DRUG|leucovorin calcium|
224289329|NCT00004150|PROCEDURE|adjuvant therapy|
224105509|NCT02510599|DRUG|solithromycin|
224105510|NCT00705900|DRUG|LCD|2 applications / day for 12 weeks
224105511|NCT00705900|DRUG|calcipotriol|2 applications / day for 12 weeks
224289330|NCT00201916|PROCEDURE|5250 cGy/20 fractions over 28 days|see above
224289331|NCT00201916|PROCEDURE|6600 cGy/33 fractions over 45 days|see above
224289332|NCT01668121|DRUG|Symbicort Turbohaler|
224289333|NCT01668121|DRUG|Budesonide/formoterol Easyhaler|
224105512|NCT00984451|BIOLOGICAL|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
224105513|NCT01690832|DRUG|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
224105514|NCT01690832|DRUG|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
224105515|NCT02652000|OTHER|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
224105516|NCT04854655|OTHER|Conventional resin composite|nanofilled resin composite
224105517|NCT04854655|OTHER|Activa Presto|calcium and phosphate hybrid material
224105518|NCT04854655|OTHER|Giomer|fluoride releasing hybrid material
224105519|NCT02914743|BEHAVIORAL|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
224105520|NCT02914743|PROCEDURE|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
223723190|NCT06979297|BEHAVIORAL|Web-based physical activity and diet intervention|Participants receive access to a theory-driven, web-based intervention for 12 weeks that provides interactive information on diet and physical activity, including goal setting, diet and activity tracking, tailored information on healthy eating and increasing exercise, and videos on topics of healthy eating and physical activity.
223952582|NCT03595670|OTHER|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
223952583|NCT03597152|DIETARY_SUPPLEMENT|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
223952584|NCT03597152|DIETARY_SUPPLEMENT|Placebo|Inert placebo custom manufactured for the sponsor
224289334|NCT01868763|DEVICE|telemedical devices (weighing machine and step counter)|
224289335|NCT01868763|BEHAVIORAL|care calls once per week for 12 weeks|
224289336|NCT03123757|OTHER|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
223952585|NCT05430555|BIOLOGICAL|Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR|Single-dose intravenous infusion of MAGE-A1 directed TCR-transgenic T cells following a conditioning chemotherapy
223952586|NCT00337610|DRUG|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
223952587|NCT00337610|DRUG|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
224105521|NCT06713551|OTHER|Big Amplitude Calisthenic Group Exercise with Music|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
224105522|NCT06713551|OTHER|Big Amplitude Calisthenic Group Exercise|The exercise program will consist of balance and mobility-oriented exercises such as reaching forward and upward while sitting on a chair, taking steps forward, backward, sideways and backward while standing, transferring weight, counting in place, sit-to-stand exercises, walking, changing directions or walking over obstacles (Appendix: Exercise Program). This exercise program will be applied to the first group with the accompaniment of classical Western music, while the other group will be applied without music. The exercise programs will be performed for both groups for 40 minutes, two days a week and for eight weeks.
224105523|NCT06592833|DRUG|Psilocybin|Psilocybin, 25mg, given once orally.
224105524|NCT06592833|DRUG|Pimavanserin|Pimavanserin, 34mg, given once orally
224289337|NCT03123757|OTHER|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
224105525|NCT06592833|DRUG|Placebo|Matching placebo.
224105526|NCT03803852|DEVICE|Intraocular Lens Implantation|"Implantation of an intraocular lens Rayner RayOne or Hoya Nanex or Hoya Vivinex Impressinto the capsular bag using an injector, after removing of the human cristalline lens.~Implantation of the Alcon Clareon toric and Rayner RayOne EMV toric IOL and PODEYE Toric IOL on the axis according to the steep meridian of the cornea"
224105527|NCT04865081|DEVICE|VACCIN box|The VACCIN box is a translucid box that can be placed over the patient's head. It has entry holes on the front and the side of the box in which nitrile gloves can be attached. The anesthesiologist can intubate with arms and hands inside the box. Its also has the capacity to create a negative pressure environment inside the box by connecting an air suction cable from the box to the OR medical aspiration line.
224105528|NCT06656962|DRUG|Telitacicept 160mg|Telitacicept for Injection combined with standard therapy (Prednisone and Cyclophosphamide) for the treatment of ANCA-associated nephritis (AAGN).
224105529|NCT06656962|DRUG|Prednisone (and methylprednisolone)|Methylprednisone shock therapy (500mg, 3 times), followed by Prednisone (1 mg·kg·d and a pre-determined tapering guideline \[PEXIVAS regimen\]).
224105530|NCT06656962|DRUG|Cyclophosphamide|Cyclophosphamide, intravenous injection, once every 2 to 3 weeks, 0.75 g/m² each time, the maximum cumulative dose of 8g
224105531|NCT04515524|OTHER|Non-Interventional|No study treatment will be administered in this study
224105532|NCT05501925|DEVICE|GlideSheath Slender® and conventional arterial sheath|Using the GlideSheath Slender® with the outside diameter 2.46mm
224105533|NCT05501925|DEVICE|Conventional arterial sheath|Placement of 6 French conventional Sheath (TERUMO, Introducer II )
224105534|NCT03650504|PROCEDURE|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
224105535|NCT03650504|PROCEDURE|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
224105536|NCT00193505|DRUG|Ifosfamide|
224105537|NCT00193505|DRUG|Carboplatin|
224105538|NCT00193505|DRUG|Etoposide|
224105539|NCT00193505|DRUG|Rituximab|
224105540|NCT00193505|DRUG|90Y Zevalin|
224105541|NCT04680923|PROCEDURE|CPPLAI|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
224289338|NCT03123757|OTHER|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
224289339|NCT02229565|DEVICE|Biopsy or prostatectomy|
224289340|NCT01345526|DEVICE|Reconval K1 Cream|
224289341|NCT01345526|DEVICE|Reconval Cream|
223723191|NCT06979297|OTHER|Wait-list control arm|Participants in the wait-list control will complete all the same measures as the intervention group for the first 12 weeks, then will receive access to the Internet-based intervention for another 12 weeks.
224289342|NCT04769752|OTHER|collection of the allocated treatment|collection of the allocated treatment
224289343|NCT04769752|OTHER|collection of medical complications|collection of medical complications
224289344|NCT03714555|DIAGNOSTIC_TEST|Safety Laboratories|Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
224105542|NCT04680923|OTHER|Placebo|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
224105543|NCT04680923|DRUG|Bupivacaine 0.25%|In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
224105544|NCT02633111|OTHER|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
224289345|NCT03714555|OTHER|AE Assessment|Assessment of Adverse Events (AE)
224289346|NCT03714555|OTHER|Physical Exam|Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
224289347|NCT03714555|OTHER|Concomitant Medication Review|Prior and Concomitant Medication Review
224289348|NCT03714555|DIAGNOSTIC_TEST|Tumor Imaging|Tumor CT or MRI
223723192|NCT07124975|BEHAVIORAL|Comparison of the treatment data with other patients|In this group, feedback will be provided as in the routine treatment data feedback group. In addition to this information, aggregated results for all participants (proportion of days with CPAP usage ≥4 hours per day and average daily usage time) and the participant's ranking based on these aggregated data will also be provided as feedback.
224105545|NCT02633111|OTHER|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
224105546|NCT02633111|DEVICE|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
224105547|NCT06663371|BEHAVIORAL|Basic Physical Fitness|The single module training paradigm followed a circuit-style format, with each training module consisting of 6 to 8 distinct exercise movements. Taking the INT training intervention on Mondays as an example, the training protocol involved completing one major module (e.g., plyometric exercises) before transitioning to another module (e.g., core stability exercises). Specific exercise methods, such as box jumps, were performed until all sets were completed before moving on to the next exercise (e.g., continuous depth jumps).
224105548|NCT06663371|BEHAVIORAL|Traditional Physical Training|In the fundamental strength training, a circuit training modality is employed, with each training segment comprising 5 to 7 exercise movements. For instance, a series of squat exercises is performed initially, followed by upper body strength training such as bench presses; each movement must be completed with the specified number of sets and repetitions before proceeding to the next exercise. Explosiveness training enhances the rapid contraction capabilities of the muscles through a series of jumping and throwing movements, while flexibility exercises improve the range of motion of muscles and joints through a combination of static and dynamic stretching.
224105549|NCT05910463|OTHER|AXOMOVE Therapy Medical Device|Personalized exercise programs for the self-rehabilitation of low back pain patients
224105550|NCT05161962|COMBINATION_PRODUCT|One group received standard oral care.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
224105551|NCT05161962|COMBINATION_PRODUCT|It was applied to the other group by aspiration.|the effect of oral care given by two different methods on the development of ventilator-associated pneumonia in patients connected to mechanical ventilators.
224105552|NCT03843580|DEVICE|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
224105553|NCT03792009|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
224105554|NCT03792009|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
224105555|NCT03792009|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
224289349|NCT03714555|DRUG|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
223723193|NCT07124975|BEHAVIORAL|CPAP data feedback|Participants will receive monthly feedback on their CPAP therapy treatment data (usage time and the proportion of days with \>4 hours of use) via mail or email for 6 months.
223723194|NCT07132112|BIOLOGICAL|GT719 Injection|GT719 Injection
224289350|NCT03714555|DRUG|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
224289351|NCT03714555|DRUG|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
224289352|NCT01980342|DRUG|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
224289353|NCT04317313|OTHER|FDG PET radiomic feature evaluation|"A total of 1245 radiomic features will be calculated and extracted from baseline FDG PET scans. These features include shape features, first order features, textural features and wavelet features.~In the second part, based on the results of least absolute shrinkage and selection operator Cox regression algorithm, the most significant radiomic features will be selected to construct the radiomic signature."
224289354|NCT01157715|BIOLOGICAL|intravitreal injection of KH902|
224289355|NCT04917081|BEHAVIORAL|Mindful Self-Compassion|Mindful Self-Compassion has been developed by Neff and Germer as a specific kind of Mindfulness-Based Interventions to promote self-compassion. It combines the skills of mindfulness and self-compassion, providing a powerful tool for emotional resilience and enhancing the capacity for emotional wellbeing. In this study, a shortened version of the MSC program is used which is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
224289356|NCT04917081|BEHAVIORAL|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a deep relaxation technique that helps relieve muscle tension and is based on the premise that mental calmness is a natural result of physical relaxation. In this study, Progressive Muscle Relaxation is applied once a week for 75 minutes throughout the patients' stay in the rehabilitation clinic.
224289357|NCT02752841|DIETARY_SUPPLEMENT|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
224289358|NCT00365287|DRUG|anti-thymocyte globulin|
224289359|NCT00365287|DRUG|cyclophosphamide|
224289360|NCT00365287|DRUG|cyclosporine|
224289361|NCT00365287|DRUG|fludarabine phosphate|
223723195|NCT07133126|DEVICE|Acumen monitoring|Patient undergoing a thoracic surgery or an aortic surgery will be monitored as usual using the CE marked medical device ACUMEN with the intelligent HPI system.
223723196|NCT07131202|DRUG|FL115+PD-1|Combined treatment
223952588|NCT05576233|PROCEDURE|disinfection of the surface that the blood culture is taken|lood cultures can be routinely performed with alcohol/povidine-iodine or alcohol/chlorhexidine. The topical disinfectants used in the two applications are the topical disinfectants included in the guidelines and currently applied in our hospital.
223952589|NCT02615132|BEHAVIORAL|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
223952590|NCT01554267|DEVICE|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
223952591|NCT02387385|DEVICE|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
224105556|NCT04884243|DRUG|CBT-006|ophthalmic solution
224105557|NCT04665102|OTHER|Image classification using deep learning algorithm|Image classification using deep learning algorithm
224289362|NCT00365287|DRUG|mycophenolate mofetil|
224289363|NCT00365287|PROCEDURE|radiation therapy|
224289364|NCT00365287|PROCEDURE|umbilical cord blood transplantation|
223723197|NCT07132021|DEVICE|Active taVNS|Protocol uses a 25 Hz frequency with 500 μs pulse width in biphasic configuration, operating at a 1:1 duty cycle with current intensity set to the maximum tolerable level without inducing pain. The total stimulation duration is 60 minutes. The stimulation is combined with physical therapy focused on upper extremity function.
223723198|NCT07132021|DEVICE|Sham taVNS|Physical therapy focused on upper extremity function with masking for transcutaneous vagus nerve stimulation
223723199|NCT07132723|OTHER|Time in minutes from admission to closed reduction|Time in minutes from admission to closed reduction measured as: From arriving time in the emergency department until the start of surgery in the operating theater.
223723200|NCT07132658|RADIATION|MR-Guided SBRT|MR-Guided SBRT
223723201|NCT07131709|OTHER|AI Generated Summary|Summary of the doctor's appointment generated by AI (either with or without the Next Steps Plan, depending on the arm participants are allocated to).
223723202|NCT06393751|BIOLOGICAL|Bevacizumab|Given IV
223723203|NCT06393751|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223723204|NCT06393751|PROCEDURE|Computed Tomography|Undergo CT
224105558|NCT03162289|OTHER|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
224105559|NCT03162289|OTHER|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
224105560|NCT04201912|DIAGNOSTIC_TEST|saliva analysis for Toll like receptor activity|Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
224105561|NCT03485612|DIAGNOSTIC_TEST|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
224105562|NCT02621333|BIOLOGICAL|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
223538567|NCT03544450|BEHAVIORAL|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
224105563|NCT02621333|DRUG|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
224105564|NCT00148239|BEHAVIORAL|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
224105565|NCT00148239|BEHAVIORAL|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
224105566|NCT00148239|BEHAVIORAL|Control|Participants given written educational materials at beginning of study; no treatment beyond this
224105567|NCT03329872|OTHER|Data collection|data collection about symptoms without any specific clinical or biological intervention
223952592|NCT03979040|BEHAVIORAL|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and \[positive\] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
224105568|NCT03880396|RADIATION|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
224105569|NCT02415725|DRUG|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
224105570|NCT01581411|DRUG|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
224105571|NCT01893177|BIOLOGICAL|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
224105572|NCT02628223|PROCEDURE|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
224105573|NCT02628223|DEVICE|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
223723205|NCT06393751|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223723206|NCT06393751|DRUG|Paclitaxel|Given IV
223723207|NCT06393751|DRUG|Tolinapant|Given PO
224105574|NCT00787735|BEHAVIORAL|Counseling compliance|Rates of attendance to call counseling session over specific time points
224289365|NCT03360357|PROCEDURE|Guided drills|"These residents will perform 5 set of exercises:~1. Needle Dance (Learning to manipulate the suture)~2. Loopy Loop (Learning to place needle through a loop)~3. Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~4. Dense Matter (Passing the needle through dense material without losing control of the needle)~5. Respect for tissue (Passing the needle through flimsy material without tearing)"
224289366|NCT02941510|DRUG|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
224289367|NCT02941510|OTHER|Placebo|Subject(s) will participate in all study activities but will receive placebo.
224289368|NCT03885219|DRUG|Nab-paclitaxel and S-1|Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
224289369|NCT00484419|DRUG|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
224289370|NCT00484419|DRUG|rosiglitazone maleate|rosiglitazone tablets 4mg
224289371|NCT00484419|DRUG|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
224289372|NCT06111079|DRUG|aspirin discontinuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
224105575|NCT05113524|OTHER|Dance|The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
224105576|NCT05113524|OTHER|No intervention|Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
224105577|NCT05047393|OTHER|Current blood vitamin D level and painDetect questionairre score will be detected|PainDETECT neuropathic pain questionnaire will be used to evaluate the presence of nociceptive, mixed and neuropathic pain in patients. Patients with a total questionnaire score of 12 or less are considered nociceptive pain without a neuropathic pain component. If the total score is in the range of 13-18, the result is uncertain, but it is accepted that the neuropathic component can be found in the mixed type, and in the scores of 19 and above, it is accepted that the neuropathic pain component is present. Patients with previously obtained and finalized vitamin D levels \< 20 ng/mL, 20-30 ng/mL, and ˃30 ng/mL will be grouped as deficiency, insufficiency and normal, respectively.
224105578|NCT01769404|BIOLOGICAL|LY2605541|
224105579|NCT01769404|BIOLOGICAL|Insulin Glargine|
224289373|NCT06111079|DRUG|aspirin continuation|Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
223952593|NCT03979040|BEHAVIORAL|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and Depression (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
223952594|NCT00002232|BIOLOGICAL|APL 400-003|
223952595|NCT05702190|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
223952596|NCT05702190|DRUG|Placebo|Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
223952597|NCT02354144|OTHER|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
223952598|NCT02354144|OTHER|Control gel|A gel not containing carrageenan
223952599|NCT00084825|DRUG|Docetaxel|30 mg/m\^2 IV on days 1, 8, 15, and 22 every 42 days
224105580|NCT01859429|OTHER|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
224105581|NCT01214512|OTHER|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
224105582|NCT00538733|DRUG|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
224105583|NCT00538733|DRUG|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
224105584|NCT00538733|DRUG|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
224105585|NCT00538733|DRUG|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
224289374|NCT04784884|DEVICE|HSI|diagnostic hyperspectral imaging
223952600|NCT00084825|DRUG|Imatinib mesylate|600 mg orally daily
224289375|NCT03349528|BIOLOGICAL|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
224289376|NCT03349528|BIOLOGICAL|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
224289377|NCT05790954|OTHER|Guided imagery|Three days before the cesarean section, the participants will be given a guided imagery audio recording and will be asked to listen to it before going to bed every evening until the day of the cesarean section. On the morning of the cesarean section, after the patient is prepared, the guided imagery audio recording will be played again.
224289378|NCT03186703|BEHAVIORAL|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
224289379|NCT04623021|DRUG|Nafamostat Mesilate|Administered intravenously as a continuous infusion
223952601|NCT01662713|DEVICE|OFDI|Imaging of skin
223952602|NCT03107156|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
223952603|NCT01543789|PROCEDURE|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
223952604|NCT01543789|PROCEDURE|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
224105586|NCT03921372|DIAGNOSTIC_TEST|Isometric exercise|Squatting for 5 minutes
223538568|NCT03544450|OTHER|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
224289380|NCT03998579|OTHER|The CanMoRe programme|An exercise intervention in Primary Health Care
224289381|NCT03998579|OTHER|Home exercise|An active control group
224289382|NCT05824117|OTHER|Individual Placement and Support (IPS)|"IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults.~Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning."
224289383|NCT01321021|DRUG|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
224289384|NCT05510024|PROCEDURE|Radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy|The regulation and monitoring of the entire soft-coagulation process are conducted via the radiofrequency generator under endoscopic guidance. Lateral out-fracture of the inferior turbinate is performed if necessary. One month after surgery, allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
224289385|NCT05510024|PROCEDURE|SCIT|Allergen immunotherapy will be conducted. Standardized Dp allergen extracts (Alutard SQ, ALK-Abell'o) were used for SCIT. According to the manufacturer's instructions, the build up phase was carried out with weekly injections of volumes of 0.2, 0.4, and 0.8 mL in the first 3 vials (nos. 1 to 3) and 0.1, 0.2, 0.4, 0.8, and 1.0 mL in vial no. 4, reaching the maintenance dose, 100,000 standardized quality units. The specialist adjusted the dose according to the patient's therapeutic response, and the cumulative allergen dose for each patient was the maximal tolerable injected dose. Then, the maintenance dose was given with an injection interval of 6±2 weeks according to the manufacturer's recommendations.
224289386|NCT00273741|DRUG|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
224289387|NCT00273741|DRUG|placebo comparator|placebo capsules
224289388|NCT03606421|RADIATION|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
224289389|NCT03606421|RADIATION|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
224289390|NCT05628779|DEVICE|TriClip TTVr system (Abbott Vascular)|Edge-to-edge leaflet approximation for the tricuspid valve
224289391|NCT05628779|DEVICE|PASCAL TTVr system (Edwards Lifesciences)|Edge-to-edge leaflet approximation for the tricuspid valve
224289392|NCT02191475|DRUG|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
224289393|NCT02191475|DRUG|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
224289394|NCT00845975|DEVICE|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
224289395|NCT00845975|DEVICE|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
224289396|NCT04221607|OTHER|Sensate Focus exercise|Structured exercise to enhance intimacy
224289397|NCT02884323|DEVICE|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
224289398|NCT00359242|BEHAVIORAL|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
223538569|NCT03776084|DEVICE|Continuous Positive Airway Pressure|CPAP indication
223538570|NCT00002414|DRUG|CPI-1189|
223538571|NCT01816048|DRUG|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
223538572|NCT01816048|RADIATION|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
223538573|NCT01816048|PROCEDURE|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
223538574|NCT01816048|PROCEDURE|Computed Tomography|Undergo 18F NaF PET/CT scan
223538575|NCT02692573|OTHER|positioning|prone positioning for the initial 5 minutes of life
223538576|NCT02692573|OTHER|positioning|supine positioning for the initial 5 minutes of life
223538577|NCT00197821|BIOLOGICAL|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
223538578|NCT04620161|DRUG|Pradigastat Tablets 20mg|20mg, once daily, oral administration
223538579|NCT04620161|DRUG|Pradigastat Tablets 40mg|40mg, once daily, oral administration
223538580|NCT04620161|DRUG|Pradigastat Tablets 20mg matching Placebo|once daily, oral administration
223538581|NCT04620161|DRUG|Pradigastat Tablets 40mg matching Placebo|once daily, oral administration
223538582|NCT05626491|DEVICE|Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
223538583|NCT05626491|DEVICE|Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)|Patients receive sham treatment (no active stimulation) every other day via a headband.
224105587|NCT02862912|DRUG|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
224289399|NCT00359242|BEHAVIORAL|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
224289400|NCT00949611|BEHAVIORAL|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
224289401|NCT00949611|BEHAVIORAL|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
224289402|NCT02770105|OTHER|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
224105588|NCT02862912|DRUG|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
224105589|NCT02862912|DRUG|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
224289403|NCT02770105|OTHER|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
224289404|NCT02770105|OTHER|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
224289405|NCT02770105|OTHER|Placebo|Oral administration of 200ml of distilled water
224289406|NCT03500042|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
224289407|NCT03421704|DEVICE|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
224289408|NCT00355472|DRUG|KW-0761|IV administration at 4 escalating dose levels.
224289409|NCT00003621|DRUG|carmustine|
224289410|NCT00003621|DRUG|cisplatin|
224289411|NCT00003621|DRUG|etoposide|
224289412|NCT00003621|RADIATION|radiation therapy|
223538584|NCT04784156|PROCEDURE|Subtalar (Talocalcaneal) Arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
223538585|NCT04784156|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
223538586|NCT03069716|DEVICE|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
224289413|NCT02733952|DRUG|Tranexamic Acid|
224289414|NCT02733952|PROCEDURE|Pericervical Tourniquet|
224289415|NCT03095118|DRUG|Daratumumab|Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
224289416|NCT04730089|DEVICE|Electrical impedance tomography|A bolus of 10ml 10% NaCl was injected during a respiratory pause (≥10s) through the central venous catheter.The results of arterial blood gas analysis and the data of EIT were collected before the first prone session (time baseline), the end of prone positioning (time P).
223538587|NCT03069716|DEVICE|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
223538588|NCT06322134|OTHER|Drowning incident|Patients categorized as drowning have been experiencing respiratory impairment from submersion or immersion in liquid and needing rescue by the Royal Danish Air Force's Search and Rescue (SAR) helicopters.
223538589|NCT05752656|OTHER|Clinical examinations|Clinical examinations and administration of clinical scales
223538590|NCT05230576|DIAGNOSTIC_TEST|Deep learning training cohort|train the deep learning model
223538591|NCT05230576|DIAGNOSTIC_TEST|Deep learning validation cohort|evaluate the model
224105590|NCT02862912|DRUG|Saline|Preservative free normal saline (0.3 ml) to bring the volume to \~ 2 ml
224105591|NCT00095121|DRUG|Placebo (PLB)|Matching placebo
224105592|NCT00095121|DRUG|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
224105593|NCT00095121|DRUG|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration \>= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained \>= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
224105594|NCT03050463|PROCEDURE|Biospecimen Collection|Undergo blood and saliva sample collection
224105595|NCT03050463|PROCEDURE|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
224105596|NCT03050463|OTHER|Questionnaire Administration|Ancillary studies
224105597|NCT04741243|DEVICE|Extracorporeal Shock wave|Dietary modifications are changes made during food preparation, processing, and consumption to increase the bioavailability of micronutrients-and reduce micronutrient deficiencies-in food at the commercial or individual/household level
224105598|NCT00576498|OTHER|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
224105599|NCT00576498|OTHER|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
223952605|NCT00602732|BEHAVIORAL|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
223952606|NCT00602732|BEHAVIORAL|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
224105600|NCT03572634|DRUG|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
224289417|NCT05705817|BEHAVIORAL|Assistive Soft Skills and Employment Training (ASSET)|The ASSET program is a 15-session training program that combines specific skill training, structured learning, social performance training and a social hour to practice skills through a manualized group intervention. Specific skills taught within the program include communication, enthusiasm and attitude, teamwork, networking, problem-solving and critical thinking, and professionalism.
223952607|NCT06237621|DEVICE|SnapshotNIR imaging|SnapshotNIR will be used for tissue oxygen-saturation imaging of all the subjects' foot along with standard of care procedures for PAD assessment.
223952608|NCT03985397|OTHER|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
223952609|NCT04788407|DRUG|Nitazoxanide|Subjects will receive nitazoxanide 500 mg TID for 7 days
223952610|NCT04788407|DRUG|Placebo|Subjects will receive placebo TID for 7 days
223952611|NCT03927118|PROCEDURE|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
224289418|NCT03581214|OTHER|No oxygen|No facemask, room air only
224289419|NCT03581214|OTHER|Oxygen|10Liters/minute oxygen by facemask
224289420|NCT06806878|OTHER|Progressive muscle relaxation|We will apply progressive muscle relaxation exercises to reduce nursing students' anxiety about intramuscular injection administration
224105601|NCT03572634|COMBINATION_PRODUCT|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
224289421|NCT03015714|OTHER|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
224289422|NCT03015714|OTHER|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
224289423|NCT04551820|PROCEDURE|Regular Hours|The regular hours cohort includes cholecystectomies performed during the day shift at the Institution during Monday through Friday, not inclusive of national holidays.
224289424|NCT04551820|PROCEDURE|After Hours|The after hours cohort includes cholecystectomies performed outside of the day shift at the Institution during Monday through Friday, on the weekend, or during a national holiday.
224289425|NCT04551820|DEVICE|Robotic-assisted Cholecystectomy|With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
224289426|NCT00093184|DRUG|Angiomax (bivalirudin) anticoagulant|
224289427|NCT01862393|DEVICE|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
224105602|NCT05334589|DEVICE|Prewarming|When patients in the study group come to the Preoperative Care Unit (PCU), their body temperature will be measured. Patients in the study group will be placed in such a way that the 3M™ Bair Hugger™ Whole Body Blanket covers the patient's body and prewarmed with the 3M™ Bair Hugger™ Warming Unit for 30 minutes before anesthesia is given in the PCU. Heating unit temperature will be adjusted to 43°C in line with company recommendations. After the patients in the study group are warmed up for 30 minutes, the preheating process will be completed and the whole body blanket will be taken and the blankets that the clinic routinely use for each patient will be covered to cover the patients' body.
224105603|NCT06294925|DRUG|Etrasimod|As provided in real world practice
224105604|NCT03352856|OTHER|Barley starch|Highly purified barley starch
224289428|NCT01862393|DEVICE|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
224289429|NCT01862393|DEVICE|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
223952612|NCT04607356|DEVICE|Blood Flow Restriction (BFR)|The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
224289430|NCT02513836|OTHER|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
223952613|NCT04607356|OTHER|Evidence-informed care|Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
223952614|NCT01742832|DRUG|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
224105605|NCT03352856|OTHER|Maize starch|Maize starch
224105606|NCT06616415|DRUG|Belumosudil|Pharmaceutical form: Tablet Route of administration: Oral
224105607|NCT06458140|PROCEDURE|Cardioneuroablation|Radiofrequency ablation of ganglionated plexi of the heart
224105608|NCT05436249|DEVICE|Neurofeedback treatment|"During the fMRI scan, the tasks consist of:~1. Overt finger tapping in time with a flashing cue.~2. Motor imagery (of finger tapping).~During overt finger tapping, feedback will consist of a slider bar that indicates tapping accuracy to target speed (1 or 4Hz). During motor imagery, neurofeedback will consist of a slider bar that indicates the success of recruiting predicted brain regions (consistent with those engaged during overt tapping)."
224289431|NCT02513836|OTHER|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
224105609|NCT05436249|BEHAVIORAL|At-home therapy|"Participants are assigned to groups where they will practice each day for 3 weeks at-home.~1. Group 1: Imagery only.~2. Group 2: Overt finger tapping only.~3. Group 3: Imagery plus overt finger tapping.~During imagery, participants will view the task while imagining that they are finger tapping in time with the flashing cue, using the imagery strategies identified during their previous neurofeedback session. During overt tapping, participants will finger tap in time with the flashing cue. A final assessment of overt tapping will be performed the day after therapy ends."
224105610|NCT03011125|DRUG|dexlansoprazole injection|
224105611|NCT03011125|OTHER|placebo|
224105612|NCT02874911|OTHER|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
224289432|NCT05215093|OTHER|Direct access physiotherapy for acute low back pain|Interventions include physiotherapeutic treatment, without prescription of the general practitioner, for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
224105613|NCT00538642|DRUG|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
224105614|NCT01857895|DRUG|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
224105615|NCT02542995|OTHER|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
223952615|NCT01742832|DRUG|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
223952616|NCT02518399|OTHER|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
223952617|NCT02518399|OTHER|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
223952618|NCT01778803|DRUG|defactinib|
223952619|NCT01778803|DRUG|Paclitaxel|
223952620|NCT04271813|DRUG|Anlotinib plus Sintilimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
223952621|NCT05329142|DIAGNOSTIC_TEST|Surplus sample toxicology analysis|Anonymised surplus blood sample will be analysed for drugs and their metabolites by way of Mass Spectrometry and LGC Group, Cambridge.
224105616|NCT07026383|BEHAVIORAL|performance test|Injury risk was evaluated using the Lower Extremity Functional Test (LEFT), which involves eight agility drills performed consecutively on a diamond-shaped course without rest intervals. The test includes eight components-forward run, backward run, side shuffle, carioca, figure-eight run, 45-degree cuts, 90-degree cuts, and a counter vertical jump-along with the single-leg hop for distance, following a standardized testing protocol known to predict injury risk. Participants who took longer to complete the test were categorized into the high injury risk group, while those with shorter completion times were classified into the low injury risk group.
224105617|NCT07031700|DRUG|Mosunetuzumab|"* Cycle 1: Day 1: 1 mg; Day 8: 2 mg; Day 15: 30 mg~* Cycles 2-8: 30 mg every 3 weeks~* Cycles 9-17: 30 mg every 3 weeks (if applicable） A treatment cycle is 21 days. Patients achieving complete remission (CR) by cycle 8 will stop treatment, while those with partial response (PR) or stable disease (SD) may continue up to 17 cycles or until disease progression or intolerable toxicity occurs."
224105618|NCT07031700|DRUG|Tislelizumab|\- Cycles 2-8: 200 mg IV every 3 weeks
224105619|NCT07031661|OTHER|This was an observational study with no intervention.|This was an observational study with no intervention.
224105620|NCT07031713|BIOLOGICAL|CAR-T Therapy|CT1192 cells infusion
224105621|NCT05158348|DRUG|Dexmedetomidine Hydrochloride|Group A will receive post-operative nebulised dexametomidine and lidocaine.
224105622|NCT05158348|DRUG|Nebulized lidocaine|Group B will receive post-operative will receive nebulised lidocaine
224105623|NCT05158348|DRUG|Local infiltration of lidocaine|group C will receive intra-operative local infiltration of lidocaine
224105624|NCT01346800|DRUG|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
224105625|NCT01346800|DRUG|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
224105626|NCT06057129|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot|During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.
224105627|NCT06057129|DEVICE|Unsupervised therapy|"After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for six weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient."
224289433|NCT05215093|OTHER|Usual care for acute low back pain|Interventions include standard of care by the general practitioner for low back pain according to current biopsychosocial national (KCE - Belgium) and international (NICE) guidelines.
224289434|NCT05917691|PROCEDURE|Bariatric surgery|Current Procedural Terminology (CPT) codes: 43644, 43645, 43770, 43775, 43842, 43843, 43845, 43846, 43847.
223723208|NCT07131917|DEVICE|Miniaturized Intracavitary Monitoring Probe|A sterile, miniaturized, biocompatible monitoring probe (≤1.5 mm diameter) is temporarily introduced into the cavity of an infected walled-off pancreatic necrosis (WOPN) during standard percutaneous drainage. The device is designed to measure local microenvironmental parameters in situ, such as acidity and related indicators, without interfering with fluid evacuation. Measurements are performed intermittently or continuously for up to 72 hours and are used solely for observational purposes. This intervention is distinct from standard WOPN management, as it allows real-time assessment of local physicochemical conditions, which are not accessible through systemic biomarkers or imaging alone.
224105628|NCT01284556|DRUG|Phenobarbital|tablet
223952622|NCT05796271|DRUG|R-Chop and Roflumilast|All subjects will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days (+/- 3 days) for a total of 6 cycles. All subjects will receive a fixed oral dose of one 500 microgram (μg) tablet of roflumilast per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses. Subjects will be asked to keep a drug diary to record the days and times when Roflumilast is taken. The first dose will be given on the day of the first R-CHOP treatment.
223952623|NCT01790659|DRUG|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
224105629|NCT01284556|DRUG|Placebo tablet|tablet
224105630|NCT02420652|DRUG|Aspirin|Given PO
224105631|NCT02420652|OTHER|Laboratory Biomarker Analysis|Correlative studies
224105632|NCT02420652|DRUG|Metformin Hydrochloride|Given PO
224105633|NCT02420652|OTHER|Placebo|Given metformin hydrochloride placebo PO
224105634|NCT02420652|OTHER|Placebo|Given aspirin placebo PO
224105635|NCT05734872|DEVICE|Virtual Reality Technology|Make a pair of glasses through virtual reality technology, through which participants can observe and participate in the treatment process.
224105636|NCT05734872|OTHER|Routine mental health course training|Conduct mental health education for patients by making a speech.
224105637|NCT04244045|OTHER|Suboccipital muscle inhibition|"The patient was asked to flex his hip joint with complete knee extension and ankle in neutral position. The therapist stretches the hamstring of the dominant side; distal hand of the therapist on planter surface of foot for dorsiflexion. and proximal hand on the knee to increase the length of the muscle, maintain this stretching for 60 seconds then relax .Sub occipital muscle inhibition:~The Patient is supine, The therapist stretch the sub occipital, flexes the head of the patient to get the chin to the manibiurim sternii, maintaining this position for 60seconds then relax Slump strtch position:Patient in comfortable short sitting position at the edge of the bed with the trunk in an millitary straight position then ask the patient to slump the flex his neck and street the knee joint in complete extension the at the end of the procedure do active dorsiflexion at the tested foot"
223729520|NCT04158440|DRUG|4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab|Biological: Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
223952624|NCT01790659|DRUG|Paromomycin|Paromomycin alone
223952625|NCT01589341|OTHER|laboratory biomarker analysis|Correlative studies
224105638|NCT02463591|DRUG|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
224105639|NCT04569539|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
224105640|NCT00772460|DEVICE|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
224105641|NCT03069768|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
224105642|NCT03069768|DRUG|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
224105643|NCT00909285|DEVICE|TMS stimulation|TMS stimulation and cognitive training
224105644|NCT00909285|DEVICE|Sham comparator|Sham comparator
224105645|NCT00909285|BEHAVIORAL|Cognitive training|TMS stimulation and cognitive training
224105646|NCT03922399|PROCEDURE|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
224105647|NCT00210561|DRUG|tramadol hydrochloride , acetaminophen|
223952626|NCT03394105|DRUG|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
223952627|NCT04913532|RADIATION|Hypofractionation with simultaneous integrated boost|Hypofractionation with simultaneous integrated boost
224105648|NCT03911674|OTHER|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
224105649|NCT00830830|DRUG|Hyalgan (sodium hyaluronate)|
224105650|NCT04763382|OTHER|experimental group: Training of caregivers|Pre-test, post-test, retention test, education, guide booklet delivery, android application installation and urinalysis
224105651|NCT04763382|OTHER|Control gruop|Pre-test, post-test and urinalysis
224105652|NCT00803088|DEVICE|The Alair System|Treatment of airways with the Alair System
224105653|NCT01398254|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
224105654|NCT05107414|PROCEDURE|Total Knee Arthroplasty|Participants have previously undergone a total knee replacement surgery.
224105655|NCT06316323|DRUG|Silver diamine fluoride|38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
224105656|NCT06316323|DRUG|Sodium fluoride|Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
224105657|NCT03167619|DRUG|Olaparib Oral Product|olaparib 300mg twice daily
224105658|NCT03167619|DRUG|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
224105659|NCT03587909|PROCEDURE|Phacoemulsification Cataract SUrgery|Phacoemulsification in eyes with shallow anterior chamber (\<2.5mm depth)
224105660|NCT03587909|PROCEDURE|Femtosecond Cataract Surgery|Femtosecond Cataract Surgery in eyes with shallow anterior chamber \< 2.5mm
224105661|NCT03065803|PROCEDURE|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
224105662|NCT03065803|PROCEDURE|Guided bone regeneration technique for post-extraction dental socket preservation|After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
224105663|NCT02453412|DEVICE|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
224289435|NCT05917691|DRUG|General anesthetic|"Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database)."
224289436|NCT05917691|DEVICE|Indeterminate|Devices were indeterminate under the current study design (observational study of a deidentified database).
224289437|NCT01604369|PROCEDURE|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
223538592|NCT06519136|OTHER|Distance Reiki|"According to Usui, the second level Reiki application will be applied for 20 minutes a day between 19.00 and 21.00 in the evening for four consecutive days by the researcher who has completed his second level training, in accordance with the Second Level Reiki Application Protocol."
223538593|NCT06519136|OTHER|Sham Reiki|It will be stated that remote energy application will be applied to the Sham Reiki group and no application will be made.
223538594|NCT02809885|BIOLOGICAL|Hepatitis E serology|
223952628|NCT01888484|BIOLOGICAL|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
223952629|NCT01683188|DRUG|vemurafenib + HD IL-2|
223952630|NCT02102724|DIETARY_SUPPLEMENT|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
223952631|NCT02102724|DIETARY_SUPPLEMENT|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
223952632|NCT03887611|DEVICE|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
223952633|NCT01448109|DRUG|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
224105664|NCT03498872|DEVICE|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
224105665|NCT03498872|OTHER|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
224105666|NCT02363647|OTHER|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
224105667|NCT01805115|DRUG|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
224105668|NCT01805115|DRUG|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
224105669|NCT01805115|DRUG|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
224105670|NCT01805115|DRUG|Control|The control group was not given any cervical priming agents or placebo.
224289438|NCT01561794|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2\) Hospital-acquired pneumonia (HAP): For the patient with Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr \> 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
223538595|NCT04285697|OTHER|infection prevention bundle|"The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family"
223538596|NCT01380665|DEVICE|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
223538597|NCT04194827|DIAGNOSTIC_TEST|Adalimumab serum trough concentration|Dose reduction based on adalimumab serum trough concentration
223538598|NCT04194827|DIAGNOSTIC_TEST|Disease activity|Dose reduction based on adalimumab diseas activity
223538599|NCT04194827|DRUG|Adalimumab|Adalimumab
224105671|NCT05036538|DEVICE|Intervention with natural sounds administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds.
224105672|NCT05036538|DEVICE|Intervention with natural sounds and binaural beats administered via headphones|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with nature sounds and binaural beats.
224289439|NCT03847194|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
224289440|NCT04766229|COMBINATION_PRODUCT|Citalopram +/- Gabapentin + Sleepio + support person|All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
224289441|NCT04219787|PROCEDURE|Long BPL LRYGB|LRYGB with an 180 cm BPL and an AL of 80 cm.
223538600|NCT04979598|OTHER|Home exercise program|A home exercise program is provided but this is an observational study. The effect of the exercise program is not under investigation.
223538601|NCT02558868|DRUG|Irinotecan|
224289442|NCT04219787|PROCEDURE|Short BPL LRYGB|The second group will receive a standard LRYGB with a 80 cm BPL and a 180 cm long AL.
223723209|NCT06853925|BEHAVIORAL|Radioactive Iodine Support (RAI Support)|RAI Support consists of multimedia content (images, videos, text, audio, and infographics across different website pages) that is written at an 8th grade reading level. RAI Support uses patient materials that are visually diverse to appeal to patients from different racial and ethnic backgrounds and inclusion of all genders. RAI Support users can access short (\~3 minutes or less) clinician-approved symptom management education videos and follow clinician-led video-guided activities such as nutrition management for dry mouth. In addition, RAI Support contains infographic pages about specific symptoms of RAI (e.g., salivary, lacrimal, and nasal symptoms with strategies for symptom management) and a resources page consisting of a printable treatment summary and survivorship plan to bring to provider appointments and access to evidence-based stress-management resources such as relaxation recordings.
223538602|NCT02558868|DRUG|Oxaliplatin|
223538603|NCT00267176|DRUG|lumiracoxib|
223538604|NCT05709847|OTHER|Coffee|24 ounces of coffee will be consumed daily
223538605|NCT02948439|OTHER|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
223538606|NCT05646082|DRUG|Dostarlimab in Combination Antiretroviral Therapy|Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
223538607|NCT06126159|DIAGNOSTIC_TEST|multiparametric and fat-detection magnetic resonance imaging (MRI)|Differentiating of renal AMLs with minimal fat and RCCs
223538608|NCT05615064|OTHER|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players|relationship between quality of life, life satisfaction and anxiety levels of wheelchair basketball players
223538609|NCT04013178|BEHAVIORAL|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
223538610|NCT04013178|BEHAVIORAL|Conventional resistance training|A conventional approach to resistance training
224105673|NCT05036538|DEVICE|Intervention with natural sounds and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds.
224105674|NCT05036538|DEVICE|Intervention with natural sounds, binaural beats and virtual reality administered via headphones and head mounted display|The preoperative intervention includes a stress-reducing relaxation phase lasting approximately 30 minutes, during which the patients are presented with a nature scene in a spherical 360° environment with associated nature sounds and binaural beats.
224289443|NCT02408120|DRUG|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
224289444|NCT02408120|DRUG|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~* If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~* If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~* If the fasting and pre-dinner BG is \>180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~* If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~* If a patient develops hypoglycemia (BG \<70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
223723210|NCT06853925|OTHER|Treatment as Usual (TAU)|The American Cancer Society (ACS) website on Radioactive Iodine (Radioiodine)Therapy for Thyroid Cancer is the TAU comparison. This website is a reputable and trusted source of information about cancer, with relevant content and web availability. Using the ACS website allows participants in both groups to receive information (addressing ethical concerns) through a website (similar delivery mode for information).
223723211|NCT06981325|DRUG|Cemiplimab|Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for up to 12 months (max. 17 cycles).
223723212|NCT05448560|BEHAVIORAL|Multi-level Intervention of shared model of survivorship care|1\) Patient survivorship education via telehealth with the cancer center- The research registered nurse (RN) will discuss the contents of the survivorship care plan and coordination between the cancer center and PCP clinic. 2) Ongoing patient-tailored education program by MyChart within the EHR patient portal- Patients will be asked to select survivorship topics of interest from a panel (e.g. school issues, fertility, fatigue, physical activity, single kidney health, emotions/coping) that will then be sent over 1 year. 3) Structured interactive phone communication between the research RN at the cancer center and community PCP clinic- The discussion will explain the patient's cancer history, tumor recurrence monitoring schedule, individualized risk of late effects and surveillance schedule, psychosocial challenges, health behaviors, and coordination between the cancer center and PCP clinic. 4) In-person visit with the PCP clinic for survivorship care.
224105675|NCT00600002|BIOLOGICAL|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
223538611|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
223538612|NCT03615885|DIETARY_SUPPLEMENT|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
223538613|NCT03615885|DIETARY_SUPPLEMENT|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
223538614|NCT00251108|PROCEDURE|Cardiorespiratory fitness training|
223538615|NCT01349114|DRUG|aliskiren 300 mg once daily|aliskiren 300 mg daily
223538616|NCT01349114|DRUG|Placebo/sugar pill|Sugar pill/placebo
224105676|NCT03194425|DIAGNOSTIC_TEST|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
224105677|NCT04752280|RADIATION|Proton irradiation|proton irradiation applied as follows: 30 x 2 Gy(RBE) 33 x 1,8 Gy (RBE), or 15 x 2,67 Gy (RBE)
224105678|NCT04752280|RADIATION|Photon irradiation|proton irradiation applied as follows: 30 x 2 Gy 33 x 1,8 Gy, or 15 x 2,67 Gy
224105679|NCT01927458|DEVICE|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
224105680|NCT04298346|OTHER|no intervention|no intervention
224105681|NCT02329925|DEVICE|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
224105682|NCT02525172|DRUG|Rituximab|
224105683|NCT02525172|DRUG|intravenous immune globulin|
224105684|NCT02525172|DRUG|Bortezomib|
224105685|NCT02525172|DRUG|Methotrexate|
224105686|NCT02238613|DEVICE|radioactive stent|radioactive stent carrying seed iodine 125
224105687|NCT02238613|DEVICE|plastic stent|common plastic stent without carrying seed iodine 125
224289445|NCT02408120|DRUG|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~* BG \>141-180 mg/dL; 2-4 units of insulin aspart~* BG between 181-220 mg/dL; 3-6 units of insulin aspart~* BG between 221-260 mg/dL; 4-8 units of insulin aspart~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~* BG between 261-300 mg/dL; 5-10 units of insulin aspart~* BG between 301-350 mg/dL; 6-12 units of insulin aspart~* BG between 351-400 mg/dL; 7-14 units of insulin aspart~* BG \> 400 mg/dL; 8-16 units of insulin aspart"
224289446|NCT02419625|BEHAVIORAL|questionnaires|questionnaires , serum samples will be used
224289447|NCT05227131|DRUG|Margetuximab|Margetuximab (15 mg/kg) will be administrated by intravenous infusion on Day 1 of each cycle.
224289448|NCT05227131|DRUG|Tucatinib|Tucatinib (300 mg) will be administrated orally twice daily (every 12 hours) continuously in 21-day cycles.
224105688|NCT00004934|DRUG|carboplatin|
224105689|NCT00004934|DRUG|epirubicin hydrochloride|
224105690|NCT00004934|DRUG|paclitaxel|
224105691|NCT00004934|PROCEDURE|conventional surgery|
224289449|NCT05227131|DRUG|Capecitabine|Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
224289450|NCT03810573|DEVICE|NB1|rhNELL-1/DBX
224289451|NCT02023840|DRUG|metronidazole gel|
224289452|NCT02023840|PROCEDURE|ultrasonics|
224289453|NCT02023840|PROCEDURE|erythritol|
224289454|NCT02023840|DRUG|placebo|
224105692|NCT01855438|BEHAVIORAL|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
224289455|NCT04657250|BEHAVIORAL|Smoking cessation + quitline linkage text messages|Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
224289456|NCT04657250|BEHAVIORAL|Passive quitline referral|Single text message with contact information for the Quitline
224289457|NCT04626752|DRUG|BCMA CAR-T|Volunteers will be treated with BCMA CAR-T cells
224289458|NCT04626752|DRUG|Fludarabine|25mg/㎡ for D-4、D-3 and D-2
224289459|NCT04626752|DRUG|Cyclophosphamide|500mg/㎡ for D-3 and D-2
224105693|NCT04883073|DEVICE|Use of Endo App|Use of Endo App
224105694|NCT02896140|OTHER|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
224105695|NCT02082184|DEVICE|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
224105696|NCT02082184|DEVICE|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
224105697|NCT05879939|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
224105698|NCT01488981|OTHER|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
223723213|NCT05448560|OTHER|Comparison Group|Participants will be contacted by study staff at their cancer center to schedule an in-person visit at the survivorship clinic that will include a comprehensive history focused on cancer-related medical and psychosocial issues, physical examination, ordering of recommended surveillance for late effects, and delivery of hard copy of their survivorship care plan.
223723214|NCT06978673|PROCEDURE|Splanchnic nerve neurolysis - 5 ml of absolute alcohol (100%)|Splanchnic neurolysis will be performed with 5 ml of absolute alcohol on each side at the level of the eleventh thoracic vertebra.
223723215|NCT06978673|PROCEDURE|Celiac Plexus Neurolysis - 5 ml of absolute alcohol (100%)|Celiac plexus neurolysis will be performed with 5 ml of absolute alcohol on each side at the level of the first lumbar vertebra.
223952634|NCT01448109|DRUG|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
223952635|NCT02203513|DRUG|LY2606368|105 mg/m\^2 intravenous (IV) once every 14 days of a 28 day cycle
223952636|NCT01196364|OTHER|Dietary Supplement: water with noncalorie sweetener|
223952637|NCT01196364|OTHER|Activity: With noncalorie sweetener or glucose|
223952638|NCT01515501|PROCEDURE|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
223952639|NCT02008916|DRUG|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
223952640|NCT02008916|DRUG|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
223952641|NCT03803475|DRUG|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
223952642|NCT03803475|DEVICE|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
223723216|NCT06986785|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223952643|NCT03803475|DEVICE|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
223952644|NCT01773746|OTHER|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
223952645|NCT02513667|DRUG|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
223952646|NCT02513667|RADIATION|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
223952647|NCT06575725|BIOLOGICAL|Balstilimab|Given IV
223952648|NCT06575725|PROCEDURE|Biopsy|Undergo biopsy
223952649|NCT06575725|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223952650|NCT06575725|BIOLOGICAL|Botensilimab|Given IV
223952651|NCT06575725|PROCEDURE|Computed Tomography|Undergo CT
223952652|NCT06575725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223952653|NCT06575725|DRUG|Regorafenib|Given PO
224105699|NCT01488981|DEVICE|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
224105700|NCT03851341|COMBINATION_PRODUCT|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
224105701|NCT03851341|COMBINATION_PRODUCT|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
224105702|NCT00147771|DRUG|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
224105703|NCT05488301|OTHER|chest physiotherapy|"chest physiotherapy session including:~* nasal ventilation~* decrease of respiratory rate without increasement of Tidal volume~* abdomino-diaphragmatic ventilation"
224289460|NCT03818386|DRUG|AGuIX®|"3 intravenous injection at 100mg/kg~* D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~* Fr1: AGuIX® injection before the first radiation session~* Fr6: AGuIX® injection before the sixth radiation session"
224105704|NCT05857956|OTHER|Proper Wild energy shot|100% plant-based energy shot containing natural caffeine, L-Theanine, purified water, pineapple juice concentrate, natural flavors, kiwi juice concentrate, organic lemon juice concentrate, organic strawberry juice concentrate, monk fruit juice concentrate, pink himalayan sea salt.
224105705|NCT03187379|DRUG|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
224105706|NCT03187379|DRUG|Bupivacaine|60cc Bupivacaine
224289461|NCT03818386|RADIATION|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
224289462|NCT01913717|RADIATION|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
224289463|NCT04553991|PROCEDURE|Ultrasound guided QL block|20 mL of 0.25% bupivacaine was applied bilaterally at the anterolateral border of the QL at its junction with transversalis fascia
224289464|NCT04553991|PROCEDURE|Ultrasound guided TAP block|20 mL of 0.25% bupivacaine was applied bilaterally in the TAP
223538617|NCT04542122|BEHAVIORAL|Choices and judgements|In the intervention arm, the participant is asked to answer clinical cases in a reverse order from the control group (control has to make moral choices then judge somebody else's choices ; intervention has to judge moral choices first, then make his own)
223538618|NCT02145884|DRUG|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
223538619|NCT01359124|BEHAVIORAL|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
223538620|NCT01359124|BEHAVIORAL|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
223538621|NCT01359124|BEHAVIORAL|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
224105707|NCT06337851|OTHER|Simultaneous burr hole craniostomy|Patients in group-1 were fixed in supine position with their heads in neutral and flexion position. Bilateral burr holes were made one after another, the dural surfaces were exposed at the same time, then the outer membranes of both sides opened and hematomas evacuated simultaneously. All the patients underwent a drainage system, performed with the insertion of a silicone tube into the subdural space and tunneled under the scalp to the exit point.
224105708|NCT06337851|OTHER|Consecutive burr hole craniostomy|In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated. The contralateral hematoma was evacuated.
223538622|NCT03890510|OTHER|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
223538623|NCT03890510|PROCEDURE|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
223538624|NCT04662450|BEHAVIORAL|ABM affective pain stimuli|Patients undergo ABM training to shift attention away from affective pain stimuli
224289465|NCT04015960|OTHER|no intervention|qualitative research and patient reported outcome measure (PROm) development
223723217|NCT06986785|DRUG|Lenvatinib|8mg (body weight \< 60kg), or 12mg (body weight ≥60kg), QD.
224105709|NCT04802356|DRUG|Belantamab mafodotin|"Dose of 2.5 mg/kg/every 8 weeks on day 1, intravenously, Induction: three induction cycles with belantamab mafodotin in combination with VRd.~Consolidation: one cycle after 90 days of transplantation with belantamab mafodotin in combination with VRd.~Maintenance: belantamab mafodotin in combination with lenalidomide until disease progression, patients withdrawal, death or up to two years, whichever occurs first"
223538625|NCT04662450|BEHAVIORAL|ABM sensory pain stimuli|Patients undergo ABM training to shift attention away from sensory pain stimuli
224105710|NCT04802356|DRUG|Bortezomib|Dose of 1.3 mg/m2, on days: 1, 4, 8 and 11 of every 28-day cycle. Subcutaneous administration Induction: 6 cycles Consolidation: 2 cycles
224105711|NCT04802356|DRUG|Lenalidomide|Dose of 25 mg/day on days 1-21 of every 28-day cycle. Oral administration. Induction: 6 cycles Consolidation: 2 cycles Maintenance: 10 mg/day on days 1-21 continuously (may increase up to 15 mg/day) until disease progression, patients withdrawal, death, whichever occurs first
224105712|NCT04802356|DRUG|Dexamethasone|Dose of 20 mg on days: 1, 2, 4, 5, 8, 9, 11 and 12 of every 28-day cycle. Oral administration Induction: 6 cycles Consolidation: 2 cycles
224105713|NCT04802356|PROCEDURE|Autologous stem cell transplant (ASCT)|High-dose melphalan (200 mg/m2) and ASCT will be performed as per routine practice
224105714|NCT06638502|DRUG|HRX215 capsules|HRX215 capsules 250 mg orally twice daily
224105715|NCT06638502|DRUG|Placebo capsules|placebo capsules matching appearance of HRX215
224105716|NCT03210077|DEVICE|Monitoring|Monitoring
224289466|NCT02640365|DRUG|MM-398|unresectable Advanced non-colorectal cancer
224105717|NCT01062399|DRUG|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
224289467|NCT02640365|DRUG|Irinotecan|unresectable metastatic colorectal cancer
224289468|NCT02640365|DRUG|Leucovorin (LV)|unresectable metastatic colorectal cancer
224289469|NCT02640365|DRUG|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
224289470|NCT02640365|DRUG|bevacizumab|unresectable metastatic colorectal cancer
224289471|NCT02640365|DRUG|MM-398|unresectable metastatic colorectal cancer
224289472|NCT03551873|DRUG|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
224105718|NCT01062399|DRUG|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
224105719|NCT01062399|RADIATION|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
224105720|NCT01062399|DRUG|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
224105721|NCT01062399|DRUG|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
224105722|NCT01062399|DRUG|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
224105723|NCT01062399|DRUG|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
223538626|NCT04662450|BEHAVIORAL|Placebo|Patients undergo ABM training to receive affective/neutral and sensory/neutral word pairs
224289473|NCT02278458|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
224105724|NCT00249379|DRUG|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
224105725|NCT04553809|PROCEDURE|ENB|ENB for biopsy sampling of peripheral lung lesion
224105726|NCT04553809|PROCEDURE|ENB in combination with rEBUS|The combination of ENB and rEBUS for biopsy sampling of peripheral lung lesions
224105727|NCT06149884|PROCEDURE|Sentinel lymph node biopsy, axillary lymph node dissection|"SLNB was performed using single or dual tracers. For the single tracer technique, Technetium 99, a radioactive substance, was administered periareolarly prior to surgery, and SLNs were identified intraoperatively via a gamma detection system (Neoprobe®). The dual tracer method employed both an isosulfan blue dye and Technetium 99 concurrently. The choice of SLNB technique was contingent upon the surgeon's discretion. SLNs were categorized as one or multiple, and any LN identified by either or both methods was defined as SLN. LNs resected during SLNB without tracer signal were not classified as SLNs.~ALND was characterized by the removal of all LNs in axillary levels I and II. Patients documented to have undergone ALND in surgical records were primarily selected from our registry. Among them, those with fewer than 10 LNs were excluded, based on the assumption that a competent ALND necessitated the removal of 10 or more LNs as defined in previous studies"
224105728|NCT05496426|DRUG|KL130008/Placebo|Drug: KL130008 Drug: Placebo
224105729|NCT05921916|DRUG|MBF-118 oral capsules|MBF-118 oral capsules PPAR gamma receptor partial agonist
224105730|NCT05921916|DRUG|Placebo oral capsule|Placebo oral capsule solid microcrystalline cellulose
224105731|NCT01447056|BIOLOGICAL|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
224289474|NCT02278458|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
223538627|NCT06157593|PROCEDURE|NAVA|weaning from mechanical ventilator using neurally adjusted ventilatory assist
223723218|NCT05304988|OTHER|Testing of the EFT|Our team will develop specific questions in EFT. Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The physiotherapists will rate the subject with the most appropriate level of physical activity.
223723219|NCT06074133|PROCEDURE|Blood collection|Undergo blood draw
223723220|NCT06074133|PROCEDURE|Chest Computed Tomography|Undergo standard of care chest Computed Tomography
223729521|NCT04158440|DRUG|4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )|Biological: Placebo by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1;Drug: Corboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m\^2 by IV infusion Q3W
223952654|NCT06445244|DIETARY_SUPPLEMENT|Alpha-ketoglutarate supplied as 1000mg capsule|AKG Double Wood® + lifestyle modification AKG Double Wood®: 500mg, qd, for one months. Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
223952655|NCT06445244|BEHAVIORAL|Behavioral: Lifestyle modification|Lifestyle modification: intake 1400-1600 kcal/day: 54% carbohydrates, 24% proteins, 22% lipids, 108 mg cholesterol, 35 g fiber; avoid smoking and alcohol consumption; performing aerobic activity 4 days per week such as 45 min on a stationary bicycle.
223952656|NCT02757469|DRUG|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
223952657|NCT03529994|OTHER|Enrollment|All infants enrolled will have work of breathing assessed.
223952658|NCT04198441|DEVICE|Wound dressing|Clean wound, fill wound, dress wound
224105732|NCT02897193|DEVICE|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
224105733|NCT02897193|DEVICE|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
224289475|NCT01144403|DRUG|Cyclophosphamide|as prescribed, 6 cycles
224289476|NCT01144403|DRUG|Fludarabine|as prescribed, 6 cycles
224289477|NCT01144403|DRUG|Mitoxantrone|as prescribed, 6 cycles
223952659|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
224105734|NCT02897193|DEVICE|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
224105735|NCT02897193|DEVICE|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
224289478|NCT01144403|DRUG|Rituximab|375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
224289479|NCT01459263|DEVICE|ClariVein|Using the ClariVein device, the GSV will be occluded.
224289480|NCT01935479|DRUG|AK159|transdermal administration of teriparatide acetate
224289481|NCT01935479|DRUG|MN-10-T|subcutaneous administration of teriparatide acetate
224289482|NCT01935479|DRUG|Placebo|Placebo AK159
224289483|NCT02788799|OTHER|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
224289484|NCT02788799|OTHER|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
224289485|NCT06655194|DRUG|Acetylsalicylic Acid (Aspirin, BAYE004465, UI1610477)|Chewable tablet, 81mg, oral
223952660|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
224289486|NCT06655194|DRUG|Acetylsalicylic Acid (BAYE004465, UI1615160)|Chewable tablet, 81 mg, oral
224289487|NCT03959995|OTHER|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
224289488|NCT03959995|OTHER|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
224289489|NCT06467565|DRUG|Liposomal irinotecan|NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
224289490|NCT06616220|DRUG|Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
224289491|NCT06616220|DRUG|0.9%NaCl|0.9% NaCl
224289492|NCT00138957|PROCEDURE|Laparoscopic parastomal hernia repair with mesh|
224289493|NCT04214665|DRUG|Alpha Lipoic acid 600 mg HR film coated tablets|
224289494|NCT03901391|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing
224289495|NCT00003130|DRUG|paclitaxel|
224289496|NCT04412486|BIOLOGICAL|COVID Convalescent Plasma|One unit of COVID Convalescent Plasma transfused on Day 0
224289497|NCT00381823|BEHAVIORAL|Cognitive Behavioral Therapy|
224289498|NCT03768284|OTHER|Saliva or buccal sample|Saliva or buccal sample
223723221|NCT06990464|DRUG|SIBP-A19|"SIBP-A19 formulation for injection. Strength: 1.0, 2.0, 3.2, 4.0, 4.8, 5.6, 6.4 and 8.0 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage, 1mg/kg and 2mg/ kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one participant. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
223723222|NCT04715997|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
223723223|NCT04715997|DRUG|Placebo|Normal saline
223952661|NCT01206972|DRUG|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
223952662|NCT01206972|DRUG|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
223952663|NCT01503970|DEVICE|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
223952664|NCT03347396|DRUG|BIVV009|Sutimlimab was administered as intravenous (IV) infusion.
223952665|NCT06509308|OTHER|Psychological Questionnaires|Patients will be asked to complete a series of questionnaires regarding disease expectations, cognitions, and representations of their health status. Additionally, sociodemographic data and clinical variables will be collected from medical records.
223952666|NCT00010868|DRUG|Omega-3 Fatty Acids|
223952667|NCT01450397|BIOLOGICAL|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
223952668|NCT04806906|DRUG|CC-486|Investigational product will be dispensed on Day 1 of each treatment cycle. 300 mg CC-486 QD for 14 days of each 28-day treatment cycle
223952669|NCT02399202|DRUG|osilodrostat|
223952670|NCT00221988|DRUG|Levetiracetam (Keppra)|
223952671|NCT00392197|DRUG|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
223952672|NCT04347148|PROCEDURE|SNAGs Treatment|a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
223952673|NCT04347148|PROCEDURE|Sham Laser Treatment|A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
223952674|NCT05514184|DIETARY_SUPPLEMENT|PLAFOND diet|PLAFOND is a pragmatic patient-centered dietary intervention supported by dietitians who provide education and counseling in the form of Medical Nutrition Therapy (MNT) consisting of 0.6-0.8 g/kg/day dietary protein with \>2/3% of the protein from plant-proteins.
224289499|NCT02605213|DRUG|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
224289500|NCT02605213|DRUG|Placebo|Placebo for control Group of primary sclerosing vhlangitis
223538628|NCT06666231|PROCEDURE|QL (quadratus lumborum) block administration|"After endotracheal intubation, patients in the supine position will be given a lateral tilt and the areas to be treated will be cleaned with surgical antiseptic solution. The convex USG probe will be covered in a sterile manner. Then, the sterile probe will be placed transversely on the crista iliaca. The probe will be directed cranially until the external oblique muscle, internal oblique muscle and transverse abdominis muscle are clearly visualized. The psoas major muscle and the transverse process of the vertebra will be visualized. The QL muscle will be visualized between the aponeuros of the transverse abdominis muscle and the psoas major muscle. A 20 G 100 mm block needle will be advanced from posterolateral to anteromedial using the in-plane technique. The needle will be directed between the QL muscle and the psoas major muscles. 20 ml of 0.25% bupivacaine (Buvasin®, Vem İlaç, Turkey) will be injected on each side between the fasciae of these two muscles and the LA distribution"
223538629|NCT06666231|PROCEDURE|External Oblique Intercostal Plane Block|After endotracheal intubation, a 20-gauge 100 mm long block needle will be inserted at the T6-T7 level under USG guidance and bilateral EOIB will be applied with 20 cc of 0.25% Bupivacaine on each side under the external oblique intercostal muscle (total 40ml bilaterally).
224289501|NCT02605252|DRUG|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
224289502|NCT00141661|DRUG|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
224289503|NCT00141661|DRUG|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
224289504|NCT00141661|DRUG|Placebo Comparator|Matching placebo.
224289505|NCT02959476|DRUG|Ropivacaine|Anesthetic
224289506|NCT02959476|DRUG|Placebos|Inactive comparator
224289507|NCT02269631|BEHAVIORAL|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
224289508|NCT02269631|BEHAVIORAL|Control diet group|no legumes in lunch or dinner meals
224289509|NCT02269631|DEVICE|Smartpill|to assess how long food takes to pass through the digestive system
224289510|NCT02269631|OTHER|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
224289511|NCT01974882|OTHER|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
224289512|NCT01513031|OTHER|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
224289513|NCT05688397|DIETARY_SUPPLEMENT|Experimental 1|L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
224289514|NCT05688397|DIETARY_SUPPLEMENT|Experimental 2|L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
224289515|NCT05688397|DIETARY_SUPPLEMENT|Placebo|One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
224289516|NCT04952831|OTHER|diffusion MRI (dMRI)|All participants underwent dMRI scan at baseline
224289517|NCT02646917|PROCEDURE|Aesthetic Microneedling Treatment|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
224289518|NCT04540055|PROCEDURE|Paravertebral block|The subjects in this group received general anesthesia and USG-guided paravertebral block
224289519|NCT04540055|PROCEDURE|General Anesthesia|The subjects in this group underwent MRM under routine general anesthesia without peripheral nerve block supplementation.
224289520|NCT00680186|DRUG|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
224289521|NCT00680186|DRUG|Dabigatran etexilate|150mg bid
224289522|NCT03978312|OTHER|Nominal consensus group|NLit-UK linguistic and cultural adaptation (NLit-UK) 2 x nominal consensus groups evidence review and topic expert engagement
224289523|NCT03978312|OTHER|Observational cohort (validity and reliability testing)|Nutrition Literacy Measurement Tool validation (NLit-UK). Target sample 366 on treatment cancer patients confirmatory binary analysis for validity and reliability.
224289524|NCT00919984|DRUG|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
224289525|NCT05589350|OTHER|saturated fat intake|Intake of saturated fat from yogurt and animal butter daily for 4-week period
224289526|NCT00606138|DRUG|ranibizumab|One 0.5 mg intravitreal injection
224289527|NCT00606138|PROCEDURE|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
224289528|NCT00028379|PROCEDURE|Transcranial magnetic stimulation (TMS)|
224289529|NCT02080507|DEVICE|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
224289530|NCT02080507|DEVICE|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
224289531|NCT04647383|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
224289532|NCT04647383|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
224289533|NCT04647383|DRUG|Placebo|COPD: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
224289534|NCT04647383|DRUG|Lemborexant 10 mg|COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
223723224|NCT06345781|BEHAVIORAL|Abdominal Functional Electrical Stimulation|Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.
223952675|NCT04780607|DEVICE|mitral valve repair|different repair techniques to construct rheumatic mitral valve lesion
223952676|NCT02962024|DRUG|Morphine Sulfate|
223952677|NCT02962024|DRUG|Bupivacaine Hydrochloride|
223952678|NCT06352307|OTHER|Diagnosis of ACM|Definite ACM diagnosis is based on the consensus-based 2010 Task Force Criteria, which include major and minor criteria in six categories (depolarization and repolarization abnormalities, arrhythmia, imaging, histology, and family history/genetics). Among these, repolarization abnormalities (T-wave inversion in the precordial leads) constitute the most commonly observed, followed by frequent premature ventricular complex. With regards to imaging techniques, both the presence of wall motion abnormalities and an abnormal ventricular volume or function are required for fulfilment. Definite ACM consists of two major criteria or one major and two minor criteria or four minor criteria from different categories. Borderline ACM consists of one major and one minor criterion or three minor criteria from different categories.
223952679|NCT01780428|DRUG|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
223952680|NCT01780428|DRUG|Placebo|
223952681|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
223952682|NCT00545909|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
223952683|NCT05547724|OTHER|Virtual reality|Virtual reality visit of the birth room, cesarean and pediatric hospitalization department: neonatology and neonatal intensive care
224289535|NCT01974128|PROCEDURE|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
224289536|NCT01176019|DEVICE|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
224289537|NCT01099631|BIOLOGICAL|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10\^5, Level 2 = 10\^6, Level 3 = 10\^7, Level 4 = 10\^8, Level 5 = 10\^9, Level 6 = 10\^10.
224289538|NCT04483531|DRUG|Odevixibat|A4250 is a small molecule and selective inhibitor of IBAT
223952684|NCT02399072|OTHER|No intervention|No intervention administered in this study
223952685|NCT06100406|OTHER|Biofield tuning|Biofield Tuning is a non-invasive, non-medical therapeutic practice in which a resonating tuning fork is used to identify and re-balance off-the-body sites at which perturbations in the tuning fork sound are detected.
223952686|NCT02947880|DRUG|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
223952687|NCT02947880|DRUG|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
224289539|NCT05766020|BEHAVIORAL|Listen training|Auditory skills with the inclusion of cognitive control.
224289540|NCT02602834|OTHER|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
224289541|NCT02602834|OTHER|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
224289542|NCT05472116|DEVICE|Mobile Health application (CapApp)|Mobile Health application (CapApp) will be used to measure capillary refill time in a healthy pediatric population and compared to two additional manual methods to include both human and computer annotation and mobile health application (Cap App).
224289543|NCT00127517|DRUG|peptide-nucleic acid solution AVR118|
224289544|NCT00873119|DRUG|belinostat, carboplatin, paclitaxel|
224289545|NCT00873119|DRUG|carboplatin, paclitaxel|
224289546|NCT03803033|OTHER|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
224289547|NCT01418677|DRUG|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
224289548|NCT01418677|DRUG|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
224289549|NCT01418677|DRUG|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
224289550|NCT01367717|DIETARY_SUPPLEMENT|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
224289551|NCT01367717|DIETARY_SUPPLEMENT|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
224289552|NCT00285584|DRUG|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
224289553|NCT00285584|DRUG|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
224289554|NCT02378051|BEHAVIORAL|Staying Strong with Schools Intervention|"1. On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~2. Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
224289555|NCT02378051|OTHER|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
224105736|NCT04770168|BEHAVIORAL|Cognitive Behavioral Therapy Curriculum|"The 3-month Harry Potter curriculum is delivered by trained teachers and includes lessons on a) risk factors that can contribute to emotional distress, b) how depression and anxiety manifest and how to access support/treatment, c) cognitive distortions, how they differ from rational thoughts and basic cognitive restructuring techniques, d) crisis planning including personalized stressbusters and hope kits, and e) how to be resilient."
223538630|NCT06629389|DRUG|Cannabidiol 100 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
223729522|NCT03182101|BEHAVIORAL|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
224105737|NCT00073333|BEHAVIORAL|Social Skills Training|Social skills training once per week
224105738|NCT00073333|BEHAVIORAL|Exposure Treatment|Exposure once per week
224105739|NCT00073333|BEHAVIORAL|Placebo|Placebo
224105740|NCT05299892|DEVICE|Phonak Audeo P or Naida P hearing aid|"Commercially available hearing aid that has access to speech enhancer feature settings off, moderate and strong"
224105741|NCT04429750|PROCEDURE|Immediate umbilical cord clamping|"In the immediate cord clamping group, the umbilical cord will be clamped within the first 20 seconds after birth and the infant will be transferred to the resuscitation room. The newborn infant will be intubated and mechanically ventilated as quickly as possible on the resuscitation table as recommended in the French Programme National de Soins.~After cardiorespiratory stabilization (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%), the infant will be transferred to the neonatal intensive care unit (NICU). Oxytocin is infused to the mother as recommended in the local protocol (usually just after birth or cord clamping)."
224289556|NCT00427674|DRUG|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
224289557|NCT01761669|DRUG|Vitamin D|
224289558|NCT00266240|DRUG|GK Activator (2)|Escalating doses po bid
224289559|NCT00266240|DRUG|Placebo|po bid
224289560|NCT00164541|BEHAVIORAL|Arts Based Program|
224289561|NCT00164541|BEHAVIORAL|Curriculum|
224289562|NCT05129254|DEVICE|Fractionated Thulium laser|For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.
224289563|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Injection|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
224289564|NCT05129254|PROCEDURE|Autologous Platelet Rich Plasma Topical Application|Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
224289565|NCT00645944|DRUG|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
224289566|NCT00645944|DRUG|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
224289567|NCT01856439|DRUG|ProSavin|Long term follow up of patients who received ProSavin in a previous study
224289568|NCT01353846|OTHER|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
224289569|NCT01353846|DRUG|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
224289570|NCT03699033|RADIATION|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
224289571|NCT03699033|DRUG|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
224289572|NCT03699033|DRUG|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
224289573|NCT00374582|DEVICE|Bodystat Quadscan 4000|device determining body composition and nutritional status
224289574|NCT00374582|DEVICE|bodystat quadscan 400|device determining body composition and nutritional status
224289575|NCT00147160|DRUG|Temozolomide, Cisplatinum|
224105742|NCT04429750|PROCEDURE|intact cord resuscitation|The umbilical cord will be kept intact during the initial phase of the resuscitation. The infant will be placed on a specifically designed compact trolley with a warmed platform, suitable for commencing resuscitation between the mother's legs in case of vaginal birth or near the operating table beside the mother in case of cesarean section. This trolley will be fully equipped for resuscitation, including a suction device, gas flowmeter/blender, ventilatory support, and monitoring system. Its height can be adjusted in order to position the infant close to the maternal perineum. The infant will be intubated and mechanically ventilated on this trolley. The cord will be clamped once cardiorespiratory stabilization will be obtained (i.e. heart rate\>120/min, increasing preductal O2 saturation or achieving acceptable preductal SpO2 targets between 80 and 95%) or in case of spontaneous placental expulsion. The infant will be then transferred to the neonatal intensive care unit (NICU).
224105743|NCT02429648|PROCEDURE|DCC first then PVI|DCC performed prior to PVI
223538631|NCT06629389|DRUG|cannabidiol 300 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
224105744|NCT02429648|PROCEDURE|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
224105745|NCT03334214|DRUG|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
224105746|NCT03334214|DRUG|Placebo|Saline 0.9%
224105747|NCT02033980|DEVICE|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
224105748|NCT00003820|DRUG|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
224105749|NCT03528252|OTHER|Written advice LDL Cholesterol|One A4 paper with written information on both sides
224105750|NCT03528252|OTHER|Written advice Triglycerides|One A4 paper with written information on both sides
224105751|NCT00312780|DRUG|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
224105752|NCT02943551|OTHER|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
224105753|NCT02943551|OTHER|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
224105754|NCT02943551|OTHER|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
224105755|NCT02943551|OTHER|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
224105756|NCT02943551|OTHER|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
224105757|NCT06108284|DEVICE|Intervention Arm (Biphasic cuirass ventilation)|Patients in this arm will be placed on Biphasic cuirass ventilation
224105758|NCT04939155|BIOLOGICAL|SARS-CoV-2 mRNA vaccine|mRNA vaccine for COVID
224105759|NCT06023914|OTHER|STRENGTH EVALUATION WITH ELECTROSTIMULATOR|Evaluation of isometric strength using an electrostimulator.
224105760|NCT06023914|OTHER|STRENGTH EVALUATION WITHOUT ELECTROSTIMULATOR|Evaluation of isometric strength not using an electrostimulator.
224289576|NCT05550220|DIAGNOSTIC_TEST|Cuff Leak Test|Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
224289577|NCT01823276|OTHER|Tyrosine-Containing Bar|
224289578|NCT01823276|OTHER|Placebo Bar|
224289579|NCT03617627|BEHAVIORAL|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
223538632|NCT06629389|DRUG|Cannabidiol 400 mg/ml|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
223952688|NCT03060525|BEHAVIORAL|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
223538633|NCT06629389|DRUG|Placebo|"The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator."
223952689|NCT00912964|DRUG|Mirabegron|Mirabegron tablets
223952690|NCT00912964|DRUG|Placebo|Matching mirabegron placebo tablets.
223952691|NCT06239532|DRUG|HAIC+TAE|Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
223952692|NCT06239532|DRUG|Tislelizumab|Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
224105761|NCT04887311|DRUG|MBM-01|Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
223952693|NCT06239532|DRUG|Surufatinib|Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
223952694|NCT05398289|DRUG|4-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
223952695|NCT05398289|DRUG|6-week duration of antibiotic therapy|The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
224105762|NCT03976089|BEHAVIORAL|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
224289580|NCT00755378|DRUG|AZD8529|Oral
224289581|NCT00755378|DRUG|Placebo|Oral
224289582|NCT01098994|DIETARY_SUPPLEMENT|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
224289583|NCT01098994|OTHER|Dummy pills|Daily placebo administration for 8 weeks
223952696|NCT01932632|OTHER|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
223952697|NCT00687869|BEHAVIORAL|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
223952698|NCT00687869|BEHAVIORAL|Case management|Usual stroke aftercare plus patient-information-notes
223952699|NCT05473806|DRUG|Pioglitazone 15 Mg Oral Tablet|24weeks dose
223952700|NCT05473806|DRUG|Evogliptin 5mg|24weeks dose
224289584|NCT01694082|BEHAVIORAL|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
223952701|NCT04486820|OTHER|Analysis Immunohistochemical|Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
223952702|NCT00336791|DRUG|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m\^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m\^2 IV on day 1 and day 4 of 21 day cycle."
223952703|NCT00336791|DRUG|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m\^2 IV on day 1 of 21 day cycle."
223952704|NCT00336791|DRUG|Doxorubicin|FAC Chemotherapy: 50 mg/m\^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
223952705|NCT00336791|DRUG|Paclitaxel|80 mg/m\^2 by vein (IVPB) over 1 hour every week for 12 weeks
224289585|NCT01694082|BEHAVIORAL|Brief brochure and assessment control|
224289586|NCT02096588|DRUG|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
224289587|NCT02096588|DRUG|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
224289588|NCT00017394|BIOLOGICAL|bevacizumab|Given IV
224289589|NCT00017394|DRUG|vinorelbine tartrate|Given IV
224289590|NCT00017394|OTHER|laboratory biomarker analysis|Correlative studies
223952706|NCT00336791|DRUG|Epirubicin|FEC: 100 mg/m\^2 IV on day 1 of 21 day cycle.
224105763|NCT03976089|BEHAVIORAL|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
224105764|NCT04754373|DIETARY_SUPPLEMENT|GFA-918|Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
224105765|NCT04754373|OTHER|Placebo|Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
224105766|NCT02337842|BIOLOGICAL|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10\^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10\^2 or 5x10\^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10\^4, 10\^3, 5x10\^2 or 5x10\^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10\^4 or 5x10\^3 or 10\^3 or 10\^2 or 10\^4 or 5x10\^2 or 5x10\^1RT-PCR units.
224105767|NCT02337842|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
224105768|NCT02886104|PROCEDURE|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
224105769|NCT02886104|DEVICE|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
224105770|NCT00378729|DRUG|Metformin and FSHr|treatment for infertility
224105771|NCT00378729|PROCEDURE|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
224105772|NCT00154505|DEVICE|Lateral trunk support of wheelchair seating|
224105773|NCT03002506|DRUG|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
224105774|NCT01940718|DRUG|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (\~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
224105775|NCT01220778|BEHAVIORAL|Exercise|
224289591|NCT02470091|BIOLOGICAL|Denosumab|Given SC
224289592|NCT02470091|OTHER|Laboratory Biomarker Analysis|Correlative studies
224289593|NCT02470091|OTHER|Pharmacological Study|Correlative studies
224289594|NCT00990847|DRUG|Procaterol, Salbultamol|
224289595|NCT01795248|DRUG|Liraglutide|1.8 mg liraglutide
224289596|NCT01795248|DRUG|Placebo|Liraglutide without the GLP-1 analogue
223952707|NCT02383043|DRUG|Cocaine|
223952708|NCT02383043|DRUG|Sustained Release d-Amphetamine|
224105776|NCT05162235|DEVICE|Augmented Reality-assisted localization of solitary pulmonary nodule|In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
224105777|NCT01573468|DRUG|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
224105778|NCT01573468|DRUG|Placebo|Placebo orally once on Day 1 of each cycle
224105779|NCT01573468|DRUG|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
224105780|NCT05929534|DEVICE|active intermittent Theta Burst Stimulation|Each patient will receive two 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
224105781|NCT05929534|DEVICE|sham intermittent Theta Burst Stimulation|Each patient will receive two sham 600-pulse iTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with five consecutive days each week.
224105782|NCT00006812|DRUG|capecitabine|
223952709|NCT03528603|OTHER|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal
223952710|NCT03528603|OTHER|Oleocanthal-low Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
223952711|NCT00348361|DRUG|Fluticasone Propionate|
223952712|NCT02709044|DRUG|Ringer lactate|
223952713|NCT04318834|OTHER|Tumour and germline molecular profiling|Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing
223952714|NCT05437653|OTHER|Nutritional Drink A|300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
223952715|NCT05437653|OTHER|Nutritional Drink B|300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
224105783|NCT02689700|OTHER|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
224105784|NCT02608164|DIETARY_SUPPLEMENT|3000IU(75μg) vitamin D3|
224105785|NCT05738980|BIOLOGICAL|Autologous RAK cells|Autologous RAK cells were treated by intravenous reinfusion
224105786|NCT00152412|DRUG|Levocetirizine oral solution|
224105787|NCT05190835|DEVICE|Optical scanner|During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
224289597|NCT00817947|DEVICE|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
224289598|NCT00653016|DRUG|norelgestromin; ethinyl estradiol|
224289599|NCT02947620|DRUG|Metformin/Atorvastatin 1500mg/40mg, QD|
224289600|NCT02947620|DRUG|Metformin 1500mg, QD|
224289601|NCT02947620|DRUG|Atorvastatin 40mg, QD|
224289602|NCT00176631|DIETARY_SUPPLEMENT|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
224105788|NCT05257122|DRUG|Fruquintinib|Fruquintinib 5mg qd, d1-21, q28d
224289603|NCT00176631|DRUG|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
224289604|NCT04480801|OTHER|Thermal Evaluation and Foot Care|Participants in the experimental group will be given foot care and thermal evaluation in the clinic and will be taught to the patient and / or their relatives. Thermal evaluation and foot care video will be uploaded to the patient and / or relative's phone.
224289605|NCT04480801|OTHER|Foot Care|Participants in the control group will be given foot care in the clinic and will be taught to the patient and / or their relatives. Foot care video will be uploaded to the patient and / or relative's phone.
224289606|NCT02240563|PROCEDURE|Low-level laser therapy|
224289607|NCT02240563|PROCEDURE|Non laser ordinary red light|
224289608|NCT02521077|DRUG|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
224289609|NCT02521077|OTHER|Normal Saline|Saline 0.9%
224289610|NCT00896194|BEHAVIORAL|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
224289611|NCT00896194|BEHAVIORAL|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
224289612|NCT06616558|OTHER|Sunscreen SPF 70|Participants will topically apply sunscreen SPF 70
224289613|NCT06616558|OTHER|Sunscreen SPF 70|On the randomized side of the half-face, the product will be applied by a qualified technician
224289614|NCT04290286|OTHER|i2TransHealth|i2TransHealth: online intervention for TGD people
223538634|NCT06694246|OTHER|Improving technique|"A checklist was developed to ensure the important steps were followed, with tips for obtaining a more adequate sample. This checklist was put in the outpatient procedures room, and each physician performing a biopsy was asked to fill it out.~Also, a diagram containing illustrative images with the basic steps was put in the procedures room.~The topic was covered in the biweekly scientific meeting, and all factors attributed to the inadequate sample were discussed.~The department lead mentioned the topic in the OBGYN department's private messaging group.~It was finally mentioned in the morning meeting."
224289615|NCT05795348|DIAGNOSTIC_TEST|Personalised Musculoskeletal Modeling|Magnetic resonance images, electromyography and dynamometry data will be used to develop and inform personalised musculoskeletal models
224289616|NCT00992368|PROCEDURE|reduction mammaplasty|patients submitted to reduction mammaplasty
224289617|NCT02036450|DEVICE|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
224289618|NCT04126616|DIAGNOSTIC_TEST|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
224289619|NCT02087917|DRUG|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
224289620|NCT02087917|DRUG|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
223538635|NCT06694246|OTHER|Using hysteroscopy in candidate patients|"Patients with focal lesions on ultrasound will undergo hysteroscopy and biopsy instead of blind endometrial sampling.~Patient with stenosed cervix or failed previous sampling might also undergo hysteroscopic guided biopsy."
223538636|NCT06694246|OTHER|Analgesia|Analgesia in the form of paracetamol or NSAIDs might be given to some patients 30- 60 minutes before the procedure to reduce the procedure-associated pain and the resultant failure to complete it and obtain an adequate sample.
224105789|NCT02515695|DRUG|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
224105790|NCT02699775|OTHER|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
224289621|NCT05854459|OTHER|HIIT and Nordic Curl exercise program|The training program in the HIIT+NC group was divided into the following parts: i) warm-up (10 minutes); ii) HIIT (25 minutes) consisting of a circuit of eight exercises; iii) Nordic curl exercise (10 mintues); and iv) stretching.
224289622|NCT05854459|OTHER|HIIT-only program|The HIIT group performed the same exercises in the warm-up, HIIT and stretching sections as the HIIT+NC group, however, they did not perform the NC eccentric exercises.
223538637|NCT01049087|RADIATION|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
223729523|NCT01974349|DRUG|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
224105791|NCT02654925|PROCEDURE|Adipose Tissue Biopsy|
224289623|NCT00933959|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
224289624|NCT00933959|BEHAVIORAL|Sleep Hygiene|Treatment as usual
224289625|NCT01215799|DRUG|Bafetinib|Bafetinib 240 mg bid
224289626|NCT04647617|BEHAVIORAL|Quantitative weight -bearing and report exercise sign data every weekly|keep their normal live style
224289627|NCT03474029|DRUG|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
224105792|NCT03359603|DEVICE|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
224105793|NCT00474253|DRUG|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
224105794|NCT00474253|DRUG|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
224105795|NCT00474253|DRUG|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
224105796|NCT02355340|OTHER|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
224105797|NCT02355340|OTHER|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
224105798|NCT01215630|BEHAVIORAL|Aerobic Interval Training|One interval training session
224105799|NCT05182736|BEHAVIORAL|TRAIL intervention|The TRAIL program is comprised of a multi-tier system of strategies: Universal strategies impact the entire school via a school-wide social norms marketing campaign and school-climate change activities. School staff trainings and professional development activities focus on enhancing protective factors for students to reduce the effects of stressful life events and trauma, improving classroom management, linking students to resources, and improving the overall school climate for students and staff. Targeted strategies include an in-school curriculum and service learning component, which impact all ninth grade students at the intervention high schools and all eighth grade students at the intervention middle schools. Intensive strategies are intended for a subset of youth and their caregivers with identified increased risk-factors, and they include peer mentoring, after-school running/positive youth development programming, summer programming, and parent workshop support.
224105800|NCT03133481|PROCEDURE|Adductor Canal Nerve Block|Adductor Canal never technique
224105801|NCT03133481|DRUG|Femoral Nerve Block|Traditional technique
224289628|NCT03474029|DRUG|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
224289629|NCT03474029|DRUG|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
223952716|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
223729524|NCT05133453|DRUG|Pirfenidone|drug intake three times daily for one year
223729525|NCT00186381|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
223952717|NCT03898505|DIETARY_SUPPLEMENT|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
223952718|NCT03898505|OTHER|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
224105802|NCT02273115|DRUG|Oxytocin|
224105803|NCT02273115|DEVICE|Transcervical Foley catheter|
224105804|NCT04348903|BEHAVIORAL|Virtual Reality Distraction|The researchers will prepare the VR device. The researches will explain the aim of using VR and adopt tell-show-do technique in introducing VR Glasses. Once VR device headset will be adapted to the child's head size and adjusted in front of his/her eyes, the selected 3D cartoon movie will be played in the waiting room and throughout the procedure of dental LA injection. After ensuring that the child is fully immersed in the cartoon movie, a needle of local anesthetic agent will be prepared and injected after explanation of the procedure.
224105805|NCT04348903|BEHAVIORAL|Positive Pre-Visit Imagery Intervention|Short narrative visual information regarding the dental chair, environment and equipment will be provided. It will be done through showing children an interactive book that contained photographs of A4 size, depicting three children model aged 4 - 6 years who are smiling while sitting in the dental chair and cooperative with the dentist. Benefit of LA in alleviating pain will be explained. The researchers also will explore the children's reflection of the children model and allow them ask questions relevant to LA injection.
224105806|NCT01409889|BEHAVIORAL|Diabetes Prevention Program|
224289630|NCT03474029|DRUG|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
224289631|NCT01523587|DRUG|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
224289632|NCT01523587|DRUG|erlotinib|erlotinib taken once daily
224289633|NCT05150418|DRUG|Oxygen gas|Oxygen 15 l/min
224289634|NCT05150418|DRUG|Air|Room air 15 l/min
224289635|NCT04959383|OTHER|Low complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept low for this group.
223729526|NCT00150449|DRUG|Pregabalin|
223952719|NCT00974805|DRUG|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
223952720|NCT03112005|PROCEDURE|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
223952721|NCT03112005|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
223952722|NCT00128765|BEHAVIORAL|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
224105807|NCT01409889|BEHAVIORAL|Healthy Living Program|
224289636|NCT04959383|OTHER|Moderate complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept moderate for this group.
224289637|NCT04959383|OTHER|High complexity Exergaming group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. Wobble board will be able to rock in all direction with Weight Transfer. Wobble board based exergame balance training group game complexity will be kept high for this group.
223723225|NCT06993142|BEHAVIORAL|Increase of physical activity volume and intensity with the use of a motivational smartphone application|A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting moderate-to-vigorous physical activity (MVPA) relative to baseline level).
223723226|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR)|The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted
223952723|NCT00128765|BEHAVIORAL|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
223952724|NCT00128765|BEHAVIORAL|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
223952725|NCT03680287|DRUG|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
223952726|NCT06100159|DEVICE|Tympanostomy tube insertion|Ventilation tube insertion in the tympanic membrane
223952727|NCT00004080|BIOLOGICAL|recombinant adenovirus-p53 SCH-58500|
223952728|NCT00004080|PROCEDURE|conventional surgery|
224105808|NCT05841849|DRUG|Aprepitant|oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3
224105809|NCT05841849|DRUG|Palonosetron|oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;
224105810|NCT05841849|DRUG|Fosaprepitant|intravenous fosaprepitant 150mg for D1 before chemotherapy
224105811|NCT00986778|DRUG|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
224105812|NCT00986778|DRUG|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
224105813|NCT00986778|DRUG|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
224105814|NCT02823912|DRUG|Capsaicin|
224105815|NCT02823912|DRUG|Magnesia calcinada|
224105816|NCT01329757|DRUG|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
224105817|NCT01329757|DRUG|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
224105818|NCT06375850|OTHER|Sesame oil|"A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air."
224105819|NCT06375850|OTHER|Saline solution|After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
224289638|NCT04959383|OTHER|Control Group|This group will receive 30 minutes of Exergame Balance Training on Modified wobble board 3 times a week for 8 weeks. This group will receive exergame balance training on Wii fit. Participants in this group will play Soccer Heading, Ski Slalom, Ski Jump, Table Tilt, Tightrope Walk, Balance Bubble, Penguin Slide and Snowboard Slalom game.
224289639|NCT01577693|DRUG|dutasteride|novel dutasteride
224289640|NCT01577693|DRUG|dutasteride|dutasteride soft gel capsule
224289641|NCT01931228|PROCEDURE|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
224289642|NCT01931228|PROCEDURE|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
224289643|NCT05656079|DRUG|Pegylated liposomal doxorubicin|Drug: Pegylated liposomal doxorubicin (35 mg/m2) will be administered by an intravenous infusion on day 1 of each21-day cycle.
224105820|NCT05689827|DRUG|Ethyl methyl hydroxypyridine succinate + Meldonium|Ethyl methyl hydroxypyridine succinate 100.0 mg/mL, meldonium dihydrate - 100.0 mg/mL (Solution for intravenous and intramuscular administration), then Ethyl methyl hydroxypyridine succinate - 250.0 mg, meldonium dihydrate based on dihydrate without adsorption moisture - 250.0 mg (oral capsules)
224105821|NCT05689827|DRUG|Placebo|Placebo was used in the same way
224105822|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
224105823|NCT02102230|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
224105824|NCT02102230|BEHAVIORAL|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
224105825|NCT04132726|OTHER|Massage therapy|Massage therapy performed by a physiotherapist
224105826|NCT04132726|OTHER|non-effective treatment|non-effective treatment
224105827|NCT00736229|DRUG|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
224105828|NCT04133324|DIAGNOSTIC_TEST|C-reactive protein|C-reactive protein at postoperative days four and two.
224105829|NCT05073289|BEHAVIORAL|Sandplay activity|The sandplay in psychiatric care, with a creative and fun approach, makes it easier for patients to verbally express their personal life stories and feelings in a safe environment, individually or as a group.
224105830|NCT05073289|OTHER|Routine Care|Routine care is the care given to the control group by the nurse to the patients in the psychiatry clinic.
223729527|NCT01124422|DRUG|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
223729528|NCT01124422|DRUG|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
223729529|NCT02086994|DRUG|misoprostol|given after the delivery of the anterior shoulder of the baby.
224105831|NCT05690321|DRUG|Opium tincture|Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
224105832|NCT05690321|DRUG|Placebo|Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
224105833|NCT00637728|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
224105834|NCT00637728|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
224105835|NCT03385668|DRUG|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
224105836|NCT03940781|BEHAVIORAL|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
223729530|NCT02086994|DRUG|carbetocin|given after delivery of anterior shoulder
224105837|NCT05225532|OTHER|Radiofrequency ablation|Radiofrequency ablation of ganglionated plexi located in the left or right atrium
224105838|NCT03172650|DIAGNOSTIC_TEST|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
224105839|NCT00184990|DRUG|Aminoguanidine|
224105840|NCT00184990|DRUG|endotoxin|
224289644|NCT05656079|DRUG|Epirubicin|Drug: Epirubicin (90 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
224289645|NCT05656079|DRUG|Cyclophosphamid|Drug: Cyclophosphamide (600 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
224289646|NCT05656079|DRUG|Trastuzumab|Drug: Trastuzumab (8 mg/kg loading dose at first day only, then 6 mg/kg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
224289647|NCT05656079|DRUG|Pertuzumab|Drug: Pertuzumab (840 mg loading dose at first day only, then 420 mg) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
224289648|NCT05656079|DRUG|Docetaxel|Drug: Docetaxel (75mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.
224289649|NCT03680079|OTHER|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
224289650|NCT05904275|DRUG|caudal epidural injection|Preoperative Ultrasound guided caudal epidural injection in lumbosacral spine surgeries for postoperative analgesia.
224289651|NCT05414864|DRUG|Ramelteon (RozeremR)|8mg daily
224289652|NCT05414864|BEHAVIORAL|sleep hygiene|sleep behavioral guidelines
224289653|NCT02306057|PROCEDURE|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
224289654|NCT02306057|PROCEDURE|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
224289655|NCT02306057|PROCEDURE|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
224289656|NCT02306057|PROCEDURE|TCPC|Surgical procedure Total CavoPulmonary Connection
224289657|NCT01298778|DRUG|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
223952729|NCT04615416|BEHAVIORAL|Emotion Regulation Training via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
224289658|NCT01298778|DRUG|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
224289659|NCT01298778|DRUG|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
223952730|NCT05906966|OTHER|Phone contact|. All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
223952731|NCT03247595|DIETARY_SUPPLEMENT|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
223952732|NCT03247595|OTHER|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
224105841|NCT05585372|OTHER|CT guided opening mobilization of cervical intervertebral foreman|"1. the patients lies in supine with his head resting comfortably at the position which cause maximum opening of the intervertebral foramen which has been determined by the 3D CT.~2. cervical lateral glide from right to left for C5, C6 and C7, Grade IV 3 × 6 on each segment.~3. Passive mobilization techniques were progressed, utilizing unilateral posteroanterior mobilization of the mid and lower cervical spine and lateral gliding movements, in both directions, progressing in duration and intensity to allow a graded exposure of load.~4. Sustained Natural Apophyseal Glides (SNAGS) were used mainly as self-treatment techniques to maintain the gains that achieved."
223952733|NCT03247595|OTHER|Dulcolax Tablets|4 Dulcolox Tablets
224105842|NCT05217862|DIAGNOSTIC_TEST|PCR for COVID-19 testing|PCR for asymptomatic adult undergoing elective cataract surgery
224289660|NCT04477551|PROCEDURE|Diode laser (device) with scaling and root planing|Combined use of diode laser device and scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
224289661|NCT04477551|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
223538638|NCT01049087|RADIATION|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
223538639|NCT06696261|DRUG|Lianxiaxiaopi Granules|The participants took orally 1 sachet of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
223538640|NCT06696261|DRUG|a simulated agent of Lianxiaxiaopi Granules|The participants took orally 1 sachet of simulated agent of Lianxiaxiaopi Granules, 3 times a day for 8 weeks.
223723227|NCT03827031|OTHER|Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up|"Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.~Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.~Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted."
223952734|NCT05331872|BIOLOGICAL|Human umbilical cord-derived mesenchymal stem cell infusion|Human umbilical cord-derived mesenchymal stem cell infusion in the management of adult liver cirrhosis
224289662|NCT04070287|COMBINATION_PRODUCT|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
224289663|NCT04070287|COMBINATION_PRODUCT|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
223723228|NCT06988566|OTHER|Intervention Group|The intervention were connected to the ECM response and coordination centre (RCC) which provided the participants with 24/7/365 access to assistance from certified RCC staff who were supported by eDoctors. Patients self-tracking activities (saturation, pulse, lung function, temperature and report on increased sputum, coughing, and shortness of breath) were monitored dayly by the RCC whoom would contact them in the event of signs of deterioration. The RCC staff together with the participant would make informed decisions, via phone or video call, on how to best manage the change in condition guided by the previous measures evaluated with graphs, including plotted trends. If there was a need for medical treatment, a treatment plan was drawn up with fixed follow-ups and a course plan.
223723229|NCT07002619|PROCEDURE|Routine cholangiography|Intraoperative cholangiography attempted regardless of indication and anatomy
223952735|NCT04919499|DRUG|BI 765128|BI 765128
223952736|NCT04919499|OTHER|Sham comparator|Sham comparator
223952737|NCT07026071|OTHER|Positional Release Technique|Positional Release Technique will be repeated 3 times in each session for each muscle with an aim to produce a decrease in perceived pain and an increase in pressure tolerance Iliopsoas Quadratus Lumborum Hamstrings
223952738|NCT07026071|OTHER|Stretching Exercises|These exercises will be performed with three repetitions per set, three sets per visit and with 30 seconds hold and 30 seconds rest Iliopsoas Quadratus Lumborum Hamstrings
223952739|NCT06699693|PROCEDURE|ultrasonography-guided PENG block|This study aimed to evaluate the effect of ultrasonography-guided PENG block prior to joint mobilization therapy on shoulder pain, function, and kinesiophobia in patients with AC resistant to conservative treatment, in comparison with a control group
223952740|NCT06699693|OTHER|Mobilization|The mobilization methods encompassed the scapula and clavicular joints, in addition to the glenohumeral (GH) joint, taking into consideration their biomechanical interactions. These exercises were supervised and administered by the physiotherapist during each session. Additionally, the patients were provided with a home exercise program that included exercises for posture, thera band, and finger ladder, with instructions to perform 10-15 repetitions twice a day independently \[
223952741|NCT06699147|DEVICE|Hyaluronic Acid (HA)|6 types of hyaluronic acid(HA) fillers that are differ in HA concentration and lidocaine were used for this study. Each type was applied to different condition or group depending on the investigators medical diagnosis
223952742|NCT06699862|BEHAVIORAL|High Intensity Interval Training|Throughout the 10-weeks intervention period, B2L-M HIIT sessions will be delivered during regular PE classes twice a week, by the schools' PE teachers. The HIIT sessions will be applied in the first 8-10 min of each PE class, including a brief warm-up involving a combination of aerobic and body weight muscle-strengthening exercises, and designed to be fun and engaging as well as vigorous in nature
223952743|NCT06699862|BEHAVIORAL|High Intensity Interval Training with Competition|Students will participate in a school competition to win points for their class for a 10-week period. In every HIIT session the heart rate will be tracked to measure the exercise intensity and also it will be used to win points for the competition. Every class will receive the same number of points as the sum of the minutes of exercise at a vigorous intensity (i.e., ≥85% max. heart rate) of each participant. This fact means that the physical fitness is irrelevant to the competition aspect, which will only consider the effort of the participants.
223952744|NCT06699329|DRUG|Enlicitide Decanoate|multiple doses, oral tablet
223952745|NCT06699329|DRUG|Semaglutide|multiple doses, oral tablet
223538641|NCT06716736|BIOLOGICAL|socket preservation using dentine graft mixed with i-PRF|surgical extraction of horizontally impacted third molar , placement of dentin graft mixed with i-PRF inside the socket , suturing
223538642|NCT06716736|BIOLOGICAL|socket preservation using bone allograft|surgical extraction of horizontally impacted third molar , placement of bone allograft inside the socket , suturing
223538643|NCT06716736|BIOLOGICAL|socket preservation using collagen cone|surgical extraction of horizontally impacted third molar , placement of collagen cone inside the socket , suturing
223952746|NCT06699537|DIETARY_SUPPLEMENT|probiotic product|During the study, subjects take one sachet of Lactobacillus rhamnosus LRa05 daily. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the intervention.
224105843|NCT02723630|DRUG|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level \>26%"
224105844|NCT02685150|DEVICE|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
223538644|NCT06715319|DRUG|OCA|OCA 5 mg once daily in combination with UDCA for 12 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
224105845|NCT02685150|DRUG|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
224105846|NCT02685150|OTHER|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
224105847|NCT00950027|DRUG|povidone iodine|oropharyngeal decontamination every 4 hours
224105848|NCT00950027|DRUG|Placebo|oropharyngeal decontamination every 4 hours
223538645|NCT06715319|DRUG|UDCA|13\~15 mg/kg/day
223538646|NCT06715319|DRUG|Placebo|Once a day (QD) by mouth (PO)
223538647|NCT06717711|DEVICE|Low-intensity Extracorporeal Shock Wave Therapy (LiESWT)|LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue.
223538648|NCT06717711|DRUG|PDE5 inhibitor (tadalafil)|Phosphodiesterase-5 (PDE5) inhibitors
224105849|NCT04036565|BEHAVIORAL|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
224105850|NCT02198144|OTHER|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
224105851|NCT00779038|DRUG|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
224105852|NCT04300725|OTHER|Video Counseling|Patients in the other study arm receive verbal + video counseling prior to their induction of labor.
224105853|NCT00537745|DRUG|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
224105854|NCT00537745|OTHER|Medication Management Therapy|Medication Management Therapy once a month.
224105855|NCT01501344|DIETARY_SUPPLEMENT|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
224105856|NCT00219180|DRUG|aliskiren|
224105857|NCT02163408|OTHER|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
224105858|NCT01231191|DRUG|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
224105859|NCT01231191|DRUG|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
224289664|NCT04070287|COMBINATION_PRODUCT|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
224105860|NCT01184989|DRUG|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
224289665|NCT04070287|COMBINATION_PRODUCT|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
224289666|NCT04070287|COMBINATION_PRODUCT|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
224289667|NCT06304909|DRUG|Dexmedetomidine injection|Dexmedetomidine group will receive 0.5 mcg/kg
223952747|NCT06699537|DIETARY_SUPPLEMENT|Maltodextrin|During the study, subjects in the control group take one sachet of maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' nasal symptoms and gut microbiota before and after the 8-week trial.
223952748|NCT06698679|OTHER|No intervention|There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.
223952749|NCT06700031|DEVICE|Inertial measurement unit|A sensor, an inertial measurement unit (IMU), will be attached to the thigh when the individual is on the postoperative ward and will be worn throughout the hospital stay. The IMU measures 7.9 x 3.2 x 0.8 cm and records body positions, movements, and gait parameters.
223952750|NCT06698965|DRUG|Chemotherapy （Etoposide and Carboplatin）|"Etoposide: 80-100mg/m2, Q3W, intravenous infusion is administered on day 1, 2 and 3 of each cycle.~Carboplatin: AUC=5, Q3W, intravenous infusion is administered on day 1 of each cycle."
224105861|NCT02242396|DRUG|Telmisartan|
224105862|NCT02242396|DRUG|Telmisartan hydrochlorothiazide|
224105863|NCT04970680|PROCEDURE|glossopharyngeal nerve block|glossopharyngeal nerve block either blindly or using the ultrasonic technique
224105864|NCT02873546|DEVICE|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
224105865|NCT04837391|DEVICE|Near Infrared Spectroscopy (NIRS)|Patients are monitored by near infrared spectroscopy before anesthesia induction until end of the operation. Graphical presentation of cerebral oxygenation during surgery evaluated by INVOS Analytics Tool Version 1.2.
224105866|NCT04837391|DIAGNOSTIC_TEST|Blood sample|Blood samples are obtained before and after surgery. S-100, Neuron specific enolase (NSE), Interleukin-6 (IL-6), High Mobility Group Box Protein (HMGB-1) are going to be studied by ELISA method after data collection process end.
224105867|NCT04837391|DIAGNOSTIC_TEST|Addenbrooke Cognitive Examination III (ACE-III)|ACE-III is administered to study participants one day before surgery, 1 week after surgery, and three months after surgery to diagnose postoperative cognitive dysfunction.
224105868|NCT04837391|DIAGNOSTIC_TEST|Confusion Assessment Method|Confusion Assessment Method is administered to study participants in postoperative recovery room to diagnose postoperative delirium.
224105869|NCT01606722|DRUG|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
224289668|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
223538649|NCT01088906|DRUG|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
223538650|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone IV drip
223538651|NCT02784340|DRUG|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
223538652|NCT02784340|DRUG|Saline (IV fluids)|IV fluids 500 cc saline infusion
223538653|NCT02784340|DRUG|Bupivicaine and Fentany|
223538654|NCT02784340|DEVICE|25G spinal needles|
223538655|NCT01580228|DRUG|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
223538656|NCT01580228|DRUG|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
223538657|NCT03758183|PROCEDURE|total knee arthroplasty|
223538658|NCT03703557|DIAGNOSTIC_TEST|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
223538659|NCT03703557|DIAGNOSTIC_TEST|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
223538660|NCT02449187|DRUG|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
223538661|NCT02449187|DRUG|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
223538662|NCT03410160|DIAGNOSTIC_TEST|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
224105870|NCT01570491|OTHER|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
223538663|NCT00457626|DRUG|Valsartan|Extemporaneous suspension of valsartan, orally.
224289669|NCT01037582|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
223538664|NCT03730519|DEVICE|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
223538665|NCT04729790|DRUG|PRIM-DJ2727|oral FMT capsules
223538666|NCT02896309|DIETARY_SUPPLEMENT|Sodium bicarbonate|
223538667|NCT02896309|DIETARY_SUPPLEMENT|Sodium chloride|
223723230|NCT07002619|PROCEDURE|Selective cholangiograpy|Intraoperative cholangiography only attempted in case of uncertainty regarding anatomy
224105871|NCT01570491|OTHER|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
223538668|NCT03279107|OTHER|Soluble corn fiber|soluble corn fiber
223538669|NCT03279107|OTHER|maltodextrin|maltodextrin
223538670|NCT01471613|PROCEDURE|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
223538671|NCT01471613|DRUG|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
223538672|NCT01471613|BIOLOGICAL|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
223538673|NCT01471613|OTHER|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
223538674|NCT04705805|BEHAVIORAL|Self-assessment of olfactory disorders through two questionnaires.|"* Assessment of sense of smell or loss of smell using an Analogue Visual Scale~* Carrying out the objective smell test (Sniffin' sticks test) (gold standard)~* Information from two self-questionnaires translated into French: a quality of life questionnaire (The Questionnaire Olfactory Disorders (QOD)) and a self-assessment questionnaire of his olfactory capacities (Self-Mini Olfactory Questionnaire (Self-MOQ))"
223538675|NCT05648812|DIAGNOSTIC_TEST|Brain contrast enhanced ultrasound, brain ultrasound elastography|To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography
223538676|NCT05648812|DRUG|Sulfur Hexafluoride|To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
223538677|NCT05120492|PROCEDURE|bariatric surgery followed by total knee replacement|The only intervention is the randomization of the priority of the 2 procedures.
223538678|NCT03906357|DRUG|Pemigatinib|
223538679|NCT05861141|OTHER|Selected physical therapy program|"Patients will receive a selected physical therapy program for 1 hr, 3 times per week, for 3 successive months in the form of:~* Balance and postural control exercises for 15 minutes, including the following:~  * Standing on balance board.~ * Stoop and recovery.~* Gait training for 45 minutes, including the following:~  * Forward, backward, and sideways walking.~ * Walking with obstacles using wedges and rolls with different diameters and heights."
224105872|NCT01582724|PROCEDURE|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
223723231|NCT07004426|PROCEDURE|Surgical treatment of renal lesions|Surgical treatment of renal lesions
224105873|NCT05575518|DRUG|Optimised rifamycin|optimised dose rifampicin with or without moxifloxacin
224105874|NCT03047213|DRUG|Sapanisertib|Given PO
224105875|NCT05434910|OTHER|Changes in mean arterial pressure|MAP set at 65 mmHg for 25 min by infusion of noradrenaline. MAP set at 80 mmHg for 25 min by infusion of noradrenaline. MAP set at 95 mmHg for 25 min by infusion of noradrenaline.
224105876|NCT01426048|OTHER|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
224105877|NCT03656640|DRUG|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
224105878|NCT03692273|PROCEDURE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
224105879|NCT03692273|PROCEDURE|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
224105880|NCT00482001|DRUG|donepezil|
224105881|NCT00482001|DRUG|Placebo (cornstarch)|
224105882|NCT00816946|BEHAVIORAL|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI \& protection against ARI"
224105883|NCT02047552|DRUG|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT \< 25%, (2) Serum iron concentration \< 150 ug/mL, and (3) Serum ferritin concentration \< 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
224105884|NCT02047552|DRUG|Oxandrolone|10 mg PO Q12 hours for seven days
224105885|NCT02047552|DRUG|IV iron placebo|100 mL normal saline
224105886|NCT02047552|DRUG|Oxandrolone placebo|similar color and size sugar pill
224105887|NCT01479790|DEVICE|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
224105888|NCT03295097|OTHER|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
224105889|NCT04468750|DEVICE|kinesiotape|During the rehabilitation program, all patients with GHS had kinesiotaping three times a week.
224105890|NCT01905735|DRUG|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
224105891|NCT01905735|DRUG|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
224105892|NCT01154725|BEHAVIORAL|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
224105893|NCT01154725|BEHAVIORAL|habitual patient education|habitual patient education
224105894|NCT01635569|BEHAVIORAL|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
224105895|NCT01635569|OTHER|Waitlist|Baseline and post-12 sessions
224105896|NCT01522495|DEVICE|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
224105897|NCT01522495|DEVICE|SPY Imaging|SPY Imaging to assess tissue perfusion
224105898|NCT01015443|BIOLOGICAL|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
224105899|NCT01015443|DRUG|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
224105900|NCT01015443|DRUG|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
224105901|NCT01015443|OTHER|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
224105902|NCT01015443|OTHER|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
223538680|NCT05861141|DEVICE|Aerobic training|"Patients will receive the same selected physical therapy program as the control group for 15 minutes in addition to treadmill training for 45 minutes, 3 times per week, for 3 successive months.~Treadmill training: Will be practiced according to the following stages:~A- Warm up: 5 minutes.~B- The exercise phase: 35 minutes (three-minute stages), the speed will be increased gradually every 3 minutes intervals until the child no longer be able to walk at the current stage.~C- Cool down: 5 minutes."
223538681|NCT03384875|DEVICE|CytoSorb|To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)
223952751|NCT06698965|DRUG|Immunotherapy （Envafolimab）|Envafolimab: 300mg, Q3W, subcutaneous injection is administered on day 1 of each cycle.
223952752|NCT06698965|DRUG|Trilaciclib|Trilaciclib: 240mg/m2, Q3W, intravenous infusion should be completed within 4 hours before daily chemotherapy
223952753|NCT06699420|DRUG|Qishenyiqi dripping pills 1 bag, three times a day|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
224105903|NCT01066416|PROCEDURE|Endoscopic Sinus Surgery|
224105904|NCT01066416|OTHER|medical therapy|Subjects will undergo surgery 6 months after randomization
224105905|NCT05760937|DRUG|BMS-986447|Specified dose on specified days
224105906|NCT05760937|DRUG|Placebo|Specified dose on specified days
224105907|NCT00380159|DRUG|Elvucitabine|Elvucitabine 10 mg in combination with background ART
224105908|NCT00380159|DRUG|Lamivudine|
224105909|NCT00380159|DRUG|Emtricitabine|
224105910|NCT05266638|OTHER|Data collection (radiological parameters, outcome information) from electronic patient files in hospital data system|Collection of medical data and medical images (MRI, radiographs) of the lumbar spine and pelvis of patients having received TLIF with degenerative spinal diseases from the years 2015-2020 and statistical analysis of the coded data.
224105911|NCT05370157|BEHAVIORAL|TeamTRACS|TeamTRACS is a team training intervention adapted from TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), a widely used evidence-based team training developed by the Agency for Healthcare Research and Quality. TeamTRACS targets knowledge, skills, and attitudes related to team member roles, shared awareness, communication, mutual support, and goal-setting. TeamTRACS is structured, easy to use, flexible in length and intensity, and requires few resources. It incorporates didactic instruction, discussion, and interactive activities and can be delivered virtually or in-person.
224105912|NCT02119208|BEHAVIORAL|Intensity and timing of exercise|
223952754|NCT06699420|DRUG|Placebo 1 bag, three times a day|Placebo, 1 bag once, three times a day, 12 months
224105913|NCT03700892|OTHER|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
224105914|NCT03700892|OTHER|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
224105915|NCT04098380|PROCEDURE|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
224105916|NCT04098380|PROCEDURE|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
224289670|NCT01037582|DRUG|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
224289671|NCT01037582|DRUG|placebo|Subjects will be randomized to receive a single dose of placebo.
224289672|NCT01037582|DRUG|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
224289673|NCT01037582|DRUG|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
224289674|NCT02804282|COMBINATION_PRODUCT|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
224289675|NCT03883282|OTHER|Not Provided|Not Provided
223952755|NCT06698913|PROCEDURE|Rotational Therapy|Sample1- Ventilator settings where adjusted with PEEP based on BMI, followed by a 2 cmH2O increase and 20 minutes in a lateral position at 30 degrees for lung recruitment for both sides. And at the end were subjected to an alveolar recruitment maneuver with pressure increases up to a plateau pressure of 45 cmH2O. Sample2- A recruitment maneuver followed by PEEP titration is performed, selecting the PEEP that is above the crossing point between the collapse and hyperdistension curves provided by EIT. And the the PEEP-ARDSNet will be selected according to the low PEEP-FIO2 table from the ARDSNet protocol. Observations are made at 4 and 24 hours, with PEEP at 24 hours adjusted to the level identified by EIT.
224105917|NCT04300218|BEHAVIORAL|internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)|"The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study."
224105918|NCT04300218|OTHER|Care as usual (CAU)|Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
224105919|NCT00414622|DRUG|DMXB-A|
224105920|NCT04293250|PROCEDURE|Compare the severity of postoperative pain of the physical activity group Vs non-physical activity group|Compare postoperative pain scores for the physical activity Vs non-physical activity group
224105921|NCT01304862|BEHAVIORAL|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
224105922|NCT01304862|BEHAVIORAL|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
223952756|NCT06699407|DRUG|Qishenyiqi dripping pills|Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
223952757|NCT06699407|DRUG|Placebo|Placebo, 1 bag once, three times a day, 12 months
223952758|NCT06698393|PROCEDURE|Suture 3.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 3.0 Diameter.
224105923|NCT03583424|DRUG|Carmustine|Given IV
224105924|NCT03583424|DRUG|Cytarabine|Given IV
224105925|NCT03583424|DRUG|Etoposide|Given IV
224105926|NCT03583424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
224105927|NCT03583424|DRUG|Melphalan|Given IV
224105928|NCT03583424|DRUG|Venetoclax|Given PO
224105929|NCT02556879|BIOLOGICAL|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
224105930|NCT02556879|BIOLOGICAL|Serum bank|Additional samples for serum bank at each visit if possible
224105931|NCT02556879|BIOLOGICAL|DNA bank|Additional sample for DNA bank at inclusion visit if possible
224105932|NCT02556879|PROCEDURE|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
224105933|NCT02556879|PROCEDURE|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
224105934|NCT06227923|DEVICE|PRO-HOME intervention|Patients are transferred to the apartment inside the hospital setting and are evaluated and assessed also using technological devices
224105935|NCT01144637|BIOLOGICAL|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
224105936|NCT01144637|OTHER|Placebo|0.5 ml TBS
224105937|NCT00258154|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
223538682|NCT04608019|OTHER|Immediate Antibiotics|increase airway clearance/start oral antibiotics right away
224105938|NCT00258154|BIOLOGICAL|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
224105939|NCT00258154|BIOLOGICAL|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
224105940|NCT04870151|PROCEDURE|Anterolateral approach|Cemented hemiarthroplasty using an anterolateral approach.
224105941|NCT04870151|PROCEDURE|Direct lateral approach|Cemented hemiarthroplasty using a direct lateral approach.
224105942|NCT04402502|DEVICE|Ultrasound Imaging|The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
224289676|NCT00489281|DRUG|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
224289677|NCT00489281|DRUG|Fludarabine|Fludarabine 30 mg/m\^2/day IV on Days -6, -5, -4, -3, and -2.
224105943|NCT01983891|OTHER|Cooking course|6-week nutrition education and cooking course
224105944|NCT05641649|DRUG|Sodium valproate and valproic acid extended release tablet|Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
224105945|NCT03731793|BIOLOGICAL|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
224105946|NCT03731793|OTHER|Placebo|Placebo
224105947|NCT01941225|DRUG|Inhaled iloprost 5.0 mcg|Single administration
224105948|NCT01941225|DRUG|Placebo|Single administration
224105949|NCT04276558|DRUG|Udonitrectag|Eye drop solution in single dose unit.
224105950|NCT04276558|OTHER|Vehicle|Eye drop solution with no active substance in single dose unit.
224105951|NCT05797129|DEVICE|CEDM|Women underwent CEDM screening
223994565|NCT06231537|DIAGNOSTIC_TEST|Visual oral examination|"Oral preventive examinations in the three groups will be conducted over a one-year period. Individuals with oral injuries will be referred to stomatology, aligning with the existing protocol. Histopathological examinations of the biopsied lesions will be performed at the Oral Pathology Laboratory of the Faculty of Dentistry at the Federal University of Rio de Janeiro, following the established procedures.~Users diagnosed with malignancy will be directed to receive treatment at the reference hospital, with monitoring carried out by the Basic Health Unit responsible for coordinating care, in accordance with the current protocol.~In addition to histopathological examinations, the Faculty of Dentistry will be available to conduct a physical examination and biopsy if the user is not attended to by the Municipal Health Department. This additional resource ensures comprehensive care for individuals who may not have immediate access to municipal health services."
224105952|NCT05450068|OTHER|Mulligan's Mobilization with movement|The Mulligan's technique will be performed as described by Brian Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets.
224105953|NCT05450068|OTHER|Spencer's muscle energy technique|Muscle energy technique that is composed of 7 stages repeated on after the other will be performed. Each movement will be repeated 10 times with 1 minute rest between each set.
224105954|NCT05450068|OTHER|Conventional Therapy|Electrotherapy-Ultrasound (5-10 mins), Exercise therapy program (isometric, capsular stretching, pectoral stretch and scapular stabilization exercises)
224105955|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
224289678|NCT00489281|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
224289679|NCT00489281|DRUG|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
223538683|NCT04608019|OTHER|Tailored Treatment|increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
223538684|NCT03549338|DRUG|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
223538685|NCT03549338|DRUG|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
223538686|NCT03549338|DRUG|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
224105956|NCT00754390|DIETARY_SUPPLEMENT|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
223538687|NCT04587037|PROCEDURE|fascia lata allograft|underwent superior capsule reconstruction using fascia lata allograft
223538688|NCT04587037|PROCEDURE|human dermal allograft|underwent superior capsule reconstruction using human dermal allograft
223538689|NCT01761708|PROCEDURE|primary ventral hernia repair with mesh|
223538690|NCT00360958|PROCEDURE|ultrafiltration|
224105957|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
224105958|NCT00754390|DIETARY_SUPPLEMENT|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
224105959|NCT00455637|BIOLOGICAL|Botulinum toxin type A|
224105960|NCT00322114|DIETARY_SUPPLEMENT|lycopene|Given orally
224105961|NCT00322114|OTHER|placebo|Given orally
224105962|NCT01532661|OTHER|observational study|data collected by investigators
224105963|NCT01009294|DRUG|Ataluren|Oral powder
224105964|NCT01009294|DRUG|Chronic Corticosteroid Therapy|Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
224289680|NCT00489281|PROCEDURE|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
224289681|NCT00489281|RADIATION|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
224289682|NCT00489281|DRUG|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
224289683|NCT00489281|BIOLOGICAL|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
223538691|NCT02539186|BIOLOGICAL|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
224105965|NCT04537442|DRUG|IM21 CAR-T cells|"IM21 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days~Other Names:~Fludarabine Cyclophosphamide"
223538692|NCT02539186|DEVICE|splint|
224105966|NCT02716376|DEVICE|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
224105967|NCT04155879|DRUG|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
224105968|NCT04155879|PROCEDURE|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
224289684|NCT00489281|RADIATION|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
223994566|NCT02466347|DRUG|Fluticasone propionate|Inhaled corticosteroid, pMDI
223994567|NCT02466347|DRUG|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
223994568|NCT01301599|DRUG|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
223994569|NCT01301599|DRUG|alpha blocker monotherapy|alpha blocker monotherapy group
223994570|NCT01301599|DRUG|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
223994571|NCT03648528|DRUG|cholecalciferol|
223994572|NCT03648528|DRUG|placebo|
224289685|NCT00792519|BEHAVIORAL|HIV support group|group support
223994573|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
224289686|NCT00792519|BEHAVIORAL|CBT|group cognitive behavioral treatment
224105969|NCT00198705|BEHAVIORAL|Improved management of severe neonatal infections|
224105970|NCT02756871|OTHER|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
224289687|NCT04471402|DRUG|Precedex|Intranasal Precedex 3mcg/kg
224289688|NCT00641784|DRUG|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
224289689|NCT00641784|DRUG|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
224289690|NCT03513042|RADIATION|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
224289691|NCT01481870|DRUG|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
224289692|NCT01481870|DRUG|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
224289693|NCT05767736|DRUG|Diroximel Fumarate|Administered as specified in the treatment arm.
224289694|NCT05767736|DRUG|Dimethyl Fumarate|Administered as specified in the treatment arm.
224289695|NCT05767736|DRUG|Disease-Modifying Therapies (DMTs)|Administered as specified in the treatment arm.
223538693|NCT00878267|BEHAVIORAL|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
223538694|NCT02944838|BEHAVIORAL|Senior Change Makers Advocacy Program|see description
223538695|NCT02944838|BEHAVIORAL|Senior Change Makers Physical Activity Program|see description
223538696|NCT03091790|DEVICE|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
223538697|NCT03091790|DEVICE|Biologic Mesh|Biologic mesh used during open ventral hernia repair
223538698|NCT06038292|RADIATION|DXA Scan|DEXA (dual x-ray absorptiometry) Scans which measure bone density (thickness and strength of bones) by passing a high and low energy x-ray beam (a form of ionizing radiation) through the body, usually in the hip, the spine and the bones of the hands and can easily diagnose osteoporosis.
223538699|NCT04337242|BEHAVIORAL|B-DIT|Blended Dynamic Interpersonal Therapy
223538700|NCT04337242|BEHAVIORAL|B-CBT|Blended Cognitive Behavioral Therapy
223538701|NCT04337242|BEHAVIORAL|DIT|Dynamic Interpersonal Therapy
223538702|NCT04337242|BEHAVIORAL|Cognitive Behavioral Therapy|CBT
223538703|NCT03702179|DRUG|Durvalumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
223538704|NCT03702179|DRUG|Tremelimumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to \>30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
223538705|NCT03702179|RADIATION|Radiotherapy|Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
223538706|NCT04633330|DRUG|AHCC®capsules|AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
223538707|NCT04633330|DRUG|Simulation of AHCC®capsules|TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
224105971|NCT06297304|BEHAVIORAL|Sedentary and physical activity behaviors|The intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: Week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to sedentary behaviors and the physical activity levels will be recorded to assess the progress of each student.
224105972|NCT01856673|BEHAVIORAL|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
224105973|NCT01856673|BEHAVIORAL|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
224289696|NCT06504147|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
224289697|NCT03897647|DEVICE|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
224289698|NCT02057445|DRUG|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
223538708|NCT04287972|PROCEDURE|DPC|The anterior fat pad is dissected until the left crura is visible, pars flaccida is open and the right crura exposed. Phreno-oesophageal ligament is sectioned starting from the right crura. Posterior and anterior vagal nerve are recognized before the oesophageal dissection. An intra-abdominal oesophagus lengths of 2 or 3 cm is obtained in order to reduce tension. Left and right crura are sutured with 2 or 3 non absorbable 2-0 stitches; an additional anterior stitch is posed if necessary to calibrate hiatus size without oesophageal deviation.
223538709|NCT04287972|PROCEDURE|LSG|After omental section close to gastric insertion, gastric stapling is realised with triple line endo stapler (normally 5 or 6 re-loads). The gastrectomy begins 5-6 cm from the pylorus; gastric fundus is totally resected keeping a distance of 5-10 mm from oesophagus. Any bleeding on staple line is controlled with surgical clips or coagulator.
223538710|NCT05522686|OTHER|Patients in the Brochure Education Group|Patients in the Brochure Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. Patients reviewed the brochure and at the end of the education, it was given to them.
223538711|NCT05522686|OTHER|Patients in the Video Education Group|Patients in the Video Education Group were informed about urodynamics in a room reserved for education. Patients watched the educational video on a computer. The urodynamics patient education video was shown to patients once during the session. They did not request to watch it again.
223952759|NCT06698393|PROCEDURE|Suture 6.0 Group|The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained.The harvesting of the epithelial-connective graft will be performed at the la. The de-epithelialised graft will be sutured at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable Polyamide Suture of 6.0 Diameter.
223952760|NCT05934175|BEHAVIORAL|Intensive treatment with prolonged exposure|Intensive treatment with prolonged exposure
223952761|NCT05934175|BEHAVIORAL|Weekly delivered prolonged exposure|Weekly delivered prolonged exposure sessions for 15 weeks
224289699|NCT02057445|OTHER|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
224289700|NCT02794935|OTHER|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
223952762|NCT05406713|DRUG|Pembrolizumab|400 mg intravenously
223538712|NCT05522686|OTHER|Patients in the Brochure-Supported Video Education Group|Patients in the Brochure-Supported Video Education Group were given information about urodynamics in a room reserved for education, and the education brochure was introduced. They examined the brochure and watched the educational video on a computer.
223538713|NCT05522686|OTHER|Control Group|Patients in this group were given routine clinical information by the healthcare professional that would perform the urodynamics procedure. After patients were given verbal information, a written text containing the necessary preparations for urodynamics was given to them. The routine patient information text included adjustment to the appointment day and time, nutrition, mechanical bowel preparation, and medications necessary for the procedure.
223952763|NCT06911788|DRUG|Vepdegestrant (Reference)|Participants will receive a single intravenous (IV) dose of Vepdegestrant on Period 1 Day 1
223952764|NCT06911788|DRUG|Vepdegestrant (Test)|Participants will receive a 200 mg single oral dose of Vepdegestrant tablet formulation on Period 2 Day 1
223952765|NCT06910293|DIAGNOSTIC_TEST|Functional Magnetic resonance imaging will be done on day 2 or 3 of the menstrual cycle, trigger-shot and egg retrieval.|Functional Magnetic resonance imaging will be done on day 2 or 3 of the menstrual cycle, trigger-shot and egg retrieval.
223952766|NCT06276660|OTHER|BCTT|"Participants will complete the Buffalo Concussion Treadmill Test, which involves individuals walking at 5.8 km/hr. (3.6 mph) at a 0.0% incline (5.1 km/hr. \[3.2 mph\] if below 5' 10 tall), the treadmill incline is increased 1 degree each minute for the first 15 minutes, then speed increased 0.64 km/hr. (0.4 mph) each minute thereafter."
223994574|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
223994575|NCT02209181|DRUG|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
223994576|NCT02209181|DRUG|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
223994577|NCT01712269|PROCEDURE|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
223994578|NCT01657747|OTHER|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
223994579|NCT04727983|DEVICE|Electrotherapy|The first group will be given Neuromuscular Electrical Stimulation (NMES) and lifestyle suggestions (LSS) (NMES group)
223994580|NCT04727983|DEVICE|Sham Electrotherapy|The second group will be given sham NMES in addition to LSS (SHAM ES group)
223538714|NCT03085901|DEVICE|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
223538715|NCT03085901|DEVICE|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
223538716|NCT04943237|DRUG|Anti-TNF agents|Group of patients using anti-TNF for the last 5 years.
223994581|NCT00343993|DEVICE|noninvasive positive pressure ventilation|
223994582|NCT03000790|DEVICE|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
223994583|NCT05716568|OTHER|Contrast dose reduction, CT-angiography|Contrast dose reduction for CT-angiography in pre-operative aorta
223994584|NCT00920647|OTHER|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
224105974|NCT01856673|OTHER|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
224105975|NCT04803812|OTHER|"Remote SMS (short message service, also known as text message) delivery"|Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
224105976|NCT01310738|DRUG|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
224105977|NCT01310738|DRUG|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
224105978|NCT01310738|DRUG|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
224105979|NCT01310738|DRUG|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
224105980|NCT01310738|DRUG|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
224105981|NCT04696406|DEVICE|RESPINOR DXT|Blinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.
224105982|NCT04332419|DEVICE|PET/CT|Standard Imaging
224105983|NCT04332419|DEVICE|PET/MR|Additional Imaging
224105984|NCT04332419|RADIATION|SIRT with Y-90|SIRT with Y-90 for palliative treatment of the liver malignancy.
224105985|NCT05981521|DIAGNOSTIC_TEST|Optimo prenatal screening test|Prenatal screening test done between weeks 11 and 13 of pregnancy to detect conditions such as trisomy 13, 18 and 21
224105986|NCT01845389|DEVICE|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
224105987|NCT01845389|DEVICE|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
224105988|NCT00172380|DRUG|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
224105989|NCT04129723|OTHER|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
224105990|NCT03020693|PROCEDURE|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
224105991|NCT03020693|PROCEDURE|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
223538717|NCT04943237|DRUG|Conventional therapy users for the last 5 years|Group of patients not using anti-TNF. Group of patients using conventional therapy (non -steroid anti-inflammatory drugs and/or salazopyrin) for the last 5 years
223538718|NCT02772029|DRUG|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
224105992|NCT02131701|BEHAVIORAL|Physical activity|
224105993|NCT02386423|DEVICE|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
224105994|NCT02197962|DEVICE|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
224105995|NCT02197962|DEVICE|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
224105996|NCT03693027|DIETARY_SUPPLEMENT|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
224105997|NCT03693027|DIETARY_SUPPLEMENT|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
224105998|NCT05804110|OTHER|Mindful Caring Education Program|A four-session education plan was prepared under the nature of action research. The Theory of Unitary Caring Science is transferred to practice through Caritas processes. In this context, ten Caritas processes and caring-healing modalities (meditation, reflection, etc.) were used in the study. The pilot study was carried out with six nurses face-to-face. The education program was conducted on an online platform. Each education took approximately 2.30-3 hours. The evaluation process in action research is an essential part of the change.
224105999|NCT01411540|DIETARY_SUPPLEMENT|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
224106000|NCT04634162|DRUG|Cangrelor|Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
223952767|NCT06276660|OTHER|Dynamic ExIT|The modified EXiT test will complete a 12 minute treadmill interval program followed by a dynamic circuit (10 squat jumps, 10 side to side push ups and 10 medicine ball rotations), jump ball toss, zig zag agility and arrow agility. Parameters will be recorded the same as the established dynamic EXiT test; heart rate and RPE will be recorded at 0, 2, 6:30 and 12 minutes of the treadmill program as well as after the second trial of each activity. The time to complete two trials of the zig zag agility and arrow agility will also be recorded.
224106001|NCT04634162|DRUG|Placebo|Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
224106002|NCT04222725|DRUG|TRS01 eye drops|Dosed 4 times a day (QID)
224106003|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
224106004|NCT04222725|DRUG|TRS01 eye drops|Dosed QID
224106005|NCT04222725|DRUG|Placebo eye drops|Dosed QID
224289701|NCT02794935|OTHER|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
223952768|NCT06952270|OTHER|plyometric exercise|Upper limb plyometric exercise (proprioceptive neuromuscular facilitation of extensor and flexor pattern, external rotation exercise at 90º-90º, chest throw, external rotation and overhead and wall flexion).
223952769|NCT06952270|OTHER|Strength training exercise|Strength training exercises (Squats, Stair climbing and jumps, Bench Press, Push-ups, Core Exercises (Plank, Bridge)).
223952770|NCT06317168|DIAGNOSTIC_TEST|Mean awake ambulatory BP measurements|Results from all four arms will be compared to the mean awake ambulatory BP measured on the same arm and started immediately following completion of the testing protocol.
224106006|NCT04937166|BIOLOGICAL|DSP107|DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
224106007|NCT04937166|DRUG|Azacitidine|Azacitidine is an analog of the pyrimidine nucleoside cytidine.
224106008|NCT04937166|DRUG|Venetoclax|Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
223538719|NCT01944020|DEVICE|CPAP|use of CPAP each night for 2 months
223538720|NCT00602693|BIOLOGICAL|umbilical cord blood transplantation|Infusion of umbilical cord blood
223538721|NCT00602693|DRUG|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
223538722|NCT00602693|DRUG|fludarabine phosphate|40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
223538723|NCT00602693|DRUG|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
223538724|NCT00602693|RADIATION|Total body irradiation|200 cGy on Day -1
223538725|NCT00602693|BIOLOGICAL|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.
223538726|NCT00602693|DRUG|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
223538727|NCT03793621|DRUG|BI 730357|single rising oral dose
223538728|NCT03793621|DRUG|Placebo|single rising oral dose
223538729|NCT02164526|OTHER|Routine therapy|Routine therapy
224106009|NCT02843711|GENETIC|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
224106010|NCT04241029|DIETARY_SUPPLEMENT|IDOFORM®Travel|Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
224106011|NCT06965933|PROCEDURE|ESP block group|The patient will undergo an ESP blockade under the control of ultrasound during the implementation of anesthetic support. A local anesthetic will be injected into the fascial space of the muscles straightening the spine: ropivacaine 0.375%, 3 mg / kg, on both sides.
224106012|NCT06965933|DRUG|IV Lidocaine|During the implementation of anesthetic support, the patient will receive a constant intravenous infusion of lidocaine: a loading dose of 1.5 mg/kg/ h (1 hour), followed by an infusion of 1 mg/kg/h for 24 hours during the perioperative period.
224106013|NCT02252861|OTHER|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
224289702|NCT02540447|PROCEDURE|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
224106014|NCT04925570|DEVICE|W-SUDs|Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
223952771|NCT04129450|OTHER|Group medical visits with mindfulness-based stress reduction|Eight weekly 90 minute sessions of mindfulness-based stress reduction in group medical visits
223952772|NCT04129450|OTHER|Usual PCP care|Usual one on one PCP care for chronic lower back pain
223952773|NCT05241873|DRUG|BLU-451|BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
223952774|NCT05241873|DRUG|Carboplatin|Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
223952775|NCT05241873|DRUG|Pemetrexed|Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
223952776|NCT02609789|DRUG|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
223952777|NCT02609789|DRUG|Placebo|0.9 percent (%) normal saline.
223538730|NCT04482725|OTHER|Trial product 1|Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
223952778|NCT05267951|DEVICE|Open-loop Stimulation|Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.
223952779|NCT05267951|DEVICE|Close-loop Stimulation|Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.
223952780|NCT05267951|OTHER|Functional Task Practice|Exercise therapy consists of repeated functional hand and arm movements
223952781|NCT04744935|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser, with surface temperature monitored by infrared camera.
223952782|NCT05298124|DEVICE|Transcatheter edge-to-edge repair|Transcatheter edge-to-edge repair
223952783|NCT05298124|OTHER|Medical therapy|Medical treatment in an intensive care unit
223952784|NCT04369664|DRUG|Statin|Participants will be given up to 80 mg oral tablets daily for the entire study period preferably at the same time each day.
223952785|NCT04369664|DRUG|PCSK9 inhibitor|Participants will receive 2 injections of 140 mg of PCSK9 inhibitor, one will be administered at baseline visit and the other will be self-administered 2 weeks later at home.
223952786|NCT04369664|DRUG|Ezetimibe 10mg|Participants who are not able to or not willing to take atorvastatin will be given 10 mg ezetimibe oral tablets daily for the entire study period preferably at the same time each day.
223952787|NCT01298219|DRUG|Lubiprostone|24 mcg administered orally twice daily (BID)
223952788|NCT01298219|DRUG|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
223952789|NCT03840200|DRUG|Ipatasertib|Ipatasertib will be administered orally.
223952790|NCT03840200|DRUG|Rucaparib|Rucaparib will be administered orally.
223952791|NCT05522777|OTHER|Drink one bottle of Yakult a day|Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota
223952792|NCT04105764|DRUG|Rocuronium|DEEP block to PTC 1-3
223952793|NCT04105764|DRUG|Rocuronium bromide|MODERATE block to TOF1-2
223952794|NCT04620122|OTHER|Progressive Muscle Relaxation Training and Music Therapy|Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
223952795|NCT02248753|DRUG|Pharmacological cardioversion - Flecainide|
223952796|NCT02248753|PROCEDURE|Electrical cardioversion|
223952797|NCT02248753|DRUG|Metoprolol|
223952798|NCT02248753|DRUG|Verapamil|
223952799|NCT02248753|DRUG|Digoxin|
223952800|NCT02248753|DRUG|Pharmacological cardioversion - Amiodarone|
223952801|NCT05230823|BEHAVIORAL|CR with added BWLT|12 week outpatient cardiac rehab (CR) program consisting of twice-weekly supervised exercise and risk factor modification (e.g. smoking cessation, support with medication). Concurrently, the patients will attend a weekly behavioural weight loss treatment (BWLT). Weekly goal-setting facilitated by the interventionist will focus on behavioural changes in nutrition and moderate calorie reduction while also emphasizing physical activity consistent with an individualized CR exercise prescription. Patients will track caloric intake, weekly exercise, weekly weight, and success/challenges with other health goals (e.g., challenging negative thoughts, body image, mindful eating, etc.) using a daily health diary. ASPIRE-AF will be delivered virtually to small groups (8-12 patients) by senior PhD students with advanced training in cognitive-behavioural therapy and motivational communication principles.
223952802|NCT06791018|OTHER|Exercise|Participants will be asked to use a cancer-specific exercise mobile app for 12 weeks. The program is designed to achieve the goal of exercising for at least 90 minutes per week, including aerobic exercise three times a week and resistance training twice a week. While exercise equipment is not required, the app supports the optional use of an elastic resistance band or a pair of dumbbells. The app comes with various features to support the exercise journey. Participants will be able to track their progress through periodic testing, access a library of resources that includes information on exercise, and log any additional workouts they perform outside the app. The exercise prescription will be tailored to daily fatigue levels that will be rated before each workout. This ensures that the program is customized to meet individual needs and abilities.
223952803|NCT02452008|DRUG|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
223952804|NCT02452008|DRUG|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
223952805|NCT06187350|DEVICE|AI cancer detection system|The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score \> 7 will be double-reviewed as normal.
223538731|NCT04482725|OTHER|Trial product 2|Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
223538732|NCT04482725|OTHER|Trial product 3|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
223538733|NCT04482725|OTHER|Trial product 4|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Glycerol 22.0 mg/mL
223538734|NCT04482725|OTHER|Trial product 5|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Mannitol 44.0 mg/mL
223538735|NCT04482725|OTHER|Trial product 6|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Sucrose 82.0 mg/mL
223952806|NCT02907502|DIETARY_SUPPLEMENT|Young-child formula with low protein content|Young-child formula with low protein content
223952807|NCT02907502|DIETARY_SUPPLEMENT|Young-child formula with protein content similar to that of cow's milk|Young-child formula with protein content similar to that of cow's milk
223538736|NCT04482725|OTHER|Trial product 7|Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: a,a-Trehalose, dihydrate 90.0 mg/mL
223538737|NCT04482725|OTHER|Trial product 8|Buffering agent: Disodium hydrogen phosphate dihydrate 5.34 mg/mL Isotonic agent: NaCl 6.72 mg/mL
223538738|NCT04482725|OTHER|Trial product 9|Buffering agent: Tris 2.4 mg/mL Isotonic agent: Propylene glycol 19 mg/mL
223538739|NCT04482725|OTHER|Trial product 10|Buffering agent: Glutamic acid 0.74 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
223538740|NCT04482725|OTHER|Trial product 10|Buffering agent: Sodium Acetate, trihydrate 0.68 mg/mL Isotonic agent: Glycerol 24.0 mg/mL
223538741|NCT04482725|OTHER|Trial product 12|Buffering agent: Glutamic acid 0.46 mg/mL, Disodium hydrogen phosphate, dihydrate 2.00 mg/mL Isotonic agent: Glycerol 15 mg/mL, NaCl 2.5 mg/mL
223952808|NCT04142398|OTHER|Cytology Specimen Collection Procedure|Undergo penile skin cell and anal swab collection
223952809|NCT04142398|PROCEDURE|High Resolution Anoscopy with Biopsy|Undergo HRA with biopsy
223952810|NCT04142398|OTHER|Laboratory Biomarker Analysis|Correlative studies
223952811|NCT04142398|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
223952812|NCT04142398|PROCEDURE|Physical Examination|Undergo targeted physical exam
223952813|NCT04142398|OTHER|Questionnaire Administration|Ancillary studies
223952814|NCT02372734|OTHER|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
223952815|NCT05755698|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
223952816|NCT03380143|BEHAVIORAL|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
223952817|NCT03380143|BEHAVIORAL|Standard Practice|Community development intervention
223952818|NCT05513417|DEVICE|Bloom Pod|Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
223952819|NCT05504720|DRUG|Pembrolizumab|200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications
223952820|NCT05504720|DRUG|Trastuzumab|loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications
223952821|NCT05504720|DRUG|FLOT|Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
223952822|NCT03497156|DRUG|Lercanidipine|Patients are tested for their normal prescription lercanidipine medication
223952823|NCT05489770|DIETARY_SUPPLEMENT|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid|Sambucol® Black Elderberry Original (Sambucus nigra) Liquid has been used as a supplement since 1991 with no reports of adverse effects received by the Manufacturer.
223538742|NCT00815386|DEVICE|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
223538743|NCT04638751|DRUG|Immunotherapy|Checkpoint inhibitor
223538744|NCT04638751|DRUG|Chemotherapy|Any form of chemotherapy
223538745|NCT04638751|PROCEDURE|CRC surgical resection|Surgical resection to remove colorectal cancer
223538746|NCT04638751|PROCEDURE|Colonoscopy|Standard-of-care colonoscopy for CRC screening
223538747|NCT02367963|BEHAVIORAL|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
223538748|NCT02367963|BEHAVIORAL|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
223538749|NCT06110403|DRUG|TRIXEO AEROSPHERE|BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
223538750|NCT02969642|DEVICE|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
223538751|NCT03257358|DRUG|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
223538752|NCT00251836|PROCEDURE|Laparoscopic hand-assisted donor nephrectomy|
223538753|NCT03048201|DEVICE|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
223538754|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
223723232|NCT07002385|BEHAVIORAL|control group|The control group received standard psychiatric care, which involved physician-led management following clinical guidelines for geriatric disease treatment, including routine medication prescriptions based on diagnostic results. At diagnosis, healthcare providers informed caregivers about the confirmed disease entity, clinical status, and necessary precautionary measures. Monthly mental health lectures were conducted for all patients, covering topics such as common psychological symptoms and coping strategies. Post-discharge, monthly outpatient follow-ups included blood pressure and glucose monitoring. Medication dosages were adjusted if patients reported changes in somatic symptoms.
223952824|NCT05489770|DIETARY_SUPPLEMENT|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra)|Placebo for Sambucol® Black Elderberry Original (Sambucus nigra) Liquid Constituents: 70% (w/w) of glucose syrup, Flavouring agent: Elderberry Blossom
224106015|NCT04925570|OTHER|Digitally-delivered Psychoeducation|A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.
223952825|NCT04276259|DRUG|Buprenorphine|Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~6 hours) and an oral placebo tablet.
224289703|NCT04776057|OTHER|catarct surgery with toric intra ocular lenses|rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
224289704|NCT05286840|DIAGNOSTIC_TEST|64Cu-SAR-bisPSMA|Diagnostic PET/CT imaging agent targeted for Prostate Specific Membrane Antigen (PSMA)
224106016|NCT00658333|DRUG|Enteric-coated Mycophenolate Acid (EC-MPA)|
224106017|NCT00658333|DRUG|Mycophenolate Mofetil (MMF)|
224106018|NCT00658333|DRUG|Placebo MMF|
224106019|NCT00658333|DRUG|Placebo EC-MPA|
224289705|NCT00604201|BIOLOGICAL|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
223952826|NCT04276259|DRUG|Naltrexone|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate reward learning signals to understand placebo effects in participants with depression. In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride (ReVia®. Toronto, ON: Teva Canada Limited; 2015) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~24 hours) and a saline IM injection.
223952827|NCT04276259|DRUG|Oral Placebo|Oral placebo: to match the oral naltrexone.
223952828|NCT04276259|DRUG|IM Placebo|IM saline placebo: to match the i.v. buprenorphine.
223538755|NCT03048201|DEVICE|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
223538756|NCT03048201|DEVICE|Physica Cruciate Retaining Knee System with LMC Liner|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
223538757|NCT04843631|DRUG|BFI-751|Single use vial, solution
223538758|NCT04843631|DRUG|EU-STELARA®|Pre-filled syringe, solution
223538759|NCT04843631|DRUG|US-STELARA®|Pre-filled syringe, solution
223952829|NCT04276259|DEVICE|Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.|Participants will receive two blocks of each TBS form. During the first block, stimulation intensity will be gradually escalated in 5% increments (from 80% to 110% rMT) in order to enhance tolerability. In all conditions, the investigators will apply 600 pulses of theta burst at 110% RMT. Each block of iTBS will consist of 20 trains, each lasting 2s with intertrain intervals of 8s, for a total of 192s. Each block of cTBS will consist of one continuous train of 40s. The sTBS will make use of two surface electrodes placed on the scalp.
224106020|NCT05802914|DEVICE|Back Exosuit|The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
224106021|NCT04210492|RADIATION|45 Gray (Gy) regimen|Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
223538760|NCT05747274|DEVICE|SRDK0921|SRDK0921 is an IVD composed of IVD kit for qPCR (SRDK0921KIT) and a cloud-based software (SRDK0921SOFT). It is a class C, rule 3k, IVD according to Regulation (EU) 2017/746.
223538761|NCT03218774|BEHAVIORAL|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
224106022|NCT04620603|RADIATION|Low Dose Rate Brachytherapy (LDR)|LDR on treatment day 1
224106023|NCT04620603|DRUG|Standard-of-Care Immunotherapy|Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
224106024|NCT04977544|DEVICE|vert|On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.
224106025|NCT04977544|DRUG|Sertraline|Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
224106026|NCT06048159|DEVICE|HD-tACS|High definition tACS will be applied during speech therapy.
224106027|NCT06048159|DEVICE|Sham HD-tACS|Sham high definition tACS will be applied during speech therapy.
224106028|NCT02971358|PROCEDURE|Radical prostatectomy|Standard radical prostatectomy with extended lymph node dissection is performed.
224106029|NCT06970626|DRUG|Dexmedetomidine infusion|Dexmedetomidine will be maintained at 0.5 μg/kg/h ideal body weight via a syringe pump until trocar removal.
224289706|NCT00789763|DRUG|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
224289707|NCT00789763|RADIATION|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
224289708|NCT00789763|DRUG|Sorafenib|200-800 mg/day p.o. during 5 weeks
224289709|NCT04719741|OTHER|Parallel Assignment|Prospective, Triple blinded, randomized, controlled trial
224289710|NCT01626963|PROCEDURE|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
224289711|NCT01626963|PROCEDURE|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
224106030|NCT06970626|PROCEDURE|Paragastric neural block|Paragastric neural block (PGNB) will be administered using a 25-gauge needle attached to a venous catheter extension, introduced through the left 12 mm port. Infiltration of 20 mL undiluted 0.5% bupivacaine will be performed at six levels in the fatty tissue of the paragastric area, including the lesser omentum, vagus nerve, esophago-gastric junction, proximal stomach, mid-stomach, distal antrum, hepatic artery, and left gastric artery, with the needle cap removed under direct vision throughout the procedure.
224106031|NCT06970626|PROCEDURE|Laparoscopic Transversus Abdominis Plane (LTAP) block|LTAP will be administered after insufflation before insertion of the right and left-handed ports. 30 mL of 0.25% bupivacaine will be injected into the posterolateral subcostal regions on both sides. The correct placement will be confirmed by observing the spread of fluid between the transversus abdominis and the internal oblique muscle layers laparoscopically
224106032|NCT06971562|DEVICE|Aquacel AG|Hydrocellulose wound dressing containing 1.2% cationic silver
224106033|NCT06971562|DEVICE|Aquacel|Hydrocellulose wound dressing
224106034|NCT06971315|DIETARY_SUPPLEMENT|Vitamin C|Three doses of 900 mg vitamin C taken orally (baseline, 12 hours and 24 hours)
224106035|NCT06971315|OTHER|Placebo|Three doses of 900 mg placebo taken orally (baseline, 12 hours and 24 hours)
224289712|NCT05202041|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
224289713|NCT05202041|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
223538762|NCT03218774|BEHAVIORAL|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
223538763|NCT02986633|OTHER|Echocardiography|
224106036|NCT06970457|BEHAVIORAL|Resistance Exercise Training|12-week progressive and individualized resistance exercise training program
224106037|NCT06970457|BEHAVIORAL|Aerobic Exercise Training|12-week progressive and individualized aerobic exercise training program
224106038|NCT06970444|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging non-invasive therapy that modulates brain activity by delivering electrical impulses to the auricular branch of the vagus nerve at the outer ear (Badran et al., 2018). taVNS subsequently stimulates the nucleus of tractus solitarius via the afferent vagus nerve fibers. The nucleus solitarius sends outputs to the hypothalamus, which is critical for sensory processing, including auditory processing, and also activates various brain regions, including the locus coeruleus, resulting in the release of neurotransmitters such as norepinephrine and serotonin, which are involved in neural plasticity and cognitive function, which is important for CAP. Another theory for taVNS effects is the release of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, which may further help to balance abnormal neural activity in auditory circuits.
224106039|NCT06970444|OTHER|Sham device|the control group received sham stimulation with the stimulator closed and electrodes placed in their left ear
224106040|NCT06971991|DEVICE|qDSA Blood Flow Measurement|The research intervention is limited to several additional qDSA image acquisitions, which include administration of additional iodinated contrast medium.
224106041|NCT06969586|DRUG|Netarsudil 0.02% Ophthalmic Solution|Topical Netarsudil 0.02% 1x daily for 30 days postoperatively
224106042|NCT06969586|DRUG|artificial tear substitute|Topical artificial tear substitute 1x daily for 30 days postoperatively.
224106043|NCT06970392|BEHAVIORAL|Bedtime Pass|The Bedtime Pass is a small paper card that children will be allowed to exchange for a trip out of their bedroom after bedtime. Once the card has been exchanged, participants will be instructed to ignore any additional pleas from their child. Participants will also be provided with general information about good sleep hygiene.
224106044|NCT06972199|BEHAVIORAL|Reflexology|Reflexology application
224106045|NCT06972199|BEHAVIORAL|Hot water foot bath|Hot water foot bath application
224106046|NCT06971718|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment of the vessel treated before and after treatment|OCT and pressure wire of the main vessel and side branch of the bifurcation are undertaken prior to and after treating the lesion and at 3-9 month follow up.
224106047|NCT06969690|OTHER|Survey questionnaire V1|Each version of the questionnaire includes a different order of statements about which study participants are asked to provide a Yes, No, or It depends response.
223952830|NCT04556227|BEHAVIORAL|Simultaneous Cycle/Cognitive Training|Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
224106048|NCT06969690|OTHER|Survey questionnaire V2|Each version of the questionnaire includes a different order of statements about which study participants are asked to provide a Yes, No, or It depends response.
224106049|NCT06970964|DIETARY_SUPPLEMENT|Intervention Name: Fermented milk containing Lacticaseibacillus paracasei strain Shirota. Intervention Name: Non-fermented milk (placebo)|Participants will ingest 80 mL per day of fermented milk containing 40 billion colony-forming units (CFU) of Lacticaseibacillus paracasei strain Shirota (LcS), starting 30 days before a triathlon competition and continuing until 14 days post-race. The fermented milk is stored refrigerated and consumed once daily.
224106050|NCT06970964|DIETARY_SUPPLEMENT|Non-fermented milk (placebo)|Participants will ingest 80 mL per day of non-fermented milk identical in taste, appearance, and packaging to the probiotic drink, but without Lacticaseibacillus paracasei strain Shirota. Administration follows the same schedule as the probiotic group.
224106051|NCT06970002|DEVICE|Use of NIV during FOB as a respiratory support method|The aim of this project is to assess the safety, indications and contrindications to perform bronchofiberoscopy for diagnostic purposes in patient with chronic respiratory acidosis with the use of Non-invasive Ventilation (NIV) and High Flow Nasal Cannula (HNFC). In addition we want to determine the extent to which the usage of respiratory support during bronchofiberoscopy (BF) will help to avoid complications such as hypoxemia, decompensation of chronic respiratory failure, deterioration of gas exchange and hemodynamic instability, as well as intubation.
224106052|NCT06970002|DEVICE|Use of HFNC during FOB as a respiratory support method|The aim of this project is to assess the safety, indications and contrindications to perform bronchofiberoscopy for diagnostic purposes in patient with chronic respiratory acidosis with the use of Non-invasive Ventilation (NIV) and High Flow Nasal Cannula (HNFC). In addition we want to determine the extent to which the usage of respiratory support during bronchofiberoscopy (BF) will help to avoid complications such as hypoxemia, decompensation of chronic respiratory failure, deterioration of gas exchange and hemodynamic instability, as well as intubation.
224106053|NCT06971653|PROCEDURE|conventional surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with conventional surgery
224289714|NCT04951414|DIAGNOSTIC_TEST|ICF core set|KOA rehabilitation regimen based on the complete core combination of ICF was accepted
224289715|NCT04799613|OTHER|walking speed|walking speed (normal speed vs. fast speed). fast speed was 25% faster than normal speed
224289716|NCT04799613|OTHER|visual loading|visual loading (walking through narrow pathway using VR)
224289717|NCT04799613|OTHER|dual task|dual task (serial subtraction using VR)
224289718|NCT04799613|OTHER|best side reduction|best side reduction (split belt mode, the speed of best side was reduced by 25% compared to the other side)
223952831|NCT06107335|DRUG|Human Albumin (colloid)|Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to \>13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
223952832|NCT06107335|DRUG|Lactated Ringer's Injection (crystalloid)|Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
224106054|NCT06971653|PROCEDURE|piezoelectric surgery|This retrospective clinical study included 30 patients who underwent extraction of impacted lower third molars with piezoelectric surgery
224106055|NCT06382194|OTHER|Decision aid|The intervention is a newly developed decision aid designed to guide decisions about storage of firearms among older gun owners with early dementia and/or depression.
224106056|NCT06572267|DRUG|Mepolizumab low dose group|Meperizumab (0.05 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
224106057|NCT06572267|DRUG|Mepolizumab middle dose group|Meperizumab (0.1 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
224106058|NCT06572267|DRUG|Mepolizumab high dose group|Meperizumab (0.2 mg/kg) was dissolved in 1 mL of sterile water and added to 100 mL of saline for intravenous infusion. The intravenous infusion shall be completed within 30 to 60 min.
224106059|NCT06572267|DRUG|Saline|Intravenous infusion of saline 100 mL shall be completed within 30 to 60 min.
224106060|NCT02605525|BIOLOGICAL|SM101|Human soluble recombinant Fcγ Receptor IIB
224106061|NCT02605525|OTHER|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
224289719|NCT06445218|OTHER|Data collection|Collection of various data from patients' medical file, such as demographic data, diagnostic results, discharge, treatment....
224289720|NCT00530543|PROCEDURE|Robot-assisted gait training|
224289721|NCT03260075|OTHER|cat|Cat living at the ward
224289722|NCT02463799|DRUG|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
223952833|NCT06107335|DEVICE|Edwards HemoSphere monitor with ClearSight-Acumen finger cuff|Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
223723233|NCT07002385|COMBINATION_PRODUCT|Intervention group|The intervention group received a structured biopsychosocial program delivered by a multidisciplinary team. Geriatricians adjusted medications biweekly; rehabilitation therapists led Baduanjin sessions and monitored daily exercises via smart wristbands. Nurses provided CBT-I manuals, and psychologists offered weekly video support. Psychological care included biweekly mindfulness sessions and daily app-guided exercises, with monthly life review activities. Social support involved community events, volunteer roles, and weekly caregiver workshops. Adherence (≥70%) was tracked via app; non-compliance triggered reminders and tailored support. Exercise intensity was regulated by heart rate; patients with ≥5-point HAMD-17 increases were referred. Monthly reviews ensured ongoing quality improvement.
223952834|NCT05487300|DRUG|Autonomic testing on and off levodopa|"Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa."
224289723|NCT02463799|BIOLOGICAL|Sipuleucel-T|3 infusions of sipuleucel-T alone
224289724|NCT00549952|OTHER|no intervention study|
224289725|NCT02801552|DEVICE|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
224289726|NCT01020799|DRUG|AZD7268|15 mg, oral, twice daily (BID)
224289727|NCT01020799|DRUG|Escitalopram|20 mg, oral, once daily (QD)
224289728|NCT01020799|DRUG|Placebo capsules|Placebo capsules to match AZD7268
223952835|NCT06235567|DRUG|Dextenza 0.4Mg Ophthalmic Insert|This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
223952836|NCT06235567|DRUG|topical prednisolone acetate 1% (PredForte) eye drops|The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.
223952837|NCT06790095|DRUG|Cyclosporine (CsA)|Intravenous (IV) injection, loading dose of 2.5 mg/kg (diluted in 0.9% NaCl to a final volume of 50 ml) given over 2 hours, immediately followed by a continuous IV infusion of of 5 mg/kg/day (diluted in 0.9% NaCl to a final volume of 250 ml) for 3 days (72-hour).
223952838|NCT06790095|DRUG|Placebo|"Intravenous (IV) injection of 0.9% NaCl with the same dosing strategy as CsA: loading dose given over 2 hours, immediately followed by a continuous IV infusion for 3 days (72-hour)."
224289729|NCT01020799|DRUG|Placebo tablets|Placebo tablets to match encapsulated escitalopram
224289730|NCT01932099|DEVICE|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
224289731|NCT03504761|DEVICE|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
224289732|NCT05349747|BIOLOGICAL|Biologic drugs|Assess the results of treatment with biologic drugs
224289733|NCT06110247|DEVICE|NIRS|After the positions of the renal NIRS probes are confirmed by ultrasonography, the average value of the three measurements will be taken and the regional oxygen saturation index (rSO2) will be accepted as the initial value.
224289734|NCT06110247|OTHER|Taking a blood sample|Pre- and Postoperative hemoglobin (Hb), hematocrit (Htc), leukocyte (WBC), blood urea nitrogen (BUN), serum creatinine (sCr), procalcitonin, interleukin-6 and CRP values will be recorded.
224289735|NCT05369078|DRUG|THR-1442 20mg Single dose|THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
224289736|NCT05369078|DRUG|THR-1442 20mg Multiple dose group|THR-1442 20mg is administrated QD for 7days, then follow till day 14.
224289737|NCT05354089|BIOLOGICAL|20 μg dose of SYS6006|20 μg dose of SYS6006 vaccine IM on day 0 and day 21.
224289738|NCT05354089|BIOLOGICAL|30 μg dose of SYS6006|30 μg dose of SYS6006 vaccine IM on day 0 and day 21.
224289739|NCT05354089|DRUG|Placebo|Placebo IM on day 0 and day 21.
224289740|NCT00788229|DRUG|AT01|eye drop for 12 weeks
224289741|NCT00788229|DRUG|AT02|eye drop for 12 weeks
224289742|NCT00788229|DRUG|AT03|eye drop for 12 weeks
223952839|NCT03736265|DRUG|Carvedilol|Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
224106062|NCT03115190|DIAGNOSTIC_TEST|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
224106063|NCT04468477|DEVICE|6 Lead ECG|Patients will be assessed with the Kardiamobile device.
224106064|NCT05502497|OTHER|Observational|No application will be made to the control group.
224106065|NCT05502497|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization will be applied to the legs of the individuals to be treated with ultrasound gel for 2 minutes.
224106066|NCT00828451|BIOLOGICAL|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
224106067|NCT04400500|DIAGNOSTIC_TEST|Approaches to differential diagnosis and risk stratification|Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
224106068|NCT01994187|PROCEDURE|Carotid endarterectomy|
224106069|NCT01994187|PROCEDURE|carotid angioplasty|
224106070|NCT03883061|OTHER|regular medical treatment|regular medical treatment
223538764|NCT05956847|PROCEDURE|gastroscopy|When performing gastroscopy, the endoscopist will perform a biopsy based on the condition of gastric mucosal lesions, with one specimen retained and the remaining specimens subjected to pathological examination
224106071|NCT03542188|BEHAVIORAL|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
224106072|NCT03542188|BEHAVIORAL|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
223538765|NCT00000413|BEHAVIORAL|Psychoeducational program|
223538766|NCT01977898|DRUG|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
223538767|NCT01977898|DRUG|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
223952840|NCT00060268|DRUG|HPPH|iv
223952841|NCT05384522|OTHER|blood samples collection|Blood samples will be drawn at baseline and at 6 and 12 months from baseline
223952842|NCT04746690|OTHER|Slider, tensioner neurodynamic mobilization techniques and stretching exercises of back, hamstrings and gastrocnemius|neurodynamic mobilization techniques of sciatic nerve and stretching exercises of back extensors, hamstrings and lower limbs for patients with chronic discogenic sciatica.
223952843|NCT04282018|DRUG|BGB-10188|Administered as specified in the treatment arm
223952844|NCT04282018|DRUG|Zanubrutinib|Administered as specified in the treatment arm
223952845|NCT04282018|DRUG|Tislelizumab|Administered as specified in the treatment arm
224106073|NCT00729430|DRUG|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
224106074|NCT00729430|DRUG|Placebo|Placebo tablets taken orally once per day for 6 months
223538768|NCT01997645|PROCEDURE|LIFT|
223538769|NCT01997645|PROCEDURE|RAF|
223538770|NCT05771714|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
223538771|NCT06320704|DEVICE|Digital occlusal adjustment using Occulosense digital device|Digital occlusal adjustment of mandibular complete denture using Occulosense digital device
223538772|NCT00046904|BIOLOGICAL|etanercept|
223538773|NCT04144777|DIETARY_SUPPLEMENT|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
224106075|NCT03191175|OTHER|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
224289743|NCT00788229|DRUG|AT04|eye drop for 12 weeks
224289744|NCT06583850|OTHER|The Neck Disability Index|The Neck Disability Index (NDI) is the most widely used self-report tool to assess neck pain status, and provides information not only about pain experiences but also about a person\&#39;s functional status. The NDI consists of 10 questions related to pain, functional activities, self-care, and quality of life that are measured on a 6-point scale (0, no disability; 5, full disability). The numeric score for each item is summed for a score ranging from 0 to 50; 0-4 points are defined as no disability, 5-14 points as mild disability, 15-24 points as moderate disability, 25-34 points as severe disability and above 35 points as complete disability.
224289745|NCT06583850|OTHER|Visual analog scale (VAS)|A 10 cm VAS numbered from 0 to 10 was used for the assessment. 0 indicates no pain and 10 indicates unbearable pain. Participants were asked to mark a point between 0-10 according to their pain status
224106076|NCT03554590|BEHAVIORAL|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
224106077|NCT03554590|BEHAVIORAL|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
223538774|NCT04441697|DIAGNOSTIC_TEST|Multiple sleep latency tests|The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.
223952846|NCT05499507|BEHAVIORAL|COH|Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
224106078|NCT02984475|DRUG|Metformin|
224106079|NCT00667277|DRUG|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
224106080|NCT00519532|DRUG|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
224106081|NCT05859958|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and ABO blood groups
224106082|NCT02039388|PROCEDURE|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
224289746|NCT06583850|OTHER|Pittsburgh Sleep Quality Index|Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report questionnaire
224289747|NCT06583850|OTHER|Cervical Range of Motion Assessment|Active Cervical Range Of Motion was measured with a universal goniometer in all three planes of motion in the cervical region: lateral flexion (frontal plane), axial rotation to both right and left sides (horizontal plane), and flexion-extension (sagittal plane).
224289748|NCT04531657|DRUG|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
224289749|NCT00705692|DRUG|Levamisole|
223952847|NCT05499507|BEHAVIORAL|COH+|Includes all components of COH plus interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).
223952848|NCT06314425|PROCEDURE|Immediate dental implants placements on fresh sockets after tooth extraction|Zirconia dental implants (SDS®, Swiss Dental Solution, Kreuzlingen, Switzerland) are to be placed within the fresh extraction sockets. The immediate implants are placed using a minimally invasive technique without vertical releasing incisions. Implant placements are performed following the SDS osteotomy protocol after sulcus marginal and crestal incision or flapless surgery. The same surgeon places implants for all patients. Infected sites are debrided using piezo surgery touch.
223952849|NCT03011801|BEHAVIORAL|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
224289750|NCT00705692|DRUG|Placebo|
224289751|NCT02610816|OTHER|1 Food Elimination Diet|Participants eliminate milk from the diet for 12 weeks
224289752|NCT02610816|OTHER|4 Food Elimination Diet|Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
224289753|NCT02610816|OTHER|4 Food Elimination Diet (post 1FED failure)|Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
224289754|NCT02610816|DRUG|Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)|Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
224289755|NCT00988936|DRUG|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
224289756|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
223952850|NCT03011801|BEHAVIORAL|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
224106083|NCT02200107|BEHAVIORAL|self management education|
224106084|NCT01179763|OTHER|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
224289757|NCT04147819|DRUG|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
224289758|NCT01974908|PROCEDURE|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
224106085|NCT05121103|DRUG|EZM0414|Immediate-release film-coated tablets: Six dose levels starting at 100 mg, and then 200 mg, 300 mg, 400 mg, 600 mg, and 900 mg as well as an optional step-down dose level of 75 mg (if needed)
224106086|NCT02267785|OTHER|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
224289759|NCT04419623|DRUG|TL-895|TL-895, administered by mouth
224289760|NCT04516408|BIOLOGICAL|Recombinant zoster vaccine|Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.
224289761|NCT04516408|BIOLOGICAL|Placebo|Sterilized water
224289762|NCT00780923|DEVICE|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
224289763|NCT02516423|DRUG|ixazomib|oral
224289764|NCT02516423|DRUG|lenalidomide|oral
224289765|NCT02516423|DRUG|dexamethasone|oral
224289766|NCT02516423|DRUG|zoledronic acid|IV
224106087|NCT02267785|OTHER|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
224106088|NCT02267785|OTHER|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
224106089|NCT06397261|DEVICE|LarynGuide|Artificial Intelligence assisted tracheal video intubation
224106090|NCT06971523|DRUG|CTS3497|CTS3497: Orally via capsules
224106091|NCT03138564|BEHAVIORAL|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
224106092|NCT03138564|BEHAVIORAL|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
224106093|NCT06315114|BEHAVIORAL|Lighthouse MBT Parenting Program (LPP)|The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.
224289767|NCT02919813|BEHAVIORAL|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
224289768|NCT02919813|BEHAVIORAL|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
224289769|NCT00065013|BEHAVIORAL|strength training|
223952851|NCT05006703|BEHAVIORAL|Breathe for Teens (Breathe4T)|A digital, self-management intervention for adolescents to control their asthma using breathing retraining. The mobile-friendly website provides information about asthma, how it affects the lungs, and how breathing patterns can be dysfunctional. Information is presented using short (30sec-2min) video clips featuring physiotherapists, researchers and adolescent role models. Users are given tips about their practice, including choosing a suitable time and place and building up gradually. Users can plan and log their practice and record their confidence in using the breathing techniques. There are 8 sessions including peer-led videos demonstrating breathing exercises with voiceovers and step-by-step instructions. All features and sessions can be accessed via a main dashboard where users can tailor the intervention to allow parental involvement, reminders and a preferred format for notifications (email/text). Other features include frequently asked questions (FAQs) and a progress chart.
223952852|NCT03095261|BEHAVIORAL|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
223952853|NCT03095261|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
223952854|NCT03095261|BEHAVIORAL|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
224289770|NCT03975413|OTHER|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
224289771|NCT04971213|DEVICE|Non invasive ventilation|Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
224289772|NCT04971213|DEVICE|High-flow nasal cannula heated and humidified oxygen|AirVO2 device (Fisher and Paykel, New Zealand)
224289773|NCT04998578|DEVICE|Comparison of aesthetic techniques|Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
224289774|NCT02335515|DEVICE|Soctec|Gastroretentive Drug Delivery System
224289775|NCT03438227|DRUG|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
224289776|NCT03438227|DRUG|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
224106094|NCT06315114|BEHAVIORAL|Care as usual (CAU)|"1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.~Parents are offered the possibility of bringing their spouse or offspring to one of the sessions."
224106095|NCT03114501|BEHAVIORAL|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
224106096|NCT03114501|BEHAVIORAL|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
223723234|NCT07001488|DRUG|Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
223952855|NCT03095261|BEHAVIORAL|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
224289777|NCT03236948|BEHAVIORAL|Women for Women International Intervention|
224106097|NCT03114501|BEHAVIORAL|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
224106098|NCT06559436|DRUG|Intravenous thrombolysis|Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
224106099|NCT06559436|OTHER|Standard medical management|Standard medical management
224106100|NCT05474092|DEVICE|Aeson Total Artificial Heart|Heart Replacement Therapy
223952856|NCT05541185|BIOLOGICAL|Nigella sativa oil|1 ml of nigella sativa oil was applied to both knee areas of the nigella sativa oil group by massaging for 2 minutes three times a day for 21 days.
223952857|NCT05541185|BIOLOGICAL|Naproxen and lidocaine gel|1 ml of Naproxen and lidocaine gel was applied to both knee areas of the Naproxen and lidocaine gel group by massaging for 2 minutes three times a day for 21 days.
224106101|NCT04515719|BIOLOGICAL|Belimumab|Belimumab 2mg/kg intravenously
224106102|NCT04515719|BIOLOGICAL|Placebo|Placebo intravenously
223952858|NCT05541185|BIOLOGICAL|Massage|1 ml of vaseline was applied to both knee areas of the massage group by massaging for 2 minutes three times a day for 21 days.
224106103|NCT04652934|OTHER|Neurodynamic|The Upper Limb Neurodynamic Test (ULNT1) technique described by Butler will be performed on the affected limb. This technique consists of performing shoulder depression, 90º shoulder abduction, hand, wrist and forearm in a neutral position, external rotation of the shoulder and extension of the elbow. After positioning the limb in this position, wrist flexion-extension movements will be performed smoothly and rhythmically of 20 movements every minute, for 3 minutes, three times per session with 1 minute of rest between each series.
224106104|NCT04652934|OTHER|Mimic group|The protocol used by Beneciuk et al. Will be used. This intervention consists of imitating NM without stressing the nervous system. It will be carried out as follow: a neutral cervical position will be maintained (0º of cervical inclination), 45º of shoulder abduction without depression, 45º of external rotation of the shoulder combined with 45º of elbow flexion with the forearm in pronation. Afterwards, 10 wrist flexion-extension movements will be performed at a rate of 6 seconds per cycle (3 seconds of flexion and 3 seconds of extension). The resistance that you will feel will stabilize when you change motion. Once the 10 cycles of movements have been carried out, a wrist flexion will be maintained for 10 seconds.
224289778|NCT02164630|BEHAVIORAL|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
223952859|NCT04765020|BEHAVIORAL|Experimental: moderate to high-intensity exercise|"Four parts:~1. Initial consultation with recommendations for general physical activity, brochure with exercise recommendations~2. Once per week multi-modal group-based exercise (endurance, strength, mobility, coordination)~3. Once per week supervised multi-modal individual training session (endurance, strength, mobility, coordination). Intensity: 60-80% of max. HR~4. Activity trackers with individual movement goals that will be adjusted every two weeks"
223952860|NCT01538056|DEVICE|Fenestrated Endovascular Graft or Company Manufactured Terumo Aortic Fenestrated TREO Endovascular Graft|PMEG endovascular graft with fenestrations or the Company Manufactured Terumo Aortic Fenestrated TREO Abdominal Stent Graft System to allow for blood flow to vital visceral vessels such as the renal arteries, celiac, and SMA (Superior Mesenteric Artery).
224106105|NCT00814710|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
224106106|NCT00814710|BIOLOGICAL|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
224106107|NCT00814710|BIOLOGICAL|Hiberix|Intramuscular injection, 3 doses
224289779|NCT02164630|OTHER|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
224289780|NCT03665948|OTHER|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
224289781|NCT03665948|OTHER|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
224289782|NCT02582372|DRUG|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
224106108|NCT00814710|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 3 doses
224106109|NCT05406908|BIOLOGICAL|tozinameran|Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
224106110|NCT01440725|BIOLOGICAL|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
224106111|NCT01440725|PROCEDURE|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
224106112|NCT00443521|DRUG|Triamcinolone Acetonide 4 mg intravitreal injection|
224106113|NCT00443521|PROCEDURE|Panretinal photocoagulation|
224106114|NCT01374698|DRUG|Aspirin|Aspirin 325 mg
224289783|NCT02582372|DRUG|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
224289784|NCT04012372|OTHER|ROSA Water|Ad libitum hydration with ROSA oligomineral water
223723235|NCT07001488|DRUG|Azvudine tablets(FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days; RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
223723236|NCT07001488|DRUG|Azvudine tablets (FNC) and Rilpivirine Tablets (RPV)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~RPV: 25 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+RPV 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
223952861|NCT06794723|DIETARY_SUPPLEMENT|5-strain probiotic plus prebiotic natural health product|"The investigational product is a 5-strain probiotic plus prebiotic natural health product for patients with Type 2 diabetes. Other ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening. There is ≥ 2 billion AFU per dose in total."
223952862|NCT06794723|OTHER|Placebo|"Ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening."
223952863|NCT06802328|DRUG|Foralumab TZLS-401 50 µg|"Foralumab 50 µg/dosing day for patients who have failed current therapies. Patients will be dosed in 3-week cycles, with foralumab dosing on Days 1, 3 and 5 of the first and second weeks, followed by a rest week. Patients will receive Day 1 doses of nasal foralumab under supervision at the Center for Clinical Investigation at BWH."
224106115|NCT03443024|BIOLOGICAL|Lebrikizumab|Sterile liquid solution administered subcutaneously.
223952864|NCT03682289|DRUG|Ceralasertib|Given orally
223952865|NCT03682289|DRUG|Olaparib|Given orally
224289785|NCT04012372|OTHER|Control water|Ad libitum hydration with other waters
224289786|NCT02394691|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
224289787|NCT04438590|DIETARY_SUPPLEMENT|Kelulut Honey|The Substance being tested to be used as an alternative
224289788|NCT04438590|DIETARY_SUPPLEMENT|Carborie|The commercially available substance
224289789|NCT01855048|BIOLOGICAL|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
224289790|NCT01855048|OTHER|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
224289791|NCT05518630|BEHAVIORAL|Nomothetic Versus Idiographic Assessment in Chronic Pain|Participants with either endometriosis, vulvodynia, and/or fibromyalgia will answer a twice-daily diary for 42 days and a short weekly diary six times in total. In addition, they will answer two longer surveys at the start and at the end of the 42 days. These questionnaires ask about psychological flexibility, depression, catastrophizing, and pain interference. The data collected is only observational and does not include any intervention.
224289792|NCT00542763|DRUG|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
223952866|NCT03682289|DRUG|Durvalumab|Given intravenously (IV)
224106116|NCT03443024|DRUG|Placebo|Solution administered subcutaneously.
224106117|NCT05116969|DRUG|PTX-35|PTX-35 is a humanized, affinity matured, IgG2 monoclonal antibody
224106118|NCT02456623|BEHAVIORAL|Intervention|Home-based session targeting the parent
224289793|NCT02212340|DRUG|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
224289794|NCT02212340|DRUG|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
224289795|NCT03927924|PROCEDURE|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
224106119|NCT02456623|BEHAVIORAL|Attention Control|Attention condition with newsletters and support phone calls
224106120|NCT04801914|PROCEDURE|Percutaneous biliary drainage|Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).
224106121|NCT04422587|OTHER|RECOP unit patient|All patients admit in RECOP unit for dyspnea can be included in this study if patient is agree. Then, doctor collects demographic variables, the usual history and treatments, the characteristics of the episode (symptomatology, evolution, treatment taken) and the data from the initial clinical examination will be identified.
224106122|NCT00820105|DRUG|ADX10059|oral administration
224106123|NCT00820105|DRUG|ADX10059|Oral administration
224106124|NCT00820105|DRUG|ADX10059|Oral administration
224106125|NCT00820105|DRUG|ADX10059 Matching Placebo|Oral administration
224106126|NCT00513344|DIETARY_SUPPLEMENT|Dark Chocolate|1 portion
224289796|NCT02596386|PROCEDURE|sialometry|potassium evaluation
224289797|NCT02596386|PROCEDURE|blood test|potassium evaluation
224289798|NCT02691741|DEVICE|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
224106127|NCT00513344|DIETARY_SUPPLEMENT|Milk Chocolate|1 portion
224289799|NCT02691741|DEVICE|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
224289800|NCT02139124|DRUG|Placebo|Oral placebo capsule
224289801|NCT02139124|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
224289802|NCT02139124|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
224289803|NCT02139124|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
224289804|NCT02139124|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
224289805|NCT01371084|BEHAVIORAL|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
224289806|NCT01371084|BEHAVIORAL|Pedal@Work|Worksite wellness program.
224289807|NCT00255255|DRUG|Budesonide/Formoterol|
223952867|NCT02301117|DRUG|TAS-102|
223952868|NCT06296277|OTHER|Intraoperative mechanical ventilation for surgery|Any IMV during general anesthesia for surgery
224289808|NCT04523402|DRUG|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy with GEMOX regimen before liver resection
224106128|NCT00513344|DIETARY_SUPPLEMENT|"Control (polyphenol-free) Chocolate"|one portion
224289809|NCT03994549|DRUG|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
223538775|NCT06308224|OTHER|Modified-Otago Exercises|"Walking for 15 minutes before or after the strengthening and balance exercises of Modified-Otago.~Strengthening exercises for 10 minutes: Knee extensor, Knee flexor, Hip adductor, Ankle plantar flexors (calf raises), and Ankle dorsiflexion (toe raises).~Balance exercises 20 minutes: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel-toe stand), Tandem walk (heel-toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backward, sit to stand and Stair walking."
223538776|NCT06308224|OTHER|Tai-Chi Exercises|"Warm-up exercises for 10 minutes.~Tai Chi Qigong Exercises for 30 minutes: Commencing form and regulating breathing, Expanding your chest, Painting a rainbow, Circling arms to separate the clouds, Fixed step invert brachial, Row a boat in the middle of the lake, Shoulder the ball, Turning the body to look at the moon, Twisting waist and pushing palms, Horse step and cloud hands, Drag the sea and watch the sky, Undulating waves, Dove spreading wings, Extend arms and punch, Wild goose flying, Flywheel turning, Bounce ball while stepping, Pressing palms in calmness.~Cool-down exercises for 5 minutes."
223723237|NCT07002398|DRUG|VG801|Administered as specified in the single treatment arm. Study Cohort: Low dose, medium dose and high dose cohort
223952869|NCT04620733|DRUG|Seladelpar 10 mg|Seladelpar 10 mg one capsule daily for double-blind period, for a duration of up to 12 months
223952870|NCT04620733|DRUG|Placebo|One capsule daily for double-blind period, for a duration of up to 12 months
223952871|NCT04620733|DRUG|Seladelpar 5 mg|If down-titration needed, one capsule daily for double-blind period, for a duration of up to 12 months
223952872|NCT05045664|RADIATION|Standard|12 x 2 Gy involved site radiotherapy plus Rituximab
224106129|NCT06511661|PROCEDURE|Complete lymphadenectomy|At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
224106130|NCT06511661|PROCEDURE|Incomplete lymphadenectomy|Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
224289810|NCT04912336|DIAGNOSTIC_TEST|Standard coagulation profile|prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
224289811|NCT04912336|DIAGNOSTIC_TEST|Specific coagulation tests|AT III, anti Xa, ACT, ROTEM
224289812|NCT04912336|OTHER|Bleeding Scores|Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
224289813|NCT00379990|DRUG|GW274150|60 mg /day
224289814|NCT00379990|DRUG|Prednisolone|7.5 mg/day
224289815|NCT00379990|OTHER|Placebo|Placebo
223952873|NCT05045664|RADIATION|Experimental|2 x2 Gy involved site radiotherapy plus Obinutuzumab
223952874|NCT05045664|DRUG|Standard|Rituximab with 12 x 2 Gy involved site radiotherapy
223952875|NCT05045664|DRUG|Experimental|Obinutuzumab with 2 x2 Gy involved site radiotherapy
223952876|NCT02004834|DRUG|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
223952877|NCT03565640|DEVICE|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
224106131|NCT06459752|OTHER|visceral manipulation and noble technique|"First, the patient will lie face-up on a massage or exam table. Physiotherapists feel viscera, major internal organs located in the abdomen by lightly pressing through abdominal muscles. Physiotherapist manual poking, pressing, and massage actions do three things:~1. Reveals visceral adhesions.~2. Find tender spots.~3. Breaks up adhesions. Massaging and pressing stretch the collagen fibers that makeup fascia, which loosens tightly bound fibers to break up adhesions. This releases the organs and allows them to move more freely.~Minor adhesions may resolve after one session. Tough, stubborn adhesions may require several sessions plus self-manipulation between sessions"
224289816|NCT04211142|PROCEDURE|Laparoscopic Transabdominal Preperitoneal Inguinal Hernia Repair (TAPP repair)|Laparoscopic inguinal hernia repair
224289817|NCT04211142|PROCEDURE|Open Inguinal Hernia Repair (Lichtenstein repair)|Open Inguinal Hernia Repair
224289818|NCT01069952|DEVICE|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
224289819|NCT01813071|BIOLOGICAL|WRSS1|
224289820|NCT04176588|DRUG|Etrasimod|Drug:Etrasimod Tablet other name:APD334
224289821|NCT04176588|DRUG|Placebo|Drug:placebo Tablet
224289822|NCT03167593|DIETARY_SUPPLEMENT|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
224289823|NCT03167593|OTHER|Control placebo|Maltodextrin
224289824|NCT04476628|DRUG|Budesonide|Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
224106132|NCT06459752|OTHER|noble technique|The patient is positioned in supine with both knees bent and feet flat on a firm surface. The patient then places her crossed hands over her abdomen to support and pull the rectus abdominis muscles towards the midline. Finally, the patient is asked to slowly raise her head until a slight contraction is felt in the abdomen, holding for 20 seconds and repeating the exercise up to 20 times a day
223952878|NCT03565640|DEVICE|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
223952879|NCT02507297|DEVICE|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
223952880|NCT02489799|BEHAVIORAL|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
223952881|NCT02489799|BEHAVIORAL|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
224106133|NCT00624338|DRUG|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
224106134|NCT00624338|DRUG|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
224106135|NCT00624338|OTHER|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
224106136|NCT05088317|DIAGNOSTIC_TEST|Exercise capacity|The incremental shuttle walking test at increasing speed (ISWT) is one of the field tests used to evaluate exercise capacity. It has been shown that ISWT is a valid and reliable assessment tool that can be used to evaluate exercise capacity in obese individuals. This test is an exercise test in which walking between two cones 10 m apart at increasing speed for 12 minutes is counted as one sit-up for each 10-meter walk between the two cones. It is continued until the patient is unable to continue the test due to shortness of breath, the heart rate reaches 85% of the maximum expected heart rate, or completes the 12-minute test. In this test, the primary measure is the distance walked, and the result is calculated based on the number of shuttles completed.
224106137|NCT02313480|OTHER|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
224106138|NCT01548638|DRUG|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
224106139|NCT00001542|DRUG|fluconazole|
224106140|NCT06970301|DRUG|glovadalen|Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.
224106141|NCT06970301|OTHER|Placebo|Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.
224106142|NCT06970600|DRUG|Artemether-lumefantrine (Coartem)|Eligible patients will be consecutively assigned to the four cohorts. Rescue therapy according to national malaria treatment guidelines will be also administered in cases of early or late treatment failure. Follow-up visits will take place on days 1, 2, 3, 7, 14,21 and 28 after enrolment or at any time point whenever the child is sick. Adverse events will be recorded and assessed for severity and association with study medication. Thick and thin Giemsa-stained blood slides will be prepared before each dose to be administered and at every follow-up visit of days 2, 3, 7, 14, 21, 28, 35 and 42. Blood samples for PCR analysis will be collected from every patient at baseline and at days 7, 14, 28, and 42 day of treatment failure or at any other unscheduled visit. To differentiate recrudescence from new infection by polymerase chain reaction (PCR) analysis.The Molecular markers associated with suboptimal response to ACTs will be investigated.
224106143|NCT05593432|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
224106144|NCT05593432|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
224106145|NCT03885284|DRUG|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
224106146|NCT03885284|RADIATION|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
223723238|NCT07002346|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|QL1706: 5 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 2 years.
223723239|NCT07002346|DRUG|Bevacizumab|Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 22 cycles.
223723240|NCT07002346|DRUG|carboplatin|Carboplatin: AUC=5, intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles
224106147|NCT03476850|PROCEDURE|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
224106148|NCT03476850|PROCEDURE|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
224106149|NCT00152256|DRUG|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
224106150|NCT00152256|DRUG|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
224106151|NCT00152256|DRUG|Placebo|Placebo Tablet, oral Daily for 6 months
224106152|NCT03411070|DEVICE|Implanted Medical Device|Undergo SCOUT reflector placement
224106153|NCT03411070|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224106154|NCT03246074|DRUG|Fostamatinib 100 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
224289825|NCT04476628|DEVICE|Mucosal Atomization Device|MAD is a device used as an addition to a syringe to atomize medication to increase area of distribution. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
224106155|NCT03246074|DRUG|Fostamatinib 150 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 150 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
224106156|NCT03246074|DRUG|Fostamatinib 200 mg bid and Paclitaxel|"Drug: Fostamatinib (oral; 200 mg bid)~Drug: Paclitaxel (60-80 mg/m2)"
224106157|NCT06674356|BEHAVIORAL|chin tuck against resistance exercise|"Both groups of patients will receive traditional swallowing rehabilitation therapy; however, the experimental group will additionally perform CTAR exercises. The procedure is as follows:Ask the patient to sit, then, press the chin firmly against the inflatable rubber ball, for isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. And for isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions. Performing both isometric and isotonic exercises constitutes one set of exercises.~For isometric exercise, the chin is pressed down against the resistance of the ball and held for 60 seconds as one round, with a total of three rounds. For isotonic exercise, the chin presses down against the resistance of the ball and holds for one second per repetition, with a total of 30 repetitions."
224106158|NCT02942498|DRUG|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
224106159|NCT02942498|DRUG|Placebo|Placebo
224106160|NCT05574153|DIAGNOSTIC_TEST|Cardiac MRI|Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
223952882|NCT06585059|DRUG|TQB2928 injection + Almonertinib Mesilate Tablets|"TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug."
224106161|NCT06159595|DEVICE|Intracranial electrodes|Surgically-implanted intracranial electrodes.
224106162|NCT02809066|OTHER|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~* 50 gr kashkaval cheese,~* 400 ml milk and~* 150 gr yogurt for each day."
224106163|NCT04004052|OTHER|Ultrasound guided injection|
224106164|NCT04004052|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|
224106165|NCT04004052|OTHER|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
224106166|NCT00470821|DRUG|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
223952883|NCT02195219|PROCEDURE|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
223952884|NCT02195219|OTHER|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
224106167|NCT00470821|DRUG|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
224106168|NCT03030040|BEHAVIORAL|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
224106169|NCT01870466|DRUG|Cilostazol|cilostazol bid for 7 days
224106170|NCT01870466|DRUG|Simvastatin|simvastatin qd for 7 days
224106171|NCT01870466|DRUG|Rosuvastatin|rosuvastatin qd for 7 days
224106172|NCT05107180|DIAGNOSTIC_TEST|drug screen|urine sample
224106173|NCT05021926|DEVICE|DKL crosslinked sodium hyaluronate 26|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of DKL crosslinked sodium hyaluronate 26 will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
224106174|NCT05021926|DEVICE|Juvéderm Voluma™ with lidocaine (Allergan, Inc)|is injected into the midface on Day 1. The volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm Voluma™ will be injected on Day 30; the volume of injection will not exceed 1 mL per side.
224106175|NCT02830802|OTHER|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
224289826|NCT04476628|DEVICE|NeilMed squeeze bottle for Impregnated Nasal Saline Irrigation|INSI is delivered using a NeilMed squeeze bottle. It is used to administer budesonide within the nasal passages and sinuses to administer medication for CRS.
223723241|NCT07002346|DRUG|Paclitaxel|Paclitaxel: 175 mg/m\^2 intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles
223952885|NCT04909593|DEVICE|Spinal Cord Stimulation|Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
223952886|NCT01018992|DRUG|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
223952887|NCT01018992|DRUG|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
223952888|NCT00215709|DRUG|docetaxel|
223952889|NCT00819078|DRUG|Bupropion|300 mg/d
223952890|NCT00819078|DRUG|Placebo|no dosage
223952891|NCT01525459|PROCEDURE|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
223952892|NCT01525459|OTHER|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
223952893|NCT06343662|BEHAVIORAL|MERAKI_ABI|"The music therapy session will focus on the themes of reidentification and involvement. The aim is to accompany the patient during the illness process, allowing them to express their emotional state, relate to music, promote listening and communication between family members, help and value preserved abilities, and promote personal involvement in the rehabilitation process.~The session will work with songs, taking into account musical preferences."
223952894|NCT05886465|DRUG|Atezolizumab|1200 mg, iv.drip, Q3W
223952895|NCT05886465|DRUG|Bevacizumab|15mg/kg, iv.drip, Q3W
223952896|NCT05886465|PROCEDURE|HAIC with FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries, Q3W
223952897|NCT03029585|DRUG|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
223952898|NCT03029585|DRUG|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
223952899|NCT03029585|DRUG|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
223952900|NCT03029585|DRUG|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
223952901|NCT03029585|DRUG|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
223952902|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
223952903|NCT01092325|DRUG|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
223952904|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
223952905|NCT01092325|DRUG|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
223952906|NCT01092325|DRUG|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
223952907|NCT01092325|DRUG|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
223952908|NCT00430586|DRUG|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
223952909|NCT00430586|DRUG|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
223952910|NCT06165497|BEHAVIORAL|Meditation practices|Participants will listen to recordings of short meditation practices drawn from the Healthy Minds Program.
223952911|NCT06165497|OTHER|Internet-as-usual|Participants will be instructed to use the internet as they typically do.
223952912|NCT03530735|OTHER|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~1. Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~2. Use a diabetic lancet to prick their cleaned fingertip.~3. Squeeze 5 drops of blood form their finger into 10ml of saline.~4. Gargle the blood-saline mixture for 5 minutes.~5. Swallow the blood-saline mixture.~6. Repeat this 4 times per day."
223952913|NCT02092285|DRUG|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
223952914|NCT01825785|DRUG|Romosozumab|Administered by subcutaneous injection
223952915|NCT01825785|DRUG|Placebo|Administered by subcutaneous injection
223952916|NCT04721600|DEVICE|Evoke Radiofrequency Device|Enrolled subjects will undergo up to 3 successive bi-weekly (every 2 weeks) treatments.Treatment area will include face and under chin
224106176|NCT02830802|OTHER|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
224106177|NCT00886990|DRUG|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
224106178|NCT00886990|DRUG|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
224106179|NCT00263926|BIOLOGICAL|wasp venom|
224106180|NCT01814423|DRUG|Chloroquine-base 50 mg|
224106181|NCT01814423|DRUG|Chloroquine-base 70 mg|
224106182|NCT00499265|DRUG|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
224106183|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
224106184|NCT00499265|DRUG|Serine Proteinase Inhibitor WX-671|oral, daily
223538777|NCT04676100|OTHER|Cardiac rehabilitation|"A CR program is defined as one that offers initial assessment, structured exercise (can be supervised or unsupervised) and at least one other strategy to control risk factors. The registry pertains to phase II CR.~Quality of care and patient outcomes are benchmarked with other countries anonymously, through 2 registry dashboards (real-time). The dashboards will also show change over time in 6-month increments; Sites will be encouraged to continue to provide data on new patients until all indicators show quality as possible.~Sites will be supported in quality improvement by the ICRR user sub-committee. High-performing programs will be recognized on ICRR's website and ICCPR's social media accounts. This mechanism may be used in future to support program accreditation."
224106185|NCT03088150|PROCEDURE|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
223723242|NCT07001774|BEHAVIORAL|Vitalis Cardio|Participants receive five free health coaching sessions with a trained student health coach, access to two health education videos, and a free wrist worn activity monitor to keep track of their physical activity and sleep behaviors.
224106186|NCT03088150|PROCEDURE|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
224106187|NCT06495151|DIAGNOSTIC_TEST|Mannose-binding lectin-associated serine protease-3 (MASP-3) Level|Measurement of venous blood serum and peritoneal fluid levels of MASP-3 level by ELISA method.
224106188|NCT06495151|DIAGNOSTIC_TEST|Adipsin Level|Measurement of venous blood serum and peritoneal fluid levels of adipsin level by ELISA method.
224106189|NCT06495151|DIAGNOSTIC_TEST|Properdin Level|Measurement of venous blood serum and peritoneal fluid levels of properdin level by ELISA method.
224289827|NCT04636593|DRUG|Almonertinib|All enrolled patients underwent positioning CT scans before the initial treatment, a radiotherapy plan was made for each patient, and the lung V20 of each patient was calculated. Patients with lung V20 ≥ 28% were enrolled in group A: Almonertinib induction therapy was given for 2 months firstly, followed by Almonertinib combined with radiotherapy; patients with lung V20\<28% were enrolled in group B: Almonertinib was synchronized with radiotherapy initially.
224289828|NCT05613751|BEHAVIORAL|Nudge|Three text messages that are sent four weeks apart reminding to obtain the vaccines
223952917|NCT04759378|DIAGNOSTIC_TEST|Upper endoscopy, esophageal manometry, 24-hour pH monitoring|upper endoscopy determines if there are structural abnormalities in upper Git. esophageal manometry determines if there are motility disorders. 24-hour pH monitoring determines if acid reflux is present or not, and specifies its rate and duration.
224289829|NCT05144347|DRUG|XL114|Tablets of XL114
224289830|NCT04989777|DEVICE|IABP (Intra-aortic balloon pump ) implantation|Eligible AMI patients in SCAI-B stage will receive IABP implantation from the femoral artery
224289831|NCT02180698|OTHER|Laboratory Biomarker Analysis|Correlative studies
224289832|NCT02180698|RADIATION|Radiation Therapy|Undergo radiation therapy
224289833|NCT02180698|DRUG|TLR4 Agonist GLA-SE|Given intratumorally
224289834|NCT04793074|COMBINATION_PRODUCT|Transforming nanoparticle dressing|Transforming nanoparticle dressing
224289835|NCT04793074|COMBINATION_PRODUCT|Conventional compression dressing|Conventional compression dressing
224289836|NCT05717582|DRUG|apalutamide|Patients receive apalutamide 240mg,qd,po.
224289837|NCT05717582|DRUG|androgen deprivation therapy|Patients receive systemic ADT.
224289838|NCT05717582|PROCEDURE|cytoreductive radical prostatectomy with/without pelvic lymph node dissection|Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.
224289839|NCT05717582|RADIATION|metastasis-directed therapy with radiation|Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.
224289840|NCT02215668|PROCEDURE|Physical exercise|Exercise muscle stretching and body warming.
224289841|NCT01425528|DRUG|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
223952918|NCT05077046|OTHER|Ergonomic handwriting pen|An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
223952919|NCT01219751|DRUG|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
223952920|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A|receive two doses of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0 and 7.
224289842|NCT06026774|BIOLOGICAL|iNeo-Vac-R01 in combination with standard adjuvant therapy|Personalized mRNA vaccine encoding neoantigen, IH injection
224289843|NCT01478282|DRUG|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
223952921|NCT05305300|BIOLOGICAL|PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B|receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
223952922|NCT01371227|DRUG|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
223952923|NCT02917434|DIETARY_SUPPLEMENT|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
223952924|NCT04999800|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
224106190|NCT06495151|DIAGNOSTIC_TEST|Complement Factor H (CFH) Level|Measurement of venous blood serum and peritoneal fluid levels of CFH level by ELISA method.
224106191|NCT06495151|DIAGNOSTIC_TEST|Cancer Antigen 125 (CA-125) Level|Measurement of venous blood serum level of CA-125 level by ELISA method.
224106192|NCT05200767|OTHER|completing surveys|"The level of usual physical activity before the disease ( COVID-19- coronavirus disease 2019) will be analysed based on the IPAQ ( International Physical Activity Questionnaire) results."
224106193|NCT00430534|BIOLOGICAL|EBV vaccine (268664)|
224106194|NCT02609399|DRUG|Oseltamivir|Oral
224289844|NCT01478282|DRUG|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
224106195|NCT02609399|DRUG|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
224106196|NCT04458857|DRUG|Fremanezumab|Dose A or Dose B subcutaneous
224106197|NCT04458857|DRUG|Placebo|Matching placebo
224106198|NCT02936895|DRUG|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
224106199|NCT02936895|DRUG|Placebo|Placebo for 2 days
224106200|NCT00404729|DRUG|Citicoline|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
224106201|NCT01272531|DRUG|Mood stabilizer treatment|lithium or valproate
224106202|NCT01615510|DRUG|Tapentadol immediate release|100 mg, single administration
224106203|NCT01615510|DRUG|placebo|placebo, single administration
224106204|NCT02986373|BIOLOGICAL|risankizumab|Risankizumab administered by subcutaneous injection.
224106205|NCT04403737|DEVICE|Rothman Index|The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
224106206|NCT06090474|DRUG|NDC-002|Combination of NDC-002B and NDC-002C
224106207|NCT00232037|DRUG|Tegaserod|
224106208|NCT04573959|DEVICE|SV-3 Capsule Endoscopy|The purpose of this study is to validate an updated version of the CapsoCam SV-3 Endoscopy System with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam SV-3 capsule endoscopy.
224106209|NCT03466554|DEVICE|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
224289845|NCT06000735|DEVICE|7-Day Continuous Glucose Monitoring with Abbott Freestyle Libre 2|All participants will go through the same intervention described above
224106210|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 1)|Single dose administered intranasally on Day 1
224106211|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 2)|Single dose administered intranasally on Day 1
224106212|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)|Single dose administered intranasally on Day 1
224289846|NCT01843309|DRUG|Spironolactone 100mg|
224289847|NCT01843309|DRUG|Spironolactone 200mg|
224289848|NCT01843309|DRUG|Placebo|
224289849|NCT02404077|DRUG|Clonidine|
224289850|NCT00842530|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
224289851|NCT00842530|BIOLOGICAL|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
223723243|NCT07132957|DRUG|14C-labeled AL8326|Oral, About 60mg (200μCi) of 14C-labeled AL8326
224106213|NCT04909021|BIOLOGICAL|Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
224106214|NCT04909021|OTHER|Placebo (single-dose)|Single dose administered intranasally on Day 1
224106215|NCT04909021|OTHER|Placebo (two-dose)|Single dose administered intranasally on Day 1, followed by an identical dose administered intranasally at the Day 29 study visit
224106216|NCT05263843|DIAGNOSTIC_TEST|Biological markers of myocardial fibrosis|Blood sample for measurements of NET activation and collagen biomarkers
224106217|NCT01322815|DRUG|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
224106218|NCT01322815|DRUG|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
224106219|NCT01665937|DRUG|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
224106220|NCT01301326|DEVICE|subthreshold and threshold laser treatment|subthreshold laser treatment
224106221|NCT01301326|DEVICE|Threshold laser treatment|threshold laser treatment
224106222|NCT02232789|DRUG|Mephedrone|Single oral dose mephedrone
224106223|NCT02232789|DRUG|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
224106224|NCT02232789|DRUG|Placebo|Single oal dose placebo
224289852|NCT00842530|BIOLOGICAL|Placebo|Sodium chloride 0.9%
224289853|NCT06011616|OTHER|Sensory training|sensory training includes superficial sensory and deep sensory activities i.e. play with dough, painting with finger, recognizing objects with blocked vision, recognizing the drawn figure on palm, oint compression, bearing the weight on the paretic hand, leaning on the paretic side, walking with hand, rolling the heavy objects, dough squeezing etc.
224289854|NCT06011616|OTHER|Motor training|Motor training would involve activitoes such as throwing and catching a ball, targeted ball throwing, hand in hand ball transferring, ball rolling, hitting a ball to ground and wall, hand roller etc.
224289855|NCT06011616|OTHER|Conventional exercises|stretching exercises, muscle strengthening exercises, static weight bearing exercises, positioning
224289856|NCT01692314|OTHER|Resistance training|
224106225|NCT04358250|PROCEDURE|Direct Superior Approach|GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.
224106226|NCT04358250|PROCEDURE|posterolateral approach|GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
224106227|NCT02894515|DRUG|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
224289857|NCT06354855|OTHER|Group is doing breathing exercises while watching videos|Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.
223952925|NCT04999800|DRUG|Anlotinib|Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor
224289858|NCT06354855|OTHER|Medium pace walking group|Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
224289859|NCT02939950|DEVICE|Bausch + Lomb Samfilcon A Soft Contact Lens|soft contact lenses
224289860|NCT02939950|DEVICE|Bausch + Lomb Pure Vision Soft Contact Lens|soft contact lenses
224289861|NCT06128694|DIETARY_SUPPLEMENT|NUTRICAN|Per serving/sachet NUTRICAN (±81g) contains 350 kcal energy, 9 g fat, 20 g protein, 48 g carbohydrate, 400 mg DHA, 300 mg EPA, 0.92 g Omega-3, 1 g L-Valine, 1.1 g L-Isoleucine, 2.1 g L-Leucine, 75 mg sodium, 12 vitamins and 9 minerals.
223952926|NCT04254965|OTHER|Music therapy|Treatment including instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process.
224289862|NCT06862713|BEHAVIORAL|pulmonary rehabilitation exercise|pulmonary rehabilitation exercise + standard protocol
224289863|NCT00486018|DRUG|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
223538778|NCT05042648|DRUG|Buprenorphine patch|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest. The skin should be dry, clean, non irritated, non hairy (hair should be trimmed with scissors, not shaved), and without large scars.
223538779|NCT01178840|DEVICE|WC then FC2|4 uses of WC followed by 4 uses of FC2
223538780|NCT01178840|DEVICE|FC2 then WC|4 uses of WC followed by 4 uses of FC2
223538781|NCT04515888|OTHER|PFDI-20 / PFIQ-7 questionnaires|PFDI-20 / PFIQ-7 questionnaires (one shot)
223538782|NCT05531552|DRUG|clinical pharmacy application|assessment clinical pharmacist in management of CAD and ICU patients.
223538783|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
223952927|NCT04254965|DEVICE|Biosignal analysis|Measurement of facial expression emotion recognition, electrodermal activity, heart rate variability, sleep pattern, blood pressure, and electromyogram.
223952928|NCT04972318|PROCEDURE|Positive end-expiratory pressure titration with driving pressure control|Positive end-expiratory pressure will be tailored during a decremental maneuver (without a formal alveolar recruitment maneuver). The best positive end-expiratory pressure will be defined as the one associated with the higher respiratory system compliance, up to 20 cmH2O. Plateau pressure limit will be 30 cmH2O. If driving pressure remains elevated after optimal PEEP setting, tidal volume will be reduced to keep driving pressure below 14 cmH2O.
223952929|NCT04972318|PROCEDURE|ARDSNet ventilatory strategy|Positive end-expiratory pressure will be set according to fixed inspired oxygen fraction values.
223952930|NCT04526171|BEHAVIORAL|Vaparshun|Participants in the intervention clusters were encouraged to improve their existing toilets.
224106228|NCT02894515|DRUG|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
224106229|NCT04931602|DIAGNOSTIC_TEST|Biochemical markers i.e. Serum Ca, PTH, CTX, Albumin, Phosphate, Vitamin D and Bone mineral density Scan|investigations for secondary causes of osteoporosis
224106230|NCT05813470|BIOLOGICAL|Omalizumab (CinnaGen)|Omalizumab (CinnaGen, Iran) was administered via subcutaneous injection
224106231|NCT05813470|BIOLOGICAL|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)|Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) was administered via subcutaneous injection
224106232|NCT06463912|OTHER|Does not apply|A descriptive cross-sectional study will be carried out in the city of Armenia-Colombia. A total of 205 PWID, 18 years to 65 years old will be included. They will be selected through the implementation of the respondent-driven sampling (RDS).
224106233|NCT00105872|BEHAVIORAL|Cognitive-Behavioral Therapy|
223952931|NCT03476954|OTHER|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
224106234|NCT01151137|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
224106235|NCT01151137|DRUG|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
224106236|NCT04409678|BEHAVIORAL|activity|physical activity
224106237|NCT03085784|DRUG|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
224289864|NCT00486018|DRUG|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
224289865|NCT00486018|DRUG|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
224289866|NCT00074750|DRUG|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
224289867|NCT04689347|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
224289868|NCT04689347|DRUG|Irinotecan|irinotecan 165 mg/sqm intravenous infusion every 2 weeks
224289869|NCT04689347|DRUG|Leucovorin|leucovorin 200 mg/sqm intravenous infusion every 2 weeks
224289870|NCT04689347|DRUG|5Fluorouracil|48-hours continuous intravenous infusion of 5-fluorouracil (5-FU) 3200 mg/sqm every 2 weeks
224289871|NCT04689347|DRUG|Temozolomide|Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
224289872|NCT00638833|DRUG|Memantine|Memantine 30 mg/day (20-10-0)
224289873|NCT00638833|DRUG|Placebo|Placebo pills
224289874|NCT03669068|PROCEDURE|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~1. Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~2. Patients undergoing elective gastrointestinal endoscopy."
224289875|NCT03630094|DRUG|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
224289876|NCT05861635|DRUG|Disitamab Vedotin combined with Tislelizumab|"Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle"
224289877|NCT05496673|DIAGNOSTIC_TEST|Pastorex Latex Agglutination Test|Rapid diagnosis of bacterial meningitis
224289878|NCT05496673|DIAGNOSTIC_TEST|Biofire PCR for meningitis|Rapid diagnosis of multiple forms of meningitis
224289879|NCT05496673|DIAGNOSTIC_TEST|Immy CrAg Lateral Flow Assay|Rapid diagnosis of cryptococcal meningitis
224289880|NCT00050882|DRUG|GM-611|
223952932|NCT01094600|DRUG|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
223952933|NCT02440919|OTHER|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
223952934|NCT02440919|OTHER|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
223952935|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
224106238|NCT05275114|DEVICE|tDCS stimulation with hand task|30 minutes of intervention including tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
224106239|NCT05275114|DEVICE|sham tDCS stimulation with hand task|30 minutes of intervention including sham tDCS stimulation with hand task and fNIRS measurements for 10 days in 4 weeks
224289881|NCT05998551|DRUG|Dexmedetomidine|intrathecal injection of dexmedetomidine added to hyperbaric bupivacaine
223538784|NCT01778075|DRUG|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
224106240|NCT02049567|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
224106241|NCT02049567|PROCEDURE|Cataract Surgery|Performed using standard microsurgical techniques
224106242|NCT02158078|DEVICE|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
224106243|NCT04002687|DRUG|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
224106244|NCT03467230|DEVICE|NoL Index|Use of the PMD-200 in an observational study
224106245|NCT03414359|DRUG|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
224106246|NCT03414359|DRUG|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
224106247|NCT05505058|BEHAVIORAL|Audio-visual material|Participants were randomized to receive a paper-based conventional material or to watch a 4-min video. Materials both included legal information required by the Swiss Federal Act on Research involving Human Beings.
224289882|NCT05998551|DRUG|Fentanyl|intrathecal injection of fentanyl added to hyperbaric bupivacaine
224289883|NCT05998551|DRUG|Bupivacaine Hcl 0.5% Inj|intrathecal injection of hyperbaric bupivacaine only
224289884|NCT03291041|DRUG|Tasimelteon|capsule
224289885|NCT03291041|DRUG|Placebo|capsule
224106248|NCT03983941|DRUG|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
224106249|NCT02273973|DRUG|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
224106250|NCT02273973|OTHER|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
224106251|NCT02273973|DRUG|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
224106252|NCT01739595|DRUG|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
224106253|NCT01739595|DRUG|Placebo|Oral capsule taken one time daily for 3 months
223538785|NCT00041340|DRUG|imatinib mesylate|Given orally
223538786|NCT00041340|OTHER|laboratory biomarker analysis|Correlative studies
223538787|NCT04263844|DRUG|Intranasal dexmedetomidine|subject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
224289886|NCT05064267|DIAGNOSTIC_TEST|phlebotomy|phlebotomy will be performed to obtain coagulation labs of interest. Specifically, in addition to standard clinical labs, the following will be drawn on study participants: thrombelastography with platelet mapping, antithrombin, DIC panel, factor VIII, vWF antigen, Protein C antigen and activity, Protein S antigen and activity, and ferritin.
224289887|NCT06085339|BEHAVIORAL|Social Media|The social media arm participants will receive a diabetes curriculum designed to address diabetes self-efficacy and independence with diabetes management over the course of 6 months. Participants will have the option to engage with the study team and other participants through Instagram posts and direct messaging.
224289888|NCT00774943|DRUG|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
223952936|NCT02440919|OTHER|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
223952937|NCT02494076|DRUG|EzPAP|
224106254|NCT04379583|DEVICE|HairDx Sample Collection Kit|Saliva collection using FDA OTC cleared sample collection device
224106255|NCT01282814|DRUG|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
224106256|NCT01282814|DRUG|Effexor® XR|150 mg Extended-Release Capsule
224289889|NCT06060184|GENETIC|Next-Generation Sequencing (NGS)|Sequencing of genomes (Long read NGS)
224289890|NCT04735731|DIAGNOSTIC_TEST|Echography|Echography of diaphragma and other respiratory muscles
224289891|NCT01398839|DEVICE|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
224289892|NCT01398839|DRUG|Riboflavin|Both treatment and sham groups will receive riboflavin
224289893|NCT00508040|DRUG|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
224289894|NCT00508040|DRUG|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
224289895|NCT00922324|DRUG|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
224289896|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Biopsy would be taken from oesophageal cancer tissue and adjacent non-cancerous mucosa
223538788|NCT04263844|DRUG|Intranasal Midazolam|subject will receive premedication with intranasal midazolam thirty minutes before induction
223952938|NCT02494076|OTHER|Standard Care|
223952939|NCT00278395|DRUG|Vorinostat|Given orally
223952940|NCT03145142|PROCEDURE|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
223952941|NCT03145142|PROCEDURE|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
223952942|NCT02857686|PROCEDURE|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
223952943|NCT02857686|PROCEDURE|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
223952944|NCT03518047|DRUG|risankizumab|rizankizumab subcutaneous (SC) infusion
224106257|NCT00957372|DRUG|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
224106258|NCT00957372|DRUG|placebo (Part I)|once daily placebo comparator
224106259|NCT00957372|DRUG|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
224106260|NCT02403206|DEVICE|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
224106261|NCT02403206|PROCEDURE|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
224106262|NCT02708511|DIAGNOSTIC_TEST|Computed Tomography|Undergo PET/CT
224106263|NCT02708511|DRUG|Copper Cu 64-DOTA B-Fab|Given IV
224106264|NCT02708511|OTHER|Laboratory Biomarker Analysis|Correlative studies
224106265|NCT02708511|OTHER|Pharmacological Study|Correlative studies
224106266|NCT02708511|DIAGNOSTIC_TEST|Positron Emission Tomography|Undergo PET/CT
224289897|NCT04425122|DIAGNOSTIC_TEST|Upper endoscopy|Upper endoscopy would be performed. Random biopsy would be taken from normal non-cancer esophageal mucosa.
224289898|NCT01810094|DEVICE|Fracture Fixation|Thoracolumbar Fracture Fixation
224289899|NCT01680874|DIETARY_SUPPLEMENT|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
224289900|NCT01680874|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
224289901|NCT02823847|BEHAVIORAL|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
224289902|NCT02823847|DEVICE|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
224289903|NCT02823847|BEHAVIORAL|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions \[PMOL\]) given printed materials and web-based programs for tobacco and alcohol cessation."
224289904|NCT02823847|PROCEDURE|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
224289905|NCT02823847|PROCEDURE|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
224289906|NCT02823847|PROCEDURE|Oral Biopsy|Premalignant and malignant oral lesions \[PMOL\]) still present 2 weeks after oral exam are biopsied.
224289907|NCT02946216|GENETIC|ctDNA analysis|
223723244|NCT07132255|DEVICE|R-One assisted tele-PCI|Surgeons perform operations using R-One vascular interventional navigation control system from remote control center via 5G. robotic slave executes at procedure site.
223952945|NCT03518047|DRUG|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
223952946|NCT00849446|DEVICE|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
223952947|NCT05676372|PROCEDURE|CRC+HIPEC|Sample prelevation of cytoreductive surgery
223952948|NCT01472796|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
223952949|NCT01472796|DRUG|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
223952950|NCT03607851|DRUG|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
223952951|NCT03607851|DRUG|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
223952952|NCT03607851|DRUG|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
223952953|NCT04876430|DRUG|Meropenem|Meropenem 2g every 8h for patients with glomerular filtration rate (GFR) equal or higher that 50 mL/min. Dose adjustment is recommended for patients with GFR \< 50mL/min.
223952954|NCT03681067|DRUG|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
223952955|NCT03681067|DRUG|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
223952956|NCT02453269|BEHAVIORAL|Transdisciplinary program|
223952957|NCT01689740|DRUG|Active Placebo Dose MDMA-assisted therapy (25 mg)|Initial dose of 25 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 12.5 mg 1.5 to 2.5 hours later.
223952958|NCT01689740|DRUG|Full Dose MDMA-assisted therapy (125 mg)|Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
223952959|NCT01689740|DRUG|Open-Label Full Dose MDMA-assisted therapy (125 mg)|Initial dose of 125 mg midomafetamine HCl administered orally at the start of each of two psychotherapy sessions, possibly followed by a supplemental dose of 62.5 mg 1.5 to 2.5 hours later.
223952960|NCT01689740|BEHAVIORAL|Psychotherapy|Non-directive psychotherapy will be conducted throughout the study.
223952961|NCT00629993|BEHAVIORAL|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
223952962|NCT00249366|DRUG|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
223952963|NCT00249366|DRUG|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
223952964|NCT02814409|DRUG|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|IV Alteplase 0.9mg/kg (max 90mg) bolus + 1h infusion
223952965|NCT02814409|DRUG|Intravenous Tenecteplase|IV Tenecteplase 0.25mg/kg (max 25mg) single bolus
223952966|NCT01477866|DIETARY_SUPPLEMENT|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
223952967|NCT01477866|OTHER|conventional therapy|conventional therapy for colon-rectal cancer
224289908|NCT03206567|DIETARY_SUPPLEMENT|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
223538789|NCT05703217|PROCEDURE|classical physical therapy with physiotherapy.|C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
223538790|NCT00987285|BEHAVIORAL|CASM +|Computer Assisted Self Management plus Social Support
223723245|NCT07132255|DEVICE|R-One assisted on-site PCI|Surgeons perform operations by controlling robot from local console .
223538791|NCT00987285|BEHAVIORAL|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
223952968|NCT05553730|BEHAVIORAL|Digital Buddy program|Six months of ICT and psychoeducation delivered by youth mentors via an e-learning platform
223952969|NCT01859689|RADIATION|brachytherapy|Undergo image-guided HDR brachytherapy
223952970|NCT01859689|RADIATION|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
223952971|NCT01859689|OTHER|laboratory biomarker analysis|Correlative studies
223952972|NCT04416100|DIAGNOSTIC_TEST|Pulmonary function tests|Spirometry or plethysmography, measurement of diffusion capacity
223952973|NCT04416100|DIAGNOSTIC_TEST|Imaging|HRCT and echocardiography as scheduled within routine clinical examinations
223952974|NCT04416100|BIOLOGICAL|Blood sampling|Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping
223952975|NCT02287948|DEVICE|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1\) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
223952976|NCT00595725|OTHER|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
223952977|NCT02529605|DIETARY_SUPPLEMENT|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
223952978|NCT02529605|DIETARY_SUPPLEMENT|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
223952979|NCT00990184|DRUG|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
223952980|NCT00990184|OTHER|placebo|tablet (s) orally given with evening meal
223952981|NCT03697018|OTHER|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
223952982|NCT04454112|DEVICE|24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).|24-hour esophageal pH monitoring application
223952983|NCT05585398|DRUG|IncobotulinumtoxinA|Intradermal injections using different delivery methods (conventional needle and microneedles)
223952984|NCT01655498|DEVICE|vaginal bowel control system (LivSure)|
223952985|NCT02270502|DEVICE|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
223952986|NCT02270502|OTHER|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
223952987|NCT02270502|OTHER|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
223952988|NCT01728090|OTHER|hand sanitizer|alcohol-based, hydroalcoholic gel
223952989|NCT01781923|BEHAVIORAL|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
223952990|NCT01781923|BEHAVIORAL|Small group social skills training|Meet once per week for duration of 40 weeks.
223952991|NCT01566552|DRUG|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
223952992|NCT02269072|DRUG|Testosterone|Testosterone cream applied daily for two weeks
223952993|NCT02269072|DRUG|Nesiritide|Administered IV once during the study
223952994|NCT02269072|DRUG|Leuprolide|Administered twice during the study by injection
223952995|NCT02269072|DRUG|Anastrozole|Daily pill for 8 weeks
223952996|NCT02269072|DRUG|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
223952997|NCT06207383|DEVICE|Conduction system pacing|Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
223952998|NCT06207383|PROCEDURE|Atrioventricular nodal ablation|Catheter ablation of the atrioventricular node
223538792|NCT05446935|PROCEDURE|HITOC|Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
223538793|NCT02877069|DEVICE|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
223952999|NCT06207383|PROCEDURE|Atrial fibrillation ablation|Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
223953000|NCT02784834|DRUG|dimethyl fumarate|
223953001|NCT02602002|DRUG|Remifentanil|IV
223953002|NCT02602002|DRUG|Placebo|Placebo
223953003|NCT00074932|BIOLOGICAL|Myozyme|20 mg/kg
223953004|NCT02720705|DRUG|Dexmedetomidine|oral dexmedetomidine
223953005|NCT02720705|DRUG|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
223953006|NCT03596775|DRUG|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
223953007|NCT03596775|DRUG|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
223953008|NCT05341713|BIOLOGICAL|inactive SARS-Cov-2 vaccine|We included epilepsy patients who were vaccinated with inactive SARS-CoV-2 vaccines
223953009|NCT02558907|OTHER|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
223953010|NCT02409888|BEHAVIORAL|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
223953011|NCT02409888|BEHAVIORAL|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
223953012|NCT02409888|OTHER|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
223953013|NCT02409888|OTHER|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
223953014|NCT06255132|DEVICE|Automated pupillometer NPi-200|"Pupillary variables in both eyes are recorded and measured with NPi-200 every 30 minutes from the induction of anesthesia. At the end of the surgery, the patient is transferred to the intensive care unit (ICU), and the pupillary variables are recorded until the patient regains consciousness (Richmond agitation sedation scale, RASS\>-3). Specific hemodynamic, respiratory, surgical, and EBP data are also recorded as well as NIRS variables.~As soon as the patient had regained consciousness (RASS \> 3), they were assessed for delirium for a total period of five days. Nursing and/or medical staff administered the CAM-ICU score to patients twice a day (morning and afternoon)."
223953015|NCT05941156|BIOLOGICAL|Anti-CD56 CAR T|CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.
223953016|NCT02090478|OTHER|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
223953017|NCT02090478|OTHER|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
223953018|NCT02835209|OTHER|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
223953019|NCT01692652|DRUG|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
223953020|NCT01692652|OTHER|warm compress only group|
223953021|NCT01090739|DEVICE|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
223953022|NCT00441168|DRUG|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
223953023|NCT00441168|DRUG|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
223953024|NCT00441168|DRUG|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
223953025|NCT00441168|DRUG|vincristine|vincristine: 0.4mg IV push on days 1 to 4
223953026|NCT04252157|OTHER|Kinesiotaping|Kinesiotape will be applied to the group. During the orbicularis oris muscle, I tape will be applied around the lip with a mechanical correction technique with 50-75% tension. I tape will be applied just below the Hyoid with a 50-75% tension mechanical correlation technique.
223953027|NCT04252157|OTHER|Plesebo Taping|An approximately 5 cm I tape will be applied to the group without applying any tension to the temporomandibular attachment for placebo taping.
223953028|NCT04252157|OTHER|Control|no kinesio or tape will be applied
223953029|NCT00005654|DRUG|clomiphene citrate|
223953030|NCT00005654|DRUG|metformin|
223953031|NCT01102699|DRUG|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
223953032|NCT06322368|OTHER|Myofunctional and respiratory training program|The patients will receive exercises included in a myofunctional approach and a respiratory training focused on inspiratory and expiratory muscles using a device.
223953033|NCT06322368|OTHER|Range of motion and thermal and mechanical stimulation exercising|The patients will receive the standard treatment of speech and language therapy including range of motion exercises (open and close the mouth) and thermal and mechanical stimulation in the orofacial region.
224289909|NCT03206567|OTHER|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
224106267|NCT00815789|BEHAVIORAL|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
224106268|NCT04278573|DRUG|Vitamin D3|Intralesional injection of 0.3 ml 40,000 IU/ml vitamin D3 into one wart
224106269|NCT04278573|DRUG|Placebo|0.3 ml injection of sterilized sesame oil with no active study ingredient
224106270|NCT02215629|DRUG|VS-4718|
224289910|NCT03492658|DRUG|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
224289911|NCT03492658|DRUG|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
224289912|NCT04329416|OTHER|Predicted depth of insertion|A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.
224106271|NCT03045146|OTHER|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
224289913|NCT04329416|OTHER|Optimized depth of insertion|The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.
224289914|NCT04329416|OTHER|Adjustment of depth of insertion|If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
224289915|NCT03839277|DEVICE|Endocuff Vision|Endocuff Vision is attached to the tip of colonoscope before intubation.
224289916|NCT01100879|DRUG|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
224289917|NCT02278419|DRUG|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
224289918|NCT02278419|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
224289919|NCT02406794|DRUG|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
224106272|NCT00863954|DEVICE|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
224289920|NCT06453525|OTHER|intubation|Tracheal intubation using one of the three existing videolaryngoscopes
224289921|NCT00635518|BEHAVIORAL|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
224289922|NCT02262195|OTHER|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
224289923|NCT02985879|DRUG|Placebo|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr.
223538794|NCT01049373|DRUG|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
223538795|NCT01049373|DRUG|Placebo solution|10 drops, t.i.d, 15 weeks
223538796|NCT02061475|DRUG|Lidocaine Patches|
223538797|NCT05531006|OTHER|retrospective cohort study|retrospective patient file review
223538798|NCT06300177|DRUG|D-1553 Tablet|D-1553 is a KRAS inhibitor.
224106273|NCT06374810|BEHAVIORAL|Conscious Connected Breathwork|Participants were taught the Conscious Connected Breathwork Technique. 2 facilitators were monitoring and coaching the participants to ensure adherence to the technique
224106274|NCT06374810|OTHER|Placebo waitlist|Participants were told the study was full and that they were placed on a waiting list until the 1st cohort had completed the breathwork program
224106275|NCT02952742|DRUG|Black Cohosh|Vital Nutrients Black Cohosh Extract
224106276|NCT02952742|OTHER|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
224106277|NCT02024581|DRUG|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
224106278|NCT02024581|DRUG|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
224106279|NCT01791439|OTHER|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
224106280|NCT01791439|OTHER|placebo|
224106281|NCT01408238|BIOLOGICAL|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
224106282|NCT04779021|OTHER|Hospitalisation for SARS-COV2 infection|Patients hospitalized for SARS-COV2 infection
224106283|NCT06170255|BEHAVIORAL|Behavioral Activation (BA)|Behavioral activation involves an exploration of the patient's individualized values and follows with goal setting to improve depression symptoms.
224106284|NCT00479362|DRUG|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
224106285|NCT00479362|DRUG|Aspirin|Aspirin is continued without interruption prior to device implantation
224106286|NCT00479362|DEVICE|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
224106287|NCT00479362|DEVICE|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
224106288|NCT01287117|DRUG|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
224106289|NCT01287117|DRUG|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
224106290|NCT01676116|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
224106291|NCT01676116|DRUG|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
224106292|NCT01676116|DRUG|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
224106293|NCT02778698|DIETARY_SUPPLEMENT|Omegaven|
224106294|NCT05870475|DRUG|Ruxolitinib|Ruxolitinib at a starting dose of 10mg, orally administered twice daily. If ruxolitinib is not tolerated, cross-over to the pegylated interferon α-2b alone group is allowed.
224106295|NCT05870475|DRUG|Pegylated interferon α-2b|Starting dose of 180ug, subcutaneous injection once a week. If complete hematological remission is not achieved after 12 weeks of treatment with pegylated interferon α-2b alone, cross-over to the pegylated interferon α-2b plus ruxolitinib group is allowed.
224106296|NCT02050932|DIETARY_SUPPLEMENT|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
224106297|NCT06304272|PROCEDURE|Irrigating Traumatic Wound with Drinking Water|Irrigating Traumatic Wound with Drinking Water and Normal Saline
224106298|NCT03505866|BEHAVIORAL|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
224106299|NCT02680301|DRUG|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
224106300|NCT02680301|DRUG|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
224289924|NCT02985879|DRUG|ABBV-8E12|Participants with 44-49 kg body weight (BW) had an intravenous infusion rate of 3.5 mL/min or 210 mL/hr; those with 50-58 kg BW, 4.0 mL/min or 240 mL/hr; and those with a BW \>59 kg, 4.7 mL/min or 282 mL/hr. For participants in Cohort 2, ABBV-8E12 doses may have been decreased after the evaluation by the Data Monitoring Committee of available safety, tolerability and pharmacokinetic data.
223538799|NCT06300177|DRUG|Docetaxel injection|Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
224106301|NCT03299504|OTHER|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
224106302|NCT04427657|PROCEDURE|autologous microfragmented lipoaspirate tissue (Lipogems®).|patient in supine position. A double contemporary operating fields is made under sedation. During arthroscopic debridement is made an injection of local anesthetic at the dermal level with a subcutaneous infiltration of Klein solution. The plastic surgeon wait for about 5 minutes for vasoconstriction and then start with liposuction of about 60 ml of adipose tissue. Then lipoaspirate was processed with Lipogems® technique that consist in a mechanical fragmentation, physiological washing and filter passage of the lipoaspirate. A volume of 8-9 ml of microfragmented adipose tissue was injected intra-articulary after arthroscopic debridement.
224106303|NCT04427657|PROCEDURE|arthroscopic debridment|patient in supine position. Under sedation is perform an arthroscopic debridement
224106304|NCT05073770|DEVICE|Titan Condom|"The test condoms have the following specifications throughout the study:~1. The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~2. The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm."
224106305|NCT05987670|DEVICE|AI-stethoscope|"Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including~1. Delivery and setup~2. Smartphone app installation and login~3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice~4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines."
224106306|NCT02378753|BIOLOGICAL|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
224106307|NCT02473653|BIOLOGICAL|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
224106308|NCT00072969|DRUG|Daclizumab|
224106309|NCT05536648|OTHER|Comparing the plaque removal ability of triple head tooth brush versus single head tooth brush among school based cerebral palsy children: A Randomized Control Trial|To compare the plaque removing ability of two different tooth brushes in school going cerebral palsy children.
224106310|NCT06301126|OTHER|Virtual reality|The system included an Xbox 360® console, a sensor that detects motion (Kinect®), and a projector device with loudspeakers. The console, which was mounted on a table, reached 1 m tall. The Kinect® motion sensor was attached to the projector, which showed images onto a wall 2.5 metres distant from the playing field. The playing field was at least 1.8 m wide and 1.8 m long, with the Kinect® sensor situated 1.2 m away. The device was calibrated before each training session to accurately follow the motions of each subject.
224106311|NCT06301126|OTHER|conventional physical therapy exercise program|Participants will receive conventional physical therapy exercise program (Deep diaphragmatic, costal breathing exercises, bronchial hygiene techniques and assisted cough) for 45 minutes, 5 days/ week for 8 weeks.
224106312|NCT02188446|BEHAVIORAL|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
224106313|NCT02677740|DEVICE|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
224106314|NCT02677740|DEVICE|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
224106315|NCT03866551|DEVICE|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
224106316|NCT01613105|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
224106317|NCT04073212|OTHER|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
224106318|NCT04073212|OTHER|Heavy Slow Load Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
224106319|NCT04073212|OTHER|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
223538800|NCT03920501|BEHAVIORAL|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
223538801|NCT06101004|DEVICE|CVA-Flow|CVA-FLOW Software Device is indicated for the detection of Stroke and LVO in patients with suspected stroke.
224106320|NCT04073212|OTHER|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
224289925|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
224289926|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
224289927|NCT01046578|DRUG|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
224289928|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
224289929|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
224106321|NCT00778999|DRUG|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
224106322|NCT02063555|BIOLOGICAL|DAR-901|
224106323|NCT02063555|BIOLOGICAL|BCG|
224106324|NCT02063555|BIOLOGICAL|Sterile saline|
224106325|NCT06859528|BEHAVIORAL|Community Walking Program|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to drive behavioral change (increased physical and social engagement in their communities) throughout the week.
224106326|NCT02032524|DRUG|Avalglucosidase Alfa|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
224106327|NCT06672328|PROCEDURE|Training with Action Observation Therapy|"AOT based mobility and balance exercises along with conventional therapy consisting of simple lower limb stretchings and strengthening.~The fun based activities inlcude reaching for objects, tower building and taking turns in various stances."
224106328|NCT06672328|PROCEDURE|Training without Action Observation Therapy|"Cerebral Palsy patients will receive balance and mobility training without action observation in various stances of sitting, standing and turning.~Activities are fun based and include reaching for objects, tower building and taking turns in different positions."
224106329|NCT06997003|DEVICE|Anterior treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
224106330|NCT06997003|DEVICE|Anterior treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
224106331|NCT06997003|DEVICE|Total treatment mode|Laser-in-situ-Keratomileusis (LASIK) surgery using OCTAVIUS treatment
224106332|NCT06856902|BEHAVIORAL|B-COMPASS implementation|The patients in the intervention arm will receive B-COMPASS enhanced engagement in addition to standard care. The enhanced engagement is implemented as educational material to the HCP who is engaging with the patient. The content of the educational material will be based on the patient's B-COMPASS patient description. The engagement will either be in person or via phone call depending on the patient visiting schedule of each recruited patient.
224106333|NCT06856902|BEHAVIORAL|B-COMPASS implementation|At the first data collection, patients will complete the BEAMER questionnaire and adherence-related measures will be collected. Based on patients' answers, the B-COMPASS will assign them into groups, list their support needs, and predict their relative adherence, forming their B-COMPASS description. Patients will then be randomised into either 1) an intervention arm, or 2) a control arm using stratified randomisation via the Adherence Intelligence Visualisation Platform (AIVP), ensuring balance in B-COMPASS descriptions, gender, and age. The patients in the intervention arm will receive B-COMPASS enhanced engagement in addition to standard care. The enhanced engagement is implemented as educational material to the HCP who is engaging with the patient. The content of the educational material will be based on the patient's B-COMPASS patient description. The engagement will either be in person or via phone call depending on the patient visiting schedule of each recruited patient.
224106334|NCT06586489|BEHAVIORAL|Virtual Reality Natural Landscape Exposure|Participants will view immersive virtual natural landscapes using virtual reality (VR) headsets for 10 minutes, three times a week, over eight weeks. They will choose the natural landscapes they wish to visit and admire, allowing for personalized engagement with the virtual environment.
224106335|NCT06586489|BEHAVIORAL|Tablet Screen Natural Landscape Exposure|Participants will watch immersive virtual natural landscapes on a tablet screen for 10 minutes, three times a week, over eight weeks. Participants can select the natural landscapes they prefer to view during the sessions, providing a personalized experience.
224106336|NCT06066736|OTHER|observational|No intervention, observational group
224106337|NCT06617481|DRUG|18F-rhPSMA-7.3 (Posluma)|PET Scan using Posluma for detection of early recurrence of prostate cancer.
224106338|NCT03885765|DIAGNOSTIC_TEST|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration \[I\] of the section to be excised / \[I\] total."
224106339|NCT03885765|PROCEDURE|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
224106340|NCT05823168|DRUG|Antiepileptic Drug|we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
224106341|NCT06869434|PROCEDURE|Group VBL (Thoracolumbal vertebral body length) received 0.2 mg x VBL cm of %0.5 hyperbaric bupivacaine|intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight. A dosage was derived using Harten's dose chart formulated for Caucasian parturients
224106342|NCT06869434|PROCEDURE|Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm|Group FD (fixed dose) received a volume of 0.5% hyperbaric bupivacaine based on a dose calculated according to the patient's height 0.065 mg/cm
224106343|NCT06869434|PROCEDURE|Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.|Group AD (adjusted dosage) got intrathecal heavy bupivacaine (0.5%) tailored to the patient's height and weight.
224106344|NCT05073692|DRUG|SU|Exposure to the class of drugs known as Sulfonylureas (SU)
224106345|NCT05073692|DRUG|DPP4|Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)
224106346|NCT05073692|DRUG|SGLT2i|Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
224106347|NCT05073692|DRUG|GLP-1RA|Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)
224106348|NCT05073692|DRUG|SGLT2i or GLP-1RA|Exposure to either SGLT2i or GLP-1RA
224106349|NCT05073692|DRUG|Linagliptin (DPP4)|Exposure to agent Linagliptin (DPP4)
224106350|NCT05073692|DRUG|Exenatide (GLP-1RA)|Exposure to agent Exenatide (GLP1-RA)
224106351|NCT05073692|DRUG|Liraglutide (GLP-1RA)|Exposure to agent Liraglutide (GLP-1RA)
224106352|NCT05073692|DRUG|Empagliflozin (SGLT2i)|Exposure to agent Empagliflozin (SGLT2i)
224106353|NCT05073692|DRUG|Glimepiride (SU)|Exposure to agent Glimepiride (SU)
224106354|NCT05073692|DRUG|Glipizide (SU)|Exposure to Glimepiride (SU)
224106355|NCT05073692|DRUG|Glimepiride (SU) or Glipizide (SU)|Exposure to agent Glimepiride (SU) or Glipizide (SU)
224106356|NCT05073692|DRUG|SU or DPP4 (excluding saxagliptin and alogliptin)|Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin
224106357|NCT05073692|DRUG|Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)|Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
224106358|NCT01186432|DRUG|PDS 1.0|
224106359|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
224289930|NCT01046578|DRUG|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
224106360|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 25 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
224106361|NCT02975349|DRUG|Evobrutinib|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
224106362|NCT02975349|DRUG|Placebo|Placebo were administered for 24 weeks in active treatment period.
224106363|NCT02975349|DRUG|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period received Tecfidera 120 mg BID orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
224106364|NCT01613612|PROCEDURE|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
224106365|NCT01613612|PROCEDURE|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
224106366|NCT00165737|DRUG|Donepezil Hydrochloride|
224106367|NCT01497171|PROCEDURE|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
224106368|NCT01497171|PROCEDURE|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
224106369|NCT07030569|DRUG|Trastuzumab deruxtecan (DS-8201a)|A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting
224106370|NCT07032012|OTHER|control - anxiety evaluation before Pre-anesthetic|If allocated to the group control, the anxiety questionnaire will be applied, and then the pre-anesthetic evaluation will be conducted.
224106371|NCT07032012|OTHER|group intervention - anxiety evaluation after Pre-anesthetic|If allocated to the group intervention, the first contact of the participant with the interviewer will be on the eve of surgery, in the ward. At that moment, the pre-anesthetic evaluation will be conducted. The next day, upon admission to the preoperative room, the anxiety questionnaire will be applied.
224106372|NCT07031882|DEVICE|Liberty Analyzer WBC System|Participants will donate capillary samples to be analysed by the Liberty Analyzer System WBC
224106373|NCT07031609|BEHAVIORAL|Robot-assisted gait training using Lokomat|This intervention involves robotic-assisted gait training with the Lokomat device. Sessions will last 40 minutes, twice a week for 6 weeks. The intervention targets lower extremity motor function in children with spastic hemiparetic cerebral palsy. The robotic system provides adjustable support and real-time feedback to improve gait patterns and mobility.
224106374|NCT07031609|BEHAVIORAL|Hydrotherapy|Participants will engage in supervised aquatic therapy including structured exercises in a therapeutic pool. Each session lasts 40 minutes, twice a week, for 6 weeks. Exercises include water walking, floating resistance training, jumping, and balance activities designed for children with spastic hemiparetic cerebral palsy to improve strength, coordination, and functional mobility.
224106375|NCT07031609|BEHAVIORAL|Conventional Physiotherapy|This intervention includes 20 minutes of faradic electrical stimulation and 20 minutes of therapeutic exercises such as stretching, positioning, range of motion, and gait training. Administered twice a week for 6 weeks. The protocol aims to support neuromuscular activation and improve gait and mobility in children with spastic hemiparetic cerebral palsy.
223953034|NCT01680432|DIETARY_SUPPLEMENT|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
223953035|NCT01680432|DIETARY_SUPPLEMENT|Regular Cheese|
224106376|NCT07030738|BEHAVIORAL|Legume-Based High-Protein Diet + Resistance Training|Participants receive a hypocaloric, high-protein diet primarily based on legumes (e.g., lentils, beans, peas) designed to meet protein goals (\~2g/kg body weight). Diet is combined with a structured home-based resistance training program performed 3 times per week for 12 weeks. The exercise includes progressive resistance exercises focusing on major muscle groups using body weight and resistance bands.
224106377|NCT07030738|BEHAVIORAL|Meat-Based High-Protein Diet + Resistance Training|Participants follow a hypocaloric, high-protein diet emphasizing animal-based protein sources, mainly lean meats, to achieve \~2g/kg body weight protein intake. This dietary intervention is combined with a 12-week, home-based resistance training protocol, performed thrice weekly, targeting major muscle groups with progressive overload using body weight and resistance bands.
224106378|NCT07030738|BEHAVIORAL|Mixed Legume and Meat High-Protein Diet + Resistance Training|Participants adhere to a hypocaloric, high-protein diet combining both legumes and lean meats as protein sources to reach \~2g/kg body weight. The dietary plan is paired with a 12-week home-based resistance training program, performed 3 times per week, emphasizing progressive resistance exercises for all major muscle groups using body weight and resistance bands.
224106379|NCT07031037|OTHER|Scales|"Five questionnaires were administered at inclusion, socio-demographic and clinical data were collected during an interview (anxiety-depression, treatments).~The following questionnaires were used: The Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Eating Disorder Examination Self-Report Questionnaire (EDE-Q), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS), the Hospital anxiety and depression scale (HAD) and the Multidimensional Assessment of Interoceptive Awareness Version 2 (MAIA-2)."
223953036|NCT02280759|DRUG|Gelatin Tannate|
223953037|NCT02280759|DRUG|Placebo|Placebo consists of an identical formulation, except active substance
223953038|NCT01474356|OTHER|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
223953039|NCT01841385|OTHER|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
223953040|NCT05334433|PROCEDURE|Local anesthesia injection|Local anesthesia administration
223723246|NCT07132164|OTHER|biobank sample collection|"At inclusion, patients will benefit from blood testing for biobank establishment, and stool sample collection for gut microbiota analysis will be organized depending on the center.~The 12-month visit (M12) will also include an additional blood sample collection as part of the biobank, as well as stool sample collection"
224106380|NCT07032181|PROCEDURE|Virtual reality, guided imagery|"Before the procedure, children will be informed via the Child Consent Form, and parents through the Informed Consent Form. Verbal and written consents will be obtained, and data will be recorded in the Child Patient Introductory Information Form. Pre-procedural pain will be assessed using the Faces Pain Scale-Revised scale, and the child will mark their pain. Parents will use the VAS scale for pain assessment. The CFS scale will be explained to both the child and parent to assess the child's fear. A pulse oximeter will measure SPO2 and pulse one minute before the procedure.~The blood collection procedure will be performed by an experienced nurse, and heart rate and oxygen saturation will be recorded in the Application Record Form.~After the procedure, measurements will be taken immediately after the procedure and one minute later.~Children will mark their pain and fear levels on the FPS-R and CFS scales. Parents and observers will also assess the child's pain (VAS) and fear (CFS)."
224106381|NCT07031232|PROCEDURE|Bone-Level Implant Placement with Transmucosal Abutment and One Abutment-One Time Protocol Using Healing Abutments|"All participants will receive a single bone-level dental implant placed in a healed posterior site of the maxilla or mandible. The implants will be placed using a biological drilling protocol and inserted with a final torque of at least 30 Ncm. A 2 mm transmucosal one-piece abutment (mono-block) will be connected at the time of surgery, following a one abutment-one time philosophy.~Each patient will receive a healing abutment immediately after implant placement according to their allocated study group (standard, wide, or customized). The assigned healing abutment will not be removed throughout the healing period. All procedures will be carried out under local anesthesia in a standard clinical setting."
224106382|NCT07031050|DEVICE|sacrocolpopexy or sacrocervicopexy|Robotic-assisted sacrocolpopexy or sacrocervicopexy with the Dexter robotic surgery system
224106383|NCT07031752|OTHER|Postprandial Vegan Meat|Postprandial responses to one single intake of vegan meat (VM) under fasting conditions.
224106384|NCT07031752|OTHER|Postprandial Meat|Postprandial responses to one single intake of genuine meat (GM) under fasting conditions,
224106385|NCT07031466|OTHER|Retrospective analysis of assigned treatment|Retrospective analysis of assigned treatment will be performed
224106386|NCT07031466|OTHER|Quality of Life (SF-36)|The quality of life will be assessed using the SF-36 (Short-Form Health Subject Questionnaire).
224106387|NCT07031466|OTHER|Quality of Life (EQ-5D)|The quality of life will be assessed using the EQ-5D (European Quality of Life Questionnaire)
224106388|NCT07031466|OTHER|Hospital Anxiety and Depression (HADS)|Hospital Anxiety and Depression will be assessed using the HADS (Hospital Anxiety and Depression Scale)
224106389|NCT07031596|DIETARY_SUPPLEMENT|WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100).|"Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100). Ingredients : Stachyose, fructooligosaccharides, isomaltooligosaccharides, maltodextrin, Lactiplantibacillus plantarum CECT7527, Lactiplantibacillus plantarum CECT7528, Lactiplantibacillus plantarum CECT7529, Lactobacillus acidophilus GOLDGUT-LA100, and Epigallocatechin gallate (EGCG).~Administration : Twice daily (2 bottles per dose) after meals for 12 weeks."
224289931|NCT00765011|DRUG|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
224289932|NCT00765011|PROCEDURE|H&N surgery|Rescue surgery
224289933|NCT06084052|DEVICE|Path Active|Participant use of Path Active insoles, mobile phone app and clinician's dashboard (where pressure and temperature changes can be reviewed by a clinician). All participants will complete a patient questionnaire relating to use of the device and EuroQol - EQ5D at the beginning and end of the study.
224289934|NCT06084052|OTHER|Control Group|Control Group will receive care as usual.
223538802|NCT01720394|DEVICE|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
223723247|NCT07132879|OTHER|No intervention - Prospective cohort study|No intervention - Prospective cohort study
223538803|NCT01720394|DRUG|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
223538804|NCT02391311|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
223953041|NCT03345706|PROCEDURE|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
223953042|NCT03345706|PROCEDURE|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
223953043|NCT06254976|BEHAVIORAL|exercise|2 weeks of home exercise
223953044|NCT06254976|BIOLOGICAL|intraarticular knee PRP injections|2 doses of intra-articular platelet rich plasma (PRP) injection, 1 week apart
223953045|NCT00952003|DRUG|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
223953046|NCT04894942|OTHER|American Orthopaedic Foot and Ankle Society Score (AOFASS)|calculation of the score AOFASS before and after the surgery
223953047|NCT03286907|BEHAVIORAL|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.
223953048|NCT03286907|BEHAVIORAL|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.
223953049|NCT03286907|BEHAVIORAL|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
223538805|NCT02782910|DEVICE|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
224289935|NCT05848778|DEVICE|Acute Intermittent Hypoxia|The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)
224289936|NCT05848778|DEVICE|Normoxia|The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
224106390|NCT07031596|DIETARY_SUPPLEMENT|WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.|"Product : WONDERLAB SHAPE100™ Ready-to-Eat Probiotic Food (S100) + WONDERLAB Weight Management Probiotic Food.~Ingredients :~S100 Components : As above. Weight Management Components : Isomaltooligosaccharides, fructooligosaccharides, maltodextrin, Lactobacillus fermentum K7-Lb1, Lactobacillus fermentum K8-Lb1, Lactobacillus fermentum K11-Lb3, Euglena gracilis, and phosphatidylserine.~Administration : Twice daily (2 bottles per dose) after meals for 12 weeks."
224106391|NCT07031596|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of maltodextrin-based placebo (identical in taste, appearance, and packaging to probiotic products) twice daily (2 bottles per dose) for 12 weeks.
224106392|NCT07031947|OTHER|Core stabilization exercise with telerehabilitation|In addition to a brochure containing patient education, showing the application method of core stabilization exercises, the number of sets and repetitions, the intervention group (G1) will receive a back school program in a total of 2 sessions of videoconference interviews, and the exercises will be explained to them, supported by visuals and videos. In addition, patients will be provided with the application that will be provided with your support, and will be provided with core stabilization exercises 3 times a week for 8 weeks.
224289937|NCT06783140|DRUG|Nab paclitaxel|Paclitaxel Powder For Injectable Suspension Nanoparticle, Albumin-bound Paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity.
224289938|NCT06783140|DRUG|Gemcitabine|Gemcitabine is a hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.
224289939|NCT06783140|DRUG|Cisplatin|Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.
224289940|NCT04974619|BEHAVIORAL|Online survey|Aim 1 Participants will be asked to complete a Qualtrics survey to identify knowledge gaps, health beliefs, attitudes, and educational learning preferences.
224289941|NCT04974619|BEHAVIORAL|Focus groups or Individual Interviews|Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
224289942|NCT04974619|BEHAVIORAL|Interviews|In-depth interviews (n=20) will be conducted with key stakeholders (10 in PR and 10 in FL) eliciting feedback to inform intervention content and delivery methods and identify potential facilitators and barriers to intervention implementation.
224289943|NCT05017649|BIOLOGICAL|Blood sample|Blood sampling.
224289944|NCT03929809|DEVICE|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
224289945|NCT06272292|DIAGNOSTIC_TEST|EOS|Every subject in this study will undergo a radiographic analysis of the hip and spine using a low-dose, full-body biplanar X-ray acquisition (in standing, sitting and squatting position, EOS imaging).
224289946|NCT06272292|DIAGNOSTIC_TEST|3D motion lab analysis|"A hip-specific 3D motion analysis will be performed. The 3D motion protocol will be divided into 2 main sections.~First section: Consist of movements categorized within the activities of daily living (walking at self-selected speed, uphill walking, standardized deep squat and non-standardized deep squat)~Second section: Consists of movements that are categorized within athletic training and have been specifically chosen to induce large hip ranges of motion (Sumo squats, dead lifts, forward lunges, running uphill and downhill)~Each movements will be repeated 6 times. Three times with the dominant foot/opposite leg on the force plate to collect kinetic data. All data will be captured using two 10-15 camera 3D motion capture systems and one capturing an instrumented treadmill (M-gait)"
224289947|NCT05473624|DRUG|HRS-1167|Participants will receive HRS-1167.
224289948|NCT06164951|DRUG|Infigratinib 0.25 mg/kg/day|Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
224289949|NCT06164951|DRUG|Placebo Comparator 0.25 mg/kg/day|Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
223538806|NCT04933292|DRUG|Methylprednisolone and Mycophenolate mofetil|Methylprednisolone combination of mycophenolate mofetil
223538807|NCT04933292|DRUG|Methylprednisolone and azathioprine|Methylprednisolone combination of azathioprine
224289950|NCT05712382|BEHAVIORAL|Parent handbook|Handbook motivating parents to discuss alcohol use with their college student.
224289951|NCT05712382|BEHAVIORAL|Coping with negative emotions|Mindfulness-based techniques are taught to improve ability to cope with negative emotions.
223538808|NCT05639959|DRUG|Mometasone Nasal 50 Mcg/Inh Nasal Spray|Mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis.
223538809|NCT05639959|DEVICE|Nasal spray|device can work properly for actuation during trials
224106393|NCT07031947|OTHER|Face-to-face core stabilization exercise|The control group (G2) will receive a brochure that includes patient education, showing the application method of core stabilization exercises, the number of sets and repetitions, as well as a face-to-face back school program in our hospital for a total of 2 sessions. The exercise program will be carried out face to face, 3 sessions per week for 8 weeks, at the Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, under the supervision of a physician, with each exercise session being in groups of 8 people.
224106394|NCT07032220|DRUG|carbon suspension|Before primary systemic therapy, a core needle biopsy or fine-needle aspiration of the most suspicious axillary lymph node was performed.22 Sterile black carbon suspension (0.5 mL: 25 mg, Chongqing LUMMY Pharmaceutical Co) was injected in the cortex of the metastatic node under ultrasound guidance using a 25G needle by a trained ultrasonographer at the time of biopsy or during a separate session. The injection volume was recorded and varied depending on node size and operator. The trained ultrasonographer had more than 5 years of puncture experience. Of note, for the patients with multiple abnormal nodes or N3 disease under ultrasound at diagnosis, only the pathologically-proven lymph node is marked with carbon suspension.
224106395|NCT07031323|BEHAVIORAL|OnTrackCF|OnTrackCF is a mHealth application co-developed with Upstream Dream. It is designed specifically to track and support adherence to CFTR modulator therapy. The app allows users to track their modulator intake and disease symptoms while supporting their adherence goals using Behavioral Change Techniques (BCTs) with empirical evidence of efficacy. The BCTs are administered primarily in the form of messages designed to deliver specific BCTs. The app sends up to 3 adherence support messages per day and provides detailed data to the user about their adherence levels, adherence goals, and disease symptoms. This process will continue until we reach an N=60 AWCF enrolled OR demonstrate that we have achieved 12 weeks of sustained user engagement with the app.
223723248|NCT07133113|OTHER|We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).|"The patients will be identified via the French Nationwide Multidisciplinary Team Meetings for Autoimmune encephalitis, which are conducted on a bi-monthly basis. All patients with newly diagnosed NMDAR, LGI1, CASPR2, IgLON5, GFAP or GAD65 encephalitis and treated for less than 8 weeks will be included. Treatment protocols at the initiation of therapy will be stratified into: 1) first-line only; 2) rituximab without cyclophosphamide; 3) rituximab combined with cyclophosphamide; 4) others.~The referral clinicians will be contacted by email and the data will be collected using standardized questionnaires, which will be sent at baseline (visit 1, V1) and 4 months after the initiation of therapy (visit 2, V2). The questionnaires will be structured into 7 sections:~* 1 Demographics~* 2 Symptoms~* 3 Cognitive screening tests (MMSE, MoCA, and/or others)~* 4 Level of dependence (ADL, I-ADL, mRS, CASE) and impact on social life~* 5 Diagnostic tests (brain MRI, brain PET, CSF, and EEG findings)"
224106396|NCT07031375|BEHAVIORAL|Social prescribing|This two-day family-centered forest therapy program incorporates the six core elements of Forest Therapy-plants, water, diet, psychology, climate, and exercise therapy-while integrating multi-sensory experiences and group interaction.
224106397|NCT06875089|GENETIC|pGS-NBS|Collection of a second DBS card if the parents accept the pGS-NBS for their newborn
224106398|NCT06875089|OTHER|Satisfaction questionnaire|questionnaire on information process of parents informed about pGS-NBS
224106399|NCT06875089|OTHER|interview with HSS researcher|interview with a member of the HSS team on reasons for declining /accepting pGS-NBS
224106400|NCT06875089|OTHER|satisfaction questionnaire|questionnaire on results delivery in parents having accepted the pGS-NBS
224106401|NCT06875089|OTHER|Qualitative and quantitative longitudinal exploration|validated anxiety and depression scales to assess the psychosocial impact and perceived utility for 90 families whose child screened negative among which 30 families will be interviewed. Interviews and validated anxiety and depression scales will be suggested to all families receiving positive screening results
224106402|NCT06875089|OTHER|Medical follow up|follow-up of true positives and false negatives based on medical records (vital status, care pathways) until 5 years after results delivery
224106403|NCT07031622|OTHER|Yoga Exercises|The control and intervention groups received birth preparation training for 45 minutes one day a week for 5 weeks. The experimental group additionally received a total of 10 sessions of a yoga program for 45 minutes, 2 days a week. The content of each yoga session included 10 minutes of mindful breathing, 20 minutes of yoga asanas, and 15 minutes of meditation.
223723249|NCT06618313|DRUG|JCXH-213,an mRNA-LNP based in vivo CAR therapy|JCXH-213 infusion
223723250|NCT06680765|BEHAVIORAL|Intervention group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
223723251|NCT06680765|BEHAVIORAL|Comparison group|These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
223723252|NCT02971254|DRUG|Sevoflurane|
223723253|NCT02971254|DRUG|Desflurane|
223723254|NCT07015892|RADIATION|Thoracic Radiotherapy 45 Gy BID|45 Gy delivered in 30 fractions of 1.5 Gy twice daily over three weeks, with 95% of the planning target volume (PTV) receiving at least 95% of the prescribed dose.
223723255|NCT07015892|RADIATION|Thoracic Radiotherapy 60 Gy BID|60 Gy delivered in 40 fractions of 1.5 Gy BID. A minimum dose of 54 Gy will be accepted if organ-at-risk tolerance is exceeded.
224106404|NCT06723561|DRUG|4.5mg daily dose of naltrexone|Study subjects will take a daily 4.5mg dose of naltrexone.
224106405|NCT06725290|DIAGNOSTIC_TEST|Ocular Surface Disease Index (OSDI) questionnaire|The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers
224106406|NCT06925581|DRUG|HRS-6768|HRS-6768
224106407|NCT06729216|DIAGNOSTIC_TEST|Antifungal susceptibility testing (AFST)|testing the fungal susceptibility to different drugs
224106408|NCT00476931|BIOLOGICAL|SB-509|60 mg dose
223723256|NCT07015892|RADIATION|Thoracic Radiotherapy SIB 45-54 Gy BID|45 Gy in 30 fractions (1.5 Gy BID) to PTV and 54 Gy in 30 fractions (1.8 Gy BID) to high-risk CTV. Both delivered simultaneously using 3D conformal planning.
223723257|NCT07014748|DIAGNOSTIC_TEST|Handheld brain hematoma detector|Near Infrared based handheld traumatic brain hematoma detector
223723258|NCT07012616|OTHER|Supraclavicular brachial plexus block|Patients will receive an ultrasound-guided supraclavicular brachial plexus block.
223723259|NCT07015593|OTHER|interview|30 for Qualitative interview and 750 for quantitative survey
223723260|NCT00534430|DRUG|busulfan|
224106409|NCT00476931|OTHER|Placebo|Saline
224106410|NCT03567187|DEVICE|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
223953050|NCT02802332|BEHAVIORAL|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
224106411|NCT00813228|DRUG|Sitagliptin (Januvia)|
224289952|NCT05712382|BEHAVIORAL|Problem-solving risky situations|Identifying and planning for barriers to change are encouraged.
224289953|NCT05712382|BEHAVIORAL|Recovering from slips|Peer and personalized techniques are discussed to facilitate resumption of moderate drinking after a heavy drinking episode.
224289954|NCT06216574|OTHER|Internet-based Intervention|Receive access to SHINE modules
224289955|NCT05618353|DRUG|Colchicine|0.6 mg tablets
224289956|NCT05618353|DRUG|Placebo|Matching placebo
224289957|NCT03702634|BEHAVIORAL|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
224289958|NCT00002473|PROCEDURE|conventional surgery|
224289959|NCT00667082|DRUG|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
224289960|NCT04808882|DRUG|Tinzaparin, Low dose prophylactic anticoagulation|"Participants randomized to the LD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: LD-PA : 3500 IU/24h. Depending on the type of tinzaparin pre-filled syringe available in the participating center, the dose of 4000 IU/24h will be allowed in place of 3500 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: LD-PA: 4000 IU/24h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
224289961|NCT04808882|DRUG|Tinzaparin, High dose prophylactic anticoagulation|"Participants randomized to the HD-PA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: HD-PA : 7000 IU/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: HD-PA: 4000 IU/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
224289962|NCT04808882|DRUG|Tinzaparin,Therapeutic anticoagulation|"Participants randomized to the TA strategie will receive the low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: TA : 175 IU/kg/24h.~If tinzaparin is not punctually available, the use of enoxaparin will be allowed as follows: TA: 100 IU/kg/12h.~After day-14, or hospital discharge, or in case of an indication for TA, or of serious adverse event related to anticoagulation, the investigational anticoagulation strategy will be discontinued and anticoagulation treatment will be left at the discretion of attending physicians.~Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone. These recommendations will be subject to modifications based on the new literature data."
224289963|NCT00368095|BEHAVIORAL|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
224289964|NCT04335188|OTHER|Prospective oberservational registry|Non interventional study.
224106412|NCT05911022|DRUG|Colchicine 0.5 MG|three times per day for three days and subsequently twice per day for four days
223953051|NCT00078832|DRUG|anastrozole|aromatase inhibitor
223953052|NCT00078832|DRUG|placebo|Arimidex placebo
223953053|NCT01379885|BEHAVIORAL|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
223953054|NCT01379885|BEHAVIORAL|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
224106413|NCT05911022|DIETARY_SUPPLEMENT|Probiotic Formula|oral sachets once daily for two weeks
224106414|NCT05911022|OTHER|Standard protocol|the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
224106415|NCT06774963|DRUG|LNCB74|LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
224106416|NCT01225068|DRUG|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
224106417|NCT01225068|DRUG|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
224106418|NCT03121690|DRUG|Prednisone|prednisone 40 mg/day for 7 days
223538810|NCT04046393|DEVICE|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
223538811|NCT04046393|DEVICE|Meridian Energy Analysis Device(MEAD)|measure meridian energy
223538812|NCT04046393|PROCEDURE|bacteria culture|use culture swab to culture nasal discharge
223538813|NCT04046393|PROCEDURE|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
223953055|NCT02624830|DRUG|Sulfonylurea|See Arm description.
224106419|NCT03121690|DRUG|placebo|5ml saline / day for 7 days
223538814|NCT04046393|COMBINATION_PRODUCT|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
223538815|NCT02953184|DRUG|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
223723261|NCT00534430|DRUG|cyclosporine|
223723262|NCT00534430|DRUG|etoposide|
223723263|NCT00534430|DRUG|mycophenolate mofetil|
223723264|NCT00534430|PROCEDURE|allogeneic bone marrow transplantation|
223538816|NCT02953184|DRUG|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
223538817|NCT02953184|DRUG|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
223538818|NCT02953184|DRUG|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
223538819|NCT02953184|DRUG|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
223538820|NCT02953184|DRUG|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
223538821|NCT02953184|PROCEDURE|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
223538822|NCT02953184|PROCEDURE|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
223538823|NCT02953184|PROCEDURE|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
223538824|NCT04935255|OTHER|Blood sampling - Pharmacokinetic assessment|Two pharmacokinetic assessments will be performed (on day 2 and day 4). Each pharmacokinetic assessment consists of 10 samples (5 ml blood).
223538825|NCT03112876|OTHER|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
223723265|NCT00534430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223953056|NCT04635657|OTHER|Long-term Cognitive testing|These patients will undergo their standard of care cognitive testing at baseline, six weeks post-operatively and one year post-operatively.
223953057|NCT05145348|BIOLOGICAL|Immune response to Sars-CoV-2 vaccinations; including COVID-19 vaccin Moderna, Comirnaty (Pfizer) and Vaxzevria (AstraZeneca)|The vaccination is not part of the study, but part of the national immunization programme of the Netherlands. Blood will be drawn at 4 time points: baseline (t=1, \<2 months prior to first vaccination); t=2: 21-28 days after first vaccination and prior to second vaccination; t=3: 28 (21-42) days after second vaccination; t=4: 12 months (+/- 1 month) after second vaccination. Mucosal Lining Fluid (MLF) samples will be collected at 28 days (3-6 weeks) (t=3) and 12 (+/- 1) months (t=4) after the second vaccination.
223953058|NCT01736488|DRUG|Fimasartan|Fimasartan 60mg
223953059|NCT01736488|DRUG|Atenolol|Atenolol 50mg
223953060|NCT04927507|BEHAVIORAL|Internet plus nursing home rehabilitation|"The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time."
223953061|NCT01097811|DRUG|Erythromycin|250 mg orally q.i.d.
223953062|NCT01097811|DRUG|Neomycin|1 g orally q.i.d.
223953063|NCT01662388|DEVICE|Separation ring|Separation ring placed along with automatrix band
223953064|NCT01662388|DEVICE|automatrix band|band placed with a tightening device
223953065|NCT00505427|DIETARY_SUPPLEMENT|Alpha Lipoic Acid|
223953066|NCT02469025|OTHER|Manual caudal traction mobilization in resting position|
223953067|NCT02469025|OTHER|Manual caudal traction mobilization in end range position|
223953068|NCT02469025|OTHER|Selftreatment|Each subject is advice to do some exercises at home
223953069|NCT03076853|OTHER|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
223953070|NCT05548049|DEVICE|Bone harvesting from ramus area with piezosurgery for autogenous bone augmentation|In this invervention, the piezo-surgical device settings were set to irrigation: '4', function: 'cortical', light: 'auto'. After the full-thickness flap was lifted with the periosteal elevator, superior and vertical osteotomies were performed with the OT-12 piezo-surgical tip. Lower horizontal osteotomies were performed using OT8-L or OT-8-R piezo tips according to the studied quadrant, combining the vertical osteotomy.
223953071|NCT05548049|DEVICE|Bone harvesting from ramus area with conventional burs for autogenous bone augmentation|In control group, After the full-thickness flap is lifted with the periosteal elevator, using a thin #9 fissure burand the surgical handpiece S-11 Straight tip , the physiodispenser settings are according to the manufacturer's recommendations. The osteotomy was performed after it was adjusted to 40,000 rpm as appropriate. Bone incisions were completed with a round bur to combine the lower horizontal osteotomies and 2 vertical osteotomies. The osteotomies were completed with the help of a thin flat drill, and the block graft was carefully separated from the donor site.
223953072|NCT03713476|OTHER|Motor task training|motor task specific training
223953073|NCT02499094|OTHER|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
223953074|NCT01144533|PROCEDURE|isotonic saline injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* isotonic saline 4ml + telebrix(contrast media) 4ml~* The number of injections : only once during the study period~* Injection site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
224106420|NCT02032875|DRUG|Daclatasvir|
224106421|NCT02032875|DRUG|Sofosbuvir|
224106422|NCT02032875|DRUG|Ribavirin|
224106423|NCT06768229|OTHER|Consumption of a freeze-dried strains-mix.|One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.
224106424|NCT04358458|BIOLOGICAL|GEN3009|GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
224106425|NCT04358458|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
224106426|NCT06935201|BEHAVIORAL|Get Back|A rehabilitation program, targeting physical activity behavior, with a person-centered approach led by a physical therapist during 12 weeks (1 week before surgery until 12 weeks after surgery) in a digital format.
224106427|NCT05575310|PROCEDURE|Total Knee Arthroplasty|Articular knee surface replacement
224106428|NCT06105957|BEHAVIORAL|Core|The core intervention will include 24 online weekly behavioral modules, an online interactive discussion board, a physical activity tracker, an e-scale with recommendations for daily self-weighing, dietary self-monitoring via an app, as well as weekly calorie and physical activity goals. Weekly tips and discussion board postings invite participants to apply skills introduced in the modules and prompt interaction and social support within the closed group which starts the program simultaneously.
224106429|NCT06105957|BEHAVIORAL|Facilitated Weekly Group Sessions|Participants will receive 24 facilitated online video-conference-based weekly group sessions. These groups will be 60 minutes long and will be facilitated by a trained professional, who reinforces the information and behavioral strategies introduced in the weekly modules, elicits the experiences of participants in applying behavioral skills to establish new diet and exercise habits, and guides problem solving. Group cohesion to offer social support is promoted.
223723266|NCT00534430|PROCEDURE|peripheral blood stem cell transplantation|
223723267|NCT00534430|RADIATION|total-body irradiation|
223723268|NCT07016490|DRUG|SSGJ-709|A bispecific antibody targeting PD-1 and LAG-3.
223723269|NCT07015580|OTHER|16S rRNA sequencing|Clinical data including medical history, clinical symptoms, imaging examination, laboratory examination will be collected. 3-5ml saliva sample of every patients will be collected for 16S rRNA sequencing of oral microbiota.
223723270|NCT06880354|DRUG|CLL1 and CD38 Dual-Target CAR-T Cell Injection|This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that targets both CLL1 and CD38.
223723271|NCT07132307|DEVICE|Mandibular advancement device (MAD)|The intervention in this study involves fitting and using a mandibular advancement device (MAD), specifically the ProSomnus Sleep Device, to treat moderate to severe obstructive sleep apnea (OSA) in patients who are intolerant to CPAP and have failed hypoglossal nerve stimulation (HGNS) therapy.
223723272|NCT07132437|DRUG|ZKY001 EYE DROPS|"On the 1st postoperative day (Day1), ZKY001 eye drops were dropped into the experimental eyes (the operative eyes were taken as the experimental eyes). ZKY001 eye drops were given at 8:00 am ±1h from Day1 to Day5. 4 times a day, 1 drop each time, recommended interval of 4 to 6 hours.~Day6 was administered at 8:00 am ±1h, and ZKY001 eye drops were dropped into the test eye (the surgical eye was taken as the test eye). Day6 was given only once, 1 drop each time."
224106430|NCT06105957|BEHAVIORAL|Counselor Crafted Feedback|Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
223953075|NCT01144533|PROCEDURE|steroid injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
223953076|NCT01144533|PROCEDURE|sodium hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
223953077|NCT01144533|PROCEDURE|steroid and hyaluronate injection into the glenohumeral joint|"* Total volume of injection drugs: 8ml~* triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~* The number of injections : only once during the study period~* Injection Site : glenohumeral joint~* Material : 22-gauze spinal needle~* Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
223953078|NCT01106885|BEHAVIORAL|Medication Care Management (MCM)|"* Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
223953079|NCT01106885|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|"* Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each"
223953080|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
223953081|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
223953082|NCT04704440|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
223953083|NCT04704440|OTHER|Placebo-ambient air (FiO2 21%) under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
223953084|NCT01884207|OTHER|MRI|
223953085|NCT06275841|DRUG|vepdegestrant|experimental
223953086|NCT06275841|DRUG|esomeprazole|Experimental treatment to assess an endpoint
224106431|NCT06105957|BEHAVIORAL|Individual Coaching Calls|Participants will receive 3 online one-on-one coaching calls to focus on identifying and addressing challenges to successful behavior change and weight loss. The first call will emphasize amplifying motivation and promoting early treatment engagement by establishing rapport, exploring personal reasons for weight loss and lifestyle change, and reinforcing and expanding change talk, and it will occur prior to starting the core program. Subsequent calls will use a motivational interviewing-informed approach to problem solve barriers to self-monitoring, particularly dietary self-monitoring because of the strong role it plays in promoting better weight loss and will occur during the first half of the program, reflecting the critical role of early engagement in the treatment program on long term weight loss success. Coaching calls will be of approximately 30 min duration and will follow a semi-structured interview format.
224106432|NCT06105957|BEHAVIORAL|Pre-Scripted Feedback|Participants will receive up to 24 weekly messages constructed from a bank of pre-scripted messages that align with success, partial success, or absence of self-monitoring within each of the following domains: dietary monitoring, physical activity monitoring, and self-weighing, as well as on weekly module completion. Feedback is automatically generated based on decision algorithms and will be sent from program staff.
224106433|NCT01122810|PROCEDURE|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
224106434|NCT04837404|PROCEDURE|Ultrasound guided femoral access for complex PCI|Ultrasound guided femoral access for complex PCI
224106435|NCT04837404|PROCEDURE|Fluoroscopy guided femoral access for complex PCI|Fluoroscopy guided femoral access for complex PCI
224106436|NCT03863444|OTHER|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
223538826|NCT04919720|BEHAVIORAL|FRAM Model and Human Factors/Quality Improvement Intervention|The group will use semi-structured interviews and ethnographic observations to inform development of a Functional Resonance Analysis Method (FRAM) model of the process for rescue of deteriorating patients in EGS, using information from 3 hospitals. A focus group approach will be used in co-designing reform of the system for responding to post-operative deterioration, working with small groups of frontline clinical staff from relevant areas in the three Trusts involved.
224289965|NCT05665673|OTHER|Physical functions test|Participants; sociodemographic and descriptive data will be recorded. The Standardized Mini-Mental Test will be used for the global cognitive assessment of participants, the Brunnstrom staging to assess lower extremity motor recovery and indicate at what motor level, and the Functional Ambulation Classification to classify them according to the basic motor skills required for functional ambulation. Gait and balance assessment will be evaluated with Tinetti Balance and Gait Assessment (POMA), functional exercise capacity will be evaluated with 6 Minute Walking Test (6MWT), and peripheral muscle strength will be evaluated with knee extension strength.
224289966|NCT06234878|DEVICE|REEV SENSE|Gait analysis with an Inertial Measurement Unit (IMU) sensor
224289967|NCT06234878|DEVICE|Motion capture system|Gait analysis with reflective markers and pressure sensors
223538827|NCT02640027|PROCEDURE|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
224289968|NCT04637035|OTHER|Supportive Oncology Care at Home|Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
224289969|NCT05466032|OTHER|Osteopathic Manual Manipulation (OMM) Curriculum|Osteopathic medical students are enrolled in the OMM curriculum while masters students are not enrolled.
224289970|NCT06270628|BEHAVIORAL|Exercise group|Live-remote exercise sessions, personalized to the patients main side-effect
224106437|NCT03863444|OTHER|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
224106438|NCT00193362|DRUG|Paclitaxel|
224106439|NCT00193362|DRUG|Carboplatin|
224106440|NCT00193362|DRUG|Gemcitabine|
224106441|NCT00193362|DRUG|Vinorelbine|
224289971|NCT05251324|OTHER|Hot Flush Induction|A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
223538828|NCT02908711|DRUG|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
223538829|NCT01198626|DRUG|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
223538830|NCT01198626|DRUG|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
224106442|NCT01326598|DEVICE|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
224106443|NCT00878046|DEVICE|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
224106444|NCT02602873|OTHER|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
224106445|NCT03412630|RADIATION|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
224106446|NCT02183467|DRUG|BI 1356, low dose|
224106447|NCT02183467|DRUG|BI 1356, high dose|
224106448|NCT02183467|DRUG|Placebo|
224106449|NCT02183467|DRUG|Moxifloxacin|
224106450|NCT03524872|DEVICE|Original CAD/CAM prosthetic abutment|Original (Sweden\&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
224106451|NCT03524872|DEVICE|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
224106452|NCT03524872|PROCEDURE|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
224106453|NCT03524872|DRUG|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
224106454|NCT03524872|DRUG|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
224106455|NCT03524872|DEVICE|Implant placement|Dental implants (Sweden \& Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
224289972|NCT03740113|BEHAVIORAL|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
224289973|NCT04673448|BIOLOGICAL|Dostarlimab|Given IV
224106456|NCT02726867|DRUG|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
224106457|NCT02726867|DRUG|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
224106458|NCT02726867|DRUG|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
224106459|NCT02726867|DRUG|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
224106460|NCT03822403|DEVICE|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
224106461|NCT03822403|DEVICE|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
224106462|NCT00336193|BEHAVIORAL|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
224106463|NCT03526432|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
224106464|NCT03526432|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
224289974|NCT04673448|DRUG|Niraparib|Given PO
223538831|NCT01198626|DRUG|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
224106465|NCT03474003|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
224106466|NCT02021968|BIOLOGICAL|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10\^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
224106467|NCT02021968|BIOLOGICAL|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10\^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
224106468|NCT02021968|BIOLOGICAL|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
224106469|NCT02175563|DEVICE|Audiovisual feedback from smartphone based app|
224106470|NCT03445039|DEVICE|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
224106471|NCT03445039|PROCEDURE|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
224106472|NCT03445039|DEVICE|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
224106473|NCT03445039|PROCEDURE|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
224106474|NCT00053612|DRUG|Vitamin A|
224106475|NCT00266110|BIOLOGICAL|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
224106476|NCT00266110|BIOLOGICAL|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
224289975|NCT04673448|PROCEDURE|Biopsy|Undergo biopsy
224289976|NCT04673448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224289977|NCT04673448|PROCEDURE|Computed Tomography|Undergo CT
224106477|NCT00266110|BIOLOGICAL|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
224106478|NCT00266110|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
224106479|NCT04681664|OTHER|High fat diet|50 % fat
224106480|NCT01232972|PROCEDURE|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
224106481|NCT01266148|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
224106482|NCT01266148|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
224106483|NCT01266148|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
224106484|NCT01266148|DRUG|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
224106485|NCT01266148|DRUG|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
224106486|NCT05523726|BEHAVIORAL|pCBT-I|Telehealth coaching
224289978|NCT04673448|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224289979|NCT04279964|BEHAVIORAL|Boot Camp Translation|Practices in the intervention arm will participate in the Boot Camp Translation process, where BCT Community Advisory group members will come together to develop and implement practice relevant materials to promote adolescent vaccination.
224289980|NCT04279964|OTHER|Control|No intervention. Practices will continue to behave as usual.
224289981|NCT02520687|DIETARY_SUPPLEMENT|Beetroot juice|70mls daily for seven days
223953087|NCT05293093|OTHER|Wheelchair Skills Training Program|a standardized training method for users of manual and powered wheelchairs and it combines evidence on motor-skills learning with evidence on how to perform specific wheelchair skills. A recent systematic review and meta-analysis provided evidence that WSTP is a safe and effective intervention that has a clinically meaningful effect on powered wheelchair skill capacity, in particular for new wheelchair users. The WSTP has shown to be effective in several wheelchair-dependent populations and promising to be used in people with complex movement disorders. Yet, adaptation to the specific needs and capabilities of individuals with complex movement disorders is necessary as it has not been assessed in this population. During the 4-week training phase, the participants will receive 3 training sessions per week of 45 minutes, including exercises as described in the Wheelchair Skill Training Program Version 5.1.2
223953088|NCT01670877|DRUG|Neratinib|
224106487|NCT05890222|BEHAVIORAL|Community Intervention|Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.
224106488|NCT05890222|BEHAVIORAL|Healthy Activity Program (HAP)|HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.
224106489|NCT03270787|DRUG|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
224106490|NCT03270787|DRUG|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
224289982|NCT02520687|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|70mls daily for seven days
224289983|NCT04843566|PROCEDURE|Transperineal MRI-guided prostate biopsy|Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
224289984|NCT04843566|PROCEDURE|Transrectal MRI-guided prostate biopsy|Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
224289985|NCT04843566|DRUG|Antibiotic (prophylaxis)|"For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy."
224289986|NCT06051968|BEHAVIORAL|Online hearing support for first-time hearing aid users|Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.
224289987|NCT06051968|BEHAVIORAL|Hearing rehabilitation according to common practice.|Participants get hearing rehabilitation according to common practice.
224289988|NCT03349827|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
223953089|NCT01670877|DRUG|Fulvestrant|
223953090|NCT01670877|DRUG|Trastuzumab|
223953091|NCT01670877|PROCEDURE|Tumor biopsy|-Optional at baseline and disease progression
223953092|NCT01670877|PROCEDURE|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
223953093|NCT06354725|OTHER|Plyometric|Players were randomly assigned to a two-times-a-week (2PLYO, n = 15) or four-times-a-week (4PLYO, n = 15) PT group. Both groups performed the same weekly total volume of jumps during PT in addition to regular basketball training and competition. After the eight-week intervention, all players underwent a one-week detraining period with no PT training while basketball training and competitions continued. Testing was performed at baseline (pre-test), after intervention (post-test), and after the detraining period. Players were assessed for lower body power using jump tests (countermovement jump \[CMJ\], drop-jump \[DJ\] from a 20-cm box, and horizontal jump \[HJ\]; change of direction ability using a planned agility test; and speed using a 20-m sprint and a 5-m split.
224106491|NCT02850250|DRUG|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
224106492|NCT01079923|DIETARY_SUPPLEMENT|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
224106493|NCT01079923|DIETARY_SUPPLEMENT|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
224289989|NCT03349827|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
224289990|NCT03349827|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
224289991|NCT03349827|DRUG|Apatinib|500mg, once daily, day 1 to day 21.
224289992|NCT06857227|DRUG|GNC-038|Administration by intravenous infusion. Once a week (IV, QW), twice in total.
224289993|NCT06857227|DRUG|Placebo|The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
224289994|NCT06147440|OTHER|Dietary intervention|Participants receive diets following different dietary patterns for 1 week.
224289995|NCT04237623|DRUG|Sargramostim|250mcg/m2/day IV starting Day +5
223538832|NCT03817489|BEHAVIORAL|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
223953094|NCT03477799|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
223953095|NCT05658900|OTHER|Enucleation with albumin PRF|"The protocol that will be used in the preparation of albumin PRF~1. A sample of venous blood, at ten milliliters, at least will be drawn from the patient in a sterile centrifuge tube.~2. The venous blood sample will be centrifuged at 700 g for 8 minutes.~   \* Betadine: Povidone-iodine, 7.5% (0.75% available iodine), Purdue Products L.P~3. The platelet-poor plasma layer will be taken and heated at uniform temperature 75 celsius for 10 minutes in a thermostatic water bath incubator to denature albumin protein forming albumin gel.~4. Once the albumin gel is cooled, to room temperature for 10 minutes, it will be mixed with the buffy coat layer of PRF using 3 way stop cock and 2 plastic syringes with Luer lock to obtain albumin PRF then leave it in the dappen dish for 5 minutes."
223953096|NCT05658900|OTHER|Enucleation without albumin PRF|"The full-thickness mucoperiosteal flap will be performed using blade no. 15 and Bard- Parker handles extending one tooth anterior and one tooth posterior to the cystic cavity.~The mucoperiosteal flap will be reflected using the periosteal elevator to expose the bone.~Removal of the overlying bone to expose the cystic lesion. Enucleation of the cyst."
223953097|NCT02464215|PROCEDURE|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
223953098|NCT02464215|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
223953099|NCT05509881|DEVICE|Continuous glucose monitoring (CGM)|"Patients in the CGM arm will undergo continuous real-time unblinded CGM using Dexcom CGM devices."
223953100|NCT05509881|DEVICE|Usual care (Self-monitored blood glucose)|Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.
223953101|NCT01308879|BEHAVIORAL|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
223953102|NCT04432155|DRUG|Xenon|30% xenon, 30% oxygen, and 40% nitrogen
223953103|NCT04432155|DRUG|Placebo|30% oxygen, and 70% nitrogen
223953104|NCT00268697|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
224289996|NCT04237623|OTHER|Control Arm|Standard G-CSF given to those who decline to receive GM-CSF
224289997|NCT00493779|PROCEDURE|Blood Collection|4 weeks
224289998|NCT03055741|DRUG|Donepezil|5mg or 10mg, once a day, 24 weeks
224289999|NCT03055741|DRUG|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
224290000|NCT03055741|DRUG|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
224106494|NCT05283707|BEHAVIORAL|Paula Method Exercises|The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
223953105|NCT00268697|DRUG|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
223953106|NCT00268697|DRUG|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
223953107|NCT00689416|DRUG|rosuvastatin|40 mg, tablet, once daily for 3 months.
223953108|NCT00689416|DRUG|placebo|40 mg, tablet, once daily for 3 months
223953109|NCT00576550|DRUG|Urea|Urea cream applied twice daily up to six months
223953110|NCT00576550|DRUG|betamethasone valerate|Application once daily for two weeks
223953111|NCT00576550|DRUG|betamethasone valerate|Application twice daily for two weeks
223953112|NCT04251325|OTHER|Basic Life Support Courses|4 hours basic life support courses for laypersons
224106495|NCT03995771|OTHER|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
224106496|NCT06351410|DEVICE|Eye Wearing Contact Lens|Each participant will be given 2 types of a different group of contact lenses for each eye and need to wear for 8 hours only. Measurements will be done pre and post wearing of lenses
224290001|NCT03216109|BEHAVIORAL|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
223538833|NCT03817489|BEHAVIORAL|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
223538834|NCT01884363|OTHER|Once ounce per day of walnuts|
224290002|NCT01951287|OTHER|Acute beverage (water) consumption|Acute beverage consumption includes water.
224290003|NCT01951287|OTHER|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
224290004|NCT01951287|OTHER|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
224290005|NCT01951287|OTHER|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
224290006|NCT01951287|OTHER|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
224290007|NCT01951287|OTHER|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
224290008|NCT02915926|BEHAVIORAL|occupational performance coaching|
223953113|NCT06498323|DRUG|tenecteplase|Intravenous thrombolytic agents administration
223953114|NCT00500604|DRUG|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
223953115|NCT00500604|DRUG|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
223953116|NCT00500604|DRUG|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
223953117|NCT00648466|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
223953118|NCT00648466|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fasting
223953119|NCT03693989|DRUG|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
223953120|NCT03693989|DRUG|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~\- Route of administration: topical ophthalmic"
224290009|NCT02915926|BEHAVIORAL|standard OT|
224290010|NCT02075034|DRUG|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
223953121|NCT03956927|OTHER|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
223953122|NCT03956927|OTHER|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
223953123|NCT02418065|OTHER|training on ergonomic bicycle|
223953124|NCT02418065|DRUG|Testosterone|
223953125|NCT02418065|DRUG|Oral nutritional supplementation|
223953126|NCT02418065|DRUG|n3 polyunsaturated fatty acid|
223953127|NCT01073722|DEVICE|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
224106497|NCT00249886|DRUG|Citalopram|
224106498|NCT01853228|DRUG|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
224106499|NCT01853228|DRUG|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
224106500|NCT01853228|DRUG|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
224290011|NCT06308133|OTHER|apheresis procedure|collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
223538835|NCT01716364|BIOLOGICAL|Anti-LeY- scFv-CD28-ζ vector,.|
223538836|NCT02563730|PROCEDURE|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
223538837|NCT05221008|DRUG|SHR6508；Placebo|Group A:SHR6508 low dose
223538838|NCT05221008|DRUG|SHR6508；Placebo|Group B:SHR6508 medium dose
223538839|NCT05221008|DRUG|SHR6508；Placebo|Group C:SHR6508 high dose
223538840|NCT05221008|DRUG|SHR6508；Placebo|Group D:SHR6508 high dose(single dose)
223538841|NCT02897115|BIOLOGICAL|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
223538842|NCT02897115|OTHER|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
223953128|NCT01073722|DEVICE|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
223953129|NCT05649891|OTHER|Emergency Manual|Collection of crisis checklists and fact sheets
223953130|NCT02591082|DEVICE|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
223953131|NCT01381445|DRUG|GW870086 0.2%|White to slightly coloured opaque cream
223953132|NCT01381445|DRUG|GW870086 2%|White to slightly coloured opaque cream
223953133|NCT01381445|DRUG|Clobetasol Propionate|White cream
223953134|NCT01381445|DRUG|Placebo|White to slightly coloured opaque cream
223953135|NCT01017159|DRUG|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
223953136|NCT05243602|DRUG|Switch to B/F/TAF|This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
223953137|NCT05243602|DRUG|Continue current regimen|Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
223953138|NCT03146845|DEVICE|ALLEVYN Life Non-Bordered|Foam Dressing
223953139|NCT03146845|DEVICE|Standard Care|Foam Dressing
223953140|NCT03403153|BEHAVIORAL|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
223953141|NCT05100511|DEVICE|ERG electrode tests for fundus image-guided focal ERG|Investigate the patient comfort, usability and signal-to-noise ratio of different commercial CE marked ERG electrodes.
223953142|NCT05100511|DEVICE|Fundus image-guided focal ERG|Record focal ERG from a healthy retinal area and from an area with visible symptoms.
223953143|NCT00187356|PROCEDURE|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
223953144|NCT00113529|DRUG|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
223953145|NCT02304445|PROCEDURE|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
223953146|NCT02304445|RADIATION|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
223953147|NCT00309673|DRUG|lidocaine / Prilocaine|
223953148|NCT01553617|DRUG|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
223953149|NCT01553617|DRUG|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
223953150|NCT00787475|OTHER|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
223953151|NCT01411605|BEHAVIORAL|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
223953152|NCT06100354|OTHER|Answering preference|Patients will answer a questionnaire with two possible choices describing several scenario of used of customized and connected prosthesis
223953153|NCT03861884|DIAGNOSTIC_TEST|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
223953154|NCT04446949|OTHER|Register follow-up|Number of adverse pregnancy outcomes
223953155|NCT04505215|OTHER|Mulligan Technique|"First, the painless application angle was determined for each patient. The lateral condyle of the humerus was fixed by the web range of the physiotherapist. The elbow joint was glided until the elbow joint and the hand tightening position were not able to cause pain.~The patients were asked to repeat the motion of the elbow joint and the ball squeezing motion given to their hands 10 times without pain. For pain control, the same procedure was performed with three sets, each containing 10 repetitions of the exercise. The interval between sets was 15 to 20 seconds, and the interval between repetitions within each set was 30 seconds."
223953156|NCT04505215|OTHER|Muscle Energy Technique|Firstly, 5-7 sec opposite isometric muscle contraction was requested from the patient in the barrier by passively stretching by the physiotherapist until the barrier of the related muscle or dysfunctional joint. After a short rest period of 2-3 seconds, the physiotherapist continued to stretch passively until the second barrier. The application continued until the tension of the muscle or dysfunction of the joint disappeared.
224106501|NCT05115201|PROCEDURE|Scaling and root planing with antibiotics|Patients will be given amoxicillin and metronidazole, 500mg and 400mg respectively (AMX+MTZ) to be taken thrice daily for 7 days, as an adjuvant to scaling and root planing.
223953157|NCT04505215|OTHER|Only Exercise (Control)|Eccentric training for the extensor Carpi Radialis Brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercise for the EKRB muscle were given as home exercise program. The best stretching position for the EKRB tendon is provided when the elbow joint is in extension, forearm pronation, when the wrist is flexed with ulnar deviation (Mills maneuver). Each exercise was taught to patients in 10 repetitions and 10 seconds, and one day of the week, participants in the control group performed their exercises under the supervision of a physiotherapist.
223953158|NCT01535261|DRUG|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
224106502|NCT05115201|PROCEDURE|Scaling and root planing only|Patients will be treated with scaling and root planing
224106503|NCT02831868|DEVICE|HAVAI|implantation of the HAVAI device to correct the IMA angle
224106504|NCT02927223|DRUG|Atropine|
224106505|NCT02927223|PROCEDURE|Exercise treadmill test|
224106506|NCT01348919|DRUG|CEP-18770|CEP-18770 will be administered per dose and schedule specified in the arm description.
224106507|NCT01348919|DRUG|Lenalidomide|Lenalidomide will be administered per dose and schedule specified in the arm description.
224106508|NCT01348919|DRUG|Dexamethasone|Dexamethasone will be administered per dose and schedule specified in the arm description.
224106509|NCT06302634|OTHER|Exercise-based cardio-oncology rehabilitation|Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.
224106510|NCT00601289|DRUG|temozolomide|
224106511|NCT00601289|GENETIC|DNA methylation analysis|
224106512|NCT00601289|GENETIC|microarray analysis|
224106513|NCT00601289|GENETIC|protein expression analysis|
224106514|NCT00601289|GENETIC|proteomic profiling|
224106515|NCT00601289|OTHER|laboratory biomarker analysis|
224106516|NCT03054727|OTHER|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
224106517|NCT03054727|OTHER|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
224106518|NCT02368444|BEHAVIORAL|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
223953159|NCT02404298|DRUG|IVIg|
223953160|NCT04812977|DRUG|Group A|Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
223953161|NCT04371029|OTHER|PSG|Polysomnography at 3 times, actimetry measure and Pittsburgh questionnaire
223953162|NCT00004400|DRUG|testosterone|
223953163|NCT05881213|DRUG|CKD-378 (low-dose)|Quaque day (QD), PO
223953164|NCT02040038|BEHAVIORAL|LIVE|3-D Virtual Environment for DSMT/S
223953165|NCT02040038|BEHAVIORAL|Website|2-D Website participation for DSMT/S
223953166|NCT05798598|OTHER|Scientific writing training course|Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
223953167|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
224106519|NCT04646317|DRUG|Dexmedetomidine injection|Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
224106520|NCT04646317|DRUG|Normal Saline|0.9% as placebo
224106521|NCT04842344|DEVICE|ECCO2R|extracorporeal carbon dioxide removal
224106522|NCT01918215|DEVICE|ICD|
224106523|NCT01918215|DEVICE|ILR|
224106524|NCT03546478|BIOLOGICAL|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
224106525|NCT02636790|PROCEDURE|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
224106526|NCT00122499|DRUG|tadalafil|
224106527|NCT00234117|DRUG|Rabeprazole|
224106528|NCT00281411|PROCEDURE|Computed Tomography Angiography|Computed Tomography Angiography
224106529|NCT00281411|PROCEDURE|Magnetic Resonance Angiography|Magnetic Resonance Angiography
224106530|NCT04463160|OTHER|"prevention program for prediabetes Say No to Diabetes"|10 therapeutic education sessions
224106531|NCT04724486|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
224106532|NCT04724486|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
224106533|NCT04724486|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
224106534|NCT04724486|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of human chorionic gonadotropin when at least three follicles become more than 16-17 mm.
224106535|NCT01196910|DEVICE|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
224106536|NCT01707823|DRUG|acetylsalicylic acid|Given PO
224106537|NCT01707823|OTHER|laboratory biomarker analysis|Correlative studies
224106538|NCT02231216|PROCEDURE|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
224106539|NCT02231216|PROCEDURE|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
224106540|NCT02231216|PROCEDURE|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
224106541|NCT05658029|DRUG|ARINA-1|Fixed-dose solution of ascorbic acid and reduced glutathione nebulized twice daily for 4 weeks (28 days)
224106542|NCT00008164|PROCEDURE|umbilical cord blood transplantation|
224106543|NCT04094506|DRUG|ASP1948|Intravenous
224106544|NCT05907928|OTHER|Scotchbond universal adhesive plus|New generation BPA free universal adhesive
224290012|NCT01300624|BEHAVIORAL|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
224290013|NCT01885182|DRUG|Oxycodone/Naloxone|
224290014|NCT01885182|DRUG|Oxycodone|
224290015|NCT01508819|OTHER|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
224290016|NCT00444236|DRUG|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
224290017|NCT00444236|DRUG|Placebo|matching placebo for active drug
224290018|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part A)|20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
224290019|NCT05576623|BIOLOGICAL|AdCLD-CoV19-1 OMI (Part B)|250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
223953168|NCT01757288|DRUG|PACLITAXEL|
223953169|NCT01757288|DRUG|NAB-PACLITAXEL|nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
224290020|NCT05576623|OTHER|Placebo (Part B)|50 participants will receive placebo via intramuscular injection in the deltoid muscle
223538843|NCT06467630|PROCEDURE|Preserving alveolar bone volume after tooth extraction|"* Visit 1: A periodontal or dental implant surgery is done aiming to preserve alveolar bone volume after extraction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* V2bis (1 month +/- 1 week) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
223953170|NCT05258929|OTHER|Data collection (Prior and planned treatments, allograft)|MHLC questionnaire (Multidimensional Health Locus of Control) when a novel therapeutic strategy is set up
223953171|NCT04202263|DRUG|Minocycline Topical|Placement of minocycline cream 0%, 1%, 2% or 3% at one of four identical allergen skin test sites.
223953172|NCT04202263|DRUG|Placebos|Placement of minocycline cream 0%
223953173|NCT03989609|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
223953174|NCT03989609|DRUG|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
223953175|NCT01505309|DEVICE|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
223538844|NCT06467630|PROCEDURE|Alveolar crest reconstruction|"* Visit 1: A periodontal or dental implant surgery is done aiming to alveolar crest reconstruction~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (5 months ± 1 month) - Late post-surgery follow-up"
223538845|NCT06467630|PROCEDURE|Covering bone defects during immediate implant placement.|"* Visit 1: A periodontal or dental implant surgery is done aiming to cover bone defects during immediate implant placement.~* Visit 2 (10 days ± 4 days) - Early post-surgery follow-up~* Visit 3 (3 months ± 1 month) - Late post-surgery follow-up"
223953176|NCT03425500|PROCEDURE|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
223953177|NCT03425500|PROCEDURE|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
224106545|NCT05907928|OTHER|Single bond Universal|Radiolucent universal adhesive
224106546|NCT04426630|OTHER|mHealth for heart failure patients in Uganda|Patients at Uganda Heart Institute will be enrolled in an mHealth program intended to promote self-care for heart failure and improve their healthcare quality of life.
224106547|NCT04219540|DRUG|XR-B (SUBLOCADETM)|XR-B (SUBLOCADETM) contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. Following induction and dose adjustment with sublingual buprenorphine, the recommended starting dose is 300 mg monthly for the first two months followed by a maintenance dose of 100 mg monthly thereafter. XR-B is administered monthly only by subcutaneous injection in the abdominal region. Study clinical staff will have flexibility to continue the 300mg dose for greater than 2 months, or use the 100mg dose for initial induction, if the participant's opioid use history or clinical status at the time of dosing support these decisions.
224290021|NCT03707041|DRUG|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
224290022|NCT03707041|DRUG|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
224290023|NCT03707041|DRUG|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
224290024|NCT03707041|BIOLOGICAL|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
224106548|NCT04219540|DRUG|XR-NTX|XR-NTX (Vivitrol®) produces a 30-day mu opioid receptor antagonist blockade Induction procedures require detoxification off opioids (5-7 days since last opioid use), a negative opioid urine toxicology, negative self-report of any recent opioid use, and a naloxone challenge. The naloxone challenge consists of 0.4-0.8mg of IV/SC/IM naloxone followed by the observation of no opioid withdrawal symptoms, or the use of oral naltrexone (12.5-25mg) followed by 1-2 hours of observation. XR-NTX is then delivered as a 380mg (4cc) intramuscular injection to the upper outer gluteus (buttock). Study interventions are FDA-approved, used in accordance with FDA-labeling and will be administered by a study clinician
224106549|NCT02924792|DEVICE|Reinfusion - Sternal IO needle|
224106550|NCT02924792|DEVICE|Reinfusion - Intravenous needle|
224106551|NCT05011552|BEHAVIORAL|Self-Compassion, Health, and Empowerment (SHE)|The SHE intervention includes 8 weekly sessions and 24-hour access to the intervener for any additional support needed. The first and last sessions will be delivered over the phone with the woman based on a brochure. The brochure describes the four major components: a) IPV information, b) Danger Assessment, c) Safety Planning, and d) Resources. It will be discussed with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Session 2-7 focus on providing mental health self-care resources, which are deep breathing, progressive muscle relaxation, visualization, general introduction and overview of self-compassion, mindfulness, and loving-kindness.
224106552|NCT05011552|BEHAVIORAL|The Control Condition|Women randomized to the control group will be provided with the same brochure and mental health care resources.
224106553|NCT03808207|OTHER|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
224290025|NCT03245034|BEHAVIORAL|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
224290026|NCT02696941|DRUG|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
224290027|NCT02696941|DRUG|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
223723273|NCT07131345|DRUG|iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy|"Novel Bispecific Checkpoint Inhibition:~QL1706(iparomlimab and Tuvonralimab) was generated by using MabPair, a new technological platform that enables the production of two antibodies close to their natural forms from a single host cell line and is manufactured as one product. QL1706 contains a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 that were produced together in a fixed ratio. Each antibody was individually optimized to achieve desirable target coverage and antibody effector functions.~Chemotherapy for first-line treatment (pemetrexed plus cisplatin or carboplatin )~Chemotherapy for second-line treatment (pemetrexed, gemcitabine or vinorelbine)"
223723274|NCT05846945|OTHER|Threshold inspiratory muscle trainer device|The threshold inspiratory muscle trainer (IMT) device offers resistance to respiration through the spring-loaded valve.
223723275|NCT05846945|OTHER|Adjusting mechanical ventilator trigger sensitivity|modifying the mechanical ventilator trigger sensitivity so that patients can only initiate inspiratory flow by producing more negative intrathoracic pressure
223953178|NCT03425500|DEVICE|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
223953179|NCT02791308|DRUG|Pimecrolimus Cream 1% (Valeant)|
223953180|NCT02791308|DRUG|Vehicle cream|
223953181|NCT02791308|DRUG|Pimecrolimus Cream, 1%|
224106554|NCT01938222|PROCEDURE|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
224106555|NCT03933501|DRUG|amoxicillin and metronidazole|375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
224106556|NCT03933501|DRUG|Placebos|Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
224106557|NCT00189358|DRUG|ZD1839|
224106558|NCT00189358|DRUG|tamoxifen|
224106559|NCT02396147|DRUG|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
224290028|NCT02932020|DRUG|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
224290029|NCT02932020|DRUG|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
224290030|NCT02932020|DEVICE|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
224290031|NCT02932020|DRUG|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
224290032|NCT06198530|BEHAVIORAL|cognitive training in NLCs|In the nurse-led clinics(NLCs) training group, CCT was given twice a week during 1-6 months and once a week during 7-12 month in nursing clinic. There is 60 minutes at a time.
223953182|NCT02212275|DRUG|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
224106560|NCT02396147|DRUG|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
224106561|NCT02396147|DRUG|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
224106562|NCT01960686|BIOLOGICAL|Low dose RSV F Antigen|
224106563|NCT01960686|BIOLOGICAL|High dose RSV F Antigen|
224106564|NCT01960686|BIOLOGICAL|Dose 1 of Aluminum Adjuvant|
224106565|NCT01960686|BIOLOGICAL|Dose 2 of Aluminum Adjuvant|
224106566|NCT01960686|BIOLOGICAL|Dose 3 of Aluminum Adjuvant|
224106567|NCT01960686|BIOLOGICAL|Dose 4 of Aluminum Adjuvant|
224290033|NCT06198530|BEHAVIORAL|cognitive training in home|In the home-based training group, CCT was given four times a week during 1-6 months and twice a week during 7-12 month in nursing clinic. There is 30 minutes at a time. Nurses teach patients to acquire and carry out CCT at home during hospitalization. Nurses set the daily reminder function at 9:00am through training system.
224290034|NCT06198530|BEHAVIORAL|cognitive training in tradition|In the traditional training group, the Home Cognitive Training Manual for Alzheimer's Disease compiled by our research team was distributed.
224106568|NCT01960686|BIOLOGICAL|Placebo|
224106569|NCT02598713|DRUG|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
224106570|NCT06140108|DRUG|Empagliflozin 10 MG|Each participant will receive empagliflozin 10mg daily for 6 months.
224106571|NCT06140108|DRUG|MetFORMIN 500 Mg Oral Tablet|Each participant will receive metformin 1000mg daily for 6 months.
224106572|NCT06482060|DEVICE|Stabilization splint|Stabilization splint application is a treatment that improves the function of TMJ and masticatory muscles by creating a balanced, stable occlusion to reduce the effects of occlusal interference and parafunctional habits and eliminate associated pain.
224106573|NCT05316363|OTHER|OMT|"Suboccipital Release - Finger pads are placed onto suboccipital musculature and a smooth, gentle, and rhythmic laterocephalad traction is applied to reduce muscle tension.~Paraspinal Inhibition - Hands are placed under the patient's thoracolumbar spine and contract the erector spinae tissue to draw the thoracolumbar spine into extension and hold until relaxation is felt.~Rib Raising - Hands are placed under the subject's thorax and contact the rib angles with finger pads. Fingers are flexed while adding an anteriolateral traction directed at the rib angle while maintaining neutral wrists. Arms are used as a lever by leaning forward thus creating a fulcrum with the treatment table with a smooth, rhythmic motion. This motion is repeated several times throughout the entire thoracic region, unilaterally and then switch sides.~Diaphragm Release - Hands apply a gentle pressure until a barrier or point of ease of the fascia is felt and hold that position until tissue response is felt."
224106574|NCT06152601|PROCEDURE|anticipated bipedal standing position in the immediate post-operative phase|"Realization of a first stand-up within 6 hours after entry into PACU or extubation for admitted patients intubated, in PACU or on admission to ICU by a state-certified physiotherapist.~Immediately postoperatively, during his stay in a Intensive Care Unit, the patient will be offered a physiotherapy session including a lifting phase in a bipedal standing position."
223723276|NCT05846945|OTHER|Chest physiotherapy|Conventional chest physiotherapy
224290035|NCT02354911|BIOLOGICAL|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (\~10 million cells/injection).
224290036|NCT02354911|OTHER|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
224290037|NCT01207440|DRUG|Ponatinib|Ponatinib tablets.
224290038|NCT06451718|DEVICE|Intracorneal implantation|Intracorneal implantation of the nitinol investigational device
224290039|NCT03804164|OTHER|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
224106575|NCT02976831|DRUG|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
224106576|NCT02976831|DRUG|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
224106577|NCT03202121|OTHER|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
224106578|NCT03202121|OTHER|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
224106579|NCT03202121|OTHER|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
224106580|NCT00812110|DRUG|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
224106581|NCT04248777|OTHER|standardised OCT-guided intervention|The first OCT run (run1) analyse plaque characteristics, identify proximal and distal landing zones (according to previously published criteria) , measure lesion length and reference segments dimensions (diameters and luminal areas). The second run (run2) aims to assess adequate guidewire recrossing point into stent jailed side branch and identify early stent mechanical non-optimal results. The third run (run3) analyse final stent expansion and identify major struts malposition and edge dissection.
224106582|NCT02750566|PROCEDURE|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
223723277|NCT06711484|OTHER|Speak up traning program|The intervention includes the training program to be applied to the experimental group. The aims and objectives of the training program, the training content and modules were prepared by the researcher in line with the needs analysis. The training program consists of four modules: Communication, Speaking UP, Patient Safety and Medical Error. Before the training program starts, the training booklet will be distributed to the experimental group participants. In the training, teaching techniques such as plain narration, question and answer, brainstorming, case study, case discussion, station technique, six thinking hats technique, video-based error scenario activity etc. will be used. The video activity to be used in the speak up session of the training program was created by recording the correct and incorrect scenarios of three patient safety errors by experienced actors.
223723278|NCT06704594|DRUG|sertraline 50 mg daily|The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.
223723279|NCT06704594|DRUG|Placebo Oral Tablet|The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.
224106583|NCT02750566|OTHER|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
224106584|NCT06153381|OTHER|Chatbot|Rehabilitation program based on standard care, but assisted via an instant messaging application using a personal smartphone
224106585|NCT06153381|OTHER|Standard car|Rehabilitation program based on standard care, assisted with one education session plus informative brochure
224290040|NCT03804164|OTHER|Quality-of-Life Assessment|Ancillary studies
224290041|NCT03804164|OTHER|Survey Administration|Ancillary studies
223538846|NCT01267474|OTHER|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
223538847|NCT01267474|OTHER|Control|The control group received only three one-hour general sessions on health issues.
223538848|NCT00487981|DEVICE|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
224106586|NCT04394169|BEHAVIORAL|Intervention program|"Medical visits:~There will be three medical visits stipulated as follows:~* Visit 1 Intervention Group, four weeks after hospital discharge.~* Visit 2 Intervention Group, eight weeks after hospital discharge.~* Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~* Interview and physical examination.~* Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~* Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control."
223538849|NCT01345448|DRUG|Brimonidine|0.1% Brimonidine Lotion, dosed once.
223538850|NCT01345448|DRUG|Placebo Lotion|Placebo Lotion dosed once.
223538851|NCT00856323|DRUG|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
224106587|NCT04964726|BEHAVIORAL|Real-time fMRI dyadic neurofeedback|Participants will attempt to regulate their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
224106588|NCT01425866|BEHAVIORAL|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
224106589|NCT05927909|DIAGNOSTIC_TEST|Low Back Activity Confidence Scale (Lobacs)|Confidence Scale (LOBACS) is a self-report questionnaire designed to assess an individual's level of confidence in performing various physical activities involving the lower back region, to evaluate their perceived functional ability, and to assess the impact of low back pain on their daily life and functional performance.
224106590|NCT04352660|DRUG|Mitomycin-C injection|MMC delivered by preoperative subconjunctival injection
224106591|NCT04352660|DRUG|Mitomycin-C sponge|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
223538852|NCT00856323|BEHAVIORAL|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
223538853|NCT02869724|OTHER|Weekly divided delivery|
223538854|NCT02869724|OTHER|Monthly divided delivery|
223723280|NCT07040787|DRUG|HRS-5965 Capsules|Oral HRS-5965 capsules.
223953183|NCT00111865|BEHAVIORAL|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
223953184|NCT02669056|OTHER|5-HT measurement|
223953185|NCT02669056|OTHER|cerebral MRI|
224106592|NCT03406195|DEVICE|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
224106593|NCT02066090|DEVICE|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
223538855|NCT04145076|DRUG|Placebo|Two oral doses of placebo.
223538856|NCT04145076|DRUG|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
223723281|NCT07040787|DRUG|Clopidogrel|Oral clopidogrel.
223723282|NCT07040787|DRUG|Clarithromycin|Oral clarithromycin.
223723283|NCT06706414|DRUG|Denosumab (Prolia)|Subcutaneous injection with 60 mg Denosumab once
223723284|NCT06706414|DRUG|Letrozole (Aromatase Inhibitors)|Letrozole oral tablet 2.5 mg once daily
223723285|NCT07035665|DRUG|HRS-5965 Capsules|Oral doses of HRS-5965 capsules at fasted and fed conditions.
223723286|NCT06723821|OTHER|Neuromodulation group|During the 12 sessions of which the treatment consists in applying 60 minutes of microcurrent in low intensity.
223953186|NCT02669056|OTHER|Video recording|
223953187|NCT02669056|OTHER|EEG|
223953188|NCT02669056|OTHER|growth curves|
223953189|NCT02669056|OTHER|ASQ questionnaire|
223953190|NCT00042939|BIOLOGICAL|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
223953191|NCT00042939|DRUG|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
223953192|NCT00042939|DRUG|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
223953193|NCT02082639|BIOLOGICAL|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
223953194|NCT02082639|BIOLOGICAL|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
224106594|NCT02066090|DEVICE|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
224106595|NCT01483404|PROCEDURE|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
224106596|NCT01466751|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
223538857|NCT04145076|DRUG|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
224290042|NCT03659084|DRUG|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
224290043|NCT01592721|BIOLOGICAL|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
224290044|NCT02516410|DRUG|VX-661 plus ivacaftor combination|
224290045|NCT02516410|DRUG|Ivacaftor|
224290046|NCT02516410|DRUG|Placebo (matched to VX-661 plus ivacaftor combination)|
224290047|NCT02516410|DRUG|Placebo (matched to ivacaftor)|
224290048|NCT02894866|DEVICE|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
224290049|NCT06429839|COMBINATION_PRODUCT|Nimotuzumab with chemoradiotherapy|Radiotherapy,40-50.4Gy/20-28f. Nimotuzumab 400mg,ivgtt,W2d. Chemotherapy, S-1,40-60mg/m2, on BSA, orally twice daily on radiotherapy days.
224290050|NCT01432574|BIOLOGICAL|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
224290051|NCT00345020|PROCEDURE|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
223538858|NCT01087593|DRUG|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
223538859|NCT00392093|DRUG|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
224290052|NCT00996931|DRUG|lenalidomide|2.5 mgs per day orally for 12 weeks
223538860|NCT03510130|OTHER|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
224106597|NCT02690896|BEHAVIORAL|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
224106598|NCT02690896|BEHAVIORAL|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
224290053|NCT04461132|OTHER|Manual Lymphatic drainage (MLD)|MLD vith vodder technique was applied to leg
223538861|NCT03619993|DEVICE|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
223538862|NCT03619993|DEVICE|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
224290054|NCT04461132|OTHER|Skin Care|Wound was cleaned with salin and covered by dressing without including active products
223538863|NCT05246969|OTHER|Sepsis detection|The aim of the study was to observe whether the treating physicians were able to detect sepsis by strictly applying the recommended SOFA score.
223538864|NCT01659450|OTHER|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
223538865|NCT01659450|OTHER|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
223538866|NCT01659450|OTHER|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
223538867|NCT03764111|DEVICE|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
223723287|NCT06723821|OTHER|Neuromodulation sham group|During the 12 sessions of which the treatment consists in applying 60 minutes of sham microcurrent in low intensity.
223723288|NCT06733285|DRUG|Sensodyne Rapid Relief|Toothpaste containing 0.454 % weight/weight (w/w) SnF2 (1100 parts per million \[ppm\] fluoride).
223723289|NCT06733285|DRUG|Colgate Cavity Protection|A regular fluoride toothpaste containing 1000 ppm fluoride.
223723290|NCT06760949|PROCEDURE|Direct anterior approach hemiarthroplasty|Direct anterior approach hemiarthroplasty
224290055|NCT04461132|OTHER|Exercise|breathing and foot pump exercise was prescribed
223723291|NCT06760949|PROCEDURE|Posterior lateral approach hemiarthroplasty|Posterior lateral approach hemiarthroplasty
223723292|NCT06807489|DEVICE|Digi-physical treatment tool|A digital treatment tool named Evira will be used to provide the treatment.
224290056|NCT04461132|OTHER|Shame Manual Lymphatic drainage|manual lymphatic drainage was applied with light touch instead of real mld techniques
224290057|NCT06465732|DRUG|Dupilumab|the active comparator arm receive dupilumab only
223723293|NCT06803823|DRUG|ONO-2020|ONO-2020 group: Two ONO-2020 tablets will be orally administered once daily.
223723294|NCT06803823|DRUG|Placebo|Two ONO-2020 placebo tablets will be orally administered once daily
223723295|NCT06780319|PROCEDURE|Standard rehabilitation|rehabilitation with a private physiotherapist. Patients usually undergo 15 rehabilitation sessions, in line with HAS recommendations; the number of sessions can go up to 25, depending on the patient's profile and needs.
223953195|NCT05481008|DEVICE|transcatheter aortic valve implantation|All subjects undergo transcatheter aortic valve implantation because of symptomatic severe aortic valve stenosis. This is a routine medical procedure, not a study intervention.
223953196|NCT03349476|DEVICE|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
223953197|NCT01308099|DEVICE|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
223953198|NCT00795639|DRUG|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
223953199|NCT00795639|DRUG|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
223953200|NCT03518450|PROCEDURE|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
223953201|NCT03518450|PROCEDURE|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
223953202|NCT03518450|PROCEDURE|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
223953203|NCT03607578|BEHAVIORAL|Other: Control Group - Minimal Intervention|Basic Campaign Folder
223953204|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
223953205|NCT03607578|BEHAVIORAL|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
223953206|NCT02297854|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
223953207|NCT01074996|DRUG|S-1|40-60mg bid , days 1-14, every 3 weeks
223953208|NCT01074996|DRUG|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
223953209|NCT02634528|DRUG|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
223953210|NCT02634528|DRUG|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
223953211|NCT00798837|RADIATION|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions~* A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
223953212|NCT04188353|DEVICE|Optic nerve sheath diameter measurement|ONSD measurements done at screening (T1), 30 minutes after mannitol infusion (T2), 60 minutes (T3) and 120 minutes (T4)
223953213|NCT04188353|DRUG|Mannitol|Mannitol at dose of 0.25 to 1 gm/kg over 20 minutes via a dedicated IV line
223953214|NCT04631874|DRUG|CDFF0318, Champix|CDFF0318: Varenicline salt changed Champix: Varenicline tartrate
223953215|NCT02525744|DRUG|LY900014|Administered SC
223953216|NCT02525744|DRUG|Insulin Lispro (Humalog)|Administered SC
223953217|NCT01709045|OTHER|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
223953218|NCT01709045|RADIATION|Dual-Energy Computed Tomography (DECT)|
223953219|NCT01709045|OTHER|Ultrasound|
223953220|NCT01709045|OTHER|Transcranial doppler|
223953221|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
223953222|NCT02938286|DEVICE|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
223953223|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
223953224|NCT02938286|DEVICE|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
223953225|NCT02938286|DEVICE|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
223953226|NCT02938286|DRUG|AHES|Topical application at test region I-IV under occlusion for 15 minutes
223953227|NCT00346359|BIOLOGICAL|anti-thymocyte globulin|
224290058|NCT06465732|DRUG|Tofacitinib|the experimental arm receive dupilumab plus tofacitinib.
223953228|NCT00346359|DRUG|busulfan|
223953229|NCT00346359|DRUG|fludarabine phosphate|
223953230|NCT00346359|DRUG|methotrexate|
223953231|NCT00346359|DRUG|tacrolimus|
223953232|NCT00346359|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223953233|NCT00346359|PROCEDURE|peripheral blood stem cell transplantation|
223953234|NCT00674765|DRUG|Seroquel|400 mg/day
223953235|NCT00674765|DRUG|Placebo|400 mg/day
223953236|NCT02370953|DEVICE|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
223953237|NCT02370953|PROCEDURE|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
223953238|NCT04117659|OTHER|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
223953239|NCT04955886|DRUG|Surufatinib(HMPL-012)|Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .
223953240|NCT03114592|OTHER|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
223953241|NCT01278511|OTHER|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
223953242|NCT00330135|DRUG|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
223953243|NCT00330135|DRUG|placebo injection|placebo injection - 1 injection
223953244|NCT02596542|OTHER|Water immersion|Different temperatures of cold water immersion will be assessed
223953245|NCT03683212|PROCEDURE|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~1. Treatment of the congestion: (international guidelines and recommendations)~2. Treatment of precipitating factors~3. NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH \< 7.35 in absence of contra indication.~4. Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
223953246|NCT02586961|DRUG|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
223953247|NCT02586961|DRUG|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
223953248|NCT02586961|DRUG|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
223953249|NCT02586961|DRUG|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
223953250|NCT01161706|OTHER|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
223953251|NCT00054730|DRUG|CX516 (Ampalex®)|
223953252|NCT02241642|DEVICE|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
223953253|NCT02785822|DRUG|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
223953254|NCT02785822|DRUG|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
223953255|NCT02270606|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
223953256|NCT02270606|DRUG|fluorouracil|Given IV
223953257|NCT02270606|DRUG|oxaliplatin|Given IV
223953258|NCT02270606|DRUG|leucovorin calcium|Given IV
223953259|NCT02270606|PROCEDURE|therapeutic conventional surgery|Undergo total mesorectal excision
223953260|NCT00972114|PROCEDURE|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
223953261|NCT00972114|PROCEDURE|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
223953262|NCT00972114|PROCEDURE|CABG alone|Coronary artery bypass graft surgery alone
223953263|NCT00879710|DRUG|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
223953264|NCT01449760|OTHER|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
223953265|NCT01449760|OTHER|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
223953266|NCT00548444|BIOLOGICAL|MVA85A|Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
224106599|NCT01742221|BIOLOGICAL|HemaMax|single subcutaneous 12 microgram dose of HemaMax
224106600|NCT01742221|DRUG|Placebo|single subcutaneous dose
224106601|NCT03471221|BEHAVIORAL|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~1. Specific treatment goals are not planned for each visit.~2. Volunteers and treatment providers are not required to take detailed notes.~3. Visit content and activities are spontaneous.~4. Visit length can be as long or as short as needed."
224106602|NCT00770185|DRUG|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
223953267|NCT00548444|OTHER|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
223953268|NCT00426205|BIOLOGICAL|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
223953269|NCT04721483|PROCEDURE|Ramicotomy|We will selectively lesion the gray rami communicantes from T3 and T4 thoracic sympathetic ganglia
223953270|NCT04266821|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and FAQ handout) meant to mimic what physicians will receive in the real-world market as they learn about the Ethos technology.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the Ethos test at the clinically-appropriate point in each case."
223953271|NCT04459572|DIAGNOSTIC_TEST|suPAR|Soluble Urokinase Plasminogen Activator Receptor (suPAR)
223953272|NCT04552015|DIAGNOSTIC_TEST|TST vs PPD microneedle test|TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
223953273|NCT00110032|DRUG|EF5|Given IV
223953274|NCT00110032|PROCEDURE|conventional surgery|Undergo surgery
223953275|NCT00110032|PROCEDURE|positron emission tomography|Undergo PET
223953276|NCT00110032|RADIATION|fluorine F 18 EF5|Given IV
223953277|NCT00110032|OTHER|pharmacological study|Correlative studies
223953278|NCT06427239|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
223953279|NCT06427239|DRUG|Adebrelimab|Adebrelimab will be administrated per dose level in which the patients are assigned
223953280|NCT04895774|OTHER|Probiotic strains|Fresh stools will be cultured in vitro in fermenters with adjunction of probiotic strains
223953281|NCT04895774|OTHER|Polyphenols|Fresh stools will be cultured in vitro in fermenters with adjunction of polyphenols
223953282|NCT04895774|OTHER|Fibers|Fresh stools will be cultured in vitro in fermenters with adjunction of fibers
223953283|NCT04620642|BIOLOGICAL|Registry|No specific intervention. Data of the usual care will be collected as the medical history, the demographic data, the biological analyses, imaging report, etc.
223953284|NCT03938207|DIAGNOSTIC_TEST|Whole-genome genotyping|Using Whole-genome genotyping from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
223953285|NCT03938207|DIAGNOSTIC_TEST|Whole-genome sequencing|Using whole-genome sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
223953286|NCT03938207|DIAGNOSTIC_TEST|TCM pattern|We want to use TCM pattern to investigate the difference among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
223953287|NCT03938207|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease will take to do the DNA Exome sequencing.
223953288|NCT03938207|DIAGNOSTIC_TEST|Physical examination indicators, blood, urine and biochemical function test|To investigate the difference of Physical examination indicators, blood, urine and biochemical function test among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
223953289|NCT03938207|DIAGNOSTIC_TEST|Demographics, personal health behavior, living environment, dietary status, family history|To investigate the difference among the demographics, personal health behavior, living environment, dietary status, family history of among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease.
223953290|NCT03938207|DIAGNOSTIC_TEST|HLA typing|Using HLA typing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
223953291|NCT03938207|DIAGNOSTIC_TEST|Full-length 16S Amplicon Sequencing|Using Full-length 16S Amplicon Sequencing from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
224106603|NCT00770185|GENETIC|gene expression analysis|
223953292|NCT03938207|DIAGNOSTIC_TEST|Epigenomic|Using Epigenomic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
223953293|NCT03938207|DIAGNOSTIC_TEST|Metabolomics|Using Metabolomics from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
224106604|NCT00770185|OTHER|immunohistochemistry staining method|
224106605|NCT00770185|OTHER|laboratory biomarker analysis|
224106606|NCT02494908|BEHAVIORAL|Playing a computer game simulating a car race|Playing a computer game simulating a car race
224106607|NCT04555213|DRUG|NOX66|NOX66 Suppository
224290059|NCT02662231|PROCEDURE|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
224106608|NCT04507308|BEHAVIORAL|Single-session sleep intervention drawn from principles of the TranS-C youth protocol|We are providing participants psychoeducation on sleep and will be going over several handouts from the Youth version of the Transdiagnostic Sleep and Circadian Intervention (TranS-C-Youth) to improve sleep.
224106609|NCT04913324|BEHAVIORAL|Virtual Care|Infants randomized at 4 months of age to the intervention arm will participate in virtual care visits for 16 weeks in addition to standard of care in-hospital visits.
224290060|NCT02053129|OTHER|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
224290061|NCT02053129|OTHER|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
224290062|NCT05017779|BEHAVIORAL|Unstuck & On Target: High School|Unstuck \& On Target: High School (UOT:HS) is a group-based curriculum for high school students that targets executive function skills using Cognitive Behavior Therapy (CBT) techniques. UOT:HS focuses on key functions needed for adult success, such as: self-advocacy, flexibility, time management, motivation, goal setting, developing plans, monitoring progress. Guided practice begins with concrete interventionist support and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Lessons are delivered by school personnel within the school setting. Home extension activities are provided to parents.
224290063|NCT05017779|OTHER|Treatment as Usual|Participants in schools assigned to the Treatment as Usual (TAU) condition will continue to receive the standard school-based IEP accommodations and school supports that would typically be provided. Data will be collected on the types of supports TAU schools offer, and what supports TAU students receive.
224290064|NCT00209287|BEHAVIORAL|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
223953294|NCT03938207|DIAGNOSTIC_TEST|Environmental Toxic|Using Environmental Toxic from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
224290065|NCT03677791|OTHER|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
223538868|NCT03764111|DEVICE|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
224290066|NCT03677791|OTHER|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
224106610|NCT05198986|OTHER|Prone Position during Extra Corporeal Membrane Oxygenation (ECMO)|Pronation will be executed according to a predefined protocol: 4 caregivers will be required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube and the ventilator lines. The others will stand at each side of the bed. In the first step, the direction of the rotation will be decided giving priority to the side of the central venous lines. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. In the third step, the patient will be moved in the sagittal plane and maintained in that position for a short while to attach the cardiac electrodes to her/his back and to set a new bed sheet. In the last step, the patient will be turned to the complete prone position.
224106611|NCT03426215|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
224290067|NCT01032772|BEHAVIORAL|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
224290068|NCT01032772|BEHAVIORAL|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
223538869|NCT01365793|DRUG|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
223538870|NCT01365793|DRUG|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
223538871|NCT01365793|DRUG|0.45% saline intravenous fluid|0.45% saline fluid
223538872|NCT01365793|DRUG|0.9% saline Intravenous fluid|0.9% saline fluid
223538873|NCT01342731|DRUG|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
223538874|NCT02808429|DRUG|Placebo|Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
223953295|NCT03938207|DIAGNOSTIC_TEST|Medical Image|Using Medical Image from Taiwan Biobank among dry eye syndrome, healthy control, Sjögren's syndrome and other inflammation disease to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences.
223953296|NCT03400748|DEVICE|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
223953297|NCT01604122|OTHER|No drug|No drug.
224290069|NCT01252719|DRUG|Single-Dose IV Oritavancin Diphosphate|Oritavancin was administered as a single IV dose.
224290070|NCT01252719|DRUG|IV Vancomycin|Intravenous vancomycin was administered for a minimum of 7 days and up to a maximum of 10 days.
224290071|NCT01252719|DRUG|Placebo|Intravenous placebo was administered thereafter, for a minimum of 7 days and up to a maximum of 10 days (oritavancin and placebo).
224290072|NCT02988479|OTHER|Out of pocket payments in patients|
224290073|NCT01582984|OTHER|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
224290074|NCT03824990|BEHAVIORAL|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
224106612|NCT04448249|BEHAVIORAL|APN intervention|"APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary,~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
224106613|NCT03847337|OTHER|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
223953298|NCT01604122|OTHER|No drug|No drug.
224106614|NCT03847337|OTHER|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
224106615|NCT02004405|OTHER|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
224106616|NCT02004405|OTHER|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
224106617|NCT03763487|DIAGNOSTIC_TEST|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
224106618|NCT03763487|PROCEDURE|spleen volumetry|Ultrasound examination of spleen to scaled the size.
224106619|NCT03388983|OTHER|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
224106620|NCT00920465|DRUG|mifegyne and cytotec|One day dosage versus two days dosage
224106621|NCT03955029|OTHER|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session).
224290075|NCT03766490|DRUG|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
224290076|NCT03766490|DRUG|Gefitinib|Tablet, P.O. 250mg qd
223538875|NCT02808429|DRUG|Atacicept 25 mg|Participants received 25 milligrams (mg) of Atacicept once weekly as SC injection during this study up to a maximum of 73.6 weeks.
223538876|NCT02808429|DRUG|Atacicept 75 mg|Participants received 75 mg of Atacicept once weekly as SC injection during this study up to a maximum of 74.1 weeks.
223538877|NCT01416961|RADIATION|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
223538878|NCT01416961|DRUG|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
223538879|NCT01416961|DRUG|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
223953299|NCT06031506|DEVICE|Implant supported hybrid maxillary prosthesis|All patients will receive immediately loaded hybrid prosthesis supported by 4 zygomatic implants.
223953300|NCT03388957|DRUG|Propranolol|This drug will be given before the extraction procedure
223953301|NCT03388957|DRUG|Midazolam|This drug will be given before the extraction procedure
223953302|NCT00361088|DRUG|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
223953303|NCT00361088|DRUG|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
223953304|NCT01930188|DRUG|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
223953305|NCT01930188|DRUG|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
224106622|NCT03955029|OTHER|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if \<6, increase by 5 watt the value of each peak at the next session)
224106623|NCT03743558|BEHAVIORAL|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
224106624|NCT04864977|DRUG|Basal Insulin|Participants administered basal insulin
224106625|NCT04221074|PROCEDURE|PECS II versus ESP|compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
224290077|NCT03766490|DRUG|Icotinib|Tablet, P.O. 125mg tid
224290078|NCT05964790|DRUG|HS-10380|Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days
224290079|NCT05964790|DRUG|Placebo|Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days
224290080|NCT05707143|OTHER|home based stabilization exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
224290081|NCT05707143|OTHER|kegel exercises|3 times per day with 10 repetitions and holding time will be 5-10 sec
223953306|NCT01930188|DRUG|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
224106626|NCT03249896|BEHAVIORAL|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
224106627|NCT05354284|OTHER|online questionnaire|Questionnaire at three timepoints
224106628|NCT01369719|DRUG|osveral|receive 20 mg/kg daily orally
224106629|NCT01369719|DRUG|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
224106630|NCT04328623|PROCEDURE|Hypnosis|"conversational hypnosis technique call the magic glove"
224106631|NCT04328623|PROCEDURE|Infiltration|Ultrasound-guided hand infiltration
224106632|NCT06554613|DRUG|Olanzapine|Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
224106633|NCT06554613|DRUG|Nivolumab|Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
224290082|NCT05626699|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
224290083|NCT04815421|OTHER|the paste group|Patients in the paste group were treated with Nanxing paste on the affected region include shoulder, neck or back and no more than 3 pieces. The paste lasted for 24 hours and then peeled it rested the pasted region for 24 hours and changed another paste on the pain region. The therapy duration was 6 days.
224106634|NCT01432314|OTHER|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
224106635|NCT01432314|OTHER|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
224106636|NCT00849693|DRUG|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
224106637|NCT00849693|DRUG|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
223538880|NCT05468502|DRUG|Human umbilical cord mesenchymal stem cell injection|Different doses of human umbilical cord mesenchymal stem cell injection were infused to the focus of patients with idiopathic pulmonary fibrosis through bronchoscope, and the tolerance of subjects to different doses of human umbilical cord mesenchymal stem cell injection was observed, and the curative effect was preliminarily observed.
223538881|NCT01794910|OTHER|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
223538882|NCT00134615|BEHAVIORAL|RQP patient health education module|
223538883|NCT01230320|PROCEDURE|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~1. the reproduction of denture-bearing tissues by means of impression techniques and casts;~2. the registration of maxillo-mandibular relations;~3. try-in of artificial teeth and carved denture bases."
223538884|NCT01469039|DRUG|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
223538885|NCT01469039|DRUG|Placebo|Placebo for IM injection, given monthly
223538886|NCT01132703|DRUG|Glyburide for Injection|Administered as specified in the Treatment Arm.
223538887|NCT01132703|DRUG|Placebo|Administered as specified in the Treatment Arm.
223953307|NCT01930188|DRUG|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
223953308|NCT02514824|DRUG|MLN0128|Investigational mTOR kinase inhibitor
224106638|NCT00849693|DRUG|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
224106639|NCT00849693|DRUG|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
223953309|NCT05702788|DRUG|Jaktinib hydrochloride tablets|75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
223953310|NCT05702788|DRUG|Jaktinib hydrochloride tablets|100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
223953311|NCT05702788|OTHER|Placebo|Placebo (given as two placebo tablets) administered orally BID with best available treatment.
223953312|NCT02173457|DRUG|Chiglitazar|Take orally
223953313|NCT02173457|DRUG|Sitagliptin|Take orally
224106640|NCT04804124|BEHAVIORAL|Regularized Sleep Schedule|Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
224106641|NCT02974075|PROCEDURE|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
224106642|NCT05435248|DRUG|HS-10375|HS-10375 will be administered orally once daily in a continuous regimen
224106643|NCT05344092|BEHAVIORAL|VetEd Mobile Application|Participants be provided with the VetEd mobile app, with instructions on how to utilize the app at home over a four-week period
224106644|NCT04364672|DRUG|18F-labeled DPA-714 PET scan|One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 within 4 weeks after completing NACT including at least 2 cycles administered; before surgery
223538888|NCT05624983|DIAGNOSTIC_TEST|acoustic otoemisions|TOAE and DPOAE
223953314|NCT01406041|BIOLOGICAL|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
224106645|NCT03352440|DEVICE|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
224106646|NCT03352440|DEVICE|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
224106647|NCT03352440|DEVICE|Control Group - Kinect|Group with typical development that will perform the task on Kinect
224106648|NCT03352440|DEVICE|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
223538889|NCT05624983|DIAGNOSTIC_TEST|Otoscopy|presence of earwax checked by video otoscop
223538890|NCT05624983|DIAGNOSTIC_TEST|Audiometry|Hearing Threshold will be measured with the AD528 interacoustics
223538891|NCT05624983|DIAGNOSTIC_TEST|Tympanometry|Tympanic mobility will be measyred with the Titan interacoustics
223723296|NCT06780319|PROCEDURE|Tele-rehabilitation|Tele-education is a digital home-based intervention involving exercises and education. Patients are monitored remotely by a physiotherapist via a secure messaging system. The system consists of a mobile application for the patient and a web portal enabling the physiotherapist to review patient data (physical activity, pain levels, medication use, exercise adherence, patient-reported results, images, videos) on a daily basis and tailor the protocol accordingly.
223953315|NCT05748184|DEVICE|ULDCT PACS prototype|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images.
223953316|NCT05748184|DEVICE|PACS viewer prototype|A PACS system mimicking the clinical PACS system used in LUMC.
223953317|NCT05748184|DEVICE|Optimized ULDCT viewer prototype version(s)|The ULDCT viewer prototype is a non-medical unreleased device that will be used by study participants on de-identified image cases in a research setting. The Prototype integrates new tools to speed up the diagnostic interpretation process of radiological images. Optimized version(s) of previous version.
224106649|NCT03531229|DRUG|Placebo|Placebo to Lu AF76432 oral solution
224106650|NCT03531229|DRUG|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
224106651|NCT01993355|OTHER|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
224106652|NCT01993355|OTHER|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
224106653|NCT01993355|BEHAVIORAL|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
224106654|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
224106655|NCT06171217|DRUG|Hydroxyurea|Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
224106656|NCT00693381|DRUG|Tacrolimus|oral
224106657|NCT00693381|DRUG|Mycophenolate Mofetil|oral
224106658|NCT00693381|DRUG|methylprednisolone and prednisone|IV and oral
224106659|NCT02018510|BIOLOGICAL|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
224106660|NCT02018510|BIOLOGICAL|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
224106661|NCT02018510|BIOLOGICAL|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
224106662|NCT02018510|BIOLOGICAL|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
224106663|NCT02018510|BIOLOGICAL|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
223723297|NCT06872671|OTHER|Experimental: Breathing Exercise Group|Eyes will be closed first. Head and neck will be relaxed. Breathing will be taken through the nose for three seconds. Then the breath will be held for three seconds. In the last step, breath will be exhaled through the mouth for three seconds. The patient will be instructed to take five normal breaths between each breathing exercise. The patient will be asked to count to three and will be told that he/she can count by using his/her fingers. The exercise will be started two minutes before the catheterisation procedure and the patient will be instructed to perform the breathing exercise twice. The patient will be asked to continue doing the breathing exercise until the PIC application process is completed.
223953318|NCT04090502|OTHER|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
223953319|NCT04090502|OTHER|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
224106664|NCT02018510|BIOLOGICAL|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
224106665|NCT04269512|PROCEDURE|lymph node dissection|At least 10 lymph nodes must be removed.
223953320|NCT06147466|DEVICE|Dexcom Continuous Glucose Monitoring|A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely
223953321|NCT01074528|BEHAVIORAL|mindfulness based stress reduction program|8-week mindfulness training program
224106666|NCT04550546|DRUG|Nystatin|600,000 U/mL of nystatin in a rinse suspension
224106667|NCT04018170|DRUG|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
224106668|NCT04018170|DRUG|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
224106669|NCT04308369|BIOLOGICAL|Blood collection arm|Blood collection will be performed before the spa therapy (Day 0), at the end of the spa therapy (Week 3) and 6 months later (M6). In this study, blood samples will be collected by a nurse of the service and centralized by the laboratory of Medical Biology of the General hospital of Dax.
224106670|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
224106671|NCT01907529|DRUG|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
224106672|NCT01094340|DRUG|Thalidomide|fixed dose over 8 clinic visits
224290084|NCT04815421|OTHER|the meridian group|Patients in the meridian group were treated with dredging the same side three yang meridian techniques(include the gliding techniques of deep tissue massage on three yang meridians of back hand (the second, fourth and fifth metacarpal bone); pinching and kneading the second, fourth and fifth phalanges of fingers of the affected side hand; Encourage the patient to try his best to roll his neck to the most tolerable degree during dredging the meridian) and the total time was about 3 to 5 minutes according the tolerance of every patient . The massage will not stop until the meridian route was relatively smooth, soft and thermal or light red. The sequence of massage is Hand Yangming meridian(LI) the first, Hand Taiyang meridian(SI) the second and Hand Sanjiao(SJ) the last. The frequency of massage was once a day.
224290085|NCT03145402|BIOLOGICAL|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
224290086|NCT03145402|BIOLOGICAL|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
223723298|NCT06872671|OTHER|Valsalva Manoeuvre Group|The valsalva manoeuvre will be performed by blowing into a plastic tube connected through a sphygmomanometer. Patients will be allowed to raise the manometer by 30 mmHg for at least 20 seconds. Care will be taken to ensure that the PIC procedure is performed by the same nurse for the patients in the Valsalva manoeuvre group. The nurses performing the PIC procedure will be informed about the research subject and will be told that the patients will start the valsalva manoeuvre before the PIC procedure. Patients who can perform the valsalva manoeuvre by the researcher will be included in the study. Haemodynamic variables (blood pressure, pulse, saturation) of the patients will be recorded before the valsalva manoeuvre. Afterwards, the researcher will instruct the patients to blow into the plastic tube for 20 seconds after a deep breath to create 30 mmHg pressure.
223723299|NCT03685578|DEVICE|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
223723300|NCT03685578|DEVICE|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter|CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
223723301|NCT03685578|DEVICE|CEREGLIDE 71 Intermediate Catheter|CEREGLIDE 71 Intermediate Catheter
223723302|NCT07132593|PROCEDURE|ventricular reconstruction|The Sandwich Procedure was developed at our institution to improve the strength and stability of heart wall reconstruction after tumor removal. It involves suturing two layers of treated biological tissue-both inside and outside the heart wall-to restore normal shape and function, while minimizing the risk of complications like aneurysm or bleeding.
223953322|NCT01827761|BEHAVIORAL|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
223953323|NCT02173990|DRUG|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~* Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin\* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~* 5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~  * \*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
223723303|NCT06418724|DRUG|Cetuximab|Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR). EGFR is over-expressed in many human cancers, including colorectal cancers.
223723304|NCT06418724|DRUG|Cemiplimab|Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). Engagement of PD-1 with its ligands PD-L1 and PD-L2, which are expressed by antigen presenting cells and may be expressed by tumour cells and/or other cells in the tumour microenvironment, results in inhibition of T cell function such as proliferation, cytokine secretion, and cytotoxic activity. Cemiplimab potentiates T cell responses, including antitumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
223953324|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
223538892|NCT04037228|DEVICE|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
223723305|NCT04090619|OTHER|Questionnaire Administration|Complete questionnaires
223723306|NCT06829264|BEHAVIORAL|Individualized Placement and Support Model|The Individualized Placement and Support (IPS) model is an evidence-based approach to supported employment designed to help individuals with disabilities achieve and maintain competitive integrated employment (CIE). IPS emphasizes person-centered planning, rapid engagement, and focusing on individual strengths and preferences. Key features include prioritizing CIE, eligibility based on the desire to work, integration of employment services with mental health support, rapid job searches, tailored job development, and time-unlimited, individualized support. IPS also provides benefits counseling to help participants manage employment while maintaining government benefits. For this study, IPS is adapted to meet the needs of autistic individuals by enhancing provider training and family involvement to improve outcomes.
223723307|NCT06829264|BEHAVIORAL|Supportive Employment Intervention|This intervention consists of a weekly series of sessions designed for adult consumers, incorporating supportive elements inspired by the ACCESS (Acquiring Career, Coping, Executive, and Social Skills) program developed at the UC Davis MIND Institute. The sessions will provide time to discuss consumer experiences, give general guidance and some training in employment-related skills, including resume building, job interviewing, and strategies for giving and receiving feedback in the workplace.
223723308|NCT06828042|BIOLOGICAL|anti-CD19 CAR T cell therapy|anti-CD19 CAR-γδ T cell therapy
223723309|NCT07122427|PROCEDURE|Graft collection|Sampling of superior venous and arterial grafts (internal mammary artery, great saphenous vein) after coronary artery bypass surgery.
223953325|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
223953326|NCT00696241|DRUG|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
223953327|NCT00696241|DRUG|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
223953328|NCT00696241|DRUG|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
223953329|NCT00976651|DRUG|human menopausal gonadotropin|200 IU per day in the late follicular phase
223953330|NCT04717570|DEVICE|Foldax TRIA Mitral Valve|Mitral Valve Replacement
223953331|NCT03738384|DEVICE|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
223538893|NCT03019887|DRUG|reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
223953332|NCT05746234|BEHAVIORAL|Emotion Regulation Course|"Each module contains a) the session outline, b) review of previous session's homework, c) theoretical background and module's rationale, d) skills activities, and e) homework assignment.~Each group will attend five 1.5-hour sessions with their allocated instructor. Participants in both groups will receive the same training modules in the same chronological order. For consistency across modalities, participants will receive an instructor's manual containing the core material for facilitating the ER4ALL training, and a companion students' workbook with supporting information and activities."
223953333|NCT02429115|OTHER|Mentoring|Six months of peer-mentoring.
223953334|NCT03158415|BEHAVIORAL|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
223953335|NCT02762201|PROCEDURE|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~* Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~* Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
223723310|NCT07132372|OTHER|Birth Memories and Recall scale|The data collection tools were applied to the participants by the researcher through face-to-face interviews. At the outset, the purpose of the study was explained to the participants. It was stated that participation in the study was completely voluntary and that they could withdraw from the study at any time. Then, their written and verbal consent was obtained.Participants who agreed to participate in the study, had no condition that would prevent communication, and had babies between the ages of 0 and 1 were included in the study.Data were collected using a personal information form, BIMF, PMBAS, and BirthMARQ.
223723311|NCT07131514|DRUG|HRS-4642+AG +Adebrelimab|HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.
223723312|NCT06205238|OTHER|CGA|"CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up."
223723313|NCT02751996|DRUG|SB 9200|SB 9200
223723314|NCT02751996|DRUG|Placebo|
223953336|NCT02762201|PROCEDURE|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
223953337|NCT00726505|DRUG|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
223953338|NCT04452383|DRUG|Ketamine + propofol|effect of adding ketamine to propofol for patients undergoing DISE surgery
223953339|NCT04452383|DRUG|propofol|effect of IV propofol alone for patients undergoing DISE surgery
223953340|NCT02508441|DRUG|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
223953341|NCT02372318|DRUG|Nalmefene|18mg of Nalmefen will be administered orally
223953342|NCT02372318|DRUG|Placebo|Placebo tablet
223953343|NCT01331408|DEVICE|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
223953344|NCT01650051|DRUG|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
223953345|NCT01650051|DRUG|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
223953346|NCT04549688|PROCEDURE|high-intensity focused ultrasound, HIFU|see above
223953347|NCT04106739|DEVICE|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
223953348|NCT04364399|BIOLOGICAL|Mumps vaccine|One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50
223953349|NCT04364399|BIOLOGICAL|measles, mumps and rubella combined vaccine, live|One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50
223953350|NCT02724501|BEHAVIORAL|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
223953351|NCT02724501|PROCEDURE|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
223953352|NCT04405310|BIOLOGICAL|Convalescent Plasma of patients with COVID-19|Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.
223723315|NCT02751996|DRUG|Tenofovir|
223953353|NCT04405310|OTHER|placebo (hartmann plus albumine)|use of albumin 20% in 250cc of Hartmann solution
223953354|NCT05461053|DRUG|LMX 4 Topical Cream|The intervention group will be prescribed a course of LMX4 with application of a non-permeable dressing (Tegaderm, 3M, St Paul, MN) until time of spontaneous drainage, treatment failure, or resolve of pain. LMX4 is a topical anesthetic consisting of 4% lidocaine which is Food and Drug Administration (FDA) approved for topical use in children.
223953355|NCT01932203|DRUG|aspirin|100mg once a day
223953356|NCT01932203|DRUG|cilostazol|200mg once a day
223538894|NCT02983240|DEVICE|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
223538895|NCT05685420|DRUG|Herombopag|Thrombopoietin receptor agonist
224290087|NCT01120652|BEHAVIORAL|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
224290088|NCT01120652|BEHAVIORAL|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
223538896|NCT02171026|DRUG|Dabigatran etexilate|
223538897|NCT02171026|DRUG|Amiodarone|
223723316|NCT06508125|DRUG|cross-linked hyaluronic acid|cross-linked hyaluronic acid injection with physical therapy
223953357|NCT06455683|PROCEDURE|Glaucoma Surgery|"One of 5 Types of Interventions will be performed~1. Trans-trabecular meshwork surgery with or without an implant~2. Trans-scleral surgery with or without implant~3. Ciliary Body Treatment~4. Suprachoroidal surgery with or without implant~5. External Non Incisional Treatment"
223953358|NCT00476385|DRUG|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
223953359|NCT05225753|DIAGNOSTIC_TEST|hemoglobin serum value|post-operative anemia evaluated with hemoglobin serum value
223953360|NCT01013584|DIETARY_SUPPLEMENT|cholecalciferol|daily dose
224290089|NCT05492370|DIETARY_SUPPLEMENT|EpiCor|2 gummies daily
224290090|NCT05492370|DIETARY_SUPPLEMENT|Placebo|2 gummies daily
224290091|NCT03629600|DRUG|Lactated Ringer|High-volume Lactated Ringer Solution
223538898|NCT03623698|DRUG|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
224290092|NCT03629600|DRUG|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
224290093|NCT05439811|PROCEDURE|Swan-Ganz Catheter|Swan-Ganz Catheter
223538899|NCT01025557|OTHER|Dietary intervention|Dietary treatments with beverages
223538900|NCT00811954|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
223538901|NCT00811954|DRUG|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
223723317|NCT06508125|DRUG|non-cross-linked hyaluronic acid|non-cross-linked hyaluronic acid injection with physical therapy
223723318|NCT03713970|PROCEDURE|celtra duo press|celtra duo press ingot
223723319|NCT03713970|PROCEDURE|IPS e.max press|IPS e.max press ingot
224106673|NCT00634543|DRUG|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
224290094|NCT01857648|OTHER|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
224290095|NCT01224028|DRUG|Tacrolimus|oral
224290096|NCT01224028|DRUG|Placebo|oral
223538902|NCT00811954|DRUG|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
223538903|NCT00811954|DRUG|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
223538904|NCT00811954|DRUG|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
223953361|NCT00090519|DRUG|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
223953362|NCT00090519|DRUG|placebo|QD oral for up to 36 months
223953363|NCT05298813|BIOLOGICAL|IBIO123|IBIO123 1 mg, 5 mg and 10 mg
223953364|NCT05298813|OTHER|Placebo|Matching Placebo
223953365|NCT04783025|BEHAVIORAL|Blended Gaming COVID-19 Training System (BGCTS)|"BGCTS is a blended training programme integrated with games and short video clips for Residential Care Home staffs to learn the principles of infection control and reinforce actions needed to stop the spread of COVID-19 within the RCHs, and to care for those residents suspected of having COVID-19. The contents of the training will refer to the evidence-based contents from The COVID-19 Risk Communication Package For Healthcare Facilities.~Dosage of the intervention. Staffs are encouraged to learn each topic independently in 15 minutes. It will take a total of 120 minutes to complete all eight topics in 2 weeks. Staffs will attend two 30-minute face-to-face group sessions conducted by research nurse (and the Infection Control Officer of the RCH) to clarify concepts (one per week; after playing the games). Scores and progress bar will be shown to the staff so as a form of motivation to encourage continuous participation in the training."
223953366|NCT04783025|BEHAVIORAL|Usual care, infection control briefing|Participants in the CG will receive usual care, the infection control briefing given by the Infection Control Officer (ICO) of the RCHs to all staffs. Usually the briefing is irregular, non-standardized and determined by ICOs, depending on when the ICOs receive the information about infection control practice from Centre for Health Protection of the Hong Kong government. The format and duration of this briefing is determined by the ICO. Some ICOs deliver the infection control information in the form of posters or a written document, and circulate these materials to all staffs.
223953367|NCT03908775|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
223953368|NCT03908775|DEVICE|Direct Laryngoscope|An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
223953369|NCT01974102|BEHAVIORAL|Lifestyle counseling|Active control group will receive weekly session for viewing relaxing video and discussion plus nutritional and physical activity counseling for 8 weeks.
223953370|NCT01974102|BEHAVIORAL|Parenting Mindfully for Health (PMH)|Active participants will receive 8 weeks of mindfulness based parenting stress reduction (PMH) plus nutritional and physical activity counseling for 8 weeks.
223953371|NCT06251336|OTHER|UroialTM Plus|Nutraceutical
223953372|NCT06251336|OTHER|Placebo|Placebo sachet
223953373|NCT03510052|BEHAVIORAL|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
223953374|NCT00333372|DRUG|Z-338|
223953375|NCT02295189|DRUG|Ketorolac Tromethamine|anti-inflammatory injection
224106674|NCT00634543|DRUG|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
223538905|NCT03436901|DIAGNOSTIC_TEST|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
223538906|NCT05680493|PROCEDURE|Manual pressure release|lengthens the muscle up to the increasing resistance, then gradually applies gentle pressure on MTrp until fingers feels a definite increase in tissue resistance (first barrier). Pressure would maintain until clinician sense relief of tension
223538907|NCT05680493|PROCEDURE|Dry needling|A filiform needle is inserted at 45 degree in to trigger point and then twirl the needle up and down to release trigger point
223953376|NCT02295189|DRUG|Triamcinolone Acetonide|corticosteroid injection
224106675|NCT03701165|DEVICE|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
224106676|NCT06382493|DRUG|Tegoprazan-containing sequential H. pylori eradication therapy|tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
224106677|NCT06382493|DRUG|Esomeprazole-containing sequential H. pylori eradication therapy|Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
224106678|NCT00731445|DRUG|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
224106679|NCT06056739|DEVICE|Alio platform|Remote monitoring platform
224106680|NCT01105403|DRUG|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
224106681|NCT00077623|DRUG|epoetin alfa or beta|iv 3 times weekly, as prescribed
224106682|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
224106683|NCT00077623|DRUG|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
223953377|NCT05474313|BEHAVIORAL|PrEP-3D package|A package of support tools for accessing, adhering to, and monitoring PrEP use, including Alto Pharmacy delivery services, PrEP-3D mobile app, and home laboratory testing.
223953378|NCT05474313|BEHAVIORAL|Standard of Care|Participants are given local standard of care navigation for initiation of PrEP
223953379|NCT00054938|DRUG|pravastatin|
223953380|NCT00054938|DRUG|aspirin|
223953381|NCT00054938|DRUG|ramipril|
223953382|NCT00054938|DRUG|Vitamins: B6, B12, and folate|
223953383|NCT00054938|BEHAVIORAL|heart health educational program|
223953384|NCT00840775|DEVICE|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
223953385|NCT01971112|DIETARY_SUPPLEMENT|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
223953386|NCT02349516|DRUG|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
223953387|NCT02161146|DRUG|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
223953388|NCT02161146|DRUG|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
223953389|NCT02161146|DRUG|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
223953390|NCT02871661|DRUG|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
223953391|NCT02871661|OTHER|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
223953392|NCT02871661|DEVICE|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
223953393|NCT05590559|DRUG|Morphine|Opiates
223953394|NCT05590559|OTHER|Ultrasound-guided erector spinae plane block|PVB
223953395|NCT05811273|OTHER|physical readiness training|Bend and Reach:5 repetitions, Rear Lunge:5 repetitions per leg, High Jumper:5 repetitions, Rower:5 repetitions, Squat Bender:5 repetitions, Windmill:5 repetitions, Forward Lunge:5 repetitions per leg, Prone Row:5 repetitions, Bent-Leg Body Twist:5 repetitions per side, Push-Up:5 repetitions.
223953396|NCT05811273|OTHER|Control group|general exercises
223953397|NCT02966249|DRUG|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
223953398|NCT02966249|DRUG|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
223953399|NCT02966249|DRUG|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
223953400|NCT02966249|DRUG|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
223953401|NCT02966249|DRUG|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
223953402|NCT02966249|DRUG|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
223953403|NCT04870398|PROCEDURE|Vital Pulp therapy-Partial pulpotomy|Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
223953404|NCT03628313|OTHER|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
223953405|NCT05537012|DIAGNOSTIC_TEST|clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.
223953406|NCT00309751|DRUG|Pitavastatin|Pitavastatin 4 mg QD
223953407|NCT00309751|DRUG|Atorvastatin|Atorvastatin 20 mg
223953408|NCT05162339|OTHER|No intervention was made|No intervention was made
223953409|NCT02613403|DRUG|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
223953410|NCT02613403|DRUG|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
223953411|NCT02280031|DRUG|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
224106684|NCT02465034|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 hertz (Hz)) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
223953412|NCT02280031|DRUG|Placebo|Capsule containing placebo pill with lactose
223953413|NCT05295706|BEHAVIORAL|Counterfactual Intervention|"The intervention occurs during the third study visit. This is a counterfactual intervention, which will involve asking the subjects to think of an alternative reality that might have been based on the concurrency of their glucose readings and the meals they ate."
223953414|NCT03650465|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
223953415|NCT03609099|DRUG|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
223953416|NCT03609099|DRUG|Placebo|once a day oral treatment during 3 days.
223953417|NCT05532072|DRUG|Rapamycin|Rapamycin plus Methylprednisolone
223953418|NCT05532072|DRUG|Methylprednisolone|Methylprednisolone Alone
223953419|NCT03512782|OTHER|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
223953420|NCT03388736|BEHAVIORAL|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
223953421|NCT02189759|OTHER|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
223953422|NCT02189759|OTHER|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
224106685|NCT02465034|DEVICE|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
224106686|NCT02465034|DEVICE|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1 milliseconds (ms) rectangular pulses at an intensity to evoke a 1 millivolt (mV) response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
224106687|NCT02465034|DEVICE|Corticocortical Paired Associative Stimulation|Cortico-cortical Paired Associative Stimulation (CC-PAS) is a combination of TMS and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25 Hz for 12 minutes. The interstimulus interval will range from 5-15 ms depending on site of stimulation.TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This CC-PAS may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
224106688|NCT02465034|DEVICE|Sham Paired Associative Stimulation|The sham PAS is a combination of TMS and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25 Hz for 12 minutes. TMS will be performed using the Magstim BiStim\^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
224106689|NCT03378401|DRUG|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
224106690|NCT03378401|OTHER|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
224106691|NCT03372954|DRUG|BMAC|retrograde administration on non-selected BMAC via coronary sinus
224106692|NCT01240993|BEHAVIORAL|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
224290097|NCT00826579|PROCEDURE|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
224290098|NCT00826579|PROCEDURE|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
224290099|NCT02769884|DEVICE|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
224290100|NCT04051684|PROCEDURE|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
224290101|NCT04051684|DRUG|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
224290102|NCT00618202|DRUG|Balsalazide|
224290103|NCT03734887|BEHAVIORAL|Social Network Feedback|Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.
224290104|NCT03734887|BEHAVIORAL|Private Feedback|Participant will receive medication adherence feedback from a pharmacist at the start of the study.
224290105|NCT04146363|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
224290106|NCT04146363|OTHER|Placebo|Subcutaneous Injection
224290107|NCT00165386|PROCEDURE|Magnetic Resonance Imaging|
224290108|NCT00165386|PROCEDURE|Bone Marrow Biopsy|
224290109|NCT06141824|DEVICE|Lucira COVID-19 & Flu Test|The Lucira COVID-19 \& Flu Test is a rapid, single-use, molecular test for the qualitative detection and discrimination of SARS-CoV-2, Influenza A, and Influenza B viral RNA in nasal swab samples.
224290110|NCT04016792|DRUG|Placebo|Placebo will be administered once daily
224290111|NCT04016792|DRUG|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
224290112|NCT02914236|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
224290113|NCT04440319|BEHAVIORAL|Intervention group|Intervention group is individual with T2DM who will receive DM Nutrition education for 3 months. There are 75 subjects in Intervention group at 2 districts and 4 Public Health Care (PHC).
224290114|NCT03995017|DRUG|Rucaparib|Rucaparib tablet
224290115|NCT03995017|DRUG|Ramucirumab|Ramucirumab intravenous solution
224290116|NCT03995017|DRUG|Nivolumab|Nivolumab intravenous solution
223953423|NCT02189759|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
223953424|NCT02189759|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
223953425|NCT05389618|OTHER|Diagnostic Tests|Assessment of socio-demographic parameters, anthropometric and body composition parameters, food intake (dietary recalls, food propensity questionnaire) and nutritional status (blood biomarkers)
223953426|NCT04809376|DRUG|Pentosan Polysulfate Sodium twice weekly|Subcutaneous Injection, 1.5mg/kg Ideal body Weight (IBW)
223953427|NCT04809376|DRUG|Placebo (Sodium Chloride Injection, 0.9%)|Placebo to match PPS
223953428|NCT04809376|DRUG|Pentosan Polysulfate Sodium Fixed Dose|Subcutaneous Injection, 100/150/180 mg if \<65kg/ ≥ 65 kg and ≤ 90kg/ \>90 kg IBW
223953429|NCT04809376|DRUG|Pentosan Polysulfate Sodium once weekly|Subcutaneous Injection, 2.0mg/kg Ideal body Weight (IBW)
223953430|NCT06163300|DIAGNOSTIC_TEST|MRI advanced techniques|Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.
223953431|NCT00042926|OTHER|immunohistochemistry staining method|
223953432|NCT00042926|PROCEDURE|conventional surgery|
223953433|NCT00042926|PROCEDURE|lymphangiography|
223953434|NCT00042926|PROCEDURE|radionuclide imaging|
223953435|NCT00042926|PROCEDURE|sentinel lymph node biopsy|
223953436|NCT00042926|RADIATION|technetium Tc 99m sulfur colloid|
223953437|NCT02018549|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
223953438|NCT00038038|DRUG|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
223953439|NCT00038038|PROCEDURE|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
223953440|NCT02440438|BIOLOGICAL|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
223953441|NCT01147471|DEVICE|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
223953442|NCT01147471|PROCEDURE|operative rib fixation surgery|
224106693|NCT01240993|BEHAVIORAL|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
223953443|NCT05473117|DIAGNOSTIC_TEST|Coronary Magnetic Resonance Angiography (CMRA)|A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis
223953444|NCT02667366|BEHAVIORAL|Tel-PT|
223953445|NCT02667366|BEHAVIORAL|TAU and text messages|
223953446|NCT00880074|DRUG|Fluorothymidine F-18|Undergo fluorine F-18 fluorothymidine PET
224290117|NCT00594113|OTHER|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
224290118|NCT00594113|OTHER|Touch screen intervention|Touch screen intervention
223953447|NCT00880074|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223953448|NCT00880074|PROCEDURE|Positron Emission Tomography|Undergo fluorine F-18 fluorothymidine PET
224106694|NCT00120796|DRUG|Lamivudine|
224106695|NCT00120796|BIOLOGICAL|Recombinant hepatitis B surface antigen|
224106696|NCT04841668|DRUG|Metformin|Patients will begin treatment with metformin administered orally at a starting dose of 425 mg / day every 12 hours for the first 15 days and then continue with a dose of 850 mg / day until the end of the study. The beginning of this treatment phase will be following the recommendations of the clinical guidelines (Comprehensive Approach to Type 2 Diabetes Mellitus, SEEN V2019.2)
224106697|NCT03717324|OTHER|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
223953449|NCT02888821|BEHAVIORAL|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
223953450|NCT02579915|BEHAVIORAL|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
224290119|NCT02785536|BEHAVIORAL|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
224290120|NCT02785536|BEHAVIORAL|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
224290121|NCT05364996|DIAGNOSTIC_TEST|bronchial endoscopy with bronchoalveolar lavage (LBA)|Bronchial endoscopy under laryngeal mask and general anesthesia. BAL of saline at room temperature of 3 milliliters per kilogram limited to 20 milliliters x 3 according to recommendations
223953451|NCT02579915|BEHAVIORAL|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
223953452|NCT02067819|DEVICE|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
223953453|NCT02067819|DEVICE|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
223953454|NCT03582566|BEHAVIORAL|Phonological Awareness|Earobics training
223953455|NCT03582566|BEHAVIORAL|Working Memory|Cogmed training
223538908|NCT05680493|PROCEDURE|Heat therapy|Hydro collator pack will be placed on affected area for relaxation and pain relief for 15 min
223538909|NCT06078475|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr (PERFALGAN® ) IV every 8 hours in the postoperative period.. If the patient's NRS score is ≥ 4 0,5 mg/kg IV meperidine (Aldolan ampul 100 mg/2 ml) will be administered.
223538910|NCT01466283|GENETIC|DNA methylation analysis|
223538911|NCT01466283|GENETIC|fluorescence in situ hybridization|
223538912|NCT01466283|GENETIC|gene expression analysis|
223538913|NCT01466283|GENETIC|reverse transcriptase-polymerase chain reaction|
223538914|NCT01466283|OTHER|laboratory biomarker analysis|
223538915|NCT00535418|DRUG|Letrozole|
223953456|NCT03582566|BEHAVIORAL|Phonological Awareness + Working Memory|Earobics + Cogmed training
223953457|NCT03582566|BEHAVIORAL|Active Control|Spashmath
223953458|NCT00800176|DRUG|Placebo|po daily for 12 weeks
223953459|NCT00800176|DRUG|RO4998452|2.5mg po daily for 12 weeks
223953460|NCT00800176|DRUG|RO4998452|5mg po daily for 12 weeks
224290122|NCT05364996|DIAGNOSTIC_TEST|Blood sampling|collection of 5 milliliters of blood for total white cells count, C-Reactive Protein, specific immunoglobulin E assays, serum sRAGE assay
223538916|NCT01941771|DRUG|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
224290123|NCT00727519|DIETARY_SUPPLEMENT|Pomegranate juice|
224290124|NCT00727519|DIETARY_SUPPLEMENT|Placebo|
223953461|NCT00800176|DRUG|RO4998452|10mg po daily for 12 weeks
223538917|NCT01941771|DRUG|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
223538918|NCT03413904|PROCEDURE|transanal TME|transanal approach to TME in rectal cancer
223538919|NCT03413904|PROCEDURE|laparoscopic TME|laparoscopic approach to TME in rectal cancer
223538920|NCT01033084|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
223538921|NCT01033084|DRUG|Sertraline|Patient will receive sertraline 50mg/day.
223538922|NCT01033084|OTHER|double placebo|double placebo arm (sham stimulation/placebo pill)
223538923|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
223538924|NCT00893841|DRUG|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
223953462|NCT00800176|DRUG|RO4998452|20mg po daily for 12 weeks
223953463|NCT00800176|DRUG|RO4998452|40mg po daily for 12 weeks
223953464|NCT04000399|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
223953465|NCT04614805|BEHAVIORAL|Mobilizing clinical leaders|Clinical leaders and clinical personnel will regularly receive feedback regarding performance of their own hospital as well as other providers in the regional health trust of North Norway.
223953466|NCT04755972|OTHER|Inhalation of N-acetylcysteine|Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
223953467|NCT04755972|OTHER|Inhalation of 5% sodium chloride|Group 2 will receive inhalation with a 5% sodium chloride solution every 12 hours from the beginning of invasive mechanical ventilation.
224290125|NCT00393536|BEHAVIORAL|Educational outreach visiting|
224290126|NCT06091228|OTHER|tongue scraper|tongue cleaning with gentle strokes twice a day covering the whole surface of the tongue
224290127|NCT04340999|DIAGNOSTIC_TEST|Nerve conduction studies and Quantitative EMG ( MUNE and IPA)|"Nerve Conduction Studies: Electrophysiological method that tests the presence/absence of peripheral neuropathy.~MUNE: Electrophysiological technique that assess number of motor units. IPA: Electrophysiological method that assess interference pattern and hence, borderline cases of neuropathy/ myopathy"
224290128|NCT01962181|DRUG|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
224290129|NCT01962181|DRUG|Placebo|
224290130|NCT03113578|DEVICE|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
224290131|NCT03507348|DRUG|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
223953468|NCT04755972|OTHER|Inhalation of 8,4% sodium bicarbonate|Group 3 will receive inhalation of 8.4% sodium bicarbonate every 12 hours from the beginning of invasive mechanical ventilation.
223953469|NCT04561089|DIAGNOSTIC_TEST|COVIDSeq Test|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
223538925|NCT00893841|DRUG|placebo|placebo
223538926|NCT00893841|DRUG|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
223538927|NCT00606645|BIOLOGICAL|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
223953470|NCT00003041|DRUG|pyrazoloacridine|
223538928|NCT00987714|PROCEDURE|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
223953471|NCT01217099|DRUG|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
223953472|NCT01217099|DRUG|azithromycin|control patients were iv azithromycin for 5 days.
224106698|NCT00581711|OTHER|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
224106699|NCT00581711|OTHER|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
224106700|NCT00581711|OTHER|1-part intervention|Provision of feedback on otitis media quality indicators
224106701|NCT05401097|DRUG|Azacitidine|Given IV or SC
224106702|NCT05401097|PROCEDURE|Biopsy|Undergo biopsy of the bone marrow
224106703|NCT05401097|DRUG|Enasidenib|Given PO
224106704|NCT05401097|DRUG|Ivosidenib|Given PO
224106705|NCT05401097|DRUG|Venetoclax|Given PO
224106706|NCT02412644|DRUG|apremilast|
224290132|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
224290133|NCT03507348|DRUG|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
224290134|NCT03507348|OTHER|Transplant Day-0|TRANSPLANTATION
224290135|NCT06037226|BEHAVIORAL|Postpartum pelvic floor rehabilitation|biofeedback with Pelvic floor muscle training (PFMT)
224290136|NCT04902625|DRUG|Naltrexone-Bupropion Combination|Naltrexone-bupropion will be added to the BOT module in the interventional arm.
224290137|NCT00180076|DRUG|Budesonide|
224290138|NCT01677923|DRUG|Metformin|Metformin 500 mg BID for 12 months
224290139|NCT00666848|DRUG|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
224290140|NCT00666848|DRUG|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
224290141|NCT00666848|DRUG|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
224290142|NCT00666848|DRUG|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
224290143|NCT00891748|GENETIC|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
224290144|NCT05311917|OTHER|home vision therapy|a group of vision therapy procedures in home to improve convergence insufficiency
224290145|NCT05311917|OTHER|base in prism prescription|base in prism prescription according to sheards criterion
224290146|NCT05311917|OTHER|conventional placebo|using near glasses with aimless eye training
224290147|NCT02483143|DRUG|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
224290148|NCT02483143|DRUG|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
224290149|NCT02483143|DRUG|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
224290150|NCT05709041|OTHER|Individualized lung-protective ventilation|"Lung-protective ventilator settings will be individualized based on the patient's transpulmonary pressures (TPP), as measured by esophageal manometry.~The ventilator will be set to volume-controlled ventilation with a tidal volume of 6 mL/kg of ideal body weight, inspired oxygen fraction of 30%, inspiratory pause of 30%, inspiration-to-expiration ratio of 1:2, PEEP of 5 cm H2O, and flow of 3 L/min). The respiratory rate will be set to 12 breaths/min in the beginning then adjusted (within 10-20 breaths/ min) to maintain EtCO2 between 35 to 45 mm Hg.~The set PEEP will be then increased by 2 cm H2O every 2 minutes (up to a max of 30 cm H2O) to identify and maintain the lowest driving pressure, maximum compliance, and positive TPP. These steps will be performed every 30 minutes after intubation, and after instillation of the pneumoperitoneum, and after steep Trendelenburg positioning. These individualized PEEP settings will be maintained until the pneumoperitoneum is released."
224290151|NCT05709041|OTHER|Standard lung-protective ventilation|Ventilator settings will be adjusted to standard lung-protective settings according to the anesthesiologist's clinical judgement for the patient, their comorbodities, and the surgical procedure.
224290152|NCT05805735|OTHER|Face care product (Eye cream)|The test material(s) will be cosmetic products to be applied around the eye region on both sides of the face daily. The test product will be applied twice daily in the morning and in the evening by the subjects
224290153|NCT02961166|DRUG|IgM enriched Immunoglobulins|Treatment for 3 days
224290154|NCT04206514|BEHAVIORAL|Person Centered Care - Post Abortion Support|Post abortion phone based support
224290155|NCT03832881|DIAGNOSTIC_TEST|ADAMTS13, VWF assay|
224290156|NCT01476735|OTHER|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
224290157|NCT01139684|BEHAVIORAL|Repeated sprint test|
224290158|NCT00500279|DRUG|Celecoxib|
224290159|NCT02976259|DRUG|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
223538929|NCT05733637|OTHER|No intervention|There will be no intervention apply to study participants.
224290160|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
224290161|NCT04056052|BEHAVIORAL|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
223953473|NCT03836651|OTHER|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
223953474|NCT03836651|OTHER|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
223538930|NCT00605059|DRUG|[123I]AV94|Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
223538931|NCT00459940|DRUG|Pioglitazone|
224290162|NCT03036241|DEVICE|Conventional angioplasty|Angioplasty with conventional balloon
224290163|NCT03036241|DEVICE|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
224290164|NCT05468788|BEHAVIORAL|Intervention: Integrative Community Therapy-based Psychodrama|Participants produce theatre scenes depicting issues that they have experienced. Group leaders then use a guide to facilitate a discussion of participants' feelings, coping strategies, and sharing of local knowledge.
223953475|NCT01584674|DEVICE|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
223953476|NCT00384514|DEVICE|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
223953477|NCT05866354|DRUG|Tisotumab Vedotin|Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of solid tumors including cervical cancer.
223953478|NCT00003984|BIOLOGICAL|lintuzumab|
223953479|NCT00268333|DRUG|fluorouracil|
223953480|NCT00268333|DRUG|leucovorin calcium|
223953481|NCT00268333|DRUG|oxaliplatin|
223953482|NCT00268333|PROCEDURE|neoadjuvant therapy|
223953483|NCT06432257|DEVICE|head mounted magnifying glass assistance|When performing thyroid surgery for patients in the experimental group, the surgeon uses a head mounted magnifying glass for assistance
223953484|NCT03187704|OTHER|HEPA air filtration|Air filters were placed in participant homes
223538932|NCT00883155|DRUG|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
223538933|NCT00883155|DRUG|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
223538934|NCT04620889|DEVICE|AV Access|Arteriovenous shunting for blood access.
223538935|NCT04620889|DEVICE|PVP|Bypass or reconstruction of diseased or occluded blood vessels
223538936|NCT05016258|DEVICE|KONTACT MB|Dental implant surgery
223538937|NCT02669498|PROCEDURE|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
223953485|NCT03020498|BIOLOGICAL|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
223953486|NCT03020498|BIOLOGICAL|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
223953487|NCT01094106|DRUG|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
224290165|NCT05468788|BEHAVIORAL|Control: Improvisational Theatre|Participants play improvisational theatre games.
224290166|NCT01731899|DRUG|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
224290167|NCT02273687|DEVICE|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
223953488|NCT01094106|DRUG|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
223953489|NCT03725020|OTHER|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
223953490|NCT02558205|RADIATION|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
223953491|NCT02558205|RADIATION|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
224290168|NCT05154812|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
224290169|NCT05154812|DRUG|Routine medical care|Routine medical care
224290170|NCT03441724|DIAGNOSTIC_TEST|Mechanocardiography|Mechanocardiographic recording
224290171|NCT04030182|DIAGNOSTIC_TEST|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
224290172|NCT01599130|DRUG|Entecavir|entecavir 0.5mg per day
224290173|NCT01599130|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
224290174|NCT04311151|PROCEDURE|own seizures visualization|At the hospital discharge, patients
224290175|NCT01305148|DEVICE|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
224290176|NCT03393455|OTHER|not accurate|not accurate
224290177|NCT01087632|DIETARY_SUPPLEMENT|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
224290178|NCT03952611|PROCEDURE|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
224290179|NCT03952611|DEVICE|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
224290180|NCT03952611|DEVICE|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
224290181|NCT01342536|BEHAVIORAL|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
224290182|NCT03840499|DRUG|Optimal medical therapy|Optimal medical therapy
224290183|NCT04642859|BEHAVIORAL|Computerized Cognitive abilities training battery for reading (CATB-R)|Specially designed Arabic computerized training program for dyslexia
224290184|NCT02978820|OTHER|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
224290185|NCT02978820|OTHER|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
224290186|NCT00336765|DRUG|XL647|Tablets supplied in 50-mg strength administered orally daily
224290187|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
224290188|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
224290189|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
224290190|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
224290191|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
224290192|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 1 x 10\^8 pfu IM 8 weeks later
224290193|NCT01373879|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10\^10vp IM followed by MVA ME-TRAP 2 x 10\^8 pfu IM 8 weeks later
224290194|NCT01373879|BIOLOGICAL|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
224290195|NCT02904499|DRUG|Dabigatran|
224290196|NCT04344197|OTHER|global survey|surgery questionnaire
224290197|NCT00207194|BEHAVIORAL|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
224290198|NCT00207194|BEHAVIORAL|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
224290199|NCT03935022|OTHER|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~1. 80g of black rice Venere (Group A)~2. 80g of black rice Artemide (Group B)~3. 80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
224290200|NCT03274622|BEHAVIORAL|Impact Parent Training|
224290201|NCT03274622|BEHAVIORAL|No Impact|
224290202|NCT00836719|DRUG|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
223538938|NCT05871619|PROCEDURE|Remin Pro|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
223538939|NCT05871619|PROCEDURE|X Pur Remin|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
223723320|NCT04122898|OTHER|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
223953492|NCT02467985|PROCEDURE|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
223538940|NCT05871619|PROCEDURE|Fluoride varnish|A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
223538941|NCT04217109|DIAGNOSTIC_TEST|Odour sampling|"Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample."
223953493|NCT04012905|DRUG|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
223953494|NCT04743388|BIOLOGICAL|BNT162b2|Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies
224106707|NCT02698761|OTHER|Comprehensive Care Plan|"Care Plan~1. Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~2. Other Medications. All medications will be given during daytime hours, if possible.~3. Pain Psychology.~4. Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~5. Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~6. Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~7. Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
223723321|NCT02113605|OTHER|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
223953495|NCT04743388|BIOLOGICAL|Other vaccine against SARS-Cov-2|Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
223953496|NCT01403285|DRUG|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
223723322|NCT04541940|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
223953497|NCT01403285|BIOLOGICAL|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
224106708|NCT04804956|PROCEDURE|Stool sample|One stool sample will be taken at baseline for microbiota characterization
224106709|NCT04804956|PROCEDURE|Rectal mucosa sample|Characterization of tissue microbiota before and after surgery.
223723323|NCT04541940|OTHER|In-person Rehabilitation Therapy|Quadriceps isometrics exercises, straight leg raises, and range of motion exercises.
223953498|NCT01403285|BIOLOGICAL|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
223953499|NCT01403285|DRUG|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
223723324|NCT00968994|DEVICE|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
223723325|NCT00968994|DEVICE|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
223953500|NCT01294644|DRUG|Deoxycholic acid injection|
223953501|NCT01294644|DRUG|Placebo|Phosphate buffered saline placebo for injection
223953502|NCT01492127|BIOLOGICAL|Blood test|Blood test
223953503|NCT01106807|DRUG|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
223953504|NCT01106807|DRUG|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
224106710|NCT04804956|PROCEDURE|Mesorectal adipose tissue sample|Characterization of tissue microbiota and dysfunction
223953505|NCT01106807|DRUG|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
223953506|NCT01106807|DRUG|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
223953507|NCT01811615|OTHER|alcohol-free experimental mouth rinse|
223953508|NCT01811615|OTHER|alcohol-containing mouth rinsing|
224106711|NCT04804956|PROCEDURE|Subcutaneous adipose tissue sample|Characterization of tissue microbiota and dysfunction
223538942|NCT05927987|BEHAVIORAL|Problem Management Plus (PM+)|Problem Management Plus (PM+) is a brief, psychological intervention program based on cognitive behavioural therapy (CBT) techniques that are empirically supported and formally recommended by the WHO (Dua et al., 2011; Tol et al., 2013). The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem-solving, stress management, behavioural activation, and accessing social support. PM+ has three core features. It is brief (five sessions given in five weeks), delivered by paraprofessionals (PM+ helpers) and transdiagnostic. The PM+ helpers will be supervised by mental health care specialists.
224290203|NCT03142035|DRUG|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
224290204|NCT03142035|DRUG|gonapeptyl|gonadotropic releasing hormone agonist
224290205|NCT03142035|PROCEDURE|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
224290206|NCT02589158|DRUG|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
224290207|NCT02589158|DRUG|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
224290208|NCT02148913|DRUG|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
223953509|NCT01705756|DRUG|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
223538943|NCT02439905|DRUG|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
223953510|NCT02992652|DRUG|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
224290209|NCT02148913|DRUG|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
224290210|NCT02148913|DRUG|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
224290211|NCT02148913|DRUG|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
223953511|NCT03750682|OTHER|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
224290212|NCT02572349|DRUG|IW-1701|
224290213|NCT02572349|DRUG|Matching Placebo|
224290214|NCT03192852|OTHER|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
224290215|NCT03192852|PROCEDURE|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
224290216|NCT05904249|OTHER|Internet Based Synchronized Telerehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
224290217|NCT05904249|OTHER|Face-to-Face Rehabilitation|"Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching"
224290218|NCT04832126|GENETIC|Genetic analysis|Genomic DNA will be purified from peripheral blood or mouth swabs. Whole blood will be collected by peripheral phlebotomy in tubes containing K2EDTA as an anticoagulant. Blood samples will be stored at 4-8 oC for up to a week before DNA purification. Mouth swabs will be collected using the ORAcollect • DNA kit (OCR-100) (DNA Genotek Inc., Canada). Genomic DNA from whole blood or mouth swab samples will be purified using DNeasy Blood \& Tissue Kit (QIAGEN).
224290219|NCT04526392|OTHER|Questionnaire|Pubertal course questionnaire
224290220|NCT00027794|PROCEDURE|conventional surgery|
223538944|NCT02439905|DRUG|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
223953512|NCT03750682|OTHER|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
224106712|NCT04804956|PROCEDURE|Visceral adipose tissue sample|Characterization of tissue microbiota and dysfunction
224106713|NCT04804956|BEHAVIORAL|Dietary assessment|Dietary assessment will be taken at baseline
224106714|NCT04317222|DEVICE|eCRRT|"eCRRT was define as:~1. Initiated within the first 24 post-transplant hours;~2. High volume (35-50ml/kg) hemofiltration;~3. Continuous at least 12 hours per day for 3 days;~4. Standard treatment"
223538945|NCT06521216|DRUG|Ferrous sulfate|all patients will receive 200 mg elemental iron (ferrous sulphate)
223538946|NCT01247064|DRUG|Nebulized 3% saline|4 mL of nebulized 3% saline once
223538947|NCT01247064|DRUG|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
223538948|NCT02054065|OTHER|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
223538949|NCT02679378|DEVICE|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
224106715|NCT05187338|DRUG|ipilimumab +pembrolizumab +durvalumab|"This study has 3 subgroups:~1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks.~2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
224106716|NCT02350829|OTHER|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
224106717|NCT02138110|DEVICE|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
224290221|NCT00780260|BEHAVIORAL|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
224106718|NCT03279237|DRUG|Irinotecan|May help shrink tumor before surgery.
224106719|NCT03279237|DRUG|Oxaliplatin|May help shrink tumor before surgery.
224106720|NCT03279237|DRUG|Leucovorin|May help shrink tumor before surgery.
224106721|NCT03279237|DRUG|5-Fluorouracil|May help shrink tumor before surgery.
224290222|NCT05175924|OTHER|Nanpharmacological method|Virtual Reality
224290223|NCT01494935|BEHAVIORAL|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
224106722|NCT03279237|DRUG|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
224106723|NCT03279237|RADIATION|Radiation Therapy|May help shrink tumor.
224106724|NCT03279237|DRUG|Carboplatin|Carboplatin may stop cancer cells from growing.
224106725|NCT00338936|DRUG|Valsartan + Hydrochlorothiazide|
224106726|NCT03671863|OTHER|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
224106727|NCT03671863|OTHER|Prenatal management|Prenatal management
223538950|NCT02776046|DRUG|High FiO2|High FiO2 with a perioperative open lung strategy
223538951|NCT02776046|DRUG|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
223953513|NCT02188459|DRUG|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
223953514|NCT00184444|BEHAVIORAL|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
223953515|NCT00184444|BEHAVIORAL|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
224290224|NCT01494935|BEHAVIORAL|Control diet|Normal fat, normal fat diet
224290225|NCT02623452|DRUG|Insulin Lispro|Administered subcutaneously (SC)
224290226|NCT00478452|BIOLOGICAL|DC-Ova|
224290227|NCT00478452|BIOLOGICAL|DC Ova with Cyclophosphamide|
224290228|NCT02340494|BEHAVIORAL|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
224290229|NCT05386524|DRUG|sintilimab|sintilimab 200mg, ivgtt，d1
224290230|NCT05386524|DRUG|bevacizumab biosimilar|bevacizumab biosimilar 15mg/kg，ivgtt d1
224290231|NCT05386524|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 30mg/m2 d1，q3w
224290232|NCT00431158|OTHER|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
224290233|NCT05602402|OTHER|CAEP-01|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
224290234|NCT05602402|OTHER|Placebo|Dose: 1 capsule Route: orally for 84 ± 3 days Regimen: one capsule before breakfast (preferably with milk/butter/ghee)
224290235|NCT02678442|DEVICE|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
224290236|NCT02678442|DEVICE|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
224290237|NCT02490306|DEVICE|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
224290238|NCT03647046|DEVICE|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
224290239|NCT06302972|OTHER|Traditional treatment|Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.
224290240|NCT06302972|OTHER|IASTM and CCEP|"Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board"
224290241|NCT03282968|DEVICE|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
224290242|NCT03282968|OTHER|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
224290243|NCT00300326|PROCEDURE|Computer assist|same implant using a computer-assisted surgical technique.
224290244|NCT04336839|PROCEDURE|Portal vein resection / reconstruction|Portal vein resection and reconstruction, with or without concommitant arterial resection
224290245|NCT00918463|DRUG|dasatinib|100 mg daily dosing
224290246|NCT04995757|DEVICE|Stent Retriever|Stent Retriever for acute ischemic stroke
224290247|NCT05714566|DIAGNOSTIC_TEST|Clostridioides difficile toxin detection|Using Genexpert kit to detect the stool samples of IBD patients. If C. difficile toxin is positive, the patient is assigned to IBD+CDI group, or else assigned to IBD group. Every sample assigned to Health control group should have negative results for C.difficile toxin tests.
224290248|NCT01784666|DRUG|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
224290249|NCT01784666|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
223538952|NCT04528238|OTHER|Relaxing Visual Immersion|During the intravenous treatment for cancer, a nature movie will be projected on the ceiling of the room, along with natural sounds or a relaxing music. The patient will choose the movie or movies he wants to watch and can decide to stop the Relaxing Visual Immersion (RVI) at any time. The RVI is a system that does not isolate the patient from his familiar or medical entourage and which integrates virtual scenarios in the environment of care.
224290250|NCT01805726|DRUG|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
224290251|NCT01805726|DRUG|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
224290252|NCT01805726|DRUG|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
223953516|NCT04317937|OTHER|Jaw opening-closing movements|"Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward)."
223538953|NCT01616212|OTHER|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
223538954|NCT01616212|OTHER|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
223953517|NCT04317937|OTHER|Specific Active exercises|"Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements."
223953518|NCT04317937|OTHER|Exercise Therapy|"Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension \& rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured."
224290253|NCT01906086|OTHER|nutritional intervention|
223538955|NCT01616212|OTHER|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
223538956|NCT01616212|OTHER|Drug Education for adolescents|Drug Education for adolescents
224290254|NCT01906086|OTHER|life style intervention|
224290255|NCT02979457|BEHAVIORAL|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
224290256|NCT00836017|OTHER|No Intervention|No intervention was administered as part of the study.
223953519|NCT04317937|OTHER|Supportive Treatment|"Postural Advice and Home Exercise Program with Dairy Postural advice and home exercise program. Postural Advise Maintain upright posture while sitting.~* Avoid prolonged neck bending.~* Avoid twisting movement of the neck.~* Use a suitable pillow to maintain cervical spine.~* Adjust computer screen at eye level.~* Avoid constant use of mobile or similar device to prevent excessive strain over neck joints and muscles.~* Carry light and even weight in both hands while shopping and other chores.•Stay hydrated.~Home Exercise Program (unsupervised) (3 times a day)~* Forward flexion (Self Resisted), 6 sec hold, number of repetitions 15~* Right side flexion (Self Resisted ), 6 sec hold, number of repetitions 15~* Left side flexion (Self Resisted) x 6 sec hold,number of repetitions 15~* Backward flexion (Self Resisted) x 6 sec hold, number of repetitions 15~Home Dairy A home dairy will be provided to maintain home exercise program record."
223953520|NCT03357237|OTHER|medical device|"patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo"
223953521|NCT05528692|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI is a non-invasive imaging modality capable of producing precise soft-tissue images in all body areas. In contrast to CT scanning, MRI does not rely on ionizing radiation. There are no known risks associated with MRI as long as patients with contraindications such as pacemakers are identified and excluded. The MRI scans in this study will be performed without use of contrast media.
223953522|NCT01868061|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
223953523|NCT01868061|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
223953524|NCT06196294|BIOLOGICAL|Cell therapy for solid tumors|Transfer γδT cells into patients for anti-ancer therapy.
223953525|NCT03511495|DIAGNOSTIC_TEST|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
223953526|NCT01666821|OTHER|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (\>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
223953527|NCT05661240|DEVICE|Tumor treating fields（EFE-P100）|Device: Tumor treating fields（EFE-P100） Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.
223953528|NCT05661240|DRUG|Docetaxel injection|Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.
223953529|NCT02548585|DRUG|MEDI0382|MEDI0382 administered subcutaneously.
223953530|NCT02548585|DRUG|Placebo|Placebo administered subcutaneously.
223953531|NCT01986348|DRUG|Selinexor|One cycle is 28 days (4 weeks).
223953532|NCT02612285|DRUG|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
223953533|NCT02757911|GENETIC|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
223953534|NCT00805441|DRUG|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
223953535|NCT00805441|DRUG|Placebo|Daily by oral route for 12 weeks
223953536|NCT00841711|BEHAVIORAL|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
223953537|NCT00629564|DRUG|Esomeprazole|20mg oral
223953538|NCT00629564|DRUG|Esomeprazole|15 minute intravenous infusion
223953539|NCT02429973|DRUG|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
223953540|NCT02875730|PROCEDURE|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
223953541|NCT02875730|PROCEDURE|CMRI|Cardiac Magnetic Resonance Imaging
223953542|NCT00011102|BEHAVIORAL|Weight Gain Prevention for Women Project|
223953543|NCT01739972|DRUG|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
223953544|NCT01739972|DRUG|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
223953545|NCT03876886|DRUG|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
223953546|NCT03876886|DRUG|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih
223953547|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*4cycles
223953548|NCT03876886|DRUG|Carboplatin|carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih
223953549|NCT03876886|DRUG|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d\*8cycles
223953550|NCT03942107|PROCEDURE|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
223953551|NCT03942107|PROCEDURE|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
223953552|NCT01211509|DRUG|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
223953553|NCT02913300|DRUG|Lignocaine 1% concentration solution|
223953554|NCT02913300|DRUG|Lignocaine 2% concentration solution|
223723326|NCT05342545|OTHER|Alert-based computerized decision support|For patients randomly assigned to the BPA intervention group (alert group), an on-screen electronic alert will be issued during the outpatient clinical encounter that notifies the responsible provider that his or her T2DM patient should be evaluated for CKD with UACR assessment. The provider then will be given on-screen options to either order a UACR assessment or follow a link to learn more about CKD assessment in T2DM. Should the alert-recipient elect to omit an order for UACR assessment and decline to follow a link to learn more about CKD assessment in T2DM, the provider will be able to continue on with clinic visit-related EHR documentation but will need to select an acknowledge reason (rationale) for not following the evidence-based clinical practice recommendation highlighted in the alert.
224106728|NCT00844298|DRUG|Nilotinib+mVPD|"1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT"
223723327|NCT06539728|DIAGNOSTIC_TEST|Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces|Participants will drop a saline solution with proteins onto the testing device. They will wait for it to dry and then report on the tactile sensation and overall feel of the surface. Feedback will include comparisons with the two reference surfaces. The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.
223723328|NCT06539728|DIAGNOSTIC_TEST|Biomechanical Measurements|Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion. These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.
224106729|NCT01435993|DRUG|GSK1223249|Intravenous infusion
224106730|NCT01435993|OTHER|Saline placebo|placebo intravenous infusion
223538957|NCT05225883|GENETIC|GWAS|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
223953555|NCT00316797|DRUG|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
223953556|NCT03734978|DIAGNOSTIC_TEST|Diagnosis|biochemistry
223953557|NCT02698956|DEVICE|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
223953558|NCT01201837|DRUG|Placebo|Weekly injection
223538958|NCT05225519|DEVICE|long-sleeved white shirt impregnated with a long-infrared irradiation|Usage of an experimental shirt for a period of 12 weeks.
223723329|NCT06539728|BEHAVIORAL|Psychophysical Tasks|Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests. These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities. The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
223953559|NCT01201837|DRUG|CER-001|Weekly injection
223953560|NCT02050555|DIETARY_SUPPLEMENT|Placebo|
223953561|NCT02050555|DIETARY_SUPPLEMENT|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
223538959|NCT05225519|DEVICE|long-sleeved white shirt|Usage of an experimental shirt for a period of 12 weeks.
223538960|NCT01063348|DRUG|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
223538961|NCT01063348|DRUG|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
224290257|NCT01014624|DRUG|Prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
223538962|NCT06419452|OTHER|Unilateral resistance training programme|A method of training that increases muscle strength and endurance by using external resistance to a unilateral limb or movement.
223538963|NCT06419452|OTHER|Bilateral resistance training programme|A training method that increases muscle strength and endurance by using external resistance on both limbs or movements,
223538964|NCT06419452|OTHER|Combined（UL+BL） resistance training programme|A method of training that uses limbs or movements to increase muscle strength and endurance by external resistance using unilateral and bilateral combined forms,
224290258|NCT01014624|DRUG|Clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, participants will receive active treatment with either prasugrel or clopidogrel for 7 days. If a participant has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the participant may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout Period depending on the time to reach both of the exit criteria."
224290259|NCT01824134|OTHER|Klean & Klear The Dandy Day Corp|
224290260|NCT01824134|OTHER|The Skin Gel Herbal Answers, Inc|
223538965|NCT06124222|PROCEDURE|Prosthetic oral rehabilitation|Prosthetic rehabilitation with fixed and/or removable prosthesis.
223723330|NCT03894462|BEHAVIORAL|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention, delivered either in-person or via telehealth: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
223953562|NCT02935894|DRUG|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
223953563|NCT02935894|OTHER|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
223953564|NCT02935894|DRUG|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
223538966|NCT00577200|DRUG|Midazolam|Midazolam
223538967|NCT00577200|DRUG|Sufentanil|Sufentanil
223538968|NCT00577200|DRUG|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
223723331|NCT03894462|BEHAVIORAL|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged.
223723332|NCT04998786|DRUG|Ixazomib|Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress
223723333|NCT04998786|DRUG|Iberdomide|Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress
223953565|NCT03230084|DEVICE|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
223953566|NCT05954247|DRUG|DWJ1543|DWJ1543
223953567|NCT05954247|DRUG|DWC202216|DWC202216
223953568|NCT03224988|DEVICE|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
223723334|NCT04998786|DRUG|Dexamethasone Oral|Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22
223723335|NCT01545986|BEHAVIORAL|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
223723336|NCT04247360|DEVICE|cuff pressure|maintaining cuff pressure according the groups
223953569|NCT01691677|DRUG|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
223953570|NCT01691677|DRUG|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
223953571|NCT01602302|DRUG|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
223953572|NCT04218877|OTHER||There will be no intervention, only observation
223953573|NCT02033174|OTHER|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
224290261|NCT04420338|BIOLOGICAL|Blood sample|rapid serological tests carried out
224290262|NCT04420338|BIOLOGICAL|Serum tube collection|SARS-COV2 seroconversion assay
223538969|NCT03177538|DRUG|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
224290263|NCT01321281|DIETARY_SUPPLEMENT|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
224290264|NCT01321281|DIETARY_SUPPLEMENT|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
223538970|NCT03177538|DRUG|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
223538971|NCT05518461|DEVICE|iThrive WI Intervention|Participants will receive COVID-19 and overdose-related educational and motivational content over the course of 12 weeks through the Thrive4Life Connect, a mobile health application. They will be invited to set goals for lowering overdose and COVID-19 risk.
223538972|NCT04842851|DEVICE|cardiac resynchronization therapy|Cardiac resynchronization therapy in patients with systemic right ventricle
223953574|NCT02033174|OTHER|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
223953575|NCT01499251|DRUG|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
224290265|NCT01311752|PROCEDURE|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.~Surgical sample will be collected to study human papillomavirus related genital pathology."
224290266|NCT02834806|DEVICE|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
223723337|NCT04761289|OTHER|Multimodal Exercise and Functional Rehabilitation Program|"1. Prescription of multimodal physical exercise.~2. Reeducation of Activities of Daily Living (ADL).~3. Prescription of support products and adaptations of the environment."
223723338|NCT00040937|BIOLOGICAL|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
223953576|NCT01499251|DRUG|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
224290267|NCT02954159|DRUG|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
224290268|NCT02954159|DRUG|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
223953577|NCT01499251|DRUG|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
223953578|NCT01696500|DRUG|Intravenous immunoglobulin|
224290269|NCT02954159|OTHER|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
224290270|NCT04289506|DIAGNOSTIC_TEST|mRNA expression|The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
224290271|NCT00303875|BEHAVIORAL|behavioral dietary and exercise intervention|
223538973|NCT05185843|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223723339|NCT00040937|BIOLOGICAL|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
223953579|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Test drug|oral, once
223953580|NCT06204107|DRUG|CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug|oral, once
223953581|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
223538974|NCT05387746|BEHAVIORAL|Caring Science, Mindful Practice and Reiki Training|Participants will complete a) 4 week internet-based course on Caring Science Mindful Practice and b) 12 hour Reiki training. The participants will also complete online post-training survey with the same questions included in pre-training survey.
223538975|NCT02840279|DRUG|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
223538976|NCT02840279|DRUG|Placebo|
223538977|NCT04828707|DEVICE|Nerivio active device|Nerivio neurostimulator of conditional pain modulation (CPM)
223538978|NCT04828707|DEVICE|Nerivio sham device|Nerivio neurostimulator with an electrical output not intended for neurostimulation
223538979|NCT04836442|OTHER|Alcohol-PTSD-PFI (AP-PFI)|Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
223723340|NCT00040937|DRUG|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
223953582|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
223953583|NCT01009359|DRUG|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
223953584|NCT05188378|BIOLOGICAL|CT-P47|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
223953585|NCT05188378|BIOLOGICAL|EU-approved RoActemra,|162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
224290272|NCT03176368|OTHER|Coconut Oil|Coconut Oil
224290273|NCT05695092|BEHAVIORAL|Progressive muscle relaxation|Progressive Muscle Relaxation (PMR): This method involved efficiently relaxing global muscles of body with the objective of mental and physical relaxation.
224290274|NCT05695092|OTHER|control|control group will not receive any intervention
224290275|NCT04815330|OTHER|increment sweep gas flow|If a sweep gas flow through the membrane lung increment has been decided upon to relieve dyspnea, a new recording will be made after each scan increment and the patient will be asked at each step.
224290276|NCT04815330|OTHER|non-invasive ventilation|In ventilated or non-ventilated patients in whom the decision to implement non-invasive ventilation has been made, an increase in PEEP in 2 cmH2O steps without exceeding a plateau pressure of 25 cmH2O and a VT of 10ml/kg of the patient's theoretical weight will be achieved.
223538980|NCT04836442|OTHER|Active Comparison Condition (C-PFI)|Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
223953586|NCT03242863|OTHER|Food proportionality|Proportions of high and low energy dense foods manipulated
223953587|NCT04267952|BEHAVIORAL|Hand hygiene intervention program developed according to planned behavior theory|The perception of the importance of hand hygiene with expression of damages of microorganisms (stories about illnesses etc.). Visually assisted hand hygiene training experiments to ensure the visibility of microorganisms in the environment. Demonstration and application of the correct hand washing technique with music. All applications will take place in three lessons (120-minute).
223953588|NCT04267952|BEHAVIORAL|Classical hand hygiene education|expression of hand hygiene with verbal presentation method in a 40-minute lecture
223953589|NCT01569399|OTHER|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
223953590|NCT04258891|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2004 in European, North American and South American centers, who have estimated glomerular filtration rate and proteinuria follow-up and data from protocol and for cause biopsies for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow-up, clinical, biological and histological data.
223953591|NCT03103945|DEVICE|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
223953592|NCT00895076|DRUG|dexamethasone|iontophoretic patch and injection
223538981|NCT04548973|DRUG|Esketamine|Esketamine
223538982|NCT04548973|DRUG|Normal saline|2ml normal saline
223723341|NCT00040937|DRUG|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
223723342|NCT00040937|DRUG|melphalan|"1. st trans: 140 mg/m2 IV over 20 mins day -1~2. nd trans: 200mg/m2 IV over 20 mins day -1"
223723343|NCT00040937|DRUG|prednisone|maint: 50 mg/d PO every other day until progression
223953593|NCT02998658|DEVICE|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
224290277|NCT05404412|PROCEDURE|Epidural Steroid Injection|This intervention is applied mostly for cervical or lumbar radiculopathy. The intervention was carried out under sterile conditions with the C-arm fluoroscopy guidance. It is performed via spinal needle and the needle is inserted into the epidural space, then a combined local anesthetic and glucocorticoids are delivered to the epidural space.
224290278|NCT03465748|DEVICE|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
224290279|NCT00004748|DRUG|colchicine|
224290280|NCT00004748|DRUG|methotrexate|
224290281|NCT00004748|DRUG|ursodiol|
224290282|NCT04094948|DRUG|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
223538983|NCT04153487|DRUG|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
224290283|NCT04094948|DRUG|Placebos|dextrose-filled capsules
224290284|NCT04891965|BIOLOGICAL|ART24|Each ART24 capsule will contain lyophilized ART24 and inactive excipients. ART24 will be supplied in a dose strength of 5×10\^9 CFU/capsule. Subjects will receive 1 capsule daily.
224290285|NCT04891965|DRUG|Placebo|Each placebo capsule is identical in appearance, weight, and packaging to ART24 capsules, but will contain only the inactive excipients. Subjects will receive 1 capsule daily.
223538984|NCT04153487|DRUG|Placebo|Placebo saline / 6 hours for 96 hours
223538985|NCT00601744|BEHAVIORAL|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
223538986|NCT00601744|BEHAVIORAL|Questionnaire|5-10 minute questionnaire to be completed after the interview.
224290286|NCT03074539|DRUG|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
224290287|NCT03074539|PROCEDURE|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
224290288|NCT03074539|PROCEDURE|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
224290289|NCT05518448|DIETARY_SUPPLEMENT|Ketone - beta-hydroxybutyrate (β-OHB)|Ketone - beta-hydroxybutyrate (β-OHB)
224290290|NCT01699386|OTHER|Control Study Formula|feed as lib
224290291|NCT01699386|OTHER|Experimental Study Formula|feed as lib
224290292|NCT02221908|DEVICE|Mespere Venus 1000 CVP System|
224290293|NCT01780779|OTHER|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
224290294|NCT03477019|DRUG|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
224290295|NCT03477019|PROCEDURE|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
224290296|NCT03946020|PROCEDURE|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
224290297|NCT04244201|DEVICE|Vaporous Hyperoxia Therapy|1 hour of treatment, 4 times per week
224290298|NCT00859001|DRUG|FM+R|Fludarabine-Mitoxantrone-Rituximab
224290299|NCT00859001|DRUG|Zevalin (Ibritumomab Tiuxetan)|
223723344|NCT00040937|DRUG|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
223723345|NCT00040937|PROCEDURE|peripheral blood stem cell transplantation|2-4 x 10\^6/kg IV day 0
223723346|NCT03217487|PROCEDURE|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
223723347|NCT03217487|PROCEDURE|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
223953594|NCT02998658|DEVICE|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
223953595|NCT02424201|DRUG|Misoprostol|experimental
223953596|NCT02424201|DRUG|vitamin c|control
223953597|NCT03570970|DRUG|Banapenem|Banapenem to be used anti-infection
223953598|NCT02739100|DRUG|Triferic|
223538987|NCT01343472|BEHAVIORAL|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
223723348|NCT03217487|DEVICE|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
223723349|NCT03217487|DEVICE|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
223723350|NCT04256070|BEHAVIORAL|education and tele-consultation|education and tele-consultation based on Watson's Human Care Theory
223723351|NCT04488900|DRUG|CKD-508 Capsule|Investigational drug
223723352|NCT04488900|DRUG|Placebo Capsule|Placebo
223723353|NCT04488900|DRUG|CKD-508 Tablet|Investigational drug
223723354|NCT04488900|DRUG|Placebo Tablet|Placebo
223953599|NCT01202513|DRUG|Bimatoprost 0.03% topical ophthalmic solution|
223953600|NCT01519557|DRUG|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
223953601|NCT01519557|DRUG|Placebo|Placebo
223953602|NCT01489774|DRUG|Placebo|single and multiple dose
223953603|NCT01489774|DRUG|CJ-12406|single and multiple dose
223953604|NCT01898299|DEVICE|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
223953605|NCT01898299|DEVICE|Sham tDCS|Sham (inactive) tDCS treatment
223953606|NCT04784650|OTHER|Pre-dialysis population|Pre-dialysis population, consisting of both Diabetes Mellitus (DM) and non-DM patients
223953607|NCT04899557|PROCEDURE|Single Port Robotic Splenectomy|Pediatric patient with splenomegaly underwent a single port robotic splenectomy.
223538988|NCT01343472|BEHAVIORAL|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
223723355|NCT00806390|DRUG|Metoprolol|Metroprolol tartrate titrated up
223723356|NCT00000383|BEHAVIORAL|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
223723357|NCT00000383|BEHAVIORAL|Child-Centered Therapy|Client-directed supportive interventions
223723358|NCT02267811|OTHER|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
223723359|NCT02267811|DEVICE|OrthoPulse™|Participants carry out daily OrthoPulse™ treatments at home.
223723360|NCT06083116|DRUG|Hydrochlorothiazide、Henagliflozin Proline|Hydrochlorothiazide and Henagliflozin Proline
223723361|NCT02581449|DIETARY_SUPPLEMENT|omega-3|dietary supplement
223723362|NCT02581449|OTHER|empty soft gelatin capsules|empty softgels of matched size, shape and color
223723363|NCT04567225|DRUG|Early Glargine|A dose of insulin glargine, 0.4 unit/kg, will be given within 4 hours from initiating the IV Insulin Infusion
223723364|NCT04567225|DRUG|Late Glargine|A historical retrospective control group for the adult patients admitted to the same ICU with a diagnosis of DKA and received insulin glargine after anion gap closure.
223723365|NCT04567225|OTHER|IV insulin infusion|Continuous weight based IV insulin infusion as per Cleveland Clinic DKA Protocol
223953608|NCT02551705|OTHER|functional Imaging|Brain responses associated with emotional memory will be investigated
223953609|NCT00126958|PROCEDURE|urinary analysis|
223953610|NCT05469516|DEVICE|Ulthera System [Ulthera, Inc.]|"The Ulthera System is indicated for: - Use for noninvasive dermatological sculpting and lifting of the dermis: Upper Face, Lower Face, Neck, Décolletage.~\- Non-invasive treatment of Axillary Hyperhidrosis"
223953611|NCT05469516|DEVICE|Merz Radiesse Injectable Implant|Radiesse injectable implant is an opaque, sterile, non-pyrogenic, semi-solid, cohesive implant. The principal component is synthetic CaHA suspended in a gel carrier that consists primarily of water (sterile water for injection, United States pharmacopeia (USP)), glycerin (USP), and sodium carboxymethylcellulose (USP). Radiesse injectable implant (1.5mL syringe unit) has a CaHA particle size range of 25-45 microns and should be injected sub-dermally with a 27 gauge needle.
223953612|NCT00132925|DRUG|Triamcinolone|
223953613|NCT04757961|BEHAVIORAL|LifeStories|The content of LifeStories is divided thematically into core ACT concepts across the four episodes as follows: 1) cultivating awareness of the transient nature of mood experiences and the benefit of trying out various strategies to cope with depression when it arises; 2) clarifying one's own values and setting personal goals related to these values; 3) developing a more accepting and nonjudgmental stance towards difficult thoughts and feelings and practicing self-compassion;and 4) living more mindfully in the present moment.
223538989|NCT04616898|DEVICE|Venus Bliss|The Venus Bliss™ system is an aesthetic medical device designed to non-invasively reduce subcutaneous adipose tissue of the abdominal area and flanks. It is intended for use in individuals with a Body Mass Index (BMI) of 30 or less. The device consists of an external treatment component and an internal control component. The treatment console is a 1060nm diode laser applicator and a radio frequency applicator. In addition, a Bliss Belt is provided with the system to properly secure one or more applicators to the patient's body during treatment. Finally, the touchscreen monitor is used by the clinician to control the setting display on the main console. It also keeps the clinician informed of the device's status and operating parameters.
223538990|NCT00916227|DRUG|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
223538991|NCT00185341|DRUG|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
223538992|NCT00185341|DRUG|Placebo|Placebo
223538993|NCT03869112|BEHAVIORAL|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
223538994|NCT03869112|OTHER|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
223538995|NCT03139448|DEVICE|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
223538996|NCT03139448|DEVICE|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
223538997|NCT00185094|DRUG|Olmesartan medoxomil|
223538998|NCT00185094|DRUG|Losartan potassium|
223538999|NCT00185094|DRUG|Atenolol|
223723366|NCT04567225|OTHER|IV fluid and electrolytes replacement|The IV fluid and electrolytes replacement will be left to the treating physician's discretion. IV fluid to contain dextrose to keep Target Blood Glucose 150 - 200 mg/dl during the DKA management and 140 - 180 mg/dl after DKA resolution.
223539000|NCT00713687|DRUG|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility"
223539001|NCT02250248|BIOLOGICAL|AttraX Putty|
223539002|NCT02250248|OTHER|Iliac Crest Bone Graft (ICBG)|
223539003|NCT04269421|PROCEDURE|calcaneo-stop: arthrosis of the subtalar joint|arthrosis of the subtalar joint with a screw in the talus bone to stop pathological pronation of the heel
223539004|NCT02442050|OTHER|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
223539005|NCT02442050|OTHER|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
223539006|NCT01363102|PROCEDURE|SOMS|Apply a number to mobilization goal for patient
223539007|NCT04582214|DEVICE|MetaNeb® System|The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
223539008|NCT00006021|DIETARY_SUPPLEMENT|ascorbic acid|
223539009|NCT00006021|DRUG|arsenic trioxide|
223539010|NCT04031729|DRUG|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
223539011|NCT04031729|DRUG|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
223539012|NCT00523978|DEVICE|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
223953614|NCT01282983|DIETARY_SUPPLEMENT|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
223953615|NCT01282983|DIETARY_SUPPLEMENT|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
223723367|NCT04369521|OTHER|low free sugar diet|low free sugar diet with nutrition and exercise recommendation
223953616|NCT06103721|DRUG|Dexmedetomidine Injection [Precedex]|Dexmedetomidine will be diluted in 20 ml of Normal Saline to produce a concentration of 20 mcg/ml. Then it will be taken from the dilution at a dose of 1.0 mcg/kg and that will be added in 2-3 ml of Normal Saline to make it a final volume of 10ml. The resultant mixture will be used to nebulize the patients for 5 minutes, 15 minutes prior to induction of General Anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
223539013|NCT00523978|DRUG|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
223539014|NCT00637351|PROCEDURE|Blood sample|One blood sample will be collected at the time of screening for subjects
223539015|NCT00637351|PROCEDURE|Urine sample|One urine sample will be collected at the time of screening for subjects
223539016|NCT02490189|BEHAVIORAL|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
223539017|NCT02490189|BEHAVIORAL|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
223539018|NCT04656405|OTHER|Online real-time quality measurement and feedback video-based CPR training|"Participants in the online real-time quality measurement and feedback video-based CPR training program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. The study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) are provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing and collect real-time performance data using the QCPR mannequin device. Using this information, the instructor will provide real-time online feedback to participants."
223723368|NCT03157778|OTHER|Obese men|Biological measures before, just before, and after lunch, in obese men
223723369|NCT03157778|OTHER|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
224106731|NCT06956521|DRUG|Magnesium sulfate|Following MT and IA injection of MgSO4, patients will also receive a continuous infusion of 16g MgSO4 diluted in 240 ml of 0.9% normal saline, infusing at a rate of 10 ml per hour for 24 hours.
223723370|NCT00345345|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
223723371|NCT01740986|DRUG|SA09012 Low dose|Tablet, b.i.d
223953617|NCT06103721|DRUG|Normal Saline|Patients in the placebo group will be nebulized with 10 ml of Normal Saline, 15 minutes prior to induction of general anesthesia. Then general anesthesia will be induced with 1mg of Midazolam, 2mg/kg of Propofol, 0.5 mg/kg of Atracurium. Prior to endotracheal tube placement, airway will be managed with bag mask ventilation for 3 minutes. Vitals will be measured pre-nebulization, pre-induction, at 1 minute intervals during bag mask ventilation and immediately after placement of endotracheal tube.
223953618|NCT04120064|DRUG|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
223953619|NCT05132088|DRUG|semaglutide 50 mg|"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."
223953620|NCT05132088|DRUG|placebo (semaglutide)|Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
223953621|NCT04765540|BEHAVIORAL|Low Intensity Nudges|"A bundle of 'low-intensity' passive interventions, including:~Large Mirrors \& hand-shaped sign posts pointing to the station"
223953622|NCT04765540|BEHAVIORAL|High Intensity Activities|"A bundle of 'high-intensity' active interventions delivered for three weeks, including:~Free soap and free facemasks for handwashing station users, a community message board \& general encouragement"
223953623|NCT04765540|BEHAVIORAL|BRAC's business-as-usual|A set of community activities to increase awareness of public handwashing stations and the need to use them. This includes in-person group sessions demonstrating hand hygiene as well as stickers and posters placed in the community to alert people to the handwashing stations.
223953624|NCT02534129|DRUG|Difinsa53|Difinsa53 cream is applied to one half of radiation field
223953625|NCT02534129|DRUG|Aquaphor|Aquaphor is applied to one half of radiation field
223953626|NCT06155487|DRUG|AJH-2947 100 mg (SAD)|Oral Tablet, Single dose of AJH-2947 100 mg
223953627|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 100 mg
223953628|NCT06155487|DRUG|AJH-2947 200 mg (SAD)|Oral Tablet, Single dose of AJH-2947 200 mg
223953629|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 200 mg
223953630|NCT06155487|DRUG|AJH-2947 300 mg (SAD)|Oral Tablet, Single dose of AJH-2947 300 mg
223953631|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 300 mg
223953632|NCT06155487|DRUG|AJH-2947 400 mg (SAD)|Oral Tablet, Single dose of AJH-2947 400 mg
223953633|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 400 mg
223953634|NCT06155487|DRUG|AJH-2947 600 mg (SAD)|Oral Tablet, Single dose of AJH-2947 600 mg
223953635|NCT06155487|DRUG|Placebo|Oral Tablet,Single dose of Placebo 600 mg
223953636|NCT06155487|DRUG|AJH-2947 800 mg (SAD)|Oral Tablet, Single dose of AJH-2947 800 mg
223953637|NCT06155487|DRUG|Placebo|Oral Tablet, Single dose of Placebo 800 mg
223953638|NCT06155487|DRUG|AJH-2947 200 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
223953639|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 200 mg
223953640|NCT06155487|DRUG|AJH-2947 400 mg (MAD)|Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg
223953641|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 400 mg
223953642|NCT06155487|DRUG|AJH-2947 600 mg (MAD)|Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg
223953643|NCT06155487|DRUG|Placebo|Oral Tablet, Multiple (once daily for 7days) oral dose of Placebo 600 mg
223953644|NCT05473130|DEVICE|Breethe Oxy-1 System|To pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass with Breethe Oxy-1 System
223953645|NCT06721663|OTHER|Multisensory environment stimulation therapy|A Multi Sensory Environment is a dedicated space or room where sensory stimulation can be controlled (intensified or reduced), presented in isolation or combination, packaged for active or passive interaction
223723372|NCT01740986|DRUG|SA09012 High dose|Tablet, b.i.d
223723373|NCT01740986|DRUG|Placebo|Tablet, b.i.d
223723374|NCT02324569|DRUG|SYR-472|SYR-472 tablets
223953646|NCT06721663|OTHER|selected physical therapy intervention|therapeutic balance training and functional therapeutic exercises
223953647|NCT05759143|BEHAVIORAL|Nest Platform|Patient- and clinician-facing portal via secure link
223953648|NCT03553056|OTHER|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
223953649|NCT03553056|OTHER|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
223953650|NCT05054517|DIETARY_SUPPLEMENT|Glutamine|Oral Supplement
223953651|NCT05181839|DRUG|Burosumab|To describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth with a focus on adolescent-reported symptoms, activity duration and intensity, and wider burden, describing change over time for those who continue and discontinue burosumab after the end of skeletal growth.
223723375|NCT02324569|DRUG|Placebo|Placebo tablets
223723376|NCT00819221|DRUG|AZD2281|capsules, oral, bd, 2 months
223723377|NCT00819221|DRUG|liposomal doxorubicin|once every 4 weeks at 40mg/m2
223953652|NCT05967156|DRUG|Empagliflozin10Mg Tab|10 mg daily
223953653|NCT05625438|DEVICE|HandyMotion Treatment Program|A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
223953654|NCT06492226|DRUG|NKF-INS(A)|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
223953655|NCT06492226|DRUG|EU-NovoRapid®|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
223953656|NCT06492226|DRUG|US-NovoLog®|Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
223953657|NCT04764695|DIAGNOSTIC_TEST|D2O dilution technique|Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
223953658|NCT02713217|OTHER|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
223953659|NCT02713217|OTHER|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
223539019|NCT04656405|OTHER|Online real-time feedback video-based CPR training without quality measurement|"Participants in the online real-time feedback video-based CPR training without quality measurement program group will access an online training center with laptop computers provided by the researcher. All education and communication is conducted online. When study participants access the online training center, study instructors shows the study participants an edited version of the CPR training video used in the conventional CPR training program. A Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) is provided so that the participants can use while watching the video and during the following hands-on practice session.~After watching the video, hands-on practice will be conducted by the instructor on-line. The instructor will watch each individual participants CPR performance via video conferencing. The instructor will provide real-time online feedback to participants."
223539020|NCT04656405|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequin (Laerdal, Stavanger, Norway) and SkillGuide (Laerdal, Stavanger, Norway) device are provided to measure and give feedback on the participants CPR performance."
223539021|NCT04145596|DRUG|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
223539022|NCT03091361|OTHER|imaging, no intervention|no intervention
223539023|NCT03899350|OTHER|No intervention|No intervention
223723378|NCT03630172|PROCEDURE|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
223723379|NCT02016560|DRUG|florbetapir F 18|
223723380|NCT02016560|DRUG|Flortaucipir F18|
223723381|NCT02016560|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
223723382|NCT01943292|DRUG|Defactinib|
223723383|NCT02559193|OTHER|Observational study, data collection only trial.|Data collection only trial design.
223723384|NCT00911820|DRUG|Bevacizumab|
223723385|NCT00911820|DRUG|Cisplatin|
223723386|NCT00911820|DRUG|Irinotecan|
223723387|NCT00911820|DEVICE|Docetaxel|
223723388|NCT00023634|BIOLOGICAL|KLH|100 mcg w/EGFRvIII
223723389|NCT00023634|BIOLOGICAL|GMCSF|arm 1: 100 mcg w/EGFRvIII
223953660|NCT02805023|BIOLOGICAL|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
223539024|NCT05430061|DIETARY_SUPPLEMENT|slowly digestible carbohydrate|carbohydrates with slow digestion rate have the capacity to induce slow gastric emptying time and potentially modify metabolic response and modulate postprandial glycemia.
223723390|NCT01852110|DRUG|MK-7622|MK-7622 capsule
223953661|NCT02805023|BIOLOGICAL|Control medium|Intramuscular injections - single treatment session
223953662|NCT05109065|DIAGNOSTIC_TEST|SCID (Standardized Clinical Interview for DSM-V)|The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for a clinician or trained mental health professional to diagnose major mental illnesses.
223953663|NCT05109065|DIAGNOSTIC_TEST|PSS (Perceived Stress Score)|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. Demographic information will also be collected.
223953664|NCT05109065|DIAGNOSTIC_TEST|Urine Toxicology Screen|Participants will be asked to provide a urine sample. Evidence of active substance abuse (marijuana, opioids, other non-prescription drugs) by the urine toxicology screen will disqualify participants from the study.
223953665|NCT05109065|DIAGNOSTIC_TEST|Vitals|Height and weight will be measured in order to calculate BMI.
223953666|NCT05109065|DIAGNOSTIC_TEST|Blood Work|A venipuncture will be performed for the purpose of collecting blood tissue for study.
223953667|NCT05109065|DIAGNOSTIC_TEST|PQ-B|The Prodromal Questionnaire - Brief Version (PQ-B) is a self-report measure designed to identify people who may be experiencing psychotic symptoms when they do not have a schizophrenia diagnosis.
223953668|NCT05109065|DIAGNOSTIC_TEST|COVID Screening|Questionnaire to assess risk of transmission of COVID-19.
223539025|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
223539026|NCT00961038|DRUG|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
223723391|NCT01852110|DRUG|Placebo|Matching placebo to MK-7622 capsule
223723392|NCT01852110|DRUG|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
223723393|NCT00218465|DRUG|GW468816|Pharmacotherapies for Relapse Prevention
223953669|NCT05109065|DIAGNOSTIC_TEST|Positive and Negative Syndrome Scale (PANSS)|Instrument that is completed by clinical interviewer to measure symptom severity in individuals with psychotic disorders.
223953670|NCT04410003|BIOLOGICAL|Fecal microbial transplant|Fecal microbial transplant
223953671|NCT04440579|PROCEDURE|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
223953672|NCT04440579|PROCEDURE|Sham Percutaneous Tibial Nerve Stimulation (PTNS)|Patients will be connected to the PTNS device but the device will remain off for the entirety of the procedure
223953673|NCT04440579|PROCEDURE|Standard Cystoscopy|Patient will undergo standard cystoscopy
223953674|NCT03809169|PROCEDURE|Rapid on-site evaluation (ROSE)|Pathologist on site for direct evaluation of specimen adequacy
223953675|NCT03809169|PROCEDURE|Slim bronchoscope without a guide sheath|peripheral endobronchial ultrasound performed with a slim bronchoscope (3.0 mm outer diameter with a 1.7mm channel) combined with a radial ultrasound probe but without the use of a guide sheath.
223723394|NCT00218465|DRUG|Placebo Comparator: Placebo|
223723395|NCT03275051|OTHER|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
223539027|NCT00961038|DRUG|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
223953676|NCT03809169|PROCEDURE|Standard pEBUS with guide sheath|Using a flexible bronchoscope with minimal outer diameter of 4.2mm.
223953677|NCT02795052|PROCEDURE|Intravenous and Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
223953678|NCT04944836|DRUG|Clomiphene Citrate|All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
223953679|NCT04944836|PROCEDURE|Rotator Cuff Repair|The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
223953680|NCT05941715|DRUG|Aflibercept 40 MG/ML|treat-and-extend
223953681|NCT05941715|DRUG|Faricimab 120 MG/ML|treat-and-extend
223953682|NCT05324605|PROCEDURE|Questionnaire and use of 3 D tools|Resulting computer tomography(CT) results are transferred to a 3 D projection. Patients will be asked to wear 3 D glasses to be able visualizing the diagnosed vascular pathology. The physician will explain the disaese and treatment. The patient is ask to fill out a questionnaire post 3D consulting
223953683|NCT05169580|DRUG|Pociredir oral capsule(s)|Participants will receive Pociredir
223953684|NCT06149416|DEVICE|Experimental Masimo RD SET SpO2 Adhesive Sensors|Masimo RD SET SpO2 Adhesive Sensors, Adult (4000 Adt), Adult \& Neonate (4003 Neo)
223953685|NCT05683821|BEHAVIORAL|Text message smoking treatment|"Facilitated enrollment in an NCI-sponsored text messaging program:~* SmokefreeTXT (if ready to set a quit date in the next 14 days)~* Practice Quit (if ready to practice quitting 1-5 days but not ready to quit permanently)~* Daily Challenges (if not ready to quit, but willing to make some changes)"
223953686|NCT05683821|DRUG|Nicotine replacement therapy sampling|"Participants may request:~* Nicotine patches that release nicotine slowly over 24 hours, in either 7 mg, 14 mg, or 21 mg doses~* Nicotine gum or lozenges that release medication quickly and can be used every 1-2 hours to prevent and cope with cravings to smoke, in either 2 mg or 4 mg doses"
223953687|NCT05683821|COMBINATION_PRODUCT|Wisconsin Tobacco QuitLine Referral|Patients will be offered referral to the Wisconsin Tobacco QuitLine that offers phone counseling and nicotine replacement starter kits (2 week supplies) to people ready to quit smoking, in addition to web-based, text messaging, and mailed support, at no cost to Wisconsin residents.
223953688|NCT05683821|COMBINATION_PRODUCT|Referral to Primary Care Provider|Patients who want to talk to their Primary Care Providers about quitting smoking will be encouraged to make an appointment with their provider to receive smoking cessation counseling and to discuss pharmacotherapy options.
224106732|NCT00882713|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
223539028|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
223539029|NCT04162106|DEVICE|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
223723396|NCT00410046|DRUG|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
223953689|NCT05683821|COMBINATION_PRODUCT|BREATHE 2 Cessation Study|Patients who are interested in participating in a separate randomized controlled trial of smoking cessation treatment will be invited to learn about and complete an eligibility screening and consent process for the trial. Those who enter the study receive both counseling and pharmacotherapy.
223953690|NCT05683821|BEHAVIORAL|Additional modalities to learn about and request treatment|Participants in Enhanced Outreach arm clinics will have the option to request e-mail and/or text message communication regarding their smoking treatment options, and to initiate treatment via phone or online survey.
223953691|NCT01811459|DRUG|Quetiapine|PO
223953692|NCT01811459|DRUG|Haloperidol|IV
223953693|NCT01811459|DRUG|Placebo|PO or IV
223953694|NCT06288685|PROCEDURE|percutaneous A1 pulley release|Treatment trigger finger by release A1 pulley by percutaneous procedure
223953695|NCT06288685|DRUG|Triamcinolone|Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
223953696|NCT00264576|BIOLOGICAL|Influenza Virus Vaccine|
223953697|NCT01921166|DRUG|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
223953698|NCT01921166|DRUG|Leuprolide flare|Leuprolide flare ovulation induction
223953699|NCT00990132|DEVICE|Home mechanical ventilation|Nocturnal non-invasive ventilation
223953700|NCT00990132|DEVICE|Long term oxygen therapy|LTOT established as per national guidelines
223953701|NCT02659059|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
223953702|NCT02659059|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
223953703|NCT02659059|DRUG|Platinum Doublet Chemotherapy|
223953704|NCT02470312|PROCEDURE|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
223953705|NCT02470312|DEVICE|MediGuide|
223953706|NCT02470312|PROCEDURE|EP|
223953707|NCT03471637|OTHER|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy \[based on Compassion-Focused Therapy for Dummies (Welford, 2016)\]"
223953708|NCT01633359|DRUG|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
223953709|NCT01633359|DRUG|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
223953710|NCT00700557|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
223953711|NCT00700557|DIETARY_SUPPLEMENT|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
223953712|NCT03976102|BIOLOGICAL|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
223953713|NCT03976102|OTHER|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
223953714|NCT04057300|DRUG|Ticagrelor 90mg|Ticagrelor tablet
223953715|NCT04057300|DRUG|Clopidogrel 75mg|Clopidogrel tablet
223953716|NCT04057300|DRUG|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
223953717|NCT05449756|OTHER|Self-administered questionnaires|Three-monthly self-administered digital questionnaires (accessed on smartphone, tablet or computer)
223953718|NCT04110392|DIETARY_SUPPLEMENT|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
223539030|NCT02462226|BEHAVIORAL|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
223539031|NCT02462226|BEHAVIORAL|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
223539032|NCT00501644|DRUG|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
223539033|NCT00501644|DRUG|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
223953719|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
223953720|NCT01342718|DIETARY_SUPPLEMENT|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
224106733|NCT01616615|DRUG|Aspirin|150 mg/day oral use
224106734|NCT01616615|DRUG|placebo|1 capsule / day oral use
224106735|NCT02094079|OTHER|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
224106736|NCT02292134|DEVICE|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
224106737|NCT02917863|DRUG|L-Thyroxine (tablet, per os)|
223539034|NCT00501644|DRUG|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
223539035|NCT02750514|BIOLOGICAL|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
223539036|NCT02750514|DRUG|Dasatinib|
223539037|NCT02750514|BIOLOGICAL|Relatlimab|
223953721|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule \[7✕100,000,000 viable cells/strain\]), 2 capsules per day (2 hours after morning and evening meal)"
223953722|NCT01342718|DIETARY_SUPPLEMENT|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
223953723|NCT03662737|DIAGNOSTIC_TEST|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
223953724|NCT01491100|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
223953725|NCT02894216|PROCEDURE|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
223953726|NCT02227888|DRUG|N91115|S nitrosoglutathione reductase inhibitor
223953727|NCT00092456|BIOLOGICAL|rotavirus vaccine, live, oral, pentavalent|Three oral doses (\~8.81 X 10\^7 IU/Dose for Lot 1; \~8.01 X 10\^7 IU/Dose for Lot 2; and \~6.91 X 10\^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
223953728|NCT00092456|BIOLOGICAL|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
224106738|NCT02917863|DRUG|L-Thyroxine (oral drops, solution)|
223539038|NCT02750514|BIOLOGICAL|Ipilimumab|
223539039|NCT02750514|DRUG|BMS-986205|Specified dose on specified days
223539040|NCT02553629|DRUG|Rocuronium|
223539041|NCT02801786|DRUG|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
223953729|NCT02834624|DRUG|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
223953730|NCT02834624|DRUG|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
223953731|NCT06202547|BIOLOGICAL|Intra-ovarian injection of bone marrow mesenchymal stromal cells-derived extracellular vesicles|he patient is anesthetized and placed in a lithotomy position, after preparing and washing the vagina with normal saline, under transvaginal ultrasound guidance (Aloka-40000 vaginal probe, Japan) using needle puncture (Reproline medical Gmbh, Rheinbach/Germany). The injection of 2 ml of extracellular vesicles derived from MSCs (equivalent to 30 million cells) will be performed into one ovary of the patient (the accessible ovary).
223539042|NCT02801786|DRUG|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
223539043|NCT02801786|DRUG|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
223539044|NCT02142088|DEVICE|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
223539045|NCT00239603|DEVICE|OV-Watch|
223539046|NCT05222685|BEHAVIORAL|Better Together Physician Coaching|Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
223539047|NCT00872300|DRUG|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
223539048|NCT03140111|DEVICE|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
223539049|NCT03140111|DEVICE|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
223723397|NCT05975021|DRUG|Istaroxime|IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.
223723398|NCT05975021|DRUG|Placebo|IV infusion via a syringe pump. Total duration 48 hours.
224290300|NCT02314572|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
224290301|NCT04595916|DRUG|Polyene phosphatidylcholine injection 930 mg QD|Polyene phosphatidylcholine injection 930mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
224290302|NCT04595916|DRUG|Magnesium Isoglycyrrhizinate injection 200 mg QD|Magnesium isoglycyrrhizinate injection 200mg, diluted with 5% glucose solution 250ml, once a day, at least 2 weeks but no more than 4 weeks.
224290303|NCT06304935|OTHER|Use of injectable platelet rich fibrin after tonsillectomy by injection of IPRF in one tonsillar bed and use of other side as control|Compare both sides of tonsillar beds in post operative healing, pain and hemostasis
223539050|NCT01932684|OTHER|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
223539051|NCT01932684|OTHER|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
223539052|NCT01932684|DEVICE|5000 Voldyne ® Sherwood Medical, USA|
223539053|NCT01932684|DEVICE|Silicone face mask|
223539054|NCT03515161|DEVICE|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
223539055|NCT02040389|BEHAVIORAL|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
223539056|NCT02040389|BEHAVIORAL|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
223539057|NCT02022540|DRUG|PAN-90806 Ophthalmic Solution|
223539058|NCT02022540|DRUG|Lucentis|
223539059|NCT01812057|DRUG|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
223539060|NCT01812057|DRUG|Placebo|Sodium Chloride 0.9% -5 ml
223539061|NCT00960089|DEVICE|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
223539062|NCT02348203|DRUG|Aspirin|Given PO
223539063|NCT02348203|OTHER|Laboratory Biomarker Analysis|Correlative studies
223539064|NCT02348203|OTHER|Placebo Administration|Given aspirin placebo PO
223539065|NCT02348203|OTHER|Placebo Administration|Given zileuton placebo PO
223953732|NCT03522909|OTHER|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~1. Primary outcome variable.~   \- Hospital length of stay~2. Secondary outcome variables.~   * Number of admissions from outside hospitals~  * Adverse outcomes~  * Intensive Care Unit admissions~  * Opioid use~  * NICU admissions~  * Patient satisfaction~  * Cost of inpatient admission~  * Cost of outpatient care~  * Hospital readmissions rate"
223539066|NCT02348203|DRUG|Zileuton|Given PO
223539067|NCT01138410|BIOLOGICAL|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
223539068|NCT05790291|OTHER|Checklist|the experimental group will practice using the checklist
223539069|NCT02563782|BIOLOGICAL|Sub-retinal transplantation of MA09-hRPE cells|transplantation
223539070|NCT02563782|DRUG|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
223539071|NCT02563782|DRUG|Placebo tacrolimus and mycophenolate mofetil|placebo
223539072|NCT02563782|PROCEDURE|Sham Surgery|Sham surgery
223539073|NCT00617864|DRUG|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
223539074|NCT00617864|DRUG|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
223723399|NCT02486432|DRUG|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
223723400|NCT02035878|OTHER|Probiotics|probiotic intervention: 400mg of probiotic capsule
223723401|NCT02035878|DRUG|Placebo|placebo comparator
223953733|NCT04783389|DRUG|CBP-201|CBP-201 subcutaneous (SC) injection.
223953734|NCT04783389|DRUG|Placebo|Placebo subcutaneous (SC) injection.
223953735|NCT03918187|DRUG|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
224290304|NCT05208658|OTHER|Experimental: Classical Vision Therapy Treatment|Do classical vision therapy treatment for improve vergence
224290305|NCT05208658|OTHER|Control: Eye Movement Therapy Treatment|Do eye movement therapy treatment in order not to improve vergence
223953736|NCT03918187|DRUG|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
223953737|NCT03918187|DRUG|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
224106739|NCT04647136|DIAGNOSTIC_TEST|Fertility Health Screening|Basic fertility health screening comprising an anti-Mullerian hormone (AMH) test and semen analysis, a doctor's consultation to explain the results, and standardised reproductive counselling by a trained nurse comprising a discussion of reproductive plans (including addressing barriers the couple face), education on age-related fertility decline and limitations of artificial reproductive technologies, advice on the optimal reproductive timing and when to seek further help. An educational brochure will be handed to the couple during the counselling session.
223723402|NCT03421028|DEVICE|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter and temporalis muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
223953738|NCT05261100|OTHER|Core stability exercises|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercises will be performed along with core stability exercises.."
223953739|NCT05261100|OTHER|Conventional Physical Therapy|"Moist heating pads will be applied on knee joint for 10 minutes before each treatment session.~Apply TENS on knee joint for 10 minutes treatment session. Knee Isometric exercise perform."
223953740|NCT04388748|BEHAVIORAL|Stress Management and Resiliency Training for Depression (SMART-D) Therapy|6 SMART-D group therapy sessions over 8 weeks
223539075|NCT00029250|DRUG|Garlic powder standardized to allicin|
223539076|NCT01523938|BEHAVIORAL|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
223539077|NCT00696878|DRUG|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
223539078|NCT00696878|BIOLOGICAL|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
223539079|NCT00696878|BIOLOGICAL|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
223539080|NCT00696878|BIOLOGICAL|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
223539081|NCT00696878|DRUG|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
223539082|NCT02259114|DRUG|Birabresib|Birabresib 10, 20 and/or 40 mg oral capsules
223539083|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
223539084|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
223539085|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
223539086|NCT03937479|DRUG|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
223723403|NCT03421028|OTHER|Classic treatment for myogenous TMD|Combination of physiotherapy (manual therapy), stabilization occlusal splint usage and counseling
223953741|NCT05591378|OTHER|core stability exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~first week:Cat camel stretch, all fours stretch and lifting one leg, cobra pose, lying on your back and raising the legs/one leg, and hamstring stretch on chair second week:Straight Leg Crunch, with first week exercises third week:Crunch, bridge exercise,and lifting the legs/one leg straight out with first week exercises fourth week:lifting the legs/one leg to the opposite hand, with first week exercises fifth week:Reverse Crunch, bridge exercise without support with first week exercises sixth week:Hamstring stretch on the Floor with first week exercises seventh week:lifting one hand and one leg, with first week exercises eight week:Exercise Ball Crunch,and stability ball bridge with first week exercise"
224106740|NCT04647136|BEHAVIORAL|Fertility Awareness Tools|Online intervention consisting of 1) video targeting fertility education and specific attitudes, social norms and perceived control for having children, 2) a fertility awareness tool (FERTISTAT) and 3) an educational brochure on fertility. This intervention can be self-administered and is therefore easily scalable.
224106741|NCT01878006|DRUG|Morphine|
224106742|NCT01878006|DRUG|Placebo|
223539087|NCT03937479|DRUG|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
223539088|NCT01901536|BEHAVIORAL|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
223539089|NCT02712788|DRUG|Milrinone|
223539090|NCT02712788|DRUG|Placebo|
223539091|NCT04337047|OTHER|questionnaire assesment|questionnaire assesment
223539092|NCT00940602|DRUG|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
223539093|NCT00940602|DRUG|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
223539094|NCT01880957|DRUG|Lithium|
224106743|NCT02389413|DRUG|PQ912 oral|
224106744|NCT02389413|OTHER|Placebo|
224106745|NCT04792151|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents|The Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C and UP-A) are transdiagnostic, behavioral interventions for youth with emotional disorders, including anxiety, depression, obsessive-compulsive disorders, and irritability.
224106746|NCT01376739|DRUG|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
224106747|NCT03663244|BEHAVIORAL|MBSR|Standardised stress reduction programme with established efficacy
224106748|NCT03663244|BEHAVIORAL|LSR|Existing stress reduction programme in a Danish municipality
224106749|NCT00100555|DRUG|zoledronic acid|
223953742|NCT05591378|OTHER|otago exercises|"exercises for 8 weeks and 3 individual sessions per week for 30-45 minutes. Each exercise will be given for 3 to 5 minuts.~Walking forward with support, standing on heel with support, side walking with support, standing on one foot with support.Walking forward without support, standing on heel without support, side walking without support, standing on one foot without support.~Walking backward with support, walking on heel with support, walking and turning around, walking on heel with support.~Walking backward without support, walking on heel without support, walking and turning around, walking on heel without"
223723404|NCT01675271|OTHER|individual exercise|individual exercise and dietary prescription
224106750|NCT00971646|OTHER|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
224106751|NCT00971646|OTHER|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
224106752|NCT00971646|OTHER|EuroQol-5D|This questionnaire grades the health condition of the subject.
224106753|NCT00971646|OTHER|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
224106754|NCT05074784|DEVICE|IOPI Therapy|Obtain IOPI reading at start of session, record the best of 3 readings as baseline strength. Calculate exercise resistance for session at 60% of baseline strength. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets.
223539095|NCT01880957|DRUG|Lamotrigine|
223539096|NCT04856878|DRUG|Vancomycin|The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
223539097|NCT04994223|DRUG|Rivaroxaban 10 MG Oral Tablet [Xarelto]|rivaroxaban has shown improved results after revascularization for PAD in terms of limb survival
223539098|NCT01120405|DRUG|Xenon|
223539099|NCT01120405|DRUG|Sevoflurane|
223539100|NCT01459809|DRUG|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
223539101|NCT01459809|DRUG|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
223539102|NCT04902989|OTHER|pollutants and pollen|Pollutants (ozone, SO3, NO3, PM2.5, diesel exhaust particles)
223539103|NCT01418521|DRUG|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
224106755|NCT05074784|DEVICE|Tongue Depressor Traditional Intervention|Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set
224106756|NCT02760602|DRUG|Solanezumab|Administered IV
224106757|NCT02760602|DRUG|Placebo|Administered IV
223723405|NCT01675271|OTHER|general exercise|general exercise counselling
224106758|NCT04391868|DRUG|Viagra Tablet|50 mg tablet on Day 1 of each period
224106759|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
224106760|NCT04391868|DRUG|Sildenafil Citrate ODF|50 mg ODF on Day 1 of each period
224106761|NCT03159754|PROCEDURE|Early Appendectomy|Removal of the appendix within 24 hours of admission
224106762|NCT03159754|PROCEDURE|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
223539104|NCT01418521|DRUG|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
223539105|NCT03053128|DEVICE|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
223539106|NCT03053128|OTHER|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
223539107|NCT03627052|DRUG|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
223539108|NCT03627052|DRUG|Placebo|Placebo administered orally twice daily in the double-blind period.
223539109|NCT04836533|OTHER|Experimental: Computerized Cognitive Training|Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
223539110|NCT04836533|DRUG|Experimental: Open-label antidepressant treatment|Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
223539111|NCT04836533|OTHER|Active Comparator: Solitaire Training|Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
223539112|NCT04836533|OTHER|Placebo Comparator: Placebo-controlled antidepressant treatment|Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
223539113|NCT04392973|COMBINATION_PRODUCT|Favipiravir and Hydroxychloroquine|"Route of Administration: Oral (or through Nasogastric tube)~Dose:~Favipiravir: Administer 1800 mg (9 tablets) by mouth twice daily for one day, followed by 800mg (4 tablets) twice daily (total days of therapy is 10 days or till hospital discharge)~Hydroxychloroquine (400mg) twice daily on day 1; for days 2-5 (200mg) twice daily."
223723406|NCT01776333|BEHAVIORAL|video decision aid|
223723407|NCT01717807|OTHER|C11-Erlotinib PET/CT|
223953743|NCT06569589|DIAGNOSTIC_TEST|23NaMRI Scan|23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
223723408|NCT01372137|DRUG|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
223723409|NCT01372137|OTHER|Glucose 5%|Placebo
223723410|NCT01007084|DRUG|Propranolol|40 mg
223539114|NCT00938301|DRUG|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
223539115|NCT00938301|DRUG|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
223723411|NCT01007084|DRUG|Propranolol ER|120 mg twice per day
223723412|NCT01007084|DRUG|Sugar pills|sugar pill
223953744|NCT06569589|DIETARY_SUPPLEMENT|Potassium Chloride (KCl)|K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level
224106763|NCT03159754|DRUG|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
224106764|NCT02137551|OTHER|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
224106765|NCT05441046|DRUG|Genakumab|genakumab plus tislelizumab 200 mg
224106766|NCT05414123|DEVICE|CNSide|The Cerebro-Spinal Fluid (CSF) of subjects enrolled into each cohort will be used for Standard of Care diagnostic assessments used for subjects with either confirmed or suspicious LM (Cytology, protein and glucose) in combination with CNSide analysis.
224106767|NCT00320671|DRUG|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
224106768|NCT00320671|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
224290306|NCT04303650|DEVICE|Ultrasound measurement of quadriceps muscle layer thickness|With patient in supine position ultrasound will be performed using a 12MHZ Transducer connected to Sonosite M Turbo machine. The probe will be placed perpendicular to the long axis of the thigh on its anterior surface at the two thirds of the length between the anterior superior iliac spine and the upper border of the patella. After identifying the muscle tissue, the thickness of the quadriceps muscle will be obtained by measuring the distance between the cortex of femur and the most superficial muscular fascia. Measurements will be performed by applying maximal compression on the probe without inflicting pain to prevent underestimation of muscle wasting linked to subcutaneous edema. measurements will be made on both sides repeatedly on ICU days 1, 3, 7, and 10. Every time three ultrasound measurements will be taken per site and the average of three measurements for each site will be used and combined to provide total muscle depth
224290307|NCT03612739|BIOLOGICAL|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
223539116|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with local anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
224290308|NCT01231750|DRUG|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
224290309|NCT01231750|OTHER|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
224290310|NCT06172413|DEVICE|transcranial alternating current stimulation (tACS)|"Three conductive electrodes will be applied to the scalp: one 4.45 × 9.53 cm electrode placed over the forehead (Fpz, Fp1, and Fp2 in the 10/20 international placement system) and two 3.18 × 3.81 cm electrodes over the mastoid areas.~The tACS stimulation waveform includes ramp-up and ramp-down periods of 180 and 12 s, respectively. It is a square-wave with an average amplitude of 15 mA and is equally distributed from the frontal region to the mastoid areas (amplitudes are reported as zero-to-peak).~Each subject will receive 40 sessions of tACS intervention during 4 consecutive weeks at a fixed day time twice per day (once in morning and afternoon, respectively) from Monday through Friday. Each session lasts 40 min."
224290311|NCT06172413|DEVICE|Sham tACS|Sham tACS
224290312|NCT05632341|DIETARY_SUPPLEMENT|Lactococcus lactis|1 capsule once a day
224290313|NCT05632341|OTHER|maltodextrin|1 capsule once a day
224290314|NCT01261741|DRUG|Memantine|Each subject will receive memantine 10mg tablets once daily
223953745|NCT06570993|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
223953746|NCT00372099|DRUG|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
223953747|NCT02014298|RADIATION|non-ablative fractional laser|3 treatments with 4-6 weeks interval
224290315|NCT01261741|DRUG|Placebo|Each subject will receive matching placebo tablets once daily
224290316|NCT03064321|BEHAVIORAL|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
224290317|NCT03064321|OTHER|Information Control|Information on websites that are general health promoting
224290318|NCT00004402|DRUG|calcitriol|
223953748|NCT02014298|OTHER|control|observation, comparison to laser-treated area
223953749|NCT04250181|OTHER|RF ablation of atrial fibrillation|Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
223953750|NCT02127645|PROCEDURE|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
224290319|NCT00004402|DRUG|interferon gamma|
223953751|NCT02127645|PROCEDURE|LRT-TEM|TEM following 46 Gy RT
223953752|NCT02127645|PROCEDURE|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
223953753|NCT02127645|PROCEDURE|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
224290320|NCT01117337|PROCEDURE|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
224290321|NCT04818749|DRUG|Saline|Saline (placebo) will be administered intravenously before block performance and after the induction of general anaesthesia.
224290322|NCT04818749|DRUG|Dexamethasone 12 mg|Dexamethasone 12 mg will be administered intravenously before block performance and saline (placebo) will be administered intravenously after the induction of general anaesthesia.
224106769|NCT06128941|OTHER|Repeated sprint|"* Duration of the study: 8 weeks of participation.~* Each repeated sprint training protocol: 2 training sessions per week for 4 weeks.~* Collection sessions: 3 collection sessions will be carried out: before the start of the training protocol - T0; at the end of the protocol, in week 4 - T1; and late, 4 weeks after the end of the protocol, in week 8 - T2.~* Training sessions: will be carried out on an ergometer and will consist of 3 sets of 5 sprints of 10s all-out with 20s of rest between sprints, and 5 minutes of rest between sets."
223539117|NCT03652714|PROCEDURE|Ganglion sphenopalatine block with placebo|Block performed with bilaterally inserted q-tips with isotone NaCl
224106770|NCT03323307|DEVICE|OCT imaging|imaging of retina using OCT device
224290323|NCT04818749|DRUG|Dexamethasone 12 mg + dexmedetomidine 1 mcg/kg|Dexamethasone 12 mg will be administered intravenously before block performance and dexmedetomidine 1 mcg/kg will be administered intravenously after the induction of general anaesthesia.
224290324|NCT03232099|DIETARY_SUPPLEMENT|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
224290325|NCT03232099|OTHER|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
223539118|NCT00508482|OTHER|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
223539119|NCT00508482|DRUG|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
223539120|NCT00508482|OTHER|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
224290326|NCT03575871|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
224290327|NCT03575871|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
224290328|NCT03575871|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
224290329|NCT00725478|DRUG|Piribedil|
224290330|NCT02818387|DRUG|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
224290331|NCT02818387|DRUG|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
224290332|NCT02818387|DRUG|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
224290333|NCT01045993|DEVICE|Heat Device|8-Hour Heatwrap
224290334|NCT01045993|DEVICE|Sham Device|Inactive wrap worn for 8 hours
224290335|NCT01045993|DRUG|marketed analgesic|2 x 200 mg ibuprofen tablets
224290336|NCT01045993|DRUG|Placebo|2 x placebo tablets
224290337|NCT01827124|DRUG|Carbetocin|
224290338|NCT01827124|DRUG|oxytocin|
224290339|NCT00795808|DRUG|Metformin|500mg tds for 6 months
224290340|NCT00795808|DRUG|Placebo|One tablet tds for 6 months
224290341|NCT00795808|DRUG|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
224290342|NCT00795808|DRUG|Metformin|500mg tds for 6 months
224290343|NCT00795808|DRUG|Clomiphene|Ovulatory dose for 6 months
224290344|NCT06394726|BEHAVIORAL|Exercise İntervention|Aerobic and Core Stabilization Exercise Intervention
224290345|NCT04414839|DEVICE|Digital Intubation (Two-finger)|In the NGT Digital Intubation group (group B), the second and third fingers were placed in the posterior pharynx and depressed the tongue downwards. The NGT was passed through the nose into the posterior pharynx with the fingers in the pharynx to reach the esophagus. The thumb was placed under the jaw and pushed it forward to pave the way for tube insertion.
224290346|NCT04414839|DEVICE|Video Laryngoscopy|In the NGT Video Laryngoscopy group (group A), first, the GlideScope blade was inserted under direct visualization via color monitor through the patient's mouth by employing jaw-thrust maneuver to preserve the cervical spine and by raising the tongue to obtain better visualization of the larynx space. Then, NGT was inserted through the selected nostril, advanced through the esophagus under direct vision to meet the measured length, and fixed after confirmation.
224290347|NCT05506358|DIAGNOSTIC_TEST|High performance liquid chromatography|High performance liquid chromatography (HPLC) using the D10 System by Bio-Rad Laboratories will be used as the gold standard test.
224290348|NCT05506358|DEVICE|Automated sickling test|The standard sickling test using 2% sodium metabisulphite will be augmented using an automated microscope (such as Octopi) and machine learning, and will be used as one of the low-cost tests.
224290349|NCT05506358|DIAGNOSTIC_TEST|HbS solubility test|Standard HbS solubility test currently used in Nepal (e.g. Sicklevue) will be used as one of the low-cost tests
224290350|NCT05506358|DEVICE|HemoTypeSC|A point-of-care lateral flow assay, HemoTypeSC (https://www.hemotype.com/), will be used as one of the low-cost tests
224290351|NCT05506358|DEVICE|Sickle SCAN|A point-of-care lateral flow assay, Sickle SCAN (https://www.biomedomics.com/products/hematology/sicklescan/), will be used as one of the low-cost tests
224290352|NCT05506358|DEVICE|Gazelle Hb Variant Test|A portable electrophoresis machine, Gazelle diagnostic device (https://hemexhealth.com/), will be used as one of the low-cost tests
224290353|NCT01659736|DEVICE|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
224290354|NCT00391079|DRUG|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
224290355|NCT00391079|DRUG|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
224290356|NCT01004042|DRUG|Botulinum Toxin Type A|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
224290357|NCT02809170|DIETARY_SUPPLEMENT|Arginine|Arginine is an amino acids
224290358|NCT02809170|DIETARY_SUPPLEMENT|Citrulline|Citrulline is an amino acid
224290359|NCT00338052|DRUG|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
224290360|NCT03165877|OTHER|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.
224290361|NCT03165877|OTHER|Control|Subjects ate standard lunches and dinners (\>60%),consisting of salad, main course and dessert, respectively.
224290362|NCT00110006|BIOLOGICAL|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
224290363|NCT00110006|DRUG|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
223539121|NCT00327912|PROCEDURE|Laparoscopic Biliopancreatic diversion with Duodenal switch|
223539122|NCT00327912|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
223539123|NCT02289469|OTHER|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
223539124|NCT06029205|BEHAVIORAL|Conscious Awareness-Based Educatıon|The effect of Conscious Awareness-Based Education on nurses
223539125|NCT06029205|BEHAVIORAL|Stress coping training|The effect of stress coping training on nurses
223539126|NCT01402921|DEVICE|V0322 BC|"* Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment"
223539127|NCT03807388|DEVICE|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
223723413|NCT02546804|PROCEDURE|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
223953754|NCT04636099|DEVICE|CT angiography（CTA）|The CTA group was peformed upper abdomen enhenced and CT Angiography before surgery
223539128|NCT03807388|OTHER|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
223539129|NCT00546481|DRUG|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
223539130|NCT00546481|DRUG|Epoetin|As prescribed, iv, 3 times weekly
223539131|NCT00157118|DRUG|Protein C Concentrate (Human) Vapor Heated|
223539132|NCT01769924|OTHER|Nephrectomy|Nephrectomy for the purposes of living kidney donation
223539133|NCT05016089|OTHER|The 16-style simplified Pilates exercise programme|The 16-style simplified Pilates exercise programme was developed by a group of experienced Pilates and rehabilitation experts from our completed pilot work.
223539134|NCT05268757|BEHAVIORAL|Oral hygiene discontinuation|Oral hygiene discontinuation for 14 days followed by 14 days of regular oral care
223539135|NCT02982330|BEHAVIORAL|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing \<10% carbohydrate, \~75% fat, and 15% protein. Matched for calories to the active comparator arm.
223953755|NCT00588042|DEVICE|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
223539136|NCT02982330|BEHAVIORAL|Guidelines Breakfast|A low fat breakfast containing \~55% carbohydrate, \<30% fat, and 15% protein. Matched for calories to the experimental arm.
223539137|NCT05115435|BEHAVIORAL|neuro linguistic programming|Sub modality Technique: People experience the world with their five senses, and the thoughts that an individual creates in his brain about a situation are coded with these five senses. When these encodings change, the individual's perception of the situation will also change
223539138|NCT04298619|DIAGNOSTIC_TEST|Standard cohort: Clinical lab follow-up|
224290364|NCT00110006|DRUG|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
224290365|NCT00110006|DRUG|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
224290366|NCT00110006|DRUG|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
224290367|NCT00110006|PROCEDURE|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat \^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
224290368|NCT00110006|RADIATION|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV.
224290369|NCT00397306|DEVICE|Bioimpedance Analysis|
223539139|NCT04298619|DIAGNOSTIC_TEST|Imaging cohort: integrated imaging follow-up|
223539140|NCT02375100|PROCEDURE|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
223539141|NCT02375100|PROCEDURE|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
223539142|NCT02375100|PROCEDURE|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
224290370|NCT06341049|PROCEDURE|Intraperitoneal local anasthetic application + local anesthetic wound infiltration|For Group Intraperitoneal local anasthetic+ loal anesthetic wound infiltration, after the birth of the newborn and placenta, the uterus is taken out and closed, the blood accumulated in the pelvis is carefully wiped with surgical towels, and after complete hemostasis is achieved, sterilely prepared 20 ml 0.5% bupivacaine + 20 ml 2% lidocaine +1 A total of 40 ml of solution containing 200,000 epinephrine will be given to the surgeon. 10 ml of this solution will be instilled into all four quadrants of the uterus before closing the parietal peritoneum or fascia. The parietal peritoneal layer will be sutured or left open, depending on the surgeon's preference. 10 ml will be infiltrated around the edges of the rectus aponeurosis, and the remaining 20 ml will be infiltrated subcutaneously into the wound area.
224290371|NCT06341049|PROCEDURE|Intrathecal morphine application|Group Morphine will be given 11.2 mg hyperbaric bupivacaine + 15 µg fentanyl + 150 µg morphine into the spinal space.
224290372|NCT06341049|PROCEDURE|Quadratus lumborum block tip 1 application|In Group Quadratus lumborum block, Quadratus lumborum block type I, a total of 40 ml of a solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200,000 epinephrine will be applied bilaterally under ultrasound guidance.
224290373|NCT04529447|OTHER|Survey|The patient satisfaction survey consisted of 8 items, including 7 Likert scale questions and 1 multiple choice question.
223539143|NCT02375100|DRUG|Bupivacaine %0.5 (hyperbaric)|
223539144|NCT02375100|DRUG|Bupivacaine %0.25 (isobaric)|
223539145|NCT02375100|DEVICE|25G Quincke needle|
223539146|NCT02375100|DEVICE|Echogenic Needle with 30° bevel|
223539147|NCT02375100|DRUG|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
223539148|NCT02375100|DRUG|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
223539149|NCT02359656|PROCEDURE|surgical treatment|C1-C1 arthrodesis
223539150|NCT02359656|OTHER|non operative treatment for odontoid non unions|specific non operative treatment protocol
223539151|NCT05753462|DRUG|Phase 1, SQY51|SQY51 is administered by intravenous infusion.
223539152|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 1)|SQY51 is administered by intravenous infusion at dose 1
223539153|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 2)|SQY51 is administered by intravenous infusion at dose 2.
224290374|NCT03301532|DRUG|Triheptanoin|Dietary supplementation with triheptanoin
223539154|NCT05753462|DRUG|Phase 2a, SQY51 (cohort 3)|SQY51 is administered by intravenous infusion at dose 3.
223539155|NCT00002143|DRUG|Acitretin|
223539156|NCT00770302|DRUG|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
223539157|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
223539158|NCT00185302|DRUG|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
223539159|NCT04418895|OTHER|Chemoradiation|Subjects will receive neoadjuvant chemoradiation per standard of care. This is typically comprised of radiotherapy of 5040 cGy (centigray) with concurrent capecitabine 825 mg/m2 by mouth (po) two times daily (bid) (typically rounded to the nearest 500 mg dose) or infusional 5-fluorouracil (5FU). However, dosing and administration are at the discretion of the treating medical and radiation oncologist.
223539160|NCT04418895|RADIATION|short course radiation therapy|An acceptable alternative approach is short-course radiation therapy per standard of care, which is typically comprised of radiotherapy of 25 Gy (gray) in 5 fractions, with surgery within 1 week of completion of therapy or delayed for 6-8 weeks. Selection of the optimal radiation therapy approach is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist. However, generally, short-course radiation therapy is not recommended for low-lying tumors less than 5 centimeters (cm) from the anal verge.
223539161|NCT04418895|DRUG|mFOLFOX6|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
223723414|NCT02546804|PROCEDURE|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
224290375|NCT01144728|DRUG|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
224290376|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques
223723415|NCT02546804|PROCEDURE|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
223723416|NCT05119205|DIAGNOSTIC_TEST|Bone marrow biopsy and compete blood count|Bone marrow biopsy and compete blood count will be done for follow up in patients with multiple myeloma
223723417|NCT03098550|BIOLOGICAL|Nivolumab|Specified dose on specified days
223723418|NCT03098550|BIOLOGICAL|Daratumumab|Specified dose on specified days
223953756|NCT00588042|DEVICE|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
223953757|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
223953758|NCT01815294|DRUG|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
223953759|NCT04287361|OTHER|Efficacy of intravenous clonazepam|Efficacy of intravenous clonazepam
223953760|NCT06026826|DEVICE|transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
223723419|NCT02804932|DIETARY_SUPPLEMENT|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
223953761|NCT06026826|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
223723420|NCT02804932|OTHER|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
223953762|NCT03872661|DRUG|IBI308|IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
223953763|NCT03872661|DRUG|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
223953764|NCT03872661|DRUG|Pemetrexed|Pemetrexed was given 500 mg/m\^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
223953765|NCT03872661|DRUG|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
223953766|NCT03872661|PROCEDURE|Thoracic surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
224290377|NCT04463498|BEHAVIORAL|Group-based cognitive behavioral therapy for insomnia and additive bb-glasses|Sleep education, sleep restriction, stimulus control, cognitive restructuring, relaxation techniques, bb-glasses worn from 3 hrs before bedtime.
224290378|NCT04463498|OTHER|8-week wait list for sleep-school|Treatment as usual in a psychiatric outpatient clinic
224290379|NCT02537847|DRUG|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
224290380|NCT02537847|DRUG|Ertapenem|Control group will be given ertapenem only for 10 days.
224290381|NCT06227624|DRUG|Oral zinc sulfate and standard phototherapy|study the role of oral zinc sulfate in reducing level of indirect hyperbilirubinemia in neonates if used with standard phototherapy
224290382|NCT00325208|DEVICE|partial-vacuum milk bottle|
224290383|NCT00325208|DEVICE|anti-vacuum milk bottle|
224290384|NCT04238832|OTHER|Salt Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine
224290385|NCT04238832|OTHER|Free Base Nicotine|Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
224290386|NCT03174106|DEVICE|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
224290387|NCT05964192|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|The theta burst stimulation (TBS) technique consists in administering bursts of transcranial magnetic stimulation (TMS) at very high frequency (50Hz) for 5 minutes (3 pulses of stimulation given at 50 hz; 10 bursts/1 s train; inter-train interval : 8 s; number of trains : 30; 100% resting motor threshold; number pulses/session : 900). Total number of sessions : 20 sessions (single daily session).
224290388|NCT01610739|DRUG|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
223539162|NCT04418895|DRUG|CAPOX|possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
223723421|NCT00664872|OTHER|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
223723422|NCT00664872|BEHAVIORAL|case management|
223723423|NCT02393508|OTHER|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
223723424|NCT02393508|OTHER|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
223953767|NCT05472194|BEHAVIORAL|InSchool Training Program|The goal of the intervention is to promote and boost the development of executive functions in preschool and elementary school-aged children by means of engagement in meaningful and challenging activities. The method to achieve this consists on weekly intervention sessions run by teachers with a set of games specially developed to train executive functions.
223953768|NCT05472194|BEHAVIORAL|Regular school activities|Children in the control group will be playing with the regular school activities.
223953769|NCT03471390|OTHER|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
223953770|NCT02121808|PROCEDURE|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
223953771|NCT02121808|PROCEDURE|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
223953772|NCT04512560|BEHAVIORAL|Surgical Training using Structured Remote Surgical Coaching in addition to Conventional Surgical Training|General surgery residents (PGY 1-5) will provide a video recording of a laparoscopic cholecystectomy that they performed as a primary surgeon. The coach will identify key moments or themes for discussion on how to improve technical skills and reduce intra-operative errors during five, 30-45 minute remote coaching sessions .
223953773|NCT04512560|BEHAVIORAL|Surgical Training using Conventional Training Program|General surgery residents (PGY 1-5) will continue their usual residency training.
223953774|NCT03670771|DIAGNOSTIC_TEST|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
223953775|NCT05491837|OTHER|Device induce acute intermittent hypoxia 9 % of Oxygen|Interventional group will be provided a brief sequence of mild hypoxia consisting of 9% oxygen for one minute followed by normoxia 21% of oxygen for a total of 15 episodes
223953776|NCT05491837|OTHER|Normoxia 21% of oxygen|SHAM group will be provided normoxia 21% of Oxygen
223953777|NCT04521647|DRUG|Nicotine|Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use
223953778|NCT06678048|DRUG|Arsenous Acid plus Chemotherapy|Arsenous Acid , Eribulin, Gemcitabine, Utidelone, Vinorelbine
223953779|NCT06579287|DRUG|SHJ002|Topical ophthalmic
223953780|NCT06579287|DRUG|Atropine|Topical ophthalmic
223953781|NCT06348394|OTHER|Intracardiac Echocardiography|Transesophageal echocardiography will be performed under general anesthesia.
223539163|NCT04418895|DRUG|fluoropyrimidine +/- oxaliplatin|possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
223953782|NCT05066230|DRUG|KSI-301|Intravitreal injection
223539164|NCT01361984|DRUG|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is \~9 minutes
223539165|NCT01361984|DRUG|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
223539166|NCT01246882|BEHAVIORAL|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
223539167|NCT01246882|BEHAVIORAL|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
223539168|NCT03475602|DIAGNOSTIC_TEST|PLA2R|Determination of serum concentration of anti PLA2R antibody
223539169|NCT03475602|DIAGNOSTIC_TEST|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
223539170|NCT03979300|OTHER|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~* Quantitative features:~  * Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~ * Sociodemographical data and others questions~* Qualitative : Grounded Theory~  * Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~ * Semi-structured interview of learners and teachers"
223953783|NCT05066230|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
223953784|NCT05872958|DRUG|AZD3152|AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
223539171|NCT01357343|OTHER|Chiropractic|Spinal manipulation and active and passive therapy.
223539172|NCT01357343|OTHER|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
223539173|NCT01343212|OTHER|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
223539174|NCT03555058|OTHER|Treatment escalation|Treatment escalation per TDM and physician's decision.
223539175|NCT01077063|PROCEDURE|paracentesis|surgical drainage of malignant ascites
223539176|NCT01077063|DEVICE|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
223539177|NCT02066649|DRUG|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
223953785|NCT05872958|OTHER|Placebo|Placebo is a matching volume of 0.9% sodium chloride, will be administered via IM injection or IV infusion, as per the assigned arms.
223539178|NCT02066649|PROCEDURE|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
223953786|NCT06512116|DRUG|SIBP-A17|"Strength: 1, 2, 4, 5, 6 or 8 mg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle.~The dose escalation stage, 1mg/kg and 2mg/kg were subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If dose-limiting toxicity (DLT) occurred, the traditional 3+3 dose escalation method was immediately switched. If DLT does not occur, the next dose group will be explored, and the dose exploration starting from 4mg/kg will adopt a 3+3 dose escalation design."
223953787|NCT05847634|DEVICE|Masimo O3 NIRS cerebral oximetry and SedLine processed EEG|Non-invasive neuromonitoring device for observational study
223953788|NCT02164578|DRUG|Rivaroxaban|
223953789|NCT02164578|DRUG|Aspirin|
223953790|NCT05690477|PROCEDURE|Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.
223953791|NCT01976156|DIETARY_SUPPLEMENT|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
223953792|NCT01976156|DIETARY_SUPPLEMENT|Placebo|Placebo consists of rice flour
223953793|NCT00002761|BIOLOGICAL|filgrastim|
223953794|NCT00002761|BIOLOGICAL|recombinant interferon gamma|
223953795|NCT00002761|DRUG|busulfan|
223953796|NCT00002761|DRUG|cyclophosphamide|
223953797|NCT00002761|DRUG|cyclosporine|
223953798|NCT00002761|DRUG|cytarabine|
223953799|NCT00002761|DRUG|idarubicin|
223953800|NCT00002761|PROCEDURE|peripheral blood stem cell transplantation|
223953801|NCT02800135|DRUG|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
223953802|NCT05426434|DRUG|Dihydroartemisinin-Piperaquine (DP)|DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
223953803|NCT05426434|DRUG|Sulfadoxine pyrimethamine (SP)|SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.
223953804|NCT03924193|DRUG|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
223953805|NCT03924193|BEHAVIORAL|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
223953806|NCT03924193|OTHER|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
223953807|NCT02446860|DRUG|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
223953808|NCT05655260|OTHER|Comparison of chemotherapy vs. chemoradiotherapy|"Chemotherapy (paclitaxel-carboplatin) vs. chemoradiotherapy (paclitaxel-carboplatin followed by whole pelvic radiotherapy)~Patients assigned to chemotherapy receive paclitaxel (175 mg/m2) and carboplatin (area under curve, 5) every 3 weeks for 6 cycles. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
223953809|NCT05655260|OTHER|Comparison of VBT vs. WPRT|"Vaginal brachytherapy vs. whole pelvic radiotherapy~Patients randomized to vaginal brachytherapy receive cuff brachytherapy at 21 Gy in 3 fractions of 7 Gy at 0.5 cm depth. The pelvic radiotherapy dose is 45 to 50.4 Gy over 5 to 6 weeks (1.8 Gy per day for 25 to 28 fractions)."
223539179|NCT00287924|DRUG|methotrexate|
223723425|NCT01020227|BEHAVIORAL|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
223953810|NCT06306222|DEVICE|Laser lithotripsy|Ureteroscopic laser lithotripsy
223539180|NCT00287924|PROCEDURE|adjuvant therapy|
223539181|NCT05562115|OTHER|Tear collection|Collection of tears by Schirmer strip (2 to 4 mm).
223539182|NCT05503329|DIAGNOSTIC_TEST|arterial lactate level|an arterial lactate level measured from arterial sample from STEMI patients
223539183|NCT02750930|DRUG|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
223953811|NCT02929758|BEHAVIORAL|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
223953812|NCT05589129|DIETARY_SUPPLEMENT|Whey Protein Supplement|Participants assigned to the intervention will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
223953813|NCT05589129|DIETARY_SUPPLEMENT|Carbohydrate Placebo Control|Participants assigned to the placebo control will consume the supplement mixed with 6-8oz of water every day, twice per day, after soccer practice or soccer games, and one hour before bedtime.
223953814|NCT02032134|BIOLOGICAL|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
224290389|NCT01612039|DRUG|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
224290390|NCT01612039|DRUG|Placebo|Matching placebo tablets
224290391|NCT03394755|BIOLOGICAL|Thrombosomes|Freeze-dried platelets
224290392|NCT03880799|BEHAVIORAL|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
223539184|NCT02750930|DEVICE|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
223953815|NCT05266209|OTHER|Coconut oil skin care group|No special technique was used for sample selection, random sample selection will be made. In the evaluation made according to the large effect size, the number of samples determined for Power: 0.80, :0.20 and :0.05 was determined as 66, with a minimum of 22 for each group. Calculations were made in computer environment using Power analysis (G\*Power 3.1.9.2) program. Random selection method will be used while creating research groups. Coconut oil, sunflower oil and control groups will be formed according to the order of admission to the unit. E.g; Coconut oil is planned for the first hospitalized newborn, sunflower oil for the second newborn, and third hospitalized newborn control group. This order will be repeated until a sufficient number of cases is reached when the newborns are included in the groups.
223953816|NCT01241448|DRUG|LY2409021|Administered Orally
223723426|NCT00102726|DRUG|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
223723427|NCT00102726|OTHER|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
223723428|NCT01216306|BEHAVIORAL|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
223953817|NCT01241448|DRUG|Placebo|Administered Orally
223953818|NCT00430911|DRUG|Radiotherapy|
223953819|NCT04998825|DIETARY_SUPPLEMENT|Proteoglycan F|Salmon proteoglycan (Proteoglycan F) was extracted from salmon (Oncorhynchus keta) nasal cartilage. Salmon cartilage PG (Proteoglycan F) was manufactured in the form of a hard capsule by Ichimaru Pharcos, Co., Ltd. (at 318-1 Asagi, Motosu-shi, Gifu 501-0475 Japan) and consisted of 50 mg proteoglycan.
223953820|NCT04998825|OTHER|Placebo product|The placebo capsule contained only dextrin powder (Ichimaru Pharcos, Co., Ltd.).
224106771|NCT04681287|DRUG|inetetamab and PD-1 inhibitor combined with chemotherapy.|"1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued."
224106772|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
224106773|NCT01373177|DIAGNOSTIC_TEST|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
224106774|NCT02185170|PROCEDURE|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
223953821|NCT02382185|OTHER|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
223953822|NCT02382185|DRUG|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
223953823|NCT02382185|DEVICE|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
223953824|NCT01961934|DRUG|Sodium Acetate C11 PET/CT Imaging|
223953825|NCT00551187|BIOLOGICAL|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
223953826|NCT00551187|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
224106775|NCT02185170|DEVICE|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
223539185|NCT05609357|DEVICE|Head-up Cardiopulmonary Resuscitation|Elevate patient's head to 30 degrees by EleGARD System during cardiopulmonary resuscitation
223539186|NCT01585402|DRUG|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
224106776|NCT02185170|DEVICE|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
223539187|NCT01585402|DEVICE|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
223539188|NCT02805543|DEVICE|Color doppler imaging|
223539189|NCT01287494|DRUG|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
223539190|NCT06011083|DRUG|Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm|using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
223953827|NCT00551187|BIOLOGICAL|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
223539191|NCT06011083|DEVICE|Fractional carbon dioxide (CO2) laser|fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque
223953828|NCT03740737|DRUG|Follitropin delta|"FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed."
223953829|NCT03740737|OTHER|Placebo|"Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed."
223953830|NCT00947895|DRUG|Methylprednisolone|IV 1000 mg daily for 3 days
223953831|NCT00947895|DRUG|ACTH|IM ACTH 80 mg/day for 5 days.
223953832|NCT00947895|OTHER|IV placebo|IV placebo (saline) daily for 3 days.
223953833|NCT00947895|OTHER|IM placebo|IM placebo (saline) daily for 5 days.
223953834|NCT00759798|DRUG|Fludarabine|25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
223953835|NCT00759798|DRUG|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
223953836|NCT00759798|DRUG|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
223953837|NCT04223323|DIETARY_SUPPLEMENT|Almonds|Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.
223953838|NCT04223323|DIETARY_SUPPLEMENT|Pretzels|Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
223953839|NCT06268782|BEHAVIORAL|Rehabilitate your core|The intervention was an online exercise program \&#34;Rehabilitate your core,\&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
223953840|NCT02932280|DRUG|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
224106777|NCT04908137|DRUG|2-octyl cyanoacrylate|Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
224106778|NCT05385614|BEHAVIORAL|de:)press|Patients will receive de:)press for the duration of six weeks. They will be encourages to use the app at least three times a week, up to once per day.
224106779|NCT00212238|BEHAVIORAL|internet behavioral weight loss program|
224106780|NCT01454089|DRUG|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
224106781|NCT01454089|DRUG|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
224106782|NCT01454089|DRUG|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
223539192|NCT03155763|PROCEDURE|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
223539193|NCT02761642|DRUG|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
223539194|NCT05845112|DIAGNOSTIC_TEST|Molecular Diagnostics|pooled sputum samples will be used at the site of sample collection on the EDGE platform using Xpert ULTRA cartridges
223539195|NCT05845112|DIAGNOSTIC_TEST|Qualitative C-Reactive Protein (CRP)|CRP qualitative (POC) rapid tests are immunochromatographic based assays for qualitative or semiquantitative determination of CRP circulating in blood, serum or plasma at the Point of Care with a time to result in 5 minutes.
223539196|NCT05845112|DIAGNOSTIC_TEST|Point of Care (POC) C-Reactive Protein (CRP): Quantitative CRP|CRP quantitative (POC) devices are platforms for quantitative determination (in mg/L) of C-reactive Protein (CRP) circulating in blood at the Point of Care with a time to result of 5 minutes. These are antibody-based assays that measure the antigen and antibody reactions between monoclonal antibodies to human CRP.
224290393|NCT06332287|DRUG|combination of Trilaciclib and Pemetrexed|This was a single-arm, exploratory study of the combination of Trilaciclib and Pemetrexed in patients with non-small cell lung cancer with leptomeningeal metastasis. Observed the incidence of chemotherapy-induced myelosuppression, and imaging was performed every six cycles to assess tumor response.
224290394|NCT00558909|DRUG|BI 44847|
224290395|NCT00558909|DRUG|placebo for BI 44847|
224290396|NCT04583020|DRUG|Camrelizumab|Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
223953841|NCT05601362|DEVICE|Gamified Attention Bias Modification|Gamified computerized behavioral therapy with therapeutic intervention based on Attention Bias Modification Training (ABMT).
223953842|NCT05601362|DEVICE|Gamified Placebo Training|Placebo version of Gamified Attention Bias Modification. (Identical version of the gamified behavioral intervention without manipulation designed to decrease negative attention bias).
223953843|NCT00433706|PROCEDURE|Control position by 3DOBI before the fraction|
224290397|NCT04583020|RADIATION|radiation|60Gy/30
223953844|NCT00433706|PROCEDURE|Standard imaging|
223953845|NCT00082667|DRUG|gefitinib|
223953846|NCT00082667|PROCEDURE|Surgery|
223953847|NCT03034863|BEHAVIORAL|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
223953848|NCT03034863|BEHAVIORAL|Individual Safety Planning Intervention|The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).
223953849|NCT01819857|DRUG|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
223723429|NCT00684307|DRUG|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
223723430|NCT00684307|DRUG|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
223953850|NCT01819857|DRUG|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
223953851|NCT01819857|DRUG|Zofran 8 mg|intravenous administration of 8 mg ondansetron
223953852|NCT02226237|PROCEDURE|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
223953853|NCT02226237|PROCEDURE|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
223953854|NCT01581320|DRUG|Test group|Once a month, administration of DP-R206 \& placebo for 16 weeks
223953855|NCT01581320|DRUG|Reference group|Once a month, administration of Bonviva \& placebo for 16 weeks
223953856|NCT06037577|DRUG|CM-101|Anti-human CCL24 monoclonal antibody (CM-101)
223953857|NCT06037577|DRUG|Placebo|Placebo Comparator
224290398|NCT04583020|DRUG|Temozolomide|Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
224290399|NCT05857826|OTHER|soft tissue release|Patient will be asked to lie in hook lying position using a clean glove will apply some water based lubricant gently sweep vaginal muscle from superficial to deep until find a trigger point press it and release it using circle motion for 1 to 2 minute until the trigger point is completely released.
224290400|NCT05857826|OTHER|vaginal dilators|Vaginal dilators will be used according to the patient's condition starting from small sizes to the wider ones.
224290401|NCT02251873|DRUG|TPV + RTV (low dose)|
224290402|NCT02251873|DRUG|TPV + RTV (high dose)|
224290403|NCT02251873|DRUG|ddl|
223723431|NCT00684307|DRUG|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
223723432|NCT04097002|BIOLOGICAL|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
223539197|NCT05845112|DIAGNOSTIC_TEST|Urine lateral flow tests|The assay combines a pair of high affinity monoclonal antibodies directed towards largely Mycobacterium tuberculosis-specific lipoarabinomannan epitopes and a silver-amplification step that increases the visibility of test and control lines. This enables the detection of urinary lipoarabinomannan concentrations that are approximately 30 times lower than that detected by a previous test called AlereLAM and improved analytical specificity compared with AlereLAM.
223539198|NCT05845112|DIAGNOSTIC_TEST|Portable Chest X Ray Image Acquisition|Qure.ai (Qure.ai, New York, USA) is a computer aided detection (CAD) software for the automated screening of tuberculosis. Qure.ai is a mobile based interpretation software that screens chest X-Ray to detect TB in less than a minute. Qure.ai can distinguish abnormal scans from normal and detect abnormalities in the lungs, pleura, mediastinum, bones, diaphragm, and heart.
223539199|NCT00682149|DIETARY_SUPPLEMENT|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
223539200|NCT01044030|DRUG|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
223539201|NCT01044030|DRUG|Placebo|7.5 mL by mouth three times daily
224290404|NCT05243186|DEVICE|Treadmill workstation|walking on a treadmill workstation next to desk with computer and screen
223723433|NCT06040060|DRUG|Ketamine|The intervention was prepared by the research team (anesthesia resident) in the form of ketamine which had been diluted to a dosage of 10 mg/cc, taken according to the required dose based on actual body weight then diluted with 0.9% NaCl to 10 cc. Then the two solutions were given to researchers without knowing the contents of the drugs that had been prepared by the resident who assisted in this research.
223723434|NCT06040060|OTHER|Placebo|While the 0.9% NaCl solution was used as placebo was prepared in a 10 cc syringe
223723435|NCT02430311|DRUG|Olaparib|Tablet-150mg, Oral
223723436|NCT02430311|DRUG|Paclitaxel|Injection
223723437|NCT02430311|DRUG|Olaparib|Tablet-100mg, Oral
223723438|NCT00286169|DRUG|Amrubicin Hydrochloride|
223723439|NCT01499745|BEHAVIORAL|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
223723440|NCT04160091|DRUG|FX006|Single intra-articular injection
223723441|NCT04160091|DRUG|Normal Saline|Single intra-articular injection
223539202|NCT00298636|DRUG|adenosine|
223539203|NCT03678545|DRUG|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
223723442|NCT06037395|BIOLOGICAL|CT-P41|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
223723443|NCT06037395|BIOLOGICAL|US-licensed Prolia|a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
223953858|NCT00027209|DRUG|prempro|
224290405|NCT05243186|DRUG|Methylphenidate|Using prescription drug
224290406|NCT03203135|BEHAVIORAL|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
224290407|NCT01415219|OTHER|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
224290408|NCT01046799|DRUG|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
224290409|NCT01173471|DRUG|AZD4017|tablet, oral, one tablet once daily, 28 days
224290410|NCT01173471|DRUG|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
224290411|NCT01173471|DRUG|AZD4017|tablet, oral 2 tablets twice daily, 28 days
224290412|NCT01173471|DRUG|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
224290413|NCT03564301|DRUG|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
224290414|NCT03564301|DRUG|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
224290415|NCT06288022|OTHER|total tubeless mini-PCNL|When finish the mini-PCNL operation, patient not receive placement both ureteral drainage tube (DJ-stent) and nephrostomy tube.
224290416|NCT06288022|OTHER|tubeless mini-PCNL|When finish the mini-PCNL operation, patient receive placement ureteral drainage tube (DJ-stent) but not receive nephrostomy tube.
224290417|NCT04636359|BEHAVIORAL|Acupuncture stimulation|The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
224290418|NCT05089474|DEVICE|Streamline Surgical System|The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
224290419|NCT00252174|DRUG|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
224290420|NCT00252174|DRUG|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
223953859|NCT03368105|DIETARY_SUPPLEMENT|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
223953860|NCT05333835|DRUG|HR17031 injection|HR17031 injection
223953861|NCT05333835|DRUG|INS068 injection|INS068 injection
224106783|NCT01454089|DRUG|Gemcitabine|Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
223723444|NCT00471068|DRUG|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
223953862|NCT05333835|DRUG|SHR20004 injection|SHR20004 injection
224106784|NCT01454089|DRUG|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
223723445|NCT00471068|DRUG|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
223953863|NCT06298747|OTHER|Selective cervical nerve root pulsed radiofrequency|A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
223953864|NCT06035627|OTHER|Prevention hypothermia|Hypothermia was prevented by warming the case group. control group remained stable. As a result, the presence of surgical site infection was followed.
223953865|NCT00506025|DIETARY_SUPPLEMENT|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
223953866|NCT00506025|DIETARY_SUPPLEMENT|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
223953867|NCT06201949|OTHER|Articaine infiltration technique|infiltration will be performed with articaine and epinephrine 1/100 000 (Artinibsa, Inibsa, Barcelona, Spain) for all patients on their second pri-mary molar. The needle tip was placed in the buccal vestibule and then directed to the apex of the tooth and about one-third to one-fourth of the cartridge will be slowly discharged
223723446|NCT00471068|DRUG|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
224106785|NCT01454089|DRUG|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
224106786|NCT06179212|DIAGNOSTIC_TEST|Exercise Tests|Patients will complete 4 different cardiopulmonary exercise tests in random order.
224106787|NCT05851846|BEHAVIORAL|Amygdala insula retraining|Mind body intrevention
224106788|NCT01362400|DRUG|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
224106789|NCT01362400|DRUG|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
224290421|NCT00252174|BEHAVIORAL|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
223953868|NCT06201949|OTHER|Articaine nerve block technique|this technique will be performed with articaine and epinephrine 1/100 000 for all patients on their second primary molar with conventional technique inferior alveolar nerve block. The thumb will be placed on the occlusal surface of intended side and protruded toward the inner oblique ridge of ramus and then placed in touch with retromolar pad. The syringe will be directed between the two mandibular primary molars of opposite side and the needle will be pushed forward until hitting the bone, then the injection will be slowly done. After three to five minutes, treatment will be started, after numbness in the lower lip is achieved
223953869|NCT03303547|DIAGNOSTIC_TEST|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
223953870|NCT04499898|DRUG|Carvedilol|Carvedilol
224290422|NCT00252174|DRUG|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
224290423|NCT02443584|OTHER|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
224290424|NCT00283322|OTHER|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
224290425|NCT00898534|DEVICE|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
223539204|NCT03678545|DRUG|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
224290426|NCT02623049|OTHER|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
223953871|NCT04499898|PROCEDURE|Endoscopic band ligation|Endoscopic band ligation
223953872|NCT01381549|DRUG|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
223953873|NCT01381549|DRUG|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
223953874|NCT01381549|OTHER|Placebo|saline placebo
223953875|NCT02386085|PROCEDURE|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
223953876|NCT02430909|BIOLOGICAL|Bimekizumab|"* Pharmaceutical form: Solution for infusion~* Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~* Route of administration: iv infustion"
224106790|NCT01264991|PROCEDURE|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
224106791|NCT01264991|PROCEDURE|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
224106792|NCT00683189|DRUG|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
224106793|NCT00052429|DRUG|cisplatin|
224106794|NCT00052429|DRUG|fluorouracil|
224106795|NCT00052429|PROCEDURE|adjuvant therapy|
224106796|NCT00052429|RADIATION|radiation therapy|
224106797|NCT01407562|DRUG|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
224106798|NCT01407562|DRUG|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
224106799|NCT01407562|DRUG|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
224106800|NCT05952219|DRUG|CKD-379|2 tablet administration under fed condition
224106801|NCT05952219|DRUG|D759+D745+D029+D150|4 tablet co-administration under fed condition
224106802|NCT05041764|OTHER|NO INTERVENTION|No INTERVENTION
224290427|NCT04075019|BEHAVIORAL|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
224290428|NCT01453413|OTHER|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
224290429|NCT03936049|DRUG|Liraglutide|Liraglutide dispensing claim is used as the exposure group
224290430|NCT03936049|DRUG|DPP-4 inhibitor|DPP-4 inhibitor dispensing claim is used as the reference group
224290431|NCT03969199|BEHAVIORAL|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
223953877|NCT02430909|BIOLOGICAL|Certolizumab Pegol|"* Pharmaceutical form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
223953878|NCT02430909|OTHER|Placebo|"* Pharmaceutical form: Solution for infusion~* Concentration: 0.9% saline~* Route of administration: Intravenous infusion"
223953879|NCT02441829|DRUG|Eleclazine|Eleclazine tablets administered orally in morning with food
223953880|NCT03262714|OTHER|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
224290432|NCT02477241|PROCEDURE|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
224290433|NCT02477241|DEVICE|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
224290434|NCT02122718|DRUG|Allopurinol|
224290435|NCT02122718|DRUG|Placebo|
224290436|NCT05690126|DIETARY_SUPPLEMENT|Saffron extract|Food supplements are taken during 6 weeks by healthy volunteers
224290437|NCT05690126|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are taken during 6 weeks by healthy volunteers
224290438|NCT00102687|DRUG|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
224290439|NCT01713426|DRUG|Qutenza|Cutaneous patch
224290440|NCT01713426|DRUG|Pregabalin|Oral capsule
224290441|NCT00903552|BIOLOGICAL|Influenza VLP Vaccine|
223953881|NCT03262714|OTHER|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
223953882|NCT03262714|OTHER|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
223953883|NCT04651426|DEVICE|The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1|"The FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1 which mechanism of action is through the ability of biominerals to reflect the far infrared radiation (FIR). Normally the human body temperature would dissipate regular far infrared radiations but, thanks to the FIT Therapy (Far Infrared Technology), these waves are reflected and allowed to reach deeper areas in the human body (wavelength spectrum is 4-21 µm with a denser concentration around 11 µm).~Every FIT device act as a mirror and they are able to induce an antalgic effect simply thanks to this biophysical process, therefore without releasing any active ingredient or creating a thermic shock.~The plasters are made of 100% polypropylene non-woven fabric, an acrylic adhesive mass and a mix of titanium dioxide printed on. This particular mix in powder form is characterized by particles sizes above 100 nm."
224290442|NCT00903552|BIOLOGICAL|Placebo|phosphate-buffered saline (PBS)
224290443|NCT04799652|OTHER|Survey|Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.
224290444|NCT00878696|PROCEDURE|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
224290445|NCT03357081|DRUG|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
224290446|NCT06177314|OTHER|correlate the molecular signatures of active lesions of contact dermatitis with allergological results|Data will be collected retrospectively and prospectively from patients' medical records, and will include: clinical information (history, treatments, lifestyle, exposures, lesion location and appearance), patch-test results, histological analysis results, molecular analysis results.
224290447|NCT03066791|DIETARY_SUPPLEMENT|Turmeric tablets|
224290448|NCT03066791|DIETARY_SUPPLEMENT|Curcumin and Bioperine tablets|
224290449|NCT03066791|DIETARY_SUPPLEMENT|Placebo tablets|
224290450|NCT04421976|PROCEDURE|PEEP|"Driving pressure (DP) is calculated as plateau pressure - PEEP. 10min after position adjustment, PEEP is increased from 2 to 10 cm H2O incrementally. Each PEEP level is maintained for 10 respiratory cycles, with DP in the last cycle recorded. Then the PEEP level producing the lowest DP will be identified and maintained intraoperatively."
224290451|NCT05051878|DEVICE|T-scan|occlusal analysis T-scan
224290452|NCT05051878|OTHER|articulating paper|articulating paper occlusal analysis
224290453|NCT04917627|DRUG|Vancomycin|one vial of vancomycin (1000 mg ) powder form.
224290454|NCT00351351|DEVICE|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
224290455|NCT00351351|DEVICE|single probe ultrasonic|FDA-approved - single probe ultrasonic
224290456|NCT01104428|DRUG|Placebo|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
224290457|NCT01104428|DRUG|"ziying granules"|granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
224290458|NCT02116894|BIOLOGICAL|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
224290459|NCT02116894|DRUG|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
224290460|NCT00314782|DRUG|ZD4054 (Zibotentan)|oral tablet
224290461|NCT00314782|DRUG|Docetaxel|intravenous infusion
223953884|NCT04604717|OTHER|Pulmonary rehabilitation|8 weeks of exercise training (twice weekly) of education and exercise
223953885|NCT02981953|DEVICE|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
223953886|NCT04510493|DRUG|Canakinumab|Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours
224106803|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
224106804|NCT02580162|BEHAVIORAL|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
224106805|NCT02580162|BEHAVIORAL|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
224290462|NCT00314782|DRUG|Placebo|
223953887|NCT04510493|DRUG|Placebo|Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
224290463|NCT02293473|DEVICE|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
223953888|NCT05651802|RADIATION|Prophylactic cranial irradiation|Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
223953889|NCT05651802|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
224290464|NCT02293473|DEVICE|BIS-Bispectral Index Monitor|Depth of anaesthesia
224290465|NCT02293473|DEVICE|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
224290466|NCT02293473|OTHER|Standard of care|Using standard of care
224290467|NCT05559463|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory (ITIS) diet for 28 days
224290468|NCT02540837|DRUG|Bupivacaine|Obturator nerve block
224290469|NCT02540837|DRUG|Saline|Obturator nerve block with saline(placebo)
224290470|NCT02493920|OTHER|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm).
224290471|NCT02493920|DEVICE|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
224290472|NCT00373191|DRUG|chemotherapy|N/A- not dictated by study
224290473|NCT00373191|DRUG|endocrine therapy|N/A- not dictated by study
224290474|NCT00373191|GENETIC|DNA methylation analysis|laboratory analysis
224290475|NCT00373191|GENETIC|protein analysis|laboratory analysis
223723447|NCT05062798|PROCEDURE|Standart bottle|"1. After the surgery, standard bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
224290476|NCT00373191|OTHER|laboratory biomarker analysis|laboratory analysis
224290477|NCT00373191|OTHER|questionnaire administration|questionnaire
224290478|NCT00373191|PROCEDURE|adjuvant therapy|N/A- not dictated by study
224290479|NCT00373191|PROCEDURE|conventional surgery|N/A- not dictated by study
224290480|NCT00373191|RADIATION|radiation therapy|N/A- not dictated by study
224290481|NCT00860691|PROCEDURE|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
224290482|NCT00860691|PROCEDURE|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
224290483|NCT00860691|OTHER|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R\&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
224106806|NCT03099759|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D2/D3
224106807|NCT01878565|DRUG|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
224290484|NCT04517929|OTHER|Group Psychotherapy|9 week group psychotherapy, given by a psychologist trained in group psychotherapy.
224290485|NCT01373060|DRUG|ASP1941|oral
223723448|NCT05062798|PROCEDURE|Squeezable bottle|"1. After the surgery, squeezable bottle will be used for feeding.~2. Following the completion of the surgery,feeding process evaluation will be performed until the discharge by using the feeding evaluation form.~3. Patients will be given a follow-up appointment 2 weeks after the operation and a feeding process evaluation will be made."
224106808|NCT01878565|DRUG|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
224106809|NCT03405103|BEHAVIORAL|Striving|
224106810|NCT03405103|BEHAVIORAL|Boning-Up|
224290486|NCT01373060|DRUG|Placebo|oral
224290487|NCT00466726|BIOLOGICAL|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
224290488|NCT00466726|BIOLOGICAL|sargramostim|
224290489|NCT04403763|DRUG|AGN-241622|Topical eye drop
224290490|NCT04403763|DRUG|Vehicle|Topical eye drop
224290491|NCT01174524|DRUG|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
224290492|NCT01174524|DRUG|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
224106811|NCT03405103|BEHAVIORAL|Personal Choice|
224106812|NCT00367471|DRUG|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
224290493|NCT02842463|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|
224290494|NCT06127017|PROCEDURE|splinting dental implants with titanium bar|splinting of dental implants will be done in the placebo comparator group by welding a titanium bar intraorally to the temporary sleeves attached to the implants.
224290495|NCT06127017|PROCEDURE|splinting dental implants with PEEK bar|in the active comparator group ,the PEEK bar will be attached to the temporary sleeves using flowable composite resin material.
224290496|NCT04909541|OTHER|CEGSSS-Canadian Endourology Group Stent Symptom Score|Patient with ureteral stent complete the Canadian Endourology Group Stent Symptom Score (CEGSSS)
224290497|NCT00004481|PROCEDURE|genetic testing|
224106813|NCT00367471|DRUG|carboplatin|An alkylating agent used in the treatment of some cancers
224106814|NCT00367471|DRUG|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
224106815|NCT00367471|DRUG|paclitaxel|A mitotic inhibitor used in cancer treatment
224290498|NCT05603455|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis|Supplement with Bifidobacterium adolescentis twice/day in morning and tonight for 6 months
224290499|NCT05603455|DIETARY_SUPPLEMENT|Placebo|Placebo
224290500|NCT05827484|BIOLOGICAL|Autologous platelets rich plasma|30 ml of venous blood were drawn from the participant by means of venipuncture. The collected blood was mixed with 3 ml anti-coagulant acid citrate dextrose in the centrifugation sterile tube. The blood sample was then centrifuged using the centrifugation machine. 3 ml of PRP from the buffy coat layer were loaded in a 5 ml syringe. After local sterilization and draping of the site of injection and under US guidance the hematoma was aspirated from the injury site and the freshly prepared PRP was injected.
224290501|NCT05827484|COMBINATION_PRODUCT|Autologous platelets rich plasma + oral LOSARTAN administration|in addition to local PRP injection, 50 mg / day of LOSARTAN (Cozaar® 50 mg film-coated tablets) were administrated to the study group orally every morning from day 5 and till day 30 after injury.
224290502|NCT00749502|DRUG|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
224290503|NCT03060850|DRUG|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
224290504|NCT01376310|DRUG|GSK1120212|up to 2 mg/day
224290505|NCT01376310|DRUG|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
224290506|NCT01376310|DRUG|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
224290507|NCT01376310|DRUG|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
224290508|NCT01376310|DRUG|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
223953890|NCT05651802|DRUG|Chemotherapy|Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
223953891|NCT01900015|DRUG|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
223953892|NCT01900015|DRUG|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
223953893|NCT03660527|OTHER|Not refered|No intervention was refered.
223953894|NCT00996164|DRUG|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
223953895|NCT00996164|DRUG|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
223953896|NCT00383812|DRUG|Intravitreal Bevacizumab|
223953897|NCT00774826|DRUG|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
223953898|NCT00774826|DRUG|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
223953899|NCT00774826|DRUG|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
223953900|NCT01228565|OTHER|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
223953901|NCT01228565|OTHER|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
223953902|NCT01962402|DRUG|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
223953903|NCT01962402|BEHAVIORAL|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
223953904|NCT06523686|PROCEDURE|Guided bone regeneration|Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
223953905|NCT00994708|DRUG|esomeprazole|
224106816|NCT05274438|DRUG|JS001+Imatinib mesylate|"This study consisted of two phases: the first phase was the dose exploration phase, and the second phase was the extension group. In phase I, 3 patients were enrolled, starting with imatinib monotherapy, 400mg qd, for 2 cycles (6 weeks), followed by imatinib 400mg qd combined with toripalimab 240mg q3w. If DLT was not observed, the original dose was extended to 37 patients in phase ii; If there was 1 DLT in the first stage, the number of patients in the first stage was extended to 6. If there was no DLT, the patients entered the extended stage. If ≥2 DLT cases occurred in the first phase, imatinib was reduced to 300mg QD and toripalimab 240mg q3W, and the 3+3 study was restarted. If DLT≤1 case, enter extended group (imatinib 300mg qd and toripalimab 240mg q3W); The longest cumulative use period of the two drugs was 2 years. When patients develop disease progression or develop intolerable toxicity, treatment is ended and follow-up for survival is entered."
223953906|NCT02504762|PROCEDURE|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
223953907|NCT02504762|PROCEDURE|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
224106817|NCT01646710|BEHAVIORAL|Pretesting food based recommendations|
224106818|NCT02214589|OTHER|Oral glucose, facilitated tucking, NNS|
224106819|NCT02214589|OTHER|Oral glucose and NNS|
224106820|NCT02214589|OTHER|Facilitated tucking and NNS|
224106821|NCT00298532|PROCEDURE|Advanced Life Support|
224106822|NCT03163342|BIOLOGICAL|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
224106823|NCT05881850|OTHER|Education Program on Increasing Osteoporosis Awareness Given to Women Aged 18-49. The research is carry out as a randomized controlled experimental in a pretest-posttest design.|The education program consisting of three sessions was held once a week and each session lasted approximately 40-50 minutes. In the realization of the education program, a power point presentation consisting of the contents of the education booklet prepared for Osteoporosis awareness, a three-dimensional bone model with Osteoporosis and normal bone tissue, some food samples containing calcium during nutrition education, and measuring cups to show portions and amounts were used. During the training, a question and answer activity was also held. The education booklet was also given to the intervention group at the end of the first session.
223953908|NCT02889900|DRUG|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
224106824|NCT00211523|DRUG|MBI 226 Acne Solutions|
223953909|NCT02769754|DEVICE|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
223953910|NCT02769754|OTHER|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
224106825|NCT01736683|DRUG|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
224290509|NCT01376310|DRUG|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
224290510|NCT01376310|DRUG|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
224290511|NCT01376310|DRUG|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
224290512|NCT02610764|PROCEDURE|Blood Test for CTC evaluation|
224290513|NCT04844021|BEHAVIORAL|Nudge|"EHR-based nudge"
224290514|NCT04844021|BEHAVIORAL|Nudge+|"EHR-based nudge plus facilitation"
224290515|NCT06502652|OTHER|hippotherapy|A hippotherapy simulator is a horse riding simulator exercise machine, mimicking a horse's gait and recreating the horseback riding experience within the safety of a therapy clinic. Child with down syndrome will be seated on the stimulator for 10-15 minutes every session. The patient's pelvis moves softly, rhythmically, and repetitively when riding this action is comparable to what the human pelvis does when walking normally
224290516|NCT06502652|OTHER|balance training|The therapist modified the railing height to suit each child, ensuring the children were standing erect on the treadmill. Treadmill training completed under three conditions in 1-min training cycles. For 15 s of each minute the child could hold on to the railings with both hands, for the next 15 s with one hand, and finally with no hands on the handrails for 30 s. Each child repeated this procedure 20 Times and cool down for 5 minutes
224290517|NCT02453633|OTHER|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
224290518|NCT02453633|OTHER|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
224290519|NCT06467552|PROCEDURE|control group|The entire process is carried out according to Severance Hospital surgical protocols.
224290520|NCT06467552|DIETARY_SUPPLEMENT|Nucare Curact group|The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery. In addition, the patients of control group will be instructed to take up to 4 doses of the nutritional supplement (Nucare Curact provided by DAESANG Wellife Inc.) per day for approximately 2 weeks before surgery and for about 4 weeks after surgery.
224290521|NCT04825015|DEVICE|VEnaRt Cardiac Output|Every patient is monitored during liver transplantation with VEnaRt Cardiac Output versus Swan-Ganz Catheter
223539205|NCT03678545|DRUG|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
223539206|NCT03051958|BEHAVIORAL|Internet mindfulness&exposure treatment|"See description under Arm."
223953911|NCT01821599|OTHER|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
223953912|NCT01821599|OTHER|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
223953913|NCT06226623|DIETARY_SUPPLEMENT|Coconut|Participants in the intervention group, unlike participants in the control group, were asked to consume 50 g of fresh coconut daily for four weeks.
223539207|NCT03051958|OTHER|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
223953914|NCT04338568|DIAGNOSTIC_TEST|Lung ultrasound|The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
223953915|NCT02198105|DEVICE|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~1. PTA with Cutting-Balloon (60-120 seconds).~2. PTA with DC-Balloon (60 seconds).~Technical success is defined as~1. no recoil \>30%~2. no dissection \>Type B~3. no stenting \>30% of lesion length."
223953916|NCT00630409|DRUG|Gemcitabine|800 mg IV day 1 and 8
223953917|NCT00630409|DRUG|Doxil|24 mg/m2 every 21 days IV
223953918|NCT02346786|DIETARY_SUPPLEMENT|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
223953919|NCT02346786|DIETARY_SUPPLEMENT|tap water|
223953920|NCT05238337|DRUG|[14C]-PBI-200|\[14C\]-radio-labeled-PBI-200
223953921|NCT06322589|DIETARY_SUPPLEMENT|SOD like Super Drink|consume 1 bottle per day
224106826|NCT04632849|BEHAVIORAL|GEM + CGM|Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
224106827|NCT02817438|BEHAVIORAL|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
223539208|NCT05922605|DRUG|S-ketamine & Ropivacaine|The experiment group (Group E) will receive a mixture of ropivacaine 0.2% 0.7 ml／kg and preservative-free S-ketamine 0.5 mg/kg caudally for postoperative analgesia.
223539209|NCT05922605|DRUG|Ropivacaine|The experiment group (Group C) will receive ropivacaine 0.2% 0.7 ml／kg plain and equial volume saline caudally for postoperative analgesia.
223539210|NCT01937520|DEVICE|acupuncture|One half of subjects will receive a standardized acupuncture regiment
223539211|NCT01937520|DEVICE|no acupuncture|placebo
223539212|NCT01111643|DEVICE|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
223953922|NCT06322589|DIETARY_SUPPLEMENT|placebo drink|consume 1 bottle per day
223953923|NCT04836871|COMBINATION_PRODUCT|DFPP combined with chemotherapy|Double filtration plasmapheresis combined with chemotherapy
223953924|NCT04785794|BIOLOGICAL|Sing2016 M2SR H3N2 influenza vaccine|This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
223953925|NCT04785794|OTHER|Placebo|This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
223953926|NCT03422705|DEVICE|Optimised programming|Optimised programming to avoid RV pacing when possible.
223953927|NCT03422705|DRUG|Lisinopril|Uptitration of lisinopril
223953928|NCT03422705|OTHER|Standard care|No pacemaker adjustment or medical therapy
223953929|NCT00690313|DRUG|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
223953930|NCT01557439|DRUG|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
224106828|NCT05977543|OTHER|Functional crackers enriched with grape seed flour|The crackers was enriched with 10% grape seed flour
223539213|NCT06104137|OTHER|course (MOOC) patient education|this is a massive open online course created by us for patient education. Patients will be given a login and password to access the MOOC from their own computer. The MOOC has 3.5 hours of content and patients will be given 3 weeks to complete.
223539214|NCT06104137|OTHER|standard patient consent process|standard consenting and shared decision making in the clinic
223539215|NCT02756403|DRUG|Azithromycin|500 mg
223539216|NCT02756403|DRUG|Doxycycline|200 mg
223539217|NCT02756403|DRUG|Metronidazole|500 mg
223539218|NCT02756403|DRUG|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
223539219|NCT01644643|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
224106829|NCT05977543|OTHER|Functional crackers with 40% barley flour and enriched with β-glucans|The crackers consisted of 60% wheat flour, 40% barley flour and was enriched with β-glucans.
224106830|NCT05293938|DRUG|Obeticholic Acid 5 MG|once daily, oral administration
224106831|NCT05293938|DRUG|Obeticholic Acid 10 MG|once daily, oral administration
223953931|NCT02749253|OTHER|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
223953932|NCT05636345|OTHER|pain science education|A full day of pain science education
223953933|NCT04148794|BEHAVIORAL|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
223953934|NCT01668498|DRUG|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
223953935|NCT01668498|DRUG|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
223953936|NCT06416605|PROCEDURE|Maxillary Alveolar Ridge Augmentation|using tooth graft or bone graft to increase alveolar ridge width to be able to insert dental implant
223953937|NCT05045456|DEVICE|Cardiologs Platform|Two Apple Watch recordings (one recording with the watch on the wrist and one on the left side of the abdomen) interpreted by Cardiologs AI done simultaneously with each 12-lead ECG
223953938|NCT01301183|DRUG|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
223953939|NCT01301183|DRUG|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
223539220|NCT01644643|DRUG|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
223953940|NCT05894551|OTHER|Evaluation of q angles different positions|Q angle evaluation in two different static postures (upright and supine position) and dynamic posture during the midstance phase of the gait
224106832|NCT05293938|DRUG|Standard of Care: UDCA|No study medication is provided by the sponsor or by the investigators. The decision to initiate, continue or discontinue UDCA, or to modify UDCA dosing, is entirely at the discretion of the treating physician as per their standard of care and is in no way influenced by the sponsor or participating institutions. UDCA utilization is recorded and included in the study record.
224106833|NCT04562324|DRUG|SSRI or SNRI or benzodiazepines or tricyclic antidepressants or other antidepressants or antipsychotics or other sedative-hypnotics|Medications to relieve anxiety
224106834|NCT04562324|DEVICE|Neurofeedback system|EEG-neurofeedback is an operant conditioning procedure in which people learn to improve the brain's functional activity and used as a way to effect long-term change in abnormal brain activity thus alter corresponding cognitive function. In addition, its potential to be used to elucidate the mechanisms underlying psychopathology by evaluating the subjective effect of the modulation of specific brain areas has become apparent. Participants receive 24 min NF sessions over the Motor sensory Cortex, 2-3 days per week, for 2 weeks
224106835|NCT06270992|DIAGNOSTIC_TEST|NCCN (National Comprehensive Cancer Network) diagnosis|For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
224106836|NCT00793923|DRUG|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
224106837|NCT00793923|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
224106838|NCT05784792|OTHER|Lugol -|Patients that undergo total thyroidectomy without Lugol solution pretreatment
224106839|NCT01359540|DEVICE|OMNI Apex Modular™ Hip Device|
224106840|NCT01359540|DEVICE|OMNI Apex ARC™ Hip Device|
223539221|NCT01644643|DRUG|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
223539222|NCT00159926|PROCEDURE|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
223539223|NCT00159926|PROCEDURE|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
223539224|NCT04645173|DEVICE|CIED envelope|Evaluation of the difference in cohorts for soft tissue healing surrounding the CIED implant and clinical outcomes and complications.
223953941|NCT05894551|OTHER|Physical examination|"With goniometric evaluations, the femoral anteversion angle will be measured. Pelvis width and thigh length will be measured with a tape measure. Quadriceps muscle strength, hamstring muscle strength, Hip abduction, adduction, internal and external rotation and extension muscle strength will be measured with hand-held dynamometer.~Joint mobility will be assessed with the Beighton score and foot posture will be evaluated with the foot posture index-6 (FPI-6)."
223953942|NCT05894551|OTHER|Functional mobility assessment|10-meter walking test will be conducted to understand functional mobility.
223953943|NCT06453759|PROCEDURE|Additional electrodes into bilateral anterior, centromedian and pulvinar thalamic nuclei|"The centromedian, anterior and pulvinar nuclei on each side will be chosen as target for new electrodes; up to 6 additional electrodes may be added but, where possible, existing electrode trajectories will be extended to facilitate recording.~At the beginning of the recording process, usually within the first 24-48 hours of implantation, we will conduct 2 study-specific stimulation experiments:~1. Single pulse electrical stimulation (SPES):~2. N-of-1 trials of simulated DBS: We will simulate high (130Hz) and low (6Hz) frequency DBS currents from each pair of thalamic nuclei (always bilateral) and record spontaneous interictal neuronal activity in all other cortical contacts for 15 minutes. We will also record SPES from each of the cortical contacts."
223953944|NCT05779254|DRUG|Neomycin Sulfate|Postoperative day-1 Oral Antibiotic Prophylaxis + patients get po. 3x1000mg Neomycin sulfate and 3x500 mg Metronidazole
223953945|NCT04977089|DIAGNOSTIC_TEST|lipid profile test .|Assesment of lipid profile of patients (cholesterol level ,TG ,VLDL )
223953946|NCT03763409|DRUG|Losartan Potassium|active drug
223953947|NCT03763409|OTHER|placebo|placebo
223953948|NCT04392856|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
223953949|NCT04392856|BEHAVIORAL|Same than experimental condition (UP), after it finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
223953950|NCT00048477|DRUG|L-NMMA and Sodium Nitrite|
223953951|NCT00635752|OTHER|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
223953952|NCT00635752|OTHER|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
223953953|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
223953954|NCT01410721|BEHAVIORAL|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
223953955|NCT02255006|DEVICE|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
224106841|NCT01923064|DRUG|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
224106842|NCT01923064|DRUG|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
224106843|NCT03910699|DEVICE|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
224106844|NCT03910699|DEVICE|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
224106845|NCT03580057|BEHAVIORAL|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
224106846|NCT03580057|BEHAVIORAL|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
224106847|NCT04649853|OTHER|Standardized nursing care|All patients will receive standardized evidence based nursing care
224106848|NCT01755481|OTHER|Probiotic|
224106849|NCT01755481|OTHER|Whey protein concentrate|
224106850|NCT01042301|OTHER|Blood samplings|
224290522|NCT01267006|DRUG|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
224290523|NCT01267006|DRUG|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
224290524|NCT03184532|DIAGNOSTIC_TEST|ultrasound|ultrasound examination of pyloric antrum
224290525|NCT00809315|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
223953956|NCT02255006|DEVICE|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
223953957|NCT02255006|DRUG|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
223953958|NCT02255006|DRUG|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
223953959|NCT01062165|DRUG|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
223953960|NCT04187456|DRUG|Savolitinib|Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
223539225|NCT06230484|DEVICE|Invisalign first palatal expander|Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
223953961|NCT04187456|DRUG|Midazolam|Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.
223539226|NCT06230484|DEVICE|Conventional rapid maxillary expansion|Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
224290526|NCT00809315|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
224290527|NCT03984045|DRUG|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
224290528|NCT03984045|DRUG|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
223953962|NCT01322386|DRUG|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
223953963|NCT00507845|DRUG|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
223953964|NCT00670852|PROCEDURE|X-rays and CT scan|CT Scan x-rays
224290529|NCT02857647|BEHAVIORAL|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
224290530|NCT06061783|DRUG|Hypotonic Solution|"Intravenous administration of 5% glucose solution 1,200ml every 8 hours for a total of 3,600ml per day.~If hyperglycemia is present, it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily."
224290531|NCT06061783|DRUG|Water Purified|administration of bottled water through the nasogastric or orogastric tube at a dose of 150 ml/hour for a total of 3,600 ml per day.
224290532|NCT00452608|DRUG|amido pill|one pill of amido/d by mouth for 10 days
223539227|NCT05173376|BEHAVIORAL|Portion size manipulation|The intervention was administered via changing portion sizes of foods served to participants.
223539228|NCT02099084|DRUG|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
224290533|NCT00452608|DRUG|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
223539229|NCT02099084|DRUG|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
223539230|NCT00784862|DRUG|Anastrozole|1mg, orally, once daily
223539231|NCT00784862|DRUG|Tamoxifen|20mg, orally, once daily
223539232|NCT00235222|DRUG|stavudine|
223539233|NCT01205503|DRUG|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
223539234|NCT01205503|DRUG|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
223953965|NCT03448302|RADIATION|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time \& permeability surface measurements will be obtained.
223953966|NCT04794465|DIAGNOSTIC_TEST|Colorectal cancer screening|Patients with IBP diagnosed during the colorectal cancer screening
223953967|NCT00883272|DIETARY_SUPPLEMENT|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
224106851|NCT01855555|DRUG|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
223539235|NCT01205503|DRUG|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
223539236|NCT01205503|DRUG|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
223953968|NCT05804734|DRUG|Vitamin K Antagonist - Drug|"Only clinical data (number and types of severe bleeding events, HAS-BLED score, CHA2DS2-VASc score) are collected during the follow-up:~* For cases when they received an anticoagulant treatment and during the 12 months preceding this treatment,~* For controls during the same periods of their cross-matched cases when reciving anticoagulant treatment."
223953969|NCT00362258|DRUG|Irbesartan (Aprovel)|Aprovel (150 \& 300mg) \& CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
223539237|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
223539238|NCT00362895|DRUG|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
224290534|NCT00914979|DEVICE|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
223723449|NCT04250870|DIAGNOSTIC_TEST|Senior Fitness Test|"Chair stand test:The number of full stands performed on a seated position that can be completed within 30 seconds was recorded.~Arm curl test: The participants were asked to lift weights starting with a full elbow extension and then full flexion.~2-minute step test: The participant was asked to begin stepping as quickly as possible to reach the marked height for two minutes.~Chair sit-and-reach test:The participant could extend right or left knee to a full extension, heel on the floor and ankle in a neutral position of 90 degrees. Then, the participant was asked to reach to the toes.~Back-scratch test:The participant was asked to stand up and place his/her preferred hand over the same shoulder, palm down and fingers extended, and reach down the middle of the back as far as possible.~8-foot up and go test:The participant was asked to get up from a chair without any arm support and walk a distance of 2.44 meters; then turn around a cone and come back to sit down on the chair."
223723450|NCT02998593|DRUG|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
223953970|NCT04873986|DIAGNOSTIC_TEST|Scoliosis Tele-Screening Test|Scoliosis Tele-Screening test will be applied to children by parents at home. Participants with moderate and high risks will be invited to the physical examination to the centers or virtual assessment via e-mail. The researchers will be evaluated the TRACE and Adams' test from the photo and sent their opinions to the parents via e-mail.
224106852|NCT02941731|DRUG|HIP1403|Oseltamivir 6mg/mL
224106853|NCT02941731|DRUG|HGP0919|Oseltamivir phosphate 6mg/mL
224106854|NCT05597046|OTHER|Interview|Interviews
224106855|NCT04154618|DEVICE|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
224106856|NCT04675346|OTHER|Questionnaire|Questionnaire
224106857|NCT06513715|DIETARY_SUPPLEMENT|Control|This intervention will be made with a placebo
224106858|NCT06513715|DIETARY_SUPPLEMENT|Jubanine|This intervention will be made with jubanine or prickly pear extract
223723451|NCT02998593|DRUG|Placebo|Oral use of placebo capsules by patients for 3 months.
224106859|NCT03223727|DIAGNOSTIC_TEST|Blood tests|Blood tests for several bone markers (see summary)
224106860|NCT04649281|DEVICE|Accelerometry|Recording of sleep and physical activity by accelerometry during one week.
224106861|NCT05603286|PROCEDURE|Home-monitoring|Questionnaires for home-monitoring will be send to the participants 11 weeks after the baseline visit via e-mail using Castor EDC and can be completed using a computer, tablet or smartphone. Home-monitoring can be done together with a parent or guardian, if needed.
223539239|NCT00776789|OTHER|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
223539240|NCT00776789|OTHER|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
223539241|NCT04607629|BIOLOGICAL|Genolar® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
224106862|NCT04303585|PROCEDURE|SAP block|The anesthesiologist performs SAP block immediately before surgery under ultrasound guide
224106863|NCT04303585|PROCEDURE|ESP block|The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
224106864|NCT00216021|DRUG|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
224106865|NCT00216021|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
224106866|NCT05428371|DIAGNOSTIC_TEST|Multiomic analyses of blood and surgical specimens|"The following items will be evaluated:~* cell free dna length and integrity~* presence or absence of SNPs in cfDNA and in DNA extracted from surgical samples~* qualitative and quantitative evaluation of serum and surgical specimens proteome (proteomics)"
224106867|NCT02297217|DRUG|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
224106868|NCT02297217|RADIATION|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
224106869|NCT03551145|OTHER|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
224106870|NCT03551145|OTHER|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
224106871|NCT05339464|OTHER|Family Wellness program|Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
224106872|NCT05806450|BEHAVIORAL|Intervention|Structured online intervention consists of three weekly sessions of cognitive therapy and psychoeducation about child sleep
224106873|NCT05806450|OTHER|Active control condition|Psychoeducation about basic sleep structure and sleep hygiene
224106874|NCT06613061|OTHER|Breathing exercise|"The researcher has a breathing exercise certificate. In our study, the breathing exercise application consists of three stages: box breathing, sigh breathing and diaphragm breathing.~Patients will be asked to continue the breathing exercise application for 2 weeks and will be reminded to do the breathing exercises. Box and sigh breathing will be done 3 times a day (morning, noon and evening) every day for 2 weeks. Diaphragm breathing exercise will be applied for 2 minutes in the first week and 4 minutes in the second week."
223723452|NCT04458974|DEVICE|Transcranial direct current stimulation|"The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour."
223953971|NCT01928888|DRUG|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
223953972|NCT01928888|DRUG|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
223953973|NCT01928888|DRUG|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
223953974|NCT03441464|COMBINATION_PRODUCT|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
223953975|NCT00068809|PROCEDURE|Short Cycle Antiretroviral Therapy|
223953976|NCT05230056|BEHAVIORAL|PG|Shoulder Digital therapy
223953977|NCT05230056|BEHAVIORAL|CTRL|Shoulder non-digital therapy
223953978|NCT00047684|BEHAVIORAL|Brief Integrative Therapy|
223953979|NCT04830345|BIOLOGICAL|ATGC-100 100U|Clostridium botulinum toxin type A
223953980|NCT04830345|BIOLOGICAL|Botox 100U|Clostridium botulinum toxin type A
223953981|NCT02271841|DEVICE|PVI|Pleth Variability Index
223953982|NCT03727334|BEHAVIORAL|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
223953983|NCT03335722|BEHAVIORAL|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
223723453|NCT04458974|PROCEDURE|Neuropsychological rehabilitation|"The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session)."
223953984|NCT03335722|DEVICE|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
223953985|NCT03335722|DEVICE|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
223953986|NCT04078373|BEHAVIORAL|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
223953987|NCT04078373|BEHAVIORAL|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
223723454|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
223723455|NCT01121822|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
224106875|NCT06095284|OTHER|Pre-Extraction Phase|This intervention requires the following procedures: Submitting data use agreement, MDS request defined and developed, Part D request, CMS public use file request defines and develop questionnaire
224106876|NCT06095284|OTHER|Extraction Phase|Procedures include: Access VRDC for 2 years, Crosswalk CMS files and MDS using ID's, Preliminary analysis for validity/accuracy, Request revision/resubmission, Linked dataset created in VRDC and Distribute Questionnaire
224106877|NCT06095284|OTHER|Post-Extraction Phase|Procedures include: De-identified data securely stored, analysis, dissemination and knowledge translation
224106878|NCT05227274|OTHER|Items completion with or without a MFM-Play|Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
224106879|NCT01980147|BEHAVIORAL|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
224106880|NCT04523792|DRUG|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
224106881|NCT05951153|COMBINATION_PRODUCT|Tributyrin|Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.
223723456|NCT05830591|OTHER|Characterization of the microbiome in oral and fecal samples|The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
223723457|NCT03458273|PROCEDURE|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
224106882|NCT02952547|DRUG|Co-administration of DWC20155 and DWC20156|
224106883|NCT02952547|DRUG|DWJ1366 Tab.|
224106884|NCT02554643|OTHER|Diet|Nutrition intervention, once a week during 12 weeks
224290535|NCT04812574|PROCEDURE|Periurethral injection|Patients were in the lithotomy position for the procedure. After preparation, topical Lidocaine gel was instilled around the meatus and a 16 F probe was attached. The catheter balloon was inflated to localize the bladder neck and to ensure that injections were performed in the correct anatomical plane. Hypertonic saline (10% NaCl) was injected to the alignment of the urethral meatus in the order of 3-6-9-12 hours of the clock (5 cc to each site, totaling 20 cc). Syringes with 27 Gauge (0.40 mm) outer diameter were used to ensure controlled injection. Since the female urethra is about 4 cm in length, the needle was advanced about 3 cm. Due to the possibility of significant pain with hypertonic saline, 2 cc of Lidocaine hydrochloride was added into the solution.
224290536|NCT04812574|DRUG|Hypertonic (10%) saline|Periurethral hypertonic saline (10%)
224290537|NCT02339740|DRUG|Arsenic Trioxide|Given IV
224290538|NCT02339740|DRUG|Cytarabine|Given IV
224290539|NCT02339740|DRUG|Dexamethasone|Given PO or IV
224290540|NCT02339740|DRUG|Idarubicin|Given IV
224290541|NCT02339740|OTHER|Laboratory Biomarker Analysis|Correlative studies
224290542|NCT02339740|DRUG|Mitoxantrone Hydrochloride|Given IV
224290543|NCT02339740|OTHER|Quality-of-Life Assessment|Ancillary studies
223539242|NCT04607629|BIOLOGICAL|Xolair® + Symbicort®|The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
223539243|NCT04305977|BEHAVIORAL|WAVE-TW|The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
223723458|NCT03458273|PROCEDURE|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
223723459|NCT03458273|PROCEDURE|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
223723460|NCT01842698|DEVICE|ultrasoundguided paravertebral catheter|
223723461|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
223723462|NCT03954925|PROCEDURE|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
223723463|NCT04684498|DRUG|Oseltamivir phosphate capsules|Treatment group vs. Control group
223953988|NCT02291861|DRUG|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
223953989|NCT02291861|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
223953990|NCT03741634|OTHER|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (\~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
223953991|NCT04610125|BIOLOGICAL|Auto CAR-T|Biological: Auto CAR-T
224290544|NCT02339740|OTHER|Questionnaire Administration|Ancillary studies
224290545|NCT02339740|DRUG|Tretinoin|Given PO
223953992|NCT04610125|DRUG|Cyclophosphamide,Fludarabine|Drug: Cyclophosphamide,Fludarabine
224290546|NCT01320020|DRUG|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
224290547|NCT04625452|BEHAVIORAL|BBCC+5A's+GS|"It is a 5-steps intervention delivered in a motivational interviewing spirit. Clearly the five steps are asking about the behaviour risk factors, assessing the level of risk factors; providing information about the pros and cons of the behaviour in a neutral way; assessing the change by probing about the importance in and the confidence of changing the risk factor; assisting the patient to come-up with a road map about changing the risk factor, connecting the patient to support networks or drugs which can increase the likelihood to change; and arranging for the next visit.~All this given by asking opened question to participant, active listening, summarizing what he is saying, evoking change through concepts or statements, empathy and asking permission to provide further information."
224290548|NCT00606502|DRUG|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
224290549|NCT00606502|DRUG|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
223723464|NCT05647434|PROCEDURE|sustained inflations|Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
223723465|NCT00751829|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
223723466|NCT00751829|DRUG|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
223539244|NCT06160141|OTHER|Resistance training|"Resistance training program. The RT program was performed over 48 weeks, three times per week (Mondays, Wednesdays, and Fridays), during the morning, in the University fitness facility. Participants were personally supervised by Physical Education professionals (1-2 supervisors per exercise) with substantial RT experience to ensure consistent and safe exercise performance.~Participants performed four exercises for the trunk and upper limbs and four exercises for the lower limbs in three sets of 8-12 repetitions. T Rest intervals were 1-2 and 2-3 min between sets and exercises. The training load was individually adjusted for each exercise weekly, according to the number of repetitions performed during the last training session, to ensure that the subjects kept performing at the ideal intensity for the repetition zone. In these situations, training loads were increased by 2-5% for upper-limb exercises and 5-10% for lower-limb exercises."
224290550|NCT00606502|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
224290551|NCT00606502|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
224290552|NCT04462484|BEHAVIORAL|videoconference|The intervention is a person-directed, individual, primary occupational intervention. It will be carried out via videoconference in six sessions of 45 minutes (on a weekly basis). Through guided dialogue, individual difficulties and opportunities of each subject will be examined in order to gain self-awareness of personal characteristics (strengths, limitations, maximum workload capacity) in their particular set of job demands and resources. Participants are encouraged to adopt the set of self-care strategies in each dimension, adapting them to their specific context. Activities will be carried out in Spanish by the researcher.
223539245|NCT01951664|OTHER|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
224290553|NCT01096979|DRUG|LIPO-102|subcutaneous injection
224290554|NCT01096979|DRUG|Placebo|Placebo
223539246|NCT01951664|BEHAVIORAL|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
223539247|NCT01951664|BEHAVIORAL|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
223723467|NCT03675698|OTHER|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
224290555|NCT05329506|OTHER|patient population|questionnaires, standard of care
224290556|NCT02854059|BIOLOGICAL|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
224290557|NCT02854059|BIOLOGICAL|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
224290558|NCT00921037|PROCEDURE|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
224290559|NCT02083926|DRUG|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
224290560|NCT02083926|OTHER|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
224290561|NCT01221246|DRUG|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
224290562|NCT01221246|DRUG|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
224290563|NCT00384176|DRUG|Cediranib|oral tablet once daily
224290564|NCT00384176|DRUG|Bevacizumab|intravenous infusion
224290565|NCT00384176|DRUG|5-fluorouracil ( in FOLFOX)|intravenous infusion
224290566|NCT00384176|DRUG|Leucovorin (in FOLFOX)|intravenous infusion
224290567|NCT00384176|DRUG|Oxaliplatin (in FOLFOX)|intravenous infusion
223723468|NCT06194565|DRUG|99mTc-ABH2|Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.
223723469|NCT04755127|PROCEDURE|Arthroscopic synovectomy of the wrist|Wrist arthroscopy in day surgery setting with debulking of synovitis, inspection of cartilage, ligament, tendon and bone damage, collection of synovial biopsies and deposition of intra-articular corticosteroids (40mg triamcinolone acetonide)
223953993|NCT04610125|PROCEDURE|Leukapheresis|Leukapheresis
224290568|NCT03603938|DRUG|potassium losartan|treated with bedtime or awakening doses of potassium losartan
224290569|NCT04731311|DEVICE|Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease|4 participants with undergo 4 usability evaluations each, inter-spaced by days when researchers will address design changes. 2 participants will be elderly healthy and 2 will have the early Alzheimer's disease. Each session will last up to 1 hour, during which participants will interact with tasks in the form of games. Games will be gradated in level of difficulty, increasing from session to session. They will be played with one game controller or with two controllers while participants wear an all-in-one head mounted display. The degree of cognitive engagement during tasks will be measured with custom biosensors and used in adjusting level of difficulty. Each participant will fill subjective evaluation form and a USE form assessing ease of use, usefulness, and perceived technology issues. Scores will be analyzed and data published, in conjunction with game performance data.
223953994|NCT06365177|OTHER|Physical consultation|"The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation."
223953995|NCT06365177|OTHER|Teleconsultation|"Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it."
224106885|NCT02554643|OTHER|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
224290570|NCT02035020|DRUG|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
224290571|NCT00105573|BEHAVIORAL|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
224290572|NCT00105573|BEHAVIORAL|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
224290573|NCT00105573|BEHAVIORAL|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
224290574|NCT02697773|OTHER|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
224290575|NCT02697773|BIOLOGICAL|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
223953996|NCT01162564|DEVICE|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
223953997|NCT02105727|BEHAVIORAL|Community-based salt reduction|
223953998|NCT00825734|DRUG|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
224106886|NCT02554643|OTHER|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
224106887|NCT05021614|DEVICE|Valveclip® Transcatheter mitral valve repair|Transcatheter mitral valve repair system
224106888|NCT04049188|RADIATION|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
224106889|NCT04628871|BIOLOGICAL|SB-318|No study drug is administered in this study. Subject who received SB-318 in a previous trial will be evaluated in this trial for long-term safety.
224106890|NCT04628871|BIOLOGICAL|SB-913|No study drug is administered in this study. Subject who received SB-913 in a previous trial will be evaluated in this trial for long-term safety.
224290576|NCT02697773|BIOLOGICAL|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
224290577|NCT03249740|DRUG|GB-102|Intravitreal injection of GB-102
224290578|NCT03249740|DRUG|Aflibercept|Intravitreal injection of Aflibercept.
224290579|NCT00613834|DRUG|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
224290580|NCT00613834|DRUG|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
224290581|NCT02227654|PROCEDURE|Abnormal Ovarian Ultrasound|Ultrasound
224290582|NCT00025636|BIOLOGICAL|filgrastim|
224290583|NCT00025636|DRUG|carmustine|
224290584|NCT00025636|DRUG|cisplatin|
224290585|NCT00025636|DRUG|cyclophosphamide|
224290586|NCT00025636|DRUG|cytarabine|
224290587|NCT00025636|DRUG|dexamethasone|
224290588|NCT00025636|DRUG|etoposide|
224290589|NCT00025636|DRUG|melphalan|
224290590|NCT00025636|DRUG|methotrexate|
224290591|NCT00025636|DRUG|vincristine sulfate|
224290592|NCT00025636|PROCEDURE|bone marrow ablation with stem cell support|
224290593|NCT00025636|PROCEDURE|peripheral blood stem cell transplantation|
224290594|NCT06461117|OTHER|Beetroot Juice|Beetroot juice (8 mmol NO3-) consumption before training at 6 days
224290595|NCT06461117|OTHER|Plesabo Drink|Plesabo drink (0,6 mmol NO3-) consumption before training at 6 days
224290596|NCT01660022|DRUG|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
224290597|NCT01660022|DRUG|Placebo|Placebo
224290598|NCT01660022|DRUG|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
224290599|NCT01660022|DRUG|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
224290600|NCT01660022|DRUG|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
224290601|NCT01660022|DRUG|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
224290602|NCT01660022|DRUG|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
224290603|NCT01380249|DRUG|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
224290604|NCT01448356|PROCEDURE|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~1. 25°C and 45% humidity;~2. 25°C and 65% humidity;~3. 30°C and 45% humidity;~4. 30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
224290605|NCT04474782|DIAGNOSTIC_TEST|There is not an intervention|There is not an intervention
223539248|NCT01951664|BEHAVIORAL|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
223539249|NCT01951664|OTHER|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
223539250|NCT05074017|DEVICE|3 nasopharyngeal swab|3 nasopharyngeal swabs to conduct 2 rapid antigen tests for SARS-CoV-2 and a RT-PCR
224290606|NCT03547726|OTHER|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
223539251|NCT01341743|DRUG|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
223539252|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
223539253|NCT01341743|DRUG|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
224290607|NCT03547726|OTHER|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
223539254|NCT02356536|DEVICE|Agilitas|WCD trial
223539255|NCT06193564|OTHER|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) A constant current of 2 mA was applied to the experimental group for 20 minutes.
223539256|NCT06193564|OTHER|Cervical Stabilization Exercises|"Before initiating the stabilization exercises, individuals included in the study were instructed on correct postural alignment. Cervical chin tuck movement was taught during the exercise along with postural alignment and craniocervical flexion movement was requested. After teaching craniocervical flexion exercises in all positions (supine, lying on the side, prone, crawling, sitting, and standing), participants were instructed to perform the movement slowly.~The purpose of this phase was to establish the relationship between vision and motor learning using the Pressure Biofeedback Stabilizer device. The device was positioned on the neck area and inflated to 20 mmHg. The pressure level gradually increased in 2-mmHg increments from 20 to 30 mmHg. For each pressure value (22, 24, 26, 28, 30 mmHg), participants were asked to maintain craniocervical flexion for 10 seconds, and this exercise was repeated ten times."
224290608|NCT00379509|DRUG|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
224290609|NCT00379509|GENETIC|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
224290610|NCT00379509|GENETIC|gene expression analysis|Genetic analysis of tumor tissue.
224106891|NCT04628871|BIOLOGICAL|SB-FIX|No study drug is administered in this study. Subject who received SB-FIX in a previous trial will be evaluated in this trial for long-term safety.
224106892|NCT03161418|DRUG|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
224290611|NCT00379509|GENETIC|microarray analysis|Genetic analysis of tumor tissue.
224290612|NCT00379509|OTHER|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
223539257|NCT06193564|OTHER|Sham-Transcranial Direct Current Stimulation (tDCS)|tDCS was administered using electrodes made of metal or conductive rubber, an electrode sponge, and an electrolyte-based contact medium applied to the sponge (6 ml of water for a 35 cm2 sponge). 'Chatanooga Ionto Iontophoresis Dual Channel System (USA)' was used in the study as a constant current stimulator for tDCS. The constant current stimulator was used to deliver the direct current in a constant manner by monitoring the resistance in the continuous system. Two electrodes were placed at 5 cm × 7 cm; 35 cm2; an anode was placed in the primary motor cortex (M1), while a cathode was placed in the contralateral supraorbital space (FP1 on the left and FP2 on the right, according to the EEG 10/20 system) (Figure 2). As shown in the figure, a constant current of 2 mA was applied to the experimental group for 20 minutes. For the sham group, electrodes were placed in the same areas and a current of 0 mA was applied.
223539258|NCT02448966|PROCEDURE|open esophagectomy|
223723470|NCT04755127|DRUG|Intra-articular corticosteroid injection|Injection with 40mg triamcinolone acetonide (kenacort) in the wrist
224106893|NCT03161418|DRUG|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
224290613|NCT00379509|PROCEDURE|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
224106894|NCT04245124|OTHER|Strategic Memory Advanced Reasoning Training|SMART focuses on three metacognitive strategies: Strategic Attention, Integrated Reasoning and Innovation.
224106895|NCT04245124|OTHER|Traditional Cognitive Rehabilitation|Participants randomized to the TCR condition will participate in a clinician-directed intervention that provides manualized, traditional clinician-directed cognitive rehabilitation that was developed for the SCORE trial (Cooper et al., 2017)
224106896|NCT03690414|DRUG|Experimental BHVI2|Experimental BHVI2 eye drops
224106897|NCT03690414|DRUG|Atropine sulfate 0.02% eye drops|Atropine eye drops
224106898|NCT03690414|COMBINATION_PRODUCT|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
223953999|NCT00825734|DRUG|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
223954000|NCT01731444|DRUG|Phenylephrine|
223954001|NCT00003412|BIOLOGICAL|recombinant interleukin-12|
223954002|NCT02802111|DRUG|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
223954003|NCT02802111|DRUG|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
223954004|NCT03233542|BEHAVIORAL|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
223954005|NCT01166191|RADIATION|Radiotherapy|Radiotherapy
224106899|NCT01260181|DRUG|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
224106900|NCT02734121|BEHAVIORAL|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~* Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~* Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~* Social worker (30 mins): values clarification exercise~* Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
224106901|NCT01330446|DRUG|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
224106902|NCT01330446|OTHER|Placebo|1 by mouth every morning for a 28 day cycle.
224106903|NCT01330446|BEHAVIORAL|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
224106904|NCT05611463|DRUG|Camrelizumab Plus Docetaxel and Cisplatin|Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
224106905|NCT02250040|OTHER|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
224106906|NCT02250040|OTHER|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
223723471|NCT05822713|DRUG|Amisulpride|5mg/2ml
223723472|NCT05822713|DRUG|Amisulpride Placebo|2ml
223954006|NCT04884191|DRUG|Pacritinib|Pacritinib
223954007|NCT00003152|BIOLOGICAL|filgrastim|
223954008|NCT00003152|BIOLOGICAL|recombinant interferon alfa|
223954009|NCT00003152|DRUG|cyclophosphamide|
223954010|NCT00003152|DRUG|prednisone|
223954011|NCT00003152|DRUG|vincristine sulfate|
223954012|NCT00003152|PROCEDURE|autologous bone marrow transplantation|
223954013|NCT00003152|PROCEDURE|bone marrow ablation with stem cell support|
223954014|NCT00003152|PROCEDURE|peripheral blood stem cell transplantation|
223954015|NCT00003152|RADIATION|radiation therapy|
223539259|NCT02448966|PROCEDURE|Minimally invasive esophagectomy|
223539260|NCT01999933|RADIATION|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
223539261|NCT01999933|DRUG|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
223539262|NCT01999933|DRUG|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
223539263|NCT01999933|DRUG|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
223539264|NCT04509258|DRUG|N-acetyl cysteine|a drug which can have an off label use as an antidot for aluminium phosphide poisoning in addition to sodium bicarbonate and ondansetron as standard of care
224290614|NCT00379509|RADIATION|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
223539265|NCT04509258|DIETARY_SUPPLEMENT|acetyl L-carnitine|Naturallu occuring amino acid derivative which can be taken as a dietary supplement involves in mitochondrial function and energy production and is suggested to have a role in lowering organ damage resulting from aluminium phosphide poisonong in addition to sodium bicarbonate and ondansetron as standard of care
223539266|NCT04509258|DRUG|medicated paraffin oil|refined mixture of liquid hydrocarbons which used as laxative and is suggested to reduce absorption of aluminium phosphide if taken within two hours of administration of the toxin in addition to sodium bicarbonate and ondansetron as standard of care
224290615|NCT03913182|DRUG|apatinib|500mg po Qd
223539267|NCT04509258|DRUG|Sodium Bicarbonate Powder and ondansetron|standard of care for treatment of aluminuim phosphide is provided for patients poisoned with aluminuim phosphide
223539268|NCT03394989|DRUG|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
223539269|NCT03394989|OTHER|Placebo|Placebo
224290616|NCT01400620|DRUG|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
223539270|NCT03394989|DRUG|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
223723473|NCT02877615|DRUG|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
223723474|NCT02877615|DRUG|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
223954016|NCT04834804|OTHER|Physical activity|12 weeks of exercise training
223954017|NCT04252638|BEHAVIORAL|Acceptance and Commitment Therapy plus Sleep Restriction|Acceptance and Commitment Therapy (ACT) is a newer form of behavioral therapy working with acceptance, and the clarification of personal values. Acceptance, in this case, means the willingness to (temporarily) experience unpleasant sensations such as sleeplessness or tiredness without attempting to control or change them. Aims are, first, to reduce suffering due to unsuccessful control attempts (such as frustration, anger, anxiety) and second, to improve processes that are typically worsened by increased control efforts (such as sleep). Clarification of values means identifying aspects of life that are perceived as rewarding and encouraging approach-behavior in valued aspects of life (instead of avoidance-behavior that is often associated with insomnia and mental disorders).
223954018|NCT04252638|BEHAVIORAL|Cognitive Behavioral Therapy including Sleep Restriction|CBT-I, the gold standard treatment for insomnia, consists of sleep education, relaxation, sleep restriction, and cognitive therapy.
223954019|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
223954020|NCT03313726|DRUG|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
223954021|NCT06231680|DRUG|Camrelizumab|Camrelizumab 200mg intravenous (IV) on Day 1 of each 21-day cycle，until progression or unacceptable toxicity
223539271|NCT00921726|DRUG|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
223539272|NCT00921726|DRUG|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
223539273|NCT02527395|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
223539274|NCT02527395|OTHER|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
223539275|NCT02527395|OTHER|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
223539276|NCT02172391|DRUG|Tiotropium inhalation powder capsules|
223539277|NCT02172391|DRUG|Placebo inhalation powder capsules|
223539278|NCT06093464|OTHER|Natural Compound A (Hinoki essential oil)|"Participants will use Natural Compound A in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
223539279|NCT06093464|OTHER|Natural Compound B (Lemon essential oil)|"Participants will use Natural Compound B in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
223539280|NCT06093464|OTHER|Natural Compound C (Control/Water)|"Participants will use Natural Compound C in a diffuser every night for 4 weeks. Diffuser will be placed near participant's bed and will be used during the entire time they are asleep (about 8 hours, every night)."
224290617|NCT04694326|DIAGNOSTIC_TEST|HbA1c|The participants' age, sex, education level, known diseases, unit of hospitalization and inpatient diagnosis were questioned and recorded. Height, weight and waist circumference measurements were taken. Fasting blood sugar and HbA1c measurements were made
224290618|NCT03913260|DRUG|LY3375880|Administered SC
224290619|NCT03913260|DRUG|Buffer Matrix (No LY3375880)|Administered SC
224290620|NCT03913260|DEVICE|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
224290621|NCT03913260|DEVICE|Manual Syringe|Manual syringe used to inject LY3375880
224290622|NCT04805619|DEVICE|Biomime Morph, a tapered drug eluting stent (DES) with hybrid design|Biomime Morph DES is a cobalt-chromium stent, with strut thickness of 65 µm, a hybrid cell design (closed cells in the extremity and open cells in the middle) and a conic shape, where the proximal part of the stent is 0.5 mm larger than the distal part (Table 1). In addition, the Biomime Morph elutes Sirolimus from a biodegradable polymer matrix.
224290623|NCT04741529|BEHAVIORAL|Healthy Minds Program app|"The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has \>100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP."
224290624|NCT02409329|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
224290625|NCT02409329|BEHAVIORAL|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
224290626|NCT02409329|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
224290627|NCT05412524|BEHAVIORAL|reading|Mothers and, if desired, mother's partner will read to preterm infant as frequently and as much as they are able to. Reading is the intervention. The variable of interest is parents' and infants' change in salivary oxytocin receptor gene methylation (OXTRm) over time.
224290628|NCT04865913|OTHER|Observational|A brief 15 min phone call 1 week, 30 and 90 days post discharge.
224290629|NCT03917511|BEHAVIORAL|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
224290630|NCT03917511|BEHAVIORAL|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
223723475|NCT02877615|DRUG|Placebo|Two sachets of placebo twice a day
223723476|NCT06408532|DRUG|IDegLira|The participants in this group will be switched to IDegLira once daily injection therapy.
223723477|NCT06408532|DRUG|Premixed insulin|The participants in this group will be have optimized premixed insulin regimen.
224290631|NCT01764243|DRUG|MT-4666|low dose, high dose
223723478|NCT01804296|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
223723479|NCT01023230|DRUG|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
223723480|NCT01023230|DRUG|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
224290632|NCT01764243|DRUG|Placebo|
224290633|NCT00831636|DRUG|CP-4055|D1-5 and D8(+2)-12(+2) q4w
224290634|NCT00831636|DRUG|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
223723481|NCT03866005|DIETARY_SUPPLEMENT|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).
223723482|NCT03866005|OTHER|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
223723483|NCT02091544|OTHER|Lifestyle intervention|
223954022|NCT06231680|DRUG|Thalidomide 50mg|Thalidomide 50mg，po qd；
223954023|NCT06231680|DRUG|Thalidomide 100mg|Thalidomide 100mg，po qd；
223954024|NCT06231680|DRUG|Thalidomide 200mg|Thalidomide 200mg，po qd；
223539281|NCT02390492|DRUG|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous \[14C\]-ipatasertib on Day 1 of study
224290635|NCT05729919|PROCEDURE|Free gingival graft technique|"A horizontal partial thickness incision will be trace at the MGJ to dissect the alveolar mucosa from the keratinized tissue. The alveolar mucosa will be dissected from the underlying periosteum to create an envelope of 4-5 mm apical to the bone dehiscence associated with the gingival recessions. The keratinized tissue coronal to the first incision and neighboring the recession will be de-epithelialized to expose the connective tissue and create a trapezoidal recipient bed having a large apical base at the MGJ and a narrower coronal base just coronal to the CEJ of the experimental units. The grafts will be taken from the palate.The grafts will be positionned with the coronal edge of the CEJ.~Interrupted sutures (6-0 polypropylene, prolene) will be positionned to stabilize the graft. Sling crossed sutures anchored to the periosteum apical to the graft and placed to ensure a tight adaptation of the graft to the root surface"
224290636|NCT06367036|OTHER|Topical hypericum perforatum oil intervention|The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
223539282|NCT02390492|DRUG|Period 2 treatment|200-mg/100-mcCi oral \[14C\]-ipatasertib on Day 15 of study
223539283|NCT03175107|DEVICE|Exergaming|
223539284|NCT00270127|DRUG|Epoetin alfa|
223539285|NCT00518050|BEHAVIORAL|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~* Screening, skin self-examination, sun protection, and other cancer preventive practices;~* Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~* Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
223723484|NCT00616200|OTHER|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
223954025|NCT06231680|DRUG|Chemotherapy|"Platinum-based chemotherapy:~1. Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;~2. Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W) maintenance for the remainder of the study or until documented PD;~3. Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles."
223954026|NCT03645161|DIAGNOSTIC_TEST|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
223954027|NCT03845517|DRUG|Placebo|Placebo
223954028|NCT03845517|DRUG|PF-06700841 15 mg|PF-06700841 15 mg
223954029|NCT03845517|DRUG|PF-06700841 30 mg|PF-06700841 30 mg
223954030|NCT03845517|DRUG|PF-06700841 45 mg|PF-06700841 45 mg
223539286|NCT00518050|BEHAVIORAL|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
223539287|NCT02850978|DRUG|Spiolto|
223539288|NCT03710356|DRUG|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
223539289|NCT03775499|DIETARY_SUPPLEMENT|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
223539290|NCT03775499|OTHER|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
223723485|NCT00948987|DRUG|Aspirin|325 mg enteric coated single dose p.o.
223723486|NCT04378218|BEHAVIORAL|High Intensity Interval Training (HIIT)|A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
223723487|NCT02612324|BEHAVIORAL|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
223723488|NCT02612324|BEHAVIORAL|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
223954031|NCT03678792|DRUG|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
223954032|NCT03678792|DRUG|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
223954033|NCT03678792|DRUG|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
223954034|NCT03500406|DEVICE|RestoreX|Penile traction therapy in the straight position
223954035|NCT03500406|OTHER|Control|No treatment
223954036|NCT00033241|DRUG|erlotinib hydrochloride|
223954037|NCT00033241|DRUG|gemcitabine hydrochloride|
223954038|NCT01906905|DEVICE|Transcranial Magnetic Stimulation|
223954039|NCT01062438|GENETIC|DNA analysis|
223954040|NCT01062438|GENETIC|RNA analysis|
224106907|NCT01588197|BEHAVIORAL|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
224106908|NCT01588197|BEHAVIORAL|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
224106909|NCT01588197|BEHAVIORAL|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
224106910|NCT00384280|DRUG|Rifampin|
224106911|NCT05891743|DIAGNOSTIC_TEST|Patch Test|The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.
223723489|NCT04159025|DEVICE|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
223954041|NCT01062438|GENETIC|gene expression analysis|
223954042|NCT01062438|GENETIC|gene rearrangement analysis|
223954043|NCT01062438|GENETIC|mutation analysis|
223954044|NCT01062438|OTHER|laboratory biomarker analysis|
223954045|NCT06022198|PROCEDURE|Bronchoalveolar Lavage|Bronchoalveolar Lavage
223954046|NCT05192902|DEVICE|Computer-controlled Local Anaesthesia (CCLA)|The computer-controlled local anesthetic injector Calaject®, (Rønvig Dental MFG, Daugaard, Denmark), which is designed to reduce the pain of performing local anaesthesia. The principle of this device is based on the fact that the less pressure and flow of a local anaesthetic injection, the less painful will be the procedure. Each device has an installed pressure sensor as well as a three-button display that allows choosing the most appropriate program in terms of different speeds and pressure. According to the anaesthesia technique, the manufacture recommends program I for intraligamentary and palatally injections, program II for infiltration and III for alveolar nerve block techniques. Conventional carpules and needles can be used in a pen-shaped part connecting to the main unit. The administration of the anaesthetic can be achieved using a foot control pedal which is adapted to the main unit, the speed of injection is related to acoustic signals.
223954047|NCT05192902|DEVICE|Conventional Local Anaesthesia|Conventional dental local anaesthetic injections.
223954048|NCT03924362|PROCEDURE|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
223954049|NCT02855762|OTHER|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
223954050|NCT02410278|DRUG|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
223954051|NCT02410278|DRUG|montelukast|As described in the treatment arm
223954052|NCT02410278|DRUG|Placebo|Matched placebo
224106912|NCT05144698|BIOLOGICAL|RAPA-201 Rapamycin Resistant T Cells|Autologous Rapamycin-Resistant Th1/Tc1 Cells
224106913|NCT05144698|DRUG|Chemotherapy Prior to RAPA-201 Therapy|Outpatient Carboplatin + Paclitaxel Regimen (CP Regimen)
223954053|NCT03691441|PROCEDURE|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
223954054|NCT03691441|RADIATION|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
223954055|NCT03691441|DRUG|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
223954056|NCT03691441|PROCEDURE|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
223954057|NCT01856062|DRUG|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
223954058|NCT01856062|DRUG|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
223954059|NCT03695185|DRUG|Ravagalimab 600 mg|Ravagalimab 600 mg was administered intravenously (IV).
223954060|NCT03695185|DRUG|Ravagalimab 300 mg|Ravagalimab 300 mg was administered subcutaneously (SC).
223954061|NCT03391700|DRUG|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
223954062|NCT03391700|DRUG|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
223954063|NCT05962099|BEHAVIORAL|Lifestyle and weight loss advice|Commercially available lifestyle and weight loss intervention
223954064|NCT03823690|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
223954065|NCT03823690|DEVICE|The pyloro-duodenal stent|As listed in the arms description
223954066|NCT02584257|OTHER|methacholine chloride|
223954067|NCT02584257|DRUG|placebo ProAir HFA|
223954068|NCT02584257|DRUG|ProAir HFA|
223954069|NCT02584257|DRUG|Lupin albuterol HFA MDI|
223954070|NCT02584257|DRUG|placebo Lupin albuterol HFA MDI|
223954071|NCT05873296|BEHAVIORAL|Health Education|The intervention will last for 12 weeks, a health education program (face-to-face meetings and information in social networks).
223954072|NCT06356142|DEVICE|Palmar Cooling|Palmar cooling device will be utilized for 2 minutes during rest breaks.
224290637|NCT00312676|PROCEDURE|Rapid versus slow conversion|
224290638|NCT03352895|DIETARY_SUPPLEMENT|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
223954073|NCT06356142|DEVICE|Placebo Palmar Cooling|Placebo Palmar cooling device will be utilized for 2 minutes during rest breaks
223954074|NCT05104684|OTHER|chest physical therapy|The program will consist of postural drainage, diaphragmatic breathing exercises, coughing, huffing, percussion, shaking, and exercise training using an incentive spirometer in addition to routine medical treatment
224290639|NCT03352895|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
224290640|NCT03026855|BIOLOGICAL|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
224290641|NCT06263062|BEHAVIORAL|Awareness-Based Coping with Fear of Cancer Programme|The content of the Training Program was created by researchers based on MBSR, in line with high-level research results and international guides.Then, the necessary arrangements were made bytaking the opinions of 10 experts ( faculty members of the department of obstetrics and gynaecology nursing, psychiatry specialist, faculty members of the gynaecology oncology department, oncology clinic psychologist, obstetrics and gynaecology clinic charge nurse). Content concluded in accordance with the comments received.
224290642|NCT04400760|DRUG|DAPA Tx|The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
223954075|NCT05104684|OTHER|routine medical treatment|medical treatment
223954076|NCT01064609|PROCEDURE|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
223954077|NCT01064609|PROCEDURE|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
223954078|NCT03169855|DIAGNOSTIC_TEST|Slit lamp (LOCS III Score)|Diagnostic procedure only
223954079|NCT01684540|OTHER|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
223954080|NCT01684540|DRUG|Sinupret forte|
223954081|NCT00457834|DEVICE|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
223954082|NCT01735214|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
224106914|NCT05144698|DRUG|Pembrolizumab (PD-1 Blocking Antibody)|Drug Therapy After RAPA-201 Therapy
224106915|NCT06145425|OTHER|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
224106916|NCT05970055|PROCEDURE|elective surgery|All elective surgical procedures performed under the study period will be included.
224106917|NCT04969393|DEVICE|High intensity laser therapy|"Fifteen treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 5 weeks in succession via EXAND MY 1064 nm Laser system, Mectronic Medicale, Italy. Patients in group (A) received HILT along with the conventional physical therapy program. The session involved 3 subphases: (1) The Initial phase Analgesic phase, (2) In the intermediate phase Trigger point phaseand (3)The final phase Bio-stimulation phase was applied for 6 minutes with a slow scanning in several parallel longitudinal lines."
223954083|NCT01577875|DEVICE|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
224290643|NCT03900117|RADIATION|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
224290644|NCT03900117|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
224290645|NCT02507817|OTHER|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
224290646|NCT00141141|DRUG|Atorvastatin|
224290647|NCT00141141|DRUG|Simvastatin|
224290648|NCT06489938|BEHAVIORAL|Mirror therapy|In mirror therapy, a wooden mirror (41×50×33 cm3) will be positioned in the participant's sagittal midplane, blocking the participant's view of the affected arm performance. We will also provide a foldable bed tray table to ensure that the participants focus on the mirror reflection of the less affected arm. The mirror therapy will consist of movement and functional practices.
224290649|NCT06489938|BEHAVIORAL|Task-oriented approach|The task-oriented approach will provide both bimanual common-goal and dual-goal tasks for the participants.
224290650|NCT06489938|BEHAVIORAL|Impairment-oriented approach|The impairment-oriented approach will focus on the movement components. Arm BASIS or Arm Ability training will be provided based on the severity of the participant's impairment.
224290651|NCT02776527|DRUG|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
224290652|NCT01019863|DRUG|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
224290653|NCT01762124|DEVICE|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
224290654|NCT01736436|DRUG|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
224290655|NCT01736436|PROCEDURE|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
223954084|NCT00950456|BIOLOGICAL|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
223954085|NCT02602548|OTHER|Culture|Specimens will be obtained and sent to the lab for cultures.
223954086|NCT04760028|PROCEDURE|Adjusting the depth of anesthesia|After the main procedure, the depth of anesthesia can be adjusted as needed
223954087|NCT02349815|DRUG|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
223954088|NCT02763657|OTHER|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
224290656|NCT01736436|PROCEDURE|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
224290657|NCT02545855|DEVICE|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
224290658|NCT02545855|DEVICE|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
224290659|NCT02149121|BIOLOGICAL|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
224290660|NCT02149121|DRUG|Rituxan|US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
224290661|NCT02149121|DRUG|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
224290662|NCT03001752|DEVICE|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
223954089|NCT00547326|PROCEDURE|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
224290663|NCT03001752|DEVICE|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
224290664|NCT03001752|DEVICE|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
224290665|NCT00472875|DRUG|Glibenclamide|
224290666|NCT04955015|PROCEDURE|carotid endarterectomy|patients with carotid atherosclerosis refering to CEA
224290667|NCT03187496|DRUG|Midazolam|Each subject will receive midazolam on Days 1 and 12.
224290668|NCT03187496|DRUG|Caffeine|Each subject will receive caffeine on Days 1 and 12.
224290669|NCT03187496|DRUG|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
224290670|NCT03187496|DRUG|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
224290671|NCT04316325|DRUG|Medical abortion|Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
223539291|NCT03775499|DIETARY_SUPPLEMENT|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
224290672|NCT03297671|DRUG|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
224290673|NCT03297671|DEVICE|ELDONCARD|ELDONCARD point-of-care test.
224290674|NCT03297671|DIAGNOSTIC_TEST|ELDONCARD Test|LHVs will perform ELDONCARD test.
224290675|NCT05993715|DIETARY_SUPPLEMENT|Nitrate supplementation|Participants ingested 2 × 70 mL/day shots of concentrate nitrate-rich (\~12.8 mmol/day nitrate) or nitrate-depleted (\~0.08 mmol/day nitrite) beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK). Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
224290676|NCT05993715|DIETARY_SUPPLEMENT|Placebo supplementtaion|2 × 70 mL/day shots of concentrate nitrate-depleted (\~0.08 mmol/day NO3-) beetroot juice. Two shots were supplemented for 5 days; one each morning (\~9 am) and one each evening (\~9 pm) except for the day of the experimental trial when both shots were taken together 2.5 h before the experimental trial.
224290677|NCT03195673|DRUG|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
224290678|NCT03195673|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
224290679|NCT00014391|BIOLOGICAL|palivizumab|
224290680|NCT00014391|DRUG|ribavirin|
224290681|NCT00622687|DRUG|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
224290682|NCT00622687|DRUG|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
224290683|NCT00622687|DRUG|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
224290684|NCT02761603|BEHAVIORAL|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
224290685|NCT02761603|BEHAVIORAL|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
224290686|NCT04178382|DIAGNOSTIC_TEST|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
223954090|NCT00547326|PROCEDURE|Treatment with placebo|Treatment with placebo
224290687|NCT06690138|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
224290688|NCT06690138|DRUG|Itraconazole|Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.
224290689|NCT06688695|BEHAVIORAL|Neurodevelopmental support|The Intervention for Neurodevelopmental Support in Preterm Infants using Responsive parenting and E-health (INSPIRE) aims to support the infant's neurodevelopment by supporting the parents to develop a responsive approach. The intervention will enhance the infant's social and environmental interactions, focusing on developing both the infant's and parent's strengths, seeking opportunities instead of problems in behaviour, enhancing mutually satisfying interaction and parental empowerment.
223954091|NCT01762839|DRUG|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
223954092|NCT01762839|DRUG|Placebo|Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.
223954093|NCT01762839|DRUG|Moxifloxacin|Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
223954094|NCT03847727|DRUG|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
223954095|NCT06252454|DRUG|Furosemide 40 mg|Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.
223954096|NCT06252454|DRUG|Levodropropizine|Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation
223954097|NCT06252454|OTHER|Placebo - saline|Placebo will be used as a comparator
223954098|NCT03921775|DRUG|Remimazolam Tosilate|For induction and maintenance of general anesthesia
223954099|NCT03921775|DRUG|Propofol|For induction and maintenance of general anesthesia
223954100|NCT00020527|DRUG|caspofungin acetate|
223954101|NCT01933945|PROCEDURE|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
223954102|NCT01933945|DRUG|Sorafenib (Nexavar, BAY43-9006)|
223954103|NCT00457314|BEHAVIORAL|Exercise|Regular exercise training
224290690|NCT03166124|DRUG|LY900014|Administered SC
224290691|NCT03166124|DRUG|Insulin Lispro|Administered SC
224290692|NCT00766831|DRUG|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram \[mg\] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
224290693|NCT02666391|BIOLOGICAL|umbilical cord mesenchymal stem cells|
224290694|NCT03755089|DRUG|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
224290695|NCT03755089|DRUG|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
224290696|NCT05719337|DEVICE|Echocardiography|Two-dimensional, color Doppler, spectral Doppler, tissue Doppler and three-dimensional echocardiographic image recordings will be taken using a Philips Epiq 7C echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed by TomTec AutoStrain Suite Software.
224290697|NCT02105155|DRUG|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
224290698|NCT02105155|DRUG|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
224290699|NCT04497272|OTHER|COVID-19 patients|It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
224290700|NCT05154552|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training, which involves both the stretching and contracting of the muscle group being targeted. PNF stretching is one of the most effective forms of stretching for improving flexibility and increasing range of motion.
224290701|NCT05154552|OTHER|Routine physical therapy|"Routine physiotherapy in Parkinson Disease will be administered according to the European Physiotherapy guidelines for Parkinson Disease and focused on the following areas based on the stage of the disease:Self-management support, prevention of inactivity and fear of falls, maintaining or improving global motor activities, improvement of physical performance, and improvement in the ability to perform transfer, balance, gait, and manual activities, reduce pain, and delay the onset of physical limitations.~Other exercises include:~1. Range of motion exercises~2. Stretching exercises~3. Upper and lower limb strengthening exercises"
224290702|NCT04778293|OTHER|Diacutaneous fibrolysis|An experienced physiotherapist in the diacutaneous fibrolysis technique will apply the treatment to the lower limb, previously randomized, in the following musculature and intermuscular septums: quadratus lumbar, gluteus maixum, biceps femoris and semitendinosus. Intervention procedure will last about 10-15 minutes
224290703|NCT04235972|OTHER|Follow-up consultation|A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
224290704|NCT00648024|DRUG|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
224290705|NCT00648024|DRUG|Agrylin® Capsules 1 mg|1mg, single dose fasting
224290706|NCT05488717|OTHER|art-based mandala application|"Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications."
224290707|NCT02801084|BEHAVIORAL|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
224290708|NCT02689999|DRUG|Dexrabeprazole 10 mg Enteric-Coated Tablets|
223723490|NCT01450436|OTHER|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
223723491|NCT03374878|OTHER|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
224106918|NCT04969393|OTHER|Conventional Physical Therapy|Fifteen treatment sessions that involved using a neutral custom volar splint alongside neural and tendon gliding exercises. the splint was used at night and while performing strenuous activities during the day for 5 weeks. While nerve and tendon gliding exercises was repeated 10 times at each session and patients were encouraged to apply exercise 3-5 times per day for 5 weeks.
224106919|NCT05255757|BEHAVIORAL|Script Intervention|This intervention provides language to participants to allow them to discuss kidney transplantation with their social network.
224290709|NCT00131755|DRUG|diazoxide|
224290710|NCT05472402|BEHAVIORAL|LADIES online intervention (R33 phase)|Participants will participate weekly online group sessions over 6 months. Participants will also receive access to written intervention materials, access to an online walking program, and access to weekly podcasts that are aligned with the intervention sessions and that support physical activity lessons with biblical scriptures.
224290711|NCT05472402|BEHAVIORAL|LADIES online control (R33 phase)|Participants will receive online access to a written self-guided curriculum that is self-paced and teaches participants how to increase physical activity. Participants will be encouraged to complete the self-guided curriculum within 6 months.
224290712|NCT02479373|OTHER|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
224290713|NCT02479373|OTHER|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
224290714|NCT02479373|OTHER|Biodex dynamometer|To study muscle strength
223723492|NCT03374878|OTHER|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
223723493|NCT00381095|DRUG|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
223723494|NCT00381095|DRUG|Placebo|Placebo
223723495|NCT05397821|PROCEDURE|UNC technique|In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
223723496|NCT04054388|BEHAVIORAL|LINE re-education|
223723497|NCT05532592|OTHER|Perceptions and attitudes towards COVID-19 and COVID-19 vaccine|Attitude towards COVID-19; Knowledge about COVID-19 vaccine
224106920|NCT05255757|BEHAVIORAL|Search Intervention|This group will complete the candidate survey, refer members of their family and social network for participation in a web survey, and be given information about the statistical likelihood that each member of their social network will be free of contraindications for living kidney donation.
224106921|NCT04520698|BEHAVIORAL|UPLIFT-AD|Access to palliative care needs screening, advance care planning conversations, palliative care consultations
224106922|NCT01677689|DRUG|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
224106923|NCT01677689|DRUG|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
224106924|NCT05772689|OTHER|Usual Care|Caregivers assigned to the usual care group will be enrolled in the course at the 3-month mark after consenting. All caregivers will then participate in quantitative interviews at post- 6months of their baseline
224106925|NCT05772689|OTHER|Caring While Black|Caregivers assigned to this group will receive a schedule for their completion of the course over the next 2 months and supplemental course materials through the mail. The Canvas platform will enable the course to monitor everyone's movement in the cohort through the asynchronous part of the course. Nudges and reminders will be sent twice a week via text or email with the participant's consent.
224106926|NCT06430892|PROCEDURE|Primary Percutaneous Coronary Intervention (PPCI)|Patients presented with acute myocardial infarction undergoing primary percutaneous coronary intervention with stent deployment
224106927|NCT01023282|DRUG|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
224290715|NCT02479373|OTHER|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
224106928|NCT01023282|DRUG|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
224106929|NCT04945382|DEVICE|Scotchbond Universal 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Scotchbond universal 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
224106930|NCT04945382|DEVICE|Single Bond 3M|The occlusal surfaces will be cleaned using water, a brush and a low-pressure handpiece; they will wash and dry; then deproteinization will be done with sodium hypochlorite (5.25%) for 60 seconds, it will be washed with a water / air spray for 30s; it will dry up; The tooth will then be etched using a 37% orthophosphoric acid gel for 15 seconds, rinsed with a water / air spray for 30 seconds, and dried with cotton balls. Single Bond 3M to the etched surface will be dried under a gentle air flow for 2-3 s, and light cured for 11 s using an LED curing unit with an output of 1500 mW / cm2 (Balloon.).
224106931|NCT02622932|DRUG|Anlotinib and 14C-labeled Anlotinib|oral
224106932|NCT05026658|DEVICE|Visibly Digital Acuity Product|"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~1. V1, E, V2~2. E, V1, V2~3. V2, E, V1~4. E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."
224106933|NCT02688413|DEVICE|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
224106934|NCT02688413|OTHER|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
224290716|NCT02479373|OTHER|Quality of life questionnaires|
224106935|NCT02495337|OTHER|Tissue Collection|
224106936|NCT01939379|DRUG|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
224106937|NCT01939379|DRUG|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
224106938|NCT01777633|RADIATION|Palliative re-irradiation for progressive DIPG in children|
224106939|NCT02065089|OTHER|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
224106940|NCT02060734|PROCEDURE|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
224106941|NCT02060734|OTHER|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
224106942|NCT05252689|OTHER|monolithic zirconia single posterior crowns with deep chamfer finish line|deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm
224290717|NCT04978116|DIAGNOSTIC_TEST|Chest X-Ray (CXR)|"The 3 following imagings will be performed in the emergency room: chest X-Ray (CXR), low-dose CT scan (LDCT) and lung ultrasonography (LUS) will be performed for all included patients, but only one will be available to the clinician in charge of the patient according to the allocation arm.~The blinding will be maintained during the first 5 days, and hence will not influence the diagnosis and the treatment of the patient.~The clinician in charge will be asked to assess on a 3-level Likert scale the probability of pneumonia (high, intermediate, low level) while considering all available clinical and biological data, plus the imaging modality according to the randomization arm."
224290718|NCT04978116|DIAGNOSTIC_TEST|Low-dose CT scan (LDCT)|See above in CXR paragraph
224290719|NCT04978116|DIAGNOSTIC_TEST|Lung ultrasonography (LUS)|See above in CXR paragraph. LUS will be performed by another clinician than the one in charge of the patient
224290720|NCT05745792|OTHER|Description of clinical, immunological and tumor features of patients harboring Hu Abs|This observationnal study involves clinical data and bio. samples (DNA and tumors block). Demographic and clinical data already in French Reference Center on PNS database will be reviewed. Additional data will be obtained from the referral physicians. The results of diagnostic tests performed to detect Hu-Abs in the patients are already in this database and will be retrospectively analyzed. In addition, the 4 available techniques (immunofluorescence, commercial immunodot, Western blot, and CBA) will be performed from Jan. 2022 to Dec. 2022.Tumor samples from 2 cohorts will be analyzed: (i) tumors of patients with Hu-Abs and PNS, and (ii) tumors of patients without PNS (mostly SCLC). After selecting patients, the study will involve 3 steps: (i) pathological confirmation; (ii) DNA sequencing and CNV analysis (panel of genes involved in anti-Hu autoimmunity; mainly ELAVL1 to 4, encoding for HuA to HuD, the 4 main proteins of the Hu family); and (iii) whole-genome RNA sequencing.
224290721|NCT01804218|DRUG|Nadolol|
224290722|NCT01804218|DRUG|Placebo|
223539292|NCT03775499|OTHER|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
224290723|NCT00231218|DRUG|dietary supplement--echinacea, propolis, and vitamin c|
223539293|NCT05754476|OTHER|Low-dose GBCA levels|MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
223539294|NCT05233124|DRUG|Rivaroxaban 15 MG|Rivaroxaban 15mg
223539295|NCT05233124|DRUG|Acetylsalicylic acid 100mg|Acetylsalicylic acid 100mg
224290724|NCT01036490|OTHER|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
223539296|NCT05233124|DRUG|Clopidogrel 75 Mg Oral Tablet|Clopidogrel 75mg
224290725|NCT04860050|DIETARY_SUPPLEMENT|Turmipure Gold®|TPG: Turmipure GOLD® - 1 capsule per day - as prescribed
224290726|NCT04860050|DIETARY_SUPPLEMENT|Placebo|Placebo: colored acacia gum - 1 capsule per day - as prescribed
223954104|NCT02469324|BEHAVIORAL|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
224290727|NCT01172821|DRUG|placebo|Placebo that represents BI drug
224290728|NCT01172821|DRUG|placebo|Placebo that represents comparator
224290729|NCT01172821|DRUG|placebo|Placebo that represents comparator
224290730|NCT01172821|DRUG|tiotropium Respimat® low dose|IMP
224290731|NCT01172821|DRUG|placebo|Placebo that represents BI drug
223539297|NCT02404168|DRUG|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
223539298|NCT02404168|DRUG|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
223539299|NCT04906031|DRUG|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on d1-5 and d15-19. 28 days per cycle.
223723498|NCT01405599|DRUG|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
223539300|NCT02959788|OTHER|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
223539301|NCT04299386|DEVICE|NeoPhylaxis|NeoPhylaxis® gel is designed for the non-surgical decontamination of the implant surface and can be used for professional regular implant maintenance, with or without peri-implant mucositis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in non-sterile form.
223539302|NCT04299386|DEVICE|ImplanTreat|ImplanTreat® gel can be used for the surgical decontamination of the implant surface and can be used to decontaminate implants with peri-implantitis. It contains the same ingredients, Magnesium Phosphate (3.02% w/v) and Sodium Phosphate (8.23% w/v) in 3 mL syringe in sterile form.
223539303|NCT01197547|DEVICE|Genesys HTA|Genesys HTA Endometrial Ablation
223539304|NCT01936883|RADIATION|HDR|High dose rate brachytherapy
223539305|NCT01936883|RADIATION|LDR|Low dose rate brachytherapy boost
223723499|NCT01713972|DRUG|dabrafenib|Given PO
223723500|NCT01713972|DRUG|pazopanib hydrochloride|Given PO
223954105|NCT02469324|BEHAVIORAL|Compassionate Mind Training|see above
223954106|NCT03804866|DRUG|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
223954107|NCT03804866|DRUG|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
223954108|NCT03804866|DRUG|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
223954109|NCT02690792|OTHER|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
224290732|NCT01172821|DRUG|tiotropium Respimat® high dose|IMP
224290733|NCT01172821|DRUG|50 mcg salmeterol HFA MDI|Active comparator
224290734|NCT01172821|DRUG|placebo|Placebo that represents comparator
223539306|NCT05325762|DRUG|Propofol|At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
223954110|NCT02690792|DIETARY_SUPPLEMENT|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
224290735|NCT03245645|OTHER|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
224290736|NCT02707133|OTHER|No intervention|
224290737|NCT01930318|DRUG|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
224290738|NCT03997214|DEVICE|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
224290739|NCT00462059|BEHAVIORAL|Treatment|
224290740|NCT00210899|DRUG|ceftobiprole medocaril|
224290741|NCT00210899|DRUG|Vancomycin plus Ceftazidime|
224290742|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of Gpi|
224290743|NCT02263417|DEVICE|Deep Brain Stimulation (DBS) of STN|
224290744|NCT06444321|BEHAVIORAL|INTERCARE-HF|Develpent of an individualized treatment and follow-up plan tailored to co-morbidities, risk areas, cognitive function and functional level as well as the patients' symptoms and needs.
224290745|NCT00094094|DRUG|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
224290746|NCT02731014|OTHER|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
224290747|NCT02731014|OTHER|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
224290748|NCT02731014|OTHER|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
224290749|NCT02731014|OTHER|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
224290750|NCT00710749|DEVICE|Disposable device|Disposable urine flow meter
224290751|NCT00710749|DEVICE|Digital device|Digital urine flowmeter
224290752|NCT00710749|DEVICE|Clinic flow measurement|Clinic gold standard flow measurement
224290753|NCT00965055|DRUG|Ezetimibe|10 mg
224290754|NCT00965055|DRUG|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
224290755|NCT01088919|DRUG|ASP1941|oral tablet
224290756|NCT01088919|DRUG|pioglitazone hydrochloride|oral tablet
224290757|NCT06920407|DEVICE|Breathing training device (Inspiratory Muscle Training)|Daily inspiratory muscle training (IMT) using the PowerBreathe IMT K3 device at varying resistance levels (15% for Sham and 65% for Experimental group) for 12 weeks. Participants will perform breathing exercises designed to assess the effects of different resistance levels on overall physical and emotional well-being, with a focus on how varying resistance impacts both respiratory strength and well-being.
223539307|NCT05325762|DRUG|Dexmedetomidine|Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
223539308|NCT05325762|DRUG|Saline|At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
223539309|NCT01953211|DRUG|combined oral contraceptives|
223539310|NCT02974829|OTHER|follow-up|
223539311|NCT06468787|DEVICE|Kosmos Anatomical Object Labeling and View Identification Algorithms|Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
223723501|NCT01713972|OTHER|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
223954111|NCT01079104|DEVICE|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
223723502|NCT06030791|DIAGNOSTIC_TEST|MRI|MRI of operated knee
223954112|NCT01079104|PROCEDURE|Standard Medical Therapy|Standard of care treatment
223954113|NCT00274196|PROCEDURE|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
223723503|NCT03653650|COMBINATION_PRODUCT|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
224290758|NCT06920407|DEVICE|Oura Ring|The Oura ring measures daily biometrics such as heart rate, sleep, and blood oxygen levels, providing personalized health data and insights. Participants have access to this data through a mobile app, allowing researchers to assess whether increased access to health data and awareness has an impact on overall physical and emotional well-being.
224290759|NCT00302302|DRUG|L-arabinose|
224290760|NCT00683982|DRUG|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
224290761|NCT00683982|DRUG|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
224290762|NCT00683982|OTHER|Oral hydration solutions|Oral hydration solutions as needed
223954114|NCT00274196|PROCEDURE|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
223954115|NCT01431157|PROCEDURE|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
223954116|NCT01431157|OTHER|No nasal oxygen|Patients will have no intervention for sleep apnea
223954117|NCT01942772|DEVICE|Ankle-Foot Orthosis|
223954118|NCT04527965|OTHER|Customized diet to reduce liver fat|"Ad libitum diet high in plant-derived PUFA and lower in carbohydrates~Carbohydrates: 30 E% Fat: 50 E% (PUFA 10-15 E%) Protein: 20 E%~Key foods are provided"
223954119|NCT04527965|OTHER|Healthy Nordic diet|"Ad libitum diet, based on Nordic foods, high in carbohydrates (high fiber/low GI) and lower in fat~Carbohydrates: 50-55 E% Fat: 25-30 E% (PUFA 5-7.5 E%) Protein: 20 E%~Key foods are provided"
224290763|NCT02350582|DEVICE|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
223723504|NCT03653650|COMBINATION_PRODUCT|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
223723505|NCT03653650|COMBINATION_PRODUCT|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
223723506|NCT03620240|BEHAVIORAL|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
223723507|NCT01382953|DEVICE|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
223723508|NCT01102400|DRUG|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
223723509|NCT00670683|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224290764|NCT02358733|PROCEDURE|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
224290765|NCT02358733|PROCEDURE|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
224290766|NCT06846853|DRUG|Gadopiclenol|The enhanced images by Gadopiclenol and Gadobutrol will be compared.
224290767|NCT06846853|DRUG|Gadobutrol (Gadavist, BAY86-4875)|Gadobutrol will be used as a comparator
224290768|NCT06927427|PROCEDURE|fiberoptic endoscopic evaluation of swallowing (FEES)|Using flexible endoscopy, the patient will be given a colored thin fluid to keep in their mouth and then swallow following the instructions of the examiner, then the examination will be repeated using semisolids (1 teaspoon of yogurt) and using solids (piece of bread). The evaluation of swallowing will involve four items: early spill of food (delayed triggering), aspiration, penetration, and retention (residue). And the results will be recorded.
224290769|NCT06928740|OTHER|Music Care® device|Installation of the Music Care® device, selection of the sequence based on the patient's musical taste, listening to at least 20-minute sequence in the preparation room. Once placed on the scanner table, the patient listens to the same sequence as in the preparation room.
224290770|NCT06928740|OTHER|EMONO|Equimolar mixture of oxygen and nitrous oxide given as usual care
224290771|NCT02709629|BEHAVIORAL|Individualized and adaptive computerized cognitive training|
224290772|NCT02709629|BEHAVIORAL|Active control|
224290773|NCT03016338|DRUG|Niraparib|200 or 300 mg daily PO, for 21 day cycle
224290774|NCT03016338|DRUG|TSR-042|500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
224290775|NCT03697330|DRUG|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
224290776|NCT03536494|BEHAVIORAL|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~* General practitioners: information and training with written material and patient-centred prescribing.~* Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~* Management support with the definition of a structured strategy.~* Monthly monitoring of the intervention."
224290777|NCT00656968|DRUG|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
224290778|NCT00656968|DRUG|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
224290779|NCT05424250|BEHAVIORAL|occasional aversive imagination|During six of the 27 exposure trials, participants in the experimental group are asked to imagine their most feared outcome towards spiders as vividly as possible while completing the specific trial.
224290780|NCT05424250|BEHAVIORAL|Exposure|• All participants complete an exposure training session (approx. 75 min) with seven exposure steps, which are repeated between one and five times (e.g. Step 4: directing the spider with a pen by touching its legs at least five times per repetition; this step must be repeated five times before continuing to the next step). One repetition per step is considered one trial, therefore each participant aims to complete 27 exposure trials.
224290781|NCT03779568|OTHER|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
224290782|NCT04141696|DRUG|Ketamine|Given intravenously over 40 minutes
223954120|NCT04527965|OTHER|Control|"Ad libitum diet in accordance with the Nordic Nutrition Recommendations~Key foods are provided"
223954121|NCT02939742|DRUG|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
223954122|NCT02939742|DRUG|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
224290783|NCT04141696|DRUG|Midazolam|Used as placebo comparator; given intravenously over 40 minutes
223723510|NCT01310621|DRUG|Bovine surfactant|"* Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)"
224290784|NCT00669981|BEHAVIORAL|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
223723511|NCT03608449|OTHER|questionnaires|questionnaire about mental health status during psychotherapy
223954123|NCT03946631|DIAGNOSTIC_TEST|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
223954124|NCT02206906|BEHAVIORAL|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
224290785|NCT06489535|OTHER|RETAIN|"There are 6 different modules that a participant in the RETAIN intervention group can be placed in: Reinforce Antibiotic Completion, Linkage to Antibiotic Treatment/Alternate Plan, Reinforce Recovery, Linkage to MOUD/Alternate Plan, Reinforce Treatment Attendance, and Harm Reduction Support. Participants may be assigned to no more than three modules at a time until they finish their antibiotics. After the completion of antibiotics, participants may only be in two modules. Participants' intervention can range from 15 minutes- 60 minutes depending on what modules they are placed in and how much support they feel they need. Interventions will begin at the two-week follow up after a participant has been discharged from Boston Medical Center (BMC)."
224290786|NCT06489535|OTHER|Unrelated videos|These videos unrelated to the study topics will last approximately 30-45 minutes. Depending on the method of communication, participants will watch a video (in person) or listen to a podcast (remote)
224290787|NCT02960087|RADIATION|Low dose rate brachytherapy|I-125 to a total dose of 144 Gy
224290788|NCT02960087|RADIATION|High dose rate brachytherapy|27 Gy in 2 fractions
224290789|NCT05640414|OTHER|Weekly Family Food Packages|Families receive weekly family food packages for 6 months
224290790|NCT05640414|BEHAVIORAL|Family Health Group Sessions|Families with children aged 6-17 years attend 6 monthly group sessions with cooking demonstrations
223954125|NCT00185692|PROCEDURE|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
224290791|NCT05626803|DRUG|Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|The first 10 sentinel subjects will receive open label high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
224290792|NCT05626803|DRUG|Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose|50 subjects will receive high dose of active vaccine. Bivalent GII.4/GI.1 high dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 1×10 to the power 11 tablets; total dose is 2×10 to the power 11 IU/dose
223954126|NCT00185692|DRUG|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
223954127|NCT00185692|DRUG|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
223954128|NCT00185692|DRUG|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
223954129|NCT00185692|DRUG|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
224290793|NCT05626803|DRUG|Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose|50 subjects will receive Bivalent GII.4/GI.1 medium dose vaccine (VXA-GII.4-NS plus VXA-G1.1-NN) 5×10 to the power 10 tablets; total dose is 1×10 to the power 11 IU/dose
223954130|NCT00185692|DRUG|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
223954131|NCT00185692|DRUG|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
223954132|NCT00185692|DRUG|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
223954133|NCT00185692|DRUG|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
224290794|NCT05626803|DRUG|Placebo|25 subjects will receive matching placebo
224290795|NCT05867329|DRUG|Cyclosporine Injection (IV)|"Drug be administered as weight-based continuous infusion (2mg/kg/day) during the second stage of treatment (if applicable).~Cyclosporine monitoring will take place approximately 18-24 hours stage of treatment (Day 4 at the earliest). The goal is to achieve whole blood levels of 300 (range 200-400) ng/ml with adjustments according to the table in the protocol. The intravenous cyclosporine dosage is rarely raised above 4 mg/kg/day, in rare patients that are fast metabolizers."
223954134|NCT03996577|DRUG|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
224290796|NCT05867329|DRUG|Cyclosporine Oral Product|"Once participants meet discharge criteria, participant's that received IV Cyclosporine (stage 2) will be transitioned to oral Cyclosporine.~The oral dose is calculated to be approximately twice the daily intravenous dose or approximately 5 mg/kg, rounded to nearest 25 mg, and is administered every 12 hours (h). Oral cyclosporine solution will be administered as Sandimmune capsules available in 25mg 100mg capsules size.~After the intervention period (during hospitalization after IV cyclosporine is complete) and during the follow-up period any cyclosporine adjustments are permissible under the current study protocol according to the discretion of the treating physician."
224290797|NCT05867329|DRUG|Upadacitinib Extended Release Oral Tablet|"This will be administered orally once daily as 45mg (stage one) or twice daily as a 30mg oral tablet (first stage and second stage) of treatment (if applicable).~Upon discharge a patient will be switched from Upadacitinib 30mg twice daily to 45mg daily for 8 weeks followed by 30mg or 15mg subsequently if Upadacitinib is to be continued after discharge. The choice of induction/maintenance agent initiated after discharge will be determined by inpatient treatment team and in consultation with the outpatient gastroenterologist. No patient will continue Upadacitinib 30mg twice daily after discharge from the hospital."
224290798|NCT05867329|DRUG|Intravenous Methylprednisolone|Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
223723512|NCT05666492|OTHER|Platelet rich plasma|Platelet-rich plasma will be placed on the olfactory epithelium topically.
223723513|NCT05666492|OTHER|Saline|Saline will be placed on the olfactory epithelium topically.
223723514|NCT04070950|OTHER|Questionnaires|Two self-questionnaires
223954135|NCT03996577|DRUG|placebo|the control group will be given the same volume of saline.
223954136|NCT04489914|DEVICE|High-Flow Oxygen Therapy|high-flow oxygen therapy after percutaneous transfemoral aortic valve replacement
223954137|NCT05931224|DRUG|D064, D702, placebo of D660|Experimental Group Subjects assigned to this group are treated with D064, D702, placebo of D660
223954138|NCT05931224|DRUG|D660, placebo of D064, placebo of D702|Experimental Group Subjects assigned to this group are treated with D660, placebo of D064, placebo of D702
223954139|NCT04657718|DEVICE|KODEX-EPD system|Cardiac pacing leads implantation for PM, ICD, CRT, HBP and LBBP
223954140|NCT04063449|DRUG|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
223954141|NCT04063449|DRUG|endostar|Antiangiogenic therapy plus chemotherapy
223954142|NCT04127747|DRUG|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day and on the 6th, 12th,18th and 24th month after that.
223723515|NCT06476262|BEHAVIORAL|This research has only one arm. The intervention focuses on occupational issue|During the post-stroke consultation, each participant is invited to complete questionnaires on occupational gaps, mood disorders, fatigue, cognition, and quality of life.
223954143|NCT04127747|DRUG|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count ≥ 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
223954144|NCT03214614|DRUG|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
223954145|NCT03214614|DRUG|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
223954146|NCT03214614|DRUG|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
223954147|NCT03214614|DRUG|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
223954148|NCT03066986|DRUG|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
223954149|NCT03066986|BIOLOGICAL|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely \<20mcg. Therefore minimum effective maintenance dose not yet defined."
223954150|NCT00405834|DEVICE|Envision® Patient Support System|
224290799|NCT05867329|DRUG|Prednisone Oral Product|Patients that received IV Methylprednisolone will be switched prior to discharge from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
224290800|NCT05674526|BIOLOGICAL|WU-NK-101 - Dose Escalation|WU-NK-101 administered on Days 1, 15, 30 and 44
223723516|NCT04459091|DIETARY_SUPPLEMENT|Amino Essential Acid|8 gr die in two administration
223954151|NCT04017598|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
223954152|NCT04017598|DIETARY_SUPPLEMENT|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
223954153|NCT04017598|DIETARY_SUPPLEMENT|Placebo of microcrystalline cellulose|placebo
223954154|NCT00452894|DRUG|varenicline tartrate|
223954155|NCT04448613|OTHER|MRI|"Patients with optic disc swelling diagnosed by a fundus and included in the study will have a brain MRI and visual pathways lasting 30 minutes.~Two additional 10-minute sequences will be added to the standard protocol."
224290801|NCT05674526|DRUG|Cetuximab - Dose Escalation|Cetuximab 500mg/m2 administered on Days 29 and 43
224290802|NCT05674526|BIOLOGICAL|WU-NK-101 - Cohort Expansion|WU-NK-101 administered on Days 2 and 16
224290803|NCT05674526|BIOLOGICAL|Cetuximab - Cohort Expansion|Cetuximab 500mg/m2 administered on Days 1 and 15
223954156|NCT03571906|BEHAVIORAL|Tele - Cardiac Pre-Rehabilitation|We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
223954157|NCT01366352|DRUG|MNTX tablet (Formulation 1)|
223954158|NCT01366352|DRUG|MNTX tablet (Formulation 2)|
223723517|NCT04459091|DIETARY_SUPPLEMENT|placebo|8 gr die in two administration
224290804|NCT06427915|OTHER|OLIPOP prebiotic soda|12oz serving containing Carbonated Water, OLISMART(TM) (Cassava Root Fiber, Acacia Fiber, Guar Fiber, Nopal Cactus\*, Marshmallow Root\*, Calendula Flower\*, Kudzu Root\*), Cassava Root Syrup, Apple Juice Concentrate, Lime Juice, Natural Cola Flavor, Alpinia Galanga Root\*, Stevia Leaf\*, Himalayan Pink Salt, Green Tea Caffeine\*, Natural Caramel Flavor, Natural Vanilla Flavor, Cinnamon\* (\*Extract)
223723518|NCT01104493|BIOLOGICAL|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
223723519|NCT01104493|OTHER|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
223723520|NCT03029377|OTHER|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
223723521|NCT00208091|DRUG|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
224290805|NCT06427915|OTHER|Traditional sugar-sweetened cola|12oz serving containing carbonated water, high fructose corn syrup, caramel color, phosphoric acid, natural flavors, caffeine
224290806|NCT01790802|DEVICE|2RT nanosecond laser|active laser therapy
224290807|NCT05866380|OTHER|heart failure risk factors|observational study with diabetes patient with heart failure risk factors
224290808|NCT06357286|BEHAVIORAL|Work opportunities|Individuals in the treated arms of the study will be offered work opportunities (sewing bags) to earn cash. The timing of these opportunities and knowledge of the amount and timing varies by experimental arm.
224290809|NCT06308640|DEVICE|Insertion of the device intraorally|"* The distalizer appliance will be checked for adaptation intraorally, the two bands of the maxillary first molars will be fitted in their accurate position on the teeth.~* The screw insertion will be carried out with the patient under local anesthesia.~* They will be placed inside the two eyelets of the anterior arms of the screw in the appliance"
223539312|NCT03938818|BEHAVIORAL|Tu'Washindi intervention|"The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
223539313|NCT03938818|OTHER|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
223539314|NCT04161690|DRUG|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
223539315|NCT04161690|DRUG|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
223539316|NCT02669589|DRUG|Heparin|
223539317|NCT02669589|DRUG|Citrate|
224290810|NCT04300413|OTHER|High-Intensity Rehabilitation plus Mobility (HeRo)|Progressive, high-intensity strengthening and functional intervention coupled with structured mobility based in principals of behavioral economics.
224290811|NCT05113459|DRUG|Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy|disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
224290812|NCT01000610|DRUG|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
223539318|NCT02307448|PROCEDURE|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
223539319|NCT02307448|PROCEDURE|Standard of Care|Patients will receive weekly standard of care.
223539320|NCT01778998|PROCEDURE|MICS-group|Micro incision cataract surgery is done
223954159|NCT06275256|PROCEDURE|Rezum|The Rezum device is inserted, a needle is deployed, and vapor is injected into the prostate for nine seconds. This vapor disperses between cells, then cools, releases heat, and gently disrupts the prostate's cells. Because of the initial swelling, a catheter is then inserted, which will remain for two to five days.
224290813|NCT01000610|DRUG|methotrexate|10-25 mg weekly (oral or parenteral)
224290814|NCT01000610|DRUG|methylprednisolone|100 mg iv prior to each rituximab infusion
224290815|NCT02917226|OTHER|Clinical decision support and monitoring system|
224290816|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
223539321|NCT01778998|PROCEDURE|SICS-group|small incision cataract surgery is done
223539322|NCT01778998|PROCEDURE|SICS pre-cut|Small incision cataract surgery with pre-cut is done
223539323|NCT01778998|PROCEDURE|SICS stab-incision|Small incision cataract surgery with stab-incision is done
223539324|NCT01880190|OTHER|Ringer's Lactate|
223539325|NCT01880190|OTHER|HES 130/0.4 and Ringer's Lactate|
223954160|NCT06275256|DEVICE|iTind|The iTind device is temporarily placed inside the prostatic urethra (the narrowed portion of the prostate), where it slowly expands and exerts gentle pressure at three precise points. The effect of the iTind is to widen the prostatic urethral opening through which urine can now flow more easily.
224290817|NCT00493246|DRUG|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
224290818|NCT05392374|DRUG|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2
223954161|NCT04292795|DEVICE|Therapeutic Ultrasound|The Intervention will be provided according to the set protocols used in previous literature.
224290819|NCT01741779|OTHER|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
224290820|NCT01741779|OTHER|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
224290821|NCT01741779|OTHER|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
224290822|NCT05476419|OTHER|Direct intra-oral scanning technique for the post space.|scanning of prepared dental post space directly inside the patient mouth by using an intra-oral scanner
223954162|NCT04292795|DEVICE|Short wave diathermy|The Intervention will be provided according to the set protocols used in previous literature.
223723522|NCT03186222|DIAGNOSTIC_TEST|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
223954163|NCT03442998|OTHER|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
223954164|NCT03442998|OTHER|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
223954165|NCT00184743|DRUG|somatropin|
223954166|NCT02597166|DRUG|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
223954167|NCT00761332|DRUG|teriparatide|treatment will be prescribed according to usual standard of care
223954168|NCT00761332|DRUG|antiresorptives|treatment will be prescribed according to usual standard of care
223954169|NCT01020578|OTHER|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
223954170|NCT00651599|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
223954171|NCT00651599|DRUG|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
223954172|NCT00711022|DEVICE|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
223954173|NCT03384342|DEVICE|Narrow-band UV-B therapy|"* Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~* For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
223954174|NCT06222437|DRUG|Semaglutide|effectiveness of semaglutide in PCOS
223954175|NCT03544047|DRUG|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
223954176|NCT04004754|DRUG|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
223723523|NCT05480085|BEHAVIORAL|School-based extracurricular intervention focusing on screen media use and time spent with friends|"The intervention includes the following components:~1. Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~2. Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~3. Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~4. Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan."
224290823|NCT05979077|OTHER|MyChart Questionnaire|Prior to clinic visits, families completing the MyChart Questionnaire will enter details about their current management and visit goals, automatically populating their electronic health record for subsequent review/revision by the health care team before and during the visit, reallocating clinic time previously used for data acquisition to individual patient priorities
224290824|NCT00301847|DRUG|sorafenib tosylate|
224290825|NCT00761449|DRUG|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
223539326|NCT03243227|OTHER|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
223539327|NCT03243227|OTHER|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
223539328|NCT00165789|DRUG|E2007|
223539329|NCT02663310|PROCEDURE|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
223723524|NCT01342796|BIOLOGICAL|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
223723525|NCT01342796|BIOLOGICAL|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
223723526|NCT04677374|OTHER|Standard of care|Standard of care referral approach which is a brief health talk conducted once every morning by a VMMC mobilizer.
223723527|NCT04677374|BEHAVIORAL|Intensified Health Education|More detailed health talk conducted during each group health talk session by the VMMC mobilizer and champions describing VMMC, its benefits and how to access the service and testimonies from men who have successfully undergone VMMC
223723528|NCT04677374|BEHAVIORAL|SMS/telephonic Tracing|SMS tracing to remind participants of VMMC appointments
224290826|NCT00735917|DRUG|saracatinib|Given PO
223954177|NCT03029156|DEVICE|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
223954178|NCT03029156|DEVICE|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
223723529|NCT04677374|BEHAVIORAL|Transportation Reimbursement|Transportation reimbursement to offset the cost of transportation for VMMC appointments
223954179|NCT01740284|DRUG|Grazax + Aerius|
223954180|NCT01740284|DRUG|Grazax + placebo|
224290827|NCT00735917|OTHER|pharmacogenomic studies|Optional correlative studies
223954181|NCT00005713|BEHAVIORAL|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
223954182|NCT00257309|DRUG|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
223954183|NCT00257309|PROCEDURE|Primary angioplasty|
224290828|NCT00735917|OTHER|pharmacological study|Optional correlative studies
224290829|NCT00735917|PROCEDURE|positron emission tomography|Optional correlative studies
224290830|NCT00735917|RADIATION|fludeoxyglucose F 18|Optional correlative studies
224290831|NCT00735917|OTHER|laboratory biomarker analysis|Optional correlative studies
224290832|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
224290833|NCT01029158|DRUG|RN1006 (Avotermin)|250 ng, intradermal injection, twice
224290834|NCT01029158|DRUG|RN1006 (Avotermin)|205 ng, Intradermal injection, once
224290835|NCT01029158|DRUG|RN1006 (Avotermin)|500ng, intradermal injection, once
224290836|NCT01029158|DRUG|Juvista (Avotermin)|250 ng, intradermal injection, twice
224290837|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
224290838|NCT01029158|DRUG|Juvista (Avotermin)|500 ng, intradermal injection, once
224290839|NCT01029158|DRUG|RN1006 (Avotermin)|500 ng, intradermal injection, twice
224290840|NCT01029158|DRUG|Placebo|Placebo
224290841|NCT04244669|DEVICE|IPG with Conventional Stimulation|In this group, a conventional stimulation with low frequency will be tried. It will be programmed according to the usual clinical practice looking for one or more combinations of poles that allow a coverage of paraesthesia with a conventional stimulation of at least 80% of the painful area. This programming will be modified until getting not only 80% coverage but also a decrease of at least 50% in that area. It can be reprogrammed as many times as necessary during the 14-21 days of margin.
223954184|NCT01128439|OTHER|No intervention|No intervention
223954185|NCT05991518|COMBINATION_PRODUCT|Injection of IAH0968+Gemcitabine+Cisplatin|Administration of IAH0968 is given once per cycle, with each cycle defined as every 3 weeks.
224290842|NCT04244669|DEVICE|IPG with SCS DTM|In this group the SCS DTM™ workflow will be programmed. Each SCS DTM™ program group has at least two programs with different pulse rate in the 20 to 1,200 Hz range and each having a maximum pulse width of 1ms
224290843|NCT05436704|PROCEDURE|EUS-FNB|EUS-FNB
224290844|NCT03321162|DIAGNOSTIC_TEST|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
224290845|NCT00690976|BEHAVIORAL|Proyecto SOL|Group intervention
223954186|NCT05991518|COMBINATION_PRODUCT|Gemcitabine+Cisplatin|Gemcitabine is administered at a dose of 1000 mg/m2 on the second day (D2) and ninth day (D9) of each cycle. At least 6 hours after the completion of gemcitabine infusion, cisplatin is administered at a dose of 70 mg/m2 on the second day (D2) of each cycle.
223954187|NCT01390753|DIETARY_SUPPLEMENT|Human donor milk|
223954188|NCT05114499|DRUG|Donepezil|Donepezil 5mg qd
223954189|NCT05114499|DRUG|GV-971|GV-971 450mg bid
224290846|NCT00690976|BEHAVIORAL|HCT|Offer of HIV counseling and testing
224290847|NCT04790123|PROCEDURE|Injection of autologous freshly collected adipose tissue|injection of fresh autologous fat, previously lipoaspirates from the patient's abdomen and centrifugated, into the fistulous tract, after curettage and closure of the internal opening.
224290848|NCT04790123|PROCEDURE|sham|curettage and closure of the internal orifice of the anal fistula and simulated intervention in the abdomen.
224290849|NCT04725448|DRUG|Toripalimab|240mg, ivgtt, d1, every 3 weeks until disease progress or intolerable toxicity, up to 2 years of administration
224290850|NCT04725448|DRUG|Bevacizumab|7.5mg/kg, ivgtt, d1, every 3 weeks, up to 2 years of administration
224290851|NCT04725448|DRUG|Nab-paclitaxel|260mg/m2,d1 or 130mg/m2,d1,8, ivgtt, every 3 weeks, up to 6 cycles
224290852|NCT04725448|DRUG|Carboplatin|AUC=4～5, d1, ivgtt, every 3 weeks, up to 6 cycles
224290853|NCT02839148|DIETARY_SUPPLEMENT|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
224290854|NCT02043613|OTHER|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
224290855|NCT02043613|OTHER|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
224290856|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
224290857|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
224290858|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
224290859|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
224290860|NCT01629394|DRUG|Sugammadex|Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]
224290861|NCT01629394|DRUG|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
224290862|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]
223954190|NCT02611193|PROCEDURE|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
223954191|NCT02611193|PROCEDURE|Simulated manipulative treatment|Simulated Manipulative Treatment
223954192|NCT05656651|BEHAVIORAL|High intensity interval exercise training|Endurance training adapted to age, resting heart rate
223954193|NCT01029639|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
223954194|NCT04430400|DIAGNOSTIC_TEST|integrated diagnostic algorithm|"Diagnostic management was as follows. An acute aortic syndrome will be considered to be ruled out without advanced aortic imaging, in clinically stable patients at low clinical pre-test probability (defined by ADD score ≤1) and a D-dimer level \<500 ng/mL FEU. The other patients will be subjected to advanced aortic imaging for conclusive diagnosis.~Attending physicians will be allowed to derogate from protocol indications based on the clinical scenario and clinal gestalt, irrespective of patient's participation to the present study."
223954195|NCT02493556|DEVICE|LLLT before muscle damage|
223954196|NCT02493556|DEVICE|Placebo LLLT before muscle damage|
223954197|NCT02493556|DEVICE|LLLT after muscle damage|
223954198|NCT02493556|DEVICE|Placebo LLLT after muscle damage|
223954199|NCT02466958|DRUG|levomilnacipran|antidepressant
223954200|NCT02466958|DRUG|Placebo|an inactive drug
223954201|NCT06037044|OTHER|Sensory integration therapy for balance and gait training|Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)
223723530|NCT01529255|DRUG|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
224290863|NCT01629394|DRUG|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
223539330|NCT02663310|PROCEDURE|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
224290864|NCT02698865|DEVICE|MONOVISC|Two (2) intra-articular injections of 4 ml MONOVISC, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
224290865|NCT02698865|DEVICE|Saline|Two (2) intra-articular injections of 4 ml saline, separated by 1 month, delivered under image guidance (ultrasound or fluoroscopy)
223539331|NCT03625076|DRUG|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
223539332|NCT03625076|DRUG|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
224290866|NCT03394911|BIOLOGICAL|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
224290867|NCT01323465|DRUG|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
223539333|NCT03089814|PROCEDURE|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
223539334|NCT04256447|DIAGNOSTIC_TEST|Urinary sodium concentrations|The urinary sodium excretion was measured using an immunochemical methodology
223539335|NCT02145936|OTHER|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
223539336|NCT02327767|DEVICE|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
224290868|NCT01323465|DRUG|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
223723531|NCT01529255|DRUG|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
223723532|NCT01075724|DEVICE|Patient Warming with Forced Air|Forced Air warming via BairHugger
223723533|NCT01075724|DEVICE|Resistive Warming|Resistive Warming via HotDog device
223723534|NCT01599234|DRUG|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
223954202|NCT06037044|OTHER|Traditional Physiotherapy for balance and gait training|Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
223954203|NCT00620139|BIOLOGICAL|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
224290869|NCT01323465|DRUG|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
223723535|NCT01599234|DRUG|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
223954204|NCT03679299|OTHER|Observational - No intervention|See outcomes
223954205|NCT02675322|DRUG|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
223954206|NCT02675322|OTHER|Placebo|Placebo with no chemical effects.
223954207|NCT03610685|DRUG|Prednisolone|Given daily for 2 weeks
224290870|NCT01323465|DRUG|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
224290871|NCT01323465|DRUG|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
223954208|NCT03610685|DRUG|Placebo oral capsule|Given daily for 2 weeks
224290872|NCT01323465|DRUG|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
223539337|NCT00930449|OTHER|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
223954209|NCT04131855|OTHER|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
223954210|NCT04131855|OTHER|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
223954211|NCT01564472|OTHER|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
223954212|NCT04955054|DIAGNOSTIC_TEST|diagnose|Patients from UAP and AMI meet the criteria of UAP or STEMI.
223954213|NCT01742585|DRUG|ASP1585|oral
223954214|NCT01742585|DRUG|placebo|oral
224290873|NCT04341857|DRUG|PD-1 Monoclonal Antibody(Sintilimab)|Sintilimab combined with FLOT regimen,Docetaxel#50mg/m2d1,iv infusion for 1 hour#,Oxaliplatin#80mg/m2d1#iv infusion for 2 hours#,Calcium,leucovate#200mg/m2d1#iv infusion# ,Fluorouracil#2600mg/m2,intravenous drip for 24h# Every 14 days is one cycle# Sintilimab#200mg, d1#iv infusion Every 21 days is one cycle.
224290874|NCT03861481|DRUG|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
223539338|NCT00930449|OTHER|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
223539339|NCT00930449|OTHER|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
224290875|NCT03861481|OTHER|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
224290876|NCT05587114|DIAGNOSTIC_TEST|frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples
224290877|NCT00773734|DRUG|Apremilast 10mg|
224290878|NCT00773734|DRUG|Apremilast 20mg|
224290879|NCT00773734|DRUG|Apremilast 30 mg|
224290880|NCT00773734|DRUG|Placebo|
224290881|NCT00773734|DRUG|Apremilast 30mg|
224290882|NCT00773734|DRUG|Apremilast 20mg|
223539340|NCT01105663|OTHER|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
223539341|NCT02432573|BEHAVIORAL|Delayed rounds|
223539342|NCT04575519|DRUG|Control group|placebo 2 months treatment: 2 tablets during 4 weeks + 1 tablet during 4 weeks
223539343|NCT04575519|DRUG|ASA group|Acetylsalicylic acid 2 months treatment: 2 tablets during 4 weeks (600 mg daily) + 1 tablet during 4 weeks (300 mg daily)
223539344|NCT04575519|DRUG|IBU group|Ibuprofen 2 months treatment: 2 tablets during 4 weeks (800 mg daily) + 1 tablet during 4 weeks (400 mg daily)
223539345|NCT04575519|DRUG|SoC TB|Standard of Care Tuberculosis treatment
223539346|NCT03751397|OTHER|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
223954215|NCT03150589|DRUG|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
223539347|NCT03751397|OTHER|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
223539348|NCT02479191|DEVICE|Ovation Abdominal Stent Graft Platform|
223539349|NCT04042805|BIOLOGICAL|Sintilimab|200mg intravenously every 3 weeks
223539350|NCT04042805|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
223539351|NCT00267930|DRUG|Vernakalant (oral)|
223539352|NCT00267930|DRUG|Placebo comparator|
223954216|NCT03150589|DRUG|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
223954217|NCT03937752|OTHER|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
223723536|NCT02496273|BIOLOGICAL|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
223723537|NCT02248155|DRUG|Pramipexole|
223723538|NCT04740788|DEVICE|Monofocal IOL|Patients are already implanted with a monofocal lens
223723539|NCT03916328|DRUG|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
223723540|NCT03916328|DRUG|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
223954218|NCT02841449|BEHAVIORAL|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
223954219|NCT02841449|BEHAVIORAL|Rehydrated|Participants rehydrate after the heat tent procedure
223954220|NCT04976829|DEVICE|Antibiotic stewardship and healthcare-associated infections surveillance assisted by computer|Implementation - in our tertiary care university hospital - of a computerized-decision support system (CDSS) facilitating antibiotic stewardship and of an electronic surveillance software (ESS) facilitating infection prevention and control activities
223954221|NCT00160758|PROCEDURE|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
224290883|NCT03118388|BEHAVIORAL|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
224290884|NCT03118388|BEHAVIORAL|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
224290885|NCT03605511|DIAGNOSTIC_TEST|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
223539353|NCT04077177|BEHAVIORAL|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
223539354|NCT02579811|DRUG|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
223723541|NCT03916328|OTHER|DMPA|Two thirds of the women will be on DMPA for contraception.
223539355|NCT02018120|PROCEDURE|connective tissue graft|
223539356|NCT02018120|PROCEDURE|platelet rich fibrin|
223539357|NCT04052373|PROCEDURE|Implantoplasty|Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.
223539358|NCT04052373|PROCEDURE|Open flap debridement alone|Open flap debridement alone
223539359|NCT05230498|DEVICE|anatomy-based fitting then default fitting|Cochlear implant with anatomy-based fitting then default fitting
223539360|NCT05230498|DEVICE|default fitting then anatomy-based fitting|Cochlear implant with anatomy-based fitting then default fitting
223539361|NCT06268899|OTHER|First mobilization protocol|The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed \>60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
223539362|NCT04445662|BEHAVIORAL|Financial incentives|Escalating financial rewards for saliva cotinine levels \<30 ng/mL, assessed 10 times over 12 weeks
223539363|NCT04445662|DRUG|Varenicline|"* Day 1 - 3: 0.5 mg daily~* Day 4 - 7: 0.5 mg twice daily~* Day 8 - Week 12: 1 mg twice daily~* Dose/schedule may be adjusted based on medical history and clinician judgement"
223539364|NCT04445662|BEHAVIORAL|Tobacco coaching|5 one-on-one tobacco cessation coaching sessions over 12 weeks
223723542|NCT05104892|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
223723543|NCT05104892|DRUG|placebo|Pharmaceutical form: Tablet Route of administration: Oral
223723544|NCT05385393|PROCEDURE|Arthroscopic posterior capsulotomy of the knee|"The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078."
223954222|NCT01020435|OTHER|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
223954223|NCT01020435|OTHER|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
223723545|NCT01443650|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
223954224|NCT00914056|DRUG|lactulose|withdrawal of lactulose
223954225|NCT03576378|DRUG|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
223723546|NCT04190394|OTHER|Intermittent retraining program.|Patient benefits from an intermittent retraining program for 8 weeks, with three 45-minute sessions per week.
223723547|NCT03764189|PROCEDURE|microosteoperforation|small holes made using large round bur
223723548|NCT04811391|BIOLOGICAL|COVID-19 vaccine|Observation of individuals who receive the COVID-19 vaccine (2 doses of PfizerBioNtech COVID-19 vaccine).
223723549|NCT02895906|DRUG|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
223723550|NCT02033694|DEVICE|NIRS-IVUS Imaging (TVC Imaging System)|Diagnostic Imaging Catheter
223723551|NCT01633333|OTHER|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
223539365|NCT05161871|DEVICE|Cathodal transcranial direct current stimulation|The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
223539366|NCT05161871|DEVICE|Sham cathodal transcranial direct current stimulation|Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
223539367|NCT04832698|OTHER|Survey Administration|Complete survey
223539368|NCT06447545|DEVICE|Changing pressure of Pneumoperitoneum to 6-10 mmHg|Result of changing pneumoperitoneum pressure on CBD injury and pain
223539369|NCT06447545|DEVICE|Changing pressure of Pneumoperitoneum to 12-15 mmHg|Result of changing pneumoperitoneum pressure on CBD injury and pain
223539370|NCT00956384|PROCEDURE|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
223539371|NCT00956384|PROCEDURE|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
223539372|NCT01448642|DRUG|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
223539373|NCT01448642|DRUG|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
223539374|NCT05320978|DEVICE|Hand grip test, computed tomography|A hand grip test, abdominal computed tomography are performed before surgery.
223539375|NCT06560944|DRUG|Combined oral contraceptive pill|Ingesting their existing combined oral contraceptive pill at a specific time of day in relation to assessment of outcome measures
223539376|NCT02916485|DEVICE|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
223539377|NCT05970328|DEVICE|Hexoskin Medical System|Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
223539378|NCT00601367|DRUG|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
223539379|NCT05471375|OTHER|Database Entry|Database entries will contain wearable sensor, audio, and video data collected during rehabilitation-related movement assessments
223539380|NCT02998190|DRUG|Single Ascending Doses of EB8018|
223539381|NCT02998190|DRUG|Single Ascending Doses of placebo|
223954226|NCT03851809|DRUG|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
223954227|NCT01000649|DRUG|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
223539382|NCT02998190|DRUG|Multiple Ascending Doses of EB8018|
223539383|NCT02998190|DRUG|Multiple Ascending Doses of placebo|
223539384|NCT01331590|DRUG|G-CSF|
223539385|NCT01331590|DRUG|Ifosfamide|
223539386|NCT01331590|DRUG|Etoposide|
223539387|NCT01331590|DRUG|Dexamethasone|
223539388|NCT01331590|DRUG|Mesna|
223539389|NCT02551588|PROCEDURE|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
223539390|NCT01445275|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
223539391|NCT01445275|OTHER|Medical Chart Review|Ancillary study
223539392|NCT01445275|OTHER|Study of Socioeconomic and Demographic Variables|Ancillary studies
223539393|NCT00656370|DRUG|recombinant human hyaluronidase|150 Units in 1mL
223539394|NCT00285571|BEHAVIORAL|Controlled Feeding Intervention|
223539395|NCT00646386|DRUG|adalimumab|40 mg eow Week 0 - Week 24
223539396|NCT00646386|DRUG|placebo for adalimumab|40 mg eow Week 0 - Week 24
223539397|NCT03833141|OTHER|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
223539398|NCT02266160|DRUG|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
223539399|NCT02266160|OTHER|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
223539400|NCT01342094|DRUG|DE-111 ophthalmic solution|
223539401|NCT01342094|DRUG|Timolol ophthalmic solution 0.5%|
223539402|NCT01342094|DRUG|Placebo ophthalmic solution|
223539403|NCT03375099|BEHAVIORAL|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
223539404|NCT03375099|BEHAVIORAL|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
223954228|NCT01000649|DRUG|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
223954229|NCT01000649|DRUG|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
223954230|NCT01000649|OTHER|Placebo|Isotonic saline infused.
224290886|NCT02473783|DRUG|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
224290887|NCT02473783|OTHER|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
224290888|NCT04722159|DEVICE|Renal denervation|Catheter-based inhibition of renal sympathetic nerve traffic.
223723552|NCT01633333|OTHER|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
224290889|NCT04158661|PROCEDURE|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
223539405|NCT05688969|OTHER|early versus late biopsy|early (3-6 weeks) versus late (6-8 months) biopsy
223539406|NCT00309218|DRUG|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
223723553|NCT00080977|BIOLOGICAL|aldesleukin|
223954231|NCT04817345|DRUG|Plerixafor|Subcutaneous
223954232|NCT03397147|BEHAVIORAL|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
223954233|NCT00425971|DRUG|BMEC-1217B|
223954234|NCT03015428|OTHER|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
223954235|NCT00668226|DRUG|Lactic acid (Dermacid)|
223954236|NCT00346398|BIOLOGICAL|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
223954237|NCT00346398|BIOLOGICAL|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
223954238|NCT05032651|DEVICE|novel artificial intelligence assisted platform|Use of a novel artificial intelligence assisted platform
224290890|NCT04158661|PROCEDURE|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
224290891|NCT04158661|PROCEDURE|no thymectomy (control)|routine medical care
224290892|NCT00005809|PROCEDURE|computed tomography|
224290893|NCT00005809|PROCEDURE|diagnostic colonoscopy|
224290894|NCT00236067|DRUG|Gabitril|
224290895|NCT00002360|DRUG|Didanosine|
224290896|NCT01220297|DRUG|Sirolimus|"Immunosuppressant administered orally to:~* Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~* Children \< 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
224290897|NCT01220297|DRUG|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
224290898|NCT01220297|DRUG|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
224290899|NCT01220297|DRUG|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
224290900|NCT01220297|DRUG|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
224290901|NCT01220297|DRUG|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
224290902|NCT00085306|BIOLOGICAL|recombinant interferon beta|recombinant interferon beta
224290903|NCT01989988|PROCEDURE|LMGB|
224290904|NCT01989988|PROCEDURE|LRYGB|
224290905|NCT01989988|PROCEDURE|SADJB|
224290906|NCT01287039|DRUG|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
224290907|NCT01287039|DRUG|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
224290908|NCT04528888|DRUG|Enoxaparin|Enoxaparin will be administered subcutaneously at standard prophylactic dose (i.e., 4000 UI once day, increased to 6000 UI once day for patients weighting more than 90 kg). The treatment will be administered daily up to ICU discharge. After ICU discharge it may be continued or interrupted in the destination ward up to clinical judgement of the attending physician.
224290909|NCT04528888|DRUG|Methylprednisolone|Methylprednisolone will be administered intravenously with an initial bolus of 0,5 mg/kg followed by administration of 0,5 mg/kg 4 times daily for 7 days, 0,5 mg/kg 3 times daily from day 8 to day 10, 0,5 mg/kg 2 times daily at days 11 and 12 and 0,5 mg/kg once daily at days 13 and 14.
224290910|NCT04528888|DRUG|unfractionated heparin|Patients in this group will receive unfractionated heparin and methylprednisolone. Unfractionated heparin will be administered intravenously at therapeutic doses. The infusion will be started at an infusion rate of 18 IU/kg/hour and then modified to attain APTT Ratio in the range 1.5-2.0. aPTT will be periodically checked at intervals no longer than 12 hours. The treatment with unfractionated heparin will be administered up to ICU discharge. After ICU discharge anticoagulant therapy may be interrupted or switched to prophylaxis with LMWH in the destination ward up to clinical judgement of the attending physician.
224290911|NCT02843594|PROCEDURE|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
224290912|NCT02843594|PROCEDURE|Standard Phaco Control|
224290913|NCT00217269|DEVICE|Coronary Artery Stenting|Endeavor Drug eluting stent
223723554|NCT04496544|OTHER|Retrospective data collection|No intervention; retrospective data collection
223954239|NCT00969007|BEHAVIORAL|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
224290914|NCT00217269|DEVICE|Coronary Artery Stenting|Taxus Drug Eluting Stent
224290915|NCT05016622|BIOLOGICAL|BNT162b2 vaccine|Administer an additional dose of the BNT162b2 mRNA vaccine to patients with cancer who have a negative SARS-CoV-2 Spike IgG at least 14 days after 2 doses of the mRNA vaccines (BNT162b2/mRNA-1273) or 28 days after the adenoviral based Ad26CoV2.S vaccine.
224290916|NCT04822571|OTHER|Reliability of 3D motion analysis protocol|The intrinsic and extrinsic reliability of the designed 3D motion analysis protocol is measured in cases of high velocity dynamic movement such as kicking a soccer ball.
224290917|NCT04284514|DRUG|AKB-9778 Ophthalmic Solution|AKB-9778 Ophthalmic Solution
224290918|NCT04284514|DRUG|Placebo Ophthalmic Solution|Matched vehicle-control
224290919|NCT00033904|DRUG|autologous human tumor-derived HSPPC-96|
224290920|NCT06226922|OTHER|No intervention|No intervention
223723555|NCT03311815|DIAGNOSTIC_TEST|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
223723556|NCT02485301|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
223723557|NCT02485301|DRUG|Placebo|A single dose administrated intramuscular
223723558|NCT06291025|PROCEDURE|PEX-FREE|The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).
223723559|NCT01021540|DRUG|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
223723560|NCT01282268|DRUG|arbaclofen|orally disintegrating tablet
223723561|NCT01282268|DRUG|placebo|orally disintegrating tablet
224290921|NCT01758822|OTHER|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
224290922|NCT00006091|DRUG|arsenic trioxide|
224290923|NCT00002199|DRUG|Indinavir sulfate|
224290924|NCT00002199|DRUG|Lamivudine/Zidovudine|
224290925|NCT00002199|DRUG|Abacavir sulfate|
224290926|NCT05051059|OTHER|Functional outcome|3D-motion analysis and strength assessment
224290927|NCT05051059|OTHER|Health related quality of life (HRQoL) assessment|Quality of Life Questionnaire C-30 (QLQ-C30), Impact on Participation and Autonomy Questionnaire (IPAQ) and Musculoskeletal Tumor Society Score (MSTS)
224290928|NCT02751970|PROCEDURE|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
224290929|NCT02751970|PROCEDURE|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
224290930|NCT02751970|PROCEDURE|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
224290931|NCT02751970|PROCEDURE|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
224290932|NCT02751970|PROCEDURE|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
224290933|NCT04686656|OTHER|nasal oxygen|Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
224290934|NCT04686656|OTHER|buccal oxygen|Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
224290935|NCT00351598|RADIATION|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
224290936|NCT00474851|DRUG|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
224290937|NCT00474851|DRUG|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
224290938|NCT05160753|PROCEDURE|Laparoscopic gastric function preserving surgery combined with resection of the anterior lymphatic drainage area|A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method., and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed.
224290939|NCT03861793|BIOLOGICAL|ALKS 4230|SC injection administered in the back of the arm or the abdomen
224290940|NCT03861793|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
224290941|NCT01922167|DIETARY_SUPPLEMENT|Leucine|
224290942|NCT01922167|DIETARY_SUPPLEMENT|Alanine|
224290943|NCT05703243|DIAGNOSTIC_TEST|Comprehensive liquid molecular panel test|Lab test
224290944|NCT05703243|OTHER|EORTC QLQ-30|Quality of life questionnaire
224290945|NCT04689763|BEHAVIORAL|Training|The programs contain sequential cognitive and exercise training, health lectures, and groups of daily living participation. We plan to assess the participants before and after the intervention programs. We expect that elders receiving training will improve on outcome measures. The results of the study will provide evidence of interventions for elderly with cognitive decline.
224290946|NCT02581163|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
224290947|NCT02581163|DRUG|Dasabuvir|Tablet
224290948|NCT02581163|DRUG|Ribavirin|Tablet
223723562|NCT04734223|DIAGNOSTIC_TEST|Neuroimaging Findings in Patients With COVID-19|MR and BT Imaging
223723563|NCT03991715|BEHAVIORAL|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
223723564|NCT03589950|DRUG|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
223954240|NCT00458094|BEHAVIORAL|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
223954241|NCT00458094|BEHAVIORAL|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
223954242|NCT01450774|DRUG|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
223954243|NCT01450774|DRUG|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
223954244|NCT05790759|OTHER|No cueing versus Haptic cueing versus Auditory cueing during parkinson's disease gait|Patients walked in three conditions in a randomized order. During control condition, patients walked without cueing on a rectangular track of 63.2 meters at their comfortable gait speed. During Auditory Cueing Condition (ACC) patients walked on the same track using auditory cueing by the mean of a smartphone app called Soundbrenner thath deliverered rhythmic auditory stimulations through earphones paced 10% faster than each patient's preferred step frequence. During Haptic Cueing Condition (HCC) patients walked on the same track using haptic cueing by the mean of a vibratory device called Soundbrenner Pulse and attached to each patient's wrist located on their most affected side. The Soundbrenner app on the smartphone was connected to the Soundbrenner Pulse by Bluetooth to deliver rhythmic vibratory stimulations also paced 10% faster than each patient's preferred step frequence, the same frequence as during ACC.
223954245|NCT02607956|DRUG|DTG|50 mg tablets administered orally, once daily
223954246|NCT02607956|DRUG|F/TAF|200/25 mg tablets administered orally, once daily
223954247|NCT02607956|DRUG|B/F/TAF|50/200/25 milligrams (mg) FDC tablets administered orally, once daily
223954248|NCT02607956|DRUG|DTG Placebo|Tablets administered orally, once daily
223954249|NCT02607956|DRUG|F/TAF Placebo|Tablets administered orally, once daily
223954250|NCT02607956|DRUG|B/F/TAF Placebo|Tablets administered orally, once daily
223723565|NCT03589950|DRUG|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
223723566|NCT04006249|DIAGNOSTIC_TEST|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
223723567|NCT06831812|BIOLOGICAL|AV-1959R (Abeta vaccine)|AV-1959R is an investigational adjuvanted vaccine designed to induce a targeted immune response against beta-amyloid (Aβ) to support the primary prevention of Alzheimer's disease and the treatment of asymptomatic preclinical Alzheimer's disease. It is administered intramuscularly (IM) at doses of 100 µg or 300 µg on Weeks 0, 4, and 14, in combination with the adjuvant.
223723568|NCT02111772|BIOLOGICAL|Rhinovirus|
223723569|NCT01091493|DRUG|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
223954251|NCT02837419|BEHAVIORAL|Health related Quality of life EQ-5D|Quality of Care
223954252|NCT03121417|BIOLOGICAL|Nivolumab|240 mg given IV
224106943|NCT05252689|OTHER|monolithic zirconia single posterior crowns with vertical finish line|using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
223539407|NCT01600287|OTHER|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
223539408|NCT01600287|OTHER|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
223539409|NCT03111030|BEHAVIORAL|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~1. An assessment of motivated the participant is to be physically active~2. A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~   B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~3. Progress and barriers will be reassessed and discussed."
223539410|NCT03703388|DIETARY_SUPPLEMENT|Arctigenin|Arctigenin capsule
223539411|NCT05311514|BIOLOGICAL|Allogeneic platelet lysate eye drops|Eye drops
223539412|NCT05477654|DIAGNOSTIC_TEST|Extensive motor-cognitive testing protocol|Screening of their functional performance while monitoring brain and muscle activity
223539413|NCT06566014|OTHER|Evaluation of XAI-assisted spina bifida diagnosis|AI feedback
223539414|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|30 µg
223539415|NCT04224701|BIOLOGICAL|BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted|300 µg
223539416|NCT04224701|BIOLOGICAL|Placebo|Tris NaCl Diluent
223539417|NCT04273360|OTHER|Systematic use group|Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
223539418|NCT04273360|OTHER|Restrictive use group|Patients in this group will be subjected to PR only in case of severe agitation, defined by a RASS ≥ +3 on any given day between day 0 and day 14
223539419|NCT04476576|BEHAVIORAL|Aerobic exercise (experimental)|3 times per week, 30 minutes each time. Entrance in heat: 8-10 min of joint mobility and / or the aerobic exercise in the main part at light intensity (OMNI 3-4) Main part: minimum 30 minutes, maximun 60 minutes. Intensity: moderate, guided by Talk Test and effort perception scale 5-6 OMNI. Type: aerobic, cycling or walking at home using a treadmill or exercise bike and / or cycling and walking outdoors according to the patient's possibilities and preferences. Return to calm: 5 min of aerobic physical activity of main part at mild intensity (OMNI 3-4), then static stretching. Pictures with each type of exercise will be offered and detailed explained.
223539420|NCT04476576|BEHAVIORAL|Flexibility exercise (active comparator)|Entrance in heat: 10 min of joint mobility. Main part: Minimum 30 minutes. Frequency: 3 times por week Intensity: The patient should be able to slowly stretch the muscle to a position of mild discomfort. Type: Static Stretch Time: 15-30 seconds 2 repetitions of each stretch Number of exercises: 12 . Pictures with each muscle group to exercise will be offered and detailed explained.
223539421|NCT05015504|BEHAVIORAL|Time restricted feeding|In Phase II the study subjects will be placed on time-restricted fasting (feeding between 4 AM - 4 PM, fasting in the rest of the day) for one week.
223539422|NCT02794571|DRUG|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
223539423|NCT02794571|DRUG|Tiragolumab|Several dose levels will be evaluated for tiragolumab administered as a single agent and in combination with atezolizumab and/or other anti-cancer therapies. Tiragolumab will be given via IV infusion on Day 1 of each cycle (21-day or 28-day depending on study cohort and phase) until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent tiragolumab may receive combination treatment with tiragolumab and atezolizumab and/or other anti-cancer therapies. Combination treatment may continue until disease progression or loss of clinical benefit.
224290949|NCT01370135|DRUG|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
224290950|NCT02765217|DRUG|Lactobacillus reuteri DSM 17938|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
223723570|NCT06038084|DRUG|Bronpass Tab.|Twice a day
224290951|NCT02765217|DRUG|Placebo|Comparison the effects of Lactobacillus reuteri DSM 17938 and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
223723571|NCT06038084|DRUG|Placebo of Erdos capsule|Three times a day (It is for the masking.)
224290952|NCT02765217|DRUG|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
224290953|NCT01563419|DEVICE|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
224290954|NCT02341950|BEHAVIORAL|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
224290955|NCT02629913|DEVICE|mementor somnium|
224290956|NCT02629913|OTHER|wait list|delayed access to mementor somnium
224290957|NCT04553861|DEVICE|Ambulatory blood pressure monitoring|Every 30 minutes from 7 AM to 10 PM and every 1 hour from 10 PM to 7 AM
224290958|NCT04553861|DEVICE|Galaxy Watch Active2|Every 1 hour by subject (on-demand) from 7 AM to 10 PM and every 5 minutes (automatic) from 10 PM to 7 AM
223539424|NCT02794571|DRUG|Carboplatin|Carboplatin, AUC of 6 milligram per milliliter per minute (mg/ml/min) for Cohorts A and B and AUC of 5 mg/ml/min for Cohort C, IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab IV infusion.
223539425|NCT02794571|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) IV infusion will be administered on day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
223539426|NCT02794571|DRUG|Pemetrexed|Pemetrexed 500 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after carboplatin or cisplatin IV infusion with combination treatment of atezolizumab and tiragolumab.
223539427|NCT02794571|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
223539428|NCT02794571|DRUG|Etoposide|Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
223539429|NCT02794571|DRUG|Capecitabine|Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
223539430|NCT02794571|DRUG|Bevacizumab|Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
223539431|NCT02794571|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
223539432|NCT06503185|BEHAVIORAL|Prehabilitation|The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
223539433|NCT02786056|OTHER|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
223539434|NCT03391882|DRUG|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
223539435|NCT03391882|DRUG|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
223539436|NCT03120845|PROCEDURE|One visit RCT|Root canal treatment in one vist
223539437|NCT03120845|PROCEDURE|Post operative pain in two-visits RCT|Root canal treatment in Two visits
223539438|NCT04641091|DEVICE|Multispectral Optoacustic Tomography (MSOT)|non-invasive transcutaneous imaging of subcellular muscle components
223539439|NCT00012441|PROCEDURE|hemodialysis|
223539440|NCT03266029|DEVICE|Cordio App|
223539441|NCT06218979|DRUG|Risperidone oral solution|See arm/group descriptions
223539442|NCT06126497|DRUG|Ropanicant|Tablet
223954253|NCT00103857|DRUG|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
223539443|NCT06573008|DRUG|GP681 40mg|2 x 20mg tablets taken orally
224290959|NCT02791893|DEVICE|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
223539444|NCT06573008|DRUG|GP681 Simulant|Placebo tablets matching GP681 40mg
223539445|NCT03913130|DRUG|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
223539446|NCT02878382|OTHER|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
223539447|NCT02878382|OTHER|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
223539448|NCT03822026|OTHER|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
223539449|NCT05728554|OTHER|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
223539450|NCT05728554|OTHER|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
223539451|NCT05728554|OTHER|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
223539452|NCT01015950|DIETARY_SUPPLEMENT|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
223539453|NCT01015950|DIETARY_SUPPLEMENT|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
223539454|NCT01015950|DIETARY_SUPPLEMENT|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
223539455|NCT01015950|DIETARY_SUPPLEMENT|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
223539456|NCT00365807|BEHAVIORAL|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
224290960|NCT02791893|DEVICE|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
224106944|NCT03873597|BEHAVIORAL|Tele-coaching + Usual Care|The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
223539457|NCT00365807|OTHER|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
223954254|NCT00103857|DRUG|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
223954255|NCT00103857|DRUG|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
224106945|NCT03741361|OTHER|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
223539458|NCT01085214|OTHER|Laboratory Biomarker Analysis|Correlative studies
224290961|NCT02880748|OTHER|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
223539459|NCT01085214|DRUG|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
223539460|NCT01482715|DRUG|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
223539461|NCT04206761|DRUG|QVM149|QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
223539462|NCT04206761|DRUG|High Dose Dual Therapy (ICS/LABA)|High dose inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) in any approved drug formulation and delivery device.
223539463|NCT01634152|DRUG|Placebo|2 actuations once daily in the evening
223539464|NCT01634152|DRUG|Tiotropium low dose mcg|2 actuations once daily in the evening
223539465|NCT01634152|DRUG|Tiotropium high dose|2 actuations once daily in the evening
223539466|NCT03526211|DEVICE|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
223539467|NCT03447873|DRUG|Continue with triple therapy|To continue with triple therapy
224290962|NCT02880748|OTHER|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
224290963|NCT03161548|DRUG|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
224290964|NCT03161548|PROCEDURE|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
224290965|NCT03161548|RADIATION|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
224290966|NCT03438396|DRUG|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
224290967|NCT03858166|DRUG|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
223539468|NCT03447873|DRUG|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
223539469|NCT03447873|DRUG|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
223539470|NCT06039514|DEVICE|GGTCA-AD mobile app|The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
223723572|NCT06038084|DRUG|Erdos capsule|Three times a day
223954256|NCT00103857|DRUG|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
223954257|NCT00103857|DRUG|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
224106946|NCT06274138|BEHAVIORAL|haptonomy|Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
224106947|NCT05422079|OTHER|Non-specific lumbar exercise group|Subjects perform a conventional lumbar exercise program twice a week.
224106948|NCT05422079|OTHER|motor control lumbar exercises|Subjects perform a lumbar stabilization exercise program.
224106949|NCT05422079|OTHER|motor control lumbar exercises with ultrasound echography feedack|Subjects perform a lumbar stabilization exercise program in conjunction with a video where participants can see how the muscles contract.
224106950|NCT01713634|OTHER|Preflight|4-d controlled diet sessions will occur twice before flight.
224106951|NCT01713634|OTHER|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
224106952|NCT01844076|DRUG|Quinacrine and Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
224106953|NCT05712421|DRUG|North Star|North Star
224106954|NCT05712421|DRUG|Levothyroxine|Levothyroxine
224106955|NCT03982667|DIAGNOSTIC_TEST|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
224106956|NCT00644579|DRUG|bLAC|bLAC high and low dose and placebo
224106957|NCT00644579|DRUG|Placebo|Placebo
223723573|NCT06038084|DRUG|Placebo of Bronpass Tab.|Twice a day (It is for the masking.)
223723574|NCT02338661|DEVICE|SBG hip stem|
223539471|NCT06039514|DEVICE|GGNeutra mobile app|"the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen."
223539472|NCT00094276|BEHAVIORAL|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
223954258|NCT00103857|DRUG|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
223954259|NCT05307653|PROCEDURE|Penile block|Penile block was performed in supine position. The penis was retracted caudally and then fixed with a leucoplast. After identifying the symphysis pubis (SP), a 22-gauge needle was inserted vertically about 1 cm lateral to the SP, and bupivacaine 0.5% (0.1 ml/kg, maximum 2.5 ml) was injected on each side after penetrating the Scarpa's fascia.
223539473|NCT00094276|BEHAVIORAL|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
223539474|NCT01233544|PROCEDURE|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
223539475|NCT04470765|DEVICE|Zida|Transcutaneous Tibial Nerve Stimulation
223539476|NCT00882089|DEVICE|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
223539477|NCT00413114|DRUG|Obatoclax mesylate (GX15-070MS)|
223723575|NCT00372125|DRUG|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
223723576|NCT01059825|DRUG|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
223723577|NCT01059825|DRUG|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
223954260|NCT05307653|PROCEDURE|Erector spinea plain block|Ultrasound guided ESPB was performed in prone position by Philips © (CX50 Extreme edition). The superficial probe was placed longitudinally at the midline just above the sacrum, and both erector spinae muscles and median sacral crests were identified. Using the in-plane approach, a 22-gauge needle was inserted in a craniocaudal direction till reaching the tip of the fourth median sacral crest. After negative aspiration to avoid intravascular or intrathecal puncture, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered.
223539478|NCT01507740|DRUG|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
223539479|NCT01507740|DRUG|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
223539480|NCT01507740|DRUG|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
223539481|NCT01152437|DRUG|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
223539482|NCT01152437|DRUG|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
223954261|NCT05307653|PROCEDURE|Caudal block|Caudal block was performed in the left lateral position. A 22 G needle was inserted through the sacral hiatus. The loss of resistance method was used to pass through the sacrococcygeal membrane and enter the caudal epidural space. Negative aspiration was then performed. When no blood or cerebrospinal fluid was observed, bupivacaine 0.25% (1 ml/kg, maximum 20 ml) was administered. The patient was returned to the supine position after the procedure was completed.
223539483|NCT01450345|DRUG|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
223539484|NCT05170685|BIOLOGICAL|Nivolumab plus Relatlimab FDC|
223539485|NCT00735657|DEVICE|needle|Peribulbar blockade with standard (25 mm) needle
223539486|NCT00735657|DEVICE|needle|Peribulbar blockade with short (12.5 mm) needle
223539487|NCT00735657|PROCEDURE|Pars Plana Vitrectomy|Peribulbar block
223539488|NCT01985022|BEHAVIORAL|Group-ESI|The Group-ESI intervention consists of weekly small group meetings where families receive information about social communication, emotional regulation, play development, and behavioral challenges in toddler playgroups in a relaxed, supportive, child-friendly setting that provides the opportunity to talk with a professional and meet other parents.
223539489|NCT01985022|BEHAVIORAL|Individual-ESI|The Individual-ESI intervention consists of twice-weekly home-based individualized coaching sessions. Parents learn how to support their child's communication, social, and play skills in everyday routines, activities, and places. Individual-ESI begins with an initial home visit, followed by a month of program planning, 6 months of intervention implementation, and 2 months of generalization. During generalization, the clinician meets with the family in a variety of community settings to teach the parent how to implement strategies in new settings.
223539490|NCT01624714|DRUG|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
223723578|NCT01059825|DRUG|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
223723579|NCT01059825|DRUG|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
223723580|NCT01059825|DRUG|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
223723581|NCT01059825|DRUG|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
223954262|NCT05764395|DRUG|Rigosertib|Given by mouth
223954263|NCT05764395|BIOLOGICAL|Pembrolizumab|Given by IV
223954264|NCT05764395|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223954265|NCT05764395|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223954266|NCT05764395|PROCEDURE|Biopsy|Undergo tissue biopsy
223954267|NCT00004939|DRUG|,4-diaminopyridine|
223954268|NCT03093064|DRUG|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
223954269|NCT03093064|OTHER|Placebo: normal saline|Normal saline, intravenous infusion
223954270|NCT04154085|OTHER|Psychotherapy|Group psychotherapy
223954271|NCT01005914|DRUG|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
223954272|NCT01005914|DRUG|cytarabine|Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
223954273|NCT01005914|DRUG|dexamethasone|Day 1-4; 11-14: 40 mg daily
223954274|NCT01005914|DRUG|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
223954275|NCT01005914|DRUG|imatinib mesylate|600 mg/day
223954276|NCT01005914|DRUG|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
223954277|NCT01005914|DRUG|methylprednisolone|Day 1-3: 50mg IV BID
223539491|NCT01624714|DRUG|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
223539492|NCT03374020|DEVICE|Notal OCT|Imaging using Notal OCT
223539493|NCT04594746|DRUG|Amiodarone Hydrochloride|Amiodarone hydrochloride 2000 mg PO to be given as a 10-capsule dose pack and ingested in a single sitting with food
223539494|NCT04594746|DRUG|Placebo|Oral placebo to be given as a 10-capsule dose pack and ingested in a single sitting with food
223723582|NCT01059825|DRUG|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
223723583|NCT05639374|BEHAVIORAL|BASICS_HealthyClassroom|First, they will complete a 22-item online questionnaire, collecting all the variables of the research. After completing it, the students in the intervention group will receive personalized feedback by mail that visually summarizes the content of the questionnaire. Students will receive a motivational intervention with the aim of increasing the university's awareness of their alcohol consumption. In the intervention session of the program, the following aspects may be addressed, whenever the participant wishes: 1) Pattern of alcohol consumption of the student; 2) Social norm of alcohol consumption; 3) Negative consequences of alcohol; 4) Costs of alcohol consumption; 5) The change; 6) Specific education on alcohol; and 7) Advice and recommendations.
223723584|NCT04830020|DRUG|HMW-HA|Aerolized administration b.i.d.
223954278|NCT01005914|DRUG|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
223539495|NCT00688714|DRUG|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
223539496|NCT00688714|DRUG|Placebo|
223723585|NCT06164223|DEVICE|VR Baby Pump|VRBaby-Pump application is a video application specially prepared with virtual reality glasses and a milking pump placed inside a toy doll. In the video content, the mother is breastfeeding her baby on an armchair in the baby room prepared for a newborn baby.
223723586|NCT01352689|DRUG|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
223723587|NCT01352689|DRUG|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
223723588|NCT02599272|OTHER|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
223723589|NCT02599272|OTHER|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
223954279|NCT01005914|DRUG|vincristine sulfate|Day 4 \& 11: 2 mg IV
223539497|NCT01623063|PROCEDURE|Hysteroscopy|hysteroscopy with guided biopsies
223539498|NCT01480167|DEVICE|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
223539499|NCT01480167|OTHER|Non-operative Management|Conservative Care
223539500|NCT01226108|DEVICE|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~\--------------------------------------------------------------------------------"
223539501|NCT02199041|DRUG|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
223539502|NCT02199041|DRUG|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
223539503|NCT02199041|DRUG|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
223539504|NCT02199041|DRUG|Melphalan|Given by intravenous infusion as part of the preparative regimen.
223723590|NCT02599272|OTHER|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
223723591|NCT03505762|DRUG|Cyclophosphamide|Given IV
223723592|NCT03505762|DRUG|Doxorubicin Hydrochloride|Given IV
223723593|NCT03505762|OTHER|Laboratory Biomarker Analysis|Correlative studies
223723594|NCT03505762|DRUG|Prednisone|Given PO
223723595|NCT03505762|OTHER|Quality-of-Life Assessment|Ancillary correlative
223723596|NCT03505762|OTHER|Questionnaire Administration|Ancillary studies
223954280|NCT01141075|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
223954281|NCT01240785|DRUG|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
223954282|NCT01240785|DRUG|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
223954283|NCT02815345|DEVICE|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
223539505|NCT02199041|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
223954284|NCT03560154|OTHER|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
223954285|NCT02978183|BIOLOGICAL|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
223954286|NCT02978183|DRUG|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
223954287|NCT02132195|DRUG|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
223539506|NCT02199041|BIOLOGICAL|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) \>2000 for 3 consecutive days.
223539507|NCT02199041|DRUG|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
223539508|NCT02199041|DRUG|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
223954288|NCT03343041|DIETARY_SUPPLEMENT|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
223539509|NCT02199041|DRUG|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
223723597|NCT03505762|BIOLOGICAL|Rituximab|Given IV
223723598|NCT03505762|DRUG|Vincristine Sulfate|Given IV
223954289|NCT03343041|DIETARY_SUPPLEMENT|Standard enteral nutrition|standard enteral nutrition
223954290|NCT00376324|DRUG|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
223539510|NCT02199041|RADIATION|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
223723599|NCT04977908|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid Lispro insulin
223723600|NCT04977908|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Dexcom G6 CGM
223954291|NCT02805075|OTHER|Fructooligosaccharide|Given PO
223954292|NCT02805075|OTHER|Laboratory Biomarker Analysis|Correlative studies
223954293|NCT01317914|OTHER|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
223954294|NCT05352555|DEVICE|Automated vertigo repositioning chair|"Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest."
223954295|NCT05352555|OTHER|Canalith Reposition Maneuver|"Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest."
223954296|NCT05223309|OTHER|Usinf thick loose sutures in seton techingues|"All patients were informed about doing fistulectomy and thick silk Seton suture placement for three months by excising the extrasphincteric part and putting the Seton suture to the intersphincteric part. Then, the second stage of operation includes the excision of the changing low type tract in which the silk Seton placed. We decrease the time of Seton placement in this study for three months to reduce the annoying symptoms of the patients. Therefore, the patient admitted to the operation theater after obtaining written consent. Most of the patients anesthetized by spinal anesthesia. In the operation theater, the patient assumed a lithotomy position~. After that, the injection of a solution, which is a mixture of methylene blue dye and hydrogen peroxide into the external opening of the fistula, was done to find the internal opening. The exit of color dye or bubbles achieved to localized of inner opening from it after using intraoperative proctoscopy examination."
223954297|NCT05990556|PROCEDURE|interventional procedure to block bilateral meningeal blood supply|"The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging."
224106958|NCT05839561|DRUG|Letrozole as monotherapy|Letrozole 5 mg daily orally for 10 days from day 0
224106959|NCT05839561|DRUG|MTX as monotherapy|MTX in a single dose of 100 mg intravenously on day 0
224106960|NCT02261441|OTHER|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
224290968|NCT02806258|RADIATION|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
224290969|NCT02806258|DRUG|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
224290970|NCT06073535|PROCEDURE|Extraction of mandibular third molar|"After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary."
224290971|NCT06073535|DEVICE|i-PRF|20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
224290972|NCT05181332|OTHER|Prediction model|Clinical models were developed and validated to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis.
224290973|NCT02239107|DRUG|N-Acetyl cysteine|
224290974|NCT02239107|PROCEDURE|laparoscopic ovarian drilling|
223954298|NCT03853941|BEHAVIORAL|Intervention|Theory-based communication training programme delivered to healthcare professionals
223954299|NCT05601167|DRUG|nirmatrelvir/ritonavir|Tablets 300/100mg, 2 times a day with 12 ±2 hours interval for 5 days
223954300|NCT05601167|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines' validated at the time of the study
223954301|NCT01772212|DRUG|Terbinafine 250 mg|Test product
223954302|NCT01772212|DRUG|Terbinafine 250 mg|Reference product
223954303|NCT05371821|DEVICE|Echocardiography|Echocardiographic parameters in obese and overweight
223954304|NCT05794074|DIETARY_SUPPLEMENT|luteine and zeaxanthine|luteine and zeaxanthine
223954305|NCT05794074|DIETARY_SUPPLEMENT|luteine|luteine
223954306|NCT05794074|DIETARY_SUPPLEMENT|zeaxanthine|zeaxanthine
223954307|NCT05794074|DIETARY_SUPPLEMENT|Placebo|Placebo
223954308|NCT01709006|RADIATION|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
223954309|NCT03065400|DRUG|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
223954310|NCT05485493|BEHAVIORAL|Internet-Based Solution Focused Short-Term Group Counseling|Sessions will be held online once a week, with an average duration of 60-90 minutes, in the form of 6 sessions, via video-conference applications.
223954311|NCT05485493|OTHER|healthy nutrition education|60-minute single session healthy eating training
223954312|NCT03072862|DEVICE|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
223954313|NCT06034977|DRUG|ADI-PEG20|Lenvatinib + ADI-PEG20 combination treatment.
223954314|NCT01790100|DRUG|VX-135|12 weeks of VX-135
223954315|NCT01790100|DRUG|Ribavirin|12 weeks of ribavirin
223954316|NCT05431322|DRUG|Dexmedetomidine|Initially give loading dose with 0.5 mcg/kg for 10 min and then keep maintenance dose with 0.5 mcg/kg/h until two-lung ventilation.
223954317|NCT02751125|DRUG|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
223954318|NCT05390710|COMBINATION_PRODUCT|LAE005 + Afuresertib + Nab-Paclitaxel|LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
223954319|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
223954320|NCT03650543|DRUG|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
223954321|NCT04243941|DRUG|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells
223954322|NCT01590134|DIETARY_SUPPLEMENT|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
223954323|NCT01590134|DRUG|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
223954324|NCT05371899|DRUG|Chiauranib|Take Chiauranib 50mg orally once daily
224290975|NCT03286478|BEHAVIORAL|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
224290976|NCT03286478|BEHAVIORAL|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
224290977|NCT03286478|BEHAVIORAL|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
223954325|NCT01966679|DRUG|AZD7325|
223954326|NCT01966679|DRUG|Placebo|
223954327|NCT04772963|GENETIC|blood sample|During the arteriography a peripheral venous sampling
223954328|NCT02198300|PROCEDURE|Coronary angioplasty with stent implantation|
223954329|NCT02198300|DRUG|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
223954330|NCT02339259|OTHER|Observation|
223954331|NCT06363604|PROCEDURE|VOMEI + PVI + linear ablation of mitral isthmus|The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
224290978|NCT04936828|OTHER|iCBT-based EMI|Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
223539511|NCT02199041|BIOLOGICAL|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
223539512|NCT02199041|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223539513|NCT03210701|OTHER|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
223954332|NCT06363604|PROCEDURE|Posterior wall isolation|PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.
223954333|NCT01355692|DEVICE|Nd: YLF laser treatment|grid selective retinal treatment
223954334|NCT00853957|DRUG|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
223954335|NCT00853957|DRUG|Amlodipine|Amlodipine 5 mg titrated to 10mg
223539514|NCT03136120|DRUG|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
223954336|NCT02158806|DRUG|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
223954337|NCT02158806|DRUG|Placebo|Matching placebo capsule containing inert bulking agent
223954338|NCT00598234|DRUG|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
223954339|NCT04990037|DRUG|CAN04|Administered intravenously
223954340|NCT04990037|DRUG|FOLFIRINOX|Administered intravenously
223954341|NCT04780685|BIOLOGICAL|hMSC|IV administration
223954342|NCT02054351|DRUG|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
223954343|NCT02056379|DRUG|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
223954344|NCT02056379|DRUG|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
223954345|NCT02340806|DEVICE|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
223954346|NCT06387550|PROCEDURE|Eccentric Training|Warm up phase that include hip circles and shoulder rolls(1 sets of 5 reps), participants are trained on bicycle ergometer for 15 minutes on 2-3 times a week and its duration is increased according to patient tolerance, after that they will be pass through exercise phase that include squating, lunges and leg press (8-10 reps of 3 sets) after that cool down phase begin that include cat cow stretch and oblique stretch (5 reps of 1 set)
223954347|NCT02819609|PROCEDURE|myomectomy|Myomectomy as part of routine clinical care
223954348|NCT02819609|PROCEDURE|endometrial ablation|Endometrial ablation as part of routine clinical care
223954349|NCT02819609|PROCEDURE|uterine artery embolization|Uterine artery embolization as part of routine clinical care
223539515|NCT03136120|PROCEDURE|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
223539516|NCT04544306|OTHER|Partial oral antimicrobial therapy|Switch intravenous antimicrobial therapy to oral after an initial period of 10 days to oral antimicrobial therapy. Antimicrobial choices will be guided by antimicrobial susceptibilities.
223954350|NCT02819609|PROCEDURE|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
223954351|NCT03535636|OTHER|Polysomnography|Sleep architecture will be assessed by polysomnography
223954352|NCT00452452|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|
223954353|NCT03758248|GENETIC|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19\*17 carriers) or higher (CYP2C19\*2 carriers) risk of major adverse cardiovascular events.
223954354|NCT02751957|BEHAVIORAL|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
223954355|NCT03731741|DRUG|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
223954356|NCT00848952|OTHER|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
223954357|NCT03941977|DEVICE|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
224106961|NCT02951273|OTHER|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
224106962|NCT02195830|OTHER|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
223723601|NCT05773430|BEHAVIORAL|Targeted Neurocognitive Training|Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
223954358|NCT03941977|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
223954359|NCT03941977|BIOLOGICAL|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
223954360|NCT02591056|DEVICE|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
223954361|NCT02591056|DEVICE|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
223954362|NCT06671353|BEHAVIORAL|video decision aid|video decision aid for advance care planning
223954363|NCT03477214|DIAGNOSTIC_TEST|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
223954364|NCT02426931|DEVICE|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
223954365|NCT02426931|DEVICE|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
223954366|NCT06681350|DEVICE|Ocular surface imaging|Telemedical examination of high-resolution, all-in-focus images of the cornea, sclera, conjunctiva, and lid margins for montioring of postoperative complications
223954367|NCT07013162|PROCEDURE|High power diode laser + SRT|2W laser will be applied to periodontal pockets
223954368|NCT07013162|PROCEDURE|Low diode diode laser + SRT|A 0.5W low laser is applicated to periodontal pockets after mechanical debridement
223954369|NCT07013162|PROCEDURE|Curettage (SRT) only|Mechanical debridement for pocket
223954370|NCT06692998|OTHER|Rehabilitation|Patients will do hand-wrist joint range of motion, stretching and strengthening exercises for 20 minutes once a day, under the supervision of the same physiotherapist.
223954371|NCT06694441|OTHER|Light Exposure|The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon). For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.
223954372|NCT06694441|OTHER|Placebo|Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux).
223954373|NCT06699745|BEHAVIORAL|Music intervention|In studies, white noise was used as a sedative in infants. It was not used in older children. In school-age children, white noise will be used to reduce fear, anxiety and pain during the endoscopy procedure.
223954374|NCT06699745|BEHAVIORAL|white noise intervention|White noise will be played at a decibel level appropriate for the children in the group.
223954375|NCT06698783|DIETARY_SUPPLEMENT|Fortimel|In this study, patients will be provided with ONS preparation (4 kinds of ready-to-drink special medical food) free of charge during the treatment period. Doctors will provide patients with different flavor nutritional preparations on a weekly basis, 2 bottles per day for patients with 1 flavor per week, and 14 bottles per day for each of 4 flavors at the recommended dosage of 400 kcal per day 28 days
224106963|NCT00121225|DRUG|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
224106964|NCT00366236|DRUG|Nitazoxanide|
224106965|NCT00635102|DRUG|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
224106966|NCT00635102|DRUG|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
224106967|NCT00635102|DRUG|Placebo D-Cycloserine PO and Glycine IV|
224106968|NCT00635102|DRUG|D-Cycloserine PO and placebo Glycine IV|
223723602|NCT04777500|DEVICE|Auricular transcutaneous electrical nerve stimulation device|We are investigating whether taVNS can relieve chronic pain symptoms associated with Fibromyalgia.
223723603|NCT02058667|RADIATION|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
223954376|NCT06699667|DIAGNOSTIC_TEST|Computed tomography|
223954377|NCT06699316|OTHER|Individualized prognostic counselling|Individualized prognostic counselling on life expectancy using the prognostic model 'OncologIQ Palliative'
223954378|NCT06700200|DEVICE|taVNS|transauricular vagus nerve stimulation
224106969|NCT01598181|DEVICE|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
224106970|NCT01598181|DEVICE|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
223954379|NCT06699043|PROCEDURE|nanocrystalline hydroxyapatite in putty form|"decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space.~* Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa~* The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty)."
223954380|NCT06699043|PROCEDURE|Demineralized Bone Matrix allograft putty|decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.
223954381|NCT06699095|DEVICE|Telerehabilitation|Patients will perform a 12 weeks rehabilitation program through telemedicine at home after intensive rehabilitation in hospital. Balance rehabilitation program will be scheduled on the patients' need and ability to be performed three times a week with high levels of satisfaction and safety at home under remote control of the physical therapist.
224106971|NCT04063683|DRUG|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"* anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
224106972|NCT03900676|DRUG|VB-1953 - 2%|Topical Gel
224106973|NCT03900676|DRUG|VB-1953 - 0% (Vehicle)|Topical Gel
224106974|NCT06447012|DIAGNOSTIC_TEST|Colonoscopy|No intervention required from this study, however images will be obtained from patient presenting for colonoscopy
224106975|NCT02437669|DRUG|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
223723604|NCT04416594|OTHER|Data collection|Only data collection
223954382|NCT00264654|DRUG|BRL29060A|
223954383|NCT00264654|DRUG|paroxetine hydrochloride hydrate|
223954384|NCT06700317|DEVICE|HSS1|Surgery performed using HSS1
224106976|NCT01570010|OTHER|Norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
224106977|NCT03792711|DIETARY_SUPPLEMENT|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
224290979|NCT05810558|PROCEDURE|glycine powder air-powered debridement|The intervention treatment consist sof glycine powder air-abrasive debridement (GPAD) using a handheld air polishing device, disposable subgingival nozzle, and glycine powder The nozzle is inserted to the depth of the pocket and all surfaces of the implant (mesial, buccal, distal, lingual) debrided for 5 seconds.
223954385|NCT06698432|DEVICE|caIMR|Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
224290980|NCT05810558|PROCEDURE|Ultrasonic instrumentation|The control treatment consists of supragingival and root debridement using an ultrasonic scaler on low-medium power and coronal polishing with fine grit paste
224290981|NCT05484843|BEHAVIORAL|telenursing training based on self-care theory|"* A training guide based on the self-care theory specific to individuals diagnosed with stroke was prepared.~* Identification of the study/control group (randomization)~* Patients were informed and consents were obtained.~* Sample suitability was evaluated in line with the cognitive levels and inclusion criteria of patients diagnosed with stroke.~* All patients included in the sample group were pre-tested before discharge.~* Training was offered for the study group patients in line with the guide prepared based on self-care theory.~* Tele-nursing training was applied to the study group patients.~* Control group patients were followed up~* Post-tests were administered at the end of the 12-week period~* The training of the control group patients was completed~* Your data has been evaluated"
224290982|NCT05484843|BEHAVIORAL|just observation|For 3 months, patients were observed without intervention. The standard discharge training of the clinic was given.
224290983|NCT02831218|PROCEDURE|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
224290984|NCT02831218|PROCEDURE|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
223723605|NCT02090569|DEVICE|Functional micro-Doppler Sonography (fmDS)|"1. Craniotomy according to MRI images~2. Dura opening~3. Sulcal Localization using neuronavigation~4. Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~5. Exeresis of the dysplasic tissue~6. Control using fmDS before wound closure"
223723606|NCT00831168|BEHAVIORAL|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
223954386|NCT06699719|BEHAVIORAL|Expressive writing|"Participants are asked to complete four 20-minute sessions of a writing task on consecutive days, which is sent to their email address via an online link. Participants are instructed for the next 20 minutes to please use the provided box to write their very deepest thoughts and feelings about a negative issue or personal problem that they are currently being affected by. In their writing, they are encouraged to let go and explore their emotions and thoughts regarding this issue or problem, and to not worry about spelling or grammar. They are asked to consider setting a timer or have a clock handy to make sure they write for 20 minutes. Instructions are accompanied by a text box, which allows participants to write freely for the allotted time."
223954387|NCT06699485|DIETARY_SUPPLEMENT|Low carb diet|Low-carbohydrate diet contains (\<26% carbohydrates) or less than 130 g/d
223954388|NCT06699069|OTHER|Control or Euthyroid group|Fed on normal standard diet
223954389|NCT06699069|OTHER|Hypothyroid group|Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
223723607|NCT06432920|DEVICE|ResWave|Prototype wearable in-phase chest wall vibration device
223723608|NCT02495168|DRUG|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
223723609|NCT02495168|DRUG|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
224106978|NCT05015361|DRUG|Remimazolam Tosilate|Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose
224106979|NCT05015361|DRUG|Propofol Injection.|Treatment group C: Propofol Injection.
223723610|NCT02495168|DRUG|Placebo|Oral inhalation, no active ingredient.
223954390|NCT06699069|OTHER|Hypothyroid group received exercise|Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am
223954391|NCT05082948|OTHER|Suture fixation of stent|Esophageal stent will be placed in the standard of care fashion by the endoscopists using standard gastroscopes. Covered self-expanding metal stent will be placed as per endoscopist preference. After esophageal stent placement, endoscopic suturing will be performed in cases of patients randomized to suture fixation.
223954392|NCT05082948|OTHER|Non suture|Standard placement of stent without suture fixation
223954393|NCT00463944|BEHAVIORAL|Effect of an electronic voting system|
223954394|NCT03582085|BIOLOGICAL|Bacillus Calmette Guerin Vaccine|Experimental
223954395|NCT03582085|BIOLOGICAL|Saline Injection|Placebo
223954396|NCT05219708|DIETARY_SUPPLEMENT|Calorie protein supplement|Participants assigned to the intervention group will receive the calorie and protein supplement (i.e. Ensure Original) to be consumed twice daily between meals for 30 days in addition to standard of care for heart failure
223954397|NCT05219708|OTHER|Control|Standard of care for heart failure
223954398|NCT06857279|DRUG|HLX43 DOSE 1|Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223954399|NCT06857279|DRUG|HLX43 DOSE 2|Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223954400|NCT06857279|DRUG|HLX43 DOSE 3|Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223954401|NCT06903455|OTHER|Fit-folk cardio dance|"Fitfolk is a new cardiovascular dance discipline that combines fitness exercises with music and dance from Chilean and Latin American folklore. This discipline promotes physical and emotional well-being and celebrates national folklore."
223954402|NCT06903455|OTHER|Conventional physical exercise|conventional physical exercise program that uses resistance exercise and cardiorespiratory training
223954403|NCT04832802|BEHAVIORAL|ACCESS|ACCESS-Vets is a customized employment intervention adapted for use in VA healthcare to help Veterans with SCI achieve competitive integrated employment. ACCESS-Vets includes the following elements: discovery, customized employment planning, job development, customized employment negotiation, and accommodations and job retention supports.
223954404|NCT04832802|BEHAVIORAL|IPS|IPS is an evidenced-based practice of supported employment that helps persons with disabilities find and maintain integrated competitive employment. IPS follows eight standardized principles: zero exclusion, integrated services, rapid job search, competitive employment, worker preferences, systematic job development, benefits planning, and time-unlimited supports.
223954405|NCT05620979|BEHAVIORAL|Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.|Providing financial navigation to blood cancer survivors.
223954406|NCT06924398|DRUG|Postoperative EGFR-TKI Therapy|"A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.~Before formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.~If the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment."
224106980|NCT06076330|BIOLOGICAL|20% Albumin|S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr
224106981|NCT06076330|BIOLOGICAL|5% Albumin|5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
224106982|NCT06076330|DRUG|Plasmalyte|Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
223954407|NCT06936696|BEHAVIORAL|Broad Target Speech Recast|"Broad Target Speech Recasts (BTSR) is a speech intervention technique in which an adult immediately recasts a child's incorrect articulation by providing a corrected version of the word in a naturalistic, meaningful context. Unlike traditional articulation therapy, which focuses on isolated sound drills, BTSR integrates correction seamlessly into conversation without requiring the child to repeat or imitate the model.~This approach is rooted in principles of implicit learning, where repeated exposure to accurate speech models facilitates phonological development over time. BTSR differs from traditional minimal pair or phonetic placement techniques in that it does not involve explicit instruction or direct prompts for self-correction. Instead, it provides high-frequency, naturalistic exposure to correct phoneme production within functional language use."
223539517|NCT05173779|PROCEDURE|Left atrial isolation by catheter ablation|Procedure: Right pulmonary vein circumferential isolation + anterior left atrial line (superior mitral annulus to right superior pulmonary vein via the anterior wall) + para-septal line (para-septal mitral annulus to the right inferior pulmonary vein, including right atrial components-especially in and around the proximal coronary sinus) + posterior left atrial line (superior mitral annulus to right superior pulmonary vein via the posterior wall).
223539518|NCT02317627|DRUG|KD025|
223539519|NCT01657357|OTHER|Routine followup|questionnaires
223539520|NCT00279214|DRUG|drotrecogin alfa (activated)|
224106983|NCT01938625|DRUG|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
223539521|NCT01903005|DRUG|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
223539522|NCT00191711|DRUG|Gemcitabine|
224106984|NCT01938625|DRUG|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
223539523|NCT03445767|OTHER|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
223539524|NCT01058850|BIOLOGICAL|Rindopepimut|250 or 500 mcg; intradermal injection
223539525|NCT03064308|OTHER|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
223954408|NCT06936696|BEHAVIORAL|Traditional Speech Therapy|"Traditional Speech Therapy is clinician-led and includes structured, drill-based approaches. Techniques such as placement cues, direct feedback, and reinforcement are used to help children achieve correct articulation. The structured nature of this approach is often more effective in remediating persistent speech errors than parent-implemented strategies alone.~This study examines whether the combination of parent-implemented BTSR and clinician-led traditional articulation therapy leads to improved speech sound production and long-term maintenance of correct articulation in elementary-aged DHH children."
223954409|NCT03127605|DRUG|Inotuzumab Ozogamicin|
223954410|NCT06951412|OTHER|Foot Reflexology Massage|Reflexology Massage
223539526|NCT02642757|BEHAVIORAL|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
223539527|NCT02642757|OTHER|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
223954411|NCT05722912|DRUG|Ruxolitinib|Ruxolitinib Cream
224106985|NCT01938625|DRUG|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
223723611|NCT01129479|DRUG|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
223723612|NCT01129479|DRUG|Placebo pill|Placebo pill each morning with food for 12 weeks.
223723613|NCT02664701|OTHER|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
223723614|NCT02664701|OTHER|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
223954412|NCT03070301|DRUG|LEE011|LEE011 200 mg daily
223954413|NCT03070301|DRUG|everolimus|everolimus 5 mg daily or 2.5mg daily
223954414|NCT04858295|DEVICE|Texting|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.
223954415|NCT04858295|DEVICE|mHealth app|Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
224106986|NCT01938625|DRUG|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
224106987|NCT01938625|DRUG|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
223539528|NCT04272164|OTHER|technical taekwando training|Light jogging followed by star jump, Different running styles (forward, backward and sideways), Stretching exercises (Upper and lower Limb), Pushups and sit ups, Punches (single, double, triple, nonstop punches including speed and power, punches with forward and backward stepping), Kicks (rising kick, front kick, middle kick, drop kick ( in +out+center), Stances (walk stance, punching stance, front deep stance, kicking stance), Blockings (solar block, upper block and lower block), Self -defense (neck gripping, hand gripping, locking), Sand bag drills, Balance training 10 repeatitions of 1 set each, 3 days a week for 8 weeks
223539529|NCT04272164|OTHER|weighted rope jump training|Basic bounce step with both feet 2. Bell jump with both feet 3. Skier's jump 4. Right foot skipping 5. Left foot skipping, 6. Alternate foot step 7. Boxer shuffle 8. Side straddle 9. Scissors 10. Bonus jump with both feet After the preparatory weighted rope jump training (WRJT) for 1 week, subjects in experimental group followed jumping training by repetition method 3 days in a week for 8 weeks in addition to the routine taekwondo training program. 3 sets per week with 30 seconds training duration and 30 seconds rest duration. with progressive increase in the intensity and no. of sets.
223539530|NCT06471543|DRUG|RN0361|Placebo
223723615|NCT02664701|OTHER|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
223954416|NCT05222906|DRUG|Venglustat|tablet; oral
223954417|NCT05222906|DRUG|imiglucerase|sterile lyophilized product; intravenous
224106988|NCT02797561|OTHER|5 year Follow-up|
224106989|NCT04861038|DEVICE|aerSleep II|Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
224106990|NCT01409317|DEVICE|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
224106991|NCT01409317|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
224106992|NCT02088034|BEHAVIORAL|Promotora-led Intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
224106993|NCT02088034|DRUG|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
224106994|NCT02088034|OTHER|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
224290985|NCT02831218|PROCEDURE|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
223954418|NCT03016091|DRUG|Pembrolizumab|anti PD-L1
223954419|NCT04843371|DIAGNOSTIC_TEST|Photoplethysmography|Photoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
224106995|NCT02517879|OTHER|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
224106996|NCT02517879|OTHER|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
224106997|NCT00300027|DRUG|BMS-582664|
224106998|NCT01937312|DRUG|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
224106999|NCT01937312|DRUG|Vehicle|Inactive ingredients used as a placebo comparator
224107000|NCT01937312|DRUG|Prostaglandin analogue|
224107001|NCT05780281|BIOLOGICAL|VIR-7831|VIR-7831 is a fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibody (mAb) derived from antibody S309 from a survivor of SARS-CoV-1.
224107002|NCT05780281|BIOLOGICAL|Placebo|Commercially available 0.9% sodium chloride solution
224107003|NCT05780281|BIOLOGICAL|Remdesivir|Antiviral agent
224107004|NCT06370247|DIAGNOSTIC_TEST|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K|HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K will measure
224107005|NCT01025336|OTHER|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
223539531|NCT06818331|OTHER|SMES+PTX|This intervention involves the combined use of medication and device, where the specific mode electroacupuncture stimulation (SMES) intervention is administered simultaneously with the intravenous infusion of paclitaxel.
223539532|NCT06818331|DRUG|Paclitaxel|Paclitaxel is administered intravenously at a dose of 135-175mg/m², repeated every 3 weeks.
223539533|NCT06818331|DEVICE|Specific mode electroacupuncture stimulation|"Patients assume a supine position. After routine skin disinfection with 75% ethanol, a stainless steel needle (size 0.25mm×40mm) is inserted into GV20 (Baihui), and another stainless steel needle (size 0.25mm×25mm, as described above) is inserted into GV26 (Shuigou). The acupoints are manually stimulated until the patient experiences soreness, distension, or heaviness (the De Qi response). Subsequently, the needles are stimulated using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng Ltd., China) at a frequency of 2/100 Hz and an intensity of 3 mA for 40 minutes (a homemade relay cycled power supply to the electrode, with 6 seconds on and 6 seconds off). The intervention is administered every three weeks, concurrently with paclitaxel treatment"
223539534|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
223539535|NCT01214837|BIOLOGICAL|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
223954420|NCT06023615|OTHER|mHealth app/dashboard|In the interventional group, the subject would receive the standard care that is provided to all post-transplant kidney recipients plus an additional remote monitoring system and follow-up by utilizing an app known as the mHealth app/dashboard. This app is integrated with home-based monitoring of blood pressures, glucoses, and pharmacist-led scheduled televisits.
223539536|NCT01214837|BIOLOGICAL|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
223539537|NCT05650866|DEVICE|Activation of pro-erectile nerves within the pelvic plexus|The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
223539538|NCT04748549|OTHER|Virtual Reality Immersive Relaxation|The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
223954421|NCT04520256|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce energy intake and gradually increase physical activity.
223954422|NCT04520256|BEHAVIORAL|Virtual Reality for Behavioral Weight Loss Skills Training|This program allows participants to practice behavioral weight loss skills using an online virtual reality system accessed via a Web browser.
223954423|NCT04520256|BEHAVIORAL|Tailored Interactive Video Feedback|Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
223954424|NCT04520256|BEHAVIORAL|Tailored Intervention for Structured Physical Activity|Periodic self-assessment is used to guide selection of a physical activity goal. Home-based instructional videos are provided to help meet the selected goal.
223954425|NCT04520256|BEHAVIORAL|Skills Training for Dysregulated Eating|Periodic self-assessment is used to guide selection of skills training modules designed to counter common causes of dysregulated eating (e.g., boredom, stress).
223539539|NCT04748549|OTHER|Immersive Audio Experience|A study team member will play from a library of music or other audible content (audiobook, podcast) that was preselected by the patient.
223539540|NCT04748549|OTHER|Sham Virtual Reality Experience|Subjects will wear VR headsets and headphones but will not view any content or listen to any audible content.
223539541|NCT06996197|OTHER|Bioimpedance analysis|BIA parameters were measured within the first 24h of ICU admission, once the patient was receiving NIV support.
223539542|NCT06994130|DIAGNOSTIC_TEST|Seravue|. This study seeks to test the performance of the SeravueTM (LC-SPIK) device alone or in combination with ultrasound as a tool for HCC surveillance in diverse patient populations and clinical settings.
223723616|NCT02664701|OTHER|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
224290986|NCT02831218|PROCEDURE|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day\[or ticagrelor 90mg po bid\]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
224290987|NCT04943159|DRUG|Afamelanotide|Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
224290988|NCT01011075|DRUG|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
224290989|NCT01011075|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
224290990|NCT03702361|DRUG|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
223954426|NCT04520256|BEHAVIORAL|Platform for Social Support & Friendly Competition|An online platform is provided for participants to connect with each other, support each other, and compete on achievement of behavioral and weight loss milestones.
223954427|NCT06200792|DEVICE|eSense device|eSense device for monitoring electrodermal activity. Visual analogic scale (VAS) for pain and discomfort; TOL-R tests for investigating working performances.
223954428|NCT06051864|DEVICE|Modius Mood Active Device|Battery powered non-invasive neurostimulation device
223954429|NCT06051864|DEVICE|Sham Device|Placebo comparator sham device (no active stimulation)
223954430|NCT06168045|DIAGNOSTIC_TEST|Cerebral tissue oxygenation and blood pressure measurement|Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
223954431|NCT05054751|DRUG|GB491+ Fulvestrant|"GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
223954432|NCT05054751|DRUG|Placebo+Fulvestrant|"Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial."
223954433|NCT02705196|GENETIC|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
223954434|NCT02705196|DRUG|gemcitabine|chemotherapy
223539543|NCT06590038|BEHAVIORAL|Single Session Psychotherapy Intervention|This is a single session intervention which incorporates elements from second- and third wave psychotherapies (Acceptance and Commitment Therapy and Behavioral Activation), as well as basic psychoeducation. Session will take approximately three hours in total, with the option for breaks between blocks of session.
223539544|NCT03162432|DRUG|Vitamin D3|Oral Vitamin D3 therapy.
223954435|NCT02705196|DRUG|nab-paclitaxel|chemotherapy
223954436|NCT02705196|BIOLOGICAL|atezolizumab|anti-PD-L1 antibody
223954437|NCT05492786|BEHAVIORAL|Alert|Non-interruptive best practice alert in the electronic health record
223539545|NCT06633393|OTHER|Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System|At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.
223954438|NCT05492786|BEHAVIORAL|Salient alert features|Larger alert header and body font size, use of different font colors and boldface
223954439|NCT05492786|BEHAVIORAL|High-risk Text|Alert header indicates patient is at high risk for flu and its complications; alert body indicates the percentage of risk (e.g., in the top 3% of risk)
223954440|NCT05492786|BEHAVIORAL|Risk factors|Alert body indicates the top 3 factors contributing to the high risk
223954441|NCT04526587|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood, tissue, ascites or pleural effusions, and fresh body fluids or fresh biopsy samples
223954442|NCT04526587|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223954443|NCT04526587|OTHER|Medical Chart Review|Patient's electronic health records are reviewed
223954444|NCT02221934|DEVICE|Altius|Electrical signal
224107006|NCT01025336|OTHER|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
223539546|NCT06633393|OTHER|Feedback on Ophthalmic Examinations|At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
223723617|NCT03026101|OTHER|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
223723618|NCT00453297|DRUG|MF101|
223954445|NCT05953415|DEVICE|active iTBS|Participants in this group will receive two sessions of 1800-pulse active stimulation per day, with an intersession interval of at least 50 minutes. The stimulation will be administered on workdays over a period of 3 weeks, totaling 15 days.
223954446|NCT05953415|DEVICE|sham iTBS|Participants in this group will receive two sessions of 1800-pulse sham stimulation per day, with an intersession interval of at least 50 minutes. The stimulation will be comprehensively mimic the active condition, and also administered on workdays over a period of 3 weeks, totaling 15 days.
224107007|NCT02910440|DRUG|DCL-101 vs Golytely|
224107008|NCT01046188|OTHER|Knowledge Questionnaire|Administered before and after teaching intervention
224107009|NCT01046188|OTHER|Perceived Stress Scale|Administered before and after teaching intervention
224107010|NCT01046188|OTHER|Satisfaction questionnaire|Administered after the intervention and at study completion
224107011|NCT01046188|OTHER|Web-based IVF teaching|Web-based IVF teaching
224107012|NCT01046188|OTHER|Didactic lecture|Didactic lecture
223539547|NCT00027560|BIOLOGICAL|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
223539548|NCT00027560|DRUG|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
223539549|NCT00027560|DRUG|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
223954447|NCT06363487|DRUG|Semaglutide, 0.5 mg/mL|Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
223954448|NCT06363487|OTHER|Placebo, 0.9% NaCl 1.5mL|Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
223954449|NCT05609097|OTHER|PRIME|PRIME is a a 'hybrid' aerobic-resistance (cardio and weights) program designed to target all major muscle groups and address the muscle limitations responsible for reduced fitness in the elderly. This occurs by minimizing the central limitations to more traditional exercise by delivering an ideal exercise stimulus to muscles in a way in which the heart is not a limiting factor. Each exercise involves contractions of specific isolated muscle groups with a moderate load, defined as 40%-50% of their maximal voluntary capacity.
223539550|NCT00027560|DRUG|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
223539551|NCT00027560|PROCEDURE|allogeneic bone marrow transplantation|
223539552|NCT00027560|PROCEDURE|peripheral blood stem cell transplantation|
223539553|NCT05638828|DRUG|RD14-01 Cell injection|RD14-01 Cell injection
223539554|NCT01880151|DEVICE|EEG|EEG recorded during a resting condition and during an episodic memory task condition
223539555|NCT03294005|DIAGNOSTIC_TEST|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
223954450|NCT05609097|OTHER|COMBO|"COMBO training includes both aerobic (cardio) and resistance (weightlifting) exercises. The aerobic component will be done on the stationary bicycle at 10-15 min duration at a target exercise intensity of 40-50% of VO2peak. This will feel like an intensity that is fairly light to somewhat hard, progressing gradually according to tolerance up to 20 mins. Intensity will be adjusted so that the difficulty remains in the target zone. The resistance component involves eight exercises, two sets of 10 repetitions, initially prescribed at 50-60% 1 repetition max. Subject will lift about half of their predicted maximal strength, 10 times, on 2 separate occasions with a rest between. Thereafter, the difficulty will be increased by approximately 10% when difficulty drops below the target range."
223954451|NCT00804765|OTHER|Therapeutic education|Intensive training individual and collective teaching
223539556|NCT00939107|PROCEDURE|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
223539557|NCT00939107|PROCEDURE|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
223539558|NCT06005532|DRUG|Adalimumab|Adalimumab injection 40 mg / 0.8 ml
223539559|NCT06005532|DRUG|Humira|Adalimumab injection 40 mg / 0.4 ml
223539560|NCT02135744|BEHAVIORAL|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
223539561|NCT05498532|DIAGNOSTIC_TEST|Functional MRI|Anatomical MRI : T2 fiesta, SSFE, HASTE ; 3D T2 ; T1 FAT SAT ; LAVA Functional MRI : T1 FAT SAT with gadolinium
223539562|NCT00140023|DRUG|Azithromycin microspheres 2.0 single dose|
223539563|NCT02905279|BEHAVIORAL|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
223539564|NCT02905279|BEHAVIORAL|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
223539565|NCT02905279|BEHAVIORAL|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
223539566|NCT02905279|BEHAVIORAL|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
223954452|NCT00804765|OTHER|Follow-up|classical follow-up with two individual consultations
223539567|NCT06112470|OTHER|Interview|Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.
223539568|NCT01506024|PROCEDURE|Total hip arthroplasty direct lateral approach|
223539569|NCT01506024|PROCEDURE|Total hip arthroplasty posterior approach|
223539570|NCT01506024|PROCEDURE|Total hip arthroplasty, anterior approach|
223539571|NCT02250976|DRUG|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
223539572|NCT02250976|DRUG|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
223539573|NCT02250976|DRUG|Livaro tab. 2mg|Pitavastatin Ca 2mg
223539574|NCT00161889|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
223539575|NCT01102595|DRUG|Temozolomide|"* Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
223539576|NCT01102595|DRUG|Bevacizumab|"* 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis."
223954453|NCT03126266|RADIATION|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
223954454|NCT04593004|DEVICE|Teledermatology|Patients will be assessed and followed-up by trained physicians through a store-and-forward system (teledermatology online service - Evita® app), which allows patients to upload pictures of skin areas affected by acne as well as their symptoms or questions related to their disease.
223539577|NCT01102595|RADIATION|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
223539578|NCT02735018|DRUG|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
223539579|NCT02735018|DRUG|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
223539580|NCT03426527|DRUG|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
223539581|NCT03426527|DRUG|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
223539582|NCT03426527|OTHER|General Anaesthesia|Using propofol, fentanyl and atracurium
223539583|NCT01674504|DRUG|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
223954455|NCT04593004|OTHER|Face-to-face consultation|Patients will be assessed and followed-up by trained physicians through regular face-to-face outpatient consultations.
223954456|NCT02173561|BEHAVIORAL|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
223954457|NCT02173561|BEHAVIORAL|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
223954458|NCT00755248|PROCEDURE|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
223954459|NCT01092689|DRUG|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP
223539584|NCT04797377|BIOLOGICAL|Autologous ovarian PRP injection|The same day, within 1 hour of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into both ovaries using 11.8 inch (30 cm) single lumen 21G needles. The ovaries will be reached using needle guide preventing vascular or other structures rupture. The needle will be advanced into the centre of the ovarian medula without rotation. The correct tip placement will be confirmed by ultrasound. The activated PRP will be slowly introduced during careful retraction of the needle across the previously traversed ovarian cortex. The final PRP volume will be deposited under the ovarian capsule and the needle exit the ovary. Approximately 0.5 ml of the PRP solution will be injected into each ovary. After the procedure, the patients will be taken to the recovery room and will be observed for 30 minutes and also be discharged home on the same day.
223539585|NCT05595200|DIAGNOSTIC_TEST|Level III portable sleep study|Recruited patients will undergo an overnight cardiorespiratory study using a Level III portable device before hospital discharge
223954460|NCT03272815|DEVICE|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
223539586|NCT02903823|DRUG|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
223954461|NCT03272815|DEVICE|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
223954462|NCT01255709|DRUG|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
223539587|NCT05510518|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|• The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
223539588|NCT00772278|PROCEDURE|carotid artery stenting|carotid artery angiography, angioplasty and stenting
223539589|NCT00772278|PROCEDURE|carotid endarterectomy|open surgery including endarterectomy
223954463|NCT01255709|DRUG|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
223954464|NCT01255709|DRUG|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
223954465|NCT01420328|DRUG|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin) for 6 weeks
223539590|NCT03795649|DRUG|Tranexamic Acid|Imunomodulatory effect
223539591|NCT03886948|DRUG|LY3074828|Administered subcutaneously (SC)
223954466|NCT01420328|DRUG|Placebo|Placebo treatment for 6 weeks
223954467|NCT01379677|DRUG|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
223954468|NCT01379677|DRUG|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
223954469|NCT00473031|BEHAVIORAL|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
223954470|NCT00473031|BEHAVIORAL|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
223954471|NCT00473031|BEHAVIORAL|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
223954472|NCT01072149|DRUG|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
223954473|NCT01072149|DEVICE|placebo|placebo
223954474|NCT05908136|OTHER|restorative materials|two types of composite with strip crown in primary molars
223954475|NCT03800563|DEVICE|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
223539592|NCT03886948|DEVICE|Pre-filled syringe (PFS)|PFS used to administer LY3074828
223539593|NCT03886948|DEVICE|Autoinjector (AI)|AI used to administer LY3074828
223539594|NCT01139541|BEHAVIORAL|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
223954476|NCT04119700|PROCEDURE|Muco-muscular endorectal advancement flap after fistulectomy|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
223954477|NCT04119700|PROCEDURE|Primary sphincter reconstruction after fistulectomy|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
223954478|NCT04161976|DRUG|LY900027|LY900027 administered to participants with T1DM using CSII.
223954479|NCT04161976|DRUG|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
223954480|NCT01846156|DRUG|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics \& Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
223539595|NCT05545592|OTHER|Low oestrogen dosage|From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
223539596|NCT05211349|OTHER|Dual-Task Timed Up and Go Test (cognitive)|It evaluates balance with a simultaneous cognitive and motor task. The cognitive task of the test is serial triple subtraction while the TUG test is a motor task. Balance performance will be recorded in seconds.
223539597|NCT05211349|OTHER|3-m Backward Walk Test|It is used to assess fall risk and balance. It is calculated in how many seconds an individual can walk backward a marked distance of 3 meters.
223954481|NCT05890781|PROCEDURE|Skin biopsy|Skin biopsy
223954482|NCT05890781|PROCEDURE|Fresh tumor sample|Fresh tumor sample
223954483|NCT05890781|BIOLOGICAL|Blood sample|Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached
223954484|NCT05890781|PROCEDURE|Healthy tissue from the tumor|Healthy tissue from the tumor site whenever possible
223954485|NCT05890781|PROCEDURE|Spinal cerebrospinal fluid (SCF)|Spinal cerebrospinal fluid (SCF) whenever possible
223954486|NCT03799965|OTHER|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
223954487|NCT03799965|OTHER|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
223954488|NCT01602900|DRUG|GSK356278|Investigational Medicinal Product
223954489|NCT01602900|DRUG|Rolipram|Challenge Agent
223954490|NCT03578744|PROCEDURE|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
223539598|NCT05211349|OTHER|Modified Four Square Step Test|It is a performance test that evaluates dynamic balance in stroke individuals with the ability to avoid obstacles and take steps in all directions. Balance performance is recorded in seconds.
223539599|NCT05211349|OTHER|Timed Up and Go Test|It is used to assess balance and functional mobility. The participant is asked to get up from the chair she/he is sitting in, walk the marked distance of 3 meters and return to her/his seat again. The elapsed time is recorded in seconds.
223539600|NCT05211349|OTHER|Berg Balance Test|It consists of 14 items and evaluates dynamic balance and functional mobility in stroke. The maximum score is 56. Higher scores indicate better balance.
223539601|NCT00658489|BEHAVIORAL|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
223954491|NCT00924755|DEVICE|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
223954492|NCT05396755|PROCEDURE|Endoscopic retrograde cholangiography (ERC)|invasive evaluation of the biliary tract with ERC and endoscopic interventions every 8 weeks until 6 months (24 weeks)
223954493|NCT04745338|DEVICE|3max cool shaping device|cryolipolysis sessions are applied on abdomen area each session for 40 min. each
223954494|NCT04745338|DIETARY_SUPPLEMENT|low calolric diet|low caloric diet (1200cal/day)
223954495|NCT05444777|DRUG|Ketamine Hydrochloride|Ketamine was given prior to wound closure.
223539602|NCT01123148|DEVICE|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
223954496|NCT03336749|BEHAVIORAL|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
223954497|NCT03336749|OTHER|Control group|Traditional task-specific training
223539603|NCT05367193|PROCEDURE|pars plana vitrectomy|pars plana vitrectomy for vitreoretinal disease in highly myopic eyes
223539604|NCT05367193|DEVICE|NGENUITY® 3D Visualization System (Alcon, TX, USA)|Injection of ICG to stain internal limiting membrane
223539605|NCT00355030|DRUG|somatropin|0.05 mg/kg/day
223539606|NCT00355030|DRUG|leuprorelin|11.25 mg/3 months
223539607|NCT05124717|DRUG|Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)|One tablet of the Test product was administered orally with 240 mL of water.
223539608|NCT05124717|DRUG|Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)|One tablet of the Reference product was administered orallyn with 240 mL of water.
223539609|NCT00983866|BEHAVIORAL|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
223539610|NCT05143333|OTHER|DANA app|The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
223539611|NCT00356070|DRUG|Strattera|
223539612|NCT00593060|DRUG|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
223539613|NCT00593060|DRUG|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
223539614|NCT06495957|OTHER|Electroacupuncture group|Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.
223539615|NCT06495957|OTHER|Micro-acupuncture group|After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
223723619|NCT02941978|BEHAVIORAL|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
223539616|NCT02690766|BEHAVIORAL|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
223723620|NCT02941978|BEHAVIORAL|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
223723621|NCT05985889|OTHER|Robot|You have to walk with a robot mounted on your lower limb. To move, to change direction.
223723622|NCT05985889|OTHER|Fizio|Patients do state-funded physical therapy.
223539617|NCT01125410|DRUG|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
223539618|NCT01125410|DRUG|Clindamycin|vaginal cream, 2%, once daily for 7 days
223723623|NCT05985889|OTHER|EXE1|Patients undergo intensive virtual reality therapy once a day.
223539619|NCT02960633|DEVICE|Corail with collar.|
223539620|NCT02960633|DEVICE|Corail without collar.|
223539621|NCT00002286|DRUG|Zidovudine|
223539622|NCT04165863|PROCEDURE|total knee replacement surgery|total knee replacement surgery
223539623|NCT01747915|DRUG|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
223723624|NCT05985889|OTHER|EXE2|Patients undergo intensive virtual reality therapy twice a day.
224290991|NCT04899193|DRUG|Pergoveris FD|Participants will be administered with 900 IU of recombinant human follicle-stimulating hormone (r-hFSH) and 450 IU of recombinant human luteinizing hormone (r-hLH) freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
224290992|NCT04899193|DRUG|Pergoveris Liquid|Participants will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Pergoveris Liquid) as subcutaneous injection using disposable pen-injector on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
224290993|NCT04899193|DRUG|Gonal-f|Participants will be administered with 900 IU of folitropin alfa (Gonal-f) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
223539624|NCT01747915|DRUG|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
223539625|NCT01747915|DRUG|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
223723625|NCT05985889|OTHER|EXE+ROB|The patients intensively performed 1 virtual reality therapy and 1 robotic therapy every day.
223723626|NCT03793777|DIETARY_SUPPLEMENT|Aronia|daily supplementation
223723627|NCT03793777|DIETARY_SUPPLEMENT|Placebo|daily supplementation
224290994|NCT04899193|DRUG|Luveris|Participants will be administered with 450 IU of lutropin alfa (Luveris) as subcutaneous injection on Day 1 in investigation period 1 or investigation period 2 or investigation period 3. There will be a washout period of 6 days between investigation period 1 and investigation period 2 and 17 days between investigation period 2 and investigation period 3.
224290995|NCT06217861|BIOLOGICAL|VGM-R02b|Administered as specified in the treatment arm.
224290996|NCT05991128|DRUG|Ferric derisomaltose|After baseline assessments patients will be randomised in a 1:1 ratio to receive ferric derisomaltose IV or placebo (normal saline). In the Treatment group, Ferric derisomaltose will be administered according to the dosing schedule.
224290997|NCT05991128|DRUG|Placebo|n the placebo group, patients will receive the equivalent number of normal saline injections.
224290998|NCT04124198|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Accelerated or hyper-fractionated radiotherapy
224290999|NCT04124198|DRUG|Cisplatin|Concurrent weekly cisplatin 40 mg/sqm to fit patients
224291000|NCT04124198|DRUG|Nimorazole.|Concurrent nimorazole
224291001|NCT04124198|PROCEDURE|Transoral Robotic Surgery (TORS) with neck dissection|Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
224291002|NCT01131793|DEVICE|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
224291003|NCT02017860|DRUG|Everolimus|Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
224291004|NCT06213467|DEVICE|diode laser 940nm|Exposure for the two implants was done at the same visit, with one implant being exposed using diode laser and the other implant using traditional method
224291005|NCT02488330|DRUG|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
224291006|NCT02488330|DRUG|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
223539626|NCT00682279|DRUG|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
223539627|NCT01330095|DIETARY_SUPPLEMENT|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
223539628|NCT05542446|DRUG|Colistin|"Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection."
223539629|NCT02961270|DRUG|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
223539630|NCT06118645|DRUG|cadonilimab combined +paclitaxel (albumin-bound)|"1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).~2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase"
223539631|NCT00002493|DRUG|cisplatin|
223539632|NCT00002493|DRUG|doxorubicin hydrochloride|
223539633|NCT00002493|RADIATION|low-LET photon therapy|
223954498|NCT02841020|PROCEDURE|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
223539634|NCT00988156|DRUG|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
223954499|NCT00913055|DRUG|octreotide acetate|subcutaneous implant
223954500|NCT03529435|BEHAVIORAL|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
223954501|NCT03529435|BEHAVIORAL|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
223954502|NCT02344706|DEVICE|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
224291007|NCT02488330|DRUG|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
224291008|NCT03242460|DRUG|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
224291009|NCT03242460|DRUG|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
224291010|NCT03242460|DRUG|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
224291011|NCT00794391|BEHAVIORAL|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller \& Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
224291012|NCT00794391|BEHAVIORAL|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
224291013|NCT05579574|DRUG|BMS-986322|Specified dose on specified days
224291014|NCT05579574|DRUG|Loestrin|Specified dose on specified days
224291015|NCT03738020|DEVICE|HA IDF (YVOIRE classic)|Treatment with HA IDF
224291016|NCT03738020|DEVICE|Restylane|Treatment with Restylane
224291017|NCT04671030|DRUG|Neostigmine and Glycopyrrolate|Intravenous followed by transdermal administration of the two drug combination.
224291018|NCT04671030|DEVICE|Iontophoresis|Application of direct current to skin using an FDA-approved device
224291019|NCT00946348|DRUG|Dronabinol|Dronabinol 10 mg or 15 mg
224291020|NCT00946348|DRUG|Cannabis|Cannabis cigarette
224291021|NCT01242930|DRUG|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
224291022|NCT01242930|DRUG|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
224291023|NCT01242930|DRUG|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
224291024|NCT03743792|DIETARY_SUPPLEMENT|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
223723628|NCT05231395|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
223954503|NCT01236144|DRUG|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1\&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
223539635|NCT00988156|DRUG|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
223954504|NCT01236144|DRUG|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1\&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
223539636|NCT01211561|DRUG|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
223723629|NCT05231395|OTHER|Control Group|"Control group will be given breathing exercises 120 times/day, 7days/week, for 8 weeks as home program.~Control group will be followed-up by telephone once a week"
223723630|NCT00320892|DRUG|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
223723631|NCT03143894|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
223723632|NCT03143894|OTHER|Sham tDCS|Sham Transcranial direct current stimulation (tDCS)..
223723633|NCT00321802|DRUG|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
223539637|NCT01211561|DRUG|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
223723634|NCT00321802|DRUG|Placebo|Placebo
223723635|NCT04956497|DEVICE|extracorporeal membrane oxygenation (ECMO)|ECMO under ongoing cardiopulmonary resuscitation (eCPR) in patients with refractory cardiac arrest
223954505|NCT01236144|DRUG|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
223539638|NCT02499887|DRUG|beclamethasone dipropionate|Inhaler
223539639|NCT02499887|DRUG|albuterol|Inhaler
223539640|NCT02499887|DRUG|Prednisone|Oral corticosteroid
223539641|NCT06338163|COMBINATION_PRODUCT|Polihexanide-based bundle|Pre- and intra-operative decontamination will be accomplished in the treatment (experimental) arm with Polihexanide-based products
223954506|NCT04004832|DIAGNOSTIC_TEST|there is not any intervention procedure|there is not any intervention procedure
224291025|NCT03743792|DIETARY_SUPPLEMENT|Control breakfast|Control drink + buttermilk biscuit sandwich
223539642|NCT06338163|COMBINATION_PRODUCT|Standard bundle|Pre- and intra-operative decontamination will be accomplished in the control arm with normal soap/shampoo and saline solution
223539643|NCT00142337|DRUG|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
223539644|NCT00142337|DRUG|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight \>60 kg) once daily, starting at the onset of labor and for one month postpartum
223539645|NCT00940550|DRUG|Prolonged-release melatonin|2 mg tablet, once.
223539646|NCT00940550|DRUG|Temazepam|20 mg capsule, once
223539647|NCT00940550|DRUG|Zolpidem|10 mg capsule, once
223539648|NCT00940550|DRUG|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
223539649|NCT02808923|OTHER|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
223723636|NCT04626297|DRUG|Lebrikizumab|Given SC
223723637|NCT04626297|DRUG|Placebo|Given SC
223723638|NCT04350489|OTHER|Non-surgical periodontal treatment|Conventional non-surgical periodontal treatment were performed
223723639|NCT04804878|PROCEDURE|Collection of blood, tissue, and other biological samples.|Behavioral health assessments, including quality of life.
224291026|NCT01678001|DRUG|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
224291027|NCT01206816|DRUG|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
224291028|NCT03525743|DEVICE|NICOM (Non invasive cardiac output monitor)|Non invasive hemodynamic device utilizing bioreactance
224291029|NCT04963595|DRUG|Pyrotinib|400 mg once daily
224291030|NCT04963595|DRUG|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsules on day 1 to be taken at the hospital, and on day 8 at home.
224291031|NCT04963595|DRUG|Inetetamab|8mg/kg iv day 1 followed by 6mg/kg iv day 1, cycled every 21 days
224291032|NCT03050203|OTHER|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
224291033|NCT03050203|OTHER|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
223539650|NCT02808923|OTHER|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
223539651|NCT03712774|OTHER|EORTC QLQ C30|standardized questionaire
223539652|NCT03712774|OTHER|EORTC QLQ OES-18|standardized questionaire
223539653|NCT03712774|OTHER|EORTC OG-25|standardized questionaire
223539654|NCT01805284|DRUG|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
223539655|NCT02895516|DEVICE|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
224107013|NCT06338449|BEHAVIORAL|Aerobic training (AT)|An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
224107014|NCT06338449|BEHAVIORAL|Resistance training (RT)|Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
223539656|NCT05254353|PROCEDURE|Analyses of proximal and distal samples|Evaluate the difference between proximal and distal CSF samples
223539657|NCT00483678|OTHER|counseling intervention|
223539658|NCT00483678|OTHER|questionnaire administration|
223539659|NCT00483678|PROCEDURE|psychosocial assessment and care|
223539660|NCT01007175|BIOLOGICAL|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
223539661|NCT01007175|BIOLOGICAL|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
223539662|NCT01007175|BIOLOGICAL|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
223539663|NCT01007175|BIOLOGICAL|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
223539664|NCT01007175|BIOLOGICAL|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
223723640|NCT04804878|OTHER|Medical Chart Review|Health data abstracted directly from patient's health records
223539665|NCT02476604|BEHAVIORAL|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
223539666|NCT03138317|BIOLOGICAL|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
223539667|NCT03138317|BIOLOGICAL|Plasma|This group will receive a knee injection with 6 ml of plasma.
223723641|NCT00808366|DRUG|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
223723642|NCT00808366|DRUG|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
223539668|NCT03138317|BIOLOGICAL|Placebo|This group will receive a knee injection with 6 ml saline solution.
223539669|NCT01004536|DEVICE|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
223539670|NCT01004536|OTHER|no treatment|left untreated during the study period
223539671|NCT00104988|DRUG|temozolomide|75 mg/m\^2/day PO daily for 6 weeks followed by a 2-week break
223539672|NCT00104988|DRUG|thalidomide|200 mg/day PO daily
223723643|NCT04829708|OTHER|MRI Surveillance|Receive MRI surveillance
223539673|NCT00615576|DRUG|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
223723644|NCT04829708|RADIATION|Prophylactic Cranial Irradiation|Receive PCI
223723645|NCT05862233|DRUG|MIL62|An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at Week 1 and Week 3.If the treatment is effective, MIL62 will continue be administered at W25 and W27
223723646|NCT05862233|DRUG|Cyclosporine|Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d in 2 divided doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks±3 days until the target blood concentration of 125\~175 ng/mL was reached.Optimized cyclosporine dose will be maintained for a maximum 52 weeks dependent on response and then tapered over 8 weeks.
224291034|NCT02310243|DRUG|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
224291035|NCT06205017|DIETARY_SUPPLEMENT|Foods for Special Medical Purposes|"In order to facilitate patient weaning and to improve the enjoyment of foods used in this semi-liquid phase, our Center intends to test Foods for Special Medical Purposes (AFMS) to ensure better nutritional intake, including vitamin D3 and calcium, good palatability, and thus better adherence to the recommended nutritional indications in the immediate postoperative period than the homogenized foods used in the standard diet."
224291036|NCT02384941|DRUG|Placebo|Placebo once daily, before first meal of the day.
224291037|NCT02384941|DRUG|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
224291038|NCT03000218|DRUG|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
224291039|NCT03000218|DRUG|Metformin|Day 29 to 56: Metformin 500mg bid
224291040|NCT03000218|DRUG|Placebo|Day 1 to 56: Placebo bid
224291041|NCT00485628|DRUG|Atomoxetine Hydrochloride|
224291042|NCT00378183|DRUG|risperidone|
224291043|NCT02493777|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
224291044|NCT02493777|DRUG|Placebo|
224291045|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
224291046|NCT03110068|DIAGNOSTIC_TEST|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
224291047|NCT00124995|DRUG|terbutaline|
224291048|NCT01832935|DRUG|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
224291049|NCT01832935|DRUG|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
224291050|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
224291051|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
224291052|NCT03519659|DIAGNOSTIC_TEST|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
224291053|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
224291054|NCT03519659|DIAGNOSTIC_TEST|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
224291055|NCT01705236|DRUG|Fingolimod|All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
224291056|NCT05348980|DRUG|Phenylephrine Hydrochloride 4 mg|Intramuscular Phenylephrine HCL 04 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
224291057|NCT05348980|DRUG|Phenylephrine Hydrochloride 8 mg|Intramuscular Phenylephrine HCL 08 mg were administered as prophylactic stat dose in Vastus lateralis muscle of thigh 05 minutes before giving spinal anesthesia.
223723647|NCT02442869|BEHAVIORAL|Stage 1 Treatment as usual (TAU)|4-8 weeks of the treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
223954507|NCT01912599|DEVICE|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
223954508|NCT01912599|DEVICE|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
223954509|NCT03807934|OTHER|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
223954510|NCT01075854|DRUG|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
223723648|NCT02442869|BEHAVIORAL|Stage 1 CAMS|4-8 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
223539674|NCT00615576|DRUG|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
223539675|NCT00812955|DRUG|ABT-143|Once daily for 8 weeks
223539676|NCT00812955|DRUG|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
223539677|NCT00650052|DRUG|Zonisamide Capsules 100 mg|100mg, single dose fasting
223539678|NCT00650052|DRUG|Zonegran® Capsules 100 mg|100mg, single dose fasting
223539679|NCT05499026|DRUG|Chenodeoxycholic Acid|Bile acid
223539680|NCT00775957|PROCEDURE|FLT-PET scan|imaging scan
223539681|NCT00775957|PROCEDURE|FDG-PET scan|imaging scan
223539682|NCT06061692|DRUG|Tongxinluo Capsule|4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
223539683|NCT04251832|DRUG|Sodium Thiosulfate|Ultrasound guided percutaneous lavage with and without Sodium Thiosulfate
223539684|NCT02536716|PROCEDURE|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
223539685|NCT02536716|PROCEDURE|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
223539686|NCT05658718|PROCEDURE|refractive surgery|refractive surgery
223539687|NCT01772550|DEVICE|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
223539688|NCT01772550|DEVICE|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
223539689|NCT01875081|BIOLOGICAL|Livercellgram|"Livercellgram~* Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20\~25℃~  * Injection Method: Directly inject into liver through hepatic artery"
223539690|NCT00486356|DRUG|capecitabine|
223539691|NCT00486356|DRUG|carboplatin|
223539692|NCT00486356|DRUG|epirubicin hydrochloride|
223539693|NCT00486356|GENETIC|microarray analysis|
223539694|NCT00486356|GENETIC|polymorphism analysis|
223539695|NCT00486356|OTHER|pharmacological study|
223539696|NCT06375395|DEVICE|Active tACS Device|Transcranial Alternating Current Stimulation
223539697|NCT06375395|DEVICE|Sham tACS Device|Placebo Device that simulates active tACS treatment
223539698|NCT00820144|BIOLOGICAL|CTB by nasal way|
223539699|NCT00820144|BIOLOGICAL|absorption of CTB by oral way|absorption of CTB by oral way
223539700|NCT00820144|BIOLOGICAL|absorption of dukoral by oral way|absorption of dukoral by oral way
223539701|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
223539702|NCT00820144|BIOLOGICAL|absorption of CTB by sublingual way|absorption of CTB by sublingual way
223539703|NCT01815424|DRUG|placebo|placebo BID for 16 weeks and then re-randomized into active groups
223539704|NCT01815424|DRUG|CP-690,550|CP-690,550 5mg BID for 52 weeks
223539705|NCT01815424|DRUG|CP-690,550|CP-690,550 10mg BID for 52 weeks
223539706|NCT03481842|BIOLOGICAL|Linifanib|in a minimally sufficient therapeutic dose
223539707|NCT03481842|DRUG|BIBW2992|in a minimally sufficient therapeutic dose
223539708|NCT03481842|DRUG|Axitinib|in a minimally sufficient therapeutic dose
223539709|NCT01309204|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
223539710|NCT01309204|DRUG|Vehicle|Inactive ingredients used as a placebo for masking purposes
223539711|NCT01309204|DRUG|Brinzolamide 1% ophthalmic suspension|
223539712|NCT01309204|DRUG|Brimonidine tartrate 0.2% ophthalmic solution|
223539713|NCT00241072|DRUG|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
223539714|NCT00595296|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
223539715|NCT03439046|DRUG|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
223539716|NCT03439046|DRUG|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
223539717|NCT03439046|DRUG|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
223539718|NCT03439046|DRUG|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
223539719|NCT05447390|DIAGNOSTIC_TEST|Handgrip strength test|The Jamar Hydraulic Hand Dynamometer device is used for measuring the handgrip strength test
223954511|NCT03699761|PROCEDURE|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
223954512|NCT03699761|PROCEDURE|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
223954513|NCT02077114|BIOLOGICAL|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
223539720|NCT04244071|DEVICE|Bair Paws Blanket 81003 and FOC device 87500|This study is a randomized, pretest - posttest controlled experimental design.
223539721|NCT04244071|OTHER|routine hospital care|routine hospital care
223539722|NCT03516175|DEVICE|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
223539723|NCT03516175|DEVICE|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
223539724|NCT04555863|DEVICE|haMSter smartphone app|the app tracks patient reported outcomes
223539725|NCT00257946|PROCEDURE|Repair of CDH w/SIS Gold|
223539726|NCT00257946|PROCEDURE|Repair of CDH w/Alloderm|
223539727|NCT05080439|OTHER|Diacutaneous Fibrolysis|Application of diacutaneous fibrolysis in teres major
223539728|NCT05080439|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
223539729|NCT03374358|DRUG|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
223539730|NCT03183063|DEVICE|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
223954514|NCT04501588|BEHAVIORAL|Responsive training with no video feedback|Parents will receive responsive training, but will not watch themselves on video to reflect on their strategy use.
223954515|NCT04501588|BEHAVIORAL|Responsive training with video feedback|Parents will receive responsive training and watch themselves on video to reflect on their strategy use.
224291058|NCT01344174|DRUG|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
224291059|NCT02107820|BEHAVIORAL|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
224291060|NCT02107820|DEVICE|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
224291061|NCT06319937|DIAGNOSTIC_TEST|Ultrasound|Ultrasound
224291062|NCT02987023|PROCEDURE|uterus transplantation|Uterus transplantation from live donor
224291063|NCT03716635|PROCEDURE|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
224291064|NCT03716635|PROCEDURE|normal saline|a room temperature saline is used as a final flush after mechanical preparation
224291065|NCT05040308|OTHER|Integrating PrEP delivery|Integration of PrEP delivery services in NSP and MAT programs
224291066|NCT02370914|DEVICE|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
224291067|NCT02370914|BEHAVIORAL|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
224291068|NCT06051084|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
224291069|NCT06051084|BEHAVIORAL|App-Delivered Coloring|An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
224291070|NCT03898830|DEVICE|eon™ FR 1064 nm device|The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
223954516|NCT02081976|BEHAVIORAL|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
223954517|NCT02081976|OTHER|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
223954518|NCT03883984|DRUG|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
223954519|NCT03883984|DRUG|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
223954520|NCT00087724|DRUG|FK962|
223539731|NCT03183063|DEVICE|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
223539732|NCT03183063|DEVICE|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
223539733|NCT01799486|DRUG|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
223539734|NCT01799486|DRUG|Enecavir|0.5 mg monotherapy supplied in tablets.
223539735|NCT01799486|DRUG|Adefovir|10 mg monotherapy supplied in tablets.
223539736|NCT01127633|DRUG|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
223539737|NCT01127633|DRUG|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
223539738|NCT02676648|BEHAVIORAL|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
223954521|NCT02283632|PROCEDURE|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
223539739|NCT02676648|BEHAVIORAL|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
223539740|NCT02676648|BEHAVIORAL|Text messages|We will send participants text messages, to support intervention adherence.
223539741|NCT02676648|BEHAVIORAL|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
223539742|NCT00037440|GENETIC|Polymorphisms measured|
223539743|NCT00481455|DRUG|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
223539744|NCT00481455|DRUG|Temozolomide|Fixed dose
223539745|NCT00688467|DRUG|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
223539746|NCT00688467|DRUG|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
223539747|NCT05656183|DIAGNOSTIC_TEST|TruGenome Cardiovascular Disease test|The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
223539748|NCT02026947|DRUG|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
223539749|NCT02026947|DRUG|Placebo|
223539750|NCT00925002|DRUG|Tafamidis|20 mg oral Fx-1006A daily
223539751|NCT00613548|PROCEDURE|CABG alone|CABG alone
223539752|NCT00613548|PROCEDURE|CABG + Mitral repair|CABG + Mitral repair
223539753|NCT03765216|DRUG|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
223539754|NCT03765216|DRUG|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
223539755|NCT05853354|BIOLOGICAL|Denosumab|Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
223539756|NCT03757429|OTHER|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
223539757|NCT04038073|DIAGNOSTIC_TEST|Antistreptolysin O Test|Test to evaluate of any histories of streptococcal infections
223539758|NCT04038073|DIAGNOSTIC_TEST|Anti-Deoxyribonuclease B|Test to evaluate of any histories of streptococcal infections
223539759|NCT04038073|DIAGNOSTIC_TEST|TLR, MyD88, IRAK-4 polymorphism|Test to evaluate of the frequency and types of genetic alterations of innate immunity
223539760|NCT04038073|DIAGNOSTIC_TEST|Anti-Basal Ganglia Antibody|Test to evaluate the autoimmune component
223539761|NCT00651222|OTHER|No intervention was required|Death records were reviewed, therefore, there was no intervention
223723649|NCT02442869|BEHAVIORAL|Stage 2 CAMS|4-16 weeks of Collaborative Assessment and Management of Suicidality (CAMS)
223723650|NCT02442869|BEHAVIORAL|Stage 2 Dialectical Behavioral Therapy (DBT)|4-16 weeks of Dialectical Behavioral Therapy (DBT)
223723651|NCT03521934|DRUG|Sotagliflozin|"Pharmaceutical form: tablet~Route of administration: oral"
223539762|NCT03200002|DRUG|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
223539763|NCT03200002|DRUG|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count \<1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count \<1000/mm3.
223539764|NCT00690794|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
223539765|NCT00690794|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
223539766|NCT03078439|OTHER|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
223539767|NCT01496287|DEVICE|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
223539768|NCT00346619|DRUG|Nelfinavir|
223539769|NCT00358319|DRUG|Karenitecin|
223539770|NCT00358319|DRUG|Valproic Acid|
223539771|NCT02259816|DRUG|Telmisartan|
223539772|NCT02259816|DRUG|Amlodipine|
223539773|NCT04353687|DEVICE|Robotic-assisted inguinal hernia repair|Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
224107015|NCT06338449|BEHAVIORAL|Combined aerobic and resistance training (AT + RT)|Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
224107016|NCT03484026|DIETARY_SUPPLEMENT|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
223539774|NCT01247454|BEHAVIORAL|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
223539775|NCT01247454|BEHAVIORAL|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
223723652|NCT03521934|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223954522|NCT05792475|DIAGNOSTIC_TEST|Define Standard of Truth (SOT) by Taihao Breast Cancer Diagnostic Software|TaiHao Breast Cancer Diagnostic Software independently define standard of truth (SOT) about108 cases.
223954523|NCT03386344|DRUG|Sotagliflozin|Pharmaceutical form: Tablet; Route of administration: Oral
223954524|NCT03386344|DRUG|Placebo|Pharmaceutical form: Tablet; Route of administration: Oral
223954525|NCT01516710|PROCEDURE|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
223954526|NCT01516710|PROCEDURE|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
223954527|NCT00195988|DRUG|tacrolimus, steroids, mycophenolate mofetil|
224107017|NCT02743637|DRUG|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
224107018|NCT04519554|DEVICE|Endometrial sampling|Endometrial sampling with 2 different forceps
223539776|NCT01247454|BEHAVIORAL|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
223539777|NCT05704153|DEVICE|Parasym 1Hz|Transcutaneous auricular vagus nerve stimulation of 1Hz
223539778|NCT05704153|DEVICE|Parasym 30Hz|Transcutaneous Auricular Vagus Nerve Stimulation of 30Hz
223539779|NCT05704153|DEVICE|Sham Intervention|Sham stimulation
223539780|NCT03940560|DEVICE|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
223954528|NCT05671055|OTHER|Custom study version of icompanion app|Patients complete patient-reported outcomes on cognition and covariates, as well as objective cognitive tests through a version of icompanion app customized specifically for this study. Patients complete all assessments remotely in an at-home situation.
223954529|NCT02416947|DIETARY_SUPPLEMENT|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
223954530|NCT02416947|DIETARY_SUPPLEMENT|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
223954531|NCT02416947|DIETARY_SUPPLEMENT|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
223954532|NCT01280721|DRUG|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
223954533|NCT01180400|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
223539781|NCT03667105|PROCEDURE|CAF|Periodontal surgical technique to treat gingival recessions.
223539782|NCT03667105|OTHER|MC|Xenogenous graft placed in the surgical site.
223539783|NCT03667105|OTHER|XDM|Xenogenous dermal collagen graft placed in the surgical site.
223539784|NCT04164433|DEVICE|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
223539785|NCT03064932|OTHER|Controlled feeding diet|Average American diet with different levels of spices
223539786|NCT04474639|DEVICE|echocardiographic examination|conducting an echocardiographic study according to a standard protocol with the determination of diastolic dysfunction of the left ventricle
223539787|NCT00819429|DIETARY_SUPPLEMENT|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
223539788|NCT00819429|BEHAVIORAL|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
223539789|NCT00819429|OTHER|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
223954534|NCT01180400|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
223954535|NCT01962376|DRUG|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
223539790|NCT00154349|DRUG|Imatinib Mesylate|
223539791|NCT05726149|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
223539792|NCT05726149|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
223539793|NCT05726149|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
223539794|NCT00216281|DRUG|Clozapine augmented with atomoxetine up to 40 mg or placebo|
223539795|NCT00659282|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
223539796|NCT02990650|BEHAVIORAL|Balance Task Training with therapist guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The therapist will provide guarding support"
223539797|NCT02990650|BEHAVIORAL|Balance task training with robotic guarding support|"Nine balance tasks:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
223539798|NCT02990650|BEHAVIORAL|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~1. long forward step~2. forward reach~3. push forward~4. push backward~5. step over hurdle~6. step up on foam surface~7. step up on solid surface~8. sit-to-stand~9. step onto slippery surface The guarding support will be provided by a robot"
223539799|NCT04340518|DEVICE|Scleral lens|Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
223954536|NCT01962376|DRUG|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
223954537|NCT04584736|DRUG|Livalo, Ezetrol|Pitavastatin+Ezetimibe Pitavastatin
223954538|NCT02301078|PROCEDURE|Percutaneous Needle Aponeurotomy|single procedure (day 0)
223539800|NCT00473018|BEHAVIORAL|standard versus enhanced risk reduction counseling|
223539801|NCT03401320|DRUG|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
223539802|NCT00429988|GENETIC|fluorescence in situ hybridization|
223539803|NCT00429988|GENETIC|polymerase chain reaction|
223954539|NCT02301078|DRUG|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
223539804|NCT00429988|GENETIC|proteomic profiling|
223954540|NCT00795392|OTHER|ASA scale|ASA scale evaluation before operation
223954541|NCT00795392|OTHER|Full-scale psychological assessment|Full-scale psychological evaluation before operation
223954542|NCT02875444|OTHER|Angio-CT|
223954543|NCT00604396|DRUG|insulin detemir|
223539805|NCT00429988|OTHER|cytology specimen collection procedure|
223539806|NCT00429988|OTHER|immunohistochemistry staining method|
223539807|NCT00429988|PROCEDURE|breast duct lavage|
223539808|NCT01343888|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
223539809|NCT01343888|DRUG|BI 201335|BI 201335 once daily high dose
223539810|NCT01343888|DRUG|BI 201335|BI 201335 once daily low dose
223539811|NCT01343888|DRUG|Placebo|
223539812|NCT03645538|OTHER|Parkinson's disease patients|"The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
223539813|NCT03645538|OTHER|No drug|The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
223954544|NCT00604396|DRUG|insulin NPH|
223539814|NCT01990742|BEHAVIORAL|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
223539815|NCT05017064|DEVICE|Cryotherapy group|The use of intraoral ice pack during root canal treatment
223539816|NCT05017064|OTHER|Control group|No cryotherapy will be used
223539817|NCT01868828|DRUG|PAD|Induction Therapy of PAD for 4 cycles.
223954545|NCT02054442|DRUG|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
223954546|NCT02054442|DRUG|Methotrexate|
223539818|NCT01868828|DRUG|VCD|Induction Therapy of VCD for 4 cycles.
223954547|NCT03118609|OTHER|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
224107019|NCT04442529|BEHAVIORAL|Mothers and Babies (MB)|Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
223539819|NCT01868828|OTHER|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
223539820|NCT03443687|BEHAVIORAL|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
223539821|NCT03443687|DEVICE|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
223539822|NCT06314009|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a functional Magnetic Resonance Imaging (fMRI) using arterial spin labeling (ASL) and other Magnetic Resonance (MR) sequences
223539823|NCT00538057|DRUG|GW685698X & GW642444M|study drug
223539824|NCT02091076|DEVICE|Silk fibroin with bioactive coating layer dressing|
223539825|NCT02091076|DEVICE|Bactigras wound dressing|
223539826|NCT00102661|DRUG|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
223539827|NCT06563856|DRUG|TEPEZZA|Administered as a SubQ injection or IV injection.
223539828|NCT06563856|DRUG|EDP|Administered as a SubQ injection.
223539829|NCT06448975|PROCEDURE|Deep cervical Lymphovenous Bypass|Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
223539830|NCT04372303|BEHAVIORAL|Compassion Fatigue Resiliency Program (CFRP)|The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
223954548|NCT05500261|DRUG|Dexmedetomidine|intranasal administration of dexmedetomidine
223954549|NCT04590625|DRUG|Apatinib Mesylate|apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
223954550|NCT04590625|DRUG|Abraxane|abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
223954551|NCT04590625|DRUG|Cis Platinum|cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
223954552|NCT04590625|DRUG|Carboplatin|carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1
224107020|NCT01480986|DRUG|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m\^2，ivgtt，90min，D1 Cisplatin 50 mg/m\^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
224107021|NCT00030576|DRUG|cisplatin|
224107022|NCT00030576|DRUG|erlotinib hydrochloride|
224107023|NCT05728801|DIAGNOSTIC_TEST|Ageing|Using comprehensive cognitive tests to quality the domain-specific cognitive changes during ageing.
224107024|NCT04227691|DEVICE|Long-pulsed Nd Yag laser treatment|One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
224107025|NCT04227691|DEVICE|IPL treatment|One treatment of the assigned axilla with IPL treatment in ten patients
224107026|NCT03402763|BEHAVIORAL|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
223539831|NCT02782442|BEHAVIORAL|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (\~2 hours per week) is a structured program of 20 hours of auditory processing exercises followed by 10 hours of social cognition exercises, combined with the personalized PRIME coaching application
223539832|NCT02782442|BEHAVIORAL|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (\~2 hours per week), combined with the personalized PRIME coaching application.
223539833|NCT06101368|BEHAVIORAL|Phsical Activity|Combined Aerobic and Resistance Training
223954553|NCT01598389|OTHER|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
223954554|NCT03003923|BEHAVIORAL|Taste exposure|Exposure to the same vegetable
223539834|NCT06101368|DRUG|Medication|The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
223539835|NCT02549079|OTHER|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
223539836|NCT01132352|DRUG|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
223539837|NCT06226961|DEVICE|cupping|The dynamic cupping will be performed for ten minutes, at a slow pace, and consisted of applying a small amount of massage cream (ATL®) over the entire shoulder (to obtain the ideal sliding surface for cupping application), insufflation of the suction cup, with two pumps, and sliding it in the direction of the muscle fibers around the shoulder and also in the transversal direction.
223539838|NCT00761488|DEVICE|AcrySof® Toric IOL|Implanted into the study eye
223539839|NCT02764996|DEVICE|Acupuncture|
223539840|NCT04904172|DEVICE|Masimo O3 Regional Oximetry|wo electrodes will be attached to the forehead area and connected to the Near Infrared Spectroscopy device after the consent of the patients who apply to Ege University Hospital Emergency Service with acute ischemic stroke and who are planned to have intravenous thrombolytic and / or endovascular thrombectomy treatment or treatments, and / or their caregivers.
223539841|NCT00800735|DRUG|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
223539842|NCT00800735|DRUG|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing \< 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
223954555|NCT03003923|BEHAVIORAL|Nutritional education|Eat Well and Strive for Five nutritional education
223954556|NCT06405516|DEVICE|Autologous blood cell salvage with in-house device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
224107027|NCT03402763|BEHAVIORAL|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
223954557|NCT06405516|DEVICE|Autologous cell salvage with i-Sep SAME device|In addition to standard procedures in this patient population, study participants will receive point-of-care analysis of platelet function and coagulation (laboratory analysis and viscoelastic tests, if not already provided by the responsible anesthesiologist) based on the clinical situation, at different time points before and after retransfusion of processed cell salvage blood.
223954558|NCT03560804|DRUG|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
223539843|NCT02805790|DRUG|Elamipretide|4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
223539844|NCT02805790|DRUG|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
223539845|NCT05469919|DRUG|Ceralasertib|Ceralasertib taken orally
223539846|NCT02097784|PROCEDURE|Echocardiography|
223539847|NCT04275076|PROCEDURE|Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia|comparison between 2 energy sources of enucleation in management of benign prostatic hyperplasia, holmium laser versus bipolar energy source in trans-urethral enucleation of the prostate
223539848|NCT01385150|GENETIC|mutation analysis|
223539849|NCT01385150|GENETIC|protein analysis|
223539850|NCT01385150|OTHER|laboratory biomarker analysis|
223954559|NCT03560804|DRUG|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
224107028|NCT02837172|OTHER|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
223539851|NCT01385150|OTHER|liquid chromatography|
223539852|NCT01385150|OTHER|mass spectrometry|
223539853|NCT02261961|BIOLOGICAL|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
223539854|NCT02261961|OTHER|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
223539855|NCT02261961|OTHER|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
223539856|NCT02261961|OTHER|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
223539857|NCT02261961|DIETARY_SUPPLEMENT|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
223539858|NCT02261961|DIETARY_SUPPLEMENT|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
223539859|NCT00051714|BEHAVIORAL|Family-Based Preventive Intervention|
223539860|NCT03387215|DRUG|ITI-214|Oral
223539861|NCT03387215|OTHER|Placebo|Oral
223954560|NCT02183272|DRUG|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
223954561|NCT02183272|DRUG|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
223954562|NCT06508762|DRUG|VX-993|Tablet and Suspension for Oral Administration.
223954563|NCT00391066|DRUG|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
223954564|NCT00391066|DRUG|FCR|Dose, schedule, and duration specified in protocol
223954565|NCT00399828|DEVICE|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
223954566|NCT04849091|DEVICE|iReadMore|Digital Alexia Therapy
224107029|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
223539862|NCT00702832|BEHAVIORAL|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
223539863|NCT00702832|OTHER|standard treatment|treatment as usual
223539864|NCT04460183|DRUG|RESP301, a Nitric Oxide generating solution|Product application requires inhalation using a standard handheld nebulizer.
223539865|NCT04460183|OTHER|Standard of Care|Participants will receive institutional SOC for the treatment of COVID-19.
223539866|NCT03986125|BEHAVIORAL|Emotional Awareness & Expression Therapy|emotion-focused
223539867|NCT03986125|BEHAVIORAL|Mindfulness Meditation Training|meditation training and practice
223539868|NCT00369837|DRUG|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
223539869|NCT03307538|RADIATION|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
223539870|NCT02734329|PROCEDURE|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
223539871|NCT02734329|PROCEDURE|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
223539872|NCT04941105|DRUG|Evolocumab|A single subcutaneous administration of 140 mg evolocumab
223539873|NCT04941105|DRUG|Saline solution|A single subcutaneous injection of 1ml of 0,9% saline solution
223539874|NCT04143230|OTHER|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
223539875|NCT04838184|DEVICE|Dental Implants (Straumann Roxolid® / SLActive®)|"In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.~In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation."
223539876|NCT02972710|OTHER|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
223954567|NCT01331174|DEVICE|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
223954568|NCT00963924|DRUG|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
223954569|NCT00963924|DRUG|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
223539877|NCT02972710|OTHER|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
223539878|NCT00263003|DRUG|Irbesartan/hydrochlorothiazide|
223539879|NCT00263003|DRUG|Irbesartan|
223539880|NCT00002139|DRUG|Azithromycin|
223539881|NCT02605356|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|
223539882|NCT02605356|DRUG|Placebo|
223539883|NCT02605356|DRUG|Bortezomib|
223539884|NCT02605356|DRUG|Dexamethasone|
223539885|NCT00825994|DRUG|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
223539886|NCT03194399|BEHAVIORAL|Personalized health care service|Physical activity coaching, other functional outcome observation
223539887|NCT02409433|DRUG|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
223954570|NCT00963924|BEHAVIORAL|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
223954571|NCT00836537|DRUG|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
223954572|NCT00836537|DRUG|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
223539888|NCT02409433|DRUG|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
223539889|NCT05545410|OTHER|MRI calibration|Non-injected thoracic aorta MRI calibration
223539890|NCT01776853|DIETARY_SUPPLEMENT|Glucose|
223539891|NCT01776853|DIETARY_SUPPLEMENT|Fructose|
223539892|NCT01776853|DIETARY_SUPPLEMENT|Fructans|
223539893|NCT03415503|DRUG|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
223539894|NCT02047448|PROCEDURE|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
223539895|NCT03395028|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
223954573|NCT01883609|BIOLOGICAL|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
223954574|NCT01883609|BIOLOGICAL|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
223954575|NCT01883609|BIOLOGICAL|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
223954576|NCT04464499|DIAGNOSTIC_TEST|ECG measurement|Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
223954577|NCT02770274|DRUG|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
223954578|NCT02770274|DRUG|Aspirin|Monotherapy with aspirin 100 mg once daily
223954579|NCT02379975|PROCEDURE|Non-surgical Periodontal Therapy|
223954580|NCT03031782|DRUG|secukinumab|secukinumab is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
223954581|NCT03031782|OTHER|placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
224107030|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
224107031|NCT00080327|DRUG|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
223539896|NCT05175274|DRUG|Colchicine|Colchicine 0.5mg/tablet
223539897|NCT05175274|DRUG|Placebo|matching placebo
223723653|NCT04997811|DRUG|Sodium Valproate, Bezafibrate, Medroxyprogesterone|Sodium valproate tablet 1 x 500mg bd, (starting 1 x 200mg bd) Bezafibrate standard release tablet 2 x 200mg tds, (starting 1 x 200mg tds) Medroxyprogesterone acetate tablet 1 x 400mg bd (starting 1 x 400mg od)
223954582|NCT02109913|DRUG|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
223954583|NCT03576118|DRUG|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
223954584|NCT03576118|DRUG|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
223723654|NCT04997811|DRUG|Danazol|Danazol 1 x 200mg capsules tds, (starting 1 x 200mg od)
223723655|NCT02315001|DRUG|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
223954585|NCT03855514|OTHER|NuShield|NuShield® is a dehydrated placental allograft.
223954586|NCT02170207|DRUG|Lansoprazole|Lansoprazole 30 mg injection
223723656|NCT02315001|OTHER|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
223723657|NCT03378362|PROCEDURE|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
223723658|NCT03733002|DRUG|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
223723659|NCT03733002|DRUG|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
223954587|NCT04619108|BIOLOGICAL|Thrombosomes®|
223954588|NCT00362284|BEHAVIORAL|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
223954589|NCT02341222|DEVICE|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
224107032|NCT00080327|DRUG|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
224107033|NCT00660140|DRUG|Gemcitabine|
224107034|NCT00660140|DRUG|Carboplatin|
224107035|NCT00325572|DRUG|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
223723660|NCT03733002|OTHER|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
223954590|NCT02341222|DEVICE|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
223954591|NCT04263688|OTHER|Non-Intervention|Non-Intervention
223954592|NCT00900302|GENETIC|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
223994585|NCT00920647|DRUG|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
224107036|NCT00325572|OTHER|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
224107037|NCT02348567|OTHER|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
224107038|NCT02348567|OTHER|announced hospital surveys|
224107039|NCT00736281|OTHER|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
224107040|NCT03611140|DIETARY_SUPPLEMENT|DP|a package containing a mix of functional foods
224107041|NCT03611140|DIETARY_SUPPLEMENT|Placebo|a package containing maltodextrins and caseinate calcium to mimic the DP
224107042|NCT06487949|DRUG|valsartan-amlodipine 80/5 mg FDC|fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill
224107043|NCT06487949|DRUG|valsartan 80 mg and amlodipine 5 mg as free combination|Free combination of valsartan 80 mg and amlodipine 5 mg given separately
223994586|NCT00920647|DRUG|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
223539898|NCT05680467|OTHER|Manual Therapy|"The protocol will last 30 minutes and will include the application of the following manual techniques:~* Lumbar soft tissue and joint cranial and lateral mobilization with the patient in the supine position~* Bilateral medial lumbar soft tissue mobilization~* Functional massage on the quadratus lumborum muscle with the patient in a lateral position on both sides~* Extension with coupled sidebending mobilization of the thoracic area with the patient in a lateral position on both sides~* Soft tissue lateral mobilization of the thoracic area with the patient in a lateral position on both sides"
223539899|NCT05680467|OTHER|Manual Therapy plus TECAR|The participants of this group will be given the same manual protocol as the first group in combination with the application of high frequency current. Soft tissue mobilization manipulations will be applied in combination with a capacitive conventional electrode and with a special electrode bracelet that makes the therapist's own hand as an antistatic electrode. The frequencies of the high frequency current will be 300khz, 500khz, and 1MHz, while as a reference electrode a flexible self-adhesive ground will be used placed on the abdomen
223539900|NCT05680467|OTHER|Control|Participants in this group will only receive general instructions about managing their back pain and counseling about avoiding activities that may worsen their symptoms.
223539901|NCT06174675|PROCEDURE|combined bilateral infraorbital and infratrochlear nerve blocks|"Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma."
223539902|NCT03486353|DRUG|FF-10501-01|FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).
223539903|NCT03486353|DRUG|Azacitidine|azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
223539904|NCT02132403|DRUG|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
223539905|NCT02132403|DRUG|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
223539906|NCT02132403|DRUG|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
223539907|NCT04280991|OTHER|Moderate intensity exercise under mild normobaric hypoxia and normoxia|The participant will perform the exercise interventions consisting of cycling at the heart rate corresponding with 50%WMAX (normoxia) or heart rate corresponding with 50% WMAX (hypoxia) for 30 minutes, twice a day, for 4 consecutive days. 24h glucose concentration will be monitored continuously.
223539908|NCT04709510|DIAGNOSTIC_TEST|Duplex Ultrasound|Duplex Ultrasound was performed for every participants for the diagnosis of symptomatic or asymptomatic deep vein thrombosis
223539909|NCT01166217|DRUG|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
223539910|NCT00255905|BEHAVIORAL|Cognitive behavioral therapy (CBT) for insomnia|
223539911|NCT00255905|BEHAVIORAL|Clinician monitoring|
223539912|NCT00413439|DRUG|Isavuconazole|Intravenous solution or oral capsules
223994587|NCT00920647|DRUG|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
223994588|NCT03855176|DRUG|Vaqta Injectable Product|Inactive vaccine against hepatitis A virus
223994589|NCT04072445|DRUG|Irinotecan|Given IV
223994590|NCT04072445|DRUG|Irinotecan Hydrochloride|Given IV
223994591|NCT04072445|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
224107044|NCT00593112|DRUG|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
223723661|NCT03020160|DRUG|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
224107045|NCT00593112|OTHER|No intervention|No intervention
224107046|NCT04610307|PROCEDURE|buffered anesthesia|patients will undergo surgery under buffered local anesthesia
224107047|NCT03446547|DRUG|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
224107048|NCT02328716|PROCEDURE|Cytoreduction|Cytoreduction
224107049|NCT02328716|DRUG|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
224107050|NCT01161836|DRUG|Iniparib|"Solution for infusion~60-minute intravenous infusion"
224107051|NCT01258439|DRUG|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
224107052|NCT01258439|DRUG|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
223539913|NCT05309681|OTHER|Epworth's sleepiness scale; unstimulated saliva sample|Unstimulated saliva sample; Epworth's sleepiness scale
223539914|NCT03731052|DRUG|188-0551 Spray|Topical Spray containing active drug
223723662|NCT04435860|OTHER|Truncal flexion-extension muscle power|Patient performs a maximum truncal flexion laying supine on the bed with cap of muscle tester placed on sternum,
223539915|NCT03731052|DRUG|Vehicle Spray|Topical Spray containing no active drug
223539916|NCT06206850|DRUG|Osimertinib|Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).
223539917|NCT05122546|DRUG|Cabozantinib S-malate|Given PO
223539918|NCT05122546|DRUG|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
223539919|NCT05122546|BIOLOGICAL|Nivolumab|Given IV
223539920|NCT01356394|OTHER|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
223539921|NCT04663594|OTHER|WofB|Online experience designed to reduce anxiety and depression and support mental health and wellbeing
223539922|NCT04663594|OTHER|Ashmolean Website|A generic museum website owned by the Ashmolean Museum of Art and Archaeology at the University of Oxford.
223539923|NCT03840213|BEHAVIORAL|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
223539924|NCT04228458|DEVICE|Thermal Imaging|Testing the effectiveness of using a Thermal Imaging camera in participants with Juvenile Arthritis.
223539925|NCT06319781|OTHER|Observational|The study is a prospective non-interventional, observational study.
223539926|NCT01459094|DRUG|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
223539927|NCT01459094|DRUG|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
223539928|NCT04173182|DIAGNOSTIC_TEST|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
223539929|NCT02325063|DRUG|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
223539930|NCT02325063|DRUG|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
223539931|NCT02325063|DRUG|Corticoid injection|Patients will be treated with an injection of Corticoids.
223539932|NCT05990244|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Undergo MRE and routine MRI
223539933|NCT05990244|PROCEDURE|Assessment and Recording|Undergo recording of tumor stiffness during surgery and molecular pathological classification through genetic analysis
223539934|NCT06141512|BEHAVIORAL|Reduced-exertion high-intensity interval training (REHIT)|Description same as Arm description.
223539935|NCT03795493|BEHAVIORAL|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy cycles of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
223539936|NCT06565364|DIAGNOSTIC_TEST|"ZYMUTEST™ HIA immunoglobulin g ELISA (enzyme-linked immunosorbent assay )"|The enzyme-linked immunosorbent assay is an in vitro test done in the laboratory to detect specific antibodies against heparin/platelet factor-4 and protamine/heparin complexes.
223954593|NCT00900302|OTHER|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
223954594|NCT00900302|OTHER|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
223954595|NCT00900302|PROCEDURE|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
223954596|NCT02099409|DEVICE|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
223994592|NCT03630406|DIAGNOSTIC_TEST|Vaginal Tactile Imaging|Vaginal Tactile Imaging
223994593|NCT01215578|DRUG|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
223994594|NCT00157235|DRUG|Tiotropium bromide|
223994595|NCT04641962|DRUG|Bocidelpar|Oral
223539937|NCT03139058|OTHER|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
223723663|NCT04435860|OTHER|Truncal extension muscle power|Patient performs a maximum truncal extension laying prone on the bed while the cap of manual muscle tester placed on vertebrae at the level of midline between superior angles of scapulae.
223539938|NCT02094391|DRUG|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
223723664|NCT04435860|OTHER|Cervical flexion muscle power|Patient performs a maximum cervical flexion sitting while the cap of manual muscle tester placed on the middle of the forehead.
223954597|NCT05647538|PROCEDURE|Bilateral uterine artery ligation|Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
223954598|NCT00886834|DRUG|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
223954599|NCT00886834|DRUG|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
223954600|NCT02535585|DEVICE|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
223954601|NCT02535585|DEVICE|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
223954602|NCT03122860|DRUG|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
223954603|NCT03122860|OTHER|Placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
223954604|NCT03122860|OTHER|Sham|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
223954605|NCT02434991|DEVICE|Barostat|"* During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~* A urine pregnancy test for females of childbearing years.~* Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~* At this point healthy controls have completed the study.~* Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~* Patients will be contacted to complete a phone survey 3 \& 6 months and 2 \& 4 years after treatment."
223954606|NCT05687825|PROCEDURE|pancreaticoduodenectomy procedure|Pancreaticoduodenectomy operation
223723665|NCT04435860|OTHER|Cervical extension muscle power|Patient performs a maximum cervical extension sitting while the cap of manual muscle tester placed on protuberantia occipitalis.
223539939|NCT03585387|PROCEDURE|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
223539940|NCT06145594|OTHER|EMA Monitoring|Weekly prompts to participants' smart phones for collection of PHQ-9 data
223539941|NCT06145594|OTHER|Scheduling Maintenance TMS sessions|When threshold score is reached, the participants is offered TMS maintenance treatments
223539942|NCT06357104|DEVICE|electroencephalogram biofeedback|EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.
223539943|NCT06357104|DEVICE|electrical brain stimulation|EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.
223539944|NCT06357104|DEVICE|ultra-low frequency transcranial magnetic stimulation|ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.
223539945|NCT06357104|DRUG|Sertraline Hydrochloride|Sertraline is taken in the morning for 150 mg per day.
223954607|NCT01138657|BIOLOGICAL|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
223954608|NCT01138657|DRUG|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
223954609|NCT01138657|DRUG|Placebo|Administered by subcutaneous injection
223954610|NCT05990868|DRUG|Tylenol|Rectal tylenol will be placed at the time of oocyte retrieval
223954611|NCT03511781|RADIATION|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
223539946|NCT06357104|DRUG|Clonazepam|Clonazepam is taken in the morning for 1 mg per day.
223994596|NCT04641962|DRUG|Placebo|Oral
223539947|NCT06357104|DRUG|Alprazolam|Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.
223539948|NCT06357104|DRUG|Metoprolol|Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.
223539949|NCT06357104|DRUG|Olanzapine|Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.
223539950|NCT06357104|DRUG|Pravastatin Sodium 20 MG|Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.
223539951|NCT06357104|DRUG|Sacubitril Valsartan Sodium Hydrate|Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
223539952|NCT00332696|DRUG|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
223539953|NCT00332696|DRUG|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
223539954|NCT00332696|DRUG|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
223539955|NCT00332696|DRUG|Placebo|Physiologic saline solution
223539956|NCT00943644|DEVICE|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
223539957|NCT00943644|DEVICE|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
223539958|NCT02657148|DRUG|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
223723666|NCT04435860|OTHER|Cervical lateral flexion muscle powers|Patient performs a maximum cervical lateral flexions on right and left sitting while the cap of manual muscle tester placed on relevant pterion.
223723667|NCT04435860|OTHER|Shoulder flexion muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior aspect of acromion and anterior elbow.
223723668|NCT04435860|OTHER|Shoulder extension muscle power|Patient performs a maximum shoulder flexion of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior aspect of acromion and posterior elbow.
223723669|NCT04435860|OTHER|Shoulder internal rotation muscle power|Patient performs a maximum shoulder internal rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between anterior elbow and wrist.
223539959|NCT02657148|DRUG|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at \> 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time \> 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time \> 6 weeks after delivery.
223539960|NCT00114491|DRUG|Rosuvastatin|
223539961|NCT03507582|OTHER|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
223723670|NCT04435860|OTHER|Shoulder external rotation muscle power|Patient performs a maximum shoulder external rotation of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line between posterior elbow and wrist.
223954612|NCT00882323|DRUG|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
223954613|NCT01357902|DRUG|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
223954614|NCT04480957|BIOLOGICAL|ARCT-021 Dose 1|ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)
223954615|NCT04480957|BIOLOGICAL|ARCT-021 Dose 2|ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
223954616|NCT04480957|BIOLOGICAL|ARCT-021 Dose 3|ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
223954617|NCT04480957|BIOLOGICAL|ARCT-021 Dose 4|ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
223539962|NCT03507582|OTHER|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
223954618|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 1|ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
223954619|NCT04480957|BIOLOGICAL|ARCT-021 Dose Regimen 2|ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the full length spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021
223954620|NCT04480957|OTHER|Placebo|Sterile 0.9% saline
223954621|NCT02055079|DRUG|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
223954622|NCT02055079|DRUG|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
223954623|NCT02578004|OTHER|biochemical and molecular analysis|
223994597|NCT04980079|PROCEDURE|Primary ureterscopy URS|Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy
224107053|NCT03619122|PROCEDURE|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
224107054|NCT00690872|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
223539963|NCT04951531|PROCEDURE|BPTB double-bundle allograft|The patient underwent surgery of arthroscopic double-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
223539964|NCT04951531|PROCEDURE|BPTB single-bundle allograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) allograft．
223994598|NCT04980079|PROCEDURE|deferred ureteroscopy URS|insertion of a double -J stent or percutaneous nephrostomy (PCN) at first , then a deferred ureteroscopy URS will be done .
223539965|NCT04951531|PROCEDURE|BPTB single-bundle autograft group|The patient underwent surgery of arthroscopic single-bundle anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone (BPTB) autograft．
223539966|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure and orthodontic treatment|subepithelial connective tissue graft and orthodontic tooth levelling and alignment
223994599|NCT02125071|OTHER|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
223994600|NCT01562106|PROCEDURE|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
223994601|NCT03007797|BEHAVIORAL|vaccination rate for influenza|
223994602|NCT00862836|DRUG|Vandetanib|100mg doses orally, once daily
223994603|NCT03876106|DRUG|LUT014|Topical
223994604|NCT00320229|DRUG|abciximab|
223994605|NCT02712190|DEVICE|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
223994606|NCT05251675|BEHAVIORAL|Physician Led Professional Coaching|This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.
223994607|NCT05251675|BEHAVIORAL|Delayed Physician Led Professional Coaching|This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
224107055|NCT00690872|DRUG|carboplatin|
223954624|NCT02166684|DEVICE|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
223954625|NCT00001255|DRUG|ADA PBSC|
223539967|NCT04255914|PROCEDURE|Periodontal plastic surgery procedure|subepithelial connective tissue graft procedure
223539968|NCT02394561|BIOLOGICAL|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
223539969|NCT06350448|DRUG|Washed Microbiota Transplantation|Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
223539970|NCT03819309|PROCEDURE|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
223539971|NCT03819309|PROCEDURE|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
223539972|NCT01882465|DEVICE|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
223539973|NCT01882465|DEVICE|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
223539974|NCT01882465|DEVICE|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
223539975|NCT05759780|DEVICE|Optical imaging of the tissues|OCT vibrography
223539976|NCT03166930|BEHAVIORAL|Spasticity Take Control|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and a stretching program for spasticity management.
223539977|NCT03166930|BEHAVIORAL|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes via video teleconference (online), one week apart, consisting of education and exercises for spasticity management from the manual.
223539978|NCT00000276|DRUG|Bupropion|
223954626|NCT00001255|DRUG|ADA Umbilical Cord Blood Cells|
223539979|NCT01814956|DRUG|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
223539980|NCT01814956|DRUG|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
223539981|NCT02987582|BEHAVIORAL|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
223539982|NCT05915611|OTHER|Combined physical and psychological intervention|"Physical therapy components will include splinting, tendon and nerve gliding exercises.~Psychological components will include cognitive-behavioral therapy (CBT), delivered in individual sessions, targeting pain catastrophizing and fear of movement.~Participants will attend 2 physical therapy sessions and one CBT session per week. for a period of 12 weeks"
223539983|NCT05915611|OTHER|Standard care|Participants will be asked to wear a prefabricated wrist splint during the night and during strenuous activity. Also, they will receive tendon and nerve gliding exercises
223539984|NCT05021952|DEVICE|mHealth App and wearable device|An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for prostate cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
223539985|NCT02148588|DRUG|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
223539986|NCT05500651|OTHER|Dance and Movement Therapy (DMT)|Dance and movement therapy is planned to be applied once a week as a total of 12 sessions of 60 minutes. First session; meeting, warming up, determining the group rules, explaining the principles, determining the expectations activities. Subsequent sessions; The greeting is completed with warm-up, initiation, continuation and closing activities. During the warm-up phase, the whole group comes together to form a circle, generally standing, in order to ensure the group dynamic. It starts with simple warm-up exercises such as breathing and muscle relaxation and continues with body awareness exercises. In the continuation (development of themes) stage, practices are included according to the characteristics and needs of the group.
223539987|NCT02633735|OTHER|Appy CDS|See description under arm/group section
223723671|NCT04435860|OTHER|Shoulder abduction muscle power|Patient performs a maximum shoulder abduction of the dominant side on upright while the cap of manual muscle tester placed on midpoint of the line lateral aspect of acromion and lateral epicondyle.
223954627|NCT00001255|DRUG|Transduced Lymphocytes|
224107056|NCT00690872|DRUG|gemcitabine hydrochloride|
223723672|NCT04435860|OTHER|Hip flexion muscle power|Patient performs a maximum hip flexion laying supine on the bed while the cap of manual muscle tester placed on middle of the anterior thigh.
223954628|NCT04901585|PROCEDURE|Totally intracorporeal distal gastrectomy|Minimally invasive distal gastrectomy with intracorporeal anastomosis and handsewn enterotomy closure
223954629|NCT06153784|DRUG|Hydroxyurea and Thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
223954630|NCT02619825|DEVICE|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
223954631|NCT02619825|DEVICE|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
223954632|NCT01396629|PROCEDURE|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
223539988|NCT00002219|DRUG|Nelfinavir mesylate|
223539989|NCT00002219|DRUG|Levocarnitine|
223539990|NCT00002219|DRUG|Adefovir dipivoxil|
223954633|NCT00074425|DRUG|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
223539991|NCT03763747|DEVICE|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
223539992|NCT00839969|PROCEDURE|Cystoscopy|Saline cystoscopy under general anaesthesia
223539993|NCT00839969|PROCEDURE|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
223954634|NCT00074425|DRUG|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
223954635|NCT00074425|DRUG|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
223954636|NCT03875729|BIOLOGICAL|teplizumab|Treatment
223954637|NCT03875729|BIOLOGICAL|Placebo|Control
223539994|NCT05104827|OTHER|Complementary Integrative Medicine|30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
223539995|NCT02812914|OTHER|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
223539996|NCT02812914|BEHAVIORAL|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
223539997|NCT02812914|BEHAVIORAL|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
223539998|NCT00834821|BEHAVIORAL|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
223954638|NCT03067337|DEVICE|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
223954639|NCT03067337|DEVICE|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
223954640|NCT06465537|GENETIC|BD113vVLP|CRISPR/Cas9 gene editing technology, called BD113vVLP (also BD113 virus-like particle) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down the mutated MYOC gene. The BD113vVLP is administrated by intracamerally injecton (sigle-dose: 4ug/p24) for each target interventional eye.
223954641|NCT03662841|PROCEDURE|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
223954642|NCT01474759|BEHAVIORAL|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
223954643|NCT01474759|BEHAVIORAL|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
223954644|NCT01474759|OTHER|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
224107057|NCT00690872|GENETIC|polymerase chain reaction|
224107058|NCT00690872|OTHER|fluorescence activated cell sorting|
224107059|NCT00690872|OTHER|immunoenzyme technique|
223539999|NCT00834821|BEHAVIORAL|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
223540000|NCT04270422|OTHER|Multidimensional physiotherapy|Multidimensional physiotherapy based on biopsychosocial approach
223954645|NCT01474759|BEHAVIORAL|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
223540001|NCT04270422|OTHER|Usual physiotherapy|Usual evidence based physiotherapy
223954646|NCT01473459|PROCEDURE|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
223954647|NCT01473459|PROCEDURE|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
223540002|NCT02578901|DRUG|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
223954648|NCT02579109|OTHER|memory test|
223954649|NCT06413459|OTHER|Luminex; scRNAsec|Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
223540003|NCT02578901|DRUG|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
223723673|NCT04435860|OTHER|Hip extension muscle power|Patient performs a maximum hip extension laying prone on the bed while the cap of manual muscle tester placed on middle of the posterior thigh.
223954650|NCT05297097|DIETARY_SUPPLEMENT|Trulacta breastmilk supplement|one supplement daily
223954651|NCT00799331|DRUG|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
223540004|NCT03048773|DEVICE|shockwave therapy|Intervention with shockwave therapy
223540005|NCT03048773|OTHER|PT|Physical therapy 3 times per week for 3 weeks
223540006|NCT03048773|OTHER|placebo|sham shockwave therapy
223723674|NCT04435860|OTHER|Hip abduction muscle power|Patient performs a maximum hip abduction laying supine on the bed while the cap of manual muscle tester placed on middle of the lateral thigh.
223723675|NCT04435860|OTHER|Hip internal rotation muscle power|Patient performs a maximum hip internal rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between lateral condyle of femur and lateral malleolus.
223723676|NCT04435860|OTHER|Hip external rotation muscle power|Patient performs a maximum hip external rotation laying supine on the bed while the cap of manual muscle tester placed on the midline between medial condyle of femur and medial malleolus.
223723677|NCT04435860|OTHER|Bath Ankylosing Spondylitis Functional Index (BASFI)|"This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being easy and 10 impossible) is used to answer the questions on the test. The final score varies between 0 and 10."
223954652|NCT00799331|DRUG|placebo|Oral suspension.
223954653|NCT04155814|DRUG|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
223540007|NCT05691387|BEHAVIORAL|Thera PEP|"Sitting comfortably, patients receiving Thera PEP will be told to place dental cotton swabs between their cheek and gum, and then under their tongue, to absorb saliva and prevent contamination of the collected sputum by the patient's own saliva. The diameter of the opening will be modified to achieve a ventilation rate of 1:4. The patient will be taught to take in a larger than normal breath but not fill the lungs to capacity in order to maintain a tight seal during exhalation. After completing ten PEP breaths, the patient will have the mouthpiece removed and be instructed to do two or three puff coughs. When secretions need to be brought up, a good cough will do the trick. During the duration of the treatment, which will last around thirty minutes, the patient will be asked to complete three cycles of ten breaths each."
223540008|NCT05691387|BEHAVIORAL|ACBT and PLB|On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
223540009|NCT04546100|OTHER|Maternal-Infant Exercise Program|"Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise."
223540010|NCT00147329|DRUG|MM-093|
223723678|NCT04435860|OTHER|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
223954654|NCT04155814|DRUG|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
223954655|NCT05376839|DRUG|Cedirogant|Capsule, Oral
223954656|NCT05303324|DRUG|ALXN1840|Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
223954657|NCT02684994|BEHAVIORAL|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
223954658|NCT03780634|PROCEDURE|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
223954659|NCT03780634|DRUG|PD-1 antibody|200mg intravenously every 3 weeks
223954660|NCT03780634|DRUG|Sorafenib|400 mg Bid Po
223540011|NCT00922961|BIOLOGICAL|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
223954661|NCT03853889|PROCEDURE|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
223954662|NCT06063915|DEVICE|Isoinertial training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using isoinertial machines
223954663|NCT06063915|OTHER|Strength Training|The subjects included in the study will undergo traditional muscle strengthening for a period of 4 weeks, with 2 sessions per week consisting of strength training using classic exercises
223954664|NCT02045914|OTHER|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
223954665|NCT04842006|DRUG|Total neoadjuvant therapy (TNT)|Short radiotherapy (5X5 Gy) and capecitabine/oxaliplatin
223954666|NCT04842006|DIAGNOSTIC_TEST|Minimal residual disease (MRD)|Postoperative MRD on circulating cell-free DNA
223954667|NCT04842006|RADIATION|Long radiation therapy|Long-course 50.4 Gy radiation with capecitabine
223954668|NCT00591136|DRUG|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
223954669|NCT02398539|DRUG|Silver Nitrate|Silver Nitrate Sticks
223954670|NCT02398539|DRUG|Triamcinolone|0.5% cream
223954671|NCT01405508|DRUG|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
223540012|NCT00922961|PROCEDURE|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
223540013|NCT01378117|DRUG|Sitagliptin|Sitagliptin 50-100mg po once daily
223540014|NCT01378117|DRUG|glargine|glargine once daily
223540015|NCT01378117|DRUG|lispro|lispro before meals
223540016|NCT04062058|RADIATION|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
223540017|NCT04062058|DRUG|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
223954672|NCT01405508|DRUG|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
223954673|NCT01405508|DRUG|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
223954674|NCT01405508|OTHER|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
224107060|NCT04407507|DRUG|Ivermectin|ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
224107061|NCT04407507|DRUG|Placebo|Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
224107062|NCT01661322|DRUG|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
224107063|NCT06490965|OTHER|Repetitive Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) involves generating a magnetic field with specific spatial and temporal properties, allowing the induction of electric current in conductive material near this field. The electro-physiological principle of TMS is based on placing a coil over the skull that will induce a magnetic field generating action potentials in neuronal tissue in response to each TMS pulse. The repetitive application of TMS pulses (rTMS) allows for the modulation of neuronal excitability for a period after rTMS, ranging from inhibition, in the case of low frequencies (\~1 Hz), or facilitation if high frequencies (equal to or greater than 5 Hz) are used.
223540018|NCT04062058|DRUG|SOX|SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
223540019|NCT04062058|PROCEDURE|Surgery|Surgery, preferred D2 lymphadenectomy
223540020|NCT00740181|DRUG|chemotherapy|
223540021|NCT03305484|OTHER|No intervention|No intervention, observation only
223540022|NCT00233532|DRUG|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
223540023|NCT03322163|OTHER|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
223723679|NCT04435860|OTHER|The Health assessment questionnaire (HAQ)|The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
223954675|NCT00866541|DEVICE|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
223954676|NCT05868356|DRUG|Treatment A|Oral adagrasib 200 mg twice daily (BID) for 8 days (Days 1 to 8). Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 2 to 7. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Days 1 and 8.
223540024|NCT04464551|DRUG|[14C]D-0316 suspension|Before administration, the drug preparation was placed at room temperature, and 40ml drinking water was added into each bottle to prepare suspension for the subjects to take. 40ml pure water was injected again. After washing the container, the subjects took orally. Repeat the previous step, and then used 160ml purified water. After the administration container was moistened for several times, the subjects took all the moistening lotion. Pay attention not to splash the liquid during mixing outside the bottle
223540025|NCT03151031|PROCEDURE|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
223540026|NCT02150239|PROCEDURE|operation|
223540027|NCT04044157|OTHER|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
223540028|NCT03988946|DEVICE|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
223540029|NCT02961244|OTHER|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
223954677|NCT05868356|DRUG|Treatment B|Oral adagrasib 200 mg BID and gemfibrozil 600 mg BID for 10 days (Days 9 to 18), with no evening dose of adagrasib or gemfibrozil on Day 18. Predose PK blood samples for the measurement of adagrasib concentration will be collected on Days 9 to 17 before the morning dose of adagrasib. Predose PK blood samples for the measurement of gemfibrozil trough concentration will be collected on Days 15 to 18 before the morning dose of gemfibrozil. Serial PK blood samples for adagrasib will be collected up to 12 hours postdose on Day 18.
223954678|NCT05904210|DRUG|SEVENFACT®|Coagulation Factor VIIa (Recombinant)
223540030|NCT02961244|DEVICE|Forced Air Warming blanket|
223540031|NCT01854528|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
223540032|NCT01854528|DRUG|Ribavirin|Tablet
223540033|NCT01854528|DRUG|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
223540034|NCT01854528|DRUG|Telaprevir|Film-coated tablet
223540035|NCT03767049|OTHER|Colection of clinical data|Colection of clinical data
223540036|NCT02017184|BIOLOGICAL|Noninvasive core temperature thermistor|
223540037|NCT03525509|DRUG|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
223540038|NCT03525509|DRUG|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
223540039|NCT05597384|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
223540040|NCT03789292|BIOLOGICAL|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
223540041|NCT03789292|BIOLOGICAL|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
223540042|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
223540043|NCT02814058|DRUG|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
223540044|NCT02717325|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
223540045|NCT02832414|BEHAVIORAL|Intensive weight loss program|behavioral and dietary supplement
223540046|NCT03012750|DRUG|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
223540047|NCT02828384|OTHER|low fodmap diet|dietary teaching
223540048|NCT02828384|DIETARY_SUPPLEMENT|Psyllium|7.1g of psyllium daily
223540049|NCT00928967|DRUG|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
223540050|NCT06239558|OTHER|Qualitative exploration|Semi-structured Interviews and focus group
223540051|NCT00465673|DRUG|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
223540052|NCT03920891|PROCEDURE|Cryoballoon Pulmonary Vein isolation|"1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223723680|NCT04435860|OTHER|Bath Ankylosing Spondylitis Metrology Index (BASMI)|Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
223540053|NCT03920891|PROCEDURE|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~3. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~4. Evaluated the procedure and radiofrequency ablation time.~5. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223723681|NCT03761160|OTHER|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
223723682|NCT03761160|OTHER|Usual care|Usual care per hospital guidelines
223954679|NCT03713229|DIAGNOSTIC_TEST|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
223954680|NCT03392805|BEHAVIORAL|physical activity|beginning of regular physical activity under the supervision of a coach
223954681|NCT06244563|DEVICE|Face mask with Hybrid-Hyrax|Participants were treated with face mask using a Hybrid-Hyrax appliance as an anchor in the maxillary arch. The anchorage of hybrid-hyrax appliance was provided by bands adapted to the maxillary first permanent molars and two mini screws in the anterior palate. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the hybrid-hyrax appliance in the maxillary canine region.
224107064|NCT06490965|OTHER|Neuronavigation|Neuronavigation is a non-invasive method that allows the creation of computerized three-dimensional models of brain structures based on neuroimaging exams of each individual (e.g., cranial magnetic resonance imaging). As such, this method has been used for various purposes, such as assisting in neurosurgery or mapping functional regions of the brain, but also in the context of TMS (Transcranial Magnetic Stimulation). In this latter area, its use as support for TMS has been employed for therapeutic, diagnostic, and research purposes. The neuronavigation system consists of several components, namely a locating camera, locators for the TMS coil, an adjustable headband with locators, a calibration system for these elements, and the neuronavigation software, which is installed on a supporting computer.
224107065|NCT06490965|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) is a non-invasive medical imaging technique that generates detailed images of the internal structures of the body using a strong magnetic field and radio waves. It provides high-resolution images of soft tissues, such as organs, muscles, and the brain, helping doctors diagnose and monitor various conditions, including injuries, tumors, and neurological disorders. MRI is particularly useful because it does not involve ionizing radiation, making it safer for patients than other imaging methods like X-rays or CT scans.
224107066|NCT02129764|DRUG|Prednisone|
224107067|NCT02129764|DRUG|Allopurinol|
224107068|NCT00212914|BEHAVIORAL|Reminder letter|
224107069|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
224107070|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
223540054|NCT01497834|DRUG|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
223540055|NCT01497834|DRUG|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
223540056|NCT01709357|OTHER|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
223723683|NCT01513473|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
223723684|NCT01513473|DRUG|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
223723685|NCT01513473|DRUG|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
223723686|NCT02414984|BIOLOGICAL|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
223723687|NCT03462082|OTHER|Asymmetric STN-DBS|Asymmetric deep brain stimulation
223723688|NCT06314542|OTHER|relaxing eligibility criteria|Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data
223540057|NCT01709357|OTHER|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
223540058|NCT01709357|OTHER|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
223723689|NCT01602146|OTHER|ultramarathon running|"* blood samples before and after ultramarathon~* urinary samples before and after ultramarathon~* voluntary ant electrically muscular forces measuring before and after ultramarathon~* Broadband ultrasound Attenuation before and after ultramarathon"
223723690|NCT03662490|DEVICE|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
223723691|NCT02150798|OTHER|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
223723692|NCT02150798|OTHER|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
223723693|NCT06138301|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a psychotherapeutic intervention that focuses on challenging and changing cognitive distortions (such as thoughts, beliefs, and attitudes) and their associated behaviours to improve emotional regulation and develop personal coping strategies that target solving current problems. In this study, patients with SI will undergo 8 sessions of CBT (45 min, once a week), remotely. Techniques and strategies of the intervention will be based on a short telepsychotherapy protocol previously published by our group (Biagianti et. al., 2021). Instead, the content of each session will be adapted to the psychopathology associated with social isolation and the age of the subject. The psychotherapeutic sessions of the patients will be audio-recorded in order to conduct retrospective analyzes of the patient's speech.
223723694|NCT06138301|BEHAVIORAL|Cognitive Remediation (CR)|The cognitive training will consist of 10 hours (30 minutes/session) of computer-based exercises focusing on working memory, attention, executive functions and social cognition, which will be performed online using BrainHQ software. This software allows for the customization of the training based on the specific characteristics of each subject. For example, it allows automatic adjustment of the difficulty of the exercises, trial by trial and session by session, in order to guarantee an adequate level of attention and motivation for the entire duration of the training and therefore favor optimal learning rates.
223723695|NCT00727181|DEVICE|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
223723696|NCT06076161|DIETARY_SUPPLEMENT|Spirulina supplementation and calorie restriction in obese men|The intervention group will be given spirulina platensis supplements at a dose of 2x2 /hr with a dose per capsule of 450 mg for 4 weeks with education about calorie restriction. The control group will be given placebo 2x2/day for 4 weeks with education on calorie restriction.
223723697|NCT02838303|OTHER|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
223723698|NCT02838303|OTHER|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
223723699|NCT04473924|DRUG|Mycophenolate Mofetil|Body surface area-based dosing of mycophenolate
223723700|NCT04473924|DRUG|Mycophenolate Mofetil|Standard (fixed) dosing of mycophenolate
224107071|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
224107072|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
223540059|NCT01709357|OTHER|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
223540060|NCT06304155|DIAGNOSTIC_TEST|Diagnostic efficacy,SUV|"The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-FDG and 18F-FAPI PET were calculated and compared to evaluate the diagnostic efficacy.~Standardized uptake value (SUV) of 18F-FDG and 18F-FAPI for each target lesion of subject or suspected primary tumor or/and metastasis."
223540061|NCT03789708|DIETARY_SUPPLEMENT|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
223540062|NCT03789708|OTHER|Placebo|Maltodextrin powder, easily soluble
223954682|NCT06244563|DEVICE|Face mask with Bonded RME|Participants were treated with face mask using a bonded RME appliance as an anchor in the maxillary arch. The anchorage of bonded RME appliance was provided by maxillary posterior teeth covered with acrylic cap. Force transmission was achieved using intermaxillary elastics that were connected to the face mask arms from the hooks of the bonded RME in the maxillary canine region.
223954683|NCT06244563|PROCEDURE|Alternative Rapid Maxillary Expansion and Contraction Protocol (Alt-RAMEC)|In the groups that started with the Alt-Ramec protocol, the parents expanded the appliance screw twice a day in the first week and closed it in the opposite direction in the following week. This process was continued for 7-9 weeks according to the patient's need for expansion.
223954684|NCT06244563|PROCEDURE|Routine Rapid Maxillary Expansion Protocol|In the groups that started with the routine protocol, parents activated the expansion screw twice a day for 1-2 weeks, depending on the patient's need for expansion.
223954685|NCT00610194|DRUG|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
223954686|NCT01775878|DEVICE|Telemonitoring Device|Telemonitoring device was installed in patients' homes
224107073|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
223540063|NCT03260712|DRUG|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
223540064|NCT03260712|DRUG|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
223540065|NCT03260712|DRUG|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
223540066|NCT05796687|BEHAVIORAL|My Future Self|My Future Self is based upon the Theory of Possible Selves, which promotes the capacity of young people to construct goals for a successful adulthood. Youth who hold a balanced set of negative and positive images of their future have both a) a positive goal to strive for and b) awareness of the personally relevant consequences of not meeting that goal. My Future Self also includes two new supportive gaming elements that reinforce learning of relevant knowledge and skills as well as provide opportunities for youth to individually practice these skills in a personalized virtual environment. Gaming interventions using interactive technology can significantly increase self-reported abstinence and lower reports of diagnosed STD in young women, as well as reduce risky sex in high-risk young men who have sex with men. Youth will participate in these gaming elements on tablets provided by CHLA. My Future Self will be implemented as a ninety-minute small group 5-week program.
223954687|NCT02767037|DEVICE|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
223954688|NCT02767037|GENETIC|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
223954689|NCT00999336|DRUG|Betrixaban|80 mg betrixaban qd for 8 days
223954690|NCT00476957|DEVICE|Stent|Stent implantation
223954691|NCT00476957|DEVICE|Stent|Stent implantation
223994608|NCT05790005|OTHER|therapeutic play|2 days after the operation, 1 hour before the dressing, a warm-up game will be played with the child in the playroom of the pediatric surgery service, aiming to put the organs prepared by the researcher in their correct places on the picture for the first 10 minutes. Then, the teddy bear, which is given the appearance of an operation area by sewing a zipper on his stomach, will be given to the child and he will be asked to make the first dressing of the teddy bear. therapeutic game, in which the dramatization method is used, will last 20 minutes. During the 30-minute play practice, the child's questions will be answered.
224107074|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
224107075|NCT00847613|DRUG|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
224107076|NCT00847613|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
224291071|NCT06616168|DIAGNOSTIC_TEST|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest)|Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest) produced by Erba Lachema leads to bacteria detection via biochemical features
224291072|NCT06616168|DRUG|Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin)|Antibiotic therapy after the results of antibiotic sensitivity test. Aminoglycosides, Carbapenems, Cephalosporins, Fluoroquinolones, Oxazolidinones are used. Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin are used for the therapy.
224291073|NCT06616168|COMBINATION_PRODUCT|Suppositoria for vaginal microflora recovery (Giynoflor)|Prescription of suppositoria for vaginal microflora recovery after antibiotic therapy. Probiotic grug includes Lactobacilli acidophillis as the main compound.
224291074|NCT06616168|DRUG|Antifungal therapy (Mostly Fluconazole, Nystatin, Amphotericin B)|Prescription of antifungal drugs. Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most
224291075|NCT04688047|BEHAVIORAL|Nursing care based on the transtheoretical model|Nursing care consists of urinary incontinence training, motivational interview and telephone/mail counseling processes.
224291076|NCT00744172|PROCEDURE|laparoscopy|laparoscopic hysterectomy
224291077|NCT00744172|PROCEDURE|vaginal|vaginal hysterectomy
224291078|NCT00744172|PROCEDURE|abdominal|abdominal hysterectomy
224291079|NCT01341587|DEVICE|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
223994609|NCT06555939|BEHAVIORAL|Collaborative Care Model|The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.
223994610|NCT06555939|BEHAVIORAL|Promoting Resilience in Stress Management|PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.
223540067|NCT01909544|OTHER|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
223540068|NCT02435654|DRUG|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
223540069|NCT03753022|OTHER|Group G5|Submitted to peep 5
223540070|NCT03753022|OTHER|Group G10|Submitted to peep 10
223540071|NCT03753022|OTHER|Group G15|Submitted to peep 15
223540072|NCT05362994|DEVICE|Selution SLR™ sirolimus-eluting balloon|If the residual stenosis is ≤30% after initial plain old balloon angioplasty, the investigators will perform angioplasty with the Selution SLR catheter, inflated at nominal pressure for at least 120 seconds. After dilatation of the entire target-lesion, biplane angiograms and IVUS imaging will be obtained. Technical success is defined as residual diameter stenosis ≤30% and adequate distal run-off. Bail-out stenting will be performed if residual stenosis is \>30%, either after plain old balloon angioplasty or angioplasty with Selution SLR. For lesions with residual stenosis \>30% but not suitable for stenting, repeat angioplasty will be performed for at most twice.
223540073|NCT05362994|DEVICE|Plain old balloon angioplasty|The investigators routinely start with a balloon catheter with a diameter ≥0.5 mm smaller than the reference vessel and ended with a balloon catheter with the size approximately equal to the reference vessel diameter. Three minutes after balloon predilation, the investigators will obtain an angiogram. If the residual stenosis is ≤30%, no further intervention will be performed in the plain old balloon (POB) group.
223723701|NCT01811160|DRUG|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
224291080|NCT00754494|DRUG|erlotinib hydrochloride|Given PO
224291081|NCT00754494|OTHER|placebo|Given PO
224291082|NCT00754494|OTHER|laboratory biomarker analysis|Correlative studies
224291083|NCT00542360|BEHAVIORAL|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
224291084|NCT00006331|PROCEDURE|renal transplant|
224291085|NCT03304340|DEVICE|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
224291086|NCT03304340|DEVICE|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
224291087|NCT03304340|OTHER|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
224291088|NCT05815368|DEVICE|REMO|REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
224291089|NCT05815368|OTHER|Task-Oriented Training|Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
224291090|NCT03553563|DRUG|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
224291091|NCT03553563|DRUG|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
224291092|NCT04715776|DIETARY_SUPPLEMENT|Brown seaweed|Uptake of 1650 mg brown seaweed product twice daily
224291093|NCT04715776|DIETARY_SUPPLEMENT|placebo|Uptake of 1650 mg placebo twice daily
224291094|NCT06616974|DRUG|TX000045- Dose A|The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
224291095|NCT06616974|DRUG|TX000045- Dose B|The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
224291096|NCT06616974|DRUG|Placebo|The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
224291097|NCT01975194|DRUG|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
224291098|NCT05127694|OTHER|Vestibular Rehabilitation|Vestibular Rehabilitation which is consist of repetitive exercises and canalit repositioning maneuvers
224291099|NCT03261362|DIETARY_SUPPLEMENT|Branched-chain amino acids reduced intake|
224291100|NCT02488668|DEVICE|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
224291101|NCT01117467|OTHER|Simulation scenario|Students performing their scenario will be paired, not solo
224291102|NCT01117467|OTHER|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
223723702|NCT01811160|DRUG|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
223723703|NCT04348773|PROCEDURE|Dehydration|Dehydration of the natural tooth by tooth isolation
223723704|NCT04348773|PROCEDURE|Rehydration|Rehydration
223994611|NCT07024017|DEVICE|Foam roller|FR will be applied to each hamstring muscle for 3 minutes per leg, totaling 6 minutes. The pressure was self-regulated by participants, who are instructed to apply as much body weight as tolerable. The rolling frequency is maintained at approximately 0.5 Hz, corresponding to one complete rolling cycle every 2 seconds. Before the intervention, participants will receive verbal and visual instructions to ensure correct execution.
223994612|NCT07024017|OTHER|dynamic stretch|"10 different exercises will be performed over a 13-meter distance, with a 10-second rest period between exercises.~During the session, participants will receive verbal feedback to ensure proper posture and technique. Exercises will be video recorded and shared with participants for review and consistency."
223723705|NCT00960778|DRUG|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
223723706|NCT00960778|OTHER|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
223723707|NCT02164760|DEVICE|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
223723708|NCT03508921|DRUG|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
223954692|NCT05951335|OTHER|m-Health Transition Care Program|The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
223954693|NCT01424345|DRUG|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
223954694|NCT01424345|DRUG|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
223954695|NCT01589211|BEHAVIORAL|Brief advice|Brief advice of about 10 min accompanied by self-help material
223954696|NCT01589211|BEHAVIORAL|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
223954697|NCT01589211|BEHAVIORAL|Standard cessation course|Cessation course over 6 dates. Group setting.
223954698|NCT06341946|DEVICE|Endoscopic third ventriculostomy|role of endoscopic third ventriculostomy in management of malfunctioning ventriculoperitoneal shunt
224107077|NCT01609283|BIOLOGICAL|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~* Group 1: single intrathecal dose of 1 x 107 cells~* Group 2: single intrathecal dose of 5 x 107 cells~* Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~* Group 4: single intrathecal dose of 1 x 108 cells~* Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
224107078|NCT00862602|BEHAVIORAL|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet \& nutrition and prevention.
224107079|NCT04935944|RADIATION|CBCT radiation|CBCT scanning
224107080|NCT02039154|BEHAVIORAL|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
223954699|NCT02159352|DRUG|Daclatasvir|
223954700|NCT02159352|DRUG|Darunavir|
223954701|NCT02159352|DRUG|Ritonavir|
223540074|NCT01855386|OTHER|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
223954702|NCT02159352|DRUG|Lopinavir/Ritonavir|
223540075|NCT01855386|OTHER|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
223540076|NCT04123730|OTHER|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
223540077|NCT00001561|DRUG|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
223540078|NCT00001561|DRUG|GM-CSF|
223540079|NCT05100134|DRUG|ceritinib|Patients receive ceritinib
223540080|NCT02449941|DRUG|PPI (proton pump inhibitor)|"1. Pre ESD (endoscopic submucosal dissection)~   * Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~  * Use of PPI for 2 months~2. Post ESD 1 (After 2 months)~   * Assess the distribution of helicobacter pylori after using PPI.~  * Stop of PPI~3. Post ESD 2 (After 4 months)~   * Assess the distribution of helicobacter pylori after stop of PPI."
223540081|NCT05236166|DRUG|Rapid withdrawal of antiepileptic|"Reduction by about 20 % of initial dosage every 15 days until complete discontinuation (total withdrawal time: 60 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
223540082|NCT05236166|DRUG|Slow withdrawal of antiepileptic|"Slow withdrawal: reduction by about 20 % of initial dosage every 40 days, until complete discontinuation (total withdrawal time: 160 days).~Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide"
223540083|NCT00956761|BIOLOGICAL|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
223540084|NCT01904721|DRUG|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
223540085|NCT01904721|DRUG|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
223540086|NCT01904721|DRUG|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
223540087|NCT01957865|DEVICE|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
223540088|NCT01957865|DEVICE|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
223540089|NCT04927221|DRUG|DC371739 Tablets|Participants received one of 5 dose levels of DC371739 administered as single oral doses.
223540090|NCT04927221|DRUG|Placebo|Placebo orally administered as comparison
223540091|NCT01082614|DEVICE|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV \> 12%.
223540092|NCT01465009|DRUG|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
223540093|NCT01465009|DRUG|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
223540094|NCT01465009|DRUG|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
224107081|NCT02039154|BEHAVIORAL|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
223540095|NCT02524561|DRUG|CEE pill|Conjugated equine estrogens 0.45 mg/day
223540096|NCT02524561|DRUG|Estradiol patch|Climara 50 mcg/day
223540097|NCT02524561|DRUG|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
223540098|NCT02524561|OTHER|Placebo tablet|Placebo tablet
223540099|NCT02524561|OTHER|Placebo patch|placebo patch
223540100|NCT02524561|OTHER|Placebo progesterone|placebo progesterone
223540101|NCT02616731|DRUG|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
223540102|NCT02616731|DRUG|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
223540103|NCT02826616|DRUG|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
223540104|NCT00811720|DRUG|Placebo|as-needed use, tablets, orally, 6 months
223540105|NCT00811720|DRUG|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
224107082|NCT05572099|DIAGNOSTIC_TEST|ExoDx Prostate|Observational only.
223954703|NCT06197035|PROCEDURE|Coping With and Caring for Infants With Special Needs|The early intervention programme for infants and young children focuses on the active inclusion of the whole family. The coaching of parents is a central component. Parents learn how they can independently and optimally support their child's development as part of the child's everyday life. The programme was developed at the beginning of the 2000s in the Netherlands by child physiotherapist Tineke Dirks and professor of developmental neurology Mijna Hadders-Algra.
223540106|NCT04127526|OTHER|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
223954704|NCT06197035|PROCEDURE|Standard Physiotherapy|Pediatric physiotherapy techniques aimed at improving the development of the baby and young child from manual therapy tools, or baby management.
223540107|NCT05874726|DIAGNOSTIC_TEST|Blood Collection|Blood collection via venipuncture
223954705|NCT02788994|DEVICE|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~* stable fracture synthesis for fast rehabilitation and early mobilization~* an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
223540108|NCT05874726|DIAGNOSTIC_TEST|Urine Collection|Free catch urine sample collection
223540109|NCT05874726|DIAGNOSTIC_TEST|Tissue Sample Collection|Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
223540110|NCT00120133|DRUG|Atorvastatin|
223540111|NCT00553631|BIOLOGICAL|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
223540112|NCT00553631|BIOLOGICAL|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
223540113|NCT02453893|DRUG|Iloperidone|
223540114|NCT02453893|DRUG|Risperidone|
223954706|NCT02788994|DEVICE|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
223954707|NCT00529529|DRUG|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
223954708|NCT00529529|DRUG|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
223954709|NCT00529529|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
223954710|NCT00529529|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
223994613|NCT05059184|OTHER|This is an observational cross-sectional study, there is no need for intervention|This is an observational cross-sectional study. There is no need for intervention
223994614|NCT07029919|BEHAVIORAL|PATH-S app|PATH-S will use casual gaming and intermittent reinforcement techniques to encourage high risk teens to adopt and persist with personalized habits to improve sleep.
223994615|NCT07030686|BEHAVIORAL|Exercise|Exercise following completion of active treatment for the primary index cancer
223540115|NCT02184676|BIOLOGICAL|Analysis of early immune modifications|"* blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
223954711|NCT03046888|PROCEDURE|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
223954712|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
223954713|NCT01214109|DRUG|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
223954714|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
223954715|NCT01214109|DRUG|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
223954716|NCT03500809|PROCEDURE|Aqueous release of the wound|"1. Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~2. This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
223954717|NCT03717558|DRUG|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
223954718|NCT03717558|DRUG|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
223954719|NCT03717558|DRUG|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
223954720|NCT03858556|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
223954721|NCT03858556|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
223954722|NCT03858556|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223954723|NCT03858556|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223954724|NCT03858556|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223540116|NCT02184676|OTHER|Collection of clinical and socio-demographic data|"1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
223540117|NCT05345548|DIAGNOSTIC_TEST|Cold Pressor test|Cold Pressor test will be done for 3 minute duration maximum
223954725|NCT03858556|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223954726|NCT03858556|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
223954727|NCT03858556|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
223954728|NCT00817739|DRUG|Leuprorelin|Leuprorelin injection
223954729|NCT00817739|DRUG|Flutamide|Flutamide tablets
223954730|NCT00098735|DRUG|FTY720|
223540118|NCT04236089|DEVICE|robotic hand|mirror therapy with robotic hand
223540119|NCT01060943|DEVICE|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
223954731|NCT05688891|OTHER|Virtual reality|"5 minutes before the burn dressing procedure, virtual reality glasses were put on the patient's head by the researcher and a 360° VR video with submarine and nature content pre-loaded on the glasses was opened.~Audio and video settings were made and started to be watched. Video monitoring with Virtual Reality continued throughout the entire dressing. This procedure was performed during 2 consecutive dressing changes. A 1-week period was given between 2 dressings."
223540120|NCT01060943|DEVICE|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
223540121|NCT03172273|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
223540122|NCT03172273|PROCEDURE|paracentesis|paracentasis plus albumine invision
223540123|NCT02774434|DEVICE|JM-105|Measurement of TcB via the JM-105 device
223540124|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
223540125|NCT03765125|DIETARY_SUPPLEMENT|collagen peptide placebo|collagen peptide placebo
223540126|NCT02616939|OTHER|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
223540127|NCT01842373|DRUG|LMX4|
223540128|NCT01842373|DRUG|BLT|
223540129|NCT01664754|DRUG|exemestane|Given PO
223540130|NCT01664754|DRUG|pemetrexed disodium|Given IV
223540131|NCT01664754|DRUG|carboplatin|Given IV
223540132|NCT01664754|OTHER|laboratory biomarker analysis|Correlative studies
223540133|NCT01664754|OTHER|pharmacological study|Correlative studies
223540134|NCT01664754|OTHER|questionnaire administration|Ancillary studies
223540135|NCT01664754|PROCEDURE|quality-of-life assessment|Ancillary studies
223540136|NCT01769053|OTHER|Variable Ventilation|
223540137|NCT00844103|DRUG|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
223540138|NCT00844103|DRUG|Placebo|10ml oral solution administered once a day over 10 days.
223540139|NCT02109289|DRUG|etanercept|Etanercept is a tumor necrosis factor antagonist
223540140|NCT05152251|OTHER|Evaluation|Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
223540141|NCT06312189|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
223540142|NCT00296218|DRUG|Irbesartan|
223994616|NCT07034027|BEHAVIORAL|Project WAVE (Wise Awareness of Visiting Emotions)|Project WAVE is an online, self-directed single-session intervention designed to foster emotional nonreactivity skills in young adults aged 18-29.
224107083|NCT03469310|DRUG|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
223540143|NCT00891696|DRUG|Rapamycin|Single 16-mg oral dose
223540144|NCT00891696|OTHER|Amino acid supplementation|Nutritional drink containing essential amino acids
223540145|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
223540146|NCT00891696|DRUG|Sodium nitroprusside|Variable rate for 3 hours
223540147|NCT00891696|DEVICE|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
223540148|NCT00891696|OTHER|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
223994617|NCT07034027|BEHAVIORAL|Emotionally Neutral Writing Control|The control condition is an online, self-directed single-session activity that includes an emotionally neutral writing task.
224107084|NCT03469310|DRUG|Tylenol #3 Oral Tablet|Narcotic medication first
223954732|NCT05688891|OTHER|Music|"5 minutes before the burn dressing procedure, the patient was asked about the type of music he preferred in the introductory patient information form. Then, the patient was started to listen after putting on headphones and adjusting the volume. The patient was asked to keep his eyes closed while listening to music. Music listening was continued throughout the entire dressing.~After the process was finished, the music was turned off and the headphones were removed.~This procedure was performed during 2 dressing changes in accordance with clinical treatment and protocols.~A 1-week period was given between 2 dressings."
223954733|NCT01394835|DRUG|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
223954734|NCT01394835|DRUG|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
223954735|NCT01394835|DRUG|AAT|Inhalation twice daily' 160mg
223540149|NCT05820048|DRUG|Lansoprazole 15 mg|"1. Short-term treatment of active duodenal ulcer~2. Short-term treatment of active benign gastric ulcers~3. Thin heat of Helicobacter pylori to prevent recurrence of duodenal ulcer~4. Maintain duodenal ulcer after treatmentLaw~5. Treatment of nonsteroidal anti-inflammatory analgesics-induced gastric ulcers~6. Reducing the risk of developing nonsteroidal anti-inflammatory analgesic-induced gastric ulcers~7. Short-term treatment of gastroesophageal reflux disease~8. Short-term treatment of erosive reflux esophagitis~9. Post-treatment maintenance therapy for erosive reflux esophagitis~10. Pathological hyperdivision, including Zolinger Ellison syndrome"
223540150|NCT06167577|DIAGNOSTIC_TEST|Psychometric scales (BPRS, MRS, HAM-D, SES, and GAF) monthly|we will correlate the clinical/neuropsychological response to antipsychotics with the presence of the functional DysBray haplotype of the DTNBP1 gene
223540151|NCT00325507|BIOLOGICAL|TroVax|TroVax 1 x 10E9 TCID 50mL
223540152|NCT00325507|DRUG|IL-2|IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
223540153|NCT04831905|DEVICE|Micro-wave ablation|Micro-wave ablation
223540154|NCT04539834|OTHER|electrolytes|measuring level of electrolytes
223540155|NCT01600404|DRUG|antimuscarinic treatment|
223540156|NCT01215656|DIETARY_SUPPLEMENT|Lactobacillus fermentum|
223540157|NCT01215656|DIETARY_SUPPLEMENT|Follow on formula without probiotics|
223540158|NCT02487160|DEVICE|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
223540159|NCT02487160|DEVICE|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
223540160|NCT01518387|DRUG|Lanthanum Carbonate (BAY77-1931)|
223540161|NCT01063790|BEHAVIORAL|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
223540162|NCT00285844|BEHAVIORAL|weight loss|
223540163|NCT00285844|DRUG|thiazolidinedione|
223540164|NCT01055613|DEVICE|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
223540165|NCT01055613|DEVICE|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
223540166|NCT06209294|DRUG|AK104|AK104(10 mg/kg) d1,22
223540167|NCT06209294|DRUG|Carboplatin|AUC=2 d1,8,15,22, 29, 36
223540168|NCT06209294|DRUG|Nab paclitaxel|125mg／m2 d1,8,15,22,29,36
223540169|NCT03707886|BEHAVIORAL|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
223540170|NCT03707886|OTHER|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
223540171|NCT02393339|DRUG|paracetamol|Pre-operative administration of Paracetamol syrup
223540172|NCT02393339|DRUG|placebo|Pre-operative administration of placebo syrup
223540173|NCT02765399|DRUG|Liraglutide|
223540174|NCT02765399|DRUG|Placebo|
223540175|NCT00768261|DRUG|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
223540176|NCT00768261|DRUG|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
223540177|NCT04858373|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223540178|NCT04858373|OTHER|Emmer bread from Greek emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Greek emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223540179|NCT04858373|OTHER|Emmer bread from Italian emmer|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from Italian emmer bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223540180|NCT04858373|OTHER|Whole wheat commercial bread|Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g available carbohydrates from whole wheat commercial bread, tested once, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
223540181|NCT04476381|PROCEDURE|Dry needling|Insertion of a Optimed 40mm x 0.30 single use, sterile acupuncture needle into a active trigger point in the infraspinatus muscle
223540182|NCT06495073|OTHER|PROMIS-10 and TOPICS-SF|"There will be no intervention. The participants will be asked to fill in questionnaires at two time points: the first time will be after informed consent when they are at the hospital for diagnostic evaluation of the TIA or ischemic stroke, and the second time will be 4 weeks later, with a window of 2 weeks (allowing a range of 2-6 weeks). The second time point is chosen because the investigators suspect that by then, around 50% will be in the improved group. At the first time point, the participants will be asked to fill in the PROMIS-10 and element D and E of the TOPICS-SF - which are the elements used to determine the functional limitations and the psychological wellbeing. At the second time point, the participants will be asked to answer the same questions, as well as three additional anchor questions."
223540183|NCT02810795|OTHER|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
223954736|NCT00007306|DRUG|Parathyroid hormone ointment|
223954737|NCT01741207|DRUG|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
224107085|NCT03469310|DRUG|Tramadol|non-narcotic medication first with narcotic as second choice
223954738|NCT00165035|DEVICE|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
223540184|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
223540185|NCT01302925|DRUG|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
223540186|NCT00989976|BEHAVIORAL|normal sleep times|8.5 h bedtimes
223540187|NCT00989976|BEHAVIORAL|bedtime restriction|4.5 h restricted bedtimes
223540188|NCT05267535|DRUG|Piromelatine 20 mg|Tablets
223540189|NCT05267535|DRUG|Placebo|Tablets
223540190|NCT03331991|BIOLOGICAL|influenza vaccine|exposure to influenza vaccine
223540191|NCT02636010|DRUG|Pembrolizumab|
223540192|NCT04915638|DIETARY_SUPPLEMENT|Experimental intervention group with enriched cookies|Enriched cookies containing a micronutrients formula (vitamins, minerals, antioxidants, and omega-3 fatty acids) each day (Monday to Friday).
223540193|NCT05023057|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training using the tablet PC application twice a week, exercise 3 times a week, nutrition education 12 times, anthropometric measurements and alcohol and smoking monitoring every 4 weeks, motivation reinforcement training 4 times.
223540194|NCT01080417|DRUG|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
223540195|NCT04138511|DEVICE|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
223954739|NCT00165035|DEVICE|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
223954740|NCT05567848|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with functional MRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses per session. Sessions will be separated by an interval of 50 minutes (up to a total of 8 per day)."
223954741|NCT01790542|OTHER|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
224107086|NCT02404506|DRUG|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
224107087|NCT00463970|BEHAVIORAL|Brief Intervention|Physical examination, education and follow up by a physiotherapist
223540196|NCT03484728|BEHAVIORAL|placebo manipulation|application of nonactive body cream on forearm
223540197|NCT04078204|DRUG|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
223954742|NCT01790542|OTHER|Iron fortified cereal with fruit|
223954743|NCT01790542|OTHER|Meat|
223954744|NCT01916109|DRUG|Gemcitabine|
223954745|NCT01916109|DRUG|Carboplatin|
223954746|NCT01916109|DRUG|Panitumumab|
223540198|NCT04078204|DRUG|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
223540199|NCT02348580|BEHAVIORAL|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
223540200|NCT01908010|DRUG|ABT-354|ABT-354 Low Dose
223540201|NCT01908010|DRUG|ABT-354|ABT-354 High Dose
223540202|NCT01908010|DRUG|Placebo|Placebo
223540203|NCT05497375|DIAGNOSTIC_TEST|The amount of intraoperative bleeding|Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
223954747|NCT01916109|PROCEDURE|radical cystectomy|
223954748|NCT04704856|BEHAVIORAL|Supervised exercise|Supervised exercise during first 6 weeks of neoadjuvant chemotherapy.
223954749|NCT00001806|OTHER|Genetic Education and Counseling|Group Education and Counseling
223954750|NCT00001806|OTHER|Genetic Education and Counseling|Individual Education and Counlseing
223954751|NCT03987815|DRUG|Nivolumab|Nivolumab
223954752|NCT05125549|DRUG|Сlopidogrel bisulfate film-coated tablets, 75 mg (JSC Farmak, Ukraine)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
223954753|NCT05125549|DRUG|Plavix® 75 mg film-coated tablets (Sanofi Winthrop Industrie, France)|One film-coated tablet was administrated orally with 240 ml of water after an overnight fast
223954754|NCT04101045|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
224107088|NCT00463970|BEHAVIORAL|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
223954755|NCT00490906|DRUG|Copaxone|20 mg, subcutaneous injections, taken daily
223954756|NCT00490906|DRUG|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
224107089|NCT00463970|DIETARY_SUPPLEMENT|Seal oil|20 capsules per day for 3 months
223954757|NCT00490906|DRUG|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
223954758|NCT01036932|DRUG|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
223954759|NCT01036932|DRUG|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
223954760|NCT00165048|DRUG|Vioxx (Rofecoxib)|
223954761|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia® bitter|"* ingredients: concentrated watery extract of olives 94%, lemon juice 6%~* 35 mg hydroxytyrosol, 0,24 mg Oleuropein"
224107090|NCT00463970|DIETARY_SUPPLEMENT|Soy oil|20 capsules per day for 3 months
224107091|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
224107092|NCT04788563|DRUG|Original antihypertensive treatment (compulsively randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
223540204|NCT05497375|DIAGNOSTIC_TEST|Quality of the intraoperative surgical field|Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)
223540205|NCT05497375|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
223540206|NCT05497375|DIAGNOSTIC_TEST|Heart rate|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
223954762|NCT04876261|DIETARY_SUPPLEMENT|Oliphenolia®|"* ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30%~* 38 mg hydroxytyrosol, 0,28 mg Oleuropein"
223954763|NCT04876261|DIETARY_SUPPLEMENT|La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol|"* extra virgin olive oil~* 5 mg hydroxytyrosol"
223540207|NCT05497375|DIAGNOSTIC_TEST|Mean arterial pressure|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
223540208|NCT05497375|DIAGNOSTIC_TEST|Peripheral oxygen saturation|From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
223540209|NCT00002548|BIOLOGICAL|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
223540210|NCT00002548|DRUG|carmustine|20 mg/m2 I.V. day 1 q 35 days
223540211|NCT00002548|DRUG|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
223954764|NCT02111499|DRUG|LAS41004-IMP1|daily topical application
223954765|NCT02111499|DRUG|LAS41004 IMP2|daily topical application
223540212|NCT00002548|DRUG|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
223540213|NCT00002548|DRUG|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
223540214|NCT00002548|DRUG|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
223540215|NCT00002548|DRUG|prednisone|40 mg/m2 PO days 1-7 q 35 days
223540216|NCT00002548|DRUG|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
223540217|NCT00002548|PROCEDURE|allogeneic bone marrow transplantation|day 0
223540218|NCT00002548|PROCEDURE|autologous bone marrow transplantation|day 0
223540219|NCT00002548|PROCEDURE|peripheral blood stem cell transplantation|day 0
223540220|NCT00002548|RADIATION|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
223540221|NCT06361004|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (GPi, amGPi, pvGPi, Cm-Spv-Voi, Cm-Voi, NA-ALIC, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
223540222|NCT05364398|PROCEDURE|ACL reconstruction|Use of hamstring tendons graft to replace the torn ACL and being passed and fixed through the femoral and tibial sides
223540223|NCT04155476|DRUG|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
223954766|NCT02111499|DRUG|LAS41004 IMP3|daily topical application
223954767|NCT02111499|DRUG|LAS41004 IMP4|daily topical application
223954768|NCT02111499|DRUG|LAS41004 IMP6|daily topical application
223954769|NCT02111499|DRUG|LAS41004 IMP5|once daily, topical
223954770|NCT01821040|DRUG|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
223540224|NCT01832610|DEVICE|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
223540225|NCT02656667|DEVICE|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
223540226|NCT02656667|DEVICE|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
223540227|NCT02656667|OTHER|Conventional pulmonary rehabilitation|excercise training on treadmill
223540228|NCT03891888|PROCEDURE|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
223540229|NCT05784181|DEVICE|bipolar transurethral resection and Laser enaculation by holmium: YAG laser|Laser enaculation by holmium: YAG laser
223540230|NCT03304366|DIAGNOSTIC_TEST|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
223540231|NCT04944576|DEVICE|Total Ankle Prosthesis, EasyMove®|Patients who will be implanted with a total ankle prosthesis, EasyMove.
223540232|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
223540233|NCT03708367|DEVICE|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
223540234|NCT05270993|BEHAVIORAL|Traditional Centre-based Cardiac Rehabilitation (CBCR) group|A 4-week centre-based outpatient cardiac rehabilitation programme where patients will receive 12 group-based sessions. Patients will also be given access to online educational resources. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
223954771|NCT01821040|DRUG|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
223954772|NCT03032965|DRUG|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
223954773|NCT03032965|DRUG|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
223954774|NCT00636168|DRUG|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
223540235|NCT05270993|BEHAVIORAL|I-CREST group|A 6-week home-based cardiac rehabilitation programme where participants will receive an I-CREST app (to deliver education, medication reminders, exercise and vital monitoring) and a wearable smartwatch device (to track physical activity). Participants will be remotely supervised by the cardiac rehabilitation team via an I-CREST web-portal. Participants will also receive all usual nursing, medical and follow-up service provided by the hospital.
223540236|NCT02093260|BIOLOGICAL|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
223954775|NCT00636168|DRUG|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
223954776|NCT02033915|OTHER|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
223540237|NCT03396159|DIAGNOSTIC_TEST|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
223540238|NCT05318508|OTHER|Measurements of sagittal spinopelvic parameters|Sagittal spinopelvic parameters will be measured from lateral cervicothoracolumbar radiographs of patients with lower extremity amputation.
223540239|NCT00624858|DRUG|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
223723709|NCT03508921|DRUG|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
223723710|NCT03508921|PROCEDURE|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
223723711|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
223723712|NCT03555955|DRUG|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
224107093|NCT04788563|OTHER|Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
223723713|NCT01101932|DRUG|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
223723714|NCT01101932|DRUG|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
223723715|NCT01101932|DRUG|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
223723716|NCT05184244|OTHER|Activity Limitation Assessment|The ACTIVLIM-CP scale evaluates the global activity performance and combined movements of the body.
223723717|NCT04446520|PROCEDURE|autogenic drainage|breathing control using expiratory airflow to mobilize secretions from smaller to larger airways. Secretions are cleared independently by adjusting the depth and speed of respiration in a sequence of controlled breathing techniques during exhalation in addition to traditional physiotherapy (deep breathing exercise, diaphragmatic breathing and splinted coughing)
224107094|NCT04788563|DRUG|Original antihypertensive treatment (voluntarily randomized arm)|In this group, patients will maintain their original antihypertensive treatment.
224107095|NCT04788563|OTHER|Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)|In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.
224107096|NCT04788563|DRUG|Original antihypertensive treatment (preference selection arm)|In this group, patients will maintain their original antihypertensive treatment.
223540240|NCT05253404|DEVICE|Ambu® AuraOnce™ Disposable Laryngeal Mask|Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
224107097|NCT03178461|OTHER|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
224107098|NCT00691574|DIETARY_SUPPLEMENT|Melatonin|up to 3 mg, daily, for up to 1 year
223540241|NCT04908293|OTHER|Biorepair toothpaste|Use of New Biorepair Advanced Sensitive for home oral care.
223540242|NCT04908293|OTHER|Colgate toothpaste|Use of Colgate toothpaste for home oral care.
223540243|NCT02525679|DRUG|BI 655130 (spesolimab)|
223540244|NCT02525679|DRUG|Placebo|
223954777|NCT01634295|DRUG|CKD-828 2.5/40mg|"* Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
223954778|NCT01634295|DRUG|CKD-828 5/40mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks."
223954779|NCT01634295|DRUG|CKD-828 5/80mg|"* Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks."
223954780|NCT01634295|DRUG|S-amlodipine 2.5mg|"* S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks."
223540245|NCT03391999|OTHER|A questionnaire; CHU9D|Measuring Health Related Quality of Life
223540246|NCT00447967|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
223540247|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
223954781|NCT01634295|DRUG|S-amlodipine 5mg|"* S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks."
223954782|NCT04618211|DRUG|Deucrictibant|deucrictibant soft capsules for oral use
223954783|NCT04618211|DRUG|Placebo|Matching placebo capsules for oral use
223540248|NCT00447967|DRUG|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
223540249|NCT00447967|DRUG|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
223540250|NCT00447967|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
223540251|NCT03322982|BEHAVIORAL|Low-fat diet|less than 20% calories from fat daily
223954784|NCT04309578|DRUG|Trastuzumab, Capecitabine and Cisplatin|"* Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1"
223540252|NCT01822665|DRUG|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
223540253|NCT01822665|DRUG|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
223540254|NCT01822665|OTHER|Placebo|Placebo tablets
223540255|NCT01828840|DRUG|epidural morphine via PCEA|
223954785|NCT00000497|BEHAVIORAL|diet, sodium-restricted|
223954786|NCT00000497|BEHAVIORAL|diet, reducing|
223954787|NCT01960738|OTHER|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
223954788|NCT05068050|PROCEDURE|Horse-assisted therapy|"12 horse-assisted therapy sessions (45 mins each) for 6 weeks.~Each session will comprise the next stages:~Groundwork, Approachment and preparation of the horse, Warm up exercises~Development of the main part (riding):~Introduction - beginning: Breathing control and body awareness, maintain sitting (riding position) while walking on the horse, perceiving the movement Exercises for the postural and balance control: Variations in the walking of the horse, realize different figures in the arena (circles, serpentines, change direction…), Stopping and Walking, Arms situation combined with the movement of the horse All exercises are determined in the track design protocol Exercises for the acquisition of motion skills: Finished the riding with relaxation activities. Final part: Dismount the horse, Unsaddled and unbridle, feedback and goodbye procedure."
223954789|NCT05068050|PROCEDURE|Physical exercise|"12 physical exercise sessions (45 mins each) for 6 weeks. Each session Each session Lessons will be held by physical activity professionals. The proposed exercises are focussed on improving the articular movements, aerobic resistance and the proprioception, always on the premises of No Pain.~Lessons will be divided in three parts :~1\. Warmup - 2. Main part - 3. Return to calm~Lessons will be hold online"
223540256|NCT01828840|DRUG|epidural fentanyl via PCEA|
223540257|NCT01828840|DRUG|epidural methadone via PCEA|
223540258|NCT01828840|DRUG|intravenous morphine via PCA|
223540259|NCT04781348|PROCEDURE|Platelet Rich Plasma plus fat grafting|The study participants fulfilling the inclusion criteria giving consent will be randomly divided into two groups, one group will receive only fat grafting whereas another group will receive Platelet Rich Plasma plus fat grafting.
223540260|NCT02940925|OTHER|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
223540261|NCT02940925|OTHER|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
223540262|NCT05691933|PROCEDURE|Block group|Patient will be subjected to bilateral external oblique intercostal plane block
223540263|NCT05691933|PROCEDURE|Morphine infusion|Patients will be subjected to morphine infusion at a rate of 0.03mg/kg/h
223540264|NCT04540367|DEVICE|Blood flow restriction therapy|The study group underwent the same exercises as the control group modified by the use of a tourniquet for blood flow restriction during those exercises.
223540265|NCT02001246|BEHAVIORAL|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
223540266|NCT02001246|BEHAVIORAL|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
223540267|NCT03257384|OTHER|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
223540268|NCT04908150|OTHER|Core training|A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
223540269|NCT05654584|PROCEDURE|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery will be performed by a single surgeon.
223540270|NCT05572840|OTHER|Training and activities|"The training program consists of two modules. The 1st module consists of a theoretical lecture (powerpoint presentation) and an activity (application of hygienic handwashing by the researcher) explaining what to do for hygienic handwashing. The 2nd module consists of the theoretical explanation (powerpoint presentation) in which the correct mask usage is explained and the activity (the make your own mask activity by painting the masks)."
223540271|NCT00508092|PROCEDURE|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
223540272|NCT05423184|OTHER|Exercise Therapy For Lower Extremities|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their standardize exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg raise with theraband, squat, lunge walk and static balance exercises. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
223723718|NCT04165785|DEVICE|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
223954790|NCT02296593|DEVICE|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
223954791|NCT03705572|DIETARY_SUPPLEMENT|Lacprodan PL20|Milk protein concentrate that is high in phospholipid content (min 16%).
224107099|NCT00691574|DEVICE|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
223954792|NCT03705572|OTHER|Placebo|Placebo milk drink.
223954793|NCT06403410|OTHER|Delirium Prevention Guideline|Each intervention group patient randomized will receive the Delirium Prevention Guideline. The guideline is designed to be followed by nurses. However, collaboration with the physician is required for some aspects of the guideline (pain control, ordering/follow-up of laboratory tests, etc.). Support will be obtained from the intensive care physician, who is a member of the research team, for these steps. The guideline includes standard practices used by intensive care nurses in patient monitoring. In addition to routine follow-ups, eye masks and earplugs will be applied to patients in the intervention group between 24:00 and 06:00.
223954794|NCT02707952|DRUG|ABT-493/ABT-530|Co-formulated tablet
223954795|NCT02707952|DRUG|OBV/PTV/r|Co-formulated tablet
224107100|NCT00073944|DRUG|forodesine hydrochloride|
224107101|NCT02472483|BEHAVIORAL|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
224107102|NCT02472483|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
224107103|NCT00446212|DRUG|Propofol|target controlled infusion of propofol
224107104|NCT00446212|DRUG|desflurane|Anaesthetic maintenance with desflurane
224107105|NCT00851110|PROCEDURE|stem cell reinfusion|hematopoietic stem cell reinfusion
224107106|NCT00851110|DRUG|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
224107107|NCT03935646|DRUG|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
224107108|NCT03935646|DRUG|Placebo|Placebo
224107109|NCT05616234|PROCEDURE|Resistance Exercise|Participants will perform a bout of lower body resistance exercise consisting of leg press, leg extension and leg curls.
223540273|NCT05423184|OTHER|Exercise Therapy For Myofascial Chains|Participants who have inclusion criterias after ACL reconstrontion pos-op 8. week will included this study. Certified Physiotherapist who have master of science degree and doctorate student will assessed them before and after treatment with face to face. Also exercise education will give face to face with same therapist. After that first sessions patients will progress their structered exercises pragram with telerehabilition during 6 weeks and 18 sessions. This program includes four directions single leg and arm raise with theraband, squat with arm participation using theraband, lunge walk with arm participation using theraband and static balance exercises with arm participation using theraband. All sessions will be supervised with physiotherapist. End of study assessments will perform again with same therapist.
223540274|NCT04089020|BEHAVIORAL|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
223540275|NCT01563055|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
223540276|NCT01563055|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
223540277|NCT00646126|DRUG|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
223540278|NCT00646126|DRUG|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
223540279|NCT00406796|DRUG|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
223540280|NCT01601184|DRUG|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
223540281|NCT01601184|DRUG|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
223540282|NCT05293340|DIETARY_SUPPLEMENT|Avocado Vouchers|Food as Medicine to demonstrate clinically meaningful benefits for underserved communities. Avocados are fruits with fats, fiber, micronutrients, and bioactive phytochemicals.
223540283|NCT00420186|DRUG|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
223540284|NCT05074225|OTHER|Electrodesiccation and Curettage vs Excision|"Factorial Assignment.~At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS)."
223540285|NCT02116179|BEHAVIORAL|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
223540286|NCT04672135|DRUG|REM0046127|Oral solution: 100 mg/mL REM0046127
223723719|NCT04165785|DEVICE|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
223540287|NCT04672135|DRUG|Placebo|Oral solution with 0 mg/mL REM0046127
223540288|NCT06547762|OTHER|Hybrid approach (in-person and remote) to pediatric rehabilitation: A look beyond the COVID-19 crisis|Hybrid rehabilitation. Out patients will receive one day a week of remote therapy and the remaining (1-4 days) in person at rehabilitation hospital
223540289|NCT01335126|OTHER|Emulsion type artificial tear|2 types of artificial tears
223540290|NCT00897884|DRUG|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
223723720|NCT04165785|PROCEDURE|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
223954796|NCT01555307|OTHER|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
223540291|NCT00959907|DRUG|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~* Dysport®: 4 units will be injected in the left or right forehead side.~* Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
223540292|NCT03200470|OTHER|No intervention: sample collection study|Sample collection and collection of laboratory values
223540293|NCT06544070|DEVICE|Entia Liberty System|Participants will donate finger-prick blood samples to be tested on the Entia Liberty System. The results will not be used to inform clinical decisions or affect routine clinical care in any way.
223954797|NCT01555307|OTHER|Typical group|Seven typical exercises, 10 times each, 3 times a day
223954798|NCT02981329|DRUG|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
223954799|NCT02981329|BEHAVIORAL|Questionnaires|Questionnaires will be completed to assess the impact quality of life
223954800|NCT03259126|DEVICE|SCUT|Two different home made curtains were attached to the angiographic table
223954801|NCT00168506|DRUG|SSRI|
223954802|NCT00168506|DRUG|CBT|
223954803|NCT00168506|DRUG|CBT/SSRI|
223540294|NCT04244266|OTHER|NO INTERVENTION, it is an observational study|No intervention
223540295|NCT01678521|PROCEDURE|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
223723721|NCT01425281|DEVICE|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
223723722|NCT01425281|DEVICE|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
223954804|NCT02648841|RADIATION|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
223954805|NCT02648841|DRUG|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
223954806|NCT02648841|DRUG|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
223723723|NCT01328925|DRUG|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
223954807|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
223540296|NCT01914250|DRUG|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
223954808|NCT01353872|DIETARY_SUPPLEMENT|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
223954809|NCT02131454|OTHER|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
223954810|NCT05871788|DIAGNOSTIC_TEST|identify biomarkers|Identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma
223954811|NCT00799838|DRUG|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
223954812|NCT00799838|DRUG|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
223954813|NCT00799838|DRUG|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
224291103|NCT01620723|OTHER|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
223540297|NCT00342134|PROCEDURE|Stem Cell Transplanataion|
223540298|NCT03958331|BEHAVIORAL|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
223540299|NCT03958331|BEHAVIORAL|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
223540300|NCT03958331|BEHAVIORAL|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
223954814|NCT03996798|OTHER|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
223954815|NCT04659382|DRUG|Atezolizumab|Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).
223954816|NCT04659382|DEVICE|Therasphere|Therasphere injected to patients to promote the release of neoantigens from their tumour and convert it into an immunogenic tumour.
223954817|NCT04659382|DRUG|XELOX|standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)
224291104|NCT01620723|OTHER|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
224291105|NCT06815601|OTHER|rTMS|Intermittent theta burst stimulation (iTBS) will be utilized since they have been reported to have a cortical neuromodulatory effect. The iTBS protocol will be applied over primary motor cortex to investigate its effect on corticospinal excitability and functional outcome. Theta burst stimulation (TBS) consists of bursts of pulses containing 3 pulses at 50 Hz (3 pulses per second) repeated at 200 ms intervals (5 Hz). During iTBS, a 2 second train of TBS is repeated every 10 seconds (600 pulses in 190 seconds).
224291106|NCT06815601|OTHER|Sham rTMS|Sham iTBS protocols will be applied with the same parameters as in iTBS protocol. However, sham coil will be used.
224291107|NCT06815601|BEHAVIORAL|Motor training|The motor training will be focused on participant's hand motor function such as grasping function.
224291108|NCT04598360|PROCEDURE|Heart-Lung-Machine|blood sample before and during a single Heart-Lung-Machine procedure
224291109|NCT06600750|PROCEDURE|Arteriovenous fistula|Patients who underwent Radiocephalic arteriovenous fistula surgery
224291110|NCT06472544|BEHAVIORAL|Culturally Grounded Intervention|Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
224291111|NCT00062101|DRUG|erlotinib hydrochloride|Given orally (PO)
224291112|NCT00062101|DRUG|celecoxib|Given PO
224291113|NCT00062101|OTHER|laboratory biomarker analysis|Correlative studies
224291114|NCT02990806|DRUG|NI-071|IV infusion.
224291115|NCT02990806|DRUG|Remicade|IV infusion.
224291116|NCT00977431|DRUG|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
224291117|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
224291118|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
224291119|NCT00977431|PROCEDURE|Radiotherapy|Day 1 to day 42
224291120|NCT00977431|DRUG|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
224291121|NCT01142531|RADIATION|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~* 90 quality ref mAs with care-dose ON~* 120 kV~* Pitch 1.4~* Rotation time 0.33 s~* Acquired images 64 x 0.6 mm"
224291122|NCT06031220|OTHER|deep breathing exercise inform of diaphragmatic and costal breathing|deep breathing exercise inform of diaphragmatic and costal breathing 3times a day for 15 repetitions each exercise for 9 weeks,
224291123|NCT00610324|DRUG|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
224291124|NCT00610324|DRUG|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
224291125|NCT01010750|DRUG|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
224291126|NCT01010750|DRUG|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
223954818|NCT04659382|DRUG|Bevacizumab|standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
223954819|NCT03437655|PROCEDURE|Carie removal|Carie removal with a low speed handpiece
223954820|NCT03437655|PROCEDURE|Relative isolation|Relative isolation with cotton and gauze.
223954821|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
223954822|NCT03437655|PROCEDURE|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
223954823|NCT03437655|PROCEDURE|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
223954824|NCT03437655|PROCEDURE|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
223954825|NCT00909909|RADIATION|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
223954826|NCT00909909|RADIATION|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
223954827|NCT00237809|DRUG|D-serine|D-serine (30 mg/kg)
223954828|NCT00237809|BEHAVIORAL|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
223954829|NCT00237809|DRUG|Placebo|Placebo D-serine Drug
223954830|NCT00237809|BEHAVIORAL|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
223954831|NCT05597215|RADIATION|Tc-99m MDP and gamma camera|Injection of radioactive element (Tc-99m MDP) then imaging with gamma camera and low dose CT (SPECT/CT)
223540301|NCT03560492|OTHER|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
223954832|NCT02613052|DRUG|normal saline|10 mL of normal saline agitated prior to IV administration
223954833|NCT02613052|DRUG|human albumin|10 mL of 5% albumin agitated prior to IV administration
223723724|NCT04555291|DRUG|Ropivacaine injection|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml
223723725|NCT04555291|OTHER|NACL|Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL
223954834|NCT02613052|DRUG|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
223954835|NCT03776565|OTHER|Ultrasound|Ultrasound of antrum of stomach
223954836|NCT02006641|DRUG|Placebo|Once daily, matching placebo capsules, orally
223954837|NCT02006641|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
223954838|NCT03165825|DRUG|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
223954839|NCT03165825|DRUG|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
223540302|NCT03560492|DEVICE|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
223954840|NCT03611985|DRUG|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
223954841|NCT03611985|DRUG|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
223954842|NCT06462248|DRUG|CUCART19|anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
223954843|NCT03930173|DRUG|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
223954844|NCT03930173|DEVICE|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
223954845|NCT01287832|DRUG|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
223540303|NCT04268914|DEVICE|Oculus Go VR|The Oculus Go is a standalone headset with built-in speakers that runs independently of a smartphone. Via the Oculus Go, participants will engage with BearBlast (developed by AppliedVR). Throughout the world, plush moles play the role of antagonist, standing in for the nuisance and distraction of pain. The VR game is equipped with a head-tracking system, enabling the player to look around the virtual environment. In addition, there is the option to interact with the VR environment using a tap pad located on the side of the helmet. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, and tactile feedback, thus supplying a multi-sensory immersive experience. The VR HMD runs independently of a smartphone and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image.
223540304|NCT04268914|DEVICE|Mira Prism VR|The Mira Prism is a portable, augmented reality (AR) HMD powered by iPhone. When paired with the iPhone, the Mira Prism goggles can superimpose computer-generated images on the user's view of the real world. Unlike the full immersion of VR, AR allows users to view the outside world while interacting with digital content. In this study, the patient will interact with Magic Mallet (developed by Miney Moe) until falling asleep during the anesthesia induction process. Magic Mallet is a distraction game designed for pain management and communication during procedures. The game automatically adjusts cognitive load for optimal effect for users. Study team iPhones specifically loaded with Magic Mallet, and without cellular capability, will be used with the Mira Prism.
223540305|NCT05204121|DRUG|Elpida|elsulfavirine, capsules
223540306|NCT04025892|BEHAVIORAL|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
223723726|NCT03867292|OTHER|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
223954846|NCT01287832|DRUG|Daptomycin|
223954847|NCT03062124|PROCEDURE|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
223954848|NCT00447109|DEVICE|Closed system suction|
223954849|NCT00582920|RADIATION|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
223954850|NCT01894503|DRUG|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
223954851|NCT03773497|OTHER|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
223954852|NCT03773497|OTHER|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
223954853|NCT03773497|OTHER|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
223954854|NCT03773497|OTHER|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
223954855|NCT04749797|DRUG|Liposomal bupivacaine|Used as cranial block for craniotomy surgery
223954856|NCT04749797|DRUG|Bupivacaine Injection|Used as cranial block for craniotomy surgery
223954857|NCT04749797|DRUG|Saline|Used as cranial block for craniotomy surgery
223954858|NCT01985256|BIOLOGICAL|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
223954859|NCT01985256|DRUG|Toca FC|
223954860|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
223954861|NCT01359163|DRUG|etynodiol diacetate|tablet, 0.5 mg, single dose
223954862|NCT01441596|DRUG|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
223954863|NCT01441596|DRUG|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
223954864|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
223954865|NCT01441596|DRUG|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
223954866|NCT05401188|OTHER|Outpatient|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
223954867|NCT05401188|OTHER|hospitalization|Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
223723727|NCT03867292|OTHER|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
223954868|NCT05114811|PROCEDURE|Self-provided perineal massage|External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
223954869|NCT05114811|PROCEDURE|Physiotherapist perineal massage: manual and instrumental (with EPI-NO)|"The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device."
223723728|NCT02988531|OTHER|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
223954870|NCT06165133|OTHER|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP)|Mesh inguinal hernia repair performed by Non-Surgeon Physicians (NSP) through an accredited training programme prior to commencing participation in the study
223954871|NCT06165133|OTHER|Mesh inguinal hernia repair performed by fully trained surgeons|Mesh inguinal hernia repair performed by fully trained surgeons, recognised by the Ghana College of Surgeons and Physicians and other recognised Surgical Colleges around the globe.
223954872|NCT03183856|DEVICE|Morning walk|a end-effector typed gait robot with a saddle
223954873|NCT03183856|OTHER|no Morning walk|ambulation voluntary or with a help of walker
223723729|NCT06064006|DRUG|NNC0487-0111|NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
223954874|NCT03745170|DRUG|Sintilimab|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
223954875|NCT03745170|DRUG|Oxaliplatin|130 mg/m\^2 Q3W on Day 1 by IV infusion
223954876|NCT03745170|DRUG|Capecitabine|1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
223954877|NCT03745170|DRUG|placebo|Weight\<60Kg: 3mg/kg Q3W Weignt\>=60Kg:200 mg Q3W on Day 1 by IV infusion
223954878|NCT04345068|BEHAVIORAL|Calm Meditation Mobile App|The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.
224291127|NCT01010750|DRUG|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
223954879|NCT04345068|BEHAVIORAL|Health Education Podcast Mobile App|The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
223954880|NCT05066022|BIOLOGICAL|CT0590 CAR T Cells|Dose-escalated CAR T cells infusion
223954881|NCT00240175|OTHER|No Intervention|No Intervention
223954882|NCT06455488|PROCEDURE|Ventricular Tachycardia Ablation|This is a surgical ablation meant to reset patients irregular rhythm back to sinus.
223954883|NCT06455488|DEVICE|ICD Implant|A pacemaker or defibrillator implant to prevent SCD
223954884|NCT06455488|DRUG|Antiarrhythmic drug|Drug therapies
223954885|NCT06455488|DIAGNOSTIC_TEST|EKG|Monitoring EKG testing done on registry patients
223954886|NCT06455488|DIAGNOSTIC_TEST|Cardioversion|Monitoring cardioversions on registry patients
223954887|NCT06455488|DIAGNOSTIC_TEST|Echocardiogram|Monitoring echocardiogram testing done on patients
223954888|NCT02417376|DEVICE|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
223954889|NCT02417376|DEVICE|Gracey curettes|set of 7 instruments number #1-14
223954890|NCT05193526|OTHER|No intervention|No intervention
223954891|NCT04250623|OTHER|Health care product (gel)|hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
223954892|NCT02669576|BEHAVIORAL|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
223954893|NCT02669576|OTHER|Usual care|Patients continue usual care by their practitioner
223954894|NCT00764582|DRUG|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
223954895|NCT00764582|DRUG|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
223954896|NCT05832593|OTHER|Immunohistochemistry|Immunohistochemical expression of ERCC1
223954897|NCT01253798|OTHER|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
223954898|NCT02434705|OTHER|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
223954899|NCT01297595|DRUG|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
223954900|NCT02745756|PROCEDURE|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
223954901|NCT02745756|BIOLOGICAL|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
223954902|NCT03637075|OTHER|intranasal insulin|intranasal administration of insulin (160 IU)
223954903|NCT03637075|OTHER|Placebo|placebo intranasal administration
223954904|NCT06510855|DEVICE|DurAVR™ THV System|DurAVR™ THV System - Transcatheter Aortic Valve Implantation (TAVI) Procedure
223954905|NCT00871715|BEHAVIORAL|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
223954906|NCT00871715|BEHAVIORAL|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
223954907|NCT00871715|BEHAVIORAL|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
223954908|NCT04919668|BEHAVIORAL|Simulated grocery shopping exercise|Participants will click a link and simulate an online grocery shopping experience by selecting items for 12 grocery categories.
223954909|NCT01047709|DEVICE|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
223954910|NCT02237937|DRUG|Paroxetine|
224107110|NCT01883583|DEVICE|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
223954911|NCT02237937|DRUG|Sertraline|
223954912|NCT02237937|DRUG|Citalopram|
223954913|NCT02237937|DRUG|Venlafaxine|
223954914|NCT02237937|DRUG|Amitriptyline|
223954915|NCT02237937|DRUG|Escitalopram|
223954916|NCT02237937|DRUG|Amitriptylinoxide|
224107111|NCT03592238|OTHER|Aerobic Exercise Intervention|The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.
224107112|NCT03592238|OTHER|Trier Social Stress Test for Children|Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.
224107113|NCT03592238|OTHER|Seated Rest|Children will be asked to sit quietly or read a book of their choosing.
224107114|NCT04341571|DIETARY_SUPPLEMENT|Probiotics|Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
224107115|NCT04341571|DRUG|Metformin|"Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention."
224107116|NCT01392690|BEHAVIORAL|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
224107117|NCT04687917|BEHAVIORAL|The facilitation, training, feedback, and consultation (FTFC) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
224107118|NCT04687917|BEHAVIORAL|The facilitation, training, feedback, consultation, and incentivization (FTFCI) Strategy|A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and incentivization.
224107119|NCT06971692|BEHAVIORAL|Metacognitive therapy (MCT)|MCT is delivered in weekly face-to-face sessions
224107120|NCT06971692|BEHAVIORAL|Unified protocol (UP)|UP is delivered in weekly face-to-face sessions
224107121|NCT06971172|DEVICE|Low energy diode Laser|Diode Laser
224107122|NCT06971172|DRUG|Medication|pulse steriod therapy and immunosuppressive drugs
224107123|NCT06970561|PROCEDURE|enlarged resection|patients underwent secondary enlarged resection within 1 month after the diagnosis of IDP combined with ADH,
223954917|NCT02237937|DRUG|Nortriptyline|
223954918|NCT02237937|DRUG|Trimipramine|
223954919|NCT00071500|DEVICE|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
224107124|NCT06970951|BIOLOGICAL|UTAA91 injection|Infusion of UTAA91 injection in subjects screened after signing informed consent.
224107125|NCT06972186|DIAGNOSTIC_TEST|Fatigue Protocol + Joint Position Sense Testing|Groups will undergo an isokinetic fatigue protocol at 180°/s using a Biodex dynamometer. Passive and active joint position sense tests will be performed before and after fatigue.
224107126|NCT06971081|OTHER|LED light|(Dental Light Cure), LED light at wavelengths of 420-480nm and will be applied for 30 seconds at a distance of 1cm from the extraction site
224107127|NCT06970210|BEHAVIORAL|Group-Based Education|The group-based education will consist of group sessions led by research staff, covering topics such as physical activity, sedentary behavior, balance and fall prevention, and activities of daily living. Social interactions amongst group members will be facilitated through group activities and discussions regarding the topics being discussed.
223723730|NCT06064006|DRUG|Placebo (NNC0487-0111)|Placebo matching NNC0487-0111 will be administered as a subcutaneous (s.c. under the skin) injection.
223954920|NCT04637100|OTHER|Mobile or tablet-based gaming applications|Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
223954921|NCT04637100|OTHER|Stroke-related educational videos|Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
223954922|NCT03221881|DRUG|Pegylated Liposomal Doxorubicin and docetaxel|
223954923|NCT01329107|BEHAVIORAL|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
223954924|NCT01656512|DRUG|zolendronic acid|"patients will receive calcium \& vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~1. Initial dose: (0.025) mg /kg~2. Subsequent doses ( 0.05) mg /kg.~3. Maximum dose of 4 mg."
223954925|NCT01656512|DRUG|calcium & vitamin D|patients will receive calcium \& vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
223723731|NCT03454997|OTHER|training including in-person and online|training, motivational interviewing practice
223723732|NCT03454997|OTHER|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
223954926|NCT01529866|DEVICE|New Abutment Connection implant|New abutment connection implant
223954927|NCT01529866|DEVICE|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
223954928|NCT03566901|DEVICE|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
223954929|NCT03566901|OTHER|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
223954930|NCT00923169|DRUG|Anti-Transforming Growth Factor-beta (GC 1008)|
224291128|NCT03288402|OTHER|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
223723733|NCT03454997|OTHER|performance coaching|to enhance ability to deliver the weight management intervention
223723734|NCT00694993|DRUG|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
223954931|NCT03015220|DRUG|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
223954932|NCT03015220|DRUG|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
223954933|NCT01673256|DEVICE|SJM Confirm ICM|
223954934|NCT02072330|DRUG|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
223954935|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
223954936|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
223954937|NCT02072330|DRUG|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
223954938|NCT02072330|DRUG|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
223954939|NCT03854565|DIAGNOSTIC_TEST|Glycocalyx measurement，respiratory mechanics measurement|ELASA measure glycocalyx, measure plateau pressure, driving pressure
223954940|NCT01670526|DRUG|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
223954941|NCT05667311|DEVICE|ECG|Finapres electrocardiography machine
223954942|NCT04880837|OTHER|Educational Intervention|Attend educational session
223954943|NCT04880837|OTHER|Informational Intervention|Receive handouts
223954944|NCT04880837|OTHER|Survey Administration|Complete surveys
223954945|NCT02358304|DRUG|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
223954946|NCT02358304|DRUG|Placebo|
223954947|NCT02221011|DEVICE|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
223954948|NCT00911404|BEHAVIORAL|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
223954949|NCT00911404|DIETARY_SUPPLEMENT|High CHO diet|Diet with 55% total calories from carbohydrates.
223954950|NCT05615285|OTHER|PERCS Triage and Referral System|Participants will undergo an assessment of physical function and psychosocial wellbeing. Researchers will apply a triage algorithm, based on findings of assessment. Participants will be referred to one of three exercise-based rehabilitation pathways which will best meet their rehabilitation needs. Participants will be re-assessed after 12 weeks. System will be evaluated using RE-AIM framework.
223954951|NCT04816305|DEVICE|rTMSc|In all rTMS protocols the patient will remain seated in a comfortable chair with adjustable arms and head rests. Before the start of the conventional rTMS (rTMSc), the resting motor threshold (RMT) of the first dorsal interosseous muscle contralateral to the lesioned hemisphere will be determined. The RMT will be defined as the lowest RMT intensity necessary to produce a motor evoked potential amplitude greater than or equal to 50 µV in at least 5 out of 10 attempts.
223954952|NCT04816305|BEHAVIORAL|Neurofunctional physiotherapy|All patients will be submitted to a protocol of exercise with different levels according to motor learning, neuroplasticity principles and motor impairment. All physiotherapists will be trained prior to the study.
223723735|NCT00694993|DRUG|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
223954953|NCT04816305|DEVICE|rTMS sham|During the rTMS sham sessions the same procedures will be used as the rTMSc protocols, however, the magnetic stimulator and its coil will be turned off.
224107128|NCT06970210|BEHAVIORAL|Individualized Coaching|Individualized coaching aims to increase the participants daily step count. Participants will be encouraged to achieve step count increases of 2%, 5%, or 10% per week or visit, depending on their readiness and willingness to progress. SMART goal-setting strategies will be employed to assist with the goal setting. Participants may also receive coaching related to reducing sedentary behavior and engaging in physical activities.
224107129|NCT06971003|BEHAVIORAL|Ho'ouna Pono|An efficacious culturally grounded substance use prevention intervention developed and tested with Hawaii Island students. Teachers deliver the 11 lesson program through 30-45 minute weekly sessions. The modular intervention can be customized to students by teachers.
224107130|NCT06971302|OTHER|Mindfullnes Based Breastfeeding Education|Pregnant women in the intervention group will receive mindfulness-based breastfeeding training, conducted face-to-face and online by the researcher at designated days and times. The intervention group will undergo a total of 12 sessions of mindfulness-based breastfeeding training over a six-week period. The training will be made memorable and easy to understand through the support of visual presentations, videos, and models prepared by the researcher.
224107131|NCT00876642|DRUG|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
224107132|NCT00351715|DRUG|Sublingual Methadone|
223723736|NCT05220202|BEHAVIORAL|Behavioral Intervention Group (MOTIVATE)|Behavioral: Behavioral Intervention Group (MOTIVATE) The behavioral intervention is designed for older Veterans with musculoskeletal pain and depression and will include 8 individual telephone sessions delivered by health coaches (for up to 5 months total), accounting for additional time between sessions (if needed).
223723737|NCT06147739|OTHER|Temporary Anchorage Devices|intrusion
223723738|NCT05695352|DRUG|Levonorgestrel 1.5mg|oral synthetic progesterone agonist
223723739|NCT05695352|DRUG|Meloxicam 15 mg|Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
223723740|NCT05695352|OTHER|Placebo|Each tablet contains Calcium Carbonate 1000 mg
223954954|NCT02717208|BIOLOGICAL|HL036|
223954955|NCT02717208|BIOLOGICAL|Vehicle|
223954956|NCT03294187|DEVICE|Wrist-worn wearables|See arm/group description.
223954957|NCT06296784|OTHER|e-health psychoeducation|e-health psychoeducation intervention provides information about BD clinical condition and symptoms, as well as identifying effective coping strategies to manage symptoms and the dysregulation of biological rhythms. The content covered the impact of the pandemic and its related restrictions on mental health, particularly on anxiety and depressive symptoms. The intervention comprised one session per week for two months, and each session lasted approximately an hour and a half. It was conducted by healthcare professionals.
223954958|NCT02398955|DEVICE|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
223954959|NCT04592926|DEVICE|Accuro SpineNav3D|The intervention will consist of a pre-procedural scan of the lumbar spine using the handheld image guidance device, Accuro, to determine spinal landmarks and anticipated depth of the intrathecal space.
223954960|NCT04592926|OTHER|Sham|The sham group will receive a pre-procedure sham scan (the handheld image guidance Accuro device will be placed on the back, but it will be turned off) followed by sham marking on the subject's back.
223954961|NCT03572907|OTHER|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
223954962|NCT02214095|DRUG|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
224107133|NCT04960358|PROCEDURE|Surface Electromyography|will be applied Surface Electromyography to assess Flexion Relaxation Response
224107134|NCT01816087|OTHER|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
224107135|NCT03395522|DEVICE|iTind|device implanted for 5-7 days
223723741|NCT04856371|DRUG|CYH33|Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
223723742|NCT04856371|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.
223954963|NCT02214095|DRUG|lactose capsules|
223954964|NCT01745666|OTHER|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
223954965|NCT01745666|OTHER|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
223954966|NCT00919815|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
223723743|NCT04856371|DRUG|Letrozole|Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.
223954967|NCT00919815|DRUG|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
224107136|NCT06532617|DRUG|Cadonilimab+S-1or Capecitabine|Eligible patients will receive Cadonilimab (6mg/k, iv, D1,Q3W)combined with S-1 (40-60mg po BID Q3W D1-14）or Capecitabine (1250mg/m2, po BID Q3W D1-14）until disease progression or unacceptable toxicity. Patients who had used S-1 in the first line should choose capecitabine; patients who had used capecitabine in the first line should choose S-1; otherwise decided by investigator's choice.
224107137|NCT05059197|DIETARY_SUPPLEMENT|AP collagen peptide|Health functional food
224107138|NCT05059197|DIETARY_SUPPLEMENT|Placebo|placebo
224107139|NCT02772783|OTHER|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of \~90 is achieved by using corn syrup as a carbohydrate source.
223723744|NCT04856371|DRUG|Palbociclib|Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.
223723745|NCT00484874|DRUG|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
223723746|NCT03487263|BIOLOGICAL|IC14|chimeric monoclonal antibody against human IC14
223954968|NCT02291549|DRUG|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
223954969|NCT02291549|DRUG|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
223723747|NCT03607162|DIAGNOSTIC_TEST|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
223954970|NCT02291549|PROCEDURE|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
223954971|NCT01794689|DRUG|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
224107140|NCT02772783|OTHER|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of \~40 is achieved by using uncooked corn starch as a carbohydrate source.
223540307|NCT03765047|BEHAVIORAL|Intervention Arm|"The physical activity intervention consists of:~1. School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~2. Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~3. PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~4. Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
223540308|NCT04074564|COMBINATION_PRODUCT|MASCT-I, Camrelizumab,Apatinib|"Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2."
223540309|NCT02559973|DRUG|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
223540310|NCT02559973|DRUG|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
223954972|NCT01794689|DRUG|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
223954973|NCT01794689|BEHAVIORAL|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
223954974|NCT01794689|BEHAVIORAL|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
223954975|NCT01489683|DRUG|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
223954976|NCT01489683|DRUG|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
223954977|NCT01000467|DRUG|probucol|group 3: 250 mg 1 tablet in the morning and evening
223954978|NCT01000467|DRUG|probucol|group 1: 250 mg
223954979|NCT01000467|DRUG|probucol|group 2: 250 mg 2 tablets at once in the morning
223954980|NCT05244954|DRUG|Dihydroartemisinin-Piperaquine|Treatment of females less than 10 years old and all males in Arm 2 and those who test positive in Arm 1.
223954981|NCT05244954|DRUG|Chloroquine|Treatment of females 10 years old and older in Arm 2 and those who test positive in Arm 1.
223954982|NCT03980236|DEVICE|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
223540311|NCT01003223|OTHER|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
223954983|NCT00147615|DRUG|Eplerenone|
223954984|NCT05123755|DRUG|AV-001 Injection|AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
223954985|NCT05123755|DRUG|AV-001 Placebo Injection|D-PBS
223954986|NCT05652114|BEHAVIORAL|Mightier|Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
223954987|NCT01763307|DRUG|RECONVAL CREAM|
223954988|NCT01763307|DRUG|PLACEBO|
223954989|NCT03335059|COMBINATION_PRODUCT|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
223954990|NCT00025376|DRUG|PS-341|
223954991|NCT00025376|PROCEDURE|Tumor Biopsy|
223954992|NCT04850092|OTHER|Positional change from supine to prone|Patient is turned from supine to prone position for spine surgery
223954993|NCT04206618|DRUG|Teriparatide|1 subcutaneous injection daily for 12 months
223954994|NCT04206618|DRUG|Denosumab|1 subcutaneous injection every 6 months for 12 months
223954995|NCT01697956|DRUG|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
223954996|NCT01697956|DRUG|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
223954997|NCT04182217|OTHER|Epidemiological description|Description of the characteristics of Peritonitis in Haiti
223954998|NCT00130026|DRUG|Caffeine|500 mg IV
223954999|NCT01846078|DEVICE|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
223955000|NCT04447287|DRUG|ASP8062|Oral
223955001|NCT04447287|DRUG|Placebo ASP8062|Oral
223955002|NCT04447287|DRUG|buprenorphine/naloxone|Sublingual
223955003|NCT03648749|BEHAVIORAL|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
223540312|NCT05736393|DEVICE|Back Exosuit|The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
223540313|NCT02025374|DRUG|Hyperbaric levobupivacaine|
223540314|NCT02025374|DRUG|Hyperbaric bupivacaine % 0.5|
223540315|NCT04456907|OTHER|platelet rich plasma|Autologous platelet-rich plasma (PRP) was prepared using the RegenKit THT system (RegenLab SA, Le Mont-sur-Lausanne, Switzerland) following the manufacturer's instructions. Medical technicians, who had been well-trained by the manufacturer, were responsible for the process of PRP preparation. For each patient, 8-10 mL of venous blood was drawn and collected to the commercial RegnLab THT tube, which contained 1 mL sodium citrate. After single centrifugation at 3400 revolutions per minute (rpm) for 8 minutes, 4-5 mL of PRP was yielded with leukocytes maintained at physiological levels and red blood cells depleted. Then, the blood components were separated, with the platelet pellet resting on the separating gel. PRP for later application was obtained by re-suspending the platelet pellet in the plasma supernatant by gently inverting the unopened RegenKit THT tube 5 to 10 times.
223540316|NCT04456907|OTHER|saline injection|saline injection
223540317|NCT01645202|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
223955004|NCT04406701|OTHER|Ceres|This will be a self-administered survey on eating habits and their relationship to coping strategies and economic level among nurses.
223540318|NCT00163098|DRUG|UK-369,003|
223540319|NCT04290624|OTHER|Experimental Dentifrice: Stannous Fluoride|Participants will be instructed to dose the toothbrush provided with a strip of dentifrice (a full brush head) on each brushing occasion containing 0.454% w/w Stannous fluoride for 2 minutes twice daily (morning and evening) for 12 weeks.
223540320|NCT04290624|DEVICE|COREGA Denture Foaming Cleanser|Participant will clean their denture using 2 pumps of the denture cleansing foam and a denture cleaning brush for 90 timed seconds outside of the mouth twice daily (morning and evening) for 12 weeks.
223540321|NCT04290624|OTHER|Mouth rinse: Sodium Fluoride|Participants will take 10 ml of the mouth rinse containing 90 ppm sodium fluoride and swished around the mouth for 1 minute twice daily (morning and evening) for 12 weeks.
223540322|NCT02234765|OTHER|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
223955005|NCT00613405|OTHER|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
223540323|NCT02234765|OTHER|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
223540324|NCT04039529|DEVICE|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
223540325|NCT03041220|PROCEDURE|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
223540326|NCT03346993|DRUG|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
223723748|NCT03374397|DRUG|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
223723749|NCT00238004|DRUG|Nicotinic acid|
223723750|NCT04370938|BEHAVIORAL|Coping strategies video|No additional description
223723751|NCT04047745|DRUG|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
223723752|NCT04047745|DRUG|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
223955006|NCT00613405|OTHER|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
223955007|NCT04197622|DRUG|Hydrochlorothiazide|12,5 mg of hydrochlorothiazide (1/2 tablet of 25 mg) administered orally in a single dose.
223955008|NCT03246724|DRUG|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
223540327|NCT05570032|DEVICE|Virtual Reality Training|In intervention the participants took part in the VR training. The X-BOX 360 (Augmented virtual reality) device was used. The participants were guided about the virtual reality training including Kinect sports gamming (Trail 1. badminton, beach volley ball, Soccer goal keeping). Each training was performed for 15 minutes with 5 minutes break time. The whole training was performed for 8 weeks. After eight weeks final assessment was done through outcome measuring tools (TUG test, MAS scale, forward stepping test and Functional reach test).
223540328|NCT05448456|DRUG|Tranexamic acid|1 gram of tranexamic acid in 100 ml of 0.9% normal saline
223540329|NCT05448456|DRUG|Placebo|100 ml of 0.9% normal saline
223540330|NCT04047056|OTHER|Labor Kinesiotherapy|"The intervention group will perform 5 minutes of warm-up with free active exercises, 10 minutes of specific resistance exercises for the cervical and upper limbs and 5 minutes of stretching and muscle relaxation.The initial free active exercises will be performed in 3 sets of 15 repetitions; Resistance exercises will be performed in 3 sets of 10 repetitions and stretching will be performed in 3 sets of 30 seconds.~Regarding the intervals between exercises, active recovery will be adopted to counteract the effects of muscle fatigue."
223540331|NCT02076945|PROCEDURE|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
223540332|NCT05511779|DRUG|Brincidofovir|BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
223540333|NCT00587119|DRUG|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
223540334|NCT06104345|BIOLOGICAL|Oral typhoid fever vaccine|Oral typhoid fever vaccine (Vivotif®) on Days 0, 2 and 4.
223540335|NCT06104345|BIOLOGICAL|Oral cholera vaccine|Oral cholera vaccine (Dukoral®) on Days 0 and 7.
223540336|NCT06032039|DRUG|Triamcinolone|Standard treatment for osteoarthritis knee pain
223540337|NCT06032039|OTHER|Platelet Rich Plasma|Alternative treatment for osteoarthritis knee pain
223955009|NCT03246724|DRUG|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
223540338|NCT02681393|BEHAVIORAL|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
223540339|NCT02681393|BEHAVIORAL|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
223955010|NCT03246724|DRUG|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
223955011|NCT03246724|DRUG|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
223955012|NCT02738307|OTHER|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
223540340|NCT05081921|DRUG|MesoCellA-Ortho administration|"Single dose of MesoCellA-Ortho product consisting of 20 mln of autologous adipose tissue-derived mesenchymal stem/ stromal cells (AT-MSCs) will be administrated intraarticularly in patients enrolled in MesoCellA-Ortho- treated groups."
223540341|NCT05081921|DRUG|HA administration|"Single dose of hyaluronic acid (HA) will be administrated intraarticularly as an active control in patients enrolled in Control Patients groups."
223540342|NCT00544856|BEHAVIORAL|complex cognitive training|
223540343|NCT00067561|DRUG|Alosetron|
223540344|NCT04422431|DRUG|Bis-Choline Tetrathiomolybdate|Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
223540345|NCT02406417|DEVICE|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
223955013|NCT05121259|OTHER|ExerciseGuide Intervention Group|The single group which will be given access to the eight-week ExerciseGuide UK website containing a tailored physical activity programme and supportive and educational resources.
223955014|NCT02978716|DRUG|Trilaciclib|G1T28
223955015|NCT02978716|DRUG|Gemcitabine|Gemcitabine
223955016|NCT02978716|DRUG|Carboplatin|Carboplatin
223955017|NCT00960206|DEVICE|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
223955018|NCT00960206|DEVICE|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
223955019|NCT00960206|DEVICE|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
223955020|NCT04988542|DIETARY_SUPPLEMENT|Circadian Wellness sleep SL strip|Participants in the intervention group will be asked to begin Circadian Wellness sleep SL strip nightly for 30 days. Participants will continue the supplementation for the 30 days.
223955021|NCT03353636|DIETARY_SUPPLEMENT|Magnesium|150mg elemental magnesium
223955022|NCT03353636|DIETARY_SUPPLEMENT|Placebo|Rice flour
223540346|NCT02406417|DEVICE|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
223540347|NCT06565468|DEVICE|Cold water immersion pool.|Participants will complete a session of cold-water immersion within one hour of finishing the last training session of the day. Cold water immersion will consist of ten minutes of submersion to the neck in a cold-water tub with a target temperature of 55 degrees Fahrenheit (daily temperatures will be recorded at the time of each session). The acceptable range for the cold water immersion protocol will be from 53-57 degrees Fahrenheit. The immersion process will not be completed if the temperature of the water is outside of this range. Participants will complete five sessions per week, with a total of 10 sessions to be completed over the 14-day intervention.
223540348|NCT06325215|OTHER|Hidrocolloid Bant|In this group, after the columella and nasal area of preterm infants were cleaned and dried with sterile water, hydrocolloid dressings were applied to the areas in contact with the nasal cannula. NasalNem nasal ointment was applied twice a day to the nasal passages in contact with the cannula. If the hydrocolloid dressings melted or peeled off, they were removed, the area was cleaned, and then reapplied.
223540349|NCT02740270|DRUG|GWN323|
223540350|NCT02740270|DRUG|PDR001|
223955023|NCT05299034|DIAGNOSTIC_TEST|Multiparametric imaging|MR perfusion or multiparametric CT including NCCT, CTA and CTP
223955024|NCT05299034|DIAGNOSTIC_TEST|Non contrast CT+CT angiography|NCCT+CTA
223540351|NCT02494414|OTHER|Long-term follow-up|Vital and neurological follow-up
223540352|NCT04117633|DEVICE|Laparoscopy|Laparoscopic Procedures for Rectopexy
223540353|NCT03168139|DRUG|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
223723753|NCT04245787|DRUG|Self assembling peptide with fluoride|peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
223955025|NCT00663819|DEVICE|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
223955026|NCT00663819|PROCEDURE|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
223955027|NCT03709849|DRUG|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
223955028|NCT03709849|DRUG|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
223955029|NCT00003087|DRUG|cisplatin|
223955030|NCT00003087|DRUG|paclitaxel|
223955031|NCT00003087|PROCEDURE|surgical procedure|
223955032|NCT00003087|RADIATION|radiation therapy|
223540354|NCT03168139|DRUG|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
223540355|NCT02152748|GENETIC|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
223540356|NCT00147576|DRUG|CP-866,087|
223540357|NCT04217434|PROCEDURE|400 µm fibre length will be used in continuous contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400 µm fibre length will be used in continuous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
223955033|NCT02334917|PROCEDURE|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
223955034|NCT04586348|COMBINATION_PRODUCT|Low Iodine Supplement|Multivitamin and mineral supplement with reduced iodine
223955035|NCT04586348|COMBINATION_PRODUCT|Standard Iodine Supplement|Multivitamin and mineral supplement with standard amount of iodine to match current leading brands of prenatal supplements
223540358|NCT04217434|PROCEDURE|400 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 400µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
223955036|NCT01397006|DRUG|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
224107141|NCT02772783|DRUG|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
224107142|NCT02772783|DRUG|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are \> 400 mg/dl or \< 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
224107143|NCT04723030|DRUG|carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)|"Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week."
224107144|NCT05091138|DRUG|Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
223723754|NCT06239454|DEVICE|interleaving stimulation|ILS consists of two rapid and alternate stimulation programs with different contacts, amplitudes, and pulse width but the same frequency up to a maximum of 125Hz. Contact selection is determined by postoperative stereotactic computed tomography and clinical evaluation to achieve a balance between motor improvement and tolerable side effects. For example, ILS is successfully applied for PD motor symptoms (stimulation of subthalamic nucleus) as well as dyskinesia (additional stimulation of zona incerta).
223540359|NCT04217434|PROCEDURE|300 µm fibre length will be used in continuous mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used continous contact mode at a power setting of 1.5 - 3W. Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
223723755|NCT06239454|DEVICE|empirical stimulation|Patients are settled with simple polar stimulation with combined parameters adjustment (monopolar mode, 60\~90µs pulse width, 130\~185Hz frequency and varied voltage) during the follow-up.
223723756|NCT01280175|PROCEDURE|charcoal block|
223723757|NCT01280175|DEVICE|Aerochamber Plus spacer|
223955037|NCT05134103|BEHAVIORAL|Mindbeacon Therapist Guided, Internet Cognitive Behavioral Therapy for Depression|"The treatment consists of 11 depression modules delivered approximately once per week (at therapists' discretion) over a period of 12 weeks. Additionally, the therapist typically tailors treatment to client's individual needs by including supplementary modules for a variety of issues such as generalized anxiety, panic, social anxiety, post-traumatic stress, insomnia, pain, and relationships etc. Clients can complete the readings, exercises, and worksheets at any convenient time, using their web-enabled smartphone, tablet, or computer. Access to the modules and all messaging is provided through the secure platform. Messaging is asynchronous meaning participants can message their therapist as often as they choose and expect a response within 1-2 business days. After 12 weeks of active treatment, they will have unguided access (without therapist support) to the treatment materials that were covered for an additional 40 weeks."
223955038|NCT05134103|OTHER|Waitlist Control Group|Participants assigned to this arm will wait for 12 weeks before receiving active treatment condition
223955039|NCT00778856|PROCEDURE|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
223955040|NCT02470806|DEVICE|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
223955041|NCT02470806|DEVICE|tNPWT System|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
224107145|NCT05091138|DRUG|Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
224107146|NCT06969859|DEVICE|PEMF|The PEMF will be delivered using a BIXEPS device (Quantum Tx, Singapore) ; It is utilised by the patient placing the leg into the machine. This device is operated by participant individualized NFC cards, which will be centrally programmed to deliver either active PEMF (uniform 1mT, 50Hz) or sham PEMF (0mT, 0Hz) for 30 minutes. Because this biophysical intervention is non-invasive, and the electromagnetic fields emitted into the legs do not generate any sensation (e.g. heat, sound), participants will be blinded to the treatment. The protocol will be 180 minutes of PEMF therapy, performed in six 30-minute sessions 3 times a week and completed in 2 weeks.
224107147|NCT06969859|BEHAVIORAL|Alfredson eccentric training program|All participants will be subject to a standardised rehabilitation exercise region consisting of stretching and eccentric exercises following the Alfredson protocol. The 12-week program will be taught by a physiotherapist or athletic trainer and supplemented by video tutorials. The regime begins with three 30-second static stretches for the gastrocnemius (knee extension) and soleus (knee flexion) muscles with 1-minute rest between each stretch. The 2nd part is eccentric exercises to the calves following the Alfredson protocol. This will be three sets of eccentric exercises lasting 12 weeks, with 15 sets twice a day. If participants are unable to complete three sets of 15 repetitions, they can start with fewer repetitions and sets (at least 2 sets of 10 repetitions each) and gradually increase to the total number of sets. Participants will perform the static stretching exercises from Step 1 at the end of each session
224107148|NCT06969755|DRUG|aripiprazole|aripiprazole arm (titrated dose)
224107149|NCT06969755|DRUG|risperidone|risperidone arm (titrated dose)
224107150|NCT06969755|DRUG|clozapine|clozapine (titrated dose)
224107151|NCT00968344|DIETARY_SUPPLEMENT|Leucine|3-4g Leucine added to daily meals
224107152|NCT00968344|DIETARY_SUPPLEMENT|Alanine|Powered amino acid
224107153|NCT05439928|DEVICE|DEXCOM G6 CGM|Continuous glucose monitoring
224107154|NCT05475873|DRUG|normal saline|A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
223723758|NCT01280175|DRUG|pMDI standard actuator|
223723759|NCT01927874|PROCEDURE|Infiltration|injection of local anesthetic, associated with general anesthesia
223540360|NCT04217434|PROCEDURE|300 µm fibre length will be used in pulsed contact mode|"Diode LASER (A.R.C Fox, Germany, UK) with wavelength of 810nm is selected for the procedure. Before applying the LASER, operating staff and the patient will wear special LASER protective eye glasses.~Local infiltration is administered with Lignox®\[ 2% lignocaine in 1:80000 adrenaline\].~LASER tip will be used in contact mode on pigmented gingiva in short light paint brush strokes using 300 µm fibre length will be used pulsed contact mode at a power setting of 1.5 - 3W. .Simultaneously, increase in temperature on site will be recorded using FLUKE 59 Mini (IR) infrared thermometer in non contact mode. Water spray will be used to keep the area moist. Same procedure will be repeated till no pigments remain.Post operative instructions will be given."
223540361|NCT01790607|DRUG|ONO-2745 /CNS 7056|
223540362|NCT06640179|OTHER|Standard medical care|Standard Care Intervention will continue to receive their regular standard clinical care during the 6-month intervention period of this study.
223955042|NCT03004625|DRUG|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
223955043|NCT03004625|DRUG|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
223955044|NCT03004625|DRUG|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
223540363|NCT06640179|BEHAVIORAL|Monitoring Contacts|Participants will receive brief conducts (\<10 minutes) remotely (telephone or video platform) with the research staff at weeks 6, 12, and 18.
223540364|NCT06640179|BEHAVIORAL|Behavioral Sessions|Participants will be provided weekly individual behavioral sessions during the 6-month intervention to assist in supporting recommended changes in energy intake (diet) and physical activity.
223723760|NCT01927874|PROCEDURE|Spinal block|injection of anesthetic
223723761|NCT01927874|DRUG|Bupivacaine|10ml 0.5% bupivacaine.
223723762|NCT01927874|DRUG|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
223723763|NCT03392701|BIOLOGICAL|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
223955045|NCT00679406|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
223955046|NCT04950920|DRUG|Y-2 sublingual tablets|30mg Edaravone+6mg d-borneo OR， Bid
223955047|NCT04950920|DRUG|d-borneol|60 μg d-borneol OR， Bid
223955048|NCT05120336|DEVICE|transcutaneous vagus nerve stimulation|Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.
224107155|NCT05475873|DRUG|Ondansetron 4 mg|A bolus of ondansetron (2 ml; 4mg) by IV was given 5 min before spinal anesthesia.
223955049|NCT05120336|DEVICE|sham stimulation|Sham procedure for active transcutaneous vagus nerve stimulation
224107156|NCT05475873|DRUG|Ondansetron 8 mg|A bolus of ondansetron (2 ml; 8mg) by IV was given 5 min before spinal anesthesia.
224107157|NCT03368404|DEVICE|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
224107158|NCT03368404|DEVICE|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
224107159|NCT04358393|DRUG|APG-115|APG-115 given once daily on day 1-5 of every 28 day cycle
224107160|NCT04358393|DRUG|5-azacitidine|5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
224107161|NCT03193905|PROCEDURE|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
224107162|NCT03193905|PROCEDURE|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
224107163|NCT04725682|DRUG|Tacrolimus|a single dose of 1 mg capsule per period
224107164|NCT00403104|DRUG|ONO-2506PO|1200 mg QD / 18 months
224107165|NCT00403104|DRUG|ONO-2506PO|0 mg QD / 18 months
224107166|NCT04065763|OTHER|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
224107167|NCT01237470|PROCEDURE|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
224107168|NCT01237470|PROCEDURE|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
224107169|NCT00041899|DRUG|CDB-2914|
224107170|NCT00041899|DRUG|COB-2914|
224107171|NCT06075914|OTHER|Ketogenic Intervention|Participants will receive ready-to-eat Ketogenic Diet meals.
224107172|NCT06075914|OTHER|Mediterranean Intervention|Participants will receive ready-to-eat Mediterranean Diet meals.
224107173|NCT06075914|DIETARY_SUPPLEMENT|Placebo|Participants will receive twice-daily placebo servings to be consumed once in the morning and once before sleep.
224107174|NCT06075914|DIETARY_SUPPLEMENT|Ketone Ester|Participants will receive twice-daily ketone ester servings to be consumed once in the morning and once before sleep.
224107175|NCT03946566|PROCEDURE|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
224107176|NCT01703312|DRUG|QGE031|Drug administered by subcutaneous injection
224107177|NCT01703312|DRUG|omalizumab|Drug administered by subcutaneous injection
224107178|NCT01703312|DRUG|placebo|Drug administered by subcutaneous injection
224107179|NCT06657664|PROCEDURE|cryotherapy with sterile saline at 2.5ºC|the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation
223540365|NCT06640179|BEHAVIORAL|Diet|An energy balanced diet to meet energy needs that will allow for weight maintenance will be prescribed. This will be estimated using the Mifflin-St. Joer equation to estimate resting metabolic rate and for most participants we anticipate using a physical activity correction of 1.3 to account for energy needs for physical activity. This will provide the initial estimate of energy intake needs to maintain weight stability; however, the prescribed level of energy intake will be adjusted at 4-week intervals across the intervention based on the observed changes in weight, eating behaviors, and physical activity patterns in an effort to prevent excessive weight gain. Within the context of this level of energy intake, we will prescribe a diet that is consistent with the dietary recommendations of the National Kidney Foundation.
224107180|NCT06657664|PROCEDURE|intaoral cryotherapy|ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes
224107181|NCT06657664|PROCEDURE|Both intracanal and intraoral cryotherapy|Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.
224107182|NCT06657664|DEVICE|Low Level Laser Therapy|laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively
223540366|NCT06640179|BEHAVIORAL|Physical Activity|Physical activity will be recommended in the form of aerobic types of activity such as brisk walking and will progress in 4-week intervals from an initial amount of 50 minutes per week to 150 minutes per week across the initial 6 months of the intervention. Moderate intensity will be prescribed, and will be anchored using RPE (rating of perceived exertion) to allow intensity to be self-regulated according to the participant's capacity. Physical activity will be prescribed in the form of walking; however, the participant will be permitted to engage in other forms of physical activity that meet the recommended dose and intensity.
224107183|NCT06657664|PROCEDURE|Control (Standard treatment)|, all occlusal contacts were reduced by 1 mm
224107184|NCT03497169|DRUG|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
223540367|NCT03414203|OTHER|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
223955050|NCT04221711|DEVICE|Repetitive pulsed magnetic stimulation|"OMNITRON ProMed is a rPMS (repetitive peripheral magnetic stimulation) device used for deep stimulation of muscles and/or neurones (outside the brain). The energy is delivered by way of a special round treatment coil, whose cover material is tested for biocompatibility.~The OMNITRON ProMed device produces a high-energy impulse field and stimulates tissue, in particular soft tissue, muscles and neurons, by means of repetitive peripheral magnetic stimulation (rPMS). Short, extremely strong magnetic fields in the microsecond range are emitted non-invasively. OMNITRON ProMed works with short-term energy emission at a peak power of up to 60 million watts and a magnetic field strength of up to 100 milliTesla.~The intensity of treatment can be set between 20 and 100 %. The device automatically adjusts the magnetic field strength and the frequency of the pulses emitted depending on the intensity selected.~For comfortable transport and application the product is compact and portable."
223955051|NCT04221711|PROCEDURE|Eccentric Calf Muscle Training for Achilles Tendinopathy|"Patients will be asked to stand with their full body weight on the injured leg. From an upright body position and standing with all body weight on the forefoot and the ankle joint in plantar flexion, the calf muscle is then loaded by having the patient slowly lower the heel beneath the forefoot. The calf muscle will only be loaded eccentrically, not concentric. Instead, the non-injured leg is used to get back to the start position. The first set of this exercise is performed in an upright position, followed by a second set with the knee bent to 45°. This regimen is performed 2x per day.~The patients are told to go ahead with the exercise even if they experienced pain. However, they are told to stop if the pain becomes disabling."
223540368|NCT00896012|PROCEDURE|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
223955052|NCT04645849|BIOLOGICAL|Immunomonitoring|"16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment.~8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules."
223955053|NCT03413826|BEHAVIORAL|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
223955054|NCT03494413|DIAGNOSTIC_TEST|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
223955055|NCT03494413|DIAGNOSTIC_TEST|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
223955056|NCT02046304|DRUG|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
223955057|NCT02046304|RADIATION|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
223955058|NCT00157105|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|
223955059|NCT03715985|DRUG|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
224107185|NCT01684826|RADIATION|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
223540369|NCT00896012|DRUG|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
223955060|NCT06318559|PROCEDURE|3D Robot-assisted laparoscopic radical prostatectomy and pelvic lymphadenectomy|"The operation is performed using the Da Vinci HD robotic system which allows the use of laparoscopic instruments, with greater mobility and the possibility of easier and more precise control of movements in three dimensions. Furthermore, the system allows the surgeon a three-dimensional view of the operating field. The surgery is performed under general anesthesia. Six or more trocars are positioned, into which the instruments operated by the robot or directly by the surgical assistants are inserted.~Then a radical prostatectomy is performed."
223955061|NCT03094546|DIETARY_SUPPLEMENT|Polyamine|12 months of polyamine supplementation (6 capsules/day)
223955062|NCT03094546|DIETARY_SUPPLEMENT|Placebo|12 months of placebo intake (6 capsules/day)
223955063|NCT03152435|BIOLOGICAL|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
223955064|NCT05655000|PROCEDURE|Neonatal thymus transplantation|The donor's neonatal thymus vessels will be dissected right after the routinary partial thymectomy. These vessels will be anastomosed into the recipient's penetrating vessels within the radial forearm by using a supermicrosurgical technique. The graft will be explanted at day 14-21 after the procedure.
223955065|NCT03434600|OTHER|Oxford UKA vs Sigma UKA|
223955066|NCT03111706|PROCEDURE|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
223955067|NCT00392899|DRUG|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
223955068|NCT06510972|PROCEDURE|Strategy for continuing oral intake|Patients will be able to ingest liquids or solid food orally, at any frequency and in any quantity they wish, according to their tolerance, with paramedical assistance if necessary.
223955069|NCT06510972|PROCEDURE|Fasting strategy|The patient will not be able to ingest liquids or solid food.
223955070|NCT01662505|DRUG|Volasertib|Patient to receive volasertib
223955071|NCT02594709|RADIATION|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
223955072|NCT04253951|DIAGNOSTIC_TEST|Lung Ultrasound (LUS)-monitored feeding trial|LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
223540370|NCT00896012|DRUG|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
223540371|NCT03938831|DRUG|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
223540372|NCT03938831|DRUG|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
223540373|NCT00148863|DRUG|Peg-interferon alpha 2a (drug)|
223540374|NCT00148863|DRUG|Ribavirin (drug)|
223540375|NCT00148863|DRUG|Interferon gamma (drug)|
223540376|NCT02735421|DRUG|ABPO Forte Gel|Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.
223540377|NCT02735421|DRUG|Vehicle gel|Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.
223540378|NCT01417221|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
223540379|NCT01169480|BEHAVIORAL|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
223955073|NCT04813666|DIAGNOSTIC_TEST|Urinary LAM ELISA:|
223955074|NCT03234959|DEVICE|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
223955075|NCT03234959|OTHER|Infant Massage|Infants will received IM by their parents
223955076|NCT01564498|OTHER|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
224107186|NCT01684826|RADIATION|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
223955077|NCT04787198|DRUG|hypertonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
223955078|NCT04787198|DRUG|isotonic saline|The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
223955079|NCT04892251|COMBINATION_PRODUCT|MORE+KAP|Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly
223540380|NCT03274011|DRUG|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
223540381|NCT02962245|DRUG|berberine|
223540382|NCT02962245|DRUG|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
223540383|NCT05272397|DRUG|Methylphenidate 20 Mg Oral Tablet|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
223540384|NCT05272397|DRUG|Placebo|20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
223540385|NCT05272397|BEHAVIORAL|Language Task|The core part of the experiment is the language task, in which the aim is to investigate two critical aspects of language processing: semantic and syntactic processing. In this task, participants will be asked to read a list of sentences.
223540386|NCT05272397|BEHAVIORAL|Rest Recording|Brain activity in the EEG is recorded at rest with eyes open and eyes closed to obtain baseline measures of alpha power as a proxy for attention and control under conditions of drug and placebo.
223540387|NCT05272397|BEHAVIORAL|Go/No-Go Task|A Go/No-Go task will be implemented in the study design to investigate the functional properties of spatial selective attention and response inhibition. An adapted cued Go/No-Go paradigm from Randall \& Smith (2011) will be employed.
223540388|NCT05272397|BEHAVIORAL|Processing Speed|A speeded button response task will be included to measure participants' general processing speed. In this task, participants will be instructed to respond to a simple shape presented in the centre of the screen as fast and accurately as possible through pressing a corresponding button.
223723764|NCT03498027|DEVICE|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
223955080|NCT04892251|BEHAVIORAL|MORE|Mindfulness-Oriented Recovery Enhancement
223955081|NCT02813174|BEHAVIORAL|Compassionate Mind Training from Compassion-Focused Therapy|
223955082|NCT02553148|OTHER|Need for children's palliative care|Need for children's palliative care
223955083|NCT03136822|OTHER|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
223955084|NCT03136822|DEVICE|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
223955085|NCT00502294|DRUG|Visilizumab (HuM291; Nuvion®)|
223955086|NCT02314975|DEVICE|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
223955087|NCT02314975|DEVICE|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
224107187|NCT00260221|BEHAVIORAL|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
223955088|NCT02314975|OTHER|Fixed appliance only|Fixed appliance treatment only
224107188|NCT06819202|OTHER|Hyperbaric oxygen treatment|HBO therapy is the process of inhaling 100% pure oxygen in an environment above one atmosphere (pressure range: 2.0-3.0 absolute atmospheres) to treat a disease.
223955089|NCT04859062|DRUG|lidocaine gel 2%|assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
223955090|NCT04859062|OTHER|control group|In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
223955091|NCT01562184|DEVICE|Sham tDCS device|Sham tDCS
223955092|NCT01562184|DEVICE|Soterix tDCS device|Active tDCS
223955093|NCT02191540|DRUG|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
223540389|NCT05272397|BEHAVIORAL|Operation Span|In the operation span task, participants are instructed to solve math operations (e.g., (1\*2) +1=?) as soon as possible and then remember a single letter. This to-be-remembered letter is followed by either another math-word combination or a recall screen, which will show up at the end of each set. When the recall screen is presented, participants have to recall all the letters in the correct order they were presented. The experimental trials contain three sets at each set size (i.e., the number of math-word pairs), with set sizes ranging from 3 to 7 items. This results in a total of 75 sets with 75 letters and 75 math problems. The order of set sizes is random for each participant. Participants' operation span will be evaluated by the total number of letters recalled in the correct serial position regardless of whether the entire trial was recalled correctly.
223540390|NCT05272397|BEHAVIORAL|Reading Span|Participants are instructed to judge whether a presented sentence makes sense or not. After each sentence, a to-be-remembered letter will be shown on the screen, which is followed by either another sentence-word combination or the final recall screen. The set size ranges from 3 to 7 items. At the end of each set of sentences, participants will be required to recall all the letters in the current set in order. There will be a total of 75 letters and 75 sentence judgements. The order of the set sizes will be at random for each participant. Participants' performance will be evaluated by calculating the total number of correctly recalled letter sets.
223540391|NCT05272397|BEHAVIORAL|Barratt Impulsiveness Scale|The Barratt impulsiveness scale (BIS-11) will be used in the experiment to measure participants' trait impulsivity. Participants will be required to rate themselves on 30 items that are related to attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness.
223540392|NCT05182450|OTHER|Mango leaf extract capsule|Single dose
223540393|NCT05182450|OTHER|Placebo capsule|Single dose
223540394|NCT01911650|OTHER|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
223540395|NCT01911650|OTHER|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
223540396|NCT01911650|OTHER|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
223540397|NCT01820650|DEVICE|iTotal G2 CR Knee Replacement System|Total Knee replacement
223540398|NCT06457477|DRUG|Sintilimab|100mg/10ml/1bottle
223540399|NCT06457477|DRUG|NAs|tablets
223955094|NCT04665583|OTHER|Prehabilitation|Prehabilitation will consist of careful pre-intervention assessment and personalized optimization, guided by Investigator judgment, with a specific focus on right ventricular function. This will be done by using a detailed echo acquisition protocol (Appendix 1). Assessments will be collected according to the schedule of events below (Table 1.). Therapy will include intravenous milrinone therapy and aggressive diuresis with evaluation for clinical and functional signs of improvement, according to standard of care.
223540400|NCT06457477|DRUG|Peg-IFNα-2b|180ug/0.5ml/1bottle
223540401|NCT01212965|DRUG|Selenium|400 μg once a day for 6 months by mouth
223540402|NCT00283946|DRUG|Zolpidem MR|Oral
223540403|NCT00283946|DRUG|Zolpidem|Oral
223955095|NCT02725697|OTHER|TCM treatment|
224107189|NCT05824767|DRUG|Angiotensin II|Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
224107190|NCT01607892|DRUG|KPT-330|
224291129|NCT03588052|PROCEDURE|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
223540404|NCT02359032|DRUG|ASP6858|Oral tablets
223540405|NCT02359032|DRUG|Placebo|Oral tablets
223540406|NCT05010070|BEHAVIORAL|diet and lifestyle program|See description of main arm.
223540407|NCT06392906|RADIATION|Short course radiation therapy|5 daily radiation treatments
223540408|NCT06392906|RADIATION|Standard course radiation therapy|10 daily radiation treatments
223540409|NCT00628498|DRUG|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
223540410|NCT00628498|DRUG|Defibrotide|
223540411|NCT05742412|DEVICE|Video streaming (smartphone camera)|Adding video streaming as a technical adjunct to the otherwise audio-based-only communication during emergency medical dispatch
223540412|NCT05742412|DEVICE|Telephone (telephone microphone)|Usual care: Audio-based-only communication using telephone during emergency medical dispatch
223540413|NCT04629391|DEVICE|Total shoulder arthroplasty|A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
223955096|NCT00814749|PROCEDURE|midureteral sling|midureteral sling
223955097|NCT00814749|OTHER|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
223955098|NCT00162318|DRUG|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
223955099|NCT02394912|DEVICE|vena cava filter implantation (LUMIFI with Crux VCF System)|
223955100|NCT02629666|BEHAVIORAL|ERS and/or Self-management Strategies|
223955101|NCT02444962|DEVICE|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
224107191|NCT04726306|DIAGNOSTIC_TEST|Otic Barotrauma Grading System|Otic Barotrauma Grading System Placards for TEED Score and the OGS grading system.
224107192|NCT02346448|PROCEDURE|endoscopic sphincterotomy|sphincterotomy during ERCP
224107193|NCT02346448|PROCEDURE|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
224107194|NCT02346448|PROCEDURE|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
224107195|NCT04642664|DRUG|Apatinib plus Camrelizumab|Patients received apatinib orally at 250 mg once a day irrespective of the patient weight. During the treatment, apatinib can reduced to half of piece or once every other day considering the grade of treatment related adverse events. Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks. The intermittent period of camrelizumab was no longer than 6 weeks. All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
223540414|NCT03142841|OTHER|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
223540415|NCT01575639|DRUG|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
223540416|NCT06275776|DEVICE|Ethicon Monocryl Smooth Suture|Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
223540417|NCT06275776|DEVICE|Ethicon Vicryl Rapide Braided Suture|Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.
223955102|NCT04588207|DRUG|Urea|"Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day."
223955103|NCT02729246|PROCEDURE|Laparoscopic Gastric Bypass|
224107196|NCT04966221|DIAGNOSTIC_TEST|Lung MRI scan|Participants will have a combination of structural and functional lung MRI scans. These scans will involve lying in a conventional MRI scanner while free breathing and may include additional breathing manoeuvres such as temporarily holding breath.
223540418|NCT06275776|DEVICE|Flexifuze Indermil Topical Skin Adhesive|Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.
223540419|NCT06275776|DEVICE|Dermabond Prineo Skin Closure System|Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
223955104|NCT01873898|DEVICE|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
224107197|NCT02156700|PROCEDURE|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
224107198|NCT03294304|DRUG|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
224107199|NCT03294304|DRUG|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
224107200|NCT03294304|DRUG|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
224107201|NCT01442584|PROCEDURE|ovarian transplantation|ovarian transplantation
223955105|NCT03121885|BEHAVIORAL|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
223540420|NCT06275776|DEVICE|Stryker Zip Skin Closure System|Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
223540421|NCT03247829|DEVICE|Hemodynamic management using CardioMEMS HF System|Using the CardioMEMS HF System, clinicians will treat to target PA pressure ranges
223540422|NCT01783444|DRUG|Capecitabine|Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)
223540423|NCT01783444|DRUG|Exemestane|Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
223540424|NCT01783444|DRUG|Everolimus|Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
223540425|NCT04222530|DIAGNOSTIC_TEST|Linear EUS first|Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
223540426|NCT04222530|DIAGNOSTIC_TEST|ME-NBI first|Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
223955106|NCT03121885|OTHER|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
223540427|NCT02314676|BIOLOGICAL|PEG-somatropin|
223540428|NCT01058239|DRUG|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
223955107|NCT03376763|DRUG|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
223955108|NCT03607591|OTHER|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
223955109|NCT00637663|DRUG|Entecavir|entecavir 0.5 mg QD
223540429|NCT01058239|DRUG|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
223540430|NCT03557125|OTHER|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
223540431|NCT03557125|OTHER|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
223540432|NCT05346328|DRUG|Injection of A166|4.8 mg/kg for each 21 (±3) -day cycle
223540433|NCT06022094|OTHER|2 months of reduced carb menus|Participants will eat a reduced carb menu for 2 months
223540434|NCT04084535|OTHER|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
223540435|NCT04084535|OTHER|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
223540436|NCT03733938|OTHER|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
223540437|NCT02868853|BEHAVIORAL|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
223955110|NCT00637663|DRUG|Lamivudine|lamivudine 100 mg QD
223955111|NCT00004496|DRUG|alpha-melanocyte stimulating hormone|
223955112|NCT05862402|DRUG|Dose-adjustment by PKPD|Dose-adjustment by pharmacokinetic and pharmacodynamic using Monte Carlo simulation
223955113|NCT05110794|DRUG|LY3502970|Administered Orally.
223955114|NCT03075878|DRUG|ALXN1830|Administered via IV infusion.
223955115|NCT03822806|OTHER|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
223955116|NCT02010684|BEHAVIORAL|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
223955117|NCT02214914|DRUG|BI 11634 drinking solution|
223955118|NCT02214914|DRUG|BI 11634 tablet|
223955119|NCT02214914|DRUG|Placebo|
223540438|NCT02868853|BEHAVIORAL|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
223723765|NCT05740397|OTHER|Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm|"The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect"
223955120|NCT05062070|DRUG|TolaSure Topical Gel|TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
223955121|NCT05062070|DRUG|Vehicle Topical Gel|TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
223955122|NCT04249115|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SK lesions using sterile single-patient use treatment tips with microneedles.
223955123|NCT01947114|DRUG|Propofol|
223955124|NCT01947114|DRUG|Ketamine|
223955125|NCT01947114|DRUG|Remifentanil|
223955126|NCT02399111|DEVICE|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
223955127|NCT02364648|DIETARY_SUPPLEMENT|MitoQ|Mitochondria targeted antioxidant
223955128|NCT02364648|DIETARY_SUPPLEMENT|Placebo|Placebo
223955129|NCT00135278|PROCEDURE|CSF Drainage|See Detailed Description
223955130|NCT00135278|PROCEDURE|No CSF Drainage|See Detailed Description
223955131|NCT03717233|DEVICE|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
223540439|NCT02868853|BEHAVIORAL|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
223955132|NCT05920538|DRUG|Nicardipine|Subcutaneous infiltrate drug at puncture site by ultrasound-guided
223955133|NCT05920538|OTHER|Normal saline|Subcutaneous infiltrate NSS at puncture site by ultrasound-guided
223955134|NCT04520321|DRUG|TTHX1114(NM141)|engineered FGF-1 delivered intracamerally
223955135|NCT04520321|OTHER|Vehicle (placebo)|Placebo
223955136|NCT06501027|BEHAVIORAL|Mindfulness Based Self Compassion|The intervention has its roots in meditations and yoga practices. However, it is independent of religious purpose or affiliation.The weekly sessions include a range of mental and bodily practices, including awareness of
223540440|NCT02399787|OTHER|blastocyst biopsy|Performed on day 5
223540441|NCT04011592|DRUG|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
223540442|NCT04011592|DRUG|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
223540443|NCT01302327|DRUG|Exenatide|Exenatide
223540444|NCT04587206|DRUG|CKD-348|QD, PO
223955137|NCT06318572|BEHAVIORAL|Psychological intervention|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will begin the program of psychological intervention. A first, session of psychoeducation will be performed, and thereafter sessions of psychotherapy will be performed at home during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days. A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
223955138|NCT06318572|BEHAVIORAL|Placebo|"Patients will have 3 visits during the 7 weeks study length. On day -7 a first visit will be made verifying that inclusion criteria are met, the informed consent will be obtained and a rectal sensitivity test will be performed. A symptom questionnaire will be delivered to the patient for daily assessment of gastrointestinal symptoms.~On day 0, a stool sample will be collected and the symptom questionnaire will be reviewed to confirm inclusion criteria. Patients will be instructed to take a capsule containing 0.5 g during 6 weeks.~At the end of treatment a last visit will be performed, collecting the symptoms scored during the last 7 days, A new stool sample will be collected and a rectal sensitivity study will be performed.~Severity of symptom questionnaire will be filled at the beginning, after 3 weeks, at the end of the treatment, at 3 months and at 6 months."
223955139|NCT00882375|DRUG|Nicotine|Nicotine administered using novel NRT user instructions
223955140|NCT00882375|DRUG|Placebo|Placebo administered using novel NRT user instructions
223955141|NCT00091572|DRUG|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
223955142|NCT00091572|DRUG|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
223540445|NCT04587206|DRUG|CKD-828, D097, D337|QD, PO
223540446|NCT05373212|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
223540447|NCT05373212|DRUG|Euglycemic clamp with Humalog® Mix25|Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
223540448|NCT04608292|DIAGNOSTIC_TEST|Single-voxel MRS|Diagnostic test is a single voxel MRS scan
223540449|NCT04608292|DIAGNOSTIC_TEST|Multi-voxel MRSI|Diagnostic test is a multi-voxel MRS imaging scan
223540450|NCT04608292|DIAGNOSTIC_TEST|Magnetization Transfer Imaging|Diagnostic test is a set of magnetic transfer weighted images
223540451|NCT04608292|OTHER|Alcohol ingestion|Participants will ingest an ethanol-containing beverage of approximately 0.5g/kg of ethanol mixed in 355 mL of a non-caffeinated, sugar-free carbonated drink which must be consumed in 5 minutes
223540452|NCT04608292|DEVICE|ClearMate|Participants will breathe through the ClearMate, an MR-compatible non-rebreathing circuit which provides oxygen and carbon dioxide that quickly decreases a person's blood alcohol level.
223540453|NCT04608292|DIAGNOSTIC_TEST|Blood sampling|Participants will have a peripheral arterial and peripheral venous line inserted and periodic arterial and venous blood samples will be measured for blood alcohol content.
223540454|NCT00888706|BEHAVIORAL|Control Condition|The group participated in the usual nursing home activities and routines.
223540455|NCT00888706|BEHAVIORAL|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
223540456|NCT00888706|BEHAVIORAL|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
223540457|NCT00888706|BEHAVIORAL|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
223540458|NCT01047007|DRUG|adavosertib 20 mg|Adavosertib 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
223540459|NCT01047007|DRUG|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m\^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
223540460|NCT01047007|DRUG|CDDP|CDDP 60 mg/m\^2 to 100 mg/m\^2 administered as an IV infusion on Day 1.
223955143|NCT05458544|DRUG|[177Lu]Ludotadipep 3.7 GBq|"Phase 1:~Patients will receive a single dose of 3.7 GBq of \[177Lu\]Ludotadipep~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 3.7 GBq~* Dosage form: solution for injection~Phase 2a:~Patients will receive 3.7 GBq of \[177Lu\]Ludotadipep every 8 \[±1\] weeks (4 to 6 times)~* Test article code/name: \[177Lu\]Ludotadipep~* Administration route: intravenous injection~* Total dose strength: 4 to 6 x 3.7 GBq~* Dosage form: solution for injection"
223955144|NCT01695044|DRUG|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
223955145|NCT05885516|PROCEDURE|intrauterine insemination|Giving washed sperm concentrate into uterine cavity via a soft catheter
223955146|NCT02942771|DRUG|0.075mg/kg TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
223955147|NCT02942771|DRUG|0.15mg/kg TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
223955148|NCT02942771|DRUG|0.25mg/kg TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
223955149|NCT02942771|DRUG|0.30mg/kg TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
223955150|NCT02942771|DRUG|Placebo|0.9% sodium chloride
223955151|NCT00798863|PROCEDURE|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
223955152|NCT00884676|DRUG|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle."
223955153|NCT00884676|DRUG|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
223955154|NCT03506802|RADIATION|18F-FHBG|Given IV
223955155|NCT03506802|BIOLOGICAL|Aldesleukin|Given SC
223955156|NCT03506802|BIOLOGICAL|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
223955157|NCT03506802|PROCEDURE|Computed Tomography|Undergo PET/CT
223955158|NCT03506802|BIOLOGICAL|Filgrastim|Given SC
223955159|NCT03506802|OTHER|Laboratory Biomarker Analysis|Correlative studies
223955160|NCT03506802|DRUG|Lenalidomide|Given PO
223955161|NCT03506802|PROCEDURE|Leukapheresis|Undergo leukapheresis
223955162|NCT03506802|DRUG|Melphalan|Given IV
223955163|NCT03506802|DRUG|Plerixafor|Given SC
223955164|NCT03506802|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223955165|NCT00803985|PROCEDURE|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
223955166|NCT00803985|PROCEDURE|Lichtenstein|Operation for primary inguinal hernias i men
223955167|NCT01453764|PROCEDURE|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
223540461|NCT01047007|DRUG|adavosertib 65 mg|Adavosertib 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
223540462|NCT01334554|DRUG|Sildenafil|20 mg three times a day.
223540463|NCT01334554|DRUG|Placebo|No active drug
223955168|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with preoperative virtual planning|In this study group, using preoperative CTs (head \& neck and thigh ) to virtually plan a guide that can be used during the surgery, this guide will determine the design and dimensions of the Alt flap to be harvested and restore the defect left on the tongue due SCC resection and hemi glossectomy.
223955169|NCT05424328|PROCEDURE|ALTF (Anterolateral thigh flap) with conventional method|ALTF (Anterolateral thigh flap) will be harvested with conventional method which depends on surgeon's own experience in determining the flap design and dimensions needed to reconstruct and restore the defect left on the tongue due SCC resection and hemi glossectomy.
223955170|NCT05107453|DRUG|Levobupivacaine|"The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery."
223955171|NCT05041894|OTHER|tilt table|The tilt table provides passive standing for the stroke patients with tracheotomy
223955172|NCT01049490|BIOLOGICAL|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
223955173|NCT02315209|DEVICE|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
223955174|NCT00044759|DRUG|Piperacillin/Tazobactam (Tazocin)|
223955175|NCT06360367|BEHAVIORAL|HI-FLY Curriculum|Participants receive the standard HI-FLY Curriculum over 6 weeks.
223955176|NCT06360367|BEHAVIORAL|HI-FLY Curriculum + PortionSize Ed app|Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
223955177|NCT06470945|PROCEDURE|Glass ceramic sectional veneer|partial laminate veneer
223955178|NCT06470945|PROCEDURE|Glass ceramic laminate veneer|Glass ceramic laminate veneer
223540464|NCT02393859|DRUG|Blinatumomab|15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
223955179|NCT04932083|DRUG|Bupivacaine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of sterile water will be added."
223955180|NCT04932083|DRUG|Fentanyl|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.5 ml of fentanyl (25µg) will be added."
224107202|NCT05674773|PROCEDURE|Endoscopic or surgical resection|endoscopic or surgical (partial, (sub)total, proctocolectomy) resection
224107203|NCT03022422|BIOLOGICAL|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
223540465|NCT02393859|DRUG|Dexamethasone|10 mg/m\^2/day intravenous (IV) on Days 1-6
223540466|NCT02393859|DRUG|Vincrisitne|1.5 mg/m\^2/day IV on Days 1 and 6
223540467|NCT02393859|DRUG|Daunorubicin|30 mg/m\^2 IV over 24 hours on Day 5
223540468|NCT02393859|DRUG|Methotrexate|1 g/m\^2 IV over 36 hours on Day 1
223540469|NCT02393859|DRUG|Ifosfamide|800 mg/m\^2 IV for 1 hour on Days 2-4
223540470|NCT02393859|DRUG|PEG-asparaginase|1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
224107204|NCT03022422|BIOLOGICAL|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
224107205|NCT03554239|GENETIC|genotyping|Blood sample
223540471|NCT02393859|DRUG|Erwinia-asparaginase|In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
223540472|NCT00954447|DRUG|Placebo|Placebo, identical to Linagliptin tablet
223540473|NCT00954447|DRUG|Linagliptin|intended final marketed dose
223540474|NCT04120129|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
223540475|NCT04120129|DEVICE|sham TMS coil|The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
223955181|NCT04932083|DRUG|Nalbuphine|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.8 mg nalbuphine hydrochloride in 0.5 ml sterile water will be added."
223540476|NCT04592341|DRUG|Gantenerumab|Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
223540477|NCT04812327|DIAGNOSTIC_TEST|BD Veritor Plus System for Rapid Detection of SARS CoV-2|Nasal Sawb for the conduct of the Veritor Antigen Test
223540478|NCT04812327|DIAGNOSTIC_TEST|rt-PCR|Nasopharyngeal Swab for the conduct of a rt-PCR
223540479|NCT04812327|DIAGNOSTIC_TEST|viral culture|Nasopharyngeal Swab for the conduct of viral culture
223723766|NCT05038423|BEHAVIORAL|5R Shared Leadership Program|"The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176"
223955182|NCT04932083|DRUG|Midazolam|"patients will be put in the sitting position and lean forward. After sterilization, Dural puncture will be performed at L4-L5 interspace or L3-L4 with a 25 gauge Quincke spinal needle.~patients will receive the local anesthetic dose of 0.5% heavy bupivacaine (12.5 mg) and 0.4 ml of midazolam (2mg) + 0.1 ml of sterile water will be added."
223955183|NCT04419571|PROCEDURE|Emergency Laparotomy|All adult patients undergoing emergency laparotomy
223955184|NCT01186809|BIOLOGICAL|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
223955185|NCT03305185|COMBINATION_PRODUCT|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
223955186|NCT03305185|DEVICE|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
223955187|NCT04878679|OTHER|Strenght training combined with WB-EMS|Bodyweight exercise training combined with WB-EMS (2 times/week) with a 85Hz electrical impulse
223955188|NCT04878679|OTHER|Cardiovascular training with WB-EMS|Cardiovascular training , using the rowing machine, combined with WB-EMS (2 times/week) with a 7Hz electrical impulse
223955189|NCT04878679|OTHER|Control group|No physical activity
223955190|NCT04851782|DEVICE|ivEAD tubing kit|ivEAD tubing designed to reduce infusion pump alarms do to air in infusion line
223955191|NCT03014037|PROCEDURE|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
223955192|NCT03014037|PROCEDURE|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
223955193|NCT04069455|OTHER|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
224107206|NCT06346795|OTHER|High-filling flowable dental composite|Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
224107207|NCT06143384|DEVICE|Telemonitoring AirView (ResMed company)|Introduction of AirView telemonitoring of HMV, during a 6-months period.
224107208|NCT00133744|DIETARY_SUPPLEMENT|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
224107209|NCT00133744|DIETARY_SUPPLEMENT|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
223723767|NCT05038423|BEHAVIORAL|12-week structured walking program|Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
223955194|NCT02761356|OTHER|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
223955195|NCT00213759|DRUG|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
223955196|NCT00213759|DRUG|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
223955197|NCT04895085|DIAGNOSTIC_TEST|BinaxNOW Rapid Antigen System|"BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more."
223955198|NCT01303744|DRUG|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
223723768|NCT01007097|DRUG|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
223955199|NCT01303744|DRUG|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
223955200|NCT01303744|DRUG|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
223955201|NCT01303744|DRUG|Placebo|oral tablet, once a day in the morning for 12 weeks
223955202|NCT00230906|PROCEDURE|Haemodialysis with either low or high flux membranes|
223723769|NCT01007097|DRUG|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
223723770|NCT01007097|DRUG|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
223723771|NCT01007097|DRUG|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
223540480|NCT06119516|OTHER|Esophageal pressure-guided strategy,|A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
223540481|NCT04818957|DIETARY_SUPPLEMENT|Oral Thin Film (OTF) Cholecalciferol (Vitamin D3)|Study participants will receive vitamin D OTF weekly for a maximum of 12 weeks. The dose may be increased or decreased based on the dosing schema.
223540482|NCT04203589|BEHAVIORAL|The Explorer Baby Early Intervention Program|Centered based intervention, once or twice a month, 6 months follow up
223540483|NCT04203589|OTHER|Neurodevelopmental Therapy|Centered based intervention, once or twice a month, 6 months follow up
223540484|NCT04772209|DRUG|Sodium bicarbonate|Dialysis catheter lumen will be filled (locked) by sodium bicarbonate solution. The amount of solution depends on the diameter and length and will be in accordance with the manufacturer's specifications.
223955203|NCT05232357|DRUG|Sodium thiosulfate and Methylene blue solution|Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
223955204|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
223955205|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
223540485|NCT04772209|DRUG|Heparin|Dialysis catheter lumen will be filled (locked) by classic heparin. The amount of pure heparin depends on the diameter and length and will be in accordance with the manufacturer's specifications.
223955206|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose open label
223955207|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily high dose
223955208|NCT01159600|DRUG|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
223540486|NCT01405183|OTHER|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
223540487|NCT04592406|OTHER|CVP screening|An appropriate dual screening process including both renal and cardiac parameters to minimize the risks of post-contrast renal adverse outcomes and of prophylactic hydration in eGFR\<30mL/min/1.73m2 patients.
223540488|NCT03313414|DRUG|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
223540489|NCT00484796|PROCEDURE|MED-SEP|intraoperative neurophysiological monitoring
223540490|NCT00484796|PROCEDURE|TRI-SEP|intraoperative neurophysiologic monitoring
223540491|NCT00484796|PROCEDURE|neuropsychological tests|neurological short- and longterm outcome
223540492|NCT03756116|PROCEDURE|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
223723772|NCT01007097|DRUG|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
223723773|NCT01007097|DRUG|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
224107210|NCT00133744|DIETARY_SUPPLEMENT|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
224107211|NCT02788539|BEHAVIORAL|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
224107212|NCT02991612|DRUG|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
223540493|NCT03756116|PROCEDURE|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
223540494|NCT00003929|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
223723774|NCT01007097|DRUG|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
223723775|NCT03925974|DRUG|KN026 10 mg/kg QW|10 mg/kg QW as safety run-in dosage
223540495|NCT00003929|DRUG|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
223540496|NCT00003929|DRUG|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
223540497|NCT00003929|RADIATION|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
223540498|NCT01014702|DEVICE|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
223723776|NCT03925974|DRUG|KN026 20 mg/kg Q2W|20 mg/kg Q2W as target dosage
223723777|NCT03925974|DRUG|KN026 30 mg/kg Q3W|30 mg/kg Q3W as another target dosage
223723778|NCT00299975|DRUG|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
223723779|NCT00299975|DRUG|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
223723780|NCT00299975|DRUG|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
223955209|NCT01159600|DRUG|BI 10773|BI 10773 tablets once daily low dose
223955210|NCT01159600|DRUG|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
223955211|NCT05894291|OTHER|Swimmer Prone Position|"Patients will be positioned with the head rotated. This rotation is followed by shoulder elevation/abduction, then 90° elbow flexion for the arm opposite to the head rotation. The hand is placed flat on the bed.~A 60° to 90° flexion is performed on the hip homolateral to head rotation, combined with knee flexion.~The position is changed to the mirror position every 4 hours."
224107213|NCT01444391|DEVICE|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
224107214|NCT01642537|DEVICE|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
224107215|NCT00653315|DRUG|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
224107216|NCT00653315|DRUG|Ultracet|Tablets, 37.5mg/325mg
224107217|NCT03331211|DRUG|TKIs|Dasatinib combined with Chematherapy
224107218|NCT04259710|BEHAVIORAL|Goal-setting intervention|The participant will meet weekly with the investigator, report steps and set goals for the following week.
224107219|NCT04259710|BEHAVIORAL|Goal setting with implementation intentions|In addition to the standard goal-setting intervention, the participant will fill out a form that directs them to perform implementation intentions at weeks 1, 5 and 9.
224107220|NCT04259710|BEHAVIORAL|Pedometer only|the participant will be given a pedometer and instructed how to use it.
223540499|NCT01014702|DEVICE|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
224107221|NCT06292312|OTHER|Craniosacral therapy|Craniosacral therapy is defined as an alternative, massage-like treatment approach using gentle manual force to address somatic dysfunctions of the head and the rest of the body.
223540500|NCT05399966|DIETARY_SUPPLEMENT|Monarda Didyma extract|Monarda Didyma extract; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
223540501|NCT05399966|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 100 mg/d. 1capsules/day; daily (1 capsule with the lunch) and plenty of water.
224107222|NCT06292312|OTHER|Conventional physiotherapy|Range of motion, stretching, resistance exercises. Spasticity inhibition Balance and coordination exercises Walking training Stabilization exercises Breathing exercises
224107223|NCT04467112|DEVICE|Breath Biopsy face masks with removable filters and fitted PVA strip|Device developed for collection of breath samples
224107224|NCT01264003|DRUG|sefazolin|In prophylaxis
223540502|NCT01041950|PROCEDURE|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
223540503|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum precipitated autoclaved L. major
223540504|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
223540505|NCT00429715|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG
223540506|NCT02095756|OTHER|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
223540507|NCT02095756|OTHER|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
223540508|NCT00180037|DRUG|Coenzyme Q10 Nanodispersion (Nanoquinone)|
224107225|NCT03901378|DRUG|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
223955212|NCT05894291|OTHER|Prone position with arms alongside the body|"The head will be positioned either straight or rotated to one side, depending on ICU habits. The arms are positioned symmetrically along the body, palms up. The lower limbs are positioned symmetrically and parallel, knees extended or slightly flexed if a cushion is used on the front of the feet.~Head rotation, if applicable, is performed every 4 hours."
224107226|NCT03731715|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
224107227|NCT03129438|DIAGNOSTIC_TEST|continuous EEG (cEEG)|differential use of continuous versus routine EEG
223540509|NCT00180037|DRUG|Placebo|
223540510|NCT02879513|DRUG|Paclitaxel|
223540511|NCT02879513|DRUG|Cisplatin|
223540512|NCT02879513|DRUG|Epirubicin|
223540513|NCT02879513|DRUG|Cyclophosphamide|
223540514|NCT02879513|DRUG|5-fluoruracil|
224107228|NCT03129438|DIAGNOSTIC_TEST|routine EEG (rEEG)|differential use of continuous versus routine EEG
223955213|NCT04015050|OTHER|milk based infant formula|Cows milk ased infant formula
223540515|NCT04160104|OTHER|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
223540516|NCT04160104|OTHER|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
224107229|NCT06940401|DRUG|JS111 capsules (AP-L1898)|In Phase I, approximately 3-12 subjects will be enrolled in each dose group (160 mg QD or 240 mg QD) and receive oral JS111 capsules once daily until any treatment discontinuation criteria are met. After all subjects have completed at least 21 days observation following the first dose, the Safety Monitoring Committee (SMC) will review safety and pharmacokinetic data to make decisions. Phase II will continue enrollment at the RP2D dose level until approximately 30 subjects have been treated at that dose.
224107230|NCT06374498|DEVICE|OCT-NIRAF|Subjects will be imaged with OCT-NIRAF research catheter during their clinically indicated coronary angiogram. In addition, the subject will also receive two Coronary Computed Tomography Angiography (CCTA) 12 months apart, and images will be analyzed.
223540517|NCT00710983|BIOLOGICAL|Oral polio vaccine|
223540518|NCT06209489|OTHER|White cover|"* A white cover will be covered over the incubator during phototherapy.~* Baby massage will be applied during phototherapy."
223540519|NCT03861182|BIOLOGICAL|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
223540520|NCT00394576|BEHAVIORAL|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
223955214|NCT04399772|BEHAVIORAL|Cognitive Functional Therapy+ pathway|"The CFT+ intervention comprises 4 main components: (1) making sense of pain: context-based patient education focusing on the multidimensional nature of pain and disability, while reducing the threat of structural damage and correcting unhelpful beliefs; (2) exposure with control: graded exposure to painful, feared, or avoided activities with body relaxation; (3) lifestyle changes: encouraged to perform physical activity based on preference and taught strategies to manage stress and poor sleep, (4) focus on coping strategies in life and how these strategies influence the current situation.~After CFT+, patients can be offered the comparator pathway should that be clinically indicated from these criteria: the patient does not feel ready to stop treatment AND Analgesic treatment is inappropriate OR Social situation is problematic OR Significantly psychological distress that requires further treatment by psychologist. This decision is based on a multidisciplinary team conference."
223955215|NCT04399772|BEHAVIORAL|Interdisciplinary pain management pathway|"Treatment at the Interdisciplinary University Pain Center are based on elements from cognitive-behavioral therapy, Acceptance and Commitment Therapy, and Mindfulness-Based Stress Reduction programs.~Individualized combination of (1) medical treatment with a specialist pain consultant+specialist pain nurse (ie, individual adjustment of analgesics to improve effect and reduce side effects), (2) one or more of the following: individual consultations with a specialist pain psychologist, physiotherapist or social worker with cognitive-behavioral therapy training as well as participation in a group program with relaxation therapy, acceptance and commitment therapy or standardized mindfulness-based stress reduction programs."
223955216|NCT03029299|DEVICE|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
223955217|NCT05144659|PROCEDURE|Double faced transverse preputial onlay island flap|A well-established one-stage repair of penile hypospadias called Double faced transverse preputial onlay island flap
223955218|NCT05144659|PROCEDURE|Transverse inner preputial onlay island flap|A second well-established one-stage repair of penile hypospadias called Transverse inner preputial onlay island flap
223540521|NCT00394576|BEHAVIORAL|usual care|usual care
223540522|NCT00692003|DRUG|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; \>= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
223955219|NCT04433091|DRUG|2-Hydroxybenzylamine|2-HOBA (2-Hydroxybenzlamine) 750mg will be given TID seven days prior to ablation and 28 days post ablation.
223955220|NCT04433091|OTHER|Placebo|Placebo will be given TID for seven days prior to ablation and 28 days post ablation.
223955221|NCT07009600|DRUG|immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)|
223955222|NCT03229291|DRUG|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
223955223|NCT03229291|DRUG|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
223540523|NCT00692003|DRUG|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
223540524|NCT04152486|BIOLOGICAL|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
223540525|NCT01369043|DIETARY_SUPPLEMENT|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
223540526|NCT04677998|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 3-6 months and 5 years, depending on severity of polyposis and performed endoscopic interventions.
223540527|NCT02418520|DEVICE|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
223540528|NCT06239038|PROCEDURE|total knee arthroplasty|total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
223723781|NCT01815593|DEVICE|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
223540529|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
223540530|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP|1 x 10\^10 PU administered in deltoid
223540531|NCT00125970|BIOLOGICAL|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
223540532|NCT00125970|BIOLOGICAL|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
223540533|NCT03895190|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
223540534|NCT01248793|DRUG|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
223540535|NCT01248793|DRUG|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
223540536|NCT01248793|DRUG|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
223540537|NCT04616937|DIETARY_SUPPLEMENT|GOS|Prebiotic
223540538|NCT04616937|DIETARY_SUPPLEMENT|Placebo|Placebo
223955224|NCT07009197|OTHER|Instrument Assisted Soft Tissue Mobilization|the treatment will start by disinfect the instrument between patients to avoid transfer of infections. It is recommended to disinfect the instrument with intermediate-level disinfectants (e.g. isopropyl alcohol), then wash it with soap and water to remove any residuals of the chemical disinfectant off the instrument. If the tools contacts blood, bodily fluids, mucous membranes, or non-intact skin then disinfecting it with high-level disinfectant should be done .IASTM will be done at 30-60 degrees angle for 40-120 seconds+ radiational therapy
223540539|NCT04016701|DEVICE|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
223540540|NCT04016701|BEHAVIORAL|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
223540541|NCT05067881|PROCEDURE|Pulmonary resection|Resection of pneumohematocele
223540542|NCT01840943|DRUG|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
223540543|NCT01840943|DRUG|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
223723782|NCT01352858|DRUG|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
223723783|NCT01352858|DRUG|Arthroscopy & saline irrigation alone|
223723784|NCT04742010|DRUG|Zoledronic Acid|"* A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes"
223723785|NCT04742010|DRUG|Placebo|as above
223723786|NCT00982878|DRUG|Maraviroc|150mg twice daily
223723787|NCT03167411|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
223723788|NCT03167411|DRUG|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
223955225|NCT07009197|OTHER|traditional therapy|the patients will receive traditional therapy in the form of ultrasound, scar massage, and stretching exercises.
223955226|NCT04097535|OTHER|PET/MRI|Imaging scan
223955227|NCT02265354|BEHAVIORAL|Collective-Intelligence computer tailored health communication|
223955228|NCT02265354|BEHAVIORAL|Rule-based computer tailored health communication|
223540544|NCT04860115|PROCEDURE|Modified pectoralis block (PEC II) and pecto-intercostal fascial plane block (PIFB)|"PECS II: Ultrasound guided block involving injection of 20 ml of 0.25% L-bupivacaine with dexmetomidine into an interfascial plane between the serratus anterior muscle and the external intercostal muscles followed by the needle withdrawal into an interfascial plane between the pectoralis major and pectoralis minor muscle where further 10ml will be administered.~PIFB: Ultrasound guided block involving injection of 10 ml of 0.25% L-bupivacaine with dexmetomidine into an iterfascial plane between the pectoralis major and the intercostal muscles approximately 2 cm laterally from the sternum to cover T2 to T6 dermatomes."
223540545|NCT03433547|PROCEDURE|Buckle|Surgical procedures of macular buckling
223955229|NCT06696105|DRUG|Resin infiltration|"Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization."
223955230|NCT06696105|DRUG|Vanish XT varnish (resin modified glass ionomer restoration)|Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
223955231|NCT06698562|OTHER|Distraction with Virtual reality glassess|the injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. The patient and the physician wore protective goggles during the whole procedure to prevent possi
223955232|NCT06698562|OTHER|Distraction with Virtual reality glassess + LLLT|The injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
224107231|NCT06358417|BEHAVIORAL|Nutrition-enhanced CHW|CHW provides nutrition education and skills training in addition to the usual care (Basic CHW) hypertension management.
224107232|NCT06358417|BEHAVIORAL|Basic CHW|CHW provide usual care for hypertension management.
223540546|NCT03433547|PROCEDURE|Vitrectomy|Surgical procedures of small gauge vitrectomy
223540547|NCT03433547|OTHER|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
223955233|NCT06698562|OTHER|Tell Show Do Group + LLLT|The injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. During the whole procedure, the patient wore virtual glasses and the physician wore protective go
224107233|NCT06499259|OTHER|Mandala coloring|Mandala Pack and Application: The mandala pack is a pack consisting of 7 different patterns suitable for adults and 12 pencils. Mandala patterns will be photocopied by the researcher. Packages will be given to the mothers about mandala coloring and their questions will be answered. The choice of the color of the paint to be used in mandala coloring will be entirely up to the mother. No guidance will be given in this regard.
223540548|NCT03433547|OTHER|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
223540549|NCT03433547|OTHER|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
223540550|NCT03433547|OTHER|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
223540551|NCT00421512|DRUG|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
223955234|NCT06698562|OTHER|Tell Show Do Group|In this session, the injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
223955235|NCT06699017|OTHER|Continuous anterior chest compression|CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
223540552|NCT04606927|OTHER|Natriuresis|Patients with insufficient decongestive response based on natriuresis (in the active arm) will be eligible for treatment adjustments according to the natriuresis guided treatment algorithm.
223540553|NCT03100318|DRUG|FYU-981|Oral daily dosing for 14 weeks
223540554|NCT03100318|DRUG|Benzbromarone|Oral daily dosing for 14 weeks
223955236|NCT06700252|OTHER|Vestibular Rehabilitation|This intervention used gaze stabilization, habituation, balance training and exertional training. Exercises utilized included visual tracking, gaze holding with head turns, saccades, visual accommodation exercises, visual convergence exercises, positional accommodation, rockerboard proprioception, single leg balance on the floor and on dynamic surfaces, tandem balance on the floor and on dynamic surfaces, double leg balance on dynamic surfaces, mirror feedback of functional activities, and physical exertion training with walking, biking or sport specific activities.
223955237|NCT06700252|OTHER|Traditional Protocol|This intervention symptom management and graduated return to physical activity involving a stepwise progression in which the participant proceeded to the next step if symptom-free at the current step for a 24-hour period. If any symptoms occurred at that step, the participant was returned to the previous step and tried to progress again after 24 hours of rest. The steps were as follows: 1) Patient to return to regular activities such as school 2) Light aerobic activity to increase the patient's heart rate achieved with 5 to 10 minutes on a stationary bike or walking but without weightlifting 3) Moderate activity which increased the heart rate with head or body movement that may have included sport specific exercise with minimal-moderate resistance 4) Heavy, non-contact activity in three planes of movement 5) Full contact practice 6) Competition
223955238|NCT06699121|DRUG|LB-P8 low-dose|One capsule QD (1×10\^10 CFU/day) oral administration
223955239|NCT06699121|DRUG|LB-P8 high-dose|One capsule QD (1×10\^11 CFU/day) oral administration
223955240|NCT06699121|DRUG|Placebo|One capsule QD oral administration
223955241|NCT06698718|PROCEDURE|Periodontal basic treatment|Accept periodontal basic treatment
223540555|NCT01078727|DEVICE|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
223723789|NCT02590367|DRUG|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks."
223723790|NCT02590367|DRUG|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
223723791|NCT02590367|DRUG|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
223723792|NCT05374434|OTHER|Conventional irrigation|The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.
223955242|NCT06699355|DRUG|Enlicitide Decanoate|Oral administration
223955243|NCT06699355|DRUG|Atorvastatin|Oral administration
223540556|NCT01508208|OTHER|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
223540557|NCT02472912|BIOLOGICAL|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
223540558|NCT02472912|BIOLOGICAL|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
223540559|NCT02472912|BIOLOGICAL|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
223723793|NCT05374434|DEVICE|Inertial cavitation|The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
223723794|NCT04071561|OTHER|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
223955244|NCT01003743|DEVICE|endolumenal tissue approximation|
223540560|NCT05617118|DRUG|Baclofen 10mg|Baclofen is a medication, a central myorelaxant, a GABAb stimulator.
223540561|NCT05617118|DRUG|Botulinum toxin type A|Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.
223540562|NCT02580877|DRUG|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
223540563|NCT02580877|DRUG|500mg oral insulin crystals every other week|human insulin crystals in capsules
223955245|NCT06083051|DEVICE|6Fr Percuflex ureteral stents|The Percuflex stent is a 6Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
223540564|NCT03186105|OTHER|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
223955246|NCT06083051|DEVICE|6Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 6 Fr is the diameter.
223540565|NCT00098033|DRUG|clofarabine|
223540566|NCT01781377|DRUG|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
223540567|NCT01781377|DRUG|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
223540568|NCT01781377|DRUG|PLACEBO|SALINE INFUSION
223540569|NCT00323531|PROCEDURE|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
223540570|NCT00323531|PROCEDURE|VATS decortication|thoracoscopic decortication
223540571|NCT00291031|BEHAVIORAL|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
223723795|NCT04071561|OTHER|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
223955247|NCT06083051|DEVICE|4.8Fr Tria ureteral stents|The Tria stent is a new stent that is designed to soften at body temperature after placement, with an additional coating that prevents calcium and magnesium build up. This is intended to increase patient tolerability of the stent. 4.8 Fr is the diameter.
223955248|NCT06083051|DEVICE|4.8Fr Percuflex ureteral stents|The Percuflex stent is a 4.8Fr polymeric, hydrophilic coated stent that is routinely used post ureteroscopy with laser lithotripsy.
223955249|NCT04228068|OTHER|Rehabilitation Program|"PT visits (two visits): The first visit will happen within a week of discharge. During this visit, the PT will assess participants, tailor the program to their needs, and coach them in carrying out the exercises at home. The last visit will be 12 weeks after the first. During this visit, the PT will reassess the participants and make adjustments to the program. The participants will be encouraged to continue exercising beyond the 12 weeks.~The PTA will visit the participants' homes with the PT and will conduct additional solo visits every other week (i.e. 7 PTA visits in total, in 1st week and at 2, 4, 6, 8, 10, and 12 weeks). The PTA will facilitate and progress the exercise program as prescribed and directed by the PT and help in delivering the education component of the program."
223955250|NCT04228068|OTHER|Pain self management|In addition to the exercise program, the intervention group will receive a pain self-management support tailored by the PT to the participants' needs.
223955251|NCT04228068|OTHER|Conventional care|The control group will receive the usual care provided by the healthcare system.
223955252|NCT05562492|DEVICE|CamAPS FX|"The automated closed loop system (CamAPS FX) will consist of:~YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor Cloud upload system to review CGM/insulin data."
223723796|NCT02627144|DRUG|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
223955253|NCT05562492|OTHER|Standard insulin therapy with CGM|Usual insulin therapy and study CGM.
223540572|NCT06349824|DRUG|injection Dextrose water|dextrose will be injected around median nerve in wrist
223540573|NCT06349824|DEVICE|USG machine|usg guided nerve hydrdissection
223540574|NCT05020301|DEVICE|external meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by External Meditation Instruction Audio.
223540575|NCT05020301|DEVICE|internal meditation guided audio|Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
223540576|NCT03341637|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
223540577|NCT03341637|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
223540578|NCT00222976|DRUG|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
223540579|NCT05547412|DEVICE|NovaGuide 2 Intelligent Ultrasound System|The NovaGuide 2 Intelligent Ultrasound system is an adjunctive mobile, non-invasive, non-ionizing radiation transcranial Doppler (TCD) diagnostic ultrasound system. The system contains a transcranial doppler ultrasound equipment combined with robotic mechanisms used to position ultrasound probes, which assist the user in the acquisition of cerebral blood flow velocity (CBFV) data via a patient's temporal acoustic windows.
223540580|NCT04085146|PROCEDURE|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
223723797|NCT02627144|DRUG|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
223955254|NCT06721728|BEHAVIORAL|Oral health educational program|Flyer distributed on the children with data about oral hygiene measures as well as diet advice related to their condition, in addition to modeling the correct tooth brushing habits using a cast and tooth brush.
223955255|NCT06721390|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 12 weeks.
223955256|NCT06721390|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 12 weeks.
223955257|NCT05400525|DIETARY_SUPPLEMENT|YMETA|1 sachet containg a total of 3g i.e. 2.5g Galacto-oligosaccharides, 0.5g Bifidobacterium polysaccharides (daily)
223955258|NCT05400525|OTHER|Placebo control|3g Maltodextrin (i.e. DE 10) daily
223955259|NCT03458494|OTHER|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
223955260|NCT03458494|OTHER|Low-fat diet|Participants will receive meals with a low content of total fat.
223955261|NCT04810351|OTHER|observational study|There is no intervention. It is an observational study
223540581|NCT04085146|PROCEDURE|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
223723798|NCT05883449|DRUG|AFM13|anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion
223723799|NCT05883449|DRUG|AB-101|NK cell therapy, intravenous infusion
223723800|NCT05883449|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy, intravenous infusion
223723801|NCT05883449|DRUG|Fludarabine|Lymphodepleting chemotherapy, intravenous infusion
223723802|NCT05883449|DRUG|Interleukin-2|Immune cytokine, subcutaneously
223540582|NCT02598141|BIOLOGICAL|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
223540583|NCT02598141|BIOLOGICAL|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
223540584|NCT04878107|DRUG|Camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd
223540585|NCT04878107|DRUG|Apatinib|Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor
223540586|NCT04878107|DRUG|Docetaxel injection|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
223723803|NCT06340750|BIOLOGICAL|LMY-920|CAR T Therapy
223540587|NCT04878107|RADIATION|SBRT|Stereotactic body radiation therapy (SBRT) is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue. SBRT involves the use of sophisticated image guidance that pinpoints the exact three-dimensional location of a tumor so that the radiation can be more precisely delivered to cancer cells.
223540588|NCT04878107|RADIATION|LDRT|low dose radation therapy
223540589|NCT04032886|OTHER|kinesio tape|This is a taping method used for correction of rounded shoulders.
223540590|NCT04032886|OTHER|exercise|Exercises include basic postural exercises.
223540591|NCT02759445|OTHER|routine treatment|No intervention, only observation and describing
223540592|NCT01690754|OTHER|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
223540593|NCT03030456|DEVICE|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
223540594|NCT05208008|OTHER|With service dog|No intervention
223540595|NCT03299478|OTHER|Will look for immune infiltration|
223540596|NCT00848887|BIOLOGICAL|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
223540597|NCT01322724|PROCEDURE|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
223723804|NCT04983654|DIAGNOSTIC_TEST|patients with limb ulcers|"For patients with limb ulcers : at inclusion visit and after healing or at 6 months if ulcer does not heal:~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis ( sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks,~* Analysis of cytokine and metalloproteases in the wound fluid,~* Assessment of healing according usual treatment"
224291130|NCT03588052|PROCEDURE|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
223540598|NCT00887159|DRUG|Cisplatin|Given IV
223540599|NCT00887159|BIOLOGICAL|Cixutumumab|Given IV
223540600|NCT00887159|DRUG|Etoposide|Given IV
223540601|NCT00887159|OTHER|Laboratory Biomarker Analysis|Correlative studies
223540602|NCT00887159|DRUG|Vismodegib|Given PO
223540603|NCT02125955|DIETARY_SUPPLEMENT|Prebiotic fiber|Dissolved in water.
223540604|NCT02125955|DIETARY_SUPPLEMENT|Placebo|Dissolved in water
223540605|NCT03181971|BEHAVIORAL|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
223540606|NCT02543853|OTHER|direct trocar entry|direct trocar entry to provide pneumoperitoneum
223540607|NCT02543853|OTHER|veres needle entry|veres needle entry to provide pneumoperitoneum
223723805|NCT04983654|DIAGNOSTIC_TEST|For patients without limb ulcers|"For patients without limb ulcers : at inclusion visit only~* Microvascular analysis (laser doppler, TcPO2),~* Neurological analysis (sensitivity testing with thermal and mechanical test),~* Analysis of physical characteristics of red blood cells and inflammatory marks"
223723806|NCT04547569|BEHAVIORAL|Speech adaptation|Sensorimotor adaptation in speech
223723807|NCT04547569|BEHAVIORAL|Vibrotactile Discrimination|Vibrotactile Discrimination
223723808|NCT04547569|OTHER|fMRI|fMRI measurement of brain activity
223540608|NCT03130829|DIETARY_SUPPLEMENT|Oligo Fucoidan|Oral, twice daily
223540609|NCT03130829|DIETARY_SUPPLEMENT|Placebo|Oral, twice daily
223540610|NCT04230967|BEHAVIORAL|Ambulation Group|Participants in the ambulation arm will be allowed ad lib activity and instructed that they should walk at least once per day out of their room with a goal of 2,000 steps per day. The Fitbit Inspire devices will be set to this goal and notifications will be given on the device for the participants meeting their goals
223540611|NCT04230967|BEHAVIORAL|Routine Care|No encouragement to ambulate will be provided to subjects. Their movement will be recorded
223540612|NCT04454346|DEVICE|Double Foley Catheter For Ripening The Unfavorable Cervix|New method
223723809|NCT04547569|BEHAVIORAL|Speech production|Speech production task
223540613|NCT02886910|OTHER|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
223540614|NCT02886910|OTHER|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
223540615|NCT02291133|PROCEDURE|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
223540616|NCT02291133|DEVICE|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
223540617|NCT02291133|DRUG|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
223540618|NCT00704067|BEHAVIORAL|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
223540619|NCT00704067|BEHAVIORAL|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
223540620|NCT01670669|DRUG|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
223540621|NCT02554799|DRUG|MMV390048 formulation A|MMV390048 formulation A, tablet
223540622|NCT02554799|DRUG|MMV390048 formulation B|MMV390048 formulation B, tablet
223540623|NCT00710398|BEHAVIORAL|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
223540624|NCT00710398|BEHAVIORAL|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
223540625|NCT04047368|PROCEDURE|Rotablation|Percutaneous Coronary Intervention using Rotablation
223540626|NCT04047368|PROCEDURE|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
223540627|NCT01461746|DRUG|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
223540628|NCT01461746|DRUG|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
223540629|NCT01461746|RADIATION|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
223723810|NCT02491203|OTHER|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
223955262|NCT03457168|PROCEDURE|Treatment of elevated asleep SBP mean|To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required
223955263|NCT04396717|BIOLOGICAL|Pritumumab|Pritumumab IgG1 human monoclonal antibody
223955264|NCT02880293|DRUG|melphalan|melphalan (140 mg/m2 IV on day -7)
223955265|NCT02880293|DRUG|fludarabine|fludarabine (40 mg/m2/d on days -5 through -2)
223955266|NCT02880293|DRUG|thiotepa|thiotepa (5 mg/kg IV on day -67)
223955267|NCT02880293|DRUG|Cyclophosphamide|cyclophosphamide (50 mg/kg IV on day +3 and +4)
223955268|NCT02880293|DRUG|Mesna|
223955269|NCT02880293|DRUG|Mycophenolate Mofetil|(15 mg/kg PO/IV TID)
223955270|NCT02880293|DRUG|Filgrastim|
223955271|NCT02880293|DRUG|Tacrolimus|
223540630|NCT00535535|DIETARY_SUPPLEMENT|Fructose|Fructose, 0.5 g/kg
223540631|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
223955272|NCT06395987|PROCEDURE|Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures.|Use Of Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures.
223955273|NCT05290155|DRUG|anti-CD7 CAR-T cells|Administration with anti-CD7 CAR-T cells in the relapsed/refractory T cell hematological malignancy patients
223955274|NCT05715957|OTHER|No intervention|No intervention
223955275|NCT06847997|OTHER|Addition of telemedicine to standard medical dispatching process (Experimental Group)|In the experimental group, the same approach is used, with the addition of telemedicine using video calls. Callers are invited to use their smartphone camera to enable real-time video assessment. The medical dispatcher sends a secure link (via a platform provided by Enovacom, Nomadeec, Bordeaux, France) to the caller's smartphone, allowing video streaming through a secure internet connection. Once the link is validated by the caller, the live video feed from the smartphone camera is transmitted directly to the dispatcher's computer screen, providing a visual evaluation to support clinical decision-making.
223955276|NCT03121261|DRUG|levobupivacaine|Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
223955277|NCT03121261|DRUG|clonidine|Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
223955278|NCT05928689|DRUG|Propranolol Hydrochloride tablet|Single dose of 40 mg propranolol tablet
223540632|NCT00535535|DIETARY_SUPPLEMENT|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
223540633|NCT03930381|OTHER|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
223540634|NCT01367379|PROCEDURE|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
223540635|NCT01367379|OTHER|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2\~4 times/month)
223540636|NCT05328869|OTHER|Relaxation training|Relaxation training will be performed under the supervision of a physiotherapist. The training is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
223723811|NCT04185545|BIOLOGICAL|Rotavirus RV3 Vaccine (Bio Farma)|Each 1 mL dose of the final product of oral liquid rotavirus vaccine contains \> 5x10\^6 fcfu/mL rotavirus vaccine strain RV3
223723812|NCT04185545|OTHER|Placebo|Each 1 mL dose of placebo contains 30% of sucrose in DMEM
223723813|NCT02137174|OTHER|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
223955279|NCT05928689|BEHAVIORAL|Reminder|Reactivation of misophonia trigger memory
223955280|NCT05928689|BEHAVIORAL|Counterconditioning|Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.
223955281|NCT05928689|DRUG|Placebo|Matching placebo tablet
223955282|NCT04693013|DEVICE|Virtual Reality for Anxiety Reduction|Virtual Reality for Anxiety Reduction during suturing of perineum
223955283|NCT03527888|DRUG|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
223955284|NCT00965471|DRUG|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
223955285|NCT00965471|DRUG|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
223955286|NCT02233075|DRUG|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
223955287|NCT01970072|DRUG|Remimazolam Tosylate|
223955288|NCT01970072|DRUG|Midazolam|
223955289|NCT03467594|BEHAVIORAL|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
223955290|NCT05203003|OTHER|Assessment of MRD|"Bone marrow aspirate for assessment of MRD will be performed at 2 years (+/- 3 month) after randomization in patients still under treatment and in complete response.~Thereafter, bone marrow aspirate for assessment of MRD will be repeated at 3 and 4 years in patients that maintain complete response, irrespective of the randomization arm and therefore of treatment administration."
223955291|NCT01163929|DRUG|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
223955292|NCT04555694|DRUG|Cyclosporine|Used to increase tear production in patients who have dry eye caused by inflammation
223955293|NCT04555694|DRUG|Loteprednol Etabonate|Used to treat inflammation of the eye
223955294|NCT04555694|DRUG|Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert|Used to treat inflammation of the eye
223955295|NCT00230009|BEHAVIORAL|Brief motivational intervention|
223955296|NCT04641156|OTHER|Exercise Therapy program added to laser therapy|a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
223955297|NCT01368549|OTHER|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
223955298|NCT00456235|DRUG|Mycophénolate Mofétil|
223955299|NCT00456235|DRUG|Ciclosporine A|
223955300|NCT00456235|DRUG|Tacrolimus|
223955301|NCT02952235|OTHER|SPF50+|Sun protection
223955302|NCT02952235|OTHER|SPF100+|Sun protection
224291131|NCT01076556|DRUG|Alvocidib Hydrochloride|Given IV
224291132|NCT01076556|DRUG|Cyclophosphamide|Given IV
224291133|NCT01076556|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223540637|NCT05328869|OTHER|No intervention|No intervention will be applied. The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
223540638|NCT04172350|OTHER|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
223540639|NCT04172350|OTHER|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
223955303|NCT04843956|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided biopsy|"Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)"
223955304|NCT00451906|DRUG|Platinum-based chemotherapy|As prescribed
223955305|NCT00451906|DRUG|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
223723814|NCT00530309|DRUG|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
223723815|NCT00530309|DRUG|Placebo|Subjects will also receive placebo.
223723816|NCT05101005|DEVICE|Drug-Coated Balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions.
223955306|NCT04004923|PROCEDURE|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
223955307|NCT04004923|PROCEDURE|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
223955308|NCT06234449|PROCEDURE|Vaginal pessary before surgery for pelvic organ prolapse|use of vaginal pessary for patients waiting for gynecological surgery for stage III and IV pelvic organ prolapse
223955309|NCT03538834|DIETARY_SUPPLEMENT|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
223955310|NCT03538834|DIETARY_SUPPLEMENT|Control|Placebo
223955311|NCT03267069|OTHER|survey|surveys will be administered at inclusion and follow-ups
223955312|NCT01578278|DRUG|Bepotastine besilate formulation|Nasal Spray
223955313|NCT01578278|DRUG|Fluticasone propionate|Nasal Spray
223955314|NCT01578278|DRUG|Bepotastine besilate-fluticasone propionate|Nasal Spray
223955315|NCT01578278|DRUG|Placebo Comparator|Nasal Spray
223955316|NCT00466856|DRUG|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~* \<10% Administer full dose of SIR-Spheres~* 10% to 15% Reduce dose of SIR-Spheres by 20%~* 16% to 20% Reduce dose of SIR-Spheres by 40%~* \>20% Do not give SIR-Spheres"
223955317|NCT00466856|RADIATION|yttrium Y 90 resin microspheres|radiation
224291134|NCT01076556|OTHER|Pharmacological Study|Correlative studies
224291135|NCT01076556|BIOLOGICAL|Rituximab|Given IV
223723817|NCT05101005|DEVICE|Sirolimus-Eluting Stent|Sirolimus-Eluting Stent is treated for coronary artery stenosis lesions.
223723818|NCT01386827|BIOLOGICAL|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml \> 2 years later
223723819|NCT01386827|BIOLOGICAL|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml \> 2 years later
223723820|NCT01386827|BIOLOGICAL|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
223723821|NCT01386827|BIOLOGICAL|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
223955318|NCT04970966|DEVICE|PuraSinus|A randomized ethmoid cavity in the patient will have PuraSinus applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
223955319|NCT04970966|DEVICE|Bioresorbable Nasal Dressing|PosiSep X will be applied to the ethmoid cavity after completion of an endoscopic total ethmoidectomy.
224107234|NCT02858193|DRUG|SCMC-lys powder 1.35 g|"Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments."
224107235|NCT02858193|DRUG|Fluifort® syrup|"Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments."
223540640|NCT03326635|OTHER|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
223540641|NCT01805687|DRUG|Zileuton extended release|
223540642|NCT03903549|DRUG|[18F]P17-059|Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
223540643|NCT02181946|DRUG|Fluconazole|
223540644|NCT02181946|DRUG|Nevirapine|
223540645|NCT02163577|BIOLOGICAL|burosumab|solution for SC injection
223540646|NCT01794624|BEHAVIORAL|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
223540647|NCT01794624|BEHAVIORAL|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
223540648|NCT05280821|DIETARY_SUPPLEMENT|daily ferrous sulfate|Daily intake of 100 mg ferrous sulfate capsules for 3 months
223540649|NCT05280821|DIETARY_SUPPLEMENT|alternate day ferrous sulfate|Alternate day intake of 100 mg ferrous sulfate capsules for 6 months
223723822|NCT05685966|OTHER|no intervention|no intervention
223723823|NCT05864872|PROCEDURE|axillary brachial plexus block|conventional group, 3 to 6 mL of bupivacaine was infiltrated blindly subcutaneously at the same level of the axilla in the anteroposterior direction prior ultrasound group:1 and 2 mL of bupivacaine was injected around each visible nerve branch (Intercostobrachial and Medial Brachial Cutaneous ); if the nerve branches were not visible, 5 mL of the local anesthetic was injected in the subcutaneous area located above the brachial fascia, with a posterior direction, toward the latissimus dorsi muscle.
223955320|NCT03072238|DRUG|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
223955321|NCT03072238|DRUG|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water.
223955322|NCT03072238|DRUG|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity.
223955323|NCT03072238|DRUG|Prednisone/Prednisolone|Oral tablets of 5 mg, taken twice daily (BID) until disease progression or intolerable toxicity.
223955324|NCT00112827|RADIATION|total marrow irradiation|Undergo irradiation
223955325|NCT00112827|DRUG|melphalan|Given IV
224107236|NCT04121910|DRUG|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
223723824|NCT00090974|PROCEDURE|quality-of-life assessment|
223955326|NCT00112827|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
223540650|NCT04284137|BEHAVIORAL|Modified FE-SaLiR|Participants will attend a 60-minute exercise program (modified Wu Qin Xi and Ba Duan Jin) in a non-clinical community setting twice a week and will perform the exercises at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
223723825|NCT01717261|RADIATION|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
223955327|NCT00112827|BIOLOGICAL|filgrastim|Given IV
223955328|NCT00112827|GENETIC|fluorescence in situ hybridization|Correlative studies
223955329|NCT00112827|GENETIC|cytogenetic analysis|Correlative studies
223955330|NCT00112827|DRUG|cyclophosphamide|Given IV
223955331|NCT00112827|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
223955332|NCT00112827|DRUG|lenalidomide|Given orally
223955333|NCT05856955|BEHAVIORAL|mHealth Coaching Intervention|The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
223955334|NCT05856955|BEHAVIORAL|Enhanced Usual Care|Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
223955335|NCT05684120|BEHAVIORAL|Mood Lifters for Undergraduates|Participants will need to attend 14 hour-long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
223955336|NCT01682447|OTHER|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
223955337|NCT01863368|OTHER|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
224107237|NCT04121910|DRUG|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
223723826|NCT01655706|DRUG|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
223723827|NCT01655706|DRUG|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
224107238|NCT05366608|DIAGNOSTIC_TEST|Serum level of 14.0- 3.0- 3.0- η protein and IL_.6|Serum level of 14.0- 3.0- 3.0- η protein and IL\_.6 were estimated for all participants by ELISA.
224107239|NCT04885049|DRUG|Racecadotril|Anti secretary
224107240|NCT04885049|DRUG|DiaResQ Children's Powder for Suspension|oral immunoglobulins
223723828|NCT01753791|DRUG|80 mg PF-06473871|80 mg of PF-06473871 or placebo
223723829|NCT01753791|DRUG|160 mg PF-06473871|160 mg of PF-06473871 or placebo
223955338|NCT01863368|OTHER|Systane® ULTRA lubricant eyedrops|
223955339|NCT01863368|OTHER|OPTIVE® lubricating eyedrops|
223955340|NCT04750902|DRUG|0.24% Sodium Fluoride Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
223955341|NCT04750902|DRUG|1.5% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
223955342|NCT04750902|DRUG|4.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
223955343|NCT04750902|DRUG|8.0% Arginine Dentifrice|Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
223955344|NCT02415335|DRUG|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
223955345|NCT02415335|DRUG|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
223955346|NCT01993342|OTHER|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
223955347|NCT01993342|OTHER|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
223955348|NCT05538156|PROCEDURE|Control group|Vitrectomy and gas tamponade without internal limiting membrane peeling
224107241|NCT00662870|BIOLOGICAL|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
224107242|NCT00662870|BIOLOGICAL|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
224107243|NCT05858411|PROCEDURE|SRP+rhPDGF|The infrabony defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in rhPDGF.
224107244|NCT05858411|PROCEDURE|SRP+collagen sponge|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and will be treated with the application of a collagen sponge soaked in saline solution.
224107245|NCT05858411|PROCEDURE|SRP alone|The infrabony defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
224107246|NCT05751005|DIETARY_SUPPLEMENT|Collagen Peptides vs. Placebo|Participants were randomized into one of three treatment groups.
224291136|NCT01652976|DRUG|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
223540651|NCT04284137|BEHAVIORAL|Unmodified Chinese Medicine Exercise|Participants will attend a 60-minute exercise program (Wu Qin Xi and Ba Duan Jin published by the General Administration of Sport of China) in a non-clinical community setting twice a week and will be expected to practice exercise at home using guided video up to three times a week. Text messages will be sent to remind the participants to do the exercise at home.
223723830|NCT01753791|DRUG|320 mg PF-06473871|320 mg of PF-06473871 or placebo
223723831|NCT01753791|DRUG|480 mg PF-06473871|480 mg of PF-06473871 or placebo
223723832|NCT05311540|DRUG|Zinc Sulfate|
223723833|NCT05349994|OTHER|Extended physiotherapy|At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
223955349|NCT05538156|PROCEDURE|Intervention group|Vitrectomy, internal limiting membrane peeling and gas tamponade
223955350|NCT05152992|BEHAVIORAL|Viewing visual stimuli and electrical stimulation of the brain|View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
223955351|NCT00307489|DRUG|tenofovir DF|300 mg tablet, once daily (QD)
223955352|NCT00307489|DRUG|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
223955353|NCT03733756|PROCEDURE|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
223955354|NCT03733756|PROCEDURE|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
223955355|NCT02006914|DIETARY_SUPPLEMENT|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
223955356|NCT01592422|BIOLOGICAL|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
223955357|NCT01592422|OTHER|Best Supportive Care|Best Supportive Care in the absence of disease progression
223955358|NCT03361202|OTHER|blood sampling|"* atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~* control group:before coronary angiography and at hospital discharge."
223955359|NCT04800263|DRUG|SHR-1905|SHR-1905 will be injected subcutaneously
223955360|NCT04800263|DRUG|Placebo|Placebo will be injected subcutaneously
223955361|NCT03583944|DRUG|Eribulin Mesylate|Eribulin mesylate IV infusion.
223540652|NCT04284137|BEHAVIORAL|Active Control|Participants will attend a 60-minute health education program once a week.
223540653|NCT03190135|BEHAVIORAL|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
223540654|NCT03190135|BEHAVIORAL|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
223540655|NCT01187654|BIOLOGICAL|AC133|intra coronary injection of bone marrow derived AC133+ cells
223540656|NCT01187654|BIOLOGICAL|MNC|intra coronary injection of bone marrow derived MNC
223540657|NCT01187654|BIOLOGICAL|CONTROL|autologous serum injection
223540658|NCT01544673|DRUG|linezolid|600 mg oral tablet twice daily for 4.5 days
223540659|NCT01544673|DRUG|Placebo|500 mg oral placebo twice daily for 4.5 days
224107247|NCT00922545|OTHER|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
224291137|NCT01652976|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
224291138|NCT00113724|DRUG|TPI 287 Injection|
224291139|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10\^9 virus particles.
223955362|NCT05235815|PROCEDURE|Retro SCTL compartment block|"For phase 1, healthy human volunteers will be positioned in the lateral position with the side to be scanned in the non-dependent position. An ultrasound scan sequence to describe the retro SCTL space will be performed on both sides.~During phase 2, participants who are scheduled for video-assisted thoracoscopic surgery (VATS) will receive an ultrasound-guided multi-level (T3-4, T5-6 and T7-8) retro SCTL compartment block. After positioning the participants, cleaning and draping the injection site, under sterile aseptic precautions and local anaesthetic infiltration, the block needle is inserted at the corresponding vertebral level (T7-T8) under ultrasound guidance in-plane to the ultrasound beam. Once the needle tip reaches the lateral aspect of the inferior articular process and behind the SCTL ligament, the desired volume (6ml/each level) of LA will be injected. This process will be continued at the remaining two vertebral levels (T5-T6 and T3-T4)."
223955363|NCT02941432|OTHER|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
223955364|NCT00006006|BIOLOGICAL|recombinant interferon alfa|
223955365|NCT00006006|DRUG|thalidomide|
223955366|NCT01520285|DRUG|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
223955367|NCT01520285|DRUG|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
223955368|NCT05046652|BIOLOGICAL|Convalescent Plasma Therapy|In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.
224107248|NCT00178412|BEHAVIORAL|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
224107249|NCT00178412|BEHAVIORAL|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
224107250|NCT06479005|DEVICE|Oura Ring|The Oura ring will remotely monitor the patients vitals at home continuously
224107251|NCT04385901|BEHAVIORAL|Therapy Intervention|Patients receive 2-4 visits (based on patient presentation and need) of physical therapy, up to 4 visits of occupational therapy, up to 4 visits of speech therapy based on need. Treatment focuses on physical strengthening, pulmonary strengthening/breathing exercises, and cognitive rehabilitation.
224107252|NCT03741881|OTHER|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
224107253|NCT05126615|DRUG|Auriculotherapy|Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
224107254|NCT05126615|BEHAVIORAL|Chronic Post-Surgical Pain evaluation|"Different questionnaires :~BPI : Brief Pain Inventory DN4"
223955369|NCT01053897|BIOLOGICAL|GBT009|Intradermal Injection following surgery
223955370|NCT01053897|BIOLOGICAL|Placebo|Intradermal Injection following surgery
223955371|NCT00086723|BIOLOGICAL|recombinant tissue plasminogen activator|
224107255|NCT02031146|PROCEDURE|Lumbar puncture|
224107256|NCT04957498|BEHAVIORAL|Guided Self-Help for Family Based Treatment|A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
223955372|NCT00086723|DRUG|captopril|
223540660|NCT03855943|BEHAVIORAL|Personalized Computer Program|Training with a personalized computerized inhibitory training program
223955373|NCT05070234|GENETIC|Blood collection for genetic analysis|Genetic tests in this study are sequential testing, including MS-MLPA, whole exome sequencing, whole genome sequencing, as well as RNA-seq.
223540661|NCT03855943|BEHAVIORAL|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
223540662|NCT03394742|BEHAVIORAL|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
223955374|NCT04025762|DEVICE|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
223955375|NCT04025762|DEVICE|Sensor augmented pump therapy|Sensor augmented pump therapy
223955376|NCT05691218|DEVICE|Standard Nebulization|Beta-2 adrenergic agonist administred by standrad nebulization
223955377|NCT05691218|DEVICE|A - Vibrating mesh nebulization|Beta-2 adrenergic agonist nebulisation using a vibrating mesh nebuliser device (Aerogen, Galway, Ireland). Nebulisation will take place under medical air at 6L/min or medical O2 at 6L/min depending on the patient's needs and for a SpO2 target between 94-96%
223540663|NCT01823107|DEVICE|Meso BioMatrix Device|
224107257|NCT04957498|BEHAVIORAL|Family Based Treatment|Standard Family Based Treatment provided for up to 15 sessions.
224107258|NCT00883194|DRUG|PRF-108|Ropivacaine
224107259|NCT00883194|DRUG|Placebo|PRF-108 Placebo
224107260|NCT00883194|DRUG|Ropivacaine|Solution
224107261|NCT00883194|DRUG|PRF-110|
224107262|NCT01582282|DIETARY_SUPPLEMENT|placebo|fiber-free placebo
224107263|NCT01582282|DIETARY_SUPPLEMENT|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
224107264|NCT01582282|DIETARY_SUPPLEMENT|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
224107265|NCT01812304|OTHER|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
224107266|NCT01812304|OTHER|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
224107267|NCT03920852|DRUG|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
223955378|NCT05691218|DEVICE|B - Vibrating mesh nebulisation and high-flow nasal cannula heated and humidified oxygen|"High-flow nasal cannula heated and humidified oxygen (HFNO) and nebulisation of beta-adrenergic agonist using a vibrating mesh device.~HFNO will be administered using an Airvo2 device and beta-2 adrenergic agonist nebulisation enabled by the use of a dedicated heated humidifier and an adaptable vibrating mesh nebuliser device"
223955379|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique|The laparoscopic spleen-preserving distal pancreatectomy using the Kimura technique is defined as a surgical procedure that aims to remove the distal part of the pancreas while preserving the spleen by maintaining the splenic artery and vein (Hepatogastroenterology. 2003;50:2242).
223955380|NCT06167421|PROCEDURE|Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique|Warshaw technique laparoscopic spleen-preserving distal pancreatectomy is defined as a surgical procedure that aims to preserve the spleen while removing the distal part of the pancreas. It involves ligating the splenic artery and vein, while preserving the left gastroepiploic artery and short gastric vessels (Arch Surg. 1988;123:550).
223955381|NCT02791009|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
223955382|NCT02791009|OTHER|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
223955383|NCT02791009|OTHER|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
223955384|NCT02791009|OTHER|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
223955385|NCT02791009|OTHER|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
223955386|NCT02791009|OTHER|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
223955387|NCT04024436|DRUG|Futibatinib|Futibatinib 20mg once daily on a 28 day cycle
223955388|NCT04024436|DRUG|Futibatinib plus Fulvestrant|Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
223955389|NCT01593137|DRUG|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin \>1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
223955390|NCT01593137|DRUG|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin \>1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
223955391|NCT00873626|DRUG|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
223955392|NCT03241121|BEHAVIORAL|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
223955393|NCT03241121|BEHAVIORAL|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
223955394|NCT03241121|DEVICE|Eating patterns|Data collection on eating patterns via the smartphone app
223955395|NCT05441176|OTHER|Questionnaires|Scoring of the DASH is performed according to references.
223955396|NCT02889172|BEHAVIORAL|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
223955397|NCT00416442|DRUG|RSV604|
224107268|NCT02076672|DRUG|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
224107269|NCT00001269|DRUG|IL-3|
224107270|NCT03626467|BIOLOGICAL|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
224107271|NCT05280015|DIETARY_SUPPLEMENT|microbiotherapy (GynMDD)|multi-target microbiotherapy add-on venlafaxine
223955398|NCT03425175|OTHER|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
223955399|NCT02065297|OTHER|1 blood sample|
223955400|NCT02065297|OTHER|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
223955401|NCT04351243|DRUG|Gimsilumab|Gimsilumab is a fully human monoclonal antibody (mAb).
224107272|NCT05280015|OTHER|placebo|placebo add-on venlafaxine
224107273|NCT05782218|DIETARY_SUPPLEMENT|Almonds|Participants will receive 2.2 oz (62 g) of almonds to ingest within 15 minutes.
224107274|NCT05782218|DIETARY_SUPPLEMENT|Coconut|Participants will receive 1 oz (30 g) of a coconut-chocolate bar and 1.4 oz (40 g) of 100% dried coconut chips to ingest within 15 minutes.
224107275|NCT04844671|DEVICE|da Vinci Surgical Systems|The da Vinci Surgical Systems enable surgeons to perform delicate and complex operations through a few small incisions with robotic assisted surgery.
224107276|NCT03968861|DRUG|Xenon|Inhaled xenon gas given via purposely designed ventilator
224107277|NCT02495077|BIOLOGICAL|Infliximab|A single dose, of 3mg/kg infusion
224107278|NCT02495077|DRUG|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
224107279|NCT02495077|DRUG|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
224107280|NCT02495077|DRUG|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
224107281|NCT02495077|BIOLOGICAL|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
224107282|NCT02495077|DRUG|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~* Tylenol, 600 to 1000mg by mouth or~* Suppository form"
224107283|NCT02495077|DRUG|Loratadine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
223955402|NCT04351243|DRUG|Placebo|Normal saline
223955403|NCT01714908|OTHER|Erlotinib w Concurrent Radiotherapy|
223955404|NCT01714908|OTHER|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
223955405|NCT01690000|DRUG|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
223955406|NCT02165202|DRUG|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
223955407|NCT02165202|DRUG|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
223955408|NCT03441256|DEVICE|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
223955409|NCT03441256|DEVICE|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
223955410|NCT04714359|DRUG|Midomafetamine HCl|Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.
223955411|NCT01773707|DRUG|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
223955412|NCT01773707|DRUG|Placebo|Saline given as 30 minute IV infusion
223955413|NCT03751761|DRUG|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
223955414|NCT03242239|BIOLOGICAL|ALT02|
223955415|NCT03242239|BIOLOGICAL|EU-licensed Herceptin|
223955416|NCT03242239|BIOLOGICAL|US-licensed Herceptin|
223955417|NCT01697605|DRUG|BGJ398|
223955418|NCT01527643|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
223955419|NCT00239642|DRUG|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
223955420|NCT00239642|DRUG|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
223955421|NCT00239642|DRUG|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
223955422|NCT06280599|BEHAVIORAL|Transitional care model|In-hospital assessments, video-based stroke education, home visits, and weekly telephone follow-up
223955423|NCT00911716|BIOLOGICAL|bevacizumab|
223955424|NCT00911716|DRUG|cyclophosphamide|
223955425|NCT00911716|DRUG|docetaxel|
223955426|NCT00911716|PROCEDURE|adjuvant therapy|
223955427|NCT04151888|DEVICE|Foley catheter|Thin sterile tube will be inserted in choana
223955428|NCT00842959|DEVICE|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
223955429|NCT00842959|DEVICE|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
223955430|NCT05771285|OTHER|Cold application|To evaluate the effect of cold application applied before subcutaneous low molecular weight heparin injection on post-injection pain, ecchymosis and hematoma formation.
223955431|NCT02837705|OTHER|blood draw|
224107284|NCT02495077|BIOLOGICAL|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
224107285|NCT02495077|DRUG|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
224107286|NCT02495077|DRUG|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~* Claritin (Loratadine) 10mg by mouth or~* Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
224107287|NCT01176396|OTHER|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
224107288|NCT01176396|OTHER|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
224107289|NCT03726671|OTHER|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
224107290|NCT03726671|OTHER|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
224107291|NCT03726671|OTHER|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
224107292|NCT00872716|DRUG|Quetiapine XR|100 mg single-dose Quetiapine XR
224107293|NCT00872716|OTHER|Placebo|Placebo
224107294|NCT04297384|OTHER|Informational Intervention|Receive standard chemotherapy educational materials
224107295|NCT04297384|OTHER|Informational Intervention|Receive personalized information about cancer, treatment, and side effects
224107296|NCT04297384|OTHER|Quality-of-Life Assessment|Ancillary studies
224107297|NCT04297384|OTHER|Survey Administration|Complete surveys
224107298|NCT02013934|DIETARY_SUPPLEMENT|Probiotic|
224107299|NCT02013934|DIETARY_SUPPLEMENT|Placebo|
224107300|NCT04898907|DRUG|ANG-3777 (Therapeutic Dose)|Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
224107301|NCT04898907|DRUG|ANG-3777 (Supra-therapeutic Dose)|Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
223540664|NCT06344637|DRUG|10 % lidocaine spray without adrenaline|Pateint with indication for manual vacuum aspiration aged between 20-60 years will received a standard injection of pethidine along with 1% lidocaine spray without adrenaline on cervical os to compare pain scores with placebo. Along with measuring side effects immediately and 30 minutes after receiving 1% lidocaine without adrenaline.
224107302|NCT04898907|DRUG|Placebo|Arms assigned to this intervention will receive normal saline, IV, Fasted
224107303|NCT04898907|DRUG|Moxifloxacin Hydrochloride|Arms assigned to this intervention will receive 400 mg, Oral, Fasted
224107304|NCT03983876|DRUG|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
224107305|NCT02742649|DRUG|Fixed Combination|Continuous elution from the ocular insert.
223540665|NCT06344637|OTHER|Placebo|4 puffs of normal saline apply on cervical os before manual vacuum aspiration
223540666|NCT05689879|DRUG|STOP arm|TNF-alpha antagonists withdrawal
224107306|NCT02742649|DRUG|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
224107307|NCT02742649|DRUG|Timolol|Continuous elution from the ocular insert. This is an active control arm.
223540667|NCT02217618|DRUG|LY2409021|
223540668|NCT03579758|DRUG|Capecitabine|Given PO
223540669|NCT03579758|DRUG|Cisplatin|Given IV
224107308|NCT02742649|DEVICE|Placebo Segment|One segment of placebo (no drug product)
224107309|NCT02742649|DRUG|Timolol 0.5%|0.5% timolol drops twice daily.
224291140|NCT01151319|BIOLOGICAL|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10\^10 virus particles.
223955432|NCT03277456|BIOLOGICAL|MVA-NP+M1|Intramuscular injection of novel vaccine
223955433|NCT04440956|DRUG|64Cu-SARTATE|"200MBq of 64Cu-MeCOSar-Octreotate (64Cu-SARTATE) given as a single bolus intravenous injection and peptide mass will not exceed 10micrograms."
223955434|NCT04998266|OTHER|Performing following WHO (World Health Organization)|The CLA group will perform exercises following WHO (World Health Organization) prescription
223955435|NCT04998266|OTHER|Performing on their needs|The IND group will perform strength, aerobic or flexibility exercises depending on their needs observed during the first assessment.
223955436|NCT00801528|DRUG|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
223955437|NCT05080556|DRUG|Carboplatin|Treatment in both arms will be administered intravenously (IV) every 21 days (q21D) and for a maximum of 6 cycles in Arm 1 and 12 cycles in Arm 2.
223955438|NCT05728372|DRUG|Copper Cu 64-DOTA-pembrolizumab|Given IV
223955439|NCT05728372|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223955440|NCT05728372|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223540670|NCT03579758|DRUG|Gemcitabine|Given IV
223540671|NCT03204760|DRUG|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
223955441|NCT01975701|DRUG|BGJ398|Capsule for oral use.
223955442|NCT01441336|PROCEDURE|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
223955443|NCT04249700|DEVICE|Curve Sauna Dome|All participants receive WBH for 80-110 minutes in an infrared sauna. Participants lay supine in the sauna during this time, and their head is external to the sauna.
223955444|NCT04065685|OTHER|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
223955445|NCT04065685|OTHER|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
223955446|NCT04492085|OTHER|Questionnaire survey|A customized questionnaire will be delivered by the social software WeChat to explore the prevalence, potential reasons and solutions of workplace violence against physicians of obstetrics and gynecology in China
223955447|NCT02717780|DRUG|Fentanyl and sevoflurane|
223955448|NCT02717780|DRUG|Remifentanil and desflurane|
223955449|NCT00242086|PROCEDURE|CT, PET and MRI|
224291141|NCT01151319|BIOLOGICAL|pSG2.HIVconsv|DNA at 4mg per dose.
224291142|NCT01151319|BIOLOGICAL|MVA.HIVconsv|Attenuated poxvirus at 4x10\^8 plaque forming units per dose.
224291143|NCT01151319|OTHER|Placebo|Phosphate buffered saline
223955450|NCT05804552|DEVICE|Dorsal genital nerve stimulation|Two types of stimulation electrodes will be used: UCon Patch Electrodes (InnoCon Medical ApS, Denmark) and ValuTrodes/EconoStim Electrodes (5x5 cm, Axelgaard Manufacturing Co. Ltd., United States). The UCon Patch Electrode acts as a cathode and will be placed on the clitoris. The ValuTrode/EconoStim acts as an anode and will be placed on the lower abdomen. The continuous stimulation consists of a train of single pulses provided continuously with a frequency of 20 Hz and a pulse duration of 200 μs. The burst stimulus pattern consists of a train of bursts. The length of the train is 10 s and will consist of 20-30 bursts/s. One burst consists of 5 identical square pulses (monophasic). The inter-pulse interval is 4 ms (time between the onset of 2 consecutive pulses) while a pulse duration of 200 μs will be used.
224107310|NCT02735317|DRUG|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
224107311|NCT02735317|DRUG|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade \> 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
223540672|NCT03204760|DRUG|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
223955451|NCT00892970|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
224107312|NCT01465737|OTHER|Histologic types|evaluate survival among different histologic types
224107313|NCT03959540|DRUG|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
224107314|NCT03959540|DRUG|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
224107315|NCT01666236|OTHER|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light \[wavelength of 689 nm\] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
224107316|NCT05127096|DIAGNOSTIC_TEST|FirstSight blood test|FirstSight blood test for colorectal cancer screening
224107317|NCT04050501|DEVICE|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
224107318|NCT06247033|DEVICE|Tibial Nerve Stimulation with TENS device|Tibial nerve stimulation was applied with TENS device transcutaneously and electrodes were positioned in medial part of the ankle. Negative transcutaneous electrode was positioned 3 centimeter posteriorly to the medial malleol. And positive transcutaneous electrode was positioned 10 centimeter above the negative electrode.
223540673|NCT01677260|DRUG|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
223540674|NCT01677260|DRUG|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
223955452|NCT00892970|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
223955453|NCT04072809|OTHER|No intervention|This study does not involve any interventions.
223955454|NCT05145634|OTHER|Patient education related oral anticoagulants (OACs)|The interventions administered to the experimental group were one-on-one instruction and Health Belief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards. Patient education related oral anticoagulant: each subject in the experimental group was taught individually according to investigators' App in the outpatient department (OPD) by researchers. Every months, participants received a follow-up phone call to clarify any questions related to the knowledge of anticoagulants. The contents of the teaching material consisted of: the purpose of taking anticoagulant, side effects, adjustments to daily diet, and precautions (i.e.how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure and medical card after pretest and routine care in the OPD. All participants completed posttest at 3-month follow-up.
223540675|NCT00417768|DRUG|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
223540676|NCT00417768|OTHER|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
223955455|NCT05185102|OTHER|Cognitive tasks|Electroencephalographic signals registration during different levels of difficulty of three tasks requiring very distinct cognitive functions: the updating of verbal memory, visuospatial span and mental motor inhibition.
223955456|NCT03108222|OTHER|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
223955457|NCT05278117|PROCEDURE|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh|outcomes of complete burst abdomen repair using posterior component separation technique with transversus abdominis muscle release reinforced by sublay mesh
223955458|NCT00997152|DRUG|JTT-654|Tablets
223955459|NCT00997152|DRUG|JTT-654 Placebo|Tablets
223955460|NCT01123005|PROCEDURE|PET Scan|radiation calculated per patient
223955461|NCT01123005|DRUG|EF5|10 mCi, IV
223955462|NCT01123005|DRUG|Carbogen|Calculated per patient
223955463|NCT01123005|DRUG|Dichloroacetate|
223955464|NCT05177029|DRUG|Lu AG06466|Lu AG06466 will be administered per schedule specified in the arm.
223955465|NCT05177029|DRUG|Placebo|Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.
223955466|NCT02958826|OTHER|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
223955467|NCT04514094|DRUG|SDF|SDF promotes enamel and dentin remineralization, as well as inhibit the growth of cariogenic bacteria. the Food and Drug Administration (FDA) approved SDF as a device for reducing tooth sensitivity in the USA.
223955468|NCT04514094|PROCEDURE|ART|The ART technique involves caries excavation by hand instruments only with care to avoid pulp exposure. Such excavation is mainly from the periphery of the lesion to achieve a good seal of the restoration and minimize leakage. The tooth is then restored by glass ionomer cement.
223955469|NCT02446015|DRUG|SYSTANE® ULTRA Lubricant Eye Drops|
223955470|NCT00553813|DRUG|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
223955471|NCT04694053|PROCEDURE|surgical debridement|The surgical team performed an extended surgical debridement to healthy tissue of external genital, as well as perineal, perianal, and infrapubic regions.
223955472|NCT01233245|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
223955473|NCT01330745|OTHER|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
223955474|NCT03799757|DRUG|40ml of 0.25% bupivacaine|
223955475|NCT03799757|DRUG|40ml of 0.9% normal saline|
223955476|NCT05350709|OTHER|mirror therapy|15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
223955477|NCT02896673|PROCEDURE|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
223955478|NCT01705444|DEVICE|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
223955479|NCT00091520|DRUG|Nesiritide|
223955480|NCT00275314|DRUG|Valganciclovir|
223955481|NCT04497818|OTHER|Cross Sectional study using scientifically validated psychometric Scales|Cross Sectional study using scientifically validated psychometric Scales (FEAR OF COVID-19, a 5 item Likert Scale \& Modified Dental Anxiety 5 item Likert Scale).
223955482|NCT04540952|DEVICE|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
223955483|NCT04540952|DEVICE|Standard Hysteroscopy Drape|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
223955484|NCT02391259|DRUG|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
223955485|NCT02391259|DRUG|Placebo|contains no active drug
223955486|NCT05387629|BEHAVIORAL|Education|Nursing students will be trained through social media.
223955487|NCT05467267|PROCEDURE|TURBT|Patients with known bladder tumor undergoing TURBT - A biopsy from the tumor tissue will be taken. Peri operation a urine sample will be taken.
223955488|NCT03563170|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223955489|NCT03563170|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
223955490|NCT03563170|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
223955491|NCT03563170|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
223955492|NCT03563170|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223955493|NCT03563170|DRUG|Cyclophosphamide|anhydrous
223955494|NCT03563170|DRUG|5-Fluorouracil|5-FU; Fluorouracil
223955495|NCT03563170|DRUG|Leucovorin|Leucovorin calcium salt
223955496|NCT03563170|DRUG|nab-Paclitaxel|ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
223955497|NCT03563170|DRUG|Sorafenib|NEXAVAR® tablets, for oral use
223955498|NCT03563170|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
223955499|NCT03563170|BIOLOGICAL|Aldoxorubicin hydrochloride|HCl
223955500|NCT03563170|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury vaccine
223955501|NCT03563170|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
223955502|NCT03563170|BIOLOGICAL|GI-6207|CEA yeast vaccine
223955503|NCT03563170|BIOLOGICAL|GI-6301|Brachyury yeast vaccine
223955504|NCT03563170|DRUG|Cetuximab|ERBITUX® injection, for IV infusion)
223955505|NCT03563170|BIOLOGICAL|N-803|Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
223955506|NCT02167230|PROCEDURE|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
223955507|NCT02167230|PROCEDURE|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
223955508|NCT02143713|DRUG|Elagolix|Elagolix tablets administered orally
223955509|NCT00976053|PROCEDURE|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
223955510|NCT05483556|DEVICE|Real tDCS|An anodal high-definition tDCS of 2 mA lasting for 20 minutes will be delivered to the left inferior frontal gyrus during speech therapy.
223955511|NCT05483556|DEVICE|Sham tDCS|An anodal high-definition tDCS of 2 mA lasting for 30 seconds will be delivered to the left inferior frontal gyrus during speech therapy.
223955512|NCT03411408|DEVICE|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
223955513|NCT03411408|RADIATION|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
223955514|NCT05487937|OTHER|Use of Toleriane Ultra to relieve face allergic skin|The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
223955515|NCT00021333|BIOLOGICAL|filgrastim|
223955516|NCT00021333|DRUG|cisplatin|
223955517|NCT00021333|DRUG|paclitaxel|
223955518|NCT00021333|RADIATION|radiation therapy|
223955519|NCT00401050|PROCEDURE|chiropractic manipulative therapy|
223955520|NCT00401050|PROCEDURE|knee exercises|
223955521|NCT00401050|PROCEDURE|Graston Instrument Soft Tissue Mobilization (GISTM)|
223955522|NCT04264156|COMBINATION_PRODUCT|Lucinactant for Inhalation|A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).
223955523|NCT04264156|OTHER|nCPAP Only|Nasal continuous positive airway pressure (nCPAP) alone
223955524|NCT01241032|DRUG|Udenafil|200mg Single Oral Dose of
223540677|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
223955525|NCT01241032|DIETARY_SUPPLEMENT|Alcohol|Alcohol 39g / 240ml
223955526|NCT01768572|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
223955527|NCT01768572|DRUG|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
223540678|NCT02795039|DRUG|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
223540679|NCT00497900|DRUG|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
223540680|NCT01056614|DRUG|fludarabine phosphate|Given IV
223955528|NCT01768572|DRUG|hydroxychloroquine|Dispensed according to local practice.
223955529|NCT01768572|DRUG|methotrexate|Dispensed according to local practice.
223955530|NCT01768572|DRUG|sulfasalazine|Dispensed according to local practice.
223955531|NCT01768572|DRUG|leflunomide|Dispensed according to local practice.
223955532|NCT01768572|DRUG|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
223955533|NCT01768572|DRUG|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
223955534|NCT03918733|PROCEDURE|surgical treatment|surgical treatment will be done of failed root canal treated teeth
223955535|NCT03918733|PROCEDURE|Non surgical retreatment|Non surgical retreatment will be done.
223955536|NCT02771561|PROCEDURE|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
223955537|NCT02891018|DEVICE|paclitaxel controlled release balloon catheter Vasoguard TM|
223955538|NCT02891018|DEVICE|paclitaxel release coronary balloon catheter SeQuent Please|
223955539|NCT03991052|DEVICE|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically by the closed-loop system
223540681|NCT01056614|DRUG|busulfan|Given IV
223540682|NCT01056614|BIOLOGICAL|anti-thymocyte globulin|Given IV
223540683|NCT01056614|DRUG|tacrolimus|Given IV and orally
223540684|NCT01056614|DRUG|methotrexate|Given IV
223955540|NCT03991052|DEVICE|Control group|This system will recommend when patients need fluid or not and nurses will adjust vasopressor administration as usual (standard of care)
223955541|NCT00391651|DRUG|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
223955542|NCT00391651|DRUG|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
223955543|NCT02332525|DEVICE|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
223955544|NCT00080119|DRUG|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
223955545|NCT00080119|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
224107319|NCT06247033|BEHAVIORAL|Pelvic muscle training exercise with bladder training|Control group was followed with sham tibial nerve stimulation, which were performed by after starting electric current with TENS device, current were decreased and completely shut off. Sham stimulation was also applied for 6 weeks, 2 times in a week, 30 minutes. All patients were followed for PFTE and BT according to given standard schedule.
224107320|NCT03723564|DRUG|Lactated Ringers Solution for Injection|Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
223955546|NCT00080119|DRUG|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
223955547|NCT05749315|OTHER|Play Based Therapy|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
224107321|NCT05506904|DEVICE|Extubation Advisor|Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
224107322|NCT04307966|BEHAVIORAL|The CIrCLE of Life Initiative|HIV and obesity prevention programme delivered directly to Grade 6 preadolescents and indirectly to their parents.
224107323|NCT04661319|PROCEDURE|video editing training|"1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation."
224107324|NCT02233725|DEVICE|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
224107325|NCT00001761|DRUG|Interleukin-10|
223540685|NCT01056614|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
223955548|NCT05749315|OTHER|Functional Communication Training|Participants' assessments of SLD will be made using the Portage Guide to Early Education. It will take three months of sessions 5 days a week, lasting 20 to 30 minutes. The individual will be asses through Speech Questionnaire on base line and after 3 months session program. The Progress of both therapies will be seen that which technique is more effective.
223955549|NCT01919489|DRUG|Liraglutide + OADs|Liraglutide subcutaneously daily
223955550|NCT01919489|DRUG|Glargine + OADs|Glargine once daily subcutaneously
223955551|NCT00950235|BEHAVIORAL|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
223955552|NCT00950235|OTHER|Usual Care|Standard nutrition counseling from Health Plan
223540686|NCT01056614|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
223540687|NCT01056614|OTHER|laboratory biomarker analysis|Correlative studies
223540688|NCT04097652|BIOLOGICAL|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
223540689|NCT04411303|BEHAVIORAL|Step length biofeedback|Participants will be provided with visual feedback of their right and left step lengths on a screen in front of a treadmill.
223955553|NCT02990845|DRUG|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
223955554|NCT01512355|DRUG|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
223955555|NCT01512355|DRUG|placebo group|normal saline\_02mcg/kg/hr
224107326|NCT02850198|DEVICE|scalp electroacupuncture|
224107327|NCT02850198|DEVICE|sham scalp electroacupuncture|
224107328|NCT03590561|OTHER|High caloric diet|After dietary counseling, subjects will receive high caloric snacks for five days.
224107329|NCT03348683|DRUG|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
224107330|NCT03348683|DRUG|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
223540690|NCT04411303|BEHAVIORAL|Propulsive force biofeedback|Participants will be provided with real-time visual feedback of anterior-posterior ground reaction forces of the paretic limb during stance phase on a screen in front of a treadmill.
223540691|NCT04411303|BEHAVIORAL|Interlimb asymmetry biofeedback|Participants will be provided with visual feedback of stride-by-stride values of their interlimb asymmetry on a screen in front of a treadmill.
223540692|NCT04411303|BEHAVIORAL|Aerobic intensity-based walking|Participants will walk at three different aerobic intensities. Aerobic intensity will be set based on target heart rate zones calculated with the Karvonen Formula. For low intensity, participants will walk at 30-40% intensity. In moderate intensity conditions, participants will walk at a 50-60% intensity level. In vigorous intensity conditions, participants will walk at an 70-80% intensity level. Aerobic intensity will be manipulated by changing walking speed.
223540693|NCT03563092|PROCEDURE|Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery|Standardized minimally invasive approach to inguinal hernia repair
223540694|NCT04097990|OTHER|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
223540695|NCT05269186|DEVICE|Virtual reality software|The patient will undergo a 20-minute virtual reality session before the planning CT scan
223540696|NCT00506038|PROCEDURE|fine needle technique|
223540697|NCT05118113|PROCEDURE|Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers|Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5
223540698|NCT00564109|PROCEDURE|retrospective Observation|retrospective Observation
223540699|NCT06332976|OTHER|Completion of questionnaires|Completion of questionnaires at the time of study entry
223540700|NCT00981721|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
223955556|NCT01863082|OTHER|exercise|practice of physical exercise
223955557|NCT00871494|DRUG|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
223955558|NCT02755909|BEHAVIORAL|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
223955559|NCT02933645|DRUG|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
223955560|NCT02933645|DRUG|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
223955561|NCT02933645|RADIATION|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq \[18F\]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
223955562|NCT02933645|DRUG|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
223955563|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
223955564|NCT01359059|DRUG|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
224107331|NCT04507217|DRUG|Tislelizumab, Carboplatin, Pemetrexed|"Tislelizumab: 200mg administered intravenously (IV) on Day 1 of each 21-day cycle~Carboplatin: AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4 cycles~Pemetrexed: 500mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle"
224107332|NCT01483846|DRUG|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
223540701|NCT01847092|DRUG|AZD1722|
223540702|NCT01847092|DRUG|Placebo|Placebo for AZD1722
223540703|NCT03540420|DRUG|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
223540704|NCT03030898|DIAGNOSTIC_TEST|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
223540705|NCT02982811|DEVICE|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
223540706|NCT03199794|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
223540707|NCT02818465|OTHER|Vascular calcifications by Xray|
223540708|NCT02818465|OTHER|Vascular calcifications by tomodentimetry|
223540709|NCT02818465|BIOLOGICAL|Blood sample withdrawn|
223540710|NCT00152204|DRUG|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
223540711|NCT00152204|DRUG|IPTi|Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
223540712|NCT00210847|DRUG|tramadol, acetaminophen|
223955565|NCT03630432|BEHAVIORAL|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
223955566|NCT03630432|OTHER|Usual Care|Usual Care
223955567|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy|
223955568|NCT02412345|PROCEDURE|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
223955569|NCT02412345|OTHER|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
223955570|NCT02079402|DRUG|Isotonic crystalloids|
223955571|NCT01913444|DRUG|Recombinant Antithrombin|
223955572|NCT05322447|DRUG|L Carnitine ( low dose)|will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
223955573|NCT05322447|DRUG|L-Carnitine ( high dose)|will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
223955574|NCT05722756|OTHER|craniosacral therapy|subtle form of applied touch, type of osteopathy
223955575|NCT02637999|DRUG|PEG IFN alfa-2a|
223955576|NCT02637999|DRUG|Myrcludex B|
223955577|NCT01430416|DRUG|AEB071|
223955578|NCT05107921|DRUG|Bromfenac Sodium|The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
223955579|NCT04909099|OTHER|Standard treatment|"Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness."
223955580|NCT03737188|DEVICE|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
223540713|NCT06498115|DRUG|Norepinephrine|Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
223540714|NCT05087498|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 32 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (2-10×107cells/kg) within 24 hours after birth
223540715|NCT05087498|BIOLOGICAL|normal saline|preterm neonates less than 32 weeks are assigned to receive normal saline within 24 hours after birth
223540716|NCT04414540|DRUG|Metformin Extended Release Oral Tablet|Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily
223540717|NCT04414540|DRUG|Pembrolizumab|Pembrolizumab q 3 weeks
223540718|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
223540719|NCT01331681|BIOLOGICAL|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
223540720|NCT01331681|PROCEDURE|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
223955581|NCT02119572|BEHAVIORAL|peer support|
223955582|NCT02119572|OTHER|usual education lectures|
223955583|NCT00582855|DRUG|AQW051|
223955584|NCT00582855|DRUG|Placebo|
223955585|NCT00358722|DRUG|Fermagate|Film coated tablet 500mg
223955586|NCT01567176|BIOLOGICAL|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
223955587|NCT01244399|DIETARY_SUPPLEMENT|Inositol|
223955588|NCT06480396|DIAGNOSTIC_TEST|High-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
224107333|NCT01483846|DRUG|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
224107334|NCT00244218|DRUG|tetrahydrobiopterin (BH4)|Either placebo or tetrahydrobiopterin (BH4) , 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
223955589|NCT06480396|DIAGNOSTIC_TEST|Lower-intensity radiological surveillance|The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.
223540721|NCT01495325|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
223540722|NCT01495325|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
223723834|NCT06460220|BEHAVIORAL|Safe Alternatives for Teens and Youth - Parent (SAFETY-P)|The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.
223955590|NCT00022490|DRUG|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
223955591|NCT00022490|DRUG|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
223955592|NCT06332118|OTHER|ice massage group|Measurement surveys will be applied to obtain pre-test data from hemodialysis patients who meet the research criteria. After the preliminary test data are obtained, ice cubes prepared by the researchers before the needle insertion into the arteriovenous fistula for the hemodialysis procedure will be wrapped in a thin sponge and an ice massage will be applied to the needle insertion area of the patient in a direction that will not disrupt the circulation. This process will take approximately 3-5 minutes or the massage will be terminated when the patient feels drowsiness. In the next stage, the patient will undergo needle intervention for hemodialysis. At the end of this stage, the patient's pain will be evaluated. Patients will be re-evaluated at 24, 48 and 72 hours for ecchymosis and hematoma and relevant measurements will be provided.
223955593|NCT04699578|DIAGNOSTIC_TEST|Covid-19 positive|All pregnant women at any stage of pregnancy afferent to obstetrics services who tested positive in confirmation tests by nasopharyngeal swab for viral RNA detection through real-time reverse transcriptase - polymerase chain reaction (rRT-PCR) will be included.
223955594|NCT06387940|OTHER|nEB Diet, followed for 36 hours|nEB diet first, then LC25 and LCEB in random order with a 5 days washout between each diet
223955595|NCT06387940|OTHER|LC25 Diet, followed for 36 hours|LC25 diet first, then nEB and LCEB in random order with a 5 days washout between each diet
223955596|NCT06387940|OTHER|LCEB Diet, followed for 36 hours|LCEB diet first, then LC25 and nEB in random order with a 5 days washout between each diet
223955597|NCT01461967|DRUG|Placebo|Single ascending doses
223955598|NCT01461967|DRUG|RO5508887|Single ascending doses
223955599|NCT01461967|DRUG|RO5508887|Single doses
223955600|NCT01595425|DRUG|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
223955601|NCT01595425|DRUG|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
223955602|NCT00607607|DRUG|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
223955603|NCT01190436|DRUG|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
223955604|NCT02378584|OTHER|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
223540723|NCT05531500|DRUG|Injection|Injection of local anesthetic + steroids
223540724|NCT05531500|DEVICE|Radiofrequency|Application of radiofrequency on the diseased nerve
223955605|NCT02721147|BEHAVIORAL|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
223540725|NCT04748692|PROCEDURE|Local exercise therapy|The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
223955606|NCT02721147|BEHAVIORAL|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
223955607|NCT02721147|BEHAVIORAL|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
223955608|NCT02721147|BEHAVIORAL|Behavioral, Psychological or Informational Intervention|Receive educational information and support
223955609|NCT02439892|BEHAVIORAL|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
223955610|NCT02439892|BEHAVIORAL|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
223955611|NCT02060175|DEVICE|Cilotax drug-eluting stents implantation|
223955612|NCT02060175|DEVICE|DESyne drug-eluting stents implantation|
223955613|NCT02450747|DEVICE|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
223955614|NCT01722097|DRUG|Rocuronium|
223955615|NCT01722097|DRUG|placebo|
223955616|NCT03619044|OTHER|2 FES-PET Imaging will be performed:|"* before treatment initiation~* before treatment cycle 3 initiation"
223955617|NCT02209376|BIOLOGICAL|CART-EGFRvIII T cells|
223955618|NCT03071523|PROCEDURE|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
223955619|NCT03071523|PROCEDURE|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
223955620|NCT00328120|DRUG|Fulvestrant|500 mg intramuscular injection
223955621|NCT00408109|DRUG|VRC-AVIDNA036-00-VP|
223955622|NCT01714479|OTHER|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
223955623|NCT01714479|OTHER|Placebo|
223955624|NCT05647941|DIAGNOSTIC_TEST|Detection of levels of circulating EV-derived lncRNA-GC1|For patients with gastric cancer receiving neo-adjuvant chemotherapy, the dynamic changes of EV-derived lncRNA-GC1 was detected to identify whether is can serve as a monitoring biomarker for treatment response.
223955625|NCT04471415|DRUG|DRP-104|"DRP-104 administered intravenously over 1 hour, three times per week (TIW) (Monday, Wednesday, Friday) for 2 consecutive weeks, one week off~DRP-104 administered subcutaneously twice weekly (Monday/Thursday or Tuesday/Friday) every week OR thrice weekly (Monday, Wednesday, Friday) every week"
223955626|NCT04471415|BIOLOGICAL|atezolizumab|atezolizumab administered intravenously over 1 hour at 1200 mg once every 3 weeks.
223955627|NCT02765204|DRUG|Dapagliflozin|
223955628|NCT02765204|DRUG|Saxagliptin|
223955629|NCT02765204|DRUG|Glucose|
223955630|NCT02107235|DRUG|oral rigosertib|
223955631|NCT02107235|DRUG|cisplatin|
223955632|NCT02107235|RADIATION|Radiotherapy|
223955633|NCT05792683|DEVICE|lumbar drain|"Patient will be placed in the lateral decubitus position; catheter will be inserted by using a Tuohy needle in the interspinous area of lumbar spine. The LD catheter will reach the lumbar subarachnoid space.The remaining part of the drainage kit will be placed along the back of the patient. The catheter insertion site will be sutured and treated with povidone-iodine ointment. Sterile drape will be used to cover the entire external part of the LD.~The CSF will be collected within the closed beg. CSF drainage through LD will be around 10 ml per hour or 200-250 ml/day."
223955634|NCT02009332|DRUG|ABI-009|ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus. Specifically, ABI-009 is a sterile lyophilized powder of albumin-bound sirolimus nanoparticles with a mean particle size of less than 100 nm.
223955635|NCT02009332|DRUG|Gemcitabine|Gemcitabine is administered after ABI-009 in the Phase 2 study.
223955636|NCT04454723|PROCEDURE|Blood and/or platelet transfusion|The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.
223955637|NCT04454723|PROCEDURE|Complete blood count (CBC) collection|CBC will be collected from patients weekly while on this protocol.
223955638|NCT04276649|DRUG|Caltrate|Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.
223955639|NCT05059145|DRUG|Chlorhexidine Gluconate|Vaginal cream 1%
223955640|NCT05059145|DRUG|Fluconazole|150 mg oral capsule
223955641|NCT04878809|OTHER|Escola L'Horitzó|Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
223955642|NCT04878809|OTHER|Escola John Talabot|John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
223955643|NCT05992584|DRUG|Lenvatinib, sintilimab plus SIRT|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. QD and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
223955644|NCT03468348|DRUG|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
223955645|NCT05188248|DEVICE|Transcranial direct current stimulation (tDCS)|Participants will complete a single 30 minutes tDCS session targeting the left DLPFC while sitting in a comfortable position. At the end of the tDCS session possible side effects experienced during the tDCS session will be recorded along with their intensity (rated using the visual analogue scale, 0-10) and duration. The session can be aborted at any time for any reason if the participant wishes.The MINDD STIM tDCS system is composed of a management component, treatment module, single-use sponge patches and supporting patches, a headband to hold in position the sponge patches, and 2 cables. A trained study technician will program the stimulation device through the management component setting to the following stimulation parameters:Stimulation intensity: 2.0 mA or 1.5 mA; Stimulation duration: 30 minutes;Ramp up duration: 30 seconds (beginning of stimulation);Ramp down duration: 30 seconds (end of stimulation)
223955646|NCT00966745|DRUG|milrinone|
223955647|NCT00966745|DRUG|placebo|
223955648|NCT05793580|DEVICE|Vibrant Soundbridge active middle ear implant|active middle ear implant
223955649|NCT05605158|DRUG|Pioglitazone 30mg|Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
223955650|NCT05605158|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
223955651|NCT05387785|DRUG|ANG-3070|Orally administered tyrosine kinase inhibitor capsule.
223955652|NCT05387785|DRUG|Placebo|Orally administered placebo capsule
223955653|NCT06301945|DIAGNOSTIC_TEST|Artificial Intelligence Diagnostics|AI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
223955654|NCT06301945|DIAGNOSTIC_TEST|Recurrence Prediction Tool|This AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.
223955655|NCT00754533|OTHER|Continuous versus interval training|Influence of different exercise training programs
223955656|NCT04642495|DIAGNOSTIC_TEST|"Visual acuity testing with SW , Landolt-C and Tumbling-E symbols"|Establish prediction intervals for acuity tests
223540726|NCT04748692|PROCEDURE|Spinal manual therapy|The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
223540727|NCT03790644|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
223540728|NCT02862977|DRUG|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
223540729|NCT02862977|DRUG|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
223540730|NCT02054975|DRUG|Vitamin D2 + vitamin D3|higher dose vitamin D
223540731|NCT02054975|DRUG|Vitamin D3|lower dose vitamin D
223540732|NCT06141551|PROCEDURE|total laminectomy decompression|Surgical decompression
224107335|NCT02502422|DEVICE|Classic laryngeal mask airway|"1. measurement of head and neck~   * Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip\~sternal notch), modified mallampati classification under sitting position, thyromental distance.~2. laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~   * \# 4.0 for female, #5.0 for male~  * initial cuff volume(air) : maximum volume recommended by the manufacturer~  * check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~  * remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
224107336|NCT03937986|DRUG|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
224107337|NCT03937986|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
223540733|NCT01976871|DRUG|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
223540734|NCT06202469|DIETARY_SUPPLEMENT|Supplement 1|Creatine monohydrate (5 g/day)
223540735|NCT06202469|DIETARY_SUPPLEMENT|Supplement 2|Creatine monohydrate (5 g/day) plus ubiquinol (200 mg/day)
223540736|NCT06202469|DIETARY_SUPPLEMENT|Placebo|Placebo (inulin)
223540737|NCT00390897|DRUG|Glivec|
223540738|NCT00390897|DRUG|Interferon|
223540739|NCT05647499|BEHAVIORAL|The Back 2 School program for problematic school absenteeism|We will use the Danish version of the revised manual developed within the B2S study in Aarhus, Denmark. The B2S program consists of a 3 to 3,5 -hour initial clinical assessment, a clinical conference, 11 sessions where the youth and/or parent are attending, and a booster session after three months including youth and parent. The B2S manual comprise four school meetings with the child, parents, school staff and therapists present. In the Norwegian pilot study, we will add an extended school module to the B2S-program. The school module includes a pre-meeting interview with the schools in week 1 and session 1 with the school in week 2 or 3. The B2S counselor and the school will decide whether there is a need for an additional meeting between school meetings 1 and 2. There is also a booster session with the child, parents, the school and the B2S team 3 months after the program.
223540740|NCT04188249|DRUG|Golimumab|This multicenter (12 centers), prospective program will register 200 RA patients routinely receiving golimumab treatment. Doctor will record the disease evaluation, concomitant drug, adverse events and laboratory tests based on patient's visit till they withdraw from clinical visit. Doctor will still collect above information whether patient interrupt or stop golimumab till the end of program or patient withdraw permanently.
223723835|NCT06460220|BEHAVIORAL|Treatment As Usual (TAU)|TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
223723836|NCT04162639|BIOLOGICAL|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
223955657|NCT05362279|OTHER|Training|"One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training."
223955658|NCT01249794|PROCEDURE|non invasive ventilation|continuous positive airways pressure
223955659|NCT03704363|DRUG|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
223955660|NCT03704363|OTHER|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
223955661|NCT00248794|BEHAVIORAL|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
223955662|NCT00248794|BEHAVIORAL|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
223955663|NCT00248794|BEHAVIORAL|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
223955664|NCT05444374|DRUG|Serplulimab|Recombinant anti-PD-1 humanized monoclonal antibody injection
223955665|NCT05444374|DRUG|Bevacizumab|Humanized anti-VEGF monoclonal antibody injection
223955666|NCT03213379|DEVICE|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
223955667|NCT05107232|OTHER|MRI|MRI
223955668|NCT03366571|DRUG|Nucleos(t)ide Analogues|Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
223955669|NCT04362059|DEVICE|COVSurf Drug Delivery System|Device introduces surfactant to the patients lungs
223955670|NCT04362059|OTHER|Standard of Care|Standard of care treatment for respiratory illness
223955671|NCT02632747|DRUG|Empagliflozin|Empagliflozin will be taken once daily
223955672|NCT02632747|DRUG|Placebo (matching empagliflozin)|Placebo will be taken once daily
223955673|NCT02632747|DRUG|ramipril|Ramipril will be taken once or twice daily
223955674|NCT03449979|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
223955675|NCT03449979|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
223955676|NCT02326493|DEVICE|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
223540741|NCT03632707|RADIATION|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
223955677|NCT03095378|PROCEDURE|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
223955678|NCT03095378|PROCEDURE|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
223955679|NCT03095378|PROCEDURE|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
223955680|NCT02732470|OTHER|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
223955681|NCT02069379|DRUG|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
223955682|NCT02069379|DRUG|Placebo|Placebo capsules prepared identically to Metformin capsules
223955683|NCT00420498|DRUG|Atomoxetine (Strattera™)|
223955684|NCT03059147|DRUG|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
223955685|NCT03059147|DRUG|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
223955686|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
223955687|NCT01201278|DRUG|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
223955688|NCT01201278|DRUG|Insulin LISPRO|Subcutaneous insulin lispro 8 U
224107338|NCT03937986|DRUG|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
224107339|NCT02752308|DRUG|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
224107340|NCT02752308|PROCEDURE|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
224107341|NCT02752308|DRUG|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
224107342|NCT02752308|DRUG|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
224107343|NCT02752308|DRUG|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
224107344|NCT02752308|DRUG|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
224107345|NCT02752308|PROCEDURE|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
223955689|NCT03195127|OTHER|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
223955690|NCT04195334|DEVICE|internal fixation by IMN|using retrograde or antegrade IMN for femooral fractures fixation using a fit nail to the femoral intramedullary canaland follow up for union
224107346|NCT01312155|OTHER|Intubation|Intubation, endotracheal
224107347|NCT05495399|PROCEDURE|Spondylectomy|Patient will be randomized to treated by spondylectomy or debulking surgery. Spondylectomy implied total resection of involved spine; while debulking surgery means partial resection of involved spine.
224107348|NCT05495399|RADIATION|SBRT|Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
223955691|NCT03964272|DEVICE|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
223955692|NCT03059056|DRUG|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
223955693|NCT00014508|BIOLOGICAL|sargramostim|
223955694|NCT00014508|DRUG|cyclophosphamide|
223955695|NCT00014508|DRUG|cyclosporine|
223955696|NCT00014508|DRUG|fludarabine phosphate|
223955697|NCT00014508|DRUG|melphalan|
223955698|NCT00014508|PROCEDURE|peripheral blood stem cell transplantation|
223955699|NCT03258099|GENETIC|detection of genotype|detection of genotype by next generation sequencing
223955700|NCT02721849|BEHAVIORAL|Yoga for adolescents|12 week hatha yoga course for adolescents
223955701|NCT02721849|BEHAVIORAL|Yoga for parents|12 week hatha yoga course
223955702|NCT02282137|DRUG|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
223955703|NCT01789593|OTHER|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
224107349|NCT01709799|BEHAVIORAL|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
224107350|NCT01709799|BEHAVIORAL|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data."
224107351|NCT01709799|BEHAVIORAL|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
224107352|NCT00917410|BEHAVIORAL|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~1. Remember to take your preventive asthma medication (sent at 8.00 am).~2. Were you awakened during the night due to your asthma? Answer YES or NO.~3. How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~4. What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
224107353|NCT05574816|DEVICE|Phi-Bra prototype measurements|"The bra prototype will be placed on the patient's breast. The patient will stay in a half-lying position during 15 min, the time duration of the measurements. Measurements will not be painful.~Measurements will only be realized one time during the first and unique visit of the patient."
223723837|NCT03107936|BEHAVIORAL|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
223955704|NCT05569018|BEHAVIORAL|Blended group transversal protocol (BLGr-TP)|It will consist in the administration of a transdiagnostic treatment protocol composed by 16 modules focused on regulating both negative and positive affect. The intervention will be administered over a 16-week period. Face-to-face group sessions will be combined with autonomous work of patients through a web platform where they will find the contents of the program. The groups will have 6-10 patients, who will attend a total of 8 face-to-face sessions of 2 hours long each one. The online part of the treatment (self-applied Online Transversal Protocol) will consist in working the contents exposed in the face-to-face sessions during between-sessions period (2 weeks). It is an interactive program with multimedia elements (videos, images,…) that allows people to perform the modules from home and at their own pace. In addition, the program is characterized by its ease of use, presenting an agile navigation.
224107354|NCT01601015|OTHER|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
224107355|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
224107356|NCT01601015|OTHER|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
224107357|NCT01601015|OTHER|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
224107358|NCT00345371|DRUG|Topiramate|
224107359|NCT00345371|DRUG|Placebo Oral Tablet|
224107360|NCT03328611|DEVICE|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
223723838|NCT03465202|DRUG|Capecitabine|
224107361|NCT05378659|BEHAVIORAL|Montreal Cognitive Assessment|Cognitive evaluation of short term memory, visuospatial abilities, executive functioning, attention, concentration, working memory, language, and orientation to time and place
224107362|NCT05378659|BEHAVIORAL|Stroop Test|Evaluates Processing Speed and Executive Control
223955705|NCT05569018|BEHAVIORAL|Face-to-face group transversal protocol (FFGr-TP)|It will consist in the administration of the transdiagnostic treatment protocol through the 16 modules focused on regulating both negative and positive affect. The intervention will be carried out in face-to-face group format and it will be administered during a 16-week period. The groups will have between 6 to 10 patients, who will attend a total of 16 face-to-face sessions of 2 hours long each one. During between-sessions period (1 week), patients will work the content of the modules exposed in the face-to-face sessions through tasks for home (traditional paper format).
223955706|NCT00992030|DRUG|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
223955707|NCT00992030|RADIATION|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
223955708|NCT04432909|DIAGNOSTIC_TEST|The level of CNV|The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. And the patient will be followed for up to 2 years.
223955709|NCT01862224|DRUG|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
223955710|NCT01862224|DRUG|Placebo|Matching placebo once daily (Week 0 to Week 12).
224107363|NCT05378659|DIAGNOSTIC_TEST|4AT Delirium|Screening tool to test for delirium post surgery
224107364|NCT05378659|BEHAVIORAL|Grooved Pegboard|Evaluation testing for dominant and non dominant sensory-motor speed
224107365|NCT05378659|BEHAVIORAL|NACC Cognitive Battery|A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.
224107366|NCT05378659|DIAGNOSTIC_TEST|ERP Testing|An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
224107367|NCT05378659|DIAGNOSTIC_TEST|Blood Plasma and Serum sampling|Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.
224107368|NCT05378659|DIAGNOSTIC_TEST|Cerebral Spinal Fluid Sample|At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
223955711|NCT01862224|DRUG|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
223955712|NCT00700999|DRUG|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
223955713|NCT06181513|DRUG|Probiotic Blend Capsule|20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)
223955714|NCT02618109|BIOLOGICAL|Collection of blood samples|Collection of blood samples
224107369|NCT05416606|PROCEDURE|transurethral bipolar enucleation and resection of the prostate|transurethral bipolar enucleation and resection of the prostate
224107370|NCT05416606|PROCEDURE|open surgical transvesical prostatectomy|open surgical transvesical prostatectomy
224107371|NCT04805372|OTHER|VD+VF group|where they should review a video of an expert performing central vein operation and a video of their own most recent operation, before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
223540742|NCT03632707|PROCEDURE|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
223955715|NCT02919865|DEVICE|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
223955716|NCT03481725|DEVICE|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
223955717|NCT03481725|DEVICE|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
223955718|NCT04182542|DEVICE|Radiofrequency|The volunteers will receive radiofrequency (TECAR-BTL® device, with epidermal temperature above 40ºC) in the right infraumbilical abdominal region, with an application time of 10 minutes (2 minutes per applicator area) and the left region will be used as control. A single session will be held. After approximately 30 days of this application the material for histological analysis will be collected during the surgical act, at which point the skin and the subcutaneous tissue of the infraumbilical region are discarded by the surgeon.
223955719|NCT04026022|DRUG|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
223955720|NCT04026022|DRUG|Placebo|Placebo plaster in the ER or PACU
223955721|NCT01016730|DRUG|Bortezomib|Given IV
223955722|NCT01016730|OTHER|Laboratory Biomarker Analysis|Correlative studies
223955723|NCT01016730|OTHER|Questionnaire Administration|Ancillary studies
223955724|NCT05813249|DRUG|Rybelsus Oral Product|Oral Semaglutide
223955725|NCT05813249|DRUG|Ozempic Injectable Product|Subcutaneous Semaglutide
223955726|NCT05813249|DRUG|Tocopherol and/or Actos|Vitamin E and/or Pioglitazone
223955727|NCT05863871|DRUG|Linperlisib|80 mg, qd
223955728|NCT05789407|DIAGNOSTIC_TEST|Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry|1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry
223955729|NCT05250362|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|"MYELOABLATIVE CONDITIONING REGIMEN: Patients with myeloid malignancies receive busulfan on days -7 to -4, fludarabine IV over 1 hour on days -7 to -3, cytarabine IV over 4 hours on days -7 to -3. Patients with lymphoproliferative disorders receive busulfan on day -7 to -4, cladribine IV over 1 hour on days -7 to -3, gemcitabine IV over 4 hours on days -7 and -3.~TRANSPLANT: Patients undergo PBSC transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, cyclosporin IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO BID beginning on day 5 for 30 days.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28."
223955730|NCT02327702|DRUG|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
223955731|NCT05264311|OTHER|Pilates exercise program|"The Pilates Exercise Program (PEP) (1 h x 2 sessions per week x 2 months) was delivered by one Pilates professional (with a mean of 6.5 years of experience in Pilates). The PEP carried out by Pilates instructor has been published in a previous study \[31\]. The exercises focused on core stability, posture, breathing, flexibility, strength, and muscle control, being the active awareness of the use of trunk muscles to stabilize the pelvic-lumbar region the main approach. The exercises performed were: the hundred, the rolled up, single leg circles with bent leg, spine stretch, rolling like a ball and single leg stretch. Each exercise was performed as follows: 4 repetitions of 30 seconds with 2 minutes of recovery between repetitions. In order to complete the 60 minutes session two exercises: the superman and the double leg bridge were added to the mentioned PEP."
223955732|NCT01623180|DEVICE|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
223955733|NCT01623180|DEVICE|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
223955734|NCT02362100|OTHER|Non operative|non operative treatment
223955735|NCT02362100|PROCEDURE|locking plate surgical fixation|
223955736|NCT03651271|BIOLOGICAL|Nivolumab Monotherapy|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
223540743|NCT03683810|DIETARY_SUPPLEMENT|Lactoferrin|Lactoferrin in tablets 4g/daily
223540744|NCT03683810|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
223540745|NCT03367169|PROCEDURE|minimally invasive method|type of surgical technique
223540746|NCT03367169|PROCEDURE|open reduction method|type of surgical technique
223540747|NCT04941469|DEVICE|Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)|"The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types."
223540748|NCT04941469|DEVICE|Plain off-the-counter foot orthosis (Medical grade foot orthosis)|The control device for this study would be the plain original Formthotics (Original Dual Hard).
223540749|NCT00373048|DRUG|mefloquine|tablet, once weekly
223955737|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab and Combination for Metastatic Cancer|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
223955738|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort A will receive nivolumab 1 mg/kg Q3W and ipilimumab 3 mg/kg every 6 weeks (Q6W) for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If the safety profile of Prostate Cohort B is deemed unacceptable, an additional 10 participants will be enrolled in Prostate Cohort A.
224107372|NCT04805372|OTHER|VD group|where they should review a video of an expert performing central vein operation before returning to do another operation. This will be repeated for a total of 5 central vein cannulation encounters and 5 video reviews.
223540750|NCT00373048|DRUG|placebo|tablet, once weekly
223540751|NCT02804490|DIETARY_SUPPLEMENT|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
223540752|NCT02804490|DIETARY_SUPPLEMENT|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
223723839|NCT04168060|PROCEDURE|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
223955739|NCT03651271|BIOLOGICAL|Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer|For nivolumab and ipilimumab combination therapy, CD8 low arm, approximately 10 participants will be randomly allocated into 1 of 2 cohorts, using different doses of ipilimumab administered in 6-week cycles. Participants assigned to Prostate Cohort B will receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity. If Prostate Cohort B is determined to have a tolerable safety profile, an additional 10 participants will be enrolled to receive nivolumab 1 mg/kg Q3W and ipilimumab 5 mg/kg Q6W for 2 cycles, then nivolumab maintenance 480 mg Q4W until PD or intolerable toxicity.
223955740|NCT05067816|BEHAVIORAL|Med-South Lifestyle Program|The Med-South Lifestyle Program (MSLP) is an evidence-based behavior change intervention that translates the PREDIMED (Mediterranean) dietary pattern for a southeastern US population and includes support for increased physical activity. To promote healthy dietary intake and increased physical activity, the intervention incorporates theory-based behavioral approaches targeting self-efficacy, self-regulation, and internal motivation. The MSLP is delivered in 4 monthly counseling sessions with 3 interim phone follow-up contacts. A maintenance phase lasting 6 months follows the 4-month MSLP and includes 2 phone contacts about 2 months apart. Participants are counseled individually, with 2 in-person counseling visits (at the 1st and 4th counseling visit) and 5 total phone contacts. Each participant is provided with program materials in a participant manual, a cookbook, and a local resource manual identifying community resources to support making targeted behavior changes.
223955741|NCT04398355|COMBINATION_PRODUCT|acupuncture|acupuncture
223955742|NCT04398355|COMBINATION_PRODUCT|Liu-Zi-Jue Gongfa|Liu-Zi-Jue Gongfa
223955743|NCT01736722|DEVICE|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
223955744|NCT01870687|DRUG|20mg VAC BNO 1095 FCT|
223955745|NCT01870687|DRUG|Placebo|
224107373|NCT04988126|OTHER|Interventions|Observational study, not applicable
224107374|NCT00612846|PROCEDURE|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
224107375|NCT00612846|PROCEDURE|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
224107376|NCT06283095|PROCEDURE|expansion palatoplasty|surgical procedure
224107377|NCT00744055|DRUG|Prazosin|prazosin (16mg/day) 2 times a day
223955746|NCT02625636|DRUG|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223955747|NCT02625636|DRUG|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223723840|NCT04168060|PROCEDURE|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
223955748|NCT02625636|DRUG|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223955749|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|50,000 units of oral vitamin D3(cholecalciferol) weekly plus 800 calcium daily
223955750|NCT01125436|DIETARY_SUPPLEMENT|Cholecalciferol|Weekly placebo plus 800 calcium alone
223955751|NCT01615523|OTHER|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
223955752|NCT03444155|DIETARY_SUPPLEMENT|Natural Panmol-B-Complex|Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) - Synthetic Vitamin B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
223955753|NCT03444155|DIETARY_SUPPLEMENT|Synthetic Vitamin B-Complex|Synthetic Vitamin B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85µg) - Natural Panmol-B-Complex: B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg)
223955754|NCT05852496|DRUG|Vitamin D|vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.
223955755|NCT00761241|DRUG|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
223955756|NCT00761241|BIOLOGICAL|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
223955757|NCT00761241|RADIATION|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
223955758|NCT00761241|PROCEDURE|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
223955759|NCT06050837|OTHER|No intervention|No intervention
223955760|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose = 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
223955761|NCT04243954|DRUG|PCA IV Hydromorphone (continuous dose ≠ 0)|Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours
223955762|NCT04243954|DRUG|Oral morphine|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours"
223955763|NCT01484015|DRUG|cefepime hydrochloride|Given IV
223955764|NCT05567029|DRUG|Risankizumab Dose A|Prefilled Syringe
223955765|NCT05567029|DRUG|Risankizumab Dose B|Prefilled Syringe
223955766|NCT00109161|DRUG|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
223955767|NCT02368977|DEVICE|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
223955768|NCT05028283|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks
223955769|NCT05664009|DIETARY_SUPPLEMENT|Redsenol-1 Plus|Two capsules of Redsenol-1 Plus will be taken three times per day for 12 weeks (84 days).
223955770|NCT05664009|OTHER|Placebo|Two capsules of Placebo will be taken three times per day for 12 weeks (84 days).
223955771|NCT02535598|BEHAVIORAL|Normal presentation|All the material will be presented as plain text.
223955772|NCT02535598|BEHAVIORAL|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
223955773|NCT02535598|BEHAVIORAL|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
223955774|NCT02535598|BEHAVIORAL|Enhanced support|Participants are offered daily support through the internet from trained therapists.
223955775|NCT01706393|DIETARY_SUPPLEMENT|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
223955776|NCT01706393|DIETARY_SUPPLEMENT|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
223955777|NCT03225092|BIOLOGICAL|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
223955778|NCT06210178|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI scans including abdominal 4D Flow MRI.
223955779|NCT03296488|DRUG|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
223955780|NCT03296488|DRUG|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
223955781|NCT01133678|DRUG|Everolimus|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel (175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus 5 mg PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
223955782|NCT01133678|DRUG|Placebo|Phase II Portion (2 21-day cycles of induction therapy) Cisplatin (75 mg/m2 day 1) Paclitaxel(175 mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Placebo PO daily. Following induction patients received \[paclitaxel (100 mg/m2 IV weekly), 5-FU (600 mg/m2 IV day 1-5), hydroxyurea 500 mg BID PO (day 1-5), and hyperfractionated twice daily radiotherapy (150 cGy per fraction) day 1-5 of a 14 day cycle which is repeated to deliver the prescribed radiotherapy dose.
223955783|NCT05096741|DEVICE|OCS Liver|Transplanted with a OCS preserved liver
223955784|NCT01795183|DRUG|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
223955785|NCT05759000|DRUG|Dapagliflozin|Sodium-glucose cotransporter-2 (SGLT2) inhibitor is considered one of the four foundational therapies (ACE-I or ARNI, beta-blockers, MRA, and SGLT2 inhibitors) for HFrEF (6). However, guidelines do not specify the sequence and the timing of which therapy to be commenced. In particular, dapagliflozin has been shown in randomized controlled trials to reduce the combined risk of cardiovascular death or HF hospitalization and improve quality of life in HF patients with both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively, regardless of the presence or absence of diabetes in the DAPA-HF and DELIVER trials (
223955786|NCT00141336|DRUG|Pregabalin|
223955787|NCT00263900|DEVICE|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
223955788|NCT03434106|DRUG|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
223955789|NCT03434106|DRUG|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
223955790|NCT05922774|DEVICE|Cervical VEMP testing|cervical vestibular evoked myogenic potentials
223955791|NCT00446095|DRUG|fostamatinib|200 mg PO BID
223955792|NCT03726502|PROCEDURE|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
223955793|NCT03726502|PROCEDURE|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
223955794|NCT03726502|PROCEDURE|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
223955795|NCT03726502|PROCEDURE|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
223955796|NCT00681135|DEVICE|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
223955797|NCT00681135|DEVICE|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
223955798|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
223540753|NCT02804490|DIETARY_SUPPLEMENT|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
223955799|NCT00681135|DEVICE|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
223955800|NCT02574286|DRUG|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
223955801|NCT02574286|DIETARY_SUPPLEMENT|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
223955802|NCT00863902|DRUG|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
223955803|NCT00863902|DRUG|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
223955804|NCT03037827|PROCEDURE|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
223955805|NCT03037827|DEVICE|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
223540754|NCT05911971|OTHER|Experimental|specific reeducation (not detailed to maintain blinding of participants)
223540755|NCT05911971|OTHER|Sham comparator|sham reeducation (not detailed to maintain blinding of participants)
223540756|NCT04231071|DEVICE|Onlay Mesh group|Primary suture repair with a small only mesh on the closed defect
224107378|NCT00744055|DRUG|Placebo|Placebo
223540757|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
223955806|NCT03340922|DEVICE|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
223955807|NCT03340922|DEVICE|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
223955808|NCT02764320|OTHER|Migraine Prophylactic Therapy Only|Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)
223955809|NCT02764320|OTHER|Discontinuation of Overused Medication|Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
223955810|NCT05008003|DRUG|Standard of care|Standard of care treatment as per the hospital guidelines
223955811|NCT05008003|DIETARY_SUPPLEMENT|Vitamin D3|A daily dose of 5000 IU vitamin D3 for 7 days.
223955812|NCT05726994|BIOLOGICAL|exhaled breath collection|Fasting children will be asked to breathe normally through a mouthpiece for the collection and analysis of exhaled breath.
223955813|NCT05726994|OTHER|Data collection|Clinical data will be collected in order to seek correlations with the exhaled breath profile.
223955814|NCT03220815|PROCEDURE|Drilling at low speed|
223955815|NCT03220815|PROCEDURE|Conventional drilling at high speed|
223955816|NCT01280656|DRUG|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
223955817|NCT01280656|DRUG|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
223955818|NCT01280656|DRUG|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
223955819|NCT01280656|DRUG|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
223955820|NCT02595788|OTHER|Change from supine to prone position|Change from supine to prone position
223955821|NCT05328817|DRUG|Antibiotics|In the absence of labor, broad-spectrum antibiotics (often called latency antibiotics) are recommended for women with PPROM less than 34 weeks to reduce chorioamnionitis, prolong latency, and decrease neonatal sepsis (12,13).
223955822|NCT00572494|DEVICE|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
223955823|NCT00572494|DEVICE|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of \>50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
223955824|NCT04330573|OTHER|No intervention. Observational study|Observational study
223955825|NCT05924373|DRUG|Human Dental Fulp Stem Cells|Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
223955826|NCT02951702|DRUG|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
223955827|NCT06473571|OTHER|Intervention Protocol (The 3GT)|"Participants will be asked to identify three things that went well that day and their role for this occurring \[What went well today, and what was your role in making it happen? as adapted from (Sexton \& Adair, 2019)\]. They will be asked to engage in this exercise for 15 days during the evening."
223955828|NCT06473571|OTHER|Control Group|Participants will be asked to reflect on early memories of their life, with no specific prompts provided, for 15 days during the evening. This activity is consistent with prior efficacy studies of 3GT (Seligman et al., 2005).
223955829|NCT04109651|OTHER|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
223955830|NCT05905068|DRUG|RN0191 INJECTION|a sterile solution in each bottle for subcutaneous (SC) injection
223955831|NCT03210298|COMBINATION_PRODUCT|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
223955832|NCT06275802|BEHAVIORAL|Nutrition Education|Nutrition interventions consisting of 8 modules (powerpoint supported classroom lesson, video demonstration, role-play, healthy plate model game, poster preparation, bookmarks, refrigerator magnets, etc. preparation of reminder messages, competitions such as slogan-painting contest, activities such as sports and nutrition festival).
223540758|NCT00658541|DRUG|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
223723841|NCT04168060|PROCEDURE|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
223540759|NCT01967745|PROCEDURE|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
223540760|NCT01967745|PROCEDURE|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
223955833|NCT06275802|BEHAVIORAL|nutritional status, eating habits|At the beginning of the study (June 2022), an introductory form (sociodemographic characteristics, body image (Stunkart scale), dietary habits, knowledge about weight status) was applied to all students. Adolescent Nutrition Literacy Scale (ANLS), Instrument of Nutrition Literacy, Mediterranean Diet Quality Index (KID-MED), Eating Attitudes Test 26 (EAT-26), International Physical Activity Questionnaire Short Form (IPAQ) were applied, anthropometric measurements and three-day food consumption records were taken
223955834|NCT02626494|DRUG|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
223955835|NCT02626494|DRUG|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
223955836|NCT06084988|BIOLOGICAL|Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|50 x 106 allogeneic bone marrow (BM)-derived MSC formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given via ultrasound-guided intra-articular injection
223955837|NCT01795989|DEVICE|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
223955838|NCT03149484|DEVICE|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
223955839|NCT03149484|OTHER|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
223955840|NCT03432871|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
223955841|NCT01970527|BIOLOGICAL|Ipilimumab|Given IV
223955842|NCT01970527|OTHER|Laboratory Biomarker Analysis|Correlative studies
223955843|NCT01970527|OTHER|Pharmacological Study|Correlative studies
223955844|NCT01970527|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223955845|NCT02090205|PROCEDURE|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
223955846|NCT02090205|PROCEDURE|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
223955847|NCT02090205|PROCEDURE|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
223955848|NCT02090205|DEVICE|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
223955849|NCT02090205|DEVICE|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
223955850|NCT00149409|DIETARY_SUPPLEMENT|Omacor|
223955851|NCT05333757|OTHER|Questionnaire|Adults with spinal deformities were asked to complete two questionnaires assessing quality of life
223540761|NCT01946659|BEHAVIORAL|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
223540762|NCT01946659|OTHER|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
223955852|NCT01964547|DRUG|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
223955853|NCT01964547|DRUG|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
223955854|NCT05690178|OTHER|Deep Tissue Massage|The Deep Tissue Massage lasted 45 minutes. The entire therapy included 4 treatments over a period of 2 weeks. The interval between treatments was 3 days. The conducted therapy included techniques for: quadratus lumborum muscle, erector spinae muscle, thoracolumbar fascia, iliopsoas muscle. All techniques were performed on both sides of the patient's body.
223955855|NCT02707302|DEVICE|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
223955856|NCT02707302|PROCEDURE|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
223955857|NCT01115309|DEVICE|XprESS Balloon Device|Sinus dilation completed with the XprESS Balloon Device with or without additional endoscopic sinus surgery procedures (dilation of the frontal recesses, maxillary ostia, and/or sphenoid sinus ostia).
223955858|NCT03715634|DRUG|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
223955859|NCT03715634|DRUG|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
223955860|NCT03715634|DRUG|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
223955861|NCT03715634|DRUG|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
223955862|NCT05475717|DRUG|Alprostadil liposome injection|Alprostadil liposome injection, iv drip, QD×4 days (1 to 3 hours before surgery and 3 days after surgery)
223955863|NCT02147093|DEVICE|Test (multi-focal)|contact lens was to be worn a daily wear.
223955864|NCT02147093|DEVICE|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
223955865|NCT03782870|DIAGNOSTIC_TEST|echocardiography, lab tests|
223955866|NCT00655824|DRUG|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
223955867|NCT04611334|BEHAVIORAL|heart rate variability biofeedback|Heart rate variability biological feedback training is carried out in the outpatient meeting room of the hospital, including once a week, 30 minutes of hospital training each time, using Medea physiological feedback device portable Bluetooth physiological signal Feedback system (Medical Device Input No. 027390). Designed as two stages, stage one (the first week) first teaches the subject how to perform abdominal breathing, and connects the physiological feedback device to monitor the patient's breathing and heart rate changes, and sets the breath per minute according to the subject's resonance frequency . Stage two (second-four weeks) guide the case to understand the resonance relationship between breathing and heart rate, and then achieve the effect of matching heart and breath. It is also equipped with a pressure relief device (Helico Inc., New York, NY, USA) for self-practice at home.
223955868|NCT00507767|DRUG|dasatinib|Given PO or via PEG tube
223955869|NCT00507767|PROCEDURE|pharmacological study|Correlative studies
223955870|NCT00507767|PROCEDURE|laboratory biomarker analysis|Correlative studies
223955871|NCT00725959|BEHAVIORAL|Online social networking HIV prevention|messages about HIV posted in online social networking sites
223955872|NCT06509581|DIETARY_SUPPLEMENT|vitamin E|Vitamin E will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
223955873|NCT06509581|OTHER|PLACEBO|placebo will be taken for 12 months for beta thalassemia patiens on regular packed red blood cell transfusion and chelators(desferoxamine,deferiprone and deferasirox )
223955874|NCT03488043|PROCEDURE|Needle lung biopsy|Needle lung biopsy
223955875|NCT03102632|OTHER|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
223955876|NCT04603300|DRUG|INT301|INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste
223955877|NCT04603300|DRUG|Placebo|Fully functional toothpaste containing no immunotherapy agents
223955878|NCT05120674|BEHAVIORAL|NAP|During the ERRT session, the tone will be played softly so as not to interfere with the session and will be played throughout the entire session. Before sleep, the veteran will play the 40-60hz tone via their smartphone while they read their rescripted nightmare. During sleep, the 40-60hz tone will be delivered during slow-wave-sleep (SWS) by the DREEM device. The pairing of the tone with the intervention is expected to trigger benefits of the exercise in reducing nightmare disturbance during sleep.
223955879|NCT05120674|BEHAVIORAL|CPT|Cognitive Therapy for PTSD
223955880|NCT05120674|BEHAVIORAL|ERRT|ERRT asks individuals to rewrite the traumatic event that triggered their nightmares and then review the rescription before bed. This technique has been proven to drastically reduce the frequency of chronic nightmares.
223955881|NCT05120674|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia that includes behavioral and cognitive interventions related to sleep hygiene, increasing sleep drive, and modifying behaviors that result in association between laying in bed and wakeful states.
223955882|NCT05266300|GENETIC|DPYD genotype|"The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)"
223955883|NCT04639999|OTHER|Echocardiography|LV vortex flow in Echocardiography
223955884|NCT03032198|DEVICE|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
223955885|NCT05095974|DEVICE|ultrasonography|Ultrasound assessment will performed with parturient in the supine position using Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz). A C60x 5-2 MHz convex transducer will used for lung ultrasound (Mindray device (DC-N6, with a phased array transducer, model P4-2, 3-6 MHz).The Echo Comet Score (ECS) will obtained by the 28-rib interspaces technique dividing the chest wall in 12 areas on the left side (from the second to the fourth intercostal space) and 16 (from the second to the fifth intercostal space) on the right anterior and lateral hemithorax.
223955886|NCT05095974|DEVICE|echocardiography|MHz cardiac transducer for echocardiography with two-dimensional, M-mode, color-flow, continuous, pulsed wave and tissue Doppler imaging.
223955887|NCT05095974|DEVICE|thoracic electrical bioimpedence|EC ICONR monitor (Osypka Medical, Inc., La Jolla, California and Berlin) will be applied to the patients through four ECG electrodes. The electrodes will be placed over the bare skin of patients at the following sites: (1) on the left neck below the ear; (2) directly superior to the midpoint of the left clavicle; (3) along the left mid-axillary line at the level of the xiphoid process; (4) two-inches caudad from the third electrode.
224107379|NCT02565823|OTHER|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
224107380|NCT00623155|DRUG|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
224107381|NCT00970203|BIOLOGICAL|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
224107382|NCT00970203|BIOLOGICAL|DC1 vaccine|3-5 x 10e6 cells total
224107383|NCT01009775|DRUG|YM155|intravenous infusion
224107384|NCT01009775|DRUG|Docetaxel|intravenous infusion
224107385|NCT02767570|OTHER|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
224107386|NCT02767570|OTHER|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
224291144|NCT03739138|BIOLOGICAL|MK-4621|"MK-4621 is delivered via the JetPEI™ in vivo linear polyethylenimine nucleic acid delivery system as follows:~For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle according to randomization.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
224107387|NCT00147108|DEVICE|ExAblate 2000|
224107388|NCT00056212|BEHAVIORAL|Yoga|
224291145|NCT03739138|BIOLOGICAL|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
224291146|NCT05540379|DEVICE|Virtual Reality Training|Training the obstetrics and Gynecologist Residents on Virtual endoscopic simulation and skills acquisition
224291147|NCT01194102|BEHAVIORAL|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
224291148|NCT01194102|OTHER|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
223955888|NCT01860300|DRUG|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
223955889|NCT01860300|DRUG|placebo|
223955890|NCT02934932|DRUG|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
223955891|NCT03536845|DRUG|Vitamin D 3|oral drops
223955892|NCT00222898|PROCEDURE|DNA analysis of pancreatic cyst fluid / buccal swab|
223955893|NCT04663256|OTHER|Cognitive stimulation group|Each week for 12 weeks, GE participants attend three 60-minute sessions of cognitive exercises.
223955894|NCT04090632|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
223955895|NCT05710757|OTHER|myofascial release|Myofascial release (MFR) is a technique that involves applying gentle sustained pressure into the myofascial connective tissue restrictions to eliminate pain and restore motion.
224107389|NCT00056212|BEHAVIORAL|Exercise|
224107390|NCT00842517|BEHAVIORAL|Contingency Management|
224107391|NCT06574269|DRUG|TLC590|Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590
224107392|NCT06574269|DRUG|TLC590|TLC590 Dose 1
224107393|NCT06574269|DRUG|TLC590|TLC590 Dose 2
224107394|NCT06574269|DRUG|TLC590|The MTD of TLC590
224107395|NCT06574269|DRUG|TLC590|TLC590 Dose 3 (The SMC-suggested dose)
224107396|NCT06574269|DRUG|Ropivacaine|Ropivacaine
224107397|NCT06574269|DRUG|TLC590|TLC590
224107398|NCT05506332|DRUG|Venetoclax|Venetoclax and 6-mercaptopurine
224107399|NCT05506332|DRUG|6-mercaptopurine|Venetoclax and 6-mercaptopurine
224107400|NCT02632058|OTHER|Cognitive Behavioral Therapy|
224107401|NCT06014814|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation
224107402|NCT06119178|DEVICE|EX-PRESS P-50 filtration device|FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
224107403|NCT06119178|DEVICE|EX-PRESS P-200 filtration device|FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
223540763|NCT05946161|BEHAVIORAL|e-Health intervention to promote mental and sexual health of prostate cancer survivors|An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
223540764|NCT02457338|DIETARY_SUPPLEMENT|Bifidobacterium|
223540765|NCT04952571|DRUG|Camrelizumab and Bevacizumab|"Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion."
223540766|NCT00730054|DRUG|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
223540767|NCT01595087|DRUG|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
223540768|NCT01767896|BIOLOGICAL|ASP7374|subcutaneous (sc)
223540769|NCT01767896|BIOLOGICAL|approved egg-derived TIV|subcutaneous (sc)
223540770|NCT06301503|DRUG|USG Guided Combined LPB-SNB with Isobaric Bupivacaine|Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)
223540771|NCT06301503|DRUG|Control|Local anesthetic infiltration of 2% lidocaine (3ml)
223540772|NCT02827721|DEVICE|impulse oscillometry|
223540773|NCT02827721|DEVICE|multiple breath washout test|
223540774|NCT02827721|DEVICE|body plethysmography|
223955896|NCT05710757|DEVICE|blood flow restriction|Blood flow restricted (BFR) exercise is the brief and non-continuous blockage of venous blood flow using a device that restricts the flow of blood while exercising. This technique is used to produce hypertrophy (muscle growth) and strength responses while exercising at a lighter load than traditionally required to produce a similar response.
223955897|NCT05710757|OTHER|myofascial release|Sham MFR.
223955898|NCT01450657|DIETARY_SUPPLEMENT|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 \& 4, three capsules three times daily (270 CFU's). Months 5 \& 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 \& 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
223955899|NCT03100370|DEVICE|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
224291149|NCT01194102|OTHER|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
223955900|NCT03100370|DEVICE|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
223955901|NCT03100370|DEVICE|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
223540775|NCT03326063|DRUG|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
223540776|NCT03326063|DRUG|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
223540777|NCT05968846|DRUG|Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)|124I-AT-01 (124I-p5+14, iodine-124I evuzamitide) is a a novel iodine-124 (124I) labeled 45 L-amino acid peptide suitable for PET/CT imaging that has been shown to bind systemic amyloid deposits of diverse types in all organs, including the heart. The peptide binds amyloid through multivalent electrostatic interactions with the amyloid fibril and ubiquitous heparan sulfate proteoglycans.
223723842|NCT05079139|PROCEDURE|surgical technique of Musset|"The one-stage rectovaginal fistula cure according to Musset is an intervention indicated in the treatment of simple post-obstetrical or simple post-surgical rectovaginal fistulas.~The procedure consists in performing a perineal section to the perineal section to the fistula pathway in order to perform local excision followed by a repair plane by plane with rectal and anal closure, then of the external sphincter of the anus, and interposition of the deep and superficial transverse elevator and perineal muscles before closing the vagina and perineum."
223955902|NCT03100370|DEVICE|Robotic-assisted training of arm and hand functions|70 minutes of robotic-assisted training (RAT) of arm and hand functions will follow each of the tsDCS sessions, five days a week, for two weeks. Robotic-assisted training will be provided by using the MAHI Exo-II device.
223955903|NCT03705663|BEHAVIORAL|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
223955904|NCT02318810|DRUG|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
224107404|NCT00151411|DRUG|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
224107405|NCT00151411|DRUG|Placebo|Placebo
224107406|NCT00151411|BEHAVIORAL|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
224107407|NCT05327478|PROCEDURE|NRP|Normothermic Regional Perfusion
224107408|NCT05327478|PROCEDURE|DHOPE|Dual Hypothermic Oxygenated Perfusion
224107409|NCT05327478|PROCEDURE|COR-NMP|Controlled Oxygenated Rewarming Normothermic Machine Perfusion
224107410|NCT00400491|DRUG|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
224107411|NCT00400491|DRUG|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
224107412|NCT03533478|DIETARY_SUPPLEMENT|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
224107413|NCT03533478|DIETARY_SUPPLEMENT|Placebo|Placebo treatment
224107414|NCT06386588|OTHER|Closed loop auditory stimulation during sleep|Short bursts of pink noise delivered at precise times during overnight sleep at home.
224107415|NCT03441191|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
224107416|NCT05447130|PROCEDURE|phacoemulsification|phacoemulsification with corneal endothelial evaluation by specular microscopy
224107417|NCT03351322|DRUG|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
224107418|NCT03351322|DRUG|Regaine|Regaine are applied for treatment of hair loss.
223955905|NCT02318810|DRUG|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
224107419|NCT00417612|DRUG|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
223955906|NCT02318810|DRUG|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
223955907|NCT02318810|DRUG|Placebo|Patients receive saline
223955908|NCT04348669|OTHER|Tele-yoga|Subjects will undergo 30-minute yoga sessions delivered remotely 2 times/week for 6-weeks. The yoga sessions will be delivered one-on-one. The sessions will include 5-7 minutes of breathing exercises, 15-20 minutes of postures, and 5-7 minutes of relaxation and meditation exercises.
223723843|NCT04873791|DIAGNOSTIC_TEST|Assessment of geriatric individuals living in home environment and nursing home.|Assessments explained in the arm section were made as described in one session in both group
223723844|NCT00440219|DRUG|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
223955909|NCT01307800|DRUG|LY2140023|Administered orally
223955910|NCT01307800|DRUG|Placebo|Administered orally
223955911|NCT03365232|DEVICE|non custom base attachment|non custom base attachment
223955912|NCT03365232|DEVICE|custom base attachment|custom base attachment
224107420|NCT00417612|OTHER|Placebo|Placebo sugar pill
224107421|NCT02318394|BIOLOGICAL|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
224107422|NCT03774745|DRUG|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
224107423|NCT03774745|DRUG|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
224107424|NCT03774745|DRUG|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
224107425|NCT03891069|DEVICE|AHA Exergame System|The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
224107426|NCT01841008|DRUG|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
224107427|NCT01841008|DRUG|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
224107428|NCT00417365|DEVICE|WaterWorks Douching Device|
223540778|NCT04277312|BEHAVIORAL|Engage|The Engage intervention was developed with input from primary school teachers and includes a range of age-appropriate educational activities related to food. Activities include videos, lesson plans, worksheets, games, talks/visits from experts, visits to industrial partners and other local food-related centres of interest and practical activities such as experiments. All 'Engage' material is mapped to the Northern Ireland School Curriculum. The 'Engage' intervention is structured into three broad topics: Farm to Fork; Pleasure on a Plate and Food Futures. Engage resources were provided to schools electronically and in hard copy and teachers delivered most of the content, with the exception of several sessions which were delivered by visiting scientists.
223540779|NCT04277312|BEHAVIORAL|Nourish|The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
223540780|NCT05111067|GENETIC|DNA and whole transcriptome mRNA sequencing|DNA and whole transcriptome mRNA sequencing, including total mutational burden and microsatellite instability, will be performed using the TruSight Oncology 500 (TSO500) platform (Illumina Canada, Ulc).
223540781|NCT01876381|DRUG|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
223540782|NCT03978845|DRUG|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
223540783|NCT02373592|BEHAVIORAL|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
223540784|NCT02373592|DEVICE|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
223540785|NCT00011544|PROCEDURE|Performance Measure|
223955913|NCT01667198|PROCEDURE|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
223955914|NCT01667198|BEHAVIORAL|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
223955915|NCT06455306|PROCEDURE|Air-polishing with erythritol at different time points|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline, 1 month and 2 months
223955916|NCT06455306|PROCEDURE|Single Air-polishing with erythritol|The air-polishing device will be inserted into each site of the peri-implant pocket at an angle ranging from 60 to 90 degrees, and each surface will be debrided for 5 seconds using erythritol powder (AIRFLOW Powder PERIO; EMS). In this group this procedure will be done ate baseline only.
223540786|NCT01499537|DEVICE|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
223540787|NCT01499537|DEVICE|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
223723845|NCT00440219|DRUG|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
223955917|NCT03985566|DIETARY_SUPPLEMENT|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
223955918|NCT03985566|DIETARY_SUPPLEMENT|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
223955919|NCT00689351|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
223955920|NCT00689351|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
224107429|NCT02268565|DRUG|Aspirin|81mg aspirin daily at bedtime over a 2 week period
223540788|NCT01985230|DEVICE|ReActiv8 Implantable Stimulation System implanted and activated.|
223540789|NCT01470157|DRUG|Ketamine|5mg/kg as oral suspension
223955921|NCT01766206|BIOLOGICAL|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
223955922|NCT03683615|PROCEDURE|repair of orbital floor fractures using resorbable plates|
223955923|NCT02633085|DEVICE|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
223955924|NCT01320800|BEHAVIORAL|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
223955925|NCT01320800|BEHAVIORAL|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
223955926|NCT03153306|DRUG|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
223955927|NCT06510673|DRUG|Platelet rich plasma|Platelet-rich plasma for the heel
223955928|NCT06510673|OTHER|High power LASER|High power LASER sessions for the heel
223955929|NCT06510673|OTHER|Shockwave therapy|Shockwave therapy sessions for the heel
223955930|NCT06510673|OTHER|Ice application|Ice application for the heel
223955931|NCT06510673|OTHER|Sham LASER|Sham LASER for the heel
223540790|NCT01470157|DRUG|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
223540791|NCT06118658|DRUG|tislelizumab|About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
223955932|NCT02544191|DRUG|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
223955933|NCT03479892|DRUG|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
223955934|NCT03479892|DRUG|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
223955935|NCT02790632|DRUG|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
223955936|NCT02790632|DRUG|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
223955937|NCT02586272|DEVICE|Daifert|
223955938|NCT02586272|PROCEDURE|Control Group|
223955939|NCT03486509|DRUG|Afatinib|afatinb 40mg po bid
223955940|NCT02255474|DEVICE|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
223955941|NCT02255474|DEVICE|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
224107430|NCT02268565|DRUG|Placebo|pill that looks like aspirin without the effects of aspirin
224107431|NCT03601338|DRUG|Bemiparin|second generation low molecular weight Heparin
223540792|NCT04961905|DRUG|NVP-2002-R1+NVP-2002-R2|NVP-2002-R1 1 tablet, once daily and NVP-2002-R2 1 tablet, once daily
223955942|NCT02255474|DEVICE|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
223955943|NCT06360978|DRUG|Docetaxel|Our patients will receive docetaxel (15 mg per meter squared) once weekly concurrently with radiotherapy.
223955944|NCT04251988|DEVICE|Oculus Go VR|virtual reality headset
223955945|NCT02779426|BEHAVIORAL|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
223955946|NCT00610337|DRUG|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
223955947|NCT00610337|PROCEDURE|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
223955948|NCT04494399|DRUG|Interferon beta-1b|5-day course of daily subcutaneous injection of interferon β-1b 16 million IU
223955949|NCT04494399|DRUG|Ribavirin|5-day course of oral ribavirin 400mg twice daily
224107432|NCT03601338|OTHER|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
224107433|NCT01712438|BIOLOGICAL|Human cl rhFVIII|
223955950|NCT04863339|DRUG|Tranexamic acid|Single preoperative dose of 1 gram of Tranexamic Acid in 100 mL of saline given 0-30 minutes prior to surgery.
224291150|NCT02654587|BIOLOGICAL|OSE2101|
223955951|NCT04863339|DRUG|Placebo|Single preoperative dose of 100 mL of saline placebo given 0-30 minutes prior to surgery.
223955952|NCT03967015|OTHER|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
223955953|NCT03479918|DRUG|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
223955954|NCT03479918|DRUG|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
223540793|NCT04961905|DRUG|NVP-2002|NVP-2002 is a combination of NVP-2002-R1 and NVP-2002\_R2 NVP-2002, 1 tablet, once daily
223955955|NCT03479918|DRUG|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
223955956|NCT03479918|DRUG|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
223955957|NCT03098199|DRUG|300IU Gonal-F|\<1.5 AMH group
223955958|NCT03098199|DRUG|150IU Menopur|\<1.5 AMH group
223955959|NCT03098199|DRUG|225IU Gonal-F|1.6-2.5 AMH group
224291151|NCT02654587|DRUG|Docetaxel|
223955960|NCT03098199|DRUG|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
223955961|NCT03098199|DRUG|150IU Gonal-F|2.6-6.9 AMH group
223955962|NCT03098199|DRUG|75IU Gonal-F|\>7.0 AMH group
223955963|NCT06211595|DEVICE|DragonFire Transcatheter Myocardial Radiofrequency Ablation System|The patients with hypertrophic obstructive cardiomyopathy were treated with a transcatheter myocardial radiofrequency ablation system and its guiding system under the guidance of echocardiography
223955964|NCT05539118|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
223955965|NCT05539118|DRUG|Toripalimab|Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
224291152|NCT02654587|DRUG|Pemetrexed|
224291153|NCT00783887|OTHER|Blood sample|Blood sample of 5 ml
224291154|NCT01419587|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
224291155|NCT01825837|DRUG|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
224291156|NCT01825837|DRUG|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
224291157|NCT01825837|DRUG|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
223540794|NCT05568329|DEVICE|Hearing Aid Program|"Each subject will listen to recordings of music processed by seven different hearing aid brands set to the default Speech in Quiet program and the default Music program. Recordings (hearing aid brand x program x music sample) will be randomized from trial to trial."
223955966|NCT05539118|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
223955967|NCT03142490|OTHER|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
223955968|NCT03142490|OTHER|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
223955969|NCT03430518|DRUG|Durvalumab|1.12g given IV on day 1 every 21 day cycle
223955970|NCT03430518|DRUG|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
223955971|NCT01535352|BEHAVIORAL|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
223955972|NCT01535352|BEHAVIORAL|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
223955973|NCT05208294|DRUG|Sulpiride 400 MG|The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
223955974|NCT05208294|DRUG|Placebo|Participants receive an inactive placebo capsule.
223955975|NCT05208294|BEHAVIORAL|High expectation manipulation|Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
223955976|NCT05208294|BEHAVIORAL|Low expectation manipulation|Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
223955977|NCT01903109|DRUG|Cevimeline|
223955978|NCT01229176|BIOLOGICAL|Vi-CRM197 vaccine|
223955979|NCT01229176|BIOLOGICAL|Vi Polysaccharide (PS) vaccine|
223955980|NCT01229176|BIOLOGICAL|Pneumococcal conjugate vaccine|
223540795|NCT00461708|DRUG|Erlotinib|100 mg, PO, once per day
223540796|NCT00461708|DRUG|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
223540797|NCT06297876|BEHAVIORAL|Storytelling|Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.
223540798|NCT06297876|BEHAVIORAL|Learn More (Active Comparator)|Informational videos that are of similar length and on the same topic as the storytelling videos.
223540799|NCT05532969|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
223540800|NCT06086964|OTHER|therapeutic diet.|gluten and casein free diet.
223955981|NCT01528683|RADIATION|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
223955982|NCT01894737|OTHER|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
223540801|NCT06086964|OTHER|physiotherapy|specific physiotherapy developmental program according to the pre evaluation of gross motor status.
223540802|NCT02803203|DRUG|osimertinib|
223955983|NCT01894737|OTHER|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
223955984|NCT06041932|DRUG|Carvedilol|Carvedilol
223955985|NCT06041932|DRUG|Pentoxifylline|Pentoxiphylline
223955986|NCT01127737|BEHAVIORAL|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
223955987|NCT01127737|BEHAVIORAL|Placebo|Completed surveys
223955988|NCT02740426|DRUG|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
223955989|NCT00078156|BEHAVIORAL|Behavior Therapy|
223955990|NCT04921540|PROCEDURE|Ingrown toenails with surgery with chemical cauterisation|Removal of the ingrown lateral part of the toenail and chemical cauterisation
223955991|NCT04921540|PROCEDURE|Ingrown toenails with only surgery|Removal of the ingrown lateral part of the toenail with directed Healing pad
223955992|NCT00234676|DRUG|Premarin ®|Premarin ® 0.625 mg per day orally
223955993|NCT01082159|PROCEDURE|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
223955994|NCT03130946|DEVICE|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
223540803|NCT02803203|DRUG|Bevacizumab|
223540804|NCT04577781|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
223955995|NCT03130946|DEVICE|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
223955996|NCT05556304|OTHER|assessment in the 8th month of pregnancy and during delivery|"* Day 0: presentation of the study~* During pregnancy between Day 0 and 36-38SA: inclusion~* During pregnancy: collection of pelvic MRI data if performed during pregnancy for maternal or fetal reasons~* Between 36 and 38 WG: collection of demographic, obstetrical, fetal ultrasound and clinical data / Perineal elastographic recording / Recording of the perineal deformation by stereovision camera~* In the delivery room, at the beginning of labor and before pushing: collection of clinical data / Collection of obstetrical ultrasound data / Perineal elastographic recordings / Recording of the perineal deformation by stereovision camera~* In the delivery room, during expulsion : recording of the perineal deformation by stereovision camera~* In the delivery room, after childbirth: collection of obstetrical, clinical and neonatal data / Perineal elastographic recordings / Cephalic and shoulder measurements of the newborn with a tape measure"
223955997|NCT00444054|BEHAVIORAL|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
223955998|NCT00788606|DRUG|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
223955999|NCT04348357|OTHER|Telemedicine|A video-call application hosted by Texas Tech University Health Science Center El Paso and easily accessible from mobile phones or video-enabled PCs will be used (webex teams)
223956000|NCT04348357|OTHER|Office visit|Patient comes to the office to receive routine postoperative care
223956001|NCT06245902|DRUG|Naltrexone and Acetaminophen|Naltrexone plus acetaminophen
223956002|NCT06245902|DRUG|Naltrexone and Acetaminophen-High Dose|Naltrexon (high dose) plus acetaminophen
223956003|NCT06245902|DRUG|Naltrexone Alone (regular dose)|Naltrexone Alone plus Placebo
223956004|NCT06245902|DRUG|Acetaminophen Alone|Acetaminophen Alone plus Placebo
223956005|NCT06245902|DRUG|Matching Placebo|Two Placebo capsules
223956006|NCT02736175|DRUG|Dexamethasone|
223956007|NCT02736175|OTHER|Placebo Vehicle|
223956008|NCT05514678|BEHAVIORAL|Cognitive Stimulation Therapy|CST consists of 14 sessions, each session with different themes. The materials used in therapy will differ according to the characteristics of each theme. For example; In the theme of physical games, one of the individuals will be selected by voting, and each individual will be asked to choose a song suitable for the theme and introduce himself/herself to the music accompaniment. Then, a small table game will be prepared with the rackets and ball used for table tennis, and individuals will be able to play a round of table tennis with the researcher and their groupmates. Sessions 10 min. introductory part, 25 min. activity section and 10 min. 45 minutes in total, including the ending. in progress.
223956009|NCT01446640|BIOLOGICAL|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10\^6 MSCs per kg; intrathecal administration of up to 1x10\^6 MSCs per kg.
223956010|NCT01295099|DRUG|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
223956011|NCT01295099|RADIATION|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
223956012|NCT01295099|DRUG|Triamcinolone|TAC 10mg in 1ml injected intralesional
223956013|NCT00834379|DRUG|pravastatin sodium|40 mg Tablet
223956014|NCT00834379|DRUG|Pravachol®|40 mg tablet
224291158|NCT01825837|DRUG|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
223540805|NCT04577781|DRUG|Placebo|Placebo powder and solvent for oral solution to be reconstituted prior to use.
223540806|NCT01768949|DEVICE|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
223540807|NCT00811460|DRUG|Placebo|sc for 4 days
223540808|NCT00811460|DRUG|taspoglutide|300micrograms/day sc for 2 days
223540809|NCT00811460|DRUG|taspoglutide|800 micrograms/day sc for 2 days
223540810|NCT04024826|BEHAVIORAL|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
223540811|NCT04024826|BEHAVIORAL|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
223540812|NCT04024826|BEHAVIORAL|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
223540813|NCT04024826|BEHAVIORAL|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
223540814|NCT04383093|DRUG|Tadalafil 5mg|Combination therapy of daily tadalafil plus tamsulosin
223956015|NCT00882050|DRUG|Exenatide 0.27 ng/kg/min|"Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.~* Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
223956016|NCT00882050|DRUG|Exenatide 0.41 ng/kg/min|"Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
223956017|NCT00882050|DRUG|Placebo|"Intravenous Placebo of NSS infused at same rate as drug comparator. Induction of anesthesia will be equal to Intubation time. Infusion will begin at this time point (+ or - 3 minutes).~* Blood samples will be obtained prior to intubation and then 10 and 30 minutes after drug initiation and every 30 minutes (+ or - 2 minutes) thereafter until the infusion is stopped. The drug infusion will be stopped at extubation. Blood will then be sampled every 30 minutes (+ or - 2 minutes) post extubation for 2 hours, and once 24 hours after extubation.~* Blood plasma levels will be collected (8-10 mls) for analysis of GLP-1, Glucose, Potassium, Insulin, Glucagon, Epinephrine, Norepinephrine, Cortisol, and free fatty acids (FFA)."
223540815|NCT04877860|OTHER|Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement."
223540816|NCT04877860|OTHER|Multimodal rehabilitation program + traditional biomedical information|"The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment."
223540817|NCT04877860|OTHER|Control group|Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
223540818|NCT01467336|PROCEDURE|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
223540819|NCT02642211|PROCEDURE|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
223540820|NCT02299310|DRUG|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
223956018|NCT03453645|PROCEDURE|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
223956019|NCT05643222|DEVICE|red tint contact lenses|to compare the performance of these lenses.
223956020|NCT02367794|DRUG|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
223956021|NCT02367794|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
223540821|NCT02299310|DRUG|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
223540822|NCT05713461|BEHAVIORAL|exercise training program|"Adapted Interval Training Intervention, three days a week, 10 weeks.~Warm-up 10': Joint mobility and cardiovascular activation~Main part:~Resistance training circuit for strengthening the main muscle groups.~Cool down Flexibility and CORE"
223540823|NCT05713461|BEHAVIORAL|Feeding training|Two workshops on healthy eating habits (Week 1 and week 5). Food Frequency Questionnaires (weekly). Feedback weekly. Mediterranean Diet Adherence Screener (MEDAS). The dietary intervention will be based on the nutritional recommendations based on the Mediterranean diet, according to the evidence from the PREDIMED trial.
223540824|NCT01355614|DRUG|QAX576|
223540825|NCT01355614|DRUG|Infliximab|
223540826|NCT03894891|DRUG|Nivolumab|Nivolumab is a type of immunotherapy.
223956022|NCT02367794|DRUG|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m\^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
223540827|NCT03894891|DRUG|Cisplatin|Cisplatin is a chemotherapy drug.
223540828|NCT03894891|DRUG|Docetaxel|Docetaxel is a chemotherapy drug.
223956023|NCT02367794|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m\^2 IV.
223956024|NCT02442557|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injection
223956025|NCT02442557|OTHER|placebo comparator|intravenous injection
223956026|NCT00115167|DRUG|Placebo|Q4W
223956027|NCT00115167|DRUG|Darbepoetin alfa|Q4W
223956028|NCT03803657|DEVICE|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
223956029|NCT00681226|DRUG|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
223956030|NCT00779805|DRUG|Pseudoephedrine hydrochloride 120 mg ER tablets|
223956031|NCT03143036|DRUG|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients \>75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
223956032|NCT01285882|OTHER|Representations|"1. A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~2. To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~   * 1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~  * 2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~3. Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
223956033|NCT00977678|OTHER|open access gastroscopy|access to gastroscopy without preceding appointment
223956034|NCT00977678|OTHER|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
223956035|NCT03234478|OTHER|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
223956036|NCT03531892|DRUG|AJM300|AJM300 film-coated tablets.
224291159|NCT04007471|OTHER|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
223540829|NCT03894891|RADIATION|Intensity-modulated radiotherapy|IMRT is definitive treatment for head and neck cancer.
223956037|NCT03531892|DRUG|Placebo|Placebo matched to AJM300 tablets.
223956038|NCT03720028|BEHAVIORAL|Observation|Describe communication and sensory profile using standardized tests and observations.
223956039|NCT03720028|BEHAVIORAL|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
224291160|NCT05171894|DRUG|Hemopfin+Green Light|All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
224291161|NCT05171894|DEVICE|Vehicle+Green Light|All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
223540830|NCT02750969|DEVICE|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
223540831|NCT02750969|OTHER|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
223540832|NCT02750969|PROCEDURE|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
223956040|NCT03949959|OTHER|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
223956041|NCT01884571|DRUG|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
223956042|NCT01884571|DRUG|Methylprednisolone|125 mg, IV (in the vein) on day 1.
223956043|NCT01884571|DRUG|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
223956044|NCT01884571|DRUG|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
223956045|NCT01884571|DRUG|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
223956046|NCT06417372|DIAGNOSTIC_TEST|intraoperative fluorescent staining combined with microscopy|Through the modified formulation of sodium fluorescein and methylene blue, the surface of the suspected cut edge of the patient's glioma was stained intraoperatively, and the surgical microscope image acquisition and processing system was used to determine whether the cut edge of the surgically resected tissue was positive or not.
223956047|NCT05448794|OTHER|injection|ultrasound-guided hydrodilatation with hypertonic Dextrose
223956048|NCT05320874|BIOLOGICAL|KM257 Bispecific antibody|"Part 1a dose escalation:~There will be 3 increasing dose levels (3mg/kg,6mg/kg,12mg/kg). Patients will be intravenously administrated with one dose of KM257, QW for continuous cycles of 21 consecutive days for each cycle. The dosing interval may be adjusted during the study based on emerging data from this trial.~Part 1b dose expansion:~Part1b:For cohort 1 and cohort2, KM257 will be given at the RP2D identified in Part1a;~For cohort 3 to 7:KM257 will be given combined with one of the following selected drug combination:~Drug: Capecitabine Combination therapy with KM257 - Cohort 3~Drug: Paclitaxel or Docetaxel or Irinotecan Combination therapy with KM257 - Cohort 4~Drug: Gemcitabine+Cisplatin Combination therapy with KM257 - Cohort 5~Drug: Gemcitabine+Cisplatin or Carboplatin Combination therapy with KM257 - Cohort 6~Drug:Carboplatin+Paclitaxel Combination therapy with KM257 - Cohort 7"
223956049|NCT01090258|DEVICE|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate \[RR\], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
223956050|NCT01090258|OTHER|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
223956051|NCT05586165|BEHAVIORAL|Reminder to boost protection against COVID-19|Patients will receive a text message reminding them to enhance their protection against COVID-19 by getting the bivalent booster. The message will contain one link to schedule an appointment at UCLA Health and one link for scheduling an appointment at CVS Pharmacy.
223956052|NCT05586165|BEHAVIORAL|Flu Tag Along|This message will also encourage patients to protect themselves against the flu by asking for their flu vaccine at the booster appointment (at UCLA Health) or adding the flu vaccine to the COVID-19 vaccine booster appointment (at CVS).
223956053|NCT05586165|BEHAVIORAL|COVID-19 Booster & Flu Bundle|This message will simultaneously encourage patients to enhance their protection against COVID-19 and the flu and will inform them that, to save time, they can bundle two vaccines at once. Patients will learn that at UCLA Health, they can book an appointment for the booster and then ask for the flu vaccine at their appointment; at CVS Pharmacy, they can book one appointment to get both the bivalent COVID-19 booster and the flu vaccine.
223956054|NCT01063465|DEVICE|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
223956055|NCT01535625|DEVICE|Momo stent|Patients with PCI
224291162|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
224291163|NCT00904748|DRUG|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
224291164|NCT00904748|DRUG|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
223956056|NCT06157294|PROCEDURE|Intra-articular pulsed radiofrequency|Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
223956057|NCT06157294|PROCEDURE|Median branch pulsed radiofrequency|Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
223956058|NCT04233411|OTHER|Mycoprotein ingestion|
223956059|NCT05299099|DRUG|IN-C006 inj.|IN-C006 will be injected continuously for 3 days.
223956060|NCT05299099|DRUG|RCN301|RCN301 will be injected continuously for 3 days.
223956061|NCT04820023|DRUG|BBT-176, QD|BBT-176 given orally alone, QD
223540833|NCT02750969|OTHER|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
223956062|NCT04820023|DRUG|BBT-176, BID|BBT-176 given orally alone, BID
223956063|NCT04827602|OTHER|Drug allergy label status in electronic health records|Registered drug allergy labels in primary care and hospital electronic medical charts
223956064|NCT06487871|DIETARY_SUPPLEMENT|Fucoidan extracted from Undaria pinnatifida (UPF)|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
223540834|NCT03122938|DIETARY_SUPPLEMENT|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
223540835|NCT03122938|DIETARY_SUPPLEMENT|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (\<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
223540836|NCT00656682|BEHAVIORAL|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
223540837|NCT00656682|BEHAVIORAL|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
223540838|NCT03017105|OTHER|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
223956065|NCT06487871|DIETARY_SUPPLEMENT|Placebo|Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
223540839|NCT03017105|OTHER|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
223540840|NCT01730872|DRUG|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
223540841|NCT01730872|DRUG|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
223540842|NCT00820547|BIOLOGICAL|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
223540843|NCT00820547|DRUG|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
223956066|NCT06029920|OTHER|Overground Walking|Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
223956067|NCT03528161|OTHER|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
223956068|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
223956069|NCT03915535|DIETARY_SUPPLEMENT|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
223956070|NCT05118009|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative.The system will send a message to corresponding physicians if positive finding.
223956071|NCT02988232|DRUG|Sogyeonghwalhyeol-tang|herbal extract
223956072|NCT02988232|DRUG|Placebo|extract powder with same appearance, odor and color as SGHH
224107434|NCT01483040|DEVICE|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
224107435|NCT01646008|OTHER|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
223540844|NCT00820547|DRUG|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
223540845|NCT00820547|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
223540846|NCT00820547|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
223540847|NCT00209937|DRUG|Gaboxadol|
223540848|NCT02844985|OTHER|No Intervention|
223540849|NCT00950651|DRUG|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
223540850|NCT00950651|DRUG|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
223540851|NCT00754689|DRUG|Rimonabant|Tablet, oral administration
223540852|NCT00754689|DRUG|Metformin|Tablet, oral administration
223540853|NCT00754689|DRUG|placebo|Tablet, oral administration
223540854|NCT00368030|DRUG|Eszopiclone|Eszopiclone 3 mg QD
223540855|NCT00368030|OTHER|Placebo|Placebo tablet
223540856|NCT00411424|DRUG|ASK8007|IV
223540857|NCT00411424|DRUG|Placebo|IV
223540858|NCT05486390|BEHAVIORAL|Nudge, health coaching and shared decision-making|"The EMPOWER app aims to nudge the participant towards successful self-management of their diabetes condition by encouraging and reinforcing positive lifestyle behaviors in 3 main aspects - diet, physical activity, medication adherence. Notifications included content based on behavioural change technique including feedback on performance, positive reinforcement, and prompts to self-monitor. Each notification focused on a single behaviour (physical activity, medication adherence or diet).~The participants in the intervention group will also interact with health coach throughout the study duration. In this study, the health coach will be responsible for the following roles :~1. Goal setting and action plan~2. After-visit summary~A report card summarizing the lifestyle behaviour, goals will be made available to facilitate shared decision making."
223540859|NCT00286377|DRUG|prosaptide|
223540860|NCT01313507|BIOLOGICAL|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
224107436|NCT01646008|OTHER|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
223540861|NCT05431647|OTHER|Sensory integration therapy|The individuals were divided into two as randomized controlled. Both physiotherapy and sensory integration therapy were applied to the intervention group. Each treatment was applied as 2 sessions per week, 2 days a week for 8 weeks. In the control group, only physiotherapy treatment was applied for 8 weeks, 2 days a week, 2 sessions per week.
223540862|NCT04858399|DIAGNOSTIC_TEST|Evaluation|To examine the differences in respiratory functions, orofacial muscle tone changes, anxiety/ depression, and quality of life of the patients according to the severity of Obstructive Sleep Apnea Syndrome.
223540863|NCT04249401|DRUG|Rivaroxaban (Xarelto)|NOAC, reduced dose
223540864|NCT04249401|DRUG|Apixaban|NOAC, reduced dose
223540865|NCT04249401|DRUG|Dabigatran|NOAC, reduced dose
223540866|NCT04249401|DRUG|Warfarin|VKA
223540867|NCT00276432|DEVICE|iSTAT point of care analyzer|
223540868|NCT01824290|DRUG|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
223540869|NCT01824290|DRUG|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
223540870|NCT01824290|DRUG|ERA as specific PAH treatment|All participants were taking endothelin receptor antagonist (ERA) (such as bosentan, ambrisentan and macitentan).
223540871|NCT06199024|DIETARY_SUPPLEMENT|Oral cinnamon supplementation|In intervention group patients will take 1500 mg daily (3 tablets of cinnamon 500 mg, Sagepad Darou Pharmaceutical Company, Iran) that is, 4 weeks before the start of the new IVF cycle and 2 weeks during the ovarian stimulation process.
223540872|NCT02681081|OTHER|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
223540873|NCT02681081|OTHER|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
223540874|NCT02681081|OTHER|Control|Normal food intake
223540875|NCT02343770|OTHER|blood sample for identifying biomarkers|
223540876|NCT00527618|DRUG|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
224107437|NCT00764972|DRUG|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
223540877|NCT00527618|DRUG|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
224107438|NCT04079556|BEHAVIORAL|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
223540878|NCT02606318|OTHER|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
223540879|NCT02606318|OTHER|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
223540880|NCT02278315|DRUG|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
223540881|NCT02278315|DRUG|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
223540882|NCT02278315|DRUG|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
223540883|NCT00750230|DIETARY_SUPPLEMENT|NEM|see Treatment Arm
223540884|NCT04642521|DEVICE|Jamar hydraulic hand dynamometer|"The strength of the dominant hand will be recorded before and after receiving intravenous iron.~Each participant will be positioned in a straight back chair with both hand and feet flat on the ground, elbow flexed to 90 degrees with forearm and wrist in the neutral position. Patient's muscle strength will then be tested three times with an interval of one minute between testing and the average of three times will be recorded to the nearest 0.1kg."
223540885|NCT01597726|DRUG|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed
223540886|NCT01597726|DEVICE|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
223540887|NCT05252286|OTHER|video watching|"Watching video In this group, when the patient conducts their rehabilitation exercise, the therapist would record the poor physical movement pattern from his/her performance by using the mobile phone or tablet. The patients will be provided with watching video exercise, containing 3-5 items of their poor physical performance, selected by the therapist as a feedback to let the patient practice when they return their bedside ward after their rehabilitation time. The content of video-watching exercise program will be changed or modified once weekly as the patient improve the physical movement performance."
223540888|NCT05252286|OTHER|paper group|In the paper sheet group, the therapist will give three to five poor movement patterns, selected from the patient conducting their rehabilitation program, to practice when returning bedside ward.
223540889|NCT05252286|OTHER|oral education group|the patient only receives the oral exercise education about how to improve their physical performance during their hospital stay.
223540890|NCT00051207|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|
223540891|NCT00051207|BEHAVIORAL|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
223540892|NCT05249205|BEHAVIORAL|REHIT1|This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
223723846|NCT04851249|PROCEDURE|Hallux Valgus - chevron osteotomy, lapidus procedure|The purpose is to compare the preoperative clinical features (previous medical history, age, BMI, occupational status etc), PROMs (Manchester-Oxford Foot and ankle questionnaire, SF-36, VAS activity scale) and radiological parameters (both two and three dimensional) with the postoperative PROMs (+ likert scale) and the postoperative radiological parameters.
224107439|NCT00440128|DRUG|Docetaxel|Docetaxel
224107440|NCT00440128|DRUG|Casopitant/Docetaxel|Casopitant/Docetaxel
224107441|NCT03499041|DRUG|LY3314814|Administered orally
224107442|NCT00253617|DRUG|porfimer sodium|
224107443|NCT00253617|PROCEDURE|adjuvant therapy|
224107444|NCT00253617|PROCEDURE|laser therapy|
224107445|NCT00253617|PROCEDURE|photodynamic therapy|
224107446|NCT00253617|PROCEDURE|phototherapy|
223956073|NCT05704465|BEHAVIORAL|Reiki Therapy|Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.
223540893|NCT05249205|BEHAVIORAL|REHIT2|This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
223540894|NCT06185426|DRUG|Methyprednisolon and low level laser theraphy|All rats will be anesthetized with ketamine hydrochloride at a dose of 50 mg/kg (i.p) (Ketalar ®, Eczacıbaşı Parke-Davis, İstanbul, Türkiye) and Xylazine HCl (Alfazyne ®, Alfasan International B.V. Woerden, Hollanda) at a dose of 10 mg/kg (intraperitoneal). A right postauricular incision will made under general anesthesia, and an external trunk of the facial nerve will be found. In the DCG and other experimental groups, the facial nerve was dissected, and it will be clamped with an average force of 150 g for about 1 minute. Afterward, the surgical area will be sutured in all rats in the DCG, L, S, and LSG groups. At the end of the 4 weeks of study, tissue samples will be taken from the facial nerve trunk in the control and experimental groups with a second surgical procedure preserved in formalin solution and sent for histopathological and biochemical examination.
223540895|NCT04373343|BEHAVIORAL|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
223540896|NCT02920307|PROCEDURE|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
223540897|NCT02920307|PROCEDURE|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
223956074|NCT05704465|BEHAVIORAL|Qi-gong Therapy|Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
223956075|NCT02450786|DRUG|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
223956076|NCT05672862|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
223956077|NCT04371471|DIAGNOSTIC_TEST|STC-19 score|Score calculated by an algorithm using a vital sign (systolic blood pressure) and biomarkers (complete blood count with differential)
223956078|NCT06174779|DRUG|HM11260C|Test drug
223956079|NCT06174779|DRUG|Placebo|Placebo drug
223956080|NCT05988619|DEVICE|Transcranial Magnetic Stimulation|TMS is a noninvasive method of brain stimulation administered by physicians in the UCLA TMS Clinical and Research Service. It is an FDA-approved treatment for Major Depressive Disorder.
223956081|NCT05988619|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy|This Way Up is an internet-based cognitive behavioral therapy (iCBT) for depression and anxiety. Participants learn about depression and anxiety symptoms, as well as behavioral strategies for addressing these symptoms. Participants are provided with homework exercises designed to help them engage in these strategies regularly.
223956082|NCT05988619|BEHAVIORAL|Psychoeducation|Stories of the Mind is an educational program that is freely available through the Public Broadcast Service (PBS). Participants view video testimonials in which individuals describe their personal experiences across a variety of mental health concerns.
223956083|NCT02655900|OTHER|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
223956084|NCT01027247|DEVICE|Ologen TM|
223540898|NCT02920307|PROCEDURE|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
223956085|NCT02625168|DRUG|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
223956086|NCT02625168|DRUG|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
223956087|NCT05582447|OTHER|ektacytometry of red blood cells|Evaluate red blood cell membrane mechanical characteristics by osmotic gradient ektacytometry
223956088|NCT05360199|BEHAVIORAL|PROMs|evaluate the impact of recall bias on post proms scores
223956089|NCT00778141|DRUG|metformin HC1 750 mg extended-release tablets|
223956090|NCT00214318|DRUG|Terbutaline plus Metoprolol or carvedilol|
223956091|NCT00515112|DRUG|AndroGel|Androgel 1%, 10g daily
223956092|NCT00515112|DRUG|placebo|placebo
223956093|NCT01771081|DRUG|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
223956094|NCT02832219|DIETARY_SUPPLEMENT|Molecular hydrogen|
223956095|NCT02832219|DIETARY_SUPPLEMENT|Placebo|
223956096|NCT01020487|DRUG|Paricalcitol|Paricalcitol capsules taken with water.
223956097|NCT01020487|DRUG|Placebo|Placebo capsules taken with water
223956098|NCT05424952|OTHER|Conversational AI Service (Chatbot)|WhatsApp or Messenger Chatbot for COVID-19 vaccines
223956099|NCT04618575|DRUG|Ursodeoxycholic acid combined with total glucosides of paeony|Ursodeoxycholic acid combined with total glucosides of paeony
223956100|NCT04618575|DRUG|Ursodeoxycholic acid only|Ursodeoxycholic acid only
223956101|NCT06582277|BIOLOGICAL|OVX836 shot|One single administration intramuscularly at Day 1.
223956102|NCT01366976|DRUG|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
223956103|NCT04358588|DRUG|iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System|Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).
223956104|NCT06056726|PROCEDURE|BIB positioning|BIB positioning in obese patients with rectal cancer elegible for neoadjuvant therapy
223956105|NCT05386537|COMBINATION_PRODUCT|MyoMo orthosis and VR games|Combining Wearable Robotic Orthosis with Visual and Haptic Feedback to Enhance the Recovery of Upper Extremity Motor Function and ADL in Persons with Acute SCI
223956106|NCT05386537|DEVICE|MyoPro robot only|Using the MyoPro wearable robotic orthosis only
223956107|NCT05386537|OTHER|Games only|Using VR-video games only
223956108|NCT05386537|OTHER|Control|conventional UE therapy at a rehabilitation facility
223956109|NCT00300339|DRUG|SL650472, Clopidogrel|
223956110|NCT02540915|OTHER|Standard of Care - Registry|Standard of Care - Registry
223956111|NCT01239641|PROCEDURE|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
224291165|NCT03579134|DEVICE|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
223540899|NCT02920307|PROCEDURE|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
223540900|NCT00997789|DRUG|Rebamide|Rebamipide 100 mg Tablet, three times a day
223540901|NCT02843412|PROCEDURE|choose two tumor tissue paraffin blocks|
223540902|NCT02537730|DEVICE|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
223540903|NCT02537730|DEVICE|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
223540904|NCT02537730|DEVICE|comfilcon A|contact lens
223540905|NCT02235571|BEHAVIORAL|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
223956112|NCT03622372|PROCEDURE|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
223956113|NCT03622372|DEVICE|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
223956114|NCT03622372|DEVICE|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
223956115|NCT04176549|OTHER|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
223956116|NCT04176549|OTHER|Management of termination of pregnancy|Surgical termination of pregnancy
223956117|NCT04176549|OTHER|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
223956118|NCT02400749|DRUG|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
223956119|NCT02400749|DRUG|Placebo|Placebo tablets will be provided to sites in blister cards.
224291166|NCT03579134|OTHER|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
224291167|NCT02221596|DIETARY_SUPPLEMENT|vitamin D|50,000IU/wk of vitamin D3
224107447|NCT05284006|DIAGNOSTIC_TEST|Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.|This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
223956120|NCT04543669|BIOLOGICAL|Adacel®|Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
224107448|NCT06569537|DRUG|Lidocaine topical|4%
224107449|NCT06569537|DRUG|BLT|Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
224107450|NCT05108324|PROCEDURE|zygomatic implant|2 zygomatic implants and 2 anterior conventional implant
224107451|NCT05108324|PROCEDURE|conventional implant|patients will receive 4 conventional dental implant
224107452|NCT03126136|DEVICE|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
224107453|NCT06062368|BEHAVIORAL|Rate of Entry|The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
224107454|NCT02819596|DRUG|Savolitinib|
224107455|NCT02819596|DRUG|MEDI4736|
224107456|NCT02819596|DRUG|Tremelimumab|
224107457|NCT02983084|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
224107458|NCT02911987|OTHER|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
224107459|NCT02911987|OTHER|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
224107460|NCT03846362|OTHER|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2\>0,1% and initial intermediate risk
224107461|NCT02242279|DRUG|BEA 2180 BR|
224107462|NCT02242279|DRUG|Tiotropium|
224107463|NCT02242279|DRUG|Placebo|
224107464|NCT00156728|DEVICE|Vitatron biventricular pacemaker|
223956121|NCT05776329|BEHAVIORAL|AIA-D|"The total energy contribution (1800 kcal/d) is 20% from protein, 25% from lipids, and 55% from carbohydrates. The recommendations include increasing protein intake primarily from plant sources, limiting the intake of red and processed meat, reducing refined sugar, and moderating dairy consumption. It also includes a list of locally produced and seasonal fruits and vegetables and a list of selected ingredients with anti-inflammatory properties to elaborate their foods. Participants will attend 3 motivational sessions of 1 h every two weeks. Besides nutrition and health, the motivational talks focused on the environmental impact of sustainability. Session 1: Planetary healthy diet. The inflammatory potential of diet. Explanation of the program. Session 2. Effect of ultra-processed food on health. Session 3. Healthy diets.~Follow-up information, recipes, and pictures of dishes that meet the given recommendations will be sent once a week through closed social media groups."
224107465|NCT01819935|DRUG|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
224107466|NCT01819935|DRUG|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
224107467|NCT02571413|OTHER|score before teaching|score the check-point of correct INCS usage before teaching
224291168|NCT02221596|OTHER|aerobic training|7 days of treadmill training during the 13th week of study
223540906|NCT02391324|PROCEDURE|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
223540907|NCT02391324|PROCEDURE|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
224107468|NCT02571413|OTHER|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
224107469|NCT02571413|OTHER|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
224107470|NCT01419990|DRUG|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
224107471|NCT01419990|DRUG|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
224107472|NCT01419990|DRUG|Placebo|Placebo oral capsules, qd, 10 days
224107473|NCT00488943|DEVICE|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
224107474|NCT03429647|DIAGNOSTIC_TEST|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
224291169|NCT03302377|BEHAVIORAL|physical activity counseling & Fitbit|Participants will receive individual counseling \& guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
224291170|NCT03381937|OTHER|speech trial|speech trial during different ventilation conditions
224107475|NCT00080210|DRUG|Puricase|
224107476|NCT04133753|BEHAVIORAL|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
223540908|NCT02391324|PROCEDURE|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
223723847|NCT03598985|DIAGNOSTIC_TEST|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
223956122|NCT05776329|BEHAVIORAL|CONV-D|"CONV-D is based on general healthy diet recommendations. The total energy contribution (1800 kcal/d) was 20% from protein, 25% from lipids, and 55% from carbohydrates.~Among the recommended food groups are fruits (5 times a day), vegetables (5 times a day), cereals (3 times a day), legumes (3 times a day), dairy products (2 times a day), food of animal origin (3 times per day).~Participants in the CONV-D group will attend one motivational and nutritional orientation session on day 1 of the intervention.~Session 1. Food and nutrition. Obesity and diet. General healthy diet recommendations. Delivery of material (table of food equivalents).~Follow-up information will be sent once a week through closed social media groups."
223956123|NCT03647800|BIOLOGICAL|APVO436|APVO436
223956124|NCT02240810|DEVICE|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
223956125|NCT06005116|RADIATION|[68Ga]-NOTA-SGC8|Participants will be irrigated with \[68Ga\]-NOTA-SGC8 intravesically, with 0.05mCi/kg per person per time according to body weight, no more than 5mCi. The participants will be instructed to urinate cleanly before irrigation, and then irrigated \[68Ga\]-NOTA-SGC8 into the bladder via catheter for 30 minutes to make full contact between the injection and tumor. After 30 minutes, the injection will be withdrawn and 300ml normal saline will be injected into the bladder to maintain the shape of the bladder.
223956126|NCT04620265|OTHER|Antigravity treadmill training 100% weight bearing|This group received antigravity treadmill training 100% weight bearing and conventional exercise program.
223956127|NCT04620265|OTHER|Antigravity treadmill training 75% weight bearing|This group received antigravity treadmill training 75% weight bearing and conventional exercise program.
223956128|NCT04620265|OTHER|Antigravity treadmill training 50% weight bearing|This group received antigravity treadmill training 50% weight bearing and conventional exercise program.
223956129|NCT04620265|OTHER|Antigravity treadmill training 25% weight bearing|This group received antigravity treadmill training 25% weight bearing and conventional exercise program.
223956130|NCT04620265|OTHER|The conventional exercise program|This group received the conventional exercise program only.
223956131|NCT04425252|DRUG|Brequinar|DHODH inhibitor, 100 mg daily x 5 days
223956132|NCT04425252|OTHER|Standard of Care|Standard of Care per institutional guidelines for COVID-19 patients
223956133|NCT05363839|DRUG|ACH-000029|ACH-000029 will be administered orally via a capsule.
223956134|NCT05363839|DRUG|Placebo|Placebo will be administered orally via a capsule.
224107477|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
224107478|NCT01157169|DRUG|Buprenorphine|8 mg Sublingual Tablets
224107479|NCT03905772|OTHER|Voluntary exercise|The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
224107480|NCT03905772|OTHER|Wide pulse responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.
224107481|NCT03905772|OTHER|Wide pulse non responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.
223956135|NCT01458288|DRUG|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
224107482|NCT03905772|OTHER|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
224107483|NCT03442127|BEHAVIORAL|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
224107484|NCT06034223|OTHER|Proprioceptive training using head mounted laser|Exercises include head relocation practice, i.e., relocating the head back to the natural head posture and to pre-determined positions in range with eyes open using feedback from a laser attached to their head. And then tracing the figure of eight with the help of laser.
223540909|NCT05278026|OTHER|guideline recommended routine treatment|
223540910|NCT02365181|PROCEDURE|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
223540911|NCT02365181|PROCEDURE|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
223540912|NCT02365181|DRUG|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
223540913|NCT05850143|DRUG|Dexamethasone|Oral Dexamethasone a longer and potent corticosteroid with lesser sideffects and good compliance
223540914|NCT05850143|DRUG|Prednisolone|Oral Multidose Prednisolone
223540915|NCT06307847|DRUG|SP5M001 inj|pre-filled syringe
223540916|NCT06307847|DRUG|Synovian inj|pre-filled syringe
223540917|NCT01344798|BIOLOGICAL|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
223540918|NCT04530201|DEVICE|Colli-Pee Small Volumes (10 mL) device|Women will self-collect two first-void urine samples at home the day prior to colposcopy using the new generation Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube will be prefilled with a non-toxic nucleic acid preservative including an internal process control.
223723848|NCT04040114|DEVICE|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
223723849|NCT03446469|OTHER|Fascial Manipulation|Myofascial release of densified centers of coordination
223723850|NCT04957693|BEHAVIORAL|vegan diet and lifestyle changes|vegan diet and lifestyle changes
223723851|NCT05487989|OTHER|Clinical examen|MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
223723852|NCT06205004|OTHER|Questionnaires|In the present study, the investigators aim to investigate the prevalence and effects of IA on the psychosocial well-being among adults in Hong Kong by measuring the level of Internet use, depression, anxiety, sleep quality, QOL together with basic demographic data in the current situation of COVID with popularity of Metaverse.
223723853|NCT03789344|OTHER|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
223956136|NCT01156922|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
223956137|NCT01448447|DEVICE|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
223956138|NCT01448447|DEVICE|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
223956139|NCT03310372|RADIATION|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
223956140|NCT03310372|DRUG|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
223956141|NCT00183222|DRUG|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
223956142|NCT04792541|OTHER|HY containing gel; GUM® Afta Clear Gel, Sunstar|
223956143|NCT04792541|OTHER|saline solution|
223956144|NCT04631341|DIETARY_SUPPLEMENT|Melatonin|Melatonin 5mg every night, for one year
223956145|NCT04221308|DEVICE|Single port laparoscopic systems|The first assistant handles the scope from the patient's right side. The second assistant, who is positioned between the legs of the patient, inserts a uterine manipulator (Rumi System; Cooper Surgical, CT). At the beginning of the surgery, a 1.5 to 2.5 cm vertical incision is made within the umbilicus using the open Hasson approach. After the bottom retractor ring of the wound retractor component of the Octo-Port is inverted (DalimSurgNet, Seoul, Korea), it is inserted through the incision deep in the peritoneum. Carbon dioxide is insufflated through the gas valve of the Octo-Port to maintain intra-abdominal pressure at 10 to 12 mm Hg. Through the 10 mm channels of the Octo-Port, a 10 mm, 30° rigid laparoscope is introduced. Rigid laparoscopic instruments are introduced through the 5 mm channels of the Octo-Port. The utero-ovarian ligament or infundibulopelvic ligament, uterine vessels, and uterine ligaments are transected by using the 5 mm LigaSure vessel sealer device
224107485|NCT06034223|OTHER|Conventional Physical therpay|Conventional physical therapy for mechanical neck pain which includes cervical range of motion (flexion, extension, lateral rotation, and rotation), neck isometric exercises, stretching's (scalene, trapezius, SCM) and TENS with heating pad.
224107486|NCT02606773|DRUG|Ascorbic Acid|Ascorbic acid in different ways and doses
223956146|NCT03709056|DRUG|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
223540919|NCT00429754|DRUG|Aprepitant|
223540920|NCT03159182|DEVICE|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
223540921|NCT03159182|DEVICE|Pressure garment|Custom made fabric pressure garment
223540922|NCT03489044|DRUG|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
223540923|NCT03489044|DRUG|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
223540924|NCT05924139|DIETARY_SUPPLEMENT|Omega-3 fatty acid|6 capsules per day of 3840 mg that included 1950 mg EPA and 1350 mg DHA
223540925|NCT05924139|DIETARY_SUPPLEMENT|Placebo|4 capsules per day of coconut oil
223540926|NCT01891981|DRUG|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
223540927|NCT00985647|DRUG|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
224107487|NCT03251690|DRUG|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
223956147|NCT03709056|DRUG|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
223956148|NCT01707277|OTHER|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
223540928|NCT03965182|DRUG|PEG|2 sachets of PEG will be used as the bowel prep regimen.
223723854|NCT03789344|OTHER|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
223723855|NCT03789344|OTHER|blank control|Blank control subjects would be observed only during this investigation.
223956149|NCT01707277|OTHER|Usual care|Usual pahramacological treatment
223956150|NCT03741985|BEHAVIORAL|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
223956151|NCT03741985|BEHAVIORAL|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
223956152|NCT02364674|RADIATION|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
223956153|NCT01717625|DRUG|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
223956154|NCT03362853|DRUG|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
223956155|NCT03362853|DRUG|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
224107488|NCT03251690|DRUG|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
223956156|NCT03362853|DRUG|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
223956157|NCT03362853|DRUG|Placebo oral capsule|Receive a single dose in a fasting state
223956158|NCT03438968|BEHAVIORAL|Exercise training|Cardiac Rehabilitation exercise training
223540929|NCT03965182|DRUG|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
223956159|NCT01279447|DRUG|0.25% Bupivacaine|10cc, single dose, US guided injection
223956160|NCT01279447|DRUG|Normal Saline|10cc, single dose, US guided injection
223956161|NCT03338491|BEHAVIORAL|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
223956162|NCT03338491|BEHAVIORAL|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer \& Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
223540930|NCT03965182|DRUG|SPMC|2 sachets will be administered as the bowel prep regimen.
223540931|NCT05055076|DEVICE|PODEYE TORIC|Patients will be contacted consecutively and will be enrolled after the patient informed leaflet has been given to them and after obtaining their consent to the scientific use of their data collected retrospectively (preoperative, surgery, postoperative routine visits). Patients will only be enrolled after the routine 4-6 months visit has been performed.
223540932|NCT00529269|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223540933|NCT05361850|PROCEDURE|Extubation|Removal of the endotracheal tube
223956163|NCT01215253|DRUG|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
223956164|NCT03733860|PROCEDURE|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
224107489|NCT05295329|DRUG|Compound Danshen Dropping Pills|use Compound Danshen Dropping Pills
224107490|NCT05295329|DRUG|Placebo|use placebo
224107491|NCT05337449|OTHER|silver diamine fluoride|silver diamine fluoride is a colorless with high PH topical fluoride solution of 38% weight/volume use for arresting early childhood caries
223540934|NCT01111162|BIOLOGICAL|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
223723856|NCT05686551|DRUG|Tominersen 60 mg|60 mg tominersen administered intrathecally every 16 weeks (Q16W).
223956165|NCT03733860|PROCEDURE|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
223540935|NCT01123226|PROCEDURE|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
223540936|NCT01123226|PROCEDURE|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
224107492|NCT05337449|OTHER|conventional composite resin restoration|Dental composite resins are dental cement made of synthetic resins which were insoluble, of good tooth-like appearance, insensitive to dehydration, and easy to manipulate.
224107493|NCT04222621|OTHER|Pregnant women without intervention|Pregnant women with those exposures of interest determined in specific research based on the registry
223956166|NCT03733860|PROCEDURE|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
224107494|NCT01123889|BIOLOGICAL|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
223956167|NCT05612113|BEHAVIORAL|Live Supervision + Session Goal Formulation|"Read under Arms"
223956168|NCT05612113|OTHER|Session Goal Formulation|"Read under Arms"
223956169|NCT02162927|DIETARY_SUPPLEMENT|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
223956170|NCT02162927|DIETARY_SUPPLEMENT|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
223956171|NCT03374423|PROCEDURE|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
224107495|NCT01123889|DRUG|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
224107496|NCT02857712|DRUG|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
224107497|NCT00117962|BIOLOGICAL|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
224107498|NCT00117962|DRUG|carboplatin|AUC = 5 q 21 days for 4 cycles
224107499|NCT00117962|DRUG|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
223723857|NCT05686551|DRUG|Placebo|Matching placebo administered intrathecally Q16W.
224107500|NCT00117962|RADIATION|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
223723858|NCT05686551|DRUG|Tominersen 100 mg|100 mg tominersen administered intrathecally Q16W.
223723859|NCT02862444|OTHER|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
224107501|NCT03730389|DEVICE|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
224107502|NCT03551886|BEHAVIORAL|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
223540937|NCT04612829|DEVICE|Medistus Antivirus Lozenges|A blend of Kistosyn Extract with Gum Arabic
223540938|NCT00039169|DRUG|ortataxel|
223540939|NCT00318669|DRUG|Paroxetine hydrochloride hydrate|
223540940|NCT03754322|DIAGNOSTIC_TEST|LAMP|LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
223540941|NCT03754322|DIAGNOSTIC_TEST|Microscopy/RDT|Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
223540942|NCT04157881|DRUG|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
223540943|NCT04157881|DRUG|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
224107503|NCT03551886|BEHAVIORAL|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
223540944|NCT05670639|BEHAVIORAL|CAPABLE Care Partner|The CAPABLE Care Partner intervention consists of three components: 1) up to 3 sessions with a Care Partner Support person focused on developing action plans for self-care goals of the care partner 2) educational materials provided in a folder at the beginning of the program 3) inclusion in the CAPABLE clinician visits as deemed appropriate by the client, CAPABLE clinicians, and care partner
223540945|NCT03215498|DRUG|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
223956172|NCT03374423|PROCEDURE|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
224107504|NCT02928419|DRUG|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
224107505|NCT02928419|OTHER|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts \< 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
224107506|NCT02928419|DRUG|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
223956173|NCT04929444|OTHER|Training on vertigo|"Online training on vertigo management in primary care with a face-to-face session.~On the one hand, the course will contain theoretical content and clinical cases will be used as the methodology of the course, with feedback paths for each correct or incorrect answer from the students and videos recorded expressly for the course. In addition, there will be a face-to-face session where all participants must perform the diagnostic and therapeutic maneuvers proposed in the course, to evaluate the use of the training and also to standardize the way of doing them for the study"
223956174|NCT01195402|PROCEDURE|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
224107507|NCT04732377|PROCEDURE|erector spinae block with bupivacaine|"Group (A) (control group):~Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5."
224107508|NCT04732377|PROCEDURE|erector spinae block with bupivacaine and dexmedetomidine|Patient will receive 20ml 0.25% levobupivacaine above + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5.
224107509|NCT01330381|DRUG|prucalopride|"prucalopride~* subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~* subjects with weight \>50 kg: prucalopride 2 mg tablet once daily"
224291171|NCT04702347|DIAGNOSTIC_TEST|Urine biomarker|Bladder urine samples (\> 10 ml) will be collected for cytology and for the methylation test before cystoscopy. Prior to semirigid and flexible ureteroscopy, urine specimens from the upper urinary tract will be obtained via a ureteral catheter.
223723860|NCT02741180|OTHER|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
223723861|NCT02741180|OTHER|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
223723862|NCT00262574|DRUG|Nesiritide,|PCI
224291172|NCT00038831|DRUG|Mylotarg|Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.
224291173|NCT00038831|DRUG|Fludarabine|30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
224291174|NCT00038831|DRUG|Melphalan|140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
223540946|NCT03215498|DRUG|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
223723863|NCT01217814|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223723864|NCT01217814|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223723865|NCT01217814|DRUG|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224107510|NCT01330381|DRUG|Placebo|Matching oral solution or oral tablets given once daily
223956175|NCT01024023|DEVICE|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
223723866|NCT01217814|DRUG|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
223723867|NCT01217814|DRUG|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
223956176|NCT06129656|OTHER|Routine diagnostics|Data collection of routine diagnostics
223956177|NCT06129656|OTHER|Routine treatment|Data collection of routine treatment
223956178|NCT06463509|OTHER|Establishment of an in-deepth tumor profiling platform|In-depth tumor profiling beyond genomics
223956179|NCT06299345|OTHER|Motor imagery training|MI for this study took the form of non-guided first-person mental practice. First-person imagery was explained to each participant where they imagined performing the target skill through their own eyes rather than if they were a bystander watching someone else do the task (third person).
223956180|NCT06299345|OTHER|NO motor imagery training|The participants performed the physical task only. It is a mirror tracing game that requires participants to trace a star shape viewed through a mirror, going as fast as possible while staying within the lines.
223956181|NCT00949234|DRUG|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance \<30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
223956182|NCT00166075|PROCEDURE|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
223956183|NCT02020902|OTHER|Cetrizine hydrochloride|As provided on the patient information leaflet
223956184|NCT05728619|DRUG|HTMC0435|Oral administration.
223956185|NCT05728619|DRUG|Temozolomide|Oral administration.
223723868|NCT01119391|BEHAVIORAL|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
223723869|NCT06963736|BEHAVIORAL|Blue light|Blue light blocking glasses use and discouraged late night eating.
223956186|NCT04464148|DRUG|Pregnenolone 250 mg|Pregnenolone 250 mg capsule BID (500 mg QD total)
223956187|NCT04464148|DRUG|Pregnenolone 400 mg|Pregnenolone 400 mg capsule BID (800 mg QD total)
223956188|NCT03785756|DRUG|Ibuprofen 300 mg Oral Tablet|2 × 300 mg tablets at Hours 0 and 12
223956189|NCT03785756|DRUG|Ibuprofen 200 mg Oral Tablet|2 × 200 mg tablets at Hours 0, 8, and 16
224107511|NCT01330381|DRUG|PEG 4000|
224107512|NCT03846947|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
224107513|NCT03245476|OTHER|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
224107514|NCT03245476|OTHER|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
223723870|NCT06963736|BEHAVIORAL|Eating|Encouraged not to eat past 8pm.
223723871|NCT06963736|BEHAVIORAL|Standing|Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
223723872|NCT02018588|DIETARY_SUPPLEMENT|tryptophan|graded levels of tryptophan will be given to each subject
223956190|NCT03785756|DRUG|Placebo of PR tablet|2 tablets up to four times in 24 hours
223956191|NCT03785756|DRUG|Placebo of IR tablet|2 tablets up to four times in 24 hours
223956192|NCT03788941|PROCEDURE|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
223956193|NCT01706055|BIOLOGICAL|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
223723873|NCT05853419|DEVICE|Robotic-assisted PCI|Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer
223723874|NCT06258642|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, Q2W, iv
223723875|NCT06258642|DRUG|Anlotinib|12 mg, qd, po for 2 consecutive weeks and then discontinued for 1 week.
223723876|NCT06851767|GENETIC|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
223723877|NCT06851767|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
223723878|NCT06851767|DRUG|Palifermin|Mucositis prophylaxis: As is standard practice prior to busulfan conditioning, IV infusion of keratinocyte growth factor (palifermin) will be administered at 60 micrograms/kg/day for 3 days before initiation of busulfan (days -6 to -4), as well as for the 3 days following study agent administration (days 1 to 3).
223956194|NCT03821285|PROCEDURE|Pulmonary Rehabilitation|Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
223956195|NCT01539902|BIOLOGICAL|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
224107515|NCT02187640|BEHAVIORAL|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
224107516|NCT02187640|BEHAVIORAL|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
224107517|NCT03414125|OTHER|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
223540947|NCT04865666|DEVICE|movr mHealth App|The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
223723879|NCT06851767|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). For this study, busulfan is administered once daily (3 mg/kg) x 2 days, targeting a daily busulfan AUC of 4500-6500 micromol\*min/L or a cumulative AUC of 9000 micromol\*min/L (for the 2 days of therapy if levels are available. Busulfan will be infused over 3 hours each day as per standard clinical practice.
223956196|NCT01539902|DRUG|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
223956197|NCT05500313|BEHAVIORAL|Hypno-breastfeeding Education|The hypnobreastfeeding education program consists of 4 sessions and 12 hours. It includes information about breastfeeding, mental preparation for the breastfeeding experience, emotional studies, motivational practices, awareness and self-compassion practices.
223956198|NCT05500313|BEHAVIORAL|Experimental: Standart Breastfeeding Education|The standard breastfeeding education program consists of 1 session and 3 hours. It contains only information and applications about breastfeeding.
223956199|NCT05466760|RADIATION|PET/MR|Study 1- pre-NAC PET/MR; Study 2- first follow-up PET/MR is performed after first dose of NAC; Study 3, second follow-up PET/MR is performed after third or fourth dose of the NAC. The NAC protocol is mainly antracycline-based followed by taxane-based regimen for a total of 6-8 cycles.
224291175|NCT00038831|DRUG|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
224291176|NCT00038831|PROCEDURE|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
223540948|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day
223540949|NCT00114127|DRUG|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
223723880|NCT06851767|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. A one-time dose \>5(SqrRoot) 10\^6 base-edited cells/kg body weight will be administered to each participant. The exact dosage depends on the number of viable cells that are repaired, cryopreserved, and thawed. The study agent will be administered by IV infusion in a volume of approximately 50 mL over about 15-30 minutes, in accordance with NIH CC DTM infusion policy.
223723881|NCT04600128|OTHER|Dairy-based greek yogurt|Plain Greek yogurt (2% M.F; Danone, Boucherville, Quebec, Canada)
223723882|NCT04600128|OTHER|Dairy-based cheddar cheese|Mild cheddar cheese (31% M.F. ; Armstrong, Saputo Dairy Products, Saint-Laurent, Quebec, Canada)
223723883|NCT04600128|OTHER|Plant-based yogurt|Plain Greek yogurt alternative (Daiya, Rupert Street, Vancouver, Canada)
223956200|NCT01131325|DRUG|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
223956201|NCT02192645|DRUG|Sanfujiu|
223956202|NCT02192645|DRUG|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
223956203|NCT03761849|DRUG|RO7234292|Intrathecal injection
223723884|NCT04600128|OTHER|Plant-based cheese|Medium cheddar style block (Daiya, Rupert Street, Vancouver, Canada)
223723885|NCT06136793|BEHAVIORAL|HomeStyles-China|2-arm \~10 week educational intervention
223723886|NCT03591991|DRUG|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
223956204|NCT03761849|DRUG|Placebo|Intrathecal injection
223956205|NCT05851521|DEVICE|Temporary prostatic stent (Exime®)|Placement of temporary prostatic stent (Exime®) following the procedure described in the product information
223956206|NCT05851521|DEVICE|Indwelling catheter|Placement of indwelling catheter
223956207|NCT03001141|OTHER|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
223956208|NCT01996514|DIETARY_SUPPLEMENT|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
223956209|NCT01996514|DIETARY_SUPPLEMENT|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
223956210|NCT01996514|BEHAVIORAL|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
223956211|NCT01996514|BEHAVIORAL|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
223956212|NCT06008665|OTHER|Action Observation Therapy and Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs.~Training Frequency and Guidance: Exercises conducted three times a week,Guidance provided by a therapist.~Training Session Duration: Each session lasts for 35-40 minutes. Warm-up and Cool-down:5-minute warm-up before each session and 5-minute cool-down after each session."
223956213|NCT06008665|OTHER|Otago Exercises|"Strength Training Component:Knee Flexor, Knee Extensor, Hip Adductors, Ankle Planter Flexors, Ankle Dorsi Flexors~Balance Training Component:~Activities include: Walking backwards, Walking in a figure of eight, Heel-toe walking, Standing on one leg, Walking on the heels, Walking on the toes, Heel-toe walking backwards, Standing up from a sitting position, Walking up stairs."
223956214|NCT04645303|DRUG|hyaluronic acid (20 mg/2 mL)|A1-Pulley infiltration for trigger finger
223956215|NCT04645303|DRUG|Triamcinolone acetonide 10mg/ml|A1-Pulley infiltration for trigger finger
223956216|NCT04585048|BEHAVIORAL|Integrated Behavioral Therapy for Selective Mutism|Cognitive Behavioral treatment including 24 weekly sessions
223956217|NCT03933098|BIOLOGICAL|Test Vaccine Vi-DT Typhoid conjugate|"* Manufacturer: SK Bioscience Co., Ltd.~* Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~* Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
223540950|NCT00114127|DRUG|Placebo|60mg placebo 1x per day
223540951|NCT03188263|OTHER|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
223540952|NCT03188263|OTHER|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
223540953|NCT03971162|DRUG|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
223540954|NCT03971162|DRUG|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
223540955|NCT00407719|DRUG|Bevacizumab|
223956218|NCT03933098|BIOLOGICAL|Control Vaccine Typbar TCV®|"* Manufacturer: Bharat Biotech~* Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~* Dose: 0.5 ml"
223956219|NCT06053983|DEVICE|Turbox CRP kit|Quantitative estimation of hs-CRP will be conducted at the beginning of the study and after the treatment period using the Turbox CRP kit, which employs turbidimetry as the method of measurement.
223956220|NCT06053983|DRUG|rosuvastatin 20 mg,|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
223956221|NCT06053983|DRUG|atorvastatin 40 mg|The statin are most commonly used agents for prevention of cardiovascular events and recurrent episodes of ACS. Apart from their anti-lipid actions, statins show pleotropic effects which include their anti-inflammatory role. Atorvastatin and rosuvastatin are both members of statin family and have showed their effectiveness in reduction of inflammatory biomarkers in addition to their lipid lowering effects
223956222|NCT03840993|DRUG|MT-2990|over 16 weeks
223956223|NCT03840993|DRUG|Placebo|over 16 weeks
223956224|NCT02246556|DEVICE|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
223956225|NCT02246556|OTHER|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
223723887|NCT03591991|OTHER|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
223723888|NCT01756898|DRUG|5 mg ASB17061|Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
223723889|NCT01756898|DRUG|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
223723890|NCT01756898|DRUG|10 mg ASB17061|Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
223723891|NCT01756898|DRUG|20 mg ASB17061|Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
223723892|NCT00634530|BEHAVIORAL|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
223956226|NCT02246556|DEVICE|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
223956227|NCT04816539|DEVICE|TetraGraph|Use of two monitoring devices of neuromuscular function during surgery
223956228|NCT01411683|DEVICE|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
223956229|NCT05670600|OTHER|foot and ankle exercise|"Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)"
223956230|NCT03348800|PROCEDURE|Dental anesthesia|A tooth extraction will be performed
223956231|NCT00551954|DRUG|acarbose|100 mg (tablets) t.i.d.
223956232|NCT00551954|DRUG|placebo|one tablet t.i.d.
223956233|NCT02788708|DRUG|Lenvatinib Mesylate|Given PO
223956234|NCT02788708|DRUG|Paclitaxel|Given IV
223956235|NCT02788708|OTHER|Pharmacological Study|Correlative studies
223956236|NCT02213094|DRUG|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
223956237|NCT02213094|DRUG|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
223956238|NCT04160871|BEHAVIORAL|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
223956239|NCT04160871|BEHAVIORAL|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
223956240|NCT00150852|DRUG|Vancomycin|
223540956|NCT05968248|PROCEDURE|MLR-DBS|"An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously. Device: MLR-DBS devices~(1) DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China); (2) Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China); (3) Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
223723893|NCT01730469|DRUG|AT1001 150 mg|AT1001 150mg is available as a capsule
223723894|NCT02959931|OTHER|High Potassium Meal|Breakfast meal that provides \~2400 mg of dietary potassium. Meals are isocaloric.
223956241|NCT00002723|DRUG|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
223723895|NCT02959931|OTHER|Low Potassium Meal|Breakfast meal that provides \~540 mg of potassium. Meals are isocaloric.
223956242|NCT00002723|DRUG|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
223956243|NCT00002723|DRUG|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
223956244|NCT00019344|DRUG|alvocidib|
223956245|NCT05340283|PROCEDURE|physiotherapy|Patients received physiotherapy treatment at home for a certain period of time. Data were collected on the assessments made at the beginning and at the end of the physiotherapy treatment.
223956246|NCT00004250|BIOLOGICAL|dactinomycin|
223956247|NCT00004250|DRUG|isolated limb perfusion|
223956248|NCT00004250|DRUG|melphalan|
223956249|NCT06416345|DEVICE|Cue2Walk|24 weeks of using of the Cue2Walk device in the own living environment + 8 weeks of naturalistic follow-up
223956250|NCT06416345|OTHER|Usual Care|24 weeks of receiving usual care + 8 weeks of using of the Cue2Walk device in the own living environment
223956251|NCT00489697|DEVICE|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
223956252|NCT00728325|BEHAVIORAL|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
223956253|NCT00728325|BEHAVIORAL|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
223956254|NCT00988429|DRUG|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
223956255|NCT00988429|DRUG|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
223956256|NCT00988429|DRUG|Placebo|Placebo tablet given QD
223956257|NCT00004045|DRUG|exatecan mesylate|
223956258|NCT04315428|BEHAVIORAL|swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
223956259|NCT04315428|BEHAVIORAL|no swaddling|The two experimenters together evaluate the child's state of awakening throughout the experiment. If the child is considered by both experimenters to be too restless or too sleepy, the experiment is immediately stopped and postponed
223956260|NCT02463292|OTHER|no intervention|no intervention
223956261|NCT01074229|DRUG|Placebo|placebo injection
223956262|NCT01074229|DRUG|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
223956263|NCT01074229|DRUG|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
223956264|NCT03555617|DRUG|TD-1473|oral capsule/tablet, QD
223956265|NCT03555617|DRUG|Itraconazole|oral solution, QD
223956266|NCT02964234|BEHAVIORAL|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
223540957|NCT05968248|PROCEDURE|Conventional rehabilitation group|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into theMLR. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.The latter will receive the same rehabilitation training under the face-to-face guidance of specialists except for the power-on (sham stimulation, power-on stimulation parameter is 0).
223540958|NCT00881894|DRUG|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
223540959|NCT01943786|DRUG|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
223723896|NCT03918083|BEHAVIORAL|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
223956267|NCT02964234|BEHAVIORAL|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
223956268|NCT00022399|DRUG|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
223956269|NCT00022399|DRUG|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
223956270|NCT01502241|DRUG|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
223956271|NCT01502241|RADIATION|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
223956272|NCT02994329|DEVICE|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
223956273|NCT02165696|OTHER|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
223956274|NCT02165696|OTHER|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
223956275|NCT03009123|OTHER|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
223956276|NCT04515745|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
223956277|NCT04515745|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
223956278|NCT02327975|OTHER|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
223956279|NCT02327975|OTHER|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
223540960|NCT00421148|DRUG|Sugammadex 0.5 mg/kg|IV infusion
223540961|NCT00421148|DRUG|Sugammadex 1 mg/kg|IV infusion
223540962|NCT00421148|DRUG|Sugammadex 2 mg/kg|IV infusion
223540963|NCT00421148|DRUG|Sugammadex 4 mg/kg|IV infusion
223956280|NCT02327975|OTHER|Control group|No received intervention.
223956281|NCT01727076|OTHER|Laboratory Biomarker Analysis|Correlative studies
223956282|NCT01727076|OTHER|Pharmacological Study|Correlative studies
223956283|NCT01727076|BIOLOGICAL|Recombinant Human Interleukin-15|Given SC
223956284|NCT04392648|DRUG|TAK-573|TAK-573 intravenous infusion.
223956285|NCT04392648|DRUG|Pomalidomide|Pomalidomide capsules orally.
223956286|NCT04392648|DRUG|Bortezomib|Bortezomib injection subcutaneously.
223956287|NCT04392648|DRUG|Cyclophosphamide|Cyclophosphamide tablets orally.
223540964|NCT00421148|DRUG|Placebo|IV infusion
223540965|NCT00421148|DRUG|Rocuronium bromide|IV infusion
223956288|NCT04392648|DRUG|Dexamethasone|Dexamethasone tablets orally.
223540966|NCT04991220|PROCEDURE|Preoxygenation|Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
223956289|NCT03669419|DIAGNOSTIC_TEST|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
223956290|NCT01107509|DRUG|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
223956291|NCT00234832|DRUG|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
223956292|NCT00234832|DRUG|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
223956293|NCT00234832|DRUG|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
223540967|NCT03576261|OTHER|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
223540968|NCT03576261|DIAGNOSTIC_TEST|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
223540969|NCT03222674|BIOLOGICAL|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
223540970|NCT01343836|OTHER|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
223540971|NCT01343836|OTHER|Saline|Intratendinous saline injection with eccentric exercises
223540972|NCT00216918|DRUG|Atomoxetine Hydrochloride|
223540973|NCT00469833|DRUG|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
223723897|NCT01961193|DEVICE|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
223956294|NCT02363153|OTHER|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
223956295|NCT02163499|DRUG|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
223956296|NCT06187155|OTHER|INR self-management|will receive full education class of minimum one-hour time and training about how to interpret INR levels independently and adjust their medication dose according to a pre-determined dose-INR schedule.
223956297|NCT00091676|BIOLOGICAL|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
223956298|NCT00091676|BIOLOGICAL|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
223956299|NCT03189550|PROCEDURE|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
223956300|NCT03189550|PROCEDURE|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
223540974|NCT00977639|PROCEDURE|Pathwork TOO test|
223540975|NCT01799343|OTHER|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
223540976|NCT01253369|DRUG|Pazopanib|
223956301|NCT03189550|PROCEDURE|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
223956302|NCT05635994|DIAGNOSTIC_TEST|AID strategy|AID strategy encompasses a hierarchical algorithm intended to investigate both obstructive and non-obstructive causes of myocardial ischaemia. AID strategy starts with an ICA. Angiographically severe-grade stenosis (≥70%) can be safely considered flow-limiting without further physiological assessment. Conversely, by means of a pressure guidewire, intermediate-grade stenosis should be evaluated with FFR and/or NHPR in order to determine if they are physiologically significant. Those patients with non-obstructive CAD or normal epicardial coronary arteries should undergo functional coronary tests to investigate the presence of microcirculatory and vasomotor coronary disorders, which would account for non-obstructive causes of ischaemia.
223956303|NCT02646878|DEVICE|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
223956304|NCT00816816|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
223956305|NCT01412398|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
223956306|NCT03536520|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223956307|NCT03536520|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223956308|NCT03369119|DRUG|Montelukast 4 Mg Oral Granule|
223540977|NCT04123301|DEVICE|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
223956309|NCT03369119|DRUG|Placebos|
223956310|NCT01701089|DRUG|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
223956311|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for 14 days
223956312|NCT01701089|DRUG|RO4602522|Multiple doses of RO4602522 for up to 17 days
223956313|NCT00559871|DRUG|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
223956314|NCT01540474|BIOLOGICAL|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
223956315|NCT01540474|BIOLOGICAL|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
223956316|NCT01540474|BIOLOGICAL|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
223956317|NCT01540474|OTHER|Controlled group-Challenged Only: no vaccination|The control group participated in the primary malaria sporozoite challenge.E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
223956318|NCT02261922|DRUG|ticagrelor|
223956319|NCT02261922|DRUG|prasugrel|
223956320|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
223540978|NCT04123301|DEVICE|Sham Theta Burst Stimulation (TBS)|The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
223540979|NCT04268069|DRUG|PL9643 Ophthalmic Solution|PL9643 Ophthalmic Solution as topical ophthalmic drops administered bilaterally for 12 weeks.
223540980|NCT04268069|DRUG|Placebo Ophthalmic Solution|Placebo solution as topical ophthalmic drops administered bilaterally for 12 weeks.
223540981|NCT02965638|OTHER|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
223540982|NCT03289533|DRUG|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
223540983|NCT03289533|DRUG|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
223540984|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
223540985|NCT01030822|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
223540986|NCT04193735|DIAGNOSTIC_TEST|MRI scans after a liquid meal|Participants will be scanned fasted, then receive a liquid meal, then be scanned every half hour, seven times
223540987|NCT06450743|DIAGNOSTIC_TEST|Lymphocyte Immunophenotyping Test|Absolute enumeration of peripheral blood lymphocyte subpopulations
223540988|NCT00539240|DRUG|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
223540989|NCT00539240|DRUG|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast \& Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
223540990|NCT00539240|DRUG|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
223540991|NCT02812745|DEVICE|recording of cardiac output|
223540992|NCT02812745|DEVICE|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
223540993|NCT04442568|OTHER|ERAS|early mobilisation, early oral intake, early discharge
223723898|NCT01961193|DEVICE|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
223723899|NCT05004870|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
223723900|NCT05298631|OTHER|Stabilization exercises|The activation of deep cervical muscle to reduce the activity of surface muscles is known as stabilization exercises
223956321|NCT00857311|BIOLOGICAL|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
223956322|NCT00857311|BIOLOGICAL|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
223540994|NCT00561522|DRUG|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
223540995|NCT00561522|OTHER|No other preventive treatment|No other preventive treatment
223540996|NCT01658085|DEVICE|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
223956323|NCT00857311|BIOLOGICAL|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
223956324|NCT04280978|DIAGNOSTIC_TEST|ABI ABC|"The assessor will administer ABaCo test through a computer device and she will marked the responses on a paper sheet. Video recordings are needed only to allow an impartial scoring. In fact, an external trained judge will do the scoring.~Furthermore the linguistic abilities will be assessed through the administration of some subtests of the Italian battery BVL 4-12. In particular, the researcher will administer the following subtests: naming, lexical comprehension and grammatical comprehension.~Moreover, some neuropsychological abilities will be analysed using the test BVN 5-11. In addition, the theory of mind and the non-verbal IQ will be assessed.~The Socio-Economic-Status of the family involved in the research will also be investigated, considering its importance on the rehabilitation outcomes."
223956325|NCT03470701|OTHER|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
223956326|NCT00004806|GENETIC|Cystic fibrosis transmembrane conductance regulator|
223956327|NCT00591084|DRUG|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
223956328|NCT00591084|DRUG|placebo|infusion placebo (group B)once a day and continued for 14 days
223956329|NCT00591084|DRUG|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
223956330|NCT02862288|DEVICE|Microwave ablation with Acculis Accu2i pMTA Applicator|
223956331|NCT01697982|BEHAVIORAL|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
223540997|NCT01658085|DEVICE|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
223540998|NCT02811822|DRUG|GMI-1271|
223540999|NCT04765566|DEVICE|Endovascular revascularization of peripheral arteries|Endovascular revascularization of peripheral arteries involves placement of a self-expanding Nitinol Stent encapsulated with ePTFE in diseased vessel segments
223541000|NCT06103344|BEHAVIORAL|4-7-8 Breathing Exercise Training|Participants in the intervention group will be taught 4-7-8 breathing exercises collectively, and the training will be repeated on specified days (twice a week for a total of 4 weeks). During the training, it will be checked whether each participant in the intervention group can perform the breathing exercise correctly and feedback will be given. Participants who fail to implement the exercise will be excluded from the study. 4-7-8 breathing exercise training, prepared in accordance with the literature, will be given by the assistant researcher who has training and certification in breathing exercises. Training will be planned in an empty classroom, for approximately 20 minutes and at the students' end time. Thus, educational activities in the institution will not be disrupted.
223723901|NCT05298631|OTHER|Dynamic exercises|The exercises in which muscle tension remains constant but muscle length changes is known as dynamic exercises
224107518|NCT03414125|OTHER|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
224107519|NCT00552799|DRUG|Penicillin VK|Biconcave tablet 250mg oral, b.d.
223541001|NCT00608049|BEHAVIORAL|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
223541002|NCT00608049|BEHAVIORAL|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
223541003|NCT00608049|BEHAVIORAL|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
223541004|NCT00608049|BEHAVIORAL|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
223541005|NCT01668160|PROCEDURE|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
223541006|NCT00363311|DRUG|Dutasteride|Dutasteride 0.5mg
223956332|NCT01697982|BEHAVIORAL|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
223956333|NCT03101098|PROCEDURE|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
223956334|NCT03101098|PROCEDURE|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
223956335|NCT03110783|BIOLOGICAL|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
224107520|NCT00552799|OTHER|placebo|biconcave tablet matching active comparator as much as possible in size and shape
224107521|NCT00863733|DRUG|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
224107522|NCT03977532|OTHER|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
224107523|NCT04889677|DRUG|Danicopan|
223541007|NCT00363311|DRUG|Matching placebo|Matching placebo
223541008|NCT05085483|DIETARY_SUPPLEMENT|Nutritional Ketogenic Supplement|This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.
223541009|NCT05085483|DIETARY_SUPPLEMENT|Isocaloric placebo supplement|Isocaloric placebo supplement
224107524|NCT04889677|DRUG|Placebo|
224107525|NCT04467541|BIOLOGICAL|Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)|Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
224107526|NCT00068952|DRUG|Edotecarin|
224107527|NCT00068952|DRUG|Temozolomide|
224107528|NCT00068952|DRUG|Carmustine (BCNU)|
224107529|NCT00068952|DRUG|Lomustine (CCNU)|
223956336|NCT06031493|COMBINATION_PRODUCT|Multimodal intervention on sexual dysfunction and quality-of-life|Multimodal intervention includes education on healthy habits, the prevention of vaginal dysfunction using vaginal moisturizers and topical estrogens, and a systematic evaluation of the need of hormone replacement therapy.
223956337|NCT06106776|DRUG|Chimeric Antigen Receptor|This study will evaluate the incidence of cardiac dysfunction at 7 days and 1 month after chimeric antigen receptor-T cell infusion (tisagenlecleucel, axicabtagene ciloleucel e brexucabtagene autoleucel).
223956338|NCT00677742|OTHER|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
223956339|NCT00677742|OTHER|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
224107530|NCT05370248|OTHER|Tidal volume 6 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
224107531|NCT05370248|OTHER|Tidal volume 10 ml/kg|Tidal volume is defined as the amount of air that moves in or out of the lungs with each respiratory cycle, given by the mechanical ventilator.
223541010|NCT01816425|DEVICE|Thermoplastic partial denture|
223541011|NCT01816425|DEVICE|CoCr partial denture|
223541012|NCT03249194|DRUG|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
223541013|NCT01823380|PROCEDURE|Blood test|Blood test
223541014|NCT04624308|DRUG|Toripalimab|Toripalimab 240mg d1，Q3W. Given with TPF during inductive chemotherapy and definitive radiotherapy.
223541015|NCT03313973|PROCEDURE|with self stretching same muscle|with self stretching
223541016|NCT03313973|PROCEDURE|with self stretching of forearm muscles|without self stretching
223541017|NCT04882943|OTHER|questionnaires|Quality of life questionnaires
223541018|NCT04088799|OTHER|No intervention|No intervention
223541019|NCT03980782|OTHER|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
223541020|NCT06388239|DRUG|Apixaban 5MG|Apixaban 5 mg Film-coated tablets
223541021|NCT03167788|DEVICE|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
223541022|NCT03167788|OTHER|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood \& Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
223541023|NCT03130725|PROCEDURE|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
223541024|NCT03130725|PROCEDURE|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
223541025|NCT00442923|DRUG|Coreg|
223541026|NCT01595529|DRUG|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
223541027|NCT01595529|DRUG|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
223541028|NCT01595529|OTHER|Placebo|Placebo to match the other four active treatments
223541029|NCT01595529|DRUG|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
223541030|NCT04016714|DRUG|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
223541031|NCT04016714|DRUG|Prevenar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
223541032|NCT04016714|DRUG|Vaxelis™|Intramuscular 0.5 mL single dose
223541033|NCT04016714|DRUG|M-M-R®II|Subcutaneous 0.5 mL single dose
223956340|NCT04462159|BEHAVIORAL|Risk Reduction Program|Education, exercise, teaching kitchen and nutrition, and psychological support
223956341|NCT05256355|OTHER|musculoskeletal ultrasound|The participants will perform four MSUS examinations which are all videorecorded. All videos will be rated by two blinded raters using the OSAUS assessment tool.
223956342|NCT02920645|OTHER|AVM-related ICH|
223541034|NCT04016714|DRUG|VARIVAX™|Subcutaneous 0.5 mL single dose
223956343|NCT00370747|DRUG|Ecabet|ophthalmic solution 2.83%
223956344|NCT00370747|DRUG|Ecabet|ophthalmic solution 3.70%
223956345|NCT00370747|DRUG|Placebo|
223541035|NCT04029207|PROCEDURE|Cesarean section|Abdominal, operative delivery of the fetus
223541036|NCT05836272|DRUG|Norepinephrine Bitartrate|"The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion."
223541037|NCT05836272|OTHER|Placebo|For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.
224107532|NCT05573165|OTHER|3 hours of preoperative fasting for breast milk|3 hours of preoperative fasting for breast milk
224107533|NCT05573165|OTHER|4 hours of preoperative fasting for breast milk|4 hours of preoperative fasting for breast milk
224107534|NCT03849469|BIOLOGICAL|XmAb®22841|Monoclonal bispecific antibody
224107535|NCT03849469|BIOLOGICAL|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
224107536|NCT00224107|DRUG|Silodosin|8 mg daily for 12 weeks
224107537|NCT00224107|OTHER|Placebo|1 capsule daily for 12 weeks
224107538|NCT05431582|DRUG|ZN-c3|Given by PO 1 time a day with a glass (about 8 ounces) of water
224107539|NCT05431582|DRUG|Bevacizumab|Given by vein over about 30-60 minutes on Day 1 of each cycle
223541038|NCT02073812|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
223541039|NCT02128737|BEHAVIORAL|Sleep|
223541040|NCT05895305|COMBINATION_PRODUCT|Paclitaxel-Coated Pulmonary Balloon Catheter|Subjects with benign airway stenosis will be treated by Airiver pulmonary DCB at index procedure
223541041|NCT04133350|BEHAVIORAL|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
223541042|NCT02246010|DIETARY_SUPPLEMENT|Lactose- free milk|Lactose- free milk
223541043|NCT02067507|BEHAVIORAL|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
223541044|NCT02067507|BEHAVIORAL|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
223541045|NCT02067507|BEHAVIORAL|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
224107540|NCT05431582|DRUG|Pembrolizumab|Given by vein over 30-60 minutes on Day 1 of each cycle.
223541046|NCT02273921|OTHER|EEG recording|EEG is recorded once for each participant
223541047|NCT05669040|OTHER|Pharmacological education|Inform the patient of the medication that is being taken and how it has to be taken; What is it for and the side effects and/or adverse reactions.
224107541|NCT00685178|DRUG|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
224107542|NCT00685178|BEHAVIORAL|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
224107543|NCT00685178|DRUG|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
223541048|NCT05669040|OTHER|Training in the use of MyPlan Aplication|Review of the use of the aplication
223541049|NCT05669040|OTHER|Patient Experience|"* How do you feel?~* Sad feelings and frustration.~* Achievements day by day, think positive.~* Importance of interpersonal relationships.~* Explain activities to relax the mind"
223541050|NCT04707079|DRUG|Duvelisib|Eligible subjects will be given duvelisib orally at a dose of 25 mg BID during each 28-day treatment cycle, for up to 12 cycles.
223541051|NCT00730886|DEVICE|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
223541052|NCT00730886|PROCEDURE|Myomectomy|Invasive surgical procedure for fibroid removal
223541053|NCT01991483|DRUG|LY2928057|Administered intravenously
224107544|NCT04076124|DEVICE|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
223541054|NCT01991483|DRUG|Placebo|Administered intravenously
223541055|NCT04344184|DRUG|L-ascorbic acid|50 mg/kg intravenous vitamin C infusion every 6 hours for up to 96 hours
223541056|NCT04344184|OTHER|Placebo|Dextrose 5% Water
224107545|NCT04076124|DEVICE|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
223541057|NCT03940716|BEHAVIORAL|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (\~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
223541058|NCT02221973|DIETARY_SUPPLEMENT|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
223541059|NCT02665260|DRUG|Cantharidin|cantharidin 0.7% topical liquid
224107546|NCT04076124|DEVICE|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
224107547|NCT02136394|OTHER|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
223541060|NCT02665260|DRUG|Placebo|Placebo topical liquid
223541061|NCT02665260|DEVICE|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
223541062|NCT05528575|DIETARY_SUPPLEMENT|Blueberry, cranberry, green tea extract, cocoa|tablet supplements, available readily.
223541063|NCT05528575|DIETARY_SUPPLEMENT|GOS, Inulin, RS2|Prebiotic combination, Inulin, GOS and RS2
223541064|NCT05528575|DIETARY_SUPPLEMENT|prebiotics and polyphenols|combination of the same prebiotics and polyphenols as above
223541065|NCT05528575|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin, 10g per day
223723902|NCT00787852|DRUG|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily~Maintenance x 2 years\*"
223723903|NCT00787852|DRUG|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib \& Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~1. 50 mg daily 100 mg daily~2. 70 mg daily 100 mg daily~3. 100 mg daily 100 mg daily Maintenance x 2 years\*"
223723904|NCT02984709|BEHAVIORAL|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
223723905|NCT02984709|BEHAVIORAL|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
223956346|NCT04034732|BEHAVIORAL|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
223956347|NCT04034732|BEHAVIORAL|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
223956348|NCT01094665|PROCEDURE|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
223956349|NCT05486988|DRUG|Immunotherapy|PD-1/PD-L1 inhibitors
224107548|NCT00974077|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
224107549|NCT00974077|OTHER|Waiting List Control|Patients receive MBCT with a delay of 6 months.
224107550|NCT01771679|BIOLOGICAL|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
224107551|NCT05134974|DRUG|Phentolamine Ophthalmic Solution 0.75%|0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
224107552|NCT05134974|DRUG|Phentolamine Ophthalmic Solution Vehicle|Phentolamine Ophthalmic Solution Vehicle
224107553|NCT01408537|BIOLOGICAL|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
224107554|NCT03287297|DIAGNOSTIC_TEST|OGTT & HBA1c|oral glucose tolerance test \& HBA1c: by measuring glycated hemoglobin
223541066|NCT01252082|PROCEDURE|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
223541067|NCT01877174|DEVICE|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
223541068|NCT01877174|PROCEDURE|transcarotid stenting|
223541069|NCT01722929|DEVICE|Skin sensor|
223541070|NCT01931917|BEHAVIORAL|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
223541071|NCT01931917|BEHAVIORAL|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
223541072|NCT02305186|DRUG|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
223723906|NCT03758209|PROCEDURE|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
223723907|NCT03758209|PROCEDURE|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
223956350|NCT05486988|DRUG|Chemotherapeutic Agent|2 cycles
223541073|NCT02305186|RADIATION|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
223956351|NCT05486988|DRUG|Chemotherapy|4\~6 cycles
223956352|NCT03274934|BEHAVIORAL|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
223956353|NCT03274934|BEHAVIORAL|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
223956354|NCT03274934|BEHAVIORAL|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
223956355|NCT01330875|OTHER|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
223956356|NCT00365599|DRUG|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
223956357|NCT00365599|DRUG|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
223956358|NCT00992849|DRUG|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
223956359|NCT01799993|DRUG|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
223956360|NCT01799993|DRUG|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
223956361|NCT00160329|DRUG|Atazanavir|300 mg with ritonavir boosting or 400 mg without
223956362|NCT02648737|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch \& Craske, 2009; Craske, 2010).
223956363|NCT02648737|OTHER|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
223956364|NCT05534854|GENETIC|Gene test|Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
223956365|NCT01181193|OTHER|Surgery|Craniotomy with total or partial removal of the brain tumor
223956366|NCT01181193|RADIATION|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
223956367|NCT01181193|DRUG|Temozolomide|"1. 75 mg/m2/day for entire period of radiotherapy~2. 150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
223956368|NCT01181193|DRUG|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
223541074|NCT01932788|DRUG|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
223956369|NCT02122354|BEHAVIORAL|"Hide and Seek videogame"|
223956370|NCT04348799|OTHER|BPD|It is a observation research.we didn't intervene anything.
223956371|NCT04105699|DEVICE|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein \[CRP\] and Procalcitonin \[PCT\]).
223956372|NCT04271254|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-surgery PET/MR within four weeks of scheduled surgery.
223956373|NCT04756986|DRUG|malic acid|1% malic acid spray
223956374|NCT03534778|DIAGNOSTIC_TEST|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
224107555|NCT06504550|OTHER|Schroth Exercises|The patients in the Schroth exercise group will start their exercise program under physiotherapist supervision.Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.These exercises include spinal elongation, de-rotation, de-flexion, stretching, strengthening exercises to maintain vertebral alignment.The participants will be asked to combine these exercises with their daily living activities (ADLs).During the Schroth exercises, rice bags, foam blocks, a stool, and long sticks will be used to adjust the posture and give passive support.Exercises are progressed from lying, sitting, or standing positions and from most to least passive support per a review of the quality of the performance.Decreasing the amount or degree of passive support, changing the patient's position, and adjusting the sets and repetitions of exercises will depend on the patient's improvement in exercise performance
223541075|NCT01932788|DRUG|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
223541076|NCT01529229|DRUG|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
223541077|NCT01529229|DRUG|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
223956375|NCT00965393|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
223956376|NCT00965393|DRUG|Placebo|Systemic infusion of placebo (saline)
223956377|NCT00965393|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
223956378|NCT06335667|DIAGNOSTIC_TEST|mpMRI + Diagnostic TURBT|mpMRI in addition to the TURBT surgical procedure
223541078|NCT01079364|DRUG|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
223541079|NCT01079364|DRUG|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
223541080|NCT01079364|DRUG|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
223541081|NCT05960838|DEVICE|Ultrasling® Quadrant|Immobilization with the Ultrasling® Quadrant (DJO Global Switzerland Sàrl, Ecublens, Switzerland) shoulder brace after surgical treatment
223541082|NCT05960838|DEVICE|Bledsoe ARC®|Immobilization with the Bledsoe ARC® (Breg Inc., Carlsbad, CA USA) brace after surgical treatment
223541083|NCT01977378|DRUG|Sustained-Release Desvenlafaxine Hydrochloride|
223541084|NCT01977378|DRUG|Sustained-Release Venlafaxine Hydrochloride|
223541085|NCT01171677|BEHAVIORAL|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
223541086|NCT04720378|BIOLOGICAL|ST266|1X ST266
223541087|NCT02308293|BEHAVIORAL|High intensity exercise|3x30 seconds 'all out' sprints
223541088|NCT02308293|BEHAVIORAL|Lay down comfortably|rest
223541089|NCT01471964|DRUG|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
223541090|NCT01143220|OTHER|No specific interventions|Observational investigation, only procedures according to local hospital standard.
223541091|NCT02194114|OTHER|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
223541092|NCT01847443|DRUG|Nicotine (2 mg)|2 mg nicotine gum in two formulations
223541093|NCT01847443|DRUG|Nicotine (4 mg)|4 mg nicotine gum in two formulations
223956379|NCT01082354|DRUG|recombinant somatropin|as per standard practice
223956380|NCT03701022|DRUG|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
223541094|NCT03534388|OTHER|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
223541095|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
223541096|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+5
223541097|NCT03381118|DRUG|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
223541098|NCT03381118|DRUG|Nivolumab|Nivolumab 40 mg IV infusion on D+1
223956381|NCT04945044|DEVICE|Computed adenoma detection system (CADe)|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps
223956382|NCT04945044|BEHAVIORAL|Control group (regular colonoscopy)|It is exclusively the endoscopist in charge of the detection of the polyps (usual practice)
224107556|NCT06504550|OTHER|Klapp Exercises|The patients in the Klapp exercise group will be treated with supervised klapp exercises. Exercise treatment program will consist of 18 sessions, 30 minutes each session, three times a week, for 6 weeks.In each session, a sequence of 8 postures of Klapp Exercises will be carried out. Each posture will be maintained for 4-5 minutes with rest breaks when needed.Positions that will be held are: 1) Lateral crawl, 2) Horizontal sliding, 3) Crawl posture near the ground, 4) Bunny hopping, 5) Arm turn, 6) Big arch, 7) Lateral crawl near the ground, 8) Big curve
224107557|NCT02502630|DEVICE|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
224107558|NCT04611464|DRUG|Misoprostol|Misoprostol is a PGE1 analog
223541099|NCT03381118|BIOLOGICAL|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
223956383|NCT02259959|DRUG|Single rising doses of BI 1744 CL, solution for oral inhalation|
223956384|NCT02259959|DRUG|Tiotropium, fixed dose, solution for oral inhalation|
223956385|NCT02259959|DRUG|Placebo|
223956386|NCT04410445|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
223956387|NCT04410445|BIOLOGICAL|Nivolumab|Specified dose on specified days
224107559|NCT06449105|BEHAVIORAL|1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
224107560|NCT06449105|BEHAVIORAL|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223956388|NCT01072058|DRUG|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
223956389|NCT01320683|DRUG|oxaliplatin|Given IV
223956390|NCT01320683|DRUG|leucovorin calcium|Given IV
223956391|NCT01320683|DRUG|fluorouracil|Given IV
223956392|NCT01320683|BIOLOGICAL|bevacizumab|Given IV
223956393|NCT01320683|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
223956394|NCT01320683|OTHER|laboratory biomarker analysis|Correlative studies
224107561|NCT06449105|BEHAVIORAL|Session 3: Unraveling the Knots of Desire and Patterns Agenda|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application"
224107562|NCT06449105|BEHAVIORAL|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223956395|NCT01320683|OTHER|pharmacological study|Correlative studies
223956396|NCT01320683|DRUG|irinotecan hydrochloride|Given IV
223956397|NCT00307671|DRUG|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
223956398|NCT00307671|DRUG|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
223956399|NCT00307671|DRUG|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
223956400|NCT04984980|DRUG|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab|Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
223956401|NCT02454647|DRUG|Induction chemotherapy|
223956402|NCT02454647|RADIATION|Radiotherapy with concurrent chemotherapy|
223956403|NCT02454647|PROCEDURE|Salvage surgery|
223956404|NCT00004662|DRUG|dehydroepiandrosterone|
223956405|NCT01628263|OTHER|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
223541100|NCT05960487|OTHER|Cervical multifidus muscle area measurement at 3 levels (C4-C5, C5-C6, C6-C7)|Cervical multifidus muscle area measurement will be performed from both the side affected by radiculopathy and the unaffected side using the magnetic resonance (MR) imaging. Measurements will be made by two researchers, independent of each other.
223541101|NCT03771339|PROCEDURE|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
223541102|NCT03771339|PROCEDURE|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
223541103|NCT03571971|OTHER|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
223956406|NCT03946345|DRUG|Iohexol Inj 300 MG/ML|"* Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~* Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~* Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
223956407|NCT02159456|OTHER|Continuous enteral feeding via infusion pump|
223956408|NCT02159456|OTHER|Intermittent enteral feeding via gravity-based infusion|
223956409|NCT01835847|DRUG|Tipepidine Hibenzate|
223956410|NCT01123356|DRUG|Ofatumumab|"* Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~* Treatment to be administered for up to 6 cycles"
223956411|NCT01123356|DRUG|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
223956412|NCT01531699|DRUG|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
223956413|NCT01531699|OTHER|saline control|single application for up to 6 hours
223956414|NCT01531699|DRUG|Betadine ophthalmic prep solution|single application for up to 6 hours
224107563|NCT06449105|BEHAVIORAL|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
224107564|NCT06449105|BEHAVIORAL|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223541104|NCT03571971|OTHER|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
223541105|NCT04264039|BIOLOGICAL|anti-CD19 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
223541106|NCT04264039|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
223541107|NCT04264039|DRUG|Cytoxan|300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
223956415|NCT06474234|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis YLGB-1496 at 1x10 log CFU/day for 12 weeks
223956416|NCT06474234|DIETARY_SUPPLEMENT|Placebo|Intervention consists of daily administration of 2g of maltodextrin, administered daily for 12-weeks)
223956417|NCT02211599|OTHER|15% protein|Meal to provide 15%en from protein.
223956418|NCT02211599|OTHER|30% protein|Meal to provide 30%en from protein.
223956419|NCT02211599|OTHER|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
223956420|NCT06502678|BIOLOGICAL|Fcr blocker of autoantibodies|in vitro assays, combined with multi-omics approach and in vitro experimental models, will gain insights into the pathogenesis of Systemic Sclerosis (SSc)dissecting the consequences of treatment with Fcblocker on functional and phenotypic cell behavior. Healthy microvascular endothelial cells, fibroblasts and monocytes will be challenged with serum and autoantibodies prior to or upon treatment with Efgartigimod in order to assess both the prevention and the recovery capacity of the FcR blocker. The putative modulatory effect of Efgartigimod on vascular remodeling, endothelial-to-mesenchymal transition, fibroblast-to-myofibroblasts transition and monocyte behavior will be evaluated in in-vitro consolidated assays. Integrated Omics analyses will support and complement the in vitro findings by unveiling potential prognostic signatures and by identifying specific treatment-related profiles that might guide the modulation of the drug usage in order to maximize its beneficial effect
223956421|NCT00759681|DEVICE|ArterX Surgical Sealant|Apply at the suture site.
223956422|NCT00759681|DEVICE|Gelfoam and Thrombin|Apply at the suture site.
223956423|NCT02426424|DEVICE|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
223956424|NCT02426424|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
223956425|NCT01608919|OTHER|blood tests|thromboelastogram platelet mapping
223956426|NCT03663049|DRUG|discontinue statin|Discontinue statin as prescribed for 12 weeks
223956427|NCT02275806|DRUG|Irinotecan|
223956428|NCT02275806|DRUG|Cisplatin|
223956429|NCT03185858|BEHAVIORAL|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
223541108|NCT04264039|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
223541109|NCT06341400|DRUG|DisitamabVedotinForIicction Toripalimab|Each subject will receive RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg intravenously every 2 weeks for a total of 4 cycles. RC48-ADC 2.0mg/kg and toripalimab 3.0mg/kg were intravenously infused every 2 weeks for 8 cycles.
223541110|NCT05555446|DIETARY_SUPPLEMENT|Bovine colostrum|Subject will receive bovine colostrum with gluten.
223541111|NCT05555446|DIETARY_SUPPLEMENT|Placebo|Subject will receive a placebo with gluten.
223541112|NCT06433583|DEVICE|transcutaneous auricular vagal nerve stimulation|"The use of TENS ECO PLUS and the vagus nerve ear electrode medical devices for transcutaneous auricular vagal nerve stimulation (taVNS) everyday for 10 minutes twice a day or 20 minutes for 8 successive weeks. Patients are included at week 0, use taVNS between week 2 and 10, and are followed up until week 22.~Patient adherence: percentage of patients performing 20 minutes of daily stimulation on at least 5 days a week for at least 6 cumulative weeks."
223541113|NCT05019209|DRUG|House Dust Mite Allergen|D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
223956430|NCT02962609|OTHER|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
223956431|NCT02962609|OTHER|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
223956432|NCT00110422|DRUG|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
223956433|NCT00110422|DRUG|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
223956434|NCT04205045|DIAGNOSTIC_TEST|Lactose Breath Test|Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
224291177|NCT02497794|OTHER|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
224291178|NCT06305520|DEVICE|Investigational medical device (SkinPlus-HYAL Implant Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
223541114|NCT05019209|OTHER|Allergen-free air|No allergen added to room ventilation of allergen challenge chamber
223541115|NCT04826198|DRUG|AsiDNA|Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion
223541116|NCT04826198|DRUG|Niraparib|"Unit dose: Hard capsule containing 100mg of Niraparib Regimen: The last dose given during the 6 previous months of Niraparib 200 mg/day or 300 mg/day, (or 100 mg/day only if the patient has received this dose since at least 6 months) Daily, 1, 2 or 3 hard capsules at 100mg once daily at approximately the same time each day.~Mode/route: Per os"
223541117|NCT04826198|DRUG|Olaparib|Product name: Olaparib Pharmaceutical form: Tablets containing 100 or 150mg of Olaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Olaparib 600 mg/day or 500 mg/day, (or 400 mg/day only if the patient has received this dose since at least 6 months) Two times daily (300mg or 250 mg or 200mg) at approximately the same time each day.
223956435|NCT04205045|OTHER|Gut permeability test|A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
223956436|NCT04205045|OTHER|Milk Test|Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
223956437|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
223956438|NCT00996905|DEVICE|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
223956439|NCT03991325|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
223956440|NCT04201847|DIAGNOSTIC_TEST|Serum test|Serum Fetuin A and fetuin B
223956441|NCT01476137|DRUG|GSK1120212|MEK inhibitor
223956442|NCT01476137|DRUG|GSK2110183|AKT inhibitor
223956443|NCT01157442|BEHAVIORAL|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
223956444|NCT02558322|OTHER|Primary medical care|All study participants receive primary care as usual in the respective region
223956445|NCT04394078|OTHER|Online survey|Volunteer individuals enrolled the study after approval an online informed consent form. Sociodemographic data of the participants recorded as an online survey. Then, patient reported outcomes were used to assess depression (Zung depression Scale) and quality of life (WHO Qualiy of Life - Bref version).
223956446|NCT02674867|OTHER|Blood draw|
223956447|NCT02005484|DRUG|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
223956448|NCT01129011|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
223956449|NCT01129011|DRUG|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
223956450|NCT02416973|DEVICE|Provant|
223956451|NCT01545271|DRUG|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
223956452|NCT01545271|DEVICE|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
223956453|NCT05815771|PROCEDURE|Micro fragmented adipose tissue mixed with bone marrow stem cells|mixture of stem cells
223956454|NCT05815771|PROCEDURE|Bone Marrow stem cells aspirate|stem cells
223956455|NCT02217891|BEHAVIORAL|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, \& qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits \& harms of tumor genomic profiling; 2) interest in \& perceived benefits \& harms of incidental findings arising from tumor genomic profiling; 3) anticipated process \& needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, \& those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; \& 6) implications of \& concerns about incidental findings for family.
223956456|NCT02435498|OTHER|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
223956457|NCT02435498|OTHER|Video|The online video will contain the same information within the website.
223956458|NCT02435498|OTHER|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
223956459|NCT02444884|DRUG|MLN8237|
223956460|NCT06644391|DIAGNOSTIC_TEST|Carebot AI Bones|The use of a deep learning-based artificial intelligence software, Carebot AI Bones version 1.2.2, designed to aid in the detection of fractures on musculoskeletal radiographs. The AI model analyzes digital X-ray images to identify fractures, highlighting areas of interest with bounding boxes.
223956461|NCT04036773|DIETARY_SUPPLEMENT|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits \& vegetables
223956462|NCT01829646|OTHER|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
223956463|NCT01829646|OTHER|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
223956464|NCT01829646|OTHER|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
223956465|NCT02823574|BIOLOGICAL|Nivolumab|
223956466|NCT02823574|BIOLOGICAL|Ipilimumab|
223956467|NCT02823574|OTHER|Placebo|
223956468|NCT06275594|DRUG|Byfavo|For induction and maintenance of sedation
223956469|NCT06275594|DRUG|Midazolam|For induction and maintenance of sedation
223956470|NCT00590759|DEVICE|GORE TAG® Thoracic Endoprosthesis|implant
223956471|NCT04422405|PROCEDURE|One Anastomosis Gastric Bypass (OAGB)|"The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel."
223956472|NCT05670457|DRUG|Diosmin|diosmin 500 mg twice daily
223956473|NCT05344209|BIOLOGICAL|UV1|UV1 vaccine
223956474|NCT05344209|DRUG|Sagramostim|for stimulation of local dendritic cell population to take up the vaccine and to mature into professional APCs
224107565|NCT06449105|BEHAVIORAL|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
223956475|NCT05344209|DRUG|Anti-PD-1/PD-L1 treatment|either pembrolizumab, atezolizumab or cemiplimab
224107566|NCT06449105|BEHAVIORAL|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
224107567|NCT00708877|PROCEDURE|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
224107568|NCT06005506|DIETARY_SUPPLEMENT|Prebiotic fiber|Moradyn active prebiotic fiber product
224107569|NCT06005506|DIETARY_SUPPLEMENT|Dietary fiber|Fibregum non-active fiber product
224107570|NCT06005506|DIETARY_SUPPLEMENT|Probiotic|Defense Plus probiotic complex
224107571|NCT00950352|DRUG|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
224107572|NCT00950352|DRUG|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
223956476|NCT04957277|OTHER|load modulation|Adding body weight (BW) up to 20% BW and subtracting body weight down to -20% BW
223956477|NCT03006718|OTHER|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
223956478|NCT03271359|BEHAVIORAL|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
223956479|NCT03271359|BEHAVIORAL|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
224107573|NCT04493710|DIAGNOSTIC_TEST|Sarcopenia estimation|Analysis of pre-existing CT imaging
223956480|NCT00015132|DRUG|Sertraline|
223956481|NCT00417885|DRUG|exemestane|25 mg, oral, daily dosing
223956482|NCT00417885|DRUG|sunitinib malate|37.5 mg, oral, continuous dosing, daily
223956483|NCT06505785|OTHER|The creative drama group|"10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development."
223541118|NCT04826198|DRUG|Rucaparib|Product name: Rucaparib Pharmaceutical form: Tablets containing 200 or 250 or 300mg of Rucaparib Route of administration: per os Dose Regimen: The last dose given during the 6 previous months of Rucaparib 1200 mg/day or 1000 mg/day, or 800mg/day (or 600 mg/day only if the patient has received this dose since at least 6 months) Two times daily (600mg or 500mg or 400mg or 300mg) at approximately the same time each day.
223541119|NCT03564236|DEVICE|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]
223956484|NCT05863585|DRUG|BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum)|100µg
223956485|NCT02104375|DIETARY_SUPPLEMENT|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
223956486|NCT02326194|BIOLOGICAL|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
223956487|NCT02326194|BIOLOGICAL|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
223956488|NCT02326194|BIOLOGICAL|placebo (one dose)|placebo, one doses
223956489|NCT02326194|BIOLOGICAL|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
223956490|NCT03612102|BEHAVIORAL|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
223956491|NCT02443532|BEHAVIORAL|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
223956492|NCT02443532|BEHAVIORAL|Individual education|Usual care (individual consultations as routinely performed)
224107574|NCT05517759|OTHER|Educational program|The sessions were delivered in form of face to face, group disscussion, brainstorming and smart cards. The educational package covered all aspect of knowledge regarding VAP such as definitions, risk factors m cause, manifestation, diagnostic criteria, and nursing care to prevent VAP. A PowerPoint and information pamphlet were used to display the material.
224107575|NCT00978575|DRUG|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
224107576|NCT00978575|DRUG|Ferrosulfate|200mg daily for 12 weeks
224107577|NCT00978575|DRUG|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
224107578|NCT05675280|OTHER|Gluten free diet|All subjects initiated a gluten free diet as mandated by their diagnosis of Celiac disease, regardless of the study
224107579|NCT02626052|BEHAVIORAL|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
224107580|NCT02626052|BEHAVIORAL|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
224107581|NCT02626052|BEHAVIORAL|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
224107582|NCT02626052|PROCEDURE|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
224107583|NCT02626052|PROCEDURE|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
223541120|NCT03564236|OTHER|Standard care|Standard regular care of a COPD exacerbation
223541121|NCT03096886|BEHAVIORAL|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
223541122|NCT05326737|OTHER|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.
223541123|NCT05326737|OTHER|In hospital questionnaires|Patients are required to fill out the PCS questionnaire between on day -1 or +1.
223541124|NCT05326737|OTHER|Telephone contact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
223541125|NCT03747367|BEHAVIORAL|Insufficient Sleep|
223956493|NCT04733573|DEVICE|Two different occlusal splints|Two different occlusal splints will be used for bruxism management, PPT would be evaluated twice - before and after 30 days of splint therapy using pressure algometer (FPX25, Wagner Instruments, US)
223956494|NCT03003715|PROCEDURE|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi \[11 C\] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
223956495|NCT03003715|PROCEDURE|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
223956496|NCT03003715|PROCEDURE|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
223956497|NCT03003715|OTHER|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
223956498|NCT03757767|OTHER|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
223956499|NCT02838888|DEVICE|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
223956500|NCT05293379|OTHER|Connected teleconsultation booth|15-minutes assessment in a connected teleconsultation booth.
223956501|NCT06359977|OTHER|Quantitative EEG monitoring and beside ultrasound evaluation|After successful spontaneous breathing trial, neurocritical patients undergo at least 2 hours of quantitative EEG monitoring before extubation. Additionally, bedside ultrasound assesses the thickness and variability of the diaphragm, intercostal muscles, rectus abdominis, transversus abdominis, and external oblique muscles. The sputum volume for the 24 hours prior to extubation is also recorded. Reintubation within 48 hours after extubation is defined as weaning failure.
223956502|NCT00096278|BIOLOGICAL|Bevacizumab|Given IV
223956503|NCT00096278|DRUG|Fluorouracil|Given IV
223956504|NCT00096278|DRUG|Leucovorin Calcium|Given IV
224107584|NCT02626052|PROCEDURE|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
224107585|NCT03224962|DEVICE|fluorescence camera|drug - diagnostic test
224107586|NCT01593982|OTHER|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
223723908|NCT06461364|PROCEDURE|Assessment of cuspal deflection of bulk-fill restorations|To assess the performance of bulk-fill restorations on premolar teeth in class II cavities using some selected FDI criteria, a total sample size of 30 (10 for each group test) will be sufficient to detect: an effect size of 1.22 at a power (1-β error) of 0.8 and using a two-sided hypothesis test and a significance level (α error) 0.05 for data. Two teeth will be added to each group to compensate drop out samples.
223723909|NCT05329610|DIETARY_SUPPLEMENT|Beta-alanine|Slow-release beta-alanine.
223723910|NCT05329610|DIETARY_SUPPLEMENT|Placebo|Taste and appearance-matched placebo (tapioca starch).
223723911|NCT02575937|BEHAVIORAL|low glycemic diet|nutrition education-based low glycemic diet intervention
223723912|NCT04271969|DEVICE|SmartVest Airway Clearance System|Pulmonary airway clearance of retained mucus via high frequency chest wall oscillation (SmartVest)
223723913|NCT00496054|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
223723914|NCT01337232|BEHAVIORAL|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
223541126|NCT01939145|DRUG|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
223541127|NCT01939145|DEVICE|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
223723915|NCT02560532|DRUG|Clazosentan|Concentrated solution for intravenous injection
223723916|NCT00035516|DRUG|Epothilone|
223723917|NCT02067871|OTHER|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
223723918|NCT02067871|OTHER|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
223723919|NCT02893943|DIETARY_SUPPLEMENT|Probiotics|
223723920|NCT02893943|DIETARY_SUPPLEMENT|Placebo|
223723921|NCT05975944|DRUG|Selinexor，Olaparib|Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
223723922|NCT00596375|PROCEDURE|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
223956505|NCT00096278|DRUG|Oxaliplatin|Given IV
223956506|NCT00041639|DRUG|hMN14 (labetuzumab)|
223956507|NCT00158847|DRUG|fluticasone 500 mcg|
223541128|NCT02279056|BEHAVIORAL|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
223541129|NCT02279056|BEHAVIORAL|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
223956508|NCT00158847|DRUG|fluticasone 500 mcg + salmeterol 50 mcg|
223956509|NCT01529372|DEVICE|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
223956510|NCT04434222|DEVICE|Compressive stockings|Compressive stockings with built in Orthotimer Sensor
223956511|NCT04062279|DIAGNOSTIC_TEST|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
223956512|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
223956513|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
223956514|NCT00597025|DIETARY_SUPPLEMENT|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
223956515|NCT01064180|DRUG|Carvedilol|Carvedilol Tablets 25 mg
223956516|NCT05398042|DIETARY_SUPPLEMENT|Ketone ester|A daily dose of 3x20g of ketone ester supplementation during a six week intervention period
223956517|NCT05398042|DIETARY_SUPPLEMENT|Medium Chain Triglyceride (MCT) oil|A daily dose of 3x12.8g of MCT oil supplementation during a six week intervention period
223956518|NCT04056598|DIAGNOSTIC_TEST|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
223956519|NCT03455153|OTHER|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
223956520|NCT05957822|DRUG|TXA|Tranexamic acid injection 8-10mg/kg
223956521|NCT05957822|DIAGNOSTIC_TEST|TEG6|performing thromboelastography (TEG6)
223956522|NCT05088122|OTHER|no intervention|no intervention, not applicable
223956523|NCT00237718|DRUG|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
223956524|NCT00237718|DRUG|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
223956525|NCT00237718|DRUG|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
223956526|NCT00237718|DRUG|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
223956527|NCT01733199|OTHER|questionnaires|Summons of patients and filling questionnaire.
223956528|NCT04552184|OTHER|GPOEM|gastric per oral endoscopic pyloromyotomy
223956529|NCT04552184|OTHER|SHAM Procedure|intrapyloric injection of saline solution
223956530|NCT01100372|DRUG|gemcitabine hydrochloride|
223956531|NCT01100372|DRUG|liposome-encapsulated doxorubicin citrate|
223956532|NCT01100372|PROCEDURE|quality-of-life assessment|
223956533|NCT02627534|PROCEDURE|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
223956534|NCT02627534|PROCEDURE|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
223956535|NCT06361576|DRUG|Nivolumab|As per product label
223541130|NCT01752803|DIETARY_SUPPLEMENT|Probiotic|mix probiotic
223541131|NCT01752803|DIETARY_SUPPLEMENT|Placebo|placebo
223541132|NCT02421757|DEVICE|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
223956536|NCT01894620|DEVICE|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
223956537|NCT01894620|DEVICE|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
223956538|NCT00003611|DRUG|acitretin|
223956539|NCT00003611|OTHER|placebo|
223956540|NCT02877680|BEHAVIORAL|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
223956541|NCT01264484|DEVICE|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
223956542|NCT03563131|DEVICE|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
223956543|NCT03022734|DRUG|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
223723923|NCT00596375|DRUG|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
223723924|NCT03798405|BEHAVIORAL|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
223723925|NCT00496821|DRUG|ALN-RSV01|
223723926|NCT05095545|DRUG|AV5080|Hard gelatin capsules with a white body
223956544|NCT03022734|RADIATION|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
223956545|NCT02545426|OTHER|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
223956546|NCT04659083|DEVICE|Neurally adjusted ventilatory assist ventilation mode|This technique uses the electrical activity of the diaphragm (Edi) to control respiratory support and the NAVA level as an amplification factor that converts the Edi signal into a proportional pressure.
223956547|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
223956548|NCT00323895|DEVICE|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
223956549|NCT00323895|DEVICE|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
223956550|NCT03424187|DIETARY_SUPPLEMENT|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
223956551|NCT05830305|OTHER|Mobile health intervention|A protocol-based intervention via phone calls, which includes anti-hypertensive drug adjustment and reinforcement of lifestyle modification, will be implemented.
223956552|NCT06266676|OTHER|micro-course|The experimental group adopts micro-course instruction, providing self-directed learning through online asynchronous courses, with instructional content delivered through short videos created by the researcher.
224107587|NCT01651923|DRUG|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
223541133|NCT02421757|DEVICE|Placebo|The placebo Transcutaneous device
223541134|NCT03358082|DRUG|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
223541135|NCT03358082|DRUG|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
223541136|NCT02806414|DRUG|Ivermectin|
223541137|NCT06497309|DEVICE|Treadmill training|Therapy with treadmill-based advanced technology device.
223541138|NCT06497309|DEVICE|Overground training|Therapy using an advanced technological device enables exercise on the ground.
223541139|NCT06497309|DEVICE|DIERS|The examination starts and ends with the DIERS motion analysis system, a light-optical scanning method based on VRS (Video Raster Stereography) and a sensor-equipped treadmill that allows the measurement of several parameters of gait and balancing ability.
223541140|NCT06497309|OTHER|Traditional physiotherapy assessments|Traditional physiotherapy assessment methods (Timed Up and Go, Berg Balance Test, 6-minute gait test, 10-metre gait test, Functional Independence Measure, Barthel) are used to assess gait pattern and self-sufficiency.
223541141|NCT04940728|OTHER|Creative thinking techniques intervention program|The intervention program based on creative thinking techniques was designed to consist of four stages: preparation, theoretical briefing, skill development and evaluation. In the first stage of the program, acquaintance and information meeting, in the second stage, the theoretical part lasts for two weeks, in the third stage, various creative thinking techniques are applied for four weeks to gain creative thinking skills.
223956553|NCT06266676|OTHER|slide presentation|Provide online presentations.
223956554|NCT05609721|OTHER|no intervention, only observational study|no intervention, only observational study
223956555|NCT04581356|DRUG|Voxelotor|daily voxelotor 1500mg oral medication
224107588|NCT02305433|OTHER|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
223956556|NCT05749939|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) combines the skills of acceptance, cognitive defusion, being present, self as context, values, and committed action to help individuals engage with a meaningful life. A goal of ACT is to help people develop psychological flexibility, meaning they can experience and live with difficult thoughts and emotions, and still pursue what matters to them. The current project is an online, self-guided, 6-session intervention. Each session is expected to take about 30 minutes each, and the entire course will take approximately 3-4 weeks to complete, as users are encouraged to take a few days in between sessions. Within each session, participants will read about concepts and ACT metaphors, apply ACT concepts to general and care- specific vignettes, and apply ACT concepts to their own lives and care situations. Interactive experiences are included in each session and ends with a printable summary with practice skills before proceeding.
223541142|NCT03974269|PROCEDURE|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
223541143|NCT02382588|DRUG|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
223541144|NCT02382588|DRUG|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
223541145|NCT03846661|DEVICE|Physiomesh|difference in risk for recurrence and postoperative complication
223541146|NCT03864068|OTHER|Placebo|Placebo
223541147|NCT03864068|DRUG|Inositol|1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
223541148|NCT03487094|OTHER|Infant formula|Multi-centered, prospective, randomized clinical trial
223541149|NCT00246363|DRUG|Silymarin|Silymarin (milk thistle)
223541150|NCT00246363|DRUG|Placebo|Placebo
223956557|NCT04491370|DRUG|Polatuzumab vedotin|All patients will receive a myeloablative conditioning regimens (BEAM or CBV, as selected by the treating physician) followed by autologous stem cell transplant (ASCT). All patients on this study will receive an autologous stem cell transplant (ASCT) on Day 0 followed by supportive care including the drugs sargarmostim and filgrastim until blood counts are stable. If a complete, partial, or stable response is achieved following ASCT, the patient will receive an IV dose of Polatuzumab Vedotin once every 21 days until he/she receives 8 doses.
223956558|NCT05104242|OTHER|Diet low in Advanced Glycation End-Products (AGE)|The low AGE diet will primarily consist in reducing the amount of AGEs in foods by changing cooking methods. Participants will also be advice to choose foods low in AGEs; however, the advice will be tailored to participants' food preferences
223956559|NCT05986279|OTHER|Rehab|6 weeks of vestibular rehabilitation guided by the MINDGAPS decision support system
223956560|NCT04080778|DEVICE|magnetic seizure therapy (MST)|MST will be performed with the MagPro XP (120 V) device under anesthesia 2-3 times a week up to 15 sessions.Treatment is performed by magnetic stimulation of both hemispheres inducing a focal stimulation above vertex, using a serial of pulse trains with a frequency of at least 25 Hz but up to 100 Hz for 4-6 s (up to 10 s), which is sufficient to induce a tonic clonic seizure.
223956561|NCT04080778|DEVICE|electroconvulsive therapy (ECT)|ECT will be performed with MECTA 5000Q, 4th generation ECT devices provided by MECTA Corporation under anesthesia 2-3 times a week up to 15 sessions. For initial procedure Seizure Threshold (ST) will be estimated by empiric titration in the first session of each participant. ST will be then determined as by the manufacturer of ECT Device by the titration schedule for the initial titration session. The subsequent treatment sessions were dosed at 6 times the charge of the seizure threshold.
224107589|NCT03431389|DEVICE|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
224107590|NCT04229147|RADIATION|Radiotherapy|Patients who received a total dose of 30 Gy
223541151|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
223541152|NCT01081158|DRUG|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
223541153|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
223956562|NCT05748808|BEHAVIORAL|Use of biofeedback and virtual reality in the treatment of aggressive outbursts|Participants are trained to identify their physiological response when they are relaxed and when an outburst is coming. They are treated with cognitive, behavioral and emotional self-regulation therapies for managing anger and learning positive coping skills. Biofeedback toghether with virtual reality help them to improve their recognition and control of emotions.
223956563|NCT01643538|BEHAVIORAL|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
223956564|NCT01643538|BEHAVIORAL|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
223956565|NCT01643538|BEHAVIORAL|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
223956566|NCT01643538|BEHAVIORAL|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
223956567|NCT05441410|DRUG|Pyronaridine Tetraphosphate, Artesunate Drug Combination|Combination drug for treatment of uncomplicated malaria
223956568|NCT05441410|BIOLOGICAL|PfSPZ Challenge (NF54)|cryopreserved Plasmodium falciparum sporozoites injected by intravenous inoculation
223956569|NCT05441410|BIOLOGICAL|MVA ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Modified Vaccinia Ankara (MVA)
223956570|NCT05441410|BIOLOGICAL|ChAd63 ME-TRAP|virally vectored subunit vaccine candidates where ME-TRAP is expressed by the non-replicating viral vector Chimpanzee Adenovirus 63 (ChAd63)
223956571|NCT05441410|BIOLOGICAL|Sodium chloride (NaCl) 0.9%|0.9% NaCl solution for injection
223956572|NCT00649402|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
223956573|NCT00649402|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
223956574|NCT00614354|DRUG|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
223956575|NCT04997499|BEHAVIORAL|watch an instructional video|watch instructional video and then perform self injection of subcutaneous depot-medroxyprogesterone based on the video teaching
223956576|NCT01864200|BIOLOGICAL|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
223956577|NCT01864200|BIOLOGICAL|Placebo|Saline placebo
224107591|NCT04751279|OTHER|Blood sample|Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml
224107592|NCT06481358|DIAGNOSTIC_TEST|Artificial intelligence|AI extract intestinal region and reconstruct into 3D image.
224107593|NCT00676559|DRUG|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
223956578|NCT00074607|DRUG|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
223541154|NCT01081158|DRUG|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
223541155|NCT02701205|BIOLOGICAL|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
223541156|NCT02701205|BIOLOGICAL|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
223723927|NCT05095545|OTHER|Placebo|Hard gelatin capsules with a white body
223956579|NCT05185167|DRUG|Anesthetics, General Desflurane Maintenance|Comparison of dna damage of desflurane maintenance with propofol maintenance according to comet analysis
224107594|NCT00676559|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
224107595|NCT01309425|DRUG|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
224107596|NCT01309425|DRUG|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
224107597|NCT01309425|DRUG|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
224107598|NCT01309425|DRUG|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
224107599|NCT03264638|DRUG|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
224107600|NCT03264638|DRUG|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
223723928|NCT05388331|OTHER|No intervention|No intervention
223956580|NCT05185167|DRUG|Anesthetics, General Propofol Maintenance|Comparison of dna damage of propofol maintenance with desflurane maintenance according to comet analysis
224107601|NCT03264638|DRUG|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
223541157|NCT02701205|DRUG|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
223541158|NCT02685397|DRUG|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
223541159|NCT02685397|DRUG|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
223541160|NCT02685397|DRUG|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
223541161|NCT02685397|DRUG|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
223541162|NCT02685397|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
223541163|NCT04270344|DRUG|Pitavastatin 4mg|combination therapy with pitavastatin/valsartan (LivaloV)
223541164|NCT06393842|DEVICE|Cardiopulmonary Management Wearable Device|Fluid status and congestion can be determined by the CPM wearable device and correlates with non-invasive measures and biochemical markers of congestion and changes in congestion.
223956581|NCT02991118|DRUG|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
223541165|NCT03212976|PROCEDURE|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
223541166|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
223541167|NCT00553410|DRUG|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
223541168|NCT04289779|DRUG|Cabozantinib|Cabozantinib 40 mg orally daily for 3 cycles
223956582|NCT02991118|DRUG|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
223723929|NCT00365729|BEHAVIORAL|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
223723930|NCT05251571|OTHER|Conventional Exercise Group with Telerehabilitation|Exercises such as conventional muscle strengthening and stretching given with telerehabilitation are applied.
223723931|NCT05251571|OTHER|Balance Coordination Group with Telerehabilitation|Functional muscle strengthening, stretching, balance and coordination exercises given with telerehabilitation are applied.
223956583|NCT02032004|BIOLOGICAL|Allogeneic Mesenchymal Precursor Cells (MPCs)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo, and cryopreserved
224107602|NCT00750347|DRUG|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
224107603|NCT04641546|PROCEDURE|Therapeutic Exercise|Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
224107604|NCT04641546|PROCEDURE|Occupation-Based Intervention|Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
224291179|NCT06305520|DEVICE|Active Comparator: Active Comparator Medical Device (RESTYLANE Lidocaine)|\* In this investigation, the same subject receives both test and control treatments, one on each side of the nasolabial folds (matched pairs design).
224291180|NCT05519657|OTHER||
224291181|NCT03990480|DRUG|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
224291182|NCT03990480|DRUG|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
223956584|NCT02032004|OTHER|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
223956585|NCT00595959|DEVICE|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
223541169|NCT04289779|DRUG|Atezolizumab|Atezolizumab 1200 mg IV every 3 weeks for 3 cycles
223541170|NCT04289779|PROCEDURE|Cystectomy|Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
223541171|NCT05135728|BEHAVIORAL|Unstuck and On Target: Preschool|Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
223956586|NCT02601859|DRUG|Lithium Carbonate|
223956587|NCT03488550|BIOLOGICAL|ANX007|Single ascending dose
223956588|NCT06251791|OTHER|conventional physiotherapy+ IMT|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. In this group addition to conventional physiotherapy inspiratory muscle training will be performed with the threshold-loaded inspiratory muscle training device, starting at 30% of the maximum inspiratory mouth pressure value, during 5 days, in 2 sessions, 4 sets per day, 6-8 breaths in each set and 2 minutes of rest between sets.
223956589|NCT06251791|OTHER|conventional physiotherapy|Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day. Conventional Physiotherapy to contain breathing and thoracal expansion exercises, bronchial hygiene techniques and gradual mobilization in 1 time a day.
223956590|NCT06117215|OTHER|Data collection|data collection
223956591|NCT06061900|OTHER|Group exercise program|Group fitness program
223956592|NCT03676504|BIOLOGICAL|CD19.CAR T Cells|Dose Level 1: 1×10\^6 transduced cells/m\^2; Dose Level 2: 5×10\^6 transduced cells/m\^2; Dose Level 3: 20×10\^6 transduced cells/m\^2; Dose Level 4: 5x10\^7 transduced cells/m\^2; Dose Level 5: 10x10\^7 transduced cells/m\^2; Dose Level 6: 20x10\^7 transduced cells/m\^2
223956593|NCT03676504|DRUG|Fludarabine|3 days of fludarabine 30 mg/m\^2/day
223956594|NCT03676504|DRUG|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m\^2/day
223956595|NCT04373967|DRUG|Victoza®.|Patients will receive Victoza®. Both products will be provided as pen-injector.
223956596|NCT04373967|DRUG|Metformin Hydrochloride|Patients who were receiving metformin prior to study will continue to receive it during the study.
223956597|NCT04373967|DRUG|TQZ2451|Patients will receive TQZ2451.Both products will be provided as pen-injector.
223956598|NCT00254124|DEVICE|The Diet Plate (R) TM portion control plate and bowl|
223956599|NCT01892176|DIETARY_SUPPLEMENT|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
223956600|NCT05017454|DRUG|the optimized sodium valproate-loaded nanospanlastic dispersion|participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
223956601|NCT05017454|DRUG|mometasone furoate lotion|participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months
223956602|NCT03190148|OTHER|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
223956603|NCT03190148|OTHER|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
223956604|NCT03190148|OTHER|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
223956605|NCT04144088|DRUG|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
223956606|NCT04144088|DRUG|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
223956607|NCT04144088|DRUG|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
223956608|NCT00829400|BEHAVIORAL|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
223956609|NCT00829400|BEHAVIORAL|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
223956610|NCT01049152|DEVICE|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
223956611|NCT06464666|PROCEDURE|Renal interlobar artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
223956612|NCT06464666|PROCEDURE|Renal inter-lobular artery US|By using convex US transducer, first find interlobar artery. Then get a pulsed wave doppler at renal interlobar artery for similar 3 to 5 waveforms. Measure peak systolic and minimum diastolic velocity and calculate RRI value.
223956613|NCT06509555|OTHER|non-intervention|non-intervention
223956614|NCT06253962|OTHER|coronary agiongraphy|severity of coronary atherosclerosis
223956615|NCT02077374|DRUG|IDN-6556|25 mg BID for 28 days
223956616|NCT02077374|OTHER|Placebo|Placebo BID for 28 Days
223723932|NCT05636683|PROCEDURE|Root surface debridement|subjects will be examined for clinical periodontal parameters, their saliva samples will be collected, and then receiving full scaling using ultrasonic device, and oral hygiene instructions and motivation. After one week, the same clinical parameters, saliva sampling will be taken, and received full root surface debridement (RSD) using curette hand instruments (Gracey, USA) (First visit). One month and three months after first visit, the same clinical measurements, saliva will characterize as second and third visits, respectively.
223723933|NCT01018966|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
223723934|NCT00680706|DRUG|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
223723935|NCT00680706|DRUG|Placebo|D5W (50 ml)
223723936|NCT00080470|DEVICE|bion|battery powered microstimulator
223723937|NCT06042452|GENETIC|Genetic|A saliva sample test will be undertaken by all participants in order to analyze their DNA for personalizing their recommendations. The Global Screening Array (GSA) will be used.
223723938|NCT04615481|OTHER|Elliptical Training Group|The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
223723939|NCT04615481|OTHER|Ergo-metric Training Group|The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
223723940|NCT05079529|DRUG|β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group|Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
223723941|NCT05079529|DRUG|Placebo Group|Takes placebo capsule 3 times daily for 90 days
223723942|NCT01753505|OTHER|64-slice Multidetector coronary CT angiography|
223723943|NCT02367937|DRUG|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
223723944|NCT05923437|OTHER|Feeding model group with a chronobiological approach|"Breast milk will be given to the newborns in the intervention group for 3 days in line with the feeding model with a chronobiologic approach simultaneously with the provision from the mother, and the newborn will be ensured to receive breast milk in accordance with the day cycle. Within the scope of the study, firstly, mothers and nurses in the NICU will be informed about the study. Mothers will be asked to put the milk mothers express between 06:00-17:59 in the daytime breast milk storage bag and the milk mothers express between 18:00-05:59 in the nighttime breast milk storage bag and bring them to the unit. The brought breast milk will be prepared by the nurses by matching day and night milk according to the dates, with the first milk brought in priority, and the newborns will be fed by using the time of day factor (cycle so that the milk collected during the day will be given during the day and the milk expressed at night will be given at night)."
223723945|NCT05037071|DEVICE|Upper body graduated compression sleeve|An over the counter light compression sleeve will be worn during game training
224107605|NCT05024838|OTHER|Machine learning methods|This is an observational study of the retrospective collection of patient data. Anesthesia-related factors such as anesthesiologist's expertise, injection site, patient position, the dosage of local anesthetics, needle size, the direction of needle bevel, and basic demographic information of the patients were used for data analysis. Patients less than 18 years old were excluded from this study. Twenty percent of the dataset was used as a testing dataset, and the remaining were used for model training. The investigators will utilize four machine learning algorithms as XGBoost (Extreme Gradient Boosting), AdaBoost (Adaptive Boosting), Random Forest (RF), and support vector machine (SVM). Model performances were evaluated visually with a confusion matrix.
224107606|NCT02046564|DRUG|ASC-01|
224107607|NCT02046564|DRUG|Placebo|
223723946|NCT00508716|BEHAVIORAL|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
223723947|NCT04051073|DEVICE|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
223723948|NCT00190697|DRUG|arzoxifene|
223723949|NCT01408446|DRUG|Menthol|Capsule 48mg three times a day after meals 8 weeks
223723950|NCT01408446|DRUG|Placebo|Capsule 48mg three times a day after meals 8 weeks
223723951|NCT05127668|DEVICE|Airglove (TM)|A sterile polythene-balloon was inflated around the forearm using the AirGloveTM to 38.5oC at setting number-3 for 3 minutes, then removed and the degree of venodilation assessed by ultrasound.
223723952|NCT05127668|DEVICE|Warm-water Immersion|The upper limbs (to the level of mid-humerus) of participants were immersed in a container filled with a mix of cold-and warm tap-water to 38.5oC for 3 minutes in the WWI method. Arms were towel-dried, and the degree of venodilation was assessed by ultrasound
223723953|NCT00739791|BEHAVIORAL|exercise intervention|
223723954|NCT00739791|GENETIC|gene expression analysis|
223956617|NCT01338532|OTHER|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
223956618|NCT01338532|OTHER|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
223956619|NCT06301620|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
224107608|NCT00149331|BEHAVIORAL|Structured education program|
224107609|NCT03933917|PROCEDURE|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
224291183|NCT05088031|DEVICE|shock waves therapy|"Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)"
224291184|NCT02399631|OTHER|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
223723955|NCT00739791|GENETIC|polymerase chain reaction|
223723956|NCT00739791|GENETIC|proteomic profiling|
223723957|NCT00739791|GENETIC|reverse transcriptase-polymerase chain reaction|
223723958|NCT00739791|OTHER|laboratory biomarker analysis|
223723959|NCT00739791|OTHER|medical chart review|
223723960|NCT00739791|OTHER|questionnaire administration|
223723961|NCT00739791|PROCEDURE|psychosocial assessment and care|
223723962|NCT00739791|PROCEDURE|quality-of-life assessment|
223723963|NCT00739791|PROCEDURE|support group therapy|
223723964|NCT00739791|PROCEDURE|therapeutic dietary intervention|
223541172|NCT04722783|BEHAVIORAL|Parent-Child-Interaction Therapy adapted for children with autism spectrum disorder (PCIT-A)|PCIT is a behavioral family therapy approach emphasizing the integration of traditional child play therapy techniques within a behavioral framework of parent-child therapy and was developed by Eyberg (1988). It is based on attachment theory, social learning theory, and parenting styles theory. Recently, the intervention was adapted to children with ASD by our team (McNeil, Quetsch, \& Anderson, 2019). PCIT-A will last about 8 months, 1 day per week, 60min per day (see Study Protocol, Fig. 2).
224107610|NCT05717179|DIAGNOSTIC_TEST|Ultrasound|At baseline and at weeks 12, 24 and 48, patients will undergo an ultrasound examination of 44 joints by one investigator, who is blinded to the strategic arm and all clinical data. The following joints will be assessed: bilateral wrists (distal radio-ulnar joint, radio-carpal, mid-carpal recesses), 1st - 5th MCP, 1st - 5th PIP, elbows, glenohumeral, acromioclavicular, sternoclavicular, knees, ankles and 1st - 5th MTP. At wrists, MCP and PIP joints, palmar and dorsal sites including synovial recess, extensor and flexor tendons will be investigated whereas at feet the dorsal site (plus the lateral aspects of MTP5) including synovial recess and extensor tendons will be evaluated. Further, we will assess the following: at elbows the dorsal and anterior recess, at shoulders the dorsal recess, at knees the suprapatellar as well as the medial and lateral femoro-tibial recess and at ankles the anterior, lateral and medial recess of the tibiotalar joint.
224107611|NCT04330508|OTHER|Depression and Cognitive Tests|Health Related Quality of Life, neurocognitive tests, PHES
223541173|NCT04722783|BEHAVIORAL|Early Start Denver Model (ESDM) intervention|ESDM intervention provides intensive teaching by trained therapists and parents during natural play and relationship-focused daily routines. It is evidence-based and uses principles of developmental psychology and applied behavior analysis. It was designed for toddlers and preschoolers with autism spectrum disorder by Rogers and Dawson (2010). The first intensive part of ESDM intervention (20h per week) will last 40 weeks of intervention within a period of 12 months. It includes 2 days per week for 6h a day clinic therapy, and 5 days per week for 1h homework tasks, and 2 days per week for 1.5h an early special needs education at home. After the first 12 months, children receive the second lower intensity part of ESDM (7 hours per week). It includes 1 days every two weeks 1h day clinic therapy, and 5 days per week for 1h homework tasks, and 1 days per week for 1.5h an early special needs education at home (see Study Protocol, Fig. 2).
223541174|NCT04722783|BEHAVIORAL|1-hour ESDM|The active control group for PCIT-A stays in the ESDM day clinic therapy for the 12 hours per week while the PCIT-A group will receive 11 hours of ESDM day clinic therapy and 1 hour PCIT-A per week (see Study Protocol, Fig. 2).
223541175|NCT04722783|BEHAVIORAL|Early special needs education (ESNE)|The wait-list control group will receive early special needs education. It consists of a 90-minute visit at participants' homes once a week by an employee educated in early special needs education. As soon as space in ESDM is available children will receive the ESDM intervention (stepped-wedge design, see Study Protocol, Fig. 2).
223541176|NCT06381336|DEVICE|TRAK-SILVER platform|"The Experimental Group used TRAK-SILVER, a cross-platform web application that empowers healthcare professionals and patients. It facilitates the management of a patient's condition by providing therapeutic exercises, monitoring activity, and administering clinical assessment scales and questionnaires. The platform's advanced artificial vision algorithm, known for its precision, enhances patient engagement with real-time measurements and corrections during exercise.~Physiotherapists monitored the sessions through the TRAK-SILVER platform's monitoring system and weekly phone calls. The TRAK-SILVER platform had an alert notification system.~The program's second part involved weekly uploads of health-promoting information pills to the platform."
223541177|NCT06482086|DRUG|Anlotinib|8/10/12 mg qd, po. Stop the medication for one week after taking it for two weeks.
223541178|NCT06482086|DRUG|Lenvatinib|8/12 mg qd, po.
224107612|NCT03183245|BIOLOGICAL|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
224107613|NCT03183245|PROCEDURE|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
223541179|NCT06482086|DRUG|Sorafenib|0.4 g bid, po.
223956620|NCT06301620|BEHAVIORAL|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
223956621|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
223956622|NCT02742805|DIETARY_SUPPLEMENT|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
224107614|NCT03183245|OTHER|Hemodialysis|Procedure that filters a person's blood when their kidneys are no longer functioning properly
223956623|NCT02742805|DRUG|Omalizumab|Standard of care dose.
224107615|NCT01804205|DRUG|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
224107616|NCT01804205|DRUG|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
223541180|NCT06482086|DRUG|Donafenib|0.3 g bid, po.
223541181|NCT06482086|DRUG|Everolimus|10 mg qd, po.
223541182|NCT06482086|DRUG|Apatinib|500 mg qd, po.
223956624|NCT00251199|DRUG|VX-950|
223956625|NCT00251199|DRUG|peginterferon|
223956626|NCT01018550|DRUG|AMG 853|AMG 853 5 mg (BID)
223956627|NCT01018550|DRUG|AMG 853|AMG 853 200 mg (QD)
223956628|NCT01018550|DRUG|AMG 853|AMG 853 25 mg (BID)
223956629|NCT01018550|DRUG|AMG 853|AMG 853 100 mg (BID)
224107617|NCT03300453|DRUG|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
224107618|NCT01414088|OTHER|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
223956630|NCT01018550|DRUG|Placebo|Placebo
224107619|NCT01414088|OTHER|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
224107620|NCT01414088|OTHER|glucose 5%|infusion, 23 ml/kg, during 50 minutes
224107621|NCT05926089|DIAGNOSTIC_TEST|Blood sampling|blood sampling to measure APR
224107622|NCT00984659|DRUG|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
223541183|NCT06482086|DRUG|Dabrafenib + Trametinib|Dabrafenib 150 mg bid, po+Trametinib 2 mg qd, po.
223541184|NCT06482086|DRUG|Cabozantinib|Cabozantinib 60mg qd, po.
223541185|NCT06482086|DRUG|Vandetanib|Vandetanib 300mg qd, po.
223541186|NCT06482086|DRUG|Entrectinib|Entrectinib 600mg qd，po.
223541187|NCT06482086|DRUG|Pralsetinib|400mg qd, po.
224107623|NCT00984659|DRUG|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
224107624|NCT00984659|DRUG|Placebo|Placebo DISKUS twice a day for 8 weeks
223541188|NCT06482086|DRUG|Larotrectinib|100mg qd，po
224107625|NCT06151756|BEHAVIORAL|Video Supported Mobile Application|The video-supported mobile application was developed to be interactively utilized on smartphones. T
223541189|NCT04287413|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination.~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
223956631|NCT04727099|DEVICE|PicoWay Laser System|The PicoWay® laser system is an alexandrite laser pumped, solid-state Neodymium:Yttruium Aluminum Garnet (Nd:YAG) laser emitting energy at user selectable wavelengths of 1064 nm, 532 nm, 785 nm or 730 nm, designed for the treatment of tattoo, benign pigmented lesions, acne scars, and wrinkles.
223956632|NCT01992497|DIETARY_SUPPLEMENT|Probiotic|
223956633|NCT03979352|DRUG|empagliflozin|Treatment with empagliflozin 25mg orally once a day
223541190|NCT04287413|BEHAVIORAL|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
223723965|NCT00471328|DRUG|Nilotinib|Nilotinib 400 mg twice daily (bid)
223723966|NCT00471328|OTHER|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
223956634|NCT03979352|DEVICE|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
223956635|NCT03630653|PROCEDURE|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
223956636|NCT00927966|DRUG|RAD001|Taken orally once a day.
223956637|NCT00927966|DRUG|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
223956638|NCT05034588|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameter
224107626|NCT05043610|BIOLOGICAL|Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)|cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
224107627|NCT05043610|OTHER|Conventional Treatment|Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
224107628|NCT06583395|BEHAVIORAL|Advanced multi-component meditation practice|The study intervention is a multi-component advanced guided meditation practice that incorporates elements of focused attention, non-dual, and loving kindness and compassion meditation techniques as well as breathwork components. The practice includes sitting, lying down, standing, and walking components and is carried out at 7-day advanced meditation retreats lead by Joe Dispenza, D.C. These retreats include lecture-based instruction and up to 35 hours of meditation practice.
224107629|NCT01395238|BEHAVIORAL|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
224107630|NCT06346275|PROCEDURE|Acupuncture|Acupoints: Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20), Taixi (KI3), Zusanli (ST36), Sanyinjiao (SP6), Neiguan (PC6), and Shenmen (HT7).
224107631|NCT04220892|DRUG|Pembrolizumab|200 mg intravenous (IV) every 3 weeks
224107632|NCT04220892|DRUG|Pemetrexed|900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
224107633|NCT04220892|DRUG|Abemaciclib|150 mg twice a day, by mouth.
224107634|NCT00850512|DRUG|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
223956639|NCT04325737|DRUG|SEP-363856|Dosing of the SEP-363856 group in Cohort 1 will be initiated at 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days. The SEP-363856 group in Cohort 2 will be dosed at 25 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 50 mg SEP-363856 as an oral once daily dose for 3 consecutive days, followed by 75 mg SEP-363856 as an oral once daily dose for 4 consecutive days, and followed by 100 mg SEP-363856 as an oral once daily dose for 7 consecutive days.
223956640|NCT04325737|DRUG|Placebo|Placebo will be orally administered according to the same administration schedule as the SEP-363856 group in each cohort.
223956641|NCT05208788|DIAGNOSTIC_TEST|Biomarker test|collection of 500µl to 1 ml of a spot urine sample
223956642|NCT04558021|DRUG|Niclosamide suspension|200mg/10ml
223956643|NCT04558021|OTHER|Placebo|10ml placebo(absent of niclosamide)
223956644|NCT05434507|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
223956645|NCT05325983|OTHER|lemonade ice cubes|Mixing 1 part lemon juice and 6 parts boiling water, make 10ml lemonade ice cubes. The experimental group was given a 10ml lemonade ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the lemonade ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The experimental group was given a brand new 10ml lemonade ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
223956646|NCT05325983|OTHER|water ice cubes|make 10ml water ice cubes. The control group was given a 10ml water ice cube. The ice cubes were weighed first and then given. The subjects were required to hold the water ice cube in their mouths without breaking them, and not to swallow saliva. 45 seconds after the intervention is given, the nurse will use tweezers to take out the ice cube from the subject's mouth and weigh it , and then place the dry cotton swab at the opening of the sublingual gland in the oral cavity, take it out after 1 minute, and collect saliva, the recorded saliva volume = the collected saliva volume minus (10 ml ice cube weight minus the remaining ice cube weight); The control group was given a brand new 10ml water ice cube. At 90 seconds, 135 seconds and 180 seconds, the above saliva collection method was repeated for a total of 5 times of saliva collection.
223956647|NCT05469607|DEVICE|Vagus Nerve Stimulator|The device consists of implantable (inside the body) and external (outside the body) components. Implantable components consist of a stimulating/recording electrode assembly that is placed around the vagus nerve in the abdomen, between the diaphragm and the stomach, a cable connecting the electrode assembly to an implantable pulse generator (IPG) that generates the stimulus and records nerve responses. The external components include a Clinical Control/Review Tool (used by the study team after implantation to adjust and periodically review the stimulation settings) and a Patient Control Unit and Charger (to turn on/off the system and perform limited adjustment of the stimulation strategy).
223956648|NCT02845921|OTHER|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
223956649|NCT02845921|OTHER|leg wrapping|Esmarch bandage is used to wrap each lower limb
223956650|NCT02845921|OTHER|control|no intervention has been done
223956651|NCT03155399|OTHER|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
224107635|NCT00850512|DRUG|Zevalin|12-week safety period for Zevalin
224291185|NCT01067716|DEVICE|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
223956652|NCT03155399|OTHER|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
223956653|NCT03647449|DIETARY_SUPPLEMENT|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
223541191|NCT06284759|OTHER|post-discharge telenursing intervention|Tele-nursing based on Orem's Self-Care Theory was applied to patients with lower extremity fracture surgery. Phone/video calls 24-48 after discharge. hours, 7-10. day,18-21. day, 28-30th day and 40-45th day. day was made. Telephone or video conference interviews were held on the day and time convenient for the patient. After each meeting, the date and time of the next meeting was planned. The video conferencing method (zoom, skype, whatsapp, etc.) was presented to the patient's preference and the decision was made together. In phone/video conference calls, patients were informed about their current problems. Additionally, patients' questions were answered. Prior to tele-nursing monitoring, the researchers identified emergent or urgent situations; Patients were informed that they should consult their doctor if this occurs. The interview with each patient lasted an average of 30 minutes.
223541192|NCT00708409|PROCEDURE|Cardiac valve surgery|Different autograft implantation techniques.
223541193|NCT03655847|DRUG|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
223541194|NCT02590289|DRUG|BBI-5000|BBI-5000 low dose, middle dose, or high doses
223541195|NCT00038948|DRUG|Sirolimus|Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
223541196|NCT00038948|DRUG|tacrolimus|
223541197|NCT00038948|DRUG|Cyclosporine A|
223956654|NCT03647449|BEHAVIORAL|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
223956655|NCT03647449|DIETARY_SUPPLEMENT|Plant-based meal|Participants will be eating \~900 kcal/day in pre-prepared plant-based meals.
223956656|NCT04449822|PROCEDURE|Emergency surgery|Surgical decompression with colostomy with or without resection and eventual re-anastomosis.
223956657|NCT04449822|PROCEDURE|Colonic stenting|The colonic stent placement to relieve the colonic obstruction.
223956658|NCT01739738|DEVICE|Ureteral Stent|patients who need to receive stent as per standard of care
223956659|NCT02428595|DEVICE|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
223956660|NCT01818999|DRUG|IXABEPILONE|injection
223956661|NCT01818999|RADIATION|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
223956662|NCT02588521|DRUG|AL-794|
223956663|NCT02588521|OTHER|Placebo/Vehicle|Suspension vehicle without active drug
223956664|NCT03374722|DRUG|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
223956665|NCT00424476|DRUG|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
223956666|NCT00424476|DRUG|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
223956667|NCT00424476|DRUG|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
223956668|NCT05504447|OTHER|"Rong-Yang Zhengyifang tea bag"|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
223956669|NCT05504447|OTHER|placebo tea bag|One tea bag is 4 grams, 3 bags per day, for a total of 7 days
223956670|NCT05526937|OTHER|Bread|Bread portions of 50 gram available carbohydrates.
223956671|NCT01653106|PROCEDURE|cryotherapy|Receive shaved ice
223956672|NCT01653106|OTHER|questionnaire administration|Participate in PROMS
223956673|NCT01653106|OTHER|pharmacological study|Correlative studies
223956674|NCT05073393|BEHAVIORAL|Sugar stress|Sucrose rinsing for 14 days (8-10 times a day) followed by 14 days without sucrose rinsing
224291186|NCT03630419|DIETARY_SUPPLEMENT|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
224291187|NCT03630419|OTHER|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
223541198|NCT06590181|OTHER|Yoga Nidra|This protocol is derived from The Origin and Clinical Relevance of Yoga Nidra (Pandi-Perumal, S. R. 2022)
223956675|NCT03014349|OTHER|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
223956676|NCT03792178|OTHER|Bulk fill composite|Composite resin dental material
223956677|NCT03792178|OTHER|Nano resin composite|Dental composite material
223956678|NCT01327014|DRUG|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
223956679|NCT01327014|DRUG|Placebo|4 capsules twice a day for 12 weeks.
223956680|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
223956681|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
223956682|NCT00657709|BIOLOGICAL|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
223956683|NCT00657709|BIOLOGICAL|Infanrix Hexa|Routine vaccination
223956684|NCT00657709|BIOLOGICAL|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
223956685|NCT00657709|BIOLOGICAL|Prevenar|Routine vaccination
224107636|NCT03078361|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
223956686|NCT02634593|BEHAVIORAL|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
223956687|NCT00004731|DRUG|Coenzyme Q10|
224107637|NCT03078361|BEHAVIORAL|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
223956688|NCT03845088|PROCEDURE|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
223956689|NCT01995981|DRUG|Pazopanib|
223956690|NCT05128799|OTHER|3 Wishes Program (3WP)|"The 3 Wishes Program (3WP) is a palliative care intervention in which small wishes are implemented by healthcare workers (HCWs) in an effort to improve the EOL experience for dying patients and their families. Examples of wishes include playing the patient's favorite music, providing a non-hospital blanket, orchestrating a final date night, decorating a patient's room to reflect their identify, and providing grieving family members with keepsakes such as thumbprint keychains, framed EKG mementos, or word clouds."
223956691|NCT04885140|BEHAVIORAL|Feedback-based health education|This study was approved by the Tianjin Hospital Ethics Committee, (2019082).The CONSORT 2010 statement: extension to cluster-randomised trials checklist.(Campbell et al., 2012) was used to guide reporting outcomes (File S1).Specific measures have been listed above.
223956692|NCT04885140|BEHAVIORAL|Routine health education|Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method.
223956693|NCT03137446|OTHER|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
223956694|NCT04245722|DRUG|FT596|Experimental Interventional Therapy
223956695|NCT04245722|DRUG|Cyclophosphamide|Lympho-conditioning agent
223956696|NCT04245722|DRUG|Fludarabine|Lympho-conditioning agent
223956697|NCT04245722|DRUG|Rituximab|Monoclonal Antibody
223956698|NCT04245722|DRUG|Obinutuzumab|Monoclonal Antibody
223956699|NCT04245722|DRUG|Bendamustine|Conditioning agent
223956700|NCT04433052|BEHAVIORAL|personalised prevention program (PPP)|Study subjects in the PPP arm will be invited to return to the study site six times over a three-year period (at V2/start of the study, V3/mo2, V4/mo6, V5/mo12, V6/mo18 and V7/mo36) to receive lifestyle coaching and exercise prescriptions led by a delegated member of the site staff and supervised by the investigator. Information on drug treatment will also be given by the investigator. These activities will be assisted by digital tools specifically designed for this study, the CoroPrevention Tool Suite.
223956701|NCT01755130|PROCEDURE|Photoacoustic Imaging|Undergo LOUISA 3D
223956702|NCT05520411|DIETARY_SUPPLEMENT|HUM Flatter Me|Proprietary Enzyme Blend: Protease 3.0 Protease 4.5 Protease 6.0 Neutral Bacterial Protease Peptidase Bromelain Papain Lipase Amylase Glucoamylase Alpha-galactosidase Invertase Diastase Hemicellulase + Cellulase Beta-Glucanase Phytase Lactase Ginger Root Fennel Seed Peppermint Leaf
223956703|NCT03204773|DIAGNOSTIC_TEST|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
223956704|NCT03204773|DIAGNOSTIC_TEST|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
223956705|NCT03204773|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|Testing for pain
223956706|NCT03204773|DIAGNOSTIC_TEST|Becks Depression Inventory (BDI)|Screening for depression
223956707|NCT03204773|DIAGNOSTIC_TEST|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
224107638|NCT03078361|BEHAVIORAL|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
224107639|NCT01708226|BEHAVIORAL|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
223541199|NCT06590181|OTHER|Yoga Nidra with Pain Acceptance Intention|Yoga Nidra with Pain Acceptance Intention
223541200|NCT06590181|OTHER|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery|Yoga Nidra with Pain Acceptance Intervention and Motor Imagery
223723967|NCT05416398|OTHER|Aerobic Exercise, High Intensity Interval Training|Aerobic exercise is a form of exercise done by consuming oxygen in order to give energy to the body. High Intensity Interval Training consists of low-intensity periods of active rest combined with short periods of intense exercise.
223956708|NCT00694902|DRUG|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
224107640|NCT02917590|OTHER|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
224107641|NCT02917590|OTHER|Single-task obstacle crossing training|Obstacle crossing training
224291188|NCT04593212|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography|Evaluation of microcirculatory dysfunction by assessment of retinal and choroidal microvasculature with optical coherence tomography angiography (OCTA)
224107642|NCT04964401|PROCEDURE|Thoracic paravertebral block vs Erector spinae plane block|Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
224107643|NCT00308620|DRUG|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
224107644|NCT00308620|DRUG|Placebo|Placebo once daily for 8 weeks
224107645|NCT05290870|DEVICE|Posterior-chamber intraocular lens|Implantation of a posterior-chamber intraocular lens to correct aphakia after removal of the crystalline lens
224107646|NCT04364217|DEVICE|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
224107647|NCT04269408|DRUG|Nicardipine|10 NicaPlant® implants releasing 4 mg nicardipine each.
223541201|NCT06656637|BEHAVIORAL|Memory Drilling|"The experimental group will receive the additional intervention during their seven sessions with their care providers. The intervention is computerized memory drills training. This training includes the completion of a list learning memory task (HVLT) and then a PM practice task conducted on the computer at each session."
223541202|NCT06656637|BEHAVIORAL|Compensatory Strategies|Participants learn compensatory strategies to assist with their memory performance. This involves both external strategies, such as calendering and setting alarms, and internal strategies, like imagery and mnemonics.
223956709|NCT00694902|DRUG|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
223541203|NCT06656637|BEHAVIORAL|Cognitive Processing Therapy|This is PTSD-targeted therapy.
223956710|NCT01875016|PROCEDURE|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
223541204|NCT01627184|DEVICE|Dexcom G4 CGM System|
223541205|NCT05710952|DEVICE|Review by Modjaw|A review by Modjaw's will be done before the braces treatment and after.
223956711|NCT00149565|DRUG|IFN-α2b|
224107648|NCT04269408|OTHER|Standard of care|Both arms receive the usual standard of care.
224107649|NCT05545397|DRUG|Propofol|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
224107650|NCT05545397|DEVICE|EEG montior|And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
224107651|NCT05631951|PROCEDURE|bone transport through induced membrane|Debridement done followed by external fixator and cement application to be followed by removal of cement (after 6 weeks) and start bone transport
224107652|NCT05631951|PROCEDURE|bone transport|Debridement done then external fixator was applied then bone transport started.
223541206|NCT03972527|DEVICE|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
223956712|NCT06500403|DIAGNOSTIC_TEST|liver and stiffness measurement|liver and spleen stiffness measurement are non-invasive tools for evaluation of cirrhosis and portal hypertension
223956713|NCT00039052|BIOLOGICAL|interleukin-4 PE38KDEL cytotoxin|
223956714|NCT06095778|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
223956715|NCT02393456|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
223956716|NCT02393456|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
223956717|NCT02558803|BEHAVIORAL|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
223956718|NCT06502067|DRUG|Analgesia mangement group A,B|1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
224107653|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
224107654|NCT00121732|DRUG|E7974|Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
224107655|NCT02757547|DEVICE|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
224291189|NCT00699478|DRUG|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
224107656|NCT02757547|DEVICE|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
224107657|NCT04915521|OTHER|erector spina plane block (ESPB) group|"An experienced anesthesiologist performed ESPB in all patients in sitting position bilaterally.~A linear ultrasound probe (6-13 MHz) was used for ultrasound guidance. Injection was done using in-plane technique. A 22G block needle (100mm, B-Braun, Germany) was inserted 3- cm lateral to the T9 spinous process and advanced in cranio-caudal direction. To separate erector spina muscle from the transverse process, initially 1-2 ml saline was injected; then 20 ml 0.5% bupivacaine and 5 ml 0.2% lidocaine were injected following separation. Diffusion of the drugs in erector spina plane at cranio-caudal line was ensured. No analgesic or sedative was used during the procedure."
224107658|NCT03411603|OTHER|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
224291190|NCT03979833|GENETIC|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
223956719|NCT04413175|OTHER|music therapy|"Patients in the music group were provided music therapy that was prepared by the Turkish Psychological Association. They listened to the music that has a calming and relaxing effect for 20 min before and during the procedure.~A portable MP3 player connected to double earphones was used in the present study. After patients took the lithotomy position for cystoscopy, their headphones were inserted and music began to be played. Music was played to the individuals for 20 minutes before and during the procedure. Headphones were removed immediately after the procedure was completed and the double earphones were cleaned with antiseptic solution after each application."
223541207|NCT03972527|OTHER|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
223956720|NCT01483131|OTHER|Exercise training|12 weeks of resistance training twice a week.
223956721|NCT01483131|OTHER|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
223956722|NCT04014686|OTHER|No exercise intervention group|no exercise intervention
223956723|NCT04014686|BEHAVIORAL|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
223956724|NCT02746783|DRUG|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
223956725|NCT02746783|DRUG|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
223956726|NCT03391778|BIOLOGICAL|ADP adoptive cell therapy|No study drug is administered in this study. Participants who received ADP adoptive cell therapy in a previous trial will be evaluated in this trial for long-term safety and efficacy.
223956727|NCT03837093|DRUG|ILT101|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
223956728|NCT03837093|DRUG|Placebo|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
223956729|NCT05245474|COMBINATION_PRODUCT|Long-course chemoradiation, with or without Tislelizumab (PD-1 inhibitor)|Tislelizumab is added to long-course chemoradiation (CRT) of LARC patients, with CRT+concurrent Tislelizumab for Arm 1, CRT+sequential Tislelizumab for Arm 2, and CRT only for Arm 3
224291191|NCT03069677|OTHER|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
224291192|NCT03069677|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
223956730|NCT01840124|PROCEDURE|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
223541208|NCT02311725|BEHAVIORAL|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
223541209|NCT02311725|BEHAVIORAL|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
223541210|NCT00497003|DRUG|Treatment with either metoprolol or carvedilol|
223541211|NCT01786590|PROCEDURE|EBUS-TBNA|Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
223541212|NCT01286597|DIETARY_SUPPLEMENT|dietary restriction|restrict intake of lactose
223541213|NCT06186908|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
223956731|NCT06540846|OTHER|No intervention|No intervention since this is an observational study
223956732|NCT04153357|DEVICE|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
223956733|NCT04153357|DEVICE|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
223541214|NCT03023306|OTHER|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
223541215|NCT01033929|BIOLOGICAL|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
223541216|NCT03401203|PROCEDURE|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
223541217|NCT03401203|PROCEDURE|Balloon angioplasty|Percutaneous coronary intervention
223956734|NCT01870895|DRUG|YM060|oral
223956735|NCT01870895|DRUG|Placebo|oral
224291193|NCT02948725|OTHER|Cross-education + standard rehabilitation|
224107659|NCT03063255|DRUG|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
224107660|NCT03063255|DRUG|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
224107661|NCT03399890|DIAGNOSTIC_TEST|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
224107662|NCT03461926|BEHAVIORAL|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
224107663|NCT04336176|DEVICE|PulseFlow DF boot|Offloading boot
224107664|NCT04336176|DEVICE|Usual standard of care|Usual standard of care (offloading device)
224107665|NCT04336176|DEVICE|Sham|Sham shoe (closest to barefoot or baseline pressures)
224107666|NCT02413515|DRUG|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
224107667|NCT02330029|DRUG|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
224107668|NCT02330029|DEVICE|Atractylodes|Atractylodes (\~10-15g)
224107669|NCT02330029|DEVICE|Paeonia Lactiflora|Paeonia Lactiflora (\~15-30g)
224107670|NCT02330029|DEVICE|Tangerine Peel|Tangerine Peel (\~10g)
224107671|NCT02330029|DRUG|Ledebouriella Root|Ledebouriella Root (\~10g)
224107672|NCT02330029|DRUG|Radix codonopsitis|Radix codonopsitis (\~10-15g)
224107673|NCT02330029|DRUG|Radix curcumae|Radix curcumae (\~10g)
224107674|NCT02330029|DRUG|Fingered citron|Fingered citron (\~10g)
224107675|NCT02330029|DRUG|Tuckahoe|Tuckahoe (15g)
224107676|NCT02330029|DRUG|Placebo|Placebo is blindly given to patients.
224107677|NCT00345111|PROCEDURE|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
224107678|NCT03619915|DIAGNOSTIC_TEST|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
223541218|NCT05152511|COMBINATION_PRODUCT|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy is a specially designed cabinet for infants and neonates with a barometric pressure equal to 760 mmHg for 20 minutes daily, then gradually increase up to one hour daily for 5 days per week (fig. 1). The chamber was kept warm. The babies were fed before entering the chamber and if signs of hunger appear during therapy. The baby was continuously monitored with pulse oximeter. Older children are managed in the conventional Hyperbaric oxygen chamber with the same regimen.
223541219|NCT00495703|BEHAVIORAL|Exercise|6-months of regular aerobic exercise
223541220|NCT00495703|BEHAVIORAL|Usual Care|6-months of behavioral strategies to aid memory/cognition
223541221|NCT02722408|DRUG|Gemcabene|300 mg tablet orally once daily for four weeks followed by 600 mg tablet orally once daily for four weeks followed by 900 mg tablet orally once daily for four weeks.
223541222|NCT05035043|OTHER|Determination of the economic burden NAFLD patients|Determination of the economic burden NAFLD patients (Healthcare costs, patient costs, burden of disease
223541223|NCT01900067|DEVICE|BARRIER® EasyWarm Active Self-Warming Blanket|
223541224|NCT03121144|DEVICE|Masimo Centroid System|Noninvasive positional monitoring device
223956736|NCT06407141|BEHAVIORAL|transcranial pulse stimulation|Participants in the experimental arm will receive six sessions of Transcranial Pulse Stimulation (TPS) over a two-week period, using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). Each session will involve delivering 6,000 ultrasound pulses at an energy level of 0.2-0.25 mJ/mm² and a frequency of 4-5 Hz, targeting specified brain regions based on MRI navigation.
223956737|NCT06407141|BEHAVIORAL|Sham TMS|Participants in the sham control group will undergo six sessions over a two-week period, utilizing the same NEUROLITH® TPS system (Storz Medical AG, Switzerland) as used in the experimental group. The key difference lies in the standoff device attached to the handpiece: while the experimental arm uses a standoff filled with silicone oil to transmit ultrasound pulses, the sham group\&#39;s standoff is filled with air. This design ensures that the sham device replicates the appearance, feel, and sound of the active treatment without transmitting any therapeutic pulses, effectively maintaining the blinding aspect of the study.
223541225|NCT00937495|DRUG|vorinostat|400 mg given PO
223541226|NCT00937495|DRUG|bortezomib|1.3 mg/m\^2 given IV
223541227|NCT00143000|DRUG|Peginterferon alfa-2a 40KD and Ribavirin|
223541228|NCT05526053|OTHER|Lung volume preservation|Extubate the patient connected to the ventilator and PEEP of 5 cmH2O after a successful SBT also using PEEP.
223541229|NCT02159625|DEVICE|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
223541230|NCT01964183|DRUG|tolterodine|Oral
223541231|NCT01964183|DRUG|mirabegron|Oral
223541232|NCT04118829|DRUG|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
223723968|NCT06045897|DEVICE|EEG 64 channels|64-channel EEG in wake and resting conditions for 1h30, with oculogram, electromyogram and electromyogram and electrocardiogram. Five minutes of eyes closed will be used for microstate analysis. 1h30 will be used for the sensorimotor task.
223956738|NCT05829668|BEHAVIORAL|ABA-based functional analysis and treatment|Functional analysis to identify environmental variables maintaining child problem behavior and function-based treatment
223956739|NCT05028257|BIOLOGICAL|COVID-19 Vaccines|Pursuit of vaccination in case of anaphylactic reaction
223956740|NCT06202898|OTHER|Baseline|At the baseline visits, all study participants will be complete an interviewer-assisted questionnaire using REDCap, and will also receive the SBIRT-T MI-based intervention. Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for strength sessions, and they will be provided with a schedule of strength session visits
223541233|NCT06042426|DRUG|Dexamethasone|Two 8 mg doses. One dose applied prior to incision and the other at POD1
223541234|NCT06042426|DRUG|Morphine|Morphine 0.1 mg per kg intravenous every 6 hours
223723969|NCT06045897|DEVICE|Polysomnography 19 electrodes|Overnight polysomnography with 19 EEG channels and ventilatory polygraphy.
223541235|NCT06042426|DRUG|Oxycodone and acetaminophen|2 tabs of oral oxycodone combined with acetaminophen every 6 hours (the same pill includes both drugs)
223541236|NCT03412825|DIETARY_SUPPLEMENT|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
224107679|NCT03619915|OTHER|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
223541237|NCT01889394|PROCEDURE|secondary wound healing|secondary wound healing
223541238|NCT01889394|PROCEDURE|primary wound closure using a limberg flap|primary wound closure using a limberg flap
223541239|NCT06199128|DIETARY_SUPPLEMENT|carboxymethyl β-glucan|It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
223541240|NCT06136143|PROCEDURE|Group 1: Autogenous bone graft|The maxillary sinus will be grafted with the autogenous bone graft.
224107680|NCT03419702|DIETARY_SUPPLEMENT|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
224107681|NCT03681860|BIOLOGICAL|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
224107682|NCT03681860|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
223541241|NCT06136143|PROCEDURE|Group 2: Plenum® Osshp|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device.
223541242|NCT06136143|PROCEDURE|Group 3: Plenum® Osshp; + i-PRF|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with i-PRF.
223541243|NCT06136143|PROCEDURE|Group 4: Plenum® Osshp + autogenous bone graft|The maxillary sinus will be grafted with the Plenum Oss hp (Plenum, Brazil) medical device associated with autogenous bone graft.
223956741|NCT06202898|OTHER|ENTRUST|Participants randomized to the ENTRUST intervention group will also be assigned to a cohort for economic strength sessions, group-based economic training through photovoice activities and adapted screening brief intervention and treatment (SBIRT-T) adapted for transgender women delivered by a facilitator or digitally.
223956742|NCT06202898|OTHER|Control|participants assigned to the control arm will have the option of participating in the four additional strength sessions.
224107683|NCT03681860|BIOLOGICAL|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
224107684|NCT04673903|OTHER|Copenhagen adduction exercise|The Copenhagen Adduction exercise is a simple isolated eccentric partner exercise and doesn't require special equipment and can be performed as a warm up activity on the pitch.
223541244|NCT00441272|DRUG|Pioglitazone|
224107685|NCT04673903|OTHER|Usual warm up|Usual warm up is defined as any basic exercises performed before a performance or practice to prepare the muscles for vigorous actions.
224107686|NCT00262704|BEHAVIORAL|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
223541245|NCT01096108|BEHAVIORAL|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
223541246|NCT01096108|BEHAVIORAL|Motivational and Problem-Solving|Counseling phone calls
223541247|NCT01096108|BEHAVIORAL|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
223541248|NCT03644719|BEHAVIORAL|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
223541249|NCT01121055|DRUG|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
223541250|NCT01121055|DRUG|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
223541251|NCT02954224|OTHER|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
223541252|NCT03929354|BEHAVIORAL|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
223541253|NCT03929354|BEHAVIORAL|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
223956743|NCT03994809|OTHER|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
223956744|NCT05750121|BEHAVIORAL|E-health enhanced motor-cognitive training|The intervention group will implement physical activity (aerobic exercise and resistance training) and cognitive training (CogniFit) intervention with the e-health components (persuasive technology). The intervention period will last for 12 weeks, with three 90 minutes sessions (60 minutes of physical activity and 30 minutes of cognitive training) per week.
223956745|NCT02850939|BEHAVIORAL|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
223956746|NCT02761317|DRUG|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
223956747|NCT02761317|DRUG|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
223956748|NCT02761317|DRUG|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
223956749|NCT00637104|DEVICE|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
223956750|NCT00637104|DEVICE|Vision Co-Cr stent implant|Implant of the Vision stent
223956751|NCT05660811|DRUG|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
223956752|NCT05660811|DRUG|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
223956753|NCT05660811|DRUG|long-term treatment with a single antiplatelet agent|continuing long-term treatment with single antiplatelet agent
223956754|NCT05660811|DRUG|6 months treatment with a single antiplatelet agent|continuing single antiplatelet agent up until 6 months
223956755|NCT03217123|DEVICE|Deep Brain stimulation|Electrical stimulation at subcortical level
223956756|NCT00027014|DRUG|St. John's Wort|
223956757|NCT00027014|DRUG|oxycodone|
223956758|NCT00027014|DRUG|fentanyl|
223956759|NCT01887002|DRUG|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
223956760|NCT01887002|DRUG|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
223956761|NCT00039884|DRUG|NESP - Novel Erythropoiesis Stimulating Protein|
223956762|NCT02207140|DIETARY_SUPPLEMENT|HOWARU Restore|
223956763|NCT01184105|DRUG|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
223956764|NCT01184105|DRUG|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
223956765|NCT00247507|DRUG|acetylcysteine|
223956766|NCT01048385|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
223956767|NCT01048385|DIETARY_SUPPLEMENT|Placebo|Treated with capsules containing the vehicle (Sesame oil).
224107687|NCT00262704|BEHAVIORAL|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
223956768|NCT00554814|DRUG|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
223956769|NCT00554814|DRUG|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
223956770|NCT00554814|DRUG|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
224107688|NCT00543647|DRUG|Fenofibrate 160 mg tablet|
224107689|NCT00543647|DRUG|Placebo|
223541254|NCT03725072|DRUG|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain \[14C\]-evobrutinib.
223956771|NCT06002672|DIETARY_SUPPLEMENT|Placebo comparator: Control group. To the control group was assigned lettuce without any change in salinity but with the same characteristic of eustress lettuce (soil, water, harvesting time).|Lettuce without any eustress was assigned to each participant belonging to the control group which ate 100gr every day for 12 day
223956772|NCT06002672|DIETARY_SUPPLEMENT|Experimental: Eustress group. To the intervention Eustress group was assigned the eustress lettuce.|100gr of eustress lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 12 days
223956773|NCT03094442|DRUG|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
223956774|NCT03094442|DRUG|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
223956775|NCT01135719|PROCEDURE|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
223956776|NCT00780078|PROCEDURE|extubation|extubation failure in patients intubated orotracheally
223956777|NCT05165420|OTHER|Cosmetic product|RV4941A is a face cream product
223956778|NCT06510751|OTHER|CGRP level|CGRP and substance P levels will be analysed by ELISA method in CSF and blood materials.
223956779|NCT00632736|DRUG|Ropinirole XL (formerly CR)|
224107690|NCT01588301|BEHAVIORAL|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
224107691|NCT01588301|BEHAVIORAL|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
224107692|NCT00990015|DRUG|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
224107693|NCT00990015|DRUG|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
224107694|NCT03894540|DRUG|IPN60090|Oral capsules given daily
224107695|NCT03894540|DRUG|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
223541255|NCT01198782|OTHER|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
223541256|NCT01856322|DRUG|Sulindac|one tablet 150mg twice daily
223541257|NCT01856322|DRUG|Placebo|One tablet twice daily
223723970|NCT06045897|BEHAVIORAL|Light hypnosis|Healthy controls will undergo a 5 min light hypnosis exercise that will be focused on proprioception.
223723971|NCT06045897|BIOLOGICAL|Biological sampling|Blood samples will be taken for genetic, epigenetic, proteomic, and metabolomic studies.
224107696|NCT03894540|DRUG|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
223541258|NCT01856322|OTHER|Validate assays and shipping methods|
223723972|NCT06045897|BEHAVIORAL|Virtual reality|Participants will undergo a virtual reality task using a head-mounted display, and their multidimensional self will be assessed prior to and after the task via the self-reference effect on episodic memory.
223723973|NCT06045897|DEVICE|Voice recording|A double channel audio recorder will be used during 30 min to assess voice characteristics of all subjects.
223723974|NCT05551039|OTHER|Retrospective patient chart review|Retrospective patient chart review to be completed by mCRC-treating physicians. Data is collected through an online case report form (CRF); physicians provide case histories of mCRC patients who initiated regorafenib treatment in most recent 3 years (2019-2021).
223723975|NCT00382278|PROCEDURE|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
223723976|NCT00467571|DRUG|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
223723977|NCT02737293|OTHER|Control Diet|4-week intake of Control Diet 5 day rotating menu
223723978|NCT02737293|OTHER|Med Diet|4-week intake of Med Diet 5 day rotating menu
223723979|NCT02737293|OTHER|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
223723980|NCT04360915|DRUG|ASK120067|Take ASK120067 tablets orally in first day at 160 mg in fast condition.
223723981|NCT04360915|DIETARY_SUPPLEMENT|ASK120067 in fed condition|Take ASK120067 tablets orally in first day at 160 mg in fed condition.
223723982|NCT01835587|DRUG|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
224107697|NCT03894540|DRUG|IPN60090 single administration|Oral capsules given once
224107698|NCT02561377|BEHAVIORAL|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
224107699|NCT02561377|BEHAVIORAL|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
223541259|NCT00427011|DRUG|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
223541260|NCT02664480|OTHER|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
223541261|NCT02018484|PROCEDURE|Unicompartmental Knee Replacement|
223541262|NCT04738994|DIETARY_SUPPLEMENT|whey protein-enriched nutritional supplement|Standard hospital diet + 80 g/die (two servings) of whey protein-enriched nutritional supplement dissolved in 125 ml of water
223541263|NCT04738994|OTHER|Control group|Standard hospital diet
223723983|NCT03210597|OTHER|Exercise|The subjects performed training in aquatic environment
223723984|NCT02300532|OTHER|No intervention|
223723985|NCT02132130|DRUG|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
223723986|NCT00838578|BIOLOGICAL|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
223723987|NCT00838578|DRUG|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
223723988|NCT06139432|DEVICE|Active tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* The stimulation level is 2mA for 20 minutes.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
223723989|NCT06139432|DEVICE|Sham tDCS|"* Anode opposite the left dorsolateral prefrontal cortex (between F3 and FP1 according to the 10-20 international placement system).~* Cathode opposite the left temporoparietal junction (between T3 and P3).~* Effective stimulation is delivered for 30 seconds (stimulation level is 2 mA), after which effective stimulation stops. The entire session is 20 minutes, with 19 minutes and 30 seconds without stimulation.~* Sessions are held twice daily on working days (with a minimum of 3 hours between sessions).~Twenty sessions will be carried out, two sessions per consecutive working day."
223723990|NCT05669495|DEVICE|ANNE Vital Sign System|The ANNE Vital Sign System is a wireless remote monitoring system consisting of two flexible, soft, and skin-mounted electronic devices for use by researchers and healthcare professionals for continuous collection of physiological data in home and professional healthcare settings. The ANNE Vital Sign System integrates simultaneous synchronized ambulatory measurement of electrocardiography, photoplethysmography with derived pulse oximetry, pulse arrival time with derived beat-to-beat blood pressure, triaxial accelerometry, respiratory rate, and temperature, which would enable accurate measurement of sleep apnea. Indeed, in compelling in-laboratory preliminary data, we show the capacity for the ANNE Vital Sign System to detect and characterize sleep apnea in older patients. The ANNE Vital Sign System is non-invasive, flexible, easy to use, comfortable, and skin safe.
223723991|NCT00357968|DRUG|Prasugrel|Administered orally
223723992|NCT00357968|DRUG|Clopidogrel|Administered orally
223723993|NCT00357968|DRUG|Placebo for Prasugrel|Administered orally
223723994|NCT00357968|DRUG|Placebo for Clopidogrel|Administered orally
223723995|NCT02882009|DRUG|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
223723996|NCT02882009|DRUG|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
223723997|NCT03181581|BIOLOGICAL|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
223723998|NCT03181581|BIOLOGICAL|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
223723999|NCT05765240|DRUG|Hyaluronic Acid Topical Gels|Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.
223724000|NCT05765240|PROCEDURE|Diode Laser Biostimulation|Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
223724001|NCT02343627|DRUG|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
223724002|NCT02343627|DRUG|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
223724003|NCT01262053|OTHER|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
223724004|NCT01262053|OTHER|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
223724005|NCT01262053|OTHER|Control|Parallel control with no intervention
223724006|NCT02273024|BEHAVIORAL|Exercise|
223956780|NCT02919059|DRUG|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
223956781|NCT02919059|DRUG|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
223541264|NCT05302427|BEHAVIORAL|Infant Massage|The training will start with a leg massage in the first session and the mother will be asked to do this once a day until the next lesson. The next week, the new massage movement will be shown to the mother and the training will continue, and the mother will be told to do the application throughout the week by integrating it with the previous movement this time, and the four-week training will be completed in this way. After the training, which massage movement was taught to the mothers every week, the application pictures of this part will be sent and at the end of the four-week training, the baby massage video and the baby massage guide will be sent to the mothers by e-mail.
223956782|NCT03024021|DEVICE|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia \[36.5 C\]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
223956783|NCT05177432|DEVICE|QPOP|QPOP will be used as a clinical decision support platform to identity suitable patient-specific drug combinations across a range of breast cancer patients, which are derived from drug sensitivity tests using patient-derived materials.
223956784|NCT01366456|DEVICE|Moxibustion|Comparison of different kinds of moxibustion
223541265|NCT02790840|DRUG|Omeprazole|20 mg oral capsules administered once daily for 10 days
223541266|NCT02790840|DRUG|Omeprazole|40 mg oral capsules administered twice daily for 10 days
223541267|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
223724007|NCT05139589|OTHER|None, observational|Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
223724008|NCT04208698|DRUG|CIN-102 Dose 1|Deuterated domperidone (deudomperidone)
223956785|NCT04256148|BIOLOGICAL|ALXN1830|Administered via intravenous (IV) infusion
223956786|NCT04256148|OTHER|Placebo|Matching placebo (sterile liquid diluent) administered via IV infusion
223724009|NCT04208698|DRUG|CIN-102 Dose 2|Deuterated domperidone (deudomperidone)
223724010|NCT04208698|DRUG|Placebo for CIN-102|Placebo
223724011|NCT01480050|DRUG|temozolomide|standard of care drug
223541268|NCT02790840|DRUG|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
223541269|NCT01101672|PROCEDURE|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
223541270|NCT01101672|PROCEDURE|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
223541271|NCT02886650|PROCEDURE|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
223541272|NCT00288015|BIOLOGICAL|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
223541273|NCT00443703|DRUG|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
223541274|NCT00443703|DRUG|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
223724012|NCT01480050|OTHER|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
223956787|NCT01257724|OTHER|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence"
223956788|NCT03400007|DEVICE|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
223956789|NCT03400007|DEVICE|Colpocystodefecography|Colpocystodefecography (CCD)
223956790|NCT00445757|PROCEDURE|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
223956791|NCT00445757|RADIATION|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
223956792|NCT02626117|DEVICE|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
223956793|NCT02626117|DEVICE|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
223956794|NCT05700851|DIETARY_SUPPLEMENT|Immuno-nutrition supplement|Oral Impact® is a powdered oral nutritional supplement that contains a unique combination of ingredients with immuno-modulating properties, namely omega-3 fatty acids, arginine and nucleotides, as well as soluble fibre.
223956795|NCT04423796|DEVICE|Robotic-assisted early mobilization|The early mobilization is done by robotic assistance devices.
223956796|NCT04423796|OTHER|Early mobilization|Early mobilization by health care professionals without robotic assistance.
223956797|NCT03961841|RADIATION|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
223956798|NCT03961841|DRUG|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
223956799|NCT03961841|DRUG|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
223956800|NCT00001958|DRUG|Hydroxyurea|
223956801|NCT00104949|BIOLOGICAL|trastuzumab|
223956802|NCT00589628|DRUG|infliximab|5mg/kg/dose IV at 4 week intervals
223956803|NCT00589628|DRUG|infliximab|10mg/kg/dose IV at 4 week intervals
223541275|NCT00443703|DRUG|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
223541276|NCT00443703|DRUG|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
223541277|NCT01042067|OTHER|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
223541278|NCT01333722|DRUG|Hydrocodone/Acetaminophen Extended Release|
223541279|NCT01333722|DRUG|Placebo|Placebo tablet
223541280|NCT00066339|DRUG|gefitinib|
223541281|NCT01440673|DRUG|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
223541282|NCT01478464|OTHER|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
223724013|NCT01480050|OTHER|pharmacological study|
223724014|NCT01480050|DRUG|Mibefradil|
223724015|NCT03092609|BEHAVIORAL|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
224107700|NCT01803165|PROCEDURE|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
223724016|NCT03092609|BEHAVIORAL|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
223956804|NCT01862159|PROCEDURE|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
223956805|NCT04078607|BEHAVIORAL|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
223956806|NCT04078607|BEHAVIORAL|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
223956807|NCT04784390|DEVICE|Binocular video games|Patients will play 1 hour of binocular video game of choice (Dig Rush and/or Monster Burner) a day 7 days a week for 8 to 12 weeks.
223956808|NCT04784390|DEVICE|Patching of the sound eye|Patients will have their sound eye (fellow eye) patched 2 hours per day 7 days a week for 16 weeks.
223956809|NCT04838860|DRUG|Siltuximab|Participants will receive intravenous (IV) infusion of siltuximab 22 mg/kg over 2 hours every 3 weeks, then possibly dose escalating to 33 mg/kg IV over 3 hours +/- 44 mg/kg IV over 4 hours every 3 weeks if clinically indicated in the absence of dose-limiting toxicity.
223956810|NCT00877305|PROCEDURE|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
223956811|NCT00877305|OTHER|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
223956812|NCT05892445|BEHAVIORAL|Graphic Warning Labels|Based on a thorough review of the literature on e-cigarette risks and adverse effects, a graphic designer will be contracted to create ten experimental aversive health warnings related to e-cigarettes. These warnings will be exported as high-quality images and shown to participants in the intervention group prior to questions that obtain data on the primary endpoint.
224107701|NCT00702312|BEHAVIORAL|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
224107702|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
223956813|NCT04871555|OTHER|MRI|structural imaging
223724017|NCT01990404|DRUG|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
223956814|NCT06081738|DRUG|Neostigmine|a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
223541283|NCT00196794|DRUG|Tolevamer potassium-sodium (GT267-004)|
223541284|NCT03620032|DRUG|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
223541285|NCT03620032|DRUG|Vinorelbine|Chemotherapy
223541286|NCT03620032|OTHER|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
223541287|NCT03053557|BEHAVIORAL|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
223541288|NCT02425787|BEHAVIORAL|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
223956815|NCT06081738|DRUG|Sugammadex|2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
223956816|NCT02428556|OTHER|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
223956817|NCT02428556|OTHER|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
223956818|NCT02428556|OTHER|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
223956819|NCT02428556|OTHER|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
223956820|NCT02428556|OTHER|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
223956821|NCT01502813|DRUG|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
223956822|NCT02302157|BIOLOGICAL|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
223956823|NCT02880306|OTHER|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
223956824|NCT05737797|PROCEDURE|cervical cytology during surgery.|Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
223956825|NCT06331533|DRUG|Botulinum toxin A|Intradermal botulinum toxin A was applied to the treatment side
223956826|NCT06331533|DRUG|Placebo|NaCl was injected into the placebo side
223956827|NCT02450123|DRUG|sunitinib|
223956828|NCT00329017|PROCEDURE|Fine needle aspiration|Fine needle aspiration
223956829|NCT00946998|DRUG|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
223956830|NCT00946998|DRUG|placebo|Placebo tablet will be identical and matched to sertraline tablet.
223541289|NCT02425787|BEHAVIORAL|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~1. With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews \&/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~2. With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
223541290|NCT02425787|BEHAVIORAL|Interview|The interview will be conducted by study team members and will center around legacy item-related questions.
223541291|NCT04177589|OTHER|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
223541292|NCT01374321|DRUG|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
223541293|NCT01374321|DRUG|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
223541294|NCT05653245|DRUG|RGD Peptide|adhesion molecules
223541295|NCT00942370|DEVICE|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~* EMG and MMG Signals of rectus abdominis of the abdomen,~* Respiratory flow,~* An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
223541296|NCT05829005|DEVICE|Transcranial magnetic stimulation (TMS)|TMS is a form of 'non-invasive brain stimulation', i.e. it is a way of stimulating the brain from outside the head. It works by holding a magnetic coil approximately the size of a small side plate against the head (it rests on the scalp) which then delivers magnetic pulses that stimulate the underlying brain. It was developed over 30 years ago and has been increasingly used to treat a number of neurological and psychiatric disorders. It is considered a relatively safe and generally well-tolerated treatment.
223541297|NCT04317339|DRUG|Zhigancao Tang granule|"Zhigancao Tang: Dissolve Zhigancao Tang granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
223541298|NCT04317339|DRUG|Zhigancao Tang placebo granule|"Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed."
223541299|NCT01364480|DEVICE|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
223541300|NCT03420755|BEHAVIORAL|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
223956831|NCT03051529|OTHER|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
223956832|NCT01961453|DRUG|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
223541301|NCT03420755|BEHAVIORAL|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
223541302|NCT04892524|OTHER|Virtual multidisciplinary review|The virtual multidisciplinary review involves participants being reviewed by a multi-disciplinary team of specialist doctors, nurses and radiologists in a virtual environment. The team will analyse radiologic scans and make a recommendations for any follow-up scans, procedures or appointments that may be required
223956833|NCT01961453|DRUG|Placebo capsule|One capsule of placebo administered once daily at 8 am.
223956834|NCT00093743|DRUG|fludarabine phosphate|Given IV
223956835|NCT00093743|DRUG|cyclosporine|Given IV or PO
223541303|NCT04776161|BEHAVIORAL|Cue-Reward Intervention|"Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf."
223541304|NCT04776161|BEHAVIORAL|Cue-Reward Intervention with possible intensification|"Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue."
223541305|NCT06421519|OTHER|BiPAP setting|"Infants in this arm of the study will each rotate through three different BiPAP settings. The following BiPAP settings will be used:~13cmH2O / 5cmH2O, 10cmH2O / 5cmH2O, 7cmH2O / 5cmH2O"
223541306|NCT01388179|DEVICE|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
223541307|NCT03203811|DRUG|HTI-2088|3 dose levels
223541308|NCT03203811|DRUG|Placebo|placebo oral tablet
223724018|NCT01990404|DRUG|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
223724019|NCT05074212|OTHER|Factorial Assignment|At the follow-up visit, two blinded observers will record their scores independently using the physician observer scar assessment score instrument (POSAS).
223724020|NCT03308734|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
223724021|NCT05048940|BIOLOGICAL|Janssen vaccine|0.5 ml millilitre(s) Intramuscular use
223724022|NCT05048940|BIOLOGICAL|Spikevax (Moderna) vaccine|0.5 ml millilitre(s) Intramuscular use
223724023|NCT02324062|OTHER|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
223724024|NCT02324062|OTHER|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
223724025|NCT03501069|DRUG|TAK-418|TAK-418 capsules.
223724026|NCT03501069|DRUG|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
223724027|NCT04344925|DEVICE|Aerosol-reducing Mask|Patient will be put on BIPAP using the aerosol-reducing mask. In the case where the patient is located in a care area where BIPAP is prohibited with a standard mask, they will assigned the aerosol-reducing mask.
223724028|NCT04344925|DEVICE|Standard Mask|Patient will be put on BIPAP using the standard mask
223724029|NCT05412511|BEHAVIORAL|MB-TB|Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
223724030|NCT05412511|BEHAVIORAL|MB-NTB|Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
223724031|NCT05195125|PROCEDURE|Direct Peritoneal Resuscitation|Direct peritoneal resuscitation involves the abdominal infusion and drainage of a peritoneal dialysate in high-risk liver transplant patients, for up to 24 hours after surgery.
223724032|NCT04659304|DRUG|Allocetra-OTS|Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
223724033|NCT05489198|PROCEDURE|cataract surgery with Centurion phacoemulsification system|Cataract surgery performed with the Centurion phacoemulsification system
223724034|NCT05489198|PROCEDURE|cataract surgery with Quatera 700 phacoemulsification system|Cataract surgery performed with the Quatera 700 phacoemulsification system
223724035|NCT02587715|BIOLOGICAL|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
223724036|NCT02587715|OTHER|Liberation therapy|
223724037|NCT03879226|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
223956836|NCT00093743|RADIATION|total-body irradiation|Undergo TBI
223956837|NCT00093743|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
223956838|NCT00093743|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
223956839|NCT00093743|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
223724038|NCT03879226|DEVICE|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
223724039|NCT04448574|OTHER|Chest Wall Deformities Questionaire|Questionaire about epidemiological data was sent to Patients and families
223724040|NCT04931745|DEVICE|Virtual reality|VR headset will be used 5-10 minutes prior to and during port access
223724041|NCT04931745|DEVICE|Tables distraction|Tablet distraction will be used 5-10 minutes prior to and during port access
223724042|NCT04931745|OTHER|No or non-technologic distraction|This approach will be used 5-10 minutes prior to and during port access
223956840|NCT00093743|DRUG|mycophenolate mofetil|Given PO or IV
223956841|NCT05826405|OTHER|No intervention|No intervention, it's an observational study
223724043|NCT06502574|OTHER|mobile application|The mobile application prepared for rational drug use andchronic disease self-management, suitable for use by olderadults, will be required to be used for 6 months.
223724044|NCT00205790|DEVICE|Vascular graft|
223724045|NCT00439244|DRUG|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
223956842|NCT05235997|DIETARY_SUPPLEMENT|Hydrolized Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
223956843|NCT05235997|OTHER|Placebo|Placebo look alike the experimental product
223956844|NCT02556541|PROCEDURE|IV puncture guided by ultrasound|
223956845|NCT02024477|DRUG|Saxagliptin|5 mg tablet once daily for 12 weeks
223956846|NCT02024477|DRUG|Placebo|1 tablet daily for 12 weeks
224107703|NCT00702312|BEHAVIORAL|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
224107704|NCT03043365|DRUG|control fish oil|4 capsules, 3 times a day after meals
223724046|NCT00439244|DRUG|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
223724047|NCT00439244|DRUG|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
223724048|NCT00386945|BEHAVIORAL|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
223724049|NCT05218460|DEVICE|MRI examination|All subjects (healthy and pathological subjects) will have an MRI examination with a component of the MRI system under development.
223724050|NCT04674410|DRUG|Antibiotic|Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
223724051|NCT00221585|BEHAVIORAL|Psychosocial treatment/Psychodynamic treatment|
223724052|NCT04051866|PROCEDURE|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
223724053|NCT04051866|OTHER|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
223724054|NCT03589872|DIAGNOSTIC_TEST|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
223724055|NCT05813015|DRUG|Docetaxel|Docetaxel 40mg/m2，every 21 days，6 cycles.
223724056|NCT05813015|DRUG|Tegafur-Gimeracil-Oteracil|S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.
223724057|NCT05024591|DEVICE|Lunit INSIGHT MMG CADe/x for medical imaging|• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis
223956847|NCT00090064|DRUG|Midomafetamine HCl|125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
223956848|NCT00090064|DRUG|Lactose placebo pill|125 mg followed by a supplemental half-dose of 62.5 mg
223724058|NCT01104350|OTHER|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~* Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~* Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~* Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
223956849|NCT00090064|BEHAVIORAL|Therapy|Non-directive therapy provided by a team of two co-therapists
223956850|NCT03428009|OTHER|Magnetic Resonance Imaging|Study interventions are minimal risk.
223956851|NCT01904253|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
224107705|NCT03043365|DRUG|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
224107706|NCT02830373|DEVICE|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
223956852|NCT01904253|DRUG|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
223956853|NCT01904253|DRUG|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
223956854|NCT03414515|DEVICE|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
223724059|NCT04102020|DRUG|Venetoclax|Tablet: Oral
223956855|NCT04962776|DRUG|Low-concentration carbohydrate and nitrates|Patients in the CHON group will be given 400 mL of a clear carbohydrate drink (12.5 g/100 mL maltodextrin, 50 kcal/100 mL) and 2 capsules of beet root extract 1 gm on the evening before surgery (8 hours) and another 200 mL of the carbohydrate drink and 1 capsule of beet root extract 1 gm on the day of surgery, 2 h before anesthesia induction.
223956856|NCT04962776|DRUG|Low-concentration carbohydrate|Patients in the CHO group will be given the same carbohydrate drink in the CHON group with 2 placebo capsules with the evening drink and one with the morning drink.
223956857|NCT04962776|OTHER|Water with placebo capsules|Patients in the W group will be given equivalent volume of drinking water with placebo capsules by evening and in the morning of surgery.
223956858|NCT06057701|OTHER|corrective exercises|"corrective exercises:~1. Strengthening exercises :~   1. Thoracic extension exercises:~      * Mckanzie's thoracic extension exercise:~     * Thoracic spine stretching position~  2. Back extension exercise~  3. Abdominal curl up exercise~  4. Scapular retraction exercises~  5. Trunk rotation exercise~2. Stretching exercises:~   1. Pectoral muscles stretch from sitting~  2. self-stretch for pectoral muscle infront of door"
223956859|NCT06057701|OTHER|resisted diaphragmatic breathing exercises|"1. Diaphragmatic breathing exercise: From the supine position, overlapping hands on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly.~2. Resisted diaphragmatic breathing exercise: From the supine position, with a weight of 1 kg on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly"
223956860|NCT03284957|DRUG|Amcenestrant|"Pharmaceutical form: capsule~Route of administration: oral"
223956861|NCT03284957|DRUG|Palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
223956862|NCT03284957|DRUG|Alpelisib|"Pharmaceutical form: tablet~Route of administration: oral"
223956863|NCT03284957|DRUG|Everolimus|Pharmaceutical form: tablet
223956864|NCT03284957|DRUG|Abemaciclib|Pharmaceutical form: tablet
223956865|NCT06005311|DEVICE|Microfluidic chip|The Sperm Separation Device - ZyMōt Multi 850µL (ZyMōt Fertility, Inc) will be used. The microfluidics chamber will be used according to the manufacturer's instructions. 850 μL of the semen sample will be inserted into the inlet port of the device and 750 μL of fertilization media will be inserted into the outlet port. The device with the semen sample inside will be incubated in 6% CO2 at 37°C. After 30 min, 500 μL of the sample at the outlet port will be removed from the outlet port and pipetted into a labelled test tube.
223956866|NCT06005311|DEVICE|Density-gradient centrifugation|After liquefaction, sperm preparation will be completed by a discontinuous density gradient centrifugation method, using Pureception (CooperSurgical, Denmark) sperm density gradient media. The resulting sperm pellet after centrifugation will be washed once with the sperm washing medium (G-IVF Plus, Vitrolife, Sweden) The washed spermatozoa will be resuspended with the same medium, adjusting the final volume to 0.5 mL.
223956867|NCT03978130|OTHER|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
223956868|NCT00114894|OTHER|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
223956869|NCT00114894|OTHER|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
223956870|NCT03227458|OTHER|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
223956871|NCT03227458|OTHER|Placebo|Participants will take placebo daily for 36 weeks.
223956872|NCT03227458|BEHAVIORAL|Exercise|bone-loading exercise on 3 days per week for 38 weeks
223956873|NCT05952908|OTHER|Proficiency-Based Progression simulation training|The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
223956874|NCT05952908|OTHER|Traditional simulation training|The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
224107707|NCT05667519|PROCEDURE|Additional guidance of lead implantation by transesophageal echocardiography|Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position
223541309|NCT05007197|BEHAVIORAL|The Effect of Diabetes Education Based on Learning Modality|"After controlling the metabolic values of the individuals in the intervention group, the education were carried out according to the learning modality of the people; Visual learners; education booklet, brochure, slides (enriched with pictures and videos), lecture, insulin injector-pen, glucose meters, introduction and demonstration of blood glucose tracking book Auditory learners; education booklet, slides, videos, lecture, question-answer, group work, peer group discussion, experience sharing Tactile learners; education booklet, slides, demonstration, insulin injector-pen, glucose meter doing the application of tools and equipment such as on the model, on himself, on his friend, filling in the blood glucose tracking book.~Group-specific diabetes trainings were completed in 2 training sessions. Each training session lasted an average of 1.5 hours The learning modality of the control group were determined and standard group training was provided with the education booklet."
223541310|NCT03865433|OTHER|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
223541311|NCT03865433|OTHER|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
223956875|NCT03901924|OTHER|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
223956876|NCT03901924|OTHER|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
223956877|NCT05543759|DIETARY_SUPPLEMENT|Ready-To-Use Therapeutic Food (RUTF)|"* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets RUTF/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
223956878|NCT06146088|BIOLOGICAL|EV71 Vaccine|Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
223956879|NCT03115879|OTHER|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
223956880|NCT03115879|OTHER|Hip manipulation simulation|Hip manipulation simulation
223956881|NCT02464306|DRUG|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
223956882|NCT05659745|OTHER|VM-02|VM-02 is a personal care product for vaginal health.
223956883|NCT05659745|DIETARY_SUPPLEMENT|Commercial Oral Probiotic Competitor|Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.
223956884|NCT05659745|OTHER|VM-02 Placebo|VM-02 Placebo is a personal care product placebo for vaginal health.
223956885|NCT04457583|DEVICE|Inspiratory muscle training with powerbreathe|Participants will be submitted to a linear pressure resistance (Powerbreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 exercises for 12 weeks.
223956886|NCT05973669|DEVICE|MED-EL Remote Care|Remote cochlear implant support
223956887|NCT06429124|BEHAVIORAL|Dietary Intervention|Participants will be instructed to follow a 16/8 regimen characterized by 16 hours of fasting and an 8-hour eating window daily, on approximately 5 days/week, for 3 months. Previous research has shown that 16 hours of fasting is feasible, safe and well-tolerated among older adults, and that most persons report easy adjustment (Anton, Lee et al. 2019, Lee, Sypniewski et al. 2020). The intervention will be implemented through individual and group sessions with participants and will involve extensive education, coaching, guidance, and support throughout the 3-month intervention. Educational materials on lifestyle factors including physical activity will be provided to each participant. We will be also be collecting data on physical activity and sedentary behavior. These data will be co-variates when we conduct the statistical analysis.
223956888|NCT06114641|DRUG|Enoxaparin sodium injection|Originator Enoxaparin with a trade name is Lovenox.
223956889|NCT01562275|DRUG|Ipatasertib|multiple doses
223724060|NCT04102020|DRUG|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
223724061|NCT04102020|DRUG|Azacitidine|Oral Tablet
223956890|NCT01562275|DRUG|Cobimetinib|multiple doses
223956891|NCT06124118|RADIATION|carboplatin chemotherapy|"Concurrent chemoradiation will be given per standard of care within 24 hours of initiation of standard of care radiation therapy. Treatment will include a paclitaxel/carboplatin chemotherapy regimen administered during the radiotherapy course (over 6-7 weeks).~Paclitaxel (50 mg/m2) will be administered intravenous over 1 hour followed by Carboplatin AUC = 2 mg/min/mL intravenous weekly (every 7 days ± 3 days) during radiotherapy 11, NCCN Non-small cell lung cancer guidelines 2023).~If a patient has a hypersensitivity reaction to weekly paclitaxel, weekly nab-paclitaxel is allowed to replace paclitaxel at the discretion of the treating medical oncologist 37. The recommended starting dose of weekly nab-paclitaxel is 40 mg/m2 to 50 mg/m2 38 39. Standard premedications with steroids, diphenhydramine, H2 receptor antagonist, and 5-HT3 receptor antagonist antiemetics must be administered per individual institutional guidelines."
223956892|NCT06124118|DEVICE|NovoTTF-200T (TTFields) System|"The NovoTTF-200T (TTFields) System is an investigational medical device delivering 150 kHz TTFields to the thorax for the treatment of patients at the age of 22 years or older. The device is a portable, battery operated system which delivers TTFields at 150 kHz to the thorax by means of insulated Transducer Arrays. The NovoTTF-200T produces electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz to the thorax will be continuous for at least 11 hours a day on average, with a recommended duration of at least 18 hours a day. Subjects may take breaks for personal needs (e.g. showering, array exchange). TTFields may be continued as long as there is no disease progression per RECIST 1.1 or any of the treatment discontinuation conditions for subject withdrawal or termination."
223541312|NCT00705913|DEVICE|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
223541313|NCT00705913|DEVICE|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
223541314|NCT04552041|DRUG|Prospekta|Oral administration.
223541315|NCT04552041|DRUG|Placebo|Oral administration.
223541316|NCT03955783|DRUG|Venetoclax|Given by mouth
223541317|NCT03955783|DRUG|Selinexor|Given by mouth
223956893|NCT06124118|DRUG|Durvalumab|Consolidation Durvalumab will be given per standard of care and institutional guidelines every 4 weeks for up to 12 cycles. Refer to package insert for detailed pharmacologic, dosing, and safety information.
223956894|NCT03450018|DRUG|SLC-0111|Oral SLC-0111
223956895|NCT03450018|DRUG|Gemcitabine Injection|1000 mg/m\^2 IV
223956896|NCT04049578|DRUG|Balovaptan|Participants were to receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
223541318|NCT06057805|DEVICE|Blinded Dexcom G7 CGM|CGM that records blood glucose but not visible to patient or provider in real time
223541319|NCT00960544|DRUG|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
223541320|NCT01106989|DRUG|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
223541321|NCT02071901|DRUG|eltrombopag olamine|Given PO
223541322|NCT05520684|DIAGNOSTIC_TEST|urine culture and urinalysis|urine culture and urinalysis
223541323|NCT05013814|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament test|Tactile function was evaluated mainly as tactile registration by using 20-item Semmes-Weinstein monofilament (SWM) kit. The monofilament was applied three times with a pseudorandom order to distal pad of the thumb, index, 4th and 5th digits (C6, C7 and C8 dermatomes). The lowest value of monofilament was recorded which the child was able to correctly identify at least one touch out of three
223541324|NCT05013814|DIAGNOSTIC_TEST|Box and Block Test|Box and Block Test (BBT) was used for dexterity assessment. The BBT measures unilateral gross manual dexterity. The child was asked to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size within 60 seconds
223541325|NCT05013814|DIAGNOSTIC_TEST|9-Hole Peg Test|9-Hole Peg Test (9-HPT) is used to measure finger dexterity. Firstly, the child takes the pegs from a container, one by one, and place them in the holes on the board; then participant removes the pegs from the holes and replaces them back into the container. The total time taken to complete the test is recorded in seconds.
224107708|NCT05372315|DRUG|Dextenza 0.4Mg Ophthalmic Insert|(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.
224107709|NCT00388739|DRUG|Intervention: Budesonide|Patients 1-5 years of age who are randomly assigned to the treatment arm will be given a one month supply as well as a prescription (for a 6 month supply) for Pulmicort respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
224107710|NCT00388739|DRUG|Usual care: albuterol + systemic steroids|All children (control and treatment arm) will be given a burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day) at discharge from the ED. All children 1-5 years of age will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor.
224107711|NCT00802477|PROCEDURE|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
224107712|NCT00802477|PROCEDURE|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
224107713|NCT04346225|DRUG|Hyperpolarized C13|Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
224107714|NCT04346225|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in your body
224107715|NCT01283620|BEHAVIORAL|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
224107716|NCT01283620|OTHER|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
224107717|NCT05561621|OTHER|Voice analysis|Voice analysis
224107718|NCT05109390|DRUG|Danicopan|Oral tablet.
224107719|NCT05109390|DRUG|Cyclosporine|Oral capsule.
224107720|NCT05109390|DRUG|Tacrolimus|Oral capsule.
224107721|NCT05109390|DRUG|Calcium Carbonate|Chewable tablet.
224107722|NCT05109390|DRUG|Aluminum/Magnesium Hydroxide/Simethicone|Chewable tablet.
224107723|NCT05109390|DRUG|Omeprazole|Oral, delayed-release capsule.
224291194|NCT04669548|DEVICE|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
224107724|NCT03570229|OTHER|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
224107725|NCT01421849|PROCEDURE|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
224107726|NCT02797873|OTHER|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
224107727|NCT02797873|OTHER|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
224107728|NCT02797873|BEHAVIORAL|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
223541326|NCT05013814|DIAGNOSTIC_TEST|Duruöz Hand Index (DHI)|Duruöz Hand Index (DHI) is an 18-item self-report questionnaire regarding ability to carry out manual tasks. Individual items are scored on a 6-point Likert scale where 0=without difficulty and 5=impossible. The total score ranges from 0-90 with higher scores indicating poorer hand function.
223724062|NCT06117709|BEHAVIORAL|I-STAMP|A patient-facing smartphone application that hosts participants' analgesic and laxative medications, provides pain-specific psychoeducation, collects patient reported outcomes, and provides feedback to participant symptoms.
223956897|NCT04748497|OTHER|Standardization of evaluation and follow-up|"Standardization of evaluation and clinical and sportive follow-up of athletes.~Made-to-measure technical supports will be tested regarding the Paralympic regulations."
224107729|NCT02797873|OTHER|SCID-II|See Detailed Study Description.
224107730|NCT02797873|OTHER|SDQ|See Detailed Study Description.
224107731|NCT02797873|OTHER|ASRS|See Detailed Study Description.
223541327|NCT05013814|DIAGNOSTIC_TEST|Jamar hand dynamometer|Hand grip strength was measured by using Jamar hydraulic hand dynamometer. Measurement was done with the participant in sitting position and the elbow at 90 degrees of flexion. The force has most commonly been measured in kilograms according to the amount of static force that the hand can squeeze around the dynamometer.
223541328|NCT05013814|DIAGNOSTIC_TEST|Hydraulic pinch gauge|Hydraulic pinch gauge is used for evaluation of finger grip strength. The evaluation method was the same as Jamar hand dynamometer.
223724063|NCT03898362|OTHER|pneumatically powered wheelchair or scooter|a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
223956898|NCT04479020|DEVICE|Mechanical Thrombectomy|Mechanical thrombectomy requiring the use an APERIO® or APERIO® Hybrid(17) Thrombectomy device due to an thrombotic occlusion in a distal vessel of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA)
223956899|NCT04003558|OTHER|No interventions|As this is a patient registry, there are no interventions.
223956900|NCT03473665|DRUG|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
223956901|NCT03473665|DRUG|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
224107732|NCT02797873|OTHER|AQ|See Detailed Study Description.
224107733|NCT02797873|OTHER|TAS-20|See Detailed Study Description.
224107734|NCT02797873|OTHER|Raven's SPM|See Detailed Study Description.
224107735|NCT02797873|OTHER|Reading ability|See Detailed Study Description.
224107736|NCT02797873|OTHER|Ishihara's tests for colour deficiency|See Detailed Study Description.
224107737|NCT02797873|OTHER|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
224107738|NCT02797873|OTHER|Brown-ADD|See Detailed Study Description.
224107739|NCT02797873|OTHER|MFQ|See Detailed Study Description.
224107740|NCT02797873|OTHER|STAI-T|See Detailed Study Description.
224107741|NCT02797873|OTHER|BIS|See Detailed Study Description.
224107742|NCT02797873|OTHER|DAWBA|See Detailed Study Description.
224107743|NCT02797873|OTHER|STAI-S|See Detailed Study Description.
224107744|NCT02797873|OTHER|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
224107745|NCT02797873|OTHER|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
224107746|NCT02797873|BEHAVIORAL|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
224107747|NCT02797873|OTHER|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
224107748|NCT02797873|OTHER|Structural T2 MRI scan|See Detailed Study Description.
224107749|NCT02797873|OTHER|DTI MRI scan|See Detailed Study Description and Outcome Measures.
224107750|NCT02797873|OTHER|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
224107751|NCT01515072|OTHER|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
224107752|NCT03887832|OTHER|SMBI digital app|Digital platform on the smartphone for the media package
224107753|NCT03887832|BEHAVIORAL|media package|The SMBI app contains a \<1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
224107754|NCT03887832|OTHER|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
224107755|NCT03990948|OTHER|Blood sampling|Blood sample collection
223541329|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App|The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
223724064|NCT03898362|DEVICE|battery powered wheelchair or scooter|a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
223541330|NCT04951102|BEHAVIORAL|Shared Decision Making Physician Training Video|Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
224107756|NCT02333539|BEHAVIORAL|Adherence behaviors and recommendations for improvement.|
224107757|NCT02333539|BEHAVIORAL|Adherence behavior that needs improvement is targeted|
224107758|NCT01508676|DRUG|Pennsaid|
224107759|NCT01508676|DRUG|Placebo (2.3% DMSO solution)|
224107760|NCT01103050|DRUG|QAV680 + Cetirizine Placebo|
224107761|NCT01103050|DRUG|QAV680 + Cetirizine|
224107762|NCT01103050|DRUG|Cetirizine + QAV680 Placebo|
224107763|NCT01103050|DRUG|QAV680 Placebo + Cetirizine Placebo|
224107764|NCT02532543|BIOLOGICAL|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
224107765|NCT02532543|BIOLOGICAL|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
224107766|NCT02532543|BIOLOGICAL|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
224107767|NCT02532543|BIOLOGICAL|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
224107768|NCT00609128|DRUG|olopatadine|olopatadine one drop in one eye for one week
224107769|NCT05087186|BEHAVIORAL|Guided imagery and FLASH technique|"Five virtual group sessions delivered by psychological therapists;~* Sessions 1 and 2: Guided imagery~* Sessions 3 and 4: FLASH technique~* Session 5: Refresher on guided imagery and FLASH technique"
224107770|NCT00650585|BEHAVIORAL|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
224107771|NCT02984878|DEVICE|Revanesse Ultra|Nasolabial Fold correction
224107772|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
224107773|NCT00923091|DRUG|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
224107774|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
224107775|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
224107776|NCT00923091|DRUG|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
224107777|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
224107778|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
224107779|NCT00923091|DRUG|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
224107780|NCT05378789|PROCEDURE|Nap|"ICU nurses can take a 20-mn nap between 2 and 5 am according to a rotation of personal.~Naps will be carried out with the help of a Nap and Up ® cocoon deckchair."
224107781|NCT02069782|OTHER|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
224107782|NCT00178321|DEVICE|earplugs|
224107783|NCT05638386|PROCEDURE|Bone plug|The investigational treatment is the use of a bone plug in the two drill-holes in the tibia, made by two pins for securing the tibial array to the bone. The pins that are used for this, are 4.0mm wide. The bone plug that is used to fill the drill-holes of tibia, is obtained from the bone that is removed during the operation to make place for the new prosthesis. A piece as wide as the drill-hole is cut off the recessed bone and put into this hole. After this, the wound is closed using surgical staples.
224107784|NCT05221294|DRUG|Modified Del Nido Versus Custodiol Cardioplegia|Modified Del Nido Versus Custodiol Cardioplegia For Myocardial Protection In Cardiac Surgery
224107785|NCT03598231|DEVICE|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
224107786|NCT04479501|OTHER|Asthma exacerbation related hospitalization|Evaluate the difference between patients with single and multiple hospitalizations for asthma exacerbation
224107787|NCT05875935|PROCEDURE|ECoG : electrocorticography|"The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA)."
224107788|NCT00239200|DRUG|Lapatinib|
224107789|NCT04626219|OTHER|Imaging|Imaging - Magnetic Resonance Imaging (MRI) scan of their heads
224107790|NCT04626219|BEHAVIORAL|fast|hungry state - refrain from eating after lunch at 12 noon until 9 a.m. the next morning
224107791|NCT04626219|BEHAVIORAL|regulated meals|standardized diet from noon until 9 a.m. the next day
223541331|NCT04951102|BEHAVIORAL|Electronic Asthma Shared Decision-Making App- Patient Data|Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
224107792|NCT05443438|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and generalization as 2D
224107793|NCT05443438|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and generalization as 3D
224107794|NCT05443438|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
224107795|NCT03879668|DEVICE|eIPOS|Electronic version of IPOS
223541332|NCT04951102|BEHAVIORAL|Standard Care|Standard Care for asthma.
223541333|NCT04754763|DRUG|Dentin-Bonding Agents|3M ESPE Scotchbond™ Universal Adhesive systems is a seventh generation single-bottled one-step self-etch adhesive system.
223541334|NCT04754763|DRUG|Propolis|Propolis was obtained from Margalla hills, Islamabad by NARC (National Agriculture Research Council, Islamabad). Plant source origin is Acacia modesta and Apis mellifera bees collect it. The 30% ethanolic extract of propolis from raw propolis was obtained in Pakistan Council of Scientific \& Industrial Research (PCSIR) by dissolving the propolis in 95% ethanol and straining out the precipitate
223541335|NCT02603679|DRUG|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
223541336|NCT02603679|DRUG|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
223541337|NCT02603679|DRUG|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
223541338|NCT02603679|DRUG|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
223541339|NCT02100293|DRUG|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
223541340|NCT02100293|DRUG|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
223541341|NCT02835586|DRUG|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
223541342|NCT02971709|BEHAVIORAL|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
223541343|NCT06218810|DRUG|Cadonilimab + bevacizumab + FOLFOX|Cadonilimab + bevacizumab + FOLFOX
223956902|NCT03473665|DRUG|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
223956903|NCT03473665|DRUG|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
223541344|NCT02492243|DEVICE|PCI|
223956904|NCT00051740|BEHAVIORAL|Cognitive Adaptation Therapy (CAT)|
223541345|NCT02492243|DEVICE|ILR implantation|
223541346|NCT05759208|DRUG|OK-101|Ophthalmic Solution
223541347|NCT05759208|DRUG|Placebo|Placebo
223956905|NCT00051740|BEHAVIORAL|Minimal Environmental Supports (MES)|
223956906|NCT02741921|DEVICE|VivaSight DL|intubation using VivaSight DL tube
223956907|NCT02741921|DEVICE|conventional double-lumen tube|intubation using conventional double-lumen tube
223956908|NCT03054194|DRUG|E2730|capsules
223956909|NCT03054194|DRUG|Placebo|capsules
223541348|NCT03672149|DRUG|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
223541349|NCT02890277|DEVICE|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
223541350|NCT02890277|DRUG|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
223541351|NCT04764721|DEVICE|18F-FDG PET-CT|Enrolled patients in Neurocog-Covid will receive a 18F-FDG PET-CT
223541352|NCT00661830|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
223541353|NCT00661830|DRUG|Placebo|Placebo
223541354|NCT00661830|DRUG|Sorafenib|Sorafenib 400 mg bid orally continuously
223541355|NCT00488514|DRUG|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
223956910|NCT01498406|DIETARY_SUPPLEMENT|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (\<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (\>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
223956911|NCT02802176|DEVICE|INVOcell device|intra-vaginal culture of embryos using INVOcell device
223956912|NCT02802176|OTHER|Traditional IVF|traditional culture of embryos in-vitro
223956913|NCT00304278|DRUG|Erlotinib (Tarceva)|150 mg daily X 7 weeks
223956914|NCT00304278|DRUG|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
223956915|NCT00304278|RADIATION|Radiation Therapy (RAD)|5 days per week X 7 weeks
223956916|NCT06462768|OTHER|Blood sample|Blood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
224107796|NCT06964360|BEHAVIORAL|REDOCVR Psychoeducational Program|A clinician-guided, group-based psychoeducational program combining pain neuroscience education, emotional regulation techniques, physical activation, and immersive virtual reality experiences. Delivered in eight weekly 90-minute sessions. Includes structured medication tapering support provided by primary care physicians.
224107797|NCT06964360|BEHAVIORAL|Standard Educational Materials|Participants receive written and audiovisual materials on chronic pain self-management. Materials are used independently without group sessions or virtual reality. No structured tapering support is provided beyond usual care.
223956917|NCT03490747|BEHAVIORAL|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan \& Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
223956918|NCT03490747|BEHAVIORAL|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
223956919|NCT05018455|OTHER|Fall prevention program training based on Otago principles|balance and strength exercises
223956920|NCT04397822|BIOLOGICAL|Blood samples|Blood samples will be collected in peripheral blood at the admission in intensive care unit or in standard care unit to compare platelet inflammasome NLRP3 and others markers
223956921|NCT03334071|BEHAVIORAL|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last \<1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
223956922|NCT00518310|DRUG|Placebo|
223956923|NCT00518310|DRUG|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
223956924|NCT01945593|BIOLOGICAL|BAX855|Antihemophilic Factor (Recombinant), PEGylated
223956925|NCT04285151|PROCEDURE|Nd:YAG laser Hyaloidotomy|Using the YAG laser for opening the posterior hyaloid in eyes with premacular hemorrhage, and evacuating the entrapped hemorrhage
223956926|NCT05855499|DEVICE|CPtcube, CPTpatch|This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
223956927|NCT04466917|DRUG|ABP 215|ABP 215 will be administered at a dose of 15 mg/kg IV
223956928|NCT04466917|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg IV
223956929|NCT04466917|DRUG|Paclitaxel|Paclitaxel will be administered 175 mg/m2 IV
223956930|NCT04466917|DRUG|Carboplatin|Carboplatin will be administered at an area under the concentration-time curve (AUC) of 5 IV
223956931|NCT06379763|OTHER|diaphragmatic breathing exercise|15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
223956932|NCT06379763|OTHER|conventional physiotherapy exercise|conventional physiotherapy exercise such as ROM, stretching exercises for superficial neck muscles
223956933|NCT01741636|OTHER|educational intervention|Undergo Survivorship Care Planning
223541356|NCT04630925|OTHER|isCGM|As previously described
223541357|NCT00203385|DRUG|Divalproex|Depakote up to 2000mg/d
223724065|NCT03853616|BIOLOGICAL|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
223956934|NCT01741636|OTHER|questionnaire administration|Ancillary studies
223956935|NCT01741636|PROCEDURE|quality-of-life assessment|Ancillary studies
223956936|NCT00674258|BIOLOGICAL|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
223956937|NCT01621321|DRUG|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
223956938|NCT01621321|DRUG|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
223956939|NCT00507429|DRUG|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
223956940|NCT00507429|DRUG|paclitaxel|200mg/m squared on Day 1
223541358|NCT00517699|DRUG|rituximab [MabThera/Rituxan]|750mg/m2 iv
223541359|NCT00517699|DRUG|Methotrexate|8g/m2 iv
223541360|NCT00517699|DRUG|Cytarabine|2g/m2 iv
223724066|NCT05318963|BIOLOGICAL|LCAR-AIO cells product|before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
223956941|NCT00507429|DRUG|carboplatin|6 AUC on Day 1 following paclitaxel
223956942|NCT02230709|OTHER|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
223956943|NCT02230709|OTHER|"TENS and dry needling"|Application of TENS current after dry needling technique
224107798|NCT06963853|DIAGNOSTIC_TEST|Blood cultures will be obtained from three sources: 1. The central venous catheter (CVC), 2. The dialysis machine circuit, and 3. A peripheral vein|PTH levels during sepsis and compare them to baseline pre-infection levels, with serial follow-up of PTH values post-recovery.
223956944|NCT03488498|OTHER|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
223956945|NCT02793557|DRUG|FOL-005|Intradermal injection of 50 μl solution
223956946|NCT02793557|OTHER|Placebo|
223956947|NCT05351788|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)
223956948|NCT05351788|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)
223956949|NCT05351788|DRUG|Carboplatin|Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)
223956950|NCT05351788|DRUG|Cisplatin|Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
223956951|NCT06233422|OTHER|No intervention involved|No intervention involved
223956952|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 68Ga-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
223956953|NCT04367948|DIAGNOSTIC_TEST|18F-FDG and 18F-NOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time
223541361|NCT00540696|DRUG|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
223541362|NCT02332187|DEVICE|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
223956954|NCT04110756|BEHAVIORAL|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
223956955|NCT05434559|DRUG|Insulin Degludec|Switch during standard routine care to Insulin Degludec.
223956956|NCT05981586|OTHER|Plyometric strengthening exercises|Comparative effects 1
223956957|NCT05981586|OTHER|Isotonic strengthening exercises|Comparative effects 2
223956958|NCT05090904|DRUG|Brensocatib|Oral tablet
223956959|NCT05090904|DRUG|Placebo|Oral tablet
223956960|NCT01587703|DRUG|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
223541363|NCT02332187|DEVICE|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
223541364|NCT05141838|DRUG|Vitamin D|Adding vitamin D preparations to the therapy in the individual required dosage to correct the deficient state
223541365|NCT05141838|DIETARY_SUPPLEMENT|Oral nutritional supplement|Adding оral nutritional supplement to the therapy depending on the degree of protein-energy malnutrition
223541366|NCT05580354|DRUG|BCG combined with Tislelizumab|Patients will receive 17 cycles of Tislelizumab (200mg per cycle) in combination with BCG (6-week induction course of 120mg followed by maintenance with 3 weekly infusions of 120mg at months 3,6,12).
223541367|NCT01370187|DRUG|Montelukast|Montelukast 4mg daily for 2 months
223956961|NCT05971615|OTHER|peripheral venous blood gases|peripheral venous blood gases
223956962|NCT04893824|DEVICE|Grappler® Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
223956963|NCT03539497|DIAGNOSTIC_TEST|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
223956964|NCT01878955|GENETIC|AMH level difference between patient with PCOS and multicystic ovaries.|
223956965|NCT05849220|DRUG|Dapagliflozin|Dapagliflozin
223956966|NCT05849220|OTHER|Standard of Care|Standard of Care
223956967|NCT00554905|PROCEDURE|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
223541368|NCT00980148|DRUG|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
223541369|NCT00980148|DRUG|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
223956968|NCT00554905|PROCEDURE|TACE|TACE first, then RFA within 2 weeks
223956969|NCT00878904|DRUG|epirubicin hydrochloride|
223956970|NCT00878904|DRUG|panobinostat|
223956971|NCT00878904|GENETIC|gene expression analysis|
223956972|NCT00878904|GENETIC|protein expression analysis|
223956973|NCT00878904|GENETIC|western blotting|
223956974|NCT00878904|OTHER|immunologic technique|
223956975|NCT00878904|OTHER|laboratory biomarker analysis|
223956976|NCT00878904|OTHER|pharmacological study|
223956977|NCT04523909|DIAGNOSTIC_TEST|Trajectory of neuroinflammatory proteins in CSF and blood|Kinetics of neuroinflammatory markers in CSF and blood
223956978|NCT03948958|OTHER|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
223956979|NCT03948958|OTHER|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
223956980|NCT03948958|OTHER|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
223956981|NCT03948958|OTHER|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
223956982|NCT03948958|OTHER|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
223956983|NCT05736237|GENETIC|Whole exome sequencing|With Next Generation Sequenzing
223956984|NCT04343989|DRUG|Clazakizumab 25 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
223956985|NCT04343989|DRUG|Clazakizumab 12.5 mg|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
223956986|NCT04343989|OTHER|Placebo|The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Placebo arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of placebo will be given no later than day 3.
223956987|NCT02068079|DRUG|Vemurafenib and Trientine|
223956988|NCT02272608|OTHER|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
223956989|NCT01396122|PROCEDURE|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA\* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
223956990|NCT02147652|OTHER|Personalized music|
223956991|NCT04944589|PROCEDURE|ROOT CANAL TREATMENT|Clinical endodontics involved in the goal of preventing and treating microbial contamination of pulps comprises of a number of treatments. Root canal endodontic therapy has one specific set of aims: to cure or prevent peri-radicular periodontitis, to conserve their natural teeth in function and aesthetics.
223956992|NCT04502745|DEVICE|Minimally Invasive Cortical Access System (MICAS)|Temporary surgical tool that provides access to the sub-dural space through the cranium.
223956993|NCT00306735|DRUG|Palonosetron|
223956994|NCT04779047|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
223956995|NCT04779047|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
223956996|NCT04779047|DRUG|Tocilizumab|Tocilizumab 800 mg once.
223956997|NCT04779047|DRUG|Lopinavir/ Ritonavir|Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
223956998|NCT04779047|DRUG|Ivermectin|Ivermectin 36 mg at day 1,3 and 6.
223956999|NCT03877133|DEVICE|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
223957000|NCT02321371|DRUG|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
223957001|NCT02321371|DRUG|Lactulose|Continuation of Lactulose therapy for further 48 hours.
223957002|NCT01573741|DRUG|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
223957003|NCT03966599|DIAGNOSTIC_TEST|Pain|Patient's pain in order to VAS
223957004|NCT03966599|DIAGNOSTIC_TEST|Hemodynamic changes|changes in hemodynamic states
223957005|NCT01693393|DRUG|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
223957006|NCT01295619|DEVICE|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
223957007|NCT04304898|OTHER|Home spirometry|"* Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~* Hospital-based spirometry will be performed according to international guidelines.~* Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months."
223957008|NCT04362722|DRUG|L19IL2 +L19TNF|Single or multiple intratumoral administration of a mixture of L19IL2 and L19TNF will be performed once weekly for up to 4 weeks into all injectable lesions present at the beginning of treatment or appearing during treatment phase The dose will be constituted by 6.5 Mio IU L19IL2 (\~1.08 mg) and 200 µg L19TNF.
223957009|NCT03117842|OTHER|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
223957010|NCT05843149|BEHAVIORAL|Manual Therapy/Exercises|Three individual therapy sessions and nine group sessions manual therapy/exercises of 60 min. duration under the guidance of a trained therapist.
223957011|NCT05843149|BEHAVIORAL|Physiotherapy/Back School|Three individual therapy sessions and nine group sessions physiotherapy/back school of 60 min. duration under the guidance of a trained therapist.
223957012|NCT02920216|DRUG|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
223957013|NCT05745259|DRUG|Alteplase|Alteplase 0.9mg/kg are being used.
223957014|NCT05745259|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg are being used.
223957015|NCT00003376|DRUG|carboplatin|
223957016|NCT00003376|DRUG|cisplatin|
223957017|NCT00003376|DRUG|doxorubicin hydrochloride|
223957018|NCT00003376|DRUG|methotrexate|
223541370|NCT04899726|DEVICE|Rectoscope (P201630551)|Rectoscope (P201630551) allows the identification of the distal section margin in oncological rectal surgery.
223541371|NCT01564251|DRUG|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
223957019|NCT00003376|DRUG|paclitaxel|
223957020|NCT00003376|DRUG|vinblastine|
223541372|NCT01564251|DRUG|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
223541373|NCT04156334|PROCEDURE|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
223541374|NCT04941690|OTHER|A questionnaire method was used.|The questionnaire included general population information, International Index of Sexual Function-5 (IIEF-5), Premature Ejaculation Diagnostic Tool (PEDT), General Anxiety Disorder-7 and CPSI.
223541375|NCT00644839|DRUG|CP-945,598|Administration of CP-945,598 alone in period 1
223541376|NCT00644839|DRUG|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
223957021|NCT03439800|OTHER|Mental and Physical Practice|"1. Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~2. They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~3. From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~4. From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~5. From 9th to final training session: both mental and physical practice of the dual task gait."
223957022|NCT03439800|OTHER|Physical Practice|"1. Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~2. Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~3. From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~4. From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
223957023|NCT00476151|DRUG|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
223957024|NCT00476151|DRUG|placebo cream|inactive placebo cream applied two times daily
223957025|NCT00110279|BIOLOGICAL|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
223957026|NCT05028322|DRUG|IMIQUIMOD cream|Cream to apply before intra-dermal vaccine injection
223957027|NCT05028322|BIOLOGICAL|HEPATITIS B SURFACE ANTIGEN|HBV Vaccine
223957028|NCT02792296|OTHER|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
223957029|NCT00893477|BIOLOGICAL|rituximab|
223957030|NCT00893477|BIOLOGICAL|sargramostim|
223957031|NCT00893477|GENETIC|gene expression analysis|
223957032|NCT00893477|GENETIC|gene rearrangement analysis|
223957033|NCT00893477|GENETIC|polymerase chain reaction|
223957034|NCT00893477|GENETIC|polymorphism analysis|
223957035|NCT00893477|OTHER|laboratory biomarker analysis|
223957036|NCT04650919|PROCEDURE|Total laryngectomy and reconstruction by stented aortic allograft (using human tissue and device).|"The procedure consists of 2 operating times:~* Surgery S1 (1st surgical procedure): total laryngectomy and placement of the stented aortic graft (human tissue + device: NOVATECH GSS TM (trademark) TD), under tracheotomy cover.~* Surgery S2 (2nd surgical procedure) (between S1 +24 weeks and S1 +36 weeks) : opening of the proximal part of the graft by endoscopic way with maintenance of the tracheotomy orifice to ensure patient safety."
223957037|NCT01025921|DRUG|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
223957038|NCT01025921|OTHER|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
223957039|NCT01498354|PROCEDURE|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
223541377|NCT05083078|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
223541378|NCT05083078|DRUG|Risankizumab|Risankizumab will be administered subcutaneously.
223541379|NCT04681989|BEHAVIORAL|Moving On After Breast Cancer|"After the MOVE-ABC interventional group participant completes their baseline assessment (T0) and been given the study survey by a research staff member she will receive the following:~1. Instructions on how to use the physical therapy-based education materials by a research staff member~2. a range of motion wand~3. a small ball~4. MOVE-ABC education booklet and video~The intervention group will complete 4 weekly follow-ups with a research staff member over the phone. The follow-ups will be completed in between the T0 (baseline) assessment, and the T1 (1 month after baseline) assessment."
223541380|NCT02361671|OTHER|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
223541381|NCT04635137|PROCEDURE|Ablation and Cementoplasty|Percutaneous thermal ablation with subsequent cementoplasty in a single procedure
223724067|NCT07132502|OTHER|ctDNA MRD|"Definition and Essence: ctDNA MRD involves detecting DNA fragments released by tumor cells into the bloodstream through highly sensitive techniques to determine the status of minimal residual disease in cancer patients.~Detection Methods: Technologies such as digital PCR and next-generation sequencing (NGS) are employed to achieve precise detection of low-frequency ctDNA mutations.~Clinical Significance: It is utilized for evaluating the prognosis of cancer patients and providing crucial evidence for the formulation of personalized treatment plans."
223957040|NCT01498354|PROCEDURE|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
223957041|NCT00295100|DRUG|Tamoxifen|
223724068|NCT07002515|OTHER|Health education|Randomized controlled studies that explain behavior change as a process through health education aimed at promoting healthy behaviors in individuals with digital game addiction.
223957042|NCT03258905|BEHAVIORAL|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
223957043|NCT03258905|BEHAVIORAL|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
223957044|NCT02018159|DRUG|menotropin|
223957045|NCT03980171|DRUG|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
223957046|NCT03980171|DRUG|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
223957047|NCT03980171|DRUG|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
223957048|NCT04544514|DIAGNOSTIC_TEST|lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.
223957049|NCT00739388|DRUG|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
223957050|NCT03896971|DRUG|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
223957051|NCT06023771|PROCEDURE|Invasive intervention for acute pancreatitis|Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
223957052|NCT04282200|DRUG|Ketorolac|intravenous ketorolac 30 mg every 6 hours
223957053|NCT05480280|DRUG|Dalpiciclib|Dalpiciclib is orally administered at 125mg qd for 21 days and discontinue for 7 days.
223957054|NCT05480280|DRUG|Oxaliplatin injection|85mg/m², ivdrip, D1
223957055|NCT05480280|DRUG|Calcium folinate|400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
223957056|NCT05480280|DRUG|5-fluorouracil|400mg/m², iv, D1; and 2400mg/m², civ, 46-48h
223957057|NCT04549948|PROCEDURE|0.017X0.025 Stainless steel|Leveling curve of Sppe using 0.017X0.025 SS archwire
223957058|NCT04549948|PROCEDURE|0.019X0.025 Stainless steel|Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
223957059|NCT04549948|PROCEDURE|0.021X0.025 B-Titanium archwire|Leveling curve of Sppe using 0.019X0.025 B-Titanium archwire
223957060|NCT02366455|PROCEDURE|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
223957061|NCT02366455|PROCEDURE|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
223957062|NCT02662023|DRUG|Bolus|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.
223957063|NCT02662023|DRUG|Basal|A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.
223957064|NCT02497547|DRUG|Oxytocin|
223957065|NCT02497547|DRUG|Placebo|
223957066|NCT01828476|DRUG|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
223957067|NCT01828476|DRUG|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
223957068|NCT01828476|DRUG|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
223957069|NCT01411176|DRUG|Menthol|20 mL NPO-11 in a prefilled plastic syringe
223957070|NCT01411176|DRUG|Placebo|The placebo is included same additives as active comparator.
223957071|NCT05619445|OTHER|Whole Liquid Egg|Subjects will consume 2 fluid ounces of whole liquid eggs per day for 120 days.
223957072|NCT05619445|OTHER|Plant-based Egg Substitute|Subjects will consume 2 fluid ounces of liquid plant-based egg substitute (JUST eggs) per day for 120 days.
223957073|NCT05719155|DRUG|CKD-379|1 tablet administration under fed condition
223957074|NCT05719155|DRUG|D759+D745+D150|3 tablet coadministration under fed condition
223957075|NCT01684345|DRUG|Placebo|Solution for subcutaneous injection
223957076|NCT01684345|DRUG|Dose 1 gevokizumab|Solution for subcutaneous injection
223957077|NCT01684345|DRUG|Dose 2 gevokizumab|Solution for subcutaneous injection
223957078|NCT04332991|DRUG|Hydroxychloroquine|"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.~For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course."
223957079|NCT04332991|DRUG|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
223957080|NCT00000499|DRUG|chlorthalidone|
223957081|NCT00000499|DRUG|reserpine|
223957082|NCT00000499|DRUG|hydralazine|
223957083|NCT00000499|DRUG|metoprolol|
223957084|NCT04043663|DEVICE|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
223957085|NCT04043663|PROCEDURE|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
223957086|NCT02067000|BEHAVIORAL|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
223957087|NCT04750447|DEVICE|XEN 63|The Xen gelatin microstent (Allergan, CA, USA) is a 6mm gelatin tube used in microinvasive glaucoma surgery (MIGS) to create a bleb. A bleb is a fluid filled blister located in the tissue covering the white portion of the eye (the conjunctiva) created after glaucoma surgery. The bleb allows the eye pressure (intraocular pressure - IOP) to be lowered by bypassing the natural pathways by which the fluid called aqueous leaves the eye and redirecting it towards the bleb to be absorbed by other pathways. Amongst the main advantages of this device is the ability to create a bleb without disrupting tissue unlike other methods of glaucoma surgery (e.g., trabeculectomy). This decreases the amount of wound healing and scarring, and potentially limiting bleb failure.
223957088|NCT03382535|BEHAVIORAL|Voice therapy|Voice therapy with direct and indirect therapy elements.
223957089|NCT03382535|BEHAVIORAL|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
223957090|NCT03382535|OTHER|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
223957091|NCT01767376|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
223957092|NCT01767376|BIOLOGICAL|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
223957093|NCT01636700|DRUG|Tramadol 2mg/kg|2mg/kg
223957094|NCT01636700|DRUG|Saline solution|saline solution- 1 dose
223957095|NCT05769361|BEHAVIORAL|UNST|Strength and balance training using different destabilizing devices
223957096|NCT05769361|BEHAVIORAL|ST|Strength and balance training over firm surfaces
223957097|NCT05990088|DEVICE|Heat Cured Conventional Polymethylmethacrylate Complete Removable Dentures based on neutral zone concept|The patients will receive complete removable dentures designed based on neutral zone concept and manufactured by heat cured conventional technique of polymethylmethacrylate
223957098|NCT05990088|DEVICE|CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.|The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
224107799|NCT03711019|DEVICE|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
224107800|NCT03711019|DEVICE|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q or MECTA Sigma machine will be used, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
224107801|NCT03711019|DEVICE|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma, which are FDA approved devices used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
224107802|NCT06097806|OTHER|low and high flow|low and high flow anesthesia are both being used. The effects of different gas flows will be evaluated.
224107803|NCT04770272|DRUG|Atezolizumab 840 MG in 14 ML Injection|840 mg Day 1 for two weeks
224107804|NCT04770272|DRUG|Atezolizumab 1200 MG in 20 ML Injection|1200 mg Day 1 every 3 weeks for 8 cycles
224107805|NCT04770272|DRUG|Carboplatin|Dosing according to Area Under the Curve of 2 Intravenous weekly x 12 cycles
223957099|NCT04387773|DRUG|GOCOVRI|"Participants will have gait and balance baseline assessment and then repeat assessment after being on full-dose of GOCOVRI for two weeks. The assessments will include measures of gait, balance and dyskinesia. Participants will also wear body-worn sensors (on wrist, feet and lumbar area) during daily-life for seven days to quantify mobility.~GOCOVRI will be started at 137mg/day for two weeks and then increased to 274mg/day for two weeks. Participants will repeat baseline assessments and then decrease to a dose of 137mg/day of GOCOVRI for one week, before stopping the medication completely.~All participants will receive GOCOVRI and they will know that they are on study drug. No placebo group."
224107806|NCT04770272|DRUG|Paclitaxel|Paclitaxel 80 mg/m² IV weekly x 12 cycles
224107807|NCT04770272|DRUG|Epirubicin|90 mg/m2, day 1 for 4 cycles (12 weeks)
224107808|NCT04770272|DRUG|Cyclophosphamide|600 mg/m2, day 1 for 4 cycles (12 weeks)
224107809|NCT04770272|PROCEDURE|Biopsy Arm A|1st Biopsy two weeks after Baseline visit. 2nd Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 3rd Biopsy with tumor size greater 10 mm in diameter.
223541382|NCT00835289|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids|Omax3\[TM\] (Cenestra Health \[TM\]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
223541383|NCT00835289|OTHER|Placebo|3 capsules of matching corn oil placebo
223541384|NCT03500211|DRUG|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
223541385|NCT03500211|OTHER|Sham Topical Patch|Sham patch after cesarean section delivery.
223541386|NCT05857566|DRUG|RDX-002|A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
223541387|NCT04985084|BEHAVIORAL|The intervention group|The intervention will last for four weeks and target six dietary behaviors related to gastric cancer. The intervention components include one session of face-to-face education prior to discharge and three sessions of telephone counselling after discharge. The face-to-face education will last for 20 to 30 minutes and each session of telephone counselling will last for 10 to 20 minutes. All the interventional sessions are individual based.
223541388|NCT04985084|OTHER|Usual care|General dietary advice provided as routine by the ward nurses before discharge from the hospital.
223957100|NCT03600506|DRUG|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
223957101|NCT03600506|DRUG|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
223957102|NCT03214055|DRUG|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
223957103|NCT04673305|OTHER|Cognitive Assessment, Cytokine dosage|Once the patient's informed consent has been acquired, a neurological examination is carried out, with functional tests required by the protocol. The patient carries out, as per clinical practice, the treatment provided for the cure of his disease. The evaluation of the tests is repeated at 6 months and 12 months after enrollment in the study. In conjunction with a venipuncture performed for the exams required by clinical management, a blood sample is taken to measure the cytokines involved in inflammatory processes.
223957104|NCT03889327|BEHAVIORAL|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
223957105|NCT03889327|BEHAVIORAL|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
223957106|NCT03012321|DRUG|Olaparib|
223957107|NCT03012321|DRUG|Abiraterone Acetate|
223957108|NCT03012321|DRUG|Prednisone|
223957109|NCT02325752|OTHER|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~1. Post discharge surveillance of the patient to ensure adherence to care plans.~2. Coordination of follow-up visits with specialist care providers.~3. Patent education and care giver training.~4. Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
224107810|NCT04770272|PROCEDURE|Biopsy Arm B|1st Biopsy after two weeks of Carboplatin + Paclitaxel + Atezolizumab therapy. 2nd Biopsy with tumor size greater 10mm in diameter.
223541389|NCT02115035|DRUG|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
223541390|NCT04614844|BEHAVIORAL|Simulation Intervention|Participants randomized to the intervention arm will receive CRI:SIS as a three-hour simulation session.
223541391|NCT04614844|BEHAVIORAL|Control|Participants randomized to the control arm will participate in four shift data collections, with no additional intervention.
223541392|NCT00225914|DRUG|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
223957110|NCT05256836|OTHER|Tablet computer-based cognitive training program|"The subject of the study executes a program mounted on a tablet personal computer (PC) (Samsung Galaxy Tab S6 Lite) and performs a cognitive training task by touching the screen with the index finger.~It consists of 10 tasks related to the activity of daily living: 1) taking medicine, 2) making a phone call, 3) taking a shower, 4) doing laundry, 5) finding directions, 6) riding the bus, 7) buying goods, 8) Money management, 9) ingredient sorting, 10) meal preparation.~It is involved in cognitive functions in various domains such as attention, working memory, processing speed, problem solving, visuospatial ability, verbal and visuospatial memory.~There are three levels of difficulty for each task, high, medium, and low, and the difficulty becomes more difficult as session 1 to 36 progresses.~One cognitive training session lasts about 30 minutes."
223541393|NCT00225914|DRUG|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
223541394|NCT03420742|DRUG|Midazolam|Midazolam syrup.
223541395|NCT03420742|DRUG|Brigatinib|Brigatinib tablets.
223541396|NCT01550601|PROCEDURE|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
223541397|NCT05192421|BEHAVIORAL|Wellness Education|Receive wellness education through a weekly email and web portal content.
223541398|NCT05192421|BEHAVIORAL|Exercise Videos|Receive pre-recorded exercise videos through a weekly email and web portal content.
223541399|NCT05192421|BEHAVIORAL|Livestream Classes|Receive 3 videoconference group exercise classes per week for 8 weeks.
223541400|NCT02799550|BIOLOGICAL|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
223957111|NCT01074099|BIOLOGICAL|BMAC|Injection of BMAC into ischemic myocardium during CABG
223957112|NCT01074099|PROCEDURE|CABG only|Control subjects will undergo CABG surgery without BMAC injection
223957113|NCT02395588|OTHER|Guideline based care|Patient education using guideline based teaching guides
223957114|NCT01113541|DRUG|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
223957115|NCT03745651|DRUG|Ruxolitinib cream|Ruxolitinib 0.75% or 1.5% cream.
223957116|NCT03745651|DRUG|Vehicle cream|Ruxolitinib matching vehicle cream.
224107811|NCT04770272|PROCEDURE|Surgery|After completion of 27-28 weeks (Arm B) or 29-30 weeks (Arm A) of neoadjuvant treatment, surgery is planned for all patients.
224107812|NCT04060992|DRUG|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
224107813|NCT00467649|DRUG|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
223957117|NCT03508882|DRUG|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
223957118|NCT03508882|DRUG|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
223957119|NCT01678755|DRUG|ABT-126|ABT-126 Low Dose
223957120|NCT01678755|DRUG|ABT-126|ABT-126 High Dose
224107814|NCT00467649|DRUG|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
224107815|NCT00467649|DRUG|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
224107816|NCT00807664|DEVICE|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
224107817|NCT00807664|DEVICE|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
223541401|NCT04593121|DRUG|BIIB107|Administered as specified in the treatment arm.
223541402|NCT04593121|DRUG|Placebo|Administered as specified in the treatment arm.
223541403|NCT03284060|BEHAVIORAL|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~1. pen and paper tasks focusing on specific emotion recognition component (20 min),~2. computerized tasks focusing on the same process (20 min),~3. a proposal of a home-based task (during 20 min)."
223541404|NCT06251414|BEHAVIORAL|Exercise Intervention|Blood Flow Restriction (BFR) training, also known as occlusion training or restricted blood flow training, involves applying external pressure to a limb using inflatable cuffs or elastic bands. This pressure partially restricts arterial blood flow while occluding venous blood flow in the pressured limb. The goal is to increase muscle strength and size by creating metabolic stress and promoting physiological adaptations, such as muscle hypertrophy, with lighter loads than traditional resistance training.
223957121|NCT01678755|DRUG|Placebo|Placebo
223957122|NCT04272099|OTHER|Administration of standardized questionnaires|Administration of questionnaires assessing subjective socioeconomic status (SES), health literacy, perceived health, health related quality of life, self-esteem and diabetes self-efficacy
223957123|NCT04272099|DEVICE|Physical activity tracker|PG1 will be asked to wear a physical activity tracker for one week to monitor activity patterns including walking distance, calorie expenditure, sedentary time and sleep.
223957124|NCT04272099|OTHER|Dietary log|PG1 (or PG2 as proxies when appropriate) will report to a study coordinator via phone a full dietary log of PG1 once per week on rotating days of the week for three weeks.
224107818|NCT00759629|OTHER|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
224107819|NCT00759629|OTHER|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
224107820|NCT05195879|DIAGNOSTIC_TEST|XTR004|Single dose intravenous injection of XTR004. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
224107821|NCT01707875|OTHER|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
224107822|NCT04835272|PROCEDURE|the Decannulation Protocol With Suctioning|In the intervention group, the decision to decannulate was based on suctioning frequency. Patients underwent decannulation when they had had no more than two aspirations every 8 hours during during a 24-hour period. Patients in this group did not undergo capping trials.
223957125|NCT04175834|DRUG|cetrizine|prophylaxis
223541405|NCT06251414|BEHAVIORAL|Instrument-Assisted Soft Tissue Mobilization|Instrument-Assisted Soft Tissue Mobilization (IASTM) is a therapeutic technique that involves the use of specially designed tools or instruments to apply controlled mechanical pressure to soft tissues in the body. These tools are typically made of stainless steel or other materials and have various shapes and edges. The primary aim of IASTM is to address musculoskeletal conditions by breaking down scar tissue, fascial restrictions, and adhesions in the soft tissues. Practitioners use the instruments to detect and treat areas of tissue dysfunction, promoting improved range of motion, reduced pain, and enhanced functional mobility.
223541406|NCT06251414|BEHAVIORAL|Tuinal|Tuinal, also known as Tui Na or Chinese therapeutic massage, is a traditional Chinese medicine (TCM) healing technique that involves manual manipulation of the body's soft tissues, including muscles and tendons. It is a form of bodywork that aims to balance the flow of vital energy (Qi) within the body and promote overall well-being. Tuina techniques may include kneading, rolling, pressing, and brushing, and they are applied to specific acupressure points or along the body's meridians. Tuina is used to address various health concerns, alleviate pain, improve circulation, and enhance the body's natural healing processes, making it an integral part of traditional Chinese medicine.
223541407|NCT04927676|DIAGNOSTIC_TEST|Blood sample|Blood samples were taken from a peripheral vein as part of clinical routine. Subsequently, a hormone status is determined.
223541408|NCT00099021|DRUG|pioglitazone hydrochloride|Given PO
223957126|NCT04175834|DRUG|diphenhydramine|prophylaxis
223957127|NCT03030053|DIETARY_SUPPLEMENT|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
223957128|NCT03030053|DIETARY_SUPPLEMENT|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
223957129|NCT03977337|PROCEDURE|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
223957130|NCT01383616|DEVICE|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
223957131|NCT03516071|DRUG|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
223957132|NCT03516071|DRUG|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
223957133|NCT01839032|DRUG|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
223957134|NCT01230359|DIETARY_SUPPLEMENT|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
224107823|NCT06198257|DEVICE|spider cage|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
223541409|NCT04298489|DIAGNOSTIC_TEST|Personalized drug sensitivity test|"The patients underwent surgery to remove tumor and took out tumor specimens for research. The tumor cells were expanded ex vivo drug sensitivity assay.~The drugs used in the study were 5-fluorouracil, Oxaliplatin, and irinotecan at C0 = 10 mM, 2.5 mM and 0.02 mM, respectively. They were applied either as single agents or in combinations of 5-fluorouracil and Oxaliplatin, 5-fluorouracil and irinotecan, or all three agents, or others. After 7 days of treatment, the tumor cells were stained with EdU, Hoechst and EpCAM with the Cell Quantitative Detection Kit. Images were acquired with an automated microscopic image-scanning system and analyzed with the built-in software."
223957135|NCT01230359|OTHER|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
223957136|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide|
223957137|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Montanide + Imiquimod|
223957138|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 + Imiquimod|
223957139|NCT00651703|BIOLOGICAL|CYT004-MelQbG10 intra nodal injection|
223957140|NCT01567150|DEVICE|Novel Dressing|Topical wound dressing
223957141|NCT01494467|DRUG|CD5024|CD5024 1% Cream, once daily
223957142|NCT01494467|DRUG|Azelaic acid 15% Gel|Topical Gel applied twice daily
223957143|NCT03836885|DRUG|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.
223957144|NCT03836885|DRUG|Placebo|Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
223957145|NCT00872859|PROCEDURE|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
223957146|NCT04775732|BIOLOGICAL|infliximab therapeutic drug monitoring|dose optimization of infliximab based on a predefined dosing algorithm
223957147|NCT04386538|BEHAVIORAL|Low Starch Diet (LSD)|6-week balanced diet program, adapted to individual energetic needs, with significant reduction of high content starchy food, naturally present in plant cells, roots, tubers, seeds, beans, legumes, fruits, and highly present in most farinaceous grains, especially in potatoes, corn, rice, pasta, bread, cookies and cakes.
223957148|NCT04386538|BEHAVIORAL|General healthy eating|6-week balanced healthy eating counseling program, according to the World Health Organization recommendations.
223957149|NCT00234585|DEVICE|Renal Artery Stent with Protective Device/Drug|
223957150|NCT02181881|BEHAVIORAL|DuoPACT|Intervention sessions are administered weekly by a counselor.
223957151|NCT02181881|BEHAVIORAL|Life Steps|Intervention sessions are administered weekly by a counselor.
223957152|NCT03743688|BIOLOGICAL|Influenza Vaccine Recipients|0.5 mL intramuscular injection
223957153|NCT02309892|DRUG|L-DOS47|A treatment cycle will be 21 days, with patients receiving L-DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
223957154|NCT04019301|OTHER|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
224107824|NCT06198257|DEVICE|modified suits therapy|5 days a week for an hour/daily with conventional exercises. Assisted sit to stand (10 to 15---15 to 20) Assisted weight shift (10 to 15---15 to 20) Assisted trunk rotation (10 to 15---15 to 20) Hip Abd / Add. exercises (10 to 15---15 to 20) Bridge exercises (10 to 15---15 to 20)
223957155|NCT04019301|OTHER|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
223957156|NCT02861716|DRUG|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
224107825|NCT02436239|DRUG|Vilazodone|Vilazodone tablets, once daily, oral administration
224107826|NCT00985452|OTHER|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
224107827|NCT00985452|OTHER|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
223957157|NCT02861716|DRUG|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
223957158|NCT02861716|DRUG|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
223957159|NCT03262389|DRUG|Fludeoxyglucose PET CT|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
223957160|NCT03262389|DRUG|Sodium Acetate C11 PET CT|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
223957161|NCT03262389|DRUG|Fludeoxyglucose PET MRI|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
223957162|NCT03262389|DRUG|Sodium Acetate C11 PET MRI|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
223957163|NCT00801606|DRUG|Zinc|Zinc 20 mg/day
223957164|NCT00801606|DRUG|Micronutrient without zinc|Multimineral 2 RDA
223957165|NCT00801606|DRUG|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
223957166|NCT00801606|DRUG|Placebo|Placebo
223957167|NCT00899795|GENETIC|cytogenetic analysis|
223957168|NCT00899795|GENETIC|fluorescence in situ hybridization|
223957169|NCT00899795|OTHER|flow cytometry|
223957170|NCT00899795|PROCEDURE|biopsy|
223957171|NCT00119782|BEHAVIORAL|Diet|A dietary intervention that will promote lower calorie intake
223957172|NCT00119782|BEHAVIORAL|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
223957173|NCT00119782|BEHAVIORAL|Environment|Increase worksite access to both healthy foods and physical activity
223957174|NCT03740386|DRUG|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
223957175|NCT01465399|BIOLOGICAL|Plasma Rich in Growth Factors PRGF-Endoret|
223957176|NCT01465399|PROCEDURE|Conventional closure of the lesion|
223957177|NCT03955406|PROCEDURE|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
223957178|NCT03955406|PROCEDURE|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
223957179|NCT04362618|OTHER|Muscle Strengthening Training|Muscle strengthening training will take place for a period of 12 weeks, in which participants will have 36 exercise sessions (18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. Muscles of the leg (i.e. quadriceps, hip ab- and adductors) will be trained at 3 set of 10 repetitions at 80% of 1RM with the use of elastic bands. 1RM will be assessed at baseline and the exercise intensity will be progressively increased by 10% of 1RM every two sessions from 50 up to 70-80 % of 1RM. Every 6 sessions, the 1RM will be reassessed and the training resistances will be adapted.
223957180|NCT04362618|BEHAVIORAL|Behavioral graded activity|Subjects will receive a behavioural treatment integrated within the concepts of operant conditioning with exercise therapy for a period of 12 weeks, in which the subjects will have maximum 36 BGA sessions (min. 13- max. 18 at the hospital under supervision of a physiotherapist; 18 unsupervised at home) planned. The purpose of BGA is to increase the level of activities in a time-contingent manner and increase the level of physical activity in the subject's daily lives. BGA consists of 3 phases: pain education (phase 1), treatment phase in which subjects increase their level of activity gradually (phase 2) and integration of learned principles in daily live (phase 3).
224107828|NCT02892097|DEVICE|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
224107829|NCT02892097|DEVICE|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
224107830|NCT02892097|BEHAVIORAL|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
224107831|NCT01848444|OTHER|Breastmilk|to measure levels of contaminants in human breastmilk samples
223957181|NCT06176118|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA supplement take three times daily for 12-weeks
223957182|NCT06506552|PROCEDURE|IMA preserving|Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall
223957183|NCT06506552|PROCEDURE|IMA sectioning|Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
223957184|NCT01052272|DRUG|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
223957185|NCT01052272|DRUG|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
223957186|NCT01052272|DRUG|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
223957187|NCT03941366|PROCEDURE|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
223957188|NCT06225323|DRUG|Lidocaine|"Patients will receive Lidocaine infusion for 6 hours. After cord clamping and according to ideal body calculate the bolus dose 1.5 mg/kg of lidocaine 1% and complete the dose by normal saline to 20 ml total volume will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of lidocaine 1% for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
223957189|NCT06225323|OTHER|Saline|"Patients will receive normal saline infusion for 6 hours. After cord clamping 20 ml total volume normal saline will be given in 10 min.~The infusion dose 1.5 mg/kg/hour of normal saline for 6 hours in automated syringe pump (aquavesar fixed variable rate 100ml volume) 100 ml then follow up without infusion up to 24 hours."
223957190|NCT02936258|PROCEDURE|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
224107832|NCT05798975|OTHER|Aerobic Exercise. 1 session of acute exercise|40 minutes on cycle ergometer, 60% of heart rate reserve
224107833|NCT05798975|OTHER|Resistance Exercise. 1 session of acute exercise|2 exercises for lower limbs and 2 for upper limbs with 4 sets of 12 repetitions at 60% 1-RM. 40 minutes
224107834|NCT05798975|OTHER|no exercise|Rest
223957191|NCT02936258|PROCEDURE|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
223957192|NCT02936258|PROCEDURE|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
223957193|NCT06501508|DEVICE|Stratafix Symmetric|Use of Stratafix Symmetric for primary fascial closure
223957194|NCT01843049|RADIATION|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
223957195|NCT01843049|DRUG|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
223957196|NCT04660110|DRUG|IPT with Dihydroartemisinin Piperaquine|A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
223957197|NCT03503500|OTHER|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
223957198|NCT03503500|OTHER|Standard care|"2\. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
223957199|NCT04739306|BIOLOGICAL|CT-P42|2mg/0.05 mL by Intravitreal injection
223957200|NCT04739306|BIOLOGICAL|Eylea|2mg/0.05 mL by Intravitreal injection
223957201|NCT02868086|DEVICE|OCT B-scans|
223957202|NCT02868086|DEVICE|OCT angiography|
223957203|NCT00993278|DIETARY_SUPPLEMENT|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
223957204|NCT00993278|DIETARY_SUPPLEMENT|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
223957205|NCT05082545|DRUG|SHR-2002 and SHR-1316|Cohort study
223957206|NCT02912338|BEHAVIORAL|Resistant Training|
223957207|NCT02912338|OTHER|Control Group|
223957208|NCT01809444|DRUG|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
223541410|NCT06209944|PROCEDURE|Cardiopulmonary resuscitation|cardiac compression, endotracheal intubation, defibrillation, and use of cardiovascular medications, to restore circulation in patients with cardiac arrest
223541411|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
223541412|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
223541413|NCT06175780|DRUG|KY-0118|KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
223957209|NCT01809444|DRUG|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
223957210|NCT04748705|DRUG|IMC-1|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
223957211|NCT04748705|DRUG|Placebo BID Tablet|Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
223541414|NCT00381654|DRUG|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
224107835|NCT04705480|DRUG|Pregabalin 50mg|Patients will receive 50 mg every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
224107836|NCT04705480|DRUG|Gabapentin 300mg|Patients will receive 300 mg PO every 8 hours without dose titration. Patients with CrCl \< 60mL/min will receive same dose given q12 hours. The q12 hour regimen may be increased to q8 hours if CrCl increases above 60mL/min during the 7 days study period or until discharge (if \< 7 days post-enrollment).
224107837|NCT04705480|DRUG|Neither Pregabalin nor Gabapentin|Patients will receive neither Pregabalin nor Gabapentin.
223957212|NCT02374294|DEVICE|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of \~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
223957213|NCT03258983|OTHER|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
223957214|NCT01077284|DRUG|Febuxostat|Febuxostat capsules
223957215|NCT01077284|DRUG|Allopurinol|Allopurinol capsules
223957216|NCT01077284|DRUG|Placebo|Placebo-matching capsules
223957217|NCT04610606|BEHAVIORAL|Multimodal intervention (MM)|"Exercise: Moderate intensity resistance and aerobic exercise, including one weekly supervised session and a home-based program. Participants were asked to 1) accumulate 30 min of aerobic exercise per day of their preferred type (ex. walking) and 2) perform 30 min of resistance exercise targeting major muscle groups, every second day for 2 sets of 8-12 reps.~Nutrition: Optimize diet with protein-rich foods to meet protein intake of \>1.2 g/kg/d and energy of 25-30 kcal/kg/d. The supplement consists of whey protein isolate (with the goal of reaching 1.5 g/kg/d, providing 25 g/meal), 6g of leucine, fruit-flavored fish oil added with vitamin D.~Relaxation strategies: private consultations with psychology-trained personnel whereby techniques aimed at reducing anxiety are practiced. Participants are also provided with a compact disc with relaxation exercises to be used at home 2-3 times per week."
223957218|NCT03796364|DRUG|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
223957219|NCT03796364|DRUG|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
223957220|NCT00741689|DRUG|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
223957221|NCT02041897|PROCEDURE|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
223957222|NCT05057767|DRUG|Midazolam injection|No premedication will be given to Patients in the group undergoing a standardized anesthesia protocol which include induction with thiopental (5 mg/kg) and fentanyl (1-2 μg/kg). Atracurium will be used as a muscle relaxant. After tracheal intubation, anesthesia will be maintained with isoflurane in a concentration of 0.8%-1.2%. Ventilation will be adjusted to produce normocapnia. At the end of surgery, reversal of residual neuromuscular blockade will be accomplished using i.v. atropine 20 μg/Kg and neostigmine 40 μg/kg.
223957223|NCT02276937|DRUG|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
224107838|NCT06971510|DEVICE|Exoskeleton Training|Using EksoNR to train balance control and walking and turning abilities in patients with incomplete spinal cord injury.
223541415|NCT00290810|BIOLOGICAL|bevacizumab|Given IV
223957224|NCT05860218|OTHER|advices|"The following advice will be given to the patients :~1. Walking as flexibly (normally) as possible~2. Advise when lifting ;~   * avoid twisting and bending.~  * for heavy objects use thighs with a vertical back.~  * at other times, use the back and flex it.~3. Heat application for 20 mins twice /day .~4. Avoid sitting or standing for prolonged period and change position every 15 mins.~5. Sitting: Sit with a back support~6. Driving: Use a back support (lumbar roll) at the curve of your back.~7. Sleeping and lying down: Select a firm mattress and box spring set that does not sag. If necessary, place a board under your mattress. You can also place the mattress on the floor temporarily if necessary."
223541416|NCT03725956|PROCEDURE|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
224107839|NCT06971510|OTHER|Conventional Physical Therapy|Using conventional physical therapy methods to train the balance control and walking and turning abilities in patients with incomplete spinal cord injury.
223541417|NCT04419545|DIAGNOSTIC_TEST|Neural network diagnosis algorithm|we feed neural network with chest x-ray radiography images for teaching the network for automatic diagnosis of interstitial pneumonia
223541418|NCT06159257|DIAGNOSTIC_TEST|Blood test|"Whenever possible, samples will be collected by the nurse in the patient's home, according to the study visit schedule. However, if this is not possible, patients will be asked to come in for sample collection at another mutually convenient time at the CERBA ALLIANCE LABORATORY closest to the patient's address.~Venous blood will be drawn on each visit."
223541419|NCT00003365|DIETARY_SUPPLEMENT|curcumin|
223541420|NCT00003365|DIETARY_SUPPLEMENT|rutin|
223957225|NCT05860218|OTHER|exercises plus advices|"In addition to the same advice of group A, a suggested functional exercise will be performed for this group.~1. Sidestepping against band resistance:~2. The quadriped opposite arm leg aganist resistance .~3. Squat row on a balance board with band resistance:~4. Front raise single leg support with band resistance:~5. The Advanced Prone Bridge:~6. Side sliding on a fitter board (lateral lunge with band):"
224107840|NCT06971419|OTHER|intervention is the use of aTriage-Based Patient Redirection Using an Electronic Decision Support Toolin the emergency department (ED)|"Name: Logibec Réorientation software-assisted triage and redirection~Type: Decision support system for emergency triage~Implementation:~* Applied during patient triage in the emergency department~* Assists in identifying low-acuity (SETS 4) and semi-urgent (SETS 3) patients eligible for redirection~* Uses standardized inclusion/exclusion criteria to guide redirection decisions~Comparator: Standard nurse-led triage and redirection based only on the Swiss Emergency Triage Scale (SETS)~Key Distinction:~* The investigated group receives Logibec-assisted triage and redirection.~* The comparator group follows traditional nurse-led triage without electronic support, limiting redirection to SETS 4 patients only."
224107841|NCT04901507|DEVICE|The Voutia System|Participants will wear the Voutia System oral irrigation device continuously through the day and night, removing for cleaning and if otherwise necessary, but not for time extending beyond six-eight hours.
224107842|NCT02054832|DIETARY_SUPPLEMENT|Glycosade|
223957226|NCT02637947|DEVICE|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
223541421|NCT00003365|DRUG|quercetin|
223957227|NCT02637947|DEVICE|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
223957228|NCT03209492|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
223957229|NCT05711745|PROCEDURE|Calf myofascial technique|A 3-pass superficial leg glide technique was applied first and then 5 minutes of the deep calf myofascial induction technique as described by Pilat.
223957230|NCT02867332|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
223957231|NCT02867332|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
223957232|NCT02867332|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
223957233|NCT04530721|OTHER|no intervention|we don't do any intervention
223957234|NCT03811743|BEHAVIORAL|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
224107843|NCT05347056|DIAGNOSTIC_TEST|Lumbar Spine Magnetic Resonance|Metal artifact reduction sequence (mars), axial t2 sequence
224107844|NCT05347056|DIAGNOSTIC_TEST|Isokinetic trunk flexion-extension trunk muscle strength and endurance test|To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s
224107845|NCT05347056|DIAGNOSTIC_TEST|Lomber Region Range of motion assessment|To evaluate for lomber region ROM with digital inclinometer
223541422|NCT00003365|DRUG|sulindac|
223541423|NCT04942132|BEHAVIORAL|Cognitive-behavioral (CBT)|Treatment includes a smartphone-delivered CBT program designed to improve the quality of life of individuals with chronic pain. The treatment is condensed in nine weeks, and contains the following modules or units of treatment: sleep quality, anxiety management, pain coping, medication use, physical conditioning, mood regulation, problem solving, decision-making and relationships with others. All the content and settings are written in Spanish.
224107846|NCT05347056|DIAGNOSTIC_TEST|Radiograph|spinal radiograph AP/Lateral
224107847|NCT05347056|BEHAVIORAL|SRS 22|SRS-22 Patient Questionnaire
224107848|NCT00863187|BIOLOGICAL|rituximab|b cell depletion
223541424|NCT04923243|PROCEDURE|hip/knee replacement|hip/knee replacement
223541425|NCT06388252|PROCEDURE|Electrochemotherapy with Intratumoral Cysplatin|ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
223541426|NCT06388252|PROCEDURE|Electrochemotherapy with Intravenous Bleomycin|ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.
223541427|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
223541428|NCT01119443|DRUG|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
223541429|NCT03500289|DRUG|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
223541430|NCT03500289|DRUG|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
223541431|NCT02329743|DRUG|RX-10045|topical therapy
223541432|NCT04177537|DEVICE|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
223541433|NCT06320600|OTHER|no intervention|It's an observational study, no intervention included
223957235|NCT03811743|BEHAVIORAL|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
223541434|NCT00753948|DRUG|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
223541435|NCT00775268|PROCEDURE|Biopsy|Biopsy taken
223541436|NCT00775268|DIAGNOSTIC_TEST|fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography|Imaging
223541437|NCT00775268|OTHER|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
224107849|NCT06970574|DRUG|Levobupivacaine|to compare the clinical intraoperative effects of intrathecal administration of fentanyl in comparison with dexmedetomidine on shoulder tip pain in patients undergoing laparoscopic cholecystectomy.
223541438|NCT00775268|PROCEDURE|computed tomography|Undergo scans
223541439|NCT00775268|PROCEDURE|fine-needle aspiration|sample collected
223541440|NCT03604497|BEHAVIORAL|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
223541441|NCT03604497|BEHAVIORAL|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
223541442|NCT04365686|DRUG|Ketofol as induction agent|Patients who received propofol (1mg/kg) plus ketamine (0.5mg/kg) at the induction of general anesthesia
223541443|NCT04365686|DRUG|Propofol as induction agent|Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
223541444|NCT02921295|DEVICE|Sidekick Stubbies|
223541445|NCT05937529|OTHER|Cream containing madecassoside and 5 % panthenol|Immediately after daylight PDT, Cicaplast is administrated as post treatment. The patients are instructed to apply the cream twice daily for 14 days.
223541446|NCT05937529|OTHER|Daylight PDT|Daylight PDT performed with 2 hours of artifical indoor light.
223541447|NCT05408273|DIAGNOSTIC_TEST|Blood samples and Microvascular function assessment evaluated through laser-Doppler flowmetry by the LASER speckle contrast analysis (LASCA) device|We enrolled 39 non-smokers, low CVR postmenopausal women, with less than 10 years of hypoestrogenism. Associations of 25(OH)D to adiposity, blood pressure, fasting aldosterone, insulin, glucose and lipid profile, HOMA-IR, parathormone and microvascular function, assessed by laser-Doppler flowmetry at cutaneous site, were investigated
223541448|NCT00895362|DRUG|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
223541449|NCT00895362|DRUG|Cetuximab|Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
223957236|NCT03811743|BEHAVIORAL|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
223957237|NCT01762345|DEVICE|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
223957238|NCT04172571|BIOLOGICAL|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
223957239|NCT04172571|DRUG|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
223957240|NCT02379078|OTHER|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
223957241|NCT02379078|OTHER|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
223957242|NCT02379078|OTHER|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
223957243|NCT03476577|DRUG|Ibuprofen|Patients are tested for their normal prescription ibuprofen medication
223957244|NCT01874717|OTHER|Conscious sedation for dental care|
223957245|NCT01874717|DRUG|midazolam|
223957246|NCT04908488|DEVICE|Verofilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
223957247|NCT04908488|DEVICE|Etafilcon A toric contact lenses|Soft contact lenses for optical correction of astigmatism
223957248|NCT05426655|OTHER|Self management|"The program will consist of 3 sessions in which everything related to pain and its management will be explained. In a first workshop, a first educational session on the neurophysiology of pain will be given by means of a Power Point presentation. In a second workshop, a tool will be used to locate those factors that can improve/worse the pain, physical documentation will be delivered with instructions for performing a self-massage and exercises of the temporomandibular region as well as advice and recommendations to manage different situations that may appear on a daily basis and on Lifestyle. A meditation session will also be held. In the third and last workshop, the game the painometer will be played and a meditation session will be held."
223957249|NCT04822025|BIOLOGICAL|MVC-COV1901 (High-Dose)|Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
223541450|NCT01069393|OTHER|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
223957250|NCT04822025|BIOLOGICAL|MVC-COV1901(Mid-Dose)|Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
223957251|NCT03395873|DRUG|Avelumab|"* Decitabine 20mg/m2 IV day 1-5, every 28 days~* Avelumab 10mg/kg IV, day 1, every 14 days"
223957252|NCT05871489|DRUG|Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)|Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
223541451|NCT05921617|OTHER|No intervention|Routine care
223957253|NCT05871489|DRUG|Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)|Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
223957254|NCT05871489|DRUG|Bdq, Lzd, Lfx, Z, Dlm (9-12 months)|Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed
223541452|NCT02658552|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
223957255|NCT05756647|DEVICE|Interventional Arm|The MAD arm will consist of participants given a fitted mandibular advancement device that they will wear for the length of the study.
223957256|NCT05756647|COMBINATION_PRODUCT|Conservative treatment Arm|Participant will undergo a nightly medicated nasal rinse that will occur for a 4 week period, prior to beginning of the other three conservative therapy interventions. The 4-part combination therapy will take place for 4 weeks total.
223957257|NCT05791786|OTHER|Patient|affected individuals diagnosed with AFE
223957258|NCT04922359|DRUG|Lidocain|Patients received 1.5mg/kg of intravenous lidocaine during induction of anesthesia and 1.5 mg/kg/h for anesthesia maintenance.
223957259|NCT04922359|DRUG|normal saline|Patients received 0.075ml/kg of intravenous normal saline during induction of anesthesia and 0.075ml/kg/h for anesthesia maintenance.
223957260|NCT06000371|DEVICE|Vacuum assisted Closure application|Vacuum assisted Closure Application in Diabetic Foot Ulcers
223957261|NCT00570622|DRUG|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
223957262|NCT00570622|DRUG|Placebo|Patients receive placebo once a day orally for 9 days
223957263|NCT03122314|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb\_UK) intravenous (IV) was given 100patients
223957264|NCT03122314|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
223957265|NCT04685395|DRUG|Ribamipide gargle \benzdymine HCL gargel|ribamipide gargle 6 time daily 5ml dosage
223957266|NCT03213587|DRUG|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
223957267|NCT03276286|DEVICE|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
223957268|NCT03530644|DEVICE|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
223957269|NCT03530644|DEVICE|P0.1|The investigational medical device will collect spectral Raman data from tissue.
223957270|NCT00879827|BIOLOGICAL|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
223957271|NCT00879827|BIOLOGICAL|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
223957272|NCT01941706|BEHAVIORAL|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
223957273|NCT05602272|PROCEDURE|General anesthesia for per-oral endoscopic myotomy|Intra-abdominal pressure measurement
223957274|NCT01373723|OTHER|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
223957275|NCT05668845|OTHER|PG-ANB performed at the outset of LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the outset of the LSG.
223541453|NCT02065492|DRUG|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
223957276|NCT05668845|OTHER|PG-ANB performed at the end of the LSG|The paragastric lesser omentum neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. The needle is capped during its introduction, and the cap is removed inside the abdomen using a grasper and kept under direct vision. Infiltration of 20 mL of non-diluted 0.5% bupivacaine is performed at six levels with careful aspiration preceding fluid infiltration. Four areas are adjacent to the vagus nerves and branches, and two are in the vicinity of the common hepatic and left gastric arteries. This is performed at the end of the LSG\>
223957277|NCT02633228|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
223957278|NCT01196286|BEHAVIORAL|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
223957279|NCT01196286|BEHAVIORAL|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
223957280|NCT02627586|OTHER|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
224107850|NCT03529214|BEHAVIORAL|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
224107851|NCT06363721|DIETARY_SUPPLEMENT|PerioPull™|PerioPull™ is a natural oil rinse formula to support overall oral/gum health, tooth stains, and natural teeth whitening. PerioPull™ includes Medium Chain Triglycerides (C8, C10, C12) (from coconut oil), Bixa orellana (Annatto) Seed Extract (GG-Gold®), Natural Mint Flavor, Bromelain, Ubiquinone, Delta Tocotrienols.
224107852|NCT06969924|DEVICE|Cardiac resynchronization therapy|Cardiac resynchronization therapy pacemaker or defibrillator with a transvenous or epicardial systemic ventricle lead
223541454|NCT02065492|DRUG|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
223957281|NCT02627586|OTHER|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
223957282|NCT02085824|DRUG|Enoxaparin|
223957283|NCT02085824|DRUG|rivaroxaban|
223957284|NCT02085824|DRUG|dabigatran|
223541455|NCT00636103|DRUG|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
223541456|NCT00636103|OTHER|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
223541457|NCT06170151|DIAGNOSTIC_TEST|Diagnostic accuracy|evaluate the role of 18F-FDG PET-CT for assessing early response after 6 months of treatment in patients with relapsed/refractory multiple myeloma.
223541458|NCT00196677|DRUG|Vitamins, minerals and medical herbs|
223541459|NCT03068897|DRUG|Metaxalone|Metaxalone 400-800mg
223541460|NCT03068897|DRUG|Tizanidine|Tizanidine 2-4mg
223541461|NCT03068897|DRUG|Baclofen|Baclofen 10-20mg
224107853|NCT01350700|OTHER|Scars assessment & QOL|Scar assessment and quality of life questionnaires
223541462|NCT03068897|DRUG|Ibuprofen 600 mg|Ibuprofen
223541463|NCT03068897|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
223541464|NCT02996422|BEHAVIORAL|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
223541465|NCT02996422|BEHAVIORAL|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
223541466|NCT01051037|RADIATION|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
223541467|NCT01051037|RADIATION|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
223541468|NCT06487234|DEVICE|Functional band|Participants will wear the functional band for 1-hour electroacupuncture stimulation
223541469|NCT06487234|DEVICE|Placebo band|Participants will wear the nonfunctioning band for 1-hour with no electroacupuncture stimulation
223541470|NCT00848419|DRUG|Epidural administration of bolus|
223957285|NCT03210025|DRUG|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
223957286|NCT03210025|DRUG|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
223957287|NCT02754375|PROCEDURE|rTMS|
223957288|NCT04151030|PROCEDURE|PEG placement|Push PEG placement
223957289|NCT00882856|DRUG|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
223957290|NCT00882856|DRUG|Placebo|placebo
223957291|NCT03463122|DEVICE|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
223957292|NCT03463122|OTHER|conventional therapy|conventional therapy for stroke rehabilitation
223957293|NCT02959866|OTHER|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
223957294|NCT00952523|DRUG|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
223957295|NCT00952523|DRUG|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
223957296|NCT02718456|BEHAVIORAL|Expedited CD4 testing|
223957297|NCT02718456|BEHAVIORAL|Supplemental peer counseling|
223957298|NCT05718492|PROCEDURE|digital subtraction angiography.|Each patient received an artery catheter procedure guided by digital subtraction angiography.
223957299|NCT05718492|DRUG|FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )|Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
223957300|NCT04414865|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
223957301|NCT00512265|DRUG|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
223957302|NCT00512265|DRUG|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
223957303|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules|Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.
223957304|NCT05265247|DRUG|Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)|Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
223957305|NCT01029925|DRUG|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
223957306|NCT04508829|DRUG|Anti-EGFR monoclonal antibody|The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy in locally advanced oropharyngeal carcinoma with induced chemotherapy resistance. The specific treatment description is included in arm description.
223957307|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
223957308|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
223957309|NCT00787371|BIOLOGICAL|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
223957310|NCT01637194|DRUG|everolimus|Given PO
223957311|NCT01637194|BIOLOGICAL|cetuximab|Given IV
223957312|NCT01637194|OTHER|pharmacological study|Correlative studies
223957313|NCT01637194|OTHER|laboratory biomarker analysis|Correlative studies
223957314|NCT03404440|OTHER|L.Reuteri|
224107854|NCT03812016|DEVICE|Feedback-enabled magnetic device|The device comprises 1 or 2 matched pairs of one near-infrared light-emitting diode and one sensor, a magnetic actuator, an iron sheet, and a biosignal acquisition module. The efficacy and safety were assessed using the feedback-enabled magnetic device.
223957315|NCT05541341|OTHER|tisagenlecleucel|Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
223957316|NCT05533788|DRUG|ABSK091 tablet|ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
223957317|NCT02442102|BEHAVIORAL|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
223957318|NCT02158845|DRUG|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
223957319|NCT02158845|DRUG|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
223957320|NCT03370094|DIAGNOSTIC_TEST|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
224107855|NCT05108376|DEVICE|Visensia Safety Index (VSI)|Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
224107856|NCT01053910|DRUG|Ramipril|tablet of Ramipril once daily
223541471|NCT03632096|RADIATION|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
223541472|NCT03632096|RADIATION|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
223541473|NCT00968773|DEVICE|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
223541474|NCT00968773|DEVICE|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
223541475|NCT04686344|DRUG|intermittent boluses of Hypertonic saline|intermittent boluses every 6 hours over 30 min for 48 hours
223541476|NCT04686344|DRUG|continuous infusion of Hypertonic saline|continuous infusion over a period of 48 hours
223541477|NCT00286897|DRUG|E2007|
223541478|NCT03420937|DRUG|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
223957321|NCT03405480|OTHER|Rehabilitation|Rehabilitation
223957322|NCT04099576|OTHER|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
223957323|NCT04099576|OTHER|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
223957324|NCT02858206|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
223957325|NCT02858206|DRUG|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
224107857|NCT01039207|OTHER|Laboratory Biomarker Analysis|Correlative studies
224107858|NCT01039207|BIOLOGICAL|Rilotumumab|Given IV
224107859|NCT00938548|DRUG|Pregabalin|Pregabalin 75 mg orally
224107860|NCT00938548|DRUG|Vitamin Complex (placebo)|Vitamin Complex orally
223957326|NCT02858206|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
223957327|NCT02858206|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
223957328|NCT02858206|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
223957329|NCT02951806|DRUG|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
223957330|NCT02951806|DRUG|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
223957331|NCT04904731|OTHER|Prone position|Patients were assisted in NIV in supine position that was switched in prone position for clinical purpouse
223957332|NCT03493906|OTHER|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
223957333|NCT05546177|OTHER|instrumented assisted soft tissue mobilization|The subject will be treated with instrumented assisted soft tissue mobilization, applied to the upper and lower fibers of Pectoral, Trapezius (upper, middle and lower), Rhomboids major , Rhomboids minor, Teres minor, Teres major, and Latissimus dorsi muscles. The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers of each one of the selected muscle
223957334|NCT05546177|OTHER|traditional therapy|the patients will receive Transcutaneous electrical nerve stimulation (TENS) to manage the pain,Ultrasound , Exercise including (Range of motion exercises, stretching exercises, and strengthening exercises (Scapular stabilization exercises and rotator cuff strengthening exercises)
223957335|NCT02793752|OTHER|Age|Maternal Age
223541479|NCT03420937|DRUG|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
223541480|NCT01100333|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
223957336|NCT03236727|DRUG|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
223957337|NCT04239976|DEVICE|FitBit|Wear FitBit for gait assessment test
223957338|NCT04239976|OTHER|Gait Assessment Test|Undergo gait assessment test
224107861|NCT02782715|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
223957339|NCT04239976|OTHER|MC5-A Scrambler Therapy|Undergo scrambler therapy
223957340|NCT04239976|OTHER|Quality-of-Life Assessment|Ancillary studies
223957341|NCT04239976|PROCEDURE|Quantitative Sensory Testing|Undergo quantitative sensory test
223957342|NCT04239976|OTHER|Questionnaire Administration|Ancillary studies
223957343|NCT00297713|DRUG|ALTU-238|
223957344|NCT01417923|DRUG|vitamin D|P.O.4000 units Vit D per day for 6 weeks
223957345|NCT02314000|DEVICE|Precision or Precision Spectra Spinal Cord Stimulator System|
223957346|NCT03239353|DRUG|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
223957347|NCT04223674|DIAGNOSTIC_TEST|Serological screen and treat|Multi-antigen sero-diagnostic test for measurement of P. vivax antibodies in plasma from finger stick as a means to detect hypnozoite carriers for treatment
223957348|NCT01233089|DEVICE|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
223957349|NCT01233089|DEVICE|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
223957350|NCT01233089|DEVICE|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
223957351|NCT01233089|DEVICE|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
223957352|NCT03528356|BEHAVIORAL|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
223957353|NCT05306483|PROCEDURE|Ventricular septal defect closure surgery|Ventricular septal defect closure surgery
223957354|NCT05306483|PROCEDURE|Ventricular septal defect closure catheter|Catheter closure of VSD
223957355|NCT02570971|DRUG|Mannitol|
223957356|NCT04449445|DIETARY_SUPPLEMENT|Isocaloric and iso-nitrogenous standard enteral tube feeds|Dietary supplement
223957357|NCT04449445|DIETARY_SUPPLEMENT|Nestle IMPACT AR|Dietary supplement
223957358|NCT00255268|DRUG|Goserelin|
223957359|NCT00255268|DRUG|Bicalutamide|
223957360|NCT00409747|DRUG|Minocycline|
223957361|NCT03132571|DRUG|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
223957362|NCT03132571|DRUG|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
223957363|NCT03132571|OTHER|Placebo|Oral placebo taken once daily for the course of the study (16 week)
223957364|NCT03733951|DRUG|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
223957365|NCT01072071|DRUG|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
223541481|NCT02901691|OTHER|musical rhythmic stimulation|
223541482|NCT01651286|PROCEDURE|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
223541483|NCT01651286|PROCEDURE|full face mask|using a standard full face mask during the induction of general anesthesia.
223541484|NCT01642550|DRUG|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
223541485|NCT01642550|DRUG|Placebo|
223541486|NCT05844202|DRUG|Alveavax-v1.2|BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
223541487|NCT05844202|DRUG|Janssen Ad26.COV2.S|COVID-19 vaccine by Janssen / Johnson \& Johnson
223541488|NCT04766320|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-3x10\^11 autologous TILs to patients i.v. in 30-120 minutes.
223541489|NCT04834908|BIOLOGICAL|Equine COVID-19 Antiserum|Equine COVID-19 antiserum is a polyclonal antibody and it contains Equine COVID-19 immune globulin G.
223541490|NCT04834908|DRUG|Standard of care|Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
223541491|NCT01194245|DRUG|Insulin lispro|
223541492|NCT01194245|DRUG|recombinant human hyaluronidase PH20|
223541493|NCT01194245|DRUG|Insulin aspart|
223541494|NCT01194245|DRUG|Insulin glulisine|
223541495|NCT01194245|DRUG|Insulin glargine|
223541496|NCT01018654|BEHAVIORAL|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
223541497|NCT01018654|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
223541498|NCT03381664|DRUG|AVP-923|capsule
223957366|NCT02222532|DRUG|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
223957367|NCT02222532|DRUG|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
223957368|NCT01738087|DRUG|NEXThaler 100/6 mcg DPI|
223957369|NCT01738087|DRUG|Flixotide Accuhaler 500 mcg|Active comparator
223957370|NCT01738087|DRUG|NEXThaler 200/6 mcg DPI|
223541499|NCT01094834|DRUG|DWP05195|tablets, oral administration, multiple administration
223541500|NCT03482986|BEHAVIORAL|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
223957371|NCT01738087|DRUG|NEXThaler placebo|Placebo comparator
223957372|NCT03959579|DIAGNOSTIC_TEST|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
223957373|NCT01027455|DEVICE|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
223957374|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
223541501|NCT00269087|DRUG|fluticasone propionate/salmeterol combination DISKUS|
223541502|NCT05207098|OTHER|Neurocognitive Tests|Baseline only: WRAT Reading Test, WMS-IV Logical Memory Subtest, Hopkins Verbal Learning Test (HVLT), Oral Trailmaking - Part A and B, NAB Digit Span, Category Fluency Test, Oral Symbol Digit Modalities Test, Brief Test of Attention, FAS - Controlled Oral Word Association Test (COWAT), Verbal Naming, Enformia Cogsuite Battery
223541503|NCT05207098|OTHER|Questionnaires|Sociodemographics, Computerized Cognitive Training Programs Questionnaire, CDC Behavioral Risk Factor (Smoking Assessment), Alcohol Consumption CDC, Current Health Rating (KPS), OARS Physical Health section, COVID Medical History, Hospital Anxiety and Depression Scale (HADS), Fatigue Symptom Inventory (FSI), Functional Assessment of Cancer Therapy-General (FACT-G V4), Functional Assessment of Cancer Therapy-Cognition (FACT-Cog V3), Sensory Gating Inventory (SGI)
223541504|NCT01173510|DRUG|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
223541505|NCT01173510|DRUG|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
223541506|NCT00777959|DRUG|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
223541507|NCT00777959|DRUG|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
223541508|NCT00777959|DRUG|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
223541509|NCT03971929|DRUG|SHR0532|once daily(QD) for 4weeks
223541510|NCT03971929|DRUG|SHR placebo|once daily(QD) for 4weeks
223541511|NCT03971929|DRUG|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
223541512|NCT03157050|OTHER|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
223541513|NCT05069649|DRUG|Ergoferon|Tablet for oral use.
223957375|NCT01027455|PROCEDURE|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
223957376|NCT03927794|OTHER|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes subsurface biomimetic remineralization of enamel. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix is formed. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
224107862|NCT02782715|PROCEDURE|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
224107863|NCT04856761|DRUG|S-1|S-1 was administered at a dose of 80-120 mg/day on 14 days of a tri-weekly cycle for 8 cycles.
223957377|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
224107864|NCT04856761|DRUG|Capecitabine|Capecitabine was administered at a dose of 1250 mg/m² bid on 14 days of a tri-weekly cycle for 8 cycles.
224107865|NCT00982722|DRUG|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
224107866|NCT00982722|DRUG|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
224107867|NCT00960817|DRUG|Statin, aspirin|
224107868|NCT00960817|DRUG|Dipyridamole|
224107869|NCT00203346|PROCEDURE|Greater Occipital Nerve Block|
224107870|NCT04169607|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Basic ventilation: Volume-controlled ventilation (VCV) mode with positive end-expiratory pressure (PEEP) of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver: ventilation parameters reset as basic ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance (Cdy).~After titration: A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM. Individualized PEEP arm: maintain individualized PEEP; PEEP8 arm: maintain a fixed PEEP of 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit (60 to 90 minutes after extubation): chest CT ."
223957378|NCT02635399|PROCEDURE|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
224107871|NCT03685656|OTHER|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
223957379|NCT01826994|DEVICE|heart type fatty acid binding protein testing|
223957380|NCT01502839|OTHER|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
223957381|NCT02471872|BEHAVIORAL|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
223541514|NCT05069649|DRUG|Placebo|Tablet for oral use.
223541515|NCT05045716|DRUG|Lecanemab|Lecanemab IV infusion.
223957382|NCT02471872|OTHER|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
223541516|NCT05045716|DRUG|Lecanemab|Lecanemab SC injection.
223541517|NCT02651116|DRUG|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
223541518|NCT02651116|DRUG|Placebo|10 mL Placebo
223541519|NCT02651116|DEVICE|Cough recording device|FDA approved device validated for use in adults and children
223541520|NCT04555174|DEVICE|Orsiro Mission DES|Percutaneous Coronary Intervention (PCI)
223957383|NCT02349802|DRUG|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
223957384|NCT02349802|DRUG|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
223957385|NCT01571947|OTHER|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
224107872|NCT03685656|OTHER|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
224107873|NCT03515187|DRUG|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
224107874|NCT03515187|DRUG|0.1% sodium bromide solution|one to two drops in eye, twice per day
224107875|NCT03515187|OTHER|Meibomian gland massage|Physiotherapy
224107876|NCT03515187|OTHER|Placebo|Vehicle
223957386|NCT00238745|DRUG|Bazedoxifene|
223957387|NCT00238745|DRUG|Placebo|
223541521|NCT04336657|OTHER|Questionnaire|Survey to identify number of people who got unusual severe flu- like illness in last October- November
223541522|NCT04336657|DIAGNOSTIC_TEST|IgG|Measure the past immunity of the disease (if possible)
223541523|NCT01184976|BIOLOGICAL|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
223957388|NCT01709630|DRUG|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
223957389|NCT00860509|OTHER|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
223957390|NCT06277011|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
223957391|NCT01721109|DRUG|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
223957392|NCT00635323|DRUG|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
223957393|NCT00709787|OTHER|Usual Care|Normal care for hypertensive patients with risk factors for CHD
223957394|NCT03933241|BEHAVIORAL|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
223957395|NCT01171950|DEVICE|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
223957396|NCT04048226|DRUG|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
224107877|NCT05572476|DRUG|Association of lurbinectedin and durvalumab|"A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.~Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks."
224107878|NCT05572476|DRUG|Association of carboplatin and etoposide|"Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.~Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.~Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks"
223957397|NCT04048226|DRUG|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
223957398|NCT00134056|DRUG|atrasentan hydrochloride|Given orally
224107879|NCT03504033|DRUG|Xenon|inhalation to maintain anesthesia
224107880|NCT03504033|DRUG|Desflurane|inhalation to maintain anesthesia
224107881|NCT03690518|OTHER|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
224107882|NCT04618705|BEHAVIORAL|Smoking Cessation|Participants will start a smoking cessation program.
223957399|NCT00134056|DRUG|docetaxel|Docetaxel given IV and prednisone given orally
224107883|NCT04868240|BEHAVIORAL|Concurrent training program|"The experimental group will perform 16-weeks of exercise. The exercise sessions will occur three times/week.~The participants should conduct their daily activities as usual outside of the study and maintain the same diet."
224107884|NCT02913807|PROCEDURE|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
224107885|NCT02913807|PROCEDURE|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
224107886|NCT02391610|OTHER|No intervention|
224107887|NCT02806401|DEVICE|landmark|
224107888|NCT02806401|DEVICE|US_Ax|
224107889|NCT02035384|DRUG|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
223541524|NCT04992468|DRUG|Ovulation triggering with GnRH-a+rhCG|recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
223541525|NCT04992468|DRUG|Ovulation triggering with GnRH-a|rFSH 225-300 IU (Gonal-F®/Puregon®/Ovaleap®/ Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®)
223957400|NCT00134056|DRUG|prednisone|Docetaxel given IV and prednisone given orally
223957401|NCT00134056|OTHER|placebo|Given orally
223957402|NCT01745835|DRUG|2L Coolprep®|\* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
223957403|NCT01745835|DRUG|1L Coolprep® and Bisacodyl|"1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
224107890|NCT00565422|DRUG|Escitalopram|10 mg/day
224107891|NCT06232434|DRUG|Prospidelong|Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.
224107892|NCT06232434|PROCEDURE|chemotherapy|"after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1"
224107893|NCT01925521|DRUG|Part1 : OPS-2071|single oral dose under fasted condition
224107894|NCT01925521|DRUG|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
224107895|NCT01925521|DRUG|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
224107896|NCT01925521|DRUG|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
224107897|NCT06652828|OTHER|Conventional Treadmill Walking (CTT)|The CTT serves as a comparison to PBT. It involves standard treadmill walking without perturbations on the same treadmill. This intervention is conducted over the same defined period as PBT (3-6 weeks), with a matched frequency and exercise time compared to the PBT group for consistency. Participants are secured with safety harnesses while walking.
224107898|NCT06652828|OTHER|Perturbation-Based Balance Training (PBT)|Overall, 9 training sessions with different objectives and progression regarding perturbation directions, predictability, and intensity will be conducted within 3-6 weeks. During the initial sessions, familiarizing participants with the treadmill and establishing their individual walking pace will be focused. Pace can be individually adjusted in each training session. Participants are secured with safety harnesses while walking.
224107899|NCT01526356|DRUG|Placebo|Study cream is applied nightly to the affected areas on the face.
223957404|NCT02474745|PROCEDURE|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
223957405|NCT02474745|PROCEDURE|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
223957406|NCT01145326|DRUG|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
223957407|NCT01145326|DRUG|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
223957408|NCT05760417|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
223541526|NCT02603276|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
223957409|NCT06049719|OTHER|NIH Task Force's Recommended Multidimensional Minimal Dataset|Questionnaire
223957410|NCT03563989|DEVICE|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
223957411|NCT01852175|DRUG|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
223957412|NCT01852175|DRUG|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
223957413|NCT00226746|DRUG|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
223957414|NCT01803945|DRUG|AVE8112|
223957415|NCT01803945|DRUG|Placebo|
223957416|NCT01622023|PROCEDURE|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
224107900|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
223541527|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
223541528|NCT02603276|DIETARY_SUPPLEMENT|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
223541529|NCT04749147|OTHER|Black and White Printed Survey|This survey will feature black and white text and graphics.
223541530|NCT04749147|OTHER|Red Printed Survey|This survey will feature red text and graphics.
223541531|NCT05207111|DRUG|Revefenacin Inhalation Solution|Revefenacin Inhalation Solution, 175 mcg/3 mL following a single nebulized inhaled 175 mcg (1 x 175 mcg/3 mL) dose administered under fasting conditions.
223957417|NCT02472808|OTHER|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
223957418|NCT02472808|OTHER|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
223957419|NCT02472808|OTHER|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
224107901|NCT01526356|DRUG|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
223541532|NCT01728285|DEVICE|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
223541533|NCT06450015|DEVICE|Vacuum Assisted Closure|VAC applied after debridement and saline packing
223541534|NCT06450015|OTHER|Saline Dressing|Wound was managed by saline dressing
223541535|NCT02051478|OTHER|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
223541536|NCT02051478|OTHER|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
223957420|NCT02472808|OTHER|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
223957421|NCT06426511|DRUG|Toripalimab+Chemotherapy|After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
223957422|NCT06426511|DRUG|Toripalimab+Chemotherapy followed by consolidation toripalimab|"After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians."
223957423|NCT05866887|BEHAVIORAL|Sleep ALL Night|Sleep intervention program comprised of a sleep action plan tool and interactive psychoeducation website.
223957424|NCT03089554|DRUG|Therapeutic Intervention|Therapeutic Intervention
223957425|NCT04089748|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
223957426|NCT03816202|DEVICE|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
223541537|NCT01460069|DRUG|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
223541538|NCT01460069|DRUG|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
223541539|NCT01886235|PROCEDURE|Diagnostic Microscopy|Undergo intravital microscopy
223541540|NCT01886235|DRUG|Fluorescein Sodium Injection|Given IV
223541541|NCT01886235|OTHER|Laboratory Biomarker Analysis|Correlative studies
223541542|NCT01886235|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223541543|NCT02780934|OTHER|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
223541544|NCT02780934|OTHER|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
223541545|NCT01662739|BEHAVIORAL|Questionnaire|
223541546|NCT05651763|OTHER|Stimulation and exercise group|Exercise protocol + application of active direct current stimulation for 30 minutes.
223957427|NCT06133595|BEHAVIORAL|Behavioral: MiBridge|A series of five conversations over three weeks to help participants understand more about themselves and their willingness to change, and to help participants connect with the care they need and want.
223957428|NCT03643770|COMBINATION_PRODUCT|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
223541547|NCT05651763|OTHER|Exercise and sham stimulation group|Sham Transcranial direct current stimulation Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
223541548|NCT02378285|DEVICE|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
223541549|NCT02378285|OTHER|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
223541550|NCT00705874|DRUG|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
223541551|NCT00705874|DRUG|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
223541552|NCT00705874|DRUG|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
223541553|NCT00705874|DRUG|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
223541554|NCT00705874|DRUG|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
223541555|NCT00705874|DRUG|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
223541556|NCT00705874|DRUG|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
223541557|NCT01813695|PROCEDURE|Preemptive genotyping in medical record|
223541558|NCT01813695|PROCEDURE|Genotyping not included in electronic medical record|
223541559|NCT06431191|PROCEDURE|lateral raw|lateral raw repair for full tear rotator cuff combined microfracture procedure, without medial raw
223541560|NCT06431191|PROCEDURE|double raw|double raw repair for full tear rotator cuff combined microfracture procedure
223957429|NCT05242874|DRUG|Fosaprepitant, tropisetron, and olanzapine-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4.
223957430|NCT05242874|DRUG|Fosaprepitant, tropisetron, olanzapine, and dexamethasone-based antiemetic regimen|Fosaprepitant 150 mg intravenously on Day 1, tropisetron 5 mg intravenously on Day 1, and olanzapine 5 mg orally on Days 1 to 4. Dexamethasone 12 mg on Day 1, followed by 8 mg on Days 2 to 4.
223957431|NCT03997552|PROCEDURE|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
223957432|NCT03997552|PROCEDURE|marginal approach by palatal incision|Periodontal reconstructive surgery
223957433|NCT03997552|PROCEDURE|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
223957434|NCT02555397|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
223957435|NCT05583331|PROCEDURE|Cataract surgery|Cataract surgery will be performed as per local practice and standard guidelines.
223957436|NCT05583331|PROCEDURE|Vitrectomy|Vitrectomy will be performed as per local practice and standard guidelines.
223957437|NCT00681915|DRUG|AZD7325|Oral
223957438|NCT05897307|DRUG|Ropivacaine|dexmedetomidine
223957439|NCT03322449|OTHER|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
223541561|NCT00041470|DRUG|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
223957440|NCT03322449|OTHER|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
224107902|NCT03449888|PROCEDURE|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
223957441|NCT06646783|DRUG|[68Ga]Ga-NODAGA-SNA014|Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.
223541562|NCT00041470|DRUG|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
223541563|NCT00041470|DRUG|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
223541564|NCT00041470|DRUG|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
223541565|NCT03384186|DRUG|Danicopan Modified Release Prototype 1|Danicopan (400 milligrams \[mg\]) oral tablet.
223541566|NCT03384186|DRUG|Danicopan Modified Release Prototype 2|Danicopan (400 mg) oral tablet.
223541567|NCT03384186|DRUG|Danicopan Modified Release Prototype 3|Danicopan (800 mg) oral tablet.
223957442|NCT00321555|DRUG|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
223957443|NCT01892982|BEHAVIORAL|Problem Solving Education tailored to NICU|
223957444|NCT03038490|DIETARY_SUPPLEMENT|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
223957445|NCT04712032|DRUG|ICG-guided bowel perfusion assessment|ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
223957446|NCT00043459|DRUG|intravenous T900607-sodium|
223957447|NCT05827185|BIOLOGICAL|Ergonomic modifications|A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. It consists of 5 domains (7 items related to office chair, 9 items related to office desk, 8 items related to keyboard and mouse, 5 items related to computer screen, 3 items related to telephone and 5 items related to the office environment -) and it has a good reliability and validity. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment. Ergonomic education and instructions were also given on an individual basis as per the report of the assessment.
223957448|NCT05827185|BIOLOGICAL|Physiotherapy|First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given. To perform the C1-C2 cervical spine manipulation (CSM) the participant was instructed to lie in a face-up position with upper and lower extremities kept aside relaxed. The head was kept in a neutral position and the treating therapist stands at the patient's head side and holds the chin of the patient with the right side hand. The therapist left hand holds the posterior aspect of the head and does two to three free rotatory movements. Afterwards, the therapist did HVLAT technique in either the right or left direction based upon the symptoms informed by the patient.
223957449|NCT05827185|BIOLOGICAL|Ergonomic modifications and Physiotherapy|"A blinded therapist used an observation-based ergonomics assessment check list for office workers to check the status of office environment, which usually took 40 - 45 minutes to complete. After assessment required modifications were done in the chair, desk, keyboard, mouse, computer screen, telephone and the office environment.~First of all, hydro collator pack was applied over the neck region for 10 minutes to relax the muscles of the neck region. Then the therapist located the sites of abnormal changes in each vertebra and then cervical manipulation was given."
223957450|NCT05827185|BIOLOGICAL|Patient education|Participants in the CNG group received the patient education through an experienced physiotherapist and each session lasting for 30 minutes for 4 weeks. According to each individual patients' abilities the therapist educated them to improve the health literacy regarding the condition. The therapist educated them about the benefits of self-care activities, maintaining good posture, stay active and doing active movements and stretching muscles for preventing the health related musculoskeletal injuries at the workstation. Also, life style modifications were taught to the patients to prevent further deterioration of the condition.
223957451|NCT01269307|PROCEDURE|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
223957452|NCT01269307|PROCEDURE|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
223957453|NCT02501694|OTHER|Auscultation|Electronic stethoscope
223957454|NCT01995214|DRUG|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
223957455|NCT01995214|DRUG|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
223957456|NCT03369483|OTHER|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
223957457|NCT04838509|OTHER|no intervention|retrospective descriptive without intervention
223957458|NCT01231074|DRUG|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
223957459|NCT06073470|DRUG|methylphenidate|The patients with ADHD will receive 12-week treatment with methylphenidate.
223957460|NCT00537914|DRUG|Omnitrope|All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
223957461|NCT02312258|DRUG|Placebo|Ixazomib placebo-matching capsules.
223957462|NCT02312258|DRUG|Ixazomib|Ixazomib capsules.
223957463|NCT01217697|DRUG|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
223957464|NCT01217697|DRUG|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
223541568|NCT03044275|OTHER|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
223541569|NCT03044275|OTHER|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
223541570|NCT00044369|PROCEDURE|Varicocele repair|
223957465|NCT05912998|PROCEDURE|cartilage regeneration technique|autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
223957466|NCT01180959|DRUG|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
223957467|NCT01180959|DRUG|Erlotinib|150 mg by mouth once a day.
223957468|NCT01204879|BEHAVIORAL|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
223957469|NCT03730727|BEHAVIORAL|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
223541571|NCT04963816|PROCEDURE|ultrasound guided quadratus lumborum block|Ultrasound guided quadratus lumborum block will be done to all groups using curved array transducer 5\_2 MHz with the patient in supine position and the block will be done by anterior approach
223541572|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
223957470|NCT03730727|DIETARY_SUPPLEMENT|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
223957471|NCT03140709|DRUG|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
223957472|NCT00303537|DRUG|metformin|
223957473|NCT02817386|OTHER|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
223957474|NCT04053491|PROCEDURE|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
224107903|NCT03449888|PROCEDURE|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
223541573|NCT04963816|DRUG|Bupivacaine Injection|Bupivacaine will be given to all groups locally with QLB
224107904|NCT03449888|PROCEDURE|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
223541574|NCT04963816|DRUG|Dexamethasone Phosphate 4 MG/ML Injectable Solution locally|Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
223541575|NCT06462313|DRUG|Dobutamine|Patients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.
223541576|NCT06462313|DRUG|Norepinephrine|Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
223957475|NCT05167578|BEHAVIORAL|Medication reconciliation|A pharmacist will go through all medicines physicians have prescribed, over-the-counter medicines (OTC) and food supplements one by one to assess the actual medicine used by the patient. If a pharmacist identifies medication discrepancies between physician's prescriptions and patient's self-reported use of medicine during the medication reconciliation, she/he will find out the patients' reasons for adjusting the medication.
223957476|NCT00663429|DRUG|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
223957477|NCT05018065|BEHAVIORAL|Women sexual dysfunctions were screened using Female Sexual Functioning Index (FSFI)|sexual dysfunction assesment
223957478|NCT01735435|OTHER|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
223957479|NCT00123500|BEHAVIORAL|Diet|Diet
223957480|NCT00123500|BEHAVIORAL|Physical Activity|Physical Activity
223957481|NCT00123500|BEHAVIORAL|Environment|Environment
223957482|NCT00123500|OTHER|Control Group|Control Group
223957483|NCT02696109|BEHAVIORAL|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
223957484|NCT02696109|BEHAVIORAL|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
223957485|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
223957486|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
224107905|NCT03449888|PROCEDURE|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease \> 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
224107906|NCT00995371|DEVICE|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
224107907|NCT00995371|DRUG|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
224107908|NCT05409105|DIETARY_SUPPLEMENT|Mangoes|Frozen mangoes, 2 cups per day, 2 weeks
223541577|NCT03573245|DRUG|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
223541578|NCT04187261|PROCEDURE|hip fracture surgeries|fixation or replacement
223541579|NCT01893710|PROCEDURE|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
223541580|NCT06101134|DRUG|relatlimab+nivolumab|Specified dose on specified days
223541581|NCT06101134|DRUG|relatlimab+nivolumab+rHuPH20|Specified dose on specified days
223541582|NCT06101134|DRUG|nivolumab|Specified dose on specified days
223541583|NCT06101134|DRUG|nivolumab+rHuPH20|Specified dose on specified days
223957487|NCT01113593|DRUG|Formoterol Fumarate|Inhalation solution
223957488|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
223957489|NCT01113593|DRUG|Foradil Aerolizer|Dry powder inhaler
224107909|NCT05409105|DIETARY_SUPPLEMENT|Water|2 cups/day bottled water, 2 weeks
224107910|NCT01849133|RADIATION|external fractionated radiotherapy|conventional external beam radiotherapy
223957490|NCT00438048|PROCEDURE|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
223957491|NCT00438048|DRUG|Artificial Saliva|5ml 3 times daily
223957492|NCT05773872|OTHER|Questionary|"In addition to the usual care, the patient will complete the following validated questionnaires :~SART (Sustained Attention to Response Task), IGT (Iowa Gambling Task), UPPS (Impulsive Behaviour Scale), TAS (Toronto Alexithymia Scale), BES (Basic Empathy Scale), FRET (Facial Emotions Recognition Task), ERF-CS, MASC (Movie for the Assessment of Social Cognition)"
223957493|NCT05248672|DRUG|CT1812|Study Drug
223957494|NCT01590056|OTHER|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~1. listening to nonverbal affect bursts corresponding to emotions~2. applying a simple go-no-go auditory test"
223957495|NCT03385447|BEHAVIORAL|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
223957496|NCT00796835|DRUG|ER OROS Paliperidone|
223957497|NCT03643445|BEHAVIORAL|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
223957498|NCT03643445|BEHAVIORAL|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
223957499|NCT00003996|DRUG|carmustine|
223957500|NCT00003996|DRUG|chemotherapy|
223957501|NCT00003996|DRUG|cisplatin|
223957502|NCT00003996|DRUG|etoposide|
223957503|NCT00003996|RADIATION|radiation therapy|
223957504|NCT00349661|DRUG|impact on VASP test|
224107911|NCT01849133|RADIATION|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
223957505|NCT03109899|BEHAVIORAL|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
223957506|NCT06126887|DEVICE|Incrediwear Daytime Back Brace|Incrediwear Daytime Back Brace
223957507|NCT06126887|DEVICE|Incrediwear Sham Daytime Back Brace|Incrediwear Sham Daytime Back Brace
223957508|NCT06126887|DEVICE|Control Daytime Back Brace|Control Daytime Back Brace
223957509|NCT06126887|DEVICE|Incrediwear 24 Hour Back Brace|Incrediwear 24 Hour Back Brace
223957510|NCT00062907|BIOLOGICAL|Recombinant DNA- pVAX/L523S|
223957511|NCT00062907|BIOLOGICAL|Recombinant adenovirus- Ad/L523S|
223957512|NCT02907905|BIOLOGICAL|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
223957513|NCT06231316|DRUG|Norepinephrine Injection|Norepinephrine is both a neurotransmitter and a hormone. It is essential vasopressor for rapid blood pressure support, crucial in maintaining hemodynamic stability
223957514|NCT03428633|DRUG|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
223957515|NCT03428633|DRUG|Morphine|Morphine intraoperatively and postoperatively
223957516|NCT01302158|DRUG|ASP1941|oral
223957517|NCT01302158|DRUG|Glimepiride|oral
223957518|NCT00276601|DRUG|arsenic trioxide|
223957519|NCT00276601|DRUG|cytarabine|
223957520|NCT00276601|DRUG|daunorubicin hydrochloride|
223957521|NCT00276601|DRUG|mercaptopurine|
223957522|NCT00276601|DRUG|methotrexate|
223957523|NCT00276601|DRUG|tretinoin|
223957524|NCT05577936|DEVICE|XPERIENCE Advanced Surgical Irrigation|A clear, colorless, aqueous solution that is indicated for use in the cleansing and removal of debris, including microorganisms, from wounds. Soak for 3 minutes for a total volume of 1L
223957525|NCT05577936|OTHER|Standard of Care Irrigation|17.5 mL povidone-iodine with 500 mL normal saline: solution (0.35%) for 3 minutes for a total volume of 1L (including a normal saline rinse)
223957526|NCT03852069|DIETARY_SUPPLEMENT|Inulin|Patient receive inulin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of inulin-rich vegetables
223957527|NCT03852069|DIETARY_SUPPLEMENT|Placebo|Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to restrict caloric intake and to enhance the consumption of vegetables poor in inulin
223957528|NCT05213312|DRUG|Nivolumab|Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
223957529|NCT05213312|DRUG|Cisplatin|80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
223957530|NCT05213312|DRUG|Paclitaxel|175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
223957531|NCT05213312|DRUG|5Fluorouracil|800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
223957532|NCT05213312|PROCEDURE|Esophagectomy (minimally invasive)|4-6 weeks after neoadjuvant therapy.
223957533|NCT04108403|OTHER|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
223957534|NCT04108403|OTHER|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
223957535|NCT04108403|OTHER|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
223957536|NCT04108403|OTHER|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
223957537|NCT01427400|DRUG|Botulinum Toxin-A|100 Units diluted in 25cc saline
223957538|NCT01427400|DRUG|Saline|Dispensed in a 25cc syringe
223957539|NCT01291472|DRUG|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
224107912|NCT02983292|DEVICE|PyroTITAN™ HRA|Humeral Resurfacing
223541584|NCT06357845|OTHER|Survey|Participants will complete a brief web-based survey asking about their experiences related to the February 3, 2023 train derailment, health experiences and concerns following the derailment, and background information regarding their health history. The survey will last approximately 15 minutes.
223541585|NCT06357845|OTHER|Biological specimen collection|Participants may possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. Participants will be asked which samples they are interested in providing. Participants will receive a specific sample collection kit based on their selection. For blood samples, participants will receive a mailed collection kit at their mailing address. A member of the research team will reach out to schedule blood sample collection, which may take place at home with a trained phlebotomist or at a designated collection site. A total of 1-2 teaspoons of blood (5-10 milliliters) will be collected at a one-time blood draw. For either saliva, hair, and/or toenail clippings, participants will be sent a sample collection kit and receive instructions at their mailing address. This kit also includes a return mailing envelope. Participants will provide the selected samples in the collection kits, place them in the return mailing envelope, and send them back to the research team.
223541586|NCT06357845|OTHER|Communications about study updates and future research opportunities|By consenting to participate in this study, the research team will send updates about the research results and any additional study opportunities to participants.
223541587|NCT06357845|OTHER|Qualitative interview|A total of 40 study participants will be recruited to participate in a 90-minute interview with open-ended questions. The interviews will be video and audio-recorded.
223541588|NCT00977210|DRUG|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
223957540|NCT03293238|PROCEDURE|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
223957541|NCT03293238|PROCEDURE|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
224107913|NCT05718115|DIAGNOSTIC_TEST|CT scan|Biphasic CT scan including arterial phase and portal venous phase after intravenous injection of 80-100 mL of non-ionic iodinated contrast at rate of 4ml/s using pressure injector.
224107914|NCT01075425|DRUG|bortezomib|Given IV
223541589|NCT02614820|PROCEDURE|Remote Ischemic Preconditioning Training Apparatus|
223541590|NCT03051191|DIAGNOSTIC_TEST|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
223541591|NCT05722587|OTHER|Pain science education|High school students receiving a day of pain science education in multiple formats, lectures, experiential, completing a task which consolidates the information.
223541592|NCT00000438|DRUG|naltrexone (Revia)|
223541593|NCT00419055|PROCEDURE|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
223541594|NCT01896973|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
223541595|NCT00443742|PROCEDURE|Validation|
223541596|NCT06458556|DEVICE|Treatment with Morpheus|Radiofrequency device treatment
223541597|NCT03796910|DRUG|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
223541598|NCT03796910|DRUG|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
223957542|NCT03293238|PROCEDURE|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
223957543|NCT03293238|PROCEDURE|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
223957544|NCT00233610|DRUG|Bicalutamide|
223957545|NCT00233610|DRUG|Tamoxifen|
223957546|NCT02647333|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
224107915|NCT01075425|DRUG|belinostat|Given IV
224107916|NCT01075425|OTHER|laboratory biomarker analysis|Correlative studies
224107917|NCT01075425|GENETIC|western blotting|Correlative studies
224107918|NCT01075425|OTHER|pharmacological study|Correlative studies
224107919|NCT01075425|OTHER|flow cytometry|Correlative studies
224107920|NCT00964795|DRUG|Intravitreal Aflibercept Injection 2mg|
224291195|NCT05044728|DRUG|Anti-PD-1 antibody combined with Paclitaxel and carboplatin.|"Anti-PD-1 antibody, 240 mg, IV infusion for 30min (not less than 20min and not more than 60min), d1, every 3 weeks for total 2 cycles. Stratified regimen: group A, 24 hours after the end of chemotherapy; Group B will be given immunotherapy on the first day of each cycle.~Paclitaxel, 135 mg/m2, IV, d1, q3w, for total 2 cycles. Carboplatin, AUC=5 (according to Calvert formula), IV, d1, every 3 weeks for a total of 2 cycles. Stratified regimen: group A, chemotherapy will be given on day 1 of each cycle; Group B will be given chemotherapy drugs 24 hours after the end of immunotherapy."
223541599|NCT03796910|DRUG|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
223541600|NCT03796910|DRUG|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
223541601|NCT04311450|BEHAVIORAL|Behavioral Weight Loss (BWL) counseling|This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
223541602|NCT04405531|OTHER|task-oriented training (TOT)|The study group received a TOT together with a conventional occupational therapy (COT). The study groups received a treatment for 20 sessions at a hospital setting.
223541603|NCT04405531|OTHER|conventional occupational therapy (COT)|The control group received only a COT program. The control groups received a treatment for 20 sessions at a hospital setting.
223541604|NCT05072899|PROCEDURE|platelet rich plasm|local injection of shoulder joint by platelet rich plasm
223541605|NCT05072899|PROCEDURE|Hyaluronic acid|local injection of shoulder joint by Hyaluronic acid
223541606|NCT01240057|PROCEDURE|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
223541607|NCT01240057|OTHER|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
223957547|NCT02647333|DIETARY_SUPPLEMENT|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
223957548|NCT04161716|DEVICE|NIRS recording|Patient has a NIRS module during their urodynamic exam.
223957549|NCT02313350|DEVICE|Chemonucleolysis with Discogel|Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .
223957550|NCT02313350|PROCEDURE|open discectomy|The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
223957551|NCT02300467|DRUG|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
223957552|NCT03064594|PROCEDURE|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
223957553|NCT01282957|BEHAVIORAL|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
223957554|NCT01282957|BEHAVIORAL|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
223957555|NCT02115659|DRUG|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
223957556|NCT02115659|DRUG|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
224107921|NCT01144273|PROCEDURE|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
223541608|NCT00734448|DIETARY_SUPPLEMENT|myo-inositol|2 g twice a day until delivery
223541609|NCT03433976|DRUG|spinal anesthesia|spinal anesthesia for planned cesarean sections
223541610|NCT03512093|OTHER|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct \< 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born \< 34+0 weeks of gestation.
223541611|NCT03512093|OTHER|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
223541612|NCT03512093|OTHER|Interviews of mothers|Interviews of mothers who delivered preterm neonates (\< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
223541613|NCT00602524|DRUG|Pilocarpine|
223957557|NCT00476463|DRUG|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
223541614|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy)|We plan to apply painting art therapy as a health-related intervention to patients coming to our department for elective major surgery of the pancreatic and lower gastrointestinal tract for malignant pathologies. Patients will have 3 patient art therapy sessions: one before surgery, one on day 3-5 after surgery during the hospital stay and one during the follow-up 6 weeks postoperative
223957558|NCT02281266|PROCEDURE|curative resection|
223957559|NCT02281266|DRUG|thymalfasin|1.6mg twice a week, 12 months
223957560|NCT02281266|DRUG|nucleoside analog (suggest to use entecavir)|
224107922|NCT03949673|DRUG|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
223957561|NCT04862598|DEVICE|Oculus Virtual Reality|The patient will receive standard care, augmented with virtual reality. Their post-operative satisfaction score will be recorded.
223957562|NCT05715632|DRUG|Carrelizumab combined with XELOX|Before surgery, the patient received standard dose of carrelizumab combined with XELOX regimen for 4 courses of treatment, and within 3-4 weeks after the completion of the fourth administration, preoperative imaging examination was conducted to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, and to receive radical hand surgery for gastric cancer
223957563|NCT01536964|DRUG|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
224107923|NCT03949673|DRUG|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
224107924|NCT03949673|DRUG|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
224107925|NCT03949673|DRUG|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
224107926|NCT03949673|DRUG|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
224107927|NCT02817607|PROCEDURE|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
223957564|NCT01536964|DRUG|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
223957565|NCT02892019|DRUG|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
224107928|NCT01215539|DRUG|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
223957566|NCT02892019|DRUG|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
223957567|NCT06509646|OTHER|Tia Chi Exercise|"• Yang style 24-posture short-form (16) for 30 minute It consists of 24 unique movements that are performed in a sequence. The form is designed to be easy to learn and can be completed in about six minutes.~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
224107929|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 5mg
224107930|NCT05513976|DRUG|SHR4640 tablet|SHR4640 tablet 10mg
224107931|NCT05513976|DRUG|febuxostat tablet|febuxostat tablet 40mg or 60mg or 80mg based on prior medication
224107932|NCT05513976|DRUG|SHR4640 placebo tablet|SHR4640 placebo tablet 5 or 10mg
224107933|NCT01328873|OTHER|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
223957568|NCT06509646|OTHER|Frenkel's Exercise|"Frenkel's exercises 30 minutes (Through these exercises, the patients would learn how to stay balanced and prevent falls by using their visual, somatosensory, and vestibular systems).~Treatment dosage will be 1 session per day of 1 hour class, 2 sets per session, and 5 repetitions per set, 3 times per week and for 12 weeks"
223957569|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a therapeutic intensity|"The active treatment group will receive inspiratory muscle training starting at a therapeutic intensity of 30% of maximum inspiratory mouth pressure (PImax) and expiratory muscle training starting at a therapeutic intensity of 30% of maximum expiratory mouth pressure (PEmax) for 4 months.~In the active treatment group, the inspiratory and expiratory threshold (intensity) will be adjusted to the perceived exertion (measured with a Borg scale)."
224291196|NCT05044728|PROCEDURE|Surgical treatment stage|After the completion of neoadjuvant immunochemotherapy, patients will be tested again for the functional subsets of peripheral CD8 positive T cells. Alternative treatments will be sought for inoperable patients. For patients who are operable will receive minimally invasive or open surgery was performed 1 month after completion of neoadjuvant chemotherapy immunotherapy, and the functional subsets of peripheral CD8 positive T cells were detected again after surgery.
224291197|NCT01130779|DRUG|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
224291198|NCT01128582|DRUG|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
224107934|NCT04399278|DIAGNOSTIC_TEST|Diagnostic Test: end-expiratory occlusion (EEO) test|"A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.)."
224107935|NCT01870492|DRUG|Activase|Patients treated with Activase
223957570|NCT05632666|OTHER|Inspiratory and expiratory muscle training at a non-therapeutic intensity|The sham-control group will receive the same training protocol as the active treatment group but with a low (10% of PImax and PEmax) and stable non-therapeutic intensity.
223957571|NCT01670799|DRUG|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
223957572|NCT01313663|DRUG|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
223957573|NCT01313663|DRUG|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
223957574|NCT06270862|BEHAVIORAL|Resilience training|Receive mini course on what is resilience and how to use different exercises to be more resilient in life.
224107936|NCT01870492|DEVICE|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
224107937|NCT02471963|DRUG|Empagliflozin|
224107938|NCT02471963|DRUG|Placebo|
224107939|NCT00586690|DEVICE|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
223541615|NCT04524260|BEHAVIORAL|perioperative painting art therapy (LOM® solution centered art therapy) - control|"usual care, no particular intervention during the perioperative setting. There will be 2-3 painting art therapy sessions after the follow-up 6 weeks postoperative. Therefore this group is called usual care- or delayed intervention group."
223541616|NCT00416117|PROCEDURE|Manual Physical Therapy and Exercise|
223957575|NCT06270862|BEHAVIORAL|cognitive training|Play games that trains attention, memory and planning using the services provided by CogniFit.
223957576|NCT06270862|BEHAVIORAL|physical exercise|Engage in age-appropriate physical exercises.
224107940|NCT00586690|PROCEDURE|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
224107941|NCT06811805|DEVICE|RenalGuard Therapy|RenalGuard Therapy
224107942|NCT06811805|OTHER|Standard of Care (SOC)|Standard of care
224107943|NCT01073189|DRUG|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
224107944|NCT01073189|DRUG|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
224107945|NCT03670173|DRUG|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
223541617|NCT00416117|PROCEDURE|Minimal Intervention|
223957577|NCT06270862|BEHAVIORAL|social interaction|Engage in social discussion with peers in the group.
223957578|NCT06270862|BEHAVIORAL|workshop series|Watch a series of workshops targeting the older adult population.
223541618|NCT05987982|PROCEDURE|Oral exercises and oral hygiene|The patients will be required to perform oral exercises and maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
224107946|NCT00857246|DRUG|Cetuximab|
224107947|NCT00857246|DRUG|Irinotecan|
223541619|NCT05987982|PROCEDURE|Oral care|The patients will be required to maintain oral hygiene twice a day. The investigators will assess their oral frailty, oral bacteria, oral odor, and other related clinical care data on the following time points: day 1 of hospitalization, day 3 of hospitalization, the day of discharge, one week after discharge, and one month after discharge.
224107948|NCT00857246|DRUG|Cisplatin|
224107949|NCT00857246|PROCEDURE|Surgery|
224107950|NCT00857246|DRUG|5-FU|
224107951|NCT00857246|RADIATION|Radiation|
223541620|NCT02003482|RADIATION|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
223541621|NCT02003482|DEVICE|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
223541622|NCT01074125|DRUG|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
223541623|NCT02985411|BEHAVIORAL|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
223957579|NCT06509282|BEHAVIORAL|Concurrent training|"Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual."
223957580|NCT01217736|DRUG|aliskiren|single dose, tablet
223957581|NCT01217736|DRUG|placebo|single dose, tablet
223541624|NCT02985411|OTHER|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
223541625|NCT04451005|OTHER|0|Elderly patients with sarcopenia
223541626|NCT02118519|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
223541627|NCT01555866|DRUG|isavuconazole|IV
223541628|NCT00871078|DEVICE|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
223541629|NCT00871078|DEVICE|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
223541630|NCT03506620|DRUG|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
223541631|NCT03506620|DRUG|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
223541632|NCT01193101|DRUG|LCZ696|LCZ696
223957582|NCT01217736|DRUG|VTP-27999|single dose, tablet
224107952|NCT00098059|DRUG|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
224107953|NCT02167269|DEVICE|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
223541633|NCT01193101|DRUG|Placebo|matching placebo to LCZ696
223541634|NCT00746187|DEVICE|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
223541635|NCT00746187|DEVICE|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
223541636|NCT02347085|DRUG|GFF MDI (PT003)|
223541637|NCT02347085|DRUG|Placebo MDI|
223541638|NCT05167812|OTHER|Observation of pregnancies after intake|Monitoring pregnancies after intake at a dedicated recurrent pregnancy loss clinic to predict pregnancy success chances in couples with recurrent pregnancy loss
223541639|NCT01267786|PROCEDURE|Liver surgery|hepatectomy
223541640|NCT00183014|BEHAVIORAL|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
223541641|NCT00183014|BEHAVIORAL|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
223957583|NCT03477032|BIOLOGICAL|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
223957584|NCT03397459|DIAGNOSTIC_TEST|Spine teleradiography EOS|
224107954|NCT02696746|OTHER|Observation|No intervention
224107955|NCT01500174|DEVICE|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
224107956|NCT01500174|DEVICE|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
224107957|NCT00458250|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|
224107958|NCT00458250|DRUG|Busulfan|
224107959|NCT00458250|DRUG|Cyclophosphamide|
224107960|NCT00458250|DRUG|CAMPATH-1H|
224107961|NCT00458250|DRUG|Cyclosporin A|
224107962|NCT00458250|DRUG|Methotrexate|
223724069|NCT07002437|OTHER|Augmented Acute Intermittent Hypoxia (aAIH)|"aAIH (augmented acute intermittent hypoxia) consists of 3, 5-minute episodes of low oxygen (9-13% O2), interspersed with 3-min room air intervals.~Each study participant will complete one session of augmented AIH (aAIH), which consists of 3, 5-minute exposures. Each exposure involves a 5-minute hypoxic episode (9-131% inspired O2), with a 3-min interval of room air breathing (21% O2). Gas mixtures will be delivered via Douglas bags (pre-filled with desired gas mixture) that are coupled to a non-rebreathing valve and facemask. A manual-control valve allows seamless gas mixture switching. Participant safety will be continuously monitored in real-time using non-invasive sensors and LabChart software. For instance, inspired and expired concentrations of O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, tidal volume, heart rate, and blood pressure) will be continuously monitored."
223724070|NCT07002437|OTHER|Acute Intermittent Hypercapnic-Hypoxia (AIHH)|"AIHH consists of 1-min episodes of low oxygen (9% O2) and elevated carbon dioxide (5% CO2), interspersed with 1.5 min room air.~Each participant will complete one session of AIHH exposure, which consists of 15, 1-minute hypercapnic hypoxic episodes (4-5% inspired CO2, 9-131% inspired O2), with 1.5-minute intervals of room air breathing (21% O2). Gas mixtures will be delivered in the same manner described for AIH intervention. Participant safety will be continuously monitored in real-time using LabChart software. For instance, inspired and expired concentrations of CO2 and O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, heart rate, and blood pressure) will be monitored."
223724071|NCT07002437|OTHER|Sham AIH|"A single session of sham AIH with episodes of normal room air (21% O2).~Sham experiments will use methods identical to AIH/AIHH protocols except that normoxic gas (21% inspired O2) will be delivered. Since the timing and intervals vary with each protocol, the sham will use a distinct protocol involving 5, 3-min episodes with 2 min intervals between each episode. The valve on the non-rebreathing mask will be turned to deliver these episodes, but 21% O2 will be delivered throughout."
223957585|NCT04335474|PROCEDURE|Surgical drainage strategy|A laparotomy is performed and the operative approach to pancreatic trauma can consist of laparotomy with drainage of the peripancreatic area, distal pancreatectomy with or without preservation of the spleen, Rouxen-Y pancreaticojejunostomy, and, more seldom, pancreaticoduodenectomy. The type of operation depends on the grade of the pancreatic lesion. Spleen-preserving surgery will be attempted to avoid the lifelong increased risk of infections after splenectomy. In case of trauma where multiple organs are involved and an acute laparotomy is performed, the damage control surgery must be applied and the pancreatic resection will be done as part of a staged surgery.
223957586|NCT04335474|PROCEDURE|Percutaneous drainage strategy|The nonoperative management consists of close monitoring of the patient's clinical condition; repeated radiological investigations such as CT, ultrasound, and MRCP; monitoring of the amylase and lipase levels, initiation of post-pyloric enteral nutrition and parenteral nutrition. In addition, ERCP with the placement of a stent in the damaged pancreatic duct is used as part of the non-operative approach. Besides, percutaneous catheter drainage (PCD) management including ultrasound or CT-guided drainage of abdominal and peripancreatic fluid collections and pancreatic pseudocysts is applied to the HGPT patient.
223957587|NCT04828915|OTHER|Machine learning|Machine learning on vital parameters, clinical symptoms and underlying diseases
223957588|NCT04828915|OTHER|Machine based evaluation|Quantification of the prediction power and identification of the most relevant predictive parameters
223957589|NCT01073761|DRUG|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
223957590|NCT06226116|PROCEDURE|socket preservation|After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
223957591|NCT06226116|PROCEDURE|placement of experimental implants|After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
223957592|NCT06226116|PROCEDURE|histological sample collection|"Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long."
223957593|NCT02610322|BEHAVIORAL|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
223957594|NCT02610322|BEHAVIORAL|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5\~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and \<30% of energy as total fat.
224107963|NCT06656949|PROCEDURE|injecting indocyanine green (ICG) dye Intraoperative|injecting indocyanine green (ICG) dye Intraoperative for patients with endometrial cancer
223957595|NCT04321109|OTHER|Allograft|Corticocancellous mineralized allograft
223957596|NCT04321109|OTHER|Collagen cone|Collagen matrix
223957597|NCT06238310|DIAGNOSTIC_TEST|Comparison of two external marker substance for measuring glomerular filtration rate|Two external marker substance compares for measuring GFR.
223957598|NCT02496559|PROCEDURE|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
223957599|NCT01801202|DEVICE|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
223957600|NCT01223053|DRUG|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
224107964|NCT05128240|DIETARY_SUPPLEMENT|Placebo|1g corn oil capsules
224107965|NCT05128240|DIETARY_SUPPLEMENT|Ceto 10|1g capsules containing oil broad spectrum marine oil from north atlantic fish
223541642|NCT04327440|BIOLOGICAL|RTS,S/AS01 malaria vaccine|Malaria vaccine: RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen combined with an adjuvant. The Phase 3 trial of three doses administered to 5-17-month-olds confirmed moderate protection, with overall efficacy estimates of 50.4% against clinical malaria and 34.8% against severe malaria after three doses. Efficacy, which waned over time, was marginally improved by boosting at 18 months. The European Medicines Agency adopted a positive scientific opinion of the vaccine for use outside of the European Union. The World Health Organization has created the Malaria Vaccine Implementation Program (MVIP) and selected Malawi as one of the sites to explore the feasibility, efficacy and safety of RTS,S vaccination in the context of routine use.
223541643|NCT04327440|OTHER|PBO bed nets|PBO nets: The PBO nets represent a new formulation of insecticide-treated bed nets with a chemical synergist, piperonyl butoxide (PBO), designed to enhance the insecticidal effect of pyrethroids. They seem to be helpful in areas like Malawi where insecticide-resistance is increasing. PBO inhibits the enzyme that detoxifies the pyrethroid, allowing the pyrethroid to act on the mosquito. The impact of PBO net use was also detectable in key entomological measures including Anopheles density, sporozoite rate and entomological inoculation rates. Following these promising preliminary results in Tanzania, Malawi's National Malaria Control Program (NMCP) is piloting the use of PBO-nets iin one of our two study sites, presenting us with the opportunity to study the effectiveness of these nets in the context of real-world program setting
223541644|NCT00548834|DRUG|CDP870|
223541645|NCT03168802|PROCEDURE|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
223541646|NCT03168802|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
223541647|NCT00800982|PROCEDURE|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
223957601|NCT01223053|DRUG|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
223957602|NCT05051709|PROCEDURE|Corrective osteotomy|First metatarsal distal corrective osteotomy
223957603|NCT05051709|PROCEDURE|Fusion of First ray|Fusion of first ray with soft tissue procedure
223957604|NCT02926313|OTHER|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
223541648|NCT00800982|DRUG|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
223724072|NCT07001709|DRUG|Oxycodone oral capsule 15 mg|Single dose of 15 mg oxycodone direct release (both arm 1 and arm 2)
223724073|NCT07001709|DRUG|Abiraterone Acetate Tablets 500 mg|Abiraterone group: 1000 mg abiraterone acetate (at steady state)
223957605|NCT04412174|BIOLOGICAL|GC022F|GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg.
223957606|NCT01199302|BIOLOGICAL|Brodalumab|Administered intravenously once every 4 weeks
223957607|NCT00506896|DRUG|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
223957608|NCT00002090|DRUG|Azithromycin|
223957609|NCT01892007|BEHAVIORAL|Cogmed RM - Online adaptive working memory training|
223957610|NCT01892007|BEHAVIORAL|Cogmed RM - Online non-adaptive (placebo) working memory training|
223957611|NCT04240197|DEVICE|CompuFlo|The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
223957612|NCT01634165|DRUG|LY2963016|Administered subcutaneously
223957613|NCT01634165|DRUG|Lantus|Administered subcutaneously
223957614|NCT04995588|OTHER|Blood test|Unique blood draw of 45mL for all the participants
223957615|NCT06096727|BEHAVIORAL|Energize!|Energize! is 3 month online physical activity program which consists of weekly physical activity goals, video lessons, action planning, and homework.
223957616|NCT06699524|DRUG|in vitro （chemotherapy）|resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.
224107966|NCT04138667|OTHER|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
224291199|NCT01128582|DRUG|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
223957617|NCT06699524|DEVICE|Adjuvant TACE（Adjuvant Transarterial Chemoembolization）|Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.
223957618|NCT06700161|OTHER|Obtaining CGF from patients|Periodontal clinical parameters and Annexin and Lipoxin parameters in CGF will be compared between the test and control groups
223957619|NCT03686839|BEHAVIORAL|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
223957620|NCT01575704|OTHER|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
223957621|NCT01575704|OTHER|Mental Training|Memorial/ mental training and relaxation, 5 times per week
223957622|NCT06721468|OTHER|Trout|rainbow trout
223957623|NCT06721468|OTHER|Child-centered nutrition phrases|"learn the phrase, trout helps your brain so you can learn and play either through researcher introduction or completing the About Trout! Pond to Plate curriculum"
223957624|NCT06721468|OTHER|Puzzle|presented with a puzzle to solve each week
223957625|NCT05512598|DRUG|HB0034|HB0034, a single dose
223957626|NCT03701607|OTHER|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
223957627|NCT03533894|DEVICE|colic capsule|colic polyp diagnosis
224291200|NCT00004876|DRUG|carboplatin|
224291201|NCT00004876|DRUG|thalidomide|
223957628|NCT03820024|BEHAVIORAL|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
223957629|NCT01605435|DRUG|Ghrelin Group 1|The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
223541649|NCT02819531|DEVICE|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
223724074|NCT07132216|DEVICE|Meta Quest 2 VR headset|The Meta Quest 2 VR headset with built-in headphones was used. Patients selected VR environments from a predefined list of five nature scenes (beach, forest, mountain, underwater, and meadow) with identical meditation audio tracks lasting 30 minutes each. Guided Meditation VR from Cubicle Ninjas (https://guidedmeditationvr.com/)featured 360-degree nature environments with standardized calming background music and guided meditation narration. VR was applied immediately after spinal anesthesia and before the surgical incision. Sessions lasted 30 minutes and were discontinued if the patient reported nausea, dizziness, or requested removal.
223724075|NCT07131085|DRUG|Allogeneic TCR-enhanced γδ T cell(QH101)|dose escalation (3+3) : dose 1 (5×10\^8 enTCR γδ cells) , dose 2 (1.5×10\^9 enTCR γδ cells), dose 3 (3×10\^9 enTCR γδ cells)
223724076|NCT07131085|DRUG|Fludarabine (FLU)|Intravenous fludarabine 20\~30 mg/m\^2/day on days -5, -4, and -3
223957630|NCT01605435|DRUG|Ghrelin Group 2|The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
223724077|NCT07131085|DRUG|Cyclophosphamide (CTX)|Intravenous cyclophosphamide 300\~500 mg/m\^2/day on days -5, -4, and -3.
223724078|NCT07132671|RADIATION|Brachytherapy and MR-Guided SBRT|HDR Brachytherapy followed by MR-guided SBRT
223957631|NCT04284592|PROCEDURE|Remote ischemic post-conditioning (RIP)|The limb RIP was applied after leaving of cardiopulmonary bypass and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on an arm and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff.
223957632|NCT03329547|DRUG|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
223957633|NCT03329547|DRUG|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
223957634|NCT04705883|DRUG|Prasterone (DHEA), Micronized|Vaginal prasterone 6,5mg/24h first month, next 5 months 6,5mg/48h, vaginal administration.
223957635|NCT02618564|DRUG|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
223957636|NCT01052870|DRUG|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
223957637|NCT04841811|DRUG|Almonertinib|ctDNA dynamic monitoring guided the Almonertinib treatment group after redical surgery orradiotherapy
223957638|NCT01857362|DRUG|Nitisinone 20 mg|Nitisinone 20 mg capsules
223957639|NCT01857362|DRUG|Nitisinone 10 mg|Nitisinone 10 mg capsules
223957640|NCT00664456|DRUG|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
223541650|NCT02819531|DEVICE|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
223541651|NCT02819531|DEVICE|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
223541652|NCT01198821|DRUG|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
223541653|NCT01198821|DRUG|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
223541654|NCT02793583|BIOLOGICAL|Ublituximab|
223541655|NCT02793583|DRUG|Umbralisib|
223541656|NCT02793583|BIOLOGICAL|Bendamustine|
223541657|NCT04924621|DEVICE|Respiratory Humidification Treatment Device, AIRVO 2 PT101AZ, Fisher & Paykel Healthcare, Inc.|"The nasal cavity was disinfected with Iodophor cotton swab, and the appropriate nasal cavity was selected for endotracheal intubation assisted by fiberoptic bronchoscope according to the experience of anesthesiologists.~After the endotracheal intubation was fixed, the anesthesia machine was connected for mechanical ventilation. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg."
223724079|NCT07131111|RADIATION|CT aortography|"Performed before and after stenting using a multidetector CT scanner (device model and parameters to be specified).~Analysis will include:~* Evaluation of aortic arch geometry (normal / gothic / crenel).~* Measurement of residual stenosis at the site of coarctation.~* Aortic diameter measurements at predefined anatomical levels:~Ascending aorta (AA), Proximal descending thoracic aorta (PDA), At the level of the diaphragm (DA), Abdominal aorta (AbAo).~\- Aortic tortuosity. All CT data will be interpreted by two independent observers blinded to clinical outcomes"
223957641|NCT00664456|DRUG|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
223957642|NCT00664456|RADIATION|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
223957643|NCT04584359|OTHER|HVLA|High velocity, low amplitude manipulation for the sacroiliac joint and T10-L2. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 5 minutes.
223957644|NCT04584359|OTHER|global osteopathic protocol|Myofascial, visceral, and articular techniques. Complete treatment in order to restore and rebalance internal tensions and improve the visceral mobility: muscle inhibition techniques for the psoas muscle; deep massage in the obturator foramen; stretching for the greater omentum; lift of the uterus, ovary, and bladder ; abdominal maneuver; and thrust of sacroiliac joint and T12-L1. The interventions were performed once a week for four weeks by a physiotherapist with a degree in in osteopathy and ten years of clinical experience. Each visit lasted about 15 minutes.
223957645|NCT04584359|OTHER|pelvic floor muscle training|Pelvic floor muscle training for four weeks, with a weekly face-to-face visit lasting 10-20 minutes. In this intervention, participants were instructed to perform three sequences of exercises: contractions and relaxations (three seconds of sustained contractions and six seconds of rest), ten sustained contractions (ten seconds of sustained contractions and 20 seconds of rest), and five contractions associated with a cough. These exercises were performed in the standing, sitting, and lying positions
223957646|NCT06192875|OTHER|Non-Interventional Study|Non-interventional study
223957647|NCT06080919|DEVICE|Drug coated-balloon percutaneous coronary intervention.|Patients will undergo DCB-PCI under IVUS guidance (OpticrossTMHD 60 MHz). Target lesion will be predilated with semi-compliant balloons or non-compliant balloons.The lesion will be then treated with DCB with a reference vessel diameter/balloon diameter ratio of 1.
223957648|NCT06080919|DEVICE|Angiography-derived coronary physiology (IMRangio)|Angiography-derived coronary physiology will be assessed after the procedure using Angio Plus software (Pulse Medical Imaging Technology, Shanghai, China). The angiography images will be used to obtain the IMRangio values, prior and post to DCB-PCI
223957649|NCT06650254|OTHER|Breastfeeding Support Program Structured According to Kolcaba's Comfort Theory|"Stage 1: The Postpartum Breastfeeding Comfort Scale will be applied to mothers before they are admitted to the support program. On the 0th day postpartum, the researcher will go to the mother, baby and father and provide mother-baby skin-to-skin contact and breastfeeding support (Module 1).~Stage 2: The videos aimed at increasing breastfeeding comfort, which were shot for Modules 2, 3, 4 and 5 and transferred to the website, will be watched by mothers and fathers/relatives after discharge. At the same time, online counseling will be provided through the website and support will be provided for applications that will increase breastfeeding comfort.~Stage 3: Mothers who have participated in at least 70% of the breastfeeding support structured according to Kolcaba's Comfort Theory will be called after 6-8 weeks and the Postpartum Breastfeeding Comfort Scale will be applied again and their final tests will be performed."
223957650|NCT04007744|BIOLOGICAL|Pembrolizumab|Given IV
223957651|NCT04007744|DRUG|Sonidegib|Given PO
223957652|NCT05040815|RADIATION|chemo-radiation treatment|Radiotherapy (RT) with concurrent 5-fluorouracil and mitomycin-C (5FU/MMC) combination is the treatment of choice for non-metastatic locally advanced anal squam
223957653|NCT05198934|DRUG|Sotorasib|Sotorasib will be administered orally
223957654|NCT05198934|DRUG|Panitumumab|Panitumumab will be administered as intravenous (IV) infusion
223957655|NCT05198934|DRUG|Trifluridine and Tipiracil|Trifluridine and Tipiracil will be administered orally
223957656|NCT05198934|DRUG|Regorafenib|Regorafenib will be administered orally
223957657|NCT05796752|DRUG|Memantine|Cognition-enhancing medication
223957658|NCT05796752|BEHAVIORAL|ComB Behavioral Therapy|Therapy for BFRBs
223957659|NCT04914897|DRUG|THOR-707|Intravenous infusion: solution for infusion
223957660|NCT04914897|DRUG|Pembrolizumab|Intravenous infusion: solution for infusion
224291202|NCT04047563|DRUG|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
223957661|NCT06719908|DRUG|AFA-281 is a small molecule, orally available|This is a study to evaluate the interaction of AFA-281 with alcohol
223957662|NCT06719908|OTHER|Alcohol (Ethanol)|Alcohol will be administered in combination with AFA-281 or AFA-281 placebo
223957663|NCT05306613|BEHAVIORAL|Prolonged sitting|After consuming breakfast, participants sat on a chair for 180 min. After 180 min, lunch was provided. After finishing lunch, participants sat on a chair for another 120 min.
223957664|NCT05306613|BEHAVIORAL|Breaking sitting|After consuming breakfast, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, lunch was provided. After finishing lunch, participants continued 2 min of walking every 20 min for the following 120 min.
223957665|NCT03020914|DEVICE|Audiovisual Distraction|watching a movie using video glasses and headphones
223957666|NCT03523897|PROCEDURE|Robot Assisted Total Knee Replacement|A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
224107967|NCT06604325|DRUG|Tranexamic acid injection|All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
224107968|NCT06604325|DRUG|Placebo|All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.
224107969|NCT06656728|OTHER|Blood-based liquid biopsy|Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center
223957667|NCT03523897|PROCEDURE|Traditional Total Knee Replacement|A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
223957668|NCT04789096|DRUG|Tucatinib|Oral tablet
223957669|NCT04789096|DRUG|Pembrolizumab|Intravenous
223957670|NCT04789096|DRUG|Trastuzumab|Intravenous
223957671|NCT04789096|DRUG|Capecitabine|Oral tablet
223957672|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox]|
223957673|NCT05797220|DRUG|Botulinum Toxin Type A Injection [Botox] + Diltiazem Hydrochloride 20 Mg/G Rectal Gel|
223957674|NCT04339543|OTHER|Cognitive dual-task walking|• The task will consist in walking while performing the phoneme monitoring task. The phoneme monitoring task will consist in listening to a text through headphones, and participants will be asked to i) answer ten questions regarding the content of the text after the task, and ii) count how many times two predefined words appeared in the text. During single and dual-task walking, participants will be asked to walk around the track at a speed that they feel would be comfortable while walking through the grocery store or walking to their car, with no instructions regarding the priority to give to each task (walking vs. cognitive task).
223957675|NCT01038206|BEHAVIORAL|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
223957676|NCT01671371|OTHER|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
223957677|NCT01364545|DIETARY_SUPPLEMENT|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
223957678|NCT01364545|DIETARY_SUPPLEMENT|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
223957679|NCT06789159|DRUG|VK-2019|VK-2019 will be administered daily starting on day 1 of cycle 1 (D1C1). Dose cohort A will dose at 600 mg dose cohort B 1200 mg and dose cohort C 1800 mg. Treatment cycles will repeat every 28 days , in the absence of disease progression or unacceptable toxicity.
223957680|NCT04127695|DRUG|ABBV-0805|ABBV-0805 administered by IV infusion.
223957681|NCT04127695|DRUG|Placebo ABBV-0805|Placebo ABBV-0805 administered by IV infusion.
223957682|NCT05644067|BIOLOGICAL|SumayaVac-1(SUM-101)|One immunization every 4 weeks for 3 months (total 3 immunizations)
223957683|NCT05644067|BIOLOGICAL|Verorab|One immunization every 4 weeks for 3 months (total 3 immunizations)
223957684|NCT00409006|DRUG|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
223957685|NCT00409006|DRUG|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
223957686|NCT00409006|DRUG|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
223957687|NCT05065099|DEVICE|Online Treatment Recovery Assistance for Concussion in Kids (OnTRACK)|Patients and families will be provided the smartphone app on their personal mobile phone (Android, iPhone) or provided with a phone if they do not own one. The patients will view educational videos on concussion management, input their daily exertional status and weekly symptom status upon receiving pre-programmed notification prompts on their phone. Healthcare Providers will monitor symptom recovery via an HCP dashboard and make management recommendations using evidence-based algorithms regarding symptom recovery status. School personnel will monitor progress via a dashboard and provide targeted supports, they may also view educational videos on concussion management. Opportunities for communication between the HCP, parent/patient and school will be provided by the app.
223957688|NCT01732055|BEHAVIORAL|Partner-Assisted Interpersonal Psychotherapy|
223957689|NCT01732055|OTHER|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
223957690|NCT00695149|PROCEDURE|Transplantation of bone marrow stromal cell|
223957691|NCT04389996|OTHER|No intervention|Patients will be sent a survey incl. EORTC QLQ-C30
224291203|NCT04047563|DRUG|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
224107970|NCT04612088|BEHAVIORAL|Cognitive Dissonance|"A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study."
224107971|NCT01958567|OTHER|Optical Coherence Tomography|
223541658|NCT04924621|DEVICE|Mask ventilation|The Control Group will receive sequential intravenous infusion of Sufentanil 5ug, midazolam 0.05mg/kg, and propofol 1-2ug/ml, to make the BIS between 70 and 80. 2ml tetracaine was injected with cyclothyroid membrane puncture, and the nasal cavity was disinfected with iodophor cotton swab. According to the experience of anesthesiologists, the appropriate nasal cavity was selected for intranasal endotracheal intubation assisted by fiberbronchoscope. After the endotracheal intubation was successful, the anesthesia machine was connected for mechanical ventilation, full narcotic inducer will be injected. The anesthesia machine was set at 50% oxygen +50% air, and the tidal volume was set at 6-8ml/kg.
223541659|NCT04924621|DRUG|Midazolam(T group)|Midazolam 0.05mg/kg, intravenous injection
223957692|NCT05157464|DRUG|Losartan|Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.
223957693|NCT01179659|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
223957694|NCT02155218|OTHER|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
223957695|NCT02155218|OTHER|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
223541660|NCT04924621|DRUG|Sufentani(T group)|Sufentanil 0.02-0.05ug/kg, intravenous injection
223541661|NCT04924621|DRUG|Propofol(T group)|Propofol 2-3ug/ml, intravenous injection
224107972|NCT05387161|OTHER|Nutritional intervention|The nutritional intervention will consist in providing general nutritional indications specific for endometriosis and an indicative ungrammatical daily diet plan, which must be followed for the entire period of intervention (6 months).
223541662|NCT04924621|DRUG|Rocuronium(T group)|Rocuronium 0.06mg/kg, intravenous injection
223957696|NCT02155218|OTHER|gadolinium contrast|
223957697|NCT05450705|BIOLOGICAL|9vHPV vaccine|A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.
223957698|NCT03261713|DEVICE|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
223957699|NCT03261713|DEVICE|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
223957700|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
224107973|NCT01098968|BEHAVIORAL|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
224107974|NCT00686751|DRUG|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
224107975|NCT02957773|BEHAVIORAL|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
224107976|NCT02957773|BEHAVIORAL|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
224107977|NCT02957773|BEHAVIORAL|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
223957701|NCT02367664|BIOLOGICAL|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
223957702|NCT02367664|BIOLOGICAL|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
223957703|NCT03763682|DEVICE|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
223957704|NCT03077958|PROCEDURE|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
223957705|NCT00028600|BIOLOGICAL|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC \>= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC \> 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
223957706|NCT00028600|BIOLOGICAL|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
224107978|NCT02957773|BEHAVIORAL|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
224107979|NCT00533000|PROCEDURE|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
224107980|NCT05612997|OTHER|Dietary Assessment|Food Frequency Questionnaire and 24h Recalls.
224107981|NCT00964418|DRUG|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
224107982|NCT00964418|DRUG|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
224107983|NCT01784471|DEVICE|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
224107984|NCT02803502|DEVICE|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
224107985|NCT02803502|DEVICE|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
224107986|NCT02803502|DEVICE|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
224107987|NCT02509546|DRUG|8-Chloroadenosine|Given IV
224107988|NCT02509546|OTHER|Laboratory Biomarker Analysis|Correlative studies
224107989|NCT02509546|OTHER|Pharmacological Study|Correlative studies
224291204|NCT04432519|PROCEDURE|Immediate dental implant placement|Dental implant insertion in the same surgical stage of the tooth extraction, consisting in implant placement in the fresh socket.
224107990|NCT01524289|DRUG|Anacetrapib|One oral tablet, orally once daily for 52 weeks
224107991|NCT01524289|DRUG|Placebo|One oral tablet once daily for 52 weeks
223541663|NCT04924621|DRUG|Drug use target(T group)|Make BIS \< 60 .
223541664|NCT04924621|DRUG|Sufentanil(C group)|Sufentanil 5ug, intravenous injection
223541665|NCT04924621|DRUG|Midazolam(C group)|Midazolam 0.05mg/kg, intravenous injection
223541666|NCT04924621|DRUG|Propofol|Propofol 1-2ug/ml, intravenous injection
223541667|NCT04924621|DRUG|Tetracaine(C group)|2ml tetracaine was injected with cyclothyroid membrane puncture.
223541668|NCT04924621|DRUG|Drug use target|Make the BIS between 70 and 80.
223541669|NCT00648037|DRUG|Rituximab|Rituximab 375 mg/m\^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is \> 200 cells/ul or a maximum of 6 doses have been given.
223541670|NCT02485587|BEHAVIORAL|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
223541671|NCT02485587|BEHAVIORAL|Treatment as usual|counseling, psychoeducation
223541672|NCT06017882|OTHER|Partial sleep deprivation|
223541673|NCT05842746|DRUG|Elemene|Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
223541674|NCT05842746|DRUG|Placebo|Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.
223541675|NCT01308359|DRUG|IV glucose 5%|500 ml glucose 5% within 30 minutes
223541676|NCT01308359|DRUG|saline|saline
223541677|NCT01951898|DRUG|Montelukast|10mg/day, once a daily after dinner, for 28dyas
223541678|NCT03457077|BEHAVIORAL|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
223541679|NCT02471313|DRUG|[18F] FMISO|\[18F\] Fluromisonidazole, 1 h-(3-\[18F\]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of \[18F\] FMISO PET imaging post TACE procedure.
223541680|NCT02706925|DRUG|BI 443651|
223541681|NCT02706925|DRUG|Placebo|
223541682|NCT04877327|PROCEDURE|Ablation|Cryotherapy and radiofrequency
223541683|NCT04731896|PROCEDURE|Amniotomy|artificial rupture of the amniotic sac
223541684|NCT04773548|OTHER|VR-JIT|Job interview with virtual interviewer
223541685|NCT00699413|DRUG|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
223541686|NCT00699413|DRUG|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
223957707|NCT00028600|DRUG|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
223957708|NCT00028600|DRUG|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
223957709|NCT00028600|DRUG|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
223957710|NCT00028600|DRUG|methotrexate|5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
223957711|NCT00028600|DRUG|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
223957712|NCT00608959|DRUG|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
223957713|NCT00608959|DRUG|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
223957714|NCT05034237|DEVICE|ND;YAG 1064NM LASER|laser hair removal sessions
223957715|NCT01156194|DRUG|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
223957716|NCT01156194|DRUG|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
223957717|NCT01156194|DRUG|Placebo|globule identical to true homeopathy comparators
223541687|NCT06090955|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs(dexmedetomidine 80 μg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
223541688|NCT06090955|DRUG|Lidocaine IV|The study drugs(lidocaine 400 mg/20 mL) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
223957718|NCT03616522|OTHER|a novel mobile phone-based intervention for automated electronic PRO collection|Over the three-month study period, patients will be prompted weekly via text message to self-report up to eleven common symptoms, as well as their performance status and quality of life.
223957719|NCT01707563|PROCEDURE|skin punch biopsy and molecular biology|
223957720|NCT01707563|OTHER|fibroblast culture and molecular biology|
223957721|NCT05419375|OTHER|Screening platform|The screening platform will be used to determine biomarker eligibility for a linked Roche study based on tissue-based testing.
223957722|NCT02568059|DRUG|Sahastara remedy alcoholic extract|comparison of different dose of drug
223957723|NCT01005602|OTHER|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
223957724|NCT01005602|DRUG|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
223957725|NCT04967014|DRUG|HIP2101|Test drug
223957726|NCT04967014|DRUG|RLD2101|Reference drug
224107992|NCT02127762|BEHAVIORAL|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
223541689|NCT06090955|DRUG|normal saline|The study drugs(normal saline) will be prepared with 20 mL syringe and marked as 'trial drug', which are identical in appearance with control and active comparator. In order to avoid anaesthesiologists' speculation about the randomised assignment, the study drugs will be infused at the same rate.
224107993|NCT02104180|DEVICE|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
224107994|NCT02104180|DEVICE|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
223541690|NCT01196013|DRUG|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
223957727|NCT01248715|DRUG|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
223957728|NCT01612897|OTHER|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
224107995|NCT03879590|DRUG|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
224107996|NCT03879590|DRUG|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
224107997|NCT03400293|OTHER|Functional Assessment of HIV Infection|Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
223957729|NCT01544894|DRUG|Raloxifene|60 mg/d for one year
223957730|NCT01544894|DRUG|Strontium ranelate|2 g/d, for one year
224107998|NCT03400293|OTHER|Patient Satisfaction Questionnaire|Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
224107999|NCT03400293|OTHER|Symptom Distress Module|Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
224108000|NCT03400293|OTHER|Patient Health Questionnaire|Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
223957731|NCT04507347|DRUG|TRC041266|TRC041266 sachet 1500 mg strengths
224108001|NCT03400293|OTHER|Internalized Stigma of AIDS Tool|Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
224108002|NCT03400293|OTHER|Medication adherence visual analogue scale|Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
224108003|NCT01595204|PROCEDURE|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
224108004|NCT04939493|OTHER|Rhythmic Auditory Cueing|"Patients will perform the same movement sequence in time with the metronome beat. The frequency of the rhythmic auditory stimulation will be matched to the participants preferred movement speed, which will be assessed prior to the start of the trial, and participants typically started moving after they had heard the metronome beat two to three times. Participants will be given sufficient practice trials to ensure full understanding before the actual recording of data, and will be given 3-minutes break between trials.~On the 3rd and 5th week, the rhythm frequency was increased by 5%."
224291205|NCT05420779|DRUG|TSL-1502 capsules(low dose)|350 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
223541691|NCT04005586|DEVICE|Light Delivery Device (LDD)|Study eye will undergo Light delivery Device treatments
223957732|NCT04507347|DRUG|Placebo|TRC041266 sachet 1500 mg matching placebo
223957733|NCT06559072|DRUG|Atorvastatin|On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
223957734|NCT02416102|DRUG|Losartan 50 mg|50 mg Losartan taken orally once daily for 4 consecutive weeks.
223957735|NCT02416102|DRUG|Losartan 100 mg|50 mg Losartan taken orally twice daily for 4 consecutive weeks.
224291206|NCT05420779|DRUG|TSL-1502 capsules(high dose)|500 mg each time, orally administered QD, every 3 weeks as a treatment cycle.
223957736|NCT05530239|OTHER|Blood sample collection|Blood sample collection
223957737|NCT01659697|BEHAVIORAL|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
224291207|NCT05420779|DRUG|Investigator's choice of chemotherapy|Capecitabine tablets, 1250 mg/m2 each time, BID oral administration; Vinorelbine tartrate injection, 25 \~ 30 mg/m2 each time, intravenous drip (15 \~ 20 min); Eribulin mesylate injection, 1.4 mg/m2 each time, intravenous injection (2 \~ 5 min)
223957738|NCT03486756|BEHAVIORAL|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
224291208|NCT00670033|DRUG|Travoprost ophthalmic solution (new formulation)|
224291209|NCT00670033|DRUG|Travoprost ophthalmic solution, 0.004%|
224291210|NCT00670033|DRUG|Vehicle|Inactive ingredients used as a placebo
224291211|NCT05039437|DIETARY_SUPPLEMENT|MGF-4|Participants were instructed to take 2 capsules of MGF-4 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
224291212|NCT05039437|DIETARY_SUPPLEMENT|MGF-7|Participants were instructed to take 2 capsules of MGF-7 twice a day, and measure own blood pressure at morning everyday throughout the duration of the study.
223541692|NCT03308682|DRUG|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
223541693|NCT05165095|DEVICE|Pacemaker implantation|De novo implantation, device upgrade to dual chamber or device replacement
223541694|NCT04095702|OTHER|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
223541695|NCT04095702|OTHER|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
223541696|NCT04912544|DEVICE|Noninvasive Ventilation Mask Microphone|Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
223541697|NCT06342765|DEVICE|Pedicle fixation surgery|Pedicle fixation surgery indicates a surgical approach in the thoracic spine down to sacral spine to either support interbody fusion (fusion of the discal space between two vertebrae) , or to correct spinal deformity.
223541698|NCT00726128|DEVICE|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
223541699|NCT01534286|DRUG|Theramine|Theramine 2 capsules 3 times per day
223724080|NCT07131111|RADIATION|CMR|"CMR examinations will be performed using a commercially available 1.5 Tesla whole-body scanner (Ingenia, Philips Healthcare, release 4.1.3.0). In pediatric or uncooperative patients, free-breathing sequences were used when breath-holding was not feasible.~Brachial blood pressure was measured in the right arm in the supine position immediately before image acquisition using automated oscillometric devices.~Cine steady-state free precession (SSFP) sequences were obtained in multiple views including the short axis of the ascending aorta (AAO) and descending aorta (DAO), as well as the aortic root to evaluate aortic valve morphology (bicuspid vs tricuspid).~Left ventricular (LV) and left atrial (LA) functional parameters were assessed by standard volumetric analysis. The following CMR-derived parameters were collected:~Left ventricular ejection fraction (LVEF) Left ventricular strain Left ventricular mass index (LVMI) Left atrial volume Left atrial strain LV and LA strain were analyzed usi"
223724081|NCT03686657|DRUG|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
223957739|NCT02422355|DEVICE|FNS|Surgical intervention using the FNS
223957740|NCT05986851|DRUG|Azeliragon|Oral capsule
223957741|NCT06437327|PROCEDURE|Electrotherapy|Hot pack for 10 minutes Interferential Current (IFC) for 10 minutes
223957742|NCT06437327|PROCEDURE|Active release technique|Active release technique is applied (patient is prone lying with knee flexed, Pressure is applied on taut band and patient is asked to move the leg in internal rotation to achieve maximal lengthening) Repetitions 5 to 7 times hold for 5 to 20 seconds
223957743|NCT06437327|PROCEDURE|Hold relax technique|This technique is applied while the patient is in supine lying with one leg crossed over the other Patient is instructed to contract the piriformis against the manual resistance for 5 to 10 secs Then 15 secs of passive stretch is given repetitions x 5 times
223957744|NCT04727463|PROCEDURE|Sphincteroplasty|Overlapping sphincteroplasty
223957745|NCT04516980|OTHER|Questionnaires administration|"Administration of Identification of Functional Ankle Instability (IdFAI) and the following assessment scales: Self-reported question assess the ankle instability as functional/stable or not functional/unstable, Foot and Ankle ability Measure Italian Version - Activity Daily Living (FAAM-I/ADL), Short-form 36-item Health Survey Italian Version (SF-36), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (VAS ankle instability).~After a week the participants will fill in the following questionnaires: Identification of Functional Ankle Instability (IdFAI), Numeric Rate Scale pain (NRS Pain), Visual Analogic Scale Ankle Instability (Vas ankle instability) with the additional question to measure the change in complaints."
223957746|NCT02529176|BEHAVIORAL|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
223957747|NCT03771300|BEHAVIORAL|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
223957748|NCT03771300|BEHAVIORAL|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
224291213|NCT05836415|PROCEDURE|Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation
224291214|NCT00802282|DRUG|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
224291215|NCT00802282|BEHAVIORAL|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
224291216|NCT00802282|BEHAVIORAL|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
223541700|NCT01534286|DRUG|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
223541701|NCT01027858|BEHAVIORAL|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
223541702|NCT01027858|BEHAVIORAL|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
223541703|NCT02014805|RADIATION|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
223541704|NCT02103062|DRUG|ABI-007|
223957749|NCT03771300|BEHAVIORAL|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
223541705|NCT03009461|PROCEDURE|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
223724082|NCT03686657|DRUG|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
223957750|NCT01330953|DRUG|Placebo|Single intravenous placebo dose.
223957751|NCT01330953|DRUG|LY2928057|Single intravenous dose.
223957752|NCT01861509|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
223957753|NCT04400045|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
223957754|NCT04888208|BEHAVIORAL|Behavioral|The intervention group will benefit from discussion sessions on tobacco within the virtual world, with a group of pairs and 2 facilitators (public health researchers).
223957755|NCT03671356|OTHER|risk score|risk score
223957756|NCT05901688|OTHER|Umbilical cord measurements & observations|"In the screening study of an unselected population at 20-22 weeks' and 35-37 weeks' gestation, women are offered an ultrasound scan as part of standard care and will be invited to take part in the study which will involve taking the following additional ultrasound measurements:~1. Umbilical cord coiling index (UCI)~2. Transverse diameter of umbilical cord (UC)~3. Transverse diameter of umbilical vein (UV) and artery (UA)~4. Umbilical vein (UV) Doppler flow characteristics~5. Presence of nuchal cord"
223957757|NCT03409276|BIOLOGICAL|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
223957758|NCT03409276|BIOLOGICAL|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
223957759|NCT03409276|BIOLOGICAL|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
223957760|NCT03409276|BIOLOGICAL|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
223957761|NCT02440698|BEHAVIORAL|Genetic test for personalized nutrition|
223957762|NCT03591263|OTHER|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
223957763|NCT05725447|OTHER|Validity and reliability study|Face-to-face questionnaire study
223957764|NCT04179799|DEVICE|Diaphragm Pacing|"Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller."
223957765|NCT03536637|DRUG|DMT310|Topical Powder
223957766|NCT03536637|DRUG|Hydrogen Peroxide|Liquid Diluent
223957767|NCT03536637|DRUG|Placebo|Placebo Topical Powder
223957768|NCT00368823|DEVICE|Electronic point-of-care delivery system|
223957769|NCT04109209|BEHAVIORAL|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
224108005|NCT04939493|OTHER|Bilateral arm training|Training will consist of 20 minutes of bilateral arm training In each session, patients will be seated comfortably at a table in the following limb positions: ankles in neutral dorsiflexion, knees and hips placed at 90°, shoulders in 0° flexion, elbows in 60° flexion, and wrists in neutral position of flexion/extension
223541706|NCT03009461|DRUG|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
223724083|NCT03686657|DRUG|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
223957770|NCT04109209|BEHAVIORAL|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
223957771|NCT05921331|DEVICE|The RJBC-APP|The RJBC-APP consists of the following features: 1. Login, logout, setting, and modification of personal information. 2. Full-course management included registering for information on the surgical treatment, viewing the results of the multidisciplinary team (MDT) discussion, generating the treatment process according to the MDT discussion, receiving the reminder of the treatment, confirming the completion of the treatment, filling in the follow-up information, and consulting a specialist nurse. 3. Questionnaire and feedback.
223957772|NCT05921331|OTHER|Routine post-surgical follow-up|The routine post-surgical follow-up is conducted in the outpatient clinic.
223957773|NCT03605745|DEVICE|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
223957774|NCT03262753|PROCEDURE|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
223957775|NCT03262753|PROCEDURE|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
223957776|NCT03262753|PROCEDURE|Stent|Primary stent dilation treatment of coarctation of the aorta
223957777|NCT04566120|DRUG|cinnamon extract mouthwash|cinnamon extract mouthwash
223957778|NCT04566120|DRUG|chlorohexidine based mouthwash|chlorohexidine based mouthwash
223957779|NCT05967377|DRUG|Sorafenib - Period 1|Sorafenib (Nexavar®) Tablet, 200 mg
224291217|NCT01473576|DIETARY_SUPPLEMENT|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
224291218|NCT01473576|DIETARY_SUPPLEMENT|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
224108006|NCT04939493|OTHER|Conventional physical therapy program|Scapular mobilization. Thoracic spine mobilization. Mechanical assisted (active and passive) exercises. Therapeutic positioning as weight bearing on the paretic arm. Opening and closing closed fist. Strengthening exercise. Stretching of spastic muscles.
224108007|NCT04831944|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
224108008|NCT02704429|DRUG|PRN1008|"Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks."
224108009|NCT03048448|DRUG|Fevipiprant|Single 450mg dose
224108010|NCT02490540|DRUG|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
224108011|NCT02490540|DRUG|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
224108012|NCT02490540|DRUG|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
224108013|NCT06207344|DRUG|Dexmedetomidine and propofol|Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
224108014|NCT06207344|DRUG|Dexmedetomidine and desflurane|Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
224108015|NCT03703531|PROCEDURE|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
224108016|NCT04415138|DEVICE|Robotic-assisted mitral valve repair|Mitral valve repair using robotic technology (DaVinci X platform)
224108017|NCT00392873|BEHAVIORAL|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
224108018|NCT01786018|DRUG|Thiotepa|
223724084|NCT06869031|BEHAVIORAL|Standard Interactive Intervention for Hypertension Management|The standard interactive intervention is a doctor-patient interaction intervention conducted by follow-up physicians using an intelligent outbound call system as part of follow-up management. It is implemented once a month and is designed based on the Health Behavior Interaction Model, covering four key aspects: health information (e.g., potential risks of poor self-management behavior), professional skills(e.g., blood pressure measurement, medication guidance), emotional support , and decision-making participation.
224108019|NCT01786018|DRUG|Busulfan|
224108020|NCT01786018|DRUG|Fludarabin|
224108021|NCT01786018|PROCEDURE|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10\^7 CD3 cells/kg recipient weight and cryopreserved.
223957780|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 1|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
223957781|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 1|XS005 Sorafenib Tablet A, 100 mg
223957782|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 2|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
223957783|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 2|XS005 Sorafenib Tablet A, 100 mg
223957784|NCT05967377|DRUG|Sorafenib - Period 2|Sorafenib (Nexavar®) Tablet, 200 mg
223957785|NCT05967377|DRUG|XS005 Sorafenib Tablet A - Period 3|XS005 Sorafenib Tablet A, 100 mg
223957786|NCT05967377|DRUG|Sorafenib - Period 3|Sorafenib (Nexavar®) Tablet, 200 mg
223957787|NCT05967377|DRUG|XS005 Sorafenib Capsule A - Period 3|XS005 Sorafenib Capsule A, 100 mg (2 x 50 mg)
223957788|NCT00233142|BEHAVIORAL|Expressive writing|Writing as therapeutic intervention
223957789|NCT00233142|BEHAVIORAL|Neutral writing|Non-expressive writing
223957790|NCT04415580|OTHER|Vestibular Rehabilitation (VR)|"VR consisted of two types of exercises, i.e., those for gaze stability and those for postural stability~* Gaze stability exercises The patients will perform the exercises while holding their gaze on a firm target (VORx1) during active horizontal and vertical head movements (one minute for each axis).~* Postural stability exercises March in Place Each patient will ask to get on a foam cushion of 10 cm in height and then will blindfold. Treadmill Training As preparation for training, all subjects underwent a 1-minute walk on treadmill with open eyes using preferred walking speed. Immediately after preparation, patients will blindfold and will ask to walk on treadmill without support of hands for 4 minutes.~When patients made the mistake of changing direction, the physiotherapist help them to keep the right position using verbal cues (e.g., you are turning left or right)."
223957791|NCT04415580|OTHER|Conventional Neurorehabilitation|muscles stretching, active and assisted limbs mobilization, four limbs coordination exercises, balance training on instable platform and gait training
223957792|NCT02025023|DRUG|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
223957793|NCT02025023|DRUG|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
223957794|NCT02025023|PROCEDURE|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
224108022|NCT01786018|RADIATION|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
223957795|NCT02025023|DRUG|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
223957796|NCT05702892|DIAGNOSTIC_TEST|ELISA|ELISA(enzyme-linked immunosorbent assay)
223957797|NCT00557518|DRUG|Alagebrium|200 mg bid
223957798|NCT00557518|DRUG|Placebo|bid
223957799|NCT05746585|BEHAVIORAL|The Talk Web-based resources|Educational videos and podcasts for parents and their sons
223957800|NCT01880359|DRUG|Cisplatin|
223957801|NCT01880359|RADIATION|Radiotherapy|
223957802|NCT01880359|DRUG|Placebo|
223957803|NCT01880359|DRUG|Nimorazole|
223957804|NCT01641848|DEVICE|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
223957805|NCT05667740|BIOLOGICAL|Gamma-PN3|Inactivated whole-cell pneumococcal vaccine
223957806|NCT05667740|BIOLOGICAL|Prevenar-13|Licensed polysaccharide conjugate pneumococcal vaccine
223957807|NCT05667740|BIOLOGICAL|Pneumovax-23|Licensed polysaccharide pneumococcal vaccine
223957808|NCT05667740|DRUG|Placebo|Saline
223957809|NCT00674609|DRUG|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
223957810|NCT00674609|DRUG|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
223957811|NCT00674609|DRUG|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
223957812|NCT04352894|DIAGNOSTIC_TEST|Fluorescence guided peritoneal exploration|Intravenous injection of ICG
223957813|NCT02174315|BEHAVIORAL|Contingency Management|
223957814|NCT05214248|OTHER|a multimedia admission orientation|A short video based on self-drawing characters and figures with Chinese dubbing and background light music, explaining the NICU environment, health care workers, and tests and examination that are essential for an infant admitted to this NICU of Cathay Hospital in Taipei, R.O.C.
223957815|NCT05229549|OTHER|GOLIKE PLUS 3-16|PKU GOLIKE PLUS 3-16 is a food for special medicinal purposes (FSMP) for the dietary management of PKU.
223957816|NCT05229549|OTHER|Free AAs|It is an immediate-release free AAs mixture with the same qualitative and quantitative composition of PKU GOLIKE PLUS 3-16.
223957817|NCT04780906|OTHER|Wrist taping|Wrist taping as used as standard in CrossFit practice
224108023|NCT01786018|DRUG|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
224108024|NCT01786018|DRUG|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
224108025|NCT01786018|DRUG|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
223957818|NCT04177849|PROCEDURE|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
224108026|NCT01786018|DRUG|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
223541707|NCT00120627|BEHAVIORAL|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
223541708|NCT00120627|OTHER|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
223541709|NCT05634473|DRUG|Methacholine Chloride|Cholinergic agonists
223541710|NCT02377557|DRUG|Topical Steroids|
223541711|NCT02030821|DRUG|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
223541712|NCT02030821|DRUG|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
223541713|NCT04092114|OTHER|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
223541714|NCT04092114|BEHAVIORAL|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~* Module A: General Partner Communication and Relationship Skills~* Module B: Partner Disclosure and Communication around PrEP Use~* Module C: Responding to Intimate Partner Violence and Safety Planning"
223541715|NCT02799589|DRUG|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
224108027|NCT01786018|PROCEDURE|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
223541716|NCT02799589|DRUG|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
223541717|NCT02799589|DRUG|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
223957819|NCT04177849|PROCEDURE|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
223957820|NCT04910399|DIETARY_SUPPLEMENT|Blue fish hydrolysate|"The experimental product is a dietary supplement composed of a hydrolysate of fatty blue fish containing low molecular weight peptides and n-3 polyunsaturated fatty acids.~One of the two study groups (28 volunteers) will take 4 capsules of the active product (blue fish hydrolysate), for 90 days.~Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
223957821|NCT04910399|DIETARY_SUPPLEMENT|Placebo|"The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~One of the two study groups (28 volunteers) will take 4 capsules of placebo per day, for 90 days.Each day the capsules will be taken as followed : 2 capsules in the morning and 2 capsules in the evening."
223541718|NCT03218969|DRUG|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
223541719|NCT03218969|DRUG|Placebo|matching placebo
223541720|NCT02153489|DRUG|Aclidinium bromide|
223957822|NCT00062478|DRUG|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
223957823|NCT03344458|DRUG|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
223957824|NCT03884478|BEHAVIORAL|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
223957825|NCT05516511|DIAGNOSTIC_TEST|Angiotensin Converting Enzyme test|blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
223957826|NCT02975609|RADIATION|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
224108028|NCT03385356|DRUG|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
223541721|NCT02153489|DRUG|Placebo|
223541722|NCT04302116|DRUG|Combination therapy with vigabatrin and prednisolone|High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
223541723|NCT04302116|DRUG|Vigabatrin Tablets|Vigabatrin (50-150 mg/kg/day) twice daily for 4 months
223541724|NCT05115266|BEHAVIORAL|Animal-assisted therapy (AAT|The activity program consists of 10 sessions with a duration of about 60 minutes. During the 10 sessions the animal is presented, in this case a dog. They caress it, dress it, educate it ...
223541725|NCT05115266|BEHAVIORAL|Usual treatment|receive usual treatment (group activities)
223957827|NCT02975609|RADIATION|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
223957828|NCT01272388|DRUG|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
223957829|NCT01272388|DRUG|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (\~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
224108029|NCT05349461|PROCEDURE|Complete patellofemoral articular contact|The patellofemoral condition is in constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
223957830|NCT00543049|DRUG|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
224108030|NCT05349461|PROCEDURE|Incomplete patellofemoral articular contact|The patellofemoral condition is in no constant contact with the femoral trochlea when the knee is bent from 30 to 90 degrees during the No thumb test.
224108031|NCT05578521|DRUG|Cerebralcare pills|a dose of 2 packages, twice a day of Cerebralcare pills
223957831|NCT00543049|DRUG|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
223957832|NCT00874172|DRUG|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
223957833|NCT00874172|DRUG|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
223957834|NCT00674791|BIOLOGICAL|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
223957835|NCT00006428|DRUG|Amitriptyline|
224108032|NCT05578521|DRUG|Cerebralcare pills placebo|Cerebralcare pills placebo will be administrated at the same rate with experimental group
224108033|NCT00720707|PROCEDURE|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
223724085|NCT06869031|BEHAVIORAL|Intensified Interactive Intervention for Hypertension Management|The enhanced interactive intervention builds upon the standard interactive intervention by increasing the frequency of interactions. In addition to the monthly intervention, patients receive an additional brief interactive intervention every two weeks via the intelligent outbound call system, reminding them to adhere to self-management behaviors for hypertension control.
223957836|NCT04232410|DIAGNOSTIC_TEST|Drug induced sleep endoscopy|DISE is performed in a semi-dark, silent operating theatre, starting with the patient in supine position. To first induce sleep, an IV bolus of midazolam (1.5 mg) is administered. Then, a flexible fiberoptic nasopharyngoscope (Olympus END-GP, 3.7 mm diameter, Olympus Europe GmbH, Hamburg, Germany) is inserted through one of the nostrils. Either at the start of the examination or while holding the scope at the level of the palate, propofol (2.0-3.0 µg/ml) will be administered via a target-controlled infusion (TCI) pump. Sleep occurrence is confirmed using the additional EEG measurement.
223541726|NCT04793516|OTHER|VR Therapy Game|Participants will complete 15 sessions of VR-based therapy modules developed for use in helping people with spatial neglect. These 15 sessions will be completed over 4-5 weeks.
223957837|NCT04232410|DIAGNOSTIC_TEST|Measurement of critical closing pressure of the uppper airway|After sleep onset, the CPAP pressure well be increased until no flow limitations are observed. This pressure is called the holding pressure and is used as a base for all the following measurements for that individual OSA patient. After observing sleep stage 2 or 3, the holding pressure is reduced abruptly by 1 cmH2O during expiration for 5 breaths. Then the pressure is set back to the holding pressure for the duration of 1 minute. This procedure is repeated until obstructive sleep apnea is noted.
223957838|NCT01807234|DRUG|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
223957839|NCT01807234|DRUG|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
223957840|NCT01807234|DRUG|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
223957841|NCT06232941|PROCEDURE|Full pulpotomy procedure|vital pulp therapy for molars with irreversible pulpitis instead of doing root canal treatment
223957842|NCT04458376|BEHAVIORAL|Internet-based self-help program|The program is divided into six short weekly lessons providing information about chronic dizziness and vestibular rehabilitation, and demonstrating the exercises by video. The program is freely available in the Norwegian electronic handbook for physicians (NEL). The participants in the study will receive the internet address after inclusion in the study.
223957843|NCT00538629|OTHER|no intervention|no intervention
223957844|NCT00538629|OTHER|no intervention|no intervention
223957845|NCT06544226|DEVICE|UH100|"This is a non-interventional pilot study. Given the within-subject and longitudinal design used in this study, traditional intervention settings are not applicable. All participants will receive weekly and tri-point assessments,~* Weekly (twice per week) Assessments: Physical vitals such as BMI, Blood Pressure, Heart Rate~* Weekly (once per week) Assessments: Sit-Up-Squat-Stand Test, Video diary entries, GAD-7, and PHQ-9.~* Tri-point (week 1, 8, 6) assessments: EDE-Q, Patient Acceptance Questionnaire and the Food-specific Stop Signal Task."
223957846|NCT01803958|RADIATION|partial breast irradiation|
223957847|NCT01803958|RADIATION|whole breast irradiation|
223957848|NCT01219400|DRUG|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
223957849|NCT01118429|DRUG|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
223957850|NCT01118429|DRUG|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
223957851|NCT04454125|BEHAVIORAL|AQI intervention|The intervention arm will receive AQI education, an asthma action plan containing AQI information and recommendations, and will be required to demonstrate ability to check AQI (either via airnow.gov website or downloaded AirNow smartphone app).
223957852|NCT04454125|OTHER|Routine care|The routine care arm will be provided with general AQI education and an asthma action plan not containing AQI information.
223957853|NCT03117218|DIAGNOSTIC_TEST|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
224108034|NCT00720707|PROCEDURE|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
224108035|NCT00114907|BEHAVIORAL|Consumption of black tea|
223541727|NCT02152189|OTHER|Screening for Fabry disease|
223541728|NCT00716274|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
223541729|NCT00716274|DRUG|Placebo|oral, daily, for 16 weeks
223541730|NCT01637896|DEVICE|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
223541731|NCT01637896|DEVICE|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
223541732|NCT06158867|DEVICE|FMD WK|micro-needle patches containing active anti-wrinkle ingredients
223541733|NCT05425017|OTHER|Range of motion with spinal adjustment|With accelerometers affixed to spine recording vibrations, the participants complete range of motion. After completing, they receive a low back spinal adjustment and repeat range of motion
223541734|NCT00578032|BEHAVIORAL|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
223541735|NCT05889091|OTHER|HRQOL instruments|These instruments include Face Q for Appearance, Eating \& drinking, Swallowing, and Saliva (patient-reported); the Neck Dissection Impairment Index (patient-reported); the Long-term ENT-Subjective/Objective/Management/Analysis (LENT-SOMA) for skin-subcutaneous tissue, muscle-soft tissue, mucosa - oral and pharyngeal, salivary gland, and mandible (patient- and clinician-reported); modified barium swallow study (8-point penetration aspiration scale).
223541736|NCT05889091|OTHER|LENT SOMA instrument|LENT SOMA instrument will also be provided to summarize objective quality-of-life-related measures recorded at 12 months postoperatively, including interincisor distance (mm); neck range of motion measured in degrees of flexion, extension, lateral flexion, and rotation to both sides; and shoulder range of motion, measured in degrees of abduction.
223541737|NCT02544854|DRUG|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended."
223541738|NCT04035889|DIETARY_SUPPLEMENT|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
223541739|NCT04035889|DIETARY_SUPPLEMENT|Placebo|Placebo
223957854|NCT02301299|BEHAVIORAL|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
223957855|NCT01189045|BEHAVIORAL|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
223957856|NCT01189045|BEHAVIORAL|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
223957857|NCT00629447|DRUG|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
223957858|NCT01448993|DRUG|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
223957859|NCT01448993|DRUG|Placebo|
223957860|NCT01125345|PROCEDURE|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
224108036|NCT03088423|RADIATION|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
223541740|NCT00893854|DRUG|Diclophenac|
223541741|NCT00893854|DRUG|Triamcinolone|
223541742|NCT03783598|BEHAVIORAL|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
223541743|NCT06556485|PROCEDURE|Catheter ablation|Preventive ablation therapy
223957861|NCT04054245|DRUG|LOXL2 Inhibitor PAT-1251|Given PO
223957862|NCT04054245|OTHER|Quality-of-Life Assessment|Ancillary studies
223957863|NCT04054245|OTHER|Questionnaire Administration|Ancillary studies
223957864|NCT02965352|DEVICE|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
223957865|NCT02965352|DEVICE|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
223957866|NCT02965352|DEVICE|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
223957867|NCT03512041|BEHAVIORAL|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
223957868|NCT03512041|BEHAVIORAL|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
223957869|NCT03512041|BEHAVIORAL|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
223957870|NCT03512041|BEHAVIORAL|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
224108037|NCT05126095|RADIATION|Radical radiotherapy|Intensity-modulated radiation therapy (IMRT)
224108038|NCT01188018|BEHAVIORAL|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
224108039|NCT01188018|BEHAVIORAL|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
224108040|NCT01188018|BEHAVIORAL|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
224108041|NCT03939910|DEVICE|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
224108042|NCT02444169|DEVICE|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
223541744|NCT06556485|DRUG|Medical therapy|Optimal medical therapy
223957871|NCT03512041|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
223957872|NCT03512041|BEHAVIORAL|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
223957873|NCT03512041|BEHAVIORAL|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
224108043|NCT02444169|DRUG|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
223541745|NCT04351594|DRUG|Biofreeze 4 % Topical Gel|Biofreeze gel with active manufactured ingredient (Menthol 4%)
223541746|NCT04351594|OTHER|Biofreeze placebo gel|Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
223541747|NCT04516603|DRUG|Fampridine SR|Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
223541748|NCT04516603|DRUG|Placebo|no active component
223957874|NCT03961178|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
224108044|NCT02444169|DEVICE|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
224108045|NCT02444169|DEVICE|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
224108046|NCT00108810|DRUG|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
224108047|NCT00108810|DRUG|Placebo transdermal patch|12 hours application for 28 days
224108048|NCT00986193|PROCEDURE|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
224108049|NCT00986193|PROCEDURE|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
224108050|NCT02768129|DEVICE|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
224108051|NCT02768129|DEVICE|sham transcranial direct current stimulation|sham stimulation
223957875|NCT03961178|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
223957876|NCT06506630|DIETARY_SUPPLEMENT|coenzyme Q10|300 mg capsule twice a day
223957877|NCT06506630|DIETARY_SUPPLEMENT|placebo|300 mg capsule twice a day
223957878|NCT03071172|DRUG|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
223957879|NCT03071172|DRUG|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
223957880|NCT03071172|DRUG|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
223957881|NCT04088305|DRUG|Individualized therapy|Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
223957882|NCT05449145|DIETARY_SUPPLEMENT|Vitamin D|1st week: Vitamin D 82285.71 IU per day (total dose: 576000IU per week); 2th to 4th week: Vitamin D 41142.86 IU per day (total dose: 288000IU per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
223957883|NCT05449145|DIETARY_SUPPLEMENT|Non-Vitamin D|1st week: 95% MCT oil 5.71 ml per day (total dose: 40 ml per week); 2th to 4th week: 95% MCT oil 2.86 ml per day (total dose: 20 ml per week); 5th to 8th week: fish oil 2 capsules per day（each capsule contains EPA 900mg)
223957884|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
223957885|NCT00555620|DRUG|oxaliplatin|Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
223957886|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
223957887|NCT00555620|DRUG|capecitabine|Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
223957888|NCT00555620|DRUG|cisplatin|Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
223957889|NCT00555620|DRUG|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
223957890|NCT03532568|OTHER|skin biopsy|4mm punch skin biopsy
223957891|NCT03532568|RADIATION|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
223957892|NCT03498456|DRUG|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
223957893|NCT03498456|DRUG|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
223957894|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
223957895|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
223957896|NCT03595306|DIETARY_SUPPLEMENT|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
223957897|NCT06068803|DIETARY_SUPPLEMENT|Ketone drink|Participants will consume three daily ketone monoester (KME) drinks (0.282g KME/kg body weight/ serving) for 4 weeks.
223957898|NCT06068803|DIETARY_SUPPLEMENT|Placebo|Participants will consume three daily taste-matched calorie-free placebo drinks for 4 weeks.
223957899|NCT05959226|BEHAVIORAL|Exercise Intervention|"1. Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..~2. Exercise: under the guidance of the rehabilitation therapist, the patient gradually recovers Exercise from discharge (7-14 days after the operation) to 6 months after the operation, and should ensure at least 150 minutes of moderate intensity exercise or a combination of equivalent activities per week;"
223957900|NCT05959226|DIETARY_SUPPLEMENT|Nutrition Intervention|(1) Nutrition intervention: From discharge (7-14 days after surgery) until 6 months after surgery, patients are required to take 400 kcal/day of oral nutrition supplement (ONS) in addition to their normal diet..
223957901|NCT03276806|BEHAVIORAL|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
223957902|NCT03276806|BEHAVIORAL|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
223957903|NCT03276806|OTHER|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
223957904|NCT03276806|OTHER|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
223957905|NCT06328296|BEHAVIORAL|Rehabilitation treatment|Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223541749|NCT02177383|DIETARY_SUPPLEMENT|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
223541750|NCT02177383|DIETARY_SUPPLEMENT|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
223541751|NCT01846702|DRUG|Placebo|Given as a SC injection.
223957906|NCT06328296|BEHAVIORAL|Myofascial Release Therapy|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
223957907|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
223541752|NCT01846702|DRUG|LY3084077|Given as a SC injection.
223957908|NCT00525642|DRUG|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
223541753|NCT05910658|BEHAVIORAL|Competence in Romance and Understanding Sexual Health (CRUSH)|Manualized curriculum targeting sexual health and behavior in intimate relationships designed to meet the specific needs of autistic adults
223541754|NCT01911351|DRUG|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
223957909|NCT00005771|DEVICE|Visual utrasound feedback|
223957910|NCT00005771|PROCEDURE|Abdominal Hollowing Exercise|
223957911|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 20mg
223957912|NCT04503629|DRUG|Anaprazole Sodium|Anaprazole Sodium 40mg
223957913|NCT04503629|DRUG|Rabeprazole sodium|Rabeprazole sodium 10mg
223957914|NCT05683639|OTHER|warming of the follicular aspiration needle|the follicular aspiration needle will be heated overnight before the ovarian aspiration procedure.
223957915|NCT00035919|GENETIC|Mx-dnG1 Retroviral Vector|
223957916|NCT03472118|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
223957917|NCT01956396|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
223957918|NCT00828139|BIOLOGICAL|ziv-aflibercept|Given IV
223957919|NCT00828139|DRUG|topotecan hydrochloride|Given IV
223541755|NCT02470702|DRUG|Oritavancin|
223541756|NCT02470702|DRUG|Placebo (D5W)|
223541757|NCT03051802|DEVICE|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
223957920|NCT01817088|PROCEDURE|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
223957921|NCT01817088|PROCEDURE|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
223957922|NCT02659488|DRUG|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
223957923|NCT01726634|OTHER|Elastic Tapping|
224108052|NCT02209597|DRUG|Bupropion XL 300|"Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
224108053|NCT05761327|OTHER|Mediterranean Diet|In the Mediterranean diet; The frequency of consumption of foods such as olive oil, olives, nuts, fish, vegetables and fruits will be given in accordance with the Mediterranean diet pyramid. During the study, it is planned to develop new recipes suitable for the nutritional habits of the individual. The researcher will be able to reach the researcher 7/24 in case of any problem experienced by the individual, and the participant's questions will be answered. Nutrition counseling to this group will be supported by an oral explanation given by the dietitian.
224108054|NCT05761327|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take a daily supplement of 1600 mg of curcumin. It is planned that the participants will use 120 capsules of curcumin supplement during the research.
224108055|NCT05761327|DIETARY_SUPPLEMENT|Resveratrol Supplementation|Participants will take a 500mg resveratrol supplement daily. Participants are planned to use 120 capsules of resveratrol supplement during the study.
224108056|NCT01364610|DEVICE|Bravo|Bravo pH Monitoring System sited manometrically.
224108057|NCT01364610|DEVICE|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
224108058|NCT03988712|DIAGNOSTIC_TEST|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
224108059|NCT00003270|BIOLOGICAL|anti-thymocyte globulin|IV
224108060|NCT00003270|BIOLOGICAL|filgrastim|IV
224108061|NCT00003270|DRUG|busulfan|IV
224108062|NCT00003270|DRUG|cyclophosphamide|IV
224108063|NCT00003270|DRUG|cyclosporine|IV
224108064|NCT00003270|DRUG|methylprednisolone|IV
224108065|NCT00003270|PROCEDURE|bone marrow ablation with stem cell support|IV
224108066|NCT00003270|PROCEDURE|umbilical cord blood transplantation|IV
224108067|NCT00003270|RADIATION|radiation therapy|High energy X-rays
224108068|NCT02253875|DRUG|Tipranavir (TPV)|
223957924|NCT03060356|BIOLOGICAL|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
223541758|NCT03092479|BEHAVIORAL|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
223957925|NCT00452322|DRUG|Testosterone Substitution by Testosterone Undecanoate i.m.|
223957926|NCT01714947|DRUG|[^14C]-alisertib|\[\^14C\]-alisertib oral solution
223957927|NCT01714947|DRUG|alisertib|Alisertib enteric coated tablets
223957928|NCT01922102|DRUG|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
223957929|NCT01922102|DRUG|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
224108069|NCT02253875|DRUG|Ritonavir|
224108070|NCT02253875|DRUG|Omeprazole|
223724086|NCT06868719|DIETARY_SUPPLEMENT|No Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with a dextrose placebo. The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
223957930|NCT01922102|DRUG|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
224108071|NCT05084989|BIOLOGICAL|Part1:Recombinant two-component COVID-19 vaccine (CHO cell)|2 doses. Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administration: Intramuscular (IM) injection
224108072|NCT05084989|BIOLOGICAL|Part1: Placebo|2 doses. Before reconstitution: Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: Not Applicable; Does Volume: 0.5ml/dose; Routine of administration: IM injection;
224108073|NCT05084989|BIOLOGICAL|Part2: Recombinant two-component COVID-19 vaccine (CHO cell)|1 dose.Before reconstitution:Lyophilized powder for reconstitution in single-use vials; After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter; Unite Does Strengths: 40ug/vial; Does Volume: 0.5ml/dose Routine of administrati
224108074|NCT05084989|BIOLOGICAL|Part2: COVID-19 Vaccine, mRNA|1 dose. Intramuscular injection, 30 μg/0.3 mL.
223541759|NCT01337778|BEHAVIORAL|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
223541760|NCT01337778|BEHAVIORAL|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
223541761|NCT03404713|BEHAVIORAL|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
223541762|NCT03404713|BEHAVIORAL|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
223541763|NCT06255769|DEVICE|Magnetocardiography|Magnetocardiography
223957931|NCT00518596|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
223957932|NCT00463957|DRUG|sildenafil|
223957933|NCT00463957|DRUG|tadalafil|
223541764|NCT06255769|DEVICE|Single photon emission computed tomography (SPECT)|Single photon emission computed tomography (SPECT)
223541765|NCT04683913|BEHAVIORAL|Foot rotation modification|"The instruction of gait modification provided via teleconferencing sessions (5 over 6 weeks) focusing on increasing toe-in or toe-out angles by as much as is comfortable."
223957934|NCT00463957|DRUG|placebo|
224108075|NCT01855789|DRUG|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to \[\>/=\] 100 kilograms \[kg\]) or every 2 weeks (if body weight was less than \[\<\] 100 kg).
223541766|NCT04683913|OTHER|Waiting Period - Delayed Group|Participants allocated to the Delayed Group will wait 6 weeks after their initial baseline, then complete a second baseline to provide a control condition. After the second baseline they will enter the intervention.
223541767|NCT06368401|DEVICE|Versa Implant|The Versa Vascular Implant and Delivery System consists of a percutaneously delivered, permanent right-atrial implant and the delivery catheter that is used to first position the implant over the native valve orifice and to then place the implant.
223541768|NCT06572293|BEHAVIORAL|Nurse-led intervention|Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
223724087|NCT06868719|DIETARY_SUPPLEMENT|High Salt, No β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). The placebo supplement will be a β-OHB-free, taste and viscosity-matched, beverage produced by KetoneAid.
223957935|NCT02854709|BEHAVIORAL|Sleep extension|Sleep extension by 1 hour for 2 weeks
223957936|NCT05203822|DRUG|Tepotinib (HydroChloride hydrate)|Participants received Tepotinib (Hydrochloride hydrate) Film-coated tablet with food on Day 1 and 12 in the morning.
223957937|NCT05203822|DRUG|Itraconazole|Participants received Itraconazole Hard-gelatin capsule with food once daily at the same time in the morning from Day 8 to Day 18; on Day 12 itraconazole is administered concomitantly with tepotinib.
223957938|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
223957939|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
223957940|NCT01304225|PROCEDURE|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
223957941|NCT03696342|DRUG|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
223957942|NCT03696342|DRUG|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
223957943|NCT01289899|DRUG|BR-A-657|120, 360mg or placebo 7days
223957944|NCT03366233|OTHER|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
223957945|NCT03366233|OTHER|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
223957946|NCT03420729|PROCEDURE|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
223957947|NCT03420729|DEVICE|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
223957948|NCT00101296|DRUG|tipifarnib|Given orally
223957949|NCT00101296|OTHER|pharmacological study|Correlative studies
223957950|NCT00101296|OTHER|laboratory biomarker analysis|Correlative studies
223957951|NCT00850954|OTHER|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
223957952|NCT00850954|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
223957953|NCT00850954|OTHER|Survey Administration|Ancillary studies
223957954|NCT00993590|BEHAVIORAL|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
223957955|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
223957956|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
223957957|NCT01524120|DEVICE|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
223957958|NCT01524120|DEVICE|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
223957959|NCT04054856|DEVICE|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm\^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
223957960|NCT01680315|BEHAVIORAL|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
224108076|NCT01855789|DRUG|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
224108077|NCT01855789|DRUG|Placebo (PBO)|PBO matching to MTX will be administered orally.
223541769|NCT05859178|OTHER|Exercise group|Along with nerve transfer surgery, individuals in the exercise group will undergo handgrip exercise for 30 minutes a day, 5 days a week for a total of 12 weeks.
223541770|NCT03648710|OTHER|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
223541771|NCT03648710|OTHER|Mobile Health|A mobile health application created as a resource for young adults transitioning.
223541772|NCT00966459|PROCEDURE|Computed Tomography|1 low-dose CT is taken
223541773|NCT05067101|PROCEDURE|Capsule Sparing Cystectomy (CSC)|Adopt endoscopic enucleation technology to preserve the prostate capsule and part of the urinary control support structure to help restore urinary control and erectile functions
223957961|NCT01680315|BEHAVIORAL|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
223541774|NCT05067101|PROCEDURE|Conventional Radical Cystoprostatectomy (CRC)|According to the consensus standard program, remove the accessory tissues including the bladder, prostate and seminal vesicles
223957962|NCT02161588|DRUG|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
223541775|NCT00543985|PROCEDURE|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
223724088|NCT06868719|DIETARY_SUPPLEMENT|High Salt, High β-OHB|Participants will consume the following for ten days. Enteric capsules will be filled with Morton's table salt. Sodium consumption will be normalized to caloric intake (2 mg Sodium/Calorie). Ketone beverage will be the β-OHB supplement produced by KetoneAid. Participants will consume 24 mL (12 grams β-OHB) of the ketone beverage three times a day (total 36 grams β-OHB).
224108078|NCT03067311|BEHAVIORAL|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
224108079|NCT03067311|BEHAVIORAL|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
224108080|NCT04102774|DEVICE|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
224108081|NCT07013175|PROCEDURE|Choosing wisely protocol|Se arm description
224108082|NCT05606939|DEVICE|intestinal ultrasound|"All patients will be evaluated using intestinal ultrasound with special emphasis on intestinal wall thickness as well as stratification and Visualization of the vascularization of the bowel using color Doppler sonography also visualization of motility.~Findings of intestinal ultrasound will be compared regrading colonoscopic findings"
224108083|NCT05135052|DEVICE|Rhenium-SCT|Rhenium-SCT irradiation device
224108084|NCT06735560|RADIATION|89Zr-TLX250 PET/CT|Patients will receive 89Zr-TLX250 for detection of CAIX-expressing tumor by PET imaging.
224108085|NCT06725303|DEVICE|Excimer|Light energy
224108086|NCT00960557|DRUG|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
224108087|NCT01843322|PROCEDURE|endoleak repair procedure (navigation technology )|
224108088|NCT06843317|BIOLOGICAL|Candidate vaccine, SCB-1019T|SCB-1019T is a novel bivalent recombinant RSV vaccine (CHO Cell) designed to broadly neutralize the two dominant circulating strains of the virus. The SCB-1019T vaccine consists of the PreF protein subunits from the two dominant circulating strains, strain A and strain B, fused to Trimer-Tag™.
224108089|NCT06843317|BIOLOGICAL|AREXVY|positive comparator
224108090|NCT06843317|OTHER|placebo|Placebo Comparator
224108091|NCT06666673|DRUG|Tizanidine|Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.
223541777|NCT02530255|DIETARY_SUPPLEMENT|cycloastragenol|Oral telomerase activator - cycloastragenol.
223541778|NCT02530255|DIETARY_SUPPLEMENT|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
223541779|NCT05182918|OTHER|Substance use disorder treatment|The study followed a heterogenous sample of patients in opioid maintenance treatment (OMT) and other substance use disorder treatment. The main focus was on health related problems in this cohort, with focus on tobacco use and substance use.
223957963|NCT02161588|DRUG|placebo|Once-daily oral administration as tablets.
223957964|NCT02539602|BEHAVIORAL|The Need to Know students received the N2K curriculum as described previously|
223957965|NCT01176747|DRUG|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
223957966|NCT00814359|DRUG|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
224108092|NCT06666673|DRUG|Placebo|Administered as control
224108093|NCT00907738|DRUG|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
224108094|NCT06509698|OTHER|virtual reality|STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.
224108095|NCT06509698|OTHER|Frenkel's exercise|Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
224108096|NCT03366311|PROCEDURE|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
223541780|NCT03367884|PROCEDURE|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
223541781|NCT03367884|RADIATION|Definitive radiotherapy|Definitive radiotherapy (70Gy)
223541782|NCT05578014|PROCEDURE|Acupuncture|To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture the sham acupoint (EX-B2 T3 point) or Dazhui point.
223541783|NCT02015039|DRUG|BoNT Injections|
223541784|NCT02015039|PROCEDURE|Occupational Therapy|
223541785|NCT03848455|DIAGNOSTIC_TEST|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
223541786|NCT02568657|DEVICE|Celox group|
223541787|NCT02568657|DEVICE|Bakri Balloon|
223957967|NCT00814359|DRUG|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
223957968|NCT00399945|DRUG|Tobramycin|
223957969|NCT03843333|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
223957970|NCT03843333|BEHAVIORAL|Behavioral Activation|BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
223957971|NCT03843333|OTHER|Resource Navigation|CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
223957972|NCT03843333|OTHER|Enhanced Usual Care|Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
223957973|NCT02632630|DRUG|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
224108097|NCT04912128|DRUG|Anlotinib|"Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.~Stereotactic Radiosurgery Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases"
224108098|NCT06944925|DRUG|BBT002|BBT002 will be administered.
224108099|NCT06944925|DRUG|Placebo|Placebo will be administered.
224108100|NCT06945627|OTHER|This research doesn't involve any kind of intervention on the study participants|This research doesn't involve any kind of intervention on the study participants
224108101|NCT05680220|DEVICE|Neurostimulation System (NSS): Active Setting|Exposure to the active device for 1 hour a day for 6 weeks
223541788|NCT03249818|DEVICE|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
223541789|NCT04821167|PROCEDURE|laparoscopic orchiopexy for intra-canalicular testis|laparoscopic orchiolysis of abnormal fibrous attachments and then lap assisted transcrotal fixation of the testis in subdartos pouch for intra-canalicular testis
223541790|NCT02947191|BIOLOGICAL|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
223541791|NCT05539326|OTHER|Performance Clinical Outcome Test|Patients will be asked to perform a fast 4-meter walk test (4mWT) and the Timed up and Go (TUG) test in the clinic during their post-operative follow-up visit. Both performance exams will be performed in a controlled environment within the physician's clinic.
223541792|NCT01329861|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
223541793|NCT04848402|DEVICE|On-Body Delivery System (OBDS)/Multiple Bolus Injector|Used to administer placebo SC.
223541794|NCT04848402|DEVICE|Single Auto Injector|Used to administer placebo SC.
223541795|NCT04848402|DRUG|Placebo|Administered SC.
223541796|NCT06214403|DRUG|MET-2|Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
223541797|NCT06214403|DRUG|Placebo|Microcrystalline Cellulose
223724089|NCT04600921|DRUG|Ertugliflozin 5 mg|The subject will receive Ertugliflozin 5mg orally once daily for 52 weeks.
223541798|NCT02330614|OTHER|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
223724090|NCT04600921|DRUG|Placebo 5mg|The subject will receive Placebo 5mg orally daily for 52 weeks.
223724091|NCT02429557|OTHER|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
223541799|NCT02330614|OTHER|Nothing - control group|Only NEO-FFI test , data used as control
223541800|NCT04049773|PROCEDURE|haemodialysis|haemodialysis, thrice weekly in-center
223541801|NCT03895073|OTHER|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
223541802|NCT06088329|BEHAVIORAL|Mindful Walking for Adults with Chronic Pain|Participants identified with chronic pain will complete 6 sessions of mindfulness based walking exercises.
223541803|NCT04046939|DRUG|Dexpramipexole|dexpramipexole twice daily oral dosing for up to 12 weeks
223541804|NCT04046939|DRUG|Placebo|placebo twice daily oral dosing for up to 12 weeks
223541805|NCT06347913|RADIATION|ultrasound|Umbilical Artery Systolic/Diastolic Ratio and Amniotic Fluid Index in Prediction of Fetal Outcome in Term Pregnancies
223541806|NCT00403130|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
223541807|NCT00403130|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
223541808|NCT00403130|DRUG|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
223724092|NCT02429557|OTHER|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
223957974|NCT02632630|DIETARY_SUPPLEMENT|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
223541809|NCT03704493|DIAGNOSTIC_TEST|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
223541810|NCT02622789|OTHER|Pilates Exercises|Pilates method based stability exercise intervention
223541811|NCT05158413|DIETARY_SUPPLEMENT|High dose|Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
223541812|NCT05158413|DIETARY_SUPPLEMENT|Low dose|Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
223541813|NCT00806260|DRUG|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
223541814|NCT00806260|DRUG|Placebo|Placebo daily for 4 weeks
223541815|NCT00806260|OTHER|Alcohol|
223541816|NCT00806260|OTHER|alcohol placebo|fruit juice
223541817|NCT02162706|OTHER|Non intervention study|
223541818|NCT01876212|BIOLOGICAL|DC vaccine|
223541819|NCT01876212|DRUG|Dasatinib|
223724093|NCT02429557|DRUG|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
223724094|NCT02429557|DRUG|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
223724095|NCT06607484|DRUG|SR-878|Intravenous infusion
223724096|NCT06607484|DRUG|Placebo|Intravenous infusion
223724097|NCT06596031|BEHAVIORAL|Health coaching|The core belief in coaching is that people are resourceful and that the participant knows what is best for themselves. If the participants are assigned to the health coaching group, they will have access to a health coach with a physiotherapist background. Instead of offering physiotherapy advice, however, the health coaching will work with the participant to come up with ideas that work the best for them to manage their health and wellness to prepare for surgery, including addressing some difficulties the participant are facing when using the online resource.
223957975|NCT02632630|DRUG|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
223957976|NCT02632630|DIETARY_SUPPLEMENT|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
223957977|NCT02823171|DRUG|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
223957978|NCT02823171|DRUG|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
223541820|NCT00237042|BEHAVIORAL|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
223541821|NCT00237042|BEHAVIORAL|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
223541822|NCT00237042|DRUG|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
223541823|NCT00003525|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223541824|NCT03322904|DIAGNOSTIC_TEST|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula \[IEC-PC¬\] - \[CC-PC\] / \[CC-PC\]."
223541825|NCT05992129|OTHER|foot exercise|These are foot and ankle muscle strengthening exercises described and evaluated by the literature
223541826|NCT05376722|DRUG|pamiparib|pamiparib 40 mg orally, twice a day
223541827|NCT05376722|DRUG|abiraterone|biraterone acetate 1000 mg orally, once a day
223957979|NCT01345253|DRUG|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
223957980|NCT01345253|DRUG|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
223957981|NCT05819177|OTHER|Rehabilitation program|This group of patients underwent standard rehabilitation programs set by national guidelines.
223957982|NCT05747352|OTHER|closed-loop hybrid insulin administration|observational non-interventional study
223957983|NCT02781233|OTHER|Progressive resistance training|Progressive resistance training program
223957984|NCT02781233|OTHER|Normal daily activities|Usual daily activities
224108102|NCT05680220|DEVICE|Neurostimulation System (NSS): Sham Setting|Exposure to the sham device for 1 hour a day for 6 weeks
223957985|NCT04726319|OTHER|FHAMe Intervention|Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.
223957986|NCT03456830|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
223957987|NCT03456830|DRUG|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
223957988|NCT03401411|BEHAVIORAL|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
223957989|NCT03401411|BEHAVIORAL|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
224108103|NCT00288470|DEVICE|Hylaform, Hylaform Plus (hylan B gel)|
224108104|NCT01089725|BIOLOGICAL|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
224108105|NCT01089725|BIOLOGICAL|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
224108106|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
224108107|NCT01089725|BIOLOGICAL|Placebo IV|1 ml placebo administered IV every 8 weeks
224108108|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
223541828|NCT05376722|DRUG|prednisone|prednisone acetate tablets (prednisone) 5 mg, once a day
223541829|NCT00767026|BEHAVIORAL|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
224108109|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
224108110|NCT01089725|BIOLOGICAL|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
223541830|NCT00767026|BEHAVIORAL|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
223724098|NCT06596031|BEHAVIORAL|Digital toolkit|This intervention provides, via a website, self-management support of preoperative rehabilitation for hip or knee replacement based on NICE guidelines Joint replacement (primary): hip and knee. This includes guidance for patients to undertake a strengthening programme that will aid recovery, lifestyle behaviours including weight management, diet and smoking cessation, and maximising functional independence and quality of life before surgery.
223724099|NCT06871410|DRUG|Autologous Anti-CD83 CAR T-cells|Given IV
223724100|NCT06871410|PROCEDURE|Biospecimen Collection|Undergo bone marrow aspiration blood sample collection
223957990|NCT04694300|DRUG|Naproxen|"440 mg by mouth immediately after completion of implant surgery followed by 220 mg 12 hours later.~Then 220 mg every 8 hours for the next two days."
224108111|NCT01089725|BIOLOGICAL|Placebo IV|1ml placebo administered IV every 8 weeks
224108112|NCT01089725|BIOLOGICAL|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
223957991|NCT04694300|DRUG|Acetaminophen|1000 mg by mouth immediately after the completion of implant surgery followed by 1000 mg every 6 hours for 3 days after surgery with a maximum daily dose of 3000 mg.
223957992|NCT04694300|DRUG|Tramadol|50 mg by mouth every 6 hours as needed for pain
223724101|NCT06871410|PROCEDURE|Chest Radiography|Undergo chest x-ray
223724102|NCT06871410|PROCEDURE|Computed Tomography|Undergo CT
223724103|NCT06871410|DRUG|Cyclophosphamide|Given IV
223957993|NCT01560962|DRUG|povidone iodine|over the counter (OTC) 5% povidone iodine (PI)
224108113|NCT01089725|BIOLOGICAL|Placebo SC|1ml placebo administered SC every 8 weeks
223724104|NCT06871410|PROCEDURE|Echocardiography|Undergo ECHO
223724105|NCT06871410|DRUG|Fludarabine Phosphate|Given IV
223724106|NCT06871410|DRUG|Hydroxyurea|Given hydroxyurea
223724107|NCT06871410|PROCEDURE|Leukapheresis|Undergo leukapheresis
223724108|NCT06871410|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223724109|NCT06871410|PROCEDURE|Positron Emission Tomography|Undergo PET
223957994|NCT01560962|OTHER|No Intervention|
223957995|NCT01560962|DRUG|Azithromycin|
223957996|NCT01560962|DRUG|tobramycin-dexmethasone|
223957997|NCT01560962|OTHER|warm soaked eyelid wash|
223957998|NCT03443739|OTHER|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
223957999|NCT05248269|PROCEDURE|Radiofrequency thermocoagulation|The 2 pertinent contacts connect to Radiofrequency thermocoagulation lesion-generator equipment (Cosman G4 with Ad-tech electrodes), expressly modified for use with SEEG electrodes. The following parameters will be adopted: current power 3 W within 180 seconds and current intensity (usually approximately 25 mA) variable according to impedance.
223958000|NCT03364556|OTHER|No intervention|
223724110|NCT06871410|OTHER|Questionnaire Administration|Ancillary studies
223958001|NCT03015961|DRUG|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
223958002|NCT03015961|DRUG|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
223958003|NCT03734588|GENETIC|SPK-8016|adeno-associated viral vector
223958004|NCT02376322|RADIATION|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
224108114|NCT01486316|DEVICE|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
224108115|NCT01486316|OTHER|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
224108116|NCT00112151|DRUG|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
223541831|NCT02167321|DRUG|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
223541832|NCT02167321|DRUG|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
223541833|NCT00210444|BIOLOGICAL|Botulinum toxin type A|
224108117|NCT00112151|BEHAVIORAL|Resistance Training|Weight training 45-60 minutes 3 times per week
224108118|NCT00112151|DRUG|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
224108119|NCT00112151|DRUG|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
224108120|NCT00830453|PROCEDURE|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
224108121|NCT02137434|OTHER|Dietary calcium|Dietary calcium from skimmed milk
224108122|NCT02137434|DIETARY_SUPPLEMENT|Supplementary calcium|Supplementary calcium from calcium carbonate
224108123|NCT01990599|OTHER|Nasopharyngeal Tube|
224108124|NCT06447181|DEVICE|3D visualization technology ; ICG fluorescence technology .|"Three-dimensional reconstruction technology is a software that can collect CT and MRI data, perform image segmentation and three-dimensional reconstruction of the liver, gallbladder, dilated bile ducts, pancreas, venous, and arterial systems step by step.~ICG fluorescence technology is a fluorescent laparoscopic technology that can detect extrahepatic biliary duct misalignment, improving surgical precision and safety."
224108125|NCT02717767|OTHER|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
224108126|NCT03020810|DRUG|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
223958005|NCT00841165|DEVICE|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
223958006|NCT00841165|DEVICE|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
223958007|NCT03337204|BEHAVIORAL|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
223958008|NCT03337204|BEHAVIORAL|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
223958009|NCT02331771|DRUG|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
224108127|NCT02031380|DEVICE|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
224108128|NCT00296348|DRUG|tacrolimus|immunosuppression
223958010|NCT02331771|DRUG|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
224108129|NCT00296348|DRUG|mycophenolate mofetil|oral
224108130|NCT00296348|DRUG|daclizumab|oral
224108131|NCT00296348|DRUG|steroids|oral
224108132|NCT04468958|BIOLOGICAL|SAB-185|SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
224108133|NCT04468958|OTHER|Normal saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
224108134|NCT04583865|OTHER|teleconsultation|In the pandemic period linked to COVID, pediatric pre-anesthesis consultations should preferably be carried out by teleconsultation. This is to assess the effectiveness of these teleconsultation and the satisfaction of parents.
224108135|NCT00664274|BEHAVIORAL|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
224108136|NCT00664274|GENETIC|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
223724111|NCT05193968|OTHER|Sympathoexcitatory stressors|Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
223724112|NCT05193968|DRUG|Sodium Nitroprusside|Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
224108137|NCT03177135|DEVICE|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
224108138|NCT05645666|BEHAVIORAL|Well-being therapy|Well-being therapy is a short-term, organized and problem-oriented treatment program that is based on Riff's psychological well-being model. Its purpose is to help patient in order to improve His/her functions in six dimensions; personal growth, environmental mastery, purposefulness of life, and autonomy, self-acceptance and positive relationships with others Therapists help patients find well-being experiences in their present and past lives and pay attention to these experiences, no matter how small or short they are.
224108139|NCT04304222|DEVICE|3D Printed Denture Framework|The Denture Framework is 3D printed from the digital image obtained from the denture mold.
223541834|NCT04630821|OTHER|Dilute Sodium Hypochlorite solution|"Subjects will be treated with the dilute bleach compresses daily for the first 3 weeks of therapy.~While these subjects are undergoing radiation therapy, they will be assessed weekly before the day's compress treatment by a physician investigator on the study team. Subjects will be evaluated and photographs will also be taken at study visits 1-3. The subjects will also complete a subject questionnaire addressing patient-reported outcomes at baseline and each weekly check-in during these two weeks. They will be also interviewed about ease of use and treatment tolerability. Subjects will complete interview questions at the end of the study to determine if they would continue the treatment and any obstacles or barriers."
223541835|NCT03189732|DRUG|Metformin Oral|
223541836|NCT03189732|DRUG|Metformin local in AT|
223541837|NCT03189732|OTHER|Exercise|
223541838|NCT01045369|DRUG|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
223541839|NCT00411489|PROCEDURE|endolumenal surgery|
223541840|NCT01758094|DRUG|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
223541841|NCT00295607|DRUG|Tacrolimus|immunosuppression
223541842|NCT00295607|DRUG|steroids, monoclonal anti-IL2R antibody|immunosuppression
223541843|NCT01010607|DEVICE|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
223541844|NCT01010607|DEVICE|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
223541845|NCT01010607|DEVICE|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
223541846|NCT01897532|DRUG|Placebo|placebo matching tablets
223541847|NCT01897532|DRUG|Linagliptin|
223541848|NCT06277440|OTHER|cognitive training|cognitive training, 15 min, three times per week, for 12 weeks
223541849|NCT06277440|OTHER|active control|Traditional rehabilitation programs
223541850|NCT05772325|OTHER|Individually tailored diet counseling|Participants in the intervention group will receive a 60 min individually tailored heart-friendly diet consultation by a dietitian
223541851|NCT05772325|OTHER|The brief standardized 4-minute heart healthy dietary advice|The brief standardized 4-minute heart healthy dietary advice will be provided by an experienced cardiologist or rheumatologists
223541852|NCT02217969|BEHAVIORAL|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
223541853|NCT03250143|DRUG|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
223541854|NCT05932173|BIOLOGICAL|Anti-CD19 Autologous CAR-T Cell Infusion|Autologous T cells modified with anti-CD19 ScFv expression and manufactured by OlyCAR platform
223541855|NCT04570618|DEVICE|Unblinded AlgoDx Sepsis Prediction Algorithm|When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
223541856|NCT04570618|OTHER|Blinded AlgoDx Sepsis Prediction Algorithm|Standard of Care, i.e. no sepsis prediction alert.
223541857|NCT05768594|OTHER|Blood sample|After blood sampling, patients will undergo a Color Doppler Echocardiogram, a non-invasive method
223541858|NCT05964894|OTHER|ergonomic training|ergonomic education \& exercise training
223541859|NCT01571622|DIETARY_SUPPLEMENT|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
223541860|NCT01571622|DIETARY_SUPPLEMENT|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
223541861|NCT06011265|DRUG|Myrbetriq 25Mg Extended-Release Tablet|Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
223541862|NCT06011265|DRUG|Placebo|Participants take empty capsule orally
223541863|NCT02461199|BIOLOGICAL|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
223724113|NCT05193968|DRUG|Acetylcholine|Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
223958011|NCT01877720|DEVICE|noninvasive respiratory support with NAVA mode and PSV|
223958012|NCT03331276|OTHER|BBN|BBN to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
223958013|NCT03331276|OTHER|Brand|Brand to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
223958014|NCT01084408|DEVICE|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
223958015|NCT01084408|DEVICE|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
223958016|NCT04667442|DIAGNOSTIC_TEST|Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)|COVID-19 Rapid Antigen Diagnostic Test
223958017|NCT00447499|DRUG|Somatuline Autogel (lanreotide acetate)|Injections
223958018|NCT00447499|BEHAVIORAL|Home administration|Questionnaire
223958019|NCT02068352|DRUG|OPA-15406|OPA-15406 topical ointment
223541864|NCT02928861|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
223541865|NCT01745653|DEVICE|Low level laser therapy|
223541866|NCT01745653|PROCEDURE|sham procedure|
223541867|NCT02392988|OTHER|acupuncture treatment|acupuncture treatment
223958020|NCT02068352|DRUG|Vehicle ointment|OPA-15406 1%-matching placebo topical ointment
223958021|NCT04891536|PROCEDURE|Salvage cryoablation of the prostate (SCAP)|Cryotherapy of the prostate through transperineal freeezing needles
223958022|NCT05465499|PROCEDURE|ERAS|This study is a cross-sectional observational study by distributing questionnaires regarding the readiness to implement ERAS at Dr Soetomo General Hospital to the subjects, so there is no treatment whatsoever on the subjects.
223958023|NCT00028509|PROCEDURE|management of therapy complications|
223958024|NCT01847599|OTHER|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
223958025|NCT06164119|OTHER|manual treatment with osteopathic techniques and nutritional treatment|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)
223958026|NCT06164119|OTHER|manual treatment with osteopathic techniques|manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)
223958027|NCT06164119|OTHER|nutritional treatment|nutritional treatment (personalized Mediterranean Diet)
223958028|NCT04283058|DRUG|Ketamine|d. Ketamine 0.5mg/kg\* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg\* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
223958029|NCT05464992|OTHER|Additional CEST sequences during PET/MRI exam|CE-Marked Advanced Technology Software Modules (ATSM) for Magnetic Resonance Imaging from General Electric Healthcare
223958030|NCT03435939|DRUG|Losartan|50 mg/day for 7 days followed by 100 mg/day for 12 weeks
223958031|NCT05729152|OTHER|Sample blood|Partecipants will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram
223958032|NCT02577848|DRUG|GLP-1|GLP-1 were taken daily for 7 days
223958033|NCT02577848|DRUG|Placebo|Placebo were taken daily for 7 days
223958034|NCT00999271|OTHER|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes"
223958035|NCT05149976|DIAGNOSTIC_TEST|Voice recording before and after dietary intake|"* A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test."
223958036|NCT01322347|DRUG|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
223958037|NCT01322347|DEVICE|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
223958038|NCT00711776|DRUG|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
223958039|NCT00711776|DRUG|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
223541868|NCT02392988|OTHER|Placebo Comparator|Placebo Comparator
223541869|NCT00002429|DRUG|Lamivudine/Zidovudine|
223541870|NCT00002429|DRUG|Nelfinavir mesylate|
223541871|NCT00002429|DRUG|Stavudine|
223541872|NCT00002429|DRUG|Didanosine|
223541873|NCT03132467|BIOLOGICAL|Durvalumab|Given IV
223541874|NCT03132467|BIOLOGICAL|Tremelimumab|Given IV
223724114|NCT05193968|DRUG|Terbutaline|Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
223724115|NCT05193968|DRUG|Norepinephrine|Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
223724116|NCT06684743|BIOLOGICAL|RSV prefusion F protein-based vaccine|For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
223958040|NCT00494286|BEHAVIORAL|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
223958041|NCT00494286|BEHAVIORAL|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
223958042|NCT06247878|DEVICE|Skiin underwear chest band|Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
223958043|NCT03237741|DRUG|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
223958044|NCT03237741|DRUG|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
223958045|NCT03237741|DRUG|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
223958046|NCT02841085|GENETIC|Genetic sample|Blood sample or saliva collection
223958047|NCT00896389|PROCEDURE|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
223541875|NCT01470105|OTHER|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
223724117|NCT04080492|OTHER|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
223724118|NCT02048605|BEHAVIORAL|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
223724119|NCT02048605|BEHAVIORAL|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
223958048|NCT00896389|DRUG|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
223958049|NCT01369147|DRUG|Parenteral Nutrition|The PN dose will be written for each 24-hr period taking into account any kilocalories (kcal) provided as part of standard of care from propofol, clevidipine, dextrose-containing IV fluid exceeding 500 mL/day, and enteral feedings.
223958050|NCT01369147|DRUG|Propofol|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL).
223958051|NCT01369147|DRUG|Clevidipine|The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in clevidipine (2 kcal/mL).
223958052|NCT01369147|DRUG|Dextrose-containing IV Fluids|The PN dose will be written for each 24-hr period taking into account calories provided from dextrose-containing IV fluid orders exceeding 500 mL/day.
223958053|NCT01369147|DRUG|Enteral feeding|Enteral nutrition is caloric intake through the gastrointestinal (GI) tract via food consumed through the mouth or a feeding tube delivering nutrition directly to the stomach or small intestines. The PN dose will be written for each 24-hr period taking into account calories provided from any enteral feedings.
224108140|NCT06554457|DRUG|Multimodal analgesia with oral strong opioids|Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics
224108141|NCT04713917|DEVICE|Hyaluronique Acid Gel|Vaginal gel based on HA with liposomal structure applicated 2 times a week
224108142|NCT04713917|DEVICE|Laser CO2|The laser energy delivered along the vaginal wall heats the tissue without damaging it.
224108143|NCT04713917|DEVICE|Hyaluronique Acid Injection|HA injection performed under the mucosae (2-3mm in depth) following one injection point every 5mm on the 3 first cm of the vagina and on the posterior part of the introitus.
223958054|NCT05633849|DIETARY_SUPPLEMENT|SMP group|Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
223958055|NCT05633849|DIETARY_SUPPLEMENT|Placebo group|Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
223541876|NCT01344343|OTHER|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
223541877|NCT04960670|OTHER|Evaluation of microbiome and maternal/infant lifestyle|Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
223541878|NCT03682965|BIOLOGICAL|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
223541879|NCT03682965|BIOLOGICAL|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
223541880|NCT05002725|DRUG|Lidocain|300mg (20ml) will be injected
223541881|NCT03271515|BIOLOGICAL|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
223958056|NCT06315621|DEVICE|Scanning using intraoral scanner with markers|Scanning different types of nasal defects using intraoral scanner with skin markers.
223541882|NCT05522738|DRUG|Combination: Fruquintinib + FOLFIRI|"Phase 1b Fruquintinib was administered in a 3 + 3 dose escalation regimen at the following doses: L1:3 mg/d, L2:4 mg/d, L3:5 mg/d.~Fruquintinib: QD po q2w~FOLFIRI regimen:~Irinotecan：180 mg/m2, i.v. , d1, q2w LV：200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w~Phase II Fruquintinib: RP2D, QD po q2w~FOLFIRI regimen:~Irinotecan： 180 mg/m2, i.v. , d1, q2w LV： 200 mg/m2, i.v., d1, q2w 5-FU：2400 mg/m2, i.v.for over 46 hours, q2w"
223541883|NCT00005935|DRUG|Mycophenolate mofetil|
223541884|NCT00005935|DRUG|Cyclosporine|
223541885|NCT06717607|DEVICE|low cylinder toric IOL|Clareon T2 toric IOL implantation
223541886|NCT06717607|DEVICE|non-toric IOL implantation|Clareon non-toric IOL
223541887|NCT06053528|DRUG|Antibiotic|Effect if treatment
223541888|NCT02425397|GENETIC|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
223541889|NCT02425397|GENETIC|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
223541890|NCT02805452|DRUG|Succinate of Solifenacin|
223541891|NCT02805452|DRUG|Placebo of Succinate of Solifenacin|
223958057|NCT06315621|DEVICE|Scanning using intraoral scanner without markers|Scanning different types of nasal defects using intraoral scanner without skin markers.
223958058|NCT06315621|DEVICE|Physical Impression|Recording different types of nasal defects using physical impressions
223958059|NCT02755948|BIOLOGICAL|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
223958060|NCT02755948|BIOLOGICAL|Influenza A/California/04/2009-likw (H1N1)|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
223958061|NCT02755948|BIOLOGICAL|Influenza A/Belgium/4217/2015 (H3N2)|Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops
223541892|NCT05814237|OTHER|Data collection|Data collection from study participants to characterise diagnostic and therapeutic practices.
223541893|NCT02670473|DEVICE|fanfilcon A (test)|contact lens
223541894|NCT05678946|OTHER|Integrated face-to-face rehabilitation and telerehabilitation|Kela´s integrated face-to-face rehabilitation and telerehabilitation services for family caregivers include two 5-day periods of face-to-face rehabilitation and a 12-week telerehabilitation period between them. It is for those over the age of 18 who work as family caregivers on a daily basis and need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation. The service, provided free of charge, is carried out in a Finnish rehabilitation centre and online over a period of 8 months, and it is implemented by a multidisciplinary team of rehabilitation experts. During the 12-week telerehabilitation period, the service providers utilise The Own Path, an acceptance and commitment therapy -based guided web intervention found beneficial for older Finnish family caregivers (Lappalainen et al. 2021). Telerehabilitation is independent of time and place.
223541895|NCT05678946|OTHER|Social Holidays|MTLH's Social Holidays for family caregivers are 5-day holidays in a Finnish hotel, spa, sports institute, or rehabilitation centre. The theme, content, and level of available assistance in Social Holidays vary, and the rehabilitation concept is lighter than that of Kela's rehabilitation services. Social Holidays include full-board accommodation and holiday activities, e.g. lectures, group discussions, instructed exercise, and a pampering treatment. MTLH organises Social Holidays for family caregivers as well as family caregivers and care recipients. The participants cover their travel expenses and pay a fixed sum of €125. Other than that, Social Holidays are provided free of charge. Social Holidays are intended for family caregivers who need recreational activities, rest, and peer support.
223958062|NCT01488240|PROCEDURE|pulsed dye laser|laser energy
223958063|NCT06361212|DRUG|Ethoximod|Ethoximod is a S1P1 modulator.
223958064|NCT04528524|OTHER|Questionnaire|QoR-15Dt
223958065|NCT05437328|BIOLOGICAL|bi-4SCAR GD2/CD56 T cells|Infusion of bi-4SCAR GD2/CD56 T cells at 10\^6 cells/kg body weight via IV
223958066|NCT05910879|BEHAVIORAL|Self-Affirmation Implementation Intentions (SAII) Intervention|"In an brief exercise, participants are asked to provide a personal story and positive experience during the challenging and sometimes stressful COVID19 pandemic, …a time when you felt successful and proud of yourself. …You can also tell us about a time that you did something to help someone in need. The self-affirmation is designed to offset effects of threats to self. In the next section participants are asked to formulate an if-then plan with one preferred self-affirmation-inducing cognition: If I feel sad, threatened, or discriminated against, then I will… a)…think about things I value about myself, b)…remember things that I have succeeded in, c) …think about what I stand for, or d)…think about things that are important to me. After selecting response, participants read the full If-Then plan out loud and are provided with a paper copy of their exercise to take home."
223958067|NCT05910879|BEHAVIORAL|Promotores de Salud (Health Education)|The Promotores de Salud intervention includes: (1) a culturally tailored health education to increase knowledge about COVID-19 and the benefits of testing; (2) motivational interviewing (MI) strategies to explore personal, social, and behavioral barriers to testing and to discuss available resources to resolve these barriers; (3) emotional support to address testing-related concerns and anxieties that may dissuade Latinx individuals from getting tested; and (4) service navigation. When promotores (community health advocates) are on-site at Mexican Consulate events, they will provide information about COVID-19 and preventive behaviors using in-person instruction on effective mask wearing, hand washing, and physical distancing, as well as the importance of repeated testing and vaccines.
223958068|NCT00224913|PROCEDURE|Neuromuscular electrical stimulation|
223958069|NCT00224913|PROCEDURE|Voluntary exercise|
223958070|NCT03420040|DEVICE|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
223958071|NCT03420040|DEVICE|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
223958072|NCT02788435|BEHAVIORAL|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
223958073|NCT03603691|DIAGNOSTIC_TEST|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
223958074|NCT03603691|DIAGNOSTIC_TEST|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
223958075|NCT03603691|DIAGNOSTIC_TEST|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
223958076|NCT03603691|DIAGNOSTIC_TEST|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
223958077|NCT03603691|DIAGNOSTIC_TEST|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
223958078|NCT03603691|DIAGNOSTIC_TEST|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
223958079|NCT02043652|DRUG|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
223958080|NCT02043652|DRUG|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
224108144|NCT02175667|PROCEDURE|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
224108145|NCT00144105|DRUG|TPV500mg/RTV200mgBID|
224108146|NCT00144105|DRUG|TPV500mg/RTV100mgBID|
224108147|NCT00144105|DRUG|LPV400mg/RTV100mgBID|
224108148|NCT00004154|DRUG|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
224108149|NCT00004154|OTHER|Placebo|Two placebo capsules for 25 days of 28 day cycle.
224108150|NCT01638689|DRUG|Escitalopram|20 mg p.o.
223958081|NCT04050514|DEVICE|H-MAD with a hinge system according to Herbst|"The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD"
223958082|NCT03129009|DRUG|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
223958083|NCT03129009|DRUG|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
223958084|NCT02073214|OTHER|Probiotic|Standard treatment plus probiotic
223958085|NCT02073214|OTHER|Placebo|Standard treatment plus placebo
223958086|NCT04095338|OTHER|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
223958087|NCT04095338|OTHER|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
224108151|NCT04021784|DEVICE|SDS|The patient is implanted with SDS.
224108152|NCT04021784|DEVICE|NEMOST|The patient is implanted with NEMOST.
224108153|NCT02016157|DRUG|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
224108154|NCT04389606|OTHER|Study Formula (SF)|New infant formula for term infants fed ad lib
224108155|NCT04389606|OTHER|Comparator Formula (CF)|Commercially available infant formula for term infants fed ad lib
224108156|NCT04735900|PROCEDURE|Liquid biopsy sampling|Biweekly liquid biopsy sampling to measure circulating tumor DNA (ctDNA) level up to and including 9 months after start first-line therapy.
224108157|NCT04296292|OTHER|In-depth interviews|In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
224108158|NCT02414295|DRUG|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
224108159|NCT00379483|DRUG|Deferasirox|
223958088|NCT04095338|OTHER|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
223958089|NCT02958722|PROCEDURE|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
223958090|NCT02958722|DRUG|physiological solution|
223958091|NCT02958722|DRUG|carbon dioxide|
223958092|NCT00870168|DRUG|chemotherapy|
223958093|NCT00870168|GENETIC|gene expression analysis|
223958094|NCT00870168|OTHER|laboratory biomarker analysis|
223958095|NCT00870168|PROCEDURE|breast biopsy|
223958096|NCT02089425|DRUG|K-103-IP|
223958097|NCT02089425|DRUG|Placebo|Placebo comparator
223958098|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Micro-coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
223958099|NCT05959057|DIETARY_SUPPLEMENT|ERr 731 - Enteric coated|natural extract of the Rheum Rhaponticum L plant (Siberian rhubarb). The primary active constituents of ERr 731® are hydroxystilbenes, primarily rhaponticin and desoxyrhaponticin.
223958100|NCT01686724|BEHAVIORAL|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
223958101|NCT01686724|OTHER|Business As Usual|
223958102|NCT01352026|DRUG|Metformin|
223958103|NCT03067870|BIOLOGICAL|Stem Cell Transplantation|"* Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~* Transplantation of autologous bone marrow derived stem cells in joints."
223958104|NCT03967457|DIAGNOSTIC_TEST|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
223958105|NCT03967457|DIAGNOSTIC_TEST|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
223958106|NCT03967457|DIAGNOSTIC_TEST|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
223958107|NCT03967457|DIAGNOSTIC_TEST|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
223958108|NCT02995707|DRUG|Thalidomide|thalidomide:50mg/d p.o at bedtime
223541896|NCT05678946|OTHER|Face-to-face rehabilitation|Kela's rehabilitation services for family caregivers and the care recipients include three 5-day periods of face-to-face rehabilitation, which are carried out in a Finnish rehabilitation centre over a 10-month period and implemented by a multidisciplinary team of rehabilitation experts. The rehabilitation services for family caregivers and the care recipients are provided free of charge. The service is intended for persons over the age of 18 who work as family caregivers on a daily basis with or without family caregiver support and who need support, tools, and coaching to understand and overcome the challenges posed by the care situation. Individual goals based on the GAS method are set, evaluated, and adjusted during the rehabilitation.
223541897|NCT06663449|PROCEDURE|subcostal transversus abdominis plane block|subcostal transversus abdominis plane block will be performed using 20 mL of 0.25 bupivacaine
223958109|NCT00599625|DRUG|Pravastatin|80mg administered daily for 6 consecutive weeks
223958110|NCT06498232|OTHER|Active Video Based Exercises|Warm-up and cool-down will consist of aerobic games (Step, Hula Hoop, Rhythm Parade Dance, Run) available in Nintendo Wii. Balance games will consist of Penguin Slide, Soccer Heading, Table Tilt, Balance Bubble, Ski Slalom, Ski Jump, Tilt City, and Snowboard Slalom. Among the sports games, Bowling, Boxing, Tennis, and Baseball will be included in the program. In all games, progress will be made by increasing the difficulty levels, and in balance games, the game will be made more difficult with an additional balance board and bosu.
223958111|NCT06498232|OTHER|Stabilization and Strengthening Exercises|Warm-up exercises will consist of active dynamic warm-up exercises. Stabilization and strengthening exercises; extremity movements will begin with teaching respiratory control in supine, prone, sitting, crawling, squat, and standing positions, and will be made more difficult with the addition of exercise tires and exercise balls. Balance exercises will start from static positions and move on to dynamic positions with the inclusion of different surfaces. In the cooling exercises, in addition to breathing exercises, stretching exercises will be performed for the trunk, upper and lower extremities.
223541898|NCT06663449|PROCEDURE|erector spinae plane block|erector spinae plane block will be performed using 20 mL of 0.25 bupivacaine
223724120|NCT06626334|DEVICE|Bright Blue Light|Bright blue light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#132, Medium Blue) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
223958112|NCT06498232|OTHER|Waiting List-Spine protection principles training|Participants will be placed on a waiting list. Following the initial evaluations, participants will be informed that they will be included in an exercise program at the end of 6 months. During this process, participants in the control group will be called by phone at the 6th, 12th, and 18th weeks to question their status and to remind them that they will start the exercise program after a while. It will be evaluated at the end of 6 months, and the end of the study, exercise training approaches in the intervention group will be applied to participants who wish to do so, with the same protocol and duration.
223958113|NCT01799603|DRUG|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
224291219|NCT02074267|DRUG|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
224108160|NCT00678496|OTHER|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
224108161|NCT00678496|OTHER|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
224108162|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
224108163|NCT00435539|DRUG|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
224108164|NCT00435539|DRUG|Sham Comparator|Intravitreal sham injection
224108165|NCT02226016|DEVICE|FG-5000A|a measuring device for the assessment of levator muscle strength
224108166|NCT00021866|BEHAVIORAL|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
224108167|NCT00021866|BEHAVIORAL|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
224108168|NCT00795626|BEHAVIORAL|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
224108169|NCT05205239|DIAGNOSTIC_TEST|Endoluminal image analysis by capsule endoscopy|Studies will be performed after discontinuation of medications that could affect gastrointestinal motility for at least 48 hours and overnight fast. Endoluminal images were obtained with the Pillcam capsule (Pillcam SB3 video capsule; Medtronic). Images will be obtained at a fixed 2 per second rate and recorded for a total of 8 hours with the subjects lying comfortably on a hospital bed and the trunk raised 30° above horizontal. Forty-five minutes after gastric exit, participants will be instructed to ingest a liquid meal (Ensure HN; Abbott; 300 mL,1 Kcal/mL). Endoluminal images of the small bowel will be analyzed with a computer program specifically developed in our laboratory for the evaluation of intestinal motility. This previously validated program is based on computer vision techniques, which allow the detection and quantification of contractile and non-contractile patterns characterizing small bowel motility.
224108170|NCT00674934|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
224108171|NCT02625519|DRUG|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
224108172|NCT02625519|DRUG|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
223724121|NCT06626334|DEVICE|Bright Full-Spectrum (White) Light|Bright full-spectrum (white) light will be administered using a Day-Light Classic Plus Light Therapy Lamp fitted with a LEE filter (#211 0.9 ND) and mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended). The light intervention will be administered at bedside for 4 hours daily during the morning/early afternoon hours, repeated for up to 3 days.
224108173|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
224108174|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
224108175|NCT02114203|DRUG|placebo for PDE9i|oral dose, every 12 hours for 28 days
224108176|NCT02114203|DRUG|PDE9i|oral dose, every 12 hours for 28 days
224108177|NCT01248806|RADIATION|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
224291220|NCT02074267|DRUG|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
224291221|NCT00168116|PROCEDURE|radiation treatment and surgery|
224291222|NCT00168116|PROCEDURE|radiation alone|
224108178|NCT02770287|DEVICE|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
224108179|NCT03630068|PROCEDURE|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
224108180|NCT05477238|PROCEDURE|walking tasks|The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
224108181|NCT01518699|DRUG|Ha44|Abametapir Lotion 0.74%
224108182|NCT01518699|DRUG|Ha44 Placebo|Ha44 Vehicle Gel without Abametapir
224108183|NCT01518699|DRUG|Moxifloxacin Placebo|Moxifloxacin Placebo
224108184|NCT01518699|DRUG|Moxifloxacin|Moxifloxacin 400mg
224108185|NCT02887846|DEVICE|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH\> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
224108186|NCT02110108|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
224108187|NCT02162875|DRUG|Praziquantel|Six different treatment strategies with praziquantel
224108188|NCT01623687|DEVICE|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
224108189|NCT01623687|DEVICE|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
224108190|NCT01623687|DEVICE|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
224108191|NCT01623687|DEVICE|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson \& Johnsson, USA).
224108192|NCT00217477|DRUG|gemcitabine hydrochloride|Given IV
224108193|NCT00217477|DRUG|paricalcitol|Given IV
224108194|NCT05019183|OTHER|Physical training|The subjects will perform 6 indoor rower sessions (30 min each, on Day 1, 2, 3, 8, 9 and 10) with a target heart rate zone of 60%.
223958114|NCT02142478|BEHAVIORAL|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~* Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~* Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~* Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
224108195|NCT05019183|OTHER|Virtual reality|The subjects will be able to move freely in virtual environments while training on the indoor rower.
224108196|NCT05019183|DEVICE|Single-photon emission computed tomography (SPECT)|SPECT allows the measurement of cerebral perfusion, reflecting the global synaptic activity, via a 3D acquisition of 20 minutes, 15 minutes after injection of 740 MBq of radiotracers (ECD - Neurolite or HMPAo - Cerestab), with iterative reconstruction. The data will be processed at the voxel scale by the SPM12 software, with analysis of brain connectivity.
224108197|NCT05019183|BIOLOGICAL|Metabolomics|This qualitative approach will aim to identify pathways that are not known (or have not been explored) to optimize the chances of detecting metabolites present depending on the group (physical activity coupled or not with VR). This method is favorable for biomarker discovery.
224108198|NCT02666911|PROCEDURE|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
224108199|NCT02666911|PROCEDURE|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
224108200|NCT05823506|COMBINATION_PRODUCT|PDE5 inhibitor (tadalafil) and BTL-6000 fSWT|The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.
224108201|NCT05823506|DRUG|PDE5 inhibitor (tadalafil)|Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
224108202|NCT01463852|DRUG|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
224108203|NCT01680224|BEHAVIORAL|Healthy Weight|
223958115|NCT02142478|BEHAVIORAL|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
223958116|NCT01995292|DEVICE|bronchoscope|
224108204|NCT01680224|BEHAVIORAL|Project Health|
224108205|NCT01680224|BEHAVIORAL|Placebo Control|Participants will view a video on overweight and obesity
223958117|NCT01995292|DEVICE|Enk Fiberoptic Atomizer|
224108206|NCT00199511|DRUG|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
224108207|NCT03375658|OTHER|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
224108208|NCT06472895|DRUG|AK112 monotherapy|A novel PD-1/VEGF bispecific antibody; RP2D intravenously (IV)，Q3W
224108209|NCT03139955|DEVICE|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
223724122|NCT06626334|DEVICE|Usual Ambient Light|"Across all arms, the usual ambient light in the inpatient room will not be modified.~For the Bright Blue Light and Bright Full-Spectrum (White) Light arms, light will be added to the environment using a Day-Light Classic Plus Light Therapy Lamp as specified in the corresponding intervention descriptions.~For the Usual Ambient Light arm, a Day-Light Classic Plus Light Therapy Lamp mounted on a healthcare-grade stand with rolling casters (Maclocks Rise Freedom Extended) will be positioned at a 12-14 inches from eye level with the on/off switch in the off position. The lamp will be positioned in this manner for 4 hours daily during the morning/early afternoon hours, for up to 3 days."
223724123|NCT06326463|DRUG|Fludarabine|40mg/m2, Day -4, -3 and -2
223724124|NCT06326463|DRUG|Cyclophosphamide|"Day -3 and Day-2~REST DAY, -1"
224108210|NCT05366907|OTHER|No intervention is done|It is a descriptive cross-sectional study so no groups like case/controls are present. All the cases are included in the study.
224108211|NCT00653796|DRUG|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
224108212|NCT00653796|DRUG|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
224108213|NCT03544060|DRUG|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
223958118|NCT03645213|DEVICE|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
223958119|NCT03645213|DEVICE|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
223958120|NCT00547456|DRUG|Oxygen|Oxygen 2-3L Nasal cannula
223958121|NCT01995565|OTHER|PLR|
223958122|NCT03451903|DRUG|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
223958123|NCT03451903|PROCEDURE|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
223958124|NCT05852197|DRUG|anticoagulant or antiplatelet drugs|combination of anticoagulant or antiplatelet drugs
223958125|NCT00648895|DRUG|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
223958126|NCT00648895|DRUG|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
223958127|NCT00083148|DRUG|capecitabine|
223958128|NCT00083148|DRUG|irinotecan hydrochloride|
224108214|NCT05615701|DIAGNOSTIC_TEST|EOSedge imaging|Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
224108215|NCT03804346|DIAGNOSTIC_TEST|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
224108216|NCT04988516|DEVICE|Virtual reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
224108217|NCT04988516|OTHER|Standard protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. The research nurse will be able to complete any information should they find it incomplete or substandard.
224108218|NCT01127425|PROCEDURE|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
224108219|NCT01127425|PROCEDURE|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
224291223|NCT02135965|DRUG|2mg of Albuterol|2mg of Albuterol on metabolic rate
223724125|NCT06326463|DRUG|CD70-CAR T cell infusion (Autologous)|Day 0 or +1
223958129|NCT00118937|DRUG|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
224291224|NCT02135965|DRUG|4mg of Albuterol|4mg of Albuterol on metabolic rate
224291225|NCT02135965|DRUG|100mg of Caffeine|100mg of caffeine on metabolic rate
224291226|NCT02135965|DRUG|200mg of Caffeine|200mg of Caffeine on metabolic rate
224291227|NCT02135965|DRUG|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
224291228|NCT02135965|DRUG|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
224291229|NCT02135965|DRUG|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
224291230|NCT02135965|DRUG|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
223958130|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
223958131|NCT00118937|DRUG|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
223958132|NCT02199444|DRUG|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
223958133|NCT02199444|DRUG|Placebo|
223958134|NCT02411175|OTHER|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
223958135|NCT02411175|DRUG|20% ethanol|
223958136|NCT01164319|PROCEDURE|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
223724126|NCT06326463|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide
223724127|NCT06630455|DIETARY_SUPPLEMENT|Meu-cinn|Meu-cinn 250 mg/day for 8 weeks
223724128|NCT06630455|DIETARY_SUPPLEMENT|Placebo|Placebo 250 mg/day for 8 weeks
223958137|NCT01293201|DRUG|STAHIST|STAHIST dosed one tablet, BID
223958138|NCT01293201|DRUG|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
223958139|NCT03873376|BEHAVIORAL|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
223958140|NCT03873376|BEHAVIORAL|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
224108220|NCT00130299|BEHAVIORAL|low glycemic load diet|
224108221|NCT00130299|BEHAVIORAL|low fat diet|
224291231|NCT01453621|OTHER|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
223541899|NCT06608589|OTHER|CoMPAS+ MNCDs Program - Quality improvement program targeting the care transitions of patients living with a major neurocognitive disorder and their caregivers|COMPAS+ is a collaborative approach to improving healthcare quality. It brings together around 30 individuals, including healthcare professionals, deciders, and patient partners, to identify improvement goals, develop action plans, and enhance the prevention and management of chronic diseases. In this study, the investigators adapt COMPAS+ to focus on improving care transitions for patients with major neurocognitive disorders (MNCDs) and their caregivers. Through reflective workshops and collaborative problem-solving, this diverse group will identify best practices and create action plans to enhance care quality.
223724129|NCT07034768|DRUG|EDG-7500|Single dose of EDG-7500
223724130|NCT07131579|DRUG|Normal Saline|equal volume of normal saline
223724131|NCT07131579|DRUG|Dexmedetomidine|0.5 mcg/kg of dexmedetomidine
223724132|NCT07132866|BEHAVIORAL|ADAPT|The ADAPT intervention consists of three group sessions (of 75-90 min), with 6-8 8th grade students in each group, administered over three consecutive weeks, plus one interactive parent component (of 45 min) administered during the three weeks (separate from the student sessions).
223724133|NCT06816459|OTHER|Cigarette smell test|Undergo cigarette smell test of 16 cigarettes in vials, then rate the overall smell on a 5 pt scale (not at all, a little noticeable, noticeable, clearly/very noticeable , do not know what this is).
223724134|NCT06816459|OTHER|Cigarette Taste Test|Participants will be present 3 vials , each containing a cigarette and sample in order specified on label, then complete a coolness measure on a 0-100 visual analog scale.
223724135|NCT06816459|OTHER|Study questionnaires|Sensory questionnaires will be administered using a web based application
223724136|NCT07131436|OTHER|Horse therapy|Participating children received horseback riding and riding training twice a week for 30 minutes over an eight-week period. The training included developing body and object use skills, relationship building skills, language skills, social and self-care skills, and sensory skills. These included mounting and dismounting a horse; sitting correctly; holding and using the reins; bustling movements on the horse, forward and backward, sideways, and reaching with the hands; naming printed pictures; reading numbers; throwing objects at targets with the right and left hands; developing a dialogue with the trainer; standing up with and without stepping on the stirrups; sitting down and standing; reaching forward and backward and lying down on the horse; petting the horse with one's hands; trying to touch the horse's front legs with the right and left hands; and holding the horse's mane. At the end of the training, the parents of the participating children completed the Autism Behavior Checklist.
223724137|NCT07131566|PROCEDURE|Sentinel Node detection and Biopsy|Fine Needle aspiration from sentinel Lymph Nodes
223724138|NCT07096622|DEVICE|perceptual learning visual treatment,HVT|After receiving guidance from a trainer, treatment was conducted using the visual perception training therapy software (HVT, version number: V1.0.10000) on a network platform for 30 minutes per day, totaling 3 months.
224291232|NCT03744221|DIETARY_SUPPLEMENT|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
224291233|NCT03744221|DIETARY_SUPPLEMENT|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
223958141|NCT03873376|BEHAVIORAL|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
223541900|NCT06604429|OTHER|Aerobic exercise|aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.
223724139|NCT07132892|DEVICE|Galaflex Lite Scaffold|The GalaFLEX LITE is a surgical mesh scaffold composed of poly-4-hydroxybutyrate (P4HB) developed to prolong strength retention and reinforce soft tissue in patients undergoing plastic and reconstructive surgery.
223724140|NCT07132476|OTHER|No adjuvant therapy|Observe and record hypoglycemia
223958142|NCT05542589|OTHER|Phenytoin phonophoresis|Phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
223724141|NCT07131462|PROCEDURE|Direct Composite Restoration|Application of direct composite resin to restore the fractured crown of permanent incisors.
223958143|NCT05542589|OTHER|Sham phenytoin phonophoresis|Sham phenytoin phonophoresis for 5-10 minute sessions, three times per week and six weeks as a total period treatment.
223958144|NCT01062776|BIOLOGICAL|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
223724142|NCT07131462|PROCEDURE|Cvek Pulpotomy|Partial pulpotomy (Cvek technique) will be performed for complicated crown fractures with vital pulp exposure. The goal is to maintain pulp vitality using biodentin.
223958145|NCT01062776|BIOLOGICAL|Placebo|No dehydration is induced
223958146|NCT04862507|OTHER|Telephone call on day 90|telephone call on day 90 to assess the primary outcome (mRs 90)
223958147|NCT04862507|DIAGNOSTIC_TEST|Quantification of lesion water uptake by CT densitometry|Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
223958148|NCT01241994|OTHER|AASD dialysis technique|
223958149|NCT01134497|DRUG|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
223958150|NCT01134497|DRUG|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
223958151|NCT03180788|PROCEDURE|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
223958152|NCT03180788|PROCEDURE|Traditional ESD|Endoscopic submucosa dissection
223958153|NCT00363389|DRUG|misoprostol and cervical ripening|
223958154|NCT02699398|BEHAVIORAL|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
223958155|NCT02699398|BEHAVIORAL|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
223958156|NCT04436965|OTHER|Standardized nutrition therapy|Standardized nutrition therapy with ONS, nasal feeding tube, PEG or parenteral nutrition
223958157|NCT04436965|DRUG|Cisplatin|Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
223958158|NCT04436965|RADIATION|Intensity Modulated Radiation Therapy|Patients in both arms received Intensity Modulated Radiation Therapy:All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose was 70-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-70 Gy to PTVnd (Planning target volume of the cervical lymph node),60- 64Gy to PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).
223958159|NCT02152111|DIETARY_SUPPLEMENT|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
223958160|NCT02152111|BEHAVIORAL|Diet|Patients were instructed to follow the dietary treatment for 6 months.
223958161|NCT02865083|DEVICE|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
223724143|NCT07131462|PROCEDURE|Endodontic Treatment|Root canal treatment will be applied to teeth with necrotic pulp or extensive pulp exposure not suitable for vital pulp therapy. Procedures will follow standard endodontic protocols.
223724144|NCT07131462|PROCEDURE|Pulp Capping|In cases of minimal pulp exposure, a direct pulp capping procedure will be performed using biocompatible materials such as calcium hydroxide to preserve pulp vitality.
223958162|NCT03317509|PROCEDURE|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
223958163|NCT03969251|DEVICE|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
223958164|NCT03969251|DEVICE|Sham (SS)|repetitive sham rTMS
223958165|NCT04430673|OTHER|Home-School based VR system trial|Commercially available VR games operated Raspberry pi micro computer and Oculus Quest VR headsets provided for 2 weeks at dose and intensity selected by participants.
223958166|NCT04626128|DRUG|CLS-AX|injectable suspension of small molecule tyrosine kinase inhibitor (TKI)
223958167|NCT04626128|DRUG|Anti-VEGF|Standard of care therapy used to block vascular endothelial growth factor
223958168|NCT00161434|DRUG|valacyclovir|1 gram daily for 8 weeks
223541901|NCT06604429|OTHER|Diet Advice|Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)
223958169|NCT00161434|DRUG|placebo|matching placebo for 8 weeks
224291234|NCT03744221|DIETARY_SUPPLEMENT|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
223958170|NCT04527679|DRUG|GC combined Lenvatinib|"1. GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 8 courses.~2. Lenvatinib (\<60kg: 8mg /d; ≥60kg, 12mg)."
223958171|NCT01290471|DRUG|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
223958172|NCT02122042|BIOLOGICAL|HBOT|
223958173|NCT01182285|DRUG|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
223958174|NCT01182285|DRUG|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
223958175|NCT00444730|PROCEDURE|Radical Prostatectomy|Surgical procedure for prostate cancer.
223958176|NCT00444730|PROCEDURE|InterStim Implantation|surgical placement of the interstim
223958177|NCT00444730|PROCEDURE|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
223958178|NCT00841321|DRUG|Ginkgo biloba|120 mg orally twice a day for 12 weeks
223958179|NCT00841321|DRUG|Placebo|One capsule orally twice a day for 12 weeks
223958180|NCT05795283|DRUG|Citalopram i.v. and p.o|"Citalopram:~i.v.: 10 mg/die for day 1-7, 20 mg/die for day 8-14 p.o.: 20 mg/die for day 15-28"
223958181|NCT05795283|DRUG|Citalopram p.o|"Citalopram:~p.o: 10 mg/die for day 1-7, 20 mg/die for day 15-28"
223958182|NCT02137603|OTHER|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
223958183|NCT05145088|BEHAVIORAL|submaximal exercise testing according to ACSM guidelines|For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate
223958184|NCT01363206|BIOLOGICAL|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
223958185|NCT01363206|BIOLOGICAL|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
223958186|NCT05146479|PROCEDURE|Fluoride varnish and pit and fissure sealants onto first permanent molars|Quarterly application of fluoride varnish. Application of pit and fissure sealant, and replacements if necessary.
223958187|NCT03419806|DRUG|Infudopa i.v.|"Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
224108222|NCT06044753|DEVICE|Virtual Reality Headset|"Non immersive VR experience basically means providing a near reality environment for viewers, however, viewers won't be able to make any changes to it as they can only watch.~This Non-immersive Virtual reality experience will be applied unto the child by using a headset that incorporates a computerized dimensional environment which will be simulated to make the child feel near reality .The VR headset consist of a cover for handphone slot, screen display, two lenses with adjustable eye pieces to focus, foam padding and adjustable elastic head mount strap."
224108223|NCT06017063|OTHER|Psychological intervention|The intervention will include a psychological intervention with counseling sessions (online/video intervention) and telephone follow-up additionally to the care as usual.
224108224|NCT00235729|DRUG|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
223958188|NCT03419806|DRUG|Infudopa s.c.|"A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg)."
223958189|NCT03419806|DRUG|LCIG (Duodopa)|"Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg."
223958190|NCT02883985|RADIATION|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
223958191|NCT00379210|BEHAVIORAL|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
223958192|NCT00379210|BEHAVIORAL|Nutrition Education course|8-week course in nutrition
223958193|NCT01598454|DRUG|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
223958194|NCT01292499|BEHAVIORAL|Psychotherapy|10 sessions (50 min)
223958195|NCT01292499|BEHAVIORAL|Psychoeducation|7 sessions + 7 phone calls
223958196|NCT01292499|BEHAVIORAL|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
223958197|NCT03917342|DEVICE|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
223958198|NCT00292409|DRUG|Aripiprazole|
223958199|NCT00062270|DRUG|cisplatin|
223958200|NCT00062270|DRUG|docetaxel|
223958201|NCT00062270|DRUG|gefitinib|
223958202|NCT00062270|DRUG|gemcitabine hydrochloride|
223958203|NCT00062270|PROCEDURE|conventional surgery|
223958204|NCT00062270|PROCEDURE|neoadjuvant therapy|
223958205|NCT00062270|RADIATION|radiation therapy|
223958206|NCT01358175|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
223958207|NCT01358175|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
223958208|NCT01358175|DRUG|Placebo|Placebo
223958209|NCT02509754|PROCEDURE|Atrial fibrillation catheter ablation|
223958210|NCT02509754|PROCEDURE|Rate control|Composite of optimal medical therapy and device implantation
223958211|NCT00847223|DRUG|ZARNESTRA (Tipifarnib)|
223958212|NCT01525875|DRUG|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
223958213|NCT01525875|DRUG|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
223958214|NCT02831088|DRUG|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
223958215|NCT02831088|DRUG|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
223958216|NCT02831088|DRUG|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
223958217|NCT05256758|DRUG|Fenofibrate Capsules|49 patients randomised to receive fenofibrate for 6 months.
223958218|NCT05256758|DRUG|Placental Lactogen|13 patients randomised to receive placebo for 6 months.
223958219|NCT01815255|DRUG|tenofovir (TDF)|
223958220|NCT04029727|DIETARY_SUPPLEMENT|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
223958221|NCT04029727|DIETARY_SUPPLEMENT|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
223958222|NCT01541176|OTHER|Absence of corticotherapy post-transplantation|No study treatment
223958223|NCT01541176|DRUG|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~* D1 to D14 : 20 mg/day,~* D15 to M1 : 15 mg/day,~* M1 to M3 : 10 mg/day,~* M3 to M12 : 5 mg/day."
223958224|NCT00003755|DRUG|MKC-1|
223958225|NCT04881045|BIOLOGICAL|PF-07257876|CD47-PDL-1 bispecific antibody
223958226|NCT00821093|DRUG|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
223958227|NCT00821093|DRUG|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
223958228|NCT00821093|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
223958229|NCT00821093|DRUG|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, \[DISKUS\]).
223958230|NCT01107912|DRUG|prasugrel|administered orally, daily for 12 days
223958231|NCT01107912|DRUG|clopidogrel|Administered orally, daily for 12 days
224108225|NCT00235729|DRUG|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
223958232|NCT03921164|PROCEDURE|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
223958233|NCT03921164|PROCEDURE|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
223958234|NCT03921164|PROCEDURE|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
223958235|NCT03268850|OTHER|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
223958236|NCT03268850|BEHAVIORAL|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
223958237|NCT03268850|BEHAVIORAL|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
223958238|NCT06150222|OTHER|Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)|The aim is to include all patients with (induced) oligo metastatic and oligo recurrent settings, irrespective of whether treated with concurrent chemoradiation, systemic chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
223958239|NCT04301063|OTHER|RV3278A|RV3278A is a non-rinsed cosmetic cream intended to be used every day on adolescents and young adults with acne-prone skin.
223958240|NCT02158793|PROCEDURE|Craniomaxillofacial allotransplantation|Transplantation of donor face
223958241|NCT05780034|DRUG|AC676|AC676 will be given orally (PO) on a 28-day cycle.
223958242|NCT01130077|BIOLOGICAL|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
223958243|NCT01130077|BIOLOGICAL|Poly-ICLC|Vaccine given every 3 weeks
223958244|NCT02562521|BEHAVIORAL|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
224108226|NCT05734781|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
224108227|NCT04925544|DRUG|VK-2019|VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
224108228|NCT02484261|DRUG|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
224108229|NCT02484261|DRUG|Pravastatin|10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
224108230|NCT01998646|DRUG|ASP4058|Oral tablet
224108231|NCT01998646|DRUG|Placebo|Oral tablet
224108232|NCT02778048|OTHER|MRI (magnetic resonance imaging)|Assessment of the sphincter
224108233|NCT02778048|OTHER|US (ultra sound)|Assessment of the sphincter
224108234|NCT02778048|OTHER|FLIP (functional lumen imaging probe)|Assessment of the sphincter
224108235|NCT02778048|OTHER|HRAM (high resolution anal manometry)|Assessment of the sphincter
223958245|NCT02562521|DRUG|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
224108236|NCT01978912|DRUG|KTP-001|KTP-001 is one time dose intradiscally.
223958246|NCT02562521|DRUG|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
223958247|NCT02562521|BEHAVIORAL|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
223958248|NCT01051648|DRUG|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly \& completely as possible after finishing anterior vitrectomy
223958249|NCT01634802|OTHER|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
223958250|NCT01634802|OTHER|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
223958251|NCT00732316|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
223958252|NCT00732316|PROCEDURE|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
223958253|NCT02649478|DRUG|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
223958254|NCT02649478|DRUG|Placebo|
223958255|NCT02649478|DRUG|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
224108237|NCT00973830|OTHER|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
224108238|NCT00380484|DRUG|Budesonide|200µg daily
224108239|NCT00380484|DRUG|Montelukast|5 mg daily
224108240|NCT06512766|DRUG|Hydroxychloroquine|Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
224108241|NCT06512766|DRUG|Methotrexate|This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
223958256|NCT05356065|OTHER|survey administration|Outcome Measures
223958257|NCT04455542|OTHER|LMND-ALS|in line with LMND -ALS inclusion criteria, and CMAP amplitude of peripheral motor nerves (CMAP amplitude of the 10 peripheral motor nerves with the most obvious CMAP amplitude decline was selected as the CMAP amplitude for grouping of the patients) was less than the median of CMAP amplitude of LMND -ALS group.
223958258|NCT04455542|OTHER|UMND-ALS|The main clinical manifestations were limb stiffness and spasm, obvious pyramidal tract signs, relatively mild muscle atrophy and fasciculation, and no significant decrease in amplitude of electromyography CMAP.
223958259|NCT04455542|OTHER|FAS and FLS|The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
224108242|NCT06512766|DRUG|Cyclosporine A|Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
224108243|NCT06512766|DRUG|Retinoids|This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
224108244|NCT06020976|DIAGNOSTIC_TEST|liver biobsy|all pationt will be subjected yo liver biobsy to confirm diagnosis
224108245|NCT04220866|DRUG|Ulevostinag|IT injection
224108246|NCT04220866|BIOLOGICAL|Pembrolizumab|IV infusion
223958260|NCT06443736|PROCEDURE|Standardized perineal massage|Patients in this arm will be educated in the perineal massage proposed by the authors; the training will be performed during a group session, (organized bimonthly) conducted by obstetrical staff specialists, in the presence of the principal investigator and/or co-authors. In these sessions, a brief lecture on aspects of primary prevention related to pelvic floor structures (healthy diet, body weight control, moderate physical activity avoiding excessive exertion, posture control, therapy minctional education) and then screened an explanatory video regarding the three-step perineal massage proposed by the authors. The adequately prepared patient should then apply such perineal massage at home from the 34th gestational week until delivery according to the procedural methods provided.
224108247|NCT02947451|OTHER|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
224108248|NCT02947451|OTHER|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
224108249|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Acacia Gum-MMST Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
224108250|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Malto-OSA Powder|Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
224108251|NCT05116982|DIETARY_SUPPLEMENT|ORGONO Living Silica Collagen Booster|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
224108252|NCT05116982|DIETARY_SUPPLEMENT|Placebo|Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
224108253|NCT05477771|PROCEDURE|Arthroscopic rotator cuff repair|The rotator cuff tears were repaired under arthroscopy. A subacromial decompression was performed in all patients. Then the long head of the biceps with severe lesions were treated by tenotomy while the others were reserved according to the surgeon's judgment during the surgery.
224108254|NCT03515538|DRUG|RRx-001|RRx-001 for injection
224108255|NCT03515538|DRUG|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
223541902|NCT06604429|OTHER|Virtual reality exercise|Virtual reality game exercise involves 25 min of exercise where adolescent girl immersed in the game and did physical activities for the upper and lower extremities according to the game's requirements, and finally a 5 min cool-down part to lower the heart rate and end the session with static flexibility routines, the total session that would be applied about 30 min of Virtual reality exercises.
223958261|NCT06443736|BEHAVIORAL|Primary prevention|Patients in this arm will be offered a group meeting in which aspects of primary prevention related to the structures of the pelvic floor (healthy diet, body weight control, moderate physical activity avoiding exertion excessive exertion, posture control, micturition educational therapy); participation in this meeting will be on a voluntary basis, and patients randomized to that group will have free choice in educating the pelvic floor pelvic floor in pregnancy.
224108256|NCT03515538|RADIATION|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
224108257|NCT04952012|DRUG|LT4|LT4 is used to improve the thyroid function of pregnant women.
223541903|NCT03276442|OTHER|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
223541904|NCT03276442|OTHER|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
223541905|NCT04971577|DRUG|Simvastatin 40mg|participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
224108258|NCT01972425|OTHER|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
224108259|NCT00784069|DRUG|Lactic Acid|Lactic Acid (Dermacyd Breeze)
224108260|NCT05418608|DRUG|Radiotracer|A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
224108261|NCT02740153|OTHER|No Intervention Given|
224108262|NCT03976856|DRUG|GB226|Geptanolimab, 210mg，q2w，ivgtt.
224108263|NCT03976856|DRUG|Fruquintinib|Fruquintinib, 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
224108264|NCT00045838|DRUG|VCR-HIVDNA006-00-VP|
224108265|NCT00445055|DRUG|Droperidol|Intravenous injection
224108266|NCT00306436|PROCEDURE|comprehensive management|
224108267|NCT00598962|DRUG|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
224108268|NCT00598962|DRUG|Rifabutin/rifampin|
224108269|NCT03828838|DRUG|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
224108270|NCT02280681|OTHER|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
223958262|NCT03345199|OTHER|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
223958263|NCT04546360|PROCEDURE|Esophagogasrtoduodendoscopy, spleen stiffness measurement and liver stiffness measurement.|Time frame between elastography measurement and esophagogastroduodendoscopy is within 2 weeks.
223958264|NCT03448783|DRUG|Apixaban|Patients are tested for their normal prescription apixaban medication
223958265|NCT06494176|BEHAVIORAL|neVR Fear the Dentist|neVR Fear the DentistTM comprises two major evidence-based interventions. First is a self-administered eHealth app for CBT/ psychoeducation with exposure therapy - delivered via a mobile tablet - that can be completed anywhere. Second is a 1-hr virtual reality exposure treatment (VRET).
223958266|NCT04928196|OTHER|Microperimtery and optical coherence tomography angiography OCTA|observational: Investigations are done to assess the retinal microvasculature and function before and after silicone oil removal
223958267|NCT02086071|PROCEDURE|re biopsy|re biopsy depending on the location of the pathology
223958268|NCT06198452|PROCEDURE|Vision Improvement|Laser Vision Improvement for Patients with Age-Related Macular Degeneration
223958269|NCT01015794|DRUG|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
223958270|NCT01015794|DRUG|ephedrine hydrochloride|single dose of 1 mg/kg body weight
223958271|NCT00003245|DRUG|irinotecan hydrochloride|
223958272|NCT03988855|DRUG|DNV3837|Treatment infusions will be administered at a constant rate resulting in a total IV infusion duration of 6 hours per day, for a total maximum daily dose of 120 mg DNV3837. Infusions will be administered once daily for 10 consecutive days.
223958273|NCT06452888|BEHAVIORAL|Clinical decision support system.|The clinical decision support system includes evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures. Patients in the intervention group will receive the organizational management based on the guidelines and conduct intervention management for patients with actue ischemic stroke. The clinical decision system will classify the patients into risk factors, automatically generate treatment measures according to the guidelines, in order to standardize the treatment of physicians. Such as the management of complications after stroke, the treatment of antiplatelet, anticoagulation, antihypertensive and hypoglycemic.
223958274|NCT06452888|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
223958275|NCT00762853|DRUG|Fluoride|Brush half mouth once with assigned study treatment
223958276|NCT00762853|DRUG|Fluoride and triclosan|Brush half mouth once with assigned study treatment
223958277|NCT02114502|DRUG|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
223958278|NCT02114502|DRUG|SAHA|1,000 mg by mouth on Days -8 to -3.
223958279|NCT02114502|DRUG|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
223958280|NCT02114502|DRUG|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
223958281|NCT02114502|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
223958282|NCT02114502|PROCEDURE|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
223958283|NCT02114502|DRUG|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
223958284|NCT02114502|DRUG|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
223958285|NCT02114502|DRUG|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
223958286|NCT02114502|DRUG|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
224108271|NCT01489787|PROCEDURE|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
224108272|NCT01489787|PROCEDURE|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
224108273|NCT01489787|PROCEDURE|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
223958287|NCT02114502|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
224108274|NCT05363007|DRUG|nanoliposomal irinotecan|"Upfront SI (Arm A): Upfront nanoliposomal irinotecan (80 mg/m2, day 1) + 5-FU/leucovorin (2400 mg/m2, 400 mg/m2) plus SI~Add-on SI (Arm B): Add-on SI following limited progression to prior nanoliposomal irinotecan (last dose used) + 5-FU/leucovorin (last dose used)"
223958288|NCT05757622|DRUG|Propofol|Procedural sedation provided with propofol and remifentanil using target controlled infusions
223958289|NCT05757622|DRUG|Remifentanil|Procedural sedation provided with propofol and remifentanil using target controlled infusions
223958290|NCT03639545|DRUG|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
223958291|NCT03639545|DRUG|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
223958292|NCT03639545|DRUG|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
223958293|NCT03639545|DRUG|Placebos|The patients receive for 12 weeks.
223958294|NCT00964756|GENETIC|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
223958295|NCT00964756|DRUG|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
223958296|NCT02659176|PROCEDURE|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
223958297|NCT02659176|PROCEDURE|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
223958298|NCT03612999|DEVICE|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
223958299|NCT03612999|DEVICE|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
223958300|NCT03612999|BEHAVIORAL|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
223958301|NCT03612999|BEHAVIORAL|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
223958302|NCT03671499|BEHAVIORAL|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
223958303|NCT02574910|DRUG|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
223958304|NCT02924051|BEHAVIORAL|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
223958305|NCT02924051|BEHAVIORAL|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
224108275|NCT05363007|RADIATION|spleen irradiation|"Upfront SI (Arm A): upfront spleen irradiation (1 Gy/fx, day 1-4) in cycle 2~Add-on SI (Arm B): add-on spleen irradiation (1 Gy/fx, day 1-4) in cycle 1 following limited progression to prior nanoliposomal irinotecan + 5-FU/leucovorin"
224108276|NCT00471380|DRUG|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
223541906|NCT05212792|BIOLOGICAL|COVID-19 vaccines|Any licensing COVID-19 vaccine platform
223541907|NCT00172809|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
223541908|NCT00172809|DRUG|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
223541909|NCT06333548|DIAGNOSTIC_TEST|Appropriate for gestational age , small for gestational age, large for gestational age, Baby of mother diagnosed with GDM|No intervention
223541910|NCT05223673|BIOLOGICAL|Futuximab/modotuximab|Concentrate for solution for infusion, futuximab/modotuximab will be administered via IV route, once weekly of each cycle at 9 mg/kg/dose at Cycle 1 Day 1 and then at 6 mg/kg/dose. Each cycle is up to 28 days.
223541911|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally before futuximab/ modotuximab administration, twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
223541912|NCT05223673|DRUG|Trifluridine/Tipiracil|Film-coated tablets of trifluridine/tipiracil (35 mg/m²/dose) will be administered orally twice a day (BID) within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 14 days, followed by a 14-day rest. This treatment cycle will be repeated every 28 days.
223541913|NCT02665091|BEHAVIORAL|Peer Education Program|
223958306|NCT05485025|BEHAVIORAL|Tai chi training|Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
223958307|NCT05485025|BEHAVIORAL|Group activity|A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
223958308|NCT04436016|DRUG|Ivabradine|Ivabradine pills will be crushed and encapsulated for adequate dosing (0, 2.5mg, 5mg or 7.5 mg) and blinding.
223958309|NCT04436016|DRUG|Placebo|Mannitol will be encapsulated for adequate blinding.
223958310|NCT02260154|DRUG|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
223958311|NCT02684435|DRUG|Perflutren lipid microsphere|Dosing per approved package label
223958312|NCT02561195|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
224108277|NCT00471380|DRUG|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
224108278|NCT04021472|BEHAVIORAL|Text message|Two months of daily text messages to support meeting a health goal
224108279|NCT06326151|BEHAVIORAL|Interdisciplinary Psychoeducational Programme|This intervention is based on the principle of complementing and integrating both disciplines in order to meet the psychological needs of family carers and to train them in knowledge and strategies aimed at the correct performance of activities of daily living in order to promote the maximum autonomy and functionality of dependent people with cognitive impairment, and that this favours discharge, self-care, improvement of the affective state and quality of life of family carers.
223958313|NCT02561195|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
223958314|NCT02394613|DRUG|ANX776|Single intravenous injection
223958315|NCT01736449|DRUG|Bevacizumab|
223958316|NCT03905512|DRUG|SEL-212|Administered as specified in the treatment arm
223958317|NCT03905512|DRUG|KRYSTEXXA®|Administered as specified in the treatment arm
223541914|NCT06248151|BEHAVIORAL|Exercise session|Session will included aerobic, resistance and flexibility exercises and will last approximately 45 minutes. The session will begin with aerobic exercises (5 min jumping jacks and 5 min stationary walking). Then, nine strength exercises will be performed for the main muscle groups (3 times of 12 to 15 repetitions, with a 1-minute rest interval) and finally stretching for the main muscle groups
223541915|NCT06248151|BEHAVIORAL|Control session|Remain seated for 60 min
223958318|NCT04990388|BIOLOGICAL|UX053|mRNA-based biologic
224291235|NCT02083419|DEVICE|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
223958319|NCT04990388|OTHER|Placebo|consists of the same components as the formulation buffer for UX053
223958320|NCT04990388|DRUG|Antipyretic|participants will receive oral premedication prior to infusion
223958321|NCT04990388|DRUG|H2 Blocker|participants will receive oral premedication prior to infusion
223958322|NCT04990388|DRUG|H1 Blocker|participants will receive oral premedication prior to infusion
223958323|NCT04769141|COMBINATION_PRODUCT|CURATE.AI|"CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic.~This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients."
223958324|NCT00004784|DRUG|methotrexate|
223958325|NCT00004784|DRUG|ursodiol|
223958326|NCT02363049|PROCEDURE|Colectomy|
223958327|NCT02363049|DRUG|Chemotherapy|
223958328|NCT02826954|OTHER|Upper airway assessment, including nasal biopsy|
223958329|NCT03547167|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
223958330|NCT03547167|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
223958331|NCT03547167|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
223958332|NCT00725972|OTHER|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
224108280|NCT06326151|BEHAVIORAL|Health Education Programme|Upon discharge from the hospital, at the end of the baseline assessment, caregivers will receive instructions and recommendations for maintaining an active and healthy lifestyle. This will be done by encouraging self-care and good practices in caring for their dependent family member, as part of a health education programme. The benefits of an active lifestyle and general guidelines are emphasized.
223541916|NCT06715722|DEVICE|hexed non hexed|A 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using one hexed and one non-hexed abutment.
223541917|NCT06715722|DEVICE|non-hexed non-hexed|a 3-unit screw-retained implant bridge over two conical internal hex implants will be supported using two non-hexed abutments
223724145|NCT07131176|OTHER|Behavior Change through Education intervention|"The I-Change Model We used behavior alteration theory to identify areas of thinking or conduct that might potentially lead to issues in the process of collecting or consuming medicine. Subsequently, we proceeded to create and improve the substance of the message, and we aligned the messages with a standardized classification of evidence-based strategies for modifying behavior.~Unclear or confusing information in infographics and television videos was revised, while information that was deemed unhelpful or insignificant by both patients and clinicians was eliminated. Patients' feedback was used to create fresh material for television videos and infographics.~1. Encourage patients about routine clinic appointments~2. Provide relevant health-related information.~3. Help participants plan and organize various treatment adherence behaviors including medication collection and taking, diet, and exercise~4. Support positive adherence-related behaviors"
224108281|NCT00893594|DRUG|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
224108282|NCT00893594|DRUG|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
224108283|NCT05648838|DEVICE|Pivot Balloon Catheter|mornitoring acute RV failure and reduction of Functional Tricuspid Regurgitation
224108284|NCT00192335|BIOLOGICAL|CAIV-T|
224108285|NCT00192335|BIOLOGICAL|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
223958333|NCT00725972|PROCEDURE|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
223958334|NCT05585632|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223958335|NCT05585632|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223958336|NCT05585632|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
223958337|NCT05585632|BIOLOGICAL|mRNA-1045|Formulation for injection
223958338|NCT05585632|BIOLOGICAL|mRNA-1230|Formulation for injection
223958339|NCT02493166|OTHER|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
223958340|NCT00894218|PROCEDURE|Arthroplasty|Hip or knee arthroplasty
223958341|NCT00866619|BIOLOGICAL|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
223958342|NCT00866619|BIOLOGICAL|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
223958343|NCT00866619|BIOLOGICAL|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
224108286|NCT00192335|BIOLOGICAL|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
223958344|NCT00866619|BIOLOGICAL|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
223958345|NCT00866619|BIOLOGICAL|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
223958346|NCT03762278|DIETARY_SUPPLEMENT|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
224108287|NCT02975323|DRUG|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
223541918|NCT06715800|DIETARY_SUPPLEMENT|Honey|Functional content analyses were performed to identify the specific properties of the different types of honey used.
223541919|NCT06715995|DEVICE|Gamma Wave Stimulation Table Lamp (Aleddra, Inc., USA)|Participants will receive light stimulation using the Gamma Wave Stimulation Table Lamp (Aleddra, Inc., USA) for 1 hour per day, 7 days a week, over 4 weeks, for a total of 28 hours.
224108288|NCT06470308|OTHER|Medication Reviews and Deprescribing|General Practitioners will be given training and education in deprescribing algorithms and the conduction of medication reviews with the use of validated deprescribing tools such as the Beers Criteria and STOPP/START criteria.
224108289|NCT00593086|PROCEDURE|Pain management|Pain mamagement for burn care procedures.
224108290|NCT00593086|OTHER|Standard of care/no virtual reality game|no intervention for standard of care
224108291|NCT06051253|DRUG|TDM-based infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
224108292|NCT06051253|DRUG|Standard infliximab intravenous therapy|Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
224291236|NCT02457884|OTHER|Temporal Group|Visual Processing Training
224108293|NCT06372639|DEVICE|Trans-Cranial Magnetic Stimulation|Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.
224108294|NCT00719173|DRUG|aprepitant|Given orally
223958347|NCT03762278|DIETARY_SUPPLEMENT|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
223958348|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
223958349|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
223958350|NCT00645411|BIOLOGICAL|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
223958351|NCT00645411|BIOLOGICAL|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
223958352|NCT03560206|BEHAVIORAL|Family SWaP intervention|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food-the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
223958353|NCT03560206|BEHAVIORAL|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
223958354|NCT03987074|DRUG|Semaglutide|Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly
223958355|NCT03987074|DRUG|Firsocostat|Tablets administered orally once daily
223958356|NCT03987074|DRUG|Cilofexor|Tablets administered orally once daily
223958357|NCT00783146|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
223958358|NCT00783146|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
224108295|NCT00719173|DRUG|cyclophosphamide|Given IV
224108296|NCT00719173|OTHER|placebo|Given orally
224108297|NCT01439958|DRUG|Inhalation|Twice daily inhalation for a maximum of three years.
224108298|NCT01047787|OTHER|Polysomnography|examination for sleep disorders
224108299|NCT06189443|OTHER|Group administered to individual telemedicine|A brochure containing incontinence patient information will be prepared and given, web-based training will be implemented, and informative/reminder messages will be sent via short messages every day.
224108300|NCT02835729|DRUG|Idarubicin|Chemotherapy
224108301|NCT02835729|DRUG|Cytarabine|Chemotherapy
224108302|NCT02835729|DRUG|Indoximod Freebase|IDO pathway inhibitor
224108303|NCT02835729|DRUG|Indoximod HCL F1|IDO pathway inhibitor
223958359|NCT00783146|DRUG|placebo|placebo, once daily for 15 days
223958360|NCT00385866|BEHAVIORAL|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
223958361|NCT00385866|BEHAVIORAL|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
223958362|NCT05752370|DEVICE|High flow oxygen|Use of HFO
223958363|NCT05752370|OTHER|Usual care|Room air or normal flow oxygen
223958364|NCT01138969|DRUG|esomeprazole|esomeprazole 20 mg qd for 6 months
223958365|NCT01334606|DEVICE|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
223958366|NCT01334606|DEVICE|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
223958367|NCT01513733|DRUG|tasquinimod|tasquinimod 0.25 mg continuously
223958368|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
223958369|NCT01513733|DRUG|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
223958370|NCT01499979|PROCEDURE|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
223958371|NCT02674399|DRUG|JointStem|
223958372|NCT02674399|DRUG|Synvisc-One|
223958373|NCT05435105|BEHAVIORAL|Virtual reality|Distraction method
223958374|NCT05435105|BEHAVIORAL|Local cold-vibration|Distraction method
223958375|NCT04805008|OTHER|Lactation cookies|1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.
223958376|NCT04805008|OTHER|Control cookies|"1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production."
224108304|NCT02835729|DRUG|Indoximod HCL F2|IDO pathway inhibitor
223958377|NCT02590770|BEHAVIORAL|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
223958378|NCT02590770|OTHER|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
223958379|NCT02128893|DRUG|Isavuconazole|oral
223958380|NCT02128893|DRUG|Esomeprazole|oral
223958381|NCT02142569|DRUG|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
223958382|NCT02142569|DRUG|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
223958383|NCT02142569|DRUG|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
223958384|NCT02142569|DEVICE|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
223724146|NCT07132580|DEVICE|Re-Timer® light therapy glasses|Participants wore Re-Timer® glasses that emitted bright white light at 506 lux for 30 minutes each morning, over a 4-week intervention period.
223958385|NCT02138838|DRUG|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
223958386|NCT02138838|DIETARY_SUPPLEMENT|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
223958387|NCT01867307|DRUG|Empagliflozin|
223958388|NCT01867307|DRUG|BI 10773|open label
223958389|NCT00518206|BIOLOGICAL|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
223958390|NCT00518206|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
223724147|NCT07132580|OTHER|Usual Care|Participants received standard follow-up care with no light therapy intervention during the 4-week period.
223958391|NCT04070937|DIAGNOSTIC_TEST|vestibular test 1|videonystagmography
223958392|NCT04070937|DIAGNOSTIC_TEST|vestibular test 2|video head impulse test
223958393|NCT04070937|DIAGNOSTIC_TEST|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
223958394|NCT04070937|DIAGNOSTIC_TEST|audiometry|tonal liminar audiometric thresholds
223958395|NCT04070937|DIAGNOSTIC_TEST|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
223958396|NCT04070937|GENETIC|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
223958397|NCT02741557|DRUG|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
223958398|NCT02741557|DRUG|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
223958399|NCT02741557|DRUG|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
223958400|NCT00051753|DRUG|levofloxacin; amoxicillin/clavulanate|
223958401|NCT01303822|BEHAVIORAL|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
223958402|NCT00269022|DRUG|SB-705498|
223958403|NCT04566185|OTHER|FDG PET|"IV application of F Dopa, 2 MBq per Kg, with a scout view (angle of view 90 °, 120 kV, 30 mAs), then an X-ray scan is performed for the attenuation correction ( 120 kV - 5mAs - pitch 0.531 - thickness // increment: 3.75mm//3.27mm -QAC filter - DFOV 25).~PET acquisition: static in 3D mode for 20 minutes, 8 minutes after the injection of 18 F Dopa, the axial field of view is 25, the matrix in 256 x 256. After OSEM reconstruction 6 iterations and 24 subsets, with correction of attenuation and diffusion, then Gaussian filter of frequency 4, 47 contiguous axial sections of 3.26 mm are obtained."
224108305|NCT01089855|DRUG|Carbamazepine|
224291237|NCT02457884|OTHER|Spatial Group|Spatial visual span training
224291238|NCT02457884|OTHER|Combined Group|Visual processing speed and spatial visual span training
224291239|NCT02457884|OTHER|Control Group|Leisure reading activities
224108306|NCT03631329|DIAGNOSTIC_TEST|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
223958404|NCT04566185|OTHER|CT scan|"Localization propeller without injection: 120kV - mA regulation (Noise Index 15) - pitch 0.969 - thickness // increment: 5mm // 5mm - Soft filter - Asir 60% - DFOV 25.~Acquisition begins 5 seconds after the start of the injection of 60 ml of contrast product (VISIPAQUE) at 4 cc / second without (acquisition characteristics: 80 kV - 100 mAs -- thickness: 5mm // 8 images / rotation - STD filter - Asir 50% display field of view (DFOV) 25 - phase1: 5s then phase2 15s).~Diagnostic quality CT: 120kV - Regulation of mA (Noise Index 15) - pitch 0.531 - thickness // increment: 1.25 // 0.625mm - Soft filter - Asir 60% - DFOV 25."
223958405|NCT04566185|OTHER|Magnetic resonance imaging (MRI)|"If the examination is performed on the SIEMENS SKYRA 3T device: 32 channel head coil antenna, if on the PHILIPPS INGENIA 1.5 T device: DStream HeadSpine Coil antenna.~The sequence begins with an axial, coronal and sagittal Survey topogram, lasting 1 minute.~Then axial sequence T1, Axial T2 \*, Axial cerebral perfusion (Injection of gadolinium (0.1 mmol / kg, 5 cc / second), coronal T2, Axial T2 Flair, Axial DWI b100, Axial 3D T1 gadolinium"
223958406|NCT01973361|DEVICE|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
223958407|NCT01973361|DEVICE|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
223958408|NCT00835328|DRUG|Exendin (9-39)|A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
223958409|NCT00835328|DRUG|Vehicle|A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
223958410|NCT00623714|DRUG|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
224108307|NCT02117089|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
224108308|NCT02220374|OTHER|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
224108309|NCT00546351|DRUG|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
224108310|NCT03952650|DRUG|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
224108311|NCT03952650|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
224108312|NCT03952650|DRUG|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
223958411|NCT00623714|DRUG|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
224108313|NCT03952650|DRUG|Coartem|Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
224108314|NCT03952650|DRUG|ibuprofen|Ibuprofen likewise is not a part of the investigational product/regimen, but will be provided to participants in the chloroquine arm (Arm 4) if required to mitigate typical symptoms of malaria infection such as headache, myalgia, fever and chills.
223541920|NCT06715774|DEVICE|Impact of Twin Block and Motion above Hyoid bone|All patients were submitted to preoperative and postoperative lateral teleradiography (Vatech D052SB, Puteaux, France), with the following exposure parameters: 75KV, Intensity10mA, exposition times 11s28, 112,8 mAs, using the Frankfort plane as reference parallel to the floor; moreover, patients were required to avoid moving and swallowing. Afterwards, digital datasets were uploaded and aligned into a digital therapeutic planning software (Orthalis®, Orqualceph®,group orqual) to accurately record the position changes of the hyoid bone at horizontal, vertical, and angular level, according the gender, facial biotype and airway complex, by measuring the following anatomical references:
223958412|NCT01314482|DRUG|Minocycline|200mg bd for 3 days before surgery
223958413|NCT05352854|DRUG|0.5% pilocarpine eye drops|Subjects will be given 0.5% pilocarpine eye drops every five minutes for three times and wait for 40 minutes
223958414|NCT04704557|DEVICE|geko Neuromuscular Electro Stimulator (NMES)|Neuromuscular Electro Stimulator (NMES)
223958415|NCT00772902|DRUG|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
223958416|NCT00772902|DRUG|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
224108315|NCT01689506|DRUG|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
224108316|NCT01689506|DRUG|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
223958417|NCT01128322|DRUG|S-Amlodipine, Telmisartan|
223958418|NCT01128322|DRUG|S-Amlodipine|
224108317|NCT05797766|BEHAVIORAL|Fluid Distribution Timetable|a scheduled distribution of predetermined amounts of fluid intake daily depicted in a 5x6 table. The timetable has three major columns. The first column has six-time points of a day with a four-hour interval. The second column, which was divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intake per day, usual level of activity, time of medication intake, and common time they encounter thirst for a day. The third column indicates the converted percentage of fluid allotment into milliliters.
224108318|NCT04062812|OTHER|the same citrate dosification in both types|match concentrated and dilute citrate protocol
224108319|NCT00628810|BIOLOGICAL|bevacizumab|
224108320|NCT00628810|DRUG|fluorouracil|
223958419|NCT01128322|DRUG|Telmisartan|
223541921|NCT06716294|DEVICE|Radiofrequency Ablation and Bone Augmentation|Percutaneous Tumor Ablation of Spine Lesions followed by Polymer Augmentation
223958420|NCT01128322|DRUG|Placebo|
223958421|NCT05596916|OTHER|High frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 5 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
223958422|NCT05596916|OTHER|Low frequency of stretching exercise|"After the randomization and evaluations, the selected postural stretching exercises will be taught to both groups in the clinic, and then a brochure will be given to the participants and they will be asked to practice these exercises at home.~In the experimental group, the exercises will be applied at the specified time and frequency, 3 days a week.~Participants will be given an Exercise Diary and exercise tracking will be provided by calling the participants once a week. The exercises will be done for 6 weeks. Participants will be evaluated twice, before and end of the treatment."
223958423|NCT05049265|BIOLOGICAL|JS007|JS007 only
224108321|NCT00628810|DRUG|irinotecan hydrochloride|
224108322|NCT00628810|DRUG|leucovorin calcium|
224108323|NCT05013528|OTHER|Bal-A-Vis-X training|"Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. ."
223958424|NCT02822092|DRUG|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
223958425|NCT06245317|DEVICE|Mechanical Ventilation Mode|Each arm will have a different ventilation mode according to the allocation.
224108324|NCT05013528|OTHER|Aerobic Training Group|"Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed"
224108325|NCT02365857|DRUG|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine \& Bupivacaine.
224108326|NCT02365857|DRUG|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
224108327|NCT06509061|OTHER|Physical Activity Self-Definition|6 week behavioural change program designed to increase PASD and PA
224108328|NCT06509061|OTHER|Control|6 week program designed to as an attention control, delivering content on general health behaviour.
224108329|NCT05654415|OTHER|Melatonin|Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg
224108330|NCT05654415|OTHER|Deprivation|Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
223958426|NCT04345588|DRUG|Dexamethasone injection|we use injection lignocaine 10 mL, injection bupivacaine 0.5% 20 mL, 5 mL normal saline (NS). In group , injection dexamethasone 0.05 mg/kg will be added to the solution along with IV NS 1cc while the other group will receive 0.05 mg/kg injection dexamethasone intravenously.
223958427|NCT02813733|PROCEDURE|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
223958428|NCT01175980|OTHER|Laboratory Biomarker Analysis|Correlative studies
223958429|NCT01175980|DRUG|Vorinostat|Given PO
223958430|NCT01451840|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
223958431|NCT01451840|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
223958432|NCT02301286|DRUG|Acetylsalicylic acid|
223958433|NCT02301286|DRUG|Placebo Acetylsalicylic acid|
223958434|NCT04913194|BEHAVIORAL|ARFID-PTP|ARFID-PTP is a two-session virtual protocol using psychoeducation, parent training skills, and exposure to decrease picky eating symptoms consistent with an ARFID diagnosis.
224108331|NCT04824261|DRUG|Clotrimazol solution 1%|50 otomycosis randomized patients will receive Clotrimazol solution 1% The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
224108332|NCT04824261|DRUG|4%boric acid in distilled water|50 otomycosis randomized patients will receive 4%boric acid in distilled water The treatment will be locally applied for at least 2 weeks. All the patients will be followed up after the 1st week, 2nd week and after 1 month.
224108333|NCT02426307|PROCEDURE|TAVR|TAVR: Transcatheter Aortic Valve Replacement
224108334|NCT02426307|PROCEDURE|SAVR|SAVR: surgical Aortic Valve Replacement
224108335|NCT00161317|BEHAVIORAL|Living with Hope Program|
224108336|NCT04100525|BEHAVIORAL|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
223958435|NCT00796575|DRUG|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
223958436|NCT00796575|DRUG|placebo tablets|placebo tablets matching active
223958437|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
223958438|NCT00796575|DRUG|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
223958439|NCT01929616|DRUG|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
223958440|NCT02216448|OTHER|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
223958441|NCT02216448|OTHER|OR Training|Training on diagnostic knee arthroscopy in the OR
224108337|NCT02672956|PROCEDURE|Ten mm trocar|
224108338|NCT01357239|DRUG|AFQ056|
223541922|NCT06715865|PROCEDURE|Thymus Transplantation|Thymus Transplantation
223724148|NCT07132814|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol combustible cigarette
223724149|NCT07132814|OTHER|Product B|8 mg nicotine oral product
223958442|NCT04445246|DRUG|Inhaled ILOPROST|Inhaled Iloprost 20 mcg every 8 hours for 5 days only delivered by nebulization.
223958443|NCT00186563|PROCEDURE|Micro-plasmapheresis|
223958444|NCT00267774|DEVICE|Fractional flow reserve|
223958445|NCT00267774|PROCEDURE|Angio-guided PCI|
223958446|NCT03455725|DEVICE|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
223958447|NCT03455725|OTHER|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
223958448|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) For Periodontal Regenerative Treatment Of Intrabony Defects.|Surgical approach using modified papilla preservation technique for regenerative periodontal therapy.
223958449|NCT05029089|DEVICE|Emdogain (EMD), Biomaterials (allograft, subepithelial connective tissue graft/sCTG)|Surgical approach using modified papilla preservation technique and devices for regenerative periodontal therapy.
223958450|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain for regenerative periodontal therapy.
224108339|NCT01357239|DRUG|Placebo|
224108340|NCT04901897|DEVICE|kalifilcon A|kalifilcon A daily disposable contact lens
224108341|NCT04901897|DEVICE|delefilcon A|DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
224108342|NCT04901897|DEVICE|senofilcon A|Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
224108343|NCT01542372|DRUG|Medication augmentation|
224108344|NCT01542372|BEHAVIORAL|CBT|
224108345|NCT05776472|DRUG|Pegcetacoplan|Pegcetacoplan will be prescribed according to the label in patients with PNH.
224108346|NCT00577590|DRUG|Metformin|Metformin is taken alone
224108347|NCT00577590|DRUG|Rosiglitazone|Rosiglitizone is taken with Metformin
224108348|NCT00577590|DRUG|Lovaza|Lovaza is taken with Metformin
224108349|NCT02333838|DRUG|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
224108350|NCT02333838|DRUG|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
224108351|NCT02333838|DRUG|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
224108352|NCT02333838|DRUG|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
223958451|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft for regenerative periodontal therapy.
223958452|NCT05029089|PROCEDURE|Modified Entire Papilla Preservation Technique (MEPPT) with Emdogain and Allograft and sCTG For Periodontal Regenerative Treatment Of Intrabony Defect|Surgical approach using modified papilla preservation technique and Emdogain and Allograft and sCTG for regenerative periodontal therapy.
224108353|NCT05755789|DRUG|Loading bolus of cefoxitin|Cefoxitin \[2g\] before incision
224108354|NCT05755789|DRUG|Intermittent cefoxitin|Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
223958453|NCT05427942|DRUG|Adalimumab|Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
223958454|NCT03798132|DIAGNOSTIC_TEST|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
224108355|NCT05755789|DRUG|Continuous infusion of placebo|Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
223958455|NCT03423992|BIOLOGICAL|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
223958456|NCT04167852|BEHAVIORAL|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
223958457|NCT04167852|BEHAVIORAL|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
223958458|NCT05316649|OTHER|Measurement of external blood loss|Measurement of external blood loss
223958459|NCT05316649|DIAGNOSTIC_TEST|Serum Hemoglobin concentration|Serum Hemoglobin concentration
223958460|NCT02893618|DRUG|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
223958461|NCT04664179|BIOLOGICAL|Dose Level 1A: 2 x 10^7 cells/m2|2 x 10\^7 cells/m2
224108356|NCT05755789|DRUG|Continuous infusion of cefoxitin|Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
224108357|NCT05755789|DRUG|Intermittent placebo|Additional bolus of placebo every 2 hours until the end of surgical closure
224108358|NCT04516902|DRUG|Lysergic Acid Diethylamide|A moderate dose of 100 μg LSD will be administered.
224108359|NCT04516902|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
223958462|NCT04664179|BIOLOGICAL|Dose Level 2A: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
223958463|NCT04664179|BIOLOGICAL|Dose Level 2B: 6 x 10^7 cells/m2|6 x 10\^7 cells/m2
223958464|NCT04664179|BIOLOGICAL|Dose Level 3B: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
223958465|NCT04664179|BIOLOGICAL|Dose Level 3A: 2 x 10^8 cells/m2|2 x 10\^8 cells/m2
223958466|NCT03444298|DRUG|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
223958467|NCT03444298|DRUG|Placebo|Each dose consists of two capsules by mouth once daily for a total of 7 days.
223958468|NCT02759406|DEVICE|coronary stent|
223958469|NCT01571440|DIETARY_SUPPLEMENT|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
223958470|NCT01571440|DIETARY_SUPPLEMENT|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
223958471|NCT04718116|DRUG|Group tapentadol 50 mg|patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
223724150|NCT07132814|OTHER|Product C|12 mg nicotine oral product
223724151|NCT07132814|OTHER|Product D|6 mg nicotine oral product
223724152|NCT07132814|OTHER|Product E|8 mg nicotine oral product
223958472|NCT04718116|DRUG|group tapentadol 75 mg|patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
223958473|NCT04718116|DRUG|group tramadol 100 mg|patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
223958474|NCT02289885|DEVICE|SonoScape|Ultrasonography device
223958475|NCT01237600|PROCEDURE|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
223958476|NCT02865109|DRUG|Nusinersen|Administered by intrathecal injection
224108360|NCT04516902|OTHER|LSD Placebo|Pure alcohol instead of an alcoholic solution containing LSD
224108361|NCT04516902|OTHER|MDMA Placebo|Mannitol capsules instead of capsules containing MDMA
224108362|NCT03614390|BEHAVIORAL|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
224108363|NCT00545818|DEVICE|OsseoSpeed™ length 6 mm|OsseoSpeed™ dental implant, length: 6 mm
224108364|NCT00545818|DEVICE|OsseoSpeed™ length 11 mm|OsseoSpeed™ dental implant, length: 11 mm
224108365|NCT06244186|DIETARY_SUPPLEMENT|Probiotics|Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
224108366|NCT06244186|DIETARY_SUPPLEMENT|Placebo|Placebo is provided by TCI CO., Ltd.
224108367|NCT03574207|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
224108368|NCT01984814|BIOLOGICAL|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
224108369|NCT04850950|DRUG|Tenofovir Alafenamide fumarate 25mg Oral Tablet|Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
224108370|NCT05659615|OTHER|Study will not have intervention|Study will not have intervention
224108371|NCT04740749|DEVICE|Compress Compliant Pre-Stress System|Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
223958477|NCT02423707|DRUG|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
223958478|NCT02423707|DRUG|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
223958479|NCT05893615|BEHAVIORAL|Cognitive Behaviour Therapy|The CBT module was adjusted as follows: (1) Health education about paroxysmal atrial fibrillation; (2) Self-awareness training; (3) Exposure training; (4) Habitual reversal training；(5) Correcting cognitive distortion; (6) Behavioral activation (7) Specific training for anxiety; (8) Practice and feedback; (9) Relapse prevention; (10) Review.
223958480|NCT01054118|DRUG|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
223958481|NCT01054118|DRUG|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
223958482|NCT01054118|DRUG|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
223958483|NCT01054118|DRUG|Placebo|Placebo suspension and placebo capsule administered as single doses
223958484|NCT04034966|DEVICE|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
223724153|NCT07132814|OTHER|Product F|8 mg nicotine oral product
223724154|NCT07132814|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine polacrilex gum
223724155|NCT07132333|BIOLOGICAL|Biologic Agent|Intervention with biologic agents
223958485|NCT02616926|PROCEDURE|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
223958486|NCT02616926|PROCEDURE|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
223958487|NCT02616926|PROCEDURE|RFA|RFA will be performed 1 week after TACE.
224108372|NCT05240937|BEHAVIORAL|mindfulness-based self-compassion will be applied|A mindfulness-based self-compassion program will be applied to this group of patients who have had breast cancer and have fully completed their treatment.
224108373|NCT02280005|DEVICE|WAK Treatment|Hemodialysis with WAK device.
223958488|NCT05950607|BEHAVIORAL|TRAIN AD 2.0|"The study intervention is a multi-component training program targeting direct care providers and healthcare proxies for NH residents with moderate to advanced dementia intended to improve the management of urinary tract infections (UTIs) and lower respiratory tract infections (LRIs). The components include: A. Provider Orientation: At NH start-up and q2 months providers will be offered orientations sessions involving two 15-minute presentations, one focused on the background and rationale for the program and one focused on describing the program components. B. A case-based on-line course, Infection Management in Moderate to Advanced Dementia, C. Posters and pocket cards for providers displaying algorithms guiding appropriate antimicrobial initiation for suspected UTIs and LRIs that integrate patient preferences, and D. Proxies of ALL residents in the facility will be sent a booklet related to infection management for persons with moderate to advanced dementia. ."
223958489|NCT00173706|DRUG|L-Carnitine Injection|
223958490|NCT00760877|DRUG|Nilotinib|Supplied in 200 mg capsules
223958491|NCT00760877|DRUG|Imatinib|Supplied in 100 mg and 400 mg capsules
223958492|NCT03829072|OTHER|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
223541923|NCT06712342|OTHER|Neuromuscular Exercise Training|"This group will receive neuromuscular exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks.~Warm-up Program - 5 minutes Postural Control-Weight Transfer - 10-15 minutes Strength Training - 30-35 minutes Proprioception - Coordination - Reaction Speed 10-15 minutes Cool-down Program - 5 minutes"
224108374|NCT02673112|BEHAVIORAL|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
223958493|NCT03829072|OTHER|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
224108375|NCT02673112|BEHAVIORAL|Light stretching (LS)|Brief daily stretching routine.
224108376|NCT05982977|OTHER|Acupuncture|The patient was placed in a supine position, selected Lianquan, Fengchi, and acupoints.
223958494|NCT00711555|DRUG|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
223958495|NCT03538223|OTHER|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
223958496|NCT03538223|RADIATION|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
223958497|NCT00470041|DRUG|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
223958498|NCT00801086|DRUG|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
223958499|NCT00801086|DRUG|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
223958500|NCT05413759|OTHER|Pharmaceutical care in multiprofessional collaboration|"In addition to usual practices: medication reconciliation and pharmaceutical motivational interviews with patients (discharge, 2 \& 6 months).~Objective of medication reconciliation (admission): to detect and resolve unintended medication discrepancies between home medication list and treatment and hospital admission medication orders. Objective of medication reconciliation (discharge): to obtain an exact list of medication, to explain the medication modifications during hospitalization.~Objective of the Disease-Modifying Antirheumatic Drugs information interview (discharge): to provide information and to answer questions on the management of treatment, to deal with practical situations to assess patients' self-management skills.~Objective of interviews (2 \& 6 months): to evaluate medications and their daily management, benefits and problems that patient may encounter, to assess the patient's ability to manage the treatment."
223958501|NCT01357447|DRUG|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
223958502|NCT01357447|DRUG|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
223958503|NCT00678132|DRUG|AZD 2281|
223958504|NCT00678132|DRUG|Cisplatin|
223958505|NCT00678132|DRUG|Gemcitabine|
223958506|NCT06185075|PROCEDURE|Implant crown delivery|Dental implant crown will be designed, fabricated by a dental lab, and delivered.
223958507|NCT05386888|DRUG|GFH018|Administered as oral
223958508|NCT05386888|DRUG|Toripalimab|Administered as an IV infusion
223958509|NCT05386888|DRUG|Paclitaxel|Administered as an IV infusion
223958510|NCT05386888|DRUG|Carboplatin|Administered as an IV infusion
223958511|NCT05386888|DRUG|Cisplatin|Administered as an IV infusion
223958512|NCT05386888|DRUG|Pemetrexed|Administered as an IV infusion
223958513|NCT05386888|RADIATION|Thoracic Radiation Therapy (TRT)|Thoracic Radiation Therapy (TRT)
223958514|NCT05386888|DRUG|GFH018|Administered as an IV infusion
223958515|NCT06811909|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method, which, briefly includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C, and electron beam sterilization.
223958516|NCT06811909|OTHER|Standard Care|"Standard Care is defined as:~* Sharp debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer followed by an alginate or foam pad to maintain a moist, warm wound bed, and~* The UrgoK2™ dual compression system providing around 40 mmHg."
223958517|NCT06325709|DRUG|Plerixafor|Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
223958518|NCT06325709|DRUG|Filgrastim|Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
224108377|NCT05982977|BEHAVIORAL|Conventional rehabilitation|swallowing training included breathing training, masticatory muscle training, oral movement training and feeding training.
223958519|NCT06325709|DRUG|Palifermin|Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
224108378|NCT02521246|DRUG|Candesartan + Chlorthalidone|
224108379|NCT02521246|DRUG|Candesartan + Chlorthalidone|
224108380|NCT02521246|DRUG|Losartan+hydrochlorothiazide|
224108381|NCT00609609|PROCEDURE|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
224108382|NCT00609609|DRUG|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
224108383|NCT04575350|GENETIC|reinterpretation of CNV|Reinterpretation of CNV of unknown significance
224108384|NCT03170284|DRUG|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
224108385|NCT00102037|DRUG|eptacog alfa (activated)|
223958520|NCT06325709|DRUG|Busulfan|Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
223958521|NCT06325709|BIOLOGICAL|Base-edited hematopoietic stem and progenitor cells|Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.
223958522|NCT06325709|DRUG|Sirolimus|Immunomodulating agent: Daily oral dosing beginning Day -1 for approximately 3 to 6 months to prevent an immune response to the protein expressed by the BE HSPCs.
223958523|NCT03357120|OTHER|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
223958524|NCT04206436|DRUG|Cftr Modulators|CFTR modulators are drugs used to treat cystic fibrosis
223958525|NCT06696534|OTHER|Survey using a questionnaire.|Preference questionnaire for colorectal cancer screening methods
223958526|NCT06696534|OTHER|Survey using a questionnaire.|Experience questionnaire into colorectal cancer screening programme
223958527|NCT04258137|GENETIC|Liquid biopsy|Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
223958528|NCT04206397|BEHAVIORAL|affective touch|Various types of touch such as brushing, pressure, and tapping, as well as heat pain
223958529|NCT05385523|PROCEDURE|Rhomboid Intercostal and Sub-Serratus block technique (RISS)|The patient will be placed in lateral position. A linear ultrasound transducer of frequency 6-12 MHz will be placed medial to the lower border of the scapula in a sagittal plane. A 38-mm 22-gauge will be inserted under real-time in-plane from craniocaudal between the rhomboid major and intercostal muscles. After negative aspiration, single injection of 10 ml of the local anesthetic mixture will be administered at the T6 7 level. The spread of local anesthetic solution under the rhomboid muscle will be visualized by ultrasonography. Then the ultrasound probe will be moved caudally and laterally to identify the tissue plane between the serratus anterior and external intercostal muscle for the sub-serratus block at T 8-9 level. The needle will be advanced from its previous position and a further of 10 ml of the local anesthetic mixture will be injected.
223724156|NCT07131280|DRUG|Gcsf|G-CSF will be given at a dose of 5 μg/kg s/c at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30
223541924|NCT06712342|OTHER|Conventional Exercise Training|"This group will be given traditional strength exercise training consisting of 60-75 minute sessions per day, 2 days per week for 8 weeks.~Warm-up Program - 5 minutes Strength Training - 30-35 minutes Manuel Dexterity - 15-20 minutes Cool-down Program - 5 minutes"
223541925|NCT06715631|DEVICE|Hands-free exoskeleton|Before the simulated-use test, the SCI user and his/her companion must attend five training sessions provided by a Wandercraft certified trainer. Training will be composed by a theoretical part including presentation and description of the personal exoskeleton and its use modes and a hands-on practice. Each session lasts between 1 to 2 hours, varying according to the user's learning pace and tolerance. The training program is representative of the intended training for the end product.
223541926|NCT03303729|DIETARY_SUPPLEMENT|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
223958530|NCT05385523|PROCEDURE|General Anaesthesia|"Fentanyl (1 μg/kg), propofol (2-3mg/kg) and atracurium (0.3-0.5 mg/kg) will be injected intravenously 3-5 minutes after oxygenation. A single-lumen endotracheal tube will be used to complete ventilation. The ventilator ventilation mode is volume control mode, and the patient's end-expiratory carbon dioxide level is maintained at 35-40 mmHg throughout the anesthesia process. During the anesthesia maintenance phase, 2% sevoflurane mixed with 60% oxygen.~After general anaesthesia induction, all patients will receive RISS block with different local anesthetic drug mixture according to randomization."
223958531|NCT05385523|DRUG|dexamedatomidine|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 1 Mcg/kg dexamedatomidine in 2 mL.
223958532|NCT05385523|DRUG|dexamethasone|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine + 8mg dexamethasone in 2 mL.
223958533|NCT05385523|DRUG|saline|Patients will receive general anaesthesia and RISS block with 20 ml of 0.25% bupivacaine+ 2 mL normal saline.
223958534|NCT04049357|DEVICE|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
223958535|NCT06957496|OTHER|Allergenic extracts|In each subject, a drop of each of the 3 concentrations of the allergenic extract, in addition to the positive control (histamine) and the negative control, will be applied. The application will be duplicated on the subject's anterior forearm, with a distance of approximately 4 cm between each application to avoid overlapping reactions and false-positives results.
223958536|NCT05878769|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W
223958537|NCT06830863|DRUG|ATR04-484|ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use
223958538|NCT06830863|DRUG|Vehicle|Topically applied vehicle.
223958539|NCT01234025|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
223958540|NCT01234025|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
223958541|NCT01234025|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
223958542|NCT01234025|DRUG|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
223958543|NCT01234025|DRUG|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
223958544|NCT03803995|PROCEDURE|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
223958545|NCT03803995|PROCEDURE|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
223958546|NCT05974410|DRUG|AVM0703|small molecule immunomodulatory drug
223958547|NCT05974410|DRUG|Hydrocortisone|physiologic circadian glucocorticoid
223958548|NCT05974410|DRUG|Proton pump inhibitor|
223958549|NCT05593016|BEHAVIORAL|Symptom Management for Improved Physical and Emotional Wellbeing (SMILE)|"Participating in the SMILE arm of the study will consist of four, 60-minute sessions delivered over 6-8 weeks to patients in their homes using videoconferencing.~Intervention will provide training in behavioral symptom management skills (e.g.,relaxation training, activity-rest cycling) and include skills from ACT and MCP targeting avoidance of uncomfortable experiences (e.g., thoughts, emotions) and promoting engagement in value-directed activity."
223541927|NCT03303729|DIETARY_SUPPLEMENT|Cluster Dextrin|75 grams of Cluster Dextrin
223541928|NCT03303729|DIETARY_SUPPLEMENT|Placebo|75 grams of Glucose
223724157|NCT07131280|DRUG|Darbepoetin|Darbepoetin will be given s/c at dose of 40mcg once a week for 1 month
223958550|NCT05593016|BEHAVIORAL|Education Control Arm|"The control arm will receive the NCI booklet, Taking Time: Support for People with Cancer, which provides basic strategies for symptom (e.g., pain, fatigue, stress) management, coping with negative emotions, and communication and will continue their usual medical care of advanced cancer."
223958551|NCT05911763|DRUG|Efanesoctocog Alfa BIVV001|Given per investigator's discretion
223541929|NCT05618444|BEHAVIORAL|Automated Management (AM)|A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
223541930|NCT03559270|DRUG|Baricitinib|Administered orally
223958552|NCT05379400|OTHER|Portable air cleaner (PAC)|Commercially available Portable air cleaners (PAC) contain carbon filters that reduce volatile organic carbons and can reduce odors. Because of this, the researchers will remove the carbon filters from all air purifiers to preserve blinding. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
223958553|NCT05379400|OTHER|Sham Portable air cleaner (PAC)|Sham Portable air cleaner (PAC) are commercially available portable air cleaners with the carbon filters and the HEPA filters removed. This will be done by unblinded research staff and devices will be labelled with an ID number to preserve blinding of the rest of the research team.
223958554|NCT05480410|DEVICE|Repetitive transcranial magnetic stimulation|rTMS is a minimal invasive technique which focus on the M1 cortex. It can stimulate the cortex by depolarizing superficial neurons. For this study we will use a MagVenture MagPro R20
223958555|NCT05356130|BEHAVIORAL|Written Educational Material on BLT|Participants in both Arms 2 and 3 will receive written information about how to obtain the greatest BLT benefit, including recommended day/time usage, session duration, eye distance from light box, the length of time to continue using, and the small risk of emergent mania or BD and how to recognize this. Written best practices for ideal BLT will be provided in both Arms 2 and 3 via secure EHR message, email, and/or USPS. PDFs of best practices for BLT will also be available for download on our study website.
223958556|NCT05356130|BEHAVIORAL|Enhanced BLT Encouragement and Adherence Promotion|BLT phone coaches will follow a four-step approach in engaging with Arm 3 participants: (a) provide encouragement to consider using BLT; (b) provide guidance regarding light box purchase and assist with obtaining compensation for purchase; (c) educate participants about ideal BLT use to obtain maximum benefit; and (d) provide ongoing brief telephonic adherence promotion and motivational interviewing (MI) where warranted to maximize persistent and appropriate BLT use.
223958557|NCT04705818|DRUG|Durvalumab|Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)
223541931|NCT01850953|DRUG|Varenicline|This is an approved smoking cessation medication.
223541932|NCT01850953|DRUG|Placebo|
223541933|NCT03836404|DEVICE|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
224108386|NCT03045380|OTHER|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
223958558|NCT04705818|DRUG|Tazemetostat|Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).
223958559|NCT03141177|BIOLOGICAL|Nivolumab|Specified dose on specified day
223958560|NCT03141177|DRUG|Cabozantinib|Specified dose on specified days
223958561|NCT03141177|DRUG|Sunitinib|Specified dose on specified days.
223958562|NCT03141177|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223958563|NCT04798898|DEVICE|RFA (radiofrequency ablation)|Preoperative RFA-induced partial necrosis of the liver metastasis
223958564|NCT03178149|DRUG|ASP7317|subretinal injection
223958565|NCT03178149|DRUG|tacrolimus|oral
224108387|NCT03045380|OTHER|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
224108388|NCT06046508|OTHER|blood samples collection|patients, who meet all the inclusion criteria and none of the exclusion criteria, will be enrolled and they will perform a blood withdrawal before PFO correction and 180 days after the intervention
224108389|NCT01333618|DEVICE|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
224108390|NCT01333618|DEVICE|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
224108391|NCT02446782|DRUG|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
224108392|NCT02446782|OTHER|saline|100 mL normal saline 15-30 minutes before the start of the procedure
224108393|NCT01585389|GENETIC|gene expression analysis|
224108394|NCT01585389|GENETIC|genetic linkage analysis|
224108395|NCT01585389|GENETIC|microarray analysis|
224108396|NCT01585389|OTHER|immunohistochemistry staining method|
223724158|NCT07131280|OTHER|Standard Medical Treatment|Standard Medical Treatment
223958566|NCT03178149|DRUG|trimethoprim-sulfamethoxazole|oral
223958567|NCT03178149|DRUG|Acyclovir|oral
223958568|NCT03178149|DRUG|Nystatin|oral
223958569|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
223958570|NCT02748109|BEHAVIORAL|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
223958571|NCT03535376|DRUG|Valsartan|Patients are tested for their normal prescription valsartan medication
223958572|NCT05569525|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy according to the full-mouth debridement protocol.
224108397|NCT01585389|OTHER|laboratory biomarker analysis|
223724159|NCT07131189|DRUG|FL115|FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
223958573|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of \[14C\]FTD administered as an oral solution on Day 1 (mass balance part)
223958574|NCT02031055|DRUG|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of \[14C\]TPI administered as an oral solution on Day 1 (mass balance part)
223724160|NCT07132788|DIAGNOSTIC_TEST|blood draw|Research blood draw
223958575|NCT02031055|DRUG|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
223958576|NCT05552326|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223958577|NCT05552326|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
223958578|NCT06226545|DRUG|LASN01|Low dose of LASN01 will be administered intravenously.
223958579|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
223958580|NCT06226545|DRUG|Placebo|Placebo will be administered intravenously.
223958581|NCT06226545|DRUG|LASN01|High dose of LASN01 will be administered intravenously.
223958582|NCT05776979|DRUG|Isatuximab|Given by vein over about 75 minutes
223958583|NCT05776979|DRUG|lenalidomide|Given by PO
224108398|NCT00001081|DRUG|Nitazoxanide|
224108399|NCT03992235|OTHER|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
224108400|NCT03992235|OTHER|Educational material|Exercise brochure with photos and explanations
224108401|NCT02348047|DEVICE|Hamilton T1|
224108402|NCT00893607|DRUG|NRL001|10mg NRL001 was administered as a slow release suppository
224108403|NCT03280329|OTHER|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
224108404|NCT03280329|OTHER|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
224108405|NCT00670111|DEVICE|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
223541934|NCT05187299|OTHER|observer tool|The observer tool is paper-based and is divided in columns (each column filled out for a dyad observed) with lines representing the above-described steps of learning and presented with visual incremental actions to be performed. The observer tool will only be used to reinforce learning and will not be used for summative evaluation. Instructors have already been involved in previous simulation studies performed in our center, and especially those in which an observer tool has been assessed (one study published, two manuscripts in preparation).
223958584|NCT02680314|DRUG|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
223958585|NCT06720064|DEVICE|Chlorhexidine Dressing|Transparent catheter cover with Chlorhexidine (3M™ CHG Tegaderm™)
223958586|NCT05066997|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|"Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
223958587|NCT05066997|DRUG|Vehicle|"Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase)."
223958588|NCT06793722|PROCEDURE|Technological device in circumcision|Circumcision is performed by watching a video/playing a game during the procedure in children who are circumcised.
223958589|NCT05651607|DRUG|Cannabidiol|Oral solution, taken 3 times a day (morning, noon and evening), 5 mg/kg/day from day D0 to day D4. If not effective and well tolerated, dose increase : 10 mg/kg/day from day D5 to day D9, then 20 mg/kg/day from day D10 to day D29, maximum 800 mg/day
223958590|NCT03188887|DRUG|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
223958591|NCT03188887|DRUG|Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)|treatment with Renin angiotensin system (RAS) blockade or SGLT2i
223958592|NCT05349123|BEHAVIORAL|Mindful Breathing|Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.
223958593|NCT05349123|BEHAVIORAL|Home-Based Pulmonary Rehabilitation|Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
223958594|NCT03968276|OTHER|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
224108406|NCT03988751|BEHAVIORAL|Ambulation|Variation in ambulatory intensity.
224108407|NCT05123287|DRUG|PD-1 immune checkpoint blockades|intravenous injection; frequency: 2-3 weeks/cycle; duration: 3 months
224108408|NCT05861947|DRUG|AUR106|Once or twice daily
224108409|NCT01277146|DRUG|OMP-59R5|IV infusion
224108410|NCT00249561|BEHAVIORAL|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
224108411|NCT00249561|BEHAVIORAL|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg \& Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
224108412|NCT05651087|DRUG|LACUDY|LACUDY:Insert 2mL twice a week for 4 weeks before going to bed
224108413|NCT02849769|DEVICE|Implant of an MR-conditional Tachy device system|
224108414|NCT00844883|DRUG|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
224108415|NCT00844883|PROCEDURE|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
224108416|NCT01673061|DRUG|Lidocaine|See associated Arm Description
224108417|NCT01673061|DRUG|Vapocoolant|See associated Arm Description
223541935|NCT00548535|PROCEDURE|Reliability of complication assessment|
223541936|NCT04750083|DRUG|HX008|HX008 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to 35 cycles
223541937|NCT04750083|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) on Day 1 of Q3W for up to 35 cycles
223541938|NCT04750083|DRUG|pemetrexed|pemetrexed 500 mg/m\^2 IV on Day 1 of Q3W for up to 35 cycles
223541939|NCT04750083|DRUG|cisplatin/carboplatin|cisplatin 75 mg/m\^2 IV OR carboplatin AUC 5 IV on Day 1 of Q3W for 4 cycles
223541940|NCT06902376|BIOLOGICAL|Cemiplimab|Cemiplimab will be administered at a dose of 350mg intravenous over 30 minutes every 3 weeks for 3 cycles (cycle length is 21 days) at weeks 1, 4, and 7.
223541941|NCT06902376|DRUG|XL092|XL092 will be administered at a dose of 100mg PO daily for 8 weeks (weeks 1-8)
223541942|NCT04743011|DRUG|Heparin sodium|Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
223541943|NCT04743011|DRUG|Placebo|Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)
223541944|NCT03910075|BEHAVIORAL|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
223541945|NCT03910075|BEHAVIORAL|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
223541946|NCT03910075|BEHAVIORAL|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
223541947|NCT03539679|OTHER|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
223958595|NCT06563882|OTHER|Home-based exercise program|"The program will comprise of six exercises aimed at improving the mobility of the thoracic spine and shoulders, strengthening the extensor muscles of the spine, and enhancing the flexibility of the chest and anterior shoulders. Progression within the program will involve increasing exercise duration or repetitions/sets, along with implementing postural corrections in compound exercises. Participants will be instructed to perform the exercises at least three times a week.~To heighten participants awareness of their daily posture, they will receive a daily scheduled message via WhatsApp reminding them to focus on their posture. Once a week, participants will be asked to submit a home exercise tracking report to monitor their adherence to the program. Additionally, exercises execution will be reviewed every two weeks, and adjustments to the program will be made accordingly."
223958596|NCT06563882|OTHER|No intervention|No intervention
223724161|NCT07132788|DIAGNOSTIC_TEST|Short Performance Physical Battery|test of physical performance, which involves measuring movement from sitting to standing, walking speed, and balance
223958597|NCT05357482|RADIATION|TBI|300 cGy total body irradiation (TBI, day -2)
223958598|NCT05357482|DRUG|Hydroxyurea|Optimized 4-12 weeks prior to planned transplant date
223958599|NCT05357482|BIOLOGICAL|briquilimab|briquilimab, anti-CD117 monoclonal antibody at 0.6mg/kg at day -11 prior to infusion of allogeneic HSCs
223958600|NCT05357482|DRUG|Filgrastim (G-CSF)|May be used to minimize the days of neutropenia, and may be administered beginning near day 10 post stem cell infusion at 5 mcg/kg (rounding to the nearest vial) at the discretion of investigator.
223958601|NCT05357482|DRUG|Sirolimus|For immune suppression (day -1)
223958602|NCT05357482|BIOLOGICAL|Alemtuzumab|Alemtuzumab 1 mg/kg of alemtuzumab divided over 5 days (-7 through -3),
223541948|NCT03436342|DRUG|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
223541949|NCT05750407|BEHAVIORAL|Lifestyle change|Three modules target healthy eating, activity, and weight control behaviors
223958603|NCT05357482|DRUG|Plerixafor|For autologous HSC collection; dose of plerixafor at 240 mcg/kg (capped at 20mg)
223958604|NCT01631318|PROCEDURE|Dynamic contrast-enhanced ultrasound imaging|Ultrasound imaging procedure
223958605|NCT01631318|DEVICE|Optical Tracking Device|Optical Tracking Device, manufactured by Atracsys LLC, Switzerland.
223958606|NCT01631318|DEVICE|Electromagnetic Tracking Device|Electromagnetic Tracking Device, Ascension Technology Corporation, Milton, Vermont.
223724162|NCT07132788|DIAGNOSTIC_TEST|Grip strength test|Measures grip strength
223724163|NCT07132788|DIAGNOSTIC_TEST|Six minute walk test|Measures distance walked in 6 minutes
223724164|NCT07132788|RADIATION|Chest CT scan|X-ray and computer technology takes detailed pictures of the organs and structures inside your chest
223958607|NCT01631318|DRUG|Perflutren|Perflutren lipid microsphere, IV 0.4 mL. Used as standard contrast agent, not the subject of the study.
224108418|NCT02623361|DRUG|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
223541950|NCT06278493|DRUG|AL2846 capsules|AL2846 is a multi -target receptor tyrosine kinase inhibitor.
223541951|NCT06278493|DRUG|Gemzar|It is a chemotherapeutic drug.
223958608|NCT03533803|DRUG|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
223958609|NCT03533803|PROCEDURE|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
223958610|NCT04588233|DIETARY_SUPPLEMENT|Melatonin|Each subject will receive 3mg of melatonin 1 hour prior to bedtime for 12 consecutive nights
223958611|NCT04588233|OTHER|Placebo|Each subject will receive a placebo 1 hour prior to bedtime for 12 consecutive nights
224108419|NCT02623361|DRUG|Sham Block|Sham Block by saline injection
224108420|NCT02220881|DEVICE|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
223958612|NCT04851444|DRUG|SI-F019|Single dose is administered IV.
223541952|NCT05726474|BEHAVIORAL|Combined exercise|Patients will exercise for 40 minutes three times a week on an ergometric bicycle at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without ergometer at 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without shortness of breathing difficulty. In addition, strength training will be performed (bench press, leg press, leg curl, leg machine, bench press, leg press, leg curl, leg curl, leg machine). leg curls, leg curls, rowing machine, triceps dips, pectoral pull-ups) twice a week. week. Strength training will be performed with 15 repetitions per exercise and per session, with a corresponding workload of 15 repetitions. session, with a workload corresponding to 60% to 65% of the 1-repetition maximum (1RM) measured at (1RM) measured at the beginning and at the end of the intervention.
223958613|NCT00228813|DRUG|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
223724165|NCT07132788|RADIATION|Dual-Energy X-ray Absorptiometry Scan|Uses X-ray technology to measure the mineral density of your bones, and provides a ratio of fat tissue to lean mass (muscle) and bone
224108421|NCT02220881|OTHER|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
224108422|NCT00000960|DRUG|Zidovudine|
224108423|NCT01938170|BIOLOGICAL|FluMist|Subjects receiving Flumist vaccine
223958614|NCT02615041|DRUG|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
223958615|NCT02615041|DRUG|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
223958616|NCT02615041|DRUG|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
223541953|NCT05726474|BEHAVIORAL|High interval training|Patients will perform three training sessions per week. Each training session begins with a 10-minute warm-up at moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, no shortness of breath) before cycling, four 4-minute intervals at high intensity (corresponding to 85-90% of VO2max, 90-95% of HRmax, 15-17 on the Borg scale, shortness of breath). Each interval will be separated by 3 minutes of active pauses, with a HRmax of 50-70%. The training session will end with 3 minutes of cool down at moderate intensity (corresponding to 50-60%). moderate intensity (corresponding to 50-60% of VO2max, 60-70% of HRmax, 11-13 on the Borg scale, without difficulty). Borg scale, no shortness of breath). The total exercise time will be 40 minutes for the HIIT group.
223958617|NCT05836831|DRUG|Tranexamic acid injection|The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml sodium chloride 0.9 % administered over 45 minutes.
223958618|NCT01246232|DRUG|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
223958619|NCT01246232|DRUG|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
223958620|NCT03334305|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
223958621|NCT03334305|DRUG|Dose-intensified TMZ|After chemoradiation, subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
223958622|NCT03334305|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Prior to chemoradiation, enrolled subjects will undergo a mobilized leukapheresis for collection of PBSCs and PBMCs for generation of DCs. One group will receive recommended dose of \> 2 x 106 CD34+ HSCs/kg. Subjects enrolled in Group B will receive HSCs during TMZ Cycle 6 before receiving DC vaccine and T-cell infusion.
223958623|NCT03334305|BIOLOGICAL|TTRNA-xALT|During TMZ Cycle 6 and with DC vaccine #8, an infusion of T-cells will be administered to all subjects.
223958624|NCT03334305|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
223958625|NCT01242345|DEVICE|Capnography|Monitoring of the capnography curve for early detection of apnea
223958626|NCT02645578|DEVICE|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
223958627|NCT03131271|OTHER|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
223958628|NCT03371849|DRUG|montelukast and levocetirizine FDC|HCP1102
223958629|NCT03371849|DRUG|Singulair + xyzal|HGP0813 + HGP1408
223958630|NCT03875794|OTHER|Osteopathic Manipulation|Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
224108424|NCT01850381|DRUG|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
224108425|NCT01850381|DRUG|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
223958631|NCT02187120|DRUG|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
224108426|NCT01479049|DRUG|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
224108427|NCT01479049|DRUG|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
223958632|NCT02187120|DRUG|Placebo|
223958633|NCT06182631|DEVICE|Buzzy Bee|The Buzzy is a vibrating palm-sized device with removable ice wings developed by MMJ Labs Atlanta, GA. It uses Melzack and Wall's Gait Control theorywhich asserts that activation of non-nociceptive fibers can interfere with signals from pain fibers thereby inhibiting pain.
223958634|NCT06182631|DRUG|Vapocoolent|Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
224108428|NCT01625169|DRUG|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
223958635|NCT06182631|OTHER|Placebo|A band will be placed on the arm before IV insertion for placebo effect.
223958636|NCT06178822|OTHER|No intervention|There is no intervention
223958637|NCT05543460|PROCEDURE|MARPE with Corticopunctures|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency aided with corticopunctures made along the mid-palatal suture
223958638|NCT05543460|DEVICE|MARPE|Maxillary Skeletal Expander (MSE II, Biomaterials Korea Inc., Seoul, Korea) used to correct the maxillary transverse deficiency
223958639|NCT04077437|BEHAVIORAL|Therapy|Standardized non-directive therapy performed by therapist team.
223958640|NCT04077437|DRUG|Midomafetamine|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
223958641|NCT04077437|DRUG|Placebo|Administration of placebo with therapy during three experimental sessions
223958642|NCT05361304|DEVICE|senofilcon A contact lenses made with a novel manufacturing technology|TEST Lens
223958643|NCT05361304|DEVICE|senofilcon A contact lenses made with the current manufacturing technology|CONTROL Lens
223958644|NCT01816165|DRUG|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
223958645|NCT01816165|DRUG|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
223958646|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
224108429|NCT04165265|DEVICE|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
224108430|NCT03000452|DRUG|DARATUMUMAB|DARATUMUMAB
224108431|NCT03000452|DRUG|DURVALUMAB|DURVALUMAB
224108432|NCT02511080|DEVICE|Spot-On|use of active hot measures
223958647|NCT06049758|DRUG|Enoxaparin 40 Mg/0.4 mL Injectable Solution|Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation
224108433|NCT01467739|DEVICE|Ambu ® aScope®|
224108434|NCT01467739|DEVICE|a conventional reusable fiberscope|
224108435|NCT00129714|OTHER|cervical collar|
224108436|NCT00129714|OTHER|physiotherapy|
224108437|NCT03083951|PROCEDURE|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
224108438|NCT03083951|PROCEDURE|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
223958648|NCT06049758|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.
223958649|NCT06049758|PROCEDURE|LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)|Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
224108439|NCT01857986|DEVICE|AnapnoGuard 100 control unit|
224108440|NCT05056480|OTHER|Surveys|Parent/caregivers participants will complete multiple repeating surveys to gather family-reported perspectives on the impact of the PCCI care management program. Clinical staff participants will complete multiple repeating surveys that gather clinician perspectives on the impact of the PCCI care management program. Parent/caregiver and clinical staff participants will also be invited to participated in one-on-one semi-structured interviews with the study team.
224108441|NCT00003530|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224108442|NCT05518591|BEHAVIORAL|Compassion Focused Therapy (CFT) combined with Breathing Pattern Retraining (BPR)|Study participants in the experimental arm of the study are being asked to take part in a 6-week, virtual, psychological therapy group involving compassion focused therapy and breathing pattern retraining. This group involves exercises in practicing self-compassion, emotional regulation, and breathing retraining. Each group session lasts less than two hours, per week.
224108443|NCT01538173|DRUG|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
224108444|NCT01538173|DRUG|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
223724166|NCT07132788|BEHAVIORAL|Activity monitoring|A device worn on your non-dominant wrist which measures motion/ movement/ activity
223958650|NCT05974371|OTHER|emotional context similarity|On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
223958651|NCT01746199|DRUG|cotrimoxazole daily prophylaxis|
223958652|NCT01746199|DRUG|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
223958653|NCT02797795|DRUG|NEV801|Dose Escalation
223958654|NCT04914520|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
223958655|NCT04914520|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
223958656|NCT02898350|DEVICE|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
224108445|NCT00537823|DRUG|Cetuximab|
224108446|NCT00537823|DRUG|Bevacizumab|
223724167|NCT07132788|BEHAVIORAL|24 hour diet recall|A research dietitian will contact you and ask you to provide details of what you ate over the previous 24 hours
223724168|NCT07132788|DIAGNOSTIC_TEST|Echocardiogram|Ultrasound technology to create moving images of your heart, valves, and chambers
224108447|NCT00537823|DRUG|Leucovorin|
224108448|NCT00537823|DRUG|Oxaliplatin|
224108449|NCT00537823|DRUG|Fluorouracil|
223724169|NCT07132788|BEHAVIORAL|Quality of Life Questionnaire (emPHasis 10)|The emPHasis-10 is a pulmonary hypertension-specific questionnaire which is scored from 0-50 (with higher scores indicating worse quality of life.)
223958657|NCT02898350|DEVICE|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
223958658|NCT02898350|DEVICE|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
223958659|NCT02898350|DEVICE|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
223958660|NCT02956915|PROCEDURE|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
223958661|NCT04038723|BEHAVIORAL|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
223958662|NCT01233193|BEHAVIORAL|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
223958663|NCT05884671|DRUG|Sulpiride 400 MG|All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
223958664|NCT05884671|DRUG|Placebo|All participants will receive placebo during one of the sessions.
223958665|NCT02478762|PROCEDURE|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
223958666|NCT02478762|PROCEDURE|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
223958667|NCT02829099|DRUG|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
223958668|NCT04283396|COMBINATION_PRODUCT|systemic treatment|Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin
224108450|NCT00542698|BEHAVIORAL|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
224108451|NCT00401583|DRUG|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
224108452|NCT00401583|DRUG|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
224108453|NCT02281058|DRUG|Abatacept|self-injected subcutaneous biologic medication
224108454|NCT03163030|DEVICE|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
224108455|NCT06070129|PROCEDURE|surgical pulmonary embolectomy|open heart surgery with cardiopulmonary bypass with opening of the pulmonary artery and its major branches and extraction of the embolus
223724170|NCT07132788|BEHAVIORAL|International Physical Activity Questionnaire Short Form (IPAQ-SF)|The IPAQ-SF is a small set of questions to obtain comparable estimates of physical activity.
223724171|NCT07133048|PROCEDURE|Levobupivakain 0.25 %|"The high tuberosity approach blocks for blockage of II. branch of trigeminal nerve.~Standard intraoral approach for inferior alveolar nerve block."
223724172|NCT07133048|PROCEDURE|NaCl 0.9 %|"The high tuberosity approach blocks for blockage of II. branch of trigeminal nerve.~Standard intraoral approach for inferior alveolar nerve block."
223724173|NCT07133022|PROCEDURE|Early Prone Positioning Protocol|A structured protocol in which non-intubated patients with Acute Respiratory Distress Syndrome (ARDS) are positioned prone for 2-4 hours per session, multiple times per day, totaling approximately 8 hours daily for 5 consecutive days. Initiation begins within 24 hours of ARDS diagnosis. Administered by trained Intensive Care Unit (ICU) nurses under medical supervision.
223724174|NCT07133022|OTHER|Standard ICU Care|Participants receive routine Intensive Care Unit (ICU) care for Acute Respiratory Distress Syndrome (ARDS) without the implementation of a structured early prone positioning protocol. Care is provided at the discretion of the treating physicians, following standard ICU management practices.
223724175|NCT06508034|PROCEDURE|Biospecimen Collection|Undergo stool and blood sample collection
223958669|NCT03792945|DRUG|local injection|In addition to the local injection, carpal tunnel brace will be given.
223958670|NCT03792945|DEVICE|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
223958671|NCT00073788|PROCEDURE|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
223958672|NCT05280522|OTHER|Volitional Contractions (VOL)|Participants are provided visual feedback showing the 20% MVIC force and instructed to produce the target force for 10 s then relax for 50 s. The timing is provided by the research personnel until 10 contractions are completed. Participants rate their pain during each contraction on a visual analog scale. The pain ratings are averaged across all 10 contractions and the average is used in the analysis.
224108456|NCT03065530|DRUG|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
224108457|NCT03065530|DRUG|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
224108458|NCT03065530|DRUG|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
224108459|NCT03065530|DRUG|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
223724176|NCT06508034|DIETARY_SUPPLEMENT|Live Freeze-Dried Lactic Acid Bacteria Probiotic|Given PO
223724177|NCT06508034|OTHER|Questionnaire Administration|Ancillary studies
223724178|NCT06931938|OTHER|Awake Prone Positioning|The clinical intervention in the Intervention Group is Awake Prone Positioning, a standard therapy in intensive care units worldwide in ARDS care. The intervention should not be started later than 24 hours after randomization. An earlier start, as soon as possible, after randomization is strongly recommended. In patients in the intervention group standard Awake Prone Positioning for at least 10 hours/day for a length of 72 hours should be applied. The reach the targeted 10 hours / day (per 24 hours), it is strongly recommended to use blocks of a longer time period (e.g. multiple 3-5 hours blocks) within the 24h period to reach the anticipated APP goal. It is recommended that the APP therapy within the targeted intervention for 10 hours/day (per 24 h period) is not interrupted for more than 2 hours till reaching the goal of 10 hours / day (per 24 h). It is further strongly recommended that one APP session should last at least 3 hours. (...) For more information please see the protol.
223724179|NCT06940271|PROCEDURE|Allografting|Undergo placement of MLG-Complete allograft
223724180|NCT06940271|OTHER|Survey Administration|Ancillary studies
223724181|NCT06301295|DIAGNOSTIC_TEST|Ultarthin bronchoscopy with intratumoral washing|Each subject suspected of early-stage, resectable lung cancer will undergo bronchooscopic procedure. Ultrathin bronchoscope is inserted and placed within tumor under radial EBUS, virtual bronchoscopic navigation, and fluoroscopy guidance. Subsequently, intratumoral washing is performed. After undergoing surgery for suspected early-stage lung cancer, the analysis of next generation sequencing is conducted on intratumoral washing, tissue from surgical specimen, and blood.
223958673|NCT05280522|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Participants are instructed to relax throughout the NMES contractions. The amplitude of the stimulation is increased until 20 percent MVIC force is achieved and the amplitude is recorded. The timing of the NMES is 12 s on: 50 s off for 10 contractions. The on-time included a 2s ramp up to the target amplitude. Participants rate their pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 contractions and the average was used in the analyses.
223958674|NCT05280522|DEVICE|Noxious Electrical Stimulation (NXES)|The intensity of the electrical stimulation is increased slowly over 30 s to the maximum tolerated level. Trains of NXES are delivered at the maximum tolerated intensity with a timing ratio of 12 s on: 50 s off for a total of 10 trains. The on-time included a 2s ramp up to the target amplitude. Participants rate the pain during each contraction on a visual analog scale. The pain ratings were averaged across all 10 trains of NXES and the average is used in the analyses.
223958675|NCT06027424|OTHER||observational study, no intervention
223958676|NCT05906056|DEVICE|Continuous Passive Motion (CPM)|CPM uses machines to move a joint passively i.e. without the patient exerting any effort. A motorized device moves the joint repetitively to a set of degrees and movement speed, determined by the caregiver either a medical doctor (physiatrist or orthopedic surgeon) or a physiotherapist. Its action preserves the joint's range of motion (ROM)
223958677|NCT05906056|OTHER|Conventional physiotherapy (PT)|Daily passive range of motion exercises (ROM) performed by the physiotherapist of the intensive care unit (ICU)
223958678|NCT05906056|DRUG|Zoledronic Acid Injection|one dose of intravenous zoledronic acid will be administered
223958679|NCT04605471|DRUG|Iopromide(Ultravist, BAY86-4877)|The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
223958680|NCT00946088|DRUG|Progesterone|Progesterone 400 mg per vagina qhs.
223958681|NCT00946088|DRUG|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
223958682|NCT01642030|DRUG|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
223958683|NCT01642030|DRUG|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
223958684|NCT01642030|DRUG|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
223958685|NCT00070161|DIETARY_SUPPLEMENT|EGb761|
223958686|NCT00070161|DRUG|donepezil hydrochloride|
223958687|NCT00070161|PROCEDURE|cognitive assessment|
223958688|NCT00197262|DRUG|GW685698X Aqueous Nasal Spray|
223958689|NCT05413954|OTHER|Control|Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
223958690|NCT05413954|OTHER|Test|Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
223958691|NCT05043298|DRUG|IBI 360 Injection|IBI 360 dose level of escalation IV Q3W Day 1
223958692|NCT05043298|DRUG|IBI 360 Injection Sintilimab|IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
223958693|NCT01388621|DRUG|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
223958694|NCT01388621|DRUG|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
223958695|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
223958696|NCT01388621|DRUG|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
223958697|NCT01388621|DRUG|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
223958698|NCT01388621|DRUG|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
223958699|NCT04883541|BEHAVIORAL|yoga and meditation|The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.
223958700|NCT04883541|BEHAVIORAL|Birth preparation training|The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
223958701|NCT01840696|DRUG|Regadenoson|Vasodilator stress testing
223958702|NCT00608387|BEHAVIORAL|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
223958703|NCT04538534|DRUG|Nicardipine|To compare the association of nicardipine and isosorbide dinitrate vs isosorbide dinitrate alone on the rate of occurrence of radial artery spasm
223958704|NCT03265262|DIAGNOSTIC_TEST|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
223958705|NCT03948815|OTHER|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
223958706|NCT02067455|OTHER|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
223958707|NCT03456089|DIAGNOSTIC_TEST|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
223958708|NCT03282877|BEHAVIORAL|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
223958709|NCT00586742|PROCEDURE|labral repair|labral repair with suture anchors
223958710|NCT00586742|PROCEDURE|biceps tenodesis|biceps tenodesis with suture anchor
223958711|NCT00586742|PROCEDURE|diagnostic arthroscopy|diagnostic arthroscopy
223958712|NCT06194318|BIOLOGICAL|Candidate vaccine, SCB-1019|The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
223958713|NCT06194318|BIOLOGICAL|placebo|placebo
224108460|NCT00168012|DRUG|Immunoglobulins Intravenous (Human)|
223958714|NCT06194318|BIOLOGICAL|candidate vaccine, SCB-1019T|The SCB-1019T vaccines contain RSV F protein subunits from the two dominant circulating strains, A and B strain. Antigens are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™
223958715|NCT06194318|BIOLOGICAL|AREXVY|AREXVY is a FDA-approved respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. Developed by GSK, it targets the prefusion F glycoprotein to protect against lower respiratory tract disease caused by RSV.
223958716|NCT04239911|BEHAVIORAL|mHealth app|The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
223958717|NCT04239911|BEHAVIORAL|Virtual training course|Virtual training course on heart failure for home health aides.
223958718|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (A) for oral administration
223958719|NCT01580306|DRUG|BI 201335|Relevant treatment dose capsule (B) for oral administration
224108461|NCT05041543|DRUG|NTX-101|Eye drops, topical administration
224108462|NCT05041543|DRUG|Placebo|Placebo as eye drops
224108463|NCT02629705|DIETARY_SUPPLEMENT|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
224108464|NCT02629705|DIETARY_SUPPLEMENT|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
224108465|NCT03455543|DEVICE|Active Provant Therapy System|Treatment with active Provant Therapy System
224108466|NCT03455543|DEVICE|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
223724182|NCT06952257|PROCEDURE|Administration of general anaesthesia|The anaesthesia will be administered intravenously
223724183|NCT06952257|PROCEDURE|Neuraxial Analgesia|Will be administered as an epidural
223724184|NCT03151837|DIETARY_SUPPLEMENT|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
223724185|NCT03151837|DIETARY_SUPPLEMENT|Placebo control|Starch
223724186|NCT02239978|BEHAVIORAL|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
223958720|NCT03823794|OTHER|No intervention|Observational analysis of usual care only
224108467|NCT02884115|DRUG|benzathine penicillin|
224108468|NCT02718677|DRUG|Refacto AF|Observational - Non-Interventional Study
224108469|NCT01917825|DRUG|MDT-15|
224108470|NCT02873221|DRUG|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
224108471|NCT02873221|DRUG|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
224108472|NCT02873221|DRUG|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
224108473|NCT05858502|BIOLOGICAL|Blood sample collection|Blood sample collection between inclusion and 3 months max 55 ml at each visit
224108474|NCT05858502|OTHER|Saliva sample collection|Saliva sample collection between inclusion and 3 months
224108475|NCT05858502|OTHER|Nasopharyngeal and nasal sample collection|Nasopharyngeal and nasal sample collection between inclusion and 3 months
223958721|NCT00065611|DRUG|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.~Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.~over 36 weeks."
223958722|NCT00545922|BEHAVIORAL|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
224108476|NCT05858502|OTHER|Exhaled Breath Condensate (EBC)|Exhaled Breath Condensate (EBC) between inclusion and 3 months
224108477|NCT00636623|OTHER|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
224108478|NCT00636623|OTHER|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
224108479|NCT05418361|DRUG|ACE inhibitor ,angiotensin receptor blockers|patients taking ACEI or ARBs with cardiovascular disease
223541954|NCT05815888|DIAGNOSTIC_TEST|Lung Ultrasound Score|"one hemithorax is consisted of 6 scanning zones. Each of them are evaluated via ultrasonography in terms of presence of vertical B lines (\<4 B lines: 1 point; \>3 B lines or thick B lines: 2 points; marked disturbance in pleural line: 3 points). Higher scores reflect worse outcomes such as atelectasis and consolidation, and totally 12 zones are evaluated.~Three different time points are defined for LUS:~T1: 5 minutes after orotracheal intubation T2: At the end of surgery, before extubation T3: 30 minutes after extubation, in postanesthesia care unit.~DeltaT= T2LUS-T1LUS~Blood gas analysis will be evaluated hourly throughout the surgery"
223724187|NCT00018837|BEHAVIORAL|Community Re-Entry Program: What is Schizophrenia|
223724188|NCT00602953|OTHER|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
223724189|NCT03158376|DRUG|Gabapentin|
223724190|NCT03158376|DRUG|Placebo|
223958723|NCT00545922|BEHAVIORAL|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
223724191|NCT05127005|PROCEDURE|Trapeziectomy|Surgical excision of trapezoideum
223724192|NCT05127005|PROCEDURE|Sham|Skin incision only
223724193|NCT01822431|RADIATION|metaiodobenzylguanidine scintigraphy|
223958724|NCT02092909|DRUG|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
223958725|NCT06475690|OTHER|Psychological interventions|Psychological interventions is used for intervention group
223958726|NCT05924971|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.
224108480|NCT01776099|DIETARY_SUPPLEMENT|Dietary supplement (4 arms, 2 active, 2 placebo)|
224108481|NCT03811951|DRUG|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
224108482|NCT05357183|DRUG|PEG-IFN|PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
224108483|NCT02491541|BIOLOGICAL|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
224108484|NCT02491541|BIOLOGICAL|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
224108485|NCT04020874|BEHAVIORAL|HuTT-2x|tackling and blocking training twice/week
224108486|NCT04020874|BEHAVIORAL|HuTT-4x|tackling and blocking training four times/week
223958727|NCT03151109|DIAGNOSTIC_TEST|CT Scan|CT scan at minimum 1 year post op
223958728|NCT05721898|DIAGNOSTIC_TEST|Cortical Bone Mechanics Technology|Cortical Bone Mechanics Technology (CBMT). CBMT testing will be performed bilaterally, and flexural rigidity (EI) will be calculated. If a participant has fractured a wrist or forearm bone in the prior 1-year, then only the arm that was not fractured will be tested. During testing, participants will lie supine in the CBMT instrument.
223958729|NCT02376062|OTHER|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~* On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~* Weekly case conferences~* Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
223958730|NCT01767025|DRUG|Oxytocin|
223958731|NCT01767025|DRUG|Sea water|
223958732|NCT04782570|DEVICE|Verum TMS|Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.
223958733|NCT04782570|DEVICE|Sham TMS|Sham stimulation with same protocol, but without magnetic stimulation
223958734|NCT04463485|PROCEDURE|Delayed Clamping|Umbilical cord clamping was delayed 60 seconds at the end of second stage of labor.
224108487|NCT06331949|OTHER|video assisted training|Ebelik bakımının yanı sıra NST konusunda eğitim içerikleri, eğitim videoları ve broşür destekli eğitimler verilecek. NST cihazı takılacak ve standart olarak işlem başladıktan 5 dakika sonra NST kaydı sırasında cihazdan gelen fetal kalp sesinin şiddeti artırılarak fetal kalp sesinin devam etmesi sağlanacaktır. Transfer edilecek hamile kadın yaklaşık 2 dakika kadar dinlenecektir.
223958735|NCT05055141|OTHER|Care to Share poster|The Care to Share poster enabled patients to share written information about who they are as people with their hospital caregivers.
223958736|NCT05072795|BEHAVIORAL|Trier Social Stress Task (TSST)|The TSST is a standardized psychological stress challenge which provokes a stress response in a laboratory setting. During the task, saliva samples will be collected for hormone testing along with physiological and subjective measures.
223958737|NCT06423976|OTHER|Sequencing study|Sequencing of tumour samples for microbiome analysis and molecular charcterisation.
223958738|NCT00138645|BEHAVIORAL|MicroDiet|MicroDiet
223958739|NCT00138645|BEHAVIORAL|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
223958740|NCT01263275|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
223958741|NCT02771184|DEVICE|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
223958742|NCT00598156|DRUG|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
223958743|NCT00598156|DRUG|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
223958744|NCT02853188|OTHER|venous thromboembolism|
223958745|NCT00098514|DRUG|talotrexin ammonium|
223958746|NCT00212888|BIOLOGICAL|Remune and ALVAC|"* Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~* Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~* Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
223958747|NCT02683317|DIETARY_SUPPLEMENT|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
223958748|NCT02683317|DIETARY_SUPPLEMENT|sunflower oil|Sunflower similar to the excipient used in experimental group
224108488|NCT00852930|PROCEDURE|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
224108489|NCT00852930|PROCEDURE|laser alone|The intervention is therapist administered laser
224108490|NCT00852930|PROCEDURE|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
224108491|NCT03827148|OTHER|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
224108492|NCT00479466|DRUG|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
223958749|NCT02457078|DIETARY_SUPPLEMENT|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
223958750|NCT02457078|DIETARY_SUPPLEMENT|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
223958751|NCT00957918|DRUG|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
223958752|NCT00957918|OTHER|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
223958753|NCT01901302|DRUG|CB-5945|
223958754|NCT01901302|DRUG|Placebo|
223958755|NCT01124916|PROCEDURE|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
224108493|NCT00479466|DRUG|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
224108494|NCT00479466|DRUG|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
224108495|NCT00479466|DRUG|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
224108496|NCT04170140|OTHER|No intervention|Questionnaire
224108497|NCT03838848|DRUG|KN046|3mg/kg, Q2W, intravenous injection (IV)
223958756|NCT01124916|PROCEDURE|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
223958757|NCT00834483|DEVICE|Knotless suture for wound closure|Angiotech Quill SRS
223958758|NCT00834483|DEVICE|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
223958759|NCT00887471|PROCEDURE|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T\&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
223958760|NCT03322475|DEVICE|PiQo4 laser system|The PiQo4 laser system
223958761|NCT02787135|BEHAVIORAL|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
223958762|NCT00995618|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
224108498|NCT03838848|DRUG|KN046|5mg/kg, Q2W, intravenous injection (IV)
224108499|NCT03838848|DRUG|KN046|5mg/kg, Q3W, intravenous injection (IV)
224108500|NCT03838848|DRUG|Carboplatin|AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
223958763|NCT00995618|DRUG|Febuxostat|Febuxostat Tablets, 40 mg, QD
223958764|NCT00995618|DRUG|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
223958765|NCT06387797|BEHAVIORAL|Cooking Matters for Adults (CMA+)|Six cooking classes + enhanced elements, such as diabetes-specific nutrition and cooking information, and online educational information as well as short assignments and activities regarding sleep, stress, physical activity, and sedentary behaviors. This arm will have the opportunity to use a continuous glucose monitor (CGM) for 10 days immediately following the baseline assessment. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up. Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
224108501|NCT03838848|DRUG|Pemetrexed|500 mg/m2, Q3W, intravenous injection (IV)
224108502|NCT03838848|DRUG|Ningetinib|Oral, QD
224108503|NCT06244966|DIAGNOSTIC_TEST|HIV diagnostic testing|Finger-prick capillary blood will be tested alongside venous blood
224108504|NCT01325493|DRUG|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
224108505|NCT01325493|DRUG|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
224108506|NCT00124423|PROCEDURE|Megavoltage CT scan|
223958766|NCT06387797|BEHAVIORAL|Cooking Matters for Adults (CMA)|Participants will attend cooking and educational sessions once per week for 6 weeks. In addition, they will receive recipes and produce boxes with instructions to prepare the recipe at some point prior to their next class. They will also be invited to the online Google Classroom site where all intervention materials will be housed for their convenience. Each week, participants will collect their own fecal samples in the privacy of their own homes and will return them at their next cooking class. They will also complete a final fecal sample before the follow-up (kits provided at the final cooking class, for a total of 6 fecal samples per participant). Finally, 6-weeks after completion of the cooking classes, researchers will follow up via phone, email, or Zoom (participants will provide their preferred method of contact) to complete follow-up assessments of current lifestyle practices and barriers to fruit and vegetable consumption.
223958767|NCT02397226|PROCEDURE|Radiofrequency ablation|
223958768|NCT02397226|PROCEDURE|High ligation/stripping|
223958769|NCT02397226|DEVICE|Radiofrequency ablation catheter|
223958770|NCT02397226|PROCEDURE|Tumescent anesthesia|
223958771|NCT02397226|PROCEDURE|General anesthesia|
223958772|NCT02397226|DEVICE|Vein stripping catheter|
223958773|NCT03925519|OTHER|Supervised aerobic exercise|
223958774|NCT06435221|DRUG|Cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
223958775|NCT06444113|DRUG|Ofatunumab|No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.
223958776|NCT03476525|DRUG|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
223958777|NCT01958346|OTHER|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
223958778|NCT01958346|OTHER|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
223958779|NCT01958346|DEVICE|Fiberoptic Intubation|
223958780|NCT00072670|DRUG|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
223958781|NCT05790317|PROCEDURE|Surgical Procedure with ERAS Protocol|It covers the period before, during and after the surgery.
223958782|NCT01442766|DRUG|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
223958783|NCT01442766|DRUG|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
223958784|NCT01259219|DRUG|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
223958785|NCT02845609|DRUG|Sialic Acid-Extended Release|Oral drug of Sialic acid
223958786|NCT03014726|COMBINATION_PRODUCT|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
223958787|NCT03958305|PROCEDURE|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
223958788|NCT01068977|DRUG|bevacizumab|Repeating intravenous dose
223958789|NCT01068977|DRUG|MetMAb|Repeating escalating intravenous dose
223958790|NCT01068977|DRUG|MetMAb|Repeating intravenous dose
224108507|NCT02610283|DRUG|QPI-1002|IV injection
224108508|NCT02610283|DRUG|Placebo|isotonic saline
223958791|NCT02627794|DEVICE|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
223958792|NCT02627794|DEVICE|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
223958793|NCT05584306|DRUG|610 30mg group|610 30mg subcutaneous (SC) Q4W，8 times
223958794|NCT05584306|DRUG|610 100mg group|610 100mg subcutaneous (SC) Q4W，8 times
223958795|NCT05584306|DRUG|610 300mg group|610 300mg subcutaneous (SC) Q4W，8 times
223958796|NCT05584306|OTHER|Placebo 30mg group|placebo subcutaneous (SC) Q4W，8 times
223958797|NCT05584306|OTHER|Placebo 100mg group|placebo subcutaneous (SC) Q4W，8 times
223958798|NCT05584306|OTHER|Placebo 300mg group|placebo subcutaneous (SC) Q4W，8 times
223958799|NCT03636958|DRUG|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
223958800|NCT03636958|DRUG|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
223958801|NCT06285578|DIETARY_SUPPLEMENT|Probiotics supplementation|Probiotics, Lactiplantibacillus plantarum TWK10, are packaged in powder form. Each participant consume one packet every day on a fasting status for 8 weeks.
223958802|NCT06285578|BEHAVIORAL|HIIT training|HIIT training is conduct at the intensity of 85-90% VO2max for 2 minutes with 1-minute inactive resting interval, repeating for 7 times. 3 sessions per week for 8 weeks.
223958803|NCT06285578|DIETARY_SUPPLEMENT|Placebo supplementation|Yeast powder replaces probiotics in each packet. Each participant consume one packet every day on a fasting status for 8 weeks.
223958804|NCT01026441|DEVICE|Vela100 (Aesthetic)|6 treatments once a week
223958805|NCT03218085|DRUG|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
223958806|NCT03218085|DRUG|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
223958807|NCT03073902|DIAGNOSTIC_TEST|Liquid biopsy|Liquid biopsy
223958808|NCT03610984|OTHER|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
223958809|NCT00378456|DRUG|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
223958810|NCT00378456|DRUG|Folinic acid|
224108509|NCT05602467|DEVICE|Transcranial Pulse Stimulation (TPS)|"A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second)."
224108510|NCT05602467|OTHER|Treatment as usual (TAU)|Treatment-as-usual (TAU) in the Hong Kong outpatient clinic without TPS intervention was given. They would receive the standard care for mild NCD including counselling, lifestyle modification, cognitive training and antidementia medications occasionally depending on the case doctor's judgement.
223958811|NCT00378456|DRUG|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
223958812|NCT00378456|DRUG|Placebo|
224108511|NCT01094899|RADIATION|Radiography|Radiography, microscanner, osteodensitometry
224108512|NCT01094899|OTHER|Urine and Blood sampling|mainly dosage of bones metabolism
224108513|NCT01094899|OTHER|Echography|body bones echography
223958813|NCT05202444|PROCEDURE|Osteotomy using piezoelectrical device|"osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla."
223958814|NCT03000725|BEHAVIORAL|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
223958815|NCT03000725|BEHAVIORAL|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
223958816|NCT05590026|DRUG|Pectointercostal and ESP block|Both Pectointercostal at between 4th and 5th costa and ESP block will apply at thoracal 6 level to the patient.
223958817|NCT01448928|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
223958818|NCT02296307|OTHER|Blood test: CA-125 biomarker|"* CA-125 biomarker blood test at visit 1, day 1.~* CA-125 biomarker blood test at visit 2, week 6."
223958819|NCT02296307|OTHER|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
223958820|NCT02296307|OTHER|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
223958821|NCT01645241|DRUG|gonadotropins plus GnRH antagonists|
223958822|NCT01645241|DRUG|ganirelix|
223958823|NCT00901459|DEVICE|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
223958824|NCT00901459|DEVICE|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
223958825|NCT00901459|DEVICE|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
223958826|NCT04478409|BIOLOGICAL|one additional blood sample during a planned blood test|The study does not change the usual course of care. Only an additional blood sample (4 ml for children under 12 and 10 ml for children 12 and over and adults) during a planned blood test is specific to research (no risk added). The benefit / risk balance therefore remains unchanged with regard to the usual care of patients.
223958827|NCT04765046|DEVICE|Bispectral (BIS™) Complete Monitoring System|The BIS™ Complete Monitoring System is a user-configurable patient monitoring system designed to monitor the hypnotic state of the brain based on the acquisition and processing of EEG signals. The BIS technology converts raw EEG data acquired from the frontal cortex into a single number to measure the level of consciousness, called the BIS index. A bilateral sensor is to be placed on the patient's forehead to collect the EEG signals and transmit them back to the system.
224108514|NCT03530163|DEVICE|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
224108515|NCT03530163|DEVICE|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
224108516|NCT01458769|DRUG|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
224108517|NCT01458769|DRUG|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
224108518|NCT01458769|DRUG|C-10297|C-10297 200 mg, oral, single dose
224108519|NCT01458769|DRUG|C-10299|C-10299 200 mg, oral, single dose
223958828|NCT04970459|BIOLOGICAL|collection of samples of blood and urine|extra samples of blood and urine will be collected and stored for research utilisation
223958829|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
223958830|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
223958831|NCT00668057|DRUG|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
223958832|NCT00668057|DRUG|Placebo|5 mg matching placebo
223958833|NCT00668057|DRUG|Placebo|10 mg matching placebo
223958834|NCT00668057|DRUG|Placebo|20 mg matching placebo
223958835|NCT05334225|OTHER|Training Program|An in-person urethral catheterization training program that utilizes training videos (demonstrating procedures, providing examples of ordinary and difficult cases, utilizing animation techniques as well)
224108520|NCT01458769|DRUG|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
223958836|NCT05343936|OTHER|Active surveillance|"The active surveillance protocol involves a TRUS prostate biopsy at eligibility, at 12 months and then every two years. MRI with or without biopsy at eligibility and then every two years. Clinical evaluation with digital rectal examination and PSA every 6 months. Every year a quality of life and anxiety evaluation are planned.~A new prostate biopsy is indicated if biochemical progression by PSA or changes in multiparametric MRI. Triggers for definitive intervention are biopsy pathological reclassification with Gleason score greater than 6, clinical progression or patient's request."
223958837|NCT05780957|OTHER|MCED|multi-cancer early detection (MCED) test
223958838|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|"Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the EMMA/ALICE test will be provided to participants and their gynecologists. Depending on the test results, there are 3 different possibilities:~1. Normal result~2. Ultralow or Dysbiotic result~3. Abnormal result (pathogens) All probiotics and antibiotics that will be used in the study are already authorized by the local health authorities and will be prescribed under their technical data sheet/brochure conditions following the medical indications."
223958839|NCT04686357|DIAGNOSTIC_TEST|EMMA/ALICE|Before randomization, an endometrial biopsy (EB) sample will be collected from all participants between day 15 and 25 of a natural cycle or after around 120 hours of progesterone (P) impregnation during a standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
223958840|NCT01579955|DRUG|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
223958841|NCT05224388|DRUG|Enoxaparin|Use of enoxaparin in either prophylactic dose regimen or therapeutic dose regimen
223958842|NCT05224388|DRUG|Heparin|Use of heparin in either prophylactic dose regimen or therapeutic dose regimen
224108521|NCT01458769|DRUG|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
224108522|NCT01458769|DRUG|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
224108523|NCT01458769|DRUG|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
224108524|NCT01923610|BIOLOGICAL|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-\~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
224108525|NCT02723435|DRUG|Midostaurin|Given PO
224108526|NCT02270177|OTHER|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
224108527|NCT02255838|DEVICE|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
224108528|NCT02255838|DEVICE|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
224108529|NCT01367132|PROCEDURE|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
224108530|NCT03792958|DRUG|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
224108531|NCT04902248|DEVICE|The OTSC® System Set|The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion
224108532|NCT04902248|PROCEDURE|angiographic embolization|Transcatheter selective embolization to bleeding arteries
224108533|NCT04076566|DEVICE|alfapump system|active implantable device for treatment of malignant ascites
223958843|NCT00233545|DRUG|miltefosine|
223958844|NCT00233545|DRUG|antimony|
223958845|NCT03379597|DRUG|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
223958846|NCT03379597|DIETARY_SUPPLEMENT|Dietary fiber|dietary fiber compound powder 30g bid
223958847|NCT01049815|DRUG|sevelamer hydrochloride|800-3200 mg with each meal
223958848|NCT01049815|DRUG|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
224108534|NCT03803215|DRUG|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
224108535|NCT01784510|PROCEDURE|distance of dissection of gastrocolic ligament from pylorus|
223958849|NCT01597856|BEHAVIORAL|SBIRT|"SBIRT Therapy overview-~1. Therapist explains purpose of the therapy.~2. Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~3. Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~4. Discuss treatment needs, administer screening, provide feedback."
223958850|NCT00175253|DRUG|alemtuzumab|
223724194|NCT03731611|PROCEDURE|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
223724195|NCT02498314|OTHER|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
224108536|NCT05763940|DIETARY_SUPPLEMENT|OmegaBoost|"An ultra-pure omega-3 fish oil supplement with no fishy aftertaste and no fish burps.~10x more omega-3 from fish oil than the leading omega-3 gummies. Gel bites have better absorption than ordinary, hard-to-swallow fish oil pills."
224108537|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (soft gel)|A commercially-available omega-3 soft gel formula
224108538|NCT05763940|DIETARY_SUPPLEMENT|Nature Made (gummy)|A commercially-available omega-3 formula in gummy form
223958851|NCT00175253|PROCEDURE|islet transplant|
223724196|NCT02498314|OTHER|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
223724197|NCT02498314|OTHER|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
223958852|NCT02618876|DRUG|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
223958853|NCT02618876|DRUG|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
223958854|NCT01979211|DRUG|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
223958855|NCT01979211|RADIATION|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
223958856|NCT05978089|DRUG|Yangxinshi tablet|The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
223958857|NCT05978089|DRUG|Yangxinshi tablet simulants|The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
223724198|NCT01004627|PROCEDURE|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
223724199|NCT02407821|DRUG|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
223958858|NCT02531061|DEVICE|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
224108539|NCT02625142|OTHER|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
224108540|NCT00066781|DRUG|gemcitabine hydrochloride|Given IV
224108541|NCT00066781|DRUG|irinotecan hydrochloride|Given IV
224108542|NCT01823653|DEVICE|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
224108543|NCT06289725|DRUG|antiviral treatment|The patient was treated with antiviral drugs according to the protocol of the Ministry of Health of Vietnam 2019
223724200|NCT02407821|DRUG|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
223958859|NCT03944889|DRUG|Capsaicin|Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
223958860|NCT03944889|DEVICE|Delsys Trigno Galileo System|This device is a wireless surface EMG device.
223958861|NCT03944889|DEVICE|Cadwell Sierra Wave|Intramuscular EMG recording machinery
223958862|NCT03944889|DEVICE|Sonosite Ultrasound Machine|Ultrasound System
223958863|NCT03944889|DEVICE|Goniometer|A device to measure angular position
223958864|NCT00579020|DRUG|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
223958865|NCT00579020|DRUG|Moxifloxacin ophthalmic solution 0.5%|
223958866|NCT00579020|DRUG|Dexamethasone phosphate solution, 0.1%|
223958867|NCT00509314|BEHAVIORAL|melanocyte self-assembly and functional analysis|
224108544|NCT00994565|BEHAVIORAL|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
223958868|NCT03956771|BEHAVIORAL|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
223958869|NCT03956771|BEHAVIORAL|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
223724201|NCT05984732|BEHAVIORAL|Reminiscence with digital storytelling|The older and young adult participants will be randomly assigned into the intervention (reminiscence) or control (social wellness) groups and then be randomly matched as dyads within each group. Older adults in the intervention group will receive 10 sessions of life-review with the trained young adult volunteers (1-1.5 hours each week for 10 weeks). During weeks 1-6, a life history interview will be carried out with different themes in each week: major turning points in life (W1), family history (W2), life/career accomplishments (W3), history of loves and hates (W4), stress experiences (W5), and meaning and purpose of life (W6). During weeks 7-10, the dyads will develop the DST together using tablets already owned by the UTA School of Social Work. The contents of sessions 7-10 will be structured as: outline/script, plan and storyboard (W7), film and record (W8), evaluate, integrate and finalize (W9), and publish/share (W10).
223958870|NCT00753896|DRUG|exenatide|subcutaneous injection, 2.0mcg, once weekly
223958871|NCT04927949|DRUG|cangrelor perfusion during PCI|Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
223958872|NCT04927949|PROCEDURE|standard PCI|primary PCI without cangrelor
223958873|NCT03277391|PROCEDURE|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
223958874|NCT03277391|DEVICE|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
223958875|NCT04347889|DRUG|Hydroxychloroquine|Oral loading dose followed by once weekly dosing
223958876|NCT04347889|OTHER|Vitamin C|Once daily vitamin C 1 gm
223958877|NCT03256305|DEVICE|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
223958878|NCT03256305|DEVICE|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
223958879|NCT02741297|DEVICE|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
223958880|NCT02350426|OTHER|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
223958881|NCT02350426|OTHER|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
223958882|NCT02350426|OTHER|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
223958883|NCT01212809|DEVICE|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
224108545|NCT04609384|DEVICE|Alcohol rub timer device|A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
224108546|NCT00231140|DRUG|Thalidomide (drug)|
224108547|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
224108548|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
224108549|NCT01565746|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
224108550|NCT06408831|BEHAVIORAL|Classroom Teaching University Students Intervention Group|Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
223958884|NCT01212809|DEVICE|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
223541955|NCT06927661|BEHAVIORAL|Consumption of vegetables|ENSAND 2.0 is designed to address challenges of low consumption of vegetables in both variety and quantity by working with smallholder farmers to increase production and promoting healthier diets through greater vegetable consumption. The project will build the capacity of smallholder farmers in vegetable production through collaborating with lead farmers to establish demonstration plots that showcase advanced agricultural techniques and technologies. These plots will serve as training hubs for other farmers in vegetable production, postharvest handling, as well as business and market planning. ENSAND aims to increase consumption among neighbors of the smallholder farmers by asking the farmers to recruit at least one neighbor family to whom they will regularly sell vegetables.
223958885|NCT00423215|DRUG|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
223958886|NCT00416585|DRUG|isotretinoin (Roaccutane)|
223958887|NCT05383586|OTHER|Creative Music Therapy|Creative Music Therapy is provided during kangaroo-care. It is an individualized, family- centered approach offering infant-directed humming and singing accompanied with the monochord.
223958888|NCT01345708|DRUG|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
223958889|NCT00963105|DRUG|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~* Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~* Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
223958890|NCT02885610|BIOLOGICAL|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
223958891|NCT02885610|BIOLOGICAL|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
223958892|NCT02885610|BIOLOGICAL|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
224108551|NCT06002581|DEVICE|rTMS real stimulation stage1|In the first stage, the early treatment group use low-frequency rTMS real stimulation,
224108552|NCT06002581|DEVICE|rTMS shame stimulation stage1|In the first stage, the control group (delayed treatment group) all use sham stimulation.
224108553|NCT06002581|DEVICE|rTMS real stimulation stage 2|In the second stage, both the early treatment group and the control group (delayed treatment group) will be treated with true stimulation low-frequency rTMS.
224108554|NCT03186469|BEHAVIORAL|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
224108555|NCT03186469|BEHAVIORAL|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
224108556|NCT00002208|DRUG|Indinavir sulfate|
224108557|NCT00002208|DRUG|Lamivudine|
224108558|NCT00002208|DRUG|Stavudine|
224108559|NCT00002208|DRUG|Zidovudine|
224108560|NCT00247325|DRUG|Iodixanol(Drug)|
224108561|NCT00846612|DRUG|Doxil|1 cycle: 3 weeks; 30 mg/m\^2, IV, every cycle
224108562|NCT00846612|DRUG|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
224108563|NCT00906789|BEHAVIORAL|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
224108564|NCT03701789|DRUG|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
224108565|NCT04928365|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 therapy
223958893|NCT02885610|BIOLOGICAL|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
223958894|NCT04680559|BEHAVIORAL|MCBI|The topics covered in the sessions are: Week 1: Introduction to mindfulness and attention to breathing. Week 2. Open awareness of bodily sensations. Week 3: Work with thoughts, introductory theory and practice in attention to sounds. Week 4: Working with thoughts, advanced theory and practice in mental landscape. Week 5: Introductory theory and practice in labeling emotions. Session 6: Advanced theory in working with emotions and practice in difficult emotions. Week 7: Introductory theory on self-compassion and compassion. Practice in self-compassion. Week 8: Practice in compassion and active compassion (acts of kindness and shared humanity).
223958895|NCT04680559|BEHAVIORAL|Active Comparator|Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
223958896|NCT05031052|DEVICE|End-ischemic normothermic oxygenated machine perfusion|Application of end-ischemic normothermic oxygenated machine perfusion at physiological temperatures for 4 hours.
223958897|NCT05031052|PROCEDURE|Static cold storage|Immediate implantation of kidney allograft after conventional and static preservation on ice
223958898|NCT00171652|DRUG|Diclofenac sodium gel 1%|
223958899|NCT05540951|DRUG|VIC|VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
223958900|NCT05540951|DRUG|Bevacizumab Plus Chemotherapy|Bevacizumab Plus Doublet or Triplet Chemotherapy
223958901|NCT05771272|DIAGNOSTIC_TEST|Sit and Reach Test|To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.
223958902|NCT05771272|DIAGNOSTIC_TEST|Weight Bearing Lunge Test|To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
224108566|NCT02562196|DEVICE|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
224108567|NCT02334267|DEVICE|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
223958903|NCT02391766|BEHAVIORAL|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
223958904|NCT02391766|BEHAVIORAL|usual care|
223958905|NCT03708744|DRUG|A: M207 3.8mg, 30 min, upper arm|A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
223958906|NCT03708744|DRUG|B: M207 3.8 mg, 30 min, thigh|B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
224108568|NCT02334267|DEVICE|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
224108569|NCT05429684|DRUG|Trastuzumab|Trastuzumab (6mg/Kg, iv.drip, d1, q3w)
224108570|NCT05429684|DRUG|Pertuzumab|Patuzumab (420mg iv.drip, d1,q3w)
224108571|NCT05429684|DRUG|Nab paclitaxel|nab-paclitaxel (200mg iv.drip, d1,d8, q3w)
224108572|NCT05429684|DRUG|Pyrotinib|Pyroltinib (400mg po qd)
224108573|NCT05429684|DRUG|Capecitabine|Capecitabine (1250mg/m2, po, bid, d1-d14, q3w).
224108574|NCT05429684|DRUG|T-DM1|T-DM1(3.6mg/Kg, iv.drip, d1, q3w)
223958907|NCT03708744|DRUG|C: M207 3.8 mg, 1 hr, upper arm|C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
223958908|NCT03708744|DRUG|D:zolmitriptan nasal spray|D: 2.5 mg/0.1 mL intranasal zolmitriptan
223958909|NCT05993247|COMBINATION_PRODUCT|Probiotics capsule|Subjects will take a probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) three times a day for 8 weeks in combination with NSAIDs
223958910|NCT05993247|COMBINATION_PRODUCT|Placebo capsule|Subjects will take a placebo capsule identical in shape and size to probiotics capsule three times a day for 8 weeks in combination with NSAIDs
224108575|NCT05429684|DRUG|Everolimus|Everolimus (4mg, po, qd)
223958911|NCT03687554|DRUG|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
224108576|NCT05429684|DRUG|CDK4/6 inhibitor|Palbociclib (125mg, po, qd)
224108577|NCT05429684|DRUG|AI|Letrozole (2.5mg, qd).
224108578|NCT05429684|DRUG|Anti-PD-1 monoclonal antibody|Cindilimab (200mg, iv.drip, d1, q3w)
224108579|NCT00244205|PROCEDURE|Identifying genes methylated in urine|
224108580|NCT01420640|BEHAVIORAL|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
224108581|NCT01420640|BEHAVIORAL|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
224108582|NCT01420640|BEHAVIORAL|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
224108583|NCT01420640|BEHAVIORAL|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
223958912|NCT06211751|DRUG|TQB3909 tablets|TQB3909 is a protein inhibitor.
223958913|NCT06211751|DRUG|TQB3702 tablets|TQB3702 is a kinase inhibitor.
223958914|NCT06179719|DRUG|Propofol|Anesthesia will be induced intravenously using the hypnotic drug propofol. The drug is used regularly in everyday clinical practice to carry out general anesthesia, and the intended concentrations are within the usual clinical dosage range. Propofol will be applied via target-controlled infusion (TCI) with a perfusor using TCI set to effect mode as described by Schnider (Schnider et al., 2016). Starting at low concentrations, the effect site concentration will be increased stepwise to achieve the target level of sedation as measured by the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale. We aim for three different levels of sedation: low (MOAA/S=5-4), mid (MOAA/S=3-2) and high (MOAA/S=1).
223958915|NCT06179719|BEHAVIORAL|visual flickering stimulation at the alpha frequency|Participants will receive visual stimulation as a flickering light during the different sedation levels, including wakefulness pre- and post-anesthesia. Stimulation will be done with eyes closed in all conditions.
223958916|NCT01429168|DRUG|Etoricoxib|One 60-mg tablet orally daily
224108584|NCT01420640|BEHAVIORAL|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
224108585|NCT05890638|DRUG|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
224108586|NCT05890638|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
224108587|NCT02361749|DRUG|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
224108588|NCT02361749|PROCEDURE|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
224108589|NCT05634590|DRUG|Fruquintinib|4mg, orally, once daily, 3 weeks on/ 1 week off
224108590|NCT05634590|DRUG|FOLFIRI|Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
224108591|NCT05634590|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w
224108592|NCT01401088|DEVICE|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
224108593|NCT01411293|OTHER|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
224108594|NCT01411293|OTHER|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
224108595|NCT05646641|OTHER|Strength exercise|The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
223958917|NCT01429168|DRUG|Placebo for etoricoxib|One 60-mg tablet orally daily
223958918|NCT00183209|BEHAVIORAL|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
223958919|NCT01891006|DEVICE|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
223958920|NCT01891006|OTHER|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
223958921|NCT01662804|DRUG|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
223958922|NCT03507452|DRUG|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
223958923|NCT03507452|DRUG|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
223958924|NCT04930263|BEHAVIORAL|Aerobic exercise|The intervention was 24 weeks walking exercise program. Participants exercised frequency at 5 sessions a week for 30 minutes per section with moderate-intensity and wearable device assisted. Each session consisted of a 5 minutes warm-up, moderate-intensity walking exercises and 5 minutes cool-down. The program included individualized education, telephone and social media counselling, and booklet guidance
223958925|NCT04930263|BEHAVIORAL|control group|control group received routine care and a manual on healthy living
223958926|NCT03529942|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
223958927|NCT05285592|OTHER|Fecal Transplantation|Fecal Transplantation
223958928|NCT05285592|DRUG|Standard Medical Treatment|Standard Medical Treatment
223958929|NCT01628939|OTHER|MRI of the lumbar spine|standard protocol, approximately 30 minutes
223958930|NCT01628939|OTHER|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
223958931|NCT03684499|OTHER|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.
223958932|NCT03684499|OTHER|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be \<15 mg/dl.(Bandyopadhyay et al, 2017)
223958933|NCT04099186|PROCEDURE|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
223958934|NCT02011789|DIETARY_SUPPLEMENT|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
223958935|NCT02011789|DIETARY_SUPPLEMENT|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
223958936|NCT04364035|BIOLOGICAL|ChAdOx1.HTI|ChAdOx1.HTI at week 0 and week 12; Vaccine delivered as one 0. 5 mL IM injection
223958937|NCT04364035|BIOLOGICAL|MVA.HTI|MVA.HTI at week 24 and week 36; Vaccine delivered as one 0. 5 mL IM injection
223958938|NCT04364035|DRUG|GS-9620|GS-9620 at week 26,28,30,32,34,38,40,42,44 and 46 Unit-dose tablet, delivered as two 3-mg tablets
223958939|NCT04364035|BIOLOGICAL|Placebo|Saline placebo delivered as one 0. 5 mL IM injection
223958940|NCT04364035|DRUG|Placebo Oral Tablet|Unit-dose placebo tablet delivered as two 3-mg placebo tablets
223958941|NCT02619045|OTHER|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~* telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~* specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~* actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
223958942|NCT00538499|DRUG|Fentanyl citrate|
223958943|NCT00538499|DRUG|Bupivacaine hydrocloride|
223958944|NCT00538499|PROCEDURE|videothoracoscopy|
223958945|NCT02648659|DRUG|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
223958946|NCT02648659|DRUG|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
223958947|NCT02648659|DRUG|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
223958948|NCT02648659|DRUG|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
223958949|NCT03073122|DIAGNOSTIC_TEST|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
223958950|NCT00001280|DRUG|itraconazole|
223958951|NCT01323244|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
223958952|NCT05321576|PROCEDURE|Erector spinae plane block (ESPB) technique without opioid use|Local anesthetic injection to the erector spinae muscle plane at T5 level on the operation side.
223958953|NCT00297089|DRUG|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
223958954|NCT00297089|DRUG|pemetrexed|Standard pemetrexed every 21 days
223958955|NCT00297089|DRUG|placebo|Placebo daily for 14 days every 21 days
223958956|NCT00349713|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
223958957|NCT00349713|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
223958958|NCT03652792|DRUG|Azilsartan (Zhaoke)|Azilsartan 20mg tablets from Zhaoke
223958959|NCT03652792|DRUG|Azilsartan (Takeda)|Azilva 20mg tablets from Takeda
223958960|NCT04543032|OTHER|sensorimotor training|Sensorimotor exercises progressed from stable surfaces to unstable surfaces, training gait in a line (tandem walk or walking straight) followed by gait including change in directions, gait without obstacles to gait with obstacles, change in the support base (feet apart and then together), physical exercises with eyes opened and closed, always respecting the functional capacity of each patient and progressively increasing the difficulty of each exercise. To help the training, cones, balance board, bars, mats and a mini-trampoline will be used. According to the patient progress, the exercises will be combined, generating circuits
223958961|NCT03573375|BEHAVIORAL|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
223958962|NCT00470990|DRUG|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
223958963|NCT00324571|DRUG|Sevelamer hydrochloride|
223958964|NCT00324571|DRUG|Calcium-based phosphate binder|
223958965|NCT05607147|DEVICE|Testing for SARS CoV2 Antigen and Antibody|Antigen testing: Rapid Antigen testing (Point-of-care) Antibody testing: ELISA testing of microsampling 'finger-prick' specimen DHCW Survey for adoption of risk mitigation practices and for perceptions of safety
223958966|NCT00082576|DRUG|Azithromycin/Chloroquine|
223958967|NCT00082576|DRUG|Mefloquine|
223958968|NCT00003778|DRUG|dolastatin 10|
223958969|NCT04566744|OTHER|fRMI|The measurements performed will be the participant's brain activity, as well as behavioral measurements associated with the tasks performed (response time, correctness of the response). Brain activity measurements will be performed on the Siemens 3T system of the MRI department of CERMEP. The subject will perform the task under study while the level of brain activity is recorded. The functional examination will be subdivided into several parts according to its total length in order to spare the subject. The total duration of MRI acquisitions will be approximately 1 hour regardless of the axis.
223958970|NCT01589380|DRUG|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP \< 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
223958971|NCT01589380|DRUG|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
223958972|NCT02504034|PROCEDURE|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
223958973|NCT02504034|DEVICE|6-French sheath|
223958974|NCT02504034|DEVICE|22-gauge chiba needle|
223958975|NCT02504034|DEVICE|260-cm-long stiff shaft wire|
223958976|NCT02504034|DEVICE|Balloon catheter|
223958977|NCT02504034|DEVICE|Bare metal stent|
223958978|NCT02504034|DEVICE|Covered stent|
223958979|NCT01320514|DRUG|Fibrin Sealant (Artiss)|
223958980|NCT01596634|OTHER|questionnaire administration|Ancillary studies
223958981|NCT01596634|PROCEDURE|quality-of-life assessment|Ancillary studies
223958982|NCT01596634|OTHER|laboratory biomarker analysis|Correlative studies
223958983|NCT01596634|DIETARY_SUPPLEMENT|bovine lactoferrin|Given PO
223958984|NCT02033343|RADIATION|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
223958985|NCT02418286|OTHER|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
223958986|NCT06058130|DRUG|Anticoagulant Oral|Anticoagulation alone
223958987|NCT06058130|DRUG|Anticoagulation combined with antiplatelet therapy|Anticoagulation combined with antiplatelet therapy
223958988|NCT02499497|DRUG|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
223958989|NCT02499497|DRUG|Placebo|The participants will receive pills containing no active drug.
223958990|NCT05588297|DRUG|CapOx(Capecitabine+ Oxaliplatin)|CapOx: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3 weeks for 4 cycles and Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 4 cycles
223958991|NCT05588297|DRUG|Bevacizumab|Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 4 cycles
223958992|NCT05588297|DRUG|Nivolumab|Nivolumab is given intravenously at 360 mg on day 1 every 3 weeks for 4 cycles
223958993|NCT03542604|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
223958994|NCT03542604|BEHAVIORAL|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
223958995|NCT01176409|DRUG|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
223958996|NCT01176409|DRUG|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
223958997|NCT00928265|DEVICE|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
223958998|NCT01536795|DRUG|WR279,396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
223958999|NCT01536795|DRUG|WR 279,396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
223959000|NCT00574301|PROCEDURE|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
223959001|NCT05266157|OTHER|Manual lymph drainage|Manual lymph drainage
223959002|NCT05266157|OTHER|Usual care|skin care, exercise and compression stocking
223959003|NCT04469517|OTHER|hypoxic induced factors|hypoxic induced factors analyzed in blood sample
223959004|NCT03198481|BEHAVIORAL|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
223959005|NCT03198481|BEHAVIORAL|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
224108596|NCT05144295|DRUG|Lubiprostone Pill|Oral pills for constipation (Lubiprostone) will be given in a dose range from 24 mcg once daily to 24 mcg twice daily according to the participant weight.
224108597|NCT05144295|DRUG|Lactulose Oral Liquid Product|"Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day)"
224108598|NCT05144295|DRUG|Bisacodyl 5 MG|Bisacodyl tablet (5 mg/tablet) in a dose of 2 tab/day for \< 12 years or 3 tab/day for \> 12 years
224108599|NCT05144295|DRUG|Sodium Picosulfate|Sodium Picosulfate 0.75% drops in a daily dose of 2.5-20 mg/day
224108600|NCT05967234|BEHAVIORAL|Telehealth solution|Telehealth solution offered for breastfeeding education.
224108601|NCT04825093|DIETARY_SUPPLEMENT|Vitamin D supplementation in pregnant women|Intervention group will be administered 1,000 UI of vitamin D and a control group will be administered 400 UI of vitamin D. Participants will take the supplementation from the enrollment to delivery.
223959006|NCT06139419|RADIATION|definitive radiotherapy|Participants were treated with definitive thoracic radiotherapy
223959007|NCT06139419|DRUG|induction chemo-immunotherapy|All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg) on d1.
224108602|NCT03630640|DRUG|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
224108603|NCT02052960|DRUG|CetuGEX™|60 mg/day 0, 930 mg/day 1, followed by 720 mg i.v. weekly administration
223541956|NCT06931106|BEHAVIORAL|HAPA and CEI behavioral intervention|The intervention group will receive a 3-month technology-facilitated PrEP intervention and tailored messages will be developed using BCTs based on theoretical guidance. PrEP teleconsultations will be delivered by certified healthcare professionals, including infectious disease specialists, CDC-affiliated prevention officers, and MSM community leaders. Participants will be stratified into peer cohorts through algorithm-driven grouping based on demographic characteristics. Six participants will form a peer group, and the economic incentive amount will be based on the group-level PrEP initiation rates (verified by physician prescriptions). The economic incentive will decrease progressively based on the average completion rate within the group and will be divided into three tiers: 22 USD (completion rate of 80-100%), 11 USD (completion rate of 50-79%), and 0 USD (completion rate \<50%).
224108604|NCT02052960|DRUG|Cetuximab|400 mg/sqm body surface area (BSA) on day 1, followed by 250 mg/sqm BSA i.v. weekly administration
224108605|NCT02052960|DRUG|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
224108606|NCT05278260|DIETARY_SUPPLEMENT|Hydrogen tablets|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy
224108607|NCT05278260|DIETARY_SUPPLEMENT|Control|Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
224108608|NCT01851096|DRUG|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
223959008|NCT06139419|DRUG|concurrent chemotherapy|Concurrent chemotherapy consists of weekly albumin-bound paclitaxel (50mg/m2) and cisplatin (25mg/m2).
223959009|NCT06139419|DRUG|Immunotheapy consolidation|Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.
224108609|NCT04068883|OTHER|Q collar|An externally-worn medical device that applies mild jugular compression
224108610|NCT04332549|DRUG|PICS (Reconstitution Method 1 or 2)|dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
224108611|NCT05004012|DEVICE|Magnetically Controlled Capsule Endoscopy|This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.
224108612|NCT04924725|PROCEDURE|Endoscopic ultrasound-guided fine needle biopsy|Endoscopic ultrasound-guided fine-needle biopsy is used to collect biopsy samples from solid pancreatic lesions throughout the digestive tract and is useful in diagnosing solid pancreatic lesions
224108613|NCT00160927|DEVICE|local heating|
224108614|NCT00160927|DEVICE|iontophoresis|
224108615|NCT00160927|DRUG|actylcholine|
224108616|NCT00160927|DRUG|sodium nitroprusside|
224108617|NCT02248376|DRUG|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
224108618|NCT03597906|PROCEDURE|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
224108619|NCT03597906|PROCEDURE|manifest refraction|using for ablation the exact manifest refraction
224108620|NCT03597906|PROCEDURE|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
223959010|NCT06139419|DRUG|Thymosin Alpha1|"Participants in the Tα1 treatment group will receive Tα1 from the beginning of induction chemo-immunotherapy until the completion of immunotherapy consolidation. In detail, Tα-1 would be administered according to the following three stages:~1. Induction chemo-immunotherapy: Tα-1 will be subcutaneously administered at 4.8 mg on d1 and d3 for each cycle.~2. Concurrent chemoradiotherapy: Tα-1 will be subcutaneously administered at 4.8mg biweekly.~3. Immunotherpay consolidation: Tα-1 will be administered concurrently with tislelizumab at 4.8mg (Q3W) for up to 12 months."
223959011|NCT06312618|DRUG|Propofol|"After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive propofol~1mg/kg over 10 minutes (group 1) ."
223959012|NCT06312618|DRUG|Dexmedetomidine|After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes (group 2).
223959016|NCT06554223|BEHAVIORAL|SUSTAIN-DSD|"Participants randomized to SUSTAIN-DSD will be enrolled into an Adherence Club and will have 6 months of ART dispensed through a pre-packed dispensing service. Participants may choose to use the decentralized pick-up point solely for medication retrieval or may opt into the peer-support aspect of the Clubs by attending the group session of up to 30 PWH, who will meet once every 6 months in a safe space (e.g., clinic meeting room, church, or local library).~At 6 months, 12 months, and every 12 months thereafter, a visiting nurse will draw a blood specimen for viral load. Optional process uptake will be recorded. Participants with a raised viral load will be called and offered enhanced adherence counselling; then recalled for a repeat viral load in 3 months."
223959017|NCT06554223|OTHER|Enhanced (guideline-driven) Standard of Care (E-SoC)|"As per current SA ART guidelines, all patients who are \>28 days late for a scheduled visit are offered enhanced adherence counselling (EAC) at reengagement and restarted on ART. Patients who are \>90 days late also have blood drawn for a CD4 count to test for advanced HIV disease. Individual clinic visits occur every 3 months, with 3-month ART dispensing. VL testing is repeated 3 months after restart, then at 12 months and annually there-after, if suppressed.~These visits will be managed by clinic staff (nurse or doctor). EAC is a single counselling session delivered by a lay counsellor.~The study team will ensure all SoC processes are complete as per the guidelines; and reported to the COCT team as appropriate."
223959018|NCT02215447|DRUG|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
223959019|NCT02215447|DRUG|Carboplatin|
223959020|NCT05656404|DEVICE|TorEx Lung Perfusion System|When donor lungs with clinical indication for EVLP are allocated to consented recipients, the lungs will be assessed using the second generation TorEx Lung Perfusion System rather than the first generation Toronto EVLP technique (standard of care).
223959021|NCT01699178|DRUG|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
223959022|NCT01699178|DRUG|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
223959023|NCT06008080|DEVICE|Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System
223959024|NCT04407442|DRUG|Azacitidine|Given IV
223959025|NCT04407442|BIOLOGICAL|Daratumumab|Given SC
223959026|NCT04407442|DRUG|Dexamethasone|Given IV or PO
223959027|NCT01107795|PROCEDURE|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
223959028|NCT04296409|OTHER|Turkish Deglutition Handicap Index|Swallowing function will be evaluated by the Turkish Deglutition Handicap Index.
223959029|NCT02066389|DRUG|Placebo|Tablets for oral administration
223959030|NCT02066389|DRUG|Upadacitinib|Tablets for oral administration
223959031|NCT05724576|BIOLOGICAL|OmniMSC-AMI|10 anterior wall STEMI patients without cardiogenic shock will be enrolled into low dose group 1 (1.5 x 10\^7 OmniMSC-AMI, n=5) and then high dose group 2 (3.0 x 10\^7 OmniMSC-AMI, n=5).
223959032|NCT02907489|OTHER|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
223959033|NCT06585761|DRUG|SGLT2 inhibitor|patients with HF are subjected to regular dose of SGLT2I member according to patient status.
223959034|NCT06585761|DEVICE|echo cardiogram|the patients are subjected to ECHO to determine their EF prior to and post the study
224108621|NCT03597906|PROCEDURE|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
224108622|NCT05189899|DEVICE|Virtual reality|One hemodialysis session with virtual reality and one other without it
223959035|NCT06584877|OTHER|sample collection|Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
223959036|NCT06584877|OTHER|Seeking consent and assent|Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
223959037|NCT02122822|BIOLOGICAL|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
223959038|NCT06376006|BEHAVIORAL|EMR STAT - Survey|Surveys are completed before and after Advanced Fellow Training.
224108623|NCT04970706|PROCEDURE|ACL reconstruction|All patients will undergo a standardized single-bundle technique with a hamstring or bone-patellar tendon-bone autograft.
224108624|NCT04460027|OTHER|Woebot Substance Use Disorder|Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
224108625|NCT00040534|DRUG|Farnesyl Protein Transferase Inhibitor|
224108626|NCT05895851|RADIATION|head and neck radiation|RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
223959039|NCT00374673|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
223959040|NCT06407193|OTHER|MRI and scintigraphy|Gastric emptying measured with MRI and scintigraphy
223959041|NCT01783379|DRUG|micafungin|100mg/day infusion in 1 hour
223959042|NCT06079047|PROCEDURE|group Dexamethasone|Adductor canal block with dexamethasone
223959043|NCT06079047|PROCEDURE|group Controle|Adductor canal block with saline solution
223959044|NCT01755598|BIOLOGICAL|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
223959045|NCT01755598|BIOLOGICAL|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
223959046|NCT02423447|DEVICE|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
223959047|NCT02423447|DEVICE|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
223959048|NCT04443881|DRUG|Anakinra 149 MG/ML Prefilled Syringe [Kineret]|Anakinra (100 mg/ 6 hours) i.v infusión during 15 days
223959049|NCT04528875|DEVICE|Ultrasound imaging|Imaging of low back with ultrasound
224108627|NCT03633331|DRUG|Palbociclib|Given PO
224108628|NCT03633331|DRUG|Letrozole|Given PO
224108629|NCT03633331|DRUG|Fulvestrant|Given IM
224108630|NCT03633331|OTHER|Questionnaire Administration|Ancillary studies
224108631|NCT03633331|OTHER|Quality-of-Life Assessment|Ancillary studies
224108632|NCT03146312|DIETARY_SUPPLEMENT|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
224108633|NCT03146312|DIETARY_SUPPLEMENT|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
223959050|NCT05983991|OTHER|Biological samples (blood and bone marrow samples).|For each included patient, biological samples (blood and bone marrow samples) will be collected at baseline visit and then during 5 years, according to the samples taken in the standard practice. No additional sampling will be performed for the study.
224108634|NCT04655625|BIOLOGICAL|Group A (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 2-week intervals
224108635|NCT04655625|BIOLOGICAL|Group A (Placebo)|Placebo twice at 2-week intervals
223959051|NCT06559098|DEVICE|Vibrotactile coordinated reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
223959052|NCT00828178|DRUG|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
223959053|NCT00828178|DEVICE|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
223959054|NCT00828178|OTHER|corn starch|3 capsules qd for 12weeks
223959055|NCT03967197|DRUG|Saline spray|Physiologic saline spray
223959056|NCT03967197|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
223959057|NCT03234010|OTHER|FT21092|An electronic cigarette
223959058|NCT03234010|OTHER|FT21093|An electronic cigarette
223959059|NCT03234010|OTHER|FT21096|An electronic cigarette
223959060|NCT03234010|OTHER|FT21097|An electronic cigarette
224108636|NCT04655625|BIOLOGICAL|Group B (AG0302-COVID19)|2 mg of AG0302-COVID19 twice at 4-week intervals
224108637|NCT04655625|BIOLOGICAL|Group B (Placebo)|Placebo twice at 4-week intervals
224108638|NCT00576914|DRUG|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
224108639|NCT03233048|DEVICE|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
224108640|NCT06430320|OTHER|NA- no intervention|NA- no intervention
224108641|NCT01309516|BEHAVIORAL|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
224108642|NCT00110643|DEVICE|CoolTouch II laser|
224108643|NCT04881539|DIETARY_SUPPLEMENT|Cannabidiol (CBD)|This group will receive an oral dose of CBD (Six Degrees Wellness).
224108644|NCT05593601|DRUG|Neomycin|Neomycin (350 mg/tablet) 1.4 g three times a day (4.2 g per day) for 5 days
224108645|NCT00084786|DRUG|docetaxel|
224108646|NCT00084786|DRUG|gefitinib|
224108647|NCT04507750|DRUG|Camrelizumab|Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
224108648|NCT03471910|DRUG|Diosmin|Diosmin 600mg tablet, once daily
223959061|NCT06153706|DRUG|Subgingival application of L-PRF loaded with metronidazole|After phase I therapy, L-PRF loaded medical grade metronidazole was applied sub gingivally into the pockets using blunt gauge needle and Perio-pack was placed (two applications with one week apart were applied subgingivally.
223959062|NCT06153706|OTHER|Subgingival application of L-PRF|The L-PRF alone was applied subgingivally into the pockets and Perio-pack was placed (two applications with one week apart.
223959063|NCT01596777|DRUG|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
224108649|NCT03471910|DRUG|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
223959064|NCT01596777|DRUG|Loperamide placebo|200 ml apple juice
223959065|NCT01596777|DRUG|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
223541957|NCT06931106|BEHAVIORAL|HAPA-based intervention|This group receives information pushes via a mini-program (3 messages per week) and two brief PrEP consultations; the first brief consultation is delivered jointly by community volunteers and a physician immediately after the baseline survey completion, based on a standardized consultation outline, and the second brief consultation is delivered jointly by community volunteers and a physician after the completion of the first monthly assessment (conducted within the mini-program), based on the standardized consultation outline and the results of that monthly assessment.
223541958|NCT06165055|DIAGNOSTIC_TEST|DNA Sample Collection + DNA genotyping|Volunteers' oral epithelial cell DNA will be collected using DNA swabs, followed by DNA isolation with the PureLink DNA Isolation Kit. The isolated DNA's quality will be assessed using the Invitrogen QUBIT 4 Fluorometer, and the samples will be stored at -20°C until analysis of specific genetic regions.
223959066|NCT01596777|DRUG|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
223959067|NCT01596777|DRUG|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
223959068|NCT01596777|DRUG|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
223959069|NCT01596777|DEVICE|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
223959070|NCT01596777|DRUG|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
223959071|NCT05642663|DEVICE|Stapler|Stapling performed with ALTUS Powered Stapler
223541959|NCT06947811|DRUG|Almonertinib|Patients will be treated with Almonertinib, 110 mg p.o., daily
223959072|NCT03819647|DRUG|stiripentol (Diacomit)|Administration of stiripentol per os
223959073|NCT00690079|DRUG|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol\*h/L
223959074|NCT00690079|DRUG|Placebo|Oral admin. of doses at 11 days through a 12 days period.
223959075|NCT00515892|DRUG|Immunotoxin therapy|
223959076|NCT00515892|DRUG|CAT-8015 Immunotoxin|
223959077|NCT00515892|PROCEDURE|Biological therapy|
223959078|NCT00515892|PROCEDURE|Antibody Therapy|
224108650|NCT04291014|DEVICE|SunRay Light Boxes|SunRay light boxes will be used to administer the light therapy.
224108651|NCT02039557|GENETIC|NiCord®/CordIn™ (omidubicel)|
223959079|NCT00515892|PROCEDURE|Monoclonal Antibody Therapy|
223959080|NCT05396573|BIOLOGICAL|RQ3013|A single dose of 30 μg/0.15 mL, a single dose of 60 μg/0.3 mL
223959081|NCT05396573|BIOLOGICAL|Comirnaty|A single dose of 30 μg/0.3 mL
223959082|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
223959083|NCT00915915|DRUG|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
223541960|NCT06947811|DRUG|Palbociclib|Patients will be treated with Palbociclib, 125 mg(dose determined from Part one of study) p.o., daily
223959084|NCT03159494|OTHER|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
223959085|NCT04093050|DRUG|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
223959086|NCT01664806|DEVICE|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
223959087|NCT03421301|DIETARY_SUPPLEMENT|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
223959088|NCT01778842|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
223959089|NCT01778842|DRUG|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
223959090|NCT00415688|BEHAVIORAL|Low carbohydrate, ketogenic diet|
223959091|NCT00415688|BEHAVIORAL|Low glycemic index, reduced calorie diet|
223959092|NCT01446718|BIOLOGICAL|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
223959093|NCT00312806|DRUG|Pantoprazole|Pantoprazole 40 mg o.d.
223959094|NCT04536766|BEHAVIORAL|Enhanced Sleep Health Education|The intervention comprehensively addresses poor sleep health behaviors. Personalized sleep health education will be delivered in two telephone sessions by Beds for Kids staff members. Sleep health information will consist of the following evidence-based pediatric sleep health behaviors: ensuring adequate sleep duration, developing a family bedtime routine, keeping a regular sleep schedule, avoiding caffeine, and eliminating electronics in the bedroom and at bedtime. The enhanced sleep health intervention sessions will also include individualized problem-solving and tailoring to meet the family's needs. Personalization will be accomplished via direct questions to families during the education phone call related to their own barriers to achieving healthy sleep habits and goals for optimal sleep.
223959095|NCT04536766|BEHAVIORAL|Beds for Kids Standard Program|The Beds for Kids program provides beds, bedding, and written healthy sleep education to families living at or below 100% of the federal poverty line and without an individual child bed to sleep in.
223959096|NCT03629366|BEHAVIORAL|Supported Employment (SE)|Supported Employment
223959097|NCT03629366|BEHAVIORAL|Treatment as usual (TAU)|Treatment as usual
223959098|NCT02502019|DEVICE|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
223959099|NCT05772338|DRUG|BNP105 (25 + 25 + 15)|BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.
223959100|NCT05772338|OTHER|Placebo|Placebo. Up to six applications per day.
223959101|NCT01317966|DRUG|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
223959102|NCT02265120|BEHAVIORAL|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
223959103|NCT00753259|OTHER|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
223959104|NCT00753259|OTHER|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
223959105|NCT00000492|DRUG|propranolol|
223959106|NCT05062343|DEVICE|Dilapan-S|Osmotic dilator
223959107|NCT05062343|DEVICE|Cook Cervical Ripening Balloon|Double balloon catheter for cervical ripening
223959108|NCT03102892|PROCEDURE|Scaling root planing|Treatment by scaling and root planing alone.
223959109|NCT03102892|PROCEDURE|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
223959110|NCT04573218|DRUG|Placebo|The placebo contains glucose
223959111|NCT04573218|DIETARY_SUPPLEMENT|250 mg OPP|250 mg Oil Palm Phenolics
223959112|NCT00624637|OTHER|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
223541961|NCT06951542|BEHAVIORAL|Stigma Reduction Counseling|The stigma reduction counseling sessions will include psychoeducation and activities to challenge myths and stereotypes, cope with experiences of discrimination, and overcome self-stigma.
223541962|NCT02982226|OTHER|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
223541963|NCT02982226|OTHER|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
223541964|NCT01520467|DRUG|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
223541965|NCT01520467|DRUG|Placebo|1 placebo tablet /day administered orally for 18 months.
223959113|NCT02766361|BEHAVIORAL|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
223959114|NCT02766361|OTHER|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
223959115|NCT01342497|DRUG|isoniazide|Tablets, dosing 3 times daily, 12 weeks
223959116|NCT01342497|DRUG|placebo|tablets, dosing 3 times daily, 12 weeks
223959117|NCT05197179|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
223959118|NCT05197179|OTHER|FB2001 placebo|Subjects will be administered with FB2001 by intravenous (IV) infusion
223959119|NCT00594282|DEVICE|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
223959120|NCT02099188|DRUG|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
224108652|NCT03797443|DRUG|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
224108653|NCT03797443|DRUG|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
224108654|NCT03797443|DRUG|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
224108655|NCT03797443|DRUG|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
224108656|NCT03518957|BEHAVIORAL|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
224108657|NCT00806117|RADIATION|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~* Lateral: 2 cm lateral to the bony margin of the pelvis~* Superior: Between L5 and S1~* Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
224108658|NCT00806117|OTHER|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
224108659|NCT00806117|OTHER|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135\~175mg/m2 over 3 hours Cisplatin 60\~75mg/m2
224108660|NCT06331585|RADIATION|low dose radiotherapy|LDRT (5Gy/5f) of oligometastasis, oligoprogression, and oligopersistence of NSCLC after immunotherapy
224108661|NCT00900432|OTHER|immunoenzyme technique|
224108662|NCT00900432|OTHER|laboratory biomarker analysis|
224108663|NCT05914272|DRUG|Osmotic drugs|Patients had used osmotic drugs within 72 hours of admission.
224108664|NCT01396525|DEVICE|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
224108665|NCT04265989|DEVICE|Single BMS|Single bare metal stent covered the coronary artery aneurysm
224108666|NCT04265989|DEVICE|Single or Double BMS|Single or double layer bare metal stents covered the coronary artery aneurysm
223959121|NCT02099188|DRUG|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
223959122|NCT02099188|DRUG|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
223959123|NCT02099188|DRUG|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
223959124|NCT02099188|DRUG|Adriamycin|20 mg/m2/day - Powder for solution for infusion
223959125|NCT02099188|DRUG|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
223959126|NCT02099188|DRUG|Leucovorin|250 mg/m2/day - Powder for solution for infusion
223959127|NCT02099188|RADIATION|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost with ENI:~   HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
224108667|NCT04265989|DEVICE|Single or Double BMS|Treated with single or double layer bare metal stents
224108668|NCT04265989|DEVICE|BMS+DES|Treated with bare metal stent combined with drug eluting stent
224108669|NCT03114969|DEVICE|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
224108670|NCT03114969|DEVICE|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
224108671|NCT03114969|DEVICE|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
224108672|NCT03114969|DEVICE|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
223959128|NCT02099188|RADIATION|Radiotherapy - Patients not needing ENI|"1. Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~2. Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
223959129|NCT02099188|RADIATION|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~1. Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~2. Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
223959130|NCT01858324|OTHER|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
223959131|NCT01929161|DRUG|Oxytocin|24 International Units
223959132|NCT01929161|DRUG|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
223959133|NCT01929161|BEHAVIORAL|Lovingkindness Meditation|
223959134|NCT01929161|BEHAVIORAL|Mindfulness Meditation|
223959135|NCT00007826|BIOLOGICAL|BCG vaccine|
223959136|NCT00007826|BIOLOGICAL|monoclonal antibody 105AD7 anti-idiotype vaccine|
223959137|NCT00007826|DRUG|alum adjuvant|
223959138|NCT02106078|BEHAVIORAL|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
223959139|NCT02106078|BEHAVIORAL|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~1. What is bipolar disorder? - Content about symptoms and diagnosis~2. Stress and triggers of illness~3. Medication and the biological basis of bipolar disorder~4. Depression - Symptoms, early detection and helpful strategies~5. Mania and hypomania - Symptoms, early detection and helpful strategies"
223959140|NCT02106078|BEHAVIORAL|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
223959141|NCT04853654|OTHER|exercise|exercise training for 8 weeks
223959142|NCT06372600|DEVICE|Extracorporeal shock wave therapy device|In the shoulder pain points, choose 2 to 3 of them for each treatment, apply the coupling agent, which is convenient for the treatment head to stick to the skin, and complete the longitudinal treatment and horizontal treatment. The setting frequency was 4 \~ 8 Hz, the length of the probe was 15 mm, and the pressure was set at 1.5 mJ/mm2. The frequency of each treatment point reached 2 000 \~ 2 500 times, and the hand-held pressure was set to medium-high level. A total of 6 treatments were completed. For patients with unclear pain points or regional pain, the treatment point should be supraspinatus tendon or infraspinatus tendon, and the treatment should be completed with the most severe pain site.
223959143|NCT06372600|BIOLOGICAL|Platelet-rich plasma|Autologous Platelet-rich plasma injection was performed under ultrasound guidance
223959144|NCT01212913|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
223959145|NCT01212913|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
223959146|NCT01212913|DRUG|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
223959147|NCT05235685|OTHER|Medical air|Exercise under medical air, both arms exposed.
223959148|NCT05235685|OTHER|Hyperoxia|Exercise under hyperoxia, only experimental arm exposed.
223959149|NCT04994093|OTHER|Collection of blood (PBMC), biopsy (FFPE) and stool samples.|Patients receiving routine treatment financed by the Polish National Health Fund (NFZ).
223959150|NCT03332875|BEHAVIORAL|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
223959151|NCT00780741|PROCEDURE|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
223959152|NCT00780741|PROCEDURE|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
223959153|NCT00237224|DRUG|Letrozole|
224108673|NCT03114969|DEVICE|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
224108674|NCT03114969|DEVICE|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
224108675|NCT03114969|DEVICE|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
224108676|NCT00949650|DRUG|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
224108677|NCT00949650|DRUG|BIBW 2992|BIBW 2992 once daily until progression
224108678|NCT00949650|DRUG|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
223545114|NCT05110326|OTHER|ERGON Technique|"* Hot pack for 15 minutes.~* Patient position: Prone with knee flexion approximately 45◦.~* Position of therapist: Standing at the affected side of patient.~* Technique:Massage cream will be applied on the hamstring and overactive or short muscle fibres that are restricted.The instrument will be applied parallel to the muscle fibers, both in a distal to proximal and them proximal to distal direction as needed.Then gentle massage stroking from the origin to the insertion will be performed using the instrument. Instrument Assisted Soft Tissue Mobilization(IASTM) will be applied for 5 minutes.~* Strengthening exercises for quadriceps and hamstring will then be performed.~* Isometrics exercises of Quadriceps: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Isometrics exercises Hamstrings: By placing a towel roll below the knee and press and hold for 20 seconds, 5 sets.~* Wall sits: For 10 seconds, 5 sets."
224108679|NCT00027131|BIOLOGICAL|Heat Shock Protein 70-peptide complexes (HSP70)|
224108680|NCT03576677|DRUG|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
224108681|NCT03576677|DRUG|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
223959154|NCT01653925|OTHER|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
223959155|NCT01653925|DRUG|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
223959156|NCT01274507|OTHER|Medical tests|All participants will undergo medical tests and will be observed.
223959157|NCT01120457|DRUG|BMS-936564 (Anti-CXCR4)|
223959158|NCT01314066|DRUG|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
223959159|NCT01314066|DRUG|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
223959160|NCT02993926|DRUG|Enantone|Enantone suspension for injection
224108682|NCT01210937|PROCEDURE|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
224108683|NCT02291380|DRUG|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
224108684|NCT02291380|DRUG|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
224108685|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
223959161|NCT02993926|DRUG|GnRH agonist|A non-Enantone GnRH agonist
223959162|NCT00540566|DEVICE|Optical Biopsy imaging|Optical Biopsy imaging
224108686|NCT01158898|DRUG|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
223959163|NCT06357455|DEVICE|Cell Salvage Autotransfusion: SAME™ device|"* Intervention studied: processing of salvaged blood using the SAME™ autotransfusion device~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Treatment group.~All perioperative measures will be performed according to international, national and in-house standards."
223959164|NCT06357455|DEVICE|Cell Salvage Autotransfusion: Autolog™ device|"* Intervention studied: processing of salvaged blood using the Autolog™ (Medtronic) autotransfusion device (in-house standard device).~* Population studied: 20 patients planned to undergo high-risk liver transplantation.~* Control group~All perioperative measures will be performed according to international, national and in-house standards."
224108687|NCT01158898|DRUG|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
224108688|NCT02875288|DRUG|liposomal bupivicaine|"1. The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~2. The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~3. Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~4. Route of drug administration; Surgical site infiltration"
224108689|NCT03154450|DEVICE|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
223959165|NCT02412904|DRUG|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
224108690|NCT03154450|DEVICE|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
224108691|NCT06130384|DRUG|Use of bromfenac 0.09% to reduce intravitreal injection pain|The eyedrop (bromfenac) will be given to the assigned eye.
223959166|NCT02412904|DRUG|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
223959167|NCT06194695|PROCEDURE|drug eluting beads-transcatheter arterial chemoembolization|transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
223959168|NCT06194695|DRUG|envatinib plus anti-PD(L)1|oral use of lenvatinib plus intravenous injection of anti-PD(L)1 antibodies. Anti-PD-L1 antibodies includes duravalumab, atezolizumab, or envolizumab, and anti-PD1 antibodies include pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, or toripalimab.
223959169|NCT05813990|OTHER|recostructive ear surgery|recostructive ear surgery in pediatric population
223959170|NCT00860457|DRUG|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
223959171|NCT00860457|DRUG|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
223959172|NCT00860457|DRUG|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
223959173|NCT05333276|DRUG|TQB3602 Capsule + AK105 Injection|TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
224108692|NCT06130384|DRUG|Use of artificial tears to reduce intravitreal injection pain|The eyedrop (artificial tears) will be given to the assigned eye.
224108693|NCT01073072|PROCEDURE|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
224108694|NCT01073072|PROCEDURE|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
224108695|NCT00477373|DRUG|depakine chrono|Depakine Chrono 500 mg
224108696|NCT05362162|PROCEDURE|cervical plexus block|local anesthetic agent injection into the either Superficial or intermediate area
224108697|NCT02232438|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
224108698|NCT05785338|DIAGNOSTIC_TEST|Posterior angle of the hard palate|Fetal ultrasound
224108699|NCT01142648|DRUG|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
224108700|NCT01142648|DRUG|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
223959174|NCT01084772|OTHER|VISIONAIRE Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.
223959175|NCT01084772|OTHER|Standard Total Knee Arthroplasty|TKA will be performed with standard instrumentation, depending on randomization assignment.
223959176|NCT02442037|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.
223959177|NCT02442037|OTHER|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
223959178|NCT04327089|DRUG|Setanaxib|Nox 1/4 inhibitor
223959179|NCT03782285|PROCEDURE|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
223959180|NCT01049854|DRUG|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
223959181|NCT01049854|DRUG|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
223959182|NCT01049854|DRUG|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
223959183|NCT01049854|DRUG|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
223959184|NCT05982366|OTHER|distal radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the distal radial artery in the anatomical snuffbox area
223959185|NCT05982366|OTHER|conventional radial artery acess side|coronary procedure (coronary angiography and/or coronary angioplasty) by the forearm radial artery in the anatomical snuffbox area
223959186|NCT02298998|OTHER|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
223959187|NCT02298998|OTHER|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
223959188|NCT04705389|OTHER|Samples|blood samples
223959189|NCT05576701|BEHAVIORAL|Laughter Therapy|In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
223959190|NCT05576701|OTHER|Control|The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
223959191|NCT00000269|DRUG|Pergolide|
223959192|NCT00651326|DRUG|bicalutamide|
223959193|NCT00651326|DRUG|buserelin|
223959194|NCT00651326|DRUG|flutamide|
223959195|NCT00651326|DRUG|goserelin|
223959196|NCT00651326|DRUG|leuprolide acetate|
223959197|NCT00651326|PROCEDURE|neoadjuvant therapy|
223959198|NCT00651326|PROCEDURE|quality-of-life assessment|
223959199|NCT00651326|RADIATION|radiation therapy|"46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks"
223959200|NCT00651326|DRUG|Docetaxel|
223959201|NCT02573129|OTHER|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
223959202|NCT02573129|OTHER|Red Meat Rich|Mediterranean diet rich in red meat
223959203|NCT04439825|DRUG|Botulinum Neurotoxin|glabella, forehead lines and/or lateral canthal lines
223959204|NCT04439825|DRUG|Placebo|Saline solution (preservative free)
223959205|NCT01799005|DIETARY_SUPPLEMENT|Flavanol (410 mg)|
223959206|NCT01799005|DIETARY_SUPPLEMENT|Control (no flavanols)|
223959207|NCT01870336|DEVICE|Combined treatment of medial knee osteoarthritis|
223959208|NCT01425398|DRUG|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
223959209|NCT01425398|DRUG|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
223959210|NCT04917315|DRUG|JLP-2002 A mg|administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.
224108701|NCT05259046|DIETARY_SUPPLEMENT|Menaquinone-7 (MK-7) tablet (333 µg)|One MK-7 tablet containing 333 µg MK-7 per day
224108702|NCT05259046|DIETARY_SUPPLEMENT|Placebo tablet|One placebo tablet per day
224108703|NCT03401177|DRUG|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
224108704|NCT03401177|DRUG|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
223959211|NCT04917315|DRUG|Placebo|administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.
224108705|NCT03401177|OTHER|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
224108706|NCT02712684|PROCEDURE|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
224108707|NCT04813679|DIAGNOSTIC_TEST|Bed side Ultrasound Sonography|Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
224108708|NCT03134963|OTHER|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
224108709|NCT03134963|OTHER|Blood pressure monitoring|Continuous blood pressure recording
224108710|NCT03134963|OTHER|Heart rate monitoring|Continuous heart rate monitoring
224108711|NCT03134963|OTHER|End tidal CO2 monitoring|Continuous ETCO2 monitoring
224108712|NCT03134963|OTHER|Addenbrooke's cognitive examination|Performance of a memory test
223959212|NCT01354080|OTHER|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
223959213|NCT01354080|OTHER|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
223959214|NCT02384122|DRUG|Octreotide|Two injections of 20 mg will be given monthly.
224108713|NCT04962165|DEVICE|Mandibular Advancement Device|The device maintain opened upper airway by moving the lower jaw slightly forward while sleeping.
224108714|NCT05448534|DIAGNOSTIC_TEST|Eletroencephalography|We used Sinek and Young Scale to classify electroencephalographic patterns and cognitive outcome with MOCA score.
224108715|NCT01852344|DRUG|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
224108716|NCT01852344|DRUG|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
224108717|NCT01852344|BEHAVIORAL|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
224108718|NCT01852344|BEHAVIORAL|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
223959215|NCT03369457|BIOLOGICAL|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
223959216|NCT04979702|BEHAVIORAL|Active Control|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses
224108719|NCT01665781|DRUG|Erythropoietin|
224108720|NCT01556919|PROCEDURE|Standard of care endoscopy|standard of care endoscopy
224108721|NCT01874782|DEVICE|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
224108722|NCT01743027|DRUG|AL-4943A ophthalmic solution|
224108723|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
224108724|NCT01743027|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.1%|
224108725|NCT01743027|DRUG|AL-4943A ophthalmic solution vehicle|
224108726|NCT00450866|BIOLOGICAL|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
224108727|NCT03558321|PROCEDURE|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
224108728|NCT03558321|PROCEDURE|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
224108729|NCT02183298|DRUG|BI 1356 BS - intravenous|
224108730|NCT02183298|DRUG|BI 1356 BS - Tablet|
224108731|NCT02183298|DRUG|Placebo|
224108732|NCT03429907|BEHAVIORAL|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
224108733|NCT03429907|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
224108734|NCT04098614|BEHAVIORAL|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
224108735|NCT06544408|DEVICE|Cool B70 AP Coil - Active (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
224108736|NCT06544408|DEVICE|Cool B70 AP Coil- Sham (dl-PFC)|One side of the coil is the active and the other is sham. The B70 AP coil will be positioned over the left dorsolateral prefrontal cortex (dl-PFC).
224108737|NCT06544408|DEVICE|Cool D-B80 AP Coil - Active (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
223959217|NCT04979702|BEHAVIORAL|mHealth technology assisted exercise counselling|Participants will complete a 3-month exercise and physical activity intervention supported by online recourses, exercise counselling sessions and mHealth technology
224108738|NCT06544408|DEVICE|Cool D-B80 AP Coil - Sham (dm-PFC)|One side of the coil is the active and the other is sham. The cool D-B80 AP coil will be positioned over the midline (bilateral) dorsal medial prefrontal cortex (dmPFC) using location 25.8% distance from nasion to inion.
223959218|NCT03824743|DRUG|Lactate Ringer|Patients managed with Lactate Ringer and obstetric hemorrhage
223959219|NCT03824743|DRUG|Plasma-lyte|Patients managed with Plasma-Lyte and obstetric hemorrhage
223959220|NCT04265235|OTHER|Home-based exercise program|see 'arm' section
223959221|NCT01848132|DRUG|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
223959222|NCT01848132|DRUG|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
223959223|NCT01848132|DRUG|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
223959224|NCT01848132|DRUG|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
223959225|NCT01848132|DRUG|Prednisone|Prednisone: oral, 100 mg, days 1-5
223959226|NCT01848132|DRUG|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
223959227|NCT04086342|DRUG|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
223959228|NCT04086342|DRUG|Placebo|Placebo is a vehicle oil that will match CHI-902.
224108739|NCT06544408|DEVICE|Cool B70 Treatment Coil - Active Only|The treatment will be the same as the left dl-PFC accel-TMS dl-PFC except that the Cool B70 Treatment coil only has an active treatment coil.
224108740|NCT06488807|OTHER|Olfactory Enrichment|Each participant will be equipped with an electrical odor dispenser which allowed to distribute 8 odors (grapefruit, lavender, lemon, peppermint, menthol, tangerine, green tea, and bergamot). The choice of odors was guided by (1) pleasantness of the odors, (2) presence of slight trigeminal activation in some of the odors, e.g., peppermint, (3) evaporation characteristics, so that the odors would last for the duration of the experiment, (4) technical issues mostly in terms of compatibility with the odor cartridge, (5) availability, and (6) inspiration from the previous studies.
224108741|NCT06488807|OTHER|Sham|The containers provided to the sham group will be odorless. The odor containers and labels will appear identical to those used in the olfactory enrichment group.
224108742|NCT06966180|BEHAVIORAL|Alcohol Intervention Program (AIP)|A brief behavioral intervention consisting of six bi-weekly group sessions based on motivational interviewing and cognitive-behavioral strategies. The aim was to reduce alcohol use and related problems and increase motivation to change.
223959229|NCT05304676|OTHER|Experimental: KTT group|This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation
223959230|NCT05304676|OTHER|Active Comparator: conventional treatment|Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
223959231|NCT02267109|BIOLOGICAL|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
223959232|NCT02267109|BIOLOGICAL|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
223959233|NCT05230394|DIAGNOSTIC_TEST|Attended Polysomnography in the Lab|Using standard Level 1 polysomnography
223959234|NCT05230394|DIAGNOSTIC_TEST|Unattended Polysomnography in the Home|Using Cerebra's Prodigy system
223959235|NCT03602807|DEVICE|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
223959236|NCT02256826|DRUG|BILR 355 BS|
223959237|NCT02256826|DRUG|Ritonavir (RTV)|NORVIR®
223959238|NCT02256826|DRUG|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
223959239|NCT06192459|DEVICE|Modality physical therapy|Magnetotherapy, low-energy laser, electrotherapy, etc.
224108743|NCT04640636|DRUG|Ketamine hydrochloride injection|single IM injection of ketamine hydrochloride 0.5 mg/kg
224108744|NCT04640636|DRUG|Midazolam injection|single IM injection of midazolam 0.06 mg/kg
224108745|NCT05096169|DRUG|Clomiphene Citrate 25mg|clomiphene citrate at a dose of 25mg daily
224108746|NCT05096169|DRUG|Clomiphene Citrate 50mg|clomiphene citrate at a dose of 50mg every other day
223959240|NCT06192459|OTHER|Combined therapy:|Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
223959241|NCT05692245|DRUG|Ondansetron|Administered Medication
223959242|NCT05692245|DRUG|Dexamethasone|Administered Medication
223959243|NCT03886207|OTHER|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
223959244|NCT03886207|OTHER|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
223724202|NCT05984732|BEHAVIORAL|Social wellness with scrapbook or journal|Older adults in the control group will have general social wellness discussion with the young adult volunteers, instead of structured reminiscence guidelines. The topics are: diet and health (week 1); exercise/activity and health (week 2); emotions and health (week 3); religious/spiritual practices and health (week 4); family/friend relationships and health (week 5); and social activities/engagement and health (week 6). For weeks 7-10, instead of DST, the young adult volunteer will work with the older adult to create an unstructured, non-digital record of the social visit related to wellness in later life (e.g. wellness scrapbook/journal).
223724203|NCT03883620|BIOLOGICAL|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
223724204|NCT03883620|BIOLOGICAL|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
223724205|NCT03883620|BIOLOGICAL|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
223959245|NCT04429672|BEHAVIORAL|The Right to your Sexual Health|which is of a socio-educational type and is made up of five thematic axes; Sexual Rights, Sexuality, Reproductive Health, Sexual Behavior and Life Project divided into ten sessions (two weekly) of 30 minutes each, each session has a structure of opening, development and closing phase
223959246|NCT04429672|BEHAVIORAL|Friendly sexual health services and reproductive for adolescents|consists of six sessions (one a week) lasting 50 minutes each, using illustrative material through official flipcharts of the secretary of health on reproductive health, sexually transmitted diseases and sexual violence
223959247|NCT05272202|DRUG|Propofol|STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
223959248|NCT05272202|DEVICE|Median nerve stimulation|The right-hand median nerve will be stimulated in the same way as for measurement with a conduction velocity or for an evoked potential. Two stimulation electrodes will be placed on the right-hand wrist according to the standards.The stimulation is transcutaneous and painless using the specific Micromed device Sd Ltm Stim Energy (Micromed, Mˆacon, France). The stimulus intensity will range between 3 and 14 mA. The stimulation duration will be 100 ms with a frequency of 0.1 Hz.
223959249|NCT05272202|DEVICE|EEG measurements|Changes in ERD and ERS patterns during median nerve stimulation according to the various propofol concentrations will be continuously monitored by an EEG amplifier. EEG signals will be acquired using the OpenViBE platform with a Biosemi Active Two 64-channel EEG system, arranged in the Biosemi's ABC system covering the entire scalp at 2048 Hz. Among all recorded sites, some of the electrodes will be localized around the primary motor cortex, the motor cortex, the somatosensory cortex, and the occipital cortex.
223959250|NCT04305496|DRUG|Fulvestrant|Patients will be administered 500 mg (2 injections) on Day 1 of Weeks 1 and 3 of Cycle 1, and then on Day 1, Week 1 of each cycle thereafter
223959251|NCT04305496|DRUG|Capivasertib|400 mg BD (2 tablets of 200 mg taken twice a day = total daily dose 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
223959252|NCT04305496|DRUG|Placebo|Placebo to match 400 mg BD (2 tablets of placebo to match 200 mg taken twice daily = placebo to match total daily dose of 800 mg) given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle
223959253|NCT00253552|BIOLOGICAL|filgrastim|
223959254|NCT00253552|DRUG|busulfan|
223959255|NCT00253552|DRUG|cyclophosphamide|
223959256|NCT00253552|DRUG|cyclosporine|
223959257|NCT00253552|DRUG|etoposide|
223724206|NCT03883620|BIOLOGICAL|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
223959258|NCT00253552|DRUG|methotrexate|
223959259|NCT00253552|PROCEDURE|allogeneic bone marrow transplantation|
223959260|NCT00253552|RADIATION|radiation therapy|
223959261|NCT03191097|DRUG|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
223959262|NCT03191097|DRUG|Placebo oral capsule|Placebo, capsules daily for 5 days.
224108747|NCT03308630|BEHAVIORAL|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
224108748|NCT06971627|BEHAVIORAL|Nurse-led Telehealth Monitoring Program|Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.
223959263|NCT03368300|OTHER|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
223959264|NCT05751720|DRUG|GIP/GLP-1a|The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
223959265|NCT00071188|DRUG|ZD6474|
223959266|NCT00071188|DRUG|Paclitaxel|
223959267|NCT00071188|DRUG|Carboplatin|
223959268|NCT03657745|DEVICE|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
223959269|NCT04817293|OTHER|Questionnaire|Questionnaire SSD-12 and EQ5D5L
223959270|NCT04817293|OTHER|medical consultation|Medical consultation during the visit with data collection
223959271|NCT00453440|PROCEDURE|Cheek swab & blood test|Cheek swab \& blood test
223959272|NCT04139486|PROCEDURE|combined EMBOTRAP II or III and Contact Aspiration|refer to title
223724207|NCT03883620|BIOLOGICAL|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
223959273|NCT04139486|PROCEDURE|Contact Aspiration alone|refer to title
223959274|NCT01045057|DEVICE|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
223959275|NCT01170936|DRUG|canakinumab|Single dose of canakinumab 300mg s.c. injection
223959276|NCT03677986|BEHAVIORAL|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
223959277|NCT03187249|BEHAVIORAL|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
223959278|NCT03187249|BEHAVIORAL|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
223959279|NCT03187249|BEHAVIORAL|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
223959280|NCT04529200|OTHER|electrotherapy treatment|physical therapy management like EMS IFT
223959281|NCT02332889|BIOLOGICAL|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be \> 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
223959282|NCT02332889|DRUG|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
223959283|NCT06812247|OTHER|Therapy dog visits|2-3 ten-minute visits by a trained therapy dog and the dog's handler
223959284|NCT06812247|OTHER|Dog handler visits|2-3 ten-minute visits by a dog handler
223959285|NCT05459584|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
224108749|NCT06971627|OTHER|No intervention|Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.
223724208|NCT03883620|BIOLOGICAL|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
223724209|NCT03883620|BIOLOGICAL|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
223724210|NCT00876772|DRUG|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
223724211|NCT01945177|DEVICE|narrow band imaging|narrow band imaging
223724212|NCT01945177|DEVICE|white light endoscopy|white light endoscopy
223959286|NCT05283876|DEVICE|Excimer light|Excimer light sessions
223959287|NCT01647802|DEVICE|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
223959288|NCT01647802|DEVICE|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
224291240|NCT01829919|DRUG|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
224291241|NCT01090375|OTHER|Exercise|
224291242|NCT01090375|OTHER|Non Exercise|
224291243|NCT01690975|DRUG|Placebo|Placebo - single dose at start of each treatment period
224291244|NCT01690975|DRUG|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
224108750|NCT06970431|OTHER|eoperative Education + Intraoperative Music Therapy Arm|The experimental group implemented standardized preoperative education one day before the operation (covering knowledge such as the surgical procedure), headphone fitting one hour before the operation (with a volume of 45-55 decibels), and music therapy throughout the operation and for 30 minutes after the operation (parturients can choose personalized music). Full-time nurses were responsible for the preoperative education, and trained operating room nurses implemented the music therapy. Meanwhile, data such as anxiety scores, pain scores, shivering index, postoperative complications, postoperative recovery status, and satisfaction surveys were collected at multiple time points through standardized tools.
223959289|NCT01647802|DEVICE|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
223959290|NCT05688605|DRUG|MRG003+HX008|Administered intravenously
223959291|NCT05127902|DIAGNOSTIC_TEST|Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy)|"Proprioceptive-stabilometric assessment machine (ProKin 252, TecnoBody®, Italy) Balance performance of subjects will be tested on the proprioceptive-stabilometric assessment machine.~Noraxon wireless TELEmyo Direct Transmission System (TELEmyo DTS) with product code of 580 (Noraxon, USA Inc., USA)~The sampling frequency will be of 1000Hz and bandwidth of 10-500Hz. Bipolar silver chloride electrodes of 15mm diameter will be used for EMG signals collection, the interelectrode distance will be fixed at 20mm. Normalization procedure will be done by asking subjects to perform isometric maximum voluntary contractions (MVC). The MVC will be measured by Lafayette hand-held dynamometer connected to flat stirrup. MVC will be tested as listed below.~The sEMG signals during each experiment will be normalized to the sEMG at isometric MVC and expressed as percentages of the maximum sEMG activity (%EMG\_max) for comparison with normalization signal processing program in Noraxon System."
224108751|NCT06970431|OTHER|Preoperative Education Alone Arm|"The control group received the same standardized preoperative education by full-time nurses one day before the operation, covering surgical procedures, precautions, anesthesia, and postoperative recovery.~Data were collected at multiple time points using standardized tools, including anxiety scores (before and 6, 12, 24 h after surgery via GAD-7), pain scores (before and 6, 12, 24 h after via VAS), shivering index (before surgery, before wearing headphones, when leaving OR), postoperative complications (wound infection, urinary retention, etc.), postoperative recovery indicators (time to get out of bed, anal exhaust, breastfeeding start, hospital stay), and satisfaction surveys (24 h after surgery).~Importantly, the control group had no music therapy intervention before, during, or after surgery."
224108752|NCT06970795|DRUG|SYS6040 for injection|"Intravenous infusion; including dose escalation and backfilling (5 preset dose groups) and cohort expansion.~Treatment Period: All subjects receive trial treatment until disease progression, death, intolerance of toxicity, loss to follow-up, withdrawal of consent, or end of the trial (whichever occurs first)"
224108753|NCT06969781|DEVICE|MWA|Enrolled participants undergo microwave ablation (MWA) after comprehensive assessment of lesion location, size, and individual condition. CT or other imaging modalities are used to monitor changes in the ablation zone. The puncture needle is appropriately distributed within the lesion based on its morphology, and ablation duration is determined by imaging-confirmed coverage of the lesion. All procedures are performed under general anesthesia. Ablation time, power, and cycles are recorded intraoperatively, with continuous ECG monitoring throughout. Immediate post-procedure chest CT or other imaging is performed to document intraoperative complications (e.g., pneumothorax, bleeding). Participants are routinely observed for 24 hours post-procedure, followed by CT re-examination and documentation of any complications.
223959292|NCT00424502|DRUG|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
224108754|NCT06969781|DRUG|TKI|"1. Study Drug: Furmonertinib (Shanghai Allist Pharmaceuticals Co.,Ltd.);~2. Administration: Oral, 80 mg once daily. In the MWA-TKI group, targeted therapy is initiated post-MWA if no significant complications occur, continuing for up to 24 months without severe toxicity. In the TKI-MWA-TKI group, a 3-month induction with Furmonertinib is followed by CT re-evaluation; if no contraindications are present, MWA is performed, and targeted therapy resumes post-procedure, continuing for up to 21 months without severe toxicity."
223724213|NCT02597075|OTHER|standard therapy + physical activity program|
223724214|NCT02597075|OTHER|standard therapy|
223724215|NCT03605459|DEVICE|Comfort Plug™|
223724216|NCT02156596|DRUG|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
223724217|NCT02156596|DRUG|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
223724218|NCT02156596|DRUG|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
223724219|NCT02156596|DRUG|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
224108755|NCT06969846|DEVICE|CSN electrode was implanted around tissue including CSN branches|Using a novel surgical approach, a custom electrode was implanted around tissue including CSN branches in anesthetized adults. Following functional mapping, presumed baroafferent fibers were identified via response and stimulated. Outcome measures included change in systolic BP (SBP), diastolic BP (DBP), and heart rate (HR) during and after stimulation using multi-level modeling. Secondarily, dose dependency was examined.
224108756|NCT06969599|DIAGNOSTIC_TEST|No intervention measures|No intervention measures
224108757|NCT06971536|DIETARY_SUPPLEMENT|Standard Green Tea|A maximum single dose of 300 mg green tea (hard gel capsules)
223959293|NCT00424502|DRUG|Methotrexate|10-25mg po/week
224108758|NCT06971536|DIETARY_SUPPLEMENT|Phytosome Green Tea|A maximum single dose of 250 mg green tea (hard gel capsules)
224108759|NCT06971536|DIETARY_SUPPLEMENT|LipoMicel Green Tea|A maximum single dose of 300 mg green tea (soft gel capsules)
223959294|NCT06826326|DRUG|Escitalopram 10mg|oral administration of escitalopram 10 mg
223959295|NCT06826326|DRUG|Placebo|Placebo
223959296|NCT07131943|DEVICE|Radiofrequency|Radiofrequency (TECAR) therapy is a non-invasive, non-ablative treatment that uses electromagnetic energy to generate endogenous heat, promoting increased blood flow and tissue healing in both superficial and deep tissues. With a long wavelength and low frequency (300 KHz to 1 MHz), it can penetrate deeply into muscles, tendons, and bones, making it suitable even in acute conditions. TECAR operates in two modes: capacitive (targeting soft tissues rich in electrolytes) and resistive (targeting high-resistance tissues like bones and tendons). The therapy stimulates natural repair processes by inducing ion flow and micro-hyperemia, leading to the release of endorphins and cortisone, which help reduce pain, inflammation, and edema, while enhancing immune response and tissue regeneration.
223959297|NCT07131943|DEVICE|Ultrasound|The ultrasound waves accelerate healing, increasing local vascularity and improving several other characteristics, including energy absorption capacity and maximum rupture resistance tension, increased collagen synthesis, fibroblast proliferation, release of growth factors stimulated by mast cell degranulation and improved response of platelets and macrophages anticipating the proliferative and remodeling phase. 1-MHz continuous ultrasound, with a half-value depth of approximately 2.3 cm, is frequently used to treat deep tissues that are approximately 2.3 to 5 cm deep.
224108760|NCT06971913|DRUG|Interleukin-2 (IL-2)|Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.
224108761|NCT06971913|DRUG|Ganciclovir (GCV)|Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.
224108762|NCT06970041|DEVICE|Use of NIV during therapeutic FOB as a respiratory support method in patients with type 2 respiratory failure|The aim of the project is to assess the safety, indications and contraindications for therapeutic bronchofiberoscopy in patients with decompensated respiratory acidosis using: invasive mechanical ventilation (IMV), non-invasive mechanical ventilation (NIV) and high-flow nasal canulla (HFNC). Additionally, we want to determine to what extent the use of respiratory support during bronchofiberoscopy (BF) will avoid complications such as exacerbation of hypoxemia and/or acidosis and the occurrence of hemodynamic instability.
224108763|NCT06970041|DEVICE|Use of HFNC during therapeutic FOB as a respiratory support method in patients with type 2 respiratory failure|The aim of the project is to assess the safety, indications and contraindications for therapeutic bronchofiberoscopy in patients with decompensated respiratory acidosis using: invasive mechanical ventilation (IMV), non-invasive mechanical ventilation (NIV) and high-flow nasal canulla (HFNC). Additionally, we want to determine to what extent the use of respiratory support during bronchofiberoscopy (BF) will avoid complications such as exacerbation of hypoxemia and/or acidosis and the occurrence of hemodynamic instability.
224108764|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version does not provide any normative feedback information."
224108765|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with descriptive norms information about local HIV testing rates."
224108766|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with injunctive norms information about local HIV stigma rates."
224108767|NCT06969677|OTHER|Survey questionnaire|"Each version of the questionnaire has similar questions about personal HIV testing intentions and perceived norms about other men and women's HIV testing intentions. The content of the prompt presented prior to the questions varies based on treatment arm.~This version provides personalized normative feedback with descriptive and injunctive norms information about both local HIV testing rates and local HIV stigma rates."
223724220|NCT00996216|DRUG|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
224108768|NCT04615871|DRUG|semaglutide|semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
224291245|NCT01690975|DRUG|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
224108769|NCT05066815|OTHER|Vita Enamic (Hybrid dental ceramic)|Vita Enamic (Hybrid dental ceramic) is provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology.
224108770|NCT05774470|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is a non-invasive monitoring device. The Sock secures the Sensor to the baby's foot. The Sensor measures the baby's SpO2, heart rate, and movement, and transmits the baby's readings to the Base Station. The Base Station records and monitors the baby's readings and can indicate prompts as needed based on the data sent from the Sensor.
224108771|NCT02261740|BEHAVIORAL|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
224108772|NCT03446170|BEHAVIORAL|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
224108773|NCT04568174|DRUG|PPSGG|an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies
224108774|NCT04568174|DRUG|Placebo|A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection
224108775|NCT00521963|BIOLOGICAL|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
224108776|NCT01275248|DRUG|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
224108777|NCT01275248|DRUG|Placebo|Oral tablet to match the experimental interventions
224108778|NCT06610630|DIAGNOSTIC_TEST|Assessment of Bowel Preparation Using AI-Driven Smartphone Applications|Assessment of Bowel Preparation Using AI-Driven Smartphone Applications
224108779|NCT06970587|PROCEDURE|percutaneous cystolithotripsy|to compare percutaneous cystolithotripsy with transurethral cystolithotripsy as minimally invasive surgical treatments for urinary bladder stones in pre-school age boys, and to assess the safety and the possible complications of both procedures
224108780|NCT04978753|DRUG|Anlotinib|"1. Anlotinib: 12mg/time (BSA≥1.6 m2) or 10mg/time (BSA\<1.6 m2), once a day orally, taking two weeks and stopping for one week;~2. Almonertinib: 110mg, orally once a day;"
224108781|NCT05395416|DRUG|HEC74647PA+HEC110114|administered orally once daily for 12 weeks
224108782|NCT05395416|DRUG|Placebo|administered orally once daily for 12 weeks
224108783|NCT02111811|OTHER|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
224108784|NCT02101008|DRUG|disulfiram and chelated zinc|
224108785|NCT02845869|DEVICE|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
224108786|NCT02845869|DEVICE|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
224108787|NCT03013595|BEHAVIORAL|TRAM feedback|
224108788|NCT02973672|DRUG|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
224108789|NCT05738616|COMBINATION_PRODUCT|Lenvatinib combined with TACE and Camrelizumab|Once subjects have signed the informed consent and passed screening, they will be randomized in a 1:1 ratio to either the experimental arm (lenvatinib combined with TACE and camrelizumab) or the control arm (lenvatinib combined with TACE).
224108790|NCT00499993|DRUG|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
223724221|NCT00996216|DRUG|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
223724222|NCT03553134|DIAGNOSTIC_TEST|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
224108791|NCT02467114|DEVICE|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
224108792|NCT02467114|DEVICE|Sham coil stimulation|Stimulation with a sham coil as a comparison
224108793|NCT02467114|OTHER|Control without stimulation|
224108794|NCT06971952|BEHAVIORAL|Conditional Cash Transfer Incentive for Household Contact Screening|Households with index people with TB (PWTB) will be consecutively recruited and offered a conditional cash transfer once all HHCs complete the facility-based tuberculosis (TB) screening procedures. The participants will be notified of the cash transfer during the consenting process for this phase. They will be informed that if all household contacts complete the recommended TB screening, the cash transfer will be given to the head of household during the home visit at 2 months.
224108795|NCT03305250|DEVICE|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
224108796|NCT06324097|DIAGNOSTIC_TEST|endocytoscopy|The colorectal lesions had been observed with EC-NBI and EC-stained by endoscopists before treatment that were ultimately performed histopathologic examination. The endocytoscopies (CF-H290ECI, Olympus, Tokyo, Japan) have a maximum magnification of ×520, focusing depth, 35 μm; field of view, 570 × 500μm. During EC-NBI , the endoscopist pushed the button of the endoscope to switch from white-light imaging to NBI and observed the lesion with full magnification. Finally, the endoscopist performed EC-stained mode diagnosis after staining the lesion surface with 1.0% methylene blue.
224108797|NCT01631162|OTHER|Breath sample in all patients|Breath sample will be collected by a special nylon bag
224291246|NCT01661634|DRUG|Ularitide|
224291247|NCT01661634|DRUG|Placebo|
223959298|NCT07131943|OTHER|The designed physical therapy program|The designed physical therapy program focuses on improving upper limb mobility and stability through a structured set of exercises targeting the shoulder joint. It includes prolonged stretching performed in a seated position to extend the thumb, fingers, wrist, elbow, and shoulder, along with scapular mobilization in side-lying and stretching of internal rotators in a supine position. The stretching progression begins with external rotation at 45° abduction and advances to 90° abduction and full reach toward the ground if pain-free. Joint stabilization exercises involve resistance band movements in various shoulder and elbow positions, including controlled abduction, flexion, scapular movements, and external rotation, all aimed at enhancing joint control and muscular coordination.
223959299|NCT06675929|DRUG|BI 770371|BI 770371
223959300|NCT06675929|DRUG|Placebo for BI 770371|Placebo for BI 770371
223959301|NCT02010086|BEHAVIORAL|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
223959302|NCT02010086|BEHAVIORAL|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
223959303|NCT06679985|DRUG|Casdozokitug|Solution for infusion
223959304|NCT06679985|DRUG|Toripalimab|Solution for infusion
223959305|NCT06679985|DRUG|Bevacizumab|Solution for infusion
223959306|NCT07005752|DRUG|CnU cap. 250mg & Ursa placebo tab. 200mg|CnU capsule(Magnesium Salt Trihydrate of Chenodeoxycholic Acid and Ursodeoxycholic Acid) and Ursa placebo tablet will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.
223959307|NCT07005752|DRUG|Ursa tab. 200mg & CnU placebo cap. 250mg|Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.
223959308|NCT07008079|PROCEDURE|Flapless punch|use of flapless puch surgery to place dental implants
223959309|NCT07008079|PROCEDURE|Flapless mini-incision|Use of a flapless mini-incision to place a dental implant
223959310|NCT07008079|PROCEDURE|Conventional flap|Use of a conventional surgical flap to place a dental implant
223959311|NCT06869785|BIOLOGICAL|Ofatumumab approved dose|Approved dosage
223959312|NCT06869785|BIOLOGICAL|Ofatumumab new dose|New dosage
223959313|NCT06870578|OTHER|Diet modification|In Study 2 only, children will be provided all meals for a 7-day period. Meals will consist of nutritious foods, calories provided will exceed the child's estimated daily caloric need, and children will be asked to consume meals ad libitum.
223959314|NCT06869226|DRUG|Camrelizumab + Nab-paclitaxel + Cisplatin|Three cycles of neoadjuvant therapy with camrelizumab (200 mg/dose D1, IV, Q3W)+Nab-paclitaxel(260 mg/m2 D1，IV，Q3W)+Cisplatin(75 mg/m2 D1，IV，Q3W); for patients with organ preservation intent entered into the watchful waiting strategy group and received radiotherapy (50.4 Gy/28 doses), with camrelizumab maintenance therapy for 4-12 weeks after the end of radiotherapy, and a total of up to one year of camrelizumab.
223959315|NCT06035588|OTHER|Daily whitening|Daily application of a 16% carbamide peroxide bleaching gel in volunteers without sensitivity.
223959316|NCT06035588|OTHER|Alternate whitening|Volunteers will apply the whitening gel at 16% carbamide peroxide, alternating a rest day with an application day. Patients should not be sensitive before starting the study.
223959317|NCT06811272|DRUG|Epcoritamab|Bispecific IgG1 antibody
223959318|NCT04447586|OTHER|Pressure measurement during exhalation through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer|"Participants performed exhalation attempts through a device consisted of a drinking straw of an inner diameter of 5mm, a disposable mouthpiece and a manometer, following the instructions of Command A and B (A:please blow continuously so that you feel low resistance during exhalation and B:please blow continuously so that you feel moderate resistance during exhalation) in a specific order for each group. Every volunteer performed 3 attempts for each command.The outputs of the 3rd attempt were used to the study."
223959319|NCT04447586|OTHER|Pressure measurement during exhalation through an alternative PEP device/soft drink straw.|"Participants were requested to exhale as indicated by the right command (Command A or B), for 3 sets of 10 repetitions. This procedure included short breaks between sets."
223959320|NCT06684314|DRUG|Efanesoctocog alfa|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
223959321|NCT06687226|DIETARY_SUPPLEMENT|Reconstitutable food powder|During the intervention week, participants will be asked take one dose of a reconstitutable food powder provided in a ziplock bag. This powder will be a mix of Gatorade Zero Powder (1 serving) and 1 serving of commercially available powders of either one or all of the following: camu camu, kelp or maqui. The powder mix in the bag will be added to water and drunk by the participant as soon as possible after having a bowel movement (baseline stool sample). Food powders are sourced from reputable companies and are safe for consumption (Gatorade is a wellrecognized brand and available in grocery stores nationally, Navitas Organics provides certified organic, third-party tested plant food powders with fairtrade certification).
223959322|NCT05409846|DIAGNOSTIC_TEST|Alfa-galactosidase activity and genetic testing for Fabry diagnosis|Dry blood spot analysis and blood sample (if necessary)
223959323|NCT07016269|DRUG|CnU capsule 500 mg(250mg 2 capsule)|According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.
223959324|NCT07016269|DRUG|CnU placebo capsule 500 mg(250mg 2 capsule)|According to the randomly assigned treatment groups, the medication will be administered orally at a dose of 500 mg (2 capsules) once daily for a total of 24 weeks, preferably at the same time each day after meals.
223959325|NCT06869213|DRUG|Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin|All subjects were given 3 cycles of neoadjuvant therapy with adebrelimab (1200 mg D1, IV, Q3W)+Nab-paclitaxel(250 mg/m2 D1，IV，Q3W)+Cisplatin(75 mg/m2 D1，IV，Q3W) preoperatively. Within 4-8 weeks of completion of neoadjuvant therapy, all subjects who were suitable for surgery underwent radical surgery, and patients who underwent radical esophageal cancer with R0 resection were given adebrelimab monotherapy postoperatively until disease recurrence or metastasis, toxicity intolerance, initiation of a new antitumor therapy, subject-initiated request to withdraw from the study, and subject's judgement that the subject needed to be withdrawn from the study. The maximum duration of adebrelimab in the adjuvant phase is 16 cycles.
223541966|NCT06132464|BEHAVIORAL|Expanding Communication and Language Generated in Conversation Treatment|ECoLoGiC Treatment is a behavioral therapy developed to improve language abilities in everyday conversation for people with aphasia. It is delivered through therapeutic use of spontaneous conversational interactions between a speech-language pathologist and a person with aphasia. ECoLoGiC Treatment is based on theories of conversational interaction in adults without communication disorders, as well as on theories of neuroplasticity, rehabilitation, and learning. The therapy consists of two components: a) Therapeutic Conversation, during which the pair discuss any topic of interest to the person with aphasia, while the speech-language pathologist uses techniques to promote social interaction; and b) Therapeutic Repair, used when communication breakdown occurs. At this time, the speech-language pathologist implements the intervention's 7-step least-to-most hierarchy, supporting the person's independence and learning in communicative problem-solving to communicate the desired idea.
223959326|NCT06424860|DIETARY_SUPPLEMENT|Fish oil|For 12 months
223959327|NCT06424860|DRUG|Metformin|12 months
223959328|NCT06424860|COMBINATION_PRODUCT|Fish Oil and Metformin|12 months
223959329|NCT07035769|DRUG|Debio 1453P|Powder for oral solution
223959330|NCT07035769|DRUG|Placebo|Oral solution
223959331|NCT06705335|OTHER|Blood sample|On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.
223959332|NCT06887543|OTHER|Meal timing|Participants either eat all of their daily calories between 8 AM and 4 PM with 16 hours fasting for six days, or they eat the same meals ad lib daily for six days. After post-testing, they crossover to the other arm.
223959333|NCT06887543|OTHER|Time restricted eating|Eating restricted to 8 AM - 2 PM for 80% of caloric intake, the remaining 20% consumed by 4 PM, subsequent 16-hour fasting (4 PM-8 AM) each day for six days while on Time Restricted Arm.
223959334|NCT06887543|OTHER|Usual feeding pattern.|Participant consumes usual diet ad lib without enforced fasting period for six days while on Usual Feeding Pattern arm.
223959335|NCT06887010|DRUG|ABBV-101|Oral: Tablet
223959336|NCT06744660|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID Test|The Metrix COVID Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2 via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
223959337|NCT06744920|DRUG|Remibrutinib (Blinded)|Remibrutinib (Blinded) active treatment
223959338|NCT06744920|OTHER|Placebo|Placebo
224108798|NCT00069121|DRUG|Capecitabine|1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
223959339|NCT06744920|DRUG|Remibrutinib (Open Label)|Remibrutinib (Open Label) active treatment
223959340|NCT05338905|OTHER|Palliative Therapy|Receive standard symptom management
223959341|NCT05338905|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaire
223959342|NCT05338905|OTHER|Questionnaire Administration|Complete quality of life questionnaire
223959343|NCT05488002|BEHAVIORAL|Pharmaceutical intervention|Pharmacists will provide clinical recommendations to patients allocated to the intervention group. Furthermore, they will monitor patients' parameters and follow-up with them. These interventions include daily medication review, weight, heart monitoring, blood glucose level, follow-up on medication adherence, and even mental status.
223959344|NCT06789692|OTHER|tobacco smoking substitution products|Offer of preference-based smoking substitution menu, consisting of e-cigarettes or nicotine pouches or nicotine patches in addition to standard of care. This menu will be offered by the treating physician during the routine cohort visit and the participant can choose one product to test as an alternative to tobacco smoking. The products will be handed out directly after the consultation and are provided free of charge for 6 months.
223959345|NCT06047080|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab
223959346|NCT06047080|DRUG|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin in combination with R-CHP
223959347|NCT06047080|DRUG|Rituximab|Participants will receive IV rituximab
223959348|NCT06047080|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide as part of CHP chemotherapy
223959349|NCT06047080|DRUG|Doxorubicin|Participants will receive IV doxorubicin
223959350|NCT06047080|DRUG|Prednisone|Participants will receive oral prednisone as part of CHP chemotherapy
224108799|NCT00069121|DRUG|Oxaliplatin|130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
224108800|NCT00069121|DRUG|Leucovorin (LV)|Administered by one of two regimens, as specified in the arm description.
224108801|NCT00069121|DRUG|5-Fluorouracil (5-FU)|Administered by one of two regimens, as specified in the arm description.
224108802|NCT01832961|DEVICE|Flutter valve exercises|30 minutes of flutter exercises
224108803|NCT01832961|DEVICE|Flutter Sham exercises|30 minutes of flutter-sham exercises
224108804|NCT01832961|DEVICE|Flutter and bronchodilator exercises|Flutter + bronchodilator exercises with an interval of 3 to 5 days
224108805|NCT06812156|OTHER|Cardiovascular Health Education|This intervention aims to promote healthy behavioral changes at both individual and community levels by supporting education with virtual reality technology.
224108806|NCT05435430|OTHER|PERSPECTIVE, MULTICENTRIC and observational|we will enroll women with 25-45ys old and previously SARS-COV2 infection. first outcome to be investigate the impact of SARS-COV2 infection on female reproductive health and the main clinical-laboratory parameters (FSH, LH, AMH) relating to women with procreative research, in a path of medically procreation assisted programm and on any quantitative variations, duration and periodicity of the menstrual cycle after Covid infection compared to the pre-infection period.
224108807|NCT00824694|OTHER|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
224108808|NCT00824694|OTHER|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
224108809|NCT00824694|OTHER|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
223959351|NCT06269640|DEVICE|Septal Scoring Along Midline Endocardium|Transcatheter ventricular myotomy called SEptal Scoring Along the Midline Endocardium (SESAME) that relies on intramyocardial guidewire navigation and transcatheter electrosurgery
223959352|NCT05588141|DRUG|Zotiraciclib|Zotiraciclib will be given orally at the DL1, DL-1, or DL 2 once a day on days 1, 4, 8, 11, 15, 18 of every 28-days cycle (18 cycles total).
223959353|NCT05058976|DRUG|Romosozumab|Monthly dose: 210 mg subcutaneous injection
223959354|NCT05058976|DRUG|Placebo|Monthly saline injection
223959355|NCT05058976|DRUG|Zoledronic acid|5 mg IV infusion at Month 12 Visit
223959356|NCT05058976|DIETARY_SUPPLEMENT|Calcium and Vitamin D|Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
223959357|NCT05332236|DIAGNOSTIC_TEST|Parent-Adolescent Communication Scale (questionnaire)|Observational psychometric validation study
223959358|NCT02836899|DRUG|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
223959359|NCT02836899|OTHER|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
223959360|NCT04861259|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 milligrams (mg) intravenous (IV) (for participants with body weight at least 40 (\>=) and up to 100 kilograms (kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and every 4 weeks (Q4W) thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight \>= 40kg to \<100kg) or 1020 mg SC (for participants with body weight \>=100kg).
224108810|NCT05476692|OTHER|AOFAS score and VAS|Clinical outcome by the Visual analogue scale (VAS) and the American Orthopaedic Foot and Ankle (AOFAS) score.
224108811|NCT03661541|DRUG|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
224108812|NCT01815398|BEHAVIORAL|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
224108813|NCT01815398|BEHAVIORAL|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
224108814|NCT00231478|DRUG|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
224108815|NCT00231478|DRUG|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
223724223|NCT03553134|DIAGNOSTIC_TEST|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
224108816|NCT02330991|DRUG|Temozolomide|
224108817|NCT00152373|DRUG|Levetiracetam|
224108818|NCT04095416|DEVICE|ACE compression wrap|Bilateral lower extremity ACE compression wraps
224291248|NCT03508869|DRUG|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
223959361|NCT05518903|PROCEDURE|Computed Tomography|Undergo CT
223959362|NCT05518903|DRUG|Gallium Ga 68 FAPi-46|Given IV
223959363|NCT05518903|PROCEDURE|Positron Emission Tomography|Undergo PET
223959364|NCT05422794|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223959365|NCT05422794|PROCEDURE|Biopsy Procedure|Undergo biopsy
223959366|NCT05422794|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223959367|NCT05422794|PROCEDURE|Computed Tomography|Undergo CT
223959368|NCT05422794|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223959369|NCT05422794|DRUG|Nab-paclitaxel|Given IV
223959370|NCT05422794|BIOLOGICAL|Pembrolizumab|Given IV
223959371|NCT04098744|DRUG|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
223959372|NCT04098744|DRUG|Placebo vaginal insert|Placebo for artesunate vaginal inserts
223959373|NCT05953389|DRUG|Pitolisant|histamine H3 receptor antagonist/inverse agonist
223959374|NCT05953389|DRUG|Placebo|Matching placebo of pitolisant tablets
223959375|NCT06092749|OTHER|Transgrade technique (TG)|Transgrade (TG) Epidural Steroid Injection technique
223959376|NCT06092749|OTHER|Interlaminar technique (IL)|Interlaminar (IL) Epidural Steroid Injection technique
223959377|NCT06444724|COMBINATION_PRODUCT|APP|Patients in the application group communicated via Line applications (APP group) with guidance on preparation before colonoscopy through video media.
223959378|NCT04630873|DRUG|Botulinum toxin|The triceps surae along with the posterior tibialis muscle will be injected. The units that will be injected are the average being injected in our University Clinic. I.e. 50 units for each head of the gastrocnemius muscle- single injection site, 100 units for the soleus muscle- two injection sites and 50 units for the posterior tibialis muscle- single injection site.
224108819|NCT04630340|DEVICE|STEADES-2|In this arm, the subjects will use a novel exhaled breath carbon monoxide measurement instrument (STEADES-2) for self surveillance of their smoking status. In addition, the subjects will download the STEADES-2 mobile phone application to pay serious games relating to smoking cessation, receive push-though motivational messages and e-coaching from trained healthcare professionals.
223959379|NCT04630873|DIAGNOSTIC_TEST|gait analysis|The gait analysis will be performed with two systems. A foot pressure sensitivity walkway (medicapteurs Win-Track), and an IMU network system (RehaGait Pro) using seven IMU's placed in specific anatomical positions. In combination those two systems can provide a wide range of spatiotemporal analytics of gait:
223959380|NCT06305416|DRUG|Ranibizumab 10mg/ml Injection|Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
223959381|NCT06305416|DRUG|Lucentis|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
224108820|NCT04138706|DRUG|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
224108821|NCT04138706|DRUG|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
224108822|NCT03715543|PROCEDURE|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
223959382|NCT04466345|BIOLOGICAL|Semaglutide|3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks
223959383|NCT04466345|BIOLOGICAL|Placebo|Semaglutide placebo capsules
223959384|NCT05655715|RADIATION|Stereotactic body radiotherapy|8 Gray x 3
224108823|NCT01134510|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
224108824|NCT01134510|DRUG|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
224108825|NCT03312010|DEVICE|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
223541967|NCT02710188|DRUG|HTL0009936 modified release|HTL0009936 modified release
223541968|NCT02710188|DRUG|HTL0009936 immediate release|HTL0009936 immediate release
223959385|NCT05655715|DRUG|Ipilimumab Injection [Yervoy]|1 mg/kg IV Q3W for four doses,
223959386|NCT05655715|DRUG|Nivolumab Injection [Opdivo]|Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W
223959387|NCT05655715|PROCEDURE|Biopsies|From soft tissue metastases.
223959388|NCT05755360|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to routine clinical practice at the discretion of the treating physician. The decision to switch from DPP4i treatment to oral semaglutide is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
223959389|NCT06100614|DIAGNOSTIC_TEST|Presepsin|"Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes."
223959390|NCT06100614|DIAGNOSTIC_TEST|Standard Care|Standard care according to the Dutch EOS guideline
224108826|NCT03312010|DEVICE|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
224108827|NCT05610969|OTHER|Music|patients in this group will receive self-selected music after the golden moment has been completed between the patient, provider, and nursing staff
224108828|NCT05610969|DRUG|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
223959391|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
223959392|NCT04015609|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
223959393|NCT04015609|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
223959394|NCT04015609|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
223959398|NCT06418711|DRUG|Clofazimine Inhalation Suspension|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
223959399|NCT06418711|DRUG|Placebo|Eligible participants will be randomized in a 2:1 ratio to 1 of 2 possible treatment assignments, Clofazimine Inhalation Suspension or Placebo.
223959400|NCT04198428|OTHER|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
223959401|NCT05503758|DEVICE|Myoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)|The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).
223959402|NCT02652299|BIOLOGICAL|Synovial biopsy|Synovial tissue for analysis and biobank.
223959403|NCT05693480|DEVICE|Balance sensor|Participants will engage in the device test, clinical assessment tests, and related user experience surveys to uncover problems in the effectiveness, efficiency, and acceptance of the device prototype. The whole test will last six months, and the outcome will be assessed pre- and post-implementation for comparison and validation. The major testing criteria include the validity and reliability of the device, user experiences, and the accuracy of the device's fall prediction.
223959404|NCT02001389|DRUG|EVP-6308|Arms 1, 2, 3, 4
223959405|NCT05535582|DIAGNOSTIC_TEST|Investigation of clinical, laboratory and imaging profile|Complete and comprehensive medical interview will be conducted in each eligible patient after revascularization. In addition, patient's laboratory data will be recorded on admission and during hospitalization. Furthermore, each patient will undergo a full echocardiographic examination with a specific protocol.
223959406|NCT04071236|DRUG|Avelumab|Given IV
223959407|NCT04071236|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224108829|NCT06596447|DEVICE|Deep Brain Stimulation|While most patients with obsessive compulsive disorder (OCD) eventually respond to treatment with medication and/or behavioral therapy, a small minority do not improve following all conventional treatments. Obsessive-compulsive disorder (OCD) can sometimes be difficult to treat with medication and psychotherapy. For these patients, in this study, we employ deep brain stimulation (DBS), an advanced surgical treatment that uses electrical impulses.
223959408|NCT04071236|PROCEDURE|Bone Scan|Undergo bone scan
223959409|NCT04071236|PROCEDURE|Computed Tomography|Undergo CT
223959410|NCT04071236|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223959411|NCT04071236|DRUG|Peposertib|Given PO
223959412|NCT04071236|OTHER|Questionnaire Administration|Ancillary studies
223959413|NCT04071236|RADIATION|Radium Ra 223 Dichloride|Given IV
223959414|NCT06588686|DRUG|Buloxibutid|Buloxibutid
223959415|NCT06588686|DRUG|Placebo|Placebo
223959416|NCT02221700|PROCEDURE|Massage Therapy|Undergo massage therapy
223959417|NCT02221700|OTHER|Quality-of-Life Assessment|Ancillary studies
223959418|NCT02221700|OTHER|Questionnaire Administration|Ancillary studies
223959419|NCT02968069|DEVICE|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
223959420|NCT04567303|DRUG|Zifibancimig|"Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter in the study eye.~Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant.~Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant."
223959421|NCT04567303|DRUG|Ranibizumab|Participants will receive ranibizumab 100 mg/mL through the PD implant
223541969|NCT03423433|BEHAVIORAL|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
224108830|NCT03244098|BEHAVIORAL|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
224108831|NCT03037905|DEVICE|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
224108832|NCT03689738|OTHER|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
224108833|NCT03689738|OTHER|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
223959422|NCT04567303|DEVICE|Port Delivery Platform|Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
223959423|NCT02518802|DRUG|Gefitinib|Gefitinib 250mg per day for 2 years.
223959424|NCT02518802|DRUG|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
223959425|NCT00540800|DRUG|docetaxel|given in combination with epirubicin or capecitabine
224108834|NCT04971590|OTHER|Participant completed survey|Participants will be required to complete the participant survey.
223959426|NCT00540800|DRUG|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
223959427|NCT00540800|DRUG|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
223541970|NCT04810364|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich,Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (OCT, IVUS, VH-IVUS, NIRS) and/ or percutaneous intervention (with implantation of the medical device).
223959428|NCT00958971|DRUG|TKI258|All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
223959429|NCT00668746|DRUG|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
223959430|NCT05117840|DEVICE|Low-dose CT scan|Standard of care screening for individuals at high-risk of lung cancer
223959431|NCT02109172|DRUG|TD-4208|
223959432|NCT02109172|DRUG|Placebo|
223959433|NCT03539237|OTHER|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
223959434|NCT05090800|DRUG|Definity contrast during ultrasound|Participants will undergo an ultrasound contrast evaluation of both kidneys. This will include placement of an intravenous (IV) catheter in a vein and the delivery of Definity ultrasound contrast agent through the IV. Imaging will be completed for each kidney. The proposed total dose for adult patients will not exceed 20 microliters/kilograms (kg). Each individual dose not to exceed 10 microliters/kg. At initiation of patient studies, the dose will start at 10 microliters/kg for the first injection and a second 10 microliters/kg dose to evaluate the contralateral kidney. However, if ultrasound findings in patient studies demonstrate a dose that is too high (unable to make accurate ultrasound assessment), the dose will be reduced.
223959435|NCT05676970|BEHAVIORAL|Telehealth: Personalized Preventative Medicine Strategies|Individuals in this arm will complete a personalized telehealth interventions that focus on nutrition, work-life balance, medication compliance, herbals, exercise targets hyperlipidemia, diabetes and hypertension around individual risks for development of the disease state. All educations will be completed one-on-one as well as small group.
223959436|NCT05676970|BEHAVIORAL|TeleHealth: Preventative Medicine Education|Individuals in this arm will complete standardized telehealth interventions that focus on nutrition, work-life balance, mental health, diabetes and hypertension general education. All educations will be completed one-on-one as well as small group.
223959437|NCT03867656|OTHER|GLP-2|GLP-2 injection
223959438|NCT03867656|OTHER|GIP|GIP injection
223959439|NCT03867656|OTHER|Placebo|Placebo injection
223959440|NCT01906073|DRUG|intranasal fentanyl spray|
223959441|NCT01906073|DRUG|slow release morphine|
223959442|NCT04184609|OTHER|Control|In this condition, the participants will not receive any medications or drugs before exercise
223959443|NCT04184609|DRUG|Albuterol|180 mcg of Albuterol will be administered before exercise
223959444|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
223959445|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
223959446|NCT00721045|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
223959447|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
224108835|NCT04971590|OTHER|Medical chart review|Data will be collected from medical charts of participants.
224108836|NCT06667128|OTHER|Rapid Uptitration of Guideline-Directed Medical Therapy|Rapid up-titration of GDMT guided by protocol-specific guideline.
224291249|NCT03508869|DRUG|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
224291250|NCT03508869|DRUG|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
223959448|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
223959449|NCT00721045|PROCEDURE|standard-of-care treatment with mock mapping and injection procedures.|Mock
223959450|NCT01107717|DRUG|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
223541971|NCT05365516|OTHER|Implementing medical safety huddles|These short, virtual huddles are led by a huddle leader and occur on a weekly or once every two week basis. Each site will be adapting the Medical Safety Huddles for their context and workflow to specifically engage physicians.
223541972|NCT05677477|OTHER|simulation training|A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
223959451|NCT01107717|DRUG|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
223959452|NCT02962622|OTHER|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
223959453|NCT01125956|BEHAVIORAL|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
223959454|NCT01125956|BEHAVIORAL|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
223959455|NCT00310024|DRUG|bortezomib|Given IV
223959456|NCT00310024|DRUG|vorinostat|Given orally
223959457|NCT00310024|OTHER|laboratory biomarker analysis|Correlative studies
223959458|NCT00310024|OTHER|pharmacological study|Correlative studies
223959459|NCT05716971|PROCEDURE|Densiron-68 (heavy silicone oil) tamponade for retinal detachment|pars plana vitrectomy using Densiron-68 at thee end of surgery
223959460|NCT02409732|DRUG|aminolevulinic acid hydrochloride|
223959461|NCT02409732|PROCEDURE|Photodynamic therapy with blue light|
223959462|NCT01167816|DRUG|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
223959463|NCT02099656|DRUG|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
223959464|NCT02099656|DRUG|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
223959465|NCT02099656|DRUG|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
223959466|NCT02099656|DRUG|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
223959467|NCT01810640|PROCEDURE|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
223959468|NCT05423171|OTHER|Intensive bimanual therapy|60-hour intensive therapy promoting the use of both hands (ex: bimanual activities, games,...)
223959469|NCT01286870|DEVICE|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
223959470|NCT01286870|DEVICE|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
223959471|NCT04967092|DRUG|Modified Xiao-Feng Powder + Antiallergics|Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
223959472|NCT04967092|OTHER|Placebo + Antiallergics|Placebo granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
223959473|NCT00079599|DRUG|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
223959474|NCT00079599|OTHER|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
223959475|NCT00841945|DRUG|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
223959476|NCT00841945|DRUG|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
223959477|NCT00841945|DRUG|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
223959478|NCT00841945|DRUG|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
223959479|NCT00841945|PROCEDURE|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
223959480|NCT06963281|DRUG|IBI3020|Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection
223959481|NCT03960437|DRUG|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
223959482|NCT01732419|BEHAVIORAL|Home-based training|Home-based exercise training for cardiac patients.
223959483|NCT01732419|BEHAVIORAL|Centre-based training|Usual exercise training in an outpatient setting.
223959484|NCT00249847|DRUG|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
224108837|NCT06667128|DIAGNOSTIC_TEST|Elecsys® NT-proBNP - Roche Diagnostics|An assay provided by Roche (Elecsys® NT-proBNP - Roche Diagnostics) will be used to assess NT-proBNP levels in the Rapid Up-Titration GDMT Group with Point-of-Care (PoC) Monitoring, with the purpose of evaluating any differences in marker dosage between the indicated method and the monitoring by the hospital laboratory analysis.
224108838|NCT06667128|OTHER|Rapid Up-Titration GDMT Group with Hospital Monitoring|Rapid Up-Titration GDMT Group guided by protocol-specific guideline and hospital monitoring.
224108839|NCT06661759|BEHAVIORAL|Clinic-based and technology-supported sleep intervention|CATS sleep intervention: The in-person sleep education and consultation will consist of 3 face-to-face, one-on-one sessions held 3 months apart during the child's routine clinic visit.The digital component of the sleep intervention will extend in-person education by providing ongoing support. Participants will receive one digital session per week for four weeks after the baseline, 3-month, and 6-month clinic visits, totaling 12 sessions.
224108840|NCT05913401|BEHAVIORAL|Aerobic Exercise|20 minutes of supervised aerobic exercise on a treadmill prior to each TMS session
223959485|NCT00249847|DRUG|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
223959486|NCT02332096|DEVICE|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
223959487|NCT05893693|OTHER|Biological|CT0594CP
223959488|NCT02320045|DRUG|ITCA 650 (Exenatide in osmotic mini pump)|
223959489|NCT01993251|DRUG|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
223959490|NCT01993251|DRUG|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
223959491|NCT01993251|DRUG|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
223959492|NCT01993251|DRUG|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
223959493|NCT00473512|DRUG|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
223959494|NCT00473512|DRUG|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
223959495|NCT00473512|DRUG|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
223959496|NCT02551471|OTHER|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
223959497|NCT02551471|OTHER|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
223959498|NCT02551471|OTHER|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
223959499|NCT01598688|OTHER|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
223959500|NCT01598688|OTHER|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
223959501|NCT03809858|OTHER|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
223959502|NCT03602547|DRUG|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
223959503|NCT05686343|DIAGNOSTIC_TEST|Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy|Ecocardiography at 1st, 3rd and 7th day of life Doppler US (cranial and renal) at 1st, 3rd and 7th day of life Near-infrared spectroscopy monitoring after birth during first 3-days of life
223959504|NCT02519829|PROCEDURE|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
223959505|NCT02519829|PROCEDURE|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
223541973|NCT05441423|RADIATION|CBCT|CBCT Scans. conventional \& ultra low dose
223959506|NCT02519829|PROCEDURE|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
223959507|NCT02519829|PROCEDURE|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
224108841|NCT05913401|BEHAVIORAL|Video Watching|20 minutes of watching documentaries or educational videos prior to each TMS session
223959508|NCT03924596|DRUG|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
223959509|NCT03924596|DRUG|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
223959510|NCT05569265|PROCEDURE|Intraoperative hemodynamic management|Goal directed Hemodynamic therapy
223959511|NCT00267956|DRUG|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
223959512|NCT00267956|DRUG|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
223959513|NCT05121649|OTHER|Video streaming|Video streaming as a supplement to telephone during emergency calls for dispatchers at EMCCs
223959514|NCT01263223|DRUG|LY2216684|Administered orally
223959515|NCT01263223|DRUG|Placebo|Administered orally
223959516|NCT01495754|OTHER|coffee|Comparison of different amounts of coffee
223959517|NCT00847847|PROCEDURE|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
223959518|NCT02246647|DIAGNOSTIC_TEST|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
223959519|NCT02246647|PROCEDURE|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
223959520|NCT02246647|PROCEDURE|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
223959521|NCT02637362|PROCEDURE|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
223959522|NCT02637362|PROCEDURE|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
223959523|NCT02637362|PROCEDURE|Metatarsal block|A metatarsal block will be performed using a standardised technique
223959524|NCT02637362|PROCEDURE|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
223959525|NCT06537570|BEHAVIORAL|Guided Imagery Practice|"Before the guided imagery application, the language translation of the guided imagery usage steps guide prepared by Owen (2010)27 was done by a translation center in a certified manner. Then, a relaxing, soothing, soft and slow-paced CD consisting of mixed nature sounds, photographs and music lasting 15 minutes and 50 seconds was prepared in the sound recording studio with the psychological counselor.~Data collection forms were filled in by the researcher using face-to-face interview technique for the women who agreed to participate in the study. The guided imagery video was shared with the women and they were made to watch it once a day for 12 weeks in a quiet, calm, uncrowded, dimly lit room in their homes. The women in the control group did not receive any interventions other than routine interventions during outpatient follow-up."
223959526|NCT00195416|DRUG|Etanercept|Etanercept 25mg Injection, 2 times/week
223959527|NCT05936944|OTHER|Exposure to totally artificial lighting|The second group of patients will be admitted to an ICU without windows and with a totally artificial lighting
223959528|NCT06095752|OTHER|blood viscosity , albumin / fibrinogen ratio and red cell distribution|In multiple myeloma patients ,we get blood viscosity , albumin / fibrinogen ratio and red cell distribution directly after confirmed diagnosis to determine the prognosis of the disease in association with these tests results
223959529|NCT05667688|DRUG|Tinlarebant (LBS-008)|A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
223959530|NCT00095251|DRUG|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
223959531|NCT00095251|DRUG|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
224291251|NCT02549846|DRUG|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
223959532|NCT03144076|OTHER|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
223959533|NCT01852851|BEHAVIORAL|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
223959534|NCT00648271|DRUG|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
223959535|NCT00648271|DRUG|Lopressor® Tablets 50 mg|1x50mg, single dose fed
223959536|NCT03557307|BIOLOGICAL|Benralizumab|Benralizumab subcutaneous injection
223959537|NCT01737034|OTHER|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
223959538|NCT03937076|PROCEDURE|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~1. between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~2. between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
223959539|NCT05692180|DRUG|Benralizumab|Benralizumab active solution will be administered SC to the patients.
223959540|NCT05692180|DRUG|Placebo|Placebo solution will be administered SC to the patients.
223959541|NCT01509599|PROCEDURE|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
223959542|NCT01509599|PROCEDURE|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
223959543|NCT00212979|OTHER|non intervention study|
223959544|NCT04158453|DRUG|AUT00201|Oral dose of AUT00201
223959545|NCT04158453|DRUG|Placebo|Oral dose of placebo
223959546|NCT02225600|DRUG|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
223959547|NCT02225600|DRUG|Placebo|Intranasal Placebo
223959548|NCT02225600|DRUG|24 IU intranasal Oxytocin|
223959549|NCT03425045|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
223959550|NCT03425045|PROCEDURE|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
223959551|NCT03425045|DRUG|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
223959552|NCT06136325|PROCEDURE|Obsidian RFP anal fistula surgery|Anal fistula closure with instillation in the fistula tract and the inner ostium of Obsidian RTF®
223959553|NCT02430935|BEHAVIORAL|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
223959554|NCT02430935|BEHAVIORAL|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
223959555|NCT04013347|PROCEDURE|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
223959556|NCT03852381|DEVICE|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
223959557|NCT05935683|OTHER|Severe Uncontrolled Chronic Rhinosinusitis patients (CRS)|Obsertvation
223959558|NCT00010322|DRUG|atamestane|
223959559|NCT00010322|DRUG|toremifene|
223959560|NCT00516178|DRUG|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
223959561|NCT00516178|DRUG|Saline|3 infusions, perioperative or post-PTCA
223959562|NCT02519270|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein.
224291252|NCT02153892|DEVICE|GDS Accucinch System|Percutaneous Coronary Intervention
223959563|NCT05580302|OTHER|Transcranial Magnetic Stimulation (TMS)|An anatomical T1 magnetic resonance image (MRI) with high resolution will be acquired on a separate day before the TMS experiment. The image will be imported into the neuronavigation system (Nexstim, Helsinki, Finland) to guide the localization of the primary motor cortex (M1) for laryngeal muscle representation. Prior to M1 mapping for laryngeal muscle representation, mapping of the representation for hand muscle representation will be performed. Hand region excitability (abductor pollicis brevis, APB) will be evaluated by using surface electrodes attached to the right-hand APB muscle. The cSP threshold is defined as the lowest TMS intensity that elicits a cSP in 5 out of 10 consecutive trials. Single-pulse cortical stimulations will be performed during the vocalization of sustained /i/ sound.
223959564|NCT04093570|DRUG|ASTX727|ASTX727 film-coated, immediate-release FDC tablets
223959565|NCT02612116|DRUG|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
223959566|NCT02612116|DRUG|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
223959567|NCT02612116|DRUG|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
223959568|NCT00483171|DRUG|CP-945,598|CP-945,598
223959569|NCT00483171|BEHAVIORAL|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
223959570|NCT00483171|BEHAVIORAL|Low Calorie Diet|Low calorie diet
223959571|NCT00205205|BEHAVIORAL|peer mentoring|
223959572|NCT02351609|BEHAVIORAL|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
223959573|NCT02351609|OTHER|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
223959574|NCT02399982|OTHER|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
223959575|NCT02399982|OTHER|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
223959576|NCT03184519|DIAGNOSTIC_TEST|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
223959577|NCT04374305|DRUG|Brigatinib|Oral daily per predetermined dosage per protocol.
223959578|NCT04374305|DRUG|Neratinib|Oral daily per predetermined dosage per protocol.
223959579|NCT01613573|DRUG|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
223959580|NCT01613573|DRUG|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
223959581|NCT05967689|DRUG|TAS6417|Oral tablets
223959582|NCT05967689|DRUG|CYP Cocktail|Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.
223959583|NCT05967689|DRUG|Transporter Cocktail|Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.
223959584|NCT02404012|DIETARY_SUPPLEMENT|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
223959585|NCT04366115|DRUG|AVM0703|Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
223959586|NCT04366115|DRUG|Placebo|Single IV infusion in normal saline over 1 hour to patients.
223959587|NCT04624854|DRUG|Clopidogrel and aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
223959588|NCT04624854|DRUG|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
223959589|NCT05417685|DEVICE|Acute and post-acute|These programs will cover patients suffering from acute or post-acute musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
224291253|NCT04916483|OTHER|group cognitive stimulation therapy|The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
224291254|NCT04916483|OTHER|usual care|The control group maintains the unit routine treatment.
223959590|NCT05417685|DEVICE|Chronic|These programs will cover patients suffering from chronic musculoskeletal conditions including, but not limited to, shoulder pain (tendinitis/impingement/bursitis), neck pain, low back pain, knee or hip pain/osteoarthritis, which significantly impact their quality of life, to the extent they seek specialised care in direct relation to these disorders.
223959591|NCT05417685|DEVICE|Post-surgical|These programs will cover patients submitted to surgery for a given musculoskeletal condition, including, but not limited to, shoulder tendon repair, shoulder replacement, spinal surgery, hip or knee replacement, meniscal repair, knee ligament reconstruction, undergoing physical rehabilitation programs after surgery.
223959592|NCT06641076|DRUG|Sonelokimab|Randomized treatment, parallel-group
223959593|NCT06641076|DRUG|Placebo|Randomized treatment, parallel-group
223959594|NCT06639074|PROCEDURE|Biopsy|Undergo biopsy
223959595|NCT06639074|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223959596|NCT06639074|PROCEDURE|Computed Tomography|Undergo CT
223959597|NCT06639074|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
223959598|NCT06639074|PROCEDURE|Leukapheresis|Undergo leukapheresis
223959599|NCT06639074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223959600|NCT06639074|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
223959601|NCT06639074|DRUG|Placebo Administration|Given ID
223959602|NCT06639074|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|Given IM
223959603|NCT04501354|DRUG|Mesenchymal Stem Cell|Mesenchymal Stem Cell + NaCl 0,9% 2ml
223959604|NCT06644235|OTHER|Cold Application|Before DFU care, the patient was given an appropriate position and the materials (forceps, scalpel, sponge, pad, bandage, etc.) and the temperature of the 0.9% NaCl solution kept in the refrigerator for 24 hours were measured with an infrared thermometer (+4°C to +8°C) and taken to the treatment area. The solution was transferred to a 50 mL syringe in a sterile manner. The solution was instilled into the wound simultaneously with wound care (5-15 min).
223959605|NCT05395754|DEVICE|App Intervention|Use of the PCheck app, an app encouraging STI prevention behaviors.
223959606|NCT00156975|DRUG|Capecitabine|
223959607|NCT00156975|DRUG|Oxaliplatin|
223959608|NCT04010981|OTHER|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
223959609|NCT04010981|OTHER|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
223959610|NCT06460155|DEVICE|3 methods intervention|Stu All participants will undergo all three methods being studied: epidurogram (gold standard), CompuFlo CathCheck, and physical exam in PACU following epidural placement.
223959611|NCT01092936|OTHER|Rating Scale administration|Movement Disorder Society\_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
223959612|NCT05568355|BEHAVIORAL|GET2HOME Intervention|Intervention bundle designed to improve discharge effectiveness
223959613|NCT05329129|DEVICE|OssDsign® Catalyst|An osteoconductive, resorbable, porous, 100 % nano synthetic calcium phosphate bone void filler
223959614|NCT02775175|BEHAVIORAL|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
223959615|NCT05609539|DEVICE|Endovascular Aortic Repair (EVAR)|"Techniques for delivery and deployment of the standard device have been well described by different papers, but for the prototype some attention is required.~Once the device was advanced at the level of the lowest RA the C-Arm has been moved to correct the parallax effect and positioned orthogonally to the origin of the artery. This procedure permits perfectly matching the scallop with the artery takeoff.~A selective angiogram was performed to assure the patency of the lower RA. After the deployment of the main body proper iliac extensions were delivered to completely exclude the aneurysm as standard practice."
223959616|NCT06513806|DRUG|Granisetron 1 Mg/mL Intravenous Solution|will receive granisetron 3 mg iv bolus
223959617|NCT06513806|DRUG|Pethidin|will receive pethidine 25 mg iv bolus
223959618|NCT05972109|OTHER|Workplace SSB sales ban|Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.
223959619|NCT05972109|BEHAVIORAL|Brief Intervention|Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.
223959620|NCT05195580|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
223959621|NCT05992298|OTHER|7 T MRI vs 3 T MRI|Adult healthy and patient volunteers will undergo a ca. 1 hour examination of non-invasive magnetic-resonance imaging at 7T, and, if appropriate, a closely matching examination at 3T as a standard of reference.
223959622|NCT05538325|DEVICE|Bubble Inclinometer and Digital Pelvic Inclinometer|They are valid and reliable devices to measure the range of motion of the lumbar spine
224108842|NCT06859554|DRUG|Glyceryl Trinitrate (GTN) 0.2% Ointment|Participants will apply 0.2% Glyceryl Trinitrate (GTN) ointment to the anal region twice daily for four weeks. GTN functions as a nitric oxide donor, reducing internal anal sphincter tone to improve blood flow and promote fissure healing. The study aims to assess its effectiveness in symptom relief, fissure healing, and associated side effects such as headaches and dizziness.
223541974|NCT06467071|BEHAVIORAL|SH+ combined with a session for PMLD|The intervention integrates WHO's Self Help Plus (SH+) and a session for Post-Migration Living Difficulties (PMLD) for Syrian women. SH+ is a guided self-help program with five weekly sessions led by facilitators, aimed at managing stress and psychological distress without requiring a diagnosis. This scalable intervention is based on solid research, proven effective in reducing stress and preventing mental health disorders (Tol et al., 2020; Turrini et al., 2019). The PMLD session, based on WHO's Problem Management Plus (PM+), involves focus groups to identify post-migration challenges. Participants share experiences, learn coping strategies, discover local resources, and strengthen social support networks. This integrated approach aims to enhance mental health, address post-migration difficulties, and improve stress reduction skills, supporting adaptation to a new country.
223959623|NCT05485441|OTHER|Digital Educational Intervention|"The educational intervention will be provided (at T1) in two ways:~(I) a video lecture in e-learning mode lasting about an hour, aimed at adolescents, using the School Institute's platform for distance education (II) the promotion of 2-minute videopills on the social channels most frequently used by students (dedicated youtube channel/school portal)"
223959624|NCT00720161|DRUG|Metformin|daily 850 mg
224108843|NCT06859554|DRUG|Glyceryl Trinitrate (GTN) 0.4% Ointment|Participants will apply 0.4% Glyceryl Trinitrate (GTN) ointment twice daily for four weeks. This increased concentration aims to determine dose-dependent efficacy and adverse effects in treating acute anal fissures. GTN acts by relaxing smooth muscle, decreasing sphincter tone, and enhancing mucosal blood flow to promote healing.
224108844|NCT06859554|DRUG|Nifedipine 0.2% Ointment|Participants will apply 0.2% Nifedipine ointment twice daily for four weeks. Nifedipine, a calcium channel blocker, reduces sphincter tone by inhibiting calcium influx into smooth muscle cells, leading to improved fissure healing. This arm will assess its effectiveness in symptom relief and healing rates, with a focus on side effects such as local irritation or hypotension.
224108845|NCT06859554|DRUG|Nifedipine 0.5% Ointment|Participants will apply 0.5% Nifedipine ointment twice daily for four weeks. This higher concentration is used to evaluate whether increased potency provides superior symptom resolution and healing rates compared to 0.2% Nifedipine. The study will also assess any potential adverse effects, including local irritation, dizziness, and hypotension.
224108846|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh no attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with no attachement of posterior mesh
223959625|NCT00720161|DRUG|Placebo|placebo
223959626|NCT03478306|DRUG|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
223959627|NCT02188745|DRUG|17B-estradiol|Anti-estrogen
223959628|NCT02188745|DRUG|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
224108847|NCT04358978|PROCEDURE|laparoscopic sacral colpopexy with posterior mesh attachment|pelvic organ prolapse correction with laparoscopic sacralcolpopexy with the attachement of posterior mesh to vagina
224108848|NCT04301453|OTHER|Maternal Scent|Mothers will wear a breast pad during their visit. The breast pad will be placed in the hats of infants for 24 hours.
224108849|NCT04596371|OTHER|pure pulmonary ground glass nodules in women preparing for pregnancy|pure pulmonary ground glass nodules in women preparing for pregnancy
224108850|NCT02628730|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
224108851|NCT02628730|DEVICE|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
224291255|NCT05876728|GENETIC|Genotyping|Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.
223959629|NCT02188745|DRUG|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
223959630|NCT02188745|DRUG|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
223959631|NCT01927484|DRUG|25 mg/week oral methotrexate tablets|active oral methotrexate drug
223959632|NCT01927484|DRUG|25mg/week oral placebo tablets|placebo comparator oral drug
223959633|NCT00680654|DRUG|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
223959634|NCT04285645|OTHER|Warmup|The intervention through exercises will consist in the application of the protocol described by Waldén et al. The objective of the application of this exercise protocol is to produce an improvement in the stability of the knee and the strength of the quadriceps. Before carrying out the exercises, a continuous race will be carried out for 5 minutes, once this first step is finished we will proceed to the realization of the exercises that will be, squats with both legs placing the hands on the hips, feet placed at the width of the shoulders, lowering with a straight back and without raising the heels of the floor, 3 series of 15 repetitions, squats on one leg with the hands on the hips and leg not supported extended forward, 3 sets of 10 repetitions with each leg and jump forward with one leg with the hands on the hips and jump back to return to the starting position, 3 sets of 10 repetitions with each leg
224108852|NCT02638246|BEHAVIORAL|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
224108853|NCT02638246|BEHAVIORAL|Internet-delivered, non-contingent incentives + Motivational Interviewing|
224108854|NCT05396118|DRUG|18F-FDG|Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging
224108855|NCT05396118|DRUG|Injection of hyperpolarized [1-13C]Pyruvate|Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.
224108856|NCT05396118|PROCEDURE|PET/MR/MRS/MRSI scanning|Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
223959635|NCT00584909|DRUG|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
223959636|NCT02869230|PROCEDURE|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
223959637|NCT02869230|PROCEDURE|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
223959638|NCT05835856|DEVICE|Virtual coach with NAO robot|The coaching device used is the softbank NAO 5 and NAO 6 humanoid interactive mobile robot. These robot platform allows multimodal natural language interaction and robot autonomous movement.
224108857|NCT02786862|OTHER|independent ventilation|comparison conventional and independent 1:1 ventilation
224108858|NCT01347164|BEHAVIORAL|RISE life coaching intervention|6 2-hour sessions
224108859|NCT01347164|BEHAVIORAL|HIV Counseling|Standard one-hour HIV counseling session
224108860|NCT02312986|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
224108861|NCT02711371|OTHER|fMRI|
224108862|NCT00393458|DRUG|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
224108863|NCT00393458|DRUG|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
224108864|NCT00393458|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
223959639|NCT05835856|DEVICE|Virtual coach with Google Nest Hub (2e generation) group|The coaching device used is Google Nest Hub (2e generation). This is a connected speaker enriched with a 7-chip touch screen. It has a loudspeaker and 3 microphones, making interaction possible.
224108865|NCT00393458|DRUG|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
224108866|NCT00603044|DRUG|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
224108867|NCT01535937|DRUG|Ketamine|0.5 mg/kg IV over 40 minutes
224108868|NCT01535937|DRUG|Midazolam|0.025 mg/kg IV over 40 minutes
224108869|NCT00949338|PROCEDURE|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
224108870|NCT03169283|OTHER|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
224108871|NCT03169283|OTHER|Cereal without B glucan|Cereal without B glucan
224108872|NCT04289883|COMBINATION_PRODUCT|Nano-particulated whey protein vs non-particulated whey protein (control)|Different particularisations of whey protein were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite and body weight based on animal studies compared to non-particulated whey protein, with nano-particulated whey protein suggested to be more efficient than micro-particulated.
224108873|NCT04289883|COMBINATION_PRODUCT|High molecular weight whey protein-alginate coacervates vs calcium alginate (control)|Different whey protein-alginate coacervates were identified to potentially delay digestion based on in vitro studies and to potentially affect appetite based on animal studies compared to calcium alginate, with high molecular weight alginate suggested to be more efficient than low molecular weight alginate.
224108874|NCT00003018|DRUG|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
224108875|NCT00003018|DRUG|fluorouracil|200 mg/m\^2/day, continuous IV, Days 1-28 of 5 week cycle
224108876|NCT00003018|DRUG|leucovorin calcium|30 mg/m\^2/day, IV, Days 1,8,15,22 of 5 week cycle
224108877|NCT00003018|DRUG|mitomycin C|10 mg/m\^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
223959640|NCT05835856|DEVICE|Virtual coach with Gatebox device|The coaching device used is the Gatebox, a hologram like device which the user can interact. There are internal sensors such as a camera and a microphone allow the user to converse with the projected character. It connects to the Internet via a wireless LAN. With infrared rays and Bluetooth, it can also be connected to household appliances and other devices.
224108878|NCT01928030|BIOLOGICAL|recombinant human hyaluronidase|Given SC
224108879|NCT03557372|RADIATION|Mathematical Model-Adapted Radiation Fractionation Schedule|"* Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~* Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~* Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
223959641|NCT05835856|DEVICE|virtual coach with CelesTE robot|"The coaching device used is the CelesTE robot, a prayer companion designed for Christian Catholic users.The intended main function of CelesTE is to be a guardian angel, especially thought for elderly people. It can be a prayer companion, and contains a vast number of teachings, including the whole Bible. Its AI is capable of keeping a short conversation, in which the user may ask and receive an answer about a sensitive topic (such as happiness, death, faith, etc.). It can also printout a selection of contents.~The coaching device CelesTE will be substituted by DarumaTO for the Japanese centers."
223959642|NCT05835856|OTHER|booklet|Participant in the control group will receive a booklet containing information and activities on well-being
223959643|NCT03345407|DRUG|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
223959644|NCT03345407|DRUG|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
223959645|NCT03345407|DRUG|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
223541975|NCT06395896|OTHER|Breast Cancer Prevention Journey Program Group|"The researcher will invite individuals to the study at Necip Fazıl Family Center and conduct a pre-test application. The day and time for the Fight Against Breast Cancer training, which is structured based on the Health Belief Model prepared by the researchers, will be determined and announced to the participants. The training will be held in a single session of 45-60 minutes. Slide presentation and a breast model showing the symptoms of breast cancer will be used as training materials. At the end of the training, it will be announced that free shuttle service will be provided for mammography screening and individuals will be invited to screening. On the specified day and time, participants will be taken to the Cancer Early Diagnosis, Screening and Education Center (KETEM) in Mamak and mammography screening will be performed. After the screening, a post-test will be performed."
223541976|NCT06395896|OTHER|Routine Cancer Screening Program Group|Participants in the control group will not receive any additional intervention. This group will only receive routine intervention within the scope of the breast cancer screening program conducted by the Ministry of Health. Health Ministry of Türkiye offers free mammography screening for breast cancer to women over the age of 40. In this context, women are called to the centers by phone and mammography screening is performed free of charge.
223959646|NCT03345407|DRUG|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
223959647|NCT03345407|DRUG|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
223959648|NCT03345407|DRUG|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
224108880|NCT02163369|DRUG|Peppermint and Lavender Essential Oils|
224108881|NCT00104104|DRUG|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
224108882|NCT05778318|DRUG|The group of patients who received Lianhua Qingwen orally|Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
224108883|NCT05778318|OTHER|The group of patients who did not receive Lianhua Qingwen orally|The group of patients who did not receive Lianhua Qingwen orally.
224108884|NCT02552407|DEVICE|Manual Aspiration Thrombectomy|Thrombus aspiration
224108885|NCT01821677|DRUG|Danazol Capsules|
224108886|NCT01821677|DRUG|Placebo|
224108887|NCT00162877|DRUG|Rabeprazole vs. Esomeprazole|
224108888|NCT00804440|DRUG|Ibuprofen Tablets, 800 mg|
224108889|NCT01894516|DRUG|GLPG0634|GLPG0634 capsules.
223541977|NCT00817323|PROCEDURE|Dietary amino-acid depletion|See detailed description
223959649|NCT03345407|DRUG|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
223959650|NCT03345407|DRUG|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
223959651|NCT02385539|DRUG|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
223959652|NCT05007002|DEVICE|Robot-based therapy|Active and passive therapy tasks for proprioception and sensory processing, with use of the Kinarm End-Point Lab (BKIN Technologies Ltd., Canada)
223959653|NCT00600366|DRUG|biphasic insulin aspart|
223959654|NCT03985228|DIETARY_SUPPLEMENT|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
223959655|NCT03985228|DIETARY_SUPPLEMENT|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose \<0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
223959656|NCT00427544|DRUG|PRA-027|
224108890|NCT01894516|DRUG|Placebo|Placebo capsules.
224108891|NCT05791825|BEHAVIORAL|Cultivating Healthy Intentional Mindful Educators|The 8-week, manualized, CHIME intervention consists of a 2-hour overview and seven weekly sessions, each lasting 90 minutes. Each CHIME session focuses on a specific mindfulness technique, such as mindful breathing, mindful listening and bringing attention to current states and surroundings to support optimal responsiveness, emotion regulation, and compassion. Social emotional learning is promoted by focusing on five broad competencies: self-awareness, social awareness, responsible decision-making, self-management, and relationship skills and these competencies are practiced and developed through small group discussions, storytelling, journal reflections, modeling, and guided awareness (e.g., meditations), and implementation activities (e.g., gratitude necklace).
224108892|NCT02002078|DRUG|methylprednisolon|
224108893|NCT05892185|DEVICE|GELA|GELA glaucoma implant
224108894|NCT05892185|DEVICE|XEN|XEN gel stent implant
224108895|NCT04833075|OTHER|blood sampling|A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
224108896|NCT01675921|OTHER|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
224108897|NCT03714386|DEVICE|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
224108898|NCT03714386|DEVICE|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
224108899|NCT02525224|DIETARY_SUPPLEMENT|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
224108900|NCT00067522|BEHAVIORAL|User-independent contraception program|
224108901|NCT00067522|BEHAVIORAL|Future Planning Perspectives program|
224108902|NCT01204112|DRUG|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
224108903|NCT05351086|DRUG|PUR3100|PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
224291256|NCT02903238|DRUG|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
223541978|NCT03352232|COMBINATION_PRODUCT|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
224291257|NCT02903238|DRUG|Placebo Oral Tablet|Lactose capsule
223959657|NCT05394727|DEVICE|Needle-free injection device, Then traditional insulin pen|Patients first received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks.
223959658|NCT05394727|DEVICE|Traditional insulin pen , Then Needle-free injection device|Patients first received conventional insulin pen for insulin injection 3\~4 times per day for 2 weeks. After the period of 2 weeks, they then received needle-free syringe for insulin injection 3\~4 times per day for 2 weeks.
223959659|NCT06451224|OTHER|Questionnaire|Online Questionnaire
223959660|NCT02617459|DRUG|Levobetaxolol eye drops|one drop per time; twice daily
223959661|NCT02617459|DRUG|Betaxolol eye drops|one drop per time; twice daily
223959662|NCT01508117|DRUG|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
223959663|NCT01508117|RADIATION|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
223959664|NCT00634348|DRUG|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
223959665|NCT00634348|DRUG|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
223959666|NCT04267549|DRUG|sintilimab|a checkpoint inhibitor via blocking PD-1 (programmed cell death-1) site of signaling.
223959667|NCT04267549|DRUG|apatinib|a multi-target anti-angiogenic tyrosine kinase inhibitor (TKI)
223959668|NCT04267549|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).
223959669|NCT04267549|DRUG|Nab paclitaxel|Nab paclitaxel is a albumin-bound well tolerated paclitaxel than traditional paclitaxel
224108904|NCT05351086|DRUG|Dihydroergotamine (D.H.E 45)|D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
223541979|NCT04472650|DRUG|Sitravatinib|Administered orally as a free base capsule
223959670|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；
223959671|NCT04945616|DRUG|Aspirin、clopidogrel、placebo or SHR2285|groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)
223959672|NCT04945616|DRUG|Aspirin、ticagrelor、placebo or SHR2285|groupC： Aspirin + ticagrelor + placebo or SHR2285
223959673|NCT00002094|DRUG|Atevirdine mesylate|
223959674|NCT05656937|PROCEDURE|internal jugular venous cannulation|internal jugular venous cannulation
223959675|NCT04815135|OTHER|Observational study|Observational study, the study did not involve any interventions
223959676|NCT04619823|OTHER|Blood sample collection|Blood sample collection Mosquito collection at home
223959677|NCT00956527|BEHAVIORAL|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
223959678|NCT00933634|PROCEDURE|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
223959679|NCT00933634|DRUG|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
223959680|NCT03466645|DRUG|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
223959681|NCT03466645|DRUG|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
223959682|NCT04379310|DRUG|ACE Inhibitors and Calcium Channel Blockers|effect of drugs on patients with covid-19 pneumonia
223541980|NCT04472650|DRUG|Sitravatinib|Administered orally as a malate salt capsule
223959683|NCT02163850|DEVICE|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
223959684|NCT02163850|DEVICE|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
223959685|NCT00337246|BIOLOGICAL|rituximab|
223959686|NCT00337246|DRUG|cyclophosphamide|
223959687|NCT00337246|DRUG|fludarabine phosphate|
223959688|NCT00337246|DRUG|mitoxantrone hydrochloride|
223959689|NCT02260726|PROCEDURE|Magnetic resonance imaging|
223959690|NCT02260726|PROCEDURE|Ultrasound|
223959691|NCT01586494|DRUG|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
223959692|NCT01586494|DRUG|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
223959693|NCT01368874|DEVICE|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
224108905|NCT05351086|OTHER|Matching Placebo for PUR3100|Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
224108906|NCT05351086|OTHER|Matching Placebo for D.H.E 45|The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
224108907|NCT03635190|DEVICE|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
223959694|NCT06475326|DRUG|Adebrelimab|Adebrelimab ,20mg/Kg per time, Q4W
223959695|NCT06475326|DRUG|Oxaliplatin 100 MG|Oxaliplatin: 60mg/m2, Q2W
223959696|NCT06475326|DRUG|Irinotecan liposome|Irinotecan Liposome: 50mg/m2, Q2W
223959697|NCT06475326|DRUG|Calcium Folinate|Calcium Folinate: 400mg/m2, Q2W
223959698|NCT06475326|DRUG|Fluorouracil|Fluorouracil: 2400mg/m2, Q2W
223959699|NCT04463004|DRUG|Mavrilimumab|Treatment infusion
223959700|NCT04463004|DRUG|Placebos|Placebo infusion
223959701|NCT02913898|BEHAVIORAL|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
223959702|NCT02913898|BEHAVIORAL|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
223959703|NCT04182451|DEVICE|Meso Wound Matrix|"Subjects who meet eligibility criteria will receive standard of care and Meso Wound Matrix.~The standard of care therapy in this study is offloading of the DFU, appropriate sharp or surgical debridement, and aggressive infection management with the use of appropriate dressings. Total contact casting or fixed ankle walker will be used for off-loading. Wound Matrix is an acellular scaffold to reinforce and repair soft tissue defects. Subjects may receive up to eight applications of Meso Wound Matrix. Subjects whose study ulcer does not heal after eight applications will receive only SOC treatment for 4 additional weeks."
224108908|NCT00893503|PROCEDURE|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
224108909|NCT06673225|OTHER|Analysis of results|Analysis of previous imaging and/or laboratory tests, vital signs, body composition, pulmonary function, peripheral muscle strength, calf circumference, nutritional risk, quality of life, frailty level, and anxiety and depression. Screening for respiratory diseases, including chronic obstructive pulmonary disease (COPD), lung cancer, tuberculosis, and other lung lesions, is based on spirometry and thoracic radiological images after the health professional's examination. After the multiprofessional procedures, patients will be evaluated by a physician to start specific treatment and/or perform complementary exams if necessary. Every year, they will be re-evaluated to record acute exacerbations of chronic respiratory diseases and assess disease progression through spirometry and thoracic radiological images.
223959704|NCT03137732|DEVICE|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
224108910|NCT06252610|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~* 6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded;~* The catheter will be flushed with 0.9% saline solution;~* The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
224291258|NCT05209906|DRUG|Fentanyl Buccal Soluble Film|Eligible patients will receive Painkyl® for dose of 200, 400, 600, 800, 1000 or 1200 mcg for the treatment of breakthrough pain according to around-the-clock morphine daily dose.
223959705|NCT05567302|OTHER|Manual therapy|"In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, manipulative correction technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.~A rotational maneuver will be performed from the posterior side of the articular pillar part of the superior vertebra, on the opposite side of the side where the movement restriction is present."
224291259|NCT02787317|DRUG|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
223959706|NCT05567302|OTHER|myofascial release|The soft tissue is palpated by the physiotherapist and pressure is applied directly to the skin until the tissue barrier is felt in the direction of restriction. Once the tissue barrier is present, it is applied for 90-120 seconds, without slipping on the skin or forcing the tissue, until the fascia complex begins to loosen and a softening sensation is achieved.
223959707|NCT01474265|DRUG|Varenicline|0.5-2 mg per day, oral use
223959708|NCT01474265|DRUG|Placebo|1-2 tablets per day, oral use
223541981|NCT02094118|BIOLOGICAL|Point-of-care washed red blood cell transfusion.|
223541982|NCT02094118|BIOLOGICAL|Standard of care red blood cell transfusion.|
223541983|NCT01861665|DRUG|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
223541984|NCT01861665|DRUG|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
223541985|NCT02869321|DRUG|Fentanyl|
223959709|NCT01474265|DRUG|Nicorette TX|10-15 mg per day, transdermal use (patches)
223959710|NCT01315418|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
223959711|NCT01315418|OTHER|2-Non fermented dairy product (control)|
223959712|NCT03834909|DRUG|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
223959713|NCT03834909|DRUG|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
223959714|NCT05614141|DEVICE|Lokomat Augmented Performance Feedback|All participants will exercise with Lokomat Augmented Performance Feedback for six weeks. Augmented Performance Feedback has different virtual reality games.
223959715|NCT05614141|OTHER|Conventional Physiotherapy|Conventional physiotherapy includes stretching, strengthening, balance, coordination and walking exercises under the guidance of a physiotherapist.
223959716|NCT03785041|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
224291260|NCT02787317|DRUG|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
223959717|NCT02961283|DRUG|ASN003 ascending doses|
223959718|NCT02961283|DRUG|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
223959719|NCT04247256|DRUG|FOLFIRI Protocol|FOLFIRI standard treatment on day 5 to 7 (both days included) of a 14 day period. repeated bi-weekly
223959720|NCT04247256|DRUG|SCO-101|Investigational Medicinal Product, oral tablet administered on day 1 to 6 (both days included) of a 14 day period. repeated bi-weekly
223959721|NCT02465632|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
223959722|NCT02465632|DRUG|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
223959723|NCT02465632|DRUG|Placebo|
223959724|NCT06646146|PROCEDURE|Fat grafting combine with hair transplantation|Patients enrolled in this experiment will be divided into two groups.The experimental group will have autologous fat tissue harvested during surgery for fat grafting in the patient's alopecia area, and a subsequent hair transplantation will be performed after three months when the transplanted fat has stabilized and survived.
224108911|NCT06252610|DRUG|Contrast Media, Magnetic Resonance|"The same intravenous catheter used to inject the radiotracer will be used to inject the hepatospecific gadolinium contrast agent Eovist (Bayer, Whippany, NJ);~* After being positioned on the PET/MRI table, the nuclear medicine technologist will connect the patient to the MRI-safe power injector;~* The catheter will be flushed before and after injection with 0.9% saline solution;~* About halfway through the imaging session, the study staff will inform the patient that they are going to be administering the contrast agent and what sensations they should and should not expect;~* The contrast will then be injected."
224108912|NCT06252610|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired When necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
223959725|NCT06646146|PROCEDURE|Hair transplantation|Patients enrolled in this experiment will be divided into two groups. The control group will undergo a simple hair transplantation surgery.
223959726|NCT04112563|PROCEDURE|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
223541986|NCT02869321|DRUG|Morphine Sulfate|
223541987|NCT02869321|DRUG|Fentanyl placebo|
223959727|NCT04112563|PROCEDURE|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
223959728|NCT04471298|DRUG|Qishenyiqi dripping pills, 6 bags|28 consecutive days
223959729|NCT04471298|DRUG|Qishenyiqi dripping pills, 9 bags|28 consecutive days
223959730|NCT04471298|DRUG|Qishenyiqi dripping pills, 12 bags|28 consecutive days
223959731|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 6 bags|28 consecutive days
223959732|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 9 bags|28 consecutive days
223959733|NCT04471298|DRUG|Qishenyiqi dripping pills placebo, 12 bags|28 consecutive days
223959734|NCT04550455|DRUG|Cladribine Tablets|Cladribine tablets will be administered according the current package insert guidelines
223959735|NCT01648491|PROCEDURE|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
223959736|NCT01648491|BIOLOGICAL|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
223724224|NCT03024450|DRUG|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
223724225|NCT01737515|OTHER|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
223724226|NCT00153075|DEVICE|Berodual Respimat|
223724227|NCT00153075|DEVICE|Berodual HFA-MDI|
223724228|NCT05436392|BEHAVIORAL|Peer Comparison Feedback|USAP anesthesia providers will receive monthly alerts via USAP's smartphone-based practice management application, text message, or email presenting individual-level data on their benzodiazepine administration patterns versus other USAP providers, using data from the USAP clinical and quality data warehouse.
223724229|NCT05436392|BEHAVIORAL|Patient Informational Letter|Breif informational letters will be distributed to eligible patients within the 2 weeks prior to surgery. Letters will be produced on USAP letterhead and signed by the USAP Chief Quality Officer. Letter text will state USAP's commitment to brain health and avoiding potentially unnecessary medications for patients undergoing surgery. It will also include a statement encouraging patients to discuss anesthesia plans with their clinicians at the time of surgery to aid tailoring of care to individual needs. Letters will be distributed directly to patients via text link, email, or hard copy as a component of standard pre-operative instructional communications and other educational and patient outreach materials related to clinical care.
223724230|NCT03194022|OTHER|Blood sample|measurement of electrolytes and blood count
223724231|NCT06287411|DIAGNOSTIC_TEST|FAPI PET/MR combined with gadoxetate disodium|Patients with clinical suspected hepatic malignancies will receive the FAPI PET/MR.
223724232|NCT04047940|DRUG|LY900020|Administered orally
223724233|NCT04047940|DRUG|Metformin XR|Administered orally
223724234|NCT04047940|DRUG|Atorvastatin|Administered orally
223724235|NCT04047940|DRUG|Valsartan|Administered orally
223724236|NCT03867006|DIETARY_SUPPLEMENT|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
223724237|NCT03867006|DIETARY_SUPPLEMENT|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
223724238|NCT05825846|DEVICE|Virtual- reality active shooter drill|"The stress protocol used for this experiment utilized a previously studied virtual reality active shooter drill (VR-ASD). The VR-ASD scenario (\~2 min) involves the participant physically walking down a \~10-foot-long virtual hallway where they will encounter wounded victims. Once at the threshold of to the attack room, they will observe one victim on the ground with a traumatic head injury and the shooter firing his handgun at the last victim, the participant will fire a shot, and the shooter will fall after being shot."
223959737|NCT04135872|OTHER|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
223959738|NCT06155123|DRUG|Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)|Monthly or quarterly mAbs administration for a year
223959739|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 68Ga-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
223959740|NCT04750772|DIAGNOSTIC_TEST|18F-FDG and 18F-DOTA-FAPI04 PET/CT|Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
223959741|NCT00481156|BEHAVIORAL|Cognitive Remediation|
223724239|NCT03902067|BIOLOGICAL|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml.
223724240|NCT03902067|BIOLOGICAL|Control Group|Routine treatment without catheter infusion
223724241|NCT02842918|PROCEDURE|Spinal Manual Therapy|
223724242|NCT02842918|PROCEDURE|Spinal Range of Motion|
223724243|NCT05439512|PROCEDURE|transantral orbital floor reconstruction by titanium mesh|reconstruction of orbital floor fracture by patient specific titanium mesh
223724244|NCT06799494|BIOLOGICAL|Gardasil-9|"The 9-valent HPV VLP vaccine is a sterile liquid suspension prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer. The 9-valent HPV vaccine, or Gardasil-9, is a sterile suspension for intramuscular administration. Each 0.5-mL dose of the vaccine also contains approximately 500 mcg of aluminum (provided as AAHS), 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 mcg of polysorbate 80, 35 mcg of sodium borate, \<7 mcg yeast protein, and water for injection. The product does not contain a preservative or antibiotics.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap. After thorough agitation, GARDASIL 9 is a white, cloudy liquid."
223959742|NCT00481156|BEHAVIORAL|Cognitive Behavioral Social Skills Training|
223959743|NCT00481156|OTHER|Retest in Health Controls|Pre/Post test performance and neuroimaging only
223959744|NCT01403922|DRUG|TC-5214|Tablet oral bid days 1 to 7
223959745|NCT01403922|DRUG|TC-5214|Tablet oral bid days 8 to 14
223959746|NCT00004578|DRUG|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
223959747|NCT00004578|DRUG|Lamivudine|150 mg, every 12 hours
223959748|NCT00004578|DRUG|Stavudine|40 mg every 12 hours
223959749|NCT03012490|OTHER|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
223959750|NCT03012490|OTHER|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
223959751|NCT03012490|OTHER|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
223959752|NCT04791917|BEHAVIORAL|Eccentric Biceps Flexion|Muscle lengthening biceps exercise
223959753|NCT04791917|BEHAVIORAL|Concentric Biceps Flexion|Muscle shortening biceps exercise
223959754|NCT00005971|DRUG|alvocidib|
223959755|NCT06169878|DEVICE|Adjustable lower limb abduction apparatus|"To ensure abduction in the lower extremities after total hip replacement surgery, a specially adjustable apparatus developed according to the height and weight of each individual was used.~This developed product was used by patients while they were lying down and walking."
223959756|NCT02784145|DIETARY_SUPPLEMENT|Resistant starch|
223959757|NCT02784145|OTHER|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
223959758|NCT01989156|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
223959759|NCT01989156|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
223541988|NCT02869321|DRUG|Morphine Sulfate placebo|
223541989|NCT02869321|PROCEDURE|Gastrostomy|
223541990|NCT04256525|DRUG|Rivaroxaban 10mg|10mg orally per day
223541991|NCT04256525|DRUG|Aspirin 100mg|100mg orally per day
223959760|NCT01989156|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
223959761|NCT04729361|GENETIC|CGH array analysis|CGH array analysis
223959762|NCT01899183|PROCEDURE|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
223959763|NCT01942551|DRUG|Tadalafil|
223959764|NCT01942551|DRUG|Dutasteride|
223959765|NCT06309771|BEHAVIORAL|Stress management, sleep improvement and fatigue reduction, sedentary behaviors reduction and physical activity promotion.|"The study seeks to quantify the impact of a complex intervention based on 3 modules :~1. Stress management~2. Sleep improvement and fatigue reduction,~3. Sedentary behaviors reduction and physical activity promotion.~Students from the interventional group will follow these 3 different health-related modules in a random order (6 predetermined order). Each module will be composed on 3 sessions. Each session includes individual interviews covering initial assessment and personalized goal setting."
223959766|NCT04237987|DRUG|Interleukin-2|Interleukin-2 was produced by Beijing Shuanglu Pharmaceutical Co., Ltd
223959767|NCT04237987|DRUG|ciclosporin and corticosteroid|ciclosporin and corticosteroid
223959768|NCT00606723|BIOLOGICAL|Hematopoietic stem cells from bone marrow or peripheral blood|\> = 2 x 10\*8 nucleated cells (WBC)/kg body weight of the recipient or rather \> = 4 x 10\*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
223959769|NCT01643018|PROCEDURE|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
223959770|NCT01643018|PROCEDURE|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
223959771|NCT03296176|BIOLOGICAL|blood sample|blood sample for metabolome analyse
223959772|NCT06328322|PROCEDURE|Percutaneous Coronary Intervention in Left Main Artery Disease|To investigate and assess the effectiveness and safety of percutaneous coronary intervention in left main coronary artery disease in sitting of acute coronary syndromes.
223959773|NCT06412809|OTHER|Combined Land- and Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented both on land and in water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~Land-based exercise:~1. Plank exercise~2. Russian twist~3. Push-up~4. Goblet squat~5. Kettle bell swing~Water-based exercise:~1. Flutter kicks~2. Isometric core crunches~3. Jump lunges~4. Kicks~5. Resisted knee flexion"
223959774|NCT06412809|OTHER|Land-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented on land. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Plank exercise~2. Russian twist~3. Dead bug~4. Push-up~5. Goblet squat~6. Nordic hamstring curl~7. Lunges~8. Kettle bell swing~9. Calf raises~10. Bird dog"
224108913|NCT03692910|DRUG|SAGE-217|SAGE-217 capsule
224108914|NCT03692910|DRUG|Placebo|SAGE-217 matching placebo capsule
223541992|NCT04256525|DRUG|low molecule heparin|0.4ml per day subcutaneous injection
223959775|NCT06412809|OTHER|Water-Based Exercise|"Strengthening exercises targeting the core and lower extremities (quadriceps, hamstring, and gastrocnemius) were implemented in the water. The exercises are done for approximately one hour/day, three days/week for two consecutive weeks. The following are the included exercises:~1. Core pulls~2. Flutter kicks~3. Water cycling~4. Isometric core crunches~5. Seated push-up~6. Jump squats~7. Jump lunges~8. Kicks~9. Ankle jumps~10. Resisted knee flexion"
223959776|NCT02835196|DEVICE|Optical Elastography|To image skin thickness, Optical Coherence Elastography (OCE)-scanning of 6 body surface areas will be preformed using the Phase-Stabilized Swept Source Optical Coherence Elastography (PhS-SSOCE) system.
223959777|NCT02835196|OTHER|Visual Assessment|Skin thickness will be visually assessed clinically in 6 body surface areas using the the modified Rodnan Skin Score (mRSS). The mRSS uses a 0-3 scale, where 0 = normal, 1= mild thickness, 2 = moderate thickness, and 3 = severe thickness
223959778|NCT04534699|DRUG|KBP-5074|KBP-5074 tablet
223959779|NCT04794439|DRUG|Dentifrices|Dentifrice on plaque
223959780|NCT01349699|DRUG|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
223959781|NCT01349699|DRUG|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
223959782|NCT01349699|DRUG|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
223959783|NCT01349699|DRUG|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
223959784|NCT02790788|DRUG|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
223959785|NCT02790788|DRUG|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
223959786|NCT03249805|DEVICE|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
223959787|NCT03249805|DEVICE|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
223959788|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
223724245|NCT06799494|DRUG|Lidocaine injection|Lidocaine 1% will be injected intradermally and subcutaneously into the margin of the lymph node to be sampled to numb the area. To confer local anesthesia, 1-2% will be injected into the tissue surrounding the area where the bone marrow will be removed.
223959789|NCT00848094|RADIATION|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
223959790|NCT00850993|DRUG|Stannsoporfin|Stannsoporfin administered as a single IM injection
223959791|NCT00850993|OTHER|Placebo|Placebo (sterile saline solution) administered as a single IM injection
223959792|NCT00850993|OTHER|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
224108915|NCT01981122|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
223541993|NCT04346511|OTHER|Acupuncture|Patients will have six, 0.25\*40mm sterilized stainless steel acupuncture needles (Dongbang Acupuncture, Inc., Seoul, South Korea) inserted into six acupoints (sites ST36, LV3, KI2, bilaterally) on their lower legs. After insertion, the needles will be stimulated at 2-4Hz, 10s at each point (1min total), immediately after insertion, 5min, 10min, 15min and just before removal.
224108916|NCT01981122|DRUG|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
224108917|NCT06535399|DRUG|BMS-986369|Specified dose on specified days
224108918|NCT06369324|OTHER|Pain education|It consisted of holding information sessions on each of the days that the subjects were scheduled for treatment. These sessions will be supported by supplementary material in the form of brochures, posters and videos which briefly explain interesting knowledge about spondyloarthropathies.
224108919|NCT06369324|OTHER|Exercise supervised by external focus|This therapeutic exercise involves proprioceptive training with external feedback to enhance exercise execution and promote optimal postural control, particularly for individuals with back pain. The method, based on research by Abdollahipour et al. and Chiviacowsky et al., focuses on automatic control, reducing the cognitive load during exercises and improving movement retention. The Motion Guidance Clinician Kit will be utilized, consisting of a panel and laser guide for precise cervical movement. Exercises progress in difficulty over 12 sessions, targeting cervical and lumbopelvic stabilization, flexion-extension, rotations, and lateral flexions. Sessions start with seated exercises and progress to standing, with increasing distance between laser targets to expand cervical range of motion. Thoracic and lumbar exercises involve 10 repetitions each. The entire program lasts around 20 minutes and follows Tidier recommendations for intervention.
224108920|NCT06369324|OTHER|Therapy by means of electrical stimulation (electro-massage)|This technique combines manual therapy (massage) with interferential current. Following a supervised therapeutic exercise program, this intervention targets the spine for 15 minutes. Using a Sonopuls 692® device, a bipolar current mode with specific frequencies is applied. The physiotherapist moistens sponges with warm water and administers the current through them while performing manual soft tissue therapy on the neck, shoulders, scapulae, thoracic, lumbar, and sacral areas. The intensity is adjusted to provide a strong but comfortable tingling sensation, without muscle twitching. The therapy sequence includes superficial stroking, deep gliding movements, trapezius kneading, muscle stretching, and deep rubbing on the thoracic and lumbar areas. The electro-massage protocol lasts 14 minutes.
223959793|NCT05226728|DRUG|pembrolizumab|Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
223959794|NCT00521807|PROCEDURE|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
224108921|NCT02293343|OTHER|blood profile|
223959795|NCT03839355|DRUG|Apixaban|Dosage either 5mg or 2.5mg for 2 years
223959796|NCT03839355|DRUG|Warfarin|Dosage assessed by your treating physician for 2 years
223959797|NCT01717755|OTHER|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
223959798|NCT04485793|DIETARY_SUPPLEMENT|Dietary supplement|"Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal"
223959799|NCT04485793|OTHER|Placebo|Oral administration: 1 tablet/day at evening meal
223959800|NCT02232958|OTHER|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
224291261|NCT05327855|DRUG|OPL-0301 Dose 1|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
224291262|NCT05327855|DRUG|OPL-0301 Dose 2|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
223959801|NCT05968898|DEVICE|Optellum Virtual Nodule Clinic|The Optellum Virtual Nodule Clinic is an FDA-approved (Class II) device for risk stratification of pulmonary nodules. It uses a convolutional neural network to evaluate CT imaging data to provide an estimate of malignancy risk for indeterminate pulmonary nodules.
223959802|NCT04362176|BIOLOGICAL|pathogen reduced SARS-CoV-2 convalescent plasma|Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.
223959803|NCT04362176|BIOLOGICAL|Placebo|Lactated Ringer's solution with multivitamins
223959804|NCT06266494|DEVICE|Long-Acting silver dressings|Mepilex Transfer Ag
223959805|NCT06266494|OTHER|Aloe Vera|Dermaid Aloe Vera
224108922|NCT05483972|BEHAVIORAL|Whole Prediabetes Diet Intervention|Participants will be instructed by RDN on how to adhere to the diet intervention and will be provided menus and recipes. For the enrolled adults in the study, the goal is to maintain complete diet adherence during the two-week intervention. The focus for children/adolescents will be on encouragement and exposure of the diet by the index parent and any additional household parent/guardian/caregiver. Participants will receive groceries that are tailored specifically to the prescribed diet menus/recipes for each week. Foods will be distributed using either a grocery delivery service or via participant pick-up. Each household will receive enough groceries to feed a household of four-persons for each week of the intervention.
224108923|NCT01717612|DRUG|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
224108924|NCT01717612|DRUG|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
224108925|NCT04111367|DRUG|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
224108926|NCT04111367|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
224108927|NCT01471873|PROCEDURE|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
224108928|NCT02392208|DRUG|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
224108929|NCT02392208|PROCEDURE|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
224108930|NCT00358592|DEVICE|Mobius™ retractor|
224108931|NCT00358592|DEVICE|traditional metal retraction instruments|
224108932|NCT03645252|PROCEDURE|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
223541994|NCT01047189|DRUG|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
223541995|NCT01047189|DRUG|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
223541996|NCT01047189|DRUG|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
224108933|NCT03645252|PROCEDURE|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
224291263|NCT05327855|DRUG|Placebo|Pharmaceutical form: Hard gelatin capsule; Route of administration: Oral
224291264|NCT01353807|DIETARY_SUPPLEMENT|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
223541997|NCT01535287|DRUG|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
223959806|NCT06266494|DRUG|Dalbavancin|1500mg IV dose
223959807|NCT00742560|BIOLOGICAL|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
223959808|NCT00742560|DRUG|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
223959809|NCT00742560|DRUG|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
224108934|NCT02448823|OTHER|Mass media and Stylish Events|"1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~2. Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
224108935|NCT02448823|OTHER|Mass Media|1\. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
224108936|NCT01277289|DRUG|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
224108937|NCT00546858|OTHER|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
224108938|NCT06024577|BEHAVIORAL|Walking|Prescribed 150 minutes per week of moderate to vigorous walking.
224108939|NCT06024577|BEHAVIORAL|Variety|Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
224108940|NCT06024577|BEHAVIORAL|Progressive|Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
224108941|NCT00000451|DRUG|sertraline|16 week outpatient study
224108942|NCT00000451|DRUG|naltrexone|16 week outpatient study
224108943|NCT03679481|DRUG|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
224108944|NCT03679481|DRUG|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
223959810|NCT00742560|DRUG|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
224108945|NCT05588492|DRUG|Rifamycin-containing regimen|Rifamycin-containing regimen
224108946|NCT05588492|DRUG|Rifamycin-free regimen|Rifamycin-free regimen
224108947|NCT06111573|DIETARY_SUPPLEMENT|Vitamin D|"Study group using Vitamin D for myofascial pain treatment. Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Study group usind Vitamin D for myofascial pain treatment. Medical treatment with Vitamin D (10,000 IU/day) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
224108948|NCT06111573|DRUG|Diclofenac Sodium|"Diagnostic Criteria for Temporomandibular Disorders was used in the diagnosis of patients with myofascial pain. Control group using Diclofenac Sodium for myofascial pain treatment. Medical treatment with Diclofenac Sodium (Voltaren 75 mg, 2x1 ) + Occlusal Splint treatment was applied. Occlusal Splints were made of hard acrylic with a flat surface and were used only for 8 hours during sleep for 3 months. 500 mg Paracetamol tablet was prescribed to the patients as a rescue painkiller if they needed painkillers."
224108949|NCT00092547|BIOLOGICAL|V501|0.5 mL intramuscular injection of V501
224108950|NCT00092547|BIOLOGICAL|Comparator: Placebo|0.5 mL intramuscular injection of placebo
224108951|NCT02772497|DRUG|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
223541998|NCT03951610|DEVICE|Test lens|contact lens
223541999|NCT03951610|DEVICE|Control lens|contact lens
223959811|NCT03223935|OTHER|Corn nuts|Roasted corn nut snack
223959812|NCT03223935|OTHER|Chickpeas|Roasted chickpea snack
223959813|NCT03223935|OTHER|Yellow peas|Roasted yellow pea snack
223959814|NCT03223935|OTHER|Pinto beans|Roasted pinto bean snack
224108952|NCT05640232|DRUG|CDE100 association|Experimental drug.
224108953|NCT05640232|DRUG|Buscopan® Composto association|Active comparator.
224108954|NCT01539837|DRUG|Deferiprone 20mg|20mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
224108955|NCT01539837|DRUG|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
224108956|NCT01539837|DRUG|Deferiprone 30mg|30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
224108957|NCT05794997|DRUG|Propranolol or Carvedilol|Propranolol or Carvedilol claim is used as the exposure group.
224108958|NCT05794997|DRUG|Atenolol, Bisoprolol or Sotalol|Atenolol, Bisoprolol or Sotalol claim is used as the reference group.
224291265|NCT01353807|DIETARY_SUPPLEMENT|Olive oil|4 1-g gelatine capsules with virgin olive oil
224291266|NCT03571659|PROCEDURE|Laser|
223959815|NCT03223935|OTHER|Soybeans|Roasted soybean snack
223959816|NCT03223935|OTHER|Almonds|Roasted almond snack
223959817|NCT01426217|DEVICE|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
223959818|NCT06203717|DEVICE|Alpha-Stim AID cranial electrotherapy stimulation|Cranial electrotherapy stimulation using a modified square, bipolar waveform of 0.5 Hz at 100 μA to be used for four weeks on off-duty days.
223959819|NCT00768911|DRUG|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
223959820|NCT00768911|DRUG|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
223959821|NCT00768911|PROCEDURE|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
223959822|NCT01812837|DEVICE|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
223959823|NCT01812837|DRUG|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
223959824|NCT01812837|RADIATION|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
223959825|NCT04889833|BEHAVIORAL|hypnosis therapy|Pre-recorded hypnosis therapy audio recording with accompanying visual of a calm ocean to be played at least once daily for 7 preoperative days, the day of surgery, and for 7 days postoperatively.
223959826|NCT04367311|DRUG|Atezolizumab|Atezolizumab 1200 mg
223959827|NCT04367311|DRUG|Docetaxel|Docetaxel 60-75 mg/m\^2
223959828|NCT04367311|DRUG|Cisplatin|60-75 mg/m\^2
223959829|NCT04367311|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2
223959830|NCT06241638|DRUG|Vitamin B12 0.5 MG/ACTUAT|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
223959831|NCT06241638|DRUG|Dapagliflozin 10mg Tab|"The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months."
223959832|NCT05834829|DEVICE|Low-intensity focused ultrasound neuromodulation|ultrasound transducer applying low intensity waveforms to targeted brain regions for neuromodulation.
223959833|NCT05834829|DEVICE|Sham Low-intensity focused ultrasound|sham application of ultrasound using blocking of the ultrasound waves of the transducer.
223959834|NCT03347084|DEVICE|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
223959835|NCT03347084|DEVICE|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
223959836|NCT03970304|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
223959837|NCT04495556|DIAGNOSTIC_TEST|MRI|The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
224291267|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
224291268|NCT01702779|OTHER|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
223542000|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
223542001|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
223542002|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
223542003|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
223542004|NCT00551031|BIOLOGICAL|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
223542005|NCT01129492|DEVICE|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
223542006|NCT05280665|OTHER|Specialization|"* Who had undergone professional training in gastric cancer surgery in specialized gastric cancer centers (in Japan or Korea),~* Who identified themselves as primarily gastric surgeons during the study period~* Whose annual gastric cancer surgery volume is more than 21"
223959838|NCT06286618|BEHAVIORAL|Psychosocial Intervention|Psychosocial intervention is an intensive behavioral therapy intervention to address dietary behaviors. Each intervention session is a one-on-one interaction that focuses on setting individualized dietary goals and following up on them and is delivered by trained personnel. Sessions are delivered in 3 modalities which include face-to-face, phone call, and telehealth delivery. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Face-to-face; Telehealth; Phone Call 2) Telehealth; Phone Call; Face-to-face 3) Phone call; Face-to-face; Telehealth.
223959839|NCT06286618|OTHER|Structural Intervention|The structural intervention is designed to supplement the diet with food resources via three modalities: voucher-based or F/V prescription, home meal delivery, or food bank box program. The voucher-based model includes a weekly $50 gift card with a prescription for having to eat more fruits and vegetables. The home meal delivery model includes a meal subscription that supplements the diet with two meals for two people each week (four total servings worth $65 including shipping). The food bank box program consists of participants picking up a box of food weekly from a food pantry located in the outpatient clinic. Each participant is randomly assigned to receive 4 weeks of each modality in one of the following orders: 1) Voucher; Meal Delivery; Food Box 2) Meal Delivery; Food Box; Voucher 3) Food Box; Voucher; Meal Delivery.
223959840|NCT06286618|OTHER|Traditional Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in a referral-based fashion in which participants will receive referral at enrollment visit.
223724246|NCT06799494|DRUG|Lorazepam|Lorazepam, an FDA-approved benzodiazepine, will be administered as an anxiolytic before the bone marrow aspirate procedure per the clinician who will perform the procedure. If needed, lorazepam will be administered sublingually per manufacturer dosing recommendations.
223959841|NCT06286618|OTHER|Integrated Psychosocial+Structural|Participants will receive a combination of psychosocial and structural intervention, based on the most feasible selections from the preparation phase of the study. The intervention will initiate in an integrated fashion in which participants will receive immediate onboard at enrollment visit.
223959842|NCT05091710|OTHER|HF follow up care|The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.
223959843|NCT05091710|OTHER|HF Standard of Care (SOC)|SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
223959844|NCT06007430|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
223959845|NCT06007430|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
223959846|NCT05712356|DRUG|certepetide|LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
223959847|NCT05712356|DRUG|Durvalumab|1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
223959848|NCT05712356|DRUG|Cisplatin|cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
223959849|NCT05712356|DRUG|Gemcitabine|gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
224291269|NCT01426737|DRUG|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
224291270|NCT01553201|DRUG|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
224291271|NCT01553201|DRUG|Placebo|Saline, 4cc, one time intramuscular administration
224291272|NCT00396461|DRUG|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
223959850|NCT05712356|DRUG|FOLFOX regimen|"The following will be given every 14 days:~* oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion~* fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes~* fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)"
223959851|NCT05712356|DRUG|Placebo|Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
223959852|NCT06349642|PROCEDURE|Biospecimen Collection|Undergo optional research blood sample.
223959853|NCT06349642|PROCEDURE|Tissue Collection|Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\&#39;t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.
223959854|NCT04501614|DRUG|Ponatinib|Ponatinib tablets.
223959855|NCT04501614|DRUG|Chemotherapy Agents|Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), daunorubicin. Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine. Chemotherapy agents for consolidation include dexamethasone, vincristine, methotrexate, PEG-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available), cyclophosphamide, etoposide, CNS-1/2: IT methotrexate chemotherapy, CNS-3: ITT chemotherapy methotrexate, hydrocortisone, cytarabine. The doses for chemotherapy agents for reinduction will be given as per standard of care.
223959856|NCT04610294|DEVICE|Functioning Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be active and will be sealed to prevent operating room personnel from opening the system and determining a unit's status."
224108959|NCT05397613|BEHAVIORAL|STAIR|Clinician led session that hones in on a particular deficit within these skills, including identifying and labeling emotions, managing emotions, tolerating distress, accepting feelings and increasing positive emotions, identifying trauma-based interpersonal schemas, identifying conflict between trauma-related feelings and goals, role plays surrounding issues of power and control, and role-plays related to developing flexibility in interpersonal situations involving power differentials. STAIR is a cognitive-behavioral treatment that addresses emotion regulation and interpersonal difficulties and their impact on daily living.
224108960|NCT02889510|DRUG|liraglutide|7-week subcutaneous liraglutide once daily
224108961|NCT02889510|DRUG|placebo|7-week subcutaneous placebo once daily
224108962|NCT01959386|DRUG|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
224108963|NCT03807973|DRUG|[Zr-89]Oxine-labeled leukocytes PET/MRI|All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
224108964|NCT03993353|DRUG|Pembrolizumab|200 mg intravenously every 3 weeks
224108965|NCT03993353|DRUG|Tadalafil|10 mg by mouth daily
224108966|NCT02988986|DRUG|TAK-228|MTORC1/2 inhibitor
224108967|NCT02988986|DRUG|Tamoxifen|Non-steroidal anti-estrogen
224108968|NCT03925844|OTHER|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
223724247|NCT05077397|DEVICE|StO2|InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
224108969|NCT06017232|OTHER|Hybrid telerehabilitation program|"The telerehabilitation program lasts 12 week (3 per week). The program includes aerobic, strength, coordination, balance, flexibility, and breathing exercises, in addition to educational components focused on disease management.~This hybrid program incorporates both supervised and unsupervised sessions. A progressive approach from synchronous (supervised) to asynchronous (unsupervised) sessions is adopted.~Each session is structured into 4 components: Warm-up; Muscle strengthening, coordination, and balance; Flexibility; and Breathing exercises.~Participants are asked to maintain a log of their aerobic activity, recording details such as the type of activity, duration, and intensity. The aim is to align with the recommended aerobic physical activity guidelines (150 min/week). Weekly assessments are conducted to provide personalized guidance based on individual progress.~Also, participants engage in weekly educational videos that cover a diverse range of PD-related topics."
224108970|NCT02706093|OTHER|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at \~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
224108971|NCT02706093|OTHER|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
224108972|NCT02706093|OTHER|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax \[25min; \~150kcals; 4d/wk\]
224108973|NCT02706093|OTHER|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax \[15min; \~90kcals; 4d/wk\]
224108974|NCT02355912|DEVICE|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
224108975|NCT02844205|OTHER|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
224108976|NCT04893330|DIETARY_SUPPLEMENT|pepticate syneo|follow up of pepticate syneo for one month
223959857|NCT04610294|DEVICE|Deactivated Aerus air filtration/sterilization|"Two units of Aerus air sterilization system will be used in each operating room, and each will be set to high. Units used for the trial will be modified internally to be inactivated and will be sealed to prevent operating room personnel from opening the system and determining a unit's status. Units will be inactivated by removing the activated carbon, high-efficiency particulate filter, and ionization chamber. However, the fan will remain active as will the run lights."
223959858|NCT01202344|OTHER|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
223959859|NCT04623398|DRUG|Lithium Carbonate|The experimental drugs in this study will be lithium carbonate capsules dosed at 62.5mg, 125mg and 250mg prepared as hospital preparations for clinical trials.
223542007|NCT02907658|BEHAVIORAL|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
223542008|NCT01030120|DRUG|etanercept|etanercept 50mg BIW S.Q.
223542009|NCT01030120|DRUG|placebo|placebo
223542010|NCT03504228|DEVICE|Roadsaver|Dual layer micromesh Roadsaver carotid stent
223542011|NCT03235453|OTHER|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
223959860|NCT04623398|DRUG|Placebo|Placebo
223959861|NCT05269212|OTHER|Usual Care trajectory|Usual care after Spinal Cord Stimulation implantation
224108977|NCT01819688|PROCEDURE|laparoscopic liver resection|
224108978|NCT00670917|OTHER|questionnaire administration|
224108979|NCT00670917|PROCEDURE|acupressure therapy|
223959862|NCT05269212|OTHER|A biopsychosocial rehabilitation program|A personalized biopsychosocial rehabilitation program specifically targeting return to work.
223959863|NCT06963775|DEVICE|Delphi-MD device (QuantalX Neuroscience Ltd., Saba Israel)|"Delphi-MD utilizes the use of transcranial magnetic stimulation evoked electroencephalography (TMS-EEG) for diagnostic purposes in a wide range of neurological disorders. Delphi-MD includes a magnetic stimulator and coil, an EEG amplifier and electrode cap and software for the acquisition and analysis of the data.~Delphi-MD stimulation protocol includes low intensities (sub motor thresholds) and frequencies over six stimulation sites (bilateral primary motor cortex, and bilateral dorsolateral prefrontal cortex)."
223959864|NCT01293500|PROCEDURE|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
223959865|NCT05527405|DEVICE|The MapHabit System|"The MapHabit System (MHS) is a commercially available visual mapping software application that utilizes visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application will be made available through tablets. Depending on the condition, participants will receive a specific version of the application. The experimental condition will receive the version that incorporates gamified structure and the Caregiver Training Program.~The MHS is a general wellness product. This functionality is not a regulated medical device."
223959866|NCT06671938|DRUG|exidavnemab|The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
223959867|NCT06671938|DRUG|Placebo Comparator|The trial medication will be administered as an intravenous (IV) infusion
223959868|NCT05555550|DRUG|18F-Fluciclovine|18F-Fluciclovine will be injected via IV prior to PET-MRI imaging
223959869|NCT04877821|DRUG|Sintilimab|200mg on days 1 (Q3W) of the neoadjuvant and adjuvant phase of the study; IV injection.
223959870|NCT04877821|DRUG|Anlotinib|12mg on d1-14 of Cycles 1-8 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
223959871|NCT04877821|DRUG|Nab paclitaxel|100 mg/m² on day 1, 8 and 15 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
223959872|NCT04877821|DRUG|Carboplatin|AUC 5 on days 1 of Cycles 1-4 (Q3W) of the neoadjuvant phase of the study; IV injection.
223959873|NCT04877821|DRUG|Epirubicin|90 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
223959874|NCT04877821|DRUG|Cyclophosphamide|600 mg/m² on day of Cycles 5-8 (Q3W) of the neoadjuvant phase of the study; IV injection.
223959875|NCT02534649|PROCEDURE|Newly obtained biopsy and Blood samples collection|"For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
223959876|NCT06229977|DRUG|Palmitoylethanolamide (PEA)|Participants will receive PEA at a dose of 600mg twice daily for 6 weeks.
223959877|NCT06229977|DRUG|Placebo|Participants will receive placebo (a tablet that contains no active ingredient) to be taken twice daily for 6 weeks
223959878|NCT06229977|DRUG|Treatment as Usual (TAU)|subjects will receive a mood stabilizer per usual care
223959879|NCT05487131|BEHAVIORAL|electrical stimulation|different types of weak electrical stimulation will be used
223542012|NCT03235453|OTHER|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
223959880|NCT06843564|OTHER|Remote Enhanced Assessment for Care at Home (REACH) Kit|"Families of 6 month old infants will receive tele-device kits that include thermometers, pulse oximeters, and tele-otoscopes and respiratory swab tests, which families will then have the option to use when they schedule telemedicine visits with their usual primary care practice.~Note that the investigators are not studying the devices themselves; the investigators are instead studying health care use and experiences when these devices are made available."
223959881|NCT06400511|DRUG|Pimecrolimus 0.3% Ophthalmic Ointment|Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
223959882|NCT06400511|DRUG|Placebo Ophthalmic Ointment|Placebo will be applied twice a day to both eyelid margins.
223959883|NCT05486819|DRUG|Propofol Injection|adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
224108980|NCT00670917|PROCEDURE|biopsy|
224108981|NCT00670917|PROCEDURE|bone marrow aspiration|
224108982|NCT00670917|PROCEDURE|pain therapy|
224108983|NCT00416351|DRUG|clofarabine|
224108984|NCT03247907|DEVICE|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
224108985|NCT03247907|DEVICE|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
223959884|NCT06153355|DRUG|LY3839840|Administered orally.
223959885|NCT06153355|DRUG|Placebo|Administered orally.
223959886|NCT06153355|DRUG|Midazolam|Administered orally
223959887|NCT05361954|DRUG|STI-1386|Second generation oncolytic virus
224108986|NCT03247907|DEVICE|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
224108987|NCT03247907|DEVICE|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
224108988|NCT03247907|DEVICE|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
223959888|NCT04529941|DEVICE|Device Implant with Active Treatment|ScNS at 3.5mA output for 2 weeks
223959889|NCT04529941|DEVICE|Device Implant without Active Treatment|No device output for 2 weeks
223959890|NCT06544772|DEVICE|Pivot cigarette smoking cessation program|The Pivot cigarette smoking cessation program comprises a mobile personal breath carbon monoxide sensor (Pivot Breath Sensor) and a smartphone app (Pivot app) with in-app asynchronous SMS text-based coaching with a certified human tobacco cessation coach.
223542013|NCT02708316|GENETIC|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
223959891|NCT02051972|DEVICE|Implanted with a Nanostim leadless pacemaker system|
223959892|NCT06541756|PROCEDURE|Fibrine Clot-augmented Meniscal Repair|The fibrin clot will be prepared from 50cc of bone marrow aspirate obtained from the iliac crest and mixed for 15 minutes. The fibrin clot will be shaped into a cylindrical form and compressed between the torn edges of the meniscus using a trocar system, then secured with sutures.
223959893|NCT06541756|PROCEDURE|Conventional Meniscal Repair|Patients in the standard repair group will undergo routine meniscus repair surgery using arthroscopic all-inside or inside-out sutures.
224108989|NCT03247907|DEVICE|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
224108990|NCT03247907|DEVICE|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
224108991|NCT03247907|DEVICE|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
224108992|NCT00218244|OTHER|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
224108993|NCT00218244|OTHER|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
223542014|NCT04481607|DRUG|TQB3454|TQB3454 tablets is a small molecule oral drug.
223959894|NCT03800602|DRUG|Metformin|Given PO
223959895|NCT03800602|BIOLOGICAL|Nivolumab|Given IV
223959896|NCT04256317|DRUG|Azacitidine|Tablets/Capsules for oral administration and powder for reconstitution to aqueous suspension for SC administration.
223959897|NCT04256317|DRUG|ASTX030 (cedazuridine + azacitidine)|FDC Capsules for oral administration.
223542015|NCT00565396|DRUG|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
223542016|NCT05056558|DRUG|Baricitinib|Continued standard of care (SOC) together with oral 4 mg Baricitinib tablet from day 1 to day 14
223542017|NCT05056558|DRUG|Placebo|Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
223542018|NCT00111072|DRUG|dexamethasone 0.01% solution|
223959898|NCT04256317|DRUG|Azacitidine|Powder for reconstitution to aqueous suspension for SC administration.
223959899|NCT04256317|DRUG|ASTX030 (cedazuridine + azacitidine)|Tablets/Capsules for oral administration.
223959900|NCT04256317|DRUG|Cedazuridine|Tablets for oral administration.
223959901|NCT04256317|DRUG|Venetoclax|Oral tablets.
223959902|NCT06521346|PROCEDURE|Active cycle breathing technique|The ACBT was included if it was described as containing three essential components: 1) breathing control, 2) forced expiration technique and 3) thoracic expansion exercises. The technique may also include postural drainage (PD) or percussion/shaking.
223959903|NCT06521346|PROCEDURE|Routine care|Routine care delivers after extubating such as percussion or chest physiotherapy
223959904|NCT03649503|OTHER|No intervention|
224108994|NCT04936672|BEHAVIORAL|Brisk walking and Tai Chi Chuan|This study includes four groups, the three experimental groups are brisk walking group, Tai chi chuan group, brisk walking combined with Tai chi chuan group, and control group. Among the three experimental groups and exercise time, exercise intensity and exercise frequency are the same over time.
224108995|NCT04137172|PROCEDURE|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
224108996|NCT04137172|PROCEDURE|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
224291273|NCT00396461|DRUG|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
224291274|NCT04149028|PROCEDURE|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
224291275|NCT00003242|DRUG|bryostatin 1|
224291276|NCT00003242|DRUG|cisplatin|
224291277|NCT00003242|DRUG|paclitaxel|
224291278|NCT02166320|DEVICE|Partially covered SEMS|
224291279|NCT02166320|DEVICE|Fully covered SEMS|
224291280|NCT00020267|DRUG|interleukin-2|
223959905|NCT06006299|DEVICE|transauricular Vagus Nerve Stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) is a form of transcutaneous electrical nerve stimulation (TENS) applied to peripheral nerves, considered a low-risk procedure. It involves the use of standard neurostimulation electrodes placed on the surface of the external ear. The taVNS method delivers low-intensity, pulsed electrical currents with a peak current amplitude of \<4 mA, which is significantly lower than those used in most over-the-counter TENS devices for pain relief or muscle stimulation. By targeting the auricular branches of the vagus nerve, taVNS aims to stimulate specific neural pathways associated with various indications and intended uses. This non-invasive approach has broad applications in research, medical device treatments, health products, and cosmetic or lifestyle products.
223959906|NCT04021277|DRUG|20 uL/kg PS101|20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
223959907|NCT04021277|DRUG|40 uL/kg PS101|40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
223959908|NCT04021277|DEVICE|Ultrasound|Ultrasound activation and enhancement
223959909|NCT05169814|DRUG|Micro/nanobubble (MNB) - Irrigation|An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
223959910|NCT05169814|OTHER|0.9% Normal Saline - Irrigation|A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
223959911|NCT05169814|DRUG|Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
223959912|NCT05169814|OTHER|0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)|NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
223959913|NCT02900937|DEVICE|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
223959914|NCT05904704|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223959915|NCT05904704|PROCEDURE|Oxygen Therapy|Receive supplemental oxygen
223959916|NCT04819204|DRUG|Cetrorelix Acetate|GnRH antagonist - subcutaneous injection. Day 1: 1-3 mg; Days 2-14: 0.25mg/daily.
223959917|NCT04819204|DRUG|Testosterone gel|Testosterone gel - transdermal application of 5mg/day on Day 7-14 of GnRH antagonist
223959918|NCT02991456|DRUG|Rolapitant|single 180 mg dose by mouth
223959919|NCT02991456|DRUG|Ondansetron|8 mg by mouth daily
223959920|NCT02264444|OTHER|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
223959921|NCT04420351|DRUG|Urokinase thrombolysis|The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
223959922|NCT04420351|DRUG|Aspirin;Clopidogrel|The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
224291281|NCT00020267|DRUG|MAGE-12 peptide vaccine|
224291282|NCT00020267|DRUG|Montanide ISA-51|
224291283|NCT02291471|DRUG|T0001，10mg|
223959923|NCT02255526|DEVICE|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
223959924|NCT04976322|DRUG|Dapirolizumab pegol|Subjects will receive dapirolizumab pegol at prespecified time-points.
223959925|NCT06318364|OTHER|NO Intervention|NO Intervention
223959926|NCT06970366|OTHER|Cold pack application|Cold pack application
223959927|NCT06970366|OTHER|Cold spray application|Cold spray application
223959928|NCT06617325|DRUG|DZP|Study participants will receive dapirolizumab pegol (DZP) at prespecified time-points.
223959929|NCT06617325|OTHER|Placebo|Study participants will receive placebo at prespecified time-points.
223959930|NCT05943535|DRUG|Placebo|Placebo administered QID
223959931|NCT05943535|DRUG|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered QID
223959932|NCT05943535|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
223959933|NCT00739362|DEVICE|Transcranial Direct Current Stimulation (TDCS)|Active tDCS (anodal left DLPFC)
223959934|NCT00739362|OTHER|Sham/no-stimulation|Sham tDCS
223959935|NCT06264557|DEVICE|SB-100|"Cognitive training will be conducted once a day, and it will take 15 to 30 minutes.~It consists of cognitive training and educational videos."
223959936|NCT06264557|OTHER|Educational book|Book of education on daily rules for preventing dementia
224291284|NCT02291471|DRUG|T0001，20mg|
224291285|NCT02291471|DRUG|T0001，35mg|
224291286|NCT02291471|DRUG|T0001，50mg|
224291287|NCT02291471|DRUG|T0001，65mg|
223959937|NCT06646822|OTHER|questionnaire|observational study
223959938|NCT05878184|DRUG|SC291|SC291 is an allogeneic CAR-T cell therapy
223959939|NCT00422786|DRUG|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
223959940|NCT04188912|PROCEDURE|Biospecimen Collection|Undergo collection of blood, tears, saliva, buccal mucosa, feces, and tissue samples
223959941|NCT04188912|PROCEDURE|Optical Coherence Tomography|Undergo optical coherence tomography
223959942|NCT04188912|PROCEDURE|Spirometry|Undergo portable spirometry
223959943|NCT04188912|OTHER|Survey Administration|Complete survey
223959944|NCT04188912|OTHER|Digital Photography|Undergo digital photography
223959945|NCT04188912|OTHER|Quality-of-Life Assessment|Ancillary studies
223959946|NCT04188912|OTHER|Medical Chart Review|Review of medical charts
223959947|NCT06252675|BIOLOGICAL|Obinutuzumab|Given intravenously (IV)
223959948|NCT06252675|BIOLOGICAL|Glofitamab|Given IV
223959949|NCT06252675|DRUG|Pirtobrutinib|Given Orally (PO)
223959950|NCT06252675|PROCEDURE|Tumor Imaging|Undergo regular care imaging/scans
223959951|NCT06252675|PROCEDURE|Biospecimen Collection|Blood and tissue samples
223959952|NCT06252675|DEVICE|ClonoSeq Assay|ClonoSEQ is an FDA-cleared, Clinical Laboratory Improvement Amendments of 1988 (CLIA)-validated measure used to determine minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.
223959953|NCT06252675|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration.
223542019|NCT04849637|DRUG|Virgin Coconut Oil|Oral supplementation of virgin coconut oil to COVID-19 patients
223542020|NCT04180111|DEVICE|CATS Tonometer|CATS Tonometer Prism
223959954|NCT06350682|BEHAVIORAL|HealthMPowerment (HMP)|Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.
223959955|NCT06572579|PROCEDURE|Ultrasound-guided pharmacopuncture treatment|Pharmacopuncture treatment using ultrasound-guidance
223959956|NCT06172257|DRUG|Dexamethasone ophthalmic suspension (OCS-01)|Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
223959957|NCT06172257|DRUG|Vehicle|Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
223959958|NCT04897321|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis. Intravenous
223542021|NCT05998486|DIAGNOSTIC_TEST|EMG in wrist flexor-pronators and extensor-supinators|The subject is asked to perform a series of tasks: resting posture, symmetrical posture arms forward, unilateral distal movement. Each task lasts 10 seconds.
223959959|NCT04897321|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA. Intravenous
223959960|NCT04897321|DRUG|MESNA|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
223959961|NCT04897321|DRUG|B7-H3 CAR T cells|The study participant will receive B7-H3-CAR T cells by vein, through either an IV or a central line.
223959962|NCT05639647|DRUG|ATM-AVI|A drug specifically designed to treat resistant gam-negative bacterial infections
223959963|NCT05639647|DRUG|BAT|BAT will be selected by the investigator and administered iv as appropriate for the selected drug(s)
223959964|NCT06563310|OTHER|Functional magnetic resonance imaging (fMRI) with Veritable-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with real neurofeedback and answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
223959965|NCT06563310|OTHER|fMRI with Sham-NF|Participants will complete 4 visits (some can be done virtually). The baseline visit will include a clinical interview. Eligible participants will complete a series of questionnaires and a practice session at visit 2, and may do a mock scan if the visit is in person. Visit 3 will take place within 5 days of the practice session. Participants will have an fMRI with neurofeedback that looks similar to real neurofeedback but does not reflect their true brain signal. Afterwards, they will answer a series of questions pertaining to the scan. 2 weeks after visit 3, participants will revisit the questionnaires they completed at baseline. Visit 4 will take place one month after visit 3 and will include a follow-up interview with an assessor and the final questionnaire collection.
223959966|NCT06041594|DEVICE|Laguna Thrombectomy System|Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
223959967|NCT06969612|DRUG|Tislelizumab|200 mg, intravenously on Day 1, every 3 weeks
223959968|NCT06969612|DRUG|Pemetrexed|administered via IV infusion
223959969|NCT06969612|DRUG|Cisplatin|administered via IV infusion
223959970|NCT06969612|DRUG|Carboplatin|administered via IV infusion
224108997|NCT04137172|PROCEDURE|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
223959971|NCT06969612|DRUG|Paclitaxel|administered via IV infusion
224108998|NCT01334125|DRUG|Metformin|Metformin 1000 mg once daily by mouth for 9 months
224108999|NCT01334125|DRUG|Placebo|2 capsules once daily by mouth for 9 months
224109000|NCT00292292|DEVICE|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
223542022|NCT00519727|DRUG|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
224109001|NCT00292292|DEVICE|Charite Artificial Disc|Insertion of the Charite
224109002|NCT03969433|DEVICE|TMSi Porti|Data collections
224109003|NCT03969433|DEVICE|Bloomlife sensor|Data collections
223959972|NCT06969612|DRUG|Albumin Paclitaxel|administered via IV infusion
223959973|NCT06969612|DRUG|Golidocitinib|75mg, once a day orally
223959974|NCT06972966|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
223959975|NCT06972966|DEVICE|Any standard of care guidewire|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
224109004|NCT06365333|PROCEDURE|Fluoroscopic-guided air-enema reduction (FGAR)|A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
224109005|NCT00270920|BEHAVIORAL|Lactation counseling|
224109006|NCT03416582|BEHAVIORAL|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
224109007|NCT03416582|BEHAVIORAL|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
224109008|NCT04901026|OTHER|An in-house manikin|Participants obtain an in-house manikin
224109009|NCT00401973|DRUG|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
224109010|NCT00401973|DRUG|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
224109011|NCT00401973|DRUG|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
224109012|NCT00401973|DRUG|zonisamide|Zonisamide, 100-400mg, oral, daily.
224109013|NCT00401973|BEHAVIORAL|Wellness education|weight management
224109014|NCT02242071|BIOLOGICAL|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
224291288|NCT02291471|DRUG|T0001，75mg|
223959976|NCT05786911|OTHER|nutritional score|correlation between a food habit and nutritional status score of the parturient and a postpartum fatigue (FSS) and pain (ENA) score
223959977|NCT04016415|BEHAVIORAL|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
223959978|NCT04016415|BEHAVIORAL|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
223959979|NCT05307302|DIAGNOSTIC_TEST|Force Sense|A measure of proprioception, using a handheld dynamometer (MicroFET2-hoggan Health Industries Inc.), in a sitting position in a standardized position of the elbow joint of the dominant upper extremity (90 degree of flexion). Measurement of the elbow joint flexion force sense will be expressed as percentages. Each of the targeted trials will be calculated as a percentage of the maximum voluntary contraction (MVC) reference measure. The difference between the targeted and the actual percentage of MVC for each of the trials will be then calculated as a percentage of the targeted MVC, to reflect the proportion of error.
223959980|NCT05307302|DIAGNOSTIC_TEST|Joint Reproduction Sense|A measure of proprioception, using a smart phone goniometer (Android Clinometer) application, in a sitting position in a standardized position of the elbow joint of the dominant upper extremity. Measurement of the elbow joint position reproduction will be expressed as degrees of reproduced angle. Absolute Error (AE) score will be calculated by the absolute value of the difference in degrees of the angle reproduced after subtracting the angle targeted.
223959981|NCT05307302|DIAGNOSTIC_TEST|Seated Medicine Ball Throw|A measure of upper limb physical performance, using 2-kg medicine ball and a standardized protocol, throwing distance expressed in meters.
223959982|NCT05307302|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|A measure of upper limb physical performance, using body weight and a standardized protocol, touches between hands expressed in number of touches.
223959983|NCT05307302|DIAGNOSTIC_TEST|Passing Accuracy|A measure of the basketball passing skills, passing of The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) test battery will be used in a standardized protocol. Accurate passes will be expressed in points.
223959990|NCT03492671|DRUG|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
223959991|NCT03492671|DRUG|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
223959992|NCT03492671|RADIATION|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
223959993|NCT06504953|OTHER|Questionnaire|Questionnaires on contraception and sports activities
223959994|NCT06504953|OTHER|Beighton test|A popular screening technique for hypermobility. It consists of a nine-point scale requiring the performance of five maneuvers, four passive bilateral and one active unilateral.
223959995|NCT06504953|OTHER|Lachman Test|"To perform this test, place your patient in a supine position and bring your patient's test leg to 30 degrees of flexion. Fix the femur with the other hand. Put the tibia in slight external rotation, then try to translate it forwards.~This test is positive if you feel a soft or limp end or if the anterior part."
223959996|NCT04979247|DRUG|Oliceridine|Near the end of surgery, patients will be given ≤1.5 mg of oliceridine as a bolus. Postoperatively, patient-controlled analgesia (PCA) will be started with no background infusion, demand doses of 0.35 mg, with a 6 minute lock-out. Additional boluses (≤1 mg) of oliceridine will be given as deemed necessary (based on NRS score and clinical assessment of the patient) as soon as 15 minutes after the initial 1.5 mg loading dose. In addition to supplemental 1 mg bolus doses, the PCA demand dose can be increased to a maximum of 0.5 mg oliceridine.
223959997|NCT04087629|DEVICE|StrataCTX® gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
223959998|NCT06193200|DRUG|Dexamethasone sodium phosphate|Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
223959999|NCT06193200|OTHER|Placebo|Placebo encapsulated in autologous erythrocytes and administered via IV infusion
224109015|NCT05523362|DEVICE|Dexcom continuous glucose monitor|The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.
224109016|NCT04789785|DIAGNOSTIC_TEST|ultrasound|observation with usg
224109017|NCT02971644|DEVICE|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
224109018|NCT01868087|DIETARY_SUPPLEMENT|Boost Plus®|
224109019|NCT01868087|DIETARY_SUPPLEMENT|Impact Advanced Recovery®|
223960000|NCT06461065|DEVICE|AIDS|mylife CamAPS application, marketed by CamDiab Ltd, in conjunction with YpsoPump, marketed by Ypsomed, Dexcom blood glucose sensor, Orbit Infusion sets and Orbit Infusion sets and Orbit inserter (used in their indications)
223960001|NCT06461065|OTHER|Brain MRI|To evaluate the neuroanatomical damage to gray matter associated with type 1 diabetes in young children according to their glycemic profile (AIDS use or not) and compared with an age-matched control subject
224109020|NCT04075604|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
224109021|NCT04075604|DRUG|Anastrozole|Specified Dose on Specified Days
223960002|NCT05077072|OTHER|Best Practice|Receive SOC
223960003|NCT05077072|OTHER|Counseling|Participate in CHAT counseling intervention
223960004|NCT05077072|PROCEDURE|Electroencephalography|Undergo EEG
223724248|NCT05077397|DEVICE|O3|O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
223960005|NCT05077072|BEHAVIORAL|Neurofeedback|Undergo NFB intervention
223960006|NCT05077072|OTHER|Questionnaire Administration|Ancillary studies
223960007|NCT06804655|DEVICE|Pharmacoscopy 1.0|The intervention is the submission of freshly obtained surgical material to ex vivo drug profiling which we term pharmacoscopy (PCY). The performance study is interventional as the test results shall influence patient management decisions and/or may be used to guide treatment.
223960008|NCT05615870|OTHER|Winix 5500-2 HEPA filtration units|To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.
223960009|NCT03750981|BEHAVIORAL|12 week pilot intervention study.|Participants will begin a 12-week high-intensity functional training program conducted at CrossFit® in the D, located in downtown Detroit, Northville Athletix in Northville and Five Lakes CrossFit® in Farmington Hills.
223960010|NCT03393884|BIOLOGICAL|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
224109022|NCT04075604|DRUG|Palbociclib|Specified Dose on Specified Days
223960011|NCT03393884|DRUG|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
223960012|NCT03393884|DRUG|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
223960013|NCT06019962|DEVICE|digital pelvic inclinometer|It is a reliable and valid instrument for measuring pelvic tilt angle
223960014|NCT05898464|BIOLOGICAL|Recombinant zoster vaccination|Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart
223960015|NCT06647654|BIOLOGICAL|ABRYSVO|"Test Negative Design: This is a non-interventional retrospective study; therefore, ABSYRVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.~Ecologic Before-and-After Design: This is an ecologic before-and-after study using aggregated data; as such, the 'exposure' of interest is time before ABRYSVO program implementation (i.e., five historical pre-ABRYSVO RSV seasons) and time after ABRYSVO implementation (i.e., post-ABRYSVO RSV seasons: 2024-2026)."
223960016|NCT01915212|BIOLOGICAL|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
223960017|NCT01915212|OTHER|Placebo|Sodium Chloride 0.9%
223960018|NCT04852887|OTHER|Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|"Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins).~Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator."
223960019|NCT04852887|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
223960020|NCT05170204|DRUG|Alectinib|Participants will receive oral alectinib twice daily with food.
223960021|NCT05170204|DRUG|Entrectinib|Participants will receive oral entrectinib once daily, with or without food.
224109023|NCT01954628|DRUG|AQX-1125|Synthetic SHIP1 activator
224109024|NCT01954628|DRUG|Placebo|Placebo control
224109025|NCT02893254|DRUG|IBI303|12 cycles. IBI303: 40 mg, iH
224109026|NCT02893254|DRUG|Adalimumab|12 cycles. Adalimumab: 40mg, iH
224109027|NCT03406949|BIOLOGICAL|obrindatamab|B7-H3 x CD3 DART protein
224109028|NCT03406949|BIOLOGICAL|retifanlimab|anti-PD-1 antibody
223724249|NCT03932227|DEVICE|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
224109029|NCT00358189|DEVICE|Deep Brain Stimulation|
224291289|NCT02743728|DEVICE|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
223960022|NCT05170204|DRUG|Durvalumab|Participants will receive IV durvalumab every 4 weeks.
223960023|NCT00317928|DRUG|Metformin|
223542023|NCT01394380|OTHER|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
223960024|NCT04636515|DRUG|F520|200mg，Q3W
223960025|NCT06244394|RADIATION|intensity-modulated radiotherapy|All patients were staged according to the 8th edition of the TNM classification by the American Joint Committee on Cancer/Union for International Cancer Control and received a standardized treatment regimen including IMRT and concurrent or adjuvant chemotherapy. Inverse IMRT treatment planning was performed on a Varian Inspiration Platform (version 10.0), using the simultaneous integrated boost technique. The prescribed doses were 68-75 Gy to the PTV of the GTVnx in 32-34 fractions; 64-75 Gy to the PTV of the GTVnd in 32-34 fractions; 60 Gy to the PTV of CTV1 in 32 fractions; and 50 Gy to the PTV of CTV2 in 28 fractions. All patients were given one fraction daily 5 days a week. The dose-volume-histograms (DVHs) of the organs at risk were evaluated as described in the radiation therapy oncology group (RTOG) 0225 protocol to prevent violation of the tolerance limits.
223960026|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 500 ml alginate beverage per meal test
223960027|NCT01101633|DIETARY_SUPPLEMENT|Alginate|a 330 ml alginate beverage per meal test
223542024|NCT02714660|OTHER|none, observational study|
223960028|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 500 ml placebo beverage per meal test
223960029|NCT01101633|DIETARY_SUPPLEMENT|Placebo|a 330 ml placebo beverage per meal test
223960030|NCT04077099|DRUG|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
223960031|NCT06101069|PROCEDURE|MRF in conjunction with IVIM MRI without contrast|MRF in conjunction with IVIM MRI scan, without contrast.
223960032|NCT05920954|PROCEDURE|ERCP|Repeat ERCP
223960033|NCT03543189|DRUG|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
223960034|NCT03543189|RADIATION|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
223960035|NCT03543189|RADIATION|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
223960036|NCT03543189|DRUG|Androgen Deprivation Therapy|Standard of care.
223960037|NCT00070317|DRUG|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
223960038|NCT00070317|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping
223960039|NCT00070317|PROCEDURE|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
224109030|NCT02352246|PROCEDURE|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
224109031|NCT02352246|PROCEDURE|Physical activity programs high intensity intermittent exercise (HIIE)|
224109032|NCT02279329|OTHER|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
224109033|NCT00370786|DRUG|bevacizumab|
224109034|NCT04767880|DIETARY_SUPPLEMENT|Whey|Doses of 10, 15, 20 and 30 gram protein of a regular whey protein compound (whey protein isolate WPI (Lacprodan® ISO.Water. from Arla Foods Ingredients))
224109035|NCT04767880|DIETARY_SUPPLEMENT|Placebo|The placebo contains \<1 kcal and 0 g protein
224109036|NCT04001686|OTHER|incidence aplastic anemia|Ambispective chart review
224109037|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using water at room temperature|The use of water at room temperature to solve the 75g glucose.
224109038|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water|The use of hot water to solve the 75g glucose.
224109039|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water|The use of cold water to solve the 75g glucose.
223542025|NCT03679390|DRUG|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
224109040|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using hot water with tea bag|The use of hot water with tea bag to solve the 75g glucose.
223542026|NCT04567524|DRUG|LYN-005|LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.
223960040|NCT00070317|DRUG|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
223960041|NCT00070317|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
223960042|NCT00070317|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
223960043|NCT00070317|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
223960044|NCT00070317|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical hysterectomy
223960045|NCT05156281|DRUG|Remibrutinib|tablet taken orally
223960046|NCT05156281|DRUG|Teriflunomide|capsule taken orally
223960047|NCT00927849|PROCEDURE|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
223960048|NCT00927849|DRUG|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
223960049|NCT00927849|DRUG|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
223960050|NCT02211872|DRUG|BI 2536 BS, intravenous|
223960051|NCT05654207|BEHAVIORAL|WeCare|WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
223960052|NCT01399606|DRUG|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
223960053|NCT06122064|OTHER|Best Practice|Receive standard of care
223960054|NCT06122064|OTHER|Communication Intervention|Use shared decision-making conversation tool
223960055|NCT06122064|OTHER|Electronic Health Record Review|Ancillary studies
223960056|NCT06122064|OTHER|Survey Administration|Ancillary studies
223960057|NCT06122064|OTHER|Video Recording|Ancillary studies
223960058|NCT06122064|OTHER|Audio Recording|Ancillary studies
223960059|NCT03249857|BEHAVIORAL|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~* cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~* Intelligence Quotient (IQ) test (PM38, Raven, 1960)~* Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
223724250|NCT03932227|DEVICE|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
223724251|NCT00412659|PROCEDURE|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
223960060|NCT03249857|BEHAVIORAL|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
223960061|NCT01014559|DRUG|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
223960062|NCT01014559|DRUG|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
223960063|NCT00508144|DRUG|Alimta|500 mg/m\^2 by vein Once Over 10 Minutes Every 3 Weeks
223960064|NCT01156454|PROCEDURE|X-ray|surgical specimen taken to radiology and contents x-rayed
223960065|NCT05169515|DRUG|SC Mosunetuzumab|Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
223960066|NCT05169515|DRUG|IV Glofitamab|Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
223960067|NCT05169515|DRUG|Iberdomide|Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
223960068|NCT05169515|DRUG|Golcadomide|Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
223960069|NCT05169515|DRUG|Obinutuzumab|Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
223960070|NCT05169515|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
223960071|NCT03226600|DEVICE|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
223960072|NCT03226600|DEVICE|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
224109041|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using room temperature water with tea bag|The use of room temperature water with tea bag to solve the 75g glucose.
224109042|NCT05508425|DIAGNOSTIC_TEST|oral glucose tolerance test using cold water with tea bag|The use of cold water with tea bag to solve the 75g glucose.
224109043|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water at room temperature|The use of bubble water at room temperature to solve the 75g glucose.
224109044|NCT05508425|DIAGNOSTIC_TEST|Oral glucose tolerance test using bubble water|The use of cold bubble water to solve the 75g glucose.
224109045|NCT04595955|OTHER|CMyLife|CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
223724252|NCT00412659|PROCEDURE|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
223724253|NCT00039832|DRUG|Abciximab (ReoPro) and Reteplase (Retavase)|
223960073|NCT02813304|BEHAVIORAL|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
223960074|NCT02813304|BEHAVIORAL|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
223724254|NCT02771002|DEVICE|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
223960075|NCT06358794|DIAGNOSTIC_TEST|Machine learning-based predictive model|The clinical features of participants were used to train, test and validate the machine learning models. Various evaluation metrics including area under the ROC (AUC), accuracy, etc. were used to evaluate the predictive performance of 8 machine learning models.
223960076|NCT00054197|DRUG|gemcitabine hydrochloride|
223960077|NCT00054197|DRUG|paclitaxel poliglumex|
224109046|NCT02127112|PROCEDURE|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
224109047|NCT02127112|PROCEDURE|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
224109048|NCT00129077|PROCEDURE|plastic wrap over eye & lubrication applied q6 hrs|
224109049|NCT03622411|DEVICE|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
224109050|NCT03622411|DEVICE|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
224109051|NCT03622411|BEHAVIORAL|aphasia therapy|language exercises provided by the speech therapist in hospital
224109052|NCT02395679|BIOLOGICAL|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
224291290|NCT02743728|DEVICE|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
224291291|NCT02743728|BEHAVIORAL|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
223724255|NCT01563302|DRUG|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
223724256|NCT03940404|DRUG|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
223724257|NCT02601690|OTHER|Blood Sampling|
223960078|NCT00054197|DRUG|vinorelbine tartrate|
223960079|NCT04346784|BEHAVIORAL|maintaining positive working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
223960080|NCT04346784|BEHAVIORAL|repressing negative working memory training|Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
223960081|NCT04346784|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
223960082|NCT04346784|BEHAVIORAL|Positive placebo ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
223960083|NCT05558748|PROCEDURE|USG-guided Caudal block|USG-guided Caudal block after general anesthesia
223960084|NCT05558748|PROCEDURE|USG-guided Ilioinguinal/Iliohypogastric block|USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
223960085|NCT06501053|RADIATION|Radiotherapy|45/50 Gy (1.8/2 Gy/fraction/5 weeks)
223960086|NCT06501053|RADIATION|Short-course radiotherapy|25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days
223960087|NCT06501053|RADIATION|Contact x-ray brachytherapy|90Gy/3 fractions/4 weeks
223960088|NCT06501053|DRUG|Chemotherapy|Capecitabine (900 mg/m2 bid, on radiation days)
223960089|NCT05466630|DIAGNOSTIC_TEST|Serological field test for HAT|Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
223960090|NCT05466630|DIAGNOSTIC_TEST|malaria rapid test|RDT detecting HRP2 plasmodium antigen.
224109053|NCT02727114|OTHER|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® \& VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
224109054|NCT04329923|DRUG|Hydroxychloroquine Sulfate 400 mg twice a day|Antimalarial compound
224109055|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg twice a day|Antimalarial compound
223960091|NCT05466630|DIAGNOSTIC_TEST|Immunologic laboratory tests|Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
223960092|NCT05466630|DIAGNOSTIC_TEST|Molecular laboratory tests|Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
223960093|NCT03800368|OTHER|Exercise|Indoor cycling exercise intervention
223960094|NCT03800368|OTHER|Non-exercise|Psycho-education
223960095|NCT01661972|DRUG|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
223960096|NCT03500276|BEHAVIORAL|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
223960097|NCT03500276|BEHAVIORAL|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
223960098|NCT04267523|BEHAVIORAL|Web parenting intervention|Parents participate in the self-delivered web-based parenting intervention for 6 modules. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
223960099|NCT04267523|BEHAVIORAL|Group parenting intervention|Parents participate in face-to-face a weekly 2-hour group for 4 sessions. Treatment includes abilities of psychological flexibility (to be open, aware and active), emotion regulation, and positive parenting strategies.
223960100|NCT00552591|BEHAVIORAL|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
223960101|NCT00442507|DRUG|Erlotinib|
223960102|NCT00442507|DRUG|Avastin|
223960103|NCT05813522|DRUG|Furmonertinib Mesilate Tablets|160mg of Furmonertinib mesilate tablets (given as four 40mg tablets) administered orally once daily
223960104|NCT02894099|OTHER|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
224109056|NCT04329923|DRUG|Hydroxychloroquine Sulfate 600 mg once a day|Antimalarial compound
224109057|NCT04329923|DRUG|Placebo oral tablet|Placebo
224109058|NCT01702012|DIETARY_SUPPLEMENT|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
224109059|NCT01702012|BEHAVIORAL|Group-Based Lifestyle Intervention|
224109060|NCT03796741|OTHER|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
224109061|NCT03370367|DRUG|13-cis retinoic acid|Taken daily.
224109062|NCT03370367|OTHER|Placebo|Placebo
223542027|NCT04258852|DRUG|Low strength nicotine e-liquid|Low strength nicotine e-liquid
223542028|NCT04258852|DRUG|High strength nicotine e-liquid|High strength nicotine e-liquid
223542029|NCT02030132|BEHAVIORAL|Feedback compared to 75th percentile|
223960105|NCT02894099|OTHER|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
223960106|NCT02894099|OTHER|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
223960107|NCT02894099|OTHER|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
223960108|NCT01111006|DEVICE|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
223960109|NCT03326037|GENETIC|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
223960110|NCT06034444|OTHER|interRAI LTCF|Standardized evaluations (interRAI LTCF) will be introduced to selected nursing homes in Quebec.
223960111|NCT01171053|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
223960112|NCT01171053|BEHAVIORAL|Therapist support|Weekly therapist support without CBT-interventions
223960113|NCT03900988|DRUG|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
223960114|NCT03900988|DRUG|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
223960115|NCT04313985|DEVICE|Tennant Biomodulator-Pro™ Device|Tennant Biomodulator-Pro™ conductive electrode pads will be placed on both sides of the wound. The device will either deliver electrical stimulation or no stimulation depending on treatment period.
224109063|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
223724258|NCT01993147|BEHAVIORAL|Dual task paradigm pilot|
223960118|NCT06191133|DRUG|Fenofibrate|Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
223960119|NCT06191133|PROCEDURE|Cervical Conization|Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
223960120|NCT06191133|PROCEDURE|Hysterectomy|In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
223542030|NCT02030132|BEHAVIORAL|Forgiveness|
223542031|NCT02030132|BEHAVIORAL|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
223542032|NCT02030132|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
224109064|NCT01272180|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
223960121|NCT06191133|RADIATION|Chemoradiation|Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
223960122|NCT03542695|PROCEDURE|Computed Tomography|Undergo PET/CT
224109065|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
224109066|NCT01272180|BIOLOGICAL|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
224109067|NCT02962635|DEVICE|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
224109068|NCT00850772|DIETARY_SUPPLEMENT|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
224109069|NCT03288467|PROCEDURE|Root canal treatment with 5% NaOCl|
224109070|NCT03288467|PROCEDURE|Root canal treatment with 1% NaOCl|
224109071|NCT03412227|BEHAVIORAL|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
223960123|NCT03542695|DRUG|Copper Cu-64-DOTA-alendronate|Given IV
223960124|NCT03542695|OTHER|Pharmacokinetic Study|Correlative studies
224109072|NCT03412227|BEHAVIORAL|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, \& Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, \& LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b).
224109073|NCT03412227|BEHAVIORAL|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall \& Hedtke, 2006; Kendall, Choudhury, Hudson, \& Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
223960125|NCT03542695|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223960126|NCT03838575|DRUG|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
223960127|NCT03838575|DEVICE|Iodophor Antimicrobial Incise Drapes (DRAPE)|"Please note: In January 2022, following the first interim analysis, arms including intervention 2 - Iodophor-impregnated incise drape (arms C, E, G and H) were closed to recruitment.~This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied."
223960128|NCT03838575|DEVICE|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
223960129|NCT03838575|OTHER|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
223960130|NCT02827110|DEVICE|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
223960131|NCT02827110|DEVICE|pentax-airway scope|Tracheal intubation using pentax-AWS
223960132|NCT02827110|PROCEDURE|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
223960133|NCT02159794|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
223960134|NCT00100009|DRUG|TAC-PF|
223960135|NCT00100009|DRUG|Triamcinolone Acetonide|
223960136|NCT00230269|PROCEDURE|PET-CT|
223960137|NCT01501825|DEVICE|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
223960138|NCT01501825|DEVICE|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
223960139|NCT05420584|PROCEDURE|Arterial chemoembolization|The blood supplying artery of the tumor is selected for drug injection with Oxaliplatin 85mg/m2 combined Raltitrexed 3mg/m2. After drug injection, gelatin sponge is used for embolization.
223960140|NCT05420584|DRUG|Tislelizumab Injection|Tislelizumab Injection 200mg i.v. q3w, A total of 3 cycles are administered.
223960141|NCT05420584|DRUG|XELOX|Capecitabine 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, i.v. day 1 Cycles are repeated on day 22. A total of 3 cycles are administered.
223960142|NCT05420584|DIAGNOSTIC_TEST|Pelvic MRI|Pelvic MRI to evaluate efficacy
223960143|NCT05420584|PROCEDURE|Laparoscopic radical resection of rectal cancer|Surgical treatment for patients who meet the surgical conditions
223960144|NCT02068053|DRUG|[14C] BMS-986020|
223960145|NCT01383785|OTHER|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
223960146|NCT01383785|OTHER|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
224109074|NCT03412227|OTHER|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
224109075|NCT03614715|DRUG|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
224109076|NCT04668378|OTHER|Time restricted eating|TRE subjects consumed 100 % of their energy needs divided into three meals consumed at 1 p.m., 4 p.m. and 8 p.m., and fasted for the remaining 16 h per 24-h period.
224109077|NCT04668378|OTHER|Normal Diet|ND group ingested their caloric intake as three meals consumed at 8 a.m., 1 p.m. and 8 p.m.
224109078|NCT01183858|DRUG|Erlotinib [Tarceva]|Single daily oral dose
224109079|NCT02241018|DRUG|CD25 monoclonal antibody|
224109080|NCT02241018|DRUG|calcineurin inhibitors|
223960147|NCT01383785|OTHER|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
223960148|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
223960149|NCT01620788|DRUG|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
223960150|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
223960151|NCT01620788|DRUG|Hyzaar®|1 tablet of Hyzaar®, oral, a day
224109081|NCT02241018|BIOLOGICAL|MSCs|
224109082|NCT02094105|PROCEDURE|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
224109083|NCT00887445|DRUG|SLV341|5 - 1000mg once daily
224109084|NCT00887445|DRUG|placebo|
224109085|NCT04332692|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
224109086|NCT04332692|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
223960152|NCT04572165|DRUG|Ozempic®|Patients have been treated with commercially available Ozempic® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Ozempic® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
224109087|NCT04332692|PROCEDURE|Blood sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed before discharge from hospital
224109088|NCT04332692|PROCEDURE|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24 months after discharge from hospital
224109089|NCT04332692|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
224109090|NCT03690622|DRUG|Dexmedetomidine|Instillation of eyedrops
224109091|NCT03690622|DRUG|Balanced salt solution|instillation of eyedrop
224109092|NCT03174743|PROCEDURE|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
224109093|NCT03174743|PROCEDURE|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
224109094|NCT03174743|PROCEDURE|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
224109095|NCT03174743|PROCEDURE|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
224109096|NCT05195905|DEVICE|PMEG|All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.
224109097|NCT06298773|OTHER|Spatial analysis of paraffin samples from solid tumors|The intervention involves the collection of tumour samples included in paraffin present in the pathological anatomy archive or requested to external archives for samples older than 2003 and the subsequent multiparametric spatial analysis of the main populations of the microenvironment tumor.
224109098|NCT01676480|BEHAVIORAL|Endurance training|12 weeks of endurance training 3 times per week
223542033|NCT01643681|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
224109099|NCT03121742|BEHAVIORAL|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
224109100|NCT03121742|BEHAVIORAL|Treatment as Usual|Standard care as part of inpatient hospitalization.
224109101|NCT04367701|DIAGNOSTIC_TEST|Hemolysis|Authors measured free plasma hemoglobin concentration in gram
224109102|NCT01940094|DRUG|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
224109103|NCT01940094|DRUG|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
224109104|NCT01496573|OTHER|laboratory biomarker analysis|Correlative studies
224109105|NCT01842893|DRUG|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
224109106|NCT03842709|DRUG|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
224109107|NCT03842709|OTHER|Placebo|Administration of placebo
224109108|NCT03512223|DRUG|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
224109109|NCT04116034|DEVICE|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
224109110|NCT06092398|OTHER|PRP and PRFG in treatment of anal fistula|The tract fistula was cleaned with betadine 10% before PRP and PRFP were applied. Then, 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. 2 ml of PRP was injected around the fistula into the tissue (the penetration depth in injection was 5-6 mm), and 4 ml PRFP was mixed with 1 m thrombin and interpositioned into the tract. The operation time was about 20-30 minutes, the clot formation usually takes about 8 minutes, but the anesthesia was extended to 20 minutes to make sure a complete clot in the place of fistula
224109111|NCT00641147|DRUG|Curcumin|Given PO
224109112|NCT00641147|OTHER|Laboratory Biomarker Analysis|Correlative studies
224109113|NCT00641147|OTHER|Placebo|Given PO
224109114|NCT04729530|DEVICE|Dyson Pure Cool - Active Purifier|Free standing air purifier
223542034|NCT04274595|DRUG|Generic antiretroviral|200mg emtricitabine plus 245mg tenofovir diisopropyl fumarate for 7 days
223542035|NCT00441766|DRUG|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
223542036|NCT00441766|DRUG|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
224109115|NCT04729530|DEVICE|Dyson Pure Cool - Placebo purifier|Placebo air purifier
224109116|NCT00791128|DEVICE|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
224109117|NCT03324256|OTHER|energy drink|16 oz cold commercially-available energy drink
224109118|NCT03324256|OTHER|caffeinated drink|16oz cold commercially-available caffeinated drink
224109119|NCT03324256|OTHER|Energy gum|2 pieces of commercially-available energy gum
224109120|NCT03324256|OTHER|placebo gum|2 pieces of commercially-available placebo gum
224109121|NCT03324256|OTHER|Control drink|16oz cold control drink
224109122|NCT03324256|OTHER|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
224109123|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
223960153|NCT04572165|DRUG|Active Comparator|Patients have been treated with commercially available active comparators according to local label and to routine clinical practice at the discretion of the treating physician. Active comparators will include the following antidiabetic agents: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin. The decision to initiate treatment with commercially available active comparators had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223960154|NCT04572165|DRUG|Rybelsus®|Patients have been treated with commercially available Rybelsus® according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Rybelsus® had been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223724259|NCT05538221|DIAGNOSTIC_TEST|SILEMA|SILEMA consists of a webcam connected to a laptop, a LED reflector, and a software. To carry out gait analysis with SILEMA, an Evaluator must place six yellow auto-adhesive markers over certain anatomical landmarks in the lower limbs, namely, greater trochanter, external femoral condyle, head of the fibula, lateral malleolus and base and head of the fifth metatarsal. The patient is asked to walk barefoot through an eight meter walkway at a self-selected speed, while a webcam connected to a laptop records a video. Then, an Operator, making use of the software, processes the video, obtaining spatio-temporal and joint kinematic parameters.
223960155|NCT01204502|BIOLOGICAL|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg"
223960156|NCT06199011|DRUG|Esketamine hydrochloride|A standardized non-opioid anesthesia will be achieved by using continuous intraoperative infusion of esketamine.
223724260|NCT01872988|DRUG|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
223960157|NCT06199011|DRUG|Opioid|A standardized opioid anesthesia will be achieved by using continuous intraoperative infusion of opioids.
223960158|NCT05735379|DRUG|Deprescribing anticholinergic and sedative mediications|Deprescribing plan targeting a reduction in Drug Burden Index score of ≥ 0.5
223960159|NCT05675748|DRUG|Azvudine|Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
223960160|NCT00397098|DRUG|SR58611A|
223724261|NCT01872988|DRUG|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
223724262|NCT00719134|DRUG|Maxalt|anti-migraine drug
223724263|NCT00719134|DRUG|placebo pill|placebo pills
224109124|NCT01629667|BIOLOGICAL|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
224109125|NCT01629667|OTHER|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
223960161|NCT05823714|DRUG|VEN+AZA+Modified BUCY|"Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days."
224109126|NCT01011205|DRUG|Advagraf|Capsule
224109127|NCT01011205|DRUG|Mycophenolate Mofetil|Solution for infusion
224109128|NCT01011205|DRUG|Basiliximab|IV infusion
224109129|NCT01011205|DRUG|Corticosteroids|IV bolus
223960162|NCT02868983|OTHER|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
224109130|NCT05085002|DRUG|Lerociclib + Letrozole or Fulvestrant|All participants (1L and 2L populations) will receive an AI (letrozole) or fulvestrant plus lerociclib 150 mg BID.
224109131|NCT00293280|DRUG|lomustine|
224109132|NCT02075164|DIETARY_SUPPLEMENT|Fructose|High oral Fructose challenge (150g per day for 56 days)
224109133|NCT02075164|DIETARY_SUPPLEMENT|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
224109134|NCT02424149|DRUG|Phenazopyridine|
224109135|NCT04708990|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
224109136|NCT04316481|DEVICE|AngelMed Guardian System|The AngelMed Guardian System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events. The Guardian System is indicated as an adjunct to patient recognized symptoms.
223960163|NCT03270098|BEHAVIORAL|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
223960164|NCT03270098|BEHAVIORAL|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
223960165|NCT02009865|DRUG|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
223960166|NCT02009865|DRUG|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
223960167|NCT01760876|DEVICE|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
224109137|NCT02283944|DEVICE|TMS|Pulsed non-invasive brain stimulation using electromagnets
224109138|NCT00475449|PROCEDURE|percutaneous coronary intervention|
224109139|NCT00475449|PROCEDURE|coronary artery bypass grafting|
224109140|NCT03317808|DIAGNOSTIC_TEST|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
224109141|NCT03379350|PROCEDURE|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
224109142|NCT05308147|DIETARY_SUPPLEMENT|First Reference product|Dextrose (containing 25 grams of carbohydrates)
224109143|NCT05308147|DIETARY_SUPPLEMENT|Second Reference product|Dextrose (containing 25 grams of carbohydrates)
223960168|NCT05777772|BEHAVIORAL|STOP Falls D Educational Intervention|This is one-arm, health-system embedded pragmatic pilot trial
224109144|NCT05308147|DIETARY_SUPPLEMENT|Third Reference product|Dextrose (containing 25 grams of carbohydrates)
224109145|NCT05308147|DIETARY_SUPPLEMENT|First Concept product|Infant Formula (containing 25 grams of carbohydrates)
223960169|NCT03609450|BEHAVIORAL|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
223960170|NCT03609450|BEHAVIORAL|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
223960171|NCT02290548|DEVICE|high flow nasal cannula|High flow nasal cannula used in postextubation patients
223960172|NCT04453930|DRUG|Camrelizumab，an engineered anti-PD-1 antibody|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6) and maintenance phase (Cycle onward).
223960173|NCT04453930|DRUG|Platinum|"Carboplatin： Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/5/6).~Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6)."
224109146|NCT05308147|DIETARY_SUPPLEMENT|Second Concept product|Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
224109147|NCT05308147|DIETARY_SUPPLEMENT|Third Concept product|Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
224109148|NCT00592683|DRUG|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
224109149|NCT00592683|DIETARY_SUPPLEMENT|fish oil|1600mg (4 capsules) daily for 12 weeks
224109150|NCT00592683|DRUG|Placebo|Placebo
224109151|NCT05466435|OTHER|Heavy Slow Resistance|Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program
223960174|NCT04453930|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 65 milligrams per square meter (mg/m\^2) on Day 1，8 of every 21-day cycle during the induction phase (Cycles 1-4/5/6).
223960175|NCT04453930|DRUG|Apatinib|Apatinib was administered at a dose of 250 mg during the maintenance phase.
224109152|NCT05466435|OTHER|Control group|Traditional physical therapy program only will be given twice a week for 12 weeks
224109153|NCT00230490|DRUG|pradefovir mesylate|
224109154|NCT00230490|DRUG|adefovir dipivoxyl|
224109155|NCT06443112|PROCEDURE|transvaginal cervical cerclage by Mc Donald technique|In the McDonald operation, a suture is is inserted around the exo-cervix as high as possible to approximate to the level of the internal os and thereby prevent second-trimester abortion.
223960176|NCT02731950|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
223960177|NCT04115670|BEHAVIORAL|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~* 3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~* Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
224109156|NCT04990570|OTHER|Telemedicine in the form Virtual clinic via video consultation|"Pediatric patients, with age ranging from 1 month-14 years, with surgical problems, encountered during the era of Covid-19 pandemic.~Some of them seen at the OPD clinic, while the majority failed to attend because of Covid-19 associated lock-down and Curfew, thus, rendering their approach to the service.~Telemedicine, in the form of Virtual clinic, was utilized to address the distressing problem of difficult approach of patients to the pedia surgery OPD because of Covid-19 pandemic restrictive regulatory precautions, to aid in conveying their concerns and bridge the gap in surgeon-patient relationship \& encounter."
224109157|NCT01742923|BEHAVIORAL|Complex tailored intervention|
224109158|NCT01742923|BEHAVIORAL|Usual care|
223960178|NCT04115670|BEHAVIORAL|Control group|The control group will follow its normal course of activity
223960179|NCT01074281|DRUG|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
223960180|NCT00255749|BIOLOGICAL|epoetin alfa|
223960181|NCT03155035|DRUG|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
223960182|NCT03155035|DIETARY_SUPPLEMENT|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
223960183|NCT02223078|BIOLOGICAL|G17DT|
223960184|NCT02223078|BIOLOGICAL|Placebo Comparator|
224109159|NCT00002187|DRUG|Fomivirsen sodium|
224109160|NCT02865369|DRUG|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
224109161|NCT02533115|DRUG|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
223960185|NCT04023266|DRUG|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
223960186|NCT02135666|PROCEDURE|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
224109162|NCT02162979|DRUG|sildenafil|sildenafil 50mg BID for 2 weeks
224109163|NCT02162979|DRUG|Placebo|
224109164|NCT03386708|PROCEDURE|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
223960187|NCT01517282|BIOLOGICAL|MOR103|Anti-GM-CSF monoclonal antibody
223960188|NCT01517282|OTHER|Placebo|Placebo to anti-GM-CSF monoclonal antibody
224109165|NCT03386708|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2 \* 10\^7 cells (2ml)
224109166|NCT03289715|DEVICE|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
224109167|NCT01644045|DEVICE|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
224109168|NCT01738399|DIETARY_SUPPLEMENT|Coffee|
223960189|NCT00488969|DRUG|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
223960190|NCT00488969|DRUG|Placebo|
223960191|NCT00704548|DRUG|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
223960192|NCT00704548|DRUG|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
223960193|NCT02644980|DRUG|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
223960194|NCT02644980|DRUG|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40\~60.
223960195|NCT02644980|DEVICE|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
223960196|NCT02644980|DRUG|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5\~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
223960197|NCT02644980|DRUG|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
223960198|NCT02644980|OTHER|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
223960199|NCT03153423|PROCEDURE|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
223960200|NCT02275351|DRUG|SM04554|Topical solution, applied once a day
223960201|NCT02275351|DRUG|Vehicle|Topical solution, applied once a day
223960202|NCT01328223|RADIATION|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
223960203|NCT00525915|DRUG|5-Fluorouracil|"Arm A = 250 mg/m\^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m\^2 IV over 48 hours on days 1 and 15."
223960204|NCT00525915|DRUG|Oxaliplatin|"Arm A: 40 mg/m\^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m\^2 IV on Day 1 and 15"
223960205|NCT00525915|RADIATION|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
223960206|NCT00525915|PROCEDURE|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
223960207|NCT05629806|DRUG|Metformin plus pioglitazone|After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
223960208|NCT05629806|DRUG|Acarbose|After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.
223960209|NCT04251845|DIETARY_SUPPLEMENT|topical melatonin|Topical melatonin at 3% concentration with dosage of 15 mg once daily will be applied on the lesion for 6 weeks followed by a follow up of 3 months
223960210|NCT04251845|OTHER|PLACEBO|Topical application of placebo once daily for 6 weeks with a follow up for 3 months
223960211|NCT01129375|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
223960212|NCT01129375|DRUG|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
223960213|NCT01129375|DRUG|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
223960214|NCT06139393|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg qd + placebo of febuxostat tablets 20mg qd from Week 1 to 4, HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd from Week 5 to 28.
223960215|NCT06139393|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg qd + placebo of HR091506 tablets 20mg qd from Week 1 to 4, febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd from Week 5 to 28.
223960216|NCT06607003|BIOLOGICAL|P. vivax challenge agent derived from PvHMB-CCE001|P. vivax challenge agent derived from PvHMB-CCE001 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
224109169|NCT01738399|DIETARY_SUPPLEMENT|Placebo|
224109170|NCT04439734|DEVICE|Electromyostimulation|WB-EMS once per week 20 min for 16 weeks
223724264|NCT00719134|DRUG|placebo pills|placebo pills
223960217|NCT06607003|BIOLOGICAL|P. vivax challenge agent derived from PvHMB-CCE002|P. vivax challenge agent derived from PvHMB-CCE002 consists of infected and uninfected erythrocytes stabilized in glycerolyte. Challenge agent derived from this bank consists of thawed, washed, infected and uninfected erythrocytes suspended in injectable-grade normal saline.
224109171|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
224109172|NCT00873444|DEVICE|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
224109173|NCT04372264|DRUG|Paracetamol|1000 mg of paracetamol ( perfalgan 10mg/ml solutionBristol- Myers Squibb\_UK) intravenous (IV) was given 70 patients,
224109174|NCT04372264|DRUG|Dexketoprofen|Second Group: dexketoprofen 50 mg ( arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 70 patients,
223960218|NCT04946721|DIAGNOSTIC_TEST|The standard care exam and biological specimens' collection|During each visit, in addition to standard of care exams, certain biological specimens ( ocular surface wash, mucocellular material, corneal filaments or impression cytology of conjunctiva, blood or serum) will be collected.
223960219|NCT06990698|DRUG|FP008 for injection|FP008 should be administered intravenous weekly. Six FP008 dose levels are planned to evaluated.
223960220|NCT05192707|DIAGNOSTIC_TEST|TcPO2 measurement on the upper limb|Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
223960223|NCT06859398|OTHER|Ocular Topography and Wavefront Aberrometry|Eyescan with Pentacam AXL Wave
223960224|NCT06664853|DRUG|Dexamethasone sodium phosphate|Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
223960225|NCT06673667|DRUG|KT-621|Oral drug
223960226|NCT06673667|DRUG|Placebo|Oral drug
223960227|NCT05598853|DRUG|intrathecal nivolumab and intrathecal ipilimumab|Patients shall be treated with a fixed dose of intrathecal nivolumab and increasing doses of intrathecal ipilimumab. From cycle 2, patients will receive systemic nivolumab/ipilimumab in addition to intrathecal treatment. Systemic nivolumab/ipilimumab corresponds to the current standard of care for non-small cell lung cancer and for melanoma patients.
223960228|NCT06997965|DRUG|Mirikizumab|Mirikizumab is an IL-23 antagonist.
223960229|NCT01532063|PROCEDURE|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
223960230|NCT06058793|DRUG|Brigimadlin|Brigimadlin
223960231|NCT07002242|DRUG|Azvudine tablets(FNC) and Aluvia|FNC 3 mg each time, 1 time a day, orally, for 5 consecutive days. Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.
223960232|NCT07002242|DRUG|Azvudine tablets(FNC)|FNC: 3 mg each time, 1 time a day, orally, for 5 consecutive days
223960233|NCT07002242|DRUG|Aluvia|Aluvia(Lopinavir / Ritonavir tablets): 400 mg/100 mg (2 tablets) each time, 2 time a day, orally, for 5 consecutive days.
223960234|NCT06678789|BEHAVIORAL|High Nicotine Dose|Will receive a 5-week supply of 6 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
223960235|NCT06678789|BEHAVIORAL|Low Nicotine Dose|Will receive a 5-week supply of 3 mg Zyn pouches. Those who smoke 5-20 cigarettes per day will receive 1 tin per day = 35 tins, whereas those who smoke more will receive 2 tins/day \[70 tins\])
223960236|NCT05891171|DRUG|AB598|Administered as specified in the treatment arm
223960237|NCT05891171|DRUG|Zimberelimab|Administered as specified in the treatment arm
224109175|NCT04372264|DRUG|Ibuprofen|third group: 400 mg Ibuprofen (İntrafen 400 mg vial-Gen-İstanbul) intravenous (IV) was given 70 patients, which determined to be applied as a group.
224109176|NCT03702933|DIETARY_SUPPLEMENT|D-serine|dosage
224109177|NCT01050062|DRUG|Telmisartan 80mg|Combination tablet
224109178|NCT01050062|DRUG|Telmisartan 40mg|Combination tablet
224109179|NCT01050062|DRUG|Hydrochlorothiazide 12.5mg|Combination tablet
224109180|NCT06073314|DIAGNOSTIC_TEST|Quantitative MRI|Patients will be asked to remain in the scanner for an additional 10 minutes while we acquire additional quantitative MR images
224109181|NCT06073314|DIAGNOSTIC_TEST|Reproducibility study|A subset of patients will be invited back for a repeat MRI scan (prior to any treatment for their condition) to help measure reproducibility of our Artificial Intelligence model
224109182|NCT05886192|DRUG|norepinephrine+vasopressin|Norepinephrine combined with vasopressin to maintain blood pressure
224109183|NCT05886192|DRUG|Norepinephrine|norepinephrine
224109184|NCT04084392|OTHER|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
224109185|NCT04084392|OTHER|Usual Care|Referral to an outpatient provider for addiction treatment.
224109186|NCT04180592|PROCEDURE|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
224109187|NCT01525394|DRUG|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
223960238|NCT05891171|DRUG|Fluorouracil|Administered as specified in the treatment arm
223960239|NCT05891171|DRUG|Leucovorin|Administered as specified in the treatment arm
223960240|NCT05891171|DRUG|Oxaliplatin|Administered as specified in the treatment arm
223960241|NCT06925477|DEVICE|DSLT treatment for Open-Angle Glaucoma|This intervention aims to determine the efficacy and safety of Direct Selective Laser Trabeculoplasty (DSLT) in reducing intraocular pressure in patients with open-angle glaucoma.
224109188|NCT01525394|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
224109189|NCT01525394|DRUG|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
224109190|NCT00299377|DRUG|Abciximab i.v.|
224109191|NCT00299377|DRUG|Abciximab i.c.|
224109192|NCT03246269|DIAGNOSTIC_TEST|MoCA|
224109193|NCT04652024|DEVICE|Anorectal manometry|, patients are instructed to isolate the anal sphincter and puborectalis muscles and improve its strength by using modified Kegel exercises in lying position with a probe in situ. Visual and verbal feedback techniques are used to reinforce the maneuvers, as they are being performed. The anal and rectal pressure changes displayed on the monitor provides visual feedback to the patient.
224109194|NCT03196713|BEHAVIORAL|Early Intensive Behavioral Intervention|
224109195|NCT05355012|OTHER|5A organizational innovation|"This project is based on three strategic axes:~* A gradation of the care offer allowing to adapt the means and resources mobilized on the territory~* Personalized care by developing specific treatment paths based on the risk factors and/or vulnerabilities of the pregnant woman~* Coordination of territorial resources to support pregnant women in quitting smoking These three key elements will make it possible to propose a partnership-based, multi-professional, coordinated and integrated approach to the territory, supported by the technical resources and expertise available in the territory. It invites a majority of non-specialized actors to invest in the process of supporting pregnant women in quitting smoking, multiplying and potentiating their actions with this population."
223960242|NCT06925477|DEVICE|SLT treatment for Open-Angle Glaucoma|To determine the efficacy and safety of using Selective Laser Trabeculoplasty for treatment of open-angle glaucoma.
223960243|NCT05348915|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
223960244|NCT06902545|DRUG|zolbetuximab|Intravenous
223960245|NCT06762964|DRUG|Dapagliflozin tablet|Patient will take a 10mg tablet of Dapagliflozin once daily for 24 weeks
223960246|NCT06762964|DRUG|Placebo Tablet|Patient will take 10mg placebo tablet once daily for 24 weeks
223960247|NCT01036581|DEVICE|MagPro X100 Magnetic Stimulator|Concurrent TMS-MRI acquisition allows us to investigate the acute effects of induced brain activity on BOLD signal and evaluate interference of the TMS pulse with the BOLD signal measurement.
223960248|NCT01036581|DEVICE|Transcranial Rotating Magnetic Stimulator|Participants will undergo transcranial rapid rotating permanent magnetic stimulation (TRPMS), with the aim of evaluating the prolonged effect of TRPMS on motor cortex excitability. In another experiment, participants will undergo TRPMS with the aim of evaluating cortical excitability changes with TRPMS. These experiments will help interpret subsequent experiments investigating the effect of TRPMS on BOLD signal.
223960249|NCT01036581|DEVICE|Magnetom Prisma Fit 3T Scanner|Type: MRI Name: Magnetom Prisma Fit 3T Scanner (Siemens) Description: Functional and structural magnetic resonance imaging techniques are used for noninvasive mapping of brain physiology and pathology and to develop advanced magnetic resonance imaging and spectroscopy (MRI and MRS) techniques for neuroimaging studies related to addiction.
223960250|NCT07204288|OTHER|Cat Scan, if applicable|Cat Scan is being used to assess fusion in previously implanted population
223960251|NCT05545891|DRUG|Placebo|A drug that contains no medicine
223960252|NCT05545891|DRUG|Aripiprazole|Atypical antipsychotic medication
223960253|NCT06135311|DEVICE|Pulse Width 260us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days
223960254|NCT06135311|DEVICE|Pulse Width 50us|electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
223960255|NCT00466622|DRUG|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
223960256|NCT00466622|DRUG|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
223960257|NCT04748861|OTHER|Indoor Cycling (IC)|Participants will ride a Peloton bike 3x/week for 18 months.
223960258|NCT05691595|OTHER|Online survey data collection|The data will be collected via a web-survey created with the SurveyMonkey® software. The web-survey will be distributed among nurses at IRCCS Policlinico San Donato (San Donato Milanese, Italy) and ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy).
223960259|NCT03323983|OTHER|data collection|data collection
223960260|NCT04774718|DRUG|Alectinib|Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
223960261|NCT06440759|DEVICE|oXiris filter|"Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris.~The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared."
223960262|NCT06440759|DEVICE|M100 filter|Continuous Renal Replacement Therapy with the adsorption membrane filter M100. The specific septic biomarkers such as interleukin 6(IL-6), procalcitonin (PCT), C-reactive protein (CRP) along with other routine blood investigation results taken at the beginning of therapy and 24 hours after the treatment will be compared.
223960263|NCT05999552|OTHER|Eye exercises|The treatment will be applied in three sessions a week for eight weeks and each session will be approximately 20 minutes. Individuals will do each exercise shown at home as a home program on other days (days when the physiotherapist does not perform the exercise by video call).
223960264|NCT05531526|DRUG|AR1001|AR1001 Active Oral Tablet
223960265|NCT05531526|DRUG|Placebo|Placebo Oral Tablet
223960266|NCT05159466|PROCEDURE|Kidney transplant|Participants will be recruited at the Tulane Abdominal Transplant Institute site where they are evaluated and followed for organ transplantation as part of standard of care. HIV-positive adult candidates on the wait list or referred for organ transplantation evaluation willing to accept an HIV positive organ will be recruited.
223960267|NCT06010303|DRUG|LBL-007|LBL-007 will be administered at a standard dose intravenously.
223960268|NCT06010303|DRUG|Tislelizumab|Tislelizumab will be administered at a standard dose intravenously.
223960269|NCT06010303|DRUG|Chemotherapy Doublet|"Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel~Choice of chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously."
223960270|NCT03884075|DRUG|Semaglutide|Semaglutide injection once weekly
223960271|NCT06786325|DRUG|Psilocybin|PEX010 is the Psilocybin produced by Filament
223724265|NCT03933345|OTHER|Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.|At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
223960272|NCT06787287|PROCEDURE|Modified compression method|In the experimental group, an improved compression method was adopted. A thick gauze block of 9cm\*16cm\*8mm was folded three times and placed at the puncture site of the patient's radial artery, and a spiral radial artery hemostatic device was placed above it. The control group was treated with traditional compression method, and the spiral radial artery hemostat was applied directly at the radial artery puncture
223960273|NCT05064826|OTHER|Observation|"Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)"
223960274|NCT06539884|OTHER|Observational|Evaluating whether the 2005 SIRS - Sepsis diagnostic and grading criteria, pSOFA, PRISM III and PELOD scores are compatible and to compare their prognostic predictive power.
223960275|NCT05079919|DRUG|Olezarsen|Olezarsen will be administered by SC injection.
223960276|NCT05079919|DRUG|Placebo|Olezarsen-matching placebo will be administered by SC injection.
223960277|NCT04428983|DIETARY_SUPPLEMENT|Hericium erinaceus mycelium|Hericium erinaceus capsules 3 tables per day for 24 months
223724266|NCT01654341|BEHAVIORAL|Exercise, dietary and educational program|
223960278|NCT05675449|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223960279|NCT05675449|DRUG|Carfilzomib|proteasome inhibitor
223960280|NCT05675449|DRUG|Maplirpacept|CD47-SIRP alpha-directed
223960281|NCT05413304|DRUG|pre-operative abemaciclib|pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
223960282|NCT05413304|DEVICE|Device for Cerebral Fluid Dialysate Collection|post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib
223960283|NCT05413304|DEVICE|Ashion Analytics GEM ExTra|resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
223960284|NCT05413304|DRUG|abemaciclib + temozolomide|abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
223960285|NCT05285111|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|The intervention consists of four modules that focus on multiple aspects of interoception including: body awareness, body sensations/movement, eating, health and self-care, emotional awareness, and understanding the self in relation to others.
224109196|NCT06399081|OTHER|Observational|Observational
224109197|NCT00955240|BIOLOGICAL|cetuximab|
224109198|NCT00955240|DRUG|cisplatin|
224109199|NCT00955240|DRUG|fluorouracil|
223960286|NCT05285111|BEHAVIORAL|Healthy Habits|"The comparator condition is called Health Habits and is matched for time and attention; participants complete modules related to healthy habits such as financial planning, hygiene, stretching, and healthy eating."
224109200|NCT00955240|OTHER|laboratory biomarker analysis|
224109201|NCT00955240|RADIATION|radiation therapy|
223960287|NCT04273243|GENETIC|AT-GTX-501|No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
224109202|NCT03244371|OTHER|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
224109203|NCT00060892|GENETIC|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
224109204|NCT05896176|DIAGNOSTIC_TEST|a clinical examination and anamnesis|The investigators compare the results of the PSQ alone with the elements provided by the clinical examination regarding the referral of patients to the Otolaryngologist (ENT) consultation.
223960288|NCT04958265|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
223960289|NCT06044870|PROCEDURE|Modified laterally stretched technique with a connective tissue graft.|Modified laterally stretched technique with a connective tissue graft.
223960290|NCT05205746|BIOLOGICAL|Recombinant NDV Vectored Vaccine for SARS-CoV-2|Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
223960291|NCT05205746|BIOLOGICAL|Placebo|Physiological saline solution of Sodium Chloride at 0.9% After mask opening ChAdOx-1-S\[recombinant\]) Intramuscular
223960292|NCT05498337|OTHER|calcium hydroxide|Dental pulp medicament material
223960293|NCT05498337|OTHER|MTA|Dental pulp medicament material
223960294|NCT05498337|DEVICE|Diode Laser|Device used in pulp therapy
223960295|NCT01861938|BIOLOGICAL|Melanoma vaccine modified to express HLA A2/4-1BB ligand|This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence. These patients will be treated with the A2/4-1BBL melanoma vaccine, a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation. The hypothesis that drives the study states that the immune response against the cell line will also be effective against the residual tumor that may still be present in the body.
223960296|NCT01791842|DRUG|Tocilizumab|8 mg/kg/month
223960297|NCT01791842|DRUG|Placebo|
223960298|NCT06845202|DRUG|ALN-4324|ALN-4324 will be administered subcutaneously (SC)
223960299|NCT06845202|DRUG|Placebo|Placebo will be administered SC
223960300|NCT05295290|DIAGNOSTIC_TEST|Cardiac Imaging|ECG, echocardiogram, ambulatory monitor, exercise stress test
223960301|NCT05156580|OTHER|No intervention|This is an observational study without any intervention
224109205|NCT00177346|DEVICE|CAS with cerebral protection|
224109206|NCT00177346|DEVICE|CAS without cerebral protection|
224109207|NCT03511339|DEVICE|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
224109208|NCT02718846|DRUG|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
224109209|NCT02718846|DRUG|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
224109210|NCT01853124|DRUG|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
224109211|NCT01853124|DRUG|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
224109212|NCT02441803|DRUG|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
224109213|NCT02441803|DRUG|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
224109214|NCT02441803|DRUG|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
224109215|NCT02441803|RADIATION|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
224109216|NCT02441803|DRUG|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
223542037|NCT00441766|DRUG|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
223542038|NCT00441766|DRUG|placebo|Part A: placebo capsule every 12 hours for 4 weeks
223542039|NCT01732991|DEVICE|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
223960302|NCT05927753|DEVICE|Deseyne Daily Disposable Contact Lens (Test Device)|Comparison of contact lens performance between the test lens under study (Deseyne Daily Disposable Contact Lens) and the control lens f(1-Day Acuvue Moist Contact Lens) for safety and effectiveness.
223960303|NCT03118050|BEHAVIORAL|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
223960304|NCT03118050|BEHAVIORAL|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
223960305|NCT03118050|BEHAVIORAL|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
223542040|NCT04658927|DRUG|Dexamethasone, 0.4mg|iLUX + dextenza
223960306|NCT05018780|OTHER|Muscle Energy Technique|"Post isometric relaxation: Patient will be asked to perform isometrics on piriformis, iliopsoas and erector spinae muscles one by one. Each isometric contraction will be held for 10 seconds. After 10 seconds, contraction will be released with an exhalation. These contractions will be repeated for 5 times in one session.~Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Muscle Energy Technique."
223960307|NCT05018780|OTHER|Sacral Manipulation|"* To manipulate an iliac anterior rotation displacement sacroiliac joint dysfunction and to restore posterior rotation of the ilium, participant will be positioned in side lying. Therapist will place one hand at Anterior superior iliac supine (ASIS) and the other at Ischial tuberosity. A quick thrust will be applied and ASIS will be pushed posteriorly while Ischial tberosity anteriorly. This will be maintained for 10 to 30 seconds.~* To manipulate an iliac posterior rotation displacement sacroiliac joint dysfunction and to restore anterior rotation of the ilium, participant will be in prone position. One hand of therapist will be at Posterior superior iliac supine (PSIS) and the other one at pubic rami. A quick thrust will be delivered and PSIS will be moved anteriorly while pubic rami posteriorly. This will be maintained for 10 to 30 seconds.~* Routine physical therapy including TENS, Hot pack and strengthening exercises will also be delivered along with Sacral Manipulation."
223960308|NCT05837325|PROCEDURE|Oocyte Pick Up - Out of Study|Aspiration of follicles. search for the oocyte(s) All oocytes are grouped in one dish.
223960309|NCT05837325|PROCEDURE|Denudation - Out of Study|All oocytes are denuded together. Maturational stages are recorded.
223960310|NCT05837325|PROCEDURE|ICSI|One oocyte injected at a time.
223960311|NCT05837325|PROCEDURE|Culture|One embryo per culture drop. Individual follow-up of the embryo development.
223960312|NCT05837325|GENETIC|Biopsy|One embryo per culture drop.
223960313|NCT05837325|PROCEDURE|Vitrification|One embryo per vitrification straw.
223960314|NCT05837325|PROCEDURE|OPU - Study Group|Measure the size of the follicle and aspirate only one follicle and flush. The needle before moving to the second ovary. Oocyte included in the study will be cultured separately (each ovary separately too).
224109217|NCT02441803|BIOLOGICAL|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or \>3.0 X 108 marrow mononuclear cells/kg if bone marrow.
223542041|NCT04658927|DRUG|Prednisone acetate|Prednisolone acetate 1% and iLux
223542042|NCT04658927|OTHER|Control|iLUX alone.
224109218|NCT02441803|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
224109219|NCT02441803|DRUG|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
223542043|NCT00901303|DRUG|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
223960315|NCT05837325|PROCEDURE|Denudation - Study Group|Oocyte included in the study will be denuded separately. Maturational stages are recorded per follicle.
223960316|NCT03569644|OTHER|qualitative study|Interviews
223960317|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including STRIDE (Single Tremelimumab Regular Interval Durvalumab), will be collected).
223960318|NCT06252753|OTHER|Durvalumab-based combination therapies in observational study setting|Data on patients who initiated durvalumab-based regimens, including durvalumab + chemotherapy combinations (e.g., Durvalumab + GemCis etc.) will be collected.
224109220|NCT02441803|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
224109221|NCT02441803|DRUG|Decitabine|20 mg/m2 by vein on Days 1 - 5.
224109222|NCT02441803|DRUG|Cytarabine|1 g/m2 by vein on Days 6 - 10.
223542044|NCT01739894|DRUG|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
223960319|NCT04250259|DRUG|Placebo|2 tablets of placebo in the morning before breakfast and one tablet of placebo in the evening before dinner for 24 months
223960320|NCT04250259|DRUG|SAMe 400 mg tablet|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
223960321|NCT00437086|DRUG|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
223542045|NCT02250872|DRUG|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
223542046|NCT02250872|DRUG|Placebo|100mg in 2 divided doses plus cisplatin
223542047|NCT02250872|DRUG|Cisplatin|All patients will receive intravenous cisplatin
223960322|NCT03624023|DRUG|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
223960323|NCT05465278|DRUG|Alirocumab|18 months treatment with alirocumab
223960324|NCT04945356|OTHER|upper limb training|The 6-week exercise program will consist of evidence-based exercises covering the breadth and depth of rehabilitation interventions. The therapist will choose the appropriate exercises for each participant's level of function from more than 15,000 exercises implemented within the Physiotec app and developed by rehabilitation experts. Personalized upper limb exercises will be based on the therapist initial assessment of participants, using the TERA+ telerehabilitation platform, and their goals. After each training session, participants will have to rate their perceived level of effort on a Borg scale (/10). The Borg scores will be monitored by the therapist as a precautionary measure to ensure safety and appropriateness of intensity of exercises. Participants will be instructed to train at a target score of around 7/10 (somewhat hard) on the Borg scale.
223960325|NCT04565392|DRUG|Famotidine 20 milligram tablet|1 tablet every 12 hours and increase to 1 tablet every 8 hours if not improved by the second day of treatment
223960326|NCT00092378|DRUG|MK0966, rofecoxib|
223960327|NCT00092378|DRUG|Comparator: diclofenac sodium, placebo|
223960328|NCT02721628|PROCEDURE|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
223960329|NCT02721628|PROCEDURE|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
223960330|NCT02721628|DEVICE|Femtosecond laser|Use in the epic-keratoplasty surgery
223960331|NCT05475925|DRUG|DR-01|DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
223960332|NCT06260774|DRUG|TTX-MC138|The starting dose of TTX-MC138 in the first cohort will be 0.4 mg/kg and will be increased incrementally in subsequent cohorts until maximum tolerated dose (MTD) determination.
223960333|NCT05242692|DRUG|S-ketamine|Loading dose: 0.25mg/kg in 10 minutes Maintenance dose: 0.1mg/kg/h
223960334|NCT05242692|DRUG|Dexmedetomidine|Loading dose: 0.2 ug/kg in 10 minutes Maintenance dose: 0.2 ug/kg/h
223542048|NCT01490255|DRUG|Ranolazine|os, 750 mg, twice per day, for 15 days
223542049|NCT01490255|DRUG|Amlodipine|os, 10 mg, once daily, 15 days
223542050|NCT03534050|RADIATION|postoperative adjuvant RT|
223960335|NCT05221684|PROCEDURE|Lymph node harvesting|Lymph node harvesting after radical resection for rectal cancer with curative intent
223960336|NCT05031026|DRUG|Dexmedetomidine|dexmedetomidine infusion rule in prevention of IRI
223960337|NCT05031026|DRUG|Normal Saline|normal saline infusion as a placebo
223960338|NCT04613219|DRUG|Tofacitinib 5 MG [Xeljanz]|Treatment with Tofacitinib
223960339|NCT06363409|OTHER|Cereal Bar as a recovery food snack|Cereal bar as a recovery snack food
223960340|NCT06363409|OTHER|Almond|Almond as a recovery snack food
223960341|NCT01521689|DRUG|Rituximab|Low doses of sub cutaneaous rituximab
224109223|NCT02441803|DRUG|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
224109224|NCT04710589|RADIATION|CTV|According to the clinical conditions of the patients, they will be assigned to two groups based on the doctor's recommendations and their own wishes
224109225|NCT02398123|OTHER|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
224109226|NCT02398123|OTHER|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
224109227|NCT02398123|DRUG|Bupivacaine|
224109228|NCT02609711|DRUG|Candesartan cilexetil|
224109229|NCT00318708|DRUG|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
224109230|NCT00318708|DRUG|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
224109231|NCT00318708|DRUG|placebo clarithromycin|placebo clarithromycin twice daily
224109232|NCT02439385|DRUG|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
224109233|NCT02439385|DIETARY_SUPPLEMENT|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
223542051|NCT02189889|DRUG|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
223542052|NCT02189889|DRUG|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
223724267|NCT02655939|DIETARY_SUPPLEMENT|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
223960342|NCT03957707|PROCEDURE|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
223960343|NCT05482295|BIOLOGICAL|In-House Recombinant Hepatitis B (Bio Farma) vaccine|3 doses of In-House Recombinant Hepatitis B (Bio Farma) vaccine
223960344|NCT05482295|BIOLOGICAL|Registered Hepatitis B vaccine recombinant (Engerix-B)|3 doses of Registered Hepatitis B vaccine recombinant (Engerix-B)
223960345|NCT03246256|OTHER|Group 1|
223960346|NCT01562587|DRUG|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
223960347|NCT01562587|DRUG|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
223960348|NCT04320810|OTHER|no intervention|It's only observational study. No interventions.
223960349|NCT05016674|DEVICE|LipoLife system|Abdominal Laser-Assisted Liposuction
223960350|NCT01808898|PROCEDURE|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
223960351|NCT05893017|OTHER|Virtual Reality Exercises|Virtual Reality Exercises will be apply for muscle strengthening
223960352|NCT05893017|OTHER|Virtual Reality Exercises and Kinesiotaping|Virtual Reality Exercises will be apply for muscle strengthening, Kinesiotaping will be applied at Quadriceps muscle and Hamstring muscle
224109234|NCT03342443|DRUG|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
224109235|NCT03342443|DRUG|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
224109236|NCT03424551|DEVICE|vibrator|Local or whole body vibration was applied at six different frequencies
224109237|NCT06128837|DRUG|Irinotecan hydrochloride liposome Injection|Irinotecan hydrochloride liposome Injection 80 mg/m² intravenously Days 1 q2wk
224109238|NCT06128837|DRUG|Topotecan|Topotecan 1.2 mg/m² intravenously Days 1-5 q3w
224109239|NCT01979744|PROCEDURE|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
224109240|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
223724268|NCT02655939|DIETARY_SUPPLEMENT|Placebo|Fructose,Orange flavor and sucralose
223724269|NCT03776383|OTHER|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
223724270|NCT00557960|DRUG|Mixed salts of a single-entity amphetamine|
223724271|NCT00557960|DRUG|Atomoxetine hydrochloride|
223724272|NCT03547180|BEHAVIORAL|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
223960353|NCT05893017|OTHER|Virtual Reality Exercises and Valgus Orthoses|Virtual Reality Exercises will be apply for muscle strengthening, Orthoses is for correction at knee alignment
223960354|NCT05195593|DEVICE|Optical 3D Scanner|An optical 3D scanner used to register spine anatomy to surgical computer navigation systems.
223960355|NCT02896335|DRUG|Palbociclib|Administered orally once per day on days 1-21 of 28-day cycles.
223960356|NCT02896335|DRUG|Pembrolizumab|Pembrolizumab is administered via intravenous (IV) infusion at a dose of 200 mg over 30 minutes once every 21 days. Pembrolizumab cycles are 3 weeks (21 days) long in this study, and participants in Cohort 2 can receive pembrolizumab as long as they are receiving study drug palbociclib.
223960357|NCT04815707|PROCEDURE|Occcult hernia repair|The occult hernia will be repaired during the same inguinal hernia repair
223960358|NCT05993832|OTHER|input cue|The object is labelled with 1) gaze only; 2) novel label only; or 3) conflicting gaze and novel label
224109241|NCT01979744|DEVICE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
223542053|NCT06131905|DRUG|Magnesium Sulfate|40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
223960359|NCT06664151|BIOLOGICAL|Fluzone Trivalent|Inactivated influenza vaccine, 0.5mL single-dose, pre-filled syringe, via intratumoral (into a tumor) injection per protocol.
223960360|NCT05061004|DEVICE|Cephea Mitral Valve System|Transcatheter mitral valve replacement
223960361|NCT04305613|OTHER|Chemoradiation|Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.
223960362|NCT06364163|DIETARY_SUPPLEMENT|Herring oil concentrate|Capsules containing herring oil concentrate, taken daily for 8 weeks.
223960363|NCT06364163|DIETARY_SUPPLEMENT|Control|Capsules containing control oil, taken daily for 8 weeks.
223960364|NCT01883297|BIOLOGICAL|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10\^7 TILs (with maximum 3x10\^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10\^8 TILs (with maximum 1x10\^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10\^8 TILs (with maximum 3x10\^8 autologous dendritic cells)
223960365|NCT01883297|BIOLOGICAL|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
223960366|NCT01883297|DRUG|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
223960367|NCT02216162|OTHER|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
223960368|NCT02216162|OTHER|No intervention|Usual clinical follow-up
223960369|NCT02337894|DIETARY_SUPPLEMENT|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
223960370|NCT02337894|DIETARY_SUPPLEMENT|Placebo|Flavored drink without essential amino acids plus arginine.
223960371|NCT05428839|DIAGNOSTIC_TEST|Pharyngeal width measurement|A simple, non-invasive measurement of the pharyngeal width inside each subjects mouth
223960372|NCT06415383|DRUG|Vitamin B6 100 MG|Vitamin B6 in for the form of pyridoxal phosphate (PLP)
223960373|NCT06415383|OTHER|Placebo|Placebo tablet containing microcrystalline cellulose
223960374|NCT02738294|DEVICE|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
223960375|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 1 session of neuro-reinforcement.
223960376|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 3 sessions of neuro-reinforcement.
223960377|NCT06420557|BEHAVIORAL|Unconscious Neuro-reinforcement|Individuals will complete an implicit fmri neuro-reinforcement task where real-time brain activity is matched to a desired activation. Individuals will also receive financial reward for activating the desired activation. Visual feedback will be presented to indicate how well individuals' brain activity matches the desired activation. Individuals will complete 5 sessions of neuro-reinforcement.
223960378|NCT04788615|DRUG|Ofatumumab|20mg Subcutaneous injection
223960379|NCT04788615|DRUG|First line DMT|any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg
223960380|NCT01971892|OTHER|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
223960381|NCT01971892|OTHER|Standard oxygen therapy with facial mask|facial Venturi mask
223960382|NCT05685238|DRUG|Mim8|Participants in arm 1 will administer Mim8 using an enhanced cartridge and switch to the DV3407 pen-injector once it is approved. Participants in arm 2 and 3 will use the DV3407 pen injector.
223960385|NCT06639594|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|RTMS is a non-invasive procedure in which a coil is placed over the scalp, and powerful, focused magnetic pulses are applied to parts of the brain through the coil.
223960386|NCT03239899|DRUG|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.
224109242|NCT01979744|PROCEDURE|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
223960387|NCT04557735|DRUG|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
224109243|NCT04976075|OTHER|no interventions|no interventions
224109244|NCT04459910|PROCEDURE|Arthroscopic Brostrom combined with Arthroscopic Deltoid Repair|After anesthesia and surgical site preparation, traditional arthroscopic portals were performed. A 4.5mm set was used to clean the joint and assess possible associated injuries. Anterolateral and anteromedial impacts were resected when needed. Lateral and medial instability were confirmed arthroscopically, and ligament repairs prepared, starting by the lateral compartment. A traditional Arthroscopic Brostrom was performed, using one anchor and suture passers. Sutures are passed but not tightened. Medial anchor insertion is executed at the medial malleolus, in the quadrant described by Vega et al. Sutures were passed respecting the safe zone illustrated by Acevedo at al. The ankle was positioned in neutral (no posterior drawer) and the lateral sutures tightened with arthroscopic knots. Finally, the medial repair is finalized by tightening the deltoid sutures with the ankle at the same position. Portals were closed and a dressing applied.
224109245|NCT01505062|DRUG|SAR421869|"Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
223542054|NCT06131905|DRUG|Propofol|An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
223960388|NCT04557735|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
223960389|NCT05168423|DRUG|CART-EGFR-IL13Ra2 Cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR and a humanized scFv targeting IL13Ra2
223960390|NCT05483738|DIAGNOSTIC_TEST|Clinical assessment, blood samples, bone marrow and bone biopsy|Assessment of blood samples, bone marrow and bone biopsy
223960391|NCT03769129|DRUG|Pembrolizumab|Pembrolizumab
223542055|NCT00287950|DRUG|carboplatin|
223542056|NCT00287950|DRUG|cisplatin|
223542057|NCT00287950|DRUG|cyclophosphamide|
223542058|NCT00287950|DRUG|etoposide|
223542059|NCT00287950|DRUG|vincristine sulfate|
223542060|NCT00287950|PROCEDURE|adjuvant therapy|
223960392|NCT03769129|PROCEDURE|microwave ablation|microwave ablation
223960393|NCT01564134|BIOLOGICAL|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
223960394|NCT04913259|OTHER|Remote monitoring|Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
223960395|NCT06090162|DIAGNOSTIC_TEST|ctDNA detection|ctDNA detection on CSF and blood
223960396|NCT04807816|DRUG|Association of berzosertib with gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~Berzosertib will be administered intravenously on days 2 and 9 every 3 weeks (210 mg/m²).~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
223960397|NCT04807816|DRUG|Gemcitabine|"Gemcitabine will be administered by intravenous 30-minutes infusion on days 1 and 8 every 3 weeks, at a fixed dose of 1000 mg/m².~A treatment cycle consists of 3 weeks (i.e., 21 days) and will be administered during hospitalization."
223542061|NCT00287950|PROCEDURE|conventional surgery|
223542062|NCT00287950|PROCEDURE|neoadjuvant therapy|
223542063|NCT00287950|RADIATION|radiation therapy|
223960398|NCT05355701|DRUG|PF-07799933|Tablet
223960399|NCT05355701|DRUG|binimetinib|Tablet
223960400|NCT05355701|BIOLOGICAL|cetuximab|Injection for intravenous use
224109246|NCT01373554|DRUG|Placebo|30mig/bid or 60mg/bid P.O
224109247|NCT01373554|DRUG|Oltipraz|30mig/bid or 60mg/bid P.O
224109248|NCT01686204|OTHER|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
224109249|NCT01686204|OTHER|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
224109250|NCT02225886|DRUG|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
223960401|NCT04863729|BEHAVIORAL|Asdzaan Be'eena Program|"The program consists of 11 weekly sessions conducted with girls ages 10-14 and their female caregivers. 5 of the 11 sessions will be taught to groups of 9-13 girls and their female caregivers, and 6 of the sessions will be taught to individual girl/female caregiver dyads. The choice to use a mix of group- and individual sessions is based on findings from the formative phase indicating certain topics should be taught in groups (e.g. Navajo history and reproductive health 101), and certain topics be taught in individual dyads (e.g. family values and the clan system).~Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers' home or another private place of their choosing, such as our local Johns Hopkins offices."
224109251|NCT01277224|BEHAVIORAL|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
223960402|NCT04649359|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
223960403|NCT05080673|PROCEDURE|5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy|The five- and ten-year colonoscopies, in addition to any unscheduled colonoscopies, will be performed according to currently accepted guidelines for the performance of quality colonoscopy. Participants will be given the standardized colonoscopy preparation instructions per institutional standards.
223960404|NCT05618509|DEVICE|STENDO session|"It is a combination enveloping the lower limbs up to the abdomen. The massage system induces pressure from the ankles to the abdomen between each heartbeat. The capacity for physical exercise is potentially improved.~STENDO : 45 minutes, 2 legs and the pelvis, pression of 65mm Hg"
224109252|NCT01512368|OTHER|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
224109253|NCT02971696|DRUG|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
224109254|NCT02971696|DRUG|Best Supportive care|Liver Support, pain management
224109255|NCT01819961|DRUG|MCT/LCT and fish oil|
224109256|NCT01819961|DRUG|MCT/LCT|
224109257|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
223542064|NCT01244711|DRUG|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
223960405|NCT05618509|OTHER|A six-minute walking distance test|Before and after STENDO session, the patient has to walk 6 minutes in a flat corridor (30m long)
223960406|NCT05618509|OTHER|Near Infrared Spectroscopy|The goal is to measure the evolution of the oxygen consumption of the right leg during an effort on a bicycle at constant power for 5 minutes.
223542065|NCT02768285|PROCEDURE|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
223542066|NCT03982017|OTHER|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
223960407|NCT05618509|DEVICE|STENDO placebo|STENDO placebo : 45 minutes, on 2 legs and the pelvis, pression of 10 mmHg
223960408|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% + ketamine 0.5 mg/kg distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
223960409|NCT04908579|DRUG|bupivacaine(intraperitoneally) and ketamine (intravenously)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml volume of ketamine 0.5 mg/kg intravenously will be given after delivering the gastric sleeve and before start closure of port sites."
223542067|NCT03982017|OTHER|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
223960410|NCT04908579|DRUG|bupivacaine(intraperitoneally)|"1. 40 ml volume of bupivacaine 0.25% only distributed as 30 ml intraperitoneally and 10 ml as port site infiltration~2. 10 ml normal saline 0.9% will be given intravenous."
223960411|NCT06495229|BIOLOGICAL|CM310|Interleukin-4 receptor(IL-4Rα) monoclonal antibody
223960412|NCT04776655|DRUG|Bevacizumab|"This is the treatment assigned to experimental arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
223960413|NCT04776655|DRUG|Cetuximab|"This is the treatment assigned to control arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
223960414|NCT04776655|DRUG|5-FU|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
223960415|NCT04776655|DRUG|Irinotecan|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
223960416|NCT04776655|DRUG|Calcium levofolinate|"FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn."
223960417|NCT04816994|DRUG|Single-dose of cannabis oil|Single-dose of cannabis oil in order to treat acute radicular pain
223960418|NCT04816994|DRUG|Control|Giving a sub-linguistic olive oil that is similar in appearance and taste to cannabis oil
223960419|NCT06216301|DEVICE|NovoTTF-200T|The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.
223960420|NCT06216301|DRUG|Pembrolizumab|Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
223960421|NCT06216301|DRUG|Platinum based chemotherapy|Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
223960422|NCT06708299|DRUG|CardiolRx|The intervention will be administered orally (via syringe) with food twice daily.
223542068|NCT04656587|DEVICE|Philips Respironics V60 Non-invasive ventilator, BPAP|Continuous albuterol will be administered through the BPAP circuit.
223542069|NCT04656587|OTHER|Standard Therapy|Standard status asthmaticus therapy with continuous beta-agonist, steroids and oxygen as needed.
223542070|NCT02452073|OTHER|Thyroid function tests|
223960423|NCT05676931|DRUG|Domvanalimab|Administered as specified in the treatment arm
223960424|NCT05676931|DRUG|Quemliclustat|Administered as specified in the treatment arm
223960425|NCT05676931|DRUG|Zimberelimab|Administered as specified in the treatment arm
223960426|NCT05676931|DRUG|Docetaxel|Administered as specified in the treatment arm
223960427|NCT05676931|DRUG|Platinum-Based Doublet|Administered as specified in the treatment arm
223960428|NCT05995340|DEVICE|ELAPR002f Injectable Gel|Intradermal Injections
223960429|NCT05995340|OTHER|Saline Active Control|Intradermal Injections
223960430|NCT02019706|RADIATION|DOTATATE PET-CT|68Ga-DOTATATE PET/CT
223960431|NCT02019706|RADIATION|F-DOPA PET CT|68Ga-DOTATATE PET/CT
223960432|NCT02019706|RADIATION|CT scan|routine CT scan
223960433|NCT02019706|DIAGNOSTIC_TEST|Routine MRI scan|routine 1.5 or 3T MRI scan
223960434|NCT02019706|DIAGNOSTIC_TEST|Gated MRI scan|Cardiac gated MRI scan
223960435|NCT02019706|DRUG|68Ga-DOTATATE|68Ga-DOTATATE radioligand
223960436|NCT02019706|DRUG|18F-DOPA|18F-DOPA radioligand
223960437|NCT06587035|DRUG|Somatrogon|Long-acting growth hormone for pediatric growth hormone deficiency.
223960438|NCT02162823|PROCEDURE|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
223960439|NCT05049174|BEHAVIORAL|Nuse-led interview and referral to municipal healthy life-centres|Usual care treatment and written information to patients and general practitionnaires about smoking cessation and the municipal healthy life-centres
223960440|NCT04102605|DEVICE|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
223960441|NCT04102605|DEVICE|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
223724273|NCT03547180|BEHAVIORAL|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
223960442|NCT05001802|PROCEDURE|transverse scan, in-plane, posterior- anterior quadratus lumborum block|transverse scan, in-plane, posterior- anterior quadratus lumborum block The patients will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
223960443|NCT05001802|PROCEDURE|paramedian sagittal longitudinal scan, in-plane, caudal-cranial quadratus lumborum block|The patients will receive the transmuscular quadratus lumborum block before surgery using the paramedic sagittal longitudinal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivacaine is injected when the correct needle location is confirmed.
223960444|NCT03362294|DRUG|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
223960445|NCT03362294|DRUG|GA Depot 25mg once monthly|Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
224109258|NCT00328198|BIOLOGICAL|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
224109259|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation during a month
224109260|NCT04432441|OTHER|Therapeutic physical exercise program for scapulo-humeral stabilitation + electrostimulation|This group realize a therapeutic physical exercise program for scapulo-humeral stabilitation added electrostimulation during a month
224109261|NCT05537363|OTHER|Health education|Participants in the control group will receive health educational guidelines. Guideline contents include home-based exercise program, nutrition recommendations, and fall prevention education.
224109262|NCT05537363|OTHER|Multicomponent training|Multicomponent exercises will be designed according to the results of Part I of our study. Results of Part I of this study will determine the contributing factors of agility, such as muscle strength, endurance, and cognitive function. A physical therapist will train the participants 3-4 exercises (3-4 factors) in each session. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
223960446|NCT06440616|DEVICE|Spectral CT images generated by a photon counting CT scanner|The reading radiologist will in the experimental arm have access to spectral CT images in the form of low virtual monoenergetic images, virtual non-contrast images, iodine maps and effective atomic number. In the non-interventional arms the reading radiologist will only have access to conventional CT images.
223960447|NCT02011568|OTHER|Therapeutic Hypothermia|
224109263|NCT05537363|OTHER|Agility training|The agility-based task-specific exercises will be conducted in this group and will incorporate stop-and-go, change in direction, change in velocity, acceleration and deceleration training. There are four training configurations with 3 levels of difficulty, which will be manipulated by increasing speed, distance, number of repetitions, number of directions, congruency, and/or complexity of the task, or by decreasing the number and duration of the rest intervals. The physical therapist will adjust the difficulty of each exercise according to the participant's ability and condition.
224109264|NCT05721885|BEHAVIORAL|nutrition management|Nutritional management was performed by clinical pharmacists and registered dietitians to develop nutritional intervention strategies based on patient clinical assessment and nutritional assessment. PG-SGA score was 0-3 points, and diet guidance was given. PG-SGA score \> 4 points, artificial nutrition intervention was carried out, and the way and amount of nutritional intervention were clarified to achieve the final daily energy and protein target requirements. Nutritional interventions and assessments were adjusted over time.
224291292|NCT06616428|OTHER|Bike group fitness class|Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.
223960448|NCT01918852|DRUG|Capecitabine|
223724274|NCT03547180|BEHAVIORAL|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
223724275|NCT02432014|BEHAVIORAL|PMTO-PTC Group clinic-based|
223724276|NCT02432014|BEHAVIORAL|PMTO Individual home-based|
223960449|NCT01918852|DRUG|Teysuno|
223960450|NCT01918852|DRUG|Bevacizumab|
223960451|NCT06466486|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
223960452|NCT06466486|DRUG|FE999302|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
223960453|NCT06466486|DRUG|FE999302 Placebo|To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
223960454|NCT04763980|OTHER|Educational Intervention|Participate in educational session with health coach
223960455|NCT04763980|OTHER|Genetic Testing|Undergo genetic testing
223960456|NCT04763980|OTHER|Survey Administration|Complete surveys throughout course of study.
223960457|NCT04763980|OTHER|ProGene Artificial Intelligence (AI) Platform|AI Platform to be used by health coach during sessions
223960458|NCT04763980|OTHER|Interviews|Participant and provider interviews will be conducted by study staff.
223960459|NCT05834725|BEHAVIORAL|Promoting Resilience in Stress Management|Resilience coaching program.
224291293|NCT06616428|OTHER|Pump Power|Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.
223960460|NCT05834725|OTHER|Usual Care|Combination of physical therapy, occupational therapy, and psychological counseling as recommended by the treating provider.
223960461|NCT02232009|DEVICE|3.0 T Neonatal MRI Scanner|Eligible subjects will undergo neonatal MRI scanning procedures.
223724277|NCT02432014|BEHAVIORAL|PMTO Individual clinic-based|
223724278|NCT02432014|BEHAVIORAL|Services as Usual|
223960462|NCT04978558|OTHER|Continuous assessment of cerebrovascular autoregulation with NIRS and TCD|Continuous monitoring of MAP, cerebral oxygenation, and cerebral blood flow velocity before, during, and after surgery to calculate two cerebrovascular autoregulation indices Cox and Mx.
223960463|NCT01316250|DRUG|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
223960464|NCT00164021|PROCEDURE|Physiotherapy, exercise, percutaneous gastrostomy feeds|
223960465|NCT00164021|DRUG|Anti-reflux pharmacotherapy|
223960466|NCT01469442|PROCEDURE|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
223960467|NCT05493891|OTHER|Visual analogue scale (VAS)|VAS is a reliable and valid method for assessing the intensity of low back pain (LBP)
223960468|NCT05493891|DEVICE|Pressure Biofeedback Unit (PBU)|PBU is a valid and reliable instrument for measuring the maximal voluntary isometric contraction of both lumbar multifidus and transversus abdominis muscles (core muscle strength)
223960469|NCT01461434|DEVICE|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
223960470|NCT05340426|DEVICE|UKidney|The intended clinical product is a kidney derived from a domestic pig that contains an intentional genomic alteration (IGA) to protect it after transplantation from the human immune response via inactivation of endogenous porcine genes responsible for expression of pig epitopes and inclusion of human transgenes to inhibit host immunogenic response.
223960471|NCT04751929|DRUG|Abemaciclib|Taken orally 2x daily
223960472|NCT04751929|DRUG|Atezolizumab|Intravenously Day 1 of 21 day cycle
223960473|NCT00781209|PROCEDURE|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:\<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
223960474|NCT02877745|OTHER|Stratification, no intervention|
223960475|NCT03754686|DRUG|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
223960476|NCT03754686|DRUG|Paracetamol|Best medical care and oral paracetamol twice daily for five days
223960477|NCT05798754|PROCEDURE|Loss of resistance (LOR) technique|The thoracic epidural space will be identified by the loss of resistance (LOR) technique
223724279|NCT00001105|DRUG|F105 Monoclonal Antibody (Human)|
223724280|NCT00441883|DRUG|PF-03187207 and Latanoprost Vehicle|
223724281|NCT00441883|DRUG|Latanoprost 0.005% and PF-03187207 Vehicle|
223724282|NCT03063567|DEVICE|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
223724283|NCT00002096|DRUG|Zidovudine|
223960478|NCT05798754|DEVICE|CompuFlo® technology|The thoracic epidural space will be identified by the CompuFlo® technology
223960479|NCT02469493|DEVICE|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25\*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
223960480|NCT01469429|OTHER|placebo|Receive lozenge placebo PO
223960481|NCT01469429|OTHER|laboratory biomarker analysis|Correlative studies
223960482|NCT01469429|OTHER|questionnaire administration|Ancillary studies
223724284|NCT00002096|DRUG|Didanosine|
223724285|NCT00002096|DRUG|Ganciclovir|
223960483|NCT01469429|DRUG|chemoprevention|Receive LBR lozenge PO
223960484|NCT01469429|DRUG|chemoprevention|Receive LBR Saliva Substitute PO
223960485|NCT01469429|OTHER|placebo|Receive Saliva Substitute placebo PO
223960486|NCT00600223|BEHAVIORAL|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
223960487|NCT04884282|DRUG|Tedopi|TEDOPI is a T-specific immunotherapy was designed to induce cytotoxic T-lymphocytes against five five tumor associated antigens (ie CEA, p53, HER-2/neu, MAGE2 and MAGE3)
223960488|NCT04884282|DRUG|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains. Nivolumab is produced from cell culture using a CHO cell line.
223960489|NCT04884282|DRUG|Docetaxel|Docetaxel is a cytotoxic microtubule inhibiting antineoplastic agent in the taxane class. Docetaxel monotherapy is indicated for locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
223960490|NCT01982266|DEVICE|GRADION™ Hip Total Cartilage Replacement (TCR)™|
223960491|NCT05234476|BEHAVIORAL|Behavioral Activation plus Savoring|Individuals in this intervention will complete two sessions of behavioral activation, where they will be provided psychoeducation on behavioral models of mood, schedule activities, and discuss barriers to completion. Additionally, they will practice savoring as a cognitive strategy to increase positive emotions with a study therapist.
223960492|NCT05234476|BEHAVIORAL|Empathic Listening|Individuals in the active control condition will complete two sessions of reflecting on tracking their mood and empathic listening with a study therapist.
223960493|NCT05285696|DRUG|CSB-111|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
223960494|NCT00376259|DRUG|telbivudine|600mg/day oral tablet for 96 weeks
223960495|NCT00376259|DRUG|adefovir dipivoxil|10 mg of adefovir by mouth once daily
224109265|NCT05006612|PROCEDURE|Serratus Anterior Plane Block|"SAPB Technique; U/S probe will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, Then, using U/S guidance, A 38-mm 22-gauge regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. After aspiration to avoid IV injection 30ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle.~SAPB combined with Modified Pectoral Nerve Block :~SAPB with injection of 20 ml levobupivacaine 0.25% as discussed before. Modified Pectoral Nerve Block:After identification of the axillary vessels, the U/S probe will turned inferolaterally till the serratus anterior and the two pectoralis muscles are detected in one plane. 10 ml of levobupivacaine 0.25%was injected between the two pectoralis muscles. After that,10 mL of levobupivacaine 0.25%is injected above this muscle."
224109266|NCT00188994|DRUG|Insulin Cardioplegia|
223960496|NCT05579587|DEVICE|Transoral Incisionless Fundoplication|Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
223960497|NCT05953818|DIAGNOSTIC_TEST|Chinese version of the Montreal Cognitive Assessment Scale (MoCA) and brain magnetic resonance high resolution structural imaging|Chinese version of Montreal cognitive assessment scale and brain magnetic resonance high resolution structural imaging
223960498|NCT00002401|DRUG|Indinavir sulfate|
224109267|NCT05814029|OTHER|Mobilization with movement for Ankle|The participant will assume a lunge position on a rigid serving table with the relevant extremity in a weight-bearing stance and the foot in a neutral position. An inelastic belt will be placed around the clinician's waist, flush with the lower edge of the medial malleolus, around the distal tibia and fibula. The clinician will stabilize the talus and forefoot with the web spacing of the hands and pressure dimensions on the talus and forefoot, and maintain posterior to anterior sliding of the tibia over the talus using the arch. The clinician will continue to apply pressure while the person is reporting discomfort and/or while the lunge moves, which will continue until the end of the range of motion. Mobilization will be performed as a 3 set of 10 repetitions.
224109268|NCT05509244|DRUG|Acetaminophen|acetaminophen 1g iv dripping at end of surgery
224109269|NCT05509244|DRUG|Ibuprofen|ibuprofen 300mg iv dripping at end of surgery
223724286|NCT05699499|OTHER|KeryFlex|KeryFlex is a painless, in-office cosmetic application of artificial nails which improves the appearance of nails damaged by various nail disorders. The composite resin creates a flexible, nonporous nail that allows the remaining natural nail to grow. KeryFlex is a three-step procedure that takes 10 to 15 minutes for a typical nail. At least 15% of the existing nail must be present for the resin application. The material used in KeryFlex is approved as a cosmetic by the FDA.
223960499|NCT00002401|DRUG|Delavirdine mesylate|
223960500|NCT00002401|DRUG|Lamivudine|
223960501|NCT00002401|DRUG|Zidovudine|
223960502|NCT01325519|OTHER|video decision aid|video
223960503|NCT03239171|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
223960504|NCT03239171|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
223960505|NCT02665806|DRUG|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
223960506|NCT02665806|DRUG|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
223960507|NCT00494416|OTHER|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
223960508|NCT01262794|BIOLOGICAL|CDP6038|100 mg/mL solution for injection, single dose
223960509|NCT01262794|BIOLOGICAL|Placebo|0.9% sodium chloride for injection Single-dose
223960510|NCT05082441|DRUG|Liposomal bupivacaine|Exparel mixed with bupivacaine to be infiltrated in the subcutaneous region of the wound instead of plain bupivacaine
223960511|NCT05082441|DRUG|Bupivacaine Hydrochloride|plain bupivacaine subcutaneous injection as standard of care control
223960512|NCT05087849|BIOLOGICAL|nonavalent human papillomavirus vaccine|Intralesional injection of nonavalent human papillomavirus vaccine (Gardasil 9) at 0 and 4 weeks
224109270|NCT02648230|DEVICE|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
224109271|NCT02648230|DEVICE|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
224109272|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
224109273|NCT01401244|DRUG|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
224109274|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
224109275|NCT03728127|DIETARY_SUPPLEMENT|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
224109276|NCT02717546|DEVICE|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
224109277|NCT05937711|OTHER|Transcutaneous Posterior Tibial Nerve Stimulation + Duloxetine 30 MG|"PTNS was applied using two 50 mm × 50 mm electrode pads per extremity. The live pad was placed superior to and medial to the medial malleolus. The ground pad was placed 5-10 cm proximal to the live pad. The PTNS was applied using biphasic square waves with a frequency of 10 Hz and pulse duration of 200 μs. The amplitude was adjusted to the level that produced painless paresthesia in each patient according to their tolerance. PTNS was applied for 30 minutes~Duloxetine 30 mg p.o 1X1 (daily)"
223960513|NCT02705456|PROCEDURE|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
223960514|NCT02705456|PROCEDURE|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
223960515|NCT01844362|PROCEDURE|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
223960516|NCT00026078|DRUG|docetaxel|
223960517|NCT00026078|DRUG|ifosfamide|
224109278|NCT05937711|DRUG|Duloxetine 30 MG|Duloxetine 30 mg p.o 1X1 (daily)
224109279|NCT05901181|BEHAVIORAL|Laughter Yoga|"Laughter yoga is a childlike practice where group members make eye contact with each other.~It is a breath yoga practiced by imitating games and fake laughing. Brain the effects of real laughter on the body, as it cannot distinguish between fake and real laughter.~showing positive effects. It consists of sessions lasting at least 20 minutes and an average of 45 minutes."
224109280|NCT02194296|DRUG|Ambroxol hydrochloride - lozenge|
224109281|NCT02194296|DRUG|Ambroxol hydrochloride - syrup|
224109282|NCT02120586|OTHER|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
224291294|NCT06616428|OTHER|Global Training|Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
223724287|NCT00812578|DRUG|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
223724288|NCT00822835|BIOLOGICAL|ILV-095|
223724289|NCT00822835|BIOLOGICAL|Placebo|
223960518|NCT05807555|OTHER|Ambulatory ECG|24h ECG monitoring
223960519|NCT05807555|BIOLOGICAL|Blood sample|The usual biological tests necessary for the management of the child and the addition of 1 tube of 2 ml
223960520|NCT03869411|BEHAVIORAL|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
223960521|NCT05873127|BEHAVIORAL|web-based guided self-help Enhanced Cognitive Behavioral therapy|The subjects would learn and practice CBT-E course through the online learning platform for 12 times, and were required to complete the course once a week.
223960522|NCT05873127|BEHAVIORAL|online Enhanced Cognitive Behavioral therapy|A closed structured group would be established by online video conference for group CBT-E therapy. Each group would receive 12 group sessions, once a week for 120 minutes each time. Each group would be led by two CBT therapists, all of whom are nationally registered psychotherapists with systematic professional training.
223542071|NCT03186430|BEHAVIORAL|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
223542072|NCT03224364|PROCEDURE|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
223960523|NCT04597047|DIAGNOSTIC_TEST|Capillary Collection & Testing|Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test
223960524|NCT04597047|DIAGNOSTIC_TEST|Venous Draw & Testing|One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
223960525|NCT01621087|OTHER|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
223960526|NCT00005843|DRUG|tipifarnib|
223960527|NCT04983147|OTHER|Obesity Training Based on Health Belief Model|Trainig was given with initiatives for cognitive and affective learning areas within the framework of health belief model.7 weeks.This application will only be made in the experimental group.
223960528|NCT04983147|OTHER|Post-training follow-up|"After 7 weeks of training to women were completed, women were included in the follow-up program.For 6 mounts. This application will only be made in the experimental group.It will be made by phone call.~This follow-up will increase motivation and answer questions regarding obesity management.~It was made by calling every 15 days."
223960529|NCT01012999|DRUG|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
224109283|NCT02120586|OTHER|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
224109284|NCT05207436|DRUG|Oxytocin nasal spray|Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each B-CBCT session.
224109285|NCT05207436|BEHAVIORAL|Brief Cognitive-Behavioral Conjoint Therapy|Eight sessions of standardized B-CBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
224109286|NCT02614794|DRUG|tucatinib|300 mg orally twice daily
224109287|NCT02614794|DRUG|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
224109288|NCT02614794|DRUG|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
224109289|NCT02614794|DRUG|placebo|Oral dose twice daily
224109290|NCT03756012|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
224109291|NCT01731691|BIOLOGICAL|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
224109292|NCT01731691|DRUG|Placebos|Placebo treatment in HIV disease will be compared with Prolastin-C treatment in HIV disease and no treatment in uninfected volunteers.
224109293|NCT03425110|OTHER|Modified Ketogenic Diet|
224109294|NCT03865342|BEHAVIORAL|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
224109295|NCT03396471|DRUG|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.
224109296|NCT03396471|RADIATION|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
224109297|NCT06094712|DRUG|CORT125134|CORT125134 150-mg capsule
224109298|NCT02140320|DRUG|RV1729 single dose|Safety and tolerability of single dose
223960530|NCT04712786|OTHER|pars plana vitrectomy|23 gauge pars plana vitrectomy was performed for retinal detachment, vitreous hemorrhage or epiretinal membrane
224109299|NCT02140320|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single dose
224109300|NCT02140320|DRUG|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
224109301|NCT02140320|DRUG|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
224109302|NCT02140320|DRUG|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
224109303|NCT02140320|DRUG|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
224109304|NCT02563873|DEVICE|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
223960531|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following fetal shoulder delivery|The intervention is to determine if initiating oxytocin as soon as the fetus is delivered decreased postpartum blood loss. 30 units in 500 milliliters of 0.9% sodium chloride
223960532|NCT04632264|OTHER|Initiation of standard postpartum oxytocin immediately following placenta delivery|Standard of care includes oxytocin administration post-delivery regardless of delivery mode. This is the comparative group. 30 units in 500 milliliters of 0.9% sodium chloride
223960533|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post placenta delivery (within 15 seconds).
223960534|NCT04632264|OTHER|Saline Placebo|Saline placebo will be initiated post fetal shoulder delivery (within 15 seconds).
223960535|NCT03043950|DRUG|Panitumumab|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC.
223960536|NCT01037829|OTHER|Non-intervention observational study|Non-intervention observational study
223960537|NCT05229848|PROCEDURE|3D electroanatomical mapping alone guided CTI ablation|3D electroanatomical mapping in combination with fluoroscopy has been traditionally used in conventional CTI ablation for AFL.
223960538|NCT05229848|PROCEDURE|ICE plus 3D electroanatomical mapping guided CTI ablation|ICE imaging catheter is typically introduced through an 11-F hemostatic sheath and positioned under fluoroscopic guidance in the right atrium. After catheter coupling to the imaging platform, imaging frequency is optimized by the operator using adjunctive gain, depth, and focal length controls to define anatomic structures and minimize noise. Imaging is performed at different levels in the right atrium, if needed. Imaging targets included the right atrium, coronary sinus orifice, fossa ovalis, interatrial septum (IAS), tricuspid valve, left atrium, left atrial appendage, orifice of all pulmonary veins, mitral valve, papillary muscles, aortic and pulmonary valve leaflets, right ventricle, RVOT, pericardial space, esophagus, aorta and adjoining left ventricular and right ventricular myocardium.
223960539|NCT03278808|DRUG|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
223960540|NCT03278808|DRUG|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
223960541|NCT03278808|DRUG|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
223960542|NCT00977340|BEHAVIORAL|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
223960543|NCT00977340|BEHAVIORAL|confrontation|Confrontation
223960544|NCT00977340|BEHAVIORAL|imagination|Imagination
224109305|NCT06274333|DRUG|Dexmedetomidine 0.5 mic/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg,
224109306|NCT06274333|DRUG|Tramadol 1mg/kg|Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
224109307|NCT06274333|DRUG|Paracetamol 10mg/kg|Group I (DP group) will receive dexmedetomidine 0.5 mic/kg and paracetamol 10mg/kg. Group II (TP group) will receive tramadol 1mg/kg and paracetamol 10mg/kg.
224109308|NCT02542449|DIETARY_SUPPLEMENT|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
224109309|NCT02542449|DIETARY_SUPPLEMENT|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
224109310|NCT02019381|DIETARY_SUPPLEMENT|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
224109311|NCT02019381|DIETARY_SUPPLEMENT|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
224109312|NCT02019381|DIETARY_SUPPLEMENT|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
224109313|NCT05934760|OTHER|High intensity interval training (HIIT)|"Each HIIT session last 15 minutes. Participants will be asked to measure their own heart rate during their rest periods and provided with an estimated max heart rate which they should be aiming to achieve within the final 2 exercises. Participants will be provided with a logbook to record the heart rate achieved in each exercise. The regimen will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot"
224109314|NCT05934760|OTHER|Resistance based training (RET)|"Each RET session lasts an estimated 20minutes. Participants will be provided with a set of resistance bands to provide resistance to their workout, and a logbook to record the number of repetitions and band used.~Each session will include:~* 2 min warm-up jogging on the spot~* 2 sets of 12-15 repetitions of:~* Squats~* Hip flexion~* Hip extension~* Hip abduction~* Seated row~* Bench press~* Lateral raises~* 2 min jogging on the spot cooldown.~Each exercise will be separated by 1-minute rest, with participants encouraged to workout to mild fatigue on their final repetition in each set. If able to perform more than the allocated maximum of 15 repetitions prior to fatigue, then participants will be informed to increase the resistance by using a tougher resistance band."
223960545|NCT01665014|RADIATION|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
223960546|NCT03227432|DRUG|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
224109315|NCT03718494|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging (MRI)|Performed on a single 3T system and sequences will be acquired in a single sitting with an exam time under 45 minutes.
223542073|NCT03224364|PROCEDURE|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
223960547|NCT03227432|DRUG|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
223960548|NCT03227432|DRUG|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
224109316|NCT03718494|DIAGNOSTIC_TEST|F-18 Florbetapir Positron Emission Tomography (PET) Imaging|After a 50-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. Injection of 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq) given. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 20-minute PET acquisition consisting of four 5-minute dynamic frames.
223960549|NCT03227432|DRUG|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
223960550|NCT02069366|DRUG|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive dronabinol.
223960551|NCT02069366|DRUG|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
223960552|NCT04092699|DEVICE|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
223960553|NCT01378533|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
223960554|NCT06199050|OTHER|Questionnaire: SPIRIT|"T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document."
223960555|NCT06199050|OTHER|Questionnaire: HADS|Hospital Anxiety and Depression Scale, 14 questions likert scale
223960556|NCT06199050|OTHER|Questionnaire: QSC-R23|Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale
223960557|NCT06199050|OTHER|General questions|"* Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline"
223960558|NCT06199050|OTHER|Clinical data collected|"Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM"
223960559|NCT03880422|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet plan
223960560|NCT03880422|OTHER|Educational Intervention|Attend educational meeting
223960561|NCT03880422|BEHAVIORAL|Exercise Intervention|Complete exercise program
223960562|NCT03880422|OTHER|Quality-of-Life Assessment|Ancillary studies
223960563|NCT03880422|OTHER|Survey Administration|Ancillary studies
223960564|NCT06281808|DEVICE|Photon Counting Detector CT|Photon counting detector CT scan with dose arbitrarily reduced compared to EID CT scan (e.g., half the dose of EID CT)
223960565|NCT05630209|DEVICE|Exablate|Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
223960566|NCT05630209|DRUG|Doxorubicin|Doxorubicin infusion
223960567|NCT04945707|DRUG|Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]|Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
223960568|NCT04945707|DRUG|Placebo|Normal saline
223960569|NCT05710783|BIOLOGICAL|AVX-COVID/12|Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
223960570|NCT05710783|BIOLOGICAL|ChAdOx-1-S[recombinant]|Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
223960571|NCT06236451|DRUG|Aripiprazole|Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.
223960572|NCT06236451|DRUG|Risperidone|Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.
223960573|NCT06317636|DRUG|Ketamine|0.5 mg/kg ketamine infused intravenously over 40 minutes
223960574|NCT06317636|DRUG|Normal saline|0.9% normal saline infused intravenously over 40 minutes
223960575|NCT06032546|DRUG|Budigalimab|Intravenous (IV) Infusion
223960576|NCT06032546|DRUG|Placebo for Budigalimab|IV Infusion
223960577|NCT06032546|DRUG|ABBV-382|IV Infusion
223960578|NCT06032546|DRUG|Placebo for ABBV-382|IV Infusion
223960579|NCT06032546|DRUG|Budigalimab|Subcutaneous (SC) Injection
223960580|NCT04458779|DEVICE|CPAP|CPAP will be given after obstructive sleep apnea being diagnosed in the acute stage of stroke.
223960581|NCT03138005|OTHER|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to \~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
223960582|NCT03138005|OTHER|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
223960583|NCT05834452|PROCEDURE|The Epley Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotated 90° towards the unaffected side around the yaw axis~4. Rotate a further 90° toward the unaffected side around the yaw axis~5. Rotates back to an upright position with a 135° backward rotation around the pitch axis."
223960584|NCT05834452|PROCEDURE|The 360 Degree Maneuver|"5 step procedure where the patient:~1. Sits upright in a neutral position~2. Rotate 45° towards the affected side around the yaw axis and then ro-tate 135° backward around the pitch axis~3. Rotate a further 90° backward around the pitch axis (total 225°)~4. Rotate a further 90° backward around the pitch axis (total 315°)~5. Rotate back to an upright position with an additional 45° backward rota-tion around the pitch axis (total 360°)."
223542074|NCT04608877|BEHAVIORAL|Take 5 and Audio Clip|Parent will receive the 5 discrete safety steps for infant crying and listen to the audio clip of infant crying and public service announcement message
223542075|NCT04608877|BEHAVIORAL|Take 5 Only|Parent will only receive the 5 discrete safety steps for infant crying
223542076|NCT03492047|DIETARY_SUPPLEMENT|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
223542077|NCT03492047|DIETARY_SUPPLEMENT|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
223542078|NCT03492047|DRUG|Paclitaxel|Paclitaxel 80mg /m2 IV
223542079|NCT01883700|OTHER|Boiled Pasta|
223542080|NCT01883700|OTHER|Boiled Chickpeas with Oil|
223542081|NCT01883700|OTHER|Instant Mashed Potatoes|
223542082|NCT01883700|OTHER|Instant Mashed Potatoes with Egg Whites|
223542083|NCT00477815|BIOLOGICAL|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
223542084|NCT00477815|DRUG|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
223542085|NCT00477815|BIOLOGICAL|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
223542086|NCT00477815|BIOLOGICAL|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
223542087|NCT00477815|RADIATION|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
223542088|NCT00477815|BIOLOGICAL|111In Zevalin|5.0 mCi by IV
223542089|NCT06286449|OTHER|Spinal tap|A spinal tap is performed on all enrolled study participants that meet the eligibility criteria
223542090|NCT02070497|OTHER|case management|case management group will accept the case manager's service; the control group will just accept the routine care
223542091|NCT05542459|DRUG|Biologics|Infliximab, adalimumab, vedolizumab, ustekinumab, and other biologics approved for IBD
223542092|NCT03024424|BEHAVIORAL|Early disclosure|
223960585|NCT05834452|DEVICE|Mechanical rotational chair|TRV chair
223960586|NCT06636383|OTHER|No Intervention|No investigational/study product will be administered in this DMP.
223960587|NCT05177068|DRUG|fruquintinib + sintilimab + SOX|fruquintinib: 4mg/d, qd po, d1-14, q3w; sintilimab: 200 mg/d, IV d1, q3w; S-1: BSA\<1.25 m2, 40mg twice/day; BSA1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, d1-14, q3w; oxaliplatin: 130mg/m2, ivgtt 2-6h, d1, q3w
223960588|NCT05930210|DRUG|ENERGI-F703 GEL|Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
223960589|NCT05930210|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
223960590|NCT02256553|BIOLOGICAL|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
223960591|NCT02256553|BIOLOGICAL|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
223960592|NCT02256553|DRUG|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
224109317|NCT03718494|DIAGNOSTIC_TEST|F-18 AV-1451 Positron Emission Tomography (PET) Imaging|Intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451 (approved under IND 124449). PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 50-60 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
224109318|NCT03718494|OTHER|Neuropsychological Testing|A comprehensive battery of standardized neuropsychological tests administered by trained personnel.
224109319|NCT02796144|DRUG|Lorcaserin|Max dose of 10 mg BID
224109320|NCT02796144|DRUG|Metformin|Max dose of 1,000 mg BID
224109321|NCT02796144|DRUG|Placebo|Matching placebos will be administered for each drug.
224109322|NCT02297893|BEHAVIORAL|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
224109323|NCT02297893|BEHAVIORAL|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
224109324|NCT03237845|DRUG|Rimegepant|75 mg tablet QD
224109325|NCT03237845|DRUG|Placebo|Placebo tablet to match rimegepant dose QD
224109326|NCT00014573|BIOLOGICAL|aldesleukin|
224109327|NCT00014573|BIOLOGICAL|autologous tumor cell vaccine|
224109328|NCT00014573|BIOLOGICAL|filgrastim|
224109329|NCT00014573|BIOLOGICAL|sargramostim|
224109330|NCT00014573|BIOLOGICAL|therapeutic autologous lymphocytes|
223960593|NCT00003634|BIOLOGICAL|oregovomab|
223542093|NCT03024424|BEHAVIORAL|Late disclosure|
223542094|NCT03087175|DEVICE|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
223542095|NCT03087175|DEVICE|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
223542096|NCT05298943|OTHER|walking in 4 situations|Recording of cerebral hemodynamic with fNIRS during gait in exoskeleton with Four strength levels of aid : total aid (A100%), partial aid (A50%), no aid (A0%) and resistance of 25 % (R25%) to walking from the exoskeleton. Each subject are recorded during 8 trials for each level (32 trials). The order is counterbalanced among the subjects
223542097|NCT01789242|DRUG|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
223960594|NCT03436797|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
224109331|NCT00014573|DRUG|carmustine|
224109332|NCT00014573|DRUG|cisplatin|
224109333|NCT00014573|DRUG|cyclophosphamide|
224109334|NCT00014573|DRUG|paclitaxel|
224109335|NCT00014573|PROCEDURE|autologous bone marrow transplantation|
224109336|NCT00014573|PROCEDURE|conventional surgery|
224109337|NCT00014573|PROCEDURE|peripheral blood stem cell transplantation|
224109338|NCT05174689|DIAGNOSTIC_TEST|Exercise challenge in the cold chamber (ECC)|Exercise challenge (defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber. Gradient: 10%, temperature 2-4°C. After the exercise challenge controlling bodyplethysmography and spirometry after 5, 10, 15 and 30 minutes. A positive reaction is a decrease of ≥ 10% of FEV1 in comparison to the initial value.
224109339|NCT05174689|DIAGNOSTIC_TEST|mRNA profile|Blood taking with full blood exam and PAXgene tube for investigation oft the micro RNA profiles. The PAXgene Blood RNA kit insulates total RNA inclusive miRNA and small RNA which are centrifugated, pelletised, washed and incubated to detach proteins. For mapping the particular miRNA there will be generated libraries with specifical codes to match the analysis to the original probe. Next generation sequencing will be performed by MISeq REagent Kit v3 and the analysis oft the different expressions in the R Version 3.2.3. The divergent expressions will be refurbished by computer and databased.
224109340|NCT05174689|DIAGNOSTIC_TEST|standard diagnostic|bodyplethysmography, spirometry, exhaled NO, skin prick test, asthma control test (ACT)
224109341|NCT01252888|DEVICE|iStents|Implantation of two iStents through a small temporal clear corneal incision
224109342|NCT06343207|DEVICE|Percussive massage gun therapy|Between pre and post-test, there was a one and half minute period during which each participant were in a prone position on a medical examination bed. The experimental PT groups received a 30-second triceps surae massage on each limb, while the control group maintained the same prone position without massage. The massage gun was set to 2100bpm and 1 bar of surface pressure was indicated by the device. The massage gun movement was performed according to the manufactu'er's instructions.
224109343|NCT06106165|OTHER|In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered in-person, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
224109344|NCT06106165|OTHER|Online In-person peer-led faith-based intervention to encourage breast, bowel, and cervical screening uptake among Muslim women|"The intervention includes a two-hour workshop, delivered online, that aims to improve the uptake of cancer screening among Muslim women.~The workshop consists of four parts:~* A peer-led discussion on barriers and facilitators to breast, cervical and colorectal cancer screening~* A health information session led by a health professional~* Videos of Muslim women talking about their experiences with cancer screening~* A religious perspective on cancer screening led by a female religious scholar"
224109345|NCT06497725|DEVICE|Teleguidance-facilitated Airway Management|tele-guidence will be provided by an experienced airway expert
224109346|NCT01943279|OTHER|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
224109347|NCT01943279|OTHER|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
224109348|NCT01256619|DRUG|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
224109349|NCT05898503|BEHAVIORAL|Walking exercise + resistance training|Walking exercise and resistance training for 12 weeks
224109350|NCT05898503|BEHAVIORAL|Resistance training|Resistance training for 12 weeks
224109351|NCT05898503|BEHAVIORAL|Walking exercise|Walking exercise for 12 weeks
224109352|NCT05898503|BEHAVIORAL|Health promotion|Health promotion for 12 weeks
224109353|NCT01889810|DIETARY_SUPPLEMENT|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
224109354|NCT04990544|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
224109355|NCT04990544|BIOLOGICAL|202-CoV low antigen dose|low dose of 202-CoV with CpG / alum adjuvant
224109356|NCT04990544|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
224109357|NCT04990544|BIOLOGICAL|Placebo|Normal saline solution
224109358|NCT04132752|OTHER|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
224109359|NCT00992303|OTHER|biologic sample preservation procedure|
224109360|NCT00992303|OTHER|medical chart review|
224109361|NCT00992303|OTHER|questionnaire administration|
224109362|NCT06135597|OTHER|This is a blood test without regarding to intervention nor diagnostic tests|This is a blood test without regarding to intervention nor diagnostic tests
224109363|NCT03291197|DRUG|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
224109364|NCT04241003|DEVICE|SmartDrive Mx2+|Rear-mounted power assist
224109365|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC: The probiotic to be used is Lactobacillus rhamnosus GG, supplied as a freeze-dried powder. Probiotic will be prepared under strict Food Manufacturing Regulations. The daily dose of 2x10\^10 cfu will be packed individually in sachets. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic must be stored at 4 degrees Celsius
224109366|NCT05165329|COMBINATION_PRODUCT|PEANUT OIT: Peanut Flour (50% peanut protein) that is prepared under food manufacturing regulations|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
223724290|NCT04932551|OTHER|Questionnaire|physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.
223724291|NCT04647578|DEVICE|GT3X Actigraph accelerometer.|GT3X Actigraph accelerometer during 7 days
224109367|NCT05165329|COMBINATION_PRODUCT|PEANUT PLACEBO: Peanut Placebo is maltodextrin powder with food colouring and peanut essence that has similar appearance, taste and smell to the active product.|PROBIOTIC PLACEBO: Probiotic Placebo is maltodextrin. The daily dose will be measured using a standardised scoop. Participants will be instructed to mix one scoop of the probiotic in water at a temperature NOT exceeding 38 degrees Celsius. The probiotic should be stored at 2-8 degrees Celsius.
224109368|NCT00887692|BEHAVIORAL|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
224109369|NCT03407391|OTHER|None - observational|No intervention - observational only
224109370|NCT04673409|DIAGNOSTIC_TEST|Novel Cardiac MRI sequences|Novel CMR sequences that allow accurate multiparametric evaluation of the whole myocardium with 3D high spatial resolution and in a patient-friendly free-breathing approach in a predictable amount of scanning time (3D T2 mapping and 3D anatomical and LGE imaging). This will be compared to the data acquired with conventional/2D sequences.
224109371|NCT00916955|OTHER|Observation|Observe development of syndrome over time
224109372|NCT01645280|DRUG|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
224109373|NCT01645280|DRUG|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
224109374|NCT01645280|DRUG|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
223960597|NCT02936609|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
223960598|NCT00275418|DRUG|beta carotene from Dunaliella algae|
223960599|NCT02955225|DEVICE|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
223960600|NCT02955225|DEVICE|Passive shoe insole|A deactivated insole measures shoe pressure only.
223960601|NCT00241475|DRUG|Gefitinib|
223960602|NCT05224596|DIAGNOSTIC_TEST|Blood draw and blood-based biomarkers analyses|blood-based biomarkers analyses
223542098|NCT01789242|DRUG|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with \<VGPR after 4 cycles.
223542099|NCT02078752|DRUG|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
223542100|NCT02078752|DRUG|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
223542101|NCT05524077|PROCEDURE|Ablation|"Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation."
223724292|NCT04173468|OTHER|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
223724293|NCT04173468|OTHER|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
223960603|NCT04692441|DIETARY_SUPPLEMENT|Heavy Cream|100 ml of dairy cream with 40.4g of total fat, to ingest orally
223960604|NCT04743141|DRUG|Rimegepant (PF-07899801)|Rimegepant 75 mg, 50 mg or 35 mg ODT
223960605|NCT02074709|DRUG|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
223960606|NCT02074709|DRUG|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
223960607|NCT06458296|OTHER|Control Group|Participants receive DS prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
223960608|NCT06458296|OTHER|AI-Guided Group|Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
223960609|NCT04993976|OTHER|Resistant training (Prehabilitation)|Resistance training (10-15 repetitions: major muscle groups of upper and lower limbs \[eg, shoulder overhead press, biceps curl, knee lift, and quadriceps extension in sitting and hamstrings curl exercises\], one to three sets each) for 20-60 minutes five days a week.
223960610|NCT04993976|OTHER|Active Comparator: Control group|Conventional physiotherapy group followed basic pre-operative respiratory physiotherapy including deep breathing exercises, instructions in coughing techniques, mobilization, and active exercises of the upper limbs and thorax. Walk 30 m in the hospital ward.
223960611|NCT04162977|BEHAVIORAL|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
223960612|NCT01951105|DRUG|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
223960613|NCT01951105|DRUG|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
223960614|NCT01951105|DRUG|Placebo|Take two placebo capsules three times a day for 12 weeks.
223960615|NCT04175392|DRUG|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
223960616|NCT04175392|DRUG|Placebos|Placebos capsule 1 capsule Once daily
223960617|NCT02153697|DEVICE|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
223960618|NCT02153697|DRUG|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
223960619|NCT03469089|DRUG|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
223960620|NCT03469089|DRUG|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
223960621|NCT03469089|DRUG|Modafinil|Modafinil tablet 100 mg placed in a capsule
223960622|NCT03469089|DRUG|Placebo for ketamine|0.9 % NaCl infusion solution
223960623|NCT03469089|DRUG|Placebo for modafinil|Placebo capsule for modafinil capsule
223960624|NCT02251405|BEHAVIORAL|One bag, stainless container|
223960625|NCT02727998|DRUG|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
223960626|NCT02727998|DRUG|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
223960627|NCT01289197|BEHAVIORAL|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
223960628|NCT01504178|DRUG|duloxetine|administration during 28 days
223960629|NCT01504178|DRUG|placebo of duloxetine|administration during 28 days
223960630|NCT01504178|DRUG|injection of apomorphine|injection performed at D28
223960631|NCT01504178|DRUG|injection of placebo of apomorphine|performed at D28
223960632|NCT01504178|DRUG|L-Dopa|performed at D28
223960633|NCT01504178|DRUG|injection of placebo of L-Dopa|performed at D28
223960634|NCT02072889|OTHER|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
224109375|NCT01645280|DRUG|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
224109376|NCT01645280|DRUG|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
224109377|NCT00916799|DEVICE|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
224109378|NCT02723162|DRUG|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
224109379|NCT02723162|DRUG|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
224109380|NCT02723162|DRUG|Placebo|Matched placebo
224109381|NCT04174885|PROCEDURE|epicardial ablation|"In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation."
224109382|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
224109383|NCT00647842|DRUG|Fentanyl Transdermal System 25 mcg/h|single application
224109384|NCT06024005|DRUG|Oral Solifenacin 5mg|Oral solifenacin (Kinzy 5mg) use once a day for 6 weeks
224109385|NCT06024005|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation (TTNS)|Application of TTNS twice a week for 6 weeks, with each session for 30 minutes
223960635|NCT03423537|DRUG|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
223960636|NCT03423537|DRUG|Placebo|100IU per day containing N/S 0.9% will be injected
223960637|NCT02105688|DRUG|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
223960638|NCT02105688|DRUG|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
223960639|NCT06496568|DRUG|Inavolisib|Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
224109386|NCT02848846|DEVICE|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
224109387|NCT00234104|DRUG|OPC-41061(Tolvaptan)|
224109388|NCT02157272|DRUG|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
224109389|NCT04215354|DEVICE|Magnetic field|Low pulsed electromagnetic field induced by BEMER machine model type: B.BOX Professional, model NO: 420200, 12-15 Volt, with maximum 300 Watt and average flux density around 35 microtesla- (BEMER Liechtenstein product, USA). Mattress which is flexible, 6 flat coil was used for whole body therapy.
224109390|NCT04215354|DEVICE|Virtual reality|Wii Fit plus machine which required balance board . It is a video game console designed by Nintendo 2009
224109391|NCT02703116|BEHAVIORAL|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
224109392|NCT02703116|BEHAVIORAL|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
224109393|NCT03476018|DRUG|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
223960640|NCT06496568|DRUG|Atezolizumab|Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
223960641|NCT05237856|DEVICE|Capnometry Monitorization|After spinal anesthesia, a non-invasive nasal cannula will be applied to the patient, ETCO2 and IPI values will be continuously measured and recorded from this cannula with a capnometry device.
223960642|NCT03553459|DIAGNOSTIC_TEST|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
223960643|NCT00329771|OTHER|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
223960644|NCT01601821|DRUG|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
223960645|NCT01601821|DRUG|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
223960646|NCT05943379|DRUG|RC48-ADC in Combination with gemcitabine|RC48-ADC IV (intravenous) 2.0mg/kg IV, Q2W, 8W; Q4W, 40W Gemcitabine Intravesical 1000mg induction QW,8W; maintenance Q4W,40W
223960647|NCT00308009|PROCEDURE|Vaginal Repair for prolapse, TVT procedure|"1. TVT at the time of Vaginal Repair~2. TVT 3 months after Vaginal Repair"
223960648|NCT00308009|PROCEDURE|TVT and Prolapse surgery|"1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery"
223960649|NCT02177058|OTHER|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
223960650|NCT02177058|OTHER|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
223960651|NCT04008238|DRUG|Trabectedin|\- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
223960652|NCT00942799|DRUG|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
223960653|NCT00942799|DRUG|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
223960654|NCT05340439|DRUG|IncobotulinumtoxinA 100 UNT [Xeomin]|"In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3)."
224109394|NCT03476018|DRUG|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
224109395|NCT04686734|OTHER|No active intervention (observational only)|No active intervention (observational only)
224109396|NCT01386099|DRUG|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
224109397|NCT01386099|DRUG|Placebo|Placebo twice a day for 12 weeks.
224109398|NCT02183545|DRUG|BI 1060469|single rising doses given as tablet
224109399|NCT02183545|DRUG|Placebo|given as tablet (matching placebo of BI 1060469)
224109400|NCT01729910|BEHAVIORAL|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
224109401|NCT01729910|BEHAVIORAL|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
223960655|NCT00464932|DRUG|Vasoactive Intestinal Peptide (VIP)|
223960656|NCT05080803|DRUG|intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone|intravitreal administration
223960657|NCT04034602|OTHER|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
224109402|NCT03166358|BEHAVIORAL|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
224109403|NCT02460822|DEVICE|MyChemoCare iPad application|
224109404|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 35%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
224109405|NCT05789004|PROCEDURE|Tooth Bleaching with Whiteness HP Automixx 6%|"* Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one."
224109406|NCT04911270|DEVICE|Computer Decision Support Tool Intervention Group|Computer Decision Support Tool using Bayesian estimation to dose IV vancomycin in pediatric patients using AUC24/MIC
224109407|NCT04911270|OTHER|Matched Historical Controls|Vancomycin dosing based on standard hospital methods, with dose adjustments based on vancomycin trough targets
224109408|NCT02126644|DRUG|70% glycolic acid|
224109409|NCT01670630|PROCEDURE|Sheathed speculum examination|
224109410|NCT01670630|PROCEDURE|Standard speculum examination|
223960658|NCT04034602|OTHER|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
223960659|NCT05469867|DEVICE|CorNeat EverPatch|The CorNeat EverPatch will be implanted subconjunctivally over an ocular implant (e.g. glaucoma shunt, exposed suture tags) and fixed to the eye wall. The overlying conjunctiva will be closed over the patch.
223960660|NCT04391218|OTHER|Multidisciplinary Approach Group|Geriatricians will introduce medication review data on a Clinical Decision Support System, that will help both pharmacists and physicians in medication reconciliation, highligting potentially inappropriate prescriptions according to Beers' criteria and STOPP/START criteria, and potential controindicated and major Drug-Drug Interactions according to Micromedex. Before Hospital at Home discharge, nurses will instruct patients and/or caregivers to the use of an App, where daily drug therapy at discharge will be inserted and scheduled. This App will automatically create an alert everytime a drug dose needs to be taken, alongside an image of the specific drug packaging. The App will register if and when the patient actually takes the drug, or the reason for the delayed/missed dose.
223960661|NCT04130373|PROCEDURE|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
223960662|NCT04130373|PROCEDURE|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
223960663|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
223960664|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 1.1 Usage|Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
223960665|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
224109411|NCT04180813|DRUG|Linagliptin|drug
224109412|NCT04180813|DRUG|Acarbose|drug
224109413|NCT06069531|DIETARY_SUPPLEMENT|Lactobacillus johnsonii, Placebo Comparator: White pomegranate extract|Group A: Placebo; Group B: heat-killed Lactobacillus johnsonii TCI250; Group C: White pomegranate extract, dosage of 500mg for 8 weeks.
224109414|NCT03849560|BIOLOGICAL|Grippol® Quadri|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
224109415|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Yamagata lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
224109416|NCT03849560|BIOLOGICAL|Grippol® Plus, trivalent (Victoria lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
224109417|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy|Derazantinib was administered orally at a dose of 300 mg once daily
224109418|NCT04045613|DRUG|Derazantinib 200 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
224109419|NCT04045613|DRUG|Derazantinib 300 mg once daily+ atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
224109420|NCT04045613|DRUG|Derazantinib 200 mg twice daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
224109421|NCT04045613|DRUG|Derazantinib 300 mg once daily monotherapy (QD)|Derazantinib was administered orally at a dose of 300 mg once daily
223960666|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 2.1 Usage|Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
224109422|NCT04045613|DRUG|Derazantinib 300 mg once daily + atezolizumab 1200 mg|Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
224109423|NCT04045613|DRUG|Derazantinib 200 mg twice daily monotherapy|Derazantinib was administered orally at a dose of 200 mg twice daily
224109424|NCT01243593|PROCEDURE|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
224109425|NCT01243593|PROCEDURE|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
223960667|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
223960668|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 3.1 Usage|Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
223960669|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
223960670|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 4.1 Usage|Participants will use their Radicle GI Health Active Study Product 4.1 as directed for a period of 6 weeks.
223960671|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
223960672|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 5.1 Usage|Participants will use their Radicle GI Health Active Study Product 5.1 as directed for a period of 6 weeks.
223960673|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control Form 7|Participants will use their Placebo Control Form 7 as directed for a period of 6 weeks.
223960674|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.1 as directed for a period of 6 weeks.
223960675|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.2|Participants will use their Placebo Control 7.2 as directed for a period of 6 weeks.
224109426|NCT04967430|DRUG|Peginterferon Lambda-1A|"Peginterferon lambda is a covalent conjugate of human recombinant non-pegylated IFN lambda (IFN L) and a 20-kDa linear PEG chain.~Peginterferon lambda Injection is a sterile, nonpyrogenic, ready-to-use solution (0.4 mg/mL) that is clear to opalescent, colorless to pale yellow, and essentially free of particles. Lambda Injection is provided in a 1-mL long Type I glass syringe (0.18 mg/syringe) with a staked 29-gauge, 1/2- inch, thin-walled needle. The syringe has a rigid needle shield and is stoppered with a plunger stopper. Syringes are prefilled with a solution of Peginterferon lambda Injection, mannitol, L-histidine, polysorbate 80, hydrochloric acid, and water for injection; they are intended for a single use at adjustable doses. The syringe is marked with dose indicator lines, which are used as a reference point for administering the correct dose."
224109427|NCT04967430|OTHER|Placebo|The placebo will be 0.9% sodium chloride (normal saline) solution. A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse.
224109428|NCT05758038|PROCEDURE|Radiofrequency ablation/Microwave ablation|thermal ablation by radiofrequency and Microwave
224109429|NCT01633060|DRUG|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
224109430|NCT01633060|DRUG|BKM120|BKM120 100 mg once daily
224109431|NCT01633060|DRUG|BKM120 matching placebo|BKM120 matching placebo, once daily
223960676|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.2.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
223960677|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.3.0|Participants will use their Placebo Control 7.3 as directed for a period of 6 weeks.
223960678|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.3.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.3.1 as directed for a period of 6 weeks.
223960679|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Placebo Control 7.4.0|Participants will use their Placebo Control 7.4 as directed for a period of 6 weeks.
223960680|NCT06376695|DIETARY_SUPPLEMENT|Radicle GI Health Active Study Product 7.4.1 Usage|Participants will use their Radicle GI Health Active Study Product 7.4.1 as directed for a period of 6 weeks.
223960681|NCT06351917|DRUG|PlexoZome® Levagen® topical spray solution|PlexoZome® Levagen® topical spray solution 10mg/g providing 1.8mg active per pump
223960682|NCT06351917|DRUG|Placebo topical spray solution|Placebo topical spray solution topical spray solution 0mg/g providing 0mg active per pump
223960683|NCT05879926|DRUG|Ovarian Function Suppression + Aromatase Inhibitor|Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
223960684|NCT05879926|DRUG|Adjuvant Chemotherapy + Ovarian Function Suppression|Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
223960685|NCT00616395|DEVICE|No intervention|
224109432|NCT01189773|DRUG|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
223724294|NCT01920789|RADIATION|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (\<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
223724295|NCT01920789|RADIATION|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
223960686|NCT05648266|DRUG|Continous SAPB (Ropivacain)|postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
223724296|NCT05213650|OTHER|non-abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Non-abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
223724297|NCT05213650|OTHER|abrasive toothpaste|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Abrasive toothpaste will be used as intervention to aligner cleaning during invisalign treatment.
223724298|NCT05213650|OTHER|Efferdent|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water.The Efferdent tablet will be used once a week as an intervention to aligner cleaning during invisalign treatment.
223724299|NCT05213650|OTHER|Cleaning Crystals|Aligners should be cleaned at least once a day, but twice is preferred to prevent them from changing color or having a bad odor. They should be treated just like teeth and cleaned often, especially after eating and drinking.Usually, dentists advise their patients to clean their plaques with only liquid soap, toothbrush and water. Invisalign Cleaning Crystals will be used once a week as an intervention to aligner cleaning during invisalign treatment.
223724300|NCT02603094|PROCEDURE|clear fluid ingestion|drinking of clear fluid in preoperative period
223724301|NCT00482612|DRUG|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
223724302|NCT00482612|DRUG|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
223724303|NCT01366521|BIOLOGICAL|Mepolizumab|Monoclonal antibody
223724304|NCT03898154|DRUG|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
223724305|NCT03898154|DRUG|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
223724306|NCT00759031|DRUG|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
223724307|NCT00759031|DRUG|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
223724308|NCT03506815|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
223724309|NCT01502449|BEHAVIORAL|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
223724310|NCT01502449|OTHER|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
223724311|NCT02681562|DRUG|olaparib|
223960687|NCT05648266|OTHER|institutional standard of care pain medication protocol|institutional standard of care pain medication protocol
223960688|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
223724312|NCT02656784|BEHAVIORAL|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
224109433|NCT01057121|DRUG|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
224109434|NCT03845283|BEHAVIORAL|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
223542102|NCT05524077|DRUG|Anti-arrhythmic Drugs (AADs)|"Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial)."
223960689|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
223960690|NCT03805022|DRUG|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
223960691|NCT03805022|DRUG|Ifosfamide or dacarbazine|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
223960692|NCT03805022|DRUG|At the discretion of the investigator|Drug at the discretion of the investigator.
223960693|NCT04445584|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI
223960694|NCT06550024|DEVICE|SakuraBead Resorbable Microspheres|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
223960695|NCT06550024|DRUG|Corticosteroid Injection|Corticosteroid injection in the knee
223960696|NCT05783271|DIAGNOSTIC_TEST|Gadolinium|"All patients will be subjected to :~MRI examinations on a 1.5-T MRI system in the supine position by using a 16-channel pelvic phased-array coil. The MRI proto col includes the following sequences: unenhanced axial T1-WI, high-resolution three planes (axial, coronal, and sagittal) T2-WI, axial DWI with b values of 0, 800, and 1600 s/mm2, axial DCE T1-WI with three-dimensional (3D) high temporal resolution. In all sequences, the small field of view (FOV) was used with the scope of viewing the entire bladder, proximal urethra, distal ureteral orifices, and adjacent pelvic organs. Gadopentetate dimeglumine (Gadovist, 0.1 ml/kg body weight) is administered at a rate of 2 ml/s using a power injector."
223960697|NCT02469155|DRUG|ITI-007|
223960698|NCT02469155|DRUG|Risperidone|
223960699|NCT02469155|DRUG|Placebo|
223960700|NCT05755490|BEHAVIORAL|PROWESS|Structured, culturally sensitive behavior change intervention comprised of six video-based or in-person sessions with psychologist or social worker. FitBit is provided by study.
223960701|NCT04929223|DRUG|Inavolisib|Inavolisib will be administered orally as per schedule specified in the respective arms.
223960702|NCT04929223|DRUG|Bevacizumab|Bevacizumab IV will be administered as per schedule specified in the respective arm.
223960703|NCT04929223|DRUG|Cetuximab|Cetuximab IV will be administered as per schedule specified in the respective arm.
223960704|NCT04929223|DRUG|Atezolizumab|Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.
223960705|NCT04929223|DRUG|Tiragolumab|Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.
223960706|NCT04929223|DRUG|SY-5609|SY-5609 will be administered by mouth as per schedule specified in the respective arm.
223960707|NCT04929223|DRUG|Divarasib|Divarasib will be administered orally as per schedule specified in the respective arms.
223960708|NCT04929223|DRUG|FOLFOX|FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.
223960709|NCT04929223|DRUG|FOLFIRI|FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.
223960710|NCT03490006|PROCEDURE|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
223960711|NCT03490006|PROCEDURE|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
223960712|NCT05609370|DRUG|LBL-007|Administered intravenously.
223960713|NCT05609370|DRUG|Tislelizumab|Administered intravenously.
224109435|NCT03845283|BEHAVIORAL|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
224109436|NCT03845283|BEHAVIORAL|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
223542103|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
223542104|NCT00439335|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
223960714|NCT05609370|DRUG|Bevacizumab or Bevacizumab biosimilar|Administered intravenously
223960715|NCT05609370|DRUG|Capecitabine|Administered in accordance with relevant local guidelines and/or prescribing information
223960716|NCT05609370|DRUG|5-Fluorouracil|Administered in accordance with relevant local guidelines and/or prescribing information
223960717|NCT00442559|DRUG|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
223960718|NCT00442559|DRUG|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
223960719|NCT02267122|PROCEDURE|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
223960720|NCT02267122|PROCEDURE|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
223960721|NCT01318356|BEHAVIORAL|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
223960722|NCT01318356|DRUG|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
223960723|NCT01318356|DRUG|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
223960724|NCT02699619|DEVICE|Pinloc|3 hook pins interlocked in plate.
223960725|NCT02699619|DEVICE|2 Hansson pins|2 isolated hook pins.(Without plate)
223960726|NCT00458510|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
224109437|NCT03845283|BEHAVIORAL|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
224109438|NCT03845283|BEHAVIORAL|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
224109439|NCT05986656|PROCEDURE|Atlas-Standard method|Hardware acupressure of the suboccipital muscles according to the Atlas-Standard method for the reduction of chronic subluxation of the first cervical vertebra.
224109440|NCT00491530|DRUG|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
224109441|NCT00491530|DRUG|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
224109442|NCT00491530|DRUG|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
224109443|NCT00491530|DRUG|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
224109444|NCT05133986|OTHER|Onion Feeding|The intervention includes feeding individuals a 120g portion of onions (experimental condition).
224109445|NCT05133986|OTHER|Couscous Feeding|The intervention includes feeding individuals a 120g portion of couscous (control condition).
224109446|NCT05133986|OTHER|Onion Supplementation Period|Three 4-day supplementation periods separated by two 3-day washout periods. Supplementation periods will provide participants with a daily portion of onions to be consumed with their evening meals. The daily quantity of onion supplementation, low (40g), medium, (80g) and high (160g), will remain constant throughout each 4-day period, and the order will be individually randomised.
224109447|NCT01293669|DRUG|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
224109448|NCT01293669|DRUG|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
224109449|NCT05643300|OTHER|Survey|Data collection from participants via questionnaire
224109450|NCT00765583|DRUG|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
224109451|NCT03321812|PROCEDURE|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
224109452|NCT03321812|PROCEDURE|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
223960727|NCT03356171|PROCEDURE|Cardiac Coherence|"* 10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~* 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective."
223542105|NCT00439335|DRUG|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
223960728|NCT03356171|PROCEDURE|Adapted Physical Activity|\- 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
223960729|NCT04953897|DRUG|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
223960730|NCT06217822|DRUG|225Ac-PSMA-Trillium (BAY3563254)|Intravenous slow injection on Day 1 of a 6 week treatment cycle.
223960731|NCT05270096|OTHER|Advice|non-interventional study
223960732|NCT02846142|DRUG|PTI-428|
223960733|NCT02846142|OTHER|Placebo|
223960734|NCT02846142|DRUG|ethinyl estradiol and levonorgestrel|
224109453|NCT01305369|DRUG|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
224109454|NCT03705923|PROCEDURE|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
223542106|NCT00439335|DRUG|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
223542107|NCT00641732|DRUG|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
223542108|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
223542109|NCT00641732|DRUG|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
223542110|NCT00641732|DRUG|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
223542111|NCT00641732|DRUG|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
223542112|NCT00641732|DRUG|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
223542113|NCT00641732|DRUG|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
223542114|NCT01615744|PROCEDURE|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
223542115|NCT01615744|PROCEDURE|Non-surgical management|Early active exercises and elevation to decrease swelling
223542116|NCT00512278|DRUG|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
223542117|NCT00512278|DRUG|Placebo|Placebo
223542118|NCT02398526|DRUG|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
223542119|NCT00881985|DEVICE|continuous positive airway pressure|Use CPAP whenever sleep
223542120|NCT01981798|BEHAVIORAL|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
223542121|NCT00194467|DRUG|valganciclovir|900 mg once a day for 8 weeks
223542122|NCT00194467|DRUG|placebo|matching placebo, once a day for 8 weeks
223542123|NCT06198062|OTHER|Paraffin wax bath therapy|this group receive paraffin wax. Each session will last between 40 and 50 min, 2 sessions per week, for total 6 weeks
223542124|NCT06198062|OTHER|Paraffin Wax Bath Therapy and Muscle Energy Techniques|This group receive paraffin wax bath therapy along with muscle energy techniques. Each session will be conducted for 40 to 50 mins, 3 sessions in a week for total 6 weeks
223542125|NCT00572429|DIETARY_SUPPLEMENT|l-carnitine|3 gram daily dose
223542126|NCT03314610|OTHER|Gait speed|No intervention, only propose water and wait for need to void
224109455|NCT02894073|DEVICE|skin transilluminator|VeinViewer
224109456|NCT02742740|BEHAVIORAL|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
224109457|NCT01580475|OTHER|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
223960735|NCT00731913|OTHER|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
223960736|NCT01912521|BEHAVIORAL|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
223724313|NCT02656784|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
223724314|NCT05486676|BEHAVIORAL|VR-Moodboost; a Virtual Reality intervention for depression to enhance positive affect and reduce depressive symptoms.|All participants receive the same VR-Moodboost treatment, they only differ in the length of the baseline; 3 or 5 weeks.
223960737|NCT03677856|PROCEDURE|Paravertebral blockade|Type of anaesthesia
223960738|NCT03677856|PROCEDURE|Thoracic epidural block|Type of anaesthesia
223724315|NCT02067169|BIOLOGICAL|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
223724316|NCT00281255|DRUG|Allopurinol|
223960739|NCT02604199|DRUG|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
223960740|NCT02604199|OTHER|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
223960741|NCT02604199|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
223960742|NCT02604199|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
224109458|NCT02168946|DRUG|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
223724317|NCT00281255|DRUG|Dobutamine|
223724318|NCT04113304|BEHAVIORAL|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
223724319|NCT06278467|DIAGNOSTIC_TEST|visual pain scale (VASpain/fatigue), Beck depression index (BDI),|VAS (0-10)
223724320|NCT06278467|DIAGNOSTIC_TEST|Pain catastrophizing scale, sleep quality with a single Likert type question in the Pittsburgh questionnaire|PCS (Pain catastrophizing scale); sleep quality with a single Likert type question in the Pittsburgh questionnaire (0-3)
223724321|NCT06278467|DIAGNOSTIC_TEST|Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36),|functional disability level with Roland Morris Disability Questionnaire, quality of life with Short Form-36 ( SF-36)
224109459|NCT02168946|DRUG|Best Available Therapy|Antibiotic(s) chosen by Investigator
224109460|NCT02846077|OTHER|No intervention. Observation only|No intervention. Observation only
223724322|NCT06278467|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale (MOCA); Standard Mini mental test (SMMT)|cognitive status was measured by Montreal Cognitive Assessment Scale (MOCA) and Standard Mini mental test (SMMT)
223724323|NCT06227845|OTHER|Fecal microbiota transplant|0.1-0.3 ml liquid containing 3.5 mg/ml of maternal fecal content, (0.35mg/kg)
223724324|NCT01393704|DRUG|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
223960743|NCT02604199|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
223960744|NCT01625494|DRUG|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
223960745|NCT01625494|DRUG|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
223960746|NCT01625494|DRUG|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
223960747|NCT01625494|DRUG|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
223960748|NCT00765791|PROCEDURE|Selective Neck Dissection Excluding Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is not dissected.
223960749|NCT00765791|PROCEDURE|Selective Neck Dissection Including Level 2B|Selective neck dissection is performed. Level 2a is dissected; level 2b is also dissected.
223960750|NCT00749840|BEHAVIORAL|Questionnaire|Questionnaire taking 60-90 minutes.
223960751|NCT03500796|PROCEDURE|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
223960752|NCT03500796|PROCEDURE|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
223960753|NCT01276080|DRUG|Donepezil|10 mg tablets
223960754|NCT02812706|DRUG|Isatuximab SAR650984|Pharmaceutical form: solution Route of administration: intravenous
223960755|NCT01532830|DEVICE|n-VNS|
223960756|NCT04150419|OTHER|Group 1|Attentional training to avoid threatening, negative or pain-related information.
223960757|NCT04150419|OTHER|Group 2|Attention training for vigilance for positive emotional information.
223960758|NCT04150419|OTHER|Group 3 (control group)|Neutral attentional training (control group).
223960759|NCT05989243|DEVICE|Conventional prosthetic socket|Participants will use their own conventional rigid socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
223960760|NCT05989243|DEVICE|Adjustable Quatro socket|Participants will use an adjustable Quatro socket and will be asked to walk on a force-measuring treadmill on level ground at 0.75, 1.0, 1.25, and 1.5 m/s for \~60 sec per speed. They will also be asked to evaluate this socket using a questionnaire.
223960761|NCT03014024|OTHER|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
223960762|NCT03014024|OTHER|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
223960763|NCT00101062|DRUG|celecoxib|
223960764|NCT00101062|DRUG|letrozole|
223960765|NCT05428215|DRUG|17beta Estradiol|Subjects will take individualized therapeutic dose of 17-beta-estradiol via sublingual and oral administration
224109461|NCT03332953|OTHER|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
223960766|NCT02558504|PROCEDURE|Oesophagectomy|
223960767|NCT02558504|DEVICE|Radiofrequency ablation|
223960768|NCT02299011|DEVICE|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
223960769|NCT02299011|DRUG|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
223960770|NCT05571189|BEHAVIORAL|Daily Activity Text|Participants will receive a text each day with instructions about the daily activity they should complete for that day.
223960771|NCT05571189|BEHAVIORAL|Control Text|"Participants will receive a text each day with no instructions about daily activity. It will have messages like have a nice day."
223960772|NCT06119802|DIAGNOSTIC_TEST|atrial fibrillation|ECG of atrial fibrillation last more than 30 seconds.
224109462|NCT02067221|DEVICE|RIRS|"* RIRS arm~* Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
223960773|NCT04472338|PROCEDURE|Biospecimen Collection|Undergo collection of blood, urine, and/or tissue samples
223960774|NCT04472338|OTHER|Laboratory Biomarker Analysis|Correlative studies
223960775|NCT04472338|OTHER|Quality-of-Life Assessment|Ancillary studies
223960776|NCT04472338|OTHER|Questionnaire Administration|Ancillary studies
223960777|NCT01116830|DRUG|Placebo|Orally daily for 6 weeks
223960778|NCT01116830|DRUG|RO4917838|10 mg daily orally for 6 weeks
223960779|NCT01116830|DRUG|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
223960780|NCT02042170|DRUG|human growth hormone self-injection|
223960781|NCT00687128|BEHAVIORAL|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
223960782|NCT00687128|BEHAVIORAL|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
223960783|NCT00687128|BEHAVIORAL|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
223960784|NCT02621944|DRUG|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
223960785|NCT02621944|OTHER|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
223960786|NCT02621944|OTHER|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
223960787|NCT02621944|BEHAVIORAL|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
223960788|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
223960789|NCT01000584|BIOLOGICAL|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
223960790|NCT03166215|DRUG|TAK-935|TAK-935 tablets.
223960791|NCT03166215|DRUG|Placebo|TAK-935 placebo-matching tablets.
223960792|NCT04649242|DRUG|Rimegepant/BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
223960793|NCT04649242|DRUG|Matching placebo|Matching 75 mg or 50 mg ODT placebo
223960794|NCT02453620|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223960795|NCT02453620|OTHER|Blood Sample|Undergo blood sample collection
223960796|NCT02453620|PROCEDURE|Bone Scan|Undergo bone scan
223960797|NCT02453620|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223960798|NCT02453620|DRUG|Entinostat|Given PO
223960799|NCT02453620|BIOLOGICAL|Ipilimumab|Given IV
223960800|NCT02453620|BIOLOGICAL|Nivolumab|Given IV
223960801|NCT02453620|OTHER|Pharmacogenomic Study|Correlative studies
223960802|NCT02453620|OTHER|Pharmacological Study|Correlative studies
223960803|NCT02453620|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223960804|NCT00472368|DRUG|LBH589|
223960805|NCT00927316|BIOLOGICAL|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
223960806|NCT05903573|BEHAVIORAL|Cognitive Training|The intervention group will receive cognitive training that provides specific training tasks directed at essential cognitive domains tied to the project's aims and hypotheses (processing speed and working memory) that correspond with the neurocognitive and functional neuroimaging measures to be studied.
223960807|NCT05903573|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will complete cognitively-stimulating computer activities. The duration is 60 min/day; the frequency is two to three days/wk, for 16 weeks with the goal of completing 40 sessions.
223960808|NCT00208832|PROCEDURE|Graphic medication schedule (Pill card)|
223960809|NCT00208832|PROCEDURE|Refill reminder postcard|
223960810|NCT06029296|DRUG|Diclofenac|100 mg
223960811|NCT06029296|DRUG|Placebo|Sugar pill
223960812|NCT05302063|DEVICE|Spinal Cord Stimulation (SCS)|Boston Scientific Spinal Cord Stimulation Systems with multiple modalities
223960813|NCT05897450|OTHER|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block: injection of a local anesthetic into a region between the internal oblique and transversus abdominis muscles.
223960814|NCT05897450|OTHER|Local anesthetic infiltration|Local anesthetic infiltration was applied to the trocar sites with the same volume.
223960815|NCT04298125|BEHAVIORAL|Exercise in Pregnancy|Women in this group will participate in psychical activity 3 times per week in their community setting.
223960816|NCT01303341|OTHER|Laboratory Biomarker Analysis|Correlative studies
223960817|NCT01303341|OTHER|Pharmacological Study|Correlative studies
223960818|NCT01303341|DRUG|Riluzole|Given PO
223960819|NCT01303341|DRUG|Sorafenib Tosylate|Given PO
223960820|NCT06801145|OTHER|Education Video|48 hour before the surgery, patients were watched the training video.
223960821|NCT06801145|OTHER|Training video will not be watched group|No training was given about the intensive care process
224109463|NCT02067221|DEVICE|MPCNL|"* MPCNL arm~* A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
224109464|NCT05067660|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.
224109465|NCT05067660|RADIATION|Current standard template-based salvage therapy|In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.
223724325|NCT02240251|OTHER|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
223960822|NCT06443099|OTHER|Different methods used after intramuscular injection|Different methods will be used during intramuscular injection. One of them is shotblocker. There are studies reporting that it reduces pain according to the gate control theory. The other method is cold injection. In this method, the injector tips will be cooled to 0-2 degrees and used in injection application.
223960823|NCT06333951|DRUG|AMG 193|Administered PO
223724326|NCT06336850|PROCEDURE|Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement|The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
223960824|NCT06333951|DRUG|Carboplatin|Administered IV
223724327|NCT04410224|DRUG|ASN004|ASN004 is an antibody-drug conjugate for the treatment of advanced or metastatic solid tumors.
223960825|NCT06333951|DRUG|Paclitaxel|Administered IV
223724328|NCT04893967|DEVICE|Magnetic Tape|Magnetic tape® is applied without creating any tension over low back
223960826|NCT06333951|DRUG|Pembrolizumab|Administered IV
223960827|NCT06333951|DRUG|Pemetrexed|Administered IV
223960828|NCT06333951|DRUG|Sotorasib|Administered PO
223960829|NCT03749837|DEVICE|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
223960830|NCT03749837|DEVICE|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
223960831|NCT04967989|PROCEDURE|Low Energy SLT|SLT performed at low energy
223960832|NCT04967989|PROCEDURE|Standard Energy SLT|SLT performed at standard energy
223960833|NCT05234632|DEVICE|PICO 14 single-use Negative Pressure Wound Therapy System|The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
223960834|NCT05770570|BEHAVIORAL|Counseling|In-person individual diet and physical activity (PA) counseling
223960835|NCT05770570|BEHAVIORAL|Text Messages|Thrice-weekly diet/physical activity(PA) text messages
223960836|NCT05770570|BEHAVIORAL|Phone calls|Weekly telephone support
224109466|NCT03647943|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
224109467|NCT03647943|DEVICE|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
224109468|NCT02457897|DRUG|Liothyronine|Oral supplement given every 8 hours
224109469|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
224109470|NCT01176851|DRUG|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
223724329|NCT04893967|DEVICE|kinesiology tape|Kinesiology Tape is applied without creating any tension over low back
223960837|NCT05770570|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools
223960838|NCT04889924|RADIATION|Axillary Radiotherapy|Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
223960839|NCT04889924|PROCEDURE|Lymphadenectomy|Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
223960840|NCT02262832|DRUG|Metreleptin|administered subcutaneously 1-2 times/day
223960841|NCT00658632|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
223960842|NCT00658632|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
223960843|NCT01524211|DEVICE|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
223960844|NCT01524211|DEVICE|Terumo Arch Branch|The Arch Branch endograft is a custom-made endograft based on the Relay thoracic stent graft platform. The device is intended to land proximally in the ascending aorta just distal to the sinotubular junction, and distally either in the native thoracic aorta for focal arch pathologies, or more extensive pathologies either extended with another commercially available thoracic endograft or mated to a pre-existing thoracic endograft, which would serve as a distal landing zone. It is constructed of polyester graft material (same as those used for the Terumo Relay Plus or Pro) sewn to self-expanding nitinol stents with suture. The graft is fully stented to provide stability and the expansile force necessary to open the lumen of the graft during deployment. Additionally, the stents provide the necessary attachment and seal of the graft to the aortic wall.
223960845|NCT01807845|DIETARY_SUPPLEMENT|enriched skimmilk with VD|enriched skimmilk with VD
223960846|NCT01807845|DIETARY_SUPPLEMENT|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
223960847|NCT01807845|DIETARY_SUPPLEMENT|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
223960848|NCT02632045|DRUG|LEE-011|600 mg capsule (3x 200 mg capsules)
223960849|NCT02632045|DRUG|Fulvestrant|500 mg injection
223960850|NCT02632045|DRUG|Placebo|600 mg capsule (3x 200 mg capsules)
223960851|NCT05263492|DRUG|Lenvatinib|Lenvatinib once a day by mouth every day
223960852|NCT05263492|DRUG|Pembrolizumab|Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
223960853|NCT03147430|OTHER|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
223960854|NCT05326035|DRUG|WJ05129|Twice daily (except for single dose), 12 hours apart, fixed time is recommended
223960855|NCT05326035|DRUG|Paclitaxel injection|80mg/m2 (The maximum dose is 80mg/m2 , and the dose can be adjusted according to the actual situation), The medication is administered on days 1, 8, and 15, and a 28-day period constitutes one cycle.
223960856|NCT05837312|BEHAVIORAL|Reconnecting to Internal Sensations and Experiences|Reconnecting to Internal Sensations and Experiences (RISE) is a novel, self-guided interoceptive intervention designed to be accessible and convenient. RISE is hosted on Qualtrics and accessed on any internet-enabled device. RISE consists of four interactive 30-minute modules: (1) Progressive Muscle Relaxation and Body Functionality, (2) Understanding, Noticing and Managing Emotions, (3) Self-care and Communication, and (4) Body Sensations. The training consists of a mix of audio clips, psychoeducation, self-guided reading, and interactive writing prompts. Intervention materials are separated by multiple free-response prompts so that participants can relate the materials to their own lives, practice the introduced skills, and problem-solve difficulties implementing the skills.
223960857|NCT00388856|DRUG|Vitamin C 1000mg and E 400IU|
223960858|NCT05410717|BIOLOGICAL|Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells|"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
223960859|NCT01400997|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
223960860|NCT06091930|DRUG|BI 765049|BI 765049
223960861|NCT06091930|DRUG|Ezabenlimab|Ezabenlimab
224109471|NCT01176851|DRUG|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
224109472|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 1 gram|after a blood draw 1 gram of vitamin c will be consumed followed by 3 additional blood draws
224109473|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 2 grams|after a blood draw 2 grams of vitamin c will be consumed followed by 3 additional blood draws
224109474|NCT04463030|DIETARY_SUPPLEMENT|Liposomal vitamin C, 5 grams|after a blood draw 5 grams of vitamin c will be consumed followed by 3 additional blood draws
224109475|NCT04463030|DIETARY_SUPPLEMENT|Placebo|after a blood draw placebo will be consumed followed by 3 additional blood draws
223542127|NCT05672940|BEHAVIORAL|Aerobic plus resistance training|Aerobic plus resistance training
223542128|NCT05672940|BEHAVIORAL|Stretching plus breathing training|Stretching plus breathing training
223724330|NCT06306040|DRUG|Nalbuphine Versus Magnesium Sulfate|"Nalbuphine is a synthetic opioid receptor agonist-antagonist (agonist К receptor, antagonistic part μ receptor) that can produce a central analgesic effect and partial sedation. Nalbuphine is a medication that is indicated for moderate to severe pain where the patient requires an opioid agent, and other alternative treatments have been insufficient. The inhibitory effect of nalbuphine on respiration is slight and it has a capping effect. Owing to these advantages, it is widely used in pediatric surgical analgesia.~Magnesium sulphate, an antagonist of N-methyl-D-aspartate (NMDA) glutamate receptors, has been reported to improve hypo-magnesia and pre-eclampsia. Recently, magnesium sulphate has been gradually used as an adjuvant for sedation and analgesia during general anesthesia. Magnesium sulphate is a medication used to manage and treat multiple clinical conditions."
223724331|NCT02899988|DRUG|Mirikizumab|Administered SC
223724332|NCT02899988|DRUG|Placebo|Administered SC
223724333|NCT01717404|DRUG|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
223724334|NCT02835807|BEHAVIORAL|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
223724335|NCT02835807|BEHAVIORAL|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
223724336|NCT01819402|DRUG|Pioglitazone vs Glimepiride|
223724337|NCT00338689|DIETARY_SUPPLEMENT|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
223724338|NCT03836937|DRUG|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
223724339|NCT01934530|PROCEDURE|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
223724340|NCT01948622|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
223724341|NCT01948622|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
223724342|NCT04425161|OTHER|Fluid challenge (0.9 % NaCl)|500 ml Fluid challenge of (0.9 % NaCl) will be given
223724343|NCT01295502|DRUG|Carboplatin|Given IV
223724344|NCT01295502|DRUG|Cisplatin|Given IV
223724345|NCT01295502|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223960862|NCT06222086|OTHER|Calisthenic exercise training with telerehabilitation|The training group will be given calisthenic exercise training 30-45 minutes a day, 3 days a week, via video conference, accompanied by a physiotherapist, for 6 weeks. The training workload of aerobic exercise training will be applied at 60-80% of peak heart rate, with dyspnea 3-4 points or fatigue 4-6 points according to the Modified Borg Scale (MBS). Blood sugar measurement will be taken before exercise training. People whose blood sugar result is \>300 mg/dL will not be allowed to exercise that day.
223960863|NCT06222086|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
223960864|NCT06337903|BEHAVIORAL|Self-compassion intervention (the Mindful Self-Compassion course)|An online 8-week mindful self-compassion course with weekly sessions.
223960865|NCT05436041|BEHAVIORAL|Collaborative Diet Goal Setting Clinical Decision Support|Receives Nutri
223960866|NCT06425549|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
224109476|NCT00553787|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
223724346|NCT01295502|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
223724347|NCT01295502|DRUG|Paclitaxel|Given IV
224109477|NCT00553787|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
224109478|NCT00553787|DRUG|VI-0521|placebo
224109479|NCT06972108|DRUG|Caffeine citrate|Caffeine citrate loading at 10 mg/kg, followed by daily maintenance of 5 mg/kg PO
224109480|NCT06972108|OTHER|Saline (NaCl 0,9 %) (placebo)|Saline PO for loading and daily maintenance
224109481|NCT06969508|OTHER|core stabilitation exercises|The core stabilization exercise program aimed to strengthen deep spinal muscles: transversus abdominis (abdominal bracing), multifidus (segmental stability), and pelvic floor muscles (pelvic support). Participants received videotaped instructions for performing these exercises at home regularly for 6 months, with a gradual increase in difficulty.
223724348|NCT01652560|DRUG|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
223960867|NCT06425549|DRUG|ustekinumab|Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.
223960868|NCT06425549|DRUG|placebo|Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
223960869|NCT06232005|DRUG|Mitomycin c|injection of antifibrotic drugs in urethral strictures after internal urethrotomy
223724349|NCT05809401|BEHAVIORAL|Pragmatic Rehabilitation|A series of behavioral activities to improve specific pragmatic abilities in patients
223724350|NCT05809401|BEHAVIORAL|Neuropsychological Rehabilitation|A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
223724351|NCT00107471|BIOLOGICAL|filgrastim|Given PO
223724352|NCT00107471|DRUG|topotecan hydrochloride|Given IV
223724353|NCT00107471|RADIATION|radiation therapy|
223724354|NCT02257944|BEHAVIORAL|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
223724355|NCT02257944|OTHER|Treatment as Usual|treatment as usual
223724356|NCT03140553|DRUG|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
223960870|NCT05240885|OTHER|Stable tracer infusion in a postabsorptive state|Multiple stable-labeled tracers of amino acids, ketoacids, glycerol, short-chain fatty acids
223960871|NCT05727176|DRUG|TAS-120|TAS-120 is an oral FGFR inhibitor
223960872|NCT05396352|DEVICE|Transcranial direct current stimulation|TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
223960873|NCT05667597|DIAGNOSTIC_TEST|Humoral immunity|determine binding and neutralizing antibody levels against the epidemiologically predominant SARS- CoV-2 variants of concern (VOC) and the wild type SARS-CoV-2 (Wuhan strain).
223960874|NCT06277765|BIOLOGICAL|CM310|Interleukin-4 receptor(IL-4Rα) monoclonal antibody
223960875|NCT06277765|OTHER|placebo|Placebo
224109482|NCT06970015|OTHER|No intervention|No intervention, this is an observational study on patients with suspected acute mesenteric ischemia
224109483|NCT06339424|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.
224109484|NCT06339424|DRUG|Bevacizumab|Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.
224109485|NCT06339424|RADIATION|Photon radiotherapy|"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from the hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"
224109486|NCT05707858|OTHER|Development of the NAPFA score|In subjects with suspected food allergy we will evaluate main anamnestic, and clinical features to develop the NAPFA score
224109487|NCT04219137|GENETIC|Molecular Profiling|This is a correlative study collecting biosamples to evaluate genomic characteristics and treatment outcomes of gastroesophageal adenocarcinoma.
224109488|NCT04491279|PROCEDURE|Home 'General' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the general exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
224109489|NCT04491279|PROCEDURE|Home 'Neuropilates' exercise instructions.|Participants will be given a home exercise programme weekly based on exercises from the neuropilates exercise class and will be asked to complete these independently at home twice more during the week and to keep a training diary.
224109490|NCT04491279|PROCEDURE|Supervised Neuropilates Group Class|Will attend a once-weekly 60-minute neuropilates exercise class over 6 weeks facilitated by the principle investigator (a chartered physiotherapist who is also a pilates instructor).
224109491|NCT04491279|PROCEDURE|Supervised General Exercises Group Class|Will attend a once weekly, 60-minute generalized exercise class which will be designed by a chartered physiotherapist to address strength, cardiorespiratory fitness and mobility
224109492|NCT06165419|RADIATION|SBRT to the spine|Stereotactic body radiation therapy (SBRT) administered to spine metastases
224109493|NCT01363843|DRUG|FOLFOX6|FOLFOX6
224109494|NCT01363843|RADIATION|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
224109495|NCT01363843|PROCEDURE|Surgery|
223724357|NCT01618994|PROCEDURE|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
223724358|NCT02889484|PROCEDURE|Lumbar disc hernia surgery|
223724359|NCT06163170|DRUG|Nivolumab +/- ipilimumab|Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma
223724360|NCT06163170|DRUG|Nivolumab|Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma
223960876|NCT04343807|PROCEDURE|PECS Block|PECS nerve block will be performed using the ultrasound-guided technique described by Blanco and colleagues. Block will be performed with a 22-gauge 100 mm needle (Stimuplex, B. Braun Medical Inc., Pennsylvania, USA) using Mindray M7 imaging system (Diagnostic Instruments Inc., China) with a high-frequency (6-13 MHz) linear array transducer.20 mL of ropivacaine 0.25% in 5-mL increments will be injected, aspirating gently between injections. The needle will be withdrawn to place the tip in the fascial plane between the pectoralis major and pectoralis minor muscles and ropivacaine 0.25%, 10 ml in 5 ml increments will be injected. Injectate spread between the muscles will be visualized. For patients in control group, no nerve block will be performed and only intravenous nalbuphine will be given.
223960877|NCT04343807|OTHER|Control Group|No nerve block will be performed and only intravenous nalbuphine will be given.
223960878|NCT04511130|DRUG|MT-401|MT-401 (zedenoleucel) is an allogeneic multi-tumor-associated antigen (MultiTAA)-specific T cell product manufactured under Good Manufacturing Practice (GMP) using donor-derived T cells obtained from apheresis.
223960879|NCT05351229|DRUG|Morphine Sulfate|5 mcg/kg intrathecal preservative free morphine sulfate
223960880|NCT05351229|OTHER|Placebo|Sterile saline, placebo
224109496|NCT02708212|PROCEDURE|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
224109497|NCT04238845|DRUG|AQSP Administration|Three days treatment of all children with AQSP for SMC
224109498|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Plumpy'Doz|Daily supplementation of children with Plumpy'Doz
224109499|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Vitamin A|Single dose supplementation with Vitamin A to all children
224109500|NCT04238845|DIETARY_SUPPLEMENT|Supplementation with Zinc|Daily supplementation with Zinc
224109501|NCT05734937|OTHER|gastric assessment of gastric volume|ultrasound assessment of gastric volume is going to bel evaluted in the Preoperative and postoperative period while the patients lay in right lateral decubitus position.
224109502|NCT05361512|DEVICE|Tsui test|The stimulator is set at frequency of 1Hz with 0.2 msec pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
224109503|NCT05361512|DEVICE|epidural waveform analysis|A pressurized 500ml normal saline bag will be connected to a pressure transducer kit and the transducer will be connected to a portable monitor with the scale set at 0-40 mmHg or to optimum scale. The transducer will be levelled with the heart approximated at the patient's manubrio-sternal angle, with the patient in the sitting position. Sterile tubing will be connected to the epidural needle and attached to transducer. The tubing connection will be filled with saline to ensure proper reflection of the pressure transducer tracing. Test will be considered positive in case of pulsatile waveform is observed in synchrony with heart rate.
224109504|NCT06971198|DRUG|HSK39004|0.75\~4mg
224109505|NCT06971198|DRUG|Placebo|0.75\~4mg
223960881|NCT06011109|DRUG|APG-157|The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
223960882|NCT05230459|GENETIC|AB-1003 dose level 1|Single intravenous infusion of AB-1003 gene therapy at dose level 1
223960883|NCT05230459|GENETIC|AB-1003 dose level 2|Single intravenous infusion of AB-1003 gene therapy at dose level 2
223960884|NCT05230459|OTHER|Placebo|Single intravenous infusion of Placebo
223960885|NCT02076594|DRUG|Docetaxel|Powder for solution for infusion
223542129|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under conscious sedation|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
223960886|NCT02076594|DRUG|Epirubicin|Solution for infusion
223960887|NCT02076594|DRUG|Oxaliplatin|Powder for solution for infusion
223960888|NCT02076594|DRUG|Capecitabine|Film coated tablets
223960889|NCT06124170|PROCEDURE|Preoperative pain managment|propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery
223960890|NCT06124170|PROCEDURE|Intraoperative pain managment|Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;
223960891|NCT06124170|PROCEDURE|Postoperative pain managment|The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
223960892|NCT01584596|BEHAVIORAL|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
223960893|NCT01584596|BEHAVIORAL|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
223960894|NCT01885559|DRUG|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
223960895|NCT01885559|DRUG|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
223960896|NCT01885559|DRUG|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
223960897|NCT03266419|DRUG|Deep NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: 0.7 mg/kg~* Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
223960898|NCT03266419|DRUG|Moderate NMB using rocuronium|"* Drug: rocuronium~* Bolus dose: none~* Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
223960899|NCT02327442|RADIATION|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
223960900|NCT00980616|DRUG|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
223960901|NCT00738400|DRUG|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
223960902|NCT00738400|DRUG|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
223960903|NCT03138499|BIOLOGICAL|Nivolumab|Specified dose on specified days
223960904|NCT03138499|BIOLOGICAL|Brentuximab vedotin|Specified dose on specified days
223960905|NCT03180541|BEHAVIORAL|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
223960906|NCT02312245|BIOLOGICAL|Bevacizumab|Given IV
223960907|NCT02312245|DRUG|Gemcitabine Hydrochloride|Given IV
223960908|NCT02312245|DRUG|Paclitaxel|Given IV
223960909|NCT02312245|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223960910|NCT02312245|DRUG|Topotecan Hydrochloride|Given IV
223960911|NCT03902626|OTHER|Physiotherapy students|
223960912|NCT03902626|OTHER|Medical students|
223960913|NCT01123200|DEVICE|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
223960914|NCT06519448|DRUG|Empagliflozin 10 miligrams (mg)|Use of empagliflozin 10 mg daily for 12 months.
223960915|NCT06189898|DIAGNOSTIC_TEST|Re Staging FDG-PET|Additional interim FDG-PET during week four of preoperative or definitive chemoradiation for esophageal carcinomas. Evaluation of standardized uptake ratio (SUR) and increased uptake of non tumor affected esophagus (Delta NTO).
223960916|NCT00780988|BIOLOGICAL|Autologous tumor cell + CpG vaccine|
223960917|NCT00780988|PROCEDURE|Autologous hematopoietic and immune cell rescue (transplantation)|
223960918|NCT02411188|BEHAVIORAL|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
223960919|NCT04047303|DRUG|CC-90010|CC-90010
223960920|NCT04953910|DRUG|ASTX727|Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
223960921|NCT06570109|OTHER|Frailty|defined as weigh loss (\>4.5 kg in one year), exhaustion, slow gait speed (below 20th percentile for sex and height), weakness (handgrip strength below 20th percentile for sex and BMI), and low physical activity (by the Physical Activity Scale for the Elderly). The presence of three or more out of five criteria is defined as frailty while one to two criteria is prefrailty
223960922|NCT05726942|OTHER|Healthi|Healthi refers to the Healthi app, which is a mobile application for weight loss
223960923|NCT07124221|DRUG|Cabergoline tablets|Cabergoline tablets will be administered for 14 weeks.The allowed dose range is from 0.25 mg (1 tablet) QW to 1mg (4 tablets) QW. Dosage adjustments are made based on the serum PRL level.
223960924|NCT07124221|DRUG|Bromocriptine mesylate tablets|Bromocriptine mesylate tablets was administered for 14 weeks.The dose is 1.25 mg (0.5 tablet) QD to 7.5mg 3 tablets) QD. Dosage adjustments are made based on the serum PRL level.
223960925|NCT07127757|DEVICE|Wavelight Plus LASIK|Wavelight plus LASIK is an advanced laser eye surgery technology designed to enhance visual outcomes through personalized treatment plans. This system integrates comprehensive diagnostics, including biometry, tomography, and wavefront measurements, to create a tailored ablation profile for each patient.
223960926|NCT07134257|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
223960927|NCT07134257|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 4 weeks, 8 weeks, and optionally at 12 weeks. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
223960928|NCT07134257|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan. In the intervention arms, walking sessions will be guided by real-time auditory and visual feedback from Smart Crutch Tips™.
223960929|NCT07134257|PROCEDURE|Lower Limb Rehabilitation Exercise Program|The program includes isometric and dynamic exercises targeting the quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility to maintain muscle tone, prevent joint stiffness, reduce swelling, and improve circulation. All exercises are performed within a pain-free range (not exceeding 4/10 on the VAS scale) with gradual progression according to the rehabilitation plan.
223960930|NCT07132424|PROCEDURE|Assesment|Foot posture, toe muscle strength and balance assesment
223960931|NCT05619627|DRUG|Dexmedetomidine|Participants will receive oral dexmedetomidine as the sole sedative agent for undergoing MRI
223960932|NCT05619627|DRUG|General Anesthesia (control group)|Participants will receive general anesthesia for their MRI
223960933|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0109 - Universal Wrist|"The ORTHOPUS mechanical wrist device is intended to provide an external wrist joint only for external upper limb prostheses with pronation/supination passive motion (activation with external force), a quick connection (with automatic lock) and manual disconnection of the mechanical wrist connectors.~The mechanical wrist connector allows to quickly switch between different type of terminal devices (hand or tools)."
223960934|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0112 - Hook|The ORTHOPUS body-powered hook is a Voluntary Opening (VO) device made of aluminium intended to provide high grasping capabilities under harsh environments.
223960935|NCT04803253|DEVICE|ORTHOPUS prosthetic terminal device: 0105 - Cosmetic Articulated Hand|The ORTHOPUS cosmetic articulated hand is intended to provide a replacement limb in order to hide the loss of the original one. It is composed of an aesthetic glove (18 colors and 3 sizes, silicone made) and of an internal structure that can be bent to achieve a given position allowing the user to grasp small and light objects.
223960936|NCT04803253|DEVICE|ORTHOPUS prosthetic accessory: 0104 - body powered harness|The ORTHOPUS body powered harness is intended to allow the patient to actuate the 0112 - Hook device. It will be installed on the patient's contralateral shoulder and linked to the 0112 - Hook device with a cable.
223960937|NCT02569294|BEHAVIORAL|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
223960938|NCT02569294|BEHAVIORAL|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
223960939|NCT02569294|BEHAVIORAL|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
223960940|NCT06592664|DRUG|certepetide|certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
223960941|NCT06592664|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
223960942|NCT06592664|DRUG|gemcitabine|gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days
223960943|NCT06592664|DRUG|placebo matching certepetide|placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given
223960944|NCT06592664|DRUG|certepetide|certepetide given as two IV pushes over 1 minute when standard treatment(s) are given
223960945|NCT06592664|DRUG|placebo matching certepetide|placebo given as an IV infusion over 4 hours when standard treatment(s) are given
223960946|NCT06592664|DRUG|placebo matching certepetide|certepetide given as a slow IV push over 1 minute when standard treatment(s) are given
223960947|NCT06988358|DIAGNOSTIC_TEST|Group of children identified by the algorithm as having asthma|150 medical files of children identified by the algorithm as having asthma will be randomly selected for expert appraisal.
223960948|NCT06988358|DIAGNOSTIC_TEST|Group of children not identified by the algorithm as having asthma|150 medical files of children not identified by the algorithm as having asthma will be randomly selected for expert appraisal.
223960949|NCT02874885|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223960950|NCT06824077|DRUG|Dexmedetomidine|Dexmedetomidine will be prepared at a concentration of 4 mcg/ml by diluting 200 mcg/2 ml vials with 48 mL of 0.9% normal saline to a total volume of 50 ml. A maintenance infusion of 0.2-1.2 mcg/kg/hr will be initiated to sustain the sedative effect and promote sleep throughout the trial period. ICU nurses are experienced in titrating dexmedetomidine for both patients on high flow oxygen (Optiflow) and intubated patients with delirium as part of routine care. The ICU bedside nurse will be responsible for using the lowest effective dose to achieve a Richmond Agitation Sedation Scale (RASS) of -2, up to a maximum of 1.2 mcg/kg/hr, while monitoring for adverse events such as bradycardia and hypotension.
223960951|NCT06824077|OTHER|Control (placebo) group|The control group will receive an infusion of 0.9% saline at 5-45 ml/hr titrated to the lowest effective dose to achieve a RASS of -2 for two nights following randomization.
223960952|NCT05099770|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants will have a kidney biopsy followed 14 weeks later with a REACT injection into the biopsied kidney, then, another 12 weeks (+28 days) later a REACT injection into their contralateral kidney.
223960953|NCT05099770|PROCEDURE|Sham Comparator|Participants will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 12 weeks (+28 days) after the first sham procedure.
223960954|NCT04449874|DRUG|GDC-6036|The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
223960955|NCT04449874|DRUG|Atezolizumab|A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
223960956|NCT04449874|DRUG|Cetuximab|Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
223960957|NCT04449874|DRUG|Bevacizumab|A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
223960958|NCT04449874|DRUG|Erlotinib|150 mg of erlotinib will be administered PO QD in 21 day cycles.
223960959|NCT04449874|DRUG|GDC-1971|The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
223960960|NCT04449874|DRUG|Inavolisib|The starting dose of inavolisib will be determined from its single-agent dose escalation.
223960961|NCT06598631|DRUG|Volenrelaxin|Administered SC
223960962|NCT06598631|DRUG|Placebo|Administered SC
223960963|NCT06594068|DRUG|Anifrolumab|Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE (Furie 2017). Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo (Furie 2019; Morand 2020). Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo (Furie 2017). These data resulted with applications to the FDA and the EMA, leading to approval by them in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
223960964|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 1|Participants will use their Radicle Spark Placebo Control Form 1 as directed for a period of 6 weeks.
223960965|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 1.1 Usage|Participants will use their Radicle Spark Active Study Product 1.1 as directed for a period of 6 weeks.
223960966|NCT06590337|DIETARY_SUPPLEMENT|Spark Placebo Control Form 2|Participants will use their Radicle Spark Placebo Control Form 2 as directed for a period of 6 weeks.
223960967|NCT06590337|DIETARY_SUPPLEMENT|Spark Active Study Product 2.1 Usage|Participants will use their Radicle Spark Active Study Product 2.1 as directed for a period of 6 weeks.
223960968|NCT05847387|DIAGNOSTIC_TEST|V-Check|Preoperative analysis of endothelial tissue staining with vital dye (Trypan Blue 0.05%) and image analysis to identify the percentage of Trypan Blue Positive Areas, corresponding to dead endothelial cells and/or denuded areas of endothelium, in tissues destined to keratoplasty
223724361|NCT03935529|BEHAVIORAL|Behavioural Activation|"Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn \& Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, \& Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood."
223724362|NCT00033215|DRUG|S-3304|
223724363|NCT02079181|RADIATION|fluorine F 18 d-FMAU|Given IV
223724364|NCT02079181|PROCEDURE|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
223960969|NCT02262806|DRUG|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
223724365|NCT02079181|PROCEDURE|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
223960970|NCT06989294|OTHER|Lean Leadership|Lean leadership was doing the right things to increase revenues, satisfying customers and reducing costs by eliminating all activities that do not add value to the product or service. It has five dimensions, namely: continuous improvement, self-development, qualification development, Gemba walk and Hoshin Kanri.
223960971|NCT04576156|DRUG|Imetelstat|Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
223960972|NCT04576156|DRUG|Best Available Therapy (BAT)|Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
223960973|NCT06115967|DRUG|AZD6912|AZD6912 will be administered as a single sub-cutaneous dose.
223960974|NCT06115967|DRUG|Placebo|Placebo will be administered as a single sub-cutaneous dose.
223960975|NCT07019922|DRUG|1mg elsunersen|24 weeks every 4 weeks intrathecally
223960976|NCT07019922|PROCEDURE|sham procedure|24 weeks of sham-procedure every 4 weeks
223960977|NCT07019922|DRUG|0.5mg elsunersen|24 weeks every 4 weeks intrathecally
223960978|NCT05503030|DRUG|Nintedanib|Nintedanib
223960979|NCT02819141|DRUG|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
223960980|NCT06716372|DEVICE|DSiHy Silicone Hydrogel Soft Contact Lens|The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
223960981|NCT06716372|DEVICE|Daily Silicone Hydrogel Contact Lenses (oB)|The daily wear, daily disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
223960982|NCT07033416|BEHAVIORAL|Approach Bias Modification|ABM is a computerised training aiming to train the participants to avoid drug-related images (by pushing a joystick which causes the image to disappear) and approach positive images (by pulling a joystick which causes the image to expand). Each training session lasts 15 minutes and it takes place once per week for 4 weeks.
223960983|NCT07033416|BEHAVIORAL|Treatment as usual|Participants receiving TAU are not trained to avoid drug-related images and approach positive images.
223960984|NCT06879002|OTHER|Ovarian stimulation with menstruation or after ovulation|Ovarian stimulation with menstruation or after ovulation
223960985|NCT06881654|PROCEDURE|Bleaching teeth|Traditionally, home bleaching has been done with soft silicone trays. Patients now wear aligners, which are rigid trays used for orthodontic treatment. The use of rigid trays for home whitening has not been validated. The aim of this clinical trial is to analyse the effectiveness, comfort and sensitivity perceived by patients when whitening with 0.5 mm rigid aligners.
223960986|NCT06724978|DRUG|S-740792 Suspension|Participants will receive S-740792 as an oral suspension.
223960987|NCT06724978|DRUG|Midazolam|Participants will receive midazolam as a syrup.
223960988|NCT06724978|DRUG|Placebo|Participants will receive placebo as an oral suspension.
223960989|NCT06724978|DRUG|S-740792 Tablet|Participants will receive S-740792 as an oral tablet.
223960990|NCT06705764|DRUG|Tezepelumab|"Tezepelumab 210 mg (1.91 ml) subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.~Open-label extension study from Day 90 to Day 180 with Tezepelumab dosing at Day 90"
223960991|NCT06705764|DRUG|Placebo|Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
223960992|NCT06925529|BEHAVIORAL|Cardio-Oncology Rehabilitation and Exercise Programme|Participants randomised to the CORE programme will receive exercise training that is analogous to cardiac rehabilitation, but Exercise Physiologists will individualise each training program using the participants baseline CPET results to maximise adherence and improve the effectiveness of the training program beyond typical cardiac rehabilitation programs. An Exercise Physiologist will supervise two training sessions a week and monitor adherence to one other independent session at home each week for the first 12 weeks of the training program whilst exercise frequency, intensity, and time is progressively increased. Supervision of the exercise training will then be stepped down gradually after 12 weeks to a fortnightly check-in to encourage intervention adherence. Patients will be provided with a training calendar and objective tools for tracking physical activity (e.g. heart rate monitor and diary). Adherence will be monitored in real-time using a research web-based platform.
223960993|NCT06722157|DRUG|BI 771716|BI 771716
223960994|NCT06722157|DRUG|Pegcetacoplan|Pegcetacoplan
223960995|NCT06722157|DRUG|Sham comparator to BI 771716|Sham comparator to BI 771716
223960996|NCT03744468|DRUG|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
223960997|NCT03744468|DRUG|Tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
223960998|NCT03744468|DRUG|LBL-007|Human anti LAG-3 IgG4-kappa antibody
223960999|NCT06736379|BIOLOGICAL|VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)|Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01
223961000|NCT06736379|DRUG|Pembrolizumab (KEYTRUDA®)|200mg twice 3 weeks apart IV
223961001|NCT06736379|BIOLOGICAL|VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)|Weekly IT injections of 3 x 10\^8 viral particles of VLPONC-01
223961002|NCT07044362|DEVICE|HistoSonics Edison® System|Histotripsy is a novel, totally non-invasive, non-ionizing, and non-thermal ablation technique that mechanically disrupts tumors through precisely controlled acoustic cavitation. Histotripsy is administered via HistoSonics Edison® System.
223961003|NCT07044362|DRUG|Chemotherapy|Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).
223961004|NCT06734130|DRUG|Luteinizing Hormone-Releasing Hormone (LHRH) analog|The choice of the standard of care LHRH analog will be at the discretion of the treating physician.
223961005|NCT06734130|DRUG|Androgen Receptor Signal Inhibitor (ARSI)|The choice of the standard of care ARSI will be at the discretion of the treating physician.
223961006|NCT06734130|DRUG|Docetaxel|Docetaxel will be given by IV infusion at 75mg/m2 once every 3 weeks.
223961007|NCT06876480|OTHER|Keyboard|Day 0 : Collection of the general data required for the study, installation of the computer device including the LifeCompanion software with the different scanning keyboards configurations and organizations. Day 0 to Day 8 : write, in copy, a text using each of the virtual keyboard configurations. Day 8 : copying a text proposed by the investigator of identical difficulty for each condition, for a duration of 15 minutes, per experimental condition. This copying exercise, with the recording of measurements, will be done for each experimental condition. Day 8 to Day 16 : write a copy of a text of his/her choice for 10 minutes, using each of the virtual keyboard configurations. Day 16 : in a text-entry evaluation situation, copying a text proposed by the investigator, of identical difficulty for each condition.
223961008|NCT06741579|DEVICE|Peripheral Nerve Stimulation|This trial studies 2 FDA approved peripheral nerve stimulation devices that may reduce pain by sending electrical pulses to the nerve. The SPR SPRINT PNS System, a matchbox-sized, battery-powered wearable stimulator that uses a Mircrolead to deliver stimulation for pain relief. There is a small wireless hand-held remote that is used to activate/ adjust intensity of stimulation. Stimulation delivered by this device may interrupt pain signals and increase non-pain signals. The SPR SPRINT device is used for 60 days before the percutaneous Microlead(s) are removed. The Nalu PNS System, a dime-sized micro-implantable pulse generator (IPG) leveraging advanced microelectronics. The micro-IPG is powered by an externally worn therapy disc via radiofrequency worn over the IPG site with an adhesive clip applied to the skin or a relief belt. The device is remote-controlled by patients via an app.
223961009|NCT06741579|PROCEDURE|Conventional Care Regimen|CMM-Only participants will receive conventional medical management for the duration of their time in the study.
223961010|NCT06897475|DRUG|LY3457263|Administered SC
223961011|NCT06897475|DRUG|Placebo|Administered SC
223961012|NCT05211570|DRUG|AB8939|Intravenous injection (from an initial dose of 0.9 mg/m²)
223961013|NCT05211570|DRUG|Venetoclax|the recommended starting dose for AML indication is 100 mg. Dose escalating regimen as per SmPC.
223961014|NCT07138066|DEVICE|Smart Crutch Tips™|Smart Crutch Tips™ are sensor-equipped crutch attachments that measure real-time axial loading during ambulation. The devices connect via Bluetooth to a mobile application and deliver auditory and visual feedback to guide patients toward prescribed weight-bearing levels. The devices continuously record loading and step-count data for clinical monitoring and analysis.
223961015|NCT07138066|PROCEDURE|Finite Element Analysis (FEA)|Finite Element Analysis (FEA) is performed up to four times postoperatively to generate individualized weight-bearing prescriptions during rehabilitation. Simulations are based on CT scans and include segmentation and biomechanical modeling of the bone-fixator system. Assessments occur at: 7 days (baseline), 6 weeks, 12 weeks, and 15 weeks. Three regions are segmented: fixation system (screws and nail), bone fragments, and fracture gap. Materials: fixator (Titanium Grade 5), bone (mapped into cortical, trabecular, soft tissue, air), and fracture gap (early connective tissue). FEA calculates personalized safe loading based on: (1) Fixator safety (stress \< 290 MPa), (2) Interfragmentary motion (target: 0.5-2.0 mm), and (3) Strain in the fracture gap (octahedral: 0.001-0.05; hydrostatic: 0.001-0.02), supporting biological healing. Output informs weight-bearing prescriptions and step-count targets, delivered via Smart Crutch Tips™ with real-time fee
223961016|NCT07138066|BEHAVIORAL|Iterative walking|Participants will perform iterative walking sessions as part of their rehabilitation program. These sessions will be repeated throughout the day, with a minimum 2-hour rest interval between sessions. Step count will be progressively increased over time, according to the individualized rehabilitation plan.
223961017|NCT07138066|PROCEDURE|Lower Limb Rehabilitation Exercise Program|The program consists of a structured set of isometric and dynamic exercises targeting the quadriceps, hamstrings, gluteal muscles, and ankle/foot mobility. Exercises are performed in a supine, prone, or seated position, as appropriate, with 2 sets of 5-12 repetitions or sustained holds of 20-30 seconds, progressing gradually according to the rehabilitation plan. All movements are conducted within a pain-free range (not exceeding 4/10 on the VAS scale), with additional hourly ankle mobility work prescribed to reduce swelling and prevent thrombosis.
223961018|NCT07138066|DEVICE|Orthopedic shoes for use during rehabilitation period|Patients are provided with orthopedic shoes to be worn during the rehabilitation period (up to 6-10 weeks).
223961019|NCT06601946|OTHER|BLS Paper Based Cognitive App|BLS Paper Based Cognitive App
223961020|NCT06601946|OTHER|First Aid App|First Aid App
223961021|NCT06601946|OTHER|Corpatch App|Corpatch App
223961028|NCT06667830|OTHER|Physical exercise program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
223542130|NCT04207515|PROCEDURE|Procedures of wisdom tooth removal surgery under local anesthesia|The first specimen of saliva was taken at the first time patient came to clinic (t1). Saliva was allowed to flow in the floor of mouth an 1 ml was then collected using a Pasteur pipette. First day after examination, patient was given an appointment. The second time of the saliva was taken was when the patient sat in the chair for extraction (t2). The other times of saliva samples were taken were before local anesthesia (t3), immediately after extraction (t4) and at 4 h after extraction (t5). Due to the localization and position of the third molar, osteotomy was performed using a 20,000-rpm hand piece under irrigation for all patients. Some cases required tooth sectioning. 3-0 silk suture was used at the end of the surgery.
223961029|NCT06667830|OTHER|Neural mobilization techniques|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
223542131|NCT00060710|DRUG|CP-461|
223961030|NCT07079969|DEVICE|Photobiomodulation therapy (PBM) device|FDA-cleared near-infrared PBM device delivering therapeutic light to the affected knee. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks (2-3 times per week).
223961031|NCT07079969|DEVICE|Sham PBM device|Identical in appearance to the active PBM device but emits no therapeutic light. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks.
223961032|NCT07079969|DRUG|Diclofenac Sodium 1 % Topical Cream|Topical nonsteroidal anti-inflammatory drug applied at a dose of 4 grams to the affected knee, once per session, immediately before PBM/sham PBM. Used in six sessions over 2-3 weeks.
223961033|NCT07079969|DRUG|Placebo topical cream|Inert cream matching the appearance of diclofenac sodium 1% gel. Applied at 4 grams to the affected knee, once per session, immediately before PBM/sham PBM. Used in six sessions over 2-3 weeks
223961034|NCT06760663|BEHAVIORAL|The load-velocity relationship: Neuromuscular adaptations to resistance training|Comparing the impact of adjusting training load based on movement velocity on hypertrophy and neural adaptations.
223961035|NCT07081087|DIAGNOSTIC_TEST|PERIBLOOD|In the study, peripheral blood will be taken from all patients, shipped and analyzed at the Weizmann Institute of Science to produce a report based on our technology. The report will contain data on the diagnosis, blast counts and karyotype. This information will be compared with the results from the bone marrow scan, taken separately to each patient, to validate the accuracy of our technology
223961036|NCT06891833|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
223961037|NCT06891833|DRUG|Pertuzumab|Administration by intravenous infusion for a cycle of 3 weeks.
223961038|NCT06748222|BEHAVIORAL|Mindfulness (MAPs) Live Online|"Exercises include breath, body, and sound meditations; eating and walking meditations; managing pain; working with difficult thoughts and emotions; and cultivating loving kindness. Home practice is a key component of MAPs, and participants will be instructed to practice mindfulness techniques daily, beginning with 5 minutes daily and increasing to 20 minutes daily using guided meditations. Attendance in the group sessions and home practice will be tracked to determine dose of the intervention received."
223961039|NCT06748222|BEHAVIORAL|Mindfulness (MAPs) Digital App|"The digital program is sequential with new content and exercises building on previous sessions. Lessons and other materials are gradually unlocked as participants progress through the program. Engagement with the MAPs App will be tracked to determine dose of the intervention received."
223961040|NCT06748222|BEHAVIORAL|Meditation Only Control Group|"Use of the meditations will be tracked to determine dose of the intervention received."
223961041|NCT06583759|PROCEDURE|Full coverage Crowns|The crown will be prepared accordingly. Try in of the best fitted crown will be done and cementation.
223961042|NCT06776783|COMBINATION_PRODUCT|APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)|Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.
223961043|NCT06776783|OTHER|Control|Subjects in the Control group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface but an empty vial will be used instead of APC-0101.
223961044|NCT05907746|DRUG|Mycophenolate Mofetil|15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)
223961045|NCT05907746|DRUG|Tacrolimus|0.02 mg/kg IV daily starting on day +5
223961046|NCT05907746|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg IV daily on days +3 and +4
223542132|NCT04439864|DEVICE|MyIDEA|An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
223542133|NCT02994745|DRUG|Fimasartan, Atorvastatin|
223542134|NCT04106544|PROCEDURE|Investigational Procedures|The investigational assessments will be performed
223961047|NCT05907746|RADIATION|Total Body Irradiation|200cGy on day -1
223961048|NCT05907746|PROCEDURE|Hematopoietic Cell Transplant|stem cell transplant on day 0
223961049|NCT05907746|DRUG|Briquilimab|Single 0.6 mg/kg IV infusion administered between days -13 and day -10
223961050|NCT05907746|DRUG|Cyclophosphamide|14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.
223961051|NCT05907746|DRUG|Fludarabine|30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
223961052|NCT06598592|OTHER|Video-Emergency|Video Emergency Call using a webbased platform
223961053|NCT06598592|OTHER|Audio-Emergency Call|Audio Emergency Call
224109506|NCT06971601|DIAGNOSTIC_TEST|Provocative test|The clinical evaluation specific to Infrapatellar fat pad is based on a series of five standardized clinical tests, extensively described in the specialized literature: provoked palpation of the fat pad, provoked passive extension, Hoffa's test, gliding test, and provoked passive flexion. These tests are performed in a randomized order to limit sequence bias. A test is considered positive if it reproduces the patient's typical anterior knee pain with an intensity greater than 2/10 on the numerical pain scale. Although widely used, these tests have not yet undergone rigorous methodological validation, which this study specifically aims to address.
224109507|NCT06969976|PROCEDURE|curl exericse|we use the curl exercise for control group to investigate the immediate effect of it on muscle strength in normal adults
224109508|NCT06969976|PROCEDURE|dry cupping and curl exercise|use dynamometer to measure biceps muscle strength in normal adults during the application of dry cupping with curl exercise
224109509|NCT06971328|OTHER|ACT-based psychoeducation|It is thought that ACT-based psychoeducation will be an effective psychiatric nursing practice in reducing the care burden of individuals caring for schizophrenia patients and increasing their post-traumatic development and psychological resilience. However, no study has been found in the literature evaluating the effects of these three parameters. In general, the number of ACT-based psychoeducation studies applied to schizophrenia caregivers is quite low. Three thesis studies were found in our country, and no study examining the effect of ACT-based psychoeducation on the post-traumatic development levels of schizophrenia caregivers was found in the domestic and foreign literature. Based on this gap in the literature, the planned study is aimed to be presented to the literature as an intervention that can be used in holistic psychiatric nursing care and to reveal its effects in the specified parameters.
224109510|NCT06971237|DRUG|Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization|"Atezolizumab ± Bevacizumab: Peri-immunotherapy with , with or without bevacizumab, given before and after SIRT.~\- Yttrium-90 Radioembolization: Selective Internal Radiation Therapy (SIRT) via intra-arterial injection of Yttrium-90 microspheres for liver tumor control"
224109511|NCT06971237|DRUG|Atezolizumab ± Bevacizumab|Standard systemic immunotherapy administered without SIRT, using atezolizumab with or without bevacizumab.
224109512|NCT03897491|DRUG|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
224109513|NCT06971965|DRUG|Levothyroxin|During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for the group's target TSH range.
224109514|NCT06970132|DRUG|SY-5933|KRAS p.G12C inhibitor
224109515|NCT06970132|DRUG|CT-707|Focal Adhesion Kinase (FAK) inhibitor
224109516|NCT06971575|DIAGNOSTIC_TEST|Magnetic resonance neurography|Patients will undergo a cervical MRI with specialized magnetic resonance neurography sequences to evaluate the extraforaminal cervical nerve roots.
224109517|NCT06971770|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224109518|NCT06964867|OTHER|Multimedia Health Education|Multimedia health education was designed as an intervention. This intervention was administered by a single vitreoretinal specialist with over a decade of clinical experience. This standardized protocol comprised a 30-minute didactic session utilizing power point presentations (PPT), systematically covering: 1) Etiopathogenesis: Molecular mechanisms of vitreous syneresis and collagen aggregation; 2) Symptomatology: Characteristic visual phenomena and differential diagnosis; 3) Therapeutic modalities: Evidence hierarchy from observation to vitrectomy (including Nd:YAG laser efficacy controversies); 4) Follow-up necessity: Red flag symptoms warranting urgent re-evaluation (sudden floaters with photopsia)
224109519|NCT05341466|OTHER|Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
224109520|NCT05341466|OTHER|SHAM Acute Intermittent Hypoxia|5 consecutive days of 15, 1.5 min episodes at 21% O2 (SHAM AIH) alternating with 21% O2 at 1 min intervals
224109521|NCT05161468|DRUG|Lidocaine injection|2ml of 1% lidocaine will be drawn into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
223961054|NCT07081841|OTHER|Observation|This is an observational study in which safety laboratories and non-invasive routine clinical assessments are conducted to gauge long term safety and efficacy.
223961055|NCT06903572|OTHER|the clinical pharmacists interventions about medication related information during transition of care|the intervention is the clinical pharmacists ' interventions regarding medication related information during transition of care .This includes reviewing medications regimen and treatment plan , documenting patients' drug history, drug related adverse events and detecting medication discrepancies.
223961056|NCT06142513|OTHER|Assessment|Between December 2023 and June 204, 46 volunteer participants aged 18 years and older who met the inclusion criteria and were followed up at Istanbul University, Istanbul Faculty of Medicine, Department of Chest Diseases and Istanbul Faculty of Medicine, Department of Internal Medicine were included in the project. Participants' body composition, comorbidities, exercise capacity, peripheral muscle strength, sleep quality and quality of life were assessed.
223961057|NCT05517213|DRUG|Etoposide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
223961058|NCT05517213|DRUG|Cyclophosphamide|Chemotherapy combined with rhG-CSF is widely used in autologous hematopoietic stem cell mobilization programs. For patients who do not meet the criteria of stem cell collection, they can be mobilized again after 1 month of rest. Chemotherapy +rhG-CSF mobilization or rhG-CSF+ ploxafo steady-state mobilization can be used.
223961059|NCT06004245|DRUG|RO7589831|RO7589831 will be administered orally and once daily (QD) in 3-week cycles.
224109522|NCT05161468|DRUG|Corticosteroid Injection|1 ml of triamcinolone acetonide (40 mg/ml) will be drawn with 1 ml normal saline into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
224109523|NCT05161468|DRUG|Protein Rich Plasma(PRP) Injection|30 ml of acid-citrate-dextrose (ACD) will be drawn into a 30 ml syringe to coat the syringe. 3 ml will be left in the syringe and then 27 ml of blood will be drawn via standard venipuncture. The 30 ml mixture of blood and ACD will then be prepared in the Peak PRP system as described in the manufacturer's instruction (PEAK® PRP System). After preparation, PRP will be withdrawn (2 mls) into a 3 ml syringe and labeled. It will then be delivered into the AC joint per standard injection procedures (estimated 1-2 ml).
224109524|NCT05542342|DRUG|Tislelizumab|200 mg IV once every 3 weeks
224109525|NCT05542342|DRUG|Sitravatinib Malate|100 mg orally once daily
224109526|NCT00278824|DRUG|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
224109527|NCT00278824|DRUG|Placebo Patch|Placebo patch applied every 3 days for 15 days
224109528|NCT06007170|DEVICE|SPIRION Laryngeal Pacemaker System Implantation and follow-up|"Timeline of Visits~* Screening~* Baseline: Official baseline, assessment primary \& secondary objectives~* Implantation of device~* Activation \& fitting: Baseline active device; implanted device has just been activated; assessment of secondary objectives only~* 8 FU Visits over 2 years after activation; Includes~  * Baseline Switch Off: results of the visit preceding a 14-day switch-off of the device; assessment of secondary objectives only~ * Endpoints for~    * Pivotal phase: 12 months after activation; official endpoint for assessment of primary \& secondary objectives~   * Active post-pivotal phase: 24-month follow-up; endpoint for all secondary objectives~   * Switch Off: 2 Visits; assessment of secondary objectives only~ * Repeated checkpoints to assess device effects over 2 years: 5 visits; assessment of secondary objectives only Device shall increase respiratory patency during inspiration, assessed by normalized PIF; other outcome measures are used to assess secondary objectives"
224109529|NCT06277661|BEHAVIORAL|MOMI PODS|MOMI PODS is an innovative, dyadic model of PP primary care. Informed by the Chronic Care Model (CCM) and extensive stakeholder engagement, the MOMI PODS suite of services addresses four primary domains, with a focus on preventing PRM and eliminating SES, racial, and ethnic disparities in PRM. First, MOMI PODS is a dyadic model of care, with mothers and infants cared for in tandem throughout the PP year, and beyond. Second, MOMI PODS was strategically designed to facilitate a coordinated obstetric to PP primary care transition. Third, MOMI PODS is delivered in a way that promotes tailored, evidence-based care informed by the obstetric history. Fourth, MOMI PODS systematically integrates clinical and supportive care to concurrently address clinical and psychosocial needs, with MOMI PODS engagement extending beyond the typical referral process to facilitate direct access to needed resources and empower patients.
224109530|NCT06277661|BEHAVIORAL|Enhanced Usual Care (EUC)|Usual care will be enhanced in by implementing an enhanced PP care handoff as an adaptation of typical institutional discharge procedures. Specifically, under current processes, birthing parents are asked to provide the name of their infant's pediatrician during the L\&D admission, must provide the name of their infant's pediatrician prior to discharge, and are assisted with identifying a pediatrician throughout this process as needed. Alternatively, under current processes, mothers are reminded to seek PP care but not required to identify the location of care or assisted with doing so. As a component of EUC, we'll provide participants with information about our 7 EUC sites and actively assist with identifying their preferred location of care and scheduling PP care. Our research team will also engage with EUC recipients throughout the study period to encourage engagement and study retention through small care packages and hand-written notes, as well as data collection.
224109531|NCT05514665|DEVICE|Diffuse Optical Tomography|Neonates once hemodynamically stable will undergo diffuse optical tomography measurements of functional brain connectivity at the bedside within 3-7 days after birth.
224109532|NCT03708900|DRUG|LCI699|osilodrostat (LCI699) is in the form of tablets 1 milligram (mg), 5 mg, and 10mg or in form of capsules 0.1 mg, 0.2 mg, 0.5 mg, 1 mg or 5 mg, both the formulations for oral administration
224109533|NCT03291379|DRUG|BTG-002814|BTG-002814 containing 100 mg vandetanib
224109534|NCT05954754|OTHER|Diaphragmatic Breathing Exercises|Diaphragmatic breathing exercise training was given individually to each pregnant women in the experimental group by one of the trained researchers. Two weeks after the first application, the researcher made the pregnant woman repeat the application 2 days a week via video call. Thus, a total of five diaphragmatic breathing exercises were applied to pregnant women in the experimental group during two weeks. They continued to do breathing exercises for 20-30 minutes a day for ten minutes each day for two weeks as they could tolerate.
224109535|NCT02603575|DRUG|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
224109536|NCT02603575|DRUG|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
224109537|NCT02603575|DRUG|Sulfanilamides|1.92g q8h
224109538|NCT05149378|DRUG|Venetoclax combined with azacitidine regimen|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
224109539|NCT06219252|DEVICE|Intraoperative aberrometer|the patient intraocular lens will be optimized during the aphakic period after cataract extraction and before intraocular lens implantation, this will produce a possible change in the dioptric power of the intraocular lens
223724366|NCT04497506|BEHAVIORAL|Wise Intervention (Self-affirmation and Incremental theory of personality)|The intervention designed to promote prosocial behavior and reduce online risks is based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. It includes two components: a self-affirmation activity and an ITP intervention. The SA component includes a list of values so that they could choose the two or three most important for them. Next, they are asked to write why those selected values are the most important to them. The ITP component includes activities such as reading scientific information about social behavior and its role in people's well-being, the meaning and value of online risk behaviors through stories and videos of the experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change.
224109540|NCT06219252|OTHER|Preoperative intraocular lens calculation|the intraocular lens in this group will be calculated preoperatively with Barrett Universal II formula
224109541|NCT04617288|OTHER|Ultrasound Therapy, SNAGs|
224109542|NCT02450357|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
223961060|NCT06004245|DRUG|Pembrolizumab|Pembrolizumab will be administered by intravenous (IV) infusion at a fixed dose of 200 mg on Day 1 of each 21-day cycle.
224109543|NCT02450357|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
224109544|NCT00097266|DRUG|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
223961061|NCT07092280|DEVICE|Active tDCS|Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation method used to modulate cortical excitability, which produces facilitatory or inhibitory effects on behaviors. The anodal electrode will be positioned at F3 (using the international 10-20 EEG system) to target the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will undergo 20 active stimulation sessions, each lasting 20 minutes at a continuous 1.0 mA intensity.
223961062|NCT07092280|DEVICE|Sham (No Treatment)|The anodal electrode will be positioned at F3 (according to the international 10-20 EEG system), targeting the left dorsolateral prefrontal cortex (DLPFC). The cathodal electrode will be placed over the right DLPFC. Participants will receive 20 sessions of sham stimulation, each 20 minutes long. At the start of each session, the current ramps up and remains active for 30 seconds. After 30 seconds, the current is DISCONTINUED (held at 0 mA) but the power indicator stays illuminated for the remainder of the 20-minute session to ensure effective blinding, as is standard in tDCS sham protocols
223961063|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
224109545|NCT00097266|DRUG|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
224109546|NCT00097266|DRUG|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
224109547|NCT03489291|GENETIC|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
224109548|NCT03195790|BEHAVIORAL|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
223961064|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 1.1 Usage|Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.
223961065|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
223961066|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 2.1 Usage|Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.
224109549|NCT05621512|OTHER|Preventive sessions|Preventive sessions between the pregnant employee, her manager and a midwife.
224109550|NCT05717322|BEHAVIORAL|TENS|apply TENS after orthognathic surgery
224109551|NCT05717322|BEHAVIORAL|sham TENS|apply non active TENS after orthognathic surgery
223961067|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
223542135|NCT00827177|DRUG|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If \< 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
223961068|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.1 Usage|Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.
224109552|NCT06969950|OTHER|App-Delivered Mindfulness Training (MT).|The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based for two weeks
224109553|NCT06969950|OTHER|Online Virtual Training|A sub-group of 25 participants, either from the both intervention or control group, the will receive a virtual online training delivered via zoom calls. It is a group session program which includes 4 mindfulness-based sessions of about 60 minutes of brief didactic and experience-based for four weeks.
223961069|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 3.2 Usage|Participants will use their Radicle Clarity Active Study Product 3.2 as directed for a period of 6 weeks.
223961070|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
223961071|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 4.1 Usage|Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.
223542136|NCT03842267|DRUG|Gemigliptin 50mg|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
223961072|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 5|Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
223961073|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.1 Usage|Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.
223961074|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 5.2 Usage|Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
223961075|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control Form 6|Participants will use their Placebo Control Form 6 as directed for a period of 6 weeks.
223961076|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1 as directed for a period of 6 weeks.
223961077|NCT06294431|DIETARY_SUPPLEMENT|Placebo Control 6.1.0|Participants will use their Placebo Control 6.1.0 as directed for a period of 6 weeks.
223542137|NCT03842267|DRUG|Gemigliptin Placebo|"* The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* \- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~* Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~  1. Dapagliflozin 10 mg / day~ 2. Metformin ≥ 1,000 mg / day"
223961078|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1.1 Usage|Participants will use their Radicle Clarity Active Study Product 6.1.1 as directed for a period of 6 weeks.
223961079|NCT06294431|DIETARY_SUPPLEMENT|Clarity Active Study Product 6.1.2 Usage|Participants will use their Radicle Clarity Active Study Product 6.1.2 as directed for a period of 6 weeks.
223961080|NCT07136012|DRUG|Olpasiran|Olpasiran will be administered via SC injection.
223961081|NCT07136012|DRUG|Placebo|Placebo will be administered via SC injection.
223961082|NCT06813911|DRUG|Pelacarsen|Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.
223961083|NCT06813911|DRUG|Placebo|Placebo will be provided as solution for injection in prefilled syringe for subcutaneous injection.
223961084|NCT06813911|DRUG|Inclisiran|All participants will be administered two loading doses of inclisiran as background treatment at Run-in 1 and Run-in 2, separated by 3 months, according to the approved label. After that inclisiran will be administered every 6 months, i.e., Month 5 and Month 11.
223961085|NCT04451668|DRUG|FT218|once nightly sodium oxybate extended release
223961086|NCT07100483|PROCEDURE|Atrial Fibrillation Ablation|Ablation of the heart to reduce Afib Occurrence
223961087|NCT04524871|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV on Day 1 of each 21 day cycle.
223961088|NCT04524871|DRUG|Bevacizumab 15 mg/kg|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21 day cycle.
223961089|NCT04524871|DRUG|Tiragolumab|Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
223961090|NCT04524871|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 8 mg/kg by IV infusion on Day 1 of each 21 day cycle.
223961091|NCT04524871|DRUG|TPST-1120|TPST-1120 will be administered at a dose of 1200 mg by mouth on Days 1-21 of each 21 day cycle.
223961092|NCT04524871|DRUG|Tobemstomig 2100 mg|Tobemstomig will be administered at a dose of 2100 mg by IV infusion on Days 1 and 15 of each 28 day cycle.
223961093|NCT04524871|DRUG|Bevacizumab 10 mg/kg|Bevacizumab will be administered at a dose of 10 mg/kg by IV infusion on Days 1 and 15 of each 28 day cycle.
223961094|NCT04524871|DRUG|Tobemstomig 600 mg|Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
223961095|NCT04524871|DRUG|Tobemstomig 1200 mg|Tobemstomig will be administered at a dose of 1200 mg every 3 weeks.
223961096|NCT04524871|DRUG|ADG126|ADG126 will be administered at a dose of 6 mg/kg by IV infusion on Day 1 of every other cycle (cycle length = 21 days).
223961097|NCT04524871|DRUG|IO-108 1800 mg|IO-108 will be administered at a dose 1800 mg by IV infusion on Day 1 of each 21 day cycle.
223961098|NCT04524871|DRUG|NKT2152|NKT2152 will be administered by mouth.
223961099|NCT04524871|DRUG|IO-108 1200 mg|IO-108 will be administered at a dose 1200 mg by IV infusion on Day 1 of each 21 day cycle.
223961100|NCT04250766|PROCEDURE|Echo-guided uterine biopsy|"Echo-guided uterine biopsy will be performed by a specialized radiologist by transvaginal and exclusive transuterine approach. 4 to 5 samples will be made.~Local anesthesia will be performed. A pain assessment will be performed during the biopsy (visual or verbal scale)."
223961101|NCT07104500|DRUG|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
223961102|NCT06915025|DRUG|IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)|100 mg/m2 IP given weekly during frontline treatment
223961103|NCT06915025|DRUG|Paclitaxel|175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment
223961104|NCT06915025|DRUG|Carboplatin|AUC 6 IV given every 21 days for 6 cycles during frontline treatment
223961105|NCT06915025|DRUG|Olaparib|Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.
223961106|NCT06915025|DRUG|Niraparib|Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \& HRD/BRCAwt.
223961107|NCT07104032|DRUG|Tirabrutinib|Administered orally.
223961108|NCT07104032|DRUG|Rituximab|Administered intravenously (IV).
223961109|NCT07104032|DRUG|Temozolomide|Administered orally.
223961110|NCT06029517|OTHER|Education Intervention|Receive Indigneous SIPin intervention
223961111|NCT06029517|OTHER|Interview|Complete interviews
223961112|NCT06029517|PROCEDURE|Discussion|Attend focus groups
223961113|NCT04143724|DRUG|ACE-536|Specified dose on specified days
223961114|NCT07107139|OTHER|Copenhagen group|Participants use product for up to 30 minutes
223961115|NCT07107139|OTHER|Snus group|Participants use product for up to 30 minutes
223961116|NCT05333471|DRUG|MTP 101-LF|Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
223961117|NCT05142345|OTHER|CONTINUUM Intervention|The intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consists of a video visit conducted by an oncology nurse practitioner within three business days of hospital discharge, to: (1) reconcile medications, (2) manage symptoms, (3) review the post-hospital care plan for hospitalization-specific issues, and (4) schedule follow-up with the outpatient oncology team.
223961118|NCT05142345|OTHER|Usual Care|Patients assigned to the usual care group will have their post-discharge follow-up scheduled per hospital, outpatient oncology team, and patient preference.
223961119|NCT06918990|BIOLOGICAL|Carfilzomib|Administered by intravenous infusion over 60 minutes.
223961120|NCT06918990|BIOLOGICAL|Belatacept|Administered by intravenous infusion over 30 minutes.
223961121|NCT07107321|BEHAVIORAL|WISE Words|WISE Words is a co-designed, multicomponent deimplementation strategy package including 6 discrete strategies. Of these, three are delivered in a standard fashion: (1) dynamic training driven by improvisation methods, (2) a peer learning collaborative, and (3) external facilitation. The additional three are tailored to each educator's preferences and goals: (4) reminders, (5) educational materials, and (6) audit and feedback. Educators are supported to set and achieve goals for one feeding practice they want to stop and one they want to start.
223961122|NCT07110376|OTHER|Nighttime Deep Brain Stimulation with Varying Amplitude Settings|Participants will undergo three different nighttime-only Deep Brain Stimulation (DBS) settings in a randomized crossover design: 0% amplitude (stimulation off), 50% amplitude of their optimal clinical DBS settings, and full clinical DBS settings (100%). Each setting is applied for two weeks during sleep, over a total six-week home monitoring period. The intervention is designed to assess how varying levels of subthalamic nucleus DBS influence sleep quality and neural oscillatory activity. Only nighttime DBS settings are modified; daytime settings remain unchanged.
223961123|NCT07204561|OTHER|CeraVe Moisturizing Cream|During the 42-day maintenance phase, subjects must apply the CeraVe emollient twice a day after washing with the basic detergent as part of their normal hygiene routine.
223961124|NCT07204561|OTHER|Galenico|During the 42-day maintenance phase, subjects must apply the emollient twice a day after washing with the basic detergent as part of their normal hygiene routine.
223961125|NCT07203222|DEVICE|Low Dose Laser|Patients with subacromial-subdeltoid bursa, m. deltoideus, m. biceps longus, m. infraspinatus, and m. supraspinatus muscles (at the most painful point of the muscles) with a 13-diode Gallium-Aluminium-Arsenide laser device (Intelect Mobile Laser) with a wavelength of 850 nm and 50 mW, 4 Joules per day, 20 seconds, for a total of 15 laser sessions.
223961126|NCT07203222|DEVICE|TENS|TENS therapy will be administered using the TENS device (Intelect Advanced Therapy System) for a total of 15 sessions, 5 days a week, 20 minutes per day, at a dose of 20-40 mA.
223961127|NCT07203222|OTHER|Conventional physical therapy|Only conventional physiotherapy is planned to be administered to patients.
223961128|NCT07204522|DRUG|Carbapenems|First-line empirical agent for febrile neutropenia complicating hematologic malignancies: carbapenem.
223961129|NCT07204522|DRUG|Anti-Gram-positive agent|Escalation to a carbapenem plus an anti-Gram-positive agent (vancomycin or linezolid) is instituted if no defervescence occurs after 48h of first-line therapy; this combination is maintained for 3 days before further escalation in febrile-neutropenia patients with underlying hematologic malignancies.
223961130|NCT07204522|DRUG|Antifungal agent|If combination therapy with a carbapenem plus an anti-Gram-positive agent (vancomycin or linezolid) remains ineffective after 72 h, empirical antifungal coverage is added while continuing antibacterial therapy for an additional 7 days; failure to defervesce thereafter mandates further therapeutic escalation in febrile-neutropenic patients with hematologic malignancies.
223961131|NCT07204522|DRUG|Ceftazidime-avibactam + Aztreonam|If the combination of a carbapenem and an anti-Gram-positive agent (vancomycin or linezolid) fails to achieve defervescence after 3 days of treatment, an antifungal agent is added while continuing the original antibacterial regimen for an additional 7 days. Should fever persist or recur with uncontrolled infection-related parameters after 12-14 days of empirical anti-infective therapy, the carbapenem/anti-Gram-positive combination is discontinued. Therapy is then switched to ceftazidime-avibactam plus aztreonam to cover multidrug-resistant pathogens, while concurrently maintaining antifungal treatment. This escalation strategy is indicated for febrile neutropenic patients with underlying hematologic malignancies.
223961132|NCT07204678|DEVICE|PRECISE PRO Rx Nitinol Stent System|The Cordis PRECISE PRO Rx Nitinol Stent System is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the carotid artery(ies). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The Cordis PRECISE PRO Rx Nitinol Stent System is indicated for use in patients with stenotic lesions of the carotid artery(ies).
223542138|NCT02351492|PROCEDURE|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
223542139|NCT02351492|PROCEDURE|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
224109554|NCT00153166|DRUG|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
224109555|NCT00153166|DRUG|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
224109556|NCT00153166|DRUG|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
224109557|NCT00153166|DRUG|placebo/placebo|placebo orally three times daily
224109558|NCT01462292|DRUG|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
224109559|NCT01462292|DRUG|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
223961133|NCT07204106|DRUG|Dexmedetomidine Injection (nasal spray) + Propofol Injection + Sufentanil Injection|"1. Preoperative intervention：30 minutes before entering the operating room, 50-100μg of Dexmedetomidine Injection is administered via nasal spray in the anesthesia preparation room.~2. Induction phase：Intravenous injection of Sufentanil Injection (Yichang Renfu Pharmaceutical Co., Ltd.) at a dose of 0.1μg/kg, and Propofol Injection (Jiabo Pharmaceutical, Guangdong, China) at a dose of 1.5-2.0mg/kg (injection time \>30 seconds). During induction, the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/s) score is evaluated every 30±10 seconds; if MOAA/s \>1 after 2 minutes, an additional sedative dose (1/2 of the initial dose, injection time ≥10 seconds) is supplemented until MOAA/s ≤1.~3. Maintenance phase：Continuous intravenous infusion of Propofol Injection at a rate of 4-12mg/kg/h; the dose is adjusted according to Bispectral Index (BIS) to maintain BIS between 40-60. If the patient shows body movement, eye opening, speech or other signs of insufficient se"
223961134|NCT07204106|DRUG|Normal Saline (nasal spray) + Dexmedetomidine Injection (intravenous) + Propofol Injection + Sufentanil Injection|"1. Preoperative intervention：30 minutes before entering the operating room, normal saline is administered via nasal spray in the anesthesia preparation room; 10 minutes before induction, 0.5μg/kg of Dexmedetomidine Injection is given via intravenous injection.~2. Induction phase：Same as Experimental Group ① (intravenous Sufentanil 0.1μg/kg + Propofol 1.5-2.0mg/kg, with MOAA/s monitoring and supplementary dose rules).~3. Maintenance phase：Same as Experimental Group ① (continuous Propofol infusion at 4-12mg/kg/h, BIS-adjusted dose, and supplementary sedation rules for insufficient sedation)."
223961135|NCT07204106|DRUG|Regular sedation protocol|"Preoperative intervention：No dexmedetomidine or normal saline nasal spray; only routine preoperative preparation.~Induction phase：Same as Experimental Group ① (intravenous Sufentanil 0.1μg/kg + Propofol 1.5-2.0mg/kg, with MOAA/s monitoring and supplementary dose rules).~Maintenance phase：Same as Experimental Group ① (continuous Propofol infusion at 4-12mg/kg/h, BIS-adjusted dose, and supplementary sedation rules for insufficient sedation)."
223961136|NCT07203131|DIAGNOSTIC_TEST|Urine sample|5 mL of urine when the patient is admitted in intensive care To look for possible acute renal failure in the patient
223961137|NCT07203131|OTHER|Phone call at day 28|"It will allow the following information to be collected:~* Post-resuscitation monitoring and length of hospitalization,~* Vital status,~* Collection of adverse events,~* Concomitant treatments."
223961138|NCT07203352|DRUG|targeted drug|Patients randomly assigned to the control group will receive standard chemotherapy treatment, but they cannot use targeted drugs in combination.The subjects randomly assigned to the experimental group received targeted drug treatment in addition to the chemotherapy regimen during the second course. Based on the results of bone marrow PCR, subjects with molecular typing of ABL1/ABL2/PDGFRB fusion were to receive chemotherapy combined with dasatinib 100mg orally once a day; subjects with molecular typing of FLT3-ITD positive were to receive chemotherapy combined with sorafenib 400mg orally twice a day.
224109560|NCT01462292|DRUG|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
224109561|NCT01462292|DRUG|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
224109562|NCT00495846|DRUG|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
224109563|NCT00495846|OTHER|Locoregional treatments|
224109564|NCT00997685|DRUG|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
223542140|NCT02351492|DEVICE|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
223542141|NCT02351492|DEVICE|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
223542142|NCT01100112|DRUG|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
223542143|NCT05411107|PROCEDURE|Biospecimen Collection|Undergo collection of sputum sample
224109565|NCT04211324|DEVICE|TENS|Volunteers in this group (n=50) will receive only one session of 5-minute extra-oral TENS applied on bilateral parotid gland with 50 HZ frequency and pulse duration 250 µs.
223542144|NCT05411107|PROCEDURE|Bronchial Brush Biopsy|Undergo bronchial brush biopsy
223542145|NCT05411107|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
223542146|NCT05411107|DRUG|Iloprost|Given PO
223542147|NCT05411107|DRUG|Placebo Administration|Given PO
224109566|NCT04211324|DEVICE|electro-acupuncture|Volunteers in this group (n=50) will receive only one session of 5-minute electro-acupuncture on local acu-points St4 and St 7 bilateraly with 2 HZ frequency.
224109567|NCT02827552|OTHER|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
224109568|NCT04387474|DEVICE|Brain-computer interface|brain-computer interface rehabilitation training.
224109569|NCT04387474|OTHER|Traditional rehabilitation|traditional rehabilitation training.
223542148|NCT05411107|OTHER|Questionnaire Administration|Ancillary studies
223542149|NCT05975346|DRUG|Ketamine|description
223542150|NCT05975346|OTHER|saline nebulization|description
224109570|NCT03993743|BIOLOGICAL|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
223542151|NCT00616642|DRUG|rosiglitazone maleate|Given orally
223542152|NCT00886418|DRUG|muscle relaxant|muscle relaxant administration throughout anesthesia
223542153|NCT00886418|DRUG|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
223961139|NCT07203118|DRUG|HTS 20mg|Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
223961140|NCT07203118|DRUG|HTS 30mg|Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
223961141|NCT07203118|DRUG|HTS 40mg|Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
223961142|NCT07203118|DRUG|TAF 25mg|Once daily, administered concomitantly with one HTS placebo tablet per dose, taken once daily with or within 30 minutes after a meal.
223961143|NCT07203313|BEHAVIORAL|Digital PE teaching app|Pocket PE 3-5 is a digital app designed for 3rd - 5th grade teachers and students. It works across common platforms and devices, online and offline, and provides simple, easy to use, standards-based PE lesson activities tailored by time, instructional setting (classroom, gym, outside), grade, student skill level, and equipment resources. The app is low-cost and includes brief teacher and student skill demonstration videos for each activity, along with printable activity cards, music, and audio cues to signal transitions to assist teachers in class management with students in real time during PE. The program also includes embedded data tracking of PE minutes and completed instructional standards to assist with school and/or state mandated reporting.
223961144|NCT07204691|DEVICE|DKL crosslinked sodium hyaluronate 20 mg/mL + Lidocaine 0.3% dermal filler|DKL crosslinked sodium hyaluronate 20 mg/mL + lidocaine 0.3% dermal filler is an injectable sterile, non-pyrogenic gel composed of crosslinked sodium hyaluronate of a non-animal origin and lidocaine in a phosphate-buffered saline solution.
223961145|NCT07204262|COMBINATION_PRODUCT|Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)|Patients in this study received systemic therapy with molecular targeted agents, including tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies, and/or PD-(L)1 inhibitor immunotherapy. Some patients also received interventional therapies such as transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). Treatment regimens, combinations, and sequencing were determined based on physician discretion and patient clinical status. This study focuses on the longitudinal monitoring of biomarkers during these therapies to evaluate their prognostic value and to develop a trajectory-based risk stratification model for advanced hepatocellular carcinoma (HCC).
223961146|NCT05966051|BEHAVIORAL|Educational interventions|The educational interventions will consist in:
223961147|NCT05296564|DRUG|CYCLOPHOSPHAMIDE and FLUDARABIN|1\. CYCLOPHOSPHAMIDE 250 mg/msq, Day -5,-4,-3 with FLUDARABIN 25 mg/msq, Day -5,-4,-3
223961148|NCT05296564|DRUG|Cyclophosphamide|CYCLOPHOSPHAMIDE 250 mg/msq, Day -6, -5,-4,-3
223961149|NCT05296564|BIOLOGICAL|HBI 0201-ESO TCRT|HBI 0201-ESO TCRT will be infused on Day 0, after lymphodepletion. Three dose levels will be evaluated: 1x10E9, 5x10E9 and 1x10E10.
223961150|NCT05296564|DRUG|Aldesleukin|Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
223961151|NCT03556891|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
223961152|NCT04396860|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced brain MRI
223961153|NCT04396860|BIOLOGICAL|Ipilimumab|Given IV
223961154|NCT04396860|BIOLOGICAL|Nivolumab|Given IV
223961155|NCT04396860|DEVICE|NovoTTF-100A Device|Wear Optune device
223961156|NCT04396860|OTHER|Quality-of-Life Assessment|Ancillary studies
223961157|NCT04396860|OTHER|Questionnaire Administration|Ancillary studies
223961158|NCT04396860|RADIATION|Radiation Therapy|Undergo radiation therapy
223961159|NCT04396860|DRUG|Temozolomide|Given PO
223961160|NCT06439121|PROCEDURE|4-7-8 Breathing Technique|Patients will be instructed to practice the 4-7-8 breathing technique once per hour (4 breaths) post-surgery. Pain and nausea-vomiting will be monitored at 0, 2, 6, 12, and 24 hours during their 24-hour hospital stay.
223961161|NCT06182709|BEHAVIORAL|online psychoeducation video + modeled exposure|Participants will watch a short psychoeducation video online. This will be followed by a modeled exposure online. In this modeled exposure participants watch a film of an exposure treatment (about 45min) conducted with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
223961162|NCT06182709|BEHAVIORAL|live psychoeducation video + modeled exposure|Participants will watch a short psychoeducation video. This will be followed by a live modeled exposure. In this modeled exposure participants watch an exposure treatment (about 45min) conducted live with one participant and the therapist. The exposure training consists of five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to four times: 2,4,5).
224109571|NCT04710940|BEHAVIORAL|Diabetes BOOST|Participants will receive supportive care using technology for DSMT in addition to usual care.
224109572|NCT04710940|BEHAVIORAL|Usual Care|Participants will receive usual care for DSMT.
224109573|NCT03992300|DEVICE|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
224109574|NCT02226510|DRUG|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
224109575|NCT02226510|DRUG|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
224109576|NCT03997630|DEVICE|High flow Oxygenation|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
224109577|NCT03997630|DEVICE|Standard oxygen|Control group: All patients included in this group will receive a low flow oxygenation (flow rate \< 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
223961163|NCT06182709|BEHAVIORAL|group exposure|Exposure training in the group is conducted live (1 spider per participant, one therapist and co-trainers). In this group exposure participants complete exposure training (about 45 min) with five exposure steps (step 1: describing the spider, step 2: catching the spider with a glass, step 3: describing the spider, step 4: touching the spider with the dominant index finger, step 5: letting the spider walk on the participant hands; the following steps have to be repeated up to three times: 2,4,5).
223961164|NCT06182709|BEHAVIORAL|mental retrieval cue|Before the group exposure, participants are asked to remember the modeled exposure they had observed the day before. Therefore, the participants are asked to recall the location where they have been during the modeled exposure and the reaction of the patient during the exposure (e.g., fear decline).
223961165|NCT05499052|DRUG|REKOVELLE®|"Subjects must be treated according to the routine clinical practice and REKOVELLE® must be prescribed in accordance with the terms of the marketing authorisation of each participating country.~According to the label the REKOVELLE® dose should be based on a recent determination of body weight and a recent determination of Anti-Müllerian Hormone (AMH) (i.e. within the last 12 months) measured by the following diagnostic tests: ELECSYS AMH Plus immunoassay from Roche or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio."
223961166|NCT04994314|DRUG|nCaF2 primer|Calcium fluoride nanoparticles was added to conventional orthodontic primers to develop bioactive primer. This primer was examined previously for its biological and physical properties
223961167|NCT04994314|DRUG|Control primer|Conventional orthodontic primer
223961168|NCT02010021|DRUG|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
223961169|NCT03456206|OTHER|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile \[33.3% of the total sample\]) and high intake of red and processed meat (defined as those above the upper tertile \[33.3% of the total sample\]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
223961170|NCT03456206|OTHER|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
223961171|NCT01551121|OTHER|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
223961172|NCT06524830|DRUG|VLS-01-203 BU|VLS-01 buccal transmucosal administration
223961173|NCT06524830|DRUG|VLS-01-BU Placebo|Placebo buccal transmucosal administration
224109578|NCT01145391|OTHER|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
224109579|NCT04606511|DIAGNOSTIC_TEST|Circumference tape measurements|centimeter and volume criterias
224109580|NCT04606511|DIAGNOSTIC_TEST|Indocyanine green lymphangiography|Presence of dermal backflow
224109581|NCT04606511|DIAGNOSTIC_TEST|bioimpedance spectroscopy|7.5 and 10 L-DEX criterias
224109582|NCT04606511|DIAGNOSTIC_TEST|Symptom score|using lymph-icf, DASH and SF-36 questionnaires
223961174|NCT05718063|BEHAVIORAL|MAP for Coaches - Complete Course|The MAP for Coaches is an eLearning (web-based) knowledge translation training course aimed at providing youth sport coaches with the evidence-based education and motivation they need to reduce the risk of musculoskeletal injuries in young athletes. Course modules include a description of: (1) musculoskeletal injuries in youth sport; (2) the importance of injury prevention, and instructions on: (1) applying best practices for musculoskeletal athletic injury prevention, including neuromuscular training programs; (2) using behavioral strategies to successfully implement neuromuscular training warm-up programs in coaching sessions.
223961175|NCT05718063|BEHAVIORAL|Map for Coaches - Overview|This is a summarized version of the MAP for Coaches. It comprises a 2-page sport-specific injury prevention e-book (reading) containing an overview of the MAP for Coaches training and an infographic summary.
223961176|NCT04543591|BIOLOGICAL|Ravulizumab|Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
223961177|NCT04543591|OTHER|Placebo|Matching placebo
223961178|NCT04543591|OTHER|Best supportive care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
223961179|NCT06800157|DRUG|Drug: LW402|Oral tablets administered BID
223961180|NCT06800157|DRUG|Other: placebo|Placebo to match LW402 administered BID
223961181|NCT06800157|DRUG|MTX|Background treatment with MTX once a week
223961182|NCT03419754|DIETARY_SUPPLEMENT|Glucose|Glucose
223961183|NCT03419754|BEHAVIORAL|Fidgetting|low intensity physical activity (fidgetting)
223961184|NCT02062827|BIOLOGICAL|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
223961185|NCT05733598|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
223961186|NCT05733598|BIOLOGICAL|Bevacizumab|Anti-VEGF therapy.
223961187|NCT05733598|BIOLOGICAL|Atezolizumab|Anti-PD-L1 monoclonal antibody.
223961188|NCT05733598|BIOLOGICAL|Durvalumab|Anti-PD-L1 monoclonal antibody
223961189|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fed state
223961190|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as tablet in fasted state
223961191|NCT02161432|DRUG|BI 187004|single dose BI 187004 given as oral solution
223542154|NCT04340492|OTHER|Education to Adapted Physical Activity|4 group sessions (5 patients) aiming at promoting physical activity, the first three focusing respectively on endurance, posture and balance and power re-enforcement at one-week interval. A fourth session, 3 months latter is a consolidating session aiming at identify and overcome obstacles to practice physical activity in everyday life.
223542155|NCT04340492|OTHER|Standard care|Standard care concerning Parkinson's disease and physical activity
223961192|NCT05444959|DIETARY_SUPPLEMENT|HMB supplementation|Group taking oral HMB free acid supplementation in a blinded liquid form.
223961193|NCT05444959|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (in a blinded liquid form).
223961194|NCT06451705|DRUG|PECS II block|Treatment group that received the PECS II block using isobaric bupivacaine 0.5% 50 mg
223961195|NCT06451705|DRUG|LIA|Treatment group that received the local infiltration anesthesia using isobaric bupivacaine 0.5% 50 mg
223961196|NCT04928235|DIAGNOSTIC_TEST|Thermal Imaging as Diagnostic Adjunct|Thermal images of the participants lower extremities will be taken and skin surface temperature values will be provided to the healthcare provider for review during the emergency department encounter.
223542156|NCT06352697|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
223542157|NCT06352697|DIETARY_SUPPLEMENT|Placebo|Placebo
223542158|NCT03391986|DEVICE|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
223542159|NCT03391986|PROCEDURE|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
223961197|NCT04057677|BEHAVIORAL|Bed Rest Intervention|The participant will remain in bed rest for 10 days at the clinical research unit at TRI, AdventHealth, Orlando.
223961198|NCT04057677|BEHAVIORAL|Exercise Program|During the first 4 weeks following bed rest, participants will perform a combination of aerobic and resistance exercise training with a certified exercise physiologist 3 days per week at the TRI exercise training facility.
223961199|NCT05587491|DEVICE|Hybrid Argonplasma coagulation (HAPC)|Gastric mucosal ablation is an endoscopic procedure which uses argonplasma coagulation in combination with submucosal injection to achieve selective ablation
223961200|NCT00582985|DRUG|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
223961201|NCT03942276|OTHER|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate\> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
223961202|NCT03942276|OTHER|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
223961203|NCT03942276|OTHER|Control|Consist of performing no exercise training.
223961204|NCT03438708|DRUG|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
224109583|NCT04940598|OTHER|high intensity interval exercise|HIIT training will be delivered two times per week for 16 weeks (32 sessions). Each session will be separated by at least 24-hrs. Participants will be allowed to choose the days and times that they feel exercise will fit into their schedule. The HIIT protocol will be determined based on peak anaerobic power measures during an arm crank Wingate Cycle test. HIIT will consist of 20 minutes of exercise consisting of four minutes of arm crank exercise at 5% of peak anaerobic power followed by 30 seconds at 30% of the peak anaerobic power; this cycle will be repeated four times, ending with two minutes of recovery at 5% of peak anaerobic power.
224109584|NCT04940598|OTHER|No-exercise control group|No-exercise control group
224109585|NCT02975154|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
224109586|NCT04914130|OTHER|Study specific testing procedures|Study specific procedures includes blood sampling, neurocognitive testing, respiratory questionnaire, brain MRI for MRI substudy group, lumbar puncture for MRI substudy group, etc
224109587|NCT05258058|BEHAVIORAL|Memory and Adaptation Training-Geriatrics|MAAT-G is a cognitive behavioral therapy-based intervention comprised of 10 workshop sessions as well as a participant workbook. The workshop sessions are delivered one on one by a health professional via videoconferencing technology.
224109588|NCT04579393|DRUG|Placebo|Placebo tablets to match fostamatinib 100 mg and 150 mg will be provided.
224109589|NCT04579393|DRUG|fostamatinib|The study intervention is fostamatinib, an inhibitor of spleen tyrosine kinase that will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses. Subjects will receive standard of care and be randomized to receive fostamatinib or matching placebo.
224109590|NCT00745316|DRUG|Tonapofylline|Oral Tonapofylline - 2 capsules bid
224109591|NCT00745316|DRUG|Placebo|Oral placebo - 2 capsules bid
224109592|NCT00101088|DRUG|imatinib mesylate|Given orally
224109593|NCT00101088|DRUG|temsirolimus|Given IV
224109594|NCT00101088|OTHER|laboratory biomarker analysis|Correlative studies
224109595|NCT06178640|DRUG|Simvastatin 40 mg film-coated tablet|Simvastatin 40 mg film-coated tablet
224109596|NCT06178640|DRUG|Zocor 40 mg film-coated tablet|Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)
223542160|NCT04284501|BEHAVIORAL|Non|questionnaire
223961205|NCT04435821|DRUG|[18F]FTC-146|Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection.
223961206|NCT00288353|DRUG|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
223961207|NCT00288353|DRUG|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
223961208|NCT05896826|DEVICE|Magnetometer|inspection equipment for magnetocardiography
224109597|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
224109598|NCT03763279|COMBINATION_PRODUCT|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
224109599|NCT03763279|DEVICE|Monofilament suture|Use of Polydioxanone monofilament suture
224109600|NCT00936949|PROCEDURE|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
224109601|NCT00936949|PROCEDURE|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
223961209|NCT05949580|DEVICE|MS Care Platform (icobrain ms and icompanion ms)|"The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant."
223961210|NCT05648279|OTHER|Personalized hemodynamic management|Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA) Preoperative baseline cardiac index will be determined with the patient being awake and resting in supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA) (usually at least one day before surgery). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
223961211|NCT05739981|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV
223961212|NCT05739981|DRUG|Carboplatin|Carboplatin AUC 5-6 IV
223961213|NCT05739981|DRUG|Bevacizumab|BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.
223961214|NCT05739981|DRUG|IMNN-001|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
223961215|NCT05741788|DEVICE|Various Stimulation Patterns|Participants will undergo a structured optimization evaluating existing types of stimulation (tonic, burst, and multistim). Each participant will try out all types of available stimulation but be blinded to the type. Over the course of four months, each participant will evaluate each type of stimulation by reporting daily pain scores. Participants will follow up routinely to collect laboratory, behavioral, and survey responses to test for the feasibility of obtaining data explaining pain phenotype.
223961216|NCT04059640|DEVICE|LiquiBand FIX8 Open Hernia Mesh Fixation Device|"Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant."
224109602|NCT05296057|DEVICE|Participants Receiving VR-Exposure Therapy Treatment|In the baseline interview with an exposure therapy specialist and a member of the research team, participants will be presented with approximately three sets of possible exposure scenarios, each associated with approximately three different scenes that increase in severity level. Through discussion with the exposure therapy specialist, the participant will choose the exposure scenario (out of the three options) that most closely resembles their own epilepsy- or seizure-related fears. As the treatment, the participant will be exposed to the scenes that are associated with their chosen exposure set in a hierarchical manner using an immersive head-mounted display. The participant will work through the three levels of the chosen exposure scenario for approximately two weeks, ideally on each level for four days.
223961217|NCT04332367|DRUG|Carboplatin|Carboplatin IV
223961218|NCT04332367|DRUG|Paclitaxel|Paclitaxel IV
224109603|NCT03762980|OTHER|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
224109604|NCT03303430|DIAGNOSTIC_TEST|MRI|Diffusion weighted imaging 24 hours after revascularisation
224109605|NCT03560895|DEVICE|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
224109606|NCT03560895|DEVICE|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
224109607|NCT04775043|DIAGNOSTIC_TEST|HFRDIS questionnaire completion|HFRDIS Questionnaire (Hot Flash Related Daily Interference Scale) completion
224109608|NCT04891601|PROCEDURE|polypropelene mesh|compare use mesh alone or combined mesh and darn repair
224109609|NCT01064089|DRUG|HSP990|
223961219|NCT04332367|DRUG|Ramucirumab|Ramucirumab IV
223961220|NCT06414993|BEHAVIORAL|Contingency Management for Emerging Adults (CM-EA)|After CM-EA is introduced, a contingency contract is developed between a parent and emerging adult (EA) that provides EAs with rewards for negative drug screens and completion of developmentally appropriate goals to build recovery capital, along with disincentives for positive screens or engaging in inappropriate behaviors. Concurrently, parents are taught to conduct random urine drug screens. Additionally, parents are trained to complete functional analyses in collaboration with their EA to identify the EA's triggers for poly-substance use and negative behaviors. Individualized triggers are targeted via self-management planning and drug refusal skills training. At the end of CM-EA, plans are made with the family for sustaining abstinence and improvements in other behaviors.
224109610|NCT05054946|PROCEDURE|Laparoscopic cystectomy|All surgeries will be performed under general anesthesia by laparoscopically.
224109611|NCT04397133|OTHER|inspiratory muscle training|inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
223542161|NCT04845594|BEHAVIORAL|MySmileBuddy (MSB)|The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
224109612|NCT04397133|OTHER|sham intervention|in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
224109613|NCT01720771|DIETARY_SUPPLEMENT|probiotic tablet|Intake of one probiotic lozenge tablet per day
224109614|NCT01720771|DIETARY_SUPPLEMENT|sugar pill|one tablet daily
224109615|NCT03972371|DEVICE|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
224109616|NCT01252329|PROCEDURE|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
224109617|NCT05418946|DRUG|Dapagliflozin 10mg|Treatment of T2D and cardio-renal prevention
224109618|NCT03540017|DRUG|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
223961221|NCT06414993|BEHAVIORAL|Standard Peer Recovery Support Services (PRSS) +Vocational/Educational (V/E) Skill Building services|Standard PRSS begin by identifying clients' needs in key domains (e.g., transportation, employment). After needs are identified, a peer worker addresses needs through informational resources and community referrals and engages clients in positive recreational activities offering advice, hope and empowerment to encourage steps toward a reduction in substance use and eventual abstinence. When desired, peer workers also link clients to a broader recovery peer community. In addition, the peer worker will dedicate time to increasing recovery capital via improving skills related to V/E advancement using a workbook, Targeting Employment for Emerging Adults: A Toolkit for Mental Health Providers, for which peer workers will be trained.
223961222|NCT05008224|BIOLOGICAL|Pembrolizumab|"200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation."
223961223|NCT05008224|DRUG|Doxorubicin|"25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age)."
223961224|NCT05008224|DRUG|Vinblastine|6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
223961225|NCT05008224|DRUG|Dacarbazine|375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
223961226|NCT05008224|DRUG|Bleomycin|10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
223961227|NCT05008224|DRUG|Etoposide|200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
223961228|NCT05008224|DRUG|Cyclophosphamide|1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
223961229|NCT05008224|DRUG|Vincristine|1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
223961230|NCT05008224|DRUG|Procarbazine|100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
224109619|NCT03666767|OTHER|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
224109620|NCT04713319|DRUG|Panavital|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
224109621|NCT04713319|OTHER|Placebo|In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
224109622|NCT00735423|DEVICE|No intervention|IDE used for outcome measurement not intervention
224109623|NCT00196885|DRUG|N-acetylcysteine|
224109624|NCT01274897|BIOLOGICAL|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
224109625|NCT01274897|BIOLOGICAL|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
224109626|NCT03667131|DRUG|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
224109627|NCT03667131|DRUG|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
224109628|NCT02042131|BEHAVIORAL|Treatment As Usual (TAU)|
224109629|NCT02042131|BEHAVIORAL|Standard Crisis Response Plan (S-CRP)|
224109630|NCT02042131|BEHAVIORAL|Enhanced Crisis Response Plan (E-CRP)|
223961231|NCT05008224|DRUG|Prednisone|40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
223961232|NCT05581121|OTHER|Standard treatment: Control arm|Standard chemo-radiotherapy and brachytherapy according to EMBRACE II and ESGO/ESTRO recommendations.
223961233|NCT05581121|PROCEDURE|Experimental arm|Pre-therapeutic para-aortic lymphadenectomy (by minimally invasive approach) followed by tailored chemo-radiotherapy and brachytherapy. Both traditional laparoscopy or robotically assisted laparoscopy approaches are accepted in the study.
223961234|NCT06343753|DRUG|Opioid free analgesia|o Group OFA: Opioid free anesthesia Analgesia will be provided by syringe containing ketamine, Lidocaine and Dexmedetomidine in induction and maintenance according to lean body weight (LBW).
223961235|NCT06343753|DRUG|Opioid based Anesthesia|o Group TBA: Traditional balanced anesthesia Analgesia will be provided by fentanyl in induction and maintenance according to Ideal Body Weight (IBW)
223961236|NCT05519111|DRUG|Dronabinol|Dronabinol, an FDA approval oral agent containing synthetic tetrahydrocannabinol (THC)
223961237|NCT05519111|DRUG|Placebo|placebo equivalent
223961238|NCT05800353|PROCEDURE|YAG vitreolysis|"A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician.~Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye."
223961239|NCT05774535|OTHER|Experimental|"Patients will undergo thyroidectomy according to the guidelines American Thyroid Association (ATA), Randolph.~The following assessments will be performed within 10 days before the thyroidectomy procedure:~* informed consent;~* personal data and medical records;~* registration of medical therapy and post-procedural pharmacological protocol~* surgical check;~* supra-aortic trunks EchocolorDoppler;~* pre-procedural blood sampling.~The following assessments will be performed after 30 days, 6 months and 12 months from the thyroidectomy procedure:~* surgical checks;~* registration of drug therapy;~* recording of all adverse events that occurred during hospitalization~* supra-aortic trunks EchocolorDoppler and cIMT measurement;~* blood sampling."
223961240|NCT04639466|DRUG|Placebo Administration|Given IM in the non-dominant upper arm
223961241|NCT04639466|BIOLOGICAL|Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1|Given IM in the non-dominant upper arm
223961242|NCT05946031|DRUG|Reat ETM|Exclusive cigarette smokers will be recruited and will be exposed to the real ETM condition in which tobacco purchases are real and they receive products from one randomly selected trial.
223961243|NCT05946031|DRUG|Hypothetical ETM|Exclusive cigarette smokers will be recruited and will be exposed to the hypothetical ETM condition in which tobacco purchases are hypothetical and they don't receive any products.
223961244|NCT04662970|DEVICE|Device programming|Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming
224109631|NCT03167697|DIETARY_SUPPLEMENT|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
224109632|NCT03167697|OTHER|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
223961245|NCT05755399|DEVICE|Brain imaging using transcranial focused ultrasound (tFUS)|All enrolled patients will be imaged using the MRI as standard of care. The patient will additionally be imaged using the tFUS system, ICC HIFU Synthesizer. Total imaging time will be limited to 15 minutes. Following image acquisition by the ultrasound, the standard of care surgery will be performed.
223961246|NCT05665504|DIAGNOSTIC_TEST|DetermaRX|A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
223961247|NCT06029127|DRUG|BGB-A445|Administered intravenously at protocol defined dose
223961248|NCT06029127|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) administered intravenously
223961249|NCT06029127|DRUG|Ramucirumab|10 mg/kg administered intravenously
223961250|NCT06029127|DRUG|BGB-15025|Administered orally at protocol defined dose
223961251|NCT04985604|DRUG|Tovorafenib|Tovorafenib tablet for oral use.
223961252|NCT06575361|DIAGNOSTIC_TEST|Combination of targeted biopsy and systematic biopsy|Before prostate biopsy, the MR images of patients were independently reviewed by MRI-AI and urogenital radiologists. Then the images with suspicious lesions highlighted by MRI-AI and urogenital radiologists. Urologists conducted targeted biopsies for all suspicious lesions and systematic biopsies. Biopsies were performed under the guidance of transrectal ultrasound (TRUS) through the transrectal or transperineal route.
223961253|NCT05443971|BIOLOGICAL|Durvalumab|Given IV
223961254|NCT05443971|RADIATION|Radiation Therapy|Undergo grid therapy
223961255|NCT05443971|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223961256|NCT01898039|BIOLOGICAL|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
223961257|NCT01898039|PROCEDURE|DNP sensititzation|"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."
223961258|NCT01898039|DRUG|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
223961259|NCT02282761|DRUG|ITI-007|
223961260|NCT02282761|DRUG|Placebo|
223961261|NCT05602766|DRUG|NGENLA (Somatrogon)|Dosage, Frequency: Refer to the latest package insert.
223961262|NCT05018338|DEVICE|Brain shift monitoring|For use to monitor brain shift during craniotomy
223961263|NCT05249452|OTHER|Preconditioning with azathiprine and hydroxyurea (3 months)|Preconditioning with azathiprine and hydroxyurea (3 months) before alemtuzumab/TBI conditioning and matched sibling donor allogeneic stem cell transplantation.
223961264|NCT04313192|DEVICE|pulse rate of 2 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 2 Hz, intensity setting to patient's tolerance, duration 30 days
223961265|NCT04313192|DEVICE|pulse rate of 10 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
223961266|NCT04313192|DEVICE|pulse rate of 150 Hz|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 150 Hz, intensity setting to patient's tolerance, duration 30 days
223961267|NCT01512719|PROCEDURE|POEM|Per Oral Endoscopic Myotomy for achalasia
223961268|NCT05878522|DRUG|sisunatovir|6 capsules administered Q12 hours for 5 doses
223961269|NCT05878522|DRUG|placebo|6 capsules administered Q12 hours for 5 doses
223961270|NCT05878522|DRUG|moxifloxacin|6 capsules of placebo administered Q12 hours for 4 doses, followed by a single tablet of moxifloxacin
223961271|NCT05878522|DRUG|sisunatovir|7 capsules administered Q12 hours for 5 doses
223961272|NCT05122559|DRUG|N-acetyl cysteine|N-acetyl cysteine (NAC) is a Glutathione (GSH) precursor with antioxidant properties which make it relevant for neuroprotection.
224109633|NCT01581190|DIETARY_SUPPLEMENT|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
223961273|NCT05122559|DRUG|Placebo|Lactose Monohydrate, USP (100%), magnesium stearate, silicon dioxide NF
223961274|NCT06475274|DRUG|RMC-035|Protein, a recombinant variant of A1M. Concentrate for solution for infusion.
223961275|NCT06475274|DRUG|Placebo|Identical to RMC-035 intervention devoid of the active substance.
223961276|NCT04483466|DRUG|Methotrexate|Methotrexate is vibrant yellow-orange colored powder with physical properties of near insolubility in water formulated into methotrexate tablets containing an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, and yellow. The chemical name is N-\[4-\[\[(2,4-diamino-6pteridinyl)methyl\]methyl amino\]benzoyl\]-L-glutamic acid. Methotrexate is an anti-metabolite that is a folate antagonist that inhibits lymphocyte proliferation and functions as an immunosuppressant in arthritis.
223961277|NCT04483466|DRUG|Placebo|Placebo
223961278|NCT03680092|DRUG|Cyclophosphamide|Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
223961279|NCT03680092|DRUG|abatacept|Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
223961280|NCT03680092|DRUG|Methotrexate|standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
223961281|NCT03680092|DRUG|Tacrolimus|Tacrolimus per institutional guidelines
223961282|NCT06511791|DRUG|FE 999302|Effect on parameters influencing pregnancy rates when administered during different time intervals in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol
223961283|NCT06511791|DRUG|Follitropin delta|The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.
223961284|NCT06511791|DRUG|Placebo FE 999302|No active ingredient, subcutaneous injection.
223961285|NCT04707924|DEVICE|Er:YAG laser|Treatment of scars with fractional Er:YAG 2940nm laser.
223961286|NCT05699460|OTHER|This is an observational study.|This is an observational study.
223961287|NCT06238622|DRUG|BI 1015550|BI 1015550
223961288|NCT03345420|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223961289|NCT04246086|DRUG|Mosunetuzumab (IV)|Participants will receive IV mosunetuzumab as defined by the study protocol
223961290|NCT04246086|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed for adverse reactions as defined by the study protocol
223961291|NCT04246086|DRUG|Lenalidomide|Participants will receive oral lenalidomide as defined by the study protocol
223961292|NCT04246086|DRUG|Mosunetuzumab (SC)|Participants will receive SC mosunetuzumab as defined by the study protocol
223961293|NCT00722228|BIOLOGICAL|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
223961294|NCT06431204|OTHER|Obstetric comorbidity index|Obstetric comorbidity index score
223961295|NCT05614102|DRUG|BAY2965501|Daily oral application
223961296|NCT05614102|DRUG|Pembrolizumab|In combination group 200mg as infusion every 3 weeks
223961297|NCT05614102|DRUG|Platinum-based Chemotherapy|Standard of care doses per tumor type will be administered.
223961298|NCT05846932|BEHAVIORAL|OTEE HORS|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided while participants are riding horses
223961299|NCT05846932|BEHAVIORAL|OT Clinic|10 weeks of occupational therapy focused on teaching and practicing self-regulation skills, provided in a traditional clinic
223961300|NCT04855708|OTHER|Virtual visit|Patients randomized to this group will have a virtual 2-week post-operative visit
224109634|NCT01565486|DEVICE|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
224109635|NCT01565486|DEVICE|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
224109636|NCT00011895|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
224109637|NCT00011895|DRUG|Efavirenz|
224109638|NCT05739708|OTHER|Questionnaires|The time to complete the different questionnaires is estimated to be 60 minutes.
224109639|NCT02725177|DRUG|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~* Initial treatment with 80 units daily for ten days (induction phase)~* Maintenance treatment with 80 units twice weekly (maintenance phase)"
223961301|NCT04855708|OTHER|Office visit|Patients randomized to this group will have a in-person 2-week post-operative visit
223961302|NCT04276142|BEHAVIORAL|ceprica (additional to treatment as usual)|ceprica is a dialogue-based online psychological intervention for patients with migraine. This intervention includes elements that address pain management, pain reduction etc. Content is adapted to users needs using interactive dialogues, illustrations and audio files. Participants may also continue with their usual treatment.
223961303|NCT04276142|BEHAVIORAL|active control intervention (additional to treatment as usual)|the active control intervention contains psychoeducational content regarding migraine
223961304|NCT02252172|DRUG|Daratumumab IV|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
223961305|NCT02252172|DRUG|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
223961306|NCT02252172|DRUG|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
224109640|NCT02725177|DRUG|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
224109641|NCT03901183|OTHER|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
224109642|NCT01125891|DRUG|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
224109643|NCT01125891|DRUG|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
224109644|NCT06163781|DEVICE|Blood culture prediction tool|Machine learning based predicition tool
224109645|NCT00793585|DRUG|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level \< 6mg/dl , the dosage changed to 200mg/d.
223961307|NCT02252172|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
224109646|NCT00793585|OTHER|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
224109647|NCT04419415|DIETARY_SUPPLEMENT|Breakfast with high protein dairy|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) for breakfast.
224109648|NCT04419415|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
223961308|NCT05216835|DRUG|Sabestomig (AZD7789)|Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.
224109649|NCT04419415|OTHER|Skipping breakfast|Participants will be asked to skip breakfast.
223961309|NCT05179603|DRUG|THOR-707|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
223961310|NCT05179603|DRUG|Pembrolizumab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
223961311|NCT06355154|OTHER|Nutritional intervention|The intervention will contain a diet with a reduced amount of carbohydrates compared to the standard treatment today but without caloric restriction.
223961312|NCT06241313|DRUG|Atogepant|Oral Tablet
223961313|NCT06241313|DRUG|Placebo for Atogepant|Oral Tablet
223961314|NCT03109275|OTHER|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
223961315|NCT06965465|BIOLOGICAL|PF-07999415|Participants will receive single doses of PF-07999415.
223961316|NCT06965465|DRUG|Placebo|Participants will receive matching placebo.
223961317|NCT01842360|BIOLOGICAL|Placebo|The participants will receive daily dose of placebo during 12 months sublingually.
223961318|NCT01842360|BIOLOGICAL|MV130|The participants will receive daily dose of MV130 during 12 months sublingually.
223961319|NCT06127667|BEHAVIORAL|aerobic exercise|use of single bout of aerobic exercise
223961320|NCT04441983|DIAGNOSTIC_TEST|7 Tesla MRI of the foot|7 Tesla MRI
223961321|NCT06422507|DRUG|8 mg aflibercept (BAY 86-5321) (High Dose)|High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.
223961322|NCT06422507|DRUG|2 mg aflibercept (EYLEA, BAY 86-5321)|"Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye."
223961323|NCT06422507|OTHER|Sham|"To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM)."
223961324|NCT05065216|DRUG|Recombinant human tissue kallikrein|DM199 administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21
223961325|NCT05065216|OTHER|Placebo for DM199 Solution for Injection|Placebo administered by a single intravenous (IV) dose followed by subcutaneous (SC) doses at 2 hours (+10 hours) of the IV dose completion and then 2 times per week up to Day 21.
223961326|NCT06084260|DIETARY_SUPPLEMENT|Diet group|Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.
223961327|NCT06084260|BEHAVIORAL|Self-compassion group|Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
223961328|NCT03985020|OTHER|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
223961329|NCT03985020|OTHER|Water Intervention|Bottled Water
223961331|NCT04563026|DRUG|DUR-928 30 mg|IV infusion
223961332|NCT04563026|DRUG|DUR-928 90 mg|IV infusion
223961333|NCT04563026|DRUG|Placebo+ Standard of Care (SOC)|IV infusion
223961334|NCT01483885|DEVICE|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
224109650|NCT01936337|DRUG|DLX105 Hydrogel|topical administration on psoriatic plaque
224109651|NCT01936337|DRUG|Placebo|topical administration on psoriatic plaque
224109652|NCT02438072|DRUG|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
224109653|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
224109654|NCT06511427|DIAGNOSTIC_TEST|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
224109655|NCT00316901|PROCEDURE|computed tomography|
224109656|NCT00316901|PROCEDURE|positron emission tomography|
224109657|NCT00316901|RADIATION|fludeoxyglucose F 18|
224109658|NCT03373786|DRUG|RG012|RG012 in 0.3% sodium chloride
224109659|NCT04711421|DEVICE|4 VIVOFIT-|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
224109660|NCT05278793|DRUG|Ferrous fumarate|Ferrous fumarate 200mg oral
224109661|NCT00377299|DRUG|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
224109662|NCT00377299|DRUG|Placebo|Placebo matching active medication in all other physical aspects
224109663|NCT04560101|DRUG|botulinum toxin A|Intramuscolar injection of botulinum toxin in affected muscles
224109664|NCT01788085|DEVICE|Bravo pH monitoring procedure|Bravo pH monitoring procedure
223724367|NCT04497506|BEHAVIORAL|Standard preventive intervention|It consists of an educational intervention that provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
223724368|NCT02062034|DRUG|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
223961335|NCT01483885|DEVICE|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
223961336|NCT01483885|PROCEDURE|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
223961337|NCT00375388|DRUG|Metformin on top of intensive insulin therapy|
223961338|NCT05227183|BEHAVIORAL|The virtual version of the Social stress task : V-TSST|The task consists in a brief presentation about the abilities of participants followed by an arithmetic task in front of a virtual 3D audience projected and one researcher in a room.First, participants have 5 minutes to prepare an exhibition about their qualities, their strengths and defects, and, why they identify with them. During this period virtual reality shows a closed curtain, and sounds from the audience can be heard. In the second phase, the curtain is raised and the participant must expose his speech during 5 minutes. Audience will remain attentive during 2 minutes, then audience will change to a restless attitude. The third phase consists of subtracting back a two-digit number from a four-digit number, as quickly as possible, starting again if participant makes a mistake. A debriefing of the test is scheduled at the end of the protocol, to remind patients of the purely fictional nature of this test. The visit will only end after a return to the baseline emotional state
223961339|NCT00006229|DRUG|carboplatin|
223961340|NCT00006229|DRUG|paclitaxel|
223961341|NCT00006229|DRUG|rebimastat|
223961342|NCT05680597|OTHER|Balance Tele-Rehabilitation Agility Boot Camp (ABC)|The intervention is tele-rehabilitation conducted by a physical therapist virtually for 60 minutes approximately three times a week for four weeks (12 sessions). Participants will be assessed for seven days pre and post intervention using wearable sensors (APDM wearable technologies) to monitor daily mobility.
223961343|NCT06967155|DRUG|• Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU|"Irinotecan + Dabrafenib + Trametinib and Cetuximab or Panitumumab in the second line of therapy Dabrafenib 150 mg twice orally daily Trametinib 2 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Irinotecan 90 mg/m2 (90-minute IV infusion) weekly.~Second-line treatment is administered until disease progression or intolerable toxicity. It may be possible to switch to a regimen of dabrafenib, trametinib, cetuximab or panitumumab if irinotecan is intolerable."
223961344|NCT05438264|DRUG|Donepezil|acetylcholinesterase inhibitor
223961345|NCT05438264|DRUG|Placebo|placebo
224109665|NCT03750162|DEVICE|VDW Ultra|supplementary disinfection technique
224109666|NCT03750162|DEVICE|AMD picasso|supplementary disinfection technique
223961346|NCT06529809|RADIATION|Hypofractionated external beam radiation|Central pelvis (19.05 Gy in 15 fractions), nodal basins (40 Gy in 15 fractions), with a simultaneous integrated boost to grossly positive lymph nodes (48 Gy in 15 fractions)
224109667|NCT03750162|DEVICE|ProtaperNext X3 gutta-percha|supplementary disinfection technique
224109668|NCT03461965|BEHAVIORAL|3D printed model|A printed 3D model of MMS will be created showing a model of skin, and a tumor to visually depict the surgery
224109669|NCT03461965|BEHAVIORAL|Verbal Counselling|Participants will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and MMS
224109670|NCT00035815|DRUG|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
223724369|NCT02062034|DRUG|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
224109671|NCT00035815|DRUG|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
224109672|NCT02627950|DRUG|Morphinhydrochloricum|5 mg morphine intravenously
223724370|NCT02062034|DRUG|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
223724371|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
223724372|NCT00329381|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
224109673|NCT02627950|DRUG|Metoclopramide|10 mg MCP intravenously
224109674|NCT02627950|DRUG|Ticagrelor|180 mg ticagrelor orally
224109675|NCT02627950|DRUG|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
223724373|NCT06045767|DRUG|Pembrolizumab 50 MG Injection [Keytruda]|Chemo-immunotherapy combination
223961347|NCT06529809|DRUG|Chemotherapy|Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
223961348|NCT06529809|RADIATION|Image-guided brachytherapy|HDR boost 7.3 Gy x 6 fractions
223961349|NCT04551053|DRUG|parsaclisib|parsaclisib will be administered QD orally
223961350|NCT04551053|DRUG|ruxolitinib|ruxolitinib will be administered BID orally
223961351|NCT04551053|DRUG|placebo|placebo will be administered QD orally
223961352|NCT06411197|OTHER|Hypertonic saline injection|Injection with hypertonic saline (7%)
223961353|NCT06411197|OTHER|Isotonic saline injection|Injection with isotonic saline (0.9%)
223961354|NCT05740371|DRUG|Argatroban|"Patients received an intravenous (i.v.) bolus of 300 μg/kg argatroban administered over a span of 3 to 5 minutes followed by the i.v. infusion of argatroban at 20 μg/kg/min until the end of the procedure. ACT was checked 5 minutes after bolus dose.~If ACT remained below the target of 300 s, the patient received an additional i.v. bolus injection of 150 μg/kg and the infusion dose was raised up to 30 μg/kg/min.~In cases ACT \> 450 s, the infusion was reduced to 15 μg/kg/min and the value was checked again after 5 minutes.~As soon as the target ACT (between 300 s and 450 s) was reached, infusion dose remained unchanged during the PCI procedure.~Depending on clinical relevancy further ACT assessments were possible."
223961355|NCT00021099|DRUG|ixabepilone|Given IV
223961356|NCT06585007|RADIATION|Radiotherapy|Progression-directed therapy (stereotactic body radiation therapy)
223961357|NCT06585007|PROCEDURE|metastasectomy|Progression-directed therapy (metastasectomy)
223961358|NCT02342652|DRUG|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
223961359|NCT02342652|DRUG|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
223961360|NCT03288688|OTHER|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
223961361|NCT01636726|DRUG|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
223961362|NCT00488267|DRUG|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
223961363|NCT00488267|DRUG|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
224109676|NCT06272253|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|Dose : 1 dose 0.5 ml containing 5 μg inactivated SARS-CoV-2 virus, Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride.
224109677|NCT04908072|DEVICE|Orbis-FundamentalVR MSICS Simulator|Cataract surgery training device, using virtual reality software combined with existing gaming technology for simulated surgery
223724374|NCT04021004|OTHER|Survey Questionnaire|Survey Questionnaire
223724375|NCT00869895|DRUG|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
223724376|NCT01549444|OTHER|presence of maternal risk factor for hypertension|
223724377|NCT02555189|DRUG|Enzalutamide|Given PO
223724378|NCT02555189|DRUG|Ribociclib|Given PO
223724379|NCT02555189|OTHER|Laboratory Biomarker Analysis|Correlative studies
223724380|NCT02555189|OTHER|Pharmacological Study|Correlative studies
223961364|NCT00488267|DRUG|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
223961365|NCT03612388|PROCEDURE|use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation|use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
223961366|NCT04847180|PROCEDURE|Biopsy|The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
223961367|NCT01829594|OTHER|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
224109678|NCT02773992|BEHAVIORAL|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
224291295|NCT01245036|DRUG|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.\<50 kg and 600 mg/day if wt. \>50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
223961368|NCT01466556|OTHER|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
223724381|NCT02555189|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223961369|NCT00272415|DRUG|INO-1001|Intravenous repeating dose
223961370|NCT00272415|DRUG|temozolomide|Oral repeating dose
223961371|NCT02877524|OTHER|Adaptive support ventilation|ASV during NIV
223961372|NCT02877524|OTHER|Pressure support ventilation|PSV during NIV
224291296|NCT02182167|DRUG|IV N-acetylcysteine (NAC)|
223961373|NCT03019289|DRUG|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
223961374|NCT04873544|PROCEDURE|ERAS protocols for TKA|ERAS protocols for TKA
224291297|NCT02182167|DRUG|Water|
223724382|NCT02555189|PROCEDURE|Biopsy|Undergo tumor biopsy
223724383|NCT02555189|PROCEDURE|Echocardiography|Undergo ECHO
223724384|NCT02555189|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223724385|NCT02555189|PROCEDURE|Bone Scan|Undergo bone scan
223724386|NCT02555189|PROCEDURE|Computed Tomography|Undergo CT
223724387|NCT02555189|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223724388|NCT01401283|DEVICE|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
223724389|NCT03007576|BIOLOGICAL|RegStem|RegStem, 1.5 ml, one injection
223724390|NCT00812890|DEVICE|semi-quantitative pregnancy test|
224109679|NCT06674382|PROCEDURE|Haploidentical hematopoietic stem cell transplantation|"This is a single-arm study in which all patients will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis.~Pre-transplant Evaluation:~Evaluation includes status of primary Disease, donor specific antibodies (DSA), organ function (assessments for heart, liver, lungs, kidneys, and the nervous system), and Spleen size.~Transplantation Protocol:~Conditioning Regimen:~Dac/TT/Bu/Flu/ATG regimen:~Decitabine 100 mg/m², on day -12. Thiotepa (TT) 5 mg/kg/day, on days -11 and -10. Busulfan 0.8 mg/kg body weight, every 6 hours, on days -8 to -6. Fludarabine 30 mg/m², once daily, on days -6 to -2. Anti-thymocyte globulin (ATG) 2.5 mg/kg body weight, once daily, on days -5 to -2.~Transplant Donor: Haploidentical donor. GVHD (Graft-versus-Host Disease) Prophylaxis Regimen: Cyclosporine, mycophenolate mofetil, and short-course methotrexate for GVHD prevention.~Graft:~Target MNC (Mononuclear Cells): 6-8 × 10⁸/kg. Target CD34+ stem cells: 5 × 10⁶/kg"
224109680|NCT06696417|DRUG|Drug group：vunakizumab (IL-17A inhibitor)|The recommended dose of vunakizumab was 240 mg, administered subcutaneously at weeks 0, 2, and 4, then every 4 weeks, with a final injection at 48 weeks
224109681|NCT07030647|DRUG|Bupivacaine 0.25%|At the end of gynecologic laparoscopic surgery and prior to trocar removal, 40 mL of Bupivacaine 0.25% is instilled intraperitoneal under direct vision to evaluate its analgesic effect.
223961375|NCT04388839|DRUG|Vincristine|IV push over 1 minute with dosing ranging from 0.24mg up to 1.5mg
223961376|NCT04388839|DRUG|Cyclophosphamide|IV over 60 minutes with dosing ranging from 220mg to 1200mg
223961377|NCT04388839|DRUG|Vinorelbine|IV push over 6-10 minutes with dosing ranging from 4mg-25mg
223961378|NCT04388839|DRUG|Actinomycin D|Actinomycin D should not be given with radiation. Will be administered through IV over 3-5 minutes with dosing ranging from 0.025mg-0.045mg
223961379|NCT04388839|DRUG|Cyclophosphamide Pill|Based on Body Surface Area (BSA) round to nearest 25mg
223724391|NCT02968407|OTHER|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
223961380|NCT02389894|DEVICE|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
223961381|NCT02389894|DEVICE|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
223961382|NCT05618717|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation using irrigated ablation catheter
223724392|NCT02037698|DEVICE|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
223961383|NCT03473275|DIAGNOSTIC_TEST|Cold Pressor test|Both feet in icy waterbath alternated with body temperature water
223724393|NCT02433483|DRUG|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
223724394|NCT02433483|DRUG|Intrathecal Triples|given IT.
223724395|NCT02433483|BIOLOGICAL|HPC-A|Given IV.
223961384|NCT03473275|DIAGNOSTIC_TEST|PinPrick test|Pricking both feet with a needle using gravity (without penetrating) alternated with cotton swap
223961385|NCT03258034|DRUG|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
223961386|NCT04168450|OTHER|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
224109682|NCT07030647|DRUG|Bupivacaine 0.25%|Before trocar insertion in gynecologic laparoscopic surgery, 5 mL of Bupivacaine 0.25% is infiltrated subcutaneously at each trocar port site to assess its effect on postoperative pain.
224109683|NCT03551522|DRUG|Seladelpar|10 mg, 20 mg, or 50 mg
223724396|NCT03012906|OTHER|the prevalence of ischemic events|
223961387|NCT04168450|OTHER|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
224109684|NCT03551522|DRUG|Placebos|Matching placebo Capsule
224291298|NCT04920526|DRUG|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine|No intervention will be administered
223961388|NCT05346848|DRUG|Association of darolutamide and EBRT|"Darolutamide will be taken orally at a fixed dose of 600 mg twice daily (1200 mg), on a continuous basis, for a maximum of 6 months. Darolutamide will start at Day 1.~\- External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated with standard schedules:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
223961389|NCT05346848|DRUG|Association of ADT and EBRT|"Treatment by Androgen Deprivation Therapy (ADT) will be prescribed as per market authorization and following investigator judgement. ADT treatment will consist on:~* Either LH-RH agonist injection given every 3 months for 6 months, or once for 6 months,~* Either LH-RH antagonist given monthly for 6 months~External Beam Radiotherapy (EBRT) will start two months after treatment initiation. All patients will be treated by high dose irradiation in stereotactic conditions:~* 78 Gy with classical 2 Gy/fractions, 5 days/7~* Or 60 Gy with 3 Gy/fractions, 5 days/7~* Use of IMRT and IGRT is mandatory~* Clinical Target Volume Definition according to GETUG Guidelines~* Organ at risk dose constraints according to RECORAD"
223961390|NCT06285422|DRUG|SC262|SC262 is an allogeneic CAR -T cell therapy
224109685|NCT06739668|DEVICE|Pascal device|The study devices consist of a tabletop Console with user interface and a head-worn applicator (Headset) that is connected via coaxial cable. The Headset is positioned on the head per instructions, and then the study subject powers on the device by pressing the power button and initiates a 15-minute treatment by pressing the start button. LED lights on the console count down during the treatment to indicate time remaining and, once the treatment is complete, the device automatically powers off.
224109686|NCT06739668|DEVICE|Sham Device|The sham device will look identical to the active device and will have the same indicator lights and sounds, but will not emit magnetic field therapy.
223961391|NCT01549951|DRUG|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
223961392|NCT02843100|OTHER|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
224109687|NCT06747624|DIETARY_SUPPLEMENT|Geranylgeraniol 300 mg|300 mg of trans-geranylgeraniol (GG)
224109688|NCT06747624|DIETARY_SUPPLEMENT|Placebo|300 mg medium chain triglycerides
224109689|NCT06131944|BEHAVIORAL|Rested & Ready to Learn|The intervention arm targets improving young children's sleep by providing parents with sleep education and activities to do at home with their child. Classroom teachers will also deliver a brief lesson aligned with intervention topics to reinforce key messaging in the classroom. The sleep intervention will focus on the benefits of sleep (physical health, social-emotional health, classroom participation/learning), creating and sticking to a bedtime routine, screen use before bed, and developmentally appropriate sleep behavior.
224109690|NCT06952439|DEVICE|Images and cines captured through the capture card (ICC)|A screen capture/recording of the entire exam performed by the ARDMS as per the Image Acquisition Protocol for the FDA Study will be obtained, and the images/cines required for the study that correspond to IUS shall be obtained. The independent research coordinator for the study will review the screen recording and identify the frame/cine for each diagnostic view (ICC) that corresponds to IUS based on the time stamps.
224109691|NCT06954766|DEVICE|CKD-981(1)|20 minutes per day, 5 days a week for 6 weeks.
224109692|NCT06954766|DEVICE|CKD-981(2)|20 minutes per day, 5 days a week for 6 weeks.
224109693|NCT06954766|DEVICE|Sham device|20 minutes per day, 5 days a week for 6 weeks.
224109694|NCT06954766|DRUG|Reference Drug|QD for 6 weeks
224109695|NCT06954766|DRUG|Placebo Drug|QD for 6 weeks
224109696|NCT05222386|OTHER|Parkinson Disease Standard Care|Under usual care, community providers will deliver their usual care and center coordinators will collect data on our outcomes every 3 months. After one year of baseline data collection, eight practices will be randomized to the intervention, which will include clinician training and coaching as well as access to online services for their patients. Per the stepped-wedge design an additional eight practices will be randomized 18 months into the data collection period, and the final eight will enter the intervention 24 months into the data collection period to allow for 12 months intervention recruitment for all practices.
224109697|NCT05222386|OTHER|Online Community-Supported Palliative Care|"Neurologist Teleconferences: Training and coaching in palliative care will be provided using the Extension for Community Healthcare Outcomes (ECHO) model augmented by a Community of Inquiry Framework to address a desire for greater peer connection, enhance self-efficacy, and to address potential weaknesses in the ECHO model for more complex interventions such as palliative care.~Additional support services provided to carepartners and patients will be through the Family Caregiver Alliance's CareNav platform, including tailored educational materials, support groups and social support."
224109698|NCT03590574|BIOLOGICAL|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10\^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
224109699|NCT02632825|DEVICE|Nasal High Flow|Nasal High Flow Therapy
223724397|NCT02835508|DRUG|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
223724398|NCT02835508|DRUG|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
223961393|NCT02843100|OTHER|Crohn's Disease Exclusion Diet|a limited whole food diet
223961394|NCT02843100|OTHER|Partial Enteral Nutrition|25-50% of Energy from formula
223961395|NCT02843100|OTHER|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
223961396|NCT00003240|DRUG|cisplatin|
223961397|NCT00003240|DRUG|ifosfamide|
223961398|NCT00003240|DRUG|mitomycin C|
223961399|NCT00003240|DRUG|vinblastine sulfate|
223961400|NCT00003240|DRUG|vindesine|
223961401|NCT00003240|DRUG|vinorelbine tartrate|
223961402|NCT00003240|PROCEDURE|conventional surgery|
223961403|NCT00003240|RADIATION|radiation therapy|
223961404|NCT06506409|DEVICE|Smart-Video Based Game Therapy|The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.
223724399|NCT02835508|DRUG|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
223961405|NCT06506409|OTHER|Otago Based Structured Exercise|Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
223961406|NCT06506409|OTHER|No intervention|A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
223961407|NCT05000359|BEHAVIORAL|text messaging intervention|Ten AYA survivors will be recruited to participate in the expanded 12-week text messaging intervention.
223961408|NCT02704637|DEVICE|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
223961409|NCT02774876|DEVICE|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
223961410|NCT02774876|DRUG|Insulin|Patient's usual fast-acting insulin analog will be used.
223961411|NCT02774876|DEVICE|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
223961412|NCT02774876|OTHER|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
223961413|NCT02395406|DEVICE|Orotracheal intubation with Totaltrack|
223961414|NCT02395406|DEVICE|Orotracheal intubation with Airtraq|
223961415|NCT06344091|DRUG|Bupivacaine Liposome Injection|Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
223961416|NCT06979232|DEVICE|Enhanced White Light Imaging|Use of E-WLI for colon inspection during both insertion and withdrawal phase of colonoscopy
223961417|NCT06979232|DEVICE|White Light lmaging|Use of WLl for colon inspection during both insertion and withdrawal phase of colonoscopy
223961418|NCT02409407|DRUG|Misoprostol , Prostaglandins E1 analogue|
223961419|NCT01381198|PROCEDURE|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
223961420|NCT06768177|DRUG|PRP injection|3 ML OF PRP
223961421|NCT06768177|DRUG|Alprostadil 20 micrograms|1 ML
223961422|NCT02929732|OTHER|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
223961423|NCT06654011|DRUG|IN10018|100 mg, orally, once daily
223961424|NCT06654011|DRUG|Nab-paclitaxel|260 mg/m², IV infusion, Q3W
223961425|NCT06654011|DRUG|Cadonilimab|10 mg/kg, IV infusion, Q3W
223961426|NCT06653985|DRUG|Hyaluronic and corticosteroid injection|Patients will receive an ultrasound-guided injection consisting of 3 ml hyaluronic acid (Durolane™) mixed with 40 mg triamcinolone (Kenalog™) into their hip joint.
223961427|NCT06653985|OTHER|Physical Therapy|Patients will receive an 8-week physiotherapy protocol, consisting of 8 visits. The protocol will consist of 1 visit per week.
223961433|NCT05977985|DRUG|Rotator interval hydro-dissection with dextrose 5%|Single injection of 20ml dextrose 5% into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
223961434|NCT05977985|DRUG|Rotator interval hydro-dissection with corticosteroid solution|Single injection of 20ml corticosteroid solution (1 ml triamcinolone 40 mg/ml + 19 ml saline 0.9%) into the rotator interval around the long head biceps tendon under ultrasound guidance using a 11-14 Hz frequency linear probe
223961435|NCT05681611|DRUG|Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.
224291299|NCT01967693|PROCEDURE|Retrospective analysis of data|Retrospective data analysis
223961436|NCT06290453|DIAGNOSTIC_TEST|micro RNA 27- FLP1 gene expression|"From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined"
223961437|NCT06290453|DIAGNOSTIC_TEST|The Expanded Disability Status Scale (EDSS)|"The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level of someone's disability over time. The EDSS has a range from 0 to 10.~Zero points is normal neurological examination. 10 points shows the MS-related death cases. Patients with EDSS score up to 5 are fully ambulatory patients."
223961438|NCT06290453|DIAGNOSTIC_TEST|Electrophysiological assessment:|Electromyography and nerve conduction velocity will be performed for all MS patients.
223961439|NCT06290453|DIAGNOSTIC_TEST|MRI examination MRI brain:|will be done on all MS patients to detect the number, the site, and the enhancement of lesions
224109700|NCT06477913|DEVICE|Rauha|A dual mental health treatment consisting of digitally-administered Cognitive Behavioral Therapy combined with National Board Health and Wellness Coach (NBHWC) trained Mental Health Coaches
224109701|NCT04652635|PROCEDURE|Nail plate removal, nail bed repair|Injection of local anesthetic, removal of nail plate, inspection of nail bed, repair of nail bed with suture and/or adhesive
224109702|NCT05842681|DRUG|Azithromycin|A single daily oral dose of Azithromycin tablet 500 mg for five days
224109703|NCT05842681|DRUG|Methylprednisolone|methylprednisolone 500 mg single intra-venous daily dose for three days
224109704|NCT06166771|DEVICE|Alma system|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
224109705|NCT03165981|BIOLOGICAL|PCV13|ACIP Recommended vaccine
224109706|NCT03165981|BIOLOGICAL|DTaP|ACIP Recommended vaccine
224109707|NCT03165981|BIOLOGICAL|IIV|ACIP Recommended vaccine
224109708|NCT04735835|OTHER|Dietary Intervention|To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.
224109709|NCT06140966|DRUG|Daratumumab|Given by vein: days 1 and 8 of each Induction cycle; days 1 and 15 of each Consolidation cycle; and day 1of each Maintenance cycle.
224109710|NCT06140966|DRUG|Carfilzomib|Given by vein: days 1,2,8 and 9 of each Induction cycle; days 1, 2, 8, 9,15, and 16 of each Consolidation cycle; days 1, 2,15, and 16 of each Maintenance cycle.
224109711|NCT06140966|DRUG|Lenalidomide|Given by mouth: days 1-7 of each Induction cycle; days 1-14 of each Consolidation cycle.
224109712|NCT06140966|DRUG|Dexamethasone|Given by mouth or by vein: days 1, 8, 15, and 22 of each Induction cycle; days 1, 8, 15, and 22 of each Consolidation cycle; and days 1 and 15 of every cycle during Maintenance
224109713|NCT06140966|DRUG|Cisplatin|Given by vein: days 1-4 of each Induction cycle
224109714|NCT06140966|DRUG|epirubicin|Given by vein: days 1-4 of each Induction cycle
224109715|NCT06140966|DRUG|Cyclophosphamide|Given by vein: days 1-4 of each Induction cycle
224109716|NCT06140966|DRUG|Etoposide|Given by vein: days 1-4 of each Induction cycle
224109717|NCT06140966|DRUG|Melphalan|Given by vein: day -1 of Transplant
224109718|NCT06140966|PROCEDURE|ASCT|day 0 of Transplant
224109719|NCT06140966|DRUG|bortezomib|given by subcutaneous injection: days 1, 4, 8, and 11 of pretrial induction chemotherapy
224109720|NCT05383157|BEHAVIORAL|Brief mindfulness|Training in mindfulness focused on breathing and pain sensations to enhance decentering, meta-awareness, and interoceptive awareness.
224109721|NCT05383157|OTHER|Usual care|Usual pain care as delivered in the clinic involving pain assessment and prescription of analgesics.
224291300|NCT03845413|BEHAVIORAL|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
223961440|NCT06465654|OTHER|Automated variable dose oxygen treatment|The participant will receive closed loop oxygen titration during a walking test based on oxygen saturation measurements every second measured by a pulse oximeter connected to the O2matic. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
223724400|NCT02933125|BEHAVIORAL|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
223961441|NCT06465654|OTHER|Fixed dose oxygen treatment|The participant will receive a fixed oxygen dose during a walking test. The participant will every minute during the walking test rate sensation of dyspnea on the BorgCR10 scale.
223961442|NCT06656663|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and LW, based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have an excellent knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
223961443|NCT06656663|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
223961444|NCT06986122|BEHAVIORAL|Pain Threat Manipulation|Participants receive brief thermal pain stimuli in certain virtual environments to examine how threat influences perception and physiological responses.
223961445|NCT06986122|BEHAVIORAL|Pain Controllability Manipulation|In some contexts, participants can reduce or avoid pain using a button; in others, no action changes the outcome. This manipulation is used to study the effects of perceived control over pain.
223961446|NCT02201459|DRUG|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
223961447|NCT02201459|DRUG|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"* Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
223961448|NCT06596915|DRUG|BA1302|BA1302 administered intravenously
223961449|NCT06600204|OTHER|lung scintigraphy|Use the SPECT/CT to predict pulmonary function
223961450|NCT00955097|DRUG|Definity®|Definity® injections given both pre-ablation and post-ablation
223961451|NCT05816798|DEVICE|Photobiomodulation|PBM is a therapeutic technique that uses light at different wavelengths (red or infrared), in a non-invasive way in which non-ionizing irradiation is used to produce a series of photophysical and photochemical effects when applied to biological tissues (humans and animals). Regarding the clinical results, numerous articles have already demonstrated the effect of PBM in improving pain and disability in patients with knee joint pain.
223961452|NCT05816798|OTHER|Standard Physiotherapy Tretament|standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)
223961453|NCT05816798|DEVICE|Photobiomodulation Placebo|The same interventions described of Photobiomodulation Group bu device will be turned off
223961454|NCT06598774|OTHER|Assessment of head posture:|Head posture was assessed using photographic methods and craniovertebral angle
223961455|NCT06598774|OTHER|Assessment of Cervical Pain Pressure Threshold|The cervical PPTs were assessed using a mechanical pressure algometer (Baseline Force Gauge Model 12-0304; Baseline, NY, USA).
223961456|NCT06598774|OTHER|Assessment of general cervical mobility|Cervical mobility was assessed using the CROM (Cervical Range of Motion) deluxe device.
223961457|NCT06598774|OTHER|Assessment of upper cervical mobility|It will be assessed using the CROM device and the flexion-rotation test.
223961458|NCT06598774|OTHER|Assessment of Body Awareness|Body awareness will be assessed using a questionnaire designed to determine normal or abnormal sensitivity levels in body composition.
224291301|NCT03845413|BEHAVIORAL|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
224291302|NCT00155233|DRUG|Nalbuphine and morphine|
224109722|NCT05872438|DIAGNOSTIC_TEST|Vaginal, Oral and anal sampling|The patients will take the samples themselves from the 3 sites (vaginal, anal and oral self-sampling) using standard swabs (brand). The sample will immediately be placed in the transport medium in each of the 3 Sigma VCM tubes labeled by the patient, depending on the collection site. The study nurse will register the inclusion of patients, identify the tubes, collect information and send them to the local laboratory for the PCR to be performed.
223961459|NCT06037057|OTHER|no intervention name|no intervention description
223961460|NCT06842355|DRUG|TYRA-300 0.125 mg/kg|Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.
223961461|NCT06842355|DRUG|TYRA-300 0.25 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
223961462|NCT06842355|DRUG|TYRA-300 0.375 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
223961463|NCT06842355|DRUG|TYRA-300 0.50 mg/kg|Subsequent dose level escalations will occur based on criteria outlined in the protocol.
223961464|NCT05771688|DEVICE|FETO therapy|placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
223961465|NCT03028961|OTHER|Stanford Letter|Receive and complete the Stanford Letter
223961466|NCT03028961|OTHER|Interview|Undergo semi-structured, research staff-led interview
223961467|NCT03028961|OTHER|Questionnaire Administration|Ancillary studies
223961468|NCT03028961|OTHER|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
223961469|NCT05070208|OTHER|NOT PROVIDED|NOT PROVIDED
223961470|NCT06610838|OTHER|Health Assessments|Participants will complete the blood tests, questionnaires, cardiovascular tests, and pulmonary test at visits 1, 2, and 4. Non-Contrast Chest CT and cardiopulmonary treadmill (VO2 max) stress tests will occur at visits 1 and 4. Visit 3 will not include cardiovascular and pulmonary tests.
223961471|NCT06856577|GENETIC|Ixo-vec|Ixo-vec will be administered intravitreally.
223961472|NCT06856577|DRUG|Aflibercept|Aflibercept will be administered intravitreally.
223961473|NCT02646098|PROCEDURE|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
224109723|NCT05176847|BEHAVIORAL|Podcasts and tips of the day (within app)|Participants will receive twice weekly podcasts and daily tips of the day, with nutrition and exercise information, audio diary and goal setting.
224109724|NCT05176847|BEHAVIORAL|mLIFE app (self-regulation features)|Diet (track by in app database), physical activity (tracked with FitBit and synced with mLIFE app), and weight (tracked with FitBit scale and synced with mL app) tracking app components. App notifications and reminders and newsfeeds.
223724401|NCT02933125|BEHAVIORAL|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
223961474|NCT01795313|BIOLOGICAL|HLA-A2 restricted synthetic tumor antigen|
223961475|NCT01795313|DRUG|Imiquimod|
223961476|NCT01795313|OTHER|enzyme-linked immunosorbent assay|
223961477|NCT01795313|OTHER|flow cytometry|
223724402|NCT05183373|OTHER|Evaluation of inflammation and clotting|Evaluation of inflammation biomarkers (such as 8-isoprostane, Il-6) and fibrin clot properties (such as clot lysis time, clot permeability)
223961478|NCT01795313|OTHER|immunohistochemistry staining method|
223961479|NCT01795313|OTHER|laboratory biomarker analysis|
223961480|NCT06990477|DEVICE|EIT-guided PEEP|PEEP titrated by EIT will be performed with a decremental trial at the enrollment. Right after completing RM, PEEP will be set to 20cmH2O and then reduced in steps of 2cmH2O from 20 to 6 every 2min.
223961481|NCT04095208|DRUG|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[80 mg\]."
223961482|NCT04095208|DRUG|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - \[240 mg\]."
223961483|NCT05548205|DEVICE|Continuous Glucose Monitor|Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.
223961484|NCT05548205|DEVICE|Blood Glucose Monitor|Self-administered according to investigator instruction.
223961485|NCT04661358|DRUG|Fenofibrate|Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
223961486|NCT04661358|OTHER|Placebo|Participants begin with a dose of either 160mg or 54mg placebo, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
223961487|NCT06598891|PROCEDURE|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
223961488|NCT06598891|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
224291303|NCT03384433|BIOLOGICAL|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
224291304|NCT00483587|DRUG|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
224291305|NCT05298787|DRUG|RLS-0071|RLS-0071 is administered as an IV infusion
224291306|NCT05298787|DRUG|Saline Placebo|Placebo is administered as an IV infusion
224109725|NCT05176847|BEHAVIORAL|mLIFE app (social support features)|"The gamified mLIFE app contains several components to help facilitate social gaming and support. This includes a newsfeed, to view the progress of other users, the ability to send others encouragement (likes/thumbs-up) for achieving goals, user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members.~For the experimental group, the app also includes features that facilitate healthy competition among participants through receipt of points for provision of social support and tracking health behaviors."
223961489|NCT06913777|DRUG|Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib|The backbone is chemotherapy which will be used in the control group. The precision group will add targeted therapy agents which were determined according to SNF classification: the SNF2 subtype add adebrelimab combined with famitinib, the SNF3 subtype receives fluzoparib, and the SNF4 subtype receives apatinib.
223961490|NCT06913777|DRUG|Chemotherapy (wP-EC)|Chemotherapy : weely nab-P \* 12- EC \* 4
223961491|NCT00555932|PROCEDURE|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
223961492|NCT05913609|DEVICE|Yaari Extractor|The Yaari Extractor device is a single-use prescription device for neonatal extraction in deliveries that are complicated by shoulder dystocia. The Study Device consists of two curved, rigid plastic-coated metal Arms with Handles which are used for control of the device outside the body, and an elastic Engagement Element which conforms to the maternal and neonatal anatomy, and which is used for direct contact with the entrapped neonate within the birth canal.
223961495|NCT02751632|BEHAVIORAL|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
223961496|NCT02751632|BEHAVIORAL|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
223961497|NCT02751632|DRUG|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
223961498|NCT02751632|DRUG|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
224109726|NCT05176847|BEHAVIORAL|standard mLIFE app (social support features)|"The standard mLIFE app has the ability to send others encouragement (likes/thumbs-up) for achieving goals and a user-to-user messaging system so active users of the app will be prompted to select send encouraging messages to other group members."
224109727|NCT00608335|DRUG|Micafungin|IV
223961499|NCT02751632|BEHAVIORAL|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
223961500|NCT05134428|DEVICE|ADAM System|The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
223961501|NCT06591598|DRUG|Aflibercept (BAY86-5321, Eylea)|8 mg, intravitreal injection
223961502|NCT05588128|DRUG|18F-DCFpyL|Administered to Cohort.
223961503|NCT07008729|DEVICE|Heart monitoring tools (data revision)|data collected by the devices will be reviewed by the treating physician in the intervention group
223961504|NCT07008729|OTHER|Control (Standard treatment)|Patients in the control group will be monitored but the information will not be available for the clinicians nor the artificial intelligence recommendations
223961505|NCT07008651|BEHAVIORAL|Digital parenting education|"Description: The digital parenting training to be given to mothers consists of 8 sessions of 20 minutes each. In the first week of the training process, a meeting will be held with the mothers in the experimental group and a brief introduction will be made to the subject. In the second week, information will be provided on the following topics: Definition and Roles of Digital Parenting, How Does the Use of Information Technologies Affect the Parent-Child Relationship?, How Does the Use of Information Technologies Affect Children's Behavior?, How Should Social Media Be Used Properly?, What are the Opportunities and Risks of Information Technologies for Parents and Children?, and What Should Parents Pay Attention to in the Use of Information Technologies? in the sixth week. In the eighth week, Question and Answer/Closing will be conducted to collect post-test data and end the training session."
223961506|NCT07008937|OTHER|Balneotherapy|"For balneotherapy, patients will be treated in a thermal pool for 15-20 minutes daily, with full-body immersion, for a total of 15 days.~For control, Volunteers in the control group will only receive a home exercise program. They will be called in for a check-up every five days to confirm that the home program is being followed correctly. In this way, the volunteers in the control group will not be left completely without treatment."
223724403|NCT01647815|PROCEDURE|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
223961507|NCT07008937|OTHER|home exercise program|home exercise program
223961508|NCT07007754|PROCEDURE|Voice recording playback|Voice recordings were created from a text containing 12 standardised messages common to both the patient's relatives and the researcher and expert opinion was obtained in terms of the applicability of the created text. Before the intervention, the postoperative patient's suitability was determined by the patient's statement and the researcher's observations. No intervention was performed if the patient had nausea/vomiting, pain or agitation before the intervention. Kingboss 8 Gb+ 650 hours uninterrupted digital voice recorder and headphones were used for voice recording. When the voice recorder and headphones were to be used in a different patient, they were wiped with 70% alcohol and used after waiting for 2 minutes in accordance with the manufacturer's instructions. The voice of one of the family members was recorded for Intervention group-1 patients and the voice of one of the researchers was (nötr voice) recorded for intervention group-2.
223961509|NCT07008300|DIETARY_SUPPLEMENT|Shoden|Shoden® powder is a commercial, dried 70% ethanolic extract of Withania somnifera (ashwagandha, WS) root and leaf, standardized to 35% withanolide glycosides. Shoden® powder is manufactured by Arjuna Natural Pvt Ltd, based in Kochi, Kerala, India.
223961510|NCT07008833|PROCEDURE|Radiochemotherapy|Maximum TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m². After 2-6 weeks of neoadjuvant chemotherapy, patients will receive radiotherapy for 4 weeks, with concomitant cisplatin at a dose of 40 mg/m² weekly.
223961511|NCT07008833|PROCEDURE|Radical cystectomy|TURBT will be followed by neoadjuvant chemotherapy with cisplatin at a dose of 35 mg/m², followed by radical cystectomy, bilateral pelvic lymphadenectomy, and reconstruction with either a Bricker procedure or a neobladder.
223961512|NCT07009054|BEHAVIORAL|Nutrition Education and Exercise|A 6-week intensive randomized controlled trial will be conducted with a total of 60 participants. Thirty participants will be assigned to the intervention group and thirty to the control group through simple randomization using a table of random numbers. The intervention group will receive one weekly theoretical-practical nutrition education session in Urdu and one physical activity session based on Nordic walking per week, for a total of six nutrition sessions and six physical activity sessions over the 6-week period.
224109728|NCT06384989|OTHER|Child restraint system with load leg feature|The primary objective is to assess the usability of the load leg design for caregivers who must install the child safety seat into a vehicle. The specific aims are to quantify any errors committed by the participants while installing the car seat (especially related to the use of the load leg) and to assess participants' opinions on the car seat's load leg design.
224109729|NCT04570943|COMBINATION_PRODUCT|Gabrinox|"Regimen: GEMBRAX~Other Names:~Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²~Regimen: FOLFIRINOX~Other Names:~Oxaliplatin 85 mg/m² + Leucovorin 200 mg/m² + Irinotecan 180 mg/m² + 5FU bolus 400mg/m² + 5FU continuous 2400 mg/m²~Gembrax + Folfirinox = GABRINOX"
224109730|NCT04570943|RADIATION|MRI-GUIDED STEREOTACTIC RADIOTHERAPY|"Radiotherapy will start between 5 and 6 weeks after the last injection of chemotherapy (FOLFIRINOX regimen) in non-progressive patients after Gabrinox.~Stereotactic adaptive radiotherapy in five fractions: prescription of five fractions of 10 Gy/each on the planning target volume (PTV). At least two sessions/week should be performed. An interval of at least 18 hours between fractions is recommended."
224109731|NCT05043116|DIETARY_SUPPLEMENT|Cholecalciferol D3|2000 IU of Vitamin D provided as oral suspension for one year
224109732|NCT05043116|OTHER|Oral placebo suspension|Oral suspension with no active substance tasting like the active supplement.
223961513|NCT07009054|BEHAVIORAL|Usual Care Group|The control group will participate in 2 theoretical sessions of nutrition education and 2 of physical exercise.
223961514|NCT07008066|OTHER|Bicycle ergometer excercise|Patients will undergo a symptom-limited ergometer cycling test under medical supervision. If the atrial fibrillation is not converted to sinus rhythm during the exercise test, the patients will be electrically converted.
223961515|NCT07008066|PROCEDURE|Standard care with electrical cardioversion|Standard care with planned electrical cardioversion without exercise intervention.
223961516|NCT07009249|BEHAVIORAL|Pelvic floor muscle training|"Women in this group will undergo pelvic floor muscle training (PFMT) using the NeuroTrac MyoPlus 4 PRO EMG biofeedback device. Prior to the training, diaphragmatic breathing will be taught to all participants in this position to facilitate relaxation and prepare for PFMT. During the training, participants will perform pelvic floor muscle contractions while observing the real-time feedback of slow and fast contractions, as well as relaxation phases, on the computer screen connected to the device. Concurrently, the physiotherapist will guide the participants with verbal cues such as squeeze-lift-release. Participants will be instructed to avoid holding their breath, pulling in their abdomen, straining, contracting the thigh or gluteal muscles, or moving the pelvis during the exercises. The PFMT protocol will follow the principles of motor learning stages to ensure proper skill acquisition."
223961517|NCT07009249|BEHAVIORAL|Dynamic neuromuscular stabilization|Women in this group will be instructed in exercises based on the principles of Dynamic Neuromuscular Stabilization (DNS). Prior to the exercises, intra-abdominal pressure regulation through breathing techniques will be demonstrated. In this study, the Core 360 belt with OhmTrack sensors will be used. Both breathing exercises and DNS exercises will be taught with the belt in place. In a corrected posture, participants will be instructed to gently press the abdominal wall toward the sensors and to maintain expansion of the abdominal wall during both inspiration and expiration, while keeping the spine in a neutral position. The exercise program will begin with a preparatory training phase, which includes fascial mobilizations applied to the feet and hands. DNS exercises will start with the 4.5-month supine developmental position for sagittal stabilization. As the program progresses, exercises will be advanced according to developmental kinesiology positions.
223961518|NCT07008755|DRUG|Peginterferon α-2b injection|During the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 45 μg per administration, to be delivered on Day 1 and Day 3.
223961519|NCT07008755|DRUG|Peginterferon α-2b injection|CoDuring the study period, patients will continue to receive symptomatic supportive therapy, along with nebulized Peginterferon α-2b injection at a dose of 90 μg per administration, to be delivered on Day 1 and Day 3.
223961520|NCT06681142|OTHER|Pharmacy-Physiotherapy Intervention|"Pharmacists will provide comprehensive 1:1 patient care, including a complete patient assessment and medication review, provide specific drug therapy recommendation(s) using shared decision making (SDM), and provide patient education, including further written materials.~Participants will be offered either individual or group physiotherapy sessions at the a private clinic."
223961521|NCT06676228|BEHAVIORAL|Fear of cancer recurrence therapy (FORT)|"FORT consists of 6 sessions in total, the scopes of the sessions are detailed below:~Session 1 (Acquiring new skills to cope with Fear of Cancer Recurrence (FCR)) HOMEWORK: Daily practice of progressive muscle relaxation exercise; creation of a thought record~Session 2 (Providing information on symptoms of cancer recurrence and increasing tolerance to uncertainty) HOMEWORK: Listening to recordings of relaxation exercises every day; practising self-calming, keeping a record of thoughts~Session 3 (Developing coping skills) HOMEWORK: Practise guided imagery daily; debunk erroneous beliefs about the benefits of worrying; keep a thought log~Session 4 (Deepening the underlying fears) HOMEWORK: Reading the worst case fear scenario every day, practising daily self-care and mindfulness practices~Session 5 (Moving beyond specific fears) HOMEWORK: Writing goals and priorities for the future~Session 6 (Review and conclusion) Reviewing all the discussed content"
223961522|NCT06676228|BEHAVIORAL|cognitive-behavioural therapy (CBT) group|"The cognitive-behavioural therapy (CBT) oriented control group consisted of a total of 6 sessions. The scopes of the sessions are given in detail below.~Session 1: Introduction and cancer-focused psychoeducation with CBT HOMEWORK: Keeping a thought diary~Session 2: Addressing the underlying causes of thoughts HOMEWORK: Keeping a thought diary about underlying beliefs~Session 3: Recognising conflicts HOMEWORK: Task: Keep a diary of thoughts about disagreements (what gives us pleasure and what we should master)~Session 4: Effective communication techniques HOMEWORK: Keeping a diary about the use of the word good enough~Session 5: Discussion of the definitions of anxiety and depression~Session 6: Anger Management HOMEWORK: HOMEWORK: Keeping a diary about the use of the breathing exercise"
223961523|NCT06263244|DRUG|Ziltivekimab|Monoclonal antibody targeting IL-6
223961524|NCT06263244|DRUG|Placebo|Placebo
223961525|NCT06682234|DRUG|obeldesivir|Tablets administered orally
223961526|NCT07014982|BEHAVIORAL|Guided Meditation|Participants who complete guided meditation will be asked to meditate for 5 minutes a day, five times a week for two 6-week periods.
223961527|NCT06627179|DRUG|Intravitreal Injection of Ultevursen|Up to 4 doses over a 24-month period
224109733|NCT05720910|OTHER|GERONTE|The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
223961528|NCT06627179|OTHER|No intervention, will not receive any active study intervention|Sham-procedure (no experimental drug administered)
223961529|NCT04581499|COMBINATION_PRODUCT|DynamiCare Motivation Support Program|DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.
223961530|NCT04581499|OTHER|Untreated or Routine Care Control Group|No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
223961531|NCT06624358|BEHAVIORAL|Increase Physical Activity|Behavioral interventions to improve physical activity
224109734|NCT02699515|DRUG|MSB0011359C|Subjects with metastatic or locally advanced solid tumors received intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
223961532|NCT05399602|DIAGNOSTIC_TEST|Lumbar puncture|Standardized lumbar puncture in L3/4 or L4/5 in diagnosis of hydrocephalus and CSF sampling (sample 1 in NfL level measurement)
223961533|NCT05399602|DIAGNOSTIC_TEST|External lumbar drainage|External lumbar drainage placement for assessing responsivity of external derivation of CSF. It is test of responsivity to ventriculo-peritoneal shunt placement
223961534|NCT05399602|DIAGNOSTIC_TEST|Lumbar infusion test|Diagnostic test accompanying the first lumbar puncture made as i diagnostic test of hydrocephalus. Based on infusion of saline by 90 mL per hour with measurement of CSF pressure each 1 minute and then count of so-called Rout (index).
223961535|NCT05399602|PROCEDURE|Ventriculo-peritoneal shunt placement|Surgical procedure based on implantation a thin catheter into brain lateral ventricle (placed through a burrhole from Kocher point) and connection to prechamber and valve (placed behind the ear under skin) and similar thin catheter pushed under skin of neck, chest and abdomen (where put intraperitoneally).
223961536|NCT05399602|PROCEDURE|General Anesthesia|Standardized combinated general anesthesia with combination of i.v. and inhalated drugs according the protocol. Given by anesthesiologist.
223961537|NCT05399602|PROCEDURE|Prechamber puncture|Puncture of prechamber (place behind the ear under the skin) by thin needle and aspiration of 5 mL of CSF (5 days, 1 month a 2 months after surgery)
223961538|NCT05399602|PROCEDURE|Blood sampling #1|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours prior surgery
223961539|NCT05399602|PROCEDURE|Blood sampling #2|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 24 hours after surgery
223961540|NCT05399602|PROCEDURE|Blood sampling #3|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 5 days after surgery
223961541|NCT05399602|PROCEDURE|Blood sampling #4 and #5|Blood sampling to get level of NfL from standarized percutaneous vein puncture by thin needle 1 and 2 months after surgery (only in interventional group)
223961542|NCT06683560|DEVICE|": photopolymer resin material graphy Tera Harz 85 will be used to print 3D printed aligners for NAM treatment"|3d printed NAM aligner is made from novel photopolymer resin as a novel device
223961543|NCT07018739|BIOLOGICAL|Wharton's jelly-derived mesenchymal stem cells|MSCs (1x10\^7 cells/kg) in 10 mL 0.9%normal saline administered intravenously within 10 days, postnatally after TH completion, every 24 h for 3 consecutive days
223961544|NCT07018739|DRUG|0.9 % Normal Saline|0.9% normal saline 10 mL administered intravenously within 10 days, postnatally after TH completion, every 24 h for 3 consecutive days
223961545|NCT05726591|DEVICE|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
223961546|NCT06630780|RADIATION|Head and Neck Cancers|All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.
223961547|NCT06699836|DRUG|350 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
223961548|NCT06699836|DRUG|700 mg leronlimab|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
223961549|NCT06700395|DRUG|TQB2029 injection|TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.
223961550|NCT03614949|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
223961551|NCT03614949|DRUG|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
223961552|NCT04880382|DRUG|ICI treatment discontinuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be discontinued. Patients will be followed as per standard mangement thereafter
223961553|NCT04880382|DRUG|ICI treatment continuation|After achieving objective response between 6 and 12 months after treatment onset, for these patients, first or second line treatment by immune checkpoint inhibitor will be continued until disease progreession or unacceptable toxicity
223961554|NCT06697236|OTHER|EPICES score|"EPICES score used to group participants as precarious and non precarious."
223961555|NCT06697236|OTHER|PICS evaluation|"* Assessment of physical symptoms using the Timed up and go test (TUG)~* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7 and screening for post-traumatic stress disorder using the IES-R~* Assessment of cognitive disorders using the MoCA"
223724404|NCT06460857|OTHER|Manual Diaphragmatic Release Technique|Manual Diaphragmatic Breathing Technique, 2 sets with a 5 min rest interval between sets will be given, patient will lie supine in a relaxed position, Therapist will stand behind the patients head with the therapist forearm aligned towards patient shoulders, the hypothenar and the last three fingers of therapist hand will make contact bilaterally with underside of 7th, 8th, 9th, and 10th ribs costal cartilages, Patient is instructed to inhale deeply, therapist will pull the contact sites towards head and slightly in a lateral direction, during expiration therapist increases the contact depth beneath costal margins and maintain the resistance, therapist will continue to increase the depth of contact in the coming deep breath. Initially patient will be asked to take 5 deep breath/ set in the first week then it will progress to 10 deep breaths in the second,third and fourth week.
223961556|NCT06697236|OTHER|PICS-F evaluation|"* Assessment of depressive symptoms using the PHQ-8 and anxiety symptoms using the GAD-7~* Screening for post-traumatic stress disorder using the IES-R"
223961557|NCT06700343|DRUG|Ocrelizumab (US)|IV infusion
223961558|NCT06700343|DRUG|Ocrelizumab (EU)|IV infusion
223961559|NCT06700343|DRUG|ABP 692|IV infusion
223961560|NCT06336109|OTHER|Hypertonic saline knee and shoulder injection|"0.25 mL injection with hypertonic saline (7%) in the infrapatellar fat pad.~1.2 mL injection with hypertonic saline (7%) in the deltoid muscle."
223961561|NCT06877429|PROCEDURE|Time of OPU|OPU procedure either at 8 am or 8 pm
223961562|NCT07039877|DRUG|Venetoclax low dose with itraconazole|The investigators will add venetoclax in low dose (100 mg) with itraconazole to the pediatric inspired regimen TACL to enchance the complete response rate
223961563|NCT07034794|DIETARY_SUPPLEMENT|Lysoveta|The Lysoveta capsules contain 500 mg of lysophosphatidylcholine-rich oil extract of Antarctic krill.
223961564|NCT07034794|OTHER|Placebo|The placebo capsules contain medium-chain triglyceride (MCT) oil, maize oil, olive oil, and palm kernel oil.
223961566|NCT06720038|BIOLOGICAL|0.5 mL of the low dose VAX-31|31 valent pneumococcal conjugate vaccine
223961567|NCT06720038|BIOLOGICAL|0.5 mL of the mid dose VAX-31|31 valent pneumococcal conjugate vaccine
223961568|NCT06720038|BIOLOGICAL|0.5 mL of the high dose VAX-31|31 valent pneumococcal conjugate vaccine
223961569|NCT06720038|BIOLOGICAL|0.5 mL dose of PCV20|20 valent pneumococcal conjugate vaccine
223961570|NCT06720038|BIOLOGICAL|0.5 mL of the High-PFS dose VAX-31|31 valent pneumococcal conjugate vaccine
223961571|NCT06884618|DRUG|RO7673396|RO7673396 will be administered as per the schedule specified in the protocol.
223961572|NCT06719570|DRUG|MK-8591A|Fixed dose combination tablet
223961573|NCT06719570|DRUG|Islatravir|Oral capsule
223724405|NCT06460857|OTHER|Chest Wall Expansion Exercises|Four different types of chest exercises will be given to second group for 2-3 days/week for 4 weeks along with generalized body stretching
223724406|NCT04271891|DEVICE|WBPC|The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.
223724407|NCT04271891|DEVICE|Without WBPC|Not treat with WBPC
223961574|NCT06719570|DRUG|Doravine|Oral tablet
223961575|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-HL|Participants will test continuous administration of investigational product for 16 weeks.
223961576|NCT06755892|DIETARY_SUPPLEMENT|Placebo syrup|Participants will test continuous administration of placebo product for 16 weeks.
223961577|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-LH|Participants will test continuous administration of investigational product for 16 weeks.
223961578|NCT06755892|DIETARY_SUPPLEMENT|ColMSM-LL|Participants will test continuous administration of investigational product for 16 weeks.
223961579|NCT06755892|DIETARY_SUPPLEMENT|Col-L|Participants will test continuous administration of investigational product for 16 weeks.
223961580|NCT05650658|DEVICE|His/LBBP|Pacing at the level His-Bundle or left bundle branch is used to correct the underlying conduction abnormality, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular defibrillator endocardial lead for LVEF≤35% and by a right atrial endocardial lead for LVEF 36-50%.
223961581|NCT05650658|DEVICE|BiVP|"Biventricular pacing has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.~For LVEF≤35% a biventricular pacemaker-defibrillator will be implanted while for LVEF 36-50% a biventricular pacemaker will be implanted."
223961582|NCT05810038|DRUG|Rimegepant|Rimegepant
223724408|NCT00709046|DRUG|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
223724409|NCT00709046|DRUG|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
223961583|NCT05810038|DRUG|Placebo|matching placebo
223961584|NCT07058805|RADIATION|Compartmentalized Postoperative Radiotherapy|Pathology- and imaging-guided compartmentalized postoperative radiotherapy (PORT), with or without concurrent systemic treatment. Based on a predefined algorithm, PORT or specific anatomical volumes may be omitted. Dose prescription and volumes are risk-adapted.
223961585|NCT06752772|DEVICE|Smart watch|Participants are required to wear the study issued smart watch for at least 8 hours a day during the intervention period and are encouraged to wear it beyond the study intervention period.
223961586|NCT06752772|BEHAVIORAL|Dashboard with nudging system|Nudges will be sent to participants' smart watch/mobile application with messages that are designed to motivate them to lead a healthy lifestyle.
223961587|NCT06752772|DEVICE|Digital Health Coach (DHC)|Participants will be assigned to a DHC and the DHC will be providing them with remote health coaching assistance for a duration of 6 months, upon successful enrolment.
223961588|NCT07055477|DRUG|Cyclophosphamide|Days -5 to -3: Cyclophosphamide 300 mg/m\^2 x 3 days
223961589|NCT07055477|DRUG|Fludarabine|Days -5 to -3: Fludarabine 30 mg/m\^2 IV daily over 30 minutes for 3 days
223961590|NCT07055477|BIOLOGICAL|Autologous CCR4 CAR T cells|Day 0: Cells will be infused intravenously (IV) over 10-30 minutes
223961593|NCT05937906|DRUG|Phase I - Mirdametinib - Level 1|Mirdametinib 4 mg twice/day for 7 days per cycle
223961594|NCT05937906|DRUG|Phase II - Mirdametinib|For phase 2 : Randomisation with 2 arm : Standard arm and experimental arm
223961595|NCT05937906|DRUG|Phase I - Mirdametinib - Level 2|Mirdametinib 4 mg twice/day for 14 days per cycle
223961596|NCT05937906|DRUG|Phase I - Mirdametinib - Level 3|Mirdametinib 6 mg twice/day for 7 days per cycle
223961597|NCT05937906|DRUG|Phase I - Mirdametinib - Level 4|Mirdametinib 6 mg twice/day for 14 days per cycle
223961598|NCT06704672|DEVICE|Accu-Chek SmartGuide CGM Solution|The Accu-Chek SmartGuide CGM solution is used for real-time continuous glucose monitoring (CGM) in the interstitial fluid. It consists of the Accu-Chek SmartGuide device and two smartphone applications (apps): the Accu-Chek SmartGuide app and the Accu-Chek SmartGuide Predict app. The Accu-Chek SmartGuide device contains a CGM sensor pre-assembled in a sensor applicator. It has connectivity to the smartphone that is running the Accu-Chek apps. The Accu-Chek SmartGuide app is the primary display of the real-time glucose values. The Accu-Chek SmartGuide Predict app is an information management tool that further visualizes and analyzes diabetes data from the Accu-Chek SmartGuide device.
223961599|NCT06704672|DEVICE|Accu-Chek SmartGuide Sensor and Blinded Apps|The participants in the SMBG control group will wear a SmartGuide sensor with blinded SmartGuide apps intermittently, i.e., during the assessment periods. It is not possible to read out the glucose data from the blinded app, hence neither the SmartGuide app nor the SmartGuide Predict functionalities can be accessed by the participants in this group.
223724410|NCT01138553|DRUG|Mifepristone|200mg capsules daily for 5-28 days
223724411|NCT06000514|DRUG|Sm29 Protein, Schistosoma Mansoni|Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
223724412|NCT06000514|DRUG|Pentavalent antimony (Sbv)|Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
223961600|NCT06704672|DEVICE|SMBG Device|With the SmartGuide apps in blinded mode, participants in the SMBG control group will continue using their own SMBG device or they may use the Accu-Chek Instant meter that will be provided for calibration of the SmartGuide device.
223961605|NCT06892288|DRUG|GLM101 (Part A, Double-blind)|IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A
223724413|NCT00031863|DRUG|rofecoxib|
223724414|NCT00031863|PROCEDURE|adjuvant therapy|
223724415|NCT03780907|DRUG|E2007|1 mg of E2007 was administered by mouth once daily.
223724416|NCT03780907|DRUG|E2007|2 mg of E2007 was administered by mouth once daily.
223961606|NCT06892288|DRUG|Placebo (Part A, Double-blind)|IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A
223961607|NCT06892288|DRUG|GLM101 (Part B, Open-label)|IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants
223724417|NCT03780907|DRUG|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
223961608|NCT06898970|BIOLOGICAL|Vusolimogene Oderparepvec (VO)|Given intratumorally
223961609|NCT06898970|DRUG|Pembrolizumab|Given IV
223961610|NCT07069595|DRUG|Datopotamab deruxtecan|Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.
223961611|NCT07069595|DIAGNOSTIC_TEST|Circulating tumor DNA (ctDNA) testing|Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.
223724418|NCT06040112|DEVICE|Atelocollagen|Tendoregen (Atelocollagen) injection
223961612|NCT04562129|DRUG|Interleukin-2|High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)
223724419|NCT01760707|BEHAVIORAL|exercise training|
223724420|NCT01760707|BEHAVIORAL|usual care|
223961613|NCT04562129|DRUG|Ipilimumab|Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.
223961614|NCT04562129|DRUG|Nivolumab|Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
223961615|NCT06334016|PROCEDURE|Biospecimen Collection|Undergo blood collection
224109735|NCT06523426|DIAGNOSTIC_TEST|Patient treated by spinal endoscopy|Questionnaire administered by surgeon; assessment of level of autonomy for activities of daily living
224109736|NCT05520619|DRUG|Paclitaxel, Cisplatin|Patients received 2 cycles of induction chemotherapy with paclitaxel/cisplatin (paclitaxel 135-175mg/m2 and cisplatin 75 mg/m2) prior to radiotherapy. Then patients will receive paclitaxel 45mg/m2 and cisplatin 25 mg/m2 once weekly for 5 weeks during radiotherapy.
224109737|NCT05520619|DRUG|tislelizumab|Patients received tislelizumab 200 mg every 3 weeks for 16 cycles in Arm A and 4 cycles in Arm B.
224109738|NCT05520619|RADIATION|Radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
223961616|NCT06334016|DRUG|Cannabis sativa Extract|Vape THC
223961617|NCT06334016|DRUG|Nicotine|Vape active nicotine
223961618|NCT06334016|DRUG|Placebo Administration|Vape placebo nicotine
223961619|NCT06334016|OTHER|Questionnaire Administration|Ancillary studies
223961620|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 30 mg of elemental iron|MMS with 30 mg iron is the active comparator group. The standard UNIMMAP MMS formulation includes 30 mg of iron which will be taken orally once daily for one month.
223961621|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 45 mg of elemental iron|MMS with 45 mg iron is an intervention group. MMS with 45 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
224109739|NCT05417971|OTHER|Fludarabine|Reduced-intensity fludarabine with intermediate-dose TBI
224109740|NCT06362408|DRUG|Dexmedetomidine|Older patients who have used dexmedetomidine(safe use range: 0.2\~1.0 μg/(kg·h)) for anesthesia induction or maintenance during surgery were classified as the DEX group. On the contrary, patients who did not use dexmedetomidine throughout the entire anesthesia process were identified as the Non-DEX group.
224109741|NCT04537390|DIAGNOSTIC_TEST|Blood sample collection|Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
224109742|NCT06396156|PROCEDURE|Anterior enclavation|Anterior enclavation of iris-claw lens
224109743|NCT06396156|PROCEDURE|Posterior enclavation|Posterior enclavation of iris-claw lens
224109744|NCT01815710|OTHER|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
224109745|NCT01815710|OTHER|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
224109746|NCT05238896|DRUG|Baricitinib Oral Tablet [Olumiant]|Baricitinib 4 mg/d oral route for 42 days
224109747|NCT05238896|DRUG|Placebo|Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
223961622|NCT06069869|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily for one month.
223961623|NCT06784947|PROCEDURE|Pre-Treatment Biopsy|The pre-treatment biopsy should be performed at least 3 days prior to C1D1 of treatment.
223961624|NCT06784947|PROCEDURE|On-Treatment Biopsy|While the acceptable window for the C3D1 biopsy is ±3 days, it is preferred that the biopsy occurs following all treatments on C3D1.
223961625|NCT06784947|DRUG|Tiragolumab|Tiragolumab is a human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. This treatment may help the immune system attack cancer cells.
223961626|NCT06784947|DRUG|Atezolizumab|Atezolizumab is a type of targeted therapy drug called an immune checkpoint inhibitor. It is a monoclonal antibody that works by binding to the protein PD-L1 (programmed death) on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
223961627|NCT06784947|DRUG|Bevacizumab|Bevacizumab works by blocking a protein called Vascular Endothelial Growth Factor (VEGF), which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow, and may help improve the immune response in the tumor. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.
223961628|NCT05844982|DRUG|Faricimab|6.0 mg intravitreal injection at randomization and every 3 months
223961629|NCT05844982|DRUG|fluocinolone acetonide|0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
223961630|NCT06780579|DRUG|Bulevirtide|10 mg BLV will be administered via subcutaneous injection
223961631|NCT05894239|DRUG|Inavolisib|Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.
223961632|NCT05894239|DRUG|Phesgo|Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
223961633|NCT05894239|DRUG|Placebo|Inavolisib-matching tablet taken PO QD on Days 1-21 of each 21-day cycle, beginning on D1 C1 of maintenance treatment.
223961634|NCT05894239|DRUG|Taxane-based Chemotherapy|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy will be administered after Phesgo.
223961635|NCT05894239|DRUG|Optional Endocrine Therapy of Investigator's Choice|Optional endocrine therapy (ET) is allowed at the discretion of the investigator, based on the standard of care. Allowed ETs are tamoxifen, or one of the specified third-generation aromatase inhibitor (AI \[anastrozole, letrozole, or exemestane\]), or fulvestrant. The investigator will determine and supply the appropriate luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
223724421|NCT00680667|BIOLOGICAL|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
223724422|NCT04271605|BEHAVIORAL|diet and exercise suggestion|diet and exercise suggestion according to blood biochemistry data and bone mineral density
223961636|NCT06680427|DEVICE|Siegel Transcatheter Aortic Valve (TAVR)|Replacement of native aortic valve with the Siegel Transcatheter Aortic Valve (TAVR) by a transfemoral approach.
223961637|NCT06496490|DRUG|TQB2102 for injection|HER2 dual-antibody-drug Conjugate (ADC).
223961638|NCT06496490|DRUG|TQB2102 for injection combined with Benmelstobart injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC); Benmelstobart injection is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1).
223961639|NCT07130513|DIETARY_SUPPLEMENT|Krill oil supplementation|Krill oil supplementation program providing 4 g/day of krill oil (Superba™ Antarctic Krill Oil, 1000 mg capsules) for 12 weeks.
224109748|NCT05099601|COMBINATION_PRODUCT|Silymarin|The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
224109749|NCT05099601|PROCEDURE|Microneedling|Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
224109750|NCT01792986|BEHAVIORAL|water-only 24-hour fasting once per week for 6 weeks|
224109751|NCT00375934|DRUG|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
224109752|NCT00375934|DRUG|Placebo|Oral placebo capsule, every 6 hours
224109753|NCT03191396|DRUG|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
224109754|NCT03191396|DRUG|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
224109755|NCT02980835|DRUG|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
224109756|NCT02980835|DRUG|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
224109757|NCT02980835|DRUG|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
224109758|NCT02980835|DRUG|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
223961640|NCT07130513|DIETARY_SUPPLEMENT|Control|Vegetable oil supplementation (4 g/day)
223961641|NCT07085338|DRUG|Temozolomide|IV, Days 1-5
223961642|NCT07085338|DRUG|Irinotecan|IV, Days 1-5
223724423|NCT01923701|BEHAVIORAL|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
223724424|NCT03446183|BEHAVIORAL|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
224109759|NCT01605305|DRUG|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
224109760|NCT01025245|DRUG|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
224109761|NCT00293072|DRUG|Rituximab|
224109762|NCT02189330|DRUG|Tafamidis|20 mg of current commercial formulation.
224109763|NCT02189330|DRUG|Tafamidis|12.2 mgA free acid tablet.
224109764|NCT02189330|DRUG|Tafamidis|20 mg new soft gelatin capsule.
224109765|NCT02189330|DRUG|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
223724425|NCT03342690|DRUG|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
223961643|NCT07085338|DRUG|hu14.18K322A|IV over 4 hours daily times 4 doses, Days 2-5.
224109766|NCT02189330|DRUG|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
224109767|NCT01677611|DRUG|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
224109768|NCT01677611|DRUG|Placebo|
224109769|NCT01300286|DRUG|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
223724426|NCT03131050|DRUG|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
223724427|NCT03131050|DRUG|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
223724428|NCT03131050|DRUG|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
223724429|NCT04519151|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
223961644|NCT07085338|DRUG|N803|Subcutaneous (SC), Day 6.
223961645|NCT07085338|DRUG|Sargramostim|Subcutaneous injection (preferred) or IV, Days 7-13.
224109770|NCT02901717|DRUG|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
224291307|NCT00700817|DRUG|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
224291308|NCT00700817|DRUG|sitagliptin|Tablets, 100 mg daily
224291309|NCT00700817|DRUG|metformin|Tablets, minimum 1500 mg daily
223724430|NCT04519151|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
224109771|NCT02901717|DRUG|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
224109772|NCT01292395|OTHER|Dietary Protein Intake|Protein intakes within the current recommendation
223961646|NCT07085923|BEHAVIORAL|Lifestyle Intervention|The Lifestyle Program consists of monthly one-on-one dietary counselling sessions with a registered clinical dietitian, monthly group-based physical activity sessions led by an instructor, and support to follow a personalized exercise plan. The intervention focuses on cardioprotective dietary changes, weight reduction, and increasing physical activity at moderate-to-high intensity to meet recommended amount. Participants will receive dietary supplementation corresponding to a therapeutic dose of 1000 mg EPA+DHA per day from fish oil. During monthly visits with the dietitian, data will be collected to monitor progress and support adherence. Participants will be encouraged to monitor body weight at home between visits (bathroom scales are loaned as needed), and follow up is carried out biweekly via phone-calls. The intervention is designed to be feasible within routine mental health care and tailored to the needs of adults with severe mental illness.
223961647|NCT07086547|OTHER|AI-Based Fever Management Education|This intervention consists of a fever management education program developed using ChatGPT 4.0, a large language model by OpenAI. The educational content includes seven pages and eight visuals explaining how to manage fever in children. The content was reviewed by pediatric specialists and revised accordingly. It is delivered as a one-time structured session to mothers in the intervention group.
223961648|NCT05950464|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223961649|NCT05950464|PROCEDURE|Biopsy Procedure|Undergo biopsy
223961650|NCT05950464|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223724431|NCT05741567|PROCEDURE|correction of anterior prolapse|percentage of failed prolapse correction
223961651|NCT05950464|PROCEDURE|Computed Tomography|Undergo CT
223961652|NCT05950464|PROCEDURE|Electrocardiography|Undergo ECG
223961653|NCT05950464|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223961654|NCT05950464|DRUG|Tuvusertib|Given PO
223961655|NCT05950464|PROCEDURE|X-Ray Imaging|Undergo x-ray
223961656|NCT06128564|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
223961657|NCT06816550|OTHER|Doing Interviews with the patients admitted to emergency department to detect whom are on chronic use of nonsteroidal anti inflammatory drugs|detection of patients on chronic use of nonsteroidal anti inflammatory drugs among total patients admitted to emergency department in Alexandria Main University Hospital
224109773|NCT00077987|DRUG|SU011248|
224109774|NCT00631722|DRUG|Quatiapine Fumarate|600-750mg/day
224109775|NCT00631722|DRUG|Haloperidol|12-20mg/day
224109776|NCT04716439|PROCEDURE|Spine Surgery|spine decompression and fixation
224109777|NCT01322607|BEHAVIORAL|High-intensity Treadmill Exercise|High-intensity treadmill walking program
224109778|NCT01322607|BEHAVIORAL|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
224109779|NCT03207256|DRUG|TGR-1202|Oral Daily TGR-1202
224109780|NCT03207256|DRUG|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
224109781|NCT04789746|BEHAVIORAL|adapted Chicago Run running program|The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
224109782|NCT02425267|OTHER|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
224109783|NCT03640091|PROCEDURE|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
224109784|NCT04547244|OTHER|echocardiographic optimization of CRTd|the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.
224109785|NCT00017316|DRUG|semaxanib|
223961658|NCT07093619|DEVICE|FERTILE Plus|The FERTILE PLUS™ method is a standardized method with an easy-to-follow protocol that is far less dependent on the skill or experience of the embryologist than other methods, such as density gradients. The FERTILE PLUS™ (850 µL) Sperm Sorting Chip is a single-use, flow-free, dual chambered, microfluidic-based sperm sorting device. FERTILE PLUS™ was previously known as Zymot, prior to a name change by the manufacturer. The lower chamber contains a sample inlet and fluid channel separated from the upper collection chamber by a microporous membrane with 8-μm pores, demonstrated as the optimal size for selection of sperm with higher motility and normal morphology \[18\].
224109786|NCT00017316|DRUG|thalidomide|
224109787|NCT05183958|RADIATION|Radiotherapy group|Stereotactic body radiotherapy (SBRT, 8Gy/time, 3 -5 times, if other segmentation schemes are used, recommend BED10 \>60Gy) or conventional fractional radiotherapy (parts that are not suitable for SBRT, the total dose is more than 30Gy); the primary lesion should be treated with conventional fractional radiotherapy with a dose of 4000cGy or more;
224109788|NCT05183958|DRUG|Camrelizumab|4 cycles for combined therapy. Camrelizumab maintenance.
224109789|NCT05183958|DRUG|Chemotherapy|4 cycles for combined therapy.
224109790|NCT01444521|DRUG|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
224109791|NCT01879605|DRUG|Docusate natrium and sorbitol|
224109792|NCT01879605|DRUG|Bisacodyl|
223724432|NCT01373801|DEVICE|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
223961659|NCT06910436|DIAGNOSTIC_TEST|Coronary Angiogram|Diagnostic/therapeutic procedure to reopen an occluded coronary artery by inflating a balloon and inserting a stent
223961660|NCT07104383|DRUG|VK2735|VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
224109793|NCT05358691|DRUG|AN0025|To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
224109794|NCT04608097|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
224109795|NCT04608097|BEHAVIORAL|Attention Placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
224109796|NCT03060577|DRUG|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
224109797|NCT03060577|DRUG|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
224109798|NCT00148629|DRUG|multivitamin, mebendazole|
224109799|NCT05483543|DRUG|Pamiparib|Patients will receive Pamiparib 40 mg bid every 3 weeks after cCRT up to 1 year or disease progression according to RECIST v1.1 occur.
224109800|NCT00005963|DRUG|carboplatin|
224109801|NCT00005963|DRUG|docetaxel|
224109802|NCT02435173|DRUG|CDZ173|CDZ173 10 and 70 mg capsules for oral administration.
224109803|NCT02435173|OTHER|Placebo|Placebo capsules for oral administration
224109804|NCT01477632|DRUG|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
223961661|NCT07112690|OTHER|Electronic Health Record Review|Ancillary studies
223961662|NCT07112690|PROCEDURE|Fluoroscopy|Undergo fluoroscopy
223961663|NCT07112690|PROCEDURE|Ganglion Impar Neurolysis|Undergo ganglion impar neurolysis
223961664|NCT07112690|OTHER|Questionnaire Administration|Ancillary studies
223961665|NCT07115862|OTHER|pomegranate juice -> habitual diet|237 ml of pomegranate juice for the first 8 weeks -\> habitual diet for the second 8 weeks
223961666|NCT07115862|OTHER|habitual diet -> pomegranate juice|habitual diet for the first 8 weeks -\> 237 ml of pomegranate juice for the second 8 weeks
223961667|NCT06912854|OTHER|Sensory Adapted Dental Environment|"The SADE condition consists of physical adaptations (visual, auditory, tactile modifications) to the dental environment meant to create a less anxiety-provoking sensory experience. Direct overhead fluorescent lighting and the regular dental overhead lamp will be turned off and darkening curtains will cover the windows. Adapted lighting will include slow moving visual color effects (Snoezelen) shining on the ceiling in the child's visual field. The dentist will wear a surgical dental headlamp directed into the patient's mouth, reducing bright lights shining in the child's eyes. Auditory stimuli will be calming rhythmic music (Dan Gibson's Exploring Nature) projected via portable speakers. The tactile deep pressure stimulus will be a commercially available weighted blanket (10-15% of the child's weight) placed on the child to provide deep hugging pressure, which produces a calming effect."
223961668|NCT06912854|OTHER|Video-based Modeling|Participants will watch an approximately 5-minute video depicting a dental cleaning being performed on a sex and age-matched cooperative child, designed to expose the participant to the activities of the dental cleaning and thereby create a less anxiety-provoking dental experience.
223961669|NCT03342625|DEVICE|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
223961670|NCT06084936|DRUG|Obinutuzumab|Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1
223961671|NCT06084936|DRUG|Glofitamab|Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).
223961672|NCT06084936|DRUG|Rituximab|Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).
223961673|NCT06084936|DRUG|Bendamustine|Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).
223961674|NCT06084936|DRUG|Lenalidomide|Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.
223961675|NCT06084936|DRUG|Tocilizumab|Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
223961676|NCT06253663|DRUG|KTE-X19|A single infusion of chimeric antigen receptor (CAR) T cells
223961677|NCT06253663|DRUG|Cyclophosphamide|Administered intravenously
223961678|NCT06253663|DRUG|Fludarabine|Administered intravenously
223961679|NCT06923189|BEHAVIORAL|Family Planning Intervention|"This multilevel intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community. The intervention is paired with health system strengthening elements implemented with the intervention health clinics (provider training, strengthening skip the queue policies, linkage of family planning services directly to dialogues)."
223961680|NCT06923189|BEHAVIORAL|Water, Sanitation, and Hygiene (WASH) Intervention|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (handwashing, food preparation) following an intervention manual that was developed for community groups in East Africa and tailored to the local Uganda context."
223961681|NCT06922942|DEVICE|MSCopilot Flower mobile application|MSCopilot Flower includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Anxiety
223961682|NCT07118722|BEHAVIORAL|Quiet Focus|Mindfulness-based cognitive therapy adapted for older adults at-risk for chronic pain and depression
223961683|NCT07118722|BEHAVIORAL|Health Enhancement Program|Time- and dose-matched control for Quiet Focus.
224109805|NCT01477632|DRUG|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
224109806|NCT01477632|DRUG|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
224109807|NCT00471471|BIOLOGICAL|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
223724433|NCT01373801|DEVICE|Control|Standard packing gauze roll bandage.
224109808|NCT00471471|BIOLOGICAL|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
224109809|NCT00471471|BIOLOGICAL|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
224109810|NCT02162745|DRUG|Isotonic solution (NaCl 0.9%)|
224109811|NCT02162745|DRUG|Hypertonic solution (NaCl 3%)|
223724434|NCT04362787|DEVICE|High pressure non invasive ventilation in acute hypercapnic respiratory failure|Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
223724435|NCT03453944|DEVICE|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
223724436|NCT03453944|DEVICE|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
224109812|NCT05706467|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
224109813|NCT05706467|DEVICE|Non-invasive continuous positive airway pressure ventilation|Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
224109814|NCT02847611|DEVICE|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
224109815|NCT02399878|DRUG|Inspiratory oxygen|
224109816|NCT03216265|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
224109817|NCT03216265|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
224109818|NCT03216265|OTHER|No treatment|No treatment.
224109819|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
224109820|NCT00569920|DRUG|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
223724437|NCT05608889|BEHAVIORAL|Total Worker Health Mindfulness Enhanced Program|"The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support."
224109821|NCT00569920|DRUG|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
224109822|NCT01257126|DRUG|diclofenac potassium|
224109823|NCT01257126|DRUG|nimesulide|
224109824|NCT03952546|DEVICE|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
224109825|NCT03952546|DEVICE|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
224109826|NCT02734992|BEHAVIORAL|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou \& Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
224291310|NCT00700817|DRUG|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
223724438|NCT05479071|DIAGNOSTIC_TEST|Blood test|Screening of antibodies against LDL
223961684|NCT06924710|DRUG|Standard Therapy|For patients with negative EGFR/ALK mutation, adjuvant chemotherapy or adjuvant chemotherapy combined with immunotherapy was administered, for patients with positive EGFR/ALK mutation, targeted therapy was administered.
223961685|NCT06924710|OTHER|Adaptive Therapy|Patients will be under close MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
224109827|NCT02734992|BEHAVIORAL|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
224109828|NCT05265013|COMBINATION_PRODUCT|ASP-1929 Photoimmunotherapy|ASP-1929 640 mg/m\^2 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion
224109829|NCT05265013|BIOLOGICAL|pembrolizumab|200 mg every three weeks on days 1 and 22 of each 6-week cycle, 30 minute IV infusion
224109830|NCT00124540|DRUG|misoprostol|
224109831|NCT00124540|DRUG|placebo|placebo resembling misoprosotl
223724439|NCT04661085|DIAGNOSTIC_TEST|Broader Medical history and clinical tests|Patients will be treated with standard care plus additional blood tests, urine culture and urine flow cytometry,
223724440|NCT04519710|BIOLOGICAL|o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B|to receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
223724441|NCT03582202|PROCEDURE|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
223724442|NCT03582202|PROCEDURE|Standard care|Nutritional handling by nurse
223724443|NCT06049745|DRUG|Misoprostol 400 Microgram Oral Tablet|S.L misoprostol 400 mcg
223961686|NCT03051984|DEVICE|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (\~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
223961687|NCT06655246|DRUG|ziftomenib|menin inhibitor
223724444|NCT02050360|DRUG|Sildenafil 40 mg|
223724445|NCT02050360|DRUG|Sildenafil 80 mg|
223724446|NCT02050360|DRUG|Placebo|
223961688|NCT06655246|DRUG|imatinib mesylate|kinase inhibitor
223961689|NCT06927999|DRUG|Placebo|Placebo solution nasal spray containing no active drug
223961690|NCT06927999|DRUG|0.5 mg epinephrine|0.5 mg epinephrine per spray
223961691|NCT06927999|DRUG|1 mg epinephrine|1 mg epinephrine per spray
223961692|NCT06928142|BIOLOGICAL|Sibeprenlimab|400 mg administered SC Q4 weeks
223961693|NCT06928142|OTHER|Placebo|Administered SC Q4 weeks
224291311|NCT00325832|DEVICE|BpTRU|
224291312|NCT00325832|DEVICE|Conventional mercury sphygmomanometry|
224291313|NCT04291807|BEHAVIORAL|Video education|Procedure was presented to the cases via a video showing the steps in ERCP and questions had been answered by an experienced nurse
224109832|NCT04102891|OTHER|Microbiota modulation diet|The Collect\&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
223961694|NCT07136402|OTHER|Educating participants about healthcare resources|MA-CEAL team members, including the community health ambassador (CHA), will assist in connecting residents with healthcare resources.
223961695|NCT07136402|OTHER|Healthcare appointments|MA-CEAL team members, including the community health ambassador (CHA), will assist residents in making physician appointments.
223961696|NCT07136402|OTHER|Workshops|Trained CHAs will provide workshops with information about diabetes and hypertension and how to be screened and get care.
224109833|NCT02612090|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry
224109834|NCT02612090|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|Placebo
224109835|NCT06145490|DIETARY_SUPPLEMENT|Caffeine|Caffeine capsule 250 mg, oral intake
224109836|NCT06145490|DRUG|Placebo|Placebo capsule, oral intake
224109837|NCT01650779|BIOLOGICAL|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
224109838|NCT00577330|DIETARY_SUPPLEMENT|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
224109839|NCT03666143|DRUG|Sitravatinib|Administered orally as a capsule
224109840|NCT03666143|DRUG|Tislelizumab|Administered intravenously
224109841|NCT06474741|BEHAVIORAL|in-app notification|Parents will receive bi-weekly prompts in a baby monitor app to change infant's orientation within crib, allow for tummy time several times per day, alternate the side from which infants are fed, alternate the side the infant faces during carrying, and in general note any side preferences of the infant so that positioning can assist in symmetry.
223724447|NCT00085631|DRUG|cisplatin|Given IV
223724448|NCT00085631|PROCEDURE|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
223961697|NCT06931509|DEVICE|Computerized mirror therapy (IVS3) + Tendon vibration (Vibramoov)|"Visit 1 : Followed by 30 movements of Paretic arm wrist extension with 4 randomized experimental conditions (Vision alone, Vibration alone, Vision + Vibration, No feedback), with EEG monitoring. Measurement of movement perception feeling for each condition.~Visit 2 : 30 movements of Paretic arm wrist extension with 4 randomized experimental conditions (Vision alone, Vibration alone, Vision + Vibration, No feedback), with EEG monitoring. Measurement of movement perception feeling for each condition."
223961698|NCT06926322|DRUG|Conventional double antibiotic paste of Metronidazole 500 mg plus Ciprofloxacin 500 mg mixed with propylene glycol|The studied medicament will be placed onto the floor of the pulp chamber.
223961699|NCT06926322|DRUG|Double antibiotic paste of Metronidazole and Ciprofloxacin loaded chitosan-coated silver nanoparticles|The studied medicament will be placed onto the floor of the pulp chamber.
223724449|NCT00085631|RADIATION|brachytherapy|Patients undergo brachytherapy for 2-3 days
223724450|NCT00085631|RADIATION|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
223961700|NCT06926322|DRUG|chitosan-coated silver nanoparticles|The studied medicament will be placed onto the floor of the pulp chamber.
223961701|NCT06758505|BEHAVIORAL|Strategy Training Only|Participants will receive ten 45-60-minute sessions (two times per week) in person in their residence to address real-world performance with an emphasis on START strategy, task-specific practice, and guided discovery to perform social participation activities. In session 1, participants will be guided to select 3 to 5 meaningful social activities and prioritize them. In sessions 2 - 9, participants will use structured START strategy worksheet to try the selected activity; assess execution (e.g., what went well, what did not); reflect on a plan with specific strategies and to address identified challenges; and try social participation activities again. The interventionist will use guided discovery to support START strategy application and to elicit problem solving skills. This process will be repeated iteratively across sessions. In session 10, participants will summarize lessons learned and generate an action plan for after the intervention.
224109842|NCT03642795|OTHER|Questionnaire|Patients are asked to complete several questionnaires
224109843|NCT04637321|PROCEDURE|Solid organ transplant|Data will be collected on all liver, kidney, pancreas and combined transplant recipients who received their graft(s) from April 1, 2015 to July 31, 2018
224109844|NCT04807569|OTHER|Peripheral magnetic neuromodulation|"Non-invasive peripheral magnetic neuromodulation using the BTL Emsella magnetic stimulator according to the manufacturer's standard protocol: pelvic floor rehabilitation"
223724451|NCT01662258|DEVICE|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
223724452|NCT03535103|DRUG|Gonal-F®|A single Subcutaneous injection, 225IU
223724453|NCT03535103|DRUG|LM001|A single Subcutaneous injection, 225IU
223724454|NCT05417945|DEVICE|JensClip transcatheter valve repair system|"Transcatheter mitral valve repair system is derived from the Edge-to-Edge technique in traditional surgery. The principle is roughly to clamp the midpoint of the anterior leaflet and the midpoint of the posterior leaflet of the mitral valve to form a double-hole inflow channel and then improve the regurgitation."
224109845|NCT04807569|DRUG|Taking drug Tamsulosin|Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
224109846|NCT03015272|BEHAVIORAL|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
224109847|NCT03015272|BEHAVIORAL|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
224291314|NCT05914545|DRUG|FZ-AD004|"Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles."
223961702|NCT06758505|BEHAVIORAL|Strategy Training embedded with Acceptance and Commitment Therapy Principles|"Participants will receive ten 45-60-minute sessions (two times per week) in person in their residence to address real-world performance with task-specific practice and an emphasis on psychological processes using ACT principles. In session 1, participants will clarify value-consistent social participation goals for engaging in 3-5 meaningful activities (Do What Matters). In sessions 2-9, participants will be guided applying ACT principles to cope with negative experiences and separate self from thoughts and feelings (Open Up) and practice mindfulness, stimulate awareness, recognize same person with different experiences, and build self-compassion (Be Present). This process (i.e., try an activity that aligns with values and committed actions; assess performance; and reflect on a plan) will be repeated iteratively. In session 10, participants reflect on lessons learned and generate an action plan for after the intervention."
223961703|NCT06930352|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224109848|NCT04083911|DRUG|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;"
224109849|NCT03477630|BIOLOGICAL|Platelet Rich Plasma|intra-articular infiltration of 8 ml of autologous PRP every 15 days.
224109850|NCT03477630|DRUG|Hyaluronic Acid|intra-articular infiltration of a single dose of HA
223961704|NCT06930352|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and/or aspiration
223961705|NCT06930352|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and/or aspiration
223961706|NCT06930352|DRUG|Cytarabine|Given cytarabine
223961707|NCT06930352|PROCEDURE|Echocardiography Test|Undergo ECHO
223961708|NCT06930352|DRUG|Hydroxyurea|Given hydroxyurea
223961709|NCT06930352|PROCEDURE|Leukapheresis|Undergo leukapheresis
223961710|NCT06930352|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223961711|NCT06930352|OTHER|Questionnaire Administration|Ancillary studies
223961712|NCT06930352|DRUG|Ziftomenib|Given PO
223961713|NCT06937801|DIETARY_SUPPLEMENT|Collagen Peptide|10g Collagen Hydrolysate per sachet
223961714|NCT06937801|OTHER|Placebo|Placebo - active ingredients: N/A
223961715|NCT07138339|DIETARY_SUPPLEMENT|Menstrual Wellness Product Placebo Control|Participants will use their Menstrual Wellness Product Placebo Control as directed for a period of 12 weeks
223961716|NCT07138339|DIETARY_SUPPLEMENT|Menstrual Wellness Product 1|Participants will use their Menstrual Wellness Product 1 as directed for a period of 12 weeks
224109851|NCT00105729|BEHAVIORAL|Intensive referral to 12-step self-help groups|
224109852|NCT01048125|DEVICE|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
224291315|NCT03500497|DIAGNOSTIC_TEST|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
223961717|NCT06947122|BEHAVIORAL|Mindfulness based smartphone app|The Mindful Journey intervention includes (1) 14 foundational modules/lessons, (2) brief check-in surveys (3 times/day) via the app, (3) app-guided momentary mindfulness coaching (max 3 times/day), and (4) brief 5 to 10-minute phone-based check-in from a trained staff member, on a weekly basis. Occurring for approximately 8 weeks following enrollment visit
223961718|NCT07147933|OTHER|phusical therapy program|physical therapy program including stretching of the hamstrings and strengthening of the quadriceps only. The program will be delivered 3 times per week for 8 weeks under therapist supervisio
223961719|NCT07147933|OTHER|physical therapy program|A targeted physical therapy program including correction of anterior pelvic tilt, strengthening of the soleus, core strengthening, stretching of the hamstrings, and strengthening of the quadriceps. The program will be delivered 3 times per week for 8 weeks under therapist supervision.
223961720|NCT07142525|PROCEDURE|Hybrid Osteoplasty|Open rhinoplasty with dorsal hump reduction performed using a powered surgical burr under irrigation and direct visualization. Bone is contoured gradually to achieve a smooth dorsum while preserving the keystone area. No dorsal osteotomy is performed in this arm. Cartilaginous work and adjunctive steps (e.g., septoplasty or tip refinement) are performed as clinically indicated but are not part of the intervention being tested.
223961721|NCT07142525|PROCEDURE|Traditional Osteotomy and Rasping|Open rhinoplasty using the conventional technique for dorsal hump reduction. The bony hump is resected with a straight osteotome, followed by manual rasping to refine the nasal dorsum, with preservation of the keystone area. Powered burrs are not used for primary dorsal contouring in this arm. Cartilaginous work and adjunctive procedures may be performed as clinically indicated but are not part of the tested intervention.
223961722|NCT00826956|PROCEDURE|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
223961723|NCT07153536|DEVICE|Spinal Cord Stimulator (Medtronic Inceptiv™ System)|The Medtronic Inceptiv™ spinal cord neurostimulation system is a rechargeable implantable pulse generator (IPG) designed to deliver electrical pulses to the spinal cord via implanted leads. The system is intended for use in patients with chronic pain.
223961724|NCT07153536|OTHER|Physical Therapy|The physical therapy intervention consists of two components: the Mind-Pod Dolphin system (targeting arm function) and the Hummingbird Hunt system (targeting hand function). Both systems use interactive gaming software that enables participants to engage in remote, game-based therapy. Each system offers multiple difficulty levels, allowing participants to progress as their skills improve.
223961725|NCT07155330|DEVICE|High-flow nasal cannula|Using high-flow nasal cannula oxygenation
223961726|NCT07153900|DEVICE|Treatment with BACK4 System|Use of combined RF and EMS therapy with BACK4 Device
224109853|NCT01048125|BEHAVIORAL|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
224109854|NCT01048125|DRUG|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
224109855|NCT01048125|OTHER|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
224109856|NCT01048125|DEVICE|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
223961727|NCT07162350|BEHAVIORAL|Food Navigation|"For those randomized to the FAME Intervention, it will begin with a Community Health Worker (CHW) Food Navigator consultation. The role of the Food Navigators is as follows:~1. Identify the top dietary and food needs of the participant and their family. The Food Navigator will perform a needs assessment to define food access, kitchen resources/capacity, and other social determinants of health.~2. Set realistic, participant and family-driven nutrition goals. The Food Navigator will utilize Motivational Interviewing (MI), an evidence-based method of counseling that promotes motivation for change.~3. Provide nutrition resources and referrals.~4. Support children and families for up to 12 months."
223961728|NCT07164287|DRUG|Lysergic Acid Diethylamide (LSD) or psilocybin|Psychedelic-assisted psychotherapy with LSD or psilocybin as a part of a clinical routine in our department
223961729|NCT05655013|DRUG|Zoledronate|zoledronate 5 mg
223961730|NCT05655013|DRUG|Placebo|isotonic saline 100 mL
223961731|NCT07176572|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated + NS IV Infusion 100 ml
223961732|NCT07176572|DRUG|Dexketoprofen Trometamol|50 mg dexketoprofen trometamol in 100 ml normal saline solution + Transcutaneous electrical nerve stimulation treatment will not be activated.
223961733|NCT07184996|DRUG|Duvakitug|Pharmaceutical form:Solution for Injection-Route of administration:SC injection
223961734|NCT07184996|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:SC injection
223961735|NCT07184931|DRUG|Duvakitug|Pharmaceutical form:Injection solution Route of administration:SC injection
223961736|NCT07184931|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration:SC injection
223961737|NCT07188818|DEVICE|Decoria Essence|Decoria® Essence is a hyaluronic acid based, BDDE-crosslinked dermal filler. Decoria® Essence dermal fillers are injected into dermal tissue to improve the volume and the contouring of the lips to desired level of correction by supporting the overlying tissue. Injection volume will be determined by the treating investigator according to the instructions for Use (IFU).
223961738|NCT07185009|DRUG|Duvakitug|Pharmaceutical form: Injection solution Route of administration: SC injection
223961739|NCT07185009|DRUG|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
223961740|NCT07190911|OTHER|Olfactory rehabilitation consists of smelling a series of spices every day for 2 months|"Olfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin.~This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8~Allergies to certain spices will be noted at the start of the study:~* in known allergy: change by another spice which belongs to the same chemical category.~* in case of allergies to several scents: patient is not included in the study.~* in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category.~* in case of allergies to several scents occuring during participation: patient is excluded from the study."
223961741|NCT07190079|DIAGNOSTIC_TEST|Saline contrast Electrical Impedance Tomography method|"This study will enroll patients with clinically suspected or confirmed acute pulmonary embolism (PE) presenting with acute respiratory failure, who undergo electrical impedance tomography (EIT) with saline contrast within 24 hours before or after computed tomography pulmonary angiography (CTPA). The EIT procedure is performed as follows:~1. Breath-Hold Maneuver: (1)Spontaneous breathing patients: Supine position, instructed to hold expiration for ≥8 seconds. (2)Mechanically ventilated patients: Expiratory hold (\>8 sec) achieved via ventilator; deeper sedation will be applied when feasible to prolong breath-hold.~2. Venous Access: (1)Preferred: Central venous catheter (internal jugular or subclavian vein).(2)Alternative: Peripheral forearm vein (preferably the median cubital vein).~3. Contrast Administration:(1)Central venous route: 10 mL of 10% NaCl.(2)Peripheral venous route: 15 mL of 5% NaHCO₃."
224291316|NCT04686227|DIAGNOSTIC_TEST|3D Ultrasound|Newly married women between the ages of 18-40 will be evaluated by 3D ultrasonography about the uterine morphology
224109857|NCT02039271|OTHER|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
224109858|NCT02747043|BIOLOGICAL|ABP 798|ABP 798 was supplied as a sterile, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
223961742|NCT07190079|DIAGNOSTIC_TEST|Computed Tomography Pulmonary Angiography (CTPA)|Patients who meet the inclusion criteria will undergo CTPA examination using conventional clinical diagnostic methods.
223961743|NCT07189559|BEHAVIORAL|Digital Bodies|The Digital Bodies intervention consists of a one-hour interactive session. The core of the intervention involves the use of cognitive dissonance techniques and the development of critical literacy skills to encourage adolescents to critically reflect on appearance ideals, as well as to foster the skills needed to challenge such ideals.
223961744|NCT07191002|OTHER|placement depth of the double lumen tube|the anesthesiologist will select the appropriate DLT size and placement depth entirely at their discretion, as per routine practice, and confirm both using fiberoptic bronchoscopy (FOB). If malposition occurs, it will be corrected under FOB guidance, and the tube will be secured in the correct position
223961745|NCT07186387|DRUG|LW402|LW402 tablets
224291317|NCT04274582|DIETARY_SUPPLEMENT|chokeberry extract|The players received 30 mL of liquid chokeberry extract, in the morning before training, once per day for 12 weeks.
223961746|NCT07186387|DRUG|LW402 placebo|LW402 placebo tablets
223961747|NCT07192926|DRUG|Immune Checkpoint Inhibitors|Retrospective analysis of patients with metastatic non-small cell lung cancer (mNSCLC) who received standard-of-care immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors (e.g., nivolumab, pembrolizumab, atezolizumab, durvalumab). Patients received these agents as part of routine clinical practice; no experimental intervention was administered in this study.
223961748|NCT07193511|DRUG|AVZO-103|Specific dose in protocol specified schedule
223961749|NCT07193511|DRUG|Combination Agent|Per label based on combination agent used
223961750|NCT07194694|DRUG|Dexmedetomidine & Bupivacaine.|Group A (Dexmedetomidine Group): patients will receive 20 ml solution containing 1 mg/kg bupivacaine + 1mcg/kg dexmedetomidine +normal saline.
223961751|NCT07194694|DRUG|ketamine and bupivacaine injection|Group K (ketamine Group): patients will receive 20 ml solution containing 1 mg/kg bupivacaine+0.5 mg/kg ketamine + normal saline.
223724455|NCT02823288|OTHER|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~1. Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~2. Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~3. Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
223724456|NCT01649687|BIOLOGICAL|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10\^7 cells of allogeneic adipose-derived mesenchymal stem cells
223724457|NCT00411645|DRUG|maribavir|100 mg twice daily for up to 12 weeks
223724458|NCT00411645|OTHER|placebo|twice daily for up to 12 weeks
223724459|NCT00389363|DRUG|ALK HDM tablet|
223724460|NCT02326753|DEVICE|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
223724461|NCT02326753|DEVICE|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
224109859|NCT02747043|BIOLOGICAL|Rituximab|Rituximab was procured from commercial supplies in the US and was supplied as a sterile, clear, colorless, preservative-free liquid concentrate for IV infusion at a concentration of 10 mg/mL in either 100-mg/10 mL or 500-mg/50 mL single-dose vials. Subjects were to receive premedications before each infusion. Premedications were to be given according to local practice for administration of rituximab therapy.
223724462|NCT02326753|DEVICE|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
223724463|NCT06153511|PROCEDURE|Robot assisted spinal transpedicular fixation|Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
223724464|NCT05728307|DEVICE|neoGuard vital signs monitor|"The neoGuard device is a 4-in-1 wearable vital signs monitor developed by Neopenda, PBC (Chicago, Illinois). The system is designed to continuously measure temperature, pulse rate (PR), respiratory rate (RR) and blood oxygen saturation (SpO2). It contains two non-invasive sensors: an optical reflectance pulse oximeter and a digital temperature sensor. These sensors measure signals from the surface of the patient's skin, and algorithms within the device calculate the pulse rate, respiratory rate, SpO2 and temperature.~The device is made of medical grade polyetherimide plastic and can be worn on the forehead through an adjustable band. The PR, RR, temperature and SpO2 data are collected, recorded and transmitted via Bluetooth Low Energy (BLE) to a tablet which can be placed within a range of 20-30 meter distance. The neoGuard technology has received CE mark certification and is also registered with the Kenya Pharmacy and Poisons Board (KPPB)."
223724465|NCT05548725|OTHER|Reguired field|Investigations to know relationship between acute kidney injury and mineral bone disease
223724466|NCT04528849|DRUG|Gonadotropin dose increment timing|Gonadotropin dose increments of 25 IU will be utilized on 7th and 14th day of ovulation induction for each study group.
223724467|NCT02302781|OTHER|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
223724468|NCT03273192|DRUG|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
223961752|NCT07194694|DRUG|Bupivacaine|Group C (Control Group): Patients will receive 20 ml solution containing 1 mg/kg bupivacaine + normal saline.
223961753|NCT07184944|DRUG|Duvakitug|Pharmaceutical form:Injection solution-Route of administration:SC injection
223961754|NCT07184944|DRUG|Placebo|Pharmaceutical form:Injection solution-Route of administration:SC injection
223961755|NCT07193940|PROCEDURE|Flexible Ureteroscopy|Flexible Ureterorenoscopy
223961756|NCT07193940|PROCEDURE|extracorporeal shock wave lithotripsy (ESWL)|extracorporeal shock wave lithotripsy (ESWL)
223961757|NCT07194148|BEHAVIORAL|Gamified Digital Education (ORNurse: Steril Setup 1.0)|A behavioral intervention utilizing a custom-developed 3D digital game designed to teach perioperative nurses or students the correct layout of surgical instrument tables in total hip arthroplasty. The game includes interactive modules, feedback mechanisms, and simulated scenarios based on a validated protocol.
223961758|NCT07194148|BEHAVIORAL|Traditional Training|A classroom-based lecture accompanied by printed materials covering the correct surgical instrument table setup for total hip replacement surgery.
223961759|NCT07192770|BIOLOGICAL|Granulocyte colony-stimulating factor (G-CSF)|Patients receive chemotherapy with prophylactic G-CSF (granulocyte colony-stimulating factor) as part of routine clinical care. Both short-acting (filgrastim) and long-acting formulations (pegfilgrastim, lipegfilgrastim) may be used according to standard oncology practice. The study does not assign the intervention but observes supportive care strategies and patient-reported outcomes related to G-CSF-induced bone pain.
223961760|NCT07192770|OTHER|Supportive Care (Analgesic and Non-Pharmacological Strategies)|Supportive care strategies including analgesic use (NSAIDs, opioids, antihistamines) and non-pharmacological interventions (rest, exercise, local heat/cold, relaxation techniques) will be recorded as part of routine practice. The study does not randomize or assign supportive care but documents their use and association with bone pain outcomes.
223961761|NCT07194044|DRUG|Vincristine|IV Push
223961762|NCT07194044|DRUG|Doxorubicin|IV
223961763|NCT07194044|DRUG|Cyclophosphamide|IV and Maintenance PO
223961764|NCT07194044|DRUG|Ifosfamide|IV
223961765|NCT07194044|DRUG|Actinomycin|IV
223961766|NCT07194044|DRUG|Irinotecan|IV
223961767|NCT07194044|DRUG|Cabozantinib|PO
223961768|NCT07194044|DRUG|Topotecan|IV
223961769|NCT07194044|DRUG|Temozolomide|IV
223961770|NCT07194044|DRUG|Etoposide|PO
223961771|NCT07194044|DRUG|Liposomal doxorubicin|IV
223961772|NCT07195227|DRUG|Camizestrant|Next-generation oral SERD molecule that is intended for the treatment of women and men with ER+ breast cancer. In addition to degradation of ERα, camizestrant also acts as a pure ER antagonist
223961773|NCT07195227|DRUG|Ribociclib|Selective inhibitor of CDK 4 and 6, with 50% inhibition (IC50) values of 0.01 μM (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated by binding to D-cyclins and are crucial to cell cycle progression and cellular proliferation. The cyclin D-CDK4/6 complex regulates the cell cycle by phosphorylating the retinoblastoma protein (pRb).
223961774|NCT07194564|BEHAVIORAL|Control Exercise|A standard exercise without self-correction, performed by all participants as the control condition.
223961775|NCT07194564|BEHAVIORAL|Self-corrective Exercise|A self-corrective exercise intervention targeting improved postural alignment and muscle activation.
223961776|NCT07195929|OTHER|Allergenic Extract|In each subject, a drop of each of the 3 concentrations of the allergenic extract, in addition to the positive control (histamine) and the negative control, will be applied. The application will be duplicated on the subject's anterior forearm, with a distance of approximately 4 cm between each application to avoid overlapping reactions and false-positives results.
223961777|NCT07195994|DIETARY_SUPPLEMENT|AMPK Charge+®|Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.
223961778|NCT07195994|DIETARY_SUPPLEMENT|AMPK Charge+® with semaglutide|Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.
223961779|NCT07179575|DRUG|LW231|LW231 tablets
223961780|NCT07179575|DRUG|LW231 placebo|LW231 placebo tablets
223961781|NCT07196683|PROCEDURE|Regenerative pulpotomy|Regenerative pulpotomy combines the use of hydraulic calcium silicate based cements; MTA, together with biodegradable scaffolds such as PRF.
223961782|NCT07201285|OTHER|Edge of laminar block|Patients will receive edge of laminar block using 20ml of bupivacaine 0.25%.
223961783|NCT07201285|OTHER|Erector spinae plane block|Patients will receive an erector spinae plane block using 20ml of bupivacaine 0.25%.
223724469|NCT01901237|BEHAVIORAL|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
223961784|NCT07196085|BEHAVIORAL|Imagery Rescripting|"Four ImRs sessions over 2 weeks, targeting autobiographical criticism memory. Therapist-guided rescripting involved modifying the hotspot scene (critical interaction) with protective interventions addressing unmet needs."
223961785|NCT07196085|BEHAVIORAL|Sham Neutral Imagery|Four neutral imagery sessions over 2 weeks. Participants imagined neutral interpersonal interactions matched in structure and duration to ImRs but with rescription of neutral instead of criticism memories.
223961786|NCT07200544|DRUG|Meloxicam 7.5 mg|This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.
223961787|NCT07200544|DRUG|Meloxicam 15 mg|This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.
223961788|NCT07200544|DRUG|Acetaminophen 500mg|This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.
223961789|NCT07204210|DEVICE|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is a treatment using powerful acoustic pulses which is mostly used to treat kidney stones and in physical therapy and orthopedics. Extracorporeal shockwave therapy is used as a second line measure to treat tennis elbow, shoulder rotator cuff pain, Achilles tendinitis, plantar fasciitis, and greater trochanteric pain syndrome. The lithotripter attempts to break up the stone with minimal collateral damage by using an externally applied, focused, high-intensity acoustic pulse. The patient is usually sedated or anesthetized for the procedure in order to help them remain still and reduce possible discomfort.
223961790|NCT07204210|OTHER|myofascial release technique|"Myofascial release (MFR, self-myofascial release) is an alternative medicine therapy claimed to be useful for treating skeletal muscle immobility and pain by relaxing contracted muscles, improving blood and lymphatic circulation and stimulating the stretch reflex in muscles. Writing for Science-Based Medicine, Harriet Hall described myofascial release as an umbrella term for several types of physical manipulation, which might more simply be described as a kind of massage based on vaguely defined scientific notions. Reviews published in 2013 and 2015 evaluating evidence for MFR efficacy found that clinical trials that had been conducted varied in quality, technique, outcome measurements and had mixed outcomes; the 2015 review noted: it is time for scientific evidences on MFR to support its clinical use."
223961791|NCT07204210|OTHER|Placebo Control|Participants were not given any interventions that had proven effective for treatment. An appointment was made for 5 weeks later.
224291318|NCT05973682|OTHER|Post-isometric relaxation and Conventional treatment|"The term refers to the effect of subsequent relaxation experienced by a muscle or group of muscles, after brief periods during which an isometric contraction has been performed. Post isometric relaxation technique was applied to levator scapulae for 5 repetition using 20% of maximal isometric contraction for 7-10 sec. with complete relaxation of all element, the stretch is maintained for 30 sec.~\+ hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30 second hold. static stretching exercises two sessions per week for 3 weeks were given to each patient"
223724470|NCT03358901|DRUG|YC-6|
223724471|NCT03358901|DRUG|Vehicle|
223724472|NCT02354079|GENETIC|hypobetalipoproteinemia genetic and genotypic screening|
223724473|NCT00910312|DEVICE|Ice-Sense|Ice-Sense Cryoprobe
223724474|NCT02157467|DRUG|BMS-955176|
223724475|NCT02157467|DRUG|Ortho Cyclen|
223724476|NCT01788332|DRUG|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
223724477|NCT01788332|OTHER|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
223724478|NCT02197845|BEHAVIORAL|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
223724479|NCT02197845|BEHAVIORAL|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
223961792|NCT07203950|OTHER|global postural reeducation with conventional therapy|"Global postural reeducation will include two postural positions aiming to improve alignment, flexibility and postural correction. Each session will be 35 minutes including each posture performed for 10 minutes each and 15 minutes for conventional therapy.~1. Coxofemoral Opening with Closed Arms Participants will begin in a supine position on a flat surface. The upper limbs will be 90° abducted, with palms facing to the ceiling. The lower limbs will be placed in hip and knee flexion, with soles of the feet together, heels close to the gluteal region, and hips in abduction between 30° and 45°.~2. Coxofemoral Closure with Closed Arms. In this posture, participants will again lie supine, with the arms abducted to 90° and palms facing upward. The hips and knees will be flexed, with the soles of the feet pressed together and placed against a wall.~   with Controlled and slow diaphragmatic breathing technique~3. Conventional therapy same as given to other group."
223961793|NCT07203950|OTHER|conventional therapy|"conventional therapy given to this group will be~* Hot pack for 15 minutes.~* Static stretching of rectus femoris and iliopsoas muscles (1 minute x 5 repetitions per session).~* Other exercises Pelvic tilt Straight leg raise Bridging Cat-camel exercise Knee-to-chest stretch Prescribed as 3 sets of 10 repetitions each, with rest in between."
223961794|NCT07204080|DRUG|TNX-1500|This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients.
223961795|NCT07204080|PROCEDURE|Kidney Transplant|Kidney Transplant
223961796|NCT07202988|OTHER|vegetable combination 1|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
223961797|NCT07202988|OTHER|vegetable combination 2|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
223961798|NCT07202988|OTHER|vegetable combination 3|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
223961799|NCT07202988|OTHER|vegetable combination 4|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
223961800|NCT07202988|OTHER|vegetable combination 5|consume 5 consecutive lunch meals, separated by at least one week, that differ in the presence and amount of potato and non-starchy vegetable
223961801|NCT07203586|PROCEDURE|Minimally invasive scoliosis surgery|Patients undergoing minimally invasive surgery have screws placed using the surgeon's preferred method: 3D navigation, robotic assistance, freehand, or combinations. A long incision of the skin is made without detaching the erector spinae muscles. Each screw is inserted through the musculature, and positioning is verified with intraoperative CT; misplaced screws are corrected. Rods are then shaped, placed, and deformity correction is performed. The surgeon may decorticate some or all facet joints using minimally invasive techniques before closing the wound.
223961802|NCT07203586|PROCEDURE|Traditional open scoliosis surgery group|In traditional open scoliosis surgery, the surgeon uses the preferred method for screw placement (3D navigation, robotic assistance, freehand, or combinations). A long incision is made, and the spinal musculature is detached to fully expose the posterior elements. All screws are inserted through this open area, and their positions are verified with intraoperative CT; misplacements are corrected if needed. Rods are shaped, placed, and deformity correction is performed. Decortication of facet joints, spinous processes, and laminae may be performed with a high-speed burr or similar technique. The wound is then closed.
223961803|NCT07204509|DIAGNOSTIC_TEST|Conventional Karyotyping|Conventional chromosomal analysis was performed using karyotyping of peripheral blood lymphocytes. Standard cytogenetic techniques were applied to identify chromosomal abnormalities in pediatric patients with congenital heart disease. This diagnostic test was used solely for observational and genetic correlation purposes.
223961804|NCT07204873|OTHER|LUSHA digital app|Children with Attention Deficit Disorder with or without Hyperactivity (ADHD) and their parents will be asked to use LUSHA app during 3 months.
223961805|NCT07203612|BEHAVIORAL|SHS|Group-based and video-based intervention to teach caregivers of young children how to supervise their children more closely to prevent unintentional injuries.
223961806|NCT07203612|BEHAVIORAL|Parenting group|This intervention was designed to teach caregivers about evidence-based behavioral methods to manage common child behavior problems.
223961807|NCT07202546|DRUG|VH4524184|Oral tablet will be administered.
223961808|NCT07202546|DRUG|Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets|Oral table will be administered.
223961809|NCT07202546|DRUG|Dolutegravir / Lamivudine (DTG/3TC)|Oral tablets will be administered.
223961810|NCT07202611|BIOLOGICAL|In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer|The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use.
223542162|NCT06257225|PROCEDURE|Guided Bone regeneration|After local anesthesia, a crestal incision will be performed followed by full-thickness mucoperiosteal flap elevation Flap advancement will be attained through periosteal scoring of the buccal; The resorbable collagen membrane (Bio Gide, Geistlich AG) will be trimmed to the defect size. Xenograft (Bio-Oss) together with scrapped autogenous bone will be mixed and placed at the surgical site. The membrane will positioned over the graft and tucked into the lingual flap. Patient allocation concealment will be broken and the patients will be randomly assigned into two groups Patients receiving horizontal bone augmentation with resorbable collagen membrane stabilized with no tacks. The first layer will be closed with horizontal mattress sutures placed 4 mm from the incision line, and single interrupted sutures are used to close the edges of the flap. Vertical incisions are closed using single interrupted sutures and mattress suture should remain in place for at least 2 to 3 weeks
223542163|NCT00001964|DRUG|Cyclosporine A|Cyclosporine A
223961811|NCT07204223|DEVICE|Tulip Airway|In this study, patients scheduled for surgery under general anesthesia who meet the criteria for anticipated difficult mask ventilation will be included. Randomization will be performed to determine which device will be used first. If the Tulip airway is selected as the first device in the randomization process, mask ventilation will be initiated with the Tulip airway.
223961812|NCT07204223|DEVICE|Guedel Airway|In this study, patients scheduled for surgery under general anesthesia who meet the criteria for anticipated difficult mask ventilation will be included. Randomization will be performed to determine which device will be used first. If the Guedel airway is selected as the first device in the randomization process, mask ventilation will be initiated with the Guedel airway.
224109860|NCT01674543|OTHER|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
224109861|NCT01674543|OTHER|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
224109862|NCT01674543|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
224109863|NCT03711071|OTHER|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
224109864|NCT04992832|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group.
224109865|NCT04992832|OTHER|human serum albumin|Saline solution containing 1 percent human serum albumin will be infused to the control group.
224109866|NCT02288975|DEVICE|CytoSorb 300ml device (3804606CE01)|
223542164|NCT00001964|DRUG|ATG|ATG
223542165|NCT00001964|DRUG|MMF|MMF
223542166|NCT00915889|BEHAVIORAL|telephone-based intervention|Either 6 or 8 telephone educational sessions
223542167|NCT00915889|OTHER|counseling intervention|counseling and communications studies
224109867|NCT02140918|DRUG|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
224109868|NCT02140918|DRUG|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
223542168|NCT00915889|OTHER|questionnaire administration|Ancillary studies
223542169|NCT00915889|OTHER|study of socioeconomic and demographic variables|Ancillary Studies
223542170|NCT00915889|PROCEDURE|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
223961813|NCT07202559|DRUG|Indometacin suppository|Administration of a 100mg indometacin suppository rectally 30 minutes prior to ESWL
223961814|NCT07202559|DRUG|Lactated ringers solution|Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
223961815|NCT07202559|DRUG|Normal Saline|Intravenous fluid infusion with normal saline (maximum of 1.5mL/kg per h or 3L per 24h)
223961818|NCT07204496|BIOLOGICAL|Ex Vivo Expanded γδ T Cell Infusion|This study involves the use of γδ T cell infusion, a non-genetically modified adoptive cellular immunotherapy. The intervention utilizes autologous γδ T cells isolated from peripheral blood and expanded ex vivo using specific activators such as zoledronate and cytokines, without genetic engineering. Its mechanism of action relies on the inherent MHC-unrestricted tumor recognition capability of γδ T cells, activating both the NKG2D-NKG2DL axis and BTN3A1-CD277 pathway for dual antitumor activity. The manufacturing process follows GMP-compliant closed-system conditions, with final product release criteria requiring ≥80% purity for CD3+γδ TCR+ cells, along with sterility testing, endotoxin detection, and cytotoxicity assays. This approach fundamentally differs from genetically modified αβ T cell-based therapies like CAR-T or TCR-T, as well as non-specific immunotherapies such as CIK/DC-CIK, and demonstrates superior ex vivo expansion and tumor-targeting capabilities compared to TIL therap
223961819|NCT07204639|DRUG|RAP103 400mg single dose|RAP103 400mg single dose, orally 8 weeks
223961820|NCT07204639|DRUG|RAP103 200mg BID|RAP103 200mg BID, orally 8 weeks
223961821|NCT07204639|DRUG|Placebo for RAP400|Placebo for RAP400mg single dose for 8 weeks
223961822|NCT07204639|DRUG|Placebo for RAP200mg|Placebo for RAP400mg single dose for 8 weeks
223961823|NCT07204067|BEHAVIORAL|Mirror Therapy Conventional Physiotherapy|"Experimental: Mirror Therapy + Conventional Physiotherapy Mirror therapy performed 20 min/session, 2 sessions/week for 1 week. A mirror is placed midsagittal, reflecting the non-paretic limb while hiding the paretic limb. Patients perform bilateral movements (wrist, finger, elbow flex/extension; reaching/grasping) while focusing on the mirror image. This is followed by 20 min of conventional physiotherapy, including strengthening, functional tasks, theraputty squeezes, finger extension with rubber band, towel wringing, lifting small objects, overhead reaching, and ball toss.~Active Comparator: Conventional Physiotherapy Only Conventional physiotherapy 20 min/session, 2 sessions/week for 1 week. Exercises include upper limb strengthening, functional task practice, theraputty squeezes, finger extension with rubber band, towel wringing, lifting small objects, overhead reaching, and ball toss."
223961824|NCT07204132|PROCEDURE|TURBT combined with cryoablation-assisted postoperative immunotherapy|After successful anesthesia, the patient underwent TURBT. Other methods such as laser resection could also be used. The tumor should be completely removed and biopsy specimens taken as much as possible. Then, under the direct vision of the electrocautery scope, cryoablation was performed on the base of the tumor lesion. The freezing area was single lesion and at least 2 freezing cycles were carried out (the freezing start to the rewarming end constituted one cycle), with each cycle lasting 3-5 minutes. If the lesion area was large, 2 more freezing cycles could be added at different positions of the lesion to ensure coverage of the lesion area. After the operation, based on the pathological and immunohistochemical results, adjuvant immunotherapy was initiated, and concurrent adjuvant rhythm chemotherapy was also combined.
223961825|NCT07204132|PROCEDURE|The conventional surgery treatment group|According to the guidelines, a radical cystectomy should be performed, and at the same time, a urinary diversion procedure should be carried out based on the specific situation, such as bladder channeling, ileal bladder substitution, ureterocutaneous fistula, in situ neobladder surgery, etc. (open, laparoscopic or robot-assisted methods are all acceptable). The biopsy and resected specimens should be sent for pathological examination. The postoperative adjuvant treatment plan is determined by the attending physician based on the patient's condition as appropriate.
223961826|NCT07202806|BEHAVIORAL|Aromatherapy|1.Aromatherapy is made from self-made sachet of traditional Chinese medicine.Its components (albizzia, Angelica dahurica, cardamom, Polygala, Evodia, Magnolia, Acorus calamus) are 10g each. Place the pillow 1 hour in advance. It is forbidden to play with your mobile phone or turn off the lights before going to bed.
223961827|NCT07203287|DRUG|Rocuronium|Will be assessing neuromuscular blockade with rocuronium and reversal with sugammadex
224109869|NCT02140918|DRUG|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
224109870|NCT02140918|DRUG|Placebo|
224109871|NCT04146272|DEVICE|Hearing Aid Mermaid Current|The current hearing aid used to treat hearing loss.
224109872|NCT04146272|DEVICE|Hearing Aid Mermaid New|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
224109873|NCT04146272|DEVICE|Power Hearing Aid Current|The current power hearing aid used to treat strong hearing loss.
224109874|NCT04146272|DEVICE|Power Hearing Aid New|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
224109875|NCT01566123|RADIATION|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
224109876|NCT01566123|RADIATION|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
224109877|NCT02353078|DRUG|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
224109878|NCT02353078|PROCEDURE|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
224109879|NCT02353078|DEVICE|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
224109880|NCT01419249|OTHER|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
224109881|NCT01295905|DEVICE|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
224109882|NCT01295905|DEVICE|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
224109883|NCT05404854|OTHER|Physical Activity|wearing an accelerometer for 7 days before and after the rehabilitation program
223961828|NCT07203287|DRUG|Cisatracurium|Will be assessing neuromuscular blockade with neostigmine and reversal with neostigmine
223961829|NCT07202689|DEVICE|Multimodal monitoring|Multimodal monitoring technology offers a novel approach to cerebral protection during the perioperative period of cardiac surgery by integrating hemodynamic parameters, autonomic nervous responses, cerebral oxygen saturation and indices, electroencephalographic activity, and cerebral blood flow velocity.
223961830|NCT07203963|OTHER|Niel-Asher Technique + sleeper stretch|Niel-Asher Technique, Manual Soft Tissue releaser, Neuro-muscular release technique for adhesive capsulitis ( This manual technique will be applied for 3 days a week for 4 weeks).Sleeper stretch will be applied passively by investigator, pressure of the stretch will be held for 30 seconds (repeated twice with 30 seconds break for 3 days a week) Conventional PT including 1: shoulder anteroposterior, posteroanterior and inferior glides ( 3 times a week for 4 week) 2: active and active assisted ROM exercises of shoulder joint (frequency: 1 set of 10 repetitions twice a day). 3: Shoulder Isometric exercises, Codman's exercises and pulley and finger ladder exercises (frequency: 1 set of 10 repetitions twice a day), 4: trigger points will be released by applying ischemic pressure (90 seconds) on trigger points found in rotator cuff muscles.
223961831|NCT07203963|OTHER|sleeper stretch + Conventional Treatment|Sleeper stretch will be applied passively by investigator, pressure of the stretch will be held for 30 seconds (repeated twice with 30 seconds break for 3 days a week). Conventional PT including 1: shoulder anteroposterior, posteroanterior and inferior glides ( 3 times a week for 4 week) 2: active and active assisted ROM exercises of shoulder joint (frequency: 1 set of 10 repetitions twice a day). 3: Shoulder Isometric exercises, Codman's exercises and pulley and finger ladder exercises (frequency: 1 set of 10 repetitions twice a day) 4: ischemic compression (90seconds hold) on trigger points found in rotator cuff muscles
223961832|NCT07204327|OTHER|Atezo+Bev plus Locoregional Therapy|Patients received atezolizumab plus bevacizumab (Atezo+Bev) in combination with at least one locoregional therapy (transarterial chemoembolization \[TACE\], hepatic arterial infusion chemotherapy \[HAIC\], transarterial radioembolization \[TARE\], ablation, or radiotherapy) within ±2 months of systemic therapy initiation, in routine clinical practice.
223961833|NCT07204457|BIOLOGICAL|EG-MCV4|single intramuscular dose on Day 0
223961834|NCT07204457|BIOLOGICAL|Menveo|single intramuscular dose on Day 0
223961835|NCT07203729|DRUG|Trastuzumab Rezetecan|Trastuzumab Rezetecan 4.8mg/kg, IV, Day 1, Q3W
223961836|NCT07203729|DRUG|Chemotherapy of Physician's Choice|Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine
224109884|NCT05404854|OTHER|sedentarity|wearing an accelerometer for 7 days before and after the rehabilitation program
224109885|NCT05404854|OTHER|Measurement of explicit motivation|Explicit motivation will be assessed using self-report questionnaires. Explicit attitudes using a 7-point bipolar response scale, participants will be asked to indicate for each of the 4 pairs of positive and negative adjectives used how much they associate them with regular PA and sedentary behaviors, respectively. Perceived behavioral control using a 7-point bipolar response scale, patients will be asked to indicate how well they felt they were able to engage in regular PA, and limit their sedentary behaviors, respectively, based on two items. Intentions using a 7-point bipolar response scale, patients will be asked to indicate how much they intend to adopt regular physical activity, and limit their sedentary behaviors, respectively, according to two items. Fears and beliefs related to physical activity and work will be measured by the FABQ in its French version
224109886|NCT05404854|OTHER|Measurement of implicit attitudes|Implicit attitudes will be assessed by administering an Implicit Association Test on physical and sedentary activities. Sitting in front of a computer, participants will see a series of words appear in the middle of the screen referring to 4 conceptual categories - located at the top of the screen. Two represent the targeted behaviours (here, physical activity versus sedentary lifestyle) while the remaining two represent attributes (here, positive versus negative adjectives). The adjectives used will be the same as those used to measure explicit attitudes. The instructions given to the participant are to classify the words as quickly as possible, according to the semantic category to which they belong
224109887|NCT03204227|BIOLOGICAL|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
223961837|NCT07203027|BEHAVIORAL|Behavioral Tasks with imaging|"Participants will complete the MDP task only during 3 separate fMRI scanning sessions.~After each session, they will complete one week of ambulatory assessment of real-world avoidance behavior (self-reported avoidance behavior) via Emory Qualtrics surveys. In a fourth scanning session, the brain signature of threat imminence constructed in the first set of participants (Aim 1) will be used to predict and modify avoidance behavior (on the task and in a further week of ambulatory assessment of avoidance) in these participants. During their last visit, the behavioral task will be modified to decrease the availability of avoidance choices; subsequent effects on EMA and passive sensing measures will be assessed."
223961838|NCT07193173|OTHER|2 minute step test|The 2-Minute Step Test (2MST) is a simple, validated field test used to assess aerobic endurance and functional fitness, especially in older adults or people with chronic conditions (e.g., cardiopulmonary disease, neurological disorders).
223961839|NCT07202975|OTHER|Mixed realities rehabilitation program|"1. Two sessions at the hospital: one session with traditional exercise + one session with traditional exercise and training with XR system ( 2 weeks)~2. Four more sessions at home with therapist (L1 therapist and L1 patients) (4 weeks)~3. Former sessions (until 120 days) with L3 therapist and L1 and L3 patients. Usual care: Group rehabilitation sessions: 8 weeks"
223961840|NCT07202975|OTHER|Usual Care|Group rehabilitation sessions: 8 weeks
223961841|NCT04976335|DEVICE|Versawrap membrane|Versawrap membrane will be placed between distal radius plate and flexor tendons
223961842|NCT07204613|BEHAVIORAL|Aquatic stimulation for child development|The intervention will be conducted in a heated pool located in the Physiotherapy building of the Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Minas Gerais, Brazil. A total of 24 twice-weekly, 45-minute aquatic stimulation sessions will be offered over a 13-week intervention period. The sessions will follow a previously tested and refined aquatic stimulation protocol for infants. The experimental group will consist of 15 dyads (infant + parent or guardian) and three supervisors. Two will be inside the pool offering support and encouragement to parents and infants, and one will be outside the pool providing overall supervision of the children and controlling the time of each activity. The activities included in the aquatic intervention plan involve stimulation of expressive language, cognitive development, gross motor skills, fine motor skills, and social interaction.
223961843|NCT07203833|BIOLOGICAL|blood sample|To assess whether circulating Vasn can become a potential diagnostic biomarker of septic shock, we will measure the concentrations of circulating Vasn
223961844|NCT07204340|DRUG|TLN-372|Specified dose on specified days
223961845|NCT07204340|DRUG|TLN-372 in combination with cetuximab|Specified dose on specified days
223961846|NCT07204340|DRUG|TLN-372 in combination with pembrolizumab|Specified dose on specified days
223961847|NCT07204184|DEVICE|Multisite transspinal stimulation at rest|The intervention, combined cervical and lumbar transspinal stimulation, will be used for the first time to reconnect the spared neuronal pathways of the injured human spinal cord. The intervention will be administered while at rest lying on the back or during robotic gait training. Cervical and lumbar transspinal stimulation will be delivered via surface active electrodes placed on the back of the neck and on low back, and four returning electrodes placed on each clavicle and iliac crest.
223961848|NCT07204184|DEVICE|Multisite transspinal stimulation during robotic gait training|The intervention, combined cervical and lumbar transspinal stimulation, will be administered during robotic gait training. Cervical and lumbar transspinal stimulation will be delivered via surface active electrodes placed on the back of the neck and on low back, and four returning electrodes placed on each clavicle and iliac crest while participants step with the help of the Lokomat 6 Pro, a robotic device that helps the legs step. Locomotor training will depend on the ability of each participant to step without foot dragging. Over the training course, we will adjust the body weight support, ankle straps position, and leg guidance force. The tension of the ankle straps will be adjusted based on the right and left tibialis anterior muscle strength evaluated every 2 weeks. Body weight support and leg guidance force will be adjusted based on presence or absence of knee buckling during standing.
223961849|NCT07203365|BIOLOGICAL|This study examines immune response differences Arexvy between individuals aged 80+ and adults aged 60-65|The RSV vaccine (Arexvy) has demonstrated efficacy against LRTD over three RSV seasons in individuals aged 60 and older, with an acceptable safety and reactogenicity profile. However, data on vaccine responses in individuals aged 80 and older, including frail individuals, remains limited. This population is particularly affected by severe RSV infections, highlighting the need for further investigation to address these gaps.
223961850|NCT07203274|DRUG|Delgocitinib cream|Delgocitinib cream
223961851|NCT07203274|DRUG|lidocaine cream|Lidocaine cream
223961852|NCT07203274|COMBINATION_PRODUCT|Lidocaine+Delgocitinib|The two cream will me mixed togheter
223961853|NCT07203274|DRUG|Vehicle (placebo)|Vehicle Cream
223961854|NCT07203274|OTHER|Histamine Dihydrochloride (HDC)|One drop of histamine will be applied on the selected areas and pierced with a lancet
223961855|NCT07203274|OTHER|Cowhage (Mucuna Pruriens)|About 30 spicules will be applied on the selected areas and inserted manually
223961856|NCT07203157|OTHER|Virtual Reiki Therapy|20-minute session once per week for 8 weeks via Webex. Each session will be delivered remotely by a Certified Reiki Practitioner Level II or higher.
223961857|NCT07202637|DRUG|Fluid bolus administration|Fluid infusion of 500 mL of a crystalloïd solution is performed for patients with signs of hypovolemia
223961858|NCT07203170|BEHAVIORAL|Readiness Supportive Leadership Training for the National Guard (RESULT-NG)|"RESULT-NG is a multi-level intervention where leaders receive the training intervention, with evaluation of effects at the subordinate, leader and spouse levels.~RESULT-NG consists of three distinct but related components: 1) a 60-minute, multimedia, interactive digital-learning training session, 2) a two-week behavior tracking exercise that takes less than 2 minutes/day after the digital learning to put what was learned into practice, and 3) a 60-minute facilitated session, either in person or virtual, with trained staff embedded within the National Guard."
223961859|NCT07204301|OTHER|Optimized Timing of Intravesical Lidocaine Gel|Procedural modification of intravesical anesthetic gel administration. Lidocaine gel is instilled before and after flexible cystoscopy or bladder instillation to optimize mucosal anesthesia. This differs from standard practice where timing is not standardized - usually just before flexible cystoscopy.
223961860|NCT07204301|BEHAVIORAL|Calming Music During Procedure|Participants listen to a standardized playlist of calming instrumental music delivered through headphones during the procedure. Intervention is intended to reduce procedural anxiety and discomfort.
223961861|NCT07204301|BEHAVIORAL|Visual Distraction with Screen Content|Participants watch standardized visual content (e.g., relaxing video) on a screen or tablet during cystoscopy or bladder instillation. Designed to distract attention and enhance comfort.
223961862|NCT07204301|OTHER|Calming Ambient Lighting|Flexible cystoscopy or intravesical instillation performed under standardized calming ambient lighting (blue-hue) instead of standard clinical lighting. Intervention aims to promote relaxation and reduce anxiety.
223542171|NCT03911856|OTHER|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
223542172|NCT03911856|OTHER|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
223542173|NCT04114175|OTHER|Exercise BE|Basic exercises related to amputation will be applied
223542174|NCT04114175|OTHER|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
223961863|NCT07204301|BEHAVIORAL|Peak-End Modification of Procedure|"Modification of the procedural ending based on the psychological peak-end rule. The end of the cystoscopy or instillation is deliberately altered to reduce final discomfort, aiming to improve overall remembered patient experience."
223961864|NCT07204756|DIAGNOSTIC_TEST|2-Week Home Monitoring|Those who are randomized into the 2-week intervention arm will be unenrolled from the postpartum remote blood pressure monitoring program and therefore will no longer be transmitting twice daily blood pressures for review.
223542175|NCT04169178|DRUG|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
224109888|NCT03204227|BIOLOGICAL|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
224109889|NCT06215339|BEHAVIORAL|diet therapy training|diet education
223724480|NCT03073044|DIAGNOSTIC_TEST|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.~we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.~The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
223961865|NCT07204756|DIAGNOSTIC_TEST|6-Week Home Monitoring|HOPE-BP provides remote monitoring for the 35% of approximately 2,800 annual births at our institution complicated by HDP. Eligible patients enroll at hospital discharge into a 6-week program, submitting blood pressure readings twice daily via Epic's MyChart Care Companion. Participants receive immediate automated feedback, and a dedicated Maternal Fetal Medicine nursing team reviews data daily (Monday-Friday, 8 AM-4 PM), initiating or adjusting antihypertensive therapy as needed.
223961866|NCT07202767|DEVICE|Swept-Source Anterior Segment OCT|"Device: Swept-Source Anterior Segment OCT The CASIA-2 (Tomey, Japan) is a high-resolution swept-source anterior segment OCT with CE certification. The device allows for incomplete visualization of the lens, including the anterior and posterior lens curvature.~Device: AS-OCT + Placido disc corneal topography The MS-39 (CSO, Italy) is a non-invasive device that combines Placido topography with OCT-based anterior segment tomography.~Device: Wave-front abberomtery The OSIRIS aberrometer is a standard tool for examining corneal aberration and measuring the ocular wavefront.~Device: Swept-Source OCT The IOLMaster 700 (Carl Zeiss Meditec, Germany) is a standard swept-source OCT used for eye examinations.~Device: AS-OCT The ANTERION (Heidelberg Engineering, Germany) is an anterior segment swept-source OCT.~Diagnostic Test: Refraction Subjective Refraction evaluation using the cross-cylinder method"
223961867|NCT07204821|DEVICE|Inspiratory muscle functional electrical stimulation by Flexistem Digital electrical muscle stimulator|The electrical current is pulsed, biphasic, and symmetric, with the Frequency of 30 hertz, Phase width of 200µs, ON time 2s: OFF time 3s. Patients will be instructed to keep their RR constant and to coordinate their breathing with the pulsing of the electrical current. The intensity of the current is the minimum necessary to obtain diaphragm muscle contraction . Four silicone-carbon electrodes (4x4cm) were placed on the clean skin with gel. 2 electrodes each will be placed above and below the right and left sides of the xiphoid process within the seventh and eighth anterior intercostal space. In addition, two electrodes each were placed on the right and left midaxillary line of the seventh and eighth anterior intercostal space Two sessions daily, each session will last for 30 minutes; the patients remained in the semi-Fowler position 30 º with the lower extremities extended and arms alongside the body
224109890|NCT03140254|DRUG|Chlorhexidine gluconate|
224109891|NCT03140254|DRUG|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
224109892|NCT03140254|DRUG|Placebo|
224109893|NCT06639347|DRUG|SHR-A2102|SHR-A2102
224109894|NCT06639347|DRUG|Adebrelimab injection|Adebrelimab injection
224109895|NCT06639347|DRUG|SHR-8068 injection|SHR-8068 injection
224109896|NCT00722605|PROCEDURE|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~* During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~* For all scans, an external monitor will be used to record your breathing.~* If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
224291319|NCT05973682|OTHER|Conventional Physical Therapy|Conventional Physical Therapy; hot pack and TENS at neck area for 10 mint upper trapezius, levator scapulae and pectoralis stretching 3 times with 30-second hold. static stretching exercises, two sessions per week for 3 weeks were given to each patient
224291320|NCT00594620|DIETARY_SUPPLEMENT|Flav-ein capsules|Soy/isoflavone supplementation
224291321|NCT00594620|DRUG|Placebo|Placebo
223542176|NCT06499103|DEVICE|Transcutaneous electrical nerve stimulation|The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
223542177|NCT01553292|DEVICE|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
223542178|NCT01553292|DEVICE|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
223542179|NCT00225862|DRUG|ropinirole|
223961868|NCT07204821|DEVICE|Expiratory muscle functional electrical stimulation by Flexistem Digital electrical muscle stimulator|FES is applied for 30 min, 2 sessions daily, until patients are weaned from mechanical ventilation, but no longer than 6 weeks.Stimulation will be applied via surface electrodes on the abdominal wall Four pairs silicone-carbon electrodes (4x9cm) were placed on the clean skin with gel, and stimulation intensity will be titrated in order to activate the external oblique, internal oblique, transversus abdominis and Rectus abdominis muscles. The patient's tolerance of expiratory muscle FES is continuously monitored;Frequency 30 Hz, pulse width 352 µs and intensity set to cause strong muscle contraction, with a maximum intensity initially set at 60 mA (tolerated intensity in healthy volunteers). Then we amend the protocol to allow a maximum intensity of 100 mA .Strong muscle contraction will verify (visible and palpable) every ten minutes throughout each FES session, and if necessary, stimulation intensity was increased.
223961869|NCT07204821|DEVICE|Early rehabilitation program|"Rehabilitation therapy which consisted of six levels:~Level 0 turning over once every 2 h for unconscious patients with unstable vital signs level 1-2 in addition to turning over, maintaining joint range of motion to prevent muscle atrophy, and placing normal limb position for conscious patients who could sit up for at least 20 min, 2 times a day Level 3 similar to level 2, but sitting on the edge of the bed for patients who could perform upper-limb anti-gravity training Level 4 similar to level 3, but standing up or sitting in a chair for at least 20 min a day for patients who could perform lower-limb anti-gravity training Level 5 patients actively moved from the bed and walked bedside"
223961870|NCT07204730|BEHAVIORAL|Direct Social Skills Training|Participants attended six two-hour sessions led by a licensed psychologist. Sessions focused on social skills, including empathy, problem-solving, stress management, and strategies to prevent and counteract cyberbullying. Outcomes were measured at baseline and three months post-intervention.
223961871|NCT07204730|BEHAVIORAL|Peer-Led Social Skills Training|A volunteer group of students attended six two-hour sessions with a psychologist and then taught their peers the same curriculum. Weekly progress reports were submitted to the psychologist to ensure fidelity. Outcomes on emotional intelligence and cyberbullying were assessed at baseline and three months post-intervention.
223961872|NCT07204730|OTHER|Control No Training|Participants in the control group received no intervention during the study period. Outcomes were assessed at baseline and three months post-intervention to provide a comparison for the experimental groups.
223961873|NCT07204379|DRUG|Novafen|Novafen analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy
223961874|NCT07204379|DRUG|Tramadol|Tramadol analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy
223961875|NCT07204379|DRUG|Naproxen|naproxen analgesic medication to be administered as pain painkiller in one group of patients undergoing root canal therapy
223961876|NCT07204379|OTHER|No intervention?placebo|multivitamins to be administered in this group
223961877|NCT07202663|DRUG|BB-025|Reversal agent for BB-031
223961878|NCT07202663|DRUG|BB-031|RNA aptamer
223961879|NCT07204483|BEHAVIORAL|Educational Leaflet|Participants will receive an educational leaflet on lifestyle modification, which provides practical advice on diet, physical activity, and stress management. The leaflet will be distributed at baseline.
223961880|NCT07204483|DEVICE|Functional Shirt (Relive brand)|Participants will receive a functional shirt designed to support posture and physical comfort (Relive brand). They will be instructed to wear the shirt daily during the 8-week intervention period. Manufacturer: Relive Inc., Japan.
223961881|NCT07204483|BEHAVIORAL|Exercise Manual|Participants will receive a structured exercise manual and will be instructed to perform moderate-intensity exercise (e.g., brisk walking, light jogging, or calisthenics) for 30 minutes, three times per week, over 8 weeks. Weekly follow-up calls or messages will be provided to encourage adherence.
223961882|NCT07204249|DRUG|Semaglutide|Semaglutide
223961883|NCT07203794|DRUG|Bupivacaine Infiltration|After removal of the gallbladder, 40 mL of 0.25% bupivacaine will be applied to the gallbladder bed with a sterile sponge for 10-15 minutes. At the end of the surgery, 15 mL of 0.25% bupivacaine will be infiltrated into trocar insertion sites (5 mL umbilical port, 5 mL epigastric port, 5 mL each auxiliary port).
223961884|NCT07203794|PROCEDURE|Erector Spinae Plane Block|Before induction of anesthesia, a bilateral ultrasound-guided erector spinae plane block will be performed at the T7 transverse process level. A total of 40 mL of 0.25% bupivacaine will be injected (20 mL per side) using an in-plane technique under ultrasound guidance.
223961885|NCT07203794|DRUG|Intrathecal Morphine|With the patient in the sitting position, a 27-gauge spinal needle will be inserted at the L3-L4 interspace. A dose of 100 mcg morphine will be administered intrathecally before induction of anesthesia.
223961886|NCT07202741|OTHER|yoga group|"A total of 50 minutes of hatha yoga practice was performed three times a week for 12 weeks.~* In the first week, two days of face-to-face yoga practice with the researcher.~* During the eighth week, online yoga practices were held twice a week via Skype with the researcher and one yoga practice per week (a list was made for the group the researcher would create via WhatsApp).~The participants were supported with weekly motivation and follow-up information to continue practicing yoga at least twice a week for the next four weeks. All yoga sessions included a 10-minute warm-up and breathing session, 50 minutes of hatha yoga, 15 minutes of relaxation and separation, and 5 minutes of feedback. At the end of the session, the participants received support regarding correct yoga asanas, motivation, and consistency."
224291322|NCT04175743|DRUG|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
223961887|NCT07204041|DRUG|Selinexor|The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral treatment, with each cycle lasting 28 days, for a total of 12 cycles of combined treatment, or until disease progression, death, or occurrence of intolerable toxicity. Alternatively, until disease progression, death, or occurrence of intolerable toxicity.
223961888|NCT07204041|DRUG|Thalidomide (100mg)|The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral treatment, with each cycle lasting 28 days, for a total of 12 cycles of combined treatment, or until disease progression, death, or occurrence of intolerable toxicity. Alternatively, until disease progression, death, or occurrence of intolerable toxicity.
223961889|NCT07204041|DRUG|Dexamethasone|The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral treatment, with each cycle lasting 28 days, for a total of 12 cycles of combined treatment, or until disease progression, death, or occurrence of intolerable toxicity. Alternatively, until disease progression, death, or occurrence of intolerable toxicity.
223542180|NCT05604573|DIAGNOSTIC_TEST|cell free DNA in blood, genetic mutation in tissue|Diagnostic test for cell free DNA in blood, genetic mutation in tissue
223961890|NCT07204444|BEHAVIORAL|standardized and manualized warm calls from providers trained in the BE training|Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration
223961891|NCT07204444|BEHAVIORAL|standardized and manualized warm calls from providers trained in the BE training + ASIST training|Weekly call dosages averaging 20-30 minutes each, for 8 weeks duration
223961892|NCT07204795|OTHER|Distilled water group|Group A participants will receive 400 mL of distilled water orally, two hours before surgery.
223961893|NCT07204795|OTHER|Carbohydrate Drink|Group A participants will receive 400 mL of a commercially available clear carbohydrate-rich drink orally, two hours before surgery.
223961894|NCT07204899|OTHER|Play digital escape room game|In addition to traditional education, the intervention group will receive a digital escape room game developed with the Genially platform. Both groups' knowledge of Hypovolemic Shock and Nursing Management will be assessed using a fact sheet and satisfaction with the GAMEX scale.
223961895|NCT04913155|RADIATION|Low-dose CT screening|Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
223961896|NCT07197190|PROCEDURE|Autologous augmentation mastopexy with subpectoral lipofilling and upper and medial pole fat grafting.|"The term 'internal bra' refers to a range of techniques that aim to stabilise the position of the breast and improve longevity of surgical results. In this study, the investigators address one of them which is dermal flap technique. Dermal flaps have two key advantages, the first of which is that they are low cost due to their autologous nature. The fact that they utilise the patient's own tissue also means they are not associated with an increased risk of infection or immunological reaction, which is their second main advantage, But it has some drawbacks on the long term, such as upper pole hollowness and lack of breast parenchymal tissue to give a good breast volume.~In this research, the investigators used the autogenous internal BRA mastopexy technique for correction of breast ptosis and sub pectoral lipofilling to help increase the breast volume and subcutaneous fat grafting to give the breast upper pole fullness."
223542181|NCT01212471|DRUG|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
223724481|NCT04691453|PROCEDURE|QM-C Hysterectomy|This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
223961897|NCT07204002|PROCEDURE|Treatment BPH|We compare 3 different types of BPH surgery - HoLEP vs. TURP vs. REZUM
223961898|NCT07204353|PROCEDURE|Papilla-preserving incision (Control)|Standard papilla-preserving incision without additional flap modification or connective tissue grafting. This group serves as the control, receiving only routine surgical access for implant site management.
223961899|NCT07204353|PROCEDURE|Modified Labial Pedicle Papilla Flap (mLPPF)|Surgical reconstruction of the peri-implant papilla using the modified labial pedicle papilla flap technique. The flap is mobilized and sutured without adjunctive grafting procedures.
223961900|NCT07204353|PROCEDURE|Modified Labial Pedicle Papilla Flap with De-epithelialized Gingival Graft (mLPPF+dGG)|Surgical reconstruction of the peri-implant papilla combining the modified labial pedicle papilla flap with placement of a de-epithelialized gingival graft (dGG) at the papillary region to enhance soft tissue volume and stability.
224291323|NCT03542084|OTHER|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
223542182|NCT01212471|DRUG|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
223542183|NCT01212471|DRUG|Placebo Comparator|sterile ophthalmic solution
223542184|NCT03191162|DRUG|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
223542185|NCT00378638|DRUG|bevacizumab combined with dose dense chemotherapy|
223542186|NCT06090630|PROCEDURE|Diffusion Weighted Imaging|Undergo DWI-MRI
223542187|NCT06090630|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopic imaging
223542188|NCT01023217|DRUG|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
223724482|NCT04691453|PROCEDURE|QM-B Hysterectomy|Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
223542189|NCT01023217|DRUG|Entecavir|Entecavir 1 mg/day orally
223542190|NCT01023217|DRUG|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
223542191|NCT00589797|DEVICE|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
223724483|NCT06221293|DIAGNOSTIC_TEST|immunoenzyme analysis|immunoenzyme analysis with EVOLIS system
223724484|NCT01943890|DEVICE|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
223724485|NCT01943890|PROCEDURE|Physiotherapy|
223724486|NCT00495339|DRUG|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
223724487|NCT03247855|PROCEDURE|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
223961901|NCT07203716|BEHAVIORAL|Virtual Reality Orientation (Home+Booster)|Age-appropriate 360° VR module (\~8-10 min) showing MRI room, sounds, positioning, and the importance of keeping still; viewed at home 24-48 h pre-scan on a smartphone/VR viewer (or flat 360° if no headset), plus a brief booster view on site immediately before positioning (\~3-5 min refresher).
223961902|NCT07203716|BEHAVIORAL|Virtual Reality Orientation (Pre-Scan Only)|The same 360° VR module (\~8-10 min) viewed once on site in the MRI area immediately before positioning; no home exposure.
223961903|NCT07203716|OTHER|Usual Care (No VR)|Standard institutional pediatric MRI preparation (verbal explanation, hearing protection demo, child-friendly coaching) without VR.
223961904|NCT07204587|PROCEDURE|Autologous Semitendinosus Tendon Graft|Meniscal reconstruction will be performed using autologous semitendinosus tendon harvested from the ipsilateral leg. The graft diameter must be at least 6 mm. A two-tunnel fixation technique will be employed, securing the graft to the tibial plateau at the anatomic meniscal root sites. The graft will be shaped and positioned to mimic the native meniscal contour. Fibertape internal brace augmentation will be added to enhance fixation strength and graft stability. If concomitant anterior cruciate ligament reconstruction is indicated, the graft choice and ACL technique will be determined by the surgeon, without restriction. Postoperative rehabilitation will follow a standardized protocol across all centers.
223961905|NCT07204587|PROCEDURE|Meniscal Allograft Transplantation (MAT)|Meniscal allograft transplantation will use size-matched, fresh-frozen allograft menisci prepared according to institutional tissue bank standards. Grafts will be fixed using a two-tunnel bone plug technique, restoring the anatomic root insertions. The allograft will be centrally positioned within the tibiofemoral compartment, and centralization sutures may be added at the discretion of the operating surgeon. All procedures will be standardized across participating centers, and postoperative rehabilitation protocols will be identical to those used in the autologous graft arm.
223961906|NCT07203300|BEHAVIORAL|multicomponent, tiered intervention|"this intervention is a multi-level collaborative health management system-a digital health platform with four core modules: the Health Education Module, the Growth Monitoring Module, the Health Behavior Module, and the Home-School Partnership Module. The platform facilitates collaboration among schools, families, and hospitals as follows: Schools utilize the platform to manage tasks outlined in health policies, such as delivering educational content, monitoring student activity and diet, and recording monthly height/weight measurements via the Growth Monitoring Module.~Families access the platform to receive multi-format health education, set goals, and review personalized feedback. The Home-School Partnership Module also enables communication for motivational interviewing sessions conducted by professionals offline or by phone.~Hospitals leverage the platform to provide professional guidance and medical support, ensuring interventions are medically sound."
223961907|NCT07202715|BEHAVIORAL|CBT Based C.A.T Project- Intervention for Anxious Adolescents.|The C.A.T Project is a structured, evidence-based intervention grounded in Cognitive Behavioral Therapy (CBT) principles, designed specifically for adolescents experiencing anxiety and related concerns. The core components includes: Psychoeducation, Cognitive Restructuring, Exposure Exercises, Coping Skills Training and Relapse Prevention. This age appropriate intervention will be delivered in Urdu language with culturally appropriate context.
223961908|NCT07203391|DRUG|roginolisib|Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)
223961909|NCT07203105|BEHAVIORAL|GAINS expert guiding technology to coach life skill teaching|GAINS expert guiding technology to coach life skill teaching
223961910|NCT07202819|DRUG|Neoadjuvant Chemotherapy|Standard neoadjuvant chemotherapy for muscle-invasive bladder cancer, typically consisting of cisplatin-based regimens such as MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) or gemcitabine and cisplatin. Administered prior to radical cystectomy to shrink the tumor and improve surgical outcomes. The post-treatment MRI findings will be analyzed for correlation with histopathological results after surgery.
223961911|NCT07202819|PROCEDURE|Radical Cystectomy|Surgical removal of the urinary bladder, typically performed in patients with muscle-invasive bladder cancer. In this study, participants in both arms will undergo radical cystectomy, either directly or following neoadjuvant chemotherapy. Histopathological examination of surgical specimens will be compared with MRI findings for staging accuracy assessment.
223961912|NCT07202624|DRUG|Dexmedetomidine (Precedex)|The ETT cuff will be filled with 4 mL of dexmedetomidine 4 mcg/mL
223961913|NCT07202624|DRUG|alkalinized lidocaine|lidocaine 2%, 2 ml will be initially injected into the cuff, and then a supplementary volume of 2 ml of sodium bicarbonate (NaHCO3) 8.4% will be added
223961914|NCT07202728|OTHER|No intervention|No intervention
223724488|NCT05076903|DRUG|OFA|Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
223724489|NCT05076903|DRUG|Control|Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.
223724490|NCT05048784|DRUG|Sotorasib|Oral tablet
223724491|NCT00226707|DRUG|Pimecrolimus Cream 1%|
223724492|NCT00825591|DIETARY_SUPPLEMENT|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
223724493|NCT00825591|DIETARY_SUPPLEMENT|Placebo Comparator|Oral administration before bed. 6 week duration.
223961915|NCT07204197|OTHER|Virtual Reality-Assisted Physical Therapy|VR Assisted PT intervention, combines a standardized postoperative physical therapy program with an additional 20-minute immersive VR session. The VR component is relaxation-focused and interactive, making the total session length 60 minutes. The distinguishing feature is the integration of VR technology into early rehabilitation after lumbar disc surgery, which is not part of conventional therapy.
224109897|NCT00640783|BEHAVIORAL|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
224109898|NCT00640783|BEHAVIORAL|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, \<30%).
224109899|NCT05624255|OTHER|Ophthalmologic consultation|Complete ophthalmologic examination including angio-OCT
224109900|NCT06178510|DEVICE|INTELLiVENT-ASV.|INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
223961916|NCT07204197|OTHER|Conventional Physical Therapy|This intervention consists of the same standardized physical therapy program as the VR group, delivered for 60 minutes daily by increasing exercise repetitions and intensity. The distinguishing feature is that it does not include any VR component, allowing direct comparison of physical therapy alone versus VR-assisted therapy.
223542192|NCT00589797|DEVICE|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
223542193|NCT03269357|OTHER|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
223961917|NCT07203196|BEHAVIORAL|Circadian Rhythm Optimization|Participants will follow a Mediterranean diet while consuming all calories within a personalized 8-10 hour daytime window. They will increase daytime light exposure to at least one hour per day, engage in a minimum of 150 minutes of moderate-intensity aerobic exercise each week (including at least two sessions lasting no less than 60 minutes), maintain a consistent 7-9 hour sleep schedule, and take supplements as recommended based on individual needs. Participants will also record all food and beverage intake, as well as exercise, using the myCircadianClock app.
223961918|NCT07203339|DEVICE|Transcranial direct current stimulation (tDCS) plus placebo.|Participants will be randomized to receive 28 sessions of active anodal tDCS (2 mA) or sham, with the anode over the left M1 and the cathode over the right supraorbital area, for 20 minutes, combined with pain neuroscience education and physical exercises. Sessions will be self-administered at home, daily for 4 weeks. Electrodes (35 cm²) will be placed using neoprene caps (sizes S to XL), adjusted according to head circumference. Monitoring: the device records session time, duration, and adherence, interrupting the session if impedance exceeds 1 mA (5-second interval) or if current varies \>10%. Developed in partnership with HCPA's Biomedical Engineering, the device is licensed by UFRGS/HCPA and registered with ANVISA (No. 80079190028).
223961919|NCT07203339|DRUG|Duloxetine (60 mg) once daily|"Duloxetine (30 mg and 60 mg) will be purchased from a commercial pharmacy and fractionated by a compounding pharmacy, which will also prepare the placebo. Capsules will be transferred into standardized jars based on dosing schedule:~* Jar 01 (white cap): 7 capsules of 30 mg~* Jar 02 (green cap): 16 capsules of 60 mg~* Jar 03 (green cap): 42 capsules of 60 mg~* Jar 04 (white cap): 7 capsules of 30 mg Placebo and duloxetine capsules will be identical in appearance. Kits will be labeled with CAEE number, participant ID (RedCap), pharmacist and PI names, and storage/use instructions. Kits will be stored at the HCPA Pharmacy Service under controlled conditions and dispensed during visits AV1 (Jars 1 and 2), AV2 (Jar 3), and AV3 (Jar 4)."
223961920|NCT07203339|DEVICE|Home-based transcranial direct current stimulaiton|Participants will be randomized to receive 28 sessions of active anodal tDCS (2 mA) anode over the left M1 and the cathode over the right supraorbital area, for 20 minutes
223961921|NCT07203339|DRUG|Duloxetine 60 mg|"Duloxetine (30 mg and 60 mg) will be purchased from a commercial pharmacy and fractionated by a compounding pharmacy, which will also prepare the placebo. Capsules will be transferred into standardized jars based on dosing schedule:~* Jar 01 (white cap): 7 capsules of 30 mg~* Jar 02 (green cap): 16 capsules of 60 mg~* Jar 03 (green cap): 42 capsules of 60 mg~* Jar 04 (white cap): 7 capsules of 30 mg Placebo and duloxetine capsules will be identical in appearance. Kits will be labeled with CAEE number, participant ID (RedCap), pharmacist and PI names, and storage/use instructions. Kits will be stored at the HCPA Pharmacy Service under controlled conditions and dispensed during visits AV1 (Jars 1 and 2), AV2 (Jar 3), and AV3 (Jar 4)."
223961922|NCT07204314|DRUG|Vortioxetine tablets|Vortioxetine tablets
223961923|NCT07204314|DRUG|Placebo tablets|Placebo tablets
224109901|NCT00676481|BEHAVIORAL|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
224109902|NCT05805371|BIOLOGICAL|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
224109903|NCT05805371|PROCEDURE|Biopsy|Undergo tumor biopsy
224109904|NCT05805371|PROCEDURE|Biospecimen Collection|Undergo blood, stool, and urine sample collection
224109905|NCT05805371|PROCEDURE|Bone Scan|Undergo bone scan
224109906|NCT05805371|PROCEDURE|Computed Tomography|Undergo CT scan
224109907|NCT05805371|RADIATION|External Beam Radiation Therapy|Undergo radiation
224109908|NCT05805371|PROCEDURE|Leukapheresis|Undergo leukapheresis
224109909|NCT05805371|PROCEDURE|Lymphodepletion Therapy|Undergo lymphodepletion
224109910|NCT03465800|BEHAVIORAL|self-monitoring|self-monitoring of physical activity
224109911|NCT03465800|BEHAVIORAL|daily incentives|daily incentive payments for physical activity
223542194|NCT01990976|DEVICE|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
223542195|NCT01990976|PROCEDURE|Biopsy|biopsy of the vastus lateralis muscle
223542196|NCT00028158|DRUG|G207, an oncolytic virus|
223961924|NCT07203599|DRUG|Human umbilical cord mesenchymal stem cell exosomes|Human umbilical cord mesenchymal stem cell exosomes are nanoscale vesicles released by mesenchymal stem cells from the umbilical cord. These exosomes act as natural carriers, transferring proteins, microRNAs (miRNAs), and other molecules to recipient cells. This communication helps the exosomes exert therapeutic effects, promoting tissue repair, reducing inflammation, and mediating cell-to-cell interactions in various disease models.
223961925|NCT07203599|DRUG|Minoxidil 5% Topical Solution|Topical minoxidil is a medicine used to help regrow the hair on your scalp. It works by increasing the blood flow to your hair and helps stimulate your hair follicles to grow.
223961926|NCT07204275|DRUG|Povetacicept|Solution for Subcutaneous Injection.
223961927|NCT07204275|DRUG|Tacrolimus|Tablets for Oral Administration.
223961928|NCT07203092|DEVICE|Active transcranial photobiomodulation|Active transcranial photobiomodulation to the forehead targeting prefrontal cortex involves administration of 1064-nm light delivered via laser with a 4 centimeter beam diameter and 250 mW/cm2 power density for 8 minutes per treatment.
223961929|NCT07203092|DEVICE|Sham transcranial photobiomodulation|Identical procedure as active group, but without 1064-nm light emitted by the device.
223961930|NCT07203144|DRUG|selenium yeast supplementation|In this intervention, patients will receive adjunctive selenium yeast supplementation at a daily dose of 100-200 μg in addition to fluoxetine. Symptom rating scales, biospecimen collection, and brain MRI will be conducted at baseline, week 4, and week 8 to investigate the adjunctive role of selenium in fluoxetine treatment for depression.
223961931|NCT07203144|DRUG|Placebo yeast supplementation|In this intervention, patients will receive standard fluoxetine treatment combined with placebo yeast supplementation (100-200 μg/day), which is identical in appearance and odor to selenium yeast. The aim is to clarify the specific role of selenium in the treatment of depression.
223961932|NCT07204912|DEVICE|MIT Powered Leg|MIT powered knee prosthesis developed by the MIT Biomechatronics Group.
224109912|NCT03465800|BEHAVIORAL|delayed lump sum incentives|delayed lump sum payments for physical activity
224109913|NCT03707977|DRUG|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
223542197|NCT05412043|BEHAVIORAL|Dance therapy|The dance group will attend choreo-based dance therapy which includes both cognitive training to remember the choreo's and motor training to execute them (with and without music). Each session will consist of a ten-minute warm up, dance training and a ten-minute cool down. The participants will be taught three choreographies, which will increase in difficulty level. 1) floor work on a slow rhythm with focus on proprioception, abdominal muscle strength, coordination and working memory. 2) slow paced with a group part and a canon part with focus on working memory, static and dynamic balance and strength. Furthermore, it will require dynamic balance, walking and cognition. 3) higher rhythm and will be danced with a cane which will require more speed, coordination and dual tasking.
223542198|NCT05412043|OTHER|Psychometric properties (Validity, Reliability) of interlimb coordination- and cognitive-fatigability|The study consists of 2 test sessions, separated by 5-7 days of interval. The sessions 1 and 2 will be composed of cognitive test battery, questionnaires to be filled, information about the use of actigraph, clinical outcomes and interlimb coordination tests
223961933|NCT07204834|BEHAVIORAL|Physical Activity|"Participants will be encouraged to progressively increase the number of daily steps (volume) and the number of minutes per day spent at a higher cadence (intensity). To achieve these goals, the investigators will support participants in the intervention group through behavior change techniques. For example, wearable devices and an online platform will be used to monitor the behavior and track progress using simple graphs; participants will be provided with small, individualized goals which will be updated every two weeks based on the activity levels achieved the prior two weeks; standardized WhatsApp messages will be sent to prompt the behavior and face-to-face coaching sessions will be delivered throughout the intervention.~Participants in this group will also receive enhanced usual care, consisting of the usual care to manage heart failure plus an education pamphlet and in-depth evaluations and reports to measure the project outcomes."
224109914|NCT03707977|BIOLOGICAL|VRC01LS|Administered by intravenous (IV) infusion
224109915|NCT03707977|BIOLOGICAL|10-1074|Administered by intravenous (IV) infusion
224109916|NCT02604719|DRUG|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
224109917|NCT04260724|DEVICE|TMS|"* stimulation intensity : motor threshold 100%~* stimulation frequency : 1600 pulses for 20 minutes~* stimulation duration :for four weaks, 20 minutes/day, 5 days per week (Monday - Friday )"
224109918|NCT04260724|DEVICE|sham coil stimulation|no stimulation Although the sound from device during stimulation is similar, no stimulation is applied.
223961934|NCT07203807|OTHER|Voluntary movement and illusory movement of the right upper limb induced by TVS.|"The protocol comprises two different modalities: Voluntary movement and illusory movement of the right upper limb induced by TVS.~The experiment will begin and end with a one-minute rest period. Participants will be asked to open and close their right hand 20 times in 10 seconds. Similarly, they will experience 10 seconds of TVS-induced illusory movement 20 times. Each task epoch will be preceded by a 12-20 second resting period.~Both conditions will be randomized and counterbalanced. Participants can start with either the voluntary movement task or the illusory."
223961935|NCT07203846|DRUG|Rifaximin|Participants receiving a 7-day course of oral rifaximin 400 mg every 12 hours
223961936|NCT07204535|OTHER|Prospective questionnaires|Post-traumatic stress disorder Checklist version DSM-5 (PCL-5) and quality of life questionnaires
223961937|NCT07203859|PROCEDURE|Quadro-İliac Plane Block(QİPB)|40 mL of 0.25% bupivacaine
223961938|NCT07203014|BEHAVIORAL|Parent-Educator Action Response (PEAR)|PEAR is a novel adjunctive intervention aimed at improving teacher and family implementation of classroom-based interventions for child ADHD symptoms and disruptive behavior in preschool.
223961939|NCT07203014|BEHAVIORAL|Daily Report Card|The Daily Report Card is a behavioral intervention for children with challenging behaviors, and provides a structure for teachers and caregivers to support a child with reducing challenging behaviors and increasing positive behaviors. The DRC has been shown to be highly effective in reducing ADHD symptoms.
223961940|NCT07203872|DEVICE|IsoDent Paro Strong (Isodent Ltd. Valtakatu 4 D, 96100 Rovaniemi, Finland) mouthwash|adjunctive anti-inflammatory mouthwash
223961941|NCT07203872|DEVICE|Placebo mouthwash|Contains all the inactive ingredients as the test mouthwash without the LXA4
223961942|NCT07203040|DEVICE|Therapeutic Ultrasound|Continuous ultrasound applied to painful/stiff cervical muscles during a single clinic visit; frequency 1-3 MHz, intensity 1.0-1.5 W/cm²
223961943|NCT07203040|DEVICE|Sham Ultrasound|Single session mimicking active procedure; device displays appear normal but acoustic output is 0 W/cm²; \~10 minutes;
224109919|NCT05568745|DEVICE|Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)|Balloon catheter is inserted by a resident or a physician under visual control. The expected volume injected in the balloon probe is 60 mL. No traction is performed on the catheter. The catheter is left in place for a maximum of 12 hours.
224109920|NCT05568745|DRUG|Oxytocin|Intravenous oxytocin addition (preceded or followed by epidural analgesia on patient's request) will be performed 6 hours after insertion of balloon catheter. Oxytocin is administered as an intravenous infusion (5 IU of oxytocin in 49 mL of 5% glucose\*) at the lowest possible dose with the aim of achieving a maximum of three to four contractions per ten minutes. After appropriate uterine activity has been achieved, the rate of the oxytocin infusion is decreased or stopped.
224109921|NCT05568745|DRUG|Misoprostol Oral Tablet|Patients will receive misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
224109922|NCT04918693|DEVICE|Ultrasound scanning|All participants will scan with and without device and trainee on 4 models. The order of the device assistance and models will be randomized between participants, but participant will always have exposure to device first before supervising the trainee.
224109923|NCT04567836|OTHER|Investigation of the prevalence of test positivity|"The study consists of an investigation by means of a prospective observational study with the aim of assess the prevalence of test positivity (swab or serological examination) ti covid-19 in relation to the duties and related occupational risk.~It is used CLIA method test designed to recognize IgG antibodies directed against the S1 and S2 domains of the SARS-CoV-2 virus spike protein, selected for their ability to provide specificity for SARS-CoV-2 compared to other Coronaviruses ."
224109924|NCT02928393|DRUG|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
223961944|NCT07203209|OTHER|thoracal mobility exercises|The exercise program given to the athletes in the mobility group will include 8 exercises specially designed for thoracic region mobility. The exercises will be practiced by the team trainer in every training session and otherwise at home twice a day.
223961945|NCT07203209|OTHER|regular training|This training program is composed of the teams daily practice exercises.
223961946|NCT07197359|OTHER|Looksmaxxing AI Facial Analysis|Participants' standardized frontal facial photographs will be analyzed using the Looksmaxxing AI application (versions 4o and 5) to determine the presence or absence of chin deviation relative to the facial midline.
223961947|NCT07204054|OTHER|Medial longitudinal arch support taping using low dye tape|Low dye Taping which is applied by patient lying supine on treatment table. No tension is applied due to the characteristics of the tape and it is described in the following steps; placement of a strip in the area of the metatarsal heads, in the dorsal area placement of a strap on the back, forming a circle with the front strap and in the plantar area; a figure of eight was made, starting from the side of the fifth metatarsal, surrounding the heel and ending at the starting point, the same operation was performed as in point but starting from the hallux. The last part is different, as a strip at the main point of pain, that is, at the insertion towards the medial edge of the foot Ultrasound, stretching and strengthening exercises. Ultrasound will be applied for duration of 7 minutes at the plantar aspect of foot with 1.5 w/cm2 output and continuous mode of frequency of 1MHz. Stretching of gastrocnemius and soleus and towel curl exercise.
223961948|NCT07204054|OTHER|Fascia Stretch taping using KT tape|Fascia Taping which is applied in which In the first step, after the metatarsophalangeal joints were dorsiflexed, the first strap was adhered firmly to the posterior heel at its proximal end. The other end of the strap was cut into four slices of equal width. Each slice was applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap was applied following the same pattern and overlapped the first strap. In the third step, the last strap was applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot. Dashed arrows denote the direction of stretch Ultrasound, stretching and strengthening exercises. Ultrasound will be applied for duration of 7 minutes at the plantar aspect of foot with 1.5 w/cm2 output and continuous mode of frequency of 1MHz. Stretching (5reps with 10 sec hold each stretch) of gastrocnemius and Soleus and toe curl exercise
223961949|NCT07203742|OTHER|mandala painting|"After the child and parent agree to participate in the study and the child indicates that they wish to do the mandala exercise, the child will be seated in a comfortable position to paint. Thirty minutes before the start of the intrathecal chemotherapy procedure (children who will receive intrathecal chemotherapy at the clinic are identified and scheduled the day before), the child, their parent, and a nurse independent of the study will be assessed using the Child Anxiety Scale-State (ÇAS-D) and the Child Fear Scale. The mandala coloring activity will then continue until the child wishes to stop (the activity will be ensured to last at least 30 minutes). When the child is called to the procedure room for intrathecal chemotherapy, the scale assessments will be repeated. Thirty minutes after the intrathecal chemotherapy procedure is completed and the child has emerged from the effects of general anesthesia, the scales will be reassessed and recorded by the same i"
223961950|NCT07203404|DRUG|RD06-05 CART Cell Injection|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
223961951|NCT07203443|OTHER|MRI|Anatomical and functional MRI
223961952|NCT07203443|OTHER|Psychological assessment|Inventories and clinical interviews
223961953|NCT07203443|BEHAVIORAL|Cognitive assessment|Attention and memory tests
223961954|NCT07203443|OTHER|Cortisol sample|Salivary test
224109925|NCT02928393|DRUG|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
224109926|NCT01225783|OTHER|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
224109927|NCT04689646|BEHAVIORAL|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
223542199|NCT01881009|DEVICE|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
223542200|NCT01881009|DEVICE|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
223961955|NCT07203937|DEVICE|RoboGait® Robotic Gait Training|RoboGait® is a robotic lower limb orthosis system with adjustable dynamic body weight support, synchronized treadmill, and biofeedback software. Participants will receive robotic-assisted gait training 2 days per week for 6 weeks, in addition to conventional rehabilitation 5 days per week.
223961956|NCT07203937|DEVICE|Treadmill Walking Training|Participants will receive treadmill walking sessions 2 days per week for 6 weeks, combined with conventional rehabilitation 5 days per week. The treadmill sessions will be matched in duration and intensity to the robotic training sessions in the experimental arm.
223961957|NCT07203235|OTHER|evaluation|Participants will undergo a series of evaluations including core muscle function tests, endurance assessments, proprioceptive measurements, balance testing, and gait analysis. These assessments are non-invasive and observational, aimed at comparing functional performance between individuals with transtibial amputation and healthy controls. No interventions will be applied; only assessments will be conducted.
223961958|NCT07202650|BEHAVIORAL|guided imagery|Guided imagery is a form of mind-body communication, defined as a flow of thoughts involving what we smell, taste, see, hear, and touch, or as the way the mind encodes, stores, and retrieves information. Guided imagery is based on the understanding that the mind and body are interconnected and that the mind can influence bodily functions. Stress and anxiety directly affect the brain and the immune system.
223961959|NCT07203560|OTHER|Neurodynamic Mobilization|In the experimental group, neurodynamic mobilization was applied in addition to the conventional physiotherapy program. For the neurodynamic mobilization tibial nerve neural mobilization was performed. For neural mobilization of the tibial nerve, the patient was placed in the side-lying position with the hip in 90° flexion, knee flexion and ankle dorsi flexion. In this position, the ankle and hip positions were maintained, and knee extension was performed. When the symptoms were at a level that would not disturb the patient, it was held for 5 seconds, and knee flexion was performed by plantar flexion of the ankle. This practice was performed twice a week with 10 repetitions by a physiotherapist. The same neurodynamic mobilization exercise was recommended to the patients in the neuromobilization group as a home program with 10 repetitions twice a day.
223961960|NCT07203560|OTHER|Conventional Physiotherapy|All participants received hot pack therapy (20 minutes), conventional TENS (60 Hz, 60 msec, 20 minutes), therapeutic ultrasound (1.5 W/cm², 10 minutes), and a prescribed home exercise program, delivered 5 days per week for 4 weeks (20 sessions in total).
223961961|NCT07203755|BIOLOGICAL|Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)|1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0
223961962|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0
223961963|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|1 dose of DTcP-Hib-MCV4 vaccine (0.5ml) on day 0
223961964|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
223961965|NCT07203755|BIOLOGICAL|DTcP-Hib-MCV4|3 doses of DTcP-Hib-MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
223961966|NCT07203755|BIOLOGICAL|Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)|3 doses of DTcP (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
223961967|NCT07203755|BIOLOGICAL|Haemophilus influenzae type b (Conjugate) (Hib)|3 doses of Hib (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
224109928|NCT04689646|BEHAVIORAL|Mind body intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
224109929|NCT04396912|PROCEDURE|Total thyroidectomy|Patients with thyroid diseases either benign (e.g. multinodular goitre) or malign (e.g. thyroid carcinoma) will be prepared for total thyroidectomy procedure and will be enrolled.
224109930|NCT01589120|BEHAVIORAL|Video decision aid|Video decision aid of the goals of care
224109931|NCT02640612|DRUG|BI 695501|
224109932|NCT01720667|DRUG|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
224109933|NCT01720667|DRUG|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
223961968|NCT07203755|BIOLOGICAL|Meningococcal Group ACYW135 (Conjugate) (MCV4)|3 doses of MCV4 (0.5ml) at 0, 2, and 4 months, followed by a booster dose at 18-24 months of age.
223961969|NCT07203755|BIOLOGICAL|MCV4|3 doses of MCV4 (0.5ml) at 0, 1, and 2 months, followed by a booster dose at 12 months of age.
223961970|NCT07203755|BIOLOGICAL|MCV4|3 doses of MCV4 (0.5ml) at 0, 2, and 4 months.
223961971|NCT07203755|OTHER|Sodium Chloride Injection (0.9%) (Saline Solution) (NS)|3 doses of NS (0.5ml) at 0, 2, and 4 months.
224109934|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, low dose
224109935|NCT04824872|DRUG|Dasiglucagon|dasiglucagon SC, high dose
224109936|NCT04824872|DRUG|Placebo|placebo for dasiglucagon
224109937|NCT03472534|DRUG|diacerein 1% ointment|diacerein 1% ointment applied to the skin of the infrascapular area of the back under occlusive patch for 21 days.
224109938|NCT03714412|DEVICE|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
224109939|NCT04174963|BEHAVIORAL|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
224109940|NCT00020852|PROCEDURE|conventional surgery|
224109941|NCT00020852|PROCEDURE|cryosurgery|
224291324|NCT03985787|BEHAVIORAL|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
224291325|NCT02815202|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-034)
224291326|NCT04133649|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
224291327|NCT03543345|DIAGNOSTIC_TEST|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~* Written consent.~* Complete history.~* Complete physical examination.~* Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~* Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
223961972|NCT07203417|BEHAVIORAL|STEP-T|Couples in the STEP-T group will meet online with a therapist for 120 minutes once a week over 8 weeks. Each meeting consists of a therapist-led session focused on the psychoeducational content from the STEP module. Sessions begin with a review of the homework completed during the previous week and end with the assignment of new sex therapy homework related to that day's session. After each session, the therapist will email the couple the module that includes the session's psychoeducational handouts and the sex therapy homework to be completed prior to the next session.
223724494|NCT05526820|BIOLOGICAL|The live attenuated varicella vaccine and the inactivated hepatitis A vaccine|"The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd,the inactivated hepatitis A vaccine was manufactured by Sinovac Biotech Co., Ltd.~The live attenuated varicella vaccine:live varicella-zoster virus in 0.5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection.~The inactivated hepatitis A vaccine:250 U inactivated virus in 0.5mL of aluminium hydroxide solution per injection.~All subjects received hepatitis A vaccine in the upper left arm and varicella vaccine in the upper right arm."
223961973|NCT07203417|BEHAVIORAL|STEP-NT|Couples in the STEP-NT group will receive STEP (i.e., one module per week for 8 weeks, including psychoeducational handouts and sex therapy homework), without the therapist-led online sessions. However, like couples in STEP-T, they will be allowed to contact the research team for clarifications related to the structure, instructions, or technical aspects of the exercises. This support will be limited to non-clinical guidance and will not involve any individualized feedback regarding participants' personal experiences or relationship dynamics.
223961974|NCT07203417|OTHER|Waitlist|While couples randomized to STEP-T and STEP-NT will complete one online baseline assessment battery before randomization, those assigned to the waitlist control condition will complete two baseline assessments online, spaced 10 weeks apart, before being randomized to one of the active treatment groups (i.e., STEP-T or STEP-NT). The 10-week waiting period was selected to match the time it takes couples to complete the 8 modules of STEP. This design allows us to determine that improvements in clinical outcomes are due to the STEP intervention rather than the mere passage of time. Following the post-waiting period assessment (i.e., the second baseline battery), waitlist participants will be randomized to STEP-T or STEP-NT.
223961975|NCT07202897|DRUG|Anticoagulant treatment Rivaroxaban|Anticoagulant treatment Rivaroxaban in addition to best medical therapy
223724495|NCT00161083|DRUG|ursodeoxycholic acid|
223961976|NCT07202897|OTHER|Best medical therapy|Best medical therapy alone
223961977|NCT07203066|OTHER|observational only|observational only
223961978|NCT07204093|DRUG|Drospirenone 4 mg orally|Daily oral administration of Drospirenone 4 mg + Transdermal estradiol; continuous administration for at least 6 months.
223961979|NCT07204093|DRUG|Dienogest 2 mg orally|Daily oral administration of Dienogest 2 mg + Transdermal estradiol; continuous administration for at least 6 months.
223961980|NCT07204769|DRUG|Antibiotic sensitivity|Molecular characterization of multidrug-resistance gene antibiotics.
223961981|NCT07204418|DRUG|Xanomeline/ Trospium Chloride|Specified dose on specified days
223961982|NCT07203248|DRUG|CGRP R Inhibitor; CGRP Inhibitor|Participants who are prescribed CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A1.Participants who are prescribed CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B1.
223961983|NCT07203248|DRUG|none-CGRP|Participants who are prescribed none-CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A2.Participants who are prescribed none-CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B2.
223961984|NCT07203001|DRUG|MAS825|Experimental drug
223961985|NCT07204886|OTHER|Multicomponent training and stability exercise|"The training program will span 14 weeks. Participants will engage in structured sessions twice a week (on Tuesdays and Thursdays), with each session lasting 60 minutes. The sessions will consist of aerobic, balance, Dynamic Neuromuscular Stabilization (DNS) and stability exercises, strength exercises (using body weight and the Swedish bar), and flexibility exercises.~Each training session will begin with a warm-up phase, including five minutes of dynamic stretching to prepare the body for the physical demands of the session. Following the warm-up, participants will perform 15 minutes of low-impact aerobic exercises, such as marching, knee lifts, leg curls, lunges, and kicks, incorporating coordinated arm movements.~Next, participants will complete 15 minutes of balance, DNS, and stability exercises. This will be followed by 20 minutes of strength training exercises. Each session will conclude with a 5-minute cooldown and flexibility segment to promote"
223961986|NCT07204574|DRUG|HCB101|QW
223542201|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)|"\- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"
223961987|NCT07204574|DRUG|Bevacizumab|5 mg/kg IV infusion, Day 1, Every 2 weeks
223961988|NCT07204574|DRUG|Cetuximab (Erbitux)|"* Initial dose: 400 mg/m² IV infusion, over \>2 hours, Day 1~* Maintenance dose: 250 mg/m² IV infusion, over 60 minutes, Day 1, weekly OR 500 mg/m² IV infusion, over \>2 hours, Day 1, every 2 weeks"
223961989|NCT07204574|DRUG|FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)|Irinotecan: 180 mg/m² IV infusion over 30-90 minutes, Day 1, Every 2 weeks Folinic acid (Leucovorin): 400 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks 5-Fluorouracil (5-FU): 400 mg/m² IV bolus, Day 1; then 1200 mg/(m²·day) × 2 days continuous IV infusion (total 2400 mg/m² over 46-48 hours, Every 2 weeks
223961990|NCT07204574|DRUG|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Folinic acid (Leucovorin): 400 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks 5-Fluorouracil (5-FU): 400 mg/m² IV bolus, Day 1; then 1200 mg/(m²·day) × 2 days continuous IV infusion (total 2400 mg/m² over 46-48 hours), Every 2 weeks Oxaliplatin: 85 mg/m² IV infusion over 2 hours, Day 1, Every 2 weeks
223961991|NCT07202949|DRUG|Treatment dose antibiotic in combination with methenamine hippurate|"Arm A includes treatment with one of three treatment dose antibiotic options, selected by the treating clinician, in combination with methenamine hippurate. Participants allocated to this arm will receive combination therapy, consisting of one of the following antibiotics:~* Cefalexin (500mg four times daily), or~* Nitrofurantoin (100mg twice daily), or~* Trimethoprim (200mg twice daily) in combination with Methenamine Hippurate (1g twice daily) for 12 weeks."
223961992|NCT07202949|DRUG|Prophylactic dose antibiotic or methenamine hippurate monotherapy|"Arm B includes treatment with one of four prophylactic dose antibiotics or methenamine hippurate, but not both, selected by the treating clinician. Participants in this arm will receive monotherapy of one of the following:~* Amoxicillin (250mg once daily), or~* Cefalexin (125mg once daily), or~* Nitrofurantoin (50mg once daily), or~* Trimethoprim (100mg once daily), or~* Methenamine Hippurate (1g twice daily) for 12 weeks."
223961993|NCT07204145|DEVICE|Laser Acupuncture (808 nm laser pen)|Participants receive laser acupuncture using an 808 nm, 100 mW semiconductor laser pen applied at acupoints GV20, bilateral ST36, and bilateral PC6. Each acupoint is irradiated for 10 seconds, three times per week, for 12 weeks.
223961994|NCT07204145|DEVICE|Sham Laser Acupuncture|Participants receive the same procedure as the laser acupuncture group, using an 808 nm semiconductor laser pen applied at acupoints GV20, bilateral ST36, and bilateral PC6. The device is identical in appearance and produces lights and beeping sounds; however, it delivers no energy output. Each acupoint is contacted for 10 seconds, three times per week, for 12 weeks.
223542202|NCT05296317|DRUG|Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)|"\- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"
223724496|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
223961995|NCT07204548|DRUG|Ivonescimab|Ivonescimab is given after definitive concurrent/sequential chemoradiotherapy
223961996|NCT07203651|DRUG|Sterile Water Injection|WE will compare effectiveness of intradermal sterile water injection with intramuscular diclofenal
223961997|NCT07203651|DRUG|Diclofenac|comparing effectiveness of diclofenac with intradermal sterile water injection
223961998|NCT07203664|COMBINATION_PRODUCT|steroids, tacrolimus and mTOR inhibitors|Patients receive immunosuppressive induction treatment with thymoglobulin (at least 1 dose and maximum of 5 doses) and immunosuppressive maintenance treatment with tacrolimus + mTOR inhibitors. Preemptive therapy will be administered as a preventive strategy, consisting of initiating antiviral treatment with valganciclovir (900 mg every 12 hours, adjusted according to renal function as per the technical data sheet) when CMV viral replication in blood exceeds 1,000 copies/ml. Treatment will be discontinued once viral load becomes undetectable in two consecutive tests.
223961999|NCT07203664|COMBINATION_PRODUCT|steroids, tacrolimus and mycophenolic acid.|Patients will receive immunosuppressive induction treatment with thymoglobulin (at least 1 dose and a maximum of 5 doses) and tacrolimus + mycophenolic acid following the guidelines of the technical file and the centre's usual protocols.
223542203|NCT06049173|DEVICE|Negative extra-abdominal pressure (NEXAP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total. After LRM, the ventilator mode was changed to its baseline settings.
223542204|NCT06049173|OTHER|stepwise positive end-expiratory pressure (PEEP)-based lung recruitment maneuver|The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
223542205|NCT04333615|BEHAVIORAL|Exercise|Three conditions will be tested: self-selected exercise, walking with pain exercise, and control session.
223542206|NCT06135948|DRUG|Extra dose of L-thyroxine, 25 mcg during Ramadan|Extra dose of L-thyroxine, 25 mcg during the month of Ramadan
223542207|NCT00870480|DRUG|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
223962000|NCT07203911|DIAGNOSTIC_TEST|Ultrasound imaging|Ultrasound will be performed during surgery in two phases: 1) in-vivo and 2) ex-vivo. In the in-vivo phase surgeons will perform intraoral ultrasound with a small intraoral transducer in order to visualize size and boundaries of tumor. Then the surgeon begins the resection periodically pausing to obtain real-time images of the resection plane and determin if resection is performed at safe distance to the tumor. In the ex-vivo phase the resected tumor will undergo ultrasound by using a motorized mechanical arm designed to hold an ultrasound transducer. This ensures standardized and reproducible scans. The purpose of the ex-vivo scan is to measure the surgical margins at the operating theatre and allow for an immediate re-resection of necessary. Surgeons in the intervention group will also have the possibility of taking biopsies for frozen section analyses.
223962001|NCT07203911|OTHER|Standard Treatment|Standard surgical treatment of oral cancer
223962002|NCT07204717|PROCEDURE|free gingival graft|standard free gingival technique
223962003|NCT07204717|PROCEDURE|ring free gingival greft|ring free gingival greft technique
223962004|NCT07203898|BIOLOGICAL|IPM514|"2 primary immunization cycles: IPM514 will be administered once a week (QW) for 3 consecutive doses per cycle, there will be a 2-week interval between the two cycles.~Maintenance treatment: 6 doses administered every 3 weeks (Q3W), and 4 doses administered every 6 weeks (Q6W), if treatment continuously benefit the participant."
223962005|NCT07203625|DRUG|Tenecteplase thrombolysis|Patients will receive intravenous Tenecteplase 0.25 mg/kg body-weight up to a maximum of 25mg before the transfer. A single bolus dose should be administered over 5-10 seconds based on patient weight. Transfer to ECCs for thrombectomy should be initiated immediately after Tenecteplase administration.
223962006|NCT07203989|BEHAVIORAL|family-supported care|Family video calling in the operating room
224109942|NCT05930873|BEHAVIORAL|Immersive room|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented on one of the four walls of the immersive room and a set of stimuli, including the target stimulus, which the subject will have to touch within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
224109943|NCT05930873|BEHAVIORAL|stimuli in a paper format|"The intervention will be structured according to Applied Behavioral Analysis. A target stimulus will be presented in a paper format and a set of stimuli, including the target stimulus, which the subject will have to indicate within a certain latency time.~There will also be a hierarchy of prompts (least to most) in case the child gives an inaccurate answer or does not answer within the established time.~Finally, as the last element of the behavioral chain, a social reinforcement will be delivered (a sound stimulus indicating applause) when the desired response is emitted.~The intervention will be divided into phases, according to a progressive increase of the task in terms of visual attention, and an achievement of the acquisition criterion. Furthermore, each participant will be subjected to stimuli belonging to different semantic categories (fruit, animals, means of transport, clothing, figures and faces)."
224109944|NCT03531268|OTHER|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
224109945|NCT03881163|DRUG|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
224109946|NCT04109443|BEHAVIORAL|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
224109947|NCT04109443|BEHAVIORAL|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
224109948|NCT02891993|OTHER|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
224109949|NCT02891993|OTHER|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
224109950|NCT00029315|DRUG|Recombinant Tissue Plasminogen Activator (rt-PA)|
224109951|NCT02004340|DEVICE|ear vagus nerve stimulator|
223542208|NCT00870480|DRUG|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
223542209|NCT05262413|DRUG|QL1706 Plus Lenvatinib|QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.
223542210|NCT02457247|DRUG|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
223962007|NCT07204470|OTHER|Breakfast cereal standardised to an isocaloric intake of approximately 350 kcal, consume entire portion within 15 minutes witnessed. No other food may be consumed during the 4 hour test period.|Cereal is in porridge form. One 350 ml bottle of water provided for the 4 hour test period 7:00-11:00 a.m.. Control dinner meal consumed the prior evening, then fast 10 hours overnight before visiting the test facility on four test days one week apart.
223962008|NCT07204431|DEVICE|the PowerBreathe and PEP Therosold tools group|Initially, the following data were collected from each subject in addition to basic epidemiological data.
224109952|NCT03921892|BEHAVIORAL|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
224109953|NCT02558699|PROCEDURE|physician's personal experience|physician's personal experience
224109954|NCT02558699|PROCEDURE|Virtual rotor mapping|Virtual rotor mapping
224109955|NCT02252952|OTHER|Beverage Consumption|
223962009|NCT07203885|BEHAVIORAL|Unaided Review First, Then AI-Assisted Review|Readers first complete Block X (Unaided) on their assigned subset SX (up to 40 slides). They then complete Block Y (AI-Assisted) on two separate subsets: SY1 (up to 40 slides; AI as Double-Check) and SY2 (up to 40 slides; AI as First Look). Within Block Y, the order of Y1 and Y2 is randomized. For each reader, SX, SY1, and SY2 are disjoint and stratified by APL status.
223542211|NCT02457247|DRUG|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
223962010|NCT07203885|BEHAVIORAL|AI-Assisted Review First, Then Unaided Review|Readers first complete Block Y (AI-Assisted) on two assigned subsets: SY1 (up to 40 slides; AI as Double-Check) and SY2 (up to 40 slides; AI as First Look), with the order of Y1 and Y2 randomized. They then complete Block X (Unaided) on subset SX (up to 40 slides). For each reader, SX, SY1, and SY2 are disjoint and stratified by APL status.
223962011|NCT07203638|DRUG|Beta Lactam Antibiotics|Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml
224109956|NCT05760625|DIAGNOSTIC_TEST|analysis BDNF|We analysed consentration of BDNF in venous blood of patient with primary headache
223542212|NCT02457247|DRUG|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
223962012|NCT07203638|DRUG|Salin|Patient will receive .9 % saline (10ml /12h/2days)
223962013|NCT07204171|DRUG|mitragynine|Mu opioid receptor partial agonist
223962014|NCT07204171|DRUG|Placebo|Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.
223962015|NCT07203508|OTHER|Tongue-to-Palate Resistance Training|The Tongue-to-Palate Resistance Training (TPRT) is a home-based, device-free exercise program. Participants were instructed to press their tongue firmly against their hard palate and hold the contraction. The protocol consisted of 30 repetitions per session, performed five days a week for a duration of eight weeks. Adherence was supported through instructional videos, a caregiver, and a training logbook. The goal of the intervention is to strengthen the intrinsic and extrinsic tongue muscles and the suprahyoid muscle group to improve swallowing function.
224109957|NCT00005860|DRUG|floxuridine|
224109958|NCT00005860|DRUG|leucovorin calcium|
224109959|NCT00005860|DRUG|oxaliplatin|
224109960|NCT06293092|DEVICE|leg pedaling cycling device|Intradialytic aerobic cycling exercise program ,each patient will receive the treatment program three times per week for three months.
224109961|NCT06293092|DEVICE|sand bags|Intradialytic resistive exercise program , each patient will receive the treatment program three times per week for three months.
223542213|NCT00269607|DRUG|Implantation of naltrexone implants|
223542214|NCT03587896|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
223542215|NCT05611255|PROCEDURE|Systematic Intermittent Catheterization|A strategy that consists of draining urine only once, in all patients, after surgery (in the operating room).
223542216|NCT05611255|PROCEDURE|Bladder Scan Guided Catheterization|A strategy of standardized and reproducible assessment of bladder volume before discharge from the post anesthesia care unit, and draining urine only in patients who require it.
223724497|NCT01101646|DRUG|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
223724498|NCT01101646|DRUG|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
223724499|NCT01890356|DEVICE|Transcranial electrical stimulation|
223962016|NCT07203508|COMBINATION_PRODUCT|Standard Dysphagia Therapy|The active comparator consists of a conventional, multi-modal standard of care for oropharyngeal dysphagia. It includes in-clinic sessions twice a week featuring either Neuromuscular Electrical Stimulation (NMES), where electrodes are placed in the submental region to stimulate the swallowing muscles, or biofeedback swallowing therapy. Additionally, participants perform unsupervised Chin Tuck Against Resistance (CTAR) exercises at home. This arm represents the established clinical rehabilitation approach against which the experimental TPRT intervention is compared
223962017|NCT07203521|DRUG|RK-4 injection|take drug RK-4 (2mg/mL, 1mL) by transcranial bone marrow injection once daily for consecutive 3 days.
224109962|NCT06293092|DEVICE|hemodialysis sessions|hemodialysis sessions ,each patient will receive the treatment program three times per week for three months.
224109963|NCT05721625|OTHER|Aerobic exercise|The aerobic exercise program will be applied at moderate intensity 3 days a week for 8 weeks. Walking will be recommended as an aerobic exercise
224109964|NCT05721625|OTHER|Connective tissue massage|Connective tissue massage will be applied by the physiotherapist 3 days a week for 8 weeks. While the patients are in the sitting position, this massage will be applied on whole back.
224109965|NCT00562510|DRUG|Raltegravir|Raltegravir 400 mg BID added to stable HAART
224109966|NCT00562510|DRUG|Placebo|Placebo BID added to stable HAART
224109967|NCT05091801|BEHAVIORAL|Intervention|Participants will have one week of increased chewing time (chew food until they reach an apple sauce consistency)
224109968|NCT03013751|DRUG|Udenafil|Active drug
224109969|NCT04820478|DIETARY_SUPPLEMENT|Beta Hydroxybutyrate Ester (KetoneAid KE4)|see arm/group description
224109970|NCT04820478|DIETARY_SUPPLEMENT|Placebo|see arm/group description
224109971|NCT01947673|OTHER|Mindfulness Meditation|
224109972|NCT01947673|OTHER|Health Education|
223962018|NCT07203521|OTHER|conventional treatment|conventional treatment of LHI other than RK-4
224109973|NCT00692705|DRUG|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
224109974|NCT00692705|DRUG|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
224109975|NCT04706390|BIOLOGICAL|covid-19 vaccine|vaccination
223962019|NCT07204236|DRUG|TVAX-008|TVAX-008
223962020|NCT07202871|DRUG|LY3537031|Administered SC
224109976|NCT01652677|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
224109977|NCT01319929|DRUG|LY2828360|Administered orally
224109978|NCT01319929|DRUG|Placebo|Administered orally
224109979|NCT05309070|DIETARY_SUPPLEMENT|N-acetyl cysteine|Study group will receive N-acetyl cysteine in unmarked boxes, in a daily dose of 1200 mg during two months
224109980|NCT05309070|OTHER|placebo|Control group will receive a placebo, in unmarked boxes, during two months
224109981|NCT02904967|BIOLOGICAL|Extra Blood Draw|
224109982|NCT00164905|DEVICE|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
224109983|NCT03037320|PROCEDURE|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
223962021|NCT07202871|DRUG|LY3537031|Administered IV
223962022|NCT07203781|OTHER|PEEP level changes|For each patient, six different PEEP levels (15-12-10-8-5-2 cmH2O) will be tested during a decremental PEEP trial. During each step, neural respiratory drive, inspiratory effort, expiratory muscle activity, lung inflation pattern through electrical impedance tomography, respiratory muscle geometry and function through ultrasound and surface EMG, gas exchange and hemodynamics data will be collected.
223962023|NCT07201272|OTHER|Transversalis fascia plane block|Patients will receive spinal anesthesia (using 3.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
223962024|NCT07201272|DRUG|Morphine|Patients will receive spinal anesthesia (using 3 mL of hyperbaric bupivacaine 0.5%) + (75 µg morphine diluted in 0.5ml saline) with sham block at the end of surgery.
223962025|NCT07204704|BEHAVIORAL|EUREKA Intervention|Participants will be asked to complete brief questionnaires about the child's sun protection up to six times daily throughout the study. During Week 2, participants will receive feedback and advice messages immediately after completing the questionnaires. During that week, participants will also be asked to collaboratively complete an action planning exercise (delivered to the child's phone) to plan sun protection for a selected outdoor activity that is likely to take place the next day.
223962026|NCT07202845|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging (mpMRI)|Multiparametric MRI (mpMRI) performed at three defined timepoints: prior to neoadjuvant chemotherapy (baseline), 24 hours after first cisplatin dose in the first NAC cycle, and after completing NAC but before radical cystectomy. Imaging protocols include T2-weighted imaging, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Quantitative imaging biomarkers such as K\^trans\^, Ve, and ADC index are extracted and analyzed to evaluate early treatment response and predict pathological outcomes following chemotherapy.
224109984|NCT01221233|OTHER|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
224109985|NCT01221233|OTHER|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
224109986|NCT04618497|DRUG|Methoxyflurane|Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
224109987|NCT04618497|DRUG|Ketorolac|Each patient in the ketorolac group will receive one dose of 30mg intramuscular ketorolac injected at gluteal muscle by nursing staff as usual daily practice.
224109988|NCT04355117|DRUG|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.|Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
224109989|NCT00092911|DRUG|DVS-233 SR|
224109990|NCT05876572|DRUG|intradermal naloxone|One time 8 mg/0.1 mL dose of naloxone to be administered intradermally
223962027|NCT07203820|BEHAVIORAL|Ready-Made Picture Template Painting Activity|The purpose of the study will be explained to the children and their parents before the painting process and verbal and written consent will be obtained from the parents who agree to participate in the study. The child will be asked to go to the child with the ready-made picture template and coloring pencils and color the given picture with the colors they want. Children's anxiety will be assessed using the Children's State Anxiety (CSA) and their fears will be assessed using the Children's Fear Scale (CFS) based on both mother's and child's reports before painting and after the painting process is completed (half an hour after the first measurement).
223962028|NCT07204808|DEVICE|High velocity resistance training + Otago Exercise Program|"Participants who will be randomized to the HVRT will receive an exercise program targeting the lower limbs, to be performed twice a week for 8 weeks. Participants will be instructed to perform the exercises in a rapid and explosive manner such that all repetitions for each shortening phase will be performed as quickly as possible while the lengthening phase of the muscle will be controlled over 2-3 s The exercise will be done (bilateral leg press, step up, sit to stand, calf raise). The 8 weeks will be divided in three phases .~OEP consists of strengthening and balance exercises. Strengthening of ankle plantar and dorsiflexors, knee extensors and flexors, and hip abductors will be focused in this program. Ankle weight cuffs (1-3 kg) provide resistance for hip and knee exercises. The ankle plantar and dorsiflexors will be strengthened by performing heel and toe raise .~plantar and dorsiflexors will be strengthened by performing heel and toe"
223962029|NCT07203547|DRUG|Layla Tab.|Layla Tab., oral, twice daily, 8 weeks.
223962030|NCT07203547|DRUG|Laybon Tab.|Laybon Tab., oral, twice daily, 8 weeks.
223962031|NCT07204925|DEVICE|RISE guided personalization of prosthetic legs by tuning experts|The personalization procedure is conducted by tuning experts based on the recommendation of RISE system
223962032|NCT07204925|DEVICE|RISE guided personalization of prosthetic legs by prosthetists|The control parameters of the prosthetic leg prototype is decided by prosthetists without detailed knowledge about the prosthetic leg with the help of developed RISE system
223962033|NCT07204925|DEVICE|Manual personalization of the prosthetic leg by tuning experts|The control parameters of the prosthetic legs are decided by tuning experts based on their knowledge of the prosthetic leg prototypes and patients' response.
223962034|NCT01730118|BIOLOGICAL|Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine|autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
223962035|NCT03707418|DRUG|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
223962036|NCT03707418|DRUG|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
223962037|NCT03154827|DRUG|BL-8040|Subjects will receive maintenance treatment consisting of subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
223962038|NCT03154827|DRUG|Atezolizumab|Subjects will receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on Day 2 of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34 treatment cycles), until early discontinuation for any reason or until disease relapse, whichever comes first.
223962039|NCT04208542|DRUG|ESP block|Ultrasound guided Erector spinae block (ESP) will perform.
223962040|NCT04212897|OTHER|Music Therapy|"Participants in the intervention arm will be asked to practice a rhythmic auditory synchronous finger tapping intervention task at home for a total of 25 minutes split between two ten-minute sets with a five-minute break between the sets every day for 8-weeks. During training sessions participants must listen to the instrumental of a pre-selected well-known Chinese melody, Moonlight over the Lotus Pond by Phoenix Legend, whose melody duration is 259s. This song was selected for its strong beat and familiarity to the participants. Participants must follow the beats of the melody and tap their right index finger simultaneously to the beats. A visual cue will be displayed to indicate the beats, identical to the one in the assessment. The training session will be conducted once daily after patients have taken their medication. Participants' primary caretaker will be asked to monitor and record completion of sessions."
223962041|NCT00489489|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
223962042|NCT00489489|DRUG|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
223962043|NCT00489489|DRUG|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
223962044|NCT06091982|PROCEDURE|Renal Replacement Therapy (RRT)|Renal Support therapy which consist of procedure of intermittent hemodialysis (IHD) or continuous veno-venous hemofiltration/hemodialysis/hemodiafiltration (CVVH/CVVHD/CVVHDF)
223962045|NCT03859700|BIOLOGICAL|DBV712 250 mcg|DBV712 250 mcg, once daily
223962046|NCT04553029|OTHER|No intervention|This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
223962047|NCT04588246|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223962048|NCT04588246|PROCEDURE|Computed Tomography|Undergo CT
223962049|NCT04588246|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223962050|NCT04588246|DRUG|Memantine|Given PO
223962051|NCT04588246|OTHER|Quality-of-Life Assessment|Ancillary studies
223962052|NCT04588246|OTHER|Questionnaire Administration|Ancillary studies
223962053|NCT04588246|RADIATION|Stereotactic Radiosurgery|Undergo SRS/fSRS
223962054|NCT04588246|RADIATION|Whole-Brain Radiotherapy|Undergo HA-WBRT
223962055|NCT01034683|DRUG|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
223962056|NCT04483791|COMBINATION_PRODUCT|DynamX Novolimus Eluting Coronary Bioadaptor System|up to two de novo native coronary artery lesions measuring between 2.25 and 3.5 mm in diameter and\<=34 mm in length receiving the DynamX Novolimus Eluting Coronary Bioadaptor System
224109991|NCT05876572|DEVICE|microneedle injection|Intradermal delivery of naloxone using microneedle
223962057|NCT03394365|BIOLOGICAL|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
223962058|NCT04701073|DEVICE|LombaStab belt|"Instruction given to the patient will be to wear the LombaStab belt from 4 to 8 hours per days, over the whole duration of the study (12 weeks). The investigator will explain to the patient how to adjust it.~The LombaStab belt will be equiped with thermosensor to evaluate the belt wearing time at the end of the study."
224109992|NCT01546220|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
224109993|NCT05782413|OTHER|mechanical vestibular stimulation|Device produces mechanical vestibular stimulation. The child was placed in a sitting position on the swing and his hands grasping the ropes at the sides then the therapist stood behind him and begin pushing the platform in fast and jerky movements in back and front, side to side, and in spinning directions with the child trying to maintain his balance in all different directions.
224109994|NCT05782413|OTHER|The design exercise program|"A selected therapeutic exercises program was based on the principles of NDTBobath neurodevelopmental therapy, which is effective in controlling spasticity in children with cerebral palsy and improving motor function.~i. Preparation of structures and mobilizations of the scapula, shoulder joint, and chest according to the NDT-Bobath concept ii. Exercises to increase shoulder mobility and elbow joint extension. iii. Fine motor skill exercises, wrist, and hand"
224109995|NCT03865407|DRUG|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
223962059|NCT03615950|DIAGNOSTIC_TEST|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
224109996|NCT02117050|DRUG|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
224109997|NCT03877185|DIAGNOSTIC_TEST|Live birth rate|Live Birth Rate and Blastulation Rate according to the protocol of COS
224109998|NCT04459299|DEVICE|Robotic-PCI (CorPath GRX System)|Robotic-PCI for acute ST elevation myocardial infarction (STEMI).
224109999|NCT03855306|DRUG|Glibesyn|1 tablet contains 5 mg Glibenclamide
224110000|NCT03855306|DRUG|Daonil|1 tablet contains 5 mg Glibenclamide
224110001|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
223962060|NCT03615950|DIAGNOSTIC_TEST|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
224110002|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
224110003|NCT03747016|DIETARY_SUPPLEMENT|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
224110004|NCT03747016|DIETARY_SUPPLEMENT|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
224110005|NCT03747016|DIETARY_SUPPLEMENT|glucose injection G1|The women in delivery room are given glucose injection 300ml.
224110006|NCT03747016|DIETARY_SUPPLEMENT|normal saline N1|The women in delivery room are given normal saline 300ml.
224110007|NCT01140516|DRUG|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
223962061|NCT03615950|DIAGNOSTIC_TEST|Height measurement|Height will be measured at baseline and 12 months.
223962062|NCT03615950|OTHER|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
223962063|NCT01764204|DRUG|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
223542217|NCT00724100|DRUG|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
223962064|NCT04568304|BIOLOGICAL|Toripalimab Injection|Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.
223962065|NCT04568304|DRUG|Gemcitabine Hydrochloride for Injection|"Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
223962066|NCT04568304|DRUG|Cisplatin for Injection / Carboplatin Injection|"Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles."
223962067|NCT04568304|DRUG|Placebo|Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
223962068|NCT05196256|PROCEDURE|Dural puncture|Dural puncture with a 25 Gauge needle without injection of local anesthetics into the dural space
223542218|NCT04582006|PROCEDURE|Bariatric surgery|Surgical treatment of morbid obesity.
223962069|NCT05196256|PROCEDURE|Combined spinal epidural analgesia|Standard epidural preceded by a dural puncture with a 25G sequential needle and intrathecal injection of 2.5 ug of Sufentanil and 2.5 mg of normobaric Levobupivacaine
223962070|NCT05196256|PROCEDURE|Epidural analgesia|Epidural analgesia
223962071|NCT05196256|DRUG|Sufentanyl/Levobupivacaine|Epidural analgesia
223962072|NCT02101554|DRUG|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
223962073|NCT02101554|DRUG|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
223962074|NCT00324363|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
223542219|NCT01061385|DEVICE|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
223542220|NCT01061385|OTHER|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
223542221|NCT04850326|DIETARY_SUPPLEMENT|AP green tea extract|single intake of AP green tea extract
223542222|NCT04662164|DRUG|hepalatide|3 different dosage will be given sequentially to T2D patients
223962075|NCT00324363|DRUG|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
223962076|NCT02236299|PROCEDURE|Right Coronary Artery Percutaneous Coronary Intervention|
223962077|NCT02236299|OTHER|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
223962078|NCT02236299|OTHER|GLP-1 Infusion|30 minute infusion GLP-1
223962079|NCT01350102|DRUG|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
223962080|NCT01350102|DRUG|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
223962081|NCT01350102|DIETARY_SUPPLEMENT|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
223962082|NCT00158886|DRUG|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
223962083|NCT00158886|RADIATION|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (\>=6 megavolt \[mv\]).
223962084|NCT00003934|DRUG|tretinoin|Given orally
223962085|NCT00003934|DRUG|daunorubicin hydrochloride|Given IV
223962086|NCT00003934|DRUG|cytarabine|Given IV
224110008|NCT01140516|OTHER|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
224110009|NCT00973908|DRUG|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
224110010|NCT00973908|DRUG|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
224110011|NCT05186558|DRUG|penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin|"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months."
224110012|NCT00493948|DEVICE|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
223962087|NCT00003934|DRUG|mercaptopurine|Given IV
223962088|NCT00003934|DRUG|methotrexate|Given IV
223962089|NCT00003934|DRUG|arsenic trioxide|Given IV
223962090|NCT04061317|OTHER|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
223962091|NCT00155376|DRUG|morphine and glucagon|
223962092|NCT00717925|DRUG|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
223962093|NCT05219747|OTHER|Mucoadhesive film containing Acmella oleracea extract|Participants will apply a mucoadhesive film containing Acmella oleracea extract on labial mucosa of lower lip by themselves at least for 2 hours
223962094|NCT05219747|OTHER|Mucoadhesive film without Acmella oleracea extract|Participants will apply a mucoadhesive film on labial mucosa of lower lip by themselves at least for 2 hours
223962095|NCT02650453|PROCEDURE|Deep venous reconstruction|PTA \& stenting with/without endophlebectomy and/or arteriovenous fistula creation
223962096|NCT05736445|BEHAVIORAL|Wellness coaching plus app use|Participants will participate in wellness coaching and interact with apps on their smartphones
223962097|NCT00612716|DRUG|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
223962098|NCT00612716|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
223962099|NCT00612716|BIOLOGICAL|Stem cell infusion|Infused on Day 0
223542223|NCT01492088|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
223962100|NCT00612716|RADIATION|Total body irradiation|165 cGy morning and evening on days -4 through -1.
223962101|NCT05809245|PROCEDURE|Corneal neurotization|Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.
223962102|NCT05461092|DRUG|Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine|Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
223962103|NCT05461092|DIAGNOSTIC_TEST|Blood Test|Blood Tests measuring inflammatory markers: IL-10, MCP-1, IL-8, IL-6, TNFa
223962104|NCT05461092|OTHER|3D CAM Delirium Severity Scoring|Questionnaire that will rate each symptom of delirium
223962105|NCT05461092|OTHER|Generalized Anxiety Disorder 7-item (GAD-7) scale|Questionnaire for screening and severity measurement of generalized anxiety disorder.
223962106|NCT05461092|OTHER|Numerical Rating Score (NRS)|Questionnaire assessing pain intensity
223962107|NCT05461092|OTHER|PROMIS-Pain Interference|Questionnaire measuring the effect of pain on patient physical, emotional, and social functioning.
223962108|NCT05461092|OTHER|Oswestry Disability Index (ODI)|Questionnaire assessing disability and quality of life impairment in adults with lower back pain.
223962109|NCT05461092|OTHER|Saint Louis University Mental Status Examination (SLUMs)|Questionnaire assessing baseline cognition.
223962110|NCT05461092|OTHER|Delirium Rating Scale-Revised-98 (DRS)|16 item clinician rated scale assessing delirium severity.
223962111|NCT05461092|OTHER|Telephone Interview for Cognitive Status - Modified (TICS-M)|Telephone interview questionnaire evaluating patient cognitive status.
223962112|NCT05461092|OTHER|Opioid Equivalents measured by Morphine Milligram Equivalents (MME)|The amount of opioids administered will be collected through patient self-report
223962113|NCT05461092|OTHER|Patient Health Questionnaire depression scale (PHQ-8)|Questionnaire used to diagnose and determine the severity measure for depressive disorders.
224110013|NCT01180140|DEVICE|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
224110014|NCT03430882|DRUG|Carboplatin|Given IV
224110015|NCT03430882|DRUG|Paclitaxel|Given IV
224110016|NCT03430882|DRUG|Sapanisertib|Given PO
224110017|NCT01082913|DEVICE|SSE|Use of SSE or not use of SSE
223542224|NCT01406600|DRUG|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
223962114|NCT05461092|OTHER|Pain Catastrophizing|Scale used to determine pain catastrophizing and it's severity.
223724500|NCT03048968|PROCEDURE|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
223542225|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Eurofarma)|
223542226|NCT02830919|DRUG|Glucosamine and chondroitin sulfate combination (Zodic)|
223542227|NCT04427293|DRUG|Lenvatinib|Lenvatinib 12mg daily for 7 days prior to surgery
223724501|NCT03048968|PROCEDURE|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
223724502|NCT03048968|DEVICE|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
223724503|NCT03048968|DEVICE|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
223724504|NCT01444118|BIOLOGICAL|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
223724505|NCT04016285|DEVICE|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
223724506|NCT04016285|DEVICE|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
223724507|NCT01572454|DRUG|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
223724508|NCT01572454|DRUG|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
223724509|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in left side|
223724510|NCT01870960|OTHER|7 patients will be recuting to received EMDOGAIM in right side|
223724511|NCT03414619|BEHAVIORAL|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
223724512|NCT02786342|PROCEDURE|blood sample collection|
223724513|NCT00064194|DIETARY_SUPPLEMENT|selenium|
223724514|NCT00064194|DIETARY_SUPPLEMENT|soy protein isolate|
223724515|NCT00064194|DIETARY_SUPPLEMENT|vitamin E|
223724516|NCT05693779|BEHAVIORAL|Home exercise training|"Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study."
223724517|NCT03090113|DRUG|Shuxuetong Injection|intravenous drip
223962115|NCT05461092|OTHER|Fear Avoidance Beliefs Questionnaire (FABQ)|Questionnaire used to help predict patients that have a high pain avoidance behavior.
223962116|NCT05461092|OTHER|Opioid Side Effects and Likeability Questionnaire|Survey determining adverse events related to opioid side effects and complications.
223962117|NCT05461092|OTHER|Daily Pain Trajectory|Questionnaire assessing pain location, severity, impact to quality of life, and medications used to alleviate.
223962118|NCT05461092|OTHER|Tampa Scale of Kinesiophobia|Questionnaire assessing Kinesiophobia
223962119|NCT05461092|OTHER|Quality of Recovery 15|Questionnaire assessing postoperative quality of recovery
223542228|NCT04427293|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on day 1
223542229|NCT00533429|DRUG|enzastaurin|1125 milligram (mg) loading dose then 500 mg, oral, daily until disease progression
223724518|NCT03090113|DRUG|Placebo Injection|intravenous drip
223724519|NCT05433714|OTHER|Assesment|The figure of walk test, Berg Balance scale, Timed 25-Foot Walk, Timed up and go test, Foursquare walk test
223724520|NCT03186560|DEVICE|gekoTM|The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
223962120|NCT02061215|OTHER|CMV viral load|
224110018|NCT01883882|BEHAVIORAL|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
224110019|NCT01819922|DRUG|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
224110020|NCT01819922|DRUG|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
224110021|NCT03120390|OTHER|Best Practice|Undergo usual care
224110022|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo AE
224110023|NCT03120390|BEHAVIORAL|Exercise Intervention|Undergo RE
224110024|NCT03120390|OTHER|Laboratory Biomarker Analysis|Correlative studies
223962121|NCT03498183|DRUG|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
223962122|NCT06747637|OTHER|Skill-building classes|Unidos en el Cuidado is a manualized, multi-family group intervention provided at no cost vis-à-vis videoconferencing or on-site by trained facilitators Sessions are held weekly for 1.5 hours. Class components include caregiver role identity; skills-building; knowledge attainment; attitudinal changes; resource-sharing; practice/role-plays; homework; videos, handouts. Classes will be provided online with some classes offered in the community, if available
223962123|NCT06747637|OTHER|Wait list control group|The intervention is the same; the wait period is longer to receive the intervention described in Group A.
223962124|NCT00535795|RADIATION|Radiation Therapy|Radiation Therapy
223962125|NCT02176512|DRUG|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
223962126|NCT02176512|DRUG|BIBR 277 SE|Treatment B - Monocomponent
223962127|NCT02176512|DRUG|HCTZ|Treatment B -Monocomponent
223962128|NCT04388917|PROCEDURE|Patial nephrectomy|Partial nephrectomy assisted with robot to remove kidney cancer
223962129|NCT00438230|DRUG|Warfarin|
223962130|NCT03598803|OTHER|Survey|Urinary Incontinence Survey
224110025|NCT03120390|DEVICE|Monitoring Device|Receive Polar heart rate monitor
223962131|NCT06458309|PROCEDURE|spine surgery|"AO Classification6 It classifies thoracolumbar fractures into 3 major groups, based on the mechanism of injury.and each of them subdivided to 3 subgroups.~A. Compression B. Distraction C. multi-directional with translation Thoracolumbar AO spine injury score"
223962132|NCT05610254|DRUG|Ringer's Lactate|"On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures."
223962133|NCT00371696|DRUG|diclofenac|
223962134|NCT00371696|DRUG|paracetamol|
224110026|NCT03120390|OTHER|Quality-of-Life Assessment|Ancillary studies
224110027|NCT03120390|OTHER|Questionnaire Administration|Ancillary studies
224110028|NCT00546819|BIOLOGICAL|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
223542230|NCT00533429|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenously ( IV), Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles every (q) 21 days x 3 cycles
223542231|NCT00533429|DRUG|carboplatin|Area under the curve (AUC) 6, IV, Day 8 cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
223542232|NCT00533429|DRUG|bevacizumab|15 milligrams/kilogram (mg/kg), IV, Day 8 of cycle 1 - 28 days, Day 1 of subsequent cycles q 21 days x 3 cycles
223542233|NCT00533429|DRUG|Placebo|oral, daily
223542234|NCT01464879|DRUG|Testosterone Gel (FE 999303)|
223962135|NCT00371696|DEVICE|heat retaining knee support|
223962136|NCT00371696|DEVICE|standard knee support|
223962137|NCT00589745|OTHER|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
223962138|NCT06549270|DRUG|MAbs|Monthly or quarterly mAbs administration
223962139|NCT04523571|BIOLOGICAL|BNT162b1|Intramuscular injection
224110029|NCT00546819|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
224110030|NCT04547296|DRUG|Sodium Bicarbonate Ringer's Solution|After the participants enter the operating room, radial artery puncture and catheterization were performed. The blood gas in the non-oxygen state was used as the basic value. A peripheral venous access was established in one upper limb, and the two groups were pre-dilated with sodium bicarbonate Ringer's solution or acetate Ringer's solution (30 min, 8 ml/kg). For laparoscopic surgery, adjust the PaCO2 value to 35-45 mmHg again 10 minutes after the establishment of the pneumoperitoneum. After the operation started, the two groups of participants were maintained with 4-5 ml/kg/h Ringer's solution during the operation. Blood gas was measured every hour after tracheal intubation during the operation, and the last blood gas was measured when the skin was sutured. When the blood gas pH \<7.2, 5% sodium bicarbonate injection was given to correct it.
223724521|NCT03890172|OTHER|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
223724522|NCT03890172|OTHER|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
223962140|NCT04523571|OTHER|Placebo|Intramuscular injection
223962141|NCT06584838|PROCEDURE|ACL reconstruction|Patients that underwent ACL reconstruction using either allograft or autograft tendons, at least 2 years of follow-up, gender male and female, no comorbidities
223962142|NCT01810328|OTHER|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
223962143|NCT01810328|OTHER|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
223724523|NCT05579821|DIAGNOSTIC_TEST|Typhoid DPP assay|The index test used in this study diagnose typhoid fever by detecting IgA antibodies against LPS and HlyE antigen in patient's serum.
223724524|NCT01283360|OTHER|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
223724525|NCT01283360|DRUG|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
223724526|NCT01929460|DRUG|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
223724527|NCT01929460|OTHER|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
223724528|NCT04728074|OTHER|The Entering Employment and Sustaining Work Program|A structured, motivation and self-awareness based group intervention
223724529|NCT04728074|OTHER|vocational rehabilitation|An individual based, focused on desired job or occupation, face-to-face intervention
223962144|NCT04064463|BEHAVIORAL|Standard care|standard treatment for substance use disorders, along with sample monitoring
223962145|NCT04064463|BEHAVIORAL|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
223962146|NCT03466775|DIAGNOSTIC_TEST|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
223962147|NCT03466775|DIAGNOSTIC_TEST|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
223962148|NCT03466775|OTHER|Allograft survival|
223962149|NCT03466775|OTHER|Allograft rejection appearance|
223962150|NCT06342635|DEVICE|Hydra Transcatheter Aortic Valve (THV) Series|The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
224110031|NCT03048721|PROCEDURE|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
224110032|NCT03048721|PROCEDURE|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
223542235|NCT02271893|DRUG|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
223962151|NCT05670678|DIETARY_SUPPLEMENT|a2 growing up stage 3 formula puls lactoferrin supplement|The participants in this group will consume 4-5 scoops (8.5g/scoop) of the assigned formula each time, and 4 times per day
223962152|NCT05670678|DIETARY_SUPPLEMENT|Enfinitas growing up stage 3 formula|The participants in this group will consume 4 scoops (10g/scoop) of the assigned formula each time, and 3 times per day
223962153|NCT02910336|OTHER|Quantitative Sensory Testing|sensory testing profile
224110033|NCT03088904|BIOLOGICAL|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
224110034|NCT03088904|BIOLOGICAL|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
224110035|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) marked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with a marked tip
224110036|NCT05399628|DEVICE|Surfactant administration with less invasive surfactant administration (LISA) unmarked tip catheter|Participants will be assigned to perform the procedure with LISA catheter with an unmarked tip
224110037|NCT05933291|DRUG|steroid|Moderate- or high-dose steroids
224110038|NCT00055419|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
224110039|NCT04399967|BEHAVIORAL|Chat-based support|Participants will receive three months of chat-based support through IM apps (e.g. WhatsApp, WeChat). The regular messages and instant messaging on psychosocial support aim to provide hygienic advice to reduce the risk of exposure to SARS-cov2, increase self-efficacy and confidence, and social support and behavioral capacity of quitting.
223542236|NCT04791293|OTHER|MELD-Na score|MELD-Na scores will be compared between the groups
223542237|NCT03115918|DEVICE|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
223542238|NCT03115918|OTHER|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
223962154|NCT02201992|OTHER|Clinical Observation|Undergo observation
223962155|NCT02201992|DRUG|Crizotinib|Given PO
223962156|NCT02201992|OTHER|Laboratory Biomarker Analysis|Correlative studies
223962157|NCT00139308|DEVICE|high frequency stimulation|
223962158|NCT01837199|DRUG|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
223962159|NCT03782545|DEVICE|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
223962160|NCT00966888|PROCEDURE|standard follow-up care|No intervention
223962161|NCT00966888|RADIATION|radiation therapy|Chest wall radiotherapy
224110040|NCT04399967|BEHAVIORAL|AWARD plus COVID-specific advice|Ask about smoking history, Warn about the risks associated with the COVID-19 and smoking (with a COVID-related health warning leaflet), Advise to quit as soon as possible during the COVID-19 pandemic, Refer smokers to SC services (with a referral card, see below for information), and Do it again: to repeat the intervention
223542239|NCT03800030|DEVICE|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
223542240|NCT03800030|DEVICE|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
223542241|NCT03800030|DEVICE|Sham tACS|NeuroConn technologies, direct current-stimulator plus
223542242|NCT03965845|DRUG|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
223962162|NCT00560209|DRUG|ONO-1101|placebo for 1 minute IV
223962163|NCT00560209|DRUG|ONO-1101|0.06 mg/kg for 1 minute IV
223962164|NCT00560209|DRUG|ONO-1101|0.125 mg/kg for 1 minute IV
223962165|NCT01581476|DRUG|Statin|10mg daily for a minimum period of 2 years
223962166|NCT01581476|DRUG|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
223962167|NCT01581476|DRUG|Placebo|Participants receive statin placebo and ACEI placebo
223962168|NCT01581476|DRUG|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
223962169|NCT04916847|OTHER|blood collection|"Depending on the weight of the child, between 5ml and 15ml of blood will be collected during a blood test necessary for the conventional care of the patient. A second blood sample will be taken one year later. The volume of blood taken does not exceed the volume allowed by the guideline Ethical considerations for clinical trials of medicinal products conducted in the paediatric population.~We will analyse:~1. Specific antibody responses (IgM, IgG, and immunoglobulin A (IgA) anti SARS-Cov-2) by quantitative chemiluminescence analysis.~2. Protective neutralizing capacity of these antibodies (neutralizing antibodies against SARS-cOV-2) by neutralization test.~3. SARS-Cov-2 specific memory T cell responses by multiparametric flow cytometry in order to characterize their maturation, differentiation, senescence, activation, secretion of interleukin (cytokines 2) , IFN-g, TNF) or Interferon-gamma (IFN-g) ELISPOT assay."
223962170|NCT04723784|OTHER|Initial Assessment|In this phase the evaluation of the participants will be done, with the application of the instrument presented in outcome measures' section. According to the age of the person, specific questionnaires will be used to gather information more concrete about the skills for mobility. This assessment will allow determining the specific needs, demands and capabilities of participants. The assessment process will be done by professionals of research groups in rooms of collaborators centers.
223962171|NCT04723784|OTHER|Implementation of assistive technology in the daily life of participants|The professionals of collaborator centers, supported by the research groups, will carry on the training in the use of AT by the participants, facilitating its incorporation during the performance of activities of daily living.
223962172|NCT04723784|OTHER|Application of outcome measures|After the process of implementation of AT (the next 2 and 6 months), members of the research group and the professionals of collaborators centers will apply the measurement instruments to determine the possible improvements in the level of functional independence (FIM scale) of people with disabilities, the impact that the AT has had on their lifes (PIADS scale) and the level of matching between person and AT (ATD PA - MPT model).
223962173|NCT00572299|DRUG|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
223962174|NCT01347099|BEHAVIORAL|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
223962175|NCT01347099|BEHAVIORAL|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
223962176|NCT05418335|OTHER|Clinical examination, functional status evaluation|Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
223962177|NCT01404377|PROCEDURE|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
224110041|NCT04399967|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
224110042|NCT04399967|BEHAVIORAL|COVID-19 related health warning leaflet|The 2-sided color printed A4 leaflet, which covers the risk of COVID-19 and smoking and the most important messages to motivate smoking cessation
224110043|NCT04399967|BEHAVIORAL|Health warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation.
223962178|NCT06616753|BIOLOGICAL|vaccination status|knowledge of own vaccination status
223962179|NCT03943771|OTHER|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
223962180|NCT04385849|BIOLOGICAL|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223962181|NCT04385849|OTHER|Saline|Sterile saline solution
223962182|NCT05530928|OTHER|Reproductive life plan counseling|The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
223962183|NCT05991947|OTHER|No intervention|No intervention measures are needed.
223962184|NCT06291220|DRUG|Obinutuzumab|Intravenous Infusion
223962185|NCT06291220|DRUG|ABBV-453|Oral; Tablet
223962186|NCT06837155|DRUG|TS-172 20 mg|oral administration of TS-172 20 mg
223962187|NCT06837155|DRUG|TS-172 90 mg|oral administration of TS-172 90 mg
224110044|NCT04399967|BEHAVIORAL|SMS-based support|Participants will receive regular SMS with similar frequency to Intervention group but with generic information on smoking cessation.
224110045|NCT04399967|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
224110046|NCT04399967|BEHAVIORAL|COSH Self-help smoking cessation booklet|A general smoking cessation self-help booklet
223962188|NCT06837155|DRUG|Moxifloxacin|oral administration of moxifloxacin 400 mg
223962189|NCT06837155|DRUG|Placebo|oral administration of placebo
224110047|NCT00175006|OTHER|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
223962190|NCT01584999|BIOLOGICAL|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
223962191|NCT05743127|DEVICE|3D-Printed Hyrax Expander|This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
223962192|NCT05743127|DEVICE|Conventional Laboratory Fabricated Hyrax Expander|This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
223962193|NCT01375777|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223962194|NCT01375777|DRUG|Ezetimibe|Administered orally once a day
223962195|NCT01375777|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
223962196|NCT05878990|BEHAVIORAL|Culturally-tailored Tobacco Treatment|Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
223962197|NCT05878990|BEHAVIORAL|Culturally-tailored Content Newsletters|Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.
223962198|NCT05878990|BEHAVIORAL|Control Preference Scale|Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
223962199|NCT05878990|BEHAVIORAL|Active Content Newsletter or Passive Content Newsletter|Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.
223962200|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
223962201|NCT01933776|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
223962202|NCT04807452|OTHER|Strength and balance training|Passive ROM to possible level of knee (flexion and extension), ankle (dorsiflexion and plantar flexion), forefoot (inversion and eversion) and toe (flexion and extension, adduction and abduction) joints.Resisted flexion and extension of knee, dorsiflexion and planter flexion of ankle, inversion and eversion of foot, flexion/extension, and abduction/adduction of toe with help of thera-band.The exercise prescription for strength training was made at approximately 50% of the estimated 1-RM. Exercise progression was achieved by instructing participants to increase the weight lifted in a specific exercise when they could perform 2 sets of 10-12 repetitions without maximal exertion on 2 consecutive training days. On basis of Borg Rating of Perceived Exertion of 10 to 13.Tandem leg stance for first 2 weeks and then it was progressed to Single leg stance toe and heel stance.For dynamic balance:backward walk Tandem walk and sideways walk.
223962203|NCT04807452|OTHER|Aerobics training|"After the baseline assessment, the participant in the Group B received Aerobic exercise with routine medical care.~All patients were followed for 3 days a week for 8 weeks treatment. Control Group received aerobic training. Control group received stretching exercise for 10 minutes and then treadmill walk for 10 minutes and then stationary bicycle for 10 minutes, and steppers for 10 minutes and 5 minute cool down ."
223542243|NCT03965845|DRUG|Palbociclib Oral Capsule or Tablet [Ibrance]|Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
223542244|NCT02636296|OTHER|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
224110048|NCT04217902|OTHER|Description of patients' experiences of diabetes care delivery and planning|Semi-directed interviews will be conducted with people living with type 1 or type 2 diabetes in person or by phone to assess and describe the care delivery pathway they have been through. Information on 3 domains will be assessed: clinical (information they consider essential for health care professionals to systematically have access to during consultations and other health-related interventions such as therapeutic education sessions), technological (what kind of digital services and technologies they use or are willing to use), and behavioural (the decision-making process and the key interactions that build the care delivery pathway).
223724530|NCT04208789|DIAGNOSTIC_TEST|Rapid Molecular Drug-Resistant Tuberculosis Test|"GeneXpert MTB/RIF assay is a nucleic acid amplification (NAA) test which simultaneously detects DNA of Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) (i.e. mutation of the rpoB gene) in less than two hours. This system integrates and automates sample processing, nucleic acid amplification, and detection of the target sequences. The primers in the XpertMTB/RIF assay amplify a portion of the rpoB gene containing the 81 base pair core region. The probes are able to differentiate between the conserved wild-type sequence and mutations in the core region that is associated with rifampicin resistance. The output of this procedure is detected, undetected, or indeterminate."
223724531|NCT04208789|OTHER|Artificial Intelligent Model|The artificial intelligent model is a model that developed from several associated factors with machine learning and deep learning method in order to classify the possibility of drug-resistant tuberculosis. The Artificial neural network will be built using deep learning software.
223724532|NCT04208789|DIAGNOSTIC_TEST|Drug Susceptibility Test|This procedure uses Löwenstein-Jensen (LJ) medium to determine whether the isolates of M. tuberculosis are susceptible to anti-TB agents. Media containing the critical concentration of the anti-TB agent is inoculated with a dilution of a culture suspension (usually a 10-2 dilution of a MacFarland 1 suspension) and control media without the anti-TB agent is inoculated with usually a 10-4 dilution of a MacFarland 1 suspension. Growth (i.e. a number of colonies) on the agent-containing media is compared to the growth on the agent-free control media. The ratio of the number of colonies on the medium containing the anti-TB agent to the number of colonies (corrected for the dilution factor) on the medium without the anti-TB agent is calculated, and the proportion is expressed as a percentage. Provisional results for susceptible isolates may be read after 3-4 weeks of incubation; definitive results may be read after 6 weeks of incubation. Resistance may be reported within 3-4 weeks.
223724533|NCT06185374|BEHAVIORAL|Text Message Instructions/Motivation|For instructional messages, earlier messages will remind patients of the colonoscopy appointment and later messages will help patients complete the bowel preparation process in real-time. Motivational messages will be sent along with instructional messages.
223724534|NCT01750242|DEVICE|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
223724535|NCT04445389|DRUG|GX-19|DNA vaccine expressing SARS-CoV-2 S-protein antigen
223724536|NCT04445389|DRUG|Saline|Saline
223724537|NCT05122676|BEHAVIORAL|More Individualized Care: Assessment and Recovery through Engagement (MI-CARE)|"This study evaluates whether offering nurse collaborative care management for 12 months by telephone or video can improve depression-related symptoms, increase access to evidence-based medication treatment for opioid use problems, as well as decreasing adverse health events. Participants randomized to the nurse support arm can work with the nurse at no cost for up to 12 months via phone or video visits.~The nurse asks questions about stress, mood, worry, pain, sleep, and medication and substance use; participants choose what to focus on. The nurse meets weekly with clinical consultants who may recommend treatment options, tailored to the patient. The participant and their regular provider(s) can discuss the options and decide which to try. The nurse and primary care provider can then help the patient access selected options. The nurse can also offer behavioral activation to help build skills to increase day-to-day positive adaptive experiences and support broader treatment gains."
223724538|NCT01380275|DRUG|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
223542245|NCT02636296|OTHER|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
223542246|NCT00066326|DRUG|imatinib mesylate|
223542247|NCT00066326|DRUG|tanespimycin|
223542248|NCT03053934|BEHAVIORAL|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
223962204|NCT05500872|OTHER|Cross-education and blood flow restriction training|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. During this training, a cuff will be worn from the upper part of the thigh muscles, as in the blood pressure devices, which will slow down the blood flow in the leg. The participant will be cross-educated with the cuff inflated to a safe pressure range that will not cause discomfort. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
223962205|NCT05500872|OTHER|Cross-education|Cross-education (training of the non-surgical leg) will be given to the participants in addition to the standard rehabilitation program after surgery. This training will be applied with isokinetic system that can be used safely in the rehabilitation field. Participants will be included in the training for a total of 16 sessions, 2 days a week for 8 weeks. Each session, cross-education will be applied as 3 sets of 12 repetitions. Pain, muscle strength, muscle thickness, knee functions will be evaluated before and after the training.
223962206|NCT00512473|DRUG|Saline infusion|0.9 % NaCl
223962207|NCT00512473|DRUG|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
223962208|NCT00512473|DRUG|Pegvisomant|30 mg Somavert administered at t = - 36 hours
223962209|NCT05135845|DRUG|Capmatinib|Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
224110049|NCT04217902|OTHER|Description of health care professionals needs and experiences in diabetes care delivery and planning|Semi-directed interviews will be conducted with health care professionals working in diabetes care in person or by phone to assess and describe their needs and experiences in diabetes care. Information on 3 domains will be assessed: clinical (the information they consider to be essential to inform decisions in diabetes care, where and if they currently find that information and problems they might encounter), technological (which software they currently use and how data is input into clinical information systems), and behavioural (how care coordination is currently managed, how interactions with patients and other professionals are undertaken).
224110050|NCT01543451|DRUG|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
223962210|NCT05135845|DRUG|Spartalizumab|Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
223962211|NCT05587907|DEVICE|FitLight Trainer|Evaluation of the reaction time before and after special training program using visual stimuli.
223962212|NCT02334202|BEHAVIORAL|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
223962213|NCT02334202|OTHER|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
223962214|NCT05163678|OTHER|monitoring naturalistic of cohort|"Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6)."
223962215|NCT05747872|BEHAVIORAL|Buerger Allen Exercises|"These exercises are specific exercises aimed at improving circulation in the feet and legs.~While doing the exercises, first of all;~1. The legs are raised at an angle of 45 degrees and supported in this position for 1-3 minutes until the skin turns white.~2. Sit on the edge of the bed and let your legs hang down (make sure there is no pressure behind the knees). In this position, move your foot left and right and up and down for 3 minutes.~3. Lie on your back for 5 minutes keeping your legs warm with a blanket.~Performing all three of these exercises in sequence means 1 session. Exercises are done 2 times a day, at least 3 sessions each time."
223962216|NCT05650437|DEVICE|Ultraviolet Radiation|The therapist cut three holes, each measuring 2 by 2 cm, into a piece of cardboard that was about 4 by 20 cm in size.The first hole was exposed for 90 seconds, the second for 60 seconds, and the third for 30 seconds
223962217|NCT05650437|BEHAVIORAL|Aerobic exercise|The postmenopausal women in groups (A and B) exercised on the treadmill; women should always warm up before beginning exercise and stop if they experience pain or shortness of breath. Each session lasted 30 minutes and included 5 minutes of warming up and 20 minutes of walking at 60% of their maximum heart rate (MHR). The maximum heart rate that the circulatory system can support during physical exercise is MHR=220. Three sessions a week for three months, followed by a five-minute cool-down
223962218|NCT05650437|DIETARY_SUPPLEMENT|Vitamin D supplementation|Throughout three months, vitamin D supplements (800 IU) will be given to all postmenopausal women in both groups (A\&B)
223962219|NCT00198666|DRUG|Zinc|Elemental Zinc
223962220|NCT02855892|OTHER|Placebo|
223962221|NCT02855892|DRUG|GV1001|
223962222|NCT02665624|DRUG|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
223962223|NCT02665624|DRUG|Senna alone|comparison of bowel cleansing and patient comfort.
223962224|NCT03598023|DEVICE|Cytal® Burn Matrix|Cytal® Burn Matrix
223962225|NCT03598023|DEVICE|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
223962226|NCT05851170|OTHER|The use of warm compresses and almond oil on the perineum during second stage|"Hot water from the tap at a temperature of (45-590c) will be poured into a container, and will be changed every 15 minutes.~Timing of the start: when the baby's head descends in the pelvic canal and the woman feels the need to push The intervention: warm compresses will be attached to the perineum between the pressures During the pressing - almond oil will be applied. Meanwhile, the compresses will be returned to a bowl containing hot water. Every 15 minutes until birth the water will be replaced with hot water at an initial temperature of 45-590c.~It is necessary to use compresses for a minimum of 10 minutes, and a maximum of 30 minutes."
223962227|NCT05851170|OTHER|Use of almond oil use (routine care) during second stage|Routine care in the department is the use of almond oil during the second stage of pregnancy, during pushing.
223962228|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection Alone|participants in this group underwent robotic assisted rectal cancer resection alone, the specimens were extracted through the incision on the abdominal wall.
224110051|NCT01543451|DRUG|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
224110052|NCT04445467|DRUG|Favipiravir|Favipiravir
224110053|NCT01380496|DRUG|doxycycline monohydrate|tablet, 100 mg, single, oral dose
223962229|NCT04265417|PROCEDURE|Robotic Assisted Rectal Cancer Resection With Natural Orifice Specimen Extraction|participants in this group underwent robotic rectal cancer resection，the specimens were extractd through anus and vagina.
223962230|NCT04639752|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
223962231|NCT04639752|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
224110054|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
224110055|NCT01380496|DRUG|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
224110056|NCT02166593|DRUG|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
223962232|NCT01440699|BIOLOGICAL|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
223962233|NCT04260100|BEHAVIORAL|Diabetes Care Self-Management Mobile Health Application|In day 1, the participant will receive a Foot Care Kit consist of a mirror, a tube of lotion, a small towel, and a nail clipper. The participant will enrol in 3-hour workshop for general management of diabetes mellitus, diabetic foot care and dietary management. The participant will be invited to install Diabetes Care Self-Management Mobile Health Application. The mobile application is meant for sources of referral for diabetic foot care and dietary care, and for record purpose (diary) of any foot care activities carried out that participant needs to enter in the application during his/her home. The participant will be trained for the use of Diabetes Care Mobile Health Application. In addition, the participant will be invited to join a WhatsApp group for the medium of communication. The program will be lasting for 5 weeks.
223962234|NCT04369547|DEVICE|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation.
223962235|NCT04369547|DRUG|Roflumilast|Roflumilast 250mcg
223962236|NCT04369547|DRUG|Placebo oral tablet|Placebo capsule matched to roflumilast capsule
223962237|NCT02183961|OTHER|Restech|
223962238|NCT02183961|OTHER|Peptest|
223962239|NCT02183961|OTHER|Detection of pepsin in adenoid specimen|
223962240|NCT00082784|DRUG|Bortezomib|Given IV
223962241|NCT00082784|DRUG|Alvocidib Hydrochloride|Given IV
223962242|NCT00082784|OTHER|Pharmacological Study|Correlative studies
223962243|NCT04223661|DRUG|Lenalidomide Pill|Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
223962244|NCT04223661|DRUG|Dexamethasone|Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
223962245|NCT04223661|DRUG|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
223962246|NCT01136733|DRUG|Lenvatinib|taken orally, once a day
223962247|NCT01136733|DRUG|Everolimus|taken orally, once a day
223962248|NCT00113334|DRUG|ABT-510|100 mg subcutaneously twice daily
223962249|NCT01343147|OTHER|Microwave diathermy|Deep tissue heating via microwave diathermy
223962250|NCT01343147|OTHER|Superficial hyperthermia|Superficial heating via hot pack application
223962251|NCT05267249|PROCEDURE|Autotransplantation and Apicoectomy|Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
223962252|NCT00128908|DRUG|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
223962253|NCT00128908|DRUG|Rapidly Cycled HAART|
223962254|NCT04226183|OTHER|pregnancy workout|"Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar"
223962255|NCT01931683|DRUG|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
224110057|NCT02166593|DRUG|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
223962256|NCT01931683|DEVICE|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
223962257|NCT00125619|BEHAVIORAL|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
223962258|NCT03293329|OTHER|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
223962259|NCT03293329|OTHER|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
223962260|NCT03293329|OTHER|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
223962261|NCT02459132|BEHAVIORAL|High-intensity aerobic interval exercise|See arm/group description
223962262|NCT01295788|DEVICE|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
223962263|NCT01295788|DEVICE|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
223962264|NCT01502202|DRUG|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
223962265|NCT01502202|DRUG|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
223962266|NCT01502202|DRUG|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
224110058|NCT03743584|PROCEDURE|Targeted temperature management|Target temperature management at 33°C
224110059|NCT03743584|PROCEDURE|Standard care, early treatment of fever|Standard of care with early treatment of fever
224110060|NCT00303342|BEHAVIORAL|mind body treatment|regulation of attention, respiration and posture
224110061|NCT00303342|BEHAVIORAL|desensitization|mentation on insomnia behaviors and cognitive activity
224110062|NCT04850040|DRUG|Apatinib Mesylate|250 mg, oral every other day. Approximately half an hour after a meal (the daily dose should be taken at the same time as possible) with warm boiled water.
224110063|NCT04850040|DRUG|Camrelizumab|200 mg, 30 minutes intravenous drip (overall dosing time no shorter than 20 minutes and no longer than 60 minutes, including tube flush time) once every 2 weeks, with the first dose administered concurrently with Apatinib Mesylate Tablets.
224110064|NCT04850040|DRUG|Oxaliplatin|85 mg/m2, once every 2 weeks, to be administered half an hour after Camrelizumab injection.
223962267|NCT04513535|OTHER|Thoracic Manipulation|A supine thoracic manipulation will be utilized. Participants will be lying supine on the plinth with their arms crossed over their chest, making sure the forearms are not crossed. An experienced clinician will place their hand on the inferior segment (T4); the superior segment (T3) will be placed in the midrange of thoracic flexion and extension. The clinician will apply a high velocity, end range, anterior to posterior thrust by using their body weight to deliver the thrust through the participants crossed elbows, thus creating a bilateral gapping of the facet joints. If a cavitation is achieved after the first thrust, the thoracic manipulation intervention is complete. If not, one more attempt will be made to achieve a cavitation. Regardless of if there was a cavitation or not, after the second attempt the intervention is complete.
223962268|NCT04513535|OTHER|Cervical Manipulation|Participants will be lying supine on the plinth on the table. A high velocity low amplitude manipulation will be performed to the cervical spine by an experienced clinician.The clinician will place the right proximal phalanx of the index finger over the posterolateral aspect of the articular pillar at the right C4/C5 segment to maximally influence the C5 myotomal distribution. The clinician's left hand will be cradling the participants head. The participant will be brought into midrange flexion-extension, ipsilateral side bend, and contralateral rotation of C4/5. Once a firm end feel is felt the manipulation will be administered into left rotation in an arc toward the left eye. If a cavitation is achieved after the first thrust, the intervention is complete. If not, one more attempt will be made to achieve a cavitation;after the second attempt the intervention is complete.
223962269|NCT04513535|OTHER|glenohumeral posterior glide mobilization|Participants will be instructed to lay supine on the plinth and a plastic orthopedic wedge will be placed under their scapula for stabilization on the side that is receiving the mobilization. The experienced clinician will stand on the same side being mobilized and held the participant's arm proximal to the medial and lateral humeral epicondyles. The clinician will hold the participant's arm in the scapular plane, approximately 55 degrees of abduction and slight ER with a grade one long axis distraction applied and sustained throughout the entire mobilization. A grade three oscillatory mobilization will be applied for three sets of 30 seconds with a 30 second rest in between.
224110065|NCT06435195|PROCEDURE|Surgical Removal|Resection of pituitary pathologies.
223962270|NCT04513535|OTHER|Sleeper stretch|Participants will be positioned in a side lying position with the arm to be stretched on the table. The arm to be tested will then be positioned at a 90-90 shoulder abduction and elbow flexion position. A support will be positioned behind the patient to ensure there is no compensatory trunk movement during the stretch, and an examiner verified the arm is in a 90-90 position. A sleeper stretch will be subsequently completed, in which the participant will internally rotate the arm to stretch the posterior shoulder musculature. Three, thirty second stretches will be completed
223962271|NCT00313963|DRUG|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
223962272|NCT00313963|DRUG|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
224110066|NCT06435195|PROCEDURE|Biopsy|Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis
224110067|NCT06284018|OTHER|Progressive Muscle Relaxation Exercises|"* Focus on the targeted muscle group.~* Take a slow, deep breath while squeezing on muscle group as hard as she can (not to the point of strain). Keep the muscle tensed for 5 seconds.~Hands and arms, forehead ,Eyes and Cheek, Mouth and Jaw , Neck and Shoulder ,Stomach , Leg and Toes"
224110068|NCT06284018|OTHER|Pilates Exercises|Pilates exercise program consisted of floor exercises on a rubber mat, including the following exercises: a- Pelvic Curl. b- Single-Leg Lift. c- Chest Lift. d- Supine Spine Twist. e- Basic Back Extension.
223962273|NCT02936193|PROCEDURE|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
224110069|NCT02741531|OTHER|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
224110070|NCT02741531|OTHER|saline solution|Saline solution will be used to partially fill patients' bladders
224110071|NCT02859415|DRUG|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
224110072|NCT02542345|PROCEDURE|magnetic resonance imaging|
224110073|NCT03644797|GENETIC|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
224110074|NCT01174784|DEVICE|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
224110075|NCT03247998|DRUG|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
224110076|NCT03247998|DRUG|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
223962274|NCT02936193|PROCEDURE|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
224110077|NCT02282332|DRUG|Ticagrelor|
223962275|NCT01854164|DIETARY_SUPPLEMENT|HGE (hydrolyzed ginseng extract)|
223724539|NCT01380275|DRUG|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
223962276|NCT01854164|DIETARY_SUPPLEMENT|Placebo|
223962277|NCT03863184|DRUG|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
223962278|NCT03863184|DRUG|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
224110078|NCT01300377|DRUG|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
223962279|NCT03863184|DRUG|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
223962280|NCT03863184|DRUG|Obinutuzumab|Obinutuzumab on days 1, 8, 15 of cycle 1, day 1 of cycles 2-6, then every 2 cycles
223962281|NCT00675519|BEHAVIORAL|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
223962282|NCT00830284|PROCEDURE|Recruitment maneuver|"Three types of maneuvers will be performed.~1. 6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~2. 6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~3. PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
223962283|NCT05980325|BEHAVIORAL|Nordic Walking|A 12-week Nordic Walking exercise programme supervised twice weekly
223962284|NCT05980325|BEHAVIORAL|Aquatic Exercise|A 12-week water-based exercise training programme supervised twice weekly
223962285|NCT05980325|BEHAVIORAL|Functional Exercise Training|A 12-week circuit-based exercise training programme supervised twice weekly
223962286|NCT01459523|PROCEDURE|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
223962287|NCT01459523|PROCEDURE|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
223962288|NCT01459523|PROCEDURE|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
223962289|NCT01459523|PROCEDURE|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
223962290|NCT00895297|DRUG|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
223724540|NCT06209177|DRUG|ARO-CFB|ARO-CFB for sc injection
223724541|NCT06209177|DRUG|Placebo|sterile normal saline (0.9% NaCl for sc injection)
223724542|NCT03597776|DRUG|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
223962291|NCT00550927|BIOLOGICAL|bevacizumab|
223962292|NCT00550927|DRUG|enzastaurin hydrochloride|
223962293|NCT00550927|OTHER|diagnostic laboratory biomarker analysis|
223962294|NCT00550927|OTHER|pharmacological study|
223962295|NCT02078947|BEHAVIORAL|High Intensity Exercise|
223962296|NCT02078947|BEHAVIORAL|Moderate Continuous Exercise|
223962297|NCT02078947|BEHAVIORAL|Usual Care|
223962298|NCT00287183|DRUG|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
223962299|NCT00287183|OTHER|Placebo|Placebo
223962300|NCT02266589|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
223962301|NCT01330719|PROCEDURE|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
224110079|NCT01300377|DRUG|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
223962302|NCT01330719|PROCEDURE|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
223962303|NCT02281214|OTHER|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
223962304|NCT04950790|DRUG|Shuxinin injection|Shuxuening injection : 5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
223962305|NCT04950790|DRUG|Basic treatment|Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
223962306|NCT04950790|DRUG|Placebo|sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
223962307|NCT03314233|PROCEDURE|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
223962308|NCT02029027|DEVICE|GYNEFFIK(R)|Vaginal electro-stimulation medical device
223962309|NCT02029027|OTHER|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
223962310|NCT03003832|OTHER|Change in electronic health record default for new opioid analgesic prescriptions|
223962311|NCT01585597|DEVICE|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
223962312|NCT00168805|DRUG|enoxaparin|40 mg once daily
223962313|NCT00168805|DRUG|dabigatran etexilate|150 mg once daily
223962314|NCT00168805|DRUG|dabigatran etexilate|220 mg once daily
223962315|NCT00302406|DRUG|methylphenidate hydrochloride|
223962316|NCT00302406|DRUG|OROS methylphenidate hydrochloride (CONCERTA)|
223962317|NCT01114217|DRUG|Ferumoxytol|IV Ferumoxytol
224110080|NCT04601272|BEHAVIORAL|Decision aid|Healthwise patient decision aids for breast, prostate, colon and lung cancer screening provide information on the pros and cons of cancer screening and guidance in process of selecting a choice.
223542249|NCT03053934|BEHAVIORAL|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
223542250|NCT05232656|BEHAVIORAL|Pre-Discharge Checklist and Patient Safety Dashboard|Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
223962318|NCT01930877|DRUG|Lidocaine|Lidocaine iv bolus followed by infusion
223962319|NCT01930877|OTHER|Placebo (normal saline)|Normal saline bolus followed by infusion
223962320|NCT06642376|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress
223962321|NCT06640075|OTHER|Community co-produced action|"Participatory workshops will be conducted with community members by a multidisciplinary team with the aim to co-develop a strategy for cervical cancer screening adapted to the local setting (including primary HPV screening, triage of HPV-positive patients and treatment of patients triaged positive). This intervention is referred to as 'community co-produced action'. Possible strategies co-developed may include collaboration with community health workers or local associations, awareness campaigns, development of health education materials, integration of primary HPV screening at local integrated health centers, organization of group transportation to the district screening center, etc.~Using purposive sampling methods, approximately 15 participants will be invited to take part in the workshops in each health area of the intervention, including approximately 3 health care providers, 3 community health workers or members of women's associations, 3 men and 6 eligible women for screening."
223962322|NCT06640075|OTHER|Standard screening strategy|Recruitment of study participants will be coordinated centrally at district level (from the Bafoussam Regional Hospital) following procedures previously established in a cervical cancer screening program in the health district of Dschang. This standard procedure includes the training of 2 community health workers (CHW) by health area to raise awareness around cervical cancer. After an initial theoretical and practical training in cervical cancer prevention, CHWs recruit women by going door-to-door or through community meetings in their respective health areas. Through a system of nominal invitation vouchers distributed to eligible women, CHWs receive a financial incentive for each woman that shows up for cervical cancer screening. Twice a year, CHWs of all health areas are invited to a feedback session to discuss difficulties encountered on the field and propose solutions to face any identified challenges.
223542251|NCT04324892|DRUG|Treat to target|All patient will received protocolized treatment with an aim to achieve SDAI remission
223542252|NCT03824392|BIOLOGICAL|Efzofitimod 1.0 mg/kg or Placebo|Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
223542253|NCT03824392|BIOLOGICAL|Efzofitimod 3.0 mg/kg or Placebo|Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
223962323|NCT02844348|OTHER|Hypnosis session|
223962324|NCT05805033|OTHER|Mucointegration|Placement of abutment on a dental implant to study mucointegration
223962325|NCT05675839|OTHER|Film (Wit) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life)|Film (Wit) (https://www.youtube.com/watch?v=2s4ozvI\_hzY\&t=160s) and a documentary (First Turkish Nurse-Safiye Hüseyin Elbi's Life) (https://www.youtube.com/watch?v=XsabHOiF0CY\&t=284s)
223962326|NCT04885764|BIOLOGICAL|Astrazeneca/Oxford Vaccine|Viral non replicated vector vaccine contains the gene that encodes for the spike protein on the surface of the SARS-CoV-2 virus given Intramuscular injection in 2 doses 3 months apart
223962327|NCT04885764|BIOLOGICAL|Sinopharm vaccine|Inactivated vaccine given intramuscular injection in 2 doses 3 weeks apart
223962328|NCT05942573|DRUG|Serplulimab+Paclitaxel+Apatinib|Immunotherapy+chemotherapy
223962329|NCT05942573|DRUG|Paclitaxel±Ramucirumab|chemotherapy±Targeted therapy
223962330|NCT05685511|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
223962331|NCT05685511|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
223962332|NCT05685511|OTHER|Usual care resources|List of resources that the patient can explore on their own
223962333|NCT02186587|DEVICE|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
223962334|NCT01183013|DRUG|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
223962335|NCT01183013|DRUG|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
223962336|NCT01183013|DRUG|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
223962337|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
223962338|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
223962339|NCT01183013|DRUG|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
223962340|NCT01183013|DRUG|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
223962341|NCT06641128|DRUG|MTX SC or IM|IM or SC Methotrexate
223962342|NCT06641128|DRUG|Empagliflozin 25mg tab|Empa tablets 25 mg once daily for 3 months.
223962343|NCT00209222|DRUG|Rituximab|antibody
223962344|NCT00209222|DRUG|Cyclophosphamide|chemotherapy
223962345|NCT00209222|DRUG|Doxorubicin|chemotherapy
223962346|NCT00209222|DRUG|Vincristine|chemotherapy
223542254|NCT03824392|BIOLOGICAL|Efzofitimod 5.0 mg/kg or Placebo|Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
223542255|NCT02230189|BIOLOGICAL|Segmental airway allergen challenge|
223542256|NCT02230189|PROCEDURE|Bronchoscopy|
223542257|NCT02230189|DIAGNOSTIC_TEST|Methacholine challenge test|
223962347|NCT00209222|DRUG|Prednisone|corticosteroide
223542258|NCT02230189|DIAGNOSTIC_TEST|Spirometry|
223542259|NCT02230189|DIAGNOSTIC_TEST|Allergen skin prick test|
223542260|NCT02363530|DEVICE|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
223542261|NCT02363530|DEVICE|BSS|Balanced Salt Solution including normal saline and glucose
223962348|NCT00209222|DRUG|Cisplatinum|chemotherapy
223962349|NCT00209222|DRUG|Ara-C|chemotherapy
223962350|NCT00209222|DRUG|Dexamethasone|corticosteroide
223962351|NCT00209222|DRUG|BCNU|chemotherapy
223962352|NCT00209222|DRUG|Melphalan|chemotherapy
223962353|NCT00209222|DRUG|Etoposide|chemotherapy
223962354|NCT00209222|DRUG|G-CSF|growth factor
223962355|NCT00209222|PROCEDURE|chemotherapy: R-CHOP|immuno-chemotherapy
223962356|NCT00209222|PROCEDURE|chemotherapy: R-DHAP|immuno-chemotherapy
223962357|NCT00209222|PROCEDURE|chemotherapy: Dexa-BEAM|chemotherapy
223962358|NCT00209222|PROCEDURE|stem cell harvest|procedure
223962359|NCT00209222|PROCEDURE|total body irradiation|radiation
223962360|NCT00209222|PROCEDURE|high-dose chemotherapy: Cyclophosphamide|chemotherapy
223962361|NCT00209222|PROCEDURE|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
223962362|NCT06027697|DEVICE|AccuFill® Porous Bone Substitute Material (BSM)|The patient will undergo a minimally invasive surgery procedure (subchondroplasty) to receive the medical device AccuFill® Porous Bone Substitute Material (BSM).
223962363|NCT01189370|DRUG|sorafenib|"Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week."
223962364|NCT00067119|DRUG|Aggrenox|
223962365|NCT00067119|DRUG|Placebo|
223962366|NCT03785210|DRUG|nivolumab|480 mg intravenous (IV) every 4 weeks
223962367|NCT03785210|DRUG|tadalafil|10 mg by mouth (PO) daily
223962368|NCT03785210|DRUG|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) by mouth (PO) from week 1 to week 3, week 4 off.
223962369|NCT03998423|BIOLOGICAL|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
223962370|NCT02615834|PROCEDURE|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
223962371|NCT03952728|BEHAVIORAL|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
223962372|NCT03952728|BEHAVIORAL|Diabetes support and education|Behavioral intervention focused on diabetes support and education
223962373|NCT00161408|BEHAVIORAL|cognitive behavioural therapy|
223962374|NCT00161408|BEHAVIORAL|psychoeducation|
223962375|NCT03379779|DIAGNOSTIC_TEST|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
223724543|NCT03597776|DRUG|Saline|Bolus of saline will be given over 5 minutes before skin incision
223962376|NCT05114161|OTHER|Novel Care Pathway|The novel care pathway will follow a decision tree based on several criteria to stratify patients in an appropriate risk category. Patients with large radiographic lobar consolidation OR POC CRP \> 60mg/L will be deemed 'appreciable risk' while patients with CRP \< 20mg/L will be deemed 'low risk'. Patients with CRP between 20 - 60mg/L will be evaluated further, as follows: if they have an oxygen saturation of \<95%, they will be 'appreciable risk', and if not, there are further decision points: if they are not tachypneic, they will be 'low risk'; if they are tachypneic and less than 1 year of age, they will be 'appreciable risk'; if they are tachypneic, over 1 year of age, but with either complete PCV13 immunization OR detectable wheezing as per the ED clinician, they will be classified as 'low risk'. Appreciable-risk participants will be given a prescription for antibiotics at ED discharge.
223962377|NCT05598138|BIOLOGICAL|Biological Collection|A blood sample (10 ml) will be taken for each patient included in the study.
223542262|NCT01527630|DRUG|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
223542263|NCT04559061|DEVICE|Cardiac ablation procedure|Retrospective data will be collected from cases where successful ablation was completed.
223962378|NCT04042259|DEVICE|Abthera|Negative Pressure Wound Therapy Device
223962379|NCT04042259|PROCEDURE|Open adbdomen for post-laparotomy without NPWT device|Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
223962380|NCT05354726|OTHER|Assessments parameters|Demographic and Clinical Characteristics, Bone Mineral Density, Sarcopenia, Body Composition, Arterial Stiffness, Endothelial Function, Echocardiography,Pulmonary Function, Respiratory Muscle Strength, Submaximal exercise capacity, Maximal Exercise Capacity, Physical Activity Level, Hand Grip Strength, Lower Extremity Muscle Strength
223962381|NCT03077178|PROCEDURE|Geriatric assessment|Geriatric assessment, questionnaire assessment
223962382|NCT03352570|DEVICE|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
223962383|NCT03490188|BEHAVIORAL|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
223962384|NCT05005338|DRUG|BIIB122 (DNL151)|Oral doses
223962385|NCT05005338|DRUG|[14C] BIIB122 ([14C] DNL151)|Intravenous doses
223962386|NCT00176969|DRUG|Capsaicin|
223962387|NCT05264506|DRUG|NOMAC-E2 COC|"Dosage Formulation: Film-coated Tablet Unit Dose Strength: Nomegestrol acetate (NOMAC) 2.5 mg and estradiol (E2) 1.5 mg; Each blister strip contains 28 tablets: 24 tablets with the active drug (number 1 to 24) and 4 tablets with placebo (number 25 to 28).~Dosing Instructions: oral. Take 1 tablet daily at about the same time as directed."
223962388|NCT00472199|DRUG|Pramipexole|
223962389|NCT00472199|DRUG|Placebo|
224110081|NCT01678846|BEHAVIORAL|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good\_school\_toolkit.php).
224110082|NCT04096937|OTHER|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
223962390|NCT01406899|BEHAVIORAL|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
223962391|NCT03024593|BEHAVIORAL|Health- and illness-related internet use|
224110083|NCT00414440|DRUG|Placebo|placebo comparator
224110084|NCT00414440|DRUG|Everolimus|experimental
224110085|NCT00112138|DRUG|gabapentin|
224110086|NCT02583750|BEHAVIORAL|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
224110087|NCT02583750|BEHAVIORAL|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
224110088|NCT02143271|DRUG|KHK7580|Oral administration
224110089|NCT02924753|DRUG|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
224110090|NCT02924753|DRUG|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
224110091|NCT02924753|BIOLOGICAL|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
224110092|NCT00802165|DEVICE|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
224110093|NCT00802165|DEVICE|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
223962392|NCT01370161|PROCEDURE|TIPS treatment|"1. A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~2. Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~3. After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
223962393|NCT01370161|DRUG|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
223962394|NCT01879488|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
224110094|NCT00005628|BIOLOGICAL|vitespen|
223962395|NCT01879488|DEVICE|Vibrating-mesh nebulizer|
224110095|NCT00364039|DRUG|AV650|
224110096|NCT00065975|PROCEDURE|massage therapy|
223962396|NCT01879488|OTHER|Gamma scintigraphy|
223962397|NCT01879488|OTHER|Preoperative spirometry|
223962398|NCT00266136|DRUG|Cytarabine|see protocol
223962399|NCT00266136|DRUG|Thioguanine|see protocol
223962400|NCT00266136|DRUG|Daunorubicin|see protocol
223962401|NCT00266136|DRUG|Cyclophosphamide|see protocol
223962402|NCT00266136|DRUG|G-CSF|see protocol
223962403|NCT00266136|PROCEDURE|Autologous stem cell transplantation|for details see protocol
223962404|NCT00266136|PROCEDURE|Allogeneic stem cell transplantation|for details see protocol
224110097|NCT00065975|PROCEDURE|chiropractic|
224110098|NCT00065975|PROCEDURE|acupuncture|
224110099|NCT01285921|OTHER|vestibular test before and after hippocampal surgery|"* Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~* HIT (testing semicircular canal function at high frequency).Results: Gain in %~* VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~* ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~* Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
223724544|NCT04843293|BEHAVIORAL|Olfactory stimulation|Newborns in the experimental group will be given the smell of breast milk during 3 consecutive feedings and for 3 days in the morning. Smell stimulation will be started 1 minute before gavage feeding and the application of breast milk odor will continue until the feeding ends. A hand-cleaning researcher will drip 15 drops of breast milk on sterile gauze to apply the smell of breast milk. Sterile gauze dripped with breast milk will be placed as close to the newborn's nose as possible and not in contact with the newborn's skin. After the feeding of the newborn is completed, the application of the smell of breast milk will be terminated and the gauze will be removed from the incubator. A new sterile gauze will be used for each feeding, and these processes will be repeated with each smell stimulation for three days.
223724545|NCT00075959|DRUG|NXY-059|
223724546|NCT02254252|DRUG|Nicorandil|nicorandil (10mg tablets, two times a day)
223724547|NCT02254252|DRUG|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
223724548|NCT06293495|DEVICE|Gamma 3 Nail (Stryker)|Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)
223724549|NCT06293495|DEVICE|Chimaera Nail (Orthofix)|Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)
223724550|NCT03056885|OTHER|Conventional One-Lung Ventilation|Vt 10 ml/kg
223724551|NCT03056885|OTHER|Protective One-lung ventilation|Vt 5 ml/kg
223962405|NCT04639076|BEHAVIORAL|Behavioral Weight Loss Program|The BWL group will receive a standard weight loss intervention based on the evidence-based interventions currently being recommended for clinical practice, with general recommendations for caloric reductions based on starting weight and progressive weekly increases of physical activity (PA). Supporting behavioral lessons based on materials used in the Diabetes Prevention Program (DPP) will also be delivered. The weight loss 'prescription' will remain consistent throughout the 3 month trial. Participants will receive digital tools including a study smart phone app that incorporates diet self-monitoring, tracking of behavioral goals, behavioral lessons and resources, and integration of data from a study-provided Wi-Fi enabled scale and physical activity tracker.
223724552|NCT02348606|DRUG|JZP-110|
223724553|NCT02348606|DRUG|Placebo oral tablet|
223724554|NCT03849898|PROCEDURE|Surgery|Surgical fracture treatment
223724555|NCT03849898|OTHER|Non-Surgical fracture treatment|Non-Surgical fracture treatment
223724556|NCT02173327|DEVICE|Continuously helm CPAP|6 hours
223724557|NCT02173327|DEVICE|Intermittent Mask CPAP|10min every 2 hour for 18 hours
223724558|NCT01984177|DRUG|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. \~15 minutes after Corticorelin/saline injection, \[11C\]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure (\[11C\]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
223724559|NCT00965042|DRUG|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
223724560|NCT00050934|DRUG|oxcarbazepine|
223724561|NCT03196102|BEHAVIORAL|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
223724562|NCT03196102|BEHAVIORAL|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
223724563|NCT03196102|BEHAVIORAL|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
223724564|NCT03053284|DRUG|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
223962406|NCT04639076|BEHAVIORAL|Personalized Behavioral Weight Loss Program|The PBWL group will receive a calorie goal based on measured resting energy expenditure and baseline PA. In Weeks 1-4, participants will be randomly assigned to test patterns that manipulate diet composition (low-fat or low-carbohydrate), meal frequency (3 or 5-6 meals/day), and PA goals (weekly minutes or daily minutes goals). Following this period, the optimal combination will be identified by the participant and interventionist, based on weight loss, blood glucose, hunger and ability to adhere to the prescription. This group will receive the same supporting behavioral lessons as the BWL group along with additional resources specific to their personalized prescription. The weight loss 'prescription' will vary across the 3-month trial based on response to treatment. Participants will receive the same digital tools as the BWL group with resources specific to following the prescription they are following during any given program week.
223962407|NCT01757171|DRUG|Cabazitaxel|20mg IV over 1 hour every 3 weeks
223962408|NCT05858047|DRUG|Placebo|Administered orally, once daily (QD)
223962409|NCT05858047|DRUG|SYHX1901|Administered orally, once daily (QD)
223962410|NCT00103116|BIOLOGICAL|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
223962411|NCT01799785|BEHAVIORAL|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
223962412|NCT01799785|OTHER|Usual Care|
223962413|NCT04236622|OTHER|Periodontal clinical exam|"The individuals will be submitted to a complete periodontal examination, with measurements obtained at four points per tooth and dental implant (mesial, distal, buccal and lingual / palatal), in all teeth / implants present, except for the third molars, the parameters evaluated will be: Probing Depth, Clinical Insertion Level, Plaque Index, Teeth Bleeding Index. The implants will be evaluated according to the parameters: presence of suppuration, probing depth, bleeding to probing and presence of biofilm around the implants. To perform the clinical examinations, the following instruments will be required: Willians millimeter probe, exploratory probe and clinical mirror.~In all participants, complete periapical radiographic examinations with 14 radiographs will be performed to verify the bone cortical height level and to assist in the periodontal diagnosis."
223962414|NCT00427297|DRUG|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
223962415|NCT00427297|DRUG|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
223962416|NCT00427297|DRUG|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
223962417|NCT00427297|DRUG|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of\<8g/dl), AZT will be substituted for d4T.
223962418|NCT00427297|DRUG|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
223962419|NCT00427297|DRUG|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
223962420|NCT00427297|DRUG|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
223962421|NCT03369652|BEHAVIORAL|Medication review|Conducted by the pharmacist and discussed with hospital physician
223962422|NCT01014013|DRUG|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
223962423|NCT01014013|DRUG|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
223962424|NCT04299698|BEHAVIORAL|lifestyle|Participants who desire to control body fat mass chose the one of lifestyle modification on their diet or exercise.
223962425|NCT03359187|OTHER|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
223962426|NCT03359187|OTHER|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
223962427|NCT03359187|OTHER|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
223962428|NCT00316121|DEVICE|HEALOS and Leopard Cage|Placement in interbody space
223724565|NCT03053284|DRUG|Saline Solution|Saline Solution injection will be given once per study visit
223962429|NCT00316121|DEVICE|Leopard Cage and Autograft|Placement in the interbody space
223962430|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
223962431|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone|
223962432|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
223962433|NCT01037699|DRUG|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
223962434|NCT03324048|OTHER|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
223962435|NCT00547885|DRUG|Dihydrocodeine|"Group 1: 2\* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3\* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4\* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4\*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6\*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8\*30 mg dihydrocodeine short acting"
223962436|NCT05274906|OTHER|Randomized, cross-over controlled feeding trial testing a Healthy Eating Index 2015 (HEI-2015) diet with and without red and processed meat|Healthy Eating Index-2015 (HEI-2015) with or without red/processed meat (HEI-2015-M)
224110100|NCT04877782|DEVICE|Transcutaneous vagus verne stimulation|Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
224110101|NCT02225067|DRUG|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
223724566|NCT04380116|DEVICE|Soberlink|Soberlink is a comprehensive alcohol monitoring system designed to remotely monitor a person's Blood Alcohol Concentration (BAC). Combining a professional grade handheld breathalyzer with wireless connectivity, the technology includes real-time facial recognition, robust tamper detection and real-time alerting.
224110102|NCT04982913|DRUG|HEC116094|Part B：Mulltiple doses up to 5 days； Part C：Each cycle was administered for 5 days
224110103|NCT01116245|BIOLOGICAL|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
224110104|NCT01116245|DRUG|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
224110105|NCT04354753|OTHER|No Intervention|No intervention
223724567|NCT04826432|DRUG|Pasireotide 0.9 MG/ML|0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
223962437|NCT03703999|DEVICE|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
223962438|NCT00003697|DRUG|vadimezan|
223962439|NCT02720978|DRUG|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
223962440|NCT02720978|DRUG|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
223962441|NCT01630239|PROCEDURE|Laser ablation|Laser ablation of hepatic tumors
223962442|NCT00038376|DRUG|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
223962443|NCT00038376|DRUG|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
223962444|NCT05048407|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
223962445|NCT03674476|DRUG|BMS-986036|Specified dose on specified days
224110106|NCT05297305|DEVICE|Tornier Ascend Flex stem|Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
224110107|NCT05297305|DEVICE|Tornier Perform Stem Reverse+|Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
224110108|NCT02498821|DEVICE|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
224110109|NCT02498821|DEVICE|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
224110110|NCT02498821|PROCEDURE|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
223962446|NCT04891263|PROCEDURE|Suture-Septoplasty|Patients receive suture-septoplasty for repair of nasal septal deviation.
223962447|NCT04891263|DEVICE|Surgical suture|Suture used for closure during septoplasty surgery.
223962448|NCT02100189|OTHER|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
223962449|NCT02100189|PROCEDURE|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
223724568|NCT04826432|OTHER|Saline water|0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours
223724569|NCT04302298|DEVICE|Virtual Reality|A machine which immerses the participant in a simulated environment where they can perform a procedure.
223724570|NCT03962010|DRUG|GX-G6|long acting anti-diabetic drug
223724571|NCT03962010|DRUG|Control|Control
223724572|NCT02486497|BIOLOGICAL|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
223724573|NCT05407935|BEHAVIORAL|ACTivity|Acceptance and Commitment Therapy for physical activity promotion plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
223724574|NCT05407935|BEHAVIORAL|Relaxercise|Relaxation training plus standard physical activity promotion strategies (i.e., goal-setting, self-monitoring)
223962450|NCT02100189|OTHER|Laboratory Biomarker Analysis|Correlative studies
223962451|NCT00245505|DRUG|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
223962452|NCT03148353|PROCEDURE|Subacromial injection|"1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection"
223962453|NCT01894750|BEHAVIORAL|group-based skill building self-care program|
224110111|NCT06969820|PROCEDURE|Low-dose Radiation Therapy (LDRT) using MRI-based imaging techniques|LDRT using MRI-based imaging techniques by developing an MRI imaging protocol, deep learning-based image enhancement and resolution increase.
224110112|NCT06970639|DRUG|Furmonertinib Mesilate Tablets|Usage and dosage: 80mg, 240mg, or 160mg QD orally Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs
223962454|NCT06646068|OTHER|Philips 66 with CBL|Each team is given six minutes to brainstorm ideas or solutions to specific clinical cases. This technique is applied during case-based learning sessions to enhance clinical judgment and critical thinking skills among nursing students.
223962455|NCT03452735|OTHER|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
223962456|NCT01702688|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
223962457|NCT01702688|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
223962458|NCT02650661|BEHAVIORAL|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
223962459|NCT02650661|BEHAVIORAL|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
223962460|NCT02650661|BEHAVIORAL|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
223724575|NCT02825056|DRUG|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
223724576|NCT02825056|DRUG|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
223724577|NCT02300688|DRUG|Treatment A|administration of 1 time administration of the test drug (Treatment A)
223724578|NCT02300688|DRUG|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
223962461|NCT02650661|BEHAVIORAL|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
223962462|NCT06570954|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations. ReACT consists of 12 sessions of therapy focused on teaching patients to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. The PNES is explained as behaviors learned through classical and operant conditioning.
223962463|NCT02469051|DEVICE|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
223962464|NCT02469051|DEVICE|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
223962465|NCT02469051|DEVICE|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
223962466|NCT01306409|DRUG|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
223962467|NCT01306409|DRUG|ESA|Sequential application of three different ESA
223962468|NCT04698499|OTHER|Swallowing exercise from home|Treatment Arm A will consist of using pen and paper to complete the exercises. This is considered standard care. Treatment Arm B will consist of using Mobili-T to complete the exercises.
223962469|NCT00441493|DRUG|fluvastatin|
223962470|NCT02526199|DRUG|Bupivacaine|Sciatic nerve block
224110113|NCT06970639|DRUG|Carboplatin Injection|"Usage and dosage: Administer via IV infusion, with a dosage of AUC5, not exceeding 750 mg.~Medication schedule: every 3 weeks as a cycle, D1 administration per cycle, immediate administration of carboplatin upon completion of pemetrexed infusion, intravenous infusion, carboplatin can be used for up to 4 cycles."
223724579|NCT02429544|BEHAVIORAL|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
223724580|NCT02429544|BEHAVIORAL|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
223962471|NCT02526199|DRUG|Epinephrine|Adjuvant to perinerual block
223962472|NCT02526199|DRUG|Dexamethasone|Adjuvant to perinerual block
223962473|NCT02213458|BEHAVIORAL|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
224110114|NCT06970639|DRUG|Cisplatin for injection|Usage and dosage: Administer via IV infusion at a dose of 75 mg/m2. Medication schedule: Every 3 weeks as a cycle, with D1 administration per cycle. Cisplatin is administered approximately 30 minutes after the infusion of pemetrexed, via intravenous infusion. Adequate hydration therapy must be received before and after cisplatin treatment. Cisplatin can be used for up to 4 cycles.
224110115|NCT06970639|DRUG|Pemetrexed Disodium for Injection|Usage and dosage: Intravenous (IV) infusion administration, dosage of 500 mg/m2 Medication schedule: Administer on the first day of each cycle (21 days per cycle, i.e. every 3 weeks) until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs.
224110116|NCT06970639|DRUG|Osimertinib Mesylate Tablets|Usage and dosage: 80mg, QD administration Medication duration: A cycle of 21 days until intolerable toxicity, disease progression, death, or initiation of new anti-tumor therapy occurs
224110117|NCT06970119|DRUG|INR102 injection|INR102 injection is a lutetium-177 (\[177Lu\])-labeled radiopharmaceutical agent targeting prostate-specific membrane antigen (PSMA). It is clinically indicated for the treatment of patients with PSMA-positive prostate cancer.
223962474|NCT03316248|OTHER|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
223962475|NCT03316248|OTHER|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
223962476|NCT02653066|OTHER|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
223962477|NCT02653066|OTHER|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
223962478|NCT00489151|DRUG|adefovir dipivoxil|
223962479|NCT00489151|DRUG|lamivudine|
223962480|NCT00910871|DRUG|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
223962481|NCT00910871|DRUG|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
223962482|NCT00787345|OTHER|simulation based training|simulation based training in aseptic techniques that included specified AT categories
223962483|NCT03759262|DRUG|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
223962484|NCT03078699|RADIATION|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
223962485|NCT02606617|DRUG|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
223962486|NCT02606617|DRUG|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
223962487|NCT05055999|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day
223962488|NCT06585189|DRUG|Pembrolizumab|
223962489|NCT06585189|DRUG|Pemetrexed|
223962490|NCT06585189|DRUG|Cisplatin|
223962491|NCT06585189|DRUG|Carboplatin|
224110118|NCT06971406|DRUG|Combination therapy prospective cohort|high-dose firmonertinib (240 mg, daily), bevacizumab (15 mg/kg, every 3 weeks), and pemetrexed (50 mg, intrathecal chemotherapy C1d1d5, then every 3 weeks)
224110119|NCT06971549|OTHER|Accelerated iTBS|Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
224110120|NCT06970197|OTHER|simülation group|İncludes high reality simulation applications.
223962492|NCT06057870|OTHER|Application on Apple watch|To determine the feasibility and engagement with remote management of acutely decompensated cirrhosis patients using CirrhoCare® App, CyberLiver ART App, and remote monitors by assessing patient adherence to the monitoring device and the Apps over a 3-month period.
223962493|NCT05584761|DRUG|unrelated umbilical cord blood|"A single unit of unrelated umbilical cord blood was reinfused within 24-72 hours after the end of AZA or chemotherapy, and the longest delay was 96 hours after the end of chemotherapy. The umbilical cord blood was matched at 0-3/10 locus.~Microtransplantation of umbilical cord blood: single unit of unrelated cord blood (HLA 0-5/10 or 0-3/6 matched, TNC 1-2×107/Kg body weight), AZA or homoharringtonine infusion 24-72 hours after the end of injection."
223962494|NCT05272254|DRUG|10% povidone iodine + FV|applied to children's teeth
223962495|NCT05272254|OTHER|Placebo +FV|applied to children's teeth
223962496|NCT00629161|DRUG|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
223724581|NCT02429544|DEVICE|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
223962497|NCT00629161|DRUG|placebo|12 months period of placebo plus 1 month period without placebo
223962498|NCT03696147|DEVICE|Magnetic resonance imaging|Diffusion weighted sequence of MRI
223962499|NCT01482871|DRUG|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
223962500|NCT01482871|DRUG|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
223962501|NCT01482871|DRUG|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
223962502|NCT01482871|DRUG|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
223962503|NCT05499117|DEVICE|Light terapy|Carex Day-Light Classic, Light intensity is white Light, 10000UX, and color temperature is 4000K
223962504|NCT05499117|DEVICE|pseudo-light therapy|The pseudo-light stimulation group was red light with intensity less than 100lux
223962505|NCT04425837|BIOLOGICAL|SARS-CoV-2 convalescent plasma treatment|Plasma transfusion of convalescent patients from COVID-19 with negative RT-PCR, and antibody titers of 1:160 or greater at a dose of 400ml distributed in two doses administered on the same day intravenous administration
223962506|NCT04425837|OTHER|Standard care|Standard care according to guidelines and national regulations
223962507|NCT05766566|PROCEDURE|Perianal fistula surgery|surgical treatment of the perianal fistula through curettage, closure with suture thread (vicryl 2/0) of the internal orifice and lipofilling of the passage with microfragmented autologous adipose tissue processed with the Lipogems® system.
223962508|NCT06415825|BEHAVIORAL|Standard advice and Preliminary muscle contraction|The maneuver groups will receive standard advice and an additional one - preliminary contraction of the muscles in the corresponding kinesiology segment. This advice will be embedded in all motor activities of daily living involving the relevant area.
223962509|NCT06415825|BEHAVIORAL|Standard advice|Standard advice includes avoiding heavy physical activity, sudden and unexpected loads, repetitive and prolonged overloads, and long periods of hypomobility.
223962510|NCT04928937|PROCEDURE|Roux-en-Y gastric bypass, sleeve gastrectomy|bariatric surgery with the goal loosing weight
223962511|NCT06032156|DIETARY_SUPPLEMENT|Low Dose β-OHB|Ingestion of a low dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.3 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
223962512|NCT06032156|DIETARY_SUPPLEMENT|High Dose β-OHB|Ingestion of a high dose \[R\]-3-hydroxybutyl \[R\]-3-hydroxybutyrate (0.6 g β-OHB/kg body weight) followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
223962513|NCT06032156|OTHER|Placebo|Ingestion of a taste-matched calorie-free placebo drink followed by 2-hours of rest. Submaximal exercise to be performed following 2-hour resting measures.
223962514|NCT00777309|DRUG|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
223962515|NCT00777309|DRUG|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
223962516|NCT00777309|DRUG|Placebo|The placebo is provided as a capsule
223962517|NCT02713776|DRUG|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
223962518|NCT02713776|DRUG|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
224110121|NCT06970197|OTHER|out-of-class educational activities group|"It includes a tour of the sales facility, a sapling planting activity and an action for the environment activity to provide experiential learning."
223962519|NCT01075815|DRUG|Recombinant human luteinizing hormone (rhLH)|
223962520|NCT01075815|DRUG|Recombinant follicle-stimulating hormone (rFSH)|
223962521|NCT01794273|DRUG|ephedrine and phenylephrine|
223962522|NCT03503188|DEVICE|Littmann ®|electronic stethoscope
223962523|NCT03867396|DEVICE|CROS|Advanced Bionics CROS
223962524|NCT03867396|DEVICE|Hearing Aid|Advanced Bionics Naida hearing aid
223962525|NCT03867396|OTHER|Cochlear Implant Alone|No hearing device on contralateral ear
223962526|NCT05456061|DRUG|3% diquafosol eyedrops|Diquas® (Santen, Osaka, Japan), six times per day.
223962527|NCT05456061|PROCEDURE|Silicone punctal plug insertion|a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
223962528|NCT03868202|DRUG|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
224110122|NCT06969729|PROCEDURE|Physician-Modified Fenestrated Stent-Graft (3D-Printed Template-Guided)|Implantation of a physician-modified fenestrated stent-graft using a patient-specific 3D-printed aortic template, performed via an endovascular approach.
223962529|NCT06119256|BIOLOGICAL|EBV-TCR-T cells|The patients with EBV infection after HSCT will receive one to three infusions of donor-derived EBV-TCR-T cells, with the escalated dose ranging from 5×10\^5/kg to 1×10\^6/kg EBV-TCR-T cells per dose.
223962530|NCT03031223|RADIATION|low-level laser therapy|low-level laser therapy
223962531|NCT03747575|DRUG|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
223962532|NCT03747575|DRUG|Placebo|Participants will receive SC placebo
223962533|NCT02288572|DIETARY_SUPPLEMENT|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
224110123|NCT05468957|DEVICE|Perclose|Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
224110124|NCT05468957|DRUG|Statseal|Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
224110125|NCT02820259|DRUG|Tacrolimus|
224110126|NCT01716169|DEVICE|Helicoll|Helicoll Collagen I Wound Dressing
224110127|NCT01716169|DEVICE|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
224110128|NCT03738956|DRUG|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
224110129|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
223962534|NCT02288572|DIETARY_SUPPLEMENT|Placebo|Taking dietary supplement on a daily basis for 3 months.
224110130|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
224110131|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
223962535|NCT01601925|OTHER|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
223962536|NCT01287624|DRUG|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
223962537|NCT01287624|DRUG|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
223962538|NCT00658177|DRUG|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
223962539|NCT00658177|DRUG|Placebo|Matching placebo
223962540|NCT00745069|DRUG|tapentadol HCl|
224110132|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
224110133|NCT00761540|DRUG|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
224110134|NCT00761540|DRUG|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
224110135|NCT03444025|DRUG|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
223962541|NCT03109600|BIOLOGICAL|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
223962542|NCT03109600|BIOLOGICAL|Vi polysaccharide vaccine|Vi polysaccharide vaccine
223962543|NCT03109600|BIOLOGICAL|Influenzae vaccine|1 dose of Influenzae vaccine
223962544|NCT03109600|BIOLOGICAL|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
223962545|NCT01060163|DRUG|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
223962546|NCT01060163|DRUG|Saline|Saline served as placebo
223962547|NCT00347425|DRUG|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
223962548|NCT00347425|DRUG|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
223962549|NCT00347425|DRUG|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
224110136|NCT00005037|DRUG|temozolomide|
224110137|NCT00005037|DRUG|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
224110138|NCT02851446|OTHER|measure dyspnoea> Borg 7|
224110139|NCT02285010|DRUG|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
224110140|NCT02285010|DRUG|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
224110141|NCT02844608|OTHER|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
223724582|NCT02429544|OTHER|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
223724583|NCT02429544|BEHAVIORAL|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
223962550|NCT00347425|DRUG|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
223962551|NCT00347425|DRUG|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
223962552|NCT00347425|DRUG|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
223962553|NCT00347425|DRUG|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
223962554|NCT00347425|DRUG|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
223962555|NCT00347425|DRUG|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
224110142|NCT04204681|DIAGNOSTIC_TEST|Ultrasonography imaging|This study aimed to measure the tongue areas of the patients two times both of study and control groups with ultrasonography imaging to compare the tongue areas.
224110143|NCT04165395|DEVICE|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
224110144|NCT04165395|DEVICE|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
224110145|NCT02700581|PROCEDURE|low PEEP conventional ventilation|
224110146|NCT02700581|PROCEDURE|moderate PEEP conventional ventilation|
224110147|NCT02700581|PROCEDURE|low PEEP protective ventilation|
224110148|NCT02700581|PROCEDURE|moderate PEEP protective ventilation|
224110149|NCT05597566|PROCEDURE|modified electroconvulsive therapy|The patient underwent MECT therapy. The treatment instrument is Xingmaitong IV ECT multifunctional treatment instrument (USA, SOMATICS THYMATRON company), fasting for 6 hours before surgery, emptying urine. Routine preoperative preparations were made, followed by intravenous injection of atropine, propofol, and succinylcholine chloride injection, artificial respiration, placement of dental pads, and electroconvulsive therapy. The whole process is completed by an anesthesiologist and a therapist in cooperation with each other. The first 3 times are once a day, and the next 5 times are once every other day. A total of 8 courses of treatment.
224110150|NCT02997189|DRUG|OTO-104|12 mg dexamethasone administered intratympanically
224110151|NCT01919372|DEVICE|Telemedic assistance with a technological system|
224110152|NCT01919372|OTHER|Standard care|
223962556|NCT00347425|DRUG|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
223962557|NCT06415695|BEHAVIORAL|Education sessions|Ten 40-minute education sessions appropriate to Saudi people will be developed and will cover essential topics for enhancing diet, lifestyle, and health. Each session comprises four modules, including activities and homework reviewed by a dietitian. Based on the EMPOWER weight loss program developed by the Nakamura lab for the US population, adjustments will be made to align with Saudi preferences, including food choices and cooking methods. Participants will access these materials online.
224110153|NCT00006168|DRUG|Methotrexate|
223962558|NCT02444195|BEHAVIORAL|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
223962559|NCT05811000|DRUG|PM012|PM012 650 mg tablet drug
223962560|NCT05811000|DRUG|PM012 Placebo|PM012 tablet placebo
224110154|NCT00939263|OTHER|assessment of disease activity using the EEsAI|disease activity index
224110155|NCT01656616|DRUG|Cyanide antidote administration|
223962561|NCT05811000|DRUG|Donepezil|Aricept 5 mg (donepezil hydrochloride) drug
223962562|NCT05811000|DRUG|Donepezil placebo|Aricept 5 mg (donepezil hydrochloride) placebo
224110156|NCT05215210|OTHER|Bitter-gourd|12-week intervention of 3.6 grams of dried bitter-gourd supplements
224110157|NCT05215210|OTHER|Cucumber|12-week intervention of 3.6 grams of cucumber supplements
224110158|NCT02400112|DRUG|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
224110159|NCT00754767|DRUG|L-carnitine L-tartrate|Given orally
224110160|NCT00754767|OTHER|placebo|Given orally
224110161|NCT04149522|DEVICE|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
223962570|NCT05883436|DEVICE|DEXA-C Cervical Interbody System|The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
223962571|NCT06731296|OTHER|Presence of a risk factor|Demographic, severity, type of surgery, diagnosis, diagnostic system, type of admission.
223962572|NCT00003088|DRUG|cyclophosphamide|given IV
223962573|NCT00003088|DRUG|doxorubicin hydrochloride|given IV
223724584|NCT04101461|DRUG|Iron|PharaFerro27; Devart Lab Company, Egypt
223724585|NCT04101461|DIAGNOSTIC_TEST|Complete blood count|to assess the anemia
223724586|NCT04101461|DIAGNOSTIC_TEST|Serum ferritin|to assess the anemia
223724587|NCT04101461|DIAGNOSTIC_TEST|Serum hepcidin|to assess the iron abosrption
223724588|NCT04101461|DIAGNOSTIC_TEST|Serum Iron|to assess the anemia
223724589|NCT04101461|DIAGNOSTIC_TEST|Serum total iron binding capacity|to assess the anemia
223724590|NCT05501730|DIAGNOSTIC_TEST|Quantra QPlus System|Coagulation monitoring system
223724591|NCT03326765|OTHER|Questionnaires|"* Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary"
223724592|NCT03326765|PROCEDURE|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
223724593|NCT03326765|PROCEDURE|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
223724594|NCT03326765|PROCEDURE|Actigraphy|type of sleep study based on bracelet around the wrist
223724595|NCT01428544|DRUG|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
223724596|NCT04982809|DRUG|Betamethasone, Dexamethasone, Prednisolone|Corticosteroids
223962574|NCT00003088|DRUG|paclitaxel|given IV
223962575|NCT02944981|DRUG|Gabapentin|Single oral dose
223962576|NCT02944981|DRUG|Placebo|Single oral dose
223962577|NCT02356874|BEHAVIORAL|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
224110162|NCT06496503|BEHAVIORAL|Physical activity Protocol|The children included in the experimental group will undergo 12 weeks of physical activity sessions, and it is mandatory that all children complete a minimum of two weekly sessions of physical activity for 50-60 minutes. The activities will consist of content such as motor and cognitive games, sports, dance, and gymnastics. The intensity of the sessions will be checked using accelerometry. The physical activity protocol is adapted from a previously described protocol (CMSP, 2021; Klem, Filha, Monteiro, 2017; Mazzoccante et al.; 2020; Paiano, 2019; Rodrigues, 2018; Rosini et al., 2014). Acceptance of the exercise program in the pediatric population has been previously observed in a pilot study.
224291328|NCT02780427|DRUG|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
224291329|NCT00135382|DRUG|Videx EC|
224291330|NCT00135382|DRUG|Epivir|
223724597|NCT06304220|DRUG|Cerazet|Comparation of the utilization of two distinct progestogens for pituitary suppression
223962578|NCT05811338|BEHAVIORAL|Project 1, Phase 2: VR Program for Social, Activity, and Cognitive Engagement|The investigators will apply a systematic approach to the design and evaluation of an immersive Cognitive Activity Social Technology (CAST) VR intervention (using the Oculus Quest 2), that provides aging adults a suite of virtual cognitive, social, and activity engagement applications. The program will allow for virtual interactions (one-on one or groups), cultural, creativity, and educational opportunities, and gaming.
223962579|NCT05811338|BEHAVIORAL|Project 2, Phase 2: Intelligent Adaptive System|An innovative intelligent adaptive software package aimed at providing social and cognitive support to older adults with MCI. The system will be designed to adapt to the needs and abilities of the user.
223724598|NCT02905552|OTHER|No intervention|
223724599|NCT06279091|BEHAVIORAL|Diaphragmatic Breathing|apply breathing exercises to evaluate the effectiveness on anxiety reduction
223962580|NCT05811338|BEHAVIORAL|Project 3, Phase 3: Intelligent Decision Support Tool|An innovative intelligent decision tool for health decisions aims at providing health management support for older adults with and without MCI.
223724600|NCT06279091|BEHAVIORAL|Bubble Blower Breathing|apply breathing exercises by using bubble blower to evaluate the effectiveness on anxiety reduction
223724601|NCT06279091|BEHAVIORAL|Tell Show Do|apply basic behavioral management technique as control group
223724602|NCT02460614|PROCEDURE|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
223962581|NCT01434732|PROCEDURE|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
223962582|NCT01434732|PROCEDURE|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
223962583|NCT03005106|BIOLOGICAL|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
223962584|NCT03005106|PROCEDURE|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
223962585|NCT01270906|DRUG|CHIR-258 (TKI258)|
223962586|NCT04594525|OTHER|Low-Intensity Psychosocial Interventions through Telemental health|Low-Intensity Psychosocial Interventions through Telemental health (Thinking healthy): The intervention will include six sessions. Each session may last to 45 min as a max, and it will be provided through telehealth. The first session will be an introduction, while the other five sessions will be covering the period from the second pregnancy trimester to the first year of the infant's life.
223962587|NCT01837368|OTHER|observational research|It is a observational research, no intervention are performed
223962588|NCT05716425|DRUG|STI-1558|STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
223962589|NCT05716425|DRUG|STI-1558 placebo|STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
223962590|NCT03163472|PROCEDURE|Axillary brachial plexus block with 10 mL oof local anaesthetic|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
223962591|NCT03163472|PROCEDURE|Axillary brachial plexus block with 30 ml of local anaesthetic|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
223962592|NCT01691404|DIETARY_SUPPLEMENT|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
223724603|NCT02460614|PROCEDURE|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
223724604|NCT02460614|OTHER|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
224291331|NCT00135382|DRUG|Sustiva|
223962593|NCT01691404|DIETARY_SUPPLEMENT|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
223724605|NCT01612936|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
223962594|NCT01691404|DIETARY_SUPPLEMENT|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
223962595|NCT01667159|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
223962596|NCT01667159|BEHAVIORAL|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
223962597|NCT00246350|PROCEDURE|massage|8 light massage treatments and hot pack
223962598|NCT00246350|PROCEDURE|massage|16 light massage treatments and hot packs
223962599|NCT00246350|PROCEDURE|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
223962600|NCT00246350|PROCEDURE|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
223962601|NCT00227422|BIOLOGICAL|Mencevax ACWY|
223962602|NCT05414825|OTHER|focus group interview|Group interview gathering words, views, symptoms and its repercussions, and main issues of the subjects regarding severe dysmenorrhea
223962603|NCT01374152|OTHER|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
223962604|NCT06380959|OTHER|Art Based Activity|"Art Based Activity Module consists of 3 art-based activities under the titles My Life Journey, The Power Within Me and Letter to the Future. Each activity consists of three stages. In the first stage, the participants were made to practice breathing exercises. At this stage, the participant was expected to become aware of himself and his ideas. In the second stage, art activity was carried out. In the final stage, the revealed art object was concretized by the participants with a verbal expression. The materials used in the activities (dry paint, pastel paint, watercolor) are dermatologically tested and consist of anti-allergen products."
223962605|NCT06012214|PROCEDURE|ROBOTIC-ASSISTED ESOPHAGECTOMY|Comparison between robotic and conventional minimally invasive esophagectomy
223962606|NCT01654198|RADIATION|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
223962607|NCT00634998|DIETARY_SUPPLEMENT|Vitamin C|1000mg Vitamin C capsules orally twice daily
224291332|NCT05440331|OTHER|Training with AnesList©|Training with AnesList© as tool
223962608|NCT00634998|DIETARY_SUPPLEMENT|Placebo|1000mg Placebo capsules orally twice daily for 90 days
224110163|NCT04635644|PROCEDURE|Erector Spinae Plane Block|Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.
223962609|NCT05606796|DRUG|Latanoprost 0.005% Ophthalmic Solution|1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
224110164|NCT04635644|PROCEDURE|Intrathecal morphine|Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
224110165|NCT05938088|DRUG|Arm I (mirogabalin group)|Take two capsules of Mirogabalin 5 mg within 30 minutes before going to the operating room. Patients take 5 mg of mirogabalin twice daily at 12-hour intervals until POD 7 days.
224110166|NCT05938088|DRUG|Arm II (placebo group)|It is performed in the same way as Arm l.
224110167|NCT03809286|DEVICE|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
224110168|NCT03809286|BEHAVIORAL|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
223962610|NCT03039556|BEHAVIORAL|Normal Daily Steps|Complete normal daily ambulation for one week
223962611|NCT03039556|BEHAVIORAL|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
223962612|NCT03039556|BEHAVIORAL|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
223962613|NCT06393855|PROCEDURE|single-step Trans-PRK|Both eyes were treated consecutively in each patient by single-step Trans-PRK performed by SCHWIND Amaris 500 S excimer laser platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany). Topical Proparacaine Hydrochloride Eye Drops 0.5% (Alcaine, Alcon, Fort Worth, TX, USA) were used to anesthetize the eyes, and use povidone-iodine to disinfect the eyelid skin. After a lid speculum had been inserted, and the other eye was blocked. Epithelial and stromal ablations were performed using a single continuous laser shooting session on an excimer laser platform. After the appeals step, Mitomycin C 0.02 % was applied to the stromal surface for 20 s, then rinse with cold salt water.
223542264|NCT03984773|BEHAVIORAL|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
224110169|NCT03809286|DEVICE|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
224110170|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Verisol®|Supplementation with Verisol® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
223962614|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.4-mm base curve in right eye and one with an 8.8-mm base curve in the left eye.
224110171|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Peptech® 2.5G|Supplementation with Peptech® collagen will be administered at a dose of 2.5 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
224291333|NCT06208826|DRUG|Toripalimab|Toripamab, IV, 240mg, every 3 weeks for 15 cycles
223962615|NCT06393855|BEHAVIORAL|Placing a bandage contact lens on the cornea,A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.|After surgery. A contact lens placed on the cornea, with an 8.8-mm base curve in right eye and one with an 8.4-mm base curve in the left eye.
223962616|NCT03147222|BEHAVIORAL|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
223962617|NCT00936065|DRUG|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
223542265|NCT01887717|DEVICE|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
223962618|NCT00936065|DRUG|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
224110172|NCT06971029|DIETARY_SUPPLEMENT|Supplementation with Peptech® 10.0G|Supplementation with Peptech® collagen will be administered at a dose of 10.0 g/day, diluted in water or water-based juice (300-500 mL), and should be consumed daily, 7 days a week, for 3 months.
224110173|NCT06971029|DIAGNOSTIC_TEST|Control group|The control group will not receive supplementation.
223962619|NCT00936065|DRUG|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
224110174|NCT06971679|BEHAVIORAL|Flipped Method|In the first week of the clinical practice, the E-learning module prepared by the researchers within the scope of the flipped education method was shared with the intervention group students and all students were shown in a conference room. After the training, PBL modules (different cases related to patient safety for each group) were shared with the students divided into groups of 3-5 students within the scope of PBL and they were given one week to prepare. In the other weeks of the clinical practice, face-to-face case discussions were held with the groups. These case discussions lasted an average of 40 minutes.
224110175|NCT06970379|OTHER|T-PRF|Patients received T-PRF placement at the fracture line.
224110176|NCT06970379|OTHER|T-PRF and Laser biomodulation|Subjects underwent the process of bio-stimulation of the fracture line using low-level laser therapy. Wavelength \[λ\]: 660 nm, Power: 100 mW, Spot size \[Ø\]: 0.06 cm2, and for 60 seconds
224110177|NCT06969911|PROCEDURE|Laminate veneer CAD/CAM|Minimally invasive therapeutic intervention with CAD/CAM veneers
224110178|NCT06969911|PROCEDURE|Laminate Veneer Convetional|Minimally invasive therapeutic intervention with CAD/CAM veneers
224110179|NCT06970808|DEVICE|Sampling from the resection margins|"After polypectomy, the base will be irrigated and assessed by the endoscopist, who may also use virtual or vital chromoendoscopy, if needed.~Any residual adenomatous tissue will be removed using the same technique. To confirm the completeness of each polypectomy, two biopsies will be taken from the resection margins for polyps ≤ 5 mm, and three biopsies for polyps 6-9 mm, using standard biopsy forces."
224110180|NCT06969560|DEVICE|Remote Physiologic Monitoring (RPM)|The intervention consists of a remote physiologic monitoring (RPM) program which makes use of a wearable Skiin chest band and ECG device, a blood pressure monitor, a pulse oximeter, and a weight scale; the RPM program will occur for 12 weeks Participants will wear the Skiin device continuously for the first 48-hours and then for a 12-hour span each day following that. Participants will measure their blood pressure, oxygen saturation, and weight once a day for the full 12 weeks.
224110181|NCT06969716|OTHER|Detailed geriatric assessment|The demographic characteristics of the patients, comorbid diseases, history and number of falls in the last 6 months will be questioned, and the thyroid stimulating hormone, calciferol, cobalamin, glycosylated hemoglobin, folic acid and glomerular filtration rate levels routinely requested from each patient in the last 3 months will be recorded. During the outpatient clinic application, the patients will undergo neurocognitive assessment, mood assessment, daily living activities assessment, balance and walking assessment, nutritional assessment and frailty assessment. The patients' handgrip strength from their dominant hand will be assessed with a hand dynamometer. The walking speed of the patients will be measured as the number of seconds it takes to walk 4 meters and recorded in seconds. All patients will be questioned about the presence of body pain with the numerical pain scale score and all patients will be evaluated for the presence of fibromyalgia syndrome.
224110182|NCT04914286|DRUG|GFH018|Subjects are planned to be dosed in oral GFH018 tablets twice daily for a continuous 14 days in a 28 days cycle (7days on 7days off may be tested based on available data from phase I dose escalation study of single agent). the starting dose of GFH018 will be derived from the maximum safe dose explored in rom phase I dose escalation study of single agent.
224110183|NCT04914286|DRUG|Toripalimab|Subjects are planned to be dosed at 3 mg/kg Toripalimab as an intravenous infusion once every 2 weeks.
224110184|NCT05279092|DRUG|Bupivacaine-Liposomal Bupivacaine|Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
223962620|NCT06505252|PROCEDURE|enoscopic Myringoplasty|"general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization~* the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat"
223962621|NCT01002209|PROCEDURE|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
224110185|NCT05279092|DRUG|Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate|Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
224291334|NCT06208826|RADIATION|Radiation Therapy|Radiation Therapy
224291335|NCT06208826|DRUG|Cisplatin|Chemotherapy agent
224291336|NCT01481740|DRUG|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
224291337|NCT01481740|DRUG|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
224291338|NCT01334684|DRUG|Metformin|Metformin, pills, 850 mg three times a day for three months
224110186|NCT06971211|DRUG|Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.|Induction therapy, fluzoparib (150mg BID orally), abiraterone acetate tablets (II) (300mg QD orally), and prednisone (5mg BID orally). IMRT was administered as follows: For patients with low metastatic burden tumors: Prostate ± pelvic lymph node radiation + metastatic lesion radiation.For patients with non-low metastatic burden tumors: Prostate±pelvic lymph node radiation.IMRT dosage:Prostate: 70 Gy in 28 fractions (2.5 Gy/fraction, 5 fractions per week).Pelvic lymph nodes: 50.4 Gy in 28 fractions (1.8 Gy/fraction, 5 fractions per week).Fluzoparib and abiraterone acetate (II) were administered concurrently with radiotherapy. Maintenance treatment,patients received the same doses of fluzoparib,abiraterone acetate (II), and prednisone. Each treatment cycle lasted 28 days.
224110187|NCT01101724|BEHAVIORAL|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
223962622|NCT01002209|PROCEDURE|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
223962623|NCT01285856|OTHER|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
223962624|NCT05832320|DRUG|Etoposide|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.
223962625|NCT05832320|DRUG|Daunorubicin|Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).
223962626|NCT04327349|BIOLOGICAL|Convalescent Plasma|Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU
223962627|NCT01034774|DRUG|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
223962628|NCT01034774|DRUG|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
223962629|NCT00106405|DRUG|Memantine HCl|
223962630|NCT02790645|OTHER|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
223962631|NCT02790645|OTHER|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
224110188|NCT00310505|DRUG|Amphotericin B deoxycholate given as daily administration|
224110189|NCT04706598|DRUG|Camrelizumab|Solution for Infusion (Intravesical)
224110190|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
223542266|NCT01887717|DRUG|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
223542267|NCT00432393|DRUG|levodopa-carbidopa|
224110191|NCT04936932|DEVICE|1064 nm long-pulse Nd:YAG laser|BCC lesion will be treated with long-pulse 1064 laser
224110192|NCT01165008|DRUG|Anakinra|
223542268|NCT04712747|PROCEDURE|Ophthalmological examinations|"* OCT (Optical Coherence Tomography): posterior pole OCT B scan , optic nerve and posterior pole OCT Angiography~* Adaptive optics (AO) : Image acquisition on the vessels at the exit of the optic nerve before the first upper temporal bifurcation OD or OG and evaluation of the photoreceptor mosaic. Adaptive optics may require dilatation of the pupil with a drop of tropicamide in the eye examined a few minutes before the examination.~* Color retinophotography~* Measurement of intraocular pressure~Patients with stroke : At the inclusion visit and 3 months after their stroke Control group : At the inclusion visit."
223542269|NCT04712747|PROCEDURE|Blood pressure measurement at rest|At the inclusion visit
223542270|NCT05749640|OTHER|Precontoured sectional matrix EZ COAT|All teeth will be treated with (Palodent ® plus sectional matrix system) (sectional matrix, biting ring, plastic diamond wedge)
223542271|NCT05749640|OTHER|PerForm™|Treated with (PerForm™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
223542272|NCT05749640|OTHER|AdDent Trimax™|Treated with (AdDent Trimax™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
224110193|NCT05569577|DRUG|Additional hCG injection|An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
224110194|NCT05569577|DRUG|estrogen and dydrogesterone|estrogen and dydrogesterone
223962632|NCT02790645|OTHER|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
224110195|NCT01478347|BIOLOGICAL|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
223962633|NCT02790645|OTHER|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
223962634|NCT04453137|BIOLOGICAL|Adalimumab originator|Subcutaneous injection every other week
223962635|NCT04453137|BIOLOGICAL|Adalimumab biosimilar|Subcutaneous injection every other week
223962636|NCT05431426|DRUG|CH6001|CHF6001 will be administered using the NEXThaler® DPI device
223962637|NCT06036485|DEVICE|Kerecis Omega 3|Decellularized intact fish skin developed for the management of chronic wounds
223962638|NCT06036485|PROCEDURE|Surgical debridement|Superficial sharp surgical debridement technique
223962639|NCT00145496|DRUG|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
223962640|NCT00145496|DRUG|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
223962641|NCT04912726|DRUG|Sildenafil Injectable Product|The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
223962642|NCT04896827|OTHER|Conditioned pain modulation test|Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
223962643|NCT00474409|DRUG|Merislon|
223962644|NCT05536869|PROCEDURE|Caesarean|Two different caesarean section techniques : intra or extraperitoneal
223962645|NCT00733174|DRUG|Rosiglitazone|tablet
223962646|NCT00733174|DRUG|Placebo|
223962647|NCT01429285|DRUG|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
224110196|NCT05176028|OTHER|conventional physiotherapy|For individuals of control group, hot pack applied for 20 minutes in the sitting position, Interferential Current was applied for the analgesic effect at a constant 100 Hz frequency on the anterior, posterior, superior and inferior part of the operated shoulder. By increasing the current slowly, the dosage of the current was adjusted to such a degree that the patient could tolerate it.
224110197|NCT05176028|OTHER|fascial release|Fascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the cervical, thoracolumbar and upper extremity areas until tissue loosening and releasing were felt.
224110198|NCT00196937|BIOLOGICAL|Cervarix|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
224110199|NCT01612910|DRUG|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
224110200|NCT01612910|OTHER|laboratory biomarker analysis|Correlative studies
224110201|NCT02556762|RADIATION|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
223542273|NCT05749640|OTHER|Contact Pro™|Treated with (Contact Pro™) as Contact Forming Instrument with (Palodent ® plus sectional matrix system)
224110202|NCT02556762|RADIATION|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
224110203|NCT02556762|DRUG|PF|Chemotherapy: Cisplatin and 5fluorouracil
223542274|NCT03110705|BEHAVIORAL|sport|recreaational sport : diving or multisport
223542275|NCT01979679|DRUG|Lurasidone 80 mg|
223542276|NCT01979679|DRUG|Lurasidone 120 mg|
223542277|NCT01979679|DRUG|Lurasidone 160 mg|
223542278|NCT06246747|OTHER|In clinic physical therapy|Patients visit the clinic to receive traditional physical therapy treatment
223962648|NCT01429285|DRUG|Usual care|Attending administers any IV opioid in any dose he chooses
223962649|NCT04780152|DEVICE|Transcranial Direct Current Stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of tDCS (30 minutes and 2 mA). Anodal stimulation will be applied on F3 according to the intentional 10/20 system, and the cathode will be applied on the contra lateral position (F4).
223962650|NCT04780152|DEVICE|Placebo-simulation of transcranial direct current stimulation|Participants receive 10 consecutive sessions followed by 1 session per week 10 weeks of placebo (30 minutes of placebo-simulation tDCS). Placebo will be administered using the same stimulation parameters and the active treatment position of the electrodes, but current wil be aborted 30 seconds after the ascending slope has begun.
223962651|NCT04780152|DRUG|Fluoxetine Tablets|Every patient will receive 10 mg of fluoxetine daily the first 2 two weeks, followed by 20 mg daily.
223962652|NCT01991275|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
223962653|NCT01991275|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
223962654|NCT01540305|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
223962655|NCT01540305|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
223962656|NCT02791295|OTHER|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
224110204|NCT04172025|DIAGNOSTIC_TEST|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
224110205|NCT00018863|DRUG|Methylphenidate|
224110206|NCT00203645|BEHAVIORAL|Self-help treatment|"Workbook Becoming a Winner,"
224110207|NCT03690258|DEVICE|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
223962657|NCT00561249|PROCEDURE|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
224110208|NCT06217406|DRUG|Intravenous acyclovir (ACYCLOVIR )|Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
224110209|NCT06217406|DRUG|Saline bags|Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
224110210|NCT03744234|PROCEDURE|PRP|Autologous platelet-rich plasma
224110211|NCT03744234|PROCEDURE|Steroid Injection|Steroid injection
224110212|NCT02904564|DRUG|MMP with 5-FU|MMP with 5-FU using tattoo device
224110213|NCT02904564|DRUG|MMP with Saline infusion|MMP with saline infusion using tattoo device
223542279|NCT06246747|OTHER|Telerehabilitation only|Patients receive remote treatment using the Wizecare platform
223962658|NCT04732611|OTHER|Pilates exercises|Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
223962659|NCT04732611|OTHER|Walking protocol|Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
224110214|NCT02513381|OTHER|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
224110215|NCT02513381|OTHER|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
224110216|NCT03403244|PROCEDURE|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
223542280|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
224110217|NCT03403244|PROCEDURE|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
223962660|NCT05703412|BEHAVIORAL|Transition-FOCUS mHealth Intervention|tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience
223962661|NCT05703412|BEHAVIORAL|Check-In|Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
223962662|NCT04373291|BIOLOGICAL|BCG-Denmark|Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.
223962663|NCT04373291|BIOLOGICAL|Saline|Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
223962664|NCT00097409|DRUG|Ispinesib|
223962665|NCT05366478|DRUG|Autologous tumor infiltrating lymphocytes (TILs)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
223962666|NCT05143099|DRUG|TEC|tislelizumab（an anti-PD-1 monoclonal antibody）+cetuximab（monoclonal antibody against EGFR）+irinotecan
224110218|NCT00033839|DRUG|Civamide (Zucapsaicin)|
223542281|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
223542282|NCT00244621|DRUG|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
223542283|NCT04067232|DIAGNOSTIC_TEST|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
223962667|NCT02735005|OTHER|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
223962668|NCT06170125|OTHER|Tiotropium treated patients|Patients who are not satisfied with their COPD treatment and will be on additional tiotropium scheme.
223962669|NCT04981431|DRUG|Elinzanetant (BAY3427080)|Oral administration
223962670|NCT04981431|DRUG|Placebo|Oral administration
223962671|NCT02452567|OTHER|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose \~8-10% of their body weight through diet-intervention.
223962672|NCT02680145|DEVICE|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
223542284|NCT00328029|DRUG|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
223542285|NCT00328029|PROCEDURE|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
223542286|NCT00328029|PROCEDURE|pharmacokinetics, done during the treatment|"12 blood collections :~* after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~* 3 hours after 2nd taken of Busulfan~* 3 hours after 3rd taken of Busulfan~* 3 hours after 4th taken of Busulfan~* 3 hours after 5th taken of Busulfan~* 3 hours after 6th taken of Busulfan."
223542287|NCT02960425|DIETARY_SUPPLEMENT|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
223542288|NCT02960425|DIETARY_SUPPLEMENT|Placebo|Topical placebo
223962673|NCT04432415|DEVICE|Silver Diamine Fluoride|Annual application od Silver Diamine Fluoride
223962674|NCT04432415|DEVICE|Soduim Fluoride Varnish|biannual apllication of Sodium Fluoride Varnish
223962675|NCT04432415|DEVICE|Placebo|biannual application of artificial saliva
223962676|NCT03982797|BIOLOGICAL|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
223962677|NCT02954783|BEHAVIORAL|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
224110219|NCT06509516|OTHER|Modified Sleeper-Stretch|Self-administered stretch in which the individual remains side-lying on the upper limb to be stretched, keeping the scapula stabilized by his/her own weight, and rolls the trunk 20-30º posteriorly, maintaining a 90º flexion in the shoulder and elbow. Using the opposite hand over the forearm of the limb to be stretched, the individual passively brings the shoulder to maximum internal rotation.
224110220|NCT01056523|DRUG|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
224110221|NCT01056523|DRUG|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
223962678|NCT02954783|BEHAVIORAL|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
223962679|NCT03958526|DEVICE|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
223962680|NCT03958526|DEVICE|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
223962681|NCT01768585|DRUG|Ivabradine|Please see description of Intervention Arm
223962682|NCT01768585|DRUG|Placebo|
223962683|NCT02694107|OTHER|Proprioceptive exercises|
224110222|NCT03425656|DRUG|Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
224110223|NCT04760132|BIOLOGICAL|COMIRNATY - BioNTech Manufacturing GmbH|Vaccination as part of the the Danish national government programme
224110224|NCT04760132|BIOLOGICAL|COVID-19 Vaccine Moderna dispersion for injection - MODERNA BIOTECH|Vaccination as part of the the Danish national government programme
224110225|NCT04760132|BIOLOGICAL|COVID-19 Vaccine AstraZeneca suspension for injection|Vaccination as part of the the Danish national government programme
223542289|NCT03053778|OTHER|Early follow-up|Early follow-up until 4 weeks after discharge
223542290|NCT04266522|OTHER|Informational Intervention|Receive printed materials
223962684|NCT02694107|OTHER|Control|
223542291|NCT04266522|OTHER|Counseling|Receive direct physicist interactions to describe the technical aspects of the treatment
223542292|NCT04266522|OTHER|Questionnaire Administration|Ancillary studies
223542293|NCT01220492|DRUG|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 8 weeks.
223542294|NCT01220492|DRUG|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
223542295|NCT05763680|DIAGNOSTIC_TEST|Molecular Culture|PCR based technique that amplifies the interspace region in bacterial DNA, that is located between the genes coding for 16S and 23S ribosomal subunits. Primers are used for the majority of known pathogenic phyla, i.e. FAFV, Bacteroidetes, Firmicutes and Proteobacteria. The nucleotide length of the Interspace region is species specific for bacterial single species. Bacteria all have one or multiple alleles for this interspace region. The combination of the amount of alleles, as well as the nucleotide strand length, makes for a specific profile that is distinctive for the species. Available software is able to match this profile to a particular pathogen, enabling confirmation and identification of bacteria in samples within 5 hours in our experimental workflow.
223962685|NCT04251455|PROCEDURE|Arthroscopy or discectomy with sampling of synovial fluid and synovial tissue|"Arthroscopic lysis and lavage: performed under general anaesthesia. Before initiation of arthroscopy synovial fluid was sampled with a push-and-pull method. The TMJ was investigated with an arthroscope during irrigation with sterile saline solution. Adhesions were addressed with a coblator. Synovial tissue biopsies were taken from the posterior attachment of the disc.~Discectomy without replacement: performed under general anaesthesia. Before initiation of surgery, synovial fluid was sampled as above described. During surgery synovial tissue biopsies were taken as described above."
223962686|NCT02034188|BIOLOGICAL|Umbilical cord mesenchymal stem cells|
223962687|NCT01542502|DRUG|Anakinra|Anakinra 100 mg daily subcutaneous injection
223962688|NCT01542502|DRUG|Placebo|Placebo daily subcutaneous injection
223962689|NCT06157684|BEHAVIORAL|Postprandial ambulation|See arm description
223962690|NCT03410680|BEHAVIORAL|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
223962691|NCT00193102|DRUG|Thalidomide|Thalidomide
223962692|NCT00193102|DRUG|Capecitabine|Capecitabine
223962693|NCT04971902|OTHER|Pharmacogenetic Test|Cheek swab sample with PGx results lab analysis
224110226|NCT03429556|BIOLOGICAL|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
224110227|NCT03429556|DRUG|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
224110228|NCT00486980|DRUG|Peramivir 150mg|
224110229|NCT00486980|DRUG|Peramivir 300mg|
224110230|NCT02153515|OTHER|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
223962694|NCT04202822|OTHER|Oral soft tissues biopsies|Oral soft tissues biopsies (alveolar mucosa, buccal gingiva, and palatal tissue) will be harvested by the examiner at the time of the surgery (immediately before to start the surgical procedure -T0) and 24 hours after surgery (T24) at the level of the vertical released incisions (VRIs) with a biopsy punch with plunger of 2.0 mm diameter.
223962695|NCT05972161|DEVICE|Thermal Imaging camera|Thermal Imaging camera used to measure respiratory flow.
223542296|NCT00818493|DRUG|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
223962696|NCT01052714|BEHAVIORAL|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
223962697|NCT05497167|OTHER|Period Kit|This is a single arm interventional study wherein the subjects enrolled will all participate in the study in the same way by being asked to answer pre-study survey questions concerning their attitudes towards menarche, receiving a period kit to explore on their own for two weeks, and then being asked to answer post-study survey questions.
223542297|NCT00818493|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
223542298|NCT00818493|DRUG|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
223962698|NCT06261515|PROCEDURE|Active periodontal treatment|Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets; periodontal surgery if needed (residual probing pocket depths ≥ 6 mm).
224110231|NCT01399827|DRUG|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
224110232|NCT01399827|DRUG|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
224110233|NCT02409498|DRUG|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
223962699|NCT01234584|PROCEDURE|spk|implants using SPK Abutments
224110234|NCT02409498|DRUG|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
224110235|NCT02519764|OTHER|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
224110236|NCT02519764|OTHER|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
223962700|NCT01234584|PROCEDURE|CPK Abutments|implants using CPK Abutments
223962701|NCT06446726|DRUG|Tislelizumab|Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg
224110237|NCT03248466|BIOLOGICAL|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
223962702|NCT06446726|RADIATION|Low-dose radiotherapy|Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)
224110238|NCT03211078|PROCEDURE|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
223962703|NCT06446726|DRUG|Nab-paclitaxel|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2
223962704|NCT06446726|DRUG|Cisplatin|Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
224110239|NCT03070132|DRUG|BIIB074|Administered as specified in the treatment arm
224110240|NCT03070132|DRUG|Placebo|Matched placebo
224110241|NCT03067558|DIAGNOSTIC_TEST|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
224110242|NCT03067558|DIAGNOSTIC_TEST|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
223542299|NCT02340884|BEHAVIORAL|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
223962705|NCT02239614|BIOLOGICAL|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
223962706|NCT02239614|BIOLOGICAL|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
223962707|NCT04095897|PROCEDURE|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
223962708|NCT02168855|DRUG|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
223962709|NCT02168855|BEHAVIORAL|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
223962710|NCT04490694|DRUG|Lenvatinib|Intervention Description：lenvatinib will be administered daily (for patients \<60kg, lenvatinib 8mg bid po for patients ≥60kg, lenvatinib 12mg bid po) until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
224110243|NCT02789696|OTHER|Diagnosis of acromegaly|Biological analysis of IGF-1
224110244|NCT01863758|BIOLOGICAL|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
224110245|NCT02603640|DEVICE|MRI scanning|
223962711|NCT04490694|PROCEDURE|TACE|Patients will be treated with TACE 2-4 weeks after randomization: the blood supply of the tumor will be evaluated by transradial / femoral artery approach, microcatheter will be inserted into the tumor feeding artery, and lipiodol plus epirubicin emulsifier will be injected (40mg epirubicin will be added to each 10ml lipiodol, the total amount should less than 20ml, epirubicin 40-60mg). Gelatin sponge particles / microspheres are used to strengthen embolization. Blood biochemical examination will be performed within 1 week before TACE, 3 days after operation and 1 month after operation.
223542300|NCT05545748|BEHAVIORAL|Zero (0) Tolerance Program (SToP)|"1. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.~2. Giving reminder objects (Magnet, sticker): For example; at the entrance door of the house: 0 TOLERANCE magnet to cigarettes; No smoking in my home label.~3. Informative materials (information notes and brochures): Brochures on the harms of second-hand smoking (SHS) and third-hand smoking (THS), the diseases they cause, and how to protect them~4. Informative telephone text messages: Reminder phone messages related to SHS and THS"
223542301|NCT05545748|BEHAVIORAL|Exposure Feedback Group|1\. Urine Cotinine Feedback: Explaining what the cotinine-sensitive dipstick test kit score mean. Cotinine-sensitive dipstick test kit is a simple, cost-effective test to determine smoking status. It is an easy-to-read test strip that can be used with either a saliva or a urine sample.
223962712|NCT02037009|OTHER|Health care organization (anesthetic surveillance)|
223962713|NCT06473194|PROCEDURE|general anesthesia drug (like Propofol, esmeron, and ketamin, .effects of pneumoperitoneum|this research will involve the selection of elective cases with ASA class I or II and assessment of patients with respiratory cardiovascular parameters and hematology perioperative
223962714|NCT01217645|RADIATION|150 mg [14C] AZD6765|
223962715|NCT03436537|OTHER|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
223962716|NCT01005563|OTHER|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
223962717|NCT01005563|OTHER|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
223962718|NCT05757063|OTHER|Sedation with propofol|After spinal anesthesia, patients will be sedated with propofol.
223962719|NCT05757063|OTHER|sedation with dexmedetomidine|After spinal anesthesia, patients will be sedated with dexmedetomidine.
223962720|NCT03807947|PROCEDURE|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
223962721|NCT03807947|PROCEDURE|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
223962722|NCT03689452|DEVICE|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
223962723|NCT03689452|DRUG|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
223962724|NCT04604899|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)
223962725|NCT00136851|DRUG|amlodipine besylate/benazepril hydrochloride|
223962726|NCT01078051|PROCEDURE|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
224110246|NCT04232501|DEVICE|Cirvo Compression device|Patients will wear Cirvo compression device during the surgery, after surgery and will be discharged to home with the device to wear at home as the per study protocol instructions.
224110247|NCT02005523|DRUG|RNS60|
224110248|NCT02005523|DRUG|Saline|
223542302|NCT02834819|DRUG|3% Nebulized Hypertonic Saline|
223542303|NCT01459692|OTHER|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
223542304|NCT01480102|DRUG|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
223542305|NCT01480102|OTHER|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
223542306|NCT02170844|DRUG|BIBR 1048 MS|
223962727|NCT01078051|DRUG|optimal medical therapy|optimal medical therapy
224110249|NCT02232646|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
224110250|NCT05440955|DEVICE|left fronto-temporal transcranial Direct Current Stimulation (tDCS)|"The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session."
224110251|NCT02369510|DRUG|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
224110252|NCT02369510|DRUG|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
224110253|NCT02369510|DRUG|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
224110254|NCT04272125|BIOLOGICAL|CD123 CAR-T cells|A single infusion of CD123-CAR-T cells will be administered intravenously
224110255|NCT01466725|DRUG|CC-930|
223542307|NCT02170844|DRUG|Placebo of BIBR 1048 MS|
224110256|NCT01466725|DRUG|Placebo|Placebo
224110257|NCT04798417|DIETARY_SUPPLEMENT|Probiotic supplement|Use of a probiotic sachet
224110258|NCT04798417|DIETARY_SUPPLEMENT|Prebiotic supplement|Prebiotic sachets
224110259|NCT04798417|DIETARY_SUPPLEMENT|Maltodextrin|Placebo comparator
224110260|NCT04118361|DIAGNOSTIC_TEST|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
224110261|NCT04118361|DIAGNOSTIC_TEST|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
224110262|NCT02109003|DEVICE|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
224110263|NCT02109003|DEVICE|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
224110264|NCT03271255|DRUG|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
224110265|NCT03271255|DRUG|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
224110266|NCT02584621|BEHAVIORAL|Check Yourself App with Feedback|
224110267|NCT04258553|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
224110268|NCT04258553|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with spectrophotometry
223542308|NCT01192880|DRUG|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
223542309|NCT01192880|DRUG|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
223542310|NCT01192880|DRUG|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
223542311|NCT04479592|OTHER|Particle counter|Particle counter to measure the aerosol generated
223542312|NCT06007417|DRUG|GenSci004|GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)
223542313|NCT06007417|DRUG|Genotropin|Genotropin
223542314|NCT05604443|OTHER|retrospective analyze|retrospective analyze of MS39 and Pentacam images
224110269|NCT04258553|DIAGNOSTIC_TEST|Ischemia Modified Albumin(IU/mL)|The serum Ischemia Modified Albumin concentrations were measured as described by Bar-Or et al. (Bar-Or et al. 2000).
224110270|NCT01058577|DEVICE|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
224110271|NCT01058577|PROCEDURE|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
223962728|NCT01383590|BIOLOGICAL|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
223542315|NCT01663792|OTHER|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
223542316|NCT01663792|OTHER|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
224110272|NCT00756977|DRUG|BLI850|multi-dose preparation for oral administration prior to colonoscopy
224110273|NCT00756977|DRUG|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
223542317|NCT01663792|OTHER|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
223962729|NCT02879669|BIOLOGICAL|ONCOS-102|
224110274|NCT01123447|PROCEDURE|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
224110275|NCT01123447|PROCEDURE|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
223962730|NCT02879669|DRUG|Pemetrexed/cisplatin (carboplatin)|
223962731|NCT02879669|DRUG|Cyclophosphamide|
223962732|NCT01964118|OTHER|Intermittent Fasting group|Intermittent fasting for 12 months
223962733|NCT01964118|OTHER|control group|usual diet for 6 months and intermittent fasting for other 6 months
223962734|NCT05925751|DIAGNOSTIC_TEST|CT/PET/WSI-based Deep Learning Signature|CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
224110276|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group|"The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
224110277|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
223542318|NCT00006356|DRUG|carboplatin|
223542319|NCT00006356|DRUG|cisplatin|
223542320|NCT00006356|PROCEDURE|conventional surgery|
223542321|NCT01251302|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
223542322|NCT02255669|DEVICE|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
223542323|NCT02255669|DEVICE|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
223542324|NCT06054399|OTHER|educational program|Education resources in Spanish through social media directed to the targeted audience mentioned above. There will be at least three interventions along the study, one for each pregnancy trimester, including topics such as: Migraine criteria, management strategies, risks of medication overuse, alarm symptoms, etc. These educational interventions will be conducted by trained health care professionals, mainly using audio-visual media.
223542325|NCT04280003|OTHER|Alogenic adipose tissue-derived stem cells|Concentration of the cells: 10 million cells / ml
223962735|NCT02676778|DRUG|E7777|
223962736|NCT04997408|DEVICE|Customized exercise app|A Wearable Device-Based Assisted Post-Stroke Rehabilitation system
223962737|NCT04997408|OTHER|In-person therapist-supervised rehabilitation|In-person therapist-supervised rehabilitation
223962738|NCT00732498|DRUG|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
223962739|NCT00732498|DRUG|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
223962740|NCT00732498|DRUG|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
223962741|NCT00732498|DRUG|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow \<25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
223962742|NCT00732498|DRUG|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
223962743|NCT00732498|DRUG|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
223962744|NCT00732498|DRUG|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from \>/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
223962745|NCT03000829|OTHER|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
224110278|NCT05913076|DEVICE|Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group|"The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months."
224110279|NCT02029430|DRUG|50 mg/m2 aldoxorubicin|
224110280|NCT02029430|DRUG|100 mg/m2 aldoxorubicin|
224110281|NCT02029430|DRUG|150 mg/m2 aldoxorubicin|
224110282|NCT05799144|BIOLOGICAL|DNA Vaccine|Given pBI-11 IM
224110283|NCT05799144|BIOLOGICAL|Human Papillomavirus Tumor Antigen Vaccine|Given into a muscle
224110284|NCT05799144|BIOLOGICAL|Pembrolizumab|Given into vein
224110285|NCT05799144|PROCEDURE|Computed Tomography (CT)|Undergo a CT
224110286|NCT05799144|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo an MRI
224110287|NCT05799144|PROCEDURE|Magnetic Resonance Imaging|Undergo blood sample collection
224110288|NCT05799144|PROCEDURE|Biopsy|Undergo tumor biopsy
224110289|NCT01411397|OTHER|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
224110290|NCT01411397|OTHER|mesh repair|mesh repair of strangulated hernia without resection
224110291|NCT05885685|DRUG|Nabilone Oral Capsule|Each oral capsule contains a 0.25 mg dose of nabilone. Participants begin by taking 1 capsule at night then 1 capsule in the morning and 1 at night for the next 2 days. On the 4th day, the dose is doubled. On the 6th day, the dose is doubled again.
224110292|NCT06667804|OTHER|Laughter yoga|Laughter yoga was applied to the experimental group for 4 weeks, 2 days a week, for 8 sessions (each session duration is 30-45 minutes on average). - The researcher is certified as an International Leader of Laughter Yoga. As a nursing intervention, patients with T2DM were made to do laughter yoga by the researcher. The laughter yoga program was conducted online (Google meet online) due to the ongoing COVID-19 pandemic at the time of the study. - The sessions were organized as follows: Monday-Thursday 10:00-10:45, Tuesday-Friday 10:00-10:45, Wednesday-Saturday 10:00-10:45. Participants participated in two sessions that were suitable for them within a week. A participant in a group was not allowed to change days in the following weeks.
224110293|NCT05078567|DEVICE|5% Natural Lactic Acid-enriched Cream|The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
224110294|NCT01571882|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
224110295|NCT01571882|OTHER|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
224110296|NCT01571882|OTHER|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
224110297|NCT04805931|BEHAVIORAL|Behavioral economics|Tailored behavioral economic text messaging vs. standard text messaging
224110298|NCT05209243|RADIATION|SBRT|SBRT (all metastatic lesions)
224110299|NCT05209243|RADIATION|STANDARD OF CARE|ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
224110300|NCT03663985|OTHER|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
224110301|NCT02571179|DRUG|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
224110302|NCT01019590|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
224110303|NCT01019590|DRUG|Benicar HCT ® Tablets 40 mg/25 mg|
224110304|NCT05331989|OTHER|patient group/ healthy group|Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
224110305|NCT04952389|DEVICE|Acupuncture Therapy|Consists of two treatments per week for five weeks
224110306|NCT04952389|DRUG|Budesonide|Twice daily nasal rinses with steroid medication (budesonide)
224110307|NCT04952389|OTHER|Olfactory Training|involves smelling 4 different essential oils (e.g. rose, lemon, clove, and eucalyptus) twice a day for 20 seconds each (after the nasal rinse)
224110308|NCT06512480|PROCEDURE|colonic resection|colonic resection with the Hugo RAS robotic platform.
224110309|NCT00934531|DRUG|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
224110310|NCT03442426|OTHER|Integrated model of primary care|Intervention includes: 1) consistent risk screening and assessment; 2) care coordination and system navigation; 3) patient/caregiver engagement and shared decision-making; and 4) enabling technology supports.
224110311|NCT02255591|DRUG|Lidocaine-adrenaline added gadolinium.|
224110312|NCT02500030|PROCEDURE|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
224110313|NCT02500030|PROCEDURE|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
223962746|NCT03000829|OTHER|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
223542326|NCT04280003|DRUG|Placebo solution|Placebo intravenous solution, same appearance stem cells solution
223542327|NCT04547465|DIAGNOSTIC_TEST|Echocardiography|2D Speckle-tracking echocardiography
223542328|NCT05722366|OTHER|Active video game|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
223542329|NCT05722366|OTHER|aerobic exercise|With the closed envelope method, the order in which the participants will perform active video games and aerobic exercise will be determined. It will be applied with 2 weeks between interventions.
223962747|NCT02529735|OTHER|efficiency study|Blood pressure values measured for comparative lower limb and arm
223962748|NCT04904354|DEVICE|AcQBlate® Force Sensing Ablation System|Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
223962749|NCT04992494|BEHAVIORAL|MBCT-Telephone|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
223962750|NCT04992494|BEHAVIORAL|MBCT-Video|"Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment."
223962751|NCT04168437|OTHER|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
223962752|NCT01430299|DEVICE|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
223962753|NCT01430299|DEVICE|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
223962754|NCT03394508|DRUG|ALK Alutard birch or 5-grasses|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.
223962755|NCT03394508|DRUG|ALK diluent 0,3% human albumin|Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval
223962756|NCT01107171|DRUG|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
223962757|NCT01107171|DRUG|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
223962758|NCT01107171|DRUG|Placebo|Tang-min-Ling pills analogue 6g,tid,po
223962759|NCT06466655|DRUG|MitoTempol|One intradermal microdialysis probes will be perfused with MitoTempol (0.5 mM) during a standard local skin heating protocol.
224110314|NCT02050048|OTHER|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~* initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~* LR fluid infusion during the procedure at 5 cc/kg/hr~* Post-procedure bolus of 20 cc/kg over 90 minutes"
223962760|NCT06466655|DRUG|Lactated Ringer's (control)|One intradermal microdialysis probes will be perfused with lactated Ringer's (control) during a standard local skin heating protocol.
223962761|NCT03214198|DRUG|Vonoprazan|Vonoprazan tablets
223962762|NCT06168994|DRUG|Eplerenone|Amiodarone vs eplerenone in AF
223962763|NCT03726528|DIAGNOSTIC_TEST|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
223962764|NCT02254200|OTHER|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
224110315|NCT03465735|COMBINATION_PRODUCT|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
223962765|NCT02254200|OTHER|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
223962766|NCT02779972|OTHER|Echo stress test|Echo stress test
223962767|NCT04552444|DRUG|Biapenem|In the course of CRKP treatment, double dose biapenem was selected.
223962768|NCT02966197|PROCEDURE|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
223962769|NCT02966197|DEVICE|Prophylactic internal iliac artery balloon|
223962770|NCT02966197|RADIATION|Radiology operation|
224110316|NCT03465735|DRUG|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
224110317|NCT00360516|BEHAVIORAL|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
224110318|NCT02377934|RADIATION|Cardiac Magnetic Resonance Imaging (MRI)|
224110319|NCT02664246|DEVICE|percutaneous coronary intervention|
224110320|NCT01884285|DRUG|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
223542330|NCT05011149|DRUG|Ibuprofen|"Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent."
223542331|NCT02757807|BEHAVIORAL|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
224110321|NCT01884285|DRUG|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
224110322|NCT01884285|DRUG|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
223962771|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with lidocaine hydrochloride injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing lidocaine hydrochloride. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
223962772|NCT05955768|PROCEDURE|Disposable cervical dilator stick combined with normal saline injection|The subject will undergo routine disinfection and receive cervical paracervical nerve block anesthesia (5mL of 1% lidocaine injection at the level of the bilateral sacral ligaments). After waiting for 2 minutes, the researcher gently checks the depth of the uterine cavity with a probe and then remove it. The nurse connects the disposable cervical dilator to the syringe containing normal saline. The researcher inserts the disposable cervical dilator into the cervical canal in line with the probe direction, and slowly inject drug from the syringe into it within a minute. The researcher waits for another minute before removing the disposable cervical dilator. The researcher removes the IUD with a ring hook. If necessary, the researcher will use metal Hegar dilators to dilate cervix.
223962773|NCT03363009|DEVICE|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
223962774|NCT03363009|DEVICE|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
223542332|NCT05547113|DIAGNOSTIC_TEST|posturography|In our stabilometric laboratory we use for the posturography two Kistler stabilometric platforms (type 5619A, Switzerland) along with MARS software (version 5.0, Switzerland). We use the SYNAPSIS Subjective Vertical device (version 1.3.2, France) to examine the perception of the subjective visual vertical. The patients should also full fill 5 questionnaires to subjective evaluation of non-vestibular symptoms within ADL and QoL, namely for difficulties related to dizziness, tinnitus, orofacial function disorders and the occurrence of anxiety and depression. For this purpose we use Dizziness Handicap Inventory, Tinnitus Handicap Inventory, Facial Disability Index, Beck's Anxiety Inventory and Beck's Depression Inventory.
223962775|NCT00363090|BIOLOGICAL|alemtuzumab|
223962776|NCT00363090|DRUG|cyclophosphamide|
223962777|NCT00363090|DRUG|doxorubicin hydrochloride|
223962778|NCT00363090|DRUG|prednisone|
223962779|NCT00363090|DRUG|vincristine sulfate|
223962780|NCT00363090|OTHER|flow cytometry|
223962781|NCT00363090|OTHER|pharmacological study|
224110323|NCT01884285|DRUG|Part D1: AZD2014 combination with AZD8186|Dose \& schedule finding of AZD8186 in combination with AZD2014
224110324|NCT01884285|DRUG|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
224110325|NCT01884285|DRUG|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
224110326|NCT02442999|OTHER|Screening for obstructive sleep apnea|
224110327|NCT02442999|DEVICE|CPAP - continuous positive airway pressure|
223962782|NCT03401099|PROCEDURE|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
223542333|NCT03988426|BIOLOGICAL|Octanorm|Octanorm
223542334|NCT00853892|DRUG|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
223542335|NCT00853892|DRUG|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
223542336|NCT02581436|OTHER|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
223962783|NCT03401099|PROCEDURE|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
223962784|NCT04650763|BIOLOGICAL|PRP injection|PRP was prepared using patient's blood and mixed with saline or mixture of calcium chloride and thrombin to form a liquid solution; in order to inject at the surgical site after placement of implant.
223962785|NCT04650763|DEVICE|Automated blood cell separator to extract PRP|Blood was withdrawn from antecubital vein and mixed with anticoagulant. Blood sample was then centrifuged to obtain platelet rich plasma which was injected at surgical site after implant placement.
223962786|NCT06428799|DEVICE|Carebot AI MMG|"Carebot AI MMG is a software solution that utilizes artificial intelligence methods, specifically deep learning and computer vision algorithms, to evaluate and localize suspicious regions of potential lesions during the interpretation of digital breast x-rays as part of standard mammography screening procedures. The Carebot AI MMG medical device is not intended for use in diagnostic mammography. The Carebot AI MMG is intended for use in women over the age of 18.~The predictive outputs of the Carebot AI MMG medical device are intended to aid decision-making in screening clinical practice, always in conjunction with other relevant patient information and based on the professional judgment of the examining clinician. The Carebot AI MMG is specifically designed to provide a supporting layer of analysis that helps in evaluating or prioritizing mammography images with additional patient information and the professional judgment of the examining physician."
223962787|NCT04295499|DEVICE|soft (hydrophilic) contact lens|The intervention is a daily wear soft contact lens
223962788|NCT05815459|DEVICE|OCOsense|Volunteers wear OCOsense glasses continuously during testing to monitor biobehavioural responses to tasks
224110328|NCT02267499|OTHER|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
224110329|NCT03212547|BEHAVIORAL|Verbal Intervention|"Promotion of verbal interventions:~1. Detecting whether the infant has social withdrawal.~2. The physician will verbally intervene.~3. Positive response (+) from the infant, the evaluator will point out this to the parents.~4. Negative response (-) from the infant, the evaluator will include the parents in the interaction.~5. If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~6. If the infant does not establish positive contact (-)with the parents, repeat step 2.~7. If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~8. At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
224110330|NCT03766997|DRUG|Compound Betamethasone Injection|local injection
224110331|NCT03766997|DRUG|Hydrocortisone Butyrate 0.1% Cream|topical use
224110332|NCT04591665|OTHER|swallowing examination|patients received swallowing examination, including high resolution impedance manometry and Video-Fluoroscopic swallowing study.
223962789|NCT03600207|OTHER|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
223962790|NCT03600207|OTHER|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
223962791|NCT03122548|BIOLOGICAL|CRS-207|Administered by IV infusion over 1 hour.
223962792|NCT03122548|BIOLOGICAL|Pembrolizumab|Administered by IV infusion over 30 minutes.
223962793|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
224110333|NCT06336824|DRUG|Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
224110334|NCT06336824|DRUG|IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline|"The choice of study drug will depend on the susceptibility of the respective isolate, expected drug interactions, contraindications, and expected side effects.~Investigators will assess whether the first-choice regimen can be given and then consider the alternative regimen. The antibiotics can be switched from first choice to the respective alternative medications during the intervention period if clinically necessary. The route of administration must be maintained according to the randomized group."
223962794|NCT01174472|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
223962795|NCT06200818|PROCEDURE|Diode laser|
223962796|NCT06200818|PROCEDURE|Er:CrYSGG|
223962797|NCT06200818|PROCEDURE|Formocresol|
223962798|NCT01946256|DRUG|Amoxicillin|
223962799|NCT01946256|DRUG|Erythromycin|
223962800|NCT04063670|OTHER|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
223962801|NCT04063670|OTHER|Control|Routine, Standard-of-Care
223962802|NCT04640779|DRUG|Choline Salicylate|Given PO
223962803|NCT04640779|DRUG|Selinexor|Given PO
223962808|NCT06359483|OTHER|Meal Frequency Manipulation|The intervention involves altering meal frequency among participants. One group consumes three standardized meals per day, while the other consumes eight smaller, more frequent meals. Meals are designed to meet nutritional needs and adhere to dietary guidelines. The aim is to assess the impact of meal frequency on bone remodeling by measuring the blood biomarker P1NP at various points during the study.
224110335|NCT06670677|OTHER|Lifestyle survey completion|For the next 10 years, starting at their inclusion in the research project and every 6 months thereafter: fill in an online survey on their lifestyle- health- socioeconomic environment. The completion of a survey lasts 5min maximum.
224110336|NCT06670677|OTHER|Unlimited on-demand blood pressure measurements with G2C|For the next 10 years: take unlimited on-demand measurements with the Aktiia G2C feature (finger measurement) while seated
223962809|NCT05174169|DEVICE|Signatera test|Central ctDNA testing for all patients
223962810|NCT05174169|DRUG|mFOLFOX6 3-6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles
223962811|NCT05174169|DRUG|CAPOX 3 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles
223962812|NCT05174169|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
223962813|NCT05174169|DRUG|mFOLFOX6 6 month|Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles
223962814|NCT05174169|DRUG|CAPOX 6 month|Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles
224110337|NCT06670677|OTHER|Continual blood pressure measurements with G1|For the next 10 years: wear their 24/7 Aktiia G1 device continuously as they would outside the context of the research project.
224110338|NCT02855814|OTHER|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
224110339|NCT05880758|BEHAVIORAL|Intermittent Short Sleep (ISS)|Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
224110340|NCT05880758|BEHAVIORAL|Social Jetlag (SJL)|2-hour delayed sleep timing.
224110341|NCT05880758|BEHAVIORAL|Sustained Adequate Sleep (SAS)|Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
224110342|NCT03536429|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
223962815|NCT06981702|OTHER|Exercise|. In our study, demographic information (age, gender, height, weight, education, marital status, occupation, where and with whom they live), additional diseases, medications used, whether they live in a rural or urban area, whether they have had any sleep problems before, and whether they have had any psychiatric diagnoses before will be recorded for all subjects. Before the exercise, students will fill out the Pittsburgh Sleep Quality Index to determine their sleep quality, the Morningness-Eveningness Scale to assess their chronotype, and the Beck Depression Inventory to measure their depressive symptom levels, and the results will be recorded. Students taking the body mechanics course will be asked to do aerobic exercises they learned in class, three days a week, including warm-up and cool-down, for a total of 60 minutes of exercise. The exercises will be performed on the same days and times each week. All exercises performed by the students for 8 weeks will be monitored by the resea
223962816|NCT02854982|PROCEDURE|therapeutic management of the prostate Cancer as usual|
223962817|NCT05172648|OTHER|oral spry|Pour sterile distilled water into a 30ml small-capacity spray bottle and spray 4 times at the patient's mouth. They are on the tongue and under the tongue, the left side and the right side of the mouth. The same spray bottle is used by the same person. Consistent dosage and strength.
223962818|NCT05172648|OTHER|Cotton swab|Moisten the mouth with sterile distilled water with an oral cotton swab.
223962819|NCT03346590|BEHAVIORAL|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
223962820|NCT04187378|DEVICE|Surgical Underbody Blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
223962821|NCT04187378|DEVICE|Surgical access blanket|Surgical blanket is used to maintain normothermia during abdominal surgery
223962822|NCT02135445|DRUG|TAK-385|TAK-385 tablet
223962823|NCT02135445|DRUG|Degarelix|Degarelix injection
223962824|NCT06985433|DEVICE|Vaginal light therapy - Once|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in single treatment session.
223962825|NCT06985433|DEVICE|Vaginal Light Therapy - Once|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in single treatment session.
224110343|NCT03536429|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
223962826|NCT06985433|DEVICE|Vaginal Light Therapy - Twice|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in two treatment sessions.
223962827|NCT06985433|DEVICE|Vaginal Light Therapy - Twice|Vaginal light therapy device will deliver UVA and blue light to target symptom causing microbes in two treatment sessions.
223962828|NCT06232395|DIAGNOSTIC_TEST|DNA test|circulating DNA test
223962829|NCT00635609|DRUG|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
224110344|NCT03619148|DEVICE|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
223962830|NCT00635609|DRUG|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
223962831|NCT06994611|PROCEDURE|MOSE application|The length of the tissue strips was judged using the specimen table and photographed for record. If the MVC of the first needle sample was ≥10mm, the tissue strip was placed into bottle A formalin for fixation. A second needle of tissue strip was pushed directly into the B-bottle formalin. If the first needle sample MVC was \< 10mm, the puncture was continued until the total length of sample MVC was ≥10mm, and all samples were placed into bottle A formalin.
223962832|NCT06994611|PROCEDURE|Conventional processing|Two needles were punctured and all tissue strips were placed into bottle A formalin.
223962833|NCT03991416|BEHAVIORAL|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
223962834|NCT03991416|BEHAVIORAL|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
223542337|NCT02581436|OTHER|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine \>25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
223542338|NCT02621437|OTHER|Osteopathy sessions|\- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
223962835|NCT01754389|DRUG|Tacrolimus|
223542339|NCT02621437|OTHER|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~* pain questionnaire with digital scale,~* quality of life survey: SF-12~* HAD (Hospital and Anxiety Depression) questionnaire"
223542340|NCT05362357|BEHAVIORAL|iSTART Web-app|30-day substance prevention web-app for students at a Hispanic Serving Institution.
223542341|NCT01100281|BEHAVIORAL|Neuropsychological examination|Examination including especially concept formation
223962836|NCT01754389|DRUG|Methotrexate|
223962837|NCT01754389|DRUG|Bortezomib|
223962838|NCT01754389|DRUG|Sirolimus|
223962839|NCT07004036|BEHAVIORAL|Occupation-based Self-Regulation Intervention Program|The intervention includes both group and individual applications. It has a large occupation/activity pool that can be selected in a person-centered manner. The activities are focused on supporting and developing the areas of influence in the sensory processing skills of individuals or the areas in executive functions, and providing occupations that will replace the screen and shape life in children for the screen abuse. It shapes the will, habits and routines necessary for the child to prefer alternative activities instead of the screen. For this purpose, an intervention program has been shaped to ensure that the child gains in the areas of daily life activities, productivity activities and leisure activities with the right developing skills, the child's wishes, the family's wishes, social expectations. As far as we know, it is the first flood regulation intervention program applied to children with screen addiction from an occupational therapy perspective.
224110345|NCT01477216|OTHER|ELSA 1-9|Measuring GI and II values for Finnish foods
224110346|NCT02088216|DRUG|N-acetylcysteine|600mg po twice a day for 12 months
224110347|NCT02088216|OTHER|On-demand treatment|receive as-needed therapy
224110348|NCT06143631|DRUG|Letrozole 2.5mg|Oral letrozole 2.5mg/day
223542342|NCT01100281|OTHER|MRI|MRI performed in T1-weighted three dimensional sequence
224110349|NCT06143631|OTHER|Placebo|Placebo capsule
224110350|NCT04661813|OTHER|EXTRA-CVD Virtual Care|"The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination."
224110351|NCT04285723|OTHER|alpelisib|Retrospective observational case-only study. There is no treatment allocation. Patients with severe or life-threatening PROS who have received alpelisib as part of a compassionate use program were invited to participate.
224110352|NCT00474227|BEHAVIORAL|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
224110353|NCT02001350|OTHER|Ultrasonography|
224110354|NCT00813475|DRUG|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
224110355|NCT00813475|DRUG|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
224110356|NCT03118843|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
223962840|NCT07004036|BEHAVIORAL|Family Awareness Training|Family awareness training on the harms of screen addiction and prolonged exposure to the screen, as a one-time event.
224110357|NCT01804595|OTHER|Sunscreen|
224110358|NCT01804595|BEHAVIORAL|Text-Message Reminders|
224110359|NCT01804595|OTHER|Sunscreen and Text Message Reminders|
224110360|NCT01804595|BEHAVIORAL|Education|
224110361|NCT04439578|DRUG|SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin|600 mg rifampicin was administered in the morning.
224110362|NCT00372164|PROCEDURE|American Society of Interventional Pain Physician Guidelines|
224110363|NCT04283877|DRUG|Methylphenidate|3 x 10 mg oral tablets. Single acute dose for all participants
224110364|NCT04283877|DRUG|Placebo oral tablet|3 x 10 mg oral lactose tablet for all participants
224110365|NCT00010023|DRUG|capecitabine|
224110366|NCT00010023|DRUG|cisplatin|
224291339|NCT04038086|DIAGNOSTIC_TEST|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
224291340|NCT04038086|OTHER|circadian rhythm|Blood and CSF will be collected five times throughout the day.
224291341|NCT04038086|DRUG|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
223542343|NCT00598819|DEVICE|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
223962841|NCT04448561|DRUG|ASP8082|oral
223962842|NCT04448561|DRUG|morphine|oral
223962843|NCT04448561|DRUG|Placebo|oral
223962844|NCT00997750|DRUG|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
224110367|NCT06209957|DRUG|Local corticosteroid injection|Local corticosteroid injection;1 ml of triamcinolone acetonide 40 milligram/1.0 mL
224110368|NCT06209957|DRUG|Platelet-rich Plasma Local injection|Platelet-rich Plasma (From 2-step centrifugation of patient blood) Local injection.
224110369|NCT04627350|OTHER|Response to pulmonary finding (nodule, mass)|Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax
224110370|NCT06345040|BEHAVIORAL|Virtual-reality intervention|For the experimental condition, participants will receive seven individual sessions of Virtual Reality Therapy conducted by a therapist trained in both eating disorder psychotherapy and virtual reality-based therapy, including avatar therapy. In the initial stage of therapy participants create a virtual avatar embodying their eating disorder voice. This enables the person to engage in real time face to face dialogue with the eating disorder voice. The main goal of the intervention is to encourage participants to stand up to the negative comments and commands made by the eating disorder voice and hereby increase their power and agency in the context of the eating disorder voice.
224110371|NCT06345040|BEHAVIORAL|TAU - specialized treatment|The control condition encompasses treatment as usual comprising seven sessions of specialized treatment, such as individual or group psychotherapy and dietary guidance, provided by interdisciplinary health professionals.
224291342|NCT00279955|DEVICE|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
224291343|NCT05106543|DEVICE|Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients|Kinesiological Taping
224291344|NCT03116321|DRUG|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
224291345|NCT05206487|DIETARY_SUPPLEMENT|Polydextrose|PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
224291346|NCT04714970|DEVICE|iTBS|Intermittent theta burst stimulation (iTBS) on left dlPFC. 90% RMT, 50Hz within train and 5Hz train for 2 second and rest for 8 second. 600 train and 200 second in total.
224291347|NCT04714970|DEVICE|Shame stimulation|TMS coil vertical to the brain surface, with same protocol as iTBS
224291348|NCT02896777|OTHER|Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
224291349|NCT02896777|OTHER|Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
224291350|NCT02896777|OTHER|Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
224110372|NCT05552638|OTHER|Telecare|The University of Kentucky (UK) will embed telehealth stations at community-based senior centers. Individuals who utilize these telehealth stations will be invited to complete a demographic survey prior to their telehealth appointment. Following their appointment, they will be invited to complete a semi-structured interview with the research team. Participants who elect to use telehealth station will be doing so as telehealth visits already scheduled with patients as Standard of Care (SOC). The telehealth station in the senior center will be used to increase ease and access to telehealth should the patient/provider choose to use such an approach (for example, in instances when the patient does not have sufficient technology, internet access, or capability to operate telehealth at home).
224110373|NCT04128657|DIAGNOSTIC_TEST|MA_LARS|Validation of the MA\_LARS and MA\_Wexner
224110374|NCT03078725|DRUG|Glyburide|oral hypoglycemic agent
224110375|NCT03078725|DRUG|Metformin|oral hypoglycemic agent
224110376|NCT02204540|BEHAVIORAL|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
224110377|NCT03175380|BIOLOGICAL|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
224110378|NCT06673186|OTHER|overdenture|Patient satisfaction (primary outcome) was measured by a visual analog scale (VAS). OHRQoL (secondary outcome) was measured by oral health impact profile (OHIP-14). Questions of VAS and OHIP-14 were evaluated after 3 months The patients were divided into two equal groups.
224110379|NCT06672263|DRUG|TQB3911 tablets|TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.
223542344|NCT04408677|DEVICE|Zilia Ocular|Measurement of the oxygen saturation in the eye fundus
223962845|NCT05968534|BEHAVIORAL|MOSAIC Plus|"This is a single-arm study. Participants will receive the intervention is called Mother AdvocateS In the Community (MOSAIC) Plus, an intervention to reduce depressive and PTSD symptoms and prevent additional intimate partner violence among pregnant women and mothers with children under 5 experiencing IPV. The MOSAIC Plus intervention will integrate interpersonal psychotherapy principles and skills into the MOSAIC intervention in order to expand it to address consequences of IPV, including depression and PTSD symptoms."
223542345|NCT01709526|BEHAVIORAL|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
223542346|NCT05745766|OTHER|Panoramic and lateral cephalometric radiography|The 2D-based assessments of the impacted maxillary canine will be achieved using panoramic and lateral cephalometric radiographs.
223962846|NCT06716385|DEVICE|MSiHy Silicone Hydrogel Soft Contact Lens|The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
223962847|NCT06716385|DEVICE|Monthly Silicone Hydrogel Contact Lenses (oA)|The daily wear, monthly disposable soft contact lens for the correction of myopia and hyperopia in person with non-diseased eyes.
224291351|NCT00654654|BIOLOGICAL|Autologous Human Fibroblasts (azficel-T)|"1. Collection of 3 mm biopsies~2. Two injection treatments of facial wrinkles and creases~3. Conduct of study assessments"
223962848|NCT02755844|DRUG|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
223962849|NCT02755844|DRUG|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
223962850|NCT02755844|DRUG|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
223962851|NCT06916156|DRUG|ANT3310|ANT3310 will be administered in combination with Meropenem. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.
223962852|NCT06916156|DRUG|Meropenem|Meropenem will be administered in combination with ANT3310. Participants will receive 3 intravenous infusions of the combination MEM-ANT3310 every 8 hours. Infusions will be delivered through an infusion line over 3 hours at a constant rate.
223962853|NCT07064473|DRUG|Vicadrostat|Vicadrostat
223962854|NCT07064473|DRUG|Empagliflozin|Empagliflozin
223962855|NCT07064473|DRUG|Placebo matching Vicadrostat|Placebo matching Vicadrostat
223962856|NCT06118931|BEHAVIORAL|Early (7:00 - 16:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 7:00 to 16:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 7:00, and not consume anything else for two hours.
223962857|NCT06118931|BEHAVIORAL|Mid (9:30 - 18:30) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 9:30 to 18:30 for 7 days. On the 8th day, they will consume a meal replacement beverage at 9:30, and not consume anything else for two hours.
223962858|NCT06118931|BEHAVIORAL|Late (12:00 - 21:00) TRE|A standardized TRE Protocol where participants eat ad libitum between the hours of 12:00 to 21:00 for 7 days. On the 8th day, they will consume a meal replacement beverage at 12:00, and not consume anything else for two hours.
223962859|NCT07065214|DEVICE|APC|For the surgical procedure for ovarian endometrioma treatment APCapplicator will be used
223962860|NCT07065214|DEVICE|Lap bipolar forceps|For ovarian endometrioma treatment the standard of care treatment will be performed.
223962861|NCT07072650|DRUG|Dexmedetomidine|Studying combining a local anesthetic with dexmedetomidine (DEX) in a quadratus lumborum block (QLB) following a cesarean section (CS) in elective surgery in Bint Al-Huda Hospital.
223962862|NCT02363296|DEVICE|TMS|Paired associative stimulation and single pulse TMS
223962863|NCT02998229|DEVICE|Artisse™ Intrasaccular Device|Intrasaccular Device
223542347|NCT05745766|OTHER|Cone beam computed tomography|The 3D-based assessments of the impacted maxillary canine will be achieved using a cone beam computed tomography (CBCT) image.
223542348|NCT05745766|OTHER|Surgery|The surgical exposure will be accomplished, and the impacted maxillary canine will be assessed by a direct vision.
223542349|NCT04389866|DEVICE|JUVÉDERM VOLUMA™ XC|Injectable gel
223542350|NCT05200312|DRUG|Zanubrutinib|160 mg capsules administered by mouth twice daily (21-day cycles).
223542351|NCT05200312|DRUG|Lenalidomide|25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
223962864|NCT07075367|OTHER|Proximal/distal protocol|The experimental group will receive a proximal/distal exercise program (trunk, hip, knee and ankle) consisting of four stages: warm-up, strengthening, sensorimotor training and relaxation.
223962865|NCT07075367|OTHER|Distal protocol|The control group will receive a distal exercise program available in the literature and previously tested. This will contain warm-up exercises, intrinsic foot muscle strengthening, extrinsic foot-ankle muscle strengthening, and functional exercises.
223962866|NCT06940674|DRUG|Cannabidiol|1 capsule CBD 200mg
223542352|NCT05200312|DRUG|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223962867|NCT06940674|DRUG|Placebo|Bovine Gel Placebo capsule
223962868|NCT07115940|DEVICE|Endovascular Thrombectomy|EVT will be provided in addition to medical management and is a procedure to remove a thrombus in one of the brain arteries that is obstructing the blood flow and is responsible for the occurrence of stroke. Removing this occlusion results in restoration of blood flow to ischemic brain tissue and salvages the parts that are still viable, which is expected to improve functional outcomes. Endovascular thrombectomy procedure will be performed using stent retrievers, aspiration devices or combination approach at the discretion of the treating physician, using devices approved by the local regulatory authority. For patients treated in the United States of America, only US Food and Drug Administration-approved neurothrombectomy devices can be used.
223542353|NCT05200312|DRUG|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223542354|NCT05200312|DRUG|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223542355|NCT05200312|DRUG|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
223962869|NCT07115940|OTHER|Medical Management|Medical management comprises various measures to prevent further deterioration, enhance patients' outcomes and prevent occurrence of a secondary stroke in short and long term. This includes 1) evidence-based practices for blood pressure management 2) Neurocritical care monitoring with appropriate osmotic therapy and neurosurgical interventions such as hemicraniectomy for management of cerebral edema that occurs due to infracted brain tissue based on local institutional protocol, 3) stroke etiology identification by requisite neurology , cardiology, immunology evaluations and 4) short and long-term strategies for secondary stroke prevention, including anticoagulation, antiplatelet therapy, medical optimization and modification of stroke risk factors such as hypertension, hyperlipidemia, diabetes and other potential comorbidities.
223962870|NCT07144436|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
223962871|NCT05579769|DRUG|Ruxolitinib|Day +40 Dosage and Route of Administration-Ruxolitinib tablets should be administered orally BID, approximately every 12 hours, continuously, Oral
223962872|NCT05579769|DRUG|Mesna|Days -3 and -2 Dosage and Route of Administration-Mesna is dosed based on the cyclophosphamide dose and generally administered in fractionated doses at approximately 20% of the total cyclophosphamide dose, Intravenous.
223962873|NCT05579769|DRUG|Anti-thymocyte globulin (ATG)|Days -3, -2 and -1 Dosage and Route of Administration-(7 mg/kg total dose); intravenous.
223962874|NCT05579769|DRUG|Cyclosporine|Day -1 Dosage and Route of Administration-3 mg/kg; dose will be adjusted to maintain a steady concentration between 250-350 ng/mL or trough concentration between 175-250 ng/mL when transitioned to intermittent dosing.
224110380|NCT06863558|DRUG|PPA Intervention|"Participants in this group will receive a pharmacological cocktail (PPA) for five days in addition to standard medical treatment for acute ischemic stroke. The regimen includes terazosin or urapidil, and propranolol or esmolol, with individualized blood pressure management. The specific protocol is as follows:~* Terazosin (no less than 1 mg orally or via nasogastric tube, nightly) or Urapidil (100 mg in 30 mL saline, IV infusion at no less than 2 mL/h)~* Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond 48 hours, switch to Propranolol)"
224110381|NCT06594640|DRUG|Mitoxantrone Hydrochloride Liposome|assigned dose according to the 3+3 dose-escalation design in part 1, RP2D in part 2, D2
224110382|NCT06594640|DRUG|Rituximab (R)|375mg/m2, D2
224110383|NCT06594640|DRUG|Cyclophosphamide (CTX)|750mg/m2, D2
224110384|NCT06594640|DRUG|Vincristin|1.2mg/m2, maximum 2mg， D2
224110385|NCT06594640|DRUG|Prednisolone|60mg/m2, D2-6
224110386|NCT04936425|DEVICE|OTSC Stentfix|The OTSC stentfix will be placed during upper endoscopy after a self-expanding metal stent has been deployed.
224110387|NCT01507246|DRUG|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
224110388|NCT01507246|DRUG|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
224110389|NCT02597595|OTHER|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
224110390|NCT03044665|DRUG|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
224110391|NCT03044665|DRUG|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
224110392|NCT01982201|DRUG|Lesinurad 400 mg|
224110393|NCT01982201|DRUG|Tums 500 mg and 750 mg|
224110394|NCT01982201|DRUG|MINTOX 10 mL|
224110395|NCT03063073|DRUG|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection \[Precedex\]
224110396|NCT03063073|DRUG|Bupivacaine|
224110397|NCT00213018|DRUG|Carraguard (PC-515)|
224110398|NCT04411238|OTHER|interview|interview
224110399|NCT04902950|DRUG|Tranexamic acid|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The Tranexamic acid soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
223962875|NCT05579769|DRUG|Cyclophosphamide|Days -3 and -2 Dosage and Route of Administration-60 mg/kg for 2 consecutive days, (120 mg/kg total dose); intravenous.
223962876|NCT05579769|DRUG|Fludarabine|Days -4, -3 and -2 Dosage and Route of Administration-50 mg/m2 daily for 3 consecutive days (150 mg/m2 total dose) intravenous
223962877|NCT05579769|DRUG|Methotrexate|Days +1, +3, +6 and +11 Dosage and Route of Administration-10 mg/m2/dose, intravenous
223962878|NCT05579769|RADIATION|Total Body Irradiation (radiation treatment)|"Days -7, -6, -5 and -4 6.2.3 Target Dose 1200 cGy total dose delivered 150 cGy per treatment fraction delivered BID over 4 days with 6 MV photons.~Dose rate should be \< 10 cGy/min in patients treated at extended SSD (450-500 cm) in the TBI couch and will be less than 15 cGy/min in young children and infants treated at extended SSD (200-220 cm) on the floor.~Intra-fraction interval should be 6 hours. Custom posteriorly placed (PA only) partial transmission lung shields (blocks) will be used to reduce the average dose to the lung to approximately 1000 cGy total dose.~An additional 400 cGy supplemental testicular radiation delivered in 2 fractions of 200 cGy delivered for males with lymphoid lineage leukemia."
223962879|NCT05579769|DRUG|Bone marrow infusion|Day 0
223962880|NCT05579769|DRUG|Busulfan|Days -4, -3 and -2 Dosage and Route of Administration-3.2 mg/kg/day; intravenous.
223962881|NCT05579769|DRUG|Thiotepa|Days -6 and -5 Dosage and Route of Administration-(10 mg/kg total dose); intravenous
223962882|NCT07143305|OTHER|Multicomponent physical exercise programme|Participants engaged in a multicomponent physical exercise programme designed specifically for older adults. The programme was based on the latest evidence and international recommendations for sarcopenia and functional maintenance in ageing population.
223962883|NCT07147803|OTHER|Pittsburgh Sleep Quality Index|PSQI (Arabic validated version) - main sleep measure; global score 0-21; PSQI \>5 = poor sleep quality.
223962884|NCT07148011|DIETARY_SUPPLEMENT|Revive Product Form - Placebo Control|Participants will use their Revive Product Form - Placebo Control as directed for a period of 12 weeks.
223962885|NCT07148011|DIETARY_SUPPLEMENT|Revive Product Form - Active|Participants will use their Revive Product Form - Active as directed for a period of 12 weeks.
223962886|NCT06954610|OTHER|No intervention|No intervention
223962887|NCT07160634|DRUG|SGT-003|Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)
223962888|NCT07160634|DRUG|Placebo|IV infusion
223962889|NCT07160712|DIETARY_SUPPLEMENT|Relief Product Placebo Control|Participants will use their Relief Product Control as directed for a period of 6 weeks.
223962890|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 1|Participants will use their Relief Active Product 1 as directed for a period of 6 weeks.
223962891|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 2|Participants will use their Relief Active Product 2 as directed for a period of 6 weeks.
224291352|NCT04816747|BIOLOGICAL|Autologous PRP|Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
224291353|NCT01770431|DRUG|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
224291354|NCT04948957|DRUG|Esmolol|
223962892|NCT07160712|DIETARY_SUPPLEMENT|Relief Active Product 3|Participants will use their Relief Active Product 3 as directed for a period of 6 weeks.
223962893|NCT05773274|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223962894|NCT05773274|DRUG|Cabozantinib|Given PO
223962895|NCT05773274|PROCEDURE|Computed Tomography|Undergo CT scan
223962896|NCT05773274|DRUG|Everolimus|Given PO
223962897|NCT05773274|DRUG|Lutetium Lu 177 Dotatate|Given IV
224291355|NCT04948957|DRUG|Nitroglycerin|
224291356|NCT02328950|DRUG|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
224291357|NCT00674401|PROCEDURE|Radiofrequency catheter ablation|"* In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~  1. Empirical pulmonary vein antrum circumferential isolation, or~ 2. High frequency sites ablation in the LA~* In case of Persistent AF, patients will be randomized into one of 2 in the study:~  1. Empirical circumferential PV antrum isolation w/out roof line, or~ 2. A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
224291358|NCT04462016|OTHER|Calamansi|250 ml of a commercially sourced calamansi drink
224291359|NCT04462016|OTHER|Glucose|75 g of glucose dissolved in 250 ml of drinking water
224291360|NCT06437418|DIAGNOSTIC_TEST|abdominal ultrasonography.|Evaluate the gallbladder ejection fraction (EF)
224291361|NCT02691832|DEVICE|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
224291362|NCT00911599|DIAGNOSTIC_TEST|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
224291363|NCT03329807|DEVICE|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
224291364|NCT03329807|BEHAVIORAL|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
224291365|NCT04008537|DEVICE|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
223962898|NCT05773274|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223962899|NCT05773274|OTHER|Quality-of-Life Assessment|Ancillary studies
223962900|NCT05773274|OTHER|Questionnaire Administration|Ancillary studies
223962901|NCT05773274|DRUG|Sunitinib|Given PO
223962902|NCT07164040|DEVICE|The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG|When activating the GLOW800 mode, the white light illumination of the Leica microscope stand is extended to InfraRed (IR), to excite the fluorophore (ICG). The technology provides ergonomic advantages as the user can maintain an upright posture while observing the surgical field. To excite the fluorophore, ICG dye is illuminated with light at its excitation wavelength band around 750 - 800nm. GLOW800 utilizes a 400w xenon illumination light source integrated as a standard component within the compatible Surgical Operating Microscope (SOM) stand. Activation of the GLOW800 mode extends the white light illumination of the SOM to the infrared (IR) spectral range using a suitable filter placed in the compatible SOM's standard filter wheel for the excitation of the ICG. Each patient enrolled in this study will undergo standard of care for the surgical procedure. No deviations to the standard of care will occur in the execution of this study.
223962903|NCT07159308|BEHAVIORAL|Intrinsic Motivation Treatment|The Intrinsic Motivation treatment utilizes principles of Motivational Interviewing to help autistic young adults increase their desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60 minutes long. The goals of the treatment are to enhance motivation and behavior change.
223962904|NCT07159308|BEHAVIORAL|Extrinsic Motivation Treatment|The Extrinsic Motivation treatment utilizes behavioral principles to help autistic adolescents and young adults create reward schedules and behavioral tracking sheets to enhance desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60 minutes long. The goals of the treatment are to enhance motivation and behavior change.
223962905|NCT07159308|BEHAVIORAL|Combined Intrinsic and Extrinsic Motivation Treatment|The Combined Intrinsic and Extrinsic Motivation treatment combines elements of both intrinsic and extrinsic motivation treatments to enhance desire and completion of daily living skills. This is a five-session intervention. Each clinical session is 60-90 minutes long. The goals of the treatment are to enhance motivation and behavior change.
223962906|NCT07166107|OTHER|EVOLV-Rx dashboard|Using the TheraDoc® platform, the investigators will deploy a custom-designed EVOLV-Rx dashboard that incorporates all 18 components of the EVOLV-Rx metric. \[Within TheraDoc®, the dashboard will display an automated report in the form of a patient list that includes the names, locations, and specific LVP practices to which Veterans under their care are subject. Pharmacists will then query specific patients on the list as part of their required medication review. The dashboard will provide detailed clinical decision support by identifying the specific EVOLV-Rx LVP criteria met by each flagged medication and provide access to the patient's full medication list, problem list, and laboratory or testing data contained within VISTA.\] Pharmacists may use the EVOLV-Rx dashboard to track Veterans' receipt of LVP practices and quickly document actions related to the intervention, such as patient and family caregiver engagement, deprescribing LVP practices, or any other medications discontinued.
223962907|NCT07170397|DEVICE|Acupuncture Laser Therapy|Application of low-level laser therapy to patients with chronic kidney disease to evaluate its effects on pain, circulation, and functional outcomes
223962908|NCT07166523|DIETARY_SUPPLEMENT|Energy Product Placebo Control|Participants will use their Energy Product Placebo Control as directed for a period of 6 weeks
223962909|NCT07166523|DIETARY_SUPPLEMENT|Energy Active Product 1|Participants will use their Energy Active Product 1 as directed for a period of 6 weeks
223542356|NCT05200312|DRUG|Prednisone (or equivalent)|40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
223962910|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223962911|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223962912|NCT07181720|BIOLOGICAL|CD70-targeted CAR-T cells|Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223962913|NCT07180342|BEHAVIORAL|Tourism-based intervention|Following the acquisition of participant consent and the signing of (electronic) informed consent forms, subjects were randomized into either an intervention group or a control group using a computer-generated randomization list. The intervention group received a tourism-based intervention, while the control group continued to receive usual care without any structured modifications to their daily living patterns or treatment plans. Both groups maintained a foundational treatment regimen of antidepressant medication.
223962914|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223962915|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223962916|NCT07179692|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223962917|NCT07204119|OTHER|Tissue Flossing Technique|Hot pack: 10 minutes, PNF (hold-relax with agonist contraction), CPM: 10 minutes, Self-stretching: End range position for 30 seconds, repeat twice. 1 to 2 minutes for Tissue Flossing Technique Description: Active and passive movement with knee wrapped in a high-quality floss band (208×5×0.15 cm), Wrapped from upper gastrocnemius to lower quadriceps and hamstring muscles using a 50% overlapping pattern with a 25% elongation stretch, Series of active and passive exercises (knee flexion and extension) with 3 repetitions.
223962918|NCT07204119|OTHER|Graston Technique|"Hot pack: 10 minutes, PNF (hold-relax with agonist contraction), CPM: 10 minutes, Self-stretching: End range position for 30 seconds, repeat twice.~2 minutes for Graston Technique Technique Description: Participant lies supine with hip and knee straight, Water-based gel used to reduce friction.~Superior and inferior longitudinal strokes delivered with GT-4 instrument at a 45° angle to soft tissues Sequence includes strokes from above patella to anterior inferior iliac spine (AIIS) and back, maintaining a 2-second cadence"
223962919|NCT07204119|OTHER|Control group|Hot pack: 10 minutes, PNF (hold-relax with agonist contraction): Gentle stretch of knee muscle for 10 seconds Isometric contraction for 6 seconds. Flex knee with therapist assistance. Hold position for 10 seconds, repeat 3 times, CPM: 10 minutes, Self-stretching: End range position for 30 seconds, repeat twice
223962920|NCT07203469|BEHAVIORAL|Universal approach|In this intervention, the whole class participates in a 12-week nature-based experiential education program
223962921|NCT07203469|BEHAVIORAL|Selective approach|In this intervention, an intentional group of pupils with an identified need is recruited from different classes within the same school to participate in a 12-week nature-based experiential education program
223962922|NCT07203469|BEHAVIORAL|Outdoor therapy|This intervention is a 10-week outdoor therapy group treatment that takes place in nearby nature
223962923|NCT07203469|BEHAVIORAL|Climbing therapy|This intervention is a 10-week climbing therapy group treatment that takes place indoors in a climbing hall
223962924|NCT07200895|DEVICE|Inspiratory Muscle Training (30% MIP)|Single supervised session of threshold-loaded inspiratory muscle training set at 30% of baseline maximal inspiratory pressure (MIP); 3 sets × 30 breaths (\~15 minutes) following a standardized diaphragmatic-breathing warm-up.
223962925|NCT07200895|DEVICE|Inspiratory Muscle Training (60% MIP)|Single supervised session of threshold-loaded inspiratory muscle training set at 60% of baseline maximal inspiratory pressure (MIP); 3 sets × 30 breaths (\~15 minutes) following the same standardized warm-up.
223962926|NCT07204652|DIAGNOSTIC_TEST|No Intervention: Observational Cohort|No Intervention: Observational Cohort
224291366|NCT03913897|OTHER|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
224291367|NCT04191798|BEHAVIORAL|Telerehabilitation using the KinexConnect system for rehabilitation after TKA.|KinexConnect subjects are asked to Perform CPM therapy for 4 weeks. Perform a KCK home exercise program (HEP) for 6 weeks.
224110400|NCT04902950|DRUG|Saline|"After the abdominal skin and subcutaneous tissue is raised, the area will be irrigated, and hemostasis achieved using electrocautery. These steps are currently preformed with every panniculectomy. The saline soaked lap sponges will be unfolded and placed beneath the two lateral portions as well as the central area of the flap for 3 minutes. The lap sponges will not be rung out prior to placement. The surface area under the flap will be measured from the xiphoid process to the pubis, from the Xiphoid process to each anterior superior iliac spine (ASIS) and across from one ASIS to the other. These measurements will be used to calculate the surface area under the flap. These measurements will only be used in data collection and do not affect the principle aim of the study. The remainder of the surgical procedure will be the same for each patient."
223962927|NCT07203703|DEVICE|Jaw Tracking Device|A jaw tracking device is a digital tool that records real-time jaw movements to accurately analyze occlusion and assist in virtual model mounting.
223962928|NCT07203456|OTHER|Virtual Patient Based Learning (VPBL)|A digital platform featuring 20 virtual patients has been built to increase predoctoral student clinical exposure to patients with TMD signs and symptoms
223962929|NCT07203456|OTHER|Clinical exposure to patients with TMD|Participants in this arm will be exposed to patients with TMD signs and symptoms, to the history taking, interview, clinical examination, diagnostic process, and treatment plan under the supervision of an orofacial pain specialist
224110401|NCT06673173|OTHER|Implant|A long cone paralleling approach with a specially made film holder will be used to assess each patient's vertical marginal bone loss to ensure standardized radiography analysis and avoid any magnification errors. The linear distance between the proximal crestal bone level and the implant shoulder will be measured at the mesial and distal aspects of the implant measured in millimeters (mm). Measurements will performed using image measurement software patient satisfaction comparison between 2 groups
223962930|NCT07203456|OTHER|Clinical exposure to TMD + VPBL|Participants will be exposed to patients with TMD signs and symptoms (including history taking, interview, clinical exam, diagnostic process, and treatment plan) under the supervision of an orofacial pain specialist, and then will be exposed to the corresponding TMD patient on the VPBL, featuring virtual patients with TMD
223962931|NCT07202962|DRUG|medication review and deprescribing|"The study protocol includes the following assessments:~* T0: first data collection upon admission to the ward;~* T1 assessment: pharmacological review at discharge. Subjects who meet all study eligibility criteria will come consecutively enrolled in the study during admission to the department (T0).~By consulting the electronic health record, interviewing patients and family members and personal documentation, the following data will be collected:~* Remote and immediate pathological history;~* Family and social history;~* Home therapy;~* BRIEF-MPI. Home therapy and therapy suggested at discharge will be compared with the STOPPandSTART criteria to evaluate the prevalence of potential therapies inappropriate and to study possible interactions and contraindications pharmacological and for reporting possible adverse reactions to drugs. The prevalence and possible prevalence of each individual STOPPandSTART criterion will be assessed association with other variables of interest."
224110402|NCT06869642|BEHAVIORAL|Doing Pasat-Test|PASAT-Test either with or without doing chest compressions
224110403|NCT06869642|PROCEDURE|Chest compressions|Performing chest compressions as desribed in the ERC Guidelines
224110404|NCT05178901|BIOLOGICAL|PHV02|live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection
224110405|NCT05178901|OTHER|Placebo|Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
224110406|NCT03199092|BEHAVIORAL|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
223962932|NCT07204743|DRUG|Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy|Participants will receive dapagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor, administered once daily at a dose of 5-10 mg. The intervention is intended to reduce proteinuria and provide nephroprotection in pediatric patients with kidney disease. Patients will be followed monthly, with monitoring of renal function markers (serum creatinine, blood urea nitrogen, and estimated glomerular filtration rate) and 24-hour urinary protein excretion normalized to body surface area, in addition to safety outcomes such as hypoglycemia, dehydration, and urinary tract infections.
223962933|NCT07203430|OTHER|45-Degree Roman Chair Exercise|Participants in the intervention group will perform 3 sets of low back extension exercise on the Roman chair until volitional exhaustion. The three sets will be performed to volitional exhaustion or 20 repetitions, whichever comes first. If more than 20 repetitions can be completed after a set the investigator will add resistance according to the NSCA's guidelines (2.5-10% increase).
223962934|NCT07202832|DRUG|potassium citrate|Potassium citrate is a medication used to alkalinize the urine, providing symptomatic relief of dysuria in patients with urinary tract infections (UTIs). In this study, participants in Arm 1 will receive potassium citrate for a period of 7 days. The treatment is aimed at reducing discomfort related to UTIs, such as burning sensations during urination and suprapubic pain. In addition to symptomatic relief, the intervention may also enhance bacterial phagocytosis and bacterial killing in the urine. Participants will be monitored for any side effects or adverse events during the treatment period.
223962935|NCT07202832|DRUG|Nitrofurantoin|Nitrofurantoin is an antibiotic commonly used to treat uncomplicated urinary tract infections (UTIs). In this arm, participants will receive Nitrofurantoin for 7 days to treat their UTI. The primary objective is to evaluate its effectiveness in reducing UTI symptoms, such as dysuria, urgency, frequency, and suprapubic discomfort. This intervention will be compared with the urinary alkalinization therapy used in Arm 1. Researchers will also monitor changes in urine culture and any adverse events related to the antibiotic treatment.
223962936|NCT05545319|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours
223962937|NCT05545319|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
223962938|NCT05545319|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir (or 1 tablet for participants with eGFR or eCrCl ≥30 to \<60 mL/min) every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
223962939|NCT00816621|BEHAVIORAL|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
223962940|NCT00816621|BEHAVIORAL|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
223962941|NCT04163185|DRUG|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
224110407|NCT03199092|BEHAVIORAL|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
223962942|NCT04163185|DRUG|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
223962943|NCT05624086|BEHAVIORAL|exercise|Hepatitis-C Men With Sexual Dysfunction (erectile dysfunction) Complaint will receive exercise-training sessions (one hour walking on treadmill, for 3 months, three walking sessions per the week)
223962944|NCT01886391|BEHAVIORAL|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
223962945|NCT03698305|DRUG|ASP5354|Intravenous
223962946|NCT03698305|DRUG|Placebo|Intravenous
223962947|NCT04309006|PROCEDURE|CTG and customized healing abutment|screw- retained customized healing abutment
223962948|NCT04309006|PROCEDURE|CTG and conventional healing abutment|conventional healing abutment
223962949|NCT05583864|DEVICE|CONDUIT Porous Titanium Spinal Cage|Already included in arm/group descriptions.
223962950|NCT05583864|DEVICE|PROTI 360 Titanium-Coated PEEK Spinal Cage|Already included in arm/group descriptions.
224291368|NCT04191798|BEHAVIORAL|Traditional outpatient PT for rehabilitation after TKA.|Control subjects are asked to undergo standard outpatient physical therapy (PT) with a licensed physical therapist plus supplemental home exercises as directed. Nominally patients are expected to have 3 PT sessions per week for 4 weeks.
223962951|NCT04851587|BEHAVIORAL|In-Person (or Remote) Intervention|Participants will be asked to engage in self-administered activities during the intervention including pleasant activity scheduling, values clarification, mindfulness practice, goal setting, standard pain coping skills, and weight management including nutrition education and physical activity monitoring.
223962952|NCT06010368|DRUG|Tranexamic acid injection|In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
223962953|NCT06010368|DRUG|Oxytocin|the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
223962954|NCT06721702|BEHAVIORAL|Motivational interviewing|Motivational interviews were administered as the intervention of the research. Motivational interviewing consists of two stages. In the first stage, the four principles of motivational interviewing (developing contradiction, showing empathy, supporting self-efficacy, and resolving resistance) are aimed at providing motivation in individuals. The second stage is strengthening the commitment to change.
223962955|NCT03697837|BEHAVIORAL|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
223962956|NCT01407302|OTHER|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
223962957|NCT02136797|BIOLOGICAL|CMVpp65 Specific T-cells|
223962958|NCT00040521|DRUG|Recombinant Human Interleukin-11 (rhIL-11)|
223962959|NCT01903928|BIOLOGICAL|ASP0113|injection
223962960|NCT06313099|OTHER|Survey|Participants' musculoskeletal system disorders were assessed using the Cornell Musculoskeletal Disorders Questionnaire (CMDQ), fatigue levels were measured using the Fatigue Severity Scale (FSS), sleep quality was evaluated using the Visual Analog Scale (VAS), depression levels were assessed using the Beck Depression Inventory (BDI), and quality of life was measured with the Nottingham Health Profile (NHP). Google Forms was used to create the data collection tools, which were then sent to the participants' email addresses and collected online.
224110408|NCT06260150|DEVICE|Intermittent Pneumatic Compression Devices|During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
223962961|NCT02039297|OTHER|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
224110409|NCT02762864|OTHER|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
224110410|NCT02762864|DRUG|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
223962962|NCT06127485|PROCEDURE|Neuropilates+occupational therapy and physiotherapy conventional|Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.
223962963|NCT06127485|PROCEDURE|Occupational Therapy and Physiotherapy conventional|Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
223962964|NCT02585752|DEVICE|Noninvasive ventilation|Expiratory pressure modulation
223962965|NCT02041845|RADIATION|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
223962966|NCT02041845|RADIATION|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
223962967|NCT04107844|DIAGNOSTIC_TEST|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
224110411|NCT02762864|DRUG|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
223962968|NCT03694210|DEVICE|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
224110412|NCT05508568|DIAGNOSTIC_TEST|ADXBLADDER|ADXBLADDER is a non-invasive, qualitative ELISA utilising a combination of two monoclonal antibodies for the detection of MCM5 in urine sediment. It is intended to aid in the monitoring of bladder cancer recurrence in non-muscle-invasive bladder cancer patients. Participants will be asked to provide a full void urine specimen, which will be centrifuged before the urine sediment is lysed. The lysed sample will then be tested with ADXBLADDER.
224110413|NCT00003803|DRUG|cisplatin|
223962969|NCT03016364|DEVICE|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
223962970|NCT02706834|DRUG|TAK-828|TAK-828 oral solution
223962971|NCT02706834|DRUG|Placebo|TAK-828 placebo-matching oral solution
223962972|NCT05358184|DEVICE|High frequency Percussive ventilation|High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
223962973|NCT03519906|DRUG|Metoprolol|Patients are tested for their normal prescription metaprolol medication
223962974|NCT00627523|DRUG|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
223962975|NCT00627523|DRUG|Control-no treatment|Control-no treatment
223962976|NCT02904291|DRUG|Amlodipine|Patients are tested for their normal prescription amlodipine medication
224110414|NCT00003803|DRUG|gemcitabine hydrochloride|
224110415|NCT00003803|RADIATION|radiation therapy|
224110416|NCT02730702|DEVICE|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
224110417|NCT04358913|DEVICE|MR scan with the Alberta linac-MR P3 system|Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
223962977|NCT05030467|BEHAVIORAL|REDUCE-BP Intervention|"Pre-visit:~Providers in the intervention arm will receive dashboards which will highlight racial/ethnic differences in rates of achieving blood pressure control within their patient panel. The dashboard will also provide individual-level information for patients with poorly controlled blood pressure.~During visit:~Providers will receive clinical decision support within relevant patients' charts that highlight the patient's under-treated blood pressure and potential impacts of social needs.~Providers will have the opportunity to provide enhanced patient education materials, which can be automatically ordered within the clinical decision support.~Post-visit:~Patient-subjects' access to the online patient portal will be streamlined by the inclusion of information about the patient portal in the patients' after-visit summary. Providers will also be able to referral patients automatically to nurse BP visits."
223962978|NCT04768491|DRUG|Dacomitinib|effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
223962979|NCT02543294|DEVICE|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
223962980|NCT02543294|DEVICE|Electrocardiogram|Electrocardiogram performed at baseline.
223962981|NCT02543294|BEHAVIORAL|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
223962982|NCT02543294|BEHAVIORAL|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
223962983|NCT05681390|DRUG|Tislelizumab|Tislelizumab 200mg iv drip, d1, Q3W;Anlotinib tablet : 10mg, PO, QD; Chemotherapy: selected by investigator following CSCO or NCCN pancreatic adenocarcinoma guideline; Tislelizumab and Anlotinib continue unless disease progression or intolerance to toxicity, chemotherapy continue upto 8 cycles unless disease progression or intolerance to toxicity
223962984|NCT00406276|DRUG|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
223962985|NCT00406276|DRUG|Docetaxel|In combination with RAD001
223962986|NCT00799188|DRUG|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
223962987|NCT00211926|BIOLOGICAL|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
223962988|NCT00211926|BIOLOGICAL|placebo|single dose of placebo
223962989|NCT00160537|DRUG|Levocetirizine|
223962990|NCT02181192|DEVICE|PET/CT|PET/CT
223962991|NCT02181192|RADIATION|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
223962992|NCT02181192|RADIATION|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
223962993|NCT01038128|DRUG|Memantine|Drug: Memantine, 10-40 mg daily
223962994|NCT01769352|DRUG|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
223962995|NCT02403414|DEVICE|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
223962996|NCT01133600|DRUG|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is \<30ml/min.
223962997|NCT01133600|DRUG|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
223962998|NCT01686256|DRUG|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
223962999|NCT04231175|DIAGNOSTIC_TEST|DWI MRI of the pelvis, abdomen and thorax|Patients in Arm A will receive a MRI scan of their pelvis, abdomen, and thorax before possible surgery. During the MRI standard Gadolinium contrast agent and Buscopan is intravenously administered, which is standard clinical practice in abdominal MR imaging. Total scan time is 35 minutes and includes T2 weighted, T1 weighted, Diffusion weighted and dynamic contrast enhanced imaging of the abdomen and the thorax. The findings of this scan will be used to determine whether to proceed with CRS/HIPEC, DLS and then possibly CRS-HIPEC, or palliative care.
223963000|NCT00487253|DRUG|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
223963001|NCT00487253|DRUG|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
223963002|NCT00800917|DRUG|Temsirolimus|25 mg weekly IV
223963003|NCT00800917|DRUG|Bevacizumab|10 mg/kg every 2 weeks
223963004|NCT05744505|PROCEDURE|1565nm Non-ablative Fractional Laser|Every 3 weeks
223963005|NCT05744505|PROCEDURE|placebo|Every 3 weeks
223963006|NCT04958434|DRUG|TST005|TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
223963007|NCT04403815|PROCEDURE|vascular access for coronary procedures|comparison of x-rays exposition of interventional cardiologist according to vascular access used
223963008|NCT03015415|PROCEDURE|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
223963009|NCT03015415|PROCEDURE|Non-surgical intervention|Rehabilitation with splinting protocols
223963010|NCT00000940|DRUG|Ritonavir|
223963011|NCT00000940|DRUG|Abacavir sulfate|
223963012|NCT00000940|DRUG|Amprenavir|
223963013|NCT00000940|DRUG|Lamivudine|
223963014|NCT00000940|DRUG|Stavudine|
223963015|NCT04203225|DRUG|LET Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%) topical gel|Topical anesthetic
223963016|NCT05494099|PROCEDURE|endoscopic maxillary mega-antrostomy|a mucosal sparing technique that facilitates mucus clearance and sinus irrigation in terminally dysfunctional maxillary sinuses. EMMA involves extending the antrostomy through the posterior half of the inferior turbinate down to the floor of the nose, creating a significantly enlarged antrostomy.
223963017|NCT05494099|PROCEDURE|Endoscopic Modified Medial Maxillectomy|In this approach, the maxillary sinus is operated upon, while the inferior turbinate and nasolacrimal duct are preserved.
224110418|NCT06117592|OTHER|Education, training and assessment intervention|Staff competence assessment documents for acute oncology knowledge and skills
224110419|NCT02975648|BEHAVIORAL|educational model + follow up|Orientation from health professionals at discharge, educational program with explanation of booklets and telephone follow-up (three calls)
224110420|NCT02975648|BEHAVIORAL|usual care|Hospital health professionals offered orientation on care after discharge
224110421|NCT03826992|DRUG|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
223963018|NCT05494099|PROCEDURE|Modified endoscopic pre-lacrimal approach|The approach involves making a curved mucosal incision on the lateral nasal wall just anterior to the head of the inferior turbinate. The nasal mucosa was then undermined off the lateral nasal wall. The maxillary sinus was entered with a chisel, and the medial bony wall of the maxillary sinus removed.
224110422|NCT03826992|DRUG|Venetoclax|"Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days"
223963019|NCT00647452|BEHAVIORAL|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
224110423|NCT04224987|DRUG|Azithromycin|"Azithromycin will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight or age-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
224110424|NCT04224987|OTHER|Placebo|"Placebo will be administered as a directly observed dose in oral suspension form for children:~1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g)~2. For children 1-11 months of age, weight-based dosing will be used~3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program"
224110425|NCT02979067|PROCEDURE|Nasal oxygen flow|Nasal oxygen flow during apnoea
224110426|NCT05588284|DEVICE|AngioJet device|A device can be used for thrombus aspiration and thrombolysis.
224110427|NCT05588284|OTHER|anticoagulation alone|a medicine for anticoagulation therapy
223963020|NCT03886688|DRUG|HEC53856|oral administration
223963021|NCT03886688|DRUG|placebo|oral administration
223963022|NCT05554991|DIETARY_SUPPLEMENT|HMO|Composition comprising of HMO
223963023|NCT05554991|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation having the same appearance and dosing regimen as the intervention
223963024|NCT05554991|BEHAVIORAL|Parental reassurance and support|Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
223963025|NCT02791685|BEHAVIORAL|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
224110428|NCT04603378|OTHER|KB195|KB195 is a novel glycan
224110429|NCT04603378|OTHER|Polydextrose|Polydextrose is an oligosaccharide
224110430|NCT04603378|OTHER|Pullulan|Pullulan is an oligosaccharide
224110431|NCT04603378|OTHER|Maltodextrin|Maltodextrin is a digestible carbohydrate
224110432|NCT06698536|DEVICE|Aktiia G2C|Study subjects are asked to stay seated while 3 successive measurements are taken with the Aktiia G2C device under investigation (BP and PR) and two references (Aktiia Bracelet G2 and Aktiia Init I1 oscillometric cuff).
224110433|NCT06626789|BIOLOGICAL|Amygdala neurofeedback|Real-time fMRI neurofeedback from amygdala's blood oxygenation level dependent (BOLD) signal + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
224110434|NCT06626789|BEHAVIORAL|Sham neurofeedback|Recorded neurofeedback from a different participant + negative emotional picture viewing. Instruction to regulate feedback via down-regulation of one's emotional response.
224110435|NCT06877988|DEVICE|AI|Retinal photography-based deep learning algorithm for detection of disease-related visual impairment cases
224110436|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
224110437|NCT05642689|OTHER|Iron fortified milk with iron salt labelled with 58Fe and 57Fe|Oral administration of a serving of iron labelled with stable isotope (2 mg Fe per serving) in 200ml of reconstituted milk once after a overnight fast. The alternate test drink was fed on the following day in the same fashion. The administration was repeated on day 3 and 4.
223963026|NCT02791685|BEHAVIORAL|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
223963027|NCT02791685|BEHAVIORAL|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
223963028|NCT05734235|DIETARY_SUPPLEMENT|Vitamin C|Two Vitamin C tablets daily for 8 days.
223963029|NCT05734235|DIETARY_SUPPLEMENT|Vitamin E|One Vitamin E tablet daily for 8 days.
223963030|NCT03635801|DEVICE|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
223963031|NCT00042510|BIOLOGICAL|Treatment group|
223963032|NCT05444231|BEHAVIORAL|Brain Training A|Interventions may include education, exercises, and/or strategies to support brain health
223963033|NCT05444231|BEHAVIORAL|Brain Training B|Interventions may include education, exercises, and/or strategies to support brain health
223963034|NCT05444231|BEHAVIORAL|Brain Training C|Interventions may include education, exercises, and/or strategies to support brain health
223963035|NCT03672188|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
223963036|NCT03672188|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
223963037|NCT06561412|BEHAVIORAL|Produce Prescription|Participants will receive either $40 (families of 2 members or less) or $60 (families of more than 2 members) produce vouchers every 2 weeks for 6 months, for a total of $480 or $720. These vouchers are sponsored by The Food Trust.
223963038|NCT05159037|BEHAVIORAL|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
223963039|NCT05159037|BEHAVIORAL|Music Booster|Participants listen to a musical track they ranked as highly liked before a stressful situation
223963040|NCT00547716|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
223963041|NCT00547716|DRUG|Placebo comparator|
223963042|NCT00984334|DRUG|Naloxone SR 5 mg capsules|
223963043|NCT00984334|DRUG|Placebo|
223963044|NCT00984334|DRUG|Naloxone SR 10 mg capsules|
223963045|NCT00984334|DRUG|Naloxone SR 20mg capsules|
223963046|NCT00984334|DRUG|Naloxone SR 2.5 mg capsules|
223963047|NCT03676400|OTHER|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
223963048|NCT03676400|OTHER|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
223963049|NCT02655536|DRUG|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
223963050|NCT02655536|DRUG|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
223963051|NCT04006652|DRUG|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
223963052|NCT04399798|DRUG|Baricitinib|4 mg/day for 7 days
223963053|NCT02169089|DRUG|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
223963054|NCT02169089|DRUG|Placebo|Placebo
223963055|NCT05911191|OTHER|Exercise based prehabilitation|A peripheral muscle strengthening program
223963056|NCT02985476|OTHER|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
223963057|NCT01730261|BEHAVIORAL|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
223963058|NCT05791552|DIAGNOSTIC_TEST|Collection of nasal secretion|Standardized collection of nasal secretion in the vicinity of the olfactory cleft
223963059|NCT00001079|DRUG|Testosterone enanthate|
223963060|NCT00001079|DRUG|Megestrol acetate|
223963061|NCT00071929|DRUG|oxaliplatin|
223963062|NCT01763502|OTHER|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
224110438|NCT06710405|DRUG|Lidocaine (drug)|a single bolus dose of lidocaine 1.5 mg/kg is administered concurrently with the induction of anesthesia, followed by a continuous infusion of lidocaine at a rate of 1.5 mg/kg/hr.
224110439|NCT06710405|DRUG|Saline infusion (placebo)|Continuous infusion of normal saline in the same volume as that administered to the lidocaine group.
223963063|NCT01763502|OTHER|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
223963064|NCT00244426|DRUG|indobufen|Indobufen capsules 100 and 200mg
223963065|NCT00244426|DRUG|aspirin|Acetylsalicylic acid capsules 300mg
223963066|NCT04004663|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
223963067|NCT00079235|DRUG|temsirolimus|Given IV
223963068|NCT00079235|OTHER|laboratory biomarker analysis|Correlative studies
223963069|NCT01309802|DRUG|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
223963070|NCT05599230|DRUG|Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening|Patients will daily perform home spirometry and complete a respiratory symptoms score before (3 days) and during (first 14 days) ETI treatment.
223963071|NCT04357522|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
223963072|NCT04357522|BIOLOGICAL|13-Valent Pneumococcal Conjugate Vaccine|4/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
223963073|NCT02161393|BEHAVIORAL|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
223963074|NCT02161393|BEHAVIORAL|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
223963075|NCT05179096|BEHAVIORAL|Mindfulness-based intervention|The program consists of a series of awareness practices: the exercises are presented in progression, starting from the awareness of the external environment, then the self-awareness in the environment, the awareness of the body and the five senses, the awareness of the interconnection among the various forms of life and, eventually, meditation exercises that characterize the awareness of the cognitive processes
223963076|NCT02873442|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
223963077|NCT02873442|BIOLOGICAL|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~\+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
223963078|NCT01690871|DRUG|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
223963079|NCT06090253|BEHAVIORAL|Gerotechnology enhanced multi-component exercise|Intervention courses will be divided into 3 categories: Musculoskeletal training course, Neuromuscular and fall prevention training course, and cardiometabolic training course. The courses will be enabled by wearable technology, digital platform and visual display. Each of the courses will be 8 weeks in length (1 session per week), and 60 minutes per session.
223963080|NCT06090253|BEHAVIORAL|Home-based exercise|The proposed elderly home gym training services will be conducted by professional fitness instructors and tailor-made for the participants. 4 personal training sessions will be assigned (once per week, 45 to 60 minutes per session).
223963081|NCT06090253|BEHAVIORAL|Walking exercise|Two interventions will be provided: A) Walk-focused intervention, B) Disease-related walk intervention for participants with chronic diseases.
224110440|NCT02903511|DRUG|Metformin|Monitoring of safety and tolerability
223963082|NCT06090253|BEHAVIORAL|Slow sports and exercise|Participants will receive 10 training sessions (once or twice per week, 2 hours per session) conducted by professional fitness instructors. The training programs can be selected according to the participants' preference, including water exercises, stretching/fitness/gymnastics, slow walking/jogging, sports massage, Tai Chi, Yoga, etc.
224110441|NCT02903511|DRUG|Placebo|Monitoring of safety and tolerability
224110442|NCT01613235|OTHER|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
223963083|NCT06090253|BEHAVIORAL|Football|The Football Training Programme will be arranged (10 training sessions+1 game day per stage, 4 stages per season). held on artificial turf football pitch or indoor sport facilities in 5 regions
223963084|NCT02035488|DRUG|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
223963085|NCT00317317|PROCEDURE|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
223963086|NCT03658018|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
223963087|NCT03964545|BEHAVIORAL|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
223963088|NCT01810406|PROCEDURE|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
223963089|NCT01810406|PROCEDURE|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
223963090|NCT03320941|DRUG|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
223963091|NCT03320941|DRUG|Placebo|Placebo will be supplied as tablets to be taken daily orally.
223963092|NCT02367339|OTHER|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
223963093|NCT03174470|DEVICE|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
223963094|NCT05829278|PROCEDURE|Acupuncture|Acupuncture will be performed at acupoints including TE17 (Yifeng), SI19 (Tinggong), GB2 (Tinghui), TE5 (Waiguan), TE3 (Zhongzhu), ST36(Zusanli ), KI3 (Taixi), and etc.
223963095|NCT00987155|DEVICE|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
223963096|NCT03881267|OTHER|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
223963097|NCT03881267|OTHER|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
223963098|NCT03881267|OTHER|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
223963099|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
223963100|NCT03083600|DIETARY_SUPPLEMENT|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
223963101|NCT03083600|DIETARY_SUPPLEMENT|Placebo|Cellulose Placebo for 12-weeks
223963102|NCT06113822|DEVICE|ultrasonography|We used ultrasonography to measure the patients' masseter muscle thickness. Measurements were performed simultaneously for both the right and left sides using a high frequency linear scanning probe (13-6 MHz) of an ultrasound device (Fujifilm Sonosite Edge II). In order to prevent possible artifacts and oblique imaging, the probe was kept perpendicular to the skin surface, and the distance between the location of the hyperechoic linear appearance of the mandibular and temporal bone in the transverse section and the muscular fascia were measured.
224110443|NCT04634123|OTHER|Pulpotomy therapy by White Portland Cement|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined using a sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White Portland Cement
224110444|NCT04634123|OTHER|Pulpotomy therapy by White MTA|Carious asymptomatic primary anterior teeth will be removed of dental caries likely to produce vital pulp exposure . The access will be refined usinga sterile no. 4 or 6 round bur in a slow-speed handpiece . The remaining pulp will be treated using pulpotomy therapy by White MTA
224110445|NCT06710444|PROCEDURE|ultrasound-guided erector spinae plane block|ESPB
224110446|NCT06710444|PROCEDURE|ultrasound-guided retrolaminar plane block|RLB
223963103|NCT00357747|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
223963104|NCT00357747|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
224110447|NCT01900548|DIETARY_SUPPLEMENT|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
224110448|NCT01900548|DIETARY_SUPPLEMENT|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
224110449|NCT01900548|DIETARY_SUPPLEMENT|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
223963105|NCT05865782|BEHAVIORAL|Schoolyard reconstruction|The current study will be designed as a quasi-experimental stepped-wedge intervention where schools undertaking schoolyard reconstruction will act as both control and intervention schools. By using the stepped-wedge study design, with internal control schools, will enable the control for the seasonal variation in children's physical activity levels and for the age-related decline in physical activity throughout childhood. That is, without control schools we would be unable to attribute a change in physical activity to the reconstruction of the schoolyards - as any difference in physical activity before and after the schoolyard reconstruction in the intervention group could be explained by the natural change in physical activity over time.
223963106|NCT02589678|BIOLOGICAL|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
223963107|NCT02589678|BIOLOGICAL|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
223963108|NCT00819676|OTHER|analysis of exhaled breath by biosensors|
223963109|NCT00819676|OTHER|measurement of exhaled nitric oxide|
223963110|NCT04871932|BIOLOGICAL|Recently Vaccination|
223963111|NCT03234049|OTHER|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
223963112|NCT00556296|DRUG|NRP104|NRP104 30mg capsule once daily in a.m.
223963113|NCT00556296|DRUG|NRP104|NRP104 50mg capsule once daily in a.m.
223963114|NCT00556296|DRUG|NRp104|NRP104 70mg capsule once daily in a.m.
223963115|NCT00556296|DRUG|Placebo|Placebo
224110450|NCT01900548|OTHER|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
224110451|NCT06706258|DRUG|Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
224110452|NCT06706258|DRUG|Pepcid (Famotidine) 20 mg q 12 hrs for 3 days|Administer 1st dose after anesthesia induction before surgical incision, 2nd dose at chest closure. Then, every 12 hrs for 2 more days.
224110453|NCT00969618|DRUG|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
224110454|NCT03401489|DEVICE|PACESETTER|Patients will be given a Viaca electronic pill tray \& blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational \& reinforcement messages guided by self-determination theory constructs of competence \& autonomous regulation. In addition to personalized messages, PACESETTERs will receive text messages 2 times per week on HTN/stroke facts, importance of med adherence, and tips on expressing questions/concerns with a physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
224110455|NCT01105351|DIETARY_SUPPLEMENT|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
224110456|NCT01105351|DIETARY_SUPPLEMENT|folic acid|folic acid 400 µg
223963116|NCT03236818|DRUG|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
224110457|NCT06884293|DRUG|IBI362|Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC): starting dose is 2.0 mg, after 4 weeks of administration, increase to 4.0 mg; After another 4 weeks, increase to 6mg; After another 4 weeks, increase to the maximum dose 9mg for 36 weeks
224110458|NCT06884293|DRUG|semaglutide|Once-weekly injections of gradually increased doses, subcutaneously (SC): starting dose is 0.25 mg, after 4 weeks of administration, increase to 0.5 mg; After another 4 weeks, increase to 1mg; After another 4 weeks, increase to 1.7mg; After another 4 weeks, increase to the maximum 2.5mg for 32 weeks
224110459|NCT06738446|DIETARY_SUPPLEMENT|Multicomponent dietary supplement group|Participants in supplement group were asked to take a capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg every day for 12 weeks
224110460|NCT00710645|DEVICE|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
224110461|NCT01039168|BEHAVIORAL|Workplace dialogue|
224110462|NCT01039168|OTHER|Care as usual|
224110463|NCT05980026|DRUG|oral omega-3 fatty acids supplementation|oral omega-3 fatty acids supplementation
224110464|NCT05980026|DIETARY_SUPPLEMENT|Placebo|Patients in placebo group received placebo that were similar in appearance to omega 3 fatty acids and the administered dose was as the same schedule as omega 3 fatty acids.
224110465|NCT00542347|DRUG|Esomeprazole first|"* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
224110466|NCT00542347|DRUG|Generic omeprazole first|"* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7"
223963117|NCT01125735|DEVICE|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
223963118|NCT01125735|OTHER|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
223963119|NCT02775123|DEVICE|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
223963120|NCT00992654|DRUG|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
224110467|NCT06748664|DRUG|Rimegepant|Take 75mg qd of oral sulfate remigipan orally disintegrating tablets
224110468|NCT06748664|DRUG|Placebo|Take 75mg qd of oral Rimegepan oral tablets with placebo
224110469|NCT06757504|DRUG|TTYP01 Tablets (12mg or 18mg)|Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
224110470|NCT06757504|DRUG|Placebo (Simulant TTYP01 Tablets)|Taken with a moderate amount of warm water or after disperse in a moderate amount of warm water, at least 60 minutes before breakfast and dinner.
224110471|NCT06752811|DRUG|paclitaxel polymeric micelles for injection|Paclitaxel polymeric micelles for injection at a dose of 300 mg/m2 (based on body surface area), administered on Day 1, with intravenous infusion for ≥ 3 hours, every 3 weeks as a cycle.
223963121|NCT04968314|BEHAVIORAL|Chicago Parent Program|Chicago Parent Program (ChiPP) is a 12-session group-based parenting skills program
223963122|NCT01838499|BIOLOGICAL|MEDI8968|SC injection at baseline, Week 4 and Week 8
223963123|NCT01838499|BIOLOGICAL|Saline|SC injection at baseline, Week 4 and Week 8
223963124|NCT03336684|BEHAVIORAL|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
223963125|NCT05364047|BIOLOGICAL|Low-dose of LVRNA009|25μg/person
224110472|NCT06752811|DRUG|Gemcitabine Hydrochloride for Injection|The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1 and D8 every 3 weeks.
224110473|NCT06752811|DRUG|Paclitaxel for Injection (albumin bound )|Patients in the control group will receive intravenous infusion of paclitaxel for Injection (albumin bound ) at a dose of 125 mg/m2 (based on body surface area), administered at D1, D8, and D15, every 4 weeks as a cycle.
224110474|NCT06752811|DRUG|Gemcitabine Hydrochloride for Injection|The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1, D8, and D15 every 4 weeks.
224110475|NCT01470339|DRUG|duloxetine|duloxetine 60mg once a day for 5 weeks
224110476|NCT00362388|PROCEDURE|Intramyocardial injection of autologous bone marrow cells|
224110477|NCT06891729|DEVICE|Delivery Lumen Access Device|Delivery Lumen Access Device use prior to Vasectomy
224110478|NCT06891729|DEVICE|DLAD|Participants will be exposed to the DLAD during their planned vasectomy
224110479|NCT06901063|DEVICE|ultrasound|Using ultrasound probe to scan and record the bilateral interscalene brachial plexus
224110480|NCT05136885|DRUG|SLS-005|Administration: Infusion Dose: 0.75 g/kg weekly
223963126|NCT05364047|BIOLOGICAL|Middle-dose of LVRNA009|50μg/person
223963127|NCT05364047|BIOLOGICAL|High-dose of LVRNA009|100μg/person
223963128|NCT05364047|OTHER|Placebo|0.5ml/person
223963129|NCT03990909|DIETARY_SUPPLEMENT|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
223963130|NCT03990909|DIETARY_SUPPLEMENT|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
223963131|NCT03990909|DIETARY_SUPPLEMENT|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
223963132|NCT01523678|DRUG|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
223963133|NCT01523678|DRUG|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
223963134|NCT01523678|DRUG|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
223963135|NCT03614923|BIOLOGICAL|Etokimab|Administered by subcutaneous injection
223963136|NCT03614923|BIOLOGICAL|Placebo|Administered by subcutaneous injection
223963137|NCT03614923|DRUG|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
223963138|NCT03959930|DEVICE|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
223963139|NCT04457245|PROCEDURE|Computed Tomography|Undergo whole body PET/CT
223963140|NCT04457245|OTHER|Fluorine F 18 DCFPyL|Given IV
223963141|NCT04457245|PROCEDURE|Positron Emission Tomography|Undergo whole body PET/CT
223963142|NCT04457245|RADIATION|Radiation Therapy|Undergo standard of care definitive radiation therapy
224110481|NCT05136885|DRUG|Matching Placebo|Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
224110482|NCT06774417|OTHER|Digital nudge|Digital help seeking advancement strategies over text and online.
224110483|NCT04892797|OTHER|Covid-19+ observational|This is observational--there is no intervention
224110484|NCT02653092|DRUG|Insulin|
224110485|NCT02653092|DRUG|Intralipid|
224110486|NCT02653092|DRUG|Dextrose|
224110487|NCT02653092|DRUG|Heparin|
224110488|NCT02653092|DRUG|GnRH|
224110489|NCT02653092|PROCEDURE|Hyperinsulinemic Euglycemic Clamp|
224291369|NCT06603987|RADIATION|BNCT|Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
224291370|NCT06603987|DIAGNOSTIC_TEST|［18F］FBPA|Intravenous injection of ［18F］FBPA and radiation exposure from PET-CT scan.
224110490|NCT06826404|DEVICE|Training provided with a wearable ostomy model and standardized patient|"The subjects of what is stoma, nursing care after stoma surgery, and care of the peristomal area will be explained to the students participating in the study theoretically by the responsible director in a session and for a maximum of 30 minutes with plain narration and discussion methods, not exceeding 30 slides. Both groups will receive this training at the same time. After this explanation, stoma care will be performed on a wearable colostomy model by a volunteer student who is doing her doctorate in Surgical Diseases Nursing in accordance with the skill guide Changing the Ostomy Bag and Nursing Care of the Peristomal Area developed by the director of the study based on literature, and nursing students will be given the opportunity to ask questions, and then the skill will be demonstrated twice on the wearable stoma model by following the steps in the learning guide."
224110491|NCT06826404|OTHER|Training low fidelity simulator|"The subjects of what is stoma, nursing care after stoma surgery, and care of the peristomal area will be explained to the students participating in the study theoretically by the responsible facilitator in one session and for a maximum of 30 minutes, using plain narration and discussion methods, not exceeding 30 slides. Both groups will receive this training at the same time. After this explanation, skill training will be carried out on a lifeless mannequin in accordance with the skill guide Changing the Ostomy Bag and Nursing Care of the Peristomal Area developed by the facilitator of the study based on literature."
224110492|NCT06892704|DRUG|Dupilumab - Standard Dose|24 weeks of dupilumab 300mg q2 weeks
224110493|NCT05363293|DRUG|AL001|a crystal engineered lithium-salicylate-proline lithium delivery product
224110494|NCT05363293|OTHER|Placebo|matching placebo formulation
224110495|NCT06013956|DEVICE|Neurostimulation|Electrical stimulation delivered via deep brain stimulation electrodes based on measurements of brain activity.
224110496|NCT06013956|DRUG|Carbidopa 25/Levodopa 100Mg Tab|Anti-parkinsonian medication.
223963143|NCT02246387|PROCEDURE|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
223963144|NCT00301730|BIOLOGICAL|aldesleukin|
223963145|NCT00301730|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223963146|NCT00301730|BIOLOGICAL|trastuzumab|
223963147|NCT00301730|DRUG|paclitaxel|
223963148|NCT00301730|PROCEDURE|conventional surgery|
223963149|NCT06505408|DIETARY_SUPPLEMENT|Multivitamin|4 capsules of Perelel Health Conception Support Multivitamin Pack (consisting of vitamins, minerals, and omega ingredients) consumed daily for 12 weeks
223963150|NCT06505408|DIETARY_SUPPLEMENT|Placebo|4 placebo capsules consumed daily for 12 weeks
223963151|NCT04286893|DIAGNOSTIC_TEST|Flow mediated vasodilatation|Measurement of brachial artery diameter change before and after limb ischaemia.
223963152|NCT04286893|DIAGNOSTIC_TEST|High resolution ECG|Measurement HRV using high resolution ECG
223963153|NCT04286893|DIAGNOSTIC_TEST|Blood withdrawal|Measurement of endothelial inflammation markers
223963154|NCT01107353|DRUG|Imipramine Pamoate|75 mg capsule
223963155|NCT00185848|RADIATION|[18F]FHBG|\< 7mCi and 2 ug, iv
223542357|NCT01680926|DIETARY_SUPPLEMENT|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
223542358|NCT01339936|DEVICE|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
223542359|NCT02901600|OTHER|Detection of the expression of DMTB1 by immunohistochemistry|
223963156|NCT03321188|PROCEDURE|HIPEC|HIPEC with cisplatin
223963157|NCT03321188|DRUG|Carboplatin|Adjuvant IV chemotherapy
223963158|NCT03321188|DRUG|Paclitaxel|Adjuvant IV chemotherapy
223963159|NCT01943370|OTHER|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
223963160|NCT01943370|OTHER|Routine Irrigation|Routine initiation of saline irrigation
223963161|NCT03068676|BEHAVIORAL|Space from Depression|internet-delivered CBT
223963162|NCT03068676|BEHAVIORAL|Space from Anxiety|internet-delivered CBT
223963163|NCT00527696|PROCEDURE|transvaginal obturator tape|
223963164|NCT04143802|DRUG|LY3437943|Administered SC
223963165|NCT04143802|DRUG|Dulaglutide|Administered SC
223963166|NCT04143802|DRUG|Placebo|Administered SC
223963167|NCT02988245|DRUG|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
223963168|NCT02988245|DRUG|JNC-8|Using JNC-8 guidelines to guide therapy
223963169|NCT02201368|DRUG|Triheptanoin (SpezialölÒ 107®)|"* Randomization: Treatment with Triheptanoin for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
223963170|NCT02201368|DIETARY_SUPPLEMENT|MCT (Medium-Chain Triglycerides)|"* Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~* Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~* Crossover: Treatment with Triheptanoin for 6 months"
223963171|NCT00036309|DRUG|Duloxetine Hydrochloride|
223963172|NCT03360071|DRUG|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
223963173|NCT03360071|DRUG|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
223963174|NCT03586739|PROCEDURE|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
223963175|NCT03586739|PROCEDURE|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
223963176|NCT03586739|DEVICE|Duplex-scan|a Duplex-scan will be performed during patient follow up.
223963177|NCT03586739|DEVICE|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
223963178|NCT03586739|DEVICE|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
223963179|NCT03586739|OTHER|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
223963180|NCT06388876|OTHER|Exercise|Members of the exercise group received an exercise intervention twice a week for six weeks accompanied by a physiotherapist.
223963181|NCT06388876|OTHER|lifestyle advice|At the beginning of the program, the members of the individuals were given lifestyle recommendations, both verbally and in writing (in the form of a brochure) within the scope of a common training initiative.The individuals groups received both written (brochure) and verbal training within the scope of lifestyle recommendations (the effects of planned and regular exercise, sleep problems, methods of coping with stress, etc.).
223963182|NCT01642888|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
223963183|NCT01642888|BIOLOGICAL|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
223963184|NCT01745380|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
223963185|NCT01745380|DRUG|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
223963186|NCT01882088|DRUG|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
223963187|NCT05222178|DRUG|HMI-103|HMI-103 is an AAVHSC15 capsid containing a functional copy of the human PAH gene
223963188|NCT01256645|OTHER|blood transfusion|application of single units of red blood cell transfusions
223963189|NCT03445507|OTHER|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
223963190|NCT03445507|OTHER|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
223963191|NCT03490942|DRUG|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
223963192|NCT03490942|DRUG|Placebo|The placebo solution is a non-active formulation containing excipients only.
223963193|NCT03364283|PROCEDURE|Surgical position|
223963194|NCT01193283|DRUG|Cyclophosphamide|30 my/kg for 4 days
223963195|NCT01193283|DRUG|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
223542360|NCT03661177|OTHER|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
224110497|NCT03673787|DRUG|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
223542361|NCT04197284|DEVICE|Biofeedback, Myomed 632|"Biofeedback is a mind-body technique that involves using visual or auditory feedback to gain control over involuntary bodily functions.~Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses."
223542362|NCT04197284|DEVICE|device for electrical stimulation, BTL 4000 Smart|Electrical stimulation is a technique used to elicit a muscle contraction using electrical impulses. Electrodes, controlled by a unit, are placed on the skin over a predetermined area. Electrical current is then sent from the unit to the electrodes and delivered into the muscle causing a contraction.
223542363|NCT04197284|OTHER|kinesitherapy|isometric exercise of the quadriceps muscle
223542364|NCT04845672|OTHER|2% chlorhexidine gluconate|Children in 2% chlorhexidine gluconate group , which is the routine practice of the hospital, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
224110498|NCT03673787|DRUG|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
224110499|NCT06911255|DRUG|Tremelimumab Plus Durvalumab (MEDI4736)|Study subjects will receive 1,500 mg of durvalumab intravenously every 4 weeks until PD is observed. However, treatment will be discontinued if unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria are met. Tremelimumab will be administered first, and durvalumab infusion will begin approximately 1 hour (up to 2 hours) after the completion of tremelimumab infusion. The standard infusion time for each drug is 1 hour, but if the infusion is temporarily interrupted, the total duration should not exceed 8 hours at room temperature.
224110500|NCT06911255|PROCEDURE|Transarterial chemoembolization (TACE)|TACE will be carried out 1 to 2 weeks (7 to 14 days) after the administration of tremelimumab + durvalumab, and thereafter, it will be performed as needed at the discretion of the investigator during the treatment period. If additional TACE is performed, there must be at least a 1-week interval between the additional TACE and the administration of durvalumab.
224110501|NCT06916364|DEVICE|Fiberoptic Assisted Endotracheal Rod Intubation|Fiberoptic-Assisted Endotracheal Rod for Endotracheal Intubation Through a Supraglottic Airway
224110502|NCT02747628|DRUG|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
223963196|NCT00788632|BEHAVIORAL|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
223542365|NCT04845672|OTHER|soap-free body cleaning solution|Children in a wiping bath with soap-free body washing solution group, and a wiping bath in accordance with the bath protocol specified. The bath procedure will take 10-15 minutes. Before wiping bath swab sample will provide from armpit and groin with circular manner and 6 hours later swap sample will be provided from the same areas again. The swab sample taken will be planted on blood agar medium and kept at + 4-8 ℃ for an average of 18-24 hours. After it is planted on blood agar medium, it will be kept at + 4-8 ℃ for an average of 18-24 hours . A total of 12 swab samples will be taken for 3 days from each child and from the same areas, body flora will be evaluated.
223963197|NCT00788632|BEHAVIORAL|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
224110503|NCT02747628|DRUG|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
224110504|NCT02747628|DRUG|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
224110505|NCT06946537|OTHER|Exposures and measurements|Anthropometry, Body composition (BIA), Nutritional screening (GLIM, SNAQ, NIS, NRS-2002), Functional tests, Seisomocardiography, Muscle strength, Blood tests, Fecal swabs, Indirect calorimetry Orientation-Memory-Concentration (OMC), Sarcopenia, Frailty (Clinical Frailty Scale), Comobidity, Polypharmacy, Portrait photo.
224110506|NCT04294264|DRUG|Oxaliplatin|Given IV
224110507|NCT04294264|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
224110508|NCT06027463|PROCEDURE|Head and neck vascular recanalization|Head and neck vascular recanalization
224110509|NCT01783522|DRUG|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
224110510|NCT01783522|OTHER|quality-of-life assessment|Ancillary studies
224110511|NCT01783522|OTHER|placebo|Given PO
224110512|NCT02605863|DRUG|Enzalutamide|160 mg by mouth daily for 12 months
224110513|NCT04290650|BEHAVIORAL|Modified CBT for insomnia|Nurses who are working closely with the patients around the clock will perform an adjusted and modified version of CBT for sleep disturbances, in addition to standard evidence based treatment for psychosis and affective disorders as per today.
223963198|NCT00788632|BEHAVIORAL|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
223963199|NCT04297423|DRUG|Plenvu|randomization 1:1
223963200|NCT00803335|DRUG|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
223963201|NCT00803335|DRUG|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
223963202|NCT01939483|DRUG|irinotecan hydrochloride|Given IV
223963203|NCT01939483|OTHER|laboratory biomarker analysis|Correlative studies
223963204|NCT02247141|BIOLOGICAL|Subgam® (Human Normal Immunoglobulin Solution)|
223963205|NCT02368691|DRUG|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
223963206|NCT06228417|OTHER|Adaptive digital intervention|Participants received reminder for medication intake on daily basis. Also, short message regarding hypertension, medication and lifestyle changes
223963207|NCT02977468|DRUG|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
223963208|NCT02977468|RADIATION|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
223963209|NCT04581772|DRUG|DNL343|Multiple oral doses
223963210|NCT04581772|DRUG|Placebo|Single oral dose
223963211|NCT04581772|DRUG|DNL343|Single oral dose
223963212|NCT01745718|OTHER|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
224110514|NCT04290650|BEHAVIORAL|Treatment as usual|All patients on the two other psychosis wards will receive standard evidence based treatment for psychosis and affective disorders as per today.
224110515|NCT02645747|DRUG|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
223963213|NCT05716152|DIAGNOSTIC_TEST|Morning blood sample and skin punch biopsy of 4 mm diameter.|"1. Morning blood sample (8:00-10:00 am) will be obtained for assessment of Total Testosterone (TT), Free Testosterone (fT), Luteinizing hormone (LH), Follicle stimulating hormone (FSH), and Estradiol (E2).~2. Skin biopsy:~Skin punch biopsy of 4 mm diameter will be obtained from both psoriasis patients (from the lesional and non-lesional sites), and the control group (normal skin). Tissue specimens will be used for formation of Paraffin embedded blocks. Slides will be stained by routine Hematoxylin and Eosin stain. The expression of AR will be measured by immune and histochemical staining by the use of a mouse monoclonal antibody"
223963214|NCT06400290|PROCEDURE|Percutaneous coronary intervention (PCI)|Coronary artery stenting for stable angina
223963215|NCT06400290|DIAGNOSTIC_TEST|Symptom assessment during experimentally induced ischaemia|Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
223963216|NCT04265911|BIOLOGICAL|ASP3772 (subcutaneous)|Subcutaneous injection
223963217|NCT04265911|BIOLOGICAL|ASP3772 (intramuscular)|Intramuscular injection
223963218|NCT04265911|BIOLOGICAL|PPSV23 (subcutaneous)|Subcutaneous injection
223963219|NCT04265911|BIOLOGICAL|PPSV23 (intramuscular)|Intramuscular injection
223963220|NCT03224689|DEVICE|PEEK-Optima Femoral Component|TKA Surgery
224110516|NCT06029816|DRUG|Neratinib tablets|Neratinib tablets
224110517|NCT04089605|DRUG|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
224110518|NCT04089605|DRUG|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
223542366|NCT05187260|DRUG|Nusinersen|SPINRAZA® (nusinersen) prescribed as part of standard of care
223963221|NCT03750305|OTHER|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
223963222|NCT03750305|OTHER|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, \& van Gent, 2008).
223963223|NCT01916447|DRUG|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
223963224|NCT01916447|DRUG|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
223963225|NCT01916447|DRUG|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
223542367|NCT01122979|DRUG|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
223542368|NCT01122979|DRUG|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
223542369|NCT01122979|DRUG|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
223542370|NCT01122979|DRUG|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
223542371|NCT04800393|DRUG|Sevoflurane|induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
223963226|NCT05654558|DEVICE|Auxiliary cantilever intrusion arches on initial archwires|"Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription. Lower first molars received double tubed bands while 2nd molars received single bondable tubes. Leveling and alignment phase then started with 0.014 inch NiTi wires engaging all teeth and synched behind 2nd molars. Two 0.017 x 0.025 TMA (Ormco) sectional wires were attached to auxiliary tubes on 1st molars with tip back bends mesial to the molars and attached with hooks distal to lateral incisors on top of basal leveling arch wire. Amount of intrusive force was measured to range between 20 and 40 grams per side. Basal leveling arches were upgraded whenever needed. All patients were assessed after 6 months of treatment."
223963227|NCT05654558|DEVICE|Routine leveling and alignment|Patients received a full set of 0.022- inch slot brackets (Mini 2000, Ormco) with Roth prescription, 1st and 2nd molars received tubes or bands according to each patient's further needs Lower arch was leveled and aligned with sequential wires starting with 14 NiTi and upgraded when needed. All patients were assessed after 6 months of treatment.
223963228|NCT00001077|DIETARY_SUPPLEMENT|Multivitamin and mineral supplements|Oral tablets taken daily
223963229|NCT00001077|DIETARY_SUPPLEMENT|Peptamen|Solution received daily
223963230|NCT00001077|DIETARY_SUPPLEMENT|NuBasics|Solution or dietary bar received daily
223963231|NCT00316459|DRUG|ERB-041|
223963232|NCT01910740|OTHER|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
223963233|NCT01910740|OTHER|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
223963234|NCT01910740|OTHER|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
224110519|NCT02222727|DRUG|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
223963235|NCT06571019|OTHER|Cool roof|Cool roofs are a heat-reflecting material that can be applied to existing household roofing in the form of a liquid-applied membrane. Cool roofs work by increasing solar reflectance (the ability to reflect the visible wavelengths of sunlight, reducing heat transfer to the surface) and thermal emittance (the ability to radiate absorbed solar energy) thereby reducing the amount of heat transferred into the home.
223542372|NCT04800393|DRUG|Propofol|propofol-based total intravenous anesthesia during breast cancer surgery
223542373|NCT00467376|DRUG|Insulin Glulisine|3 times a day before each meal
223542374|NCT00467376|DRUG|Lispro|3 times a day before each meal
223963236|NCT03185910|BEHAVIORAL|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
223963237|NCT03185910|BEHAVIORAL|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
223963238|NCT06306677|DIAGNOSTIC_TEST|AI-clincial-based hybrid system for radiographic image analysis|The Index test is a novel AI-clinical-based hybrid system for radiographic image analysis. Its diagnostic performance will be compared to the reference represented by a panel of experts.
223963239|NCT05317377|OTHER|Exercise Therapy|Structured exercises focused on hand functionality
223963240|NCT05317377|DEVICE|Leap Motion Based Exergame|Appropriate games from Leap Motion Based Exergame system focused on hand functionality
223963241|NCT00352963|BIOLOGICAL|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
223963242|NCT05804981|OTHER|PRO-CS|4 questions about cognitive function added to annual wellness visit protocol
224110520|NCT05484986|OTHER|A questionnaire with 47 items|A form consisted of questions on introductory characteristics (age, sex, and class, among others), Big Five Inventory (BFI) to evaluate personality traits, and Management of Workplace Violence Competence Scale for Nursing Students in Areas of Clinical Practice.
223542375|NCT00467376|DRUG|Insulin Glargine|once daily
223542376|NCT01234493|PROCEDURE|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
223542377|NCT01234493|PROCEDURE|no fixation|No syndesmosis fixation.
224110521|NCT01438710|DRUG|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
223963243|NCT02879539|DEVICE|MP3000 sound coding strategy or ACE strategy with lower stimulation|
223963244|NCT02720198|DRUG|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
223963245|NCT02720198|DRUG|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
223963246|NCT06539325|DIAGNOSTIC_TEST|Diagnosis algorithm according to the delay between travel and consultation|Tests : RT-PCR for the most common arboviruses (Dengue, Zika, Chikungunya, and West Nile virus) and serology for dengue infection (NS1 antigen, and IgM and IgG), serologies for chronic viral infections (HIV, HBV and HCV) and schistosomiasis, Blood cultures and Innovativ Diagnostics : panel Dragonfly and two metagenomic analyses
223963247|NCT05135741|DEVICE|pressure bio feedback|The pressure biofeedback unit was placed between the plinth and the posterior aspect of the neck just below the occiput and inflated to a baseline of 20 mmHg. A trained physiotherapist was observing and correcting any substitution movements to ensure that all subjects could perform the exercises correctly. All exercise protocols and programs were taken from previously published studies8-10. A conventional DCF exercise protocol was performed three times a week for four weeks in both groups. The duration of the conventional DCF exercise protocol was 20-30 minutes, once a day in the control group, and 15-20 minutes, once a day in the experimental group
223963248|NCT01655862|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
223963249|NCT03897075|DRUG|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
223963250|NCT03897075|DRUG|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
223963251|NCT06011642|DIAGNOSTIC_TEST|Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter, digitale Version (Kinder-eDIPS)|The Kinder-eDIPS is a digital, structured interviews which assesses the most frequent psychological disorders. It exists in a parent and a child version. It can be delivered by trained clinicians and takes between 60 and 120 minutes.
223963252|NCT04114903|OTHER|Study A: Single use of cannabis flower product|Participants are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
223963253|NCT04114903|OTHER|Study B: Ad libitum cannabis use for four weeks or no cannabis use|Participants choose whether to use a cannabis flower product ad libitum for four weeks or to not use cannabis for four weeks. Participants who choose to use cannabis are asked to purchase and use one of three cannabis flower strains with differing levels of THC and CBD: 1) CBD (\~14% CBD/0% THC), 2) THC (\~14% THC/0% CBD), or 3) THC+CBD (\~7% THC/7% CBD).
223963254|NCT04503772|PROCEDURE|Preoperative SRS|Patient will be treat with preoperative SRS and then surgery for brain metastases is realized within 3 days.
223963255|NCT00426218|DRUG|ACZ885|
223963256|NCT00142532|PROCEDURE|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (\~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (\~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
224110522|NCT01438710|DRUG|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
224110523|NCT01775488|DEVICE|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
223963257|NCT00142532|PROCEDURE|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (\~1.25cm) from the spine. The leg studs will be placed at 2 cun (\~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (\~ 5cm) proximal and 3 cun (\~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
223542378|NCT02590536|DRUG|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
223542379|NCT02590536|DRUG|placebo|
223963258|NCT00003732|DRUG|carboplatin|
223963259|NCT00003732|DRUG|paclitaxel|
223963260|NCT00003732|DRUG|topotecan hydrochloride|
223963261|NCT01189994|PROCEDURE|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
223963262|NCT01189994|BEHAVIORAL|Orientation|Orientation sessions focusing in fibromyalgia
223963263|NCT02216994|DRUG|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
223963264|NCT02216994|BEHAVIORAL|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
223963265|NCT02216994|DRUG|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
223963266|NCT05236218|OTHER|Discrete Choice Experiment (DCE) Patients DCE Questionnaire|Discrete Choice Experiment (DCE) Patients
223963267|NCT05236218|OTHER|Semi-Structured Interview Patients Interview|First version of questionnaire (readability/comprehension check)
223963268|NCT04391439|DRUG|Intravenous Methylprednisolone|
223963269|NCT01525888|PROCEDURE|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
223963270|NCT01373359|DRUG|Misoprostol|400 µg sublingual misoprostol
223963271|NCT01373359|DRUG|Oxytocin|10 IU IM
223963272|NCT02607293|DRUG|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
223963273|NCT02607293|DRUG|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
223963274|NCT02607293|DRUG|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
223963275|NCT02869308|DRUG|stannous pyrophosphate|Injection of 1ml Angiocis
223963276|NCT02869308|DRUG|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
223963277|NCT02869308|DEVICE|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
223963278|NCT02869308|DEVICE|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
223542380|NCT00997854|OTHER|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
223542381|NCT04412681|DIAGNOSTIC_TEST|Enhanced PE Screening|To better identify women at risk for pre-eclampsia during pregnancy.
223963279|NCT01725087|DRUG|Matching Placebo|
223963280|NCT01725087|DRUG|Low Dose GRT6005|
223963281|NCT01725087|DRUG|Medium Dose GRT6005|
223542382|NCT02525640|DEVICE|Hearing Aid|Hearing aid comparison
224110524|NCT03554499|PROCEDURE|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
224110525|NCT03554499|PROCEDURE|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
223963282|NCT01725087|DRUG|High Dose GRT6005|
223963283|NCT01725087|DRUG|Tapentadol|
223542383|NCT05818826|DRUG|normal saline solution|Prepare 100 ml of normal saline solution, packed out in the same format, dose, and administration of the drug were exactly the same as in the conventional cessation group.
224110526|NCT02452970|DRUG|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
224110527|NCT02452970|DRUG|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
224110528|NCT02372292|DRUG|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
224110529|NCT06177834|DEVICE|Alisklamp|Alisklamp
224110530|NCT06177834|OTHER|Dorsal slit circumcision technique|In this group, included the patients who will operated with dorsal slit circumcision technique
224110531|NCT05480137|PROCEDURE|NSE scoring balloon and plain balloon angioplasty|Using NSE scoring balloon or plain balloon in BPA surgery.
223963284|NCT01699802|OTHER|Inhaled anaesthetic agent|
223963285|NCT04117711|DRUG|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
223963286|NCT04117711|DRUG|Placebo|Matching placebo will be administered once in the morning before breakfast
223963287|NCT04734171|BEHAVIORAL|Digital social activity video intervention|A 150 seconds video aimed at encouraging the use of a digital device (i.e. not in person contact) to meet with friends during the COVID-19 pandemic. Two friends meet via zoom instead of in person and share their experiencing supporting each other.
224110532|NCT03518229|DEVICE|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
223542384|NCT05818826|DRUG|Hydrocortisone and normal saline solution|Prepare hydrocortisone with normal saline solution 100 ml starts dose at least 200 mg/day according to doctor's order after patient meets the criteria of refractory septic shock then continues conventional cessation of hydrocortisone according to doctor's order after required dose of vasopressor less than 0.1 mcg/kg/min.
223963288|NCT04734171|BEHAVIORAL|Informational sheet|An informational sheet to learn about the COVID-19 outbreak (standard).
223963289|NCT04734171|BEHAVIORAL|Stigma awareness video intervention|A video aimed at sensitizing participants to COVID-19 related stigma. A COVID-19 + individual share their experience.
223963290|NCT00367445|DRUG|Inhaled Human Insulin (Exubera)|
223963291|NCT00367445|DRUG|Insulin Glargine (Lantus)|
223963292|NCT00731276|DRUG|irinotecan hydrochloride|
223963293|NCT00731276|OTHER|pharmacogenomic studies|
223963294|NCT00731276|OTHER|pharmacological study|
224110533|NCT03518229|DEVICE|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
224110534|NCT03095534|BEHAVIORAL|3-Step Workout for Life|a 10-week moderate exercise program
224110535|NCT00004106|DRUG|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
224110536|NCT02009137|DEVICE|EVERA|EVERA apply for 12 weeks
224110537|NCT02009137|DEVICE|ESTES|ESTES apply for 12 weeks
224110538|NCT00683241|BIOLOGICAL|DCVac-L|Subjects will receive three doses of intradermal vaccination with \~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
223963295|NCT03635242|OTHER|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
223542385|NCT02694601|DIETARY_SUPPLEMENT|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
223542386|NCT02694601|DIETARY_SUPPLEMENT|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
223963296|NCT03635242|OTHER|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
223963297|NCT01540071|DRUG|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
223963298|NCT04132388|OTHER|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 \& 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
223963299|NCT04132388|DRUG|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
223963300|NCT02357355|DEVICE|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
223963301|NCT00475436|DRUG|GSK573719|
223963302|NCT01670032|DRUG|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
223963303|NCT01670032|DRUG|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
223963304|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
223963305|NCT01670032|DRUG|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
223963306|NCT01268488|DEVICE|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
223963307|NCT00517270|DRUG|Rabeprazole 20mg twice daily|
223963308|NCT03853642|OTHER|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
223963309|NCT00266747|DRUG|SR58611A|
223963310|NCT00537758|BEHAVIORAL|Cognitive Behavior Therapy|
223963311|NCT00537758|BEHAVIORAL|CBT and BWL|
223963312|NCT00537758|BEHAVIORAL|Behavioral Weight Loss Treatment|
223963313|NCT06575998|OTHER|Training|A 4-hour training for PCPs consisting of an onsite training, an e-learning and a webinar on the treatment of insomnia.
223963314|NCT06575998|OTHER|Pro-active identification|Pro-active identification of patients with clinical insomnia symptoms. Patients receiving care from the participating practices will be asked to fill-out the Insomnia Severity Index (ISI).The ISI is used to identify patients with clinical insomnia symptoms in the general practice. Trained practices will receive feedback on the ISI for half of the patients with clinical symptoms according to the ISI.
223963315|NCT02419664|DRUG|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
224110539|NCT01247818|DRUG|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
224110540|NCT01247818|DRUG|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
224110541|NCT01247818|DRUG|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
223963316|NCT05453292|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|Patients will be first assessed by DFI-EUS and CE-EUS. Then. EUS guided RFA will be performed using the 19G electrode ablation needle connected to the Starmed radiofrequency generator (Taewong Medical, Seoul, South Korea). After EUS identification of the GIST, a place without interposing vessels will be found by the endosonographer. Puncture of the tumor will be performed directly with the ablation probe inserted through the working channel of the echoendoscope. Time - seconds will depend by the tumor dimension, localization, distance from vital structures (e.g., aorta) and EUS appearance (e.g., hyperechoic). Power will be set at no more than 30W. If the tumor is in contact with vital structures a 10mm safe margin will be kept from these to avoid thermal injury. Multiple applications can be performed in the same or separate session depending on the residual tumor tissue evaluated with DFI-EUSor CE-EUS immediately after procedure.
224110542|NCT01247818|DRUG|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
223542387|NCT02694601|DIETARY_SUPPLEMENT|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
223542388|NCT03457714|BEHAVIORAL|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
223963317|NCT04264416|DEVICE|WB-EMS|16 weeks of WB-EMS
223963318|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
223963319|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
223963320|NCT04930185|BEHAVIORAL|Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme|"Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention.~They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention.~Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated."
224110543|NCT02654327|DEVICE|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
224110544|NCT01025180|OTHER|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~* \< 0.25 ng/ml: antibiotic should be stopped~* 0.25 \< PCT \<0.5: antibiotic prescription is not recommended~* \> 0.5 ng/ml: antibiotic should be used"
223963321|NCT02230423|PROCEDURE|Nasal surgery|
223963322|NCT03771183|OTHER|Patients in long response during Halaven® treatment|Data collection
223963323|NCT01689285|DRUG|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
224110545|NCT02400346|DRUG|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
224110546|NCT02400346|DRUG|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
224110547|NCT01915875|OTHER|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
223542389|NCT03457714|OTHER|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
224110548|NCT00688493|DRUG|Dapagliflozin|3 x 50 mg tablets, single oral dose
223963324|NCT01689285|DRUG|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
224110549|NCT00688493|DRUG|Dapagliflozin|2 x 10 mg capsules, single oral dose
224110550|NCT00688493|DRUG|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
224110551|NCT00688493|DRUG|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
224110552|NCT06332053|DRUG|SY-5007|SY-5007 80 mg, Tablets, 2 discrete single doses at Day 1 and Day 11
224110553|NCT06332053|DRUG|Itraconazole|Itraconazole 200 mg, Capsules, Day 8-Day 18
224110554|NCT06332053|DRUG|SY-5007|SY-5007 160 mg, Tablets, 2 discrete single doses at Day 1 and Day 16
224110555|NCT06332053|DRUG|Rifampin|Rifampin 600 mg, Capsules, Day 8-Day 21
224110556|NCT01682369|BIOLOGICAL|TIV (Aggripal)|
224110557|NCT01682369|BIOLOGICAL|ATIV (Fluad)|
223963325|NCT00748488|OTHER|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
223963326|NCT00748488|OTHER|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
223963327|NCT06099119|DRUG|creon 35.000 Ph.U (R)|Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.
223963328|NCT06099119|OTHER|Best Standarard of Care|Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month
223963329|NCT00222209|BEHAVIORAL|Experimental heat pain model|
223963330|NCT05404802|DEVICE|Experimental group intervention|"Training session~Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.~Free-play session~In these sessions, every participant can interact with one PARO without instructions but are under the safety supervision of a PARO facilitator."
223963331|NCT05404802|DEVICE|Control group intervention|Facilitators will facilitate participants' interaction with PARO for 7 main activities, namely: (1) hugging PARO; (2) expressing emotions to PARO: (3) remembering PARO; (4) feeding PARO; (5) sleeping PARO; (6) bathing PARO; (7) decorating PARO.
223963332|NCT02896556|DEVICE|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
224110558|NCT01283581|DRUG|Delafloxacin|300mg IV every 12 hours for 5-14 days
224110559|NCT01283581|DRUG|Linezolid|600mg IV every 12 hours for 5-14 days
224110560|NCT01283581|DRUG|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
224110561|NCT03474523|OTHER|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
223963333|NCT02473549|DEVICE|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
223963334|NCT02473549|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
223963335|NCT02473549|DEVICE|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
224110562|NCT03474523|OTHER|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
223542390|NCT05887037|DIAGNOSTIC_TEST|mNGS|mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time
224110563|NCT00959296|DEVICE|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
224110564|NCT04457726|BIOLOGICAL|SARS-CoV-2 Specific T Cells|Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
224110565|NCT00486226|DEVICE|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
224110566|NCT06497426|OTHER|Study intervention|Participants will be asked to drink water. Water intake will be supervised by a nurse/nurse assistant/dietitian team to ensure adherence, and registered to assess intervention compliance.
224110567|NCT02983903|PROCEDURE|transbronchial biopsy|
224110568|NCT05682807|DRUG|Caffeine|5-10 mg/kg/day IV maintenance dose given after 24 h for 2 months.
224110569|NCT05682807|DRUG|Probiotic Formula|probiotics sachets supplementation orally, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement after two months.
224110570|NCT04704882|OTHER|omental patchwork|the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
224291371|NCT01344382|BEHAVIORAL|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
224110571|NCT01869894|PROCEDURE|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
224110572|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
224110573|NCT01869894|PROCEDURE|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (S\&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
223963336|NCT02473549|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
223963337|NCT01115153|OTHER|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
223963338|NCT01115153|OTHER|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
224110574|NCT00366834|DRUG|Casopitant (GW679769) oral tablets|
224110575|NCT00366834|DRUG|Casopitant (GW679769) intravenous|
224110576|NCT00366834|DRUG|Dexamethasone intravenous|
224110577|NCT00366834|DRUG|Ondansetron oral tablets|
224110578|NCT00366834|DRUG|placebo|casopitant placebo
224110579|NCT01259492|DRUG|Placebo|Placebo Comparator: Placebo
224110580|NCT01259492|DRUG|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
224110581|NCT01259492|DRUG|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
223542391|NCT05887037|DIAGNOSTIC_TEST|The traditional microbiological cultures|Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
223963339|NCT03075475|BEHAVIORAL|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
224110582|NCT01685294|BEHAVIORAL|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
224110583|NCT01565629|BEHAVIORAL|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
224110584|NCT00989430|BEHAVIORAL|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
224110585|NCT00734422|BEHAVIORAL|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
224110586|NCT05393583|PROCEDURE|Outpatient hysterectomy|Discharge on the day of the hysterectomy
223542392|NCT03793686|DRUG|PBCLN-003|Investigational drug
223963340|NCT02342275|DRUG|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
223542393|NCT03793686|DRUG|Placebo|Placebo
223542394|NCT00499200|DRUG|SRA-444|
223542395|NCT00131521|DRUG|mucomyst|
223542396|NCT00131521|DRUG|sodium chloride (saline)|
223963341|NCT02342275|DRUG|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
223963342|NCT04975386|DEVICE|Transthoracic echocardiogram|Transthoracic echocardiogram will be performed before the operation and at certain time intervals during the operation.
223963343|NCT01351597|DRUG|docetaxel/ oxaliplatin|"1. docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~2. oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
223963344|NCT00460577|DRUG|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
223963345|NCT00460577|DRUG|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
223963346|NCT01628822|BEHAVIORAL|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
223963347|NCT01628822|BEHAVIORAL|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
223963348|NCT01860222|PROCEDURE|SR|
223963349|NCT01860222|PROCEDURE|PLAT|
223963350|NCT02623101|DEVICE|Reflectance confocal microscopy|Non-invasive imaging of the lesion
223542397|NCT03659110|BIOLOGICAL|HPV 4|1000 subjects will be received the HPV 4 vaccine
223542398|NCT00395109|DEVICE|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
223542399|NCT01490918|DRUG|Acarbose|Acarbose 50mg b.i.d at first, at the 2nd week 50mg t.i.d and the 4th week, 100mg tid.
223542400|NCT01490918|DRUG|Placebo acarbose|acarbose placebo
223542401|NCT01490918|DRUG|placebo metformin|metformin placebo
223963351|NCT02623101|PROCEDURE|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
223963352|NCT02623101|PROCEDURE|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
223963353|NCT01047306|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
223963354|NCT03343509|DRUG|Metronidazole Oral|Oral Metronidazole
223963355|NCT03343509|DRUG|Metronidazole Ointment|Metronidazole Ointment
223963356|NCT03343509|DRUG|Placebo Oral Tablet|Placebo Tablet
223963357|NCT03343509|DRUG|Placebo Ointment|Placebo Ointment
223963358|NCT05390697|OTHER|Educational videos|Educational videos include (1) danger and prevention of VPD; (2) rationales of completing immunization; (3) immunization amid the COVID-19 pandemic; (4) vaccine misconception; and (5) adverse events following immunization and how to treat it. Each video was less than 2 minutes with clear and straightforward messages according to the National Institute of Health guideline for health education. Materials were distributed through WhatsApp and viewed for five weeks.
224110587|NCT05393583|PROCEDURE|Inpatient hysterectomy|1 night hospital stay after hysterectomy
224110588|NCT01062646|BEHAVIORAL|Multimodal music therapy|
224110589|NCT01062646|BEHAVIORAL|Community treatment as usual|
224110590|NCT04413240|DEVICE|Telerehabilitation|"* VRRS is a medical device to perform cognitive telerehabilitation and home speech therapy in online or offline mode.~* K-Wand is an additional device to VRRS for motor telerehabilitation of the upper limb and trunk. It works with a set of motion sensors through light recognition technology.~* Khymu is a set of sensors added to the VRRS used to carry out motor telerehabilitation activities of the lower limb. The use in combination with the K-Wand is able to allow full-body motor telerehabilitation.~Patients will have at their home a special workstation connected to the internet. The same equipment will also be present in the reference structure. Only the online telerehabilitation mode will be used, including an audio and video teleconference. The rehabilitator will be able to remotely control the patient's system. The patient, will see on his screen the exercises to be performed, their realization and the results achieved."
224110591|NCT04413240|OTHER|Conventional rehabilitation|It is not possible a priori to precisely define the instruments that will be used during rehabilitation management. The telerehabilitation or conventional treatment methods (type of therapeutic exercise, modality of cognitive stimulation and/or taking care of speech therapy) will be determined for each patient on the basis of the needs emerging from the physiatric examination performed at T0, defined according to the Individual Rehabilitation Project and applied according to each Rehabilitation Program (motor, cognitive and/or speech therapy) periodically updated.
223963359|NCT03045549|DEVICE|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
224110592|NCT02135601|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
224110593|NCT02773758|OTHER|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
224110594|NCT02773758|OTHER|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
224110595|NCT02123017|DRUG|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
224110596|NCT02123017|DRUG|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
224110597|NCT02123017|DRUG|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
223963360|NCT03045549|OTHER|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
223963361|NCT01878253|DEVICE|Sidus Stem-Free Total Shoulder Arthroplasty System|
224110598|NCT02286115|BEHAVIORAL|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
224110599|NCT01592851|DRUG|Stannous Fluoride|dentifrice containing stannous fluoride
224110600|NCT01592851|DRUG|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
223542402|NCT03046836|DRUG|Oxytocin|40 IU oxytocin nasal spray
223542403|NCT03046836|DRUG|Placebo|Saline
223542404|NCT04256239|BEHAVIORAL|Dignity Therapy|Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress
223542405|NCT02753478|OTHER|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
223963362|NCT01304953|DRUG|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
223542406|NCT01022970|DRUG|QAX576 placebo|
223542407|NCT01022970|DRUG|QAX576|
223963363|NCT01304953|DRUG|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
223963364|NCT01304953|DRUG|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
223963365|NCT01304953|DRUG|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
223963366|NCT01224509|DRUG|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
223963367|NCT01224509|OTHER|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
223963368|NCT04608006|DRUG|Bupivacaine-fentanyl|Initial epidural bolus of 10 ml Bupivacaine 0.125% plus 50 mcg Fentanyl, followed by continuous infusion pf Bupivacaine 0.0625%™ plus 1mcg/dl Fentanyl
223963369|NCT04043806|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
223963370|NCT04043806|DRUG|IVA|Tablet for oral administration.
223963371|NCT00852345|DRUG|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
223963372|NCT03985826|OTHER|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
223963373|NCT01856647|PROCEDURE|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (\~3 ml) will be obtained from the lower abdomen following local anesthesia.
223963374|NCT05168696|OTHER|Virtual Reality Glasses|Virtual Reality Glasses
223963375|NCT05416970|BEHAVIORAL|SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES|To assess the impact of the SARS-CoV-2 spread related lifestyle changes on body composition analysis and metabolic syndrome components worsening as well as hepatocellular carcinoma occurrence.
223963376|NCT03327688|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
224110601|NCT05720611|BEHAVIORAL|Digitally delivered gardening and healthy eating course|The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
224110602|NCT01058369|DRUG|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
224110603|NCT00483288|OTHER|educational intervention|
224110604|NCT00483288|OTHER|questionnaire administration|
224110605|NCT00483288|OTHER|study of socioeconomic and demographic variables|
224110606|NCT00483288|OTHER|survey administration|
224110607|NCT05615597|PROCEDURE|Para-discal injection of corticoid|In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
224110608|NCT04473261|DRUG|Iodine Complex|Iodine Complex capsule (200mg) will be given three times a day
223963377|NCT03027999|OTHER|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~1. a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~2. A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP \> 2.7"
223963378|NCT02351388|DEVICE|Transcranial Direct Current Stimulation|
224110609|NCT04473261|DRUG|Iodine Complex|Iodine Complex syrup form (40ml) will be given three times a day
223963379|NCT02351388|OTHER|Sham Stimulation|
223963380|NCT01670747|RADIATION|Chest computed tomography|
223963381|NCT02578628|OTHER|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
223963382|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 2 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 2 minutes and then spat it out.
223963383|NCT05069844|DIETARY_SUPPLEMENT|Gum chewing for 4 minutes|In the preoperative waiting area before transfer to the operating room, patients will chew 1 piece of herbal sugar-free for 4 minutes and then spat it out.
223963384|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac Acumen IQ® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management. It incorporates predictive parameters such as the hypotension prediction index and decision support parameters such as dynamic arterial elastance and maximum dP / dT.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
223963385|NCT04301102|DEVICE|Hemosphere platform® together with the FloTrac® sensor|"Clinical platform that, analyzing the pulse wave contour, obtained from the previously catheterized radial artery, is able to make available to the clinician both a continuous monitoring of blood pressure and advanced hemodynamic parameters that help patient management.~It also has the possibility of assessing regional oxygen saturation, measured by near-infrared light photoplethysmography, and the sensor can be applied in different locations (cerebral, muscular ...)."
224110610|NCT04473261|DRUG|Placebo|Empty capsule will be given as placebo
223963386|NCT02035345|DRUG|Carboplatin|
223963387|NCT04868734|BEHAVIORAL|Supportive Psychotherapy|Supportive Psychotherapy give to patient with Acute Coronary Syndrome
224110611|NCT04473261|DRUG|Idoine Complex|Iodine Complex spray form 2 puffs will be given three times a day
224110612|NCT01107977|BEHAVIORAL|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
224110613|NCT00097422|DRUG|OPT-80|
224110614|NCT02884466|BEHAVIORAL|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
224110615|NCT04797975|BIOLOGICAL|KDS-1000|"Non-randomized part of study:~* At the beginning of each dose level (Cohort), 3 patients will receive KDS-1000. These initial patients will be enrolled in a staggered manner to ensure detection of any early safety signals.~Randomized part of the study (Can start when there are no safety concerns in the non-randomized cohorts):~* Cohort 1: Low Dose, 2x10E8 cells/dose~* Cohort 2: High Dose, 1x10E9 cells/dose"
224110616|NCT04797975|OTHER|Placebo|0.9% Normal Saline
224110617|NCT06332144|BEHAVIORAL|Structural vs. Random sequences of stimuli|Participants will see or listen to sequences of sounds and images either in a structured condition or a random condition.
223963388|NCT06420206|OTHER|Standard of Care (Acute Cancer Care Center)|In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
223963389|NCT06420206|OTHER|Standard of Care (Goals of Care)|In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
223963390|NCT00881972|BEHAVIORAL|Exercise|walking/running/cycling
223963391|NCT02948686|OTHER|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
223963392|NCT02948686|OTHER|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
223963393|NCT02948686|OTHER|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
223963394|NCT02948686|OTHER|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
223963395|NCT05165563|PROCEDURE|Treatment of implant single crown|Digital or Conventional Workflows for treatment of implant single crown and materials used.
223963396|NCT04143100|OTHER|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
223963397|NCT01095237|DEVICE|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
223963398|NCT06268600|RADIATION|Modified neck target volume delineation|Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
223963399|NCT06226896|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily plus RAS inhibitor
223963400|NCT06355271|PROCEDURE|Fentanyl 1|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and no fentanyl
223963401|NCT06355271|PROCEDURE|Fentanyl2|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 10 mcg of of fentanyl
224110618|NCT06332144|BEHAVIORAL|Intact vs. Degraded speech|"Participants will listen to an audiobook Alice in Wonderland in the MRI scanner. The speech is either intact or degraded."
224110619|NCT06332144|BEHAVIORAL|Repeating 5-syllable nonwords or 2-syllable nonwords|Participants will listen to nonwords (either 5-syllable or 2-syllable) and then repeat them as accurately as possible in the MRI scanner.
224110620|NCT06332144|BEHAVIORAL|Recall letter or syllable strings that either contain highly frequent bigram/trigram items or infrequent items according to English Corpus data.|Participants will read (orthographic serial recall) or listen to (phonological serial recall) strings.
224110621|NCT06328075|OTHER|non interventional study|non interventional study
224110622|NCT04713020|OTHER|Intervention:APP educational programs|Use mobile device education programs to improve disease knowledge and self-efficacy of stroke patients, and reduce depression
224110623|NCT04713020|OTHER|No Intervention:general care|general care
224110624|NCT06027320|BEHAVIORAL|Brain Health Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and brain health education, in addition to text message communication.
224110625|NCT06027320|BEHAVIORAL|Alzheimer Disease Education|Subjects will receive an Alzheimer's risk assessment, memory testing, and general education about Alzheimer's disease, in addition to text message communication.
224110626|NCT04315363|BEHAVIORAL|Motivational MRI and Behavioral Intervention|Motivational messaging delivered during a functional brain MRI scan and with daily messaging
224110627|NCT04315363|BEHAVIORAL|Control MRI and Behavioral Intervention|Control messaging delivered during a functional brain MRI scan and with daily messaging
223542408|NCT02264743|DRUG|Femoston Conti|Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
223963402|NCT06355271|PROCEDURE|Fentanyl 3|Spinal anesthesia with a 27- gauge Whitacre needle at the L2-3 or L3-4 intervertebral space with the patient in sitting position with hyperbaric bupivacaine 0,5 %12 mg, 100 mcg of morphine, and 20 mcg of fentanyl
223963403|NCT06124599|OTHER|Identification of symptoms of menstrual staphylococcal toxic shock in last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other
223963404|NCT06124599|OTHER|Identification of symptoms of menstrual in control patient in the last three menstrual period|questionnaire including : fever felt or measured; chills; malaise or feeling of malaise (dizziness when standing up); unusual fatigue; headache; confusion, disorientation; nausea; vomiting; diarrhea; abdominal pain; muscle pain, aches; sore throat or pain when swallowing; red tongue or mouth ulceration; skin rashes (redness, patches...); other...
223963405|NCT03519893|DRUG|Losartan|Patients are tested for their normal prescription losartan medication
223963406|NCT04967521|DRUG|Abemaciclib|Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.
223963407|NCT04967521|DRUG|Placebo|Placebo will be administered orally twice a day. Each cycle is 28 days.
223963408|NCT05004740|OTHER|Vaccinated Pregnant or Lactating persons|vaccinated lactating persons from Sinai Health System or the general public
223963409|NCT03623776|DRUG|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
223963410|NCT03623776|DRUG|Pemetrexed|Subjects receive pemetrexed of 500 mg/m\^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
223963411|NCT03623776|DRUG|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
223963412|NCT03623776|PROCEDURE|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
223963413|NCT03476603|DRUG|Irbesartan|Patients are tested for their normal prescription irbesartan medication
223963414|NCT06471842|OTHER|MCH (Montreal Children's Hospital) feeding scale questionnaire and parental questionnaire|The patient's parents will answer the questionnaire and the investigator will complete the parental questionnaire while asking the questions.
223963415|NCT04799587|OTHER|Magnet at P6|Magnet applied at P6 and attached with adhesive tape. The P6 pressure point is 2 inches proximal to the flexor retinaculum, between the flexor carpi radialis and palmaras longus.
223963416|NCT04799587|OTHER|Magnet applied to arm not at P6 pressure point.|Magnet applied to arm not at P6 pressure point and affixed with adhesive tape.
223963417|NCT04387916|DRUG|KC1036|Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.
223963418|NCT04798833|DEVICE|Integrated Newborn Care Kit (iNCK)|"Contents of the integrated newborn care kit:~* Clean birth kit: sterile blade, clean plastic sheet, plastic gloves, hand soap, cord ties/clamp, maternity pad to absorb post-natal bleeding, 10 cotton balls for applying Chlorhexidine (CHX) to the umbilical stump.~* 3x200 µg dissolvable tablets of misoprostol to be ingested prophylactically following delivery of the baby and before delivery of the placenta to prevent post-partum hemorrhage~* 4% CHX solution (15 mL)~* Sunflower oil emollient (50 mL)~* Temperature monitoring strip or sticker~* Fleece blanket for the newborn~* Click to heat warmer~* Pictorial guide that illustrates how and when to use each kit component~* Handheld electronic scale with suspended cloth sling (the scale will not be included with the kit but rather one will be issued to each Lady Health Worker in the experimental arm)~Other Names: Neonatal Care Kit"
223963419|NCT05651347|OTHER|Placebo|Tablets, visually identical to the melatonin tablets, but containing no active ingredient are administered three times a day.
223963420|NCT05651347|DRUG|Melatonin 10 MG|Melatonin 10 mg tablets will be administered three times a day, up to a maximum of 30 mg daily
223963421|NCT05341960|BEHAVIORAL|Food Delivery|Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
223963422|NCT05341960|OTHER|Financial Support|Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
223963423|NCT00515281|DRUG|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
223963424|NCT00515281|DRUG|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
223963425|NCT04929236|DRUG|Panzyga|PANZYGA is a human immunoglobin solution with 10% protein content for intravenous (IV) administration.
223963426|NCT03074097|DRUG|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
223963427|NCT05155553|DEVICE|QIAstat-Dx® Meningitis/Encephalitis (ME) Panel|The performance of QIAstat-Dx® Meningitis/Encephalitis Panel will be evaluated in comparison with another validated comparator method, followed by bidirectional sequencing using residual specimens of cerebrospinal fluid (CSF) obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis.
224110628|NCT01509586|DRUG|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
224110629|NCT02584634|DRUG|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
224110630|NCT02584634|DRUG|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
224110631|NCT02584634|DRUG|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
224110632|NCT03976232|DEVICE|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
224110633|NCT03976232|OTHER|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
224110634|NCT03976232|OTHER|tDCS+ CST|This group will receive tDCS along with CST
224110635|NCT03345212|OTHER|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
223963428|NCT06416540|OTHER|Theraband Exercises plus Conventional Physiotherapy and Rehabilitation Program|"Upper extremity, shoulder flexion, abduction, elbow flexion and wrist extension movements will be applied to the study group by the physiotherapist in combination with the breathing pattern. The program will start with yellow therabant and the difficulty level will be increased according to the patient's condition. Exercise training will be applied in a total of 3 sets, 30-60 min/session, 5 days/week, 8-10 repetitions/set, depending on the condition of each patient, during the patients' stay in the intensive care unit.~Conventional Physiotherapy and Rehabilitation Program Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient."
223963429|NCT06416540|OTHER|Conventional Physiotherapy and Rehabilitation Program|Normal joint range movements, airway clearing techniques, breathing exercises and mobilization will be applied to both groups included in the study by the physiotherapist. Hemodynamic and respiratory values for each level are monitored on the monitor. In addition, the patient will be monitored for symptoms such as blackness and dizziness by asking the patient.
223963430|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Niacinamide|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
223963431|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
224110636|NCT00241111|DRUG|zoledronic acid|
223963432|NCT05642702|OTHER|Peptide complexed HA Age Defying Gel with Vitamin C & Natural Extracts|Semi Solid, Hydrophilic - Gel, A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
223963433|NCT05642702|OTHER|1% w/v Sodium Lauryl Sulphate (SLS) solution|1g of Sodium Lauryl Sulphate will be dissolved in distilled water and made up to 100 mL solution using distilled water. A 0.04 mL of test sample will be dispensed onto the center of an appropriately sized filter paper will be placed in the designated IQ/Finn chambers prefixed to a micropore tape.
223963434|NCT05642702|OTHER|Sodium chloride (Isotonic Saline Solution) Injection IP 0.9 % w/v|A 0.04 mL of 0.9% w/v solution of Isotonic Saline Solution will be dispensed on the center of an appropriately sized filter paper, which will be further placed in the designated IQ/Finn chambers prefixed to a micropore tape.
223963435|NCT04867044|OTHER|STUDY|One Hundred Fifty woman patients diagnosed with fibromyalgia according to the American College of Rheumatology 2010 diagnostic criteria
223963436|NCT04867044|OTHER|Control|healthy woman volunteers
224110637|NCT03131297|PROCEDURE|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
224110638|NCT01790061|PROCEDURE|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
224110639|NCT01790061|DRUG|Traditional treatments|Medications
224110640|NCT00243893|DRUG|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
224110641|NCT00243893|DRUG|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
224291372|NCT01344382|BEHAVIORAL|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
223542409|NCT02264743|DRUG|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
223542410|NCT02967679|DRUG|MD1003|
223542411|NCT01654874|DRUG|99mTc-MIP-1404|
223542412|NCT00133341|DRUG|Goldnatriomthiosulphate, MDBGN, parthenolide|
224110642|NCT04904042|DEVICE|Use of plasma of neutral argon|"Evaluation of the mesentery or peritoneum area infiltrated by miliary implants that is going to be treated. Determination of the PCI. Collection of several samples of the mesenteric peritoneum or parietal peritoneum with tumor involvement (implants between 1-2.5mm of diameter).~It will established a matrix which will be divided into 12 quadrants where the tissue with implants will be placed and it will be treated according to specific power (80-100%), and for an action time of 2-4 seconds or until macroscopic tumor destruction. For each power, application of Plasmajet at 1, 2 and 3 cm from the target tumor tissue.~The in-vivo effect will be evaluated with the use of ball-tip in terms of damage to the serosa or vascularization of the mesentery."
224110643|NCT06097585|DRUG|SGLT2 inhibitor|case control study in which group will receive SGLT2I and group will not , to detect impact of the drug in changing NYHA class for heart failure and echographic parameter
224110644|NCT01709877|PROCEDURE|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
223963437|NCT06080802|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin
223963438|NCT05534230|DRUG|Dexmedetomidine Injectable Solution|Intravenous dexmedetomidine infusion started after induction at a standard dose of 0.5mcg/kg/hr and continued until extubation.
223963439|NCT05534230|DRUG|Saline|Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
223963440|NCT04209322|PROCEDURE|pulsed Radiofrequency|Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging
223963441|NCT04209322|PROCEDURE|Transforaminal Epidural Steroid Injection|Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
223963442|NCT05860894|DEVICE|Implantable ECG holter device (Biomonitor3, Biotronik)|Subcutaneous implantation of ECG holder device to monitor ECG
223963443|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|3 capsules daily.
223963444|NCT03690609|DIETARY_SUPPLEMENT|CytoQuel|2 capsules twice daily.
223963445|NCT01613599|DRUG|Rituximab|Participants received rituximab at the discretion of their treating physicians.
223963446|NCT02091102|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
223963447|NCT02003885|DRUG|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
223963448|NCT02705729|DEVICE|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
223963449|NCT02705729|DEVICE|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
223963450|NCT00228657|DRUG|4% Albumin / 0.9% Sodium Chloride|
223963451|NCT01049633|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
223963452|NCT01049633|DRUG|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
224110645|NCT00051688|DRUG|tezacitabine|
224110646|NCT00051688|DRUG|oxaliplatin|
224110647|NCT01713985|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
224110648|NCT01713985|DEVICE|Thermage|Radiofrequency treatment focusing radiofrequency energy
224110649|NCT01977534|DEVICE|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating \[formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating\].
223963453|NCT01049633|BIOLOGICAL|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
223963454|NCT01049633|DRUG|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
223963455|NCT01049633|DRUG|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
224110650|NCT05164952|DRUG|Zoledronic Acid 4 MG|(4 mg via 15-min infusion every 6 months) for 24 months
224110651|NCT03839433|DRUG|Ciclesonide|
223963456|NCT01049633|DRUG|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
223963457|NCT01049633|DRUG|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
224110652|NCT01759784|BIOLOGICAL|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
224110653|NCT04471103|OTHER|Participation in a Delphi survey|Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
224110654|NCT03952923|BIOLOGICAL|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
224110655|NCT02687113|DEVICE|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
223542413|NCT06525038|OTHER|All groups were observed for clinical end-points described in the study protocol|All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
223542414|NCT01545765|DRUG|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
223542415|NCT03351946|PROCEDURE|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
223963458|NCT01049633|DRUG|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
224110656|NCT03321786|OTHER|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
223963459|NCT01049633|DRUG|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
223963460|NCT01049633|DRUG|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
223963461|NCT01049633|DRUG|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
223963462|NCT01049633|DRUG|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
224110657|NCT01680406|DRUG|Artemether-lumefantrine combination|
223542416|NCT03351946|PROCEDURE|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
223542417|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
223542418|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
223542419|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
223963463|NCT01565031|PROCEDURE|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
223963464|NCT00617708|BIOLOGICAL|cixutumumab|Given IV
223963465|NCT00617708|DRUG|erlotinib hydrochloride|Given PO
223542420|NCT03400241|DRUG|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
223542421|NCT04319250|OTHER|ischemic compression|ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
223963466|NCT00617708|DRUG|gemcitabine hydrochloride|Given IV
223963467|NCT04937309|DEVICE|non invasive auricular vagal stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
223963468|NCT04937309|DRUG|usual medical treatment|Standard anti emetic treatments to prevent emesis due to chemotherapy
223963469|NCT04937309|DEVICE|sham stimulation|Stimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device
223963470|NCT06500169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223963471|NCT06500169|PROCEDURE|Discussion|Ancillary studies
223963472|NCT06500169|OTHER|Exercise Intervention|Complete golf related exercises
223963473|NCT06500169|OTHER|Interview|Ancillary studies
223963474|NCT06500169|OTHER|Medical Device Usage and Evaluation|Wear activity tracker
224110658|NCT01680406|DRUG|Primaquine|
224110659|NCT01680406|DRUG|Chloroquine|
224110660|NCT03952364|OTHER|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
224110661|NCT05836961|OTHER|Benazir Nashonuma Program (BNP)|"Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy (1/4 of daily energy requirements for children in this age range)~Conditional Cash Transfers (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months"
224110662|NCT00251797|DRUG|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
224110663|NCT00251797|DRUG|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
223963475|NCT06500169|PROCEDURE|Physical Examination|Ancillary studies
223963476|NCT06500169|OTHER|Physical Performance Testing|Ancillary studies
223963477|NCT06500169|OTHER|Questionnaire Administration|Ancillary studies
223963478|NCT06500169|OTHER|Recreational Therapy|Participate in golf program
224110664|NCT04696835|DIAGNOSTIC_TEST|speech audiometry|65dB, 55dB or 75dB SPL speech audiometry
223724606|NCT01612936|PROCEDURE|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
223963479|NCT01158716|OTHER|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
223963480|NCT02058992|DRUG|Ramelteon|Ramelteon 8 mg tablets
223542422|NCT04319250|OTHER|IASTM|"In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way."
223963481|NCT03796585|BEHAVIORAL|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
223963482|NCT03796585|BEHAVIORAL|Informational flyer|Informational flyer with ImmPRINT contact information
223963483|NCT00002045|DRUG|Zidovudine|
223963484|NCT02512315|DRUG|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
223963485|NCT02512315|DRUG|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
224110665|NCT00941980|BIOLOGICAL|Osteocel Plus|biologic
224110666|NCT03227926|DRUG|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
223724607|NCT02365792|PROCEDURE|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
224110667|NCT03227926|DIAGNOSTIC_TEST|Molecular Screening|Patients without plasmatic evidence of potentially resistant clones harbouring RAS or EGFR-ectodomain mutations in the RML liquid biopsy, will be molecular eligible for the trial phase
224110668|NCT02584985|PROCEDURE|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
224110669|NCT02584985|PROCEDURE|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
224110670|NCT03661385|DRUG|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
224110671|NCT04373122|DEVICE|REBOA|Resuscitative Endovascular Balloon Occlusion of the Aorta
223963486|NCT02512315|RADIATION|Concurrent chemoradiation (CCRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
223542423|NCT04319250|OTHER|Rehabilitation Program|A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
223542424|NCT02379195|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
223963487|NCT04485975|DEVICE|Therapeutic plasma exchange|Therapeutic plasma exchange filtrates plasma and decreases thyroid hormone concentration in the blood
223963488|NCT00046488|DRUG|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
223963489|NCT04172974|OTHER|eHealth intervention|Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping
223963490|NCT04172974|OTHER|Usual Care|Treatment according to national clinical guideline (referral to GP)
223963491|NCT00293085|DRUG|Docetaxel|
223963492|NCT00293085|DRUG|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
223963493|NCT04734236|DIAGNOSTIC_TEST|New technique vs Xpert|New technique vs Xpert
223963494|NCT02391389|PROCEDURE|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
223963495|NCT03722602|OTHER|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
223963496|NCT03583034|PROCEDURE|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
224291373|NCT04079127|DEVICE|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
224291374|NCT04810520|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
224291375|NCT04810520|OTHER|Point-of-care ultrasound without tele-supervision|Point-of-care ultrasound of critically ill patients (acute dyspnoea, circulatory failure, trauma) will be performed with tele-supervision.
224291376|NCT02409394|DRUG|Hetrombopag Olamine|
224110672|NCT03689231|OTHER|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
224110673|NCT00283712|DRUG|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
224110674|NCT00283712|OTHER|Placebo Comparator|Placebo administered in place of infliximab for control group
224110675|NCT00480194|DRUG|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
224110676|NCT03989687|DEVICE|Fuji Triage|glass ionomer sealant
224110677|NCT03989687|OTHER|isolation|rubber dam or cotton roll isolation
224110678|NCT04635735|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
223963497|NCT03522844|OTHER|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
223963498|NCT03522844|DRUG|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 10 mg/day; at week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
224110679|NCT03609229|PROCEDURE|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
223963499|NCT00872404|DRUG|CP-751,871|20mg/kg/3 weeks
223963500|NCT02488733|PROCEDURE|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
224110680|NCT03609229|PROCEDURE|Abdominal Sacrocolpopexy|"* By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~* The right-handed operator double gloves, and places the left hand in the vagina.~* With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~* Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
224110681|NCT05718076|PROCEDURE|cataract surgery|Phacoemulsification combined trifocal lens implantation
224110682|NCT03466710|PROCEDURE|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
224110683|NCT03466710|OTHER|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (\>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (\</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or \>LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is \>/=CIN II. Results of \</=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
224291377|NCT05754229|DEVICE|AI-assisted colonoscopy|The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
224291378|NCT02999594|DRUG|Tramadol Hydrochloride|50mg intramuscularly
224291379|NCT02999594|DRUG|Distilled Water|2ml intramuscularly
223963501|NCT02488733|DRUG|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
223963502|NCT00441571|DRUG|177Lu-CYT-500|
223963503|NCT04878861|BEHAVIORAL|Training in the blind field|Participants will complete visual training at two locations in the blind field. These two locations of training will be determined at the baseline study visit (0 months) and will be located within the perimetry-defined blind field. The training programme involves discriminating the direction of motion in a small circle of moving dots. The computer software and a chin-rest will be loaned to each participant to complete training at home. Participants will perform 300 trials at each location in their blind field, 5 days a week for at least 24 weeks (40-60 minutes in total). The computer programme will automatically generate a record of participant performance after each home training session.
223963504|NCT00336375|DRUG|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
223963505|NCT02241980|OTHER|Patient survey|
223963506|NCT02241980|OTHER|Physician survey|
223963507|NCT01292005|DRUG|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
223963508|NCT01292005|DRUG|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
223963509|NCT00125723|OTHER|PI Discretion|PI Discretion
223963510|NCT04430153|OTHER|"Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer"|Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
223963511|NCT00930319|OTHER|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
223963512|NCT04682483|DRUG|Vasopressor|The vasopressors include phenylephrine, norepinephrine, epinephrine, dopamine and vasopressin.
223963513|NCT04682483|DRUG|Inotrope|Inotropes include dobutamine and milrinone.
223963514|NCT04682483|DEVICE|Acute Mechanical Circulatory Support Devices|Acute Mechanical Circulatory Support devices include ECMO (VV), ECMO (VA), Impella CP, Impella 2.5, Impella 5.0, Impella 5.5, Impella RP, IABP, Centrimag, Tandem Heart and ProTek Duo.
223963515|NCT02130401|DEVICE|TNM Device|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
223963516|NCT00176319|BEHAVIORAL|Aerobic endurance exercise training (ergometer)|
223963517|NCT03596385|DRUG|Beta blocker|long-term maintenance beta-blocker therapy
223963518|NCT04453982|OTHER|Human milk donors|Human milk donors for the Rogers Hixon Ontario Human Milk Bank
223963519|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
223963520|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 60 minutes.
223963521|NCT00321672|DRUG|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
223963522|NCT00321672|DRUG|0.04% capsaicin patch|Up to 4 control patches of 280 cm\^2 each were applied to the feet (2 per foot) for 30 minutes.
223963523|NCT01731210|DEVICE|implantation of the new LV lead: NANO system.|
223963524|NCT06509295|OTHER|Calcium Hypochlorite as Root Canal Irrigant|Calcium Hypochlorite used as root canal irrigant during chemo-mechanical preparation
223963525|NCT05693428|DRUG|Propofol|To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
223963526|NCT05693428|DRUG|Isoflurane|isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
223963527|NCT05693428|DRUG|Sevoflurane|sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
223963528|NCT03310255|DIAGNOSTIC_TEST|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
223963529|NCT05836844|DEVICE|The Anchorsure System®|Sacrospinous ligament fixation performed with the Anchorsure Device
223963530|NCT00512902|DRUG|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
223963531|NCT00512902|DRUG|Imatinib|Up to 600 mg QD PO for up to 1 year.
223963532|NCT04019925|DEVICE|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
223963533|NCT01151397|DRUG|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
223963534|NCT01151397|DRUG|Peg + Ribavirin|Peg+ Ribavirin for 6 months
224110684|NCT03466710|DIAGNOSTIC_TEST|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
223963535|NCT02502136|PROCEDURE|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
223963536|NCT02502136|PROCEDURE|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
223963537|NCT00523458|DRUG|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
224110685|NCT00098345|DRUG|ZD6474 (vandetanib)|oral once daily tablet
224110686|NCT03606746|BIOLOGICAL|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
224110687|NCT06637826|BEHAVIORAL|Quaternary Ammonium Compound Disinfectants|"Participants are instructed to use quaternary ammonium compound disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
224110688|NCT06637826|BEHAVIORAL|Alcohol-based Disinfectants|"Participants are instructed to use alcohol-based disinfectants during the 1st month (first intervention) and the 3rd month (second intervention) after enrollment, following the guidelines provided. The products include:~* Laundry disinfectant: Use at least twice per week.~* Hand sanitizing wipes: Use at least twice per day, individually packaged, recommended for use before meals.~* Surface disinfecting wipes: Use at least twice per day, individually packaged or multi-pack, recommended for use on surfaces in dormitories or classroom desks.~* Floor disinfecting wipes: Use at least twice per week, in multi-pack, recommended for use on the floor in personal activity areas in dormitories. These wipes can be used by hand or foot to wipe the floor.~After each use of the disinfectant products, participants are required to take a photo and send it to the research team as documentation."
224110689|NCT04919486|BEHAVIORAL|visual feedback with non-weight bearing exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
224110690|NCT04919486|BEHAVIORAL|elastic band exercise|the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
224110691|NCT05595473|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV
224110692|NCT05595473|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV
224110693|NCT05595473|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV
224110694|NCT05595473|DRUG|RZ-001 Dose 4|RZ-001 Dose 4 and VGCV
224110695|NCT01958606|OTHER|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
224110696|NCT01958606|OTHER|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
224110697|NCT05032443|OTHER|Awareness survey|The 33-item questionnaire will sent to pediatric endoscopy nurses in our country. Questionnaires will be delivered to nurses through hospital visits or electronic media.
224110698|NCT05458232|DRUG|Tadalafil 5mg|Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
224110699|NCT05035186|DRUG|Amoxicillin|Anti-H. pylori regimens
224110700|NCT06498063|OTHER|Glucagon|Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.
224110701|NCT06498063|OTHER|Placebo|Placebo (0.9% NaCl).
223542425|NCT02379195|DRUG|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
223542426|NCT02379195|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
223963538|NCT02632188|PROCEDURE|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
223963539|NCT02632188|BIOLOGICAL|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
223963540|NCT01779089|DRUG|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
223963541|NCT01779089|DRUG|placebo|
223963542|NCT02440256|OTHER|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
223963543|NCT04451720|DRUG|Risankizumab|Subcutaneous (SC) injection
223963544|NCT04451720|DRUG|Placebo|Subcutaneous (SC) injection
223963545|NCT01670942|OTHER|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
223963546|NCT00309439|PROCEDURE|ALA-rich diet|
223963547|NCT03120936|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
223963548|NCT03120936|BEHAVIORAL|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
223963549|NCT00448344|BEHAVIORAL|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
223963550|NCT00448344|BEHAVIORAL|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
224110702|NCT06498063|OTHER|Glucagon and exendin 9-39|Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).
223542427|NCT02379195|DRUG|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
223542428|NCT02379195|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
223542429|NCT04554459|DRUG|Ponatinib 15 MG Oral Tablet|ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
223542430|NCT00020150|DRUG|O6-benzylguanine|
223963551|NCT03382704|DIAGNOSTIC_TEST|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
223963552|NCT06510400|OTHER|OMNICHROMA|supra nano filled composite
223963553|NCT06510400|OTHER|Ceram. x spectra|nano hybrid composite resin
223963554|NCT00410150|DRUG|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
223963555|NCT00410150|DRUG|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
223963556|NCT00886548|PROCEDURE|Ultrasound performed|Nurse-driven ultrasound performed
223963557|NCT03478072|DEVICE|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
223963558|NCT01389791|DRUG|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
223963559|NCT01389791|DRUG|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
223963560|NCT01389791|DRUG|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
223963561|NCT02168153|OTHER|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
223963562|NCT02168153|OTHER|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
223963563|NCT02991573|DEVICE|Prime & Bond Universal|Prime \& Bond Universal
223963564|NCT02991573|DEVICE|Ceram X|
223542431|NCT00020150|DRUG|temozolomide|
223542432|NCT06251622|OTHER|Volumetric ultrasound of the quadriceps and fitting of an accelerometer|The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
223542433|NCT05695170|BEHAVIORAL|PreventT2 (Individual intervention)|"PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years."
223963565|NCT02991573|DEVICE|Prime & Bond XP|Control
223963566|NCT02991573|PROCEDURE|technique 1|
223963567|NCT02991573|PROCEDURE|technique 2|
223963568|NCT00121589|DRUG|Lutein|
223963569|NCT05871502|DEVICE|Subcutaneous blood glucose monitoring device|After signing the informed consent and before the start of the endovascular procedure, a subcutaneous blood glucose monitoring device will be implanted, which will be removed on day 15 (or at hospital discharge if this takes place before 15 days). This device will be selected from those currently available on the market, with CE marking, and with previous studies documenting its safety and feasibility for radiological procedures.
223963570|NCT03998956|PROCEDURE|CPVI|Circumferential PV isolation only
224110703|NCT04879446|PROCEDURE|Concentrated growth factor(CGF)|Concentrated growth factor(CGF) liquid applied to the implant cavity and implant surface.
224110704|NCT04879446|PROCEDURE|Advanced platelet rich fibrin (A-PRF)|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity and implant surface.
224110705|NCT04879446|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied.
223963571|NCT03998956|PROCEDURE|CPVI+BOX|Circumferential PV and BOX isolation
223963572|NCT03998956|PROCEDURE|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
223963573|NCT02492126|OTHER|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
223963574|NCT01858909|DRUG|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
223963575|NCT00605605|DRUG|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
223963576|NCT01853904|PROCEDURE|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
223963577|NCT01853904|PROCEDURE|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
223963578|NCT01821222|DEVICE|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
223963579|NCT05209256|DRUG|Chemotherapy|Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
223963580|NCT05209256|DRUG|Alflutinib plus chemotherapy|Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
223963581|NCT05700656|DRUG|Galunisertib plus capecitabine|Combination therapy with galunisertib plus capecitabine
223963582|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
223963583|NCT00611598|OTHER|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
223963584|NCT02338505|DEVICE|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
223963585|NCT05799534|OTHER|Physical Therapy Rehabilitation|Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
223963586|NCT00021996|DRUG|valdecoxib|
223963587|NCT03662009|OTHER|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
223963588|NCT02521337|OTHER|observation|observation
223963589|NCT01748058|BEHAVIORAL|Exercise based on active video gaming|
223963590|NCT04158323|DEVICE|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
223963591|NCT00992693|DRUG|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1\) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
223963592|NCT01288729|DEVICE|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
223963593|NCT01288729|DEVICE|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
223963594|NCT00267865|DRUG|Methotrexate|6000 mg/m\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
223963595|NCT00267865|DRUG|Rituximab|375 mg/m\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate
223963596|NCT00267865|DRUG|Leucovorin|Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes
223963597|NCT01177644|DRUG|PDS 1.0|
223963598|NCT04119778|BEHAVIORAL|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
223963599|NCT03115619|DRUG|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
223963600|NCT03640078|OTHER|acquisition imaging|The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
223963601|NCT03556059|OTHER|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
223963602|NCT05866289|OTHER|Prone position|Each prone position session had a minimum duration of one hour and a maximum duration of 12 hours for a minimum of 3 hours per day.
223963603|NCT01923935|DRUG|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)
223963604|NCT01923935|DRUG|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
223963605|NCT03603275|DRUG|New FVIII products|Kovaltry or Jivi prescribed by the treating Physician
223963606|NCT00857909|DRUG|Amiloride|1 tablet twice a day
223963607|NCT00857909|DRUG|Spironolactone|1 tablet twice a day
223963608|NCT00857909|DRUG|Placebo|Placebo
223963609|NCT00857909|DRUG|Placebo and spironolactone|5mg twice daily
223963610|NCT00857909|DRUG|Spironolactone|25mg twice daily
223963611|NCT03853525|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
223963612|NCT03853525|OTHER|Semisolid vaseline|Product is applied to one side of the inguinal region.
223963613|NCT02973035|DRUG|Amlodipine|
223963614|NCT02973035|DRUG|Valsartan|
223963615|NCT06267326|PROCEDURE|debridment|resection of dead bone
223963616|NCT04546178|BEHAVIORAL|Prolonged exposure (PE)+ therapy|The intervention will be adapted prolonged exposure therapy, called PE+ therapy. Participants will receive 15 weekly 90-minute sessions of PE+; these appointments will be divided into five sets of three sessions each: 1) psychoeducation about AEs, SM, and the interplay of both with psychosis; 2) emotion regulation strategies; 3) imaginal exposures, 4) in vivo exposures, and 5) review of treatment and planning for termination and maintenance.
224110706|NCT04879446|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied.
223963617|NCT04546178|OTHER|Treatment as usual (TAU)|The intervention will be antipsychotics prescribed by clinicians working within the Nova Scotia Early Psychosis Program (NSEPP) as well as case management supplied by their primary nurse. Program participants will have access to educational programs about psychosis, skills/vocational training, as well as familial education and support.
223963618|NCT03686176|OTHER|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
223963619|NCT02400372|DEVICE|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
223963620|NCT01823458|BEHAVIORAL|Lottery Insurance|
223963621|NCT01823458|BEHAVIORAL|Standard Lottery|
223963622|NCT04882956|DRUG|intravitreal injection|Brolucizumab-Dbll intravitreal injection
223963623|NCT04882956|DRUG|intravitreal injection|Aflipercept intravitreal injection
223963624|NCT00515879|DRUG|D-cycloserine|50 mg
223963625|NCT00515879|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
223963626|NCT00515879|DRUG|Placebo|Same dosage as active pill
223963627|NCT00391794|BEHAVIORAL|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
223963628|NCT00391794|BEHAVIORAL|Educational Seminar|4 hour education session led by trained facilitators
223963629|NCT04880135|OTHER|Supervised stretching and strengthening exercise|The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
223963630|NCT04880135|OTHER|Home-based stretching and strengthening exercise|The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
223963631|NCT06181968|DIAGNOSTIC_TEST|Cardiothoracic ultrasound protocol|Combined echocardiography and lung ultrasound for guiding therapy
223963632|NCT01434355|OTHER|Laboratory Biomarker Analysis|Correlative studies
223963633|NCT01434355|OTHER|Questionnaire Administration|Ancillary studies
223963634|NCT02131792|PROCEDURE|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
223963635|NCT02286297|DEVICE|McGRATH® MAC|video-laryngoscopy-1
223963636|NCT02286297|DEVICE|AirTraq|video-laryngoscopy-2
223963637|NCT02286297|DEVICE|GlideScope|video-laryngoscopy-3
223963638|NCT02286297|DEVICE|Miller|Direct laryngoscopy
223963639|NCT06479499|OTHER|Pilates Exercises|Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
223963640|NCT06479499|OTHER|Aerobic Exercises|Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
223963641|NCT04288440|PROCEDURE|Surgery|Removal of epiretinal membrane and ILM
223963642|NCT04288440|DEVICE|Vitrectomy machine|Pars plana vitrectomy
223963643|NCT02115945|OTHER|DN4 test|The DN4 test was used to evaluate neuropathic pain.
223963644|NCT02115945|OTHER|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
223963645|NCT02115945|OTHER|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
223963646|NCT02115945|OTHER|Visual analogue score|Visual analogue score vas used to evaluate pain.
223963647|NCT02115945|PROCEDURE|femoral block|
223963648|NCT02115945|PROCEDURE|epidural block|
223963649|NCT04081818|OTHER|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
223963650|NCT00991133|DRUG|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
223963651|NCT05910359|DIAGNOSTIC_TEST|Ultrasound|transabdominal and transperineal ultrasound by expert sonographers
223963652|NCT00559195|BIOLOGICAL|epoetin beta|
223963653|NCT00559195|PROCEDURE|quality-of-life assessment|
223963654|NCT00329186|DRUG|desvenlafaxine SR|
223963655|NCT00329186|DRUG|venlafaxine ER|
223963656|NCT02984787|PROCEDURE|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
223963657|NCT02984787|PROCEDURE|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
223963658|NCT00083122|DRUG|cisplatin|Given IV
223963659|NCT00083122|DRUG|alvocidib|Given IV
223963660|NCT00083122|DRUG|cisplatin/flavopiridol|Given IV
223963661|NCT01154699|DEVICE|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
223963662|NCT01154699|OTHER|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
223963663|NCT01154699|OTHER|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
223963664|NCT00642499|DRUG|Dronabinol|2.5 mg to 40 mg
223724608|NCT05238090|OTHER|Passive and active analytical stretching exercises|"For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process."
223724609|NCT05238090|OTHER|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature|Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
223963665|NCT00642499|DRUG|Placebo|placebo
223963666|NCT04246099|OTHER|Post-operative care|"Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients."
223963667|NCT03949699|OTHER|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
223963668|NCT00449917|DRUG|lutein|
223963669|NCT00449917|DRUG|DHA|
223963670|NCT00449917|DRUG|vitamins|
223963671|NCT02154893|DEVICE|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
223963672|NCT02154893|DEVICE|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
223963673|NCT02154893|DEVICE|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
223963674|NCT02951416|OTHER|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
223963675|NCT04988958|PROCEDURE|hydatid cyst resection|radical resection of hydatic cyst
223963676|NCT05219409|DRUG|Sitagliptin|The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
223963677|NCT05219409|DEVICE|Professional CGM|The sensor records the patient's glucose readings every 15 minutes for up to 14 days.
223963678|NCT04117256|DEVICE|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
223963679|NCT04117256|DEVICE|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
223963680|NCT01843699|DRUG|Topiramate flexible dosage|
223963681|NCT01843699|DRUG|Placebo matching tablets|
223963682|NCT01843699|BEHAVIORAL|4-session gambling cognitive restructuring|
223963683|NCT01846988|DEVICE|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
223963684|NCT01237509|DEVICE|Hypo device|
223963685|NCT03875599|OTHER|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
223963686|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
223963687|NCT02936739|DEVICE|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
223963688|NCT03663699|BEHAVIORAL|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
223963689|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Antecubital Approach|Patients assigned to the antecubital approach group (experimental group) will undergo AVS via antecubital approach.A 5F introducer sheath will be introduced into the antecubital vein. After heparinization,a diagnostic catheter with side holes will be introduced. Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
223963690|NCT06029803|PROCEDURE|Adrenal Venous Sampling via Femoral Approach|Patients assigned to the femoral approach group (active comparator group) will undergo AVS via femoral vein approach.The introducer sheath will be introduced into the femoral vein.Two blood samples (about 4mL each) will be collected from the inferior vena cava, right adrenal vein and left adrenal vein for the determination of cortisol and aldosterone concentrations.
223963691|NCT01033097|DRUG|DNK333 5 mg|5 mg oral
223963692|NCT01033097|DRUG|Placebo to 5 mg|5 mg placebo oral
223963693|NCT01033097|DRUG|DNK333 25 mg|25 mg oral
223963694|NCT01033097|DRUG|Placebo to 25 mg|25 mg placebo oral
223963695|NCT01033097|DRUG|DNK333 100 mg|100 mg oral
223963696|NCT01033097|DRUG|Placebo to 100 mg|100 mg placebo oral
223963697|NCT01033097|DRUG|Betamethasone 4 mg|4 mg oral
223963698|NCT01033097|DRUG|DNK333 1mg|1 mg oral
223963699|NCT01033097|DRUG|Placebo to 1mg|1 mg placebo oral
223963700|NCT03813602|DRUG|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
223963701|NCT06147115|OTHER|Assessment tool to determine severity of GI bleeding|The Rockall score is a validated mortality risk assessment for patients admitted with upper GI bleeding.
223963702|NCT02995447|OTHER|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
223963703|NCT02815800|DIETARY_SUPPLEMENT|ETHNODYNE VISIO|
223963704|NCT02871245|PROCEDURE|Laparoscopic Surgery|
223963705|NCT02871245|DEVICE|Acupuncture treatment|
223963706|NCT03854032|BIOLOGICAL|Nivolumab|Given IV
223963707|NCT03854032|BIOLOGICAL|IDO1 Inhibitor BMS-986205|Given PO
223963708|NCT03854032|PROCEDURE|Therapeutic Conventional Surgery|Undergo Surgery
223963709|NCT03854032|OTHER|Questionnaire Administration|Ancillary studies
223963710|NCT05347849|DRUG|BPL-003|A single dose of BPL-003 will be administered intranasally
223963711|NCT05347849|OTHER|Placebo|A single dose of placebo will be administered intranasally
223963712|NCT06034145|OTHER|No intervention|No intervention
223963713|NCT05746026|BEHAVIORAL|Psycho-educational Program|"This program consisted of five (5) sessions during two weeks.~* Session 1: introduction and basic information about Climate Change~* Session 2: causes and factors that contribute to climate change by humans and nature~* Session 3: explain climate change risks, describe and explain the impact of climate change on elder health and well-being.~* Session 4: teaching proper behaviors that contribute the most to climate-driving emissions.~* Session 5: learning how adapting and coping with climate change. Adaptation includes a range of coping actions that individuals may take, as well as psychological processes (e.g. emotion management, problem solving, and cognitive reframing responses) that influence reactions to (and preparations for) adverse impacts of climate change, including chronic environmental conditions and extreme events."
223963714|NCT00794274|DRUG|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
224110707|NCT03897712|DEVICE|Custom Samfilcon B Contact Lenses|Contact lens
223963715|NCT06277206|DIAGNOSTIC_TEST|18F-FAPI PET/CT|Enrolled patients underwent 18F-FAPI PET/CT at diagnosis. And preoperative 18F-FAPI PET/CT was completed in the patients met the criteria for conversion surgery after systemic treatment. The correlation between changes of parameters before and after treatment and pathologic response was analyzed.
223963716|NCT01533194|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223963717|NCT01533194|BIOLOGICAL|Wild-type Reovirus|Given IV
223963718|NCT07008573|OTHER|probiotics in soybean concentrate|treatment with topical probiotics on DFU
223963719|NCT07007650|DRUG|High-concentration Ropivacaine|After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.
223963720|NCT07007650|DRUG|Low concentration ropivacaine group|After the first pump fluid is depleted, switch to 0.12% ropivacaine to continue labor analgesia.
223963721|NCT07008690|DIAGNOSTIC_TEST|MRI|This exploratory study will longitudinally image patients diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 18 months using 3T MRI.
223963722|NCT07008690|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|For comparison, this exploratory study will image patients that are not diagnosed with DJD, capturing multiple bilateral TMJ MRI scan images over the course of 4 weeks.
223963723|NCT07009314|BEHAVIORAL|Implementation package (training, facilitation, electronic health record nudge)|"Training will consist of an initial presentation on S.A.F.E. Firearm by the study team, informational resources to support program delivery, and recommendations for self-guided continuing medical education programs.~Facilitation will last 6 months at each site. It may involve 1) a readiness assessment for each clinic to identify implementation barriers and develop relationships with constituents; 2) kick-off meetings at trial launch, at which staff will identify how to implement S.A.F.E. Firearm in the clinic; 3) goal-setting within the first few months of the program; 4) trouble-shooting to address barriers identified during the pre-implementation readiness assessment and emergent challenges; and 5) designing a sustainment plan to maintain the program for future years.~A clinician decision support (nudge), designed to align with best practices within each health system, will be deployed in the EHR workflow to remind clinicians to deliver S.A.F.E. Firearm and offer a cable lock."
223963724|NCT03167645|DRUG|Human albumin|Substitution according to pre-specified dosage
223963725|NCT00116233|DEVICE|REPEL-CV|
223963726|NCT02244775|DEVICE|SR™MCP|
223963727|NCT03015844|DRUG|131-I-meta-iodobenzylguanidine|
223963728|NCT04999956|PROCEDURE|dynamic navigation surgery|immediate implant placement using dynamic navigation
223963729|NCT04999956|PROCEDURE|freehand surgery|immediate implant placement using freehand surgery
223724610|NCT05130320|OTHER|Not Interventional their treatments are their routine NHS care|Not Interventional their treatments are their routine NHS care
223963730|NCT00924599|BEHAVIORAL|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
223963731|NCT00924599|BEHAVIORAL|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
223963732|NCT04176926|DIAGNOSTIC_TEST|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
223963733|NCT02591914|DRUG|Fovista™|Anti-PDGF-B pegylated aptamer
223963734|NCT02591914|DRUG|Lucentis®|Anti-VEGF
223963735|NCT02591914|DRUG|Avastin®|Anti-VEGF
223963736|NCT02591914|DRUG|Eylea®|Anti-VEGF
223963737|NCT00508859|DRUG|Sertraline|maintenance treatment with sertraline
223963738|NCT00508859|DRUG|placebo|placebo
223963739|NCT05854056|PROCEDURE|Accelerated rehabilitation protocol|See Arms section
223963740|NCT05854056|PROCEDURE|Conservative rehabilitation protocol|See Arms section
223963741|NCT01709643|DIETARY_SUPPLEMENT|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
223963742|NCT01709643|DIETARY_SUPPLEMENT|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
223963743|NCT02178878|GENETIC|Progress, Pain|Progress, Pain
223963744|NCT01748578|DRUG|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
223963745|NCT01748578|DRUG|EBI-005-1 Placebo|
223963746|NCT06136507|DRUG|FRSW107|experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
223963747|NCT01252199|DRUG|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
223963748|NCT01252199|DRUG|Placebo|Placebo administered over 1 hour + standard of care
224110708|NCT03897712|DEVICE|Alden Optical HP Sphere Contact Lens|Hioxifilcon D, 54% water, Alden Optical HP Sphere lens
224110709|NCT03897712|DEVICE|ReNu MultiPlus Lubricating and Rewetting Drops|For use as needed during the study.
224110710|NCT03897712|DEVICE|Biotrue Multi-Purpose Solution|For daily rinsing, cleaning, disinfecting, and storing their lenses in lens cases during the study.
224110711|NCT05923905|DRUG|FB1006|30mg/day
224110712|NCT05923905|DRUG|Placebo|30mg/day
224110713|NCT01966731|DRUG|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
224110714|NCT00641940|BEHAVIORAL|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
224110715|NCT00641940|BEHAVIORAL|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
224110716|NCT00353977|BIOLOGICAL|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
224110717|NCT03240640|PROCEDURE|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
224110718|NCT03240640|PROCEDURE|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
224110719|NCT01380093|DRUG|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
224110720|NCT01380093|DRUG|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
224110721|NCT01380093|DRUG|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
223963749|NCT06520020|DEVICE|Transcutaneous Spinal Cord Stimulation (Tc-SCS)|This study will employ a DS8R Biphasic Constant Current Stimulator (Digitimer, Hertfordshire, United Kingdom) to administer transcutaneous (Tc) SCS through bursts of biphasic rectangular pulses, each lasting 400 μs to 1 ms, at 30 Hz frequency on a carrier frequency is 10 kHz. The intensity of stimulation will be 120% the threshold intensity that elicits visible twitch or motor evoked potential (MEP) triggered in the biceps brachii (BB) or abductor pollicis brevis (APB) muscle for upper extremity, and quadriceps femoris (QF) or tibialis anterior (TA) in the lower extremity.
223963750|NCT05017883|DRUG|TAA05 cell injection|"Chimeric antigen receptor T cells (car-t)~Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells."
223963751|NCT06552910|PROCEDURE|Nerve Block|Since this study was conducted retrospectively, the choice of anesthesia method was made based on our own experience. For every patient undergoing LEA under PNB, a popliteal sciatic nerve block was carried out. A saphenous nerve block was also carried out if the procedure was on a level that was close to the metatarsal bone. In some circumstances (distal surgery, such as the metatarsal bone), a sensory block on the surgical site was tried following the popliteal sciatic nerve block to demonstrate that the saphenous nerve's anatomic abnormalities required an additional saphenous nerve block. The related block was later carried out, if needed. Under ultrasound guidance, every PNB was finished.
223963752|NCT06584786|COMBINATION_PRODUCT|Jing Si herbal tea (JSHT)|JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).
223963753|NCT06584786|OTHER|Placebo|Placebo of JSHT
223963754|NCT05669287|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
223963755|NCT04925245|OTHER|Clinical Reminder|Clinical reminder in the electronic medical record
223963756|NCT03050372|DEVICE|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
224110722|NCT06511154|OTHER|Cognitive Rehabilitation|"Cognitive rehabilitation is a treatment method used to regain or improve cognitive abilities.For the cognitive rehabilitation program, the Daily Exercise Package of the Norosoft Program, which mainly includes exercises to improve attention, information processing speed, verbal and visual memory functions, will be applied.~Core-based Upper Extremity Exercises~Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises"
224110723|NCT06511154|OTHER|Core-based Upper Extremity Exercises|Breathing exercises, Core based stabilization and mobilization exercises Upper extremity exercises Coordination ve proprioception exercises
224110724|NCT05668156|OTHER|Consensus Decision Making|Consensus-based decision-making process, where experts are asked to comment definitions of terms used for fasting interventions
224110725|NCT04734873|DRUG|CPI-006 2 mg/kg + SOC|IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
224110726|NCT04734873|DRUG|CPI-006 1 mg/kg + SOC|IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
224110727|NCT04734873|DRUG|Placebo + SOC|IV placebo plus standard of care
224110728|NCT04230850|OTHER|Static Cupping|Two cups will be applied unilaterally to the lumbar paraspinals. The skin will be elevated to 1.5 cm ensuring standardized pressure. Cups will remain on the treatment area statically for 4 minutes prior to removal. Another 4 minute bout of identical treatment to the contralateral side will follow. (Participants will be equally dispersed into three treatment groups via stratified randomization).
224110729|NCT04230850|OTHER|Dynamic Cupping|One cup will be applied ipsilaterally, raising skin to 1.2 cm of standard pressure. The cup will be continuously moved in a sweeping motion between L1 and L5 within a defined width. This process will be repeated on the other side. Each side will be treated for 4 minutes dynamically for a total treatment duration of 8 minutes. (Participants will be equally dispersed into three treatment groups via stratified randomization).
224110730|NCT04230850|OTHER|Stretching|The stretching program performed will involve a double knee to chest stretch, cat stretch, camel stretch, and pelvic tilts. Participants will receive a 30 second rest break between each of the four stretches. (Participants will be equally dispersed into three treatment groups via stratified randomization).
224110731|NCT03077048|DRUG|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
224110732|NCT01939262|OTHER|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
224110733|NCT01939262|OTHER|Control|Participants assigned to the control group will be instructed to follow their usual diets.
224110734|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
223963757|NCT03050372|DEVICE|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
223963758|NCT00161954|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
223963759|NCT05727553|RADIATION|Online adaptive radiotherapy|Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
223963760|NCT02510404|BIOLOGICAL|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
224110735|NCT04177030|BEHAVIORAL|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
223963761|NCT06047795|OTHER|Experimental|"Cycling 2 days per week with Borg dyspnea 4-6 level for 15-20 minutes/ day with 5 minutes warm-up and cool-down.~Strengthening exercises for upper limb muscles (pull-ups and biceps curls) and for lower limb muscles (sit-to-stand and step-up exercises) with 3 sets of 8-12 repetitions \* 2 days per week.~Pursed Lip breathing exercise 3 sets of 5-10 repetitions for 6 weeks"
224110736|NCT04024410|OTHER|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
224110737|NCT03291002|BIOLOGICAL|CV8102|CV8102 alone
223963762|NCT06047795|OTHER|Control|"Usual care: frontal chest radiographs, verbal advice to quit smoking, and reduce exposure to biomass smoke.~Spirometry to screen for airway diseases. Antibiotic and systemic glucocorticoid therapy."
223963763|NCT03716947|PROCEDURE|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
224110738|NCT03291002|BIOLOGICAL|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
223963764|NCT03716947|PROCEDURE|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
223963765|NCT03716947|PROCEDURE|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
223963766|NCT02344602|DRUG|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
223963767|NCT03119051|BEHAVIORAL|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
223963768|NCT03119051|BEHAVIORAL|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
224110739|NCT04637451|PROCEDURE|Root coverage treatment|Gingival unit graft Connective tissue graft
223963769|NCT06375317|DRUG|PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets|"PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses."
223963770|NCT00722514|BEHAVIORAL|patient education|"* complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* Patient education 6 x 90 Minutes"
223963771|NCT00722514|BEHAVIORAL|Standard Care|"* complex individual antiinflammatory rehabilitation program during inpatient~* complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~* further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
223963772|NCT05770193|OTHER|Pursed lip breathing|The position for every patient will be long sitting, and then he will be instructed to breathe in through the nose for 2 seconds. Purse the lips as if about to blow out the candles on a cake. Breathe out very slowly through pursed lips for 4 to 6 seconds, and then repeat for 5 to 10 minutes. The intervention will be done two days a week, through six weeks for all participants by a physiotherapist.
223963773|NCT05770193|OTHER|Cognitive Behavior Therapy|A structured, 6-session psycho-therapeutic intervention, occurring once weekly, will be performed According to the CBT session structure provided by Cully and Teten, with some modifications, Each session will be approximately 1 hour.
223963774|NCT05770193|OTHER|Diaphragmatic breathing exercise|"The patient will lie in supine position, and then he will be asked to rest for 5 min and lay on their back on a flat surface with pillows under their head and knees for support. One hand will be placed on the abdomen and the other on the upper part of the chest wall. When inhaling, the hand on the abdomen will move upward, while the other hand will remain as still as possible. When exhaling, the hand on the abdomen will move downwards, while the other hand will remain as still as possible again. Breathing will be performed quickly, deeply and without causing tiredness. The breaths should be inhaled through the nose and exhaled through the mouth.~The diaphragmatic breathing exercise will consist of three sets of 10 repetitions, with 30 seconds of rest between each set"
223963775|NCT05770193|OTHER|Kinesio tape|"The position for every patient will be sitting during application of the tape. The diaphragm muscle will be covered with kinesio tape both anteriorly and posteriorly along the subcostal region. Anteriorly, the base point of an I shaped kinesio tape will be applied on xiphoid process with 50\_75% tension on the linea Alba and the tails of the tape were applied toward subcostal curvature. Posteriorly, a second I shaped Kinesio Tape will be applied from the back The base point of the tape will be applied on the projection of 12th Thoracic vertebra with 50 \_75% tension and the tails will be applied toward the ribs."
223963776|NCT01092585|DRUG|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
223963777|NCT04554615|DRUG|Insulin|insulin infusion to control postoperative hyperglycemia
223963778|NCT01648075|DIETARY_SUPPLEMENT|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
223963779|NCT03590067|OTHER|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
223963780|NCT03205345|DRUG|Emricasan (25 mg)|25 mg emricasan
223963781|NCT03205345|DRUG|Emricasan (5 mg)|5 mg emricasan
223963782|NCT03205345|DRUG|Placebo|Matching Placebo
223963783|NCT03292744|DRUG|Alfacalcidol|alfacalcidol 0,5 mcg
223963784|NCT01529853|DRUG|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223963785|NCT01529853|DRUG|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223963786|NCT04595110|OTHER|Observational study|Coagulation factors, Hypercoagulation biomarkers, Endothelial, Fibrinolysis and neutrophil activation biomarkers
223963787|NCT00396409|DRUG|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
223963788|NCT00396409|DRUG|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
223963789|NCT00396409|DRUG|Placebo|Placebo given during the 2006 core study
223963790|NCT00331799|DRUG|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
224110740|NCT00201201|OTHER|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
224110741|NCT00201201|OTHER|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
224110742|NCT00000110|PROCEDURE|magnetic resonance spectroscopy|
224110743|NCT00000110|DRUG|dietary fat|
224110744|NCT00564928|DRUG|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
224110745|NCT02175550|DEVICE|NR CC|
224110746|NCT05573685|DEVICE|DiNaMo Study App|Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
224110747|NCT05573685|DEVICE|Placebo App|Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
223724611|NCT01635192|BIOLOGICAL|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
224110748|NCT01172080|OTHER|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
224110749|NCT01342640|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
224110750|NCT00043147|DRUG|beclomethasone dipropionate|
224110751|NCT00043147|DRUG|methylprednisolone|
224110752|NCT00043147|DRUG|prednisone|
224110753|NCT01683500|DEVICE|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
224110754|NCT00887081|DRUG|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
224110755|NCT03004560|PROCEDURE|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
224110756|NCT03004560|PROCEDURE|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
224110757|NCT05399693|PROCEDURE|platelet transfusion|platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
224110758|NCT04885738|OTHER|no intervention|"For Chronic Cough，follow《Guidelines for the diagnosis and treatment of cough》(2015).~For Asthma, follow GINA For COPD, follow GOLD."
224110759|NCT05071339|DRUG|Ganirelix Acetate, Cetrolix Acetate|3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
224110760|NCT03863938|DRUG|Tegoprazan 50mg|K-CAB
224110761|NCT05361096|OTHER|Educational approach (Flipped learning)|"In the intervention group, the out-of-class stage started one week before the in-class stage of the relevant week. The researchers covered the topic of the week asynchronously in the virtual classroom in the learning management system. Students have been able to log into the system at anytime and anywhere and study the course video and other course materials repeatedly.~The in-class stage is the session in which the students in the intervention group come together with the researcher synchronously and conduct an online lesson. It was conducted one session per week for four weeks. The course was carried out synchronously on the Zoom platform during the in-class stage."
224110762|NCT02267577|DEVICE|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
224110763|NCT02267577|DEVICE|GE Dinamap ProCare Automatic Blood Pressure Monitor|This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
224110764|NCT00442312|DRUG|Combigan Ophthalmic Solutiom|
224110765|NCT05446597|PROCEDURE|Symptom-specific Headache Treatment|Greater Occipital Nerve Block
224110766|NCT05446597|OTHER|Symptom-specific Dizziness &/or Neck Pain Treatment|Cervicovestibular Physiotherapy Treatment
224110767|NCT05446597|BEHAVIORAL|Multimodal Concussion Treatment|Lite combination of headache advice, general physiotherapy exercises, mindfulness, visualization, and relaxation
224110768|NCT04101422|BEHAVIORAL|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
224110769|NCT04101422|BEHAVIORAL|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
224110770|NCT04101422|BEHAVIORAL|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
224110771|NCT04101422|BEHAVIORAL|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
224110772|NCT01834326|BIOLOGICAL|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
224110773|NCT01834326|BIOLOGICAL|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
224110774|NCT02393599|DRUG|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
224110775|NCT02393599|DRUG|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
223724612|NCT01635192|BIOLOGICAL|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
224110776|NCT02393599|DRUG|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
224110777|NCT06498102|OTHER|Intermittent Fasting: Time Restricted Feeding During 6 Weeks|Thirty-one healthy, young males (age: 27.5±6 years, body mass: 76.5±8.4 kg, and maximal oxygen uptake \[V̇O2max\]: 43.9±6.6 mL/kg/min) were randomly assigned to either TRF (n=14) or control group (n=17). TRF group followed an 16:8 intermittent fasting diet program for 6 weeks. Body composition, insulin sensitivity, resting substrate oxidation, and fat oxidation during cycling at 40% V̇O2max were assessed before and after the diet program.
223963791|NCT02746497|PROCEDURE|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
223963792|NCT04107688|OTHER|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
224110778|NCT00718861|DRUG|Placebo|
224110779|NCT00718861|DRUG|Zoledronic acid|
223963793|NCT04107688|OTHER|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
223963794|NCT04564222|DIETARY_SUPPLEMENT|Micronutrient Enriched Crackers (MECs)|"MECs are manufactured according to the Standard Operational Procedures which have been developed taking into account the Hazard Analysis and Critical Control Point (HACCP) to maintain quality and safety and ensure the Ready-to-eat MEC products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detectable) in the MEC products have been obtained from analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of MEC products will be repeated at the middle and the end of the RCT to check on the quality and safety of the MEC product."
223963795|NCT04564222|DIETARY_SUPPLEMENT|Placebo|"Placebo crackers are manufactured according to SOPs which have been developed taking into account the HACCP to maintain quality and safety and ensure the Ready-to-eat placebo products are safe. Data on the micronutrient concentrations and any potential bacteriological (Salmonella sp is negative, Bacillus cereus, Enterobacteriaceae, and Coagulase positive streptococci level are considered safe) and chemical contaminants (Pb, Hg, Cd, As, and Sn are not detected) in the placebo have been obtained based on the analysis in the laboratory of Saraswanti Indo Genetech, which has been accredited by KAN LP-184-IDN with SNI ISO/IEC 17025: 2008. Laboratory analysis of placebo samples will be repeated at the middle and the end of the RCT to check on the quality and safety of the placebo product."
223963796|NCT06436612|RADIATION|Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy|stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
224110780|NCT01690234|PROCEDURE|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
224110781|NCT01690234|PROCEDURE|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
224110782|NCT02004990|PROCEDURE|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
224110783|NCT01749735|DEVICE|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
224110784|NCT01749735|DEVICE|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
224110785|NCT01749735|DEVICE|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
224110786|NCT04549038|OTHER|12-16 hour nutrition|Cases will receive their nutrition over a period of 12-16 hours, with minimum 8 hours of fasting and maximum 12 hours of fasting. Feeding will begin in morning hours unless otherwise directed by an investigator or registered dietician.
224110787|NCT00084422|DRUG|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
224110788|NCT00282958|DRUG|Botulinum Toxin type a (Botox)|
224110789|NCT01439529|OTHER|Device programming: nominal|CRT device is programmed to nominal values
223724613|NCT05616910|DRUG|inhaled nitric oxide|iNO will be provided by ventilator or nasal cannula for 4 hours each day.
224110790|NCT01439529|OTHER|Programming optimization by QRS|CRT device is programmed by QRS optimization
224110791|NCT00416637|BIOLOGICAL|Bevacizumab (Avastin)|
224110792|NCT02676310|DRUG|Bimatoprost|
224110793|NCT03576027|OTHER|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
224110794|NCT05094440|BEHAVIORAL|Dialectical behavioral therapy skills training (DBT-ST)|Pocket Skills is a dialectical behavior therapy skills training (DBT-ST) webapp that includes video lessons, an interactive chatbot AI coach, and in-app exercises to practice DBT skills. The delivery of the app will occur primarily over 1 month, followed by 2 months of follow-up, and will be supplemented with a walk through manual and links to DBT worksheets.
224110795|NCT00933946|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
224110796|NCT00107107|DRUG|pramlintide acetate|Syringe vial and Pen-cartridge
224110797|NCT04971811|OTHER|Snack with energy density less than 1.5 kcal/g|Snack meal with snack food having energy density less than 1.5 kcal/g
224110798|NCT04971811|OTHER|Snack with energy density greater than 1.5 kcal/g|Snack meal with snack food having energy density greater than 1.5 kcal/g
224110799|NCT00002993|DRUG|cisplatin|
224110800|NCT00002993|DRUG|doxorubicin hydrochloride|
224110801|NCT00002993|DRUG|mitomycin C|
224110802|NCT02360943|OTHER|4 blood samples|PK and / or PD measurements during hospitalization
224110803|NCT00539786|DRUG|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
224110804|NCT04382651|DRUG|MAS825|MAS825 liquid solution for intravenous infusion
224110805|NCT04382651|OTHER|Placebo|Placebo liquid solution for intravenous infusion
224110806|NCT04382651|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
224110807|NCT00004048|BIOLOGICAL|filgrastim|
224110808|NCT00004048|DRUG|doxorubicin hydrochloride|
224110809|NCT00004048|PROCEDURE|autologous bone marrow transplantation|
224110810|NCT00004048|PROCEDURE|peripheral blood stem cell transplantation|
223724614|NCT05285813|DRUG|Vibecotamab|Given by vein (IV)
223724615|NCT05285813|DRUG|Dexamethasone|Given by vein (IV) over about 60 minutes before the dose
223724616|NCT05285813|DRUG|Acetaminophen|Given by mouth (PO) about 30-60 minutes before the dose
224110811|NCT00004048|RADIATION|indium In 111 monoclonal antibody MN-14|
224110812|NCT00004048|RADIATION|yttrium Y 90 monoclonal antibody MN-14|
224110813|NCT05669885|DRUG|Sildenafil|Study participants will be allocated to receive oral administration of 100 mg sildenafil.
224110814|NCT05669885|DRUG|Placebo|Study participants will be allocated to receive oral administration of placebo.
224110815|NCT03414918|DRUG|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
224110816|NCT00126451|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
224110817|NCT00126451|DRUG|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
224110818|NCT06480071|DRUG|Oxymetazoline, 0.05% Nasal Spray|2 sprays each nostril before the excercise test.
224110819|NCT01873742|OTHER|STIC feedback system|This condition includes the use of the STIC feedback system.
224110820|NCT02035072|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2
224110821|NCT02035072|DRUG|Oxaliplatin|Oxaliplatin 100 mg/m2
224110822|NCT02035072|RADIATION|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
224110823|NCT03545152|BEHAVIORAL|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
224110824|NCT03545152|BEHAVIORAL|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
224110825|NCT03545152|BEHAVIORAL|New life-style|Combination of exercise and cognitive interventions
224110826|NCT03739983|DEVICE|Vaginal Renewal Program|Therapeutic vibrating wand.
224110827|NCT05839990|PROCEDURE|Surgery|Replacement of the ascending aorta in case of anerysm and dilatation
224110828|NCT00790296|DRUG|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
224110829|NCT00790296|DRUG|Placebo|Saline
224110830|NCT05541692|BEHAVIORAL|Sleep Hygiene Toolkit|The sleep hygiene toolkit includes multiple resources including assistive devices (ie. eye masks and ear plugs), sensory-based tools (ie. aromatherapy, music, meditation, and breathing techniques), cognitive behavioral therapy (CBT) activities (ie. addressing anxiety and worry), and education and training on sleep hygiene.
224110831|NCT04704765|OTHER|abdominal breathing training|The abdominal breathing training at the outpatient clinic (every day 30 minutes, can include every time during the day). When the subjects were at home, they received self-training using the abdominal breathing training video (once every day and 30 minutes every time).
224110832|NCT02612077|OTHER|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
223963797|NCT05065918|BEHAVIORAL|sexual violence and alcohol use harm reduction text message content|The multi-target sexual violence harm reduction and alcohol use intervention will use a similar model to the alcohol use reduction intervention previous developed and implemented. Students will be: 1) queried via TM prior to typical drinking days regarding both alcohol use and SV harm reduction goal setting; 2) provided with goal reminders during drinking period; and 3) assessed for goal attainment and given feedback following drinking episodes. As with the control condition, post-drinking assessment happens weekly on Sundays. Monday thru Saturday participants will randomly receive or not receive one appropriate message pathway from the message library using the pre-determined pathways for messages.
223963798|NCT05065918|BEHAVIORAL|alcohol use reduction content|"The control condition will be a previously tested TM-delivered alcohol use reduction intervention. Prior to typical drinking occasions, individuals planning a drinking event are prompted to consider committing to a drinking limit goal, i.e.: Would you be willing to set a goal to drink less than X drinks when drinking?. Based on willingness to commit to the goal, a feedback message is provided. During typical drinking periods, individuals receive a goal reminder. Each week, the program provides goal success/failure feedback or drinking quantity feedback. For example, those occasions where an individual committed to a drinking limit goal triggers either messages to reinforce goal successes or reframe goal failures. When an individual did not commit to a drink limit goal, they are provided feedback based on alcohol quantity (e.g. high risk drinking feedback)."
223963799|NCT00003116|BIOLOGICAL|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
224110833|NCT02612077|DRUG|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
224110834|NCT00247910|DRUG|Hydrochlorothiazide|Not recorded in detailed description.
223963800|NCT00003116|DRUG|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
223963801|NCT00003116|DRUG|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
223963802|NCT00003116|DRUG|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
223963803|NCT00003116|PROCEDURE|bone marrow ablation with stem cell support|
223963804|NCT00003116|PROCEDURE|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
223963805|NCT05707585|DIAGNOSTIC_TEST|Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)|Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs
223963806|NCT04203199|DEVICE|Real rTMS to the mPFC using H7 Coil|This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
223963807|NCT04203199|DEVICE|Real rTMS to the dlPFC using H1 Coil|This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
223963808|NCT03149887|DRUG|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
223963809|NCT03149887|DRUG|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
223963810|NCT02502188|DRUG|CC-90005|
223963811|NCT02502188|DRUG|Placebo|
223963812|NCT05324527|OTHER|Hand Massage|Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
223963813|NCT03800745|DRUG|Colace 100Mg Capsule|Prescribed to Arm B
223963814|NCT03800745|DRUG|Miralax|Prescribed to Arm C
223963815|NCT01489163|BEHAVIORAL|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
223963816|NCT00553800|DRUG|bevacizumab|
223963817|NCT00553800|DRUG|Erlotinib|
223963818|NCT05527054|OTHER|Diuretics|Inpatients using diuretics
223963819|NCT00907699|GENETIC|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
223963820|NCT00907699|GENETIC|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
223963821|NCT00907699|GENETIC|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
223963822|NCT00907699|GENETIC|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
224110835|NCT01914445|DRUG|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
224110836|NCT05055635|RADIATION|Pencil beam proton therapy|Neo-adjuvant or definitive pencil beam proton therapy: 55 Gy(RBE)/44fx - 65 Gy(RBE)/52 fx (1.25 Gy per fraction), two fractions a day
224110837|NCT05588362|OTHER|Fitz Frames 3-D Printed Glasses|The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
224110838|NCT01962259|BEHAVIORAL|Physical activity|
224110839|NCT01220310|BEHAVIORAL|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
224110840|NCT01720511|DIETARY_SUPPLEMENT|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
224110841|NCT01720511|DIETARY_SUPPLEMENT|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
223963823|NCT00907699|GENETIC|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
224110842|NCT03726216|DRUG|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration \[e.g. hospital, ICU\]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
224110843|NCT02060396|DRUG|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
224110844|NCT03927534|BEHAVIORAL|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
223963824|NCT00907699|GENETIC|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
224110845|NCT04045223|OTHER|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
223963825|NCT00907699|GENETIC|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
223963826|NCT00907699|OTHER|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
223963827|NCT03967093|DRUG|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
223963828|NCT00274976|BIOLOGICAL|alemtuzumab|
223963829|NCT01317771|PROCEDURE|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
223963830|NCT04096261|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
223963831|NCT00721019|OTHER|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
223963832|NCT00721019|OTHER|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
223963833|NCT00319670|DRUG|MiraLax|
223963834|NCT05127122|DRUG|Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|Injectable
224110846|NCT01971476|DRUG|volasertib|intravenous administration on day 1of a treatment course
224110847|NCT02498080|PROCEDURE|DEB PTA|paclitaxel drug eluting balloon PTA
224110848|NCT02498080|PROCEDURE|Standard PTA|Standard PTA
224110849|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
223963835|NCT05127122|OTHER|Saline|Placebo Saline
224110850|NCT02075255|BIOLOGICAL|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
224110851|NCT02075255|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
224110852|NCT00020930|BIOLOGICAL|cetuximab|
224110853|NCT05895825|DRUG|EOC237|EOC237 for orally
224110854|NCT00000539|DRUG|niacin|
224110855|NCT00000539|DRUG|pravastatin|
224110856|NCT00000539|DRUG|beta-carotene|
224110857|NCT00000539|DRUG|vitamin E|
224110858|NCT00000539|BEHAVIORAL|dietary supplements|
224110859|NCT00000539|DRUG|vitamin C|
224110860|NCT00000539|DRUG|warfarin|
224110861|NCT03994926|DEVICE|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
224110862|NCT03994926|DRUG|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
224110863|NCT04742517|DRUG|ASP1128|Intravenous
223963836|NCT05872984|DIAGNOSTIC_TEST|adjustment of dry weight based on absolute blood volume measurement|adjustment of dry weight based on absolute blood volume measurement
223963837|NCT04695249|BEHAVIORAL|Exposure intervention using 360 degree videos|The intervention consists of eleven sessions. The first five sessions are dedicated to functional assessment and psychoeducation. The second five sessions are dedicated to exposure in 360-degree videos. The last session is provided for relapse prevention.
223963838|NCT00391521|DRUG|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
223963839|NCT00391521|DRUG|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
223963840|NCT00391521|DRUG|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
223963841|NCT01239225|DEVICE|Abdominal ultra-sound|
223963842|NCT01239225|PROCEDURE|Abdominal ultrasound|
223963843|NCT04809545|OTHER|Acusticare|Acusticare is an internet connected speaker which delivers an environmental intervention by playing sounds to adjust the soundscape in the room.
223963844|NCT04809545|OTHER|Treatment as usual|Usual care provided on the Specialized Dementia Unit
223963845|NCT00014235|DRUG|fludarabine phosphate|Given IV
223963846|NCT00014235|RADIATION|total-body irradiation|Undergo TBI
223963847|NCT00014235|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
223963848|NCT00014235|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
223963849|NCT00014235|DRUG|cyclosporine|Given PO or IV
223963850|NCT00014235|DRUG|mycophenolate mofetil|Given IV or PO
223963851|NCT00014235|OTHER|laboratory biomarker analysis|Correlative studies
223963852|NCT01870999|DRUG|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
223963853|NCT01870999|DRUG|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
223963854|NCT03034772|DRUG|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
223963855|NCT03034772|OTHER|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
223963856|NCT00936195|DRUG|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
223963857|NCT00936195|DRUG|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
223963858|NCT00662415|DEVICE|mirror-box treatment|15 minutes daily for 4 weeks
223963859|NCT00662415|BEHAVIORAL|observation|observation
223963860|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 18%-protein diet|
223963861|NCT02559479|BEHAVIORAL|Weight loss interventional study with a low-calorie 35%-protein diet|
223963862|NCT02660034|BIOLOGICAL|Tislelizumab|
223963863|NCT02660034|DRUG|Pamiparib|
223963864|NCT02473588|DEVICE|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
223963865|NCT00952016|DRUG|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
224110864|NCT04742517|DRUG|Placebo|Intravenous
223963866|NCT03377283|BIOLOGICAL|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
223963867|NCT03377283|OTHER|organ perfusion with saline|
223963868|NCT01065493|OTHER|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
223963869|NCT01065493|BEHAVIORAL|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
223963870|NCT04297436|BIOLOGICAL|4CMenB (Bexsero®) vaccine|Tthe 4CMenB vaccine (Bexsero®) contains the MeNZB OMV component plus three recombinant antigens (NadA, fHBP-GNA2091, and NHBA-GNA1030. The 4CMenB vaccine (Bexsero®) induces antibodies in humans that recognise gonococcal proteins.
223963871|NCT05394389|OTHER|sensory stimulating therapy|therapy session in the snoozlen room accompanied by social support.
223963872|NCT05394389|OTHER|social support|ten minutes of conversing.
223963873|NCT05181878|DEVICE|The AcQMap 2.1 System with Electro-Magnetic Tracking Feasibility System|Demonstrate the ability of the AcQMap 2.1 System to support EMT in conjunction with the existing impedance localization capabilities. The new EMT technology is expected to continuously provide fully synchronized and similar localization information to the impedance-based localization information associated with the location of the catheter's magnetic sensor position.
223963874|NCT01493947|DRUG|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
223963875|NCT01493947|DRUG|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
223963876|NCT00618384|DRUG|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
223963877|NCT01533181|OTHER|Laboratory Biomarker Analysis|Correlative studies
223963878|NCT01533181|DRUG|Linsitinib|150 mg given orally (PO) twice a day (BID)
223963879|NCT01533181|OTHER|Pharmacological Study|Correlative studies
224110865|NCT06970548|DRUG|Levobupivacaine|To evaluate efficacy of addition of dexamethasone to levopubivacaine in tranversusabdominis plane block (TAP) in postoperative pain management, postoperative analgesic consumption, and patient comfort after laparoscopic bariatric surgery.
224110866|NCT06970899|DEVICE|PATH EX CycloPE® Device|Participants in this arm will receive two extracorporeal blood filtration treatments using the PATH EX CycloPE® device. The first treatment will be initiated following baseline assessments, and the second treatment will occur 24-36 hours after the start of the first treatment. Each treatment will last up to 4 hours. The device is designed to target and remove bacteria from the bloodstream. All participants will also receive standard-of-care treatment for sepsis, including IV antibiotics, as determined by the treating physician.
223963880|NCT01533181|DRUG|Topotecan Hydrochloride|1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
223963881|NCT03317678|DIETARY_SUPPLEMENT|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
223963882|NCT03317678|DIETARY_SUPPLEMENT|Non-fermented milk|A non-fermented milk drink.
223963883|NCT01333137|DRUG|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
223963884|NCT01333137|DRUG|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
223963885|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol Env A/B/C|1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
224110867|NCT06969885|BEHAVIORAL|Intervention application with virtual reality glasses|In the preoperative period, approximately 1 hour before the procedure, a video will be watched for 15 minutes with virtual reality glasses. Approximately 10 minutes before the procedure, the patients will be administered the Physiological Parameters Monitoring Form, Distress Thermometer and VAS, and the data collection process will be completed.
224110868|NCT06969885|BEHAVIORAL|Standard application|No intervention will be made to the patients outside of the hospital routine, and approximately 10 minutes before the procedure, the Physiological Parameters Monitoring Form, Distress Thermometer and VAS will be applied again and the data collection process will be completed.
224110869|NCT06971809|BEHAVIORAL|Pain resilience|A strengths-based approach to pain recovery
224110870|NCT06971809|BEHAVIORAL|Pain education|A health literacy approach
223963886|NCT01159990|BIOLOGICAL|rAd5 Gag-Pol|5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
224110871|NCT01568411|DRUG|TD-1211|Period 1
224110872|NCT01568411|DRUG|TD-1211+ itraconazole|Period 2
224110873|NCT03304951|DEVICE|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
223724617|NCT05285813|DRUG|Diphenhydramine|Given by mouth (PO) or Given by vein (IV) about 30-60 minutes before the dose
224110874|NCT02011503|PROCEDURE|Multi-layer compression therapy|Application of multi-layer compression therapy.
224110875|NCT02011503|OTHER|Application of dHACM|Application of dHACM to ulcer.
224110876|NCT01088412|DRUG|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
224110877|NCT02031900|DEVICE|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
224110878|NCT02231203|DRUG|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
223724618|NCT03691792|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
223724619|NCT03691792|OTHER|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
224110879|NCT02231203|DRUG|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
223724620|NCT04488068|PROCEDURE|Sham Magnetic stimulation|Sham Magnetic stimulation for comparison.
223724621|NCT02063620|DRUG|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
223963887|NCT03730311|DRUG|Elpida|elsulfavirine, capsules
223963888|NCT03730311|DRUG|placebo|placebo
223963889|NCT01074437|DRUG|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
223963890|NCT01074437|DRUG|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
223963891|NCT01074437|DRUG|Placebo|Liquid placebo will be given during the two month treatment trial.
223963892|NCT00953342|BEHAVIORAL|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
223963893|NCT00953342|BEHAVIORAL|Usual care|Standard medical care
223963894|NCT02222844|OTHER|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
224110880|NCT00611793|DRUG|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
224110881|NCT02236585|PROCEDURE|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
224110882|NCT02236585|PROCEDURE|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
223963895|NCT06003738|PROCEDURE|fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of 0.25% bupivacaine will be injected."
224110883|NCT01948934|PROCEDURE|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
224110884|NCT06971380|BIOLOGICAL|HBI0101 CART|HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART may be provided fresh or cryopreserved.
224110885|NCT06969625|PROCEDURE|(SHAC) block|The shoulder anterior capsular block targets interfacial and pericapsular space. A 25-gauge 80-mm insulated stimulating needle will be used for injections and in-plane needling will be from lateral to medial side. After aspiration is negative, 10 ml of 0.5 % bupivacaine plus dexamethasone 4 mg as adjuvant will be injected in the interfacial plane. Once the injection into the fascial space is achieved, the operator can proceed towards the glenohumeral pericapsular space by crossing the subscapularis muscle with the needle and the second injection after negative aspiration will be 10 ml 0.5 % bupivacaine plus dexamethasone 4 mg in pericapsular space.
224110886|NCT06969625|PROCEDURE|(SSNB-ANB) block|"Suprascapular Nerve Block (SNB): Using an in-plane ultrasound guidance from the medial side, 10 mL of 0.5% bupivacaine plus dexamethasone 4 mg as adjuvant will be injected after contacting the lateral aspect of the supraspinous fossa and negative aspiration confirmed. The LA should spread beneath the supraspinatus, lifting up the muscle.~Axillary Nerve Block (ANB):~The ANB is performed from behind the patient with the patient seated. The axillary nerve will be identified within the quadrilateral space by placing high frequency linear probe (Sono site M turbo) parallel to the long axis of the humeral shaft. The nerve was identified next to the circumflex artery. The skin will be anesthetized with 1% lidocaine (3mL). 10 mL of 0.5% bupivacaine plus dexamethasone 4 mg will be injected against the surface of the humerus, just posterior and lateral to the artery after confirming negative aspiration."
224110887|NCT06970171|DEVICE|MAD of the Scheu Dental type with lateral guidance wings (MAD-1)|The vertical dimension is raised to achieve an incisal edge distance (IED) of 5 mm using a George Gauge, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.
224110888|NCT06970171|DEVICE|MAD of the Panthera X3 type with lateral guidance wings (MAD-2)|The vertical dimension is raised to achieve a minimum 2 mm interocclusal cusp distance and the lowest possible IED, with a mandibular advancement of 5 mm at insertion, progressing to final titrated advancement during the treatment phase.
224110889|NCT06972082|DEVICE|VEXUS|Goal-directed fluid and drug therapy according to VEXUS measurements to minimize AKI
224110890|NCT06095674|DRUG|Anti-PD-1 antibody balstilimab|Both antibodies will be neoadjuvantly administered around the cervical tumor.
224110891|NCT01670851|DEVICE|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
224110892|NCT05848713|DRUG|Heparin|"Preference is for LMWH given ease of administration and possibility of a more favorable safety profile, if no contraindication is present. Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.~Alternatively, intravenous UFH may be used and may be preferred in the presence of significant renal compromise. Intravenous UFH is typically dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value, or a corresponding UFH anti-Xa level. If UFH is used, the availability of a local site policy that specifies an aPTT target in this range or a corresponding anti-Xa value is a requirement."
224110893|NCT01030042|DRUG|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
224110894|NCT01030042|DRUG|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
224110895|NCT03912467|OTHER|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
224110896|NCT00301067|DIETARY_SUPPLEMENT|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
224110897|NCT00301067|DRUG|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
224110898|NCT06387719|DIAGNOSTIC_TEST|Magnetic resonance imaging|"* Basic sequence for ethical consideration: evaluation of casual findings.~* Structural MRI.~* Functional MRI (fMRI) in the Resting-state~* fMRI- task based. Presented in a computer screen on a magnetically compatible googles."
224110899|NCT02533648|DRUG|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
224110900|NCT02533648|DRUG|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
223963896|NCT06003738|PROCEDURE|pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of 0.25% bupivacaine will be injected .
223963897|NCT06003738|PROCEDURE|palcebo fascia iliaca compartment block|"Block will be performed using an ultrasound machine with a high-frequency linear probe covered with a sterile sheath and 100 mm needle.~The patient will be positioned supine to perform the block, the skin is disinfected and the transducer positioned to identify the femoral artery and the iliopsoas muscle and fascia iliaca. The transducer is moved laterally until the sartorius muscle is identified. The in-plane technique will be used, and the tip of the needle will be inserted between the fascia iliaca and iliopsoas muscle. a syringe containing 15ml of normal saline will be injected."
223963898|NCT06003738|PROCEDURE|palcebo pericapsular nerve block|The block will be performed using the curvilinear low-frequency ultrasound probe to be placed over the line parallel to the inguinal ligament then It will be rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will be inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly a syringe containing 15ml of normal saline will be injected .
223963899|NCT00119756|DRUG|paliperidone palmitate|
223963900|NCT04542200|BIOLOGICAL|Antibody testing|The antibody results include understanding modifications from environments at work and the community.
223963901|NCT01837719|DRUG|Atazanavir|300-mg capsule
223963902|NCT01837719|DRUG|Cobicistat|150-mg tablet
223963903|NCT01837719|DRUG|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
224110901|NCT06971159|DEVICE|Systemic vibratory therapy|Systemic vibratory therapy is an intervention in which mechanical vibration, generated by the vibrating platform, is transmitted to the whole-body of the individual generating whole-body vibration exercise.
224110902|NCT06971159|OTHER|Osteopathic manipulative treatment|Osteopathic manipulative treatment is defined by the WHO as a diagnostic and therapeutic method that uses manual contact for these purposes. It concerns the relationship between body, mind and spirit in health and illness, emphasizing the structural and functional integrity of the body and the body's intrinsic tendency to direct itself towards healing.
224110903|NCT06971159|OTHER|Sham|In the sham group, the interventions are simulated, as described in the sham group protocol.
224110904|NCT02186327|BEHAVIORAL|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
224110905|NCT06244368|DRUG|GVM±R regimen|"Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1； Gemcitabine (800 mg/m\^2) on day 1,8； Vinorelbine (20mg/m\^2) on day 1,8； Rituximab (375mg/m\^2) on day 1;~The regimen will be administered every 3 weeks, for a maximum of 6 cycles. The choice of CD20 monoclonal antibody will be determined by the attending physician."
224110906|NCT05937685|BEHAVIORAL|BP REACH Intervention|Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
224110907|NCT06483633|BEHAVIORAL|MICT + CPT, HIIT + CPT, SIT + CPT|Single acute intervention, each exercise mode had a washout period of at least 7 days.
224110908|NCT03411733|OTHER|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
223963904|NCT04238559|OTHER|Self-report questionnaire|Fill in the SWAMECO questionnaire
223963905|NCT01475019|DRUG|Orlistat|Tablet, 120 mg, three times daily, for six months
223963906|NCT01475019|DRUG|Sibutramine|Tablet, 10 mg, once daily, for six months
223963907|NCT01475019|BEHAVIORAL|Diet and physical exercise|Hypocaloric diet and regular physical exercise
223963908|NCT05286008|DRUG|Normal saline|Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223963909|NCT05286008|DRUG|Ropivacaine at high concentration|Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223963910|NCT05286008|DRUG|Ropivacaine and dexamethasone|Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
223963911|NCT04466397|DEVICE|3D printed individualized porous implants|Use 3D printed individualized porous implants to reconstruct the large bone defects caused by tumor, infection or trauma.
223963912|NCT02343978|DRUG|KWA-0711|
223963913|NCT01703988|DRUG|Nusinersen|Single IT injection for each dose
224110909|NCT06249542|OTHER|Care Delivery Improvement Intervention|"KPWA clinical leaders and clinicians in each clinic implemented all aspects of the care delivery improvement intervention, including screening, assessment, and shared decision-making followed, as appropriate, by treatment. The implementation strategy, which was refined during the pilot phase, included:~1. Identification of a clinical champion and local implementation team~2. Participatory design~3. Training of primary care providers and medical assistants~4. Use of EHR clinical decision support tools~5. Weekly facilitated local implementation team meetings~6. Performance monitoring with feedback, including monthly meetings with the local implementation team and clinic leaders~7. Learning sessions for primary care providers during implementation~8. Social worker use of an EHR registry with weekly supervision~9. Use of a video and informational handouts to shift attitudes and reduce stigma associated with unhealthy substance use"
223963914|NCT05194813|OTHER|Aqua alvim CM, neodent implant (Test)|Acqua, Hydrophilic sandblasted, and acid-etched dental implants
223963915|NCT05194813|OTHER|Neoporous alvim CM, neodent implant (Control)|Neoporous, Hydrophilic sandblasted, and acid-etched dental implants
223963916|NCT03743987|PROCEDURE|control group|a procedure used to prevent or resolves apical periodontitis.
223963917|NCT03743987|PROCEDURE|MTA group|a procedure used to prevent or resolves apical periodontitis.
223963918|NCT03743987|PROCEDURE|PRF group|a procedure that is used for wound healing
223963919|NCT03743987|PROCEDURE|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
223963920|NCT05885841|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
223963921|NCT06247488|DRUG|Placebo|Participant will receive oral dose of placebo.
223963922|NCT06247488|DRUG|Oxycodone 20 mg|Participant will receive oral dose of oxycodone 20 mg.
223963923|NCT06247488|DRUG|GE-IR 200 mg|Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.
223963924|NCT06247488|DRUG|GE-IR 450 mg|Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.
223963925|NCT02749175|DEVICE|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
223963926|NCT02749175|DEVICE|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
224110910|NCT00346515|DEVICE|FiberNet Emboli Protection System|
224110911|NCT01634347|DRUG|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
223963927|NCT02995733|DRUG|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
223963928|NCT00790777|DRUG|Paliperidone ER|
223963929|NCT04775173|DRUG|Sirolimus|Use of different doses of the same drug
223963930|NCT03802487|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
223963931|NCT03802487|DRUG|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
224110912|NCT01634347|DRUG|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
224110913|NCT02195648|OTHER|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
223963932|NCT03802487|DRUG|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
223963933|NCT05550077|DIAGNOSTIC_TEST|Optical Coherence Tomography|Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography
223963934|NCT05550077|PROCEDURE|Percutaneous transluminal angioplasty and stenting|Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
223963935|NCT04697641|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg twice a day for two weeks
223963936|NCT04697641|DRUG|Amoxicillin 1000 MG|Amoxicillin 1000mg twice a day for two weeks
223963937|NCT04697641|DRUG|Pantoprazole 40mg|Pantoprazole 40 mg or equivalent for eight weeks
223963938|NCT04697641|DRUG|Levosulpiride|Levosulpiride 25 mg as and when required before meals
223963939|NCT04697641|DRUG|Acotiamide|Acotiamide 100mg as when required before meals
223963940|NCT04697641|DRUG|Itopride|Itopride 50mg as when required before meals
223963941|NCT06353919|OTHER|Yoga Nidra|"Recordings were created to allow participants access to a variety of Yoga Nidra practices. Participants will be instructed to complete a 30-minute Yoga Nidra 3-5 times per week, at any time of day or night (including before bed and/or during bouts of sleeplessness). This duration and frequency is informed by previous studies.~Related to intentionally decreasing BZRA use, the recording requests each practitioner to set a resolve/personal goal at the start of each practice, and they are asked to repeat it again at the end. In our study, participants will be asked to develop a short and simple resolve in their own words, related to reducing BZRA use, improving sleep and decreasing anxiety, and they will be asked to recite it at each practice."
224110914|NCT05646550|DRUG|CC-1 Infusion|Short term (3h) infusion of CC-1
224110915|NCT04036266|PROCEDURE|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
224110916|NCT03520049|DRUG|Oseltamivir|
224110917|NCT03520049|DRUG|Placebo|
223963942|NCT06353919|OTHER|Sleep Hygiene, Anxiety, and Benzodiazepine Receptor Agonist Education|Participants will be instructed to access excerpts from standardized and trusted materials through our online platform for 30 minutes, 3-5 times per week.
223963943|NCT00905814|DRUG|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
223963944|NCT00905814|DRUG|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
223963945|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)|0.25 mL per dose.
223963946|NCT06642558|BIOLOGICAL|Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)|0.5 mL per dose
223963947|NCT06642558|BIOLOGICAL|Placebo (Saline solution)|0.5 mL per dose
223963948|NCT00243633|PROCEDURE|Real-time contrast-enhanced ultrasound sonography|
224110918|NCT03622645|DEVICE|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
224110919|NCT03929042|DEVICE|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
224110920|NCT04170621|DEVICE|Ablation|Ablation using the FARAPULSE Endocardial Multi Ablation System
223724622|NCT04165447|BEHAVIORAL|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
223724623|NCT00717132|BEHAVIORAL|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
223724624|NCT00717132|BEHAVIORAL|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
223963949|NCT00000236|DRUG|Buprenorphine/naloxone|
223963950|NCT05023941|DRUG|Acetazolamide|Start orally take acetazolamide 125mg twice daily, 2 days before entering the hypoxic chamber. Subjects will enter the hypoxic room at 9am on the third day. At that time, the subject should have taken the drug 5 times.
223963951|NCT05023941|DEVICE|Doctormate® (twice daily for 6 days)|Start RIPC training twice daily, 6 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the seventh day. At that time, the subject should have finished 13 times of RIPC training.
224110921|NCT05263882|DRUG|Gemcitabine combined with eribulin|"* Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur."
224110922|NCT01661647|DEVICE|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
224110923|NCT03777930|DRUG|Chemotherapy drugs|According to the NCCN Guidelines
224110924|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
224110925|NCT03777930|OTHER|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
224110926|NCT03777930|DRUG|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
224110927|NCT01172171|DRUG|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
224110928|NCT01172171|DRUG|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
224110929|NCT05777525|COMBINATION_PRODUCT|"application of cream La Chinata"|application of cream enriched with essential oil
224110930|NCT01208181|DRUG|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
224110931|NCT01208181|DRUG|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
224110932|NCT01208181|DRUG|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
224110933|NCT01208181|DRUG|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
224110934|NCT03856450|DEVICE|DTS|Subjects undergo wrist imaging using DTS.
224110935|NCT03856450|DEVICE|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
224110936|NCT03856450|DEVICE|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
224110937|NCT00527852|DEVICE|Flocked swab|
223963952|NCT05023941|DEVICE|Doctormate® (forth daily for 3 days)|Start RIPC training forth daily, 3 days before entering the hypoxic chamber. RIPC will be induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®). Each training will be comprised of 5 cycles of bilateral upper limb ischemia and reperfusion, which will be induced by 2 cuffs placed around the upper arms respectively and inflated to 200mmHg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Subjects will enter the hypoxic room at 9am on the forth day. At that time, the subject should have finished 13 times of RIPC training.
223963953|NCT01599377|DRUG|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
223963954|NCT01599377|DRUG|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
223963955|NCT01021202|PROCEDURE|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
223963956|NCT02946450|DRUG|Other: Not applicable-observational study|
223963957|NCT00740298|OTHER|sucrose|sweet taste
223963958|NCT00740298|OTHER|warmth|warmth
223963959|NCT00574626|PROCEDURE|PBSCT|Peripheral Blood Stem Cell Transplant
223963960|NCT00574626|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant
224110938|NCT00987766|DRUG|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
224110939|NCT00987766|DRUG|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
224110940|NCT00987766|DRUG|oxaliplatin|Given through a vein in the arm 1 time every other week.
223963961|NCT04636021|DIAGNOSTIC_TEST|COVID-19 testing|Pre and post procedure COVID-19 testing for patients undergoing outpatient cardiac procedures.
223963962|NCT06545721|OTHER|Adjusting dietary structure + exercise + behavioral intervention|Adjusting to a healthy diet involves consuming low GI and low-fat foods, avoiding sugary drinks, increasing dietary fiber intake, reducing saturated fat while increasing omega-3 unsaturated fat intake, and limiting trans fat consumption. A weight loss program includes a high-protein diet, exercise, and behavioral intervention with daily total energy needs calculated based on ideal body weight (kg) x 15-20 kcal/kg/d; developing a daily meal plan with regular protein supplementation; limiting salt intake to ≤5 g/d; ensuring adequate water consumption at 2-3L/d; aiming for a dietary fiber intake of 25-30g/d; recommending micronutrient supplementation as needed; maintaining daily aerobic exercise (40 minutes at 70-80% HRmax) along with resistance training (20 minutes); establishing an early bedtime before 11pm and an early wake-up time.
224110941|NCT00987766|OTHER|laboratory biomarker analysis|Blood and tissue collection.
224110942|NCT00411515|DRUG|Mycophenolate Mofetil 2x 1g|
224110943|NCT00451087|PROCEDURE|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
224110944|NCT00451087|PROCEDURE|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
224110945|NCT04598438|BEHAVIORAL|Music behavioral early intervention program|The program consists of carefully designed play-based enhancement strategies implemented in the form of hybrid online/in-person playgroups. Following a teach-model-coach-review approach, parents will learn to implement various skills that are expected to enhance infant's language and communication skills through singing and engaging in musical play with their child at home.
224110946|NCT04598438|BEHAVIORAL|Arts and crafts early enhancement program|The program follows the same general structure with the music intervention program. Parents will learn how to implement a series of arts and crafts activities at home, with an aim to enhance infant's visual-perceptual, motor, and sensory integration development.
224110947|NCT00256555|DRUG|Nutropin AQ|
224110948|NCT00810160|DIETARY_SUPPLEMENT|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
224110949|NCT00810160|DIETARY_SUPPLEMENT|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
224110950|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
224110951|NCT00810160|DIETARY_SUPPLEMENT|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
223963963|NCT06003868|OTHER|traditional physiotherapy|Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
224110952|NCT02772380|DEVICE|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
224110953|NCT01457339|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
224110954|NCT01457339|DRUG|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
223963964|NCT06003868|OTHER|hippotherapy-assisted physiotherapy|"The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level."
223963965|NCT00210964|DRUG|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
223963966|NCT00210964|DRUG|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
223963967|NCT05303415|OTHER|Neuromodulation with low-intensity focused ultrasound|Application of LIFU to induce temporary neuromodulation, effects tested with resting state and heat evoked (QST) fMRI signals
223963968|NCT04879823|DRUG|Dexamethasone|IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup
223963969|NCT04879823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
224110955|NCT02660658|DRUG|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
224110956|NCT00765479|DIETARY_SUPPLEMENT|soy protein isolate|Given orally
224110957|NCT00765479|OTHER|placebo|Given orally
224110958|NCT03831503|BIOLOGICAL|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
224110959|NCT03831503|DEVICE|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
224110960|NCT03831503|DEVICE|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
224110961|NCT03495505|DEVICE|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
224110962|NCT05115318|DRUG|Medical Cannabis|Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
224110963|NCT04575129|OTHER|No intervention will be applied|No intervention will be applied
223963970|NCT04879823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
223963971|NCT04879823|DRUG|Placebo|An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
223963972|NCT05313178|DIETARY_SUPPLEMENT|Bacillus Coagulans GBI-30, 6086|In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
223963973|NCT04047225|DEVICE|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
223963974|NCT04468633|DEVICE|Baerveldt 350 implant|The Baerveldt implant is an FDA-approved silicone, non-valved implant.
223963975|NCT04468633|DEVICE|Ahmed ClearPath 350 implant|The Ahmed ClearPath is a non-valved glaucoma drainage device.
223963976|NCT05653050|DEVICE|CamAPS HX|Fully automated closed-loop system (CamAPS HX) with ultra-rapid insulin aspart.
224110964|NCT05999305|OTHER|Teaching the critical care nursing course with an Escape Room game|A teacher will begin with a 1.5-hour lecture, followed by an escape room game to reinforce learning through case studies for another 1.5 hours. The first section of the game will be a ten-minute pre-brief. The game will then begin promptly at a designated time and will be played in groups of six to seven students, with each group seated separately in a classroom. The game will last up to fifty minutes, during which all groups will be assisted to complete puzzles within the time limit. After the game, a fifteen-minute debriefing session will be held by the teacher, during which the students will reflect on their performance and what they learned about the cases and related topics. The teacher will finally provide feedback and support to the groups during this session.
224110965|NCT05999305|OTHER|Teaching the critical care nursing course with a case-based learning|Students in the comparison group will also receive a 1.5 hour lecture which is the same as those in the intervention group. Another 1.5 hour is a case-based learning session, with six sessions in total over six weeks. The case-based learning sessions will include a pre-brief, teamwork, and debrief, and will be facilitated by the same teacher and teaching assistant and will primarily be provided with paper-based case studies.
224110966|NCT01112215|DRUG|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
224110967|NCT01112215|DRUG|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
224110968|NCT03085732|DRUG|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
224291380|NCT04387682|DIETARY_SUPPLEMENT|β-glucan|β-glucan, a biological response regulator, derived from yeast has been known for more than 45 years, and has anti-infective and anti-tumor activities. β-glucan is a molecule with a β-1,3-linked D-glucose backbone and β-1,6-linked side chains. Thus far, at least 4 receptors for β-glucan have been discovered in humans, which are surface antigens associated with macrophages or myeloid precursor cells as complement receptor 3 (CR3; CD11b/CD18, Mac-1, αMβ2 integrin) (Vetvicka et al. 1996; Xia et al. 1999), lactosylceramide (Zimmerman et al. 1998), scavenger receptor (Rice et al. 2002) and dectin-1 (Brown et al. 2003; Taylor et al. 2007; Saijo et al. 2007).
223963977|NCT05653050|DEVICE|Standard insulin pump therapy with CGM|Participants usual insulin pump therapy with Freestyle Libre 3 CGM
223963978|NCT05185089|DRUG|Orvepitant Maleate|Orvepitant tablets 30mg or 10mg
223963979|NCT05185089|DRUG|Placebo|Placebo tablets to match orvepitant 30mg and 10mg tablets
223963980|NCT02592902|PROCEDURE|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
223963981|NCT02592902|PROCEDURE|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
223963982|NCT01033123|DRUG|BSI-201|IV infusion, 5.6 mg/kg
223963983|NCT06398015|PROCEDURE|Surgical reconstruction of hip abductor tendon tear|"If the patient is allocated to surgical reconstruction, the incision from the sham surgery is continued into the iliotibial band (ITB) and down to the hip abductor tendon complex/greater trochanter. A standardized reconstruction of the HAT with bone anchors is then performed.~This standardized procedure has been used by the surgeons for the last 6 years. The ITB is then closed with looped suture, the subcutaneous tissue sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing is applied."
223963984|NCT06398015|PROCEDURE|Sham surgery of hip abductor tendon tear|If the patient is allocated to sham surgery, the incision will only include the skin and subcutaneous tissue. Subsequently, the subcutaneous tissue will be sutured with standard resorbable single sutures, the skin stapled and a standard wound dressing applied. The patient will be kept in general anesthesia for 10 minutes after the procedure is finalized to mimic a true intervention (to hinder staff or relatives to comment on the duration of the procedure). The normal standard procedure takes approximately 40 minutes.
223963985|NCT00289952|DRUG|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
223963986|NCT00289952|DRUG|HAART|As per standard of care.
223963987|NCT01843920|DRUG|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
224291381|NCT00946049|DEVICE|Vicryl Plus|
224291382|NCT00946049|DEVICE|Vicryl|
223963988|NCT01843920|DRUG|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
223963989|NCT01086514|PROCEDURE|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
223963990|NCT03398889|DIAGNOSTIC_TEST|Plasma levels of metabolites|plasma levels of metabolites
223963991|NCT03398889|BEHAVIORAL|Dietary questionnaire|Harvard food frequency questionnaire
223963992|NCT03398889|DIAGNOSTIC_TEST|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
223963993|NCT00244556|DRUG|Methotrexate plus ENBREL or ENBREL alone|
223963994|NCT00460434|DEVICE|TVT|Prophylactic TVT
223963995|NCT00460434|OTHER|Sham|Sham TVT
223963996|NCT02292056|BEHAVIORAL|1-on-1 counseling|"1. Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~2. Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~3. Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~4. 10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~5. Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~6. Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
223963997|NCT03426709|BEHAVIORAL|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
223963998|NCT01381185|DRUG|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
223963999|NCT03593798|OTHER|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
223964000|NCT04653987|PROCEDURE|Percutaneous biliary drainage|
223724625|NCT00796198|DRUG|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
223724626|NCT00796198|DRUG|Xalatan|Xalatan ophthalmic solution one drop at 10pm
223724627|NCT05391516|DIAGNOSTIC_TEST|Evaluation of shoulder problems|The developed items and Shoulder Pain and Disability Index-SPADI will be directed to the participants.
223964001|NCT04232202|DEVICE|Er:YAG and Nd:YAG lasers|Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.
223964002|NCT04232202|PROCEDURE|Standard extraction|Standard extraction procedure
223964003|NCT01358201|DRUG|vINCRISTINE|
223964004|NCT01358201|DRUG|Dexamethasone|
223964005|NCT01358201|DRUG|Methotrexate|
223964006|NCT01358201|DRUG|Cytosine arabinoside|
223964007|NCT00604344|DRUG|insulin detemir|
224291383|NCT04432675|DRUG|hydroxyethl starch|10 ml/kg hydroxyethl starch as well as goal-directed fluid therapy with 3ml/kg hydroxyethl starch
224291384|NCT04432675|DRUG|Lactated Ringer's solution|10 ml/kg Lactated Ringer's solution as well as goal-directed fluid therapy with 3ml/kg Lactated Ringer's solution
223964008|NCT00604344|DRUG|insulin NPH|
223964009|NCT00641797|DRUG|Meclizine|medication administration 25mg PO one time
223964010|NCT00641797|OTHER|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
223964011|NCT00641797|DRUG|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
223964012|NCT00641797|DRUG|Diphenhydramine|25 - 50mg PO/IV once prn
223964013|NCT00641797|DRUG|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
223964014|NCT05481996|OTHER|App-Based Pain Education and Exercise|Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a smartphone application created especially for the study that will contain a program of progressive physical exercises with images and descriptions, educational messages and an online booklet for the study subjects, totaling 8 weeks of training and pain education.
223964015|NCT05481996|OTHER|Online booklet|An online booklet containing information about chronic low back pain and weekly messages about low back pain causes, suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
223964016|NCT01605084|DRUG|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
223964017|NCT01605084|DRUG|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
223964018|NCT01605084|DRUG|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
223964019|NCT01605084|DRUG|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~\- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~* Didanosine + Stavudine~* Zidovudine + Stavudine~* Lamivudine + Emtricitabine"
223964020|NCT01090856|PROCEDURE|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
223964021|NCT00845286|BEHAVIORAL|Munich Marathon|42,195 km marathon run
223964022|NCT02782273|DRUG|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
224110969|NCT06034730|DEVICE|Portable GC device for brath analysis|Patients were asked to orally exhale 1-2 L breath into a 5 L Tedlar bag via a one-way mouthpiece and Nafion filter for moisture removal, as shown in Figure 1B. The process usually takes about a few minutes. The breath analysis took place either in-situ immediately after the breath sample collection or within 24 h of breath collection. The Tedlar bags were stored under ambient condition until analyzed. During the breath analysis, the Tedlar bag was connected to the sampling port of the portable GC (Figure 1C). Approximately 350 mL of breath was pulled from the Tedlar bag into the GC for analysis. The GC operation was controlled using LabView via a laptop. The total assay time was 30 min, including 5 min of breath sampling time from the Tedlar bag at a flow rate of 70 mL/min (see the blue path in Figure 1A), 5 min of desorption/transfer time, 10 min of chromatographic separation time (see the orange path in Figure 1A), and 10 min of GC system cleaning time.
223964023|NCT02782273|DRUG|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
223964024|NCT05655689|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|In the observational study, patients treated with topical antibiotic moxifloxacin 0.5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964025|NCT05655689|DRUG|Ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with topical fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964026|NCT05655689|DRUG|Gentamicin 1.4% + vancomycin 5%|In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964027|NCT05655689|DRUG|Natamycin 5% Oph Susp|In the observational study, patients treated with the topical natamycin 5% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964028|NCT05655689|DRUG|Voriconazole 1%|In the observational study, patients treated with voriconazole 1% antifungal eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964029|NCT05655689|DRUG|Natamycin 5% + voriconazole 1%|In the observational study, patients treated with the topical natamycin 5% and voriconazole 1% antifungals eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964030|NCT05655689|DRUG|Natamycin 5%+ ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical natamycin 5% and antifungal and the fortified antibiotic ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964031|NCT05655689|DRUG|Voriconazole 1% + ceftazidime 5% + vancomycin 5%|In the observational study, patients treated with the topical voriconazole 1% antifungal and the fortified antibiotics ceftazidime 5% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
223964032|NCT03363100|BEHAVIORAL|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
223964033|NCT03890692|PROCEDURE|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~* Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\\ septum\\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
223964034|NCT05971199|DRUG|Fruquintinib|Fruquintinib:5 mg capsule orally once daily on day 1-21 in 28-day cycles；
223964035|NCT05971199|DRUG|Sintilimab|Sintilimab: 200 mg i.v. every 3 weeks
223964036|NCT05971199|DEVICE|Transcatheter arterial chemoembolization（TACE）|Transcatheter arterial chemoembolization（TACE）
223964037|NCT01952002|OTHER|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
223964038|NCT03249961|DEVICE|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
223964039|NCT03249961|DEVICE|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
223724628|NCT00502645|DEVICE|CS-1 DECISION SUPPORT SYSTEM|
223964040|NCT03249961|DEVICE|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
223964041|NCT05438745|OTHER|Copenhagen Burnout Inventry|Questionnaire
223964042|NCT01940913|DIETARY_SUPPLEMENT|Probiotic capsules|
223964043|NCT01940913|DIETARY_SUPPLEMENT|Placebo capsules|
223964044|NCT05785975|OTHER|Certain ommunications(Nudge), community-outreach(landline call), and single FIT testing|The intervention is an integrated system made up of single FIT testing, community outreach (landline call), and specific messages (Nudge). In order to encourage people to attend the screening, a primary care physician will be used in addition to text messages that participants at the outreach get for information, education, and communication (IEC).
223964045|NCT03460444|DIETARY_SUPPLEMENT|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
223964046|NCT00908193|DEVICE|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
223964047|NCT00908193|PROCEDURE|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
223964048|NCT05064475|DIAGNOSTIC_TEST|PET/CT|Patients with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients will underwent 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT. The final diagnosis of relapse will be derived from histopathological sampling As much as possible or radiological follow up for at least 6 months will be compared with PET/CT results.
223964049|NCT00004276|DRUG|thalidomide|
223964050|NCT02722278|DRUG|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
223964051|NCT02722278|DRUG|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
223964052|NCT00490243|DRUG|budesonide and montelukast|
223964053|NCT00490243|DRUG|budesonide and formoterol|
223964054|NCT00490243|DRUG|montelukast|
223964055|NCT00490243|DRUG|budesonide|
223964056|NCT00490243|DRUG|placebo|
223964057|NCT02465866|DRUG|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
223964058|NCT02465866|DRUG|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
223964059|NCT02465866|DRUG|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
224110970|NCT00918762|PROCEDURE|assessment of therapy complications|
224110971|NCT00918762|PROCEDURE|diagnostic endoscopic surgery|
224110972|NCT00918762|PROCEDURE|quality-of-life assessment|
224110973|NCT00918762|PROCEDURE|therapeutic conventional surgery|
224110974|NCT00918762|PROCEDURE|therapeutic endoscopic surgery|
224110975|NCT00918762|PROCEDURE|transoral robotic surgery|
224110976|NCT00918762|PROCEDURE|video-assisted surgery|
223964060|NCT02465866|DRUG|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
223964061|NCT05038319|PROCEDURE|EUS|The procedures would be performed by a therapeutic endoscope with the through the scope method. The endoscope would be used to reach the site of Varices.
223964062|NCT03180086|OTHER|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
223964063|NCT05591456|RADIATION|adjuvant radiotherapy|Treatment schedule and delivery The patients who met the inclusion criteria were randomly divided into two groups, each group of 50 patients. The first group (arm A) will receive a dose of 27 Gy to the chest wall using 3D conformal radiotherapy (5.4 Gy per fraction) over one week, whilst, the second group (arm B) will receive a dose of 40 Gy to the chest wall (2.67 Gy per fraction) over three weeks.
223964064|NCT06384859|DEVICE|ESWT|Receive ESWT once a week for 4 weeks
223964065|NCT06384859|BIOLOGICAL|PRP|Receive PRP injection at week 5
223964066|NCT02295293|DRUG|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
223964067|NCT02295293|DRUG|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
223964068|NCT01562288|GENETIC|DNA analysis|
223964069|NCT01562288|GENETIC|gene expression analysis|
223964070|NCT01562288|GENETIC|polymerase chain reaction|
223964071|NCT01562288|OTHER|enzyme-linked immunosorbent assay|
223964072|NCT01562288|OTHER|laboratory biomarker analysis|
223964073|NCT00203502|DRUG|Bevacizumab|IV 15mg/kg 21 days
223964074|NCT00203502|DRUG|Cyclophosphamide|500mg per meter squared, IV every 21 days
223964075|NCT00203502|DRUG|Docetaxel|60 mg per meter squared, IV every 21 days
223964076|NCT02023099|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
223964077|NCT02023099|DRUG|Placebo|Tablet
223964078|NCT00597779|DEVICE|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
223964079|NCT02450279|DRUG|technetium-99m - Diethylenetriaminepentaacetic acid|
224110977|NCT03330691|BIOLOGICAL|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
224110978|NCT00001737|DRUG|Cyclosporin A Implant|
223964080|NCT02450279|DEVICE|Vibrating-mesh nebulizer|
224110979|NCT06513195|PROCEDURE|endoscopic ultrasound-guided portal pressure measurement|The portal pressure gradient will be determined by endoscopic ultrasound-guided pressure measurement in the hepatic vein and the portal vein. The gradient will be calculated by substracting the hepatic vein pressure from the portal vein pressure.
223964081|NCT02450279|DEVICE|Jet Nebulizer|
223964082|NCT02450279|OTHER|Planar scintigraphy|
223964083|NCT02450279|OTHER|Preoperative spirometry|
223964084|NCT02916524|BEHAVIORAL|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
224110980|NCT01894282|PROCEDURE|Manual Therapy|Manual Therapy Arm
224110981|NCT01894282|PROCEDURE|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
224110982|NCT03427840|PROCEDURE|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
224110983|NCT01094483|DRUG|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
223964085|NCT00801905|DRUG|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
223964086|NCT00801905|OTHER|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
223964087|NCT01071720|DRUG|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
223964088|NCT02699437|OTHER|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
223964089|NCT01088347|DRUG|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
223964090|NCT01088347|DRUG|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
223964091|NCT01088347|RADIATION|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
223964092|NCT05147545|OTHER|Moderate intensity physical effort|Pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer
223964093|NCT05147545|OTHER|Low intensity physical effort|Pedaling 3 minutes at the 30 Watt level of the ergometer
223964094|NCT05147545|OTHER|Hyperlipidic meal|Eating an hyperlipidic meal 60 minutes after a physical effort
223964095|NCT05147545|DIAGNOSTIC_TEST|Measure of circulating DNA|"Multiple measure of circulating DNA: on an empty stomach, at the end of the physical effort, after 15, 30 and 60 minutes of rest, 120 minutes after an hyperlipidic meal.~An additional measure will occur for subjects free of malignancy during the effort."
223964096|NCT01469819|DRUG|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
223964097|NCT02093078|BEHAVIORAL|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
223964098|NCT00967915|PROCEDURE|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
223964099|NCT00967915|OTHER|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
223964100|NCT00935129|DEVICE|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
224110984|NCT01094483|DRUG|ASA|Asprin 81 mg enteric coated tablet
224110985|NCT01094483|DRUG|Placebo|
224110986|NCT02333045|DRUG|Truvada qd|Truvada 1 tablet PO daily for 7 days
224110987|NCT02333045|DRUG|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
224110988|NCT01863862|RADIATION|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
224110989|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
224110990|NCT01751646|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
224110991|NCT02997514|BEHAVIORAL|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
224110992|NCT02997514|BEHAVIORAL|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
224110993|NCT00165568|DRUG|Bevacizumab|
223964101|NCT00935129|DEVICE|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
223964102|NCT03856294|DRUG|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
223964103|NCT03856294|DRUG|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
223964104|NCT04284722|DRUG|Metformin Hydrochloride|Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals
223964105|NCT06431360|OTHER|hyperthermia|hyperthermia (using a heater, 44℃for 15 min)
223964106|NCT02686983|DRUG|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
223542434|NCT05695170|BEHAVIORAL|PreventT2 Together (Couple-based intervention)|PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
223964107|NCT04501107|DRUG|Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)|Administration of IMP1 during a 12-hour euglycaemic clamp.
223964108|NCT04501107|DRUG|Administration of Ready-to-use BioChaperone insulin lispro (IMP2)|Administration of IMP2 during a 12-hour euglycaemic clamp.
223964109|NCT04501107|DRUG|Administration of US-approved Humalog® (IMP3)|Administration of IMP3 during a 12-hour euglycaemic clamp.
223964110|NCT04501107|DRUG|Administration of EU-approved Humalog® (IMP4)|Administration of IMP4 during a 12-hour euglycaemic clamp.
223964111|NCT02274350|RADIATION|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
223964112|NCT02301871|DEVICE|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
223964113|NCT02301871|PROCEDURE|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
224110994|NCT01475292|DRUG|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
224110995|NCT01475292|DRUG|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
224110996|NCT01475292|DRUG|Placebo|Placebo administered via a nebuliser once daily for 14 days
224291385|NCT04656730|DRUG|Iberogast® and Iberogast® N|Oral intake of the investigation drug 20 drops three times per day (TID) for 14 days,
224291386|NCT00102830|DRUG|AMG 386|
224110997|NCT02335450|BEHAVIORAL|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
223964114|NCT02301871|PROCEDURE|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
223964115|NCT03035149|OTHER|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
223964116|NCT02250911|OTHER|webcasts|
223964117|NCT02250911|BEHAVIORAL|Assessments|
224110998|NCT02335450|DEVICE|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
224110999|NCT02937610|PROCEDURE|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
223964118|NCT02250911|OTHER|Usual care|
223964119|NCT03341754|BIOLOGICAL|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
223964120|NCT03341754|BIOLOGICAL|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
223964121|NCT03341754|OTHER|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
223964122|NCT02243488|DEVICE|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
223964123|NCT04554316|DEVICE|Steri-strip|Steri-Strips (3M Health Care, St. Paul, Minn) are a commonly used means of covering surgical incisions following many operations. Use of adhesive surgical tape over incisions maintains epidermal approximation in primary skin closure while limiting exposure to the environment, theoretically improving cosmesis and limiting risk of infection.
223964124|NCT05257434|BEHAVIORAL|inbody|Body fluid composition
223964125|NCT05697822|OTHER|Mobile Phone and Cloud-based Electronic Contact and Recording System|A mobile phone application has been developed which is intended to be used by pregnant women and their healthcare workers. A pregnant woman can get registered in this app and enter information and data related to their health and current pregnancy. Their health worker at their health post can access this information on their mobile phone too. The pregnant woman can also input her daily symptom on this app. She can also input and/or access information on examination and tests that have been carried out. If a concerning symptom or event has been entered by a user in the app, the health worker will be notified through this app. The health worker can also track the pregnant women under their care through this application. A cloud-based database of pregnant women will have the details of all the pregnant women in a given ward or rural municipality. Health coordinators in the municipality will be able to access the database for their municipality and track the pregnant women, if needed.
224111000|NCT05677945|DRUG|3Mixtatin paste: Simvastatin mixed with modified triple antibiotic|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
223964126|NCT06086665|DRUG|Niraparib|Niraparib
223964127|NCT01029418|DRUG|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
223964128|NCT04057937|DRUG|Apremilast|Apremilast
223964129|NCT04057937|DRUG|Placebo|Placebo
223964130|NCT04320433|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75g anhydrous glucose dissolved in a volume of 200mL of water (NUTER.TEC GLUCOS, Subra, Toulouse, France).
223964131|NCT02394171|BEHAVIORAL|Group Cohesion|See description in arm/group above
223964132|NCT02878720|DEVICE|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy during the real or sham tVNS stimulation"
224111001|NCT05677945|DRUG|3Mix: Modified triple antibiotic mix in propylene glycol|"* Drying the mucosa with gauze,topical anesthesia will be applied.~* Administration of local anesthesia with vasoconstrictor.~* Rubber dam isolation.~* Caries removal \& access cavity using a round bur mounted on a high-speed contra with coolant.~* Removal of necrotic pulp tissue in coronal portion of the tooth using sharp excavator.~* Radicular section will be kept untouched,no instrumentation.~* Using disposable syringe Irrigation of the pulp chamber with 2.5% NaOCl.~* In case of hemorrhage moist cotton immersed in 1% NaOCL will be placed to achieve hemostasis.~* Drying the access cavity with sterile cotton pellets.~* Freshly mixed 3Mix-MP or 3Mixtatin paste (according to group of intervention) will be transferred to the floor of the pulp chamber using an amalgam carrier \& condensed over orifices using a moist cotton pellet.~* Cavity sealing with RMGI capsules.~* Same visit placement with preformed Stainless-steel crown(3M® ESPE)cemented with glass ionomer cement."
224111002|NCT04371510|OTHER|blood sample|a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
224111003|NCT02973815|BEHAVIORAL|NU-HOME Intervention|The NU-HOME family intervention program consists of seven monthly group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
224111004|NCT02613572|DRUG|alpha lipoic acid|
224111005|NCT02613572|DRUG|Placebo|
224111006|NCT02124720|BEHAVIORAL|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
224111007|NCT04542291|DRUG|Dapagliflozin|Dapagliflozin will be provided for this trial
223964133|NCT02324088|DRUG|Docetaxel|
223964134|NCT02324088|DRUG|Cyclophosphamide|
223964135|NCT02324088|DRUG|Epirubicin|
223964136|NCT00682344|DRUG|Levobupivacaïne|1,75mg/kg
223964137|NCT00312871|DRUG|Epoetin alfa|
223964138|NCT02446912|BIOLOGICAL|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
223964139|NCT02446912|DRUG|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
224111008|NCT04542291|DEVICE|BIOSENSE meters|-Being used in this trial to evaluate utility for assessing breath ketones
224111009|NCT00907725|OTHER|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
224111010|NCT00907725|OTHER|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
223964140|NCT00015171|DRUG|Buprenorphine/naloxone|
223964141|NCT02210949|DRUG|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
223964142|NCT00147745|DRUG|Colesevelam|Colesevelam 3.8g for 12 weeks
223964143|NCT00147745|DRUG|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
223964144|NCT00147745|DRUG|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
223964145|NCT05430607|BEHAVIORAL|Running therapy|A 9-week running program.
223964146|NCT04212559|OTHER|Received negative pressure ventilation|Patients who received a negative pressure during inspiratory phase.
223964147|NCT05903118|BIOLOGICAL|RBMRNA-176|Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection
223964148|NCT05903118|OTHER|Placebo|0.9% sodium chloride (normal saline) injection
223964149|NCT03151161|DRUG|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
223964150|NCT03151161|DRUG|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
223964151|NCT02829411|BEHAVIORAL|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
224111011|NCT00953121|DRUG|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
224111012|NCT00731029|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
224111013|NCT00731029|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
223964152|NCT02829411|BEHAVIORAL|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
223964153|NCT02409823|DRUG|Atypical Antipsychotics|any atypical antipsychotic
223964154|NCT05364541|DEVICE|MyoVista wavECG|A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
223964155|NCT00912275|DRUG|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
224111014|NCT00847717|PROCEDURE|Selective neck dissection|Level IIb preserving neck dissection
224111015|NCT00847717|PROCEDURE|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
224111016|NCT00000681|DRUG|Bleomycin sulfate|
224111017|NCT00000681|DRUG|Vincristine sulfate|
224111018|NCT00000681|DRUG|Doxorubicin hydrochloride|
224111019|NCT00000681|DRUG|Zidovudine|
224111020|NCT00000681|DRUG|Sargramostim|
224111021|NCT02342561|DEVICE|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
224111022|NCT01145105|PROCEDURE|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
224111023|NCT01145105|PROCEDURE|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
224111024|NCT01143597|OTHER|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
223964156|NCT04388514|PROCEDURE|Medical Ozone procedure|The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
223964157|NCT00796640|DRUG|ER Paliperidone|
223964158|NCT01509040|OTHER|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
223964159|NCT01509040|DEVICE|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
223964160|NCT01509040|DEVICE|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
223964161|NCT01878188|DRUG|BC-819/PEI|Intravesical instillation
223964162|NCT01878188|DRUG|BCG Vaccine|intravesical instillations
223964163|NCT02739841|OTHER|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
223964164|NCT02739841|OTHER|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
223964165|NCT06379451|DRUG|NKG2D Chimeric Antigen Receptor NK Cell Injection|Administer KN1102 cell injection three times on day 0, day 7, and day 14, respectively.
223964166|NCT02461719|DRUG|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
224111025|NCT05228912|DRUG|COVID-19 Vaccines|Each group will receive a complete scheme of the vaccine according to local government assignation
224111026|NCT04634968|BEHAVIORAL|Brief Motivational Interviewing interaction|Telephone peer counselling+ Brief Motivational Interviewing interaction, and telephone-based interview after receiving all information.
224111027|NCT04634968|BEHAVIORAL|General health communication|Telephone peer counselling+ General health communication, and telephone-based interview, and telephone-based interview after receiving all information.
223964167|NCT02461719|DRUG|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
223964168|NCT03660254|BEHAVIORAL|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
223964169|NCT01580735|DRUG|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
223964170|NCT02389725|DEVICE|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
223964171|NCT02389725|DEVICE|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
224111028|NCT04494711|BEHAVIORAL|Physical Functional Literacy for Adults|A 5 week physical literacy for program focused on virtual knowledge translation strategies to improve function and mobility for adults with multiple chronic conditions. This is a population -based approach to rehabilitation
224111029|NCT06656741|BEHAVIORAL|Resting State|Resting state is a mental state and a research paradigm that people do nothing and idle as much as possible to show their baseline neuro signals. In this task, we instructed participants to rest with their eyes opened for 6 minutes. The VR environment of blue sky and swaying meadow was presented to the participants throughout this task.
223964172|NCT05422859|OTHER|MobiDig|"The application will contain the following modules:~1. information and knowledge about heart failure;~2. vital sign diary, which can be sent to the certified HFU~3. pedometer (individualized step-goal), cardiac home training videos~4. frequently asked questions and connection to a certified HFU provider by a heart failure hotline"
224111030|NCT06656741|BEHAVIORAL|Mindful Breathing|Mindful breathing is a state that people focus on their inner sensation. In this task, the meadow's motion in the VR environment corresponded to the participants' inhalation and exhalation, as detected by the respiration belt. The participants were instructed to focus mentally on their bodily sensations as they breathed, with the meadow's sway as a visual cue.
224111031|NCT06656741|BEHAVIORAL|Guided Breathing|Guided breathing refers to the breath training technique that trainees are guided to inhale and exhale according to a fixed tempo. In this task, meadow swayed in a fixed tempo of 4 seconds back and 6 seconds forth. The participants were instructed to synchronize their inhalation with the meadow's backward motion (lasting 4 seconds) and their exhalation with its forward motion (lasting 6 seconds).
223964173|NCT06446531|DRUG|Placebo|Oral tablet administered once daily
223964174|NCT06446531|DRUG|Rybelsus Tablet|Oral tablet started at a 3mg dose once daily and increased to 7mg once daily or maximum tolerable dose.
223964175|NCT06446531|DRUG|Jardiance 25Mg Tablet|Oral 25 mg Sodium-Glucose Co-Transporter (SGLT2) inhibitor administered once daily
223964176|NCT06446531|DRUG|Metformin|Oral tablet started at a dose of 500mg with an increase of 500mg weekly up to a maximum dose of 2000mg (4 tablets)
223964177|NCT06446531|DRUG|Actos|Oral tablet dosed at 15mg once daily
223964178|NCT03912298|OTHER|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
223964179|NCT04021927|DEVICE|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
223964180|NCT00420797|DRUG|10% Phenylephrine hydrochloride gel|
223964181|NCT03741283|OTHER|Optimisation of nutrition and medication|"1. Inter-professional optimisation of medication prescribing:~   Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~2. Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~* Dysphagia: occupational therapy intervention.~* Oral cavity problems: odontological intervention.~* Depression: geriatric intervention.~* Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
223964182|NCT02146300|BIOLOGICAL|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
223964183|NCT03761134|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223964184|NCT03761134|DRUG|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223964185|NCT03761134|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223964186|NCT03761134|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
223964187|NCT04340726|PROCEDURE|One time abutment|
223964188|NCT00724750|DEVICE|Gauze suction (G-SUC)|Negative pressure wound therapy
223964189|NCT00724750|DEVICE|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
223964190|NCT05269303|DEVICE|Live With Wearable Monitoring Device program|The participants in the intervention group will receive a home visit by a Community Healthcare Worker in the first month, and biweekly motivational messages via Whats App in the second and third months.
223964191|NCT00001436|DRUG|OncoLAR® (Registered Trademark)|
223964192|NCT00001436|DRUG|tamoxifen|
223964193|NCT05610943|PROCEDURE|ultrasound-guided quadratus lumborum nerve block|The patient was placed in the lateral position with the side to be blocked on top. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed transversely between the iliac crest and the costa edge. After imaging the external-internal oblique and transversus abdominis muscles, the probe was advanced posteriorly. Quadratus lumborum, Psoas Major and Erector Spina muscles were visualized. The needle was advanced towards the middle thoracolumbar fascia between the Quadratus lumborum muscle and the Erector Spina muscle with the in-plane technique, and the location was confirmed by injecting 1 ml of 0.9 saline. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
224111032|NCT06656741|BEHAVIORAL|Breath Counting|Breath counting refers to the breath training technique that trainees mentally count the numbers of breath cycles they have finished in a certain period of time. In this task, similar to the mindful breathing task, the meadow's motion was synchronized with the participants' breathing patterns. During the 6 minutes, we instructed the participants to breathe naturally and mentally count their breathing cycles.
224111033|NCT06326229|OTHER|ICF entities assessment|A visual analog scale will be used by the participants to evaluate the relevance of the ICF entities in relation to their musculoskeletal condition. The scale will range from 0 (no problem) to 100 (complete problem).
224111034|NCT02818634|PROCEDURE|Harvesting rib cartilage|
224111035|NCT04538950|DIAGNOSTIC_TEST|PET/CT|Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
224111036|NCT04538950|DRUG|radioactive drug (tracer)|A radioactive drug (tracer) is used in the PET scan.
224111037|NCT04219267|BEHAVIORAL|character strengths-based intervention|"Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths."
224111038|NCT04219267|BEHAVIORAL|early memories|In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
224111039|NCT00853905|DRUG|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
223964194|NCT05610943|PROCEDURE|ultrasound-guided Ilioinguinal Iliohypogastric Nerve Block|The patient was placed in the supine position. After providing skin antisepsis with 5% povidone iodine, sterile dressing was applied. After the USG probe was covered with a sterile sheath, it was placed on the anterior abdominal wall parallel to the imaginary line between the umbilicus and the anterior superior iliac wing. After imaging the external-internal oblique and transversus abdominis muscles, the ilioinguinal-iliohypogastric nerve was visualized as two small hypoechoic areas between the internal oblique muscle and the transversus abdominis muscle. The location was confirmed by injecting 1 ml of 0.9 saline by advancing the needle with the in-plane technique close to the nerve structures. 0.25% Bupivacaine was injected at a dose of 0.5 mL/kg after negative aspiration.
223964195|NCT01890798|DRUG|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
223964196|NCT01998997|BEHAVIORAL|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
223964197|NCT00510783|DRUG|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
223964198|NCT00510783|DRUG|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
223964199|NCT00510783|DRUG|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
223964200|NCT05476770|DRUG|Tagraxofusp|Dose will be assigned at study entry. Give IV over 15 minutes.
223964201|NCT05476770|DRUG|Fludarabine|"30 mg/m\^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5."
223964202|NCT05476770|DRUG|Cytarabine|2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
223964203|NCT05476770|DRUG|Dexamethasone|"* 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~* Any oral formulation of dexamethasone is acceptable.~* IV may be given if oral formulation is not tolerated"
223964204|NCT05476770|DRUG|Vincristine|"* 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~* Infusion will start 30 minutes after start of tagraxofusp on day 8."
223964205|NCT05476770|DRUG|Azacitidine|"* 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion."
223964206|NCT05476770|DRUG|Methotrexate|"Give intrathecally:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients ≥9 years of age"
223964207|NCT05476770|DRUG|Cytarabine IT|"Give intrathecally:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg"
223964208|NCT05476770|DRUG|Hydrocortisone|"Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg"
223964209|NCT04044820|DRUG|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
223964210|NCT04949113|DRUG|Neoadjuvant ipilimumab + nivolumab|2 cycles ipilimumab (80mg) + nivolumab (240mg) every 3 weeks followed by total lymph node dissection
223964211|NCT04949113|DRUG|Adjuvant nivolumab|Upfront total lymph node dissection followed by 12 cycles of nivolumab (480mg) every 4 weeks.
223964212|NCT05990075|BEHAVIORAL|self-monitoring|This research study will evaluate a self-monitoring intervention to increase awareness, provide support, and promote motivation to initiate treatment after referral to mental health. The proposed intervention is a user-driven program delivered online and by mobile text. This will be initially piloted for acceptability among Veterans referred to mental health service for depression treatment.
223964213|NCT05099978|GENETIC|NGS analysis of ctDNA|Diagnostic Test: plasma circulating tumor DNA
224111040|NCT00853905|DRUG|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
224111041|NCT01057303|GENETIC|RNA analysis|
224111042|NCT01057303|GENETIC|gene expression analysis|
224111043|NCT01057303|GENETIC|reverse transcriptase-polymerase chain reaction|
224111044|NCT01057303|OTHER|laboratory biomarker analysis|
223964214|NCT00002792|DRUG|busulfan|
223964215|NCT00002792|DRUG|cyclophosphamide|
223964216|NCT00002792|DRUG|cyclosporine|
223964217|NCT00002792|DRUG|methotrexate|
224111045|NCT00974779|DEVICE|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
224111046|NCT00974779|DEVICE|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
224111047|NCT01716260|DRUG|Chloroquine|
223964218|NCT00002792|DRUG|tacrolimus|
223964219|NCT00002792|PROCEDURE|allogeneic bone marrow transplantation|
224111048|NCT01716260|DRUG|Primaquine|
224111049|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
223964220|NCT00002792|PROCEDURE|peripheral blood stem cell transplantation|
223964221|NCT02001207|OTHER|Salivary cortisol test|
224111050|NCT03742492|DIETARY_SUPPLEMENT|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
224111051|NCT04338945|BEHAVIORAL|COVID-surgRES questionaire|The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
224111052|NCT01748695|DRUG|V158866|
224111053|NCT01748695|DRUG|Placebo|
224111054|NCT05294900|DRUG|paclitaxel/carboplatin|"Induction chemotherapy : total 2 cycle every 3weeks as below:~* Paclitaxel 175mg/m2~* Carboplatin AUC5"
224111055|NCT00970294|BEHAVIORAL|Health Promotion Program|10 week health promotion program 3-4 times per week
223964222|NCT02305797|DRUG|Extended-release lorazepam|Extended-release lorazepam capsules
223964223|NCT02305797|DRUG|Placebo|Placebo capsules
223964224|NCT00422162|DRUG|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
223964225|NCT00422162|DRUG|Placebo|placebo capsule by mouth
223964226|NCT01526486|PROCEDURE|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
223964227|NCT01526486|PROCEDURE|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
223964228|NCT06337045|BEHAVIORAL|Complex prevention and rehabilitation intervention|The complex intervention started and ended with individual consultations with health professionals and furthermore included physical exercise, smoking cessation, alcohol treatment, dietary interventions, AF specific patient education, MediYoga, and/or psychosocial support.
223964229|NCT05159726|OTHER|Video Education|12-minute educational video covering postpartum topics of hemorrhage, infection, hypertension, and depression. Created by Cicatelli Associates Inc.
223964230|NCT00144937|DRUG|Stepwise therapy for dyslipidemia, hypertension and diabetes|
223964231|NCT00144937|BEHAVIORAL|Dietary recommendations|
223964232|NCT00144937|BEHAVIORAL|Increase in physical activity|
223964233|NCT00144937|BEHAVIORAL|Smoking cessation|
223964234|NCT05658445|OTHER|evacuation|after complete evacuation of uterus follow abortion
223964235|NCT00075699|DRUG|cisplatin|
223964236|NCT00075699|DRUG|mitomycin C|
223964237|NCT00075699|DRUG|vincristine sulfate|
223964238|NCT00075699|DRUG|vinorelbine tartrate|
223964239|NCT00075699|PROCEDURE|pain therapy|
223964240|NCT00075699|PROCEDURE|psychosocial assessment and care|
223964241|NCT00075699|PROCEDURE|quality-of-life assessment|
224111056|NCT03709615|BEHAVIORAL|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
224111057|NCT06600698|DRUG|INM176|The active ingredient INM176 was prepared using a proprietary technology to extract AGN with ethanol and powderize with cellulose into a finished granular powder product that is 1/5 the weight of the raw herbal root. This product was chosen because its close match with the AGN extracts studied in the TRAMP model in the phytochemical profiles. It will be donated from the manufacturer Nutragen Co., Ltd. Korea.
224111058|NCT00307229|BIOLOGICAL|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
224111059|NCT03235908|OTHER|Observation only|Observation only
224111060|NCT00847561|BEHAVIORAL|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
224111061|NCT00847561|BEHAVIORAL|Information Monitoring|Packet providing information on strategies for coping with anxiety
224111062|NCT02757495|DRUG|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
224111063|NCT04146532|DRUG|Aspirin 500 MG|Single 500mg aspirin capsule.
224111064|NCT04146532|DRUG|Placebo|Single 500mg placebo capsule.
224111065|NCT04783207|DIETARY_SUPPLEMENT|Mitopure|Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily
224111066|NCT04783207|DIETARY_SUPPLEMENT|Placebo|Softgel containing only excipients. 4 soft-gels to be taken daily
224111067|NCT00002828|DRUG|fluorouracil|
223964242|NCT02522299|DRUG|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
223964243|NCT02522299|DRUG|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
223964244|NCT02522299|DEVICE|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
223964245|NCT02522299|DEVICE|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
223964246|NCT03639792|PROCEDURE|gastric cancer surgery|Gastric cancer surgery
223964247|NCT01256814|BEHAVIORAL|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
223964248|NCT01979822|OTHER|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
224111068|NCT00002828|DRUG|raltitrexed|
224111069|NCT01333189|OTHER|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
223964249|NCT04277273|OTHER|Questionnaire|Questionnaires WHOQOL-BREF and GOHAI
223964250|NCT06244888|BEHAVIORAL|Intervention Targeting Stress and Emotion Regulation|This intervention involves learning and practicing relaxation exercises and setting aside time for pleasurable activities.
223964251|NCT06244888|BEHAVIORAL|Intervention Targeting Motivation and Self-efficacy for Weight Management|This intervention involves identifying values related to weight, lifestyle, and health; identifying barriers to value-consistent living; exploring the consequences of letting barriers drive behavior; and 4) setting goals that are small, specific, attainable, and values-consistent.
223964252|NCT06244888|BEHAVIORAL|Intervention for Normalization of Eating|This intervention involves dietary self-monitoring with the goal of staying within a calorie goal ranging from 1,200 kcal/day to 1,800 kcal/day. Participants are also provided with meal planning tools and encouraged to addresses hunger and cravings by promoting feelings of satiety via consumption of foods that are high in volume but low in calories.
224111070|NCT01333189|OTHER|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
224111071|NCT01363505|DEVICE|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
224111072|NCT03477916|BIOLOGICAL|FMT|fecal microbial transplantation (FMT)
224111073|NCT03477916|BIOLOGICAL|Placebo FMT|Placebo fecal microbial transplantation (FMT)
224111074|NCT03477916|DIETARY_SUPPLEMENT|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
224111075|NCT03477916|DIETARY_SUPPLEMENT|Cellulose|Cellulose
224111076|NCT00006072|DRUG|Rituxan|
224111077|NCT02107664|RADIATION|Palliative RT for bone cancer pain|
224111078|NCT02620540|DEVICE|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
224111079|NCT05828940|DRUG|Losartan Potassium|oral tablet, over-encapsulated
224111080|NCT05828940|DRUG|Placebo|oral tablet, over-encapuslated
224111081|NCT01240018|DIETARY_SUPPLEMENT|Probiotic|Parallel, randomized, controlled 2 arms study.
224111082|NCT03556696|DEVICE|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
224111083|NCT03556696|DEVICE|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
224111084|NCT03556696|DRUG|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
223964253|NCT06244888|BEHAVIORAL|Intervention Targeting Physical Activity and Sleep|This simple intervention prompts participants at the start of the day to schedule up to 30 minutes of moderate-to-vigorous intensity physical activity; brisk walking is encouraged. Participants also set a bedtime and wake time and are encouraged to set a reminder alarm to ensure at least 8 hours of sleep.
224111085|NCT03556696|DRUG|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in \[40-60\] range
224111086|NCT03556696|DEVICE|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std\_practice arm for guidance of the remifentanil Ce target"
224111087|NCT03163238|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
224111088|NCT03163238|DRUG|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
224111089|NCT02343328|BIOLOGICAL|Fecal Microbiota Transplant|
224111090|NCT02343328|BIOLOGICAL|Placebo|
224111091|NCT00661765|DRUG|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
224111092|NCT00661765|DRUG|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
224111093|NCT06405204|DRUG|Myoinositol|an enzymatic isoform of inositol and belongs to the vitamin B complex family
224111094|NCT06405204|DRUG|Co-Enzyme Q10|a lipid-soluble quinone, acting as an effective antioxidant,
223964254|NCT01827176|OTHER|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
223964255|NCT05199597|DRUG|0.01% atropine|0.01%, room temp, Lab A
223964256|NCT05199597|DRUG|0.05% atropine|0.05%, room temp, Lab A
223964257|NCT05199597|DRUG|0.05% atropine|0.05%, refrigerated, Lab A
223964258|NCT05199597|DRUG|0.05% atropine|0.05%, room temperature, Lab B
223964259|NCT05255276|DRUG|Sitravatinib 50 mg|50 mg Sitravatinib on Day 1 (Group 1A)
223964260|NCT05255276|DRUG|Sitravatinib 100 mg|100 mg Sitravatinib on Day 1 (Group 2A)
223964261|NCT05255276|DRUG|Itraconazole|Itraconazole QD from Day 9 to Day 18, and Sitravatinib 50 mg at Day 12 (Group 1B)
223964262|NCT05255276|DRUG|Rifampin|Rifampin QD from Day 9 to Day 22, and Sitravatinib 100 mg at Day 16 (Group 2B)
223964263|NCT01543009|OTHER|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
223964264|NCT02053402|DRUG|Vitamin D|Vitamin D daily for six months
223964265|NCT03097458|BEHAVIORAL|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
223964266|NCT01622088|DRUG|Dexpramipexole|Oral tablet 150 mg given twice daily (BID)
223964267|NCT00730496|PROCEDURE|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
223964268|NCT04038034|DIETARY_SUPPLEMENT|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
223964269|NCT04038034|DIETARY_SUPPLEMENT|Placebo|Placebo
223964270|NCT04673071|OTHER|Thread Embedding Acupuncture (TEA)|"TEA in 1 month for 4 months The six TEA points used in this study are GV20, BL15, BL18, ST40, GV14 and GB34.~Acupuncture point Procedure Baihui (GV20) oblique insertion toward nose, 3cm Both Xin Shu (BL15) perpendicular insertion, 3cm Both Gan Shu (BL18) perpendicular insertion, 3cm Both Fenglong (ST40) perpendicular insertion, 3cm Dazhui (GV14) perpendicular insertion, 3cm Both Yanglingquan (GB34) perpendicular insertion, 3cm"
224111095|NCT06405204|DRUG|Melatonin|an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
224111096|NCT06405204|DRUG|Folic acid|control
224111097|NCT00934063|DRUG|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224111098|NCT00934063|OTHER|No treatment given|Control group not receiving treatment
224111099|NCT01668069|DRUG|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
224111100|NCT04718090|PROCEDURE|PENG Block|Pericapsular nerve group block in shoulder surgery.
224111101|NCT02218203|DRUG|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
224111102|NCT02218203|DRUG|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
224111103|NCT02218203|DRUG|Placebo (Dextromethorphan)|0mg Dextromethorphan
223964271|NCT04673071|OTHER|Sham-TEA (STEA)|STEA in 1 month for 4 months All procedure of Sham-TEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
223964272|NCT00538616|DRUG|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
223964273|NCT00538616|DRUG|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
223964274|NCT00274846|BIOLOGICAL|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
223964275|NCT00274846|BIOLOGICAL|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10\^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10\^9
223964276|NCT00274846|DRUG|cyclophosphamide|Days -5 and -4: 60 mg/kg
223964277|NCT00274846|DRUG|fludarabine phosphate|Days -5 through -2: 25 mg/m\^2
223964278|NCT00274846|PROCEDURE|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
223964279|NCT00396721|DRUG|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
223964280|NCT00396721|DRUG|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
223964281|NCT03770299|BIOLOGICAL|Nivolumab|Specified dose on specified days
223964282|NCT03770299|DRUG|Vinorelbine|Specified dose on specified days
223964283|NCT03770299|DRUG|Gemcitabine|Specified dose on specified days
223964284|NCT03770299|DRUG|Docetaxel|Specified dose on specified days
223964285|NCT03770299|DRUG|Pemetrexed|Specified dose on specified days
223964286|NCT03770299|DRUG|Cisplatin|Specified dose on specified days
223964287|NCT03770299|DRUG|Carboplatin|Specified dose on specified days
223964288|NCT03770299|DRUG|Paclitaxel|Specified dose on specified days
223964289|NCT03770299|OTHER|Observation|Observation by the investigator
223964290|NCT03451994|OTHER|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
223964291|NCT05788406|OTHER|Short foot exercises, Dynamic balance exercises and insole|Short foot exercises is used to improve muscle strenght, Dynamic balance exercises is used to improve balance and insole is used to improve MLA
223964292|NCT01001637|DIETARY_SUPPLEMENT|Curcumin Formulation|2000mg or 3000mg daily BID
223964293|NCT01001637|DIETARY_SUPPLEMENT|Placebo|Placebo
223964294|NCT02524951|DRUG|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
223964295|NCT06035003|BEHAVIORAL|Internet-based Mindfulness Intervention for Emotional Distress (iMIED)|Internet-based Mindfulness Intervention for Emotional Distress (iMIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
223964296|NCT01171885|DRUG|0.9% saline|20 ml of 0.9% saline
223964297|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.25%.
223964298|NCT01171885|DRUG|Ropivacaine|20 ml of Ropivacaine 0.5%.
223964299|NCT03045302|DRUG|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
224111104|NCT02218203|DRUG|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
224111105|NCT06482879|DEVICE|Oxygen delivery|Oxygen is delivered with high flow nasal canula or simple nasal canula to prevent hypoxia during procedures under deep sedation.
224111106|NCT00989703|DRUG|placebo|oral solution, daily for 14 days
224111107|NCT00989703|DRUG|GLPG0259|oral solution
223964300|NCT01995253|DEVICE|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
223964301|NCT01995253|DEVICE|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
223964302|NCT01248663|PROCEDURE|antecolic reconstruction|see study arm description
223964303|NCT01248663|PROCEDURE|retrocolic reconstruction|see study arm description
223964304|NCT04409132|DRUG|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
223964305|NCT02633345|DIETARY_SUPPLEMENT|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
223964306|NCT02633345|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
224111108|NCT00989703|DRUG|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
224111109|NCT02650011|OTHER|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
224111110|NCT02765893|OTHER|No Foley|Patients will have Foley catheter removed 6 hours post-op.
224111111|NCT00298571|DRUG|.5% bupivacaine with epinephrine|
224111112|NCT02203682|DRUG|Doxycycline hyclate|Tab. Doxycycline 50 mg PO per day for 12 weeks
223964307|NCT00812825|DRUG|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
223964308|NCT00812825|DRUG|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
223964309|NCT00812825|DRUG|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
224111113|NCT02203682|DRUG|Placebo|Tablet placebo for 12 weeks
223964310|NCT00812825|DRUG|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
224111114|NCT02449564|DRUG|sirolimus|sirolimus 1mg daily
224111115|NCT04044638|OTHER|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G \* Tech-branded automatic digital device (MASTER model).
224111116|NCT03551899|OTHER|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
224111117|NCT05045053|DRUG|Xiidra 5% Ophthalmic Solution|lifitegrast 0.5% ia applied twice daily after corneal collagen cross linking
224111118|NCT01787591|OTHER|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
223964311|NCT00812825|DRUG|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
223964312|NCT00737997|DRUG|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
223964313|NCT00737997|OTHER|Saline|10 ml saline alone
223964314|NCT03681002|BEHAVIORAL|structured lifestyle program|Intensive Lifestyle counseling during one year
223964315|NCT02860858|BIOLOGICAL|Intravitreous aflibercept injection|
223964316|NCT05070637|PROCEDURE|No-touch laparoscopic radical nephrectomy|We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
223724629|NCT01841983|OTHER|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~1. Motivate individual staff members to engage in targeted health and safety behavior changes;~2. build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~3. facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~4. promote co-worker and supervisor support for targeted health and safety behaviors."
223724630|NCT00813735|DRUG|Eszopiclone|Eszopiclone 2mg daily at bedtime
223964317|NCT05070637|PROCEDURE|Conventional laparoscopic radical nephrectomy|Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
223964318|NCT05070637|PROCEDURE|Laparoscopic total nephrectomy control arm|Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
223964319|NCT02971995|DEVICE|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
223964320|NCT02971995|DEVICE|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
223964321|NCT01063127|OTHER|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
224111119|NCT01787591|OTHER|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
223724631|NCT00813735|DRUG|Placebo|Placebo daily at bedtime
223964322|NCT01063127|OTHER|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
224111120|NCT01787591|OTHER|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
224111121|NCT01787591|OTHER|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
224111122|NCT05275413|BEHAVIORAL|family-based mHealth Intervention|The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.
224111123|NCT05275413|BEHAVIORAL|mother-only mHealth Intervention|The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.
223724632|NCT00813735|DRUG|Escitalopram|Escitalopram 10mg or 20mg
223724633|NCT02438098|DRUG|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
223724634|NCT05495516|GENETIC|without Intervention|without Intervention
223964323|NCT03653689|DIETARY_SUPPLEMENT|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
223964324|NCT03653689|DIETARY_SUPPLEMENT|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
223964325|NCT03653689|DIETARY_SUPPLEMENT|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
223964326|NCT01463397|DRUG|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
223964327|NCT01463397|DRUG|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
223964328|NCT03710850|DIETARY_SUPPLEMENT|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
223964329|NCT05310058|DIETARY_SUPPLEMENT|C6 ketone di-ester|C6 ketone di-ester
223964330|NCT05703477|PROCEDURE|Fecal microbiota transplantation|Fecal microbiota transplantation (FMT) achieves the purpose of treating intestinal and extra-intestinal diseases by transplanting the functional microbes in the feces of healthy people into the patient's intestine through the upper or lower alimentary tract routes to rebuild the patient's intestinal microbiota.
223964331|NCT02933996|DEVICE|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
224111124|NCT05275413|OTHER|Health education|The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
224111125|NCT00649298|PROCEDURE|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
223964332|NCT02933996|DEVICE|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
223964333|NCT01357564|OTHER|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
223964334|NCT01357564|OTHER|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
223964335|NCT00346242|DRUG|Zoledronic Acid|
224111126|NCT01513018|OTHER|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
224111127|NCT01513018|OTHER|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
224111128|NCT01902160|DRUG|Brentuximab Vedotin|Given IV
224111129|NCT01902160|OTHER|Laboratory Biomarker Analysis|Correlative studies
224111130|NCT01902160|DRUG|Temsirolimus|Given IV
224111131|NCT02234011|DRUG|Ketamine|
224111132|NCT02234011|DRUG|Placebo|
223724635|NCT06036212|DEVICE|Robotic System|Robotic assisted Unicompartmental Knee replacement (UKA)
223724636|NCT06036212|DEVICE|Conventional|Unicompartmental Knee Arthroplasty (UKA) with conventional approach and conventional manual instrumentation
224111133|NCT02489630|DRUG|Ketamine|0.1mg/kg ketamine IV
223724637|NCT01025752|BEHAVIORAL|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
223964336|NCT06286592|BEHAVIORAL|Ultra-brief mindfulness intervention video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
223964337|NCT06286592|BEHAVIORAL|Forgiveness video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
223964338|NCT06286592|BEHAVIORAL|ACT values video|"Details of the specific intervention will be selected in collaboration with the Community Advisory Board.~Then, in a Phase IB trial, we will use a MOST design to assign patients to promising intervention components, combining them and altering exposure time, measuring preliminary effects of possible components of interventions. Details of the specific interventions will be selected in collaboration with the Community Advisory Board."
223964339|NCT03778606|DIETARY_SUPPLEMENT|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
223964340|NCT04978688|DRUG|Relugolix|Administered as an oral tablet once daily.
223964341|NCT04978688|DRUG|E2/NETA|Administered as an oral tablet once daily.
223964342|NCT03421600|DEVICE|blue laser imaging|blue laser imaging
223964343|NCT03421600|DEVICE|White light imaging|White light imaging
223964344|NCT01102985|BEHAVIORAL|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
223964345|NCT01102985|BEHAVIORAL|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
224111134|NCT02489630|DRUG|Normal Saline|1ml/kg normal saline placebo
224111135|NCT02489630|DRUG|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
224111136|NCT00025649|BIOLOGICAL|filgrastim|
224111137|NCT00025649|DRUG|busulfan|
224111138|NCT00025649|DRUG|carboplatin|
223964346|NCT05287178|BEHAVIORAL|DBT Skills + Parent Training|The DBT Skills +PT group intervention integrates DBT Skills, Parent Management Training (PMT), and Emotion Coaching (EC). Each session includes a mindfulness practice, homework review to discuss use of skills previously learned, didactics to learn a new set of DBT and PT skills, and assignment of homework. The DBT Skills portions cover the four modules of traditional DBT Skills: Mindfulness, Emotion Regulation, Distress Tolerance (including skills specifically focused on managing difficulties with addiction), and Interpersonal Effectiveness. PT skills include both PMT and EC components such as: praise, use of parental attention to reward positive behavior, reward systems, effective commands and consequences, psychoeducation on children's emotional development, teaching children to label emotions, validating children's emotions, and handling children's negative emotions, and fostering positive emotions.
223964347|NCT01648699|DRUG|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
223964348|NCT03521076|DEVICE|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
223964349|NCT03075111|DIAGNOSTIC_TEST|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
223964350|NCT02433392|PROCEDURE|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
223964351|NCT02267746|DRUG|Tazarotene (Fabior™)|
223964352|NCT02267746|DRUG|Tazarotene (Actavis)|
224111139|NCT00025649|DRUG|cyclophosphamide|
224111140|NCT00025649|DRUG|doxorubicin hydrochloride|
224111141|NCT00025649|DRUG|etoposide|
223724638|NCT01025752|BEHAVIORAL|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
223724639|NCT00673803|PROCEDURE|cataract surgery|cataract surgery with implantation of an IOL
223724640|NCT06024356|DRUG|Thymalfasin|Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.
223964353|NCT02267746|DRUG|Vehicle foam|
224111142|NCT00025649|DRUG|melphalan|
224111143|NCT00025649|DRUG|vincristine sulfate|
224111144|NCT00025649|PROCEDURE|autologous bone marrow transplantation|
224111145|NCT00025649|PROCEDURE|conventional surgery|
223964354|NCT06336707|DRUG|HS-20089|Intravenous infusion
223964355|NCT06336707|DRUG|Adebrelimab|Intravenous infusion
224111146|NCT00025649|PROCEDURE|peripheral blood stem cell transplantation|
224111147|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate|Participants have a one in three chance of consuming a carbohydrate beverage between two bouts of high-intensity exercise.
224111148|NCT04859491|DIETARY_SUPPLEMENT|Carbohydrate-Protein|Participants have a one in three chance of consuming a carbohydrate-protein beverage between two bouts of high-intensity exercise.
224111149|NCT04859491|DIETARY_SUPPLEMENT|Placebo|Participants have a one in three chance of consuming a placebo beverage between two bouts of high-intensity exercise.
224111150|NCT02108730|PROCEDURE|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
223964356|NCT06336707|DRUG|Bevacizumab|Intravenous infusion
223964357|NCT06336707|DRUG|Cisplatin / carboplatin|Intravenous infusion
223964358|NCT03720717|DRUG|Baclofen 10mg|Baclofen administration pre-operatively
223964359|NCT03720717|OTHER|Placebo|Placebo administration
223964360|NCT06370572|OTHER|PAINAD EHR Prompt|Implementation of PAINAD EHR prompt in the ED workflow for PLWD presenting to the ED with hip pain
223964361|NCT05078450|BEHAVIORAL|Mood Lifters|Participants will need to attend 12 hour long virtual weekly meetings on Zoom that focus on helpful mental health strategies and skills. Participants will be encourage to practice what they learn at home in order to improve their mood or mental wellness.
223964362|NCT05095506|OTHER|eHealth Intervention|The intervention platform is interactive, and uses multimedia-assisted components. The system uses three SCI-QOL computer-adaptive tests (CATs) to assess depression, anxiety, and resilience; cut scores are used to tailor multi-media content that specifically addresses users' emotional health concerns.
223964363|NCT05095506|OTHER|Active Control Condition|The active control condition is a static site that displays symptom assessments followed by one educational video each week. These videos, which play in a predetermined order, provide education about managing physical health in individuals with SCI.
223964364|NCT06329011|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223964365|NCT06329011|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223964366|NCT06329011|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
223964367|NCT06329011|BEHAVIORAL|Placebo Transcranial direct current stimulation|The Transcranial direct current stimulation will be performed without being turned on.
223964368|NCT03441750|DRUG|metformin|Metformin tablets will be administrated in the experimental arm.
223964369|NCT03441750|OTHER|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~* All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~* The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~* Moderate intensity physical activity (150 minutes per week) is recommended.~* Smoking cessation is encouraged for the smoker.~* Excessive alcohol intake is encouraged to avoid."
223964370|NCT05923554|OTHER|Changes in Probing Depth to non-surgical periodontal therapy|Changes in Probing Depth following non surgical periodontal treatment performed with hand and ultrasonic tips
223964371|NCT04453709|BEHAVIORAL|Problem Management Plus for Immigrants at family settings|"PMP-I is a 5-week, peer-led, culturally tailored psychoeducation, behavioral activation (90 minutes), breathing and yoga intervention (90 minutes) in a family setting. PMP-I will use a structured approach, including once a week face-to-face sessions, breathing and yoga practices.~1. Managing Stress: Breathing and yoga practices, stress-management sessions, and behavioral activation exercises to strengthen positive coping strategies.~2. Managing Problems: Practice exercises to identify the problems, develop solutions, and plan a strategy to carry out those solutions.~3. Get Going, Keep Doing: Communication skill sessions and practice exercises to identify and carry out pleasant tasks.~4. Strengthening Social Support: Social skills session and practice exercise to identify social support.~5. Staying Well: Make a plan that helps to create supportive family environment."
224111151|NCT02054650|OTHER|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
224111152|NCT02054650|OTHER|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
224111153|NCT00575796|DRUG|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
224111154|NCT03077295|OTHER|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
224111155|NCT03077295|OTHER|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
224111156|NCT02035423|DIETARY_SUPPLEMENT|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
224111157|NCT02035423|DIETARY_SUPPLEMENT|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
223964372|NCT04453709|BEHAVIORAL|Talk program with Community Support Service Pamphlet (CSS)|Pamphlet including list of community support service institutions
223964373|NCT03590847|BEHAVIORAL|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
223964374|NCT06562244|BEHAVIORAL|Parenting for Lifelong Health for Parents and Teens (PLH)|The PLH program is the core intervention and will be delivered over 6 sessions with adolescents and caregivers, focusing on building positive parent-child relationships, problem-solving skills, stress management, effective limit-setting, and emotional regulation. There will also be a pre-program visit with the facilitator and families prior to the group sessions. Sessions will include both separate and joint activities between adolescents and caregivers. Engagement boosters will be provided during the PLH sessions and are part of the PLH intervention.
223964375|NCT06562244|BEHAVIORAL|Helping Adolescents Thrive comics|UNICEF's Helping Adolescents Thrive (HAT) comics will be used to guide adolescents through content on improving relationships, handling conflict, understanding emotions, and problem solving. These sessions will be group-based and cover the content in the HAT manual with the adolescents in an interactive format.
223964376|NCT06562244|BEHAVIORAL|I Support My Friends|"An adapted version of UNICEF's I Support My Friends program will be provided to adolescents by a facilitator in a group-based workshop format over the course of 1 day."
223964377|NCT04614558|DRUG|Isatuximab|"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."
223964378|NCT04946656|PROCEDURE|sphenopalatine ganglion block|The sphenopalatine ganglion will be blocked with bupivacaine for this study
223964379|NCT06315647|PROCEDURE|DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation|comparison between different technique in difficult CBD cannulation
223964380|NCT03627130|DRUG|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
223964381|NCT03627130|DRUG|Potassium Chloride|Potassium Chloride capsules for 5 days
223964382|NCT00003049|DRUG|fluorouracil|
223964383|NCT00003049|DRUG|leucovorin calcium|
223964384|NCT00003049|PROCEDURE|conventional surgery|
223964385|NCT00003049|RADIATION|radiation therapy|
223964386|NCT02060071|OTHER|Blood test|Blood test
223964387|NCT02672345|DRUG|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
223964388|NCT03979144|BEHAVIORAL|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
223964389|NCT00796497|DRUG|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
223964390|NCT05441293|PROCEDURE|flap reconstruction|received flap reconstruction over sacrum, back, trochanter, ischium, elbow, and lower extremities
223964391|NCT00138814|PROCEDURE|Radiotherapy (boost versus no boost)|
223964392|NCT05386706|BEHAVIORAL|Digital Intervention|This study developed a mini-program that combined diet, exercise, sleep, and mood interventions for PCOS women.
223964393|NCT05386706|DRUG|Metformin|Traditional metformin monotherapy.
223964394|NCT04677985|COMBINATION_PRODUCT|Menthol based topical analgesic|Topical analgesic or placebo was applied to upper and lower body muscles and tendons and pain pressure threshold was measured with a handheld algometer.
223964395|NCT05888285|PROCEDURE|Erector spina plane block|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection
223964396|NCT05888285|PROCEDURE|Erector spina bale block and pulsed radiofrequency|The transverse processes of the thoracic vertebrae are treated with ultrasound-guided drug injection and pulsed radiofrequency treatment
223964397|NCT04005248|DIAGNOSTIC_TEST|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
223964398|NCT05832489|DRUG|Placebo|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
223964399|NCT05832489|DRUG|Methylphenidate immediate release 25mg|"Patients will have 2 imaging sessions (MRI and EEG) after either:~* methylphenidate immediate release 25 mg~* placebo~in a cross-over design. The two imaging sessions will be separated by 11 to 87 days."
223964400|NCT02228889|PROCEDURE|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
223964401|NCT02228889|OTHER|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
223964402|NCT02228889|OTHER|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
223964403|NCT02228889|OTHER|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
223964404|NCT02228889|OTHER|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
223964405|NCT02228889|OTHER|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
223964406|NCT02228889|OTHER|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
223964407|NCT02228889|OTHER|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
223964408|NCT02228889|OTHER|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
223964409|NCT02228889|OTHER|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
223964410|NCT02228889|OTHER|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
223964411|NCT02228889|OTHER|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
223964412|NCT02228889|OTHER|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
223964413|NCT02228889|OTHER|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
223964414|NCT02228889|OTHER|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
223964415|NCT02228889|OTHER|Assess overall complications at 30 days postoperatively|
223964416|NCT02228889|OTHER|Assess overall complications at 1 year postoperatively|
223964417|NCT02228889|PROCEDURE|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
223964418|NCT02228889|DEVICE|Strattice|Strattice mesh
223964419|NCT02228889|DEVICE|XenMatrix|Xenmatrix mesh
223964420|NCT03460366|DRUG|Enalapril|Patients are tested for their normal prescription enalapril medication
223964421|NCT05621902|OTHER|Weekly symptom monitoring|Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
223964422|NCT05503407|PROCEDURE|Baseline V-RESOLVE score-guided PCI|"Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting."
223964423|NCT05503407|PROCEDURE|Angiography-guided PCI|The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
223964424|NCT01443572|DRUG|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
223964425|NCT01443572|DRUG|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
223964426|NCT04526132|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
223964427|NCT04526132|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h、16h 、24h、32h and 40h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 6 times,3 times/day,once every 8 hours."
223964428|NCT06173167|DEVICE|Crowns self-adhesively luted|After cavity preparation, the zirconia chairside crown will be placed using SpeedCEM Plus. The excess will be light cured with Bluephase G4 in PreCure mode (950 mW/cm\^2). After removal of the excess, the luting material margins will be light-cured again for 20s (1200 mW/cm\^2).
223964429|NCT06173167|DEVICE|Crowns conventionally cemented|After cavity preparation, the zirconia chairside crown will be placed using ZirCAD Cement. The excess cement will be removed in the gel phase, either following light curing (5 - 10 seconds per segment) or following self-curing (approximately 2 min after placement). The restoration will be held in position during final curing that is complete 4 min 30 s after placement.
223964430|NCT02070640|DRUG|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
223964431|NCT02070640|DEVICE|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
223964432|NCT00104442|DRUG|Rivastigmine|
223964433|NCT06459167|OTHER|The position adopted when patients undergoing procedure or surgery|For patients requiring sedation for procedures or surgery, they are randomly assigned either to supine position or lateral position before they are sedated, and kept during procedure or surgery.
223964434|NCT00990314|DRUG|Beraprost Sodium Modified Release|
223964435|NCT01720407|DRUG|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
223964436|NCT01720407|DRUG|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
223964437|NCT04749641|BIOLOGICAL|Histone H3.3-K27M Neoantigen Vaccine Therapy|"The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a 6+3 dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC."
224111158|NCT02035423|DIETARY_SUPPLEMENT|Non-Fortified Milk|Daily consumption of non-fortified milk
224111159|NCT01326962|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
224111160|NCT04936880|DEVICE|Experimental : Virtual reality + analgesia-sedation|Use of a virtual reality device + analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
224111161|NCT04936880|DRUG|Control: Analgesia-sedation|Use of analgesia-sedation drugs according to SFMU/SFAR 2010 guidelines during reduction procedure
223724641|NCT04026308|OTHER|Safety Net App|The Safety Net app is an electronic version of a safety plan and it is available for download in Apple's App Store. A preview of the app is available at: https://apps.apple.com/us/app/stanley-brown-safety-plan/id695122998. This app is owned by Two Penguins Studios, LLC. It was developed in partnership with the New York State Office of Mental Health. Unlike the paper version, the Safety Net app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
223964438|NCT00631202|DRUG|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
223964439|NCT02355106|DEVICE|PolarStart System|Atrial flutter Ablation
223964440|NCT00380809|PROCEDURE|Rotational Atherectomy + PES|
223964441|NCT00380809|PROCEDURE|Standard Treatment (PES without Rotational Atherectomy)|
224111162|NCT03550144|BEHAVIORAL|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
223542435|NCT04495686|BEHAVIORAL|Telehealth-delivered Care Coordination Program|"Participants in the interventional arms of this program will be assigned a Dementia Care Manager (DCM) who will work with caregivers to develop goals and plans that are aimed at providing the best support possible, specific to your needs. These services include supportive counseling, education on dementia, information and referrals to community-based organizations, behavioral symptom management training and assistance with finding available community and government-sponsored programs.~DCM's will meet with you at least once monthly and will be available if you need assistance between meetings. At the first meeting, your DCM will explain the questionnaires you will take and how to use the technology in the program. They will then provide a link, via email, where you will download the free teleconferencing software that will be used throughout the program. Questionnaires will then be sent via email invitations through a secure survey platform."
223542436|NCT04375956|DRUG|Pembrolizumab|Experimental
223542437|NCT05945381|COMBINATION_PRODUCT|GIC on MIH|Subjects will be seated in a dental chair set-up using standard infection control guidelines. Then the study and its objectives will be explained to the patients and their caregivers. The tooth will be cleaned with a prophylactic paste and brush for complete debris and plaque removal. The tooth will then be dried with a cotton roll, as the patient doesn't tolerate the air-drying (which is the case in SCASS 2 and 3). Moisture control will be kept with cotton roll, the tooth is then sealed with a hard setting glass-ionomer cement (IonoStar Plus, VOCO, Germany) followed by an application of a surface coat (Easy Glaze, VOCO, Germany) for moisture and dehydration protection after sealant application. The distributed questionnaire will include questions regarding the attitude of the child's caregiver to the idea and their estimation of the child's fair regarding dental visit.
223542438|NCT02372695|DRUG|Paricalcitol|
223724642|NCT01625702|DEVICE|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
223724643|NCT00112060|DRUG|PT-523 for Injection|
223724644|NCT05177978|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
223964442|NCT03584282|BEHAVIORAL|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
223964443|NCT03584282|BEHAVIORAL|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
223964444|NCT02704156|DEVICE|Cyberknife plus Pembrolizumab and Trametinib|Radiation therapy plus drug
223724645|NCT05177978|DIETARY_SUPPLEMENT|Placebo|Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
223724646|NCT02984748|DEVICE|Cochlear implant|
223964445|NCT02704156|DEVICE|Cyberknife plus Gemcitabine|Radiation therapy plus drug
223964446|NCT02978040|DRUG|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
223964447|NCT02978040|DRUG|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old) .
224111163|NCT03550144|BEHAVIORAL|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
224111164|NCT05164523|DIAGNOSTIC_TEST|24-hour rhythm Holter|Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.
224111165|NCT05164523|DIAGNOSTIC_TEST|36 item Short Form Survey (SF-36)|Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.
224111166|NCT04786288|OTHER|massage with lavender essential oil mixed in a carrier oil|22 elderly participants received a one session M technique hand massage that lasted 10 minutes for both their hands and arms using 2% lavender essential oil diluted with odourless baby oil (12 drops of lavender essential oil mixed in 30 ml of carrier oil) was used to apply the M technique hand massage
224111167|NCT04786288|OTHER|massage with odourless baby oil|odourless baby oil was used for the application of one session M technique hand massage on both hands and arms for 10 minutes for the 22 elderly participants.
223964448|NCT02978040|DRUG|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight \< 60 kg or age \> 75 years old).
224111168|NCT04362267|OTHER|self-administered questionnaire|Every14 days, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
224111169|NCT04362267|DIAGNOSTIC_TEST|SARS-Cov2 testing|Every14 days, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
224111170|NCT01910662|OTHER|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
224111171|NCT01910662|OTHER|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
223542439|NCT00769795|DRUG|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
223542440|NCT00769795|DRUG|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
223542441|NCT00769795|DRUG|Goserelin|10.8 mg subcutaneous once
223724647|NCT00905073|DRUG|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
223964449|NCT00587405|PROCEDURE|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
223964450|NCT00587405|PROCEDURE|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
223964451|NCT03430362|DRUG|Hyoscine N Butylbromide|7\. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
223964452|NCT03430362|DRUG|Normal Saline 0.9%|Group B, will receive 2 ml of normal saline single intravenous dose
223964453|NCT01798537|DRUG|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
223964454|NCT02995278|OTHER|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
223964455|NCT00147394|DRUG|Risperidone|
223964456|NCT04578691|DEVICE|"Anatase Spine Surgery Navigation System"|using navigation system in pedicle screw placement in spine surgery
223964457|NCT04578691|DEVICE|Medtronic Stealthstation S7 Treatment Guidance System|using navigation system in pedicle screw placement in spine surgery
223964458|NCT02195180|DRUG|ERY001|
223964459|NCT02195180|DRUG|Gemcitabine|
223964460|NCT02195180|DRUG|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
224111172|NCT01910662|OTHER|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
223542442|NCT04725019|DEVICE|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.
223542443|NCT04725019|BEHAVIORAL|Motor training|Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
223542444|NCT03483454|OTHER|Exercise class|Same as above.
223542445|NCT03483454|OTHER|Home exercise|Same as above.
223542446|NCT03138785|DRUG|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
223964461|NCT02932124|DEVICE|mechanical chest compression device|
223964462|NCT05652985|BEHAVIORAL|Inter-professional Collaboration Training|the participated nurses will receive session about Inter-professional Collaboration followed by activity which can boost Inter-professional Collaboration
223964463|NCT01217294|PROCEDURE|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
223964464|NCT01217294|PROCEDURE|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
223964465|NCT03455751|GENETIC|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
223964466|NCT02836184|DRUG|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
223964467|NCT02836184|DRUG|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
224111173|NCT01910662|OTHER|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
223964468|NCT04572425|OTHER|Guided imagery|10 minutes of guided imagery experience delivered on tablet
223964469|NCT04572425|OTHER|Virtual reality|10 minutes of virtual reality experience delivered by Facebook Oculus Go VR device
223964470|NCT01636778|DRUG|SB-497115-GR|TPO receptor agonist to increase platelet count
223964471|NCT03458416|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
223964472|NCT02501876|OTHER|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
223964473|NCT02371278|DIETARY_SUPPLEMENT|Leucine|5 g leucine with sucrose and maltodextrin
223964474|NCT02371278|DIETARY_SUPPLEMENT|Placebo|5 g glycine with sucrose and maltodextrin
223964475|NCT00563433|DRUG|ofloxacin|400 mg twice a day for 14 days
223964476|NCT00563433|DRUG|MSI-78|1%/2% topical cream twice a day for 14 days
223964477|NCT01441258|BEHAVIORAL|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
223964478|NCT01441258|BEHAVIORAL|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
223964479|NCT01441258|BEHAVIORAL|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
223964480|NCT05746676|DRUG|Insulin|in treatment of periodontal defects
223964481|NCT05746676|DRUG|Hyaluronic acid|in treatment of periodontal defects
223964482|NCT03530345|DRUG|Neridronic acid 100 mg|100 mg neridronic acid supplied in glass vials in 8 mL of excipients.
224111174|NCT02262130|DRUG|Omalizumab|
223964483|NCT03530345|DRUG|Placebo|Glass vials with matching placebo.
223964484|NCT04652050|DRUG|Tolsura|Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
223964485|NCT01095809|DRUG|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
223964486|NCT01095809|DRUG|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
223964487|NCT03392688|OTHER|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
223964488|NCT03392688|DIAGNOSTIC_TEST|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
223964489|NCT03392688|OTHER|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
223964490|NCT03282071|BEHAVIORAL|Joyful Parenting Intervention|"* Two-session interactive talks for parents to promote praise \& appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
224111175|NCT00000530|DRUG|nifedipine|
224111176|NCT00000530|BEHAVIORAL|biofeedback (psychology)|
224111177|NCT00000530|PROCEDURE|electromyography|
224111178|NCT05466110|DEVICE|Spinal Cord Stimulation|Epidural application of electrical current to the spinal cord
224111179|NCT05466110|PROCEDURE|Spinal Fusion Surgery|screw-rod system based spinal instrumentation
223964491|NCT01221532|BEHAVIORAL|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~1. a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~2. two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~3. the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
223964492|NCT00212459|BEHAVIORAL|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
223964493|NCT00212459|BEHAVIORAL|Control|No more contacts are made with control patients after the initial counseling session.
223964494|NCT04117386|DIAGNOSTIC_TEST|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
223964495|NCT04117386|DIAGNOSTIC_TEST|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
223964496|NCT04472715|PROCEDURE|follicular unit extarcation and platelet rich plasma|hair transplantation procedure
223964497|NCT01377545|PROCEDURE|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
223964498|NCT01377545|PROCEDURE|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
223964499|NCT00253851|DRUG|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
223964500|NCT04229940|PROCEDURE|Peritoneal bridging|The defect is covered by peritoneal bridging
223964501|NCT04229940|PROCEDURE|No peritoneal bridging|The defect is left without bridging
223964502|NCT04889820|DRUG|Neoadjuvant chemotherapy|In this study, patients with obstructive colon cancer will be divided into two groups; in the control group, curative surgery will be performed within 2 weeks after successful SEMS placement, and in the experimental group, 3 cycles of neoadjuvant chemotherapy will be administered into patients who undergo successful SEMS placement and then curative surgery will be performed after neoadjuvnat chemotherapy. After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
223964503|NCT04889820|DRUG|Adjuvant chemotherapy|After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
223964504|NCT04889820|PROCEDURE|Curative resection|After successful SEMS placement, curate resection will be performed for all enrolled patients regardless of neoadjuvant chemotherapy.
223964505|NCT06471153|BEHAVIORAL|Empowerment Program Based on BASNEF Model|Initially, the researcher established rapport with children of both groups and their gradians, screened them for the eligibility criteria, explained the aim of the study, the duration and nature of the training sessions, and obtained informed assent. The researcher established the session objectives and learning activities and prepared the learning materials. The researchers also prepared the learning environment. The Empowerment program is implemented in accordance with the BANCEF model for behavior transformation into four educational sessions. After the intervention, children's nail-biting knowledge, practice, attitude, and self-efficacy were reassessed.
223964506|NCT06471153|BEHAVIORAL|Routine Health Education|Children in the control group received routine health education about the problems of nail-biting and routine advice to quit nail-biting.
223964507|NCT05190289|OTHER|Pre-existing degenerative factors of paraspinal muscles and bone mass|Pre-existing degenerative factors of paraspinal muscles, including muscle atrophy and fat infiltration; bone mass
223964508|NCT06490497|OTHER|Interview|individual interviews semi-directive
223964509|NCT05360771|DEVICE|SnowyTM PFO closure system|Percutaneously occlusion of PFO with SnowyTM PFO closure system
223964510|NCT05360771|DEVICE|Cardi-o-fix PFO occluder|Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
223964511|NCT00318591|DEVICE|SpeediCath|hydrophilic coated urinary intermittent catheter
223964512|NCT00318591|DEVICE|Conveen Uncoated|Uncoated urinary intermittent catheter
224111180|NCT04963218|DIAGNOSTIC_TEST|AI Algorithm to detect LVEF in ECG|A clinical decision support software as a medical device that detects whether a patient has LVEF less than or equal to 40% based upon the input of one or more ECG vectors at the point-of-care.
224111181|NCT00004429|DRUG|growth hormone|
223964513|NCT04853394|BEHAVIORAL|MASLIHAT|peer educator intervention
223964514|NCT04853394|BEHAVIORAL|TANSIHAT|health education intervention
223964515|NCT01184755|BEHAVIORAL|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
223964516|NCT01184755|DEVICE|RESPeRate|
224111182|NCT00298662|DRUG|Interferon beta-1b and Tacrolimus|
224111183|NCT03996538|DRUG|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
223964517|NCT04911322|DEVICE|ultrasonography|"A full obstetric ultrasound scan will be performed to assess signs of placental invasion, to document fetal biometry, estimated fetal weight, amniotic fluid index, assess fetal lung maturity parameters as pulmonary artery Doppler waveforms, amniotic fluid free floating particles, bowel echogenicity, fetal epiphyseal ossific centers, liver/lung echogenicity and kidney length.~Pulmonary artery Doppler: Fetal echocardiography will be done. Pulmonary artery Doppler ﬂow waveforms, including pulsatility index, resistance index, systolic-to-diastolic ratio, peak systolic velocity, and acceleration time to ejection time ratio will be measured in the main pulmonary artery."
223964518|NCT04212299|DEVICE|Northwestern University Flexible Sub-Ischial Suction Socket (NU-FlexSIS)|"The sub-ischial socket includes a firm, compressive, preferably cylindrical, fabric-covered silicone liner, a flexible inner socket, and a shorter rigid outer socket. The socket has proximal trim lines that do not impinge on the pelvis; they terminate distal to the ischial tuberosity and greater trochanter. For the NU-FlexSIS Socket, passive suction suspension is achieved using a one way valve and a liner with an internal seal.~Since the prosthetic socket is a custom-made device, it is considered Class I exempt by the Food and Drug Administration (FDA)."
223964519|NCT06976502|PROCEDURE|Blood Draw|Participants will be asked to contribute approximately 36 mL of blood using standard procedures and obtained at the time of a clinically ordered routine blood draw or a study ordered blood draw. Participants may be asked to contribute additional blood samples over the course of their participation in the study.
223964520|NCT06976502|PROCEDURE|Tissue Collection|If the participant is undergoing a clinically ordered procedure (e.g. heart surgery/biopsy/transplant), then they will be asked to contribute tissue to the study before any tissue is collected during the procedure. Most samples collected by the HeH BioBank will be tissue that would be normally discarded after the procedure.
223964521|NCT06976502|PROCEDURE|DNA Collection|Participants will be asked to contribute their DNA for Whole Genome Sequencing (WGS) to help identify genetic markers of heart disease. DNA will be obtained at the time of the blood draw or obtained through DNA collection kits administered to participants who are unable or unwilling to undergo a blood draw.
223964522|NCT06976502|OTHER|Medical Chart Review|Demographic, clinical, and pathologic information will be extracted from the participant's medical record.
223964523|NCT00943371|DRUG|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
223964524|NCT00943371|DRUG|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
223964525|NCT03507699|RADIATION|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
223964526|NCT03507699|DRUG|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
223964527|NCT03507699|DRUG|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
223964528|NCT03507699|DRUG|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
223964529|NCT03577054|BEHAVIORAL|HBB Prompt|Mobile app developed through user-centred design in phase 1 of this study
224111184|NCT03996538|BIOLOGICAL|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
224111185|NCT06070038|BEHAVIORAL|Integrated Behaviour Change Based Intervention Materials|The intervention will be delivered over a three-month period as a series of four zoom hosted workshops, online content, and a moderated social support group. Zoom workshops will last 45 minutes and will target key constructs from the integrated behavior change model. Main topics of the workshops are autonomy Supportive parenting (Week 1), goal setting and outcome beliefs (Week 3), physical activity norms (Week 5), and encouraging self-efficacy and maintenance (Week 8). Following each workshop, participants will receive links to online content that builds on workshop themes, such as messages, worksheets, and reflection tasks. Throughout the trial, participants will be able to participate in social support chat groups to discuss their progress with other members of the intervention group and intervention facilitators.
224111186|NCT02499965|DRUG|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
224111187|NCT02499965|DRUG|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
224111188|NCT01874704|BEHAVIORAL|Comparison of biomarkers of stress|
224111189|NCT05333562|OTHER|Motor control exercise|Motor control exercise was given with total of 8 sessions for 30 min for 4 weeks twice a day. Each exercise was performed 10 repetitions for 10 sec.
224111190|NCT05333562|OTHER|Motor control exercise with mobilization|this was given motor control exercise for 30 min, 4 weeks twice a day plus neural gliding applied for 3 sets of 10 repetitions on each session. Neural gliding applied 5 min before motor control exercise. Total 8 sessions were given
224111191|NCT01821248|DRUG|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
224111192|NCT05417529|OTHER|music therapy intervention|"Participants did not receive premedication with midazolam 0,02 mg/kg intravenous and received music therapy intervention by a certified music therapist FAMI . Music Treatment consisted of 3 steps:~(1)30 minutes before surgery, music therapist (MTp) engaged the patient in an individual brief conversation (10 min.) to identify preferred musical genre/songs and prepared a customized playlists to listen to during induction; (2)After being monitored in the operating room, patients were prepared to listening to music ; (3)Music listening during anesthesia induction. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation"
223964530|NCT03577054|BEHAVIORAL|Low-Dose High Frequency training|Participants will be encouraged to practice their HBB skills daily
223964531|NCT03987698|BIOLOGICAL|SHR-1210|SHR-1210 injection
223964532|NCT03987698|BIOLOGICAL|CIK cells|CIK cells injection
223964533|NCT03202056|OTHER|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
224111193|NCT05417529|DRUG|Standard Preparation|Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
224111194|NCT05046210|BEHAVIORAL|LHA intervention|The participants in the EG received 4 lessons from a LHA over 4 weeks. Four lessons were taught one-on-one once a week by a certified LHA at the participants' homes. The lessons including understand oral structure, learn oral self-care skills and oral function promotion, understand the status of oral self-care and the relationship between oral diseases and systemic diseases, understand swallowing dysfunction and safe eating skills and review.
224111195|NCT05046210|BEHAVIORAL|Oral exercise intervention|Oral exercise intervention is designed to increase the range of movement in tongue, lips, and jaw as well as salivary gland massages, which will help speech and/or swallow functioning. All participants performed oral exercise before three meals a day.
223964534|NCT03202056|OTHER|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
224111196|NCT04799782|DRUG|Mirtazapine|15 mg dose before bed-time
224111197|NCT04799782|DRUG|Placebo|One placebo pill before bed-time
224111198|NCT04666961|DRUG|Tamoxifen 20 mg|Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
223724648|NCT02528071|OTHER|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
224111199|NCT04666961|DRUG|Anastrozole 1Mg Tab|Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
224111200|NCT06511609|PROCEDURE|double-flap technique（DFT）; double-tract reconstruction(DTR),|DFT (experiment group). Patients receive double flap technique after laparoscopic proximal gastrectomy. DTR (control group). Patients receive double-tract reconstruction after laparoscopic proximal gastrectomy.
224111201|NCT03727711|OTHER|TPTNS|We will be comparing hospital treatment to TPTNS at home
224111202|NCT03687177|OTHER|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
224111203|NCT03687177|OTHER|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
224111204|NCT02606877|DRUG|nintedanib|
224111205|NCT02606877|DRUG|pirfenidone|
223964535|NCT06456164|DEVICE|Cook Cervical Ripening Balloon|The Cook Cervical Ripening Balloon is a double-balloon catheter designed to mechanically ripen the cervix prior to labor induction when the cervix is unfavorable for induction.
223964536|NCT06993129|OTHER|Emergency Care Action Plan|An Emergency Care Action Plan (ECAP) is a brief, pre-populated summary of suggested emergency management for children with medical complexity, embedded in a patient's electronic health record for access by providers in an emergency. Patients/families will have digital access to the ECAP and be given a paper copy. The patient's care team and caregiver(s) (parent/legal guardian) will collaborate to create an individualized ECAP containing the following content: caregiver contact information, patient summary, anticipated emergency presentations with suggested management, problem list (emergency relevant only), medication list, technology dependence, baseline important physical exam findings, baseline vital signs, allergies, advance directive information, contact information for established care providers, and other important information.
224111206|NCT02989727|DRUG|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
224111207|NCT02989727|DRUG|Placebos|Placebo tablets
224111208|NCT03633643|DRUG|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
224111209|NCT03633643|DRUG|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
224111210|NCT01361529|DRUG|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
224111211|NCT06279585|OTHER|Physical therapy|Health education sessions and combined therapeutic exercise sessions, based on muscular strength training and cardiorespiratory endurance.
224111212|NCT04986293|DEVICE|CPAP|Different settings of CPAP and BiPAP will be tested using a home mechanical ventilator
224111213|NCT00116311|BEHAVIORAL|allergen inhalation|
224111214|NCT00116311|BEHAVIORAL|withdrawal of medication|
224111215|NCT00116311|PROCEDURE|sputum induction|
224111216|NCT00259805|DRUG|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
224111217|NCT06110234|BEHAVIORAL|Episodic Specificity Induction|Recalling complex scenes using the Episodic Specificity Induction
224111218|NCT06110234|BEHAVIORAL|Associative Memory|Recalling word/picture pairs
223542447|NCT03138785|RADIATION|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
223542448|NCT00003631|BIOLOGICAL|filgrastim|
223542449|NCT00003631|DRUG|carboplatin|
223542450|NCT00003631|DRUG|carmustine|
223542451|NCT00003631|DRUG|cyclophosphamide|
224111219|NCT02417220|BEHAVIORAL|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
224111220|NCT02417220|OTHER|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
223542452|NCT00003631|DRUG|cytarabine|
223542453|NCT00003631|DRUG|etoposide|
223542454|NCT00003631|DRUG|ifosfamide|
223542455|NCT00003631|DRUG|melphalan|
223542456|NCT00003631|PROCEDURE|bone marrow ablation with stem cell support|
223724649|NCT01417234|DEVICE|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
224111221|NCT04036617|DRUG|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
224111222|NCT04036617|DRUG|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
223964537|NCT06988540|OTHER|Personalized Health Planning Program Administration|The T2D PHP program is 8 hour-long sessions offered over 16 weeks. The program includes development of a personal health plan supported by a patient-provider health risk assessment; group session structure supplemented by educational, video sessions; lessons, discussions, and activities based on behavioral modification, health engagement, and diabetes distress; goal progress tracking; social support; mindful awareness practices and qualitative health evaluations via surveys and a one-on-one consultation with a personal health coach. Participants will be provided a group participant notebook that provides information discussed during the program. The T2D PHP program is a complement to routine care.
223964538|NCT06988540|OTHER|Usual Care|Patients will be encouraged to see their diabetes provider. Patients will not participate in the T2D PHP program but will complete laboratory tests and surveys as listed in the section on outcomes.
223964539|NCT06614582|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|"The ssNPA device is a flexible, medical-grade silicone, nasal tube that is self-inserted into the airway through one nostril and worn during the night. It can also be used during the day. The device works by supporting collapsed airway muscles and keeping the airway open.~In addition to wearing the device, study team members will call monthly and collect certain data, and medical information and participants will be asked to have a sleep study at the 12-month visit."
223964540|NCT06661252|DEVICE|ABEL microsampler device|The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
223964541|NCT06999382|BEHAVIORAL|Active Dissemination and Implementation|This intervention is designed to accelerate the uptake of evidence-based interventions that help maximize the impact of the addition or renovation of public open spaces on their utilization for active recreation among community members, ultimately effective physical activity levels in communities. The intervention targets implementation partners: local stakeholders/decision makers and community leaders, to increase their awareness of these evidence-based approaches for place-activation, and their willingness to adopt and implement them in their neighborhood settings. Intervention components include capacity building workshops, newsletters, targeted messaging and access to a knowledge broker and implementation support for 1-year.
223964542|NCT06999382|BEHAVIORAL|Passive Dissemination|Delivery of booklet with menu of evidence-based interventions for place-activation; and of pamphlet summarizing importance of healthy lifestyle promotion.
224111223|NCT01481246|BEHAVIORAL|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
224111224|NCT01481246|BEHAVIORAL|Psychosocial and Psychoeducational Group training|Group treatment with a focus on psychosocial and psychoeducational intervention in healthy adults and in adults with cognitive decline. Ten week cycle, 2 hours per week group intervention study.
224111225|NCT06768164|PROCEDURE|Billroth 2 (B2)|B2 technique requires a single anastomosis (gastro-jejunostomy) after distal gastrectomy
224111226|NCT06768164|PROCEDURE|Roux-En-Y (REY)|REY technique requires 2 anastomoses (gastro-jejunostomy and entero-enterostomy) after distal gastrectomy
224111227|NCT06743828|OTHER|Fermented meat alternative|Participants incorporate a novel fermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
224111228|NCT06743828|OTHER|Unfermented meat alternative|Participants incorporate an unfermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
224111229|NCT06888414|DIAGNOSTIC_TEST|transvaginal ultrasound|Fifty perimenopausal women presenting with AUB were recruited from the outpatient clinic. Baseline data, including demographic, obstetric, and medical history, BMI, and laboratory investigations (CBC, renal and liver function tests, coagulation profile), were collected. All patients underwent transvaginal 3D ultrasonography and hysteroscopy.
224111230|NCT06528873|COMBINATION_PRODUCT|Concurrent optical and magnetic stimulation (COMS) treatment|"COMS treatment will be performed 2-3 times per week for at least 8 weeks, unless the wound heals sooner, with a minimum of 16 applications. Missed sessions can be made up in the 4-week follow-up period. Treatment will occur during standard care procedures, including dressing changes and debridement, and will follow these steps:~Remove old dressing Apply analgesic if necessary Perform debridement if necessary Cleanse the wound Apply COMS One device Apply new dressing Apply compression therapy as per study procedures (section 6.1)~If the patient is at home, a caregiver will perform this procedure. Study staff, including the PI, nurses, and caregivers, will receive training and a step-by-step document on using the COMS One device."
224111231|NCT06321419|BEHAVIORAL|Advanced Trauma Life Support training|Advanced Trauma Life Support (ATLS) is a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill stations, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS training facility in India.
224111232|NCT04715802|PROCEDURE|Immediate breast reconstruction with implant|Because most fillers are under the mammary gland, it is better to place the prosthesis into the opening under the pectoralis major muscle, which avoids contact between the prosthesis and the residual hydrogel to reduce the chance of infection. If postoperative complications disappear and imaging shows no filler remnants after more than 3-month follow-up, secondary breast augmentation can be planned. For placement of the prosthesis, the plane under the pectoralis major is preferred, which avoids prosthesis contact with the residual hydrogel to thus reduce the chance of infection.
224111233|NCT04715802|PROCEDURE|delayed breast reconstruction with implant|The first stage included maximal gel removal and purulent tissue debridement, if necessary. Thereafter, patients were invited for a clinical follow-up and discussion about DBR 3 months later. The latter was offered as a second stage in those opting for it.
224111234|NCT04715802|PROCEDURE|delayed breast reconstruction with autologous fat transplantation|Because fat injection after PAAG removal has a high infection risk, it is recommended to be conducted after 3-6 months of follow-up. The advantage of autologous fat transplantation is its ability to repair a variety of breast shape deformities caused by PAAG removal. Fat injections may need to be repeated several times. The interval between injections should be at least 3 months. Usually, the amount of transplanted fat is 150-200 mL/side. A multilayer and multi-tunnel injection method is commonly used.
223964543|NCT06999447|OTHER|ChatGPT-Supported Case-Based AI Education (C-CASE)|In the intervention group (C-CASE), after informed consent and pretest completion (including a sociodemographic form and CDMNS), the case scenario was introduced by the course instructor. Students were divided into small groups, and each group selected a representative who accessed ChatGPT-4.0 Premium via credentials provided by the research team. Using a collaborative problem-solving format, each group worked through a structured case scenario involving pediatric surgical emergencies. Questions were distributed sequentially, with 5-minute intervals allocated per question. Students used ChatGPT to support reasoning and clinical decision-making within their group. After each interval, responses were submitted, and the next question was handed out. Sessions were proctored by research assistants, and the full implementation, including discussion, lasted approximately two hours. The intervention aimed to foster decision-making, teamwork, and AI literacy in a clinical nursing education.
223964544|NCT06999447|OTHER|Standard Education|In the control group (Standard Education), students followed the same structured case-based learning session as the intervention group, without access to AI tools. After providing informed consent and completing the pretest (sociodemographic form and CDMNS), the case scenario was introduced by the instructor. Students were divided into small groups and selected a representative to use a personal computer during the session. To ensure no access to AI-based tools, the Mobile Guardian app was installed to block websites such as ChatGPT. Students were allowed to use only academic databases and the university's online library. Each group answered a series of timed case questions (5 minutes per item), submitting responses before receiving the next question. Research assistants monitored the session in both classrooms to ensure standardization and prevent external support. The session concluded with a class-wide case discussion, led by the course instructor.
223964545|NCT03543982|DIETARY_SUPPLEMENT|Oral probiotic product|Once per day (QD), 28 days
223964546|NCT07009574|DRUG|anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization|"All patients underwent one intravitreal injection at baseline (0.5 mg ranibizumab or 2.0 mg aflibercept); additional intravitreal injections were administered over the follow-up period based on the above-mentioned activity signs with a pro-re-nata (PRN) treatment protocol. The patients have been followed on a monthly or bimonthly basis. The number of visits and examinations in the 12-month study period will be collected.~Clinical and imaging data of the baseline examination as well as of the 12-month visit (M12) after the first intravitreal injection."
224111235|NCT06906471|DRUG|AS1986NS|Single dose, IV, 100 µg of AS1986NS
224111236|NCT06908031|RADIATION|Short-Course Radiotherapy|Patients undergo SCRT at a dose of 5Gy × 5 fractions
224111237|NCT06908031|DRUG|PD-1 monoclonal antibody|Patients complete immune therapy with PD-1 monoclonal antibody for 4 cycles.
223724650|NCT02513953|PROCEDURE|Laparoscopic|Four Port Laparoscopic cystectomy
223724651|NCT05559138|OTHER|no intervention|no intervention
223724652|NCT00023764|DRUG|bortezomib|Given IV
223724653|NCT04150393|DRUG|MaaT033 capsule|Oral capsule
224111238|NCT06908031|DRUG|mFOLFOX6 regimen|Patients complete chemotherapy with mFOLFOX6 regimen for 4 cycles.
224111239|NCT06908031|DRUG|Cetuximab|Patients with RAS/BRAF wild-type receive targeting therapy with Cetuximab for 4 cycles.
224111240|NCT06908031|DRUG|Bevacizumab|Patients with RAS/BRAF mutations receive targeting therapy with Bevacizumab for 3 cycles. (Bevacizumab is not used in the last cycle of the bevacizumab group)
224111241|NCT06908031|PROCEDURE|Surgical resection|Surgery either local excition or total mesorectal excision is performed 8-10 weeks after the completion of short-course radiotherapy.
223964547|NCT07008339|PROCEDURE|Areola Micropigmentation|Areola micropigmentation performed by trained nurses
223964548|NCT07008339|DEVICE|Hyaluronic Acid Filler Injection|Subcutaneous injection of cross-linked hyaluronic acid filler (Juvederm®) for nipple projection.
223964549|NCT07009223|BEHAVIORAL|Mediterranean Diet|Participants will receive only the educational intervention about the Mediterranean diet. The program consists of 4-5 online sessions conducted by a nutritionist.
223964550|NCT07009223|BEHAVIORAL|Physical Activity|In addition to educational sessions on the Mediterranean diet, there will be 2-3 weekly personalized exercise sessions, followed by a dedicated personal trainer at a partner gym. The treatment will last 12 weeks.
223964551|NCT07009223|BEHAVIORAL|Cognitive Training|In addition to educational sessions on the Mediterranean diet, there will be one weekly cognitive training session in groups, supervised by qualified staff at the IRCCS FBF. The treatment will last for 12 weeks.
223964552|NCT07008053|DRUG|BR+OR|Patients who meet the inclusion criteria will enter the treatment period, which consists of an induction phase followed by a maintenance phase. During the induction treatment period, a combined treatment of 3 cycles of the BR regimen and 3 cycles of the OR regimen will be administered, every 28-day cycle for 6 cycles. After the induction treatment, the efficacy assessment will determine whether patients with CR or PR proceed to the maintenance treatment period. Orelabrutinib monotherapy will used as maintenance therapy, every 28-day cycle for up to 24 cycles, or until disease progression/recurrence, unacceptable toxicity, death or consent withdrawal.
224111242|NCT02726750|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224111243|NCT02726750|OTHER|Laboratory Biomarker Analysis|Correlative studies
224111244|NCT04109079|PROCEDURE|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
223964553|NCT07007845|BEHAVIORAL|CVT Support intervention|The CVT Emergency Aid program focused on optimising the work on the diaphragm was conducted in 3 steps. Step 1 related to establishing diaphragmatic breathing by feeling expansion around lower ribs at inhalation. Step 2 related to establishing connection between pulmonary pressure and subtotal pressurisation by invoking inwards abdominal movements on controlled exhaled voiceless exercises (ssss-sound) Step 3 related to establishing dynamic control of subglottal pressure by performing fricative voice sounds (vvvf- and zzz-sounds) while contracting the abdominal wall inwards and thereby pressurising the pulmonary space leading to increased subglottal pressure on accents and extended pitch accents.
223964554|NCT07007845|PROCEDURE|Dooming Diaphragm|Osteopathic treatment: Dooming Diaphragm. The inferior costal margin was contacted with the hands, allowing the thumbs to rest just below the ribcage anteriorly. Care was taken to avoid contact with the xiphoid process, as this could cause discomfort for the patient. The patient was instructed to breathe deeply, and as they exhaled, gentle pressure was applied superiorly and laterally with the thumbs, rolling them underneath the ribcage as far as was comfortable. This process was repeated for 3-5 breath cycles or until no tension was felt in the thumbs during exhalation.
223964555|NCT07008872|BIOLOGICAL|CD7 CART|For intravenous infusion
224111245|NCT04109079|RADIATION|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
224111246|NCT04109079|RADIATION|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
224111247|NCT01318902|DRUG|Ixazomib|Ixazomib capsules.
224111248|NCT01318902|DRUG|Dexamethasone|Dexamethasone tablets.
224111249|NCT06045572|DEVICE|VTM examination and breast biopsy|VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
224111250|NCT06912607|BEHAVIORAL|Balance in Motion Exercise class|8 weeks of 2 meetings/wk exercise class, with a once weekly homework exercise, delivered entirely in ASL
224111251|NCT06828692|COMBINATION_PRODUCT|Group A (clinical guideline+machine learning)|Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.
224111252|NCT06828692|COMBINATION_PRODUCT|Group B (clinical guideline+impedance cardiograph+machine learning)|Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.
224111253|NCT06828692|OTHER|Group C (usual care)|Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.
224111254|NCT05303675|OTHER|exercise and training|"Preoperative: An introductory information form will be filled out, and a lymphedema self-care and exercise booklet will be given.~Postoperative: Patients will be applied Progressive Upper Limb Exercises and Muscle Relaxation Training (PULE-MRT), lymphedema upper extremity circumference measurement, and symptom alert model until discharge, and Muscle Relaxation Training will continue until discharge.~Post-Discharge: They will be asked to record a diary at home. PULE-MRT will continue until day 15. The 15-day exercise program will continue for up to 3 months. Follow-up will be made by telephone according to the symptom alert model at the 1st, 2nd, and 3rd months, and at the end of the 3rd month, the breast cancer-related lymphedema self-care scale will be administered."
223542457|NCT00003631|PROCEDURE|peripheral blood stem cell transplantation|
224111255|NCT06916468|DEVICE|VAD with Cotton Dampener|A standard pen-like Vibratory Anesthetic Device (VAD) with and without cotton will be applied across five anatomical sites (lateral nasal wall, sub-malar region of the cheek, ear helix, lateral neck, and dorsal side of the forearm) of participants. For each anatomical site, one side (either right or left) will receive vibration with cotton, and the opposite side will receive vibration without cotton in a randomized order.
223964556|NCT07007572|COMBINATION_PRODUCT|Digitally-fabricated implant supported supra-structure fabricated from reinforced resin|A comprehensive clinical examination with an understanding of patients' chief complaints and needs will be carried out. For each patient, two implants will be placed in the edentulous area, and the patient will receive a screw-retained bridge supported by both implants made of milled monolithic zirconia (Dental Direkt Zirconia, Germany). After 6 months, the zirconia restoration will be replaced with a milled resin-reinforced composite (Nanoska G Plus, USA), allowing the same patient to use the new restoration for another 6 months. Randomization will be performed to determine the sequence of bridge material for each participant. Accordingly, the two restorations will be sequentially delivered to each participant with no gap (wash-up period) between them. Consent will be signed by the selected participants after explaining the detailed information of the trial.
223964557|NCT07007572|COMBINATION_PRODUCT|Digitally-fabricated implant supported supra-structure fabricated from monolithic zirconia|Digitally-fabricated implant supported supra-structure fabricated from monolithic zirconia
223964558|NCT07008950|OTHER|The Self-Efficacy and Knowledge Trial|The intervention is composed on 8 sessions given over a period of 8 weeks covering topics of emotional regulation, communication, problem management, decision making, self-efficacy and others in relation to sexual reproductive health, family planning, and wellbeing. The intervention package will be delivered by trained non-specialists with at least 12 years of formal education. The package will be administered once a week for a duration of 90 minutes.
224111256|NCT06916468|DEVICE|Vibratory Anesthetic Device (VAD)|A standard pen-like Vibratory Anesthetic Device (VAD) with and without cotton will be applied across five anatomical sites (lateral nasal wall, sub-malar region of the cheek, ear helix, lateral neck, and dorsal side of the forearm) of participants.
224111257|NCT06735131|RADIATION|radiotherapy 5 Gy × 5 fractions, once a day|5 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
224111258|NCT06735131|RADIATION|radiotherapy 8 Gy × 5 fractions, once a day|8 Gy × 5 fractions, once a day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
224111259|NCT06735131|RADIATION|radiotherapy 8 Gy × 3 fractions, once every other day|8 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
224111260|NCT06735131|RADIATION|radiotherapy 10 Gy× 3 fractions, once every other day|10 Gy × 3 fractions, once every other day, beginning on the day within 4 weeks before the initiation of cycle of toripalimab and chemotherapy
224111261|NCT06735131|RADIATION|radiotehrapy 0.5Gy twice-a-day × 2 days, repeat for 4 cycles (total 8Gy)|0.5 Gy twice-a-day × 2 days, on the first 2 days of the first 4 cycles of toripalimab and chemotherapy (total 8Gy)
224111262|NCT06735131|DRUG|Toripalimab|Toripalimab (240 mg IV, d1, Q3W)
224111263|NCT06735131|DRUG|chemotherapy regimen selected by the investigator|Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)
224111264|NCT06920537|OTHER|Postpartum Cardio-obstetric Rehabilitation Program|The intervention consists of an 8-week exercise and education program with a hybrid format (in person, virtual and pre-recorded sessions). The aerobic exercise intensity will progressively increase from 50 to 85% of Targeted Heart Rate Range (THRR), calculated for middle-aged women using the maximal heart rate (HR) estimated as 206 - (0.88 x age) . First and second weeks training will target an intensity of 50-65% THRR, third and fourth weeks will target 65 to 75% of THRR, fifth to seventh weeks will target 75 to 80%, and eighth week will target 85%. Participants will use Fitbit Charge-6 to monitor THRR during exercise sessions. Pelvic floor, body alignment/core stability, balance, and low back pain prevention exercises will be added to each in-person session and repeated during the online session. Participants from the intervention group will receive recommendations to progressively reach daily 10,000 steps throughout the intervention period.
224111265|NCT06922357|DRUG|HRS-6719|HRS-6719
224111266|NCT04857645|DRUG|ASTX727|Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation
224111267|NCT04857645|OTHER|Donor Lymphocyte Infusions|In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles
223542458|NCT00003631|RADIATION|radiation therapy|
223724654|NCT03550898|DIAGNOSTIC_TEST|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
223724655|NCT04757870|OTHER|frequency|Macro-scale risk factors for the frequency of and mortality of infection
223964559|NCT07009405|DEVICE|non-invasive thermal infusion site monitoring NTISM device|Non-invasive thermal infusion site monitoring NTISM device for detecting extravasation and infiltration events using thermal anisotropy measurements
223964560|NCT07007871|OTHER|Tutoring and Counselling (1)|During the intervention, students participate in a structured program designed to support those with confirmed or suspected mental illness. The program includes two weekly group tutorial sessions lasting 1.5 hours each, organized in small groups of 4-5 students to foster interaction and peer support. Students also receive two individual counseling sessions per month, each lasting one hour. Tutor-group assignments are based on tutor availability and location for logistical efficiency.
223964561|NCT07007871|OTHER|Tutoring and Counselling (2)|Students assigned to the waitlist control group receive the program after the experimental group completes it. Students participate in a structured program designed to support those with confirmed or suspected mental illness. The program includes two weekly group tutorial sessions lasting 1.5 hours each, organized in small groups of 4-5 students to foster interaction and peer support. Students also receive two individual counseling sessions per month, each lasting one hour. Tutor-group assignments are based on tutor availability and location for logistical efficiency.
223964562|NCT07008040|OTHER|Silver dressing|Silver dressing will be applied to the sternotomy and donor site wounds for the CABG patients
223964563|NCT07008144|OTHER|Digoxin alarm|A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.
223964564|NCT07009236|DEVICE|MIGS|Implant MINIject S+ in supraciliary space
223964565|NCT07008703|DRUG|Injection of humanized nerve growth factor (NGF) antibody|Subcutaneous injection, 20mg
223964566|NCT07008820|OTHER|Health-related quality of life questionnaires|"Questionnaires include:~EORTC-QLQ C30 FACT-An PGI-S EQ-5D-5L"
223964567|NCT07008820|OTHER|Qualitative interviews|For participants that meet eligibility criteria
223964568|NCT04702191|BEHAVIORAL|Triple P|Triple P - level 4 group is a group-based parenting intervention for families with children who exhibit behavioural or emotional difficulties. Group sessions typically focus on topics such as positive parenting, helping children develop, managing misbehaviour, and planning ahead. Practitioners then provide individual feedback on progress using positive parenting strategies and goal setting. Trained practitioners will deliver the program according to the manualized protocol (Turner, Markie-Dadds, \& Sanders, 2010). This will include eight weekly sessions with maximum of 12 parents. The first four sessions will be as group sessions. These four group sessions will be followed by three one-to-one practical and personalised telephone consultations. Finally, there will be one group session, which will complete the programme and parents' contact with the Triple P practitioners. The main aim of this session is to review progress and plan for the future.
223964569|NCT04702191|BEHAVIORAL|Circle of Security Parenting|Circle of Security - Parenting (COS-P) will be delivered according to the protocol outlined by Cooper, Hoffman and Powell (Cooper et al., 2009). COS-P is a manualized eight-session parent-education group program which has the same broad aims and core components of the COS-Intensive model from which it was developed (i.e., to increase caregiver sensitivity and responsiveness to child cues, empathy for the child by supporting parental reflective functioning, recognition and understanding of child attachment cues, and awareness of the impact of the caregiver's own attachment history on caregiving patterns). The program is led by one or two facilitators and includes 10-12 caregivers. The program uses clinical DVD clips of problematic parent-child interaction and healthy alternatives to illustrate attachment patterns and parenting styles, and to promote group discussion.
223964570|NCT01613807|DRUG|Insulin LISPRO|Humalog® Mix50/50™ \[50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)\], three times daily at mealtime. Dose determined by blood glucose history.
223964571|NCT01613807|DRUG|Insulin, Long-Acting and Insulin|Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
223964572|NCT04226651|DEVICE|Virtual Reality Device|The Virtual Reality system (PlayStation 4 VR, Sony Inc.) is a simple and easy to use distraction device. The system consists of a screen mounted on a binocular headset connected to a console or personal computer. The head-mounted display provides a high-resolution visual display and unmutes the sound from the headphones using a soundproof mechanism that provides clear sound.
224111268|NCT06933485|OTHER|Exercise|These sessions of the postural exercise aim to increase student's knowledge and awarenes their benefits for trunk stabilization, posture correction and diaphragmatic breathing will be explained by the expert physiotherapist. In the exercise planning; the exercise session start with warm-up exercises; A transition to the flow of exercise is ensured with warm-ups that include arm, leg and trunk movements for approximately 10 minutes, and then all extremities are worked for approximately 40 minutes in the main exercise session to ensure trunk alignment. The last 10 minutes of the exercise session is completed with approximately 10 minutes of cool-down exercises to which light stretching is added, making the exercise session a total of 60 minutes.
224111269|NCT06509932|DEVICE|Jefcare Sterile Medical Sheets|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: Jefcare Sterile Medical Sheets and skin care regimen.
223542459|NCT00600067|DRUG|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
223542460|NCT00600067|DRUG|Placebo|Oral placebo capsules, once daily, 28 weeks
223542461|NCT00869167|DRUG|Ramelteon|melatonin agonist
223542462|NCT05847647|OTHER|Retrograde Filling Group|Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and no material will be applied to the bone defect.
223542463|NCT05847647|OTHER|Retrograde Filling+L-PRF Group|2\. Group: Surgical curettage of the periapical lesion and root tip resection will be performed, MTA will be applied retrogradely and L-PRF will be applied to the bone defect (
223542464|NCT05847647|OTHER|(Orthograde Filling Group / OG Group).|3\. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and no material will be applied to the bone defect
224111270|NCT06509932|DEVICE|MoliCare Premium Bed Mats|Screening period (day 0): normal routine medical sheet and skin care regimen. Intervention days 1, 2, 3, 4, 5: MoliCare Premium Bed Mats and skin care regimen.
223964573|NCT04226651|DEVICE|Protective glasses|Each patient was informed about the dental procedure and was provided with protective glasses. All patients were told that they were wearing these glasses to ensure a pain- and stress-free treatment, and that the dentist would devote additional attention to the treatment.
223964574|NCT01612221|DRUG|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
223964575|NCT01612221|OTHER|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
224111271|NCT06943885|OTHER|5G Mobile Stroke Unit Management|5G MSU is a specialized stroke ambulance equipped with point of care lab, CT scanner, Telemedicine, allowing patients to receive intravenous thrombolysis.
224111272|NCT06943885|OTHER|Standard Management|A regular ambulance. The standard management by EMS includes Electrocardiographic（ECG）monitoring, blood glucose management, airway, respiration, and blood pressure control, complication management, intravenous access establishment and other emergency measures.
224111273|NCT02646436|OTHER|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
224111274|NCT02646436|OTHER|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
224111275|NCT00432133|BEHAVIORAL|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
224111276|NCT00432133|BEHAVIORAL|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
223964576|NCT05838976|DIAGNOSTIC_TEST|Shorter Version of the CTQ-SSS|The intervention in this study is the administration of the shorter version of the CTQ-SSS, a validated questionnaire designed to assess the severity of symptoms and functional limitations associated with carpal tunnel syndrome. The CTQ-SSS consists of 8 items related to symptom severity and 2 items related to functional status. The scores for each set of items are combined to generate symptom severity and functional status scores, which will be used to assess the validity and reliability of the CTQ-SSS in patients with carpal tunnel syndrome undergoing nonsurgical management.
224111277|NCT06949813|BEHAVIORAL|BE-OR: Brief Intervention to the Operating Room|See intervention group section for details
223542465|NCT05847647|OTHER|(Orthograde Filling+L-PRF Group|4\. Group: Surgical curettage of the periapical lesion will be performed, MTA will be applied orthogradely without root tip resection and L-PRF will be applied to the bone defect
223964577|NCT00569036|DRUG|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
224111278|NCT06949813|OTHER|Interaction: Facetime with Clinical Provider|See Interaction group section for details
224111279|NCT01859351|DRUG|WX-037|
224111280|NCT01859351|DRUG|WX-554|
224111281|NCT00584064|DEVICE|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
224111282|NCT06503991|BEHAVIORAL|Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP)|Clinic-based hypertension educational intervention delivered by a Community Health Worker.
224111283|NCT06503991|BEHAVIORAL|Control of Blood Pressure and Risk Attenuation (COBRA)|Multi-component counseling program addressing patient education, provider training, coordination of care, and subsidizing care costs.
224111284|NCT05738252|DIAGNOSTIC_TEST|Clinical Frailty Scale|A way to summarize the overall level of fitness or frailty of an older adult after they had been evaluated by an experienced clinician
223542466|NCT04339413|DRUG|Gantenerumab|Gantenerumab was administered as SC injection Q4W.
223542467|NCT01684839|DEVICE|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
223724656|NCT04294472|DRUG|MAU868|MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
223724657|NCT04294472|OTHER|Placebo|250 mL D5W placebo IV to be labeled to match that of MAU868
223964578|NCT01613183|DRUG|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
223964579|NCT01613183|OTHER|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
224111285|NCT05738252|DIAGNOSTIC_TEST|Frailty Phenotype|Defined by the presence of three from the following five clinical features: weakness, slow walking speed, unintentional weight loss, exhaustion, and low physical activity
224111286|NCT05454176|DEVICE|Libre 2|"The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level \<=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use."
223964580|NCT05490147|PROCEDURE|conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group|In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12.
223964581|NCT05490147|PROCEDURE|low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume|In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8.
223964582|NCT00705614|BIOLOGICAL|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
223964583|NCT00742014|DRUG|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
224111287|NCT05454176|DEVICE|Device for SMBG and Libre Pro|"A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group."
224111288|NCT05667428|DRUG|leuprorelin|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of leprorelin in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
224111289|NCT05667428|DRUG|normal saline|From the initial chemotherapy after diagnosis, patients received a subcutaneous injection of normal saline in each cycle of chemotherapy including the conditioning treatment prior to transplantation.
223964584|NCT01044901|PROCEDURE|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
223964585|NCT05381077|OTHER|MRI|Whole body MRI (ZTE sequence)
224111290|NCT01429246|DIETARY_SUPPLEMENT|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
224111291|NCT01429246|DIETARY_SUPPLEMENT|Salt Substitute|Estimated 30 grams per day per household member
224111292|NCT03444363|DEVICE|Laser group|Laser application in addition to SRP
223724658|NCT01191398|DRUG|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
223964586|NCT00676195|DRUG|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
223964587|NCT01676883|DEVICE|Bioelectric impedance|removal of calluses and corns by pedicure
223964588|NCT01676883|DEVICE|Air displacement plethysmography|
224111293|NCT03444363|DEVICE|Control group|Placebo laser application in addition to SRP
224111294|NCT04340869|OTHER|Theobromine|Natural extract from Cocoa
224111295|NCT04340869|OTHER|Remin Pro|Remin Pro
224111296|NCT01394029|DRUG|deferasirox|
223724659|NCT01191398|DRUG|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
223724660|NCT01191398|DRUG|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
223964589|NCT00213226|DRUG|dexamethasone|
223964590|NCT01414543|OTHER|Information Sheet|Providing the Participant with information regarding the aim of the experiment
223964591|NCT01414543|OTHER|Consent|Providing a consent form for participants. The participant is aware of his or her rights
223964592|NCT01414543|OTHER|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
223964593|NCT01414543|OTHER|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
223964594|NCT00978783|DEVICE|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
223964595|NCT00978783|DEVICE|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
223964596|NCT03787719|OTHER|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment
223964597|NCT03498885|PROCEDURE|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
224111297|NCT04192448|OTHER|Alcohol Administration|The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
224111298|NCT04192448|OTHER|Mood Induction|The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
224111299|NCT01383200|DRUG|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
224111300|NCT01383200|DRUG|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
223964598|NCT03498885|PROCEDURE|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
223964599|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
223964600|NCT02661490|DRUG|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
223964601|NCT02661490|BIOLOGICAL|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
223964602|NCT00185796|PROCEDURE|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
224111301|NCT01842061|BEHAVIORAL|Active Living Program|
224111302|NCT01842061|BEHAVIORAL|Education|
224111303|NCT00128206|DRUG|Isoniazid|Isoniazid 900 mg twice weekly
224111304|NCT00128206|DRUG|Rifampin|Rifampin 600mg once per day
224111305|NCT00250471|PROCEDURE|Percutaneous Coronary Intervention (PCI)|
224111306|NCT01959867|DEVICE|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
224111307|NCT01959867|OTHER|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
224111308|NCT01757639|BIOLOGICAL|Ipilimumab|Given IV
224111309|NCT01757639|OTHER|Laboratory Biomarker Analysis|Correlative studies
224111310|NCT02041715|DRUG|TKM-100802 for Injection|IV infusion
223964603|NCT00185796|PROCEDURE|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
223964604|NCT03448354|PROCEDURE|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
223964605|NCT00019019|DRUG|carboxyamidotriazole|
224111311|NCT02041715|DRUG|Placebo|IV infusion
224111312|NCT03958682|DEVICE|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
224111313|NCT05664048|BEHAVIORAL|Dry heat application|Self- dry heat application on the foot during menstrual period with pain.
224111314|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
224111315|NCT02855346|COMBINATION_PRODUCT|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
223964606|NCT00019019|DRUG|paclitaxel|
223724661|NCT05833854|OTHER|Virtual reality glasses group|It is suggested that the use of virtual reality glasses during the injection will positively affect the pain and fear levels in children who received penicillin injection in the pediatric emergency department where the study was conducted.
223724662|NCT05833854|OTHER|Manual pressure group|In the pediatric emergency department where the study was conducted, pressure will be applied to the area to be injected for 10 seconds before the injection procedure in children who received penicillin injection. Pressing with the thumb of the hand, which will be passive in the pressing application, will be understood by the whitening of the nail, and thus pressure will be applied to the skin. It is suggested that it can positively affect pain and fear levels.
223964607|NCT04891159|OTHER|Shared decision making|The intervention consists of 5 components: 1) Online shared decision making training (2 hours, e-learning); 2) Individual coaching for doctors by a shared decision making expert; 3) Implementation of the shared decision making; 4) Link to institutional approaches to patient engagement; 5) Integration of the shared decision making into the multidisciplinary consultation meetings of the Cystic Fibrosis Centers Competences.
223964608|NCT05381181|BIOLOGICAL|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.
223964609|NCT05441371|OTHER|Toothpaste; Paradontax|Comparison of Paradontax toothpaste anti-plaque abality versus regular toothpaste
223964610|NCT05918289|BEHAVIORAL|Blended& integrated happy aging active aging program(BIHAAAP)|12 Weeks intervention devided in to two phases( face to face and home based)
224111316|NCT03387904|DRUG|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
224111317|NCT03387904|DRUG|Irinotecan|Irinotecan Day 1,8 ivgtt
224111318|NCT01591590|OTHER|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
224111319|NCT01591590|OTHER|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
224111320|NCT01591590|OTHER|Blood samples (plasma preparation and CTC)|
224111321|NCT00896519|BIOLOGICAL|rituximab|
224111322|NCT00896519|BIOLOGICAL|sargramostim|
224111323|NCT00896519|DRUG|cyclophosphamide|
224111324|NCT00896519|DRUG|doxorubicin hydrochloride|
223964611|NCT02782598|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
224111325|NCT00896519|DRUG|prednisone|
224111326|NCT00896519|DRUG|vincristine sulfate|
224111327|NCT00896519|GENETIC|gene expression analysis|
224111328|NCT00896519|GENETIC|gene rearrangement analysis|
224111329|NCT00896519|GENETIC|polymerase chain reaction|
224111330|NCT00896519|OTHER|R-CHOP regimen|
224111331|NCT00896519|OTHER|laboratory biomarker analysis|
224111332|NCT03270085|DRUG|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
224111333|NCT03270085|OTHER|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
224111334|NCT00397956|DRUG|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
224111335|NCT05429515|PROCEDURE|HFR-SUPRA|HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.
224111336|NCT05429515|PROCEDURE|hemodialysis|hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.
224111337|NCT05429515|DRUG|Chemotherapy|chemotherapy protocol will be made by hematologists.
224111338|NCT02688855|DEVICE|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
224111339|NCT02688855|DEVICE|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
224111340|NCT04286308|OTHER|electrophysiological data collection|Electrophysiological data collection at the time of DBS surgery.
223724663|NCT04216771|DRUG|Idarubicin|Idarubicin 10mg/m²/day, D1 (IV)
223964612|NCT04591964|COMBINATION_PRODUCT|"mobile application M-Cardio based on android"|"Mobile apllication M-Cardio (android) for remote monitoring of patients with CHF developed on algorithms of clinical indicators, that's give us to evaluate current condition of patient, depends from quantity points of abnormals higher or lower threshold values, with automatically notification for doctor and patient for timely medical service."
223964613|NCT02880969|BEHAVIORAL|answering questionnaires|
223964614|NCT04266613|DIAGNOSTIC_TEST|TruGraf® Testing|5 mL collection PAXgene blood sample
223964615|NCT00814632|DRUG|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
223964616|NCT03022110|DEVICE|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
223964617|NCT01755247|DRUG|Topical Gel Vehicle|
223964618|NCT01755247|DRUG|8% NVN1000 Topical Gel|
223964619|NCT01755247|DRUG|8% NVN1000 Topical Gel and moisturizer|
223964620|NCT00202306|DRUG|lithium carbonate|
223964621|NCT02243436|DRUG|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
223964622|NCT02243436|DRUG|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
223964623|NCT02243436|DRUG|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
223964624|NCT02243436|DRUG|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
223964625|NCT02243436|DRUG|Ara C|Intravenous use, 2g/m2, day 5
223964626|NCT05947708|DEVICE|Dialysate Flow Rate|Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
223964627|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
223964628|NCT02295852|DIETARY_SUPPLEMENT|LOW-SODIUM LOW LIPID DIET|2\. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
223964629|NCT02206087|DRUG|PER977|Reversal of heparin-induced anticoagulation
223964630|NCT02206087|DRUG|Placebo|Reversal of heparin-induced anticoagulation
223964631|NCT02206087|DRUG|Heparin Sodium|
223964632|NCT02646189|DRUG|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
223964633|NCT02646189|DRUG|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
223964634|NCT02646189|DRUG|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
223964635|NCT00192322|BIOLOGICAL|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
223964636|NCT00192322|BIOLOGICAL|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T \<10\^5
223964637|NCT00192322|BIOLOGICAL|Placebo|a single intranasal 0.2 mL dose of placebo
224111341|NCT06408090|OTHER|IDECIDE-HOSPICE|12-pg educational booklet detailing information about hospice including what hospice is, why someone would use hospice, who pays for hospice, and where hospice services are delivered
223724664|NCT04216771|DRUG|ID cytarabine|Cytarabine 1.5g/m² /12h, D1-D3 (IV)
223964638|NCT00192322|BIOLOGICAL|TIV|commercially available TIV injected intramuscularly
223964639|NCT01860495|PROCEDURE|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
223964640|NCT01860495|PROCEDURE|G2|tradetional occlusive collagen membrane
223964641|NCT01984853|OTHER|OBSERVATIONAL REGISTRY|
223964642|NCT04617262|BEHAVIORAL|Remote Problem Management Plus|Five sessions of low-intensity, trans-diagnostic psychological intervention including the teaching and practice of the following strategies: stress management, problem solving, behavioral activation, and strengthening social support
223964643|NCT01064505|DRUG|QPI-1007 at various doses|Single Intravitreal Injection
223964644|NCT00672672|BIOLOGICAL|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
223964645|NCT05698199|DRUG|ITI-1001|ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
223964646|NCT05530460|DEVICE|retinal imaging with low-cost OCT device|Retinal imaging with low-cost OCT device
223964647|NCT05530460|DEVICE|retinal imaging with commercial OCT device|retinal imaging with commercial OCT device
223964648|NCT04922645|DRUG|Ferric Citrate 1 gram Oral Tablet|Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
223964649|NCT04922645|DRUG|Standard of care phosphate-lowering therapy|Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
223964650|NCT05608408|DEVICE|Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system|Stimulation of site with the Medtronic Percept PC system using low frequency stimulation at 0.5 Hz.
223964651|NCT05608408|DEVICE|Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system|Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system using standard of care high frequency stimulation parameters.
223964652|NCT06047379|DRUG|NEO212 Oral Capsule|NEO212 is a novel chemical entity that was generated by covalent conjugation of temozolomide (TMZ) with perillyl alcohol (POH).
224111342|NCT01724606|RADIATION|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
223964653|NCT06047379|DRUG|Ipilimumab|Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes can recognize and destroy cancer cells.
223964654|NCT06047379|DRUG|Pembrolizumab|Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.
223964655|NCT06047379|DRUG|Nivolumab|Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer.
223964656|NCT06047379|DRUG|Regorafenib|Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
223964657|NCT06047379|DRUG|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used by injection into a vein.
223964658|NCT06047379|DRUG|Paclitaxel|Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection
223964659|NCT06047379|DRUG|FOLFIRI Protocol|"FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer. It is made up of the following drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative with multiple applications, which in this context increases the cytotoxicity of 5-fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops synthesis; and IRI - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating."
223964660|NCT06047379|DRUG|Bevacizumab|Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma
223964661|NCT02228083|DRUG|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
223964662|NCT00156377|DRUG|Mupirocin|
223964663|NCT03562897|DIETARY_SUPPLEMENT|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
224111343|NCT01724606|DRUG|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
224111344|NCT01654575|DRUG|Methotrexate|Methotrexate 25mg/week for 16 weeks
223964664|NCT00944996|DRUG|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
223964665|NCT06164769|PROCEDURE|blocking both the abdominal trunk and superior mesenteric artery in the pancreatic enucleation|In the pancreatic enucleation, Kocher Maneuver was routinely performed at first. Then free the left side of the abdominal trunk and superior mesenteric artery, loose tissues easy to free.After Kocher Maneuver and other surgical procedures, the abdominal trunk and superior mesenteric artery exposed. Before resection of pancreatic tumors, a vascular occlusion clamp clip was used to block the root of both the abdominal trunk and superior mesenteric artery to control the pancreatic blood flow.
223964666|NCT04890483|DEVICE|Transcranial direct current stimulation|tDCS: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: five times, once per day.
223964667|NCT06529783|OTHER|Shockwave Therapy|The proposed model for radial shockwave therapy at Clínica Osteopática Dr. David Ponce is the DolorClast® by EMS, made in Nyon, Switzerland. Treatment parameters include 2500 impulses, 0.2 mJ/mm² energy density, and 15 pulses per second, using a 15 mm diameter applicator with ultrasound gel applied to the treatment area. The patient will be positioned laterally on the table with specific leg positions to ensure comfort and effectiveness.
224111345|NCT01654575|DRUG|Placebo|Placebo tablets once a week for 16 weeks
224111346|NCT01223911|DRUG|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
224111347|NCT01223911|DRUG|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
223724665|NCT03489824|PROCEDURE|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
224111348|NCT03957083|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
224111349|NCT06211283|DRUG|Sodium valproate|fasted
224111350|NCT06211283|DRUG|Sodium valproate|fed
224111351|NCT02533960|OTHER|not applicable (observational study)|Observational study without study related intervention.
224111352|NCT02501356|DIETARY_SUPPLEMENT|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
223964668|NCT06529783|OTHER|Therapeutic Exercises|The exercise protocol was followed daily, with continuous physiotherapist supervision to ensure correct execution and avoid improper postures. The protocol includes four exercises: bilateral low-load supine abduction, unilateral isometric hip abduction in medial rotation, hip abduction with sliding, and bilateral supported glute bridge. A maximum of 4/10 on the VAS pain scale is allowed during exercise; exceeding this threshold means skipping exercises for that day.
223964669|NCT06529783|OTHER|Ultrasound-Guided Percutaneous Neuromodulation:|"This technique was applied only to the experimental group before shockwave therapy. An ultrasound-guided approach to the superior gluteal nerve used a 7-12 MHz linear probe from Esaote MyLab™Alpha and Physio Invasiva® equipment. The needle length varied with patient anatomy, with a typical safety reference from 0.30 x 60 to 0.35 x 70 mm. A biphasic current with 10 Hz frequency and 240 μs pulse width was used, with intensity adjusted for a visible but non-painful motor response, following the 10-10-10 protocol.~To locate the superior gluteal nerve, a longitudinal scan of the lateral iliac crest identified the nerve between the gluteus minimus and medius. The procedure used a short-axis approach at 80º to target the nerve's perineurium, with the area disinfected with chlorhexidine before needle insertion."
223964670|NCT06846463|DRUG|Zanubrutinib|Investigational Agent Administration. Zanubrutinib will be first administered on Cycle 2 Day 1 of rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP). It is up to the discretion of the treating physician how many cycles of R-CHOP the treatment would require, but it is not to exceed 6 cycles of R-CHOP and 5 cycles of zanubrutinib. The number of cycles of R-CHOP should be per standard of care, with the number of zanubrutinib cycles being 1 less than the number of total R-CHOP cycles.
223964671|NCT05335005|DRUG|MK-2060|MK-2060 administered via IV infusion
223964672|NCT04050722|DRUG|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
224111353|NCT02501356|DIETARY_SUPPLEMENT|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
223964673|NCT04050722|DRUG|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
223964674|NCT04462653|DEVICE|Wearable Dynamic ECG Recorder|use a Wearable Dynamic ECG Recorder to record heart rate and atrial fibrillation
223964675|NCT04462653|DEVICE|12-lead ECG recordings|use a 12-lead ECG recordings to record heart rate and atrial fibrillation
223964676|NCT01181206|PROCEDURE|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
223964677|NCT01316809|DRUG|AZD8055|Patients will start at 120 mg once daily
223964678|NCT00527371|DEVICE|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
223964679|NCT00527371|PROCEDURE|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
223964680|NCT00349648|PROCEDURE|acromioplasty|
223964681|NCT03162523|RADIATION|High-Dose Rate Brachytherapy|
223964682|NCT00644332|DRUG|Ranolazine|Oral dosage form.
224111354|NCT03946306|DRUG|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
224111355|NCT03946306|DEVICE|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
223964683|NCT01863537|BEHAVIORAL|Multimedia Connect|
223964684|NCT01863537|BEHAVIORAL|Traditional Connect|
223964685|NCT02132598|DRUG|cabozantinib|
223964687|NCT06538831|OTHER|Diet N-P-|Low in saturated fatty acids (SFAs), free sugar and sodium; Low in ultra-processed foods (UPFs)
223964688|NCT06538831|OTHER|Diet N+P-|Rich in SFAs, free sugar and sodium; Low in UPFs
223964689|NCT06538831|OTHER|Diet N-P+|Low in SFAs, free sugar and sodium; High in UPFs
223964690|NCT06538831|OTHER|Diet N+P+|Rich in SFAs, free sugar and sodium; High in UPFs
223964691|NCT04607889|OTHER|Survey|Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
223964692|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
223964693|NCT00734253|DRUG|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
223964694|NCT00734253|DRUG|Placebo|Placebo capsules taken twice a day for 1-year
224111356|NCT00683553|DRUG|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
224111357|NCT00683553|DRUG|Placebo|Single IV injection of saline
224111358|NCT02340104|DRUG|Baricitinib|4 milligrams (mg) administered orally
224111359|NCT02340104|DRUG|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
224111360|NCT01269125|DRUG|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
224111361|NCT01269125|PROCEDURE|IVF|Assisted Reproduction Technique.
224291387|NCT01785121|BEHAVIORAL|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
224111362|NCT03337841|DRUG|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
224111363|NCT00449059|DRUG|acute infusion of nitroglycerine into the pulmonary artery|
224111364|NCT01040832|DRUG|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
224111365|NCT01040832|DRUG|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
224111366|NCT01067638|DRUG|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
224111367|NCT03311178|DRUG|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
224111368|NCT03492450|OTHER|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
223964695|NCT01236963|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
223964696|NCT01236963|DEVICE|Dental Floss|
223964697|NCT00355784|OTHER|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
223964698|NCT00355784|DRUG|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
223964699|NCT02181751|OTHER|Trauma Focused Cognitive Behavioural Therapy Group|Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
223964700|NCT02794441|DRUG|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
224111369|NCT04510922|DRUG|Droxidopa 100 MG [Northera]|droxidopa taken three times a day titrated up to a maximum of 600 mg.
224111370|NCT06573489|DRUG|Fospropofol|Use fospropofol for general anesthesia maintenance
224111371|NCT06573489|DRUG|Propofol|Use propofol for general anesthesia maintenance
224111372|NCT04579081|DEVICE|Contour Neurovascular System|Intrasaccular flow disruptor/divertor
224111373|NCT00318838|DRUG|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
224111374|NCT00318838|DRUG|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
224111375|NCT01772225|OTHER|Data collection|Medical record abstraction form and patient survey questionnaire.
224111376|NCT03556722|DEVICE|Repetitive Transcranial Magnetic Stimulation.|High frequency rTMS on left dorsolateral prefrontal cortex.
224111377|NCT03556722|DEVICE|Sham rTMS|Sham rTMS without active magnetic coil on left dorsolateral prefrontal cortex.
223964701|NCT02794441|OTHER|Placebo|Matched oral solution
223964702|NCT03258788|PROCEDURE|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
223964703|NCT03602053|BIOLOGICAL|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
223964704|NCT03602053|BIOLOGICAL|ROTAVAC 5D|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
223964705|NCT03602053|BIOLOGICAL|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
223964706|NCT00575900|BEHAVIORAL|dietary intervention|12 weeks of dietary intervention
223964707|NCT03622242|DEVICE|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
224111378|NCT03549273|DIETARY_SUPPLEMENT|Glizigen® + Ocoxin-Viusid®|"* Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~* Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
224111379|NCT01005472|DRUG|sunitinib malate|
224111380|NCT01005472|DRUG|temozolomide|
224111381|NCT01348178|PROCEDURE|Follow-up|Follow-up
224111382|NCT00005655|BIOLOGICAL|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
224111383|NCT00005655|BIOLOGICAL|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
224111384|NCT05682664|OTHER|Luchtbrug Junior (online monitoring)|Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.
223964708|NCT03622242|DEVICE|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
224111385|NCT05682664|OTHER|Usual care|Routine outpatient clinical visits every 3 months.
223964709|NCT04851288|DIETARY_SUPPLEMENT|MitoQ|MitoQ is a biochemically modified form of ubiquinol
223964710|NCT04851288|DIETARY_SUPPLEMENT|Placebo|Each placebo capsule contains inert excipient and is identical in appearance
223964711|NCT05099068|BIOLOGICAL|Blood and tumor samples|Longitudinal molecular profiling of tumor and liquid biopsies.
223964712|NCT01572493|BIOLOGICAL|rh IL-15 (10 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle
223964713|NCT01572493|BIOLOGICAL|rh IL-15 (5 DAYS)|Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle
223964714|NCT00609245|DRUG|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
223964715|NCT00609245|DRUG|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
223964716|NCT01234675|DRUG|Milnacipran|50 mg twice daily
223964717|NCT01234675|DRUG|Placebo|50 mg twice daily
223964718|NCT00454545|DRUG|Atorvastatin|
223964719|NCT05673421|OTHER|Exergaming Training|VR game-assisted intervention will perform for 30-45 min, 5 sessions per week for a duration of 8 weeks
223964720|NCT05673421|OTHER|Visual Feedback Training|During the visual feedback practices, patients will be seated or in a standing phase close to a table on which a mirror would be placed vertically. The practice would be consisted of nonparetic-side shoulder, elbow, wrist and finger flexion, extension, abduction, adduction movements, task oriented activities like, unscrewing lid of jar ,card stacking, moving coins or marbles from one box to another, Folding towels and stacking them, picking glass, while patient will look into the mirror, -watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. After watching the practices on the uninvolved side, patient will be asked to try to do the same movements with the paretic limb while they will be moving the nonparetic limb.Each activity will be performed for 4 min, with a 1 min preparation time between tasks.
223964721|NCT04183803|PROCEDURE|anatomic anterior cruciate ligament (ACL) reconstruction|The reconstruction will be performed with hamstring tendon graft or patellar tendon graft. The femoral and tibial tunnels placement will be guided by the Rosa robot (Zimmer®).
223964722|NCT06422559|DEVICE|Transmagnetic stimulation|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
223964723|NCT06422559|DEVICE|TMS|Stimulatory TMS protocol using MagVenture MagPro R30 stimulator with the Cool-B65 coil
223964724|NCT06275906|OTHER|Mediterranean diet and moderate intensity physical exercise (outdoor walking).|Mediterranean Diet, based on the different percentage of carbohydrates and lipids, associated with a program of moderate intensity aerobic physical exercise (outdoor walking), in patients with obesity and NAFLD.
223964725|NCT02889809|DRUG|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
223964726|NCT02889809|DRUG|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
223964727|NCT02889809|DRUG|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)
223964728|NCT02889809|DRUG|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
223964729|NCT03934944|DEVICE|Phone application|Weekly foot alerts and educational video
224111386|NCT02046031|DRUG|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
224111387|NCT04749108|DRUG|Induction chemotherapy - modified FOLFIRINOX regimen|An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
223964730|NCT03934944|OTHER|Usual care|Usual routine of diabetic foot education
223964731|NCT05208593|BEHAVIORAL|Negative Event + Counterfactual Task|Participants will complete a counterfactual based intervention where they come up with three if only..then statements about how a past drinking behavior could have been altered to be better and to think about protective behavioral strategies that they could use in a future similar situation to make the outcome better.
224111388|NCT04749108|OTHER|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
224111389|NCT04749108|RADIATION|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).
224111390|NCT04749108|PROCEDURE|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
223964732|NCT05208593|BEHAVIORAL|Personalized Normative Feedback|Participants will be asked to rate the frequency and quantity of students who use protective behavioral strategies while drinking. They will be given feedback on how close their estimate is from the national averages.
223964733|NCT05208593|BEHAVIORAL|Negative Event + Factual Thinking Task|Active Control condition where participants write about a negative event and list three facts about it
223964734|NCT05208593|BEHAVIORAL|Negative Event Only|Participants are asked to write about a negative event related to alcohol and write about it
223964735|NCT01680302|BEHAVIORAL|High intensity exercise|
223964736|NCT01680302|BEHAVIORAL|Moderate intensity exercise|
223964737|NCT01680302|BEHAVIORAL|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
223964738|NCT03104309|DEVICE|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
223964739|NCT03388021|PROCEDURE|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
223964740|NCT05576727|OTHER|Unruptured intracranial aneurysms|Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
223964741|NCT02332122|PROCEDURE|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is \>= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
224111393|NCT05241171|DEVICE|Fitbit|The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
224111394|NCT06169748|DEVICE|Real UHCDS a-tDCS|Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
224111395|NCT06169748|DEVICE|Sham UHCDS a-tDCS|Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
224111396|NCT06169748|DEVICE|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.
224111397|NCT04744415|OTHER|Epidemiology of admissions|Cardiology Intensive Care Unit admission
224111398|NCT00815984|PROCEDURE|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
224111399|NCT02571361|DRUG|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
223542468|NCT06261008|BEHAVIORAL|TI group|CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
224111400|NCT02571361|DRUG|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
224111401|NCT02571361|DRUG|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
224111402|NCT02571361|DRUG|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
224111403|NCT02571361|DRUG|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
224111404|NCT00663858|DRUG|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
224111405|NCT00663858|DRUG|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
224111406|NCT00663858|OTHER|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
224111407|NCT04685330|PROCEDURE|Ultrasound guided procedure|Single-arm, open-label device efficacy study to enroll 200 patients who have been ordered to have an ultrasound-guided procedure by the MGH Interventional Radiology department, including paracentesis, thoracentesis, biopsy, or ultrasound-guided drain placement. Patients will be restricted to adults who can consent.
223542469|NCT02132897|DRUG|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
223542470|NCT02132897|DRUG|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
223542471|NCT03654118|OTHER|Phone follow-up|"Through a short phone interview :~* Determination of a complication (Infection, capsulitis, recurrence)~* Determination of the Rowe score~* Determination of the Walch-Duplay score"
224111408|NCT04685330|DEVICE|Portable ultrasound|The FDA approved Healcerion SONON portable ultrasound (linear and curved) will be used during clinically indicated standard ultrasound-guided procedures following clinical standard of care. A standard clinical ultrasound will subsequently be used for image guidance as the gold standard. Images will be compared and improved. The efficacy of the portable ultrasound will be monitored by the clinical user and any complications within 30 days will be determined by chart review.
224111409|NCT00619541|DRUG|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
224111410|NCT00619541|DRUG|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
224111411|NCT00520689|DEVICE|Silicone Hydrogel Contact Lens|use of lens over 2 days
224111412|NCT02940886|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
223964742|NCT02332122|PROCEDURE|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (\>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of \>= 3mm is a positive result.
223964743|NCT02332122|OTHER|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
223964744|NCT04905511|BIOLOGICAL|natural human collagen arteriovenous graft for hemodialysis access|The True Vascular Graft will be implanted in the forearm or upper arm in a straight or curved configuration.
223964745|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
223964746|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
223964747|NCT00113880|BIOLOGICAL|FluMist|Nasal Sprayer dose of FluMist with annual follow up
223964748|NCT03591328|DIAGNOSTIC_TEST|Coronary CT angiography|"Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings."
223964749|NCT02630147|OTHER|Vanilla scent|A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
223964750|NCT00119314|DRUG|capecitabine|
224111413|NCT02940886|DRUG|Iron sucrose|"Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial.~Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended."
223964751|NCT00119314|DRUG|docetaxel|
223964752|NCT00119314|DRUG|gemcitabine hydrochloride|
223964753|NCT00119314|PROCEDURE|positron emission tomography|
223964754|NCT06048471|OTHER|HiTop|High tone transcutaneous electrical stimulation
223964755|NCT01634620|DEVICE|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
223964756|NCT01604499|BEHAVIORAL|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
223964757|NCT01604499|BEHAVIORAL|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
223964758|NCT00940914|DRUG|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
223964759|NCT01518127|OTHER|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
223964760|NCT05939349|OTHER|Produce Prescription Group|"Participants will receive vouchers equal to $40/household/month, with an additional $5/month per additional household member, for the purchase of fresh fruits and vegetables during the six-month intervention period. The vouchers will be administered in the form of a restricted Mastercard debit card.~A variety of nutrition education options will be offered throughout the intervention period and participation will be tracked. The Nutrition education options will include a periodic newsletter to participants that will include nutrition and diabetes prevention and management opportunities available through Griffin Hospital Population Health Team, the local health department, program and education opportunities available through the Registered Dietitians, local offerings by SNAP-Education and The Expanded Food and Nutrition Education Program."
224111414|NCT06451237|DRUG|Isotretinoin capsules|A one year follow up for patients on three maintenance regimens after acne clearance, including weekend isotretinoin and adapalene gel.
224291388|NCT01785121|BEHAVIORAL|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
224111415|NCT03188211|OTHER|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
224111416|NCT03188211|OTHER|Control|Any educational program will be delivered to clinicians assigned to control arm
224111417|NCT05746780|PROCEDURE|Elective bilateral neck dissection in cN0 patients|Radical modified type 3 selective bilaterale elective neck dissection
224111418|NCT00502905|DRUG|Busulfan|130 mg/m\^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
224111419|NCT00502905|DRUG|Fludarabine|40 mg/m\^2 through a central venous catheter over one hour, once a day, for four days.
224111420|NCT01818375|PROCEDURE|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
224111421|NCT01818375|OTHER|Standard fluid therapy|
223964761|NCT02064361|OTHER|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
223964762|NCT00555334|PROCEDURE|RFA|radiofrequency ablation
223964763|NCT00555334|DRUG|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
223964764|NCT01523028|OTHER|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter"
223964765|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
223542472|NCT02043990|DEVICE|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
223964766|NCT00927537|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
223964767|NCT00411463|BEHAVIORAL|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
223542473|NCT02644824|DEVICE|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
223542474|NCT00107731|DRUG|quetiapine fumarate|
224111422|NCT02778880|DRUG|Ketamine|
224111423|NCT02778880|DRUG|Fentanyl|
223542475|NCT00107731|DRUG|lithium|
223542476|NCT00107731|DRUG|divalproex|
223542477|NCT05073939|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
223542478|NCT05073939|DRUG|Oral Placebo|Administration of placebo orally
223542479|NCT01224236|DRUG|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
223542480|NCT01224236|DRUG|control|multivitamin solution without iron
223542481|NCT06511947|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
224111424|NCT05492383|DEVICE|TAVI|Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
224111425|NCT01374581|DRUG|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to \< 15 kg 1 tablet per dose 15 to \< 25 kg 2 tablets per dose 25 to \< 35 kg 3 tablets per dose"
224111426|NCT01374581|DRUG|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to \< 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to \< 18 kg)1 tablet(25mg/67,5mg)for 3 days"
224111427|NCT01374581|DRUG|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to \< 11 kg: ½ tablets 12 to \< 19 kg: 1 tablets per dose 20 to \< 27 kg: 1½ tablets per dose 28 to \< 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
224111428|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
223964768|NCT00411463|DRUG|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
223964769|NCT01418599|DRUG|Torrent's Alfuzosin Extended Release Tablet|
223964770|NCT05129371|OTHER|Breathing exercise|Following the protocol prepared, the breathing exercise group is given breathing exercises for about 20 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application. Reminders (by text message or voice call) are used for the remaining 4 days of the week, allowing the patient to do it on their own.
223964771|NCT05129371|OTHER|Placebo Breathing Group|The placebo group is asked to breathe normally through the nose with eyes closed, sitting in the same position as the intervention group for 10-15 minutes, 3 times a week for 8 weeks, under the supervision of the trainer, in the hospital face-to-face, and after discharge through video calls over the WhatsApp application.
223964772|NCT00591188|DRUG|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
223964773|NCT02884921|DRUG|Paracetamol|Paracetamol
223964774|NCT02884921|DRUG|Paracetamol|Paracetamol
223964775|NCT02884921|DRUG|Placebo|Placebo
223964776|NCT03360227|DEVICE|implantation of cardiac devices|implantation of cardiac devices
223964777|NCT05820542|OTHER|miller laryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
224111429|NCT02295930|OTHER|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~* CETUXIMAB 500 mg/sqm IV over 1-h\* , day 1 followed by~* IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm IV over 2-h, day 1 followed by~* 5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
224111430|NCT01008930|PROCEDURE|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
224111431|NCT01969175|OTHER|Low-glycemic-load and milk-free diet|
223964778|NCT05820542|OTHER|McGrath MAC videolaryngoscope|The percentage of glottic opening (POGO) will be evaluated according to the method of lifting the epiglottis (direct imaging).
224111432|NCT01306058|DRUG|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
224111433|NCT01306058|DRUG|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
224111434|NCT05413967|OTHER|Mills manipulation in addition to myofasical release therapy|Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
224111435|NCT05413967|OTHER|Nirschl exercises in addition to myofascial release therapy|Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
224111436|NCT00680420|PROCEDURE|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
224111437|NCT01947374|PROCEDURE|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
224111438|NCT01947374|PROCEDURE|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
224111439|NCT01666444|DRUG|pegylated liposomal doxorubicin (PLD)|
224111440|NCT01666444|DRUG|VTX-2337|TLR8 Agonist
224111441|NCT01666444|DRUG|Placebo|
224111442|NCT01949064|DEVICE|Grindcare|
223964779|NCT02798861|DEVICE|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
224111443|NCT01949064|DEVICE|Michigan-type occlusal splint|
224111444|NCT06529289|OTHER|Training|"We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills."
224111445|NCT02158143|DIETARY_SUPPLEMENT|vitamin D3|
223964780|NCT05614843|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
223964781|NCT05614843|DEVICE|Sham placebo|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
224111446|NCT02098317|DRUG|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
224111447|NCT02098317|DRUG|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
224111448|NCT01390701|DEVICE|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
224111449|NCT01390701|DRUG|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
224111450|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
223724666|NCT04368767|BEHAVIORAL|Skin-to-skin|Skin-to-skin contact will be performed for two hours daily for three consecutive days in the first week of life, usually in the afternoon. This time interval will allow all pre-intervention sample collection to begin 1 hour after the infant's feeding schedule in the afternoon. After pre-intervention measures of axillary temperature, heart rate, respiratory rate, and oxygen saturation by pulse oximetry (SPO2) are obtained; cotton balls placed in the diaper for urine collection will be removed and stored in an appropriate container. Salivary oxytocin and cortisol will be collected per protocol below. Mothers will be requested to sit in reclining chairs with a front opened blouse or hospital gown. Infants will be removed from the incubator and placed naked except for a diaper and hat directly onto the skin between the mother's breasts and covered with a blanket. All infants will be monitored. After the two hours of SSC is completed, the infant will be returned to the incubator.
223964782|NCT01968083|BIOLOGICAL|RSV cps2 Vaccine|10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
223964783|NCT01968083|BIOLOGICAL|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
223964784|NCT01785797|DEVICE|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
223964785|NCT02186015|DRUG|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
223964786|NCT05952583|DIAGNOSTIC_TEST|Ultrasound|Additional ultrasound measurements during pregnancy
223964787|NCT00355602|DRUG|Cefuroxime|
223964788|NCT00355602|DRUG|Ciprofloxacin|
223964789|NCT00355602|DRUG|Clarithromycin|
223964790|NCT00355602|DRUG|Cotrimoxazole|
223964791|NCT00355602|DRUG|Coamoxiclav|
223964792|NCT00355602|DRUG|metronidazole|
223964793|NCT00355602|DRUG|neomycin|
223964794|NCT00355602|DRUG|rifaximin|
223964795|NCT00355602|DRUG|Vancomycin|
223964796|NCT00355602|DRUG|Doxycycline|
223964797|NCT02503839|DRUG|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
224111451|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
223724667|NCT01528488|OTHER|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
224111452|NCT05163561|BIOLOGICAL|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.
224111453|NCT05163561|BIOLOGICAL|Sii Licensed IPV|Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
224111454|NCT02615106|DRUG|Endostar|7.5 mg/m2/day, day 1-14
224111455|NCT02615106|RADIATION|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
224111456|NCT00935857|DEVICE|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
224111457|NCT00935857|DEVICE|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
224111458|NCT03454048|DRUG|Piperaquine (low dose)|subcurative regimen (480 mg)
223724668|NCT01528488|OTHER|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
223724669|NCT04086862|PROCEDURE|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm\^2 and 100% duty cycle sequentially to each masseter muscle.
223724670|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using total-breath method
223964798|NCT02503839|BIOLOGICAL|H56:IC31|Therapeutic and prophylactic TB vaccine
223964799|NCT00784771|BEHAVIORAL|Hypnotherapeutic Olfactory Conditioning (HOC)|
223964800|NCT01521221|OTHER|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
223964801|NCT02325258|OTHER|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
223964802|NCT05990283|PROCEDURE|Socket shield technique|For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.
223964803|NCT05990283|PROCEDURE|Guided bone regeneration|For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
223964804|NCT04348383|DRUG|Defibrotide|6.25 mg/kg every 6 hours in 2 hours infusion for 7 or 15 days
224111459|NCT03454048|DRUG|Piperaquine (high dose)|Curative regimen (960mg)
224111460|NCT03454048|DRUG|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
224111461|NCT03454048|DRUG|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
223964805|NCT04348383|DRUG|Placebo|Placebo 250 cc every 6 hours for 7 or15 days
223964806|NCT00571558|DRUG|aminolevulinic acid hydrochloride|Given PO
223964807|NCT00571558|DRUG|photodynamic therapy|Undergo photodynamic therapy
223964808|NCT00571558|OTHER|laboratory biomarker analysis|Correlative studies
223964809|NCT01797705|DEVICE|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
223964810|NCT01838447|DIETARY_SUPPLEMENT|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
223964811|NCT04747847|DRUG|Atorvastatin and anakinra|Anakinra up to 8 mg/kg/day and atorvastatin at 0.75 mg/kg/day in children with acute KD at least 1 year old with CAA
223964812|NCT00733577|DRUG|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
224111462|NCT03454048|OTHER|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
224111463|NCT03454048|OTHER|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
224111464|NCT01143350|OTHER|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~* after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~* of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
224111465|NCT01143350|OTHER|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
224111466|NCT01008254|BEHAVIORAL|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
224111467|NCT01008254|BEHAVIORAL|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
224111468|NCT01008254|OTHER|No musical prompt|No intervention.
224111469|NCT03843658|OTHER|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
223964813|NCT01394783|DEVICE|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
224111470|NCT00592358|DRUG|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
224111471|NCT05197868|PROCEDURE|Intubation with traditional laryngoscope|Participants will be invited to intubate the mannequin with a traditional laryngoscope
224111472|NCT05197868|PROCEDURE|Intubation with a straight blade video laryngoscope|Intubation with a straight blade video laryngoscope
223542482|NCT03606148|DIAGNOSTIC_TEST|SurePathTM|In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
223724671|NCT04531293|DEVICE|Respiratory Analysis System|Measurement of total lung capacity using standard method
223964814|NCT01394783|DEVICE|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
223964815|NCT03204045|DRUG|fentanyl|2 mL mixture of fentanyl with isotonic saline
223964816|NCT03204045|DRUG|Oxycodone|2 mL mixture of oxycodone with isotonic saline
223964817|NCT03204045|DRUG|control|isotonic saline 2 mL
223964818|NCT05036499|BEHAVIORAL|Personalized Feedback Intervention|Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
223964819|NCT03340818|OTHER|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
223964820|NCT03340818|OTHER|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
223964821|NCT01120561|DRUG|trastuzumab-MCC-DM1|Intravenous repeating dose
223964822|NCT03919318|OTHER|Root Canal Filling Sealers|Root Canal Obturation
223964823|NCT00220441|BEHAVIORAL|Aerobic exercise|
223964824|NCT02030847|BIOLOGICAL|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10\^8 transduced CAR T cells
223964825|NCT02030847|BIOLOGICAL|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10\^7 CART-19 cells.
224111473|NCT05197868|PROCEDURE|Intubation with a hyper-angulated video laryngoscope|Participants will be asked to intubate the mannequin with a hyper-angulated video laryngoscope
224111474|NCT00000615|BEHAVIORAL|diet, reducing|
224111475|NCT00084682|DRUG|romidepsin|Given IV
224111476|NCT01166659|DEVICE|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
224111477|NCT04011436|OTHER|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
224111478|NCT00813553|DIETARY_SUPPLEMENT|placebo|daily
224111479|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
224111480|NCT00813553|DIETARY_SUPPLEMENT|beta-alanine|daily
223964826|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10\^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
223964827|NCT02030847|BIOLOGICAL|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10\^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10\^7), 30% on Day 2 (3x10\^7-1.5x10\^8), 60% on Day 3 (6x10\^7-3x10\^8).
223964828|NCT02908412|DRUG|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
223964829|NCT01099150|DIETARY_SUPPLEMENT|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~900 mg of total flavan-3-ols and procyanidins.
223964830|NCT01099150|DIETARY_SUPPLEMENT|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing \~400 mg total flavan-3-ols and procyanidins.
223964831|NCT01099150|DIETARY_SUPPLEMENT|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
223964832|NCT02326740|DRUG|gevokizumab|
223964833|NCT02326740|DRUG|Placebo|
223964834|NCT02326740|DRUG|gevokizumab open-label|
223964835|NCT04193397|BEHAVIORAL|Exercise training|Resistance training program performed during 6 months, 3 sessions per week
223964836|NCT02840175|DRUG|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
223964837|NCT02840175|DRUG|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
223964838|NCT02840175|DRUG|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
223964839|NCT02840175|DRUG|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
223964840|NCT02431832|DRUG|Augmentin tab|
224111481|NCT03152136|DEVICE|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
223964841|NCT00449202|DRUG|oleoyl-estrone (MP 101)|
223964842|NCT03185845|DRUG|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
223964843|NCT03199261|DRUG|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
223964844|NCT03199261|DRUG|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
223964845|NCT04157959|DRUG|SHR4640 dose1|Tablet,dose1,QD
223724672|NCT04922437|PROCEDURE|Native bladder implantation|Continent catheterizable channel implanted in the detrusor of the native bladder
223724673|NCT04922437|PROCEDURE|Enterocystoplasty implantation|Continent catheterizable channel implanted by seromuscular plicature on the front wall of the bladder augmentation
223964846|NCT04157959|DRUG|Febuxostat dose2|Tablet,dose2,QD
223964847|NCT04344886|PROCEDURE|Conventional (dual-phase) SPECT/CT|Conventional (dual-phase) SPECT/CT (after 10 and 150 minutes)
223964848|NCT04344886|PROCEDURE|Multi-phase SPECT/CT|Multi-phase SPECT/CT (after 10, 90, 150, 210 minutes)
223964849|NCT04344886|PROCEDURE|Conventional minimally-invasive radio-guided parathyroidectomy|Conventional minimally invasive radio-guided parathyroidectomy in a time span of 2-3 hours from radionuclide administration
223724674|NCT00589563|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
223964850|NCT04344886|PROCEDURE|Individualised minimally-invasive radio-guided parathyroidectomy|Individualized minimally-invasive radio-guided parathyroidectomy performed in a recommended time span based on standardized uptake value calculation.
223964851|NCT04061772|DRUG|Bortezomib|Bortezomib injection
223964852|NCT04061772|DRUG|Etoposide|Etoposide injection
223964853|NCT04061772|DRUG|Cyclophosphamide|Cyclophosphamide injection
223964854|NCT04061772|DRUG|Pharmorubicin|Pharmorubicin injection
223964855|NCT04061772|DRUG|Prednisone|Prednisone tablet
223964856|NCT00653419|DRUG|buspirone HCl|Tablets, 30 mg, single-dose
223964857|NCT00653419|DRUG|Buspar|Tablets, 30 mg, single-dose
223964858|NCT02668796|DRUG|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
223964859|NCT02668796|DRUG|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
223964860|NCT02668796|DRUG|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
223964861|NCT02366702|DEVICE|Lower Limb Powered Knee-Ankle Prosthesis|
223964862|NCT00993018|DRUG|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
223964863|NCT00993018|DRUG|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
223964864|NCT00993018|DRUG|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
223964865|NCT00993018|DRUG|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
223964866|NCT00049751|DRUG|Adalimumab|
224111482|NCT03623984|DRUG|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
224111483|NCT01587872|PROCEDURE|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
224111484|NCT02657252|DRUG|Glucose|Sclerotherapy of telangiectasis in one lower limb.
224111485|NCT02657252|DRUG|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
224111486|NCT05826197|OTHER|Radiomics|PET Radiomics
224111487|NCT04346069|OTHER|PCIT (parent child interaction therapy)|Parent child interaction therapy is a treatment strategy that nurture parent child relationship and teach effective parenting strategies to decrease child non compliance behavior (BodifordMcNeil; Hembree-Kigin, 2010).Parent-Child Interaction Therapy (PCIT; Eyberg; Robinson, 1982 ; Zisser; Eyberg, 2008 ) is a manualized parent training intervention that has received substantial empirical support in the treatment of disruptive behavior across multiple reviews (e.g., Brestan; Eyberg, 1998 ; Gallagher, 2003 ; Thomas \&amp; Zimmer-Gembeck, 2007 ). PCIT established strong relation among parenting, social learning, and attachment theories and proceeds.
224111488|NCT03455478|DEVICE|spectacles|dispending spectacles for uncorrected refractive error
224111489|NCT02024711|DEVICE|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
224111490|NCT02024711|DEVICE|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
223964867|NCT03366727|DEVICE|drug-coated balloon catheter （Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
223964868|NCT03366727|DEVICE|plain balloon catheter (Admiral, medtronic)|After predilation, using plain balloon catheter to cover the whole treated segment
223964869|NCT04714697|DRUG|Cabometyx|Cabometyx 60mg once daily, oral , up to Progression disease
224111491|NCT05070273|DIAGNOSTIC_TEST|Hypoglossal nerve conduction study|"NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms."
224111492|NCT05070273|DIAGNOSTIC_TEST|Transcranial magnetic stimulation of hypoglossal nerve|"TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold."
224111493|NCT01366222|DIETARY_SUPPLEMENT|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
223724675|NCT00589563|DRUG|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
223964870|NCT04301947|OTHER|Standard warm-up protocol|Stationary cycling and lower limb stretching exercises
223964871|NCT04301947|OTHER|Gluteal activation warm-up protocol|Standard warm-up protocol + Clam exercise (3 sets of 12 repetitions each)
223964872|NCT02884219|DRUG|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
223964873|NCT02884219|OTHER|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
223964874|NCT02884219|DRUG|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
223964875|NCT01103141|DEVICE|Micropuncture needle set|Groin access for vascular intervention
224111494|NCT06105879|DEVICE|covered or open skin|transcutaneous mesarument of covered or open skin area
223724676|NCT00589563|DRUG|etoposide|60mg/kg on day -4 from stem cell transplant
223542483|NCT04711239|DIAGNOSTIC_TEST|PGT-A / niPGT-A|PGT-A and niPGT-A will be performed using next generation sequencing (NGS) analysis for chromosome copy number variation (CNV). Embryo transfers will rely solely on the results of PGT-A for trophectoderm biopsies.
223964876|NCT01103141|DEVICE|Standard gauge-18 needle set|Groin access for vascular intervention
223964877|NCT03082196|DRUG|Test varnish|Topical application of test varnish to the teeth 4 times per year.
223964878|NCT03082196|DRUG|Standard varnish|Topical application of test varnish to the teeth 4 times per year
223964879|NCT04051190|DIETARY_SUPPLEMENT|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and at 1 year.
223964880|NCT04051190|PROCEDURE|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
223964881|NCT04051190|PROCEDURE|Gastric Bypass group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (gastric bypass)
223964882|NCT01403805|BIOLOGICAL|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
223964883|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
223964884|NCT01403805|BIOLOGICAL|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
223964885|NCT01403805|OTHER|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
223964886|NCT00669149|DRUG|clopidogrel + aspirin|
223724677|NCT00589563|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
223724678|NCT00589563|DRUG|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
223724679|NCT00589563|DRUG|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
223964887|NCT00669149|DRUG|heparin + clopidogrel + aspirin|
223964888|NCT00669149|DRUG|enoxaparin + clopidogrel + aspirin|
223964889|NCT00669149|DRUG|bivalirudin + clopidogrel + aspirin|
223964890|NCT01695993|DEVICE|Acupressure bands|Bilateral acupressure wrist bands
223964891|NCT01695993|OTHER|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
223964892|NCT01695993|BEHAVIORAL|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
223964893|NCT01695993|OTHER|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
223964894|NCT01695993|BEHAVIORAL|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
223964895|NCT01747616|DEVICE|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
223964896|NCT01747616|OTHER|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
223964897|NCT02548052|DRUG|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
223542484|NCT05501639|DRUG|tiotropium|tiotropium
223542485|NCT05501639|DRUG|long-acting β2-agonists (LABA)|long-acting β2-agonists (LABA)
223542486|NCT05501639|DRUG|inhaled corticosteroids (ICS)|inhaled corticosteroids (ICS)
223542487|NCT04888806|DRUG|Camrelizumab|d1，200mg, iv, q3w
223542488|NCT04888806|PROCEDURE|ablation|the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
223542489|NCT04888806|DRUG|chemotherapy|standard treatment plan for mCRC, determined by the investigator
223542490|NCT00104390|BIOLOGICAL|Grass MATA MPL|
223542491|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
223542492|NCT00251693|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
223542493|NCT00251693|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
223964898|NCT02548052|DRUG|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
223964899|NCT02548052|DRUG|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
224111495|NCT00120445|PROCEDURE|air|0.3 ml of filtered air
224111496|NCT00120445|PROCEDURE|expansile gas|0.3 ml of perfluoropropane gas
224111497|NCT03238248|DRUG|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
223542494|NCT05657535|DEVICE|Low-intensity continuous ultrasound stimulator|Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
223542495|NCT00973336|DRUG|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
224111498|NCT03238248|DRUG|Pevonedistat Infusion|20 mg/m2
224111499|NCT03238248|PROCEDURE|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
224111500|NCT04536324|PROCEDURE|Subcutaneous parenteral hydration|Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
224111501|NCT04730323|DRUG|Tocilizumab|"Participants received an initial dose calculated as per the body weight (8mg/kg) maximum 800mg/dose) over 1 hour, followed by up to three additional doses if required as per the response after the first dose with 8 hours intervals. Predefined Parameters of disease severity were assessed 12 to 24 hourly. Injection Paracetamol 1g was administered before infusion. The response of the participants after Tocilizumab administration was recorded based on clinical parameters (Oxygen requirement, Fever, Need for invasive positive pressure ventilation), biochemical parameters (D-dimers, C-reactive protein (CRP), Ferritin, Lactate dehydrogenase (LDH) levels), Chest X-ray findings, and Repeated PCR test for COVID-19. Any side effects noted after administration of TOCILIZUMAB were recorded.~Any side effects noted after administration of TCZ/ Corticosteroid were recorded."
224111502|NCT05874245|DRUG|oral Dexmedetomidine|will receive 4 micrograms/kg oral Dexmedetomidine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
223964900|NCT02548052|DRUG|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
223724680|NCT00589563|DRUG|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
223964901|NCT02548052|DRUG|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
223964902|NCT02548052|DRUG|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
223724681|NCT00589563|DRUG|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
223724682|NCT00589563|PROCEDURE|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
223724683|NCT00589563|PROCEDURE|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
224111503|NCT05874245|DRUG|oral ketamine|will receive 6 mg/kg oral ketamine diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg 45 minutes before the induction of anaesthesia
224111504|NCT05874245|DRUG|oral Midazolam|will receive 0.3 mg/kg (maximum 20 mg) oral Midazolam diluted in paracetamol \[Paracetamol syrup 150 mg/5ml\] at a dose of 15 mg/kg given 45 minutes before the induction of anaesthesia
224111505|NCT03463265|DRUG|nab-sirolimus|nab-sirolimus, single agent
224111506|NCT03463265|DRUG|nab-sirolimus + temozolomide|temozolomide, combination
224111507|NCT03463265|DRUG|nab-sirolimus + bevacizumab|bevacizumab, combination
224111508|NCT03463265|DRUG|nab-sirolimus + lomustine|lomustine, combination
223964903|NCT03011554|DEVICE|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
223964904|NCT01870414|OTHER|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes \[2, 17\], temperature of 4º C \[22, 24\], water level at 20 cm
223964905|NCT02029521|DIETARY_SUPPLEMENT|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
224111509|NCT03463265|DRUG|nab-sirolimus + marizomib (MRZ)|marizomib (MRZ), combination
224111510|NCT03463265|DRUG|nab-sirolimus + temozolomide + radiotherapy|temozolomide + radiotherapy, combination
224111511|NCT04020237|BEHAVIORAL|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~* 1\) Start air purifier~* 2\) Do not go out and make it to the minimum when absolutely necessary~* 3\) It is recommended to wear a mask when going out.~* 4\) The investigators recommend a lot of water, fresh fruit and vegetables.~* 5\) Prepare an inhaler and use it when symptoms get worse."
224111512|NCT03796169|BEHAVIORAL|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
224111513|NCT03796169|BEHAVIORAL|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
224111514|NCT03796169|BEHAVIORAL|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
224111515|NCT05319951|DRUG|Oral Rehydration Salts power (iii)|Dissolve 2 packs of Oral Rehydration Salts Power (iii) (5.125g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
223724684|NCT00589563|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
223724685|NCT00589563|PROCEDURE|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
223724686|NCT00589563|RADIATION|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
223724687|NCT04756492|DRUG|sandimmun|follow up for treatment response
223724688|NCT00740701|DEVICE|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
223724689|NCT06049290|DRUG|LBL-034 for Injection|Initial dose - MTD; Q2W; intravenous infusion
223724690|NCT02680080|DRUG|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
224111516|NCT05319951|DIETARY_SUPPLEMENT|water with white granulated sugar|Dissolve 2 packs of Taikoo white granulated sugar (5g/pack) in 500ml water and let the subjects drink it up in 20 minutes prior to donation.
223964906|NCT02029521|DIETARY_SUPPLEMENT|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
223964907|NCT02899676|OTHER|neuropsychological testing|
223964908|NCT02899676|OTHER|functional magnetic resonance imaging|
223964909|NCT02899676|OTHER|simple arithmetic operations|
224111517|NCT05319951|DIETARY_SUPPLEMENT|water|Recommend the subjects to drink up 500ml water in 20 minutes prior to donation.
223724691|NCT02680080|DIETARY_SUPPLEMENT|Grapefruit group|one liter of fresh pink-grapefruit juice
223724692|NCT03342105|PROCEDURE|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
223964910|NCT04479176|PROCEDURE|Transnasal Sphenopalatine Ganglion Block|In transnasal approach, several authors described the traditional technique using sterile 10cm cotton tipped applicators that are dipped in the chosen anesthetic and then advanced along the superior border of the middle turbinate, until it reaches the posterior wall of the nasopharynx. Some other techniques had described dripping one or two ml of the anesthetics into the nostril.
223964911|NCT02103816|DEVICE|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
223964912|NCT01072396|DRUG|Tiotropium|double blind randomized crossover
224111518|NCT01371838|DRUG|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
224111519|NCT01371838|DRUG|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
224111520|NCT01275261|BEHAVIORAL|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
223964913|NCT01072396|DRUG|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
223964914|NCT01007851|DRUG|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
223964915|NCT01007851|DRUG|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
223964916|NCT03748680|DRUG|Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy|"Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)"
224111521|NCT01369693|PROCEDURE|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
223964917|NCT03748680|OTHER|Intensified Follow-up Schedule|Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
223964918|NCT00828542|DRUG|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
223964919|NCT00828542|DRUG|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
223964920|NCT00340184|DRUG|paclitaxel, carboplatin|
223964921|NCT02551926|BEHAVIORAL|mobile text messages|
223964922|NCT02551926|BEHAVIORAL|virtual community|
223964923|NCT02551926|BEHAVIORAL|brochures|
224111522|NCT06957002|DRUG|Bosentan|Bosentan : 62.5 mg twice a day for 4 weeks and 125 mg twice a day during 9 weeks (treatment length 3 months)
224111523|NCT06957002|DRUG|Glucocorticoids|prespecified GC tapering schedule
224111524|NCT03525977|PROCEDURE|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
224111525|NCT03341104|DRUG|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
224111526|NCT02241512|DRUG|Ibuprofen|
224111527|NCT02241512|DRUG|placebo|
224111528|NCT04013737|DEVICE|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
224111529|NCT01970579|DEVICE|Paclitaxel coated balloon|"* Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
224111530|NCT01970579|DEVICE|uncoated PTA catheter|"* Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~* Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~* Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~* If two treatment balloons are necessary overlap between the balloon must be 10 mm~* Inflation pressure 7-10 atm~* Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
223964924|NCT02551926|OTHER|Usual care|
223964925|NCT02551926|DEVICE|mobile phone|
223964926|NCT02658032|BEHAVIORAL|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
223964927|NCT02658032|BEHAVIORAL|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
223964928|NCT02658032|OTHER|standard care|
223964929|NCT06255899|BEHAVIORAL|Education Program on Injury Prevention|The didactic component of the injury prevention education program includes information on prevalence of injuries in female athletes, biomechanical risk factors for injury, and effectiveness of injury prevention programs (IPP) for mitigation of injury risk. Examples of different activities from the IPP, including proper and improper movement strategies will be provided. Athletes will be instructed as a group on how to properly perform of each activity of the IPP, and will be given an opportunity to practice. Athletes, coaches, and staff will be provided with links to written instructions and videos of proper performance for each activity. The IPP will be performed at least 3 times/week prior to practice. Coaches, staff, and athletes will be encouraged to provide supervision and feedback on performance of the IPP throughout the season.
224111531|NCT02952066|PROCEDURE|Bronchial biopsy|Bronchial tissue taken during biopsy
224111532|NCT01264133|DRUG|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
224111533|NCT02203253|DRUG|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
223964930|NCT06255899|BEHAVIORAL|Individualized Feedback + Education Program on Injury Prevention|In addition to the education program, participants in this group will receive individualized feedback on performance of the IPP. The participant will be videotaped while performing the IPP, and movement errors and compensations will be identified to provide a basis for feedback sessions to correct movement. The session will include different forms of feedback including showing the athlete their video, identifying the error or compensation, and providing verbal, tactile, and visual feedback to correct the error or compensation. Common errors and compensations, along with verbal cues and corrections, have been identified and manualized for the study. Two additional feedback sessions will be scheduled at regular intervals during the season to provide feedback on performance throughout the season. Participants in this group will be encouraged to provide peer feedback to one another.
223964931|NCT05223283|OTHER||
223964932|NCT00003057|DRUG|loperamide hydrochloride|
223724693|NCT03342105|PROCEDURE|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
223964933|NCT00003057|DRUG|octreotide acetate|
223964934|NCT04257786|PROCEDURE|1ry cyto-reductive surgery|1ry surgery then chemotherapy
223964935|NCT04257786|COMBINATION_PRODUCT|Neoadjuvant chemotherapy followed by surgery|chemotherapy then surgery
223964936|NCT05966623|OTHER|Video Remote Interpretation|To assess the effectiveness of the VRI system in improving communication outcomes between Deaf patients and doctors Produce a VRI model addressing the challenges faced by Deaf people that will be tested, implemented, and sustained in Bogota Colombia.
223964937|NCT02504502|OTHER|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
223964938|NCT00105521|DRUG|Sarizotan|Sarizotan will be administered twice daily.
223964939|NCT00105521|DRUG|Placebo|Placebo matching to sarizotan will be administered twice daily.
223964940|NCT00658801|RADIATION|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~1. Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~2. Group 2: 5cm \<Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
223964941|NCT04723888|DIETARY_SUPPLEMENT|alpha-ketoglutarate|alpha-ketoglutarate supplements
224111534|NCT02203253|DRUG|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
224111535|NCT02203253|DRUG|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
224111536|NCT00641043|DRUG|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
224111537|NCT00641043|DRUG|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
224291389|NCT04854564|BEHAVIORAL|Prehabilitation intervention|The investigators will identify participants' perceived important information to develop a prehabilitation intervention in this study. Prehabilitation intervention consisting of physical activities, nutrition, and stress management.
224291390|NCT04854564|BEHAVIORAL|Caregiver intervention|The investigators will provide caregivers with variety of educational resources for patients experiencing ESLD.
224111538|NCT01629342|BEHAVIORAL|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)"
223964942|NCT05256914|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
223964943|NCT05256914|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
223964944|NCT05128539|DRUG|JS001(Toripalimab)+JS002|"Part A: In this phase, 3 dose levels will be preliminarily set up. The dose level of Toripalimab is fixed as 240 mg, intravenous infusion, Q3W. The dose levels of JS002 are fixed at 75 mg,150 mg and 300 mg subcutaneously, and the traditional 3+3 design will be used for dose escalation with 21 days as entire treatment cycle. In addition, the period of 21 days after the first administration is defined as the DLT observation period.~Part B: Based on the data of the safety, PK and preliminary efficacy in Part A patients, the dosage will be determined for advanced tumor patients who had received at least first-line therapy in this part. Two to three groups with different tumor types will be further enrolled, and about 30 patients will be included in each group (the specific number and cohort will be adjusted according to the research progress). Toripalimab is a humanized IgG4κ mAb specific against human PD-1."
223964945|NCT03347773|DIETARY_SUPPLEMENT|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
224111539|NCT00455247|DRUG|Glutamine|
224111540|NCT00474630|DRUG|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
223964946|NCT02286427|DEVICE|Amniotic Membrane|
223964947|NCT02725359|DRUG|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
224111541|NCT00474630|DRUG|Placebo|
224111542|NCT00474630|BEHAVIORAL|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
224111543|NCT01613469|DRUG|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
224111544|NCT06192199|DIAGNOSTIC_TEST|2018 edition of the Guidelines for Diagnosis|According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
224111545|NCT04685603|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
224111546|NCT00538603|DRUG|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
224111547|NCT00538603|DRUG|Paclitaxel & Carboplatin|Chemotherapy
223964948|NCT02725359|DRUG|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
224111548|NCT00077181|DRUG|cytarabine|Given IV
224111549|NCT00077181|DRUG|triapine|Given IV
224111550|NCT00077181|OTHER|laboratory biomarker analysis|Correlative studies
224111551|NCT05696366|DRUG|Sotagliflozin|Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
224111552|NCT05696366|DRUG|Volagidemab|Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
224111553|NCT04275310|BEHAVIORAL|Microeconomic Intervention|The intervention will consist of six sessions on six different days. Sessions will be held at VCU or at one of VCU's community partners. Each session will last for around 2 ½ hours (around 15 hours total). There will be breaks and food will be provided. During the sessions the facilitators will provide education on a variety of topics, including economic services that are available to people living in Richmond, job skills (such as creating a resume and dealing with discrimination at work), personal finance education, gender transition ideas, and HIV prevention. The sessions will occur in a group of about 4-10 transgender women.
224111554|NCT05506371|DRUG|Az+SRP|Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
223964949|NCT02725359|DRUG|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
223964950|NCT02725359|DRUG|Saline|USG guided SCPB with saline bilaterally 10 ml each side
224111555|NCT05506371|DRUG|SRP|Scaling and root planning (SRP) treatment of periodontitis
224111556|NCT05506371|DRUG|No interventions|Diagnostocs to confirm the healthy state of the gingiva
224111557|NCT03088605|DRUG|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
224111558|NCT03088605|DRUG|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
224111559|NCT00987051|PROCEDURE|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
224111560|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
224111561|NCT00856752|DRUG|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
223964951|NCT00885859|DEVICE|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
223964952|NCT05051696|DRUG|H101|Intra-tumor injected oncolytic viruses H101 within 5 consecutive days,3 weeks for a cycle (1-4cycles)
223964953|NCT06164041|BEHAVIORAL|The use of mobile applications promoted from the physical education classroom to improve adolescent health.|"Before starting the intervention, a total of 465 adolescents participated in pretest measurements (T1).~Researchers in charge of explaining how the apps worked were not involved in the measurements or subsequent analysis, as they knew which student belonged to each App and control group. Once each app had been described and its use explained, a training plan was drawn up to be followed during the period of mandatory use.~The adolescents were motivated to utilize the app for a duration of ten weeks, aiming for a minimum usage of three times per week.~After the mandatory intervention with the mobile apps, post-test measurements were carried out (T2). Then, a period of 10 weeks was provided in which the use of the app was neither mandatory nor promoted from the physical education subject, after which the post-test 2 measurements (T3) were taken."
223964954|NCT00862225|DRUG|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
223964955|NCT00862225|DRUG|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
223964956|NCT00862225|DRUG|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
223964957|NCT00482417|DRUG|MK0359|
223964958|NCT06170931|PROCEDURE|posterior cruciate ligament-retaining prostheses|Posterior cruciate ligament protective approach in patients with knee osteoarthritis
223964959|NCT06170931|PROCEDURE|posterior cruciate ligament-substituting prostheses|Posterior cruciate ligament transection approach in patients with knee osteoarthritis
223964960|NCT00415883|DRUG|Valsartan|
223964961|NCT03892122|DRUG|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration- and depth of anesthesia-as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
223964962|NCT03892122|DRUG|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
223964963|NCT05819983|DRUG|Ivermectin Tablets|Ivermectin 200µg/kg BW
223964964|NCT05819983|DRUG|Permethrin Cream|Permethrin cream 5%
223964965|NCT00692250|DRUG|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
223964966|NCT03410953|BIOLOGICAL|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
223964967|NCT02744898|DRUG|Carboplatin AUC|
223964968|NCT02744898|DRUG|Abraxane|100mg/m2
223964969|NCT01285596|DRUG|Mirabegron|oral
223964970|NCT05657418|DRUG|JS107|JS107, i.v., q3w
223964971|NCT05657418|COMBINATION_PRODUCT|JS107 combination with Toripalimab|JS107 i.v., q3w combine with Toripalimab
223964972|NCT05319756|DRUG|gabapentin 600 mg|Participants will receive a single oral dose of gabapentin 600 mg and a placebo that looks like oxycodone HCl
224111562|NCT00856752|DRUG|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
223964973|NCT05319756|DRUG|gabapentin 1200 mg|Participants will receive a single oral dose of gabapentin 1200 mg and a placebo that looks like oxycodone HCl
223964974|NCT05319756|DRUG|gabapentin 600 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 600 mg and oxycodone HCl 20 mg
223964975|NCT05319756|DRUG|gabapentin 1200 mg and oxycodone HCl 20 mg|Participants will receive a single oral dose of gabapentin 1200 mg and oxycodone HCl 20 mg
223964976|NCT05319756|DRUG|oxycodone HCl 20 mg|Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin
223964977|NCT05319756|DRUG|placebo|Participants will receive a single oral dose of a placebo that looks like gabapentin and a placebo that looks like oxycodone HCl
223964978|NCT00763087|BEHAVIORAL|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
223964979|NCT00763087|BEHAVIORAL|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
223964980|NCT00763087|BEHAVIORAL|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
223964981|NCT06399003|BIOLOGICAL|SIBP MMR Vaccine|This is a live attenuated measles, mumps, and rubella combined vaccine (Shanghai MMR) in a freeze-dried powder form, developed and manufactured by Shanghai Institute of Biological Products. A single dose of 0.5 mL, containing not less than 3.0 log CCID50 of both live measles virus and rubella virus and 4.3 log CCID50 of live mumps virus. 0.5ml per dose.
224111563|NCT03835208|BEHAVIORAL|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
223964982|NCT06399003|BIOLOGICAL|GSK MMR Vaccine (PRIORIX)|PRIORIX (combined measles, mumps and rubella vaccine, live, attenuated) is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses, separately obtained by propagation either in chick embryo tissue cultures (mumps and measles) or MRC5 human diploid cells (rubella). 0.5ml per dose.
223964983|NCT06399003|BIOLOGICAL|Yellow Fever Vaccine (Stamaril)|This is a live, attenuated, lyophilized yellow fever vaccine manufactured by Sanofi Pasteur Europe, Lyon, France. A single dose of 0.5 mL contains with not less than 1000 IU of yellow fever virus 17D-204 strain. 0.5ml per dose.
223964984|NCT00108407|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|
223964985|NCT00108407|BEHAVIORAL|Twelve Step Facilitation Therapy|
223964986|NCT02854657|BEHAVIORAL|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
223964987|NCT02237456|PROCEDURE|Comparison of OCT scans|
223964988|NCT02237456|PROCEDURE|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
223964989|NCT01803828|DRUG|Tadalafil|20 mg/die (1 capsule)
224111564|NCT05132738|DRUG|Ripretinib treatment|"Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters.~The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen."
223964990|NCT01803828|DRUG|Placebo|Placebo 20 mg/die (1 capsule)
224111565|NCT02225223|DEVICE|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
224111566|NCT02225223|DEVICE|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
224111567|NCT00352781|DRUG|nicotine replacement therapy|nicotine transdermal patches as per product monograph
224111568|NCT00352781|BEHAVIORAL|behavioural intervention|Smoking cessation counselling and relapse prevention
224111569|NCT01810159|OTHER|Integrated collaborative care|
224111570|NCT01810159|OTHER|Education and Resources|
223964991|NCT00393185|BIOLOGICAL|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
224111571|NCT05272059|DRUG|MHS552|MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
224111572|NCT05272059|DRUG|Placebo|Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
224111573|NCT00355589|DRUG|Ramipril and hydrochlorothiazide|
224111574|NCT02538146|DIETARY_SUPPLEMENT|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
224111575|NCT00004033|DRUG|liposomal NDDP|
224111576|NCT00004033|PROCEDURE|therapeutic thoracoscopy|
224111577|NCT03267329|DRUG|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%\~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
224111578|NCT03267329|DRUG|Telmisartan|telmisartan 80mg
224111579|NCT02028689|DRUG|Lesinurad 400 mg|
224111580|NCT02028689|DRUG|Metformin 850 mg|
224111581|NCT02028689|DRUG|Furosemide 40 mg|
224111582|NCT02711670|DRUG|chlorthalidone|
224111583|NCT02711670|DRUG|Hydrochlorothiazide|
224111584|NCT03318107|DEVICE|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
223964992|NCT05802498|DEVICE|IRMA|For patients in an advanced state of illness, advanced neuromotor rehabilitation treatment included 1) robot therapies, 2) specific water courses (e.g. walking pools, hydrokinesiotherapy pools, etc.), 3) advanced cognitive treatments (e.g. virtual reality courses); 4) augmentative immersive therapy in a virtual environment; 5) courses also dedicated to social reintegration and inclusive activities (theatre-therapy, art-therapy, dance-therapy, agro-therapy, etc.).
223964993|NCT03562702|OTHER|Standard IV Rehydration Therapy|IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
223964994|NCT03562702|OTHER|Oral Rehydration Therapy (ORT)|Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
223964995|NCT04816435|DIAGNOSTIC_TEST|Ultrasound test|Ultrasound evaluation of airway
223964996|NCT03508830|DRUG|Liposomal bupivacaine|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
224111585|NCT03827577|PROCEDURE|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
224111586|NCT03827577|RADIATION|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
224111587|NCT03827577|DRUG|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
224111588|NCT03399539|DRUG|Dexamethasone|Given PO
224111589|NCT03399539|DRUG|Ixazomib Citrate|Given PO
224111590|NCT03399539|OTHER|Laboratory Biomarker Analysis|Correlative studies
224111591|NCT03399539|DRUG|Venetoclax|Given PO
224111592|NCT04715724|OTHER|Positioning and Attachment video-based simulation (telesimulation)|Participants will teach a standardized patient actor (SP) to position and attach the baby doll at the breast of the Lactation Simulation Model in a video-based simulation (telesimulation)
224111593|NCT00404781|DRUG|cilostazol in addition to aspirin and clopidogrel|
224111594|NCT03912571|DIAGNOSTIC_TEST|Structural 3T MRI|measures of global and hippocampal atrophy)
224111595|NCT03912571|DIAGNOSTIC_TEST|MRI Based Perfusion Imaging|brain blood flow
224111596|NCT03912571|DIAGNOSTIC_TEST|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
224111597|NCT03645837|OTHER|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
224111598|NCT04897503|DRUG|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration (riboflavin/dextran -vs- riboflavin/methylcellulose) every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive either the riboflavin/dextran solution or the riboflavin/HPMC solution.
224111599|NCT00000800|DRUG|Methadone hydrochloride|
223964997|NCT03508830|DRUG|Bupivacaine Injection|5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.
224111600|NCT00000800|DRUG|Zidovudine|
224111601|NCT04241237|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
224111602|NCT02381756|DEVICE|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
224111603|NCT00958568|DRUG|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
224111604|NCT00958568|DRUG|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
224291391|NCT03407521|DRUG|Misoprostol|induction of abortion using misoprostol
224111605|NCT00434850|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
224111606|NCT00434850|DRUG|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
224111607|NCT00434850|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
224111608|NCT00434850|BIOLOGICAL|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
224111609|NCT00434850|DRUG|Sirolimus|Maintenance immunosuppressive therapy
223964998|NCT02064335|BEHAVIORAL|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
223964999|NCT00065247|BEHAVIORAL|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
224111610|NCT00434850|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
224111611|NCT00434850|BIOLOGICAL|Etanercept|Blocks TNF-alpha which is toxic to islet cells
224111612|NCT03517046|DRUG|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
224111613|NCT01340235|DRUG|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
224111614|NCT00845923|DRUG|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
224111615|NCT02917187|DRUG|BIIB074|Administered as specified in the treatment arm
224111616|NCT02917187|DRUG|Placebo|Matched placebo
223965000|NCT00640354|DEVICE|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
223965001|NCT00640354|DEVICE|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
224111617|NCT05426148|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®|The bivalent HPV 16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with aluminum adjuvant.
224111618|NCT00262106|DRUG|PRO 2000/5|Gel
223965002|NCT05487209|DIAGNOSTIC_TEST|MRI,SCC-Ag|Magnetic Resonance Imaging examination,serum squamous cells carcinoma antigen
223965003|NCT02765347|DRUG|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
223965004|NCT02765347|DRUG|Insulin|For arm 2, just accept insulin for 24 weeks
224111619|NCT00262106|DRUG|Placebo|Placebo
224111620|NCT03586804|OTHER|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
224111621|NCT04284644|DRUG|Induction using propofol|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.
224111622|NCT04284644|DRUG|Induction using sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.
224111623|NCT04284644|DRUG|Induction using propofol and sevoflurane|Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
224111624|NCT03413644|DIAGNOSTIC_TEST|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
224111625|NCT06060080|DRUG|pegylated recombinant human granulocyte-colony stimulating factor|Lymphoma/multiple myeloma patients who meet the inclusion criteria will be administered PEG-rhG-CSF injection at a fixed dose of 6 mg on the second day after hematopoietic stem cell infusion, and the effectiveness and safety of the treatment will be observed.
224111626|NCT04978376|BEHAVIORAL|Time restricted eating|We will compare the effects of time restricted eating alone and combined with resistance exercise of endurance exercise versus a no intervention control group.
224111627|NCT04239560|DRUG|Boron-based Gel (Fibore)|During each radiotherapy session, 15 minutes before radiotherapy, the gel used and patients followed up.
224111628|NCT04239560|DRUG|Placebos|During each radiotherapy session, 15 minutes before radiotherapy, the Placebo gel which be free of any chemical used and patients followed up.
224111629|NCT02383394|OTHER|follow up antenatal care|ultrasound follow up of pregnancy
224291392|NCT03407521|DRUG|isosorbide mononitrate|isosorbide mononitrate
224291393|NCT03407521|DRUG|Placebo|Placebo
224111630|NCT06032403|BEHAVIORAL|flexible patient centred consultations|In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
223965005|NCT00720629|DRUG|Visilizumab|3 mg/m\^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
223965006|NCT00720629|DRUG|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
223965007|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
223965008|NCT00720629|DRUG|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
223965009|NCT00720629|DRUG|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
223965010|NCT00720629|DRUG|Methotrexate|15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
223965011|NCT05624229|DRUG|Proton Pump Inhibitors|PPI infusion continued to use for 5 days in experimental group
223965012|NCT05624229|DRUG|No Proton Pump Inhibitors|PPI infusion stopped in standard group after endoscopy.
223965013|NCT02713698|DRUG|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
223965014|NCT00730392|DRUG|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
223965015|NCT00730392|DRUG|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
223965016|NCT06037109|DEVICE|Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 Test|Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
223965017|NCT04908800|DRUG|KRP-A218|KRP-A218 tablet
224111631|NCT03321617|DRUG|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
224111632|NCT00038194|DRUG|imatinib mesylate|
223724694|NCT04702334|DRUG|Hyaluronic Acid|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
223965018|NCT04908800|DRUG|Placebo|Placebo tablet
223965019|NCT04908800|DRUG|itraconazole|10 mg/mL oral solution
223965020|NCT04370392|PROCEDURE|intraperitoneal local anaesthetic instillation|intraperitoneal anesthetic instillation (40 ml total volume containing bupivacaine 0.25) through the trocar at the subdiaphragmatic space in Trendelenburg's position for 5 min with intravenous infusion of 50 ml normal saline over 10 minutes.
223965021|NCT05153161|DEVICE|Memesto|Edgewater plans to develop the next generation Memesto, a wearable device able to sense increasing agitation in ADRD sufferers and automatically deliver agitation-reducing personalized voice messages and music most effective at calming the individual based on past interventions. This innovative product will be the first wearable ADRD device to track agitation via body-worn sensors and automatically deploy agitation-reducing voice and music therapy without any caregiver interaction. The new system will use analytics to track the effectiveness of the various media and update the calming 'play list' over time.
223965022|NCT06249594|PROCEDURE|targeted sensory reinervation|targeted sensory reinnervation (TSR) in hand amputation by using and reactivation of existing nerves to treat and prevent phantom pain
223965023|NCT05142553|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive one injection of COVID-19 Vaccine HIPRA
223965024|NCT05142553|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive one injection of Cominarty Vaccine
224111633|NCT00038194|DRUG|docetaxel|
224111634|NCT00915967|DRUG|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
223724695|NCT04702334|DRUG|Lidocain|After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
223965025|NCT03987672|DIETARY_SUPPLEMENT|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
223965026|NCT03771573|OTHER|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
223965027|NCT03771573|OTHER|monitoring|the patients will be under monitoring to investigate the evolution of the disease
224111635|NCT00915967|DRUG|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
224111636|NCT01501149|DRUG|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
223965028|NCT04503889|DEVICE|Transauricular electrical vagal nerve stimulation|transauricular electrical vagal nerve stimulation will be applied to the cymba conchae of both ears using ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany) with currency intensity of max 10 mA and current frequency 2/100 Hz.
223965029|NCT04503889|DEVICE|taVNS sham|ECO2 TENS device (manufactured by Schwa-Medico GmbH/Germany)
223965030|NCT01532024|OTHER|Microdose of NAP|Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
224111637|NCT01501149|DRUG|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
224111638|NCT01823796|OTHER|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
224111639|NCT01823796|OTHER|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
224111640|NCT02605733|DEVICE|EEG|amplitude integrated electroencephalography
224111641|NCT02605733|DEVICE|NIRS|regional tissue oximetry
224111642|NCT05167292|OTHER|Observational study|Routine clinical care was provided to all AKI cases presenting to the TTM Hospital in Samoa. This prospective observational study reviewed incidence, aetiology and outcomes for these cases.
224111643|NCT02078622|OTHER|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
224111644|NCT02349906|DRUG|Treosulfan|
224111645|NCT02349906|DRUG|Busilvex|
224111646|NCT04546256|DRUG|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
223724696|NCT03170401|DIETARY_SUPPLEMENT|Protein supplementation|enteral protein supplementation
223724697|NCT03170401|OTHER|Standard enteral nutrition|Standard enteral nutrition.
223724698|NCT01598012|DRUG|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
224111647|NCT04546256|DRUG|ADVAIR DISKUS® 500/50|2 inhalations of Test and Reference product in each study period
223724699|NCT01598012|DRUG|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
223724700|NCT02589184|OTHER|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
223724701|NCT02589184|OTHER|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
223724702|NCT02589184|OTHER|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
224111648|NCT04297163|OTHER|Telemedicine|Remote CPAP monitoring, mobile app and voice mail
224111649|NCT04297163|OTHER|In Hospital|Face-to-face follow up
224111650|NCT06555094|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
224111651|NCT06555094|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
224111652|NCT06555094|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
224111653|NCT05321797|OTHER|Aerobic Training|This group will be administered with the cycling exercises in addition to the complete plan of care that is being administered to the control group. The cycling intervention will be performed 3 times per week, for 30 minutes, within a 12-week period
224111654|NCT05321797|OTHER|Conventional Physiotherapy|This group will be administered with Conventional Physiotherapy that includes 5 minutes of stretching exercises for quadriceps, hamstrings and gastrocnemius, 5 minutes of trunk control training, 5 minutes walking in the hall with and without the therapist assistance, walker or crutches, and finally 5 minutes of breathing exercises for Relaxation
224111655|NCT00402974|DRUG|menaquinone 7|
224111656|NCT06430749|DEVICE|Microtaze|Targeted Microwave Tissue Coagulation
224111657|NCT05255562|PROCEDURE|Combined Serratus Anterior Plane Block|Combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
224111658|NCT05255562|DRUG|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
224111659|NCT01263535|DEVICE|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
223965031|NCT05815693|BEHAVIORAL|mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)|Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
223965032|NCT00950430|DRUG|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
223965033|NCT00950430|DRUG|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
223965034|NCT00950430|DRUG|Tau (18-F-AV-1451)|"1. PIB PET scan, Tau PET scan and/or FDG PET scan~2. Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
223965035|NCT04002856|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
223965036|NCT06647212|OTHER|introducing breathing exercises with the harmonica|In addition to regular breathing exercises, participants will perform harmonica exercises
223965037|NCT05082493|DRUG|Berubicin Hydrochloride|Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions
223965038|NCT02899481|OTHER|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
224111660|NCT00006270|DRUG|cosyntropin|
224111661|NCT00006270|DRUG|metyrapone|
224111662|NCT01576861|DRUG|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
224111663|NCT00126542|BIOLOGICAL|bevacizumab|Given IV
224111664|NCT00126542|DRUG|erlotinib hydrochloride|Given orally
224111665|NCT00126542|OTHER|laboratory biomarker analysis|Correlative studies
224111666|NCT01936649|DRUG|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
224111667|NCT03510143|DEVICE|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
224111668|NCT03999567|OTHER|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
224111669|NCT03999567|OTHER|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
224111670|NCT01810367|DRUG|ABX Combined With Cisplatin|
224111671|NCT01810367|DRUG|Gemcitabine Combined With Cisplatin|
223965039|NCT03873922|OTHER|Ketogenic diet intervention|Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
224111672|NCT03827876|DRUG|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
224111673|NCT00824538|DRUG|sunitinib malate|
224111674|NCT00824538|OTHER|flow cytometry|
224111675|NCT00824538|OTHER|immunohistochemistry staining method|
224111676|NCT00824538|OTHER|laboratory biomarker analysis|
224111677|NCT03675399|OTHER|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
224111678|NCT03675399|OTHER|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
224111679|NCT04707144|DEVICE|MRI 1.5 tesla|"* standard imaging protocol prescribed as part of the usual treatment: sagittal T1 and T2 slices after injection of contrast product (Gadolinium), o 3D STIR sequence.~* 3D PSIR sequence at the level of the cervical cord for the duration of the additional sequence is 10 minutes, for a total examination time of 45 minutes (instead of 35 minutes)"
224111680|NCT01745055|DRUG|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
224111681|NCT01745055|DRUG|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
224291394|NCT05307159|DIETARY_SUPPLEMENT|bean protein supplement|They will have a snack with bean protein for 21 days Participants will follow their usual diet, which will be quantified and evaluated.
223965040|NCT06472882|DEVICE|tDCS targeting DLPFC|The anodic electrode will be placed on the left DLPFC (area F3) and the cathode on the right orbitofrontal cortex (area Fp2). Participants will receive 20 minutes of tDCS at 2 mA while seated.
223965041|NCT06472882|DEVICE|tDCS targeting M1|The anodes will be placed over C3 and C4 (according to EEG 10-20 system), and the cathodes over the ipsilateral shoulders. Participants will receive 20 minutes of tDCS at 2 mA while seated.
223965042|NCT06472882|DEVICE|SHAM tDCS|The electrodes will be placed as in the other conditions, but the stimulation will be switched off after 30 seconds, providing an initial stinging sensation without continuous stimulation.
223965043|NCT03538457|DRUG|Paracetamol|Patients are tested for their normal prescription paracetamol medication
223965044|NCT03779776|OTHER|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at 1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
223965045|NCT03779776|OTHER|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
223965046|NCT02501616|DRUG|Metformin|
224111682|NCT06498271|DEVICE|Personalized and automated digital coaching using a mobile application|Participants allocated to the experimental group will be invited to download a smartphone application which will appraise their motivation and automatically propose: 1) exercises to be performed at home and adapted to their pain levels; 2) audio recordings for pain management; and 3) educational and coaching content adapted to their motivation. In addition, the smartphone application enables users to plan their home exercises
224111683|NCT06512090|DIETARY_SUPPLEMENT|LGI steam bread|"LGI Steam bread called Mangusteam bread"
224111684|NCT06512090|DIETARY_SUPPLEMENT|Diabetic diet|the calorie intake of Diabetic diet will by recommended by nutritionist
224111685|NCT06067646|BEHAVIORAL|Semistructured interview|Semistructured interview and validated quality of life assesment using EQ5-DL
224111686|NCT01970150|DEVICE|rTMS real|
224111687|NCT05197101|PROCEDURE|balloon catheter combined with oxytocin induction|Balloon catheter for 12 hours and oxytocin for up to 3days.If failed , they will be treated ceacrean.
224111688|NCT04498910|DRUG|LY3451838|Administered IV
224111689|NCT04498910|DRUG|Placebo|Administered IV
224111690|NCT04002323|DRUG|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
224111691|NCT04002323|DRUG|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
223965047|NCT02501616|DRUG|Dapagliflozin|
223965048|NCT04933188|DIAGNOSTIC_TEST|Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure|Baseline and follow-up examination of echocardiography is to be performed on study subjects.
223965049|NCT05271799|DRUG|Gepotidacin|Gepotidacin will be administered
223965050|NCT01920399|DRUG|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
223965051|NCT01920399|DRUG|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
223965052|NCT04303598|DRUG|FNC|3mg, 1 tablet，QD
223965053|NCT04303598|DRUG|3TC|300mg, 1 tablet，QD
223965054|NCT04303598|DRUG|TDF|300mg, 1 tablet，QD
223965055|NCT04303598|DRUG|EFV|200mg, 1 tablet，QD
223965056|NCT04303598|DRUG|FNC placebo|1 tablet，QD
223965057|NCT04303598|DRUG|3TC placebo|1 tablet，QD
224111692|NCT03232723|DIAGNOSTIC_TEST|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
224111693|NCT00483951|DEVICE|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
224111694|NCT00483951|DEVICE|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
224111695|NCT02049528|DRUG|CC-122|CC-122
223724703|NCT06066684|OTHER|n/a, observational|n/a, observational study
224111696|NCT02049528|DRUG|CC-122|CC-122
224111697|NCT02049528|DRUG|CC-122|CC-122
224111698|NCT06498375|DIAGNOSTIC_TEST|Bioelectrical impedance|Fluid distribution measured by bioelectrical impedance Bodystat Multiscan 5000 Bodystat Ltd, Isle of Man, British Isles
224111699|NCT05212532|DRUG|EOM613|peptide nucleic acid (PNA)
224111700|NCT00909090|DIETARY_SUPPLEMENT|12 mg Lutein + Zeaxanthin|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year
224111701|NCT00909090|DIETARY_SUPPLEMENT|Visually identical placebo|Visually identical placebo, taken once daily for one year
223965058|NCT06014788|DEVICE|NPWTi|The wound was filled with black foam (Granufoam®, KCI). The instillation was performed via gravity from i.v. bag through a drain put within the foam. Chlorhexidine 0.1% 300 ml in 700 ml saline was used for continuous instillation three times daily (3 L per day) on the background of continuous pressure of 125 mmHg.
223965059|NCT06014788|DEVICE|Conventional NPWT|Conventional NPWT
223965060|NCT03252899|OTHER|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
223965061|NCT03252899|OTHER|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
223965062|NCT04789616|DRUG|Maraviroc|Half of the participants will take maraviroc for a period of 8 weeks.
223724704|NCT04954703|OTHER|Muscle energy technique of gluteus maximus and tensor fascia lata|it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
224111702|NCT05497505|DEVICE|Pacmed Critical|For patients in the On-period, Pacmed Critical will be available as decision support after initial eligibility screening for ICU discharge by treatment team
223965063|NCT04789616|BEHAVIORAL|Exercise Program|"All participants will take part in an 8-week exercise program. While in-hospital, participants will undergo standard of care rehabilitation (estimated at 45 minutes each daily for physiotherapy \& occupational therapy) plus a supplementary upper extremity exercise program (Graded Repetitive Arm Supplementary Program (GRASP); estimated at 1 hour daily).~After discharge from inpatient care, participants will complete an at-home supplementary upper and lower extremity exercise program. This program will include 30 minutes daily walking or sit-to-stand exercises and 30 minutes daily practice using the GRASP program."
223965064|NCT04789616|OTHER|Placebo|Half of the participants will take a placebo for a period of 8 weeks.
224111703|NCT05068596|OTHER|expermintal|progressive resistive functional strength training in the plantigrade foot position plus designed physical therapy program
224111704|NCT05068596|OTHER|CONTROL|Designed physical therapy program
224111705|NCT05000606|OTHER|A home visit program|A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
224111706|NCT02057237|DRUG|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
224111707|NCT01742351|BEHAVIORAL|Guided internet-based cognitive behavior therapy|
224111708|NCT03197675|OTHER|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
224111709|NCT00306566|BIOLOGICAL|CYT004-MelQbG10|
224111710|NCT02337504|OTHER|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
224111711|NCT04182191|DRUG|Tenoxicam|After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.
223724705|NCT04954703|OTHER|Myofascial release of iliotibial band syndrome|Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
223724706|NCT03932721|DRUG|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
223724707|NCT03013478|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
223724708|NCT03013478|BEHAVIORAL|CBT4CBT program|
223965065|NCT04789616|DEVICE|Activity Sensor|"Participants will be asked to wear small activity sensors (one on each wrist and one on each ankle, total of four sensors) at the baseline, 4-week, 8-week, and 6-month assessments for 7 consecutive days. Activity related to walking, sleep, physical activity, and arm and leg movement throughout the day will be measured.~The sensors will be worn for a total of 28 days throughout the study."
224111712|NCT03336398|DRUG|Ketamine Hydrochloride in saline|0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
224111713|NCT03336398|DRUG|Saline|Saline will be administered with the other MRS scan
224111714|NCT05180305|DIAGNOSTIC_TEST|Mitomic Prostate Test|Mitomic Prostate Test
224111715|NCT02648048|DRUG|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
224111716|NCT02648048|DRUG|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
224111717|NCT03099369|BEHAVIORAL|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
224111718|NCT03099369|BEHAVIORAL|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
224111719|NCT03099369|OTHER|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
223965066|NCT04789616|BEHAVIORAL|Motor Learning|Participants will be asked to perform a computer-based motor learning assessment at the baseline, 4-week, 8-week, and 6-month assessments. A retention task, which involves shorter versions of the initial tasks, will also be completed within 72 hours of the initial assessment (initial test and retention test).
224111720|NCT04748276|DRUG|FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)|Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.
224111721|NCT00611455|DRUG|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
223965067|NCT02944526|DRUG|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
223965068|NCT02944526|DRUG|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
223965069|NCT00214162|BEHAVIORAL|Comprehensive Health Enhancement Support System|Full CHESS
224111722|NCT00611455|DRUG|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
224111723|NCT04983901|DRUG|Imipenem/Cilastatin/Relebactam|Given IV
223965070|NCT00214162|BEHAVIORAL|computer with internet|computer with internet use x 1 year
223965071|NCT02815709|DRUG|Oliceridine|
223965072|NCT02815709|DRUG|Placebo|
223965073|NCT02815709|DRUG|Morphine|
223965074|NCT01825018|BEHAVIORAL|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
223965075|NCT01825018|BEHAVIORAL|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
223965076|NCT06266065|DEVICE|Coronary Sinus Reducer|Implantation of Coronary Sinus Reducer
223965077|NCT04194671|BIOLOGICAL|Mesenchymal stem cells|In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7
223965078|NCT04194671|OTHER|Saline|In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
223965079|NCT01994135|OTHER|Reference food|Reference food will be used to which test food samples will be compared to.
223965080|NCT01994135|OTHER|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
223965081|NCT01994135|OTHER|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
223965082|NCT03959735|OTHER|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
223965083|NCT04004169|DEVICE|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
223965084|NCT04004169|DEVICE|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
223965085|NCT04004169|DEVICE|Stimulation-ON Active Control|Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
223965086|NCT00639639|BIOLOGICAL|tetanus toxoid|Given by injection
223965087|NCT00639639|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
223965088|NCT00639639|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
224111724|NCT04983901|DRUG|Cefepime|Given IV
223965089|NCT04390971|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
223965090|NCT00448786|DRUG|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
223965091|NCT00448786|DRUG|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
223965092|NCT00448786|DRUG|AMG 706|AMG 706 125 mg daily continuously (Arm A)
223965093|NCT00166361|DEVICE|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
223965094|NCT00166361|DEVICE|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
224111725|NCT04983901|DRUG|Meropenem|Given IV
224111726|NCT04983901|DRUG|Piperacillin-Tazobactam|Given IV
224111727|NCT04983901|DRUG|Vancomycin|Given IV
224111728|NCT04983901|DRUG|Daptomycin|Given IV
224111729|NCT04983901|DRUG|Linezolid|Given IV or PO
224111730|NCT00813839|OTHER|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
224111731|NCT00827619|DEVICE|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
224111732|NCT05187195|OTHER|Home-based telerehabilitation with exercise videos|Balance, walking, strengthening, posture videos etc. taken in different positions will be uploaded to the telerehabilitation system. A personalized exercise program will be created from these exercises. This program will be defined to the account of the patient and the follow-up of the person will be carried out through the system.
224111733|NCT05187195|OTHER|Exercise brochure|Photos and explanations of exercises taken in different positions such as balance, walking, strengthening, posture etc. will be uploaded to the telerehabilitation system. A personalized exercise brochure will be created from these exercises. This program will be defined for the patient's account and the patient will be asked to follow the exercises with this brochure.
223965095|NCT00652496|DRUG|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
223965096|NCT00652496|DRUG|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
223965097|NCT00652496|DRUG|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
223965098|NCT00652496|DRUG|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
223965099|NCT00652496|DRUG|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
223965100|NCT03664271|BEHAVIORAL|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
224111734|NCT02061137|DRUG|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
224111735|NCT06399549|DIAGNOSTIC_TEST|Dead bug exercise|the participant in supine, lying on a mat with shoulders, hip joints and knees flexed to 90°. With the lumbopelvic region being maintained in the neutral position, the participant will be instructed to draw in the abdomen, lower two contra lateral limbs (opposite arm and leg) toward the floor, hold for the stipulated time, then return to starting position. The same movement will be repeated with the opposite limbs. In the DBG, both pairs of limbs will be moved an equal number of times withinthe stipulated time. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises.
223965101|NCT03664271|BEHAVIORAL|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
223724709|NCT02421276|OTHER|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
223965102|NCT01452204|OTHER|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
223965103|NCT04007822|BEHAVIORAL|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
223965104|NCT03613571|DRUG|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
223965105|NCT02259296|PROCEDURE|Lower eGFR for AVF construction|Lower eGFR patients (eGFR\<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR\<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
223965106|NCT02259296|PROCEDURE|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
223724710|NCT02925494|DRUG|Estradiol/Norethindrone Acetate|capsules
223965107|NCT05742256|DRUG|Oxycodone 1mg/kg|Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
223965108|NCT05742256|DRUG|Oxycodone 1.5mg/kg|Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
223965109|NCT05742256|DRUG|Sufentanil|Control group (SF group): sufentanil 2ug/kg + flurbiprofen + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
223724711|NCT02925494|DRUG|Elagolix|film-coated tablets
223965110|NCT02538055|BEHAVIORAL|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
223724712|NCT05929014|DEVICE|Bilateral-Transcranial direct current stimulation (bilateral-tDCS)|The tDCS is non-invasive brain stimulation technique applied over the participant's scalp using a reference to the International 10-20 electrode Placement System for EEG electrode placement. The cathodal and anodal electrodes will be applied over the right and left primary motor areas, respectively.
223965111|NCT02538055|BEHAVIORAL|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
223965112|NCT04627259|OTHER|Thumb Disability Examination|Turkish Version of Thumb Disability Examination. The Turkish Version of Thumb Disability Examination consists of 20 questions related with thumb pain and functionality.
223965113|NCT05045638|DRUG|Rosuvastatin|Oral dose
223965114|NCT05045638|DRUG|Sotorasib|Oral dose
223965115|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
223965116|NCT00348283|BIOLOGICAL|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
223965117|NCT00348283|BIOLOGICAL|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
223965118|NCT05492721|DEVICE|2-Octylcyanoacrylate|Incisions on left will have one glue and on right will have the other glue
223965119|NCT05492721|DEVICE|N-butyl-2-cyanoacrylate|Incisions on left will have one glue and on right will have the other glue
224111736|NCT06399549|DIAGNOSTIC_TEST|The McGill Curl Up|"Lie down on your back. Extend one leg and bend the knee of the other leg. The Side Bridge. Lie on your side, with your forearm on the floor and elbow underneath your shoulder.~The Bird Dog. Assume a hands-and-knees position on the floor. The patients in both groups will perform the corresponding exercises 3 days a week for a period of 3 weeks and a rest interval of 2 minutes between exercises along with conventional physiotherapy exercises. The exercise program includes a warm-up session of five exercises (awareness of the back, pelvic tilt, lumbar rotation, arm movements, whole-body movement in standing), well-known exercises targeting the muscles of the back extensors, abdominals, lateral buttocks, trunk rotators, posterior buttocks, leg muscles, oblique abdominals (e.g. the plank, diagonal arm and leg lift), as well as exercises for flexibility. The exercises will be taught to the patients at the end of the first session in both groups."
224291395|NCT04108559|PROCEDURE|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
223965120|NCT05337722|BEHAVIORAL|SFT 2.0|The SFT 2.0 intervention will include the use of the SFT 2.0 smoking cessation app, Motivational Interviewing (MI) counseling, and the support of a peer person
223965121|NCT05337722|BEHAVIORAL|Active control|Low dose prenatal and postnatal MI video counseling, defined as one prenatal session and one postnatal session
223965122|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: Virtual Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. Virtual interventions included in the bundle may consist of: phone or e-consults for medication reconciliation, virtual teach-to-goal \[V-TTG\] or tele-TTG inhaler education, and post-discharge phone call communication and/or texts/ and/or electronic portal use, among others.
223965123|NCT05568043|BEHAVIORAL|COPD Transitions of Care Intervention Bundle: In-Person Interventions|The COPD Transitions of Care Intervention Bundle will be site-specific determined through Aim 1 contextual assessments and will consist of 2-3 evidence-based COPD transitions of care interventions. In-person interventions include face-to-face general COPD education, inhaler education, medication reconciliation, post-discharge clinic visits, community health worker home visits, pulmonary rehabilitation, smoking cessation programs, among others.
223965124|NCT01996098|DRUG|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
223965125|NCT01996098|DRUG|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
223965126|NCT06233682|OTHER|Enriched environment|In the experimental group (enriched environment), assistants will supervise participants sponatneoulsy engaging in activities, including listening to music, drawing, playing cards or board games, exercising the affected upper limb with constructions or puzzles, etc., in the living room and personal rooms. Posters and clocks will also aid in orientation and improve the physical environment.
223965127|NCT04374435|PROCEDURE|MKTP with Surgical blade|In this procedure, the donor skin will be harvested with a surgical blade and the donor skin will be dissociated
223965128|NCT04374435|DEVICE|MKTP with Negative Pressure Instrument|In this procedure, the investigator uses a negative pressure instrument to create a few blisters on the donor skin and use the blisters for grafting after cell dissociation.
223724713|NCT05929014|DEVICE|Sham bilateral-tDCS|Sham bilateral-tDCS
223724714|NCT04210687|PROCEDURE|trapeziometacarpal limited excision|Narrow pseudarthrosis CMC1
223724715|NCT04210687|PROCEDURE|Trapeziectomy|Simple trapeziectomy
223724716|NCT03256916|DRUG|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
224111737|NCT04880057|OTHER|Resistance+Aerobic training|"The RT focuses on lower extremity workout, including leg press, hamstring curls, and calf raises. The participants start with intensity at 12 RM and finished with intensity at 8 RM after 3 weeks. There are 8 repetitions, 2 sets for each action. It will take 15 minutes to complete RT.~The AeT is composed by cycling on stationary bikes in the first week, stepping on steppers in 2nd week, and running on treadmills in the last week. Participants are asked to wear a portable heart rate monitor throughout the experiments. They have to maintain their heart rates in 60%-75% of predicted maximal heart rate (moderate intensity exercise), which has been shown to be benefit on cognition\[3\]. It took the participants 25 minutes to complete AeT."
224111738|NCT04880057|OTHER|Agility training|AT program consists of three parts: technical drills, pattern running and reactive agility training. There will be nine sessions over 3 weeks and progress the intensity, complexity or velocity every week.
223965129|NCT04374435|DEVICE|Suction blister grafting without cell dissociation|In this procedure, an automated suction blister device will be used to create micro domes and these micro domes will be used directly for grafting without dissociation.
224111739|NCT02046135|DRUG|Sodium Bicarbonate|
223965130|NCT05542004|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
223965131|NCT06408194|DRUG|CD22CART infusion|CD22CART will be administered after Standard of Care (SOC) administration of tisagenlecleucel.
223965132|NCT06408194|DRUG|Tisagenlecleucel|All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.
223965133|NCT05488678|DRUG|VNRX-7145|single oral dose
223965134|NCT05488678|DRUG|Ceftibuten|single oral dose
223965135|NCT03613363|DEVICE|Helix Ventilator|The Helix ventilator is a non-FDA cleared ventilator device. The Helix ventilator has similar modalities to the Trilogy ventilator, which has FDA clearance. The Helix device has improved algorithms, controls, and features to enhance the therapy delivery. Additionally, Helix has an updated hardware platform which has been adequately tested to ensure that the device specifications are met. No pre-clinical or developmental clinical work was required because of Trilogy being the established predicate.
223965136|NCT06312566|DRUG|brivaracetam (BRV) tablet|Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.
223965137|NCT06312566|DRUG|brivaracetam (BRV) dry syrup|Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.
223965138|NCT05208255|OTHER|Exercise|"NEP is a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercises are progressed from simple to complex tasks. Varied equipment (such as different sized balls, rackets, tulles, exercises balls, eye bands, ropes etc.) is used during different exercises containing cross-limb movements, throwing, jumping, walking, and cognitive tasks. Although the stages of the NEP and exercise selection are the same for each participant, the use of materials or cognitive tasks selection may differ according to the age and skill of the participant. The cognitive tasks were performed by using different visual (colored cards, numbered cards etc.) or auditory cues.~Motor Imagery Program: Motor imagery (MI) is a dynamic mental state during which the representation of a given motor movement is rehearsed in working memory without overt motor output. MI training will be performed in the form of imagined NEP exercises in the last 15 minutes of the session."
223965139|NCT05010031|RADIATION|Palliative radiotherapy|An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
223724717|NCT03256916|DRUG|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
223965140|NCT02430597|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
223965141|NCT02430597|DEVICE|NanoKnife|
223965142|NCT05039047|OTHER|Standard stroke acute care and rehabilitation|According to Swiss national guidelines and local protocols
224111740|NCT02046135|DRUG|Sodium Chloride|
223965143|NCT04736472|DEVICE|Pharmacogenetic test|Patients with reduced function alleles (DPYD intermediate or poor metabolizer and/or UGT1A1 poor metabolizer) will be recommended to receive dose reductions per clinical pharmacogenetic guidelines. Patients that do not carry actionable alleles (DPYD normal metabolizer and/or UGT1A1 normal or intermediate metabolizer) will receive standard dosing.
223965144|NCT06178471|DIAGNOSTIC_TEST|Transesophageal Echocardiography|The use of transesophageal echocardiography to diagnose cardiopulmonary failure in ICU patients with suboptimal or inadequate transthoracic echocardiography examinations.
223965145|NCT01765439|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
223965146|NCT04476849|DRUG|fezolinetant|Oral
223965147|NCT04391803|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
223965148|NCT04060641|GENETIC|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
223965149|NCT06012305|OTHER|Taping|Taping has the effect of accelerating the flow in the tissue by increasing the epidermal dermal distance. The muscle technique used in the study will be applied to the trapezius muscle and aims to reduce the working level of the muscle. The EDF technique, which will be used in another group, aims to create a stronger base taping effect.
223965150|NCT05626920|DRUG|Disulfiram 250 mg|Disulfiram treatment
223965151|NCT05626920|DRUG|Placebo|Placebo treatment
223965152|NCT01533896|BEHAVIORAL|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
223965153|NCT02978235|DRUG|TAS4464|Intravenous (IV) Infusion
223965154|NCT04895202|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.
223965155|NCT02465944|DRUG|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
223965156|NCT02465944|DRUG|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
224111741|NCT03320148|BEHAVIORAL|Physiotherapist-led primary care model for back pain|"1. Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~2. Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~3. Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~4. Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
224111742|NCT03320148|OTHER|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
224111743|NCT02278146|DEVICE|ParaPatch|A device for the treatment of urinary incontinence
224111744|NCT04408157|BEHAVIORAL|Self-management booklet (SWitCh: Stay well during COVID-19)|The purpose of this booklet is to support adjustment to the current circumstances of the COVID-19 pandemic and facilitate the development and maintenance of healthy behaviours at home. The booklet covers a range of topics, including understanding bodily sensations and symptoms of COVID-19, managing the uncertainty surrounding COVID-19, physical activity, sedentary behaviour, sleep, social support and isolation, nutrition and alcohol consumption, sex and intimate relationships, and coping with children at home. The booklet will provide structured guidance on the various topics through the use of effective behaviour change techniques, in particular self-monitoring, goal setting, and problem solving and signposting to additional helpful resources, such as drinking or nutrition tracking apps.
224111745|NCT03671369|OTHER|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) were collected as part of safety data in this PMS."
224111746|NCT02060708|DEVICE|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
223965157|NCT03861078|OTHER|Own Brand Cigarette|Effects of own brand cigarette use.
223965158|NCT03861078|OTHER|ECIG 15 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, sweetened liquid
223965159|NCT03861078|OTHER|ECIG 15 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 15 mg nicotine, unsweet liquid
223965160|NCT03861078|OTHER|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
223965161|NCT03861078|OTHER|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
223965162|NCT06339385|BEHAVIORAL|PADIS assessment|Hospital and nursing records from the 24 hours preceding enrollment were examined to document the assessment rate of pain, agitation-sedation, and delirium.
223965163|NCT02950870|DRUG|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
223965164|NCT02950870|DRUG|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
223965165|NCT02950870|DRUG|Ribavirin|Patients will be treated with ribavirin if necessary.
223965166|NCT04050319|DIAGNOSTIC_TEST|Screening and diagnosis if injured|physical therapy
224111747|NCT04828876|BEHAVIORAL|Yoga practice|"Yoga basically consists of breathing techniques, asanas (postures) and relaxation phases.~Practiced Yoga Stages; 10 min. standing breathing exercise, 10 min. breathing exercise with seated asana, 10 min. lying down breathing exercise with asana, 20 min. sitting breathing exercise, 10 min. The session will be completed in 60 minutes, including deep relaxation stages by lying down. At the end of each session, patients' feedback about yoga practice will be received."
223965167|NCT00955565|PROCEDURE|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
223965168|NCT00955565|PROCEDURE|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
223965169|NCT02971683|DRUG|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
223965170|NCT02971683|DRUG|Placebo|Placebo of Abatacept subcutaneous
223965171|NCT02038114|BEHAVIORAL|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
223965172|NCT05692232|OTHER|Pressure biofeedback guided DCFM strength training|A pressure biofeedback guided DCFM strength training was carried out according to the Jull protocol. Keeping the participant's cervical spine in a neutral position and ensuring a stabilizer pressure biofeedback unit placed beneath the cervical lordosis. The pressure sensor was inflated at 20mm Hg. The participants were asked to nod their heads slowly. As the DCFM is activated, the cervical lordosis gently flattens, and the pressure sensor measures an increase in pressure. The activation score is the maximum pressure that can maintain for 10 seconds.
223965173|NCT05692232|OTHER|Manual therapy|A manual therapy, including a slow, sustained elongation of muscles with a holding period of 7-10 seconds and a superficial oscillatory mobilization (grade-I) with 1-2 oscillations per second for 30 seconds per session was performed on the DCFM and at the cervical spine (C0-C5), respectively. The participants were asked to lie supine and prone while delivering stretching and mobilization, respectively.
224111748|NCT02732912|DEVICE|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
224111749|NCT02732912|DEVICE|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
224111750|NCT02732912|DRUG|Zopiclone|This night sedation will be given to any patient requesting it, in either group
224111751|NCT00062738|DRUG|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
224111752|NCT00062738|DRUG|Nortriptyline|nortriptyline 25 - 75 mg q hs
224111753|NCT00062738|OTHER|placebo|matching placebo
224111754|NCT00090649|DRUG|DVS-233 SR|
224111755|NCT00163722|OTHER|Culture and histology|
223965174|NCT05692232|OTHER|Conventional intervention|A hot pads was applied for 20minutes underneath the cervical spine covering either side of shoulder in a relaxed supine position.
223965175|NCT06169774|OTHER|Educational video|Watch the 17-minute educational video as many times as needed within a 12-month period.
223965176|NCT04206501|DEVICE|Medtronic ICD with Opti Vol-Monitor|Physiologic and functional data from Cardiac Implantable Electronic Devices (CIEDs), including information on heart rate, activity, and fluid status derived from the OptiVol monitor, together with a concurrent patient engagement strategy through remote interactions, can be used to optimize the medical management of HF patients implanted with an ICD.
223965177|NCT03408821|OTHER|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
223965178|NCT00067925|BEHAVIORAL|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
223965179|NCT02268526|BIOLOGICAL|CSJ148|CSJ148 IV q 4weeks
223965180|NCT02268526|DRUG|Placebo|Placebo IV q 4weeks
223965181|NCT00023621|DRUG|celecoxib|
223965182|NCT02451553|DRUG|Afatinib Dimaleate|Given PO
223965183|NCT02451553|DRUG|Capecitabine|Given PO
223965184|NCT02451553|OTHER|Laboratory Biomarker Analysis|Correlative studies
223965185|NCT00596960|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
223965186|NCT00596960|BEHAVIORAL|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
223965187|NCT03147742|DRUG|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
223965188|NCT00801151|DRUG|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
223965189|NCT05689424|DRUG|HDV-Insulin Lispro|The name of the investigational drug is Hepatic Directed Vesicles + Insulin Lispro (HDV-bound LIS). It is a nano-carrier-based formulation of insulin which is the active therapeutic ingredient in the product. The nano-carrier component of the formulation contains a hepatic target molecule, biotin phosphatidylethanolamine, which has an affinity for hepatocytes and enables the product to deliver insulin directly to the liver.
224111756|NCT00163722|OTHER|Aspergillus galactomannan and PCR|
224111757|NCT02221427|OTHER|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
224111758|NCT02221427|OTHER|Static labour progression curve (F)|
224111759|NCT03340441|DEVICE|Prizma|sensor unit with mobile application installed on smartphone
223965190|NCT00231166|DRUG|HCD122|
223965191|NCT01305837|DRUG|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
223965192|NCT04258306|DIETARY_SUPPLEMENT|Revifast|Revifast® is based on natural resveratrol supported on Magnesium hydroxide. Revifast® particles confer an improved dissolution rate in tests that mimic the gastric environment compared to Polygonum cuspidatum resveratrol (98%).
223965193|NCT04258306|DIETARY_SUPPLEMENT|pure resveratrol|resveratrol extracted from Polygonum cuspidatum resveratrol (98%).
223965194|NCT03874091|PROCEDURE|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
223965195|NCT03874091|PROCEDURE|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
223965196|NCT03874091|DRUG|Morphine PCA pump|Morphine given postoperatively.
223965197|NCT00916318|BEHAVIORAL|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
223965198|NCT01117532|BEHAVIORAL|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
223965199|NCT04201275|DRUG|HEC74647PA capsule|Capsule administered orally once daily
223965200|NCT04201275|DRUG|placebo|HEC74647PA capsule matching placebo administered orally once daily
223965201|NCT05945979|DIETARY_SUPPLEMENT|A power supplement with biotin|A power dietary supplement containing aminoacids and vitamins
223965202|NCT03307993|DRUG|Idalopirdine|Idalopirdine 60-120 mg daily dose
224111760|NCT00211822|PROCEDURE|fMRI|fMRI
224111761|NCT02439762|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
223965203|NCT05910788|DEVICE|high flow nasal cannula|"The purpose of this intervention is clarify the benefit with the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications.~is to clarify whether there is benefit from the perioperative use of HFNC, in thoracic surgeries, from intubation to the postoperative period, evaluating mortality and in-hospital complications."
223965204|NCT00459433|PROCEDURE|Biopsychosocial intervention|Psychosocial versus usual care
223965205|NCT04400214|BEHAVIORAL|Food Allergy Superheroes Training (FAST) Program|The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.
223965206|NCT04400214|OTHER|Food Allergy Knowledge Intervention|"The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session."
223965207|NCT02303509|DRUG|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
223965208|NCT02303509|DRUG|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
223965209|NCT02303509|OTHER|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
223965210|NCT05360134|DRUG|Carica Papaya Leaf Extract|Carica Papaya Leaf Extract 1100 mg X TDS started at least 3 days preoperatively and continued on post operative day 3 to day 7
223965211|NCT05360134|OTHER|Placebo|Placebo will be given in a similar manner
223965212|NCT00327314|PROCEDURE|Transplantation|
223965213|NCT00327314|PROCEDURE|Hematopoietic cell transplantation|
223965214|NCT02303613|OTHER|Mapping|Mapping of current triage situation regarding 30 days mortality
223965215|NCT05404178|OTHER|Type 2 diabetes group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
224111762|NCT02439762|BEHAVIORAL|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
223965216|NCT03941769|BIOLOGICAL|Recombinant Interleukin-7|Given IM or SC
223965217|NCT06646757|BEHAVIORAL|APP|1\) My IBD Care (APP) is a free smartapp that supports patients' tracking of symptoms, medical appointments, and medications; self-paced behavioral change programs
223965218|NCT06646757|BEHAVIORAL|CBT|"2\) Coping with Crohn's and Colitis: A Patient and Clinician's Guide to CBT for IBD (CBT) is an IBD-specific cognitive behavioral therapy (CBT) workbook (e-book or hardcopy)"
223965219|NCT06646757|BEHAVIORAL|HELP|3\) IBD Help Center (HELP) is a resource operated by the Crohn's and Colitis Foundation (CCF) for individuals to connect with an information specialist via email, call, or online live chat at no cost
223965220|NCT06646757|BEHAVIORAL|PEER|4\) Power of Two (PEER) is a one-on-one peer mentoring program operated by the Crohn's \& Colitis Foundation
223965221|NCT06646978|DRUG|Imatinib (STI571)|Imatinib-based regimen
223965222|NCT06646315|BEHAVIORAL|Early Intervention|The Early Intervention consists of the proper attention given to those patients who participate in a Phase I Clinical Trial. The attention will be based on a monthly assessment of their physical, psychological/emotional symptoms and, also their sociofamiliar needs. After having discussed patients's needs in a multidisciplinary committee, each professional (paliiative physician, clinical psychologist and/or wocial orker) will proportionate them the required attention in order to increase their quality of life.
223965223|NCT03145909|DRUG|ABBV-176|Intravenous infusion
224111763|NCT05196932|DEVICE|Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies|"A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system."
224111764|NCT02235285|PROCEDURE|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
224111765|NCT04569305|PROCEDURE|Negative Pressure Wound Therapy|NPWT technique was applied to injured area of the foot and ankle after debridement and cleaning of the necrosed tissue and using Vacuum Assisted Closure (VAC) consisting of evacuation tube, vacuum pump, collecting canister and a multiporous polyurethane sponge. VAC dressings were changed every 72 hours.
224111766|NCT04569305|PROCEDURE|Conventional treatment|In conventional treatment moist gauze dressings were applied and change of dressings were done daily.
224111767|NCT02796950|DRUG|Acipimox|P.o. administration of 250 mg acipimox
223965224|NCT06247761|DEVICE|Skin closure at end of hand surgery|skin closure with vicryl rapide suture
223965225|NCT01445379|DRUG|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
223965226|NCT00763919|BEHAVIORAL|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
223965227|NCT00763919|BEHAVIORAL|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
223965228|NCT00763919|BEHAVIORAL|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
223965229|NCT00763919|BEHAVIORAL|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
223965230|NCT05253066|DRUG|Chidamide combined with exemestane (+/- goserelin)|Chidamide combined with exemestane (+/- goserelin)
223965231|NCT05253066|DRUG|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)|Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
223965232|NCT02884622|OTHER|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
223965233|NCT02884622|OTHER|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
223965234|NCT06030999|DIETARY_SUPPLEMENT|Study product A (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
223965235|NCT06030999|DIETARY_SUPPLEMENT|Study product B (Wonderlab wonder4shape)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
223965236|NCT06030999|DIETARY_SUPPLEMENT|Study product C (placebo)|Participants in this arm need to consume one bottle (2g) of this product once a day for 10 weeks
223965237|NCT02816645|PROCEDURE|Magnetic Resonance Imaging (MRI)|
223965238|NCT00751088|PROCEDURE|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
224111768|NCT06313905|DIETARY_SUPPLEMENT|EVADRY|"The EVADRY oral spray and the placebo are produced by Wellnet laboratory.~• EVADRY spray: It is a phytotherapy-based medication in the form of an oral spray. It is a 100 ml bottle containing ALEO BARBADENSIS LEAF WATER (1 ml), Chamomilla Recutita Flower extract (30 mg), TOCOPHEROL (10 mg), hyaluronic acid (2 mg), mentha spicata herb oil (10 mg), and eugenol (40 µg)."
224111769|NCT06313905|OTHER|Placebo|"The placebo corresponds to flavored water (mint extract) with the same taste as EVADRY. It is placed in a bottle with the same appearance as EVADRY.~Both products are administered at a rate of 5 intra-oral sprays per day."
224111770|NCT02881307|DIETARY_SUPPLEMENT|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
224111771|NCT02881307|BEHAVIORAL|Dietary Counseling|Dietary Counseling
224111772|NCT02881307|BEHAVIORAL|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
223965239|NCT00751088|PROCEDURE|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
223965240|NCT00751088|PROCEDURE|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
223965241|NCT00751088|PROCEDURE|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
223965242|NCT02374476|DEVICE|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
223965243|NCT03795792|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
224111773|NCT05331365|OTHER|Construction and evaluation of a composite score evaluating post ankle surgery residual instability by completing questionnaires and undergoing physical tests|"Four tests and two questionnaires, each evaluating specific physical or psychological dimensions will be used to construct the composite score Ankle Go Test composite score:~* Foot and Ankle Ability Measure Questionnaire (FAAM)~* Ankle ligament reconstruction-return to sport after injury Questionnaire(ALR-RSI)~* Single Leg Stance Test (SLST)~* Side Hop Test (SHT)~* Star Excursion Balance Test (SEBT)~* Figure-of-8"
223965244|NCT03795792|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Will be provided in capsules.
223965245|NCT06585735|DIETARY_SUPPLEMENT|Proteolytic enzyme fortified protein supplement|Group I receive Enzotein 15 gms (proteolytic enzyme with 70000 Hb unit tyrosine (HUT) fortified with 15 gms of whey protein), given for 6 weeks. Enzotein will be provided by (Mylin Biotech India Ltd.)
223965246|NCT06545669|BEHAVIORAL|C-Raven Virtual Tobacco Cessation Counseling|A two-module tobacco cessation intervention that involves interaction with a virtual counselor and includes instruction about addiction and the use of pharmacotherapy for cessation. Each module takes approximately 20 minutes to complete.
223965247|NCT06545669|DRUG|Nicotine Replacement Product|Participants will be offered a 12-week supply of nicotine patches and either nicotine gum or lozenges.
224111774|NCT03084159|BEHAVIORAL|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
224111775|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist|anti-IL6 alone
224111776|NCT04486521|DRUG|Interleukin 6 (IL6) Antagonist and corticosteroids|anti-IL6 + corticosteroid combination
224111777|NCT04486521|DRUG|corticosteroid alone|"dexamethasone, hydrocortisone, methylprednisolone, prednisone. All steroids  other than dexamethasone will be converted to dexamethasone equivalent"
224111778|NCT04565561|DEVICE|Neovas BRS or DCB|"All STEMI patients were predilated (including predilated balloon or cutting balloon) before randomization. Thrombus aspiration was determined by the surgeon according to the specific situation.~Sufficient predilation criteria: the following two conditions must be met: A. residual stenosis \< 30%; B. no flow limiting dissection or TIMI grade 2-3."
224111779|NCT02477865|DRUG|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
224111780|NCT02477865|DRUG|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
224111781|NCT02477865|DRUG|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
224111782|NCT00999128|DRUG|GDC-0941|Oral repeating dose
224111783|NCT00999128|DRUG|rabeprazole|Oral repeating dose
224111784|NCT01666873|PROCEDURE|patients that undergo a total knee prosthesis|
224111785|NCT01507545|DRUG|MORAb-004|MORAb-004 8mg per kg IV once a week
224111786|NCT01507545|DRUG|Placebo|Placebo - normal saline IV once a week
224111787|NCT01507545|OTHER|Best supportive care|Best supportive care to improve quality of life
224111788|NCT02508714|DEVICE|Orsiro|stents will be implanted in case of significant coronary artery disease
224111789|NCT02508714|DEVICE|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
224111790|NCT00193674|DRUG|Dydrogesterone|20 mg/day, oral
223965248|NCT06545669|OTHER|Community Health Worker|A community health worker will meet with each participant throughout the study period to teach appropriate NRT usage, discuss barriers/facilitators to NRT use and cessation, conduct shared decision-making about lung cancer screening, and provide health system navigation when needed.
223965249|NCT06545669|OTHER|Lung Cancer Screening|After participating in shared decision-making, eligible participants will be referred to their primary care physician or existing specialist to complete lung cancer screening.
224111791|NCT00193674|DRUG|Placebo|Placebo
223724718|NCT03256916|RADIATION|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 45- 50Gy/23-25 #/5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
224111792|NCT02178618|DEVICE|Deployment of Partially covered biliary self expandable metal stent|
224111793|NCT02178618|DEVICE|Deployment of uncovered biliary self expandable metal stent|
224111794|NCT03482310|DEVICE|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
224111795|NCT05700344|DRUG|Avelumab|Single Group Assignment
223965250|NCT06584578|OTHER|Whole-Body Electromyostimulation|Participants were included in tree exercise programs (Yoga, Pilates, WB-EMS) by an expert trainer 2 days a week for 12 weeks. At the same time, an active control group conducted a weekly diet counseling for 12 weeks by an expert dietician.
223965251|NCT06584578|OTHER|Pilates|Pilates exercise twice weekly for 12 weeks
223965252|NCT06584578|OTHER|Tai Chi|Pilates exercise twice weekly for 12 weeks
223965253|NCT06584578|OTHER|Nutritional counseling|Nutritional counseling for 12 weeks
223965254|NCT06584994|OTHER|sample collection|Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).
224111796|NCT02206711|DRUG|BMS-955176|Single dose of drug on Day 1
224111797|NCT01671488|BIOLOGICAL|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
224111798|NCT01671488|DRUG|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
224111799|NCT01671488|DRUG|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
224111800|NCT01671488|RADIATION|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
224111801|NCT01312350|DRUG|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
224111802|NCT01312350|DRUG|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
224111803|NCT02251730|BEHAVIORAL|Smoking cessation|Refer for smoking cessation
224111804|NCT01022853|DRUG|BI 6727|intravenous each 21 days
224111805|NCT01022853|DRUG|BIBF 1120|oral continuously
224111806|NCT04846153|OTHER|Human-based Quantification of Airway Stenosis|Human-based Quantification of Airway Stenosis From Bronchoscopic Images.
224111807|NCT04846153|DEVICE|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.|Computer-based Quantification of Airway Stenosis From Bronchoscopic Images.
224111808|NCT02807116|DRUG|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
224111809|NCT02807116|DRUG|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
224111810|NCT02807116|DRUG|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
224111811|NCT03391011|DEVICE|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
224111812|NCT01753518|DEVICE|Subcuticular suture|subcuticular Monocryl suture closure
224111813|NCT01753518|DEVICE|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
224111814|NCT03629626|PROCEDURE|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
223965255|NCT03293147|OTHER|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
224111815|NCT03614429|DRUG|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
224111816|NCT01214434|DEVICE|Promiseb Topical Cream|topical non steroidal cream, twice daily
223965256|NCT03293147|OTHER|Standard care|Standard care for hypertensive patients
224111817|NCT01214434|OTHER|Bland emollient|Eucerin cream twice daily
224111818|NCT00138151|BIOLOGICAL|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
224111819|NCT00138151|DRUG|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
224111820|NCT00138151|DRUG|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
224111821|NCT05216991|OTHER|TetraGraph on dominant hand|Using standard of care TetraGraph device on dominant hand
224111822|NCT05216991|OTHER|TetraGraph on non-dominant hand|Using standard of care TetraGraph device on non-dominant hand
223965257|NCT04847284|RADIATION|Intraoperative radiotherapy|Intraoperative radiotherapy application immediately following resection of brain metastases.
223724719|NCT03636061|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
223965258|NCT04140422|OTHER|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
223965259|NCT04140422|OTHER|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
223965260|NCT03305458|BEHAVIORAL|TFCBT|treatment as usual
223965261|NCT03305458|BEHAVIORAL|eTFCBT|tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
223965262|NCT03831698|DRUG|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
223965263|NCT03010878|OTHER|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
223965264|NCT03010878|OTHER|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
224111823|NCT05864157|OTHER|Gait training without rhythmic auditory cues|Gait training on treadmill and overground without any rhythmic auditory cues
224111824|NCT05864157|OTHER|TRAC|Metronome set to 85% on treadmill and 115% when walking overground
224111825|NCT05864157|OTHER|dTRAC|Metronome set around 85% on treadmill and around 115% when walking overground
224111826|NCT03503773|DRUG|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
224111827|NCT03503773|OTHER|Sham control|endovascular, renal angiography
224111828|NCT00607828|RADIATION|stereotactic body radiation therapy|Undergo radiotherapy
224111829|NCT06392100|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness-based stress reduction interventions include: breathing awareness, loving-kindness meditation, body scan, walking meditation, sitting body awareness, eating meditation, and deep breathing exercises.
224111830|NCT06369467|DRUG|linvoseltamab|Administered by intravenous (IV) infusion
224111831|NCT06369467|DRUG|dupilumab|Administered by subcutaneous (SC) injection
224111832|NCT03145857|DRUG|[68]Ga-HA-DOTATATE|All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
223965265|NCT05431543|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
223965266|NCT05431543|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
223965267|NCT05431543|DRUG|Vehicle proprietary ophthalmic solution|Proprietary Vehicle ophthalmic solution
223965268|NCT00440037|BIOLOGICAL|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
223965269|NCT05840822|DRUG|Cannabidiol (CBD) Capsule 75mg|Cannabidiol (CBD) capsule containing 75mg CBD
223965270|NCT05840822|DRUG|Placebo|Placebo capsule without cannabidiol
224111833|NCT02624700|DRUG|Experimental Arm A: Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
224111834|NCT02624700|DRUG|Experimental Arm A: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg.
224111835|NCT02624700|DRUG|Experimental Arm B: Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
224111836|NCT02624700|DRUG|Experimental Arm B: Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
223965271|NCT00998517|DIETARY_SUPPLEMENT|Soy/peanut fortified spread|75kcal/kg/day
224111837|NCT02596490|BEHAVIORAL|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
224111838|NCT02596490|BEHAVIORAL|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
224111839|NCT02596490|BEHAVIORAL|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
224111840|NCT05979090|BEHAVIORAL|Mastery learning in communication skills|Participants will undergo simulation-based mastery learning curriculum in difficult conversations.
224111841|NCT01801397|DRUG|osteoanabolic therapy|
224111842|NCT00004177|BIOLOGICAL|filgrastim|as prescribed by physician
223965272|NCT00998517|DIETARY_SUPPLEMENT|Milk fortified corn/soy blend|75 kcal/kg/day
223965273|NCT00998517|DIETARY_SUPPLEMENT|Supplementary Plumpy®|75 kcal/kg/day
223965274|NCT06186349|GENETIC|Genomic sequencing|Newborns with neonatal hyperbilirubinemia who did not randomly receive genome sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
223965275|NCT03742882|DRUG|CC-90001|CC-90001
223965276|NCT01992276|BIOLOGICAL|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
224111843|NCT00004177|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks from treatment
224111844|NCT00004177|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
224111845|NCT00004177|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
223724720|NCT03636061|DRUG|Placebo (vehicle) nasal spray|Placebo
223965277|NCT01992276|BIOLOGICAL|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
223965278|NCT01992276|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
223965279|NCT04439591|OTHER|Computerised cognitive training|A 12-week bi-weekly group-based computerised cognitive training programme conducted in community centres
223965280|NCT02648555|BEHAVIORAL|Daily walking|Participants will be instructed to walk briskly for \>40 minutes, 7 days a week.
224111846|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W; Xihuang Pill：3g po bid，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W；Xihuang Pill：3g po bid，4 cycles
224111847|NCT05914753|DRUG|Epirubicin, Cyclophosphamide, Docetaxel|Epirubicin :90 mg/m2, D1, q3W; Cyclophosphamide :600 mg/m2, D1, q3W，4 cycles, Follow Docetaxel :100 mg/m2, D1, q3W，4 cycles
224111848|NCT02675517|DRUG|Spiolto Respimat|Tiotropium bromide + Olodaterol
224111849|NCT03869073|DRUG|Evolocumab|Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
224111850|NCT03869073|DRUG|Placebo|Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
224111851|NCT00425438|DRUG|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
224111852|NCT00425438|DRUG|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
224111853|NCT00425438|DRUG|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
224111854|NCT00425438|DRUG|Cyclophosphamide|0.75 g/m\^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m\^2 to maintain a minimum WBC count of ≥ 2500 per mm\^3 from Weeks 5 through 24
224111855|NCT00675285|DRUG|montelukast sodium|one tablet 5 mg once/day for 4 weeks
223965281|NCT02648555|BEHAVIORAL|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
223965282|NCT00504205|DRUG|multitargeted receptor tyrosine kinase inhibitor MP470|
223965283|NCT00504205|OTHER|laboratory biomarker analysis|
223965284|NCT00504205|OTHER|pharmacological study|
223965285|NCT00504205|PROCEDURE|positron emission tomography|
224111856|NCT00675285|DRUG|placebo|one tablet 5 mg once/day for 4 weeks
224111857|NCT06065956|DRUG|Intravenous morphine|"Morphine group(an opioid), participants were given intravenous morphine(an opioid) at induction of General Anaesthesia before laryngoscopy and intubation.~The other group,Esmolol group(cardioselective beta blocker), participants were given intravenous esmolol(cardioselective beta blocker) during induction of General Anesthesia before laryngoscopy and intubation."
224111858|NCT05762822|DIETARY_SUPPLEMENT|3-OHB (KE4)|60 ml (30 g) of 3-OHB
224111859|NCT05762822|DIETARY_SUPPLEMENT|water|60 ml water (added bitter taste)
224111860|NCT03988816|DRUG|Roflumilast|500Mcg Tab, once daily
224111861|NCT03988816|DRUG|Placebo oral tablet|once daily
224111862|NCT06260176|BEHAVIORAL|exposure to healthy labels only|Green labels only for beverages and foods scored as healthy
224111863|NCT06260176|BEHAVIORAL|exposure to healthiness information|All beverages and foods labeled as either healthy (green), moderately healthy (yellow), or less healthy (red)
224111864|NCT06260176|BEHAVIORAL|exposure to physical activity equivalents|All beverages and foods labeled with physical activity required to burn their calories
223965286|NCT00372476|DRUG|Imatinib and Vinorelbine|
223965287|NCT04413188|OTHER|Warm foot bath|The participants in experimental group were asked to soak their feet in warm water (38-40°C) for 20 minutes one hour before their bedtimes for six weeks. A special foot bath (Beurer FB50 luxury foot bath spa with water heater) was used for this purpose. The bath is 10 cm deep; it keeps water at a constant temperature of 35-48°C for 15-60 minutes, has a display screen for water temperature and duration of use, and turns off automatically.
223965288|NCT03471884|PROCEDURE|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
223965289|NCT03471884|PROCEDURE|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
224111865|NCT06260176|BEHAVIORAL|exposure to sweetened beverage tax messaging|Message reminding consumers to make healthier choices
224111866|NCT02018250|DRUG|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
224111867|NCT02018250|DRUG|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
224111868|NCT00187161|DRUG|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
224111869|NCT02440724|DEVICE|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
224111870|NCT02440724|DEVICE|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
224111871|NCT04199754|DRUG|Omnipaque 300mg/mL Solution for Injection|Prior to the contrast enhanced Cone Beam CT, 100mL of Omnipaque will be administered by IV at a rate of 2mL per second, followed by administration of 50mL of 0.9% saline.
224111872|NCT04199754|RADIATION|Cone Beam CT|60 seconds after contrast administration, a Cone Beam CT will be performed.
224111873|NCT04199754|RADIATION|Radiation Therapy|Standard of Care Radiation Therapy will be administered, dosage depends on the type of tumor being treated.
224111874|NCT04199754|DRUG|0.9% Saline|50 ML of 0.9% Saline will be administered immediately after Omnipaque administration
224111875|NCT05734547|BEHAVIORAL|Stepping Together for Children after Trauma (ST-CT)|ST-CT is Step One of Stepped Care CBT for Children after Trauma (previously called Stepped Care Trauma-focused Cognitive Behavioral Therapy; Salloum et al., 2014). It consists of five components: psychoeducation, stabilization, trauma narrative, in-vivo exposures and consolidation. The parent and child have 11 at-home-meetings and complete tasks in a workbook, Stepping Together (from the Preschool PTSD Treatment by Michael Scheeringa et al), over 6-9 weeks. In addition, there are weekly calls and five sessions with the therapist. Children who meet responder-criteria (i.e., no more than four symptoms of PTSS) continue to a 6-week maintenance phase, after which treatment is complete if the child still meets responder criteria. For those who do not meet responder-criteria, or are not able to complete the workbook, the responsibility for the treatment is transferred from the municipal service level to the corresponding child and adolescent mental health service (BUP).
223965290|NCT01644604|DEVICE|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
224111876|NCT05734547|BEHAVIORAL|Usual care|Therapists in the control group will provide the treatment they usually provide, and develop a treatment plan in collaboration with the parents. This may consist of individual sessions with the child, parent sessions, group treatment, meetings with the school and other collaborating services, or referral to the second line mental health centres (BUP).
224111877|NCT04102839|OTHER|Interview|Qualitative Interview
224111878|NCT01963052|DRUG|AGS15E|intravenous (IV) infusion
223965291|NCT00449254|DRUG|oleoyl-estrone (MP-101)|
224111879|NCT06972160|OTHER|Arm1: intervention 1 (SMS+call)|The intervention will consist in two text messages (one and two weeks after received the screening test, respectively), an automated non-human call or a call made by the administrative assistant (three weeks after received the screening test), and a phone call made by a physician (four weeks after received the screening test)
224111880|NCT06972160|OTHER|Control group|The control group will not be subjected to any interventions to increase the adherence to screening.
224111881|NCT06969742|OTHER|Psycho-education and Psychological intervention_After cancer treatment|"The intervention program consists of Psycho-education and Psychological intervention that includes cognitive behavioral therapy sessions and interventions for patients and caregivers.~It integrates and applies various evidence-based theories; mindfulness theory, solution-focused theory, resilience theory, and family intervention theory.~The intervention is divided into two sessions; core sessions and elective sessions. The after cancer treatment group undergoes 7 core sessions and 3 elective sessions, a total of 10 sessions.~The sessions are conducted 1:1, either face-to-face or remote, and 1 to 2 times a week, approximately 50 minutes per session."
224111882|NCT06969742|OTHER|Psycho-education and Psychological intervention_In cancer treatment|"The intervention program consists of Psycho-education and Psychological intervention that includes cognitive behavioral therapy sessions and interventions for patients and caregivers.~It integrates and applies various evidence-based theories; mindfulness theory, solution-focused theory, resilience theory, and family intervention theory.~The intervention is divided into two sessions; core sessions and elective sessions.~The intervention is divided into two sessions; core sessions and elective sessions. The in cancer treatment group undergoes 4 core sessions and 1 elective session, which is selected out of the given three topics, a total of 5 sessions.~The sessions are conducted 1:1, either face-to-face or remote, and 1 to 2 times a week, approximately 50 minutes per session."
224111883|NCT04471220|DEVICE|High-flow nasal cannula|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
224111884|NCT04010422|DIAGNOSTIC_TEST|no intervention|no intervention
224111885|NCT05191082|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
223965292|NCT05953025|BEHAVIORAL|Questionnaire|No intervention on care- questionnaire to see effect of standard care treatment on symptoms
223965293|NCT05080348|PROCEDURE|Ropivacaine iPACK Injection|Injection of 20mL of 0.25% Ropivacaine with 1:400,000 Epinephrine between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
223965294|NCT05080348|PROCEDURE|Normal Saline iPACK Injection|Injection of 20mL of 0.9% Normal Saline between in the Interspace between the Popliteal Artery and the Capsule of the Knee (iPACK) using ultrasound guidance at the level of the femoral condyles
223965295|NCT04281355|PROCEDURE|Omission of axillary lymph node dissection|Axillary lymph node dissection will be replaced by axillary radiotherapy in Randomisation B
223724721|NCT06149247|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.
223965296|NCT04281355|RADIATION|Omission of regional irradiation|Regional irradiation will be omitted in the interventional arm of Randomisation A.
223965297|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
223965298|NCT00141271|DRUG|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
223965299|NCT00141271|DRUG|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
223965300|NCT00816205|DRUG|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
223724722|NCT06149247|DRUG|Mechlorethamine Topical Gel|Valchlor is an FDA-approved drug for the treatment of CTCL.
223724723|NCT06108739|DRUG|Cyclophosphamid|A total of 10mg/kg ATG was administered, and two doses of 14.5 mg/kg Cy were given on days 3 and 4 post-HCT in ATG-PTCy cohort.
223965301|NCT01249144|DEVICE|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
223965302|NCT00079222|DRUG|itraconazole|
223965303|NCT00079222|DRUG|voriconazole|
223965304|NCT06176131|OTHER|Telemedicine-based cross-sector collaboration for patient management|Telemedicine support from the hospital-based cardiology heart-failure team is provided on demand defined by the needs from Primary Care and from the patient rather than plain guideline-based targets
223965305|NCT03139045|BIOLOGICAL|Venous puncture in elderly patients|Venous puncture in elderly patients
223965306|NCT04623996|DRUG|TP-0184|Oral dose
223965307|NCT05111340|BEHAVIORAL|Perioperative score|Creation and validation of a perioperative walk score. The patient has to answer different items.
223965308|NCT00255242|DRUG|Simvastatin treatment for 28 days|40 mg / day
223965309|NCT04711018|DIAGNOSTIC_TEST|Laryngoscopy|The laryngoscopy is performed with the help of an appropriate size Macintosh blade. The patient's head is held in the sniffing position. External manipulation is not used for improving the view in this investigation.
223965310|NCT00715182|DRUG|TKI258|
223965311|NCT03754166|OTHER|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
223965312|NCT02765867|DRUG|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
223965313|NCT01617889|OTHER|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
223965314|NCT01617889|OTHER|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
223965315|NCT02442622|OTHER|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
223965316|NCT02442622|DEVICE|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
223965317|NCT03430440|DEVICE|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
223965318|NCT03430440|DEVICE|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
223965319|NCT06987500|DRUG|XNW29016|Oral Medication. The study set 7 dose level cohorts in dose escalation part.
223965320|NCT06987500|DRUG|XNW29016|Oral Medication
223965321|NCT05836753|DRUG|Sarecycline Tablet|Each tablet contained 100 mg of Sarecycline.
223965322|NCT05836753|DRUG|Placebo tablets of Sarecycline tablets|Each tablet contained 0 mg of Sarecycline.
223965323|NCT04890158|OTHER|Prone positioning for a total of 6 hours daily|Prone positioning for 6 hours daily
223965324|NCT06993714|PROCEDURE|Breast restoration surgery based on 3D printed degradable biological implants|In the experimental group, the surgeon makes an incision on the skin and creates an electrosurgical free flap with a thickness of approximately 3mm. Based on the tumor size simulated by the computer and combined with real-time exploration during the operation, the tumor is resected. The incision margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the resected specimen. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are excluded from the clinical trial). Corresponding surgical treatment is provided. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The wound is soaked and rinsed, hemostasis is thoroughly achieved, the designed 3D printed filler is implanted, and sutured and fixed. After placing the drainage, the skin is sutured layer by layer. The corresponding operation time is recorde.
223965325|NCT06993714|PROCEDURE|Traditional breast-conserving surgery|In the control group undergoing traditional breast - saving surgery, tumor segment resection is performed according to the clinical routine. The resection margin is more than 1cm away from the tumor boundary. Eight to ten points are selected at equal intervals around the circumferential specimens after resection. Samples are taken and sent for frozen tissue pathological section examination to ensure a negative resection margin. The volume of the resected part during the intraoperative section is replaced by autologous tissue. Axillary lymph node dissection or sentinel lymph node biopsy is routinely performed. The corresponding operation time is recorded.
223965326|NCT06993714|PROCEDURE|Traditional silicone prosthesis breast reconstruction|In the control group of traditional prosthesis reconstruction, subcutaneous gland resection with nipple and areola preservation combined with prosthesis for concurrent breast reconstruction is carried out according to the clinical routine. The incision method is selected by the surgeon. During the operation, the tissue behind the nipple is sent for frozen tissue pathological section examination to ensure a negative incision margin (those with a positive incision margin are considered out of the clinical trial and given corresponding surgical treatment), and the surgeon decides whether to use the patch in combination. The corresponding operation time is recorded.
223965327|NCT06999850|OTHER|Instrumented Stair Climb Test|Instrumented test of climbing and descending stairs for the evaluation of kinematic and electromyographic variables. The test consists of repeating the ascent and descent of a flight of 10-12 steps;
223724724|NCT06108739|DRUG|ATG|A total of 10mg/kg ATG was administered.
224111886|NCT05191082|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
224111887|NCT05191082|DEVICE|Palatal Wound treated with Neurotensin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with neurotensin and 4.0 silk sutures.
224111888|NCT02764840|OTHER|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
224111889|NCT02764840|OTHER|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
224111890|NCT00959244|OTHER|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
224111891|NCT00959244|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
224111892|NCT00959244|OTHER|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
223965328|NCT06999850|OTHER|Walk Test|"Assessment of climbing and walking skills through test series:~Borg scale: An evaluation scale for measuring effort perception. The evaluation scale consists of answering some questions at the end of the exercise described above; 10-metre walk test (10MWT): Test to assess walking speed in metres per second over a short distance. Can be used to determine functional mobility, gait and vestibular function. The test consists of walking at a steady speed and safely for 10 metres; 30 second sit to stand test: test for the evaluation of strength and endurance of the legs in the elderly. The test consists in performing the movement of standing up and sitting down from a chair for 30 consecutive seconds; Timed Up \& Go test (TUG): test to assess the risk of falling and balance. During the test, patients wear normal footwear and may use a walking aid if necessary. The patient starts in a sitting position, gets up on the therapist's command, walks in a straight line for a distance of 3 m"
223965329|NCT06999850|OTHER|Repaeted Instrumented Stair Climb Test|Instrumented test of climbing and descending stairs for the evaluation of kinematic and electromyographic variables. The test consists of repeating the ascent and descent of a flight of 10-12 steps. In this case, the ascent and descent of the stairs must be repeated two times. Between the two trial the IMU units must be repositioned.
223965330|NCT07000305|DRUG|Cetuximabβ combined with Envolimab and mFOLFOX6|Envolimab, 200 mg, sc, day 1; Cetuximabβ 500 mg/m2 IV over 60- 120 min, day 1; chemotherapy mFOLFOX6; with the above regimen every 14 days for 1 treatment cycle. Then patients who did not experience disease progression within 8-12 cycles were entered into maintenance therapy, which consisted of a fluorouracil-based-chemotherapy with Cetuximabβ and Envolimab regimen until progression or unacceptable toxicity.
223965331|NCT07000253|DRUG|Chemotherapy|Chemotherapy preferably CapOx (capecitabine + oxaliplatin) or FOLFOX (5-fluoruracil, leucovorin and oxaliplatin) will be combined with immunotherapy (preferably nivolumab or pembrolizumab) and/or targeted therapy (for example trastuzumab in the case of HER2 overexpression or zolbetuximab in the case of Claudin 18.2 overexpression). These regiments are the standard-of-care (SOC) combination therapies used in this study. Acceptable chemotherapy regimens predominantly for Asian centers include SOX (S-1 and Oxaliplatin).
223965332|NCT07000253|DRUG|Targeted Systemic Therapy|Biomarker selected patients will receive trastuzumab, zolbetuximab or any other targeted agent according to standard of care.
223965333|NCT07000253|DRUG|Immunotherapy|Biomarker selected patients will recieve checkpoint inhibitors according to standard care
223965334|NCT07000253|PROCEDURE|Surgery|If the primary tumor is present, this tumor will be surgically removed. Metastases may also be removed by surgery.
223965335|NCT07000253|RADIATION|Radiotherapy|Metastases may be irradiated
223965336|NCT07002658|PROCEDURE|Harvesting of the saphenous vein graft|"Most existing studies on endoscopic saphenectomy have been conducted in CABG with cardiopulmonary bypass (CBP), whereas most CABG surgeries at the study center are performed without CBP.~The following outcomes will be identified:~* Days of admission or need for hospitalization~* Use of antibiotic therapy for saphenectomy wound infections~* Need for wound dressings due to necrosis and/or wound infection~* Need for analgesic treatment for wound pain"
223965337|NCT07001670|OTHER|Tele-Yoga Training|The Tele-yoga group will participate in real-time yoga sessions three times a week for eight weeks, including individual sessions for the first two weeks and small group sessions for the remaining six weeks, with all sessions supervised by a certified instructor. Each session will last approximately 45-60 minutes and include a 5-10 minute warm-up, 15-20 minutes of yoga postures, 15-20 minutes of yogic breathing exercises, and 5-10 minutes of relaxation and meditation.
223965338|NCT07009392|DIAGNOSTIC_TEST|NGS Analysis|NGS (Next Generation Sequencing) analysis is performed on tissue from ACL
224111893|NCT00959244|OTHER|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
224111894|NCT05110586|OTHER|Electrotherapy|Applications will be applied for 4 weeks, 5 days a week
224111895|NCT01729832|PROCEDURE|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
223965339|NCT07008625|DEVICE|virtual reality glasses|"Experimental Group (Those who applied virtual reality glasses):~1.Stage: The mothers who will be included in the experimental-application group will first be informed about the study and the Informed Volunteer Consent Form will be filled out. Then to mothers (breast milk, methods of milking, etc.) information will be provided about. Before milking, the Personal Information Form, the Status Anxiety Scale, the Inadequate Milk Perception Scale will be applied. After the application of the forms and scales to be used in the study 1.the milking process will be performed (If milking is to be done with a milking machine, the device used will be Babyvacc Model TBM3100.) and the amount of milk milked will be measured (in a plastic 150 ml sized bottle contained in the Milkvacc breast milk milking and storage kit belonging to Ankalaps Company), and attention will be paid to the inclusion of mothers who have never been able to breastfeed for medical reasons in the study.~Mothers in the"
224111896|NCT01729832|PROCEDURE|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
224111897|NCT05321953|OTHER|Standard Physical Therapy Care|Standard physical therapy care. Six to eight, one hour sessions over the course of 4-6 weeks. For individuals with chronic constipation that includes biofeedback therapy, breathing techniques on the toilet, manual therapy to the abdominal wall, and education on toileting posture and favorable lifestyle habits for gut health.
224111898|NCT05321953|OTHER|Aerobic and Inspiratory Muscle Training|The exercise-based 3 times per week for 8 weeks intervention will consist of aerobic interval training and inspiratory muscle training (IMT) for a total duration of 30 minutes. Aerobic-based intervals will be performed at a moderate intensity. Aerobic modes of exercise will include upper extremity ergometer, treadmill, bike, or elliptical.
224111899|NCT06136338|BEHAVIORAL|Mindfulness training|Women in the experimental group underwent four sessions of mindfulness training. The mindfulness training started at the 28th week of pregnancy for the women, the second training was at the 30th week of pregnancy, the third was at the 32nd week of pregnancy, and the last was at the 34th week of pregnancy, with each session lasting 45 minutes.
224111900|NCT04446143|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
224111901|NCT05870501|DRUG|Ketamine|0.5mg/kg IV infusion
224111902|NCT05870501|DRUG|Midazolam|0.045mg/kg IV infusion
224111903|NCT03285880|BEHAVIORAL|Napping|Children nap during the nap opportunity
224111904|NCT06672380|OTHER|Remote Physical Exercise Program for Breast Cancer Survivors|Structured and remotely guided physical exercise program The participants in the intervention group took part in a remote physical exercise program for 12 weeks. The telepresence sessions, conducted three times a week via Google Meet®, lasted 60 minutes and consisted of three phases: warm-up (10 minutes), multi-joint functional exercises (40 minutes) and stretching (10 minutes). The exercises were progressively intensified over the weeks, using the Borg scale to monitor effort. The intensity was adjusted in three cycles: in the first 4 weeks (60 seconds of exercise/90 seconds of rest), in weeks 5 to 8 (75 seconds of exercise/60 seconds of rest) and in weeks 9 to 12 (90 seconds of exercise/30 seconds of rest).
224111905|NCT06672380|OTHER|Initial Consultation and Exercise Guidance via Ebook for Women Surviving Breast Cance|Participants in the Ebook group received an illustrated manual containing detailed guidelines for practicing simple physical exercises at home, using only their body weight. The manual suggested a frequency of 3 to 5 times a week, with 30 to 60 minutes of activities such as stretching, squats and exercises for the upper and lower limbs. The participants were encouraged to follow these guidelines and, 30 days after receiving the ebook, an additional stimulus was sent by text message, reinforcing the importance of following the protocol.
224111906|NCT06672380|OTHER|Initial Incentive for Eating Habits in Women Surviving Breast Cancer|The control group only received general guidance on the importance of regular physical activity. The recommendations followed health guidelines, suggesting between 150 and 300 minutes of moderate-intensity physical activity per week.
223724725|NCT05962697|OTHER|SA controller|Novel controller to be tested
223724726|NCT05962697|OTHER|TA controller|original controller to be tested
223724727|NCT05962697|OTHER|SA controller early testing|Novel controller to be tested early testing
223724728|NCT00017446|DRUG|CP4071|
223724729|NCT02289417|DRUG|Apremilast|
223724730|NCT02289417|DRUG|Placebo|
223724731|NCT01837433|DRUG|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
223724732|NCT01837433|DRUG|Prednisone 6 weeks|Guidelines recommend
223724733|NCT02283385|BEHAVIORAL|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
224111907|NCT01111981|DRUG|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
224111908|NCT03651999|OTHER|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
224111909|NCT03112837|OTHER|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
224111910|NCT02008929|BIOLOGICAL|MG4101|Ex vivo expanded allogeneic NK cell
224111911|NCT05773157|BEHAVIORAL|Online Modules|Participants receive modules to improve responsive feeding practices of caregivers
224111912|NCT02619253|DRUG|Pembrolizumab|
224111913|NCT02619253|DRUG|Vorinostat|
224111914|NCT06970717|DEVICE|M5Stick Programmable watch|This smart watch is fashioned using a M5StickC, an IOT platform which is programmable and allows us to measure specific exercises.
223965340|NCT07008625|BEHAVIORAL|routine care|"1.Stage: The mothers who will be included in the control group will first be informed about the study and the Informed Volunteer Consent Form will be filled out. Then to mothers (breast milk, methods of milking, etc.) information will be provided about. Before milking, the Personal Information Form, the Status Anxiety Scale, the Inadequate Milk Perception Scale will be applied. After the application of the forms and scales to be used in the study, 1.the milking process will be performed (If milking is to be done with a milking machine, the device used will be Babyvacc Model TBM3100.) and the amount of milk milked will be measured (in a plastic 150 ml sized bottle contained in the Milkvacc breast milk milking and storage kit belonging to Ankalaps Company), and attention will be paid to the inclusion of mothers who have never been able to breastfeed for medical reasons in the study.~Mothers in the control group were given 1 during the waiting for the next milking time. and 2. r"
223965341|NCT07008222|COMBINATION_PRODUCT|we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate|Either 3cc of unbuffered lidocaine (control) or 3cc of buffered 1% lidocaine (intervention) will be prepared and administered by the clinician. In a study investigating buffered lidocaine versus unbuffered lidocaine in intrauterine device insertion, investigators prepared 20cc of buffered lidocaine utilizing 18cc of 1% lidocaine (90%) and 2cc of 8.4% sodium bicarbonate (10%). 3 Thus, we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate.
223965342|NCT07008222|OTHER|Unbuffered lidocaine|For the control, 3cc of unbuffered lidocaine will be prepared and administered by the clinician.
223965343|NCT07009652|PROCEDURE|Extracorporeal cardiopulmonary resuscitation (ECPR)|Extracorporeal cardiopulmonary resuscitation (commonly known as ECPR) is a method of cardiopulmonary resuscitation (CPR) that passes the patient's blood through a machine in a process to oxygenate the blood supply.
223965344|NCT07009145|DRUG|QL1706|QL1706 (Iparomlimab and Tuvonralimab) is administered at a dose of 5 mg/kg via intravenous infusion on Day 1 of each 3-week cycle (Q3W).
223965345|NCT07009145|DRUG|Bevacizumab|Bevacizumab is administered at a dose of 7.5 mg/kg every 3 weeks (Q3W) via intravenous (iv) infusion.
223965346|NCT07009613|DIAGNOSTIC_TEST|Parasitological tests|The primary outcome was reported based on the technicians' answers collected with a structured questionnaire. The individuals screened underwent testing with the tests detailed above
223965347|NCT07009613|OTHER|Questionnaire|The primary outcome was based on the technicians' evaluation, based on their answers collected in a questionnaire. The individuals screened were tested with assays used for the national control programmes
223965348|NCT07008196|DRUG|Telitacicept|Telitacicept 160mg qw subcutaneous injection
224111915|NCT06970834|DIETARY_SUPPLEMENT|bitter melon peptides|Momordica charantia extract
224111916|NCT06971471|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
223965349|NCT04344236|DRUG|Saline oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
224111917|NCT06969417|DRUG|Pregabalin|o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
224111918|NCT06969417|DRUG|Lacosamide|o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
224111919|NCT05470790|OTHER|patient reported outcome measures|Activity Rating Scale, Knee Stability in Sports/Cutting-Pivoting Ability scale, Knee Injury and Osteoarthritis Outcome Score, Lysholm Knee Score, and International Knee Documentation Committee Subjective Knee Form.
224111920|NCT00514449|DRUG|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
224111921|NCT00514449|DRUG|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
223965350|NCT04344236|DRUG|0.5% Povidone/Iodine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
223965351|NCT04344236|DRUG|0.12% Chlorhexidine oral/nasal rinse|5 cc of nasal rinses total for both nostrils + 20 cc of oral gargles, 4 times a day, for 7 days.
223965352|NCT07008508|DRUG|Cyclin-dependent Kinase 4/6 Inhibitor|Planned new line of Cyclin-dependent Kinase 4/6 Inhibitor
223965353|NCT07007910|DRUG|HSK46575|co-administered with glucocorticoid and fludrocortisone, orally daily
223965354|NCT07008521|PROCEDURE|Universal exercise unit|universal exercise unit (UEU) for study groip (A)
223965355|NCT07008521|PROCEDURE|Rebound Therapy|rebound therpay for study group (B)
223965356|NCT07008521|PROCEDURE|Traditional physical therapy program|traditional physical therapy program for contrl group
223965357|NCT07009158|DRUG|Ketamine Infusion|Ketamine hydrochloride (DIN: 02246795, 02246796) will be administered over 40-min intravenous (IV) infusion twice per week on non-consecutive days for the first two weeks of study treatment (four treatment sessions in total). We will use a standard dose of 0.5mg/kg which has demonstrated efficacy in safety in individuals with PTSD.
223965358|NCT07009158|BEHAVIORAL|Mindfulness-based cognitive therapy|The Mindfulness-based cognitive therapy (MBCT) will be an 8-week group program adapted from a protocol developed to treat PTSD to include psychoeducation about chronic pain and mutual maintenance factors through which chronic pain and PTSD facilitate each other. The MBCT group will be delivered by trained professionals in weekly 2-hour sessions through Microsoft Teams. The 8-week program will include 1) mindfulness techniques; 2) psychoeducation regarding chronic pain, PTSD and stress responses; 3) psychoeducation on mutual maintenance factors that contribute to negative interactions between pain and PTSD symptoms, 4) promoting mindful awareness of these factors' impact on daily life and 5) feedback and supportive group discussion of exercises. Participants will be asked to complete daily mindfulness exercises between sessions to practice skills learned for a recommended minimum of 20 minutes per day.
224111922|NCT05562570|BEHAVIORAL|Physical activity intervention coupled with standard post-cancer directed treatment care|AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.
224111923|NCT05562570|OTHER|Standard post-cancer directed treatment care control|AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
224111924|NCT04557904|OTHER|Craniocervical flexion exercises|Command the subject to be in crook lying position. Lock their finger to place their finger below the skull and retract the lower jaw and retract chin as far as possible. Subject has to slightly raise his/he skull a few centimeters. Fingers should be touching the cranium but not supporting it. Subject had to respire and hold the position. Subject has the move out the chin. Stop exercise and restart again. Perform this exercise for 10 times by holding this position for 20 sec at the start of the exercise, increasing it by 10 seconds every session commonly underwent pectoralis minor stretching before every session of exercise of 4 sets with 30 second's hold
224291396|NCT04108559|PROCEDURE|Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
223965359|NCT05022472|BEHAVIORAL|COVID-19 Individual Awareness and Education.|The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration \[2-dose series and importance of vaccine completion\]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
223965360|NCT05022472|BEHAVIORAL|COVID-19 Community Outreach & Health Promotion.|Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
223965361|NCT05022472|BEHAVIORAL|COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.|SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
223965362|NCT05022472|BIOLOGICAL|Pop-up community vaccination sites|We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
223965363|NCT06634199|DRUG|Durvalumab|Chemo-radiotherapy + Durvalumab for non-resectable stage III NSCLC patients according to clinical practice of each participant hospital
223965364|NCT06720649|OTHER|isokinetic test|Bilateral strength will be measured using a Contrex ® dynamometer equipped with an exercise table. Each subject will perform isokinetic tests of the right and left knee extensors and flexors. Subjects will be stabilized by straps during testing and the joint rotation axis will be aligned with the input shaft of the dynamometer.
224111925|NCT04557904|OTHER|Scapular stabilization exercises|The scapular stabilization exercises were made up of four stages: (1) In supine position, the patient was commanded to deep respire for the sake of relaxation by maintain the cervical and shoulder in relaxing position to take a deep breath to relax the body while holding her shoulders and neck in relaxing position. (2) The patient then flex her knees and placed her feet flat on the plinth, and maintain the pose without any cervical movement. Then the patient asked to raise her dominant arm to 90° shoulder flexion with full elbow extension and scapular protraction. This position was sustained for 10 seconds before going to initial position. Three laps of 10 repetitions with one-minute interval in between were performed. (3) In quadruped position, the patient raise her arms alternatively with shoulder abduction and 120 ° flexion. That posture was held for 10 seconds before returning to the starting position. (4) In sitting position
223724734|NCT05011565|OTHER|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function|Demographic and Clinical Characteristics, Maximal Exercise Capacity, Submaximal Exercise Capacity, Hemodynamic Parameters, Muscle Strength, Muscle Oxygenation, Vascular Function
223965365|NCT06720649|OTHER|Ballistic test|ballistic squat jumps performed in the supine position on a frictionless sled at a resistance between 0% of body weight (BW)
223965366|NCT06720649|OTHER|K-STARTS test|"The K-STARTS (Knee Health Athletic Return To Sport) test brings together a set of 7 tests validated in the scientific literature to assess the control and neuromuscular capacities of the lower limb when performing dynamic movements as well as apprehension when resuming activity.~Test in 30 minutes with physical exercises and questionnaire."
223724735|NCT04786990|DRUG|SPN-812|Viloxazine extended-release capsule
223965367|NCT06720649|OTHER|Questionnaires|KOOS (Knee Injury and Osteoarthritis Outcome Score) Questionnaire
223965368|NCT06721806|PROCEDURE|PRP & bone regeneration|PRP effect on bone healing
224111926|NCT06971900|DRUG|PORT-77|Active oral dose form
224111927|NCT06971900|DRUG|Placebo|Matching inactive oral dose form
223724736|NCT00714181|DRUG|hydroxychloroquine|
223724737|NCT00714181|DRUG|temozolomide|
223724738|NCT00714181|GENETIC|TdT-mediated dUTP nick end labeling assay|
223724739|NCT00714181|GENETIC|western blotting|
223724740|NCT00714181|OTHER|electron microscopy|
223724741|NCT00714181|OTHER|high performance liquid chromatography|
223724742|NCT00714181|OTHER|immunoenzyme technique|
223724743|NCT00714181|OTHER|immunohistochemistry staining method|
223724744|NCT00714181|OTHER|laboratory biomarker analysis|
223724745|NCT00714181|OTHER|mass spectrometry|
223724746|NCT00714181|OTHER|pharmacological study|
223724747|NCT06446167|OTHER|Exercises|All groups received a regimen of daily exercises, including stretches for the plantar fascia and Achilles tendon, and strengthening exercises for the calf muscles and foot intrinsic muscles. Each type of exercise was demonstrated to the participants by the same physiotherapist at the beginning of the treatment process, to be performed twice a day with 10 repetitions each time.
223724748|NCT06446167|OTHER|MLS Laser Treatment|The MLS Laser applied to the treatment group was administered using an ASA brand Mphi model device. Patients in the Laser group were positioned in a prone position. Treatment was applied continuously for 7 minutes along the plantar fascia, sole of the foot, heel area, and Achilles tendon in accordance with the plantar fasciitis treatment program on the device, at a dose of 1.73 J/cm2 and a frequency of 700 Hz. A treatment program was established with 3 sessions per week, totaling 10 sessions
223724749|NCT06446167|OTHER|ESWT treatment|The treatment group was administered with the Swiss DolorClast Master ESWT device, which produces radial shock waves. Patients in the ESWT group were positioned in a prone position. The most painful point in the heel area was identified through palpation. Gel was applied to this area, followed by the surrounding soft tissues, towards the plantar fascia and the attachment area of the Achilles tendon at the dorsal aspect of the heel. Radial ESWT treatment was applied at a frequency of 10 Hz, pressure of 2.5 bars, and 2000 impulses per session, once a week for a total of 4 sessions
224291397|NCT04108559|OTHER|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
224291398|NCT05418075|OTHER|Psychotherapy|If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
223724750|NCT06347835|DIETARY_SUPPLEMENT|symbiotic|The intervention is made up of multiple probiotics and prebiotics (20g/d) and dietary pattern modification.
223965369|NCT06720129|DEVICE|the modified pressure-reducing fixation protective nasal strip|Materials Preparation consists of one foam dressing, one piece of 3M tape, and two pairs of scissors. 2. Manufacturing Procedure: step 1 Cut the foam dressing into two large rectangles and one little T-shape based on the patient's face shape and size as well as the width of the nasolabial fold. Attach these sections to the nasolabial fold region and both cheeks, respectively . Step 2: Based on the size of the oxygen cannula, set up small, medium, and large fixation patch models. Select the appropriate model according to the patient's condition and make the necessary cuts to properly secure the nasal prongs. Step 3: Check the tightness of the head strap, ensuring it is snug enough to fit one finger beneath it to avoid pressing on the skin around the ears. Ensure proper placement on the patient. See Figure 1 for detailed application.
223965370|NCT06720129|DEVICE|Standard care alone|standard care plus a hydrocolloid dressing for protection
223965371|NCT06703099|DIETARY_SUPPLEMENT|Magnesium Supplementation|Life Extension® Extend Release Magnesium 250 mg/day of oral magnesium in capsule form to be taken once a day at breakfast/morning over 8 weeks.
223965372|NCT06720493|DEVICE|echocardiographic assessment of shocked patients to fluid administration|hemodynamic assessment of pediatric shocked patients using different modalities like echocardiography and electrical cardiometry
223965373|NCT03476538|DRUG|Gabapentin|Patients are tested for their normal prescription gabapentin medication
223965374|NCT04113187|DRUG|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
223965375|NCT04113187|DRUG|Placebo|per os, twice a day (morning and evening) during three months
223965376|NCT03728803|DEVICE|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
223965377|NCT01503437|DRUG|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
223724751|NCT06347835|DIETARY_SUPPLEMENT|whey protein|The intervention is made up of whey protein supplements (20g/d) and dietary pattern modification.
223724752|NCT06347835|DIETARY_SUPPLEMENT|symbiotic placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
223724753|NCT06347835|DIETARY_SUPPLEMENT|whey protein placebo|The intervention is made up of maltodextrin (20g/d) and dietary pattern modification.
223965378|NCT01802892|DRUG|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
223965379|NCT01802892|DRUG|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
223965380|NCT01802892|DRUG|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
223965381|NCT00874484|DRUG|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
223965382|NCT04983225|DRUG|Human Dental Pulp Stem Cells|Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;
223965383|NCT04983225|OTHER|Saline solution|Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
223965384|NCT04826419|OTHER|ozone therapy|The treatment session of oxygen-ozone was 80 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) five times a week for the first week.The treatment session of oxygen-ozone was 40 mg/mL ozone (total volume: 60-100 mL) in a special bag using the ozone generator device (Humazon Promedic, German) twice a week after first week.
223965385|NCT06008106|DRUG|tunlametinib|12mg BID
223965386|NCT06008106|DRUG|paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin|according to investigators' suggestion
223965387|NCT00312364|DRUG|MRE0094|
223965388|NCT03618927|BEHAVIORAL|Daily physical activity intervention|
223965389|NCT00002519|DRUG|chemotherapy|
223965390|NCT00002519|DRUG|paclitaxel|
223965391|NCT00002519|RADIATION|radiation therapy|
223965392|NCT04809298|DEVICE|Free-hand therapeutic CT-guided punction for lumbar pain|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
223965393|NCT04809298|DEVICE|Puncture Cube|Diagnostic or therapeutic CT-guided intervention for lumbar pain management using the Puncture Cube® as a needle navigation device.
223965394|NCT02878590|DEVICE|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
223965395|NCT03945097|BEHAVIORAL|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
223965396|NCT00770640|DRUG|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
223965397|NCT00770640|DRUG|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
223965398|NCT03322514|DIETARY_SUPPLEMENT|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
223965399|NCT03322514|DIETARY_SUPPLEMENT|Inulin|Inulin
223965400|NCT00541840|DRUG|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
223965401|NCT03220659|DEVICE|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
223965402|NCT03220659|DEVICE|Standard settings|Normal bipolar LV pacing
223965403|NCT05017688|PROCEDURE|Blood and stool sample collection|Collection of blood samples (55 mL) Collection of fecal samples (10g)
223965404|NCT06475027|OTHER|TBDESJS|Chinese herbal tea TBDESJS
223965405|NCT06475027|OTHER|Acupuncture|acupuncture GB20 or GB20 plus BL2
223965406|NCT01827449|DEVICE|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
223965407|NCT00317850|DRUG|Gabapentin (Neurontin)|
223965408|NCT04358614|DRUG|Baricitinib 4 MG Oral Tablet|Baricitinib+antiviral therapy administration for 2 weeks
223965409|NCT02016664|DRUG|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
223965410|NCT02475005|BEHAVIORAL|pain self management app on smartphone|
223965411|NCT00675038|PROCEDURE|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2\* MRI
223965412|NCT06127940|RADIATION|Stereotactic body radiation therapy (SBRT)|SBRT is delivered using institutional standard dosing while sotorasib is withheld during radiation.
223965413|NCT06127940|DRUG|Temporary Stopping|Temporary stop of sotorasib during SBRT
223965414|NCT03867552|PROCEDURE|Altered gas (86% CO2, 10% N2O, 4% O2)|Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
223965415|NCT03867552|PROCEDURE|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
223965416|NCT02712307|DRUG|Phenoxymethylpenicillin|
223965417|NCT03583411|OTHER|Epidemiological data collection|To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
223965418|NCT00392704|DRUG|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
223965419|NCT00392704|DRUG|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 \& Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
223965420|NCT00392704|DRUG|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
223965421|NCT00392704|DRUG|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
223965422|NCT00392704|RADIATION|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
223965423|NCT05854121|DIAGNOSTIC_TEST|Functional Electrical Stimulation|Functional Electrical Stimulation for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
223965424|NCT05854121|DIAGNOSTIC_TEST|Constrained Induced Movement Therapy|Constrained Induced Movement Therapy for Motor Recovery and Spasticity in Upper Limb Hemiparetic Chronic Ischemic Stroke Patients
223965425|NCT03292198|OTHER|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
224291399|NCT03293173|COMBINATION_PRODUCT|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
223965426|NCT03292198|OTHER|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
223965427|NCT05098756|OTHER|Art therapy|The art therapy in this study is once a week, 90 minutes each section for a total of 8-week, and using theme-oriented group art therapy. Each section has one theme, and the researcher guides the elderly to make artistic creations. Each section includes a warm-up phase is 15 minutes, the creative phase is 60 minutes, and sharing phase is 15 minutes.
223965428|NCT05992662|BEHAVIORAL|Mindfulness-Based Training Programme in Bariatric Surgey Patients|"ACTION Conducting mindfulness-based 4-session training program Focus group discussion after the training Within the scope of mindfulness-based training: Mindful Eating practices; qigong exercises; meditation exercises; breathing exercises; training specific to the bariatric surgery process was given.~FOLLOW-UP PHASE (3rd MONTH/6.MONTH POSTOPERATIVE)~* Reminder of weekly practices~* Recording changes in mindful eating in participant experience diaries during the follow-up"
223965429|NCT03390270|OTHER|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
223965430|NCT03163836|PROCEDURE|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
223965431|NCT03163836|PROCEDURE|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
223965432|NCT00945178|DRUG|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
223965433|NCT00945178|DRUG|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
223965434|NCT00945178|DRUG|Naproxen|Tablet, single oral dose, 500mg
223965435|NCT00945178|DRUG|Placebo for Naproxen|Tablet, single oral dose
223965436|NCT03158935|DRUG|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
223965437|NCT03158935|DRUG|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
223965438|NCT03158935|PROCEDURE|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
223965439|NCT03158935|BIOLOGICAL|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10\^10 - 1.6x10\^11 cells
223965440|NCT03158935|BIOLOGICAL|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
224111928|NCT02172612|OTHER|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
224111929|NCT05117710|DRUG|Ebselen|Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
223965441|NCT01585818|OTHER|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
223965442|NCT01585818|OTHER|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
223965443|NCT03756025|PROCEDURE|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique \[20\], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
223965444|NCT05033899|OTHER|ERAS protocol|to compare between Enhanced Recovery After Surgery (ERAS) protocol and conventional care in non-insulin dependent diabetic patients undergoing lumbar spine surgery.
224111930|NCT05117710|DRUG|Placebo|Matched placebo capsules
224111931|NCT05761951|DRUG|DKN-01|Given by IV (vein)
224111932|NCT05761951|DRUG|Pembrolizumab|Given by IV (vein)
224111933|NCT05227651|DRUG|AK104|IV infusion,Specified dose on specified days
224111934|NCT04116502|DRUG|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
224111935|NCT04116502|DRUG|Hydroxycarbamide|Via standard hospital mechanisms
224111936|NCT04116502|DRUG|Interferon-Alpha|Any formulation, via standard hospital mechanisms
224111937|NCT04353947|DIAGNOSTIC_TEST|Mini Cognitive Examination (MCE)|This test provides information on temporal and spatial orientation, fixation, concentration and calculation, memory and language and construction.
224111938|NCT04353947|DIAGNOSTIC_TEST|Beck Depression Inventory-II (BDI-II)|This test evaluates the absence or presence of depressive symptoms.
223965445|NCT04680793|OTHER|Rehabilitation|The program takes place over a total period of 9 weeks: for 4 weeks they will be cared for two days a week, then after a week's break, for 4 weeks they will be cared for three days a week for a total of approximately 80 hours of care. The program is multidisciplinary and includes: balneotherapy, ergometry, occupational therapy, gymnastics, physiotherapy, walking, sophrology, yoga as well as different workshops for the therapeutic education of the patient led by several professionals (dieticians, physiotherapists, doctors, psychologists).
223965446|NCT04200404|DRUG|CS1001|One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).
223965447|NCT04200404|DRUG|Regorafenib|One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.
223965448|NCT04467398|PROCEDURE|trigeminal nerve block|Trigeminal nerve or branch block using 22 gauge Quincke or Tuohy needle under fluoroscopic guidance.
223965449|NCT02388932|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223965450|NCT02388932|DEVICE|Positron Emission Tomography|Undergo PET/CT
223965451|NCT02388932|DEVICE|Computed Tomography|Undergo PET/CT
223965452|NCT02388932|OTHER|Quality-of-Life Assessment|Ancillary studies
223965453|NCT05842915|BEHAVIORAL|Questionnaire|Baseline and 3 month questionnaire
223965454|NCT06041178|DRUG|2.5% flurbiprofen|Gel was made of 20% poloxamer and 10% ethanol as an Optimum formulation with sustained release up to 48 hours and a reasonable sol gel transition phase (adjunctive to SRP)
223965455|NCT06041178|DRUG|98% aloe vera|the Aloe vera gel employed possessed a concentration of 98% and was obtained from the reputable brand Avivir (Denmark). The remaining 2% comprised normal saline. The process of obtaining the 98% Aloe vera gel involved meticulous washing of mature Aloe Vera leaves under running water, followed by the removal of their outer skin. Subsequently, each leaf was divided into smaller pieces, from which the gel was allowed to seep out and carefully collected in a sterile container. The collected gel was then stored at 4°C until the time of its application in the study (adjunctive to SRP)
223965456|NCT06041178|OTHER|Placebo|saline
223965457|NCT05054283|DIAGNOSTIC_TEST|Inflamatory biomarkers|laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.
223965458|NCT06442293|DIETARY_SUPPLEMENT|Treatment 1|A dietary supplement containing beet root extract, arginine and citrulline
223965459|NCT06442293|DIETARY_SUPPLEMENT|Treatment 2|A traditional Chinese medicine (TCM)-based dietary supplement containing chrysanthemum extract and eucommia bark extract
223965460|NCT06442293|DIETARY_SUPPLEMENT|Placebo|a placebo supplement that is similar in appearance to treatment 1
223965461|NCT03690336|DRUG|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
223965462|NCT04245878|OTHER|gastric ultrasound|gastric ultrasound for measurement of the antral area
223965463|NCT03194789|DEVICE|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
223965464|NCT03194789|OTHER|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
223965465|NCT05664711|DRUG|Bupivacaine Injection|"Reciprocal unilateral stellate ganglion blocks, separated by at least 16 hours, will be given once per week for three weeks (for a total of 6 blocks).~This study is not intended to be reported to FDA as a well-controlled study in support of a new indication for bupivacaine or to support any other significant change in the labeling for the drug."
223965466|NCT00231517|DRUG|topical opiod|
223965467|NCT00231517|DRUG|morphine sulphate in intrasite gel|
223965468|NCT01828593|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
224111939|NCT04353947|DIAGNOSTIC_TEST|Global Deterioration Scale (GDS)|This scale measures the level of deterioration of the subject.
224111940|NCT04353947|DIAGNOSTIC_TEST|Memory alteration test (M@T)|In this test different memory subtypes are evaluated.
224111941|NCT04353947|DIAGNOSTIC_TEST|Spanish-Complutense Verbal Learning Test (TAVEC)|This test is used to assess immediate memory, deferred memory and learning ability.
223724754|NCT03921671|COMBINATION_PRODUCT|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
223965469|NCT01828593|OTHER|Placebo|Matching placebo
224291400|NCT03293173|COMBINATION_PRODUCT|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
224111942|NCT04353947|DIAGNOSTIC_TEST|Barcelona test (BT)|"This test evaluates categorical evocation and verbal fluency. The categorical recall subtest consists of recalling the maximum number of words linked to a specific category animals in 1 minute. In the case of verbal fluency, the subject is asked to evoke the maximum number of words that begin with the letter p in 3 minutes."
224111943|NCT04353947|DIAGNOSTIC_TEST|Rey-Osterrieth Complex Figure Test (ROCFT)|In this test, the person must carefully copy a complex geometric drawing, which must be memorized later. The first part evaluates multiple cognitive processes such as planning, motor skills, working memory, and visual-constructive and spatial skills. In the second part, memory is evaluated.
223965470|NCT04462497|OTHER|Prototype device|Patients will receive the prototype head and neck support device to be used intraoperatively.
223965471|NCT02411695|DRUG|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
224111944|NCT04353947|DIAGNOSTIC_TEST|Frontal assessment battery (FAB)|This test is a composite tool for assessing executive functions related to the frontal lobe.
224111945|NCT04353947|DIAGNOSTIC_TEST|Positive and Negative Affect Scale (PANAS)|It is a self-report questionnaire made up of 20 items (10 of positive affect and another 10 of negative affect) that the subject must answer, obtaining in this way a score in positive affectivity (AP subscale) and another in negative affectivity (AN subscale).
223542496|NCT04347343|PROCEDURE|Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction|"Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM."
223965472|NCT02028234|DRUG|Pantoprazole,|os, 20 mg, once per day, for 30 days
223965473|NCT02028234|DRUG|Omeprazole|os, 20 mg, once per day, for 30 days
223965474|NCT01580462|OTHER|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
223542497|NCT00495235|BEHAVIORAL|Questionnaire|Questionnaire taking about 20 minutes to complete.
223542498|NCT01284959|DRUG|risperidone|risperidone 3mg, PO, 3 times
223542499|NCT01284959|DRUG|paliperidone ER|paliperidone ER 6mg, PO,3 times
223542500|NCT01284959|DRUG|placebo|lactose PO, 3times
223542501|NCT03924544|DRUG|Decorin|Antifibrotic agent
223542502|NCT03924544|DRUG|Mitomycin c|Antifibrotic agent
223965475|NCT00725036|DRUG|inhaled human insulin|
223965476|NCT00725036|DRUG|insulin aspart|
223965477|NCT00725036|DRUG|insulin NPH|
223965478|NCT03353649|BEHAVIORAL|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
223965479|NCT03353649|DEVICE|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
223965480|NCT06487897|DEVICE|Optimal laser keratoplasty|Laser
223965481|NCT02848885|OTHER|Active TDCS|Participants will receive active tDCS stimulation.
223965482|NCT02848885|OTHER|Sham TDCS|Participants will receive sham tDCS stimulation
223965483|NCT01602003|DRUG|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
223965484|NCT01602003|DRUG|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
223965485|NCT01602003|DRUG|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
223965486|NCT05641155|DEVICE|Focused Multipolar Stimulation (FMS) strategy|Adult cochlear implant recipients receiving different combinations of alternative modes and, sound coding parameters.
223965487|NCT03497143|DRUG|Lamotrigine|Patients are tested for their normal prescription lamotrigine medication
223965488|NCT03460327|DRUG|Candesartan|Patients are tested for their normal prescription candesartan medication
223965489|NCT01823926|OTHER|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
224111946|NCT04353947|DIAGNOSTIC_TEST|Auto-Assessment Manikins (SAM)|It is a self-report questionnaire that assesses the emotional response of the subject, in this case, through a mood induction task that plays different films scenes.
224111947|NCT04916197|DRUG|Dexmedetomidine prolonged sedation|Dexmedetomidine for 24h after patients finished endovascular thrombectomy and returned to ICU.
224111948|NCT04916197|DRUG|0.9% saline|An equal dose of 0.9% saline 24h after patients finished endovascular thrombectomy and returned to ICU.
223542503|NCT03480893|PROCEDURE|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
223724755|NCT05288244|OTHER|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath applied for 2 weeks on insomnia in cancer patients.
223724756|NCT05288244|OTHER|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.|To evaluate the effectiveness of smelling lavender oil applied to cancer patients for 2 weeks on sleep.
223965490|NCT01823926|DEVICE|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
224111949|NCT05564624|OTHER|Fasting mimicking diet (FMD)|The ProLon(TM) Fasting Mimicking Diet regimen is a meal replacement plan that mimics water only fasting. It consists of 100% natural ingredients, which are generally regarded as safe (GRAS). It is comprised of bars, soups, and beverages aiming to achieve consistent and effective short-term calorie restriction, while providing adequate micronutrients. The very low protein and very low sugar content are essential characteristics of the diet. Complex carbohydrates and polyunsaturated fatty acids are its main components.
224111950|NCT03925428|DRUG|Entinostat|Given PO
224111951|NCT03925428|DRUG|Molibresib|Given PO
224111952|NCT01430221|BEHAVIORAL|Mindfulness-based Personalized Health Planning|
224111953|NCT01430221|OTHER|Structured & Guided Education|
223965491|NCT01823926|DEVICE|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
223965492|NCT00155662|BEHAVIORAL|work-hardening program|
223965493|NCT06584643|DIAGNOSTIC_TEST|gasdermin d|evaluation of serum gasdermin d in vitligo patients and healthy controls
223965494|NCT05599516|BIOLOGICAL|LIBP-Rec-Vaccine|Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
223965495|NCT05599516|BIOLOGICAL|BIBP-Rec-Vaccine|Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
223965496|NCT05599516|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
223965497|NCT03087851|DRUG|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
223965498|NCT00468884|DRUG|Increasing doses of GLP-1|
223965499|NCT00468884|DRUG|PYY3-36|
223965500|NCT04764864|PROCEDURE|Angioembolization|"Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials."
223965501|NCT04764864|PROCEDURE|Preperitoneal Pelvic Packing|"Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours."
224111954|NCT05464277|OTHER|Oxygen|Oxygen to achieve assigned SpO2 (or FiO2) targets will be administered to study subjects. The treating clinician can alter oxygenation targets at any time if deemed necessary. The oxygenation goal will be based on SpO2 rather than arterial oxygen saturation (SaO2) or arterial pressure oxygen (PaO2) from arterial blood gases. However, PaO2 can be used instead in situations where the treating clinician considers that peripheral perfusion is poor or SpO2 readings are unreliable. Assigned SpO2 targets will apply to the study subjects for a total duration of 6 hours from intubation or until death or until transfer to the operating theater (whatever comes first).
223965502|NCT03684356|PROCEDURE|socket shield technique|immediate implant placement with buccal part of the root is retained
223965503|NCT03684356|PROCEDURE|xenograft|immediate implant placement with filling the buccal gap with xenograft
223965504|NCT06117345|BEHAVIORAL|PICU Journal|A hard-copy, customizable educational/therapeutic/expressive journal for parents/caregivers to seek information and document their child's PICU experiences and outcomes.
223965505|NCT03687918|OTHER|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~* To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~* To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
224111955|NCT06430255|OTHER|Global Postural Re-education|Program for treatment
223965506|NCT04335695|BEHAVIORAL|Vascular Rehabilitation|Vascular rehabilitation is a supervised exercise therapy program that includes healthy lifestyle changes to help patients gain strength, energy and confidence to return to daily activities. A program of supervised exercise rehabilitation is considered a primary treatment for people with Peripheral Artery Disease and Intermittent Claudication. In addition, patients will be given a wrist-worn activity tracker and be in contact with a research coordinator every 3 months after they are discharged from the Vascular Rehab program.
223965507|NCT02515500|BEHAVIORAL|Gradual Cessation|
223965508|NCT02515500|BEHAVIORAL|Gradual Cessation w/ Quitbit|
223965509|NCT01654445|DRUG|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
223965510|NCT03759132|PROCEDURE|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
223965511|NCT03637621|OTHER|ORIF|open reduction internal fixation of the distal humerus
224111956|NCT06430255|OTHER|Laser-guided Supervised Exercise|Program for treatment
223724757|NCT05288244|OTHER|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.|To evaluate the effect of foot bath and lavender oil applied for 2 weeks on insomnia in cancer patients.
223724758|NCT03035370|BIOLOGICAL|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
224111957|NCT05840705|PROCEDURE|Small curved incision with apex lateral|Small curved incision with apex lateral
223965512|NCT01896921|DRUG|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
223965513|NCT00185783|DRUG|Hydrocortisone Administration (Standard of Care Therapy)|
223965514|NCT05499247|OTHER|SkinQ Glow Bright Wonder Mask|"Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical"
223965515|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (CDT, WDT, CPT, HPT) with the method of limits|The testing will be carried out using the classical method of limits, i.e. a continuous heating/cooling stimulus will be applied to the skin at a rate of 1°C/s, until the subject signals that he/she felt the targeted sensation by pressing a button (Rolke, Baron, et al., 2006). The temperature reached by the time the subject pressed the button will be considered the threshold. Baseline temperature will be set at 32°C. The stimuli will not go lower than 0°C and higher than 50°C.
223965516|NCT04611048|DIAGNOSTIC_TEST|Thermal QST (cold and warm detection, heat pain) with the psi method|The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
223965517|NCT04611048|DIAGNOSTIC_TEST|Neurological examination|A standardized neurological examination will be performed to assess all the items included in the Utah Early Neuropathy Scale (UENS ) (Singleton et al., 2008) and the Toronto Clinical Neuropathy Score (TCNS)(Perkins, Olaleye, Zinman, \& Bril, 2001). This will include: questions about symptoms (presence or absence of foot pain, numbness, tingling, weakness, imbalance and upper limb symptoms); evaluation of knees and ankles deep tendon reflexes; evaluation of pinprick, temperature, light touch, vibration (128 Hz tuning fork) compared to that of an unaffected sites (e.g., sternum); position sensation in the big toes; mapping of pinprick sensitivity in the lower leg; and evaluation of the active extension of the big toes. Pinprick evaluation will be performed using a disposable pin designed for that purpose (Medipin, The United-Kingdom).
223965518|NCT01291043|OTHER|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
223965519|NCT01862614|DRUG|Articaine Hydrochloride + Epinephrine|
223965520|NCT01862614|DRUG|Buffered Articaine Hydrochloride + Epinephrine|
223965521|NCT05811455|OTHER|Aerobic exercises|To compare the effects of aerobic exercise and progressive muscle relaxation exercises on pain and quality of life in premenstrual syndrome
223965522|NCT05811455|OTHER|Progressive muscle relaxation|progressive muscle relaxation exercises.
223965523|NCT01792583|DRUG|Modafinil/armodafinil|
223965524|NCT02062281|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
223965525|NCT02062281|BIOLOGICAL|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
223965526|NCT02062281|BIOLOGICAL|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
223965527|NCT03932422|DIAGNOSTIC_TEST|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
223965528|NCT01319227|PROCEDURE|Hip replacement|Hip arthroplasty with uncemented components
224111958|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
223724759|NCT03035370|BIOLOGICAL|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
223965529|NCT02603861|DRUG|LY3154207|LY3154207 administered orally.
223965530|NCT02603861|DRUG|Placebo|Placebo administered orally.
223965531|NCT02603861|DRUG|Modafinil|Modafinil administered orally.
223965532|NCT00678899|DEVICE|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
223965533|NCT03451292|DRUG|Albutein 20%|Injectable solution
224111959|NCT00735358|PROCEDURE|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
223724760|NCT03035370|BIOLOGICAL|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
223965534|NCT03451292|OTHER|SMT|Participants received SMT according to institution standards for the management of decompensated cirrhosis.
224111960|NCT00145340|DRUG|pioglitazone|30 Mg/day
224111961|NCT05878444|DIETARY_SUPPLEMENT|Probiotic|Resistant gastrointestinal capsules will be provided daily to the participants.
224111962|NCT02894983|OTHER|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
224291401|NCT01330667|DIETARY_SUPPLEMENT|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
223965535|NCT00702338|DRUG|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
223724761|NCT03035370|BIOLOGICAL|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
223965536|NCT00702338|BIOLOGICAL|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
223965537|NCT00702338|BIOLOGICAL|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
223965538|NCT00702338|BIOLOGICAL|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
223965539|NCT05399667|OTHER|Early stimulation|Preterm born children submitted to skin-to skin care (kangaroo care ) plus massage therapy by their mothers. This group received tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
224111963|NCT02894983|OTHER|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
224111964|NCT01914133|DRUG|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
224111965|NCT01914133|DRUG|Placebo|Placebo given prior to meal the standardized meal
224111966|NCT02694029|DEVICE|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
224111967|NCT02694029|DEVICE|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH.
223965540|NCT05399667|OTHER|Conventional care|Preterm born children submitted to skin-to skin care by their mothers (kangaroo care), associated to standard care according to the routine care in the Neonatal Intensive Care Unit (NICU).
224111968|NCT02609893|OTHER|modified directly observed therapy (mDOT)|
223965541|NCT00266305|BEHAVIORAL|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
224111969|NCT02609893|OTHER|unobserved dosing|
224111970|NCT02609893|OTHER|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
224111971|NCT04726267|DEVICE|Wide-field optical coherence tomography|Merged 4 images of wide-field optical coherence tomography, 2 images of vertical scan and 2 images of horizontal scan.
224111972|NCT02680067|DRUG|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
223965542|NCT05206552|OTHER|Questionnaire|Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
223965543|NCT06381297|DIAGNOSTIC_TEST|Hearing test|Hearing and speech tests of MS group and control group in the presence and absence of noise will be evaluated. Suppression test will be performed with OAE test in the presence and absence of noise.
223965544|NCT06381297|DIAGNOSTIC_TEST|Speech in noise discrimination test|Speech discrimination in noise (SDN) test will be performed in a quiet room in accordance with the Industrial Acoustic Company (IAC) standard using the Grason-Stadler GSI 61 Clinical Audiometer. After pure tone audiometry and speech tests, the GKAE test will be performed. The speech in noise discrimination test will be performed with a signal-to-noise (S/N) ratio of +10 dB. A word list at 50 dB SL will be presented to the tested ear using live sound, while simultaneously white noise at 40 dB SL will be presented to the test ear (Beattie et al. 1997). This will be done for both ears. The speech in noise discrimination test scores will be calculated as percentages (%) for both ears.
223965545|NCT06381297|DIAGNOSTIC_TEST|Montreal Cognitive Assessment Scale|Translated into Turkish as the Montreal Cognitive Assessment Scale and abbreviated as MOBID, MOCA assesses attention, executive/managerial functions, memory, visual-spatial skills, language, abstract thinking and arithmetic. It is easy and practical to apply. The score that can be obtained varies between 0-30. The cut-off point for cognitive impairment is 21. Patients who perform below 21 points are considered to have cognitive impairment. Although it is not a battery used in the MS patient group, a study conducted on 39 MS patients and 20 healthy people showed that it can be used safely for screening purposes in patients with MS (Aksoy et al., 2013; Nasreddine et al., 2005; Selekler \& Cangoz, 2009).
223965546|NCT06381297|DIAGNOSTIC_TEST|Symbol Number Modalities Test (SDMT)|Attention, visuospatial information processing speed and working memory are assessed. It is one of the subtests of the Short Repeatable Neuropsychological Battery developed to assess cognitive functions in MS (Smith, 1973).
223965547|NCT05051488|PROCEDURE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
223965548|NCT05051488|DEVICE|Dynamic craniotomy|Dynamic decompressive craniotomy with semi-rigid bone flap fixation
224111973|NCT02680067|DEVICE|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
224111974|NCT00942708|DRUG|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
224111975|NCT02427581|BIOLOGICAL|Personalized synthetic long peptide vaccine (Poly ICLC)|
224111976|NCT02427581|DRUG|Poly ICLC|
223965549|NCT00936364|OTHER|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
223965550|NCT00936364|OTHER|Modified fast|Minimal caloric intake on days -2 and -1
223965551|NCT00936364|OTHER|Fasting|Day -1
223965552|NCT00936364|OTHER|Fasting|Days -2 and -1
223965553|NCT00936364|OTHER|Fasting|Days -3, -2, and -1
223965554|NCT00936364|OTHER|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
223965555|NCT02144116|OTHER|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
223965556|NCT02144116|OTHER|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
223965557|NCT05955222|DEVICE|PEEK|Participants receiving splints produced with CAD/CAM from PEEK blocks,
223965558|NCT05955222|DEVICE|PMMA|Participants receiving splints produced with CAD/CAM from PMMA blocks,
223965559|NCT05955222|DEVICE|Traditional|Participants receiving splints from vacuum forming system
224111977|NCT00943878|BIOLOGICAL|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
224111978|NCT00943878|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
224111979|NCT00943878|DRUG|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
224111980|NCT01426386|DRUG|FE 999049|
224111981|NCT01426386|DRUG|Gonal - F|
223965560|NCT01124656|DRUG|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
223965561|NCT05129592|BEHAVIORAL|Coherent corrective messages|Participants will be randomized to one of four message conditions: condition 1 will not contain either component of the coherence; condition 2 will contain one element of coherence (a causal explanation for why the corrective information is accurate); condition 3 will contain the other element of coherence (an explanation for why the misinformation came to be believed); condition 4 will include both elements of coherence.
223965562|NCT04769219|OTHER|Secondary prevention training|Secondary prevention training will be given after acute myocardial infarction
223965563|NCT05450939|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
223965564|NCT03321175|OTHER|subcutaneous saline irrigation|200 cc saline irrigation
223965565|NCT03003884|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
223965566|NCT03003884|DRUG|Propofol|Initial dose plus supplemental doses as necessary.
223965567|NCT02788305|DRUG|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
223965568|NCT06181019|DRUG|50 mg of mirabegron|Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.
223965569|NCT06181019|COMBINATION_PRODUCT|acupuncture combined with mirabegron.|Patients in the treatment group were treated with acupuncture combined with mirabegron.
223965570|NCT06055478|PROCEDURE|Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block|"Preemptive ultrasound-guided suprascapular nerve block and axillary nerve block using ropivacaine or saline.~Low fixed dose patient controlled analgesia (PCA) were done in the two group."
223965571|NCT02871453|DEVICE|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
224111982|NCT01157858|DRUG|Everolimus|2.5 mg every day orally
224111983|NCT01157858|DRUG|Octreotide LAR|40 mg every 28 days IM
224111984|NCT03940144|DEVICE|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
224111985|NCT01096667|DRUG|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
224111986|NCT01096667|DRUG|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
224111987|NCT01096667|DRUG|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
224111988|NCT01096667|DRUG|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
224111989|NCT01096667|DRUG|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
224111990|NCT01096667|DRUG|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
224111991|NCT01096667|DRUG|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
224111992|NCT03260738|DEVICE|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
224111993|NCT03260738|OTHER|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
224111994|NCT05465681|DRUG|HR20013 for injection；dexamethason|"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"
224111995|NCT00306891|DRUG|Cediranib|45 mg oral dose
223965572|NCT02871453|OTHER|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
223542504|NCT03480893|PROCEDURE|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
223542505|NCT05842486|OTHER|Anti-C5 antibody treatment|Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
223542506|NCT03291106|DIAGNOSTIC_TEST|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
223542507|NCT03291106|DIAGNOSTIC_TEST|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
223965573|NCT04422509|BIOLOGICAL|lanadelumab|single dose, or two doses administered iv
223965574|NCT04422509|OTHER|regular care|no lanadelumab administration, treated according to regular care
223965575|NCT00003541|BIOLOGICAL|filgrastim|
223965576|NCT00003541|DRUG|CHOP regimen|
223965577|NCT00003541|DRUG|carboplatin|
224111996|NCT00306891|DRUG|Cediranib 30 - 90 mg|oral tablet dose escalation
224111997|NCT02657239|BEHAVIORAL|MOVE UP|Weight management behavioral program
224111998|NCT00673673|DRUG|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
224111999|NCT00673673|DRUG|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
223542508|NCT03291106|DIAGNOSTIC_TEST|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
223542509|NCT03291106|DIAGNOSTIC_TEST|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
223542510|NCT04304079|DEVICE|ARssist system|As stated in ARssist system arm description
223965578|NCT00003541|DRUG|cyclophosphamide|
223965579|NCT00003541|DRUG|doxorubicin hydrochloride|
223965580|NCT00003541|DRUG|etoposide|
223965581|NCT00003541|DRUG|ifosfamide|
223965582|NCT00003541|DRUG|prednisone|
223965583|NCT00003541|DRUG|vincristine sulfate|
223965584|NCT00003541|PROCEDURE|peripheral blood stem cell transplantation|
223965585|NCT00003541|RADIATION|radiation therapy|
223965586|NCT01090076|DIETARY_SUPPLEMENT|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
223965587|NCT06963138|DEVICE|Visual Acuity|VA will be measured for near and distance vision with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
223965588|NCT06963138|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
223965589|NCT06963138|DEVICE|Standard Subjective refraction|Standard subjective refraction for distance vision will be performed with Vision-R™
223965590|NCT06963138|DEVICE|Near vision examination and determination of additions|"Near vision examination and determination of additions will be performed with Vision-R™. The following objective and subjective measurement methods will determine the values of the various additions:~1. Determination of addition using the retinoscopy method (Add\_OBJ)~2. Randomization and administration of addition determination tests: FCC; R/G; PRA-NRA"
224112000|NCT02435628|OTHER|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
224112001|NCT03078517|DEVICE|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
224112002|NCT03078517|DEVICE|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
224112003|NCT03672617|OTHER|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
224112004|NCT01224899|PROCEDURE|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
224112005|NCT03156153|DRUG|Bumetanide|bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
224112006|NCT03156153|DRUG|Placebo|placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm
224112007|NCT03224533|DIAGNOSTIC_TEST|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
224112008|NCT04760795|OTHER|PTSD Check List (PCL) scale|PTSD Check List (PCL) scale will be realized to evaluated post-traumatic stress disorder.
224112009|NCT04760795|OTHER|Brief COPE scale|Brief COPE scale dispositional version will be realized to evaluated usual coping strategies. It was assessed during the teleconsultations and post containment.
224112010|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (during containment)|GAD 7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
224112011|NCT04760795|OTHER|Analog scale|Analog scale will be realized to evaluated anxiety during containment. It was assessed during the teleconsultations.
223542511|NCT03627949|BEHAVIORAL|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
223965591|NCT06963138|DEVICE|Binocular vision tests|"The following measurements will be taken in trial glasses equipped with the final addition:~1. Stereoscopic acuity measurement~2. Measurement of the Near Point of Accommodation (PPA)~3. Measurement of the Near Point of Convergence (PPC)~4. Measurement of fusion reserves~5. Measurement of prismatic rock~6. Subjective questionnaire on the different methods used"
223965592|NCT06963138|DEVICE|Extended trial of addition|"The following measurements will be performed using trial glasses equipped with the final addition:~1. Submission of the CISS questionnaire and distance adaptation~2. Initial measurements of accommodative positioning and phorias~3. Completion of three smartphone tasks: reading, memorization, and video viewing~4. Final measurements of accommodative positioning and phorias~5. Submission of the QoL questionnaire regarding visual discomfort during the trial."
223965593|NCT02894385|DRUG|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
223965594|NCT00148499|DRUG|Ambroxol hydrochloride (Mucoangin?)|
223965595|NCT00148499|DRUG|benzocaine|
223965596|NCT00582192|OTHER|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
223965597|NCT01636258|BEHAVIORAL|Stress Management|Every other week
223965598|NCT01636258|BEHAVIORAL|Diet|Every other week
223965599|NCT01636258|BEHAVIORAL|Exercise|Every week
223965600|NCT01636258|BEHAVIORAL|Culinary education|Every other week
223965601|NCT01406171|DRUG|Isavuconazole|oral
223965602|NCT01406171|DRUG|Midazolam|Oral
223965603|NCT01763346|DRUG|Metformin|metformin 1000 mg bid
223965604|NCT01763346|DEVICE|gastric banding|LAP-BAND
223965605|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
223542512|NCT01111227|DRUG|Propofol and isoflurane|Comparison of two anesthetic drugs
223965606|NCT01214499|PROCEDURE|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
223965607|NCT00116584|DRUG|heliox|continuous heliox therapy
223965608|NCT00116584|DRUG|oxygen|continuous oxygen therapy
223965609|NCT05650580|DRUG|TR115|TR115 is supplied as tablet with dosage strength of 100mg. TR115 tablet will be administered orally on a continuous twice daily (BID) schedule and a treatment cycle is defined as 28 days for the purposes of scheduling procedures and evaluations. TR115 tablets will be given until there appears evidence of progressive disease , intolerable toxicity, or the subject discontinues from the study treatment for other reasons. Proposed daily dose (BID): 100mg, 200mg, 400mg, 800mg, 1200mg, 1600mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the Maximum Tolerated Dose (MTD) in order to better understand safety, Pharmacokinetic (PK) or Pharmacodynamic (PD).
223965610|NCT04011995|BEHAVIORAL|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
223965611|NCT04011995|BEHAVIORAL|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
223965612|NCT04011995|BEHAVIORAL|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
223965613|NCT05828602|OTHER|Conventional treatment|Conventional treatment
223965614|NCT05828602|OTHER|TeleRehabilitation|TeleRehabilitation
223965615|NCT01798238|DRUG|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
223965616|NCT01798238|DRUG|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
223965617|NCT02239666|OTHER|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
223965618|NCT02547025|DRUG|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
223965619|NCT02547025|DRUG|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
223965620|NCT02547025|DRUG|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
223965621|NCT03055819|DEVICE|Brow Lift|Minimally Invasive Brow Lift
223965622|NCT00907517|DRUG|MK-8776|IV infusion
223965623|NCT00907517|DRUG|Cytarabine|IV infusion
224112012|NCT04760795|OTHER|GAD-7 (Generalized Anxiety Disorder) scale (post containment)|GAD-7 (Generalized Anxiety Disorder) scale will be realized to evaluated anxiety during post containment.
223965624|NCT01116453|PROCEDURE|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
223965625|NCT01116453|PROCEDURE|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
223965626|NCT06167915|BIOLOGICAL|30μg dose of LYB002V14|30μg dose of LYB002V14 vaccine IM, on day 0
223542513|NCT05843461|OTHER|Pulmonary Index of Microcirculatory Resistance|PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.
223542514|NCT05843461|OTHER|Right Ventricle Index of Microcirculatory Resistance|RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.
223965627|NCT06167915|BIOLOGICAL|60μg dose of LYB002V14|60μg dose of LYB002V14 vaccine IM, on day 0
223965628|NCT06167915|BIOLOGICAL|placebo|placebo IM, on day 0
223965629|NCT03467802|BIOLOGICAL|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
224112013|NCT04760795|OTHER|Big Five Inventory (BFI) scale|Big Five Inventory (BFI) will be realized to evaluated personality.
224112014|NCT04760795|OTHER|Relationship Scales Questionnaire (RSQ)|Relationship Scales Questionnaire (RSQ) will be realized to evaluated attachment style.
224112015|NCT01180725|DIETARY_SUPPLEMENT|Dried Plum|
224112016|NCT01180725|DIETARY_SUPPLEMENT|Metamucil|
224112017|NCT00206518|DRUG|Taxotere/Docetaxel|Taxotere
224112018|NCT00206518|DRUG|Adriamycin/Cytoxan|Adriamycin/Cytoxan
224112019|NCT00206518|DRUG|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
224112020|NCT02083250|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
224112021|NCT02083250|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
224112022|NCT02083250|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224112023|NCT02083250|DRUG|Busulfan|Given IV
224112024|NCT02083250|DRUG|Clofarabine|Given IV
223965630|NCT03467802|DEVICE|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
223965631|NCT02333071|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
223542515|NCT05843461|OTHER|Pulmonary artery OCT|OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.
223542516|NCT00401843|BIOLOGICAL|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
223542517|NCT00401843|DRUG|Bortezomib|Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
223542518|NCT00401843|DRUG|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
223542519|NCT00401843|DRUG|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
223965632|NCT02333071|OTHER|Placebo|Placebo
223965633|NCT04271514|DRUG|RPT193|Antagonist of the CCR4 chemokine receptor
223965634|NCT04271514|DRUG|Placebo|Matching placebo
223965635|NCT01537900|DRUG|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
223965636|NCT02133183|OTHER|Laboratory Biomarker Analysis|Correlative studies
223965637|NCT02133183|OTHER|Pharmacological Study|Correlative studies
223965638|NCT02133183|DRUG|Sapanisertib|Given PO
224112025|NCT02083250|DRUG|Fludarabine Phosphate|Given IV
224112026|NCT02083250|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
224112027|NCT02083250|OTHER|Pharmacological Study|Correlative studies
224112028|NCT02083250|DRUG|Vorinostat|Given PO
224112029|NCT02093975|DEVICE|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
224112030|NCT06180551|DIAGNOSTIC_TEST|DKK-3|DKK-3-Urine measurement
224112031|NCT04705298|DIETARY_SUPPLEMENT|Prebiotic|Oligofructose-enriched inulin. 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
223965639|NCT02133183|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223965640|NCT03800264|DRUG|Bisoprolol|PREVENTIVE DOUBLE BLINDED
223965641|NCT04420897|PROCEDURE|Arterial blood gas samples|Blood gases taken during the operation will be analyzed retrospectively. Whether these results have an effect on graft survival will be examined by reaching their records in the postoperative period.
223965642|NCT05453877|OTHER|No intervention will be applied.|This is an observational study.
223965643|NCT05304884|COMBINATION_PRODUCT|combined oxygen-ozone and corticosteroid|Subacromial injection using Ultrasound
223965644|NCT05164133|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab
223965645|NCT02213224|DRUG|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
223965646|NCT02213224|DRUG|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
223965647|NCT02213224|DRUG|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
223965648|NCT01189318|DRUG|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4\~28 50\~150mg (increments and deduction of 50mg are allowed)
223965649|NCT01498445|DRUG|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
224112032|NCT04705298|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 4 grams daily for ≤ age 6; or 8 grams daily for \>6 years
223965650|NCT01498445|DRUG|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
224112033|NCT01746992|DRUG|Cyclophosphamide 750mg/m2|day 1 in both arms
223965651|NCT01498445|DRUG|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
223965652|NCT02305667|DEVICE|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
224112034|NCT01746992|DRUG|Vincristine 1.4mg/m2|day 1
224112035|NCT01746992|DRUG|Doxorubicin 50mg/m2|day 1
224112036|NCT01746992|DRUG|prednisone 60mg/m2|day1-day5
224112037|NCT01746992|DRUG|ifosfamide 2000mg/m2|day 22-day 24
224112038|NCT01746992|DRUG|pirarubicin 50mg/m2|day 1
224112039|NCT01746992|DRUG|pirarubicin 25mg/m2|day 22
224112040|NCT01746992|DRUG|Etoposide phosphate 100mg/m2|day 22-day 24
224112041|NCT01746992|DRUG|methotrexate 1500mg/m2|day 43
224112042|NCT01558817|BEHAVIORAL|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
224112043|NCT01558817|BEHAVIORAL|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
224112044|NCT06821126|BIOLOGICAL|LVT-001|Intranasal administration
224112045|NCT06821126|BIOLOGICAL|Cormirnaty|Intramuscular administration
224112046|NCT05717738|PROCEDURE|TACE|Procedure of TACE is standardized.
224112047|NCT05717738|DRUG|Lenvatinib|8mg; p.o.; q.d.
223965653|NCT02305667|DEVICE|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
223965654|NCT02305667|DEVICE|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
223965655|NCT02305667|DEVICE|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
223965656|NCT04441073|DRUG|Lignocaine|preoperative nebulization of lignocaine
223965657|NCT04441073|DRUG|Placebo|preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
223965658|NCT01526850|BIOLOGICAL|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
223965659|NCT01526850|DRUG|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
223965660|NCT00183235|DRUG|aripiprazole (up to 15 mg/day) for 8 days|
224112048|NCT05717738|DRUG|Anti-PD-1 monoclonal antibody|Advanced HCC Patients treated with TKI plus anti-PD-1 monoclonal antibody as systemic therapy were recruited. Anti-PD-1 monoclonal antibodies include pembrolizumab (200 mg, q3w), nivolumab (3mg/kg, q2w), camrelizumab (200mg, q2w), tislelizumab (200mg, q3w), sintilimab (200 mg, q3w), or toripalimab (240mg, q3w).
224112049|NCT05717738|DRUG|Bevacizumab Biosimilar IBI305 plus sintilimab|Bevacizumab Biosimilar IBI305 (15mg/kg, q3w), and sintilimab (200 mg, q3w)
224112050|NCT05717738|DRUG|Bevacizumab plus Atezolizumab|Bevacizumab (15mg/kg, q3w) plus Atezolizumab (1200 mg, q3w)
224112051|NCT05717738|DRUG|apatinib plus camrelizumab|Apatinib(250 mg; p.o.; q. d.); camrelizumab (200 mg; iv drip; q2w)
224112052|NCT05717738|DRUG|Sorafenib|400mg; p.o. bid
223542520|NCT03175731|DRUG|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
223965661|NCT06376344|OTHER|myofascial release with tennis ball|Movement of the Tennis Ball on the Sole of the Foot: The tennis ball is moved under the foot by back and forth movements and by applying pressure. The aim is to briefly keep the pressure of the ball on the body and the stress indicated by the massage on.
223965662|NCT02592434|DRUG|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg."
223965663|NCT02592434|OTHER|placebo|matching placebo tablet or solution for tofacitinib
223965664|NCT04479137|DIAGNOSTIC_TEST|PCR for COVID-19|Novel Coronavirus 2019 DNA will be analyzed by PCR in nasopharyngeal swab
223965665|NCT02261519|DRUG|NaBen®|500 mg twice daily (1000 mg total)
223965666|NCT02261519|OTHER|Placebo|0 mg twice daily (0 mg total)
224112053|NCT05717738|DRUG|Donafenib|200mg; p.o. bid
224112054|NCT05717738|DRUG|Regorafenib|160 mg; p.o.; q.d.
224112055|NCT04022369|BEHAVIORAL|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
223542521|NCT03175731|DRUG|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
223542522|NCT04649658|BEHAVIORAL|Prone position|Prone position maintained at least 3 hours/day
223542523|NCT01508910|BIOLOGICAL|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
223542524|NCT01508910|BIOLOGICAL|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
223542525|NCT01508910|OTHER|Standard of care|Standard of care for refractory angina
224112056|NCT03899740|OTHER|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
224112057|NCT03899740|OTHER|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
224112058|NCT03899740|OTHER|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
224112059|NCT03899740|OTHER|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
223965667|NCT06181123|OTHER|Cardiorespiratory Assesments|The following were evaluated to make comparisons between the two groups: Demographic data, clinical characteristics, exercise capacity (6 MWT, 3 min. Step test), functionality (vertical jump test, functional reach test), respiratory parameters (Respiratory muscle strength, pulmonary function test, MMRC scale), physical activity level (IPAQ, short form).
223965668|NCT03597542|OTHER|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
223965669|NCT00291928|DRUG|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
223965670|NCT00291928|DRUG|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
223965671|NCT03992599|PROCEDURE|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
223965672|NCT05382390|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
223965673|NCT05382390|DRUG|Decitabine|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
223965674|NCT00561678|DRUG|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
223965675|NCT00561678|DRUG|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
223965676|NCT00718744|OTHER|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
223965677|NCT03263104|DIETARY_SUPPLEMENT|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
223965678|NCT03263104|DIETARY_SUPPLEMENT|Maltodextrin|
223965679|NCT00840918|DRUG|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
223965680|NCT00840918|OTHER|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
223965681|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHPy|Pyrotinib combined with docetaxel, carboplatin and trastuzumab (TCbHPy) for neoadjuvant therapy of HR+/HER2+ breast cancer
223965682|NCT05430347|COMBINATION_PRODUCT|Neoadjuvant therapy: TCbHP|Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer
223965683|NCT04301609|DIETARY_SUPPLEMENT|Active|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
223965684|NCT04301609|DIETARY_SUPPLEMENT|Placebo|Take 4 capsules daily (2 capsules on an empty stomach + 2 capsules 30 minutes before dinner).
223965685|NCT03635047|BIOLOGICAL|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
223965686|NCT03635047|OTHER|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 10 active and 2 placebo for patients
223965687|NCT04260282|DIAGNOSTIC_TEST|Polymerase Chain Reaction (PCR) for viruses and bacteria in nasal swab|PCR for viruses and bacteria in nasal swab
224112060|NCT02426866|DRUG|Efavirenz|
224112061|NCT03526640|DEVICE|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
224112062|NCT03490786|DRUG|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
223965688|NCT04260282|DIAGNOSTIC_TEST|Induced sputum microbiome|Microbiome in induced sputum
223965689|NCT01938209|OTHER|seated thoracic manipulation|seated general thoracic spine manipulation
223965690|NCT01938209|OTHER|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
223965691|NCT05584709|BIOLOGICAL|STI-6129|Repeated 4-week intravenous infusion cycles of STI-6129 will be given. (one infusion every four weeks).
223965692|NCT04562571|OTHER|Charter & patient information leaflets|Public commitment charter, non-prescription pad, information leaflet in case of antibiotic prescription
223965693|NCT04748445|DIAGNOSTIC_TEST|SARS-CoV-2/Influenza/RSV RT-PCR|nasal swab
223965694|NCT03092323|DRUG|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
223965695|NCT01827202|OTHER|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
223965696|NCT01827202|DRUG|Aliskiren|
223965697|NCT01827202|DRUG|Candesartan|
224112063|NCT03854487|BEHAVIORAL|Mirror therapy|A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
223965698|NCT04745819|BEHAVIORAL|1. The Child Behavior Checklist (CBCL), parent form|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
223965699|NCT01481701|DRUG|Oxaliplatin|85 mg/m² / 14days
223965700|NCT01481701|DRUG|oxaliplatin|oxaliplatin
223965701|NCT00053391|BIOLOGICAL|recombinant CD40-ligand|
223965702|NCT00053391|BIOLOGICAL|therapeutic autologous dendritic cells|
223965703|NCT03779126|DEVICE|Electrical stimulation|1\) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
223965704|NCT05312190|DRUG|ZhenQi BuXue KouFuYe|Zhenqi Buxue Oral Liquid consists of sheep placenta, pearl, red ginseng, wolfberry, astragalus, angelica, coix seed, ginger and jujube. The excipients are protein sugar and sodium benzoate. Nourishes qi and blood. It is suitable for dizziness, pale complexion, fatigue, lack of energy and lazy words caused by insufficient qi and blood.
223965705|NCT05312190|DRUG|Progesterone Capsules|The main ingredient of Progesterone Capsules is abbsolutely progesterone,a kind of hormone,which is the main method of western medicine for the treatment of menstrual disorders
223965706|NCT01106586|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
223965707|NCT01106586|DRUG|ATV|Atazanavir 300 mg capsule administered orally once daily
223965708|NCT01106586|DRUG|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
223965709|NCT01106586|DRUG|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
223965710|NCT01106586|DRUG|Stribild Placebo|Placebo to match Stribild administered orally once daily
224112064|NCT03854487|BEHAVIORAL|Sham mirror|A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
223965711|NCT01106586|DRUG|ATV Placebo|Placebo to match ATV administered orally once daily
223965712|NCT01106586|DRUG|RTV Placebo|Placebo to match RTV administered orally once daily
223965713|NCT01106586|DRUG|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
223965714|NCT05113212|DEVICE|Macular surgery with NGENUITY surgical display system|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon
223965715|NCT05113212|DEVICE|Macular surgery with standard operating microscope|Patient undergoes VR surgery with visualization using standard operating microscope
223965716|NCT01379521|DRUG|everolimus|
224112065|NCT03854487|BEHAVIORAL|Covered mirror|A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
223965717|NCT01379521|DRUG|everolimus placebo|
223965718|NCT02502721|DRUG|DWC20151|
223965719|NCT02502721|DRUG|DWC20152|
223965720|NCT03894280|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
223965721|NCT03894280|DRUG|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
223965722|NCT03894280|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
223965723|NCT00938041|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
223965724|NCT04893902|DEVICE|medit intra oral scanner|ear scanning with intra oral scanner
224112066|NCT00649961|DRUG|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
224112067|NCT02471417|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
224112068|NCT02471417|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
223965725|NCT04464434|PROCEDURE|Upfront autologous HSCT|"HSCT comprises the following consecutive steps:~1. Mobilisation~   * Infusions of CYC 2g/m2 on 1 day.~  * Hyperhydration, alkalinisation of urine and mesna to prevent haemorrhagic cystitis.~  * Filgrastim (G-CSF) 5-10 μg/kg/day subcutaneously for 5 days (or more when necessary).~2. Leukapheresis Prompt start of leukapheresis is required at a CD34+ cell count of ≥10-20/μL. Goal: at least 2 x 10\^6 CD34+ cells per kilogram body weight.~3. Conditioning~   * CYC 50 mg/kg/day intravenously for 4 consecutive days (total 200 mg/kg)~  * Rabbit Antithymocyte Globulin (rbATG), a total dose of 7.5 mg/kg i.v., from Genzyme.~   Hyperhydration, alkalinisation of the urine and mesna will be given to prevent haemorrhagic cystitis.~   I.v. methylprednisolone 2 mg/kg will be administered on the days ATG, to improve tolerability of the ATG.~4. Peripheral stem cell infusion The number of CD34+ cells to be reinfused should be ≥ 2.0 x 10\^6/kg."
224112069|NCT03610412|OTHER|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
224112070|NCT03610412|OTHER|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
224112071|NCT00465738|DRUG|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride \[NaCl\] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
223965726|NCT01714414|DRUG|FZD|
224112072|NCT00467883|DRUG|Liposomal Amphotericin B|high dosage
223965727|NCT01714414|DRUG|3TC|
223965728|NCT01714414|DRUG|EFV|
223965729|NCT01714414|DRUG|AZT|
223965730|NCT01026103|DEVICE|Tri Staple Technology stapler|This is a single arm study.
223965731|NCT00281983|BIOLOGICAL|alemtuzumab|
223965732|NCT00281983|BIOLOGICAL|anti-thymocyte globulin|
223965733|NCT00281983|BIOLOGICAL|filgrastim|
223965734|NCT00281983|BIOLOGICAL|rituximab|
224112073|NCT02792777|OTHER|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
223965735|NCT00281983|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223965736|NCT00281983|DRUG|busulfan|
223965737|NCT00281983|DRUG|cyclophosphamide|
223965738|NCT00281983|DRUG|cyclosporine|
223965739|NCT00281983|DRUG|fludarabine phosphate|
223965740|NCT00281983|DRUG|methotrexate|
223965741|NCT00281983|DRUG|mycophenolate mofetil|
223965742|NCT00281983|PROCEDURE|peripheral blood stem cell transplantation|
223965743|NCT00281983|RADIATION|radiation therapy|
223965744|NCT03103178|OTHER|Quality of life questionnaire|Measurement of quality of life
223965745|NCT06401447|RADIATION|Radiotherapy|Simultaneously optimizing the target, dosage, and synchronized drugs for radiotherapy.
223724762|NCT06175910|PROCEDURE|percutaneous nephrolithotomy|"A 7 Fr ureteric catheter was placed into the ipsilateral ureteric orifice. The patients were then placed in the prone position. Opacification of the pelvicalyceal system was performed. The puncture was done by a 22-guage puncture needle was advanced into the posterior lower calyx under fluoroscopic guidance. After successful access is established, a 0.035-inch curved guide wire was advanced through the puncture needle into the kidney. The central Alkane Rod was passed over the guide wire. Under fluoroscopic guidance serial Amplatz dilators up to 30 Fr were advanced over central Alkane rod and guide wire. Then 30 Fr long Amplatz sheath was advanced over the last dilator.~26 Fr rigid long nephroscope used for stone fragmentation and retrieval. Stone fragmentation was done by pneumatic Swiss Lithoclast. Fragments removal was done using toothed peanut stone retrieval forceps."
223965746|NCT03999697|DRUG|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
223542526|NCT01862406|OTHER|Label|Participants were presented with either a generic label or a brand-name label
223965747|NCT03053908|PROCEDURE|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
223965748|NCT03053908|PROCEDURE|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
223965749|NCT00826527|DRUG|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
223965750|NCT05800483|BEHAVIORAL|Healium|web-based platform to elicit patients' preferences about prostate cancer treatment and designed for low health literature populations
223542527|NCT04878601|OTHER|Home-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and ART initiation with a 30-day supply. Monthly home-based ART follow-up visits with male-specific messaging and 30-day supply distribution will take place for 3-months. At 4-months providers will provide assisted linkage to a nearby facility to join the facility-based ART program. Additional counseling will be provided.
223965751|NCT05202327|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient.
223965752|NCT05202327|DRUG|Placebo|The placebo contained corn starch.
223965753|NCT05876364|BIOLOGICAL|QTP104 1ug|Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
223965754|NCT05876364|BIOLOGICAL|QTP104 5ug|Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
223965755|NCT05876364|BIOLOGICAL|QTP104 25ug|Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
223965756|NCT00495261|BEHAVIORAL|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
223965757|NCT00495261|BEHAVIORAL|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
223965758|NCT01014663|BEHAVIORAL|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
223965759|NCT01014663|BEHAVIORAL|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
223965760|NCT02578667|DEVICE|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
223965761|NCT00428441|DRUG|Warfarin|tablets, based on INR levels, according to D-dimer levels
223965762|NCT01504919|BEHAVIORAL|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
223965763|NCT01504919|BEHAVIORAL|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
223965764|NCT01504919|BEHAVIORAL|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
223724763|NCT06175910|PROCEDURE|retrograde intrarenal surgery|"urethrocystoscopy was carried out then inserting of a 7F open ended ureteral catheter over the 0.035-inch straight floppy tip guide wire in the working channel of the 22Fr cystoscope under fluoroscopic guidance, access to the ureter was made.~Teflon ureteric dilators are used to dilate the distal ureter till 14 FR. ureteral access sheath placement 12 or 14 Fr. OTU, a disposable digital flexible ureteroscope, is then used then the tip of a 272 m holmium laser fiber is placed on the surface of the stone for fragmentation.~Intra renal lithotripsy was carried out using a 30 W Holmium: YAG laser (Sphinx Jr.) via a 272 m silica quartz laser fiber. 1.9 Fr tipless nitinol baskets were finally used to remove the large fragments. A Double-J (6 Fr) stent is generally applied at the end of the procedure, and a urethral catheter was applied."
223965765|NCT01504919|DRUG|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
223965766|NCT04360642|OTHER|singing|Singing for Wellness will use an uncontrolled observational study design. Two mixed-cohort, 12-week community choirs will be delivered by experienced vocal practitioners in South Devon localities:
223965767|NCT06123819|DEVICE|elastography|. First, strain elastography (it is based upon the fact that hard tissue is more difficulty compressed than soft tissue. SE is a technique that measures the tissue deformation generated by compression, which may be applied with a probe on the body surface for static imaging) will be performed. The elastogram image of the detected lesion, will be evaluated Using color coding ranging from blue, through green and red. All lesions will be scored on elastogram in terms of their Stiffness compared to normal parenchyma. Second, shear wave elastography (is a method to generate shear waves and measure SWV ,based on the principle of fast propagation of shear wave speed in hard tissue and slow propagation in soft tissue , the hardness of tissue is indirectly reflected by measuring shear wave speed ) , will also be calculated individually.
223965768|NCT02475733|DRUG|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
223965769|NCT02475733|DRUG|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
223965770|NCT02475733|DRUG|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
224112074|NCT02792777|OTHER|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
223965771|NCT00404547|DRUG|Ciclesonide|Asthma Care with Alvesco
224112075|NCT02729129|OTHER|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
224112076|NCT02729129|OTHER|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
224112077|NCT04205422|PROCEDURE|BIPAP|Biphasic Intermittent Positive Airway Pressure
224112078|NCT04205422|PROCEDURE|APRV|Airway Pressure Release Ventilation
224112079|NCT03614624|DEVICE|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
224112080|NCT03619785|DRUG|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
224112081|NCT03619785|DRUG|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
224112082|NCT05960955|DRUG|Cadonilimab|IV infusion,Specified dose on specified days
224112083|NCT05960955|DRUG|AK117|IV infusion,Specified dose on specified days
223542528|NCT04878601|OTHER|Facility-Based ART|Healthcare provider will ask ART client for permission to conduct a home visit with their HIV+ partner. Providers will conduct a home visit with HIV+ partners to provide confirmatory HIV testing and assisted linkage to a nearby facility for facility-based ART initiation and continuation. Male clients will receive a 30-day supply each visit and return monthly.
223542529|NCT06373666|DEVICE|Spatz4 Adjustable Balloon System|Implantation of Spatz4 Adjustable Balloon system for weight loss treatment for Overweight and Obese patients and Adjustment of the balloon volume at week 16
224112084|NCT05960955|DRUG|Oxaliplatin|IV infusion,Specified dose on specified days
223542530|NCT04846335|DRUG|Doxycycline Hcl|tablets of DOXY hydrocloride (Bassado)
223542531|NCT04846335|DRUG|Placebo|tablets of placebo
223542532|NCT02358993|DRUG|methenamine hippurate|A urinary antiseptic used for prevention of UTI
223542533|NCT02358993|DRUG|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
223542534|NCT04963023|OTHER|Physical examinations|BPCO physical examinations
223542535|NCT04963023|DIAGNOSTIC_TEST|blood test|blood test in order to study immunologic markers
223542536|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
223965772|NCT00404547|DRUG|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
223965773|NCT00094497|DRUG|Etoposide|
223965774|NCT00094497|DRUG|Doxorubicin|
223965775|NCT00094497|DRUG|Cisplatin|
223965776|NCT00094497|DRUG|Streptozotocin|
223965777|NCT00094497|DRUG|Mitotane|
223965778|NCT00880152|BEHAVIORAL|Mindfulness-based stress reduction|An 8-week course in mindfulness training
224112085|NCT05960955|DRUG|Tegafur-gimeracil-oteracil potassium|Oral,Specified dose on specified days
223542537|NCT00613184|DEVICE|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
223965779|NCT00917631|PROCEDURE|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
223965780|NCT03735641|PROCEDURE|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
223965781|NCT05143437|BEHAVIORAL|Love Together Parent Together|A brief, low-intensity writing intervention adapted for parents of young children, designed to reduce conflict-related distress, prevent relationship deterioration and encourage the use of conflict reappraisal strategies designed to reduce conflict-related distress, etc.
223965782|NCT06480851|PROCEDURE|Ecoguided Percutaneous Neuromodulation|Ecoguided Percutaneous Neuromodulation over the posterior branch of the cervical multifidus, for 10 minutes, with a frequency of 10 HZ.
223965783|NCT05262218|DRUG|PBF-680 10mg|PBF-680 10mg administered orally once a day
223965784|NCT05262218|DRUG|Placebo|Placebo administered orally once a day
223965785|NCT03047278|PROCEDURE|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
223965786|NCT03047278|PROCEDURE|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
223965787|NCT03047278|DRUG|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
223965788|NCT03047278|DRUG|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
224112086|NCT05960955|DRUG|Docetaxel|IV infusion,Specified dose on specified days
224112087|NCT05960955|DRUG|5-Fluorouracil|IV infusion,Specified dose on specified days
224112088|NCT02648815|PROCEDURE|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
224112089|NCT02648815|PROCEDURE|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
224112090|NCT03636412|OTHER|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
224112091|NCT00315601|DRUG|Telithromycin|800 mg once a day for 5 days
224112092|NCT00315601|DRUG|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
224112093|NCT00315601|PROCEDURE|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
223542538|NCT04415554|DIAGNOSTIC_TEST|echocardiography|echocardiography exam of the infant
223965789|NCT04147091|OTHER|ApaCare & Repair|Initial cariuos lesions were treated.
223965790|NCT01249599|PROCEDURE|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
223965791|NCT00452985|DRUG|Docetaxel|60-75 mg/m²
223965792|NCT00452985|DRUG|Carboplatin|AUC 5
223965793|NCT04427397|OTHER|Sulcular Bristle Tip Technique (SBTT)|Tooth brushing should begin on the distal of the most posterior tooth on one side of the mouth and proceed anteriorly and then posteriorly overlapping areas to the most distal surface of the most posterior tooth on the contra lateral side. The lingual is done in like fashion ending where the brushing began. The opposing arch is brushed in the same manner. When moving from one area to the next, disengage the brush bristles entirely off the teeth to allow them to straighten, and then reposition the brush in the next overlapping area. Do not to drag the bristle tips from one area to the next area. For the lingual of the anterior teeth, the narrow portion of the brush is used with the exact same technique as described above. For the lingual of the mandibular molars, the angulation of the toothbrush bristles to the tooth needs to be somewhat more perpendicular to the tooth than on the buccal to ensure that the bristle tips enter the gingival crevice.
223965794|NCT00411177|PROCEDURE|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
223965795|NCT00411177|PROCEDURE|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
223965796|NCT04171258|DRUG|Botulinum toxin type A injection|Experimental
223965797|NCT04171258|DRUG|Botulinum Toxin Type A Injection [Botox]|Active Comparator
223965798|NCT03556540|OTHER|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
223965799|NCT02411253|DRUG|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
223965800|NCT02411253|DRUG|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
223965801|NCT04075097|BEHAVIORAL|Aerobic exercise|1 session
223965802|NCT04075097|BEHAVIORAL|Iyengar yoga|1 session
223965803|NCT06214754|PROCEDURE|PCI|The subjects underwent immediate coronary angiography after Percutaneous transluminal coronary angioplasty to evaluate the success rate of instruments, and immediate coronary angiography after PCI to evaluate the success rate of clinical treatment
223965804|NCT05574244|PROCEDURE|Partial surgery preserving the prostatic apex|Partial Endoscopic resection of prostate to conserve apex
224112094|NCT00315601|DRUG|Telithromycin|Telithromycin 800 mg once a day
223965805|NCT05574244|PROCEDURE|Conventional endoscopic prostatic surgery|Endoscopic resection of prostate.
223965806|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in plasma|
223965807|NCT02172937|BIOLOGICAL|Decidual Stromal Cells thawed in human albumin|
223965808|NCT06207084|BEHAVIORAL|asynchronous content only|Receives asynchronous exercise content and no live training
223965809|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and no live training|Receives asynchronous content, health coaching and no live training.
223965810|NCT06207084|BEHAVIORAL|asynchronous content only and 1 on 1 live training|receives asynchronous content and live 1 on 1 training
223965811|NCT06207084|BEHAVIORAL|asynchronous content and health coaching and 1 on 1 training|receives asynchronous content, health coaching, and live training
223965812|NCT06207084|BEHAVIORAL|asynchronous content and group training|receives asynchronous content and live group training
223965813|NCT06207084|BEHAVIORAL|Asynchronous content and health coaching and group training|receives asynchronous content, health coaching, and live group training
223965814|NCT01973478|DEVICE|DBS|
223965815|NCT01973478|DEVICE|SHAM|
223965816|NCT02416297|PROCEDURE|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
223965817|NCT03955341|DEVICE|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
224112095|NCT00385086|DRUG|TNF blocker|Treatment with TNF-alpha blocker
224112096|NCT00385086|DRUG|Placebo|Treatment with placebo
224112097|NCT04151004|OTHER|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
224112098|NCT04151004|OTHER|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
224112099|NCT04151004|OTHER|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
224112100|NCT04151004|OTHER|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
223965818|NCT03955341|OTHER|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
223965819|NCT03803488|DEVICE|DropSafe safety pen needle|
223965820|NCT06207747|DIAGNOSTIC_TEST|additional PET/CT at 4 weeks, analysing using quantative analysis|Patient with metastatic melanoma will be monitored with additional PET/CT at 4 weeks, analysing using quantative analysis will be done.
223965821|NCT03906240|BEHAVIORAL|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
223965822|NCT02080117|PROCEDURE|kidney transplantation, living or deceased donor|
223965823|NCT06292247|BEHAVIORAL|Cognitive behavioral therapy|CBT aims to treat anxiety by restructuring unfavorable beliefs and controlling negative thoughts so as to reduce dental anxiety.
223965824|NCT06292247|BEHAVIORAL|Auricular plaster therapy|APT involves the application of plaster with seeds on specific points of the outer ear, known as auricular points (acupoints). This process is believed to restore balance and harmony within the body's system and achieve a therapeutic effect (e.g. reduce anxiety)
223965825|NCT06292247|BEHAVIORAL|Tell Show Do|TSD is composed of 3 phases. The Tell phase involves an age-appropriate explanation of the procedure. The Show phase is used to demonstrate a procedure up to the point where the instrument is performed. The Do phase is then initiated, and the treatment is performed.
223965826|NCT05223452|DEVICE|UltraSound|we use prob that admit some of radiation to patient to see the organs inside the abdomen
223965827|NCT03219788|DRUG|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
223542539|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2|
223965828|NCT03219788|DRUG|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
223965829|NCT03219788|DRUG|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
223965830|NCT03152409|DRUG|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
223965831|NCT03152409|DRUG|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
223965832|NCT01918943|DEVICE|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
223965833|NCT04737499|BEHAVIORAL|CASCADe|Culturally tailored diabetes self-management and education sessions with mHealth integration
223965834|NCT05085015|OTHER|Functional Exercise Training Group|"Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. The training will be given on the treadmill Treadmill Technogym. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end."
223965835|NCT05085015|OTHER|Home Exercise Training Group|Training will start with Stretching Training and end with stretching training. Stretching exercises targeting actively applied shoulder girdle, chest, neck, trunk, hip, front and back leg and ankle muscle groups will be given. Afterwards, it will be continued with Aerobic Exercise Training. They will walk at least 30 minutes, 3 days a week for 8 weeks at outdoor. Afterwards, it will be continued with Strengthening Training. Strength training will consist of a strengthening program that includes the lower extremity, upper extremity, trunk and core region. Elastic bands will be used in the training. Then, balance training will be given at the end.
223965836|NCT04520620|DRUG|Lovenox 40 MG in 0.4 mL Prefilled Syringe|"Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours"
223965837|NCT04520620|DEVICE|Ultrasound of the lower limbs|A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
224112101|NCT04151004|OTHER|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
224112102|NCT04251312|OTHER|Oral Hygiene Education and Oral Hygiene Packets|Patients will be educated on oral hygiene and will be given packets containing toothpaste, mouth rinse, floss and a toothbrush
224112103|NCT05376202|DRUG|Cetuximab-IRDye800CW|Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
224112104|NCT01347684|BEHAVIORAL|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
223542540|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2|
223542541|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2|
223542542|NCT02422979|COMBINATION_PRODUCT|PIT: 75 J/cm^2 for superficial lesions or 150 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
223965838|NCT01745445|OTHER|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
223965839|NCT04405089|DEVICE|Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.
223965840|NCT04405089|DEVICE|Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
223965841|NCT02217098|PROCEDURE|GIC Restorations|Restorations using Glass Ionomer Cement
223965842|NCT02217098|PROCEDURE|Carbomer Restorations|Restorations using Glass Carbomer
223965843|NCT02217098|PROCEDURE|Compomer Restorations|Restorations using Compomer
223965844|NCT00412802|DRUG|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
223965845|NCT00412802|DRUG|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
223965846|NCT01384916|BEHAVIORAL|Yoga|2x weekly
223965847|NCT01384916|BEHAVIORAL|Healthy Living Workshop|2x weekly
224112105|NCT01347684|DRUG|Standard care using current drugs|Standard Drug therapy
224112106|NCT00472927|DRUG|Premarin/MPA 0.45 mg/1.5 mg|
224112107|NCT01319760|DEVICE|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
224112108|NCT01319760|OTHER|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
224112109|NCT04534894|DIAGNOSTIC_TEST|fluorescence lifetime imaging microscopy|collect 2mL of venous blood and use fluorescence lifetime imaging microscopy to exam NADH fluorescence characteristics of it
223542543|NCT02422979|COMBINATION_PRODUCT|PIT: 100 J/cm^2 for superficial lesions or 200 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
223965848|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Naive-patients|Duration of treatment : 1 month Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, Cognitive behavioral therapy(CBT), Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
224112110|NCT01236222|BEHAVIORAL|Cycling to school|Regular cycling to school
224112111|NCT02616822|DIETARY_SUPPLEMENT|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
224112112|NCT02616822|OTHER|Placebo|Used for placebo substance single dose
223965849|NCT04787692|BEHAVIORAL|Opioid and Benzodiazepine Tolerant-patients|Duration of treatment : 6 months Lucid Lane is a service that will be used by patients scheduled for elective orthopedic or neurosurgical spine surgery that will incorporate continuous MEASUREMENT \& MONITORING, PERSONALIZED TREATMENT PLANNING and REAL-TIME INTERVENTIONS (MPI) as the patient is tapering off of opioids and/or benzodiazepines. Patients will participate in the Lucid Lane program.Daily support will include 1 or more from the following: Therapist chat, and/or audio psychotherapy sessions, and/or group therapy sessions, CBT, Mindfulness, and/or peer support. Patients will submit a weekly survey and the therapist will submit weekly reports to the physician.
224112113|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
224112114|NCT00515463|BIOLOGICAL|denosumab|60 mg denosumab in 1mL
224112115|NCT01081210|OTHER|Ultrasound examination|Screening with bedside ultrasound examination
224112116|NCT05045755|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
224112117|NCT05242588|BIOLOGICAL|JS005|30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
224112118|NCT05242588|BIOLOGICAL|Placebo|10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).
224112119|NCT06667440|OTHER|Cryotherapy|Women in the intervention group will apply cryotherapy on their hypogastrium with a coldpack
224112120|NCT03074305|DEVICE|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~1. DEB strategy~2. DES strategy"
224112121|NCT06672393|DRUG|HS-10374 6mg tablets|Specified dose of HS-10374 tablets administered orally QD on specified days
224112122|NCT06672393|DRUG|HS-10374-matched placebo tablets|Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
223965850|NCT00764855|PROCEDURE|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
223965851|NCT05289778|OTHER|Survey|Students will complete structured questionnaires in classroom settings, and parents will complete telephone interviews in the absence of their children.
223965852|NCT06645990|DEVICE|Impella|LV unloading with Impella (ECMELLA) before or within 24 h of ECMO initiation
223965853|NCT06645990|DEVICE|IABP|LV unloading with IABP before or within 24 h of ECMO initiation
223965854|NCT06647355|OTHER|Effectiveness of physical exercise in preventing pain and improving plantar pressure distribution|At the beginning of the study, the participants underwent a baropodometric and photometric analysis. At the same time, anthropometric data and self-assessed body pain data were collected. For 12 continuous weeks, the participants completed a training programme that included specific exercises designed for each group. At the end, the baropodometry images were analysed again, which led to the final conclusion of the study.
223965855|NCT06647108|DIETARY_SUPPLEMENT|Food Supplement|The composition of the dietary supplement is the following (for 1 sachet): 450 mg glucomannan, 250 mg white mulberry dry extract (d.e.), 200 mg gymnema (d.e.), 200 mg olive (d.e.), 200 mg Cassia nomame (d.e.), 200 mg Nopal, 5 mg policosanols and 20 µg chromium
224291402|NCT01612416|DEVICE|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
224291403|NCT06420414|OTHER|Virtual Reality|"Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance."
223542544|NCT02422979|COMBINATION_PRODUCT|PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640mg/m^2|
223965856|NCT06647108|OTHER|Placebo|Placebo
223965857|NCT06646367|OTHER|Conventional therapy|All participants in the two groups will receive conventional therapy in the form of TENS and moist heat for 5 weeks.TENS will be applied 5 times a week for 5 weeks at a frequency of 80Hz with 10- to 30-mA intensity for 25 minutes. Four surface electrodes (5x5 cm each) were situated over the painful region in the neck (two electrodes will be placed in either side of the spine high on neck, just underneath the skull and the other two electrodes will be placed about 5cm underneath them) with intensity in the tactile sensation threshold. The hot packs will be applied for 30 minutes on the cervical area, 5 times per week for 5 weeks.
223965858|NCT06646367|OTHER|Alexander technique|Women in the experimental group will attend 10 Alexander Technique classes (60 minutes each, twice a week for 5 weeks). The Alexander Technique focuses on body awareness, reducing muscle tension, and improving coordination through three principles: enhanced awareness, purposeful inhibition, and mental imagery. Participants will learn to release habitual muscle tension and explore alternative movement patterns, covering biomechanics and ergonomics of the neck, spine, and limbs. The sessions involve hands-on guidance, verbal instruction, and group activities. Daily practice in a semi-supine position is encouraged to improve posture, coordination, and overall well-being.
223965859|NCT03751280|DEVICE|PEAR-004|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
223965860|NCT03751280|DEVICE|Sham|PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
223965861|NCT01112163|DEVICE|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
223965862|NCT05165303|DRUG|lidocaine with propofol|different concentrations of lidocaine added to propofol varying from
223965863|NCT02468037|PROCEDURE|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
223965864|NCT03158519|BEHAVIORAL|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
223965865|NCT03245996|DEVICE|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
223965866|NCT03245996|DEVICE|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
223965867|NCT03245996|DEVICE|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
223965868|NCT03245996|DRUG|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
223965869|NCT03245996|DRUG|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
223965870|NCT03245996|DRUG|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
223965871|NCT06646744|BIOLOGICAL|mRNA COVID-19 vaccine|Children will be vaccinated according to standard local procedure
223542545|NCT03844308|BEHAVIORAL|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
223542546|NCT01203709|DRUG|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
223542547|NCT00761345|DRUG|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
223542548|NCT00761345|DRUG|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
223965872|NCT06647368|OTHER|PET with 18-FDG|The intervention is a 1,5 hour PET scan, which will be performed in three steps (heart scan, brain scan and heart scan) and administration of radioactively labelled glucose (18-FDG) in two doses.
223965873|NCT05741866|DEVICE|Chlorhexidine gluconate impregnated bordered polyurethane dressing|"PIVCs will be dressed and secured at the participating sites~* RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing.~* QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
223965874|NCT05741866|DEVICE|Standard bordered polyurethane dressing|"PIVCs will be dressed and secured as per standard practice at the participating sites~* RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing.~* QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference."
223965875|NCT00194961|DRUG|Recombinant Human Growth Hormone|
223965876|NCT05680415|BIOLOGICAL|Mycobacterium Vaccae for Injection|The experimental group was alternately injected with 1 dose of microcard every two weeks (0-2-4-6-8-10 weeks) in the left and right hip muscle deep, and a total of 6 doses were injected.
223965877|NCT05823051|OTHER|VASIDS-TP and Counseling Practice|VASIDS-TP will be implemented online as an individual training to the intervention group through the Microsoft Teams program, to be completed in 5 days-5 sessions in the time frames determined by the participants. The consultancy practice will start with a pre-test and participants will be assured that they can call the researcher 24/7, and the consultancy practice will be continued by phone call or messaging.
223965878|NCT03287947|DRUG|nintedanib|Oral nintedanib, taken twice daily
223965879|NCT04609579|DRUG|SNX281|SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
223965880|NCT04609579|DRUG|pembrolizumab|pembrolizumab (KEYTRUDA®) will be administered as an intravenous infusion on Day 8 in Cycle 1 (28-day cycle) and on Day 1 of each 21-day cycle thereafter for up to 6 cycles, or until disease progression or unacceptable toxicity occurs.
223965881|NCT02536729|DRUG|Oral Sodium Phosphate - Normal preparation|
223965882|NCT02536729|DRUG|Oral sodium phosphate - Modified Preparation|
223965883|NCT02536729|DRUG|polyethylene glycol + Electrolytes|
223965884|NCT01973296|BEHAVIORAL|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
223965885|NCT01973296|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
223965886|NCT05797116|OTHER|Survey|29-item Dutch survey about the implementation and practice variation of preoperative multidisciplinary team (MDT) meetings for high risk noncardiac surgical patients in the Netherlands.
223965887|NCT03556345|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
223965888|NCT04074304|OTHER|I-HoME|A multi-component technology-based care intervention.
223542549|NCT00761345|RADIATION|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
223965889|NCT01436604|OTHER|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~* Sequences locating anatomical~* T2 black blood (such as ESF)~* rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~* T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
223965890|NCT00296504|DRUG|fosamprenavir (GW433908)|
223965891|NCT00296504|DRUG|ritonavir|
223965892|NCT01391533|DRUG|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
223965893|NCT03606863|DRUG|Perioperative peripheral parenteral nutrition|
223965894|NCT04241380|DRUG|Anticoagulant Solutions|Patients in this group will received continuous infusion heparin 6 hours postoperatively (initial dose 10 iu/kg/h, dynamic regulation according to ACT 160-180s). After the removal of deep vein catheter, aspirin 5 mg/kg will be given every eight hours subsequently for 3 months.
223965895|NCT04241380|OTHER|No anticoagulant solutions|They will receive non-coagulant or coagulant treatment according to clinical conditions.
223965896|NCT04241380|DRUG|Anticoagulant management|"Continuous infusion heparin (initial dose 10 iu/kg/h and dynamic regulation until the activated coagulation time (ACT) 160-180 s) for a few days.~Aspirin 5 mg/kg will be given every eight hours subsequently for 3 months."
223965897|NCT04872465|DEVICE|TBS|We initially used cTBS (continuous TBS) over right DLPFC with 120-s train of uninterrupted bursts (1800 pulses) in each session per day. After that, we continuous use iTBS (intermittent TBS, iTBS) over left DLPFC with 2-s train of bursts was repeated every 10 s for a total of 570 s (1800 pulses).
223965898|NCT04872465|DEVICE|sham|Participants will receive sham (placebo) TBS treatment the same as experimental group
223965899|NCT05118737|DRUG|Colchicine|colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
223965900|NCT02453971|OTHER|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
223965901|NCT03044951|PROCEDURE|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
223965902|NCT03044951|PROCEDURE|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
223965903|NCT02162771|BIOLOGICAL|Rituxan|
223965904|NCT02162771|BIOLOGICAL|CT-P10|
223965905|NCT02162771|DRUG|Cyclophosphamide|
223965906|NCT02162771|DRUG|Vincristine|
223965907|NCT02162771|DRUG|Prednisone|
223965908|NCT00685659|OTHER|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
223965909|NCT00685659|OTHER|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
223965910|NCT00685659|OTHER|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
223965911|NCT01348763|DRUG|Maraviroc|Maraviroc 150 mg daily
223965912|NCT01348763|DRUG|Truvada|daily until 10. day then stop
223965913|NCT01348763|DRUG|Darunavir|daily until 10. day then stop
223965914|NCT06493448|OTHER|observation|This is an observational study.
223965915|NCT05990309|DIAGNOSTIC_TEST|skin biopsy|skin biopsy for immunohistochemical staining and assessment of tissue expression of tristetraprolin
223965916|NCT03154684|OTHER|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active"
223965917|NCT03154684|OTHER|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
223965918|NCT00223743|DRUG|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
223965919|NCT01078571|BIOLOGICAL|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
223965920|NCT03022747|DRUG|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
223965921|NCT03022747|DRUG|Standard treatment|Oral 6-mercaptopurine and methotrexate
223965922|NCT00004311|DRUG|leuprolide acetate|
223965923|NCT00004311|DRUG|spironolactone|
223965924|NCT03599934|OTHER|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
223965925|NCT03599934|OTHER|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
223965926|NCT00574106|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
223965927|NCT03317288|DEVICE|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
223965928|NCT03548272|PROCEDURE|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
223965929|NCT03981120|PROCEDURE|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
223965930|NCT05074004|OTHER|Psychoeducation|Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
223965931|NCT03594266|DEVICE|Therapy A spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy A stimulation patterns
223965932|NCT03594266|DEVICE|Therapy B spinal cord stimulation parameter set using BIO-RNA system and associated components|Therapy B stimulation patterns
223965933|NCT01132378|PROCEDURE|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
223965934|NCT02956876|DRUG|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
223965935|NCT02956876|OTHER|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
223965936|NCT02956876|OTHER|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
223965937|NCT03647709|OTHER|opioids|dosage frequency and duration
223965938|NCT06154733|PROCEDURE|Photobiomodulation usinf low level laser therapy|Diode laser will be used (SIROLaser Blue®, Sirona, Germany) at a wavelength of 660 nm and a power of 100 mW for 10 sec, corresponding to an energy dose of 1 J. Irradiation will be performed at the hypomineralized area: two irradiations scanning the surface in the mesiodistal direction and two in the occlusogingival direction (perpendicular to the tooth surface) precisely over the lesion, in a uniform scanning motion with relative isolation. Treatment will be performed in 3 sessions with a 72-hour interval between sessions.
223965939|NCT06154733|PROCEDURE|Resin-based sealant|Cotton rolls and a four-handed technique will be applied for isolation. Scotchbond Universal will be rubbed in the cleaned surface for 20 seconds and air dried for 5 seconds. Afterwards, Fissured Novo Plus will be applied with a syringe. Before light-curing, the presence of air bubbles will be checked and teased out. Light curing for 40 seconds will be done. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.
223965940|NCT06154733|PROCEDURE|Glass ionomer sealant|"Fuji triage will be applied after activating and mixing the capsule. Light cure for 20 seconds. Occlusion will be checked using articulating paper and necessary adjustments will be done using finishing burs.~For the duration of the study, children will be instructed to undergo regular tooth brushing and flossing. Any other needed treatment will be done for the child."
223965941|NCT01818245|DRUG|LY2605541|
223965942|NCT03856424|PROCEDURE|Modality 1|Pressure support ventilation (PSV) modality
223965943|NCT03856424|PROCEDURE|Modality 2|T-Piece modality
223965944|NCT03856424|PROCEDURE|Modality 3|High-flow oxygen
223965945|NCT05068687|DIAGNOSTIC_TEST|high-resolution PET-CT specimen imaging.|"Included patients are given a single weight-dependent activity of 18F-FDG at the department of Nuclear Medicine. After administration, patients are brought to the operating room where standard of care surgical removal of the malignancy is performed.~The resected specimen(s) are brought to the imaging lab and scanned using a preclinical and/or a dedicated specimen PET/CT device. Following PET/CT imaging, the specimen is brought to the department of pathology, where it is sliced. Some of these slices are then rescanned using the preclinical PET/CT device. Moreover, frozen sections are made from one of these slices with macroscopically visible malignant tissue and placed on an autoradiograph overnight. Finally, the imaging results are then correlated to the results found during histopathological analysis of the specimens."
224112123|NCT06671223|DRUG|Infiltration|The intervention consists of the administration of infiltrations in the affected plantar fascia of participants with a diagnosis of plantar fasciopathy. A drug such as a corticosteroid, PRP or hyaluronic acid will be used, which will be injected under ultrasound guidance to ensure precision at the site of the injury. This intervention aims to reduce inflammation and pain, thus improving the functionality of the foot. Up to three infiltrations will be performed, depending on the patient\&amp;amp;#39;s response to treatment and medical evaluation. The infiltrations will be compared with a control group that will receive conservative treatment without infiltrations, to evaluate the relative effectiveness of this pharmacological intervention in the management of plantar fasciopathy.
224112124|NCT06671223|OTHER|Conservative treatment|The control group is used to compare the effectiveness of infiltrations with a non-invasive approach in the treatment of plantar fasciopathy. This group will not receive any infiltration and will focus on conservative interventions.
224112125|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training for Pain|CBOT device with beta-caryophyllene
224112126|NCT06671132|COMBINATION_PRODUCT|Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT)|CBOT device administering continuous olfactoy stimuli with no BCP
224112127|NCT02269319|DRUG|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
224112128|NCT02269319|DRUG|Linezolid|Oral linezolid 600mg given twice a day for 10 days
224112129|NCT00792766|DRUG|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
224112130|NCT05979844|DRUG|3,4-methylenedioxymethamphetamine (MDMA)|2 MDMA sessions; PTSD+ Veteran partner only
224112131|NCT05979844|BEHAVIORAL|Brief Cognitive Behavioral Conjoint Therapy (bCBCT)|8 bCBCT sessions; Both partners
224112132|NCT04762290|OTHER|Dance|The intervention is a series of expressive dance movements.
224112133|NCT05457829|DRUG|Doxorubicin Hydrochloride Liposome+Irinotecan|Q3W, 2 cycles.
224112134|NCT05457829|DRUG|Temozolomide+Irinotecan+Vincristine|Q3W, 2 cycles.
224112135|NCT05339308|OTHER|Magnesium oil (BetterYou) dermal application|10 sprays (200 mg) of magnesium oil (BetterYou) will be applied to skin covering knee extensor muscles. The magnesium oil will be applied only once
223965946|NCT00449033|DRUG|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
223965947|NCT00449033|DRUG|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m\^2 IV, Cisplatin 75 mg/m\^2 IV
223965948|NCT00449033|DRUG|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m\^2 IV
223965949|NCT00449033|DRUG|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m\^2 IV
223965950|NCT01257698|DRUG|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
223965951|NCT06021834|OTHER|rehabilitation|The subjects will be invited to attend the program three times per week.
223965952|NCT04393779|DEVICE|HARPOON Beating Heart Mitral Valve Repair System (MVRS)|Repair of the chordae tendinae in the mitral valve.
223965953|NCT04018534|BEHAVIORAL|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
223965954|NCT04018534|BEHAVIORAL|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
224112136|NCT05339308|OTHER|Placebo Control|Natural mineral-free oil (10 sprays) will be applied as the control condition. This will be done only once
224112137|NCT04115033|DEVICE|Alpha-stim|The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
223965955|NCT04018534|BEHAVIORAL|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
223965956|NCT02959255|DRUG|Esomeprazole|dosage difference
223965957|NCT05915884|OTHER|SGLT-2 inhibitors|This study is an observational study. It is not planned to do an interventional activity.
223965958|NCT00666913|OTHER|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
223965959|NCT06340334|BIOLOGICAL|Tegoprazan-amoxicillin dual therapy|A total of 600 Hp-positive patients who had not received Hp eradication therapy before or had had Hp eradication in the early stage but had not undergone eradication therapy in the past six months were randomly divided into two groups: group A subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, tid; Group B subjects received Tegoprazan 50 mg, bid + amoxicillin 1000 mg, bid + furazolidone 100 mg, bid + colloidal pectin bismuth 300 mg, bid. The duration of treatment is 14 days. The eradication rate, adverse reactions, and compliance of the two groups were compared.
223965960|NCT05570578|DEVICE|HD-tDCS|The anode electrode will be placed over Broca's area, 4 cathode electrodes will be placed at about 2 cm distance each from the anode in 4 directions.
223965961|NCT00722488|DRUG|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
223965962|NCT04739293|DRUG|ON123300|ON 123300 hard gelatin capsules
223965963|NCT00006747|DRUG|carmustine|IV
223965964|NCT00006747|DRUG|melphalan|IV
223965965|NCT00006747|DRUG|etoposide|IV
223965966|NCT00006747|DRUG|cytarabine|IV
223965967|NCT00006747|DRUG|tacrolimus|IV
223965968|NCT00006747|DRUG|methotrexate|IV
223965969|NCT00006747|DRUG|sargramostim|IV
223965970|NCT00006747|PROCEDURE|transplant|
224112138|NCT05287893|DRUG|Pyronaridine|Single dose
224112139|NCT05287893|BIOLOGICAL|P. falciparum IBSM infection|Induced Blood Stage Malaria
223965971|NCT00187122|DRUG|Vincristine|See Detailed Description section for description of treatment plan.
223965972|NCT00187122|PROCEDURE|Radiation Therapy|See Detailed Description section for description of treatment plan.
223965973|NCT00187122|DRUG|Daunomycin|See Detailed Description section for description of treatment plan.
223965974|NCT00187122|DRUG|L-Asparaginase|See Detailed Description section for description of treatment plan.
223965975|NCT00187122|DRUG|Cytarabine|See Detailed Description section for description of treatment plan.
223965976|NCT00187122|DRUG|Methotrexate|See Detailed Description section for description of treatment plan.
223965977|NCT00187122|DRUG|Mercaptopurine|See Detailed Description section for description of treatment plan.
223965978|NCT00187122|DRUG|Etoposide|See Detailed Description section for description of treatment plan.
223965979|NCT00187122|DRUG|Cyclophosphamide|See Detailed Description section for description of treatment plan.
223965980|NCT00187122|DRUG|Prednisone|See Detailed Description section for description of treatment plan.
223965981|NCT00187122|DRUG|Dexamethasone|See Detailed Description section for description of treatment plan.
223965982|NCT01190228|BIOLOGICAL|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
223965983|NCT01190228|BIOLOGICAL|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
223965984|NCT01516502|OTHER|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
223965985|NCT02032420|BEHAVIORAL|STAR|
223965986|NCT02032420|BEHAVIORAL|ART|
223965987|NCT03869541|OTHER|Mobilization|Physical rehabilitation
223965988|NCT05582421|DRUG|Diclofenac Sodium|intracanal medication
223965989|NCT00447356|DRUG|recombinant interferon alfa|
223965990|NCT01889277|DRUG|MT-3995-Low|
223965991|NCT01889277|DRUG|MT-3995-High|
223965992|NCT01889277|DRUG|Placebo|
223965993|NCT02037750|BEHAVIORAL|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
223965994|NCT00398749|DRUG|Epoetin alfa|40,000 IU once weekly, variable treatment length
224112140|NCT05243550|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
224112141|NCT06099717|DEVICE|Dual-cantilevered implant bridge|A 3-unit supported by one implant in the middle
223965995|NCT05817864|DIAGNOSTIC_TEST|Capnography|"Index test: Capnography, which monitors ETCO2, the percentage concentration, or partial pressure of CO2 at the end of exhalation, will serve as the index test. It will be performed by connecting the end of the nasogastric tube with the sensor of the bedside sidestream capnography device. Placement within the airway is defined as detecting a capnogram waveform or an ETCO2 level \> 10 mmHg.~Reference standard: This study will use radiography (chest/abdominal X-ray) as the reference standard for determining the correct placement of nasogastric tubes. Radiology will be performed as soon as possible and interpreted by a physician. A repeat radiography will be performed if necessary. We will also use pH-Fix-4.5-10 to determine the pH value, and its accuracy is +/- 0.2 pH with minimum increments of 0.5. A pH of 5.5 or below indicates gastric placement."
223965996|NCT01592565|OTHER|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
223965997|NCT04979234|DEVICE|Endomina- Endoscopic Sleeve Gastroplasty|Endoscopic gastric reduction
223965998|NCT04979234|BEHAVIORAL|Diet|Multidisciplinary follow up
223965999|NCT01107249|DEVICE|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
223966000|NCT04958629|OTHER|familial hypercholesterolemia|Among the selected patients with hyperlipidemia, those who met the diagnostic criteria of FH were included in the study cohort as FH group.
223966001|NCT00254722|DRUG|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10\^6 mononuclear cells/kg body weight, administered within 36 hours of injury
224112142|NCT06099717|DEVICE|3-unit iFDP|3-unit fixed dental prosthesis supported by two implants
224112143|NCT03277170|DRUG|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
224112144|NCT06265532|DRUG|EGCG 300 mg|"Participants will be administered EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
224112145|NCT06265532|DRUG|Placebo for EGCG 300 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
224112146|NCT06265532|DRUG|EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
224112147|NCT06265532|DRUG|Placebo for EGCG 600 mg|"Participants will be administered placebo for EGCG as part of the phase I study: Dose ranging study of oral epigallocatechin-3-gallate (EGCG) given daily for 12 weeks to patients with Idiopathic Pulmonary Fibrosis (IPF) evaluating safety, PK interactions with standard of care drugs, and biomarkers of drug effect."
224112148|NCT04185610|OTHER|Qi Gong|Guided Qi Gong class
224112149|NCT05217069|DRUG|5-FU|400 mg/m2 (i.v. bolus) 2400 mg/m2 (i.v. 46h)
224112150|NCT05217069|DRUG|Folinic Acid|400mg/m2
224112151|NCT05217069|DRUG|Irinotecan|180 mg/m2
224112152|NCT05217069|DRUG|Cetuximab|400 mg/m2 i.v. 120min initial dose 250 mg/m2 i.v. 60min q 1w
224112153|NCT05217069|DRUG|Avelumab|10mg/kg IV (day 1 q2w)
224112154|NCT02948231|DEVICE|Mistral implantation|Mistral Implant is implanted in the Mitral valve
224112155|NCT03729869|DRUG|Progesterone|200 mg of exogenous progesterone twice a day
224112156|NCT03729869|DRUG|Placebo|One dose of matched placebo twice a day.
223966002|NCT00802334|DRUG|generic lopinavir/ritonavir|"1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
223966003|NCT02038803|DRUG|TOBIpodhaler|
223966004|NCT05859529|DRUG|JS002|The drug was administered by a single subcutaneous injection
223966005|NCT06802991|OTHER|ERAS 3.0 (Enhanced Recovery After Surgery)|Nutritional support at discharge and home visits which include comprehensive geriatric assessment, nutritional guidance by dietitian, and instructions on exercise and physical activity.
223966006|NCT06369987|DEVICE|Deleficon A (multifocal)|Daily disposable silicone hydrogel contact lenses indicated for presbyopia, in addition to myopia or hyperopia.
223966007|NCT06369987|DEVICE|Senofilcon A (multifocal)|Daily disposable silicone hydrogel contact lenses indicated for presbyopia, in addition to myopia or hyperopia
223966008|NCT05073835|DRUG|Semaglutide 3 mg|Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
223966009|NCT05073835|DRUG|Placebo|Placebo
223966010|NCT05977699|DRUG|salbutamol aqueous solution|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a vibrating mesh nebulizer
223966011|NCT05977699|DRUG|salbutamol pressurized metered dose inhaler|administration of 200microliters of salbutamol to reverse methacholine induced bronchoconstriction using a pressurized metered dose inhaler plus spacer
223966012|NCT05977699|OTHER|placebo|matching placebo delivered via pressurized metered dose inhaler plus spacer or normal saline via vibrating mesh nebulizer
223724764|NCT03101683|RADIATION|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
223966013|NCT06281938|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
223966014|NCT06281938|OTHER|Standard care weight estimation|Standard care (unspecified) will be used to determine weight-based dosing and other management.
223966015|NCT05837650|BEHAVIORAL|Emotional Awareness and Expression Therapy (EAET)|"Each EAET session will use an educational lecture, discussion, in-class experiential exercises, and homework assignments. During sessions, participants will be encouraged to identify their stressors and experience and express their avoided or suppressed emotions, using exercises such as emotional disclosure, role playing, and the empty chair technique. Participants will be given homework assignments to complete between sessions, including expressive writing, identification of stressors and avoided emotions, and healthy communication skills practice. The planned topics of the EAET sessions include the emotions-stress-pain model, expressing and experiencing emotions (anger, sadness, hurt, etc.), letting go/forgiveness of self and others, and healthy communication, including assertiveness and intimacy."
223966016|NCT04372186|DRUG|Placebo|Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
223724765|NCT06332235|DRUG|Silodosin 8 mg|Dosing schedule: Oral, once daily
223966017|NCT04372186|DRUG|Tocilizumab|Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
223966018|NCT06435520|BEHAVIORAL|Digital Cognitive Behavioral Therapy|Adaptive cloud-based software delivering cognitive behavioral therapy tailored to the needs of the individual patient.
223966019|NCT06435520|BEHAVIORAL|Structured Medication Tapering|A structured tapering of hypnotic (or other) medication to promote successful discontinuation by patients seeking to discontinue use.
223966020|NCT02116582|DRUG|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
223966021|NCT05852353|OTHER|Digital Pediatric Bladder Health Patient Education Curriculum|"Bladder Basics is designed to be a digital health intervention to improve knowledge of healthy bladder practices. It is a video-based bladder health curriculum based on 1) principles of Urotherapy 2) stakeholder need for a gold-standard resource 3) behavioral change theory 4) education design standards for inclusion as a comprehensive school health program (CSHP).~The overall mission of the course is to teach children and their families about pediatric bladder health. The development of the course has followed the NIH's Clear \& Simple standards for patient education. The 7 video lesson plan spans 60 minutes total. The course is designed to support families awaiting medical care, which would provide the continued support. In addition, one lesson shares solutions to common home and school-based barriers to behavioral change. The 4 healthy bladder practices that are promoted are- 1) pee every 3 hours 2) drinking water 3) daily poop without straining 4) toilet postures."
223966022|NCT04848064|DRUG|Cyclophosphamide|Given IV
223966023|NCT04848064|DRUG|Fludarabine|Given IV
223966024|NCT04848064|BIOLOGICAL|Mogamulizumab|Given IV
223966025|NCT04848064|BIOLOGICAL|Natural Killer Cell Therapy|Given via infusion
223966026|NCT04848064|OTHER|Quality-of-Life Assessment|Ancillary studies
223966027|NCT04848064|OTHER|Questionnaire Administration|Ancillary studies
223966028|NCT03621683|PROCEDURE|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
223966029|NCT03621683|DIETARY_SUPPLEMENT|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
223966030|NCT06128330|DRUG|Tranexamic acid bolus 20 mg/kg|Bolus of tranexamic acid in the standard dose group
223966031|NCT06128330|DRUG|Tranexamic acid bolus 10 mg/kg|Bolus of tranexamic acid in the low dose group
223966032|NCT06128330|DRUG|Tranexamic acid bolus 1 mg/kg|Bolus of tranexamic acid in the low dose group (to add into the CPB prime)
223966033|NCT06128330|DRUG|Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group|Tranexamic acid continuous infusion during the procedure
223966034|NCT03219216|DRUG|Glecaprevir/Pibrentasvir|Film-coated tablet
223966035|NCT02332824|DRUG|TAK-272|TAK-272 tablets
223966036|NCT02332824|DRUG|TAK-272 Placebo|TAK-272 placebo-matching tablets
223966037|NCT02332824|DRUG|Candesartan cilexetil|Candesartan cilexetil tablets
223966038|NCT02332824|DRUG|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
223966039|NCT00498797|DRUG|Zactima (vandetanib)|
223966040|NCT00498797|DRUG|Docetaxel|
223966041|NCT00498797|DRUG|Prednisolone|
223966042|NCT02852499|OTHER|Urine sampling|
223966043|NCT02852499|OTHER|Carry a GPS and BET|
223966044|NCT02852499|OTHER|Carry pollution sensor|
223966045|NCT02852499|OTHER|Sampling at the maternity|
223966046|NCT02852499|OTHER|Self-questionnaires|
223966047|NCT02852499|OTHER|Sampling in partum period|Meconium and a strand of hair.
223966048|NCT02531997|BEHAVIORAL|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
223966049|NCT02531997|BEHAVIORAL|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
223966050|NCT06585163|DRUG|Hydrocodone Bitartrate|Hydrocodone bitartrate oral suspension
223966051|NCT06585163|DRUG|Doxapram Hydrochloride|Doxapram hydrocholoride oral suspension
223966052|NCT05419921|DIAGNOSTIC_TEST|Hysterosalpingo-lidocaine-foam-sonography combined with power doppler (HyLiFoSy-PD)|"Women in the reproductive age group between 18- and 40-years old presenting with primary or secondary infertility who underwent HSG in the previous 5 years as a part of their infertility work-up with availability of good-quality HSG images, \& did not get pregnant in this period, and gave no history of incidences that might affect their tubes, such as : abdominal surgery or laparoscopy, pelvic inflammatory disease, smoking, and intrauterine device insertion.~Women fitting these inclusion criteria and scheduled for LDT as part of their infertility work up will be considered. HyLiFoSy-PD will be carried out few days before the already scheduled LDT."
223966053|NCT06200480|OTHER|Telephone by nurse|Patient-initiated follow-up at week 2 and 6
223966054|NCT05978947|DEVICE|ZyMōt Multi 850µL device|The ZyMōt Multi 850µL device is a laboratory tool designed for use in assisted reproductive technology (ART) procedures such as intrauterine insemination (IUI) and in vitro fertilization (IVF). It is a sperm preparation device that uses a proprietary patented technology to isolate and select motile sperm from semen samples for use in ART procedures.
223966055|NCT05978947|DEVICE|Density Gradient Centrifugation Method|Density gradient centrifugation is a laboratory technique used to separate and isolate different types of cells or particles based on their density. It is commonly used in various applications, including cell biology, immunology, and assisted reproductive technology (ART).
224112157|NCT05782920|DEVICE|Platelet rich plasma|PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
224112158|NCT05782920|DEVICE|non cross-linked hyaluronic acid|HA filling is a known modality for rejuvenation
224112159|NCT05782920|DEVICE|topical HA gel|the standard treatment of vaginal atrophy and dryness
224112160|NCT05337267|DRUG|sintilimab (after the change)|0.3mg/kg，I.V.，single dose
224112161|NCT05337267|DRUG|sintilimab (before the change)|0.3mg/kg，I.V.，single dose
224112162|NCT03215472|OTHER|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
224112163|NCT03215472|OTHER|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
224112164|NCT03856073|BEHAVIORAL|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
223966056|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
223966057|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose \[2x10\^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose\] by intradermal (ID) route on Days 0 and 28.
223966058|NCT00914732|BIOLOGICAL|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10\^8 TCID50 per 0.5 mL dose on Days 0 and 28.
224112165|NCT02806427|OTHER|Enteral Formula|
223966059|NCT02954276|DRUG|Omexa Sublingual Sumatriptan tablet|75 mg
223542550|NCT00948077|DRUG|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---\> Treatment B (6th day) ; Treatment B (5th day) ---\> Treatment A (6th day)"
223966060|NCT02954276|DRUG|Imitrex Oral Product|100 mg
223966061|NCT03658395|PROCEDURE|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
223966062|NCT03658395|PROCEDURE|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
223966063|NCT00002405|DRUG|Amprenavir|
223542551|NCT04255771|DRUG|Gemcitabine|Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.
223542552|NCT04255771|DRUG|Placebos|Use a placebo as a comparison
223966064|NCT03312621|BEHAVIORAL|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
223966065|NCT01855399|BEHAVIORAL|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
223966066|NCT01855399|BEHAVIORAL|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
223966067|NCT01753674|DIETARY_SUPPLEMENT|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
223966068|NCT01753674|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
223966069|NCT03953079|DRUG|Drug: GB-102|Intravitreal injection of GB-102
223966070|NCT03953079|DRUG|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
223966071|NCT05550441|DRUG|Dapagliflozin|The experimental group received dapagliflozin (10 mg qd) for 1 year.
223966072|NCT05550441|DRUG|Placebo|The Placebo group received placebo for 1 year.
223966073|NCT04394624|DRUG|SAR408701|Pharmaceutical form:concentrate for solution for injection Route of administration: intravenous infusion
223966074|NCT04394624|DRUG|ramucirumab|Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
223966075|NCT04394624|DRUG|pembrolizumab|Pharmaceutical form: concentrate for solution for injection Route of administration: intravenous infusion
223966076|NCT04306081|DRUG|Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of evolocumab 420 mg in the abdomen, thigh or upper arm. The study drug (evolocumab) prefilled injector pens are provided by Amgen
223966077|NCT04306081|OTHER|Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.|The study subjects randomized to the treatment study arm will receive monthly subcutaneous injections of Placebo in the abdomen, thigh or upper arm. The Placebo prefilled injector pens are provided by Amgen
223966078|NCT04004806|DEVICE|Hill Rom tracking device|Location tracking devices from Hill Rom company.
223966079|NCT01165944|DRUG|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
223966080|NCT06550674|GENETIC|Constitutional exome analysis|"For each patient included:~* A family tree is drawn up, reporting personal and family histories of cancer. The patient's anatomopathological reports, related to his or her tumor lesions, are retrieved, in order to confirm/clarify individual or family diagnoses.~* A blood sample and a jugal smear are taken to enable constitutional genetic exome analysis for research purposes."
223966081|NCT01026207|DEVICE|Polysomnography|Sleep study polysomnography compared with portable monitoring
223966082|NCT04236700|OTHER|Oral clinical exam|Detailed anamnesis, with information regarding the time of sun exposure, protection measures, medical history and application of questionnaires will be carried out. Dental dental and tissue examination should be performed
223966083|NCT04617574|DEVICE|AEON Endostapler|Surgery with AEON Endostapler
223966084|NCT04617574|DEVICE|Endo GIA Reloads with Tri-Staple Technology|Surgery with Endo GIA Reloads with Tri-Staple Technology
223966085|NCT00254241|DRUG|Seroquel and Risperidone|
223966086|NCT04728100|OTHER|LQT|Patients with LQT syndrome diagnosis.
223966087|NCT04806659|DRUG|SH1573 Capsules|Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
224291404|NCT06420414|OTHER|Traditional HIIT|"Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency."
223542553|NCT03992950|OTHER|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
223966088|NCT06272526|OTHER|Internet Based Intervention - GUIDED|The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
223966089|NCT03480815|DEVICE|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
223966090|NCT03480815|OTHER|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
223966091|NCT01150305|BIOLOGICAL|blood sample|Peripheral whole blood sample, 5 ml
223966092|NCT01490047|DRUG|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
223966093|NCT01490047|DRUG|Liposomal doxorubicin|Infusion over 60 minutes
223966094|NCT01490047|DRUG|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
223966095|NCT01490047|DRUG|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
223966096|NCT02408978|DRUG|OXP005|
223966097|NCT02408978|DRUG|Naproxen|
223966098|NCT00561275|BIOLOGICAL|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
224112166|NCT01378390|DRUG|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
224112167|NCT01378390|DRUG|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
224112168|NCT06378658|DRUG|BAY2927088|Oral administration
224112169|NCT06378658|DRUG|Esomeprazole|Oral administration
224112170|NCT06378658|OTHER|Food|light low-fat meal or high fat, high calorie meal
224112171|NCT00893113|DRUG|Placebo|Alfuzosin-matched One tablet once daily
223966099|NCT03829566|DRUG|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
223542554|NCT04278248|BIOLOGICAL|23-Valent Pneumococcal Polysaccharide Vaccine|1 dose according to age of subjects. Single intramuscular dose contains 0.5ml 23-Valent Pneumococcal Polysaccharide Vaccine.
223542555|NCT00390377|PROCEDURE|Cutting scalp hair|
223966100|NCT03829566|DRUG|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
223966101|NCT03829566|DRUG|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
223966102|NCT03829566|DRUG|rATG|A rabbit polyclonal antibody to lymphocytes
224112172|NCT00893113|DRUG|Alfuzosin|10 mg once daily
224112173|NCT02091622|OTHER|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
223966103|NCT03829566|DRUG|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
223966104|NCT03829566|DRUG|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
223966105|NCT03829566|BIOLOGICAL|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
223966106|NCT03829566|BIOLOGICAL|Autologous Stem Cells|Infusion of patient's own stem cells
223966107|NCT01844063|GENETIC|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
223542556|NCT05775302|OTHER|IASTM of Gastrocnemius + Conventional therapy|The SWEEP technique will be performed downwards from the popliteal region to the Achilles tendon for 60 seconds, 30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
223542557|NCT05775302|OTHER|IASTM of AchillesTendon + Conventional Therapy|Participants will receive a maximum of 60 seconds\<30 times 12 sessions over a time frame of 4 weeks at a frequency of 3 sessions per week.
223966108|NCT01844063|GENETIC|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
223966109|NCT01844063|DRUG|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
223966110|NCT00604461|DRUG|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
223966111|NCT00504101|DRUG|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
223966112|NCT00504101|DRUG|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
223966113|NCT00504101|DRUG|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
224112174|NCT05087602|DRUG|Toripalimab and Anlotinib|Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
223542558|NCT06017492|BEHAVIORAL|video assisted discharge teaching|Patients will be educated using the video assisted discharge teaching. The educational content will be in English and will focus on the following topics: surgical process, medication use complication after surgery, pain management, wound care, nutrition, self-care after, surgery, home care after surgery and situations to refer to a physician.
223542559|NCT03435068|DEVICE|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
223542560|NCT03435068|DEVICE|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
223542561|NCT03435068|DEVICE|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
223542562|NCT02913963|DEVICE|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
223966114|NCT00504101|BIOLOGICAL|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
223966115|NCT05928520|DRUG|Tramadol 5%|Topical tramadol 5%
224112175|NCT04561843|DIAGNOSTIC_TEST|pelvic floor ultrasound|2D and 3D trans-perineum ultrasound examinations will be performed by single examiner who was blind to clinical data, using a GE Voluson 730 machine (GE Medical System Kretz Technik, Zipf, Austria) with a RAB 4-8 MHz curved array volume transducer. In the supine position, with flexed and slightly abducted hips after urine voiding. The transducer was placed on the perineum, in the mid sagittal plane with minimal pressure being applied after covering it with an un-powdered glove or thin plastic wrap for hygienic reasons
224112176|NCT02074215|OTHER|Aerobic exercises|Aerobic exercises + dual task
223542563|NCT02913963|DEVICE|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
223542564|NCT00484263|DRUG|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
223542565|NCT04314817|DRUG|Any drug used to treat Covid-19|lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.
223542566|NCT03192137|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
223542567|NCT03192137|OTHER|Vehicle|Vehicle twice daily for 16 days
223966116|NCT05928520|DRUG|Lidocaine 2%|Topical Lidocaine 2%
223966117|NCT06201000|DRUG|SGLT2 inhibitors (Dapagliflozin and Empagliflozin)|10 mg of dapagliflozin or empagliflozin
223966118|NCT05125614|OTHER|No adjuvant chemotherapy|There is no intervention differences between 2 groups. We analyzed the data of the patients who did not receive adjuvant chemotherapy.
224112177|NCT02074215|OTHER|Stretch exercise|Stretch exercise
224112178|NCT03952208|OTHER|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
224112179|NCT04343170|DRUG|Placebo|Patients of this group received placebo treatment consisted of two subcutaneous injections of 1 mL saline and an oral placebo
224112180|NCT04343170|DRUG|ferric carboxymaltose , α erythropoietin, vitamin B12, oral folic acid|Patients of this group received Combination treatment consisted of a slow (30 min) intravenous infusion of 20 mg/kg ferric carboxymaltose (maximum of 1000 mg), 40 000 U subcutaneous α erythropoietin,1 mg subcutaneous vitamin B12(, and 5 mg oral folic acid (acidum folicum)
224112181|NCT04843111|BIOLOGICAL|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
224112182|NCT05462587|DRUG|AVTX-803 (L-Fucose)|L-fucose crystalline powder
224112183|NCT02751307|DRUG|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
223966119|NCT04834167|DEVICE|OneDoc Picopulse|Eligible patients will proceed to receive skin cleansing prior to OneDoc Picopulse treatment. After the cleansing, the patients will receive OneDoc Picopulse treatment for 15 mins. Patients will receive ten picopulse treatments for bi-monthly.
223966120|NCT05473468|DRUG|Famitinib|a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)
223966121|NCT00065663|GENETIC|GAM501|
223966122|NCT00702871|DRUG|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
224112184|NCT02751307|DRUG|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
223542568|NCT01591629|DRUG|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
223966123|NCT00702871|DRUG|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
223542569|NCT01591629|DRUG|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
223542570|NCT01591629|DRUG|Placebo|Placebo
223542571|NCT00657267|DRUG|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
223966124|NCT05208021|BEHAVIORAL|Intervention group (Motivational Interviewing)|The Health Promotion Model and the Motivational Interview-Based Health Protection and Promotion Program were applied to the experimental group, which consisted of 6 sessions and lasted an average of 60-120 minutes. Sessions were held in the form of individual interviews due to the pandemic and social distance conditions.
223966125|NCT01844908|PROCEDURE|Electroacupuncture|
223966126|NCT00593528|DEVICE|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
223966127|NCT00593528|DEVICE|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
224112185|NCT02860468|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
224112186|NCT02860468|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
224112187|NCT04827056|DRUG|Placebo|Placebo will be administered orally, as individual films in the SL space.
223724766|NCT06504641|OTHER|Isla for Frailty|"Isla for Frailty - video-based patient records. Isla is a technology company providing a visual patient record platform. The platform allows anyone involved in a patient's care to capture and review visual data (photographs, videos) relating to a patient's health. The platform is web-based (a progressive web application) and supports secure capture of visual data with encrypted storage in the cloud.~Isla interfaces with Electronic Health Record (EHR) systems including Cerner, enabling health professionals to view data held on Isla's servers from within the electronic patient record, via the 'Cerner Red Button'. Health professionals can also view a patient's visual record through a secure weblink requiring an NHS email address and password."
223966128|NCT00593528|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
223966129|NCT01766323|DRUG|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
223966130|NCT01766323|DRUG|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
223966131|NCT05852379|DEVICE|active taVNS|Transcutaneous auricular vague nerve stimulation
223966132|NCT05852379|DEVICE|sham taVNS|Scham transcutaneous auricular vague nerve stimulation
223966133|NCT05507372|DRUG|Pimozide 1 MG|Dopamine Receptor Antagonist - Oral Pimozide
223966134|NCT00986661|DRUG|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
223966135|NCT02199171|DRUG|carboplatin|Given via HIPEC
223966136|NCT04363645|OTHER|Multicontext (MC) approach|The Multicontext approach is a metacognitive intervention designed to improve awareness, strategy use, and executive functioning.
223966137|NCT02135419|DRUG|imiquimod|Applied topically
223966138|NCT02135419|DRUG|fluorouracil|Applied topically
223966139|NCT02135419|DEVICE|infrared photocoagulation therapy|Undergo infrared coagulation
223966140|NCT02135419|DEVICE|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
224112188|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg|BXCL 501 40µg will be administered orally, as individual films in the SL space.
224112189|NCT04827056|DRUG|Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg|BXCL 501 80µg will be administered orally, as individual films in the SL space.
224112190|NCT04827056|PROCEDURE|Ethanol Infusion|Study team will be using a modified alcohol-IV clamp procedure developed and standardized by Subramanian and colleagues (Subramanian, Heil et al. 2002). The infusion will be performed using a 6% ethanol solution in 0.9% saline. The computer assisted administration program automatically calculates and corrects the infusion rate based on real-time BrAC data entry by staff, based on the pharmacokinetic profile of each subject (targeting a breath alcohol concentration (BrAC) of 100 mg%).
224112191|NCT04827056|BEHAVIORAL|PTSD Reactivity Condition|Participants will be exposed to two conditions in random order: PTSD cues and neutral cues. The cues will consist of a 5 minute presentation of the stimulus (trauma or neutral) followed by immediate evaluation of craving and anxiety. There will be a relaxation procedure between each condition. The imagery scripts are developed based on the scene construction questionnaire developed by Lang et al (Lang, Kozak et al. 1980, Lang, Levin et al. 1983) using a standardized format designed by Sinha (Sinha 2001).
224112192|NCT04827056|BEHAVIORAL|Alcohol Cue Reactivity|Participants will be exposed to two conditions: a neutral cue (water) followed by an alcohol cue. Individuals will be instructed that they may smell and handle the beverage, but they cannot consume the beverage. Following the presentation, the research assistant takes the beverage and leaves the room, while the subject completes the anxiety and alcohol craving assessments.
224112193|NCT02698592|DEVICE|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
223724767|NCT01782222|DRUG|Rotigotine|"Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
223966141|NCT02135419|DEVICE|laser therapy|Undergo laser therapy
223966142|NCT02135419|OTHER|clinical observation|Undergo active monitoring (High Resolution Anoscopy \[HRA\]) with biopsies
223966143|NCT02135419|OTHER|laboratory biomarker analysis|Correlative studies
223966144|NCT06311448|DRUG|Single target immunomodulation|Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
223966145|NCT06311448|DRUG|Standard of care|Standard of care during COVID-19 pandemic including steroids.
223966146|NCT00990821|DRUG|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
223966147|NCT00990821|DRUG|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
223966148|NCT00990821|DRUG|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
223966149|NCT00990821|DRUG|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
223966150|NCT00990821|DRUG|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
223966151|NCT00990821|DRUG|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
223966152|NCT00990821|DRUG|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
223966153|NCT00990821|DRUG|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
223966154|NCT00990821|DRUG|Placebo|Placebo matching MK-0517
223966155|NCT00990821|DRUG|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
223966156|NCT00990821|DRUG|125 mg Aprepitant|Aprepitant oral tablet, single dose
223966157|NCT00990821|DRUG|2 mg Midazolam|Midazolam oral tablet, single dose
223966158|NCT05306223|DRUG|Bedaquiline|Bedaquiline uncoated tablets will be administered orally.
223966159|NCT05306223|DRUG|Levofloxacin|Levofloxacin filmcoated will be administered orally
223966160|NCT05306223|DRUG|Linezolid|Linezolid tablets will be administered orally
223966161|NCT05306223|DRUG|Cycloserine|Cycloserine capsules will be administered orally.
223966162|NCT05306223|DRUG|Clofazimine|Clofazimine capsules will be administered orally.
223966163|NCT05306223|DRUG|Pyrazinamide|Pyrazinamide tablets will be administered orally.
223966164|NCT05306223|DRUG|Protionamide|Protionamide enteric-coated tablets will be administered orally.
223966165|NCT00158561|DRUG|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
223966166|NCT02862158|DEVICE|FDT visual field|
223724768|NCT01782222|OTHER|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
223966167|NCT02862158|DEVICE|Standard HVF|
223966168|NCT03550014|PROCEDURE|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
223966169|NCT03550014|PROCEDURE|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
223966170|NCT05711017|DRUG|Huashibaidu granule|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
223966171|NCT05711017|DRUG|Placebo|Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
223724769|NCT01500694|DRUG|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
223966172|NCT05781984|PROCEDURE|Microsugical Excsosion|Microsurgical excision of pineal region tumor or endoscopic biopsy
223966173|NCT01631799|DEVICE|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
223966174|NCT01631799|DEVICE|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
223966175|NCT04150250|DRUG|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhibit the cystic fibrosis transmembrane conductance regulator chloride channel.
223966176|NCT04150250|DRUG|Placebo|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
223966177|NCT04150250|OTHER|V. cholerae Challenge|Freshly-harvested, wild-type Vibrio (V.) cholerae El Tor Inaba strain N16961,10\^6 cfu suspended in 30 mL of sodium bicarbonate solution ingested orally.
223966178|NCT04150250|DRUG|Antibiotics|"Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)"
223966179|NCT04758156|DRUG|CleanViewAL|1L PEG + ascorbic acid bowel preparation for colonoscopy
223966180|NCT04758156|DRUG|SUPREP|Oral sulfate solution for colonoscopy bowel preparation
223966181|NCT03468387|PROCEDURE|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
223966182|NCT03468387|PROCEDURE|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
223966183|NCT01112371|DRUG|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
223966184|NCT03885622|DEVICE|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
223966185|NCT02511847|DRUG|Afatinib|"1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
224112194|NCT02698592|DEVICE|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
223542572|NCT05784818|BEHAVIORAL|Up To Me Intervention + No Booster|Participants will complete two-hour sessions once a week over three weeks in which they complete modules in the Up To Me Workbook. These sessions are facilitated by a peer facilitator and a member of the USF Counseling center. Other members in the group sessions are university students who are peers who are also experiencing some form of shame around their mental health challenges.
223542573|NCT05784818|BEHAVIORAL|Up To Me Intervention + Booster|In addition to the Up To Me Intervention, participants also complete a booster/additional session where additional topics of the Up To Me workbook are covered. This additional session occurs four weeks after the completion of the third session.
223724770|NCT04260152|DEVICE|Geistlich Fibro-Gide|Surgical recession root coverage with coronally advanced flap in combination with Geistlich Fibro-Gide
223966186|NCT01309633|DRUG|12.5mg sunitinib with Cisplatin and Gemcitabine|"1\) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
224112195|NCT02698592|DEVICE|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
224112196|NCT01187797|OTHER|Emotional stimulation|Increase of the physical correlates of an emotion
223724771|NCT04260152|PROCEDURE|Connective Tissue Graft (CTG|Surgical recession root coverage with coronally advanced flap in combination with CTG
223724772|NCT00833794|DRUG|Tramadol Once a day|
223724773|NCT00833794|DRUG|Placebo|
223966187|NCT01309633|DRUG|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
223724774|NCT00663169|BIOLOGICAL|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
223724775|NCT00663169|DRUG|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
223966188|NCT01309633|DRUG|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
223966189|NCT01309633|DRUG|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
223724776|NCT00663169|OTHER|placebo matching canakinumab|5% glucose in water intravenous infusion.
223724777|NCT00663169|OTHER|placebo matching dexamethasone|Placebo intravenous infusion.
223724778|NCT02983344|DRUG|Ropivacaine|Fascia iliaca compartment block using ropivacaine
223724779|NCT02983344|DRUG|Fentanyl|Intravenous fentanyl
223966190|NCT05200299|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150-165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400-2800mg/m2 as a 46-48 hour continuous infusion on day 1)
223966191|NCT05200299|DRUG|mFOLFOX6 OR CapeOx|"mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)"
223966192|NCT01243658|DRUG|Oxytocin|Oxytocin
223966193|NCT01243658|OTHER|placebo|placebo
224112197|NCT06435715|OTHER|10 Repetitions of Deep Breathing Exercise|Respondents in the intervention group performed 10 repetitions of deep breathing exercises every 3 hours for 3 days.
224112198|NCT06435715|OTHER|3 Repetitions of Deep Breathing Exercise|Respondents in the control group performed 3 repetitions of deep breathing exercises for 3 days.
224112199|NCT00082082|DRUG|Thymalfasin (thymosin alpha-1)|
224112200|NCT00082082|PROCEDURE|Trans arterial chemoembolization (TACE)|
224112201|NCT04210973|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
223724780|NCT02983344|DEVICE|Ultrasound|Ultrasound-guided fascia iliaca compartment block
223966194|NCT06269796|DIAGNOSTIC_TEST|Little Developmental Coordination Disorder Questionnaire (LDCDQ)|"The Little Developmental Coordination Disorder Questionnaire (LDCDQ) is a parent questionnaire consisting of 15 items designed to screen for motor coordination difficulties in 3- and 4-year-old children. It comprises 15 items grouped into two distinct factors: gross motor skills and fine motor skills. A Likert scale is used, ranging from one to five, where one (1) indicates Not at all like your child and five (5) indicates Very much like your child. The total of the 15 items is added up to obtain a total score of 75."
223966195|NCT06269796|DIAGNOSTIC_TEST|Bruininks- Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2)|The BOT-2 is standardized for children and adolescents aged 4 to 21 years and 11 months, and the full test takes 45 to 60 minutes to perform. The BOT-2 test was used to detect deviation from the norm and the likelihood of a diagnosis for DCD. The BOT-2 measures fine and gross motor proficiency, with subtests focusing on stability, mobility, strength, coordination, and object manipulation.
223966196|NCT06072352|OTHER|Perineal cleansing using chlorhexidine acetate solution|Perineal cleansing using chlorhexidine acetate solution
223966197|NCT06072352|OTHER|Normal saline|Perineal cleansing using normal saline
223966198|NCT01786551|DRUG|Eplerenone|50 mg daily for 14 days
223966199|NCT06167642|DRUG|Ofatumumab|Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
223966200|NCT00692757|DRUG|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
223966201|NCT00692757|DRUG|Iodopovidone|Iodopovidone
223966202|NCT00507702|PROCEDURE|phlebotomy|Standard of care
224112202|NCT04210973|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
224112203|NCT03887572|OTHER|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
224112204|NCT00389415|DRUG|Vildagliptin|
224112205|NCT03964012|BIOLOGICAL|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
223966203|NCT04018521|BEHAVIORAL|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
223966204|NCT04018521|BEHAVIORAL|CSC Usual Care|standard of care provided to youth following first episode of psychosis
223966205|NCT05563987|BEHAVIORAL|ACT-DE|The acceptance and commitment therapy is a psychological component to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the hexagonal model of ACT, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
223966206|NCT05563987|BEHAVIORAL|DE|DE
224112206|NCT03964012|BIOLOGICAL|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
223966207|NCT01391234|RADIATION|STAT RT planning and delivery workflow|"* Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
223966208|NCT00308113|DRUG|Prednisone|Prednisone 0/75 mg/kg/day.
223966209|NCT00308113|DIETARY_SUPPLEMENT|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
223966210|NCT04282863|PROCEDURE|RM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained. Trocar sites varied according to different procedures. Generally, umbilical site for the scope and 8-10 cm lateral to the scope at 15 degrees for the arms are the most commonly adopted sites for robotic myomectomy.
223966211|NCT04282863|PROCEDURE|LM|All patients were positioned in a lithotomy position. A uterine manipulator and a Foley catheter were inserted. Four trocars were used after pneumoperitoneum was obtained: a 10 mm port is inserted through the umbilicus to introduce the video-laparoscopic system. Other three accessory 5 mm trocar are inserted into the abdomen to the left lower quadrant, right lower quadrant, suprapubic area, for operative instruments and the suction irrigator cannula.
223966212|NCT05280509|DRUG|TL-895|TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
223966213|NCT05280509|DRUG|Ruxolitinib|Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
223966214|NCT05828654|BEHAVIORAL|Focus Group Discussions and Semi-structured Interviews|Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
223966215|NCT05828654|BEHAVIORAL|Training community lay navigators|Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
223966216|NCT03537014|BEHAVIORAL|Therapy|Non-directive therapy performed by therapist team
223966217|NCT03537014|DRUG|midomafetamine HCl|Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental dose 1.5 to 2 hrs later of 40 or 60 mg midomafetamine HCl, respectively, during three experimental sessions
224112207|NCT01903239|PROCEDURE|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
224112208|NCT06338865|OTHER|Carbon dioxide|Gas used for insufflation pressure
223966218|NCT03537014|DRUG|Placebo|Administration of placebo during three experimental sessions
223966219|NCT04070521|OTHER|Observational EEG Monitoring|Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
223966220|NCT02056925|OTHER|Echocardiography|
223966221|NCT03962127|OTHER|no intervention|no intervention
224112209|NCT06338865|DRUG|Bupivacaine|Local subcutaneous infiltration of all port sites with 0.25% bupivacaine will be performed prior to each incision. Remaining local anesthetic will be administered into the incision sites prior to the conclusion of the case (30cc total).
224112210|NCT06338865|DRUG|Oxycodone|All patients will be prescribed a total of 10 pills of oxycodone 5mg, which is the standard amount that our practice prescribes for patients after laparoscopic surgery.
224112211|NCT04356105|DRUG|Minimal stimulation protocol|Letrozole, Recombinant FSH, GnRH antagonist
224112212|NCT04356105|DRUG|Microflare protocol|OCP, GnRH agonist, Recombinant FSH
224112213|NCT04356105|PROCEDURE|IVF/ICSI cycle|Involving ovum pickup and embryo transfer
224112214|NCT01591018|PROCEDURE|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
224112215|NCT01591018|PROCEDURE|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
224112216|NCT06326840|DRUG|Metformin|All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
223724781|NCT05081973|OTHER|A model for predicting extubation success based on extubation readiness estimator and lung ultrasonography score|"Parameters to be recorded before and after extubation to create a new dual extubation model from all babies who met the extubation criteria included in the study:~1. Lung ultrasound score: Lung ultrasound will be performed prior to the extubation and after the extubation. Lung aeration will be scored based on three chest areas for each side (upper anterior, lower anterior and lateral) and a score of 0 to 3 points will be given for each area (Total score ranges from 0 to 18 points).~2. Probability of Successful Extubation: It will be calculated by extubation readiness estimator provided by the website named http://extubation.net/.~This parameter will be calculated only 1 hour prior to the scheduled extubation time."
223966222|NCT01324011|BEHAVIORAL|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
223966223|NCT06819579|DRUG|1.5% Lidocaine|After successful epidural puncture, 3ml of 1.5% lidocaine was injected as a test dose
223966224|NCT06819579|DRUG|1.0% Lidocaine|After successful epidural puncture, 5ml of 1% lidocaine was injected as a test dose
223966225|NCT06819579|DRUG|0.5% Lidocaine|After successful epidural puncture, 10ml of 0.5% lidocaine was injected as a test dose
223966226|NCT06900140|DRUG|Methylene Blue|Continuous methylene blue infusion at a fixed dose of 0.50 mg/kg/hour (diluted in 500 mL of dextrose 5% in water) over 6 hours once daily, for a total of up to 3 doses.
223966227|NCT06900140|OTHER|Usual Care|Usual guideline-directed care for adult septic shock.
223966228|NCT04414254|DRUG|Cefprozil 125mg/5ml Susp; Cefprozil granule (125mg)|"Subjects were allocated to one of two groups randomly and equally with a 3-day washout interval between the two periods.Cefprozil for Suspension® (125mg/5mL, 50mL/bottle, batch no. F701087, manufactured by Lupin Pharmaceuticals, Inc.) and cefprozil granule (125mg, batch no. 8G001F07, manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study."
223966229|NCT04728217|DRUG|Efmoroctocog Alfa Injection [Eloctate]|Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
223966230|NCT00657475|DRUG|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
223966231|NCT00657475|DRUG|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
223966232|NCT01414725|OTHER|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al \[2009\]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
223966233|NCT01414725|OTHER|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
223966234|NCT01414725|OTHER|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
223966235|NCT01239537|DRUG|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
223724782|NCT04079608|BEHAVIORAL|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
223966236|NCT06309849|OTHER|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique)|Manual physiotherapy intervention( cervical traction, suboccipital release, muscle energy technique) strengthening exercises for neck muscles, ultrasound with parameters 5 min × 3 times × 4 weeks, 1 MHz, continuous: 1.5 W/cm2; pulsed: 2.5 W/cm2.
223966237|NCT04389918|OTHER|Tality|Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.
223966238|NCT04233333|DEVICE|method of fixation of the orogastric tube|Methods of fixation of the orogastric tube will be randomized
223966239|NCT03950596|OTHER|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
223966240|NCT03950596|BEHAVIORAL|Background Questionnaire|Background questionnaire will be filled out by participants
223966241|NCT03950596|OTHER|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
223966242|NCT03950596|GENETIC|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
223966243|NCT03950596|DIAGNOSTIC_TEST|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
223966244|NCT03950596|DIAGNOSTIC_TEST|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
223966245|NCT01151878|DIETARY_SUPPLEMENT|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
223966246|NCT01151878|DIETARY_SUPPLEMENT|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
223966247|NCT06086522|DRUG|QN-302|Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
223966248|NCT00439348|BEHAVIORAL|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
223966249|NCT00439348|BEHAVIORAL|Prescription|Patients receive a prescription for a specific over-the-counter medication.
223966250|NCT05990270|BEHAVIORAL|education|Cervical cancer education will be provided. (The training will be in three sessions, each session will last 20-30 minutes. In the training; ppt presentation for cervical cancer, HPV virus, question and answer method will be used. In addition, female pelvic anatomy, gynecological examination, how the Pap Test is done, and cervical exam on the gynecological examination model. will be explained by showing cancer pathologies ) After the training, the final test data will be obtained by applying the questionnaire again.
223966251|NCT05347121|DIAGNOSTIC_TEST|difficult airway|ultrasonography of airway
224112217|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (active)|"Exopulse Mollii suit is a new assistive device that has been developed by Exoneural Network (initially Inerventions AB), a Swedish med-tech company. Exopulse Mollii suit is a full-body garment with integrated 58 electrodes that can transcutaneously stimulate several groups of muscles.~This stimulation is not intended to obtain a motor effect (contraction of the muscles in question), but rather to decrease the spasticity in spastic muscles by activating the antagonistic muscles via the physiological mechanism of reciprocal inhibition. The device is CE labelled and is intended to use for reducing spasticity and improving blood circulation. The outfit is very easy to put on, it can be used for one hour every day and the analgesic effects last 24 hours or more"
223966252|NCT06244030|OTHER|core stabilization group|The athletes in the training group will be applied 15-20 repetitions of core stabilization exercise program 3 days a week for 6 weeks by the researcher.
223966253|NCT00445861|BIOLOGICAL|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
223966254|NCT00445861|BIOLOGICAL|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
223966255|NCT00445861|BIOLOGICAL|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
224112218|NCT06266286|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off
224112219|NCT01748396|DRUG|Calcitriol|
224112220|NCT01748396|DRUG|Calcium Carbonate|
224112221|NCT03136705|DRUG|Nicotinamide|Nicotinamide tablet
224112222|NCT03136705|DRUG|Lanthanum Carbonate|Lanthanum Carbonate tablet
223966256|NCT00445861|PROCEDURE|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
224112223|NCT03136705|DRUG|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
224112224|NCT03136705|DRUG|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
224112225|NCT03859999|DIAGNOSTIC_TEST|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
223966257|NCT06347029|PROCEDURE|Urine sampling|Urine sampling
223966258|NCT06347029|PROCEDURE|Blood sampling|Blood sampling
223966259|NCT06347029|DEVICE|Flow mediated dilatation test|The flow mediated dilation (FMD) test is the most commonly utilized, non-invasive, ultrasound assessment of endothelial function in humans.
223966260|NCT00598117|BEHAVIORAL|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~* Initial QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~* Follow up QOL form~* FACT-E, PAR, Symptom Assessment Scale, MDSS"
223966261|NCT04693650|DEVICE|NeuroBlock UHF stimulation|NeuroBlock ultrahigh frequency (UHF) stimulation with 500kHz intra-pulse
223966262|NCT02872818|DRUG|17β estradiol hemihydrate|4mg/kg/day for 20 days
224112226|NCT06038474|DRUG|Descartes-08|Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
224112227|NCT04103372|DIAGNOSTIC_TEST|MRI scan|MRI scans will be recommended for all rectal polyps ≥20mm in size, or with other features suspicious of malignancy, prior to removal. This is designed to reduce the numbers of Early Rectal Cancers missed in endoscopy.
224112228|NCT04103372|OTHER|Radiologist training|Radiologist training in the use of the PRESERVE mrSRT for suspected Early Rectal Cancer.
223542574|NCT04373421|DRUG|Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
223966263|NCT02872818|DRUG|Metformin|50 mg/kg/day last 10 days
223966264|NCT02872818|DRUG|medroxyprogesterone acetate|1mg/kg/day last 10 days
223966265|NCT05964270|DEVICE|e-coach multipel myeloma (MM)|In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
223966266|NCT00092365|DRUG|MK0966, rofecoxib|
223966267|NCT00092365|DRUG|Comparator: celecoxib, placebo|
223966268|NCT03219255|DRUG|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
223966269|NCT05242913|DIETARY_SUPPLEMENT|Resistant Potato Starch|Unmodified potato starch containing \>60% resistant starch Type 2
223966270|NCT05242913|DIETARY_SUPPLEMENT|Placebo|Fully digestible corn starch
223966271|NCT04346433|BEHAVIORAL|Restricted Sleep|During the restricted sleep condition adolescents will sleep 4 hours ±1 hour (0100-0500). This condition will last 1 night.
223966272|NCT04346433|BEHAVIORAL|Adequate Sleep|During the adequate sleep condition adolescents will sleep 9 hours ±1 hour (2100- 0800). This condition will last 1 night.
223966273|NCT01178281|DRUG|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
223966274|NCT01178281|DRUG|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
223966275|NCT01178281|DRUG|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
223966276|NCT01184859|DRUG|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
223966277|NCT01184859|DRUG|Placebo|Placebo melt tablet for sublingual administration
223966278|NCT04549142|OTHER|There is no intervention|There is no intervention
223966279|NCT05460429|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.
223966280|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 30 grams|Roasted walnuts without salt or sugar.
223966281|NCT04037943|DIETARY_SUPPLEMENT|Walnuts 60 grams|Roasted walnuts without salt or sugar.
223966282|NCT00329498|DRUG|L-Ascorbic Acid|
223966283|NCT00961298|DRUG|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
223966284|NCT06414759|DRUG|Acetazolamide|"Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily."
223966285|NCT06414759|DRUG|Metolazone|"Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily."
223966286|NCT06414759|DRUG|IV Loop Diuretics|IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
223966287|NCT05144438|DIAGNOSTIC_TEST|Toxseek test|Hair taking
223966288|NCT03184142|BEHAVIORAL|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
223966289|NCT03184142|BEHAVIORAL|Video|Student watch a 15-minute intimidation video (see arm description).
224112229|NCT06539897|BEHAVIORAL|Sexual education|These sessions of the sexual education program aim to increase women's knowledge and awareness about their own bodies. Women are informed about their own bodies, their identities, and the stages of sexual response, aiming to make the process clearer and more understandable. They will be encouraged to discover what sexuality means to them, their knowledge about sexuality will be questioned, and sexual myths, if any, will be revealed, and correct information about sexual myths will be provided to normalize sexuality. In addition, discussions will be held on the meanings of being a woman and an older woman, and women's perspectives on themselves and their self-esteem will be emphasized. In the third session, participants will be taught effective communication techniques to improve their communication skills with their partners.
224112230|NCT02267512|DRUG|ATG-F|Intravenous (IV)
224112231|NCT02991300|DEVICE|BioPoly RS Partial Resurfacing Patella Implant|
224112232|NCT04470752|DRUG|Capsaicin 1% oral solution|Capsaicin 1.0 micrograms/ml
224112233|NCT04470752|DRUG|InOrpha Solution|glycerol based suspension vehicle
224112234|NCT04610242|DIAGNOSTIC_TEST|skin test|"For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours."
223966290|NCT03184142|BEHAVIORAL|Control group|No intervention. The students suture for 70 minutes
223966291|NCT01232569|DRUG|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
224112235|NCT00510588|OTHER|training|regular physical exercise training for 6 months
223966292|NCT01232569|DRUG|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
223966293|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Slow activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.
223966294|NCT04225637|DEVICE|Miniscrew-Supported Maxillary Expander- Rapid activation|A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
223966295|NCT04044352|BIOLOGICAL|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
223966296|NCT00651937|DRUG|Melphalan|100 mg/m\^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
223966297|NCT00651937|PROCEDURE|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10\^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10\^6 CD34/kg On Day 0."
223966298|NCT00651937|BEHAVIORAL|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
223966299|NCT00651937|DRUG|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
223966300|NCT00651937|PROCEDURE|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
223966301|NCT05154539|DIAGNOSTIC_TEST|Remote digital assessment|Remote digital assessment of test group participants
223966302|NCT05154539|DIAGNOSTIC_TEST|Conventional physical assessment|Conventional physical assessment of control group participants
223966303|NCT06479330|OTHER|Milk Chocolate|Acute intake
223966304|NCT01778647|DIETARY_SUPPLEMENT|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
223966305|NCT01778647|DRUG|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
223966306|NCT02306213|DRUG|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
223966307|NCT02306213|OTHER|standard volume therapy|
223966308|NCT06399341|DEVICE|Papilocare vaginal gel|Treatment with Papilocare® for 6 months (1 cannula/day for 21 days during first month + 1 cannula/alternate days for subsequent 5 months)
223966309|NCT04282564|OTHER|Co-OP treatment|"The Cognitive Orientation to daily Occupational Performance (CO-OP) approach is described as a patient-centred, performance-oriented approach to activities and problem solving that allows skills to be acquired through a process of strategy use and guided discovery. The CO-OP protocol is composed of seven key characteristics: i) the goals chosen by the patient, ii) dynamic performance analysis, iii) the use of cognitive strategies, iv) guided discovery, v) the principles of empowerment, vi) the involvement of a relative, vii) the structure of the intervention (Polatajko and Mandich, 2004/2017). CO-OP is an evidence-based approach to intervention, including evidence of its effectiveness on a physical, cognitive and emotional dimension in adults with stroke"
223966310|NCT01517490|OTHER|Insulin pump|Insulin pump therapy
223966311|NCT01517490|OTHER|Multiple daily insulin injections|Multiple daily insulin injections
223966312|NCT01517490|PROCEDURE|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
223966313|NCT01517490|OTHER|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
223966314|NCT05607485|PROCEDURE|Randomized video numbers|See arm/group description
224112236|NCT00510588|OTHER|training + metformin|regular physical exercise training in combination with metformin for 6 months
224112237|NCT00510588|OTHER|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
223966315|NCT04125771|DIAGNOSTIC_TEST|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
223966316|NCT04125771|DIAGNOSTIC_TEST|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
223966317|NCT00260676|PROCEDURE|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
223966318|NCT05189171|DEVICE|MicroOrganoSphere (MOS) drug screen|Patient-derived models of cancer, called MOS, will be generated from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and a drug screen using standard-of-care drugs used will be completed (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab). Subjects will receive standard-of-care therapy for CRC dictated by their treating physicians.
224112238|NCT01651130|DRUG|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
224112239|NCT01943123|DIETARY_SUPPLEMENT|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
224112240|NCT01943123|DIETARY_SUPPLEMENT|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
224112241|NCT00861042|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
224112242|NCT01215318|DEVICE|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
224112243|NCT02777840|DEVICE|face mask oxygen|oxygen given by face mask as per routine practice
223966319|NCT04237519|BEHAVIORAL|SFL training|"The SFL training program comprises:~* Physical exercises: 50 video exercises to improve balance, muscle strength and physical capabilities in older adults;~* Cognitive exercises: Four ludic activities targeting problem solving (4 Images/ 1 word), memory (Quiz and Recall me), speed processing and divided attention (Attention!).~In addition, the SFL program includes a series of unique components:~* Chat rooms: to share views about topics of interest and tips for common real-life problems;~* Psycho-education content: to improve self-management and promoting cognitive transfer though 22 different topics (provide recommendations usually given in psychotherapy sessions);~* Virtual coach: to guide participants along the proposed exercises by giving them instructions, reminding them regularly to practice a variety of available activities repeatedly, providing appropriate and timely feedback on participant's performances and rewarding assiduity, perseverance and performance."
223966320|NCT04237519|BEHAVIORAL|Active controlled training|"The active control training program is structured in the same manner as the SFL training program and will also offer different physical and cognitive activities:~* Physical exercises: 12 different exercises trains upper and lower extremity strength, mobility and balance offered through a computerized version of a health insurance company physical training program;~* Cognitive activities: Four commercially available leisure activities (Sudoku. Cross Words, Pac-Man and Countdown activities) that are appreciated by older adults but do not teach cognitive strategies and are were not designed to improve cognition per se.~No chat room, psycho-educational content or virtual coach were included in the active control training program."
223966321|NCT00235014|DRUG|trandolapril|2 mg QD
223966322|NCT00235014|DRUG|trandolapril/verapamil|180/2 mg QD
223966323|NCT00235014|DRUG|placebo|1 tablet QD
223966324|NCT00235014|DRUG|verapamil|SR 240 mg QD
223966325|NCT00826371|DRUG|ranibizumab 0.5 mg|
223966326|NCT02589418|PROCEDURE|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
223966327|NCT02589418|PROCEDURE|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
223542575|NCT04373421|PROCEDURE|St. John's wort oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
223966328|NCT02589418|PROCEDURE|No Acupuncture|Control intervention: No needle insertion and manipulation
223966329|NCT01100268|DRUG|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
223966330|NCT05264064|OTHER|The motor assessment to establish validation of the Polish version of the AIMS|The translation, cultural adaptation, and validation were conducted according to existing recommendations. The motor development of infants was assessed with the Polish scoresheet of the AlMS and the PDMS v.2. The examination was conducted by two peadiatric physiotherapists with a minimum 7 years of experience.The examination methodology was concordant with the recommendation of the authors of AIMS and PDMS-2.The intrarater reliability test included two assessments (with one-month interval) performed by one researcher (Rater A). For the second assessment, the videos of spontaneous motor performance of infants were recorded during the examination. The interrater reliability involved assessments by two researchers (Rater A, Rater B). The Gross Motor Scales of the PDMS v.2 was administered to estimate concurrent validity (participants at the age of 0-12 months).
223966331|NCT02217241|OTHER|Handoff Workshop|
223966332|NCT00962221|PROCEDURE|laboratory analysis|laboratory analysis
223966333|NCT01905371|DRUG|Dextroamphetamine|
223966334|NCT01905371|OTHER|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
224112244|NCT02777840|DEVICE|High flow oxygen|High flow oxygen given via optiflo machine / device
223966335|NCT01905371|DRUG|Placebo|
223966336|NCT04059913|DRUG|Roxadustat|Roxadustat will be dosed orally per dose and schedule specified in the arm description.
223966337|NCT03632902|DEVICE|supraglottic device|airway management will be collected
223966338|NCT02440646|RADIATION|Coronary computed tomography angiography|The coronary arteries will be visualized with the MSCT scan CT 5000 Ingenuity (Philips, The Netherlands) or systems from any other vendors.
223966339|NCT02440646|RADIATION|Quantitative coronary angiography, intravascular imaging with percutaneous intervention|Coronaries will be shot with Artis zee (Siemens, Germany) or systems from any other vendors. In case if necessary the procedure will be delayed for intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (with implantation of the medical device).
223966340|NCT04488978|DRUG|Irbesartan/Amlodipine|QID
223966341|NCT03494621|BEHAVIORAL|Protecting Babies While they Sleep Curriculum|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
223966342|NCT00549861|PROCEDURE|Cardiac Magnetic Resonance study|Cardiac MRI study
224112245|NCT01466114|DRUG|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
224112246|NCT01466114|OTHER|Placebo|4 capsules PO QD
223966343|NCT03586141|DIAGNOSTIC_TEST|Pronto® hemoglobin measurement tool|All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
223966344|NCT00282828|DRUG|Sertraline|
223966345|NCT00282828|DRUG|Venlafaxine|
224112247|NCT01466114|DRUG|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
224112248|NCT01466114|OTHER|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
224112249|NCT01900275|OTHER|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
223542576|NCT04373421|PROCEDURE|Virgin olive oil|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
223542577|NCT04794348|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Autologous units of fresh frozen plasma collected from the subject by plasmapheresis
223966346|NCT00282828|DRUG|Placebo|
223966347|NCT00282828|DRUG|Clonazepam|
224112250|NCT05575804|DRUG|GQ1001+pyrotinib|GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
224112251|NCT05575804|DRUG|pyrotinib+capecitabine|pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
224112252|NCT01924715|BEHAVIORAL|ISTDP|An emotion focused brief psychotherapy format.
224112253|NCT04655586|DRUG|rNAPc2|two dose levels of rNAPc2
223966348|NCT05451641|BEHAVIORAL|Blood flow restriction resistance training|The participants will receive a 2-week exercise training program (3 times per week). Each training session will consist of 3 resistance training exercises with two blood flow restriction devices (wide-rigid cuff and narrow-elastic band). For both arms, the participants will perform the same exercise with different BFR devices.
223966349|NCT03590717|BEHAVIORAL|BCC-Only|Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
224112254|NCT04655586|DRUG|Heparin|standard of care heparin per institution (therapeutic or prophylactic regimen)
223966350|NCT03590717|OTHER|Small-voucher|Households in the 'Small-voucher' arm receive a voucher (\~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
223966351|NCT03590717|OTHER|Large-voucher|Households in the 'Large-voucher' arm receive a larger voucher (\~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
223966352|NCT02490059|OTHER|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
223966353|NCT01486277|DRUG|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
223966354|NCT01503515|DRUG|Caspofungin Acetate|Given IV
223966355|NCT01503515|DRUG|Fluconazole|Given IV or PO
223966356|NCT01503515|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223966357|NCT01503515|DRUG|Voriconazole|Given IV or PO
223966358|NCT01007617|DEVICE|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
224112255|NCT02243124|DRUG|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
223966359|NCT01563445|DRUG|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
223966360|NCT01563445|DRUG|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
223966361|NCT00515697|BIOLOGICAL|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
223966362|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery
223966363|NCT04869761|DRUG|Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions|Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery
224112256|NCT02243124|DRUG|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
224112257|NCT03045484|DRUG|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
224112258|NCT03045484|OTHER|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
223542578|NCT04794348|BIOLOGICAL|Freeze Dried Plasma (FDP)|Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
223542579|NCT03622047|DRUG|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
223966364|NCT05341063|BEHAVIORAL|Online Education|"Diabetes education presentations prepared beforehand were explained in two parts in each training. Training interventions were carried out weekly over Zoom for 4 weeks, lasting approximately 40 minutes. Patients' questions were answered.~Two months after the training was completed, the current routine analysis results of the participants were taken again, and height and weight measurements were made with the same measurement tools. Participants were allowed to fill in the data collection forms again."
223966365|NCT05341063|OTHER|Control Group|The control group didn't apply any interference during the study. Participants in the control group continued their routine follow-up.
223966366|NCT01742949|DEVICE|Heated humidification (ThermoSmart)|Heated Humidification (ThermoSmart) Turned On
223966367|NCT01742949|DEVICE|No Humidification|Heated Humidification (ThermoSmart) Turn Off
223966368|NCT00443755|DRUG|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
223966369|NCT00443755|DRUG|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
223966370|NCT00443755|DRUG|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
223966371|NCT03520088|PROCEDURE|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
223966372|NCT03520088|PROCEDURE|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
223966373|NCT04225247|DRUG|Single Bond Universal|Single bond universal (by 3M ESPE) is a seventh generation bonding agents used as desensitizers in the present study.
223966374|NCT04225247|DRUG|Bifluorid 12|it is a fluoride varnish by VOCO.
223966375|NCT04225247|DRUG|Xeno V+|Xeno V+ (by Dentsply) is a seventh generation bonding agents used as desensitizers in the present study.
223966376|NCT01588171|DRUG|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
223966377|NCT01588171|DRUG|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
223966378|NCT04739462|BEHAVIORAL|mHealth Platform|All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
223966379|NCT06159933|PROCEDURE|Supine positioning|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
223542580|NCT03622047|DRUG|No analgesia labor|No analgesia labor control group
223542581|NCT04044014|DEVICE|Gellan sheet|Gellan sheet.
223542582|NCT04044014|DEVICE|Gellan fluid gel|Gellan fluid gel.
223542583|NCT04044014|DEVICE|Mepitel One|Control dressing-- Mepitel One.
223542584|NCT00437749|DRUG|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
223542585|NCT00437749|OTHER|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
223542586|NCT02737501|DRUG|Brigatinib|Brigatinib tablets
223542587|NCT02737501|DRUG|Crizotinib|Crizotinib tablets
223542588|NCT01261975|PROCEDURE|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
223542589|NCT01261975|PROCEDURE|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
223542590|NCT02785692|RADIATION|Radiation|preoperative Radiotherapy/ IMRT
223542591|NCT02582827|DRUG|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
223542592|NCT00551889|DRUG|celecoxib|
223542593|NCT00551889|DRUG|cyclophosphamide|
223542594|NCT00551889|OTHER|laboratory biomarker analysis|
223542595|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (1RDA+CoQ10)|
223542596|NCT02381964|DIETARY_SUPPLEMENT|Supradyn® (3RDA)|
223542597|NCT02381964|DIETARY_SUPPLEMENT|Placebo|
223542598|NCT00405288|DRUG|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
223542599|NCT03523689|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
223966380|NCT06159933|PROCEDURE|Early pronation|According to our local protocol, starting from January 2022, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
223966381|NCT06159933|PROCEDURE|Late pronation|According to our local protocol, until December 2021, all patients developing PGD \>1 after LT were monitored in supine position for at least 24 hours, aiming at optimizing mechanical ventilation settings and right ventricular function, before considering PP. Only in case of radiological worsening or reduction in PaO2/FiO2 ratio patients were turned prone, generally between 24 and 48 hours after the diagnosis ('late PP' group), otherwise they were maintained supine ('supine' group).
223966382|NCT04782505|DRUG|DWJ1248|Camostat mesylate Tablet from Daewoong
223966383|NCT01695525|OTHER|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
223966384|NCT05849571|OTHER|coconut oil|• The patient's mouth is evaluated using the World Health Organization Mucositis Classification and the International Child Mucositis Evaluation Scale (ChIMES) on days 0, 7, and 14, and after each assessment, the frequency of oral care is determined and applied for 21 days. The final assessment is made on Day 21.
223966385|NCT04441996|BIOLOGICAL|Therapeutic plasma exchange (TPE)|Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.
223966386|NCT04441996|OTHER|Standard of care|Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
223966387|NCT00159341|PROCEDURE|Nasal lavage|Nasal lavage was carried out at specified timepoints
223966388|NCT00159341|PROCEDURE|Nasal filter paper|Nasal filter paper was placed at specified timepoints
223966389|NCT00159341|PROCEDURE|Blood sampling|Blood sampling was performed as a routine safety check
223966390|NCT01543906|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
223966391|NCT05289375|DRUG|Vacucis autovaccine|A sample will be taken from all participants in group T following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory. After 1 month from the sample collection, the laboratory will send in a container/dispenser (with the same appearance in both groups) to the T group will be administered the complete autovaccine ((with two applications per day for 7 weeks)
224112259|NCT02345369|DEVICE|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
223966392|NCT05289375|DRUG|Placebo|A sample will be taken from all participants in group P following the manufacturer's instructions for the design of the autovaccine, using a sterile swab that will be placed in a transport medium and sent to the laboratory (as in group T). After 1 month from the collection of the sample, the laboratory will send it in a container/dispenser (with the same appearance in both groups). The content in group P will receive a placebo in the same dosage and temporality as group T, it will be the same except for the active ingredient, that is, only thimerosal, methylcellulose, sodium chloride and orange essence.
223966393|NCT02160496|BEHAVIORAL|Weight loss interventional study with 20% protein-diet|
223966394|NCT02160496|BEHAVIORAL|Weight loss interventional study with 27% protein-diet|
224112260|NCT02345369|DEVICE|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
224112261|NCT04578145|DIAGNOSTIC_TEST|HIV self-testing among female sex workers|"Barriers faced by FSWs in terms of undergoing HIV blood test seemingly overcome through the implementation of alternative strategy of testing, by using OFT self-testing (Ora-Quick).~Ora-Quick test used in this study measures antibody in oral fluid of participants. The oral fluid is collected used a test swab from participant's gum by wiping upper and lower gums once. The specimen mixed with buffered developer solution in test tube. Test result will appear in a short time, by 20 to 40 minutes and leading to interpret."
224112262|NCT04818450|DRUG|Gabapentin|Gabapentin 100-300 mg is given to the intervention group
224112263|NCT02405039|DRUG|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
224112264|NCT02405039|DRUG|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
223966395|NCT02160496|BEHAVIORAL|Weight loss interventional study with 35% protein-diet|
223966396|NCT03932253|OTHER|FCN-159|Administered orally once a day
223966397|NCT01243086|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
223966398|NCT01243086|DRUG|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
223542600|NCT03523689|PROCEDURE|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
223542601|NCT01642303|OTHER|vodcasting|listening to downloaded vodcasting files
223542602|NCT01642303|OTHER|no intervension|Listen to student book listening files
223966399|NCT01093976|DRUG|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
223966400|NCT00376935|DRUG|Palifermin|Keratinocyte growth factor administered via injection
223966401|NCT00376935|DRUG|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
223966402|NCT00840788|PROCEDURE|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
223966403|NCT00840788|PROCEDURE|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
223966404|NCT01217723|BIOLOGICAL|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
223966405|NCT01217723|OTHER|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
223966406|NCT06141694|DEVICE|The LIBERTY® Robotic System|"The LIBERTY® Robotic System is intended for use in the remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, to facilitate navigation to anatomical targets in the peripheral vasculature.~The LIBERTY® Robotic System is not intended for coronary or neurointerventional procedures."
223966407|NCT00084409|DRUG|iloprost|Given orally
223966408|NCT00084409|OTHER|placebo|Given orally
224112265|NCT05795465|DRUG|GEn-1124|Intravenous infusion
223966409|NCT02219529|DEVICE|MCE|
223966410|NCT02219529|DEVICE|Standard gastroscopy|
223966411|NCT04009902|BEHAVIORAL|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
224112266|NCT05795465|DRUG|Placebo|Intravenous infusion
224112267|NCT04418583|DIAGNOSTIC_TEST|Three-dimensional imaging|Three-dimensional surface images, acquired by the Artec Leo
224112268|NCT02432677|DRUG|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
223966412|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
223966413|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
223966414|NCT01291524|DRUG|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
223966415|NCT01291524|DRUG|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
223966416|NCT06344494|DEVICE|Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system|Novel ICE catheter and combined ultrasound system
223966417|NCT06344494|DEVICE|SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system|Commercially available devices
223966418|NCT02080143|DEVICE|Thermal Adhesion Patch|
223966419|NCT02080143|DEVICE|Thermal Adhesion Patch|
223966420|NCT03639649|DIAGNOSTIC_TEST|STHLM3|
223966421|NCT03296423|BIOLOGICAL|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
223966422|NCT03296423|BIOLOGICAL|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
223966423|NCT05921929|DRUG|Fluoroethylnormemantine (FENM)|Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
223966424|NCT01763489|BEHAVIORAL|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
223966425|NCT00122707|DEVICE|catheters|
223966426|NCT03110640|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
223966427|NCT03110640|DRUG|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
223966428|NCT03110640|DRUG|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
223966429|NCT02339506|DRUG|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
223966430|NCT02339506|DRUG|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
223542603|NCT03643835|DEVICE|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
223542604|NCT03643835|OTHER|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
223966431|NCT02112799|DRUG|NVR 3-778|
223966432|NCT02112799|DRUG|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
223966433|NCT02112799|DRUG|Pegasys|
223966434|NCT01257386|DRUG|Asacol®|400mg tablets
223966435|NCT01257386|DRUG|Mesalazine|400mg tablets
223966436|NCT03694249|DRUG|Ifetroban Sodium|Given by mouth
223966437|NCT03694249|OTHER|Placebo|Given by mouth
223966438|NCT05166317|OTHER|This is an observational study|This is an observational study
223966439|NCT02232919|DEVICE|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
223966440|NCT05834647|DRUG|Prilocaine 2%|50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure
223966441|NCT05834647|DRUG|Hyperbaric Lidocaine 5%|50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
223966442|NCT03997409|OTHER|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
223966443|NCT04463888|OTHER|occupational therapy|occupational therapy targeted to goals that are relevant to the functional needs of the patient
223966444|NCT02581826|DRUG|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
223966445|NCT02581826|DRUG|Placebo|No column specified.
223966446|NCT04975646|BEHAVIORAL|Prescribed exercise program|Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
223966447|NCT00599599|BEHAVIORAL|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
223542605|NCT00994864|DRUG|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
223542606|NCT05527600|DIAGNOSTIC_TEST|intensity of acute pain evaluation|the facial expression of each patient will be collected from a short video of 10 seconds, follow by with the evaluation of the pain intensity.
223966448|NCT01975259|DRUG|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution \& have glucose levels recorded up to every 30 mins for 2hours
223966449|NCT01975259|DRUG|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution \& have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
223966450|NCT01975259|DRUG|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
223966451|NCT01975259|DRUG|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
223966452|NCT01975259|DRUG|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
223966453|NCT01975259|DRUG|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
223966454|NCT01975259|OTHER|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
223966455|NCT01975259|OTHER|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
223966456|NCT01975259|OTHER|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
223966457|NCT01975259|DEVICE|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid \& every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
223966458|NCT01062854|OTHER|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
223966459|NCT00562926|PROCEDURE|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
223966460|NCT01323335|DRUG|IV Uric Acid|
223966461|NCT01323335|DRUG|IV Rasburicase|
224112269|NCT02432677|DEVICE|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
223542607|NCT00185887|DRUG|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
223542608|NCT02405988|DRUG|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
223966462|NCT03807271|DEVICE|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
223966463|NCT04730570|BEHAVIORAL|Essential Coaching for Every Mother|Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
223966464|NCT05734976|DEVICE|electroacupuncture|This is the group that receives real electroacupuncture, applied to selected acupuncture points both on the arms and legs, and on the scalp. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length.
223966465|NCT05115721|OTHER|no intervention|It's only observational study. No interventions.
223966466|NCT04067206|OTHER|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
223966467|NCT04067206|OTHER|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
223966468|NCT04067206|OTHER|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development.
223966469|NCT00501111|DRUG|AZD3480|3 oral doses
223966470|NCT00501111|DRUG|Donepezil|
223966471|NCT03300661|BEHAVIORAL|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
223966472|NCT01753323|DRUG|KAF156|KAF156 was supplied as tablets for oral use.
223966473|NCT01657071|DRUG|YH14659|YH14659 capsule by oral
223966474|NCT01657071|DRUG|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
223966475|NCT02650388|BEHAVIORAL|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
223966476|NCT02115542|DRUG|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
223966477|NCT03558750|BIOLOGICAL|Nivolumab|Given by IV
223966478|NCT03558750|BIOLOGICAL|Rituximab|Given by IV
223966479|NCT03558750|DRUG|Lenalidomide|Given by mouth
223966480|NCT01110161|DEVICE|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
223966481|NCT01116440|DRUG|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
223966482|NCT01116440|DRUG|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
223966483|NCT01103271|OTHER|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
223966484|NCT05279417|DRUG|ATI-450 50 mg oral tablet BID|Oral, small molecule MK2 inhibitor
223966485|NCT05279417|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
223966486|NCT05279417|DRUG|Methotrexate|15 mg to 25 mg weekly
223966487|NCT05279417|DRUG|ATI-450 20 mg oral tablet BID|Oral, small molecule MK2 inhibitor
224112270|NCT02432677|DEVICE|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
224112271|NCT02432677|DRUG|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
223966488|NCT02245971|PROCEDURE|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
224112272|NCT03988777|DEVICE|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
224112273|NCT02945761|PROCEDURE|High concentration of sugar solution|
223966489|NCT02245971|PROCEDURE|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
223966490|NCT03199170|DRUG|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
223966491|NCT03199170|DRUG|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
223966492|NCT03199170|DRUG|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
223966493|NCT05959109|DRUG|Peresolimab|Administered SC
223966494|NCT00203788|BEHAVIORAL|Individual Placement and Support|Supported education/employment
224112274|NCT02945761|PROCEDURE|conventional surgical dressing change|
224112275|NCT05911958|DRUG|SHR-A1811 for injection|SHR-A1811 for injection
224112276|NCT05588895|OTHER|Notification|"For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician."
224112277|NCT03952286|DRUG|ED-Dispensing home and school supervision|"1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~2. 360 ug of budesonide inhalation powder once-daily for at-home use, and~3. albuterol sulfate as needed for relief of acute respiratory symptoms."
224112278|NCT00002516|BIOLOGICAL|dactinomycin|
224112279|NCT00002516|DRUG|cyclophosphamide|
224112280|NCT00002516|DRUG|doxorubicin hydrochloride|
224112281|NCT00002516|DRUG|etoposide|
224112282|NCT00002516|DRUG|ifosfamide|
224112283|NCT00002516|DRUG|mesna|
224112284|NCT00002516|DRUG|vincristine sulfate|
224112285|NCT00002516|PROCEDURE|conventional surgery|
224112286|NCT00002516|RADIATION|low-LET cobalt-60 gamma ray therapy|
224112287|NCT00002516|RADIATION|low-LET photon therapy|
224112288|NCT05425771|PROCEDURE|Anti Reflux Mucosa Ablation|Mucosa ablation with Argon plasma coagulation performed in inversion at the gastroesophageal junction in a crescent or horseshoe shape over a width of 1.5 - 2 cm in patients with refractory reflux symptoms
224112289|NCT04996576|PROCEDURE|infrazygomatic approach sphinopalatine ganglion block|"A lateral fluoroscopic view of the face will be obtained with the C-arm by superimposing the mandibular rami on top of each other spinal needle with a slightly bent tip is inserted with lateral fluoroscopic guidance. superiorly and medially toward the sphinopalatine fossa.~(AP) view intermittently obtained to check the depth 0.2 mL of contrast material will be injected to rule out intravascular spread and confirm spread of the dye within the sphinopalatine fossa .Local anesthetic, such as 2 mL of 1% lidocaine will be slowly injected"
224112290|NCT04996576|PROCEDURE|intranasal injection approach of sphinopalatine ganglion block|method 2 ml Lidocaine with Epinephrine 1/200000 will be injected posterior to meatus of middle concha to block terminal nerve branches of sphinopalatine ganglia
223966495|NCT00203788|BEHAVIORAL|Workplace Fundamentals Module|Group skills training on job/school topics
223966496|NCT00203788|BEHAVIORAL|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
223966497|NCT00203788|DRUG|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
224112291|NCT01772979|DRUG|Trabectedin|
224112292|NCT00631319|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
224112293|NCT00631319|DRUG|Placebo|Placebo
224112294|NCT01037712|DRUG|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
224112295|NCT01037712|DRUG|Placebo|placebo
224112296|NCT00891657|DEVICE|SprayShield™|Anti-adhesion barrier
224112297|NCT00326261|PROCEDURE|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
223966498|NCT00203788|BEHAVIORAL|Skills training group|Group social skills training that did not focus primarily on work situations
223966499|NCT01100593|PROCEDURE|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
223966500|NCT03491774|BEHAVIORAL|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
223966501|NCT03416335|DRUG|DSP-0509|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump.
223966502|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the dose fixed for that Part or cohort administered as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
223966503|NCT03416335|DRUG|DSP-0509, Pembrolizumab|Each patient treated will receive DSP-0509 at the Recommended Phase II Dose (RP2D) level as determined in Part B. It is given as a constant rate IV infusion over 10 minutes using a syringe pump and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (400 mg IV q6w)
223966504|NCT02173249|DRUG|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
223966505|NCT00788879|BEHAVIORAL|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
224112298|NCT00326261|PROCEDURE|Ultrasound|
224112299|NCT04207073|DEVICE|Mobilization of median nerve|Neural mobilization
223542609|NCT02405988|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
223542610|NCT00440817|OTHER|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
223542611|NCT02447185|DRUG|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
223542612|NCT02447185|DRUG|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
223542613|NCT03593148|OTHER|Lifestyle|Lifestyle treatment
223542614|NCT05545943|OTHER|2-days of zero calorie restriction and whole-body cold-water immersion|The 2-days (48 hours) of zero-calorie restricted diet (with water provided ad libitum) with two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min.
223966506|NCT00788879|BEHAVIORAL|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
223966507|NCT00733551|DRUG|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
223966508|NCT00733551|DRUG|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
223966509|NCT01048983|DRUG|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
223966510|NCT01048983|DRUG|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
223542615|NCT05545943|OTHER|6-days of calorie restriction|The 6-days (144 hours) of prescribed zero-calorie prescribed diet with water provided ad libitum.
223542616|NCT05545943|OTHER|2-days of zero calorie restriction without whole-body cold-water immersion|2 days (48 hours) of prescribed zero-calorie diet with water provided ad libitum .
223542617|NCT05545943|OTHER|2-days of usual diet with whole-body cold-water immersion|Two whole-body cold-water immersion sessions on separate days. During cooling procedures, the participant was immersed in 14° water bath in semi recumbent position up to the level of the manubrium for 10 min. During intervention, participants were instructed to maintain their previous eating habits.
223966511|NCT01048983|DRUG|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
223966512|NCT01048983|DRUG|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
223966513|NCT01048983|BEHAVIORAL|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
223966514|NCT02396550|BEHAVIORAL|Positive Expectations|Give positive expectation of the treatment efficacy to patients
223966515|NCT02396550|PROCEDURE|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
223966516|NCT00201214|DRUG|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
223966517|NCT04134221|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
223542618|NCT01993134|PROCEDURE|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
223542619|NCT01993134|PROCEDURE|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
224112300|NCT05671120|PROCEDURE|Transcutaneous levator recession|recession of the upper and lower eyelid retractors can improve the upper eyelid contour if the patient has lateral flare (common in TED). The choice of procedure depends on severity of lid retraction and associated features like proptosis, status of extraocular muscles, and corneal condition
223966518|NCT04596917|BEHAVIORAL|Preferred music listening|The preferred music listening group will receive 15 minute patient-preferred music listening selection intervention in the Prep Room and unlimited music listening selection intervention in the PACU once cognitively ready until discharge criteria met.
223966519|NCT04596917|BEHAVIORAL|Relaxation breathing narrative over hypnotic music listening|The relaxation breathing group will receive the relaxation and breathing instructions over soft monotone hypnotic music in the PreOp unit before surgery and then in the PACU once cognitively ready to listen to the hypnotic music until discharge criteria met.
224112301|NCT05171738|DEVICE|skeletally anchored distal jet|used from day one and activated every month
224112302|NCT02739698|DRUG|Paclitaxel|
223966520|NCT00083473|DRUG|Pivanex|
223966521|NCT01876719|DRUG|AR08|
224112303|NCT02739698|PROCEDURE|Radical surgery-peritonectomy|
224112304|NCT02927171|OTHER|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
224112305|NCT01065480|BEHAVIORAL|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
224112306|NCT01065480|BEHAVIORAL|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
224112307|NCT02410369|DRUG|S-588410|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
224112308|NCT02410369|DRUG|Placebo|Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
224112309|NCT00147628|DRUG|sildenafil citrate|
223966522|NCT01876719|DRUG|Placebo|
223966523|NCT05414435|BEHAVIORAL|Reading of informed consent form|Patients that adequately read informed consent forms
223966524|NCT00219635|DRUG|UK-390,957|
223966525|NCT00465699|DRUG|Topical B12 0.07%|
223966526|NCT04557332|BEHAVIORAL|On the Dot Mobile app|On the Dot is a mobile app to support HIV medication adherence. The mobile app is linked to a clinician portal through which participants can receive adherence support.
223542620|NCT04819113|BIOLOGICAL|Nimenrix|MenACWY-TT vaccine
223542621|NCT04141319|DRUG|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
223542622|NCT04141319|DRUG|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
223966527|NCT03455569|BEHAVIORAL|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
223966528|NCT03455569|BEHAVIORAL|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
223966529|NCT03698721|PROCEDURE|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
223966530|NCT03681171|OTHER|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
223966531|NCT02686359|BIOLOGICAL|sample|
223966532|NCT04364022|DRUG|Lopinavir/ritonavir|2x 200mg/50mg, twice daily for 5 days (bid, PO)
223966533|NCT00002471|DRUG|asparaginase|
223966534|NCT00002471|DRUG|cyclophosphamide|
223966535|NCT00002471|DRUG|cytarabine|
223966536|NCT00002471|DRUG|daunorubicin hydrochloride|
223966537|NCT00002471|DRUG|dexamethasone|
224112310|NCT00147628|DRUG|placebo for sildenafil citrate|
224112311|NCT02420964|OTHER|video instruction|Patient Directed Video Instruction
224112312|NCT02420964|OTHER|Nurse instruction|Nurse directed instruction
224112313|NCT02677701|DRUG|azithromycin|500mg tablet over-encapsulated to match placebo
224112314|NCT02677701|DRUG|placebo (for azithromycin)|
223966538|NCT00002471|DRUG|etoposide|
223966539|NCT00002471|DRUG|leucovorin calcium|
224112315|NCT02677701|DRUG|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
224112316|NCT03805295|OTHER|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
224112317|NCT03520023|OTHER|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
223542623|NCT04141319|DRUG|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
223542624|NCT02874443|OTHER|Knowledge Translation of labor management guidelines|
223966540|NCT00002471|DRUG|methotrexate|
223542625|NCT05014373|COMBINATION_PRODUCT|Favipiravir + Standard of Care|"1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily~Plus Standard of Care"
223966541|NCT00002471|DRUG|methylprednisolone|
223966542|NCT00002471|DRUG|therapeutic hydrocortisone|
223966543|NCT00002471|DRUG|thiotepa|
223966544|NCT00002471|DRUG|vincristine sulfate|
224112318|NCT05200949|PROCEDURE|Kidney transplant|Transplant surgery of Kidney
224112319|NCT00638066|DRUG|botulinum toxin|500 units of botulinum toxin for the second arm
224112320|NCT00638066|DRUG|botulinum toxin A|250 units of botulinum toxin A once
224112321|NCT03189225|OTHER|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
224112322|NCT02808715|OTHER|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
223542626|NCT05014373|PROCEDURE|Standard of Care|Best supportive care includes Standard treatment included oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
223542627|NCT04379674|OTHER|FACILITATION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps brachii muscle. Taping was done with 25% tension with Y tape from the origin to insertion of the muscle.
223542628|NCT04379674|OTHER|INHIBITION TAPING|The muscle technique, which is a kinesio tape technique, will be used in the biceps braki muscle. Taping was done with 25% tension with Y tape from the insertio to origo of the muscle.
223542629|NCT04379674|OTHER|PLACEBO TAPING|Unlike Kinesio taping muscle technique, it was performed with horizontal taping on the muscle. The ends of the kinesio tapes will be applied tension-free without overlapping with I tape.
223966545|NCT02391714|PROCEDURE|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
223966546|NCT02391714|DRUG|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
223966547|NCT02391714|DRUG|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
223966548|NCT02391714|OTHER|Oxygen|100% oxygen via nasal mask.
223966549|NCT02391714|OTHER|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
224112323|NCT00816972|DRUG|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
224112324|NCT00816972|DRUG|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
224112325|NCT00816972|DRUG|Placebo for Desloratadine 2.5 mg|Placebo BID
223542630|NCT04067492|DRUG|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223542631|NCT04067492|DRUG|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
223542632|NCT02055950|PROCEDURE|Storage of kidney in refrigerated solution|
223542633|NCT02055950|PROCEDURE|Kidney perfused by pulsatile machine|
223542634|NCT04601116|DRUG|Atorvastatin 80 Mg Oral Tablet|Atorvastatin 80 mg per day for 2 years
223542635|NCT04601116|DRUG|Placebo oral tablet|Placebo 1 tablet per day for 2 years
223542636|NCT04548427|DRUG|CKD-352|Eye Drop
223542637|NCT04548427|DRUG|Diquafosol Sodium 3%|Eye Drop
223542638|NCT03539757|DEVICE|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
223966550|NCT03543540|BIOLOGICAL|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
223966551|NCT03543540|BIOLOGICAL|Placebo|Placebo injections: 14 in total at twice weekly intervals
223966552|NCT02701595|DRUG|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients \>70kg)
223966553|NCT02701595|PROCEDURE|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
223966554|NCT05324384|DRUG|Sirolimus|Use of different doses of the same drug
223542639|NCT05958589|DRUG|Caudal block with levobupivacaine|After the introduction of general anesthesia, a single shot caudal block will be performed with levobupivacaine 0.25% (2.5 mg/kg; maximal dose 75 mg).
223966555|NCT01446042|DRUG|Testosterone|Intranasal testosterone
223966556|NCT01446042|DRUG|Testosterone|Intranasal testosterone
223966557|NCT02724423|DRUG|NRL-1|
223966558|NCT01871597|DEVICE|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
223966559|NCT03999398|PROCEDURE|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
224112326|NCT00816972|DRUG|Placebo for Oxybutynin 2.5 mg|Placebo BID
224112327|NCT01789073|DIETARY_SUPPLEMENT|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
224112328|NCT03670082|DRUG|Lu AF35700|20 mg Lu AF35700 single oral dose
224112329|NCT03670082|DRUG|Lu AF35700 iv|100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
224112330|NCT02265211|BEHAVIORAL|Self-Help App|
224112331|NCT02201823|DRUG|ABTL0812|ABTL0812. Five cohorts and one extension phase.
224112332|NCT04530825|OTHER|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
223966560|NCT05791305|BEHAVIORAL|double duty intervention packages|The intervention employed in this study will serve as double-duty interventions. The WHO policy short report from 2017 and Hawkes et al2020 .'s were amended and used as the basis for the DDIs packages. The main components of the intervention packages are the promotion of a minimum level of dietary diversity, avoiding unwarranted harm from high-energy foods, and controlling market foods from the perspective of the consumer. The following central criteria will be used to evaluate the study's intervention packages.
223966561|NCT03575572|DRUG|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
224112333|NCT04530825|OTHER|PREVENT Tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
224112334|NCT03870022|DEVICE|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
224112335|NCT03870022|DEVICE|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
224112336|NCT02251223|DRUG|Tipranavir low dose|
223542640|NCT05958589|DRUG|General anesthesia|On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
223542641|NCT05958589|PROCEDURE|Inguinal hernioplasty|Elective inguinal hernioplasty
223966562|NCT02845557|OTHER|OGTT and IVGTT tests|
223966563|NCT00557154|DEVICE|ultrasound|ultrasound used to identify target vein
223966564|NCT00557154|DEVICE|standard technique for venipuncture|routine equipment
224112337|NCT02251223|DRUG|Tipranavir medium dose|
224112338|NCT02251223|DRUG|Tipranavir high dose|
224112339|NCT02251223|DRUG|Ritonavir low dose|
224112340|NCT02251223|DRUG|Ritonavir high dose|
223966565|NCT00157209|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
223966566|NCT00157209|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
223966567|NCT00157209|OTHER|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
223966568|NCT06646393|OTHER|Skin to skin contact|Father-baby skin-to-skin contact was applied within the first hour immediately after the cesarean delivery. During the Father-Baby Skin-to-Skin Contact stage, the newborns were laid face down on their father's bare chest and covered with a blanket.
223966569|NCT00210288|BIOLOGICAL|SC599|
223966570|NCT03684434|BEHAVIORAL|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
223966571|NCT03684434|BEHAVIORAL|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
223966572|NCT02137928|DRUG|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
223966573|NCT02137928|DRUG|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
223966574|NCT06032702|PROCEDURE|tooth alignment|Alignment will be assessed by Little's Irregularity Index
223966575|NCT02595593|DEVICE|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
223966576|NCT00029276|PROCEDURE|Prefrontal transcranial magnetic brain stimulation|
223966577|NCT05521555|PROCEDURE|Total knee arthroplasty|First intention total knee arthroplasty
223966578|NCT03802513|OTHER|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
224112341|NCT04080115|BEHAVIORAL|Attention Training Technique|ATT will be administered through a customized Expiwell smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
224112342|NCT04080115|BEHAVIORAL|Sham intervention control condition|The sham control condition consists of the same 12 minutes of simultaneous sounds as the ATT technique, but will not include any verbal instruction, thus isolating the effects of intentional orientation of attention.
224112343|NCT03855254|BEHAVIORAL|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
223966579|NCT02382913|BIOLOGICAL|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
223966580|NCT02382913|BIOLOGICAL|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
223966581|NCT02382913|BIOLOGICAL|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
223966582|NCT03623308|OTHER|Fiber cereal|Whole grain and bran cereal
223966583|NCT03788421|DEVICE|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
223966584|NCT03788421|PROCEDURE|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
223966585|NCT04727190|PROCEDURE|Transbronchial Cryobiopsy|The eligible patient will be randomized to TBCB group to receive transbronchial cryobiopsy.
224112344|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 25 mg tablet
223966586|NCT04727190|PROCEDURE|Transbronchial Forceps Biopsy|The eligible patient will be randomized to TBFB group to receive transbronchial forceps biopsy.
223966587|NCT00000121|DEVICE|Prisms in Eyeglasses|
223966588|NCT06009770|DEVICE|"medical device Homing (TecnoBody); medical device Icone (Heaxel)"|Rehabilitation activities for PD and MS will be aimed at improving motor performance and balance using a task-oriented approach with Homing system technology; post-stroke patients will perform a home-based upper limb rehabilitation with the iCONE robotic device for robot-assisted neurorehabilitation of the upper limb.
224112345|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 50 mg tablet
223966589|NCT06009770|BEHAVIORAL|Usual Care|Standard motor exercise training aimed at muscle mobilization and strengthening (MS and PD groups) or to mobilize and enhance motor control of upper limb functions (post-stroke group)
223966590|NCT01803789|DEVICE|Single Kirschner Wire|
223966591|NCT01803789|DEVICE|Double Kirschner Wire|
223966592|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Probiotic product were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 15 mL of sterile water were added to the probiotic product.
224112346|NCT01083290|DRUG|Spironolactone|single dose of one tablet; 100 mg tablet
224112347|NCT05170139|DIETARY_SUPPLEMENT|Caffeine|Participants will ingest a drink with 3mg/kg of body weight mixed with carbohydrates
224112348|NCT05170139|DIETARY_SUPPLEMENT|Placebo drink|Participants will ingest the exact same drink without caffeine
224112349|NCT03909685|BEHAVIORAL|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
224112350|NCT00850499|DRUG|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
223966593|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus inulin|The Syn-inulin products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of inulin (BENEO GmbH) were diluted in 15 mL of sterile water and added to Syn-inulin products.
223966594|NCT05423015|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota plus fructans from A. salmiana|The Syn-A. salmiana products were made in a Class II biosafety cabinet. Fifteen milliliters of the fermented milk food wich contains LcS were taken with a sterile syringe, and, at a subsequent time, 3 g of fructans from A. salmiana were diluted in 15 mL of sterile water and added to Syn-A.salmiana products.
223966595|NCT02619279|OTHER|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
224112351|NCT00850499|DRUG|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
224112352|NCT00850499|DRUG|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
223966596|NCT00024102|DRUG|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 \& 8 and 5-FU 600 mg/sq m IV push d 1 \& 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
223966597|NCT00024102|DRUG|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
223966598|NCT00974402|BEHAVIORAL|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
223966599|NCT04083690|DEVICE|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
224112353|NCT05810779|OTHER|dynamic surface exercise|Optimal arousal Physio ball Make the child bounce, active/passive on the Swiss ball, slow/fast 5 times 5 sets Combined frontal and transverse plane movements Physio ball/ bolster High sitting: one hand weight bearing followed by trunk rotation to reach the toy on opposite side 5-7 each side 1 set Combined frontal and transverse plane movements Platform swing Reaching the toy with both the hands kept overhead and 45°-60° diagonal to the mid line 5-7 times each side 1 set
224112354|NCT05810779|OTHER|trunk targeted training|"trunk training group (TTG) consist of exercises and activities focusing on the activation of the trunk muscles, pelvic control and proximal stabilization and these were combined with the trunk and gluteal muscle strengthening exercises.~The trunk elongation activities, the facilitation of spinal extension, weight shifting and weight-bearing activities The children in the TTG received 45-75-minute of physiotherapy twice a week for 8 weeks"
223966600|NCT04187963|OTHER|Physical therapy|"The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances."
223966601|NCT02488070|PROCEDURE|Computed Tomography|Part of PET/CT scan
223966602|NCT02488070|DRUG|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
223966603|NCT02488070|PROCEDURE|Magnetic Resonance Imaging|Part of PET/MRI scan
223966604|NCT02488070|PROCEDURE|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
223966605|NCT02445781|DEVICE|Glucose clamp|Different levels of hypoglycemia
223966606|NCT01662661|DRUG|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
223966607|NCT01662661|DRUG|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
223966608|NCT04789889|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy
223966609|NCT04789889|RADIATION|postoperative radiotherapy|postoperative radiotherapy
223966610|NCT02588027|DRUG|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
223966611|NCT02588027|DRUG|Placebo|Pharmacy formulated placebo
223966612|NCT05476601|BEHAVIORAL|CMAP Plus|The CMAP Plus intervention will be delivered individually, weekly over a period of 12 weeks.
223966613|NCT05144854|DRUG|ONO-4538|Specified dose on specified days
223966614|NCT05144854|DRUG|Ipilimumab|Specified dose on specified days
223966615|NCT05144854|DRUG|Oxaliplatin|Specified dose on specified days
223966616|NCT05144854|DRUG|Capecitabine|Specified dose on specified days
223966617|NCT05144854|DRUG|S-1|Specified dose on specified days
223966618|NCT02261675|DRUG|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
224112355|NCT05391763|PROCEDURE|Fascia pectoralis preservation|A total mastectomy will be performed in the control breast: a procedure which includes removal of the breast glandular tissue including the PF and subcutaneously excision of the nipple-areolar complex, while the pectoralis muscle will be spared. As much of the healthy skin envelope will be preserved to enable the performance of an effective breast reconstruction afterwards. When a nipple-sparing mastectomy is performed, the skin envelope together with the nipple-areolar complex will be spared. The investigational part of the operation is preservation of the PF. Dissection of cutaneous flaps and the breast with or without the PF will be performed with electrocautery.
224112356|NCT03749642|DRUG|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
224112357|NCT03749642|DRUG|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
223966619|NCT04290416|DIAGNOSTIC_TEST|Microwire electrodes|
223966620|NCT06646198|PROCEDURE|Transjugular intrahepatic portosystemic shunt (TIPS)|Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
223966621|NCT06646198|DRUG|Donafenib|Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
223966622|NCT01770509|DEVICE|NMBM|Daily application of NMBM in addition to compression therapy
223966623|NCT01770509|OTHER|Compression garments|Compression garments
223966624|NCT01658176|DRUG|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
223966625|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
223966626|NCT01658176|DRUG|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
223966627|NCT03759405|BIOLOGICAL|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
223966628|NCT05888402|DRUG|Toripalimab|Two cycles of induction Toripalimab (240mg every 3 weeks) plus platinum-based doublet chemotherapy as induction chemoimmunotherapy.
224112358|NCT03749642|DRUG|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
223542642|NCT05831904|DEVICE|whole-body vibration|After attaching the surface electromyography(EMG) to bilateral hip girdle muscles, participants will walk and jump at their comfortable speed. After investigator record the muscle activation values, participants will be asked to stand on the vibration device. While the whole-body vibration is applied, the hip girdle muscles activation values will be recorded accordingly via sEMG.
223966629|NCT05888402|RADIATION|Concurrent chemoradiation therapy and consolidation immunotherapy|Thoracic radiation therapy (54-66Gy/25-33F/5-7week), concurrently with platinum-based doublet chemotherapy, followed by consolidation Toripalimab (240mg every 3 weeks) as consolidation immunotherapy for up to 12 months.
223966630|NCT00207935|BEHAVIORAL|Swallow instruction|
224112359|NCT03749642|DRUG|Gabapentin|"The total daily doses administered will be:~* 600 mg from day 0 to day 6 (±1)~* 900 mg from day 7 (±1) to day 13 (±1)~* 1200 mg from day 14 (±1) to day 20 (±1)~* 1800 mg from day 21 (±1) to day 56 (±2)"
223542643|NCT00833027|DRUG|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
223542644|NCT01406132|DRUG|ASP015K|oral
223966631|NCT04321915|OTHER|Analysis of intestinal microbiota in autism spectrum desorder|This analysis permit to describe the diversity and composition of microbiota and the factors that may influence them. In fact, the gut microbiota plays a key role in regulating the gut-brain axis
224112360|NCT03749642|DRUG|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
224112361|NCT01472237|OTHER|Nutritional intervention|Modification of diet
223542645|NCT01669694|OTHER|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
223542646|NCT04321005|PROCEDURE|arthroscopic rotator cuff reconstruction|arthroscopic rotator cuff reconstruction and assessment with evaluation and prediction of core outcomes
223542647|NCT02996812|DRUG|Exendin (9-39)|
224112362|NCT01977144|OTHER|Comprehensive Chromosomal Screening|
223966632|NCT04321915|OTHER|Analysis of neuroinflammation markers in autism spectrum desorder|This analysis permit to reveal the integrity of the blood-brain barrier (BBB) which is affected in autism spectrum desorder.
223542648|NCT06252376|DIAGNOSTIC_TEST|Head-up tilt table|Different versions of cognitive assessments will be administered in the supine and upright positions while the participant is on the tilt table.
223542649|NCT03092180|DRUG|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
223542650|NCT01661543|DIETARY_SUPPLEMENT|Beans|120g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
223966633|NCT03928821|BIOLOGICAL|PGT121|20 mg/kg administered intravenously
223966634|NCT03928821|BIOLOGICAL|PGDM1400|20 mg/kg administered intravenously
223966635|NCT03928821|BIOLOGICAL|10-1074|20 mg/kg administered intravenously
223966636|NCT03928821|BIOLOGICAL|VRC07-523LS|20 mg/kg administered intravenously
224112363|NCT01675037|OTHER|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
224112364|NCT01579201|DRUG|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
224112365|NCT02012972|BEHAVIORAL|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
224112366|NCT04765462|BIOLOGICAL|Allogeneic γδ T cells|"Phase 1:Enrolled patents will be administered allogeneic γδ T cells from 2x10\^6/kg, 1 x10\^7/kg to 5x10\^7/kg every 2-4 weeks to determine the recommended dose level.~Phase 2: Enrolled patents will be administered allogeneic γδ T cells at the recommended dose level to confirm the efficacy.~Whether or not in combination with other therapies will be determined by research physicians according to the disease status of enrolled patients."
224112367|NCT00856427|RADIATION|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
223966637|NCT05291962|OTHER|Retrospective observational study|Data from anesthesia charts and electronic medical records of 14 patients with SMA type I, II and III who underwent procedural sedation,such as; the demographics data of the patients (age, gender, weight, American Society of Anesthesiologist (ASA) Physical Status), which anesthetic agent was used and their doeses, during of anesthesia, presence of scoliosis, by whom the procedure was performed etc. was reviewed.
223966638|NCT02181400|DEVICE|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
223966639|NCT00511459|DRUG|AMG 386 Placebo|AMG 386 Placebo \[blinded\]
223966640|NCT00511459|DRUG|AMG 386|AMG 386 3mg/kg IV QW \[blinded\]
223966641|NCT00511459|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
223966642|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[Open-Label\]
223966643|NCT00511459|DRUG|AMG 386|AMG 386 10mg/kg IV QW \[blinded\]
223966644|NCT00511459|DRUG|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
223966645|NCT01626677|BIOLOGICAL|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
223966646|NCT01626677|PROCEDURE|Microfracture|Active control
223966647|NCT06184295|DEVICE|TBI - Intervention Group|The participants will receive 10 customized robotic balance training sessions to improve balance using the Hunova robotic device. Each session will last for up to 1.5 hours. The training may include standing or sitting on the robotic balance platform and performing the following tasks: maintaining balance when the platform becomes unstable or moving in various directions, or in an inclination; these tasks may be performed as instructed with eyes open or eyes closed condition; move in different directions to reach targets with my hands; stand on one leg or heel to toe and maintain balance; perform head or torso rotation while standing or sitting. All training will be performed with an overhead harness and a spotter will be present at all times.
223966648|NCT04310800|PROCEDURE|LIFT-plug technique|Small-intestine submucosa extracellular matrix plug was soaked in saline for 5-10 min, then placed into the intersphincteric groove and pulled through the curetted tract to the external opening. The plug was secured with a figure-of-eight 3/0 absorbable suture to the fistula opening in the external sphincter and ligated. Excess plug protruding from the external opening was trimmed flush with the skin without fixation. The wound was loosely closed with 2-3 interrupted 3/0 absorbable sutures
223966649|NCT00719277|DEVICE|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
224112368|NCT00856427|PROCEDURE|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
224112369|NCT01984112|DEVICE|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
224112370|NCT01984112|DEVICE|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
224112371|NCT00552305|DRUG|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
224112372|NCT05646771|BEHAVIORAL|Partner support|Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)
224112373|NCT06077422|DRUG|bupivacaine liposome injectable suspension|Bupivacaine liposome injectable suspension (Exparel) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
224112374|NCT06077422|DRUG|Bupivacaine Hydrochloride|Bupivacaine HCl (Marcaine) will be administered by ultrasound-guided ESP block, unilaterally if thoracotomy on ipsilateral side, bilaterally if median sternotomy.
224112375|NCT02958163|PROCEDURE|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
224112376|NCT02958163|DRUG|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
223966650|NCT00355732|PROCEDURE|Weaning from mechanical ventilation|
223966651|NCT06288347|DEVICE|GGON mobile app.|The intervention will be done through an app named GGON, which is used to work on the dysfunctional beliefs that are associated with orthorexia nervosa. The app is made up of a series of levels comprising the topics based in cognitive-conductual perspective that are related to Orthorexia Nervosa. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
224112377|NCT02958163|RADIATION|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
224112378|NCT01849848|DRUG|SyB L-0501|The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
224112379|NCT04068389|PROCEDURE|Pulmonary Tissue Collection|Pulmonary Tissue Collection
224112380|NCT03501355|DEVICE|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
224112381|NCT03501355|DEVICE|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
224112382|NCT00659685|DRUG|Ondansetron|ODT, single-dose, fasting
224112383|NCT00659685|DRUG|Zofran ODT|
224112384|NCT05777811|PROCEDURE|Vertically coronally advanced flap combined with connective tissue graft.|The exposed root surfaces are planed with Gracey 1-2 curettes. An intrasulcular incision is made with a blade on the buccal aspects of the involved teeth. The incision is extended horizontally to the adjacent papilla. Then, slightly divergent vertical releasing incisions are carried 2 mm beyond the mucogingival junction. A full-thickness flap is raised with a periosteal elevator towards the mucogingival junction. After that, a partial-thickness dissection is carried out in the apical direction to release muscle tension and provide coronal advancement of the flap. The adjacent papillae are de-epithelialized. The connective tissue graft (CTG) is harvested from the lateral palate using the de-epithelialized gingival graft technique. After harvesting, the connective tissue graft is sutured to the recipient bed. Finally, the flap is positioned 2 mm over the cementoenamel junction and sutured with 6-0 polypropylene sutures. No periodontal dressing is applied.
224112385|NCT05777811|PROCEDURE|Free gingival graft|A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
223966652|NCT02822040|OTHER|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
223966653|NCT02916745|DRUG|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
223966654|NCT02916745|DEVICE|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
224112386|NCT00644319|DRUG|ibuprofen|
224112387|NCT00644319|DRUG|morphine sulfate|
224112388|NCT00644319|PROCEDURE|management of therapy complications|
224112389|NCT00644319|PROCEDURE|pleurodesis|
224112390|NCT02944747|BEHAVIORAL|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
224112391|NCT02944747|BEHAVIORAL|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
224112392|NCT02944747|BEHAVIORAL|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
223966655|NCT04950010|BEHAVIORAL|High-Intensity Interval Training|HIIT is a type of training in which short periods of high-intensity anaerobic exercise (1-4 minutes at 80-95% of VO2peak) are alternated with less intense aerobic recovery periods (1-3 minutes at 50-60% VO2peak). Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise (i.e., number and intensity of intervals) increases across weeks. Intervals will progress from a heart rate corresponding with 75% VO2peak in Week 1 to 90-95% VO2peak in Weeks 5-8. Sessions will be \~30 minutes in length. Indoor cycling is the primary mode of exercise.
224112393|NCT00674336|PROCEDURE|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
224112394|NCT00602862|DRUG|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
223966656|NCT04950010|BEHAVIORAL|Moderate-Intensity Exercise|Individually-tailored exercise prescriptions will be developed based upon each participant's baseline maximal graded exercise test (heart rate corresponding with %VO2 peak) and symptom limitation. Sessions will be progressive in nature such that the volume of exercise increases across weeks. Indoor cycling is the primary mode of exercise. Sessions will include moderate-intensity cycling that progresses from a heart rate corresponding with 55-60% VO2peak for 30 minutes in Week 1 to 65-70% VO2peak for 45-50 minutes in Weeks 5-8.
223966657|NCT04964297|DEVICE|Obtaining bowel gas samples|"The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings."
223966658|NCT03867123|DRUG|LAM561|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
223966659|NCT03867123|RADIATION|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
223966660|NCT03867123|DRUG|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
223966661|NCT03840148|DRUG|Cefepime/VNRX-5133 (taniborbactam)|Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
223966662|NCT03840148|DRUG|Meropenem|Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
223966663|NCT02084615|DRUG|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
223966664|NCT03615404|BIOLOGICAL|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
223966665|NCT03615404|BIOLOGICAL|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
223966666|NCT03370588|DRUG|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
223966667|NCT03370588|DRUG|Normal saline|Group B: Saline infusion during same time period.
223966668|NCT04008004|DRUG|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).
223966669|NCT04008004|DRUG|Placebo|Placebo to match EDP-514
224112395|NCT00602862|DRUG|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
224112396|NCT00602862|DRUG|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
224112397|NCT02602236|DEVICE|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
224112398|NCT00565695|DEVICE|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
224112399|NCT05221450|PROCEDURE|primary endodontic treatment|
223542651|NCT01661543|DIETARY_SUPPLEMENT|Control (rice)|110g (3/4 c) of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group. This amount of rice equates to a similar volume as 120g of cooked beans or peas.
223542652|NCT01661543|DIETARY_SUPPLEMENT|Peas|120 grams of peas will be consumed 5 out of 7 days per week
223542653|NCT06289400|DEVICE|Magnetic field application|The applicator (Size: 15x15 cm) has placed 1-3 cm above the skin surface at the painful area. During the treatment, treatment has applied with ready-made protocols included in the device.
224112400|NCT01839188|BIOLOGICAL|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Hepatitis B \[HB; Recombinant DNA\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
224112401|NCT01839188|BIOLOGICAL|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed \[DTaP\], Inactivated Poliovirus \[IPV\], and Haemophilus influenzae type b \[Hib\] conjugate vaccine \[adsorbed\]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
224112402|NCT01839188|BIOLOGICAL|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
223966670|NCT01116700|DRUG|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
223966671|NCT00455715|DRUG|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
223966672|NCT01774929|DRUG|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
223966673|NCT05464082|OTHER|Functional Precision Oncology|Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
223966674|NCT01845337|DRUG|Teysuno|
223966675|NCT01845337|DRUG|Capecitabine|
223966676|NCT00939211|DRUG|AZD9164|Solution for inhalation through nebulization, single dose
224112403|NCT01839188|BIOLOGICAL|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
224112404|NCT01839188|BIOLOGICAL|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine \[PCV; 13-valent, adsorbed\]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
224112405|NCT04420455|DRUG|Enoximone|Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval.
224112406|NCT01615003|DRUG|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
223966677|NCT00939211|DRUG|Tiotropium|Dry powder for inhalation, single dose
223966678|NCT00939211|DRUG|Placebo|Placebo
223966679|NCT00603278|DRUG|GW685698X|GW685698X
223966680|NCT00603278|DRUG|placebo|placebo
223966681|NCT04943614|OTHER|Biodex balance system|BIODEX stability system (BIODEX Medical Systems Inc; Shirley, New York) offers a system that can deliver particular hip and ankle postural training strategy with external biofeedback as a monitor to enhance the reduced subclinical limitations of patients with diabetic neuropathy
223966682|NCT04943614|OTHER|conventional exercises|balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program. Same duration treatment
223966683|NCT04553627|DEVICE|ZELTIQ thermoelectric device|This is a feasibility study to determine if cryolipolysis in this area produces a desirable lifted appearance to the buttocks. Typically, a lifted more youthful appearance is obtained through surgical means. Study participants will be recruited from the population of patients who have suitable, treatable subcutaneous fat on the medial infragluteal folds and desire a lifted appearance. Subjects will receive treatments with a cooled cup cryolipolysis applicator from the CoolAdvantage family of applicators (cooled cup vacuum applicator). Treatments will be performed with a treatment temperature of - 11°C for up to 35 minutes. Subjects will complete all study-required follow-up visits, including an 8-week follow-up which may include a second treatment session, as well as a 12-week post final treatment follow-up visit
223966684|NCT00729170|DIETARY_SUPPLEMENT|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
223966685|NCT06509269|PROCEDURE|intraoral scanning|Intraoral Scanning of edentulous Jaw
223966686|NCT06509269|PROCEDURE|Desktop scanning|Desktop scanning of definitive impression
223966687|NCT04222400|DIAGNOSTIC_TEST|Frailty Assessment|Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
223966688|NCT04937049|OTHER|EMAeHealth digital tool|eHealth intervention to support Maternal Education
224112407|NCT01615003|DRUG|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
224112408|NCT01089777|DEVICE|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
224112409|NCT03418246|DEVICE|GIC|tooth colored filling
224112410|NCT03418246|DEVICE|Biodentine|White filling -Biodentine
224112411|NCT00006246|DRUG|busulfan|
224112412|NCT04995744|PROCEDURE|Pectoralis Major Pedicle Bone Graft|It is aimed to restore the integrity of the medial cortex with the bone pedicle from the insertion region of the pectoralis major muscle in middle-aged patients with Neer type 4 proximal humerus fractures. Researchers aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method. The investigators aim to reduce the risk of avascular necrosis with a vascular living bone tissue, as well as providing mechanical support with this method.
224112413|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's polyp detection function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
224112414|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy with the assistance of EndoAngel's quality monitoring function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
224112415|NCT04453956|DIAGNOSTIC_TEST|Colonoscopy without the assistance of EndoAngel's any function.|Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
224112416|NCT03538873|BEHAVIORAL|Physical activity|
224112417|NCT06970678|DRUG|Dexmedetomidine infusion|Patients will receive intravenous loading dose of dexmedetomidine at 0.5 μg/kg ideal body weight (concentration 2 μg/ml) over 15 minutes prior to anesthesia induction, followed by 10 ml of 0.9% sodium chloride over 60 seconds during anesthetic induction. Post-intubation, Dexmedetomidine will be maintained at 0.5 μg/kg/h ideal body weight via a syringe pump until trocar removal.
223966689|NCT02406859|BEHAVIORAL|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
223966690|NCT02406859|BEHAVIORAL|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
223966691|NCT00312546|DRUG|Enfuvirtide|90 mg subcutaneously twice daily
223966692|NCT00312546|DRUG|Valproic acid|500 to 750 mg, taken orally twice daily
223966693|NCT05384808|BEHAVIORAL|Standard Psychotherapy|Participants receive a standard psychotherapy session with no dog being present.
223966694|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog actively integrated.|A dog is present and actively integrated into the therapeutic narrative.
223966695|NCT05384808|BEHAVIORAL|Canine-assisted psychotherapy with dog passively integrated.|A dog is present but not actively integrated into the therapeutic narrative.
223966696|NCT01990183|DEVICE|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home - session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
223966697|NCT01990183|OTHER|Standard Care|Current care advices in the management of preterm infants in the first months of life
223966698|NCT05024578|DEVICE|DREEM2|Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.
223966699|NCT05024578|DEVICE|Placebo|EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
223966700|NCT04374253|DRUG|Gantenerumab|Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
223966701|NCT04374253|DRUG|Gantenerumab|Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
223966702|NCT04716283|OTHER|Validated questionnaire : The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)|"The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. Nineteen individual items generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score.~The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness .The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities."
223966703|NCT00959634|DRUG|ABT-126|Dose administered twice daily on Study Days 1-10
223966704|NCT00959634|DRUG|Placebo|Dose administered twice daily on Study Days 1-10
223542654|NCT06289400|OTHER|Conventional treatment|Within the scope of conventional treatment, hotpack application, transcutaneous electrical stimulation (TENS), interferential current and ultrasound treatment modalities will be applied. In addition, strengthening exercises will be applied to the muscles around the hip and knee and stretching exercises will be applied to the short muscle groups.
223966705|NCT06190145|DRUG|Teriflunomide|Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
223966706|NCT06296888|PROCEDURE|Radiofrequency balloon catheter ablation|Radiofrequency balloon ablation using the HELIOSTAR™ ablation catheter.
223966707|NCT06185699|DIAGNOSTIC_TEST|standard superficial skin biopsy (SSSB)|standard superficial skin biopsy (SSSB) was applied to the face that was wiped with dry sterile gauze after dropping cyanoacrylate by marking 1 cm2 area on the slide that was wiped with dry sterile gauze from 3 areas of the face, right cheek, nose and the mid-forehead. After the slide was left for 60 seconds and slowly removed from the face, immersion oil was dripped onto the slide and covered with a coverslip, and Demodex mites were counted first under the light microscope at x10 and then x20 magnification (Demodex foliculorum and brevis were not differentiated). The process was repeated for each region.
223966708|NCT00023465|PROCEDURE|FDG-PET|
223966709|NCT00023465|PROCEDURE|spirometry|
223966710|NCT00023465|PROCEDURE|bronchoscopy with BAL|
223966711|NCT05842278|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223966712|NCT05842278|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223966713|NCT05842278|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223966714|NCT05842278|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223966715|NCT05842278|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223966716|NCT04117334|OTHER|Bracing|
223966717|NCT01249976|OTHER|blood culture|blood culture
223966718|NCT02544841|BEHAVIORAL|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
223966719|NCT02544841|BEHAVIORAL|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
223966720|NCT04357587|DRUG|Pembrolizumab|200 mg intravenously (IV) on days 1, 22, and 43
223966721|NCT04357587|RADIATION|External beam radiation|Daily fractions of 200 cGy, 5 days a week for the first 5 weeks of the study, excluding weekends
223966722|NCT04357587|DRUG|Capecitabine|825 mg/m2 orally twice a day on days where radiation therapy is given
223966723|NCT02135588|DRUG|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
223966724|NCT02338310|DRUG|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
223966725|NCT05007600|OTHER|Online Interactive Courses|In the experimental group, after consensus was reached in the expert meeting (consisting of a doctor specializing in occupational therapy, a doctor specializing in nursing, and a doctor specializing in public health), a 5-days-per-week (Monday to Friday) 8-week intensive online interactive course was designed. The course was made accessible to the participants through a social network app (Line) from 12:00 to 20:30.
223966726|NCT00266162|DRUG|Bosentan administration|
223966727|NCT02020551|DRUG|Lidocaine Spray|
223966728|NCT02020551|DRUG|Placebo|
223966729|NCT00797186|OTHER|Intensive risk factor management|Aggressive medical and lifestyle therapy.
223966730|NCT01599221|DEVICE|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
223966731|NCT00234299|DRUG|Aspirin|325mg, one tablet orally, six months
223966732|NCT00234299|DRUG|Placebo|325mg, one tablet orally every day, 6 months
223966733|NCT01394263|DRUG|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
223966734|NCT01394263|DRUG|Zoladex goserelin implant|goserelin implant injection.
223966735|NCT05951556|DEVICE|Use of BCI|Clients will utilize BCI with training to communicate wants and needs
224112418|NCT06970678|PROCEDURE|paragastric autonomic neural block|Paragastric autonomic neural block (PGANB) will be administered using a 25-gauge needle attached to a venous catheter extension, introduced through the left 12 mm port. Infiltration of 20 mL undiluted 0.5% bupivacaine will be performed at six levels in the fatty tissue of the paragastric area, including the lesser omentum, vagus nerve, esophagogastric junction, proximal stomach, mid-stomach, distal antrum, hepatic artery, and left gastric artery, with the needle cap removed under direct vision throughout the procedure.
224112419|NCT00276289|DRUG|Spironolactone|
223966736|NCT03045289|BEHAVIORAL|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
224112420|NCT05144022|BEHAVIORAL|Bungee jump|Bungee jump from a cran
224112421|NCT04674163|BIOLOGICAL|Blood sample and Cerebrospinal fluid (CSF) collection.|An additional blood sample (25 ml) and a cerebrospinal fluid (CSF) sample (2 ml) will be taken.
224112422|NCT00009867|DRUG|arsenic trioxide|Given IV
223966737|NCT01358643|OTHER|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI \> 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
223966738|NCT03487302|OTHER|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
223966739|NCT03487302|OTHER|Neuropsychological test battery|"1. Mini Mental State Examination (MMSE), Measso et al. (1993);~2. Frontal Assessment Battery (FAB), Appollonio et al. (2005);~3. Symbol Digit Test, Amodio et al. (2002);~4. Digit Cancellation Test, Della Sala et al. (1992);~5. Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~6. Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~7. Digit Span, Orsini et al (1987);~8. Corsi block-tapping test, Orsini et al. (1987);~9. Babcock story recall test, Carlesimo et al. (2002);~10. Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~11. Semantic verbal fluency, Novelli (1986);~12. Imitating gestures, De Renzi et al. (1980);~13. Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
223966740|NCT00998114|BEHAVIORAL|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
223966741|NCT02905877|OTHER|Behavioural study|reaching studies and other behavioural studies.
223966742|NCT04368533|DRUG|Livionex Dental Gel|The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
223966743|NCT04368533|DRUG|A standard children's toothpaste containing 1500 ppm fluoride|The subjects will brush their teeth with a standard children's toothpaste containing 1500 ppm fluoride twice a day for up to 12 months.
224112423|NCT00169468|DRUG|Rituximab -CHOP plus Velcade|
224112424|NCT05701852|OTHER|reward learning task|during usual follow-up patients will complete a remard learning task questionnaire. This questionnaire cannot be assimilated to a clinical intervention.
224112425|NCT03421223|OTHER|No intervention|No intervention
224112426|NCT03320733|DIAGNOSTIC_TEST|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
224112427|NCT05069363|DEVICE|Whole-Body Photobiomodulation Therapy|"* All participants entering the trial will receive a course of whole-body PBM therapy~* The NovoTHOR Whole-Body PBM therapy device consists of a hinged, clamshell design with light-emitting diodes (LEDs) arranged to emit near-infrared and visible red light therapy is delivered to the entire body at once.~* Participants will be expected to lie horizontal in the device with the lid as closed as they are comfortable with.~* 18 sessions is the currently recommended and widely instituted and accepted practice with the NovoTHOR device.~* The LED equipment delivers red and near infrared light therapy to the participant~* Session 1 = 6 minutes~* Session 2 = 12 minutes~* Sessions 3-18 = 20 minutes~* Timescale: 3 treatments/week for 6 weeks~* The dosage of LED light (also known as 'fluence') will be equivalent to 25J/cm2. The device will supply a dual wavelength of red and near-infrared light with a 50:50 ratio; 660nm and 850nm respectively"
224112428|NCT04982549|DRUG|Durvalumab|Durvalumab (intravenous infusion)
223542655|NCT05119582|DEVICE|TOOsonix System ONE-M|Selected neurofibromas will be treated by high intensity focused ultrasound. Untreated fibromas will be used for controls.
223542656|NCT04857554|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
223966744|NCT05556070|OTHER|Arm 1|: Local retailer produce vouchers ($25 value) will be distributed to the families biweekly over a 32-week period for a total of 16 vouchers. The vouchers can be redeemed for fresh produce at the grocery store that issued the vouchers.
223966745|NCT05556070|OTHER|Arm 2|Boxes of fresh fruits and vegetables (F\&V), each containing approximately 50 servings of F\&V, will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V boxes will be distributed to families every 2 weeks over 32 weeks.
223966746|NCT05556070|OTHER|Arm 3|subjects in this arm will receive the usual standard of care at the clinic for the study period
224112429|NCT04982549|DRUG|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
224112430|NCT04982549|DRUG|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
224112431|NCT04982549|DRUG|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
224112432|NCT04982549|RADIATION|Radiation|5 fractions/ week for \~6 weeks (±3 days) (Total 60 Gy)
223966747|NCT05556070|OTHER|Brighter Bites app|"Participants in Arms 1 and 2 will also receive nutrition education using the Brighter Bites app which includes recipes for a variety of meal types or produce types, all of which are searchable. Recipes include the average cost to prepare, the number of servings, and the calories for the recipe. The Brighter Bites app also includes healthy living Brighter Choices suggestions such as tips for how to store different types of foods, gardening tips, and tips to pack a healthy lunchbox. In addition to the Brighter Bites app, trained staff will facilitate virtual nutrition education for patient families."
223966748|NCT05531136|OTHER|Foot strengthening training|a 12-weeks exercise program consisting of foot strengthening exercises prescribed for 5 daily sessions a week, of which 1 supervised, 20 minutes per session on top of the regular exercise therapy to prevent falling
223966749|NCT06330363|OTHER|Laser therapy|The Cube plus30 from Eltech K-Laser s.r.l. (Italy, www.k-laser.com) will be used for LLLT. The laser devices from Eltech K-Laser s.r.l. have been used in (clinical) studies with a variety in patient populations (38-41) and clinical practice (https://resources.k-laser.com.au/medical-laser-clinical-applications). The device is a registered medical device in the EU confirmed by Kiwa Cermet Italia.
223966750|NCT06330363|OTHER|Sham|The laser device has sham light option that will be used.
223966751|NCT04830163|COMBINATION_PRODUCT|Brain state-dependent paired corticomotoneuronal stimulation (PCMS)|Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
223966752|NCT05542836|BEHAVIORAL|Expedited postoperative activity instructions|Ad lib postoperative activity and return to work recommendations
223966753|NCT05542836|BEHAVIORAL|Standard postoperative activity restructions|Standard conservative postoperative activity and return to work recommendations
223966754|NCT06291298|BEHAVIORAL|COGMUSE-AUT|The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
223966755|NCT03256760|BIOLOGICAL|Endotoxin|Endotoxin
223966756|NCT03256760|BIOLOGICAL|Placebo|Placebo
223966757|NCT04758559|OTHER|myfood24|An app to support monitoring of food and nutrient intake using robust validated methodology.
223966758|NCT04758559|OTHER|usual care|Patients will receive standard advice as provided by the clinical team, this may or may not include nutrition.
223966759|NCT05065580|PROCEDURE|Osteopathic Manipulative Treatment|Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques
223966760|NCT06645522|DRUG|Edaravone dexborneol|Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.
223966761|NCT06645522|DRUG|Placebo|Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
223966762|NCT06646900|BEHAVIORAL|Culturally adapted CBT (CaCBT) based guided self-help manual|The intervention consists of seven modules including cognitive restructuring, problem solving, behavioural activation and conflict management. Three additional modules focus on interpersonal relationships, mental health wellbeing and self-care. Each module is delivered over one week. The intervention uses culturally appropriate stories, drawings, examples from local folklore and religious context to describe the concepts of CBT.
223966763|NCT06646900|BEHAVIORAL|Standard CBT Manual|The standard CBT manual will follow conventional CBT techniques without specific cultural adaptations
223966764|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)|Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
223966765|NCT06264869|PROCEDURE|Interdental guided creeping technique (IGCT) and collagen membrane (CM)|Interdental guided creeping technique (IGCT) and collagen membrane (CM)
223966766|NCT02737670|DRUG|Sulodexide|25 mg morning and evening for 40 days
223966767|NCT02737670|DRUG|Placebo|1 tablet morning and evening for 40 days
223966768|NCT05876013|PROCEDURE|ACL reconstruction|Randomized between hamstring and patellar tendon graft
223542657|NCT04857554|OTHER|White bread as reference food|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
223966769|NCT04453969|OTHER|COVID-19|Exposure of interest for this observational study is current COVID-19 positive status or COVID-19 positive status during pregnancy
223966770|NCT03057197|PROCEDURE|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
223966771|NCT03740932|DIAGNOSTIC_TEST|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
223966772|NCT01275911|DRUG|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
223966773|NCT01275911|DRUG|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
223966774|NCT03133572|DEVICE|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
223966775|NCT03133572|DEVICE|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
223966776|NCT00131404|DRUG|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
223966777|NCT00131404|DRUG|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
223966778|NCT05054556|DIAGNOSTIC_TEST|Labaratory tests|"Estimation of serum levels of the following parameters:~galectin-3, proBNP, TNI, proGRP, CA15-3, CK, creatinine, urea, crp, pct, leucozytes"
223966779|NCT01615614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
223966780|NCT01615614|DRUG|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
223966781|NCT03784222|DRUG|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
223966782|NCT03784222|OTHER|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
223966783|NCT00546884|BEHAVIORAL|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
223966784|NCT00546884|BEHAVIORAL|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
223966785|NCT02263859|DEVICE|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
223966786|NCT02367248|DRUG|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
223966787|NCT02367248|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
224112433|NCT02795598|PROCEDURE|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
224112434|NCT02795598|PROCEDURE|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
224112435|NCT00939172|DRUG|TTP607|3.3 mg/m\^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
223542658|NCT04857554|OTHER|White bread with apricot jam|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from white bread together with apricot jam along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
223724783|NCT04079608|BEHAVIORAL|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
223966788|NCT02367248|DRUG|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
223966789|NCT01624532|BIOLOGICAL|GC1109 or Placebo of GC1109|"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."
223966790|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
223966791|NCT01346722|OTHER|Diet- CR|conventional rice-based diet
223966792|NCT01346722|OTHER|Diet-ZnBfR|zinc biofortified rice-based diet
223966793|NCT01346722|OTHER|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
223966794|NCT06107205|DRUG|TTYP01|1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
223966795|NCT06107205|DRUG|Radicava|1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
223966796|NCT06107205|DRUG|Radicava ORS|1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
223966797|NCT03455140|DRUG|PEG- BCT-100|PEGylated recombinant human arginase 1
223966798|NCT00105222|DRUG|Sodium Nitrite|
223966799|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
223966800|NCT02571959|DRUG|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
223966801|NCT02543307|PROCEDURE|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
223966802|NCT04725552|BEHAVIORAL|'Change' - an e-health intervention|The aim of the e-health intervention is to support the patient's change process and facilitate the doctor's ability to help. We plan for a web-application instead of a native application. A web-application enables use from mobile devices and from computers and is thus not dependent on a specific mode or system. Before including patients (postponed to September 2020 because of the Corona-virus pandemic), about 30 members of the general public have tested the e-health intervention.
223966803|NCT02848586|OTHER|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
223966804|NCT02848586|BEHAVIORAL|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
223966805|NCT02848586|OTHER|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
223966806|NCT04927806|DEVICE|Silver Knight|"Silver Knight breathing systems are all validated for up to seven days use, and remain active, in unopened packaging, for up to five years. Silver Knight is proven to help reduce the incidence of MRSA infection and other organisms including:~* Staphyloccus epidermis~* Pseudomonas aeruginosa~* Klebsiella pneumoniae~* Acinetobacter calcoaceticus~* Escherichia coli"
223966807|NCT02495402|BEHAVIORAL|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
224112436|NCT05308095|OTHER|Controlled hypoglycaemic state while driving|Participants will drive on a designated circuit with a real car on a test track accompanied by a driving instructor. Initially, a euglycaemic state (5.0 - 8.0 mmol/L) is established and blood glucose is then declined to hypoglycaemia (3.0 - 3.5 mmol/L) by administering insulin. Thereafter, blood glucose is raised again to euglycaemia (5.0 - 8.0mmol/L). During the procedure, driving data is recorded. Additionally, eye movement, head pose, facial expression, heart rate, skin conductance, and CGM values are recorded throughout the glycemic trajectory. Participants are blinded to the blood glucose values during the procedure.
224112437|NCT06510465|DRUG|utidelone|utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
224112438|NCT06510465|DRUG|Cisplatin|cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
224112439|NCT06510465|DRUG|Trastuzumab|Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
224112440|NCT06510465|DRUG|Pertuzumab|Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase
224112441|NCT00317070|DRUG|dimethyl sulfoxide|intravesical installation 50 ml
223724784|NCT05608798|DEVICE|ODI-Tech medical device|"The device captures and stores frames of the movement of blood in capillaries and spectra containing information on oxygen saturation. Proprietary software is used to analyse the obtained frames and spectra to calculate microvascular parameters such as functional capillary density and microvascular oxygen saturation.~ODI-Tech can be brought to the patient's bedside and operates non-invasively. The device parts are in contact with the patient for less than 5 minutes."
223724785|NCT04051008|BEHAVIORAL|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
224112442|NCT00317070|DRUG|IC Cocktail|"* Heparin 10,000 units~* Gentamicin 80 mg~* Hydrocortisone sodium succinate (Solucortef) 100 mg~* Lidocaine hydrochloride 1% 10 ml~* Sodium Bicarbonate 8.4% 5 ml"
223966808|NCT06130904|BEHAVIORAL|Academic detailing|"Eligible dentists/oral surgeons will have one visit (30 minutes or less) at the dentist's office. During the initial visit, the detailers will discuss the evidence against routine opioid prescribing to adolescents and young adults for most common surgeries performed by dentists and oral surgeons, the harms of dental opioid exposure in adolescents and young adults, and the benefits and feasibility of relying on non-opioids as a first line option for routine dental procedures among adolescents and young adults. A survey will be completed to assess the satisfaction regarding the intervention. A professionally designed packet of information on reducing use of opioids for routine procedures will also be given.~There may also be a second optional follow-up visit conducted virtually for any participants that wish to discuss further with the detailer. The second visit may occur any time between the initial visit and March 31, 2024."
223966809|NCT05374967|BEHAVIORAL|Lifestyle intervention: Live with IBD|"A digital lifestyle intervention divided into two phases:~1. An intensive phase lasting six months~2. a facultative phase lasting six months~During the Intensive Phase, participants will receive regular counseling by a nutritionist and a lifestyle coach in groups of 25 people. Participants will also follow five online meetings focusing on either nutrition, exercise, sleep, and stress. In addition, participants will have 24/7 access to an online platform that contains additional information, challenges, recipes, and peer-support groups. Finally, during the facultative phase, participants can attend smaller group sessions for additional counseling by a nutritionist or a lifestyle coach; these sessions will be organized every six to 12 weeks."
223966810|NCT05374967|OTHER|Control group|The standard of care for patients with IBD suffering from chronic fatigue.
223966811|NCT01794351|DIETARY_SUPPLEMENT|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
223966812|NCT01794351|OTHER|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
224112443|NCT00541359|DRUG|bortezomib|Given IV
224112444|NCT00541359|DRUG|topotecan hydrochloride|Given IV
224112445|NCT00541359|OTHER|immunohistochemistry staining method|Correlative studies
224112446|NCT00541359|OTHER|pharmacological study|Correlative studies
224112447|NCT05938881|PROCEDURE|self-cut mesh procedure|transvaginal mesh procedure using self-cut mesh
224112448|NCT05938881|PROCEDURE|mesh-kit procedure|transvaginal mesh procedure using mesh-kit
224112449|NCT03494725|DIETARY_SUPPLEMENT|Lpc-37|Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10\^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide
224112450|NCT03494725|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose, magnesium stearate, silicon dioxide
224112451|NCT00337298|DRUG|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
224112452|NCT00337298|DRUG|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
224112453|NCT04097717|BEHAVIORAL|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
224112454|NCT04097717|OTHER|Usual Care|Usual medical care will vary among participants.
224112455|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Active)|Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
224112456|NCT04083144|DEVICE|Deep Repetitive Transcranial Magnetic Stimulation (Sham)|Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
224112457|NCT04083144|DRUG|Varenicline|12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
223724786|NCT04051008|BEHAVIORAL|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
223966813|NCT04382053|DRUG|DFV890|DFV890 25 mg tablets orally/nasogastrically administered 50 mg b.i.d for 14 days in addition to SoC.
223966814|NCT04382053|DRUG|Standard of Care (SoC)|SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
223966815|NCT05665348|DRUG|Ipilimumab Injection|Administration of a combine treatment by atezolizumab and bevacizumab, with addition of ipilimumab for patients enrolled in the experimental arm
223966816|NCT05665348|DRUG|Atezolizumab Injection|One of the standard treatment's product for HCC management
223966817|NCT05665348|DRUG|Bevacizumab|One of the standard treatment's product for HCC management
223966818|NCT01959009|OTHER|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
223966819|NCT05022953|OTHER|Education, dijital storytelling|Digital story
223966820|NCT00924833|DRUG|placebo|placebo tablet BID
223966821|NCT00924833|DRUG|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
223966822|NCT00924833|DRUG|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
223966823|NCT05143580|BEHAVIORAL|Cognitive therapy|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education.~* Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~* Use gamification to evaluate: pain relief skills, lung expansion skills."
223966824|NCT05143580|BEHAVIORAL|Routine care|"* The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~* The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~* Provide a manual for disease health education."
223542659|NCT04857554|OTHER|Cereal bar with cranberries|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from a cereal bar with cranberries along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
223542660|NCT04857554|OTHER|Cocoa drink|Twelve healthy, normal weight subjects (male: 6,female: 6) after 10-14 hr fast, consumed 25g available carbohydrates from cocoa powder mixed with 500ml fat-free milk, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45,60, 90 and 120min.
223542661|NCT00003109|DRUG|irinotecan hydrochloride|
223542662|NCT00003109|DRUG|raltitrexed|
223966825|NCT01153997|DRUG|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
223966826|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
223966827|NCT01153997|DRUG|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
223966828|NCT01153997|DRUG|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
223966829|NCT04779463|DIAGNOSTIC_TEST|Parasternal intercostal muscles thickness ultrasound indicies|"Parasternal intercostal muscles thickness ultrasound indicies includes:~* Parasternal Intercostals Thickness Fraction.~* Parasternal Intercostals Thickness at the End of Inspiration.~* Parasternal Intercostals thickness at the End of Expiration."
223966830|NCT04999722|BEHAVIORAL|Traditional mode of management|Traditional model management of Diabetes Mellitus patients
223966831|NCT04999722|BEHAVIORAL|Mobile APP management|Management of diabetic patients with mobile phone APP
223966832|NCT05568277|BEHAVIORAL|Education on preventive health behaviors based on Pender's Health Promotion Model|Pregnant women included in the study will be given education on preventive health behaviors based on Pender's Health Promotion Model on the prevention of gestational diabetes over the web (ZOOM/Teams etc.) every two weeks. Pregnant women's questions will be answered. At the end of each training, data will be collected from pregnant women and follow-up charts will be filled. The education booklet prepared by the researcher will be given to the pregnant women after the first education and will be sent to their e-mail addresses.
223966833|NCT02397902|DIETARY_SUPPLEMENT|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
223966834|NCT02397902|DIETARY_SUPPLEMENT|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
223966835|NCT03945409|DEVICE|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
223966836|NCT02313077|BIOLOGICAL|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
223966837|NCT02313077|BIOLOGICAL|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
223966838|NCT02313077|OTHER|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
223966839|NCT04126993|DRUG|Camrelizumab,|Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
224112458|NCT01898312|DRUG|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
224112459|NCT01334112|DRUG|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
224112460|NCT02879500|OTHER|Diet beverages|
224112461|NCT01516801|OTHER|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
224112462|NCT05677789|DIAGNOSTIC_TEST|Medical observation|Likely suitable for home treatment
224112463|NCT05677789|DIAGNOSTIC_TEST|Supportive treatment (BSC)|Consider hospital supervised treatment
224112464|NCT05677789|DIAGNOSTIC_TEST|Intensive care management|Manage in hospital as severe pneumonia
224112465|NCT04194593|OTHER|PCR (Polymerase Chain Reaction)|"Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm."
224112466|NCT01417286|RADIATION|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
223542663|NCT01153035|DEVICE|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
223542664|NCT05324579|BEHAVIORAL|Behavioral testing during neuronal recordings|Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
223966840|NCT04126993|DRUG|Apatinib|Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
224112467|NCT05873140|BEHAVIORAL|application LINE|Online lifestyle modification education for weight loss
224112468|NCT05955859|PROCEDURE|Samplings from patient's affected paranasal sinus|Samplings from patient's affected paranasal sinus during endoscopic surgery.
224112469|NCT03662152|DEVICE|Foam roller|Foam roller massage after DOMS
224112470|NCT03662152|DEVICE|Vibration foam roller|Foam roller massage with vibration after DOMS
224112471|NCT00149825|DRUG|Escitalopram|5 to 20 mg for 12 weeks
224112472|NCT00149825|BEHAVIORAL|CBTI|Cognitive Behavioral Treatment for Insomnia
224112473|NCT00149825|BEHAVIORAL|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
224112474|NCT01359982|DRUG|RRx-001|Dose level 1 (10 mg/m2)
224112475|NCT01359982|DRUG|RRx-001|Dose Level 2 (16.7 mg/m2)
224112476|NCT01359982|DRUG|RRx-001|Dose Level 3 (24.6 mg/m2)
224112477|NCT01359982|DRUG|RRx-001|Dose Level 4 (33 mg/m2)
224112478|NCT01359982|DRUG|RRx-001|Dose Level 5 (55.0 mg/m2)
224112479|NCT01359982|DRUG|RRx-001|Dose Level 6 (83 mg/m2)
224112480|NCT01062451|DRUG|Perindopril|8 mg taken orally from days 0 through 7.
223966841|NCT03042572|DRUG|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
223966842|NCT03042572|OTHER|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
223966843|NCT02097316|DEVICE|JewelPump|
223966844|NCT02097316|DEVICE|usual insulin pump|
224112481|NCT01062451|DRUG|Placebo|Placebo treatment daily.
223966845|NCT05224245|DEVICE|ACURATE Prime XL Transfemoral Aortic Valve System|ACURATE Prime™ Transfemoral Aortic Valve system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).
224112482|NCT01062451|DRUG|Candesartan|16 mg taken orally from days 0 through 7.
224112483|NCT06518863|BEHAVIORAL|Education|Educational handouts on how to adhere to the corresponding diet.
223966846|NCT02619578|OTHER|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
223966847|NCT02619578|OTHER|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
223966848|NCT02619578|DRUG|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
223966849|NCT02619578|OTHER|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
223966850|NCT01399905|DRUG|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
223966851|NCT00243568|DRUG|Vicriviroc|
223966852|NCT01898026|DIETARY_SUPPLEMENT|Bread|Samples of white bread, with or without the addition of PGX fibre blend
223966853|NCT01898026|DIETARY_SUPPLEMENT|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
223966854|NCT01898026|DIETARY_SUPPLEMENT|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
223966855|NCT01898026|DIETARY_SUPPLEMENT|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
223966856|NCT00389285|DRUG|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
223966857|NCT00389285|DRUG|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
223966858|NCT02577315|DRUG|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
223966859|NCT02577315|DRUG|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
223966860|NCT02577315|DRUG|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
223966861|NCT02577315|DRUG|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
223966862|NCT03247985|DEVICE|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
223966863|NCT03247985|DEVICE|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open \& laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
223966864|NCT05512988|BIOLOGICAL|UC-MSC|"Usage: The stem cell preparation in this study is used intravenously in the elbow.~Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person."
223966865|NCT05512988|BIOLOGICAL|Saline solution|"Usage: The saline solution in this study is used intravenously in the elbow.~Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time.~Duration: 2 injections per person for the entire duration of the course"
223966866|NCT05773599|OTHER|laughter yoga|A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
223966867|NCT01558245|DRUG|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
223966868|NCT06386575|OTHER|control group; Patients who received physiological saline|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.
223966869|NCT06386575|OTHER|suprainguinal fascia block; Patients receiving local anesthetic|All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
223966870|NCT00703365|DRUG|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
223966871|NCT05530434|OTHER|transpulmonary pressure guided positive end expiratory pressure|Positive end expiratory pressure will be titrated to achieve a transpulmonary pressure of 0-2 cm H2O
224112484|NCT02165852|PROCEDURE|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
224112485|NCT02165852|PROCEDURE|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
224112486|NCT04984226|DRUG|Sodium bicarbonate|Sodium bicarbonate will be dosed at 0.8meq per kilogram of ideal body weight daily (1meq is approximately 84mg). We will use the Devine formula to determine ideal body weight. Investigational Drug Services at both UC Davis and Vanderbilt will compound the sodium bicarbonate. Sodium bicarbonate 650 mg tablets will be over-encapsulated and matching placebo capsules will be prepared. Participants will be limited to a maximum of 9 capsules daily (maximum dose = 5850mg of sodium bicarbonate). Capsules will be dispensed to patients in two separate 8-week allotments. The dose will be rounded to the nearest whole capsule and depending on participant preference may be divided into portions taken twice or thrice daily. Given the high probability of interruption in sodium bicarbonate supply and availability, we may need to change brands of sodium bicarbonate intermittently.
223542665|NCT01461525|PROCEDURE|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
223542666|NCT01461525|PROCEDURE|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
223966872|NCT05530434|OTHER|standard positive end expiratory pressure|Positive end expiratory pressure will be set to a standard 5-8 cm H2O by the clinician for spontaneous breathing trials
223966873|NCT03640793|DEVICE|Implantation|Implantation of 6 PPIS implants
224112487|NCT04984226|DRUG|placebo|The placebo and filler for for sodium bicarbonate capsules will be comprised of microcrystalline cellulose. Capsule appearance for control and sodium bicarbonate will be the same.
224112488|NCT00607750|DRUG|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
224112489|NCT00607750|DRUG|Placebo|Placebo eyedrops, BID, 48 weeks
224112490|NCT04697147|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
224112491|NCT05086237|OTHER|Text message reminders|Text messages will be sent to parents/guardians of children ages 0 to 17 years who missed their well child visits.
224112492|NCT02785757|OTHER|Thrombin Generation Assay|
224112493|NCT03466762|OTHER|Non applicable|Non applicable
224112494|NCT00705510|DRUG|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
224112495|NCT02354001|DRUG|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
224112496|NCT02354001|DRUG|Placebo|1 capsule daily for 12 week trial - lactose
223966874|NCT01469884|DRUG|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
223966875|NCT01469884|DRUG|Cyclosporine|Trough level should be between 100 and 200ng/ml.
223966876|NCT01469884|DRUG|Tacrolimus|Trough level should be between 5 and 10ng/ml.
223966877|NCT01668992|BEHAVIORAL|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
223966878|NCT03063983|DRUG|Cyclophosphamide|Continuous oral cyclophosphamide
223966879|NCT03063983|DRUG|Methotrexate|Continuous oral methotrexate
223966880|NCT03994185|DEVICE|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
223966881|NCT01305551|DRUG|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
223966882|NCT01305551|DRUG|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
224112497|NCT01430195|DRUG|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
224112498|NCT01430195|PROCEDURE|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
224112499|NCT05207267|DEVICE|driving pressure guided tidal volume|Volume control mode without spontaneous breathing, PEEP will be set according to best respiratory compliance method, and tidal volume (VT) will be set to reach three levels of driving pressure (High 14-15cmH2O, moderate 10-11 cmH2O, and low 7-8 cmH2O). Each level of VT was maintained 10 minutes in supine and/or prone position.
224112500|NCT00855712|DEVICE|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
224112501|NCT00855712|DEVICE|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
224112502|NCT01115712|DRUG|Placebo|Placebo (to match pioglitazone 30 mg) once daily
224112503|NCT01115712|DRUG|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
224112504|NCT01115712|DRUG|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
223542667|NCT05488054|PROCEDURE|Physical Therapy|Patients will undergo physical therapy following surgical intervention
223542668|NCT05488054|PROCEDURE|Monitored Work-out|Healthy volunteers will undergo a monitored workout for comparison of data
223542669|NCT05488054|DEVICE|Moxy Oxygen Sensor Device|Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
224112505|NCT06232122|DIAGNOSTIC_TEST|68Ga-FAPI-46|Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
223542670|NCT04406987|PROCEDURE|decompression|surgical technique for neural decompression varied based on surgeon's preference, but always with preservation for spinous processes. Either open with or without microscope or using tubular retractors.
223966883|NCT01305551|DRUG|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
223966884|NCT02703519|PROCEDURE|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
223966885|NCT02070289|DRUG|PF-06372865|Tablets, 2.5 mg BID, 14 days
223966886|NCT02070289|DRUG|Placebo|Tablets, BID, 14 days
223966887|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
223966888|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
223966889|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
223966890|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
223966891|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
223966892|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
223966893|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
223966894|NCT02070289|DRUG|Placebo|Tablets, BID or titration, 14 days
223966895|NCT02070289|DRUG|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
223966896|NCT03074968|DRUG|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
223966897|NCT03074968|DRUG|Normal saline|normal saline application
224112506|NCT06232122|DIAGNOSTIC_TEST|18F-FDG|Intravenous injection of one dosage of 5-10mCi 18F-FDG
223966898|NCT02274116|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
223966899|NCT02274116|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
223966900|NCT04867499|OTHER|No intervention|Descriptive study. No intervention.
223966901|NCT05588661|OTHER|Perturbation Exercises|"Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients."
223966902|NCT05588661|OTHER|Whole Body Vibration|"It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks"
223966903|NCT01895868|OTHER|Simulation-based ultrasound training|
223966904|NCT01776749|DEVICE|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
223966905|NCT05301725|OTHER|PPI regimen|All patients received PPI regimen( lansoprazole or esomeprazole,bismuth amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
223966906|NCT05301725|OTHER|P-CAB regimen|All patients received P-CAB regimen(vonoprazan,bismuth ,amoxicillin,clarithromycin for14 days). Demographic data,treatment regimens, outcomes of therapy, adherence to therapy and adverse event were retrieved.
223966907|NCT00104845|BIOLOGICAL|human gp100 plasmid DNA vaccine|
223966908|NCT00104845|BIOLOGICAL|mouse gp100 plasmid DNA vaccine|
223966909|NCT03984734|PROCEDURE|Pancreatoduodenectomy with antrectomy|
223966910|NCT03984734|PROCEDURE|Pylorus-preserving pancreatoduodenectomy|
223966911|NCT03036722|OTHER|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
223966912|NCT03036722|OTHER|Placebo control porridge|control porridge matched for energy and fat content.
223966913|NCT03750175|OTHER|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
223966914|NCT03879252|DEVICE|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
223966915|NCT03879252|DRUG|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
223966916|NCT02226029|OTHER|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~* Lipid emulsion 1: acid stable, particle size 0.6 µm~* Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~* 13C-markers will be mixed with emulsions"
223966917|NCT04992884|DEVICE|Gastric Alimetry|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
223966918|NCT01425697|OTHER|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
223966919|NCT01425697|OTHER|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
223966920|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight \<75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
223966921|NCT01596517|DRUG|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
223966922|NCT05058547|DEVICE|SWEPPE|In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
223966923|NCT03743597|DEVICE|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
223966924|NCT03743597|DEVICE|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
223966925|NCT06085859|DEVICE|Routine nasal catheter group|The anaesthesia provider supplied oxygen via a nasal cannula at an oxygen flow rate of 8 Litres/minute supplied from an oxygen flowmeter as described in the guide
223966926|NCT06085859|DEVICE|Mask group|The study team applied the mask with a head strap to ensure a proper seal,simultaneously ensuring the same oxygen flow rate as the control group
223966927|NCT00683371|PROCEDURE|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
223966928|NCT00683371|PROCEDURE|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
223966929|NCT00417989|DEVICE|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
223966930|NCT06319924|DRUG|Simethicone combined with Macrogol 4000 (PEG)|bowel preparation product for colonoscopy as part of CRC screening
223966931|NCT01245699|BEHAVIORAL|scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing|scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
223966932|NCT03761979|DIETARY_SUPPLEMENT|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
223966933|NCT04342910|DRUG|camrelizumab|200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
223966934|NCT04342910|DRUG|Apatinib Mesylate|250 mg qd
223966935|NCT04342910|DRUG|Paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
223966936|NCT04342910|DRUG|Irinotecan|180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
223966937|NCT04247906|DRUG|Narsoplimab|
223966938|NCT01945086|DRUG|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
223966939|NCT01945086|DRUG|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
224112507|NCT05082870|BEHAVIORAL|Supportive-expressive group therapy (SEGT)|The SEGT approach fosters mutual support, promotes openness and emotional expression. SEGT will be delivered and co-facilitated by a psychiatrist and an allied healthcare professional. It is a 6-module program held over a 3-week period (approximately 2 hour sessions X 2 week) that is framed within social cognitive theory, whereby resilience to adversity (limb loss in this instance) relies on personal enablement.
224112508|NCT01975025|PROCEDURE|Short daily dialysis for 2 weeks|
224112509|NCT02243566|DRUG|MicardisPlus®|
224112510|NCT03836521|DEVICE|Transcatheter aortic valve replacement|
224112511|NCT02355379|DRUG|LV5FU2 or capectitabine|
224112512|NCT02355379|DRUG|FOLFOX4 or XELOX|
224112513|NCT02355379|OTHER|Observation|
224112514|NCT02355379|DRUG|LV5FU2 or capecitabine|
223966940|NCT01945086|OTHER|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
223966941|NCT03669965|DRUG|KRT-232|KRT-232, administered by mouth
223966942|NCT03669965|DRUG|Ruxolitinib|Ruxolitinib per approved prescribing label
223966943|NCT03576625|DIETARY_SUPPLEMENT|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
223966944|NCT03576625|DIETARY_SUPPLEMENT|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
224112515|NCT00954577|BEHAVIORAL|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
223966945|NCT04644692|OTHER|Lung ultrasound|A lung ultrasound before and at the end of the stress test.
224112516|NCT01134484|DRUG|Velcade|"* INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~* REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
224112517|NCT01134484|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
224112518|NCT01134484|DRUG|Dexamethasone|"* INDUCTION THERAPY~  1. VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~ 2. TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~* AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~* REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~  1. VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~ 2. TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
223966946|NCT03852485|DEVICE|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
223966947|NCT05986799|DIETARY_SUPPLEMENT|Amway Herbal Drink|1 sachet per time, 3 times daily, for 3 months period.
223966948|NCT05986799|DIETARY_SUPPLEMENT|Placebo Drink|1 sachet per time, 3 times daily, for 3 months period.
223966949|NCT01556087|BEHAVIORAL|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
223966950|NCT01556087|BEHAVIORAL|Health Education|7 individual sessions with didactic health education information
223966951|NCT00748098|DRUG|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
223966952|NCT00748098|DRUG|Placebo|Placebo
223966953|NCT00488761|DRUG|Tigecycline|
223966954|NCT03136588|DEVICE|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
224112519|NCT01134484|PROCEDURE|Peripheral Blood Stem Cell (PBSC) collection|"* Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~* G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
224112520|NCT01134484|PROCEDURE|First Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
224112521|NCT01134484|PROCEDURE|Second Autologous Transplantation|"* HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~* G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10\^9/L for 3 consecutive days"
224112522|NCT00156078|DRUG|pregabalin|
224112523|NCT02443844|PROCEDURE|Transurethral Resection|Endoscopic treatment of bladder cancer
224112524|NCT02443844|DRUG|Tamsulosin|Medical treatment for benign prostate hyperplasia
224112525|NCT02596880|DRUG|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
223542671|NCT04406987|PROCEDURE|fusion|fusion techniques consisted besides decompression of additional implantation of pedicle screws with rods, with or without intervertebral fusion and cage(s). Non-instrumented technique with allograft bone. Fusion technique on surgeon's discretion.
223542672|NCT04330209|OTHER|weight loss diets|The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
224112526|NCT02596880|DRUG|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
224112527|NCT02596880|DRUG|Ribavirin|1000 mg/day if \<75 kg, 1200 mg/day for \>75 kg. Divided into two daily doses
224112528|NCT00974662|DRUG|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 \& 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
223966955|NCT05085678|DEVICE|Co'moon (online website to support women with AET)|"The tool contains three parts:~1. e-learning based on the brochure on adjuvant endocrine therapy (AET) in the University Hospital Leuven,~2. serious game where patients are confronted with scenes of their daily life and motivational guidelines to stimulate their self-management,~3. a patient-reported-outcome questionnaire (PROMs), reported in the patient medical file.~The tool is designed to stimulate patients self-management of their menopausal AET-related complaints and to discuss them with their health care professionals ."
223966956|NCT03771261|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
223966957|NCT03771261|DIETARY_SUPPLEMENT|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
223966958|NCT01946477|DRUG|Pomalidomide|
223966959|NCT01946477|DRUG|Dexamethasone|
223966960|NCT01946477|DRUG|Daratumumab|
223966961|NCT06993181|DRUG|DA-5222|single dose administration (DA-5222 one tablet once a day)
223966962|NCT06993181|DRUG|DA-5222-R1|single dose administration (DA-5222-R1 one tablet once a day)
223966963|NCT06993181|DRUG|DA-5222-R2|single dose administration (DA-5222-R2 one tablet once a day)
223966964|NCT06993181|DRUG|DA-5222-R3|single dose administration (DA-5222-R3 one tablet once a day)
223966965|NCT06860763|DRUG|Chinese herbal medicine|The general treatment strategy will follow principles of clearing excess and replenishing deficiency, regulating the internal organs, and balancing yin and yang. Based on the patient's specific syndrome in TCM.
223966966|NCT06860763|DEVICE|Acupuncture|The acupuncture needles used will be 0.25 mm in diameter and 25 mm in length, inserted quickly with even supplementation and reduction techniques.
223966967|NCT06859775|DRUG|SHR-A1811|SHR-A1811 injection.
223966968|NCT06859775|DRUG|Adebelimab injection|Adebelimab injection.
223966969|NCT06859775|DRUG|Bevacizumab injection|Bevacizumab injection.
224112529|NCT03389672|PROCEDURE|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
223966970|NCT06859775|DRUG|SHR-8068|SHR-8068 injection.
223966971|NCT06859775|DRUG|Cisplatin injection|Cisplatin injection.
223966972|NCT06859775|DRUG|Carboplatin injection|Carboplatin injection.
223966973|NCT07000097|DEVICE|PTA planning supported by 3D-printed model|Custom-made 3D-printed model as an additional tool to computed tomography angiography for planning Percutaneous Transluminal Angioplasty in aorto-iliac-femoral-popliteal artery disease
223966974|NCT07000097|DEVICE|PTA (Standard of Care)|Preoperative planning performed based on computed tomography angiography
223966975|NCT04907877|DIETARY_SUPPLEMENT|Probiotic|Probiotic will be taken 1 time a day before breakfast for 28 days.
223966976|NCT04907877|DIETARY_SUPPLEMENT|Placebo|Placebo will be taken 1 time a day before breakfast for 28 days.
224112530|NCT03389672|PROCEDURE|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
224112531|NCT03389672|PROCEDURE|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
223966977|NCT07003256|DRUG|Romiplostim|After transplantation + 6 days, the subcutaneous injection of roprastine 3ug/kg was started, and the number of platelets in the machine-taken platelet suspension was increased by 2 µg/kg per week, and the maximum dose was 10 μg/kg. Discontinued until platelets rose to 100 × 109/L. If platelets ≤ 20 X 109/L were used for + 20 days, roprastine combined with atropopa 25mg was given orally once a day. Patients were given 1 therapeutic dose of fresh machine-taken platelet suspension when platelets were ≤ 20 X 109/L, or when there was active bleeding at 21\~ 50 × 109/L. The number of platelets in the machine-taken platelet suspension per therapeutic dose was \> 2.5 × 1011. If not implanted at + 28 days after transplantation, re-transplantation is required, and roprastine is considered ineffective.
223966978|NCT07008547|BIOLOGICAL|Netakimab|Netakimab administered subcutaneously
223966979|NCT07008547|DRUG|Placebo|Placebo administered subcutaneously
223966980|NCT07008846|DRUG|To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis|This intervention is open label. Both patient and investigator will know about the intervention. Participants are allocated according to block randomization. Total two groups with each contain 48 patients. One group will be given Tofacitinib, Methotrexate and another group will be given Upadacitinib, Methotrexate
223966981|NCT07007858|OTHER|Exercise|In addition to standard physical therapy (including strengthening exercises, weight-bearing, balance, proprioception, and gait training), stretching will be applied to the ankle joint as described by Tardieu: first at a velocity as slow as possible (V1) for 5 minutes, followed by stretching at the fastest possible velocity (V3), sufficient to elicit a catch, for 10 minutes. A 1-minute rest period will be provided between each stretch. This protocol will be conducted three times per week for four weeks under the supervision of a physiotherapist. Afterward, the exercise will be taught to the families and continued at home as a home-based program for up to six months, without velocity measurement.
224112532|NCT01784549|DRUG|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
224112533|NCT02730247|DRUG|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
224112534|NCT02730247|DRUG|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
224112535|NCT06092502|OTHER|Graded Motor Imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
224112536|NCT06092502|OTHER|Traditional Physiotherapy Program|This protocol included stretching and strengthening exercises
224112537|NCT04155385|OTHER|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
224112538|NCT04155385|OTHER|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
224112539|NCT00002423|DRUG|Indinavir sulfate|
224112540|NCT00002423|DRUG|Abacavir sulfate|
224112541|NCT00002423|DRUG|Amprenavir|
224112542|NCT00002423|DRUG|Nelfinavir mesylate|
224112543|NCT00002423|DRUG|Lamivudine|
223542673|NCT01302184|DEVICE|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
223966982|NCT07007858|OTHER|Exercise|In addition to standard physical therapy (including strengthening exercises, weight-bearing, balance, proprioception, and gait training), standard stretching will be applied to the ankle joint three sessions per week. Stretching will be performed for a total of 15 minutes per leg in each session, consisting of 10 repetitions of 60 seconds with 30-second rest intervals. During the 4-week intervention period, the exercises will be taught to the families and continued at home as a home exercise program for up to six months
223966983|NCT07008092|DIAGNOSTIC_TEST|Blood specimen collection|Blood specimen collection for analysis of C-reactive protein, white blood cell count and neutrophile count.
223966984|NCT07008092|DIAGNOSTIC_TEST|Urine collection|Urine sample collection for analysis of creatinine and prostaglandin E urinary metabolites
223966985|NCT07007975|BEHAVIORAL|Web based training|This group will receive information about healthy lifestyle behaviors and gynecological cancer awareness.
223966986|NCT07009275|OTHER|The game-based simulation application developed using 3D animation technology|The intervention group consisted of students using the game-based simulation application developed using 3D animation technology, while the control group consisted of students using traditional learning methods.
223966987|NCT07008183|OTHER|self-questionnaires|Patients who volunteer to take part in the research will complete self-questionnaires before their appointment with the psychiatrist.
223966988|NCT07007988|DRUG|SIM0388|Abdominal perfusion
223966989|NCT07007988|DRUG|SIM0388|Abdominal perfusion
223966990|NCT05183802|DRUG|Setmelanotide, administered subcutaneously [SC], once daily.|Dosing based on age, and titrated from starting dose to target dose.
223966991|NCT05843695|BEHAVIORAL|iTCBT-I|Individual format over 2 weeks
223966992|NCT05843695|BEHAVIORAL|iTCBT-G|Group format over 2 days
223966993|NCT05843695|BEHAVIORAL|TAU|Standard care
223966994|NCT07009028|COMBINATION_PRODUCT|Storigami figure|Combination Produc: The origami figure that will be formed as a result of the process will be used as a distraction method
223966995|NCT07007728|DRUG|Iparomlimab/Tuvonralimab|5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days). Duration: 3 or 6 cycles
223966996|NCT07007728|DRUG|Bevacizumab + CAPEOX|"Bevacizumab: 7.5mg/kg intravenous infusion on Day 1 of each cycle (every 21 days).~Capecitabine: 1000 mg/m2 twice daily orally on Day 1-14 of each cycle (every 21 days).~Oxaliplatin: 130 mg/m2 intravenous infusion on Day 1 of each cycle (every 21 days).~Duration:~Conversion therapy phase: 3 or 6 cycles; Postoperative follow-up phase (for patients with successful conversion surgery ): 3 or 6 cycles (a total perioperative duration of 9 cycles); Maintenance phase (for patients without successful conversion surgery ): Continuous therapy until disease progression, intolerable adverse events, withdrawal of consent, loss to follow-up, death, or study termination."
224112544|NCT05450861|OTHER|SF DNA extraction composition|the composition of small fragments of DNA from fish
223966997|NCT07007728|PROCEDURE|Surgical resection ± ablation or stereotactic radiotherapy (if applicable)|After 3 or 6 cycles of conversion therapy, surgical resection ± ablation or stereotactic radiotherapy will be provided if applicable.
223966998|NCT07007546|DRUG|ABSK061|A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.
223966999|NCT07007546|DRUG|ABSK061|A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.
224112545|NCT05450861|OTHER|Placebo|the scalp conditioning solution without SF DNA extraction composition
224112546|NCT04977999|OTHER|Exercise|Both arms/conditions use varying forms of exercise as the intervention.
224112547|NCT03890224|DEVICE|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
224112548|NCT02949661|PROCEDURE|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
224112549|NCT02949661|PROCEDURE|Local wound infiltration|Patients will receive local wound infiltration
224112550|NCT05310383|COMBINATION_PRODUCT|Tislelizumab plus radiotherapy|During the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.
224112551|NCT03694522|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
224112552|NCT03694522|DRUG|Placebo|Administered by intravenous infusion over approximately 30 minutes
224112553|NCT03694522|DRUG|Modified FOLFOX6|"mFOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours"
224112554|NCT02391727|BIOLOGICAL|SYN004|subjects who have received effective treatment for their cancers are eligible
224112555|NCT00434460|BEHAVIORAL|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
224112556|NCT02760407|DRUG|Olokizumab 64mg q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
224112557|NCT02760407|DRUG|Olokizumab 64mg q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
224112558|NCT02760407|DRUG|Adalimumab 40mg q2w|0.4 or 0.8 mL prefilled, single-dose syringe
224112559|NCT02760407|DRUG|Placebo q2w|sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
224112560|NCT01533155|DRUG|Nektar 118|Oral 25 mg tablet
224112561|NCT01533155|DRUG|Quinidine|Oral 200 mg tablet
224112562|NCT01533155|DRUG|Quinidine placebo|Oral Tablet
224112563|NCT01533155|DRUG|Morphine|10 mg/ml, intravenously
224112564|NCT02320331|BEHAVIORAL|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
224112565|NCT03768401|OTHER|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
224112566|NCT03768401|BEHAVIORAL|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
224112567|NCT02976467|DRUG|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
224112568|NCT02976467|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
224112569|NCT03744169|DIAGNOSTIC_TEST|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for participant stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to participant history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the participant. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the participant's respiratory failure. Images will be acquired by pediatric critical care trainees and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
224112570|NCT03744169|DIAGNOSTIC_TEST|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the participant will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the participant's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
224112571|NCT03744169|DIAGNOSTIC_TEST|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
224112572|NCT05427630|DRUG|THC ~2.5%|Cannabis flower containing THC \~2.5%
224112573|NCT05427630|DRUG|THC ~5%|Cannabis flower containing THC \~5%
224112574|NCT05427630|DRUG|THC ~10%|Cannabis flower containing THC \~5%
224112575|NCT05427630|DRUG|Sham Cannabis|Cannabis flower from which the THC and CBD have been extracted
223967000|NCT07007546|DRUG|ABSK061|Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).
223967001|NCT05827549|DRUG|Reinduction(4weeks)|Prednisolone 60 mg/m2/day tid days 1-28, Vincristine 1.5 mg/m2 on days 1, 8, 15, 22, L-asparaginase 6,000 IU/m2(days 2-4 start, total 9 doses for 3 weeks), Idarubicin 10 mg/m2 on days 1, 8, (15\~17), IT Ara-C on days 1, IT MTX on days 8, 29
223967002|NCT05827549|DRUG|Cosolodation 1st(3weeks)|Ifosfamide: 1.8 g/m2 (days 1, 2, 3, 4, 5), Etoposide: 100 mg/m2 (days 1, 2, 3, 4, 5), IT MTX on day 1
223967003|NCT05827549|DRUG|Consolidation 2nd(3weeks)|MTX: 500 mg/m2 over 30 min followed by 1,000 mg/m2 over 23.5 hr (day 1), Ara-C: 3,000 mg/m2/dose (day 2, 3), IT MTX on day 1
223967004|NCT05827549|DRUG|Blinatumomab 1st(High Risk Group)_4 Weeks|Blinatumomab 15 mcg/m²/day(Days: 1-28), Dexamethasone 5 mg/m2/dose on Day 1, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
224112576|NCT03319550|DIETARY_SUPPLEMENT|Casein|see experimental description
224112577|NCT03319550|DIETARY_SUPPLEMENT|Whey|see experimental description
223967005|NCT05827549|DRUG|Blinatumomab 2nd (High Risk Group)_4 Weeks|Blinatumomab 15 mcg/m²/day(Days: 1-28), IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
223967006|NCT05827549|DRUG|Blinatumomab-Salvage 1st (Very High Risk Group)_4 Weeks|Blinatumomab 9 mcg/day(Weight ≥ 45kg) or 5 mcg/m²/day(Weight \< 45kg) on 1-7 days, 28 mcg/day(Weight ≥ 45kg) or 15 mcg/m²/day(Weight \< 45kg) on 8-28 days, Dexamethasone 5 mg/m2/dose on day 1 and day 8, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
223967007|NCT05827549|DRUG|Blinatumomab-Salvage 2nd (Very High Risk Group)_4 Weeks|Blinatumomab 28 mcg/day(Weight ≥ 45kg) or 15 mcg/m²/day(Weight \< 45kg) on 1-28 days, IT MTX on day 15, 29 (CNS 1, 2 patients), TIT on day 15, 29 (CNS 3 patient)
223967008|NCT05827549|DRUG|Intensification course|"\<Intensification 1st(3 Weeks)\> Etoposide: 100 mg/m2 on day 1, 2, 3, Ifosfamide 3.4 g/m2 on day 1, 2, 3~\<Intensification 2nd(2 Weeks)\> Oral 6-mercaptopurine 50 mg/m2/day PO (days 1-14), Methotrexate: 25 mg/m2 on day 1, 8, TIT on day 1~\<Intensification 3rd(3 Weeks)\> Ara-C 1.0 g/m2 (days 1-3), Idarubicin: 5mg/m2 (days 1- 3)~\<Intensification 4th(2 Weeks)\> Dexamethasone 8 mg/m2/day on days 1-14, Vincristine 2 mg/m2 on days 1 and 8, L-asparaginase 10,000 IU/m2 on days 1 and 8"
224112578|NCT03319550|DIETARY_SUPPLEMENT|Leucine-enriched whey|see experimental description
224112579|NCT01748760|BEHAVIORAL|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
224112580|NCT01748760|OTHER|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
223967009|NCT05827549|DRUG|Maintenance(12 Weeks/Cycle)|Prednisolone: 15 mg/m²/dose(Days 1-5, 29-33, 57-61), Vincristine: 1.5 mg/m²/dose(Day 1, 29, 57), Oral 6-mercaptopurine: 50 mg/m²/dose (Days 1-84), Methotrexate: 20 mg/m²/dose (Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78), Intrathecal methotrexate (Day 1)
223967010|NCT05827549|PROCEDURE|Stem Cell Transplantation|All matters related to hematopoietic stem cell transplantation are subject to each institution's practice.
223967011|NCT02304289|DRUG|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
223967012|NCT06697431|DRUG|Anakinra|"Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase."
223967013|NCT06697431|DRUG|Intravenous Immunoglobulins, Human|see previous section
223967014|NCT04300478|BEHAVIORAL|REx Condition First|REx condition: Participants will complete a whole-body REx workout consisting of 1-set to failure (e.g. RPE of 9-10 on 10-point scale on final reps) on 12 exercises in the Exercise Research Laboratory (located in the CTRC), with a 3-minute rest between exercises. Participants will complete the following exercises: leg press; leg extension; leg curl; hip abduction; hip adduction; chest press; overhead press; seated row; overheard pulldowns and assisted triceps dips on Cybex resistance equipment; barbell calf raises on a Smith machine; and dumbbell biceps curls. Resistance for the REx trial will be determined based on the exercise familiarization session. Specifically, we will target a resistance level needed for each participant to complete \~12-15 repetitions per exercise, using proper form, with an RPE of 9-10 on a 10-point scale on final reps. This protocol eliminates the need for max testing in order to set an exercise protocol off of a specific intensity based on % of 1RM.
223967015|NCT04300478|BEHAVIORAL|Sedentary Control Condition First|Sedentary control condition: Participants will sit quietly in a seated position for the entire duration of this condition.
223967016|NCT06720519|DIAGNOSTIC_TEST|QIAstat-Dx®Meningitis/Encephalite Panel|"The analytical sensitivity of the test is assessed by comparing the results obtained with those known from routine diagnostic tests.~For viruses only, the semi-quantitative value of Ct is also evaluated with the viral load provided by qPCR."
223967017|NCT06721819|COMBINATION_PRODUCT|Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention|Preoperative Sleep Hygiene and Brain game followed by post operative IV acetaminophen administration
223967018|NCT06721819|DRUG|Control|Three doses of IV acetaminophen (as following ERAS protocol) at 1000mg per dose within 48 hours post operatively.
223967019|NCT06720116|OTHER|sustained natural apophysial glide|"The patients will be in the sitting position and asked to move their head in the direction that particularly produces their symptoms. As the participant moves their head, the physiotherapist gently glides the painful vertebra anteriorly and sustains the glide through the movement.~During the application of the glide, the participant should stay symptom free and is instructed to stop moving if any PAIN is produced. This movement was repeated for 10 times for 3 sets, The interval between the sets was 15 to 20 seconds.After mobilization subject had to perform same exercises as conventional group plus conventional physical therapy"
223967020|NCT06720116|OTHER|instrument assisted soft tissue mobilization|"The subject will be in comfortable sitting position leaning on a treatment table with the arm crossed to rest the head. After cleaning the skin of the subject and the blade with alcohol swabs, a lubricant (Vaseline) was applied, and a sweeping technique was used to apply a deep yet comfortable soft tissue mobilization on the upper trapezius from origin to insertion for approximately 3 min.~First, M2T blade will be utilized to locate the precise locations of limitation in the affected muscles. Second, the M2T blade was put at 45 degree angle by using convex surface to apply gentle strokes along the muscle. Subjects were instructed that slight hyperemia on the skin is a normal feeling and should subside before the next session."
223967021|NCT06720116|OTHER|conventional physical therapy|the patients will receive conventional physical therapy in the form of Infrared, TENS , stretching exercices, isometric exercises
223967022|NCT06721546|OTHER|Nursing interventions|"The data collection process took place between March and June 2024. The implementation process took place between July 9 and October 24, 2024. In this process, education, reminder messages and telephone counseling for individuals with type 2 diabetes continued for 12 weeks.~Introduction and Preliminary Preparation: Before randomization, both oral and written informed consent form and pretest forms (Personal Information Form, Nutrition Habits, Functional Foods Information Form, Functional Foods Consumption Form, Diabetes Self-Efficacy Scale, Healthy Lifestyle Behaviors II Scale Application) were administered by the researcher to individuals with type 2 diabetes who agreed to participate in the study between March and June 2024. After reaching the sample size (n=86), randomization was performed. Appointments were made for the intervention group for training at KEAH via telephone on Tuesday-Thursday of the week in groups."
224112581|NCT06035718|DRUG|Probiotic Blend Capsule|By a probiotic blend capsule a specific product is intended which contains the following: Lactobacillus rhamnosus Lactobacillus plantarum Lactobacillus casei Lactobacillus helveticus Lactobacillus acidophilus Lactobacillus bulgaricus Lactobacillus gasseri Bifidobacterium bifidum Bifidobacterium lactis Bifidobacterium breve Bifidobacterium longum Streptococcus thermophile Fructooligosaccharides (FOS).
224112582|NCT06035718|DEVICE|tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp.
224112583|NCT06035718|DEVICE|Sham tDCS|Using a tDCS device, a mild direct electric current is going to be non-invasively administered to the brain using rubber electrodes placed over the scalp. At this arm the electric current will be applied for a very short time (30 s) after which the device will turn off, thus providing the initial tingling sensation over the scalp but not interfering with the ongoing brain activity.
224112584|NCT05413694|OTHER|telephone interview 24 months after hospitalization for Covid-19|telephone interview 24 months after hospitalization for Covid-19
224112585|NCT02085655|DRUG|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224112586|NCT02085655|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224112587|NCT02085655|DRUG|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
223967023|NCT06721546|OTHER|reminder messages|Reminder messages: Address and telephone numbers of individuals with Type 2 diabetes in the intervention group were obtained after obtaining their informed consent at the first meeting. After the group training, the messages were sent to the groups (groups A, B, C and D) on Tuesdays and Thursdays during daylight hours every week on the 2nd (July 23-August 15) and 6th (August 20-September 12) weeks. The message was a reminder to the participants about healthy nutrition and consumption of functional foods.
223967024|NCT06721546|OTHER|Telephone counseling|Telephone counseling: After the group trainings applied to the intervention group, in the 4th (August 6-August 29) and 8th (September 3-September 26) weeks of each week on Tuesdays and Thursdays during daylight hours, individuals with diabetes mellitus were questioned about 'the obstacles they encounter during healthy eating and functional food consumption and whether they have the belief that they can overcome these obstacles and whether there is a change in their healthy eating and functional food consumption behaviors'. Reinforcement was made with reminder questions. In this process, the importance of functional food consumption was emphasized. The first telephone interview with 43 individuals with type 2 diabetes lasted 575 minutes in total and the second telephone interview lasted 495 minutes in total.
223967025|NCT05420701|PROCEDURE|TEE|Patients in the surgical arm (LAAC) will be arranged to do TEE, which is not considered standard of care.
223967026|NCT06721780|DEVICE|Participants randomised to wear AR headset|Participants will use an AR headset that employs a distraction game specifically designed for children and young adults undergoing painful procedures.
223967027|NCT06721780|DEVICE|Participants randomised to wear VR headset|Participants will utilise a VR headset, running a calming virtual environment or an interactive game during the dressing change.
223967028|NCT06717503|OTHER|data collection|data will be collected from data sheets of acute spinal cord injury patients (Patients' demographic and epidemiological ,Mode of trauma, Cause of injury, Method of arrival to hospital, Time passed between trauma and arrival at hospital,How to deal with the TSI patients from the time of the injury until arrival at hospital, Examination findings, Imaging findings, Type and level of the injury, Sequels, Hospital stay period and operations)
223967029|NCT06719960|DRUG|Dexmedetomidine group|To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the dexmedetomidine group, in addition to propofol infusion at the same doses, dexmedetomidine 0.5 μg/kg-1 loading dose was administered within 10 minutes and then continued as infusion at a dose of 0.2-0.7 μg/kg/h.
223967030|NCT06719960|DRUG|Propofol group|To evaluate cognitive function, Mini Mental State Examination (MMSE) was administered 3 times before the procedure and 2 hours and 24 hours after the procedure. Frailty level of the patient was determined using the frail frailty questionnaire. Each patient received 0.5µg/kg fentanyl (iv). In the propofol group, propofol loading dose: 0.2-0.5mg/kg, maintenance infusion dose: 0.5-4mg/kg/h was continued.
224112588|NCT02085655|DRUG|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223967031|NCT06720324|DRUG|Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
223542674|NCT01302184|DEVICE|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
223967032|NCT04264884|DRUG|Daratumumab|Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
224112589|NCT02085655|DRUG|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224112590|NCT02085655|DRUG|Thalidomide|100-200mg, PO, after chemotherapy
224112591|NCT03245814|BEHAVIORAL|Service Dog|A service dog trained to perform tasks that are specific to PTSD
223542675|NCT02394158|DRUG|Metformin|
223542676|NCT02394158|DRUG|placebo|
223967033|NCT06892587|BEHAVIORAL|An 8-week virtual group intervention designed to promote sustainable health behavior changes in participants|"The Healthy YOU Program is an 8-week virtual group intervention designed to help participants make lasting health behavior changes, focusing on diet and physical activity. Delivered via confidential Zoom sessions, it offers flexibility and support in a group setting. Participants engage in facilitated discussions, interactive activities, and expert guidance.~Participants receive a structured curriculum with a printed workbook, covering evidence-based topics like nutrition, exercise, and well-being. Learning methods include:~Weekly Newsletters: Provide health tips, resources, and reflections to support behavior change.~Facilitated Group Discussions: Live sessions to share experiences, ask questions, and support each other.~Applied Activities: Hands-on tasks like meal planning and goal-setting to build confidence.~Demonstrations: Live sessions on healthy cooking, home exercises, and overcoming barriers.~The program encourages goal setting, progress tracking, and self-regulation."
223967034|NCT06892587|BEHAVIORAL|Standard of care Nutritional Information|The standard of care will involve providing participants with 8 weeks of nutrition information through printed handouts. These handouts will be generic, similar to materials typically provided by healthcare providers or available on public-facing health/nutrition websites. While they will cover the same topics as the experimental group, the handouts will contain only basic, publicly available nutritional information and will not include guidance for application. These handouts are also included in the Healthy YOU curriculum as background material for weekly class preparation. Participants will be instructed to review and utilize the handout information in a self-paced manner over the 8-week period.
223967035|NCT06736600|BEHAVIORAL|Goal Attainment Scaling (GAS)|Goal-setting tele-coaching and the well-studied Patient Priorities Care framework will assist participants with bothersome CIPN identify their most important health goals and scale them into specific, measurable, achievable, relevant, and time-bound (SMART) goals
223967036|NCT01819233|BEHAVIORAL|Behavioral dietary intervention|Receive caloric restricted dietary intervention
223967037|NCT01819233|PROCEDURE|Therapeutic conventional surgery|Undergo definitive lumpectomy
223967038|NCT01819233|RADIATION|Radiation therapy|Undergo radiation therapy
223967039|NCT01819233|OTHER|Counseling intervention|Receive dietary counseling
223967040|NCT01819233|PROCEDURE|Quality-of-life assessment|Ancillary studies
223967041|NCT05262244|DRUG|Bevacizumab-IRDye800CW|Bevacizumab-800CW is administered to the patient and angiography is performed before and directly after tracer administration and after 48-96 hours.
223967042|NCT02026583|DRUG|Simvastatin|
223967043|NCT01651650|DEVICE|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
223967044|NCT02630927|DRUG|AG-519|AG519 will be tested.
223967045|NCT02630927|DRUG|Placebo|Placebo will be tested.
223967046|NCT05657275|DIAGNOSTIC_TEST|CRP dosage|multimodal algorithm
223967047|NCT05657275|DIAGNOSTIC_TEST|multiplex PCR|multimodal algorithm
223967048|NCT05657275|DIAGNOSTIC_TEST|chest scan without injection|multimodal algorithm
224112592|NCT01665638|DRUG|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
224112593|NCT01665638|DRUG|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
223967049|NCT04991623|DEVICE|Kinesiology taping|We used kinesiology taping in abdominal muscles
223967050|NCT04991623|OTHER|Conventional physiotherapy|We used conventional physiotherapy to comparate
223967051|NCT05497037|DEVICE|PRF stimulation|One time 500 kHZ stimulation for 15 min
223967052|NCT05497037|DEVICE|Sham stimulation|Sham stimulation for 15 min
223967053|NCT03809650|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
223967054|NCT02946307|DEVICE|Restore DEB（dimeter>2.00 mm）|
223967055|NCT02946307|DEVICE|Resolute DES|
223967056|NCT02946307|DEVICE|Restore DEB（dimeter:2.00 mm）|
223967057|NCT05530382|OTHER|self-guided learning|video-based self-directed learning for medical device training
223967058|NCT01319864|DRUG|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
223967059|NCT02493881|DEVICE|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
223967060|NCT00082511|DRUG|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
223967061|NCT05611489|PROCEDURE|Open appendectomy|performed With the patient in supine position.incision made lateral to McBurney's point.layers of the abdomen is exposed. If the cecum can be visualized, it can be mobilized and used to identify the appendix. Once the appendix is identified, the mesoappendix should be dissected and the appendiceal vessels divided between clamps. The appendiceal vessels are then ligated with silk sutures. A silk purse-string suture can then be placed around the appendiceal base.A 15-blade knife is then used to excise the appendix proximal to the right angle clamp.The appendiceal stump mucosa can be obliterated using electrocautery. Then good haemostasis and layered closure is done.
223967062|NCT05611489|PROCEDURE|Conventional Lap appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
223967063|NCT02622464|OTHER|micro injection of SVF in vocal cords|
223967064|NCT00420563|DRUG|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
223967065|NCT00420563|DRUG|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
223967066|NCT02004132|DRUG|Axiron|Solution administered topically using pump and applicator
223967067|NCT02073721|OTHER|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
223967068|NCT02073721|OTHER|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
223967069|NCT03540615|DRUG|BAY1830839|Dose escalation in healthy male subjects
223967070|NCT03540615|DRUG|Placebo|Matching placebo
223967071|NCT01363336|DRUG|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
223967072|NCT00664261|BEHAVIORAL|smoking cessation intervention|
223967073|NCT00664261|OTHER|cancer prevention|
223542677|NCT00786422|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
223967074|NCT00664261|OTHER|counseling intervention|
223967075|NCT00664261|OTHER|educational intervention|
223967076|NCT00664261|OTHER|laboratory biomarker analysis|
223542678|NCT06414044|DRUG|Atogepant 60 mg|Patients using atogepant 60 mg tablet daily as migraine prevention
223542679|NCT01646814|DRUG|PL2200|PL2200, containing 325 mg aspirin active ingredient
223542680|NCT01646814|DRUG|Aspirin tablets|325 mg aspirin tablets (USP)
223542681|NCT03941847|OTHER|music|listening music
223542682|NCT05658328|BEHAVIORAL|SHARP - Physical and social activity|Technology-enabled neighborhood walking 3x/week for 16 weeks with conversational reminiscence
223967077|NCT00664261|OTHER|questionnaire administration|
223967078|NCT00664261|OTHER|survey administration|
223967079|NCT00664261|PROCEDURE|study of high risk factors|
223967080|NCT05566353|OTHER|Remote Check|Remote Check is a remote monitoring tool which permits patients with Cochlear Nucleus CP1000 or CP1150 processors to complete hearing tests (pure-tone and speech-in-voice audiometry, electrode impedance measures, implant functioning assessment) at home,
223967081|NCT00003502|DRUG|antineoplaston A10|
223967082|NCT00003502|DRUG|antineoplaston AS2-1|
223967083|NCT00003502|PROCEDURE|alternative product therapy|
223967084|NCT00003502|PROCEDURE|biological therapy|
223967085|NCT00003502|PROCEDURE|biologically based therapies|
223967086|NCT00003502|PROCEDURE|cancer prevention intervention|
223967087|NCT00003502|PROCEDURE|complementary and alternative therapy|
223967088|NCT00003502|PROCEDURE|differentiation therapy|
223967089|NCT04231747|BIOLOGICAL|CC-97540|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection."
223967090|NCT02652390|DRUG|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
223967091|NCT02652390|DRUG|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
223967092|NCT02652390|OTHER|Saline|2 mL saline + 1 mL lidocaine
223967093|NCT04387903|PROCEDURE|Surgical re-interventionafter pancreaticoduodenectomy|Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
223967094|NCT01586533|DRUG|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
224112594|NCT01665638|DRUG|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
224112595|NCT01665638|DRUG|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
224112596|NCT02122289|DEVICE|Application of Smartphone|Weekly questionnaire on smartphone
224112597|NCT02122289|OTHER|No application Smartphone|No weekly questionnaire on smartphone
224112598|NCT01708564|BIOLOGICAL|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
224112599|NCT05374356|DRUG|Intrathecal bupivacaine and morphine|Spinal group: will receive high spinal anesthesia with hyperbaric bupivacaine (0.3 to 0.6 mgs/kg) + preservative free morphine (3 mcg/kg).
224112600|NCT04302181|DRUG|Ropivacaine injection|6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
224112601|NCT04320303|BIOLOGICAL|expanded NK cells|Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.
224112602|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
223967095|NCT01586533|DRUG|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
223967096|NCT01583738|DRUG|V0251|single dose
223967097|NCT01583738|DRUG|placebo|single dose
223967098|NCT00347737|DRUG|teriparatide|Teriparatide
223967099|NCT00729053|DRUG|IMO-2055|immunostimulatory oligonucleotide
223967100|NCT01537120|DRUG|Vildagliptin|
223967101|NCT01537120|DRUG|Placebo|
223967102|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
223967103|NCT01495234|DEVICE|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
224112603|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
224112604|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
224112605|NCT01164501|DRUG|BI 10773|BI 10773 tablets once daily
224112606|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 low dose
224112607|NCT01164501|DRUG|Placebo|Placebo tablets identical to BI 10773 high dose
224112608|NCT01235533|DIETARY_SUPPLEMENT|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
224112609|NCT04771715|DRUG|Regorafenib|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
224112610|NCT04771715|DRUG|Nivolumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
223967104|NCT05899621|DRUG|Obinutuzumab|Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.
223967105|NCT05899621|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
223967106|NCT05899621|DRUG|Bendamustine|Bendamustine IV infusion will be administered as per the schedule specified in the respective arm.
223967107|NCT05899621|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
223967108|NCT05899621|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
224112611|NCT04771715|DRUG|Pembrolizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
223542683|NCT05942716|DRUG|Administration of a PET radiotracer|"A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic."
223967109|NCT05899621|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
223967110|NCT05899621|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223967111|NCT02657421|PROCEDURE|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
223967112|NCT03628183|OTHER|Hydrolysate Infant Formula 1|Feed ad lib
223967113|NCT03628183|OTHER|Hydrolysate Infant Formula 2|Feed ad lib
223967114|NCT02760472|DRUG|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
223967115|NCT02760472|DRUG|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
223967116|NCT01532583|OTHER|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
223967117|NCT05114369|PROCEDURE|Curative surgery|
223967118|NCT03695198|DRUG|LY3361237 - SC|LY3361237 administered SC
223967119|NCT03695198|DRUG|LY3361237 - IV|LY3361237 administered IV
223967120|NCT03695198|DRUG|Placebo - SC|Placebo administered SC
223967121|NCT03695198|DRUG|Placebo - IV|Placebo administered IV
223967122|NCT02985034|PROCEDURE|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
223967123|NCT04966936|OTHER|questionnaires for clinical assessments|Amputee Mobility Predictor, Locomotor Capacity Index, visual analog scale (VAS)
223542684|NCT06112301|DIAGNOSTIC_TEST|IdentiClone Dx IGH (IC IGH Dx) Assay|The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
223967124|NCT04966936|OTHER|2 minute walking test|the individual is asked to walk in his natural course within 2 minutes on a track whose distance is measured beforehand, and at the end of two minutes, the distance he walks will be recorded in meters (m).
223967125|NCT04966936|OTHER|The gait analysis at the motion analysis laboratory.|Temporo-spatial parameters (gait speed (m/s), cadence (step/s), other foot contact (%), double support time (second), single support time (second), stance phase time (sec), swing phase time (sec), stride length (meters)) and kinematic parameters (hip, knee, ankle joint angles (frontal, sagittal, transverse plane), maximum knee flexion angles in the stance and swing phase, velocity-dependent maximum knee flexion angles in the swing phase, knee flexion moments will be compared
223967126|NCT03749148|DRUG|Dupilumab|anti-IL4-Receptor alpha
223967127|NCT03749148|DRUG|Placebo|Placebo
223967128|NCT03330171|BIOLOGICAL|Measles vaccine|All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
223967129|NCT03330171|BIOLOGICAL|Hepatitis-A vaccine|Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
223967130|NCT03330171|BIOLOGICAL|Varicella vaccine|Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
223967131|NCT02514577|DRUG|IDP-122 Lotion|Topical lotion
223967132|NCT02514577|DRUG|IDP-122 Vehicle Lotion|Topical lotion. No active ingredient.
223967133|NCT01730547|BIOLOGICAL|Autologous mesenchymal stem cells|
223967134|NCT02907450|DEVICE|TwiCare®.|
223967135|NCT00003162|PROCEDURE|pain therapy|
223967136|NCT00003162|RADIATION|radiation therapy|
223967137|NCT06171503|BEHAVIORAL|letter of invitation on MI in PMTCT service|A non randomized control trial for the total of six month duration will be employed: the first phase is base line survey (pretest) to determine the magnitude of MI and qualitative method using FGD, IDI and KI with selected group to complement the base line will be conducted. Phase 2 Simultaneously with base line, the intervention will be employed to evaluate the effectiveness of invitation letter through mother support group to pregnant women attending antenatal clinic with out her partner as a strategy for male involvement in PMTCT/ANC services. End line data using qualitative approaches will be collected from partners attending antenatal care clinic following letter of invitation to evaluate the effectiveness of letter of invitation.
223967138|NCT02552810|DEVICE|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
223967139|NCT02552810|DEVICE|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
223967140|NCT05692271|DRUG|Propranolol|40 mg teva-propranolol taken twice daily for 12 weeks
223542685|NCT01011608|OTHER|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
223542686|NCT01011608|OTHER|standard hospital food|standard hospital diet ad. lib.
223542687|NCT06391268|BEHAVIORAL|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.|Emotional Freedom Technique (EFT) works on cognitive and energetic levels.
223967141|NCT05692271|DRUG|Placebo|Matching placebo
223967142|NCT04816708|BEHAVIORAL|LIFT Mindfulness|Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
223967143|NCT02533349|DRUG|Motilitone|30mg, 1 tablet, 3 times a day
223967144|NCT02533349|DRUG|Pantoprazole|40mg, 1 tablet, 1time a day
223967145|NCT02533349|DRUG|Placebo|30mg, 1 tablet, 3 times a day
223967146|NCT00229086|DEVICE|Gatekeeper Reflux Repari System (Device)|
223967147|NCT05373225|DEVICE|Acetic acid shockwave phonophoresis therapy|This group composed of subjects. They will take 6 sessions with Time between sessions 5-7 days plus exercise and dietary advice
223967148|NCT05373225|DEVICE|Shock wave Therapy|This group composed of subjects and represented the control group who will receive shock wave therapy
223967149|NCT05373225|OTHER|conventional physical therapy program|"Exercise program:~* Standing calf-stretching exercise~* Towel stretch: stretching exercise~* Ice bottle~* Towel pickup exercise~* Marble pickups exercise~* Calf raises exercises -Static and dynamic balance exercise"
223967150|NCT04794894|BEHAVIORAL|outpatient rehabilitation|Treatment provided after completion of inpatient, acute rehabilitation.
223967151|NCT04713176|DRUG|DWJ1248 with Remdesivir|1 tablet of DWJ1248 TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
223967152|NCT04713176|DRUG|Placebo with Remdesivir|1 tablet of placebo TID(up to 14 days) PO, Remdesivir(up to 5 or 10 days) IV
223967153|NCT04174222|OTHER|Moderate NMB|Neuromuscular block was maintained at train of four count 1-2.
223967154|NCT04174222|OTHER|Deep NMB|Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
223967155|NCT04031196|PROCEDURE|QLB|QLB type 2 approach
223967156|NCT04031196|PROCEDURE|TAP block|classic TAP block approach
223967157|NCT00199160|DRUG|BAY 43-9006|
223967158|NCT02267564|PROCEDURE|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
223967159|NCT02267564|PROCEDURE|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
223967160|NCT04919330|BEHAVIORAL|Family Acceptance and Commitment Therapy-based Eczema Management Programme|"The parent-child dyads will receive four weekly 2-hour sessions of family ACT-based eczema management programme (FACT-EMP). In each session, a group of 6-8 parent-child dyads will receive 90 minutes of ACT, followed by 30 minutes of education related to eczema management. Throughout the sessions, ACT strategies will help the dyads achieve the following therapeutic processes: To weaken the rumination cycle and fused thoughts related to eczema with body-image concern, shame and self-criticism for extending kindness and understanding to oneself; to build self-perspective-taking when seeing one's experience as part of the larger human experience; to strengthen their stands for their values related to self-kindness with acceptance of one's experience; and to take steps to act on values while practising kindness and compassion. Same as the waitlist control, the dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation."
223967161|NCT04919330|BEHAVIORAL|Wait-list Control Group|The parent-child dyads will receive routine eczema care provided by the study hospital, including medical follow-ups and nurses' consultation. To ensure equity of access to potentially effective treatment (i.e., family ACT-based eczema management programme), the dyads in the wait-list control group will receive the same programme after the completion of all assessments of the intervention arm.
223967162|NCT00158236|DRUG|Buprenorphine|
223967163|NCT00158236|DRUG|Buprenorphine and Naloxone|
223967164|NCT00158236|DRUG|Hydromorphone|
223967165|NCT00224198|PROCEDURE|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
223967166|NCT04263558|BEHAVIORAL|Emotion child|The MFS will include an idiographic measure of personal aims, symptom burden, displayed on a visual data dashboard to guide further intervention. The EMOTION intervention for children 9 to 12 years with symptoms of anxiety and/or depression will be used in a standard/long version (16 sessions) and a short (8 sessions) but optimized version, using a partial web-based solution with virtual reality (VR)-technology for behavioral experiments and exposure (in short and long version). Parental involvement: Parental participation in a 5-session parent group (high involvement) versus sharing information with parents via a brochure (low Parental involvement).
223967167|NCT03568708|DRUG|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
223967168|NCT00511147|BIOLOGICAL|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
224112612|NCT04771715|DRUG|Camrelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
224112613|NCT04771715|DRUG|Sintilimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
224112614|NCT04771715|DRUG|Toripalimab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
223967169|NCT06003478|PROCEDURE|Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy (Liwen Procedure)|Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
224112615|NCT04771715|DRUG|Tislelizumab|Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
224112616|NCT00581607|DRUG|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
224112617|NCT00581607|DRUG|Placebo|Placebo twice a day
223967170|NCT00292305|PROCEDURE|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
223967171|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 10 mg
223967172|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 5 mg
223967173|NCT00809783|BIOLOGICAL|tanezumab|Tanezumab 2.5 mg
224112618|NCT00581607|DRUG|Bosentan|drug given for 16 weeks
224112619|NCT00581607|DRUG|Placebo|placebo
224112620|NCT05449353|BEHAVIORAL|Trauma-informed Cognitive Behaviour Therapy (TiCBT)|Group: Experimental (n=24 participants) will receive the TiCBT which consists of a total of 8-group integrated sessions lasting approximately 60 minutes per session every 3 days interval with 24 persons in the single group.
224112621|NCT01513915|OTHER|Group cognitive behavioral intervention|A Group cognitive behavioral intervention \_based on parent training component of FRIENDS program\_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
224112622|NCT03891277|DRUG|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
224112623|NCT04368130|BEHAVIORAL|SIGNAL|"SIGNAL is a smartphone-based mobile health intervention designed to improve important outcomes in cancer patient patients (e.g., symptom burden, physical functioning).~Patients will download the adapted Beiwe app for a 6-month period and investigators will collect passive smartphone sensor data and active PRO data bi-weekly."
223967174|NCT00126555|DRUG|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
223542688|NCT06482567|BEHAVIORAL|iCOVER|"The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., I'm right here with you); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior."
223967175|NCT00126555|RADIATION|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
223967176|NCT00126555|PROCEDURE|Conventional surgery|Undergo surgery
223967177|NCT00126555|OTHER|laboratory biomarker analysis|Correlative studies
223967178|NCT04514289|DRUG|Indocyanine green solution|Indocyanine green (ICG) is a cyanine dye used in medical diagnostics.ICG is a fluorescent dye that is used in medicine as an indicator substance.
223967179|NCT03973645|OTHER|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
223967180|NCT05309356|OTHER|ACCEPT Decision Intervention|The intervention consists of the CPM (ACCEPT) that is integrated with a decision aid, together called the ACCEPT Decision Intervention (ADI). The ADI will provide physicians with a quantification of the exacerbation risk for each patient and the corresponding treatment recommendation, as well as information about the benefits and risks of different inhaled therapies to discuss with the patients. The intervention also includes a 1-page take-home pamphlet on evidence-based risk behaviour factor modification for COPD, tailored to the treatment recommendation.
223967181|NCT05309356|OTHER|Comparator|The patient will receive the physician-recommended treatment for COPD (usual care). All physicians will be provided refresher training on the Canadian Thoracic Society COPD guidelines during the phase in period (month 1).
223967182|NCT02133066|PROCEDURE|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
223967183|NCT02133066|DEVICE|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
223967184|NCT02133066|PROCEDURE|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
223967185|NCT06299696|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration
223967186|NCT00462202|DRUG|sulodexide|
223967187|NCT04798508|OTHER|Evoked related potential - P3 paradigm|Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
223967188|NCT05087797|DRUG|nicorandil|Patients in the nicorandil group were also given nicorandil (Tohoku Nipro Pharmaceutical Corporation, Japan) orally 5 mg three times per day for 3 months
223967189|NCT01204593|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
223967190|NCT01204593|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
223967191|NCT02843542|DEVICE|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
223967192|NCT02843542|DEVICE|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
224112624|NCT06972043|OTHER|Intervention Group|The functions performed by the robot include guiding patients through unit-specific locations for environmental orientation and equipment usage instructions, playing educational videos related to care, reminding patients of important examination precautions, providing health education on specimen collection, and delivering responses through an expert-developed medical Q\&A system.
224112625|NCT01804361|DRUG|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
224112626|NCT01804361|DRUG|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
224112627|NCT00945191|DRUG|CS-1008|CS-1008 intravenous (IV) infusion 10 mg/kg on Day 1 of Cycle 1 and 8 mg/kg once every 3 weeks (1 cycle) for Cycle 2-6
224112628|NCT00945191|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
224112629|NCT00945191|DRUG|Carboplatin|Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
224112630|NCT01052285|PROCEDURE|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
223967193|NCT01399684|DRUG|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m\^2) intravenous (IV) bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
223967194|NCT01399684|DRUG|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
223967195|NCT01399684|DRUG|Folinic acid|Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
223967196|NCT01399684|DRUG|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
224112631|NCT01052285|PROCEDURE|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
224112632|NCT01052285|PROCEDURE|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
224112633|NCT05585385|DEVICE|Backward Walking Training|The subjects in this group will receive BW training program on an electric treadmill. The subject will be asked to walk, arms beside, in a backward manner on a level treadmill, zero inclination, with a warming up and cooling down period (5 minutes for each period). The subject walks at his self-selected and comfortable walking speed. A warm-up and cool-down period, in form of light jogging on a treadmill, will be done at speed of 1-2 m/sec. The total training is 30 minutes, three times a week for six consecutive weeks.
224112634|NCT05585385|DEVICE|Balance Training|"Subjects in this group will receive balance training on Biodex Balance System for 3 sessions/ week, over 6 weeks period. Each subject will be instructed to stand with both legs on the locked platform. The researcher advances the platform to an unstable state while instructing the subject to focus on the visual feedback screen. Arms are free at the side of the body and not grasping handrails.~After selecting the stability training program (dynamic balance training), Stability levels are changed depending on the subject's ability to maintain balance, and subjects are instructed to maintain their Center of Pressure (COP) in the smallest concentric rings (balance zones) of the Biodex Balance System monitor, named A zone.~The stability level of the platform is set at level plate stability 8 (the most stable) for the first two sessions. After that, the plate stability is decreased by one level every two sessions to increase the difficulty in training."
224112635|NCT05585385|OTHER|Conventional treatment|Patients in this group will receive the traditional physical therapy program only for 3 sessions/ week, over 6 weeks period. The traditional physical therapy program is (evertors strengthening, short foot ex, heel raise ex, and calf stretch).
223967197|NCT01399684|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
223967198|NCT01399684|DRUG|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
223967199|NCT05804526|DRUG|RC88|1.5mg/kg ，2.0mg/kg ，2.5mg/kg by intravenous (IV) infusion，every 3 weeks
223967200|NCT05804526|DRUG|Sintilimab Injection|Sintilimab 200mg by intravenous (IV) infusion，every 3 weeks
223967201|NCT00647985|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fed
223967202|NCT00647985|DRUG|Allegra® Tablets 180 mg|180mg, single dose fed
223967203|NCT05982028|PROCEDURE|Minimally invasive pit-picking surgery|Midline pits and secondary fistula openings were probed to determine the direction and length of any associated sinus tracts, followed by an excision with a 3 or 5 mm punch biopsy needle, depending on the size of the pit. A 2 cm lateral incision was made parallel to the pilonidal cyst. Hair and granulations within the sinus tracts were removed, and the cyst cavity was drained through the incision. Nonabsorbable monofilament sutures were used to close the excisional wounds of the pits and secondary fistula. Once haemostasis was achieved, the wound was covered with a sterile gauze with 10 % povidone-iodine solution.
224112636|NCT04086134|OTHER|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
224112637|NCT03032887|BEHAVIORAL|voice prompts|voice prompts on disinfectant dispenser
224112638|NCT03032887|BEHAVIORAL|agitation|Education, reminders and optimising materials
224112639|NCT01004107|DEVICE|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
224112640|NCT00221845|DRUG|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
224112641|NCT00221845|DRUG|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
224112642|NCT00221845|DRUG|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
223967204|NCT05982028|PROCEDURE|Radical surgical excision without suturing|Under the guidance of brilliant green, the cavity of the pilonidal cyst, along with the sinus tracts and fistulas, was marked. A symmetric elliptical incision was made to excise the pits and secondary fistula openings. The pilonidal cyst was removed from the healthy subcutaneous tissue and sacrococcygeal fascia using monopolar electrocautery. The wound was not sutured and was left open to heal by secondary intention. After haemostasis was achieved, the wound was covered with sterile gauze with 10 % povidone-iodine solution.
223967205|NCT01949649|BEHAVIORAL|Peer-Led Group Intervention|
223967206|NCT01949649|BEHAVIORAL|Internet-Based Intervention|
223967207|NCT01949649|BEHAVIORAL|Clinician-Led Group Intervention|
223967208|NCT01949649|BEHAVIORAL|Education Video|
223967209|NCT03792035|DRUG|Tongxinluo|tid, po.
223967210|NCT03792035|DRUG|Placebos|tid, po.
223967211|NCT05750017|BIOLOGICAL|Low Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 50 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
223967212|NCT05750017|BIOLOGICAL|High Dose Recombinant Herpes Zoster Vaccine (LZ901)|0.5 mL per dose, containing a total of 100 µg recombinant herpes zoster virus glycoprotein E, adjuvanted with alumina adjuvant.
223967213|NCT05750017|DRUG|Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride.
223967214|NCT04448925|OTHER|inertial-load exercise (ILE)|Length of time between exercise bouts
223967215|NCT00276783|DRUG|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
223967216|NCT02411422|DEVICE|Conventional endotracheal tube|Conventional endotracheal tube
223967217|NCT02411422|DEVICE|Reinforced endotracheal tube|Reinforced endotracheal tube
223967218|NCT03308383|OTHER|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
223967219|NCT03550183|BIOLOGICAL|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
224112643|NCT00394914|DRUG|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
224112644|NCT00394914|DRUG|Placebo to Pleconaril|Placebo nasal suspension
224112645|NCT02379910|DRUG|AM1030-CREAM or placebo|
224112646|NCT05916638|OTHER|blood sample|blood sample collection
224112647|NCT02092415|DEVICE|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
224112648|NCT04706182|PROCEDURE|Platelet-rich fibrin (PRF)|Platelet rich fibrin (PRF) serves as a structural reservoir of cytokines such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-b), insulin-like growth factor (IGF), platelet factor 4 (PF4) and vascular endothelial growth factor (VEGF) which aids in healing and preventing infection. PRF will be prepared as recommended by the manufacturer (Intra-Lock International) by centrifuging 20 mL of the subject's venous blood for 12 minutes at 2700 rpm, followed by compression. The fibrin clot will then be applied to the SSO site prior to fixation. The blood draw for the PRF will be performed approximately 15 minutes prior to fixation of the mandible. 20 mL will be drawn for each PRF side treated. The blood venous draw will be from the subject's arm or from an existing intra-venous line.
224112649|NCT04706182|PROCEDURE|Proximal segment grooving (PSG)|Proximal segment grooving is a mechanical method to create additional space within the inferior alveolar canal to allow the IAN to rest without compression or trauma. The surgeon uses a round or acrylic bur to cautiously remove any bony spicules, and remove cancellous bone in the proximal mandibular segment. PSG will be done by using an acrylic round bur on a surgical handpiece to remove 3 to 4 mm of cancellous bone where the IAN will passively rest into prior to fixation.
224112650|NCT01499238|DEVICE|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
224112651|NCT01499238|DEVICE|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
224112652|NCT04135781|DRUG|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
223967220|NCT04614285|PROCEDURE|Partial excavation|"Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude."
223967221|NCT02584075|DRUG|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
223967222|NCT02584075|DRUG|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
223967223|NCT02449837|OTHER|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up visit to UNC (roughly \~1 month interval), up until 24 months after completion of radiation.
223967224|NCT02186496|DRUG|CKD-330 8/5mg|
223967225|NCT02186496|DRUG|Candesartan 8mg and Amlodipine 5mg|
223967226|NCT01381614|DRUG|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
223967227|NCT01247870|DRUG|Metformin|Metformin 1 g twice daily for 28-35 days
223967228|NCT01247870|DRUG|Placebo|Placebo
223967229|NCT04520685|DRUG|Oral cannabidiol 100mg/mL|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
223967230|NCT04520685|DRUG|Placebo|In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
223967231|NCT01256372|DRUG|AP214|AP214
223967232|NCT01256372|DRUG|Placebo|Placebo; intravenous infusion
223967233|NCT04440514|PROCEDURE|endoscopic preperitoneal repair of parastomal hernia|repair of parastomal hernia after the Sugarbaker principle with TAR and preperitoneal mesh reinforcement
224112653|NCT04135781|DRUG|Tegafur|S-1 （\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
224112654|NCT04135781|DRUG|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
224112655|NCT04135781|DRUG|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
224112656|NCT04337138|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination
223967234|NCT03344913|BEHAVIORAL|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
223967235|NCT04148716|PROCEDURE|additional biopsies|additional biopsies during a fibroscopy planned in the care
224112657|NCT06039254|DRUG|HRS-1780|Single dose in each arm
224112658|NCT02909166|DRUG|aliskiren|
224112659|NCT00879268|DEVICE|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
224112660|NCT00387660|DRUG|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
224112661|NCT00387660|DRUG|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
224112662|NCT01786616|DRUG|Formoterol|
224112663|NCT05323552|PROCEDURE|Laparoscopic TEP hernia repair without curare and without orotracheal intubation.|"All the techniques and protocols used for this monocentric study are standardized:~* The anesthesia is general, the anesthetic products administered are identical,~* ventilation is ensured by the use of a laryngeal mask airway, without curare administered~* the surgery is an extraperitoneal laparoscopy with an optical trocar under the umbilical and two operators with the placement of a preformed type 3G polypropylene prosthesis~* the analgesic protocol is free of opioids (Opioid Free Anesthesia - OFA)"
223967236|NCT03284489|OTHER|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
223967237|NCT01372826|DRUG|NKTR118 Group1|Oral dose, 25 mg
223967238|NCT01372826|DRUG|NKTR118 Group 2|Oral dose, 25 mg
223967239|NCT01372826|DRUG|NKTR118 Group3|Oral dose, 25 mg
223967240|NCT01372826|DRUG|NKTR118|Oral dose, 25 mg
223967241|NCT05814679|OTHER|Relaxation with virtual reality|In this research, a virtual reality relaxation video will be used in which the natural wonders are presented to the audience in an immersive environment.
223967242|NCT05814679|OTHER|Attention match|kidney function instruction
223967243|NCT00168714|DRUG|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
223967244|NCT00543634|DRUG|Premarin/MPA|0.625 mg/2.5 mg X4
223967245|NCT00543634|DRUG|Premarin/MPA|0.625 mg/5 mg X 2
223967246|NCT00543634|DRUG|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
223967247|NCT02445183|OTHER|None, N/A|
223967248|NCT01498523|OTHER|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
223967249|NCT01498523|OTHER|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
223967250|NCT01498523|OTHER|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
223967251|NCT01498523|OTHER|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
223967252|NCT02423252|BEHAVIORAL|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
223967253|NCT02423252|OTHER|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
223967254|NCT00926952|DRUG|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
223967255|NCT00926952|DEVICE|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
223967256|NCT01250847|DRUG|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
223967257|NCT03824353|BEHAVIORAL|Social Intelligence Training|The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
223967258|NCT03824353|BEHAVIORAL|The Healthy Living Program|A placebo condition delivered online which presents health-related information only.
224112664|NCT03689725|OTHER|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
224112665|NCT06657534|PROCEDURE|Push-pull technique|push-pull technique as described by McBride et al, J Infus Nurs 2018
224112666|NCT06657534|PROCEDURE|SOC (Standard of care)|Standard of care method to obtain blood with waste blood
223967259|NCT02574897|OTHER|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
223967260|NCT02574897|OTHER|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
223967261|NCT03669900|PROCEDURE|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
223967262|NCT04433949|OTHER|Best Practice|Receive standard of care
223967263|NCT04433949|RADIATION|Low Dose Radiation Therapy|Undergo LDRT
223967264|NCT03009877|DEVICE|Optiflow F&P 850™ System|"Optiflow™ (Fisher \& Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
223967265|NCT03009877|DEVICE|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
223967266|NCT03009877|DRUG|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
223967267|NCT03009877|DRUG|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
223967268|NCT03009877|DRUG|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
223967269|NCT03009877|DRUG|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
223967270|NCT03009877|DEVICE|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
223967271|NCT02107729|PROCEDURE|Large needle gauge lidocaine injection|21 G
223967272|NCT02107729|PROCEDURE|Normal needle gauge lidocaine injection|23 G
223967273|NCT02107729|PROCEDURE|Small needle gauge lidocaine injection|27 G
223967274|NCT02931240|DEVICE|Revivent TC|Treatment of LV scar
223967275|NCT02915354|DRUG|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
223967276|NCT01939405|BEHAVIORAL|built environment use counseling|
223967277|NCT01960985|OTHER|Physicaltherapy|
223967278|NCT00614536|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
223967279|NCT01956071|DEVICE|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
223967280|NCT03326050|DRUG|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
223967281|NCT03326050|DRUG|Ciprofloxacin|cipro 750 tablet twice daily
223967282|NCT03326050|DRUG|Rifampicin|Rifampicin 150Mg Capsule twice daily
223967283|NCT02617433|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
223967284|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
223967285|NCT00396097|DRUG|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
223967286|NCT01995318|OTHER|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
223967287|NCT00981929|DRUG|Tramadol|50 mg single oral dose
223967288|NCT00981929|DRUG|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
223967289|NCT00981929|DRUG|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
223967290|NCT02571283|DRUG|Cocktail|Administered as a single dose injection.
223967291|NCT02571283|DRUG|Exparel|Administered 20 minutes+ before additional medications.
223967292|NCT02571283|DRUG|Marcaine|Administered 20 minutes or more after Exparel is administered.
223967293|NCT01089387|BIOLOGICAL|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
223967294|NCT03187041|OTHER|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
223967295|NCT01470664|DRUG|FST-100|0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)
223967296|NCT01470664|DRUG|FST-100 (Component #1)|0.6% PVP-Iodine ophthalmic solution alone
223967297|NCT01470664|DRUG|FST-100 Vehicle|FST-100 Vehicle
223967298|NCT06395961|PROCEDURE|high ankle block|"The block position is in the middle and lower third of the calf, about 15cm above the inner or outer ankles. 0.375% ropivacaine is used for the block and the total dose is 35ml. The ultrasound probe is placed vertical to the longitudinal axis of the body. On the lateral of tibia and fibula, 5ml of local anesthetic was injected to block the superficial peroneal nerve and 10ml for the deep peroneal nerve. On the posterior of the calf, 10ml of local anesthetic was injected to block the tibial nerve and 5ml for the sural nerve. On the inner side of the calf, 5ml of local anesthetic was injected to block the saphenous nerve. The water separation technique is used and 2ml of physiological saline is injected before blocking to clarify the position of the needle tip and avoid nerve damage. 20 minutes after, the effect was measured using acupuncture by visual analogue scale (VAS) score. If the VAS score is less than 3, the block is considered successful and surgery is immediately performed."
223967299|NCT06395961|PROCEDURE|general anesthesia|intravenous injection of midazolam 0.03-0.05 mg/kg, etomidate 0.15-0.20 mg/kg, cisatracurium 0.15-0.20 mg/kg, and sufentanil 0.3-0.5 μg/kg. Intraoperative anesthesia maintenance using intravenous infusion of remifentanil 0.1-0.3 μg/kg·min, propofol 4-6 mg/kg·h, maintain bispectral index (BIS) value of 40-60, maintain intraoperative blood pressure and heart rate fluctuations within ± 20% of the baseline value, intermittently inject cisatracurium intravenously as needed. After the surgery, the patient was transferred to post-anaesthesia care unit (PACU). After regaining consciousness and regaining autonomous breathing, the tracheal catheter was removed and transferred to the ward when the indications for transfer were met.
223967300|NCT03703349|DRUG|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
223967301|NCT03703349|DRUG|Placebo Oral Tablet|Placebo for Magnesium
223967302|NCT01732588|DRUG|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
223967303|NCT01732588|DRUG|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
223967304|NCT01732588|DRUG|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
223967305|NCT04875598|PROCEDURE|Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block|Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.
223967306|NCT02945007|DRUG|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
223967307|NCT05470881|DRUG|Atropine Sulfate|Administration of one drop QD on both eyes for 14 days.
223967308|NCT05287698|OTHER|Cold vapor|Before surgery, socio-demographic data of the patients, ASA and Mallampati scores, sore throat level, and dysphagia level will be recorded. After surgery, patients will be evaluated in the recovery room for their suitability to participate in the study with the Ramsay sedation scale and the Modified Aldrete Scale. Cold vapor will be applied to the patients for 15 minutes in the recovery room during the postoperative period. The parameters to be set on the device for the cold vapor to be applied to the patients in the early postoperative period will be vapor intensity level 5, air blowing intensity 5, heater intensity 1 (+10C), and timer 15 minutes. The patients will be evaluated by the researchers in terms of sore throat and dysphagia before and 15 minutes after the cold vapor application in the recovery room and at the 6th, 12th, and 24th hours after the cold vapor application in the postoperative service.
223967309|NCT05171465|DEVICE|Neqstent or Contour|All patients included will be treated the same: after catheterizing the affected vessel and microcatheterizing the aneurysm with a microcatheter of 0.021'' or 0.027'', the intrasaccular device (Neqstent® or Contour®) will be positioned. Depending of the operator preference, the use of an intrasaccular device could be associated with coiling (mandatory in the case of Neqstent®). Treatment must be performed without previous double antiplatelet treatment (allowing antiplatelet after aneurysm exclusion). Before the treatment all patients should undergo a flat panel CT.
223967310|NCT01315197|OTHER|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
223967311|NCT05585671|DRUG|Belimumab|Lupus patients without previous involvement of kidney are enrolled, and receive 2-year of 10mg/kg belimumab intravenously on the background of standard of care (SOC). During follow-up, we observe whether these patients will develop new-onset lupus nephritis.
223967312|NCT02164136|PROCEDURE|L-PANP-TME|
223967313|NCT02164136|PROCEDURE|O-PANP-TME|
224112667|NCT04914637|PROCEDURE|Cervical interlaminar epidural steroid injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 cc 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the rest room after the procedure and followed up for any complications.
224112668|NCT04914637|PROCEDURE|Dry needling|Dry needling will be applied to the active trigger points for the patients in this group. After cleaning the area of interest with an antiseptic solution, dry needling will be applied with the fast-in/fast-out technique for the active trigger point. During needle maneuvers, local contractions (local twitch response-LTR) are obtained and rapid needle movements are continued until the contractions end. Afterwards, the needle is removed and compression is applied to ensure hemostasis in the relevant area.
223724787|NCT05952011|PROCEDURE|Left stellate ganglion block|patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
223724788|NCT05952011|DRUG|Topical Nitroglycerine|Application of topical Nitroglycerin solution to the LIMA pedicle graft during dissection of the vessel in both study arms.
223724789|NCT06013670|PROCEDURE|Endoscopy+NSBBs|Endoscopic treatment+NSBBs group: After admission, carvedilol 6.25mg qd p.o. was administered to lower portal vein pressure. After one week without any adverse reactions, add the dosage to 12.5mg qd, maintained for a long time, with close monitoring of blood pressure and pulse (morning and evening monitoring) during dosing and later use, to maintain systolic blood pressure\>90mmHg and heart rate\>55bpm. Otherwise, dosage reduction or even discontinuation of medication is necessary. Endoscopic treatment adopts sequential treatment, with an interval of four weeks, until the varicose vein becomes mild or disappears.
223724790|NCT06013670|PROCEDURE|Transjugular intrahepatic portosystemic shunt|TIPS group: All TIPS procedures are completed by a professional liver disease intervention treatment team.
223967314|NCT06225986|BEHAVIORAL|LMH-4-DCP|Reminiscence-based intervention for family caregiver-Persons with Dementia (PwD) dyads to record and reflect on meaningful memories to address family caregivers' pre-loss grief and enhance relationship quality.
223967315|NCT06225986|BEHAVIORAL|LMH-4-DCP access without reminiscence activities|Participants in the attention control condition will have access to a version of LMH-4-DCP excluding reminiscence-specific activities.
223967316|NCT00634426|PROCEDURE|Surgical excision of the metastatic process|Surgical excision of the metastatic process
223967317|NCT00634426|RADIATION|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
223967318|NCT00645320|DRUG|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
223967319|NCT00319878|DRUG|Sirolimus|"Oral loading dose followed by a once daily dose:~* Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~* Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~* Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~* Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
223967320|NCT00319878|DRUG|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
223967321|NCT06516562|DRUG|Optimal treatment|Optimal treatment using current National Guidelines for the diagnosis and treatment of chronic heart failure
223967322|NCT02912104|BIOLOGICAL|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.
223967323|NCT04196517|OTHER|Educational Tool, PALS|The Patient Activated Learning System is a free, health education platform.
223967324|NCT04196517|OTHER|WebMD|WebMD is a widely used educational platform for health information.
223967325|NCT03199456|DEVICE|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
223724791|NCT00313378|DRUG|Hypothetica|
223967326|NCT03199456|DEVICE|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
223967327|NCT00113009|DRUG|VLTS-934|
223967328|NCT00605384|DRUG|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
223967329|NCT00605384|DRUG|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
224112669|NCT04914637|PROCEDURE|Sham dry needling|Although the method of intervention is like dry needling, the only difference is that the blunt end of the needle is used and it does not penetrate the skin.
224112670|NCT04855721|DRUG|AUR101|Oral ROR-gamma inverse agonist
224112671|NCT04855721|DRUG|Placebo|Placebo
224291405|NCT04127955|OTHER|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
223967330|NCT04676672|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
223967331|NCT03599440|OTHER|Pressure line extensions|"Two types of extension lines are connected:~* Perfusor® line 150cm (polyethylene)~* conventional arterial extension line"
223967332|NCT00730925|DRUG|BIBW2992|tablet BIBW high dose
223967333|NCT00730925|DRUG|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
223967334|NCT01827800|BEHAVIORAL|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
223967335|NCT01955720|DRUG|BI 655075|
223967336|NCT01955720|DRUG|BI 655075|
223967337|NCT01955720|DRUG|Placebo|
223967338|NCT01955720|DRUG|BI 655075|
223967339|NCT01955720|DRUG|Placebo|
223967340|NCT01955720|DRUG|Placebo|
223967341|NCT01955720|DRUG|Placebo|
223967342|NCT01955720|DRUG|BI 655075|
223967343|NCT02231814|DIETARY_SUPPLEMENT|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
223967344|NCT02231814|OTHER|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
224112672|NCT04444700|DRUG|Therapeutic anticoagulation|The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
224112673|NCT00312377|DRUG|Docetaxel|infusion
224112674|NCT00312377|DRUG|Vandetanib|oral
224112675|NCT05064345|DRUG|HB0034|Recombinant Humanized Anti-IL-36R Monoclonal antibody
224112676|NCT05064345|DRUG|Placebo|Palcebo
224112677|NCT03151525|DRUG|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
224112678|NCT03151525|DRUG|Infliximab|IFX treatment for maintenance of remission
224291406|NCT04798235|BIOLOGICAL|TSHA-101|AAV9 viral vector containing HEXA and HEXB genes to be administered via Intrathecal injection
224112679|NCT00389077|DRUG|Perifosine|Perifosine 50 mg tablets
224112680|NCT00872898|DRUG|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
223967345|NCT05281419|OTHER|Intralesional triamcinolone injection|Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week
223967346|NCT05281419|OTHER|No intralesional triamcinolone injection|No intralesional triamcinolone injection
223967347|NCT05071378|BEHAVIORAL|Our Family, Our Voices|Many Men, Many Voices (3MV) is a seven-session, group-level intervention developed to prevent HIV and sexually transmitted diseases (STDs) among black men who have sex with men (MSM) who may or may not identify themselves as gay. The intervention addresses factors that influence the behavior of black MSM: cultural, social, and religious norms; interactions between HIV and other STDs; sexual relationship dynamics; and the social influences that racism and homophobia have on HIV risk behaviors. Our Family, Our Voices seeks to create an adaptation of Many Men, Many Voices specifically tailored to young people who are members of the house ball community by incorporating elements of family support and resilience afforded to participants in the intervention.
223967348|NCT01386411|GENETIC|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
223967349|NCT01249378|OTHER|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
223967350|NCT00191984|DRUG|pemetrexed|400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
223967351|NCT00191984|DRUG|irinotecan|180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles
223967352|NCT03005483|DRUG|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
223967353|NCT03005483|OTHER|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
224112681|NCT00872898|DRUG|Placebo|Placebo capsules, once daily, oral administration.
223967354|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
223967355|NCT01732627|BIOLOGICAL|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous (SC)
223967356|NCT01942538|DEVICE|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
223967357|NCT01942538|DEVICE|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
223967358|NCT05128227|BEHAVIORAL|Pharm-SAVES|A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
224112682|NCT03709433|BEHAVIORAL|ACT groups and mobile app|See arm description.
224112683|NCT01258829|OTHER|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
224112684|NCT01258829|OTHER|ECHO optimisation|Standard ECHO optimisation method
224112685|NCT05661565|OTHER|No intervention|We try to find an association between insulin resistance with ovarian hormonal and morphological characteristics in patients with polycystic ovarian syndrome
224112686|NCT00447213|DRUG|Insulin glargine|Patient specific, injected, daily, 24 weeks
224112687|NCT00447213|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
224112688|NCT00447213|DRUG|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
223967359|NCT05128227|BEHAVIORAL|Interactive video cases|Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
223967360|NCT02467049|DEVICE|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
223967361|NCT02467049|DEVICE|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
223967362|NCT02592044|PROCEDURE|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
223967363|NCT02592044|PROCEDURE|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
223967364|NCT02592044|PROCEDURE|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
223967365|NCT04872842|OTHER|Obervation|This study is an observational study without any intervention
223967366|NCT04086576|DEVICE|Alcohoot|Alcohoot branded smartphone-paired breathalyzer
223967367|NCT04086576|DEVICE|BACtrack Mobile Pro|BACtrack Mobile Pro branded smartphone-paired breathalyzer
223967368|NCT04086576|DEVICE|DRIVESAFE Evoc|DRIVESAFE Evoc branded smartphone-paired breathalyzer
223967369|NCT04086576|DEVICE|BACtrack Vio|BACtrack Vio branded smartphone-paired breathalyzer
223967370|NCT04086576|DEVICE|Drinkmate|Drinkmate branded smartphone-paired breathalyzer
223967371|NCT04086576|DEVICE|Floome|Floome branded smartphone-paired breathalyzer
223967372|NCT04086576|DEVICE|Intoxilyzer 240|Intoxilyzer 240 police grade breathalyzer
223967373|NCT00005908|DRUG|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
223967374|NCT00005908|DRUG|Anastrozole|1 mg orally daily for five years
224112689|NCT04095910|BEHAVIORAL|Planet Nutrition program|"1. \- Nutritional education sessions: The study team previously worked on the development of a handbook called Planet Nutrition which contains around 26 topics of nutrition and health. Interns from the Nutritional Sciences Degree of the University of Sonora implemented the sessions. 2 classes of 1 hour were given weekly, adding 18 sessions in total, during regular school hours. The program contemplates the establishment of different objectives.~2. \- Physical activity: The classes were designed and implemented by interns from the Bachelor of Physical Culture and Sport from the University of Sonora along with a teacher from the study team. 3 weekly sessions of 1 hour were provided. The activities were held on the schoolyard court during normal school hours, independent of the physical activity classes of the school.~3. \- Indirect family participation: Six information brochures with different nutrition and health topics were sent to parents."
224112690|NCT04792138|DIAGNOSTIC_TEST|VERDICT MRI|Advanced Diffusion Model
223542689|NCT06482567|BEHAVIORAL|Physical Presence with Reassurance|The RA who performed randomization, initially approached the individual, and obtained assent will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
223542690|NCT06060210|DRUG|normal Saline|50-ml Saline
223542691|NCT06060210|DRUG|Ketamine|50-ml volumes, and the ketamine concentration is 1 mg/ml
223542692|NCT06646952|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET/ CT scan.
223967375|NCT00005908|DRUG|cyclophosphamide|600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
223967376|NCT00005908|DRUG|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
223967377|NCT00005908|DRUG|Doxorubicin hydrochloride|60 mg/m\^2 will be administered as a slow intravenous push on day 1
223967378|NCT00005908|DRUG|Tamoxifen Citrate|20 mg/day orally for five years
223967379|NCT00005908|DRUG|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
223967380|NCT00005908|DRUG|Capecitabine - Dose A|capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
223967381|NCT00475787|PROCEDURE|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
223967382|NCT00475787|PROCEDURE|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
223967383|NCT05983328|DRUG|HUYPS-1 one tablet|After 7-day washout time, subjects will receive HUYPS-1 1 tablet.
223967384|NCT05983328|DRUG|HUYPS-1 nine tablets|After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
223967385|NCT04736602|DRUG|Triptorelin pamoate 15mg|Intramuscular injection (IM)
223967386|NCT00578929|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
223967387|NCT00578929|DRUG|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
223967388|NCT03253783|BEHAVIORAL|Pulse|
223967389|NCT01651416|DRUG|Artemether-lumefantrine combination|
223967390|NCT01651416|DRUG|Dihydroartemisinin Piperaquine combination|
223967391|NCT01651416|DRUG|Amodiaquine plus sulphadoxine-pyrimethamine combination|
223967392|NCT04299971|DRUG|Methotrexate Tablets|"The methotrexate group is prescribed with methotrexate Tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of methotrexate is maintained for another 24 weeks, otherwise (resistant), patients would be given tofacitinib (5.0mg.bid.p.o.) for 24 weeks instead."
223967393|NCT04299971|DRUG|Tofacitinib tablet|"The tofacitinib group is prescribed with tofacitinib tablets for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated, then the usage of tofacitinib is maintained for another 24 weeks, otherwise (resistant), patients would be given methotrexate (15.0mg.qw.p.o.) for 24 weeks instead."
223967394|NCT05063292|PROCEDURE|Patients in Group II will receive active prewarming with an air forced blanket (full body blanket) 30 minutes prior to the operation|Core temperature and 4-points skin temperatures measurements will be recorded all over the operation. Patients will be delivered 2 Litre/minute oxygen with a nasal cannula.Iv hydration will be continued by room temperatured balanced electrolyte solution with an infusion rate of 2mL/kg/hr. Spinal anesthesia will be applied at the level of L3-L4 by a 25 Gauge Quincke needle with a dose of 12.5-15 mg hyperbaric bupivacaine in the sitting position.
223967395|NCT00072826|DRUG|Oxypurinol|
223967396|NCT00072826|DRUG|L-NMMA|
223967397|NCT00072826|DRUG|Acetylcholine|
223967398|NCT02690025|DRUG|ZP1848|
223967399|NCT00317135|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
223967400|NCT00317135|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
223967401|NCT05987839|PROCEDURE|robotic system|Total knee arthroplasty assisted by knee navigation and positioning system
223967402|NCT02884336|OTHER|No intervention|
223967403|NCT01468025|DRUG|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
223967404|NCT01468025|OTHER|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
223967405|NCT01468025|DRUG|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
223967406|NCT00765921|DRUG|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
223967407|NCT03223714|DRUG|Conbercept Ophthalmic Injection|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
223967408|NCT03223714|DRUG|sham injection|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 \~ 11)."
223967409|NCT00957671|DRUG|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
224112691|NCT04792138|DIAGNOSTIC_TEST|Luminal Index Imaging|Advanced T2 mapping
224112692|NCT03578354|DRUG|4-aminopyridine|an oral drug to be swallowed
223542693|NCT04326790|DRUG|Colchicine|Low-dose colchicine treatment, 0.5 mg bid
223542694|NCT04326790|DRUG|Standard treatment|Standard treatment
223967410|NCT05107999|DRUG|Zhizhu Kuanzhong capsules (ZZKZ)|FD patients were treated with ZZKZ and omeprazole for 4 weeks.
223967411|NCT05107999|DRUG|Doxepin Hydrochloride (Doxepin)|FD patients were treated with doxepin and omeprazole for 4 weeks.
224112693|NCT03578354|DRUG|Atenolol|an oral drug to be swallowed
224112694|NCT03578354|OTHER|Placebo|a masked placebo to be swallowed
224112695|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
224112696|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
224112697|NCT01343719|DRUG|BI 661051|medium dose solution for oral administration
223542695|NCT00156325|DRUG|Escitalopram (Lexapro)|
223542696|NCT01218269|DEVICE|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
223542697|NCT03787329|OTHER|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
223542698|NCT03787329|OTHER|Core decompression surgery|Core decompression surgery only
224112698|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
224112699|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
224112700|NCT01343719|DRUG|BI 661051|low dose solution for oral administration
224112701|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
224112702|NCT01343719|DRUG|BI 661051|high dose solution for oral administration
224112703|NCT01343719|DRUG|BI 661051|low dose tablet
224112704|NCT01343719|DRUG|Placebo|solution for administration
224112705|NCT01343719|DRUG|BI 661051|medium dose tablet
224112706|NCT02868502|DEVICE|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
224112707|NCT02868502|DEVICE|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
224112708|NCT02868502|DEVICE|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
224112709|NCT02868502|DEVICE|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
224112710|NCT01583192|PROCEDURE|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
224112711|NCT03760380|DEVICE|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
224112712|NCT03760380|DEVICE|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
223967412|NCT06477887|BIOLOGICAL|Allogeneic Dentin Matrix|"Steps of Allogenic Dentin Processing:~Wash with distilled water for 30-120 minutes. Ultrasonic Cleaning Cycles: 1st with distilled water for 5-10 minutes, 2nd with 5-7% hydrogen peroxide for 10-30 minutes, then the 3rd with distilled water for 5-10 minutes at 60-80.~Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours. Demineralization with 0.5N HCL for 10-60 min. Dehydration with Neutral Ethyl Alcohol for 30 minutes, then Defatting with Chloroform Methanol Solution 1:0.5 for 3-12 hours.~Wash with normal saline and freeze dry, then sterilise using ethylene oxide gas.~The extracted socket will be filled with allogenic dentin"
223967413|NCT06477887|BIOLOGICAL|Autogenous Partially Demineralized Dentine Matrix|"The extracted tooth will be cleaned with a diamond bur under abundant irrigation with physiological water. All filling materials (gutta-percha, composite, luting cements, etc.) will be removed with the outmost care and under magnification.~Subsequently, the tooth will be cut into fragments (5 × 5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). According to the manufacturer, a disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.~After 25 minutes, particle graft biomaterials will be obtained. The particle size will range from 815 µm with peaks up to 1110 µm.~The socket will be filled with the graft."
223967414|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
223967415|NCT02160834|BEHAVIORAL|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
223967416|NCT04973332|DEVICE|Intracranial thrombectomy stent|Intracranial thrombectomy stents for ischemic stroke patients within 24 hours of symptom onset
223967417|NCT00530049|OTHER|questionnaire administration|
223967418|NCT00530049|PROCEDURE|assessment of therapy complications|
223967419|NCT00530049|PROCEDURE|psychosocial assessment and care|
223967420|NCT00530049|PROCEDURE|quality-of-life assessment|
223967421|NCT03732950|BIOLOGICAL|Pembrolizumab|Given IV
223967422|NCT00666991|DRUG|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
223967423|NCT02131155|DRUG|Placebo|Once daily
223967424|NCT02131155|DRUG|Afatinib|Once daily
223967425|NCT01887418|DRUG|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
223967426|NCT01887418|DRUG|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
223967427|NCT01887418|DRUG|Delatestryl 200 mg IM Treatment C|Standard of care
223967428|NCT02238691|PROCEDURE|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
223967429|NCT04787718|OTHER|Almond|2.0 oz of raw, shelled, unsalted almonds
223967430|NCT04787718|OTHER|Control group|an isocaloric amount of unsalted pretzels
223967431|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
223967432|NCT01248078|DRUG|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
223967433|NCT01248078|DRUG|saline solution|100cc administered before skin incision
223967434|NCT02584218|PROCEDURE|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
223967435|NCT02584218|PROCEDURE|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
223967436|NCT00475735|DRUG|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
223967437|NCT00475735|DRUG|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
223967438|NCT00475735|DRUG|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
223967439|NCT03132753|BEHAVIORAL|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
223967440|NCT00125853|DRUG|Nebivolol|Nebivolol 2.5mg daily
223967441|NCT00125853|DRUG|Atenolol|Atenolol 25mg daily
223967442|NCT03255785|DEVICE|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
223967443|NCT00369239|DRUG|risperidone long acting injectable|
223967444|NCT01614899|DRUG|SM-13496 40mg|once daily orally
223967445|NCT01614899|DRUG|SM-13496 80mg|once daily orally
224112713|NCT03760380|DEVICE|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
224112714|NCT03760380|DEVICE|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
224112715|NCT01004146|PROCEDURE|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
223967446|NCT01614899|DRUG|Placebo|once daily orally
223967447|NCT03437902|DIETARY_SUPPLEMENT|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.\& CHEM. IND. Company
223967448|NCT03437902|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
223967449|NCT01000415|OTHER|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
223967450|NCT02521428|OTHER|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
223967451|NCT02350127|BEHAVIORAL|Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative group movement program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely between sitting and standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
224112716|NCT00044044|DRUG|Lurasidone 20 mg|Lurasidone 20mg/day tablets
224112717|NCT00044044|DRUG|Lurasidone 40mg|Lurasidone 40mg/day tablets
224112718|NCT00044044|DRUG|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
224112719|NCT00044044|DRUG|Haloperidol 10mg|Haloperidol 10mg/day tablets
224112720|NCT00044044|DRUG|Placebo|Matching Placebo to Lurasdione and Haloperidol
224112721|NCT01269034|DRUG|Exenatide|1.25 mcg before the boost sub-cutaneously.
223967452|NCT02350127|BEHAVIORAL|Usual Care|Usual care activities will vary between participants. Some will be attending the adult day center and may be engaging in structured physical, mental and/or social activities. Other participants will be living in the community and may engage in physical, mental, and/or social activities on their own or with a caregiver.
223967453|NCT02097056|DRUG|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
223967454|NCT02525497|DEVICE|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
223967455|NCT02525497|DEVICE|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
223967456|NCT01050699|DRUG|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
224112722|NCT01269034|DRUG|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
224112723|NCT01269034|DRUG|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
223967457|NCT01050699|DRUG|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
223967458|NCT00719056|DRUG|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
223967459|NCT00719056|DRUG|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
223967460|NCT01829685|DRUG|Entecavir, Adefovir|
223967461|NCT02732899|DRUG|Sirolimus|
223967462|NCT02732899|DRUG|EYLEA|
223967463|NCT01953406|DRUG|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
223967464|NCT01953406|DRUG|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
223967465|NCT03264599|DEVICE|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
223967466|NCT02233504|DRUG|Exjade® (deferasirox, ICL670)|
223967467|NCT03856645|DRUG|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
223967468|NCT04488809|OTHER|Exercise|Exercise sessions will include 10 minutes of warming up, 30 minutes of loading, and 10 minutes of cooling down. The exercises will be performed two times in a week for eight weeks.
223967469|NCT06270849|OTHER|Questionnaire|The questionnaire to assess severity of LUTS in women.
223967470|NCT00472056|DRUG|Carmustine|300 mg/m\^2 IV for 1 Day
223967471|NCT00472056|DRUG|Etoposide|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
223967472|NCT00472056|DRUG|Cytarabine|Arm 1 = 200 mg/m\^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m\^2 IV Every 12 Hours x 4 Days
223967473|NCT00472056|DRUG|Melphalan|140 mg/m\^2 IV x 1 Day
223967474|NCT00472056|DRUG|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m\^2 IV On Days +1 and +8 After Stem Cell Infusion.
223967475|NCT01421797|DRUG|Dexamethasone|1 mg PO
223967476|NCT01421797|DRUG|Cortrosyn|single IV bolus of 0.25 mg will be administered
223967477|NCT01110551|DRUG|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
223967478|NCT01110551|DRUG|Placebo (ID)|Phosphate buffered saline administered intradermally.
223967479|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
223967480|NCT01110551|BIOLOGICAL|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
224112724|NCT06656247|OTHER|Online consenting|The design and establishment of an innovative digital tool (a software application) to implement the dynamic consent and allowing interaction among healthcare professionals and patients
223967481|NCT01309555|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
223967482|NCT02359552|DRUG|Rasagiline|
223967483|NCT02359552|DRUG|Placebo|
223967484|NCT01209936|DEVICE|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
224112725|NCT00148590|DRUG|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
224112726|NCT00148590|DRUG|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
224112727|NCT06664515|PROCEDURE|Ciro Costagliola|invert flap tecnique
223542699|NCT01333436|OTHER|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
223967485|NCT03363542|DIETARY_SUPPLEMENT|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
223967486|NCT02218671|DRUG|WE 941 OD tablets|
223967487|NCT01591655|DRUG|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
223967488|NCT01591655|DRUG|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
223967489|NCT01109602|OTHER|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
223967490|NCT02572999|PROCEDURE|Not applicable (observational design)|
223967491|NCT01567670|DRUG|Naloxone|2 mg x 1-2
223967492|NCT01567670|DRUG|naloxone placebo|h2o placebo spray
223967493|NCT01258296|DRUG|Fentanyl|25 mcg/hr transdermal patch
223967494|NCT01258296|DRUG|Inactive patch|placebo patch (no drug)
223967495|NCT04238299|DIAGNOSTIC_TEST|Multiparametric renal MRI|Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping
223967496|NCT00748358|DRUG|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
223967497|NCT02511808|BEHAVIORAL|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
223967498|NCT02511808|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
223967499|NCT02511808|BEHAVIORAL|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
223967500|NCT03331848|DRUG|Placebo oral capsule|BID
223967501|NCT03331848|DRUG|PXT002331 - 20mg|Oral
223967502|NCT00161902|DRUG|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
223967503|NCT03630458|OTHER|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
224112728|NCT04286867|OTHER|Alcohol Moderation Mobile Application|This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
224112729|NCT04286867|BEHAVIORAL|Alcohol Moderation Drink Tracker|This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
223967504|NCT03630458|OTHER|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
223967505|NCT03630458|OTHER|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
223967506|NCT03630458|OTHER|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
223967507|NCT03630458|OTHER|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
223967508|NCT03126721|DRUG|midazolam|a single oral dose of 2 mg midazolam
223967509|NCT03126721|DRUG|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
223967510|NCT00092209|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium|
223967511|NCT00092209|DRUG|Comparator: placebo, losartan, hydrochlorothiazide|
223967512|NCT05451056|DRUG|sotorasib|Sotorasib will be given 960mg daily PO until disease progression or unacceptable toxicity.
223967513|NCT06276751|PROCEDURE|End-tidal CO2 monitor|Throughout the study, measurements were taken at 2 and 4 hours after tube thoracostomy was applied to every patient undergoing the procedure.
223967514|NCT03672071|OTHER|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
223967515|NCT04773054|DIAGNOSTIC_TEST|Microbiological analysis of periprosthetic tissue|Microbiological culture of tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
223967516|NCT04773054|DIAGNOSTIC_TEST|Histological analysis of periprosthetic tissue|Histological assessment of cellular reactivity associated with the infection on tissue samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone.
223967517|NCT04773054|OTHER|Characterization of tissue microbiota|"Assessment of tissue microbiome composition using the next-generation sequencing of DNA extracted from samples collected intraoperatively from the newly-formed joint capsule, between prosthesis stem and femoral bone, and between the acetabular prosthesis and iliac bone."
223967518|NCT04773054|OTHER|Characterization of gut microbiota|"Assessment of gut microbiome composition using the next-generation sequencing of DNA extracted from stool samples."
223967519|NCT04773054|OTHER|Characterization of oral microbiota|"Assessment of oral microbiome composition using the next-generation sequencing of DNA extracted from a buccal swab obtained by rubbing the mucosa of cheeks, gingivae, and palate."
223967520|NCT06263296|BEHAVIORAL|Self Management Education|Smartphone assisted self management education incorporated with the concept of motivational interviewing
223967521|NCT01395914|DRUG|Anamorelin HCl|
223967522|NCT01395914|DRUG|Placebo|
223967523|NCT02605772|DRUG|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
223967524|NCT02605772|DRUG|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
223967525|NCT02605772|DRUG|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
223967526|NCT00400257|BEHAVIORAL|Early detection of heart failure|Early detection of heart failure
223967527|NCT00700518|DRUG|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
223967528|NCT00700518|DRUG|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
224112730|NCT06670924|PROCEDURE|Running suture for vesico-urethral anastomosis in open radical prostatectomy|The surgical technique of the RS followed the description of Van Velthovens, was applied with slight modifications. Two 3/0 absorbable monofilament (polydioxanone) sutures were used. The first needle is started from bladder neck at 3 o'clock, and terminated in the urethra at 9 o'clock. After completion of the posterior anastomosis, a transurethral catheter is placed. The second sutures' needle is passed from the bladder at 9 o'clock and ended in the urethra at 3 o'clock. The bladder neck and urethra are merged by gentle traction of the anterior and posterior sutures at 3 and 9 o'clock.
223967529|NCT00700518|DRUG|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
223967530|NCT00700518|DRUG|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
224112731|NCT06670924|PROCEDURE|interrupted suture for vesico-urethral anastomosis in open radical prostatectomy|The technique described by Walsh for interrupted anastomotic suturing was applied with minor modifications. Six 3/0 absorbable monofilament (polydioxanone) sutures were placed at 1, 3, 5, 7, 9 and 11 o'clock to accomplish the vesicourethral anastomosis.
224112732|NCT04472104|BEHAVIORAL|MBCT-S|Group mindfulness treatment for sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
224112733|NCT04472104|BEHAVIORAL|SexEd|Group sex education on sexual desire, sexual distress, and sexual pain in breast cancer (BrCa) survivors.
224112734|NCT01001494|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
224112735|NCT01001494|DRUG|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
224112736|NCT01001494|DRUG|Placebo|Placebo twice-daily by inhalation for 24 weeks
224112737|NCT02179398|BIOLOGICAL|Allocation to the Lab-score group|
223967531|NCT00700518|DRUG|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
223967532|NCT01261455|PROCEDURE|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
223967533|NCT01769729|BEHAVIORAL|PEPP|
224112738|NCT02179398|BIOLOGICAL|Allocation to the control group|
224112739|NCT01914718|DRUG|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
224112740|NCT02905773|OTHER|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
224112741|NCT02905773|OTHER|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
223967534|NCT01769729|BEHAVIORAL|Care management|
223967535|NCT01673100|BEHAVIORAL|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
223967536|NCT02316145|BEHAVIORAL|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
223967537|NCT02843698|DRUG|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
223967538|NCT02843698|DRUG|Normal saline|Normal saline
224112742|NCT00591383|DRUG|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
223967539|NCT06381219|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms to assess maintained remission of EoE
223967540|NCT06381219|OTHER|Implementation of hen's egg in decreasingly heated forms|Implementation of hen's egg in decreasingly heated forms to assess maintained remission of EoE
223967541|NCT04647409|OTHER|screening|The determination of the prevalence of NAFLD in a general population in Flanders, Belgium
224112743|NCT00591383|DRUG|erlotinib|erlotinib taken at 150 mg every morning with food.
223967542|NCT01531478|OTHER|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
224112744|NCT01011686|BIOLOGICAL|ANT-SM|autologous adipose-derived stem cell
224112745|NCT05969210|OTHER|Toe strengthening exercise|12 participants will be in experimental group giving them Toe strengthening exercise protocol along with running training for three weeks, measure all values before giving them protocol and after protocol.
224112746|NCT05969210|OTHER|Control Group|12 participants will be in control group they will do only there running training.
224112747|NCT00233571|BIOLOGICAL|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
224112748|NCT06010667|DRUG|Envafolimab|With or without Envafolimab
224112749|NCT00163137|DRUG|lasofoxifene|lasofoxifene 0.25mg
224291407|NCT03643679|OTHER|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
224291408|NCT00049842|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
223542700|NCT00444106|DRUG|Artesunate-mefloquine|
223542701|NCT00444106|DRUG|Atovaquone-proguanil|
223542702|NCT00444106|DRUG|Artemether-lumefantrine|
223542703|NCT00011583|DEVICE|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
223542704|NCT00011583|DEVICE|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
223542705|NCT01478022|DRUG|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
223542706|NCT01478022|DRUG|Ibuprofen|Ibuprofen 200 mg daily, capsules
223542707|NCT01478022|OTHER|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
223542708|NCT04570384|DRUG|L-Citrulline|L-Citrulline (Turnobi) for Injection. Patients will receive an initial bolus of 20 mg/kg (maximum 1500 mg), followed by study infusion of 9 mg/kg per hour (maximum 700mg) for up to 10 days.
223542709|NCT04570384|DRUG|Placebo|Patients randomized to placebo will receive equal volume bolus and study infusion of 5% dextrose water for a maximum of 10 days.
223542710|NCT02192957|DEVICE|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
223542711|NCT01900665|DRUG|Solanezumab|Administered Intravenously (IV)
223542712|NCT01900665|DRUG|Placebo|Administered IV
223542713|NCT01935453|BIOLOGICAL|Recombinant hGM-CSF Herpes Simplex Virus Injection|
224112750|NCT00163137|DRUG|raloxifene|raloxifene 60 mg/day
224112751|NCT00163137|DRUG|Placebo|0 mg/day
223967543|NCT04707287|OTHER|No Intervention|No intervention used. This is observational study
223967544|NCT06430151|DEVICE|CUE1|Sternal worn focused vibrotactile stimulation and cueing device
223967545|NCT01642771|DRUG|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
223967546|NCT01642771|DRUG|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
223967547|NCT03023878|DRUG|Blinatumomab|Blinatumomab monotherapy was supplied in single-use sterile glass injection vials and administered as an IV infusion.
223967548|NCT03023878|DRUG|Investigator's Choice Chemotherapy|"During the run-in period participants received 6 cycles of standard of care rituximab-chemotherapy dosed per investigator's institution standard as follows:~* R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)~* R-DA-EPOCH (rituximab and dose adjusted-etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) or~* R-CHOEP (rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide)."
223967549|NCT03023878|DRUG|Dexamethasone|Dexamethasone 20 mg IV: within 1 hour prior to start of treatment in each treatment cycle, and within 1 hour prior to dose-step (increase).
223967550|NCT01198899|OTHER|blood sampling|Blood sampling will be used.
223967551|NCT04478799|DEVICE|Transcutanous Posterior Tibial Nerve Stimulation|children were managed by bilateral TPTNS following the procedure described in 2006 by Queralto et al(11). A positive auto-adhesive electrode was applied 1.5 inch above the medial malleolus over the S3 dermatome. A second negative electrode was applied just below the same malleolus. Electrical stimulation device (EMS physio Ltd, OX129 F, England) was connected to both electrodes. This device delivers a low frequency current (10 Hz), and the intensity was gradually increased till flexion of the big toe or spread out of the other toes in a fan shape occurred. Then the intensity was lowered to (10 Hz) again to avoid the motor response of the toes. Intensity was determined by the child's sensitivity. The procedure was done for 20-30 minutes and repeated2 times per week for 3 months
223542714|NCT03518021|DRUG|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
223967552|NCT04478799|DEVICE|Sham Transcutanous Posterior Tibial Nerve Stimulation|Sham transcutaneous stimulation Patients also had twice-weekly 20-30-min sessions for 3 months. The same self-adhesive electrodes as used for group A were employed, placed in a similar position. The stimulator was briefly switched on for 30 s to induce only a minor electrical sensation in the skin, and was then turned off for the rest of the treatment. This short duration was given for only for a few seconds to avoid lower limb stimulation. Patients in all TWO groups were told that they may or may not have any perception of the electrical stimulation. Without prior knowledge of what to expect from treatment, this enabled the sham group to act as a control. In order to improve on the blinding effect of the study, the electronic display window of the stimulators was shielded from the patients in the TWO groups. All patients underwent therapy in individual screened cubicles to prevent comparison between patients of the treatment being administered.
223967553|NCT04382183|BEHAVIORAL|Ketogenic weight loss maintenance diet|The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
223967554|NCT04382183|BEHAVIORAL|Isocaloric balanced weight loss maintenance diet|The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
223967555|NCT02332421|DEVICE|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
223967556|NCT00721708|DIETARY_SUPPLEMENT|pure carnosine|one time dose of pure carnosine (450 mg)
223967557|NCT00721708|OTHER|Beef|one time dose, 150 g of beef
223967558|NCT00721708|OTHER|Chicken|One time dose, 150g of chicken breast
223967559|NCT00721708|OTHER|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
223967560|NCT05115136|DRUG|Doxepin|25mg dose of Doxepin will be administered one time, by mouth
223967561|NCT05115136|DRUG|Diphenhydramine|50 mg dose of Diphenhydramine will be administered one time, by mouth
223724792|NCT03585257|BIOLOGICAL|25% IV albumin|"Intravenous 25% albumin infusion 1.0 g/kg body weight (maximum 100gm) once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
223967562|NCT04031547|DEVICE|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
223967563|NCT04063345|PROCEDURE|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
223724793|NCT03585257|OTHER|Placebo|"Normal saline infusion 1.0g/kg body weight once a week for five weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if \>4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
223724794|NCT03778762|PROCEDURE|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
223967564|NCT04063345|PROCEDURE|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
223967565|NCT06296797|BEHAVIORAL|Control arm: Existing educational website|Information about tubal sterilization currently provided on the Planned Parenthood website
223967566|NCT06296797|BEHAVIORAL|Advancing Access Website|A website comparing tubal sterilization to long-acting reversible contraceptives informed by recent patient centered outcomes research.
223967567|NCT04064840|DRUG|IVF: Decapeptyl and hCG|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
223967568|NCT04064840|DRUG|FET: Decapeptyl|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
223967569|NCT04064840|DRUG|IVF: hCG and normal saline|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
223967570|NCT04064840|DRUG|FET: Normal Saline|On the day of FET, normal saline will be injected subcutaneously.
223724795|NCT03778762|PROCEDURE|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
223967571|NCT03418701|BEHAVIORAL|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
223967572|NCT05452005|DRUG|[18F]-αvβ6-BP|Subjects will be injected twice with up to 10 millicurie (mCi) of 18F-αvβ6-BP as a rapid intravenous (i.v) bolus.
223967573|NCT05118308|PROCEDURE|Transjugular hepatic venous pressure gradient measurement with liver biopsy|This procedure will be performed by an experienced interventional radiologist who will be supported by a radiology technician and nurse. Transjugular hepatic venous pressure gradient measurement will be performed using standard procedure. Following this, a transjugular liver biopsy will be obtained using an 18-gauge transjugular liver biopsy needle.
223724796|NCT00724360|DRUG|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
223967574|NCT05118308|PROCEDURE|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy|A linear echoendoscope is inserted with the patient under conscious sedation. Using a through the scope 25-gauge needle connected to a digital manometer, portal and hepatic veins will be punctured under EUS guidance from a trans-gastric/hepatic approach. Following this, EUS-Liver biopsy is then performed immediately following EUS-PPG using a 19-gauge fine needle biopsy (FNB).
224112752|NCT03896425|DEVICE|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (\~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
224112753|NCT03004846|DRUG|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
224112754|NCT03004846|DRUG|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
224112755|NCT00408681|DRUG|lithium carbonate|Given orally
224112756|NCT00408681|OTHER|laboratory biomarker analysis|Correlative studies
224112757|NCT03790735|DIAGNOSTIC_TEST|FISH|Targeted chromosomal aberrations detection
224112758|NCT01050660|OTHER|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
223724797|NCT00451308|PROCEDURE|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
223724798|NCT00451308|PROCEDURE|Induction of labor with foley balloon with 30cc|30cc of saline in foley
223724799|NCT00510120|BEHAVIORAL|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
223967575|NCT06552897|PROCEDURE|Intervention 1: Adductor Canal Block (ACB)|"For the Interventions section, you should describe the specific procedures or treatments administered in each arm of your study. Here's how you might present the interventions:~Intervention 1: Adductor Canal Block (ACB) Name: Adductor Canal Block (ACB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block. Dose and Administration: 20 ml of 0.25% bupivacaine is injected to target the saphenous nerve within the adductor canal.~Objective: To provide analgesia to the anterior and medial aspects of the knee, preserving motor function to facilitate early mobilization."
223967576|NCT06552897|PROCEDURE|Intervention 2: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB)|"Name: Combined Adductor Canal Block and Selective Tibial Nerve Block (ACB + STNB) Type: Procedure~Description:~Participants receive an ultrasound-guided adductor canal block followed by a selective tibial nerve block.~Dose and Administration:~Adductor Canal Block (ACB): 20 ml of 0.25% bupivacaine. Selective Tibial Nerve Block (STNB): 20 ml of 0.25% bupivacaine. Objective: To provide comprehensive analgesia to both the anterior and posterior aspects of the knee, aiming to enhance pain relief and reduce opioid consumption."
223967577|NCT01248143|DIETARY_SUPPLEMENT|Green tea|9 gram per day
223967578|NCT01248143|DIETARY_SUPPLEMENT|FPP|2 sachets twice daily
223967579|NCT00586807|OTHER|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
223967580|NCT06051721|DRUG|CYB004|CYB004 is a synthetic deuterated N, N-Dimethyltryptamine (DMT) analog.
223967581|NCT06051721|BEHAVIORAL|Psychotherapy|Manualized psychotherapy (called EMBARK) performed by facilitators
223967582|NCT04679597|DRUG|Capecitabine|comparison of two treatments
223967583|NCT06648707|OTHER|Dual-task training|Participants will receive a one-hour face-to-face group-based dual-task training session twice a week for 6 weeks. Training included cognitive components and physical components to be conducted simultaneously.
223967584|NCT00649142|PROCEDURE|Open sutured mesh repair|Open sutured mesh repair
223967585|NCT00649142|PROCEDURE|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
223967586|NCT04265742|RADIATION|bone densitometry|Bone Mineral Density (BMD), body composition, vertebral fractures
223967587|NCT04265742|RADIATION|High resolution peripheral QCT|High resolution peripheral QCT (HR-pQCT): bone microarchitecture and bone strength
223967588|NCT04265742|DIAGNOSTIC_TEST|Collection of biological samples|Peripheral blood and urine samples to assess bone turnover markers and cytokines; and faeces to assess gut microbiota composition
223967589|NCT04265742|OTHER|questionnaires|Epidemiologic and nutritional questionnaire and physical activity scale
223967590|NCT04265742|OTHER|clinical tests|physical performance tests and grip strenght measurement
224112759|NCT01050660|OTHER|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
224112760|NCT00652587|PROCEDURE|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
224112761|NCT00652587|PROCEDURE|hepatectomy|hepatectomy alone
224112762|NCT04986527|PROCEDURE|Chest tube suction|The chest tubes will be inserted using our institutional standard chest tube insertion tray. The chest tubes used will be our institutional standard and will range from 14 to 32Fr in size. After chest tube placement, an Atrium Oasis Dry Suction Water Seal Chest Drain (Getinge USA Sales, LLC) will be used.
223542715|NCT03518021|DRUG|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
223542716|NCT03518021|DRUG|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
223967591|NCT00000521|BEHAVIORAL|diet, sodium-restricted|
223967592|NCT00000521|BEHAVIORAL|diet, potassium-supplemented|
223967593|NCT05282316|DIETARY_SUPPLEMENT|EVOO polyphenols enriched|Addition of 40 ml daily of healthy polyphenols enriched EVOO to mediterranean diet for 6 months
223967594|NCT05282316|DIETARY_SUPPLEMENT|EVOO standard|Addition of 40 ml daily of standard EVOO to mediterranean diet for 6 months
223967595|NCT01247922|DRUG|Erlotinib|continuous oral Erlotinib 85 mg/m\^2 per day
223967596|NCT04281875|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid."
223967597|NCT06645106|DEVICE|Rapid Point of Care (POC) Syphilis testing|Participants will undergo the point of care (POC) FDA cleared syphilis health check (SHC) POC test by a research staff using 50 microliters or 1-3 drops of whole blood via finger stick. The analyzer is handheld, and all testing equipment is temperature stable and does not need refrigeration. The SHC-Syphilis results will be available within 10 minutes of receipt given the published turnaround time to results of 15 minutes per package insert and will be recorded as a research note in the electronic medical record (EMR) while the provider assigned to the patient and the Houston Health Department will be notified of results and further treatment will be done if results are positive.
223967598|NCT04788472|DRUG|CAR-T cells targeting CD19 and CD22|Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion
223967599|NCT02570815|DRUG|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
223967600|NCT04506359|OTHER|Experimental Group|The Ex group is COPSCCP+ UC+ case manager care. In this group, a 6-month intervention providing for each time while subject visit their chest surgeon(s) in the OPD (from the first time before hospital discharge/T1).
223967601|NCT05204472|DEVICE|Burst DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of of Burst-stimulation followed by 12 days active tonic stimulation (Burst-DBS -\> tonic-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
223967602|NCT05204472|DEVICE|Tonic DBS|"Patients undergo stereotactic implantation of DBS electrodes in the thalamus under local anesthesia. The DBS electrodes will be connected to an external pacemaker for a time period of four weeks. On the first day following surgery, patients will undergo an empirical clinical testing of the stimulation parameter settings. At the same day patients will undergo somatosensory- and contact heat-evoked potential recording for phenotype-stratification (post-hoc analysis).During the next 24 days with the electrodes externalized and connected to the external pacemaker, patients will be randomly assigned in a 1:1 ratio to one of the two groups that undergo two blocks of stimulation:~12 days of active tonic stimulation followed by 12 days of Burst-stimulation (tonic-DBS -\> Burst-DBS) Between each stimulation block the stimulator will be switched off for one day to prevent any hang-over effects of stimulation (wash-out period)."
223967603|NCT04542642|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
223967604|NCT04542642|DEVICE|PEAR-008|PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
223967605|NCT06394193|BEHAVIORAL|Community-based participatory research intervention|Two training sessions (roughly two hours each) to train them in the intervention structure and curriculum
223542717|NCT03518021|DRUG|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
223967606|NCT05609682|DRUG|Gabapentin|Scheduled gabapentin given for two weeks after surgery
223967607|NCT05609682|DRUG|Placebo|Placebo given for two weeks after surgery
223967608|NCT01876823|DRUG|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
223967609|NCT01876823|DRUG|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
223967610|NCT00131690|DRUG|Nescafé Gold Blend (exposed)|
223967611|NCT00131690|DRUG|Nescafé Decaffeinated (controls)|
223967612|NCT02849509|DRUG|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
223967613|NCT02849509|DRUG|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
223967614|NCT02735278|OTHER|different test paradigms|
223967615|NCT00006578|DRUG|Ritonavir|
223967616|NCT00006578|DRUG|Abacavir sulfate|
223967617|NCT00006578|DRUG|Amprenavir|
223967618|NCT00006578|DRUG|Lamivudine|
223967619|NCT00006578|DRUG|Filgrastim|
224112763|NCT05558345|BEHAVIORAL|Contingency Management|A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.
224112764|NCT02519231|DRUG|Naproxen|Naproxen 440mg 1x pid
224112765|NCT02519231|DRUG|Placebo|Placebo tablet 440mg 1x pid
224112766|NCT03714841|OTHER|CRP|Knowledge of CRP value
224112767|NCT00447421|DRUG|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
224112768|NCT00447421|DRUG|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
223542718|NCT04749914|DRUG|Lasmiditan|Administered orally.
223542719|NCT04749914|DRUG|Dabigatran Etexilate|Administered orally.
223542720|NCT04749914|DRUG|Rosuvastatin|Administered orally.
223542721|NCT01673126|DEVICE|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
223542722|NCT01673126|DEVICE|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
223542723|NCT03076606|DIAGNOSTIC_TEST|ophthalmologist examination|ophthalmologist examination after geriatric consultation
223967620|NCT06545045|BEHAVIORAL|Metacognitive Strategy Training (MCST)|The MCST group will follow procedures for the Cognitive Orientation to daily Occupational Performance intervention. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, the therapist introduces the approach to the subject and teach a global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition. The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
223967621|NCT06545045|BEHAVIORAL|Inactive Control Group|Weekly contact will be made via telephone call to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce cognitive symptoms. The content of each of these meetings will be tracked in intervention notes.
223967622|NCT03686917|OTHER|CHAT-P|Survey
224112769|NCT00447421|RADIATION|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
223967623|NCT05774418|BIOLOGICAL|BNT162b2 COVID-19 Vaccine|BNT162b2 is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people from the age of 18 years. BNT162b2 contains tozinameran, a messenger RNA (mRNA) molecule with instructions for producing a protein from the original strain of SARS-CoV-2, the virus that causes COVID-19. BNT162b2 is given as two injections, usually into the muscle of the upper arm, 3 weeks apart.
223967624|NCT02990299|BEHAVIORAL|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
223967625|NCT04655222|DRUG|Interferon Beta Therapy|Administered as specified in the treatment arm.
223967626|NCT04749771|BEHAVIORAL|Filming Interactions to Nurture Development|FIND is a brief video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home.
223542724|NCT03836443|OTHER|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
224112770|NCT03566966|BIOLOGICAL|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
224112771|NCT03566966|BIOLOGICAL|Non-organ-specific Ab negative|direct-acting antiviral agents
224112772|NCT00233779|DEVICE|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
223542725|NCT04462601|OTHER|Biomarker detection|Quantification of serum markers of intestinal permeability and bacterial and fungal translocation
223542726|NCT04282850|PROCEDURE|Pulmonary Vein Isolation|The intervention will involve standard of care electrophysiology ablation for rhythm management of atrial fibrillation with a procedure called a pulmonary vein isolation.
223967627|NCT04749771|BEHAVIORAL|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly sessions alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction.
223724800|NCT00510120|BEHAVIORAL|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
223724801|NCT00510120|BEHAVIORAL|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
223967628|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after phage treatment.
223967629|NCT06368388|OTHER|Prospective data collection|Prospective data collection prior to, during and after standard infection treatment.
223724802|NCT05979701|OTHER|Simulation training|The intervention will consist of training participants through simulation in addition to theoretical training. The simulation will cover 3 themes, including diagnosis of haemorrhage, communication between healthcare providers, management of post-partum haemorrhage and transfusion monitoring.
223967630|NCT05621720|OTHER|Case management|On enrolment, the nurse case manager will perform the initial comprehensive assessment based on the Omaha domains of environment, psychosocial, physiological and health-related behavior. The nurse case manager will execute the intervention scheme of teaching, guidance \& counseling, treatments \& procedure, case management, and/or surveillance, with the mutual goal set with clients to promote health and self-efficacy. Home visits and telephone calls will be employed. The referral network to health and social service will be activated as appropriate.
223967631|NCT05621720|OTHER|Social control call and usual are|Subjects in the control group will receive usual community service. in addition, a monthly social control call from trained community workers will be given to rule out the possible social effects of the intervention. These social calls will not be related the participants' health condition nor delivery of any health information.
223967632|NCT06448390|BEHAVIORAL|Physical training|The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
223967633|NCT05899868|DEVICE|Time to Intubation using FASTER device|Time from fiberoptic placement onto airway to documentation of end-tidal carbon dioxide waveform through the endotracheal tube.
223967634|NCT06577376|DRUG|DP303c|DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
223967635|NCT06577376|DRUG|Simmitinib tablets|A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
224112773|NCT01383122|DEVICE|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
224112774|NCT01383122|DEVICE|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
224112775|NCT00296439|BEHAVIORAL|Behavior|
224112776|NCT02764619|DRUG|Spironolactone|
223542727|NCT02347384|DEVICE|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head \& SL-TWIN Stem
223724803|NCT00757887|BIOLOGICAL|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
223724804|NCT01307007|DRUG|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
223967636|NCT06577376|DRUG|Irinotecan liposomes|A chemotherapy
223967637|NCT06577376|DRUG|Paclitaxel or docetaxel or irinotecan|Paclitaxel or docetaxel or irinotecan is used as a control.
223967638|NCT06574503|DRUG|GP681 40mg|2X20mg tablets taken orally
223967639|NCT06574503|DRUG|GP681 Simulant|Placebo tablets matching GP681 40mg
223967640|NCT03749538|OTHER|Transcranial direct current stimulation session.|Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
223967641|NCT02214017|DEVICE|A videotelephone, TandBerg E20,|
224112777|NCT02764619|DRUG|Placebo|
223542728|NCT02347384|DEVICE|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head \& SL-PLUS Stem
223542729|NCT01039389|DRUG|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
223542730|NCT01039389|DRUG|Placebo|bid placebo
223542731|NCT02606630|DRUG|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
223542732|NCT03132285|DEVICE|PrePex|Prepex is a non surgical male circumcision device
223724805|NCT01307007|DRUG|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
223724806|NCT05647655|DEVICE|Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.
224112778|NCT02408250|PROCEDURE|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
224112779|NCT02106208|OTHER|Cheese diet|
224112780|NCT02106208|OTHER|Butter diet|
224112781|NCT02106208|OTHER|CHO diet|
224112782|NCT02106208|OTHER|MUFA diet|
223967642|NCT02214017|BEHAVIORAL|Behavioral motivation|Optimization of medical care in diabetes
223967643|NCT03806218|DEVICE|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
223967644|NCT03806218|DEVICE|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
223967645|NCT03806218|DEVICE|Twin internally cooled-wet electrodes|Saline-enhanced twin internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
223967646|NCT03806218|DEVICE|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
223967647|NCT06182800|DRUG|Adebrelimab Combined with Bevacizumab and Docetaxel|"Adebrelimab: 1200 mg Adebrelimab is given on day 1 of each cycle, with 1 dosing cycle every 3 weeks. The dosing time window may be ±5 days, but within 72 hours before each dose, subjects must complete an examination including all clinically necessary tests to assess tolerability of continued dosing, in addition to imaging. Subjects are also advised to remain in the hospital for observation 72 hours after the first dose.~Bevacizumab: 7.5 mg/kg Bevacizumab administered intravenously on day 1 of each cycle, with 1 dosing cycle every 3 weeks.~Docetaxel: 60-75 mg/m2 Docetaxel is given on days 1 of each cycle by intravenous infusion for 1 dosing cycle every 3 weeks."
223967648|NCT00985621|BIOLOGICAL|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
223967649|NCT00985621|BIOLOGICAL|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
223967650|NCT00985621|DRUG|oxycodone|oxycodone CR, 10-40 mg q12h
223967651|NCT00985621|OTHER|placebo|placebo
223967652|NCT00065234|PROCEDURE|Acupuncture|
224112783|NCT02106208|OTHER|PUFA diet|
224112784|NCT02167555|DIETARY_SUPPLEMENT|Active Comparator|Wild Blueberry Beverage
224112785|NCT02167555|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Beverage
224112786|NCT04698408|OTHER|high-protein, carbohydrate-reduced diet|the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
224112787|NCT04698408|OTHER|Dutch Nutritional Guidelines|the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids \<10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
224112788|NCT06388369|RADIATION|[177Lu]Lu-PSMA-617|2 cycles of 7,4 GBq \[177Lu\]Lu-PSMA-617 at 6 weeks intervals
223542733|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
223542734|NCT03668964|DIETARY_SUPPLEMENT|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
223542735|NCT03668964|DIETARY_SUPPLEMENT|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
223542736|NCT03668964|DIETARY_SUPPLEMENT|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
223542737|NCT03668964|DIETARY_SUPPLEMENT|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
223542738|NCT03668964|DIETARY_SUPPLEMENT|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
224112789|NCT06388369|DRUG|Ipilimumab|4 cycles of Ipilimumab 3mg/kg at 3 weeks intervals
223967653|NCT05550584|DEVICE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE).|In the THRIVE group, dedicated Optiflow THRIVE nasal cannulas will be positioned for 100% high flow oxygen therapy at an initial flow of 30 L/min. After induction of anesthesia and throughout the procedure the flow of oxygen will be increased to 70 L/min.
223967654|NCT05550584|DEVICE|LMA|Mechanical ventilation performed by a laringeal mask
223967655|NCT04153851|PROCEDURE|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
224112790|NCT01421368|DRUG|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
224112791|NCT01421368|DRUG|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
224112792|NCT01421368|DRUG|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
224112793|NCT04756895|OTHER|Vancomycin dose adjustment using the Bayesian method|This intervention is the experimental method. The AUC/MIC target is 400-600 mg\*hour/L.
224112794|NCT04756895|OTHER|Vancomycin dose adjustment using the trough level method|This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.
224112795|NCT03958201|COMBINATION_PRODUCT|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
223724807|NCT00121745|GENETIC|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
223724808|NCT00121745|GENETIC|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
223967656|NCT00296309|DRUG|Tacrolimus|Immunosuppression
223967657|NCT06385288|OTHER|Blood and tissue collection for immunological studies, advanced imaging.|Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.
223967658|NCT06385288|OTHER|neoadjuvant Therapy|neoadjuvant Therapy
223967659|NCT01911819|PROCEDURE|Sinus augmentation|
223967660|NCT01911819|DRUG|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
223967661|NCT01911819|DRUG|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
223967662|NCT01911819|DRUG|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
223967663|NCT00257556|DRUG|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
223967664|NCT00257556|DRUG|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
223967665|NCT02225288|DRUG|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
223967666|NCT03760809|DRUG|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
224291409|NCT02399098|BEHAVIORAL|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
224291410|NCT02923882|OTHER|'$100Kitchen and improved cookstove'|
224291411|NCT02778503|OTHER|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
223724809|NCT00121745|GENETIC|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
223967667|NCT03760809|DRUG|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
223967668|NCT03903185|DRUG|Ledipasvir / Sofosbuvir Oral Product|45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
223967669|NCT05619991|OTHER|Group watching video|The video will include preparation for the surgery, the operating room environment and the post-operative process.
224291412|NCT02778503|OTHER|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
223724810|NCT00121745|GENETIC|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
223724811|NCT00387023|DRUG|Rituximab|250 mg/m\^2 IV over 4-6 hours for 2 weeks.
223967670|NCT05619991|OTHER|Scheduled training group|The scheduled training will include preparation for the surgery, the operating room environment and the post-operative process.
223967671|NCT03849300|OTHER|Aquatic walking exercise program group 1|12 week aquatic walking exercise program
223724812|NCT00387023|DRUG|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
223967672|NCT03849300|OTHER|Aquatic walking exercise program group 2|12 week aquatic walking exercise program
223967673|NCT03849300|OTHER|Land-based walking exercise group|12 week land-based walking exercise program
223967674|NCT06383507|DRUG|CHT101|After lymphodepletion with Fludarabine and Cyclophosphamide, CD70 UCAR T cells were transfused intravenously.
223967675|NCT02506322|BEHAVIORAL|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~1. psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~2. Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~3. dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~4. behavior changes, (social, problem solving) skill training, communication skills, crisis management"
223967676|NCT02506322|BEHAVIORAL|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
223967677|NCT00807053|DRUG|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
223967678|NCT00807053|DRUG|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
223967679|NCT00807053|DRUG|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
223967680|NCT00807053|DRUG|Placebo|Placebo
223967681|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer A|Commercially available receiver-in-canal hearing instrument from manufacturer A
223967682|NCT04839289|DEVICE|Receiver-in-canal hearing instrument; Manufacturer B|Commercially available receiver-in-canal hearing instrument from manufacturer B
224291413|NCT01072266|DRUG|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
224291414|NCT03326674|DRUG|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
224291415|NCT03326674|DRUG|Capecitabine|Capecitabine alone at approved dose
223724813|NCT04384211|OTHER|Computer Assisted Detection Software For Vertebral Fractures|A device named Smart Bone that is using CT image retrospectively acquired to entails a second review of CT images with Vertebral Compression Fractures through an interactive AI program developed by Quanta Computer Inc. was applied to the CT images. The device is a computer-aided detection (CADe) software application and is designed to assist radiologists to analyze Spine CT images. The device uses deep learning methods to perform vertebrae detection and classification of images.
223724814|NCT02616055|DRUG|tesevatinib|
224291416|NCT04133766|BEHAVIORAL|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
224291417|NCT00231257|DEVICE|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
223967683|NCT02297945|DRUG|metyrapone|Single arm study
223967684|NCT03826056|BEHAVIORAL|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
223967685|NCT03826056|BEHAVIORAL|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
224291418|NCT00231257|PROCEDURE|Brachytherapy|Brachytherapy
224291419|NCT00307931|BIOLOGICAL|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
223724815|NCT05281939|DIAGNOSTIC_TEST|Artificial intelligence diagnosis|Participants were divided into the intervention group and the control group using a random number table. The intervention group participants' cervical colposcopic image data and non-image data as follow：age, the infection of high-risk human papillomavirus (HR-HPV),the type of HR-HPV infection,the duration of HR-HPV infection, cervical cytology (TCT) results, HIV/sexually transmitted infection history, marriage and childbearing history,first sexual life history, sexual partner history, smoking history,oral contraceptives history,the use of immune drug and possible clinical symptoms of cervical lesions such as postcoital bleeding, abnormal vaginal secretions, vaginal bleeding symptoms, etc.
223724816|NCT06436872|OTHER|informing patients with using a booklet|The intervention group was informed before discharge and was given an information booklet. A phone number was given so that the researcher could contact the nurse. In the 4th week, 8th week and 12th week, information was given according to the information needs of the patient and caregiver.
223967686|NCT00120952|DEVICE|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
223967687|NCT06212180|DEVICE|mask|patients will be their own comparator. Patients will try both mask for 10 min and then decide which mask they want for the rest of the ventilation
223967688|NCT05357599|DIAGNOSTIC_TEST|EUS|The decision to start a beta-blocker will be made at the conclusion of the EGD based on the endoscopic findings (presence of esophageal varices)
223967689|NCT00874393|DRUG|Dopamine|Dopamine
223967690|NCT00874393|DRUG|Hydrocortisone|Hydrocortisone
224291420|NCT00854373|DRUG|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
223967691|NCT00874393|DRUG|Infusion Placebo|Dextrose (D5W)
223967692|NCT00874393|DRUG|Syringe Placebo|Normal saline
223967693|NCT06061588|DEVICE|Virtual Reality|The use of virtual reality as an adjunct to routine treatment.
224291421|NCT00854373|OTHER|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
224291422|NCT02161120|OTHER|Traditional Finnish rye bread|
224291423|NCT02161120|OTHER|Low FODMAP rye bread|
223724817|NCT05782491|PROCEDURE|Interscalene Block|It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
224112796|NCT03851861|OTHER|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
224112797|NCT02124798|DEVICE|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
224112798|NCT01435512|BEHAVIORAL|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
224112799|NCT06487884|OTHER|escape games|A suitable day and time will be determined in the curriculum of the students in the intervention group and escape games consisting of various games involving intravenous drug administration will be played. Games will be played within the determined game guidelines. Each group will play the games at the stations respectively and get a clue at the end of each game. After completing the last game, the time it takes to find the password and complete the game will be recorded. After all groups complete the game, the group that completes the games in the shortest time will win the game and receive the prize in the chest.
224112800|NCT00827203|DRUG|Elesclomol Sodium|Chemotherapy agent
224112801|NCT02862795|PROCEDURE|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
224112802|NCT04018287|OTHER|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
224112803|NCT05968950|DEVICE|Thoracic ultrasound|The use of ultrasound to count ribs in order to surface mark the corresponding spinal level
224112804|NCT01707147|DRUG|Trajenta tablet|Linagliptin
223967694|NCT06367244|BEHAVIORAL|Transplant Wellness Program - Kidney and Liver|The exercise prescription for the intervention will be multimodal, , will follow current chronic disease exercise guidelines, and will be tailored to meet the unique needs of each participant. . All participants will receive two 30-45-minute individual session with a CEP during their first week and two additional sessions during the second week if needed. The individual sessions will be followed by group sessions. Each participant will get a total of 24 individual and group sessions combined. These sessions can be conducted either in-person or online, based on participant preference and TWP logistics. For aerobic-based activities, a moderate rate of perceived exertion of 4-6 on a scale of 0-10 will be used. Resistance exercise will begin with functional movements and bodyweight exercises targeting major muscle groups with modifications for beginners and exercise progressions when deemed. Balance and flexibility training activities will also be included.
223967695|NCT04617197|DEVICE|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy|Transcutaneous electrical nerve stimulation with frequency-specific microcurrent resonant therapy using (Dragon Waves Resonant Home Care Electronic Nerve Stimulator (DW-1330), Taiwan Resonance Wave Research Co., Taiwan R.O.C,)
223967696|NCT00163748|DRUG|gemcitabine, vinorelbine|
223967697|NCT03031353|DRUG|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
223967698|NCT03031353|DRUG|Placebos|placebos tablet will be given before elective Cesarean sections
223967699|NCT04974021|DRUG|Ferric carboxymaltose|Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.
223967700|NCT05602961|DRUG|GLB-COV2-043|COVID-19 vaccine, administered as a booster
223967701|NCT05602961|DRUG|BNT162b2/COMIRNATY®|active control
223967702|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223967703|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223967704|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223967705|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223967706|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223967707|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223724818|NCT05782491|PROCEDURE|PECS II Block|PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
223967708|NCT01428622|DEVICE|Respimat|aqueous and ethanolic solution
223967709|NCT01428622|DRUG|Olodaterol|aqueous solution
223967710|NCT01428622|DRUG|Olodaterol|aqueous solution
223967711|NCT01428622|DRUG|Olodaterol|aqueous solution
224112805|NCT03364998|DRUG|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
224112806|NCT03364998|DRUG|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
224112807|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
224112808|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
224112809|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
223967712|NCT01428622|DRUG|Olodaterol|aqueous solution
223967713|NCT01428622|DRUG|Olodaterol|aqueous solution
223967714|NCT01428622|DRUG|Olodaterol|aqueous solution
223967715|NCT01428622|DRUG|Olodaterol|aqueous solution
223967716|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967717|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967718|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967719|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967720|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967721|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967722|NCT01428622|DRUG|Olodaterol & BI54903|ethanolic solution
223967723|NCT01428622|DRUG|BI54903|ethanolic solution
223967724|NCT01428622|DRUG|BI54903|ethanolic solution
223967725|NCT01428622|DRUG|BI54903|ethanolic solution
224112810|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
223542739|NCT03668964|DIETARY_SUPPLEMENT|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
223967726|NCT01428622|DRUG|BI54903|ethanolic solution
224112811|NCT02100553|DRUG|Itraconazole|Two 100 mg capsules, once daily for 7 days
224112812|NCT02100553|DRUG|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
224112813|NCT01652833|OTHER|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
223724819|NCT05782491|PROCEDURE|Superficial Cervical Plexus Block|This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
223967727|NCT01428622|DRUG|BI54903|ethanolic solution
223967728|NCT01428622|DRUG|BI54903|ethanolic solution
223967729|NCT01428622|DRUG|BI54903|ethanolic solution
223967730|NCT05776745|BEHAVIORAL|Speech|Patients read specific words and sentences
223967731|NCT05776745|DEVICE|Stereoelectroencephalography|Using stereoelectroencephalography to record the Intracranial EEG of the patient
223967732|NCT00386802|DRUG|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
223967733|NCT04743999|OTHER|Quality of life questionnaire|We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
223967734|NCT03191526|DRUG|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
223967735|NCT03191526|DRUG|Placebo (saline)|Intravenous injection every 12 weeks.
223967736|NCT01597999|RADIATION|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
223967737|NCT00003731|DRUG|temozolomide|
223967738|NCT01400945|DRUG|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
223967739|NCT01786915|DRUG|Bendavia 10mg|
223967740|NCT01786915|DRUG|Bendavia 50mg|
223967741|NCT01786915|DRUG|Placebo|
223967742|NCT04733989|OTHER|Biomarker Data Collection|During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.
223967743|NCT06450275|DRUG|Dolutegravir 50 MG Film Coated Tablet|1 tablet of Dolutegravir 50mg film-coated tablets
223967744|NCT06450275|DRUG|Tivicay 50mg, film-coated tablets|1 tablet of Dolutegravir 50mg film-coated tablets
223967745|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
223967746|NCT00464737|DRUG|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
224112814|NCT00184847|DRUG|acetylcholine|
223967747|NCT00464737|OTHER|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
224291424|NCT02405663|PROCEDURE|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
223967748|NCT03094520|DEVICE|tDCS|Transcranial direct current stimulation (tDCS)
223967749|NCT03094520|DEVICE|sham-tDCS|sham stimulation
223967750|NCT02033668|DRUG|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
223967751|NCT02033668|DRUG|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
223967752|NCT02033668|DRUG|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
223967753|NCT01207453|DRUG|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
223967754|NCT01207453|DRUG|Placebo|
223967755|NCT02814279|PROCEDURE|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
223967756|NCT02814279|PROCEDURE|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
223967757|NCT02814279|DRUG|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
223967758|NCT02814279|DRUG|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
223967759|NCT05347524|OTHER|Baseline blood draw and blood-based biomarkers analyses|Baseline blood draw and blood-based biomarkers analyses
223967760|NCT00676663|DRUG|entinostat|Entinostat 5 mg tablet orally once per week
224112815|NCT00184847|PROCEDURE|twenty minutes of forearm ischemia|
224112816|NCT00184847|PROCEDURE|three 5-minute periods of forearm ischemia|
224112817|NCT00184847|DRUG|adenosine|
224112818|NCT00184847|DRUG|caffeine|
223967761|NCT00676663|DRUG|exemestane|Exemestane 25 mg tablet orally once daily
223967762|NCT00676663|DRUG|Placebo|Placebo-matching entinostat tablet orally once per week
223967763|NCT05434533|DRUG|Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)|IV 1gm
223967764|NCT03214471|BEHAVIORAL|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
223967765|NCT00587899|PROCEDURE|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
223967766|NCT00354809|DRUG|GW679769|
223967767|NCT04475016|DRUG|Albumin-Bound Paclitaxel|260 mg/m² IV over 30 minutes on Day 1
223967768|NCT04475016|DRUG|Ifosfamide|1200 mg/m² IV over 2 hours on Days 1-3
223967769|NCT04475016|DRUG|Cisplatin|25 mg/m² IV over 2 hours on Days 1-3
223967770|NCT04475016|DRUG|Nimotuzumab|400 mg IV on Day 1
223967771|NCT04475016|DRUG|Triprilimab|240 mg IV on Day 1
223967772|NCT03814278|BEHAVIORAL|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
223967773|NCT03814278|BEHAVIORAL|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
223967774|NCT03721900|DRUG|SHX-001 Active low dose|ketamine transdermal patch
223967775|NCT03721900|DRUG|Placebo|transdermal patch
223967776|NCT03721900|DRUG|SHX-001 Active High dose|ketamine transdermal patch
223967777|NCT00580047|DRUG|Zoledronic Acid|4mg IV Annually
223967778|NCT00580047|COMBINATION_PRODUCT|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
223967779|NCT00580047|DRUG|Alendronate|70mg weekly
223967780|NCT02674555|DRUG|radio-labeled naquotinib|Oral administration
224112819|NCT02355093|PROCEDURE|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
224112820|NCT02355093|PROCEDURE|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
224112821|NCT02355093|DRUG|ropivacaine|
224112822|NCT04905329|DRUG|Empegfilgrastim|Extimia®
224112823|NCT05873530|OTHER|Grape|Reconstituted whole grape powder
224112824|NCT05171530|DRUG|Lenvatinib plus taxane drugs|"* Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX~* Drug: Docetaxel Dose: 75mg/m2 Other Name: FA~* Drug: Lenvatinib Dose: 4mg, 8mg, 12mg,16mg Other Name: FA"
224112825|NCT02011022|DRUG|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
224112826|NCT02011022|DRUG|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
224112827|NCT04330625|BIOLOGICAL|REMD-477|REMD-477 will be administered as a subcutaneous injection for four weekly doses
224112828|NCT05596825|DEVICE|Mandibular Advancement Device|"To analyze the phenotypic characteristics of different subgroups of patients with obstructive sleep apnea syndrome who respond better (complete responders) or worse (partial responders or non-responders) to treatment with mandibular advancement devices.~Responders will be defined as a post-treatment AHI of less than 10/h and at least a 50 percent reduction in their AHI. Partial responders will be defined as a post-treatment AHI greater than 10/hour but at least a 50 percent reduction in AHI, and non-responders as less than a 50 percent reduction compared to baseline."
223967781|NCT02674555|DRUG|naquotinib|Oral administration
223967782|NCT06212934|OTHER|Acupuncture|"Chou's Tiaoshen acupoints includes Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1), Sanyinjiao (SP-6), Shenmen (HT-7) . Using stainless steel needles (0.32×40)mm, HuaTuo, China). Then some other points like, Danzhong(CV-17), Daling(PC-7), Taixi (KI-3), Qihai (CV-6), Taichong (LR3), and Qiuxu(GB-40) are chosen. Operation: Patients in supine position. Baihui (GV-20), Shenting (GV-24), and Sishencong (EX-HN1) are punctured at a depth of 20-25mm obliquely. Sanyinjiao (SP-6) and Shenmen (HT-7) are inserted 15mm perpendicularly. Until feeling tactile sensation then manually manipulated by rotation methods to produce a characteristic sensation known as De Qi; Technique: Mild reinforcing and attenuating, retaining the needle for 30minutes. The treatment will be givenonce a day and 5 times a week in weekdays, the course will last two weeks."
223967783|NCT06212934|DRUG|Estazolam|Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
223967784|NCT01707498|PROCEDURE|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
223967785|NCT01707498|PROCEDURE|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
223967786|NCT00662883|DRUG|PMI-150 (intranasal ketamine HCl); mometasone furoate|"* 1 dose PMI-150 (intranasal ketamine HCl); day 1~* mometasone furoate, daily; days 2-15~* 1 dose PMI-150 (intranasal ketamine HCl); day 15"
223967787|NCT05959382|DEVICE|Dental Loupe|Magnification aid
223967788|NCT05959382|DEVICE|Dental Operation Microscope|Magnification aid
223967789|NCT03238599|BEHAVIORAL|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
223967790|NCT05432258|DEVICE|Bulk-fill composite resin|Restoration of the mandibular first molars with bulk-fill composite resin as the manufacturer advises after the cavity preparation
223967791|NCT05432258|DEVICE|Nano-fill composite resin|Restoration of the mandibular first molars with nano-fill composite resin as the manufacturer advises after the cavity preparation
223967792|NCT02363933|DRUG|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
223967793|NCT00365183|DRUG|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
223967794|NCT06212596|DRUG|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumour suppressor proteins (TSPs). Selinexor is an oral, first-in-class, potent, slowly reversible, covalent-binding Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks the karyopherin protein Exportin 1 (XPO1), also called chromosome region maintenance 1.
223967795|NCT06212596|DRUG|Cyclophosphamide|Cyclophosphamide is a long used conventional chemotherapy with potent anti-myeloma activity and low toxicity when administered at low doses as in the current protocol (Hajek et al. (2016)). It is being extensively used in combination with novel agents, including bortezomib, lenalidomide, and pomalidomide, and provides a cost-effective and well-tolerated alternative as a combination partner (Morgan et al. (2007); Mai et al. (2015); Baz et al. (2016)).
223967796|NCT06212596|DRUG|Prednisone|Steroids have been a very effective backbone for every myeloma combination therapy developed so far. Prednisone is the standard steroid in a number of widely used regimens (Mateos et al. (2010);Palumbo et al. (2006)). Decreasing the morbidity associated with high dose steroid use by using better-tolerated regimens addresses a large unmet need of the myeloma patient population.
223967797|NCT05189288|DRUG|D418 Tab.|1T
223967798|NCT05189288|DRUG|CKD-388 Tab.|1T
223967799|NCT04454671|OTHER|Ultrasound-guided percutaneous neuromodulation (NMPE)|It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
223967800|NCT04454671|OTHER|Ultrasound-guided dry needling|Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
223967801|NCT00403299|PROCEDURE|MDCT of the coronary arteries.|
223967802|NCT01126177|DRUG|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
223967803|NCT01126177|DRUG|Placebo|Placebo (excipients of the SNG001 solution only)
223967804|NCT05126199|OTHER|Time restricted eating|"Following a 3 day baseline dietary assessment using the Nutritics 'app', patients will immediately commence time-restricted eating on a 18:6 basis (18 hours fasting, 6 hours eating window) for 12 weeks.~Participants will consume all their meals within a daily 6-hour period of their choosing, and this may change according to patient's lifestyle and preference to reflect a real-world situation. Participants may eat ad libitum / according to appetite during the eating period. Participants will fast for 18 hours per day, consuming only plain water, unflavoured/unsweetened sparkling water, black breakfast tea or black coffee. Alcohol must not be consumed during fasting periods~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
223967805|NCT05126199|OTHER|Normal ad libitum diet|"Following a 3-day baseline dietary assessment using the Nutritics 'app', participants with be directed to continue with their usual dietary intake without any time-related restrictions for 12 weeks. There will be no defined eating window and fasting or restrictions regarding types of food or drink consumed.~Dietary intake will again be measured using the Nutritics 'app' midpoint through the 12-week period (week 6 +/- 1 week) and in the last week of the intervention (week 11/12)."
223967806|NCT02375607|DEVICE|Algometer|Algometer performed patients
224112829|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
224112830|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
224112831|NCT00629824|DRUG|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
224112832|NCT02053246|DRUG|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
224112833|NCT05127772|DRUG|HEC93077|Paticipants recieve HEC93077 orally single or Mulltiple doses up to 14 days
224112834|NCT05127772|DRUG|Placebo|Paticipants recieve placebo matching HEC93077 orally single or Mulltiple doses up to 14 days
224112835|NCT02795156|DRUG|Afatinib|40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
223967807|NCT02985255|DRUG|Docetaxel|Neoadjuvant Arm
223967808|NCT02985255|DRUG|Cisplatin|Neoadjuvant Arm
223967809|NCT02985255|DRUG|5FU|Neoadjuvant Arm
223967810|NCT02985255|RADIATION|Radiotherapy|Neoadjuvant Arm
223967811|NCT02985255|PROCEDURE|Glossectomy|Neoadjuvant Arm
224112836|NCT02795156|DRUG|Regorafenib|160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
224112837|NCT02795156|DRUG|Cabozantinib|60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
223967812|NCT01114334|BEHAVIORAL|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
223967813|NCT01114334|BEHAVIORAL|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
223967814|NCT04747717|PROCEDURE|chemotherapy/surgery|NEO chemotherapy/interval debulking surgery/AD chemotherapy
223967815|NCT05333133|DIETARY_SUPPLEMENT|high calorie formula (oral nutritional supplement/ONS)|"every subject is given 400 ml (equal with 400 kcal) high calorie formula for 90 days. before (day 0) and after (day 91) the intervention was enrolled, blood samples was taken to investigate IGF-1 and total lymphocyte counts.~The body weight and body height will be measured at day-0, day-14, day-30, day 60 and 90."
223967816|NCT01432223|DRUG|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
223967817|NCT05464199|OTHER|Neurofeedback training|"Self-administered neurofeedback treatment using headset and tablet-based application, designed with the purpose of alleviating chronic pain by providing the user with feedback of, and allowing them to modulate, their own brain EEG signals associated with activity in brain networks related to pain perception and pain modulation.~Visual feedback will be provided onscreen representing the participant's real time EEG activity measured by the headset. Each session will be split into five blocks of five minutes each, with a one-minute rest period in between, in order to avoid fatigue and allow the participant to move around and adjust their position. After each rest block, participants will be asked if they are ready to proceed and when ready, the next block can be started. After the end of the session (5 blocks) the participant will then be asked to perform a post-session eyes-open EEG recording, similar to the eyes-open baseline taken at the start of the session."
223967818|NCT04685434|OTHER|Shriners Hospital for Children Upper Extremity Evaluation|The interventions are evaluating tools for the functional performance of the upper extremity.
223967819|NCT01072734|DRUG|Vaccine|Influenza vaccine
223967820|NCT04091945|DRUG|LT3001 Drug Product|Active comparator
223967821|NCT04091945|DRUG|Placebo|Placebo comparator
223967822|NCT01879735|DRUG|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
223967823|NCT01879735|DRUG|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
223967824|NCT00782353|DRUG|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
223967825|NCT00782353|DRUG|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
223967826|NCT00782353|DRUG|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
223967827|NCT04661189|BEHAVIORAL|Physical exercise training|Participants will be encouraged to complete exercise training programs in the form of video capsules available via Facebook or Youtube, created by kinesiologists of the Montreal Heart Institut EPIC prevention center. The videos last about 15 minutes and include a warm-up of 3 to 5 minutes, followed a 10-minute training and finally a 2-minute cool-down period. The exercises on video do not require any equipment and integrate, depending on the video, aerobic, muscular strengthening, flexibility and/or balance exercises. Several intensities are described according to the participants' level. Participants will be invited to perform exercise sessions at least 5 times a week, and will be monitored weekly by phone by a member of the research team. The exercise sessions can be performed at home using the video training program, as well as in sports centre or outdoors. For each session, participants have to report its duration, intensity, and the nature of the activity via a follow-up agenda.
223967828|NCT04661189|BEHAVIORAL|Cognitive training|Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed different mnemotechnic, as well as be taught about memory in aging in general. The memory training will be provided by videos capsules. To track adherence to cognitive training, participants will be asked to complete a journal and mark days and times where they took part in the various cognitive training sessions.
223967829|NCT02465606|DRUG|Lebrikizumab|Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
223967830|NCT02465606|DRUG|Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)|Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
223967831|NCT05076578|DEVICE|Autologous Regeneration of Tissue (ARTTM) system|The ART Skin Harvesting System is intended to harvest full thickness skin microcolumns in a minimally invasive manner and scatter them at the recipient site. It consists of three components: (1) a non-sterile, reusable handheld device; (2) a sterile, single-patient use needle cartridge containing the needle array for harvesting skin micrografts from the patient donor site; and (3) a sterile, disposable handheld protective sleeve to cover the handheld device (figure 1). The sterile sleeve reduces contamination of the reusable handheld device and provides a sterile barrier between the non-sterile handheld device and the patient.
224112838|NCT03985137|OTHER|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
224291425|NCT02405663|PROCEDURE|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
223724820|NCT04338698|DRUG|Hydroxychloroquine|Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)
223724821|NCT04338698|DRUG|Oseltamivir|Oseltamivir (75 mg orally twice a day for 5 days)
223724822|NCT04338698|DRUG|Azithromycin|Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
223724823|NCT01580618|DRUG|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
223724824|NCT01580618|DRUG|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
223724825|NCT01179568|DRUG|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
223724826|NCT01179568|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
223724827|NCT01179568|OTHER|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
223967832|NCT02293278|BEHAVIORAL|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
223967833|NCT04640376|DRUG|Paracetamol Uniflash 125mg|Oromucosal solution 1.25 mL for buccal use
223967834|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X1|Tablet masked in capsule
223967835|NCT04640376|DRUG|Panadol 500 MG Oral Tablet X2|Tablet masked in capsule
223967836|NCT04640376|DRUG|Placebo|Dummy treatment
224291426|NCT00293202|DRUG|Etanercept|Hemodialysis patients will receive Etanercept at a dose of 25 mg by subcutaneous injection twice a week
224291427|NCT00293202|DRUG|Placebo|Hemodialysis patients will receive Saline by subcutaneous injection twice a week
224291428|NCT00717184|DRUG|Interleukin, NK cells|
223724828|NCT03310775|BEHAVIORAL|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
223724829|NCT02837198|DRUG|FYU-981|
223724830|NCT02837198|DRUG|Topiroxostat|
223724831|NCT04372030|OTHER|Online questionnaire|this is an online questionnaire collecting retrospective data on health care use and non-use
223724832|NCT06214338|DIETARY_SUPPLEMENT|Low dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 2.5, separated by 1 hour and 15 min.
223724833|NCT06214338|DIETARY_SUPPLEMENT|High dose|Consumption of a β-alanine sustained-release supplement, 10 mg by 4 intakes of 5 separated by 1 hour and 15 min.
223724834|NCT03418415|DEVICE|Renal denervation|multi-electrode catheter-based renal denervation
223724835|NCT00909051|DRUG|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
223967837|NCT00672100|DRUG|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
223967838|NCT00672100|DRUG|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
223967839|NCT00672100|DRUG|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
223967840|NCT01549171|DRUG|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
223967841|NCT01549171|OTHER|normal saline|Supplement with vehicle only no Iloprost.
223967842|NCT04963998|DEVICE|Application of Wound Dressings with Copper Oxide|Application of Wound Dressings with Copper Oxide on chronic foot wounds in diabetic patients
223967843|NCT00513292|DRUG|Cyclophosphamide|Given IV
223967844|NCT00513292|DRUG|Epirubicin Hydrochloride|Given IV
223967845|NCT00513292|OTHER|Laboratory Biomarker Analysis|Correlative studies
223967846|NCT00513292|DRUG|Paclitaxel|Given IV
223967847|NCT00513292|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223967848|NCT00513292|BIOLOGICAL|Trastuzumab|Given IV
223967849|NCT03734172|DIAGNOSTIC_TEST|Sample collection|Specimen collection
223967850|NCT05406206|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.
223967851|NCT05406206|PROCEDURE|Hepatic Arterial Infusion Chemotherapy|HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W
223967852|NCT03038152|PROCEDURE|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
223967853|NCT03038152|PROCEDURE|Localization|Undergo axillary lymph node localization
223967854|NCT03038152|DEVICE|Medical Device|Receive Magseed via ultrasound guided injection
223967855|NCT05534451|BEHAVIORAL|video laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
223967856|NCT05534451|BEHAVIORAL|video rigid laryngoscope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
223967857|NCT05534451|BEHAVIORAL|video fiberoptic scope guided nasotracheal intubation|According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
223967858|NCT05513222|PROCEDURE|flipped autograft|Thick lingual flap was de-epithelized and partially dissected to increase its length then flipped and sutured to the buccal flap to obtain primary closure
223967859|NCT04892004|BEHAVIORAL|Symptom recognition|The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
223967860|NCT01630161|BEHAVIORAL|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (\<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
223967861|NCT01630161|BEHAVIORAL|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
223542740|NCT01079312|DEVICE|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
223542741|NCT01079312|DEVICE|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
223542742|NCT01079312|DRUG|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
224291429|NCT05265221|PROCEDURE|Endoscopic submucosal dissection|ESD was performed under conscious sedation. For sedation, midazolam and/or propofol were administered intravenously, with cardiorespiratory monitoring. Initially, indigo carmine dye was sprayed onto the tumor to clarify the margin. Then, markings were made 10 mm outside the tumor margin using argon plasma coagulation. After marking, a mixture of sodium hyaluronate with indigo carmine and epinephrine was injected into the submucosa outside the marking dots. Circumferential mucosal incision and submucosal dissection were performed using a Dual and/or IT knife. During the procedure, immediate bleeding was treated by Coagrasper. After ESD, chest and abdominal plain radiography were performed routinely for detection of gastric perforation.
224291430|NCT01414751|BEHAVIORAL|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
224291431|NCT01414751|BEHAVIORAL|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
224291432|NCT01251978|DRUG|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
223967862|NCT00401791|BEHAVIORAL|Exercise|"* Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~* Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
223967863|NCT05611476|BEHAVIORAL|Cognitive Muscular Therapy for low back pain|Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
224291433|NCT01251978|DRUG|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
224291434|NCT05715554|OTHER|Homeopathy|Individualized homoeopathic medicines on impregnated lactose pellets was prescribed based on totality of physical, emotional, and mental symptoms.
223542743|NCT01079312|DRUG|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
223967864|NCT00665106|DRUG|"NOVA63035 Corticosteroid"|Single injection in the study eye
223967865|NCT04542109|BEHAVIORAL|READyR A|Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.
223967866|NCT04542109|BEHAVIORAL|READyR B|Active comparator. Two sessions to deliver general information about dementia-related care needs.
223967867|NCT00469352|DRUG|Ranibizumab|Ranibizumab as needed
223967868|NCT05833399|DRUG|Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone|Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
223967869|NCT01436045|DRUG|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
224291435|NCT03531801|OTHER|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
224291436|NCT01508754|PROCEDURE|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
224291437|NCT06206083|GENETIC|Descriptive and analytical|Patients with EC endometroid
224291438|NCT05123677|DIAGNOSTIC_TEST|Non-invasive haemodynamic assessment|Maternal non-invasive haemodynamic assessment: a pressure cuff (similar to the one used to measure blood pressure) is applied to the arm and thigh, and a further neck sensor applied. Information about the function of heart and major blood vessels are recorded
224291439|NCT05123677|DIAGNOSTIC_TEST|Maternal ophthalmic artery doppler|Maternal ophthalmic artery doppler: an ultrasound probe is applied gently over the eyelid for a few seconds to study the blood flow of the main artery to the eye
224291440|NCT02442271|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
224291441|NCT02442271|DRUG|ribavirin|Tablet
224291442|NCT04764955|DIETARY_SUPPLEMENT|Placebo|This product is identical in appearance, taste and texture to the experimental formulation but does not include any vitamin D3.
224291443|NCT04764955|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). Each weekly dose consists of a single tablet. Vitamin D3 content of the dose depends on the intervention group.
224291444|NCT05955495|OTHER|Food|Post-operative feeding includes water, liquid diet, soft diet.
224291445|NCT04878614|DRUG|Levothyroxine Tablet|Standard clinical management
224291446|NCT04878614|DRUG|Levothyroxine Sodium|Liquid levothyroxine through enteral feeding tube
223967870|NCT01436045|DRUG|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
223967871|NCT03314116|OTHER|Guidance on auditory protection|by video or medic
223967872|NCT05664061|DRUG|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|twice daily inhalation throughout the treatment period
223967873|NCT05664061|DRUG|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the treatment period
223967874|NCT05664061|DRUG|Placebo|twice daily inhalation throughout the treatment period
223967875|NCT01265914|BIOLOGICAL|FP-01.1|Ascending doses of FP-01.1 will be administered
223724836|NCT05171595|DEVICE|Lifetouch single-lead ECG monitoring|The continuous wireless monitoring is a single-lead ECG patch (Isansys Life Touch patch) which consists of two ECG electrodes placed on the left side of the patients' thorax. The patch measures respiratory rate (RR), heart rate (HR), heart rate variability (HRV) and electrocardiogram (ECG)s.
223967876|NCT01265914|BIOLOGICAL|placebo|
223967877|NCT04532008|BEHAVIORAL|Group based treatment|12 sessions of group based therapy that included cognitive restructuring, behavioral activation, and interpersonal therapy
224291447|NCT04254835|DRUG|Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein|Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
223967878|NCT02580981|OTHER|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
223967879|NCT01328483|PROCEDURE|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
224112839|NCT06187415|BEHAVIORAL|Mobile app to reduce harm of chemsex|Access to the mobile app which includes PrEP diary, demistification of chemsex urban legends, information on the location of needle and syringe services program, and alert sending to emergency contact.
224112840|NCT05888337|DEVICE|Contoura LASIK with Phorcides planning strategy|Bilateral treatment with topography guided LASIK
224291448|NCT04254835|DRUG|Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein|Conventional Fluoride varnish
224291449|NCT02080832|DRUG|Citalopram|20 mg or 40 mg daily for 8 weeks
224112841|NCT05888337|DEVICE|Contoura LASIK with manifest refraction planning strategy|Bilateral treatment with topography guided LASIK
224112842|NCT04663620|BEHAVIORAL|Saving Babies Lives Programme|Comprehensive neonatal healthcare package
224112843|NCT04663620|BEHAVIORAL|No Saving Babies Lives Programme|No comprehensive neonatal healthcare package
224112844|NCT00404040|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
224112845|NCT00404040|DRUG|Lactulose|
224112846|NCT04874740|OTHER|No intervention|No intervention
224291450|NCT02080832|DRUG|Placebo|Placebo daily for 8 weeks
223724837|NCT05171595|DIAGNOSTIC_TEST|high-sensitive TnT measurements|Another monitoring device in the study was the plasma concentration of high-sensitive cardiac troponin T (hsTnT).
223724838|NCT04359550|BIOLOGICAL|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)|Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)
223967880|NCT03559296|DIAGNOSTIC_TEST|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
223967881|NCT05588739|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
223967882|NCT03852771|DEVICE|Cirvo(TM) therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
223967883|NCT01019824|DRUG|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
223967884|NCT00294879|PROCEDURE|pressure support ventilation at 0, 5, and 10% IRT|
223967885|NCT06416189|DEVICE|Fixed appliances|MBT Brackets 0.022 inch
223967886|NCT06301529|DRUG|Invokana Pill|100 mg and 150 mg doses, taken every day and every-other day, respectively.
223967887|NCT00170950|DRUG|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
223967888|NCT00170950|DRUG|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
223967889|NCT00170950|DRUG|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
223967890|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
224112847|NCT04430530|BIOLOGICAL|Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20|Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
224112848|NCT04132544|OTHER|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).
224112849|NCT04132544|OTHER|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home."
224291451|NCT01560507|DRUG|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
223724839|NCT04359550|OTHER|placebo|placebo
224112850|NCT04132544|OTHER|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
223967891|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
223967892|NCT00170950|DRUG|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
223967893|NCT06983808|OTHER|Digital Cardiac Prehabilitation|Digital Cardiac Prehabilitation - A combined telehealth and app-based preparation for cardiac surgery
223967894|NCT06983808|OTHER|Control (Standard treatment)|Standard preparation for surgery as per Melbourne Health hospital procedures and processes. This may include information sessions, pamphlets, and meetings with clinicians. This does not include a prehabilitation program.
223967895|NCT05351411|OTHER||Participants in the control group maintained their therapeutic routine and had the opportunity to take part in the combined progressive functional exercise intervention after follow-up assessments had been conducted.
223967896|NCT01307540|DEVICE|phototherapy|low level light therapy, broad band light wavelengths.
223967897|NCT03275467|OTHER|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
223967898|NCT06599632|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for spinal cord injury (SCI). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
223967899|NCT06752577|DRUG|Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)|Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
223967900|NCT06910241|DRUG|Lidocaine|Lidocaine local infiltration
223967901|NCT06910241|DRUG|Diphenhydramine|Diphenhydramine local infiltration
223967902|NCT01913288|OTHER|Biological Maternal Sounds|
223967903|NCT06096818|BEHAVIORAL|Experimental Group: Kegel exercises and abdominal exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6thweek+12th week). Each training: approx. 30 min.~First session:Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form,International Urinary Incontinence Consultation Questionnaire-Short Form,Pittsburgh Sleep Quality Scale) Information about stress urinary incontinence is given The woman is given kegel exercise and abdominal exercise training face to face by the researchers.~Kegel and abdominal exercise application chart is explained and given as homework.~Relevant brochure is provided. Second Session:Greeting-Kegel and abdominal exercise application chart is being checked Kegel and abdominal exercises are performed again under the supervision of the researcher.~Third session:Greeting-Kegel and abdominal exercise application chart is being checked Data collection tools are being refilled."
223967904|NCT06096818|BEHAVIORAL|Control Group: Kegel exercises|"The training was planned to occur 3 times in a 12-week period (first meeting+6th week+12th week). Each training: approx. 20 min.~First session: Meeting the woman Consent and data collection forms (Descriptive characteristics of women, Incontinence Impact Questionnaire-Short Form, International Urinary Incontinence Consultation Questionnaire-Short Form, Pittsburgh Sleep Quality Scale).~Information about stress urinary incontinence is given The woman is given kegel exercise training face to face by the researchers. Kegel exercise application chart is explained and given as homework. Relevant brochure is provided. Second Session:Greeting-Kegel exercise application chart is being checked Kegel exercises are performed again under the supervision of the researcher. Third session:Greeting-Kegel exercise application chart is being checked Data collection tools are being refilled."
223967905|NCT04137978|DRUG|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
223967906|NCT04137978|DRUG|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
223967907|NCT02956122|BIOLOGICAL|GLASSIA|GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]
223967908|NCT02956122|DRUG|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
223967909|NCT02956122|BIOLOGICAL|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
223724840|NCT02421523|PROCEDURE|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of \~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
223724841|NCT02421523|PROCEDURE|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of \~30% of the subject's MVC. Subjects will be asked to perform \~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (\~50% MVC). Similarly, if no damage has occurred at \~50% MVC, four more subjects exercise at \~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
223967910|NCT02868619|OTHER|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
223967911|NCT02868619|OTHER|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
223967912|NCT02868619|OTHER|R-CMAS scale|Evaluate the anxiety
223967913|NCT04882033|DRUG|Concurrent chemoradiotherapy plus anlotinib|"Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy."
223967914|NCT02364505|BEHAVIORAL|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
223967915|NCT02364505|BEHAVIORAL|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
223967916|NCT00635570|DRUG|Ortho Tri-cyclen Lo|Low dose oral contraceptive
224112851|NCT04132544|OTHER|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health \[series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address."
224112852|NCT00815308|DRUG|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
224112853|NCT00815308|DRUG|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
223967917|NCT00635570|DEVICE|NuvaRing|Contraceptive vaginal ring
224112854|NCT00815308|DRUG|Cisplatin|Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
224112855|NCT00815308|RADIATION|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
223724842|NCT02421523|PROCEDURE|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
223967918|NCT05298293|DEVICE|ONCOLAXY Follow-up|"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."
223967919|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
223967920|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
223967921|NCT01064882|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
223967922|NCT02303002|BIOLOGICAL|Botulinum Toxin Type A|Intramuscular injection (IM)
223967923|NCT02303002|BIOLOGICAL|Active Comparator botulinum toxin|IM injection
223967924|NCT02303002|BIOLOGICAL|Placebo Comparator|IM injection
223967925|NCT00092313|DRUG|MK0966, rofecoxib|
223967926|NCT00092313|DRUG|Comparator: oxycodone and acetaminophen|
223967927|NCT03053115|DRUG|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
223967928|NCT03053115|DRUG|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
223967929|NCT03053115|DRUG|Placebos|Controls will take placebo two hours after dinner
223967930|NCT02384083|DRUG|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 \& 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 \& 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
223967931|NCT03168009|PROCEDURE|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
223967932|NCT02657759|DIETARY_SUPPLEMENT|CARDICHOL|
223967933|NCT02657759|DIETARY_SUPPLEMENT|PLACEBO|
223967934|NCT02413099|DRUG|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
223967935|NCT03618212|DIAGNOSTIC_TEST|MRI|Skeletal MRI and pelvic and spinal MRI
223967936|NCT05384236|OTHER|kinesiology taping|To apply kinesiology taping in plantar fascia
224112856|NCT04541823|DRUG|Desﬂurane|Investigators administrated desflurane with target of BIS 40-60 during the maintenance of anesthesia
224112857|NCT04541823|DRUG|Propofol|Investigators administrated propofol with target of BIS 40-60 during the maintenance of anesthesia
223542744|NCT01079312|DRUG|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
223967937|NCT05384236|OTHER|taping or Low-dye taping|To apply taping or Low-dye taping in plantar fascia
224112858|NCT00456937|DRUG|Escitalopram|
224112859|NCT02940665|OTHER|ERAS|Patients in the ERAS group received the ERAS protocol
224112860|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
223542745|NCT01079312|DRUG|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
223724843|NCT05725109|OTHER|Hepatitis C Treatment Alerts in CHORUS™|Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based healthcare analytics and reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients with certain conditions who have a scheduled appointment in the coming week and may require close attention. CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. In the after period of this study, the alert will identify patients with active hepatitis C infection.
223967938|NCT05117385|DIETARY_SUPPLEMENT|Botanical extract|1 capsule per day
224112861|NCT02171715|DRUG|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
224112862|NCT02171715|DRUG|BIBW 2992 MA2|powder for oral solution
224112863|NCT05205707|DIAGNOSTIC_TEST|ACE serum levels|Circulating ACE2 level will be measured
224112864|NCT04370262|DRUG|SOC + Intravenous Famotidine|Standard of Care treatment plus IV famotidine
224112865|NCT04370262|DRUG|SOC + Placebo|Standard of Care treatment plus IV placebo
224112866|NCT00046826|DRUG|docetaxel|
224112867|NCT00046826|DRUG|estramustine phosphate sodium|
224112868|NCT00046826|DRUG|thalidomide|
224112869|NCT02307968|OTHER|insulin injection site|insulin injected site between inner thigh and out thigh
224112870|NCT05783258|PROCEDURE|Periodontal surgery with CAF+tSCTG|Coronally advanced flap and subepithelial connective tissue graft harvested from the maxillary tuberosity area.
224112871|NCT05783258|PROCEDURE|Periodontal surgery with CAF+L-PRF|Coronally advanced flap and L-PRF membranes
224112872|NCT01520792|DRUG|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
224291452|NCT01560507|DRUG|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
223967939|NCT00613223|DRUG|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
223967940|NCT05515913|OTHER|Nutritional status|Nutritional status of children as analyzed by anthropometric indices was under study
224112873|NCT03320512|BEHAVIORAL|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
224112874|NCT03320512|BEHAVIORAL|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
224112875|NCT03320512|BEHAVIORAL|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
224112876|NCT01460836|DRUG|Tobramycin solution for inhalation|
224112877|NCT01460836|DRUG|Aztreonam lysine for inhalation|
224291453|NCT01560507|DRUG|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
224291454|NCT05318209|OTHER|Exercise|Closed-chain Shoulder Girdle Scapular Depression Exercise
224291455|NCT03173053|DRUG|Doxycycline|tablet
224291456|NCT03173053|DRUG|Trimethoprim|tablet
224291457|NCT03173053|DRUG|Sulfamethoxazole/trimethoprim|tablet
224291458|NCT03173053|DRUG|Clindamycin|tablet
224291459|NCT03173053|DRUG|Clarithromycin|tablet
223967941|NCT05515913|BEHAVIORAL|Eating behavior|The eating behavior of ASD children as analyzed by frequency of refusal of new food, sensitivity to food, food allergy and gastrointestinal systems was under study
223967942|NCT05515913|OTHER|Urine iodine concentration|the 24 urine iodine concentration of all subjects was under study
223967943|NCT05515913|OTHER|Nutrient intake|The nutrient intake as analyzed by three days food diary and major meal proximate analysis of subjects was under study
223967944|NCT05515913|OTHER|Dietary assessment|The food frequency and dietary diversity of all subjects as analyzed by food frequency questioner, dietary diversity score and food variety score was under study
224291460|NCT03173053|DRUG|Ciprofloxacin|tablet
224291461|NCT03173053|DRUG|Fusidic Acid|tablet or ointment
224291462|NCT03173053|DRUG|Rifampin|tablet
224291463|NCT03173053|DRUG|Chlorhexidine|Mouthwash or bodywash
224291464|NCT03173053|DRUG|Mupirocin|Nasal ointment
224291465|NCT03173053|DRUG|Betadine|Shampoo
224291466|NCT00333723|DRUG|Rosiglitazone|
224291467|NCT00893451|DRUG|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
224291468|NCT00893451|DRUG|Placebo|Placebo orally twice daily
224291469|NCT00785681|DRUG|Dermacyd PH_DETINBACK (Lactic Acid)|
224291470|NCT03199313|DRUG|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
223542746|NCT06047743|OTHER|Alternating unilateral Isometric Handgrip Exercise|Participants (n=19) will be performing alternating unilateral Isometric Handgrip exercises using a dynamometer for 3-5 days a week for a total duration of 8 weeks. The participant will be seated with their elbow resting on the armrest and wrists off the supporting surface. A single session will consist of 4 sets of 30%MVC (calculated by dynamometer) of handgrip exercise with a maximum 2 minutes contraction time/ hold time followed by a rest period/ recovery period of 1 minute during each set.
223542747|NCT06047743|OTHER|Dominant knee extension Isometric Exercise|Participants enrolled in this group will be performing dominant leg isometric knee extension. The knee will be 35° flexed from a fully extended position when performing isometric knee extension using a hand-held dynamometer retrained by a belt. The intervention duration will be 8 weeks. A single session will consist of performing 4 sets of 30% MVC (calculated using a dynamometer) of unilateral knee extension isometrics with a maximum 2 minutes contraction time/ hold time followed by a rest/ recovery period of 1 minute during each set.
223967945|NCT05515913|OTHER|Childhood autism rating scale|The autistic severity of ASD diagnosed children was under study as analyzed by childhood autism rating scale diagnosis
223542748|NCT02795494|BEHAVIORAL|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
223542749|NCT02795494|BEHAVIORAL|ASK-P questionnaire at baseline|Patient-reported activity level score
223542750|NCT02795494|BEHAVIORAL|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
223967946|NCT06640998|DEVICE|Matrix Pro|Study subjects received up to three (3) study treatments with the Matrix Pro applicator
223967947|NCT01189617|DEVICE|Formula PD-F-7619|Off-White to Beige Lotion
223967948|NCT00021021|BIOLOGICAL|anti-FLT-1 ribozyme|
224112878|NCT02128581|DRUG|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
224112879|NCT02128581|OTHER|Saline|
224112880|NCT00487812|PROCEDURE|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
224112881|NCT04248010|DEVICE|neuroConn DC-Stimulator MR|standard tDCS, active \& sham
224112882|NCT04248010|DEVICE|Soterix MxN HD-tES|HD-tDCS, active \& sham
224112883|NCT03844971|PROCEDURE|Computer assisted arthrocentesis of|Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
224112884|NCT04076761|DRUG|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
224112885|NCT06449261|OTHER|Spinal Manual therapy used in Physiotherapy Practice|C5-C6 and thoracic spine mobilization with postural correction
224291471|NCT03199313|DRUG|Placebo|Matching Sutezolid placebo
224291472|NCT01118117|DEVICE|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
224291473|NCT04881734|OTHER|Overtime pancreaticoduodenectomy|Compared with daytime surgery, the intervention in this study is to work overtime after 17:00 to perform pancreaticoduodenectomy.
223542751|NCT02550015|BEHAVIORAL|High intensity interval training|Uphill treadmill walking
223542752|NCT02550015|BEHAVIORAL|General information|Standard care
223967949|NCT05389254|DEVICE|continuous glucose monitoring system|use real-time CGM system to check and adjust blood glucose
223967950|NCT05389254|DEVICE|capillary blood glucose monitoring|monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
223967951|NCT01565239|DEVICE|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
223967952|NCT02452125|DIETARY_SUPPLEMENT|Nicotine gum|Nicotine chewing gum
224112886|NCT06096194|DIETARY_SUPPLEMENT|vitamin D-enhanced egg|"In our study, the vitamin D3-enhanced eggs were produced by hens that received 23,500 IU of vitamin D3 per kg of feed. Which does not confer them any harm or danger of intoxication. This experiment was carried out at the Center for Teaching, Research and Extension in Poultry Production (CEIEPAv, FMVZ-UNAM) and lasted 40 weeks.~This ensured that the hens eggs were enhanced with vitamin D achieving a final concentration of approximately 400 IU of vitamin D"
223967953|NCT02640807|DRUG|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) \>2.5 or platelet count \< 35,000
224112887|NCT06096194|OTHER|Control|Unfortified eggs were used for the control group with a concentration of approximately 43 IU of vitamin D
223724844|NCT05725109|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients with active hepatitis C infection will be disseminated.
223724845|NCT04047394|DRUG|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
223967954|NCT02640807|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
223967955|NCT04493983|PROCEDURE|laparoscopic salpingo-oophorectomy|Laparoscopic bilateral salpingo-oophorectomy
224112888|NCT00638846|DEVICE|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
224112889|NCT00638846|DEVICE|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
224112890|NCT01667744|DRUG|Citalopram|10 mg/day
224112891|NCT02569489|DRUG|HBI-8000|
224112892|NCT02569489|DRUG|Trastuzumab|
224112893|NCT02569489|DRUG|Paclitaxel|
224291474|NCT00549016|DEVICE|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
223967956|NCT04493983|PROCEDURE|Laparoscopic bilateral salpingo-oophorectomy|Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
223542753|NCT06168240|OTHER|Manual lymphatic drainage. will be applied three days per week for four weeks.|Training will applied 3 days a week, for a total of 4 weeks.
223542754|NCT05691920|PROCEDURE|Pectointercostal plane block and external oblique intercostal plane block|Patients will be subjected to bilateral external oblique intercostal plane and pectointercostal plane blocks
223542755|NCT05691920|PROCEDURE|Fentanyl infusion|Patients will be subjected to fentanyl infusion at a rate of 1μg/kg/h
223542756|NCT01298843|DRUG|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
223967957|NCT02599077|DRUG|Dienogest|patients assigned to this treatment receive 2 milligrams per day
223967958|NCT02599077|DRUG|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
223967959|NCT04902196|OTHER|high intensity cardiorespiratory exercise protocol|During the high intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, a high-intensity interval protocol is started, consisting of five one-minute bouts (110 reps/minute at 100% VO2max workload), separated by one minute of active rest (75 reps per minute at 50% VO2max workload).
223967960|NCT04902196|OTHER|moderate intensity cardiorespiratory exercise protocol|During the moderate intensive cardiorespiratory exercise protocol, a bicycle ergometer (eBike Basic, General Electric GmbH, Bitz, Germany) with pulmonary gas exchange analysis (MetaMax 3B, Cortex Biophysik GmbH, Leipzig, Germany) will be used. Oxygen uptake (VO2max), expiratory volume (VE) and respiratory exchange rate (RER) will be tracked every breath and an average will be taken every 10s. Heart rate is continuously monitored using a heart rate chest strap (Polar Electro Inc., Finland). After a five-minute warm-up, participants begin a moderately-intensive continuous 14-minute exercise protocol at a stable resistance (90 repetitions per minute at 60% VO2max workload).
223967961|NCT01502787|DRUG|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
224112894|NCT04055935|PROCEDURE|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
224112895|NCT04055935|DEVICE|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
224112896|NCT02428140|DEVICE|Medtronic Reveal LINQ|
224112897|NCT02428140|DEVICE|Sorin Spiderflash-t|
224112898|NCT04653415|DRUG|Gabapentin 300mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
224112899|NCT04653415|DRUG|Methylprednisolone 125 mg|"The study group will receive as pre-emptive analgesia a single dose of 300 mg oral gabapentin and 125 mg intravenous methylprednisolone."
224112900|NCT04653415|DRUG|Tablet|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
224112901|NCT04653415|DRUG|Normal Saline 10 mL Injection|The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
223724846|NCT04633694|DIETARY_SUPPLEMENT|insect, pea or whey protein|The protein powder is dissolved in 400 mL water and given relative to lean body mass, 0.25 g protein pr kg lean body mass.
223967962|NCT01502787|DRUG|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
223967963|NCT01502787|PROCEDURE|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
223967964|NCT01502787|PROCEDURE|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
223967965|NCT01502787|PROCEDURE|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
223967966|NCT01502787|PROCEDURE|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
223967967|NCT01502787|DRUG|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
223967968|NCT00377312|DRUG|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
223967969|NCT02775214|DEVICE|Video Laryngoscopy|
223967970|NCT06227442|DIAGNOSTIC_TEST|KDIGO criteria of 2010|They are guidelines for the diagnosis, evaluation, and management of chronic kidney disease (CKD). They cover the classification of CKD stages based on glomerular filtration rate and albuminuria, criteria for diagnosing acute kidney injury, and recommendations for managing CKD-related complications.
223967971|NCT00192166|BIOLOGICAL|CAIV-T|
223967972|NCT03398434|DRUG|MAA868|3 MAA868 doses, single administration, subcutaneous,
223967973|NCT03398434|DRUG|Apixaban|Apixaban 5 mg b.i.d
223967974|NCT00762723|DEVICE|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
223967975|NCT02751645|PROCEDURE|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
223724847|NCT00600483|DRUG|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
223724848|NCT04540211|DRUG|Atezolizumab|Atezolizumab at a fixed dose of 1200 milligrams (mg) administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.
223967976|NCT02145897|BIOLOGICAL|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
223724849|NCT04540211|DRUG|Tiragolumab|Tiragolumab at a fixed dose of 600 mg administered by IV infusion every Q3W on Day 1 of each 21-day cycle.
223724850|NCT04540211|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
223724851|NCT04540211|DRUG|Cisplatin|Cisplatin 60-80 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle for 6 cycles.
224112902|NCT01070615|DRUG|Prucalopride|
223967977|NCT02145897|BIOLOGICAL|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
223967978|NCT02145897|OTHER|Control|
223967979|NCT03279536|COMBINATION_PRODUCT|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
223967980|NCT03279536|COMBINATION_PRODUCT|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
223967981|NCT02671578|DRUG|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
223967982|NCT01145417|DRUG|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
223967983|NCT00045097|DRUG|ixabepilone|
223967984|NCT02779283|DRUG|Cyclophosphamide|Given IV
223967985|NCT02779283|DRUG|Cytarabine|Given IV
224112903|NCT05519943|BEHAVIORAL|The Friends program|A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
224112904|NCT05519943|BEHAVIORAL|TAU condition|A TAU waitlist condition during which participants received routine care services tailored to each child individually.
224112905|NCT00823329|DEVICE|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
224291475|NCT00961454|DEVICE|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
224291476|NCT03327090|OTHER|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
224112906|NCT04135625|BEHAVIORAL|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
224291477|NCT05530473|DEVICE|capsular tension ring|To insert a capsular tension ring during the cataract surgery
224291478|NCT00403182|DRUG|chemotherapy|
224291479|NCT00403182|DRUG|letrozole|
224291480|NCT04948229|OTHER|Blood serum samples|Blood serum samples will be taken.
224291481|NCT06616376|OTHER|Anti-Embolism Stocking|To prevent patients undergoing TKA surgery from being affected by one another, the patients were hospitalized in separate rooms, and the orthopedic clinic team was made aware of the situation. The patients in the control group were told not to remove their socks until the sutures were removed after the operation, whereas the patients in the experimental group were told to remove their socks on the 10th day after the operation, so the patients had no idea which group they were in.
223724852|NCT04540211|DRUG|Atezolizumab Matching Placebo|Atezolizumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
224291482|NCT05061576|BEHAVIORAL|Standard of Care advice on physical activity|Oral advice on exercise from a physician.
224291483|NCT05061576|BEHAVIORAL|Structured advice on physical activity|A leaflet with instructions and images on different forms of physical activities as well as clear recommendations on when to perform these.
224291484|NCT04579276|PROCEDURE|Thoracic paravertebral block|Intrathoracic method undergone through video assisted surgery (VATS
224291485|NCT04579276|PROCEDURE|thoracic epidural analgesia|locoregional analgesia under ultrasound control
224291486|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique + PRF|
223967986|NCT02779283|DRUG|Dasatinib|Given PO
223967987|NCT02779283|DRUG|Dexamethasone|Given PO
223967988|NCT02779283|DRUG|Doxorubicin Hydrochloride|Given IV
224291487|NCT03169920|PROCEDURE|Modified-Minimally Invasive Surgical Technique|
224291488|NCT00398931|DRUG|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
224291489|NCT00398931|DRUG|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
224291490|NCT05402462|DIAGNOSTIC_TEST|upper endoscopy|detect esphageal motility disorder by upper endoscopy and esophageal manometry
224291491|NCT03545191|DRUG|Daridorexant 25 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
224291492|NCT03545191|DRUG|Daridorexant 50 mg|Daridorexant will be administered as tablets, orally, once daily in the evening.
224291493|NCT03545191|OTHER|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
224291494|NCT00196131|DRUG|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
223967989|NCT02779283|DRUG|Idarubicin|Given IV
223967990|NCT02779283|DRUG|Idelalisib|Given PO
223967991|NCT02779283|DEVICE|In Vitro Kinase Inhibitor Assay|Correlative studies
223967992|NCT02779283|DRUG|Leucovorin Calcium|Given IV
223967993|NCT02779283|DRUG|Methotrexate|Given IV
223967994|NCT02779283|DRUG|Methylprednisolone Sodium Succinate|Given IV
223967995|NCT02779283|DRUG|Ponatinib Hydrochloride|Given PO
223967996|NCT02779283|BIOLOGICAL|Rituximab|Given IV
223967997|NCT02779283|DRUG|Ruxolitinib Phosphate|Given PO
223967998|NCT02779283|DRUG|Sorafenib Tosylate|Given PO
223967999|NCT02779283|DRUG|Sunitinib Malate|Given PO
223968000|NCT02779283|DRUG|Vincristine Sulfate|Given IV
224291495|NCT04765774|OTHER|Ekspressive touch|Patients will be divided into three groups. The expressive touch group will touch the patient's hand.
224291496|NCT04765774|OTHER|Music|The music chosen by the patient will be played in the music group.
224291497|NCT05585931|DRUG|TPN171H 10mg|Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.
223968001|NCT05082662|DRUG|Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)|One Diclofenac tablet was administered orally.
224291498|NCT05585931|DRUG|TPN171H Placebo|Subjects were given Placebo with 240 mL warm water under fasting condition.
224291499|NCT03179163|DRUG|Captopril Pill|ACEi+SH
224291500|NCT03179163|DRUG|Enalapril Pill|ACEi
224291501|NCT03179163|DRUG|Hydrochlorothiazide|diuretic
224291502|NCT01709279|BIOLOGICAL|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
224291503|NCT02139917|BEHAVIORAL|Transitional community based palliative care|"transitional palliative care include:-~* telephone follow up for early identification of signs and symptoms~* relief of signs and symptoms encountered~* home visit with spiritual support"
224291504|NCT01277718|DRUG|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
224291505|NCT01277718|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
224291506|NCT01524913|DRUG|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
223968002|NCT05082662|DRUG|Cataflam® 50 coated tablet|One Diclofenac tablet was administered orally.
223968003|NCT02185365|RADIATION|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
223968004|NCT01191697|DRUG|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
223968005|NCT01191697|DRUG|trastuzumab|Given intravenously on day 1 of each treatment cycle
223968006|NCT01191697|DRUG|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
223968007|NCT01191697|DRUG|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
223968008|NCT03939793|BEHAVIORAL|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~1. Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~2. Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
223968009|NCT03939793|BEHAVIORAL|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
223968010|NCT03939793|OTHER|Usual Care|Usual Care
223968011|NCT06154798|BEHAVIORAL|World Digital Detox Women's Health Program|World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
223968012|NCT04232488|PROCEDURE|coronary angiography using distal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using distal radial artery ('snuff box'); color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
223968013|NCT04232488|PROCEDURE|coronary angiography using proximal radial artery|Patients undergoing coronary angiography with or without percutaneous coronary intervention will be catheterised using proximal radial artery; color doppler will be performed after 3 months to estimate eventual occlusion of the radial artery
223968014|NCT00635011|BEHAVIORAL|psychotherapy|Cognitive Behavioral therapy
224112907|NCT04135625|BEHAVIORAL|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
224112908|NCT06126445|DEVICE|Battery operated toothbrush|Device on plaque removal efficacy
224112909|NCT06126445|DEVICE|Manual toothbrush|Device on plaque removal efficacy
224291507|NCT01524913|DRUG|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
224291508|NCT01524913|DRUG|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
224291509|NCT01598519|BEHAVIORAL|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
224291510|NCT00005823|DRUG|cytarabine|
224291511|NCT00005823|DRUG|daunorubicin hydrochloride|
224291512|NCT00005823|DRUG|etoposide|
224291513|NCT00005823|DRUG|hydroxyurea|
224291514|NCT00005823|DRUG|idarubicin|
224291515|NCT00005823|DRUG|mitoxantrone hydrochloride|
224291516|NCT00005823|DRUG|thioguanine|
224291517|NCT00005823|DRUG|tretinoin|
224291518|NCT00005823|DRUG|valspodar|
224291519|NCT04334655|OTHER|Physical Therapy|Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
223968015|NCT04113902|BEHAVIORAL|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
223724853|NCT04540211|DRUG|Tiragolumab Matching Placebo|Tiragolumab matching placebo administered by IV infusion, Q3W on Day 1 of each 21-day cycle.
223724854|NCT01482884|DRUG|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
223968016|NCT01514630|DRUG|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
224112910|NCT02758145|OTHER|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
224291520|NCT04706923|DRUG|BCV|Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.
223968017|NCT01170871|DRUG|Ixabepilone|
223968018|NCT01170871|DRUG|Pemetrexed|
223968019|NCT03861429|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
224112911|NCT04589494|DRUG|Tramadol Hydrochloride|tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily
224112912|NCT05767957|OTHER|Rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist using conventional technique alone.
223724855|NCT01482884|DRUG|placebo|2 sc injections of every 2 weeks for 12 weeks.
223724856|NCT01408004|DRUG|Pazopanib|Tablet 800mg qd til progression
223724857|NCT01408004|DRUG|Everolimus|tablet 10 mg qd til progression
223724858|NCT01408004|DRUG|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
223724859|NCT01408004|DRUG|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
223724860|NCT01408004|DRUG|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
223724861|NCT01408004|DRUG|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
223724862|NCT04966715|PROCEDURE|Epigastric lymph node biopsy|epigastric lymph node biopsy and analysis to evaluate rate dissemination of colorectal carcinomatosis by this way
223724863|NCT04147208|DRUG|GLS4|Administered GLS4 120 mg orally three times daily in fed state
223724864|NCT04147208|DRUG|RTV|Administered RTV 100 mg orally three times daily in fed state
223968020|NCT02338778|BIOLOGICAL|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
223968021|NCT02338778|OTHER|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
223968022|NCT01447251|BEHAVIORAL|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.
223968023|NCT00529555|DRUG|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
223968024|NCT00529555|PROCEDURE|Scaling and root planing|scaling and root planing
223968025|NCT04985747|OTHER|Polished palatal surface|Polishing of the anterior palatal surface using a polisher
223968026|NCT04985747|OTHER|Roughened palatal surface|Roughening of the anterior palatal surface using a sandblaster
224112913|NCT05767957|OTHER|Cognitive-behavioral therapies in addition to rehabilitation physiotherapy|Rehabilitation physiotherapy by physiotherapist according to conventional technique, with the addition of techniques from cognitive-behavioral therapies.
224112914|NCT05502848|BEHAVIORAL|Internet Cognitive Behavior Therapy|ICBT helps change patterns of thinking (cognitions) and behaviors of psychological distress, including relaxation, stress management, while using ICBT can increase personal tolerance for negative thoughts and negative emotions, help patients reduce negative perception of the disease due to long-term recurrent itching, and break the vicious cycle
224291521|NCT04969159|OTHER|no intervention|standard treatment in the clinical routine
224291522|NCT05094752|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
224291523|NCT05094752|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
224291524|NCT04566705|OTHER|Risks factors, maternal and neonatal outcomes/complications|Risks factors, maternal and neonatal outcomes/complications
224291525|NCT03339505|DIETARY_SUPPLEMENT|Salovum|Dietary supplement with high concentration of anti-secretory factor
224291526|NCT03339505|DIETARY_SUPPLEMENT|Placebo|Placebo for Salovum
224291527|NCT04785508|DEVICE|neuromuscolar tape|neuromuscalar tape application in decompression technique (hand and arm)
224291528|NCT04785508|BEHAVIORAL|antigravity arm position|antigravity arm position
224291529|NCT00872326|PROCEDURE|Autologous Bone Marrow Mononuclear Cells|Infusion \> 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
224291530|NCT04758663|BEHAVIORAL|Nap/wake conditions on memory|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities.
224291531|NCT04758663|BEHAVIORAL|Nap/wake conditions on overnight physiology|Habitual and non-habitual napping children will complete a two conditions-a nap condition where they are encouraged to nap in the afternoon and a wake condition where instead of napping, they spend an equal amount of time awake engaging in quiet activities. On the nights of the nap and wake conditions, physiology will be recorded in habitual and non-habitual nappers.
224291532|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg on alternate weeks
224291533|NCT00686439|DRUG|adalimumab|subcutaneous injection 40mg every other week
224291534|NCT02728011|OTHER|Scientific Brain Training (SBT)|Cognitive training
223968027|NCT04985747|OTHER|Opened palatal surface|Opening of the anterior palatal surface using acrylic bur
223968028|NCT03974451|DEVICE|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
224291535|NCT02728011|OTHER|Tetris|
224291536|NCT06371144|DRUG|Paracetamol|Analgestic
224291537|NCT02181296|DRUG|ropivacaine|
224291538|NCT00378716|DRUG|5-fluorouracil|
224291539|NCT00378716|DRUG|leucovorin calcium|
223724865|NCT04147208|DRUG|ETV|Administered orally ETV 0.5 mg once daily in fasted state
223968029|NCT03974451|DEVICE|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
223968030|NCT06538727|OTHER|Osteopathic Manipulation Treatment - Scapular Release|First, the patient will be positioned in the supine position. The physician or trained fellow will then place his/her hands on the medial border of the scapula on the affected side. From the paraspinal fascia to the medial border of the scapula a lateral traction is added along with a superior to inferior traction and additionally an inferior to superior traction. The shoulder will be used as an additional fulcrum by having the shoulder in the forward flexion position at 90 degrees and then adduction of the humerus to aid in addition movement of the scapula by moving the upper arm into adduction and abduction in a rhythmic motion. The treatment with a rhythmic and/or static traction in the motions described above and manual movement of the scapula will be done for a maximum of 15 minutes.
223968031|NCT01372735|RADIATION|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
224112915|NCT00390923|DRUG|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
224112916|NCT00390923|DRUG|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
224112917|NCT04397055|DIETARY_SUPPLEMENT|Cottonseed Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Cottonseed Oil
224112918|NCT04397055|DIETARY_SUPPLEMENT|Olive Oil|Participants are provided about 60% of their required energy for 8 weeks as foods from a 5 day cycle menu that are enriched with Olive Oil
224112919|NCT01171521|DEVICE|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
224112920|NCT03604328|DRUG|PA5108|single ocular implant, administered on day 1
224112921|NCT04441931|DRUG|LY3832479|Administered IV.
224112922|NCT04441931|DRUG|Placebo|Administered IV.
223968032|NCT01372735|RADIATION|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
224112923|NCT04252807|BEHAVIORAL|Intervention arm|In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
223968033|NCT01553578|OTHER|questionnaire administration|Ancillary studies
223968034|NCT01553578|PROCEDURE|therapeutic touch|Receive healing touch therapy
223968035|NCT01553578|BEHAVIORAL|management of therapy complications|Receive healing touch therapy
223968036|NCT01553578|BEHAVIORAL|management of therapy complications|Receive guided imagery audiotapes
223968037|NCT01553578|PROCEDURE|standard follow-up care|Receive standard care
224112924|NCT04252807|OTHER|Treatment as Usual|The participants in the control arm will receive the routine visits by LHWs of their respective areas. The LHWs are trained to provide antenatal care and referral, immunization services and support to community mobilization, provision of family planning and basic curative care via door to door visits to the households of their allocated areas.
224291540|NCT00378716|DRUG|tegafur|
224291541|NCT00378716|DRUG|uracil|
223724866|NCT02304172|DEVICE|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
223724867|NCT02304172|DEVICE|Harmonic (Group B)|hemostatic device utilized intraoperatively
223724868|NCT05403905|PROCEDURE|non surgical treatment|Conservative treatment is required to use a curved splint for 6 weeks to keep the feet on the ground, bathing and sleeping without loosening the utensils and taking no steroids during the period. Physical examination and magnetic resonance imaging were performed after 6 weeks. If laxity remained unsatisfactory, the outcome was recorded as failure and surgery was changed.
223968038|NCT03383029|BEHAVIORAL|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
223968039|NCT01842399|DIETARY_SUPPLEMENT|Resveratrol|Nutriceutical
223968040|NCT01842399|DRUG|Placebo|2x/day orally
223968041|NCT03661749|OTHER|clean catch|clean catch technique applied to collect urine for PR/CR ratio
223968042|NCT04330261|OTHER|Exposure (not intervention) - SARS-CoV-2 infection|Exposure is infection with the virus. There is no intervention
223968043|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
223968044|NCT01149499|DRUG|Valacyclovir|1000 mg Tablet
223968045|NCT03327051|DRUG|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
223968046|NCT03327051|DIETARY_SUPPLEMENT|VSL #3|Probiotics
224112925|NCT04591288|OTHER|Functional Electrical Stimulation protocol|FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
223968047|NCT03327051|DRUG|Placebo|Placebo to match omeprazole
223968048|NCT03266003|OTHER|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
223968049|NCT03266003|OTHER|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
223968050|NCT00424723|DRUG|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
223968051|NCT02271737|BEHAVIORAL|Training HC/VHSG, Health Education, and Supportive Supervision|1\. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
223968052|NCT02790047|DEVICE|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
223968053|NCT02790047|OTHER|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
223968054|NCT02790047|OTHER|Health education|"Health education include~1. Knowledge of COPD disease~2. Smoking status and smoking cessation~3. Medication correctly~4. Self dyspnea management~5. Basic nutrition for COPD"
223968055|NCT02790047|OTHER|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~1. Control breathing~2. Pursed lip breathing (PLB)~3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~4. Force expiratory technique (FET) with low to medium lung volume~5. Huffing or coughing"
224112926|NCT04591288|OTHER|Treadmill only protocol|We will implement a 12-wk Treadmill training protocol consisting of treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
224112927|NCT00703807|DRUG|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
224112928|NCT00703807|DRUG|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
224112929|NCT03384511|DRUG|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
224112930|NCT00652093|DRUG|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
224112931|NCT00652093|DRUG|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
223724869|NCT05403905|PROCEDURE|surgical treatment|The patient underwent knee arthroscopic anterior cruciate ligament surgery at the Institute of Sports Medicine of the Third Hospital of Peking University. The surgical methods were all anatomical single-bundle.
224112932|NCT00652093|DRUG|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
223724870|NCT00580606|DRUG|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
223724871|NCT00580606|DRUG|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
223968056|NCT02790047|DRUG|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~3. Xanthine derivative (sustained release theophylline)~4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
223968057|NCT05789927|PROCEDURE|Assessment of the microbial exposome|The assessment of the microbial exposome will be carried out by the deployment of 4 dust collectors (1 per season) at the patient's home. The evaluation of the endogenous myco-microbiome will be carried out by analyzing patient sputum obtained during follow-up visits or during routine care in the event of an exacerbation.
223968058|NCT06108752|OTHER|Scapular stabilization exercises|The scapular stabilization exercises will be comprised of four exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
223968059|NCT06108752|OTHER|Thoracic extension exercises|Thoracic extension exercises will be comprised of three exercise programs. Each exercise will be performed with two sets of 15 reps, 10 sec per rep 40 min per day, thrice per week for a total of six weeks. Baseline treatment will be the application of a hot pack for 7-10 minutes and cervical active range of motion exercises.
223968060|NCT03086070|DRUG|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
224112933|NCT00652093|DRUG|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
223724872|NCT05376124|OTHER|original therapy|* Patients on ETV 0.5mg/ day or TDF 300mg/ day or TAF 25mg/ day continued the original regimen (ETV 1.0mg/ day or TDF 300mg/ day or TAF 25mg/ day), Oral treatment lasted 48 weeks ②Patients who received TDF 300mg/ day plus ETV 0.5mg/ day on initial treatment continued with the original regimen (TDF 300mg/ day plus ETV 0.5mg/ day) and oral therapy for 48 weeks ③Patients who received TAF 25mg/ day plus ETV 0.5mg/ day as initial treatment continued the original regimen (TAF 25mg/ day plus ETV 0.5mg/ day) for 48 weeks of oral therapy
223724873|NCT05376124|OTHER|rescue therapy|TDF 300mg/ day +ETV 1.0mg/ day or TAF 25mg/ day +ETV 1.0mg/ day, oral treatment for 48 weeks.
223724874|NCT05730751|PROCEDURE|spinal anesthesia|spinal anesthesia
223724875|NCT05730751|PROCEDURE|caesarean section|LSCS
223724876|NCT01831193|DRUG|Curcumin|
223724877|NCT05951504|DRUG|Methylprednisolone|Patients with an odontogenic cervicofacial infection were randomized between two intervention groups. Patients in one group were treated with one dose of Solumedrol 125mg intravenous at time of surgery. Patients with an odontogenic cervicofacial infection in the other group were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.
223968061|NCT03086070|DRUG|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
223968062|NCT04939883|DRUG|Carvedilol|Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
224112934|NCT00652093|DRUG|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
224112935|NCT00652093|DRUG|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
224112936|NCT06048016|DIAGNOSTIC_TEST|Scaling and Root Planning|Scaling and Root Planning by using ultrasonic scaler ,and Gracy currettes.
224112937|NCT02502877|DRUG|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
223968063|NCT04939883|DRUG|Placebo|Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
223968064|NCT05335239|OTHER|Professional dental cleaning|The dental nurse will visit at home and delivers professional dental cleaning, a reminder to use the fluoridated toothpaste (\> 4000 ppm ) and oral hygiene instruction to participants accompanied by home care aides, with manual toothbrush, fluoridated toothpaste (\> 4000 ppm) and relevant interproximal aids.
223968065|NCT04015128|DEVICE|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
223968066|NCT04402021|BEHAVIORAL|Outdoor Walking|Unsupervised outdoor walking will be the mode used for moderate-intensity aerobic exercise. The walking intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
223968067|NCT04402021|OTHER|Quiet Rest|The quiet rest condition will consist of watching a nature documentary in a quiet room. The quiet rest intervention will consist of 3 sessions (completed within the span of 7 days) that are conducted in the morning.
223724878|NCT02352350|OTHER|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
223724879|NCT02352350|OTHER|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
223968068|NCT01846637|PROCEDURE|laparoscopic sleeve gastrectomy|
223968069|NCT03440788|DRUG|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
223968070|NCT04717362|DRUG|Natesto Nasal Product|Nasally administered exogenous 4.5% testosterone gel, administered from a non-pressurized, manual pump dispenser equipped with a specialized nasal applicator which administers 125uL (5.5mg of testosterone).
223968071|NCT02650726|DIETARY_SUPPLEMENT|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
223968072|NCT02650726|OTHER|Placebo|placebo 320mg daily for 24 weeks
224112938|NCT02502877|DRUG|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
224112939|NCT02502877|DRUG|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
224112940|NCT02502877|DEVICE|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
224112941|NCT06080347|OTHER|Anti-inflammatory Diet|Dietary intervention
224112942|NCT06080347|OTHER|Healthy Diet|Dietary intervention
223968073|NCT03586752|OTHER|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
223968074|NCT03586752|OTHER|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
223968075|NCT04595097|DEVICE|inspiratory muscle traiing|The patients are encouraged to inhale against a load to increase the inspiratory muscle strength and endurance
223968076|NCT01259440|BEHAVIORAL|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
223968077|NCT01259440|BEHAVIORAL|Usual Care|Consists of one week telephone call and one month clinic visit
223968078|NCT02924181|DEVICE|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
223968079|NCT06423859|DRUG|Articaine|supraclavicular brachial plexus block with articaine 2%
223968080|NCT06423859|DRUG|Dexmedetomidine|supraclavicular brachial plexus block with articaine 2% in addition with Dexmedetomidine
223968081|NCT01862185|OTHER|semi-quantitative procalcitonin|
223968082|NCT02966600|OTHER|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
223968083|NCT02966600|OTHER|Physical Activity|The control group followed its usual weekly physical activity routine
223968084|NCT03058237|DRUG|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
223968085|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
223968086|NCT03058237|DRUG|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
223968087|NCT03058237|DRUG|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
223968088|NCT05269147|PROCEDURE|Sphenopalatine Ganglion Block (SPGB)|"The SPGB will be done after the patient is generally anesthetized and will be performed by the operating surgeon using a transnasal endoscopic approach through the posterior and over the middle turbinate tail in the pterygopalatine fossa.~The patient will be placed in the supine position with head extension. The prepared solution (4 ccs 2% lidocaine or 0.5% bupivacaine or normal saline and 1 cc 8 mg dexamethasone) will be given (2,5 cc) to each side of the nose.~The surgery was started 10 minutes after the application of SPBG to allow sufficient time for the block to develop."
223968089|NCT02150083|PROCEDURE|OR retrograde fill|
223968090|NCT03461211|BIOLOGICAL|Teprotumumab|Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
223968091|NCT01284634|DRUG|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
223968092|NCT01284634|DRUG|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
223968093|NCT01284634|DRUG|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
224112943|NCT06672614|OTHER|Post-Exercise Hot Water Immersion|Participants will cycle for 60 minutes at 50% of maximal oxygen uptake (VO2 max) followed by 30 minutes post-exercise hot water immersion (40oC) for 5 consecutive days.
224112944|NCT06672614|OTHER|Control Group|Participants will cycle for 60 minutes at 50% maximal oxygen uptake (VO2 max) for 5 consecutive days. There is no water immersion following the exercise.
224112945|NCT06673329|DRUG|Brodalumab|Brodalumab 210 mg subcutaneous injection
223968094|NCT01284634|DRUG|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
224112946|NCT06673329|RADIATION|CT scan|CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment
224112947|NCT05421377|DIAGNOSTIC_TEST|clinical assessment|screening of patients at risk for developing unilateral or bilateral lower limb lymphedema
224112948|NCT01589094|DRUG|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
223968095|NCT06408922|OTHER|prp injection|intraarticular prp
223968096|NCT04873297|DRUG|Metoclopramide 10mg|Tab. Metoclopramide 10mg TDS via NG tube
224112949|NCT02214758|OTHER|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
224112950|NCT05821504|BEHAVIORAL|High-Intensity Interval Training|The training intervention is a popular exercise format that consist of alternating brief bouts of high-intensity efforts with bouts of light effort or complete rest.
223968097|NCT04873297|DRUG|Placebo|Placebo 10 ml of plain water Via NG
223968098|NCT01271153|DRUG|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
223968099|NCT01271153|DRUG|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
223968100|NCT01620398|BEHAVIORAL|BALANCE|
223968101|NCT01620398|BEHAVIORAL|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
223968102|NCT02751801|OTHER|no intervention|
223968103|NCT04811118|DRUG|Docetaxel for Injection (Albumin-bound)|Docetaxel for Injection (Albumin-bound) by intravenous infusion
223968104|NCT04811118|DRUG|Taxotere|Taxotere
223968105|NCT02555488|DEVICE|diode laser|MB and diode
223968106|NCT02555488|DEVICE|diode laser|diode laser
223968107|NCT02555488|DRUG|Methylene blue|Methylene blue and diode laser was used
223968108|NCT01451697|BEHAVIORAL|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
223968109|NCT01451697|BEHAVIORAL|Control (Placebo)|The control condition will involve relaxation training.
223968110|NCT04335370|OTHER|Blood Draw|"Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion"
223968111|NCT00356564|BIOLOGICAL|hepatitis B vaccine|
223968112|NCT02205723|BEHAVIORAL|Asthma teaching in ER|Asthma teaching
223968113|NCT02205723|BEHAVIORAL|Smartphone Asthma Control|Smartphone Asthma Control
223968114|NCT04056741|COMBINATION_PRODUCT|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
223968115|NCT03690921|DRUG|Cisplatin|Given IV
223968116|NCT03690921|DRUG|Fluorouracil|Given IV
223968117|NCT03690921|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
223968118|NCT03690921|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223968119|NCT03690921|OTHER|Questionnaire Administration|Ancillary studies
223968120|NCT03772041|DRUG|OPC-61815|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
223968121|NCT03772041|DRUG|Tolvaptan Tab 15 MG|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
223968122|NCT01525641|DRUG|Mirapex LA|Pramipexole Hydrochloride Hydrate
223968123|NCT02183350|DRUG|BI 1356 BS - single rising dose|
223968124|NCT02183350|DRUG|Placebo|
223968125|NCT02795819|DRUG|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
223968126|NCT02795819|DRUG|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
223968127|NCT04935918|DEVICE|ACT|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck. The ACT system is a permanent implant designed for the correction of incontinence in patients.
224112951|NCT06697327|DRUG|(Daunorubicin, Cytarabine, Venetoclax)|"* Drugs：Daunorubicin~  * Dosage: 40 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 5~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U~* Drugs：Venetoclax~  * Dosage: 100 mg on day 1, 200 mg on day 2, and 400 mg from days 3 to 14~ * Other names: ABT-199, Venclexta, Venclyxto"
224112952|NCT06697327|DRUG|(Daunorubicin, Cytarabine)|"* Drugs：Daunorubicin~  * Dosage: 60 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 7~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U"
224112953|NCT03427775|COMBINATION_PRODUCT|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
223968128|NCT02737202|DRUG|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
224291542|NCT04336124|DRUG|CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)|"Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles.~Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing.~A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day.~If 2 or more patients experience a DLT, no further dose escalation will occur."
224291543|NCT06338735|OTHER|Ultra-High Frequency Ultrasound scan of minor salivary glands|Patients will undergo ultra-high frequency ultrasonography (70 MHz) of minor salivary glands, and the scans will be assessed using the OMERACT scoring system. Score 0 will be assigned in the presence of normal glandular tissue, Score 1 will correspond to mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 will be assigned to moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, while in Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis will be observed.
224291544|NCT04043936|BEHAVIORAL|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
223968129|NCT05871190|OTHER|İnjectable platelet rich fibrin|I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
223968130|NCT05871190|PROCEDURE|Gingivectomy anad gingivoplasty|leveling and regulation of the gingiva
223968131|NCT06318130|DEVICE|Fixed helix, lumenless pacing lead.|Patients will be randomised to the fixed helix, lumenless pacing lead design during LBBP implantation.
223968132|NCT06318130|DEVICE|Extendable helix, stylet-driven pacing lead.|Patients will be randomised to the extendable helix, stylet-driven pacing lead design during LBBP implantation.
223968133|NCT02274051|DIETARY_SUPPLEMENT|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
223968134|NCT03643705|OTHER|Multi-component intervention|4 components as described
223968135|NCT03643705|OTHER|General prevention education|General education as described
224112954|NCT06742294|BEHAVIORAL|Movement education|(1) providing preschool teachers professional development training in pedagogical knowledge and methods in the physical domain, (2) creating a set of teaching materials (in printed and digital formats) and methods that could be incorporated into the overall and preschool-based curricula, (3) creating a parental toolkit with contents mirroring the school materials, to enhance parents' knowledge and promote family-school collaboration, and (4) developing a smartphone-based artificial intelligence rating system to help preschool teachers conveniently and accurately assess children's motor skills, and provide appropriate instructional feedback.
223968136|NCT05012397|DRUG|RAIN-32|260 mg once daily orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle
223968137|NCT06054633|DIETARY_SUPPLEMENT|L-arginine tablet|L-arginine, 2 g, three times daily, for 12 weeks
223968138|NCT06054633|DIETARY_SUPPLEMENT|Placebo tablet|Identical inert placebo, three times daily, for 12 weeks
223968139|NCT00003588|BIOLOGICAL|Ad5CMV-p53 gene|
223968140|NCT00003588|PROCEDURE|laparoscopic surgery|
223968141|NCT04240418|OTHER|Survey|The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.
223968142|NCT02552706|DIETARY_SUPPLEMENT|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
224112955|NCT06755671|DRUG|Danning Tablet|Danning Tablet is the only exposure in this observational study.
223968143|NCT02552706|DIETARY_SUPPLEMENT|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
223968144|NCT00183599|BEHAVIORAL|5 Minutes of Simple Advice|
223968145|NCT00183599|BEHAVIORAL|Motivational Enhancement Therapy (MET)|
223968146|NCT00183599|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
223968147|NCT04636463|PROCEDURE|Intraoperative Music|Hand Surgery performed with the participant awake, using local anesthesia. Headphones will be worn by the participant and surgery will be performed while the participant is listening to music
223968148|NCT03279172|PROCEDURE|direct laryngoscope|procedure entubatıon
223968149|NCT03279172|PROCEDURE|videolaryngoscope|
224112956|NCT03575468|BEHAVIORAL|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
224112957|NCT03575468|BEHAVIORAL|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
224112958|NCT04950985|OTHER|Observational Study|Observational study
224112959|NCT02211495|DEVICE|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
224112960|NCT02211495|OTHER|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
224112961|NCT02463123|DEVICE|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
224112962|NCT02924675|DRUG|Pregabalin|150mg daily in three doses during three weeks
224112963|NCT02924675|DRUG|Placebo|Three doses daily with lactose
224112964|NCT05534334|DRUG|Solu-Cortef|A vial sol. used for intra-mascular injection
224112965|NCT06270797|PROCEDURE|intubation for general anesthesia|routine intubation for general anesthesia
224112966|NCT05782556|DEVICE|Implantation of a transjugular intrahepatic portosystemic shunt (TIPS)|For TIPS implantation, a transjugular approach is used in all patients and a puncture needle was advanced into a hepatic vein. Puncture of the portal vein is performed using ultrasound guidance followed by portography after successful puncture of the portal vein. Further, the parenchymal tract isdilated and the stent graft is placed. Before and after TIPS implantation, portal venous and central venous pressures are measured to calculate the porto-systemic pressure gradient
224112967|NCT03339427|OTHER|vitamin D|different doses of vitamin D supplementation
224112968|NCT03339427|OTHER|control|control group
224112969|NCT06512428|DRUG|simmitinib plus irinotecan liposome|simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
224112970|NCT06512428|DRUG|irinotecan liposome|irinotecan liposome 70 mg/m\^2 every 2 weeks
224112971|NCT06512428|DRUG|irinotecan|irinotecan 180mg/m\^2 every 2 weeks
224112972|NCT03237208|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
224112973|NCT03237208|DEVICE|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
224112974|NCT05613010|BEHAVIORAL|mHealth Messaging Intervention Group|Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.
224291545|NCT04043936|BEHAVIORAL|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
224112975|NCT06272175|OTHER|Open Kinetic Chain Activity|PNF Flexion-Abduction-External Rotation and Flexion-Adduction-External Rotation patterns will be actively performed on the hemiplegic upper extremity.
224112976|NCT06272175|OTHER|Closed Kinetic Chain Activity|Weight-bearing on the hemiplegic hand with extended elbow in standing position
224112977|NCT06583096|BEHAVIORAL|Surveys|Participants (in both arms) will complete surveys once per week and participants in the intervention arm will also complete additional 1-minute surveys daily. Study participation will be completed at the conclusion of the final follow-up survey administered 6-weeks after study enrollment.
224112978|NCT06583096|BEHAVIORAL|Supportive Text messages|Text messages will be sent Mondays-Sunday if participants are randomized to receive them in a given week, with a daily 50:50 send/no-send randomization. A bank of 25 text messages will be used for the study, providing tips/strategies across a range of topics, including managing time and academic stressors, recommendations for self-care and mood management, and messages geared towards fostering social connections and support. Some messages will contain links to videos, websites, or articles for more information on a topic.
224112979|NCT06583096|BEHAVIORAL|Personalized Feedback (PF) Report|For individuals that are randomized to receive a Personalized Feedback Report, the study team will send participants a text on a Monday with the feedback from the prior survey (baseline survey in the first week, weekly survey in the next five weeks). There will be graphs for depression, anxiety, stress, and flourishing.
224112980|NCT00260559|PROCEDURE|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
224112981|NCT05378399|DRUG|Descovy or Truvada|Descovy or Truvada prescribed with digital pills for PrEP
224112982|NCT05378399|DEVICE|ID-Cap System|Digital pills overencapsulating Descovy or Truvada for PrEP
224112983|NCT05378399|DEVICE|Beiwe|Digital phenotyping app
224112984|NCT04841304|DEVICE|Loop recorder (Reveal LINQ, Medtronic)|Implantation of a loop-recorder
224112985|NCT04841304|DEVICE|Continuous Glucose Measurement (G6, Dexcom)|Monitoring with a continuous glucose monitor
224291546|NCT04043936|BEHAVIORAL|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, \& treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
224291547|NCT04527328|DEVICE|AKST1210|AKST1210
224291548|NCT04527328|OTHER|Sham Control (No Intervention)|A covered surrogate object of similar size and shape as the investigational device
223968150|NCT05362253|PROCEDURE|Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation|"1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing."
224112986|NCT03559985|DRUG|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
223968151|NCT05362253|PROCEDURE|Conventional Autologous Conjunctival Transplantation|"1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation."
223968152|NCT01016275|DEVICE|Misago (stent placement)|Misago iliac stent
224291549|NCT04527328|PROCEDURE|Hemodialysis|Hemodialysis
224291550|NCT06416917|DEVICE|bubble inclinometer|to measure range of motion
223968153|NCT04306445|DEVICE|GF-IGB: Obalon Balloon|The balloon, which is attached to a thin catheter, is swallowed by the patient in a standing position. Once the two-step verification of balloon passage into the stomach by both fluoroscopy and pressure reading, the balloon is inflated to a volume of 250 ml with a nitrogen-mix gas, additional imaging of the inflated balloon is obtained, the catheter is ejected from the balloon, and the catheter is pulled out through the patient's mouth. The process is repeated at week 2 for the second balloon and between weeks 4-8 for the third balloon. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. The balloons are removed endoscopically 6 months after placement of the first balloon. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
223968154|NCT04306445|DIETARY_SUPPLEMENT|Medically Supervised Meal Replacement Program: My New Weigh|Patients are given an individualized calorie prescription by a registered dietitian for a goal of 2 pounds weight loss per week. Patients are seen in a group-based program once a week focused on long-term behavior change and use meal replacements for a nutritionally balanced very low-calorie diet for 20 weeks. 4-5 meal replacements are consumed per day. If only 4 meal replacements are consumed, individuals eat 3 servings of vegetables and 2 servings of fruit per day as well.
223968155|NCT04306445|PROCEDURE|Endoscopic sleeve gastroplasty: (ESG)|Endoscopic sleeve gastroplasty is a weight loss procedure that uses an FDA 510K cleared endoscopic suturing device known as Overstitch to reduce the size of the gastric body. The procedure is completed with an endoscope. It is inserted through the mouth, down the esophagus, and into the stomach. Sutures with 8-10 bites 1.5-2 cm apart in a U-shape pattern are placed starting distally 6 cm proximal to the pylorus. Additional sutures are placed moving proximally up to 2 cm distal to the gastroesophageal junction. An additional row of sutures is then placed again in the distal to proximal stomach to complete the gastroplasty. All patients are given an individualized calorie prescription by a registered dietitian for a goal of up to 2 pounds of weight loss per week. Patients also attend monthly virtual individual diet coaching and monthly virtual group behavior coaching sessions both delivered by a registered dietitian for twelve months focused on long-term behavior change.
224112987|NCT03559985|OTHER|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
224112988|NCT00746577|OTHER|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
224112989|NCT04755400|OTHER|isotonic saline 9%|1 Liter of Isotonic saline administered I.V.
224112990|NCT04755400|DIETARY_SUPPLEMENT|Potassium nitrate|24 mmol of Potassium nitrate is the active comparator substance, that is ingested every morning for 4 days before and on the examination day.
224112991|NCT04755400|DIETARY_SUPPLEMENT|Potassium chloride|24 mmol of Potassium nitrate is the placebo substance, that is ingested every morning for 4 days before and on the examination day.
224112992|NCT01074411|DRUG|Bortezomib|Given IP
224112993|NCT01074411|DRUG|Carboplatin|Given IP
224112994|NCT01074411|OTHER|Laboratory Biomarker Analysis|Correlative studies
224112995|NCT01074411|OTHER|Pharmacological Study|Correlative studies
224112996|NCT05724667|OTHER|Flippin' Pain Seminar Series|A chronic pain education campaign
224112997|NCT01029288|OTHER|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
224112998|NCT01029288|OTHER|Statin Choice Decision Aid|Statin Choice Cards
224291551|NCT04117737|OTHER|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
223968156|NCT01123044|BIOLOGICAL|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
223968157|NCT01123044|PROCEDURE|Medical Therapy|Under usual care treatment
224291552|NCT03443817|BEHAVIORAL|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
224291553|NCT05486832|DEVICE|Cardiovalve TR valve replacement System|The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
223968158|NCT03417375|PROCEDURE|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
223968159|NCT01493388|DRUG|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
223968160|NCT05005572|OTHER|Payment adjustment for home dialysis and transplant|The ETC model makes two types of payment adjustments for facilities and managing clinicians, an adjustment to the reimbursement rate for home dialysis, and a performance adjustment. The first adjustment, Home Dialysis Payment Adjustment (HDPA), raises the reimbursement rate for home dialysis for the first three years of the program; the amount of increase is 3% in 2021, and reduces to 2% in 2022, and 1% in 2023. The second adjustment, Performance Payment Adjustment (PPA), is an increase or decrease in the reimbursement rate based on the home dialysis rate and the transplant rate attributable to the participating facility or clinician.
223968161|NCT04051645|DEVICE|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
223968162|NCT00856453|BEHAVIORAL|Home yoga practice|training for and tracking of patient's practice of yoga at home
223968163|NCT00856453|BEHAVIORAL|yoga classes|organized out of home classes for yoga
223968164|NCT03939871|DRUG|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
224112999|NCT01029288|OTHER|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
224113000|NCT01029288|OTHER|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
224113001|NCT03919890|DRUG|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
224113002|NCT03919890|DRUG|ONO-7684 Placebo|Placebo comparator
224113003|NCT05094154|DRUG|anti-pseudomonal cephalosporin|Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
224113004|NCT05094154|DRUG|anti-pseudomonal penicillin|Providers will be prompted to order anti-pseudomonal penicillin, such as piperacillin-tazobactam with a dose range of 3.375 g or 4.5 g and frequency every 6, 8, or 12 hours based on provider discretion.
224113005|NCT05732155|DRUG|methylenedioxymethamphetamine|The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of MDMA HCl, in participants with PTSD and moral injury, in individual and group treatment settings
223968165|NCT04097314|DRUG|Zibotentan|10mg OD Zibotentan
223968166|NCT04097314|DRUG|Placebo oral tablet|Placebo
223968167|NCT05557253|DRUG|Remimazolam|Anesthesia induction: remimazolam 6-12 mg/kg/h Anesthesia maintenance: remimazolam 1-2 mg/kg/h
223968168|NCT05557253|DRUG|Balanced Anesthesia|Anesthesia induction: propofol 1.5-2 mg/kg Anesthesia maintenance: Desflurane 6-8 vol%
224113006|NCT00878540|DRUG|mirtazapine|30 mg mirtazapine once daily for 7 days
223968169|NCT03994900|DIAGNOSTIC_TEST|Blood sampling for HbNO assessment|Blood sampling
223968170|NCT00293332|BIOLOGICAL|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
223968171|NCT00293332|DRUG|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
223968172|NCT00293332|DRUG|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
223968173|NCT00293332|PROCEDURE|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
223968174|NCT03334747|DRUG|KAE609|Exploration of different doses of KAE609 to establish safety profile.
223968175|NCT03334747|DRUG|Coartem|Control Arm
223968176|NCT02513810|DEVICE|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
224113007|NCT04066556|OTHER|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~* Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~* Cut-off values in areas of irreversible changes according to non-contrast CT images~* Cut-off values in occlusion sites and collateral scores according to CT angiographies~* Cut-off values of consolidated CT imaging index including clot, core, and collateral score~* Cut-off values of comorbidity index~* Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
224113008|NCT00945750|DRUG|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
224113009|NCT00945750|DRUG|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
223968177|NCT02513810|DEVICE|BioMatrix or Ultimaster with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
223968178|NCT04759599|PROCEDURE|Shock Wave Lithotripsy (SWL)|Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
223968179|NCT02567227|OTHER|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
223968180|NCT02567227|OTHER|Active Control|Computer, multimedia and group based health education programs.
223968181|NCT01961804|DRUG|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
223968182|NCT05112172|OTHER|Oxygen Therapy|Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
223968183|NCT05422040|OTHER|Dry needling|Invasive treatment will be performed on the most symptomatic lumbar iliocostalis muscle.
223968184|NCT05422040|OTHER|Tecartherapy treatment|Treatment will be carried out with deep thermotherapy in the lumbar region.
223968185|NCT02137239|DRUG|Thymoglobulin|
223968186|NCT02137239|DRUG|Belatacept|
223968187|NCT02137239|DRUG|mycophenolate mofetil(MMF)|
223968188|NCT02137239|DRUG|Corticosteroids|
223968189|NCT02137239|DRUG|Everolimus(EVL)|
223968190|NCT02137239|DRUG|Tacrolimus(TAC)|
223968191|NCT04185142|COMBINATION_PRODUCT|cryoballoon ablation combining with left atrial appendage closure|cryoballoon ablation using either 1st or 2nd generation of cryoballoon and left atrial appendage closure using devices including WATCHMAN, Lefort and Lacbes.
223968192|NCT00100945|DRUG|gefitinib|
223968193|NCT03570996|PROCEDURE|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
223968194|NCT03570996|PROCEDURE|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
223968195|NCT03570996|PROCEDURE|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
223968196|NCT01679457|BEHAVIORAL|ACT-Focused ERP|
223968197|NCT01679457|BEHAVIORAL|TAU-ERP|
223968198|NCT06254079|PROCEDURE|video based education|The patients in the experimental group will be shown a video containing information about the operating room environment and care during surgery. The video content includes the following details: the operating room temperature being maintained at 18-24°C; the patient being placed on the operating table by the staff in the presence of an anesthesia technician; the establishment of intravenous access by the anesthesia technician; monitoring of blood pressure, pulse, respiration, and EKG indicators; the insertion of a urinary catheter by the surgical nurse after the patient is anesthetized; post-awakening transfer to the postoperative recovery unit with the anesthesia technician and personnel; reception and monitoring of vital signs, pain assessment, intervention, and observation for a period by a nurse in this unit; and finally, transfer to the General Surgery Service.
223968199|NCT05331716|PROCEDURE|Cardiac ablation therapy|In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
223968200|NCT04362111|DRUG|Anakinra|The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
223968201|NCT04362111|DRUG|Normal saline|The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
223968202|NCT02831439|BEHAVIORAL|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
224113010|NCT03005847|DIETARY_SUPPLEMENT|fermented papaya preparation|dietary supplementation with fermented papaya preparation
224113011|NCT01513798|BEHAVIORAL|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
224113012|NCT01513798|BEHAVIORAL|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
224113013|NCT04922892|PROCEDURE|Parathyroidectomy|Total Parathyroidectomy With Autotransplantation or Total Parathyroidectomy Alone
224113014|NCT06555692|BIOLOGICAL|Transplant acellular dermal matrix(ADM)|The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
223968203|NCT02831439|BEHAVIORAL|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
223968204|NCT02831439|BEHAVIORAL|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
223968205|NCT03595826|DRUG|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
223968206|NCT02604147|DEVICE|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
224291554|NCT01980160|DEVICE|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
224291555|NCT01980160|DEVICE|Unactivated Nometex Device|
224291556|NCT06297655|DRUG|Recombinant human activated coagulation factor VIII for injection|Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.
224291557|NCT01122589|BEHAVIORAL|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
224291558|NCT01122589|OTHER|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
224291559|NCT01469741|BEHAVIORAL|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
223724880|NCT02063022|DRUG|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
223724881|NCT02063022|DRUG|Intensified chemotherapy|"* Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~* Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~* Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
223968207|NCT02604147|DEVICE|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
223968208|NCT05307120|DEVICE|Diameter integrated in secondary diabetes care|Regular T2DM treatment in secondary care will be complemented with the Diameter: a mobile application on smartphones that enables continuous monitoring of physical activity (via activity tracker Fitbit and self-reported activities) and nutrition (via food diary) and blood glucose values (via Freestyle Libre sensor). The Diameter also provides autonomous lifestyle coaching via daily coaching messages, short weekly e-mails and exercises aimed at goal achievement.
223968209|NCT03742232|DRUG|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
223968210|NCT03742232|DRUG|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
223968211|NCT06210737|BIOLOGICAL|PCV13|3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10
224113015|NCT02426983|DEVICE|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
224113016|NCT02426983|DRUG|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
224113017|NCT01823627|PROCEDURE|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
223968212|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13, and a booster dose
223968213|NCT06210737|BIOLOGICAL|PCV13|2 doses of PCV13
223968214|NCT06210737|BIOLOGICAL|PCV13|single dose of PCV13
223724882|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
223968215|NCT01211717|DIETARY_SUPPLEMENT|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
223968216|NCT01211717|OTHER|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
223968217|NCT00019136|BIOLOGICAL|MOv-gamma chimeric receptor gene|
224113018|NCT00983450|OTHER|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
224113019|NCT00983450|OTHER|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
223968218|NCT00019136|BIOLOGICAL|aldesleukin|
223724883|NCT01684007|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
223968219|NCT00019136|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223968220|NCT00301015|DEVICE|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
223968221|NCT05682040|DIAGNOSTIC_TEST|Bedside Compression Ultrasonography|Point of Care Ultrasound (Bedside Compression Ultrasonography) vs formal lower extremity Doppler
223968222|NCT02042625|PROCEDURE|Nasopharyngeal|
223968223|NCT03291899|COMBINATION_PRODUCT|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
223968224|NCT00935649|DEVICE|PinPointe FootLaser|Medical laser
223724884|NCT01613729|DRUG|Rosuvastatin 5 mg|Rosuvastatin 5 mg
223724885|NCT01613729|DRUG|Rosuvastatin 10 mg|
223724886|NCT00002136|DRUG|Tecogalan sodium|
223968225|NCT04879875|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
223968226|NCT04879875|DEVICE|IscAlert 72h|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
223968227|NCT02498418|DRUG|Rifaximin|Tablets, generic formulation of the brand product.
223968228|NCT02498418|DRUG|Xifaxan®|Tablets, brand product.
223968229|NCT02498418|DRUG|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
223968230|NCT00786721|DEVICE|Diffuse Optical Spectroscopy|muscle properties scanning
223968231|NCT00002347|DRUG|Saquinavir|
223968232|NCT00002347|DRUG|Nevirapine|
223968233|NCT00002347|DRUG|Zidovudine|
223968234|NCT00002347|DRUG|Zalcitabine|
223968235|NCT00762502|DEVICE|senofilcon A toric contact lens|soft contact lens
223968236|NCT00762502|DEVICE|balafilcon A toric contact lens|soft contact lens
223968237|NCT05582135|DRUG|2 mg morphine sulfate|The parturients were administered 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
223968238|NCT05582135|DRUG|0.25mg/kg esketamine|The parturients were administered 0.25mg/kg of esketamine through the epidural catheter. Sterile saline was added to make a total volume of 8 mL.
223968239|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 2 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 2 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
223968240|NCT05582135|DRUG|0.25mg/kg of esketamine in combination with 1 mg morphine sulfate|The parturients were administered 0.25mg/kg of esketamine in combination with 1 mg morphine sulfate through the epidural catheter. Sterile saline was added to all combinations of the analgesic drugs to make a total volume of 8 mL.
224291560|NCT01950676|DEVICE|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
223968241|NCT03042559|DEVICE|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
223968242|NCT03042559|DEVICE|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
223968243|NCT04596241|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
223724887|NCT03655691|BIOLOGICAL|Vehicle|Vehicle Formulation
223968244|NCT01861795|OTHER|Preterm Neonates|Preterm Neonates
223968245|NCT06057259|DEVICE|Joint position sense measurement|The participants' wrist joint position sense was evaluated.
223968246|NCT01994538|OTHER|Longer therapy duration|14 days of antimicrobial treatment
223968247|NCT01994538|OTHER|Shorter therapy duration|7 days of antimicrobial treatment
223968248|NCT00850798|DRUG|Intensive glycemic control|Intensive glycemic control
223968249|NCT00850798|DRUG|Conservative glycemic control|OADs and insulin
224291561|NCT02305173|DRUG|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
224291562|NCT02305173|DRUG|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
224291563|NCT04430127|OTHER|No supplementary intervention is performed|No supplementary intervention will be applied
223724888|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
223968250|NCT02581371|DRUG|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
223968251|NCT02581371|OTHER|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
223968252|NCT01225705|DRUG|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
223968253|NCT01225705|DRUG|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
223968254|NCT02896439|DEVICE|Neurophysiological MONITORING|"The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention"
223968255|NCT05216952|DRUG|Ulipristal Acetate Tablets|90mg (three 30mg tablets) administered orally once
223968256|NCT05216952|DRUG|Misoprostol Pill|800mcg (four 200mcg pills) administered vaginally once 6-18 hours following ulipristal acetate
223968257|NCT00385697|BIOLOGICAL|Teplizumab|Daily IV dosing for 14 days, repeated at Week 26
224291564|NCT00788593|DRUG|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
224291565|NCT00788593|DRUG|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
224291566|NCT00788593|DRUG|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
223724889|NCT03655691|BIOLOGICAL|botulinum toxin, Type A|botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline
223724890|NCT03267108|COMBINATION_PRODUCT|INOpulse®|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
223724891|NCT03267108|COMBINATION_PRODUCT|Placebo|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
223724892|NCT03267108|COMBINATION_PRODUCT|Open Label Extension|Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
223968258|NCT00385697|DRUG|Placebo|Daily IV dosing for 14 days, repeated at Week 26
223968259|NCT00376207|BEHAVIORAL|Physical exercise|
223968260|NCT04117906|BEHAVIORAL|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
223968261|NCT01485991|DRUG|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
223968262|NCT01485991|DRUG|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
224291567|NCT04226131|OTHER|Blood Draw|A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
224291568|NCT04226131|OTHER|Disease Activity (DAS-28) Assessment|Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
223968263|NCT01031186|DRUG|GSK356278|GSK356278
223968264|NCT01031186|DRUG|PLACEBO|PLACEBO
224113020|NCT06126705|DRUG|Radiation: 18F-AlF-FAPi-04|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
224113021|NCT06126705|DRUG|Radiation: 18F-FDG|Subjects who meet all the inclusion criteria will receive intravenous administration of 18F-AlF-FAPi-04 with a dosage range of 0.1-0.2 mCi/Kg. After administration, PET/CT scans will be performed at three time points: 1h, 2h, and 4h post dose. The subjects will also receive administration of 18F-FDG and undergo PET/CT scans for self-control analysis.
224113022|NCT05017285|PROCEDURE|HoLEP with median lobe preservation|Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
224113023|NCT05017285|PROCEDURE|HoLEP classic|Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
224113024|NCT01311206|OTHER|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
224113025|NCT01311206|OTHER|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
224113026|NCT06196476|BEHAVIORAL|Interactive digital-based educational program|"The Interactive digital-based educational program Sessions:~Session 1: The road start to green planet: Introductory to climate change concept Session 2: Towards Climate Change Literacy Modifications: remove the cover on illiteracy.~Session 3: Green scrubs and green environment: raising climate activities and environment self-efficacy Session 4: Strengthen resilience to overcome climate related anxiety Session 5: Sustaining phase: closing session"
223968265|NCT00815347|DRUG|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
223968266|NCT00815347|DRUG|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
223968267|NCT02403284|DRUG|Liraglutide|Subcutaneous injection by patient
223968268|NCT02403284|DRUG|Sugar Pill|Subcutaneous injection daily
223968269|NCT01909947|OTHER|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~1. A 60-minute period while the infant receives any mode of conventional mechanical ventilation~2. A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
223968270|NCT04715711|OTHER|Forearm coolng|forearm immersion will be performed for active cooling assessment
223968271|NCT04715711|OTHER|Wet-towel cooling|Wet towels will be wrapped around the participant's arms for active cooling
223968272|NCT04715711|OTHER|mist-fan|a mist-fan will be placed in front of the participant for active cooling
224113027|NCT05807022|PROCEDURE|Percutaneous or transbronchial argon-helium cryoablation|The participants would undergo Percutaneous or transbronchial argon-helium cryoablation.
224113028|NCT05553548|PROCEDURE|biologically oriented alveolar ridge preservation|xenogenic bone graft placed in coronal part of the non molar socket ,, collagen plug placed in appical part of socket and as socket seal
224113029|NCT05553548|PROCEDURE|xenogenic bone graft in entire (apico-coronal) extension|xenogenic bone graft placed in the entire apico coronal extension and sealed with collagen plug
223968273|NCT04715711|OTHER|passive cooling|"participants will sit in a chair and passively cool (no active intervention)"
223968274|NCT02212483|OTHER|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
223968275|NCT02212483|OTHER|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
223968276|NCT02212483|OTHER|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
223968277|NCT02538471|RADIATION|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
223968278|NCT02538471|DRUG|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
224113030|NCT02133235|PROCEDURE|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
224113031|NCT02133235|PROCEDURE|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
224113032|NCT02531035|DRUG|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
224113033|NCT02531035|DRUG|Placebo|Placebo, once daily, before the first meal of the day
224113034|NCT01002859|DRUG|Sandimmum|Intravenous injection of cyclosporine
224113035|NCT01002859|DRUG|Placebo|Intravenous Injection of NaCl solution
224113036|NCT02892461|PROCEDURE|Umbilical cord milking|As same as that in arm descriptions.
224113037|NCT02030561|DRUG|Trastuzumab + NK cells|
223968279|NCT01365351|OTHER|Growth hormone|Drug given by prescription
223968280|NCT01475370|DRUG|OCV-501|"1. Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~2. After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
223968281|NCT03895892|BEHAVIORAL|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
223968282|NCT03895892|BEHAVIORAL|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
223968283|NCT03895892|DIETARY_SUPPLEMENT|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
223968284|NCT03895892|DIETARY_SUPPLEMENT|Ketone|Dietary supplement containing only ketone salts
223968285|NCT03895892|DIETARY_SUPPLEMENT|Water Placebo|Dietary supplement containing only water
223968286|NCT01243398|PROCEDURE|quality-of-life assessment|
223968287|NCT02429752|OTHER|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
223968288|NCT00206609|PROCEDURE|Oxygen and air administration|
223968289|NCT03726125|DRUG|LY3374849 - SC|Administered SC
223968290|NCT03726125|DRUG|Insulin Degludec - SC|Administered SC
223968291|NCT03726125|DRUG|LY3374849 - IV|Administered IV
223968292|NCT03726125|DRUG|Insulin Degludec - IV|Administered IV
223968293|NCT05476978|DIAGNOSTIC_TEST|EUS-AI model|The test subset (approximately 20% of total patients) is reserved for the final evaluation of the EUS-AI model. Clinical parameters and EUS pictures of each patient in the test subset will be inputed into the trained EUS-AI model, and the most possible diagnosis will be given by the model.
223968294|NCT01388088|DRUG|Spironolactone|25 mg twice a day
223968295|NCT01388088|DRUG|Amiloride|5 mg twice a day
223968296|NCT01388088|DRUG|Placebo|twice a day
223968297|NCT04864236|DEVICE|Novel isolation device to contain aerosol|"The novel isolation device is called SLACC (Suction-assisted Local Aerosol Containment Chamber). SLACC has the ability to isolate the atmosphere around the patient's upper airway (nose, mouth, throat) via negative pressure in a manner analogous to isolation rooms used to house patients with communicable diseases spread by aerosol (e.g. tuberculosis).~The SLACC uses an external suction source to maintain a negative pressure micro-atmosphere around a patient's head (the source of infectious aerosols). The components of SLACC include a clear polymer frame, a flexible drape, and integrated sealed arm sleeves to protect the hands and forearms of the health care provider. The structure is flexible during use, transparent, can be rapidly assembled, and easily collapsible for removal and transport. Once deployed with the patient's head inside the chamber, the drape is secured across the open side of the chamber with adhesive and covers the patient's torso."
223968298|NCT05056298|OTHER|Custom made insole|Custom made arch support insole with semi-rigid arch support will be made using the casting method, plaster cast of both feet in a subtalar neutral position will be taken from each subject by highly specialized orthotist. The negative casts will be placed in calcaneal vertical position and custommolded orthosis will be fabricated to positive molds obtained from the negative casts with the goal to control the pronation movement of the foot
223968299|NCT05056298|OTHER|Strengthening exercises of extrinsic foot muscles|Participants will perform extrinsic foot muscles strengthening exercises with both ankles 3 times per week, 20 minutes for 8 weeks. they will be trained using a progressive resistance protocol using Thera-Band elasticated bands. Subjects will be progressed weekly throughout the training period according to progressive resistance protocol for dorsiflexors, planterflexors, evertors and investors muscles.
223968300|NCT05056298|OTHER|Strengthening exercises of intrinsic foot muscles|The patient will assume the same position as in intrinsic foot muscle assessment, then he will be instructed to hold the position for a count of 10 seconds and attempt to maintain the MLA as steady as possible during the entire time without any compensatory extrinsic foot muscle activity. Following the 10-seconds, slowly and with eccentric control allow the foot to pronate and the MLA to lower to a relaxed state .
223968301|NCT05056298|OTHER|Standard insole|Patient will be instructed to wear a standard prefabricated flat insole as a placepo treatment iniside his shoes for 2 months (8 weeks), 6 to 8 hours per day, and adhere to wearing the orthoses during outdoor walking and during extrinsic foot muscle training.
223968302|NCT04770740|DIETARY_SUPPLEMENT|Vitamin K2 in the form of Menaquinone-7 (MK-7)|Patients will take three tablets of vitamin K2 menaquinone-7 (333mcg) per day. Patients taking vitamin K2 MK-7 will receive the total of 999mcg per day from day 1 until day 14 or discharge, whichever occurs earlier. All subjects can be treated with prophylactic or therapeutic heparin-based (heparin or any low-molecular weight heparin) anticoagulants, according to local hospital protocols. Provided by Kappa Bioscience.
223968303|NCT04770740|DIETARY_SUPPLEMENT|Placebo|Patients will take three tablets of placebo containing only inactive ingredients per day, from day 1 until day 14 or until discharge, whichever occurs first. The placebo is provided by Kappa Bioscience.
223968304|NCT00988897|DRUG|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
224113038|NCT00384540|PROCEDURE|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
224113039|NCT02898207|DRUG|Olaparib|Given PO
224113040|NCT02898207|DRUG|Onalespib|Given IV
224113041|NCT00071201|DRUG|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
224113042|NCT05768620|OTHER|CAVE|The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
224113043|NCT05768620|OTHER|TAU|This is the usual care used to train visuospatial processes
224113044|NCT02069223|PROCEDURE|Gastrectomy|
224113045|NCT02069223|PROCEDURE|BPD-DS|
223968305|NCT00988897|DRUG|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
223968306|NCT00988897|DRUG|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
223968307|NCT00988897|DRUG|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
223968308|NCT06321900|DIAGNOSTIC_TEST|Personalized risk model|WE will test the hypothesis that interpretable artificial intelligence models including clinical, bio-humoral, genetic, electrocardiography, echocardiography, cardiac magnetic resonance, and nuclear imaging data will predict the risk of SCD in patients with left ventricular dysfunction more accurately than NYHA class and LVEF, and this will translate in a more cost-effective use of ICDs compared to current clinical practice.
223968309|NCT01314638|OTHER|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
223968310|NCT02919397|DEVICE|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
223968311|NCT02919397|BEHAVIORAL|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
223968312|NCT02919397|BEHAVIORAL|Motivational messaging|Messages sent via smartphone application
223968313|NCT02216149|DRUG|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
224113046|NCT01009801|DRUG|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
224113047|NCT01009801|DRUG|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
223724893|NCT03982628|DIAGNOSTIC_TEST|Abdominal CT imaging|Routine abdominal CT imaging
223968314|NCT02216149|DRUG|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
224113048|NCT01009801|OTHER|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
224113049|NCT02193269|DRUG|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
224113050|NCT02193269|DRUG|Minocycline|you will receive 200 mg as a single daily dose for 4 days
223968315|NCT02216149|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
223968316|NCT01439997|DRUG|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
223968317|NCT00629551|DRUG|saredutant (SR48968)|oral administration,capsules
223968318|NCT00629551|DRUG|paroxetine|oral administration, capsules
223968319|NCT00629551|DRUG|placebo|oral administration, capsules
223968320|NCT00084747|DRUG|bortezomib|
223968321|NCT03665753|DRUG|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
223968322|NCT03275441|DIAGNOSTIC_TEST|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
223968323|NCT00631098|PROCEDURE|venous cannulation|External jugular and cubital vein cannulation
223968324|NCT02157129|DEVICE|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
223968325|NCT02157129|OTHER|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
223968326|NCT01076322|DRUG|Meptin® Swinghaler|"Meptin® Swinghaler®~* Ingredient: Procaterol HCL~* Dosage form: 10g/puff~* Dose(s): 10g~* Dosing schedule: 20g (total 20g)"
223968327|NCT01076322|DRUG|Ventolin® MDI|"Ventolin® MDI~* Ingredient: Salbutamol sulfate~* Dosage form: 100g/puff~* Dose(s): 100g~* Dosing schedule: 200g (total 200g)"
224113051|NCT00912158|OTHER|standard therapy (ST)|standard medical therapy
224113052|NCT00912158|DEVICE|CPAP|Non-invasive mechanical ventilation (CPAP)
224113053|NCT00912158|DEVICE|BIPAP|Non-invasive mechanical ventilation (BIPAP)
224113054|NCT04885491|DRUG|Sodium chloride (placebo)|Placebo (NaCl, commercially available dilution solution for parenteral use, 9 mg/mL)
224113055|NCT04885491|DRUG|PDNO|PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
224113056|NCT02252874|BEHAVIORAL|Slow-paced action video game|20 hours slow-paced action video games
224113057|NCT02252874|BEHAVIORAL|Fast-paced action video game|20 hours fast-paced action video games
224113058|NCT02252874|BEHAVIORAL|Control|20 hours leisure activities
224113059|NCT00900380|OTHER|flow cytometry|
223968328|NCT05621213|OTHER|Teleconsultation assisted by a physiotherapist or nurse|"A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions.~This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver."
223968329|NCT00877188|OTHER|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
223968330|NCT04313790|DRUG|Heparin Infusion|500 unit heparin infusion \\ hour for DVT prophylaxis experimental group (n=20)
223968331|NCT04313790|OTHER|subcutaneous heparin|5000 unit subcutaneous heparin /8 hours control group n=(20)
223968332|NCT00386997|DRUG|liposomal amphotericin B (AmBisome®)|
223968333|NCT01136798|DRUG|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
223968334|NCT01136798|DRUG|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
223968335|NCT00919009|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
224113060|NCT00900380|OTHER|immunological diagnostic method|
224113061|NCT00900380|OTHER|laboratory biomarker analysis|
223968336|NCT01032746|OTHER|educational intervention|
223968337|NCT01032746|OTHER|internet-based intervention|
223968338|NCT01032746|PROCEDURE|evaluation of cancer risk factors|
223968339|NCT01032746|PROCEDURE|fecal occult blood test|
223968340|NCT01032746|PROCEDURE|screening colonoscopy|
223968341|NCT03383809|DIETARY_SUPPLEMENT|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
223968342|NCT03383809|DIETARY_SUPPLEMENT|Strawberry Juice|Source of Polyphenols
223968343|NCT03383809|DIETARY_SUPPLEMENT|Inulin|Source of non digestible carbohydrate
223968344|NCT02382406|DRUG|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
223968345|NCT02382406|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
223968346|NCT02382406|DRUG|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
223968347|NCT02382406|DRUG|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
223968348|NCT01625949|PROCEDURE|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
224113062|NCT04424433|DRUG|Oxygen|Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
224113063|NCT03254017|PROCEDURE|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
223968349|NCT01625949|PROCEDURE|coronary dilatation and stenting|coronary dilatation and stenting
223968350|NCT01093183|DRUG|lenalidomide|Given PO
223968351|NCT01093183|DRUG|cyclophosphamide|Given PO
224113064|NCT03254017|OTHER|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
224113065|NCT03490669|BIOLOGICAL|MSC-1|humanized monoclonal antibody for intravenous administration
224113066|NCT04962542|OTHER|ventilation|low volume positive pressure ventilation is better than continuous positive airway pressure and passive deflation on arterial oxygenation and PPD after CPB in pediatrics undergoing cardiac surgeries for non-cyanotic congenital heart defects.
224113067|NCT04817085|DEVICE|Visant Medical Canalicular Plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
223968352|NCT01093183|OTHER|laboratory biomarker analysis|Correlative studies
223968353|NCT01093183|OTHER|questionnaire administration|Ancillary studies
223968354|NCT01093183|OTHER|quality-of-life assessment|Ancillary studies
223968355|NCT01936298|DEVICE|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
223968356|NCT01936298|DEVICE|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
223968357|NCT03841006|DEVICE|MRI|dynamic MRI pelvis
223968358|NCT01436383|OTHER|Hypoxic exposure|Hypoxic exposure
223968359|NCT02360865|OTHER|Exercise|
223968360|NCT04543942|DRUG|Alcohol|Alcohol will be administered by IV infusion (60mg%).
223968361|NCT04543942|DRUG|Saline|Saline is administered as the placebo
224113068|NCT04817085|DEVICE|Commercially available canalicular plug|Plug is inserted into the inferior canaliculi and assessed for 6 months
224113069|NCT03032068|OTHER|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
224113070|NCT04747548|BEHAVIORAL|Kurbo Only|Kurbo is a structured behavioral weight management program for youth that focuses on diet, physical activity and mindset skills and is based on the traffic light diet developed at Stanford University. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories consumed. Foods are categorized into the colors of a traffic light signal based on their nutritional and caloric content, such that youth are encouraged to eat more of green and yellow foods, and less of red foods. Participants will log their daily food intake and self-monitor dietary and physical activity behaviors, incorporating behavior substitution and habit formation. Participants will also have 15 minute weekly individualized coaching sessions.
224113071|NCT04747548|BEHAVIORAL|Kurbo + PolyRules!|In addition to Kurbo, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
224113072|NCT03080220|DEVICE|Astym|therapeutic massage instrument
224113073|NCT03080220|DEVICE|Stick|massage instrument
223968362|NCT06119386|DEVICE|Rexon-Eye|In this prospective, interventional study, 81 patients were randomly allocated to received 4 treatment sessions of QMR at one-week intervals (Rexon-Eye ® , Resono Ophthalmic, Trieste, Italy) (QRM group) or tear substitute 4 times daily, containing 0.15% sodium hyaluronate and 3% trehalose (Thealoz Duo ® , Thea Pharma, France) (SH-TH group). Outcomes measures included ocular surface disease index (OSDI) questionnaire, tear meniscus height (TMH), tear breakup time (TBUT), non-invasive breakup time (NIBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), tear film osmolarity (OSM) and meibomian gland dysfunction (MGD) grade, which were assessed at baseline, 1-month and 3-months follow-up.
223968363|NCT01400217|DRUG|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
223724894|NCT06971055|DRUG|Sodium hypochlorite|sodium hypochlorite solution will be used as a root canal irrigant during pulpectomy in primary molars. A volume of 3 mL will be delivered into each canal using a syringe with a side-vented needle. Irrigation will be followed by microbial sampling for blood agar
223724895|NCT06971055|BIOLOGICAL|Moringa Oleifera Leaf Extract|extract of Moringa oleifera leaves will be used as an intracanal irrigant during pulpectomy. A volume of 3 mL will be used per canal, and post-irrigation microbial samples will be analyzed using the same methods as the control group.
223968364|NCT01400217|DRUG|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
223968365|NCT03127475|DEVICE|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
224113074|NCT03080220|DEVICE|Massage|massage instruments
224113075|NCT04656964|DRUG|remimazolam tosilate group|Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
224113076|NCT04656964|DRUG|Midazolam group|Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
224113077|NCT00841503|OTHER|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
224113078|NCT00146393|BEHAVIORAL|People with Arthritis Can Exercise program|
224113079|NCT01597622|DRUG|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
224113080|NCT05238948|DRUG|Midazolam|Substrate of CYP3A4
224113081|NCT05238948|DRUG|CKD-506|Perpetrator of CYP3A4
224113082|NCT04126967|DIAGNOSTIC_TEST|NGS patients|The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
224113083|NCT01358500|DRUG|Fentanyl|Intravenous infusion using STANPUMP
224113084|NCT04065022|DEVICE|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
223724896|NCT02061982|DIETARY_SUPPLEMENT|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
223724897|NCT00225173|DRUG|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
223724898|NCT00225173|DRUG|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
223724899|NCT00225173|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
223724900|NCT00225173|DRUG|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
223724901|NCT00225173|DRUG|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
223724902|NCT00225173|DRUG|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
223724903|NCT00225173|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
223724904|NCT00225173|DRUG|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
223968366|NCT02328209|DRUG|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
223968367|NCT04028128|DIETARY_SUPPLEMENT|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
224113085|NCT00673998|DEVICE|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
224113086|NCT02601885|DRUG|ABT-555|Intravenous Infusion
224113087|NCT02601885|OTHER|Placebo|Intravenous Infusion
224113088|NCT00000581|PROCEDURE|leukocyte transfusions|
224113089|NCT01579539|DRUG|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
224113090|NCT01579539|DRUG|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
224113091|NCT03466346|DRUG|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
224113092|NCT03466346|BEHAVIORAL|Interpersonal Psychotherapy|IPT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
224291569|NCT04226131|OTHER|Skeletal Muscle Mitochondrial Respiratory Capacity|Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
224291570|NCT04226131|OTHER|Muscle Biopsy|After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
223968368|NCT04028128|DIETARY_SUPPLEMENT|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
223968369|NCT05174988|PROCEDURE|Angle stitch|Surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) vaginal cuff apexes.
223968370|NCT04869046|DRUG|Instillation of levobupivacaine in surgical wound|Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
224113093|NCT01207739|DRUG|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
224113094|NCT01207739|DRUG|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
224113095|NCT01207739|DRUG|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
224113096|NCT03716063|DRUG|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
223724905|NCT00225173|DRUG|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
223968371|NCT04203368|DRUG|adenosine|patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
224113097|NCT03041376|BEHAVIORAL|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
224113098|NCT05002192|DRUG|Eucalyptol, Limonene and Pinene Enteric Soft Capsule|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
224113099|NCT05002192|DRUG|Ambroxol injection|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and cohort EXP+AMB Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP+AMB and AMB\_ONLY cohort
224113100|NCT05002192|DRUG|Other oral mucolytic drugs|Compare the efficacy, safety and economic evaluation of pneumonia expectorant treatment in the cohort of ELP\_ONLY and EXP\_ONLY cohort
224113101|NCT04393181|PROCEDURE|Heart transplantation 1|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with left ventricular dysfunction, defined as an ejection fraction less than 50% or regional hypokinesia.
224113102|NCT04393181|PROCEDURE|Heart transplantation 2|Heart transplantation will be performed according to local routines. Recipients will be transplanted with a donor heart with normal function, according to the recommendations from The International Society for Heart and Lung Transplantation (ISHLT).
224113103|NCT03092258|OTHER|Questionnaire|Questionnaire to be completed by staff
223968372|NCT04203368|DRUG|verapamil|patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
223968373|NCT02721420|DRUG|dihydroartemisinin-piperaquine|
223968374|NCT02721420|OTHER|message(SMS) reminder|
223968375|NCT02721420|OTHER|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
223968376|NCT02721420|OTHER|short message(SMS) reminder|
223968377|NCT06645587|DEVICE|Active HD-tDCS over pre-SMA|Active cathodal HD-tDCS over pre-SMA cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over Fz. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
224113104|NCT01315119|PROCEDURE|SPY Intra-Operative Angiography|Calculated per patient
223968378|NCT06645587|DEVICE|Active HD-tDCS over left DLPFC|Active cathodal HD-tDCS over left DLPFC cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using small circular electrodes (diameter 1 cm) will be applied with the cathode placed centrally over F3. The current intensity will be set at 0.5 mA for a total of 20 minutes (30 s ramp up/down).
223968379|NCT06645587|DEVICE|Sham HD-tDCS|Sham HD-tDCS will be delivered over pre-SMA or left-dlPFC cortex for 10 days (3 sessions per week). The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. Each Sham session will last 20 minutes.
223968380|NCT00725127|DRUG|aspirin|100 mg/day upon awakening for five years
223968381|NCT00725127|DRUG|aspirin|100 mg/day at bedtime for five years
223968382|NCT04536779|OTHER|Training in the local departments of TT and cycling trips with CUA|in a minimum of 3 months, the individuals with low physical mobility will conduct a minimum of 8-10 training and cycling sessions.
223968383|NCT02618200|DEVICE|3D prostate ultrasound|
223968384|NCT06645691|DRUG|Hyperpolarized 13C-pyruvate|Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner
224113105|NCT00500149|DRUG|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
224113106|NCT00500149|DRUG|Placebo|Placebo
224113107|NCT06444737|DRUG|Intravenous ondansetron|Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia
224113108|NCT06444737|DRUG|Intravenous normal saline|Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia
224113109|NCT06516796|OTHER|No intervention|Patients were retrospectively screened.
224113110|NCT04747574|DRUG|EXO-CD24|The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
224113111|NCT03557398|DEVICE|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
224113112|NCT04138524|OTHER|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
223968385|NCT06645639|OTHER|Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)|"The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by:~1. implementing nutrition screening at point-of-admission~2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient~3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and~4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care.~In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment)."
224291571|NCT04226131|OTHER|Body Composition|Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
223968386|NCT02521025|OTHER|Intermittent feeding pattern|Intermittent feeding
223968387|NCT02521025|OTHER|Continuous feeding pattern|Continuous feeding
223968388|NCT01979757|OTHER|Puregraft|
223968389|NCT01979757|OTHER|Centrifugation|
223968390|NCT06125639|BEHAVIORAL|Sauna Bathing|Participants will take part in 9 evening sauna bathing session over the course of 3 weeks
223968391|NCT05812547|DEVICE|Lumen|subjects will use the Lumen device and mobile phone application, which will guide them once a day after the night fast regarding their daily diet, sleep, and routines according to their Lumen measurements. Subjects will need Google Fit (Android) or Apple Health Kit (iOS) and will be encouraged to communicate with a study investigator via the app during the entirety of the study to resolve technical questions about the device and data collection.
223968392|NCT05812547|OTHER|Glucose monitoring mobile app|The control group will use a designated glucose monitoring mobile app to record their glucose levels
223968393|NCT00946010|BIOLOGICAL|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
223968394|NCT04167150|DIETARY_SUPPLEMENT|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
223968395|NCT04842227|PROCEDURE|Nerve block|"Step 1: A small amount of local anesthetic (3-5cc of 0.5% ropivacaine) is administered under ultrasound guidance in the area of the supraclavicular nerve at the base of the neck under sterile conditions. This provides dense anesthesia of the skin and eliminates the need to introduce larger quantities of local anesthetic directly to the skin around the incision (usually 20mL).~The second step involves introducing 10-15cc of 0.5% ropivacaine under ultrasound guidance into the compartment between the pectoralis major and minor muscles to anesthetize the medial and lateral pectoral nerves. NOTE: Usual care involves blind administration of local anesthetic diffusely to the tissues in this region without targeting any particular nerves, and requires larger volumes of anesthetic (40mL for the blind approach vs 10-15mL for the nerve block)."
223968396|NCT05834972|DEVICE|Ultrasound-guided percutaneous dilatational tracheosyomy|All of the participants will be examined two times. First, the landmark-guided technique will be performed. Then, the ultrasound-guided technique will be performed.
223968397|NCT06090318|DRUG|Milademetan|260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
223968398|NCT06090318|DRUG|Atezolizumab|1680mg administered every 4 weeks
223968399|NCT04161872|DRUG|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
223968400|NCT04161872|DRUG|Placebo|Placebo
223968401|NCT04837235|DRUG|Hemay005|oral
223968402|NCT04818918|DEVICE|Absolute coronary flow measurement|Absolute coronary flow will be measured.
223968403|NCT04818918|DEVICE|Microvascular resistance measurement|Microvascular resistance will be measured.
223968404|NCT04818918|OTHER|Cardiac MRI|Cardiac MRI will be performed to evaluate myocardial viability.
223968405|NCT06645730|DIAGNOSTIC_TEST|hypertension|diagnosed with hypertension
223968406|NCT06645730|DIAGNOSTIC_TEST|diabetes|diagnosed with diabetes
223968407|NCT06645730|DIAGNOSTIC_TEST|fatty liver|diagnosed with fatty liver on CT
223968408|NCT06645548|OTHER|Weight estimation using 3D camera|Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
223968409|NCT05148247|BEHAVIORAL|The Perceive, Recall, Plan and Perform System of Intervention|The aim of the PRPP intervention is to enhance mastery in performance of needed or desired occupations, and extend traditional task training. Systematic instructions to support the clients' cognitive capacity to think about doing in different tasks and contexts are given by the OT, based on the results of PRPP Assessment stage 2. Further, the OT uses graded verbal, visual or physical prompts and cues directly during the participants task performance, progressing from content-free meta-prompts 'Stop' to alert the participant to process information required for the task, and for errorless learning. Then the OT prompt 'sense/attend, think and do', to more specific behavioural prompts selected by the therapist based on the components from the PRPP Assessment stage 2. At best the skills are generalized throughout all everyday activities, and the OTs' role as a cognitive mediator fades as the person internalize the strategies.
223968410|NCT01385683|DRUG|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
223968411|NCT01385683|DRUG|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
223968412|NCT00176761|DRUG|Interleukin-2 (IL-2)|
223968413|NCT00913562|DRUG|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
223968414|NCT00913562|DRUG|Placebo|one tablet a day for 12 weeks
223968415|NCT05961488|OTHER|Coronary Calcium Score and Coronary CT angiogram|Introduction of early Coronary CT angiogram and Coronary Calcium Score in the first days after a resuscitated out-of-hospital cardiac arrest.
223968416|NCT01309399|DRUG|Teriparatide|six weeks of teriparatide
223968417|NCT01309399|OTHER|placebo|placebo
223968418|NCT02819271|DRUG|CXL-1427 Ascending Dose|
223968419|NCT02819271|OTHER|Placebo|
223968420|NCT02819271|DRUG|CXL-1427 Descending Dose|
223968421|NCT01323309|BEHAVIORAL|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
223968422|NCT01323309|BEHAVIORAL|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
223968423|NCT01323309|BEHAVIORAL|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
223968424|NCT02200016|PROCEDURE|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
223968425|NCT02200016|PROCEDURE|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
223968426|NCT02200016|DEVICE|B Braun Contiplex S catheter|
223968427|NCT00437619|DRUG|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.
223968428|NCT02961777|OTHER|implementation of care pathway|implementation of a care pathway
224113113|NCT02588846|DEVICE|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
224113114|NCT02929992|OTHER|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
223968429|NCT05033158|OTHER|Blood sampling|Blood sampling before and after COVID-19 vaccination
224113115|NCT02929992|OTHER|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
224113116|NCT02929992|OTHER|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
224113117|NCT02929992|OTHER|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
224113118|NCT03251014|OTHER|YSS|Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks
224113119|NCT03251014|OTHER|Salmon|Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
223724906|NCT01311479|PROCEDURE|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
223724907|NCT04138654|DIETARY_SUPPLEMENT|Processed meat product|300 grams per day during 2 weeks
223724908|NCT04138654|DIETARY_SUPPLEMENT|White meat wash-out|300 grams per day during 2 weeks
223724909|NCT04138654|DIETARY_SUPPLEMENT|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
223724910|NCT04138654|DIETARY_SUPPLEMENT|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
223724911|NCT00231205|PROCEDURE|Revascularization|
223968430|NCT01341418|PROCEDURE|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
223968431|NCT01341418|PROCEDURE|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
223968432|NCT04728659|DRUG|Desogestrel 0.075 MG|It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
223968433|NCT04728659|DRUG|Orgalutran|It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
223968434|NCT00310050|DRUG|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
223968435|NCT00310050|DEVICE|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
223724912|NCT03159624|OTHER|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
223724913|NCT03159624|OTHER|Doyle silastic sheet|Doyle silastic sheet
223724914|NCT04532944|DIAGNOSTIC_TEST|imaging of energy dysfunction|7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
223724915|NCT02956421|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
223724916|NCT02956421|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
223724917|NCT01325584|DRUG|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
223968436|NCT06209905|PROCEDURE|Alveolar ridge augmentation|Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
223968437|NCT03048058|DRUG|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
223968438|NCT03048058|DRUG|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
223968439|NCT02943109|OTHER|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
223968440|NCT02943109|OTHER|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
223968441|NCT02943109|OTHER|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
223968442|NCT02943109|OTHER|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
223968443|NCT02794558|DEVICE|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
223968444|NCT05848102|DRUG|dapagliflozin|FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
223968445|NCT04893993|DRUG|Thiamine|Tablets. 300mg/tablet. Dosage depends on gender and weight
223968446|NCT04893993|DRUG|Placebo|Tablets. Same number of tablets as Thiamine
223968447|NCT01654835|OTHER|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP \<80 mmHg)will trigger an page to be sent to all anesthesia providers in \<1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
223968448|NCT01654835|OTHER|standard of care|A Low Blood Pressure condition as specified (SAP \<80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
224113120|NCT04503486|DIAGNOSTIC_TEST|handgrip strength|measure of handgrip strength using Jamar Dynamometer and a standardized protocol, strength expressed in kg
224113121|NCT04503486|DIAGNOSTIC_TEST|quadriceps strength|maximal isometric quadriceps strength measured using a handheld dynamometer and a standardized protocol, strength expressed in Newton
224113122|NCT00521339|DRUG|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
224113123|NCT00426049|DRUG|Everolimus|
224113124|NCT02847936|PROCEDURE|vicryl plus suture|episiotomy with triclosan-coated sutures
223968449|NCT03244202|OTHER|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
223968450|NCT03244202|OTHER|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
224113125|NCT02847936|PROCEDURE|vicryl suture|episiotomy with non antibacterial coated suture
224113126|NCT00038545|DRUG|Filgrastim SD/01|
224113127|NCT00038545|DRUG|Paclitaxel|
224113128|NCT00038545|DRUG|Topotecan|
224113129|NCT00089843|DRUG|Testosterone|Testosterone patch 150mcg daily
224113130|NCT00089843|DRUG|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
224113131|NCT00089843|DRUG|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
224113132|NCT00089843|DRUG|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
224113133|NCT00648843|DRUG|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
223724918|NCT02344277|DEVICE|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
223724919|NCT00887978|DRUG|UT-15C SR|treprostinil diolamine sustained release tablets
223724920|NCT00887978|DRUG|Placebo|
223724921|NCT05416593|BEHAVIORAL|General exercise prescription (FITT)|The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
223968451|NCT00333554|DIETARY_SUPPLEMENT|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
223968452|NCT00333554|DIETARY_SUPPLEMENT|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
223968453|NCT03937596|DRUG|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
223968454|NCT03937596|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
223968455|NCT03937596|DRUG|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
223968456|NCT04422210|DRUG|Venetoclax|Venetoclax will be administered orally at escalating doses from 200mg to 800mg as 100mg tablets as per the dosing schedules described above.
224113134|NCT00648843|DRUG|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
224113135|NCT02467907|DRUG|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
224113136|NCT02467907|DRUG|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 every 3 weeks for at least 6 cycles
224113137|NCT02467907|DRUG|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
224113138|NCT02697461|OTHER|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
224113139|NCT02697461|OTHER|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
224113140|NCT02996539|OTHER|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
224113141|NCT03234868|DEVICE|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
224113142|NCT03234868|DEVICE|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
223968457|NCT04422210|DRUG|Atezolizumab|Atezolizumab will be administered via intravenous (IV) infusion at a fixed dose of 1200mg as per the dosing schedules described above.
224113143|NCT05406297|PROCEDURE|pressure-temperature sensor guidewire-based measurement|"In brief, a 6-F angioplasty guiding catheter without side-holes will be used first used to engage the left main coronary artery. A pressure-temperature sensor guidewire ( PressureWire™ X Guidewire) will be used for physiology measurements including IMR measurements.~Pressure measurement from the wire was first equalized with that of the guiding catheter. Then the pressure sensor will be positioned two-thirds of the way down the LAD artery. Intracoronary nitroglycerin will be administered (100 to 200 μg). Hyperemia will be induced with adenosine intracoronary injections."
224113144|NCT01386580|DRUG|2B3-101|IV every 21 days
224113145|NCT01386580|DRUG|Trastuzumab|IV every 21 days
224113146|NCT01386580|DRUG|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
224113147|NCT01386580|DRUG|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
224113148|NCT02560688|DRUG|DS-1040b|20 mg single 12-hour intravenous infusion
224113149|NCT02560688|DRUG|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
223968458|NCT04422210|DRUG|Carboplatin|Carboplatin will be administered via IV infusion at a dose of 5mg/mL/min as per the dosing schedules described above.
223968459|NCT04422210|DRUG|Etoposide|Etoposide will be administered via IV infusion at a dose of 100mg/m\^2 as per the dosing schedules described above.
224113150|NCT00206999|DRUG|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
224113151|NCT04497662|DRUG|KPL-404|humanized IgG4 monoclonal antibody
224113152|NCT04497662|OTHER|Matching Placebo|Placebo
224113153|NCT03314519|DIAGNOSTIC_TEST|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
224113154|NCT03314519|DIAGNOSTIC_TEST|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
224113155|NCT05795218|DEVICE|Deep Brain Stimulation|implant and DBS therapy with the directSTIM™ DBS system
224113156|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Treatment of target lesions in the common and/or external iliac arteries by stenting with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
224113157|NCT05811364|DEVICE|Stenting of the Common and/or External Iliac Arteries with Bare Metal Stent|Treatment of target lesions in the common and/or external iliac arteries by stenting with a commercially available bare metal stent that is approved for treatment of the disease.
224113158|NCT05864014|DRUG|Hetrombopag|Hetrombopag
224113159|NCT05864014|DRUG|Hetrombopag plus Placebo|Hetrombopag plus Placebo
224113160|NCT05864014|DRUG|Placebo|Placebo
224113161|NCT05519579|DRUG|Methotrexate|Methotrexate 12mg given intrathecally within 24 hours prior to blinatumomab administration
224113162|NCT05519579|DRUG|Blinatumomab|Blinatumomab 28ug/day continuous infusion for 4 weeks
224113163|NCT06359236|OTHER|BI'KILO Intervention|"The study consists of three stages: preparation phase, implementation phase and follow-up phase. During the preparation phase, participants' weight and body fat ratio will be calculated using a body analysis scale, and their height, waist and hip circumference will be measured.~The implementation phase will last six weeks and consists of six modules, each lasting one week. The skills and practices aimed to be acquired in each module will be required to be applied in the following practice modules.~At the end of the implementation phase, participants' weight, waist and hip circumferences will be measured again.~The final phase, called the follow-up phase, will last four weeks. During this phase, participants will continue to keep a self-monitoring record of their eating and physical exercise, complete a hunger scale, and application card notifications will continue to be displayed."
224113164|NCT02517112|OTHER|Parabolic flight|
224113165|NCT02517112|OTHER|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
224113166|NCT02517112|DEVICE|3D-BCG sensor|
224113167|NCT04897412|DRUG|CBL-514 Injection|Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.
224113168|NCT04897412|OTHER|Placebo|Sodium Chloride (0.9% NaCl) placebo for injection
223968460|NCT00966056|DRUG|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
223968461|NCT00966056|DEVICE|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
223968462|NCT04232475|OTHER|1 minute of stair climbing and descending|1 minute of stair climbing and descending
223968463|NCT04232475|OTHER|3 minute of stair climbing and descending|3 minute of stair climbing and descending
224113169|NCT04347811|BEHAVIORAL|Death Cafe|Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
224113170|NCT00312351|DRUG|Pegaptanib sodium|
224113171|NCT03042611|DRUG|Rivoceranib|Oral tablet
224113172|NCT03042611|DRUG|Placebo|Oral tablet
224113173|NCT01741272|PROCEDURE|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
224113174|NCT01741272|PROCEDURE|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
224113175|NCT01809990|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy|
223968464|NCT04232475|OTHER|10 minute of stair climbing and descending|10 minute of stair climbing and descending
223968465|NCT02200029|DRUG|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
223968466|NCT02200029|DRUG|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
223968467|NCT06537219|OTHER|Assessment|Assessment of pain severity,pain thresold of the fascia, pain sensitivity
223968468|NCT02894359|DEVICE|cone beam imagery of cervical spine|
223968469|NCT00570804|BEHAVIORAL|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
223968470|NCT00570804|BEHAVIORAL|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
223968471|NCT03081351|PROCEDURE|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
223968472|NCT03081351|PROCEDURE|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
223968473|NCT04833842|OTHER|Web-based childbirth preparation program developed based on health belief model and supported by motivational interview|In the three-month study, primigravida women in the initiative group will be given a web-based childbirth preparation program, which is prepared based on the Health Belief Model and supported by motivational interviews. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
223968474|NCT04833842|OTHER|Web-based childbirth preparation program based on health belief model|In the three-month study, a web-based childbirth preparation program based on the Health Belief Model will be applied to primigravida women in the control group. Before starting the training program, pre-test will be applied to pregnant women and a five-week program will be implemented. A final test will be applied at the end of the program. The birth process will be evaluated immediately after the pregnant women give birth.
223968475|NCT05240729|PROCEDURE|Infraclavicular brachial plexus block|Using ultrasound in 3different techniques of infraclavicular brachial plexus block
223968476|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
223968477|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
223968478|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
223968479|NCT01078376|DRUG|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
223968480|NCT02802579|RADIATION|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
223968481|NCT02802579|RADIATION|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
223968482|NCT02802579|RADIATION|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
223968483|NCT06196073|OTHER|Osteopathic manual therapy|Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization
223968484|NCT06196073|DIETARY_SUPPLEMENT|conservative treatment|Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
223968485|NCT02031445|DRUG|MRX-6|
223968486|NCT02031445|OTHER|Placebo|
223968487|NCT05439720|DIETARY_SUPPLEMENT|Ketone ester|A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
223968488|NCT05439720|DIETARY_SUPPLEMENT|Placebo|Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
223968489|NCT05439720|BEHAVIORAL|Exercise|A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
223968490|NCT05908149|DEVICE|Insole Splint|Insole splint used in 'Pes equinus' in patients with hemiplegia
223968491|NCT03772119|PROCEDURE|Surgical resection|Surgical resection of hemivertebra
223968492|NCT00739024|DRUG|Ramelteon|8 mg tablet, oral, once daily
223968493|NCT00739024|DRUG|Placebo|Placebo tablet, oral, once daily
223968494|NCT05174871|BEHAVIORAL|Lifestyle intervention|Lifestyle intervention (usual treatment for patients with obesity). The behavioral intervention will last for 2 months.
223968495|NCT05174871|BEHAVIORAL|TRF intervention|Food intake restricted to 8 hours per day during the window between 10h and 22h. Time restricted feeding will take place 6 days per week, with the seventh day unrestricted. The intervention will last for 2 months.
223968496|NCT00685347|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
223968497|NCT00685347|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
223968498|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
223968499|NCT00577096|BEHAVIORAL|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
223968500|NCT00577096|BIOLOGICAL|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
223968501|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
223968502|NCT00577096|DRUG|Thalidomide|Fifty percent of the participants received 400 mg daily
223968503|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
223968504|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
223968505|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
223968506|NCT00577096|DRUG|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
223968507|NCT00577096|DRUG|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
223968508|NCT00577096|BIOLOGICAL|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
223968509|NCT00577096|DRUG|Thalidomide|Fifty percent of participants received 400 mg daily
223968510|NCT00577096|DRUG|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
223968511|NCT00577096|BIOLOGICAL|Platelet Transfusion|Platelet transfusions were administered as needed
223968512|NCT00577096|DRUG|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
223968513|NCT02290197|PROCEDURE|Surgery|Surgical reconstruction of all injured ligaments.
223968514|NCT02290197|DEVICE|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
223968515|NCT02290197|DEVICE|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
223968516|NCT01956955|DRUG|enoxaparin ,alteplase, unfractionated heparin|
223968517|NCT05359705|DEVICE|DJO 456|Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
223968518|NCT05359705|DEVICE|Aspen 456|Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
223968519|NCT05359705|DEVICE|DJO 464|Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
223968520|NCT05359705|DEVICE|Aspen 464|Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
223968521|NCT01537263|DEVICE|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
223968522|NCT04694859|DEVICE|Transcatheter Aortic Valve Implantation|Transfemoral or transapical Transcatheter Aortic Valve Implantation
223968523|NCT01849185|OTHER|Food supplement|
223968524|NCT04031534|DRUG|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
223968525|NCT03909334|DRUG|Osimertinib|Osimertinib 80 mg orally on Day 1
223968526|NCT03909334|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes
223968527|NCT00832650|DRUG|fesoterodine fumarate|8 mg OD for 14 days
223968528|NCT00832650|DRUG|placebo|OD for 14 days
223968529|NCT00832650|DRUG|solifenacin|10 mg OD for 14 days
223968530|NCT06367426|DRUG|DDN-A-0101 (SAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
223968531|NCT06367426|DRUG|DDN-A-0101 (MAD)|"Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
223968532|NCT06367426|DRUG|Placebo (SAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture"
223968533|NCT06367426|DRUG|Placebo (MAD)|"Placebo drug~* Development name: placebo of DDN-A-0101~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: repeated oral administration (150, 300, 450, 600 mg, 2 times/day, 2 weeks of repeated administration)~* Expiration date: 36 months from the date of manufacture"
223968534|NCT02518659|DIETARY_SUPPLEMENT|Inulin|This is the Intervention
223968535|NCT05778799|OTHER|Balance test|10 second left- or right-leg stance with eyes open, and single 10 second left- or right-leg stance with eyes closed
223968536|NCT06360445|DRUG|Olaparib Tablet test formulation 100mg|A generic product manufactured by CSPC Ouyi Pharmaceutical Co., Ltd.
223968537|NCT06360445|DRUG|Olaparib Tablet reference formulation 100mg|Olaparib Tablet reference formulation 100mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
223968538|NCT06360445|DRUG|Olaparib Tablet test formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
223968539|NCT06360445|DRUG|Olaparib Tablet reference formulation 150mg|Olaparib Tablet reference formulation 150mg were used as a comparator drug for the bioequivalence study, manufactured by AbbVie Limited.
223968540|NCT05185739|DRUG|Pembrolizumab|Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
223968541|NCT05185739|DRUG|Lenvatinib|Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight \<60gk≥) for 6 weeks
223968542|NCT05185739|DRUG|Pembrolizumab and Lenvatinib|Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
223968543|NCT05616312|BEHAVIORAL|Educational Teach Back|Patients will receive teach-back education while they fill out questionnaires.
223968544|NCT06584773|DRUG|Everolimus|mTORi added as the fourth maintenance immunosuppressive drug in recipients
223968545|NCT06584773|DRUG|standard maintenance immunosuppression|standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
223542757|NCT03111316|DRUG|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
223724922|NCT05416593|BEHAVIORAL|Affective regulation (AFFECT)|As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
223724923|NCT06064604|OTHER|Control|The stroke survivors will serve as their own control group. The participants will complete the required tasks without an exoskeleton device.
223968546|NCT06584669|DIETARY_SUPPLEMENT|Krill oil|The krill oil capsules contain Superba™ krill oil extracted from Antarctic krill (Euphausia superba).
223968547|NCT06584669|OTHER|Placebo|The placebo capsules contain a medium-chain triglyceride (MCT) oil obtained by fractionation of coconut and palm kernel oil, which has no detectable levels of EPA, DHA, astaxanthin, or phospholipids.
223968548|NCT06584565|OTHER|microbiome; metabolomics; proteomics|post-stroke change of microbiome; metabolomics; proteomics
223968549|NCT03771378|DRUG|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
223968550|NCT03771378|DRUG|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count \> 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
223968551|NCT02395224|OTHER|cancer treatment and follow-up according to current regional and national guidelines|
223968552|NCT02383121|DRUG|Midodrine|Not appliciable
223968553|NCT05043428|BEHAVIORAL|The roles of peers and functional tasks in enhancing exercise training for adults with COPD: a pilot randomized controlled trial|An 8 week two-arm pilot randomized control trial aimed to evaluate the effects of an online exercise and peer support intervention for people living with COPD.
223968554|NCT06385418|DRUG|Colonic local administration of fluorouracil with enhanced adhesion|Fluorouracil is administered via the colon as an injectable solution at a dose of 500 mg per day for 6 days, along with poloxamer 407 and poloxamer 188 used as thermosensitive hydrogel to enhance adhesion.
223968555|NCT01881100|OTHER|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
223968556|NCT01881100|OTHER|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
223968557|NCT05555121|DRUG|Progesterone Effervescent Vaginal Tablet|On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
223968558|NCT02078778|DEVICE|CPAP|3 months of CPAP treatment
223968559|NCT00002099|DRUG|Lentinan|
223968560|NCT00002099|DRUG|Didanosine|
223968561|NCT04419961|BEHAVIORAL|Educational program|"The educational program includes a group discussion and a booklet.~The group discussion lasts for 90 minutes, discussing importance of sexual activity during pregnancy, improving sexual experience during pregnancy, physical and mental changes of pregnant women, and measures to cope with discomfort, anxiety, fear and other issues. It includes a 30-minutes presentation, followed by 1-hour discussion.~The booklet is a color-printed A5-size booklet containing in-depth information of the content given during the discussion. Each participant can only receive one copy of the booklet, and the booklet is not given to the control participants."
223968562|NCT00639236|OTHER|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
223968563|NCT03672383|DEVICE|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
223968564|NCT04290156|OTHER|joint visits|The intervention is the implementation of joint transition visits with the participation of both the pediatric and the adult gastroenterologist. One-year intervention period was chosen. In total, there are four joint visits every third months for the adolescents aged 17-18. Each joint visit lasts for at least for 20 minutes, although in case of complex medical history, there is no restriction with respect to the length of the visit. Joint transition visits 1, 2 and 3 (V1-3) are led by the pediatric gastroenterologist, and visit 4 (V4) is led by the adult gastroenterologist.
223968565|NCT05028647|DEVICE|Virtual reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a VR device (Oculos)
223968566|NCT05028647|DEVICE|Augmented reality training|one hour a day for 5 days of engagement in tasks proposed by a specially crafted software through a AR device (tablet)
223968567|NCT04593641|BIOLOGICAL|CT-P59|administered
223968568|NCT00214071|BIOLOGICAL|Influenza vaccine|
223968569|NCT03074383|BEHAVIORAL|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
223968570|NCT03074383|BEHAVIORAL|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
223968571|NCT01370564|DRUG|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
223968572|NCT05300698|DEVICE|MRI|compare between MRI and ultrasound for indirect assessment of ocular layers
223968573|NCT03143634|BEHAVIORAL|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
223542758|NCT03111316|DEVICE|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
223968574|NCT03143634|BEHAVIORAL|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
223968575|NCT06390124|DRUG|Platelet Derived Growth Factor (PDGF)|Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
223968576|NCT05958784|DIETARY_SUPPLEMENT|L-Phenylalanine|100 mg/kg
224113176|NCT01099410|PROCEDURE|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
223542759|NCT01468480|DRUG|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
223542760|NCT01468480|DRUG|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
223542761|NCT01468480|DRUG|MultiCal|application of Multical in forth group as a pulp dressing agent
223542762|NCT01468480|DRUG|Dycal|application of Dycal in first group as a pulp dressing agent
223542763|NCT05739292|BIOLOGICAL|EuNmCV-5|0.5mL single intramuscular dose on Day 0
223542764|NCT05739292|BIOLOGICAL|Menveo|0.5mL single intramuscular dose on Day 0
223542765|NCT03402100|DRUG|eye drops|children who received daily eye drops for myopia
223542766|NCT05999331|OTHER|initial aspartate aminotransferase (AST) to platelet (PLT) ratio index|All eligible patients were given antibiotics therapy, actively control infection source, as well as other supportive therapy to maintain organ function.
223968577|NCT04235894|DRUG|Propofol|Intravenous anesthesia with propofol started with 0.5 mg kg-1, and was titrated until a patient was unresponsive to painful stimuli \& maintaining spontaneous breathing during gastrointestinal endoscopy
223968578|NCT06310330|DIAGNOSTIC_TEST|Comprehensive echocardiographic follow-up|Comprehensive echocardiographic follow-up for identification of CRTCD in breast cancer patients
223968579|NCT06310330|DIAGNOSTIC_TEST|Simplified echocardiographic follow-up|Simplified echocardiographic follow-up for identification of CRTCD in breast cancer patients
224113177|NCT01099410|PROCEDURE|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
224113178|NCT01099410|PROCEDURE|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
223968580|NCT03123224|BEHAVIORAL|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
223968581|NCT03123224|BEHAVIORAL|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
223968582|NCT01260259|PROCEDURE|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
223968583|NCT01260259|PROCEDURE|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
223968584|NCT04887597|DRUG|Secukinumab|The study is composed of a single arm receiving secukinumab for the duration of 6 months.
223968585|NCT01998334|OTHER|CVVH 6h|CVVH 6h for first three days
224113179|NCT02967848|OTHER|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
224113180|NCT02967848|OTHER|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
224113181|NCT02967848|OTHER|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
223724924|NCT06064604|DEVICE|Hip Exoskeleton|The Georgia Tech Hip Exo is a wearable robotic device for hip extension/flexion assistance. This device will be used to study the lower limb movement and how to effectively assist users. It makes use of a responsive controller that considers information such as joint angles to understand the user's state and assists with the appropriate level of power accordingly.
223968586|NCT01998334|OTHER|CVVH 10h|CVVH 10h for first three days
223968587|NCT01998334|OTHER|CVVHDF 6h|CVVHDF 6h for first three days
223968588|NCT05060406|DRUG|LY06006|60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
223968589|NCT05283642|DIETARY_SUPPLEMENT|DCI|Oral supplementation with D-chiro-inositol once daily
223968590|NCT04681209|BEHAVIORAL|DRT Condition|"Children were asked to provide five descriptors of two children who each engaged in defending behaviors. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what friendship heroes are like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity."
223968591|NCT04681209|BEHAVIORAL|Empathy Condition|Children in the empathy-based condition were asked to provide five descriptors of how two children who were bullied would fee. Two weeks later they were told the top seven descriptors given by the hundreds of children participating in the project. This was followed by a brief discussion of how one could best help another kid who was getting bullied. Children then made posters to share with younger grades as to what being bullied feels like, using the descriptor words shared with them, and how to be a friendship hero (i.e., how to help someone who is being bullied). Posters were hung for two-to-four months after the intervention activity.
224113182|NCT00260741|DRUG|Smoked Cannabis|
224113183|NCT03428191|DRUG|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
224113184|NCT03218852|DRUG|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
224113185|NCT03218852|DRUG|prednisone alone|Prednisone is administered to participants in this group.
224113186|NCT04030481|OTHER|inhalation anesthesia|sevoflurane was used to maintain anesthesia
224113187|NCT04030481|OTHER|Total intravenous anesthesia|propofol was used to maintain anesthesia
224113188|NCT03198169|DEVICE|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
224113189|NCT03198169|DEVICE|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
223542767|NCT03081104|DEVICE|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
223968592|NCT03473652|OTHER|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
223968593|NCT01341106|DRUG|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
223968594|NCT00794573|DRUG|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
223968595|NCT00794573|OTHER|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
223968596|NCT04433247|BEHAVIORAL|Peer Led Group Intervention|Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
223968597|NCT00246389|DRUG|cyclobenzaprine hydrochloride|
223968598|NCT05888272|BEHAVIORAL|Stress managment|The Doing What Matters in Times of Stress self-help manual materials and lay helper scripts utilized in the study are rooted in the principles of Acceptance and Commitment Therapy (ACT). They are designed to improve psychological flexibility which refers to an individual's ability to adapt to changing situations, reallocate mental resources, shift perspectives, and balance competing priorities. The ACT approach teaches individuals how to manage challenging thoughts and emotions through mindfulness techniques, while also guiding them to live in alignment with their personal values.
223968599|NCT06454578|DRUG|Adebrelimab + Apatinib|"the first 6 months or 8 cycles: Adebrelimab 1200 mg, every 3 weeks； Apatinib 250 mg/day~Maintenance phase： Adebrelimab 1200 mg, every 3 weeks, Maximum maintenance up to 2 years"
224113190|NCT03527056|BIOLOGICAL|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
223968600|NCT02885376|DEVICE|Dentoxol|Mouthrinse
223968601|NCT02885376|DEVICE|Placebo|Mouthrinse
224113191|NCT04076722|BEHAVIORAL|Stress reactivity stimuli|An evaluated speech task delivered to participants after baseline testing.
224113192|NCT00950690|DRUG|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
224113193|NCT02629081|OTHER|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
223968602|NCT00490113|DRUG|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
223968603|NCT01142154|DRUG|Prodarsan|Prodarsan TID, oral solution, 6-8 days
223968604|NCT02637466|DRUG|Vortioxetine|
223968605|NCT05967793|OTHER|kinesio tape|Kinesio Tape will be applied on paraspinal trunk extensors muscles for 8 weeks, changed every 3 days.
223968606|NCT01595724|DRUG|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
223968607|NCT06585475|BEHAVIORAL|Structured training according to premenstrual syndrome symptom map|A symptom map consisting of evidence-based practices for coping with PMS symptoms was created. An educational content based on this map was prepared and applied to women with PMS to evaluate whether it was effective compared to the control group.
223968608|NCT06584617|DEVICE|Berovenal®|Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.
223968609|NCT06584617|DEVICE|NU-GEL Hydrogel with Alginate|Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
223968610|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages
223968611|NCT04260776|BEHAVIORAL|Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages|Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
223968612|NCT04260776|BEHAVIORAL|Phase 2: re-engagement text messages|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive interactive text messages designed to promote re-engagement
223968613|NCT04260776|BEHAVIORAL|Phase 2: re-engagement emails|In addition to Phase 1 intervention components, 1/3 of participants who disengage with the website will receive a personalized email designed to promote re-engagement
223968614|NCT01540877|PROCEDURE|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
223968615|NCT01540877|PROCEDURE|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
223968616|NCT01540877|PROCEDURE|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
223968617|NCT01540877|PROCEDURE|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
223968618|NCT03928171|OTHER|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
223968619|NCT03588195|OTHER|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
223968620|NCT03588195|DEVICE|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
223968621|NCT01637337|PROCEDURE|laparoscopic pyelolithotomy|laparoscopy
223968622|NCT01637337|PROCEDURE|percutaneous nephrolithotomy|percutaneous nephrolithotomy
223968623|NCT06059963|DEVICE|Signal-C™|Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).
223968624|NCT00433498|DRUG|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
224113194|NCT01713036|DRUG|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) \[14C\] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries \[mcgCi\]) of \[14C\] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
223542768|NCT03081104|DEVICE|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
223968625|NCT00433498|DRUG|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
223968626|NCT00433498|DRUG|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
223968627|NCT00433498|DRUG|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
223968628|NCT05351697|DRUG|BR105 injection|0.2mg/kg, 1mg/kg, 3mg/kg, 10mg/kg, 20mg/kg, 30mg/kg, 40mg/kg respectively
223968629|NCT05563961|DRUG|Panadol®|Reference Drug. Multiple-dose stage: Cohort 1, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg)
223968630|NCT05563961|DRUG|SafeTynadol®|"Test Drugs. Multiple-dose stage:~Cohort 2, 2 tablets Q6H (total 4 dosages, 8 tablets or 4,000 mg) Cohort 3, 3 tablets at first dosage and 2 tablets at second to forth dosage Q6H (total 4 dosages, 9 tablets or 4,500 mg) Cohort 4, 3 tablets at first to second dosage and 2 tablets at third to forth dosage Q6H (total 4 dosages, 10 tablets or 5,000 mg) Cohort 5, 3 tablets Q6H (total 4 dosages, 12 tablets or 6,000 mg) Cohort 6, 4 tablets Q6H (total 4 dosages, 16 tablets or 8,000 mg) Cohort 7, 5 tablets Q6H (total 4 dosages, 20 tablets or 10,000 mg) Cohort 8, 6 tablets Q6H (total 4 dosages, 24 tablets or 12,000 mg)"
223968631|NCT05830422|OTHER|nothing|Follow-up observation was conducted without any intervention in an outpatient setting.
223968632|NCT04178876|PROCEDURE|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
223968633|NCT04178876|PROCEDURE|stripping technique|Endometrioma laparoscopic cystectomy
224113195|NCT05099757|BIOLOGICAL|20 µg dose hepatitis B vaccine|one-dose, two-dose or three-dose, 20 µg per dose
224113196|NCT00216359|DRUG|Fuzeon (Enfuvirtide)|
224113197|NCT00216359|PROCEDURE|Laboratory diagnostic (CD4-cells)|
224113198|NCT00216359|PROCEDURE|Laboratory diagnostics (HIV-1 viral load)|
224113199|NCT00216359|DRUG|antiretroviral co-medication beside Fuzeon|
224113200|NCT02897973|OTHER|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
223968634|NCT00383994|DRUG|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
223968635|NCT00383994|DRUG|Rituximab|375 mg/m\^2 by vein followed by 1000 mg/m\^2 weekly for 3 weeks for a total of 4 doses.
223968636|NCT00383994|BIOLOGICAL|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
223968637|NCT03479502|DRUG|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
223542769|NCT03081104|PROCEDURE|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
223968638|NCT03479502|DRUG|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
223968639|NCT02716272|DRUG|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
223968640|NCT02716272|DRUG|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
223968641|NCT02821572|BIOLOGICAL|blood sample|
223968642|NCT02821572|PROCEDURE|spleen sample|
223968643|NCT05274490|PROCEDURE|intubation and mechanical ventilation|patients who were in need were intubated and mechanically ventilated
223968644|NCT05959837|OTHER|Adaptive Rowing Exercise|Participants will perform two bouts of rowing exercise each with a 2-minute warm up and cool down in addition to the following: (1)10 minutes of steady state rowing with goals to achieve moderate intensity exertion levels, followed by a variable rest period to return exertion and heart rate to initial levels, (2) 10 minutes of interval rowing alternating between one minute of low-moderate intensity and 30 seconds of moderate-vigorous intensity.
223968645|NCT02400398|OTHER|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
223968646|NCT03529006|PROCEDURE|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
223968647|NCT03529006|PROCEDURE|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
223968648|NCT00966706|DRUG|capecitabine|Given systemically
223968649|NCT00966706|DRUG|cisplatin|Given systemically
224113201|NCT03697278|DEVICE|Smith medical CADDsolis|This group will be monitoring from a network.
224113202|NCT03851393|OTHER|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
223542770|NCT01074931|DRUG|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
223542771|NCT00953706|DRUG|Ivacaftor|Tablet
223968650|NCT00966706|DRUG|docetaxel|Given systemically
223968651|NCT00966706|DRUG|epirubicin hydrochloride|Given systemically
223968652|NCT00966706|DRUG|gemcitabine hydrochloride|Given systemically
223968653|NCT01855672|DEVICE|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
223968654|NCT01681394|DIETARY_SUPPLEMENT|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
223968655|NCT01681394|DIETARY_SUPPLEMENT|Chocolate cream|
223968656|NCT01299324|DEVICE|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
223968657|NCT05698888|DRUG|VP301|VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
223968658|NCT02418819|DRUG|PF-06412562 3mg BID|PF-06412562
223968659|NCT02418819|DRUG|PF-06412562 9mg BID|PF-06412562
223968660|NCT02418819|DRUG|PF-06412562 45mg BID|PF-06412562
223968661|NCT02418819|OTHER|Placebo|Placebo
223968662|NCT02523417|PROCEDURE|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
223968663|NCT01721759|DRUG|Nivolumab|
223968664|NCT00040729|GENETIC|mutation analysis|
223968665|NCT00579475|DRUG|Mifegyne|tablets, 50 mg every other day
223968666|NCT00579475|DRUG|placebo|
223968667|NCT05789199|DRUG|Cefiderocol|Cefiderocol is a novel siderophore cephalosporin developed for the treatment of infections caused by Gram-negative bacteria (GNB), including those resistant to carbapenems.
224113203|NCT03851393|PROCEDURE|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
224113204|NCT03851393|DIAGNOSTIC_TEST|Peptest™|The Peptest™ lateral flow device
224113205|NCT05014698|GENETIC|WGS|Whole Genome sequencing
224113206|NCT04151563|BIOLOGICAL|nivolumab|Specified dose on Specified days
224113207|NCT04151563|BIOLOGICAL|ipilimumab|Specified dose on Specified days
224113208|NCT04151563|DRUG|cabozantinib|Specified dose on Specified days
224113209|NCT04151563|BIOLOGICAL|docetaxel|Specified dose on Specified days
224113210|NCT04151563|BIOLOGICAL|ramucirumab|Specified dose on Specified days
224113211|NCT04151563|DRUG|lucitanib|Specified dose on Specified days
224113212|NCT02418403|BEHAVIORAL|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
224113213|NCT02418403|BEHAVIORAL|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
224113214|NCT05874219|DRUG|Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU|The intervention Sprayed 1 to 3 times /day
224113215|NCT05874219|DRUG|Mupirocin 2% ointment|10 mm of mupirocin ointment squeezed directly on to their exit sites from a 15 g tube with an outlet diameter of 5 mm
223968668|NCT03209336|RADIATION|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
223968669|NCT06461949|DRUG|Dupilumab|Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma and Eosinophilic Esophagitis.
223968670|NCT04121949|DEVICE|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
223968671|NCT00390806|DRUG|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
223968672|NCT00390806|RADIATION|Radiation|Whole brain radiation
223968673|NCT02074865|BIOLOGICAL|biological samples|
223968674|NCT06270004|OTHER|nonsurgical periodontal therapy|sonic scaler for scaling and polishing. Graces curettes numbers(1-2,3-4,5-6,7-8,9-10,11-12,13-14)for root surfaces debridement(RSD), instructions and motivation for dental arch
223968675|NCT03188549|OTHER|AniosGel 85 NPC|Hand hygiene formula
223968676|NCT03188549|OTHER|Softa-Man (Braun)|Hand hygiene formula
223968677|NCT03188549|OTHER|Septol|alcohol-based hand rub
224113216|NCT00392002|DRUG|Esomeprazole|
224113217|NCT02470013|DIETARY_SUPPLEMENT|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
223542772|NCT00953706|DRUG|Placebo|Tablet
223542773|NCT01404234|DRUG|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
223968678|NCT05414656|DEVICE|Saddle contoured metal matrix, Pre-contoured self-adhesive matrix|Saddle contoured metal matrix placed with the small clipper. The -contoured self-adhesive matrix has self adhesive ability.
223968679|NCT06077695|OTHER|therapeutic education|The themes covered concern head trauma in the chronic phase.
223542774|NCT04859192|OTHER|gamified flipped classroom|moodle will be gamified
223968680|NCT06077695|OTHER|tDCS|The constant electric current will be delivered at an intensity of 2 mA for 20 minutes.The anode will be placed opposite the dorsolateral prefrontal area on the right. The cathode (or reference electrode) will be positioned opposite the supraorbital area on the left. This methodology is based on the general directions and results from scientific studies which aimed to improve the efficiency of neural networks engaged in attentional processes and working memory.
223968681|NCT06077695|OTHER|cognitive remediation|"Personalized sessions combining 2 approaches:•Retraining deficit components of working memory.exercise the strengthening of metacognition and the learning of reorganization-facilitation strategies. At the end of each exercise, the participant will be asked to analyze their performance and will benefit from feedback from the rehabilitator as well as a discussion on the use of the strategies. Finally, all of the proposed tasks will be made up of several levels of complexity; moving to a more complex stage will require more than 90% success in the exercise.•More ecological exercises will also be carried out in order to get as close as possible to the difficulties encountered by the patient on a daily basis. The examiner will guide the rehabilitation and propose tasks imitating his daily life."
223542775|NCT05548764|PROCEDURE|Prevention Bundles for SSIs|10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.
223542776|NCT05007327|OTHER|Exposure to pollen and air pollution|For all subjects of the cohort, we will follow exposure to pollen and air pollution.
223542777|NCT06717386|PROCEDURE|diagonal pelvic osteotomy|supraacetabular pelvic osteotomy in oblique shape
223542778|NCT05528406|DRUG|HLX208|900mg bid po
223542779|NCT00408980|BEHAVIORAL|Fat and calorie controlled diet|
223968682|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
223968683|NCT00714688|DRUG|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
223968684|NCT00714688|DRUG|Placebo|2xplacebo once daily for 13 weeks
224113218|NCT01795469|DEVICE|Zoex compression garment|5-strap compression of abdomen, thighs and legs
224113219|NCT04919993|BEHAVIORAL|Cognitive Behavioral Therapy-Insomnia|Group presentation
223542780|NCT00737932|DRUG|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
223542781|NCT00737932|OTHER|placebo|Matching placebo for 8 weeks of treatment
224113220|NCT00758914|DIETARY_SUPPLEMENT|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
224113221|NCT01096771|DRUG|ClinOleic 20%|96 hour continuous infusion.
224113222|NCT01096771|DRUG|Intralipid 20%|96 hour continuous infusion.
223968685|NCT02391571|DRUG|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
223968686|NCT02391571|DRUG|Oxycodone|Oxycodone to be taken with stable dose of Methadone
223968687|NCT02391571|DRUG|Placebo|2 day placebo run in prior to test and active drug phase of study
223968688|NCT02931994|OTHER|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
223968689|NCT04910061|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide (NMN-C)|Daily supplementation with NMN-C at 400 mg for 29 days in total
223968690|NCT05480202|OTHER|Thoracic block technique|Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation
223968691|NCT05480202|OTHER|Designed chest physical therapy program|Percussion, vibration and postural drainage
223968692|NCT06045364|DRUG|Glycopyrrolate|During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
223968693|NCT06045364|DRUG|Anisodamine|During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
223968694|NCT00124644|DRUG|cytarabine|
223968695|NCT00124644|DRUG|daunorubicin hydrochloride|
223968696|NCT00124644|DRUG|etoposide|
223968697|NCT00124644|DRUG|tipifarnib|
223968698|NCT00124644|PROCEDURE|chemotherapy|
223968699|NCT00124644|PROCEDURE|enzyme inhibitor therapy|
223968700|NCT00124644|PROCEDURE|high-dose chemotherapy|
223968701|NCT02319304|DRUG|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
223968702|NCT02319304|RADIATION|Low dose fractionated radiation therapy (LDFRT)|see arm description
223968703|NCT04915456|DRUG|Systemic Steroid (Prednisolone)|Systemic steroids (Prednisolone) additive to topical steroids (Mometasone fuorate) in a postoperative setting after FESS
223968704|NCT04915456|OTHER|Placebo|Placebo additive to topical steroids in a postoperative setting after FESS
223968705|NCT04685759|OTHER|In-Person Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes per in-person session.
223968706|NCT04685759|OTHER|Virtual Exercise Protocol|Supervised aerobic, resistance, flexibility, balance, and agility exercises, which could include yoga for a total of approximately 75 minutes each virtual session. A TheraBand (resistance band) will be provided to patients in this group to be used for resistance and flexibility training.
223968707|NCT05206916|PROCEDURE|cryotherapy|Cryotherapy at sites of vibration as origin of snoring and site of collapse for patients with obstructive sleep apnea syndrome
223968708|NCT02077556|DRUG|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
223968709|NCT02077556|DRUG|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell \< 4000/mcL)
223968710|NCT02077556|DRUG|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
223968711|NCT02077556|DRUG|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
223968712|NCT02077556|DRUG|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
223968713|NCT01808144|DRUG|lesinurad|Tablets, 400 mg once daily (QD)
223968714|NCT01808144|DRUG|lesinurad|Tablets, 200 mg QD
223968715|NCT01808144|DRUG|febuxostat|Tabletsm 80 mg QD
223542782|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
223968716|NCT05493605|PROCEDURE|Delivery of a long-term Holter 21 days Or placement of an implantable holter from the outset so syncope|The intervention consists of setting up a morphological and rhythmological cardiological follow-up of patients with confirmed Wilson's disease. It will require the wearing of a long-term Holter (21 days) and for some patients the installation of an implantable cardiac monitor.
223968717|NCT06133569|BEHAVIORAL|ReDirection|Self help program based on principles for cognitive behavioral therapy
223968718|NCT04425070|COMBINATION_PRODUCT|ICE [ifosfamide+carboplatin+etoposide]|"• Combined with ICE chemotherapy regimen:~* Ifosfamide: 5 g/m2, continuous intravenous (iv) infusion (mesna 5 g/m2 synchronously iv infusion for rescue), on Day 2;~* Carboplatin: with concentration-area under time curve (AUC)=5 (highest concentration to 800 mg), iv infusion, on Day 2;~* Etoposide l00 mg/m2, iv infusion, on Days 1-3;~* ATG-010 60 mg/once, oral, on Days 4 and 11. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
223968719|NCT04425070|COMBINATION_PRODUCT|GEMOX [gemcitabine+oxaliplatin]|"• Combined with GEMOX chemotherapy regimen:~* Gemcitabine 1000 mg/m2, iv infusion, on Days 1 and 8;~* Oxaliplatin 130 mg/m2, iv infusion, on Day 1;~* ATG-010 60 mg/once, oral, on Days 2 and 9. After the treatment with combination chemotherapy, the patients will continue to receive maintenance treatment of ATG-010 60 mg/once per week (QW)."
223968720|NCT04425070|COMBINATION_PRODUCT|Tislelizumab|Tislelizumab will be administered intravenously at a fixed dose of 2 0 0 mg every 3 weeks on Day 1 of each cycle
223968721|NCT06647121|BEHAVIORAL|ACT Psychoeducational Workshop|The 1-hour ACT psychoeducational workshop will introduce participants to Acceptance and Commitment Therapy and include guided practice of the mindfulness exercise that they will be asked to practice for two weeks.
223968722|NCT06647121|BEHAVIORAL|ACTaide Mobile App|The ACTaide mobile app is a novel app that is designed to support home practice of exercises from ACT via annotated image sequences and reminder notifications. A prototype version that features the dropping anchor mindfulness exercise will be investigated in this study.
223968723|NCT06647121|BEHAVIORAL|Reminders-only mobile app|This app will include only reminder notifications to encourage home practice of the dropping anchor mindfulness exercise in the comparator condition. It will not include the annotated image sequence for the exercise (i.e., the primary feature of the ACTaide app to be investigated in the intervention condition).
223968724|NCT02744105|DIETARY_SUPPLEMENT|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
223968725|NCT06601504|DRUG|HMPL-760 planned dose 1|HMPL-760 planned dose 1 daily (QD) orally
223968726|NCT06601504|DRUG|R-GemOx|R-GemOx regimen includes Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection. R-GemOx regimen in 21-day cycle for a total of 6 cycles. Rituximab 375 mg/m\^2 ivgtt is given on day 1 of each cycle, and gemcitabine 1000 mg/m\^2 ivgtt is given, followed by oxaliplatin 100 mg/m\^2 ivgtt on day 2 of each cycle.
223968727|NCT06601504|DRUG|HMPL-760 placebo planned dose 1|HMPL-760 placebo planned dose 1 daily (QD) orally
223968728|NCT06601504|DRUG|HMPL-760 planned dose 2|HMPL-760 planned dose 2 daily (QD) orally
223968729|NCT06601504|DRUG|HMPL-760 placebo planned dose 2|HMPL-760 placebo planned dose 2 daily (QD) orally
224113223|NCT02590016|DRUG|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
224113224|NCT01858883|DRUG|itacitinib|
224113225|NCT01858883|DRUG|Gemcitabine|
223968730|NCT06996327|OTHER|Evaluation of dietary consumption of UPFs|Evaluation of dietary consumption of ultraprocessed foods
224113226|NCT01858883|DRUG|nab-paclitaxel|
224113227|NCT01858883|DRUG|filgrastim|
224113228|NCT03626051|DEVICE|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
224113229|NCT03626051|DEVICE|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
223968731|NCT02697552|DRUG|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly \[BIW\].
223968732|NCT00383500|DEVICE|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
223968733|NCT00383500|DEVICE|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
223968734|NCT06519981|DRUG|HRS-9231or matching placebo|HRS-9231 injection or matching placebo will be administered through IV injection.
223968735|NCT07000435|DEVICE|3D printed custom-made mouth guards|Participants in the first group will receive 3D printed custom-made mouth guards
223542783|NCT05741476|OTHER|Placebo|DBV712 matching placebo epicutaneous system.
223968736|NCT07000435|DEVICE|Traditional custom-made mouth guards|Participants in the active comparator arm will receive traditional custom-made mouth guards as an intervention
223968737|NCT07001228|BEHAVIORAL|SD rehabilitation|"For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks.~For SD rehabilitation, shoulder external rotation, push up plus, and shoulder rolls were performed. In the experimental group, rehabilitation for scapular dyskinesis will begin at the second outpatient visit, which takes place three weeks after the subacromial steroid injection."
223968738|NCT07001228|BEHAVIORAL|No SD rehabilitation|"For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks.~In the sham group, rehabilitation for scapular dyskinesis will not begun at the second outpatient visit, which takes place three weeks after the subacromial steroid injection."
223968739|NCT00747721|DRUG|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
223968740|NCT00925288|BIOLOGICAL|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
223968741|NCT04041661|OTHER|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
223968742|NCT04041661|OTHER|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
223542784|NCT05741476|DRUG|DBV712|DBV712 250 mcg epicutaneous system.
224113230|NCT03391518|PROCEDURE|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
224113231|NCT00000289|DRUG|Ondansetron|
223968743|NCT04701970|PROCEDURE|relining of mandibular complete denture|Relining of mandibular dentures was performed by reducing one mm of the denture fitting surfaces and borders to make a right-angled border. apply two separate layers of Mucopren adhesive upon the vestibular surface of the mandibular denture and allow each layer to dry for about 40 seconds. then, the lower denture was inserted and molded in patient mouths; while biting in centric occlusion with the opposing maxillary complete dentures.
223968744|NCT02847819|DEVICE|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
223968745|NCT00518583|DRUG|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
223968746|NCT06050083|BEHAVIORAL|Hypnosis audio recordings|Hypnosis recordings created by the investigators that guide participants through using hypnosis to manage chronic pain.
224113232|NCT03567291|DRUG|TEV-50717|6, 9, and 12 mg oral tablets
224113233|NCT03567291|DRUG|Placebo|Placebo comparator
223968747|NCT03354897|DRUG|Torasemide 5Mg Tablet|16 weeks treatment
223968748|NCT02862652|OTHER|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
224113234|NCT05649124|BEHAVIORAL|Acupressure group|A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
224113235|NCT03799315|DRUG|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
224113236|NCT03799315|BEHAVIORAL|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
223968749|NCT03465085|DRUG|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
223968750|NCT03465085|DRUG|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
223968751|NCT00074178|BIOLOGICAL|filgrastim|
223968752|NCT00074178|BIOLOGICAL|pegfilgrastim|
223968753|NCT00074178|DRUG|cyclophosphamide|
223968754|NCT00074178|DRUG|cytarabine|
223968755|NCT00074178|DRUG|dexamethasone|
223968756|NCT00074178|DRUG|etoposide phosphate|
223968757|NCT00074178|DRUG|methotrexate|
223968758|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
223968759|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
224113237|NCT01103349|DRUG|BI 671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI 617800 in patients with symptomatic asthma
224113238|NCT01103349|DRUG|Placebo|Patients receive placebo capsules and/or encapsulated tablets
223968760|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
223968761|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
223968762|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
223968763|NCT00123435|BEHAVIORAL|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
224291572|NCT04226131|OTHER|Cardiopulmonary Exercise Test (CPET)|Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
223968764|NCT00123435|BEHAVIORAL|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
223968765|NCT00123435|DEVICE|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
223968766|NCT00123435|DEVICE|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
223968767|NCT05572385|BEHAVIORAL|CIAT + Conventional neurorehabilitative therapy|CIAT = Constrained induced aphasia therapy
223968768|NCT03000647|PROCEDURE|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
224113239|NCT01103349|DRUG|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI 671800 in patients with symptomatic asthma
224113240|NCT00000348|DRUG|Dihydrexidine|
224113241|NCT00158652|PROCEDURE|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
224291573|NCT04226131|OTHER|Strength Testing|Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
224291574|NCT04226131|OTHER|Questionnaires|Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
224291575|NCT04226131|OTHER|Skeletal Muscle Biomechanical Property Assessment|Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
224291576|NCT00745719|PROCEDURE|parathyroidectomy|total parathyroidectomy with forearm autografting
224291577|NCT00339872|DRUG|IMA-638|
224291578|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
224291579|NCT00515034|DRUG|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
224291580|NCT00515034|DRUG|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
223968769|NCT03000647|PROCEDURE|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
223968770|NCT05672498|DRUG|Traditional Chinese Medicine Formulation|The TCM Treatment Group：The patient are given a traditional Chinese medicine formulation, taking 150 ml of liquid medicine every morning and evening for 7 days.
223968771|NCT05672498|OTHER|Placebo Treatment|Placebo Treatment Group:The patient are given placebo, taking 150 ml of liquid placebo every morning and evening for 7 days. All medications and placebo are packed identically in packing bags with the same labeling form.
223968772|NCT04526314|OTHER|observational|observational
224113242|NCT00158652|PROCEDURE|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
224113243|NCT00158652|PROCEDURE|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
224113244|NCT00158652|DRUG|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
224113245|NCT05058131|DIETARY_SUPPLEMENT|Dietary fibre|Dietary fibre as a powder, 24 g per day for 6 weeks
224113246|NCT05058131|DIETARY_SUPPLEMENT|Placebo compound|Maltodextrin powder, 24 g per day for 6 weeks
223968773|NCT03767400|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
224291581|NCT00515034|DRUG|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
224291582|NCT00764231|BEHAVIORAL|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
223968774|NCT03767400|OTHER|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
223968775|NCT01314898|DRUG|3 mg PF-03882845|3 mg PF-03882845, single oral dose
223968776|NCT01314898|DRUG|10 mg PF-03882845|10 mg PF-03882845, single oral dose
224291583|NCT00764231|BEHAVIORAL|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
224291584|NCT02304068|OTHER|Home monitoring|
224291585|NCT02304068|OTHER|Hospital assessment|
224291586|NCT05482204|OTHER|Low Climate Impact label|Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.
224291587|NCT05482204|OTHER|High Climate Impact label|Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
223968777|NCT01314898|DRUG|30 mg PF-03882845|30 mg PF-03882845, single oral dose
223968778|NCT01314898|DRUG|100 mg PF-03882845|100 mg PF-03882845, single oral dose
223968779|NCT01314898|DRUG|Spironolactone|100 mg spironolactone, single oral dose
223968780|NCT00104013|DRUG|xaliproden (SR57746A)|
223968781|NCT03698617|DRUG|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
223968782|NCT03698617|DRUG|Propofol|For induction of general anesthesia
223968783|NCT04739488|DEVICE|Inhaler training|This training was given to both intervention groups. How the patients used their inhaler medication was evaluated. The steps to use the correct inhaler medication were taught sequentially. It was applied with the patient. At the end of the training, brochures prepared by the researchers were given to the patients.
223968784|NCT04739488|BEHAVIORAL|Breathing exercises|"This training was given only to the group that received breathing exercise and inhaler training.~Pursed lips breathing exercises were taught to the patients. Patients were asked to continue their breathing exercise for 10 minutes before using their inhaler medication.~Thus, it was evaluated whether breathing exercises performed before using inhaler drugs provided benefit on drug effectiveness."
223968785|NCT01488838|DRUG|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
223968786|NCT01488838|RADIATION|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
223968787|NCT03614221|DRUG|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
223968788|NCT03614221|DRUG|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
224291588|NCT03912402|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
224291589|NCT03912402|BIOLOGICAL|Bevacizumab|IV infusion
224291590|NCT03912402|DRUG|Paclitaxel|IV infusion
224291591|NCT03912402|DRUG|Cisplatin (or carboplatin)|IV infusion
224291592|NCT01862419|OTHER|Alert|
224291593|NCT04094740|DEVICE|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
223968789|NCT06271083|BEHAVIORAL|Exposure with response prevention|The central component of the intervention will be ERP. During the treatment, participants will receive information about tics and how to work with ERP. Continuously throughout the treatment patients will work with exposing themselves to situations that trigger their premonitory urges and practice suppressing their tics. They will learn different strategies to provoke their premonitory urges to make suppression of their tics more challenging and gradually increase the time they can suppress the tics. A central tool in the treatment will be the Ticstimer, a worksheet where patients will continuously record their ERP practice, and the time they manage to suppress tics. The patients will be encouraged to work with the Ticstimer daily.
223968790|NCT06271083|BEHAVIORAL|Brief psychoeducation with general psychological support|Participants who are randomized to the control group will receive access to brief psychoeducational content in the platform in combination with general psychological support from a therapist. No active BT components (BT, Habit Reversal Training, applied relaxation) are provided to the participants in the control group. The therapists will welcome the patients to the treatment, encourage them to engage in the treatment content and reach out to the therapist if they have any questions. Thereafter, the therapists will only reply to the patients' messages without taking any contact initiative themselves (unless there is an indication of severe deterioration or severe depressive symptoms or suicidal ideation requiring medical attention)
223968791|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
223968792|NCT00793377|DRUG|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
223968793|NCT03856398|DEVICE|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
223968794|NCT06363513|DRUG|Aescin in Horse Chestnut|Can aescin reduce bleeding in early hemorrhoid
223968795|NCT06363513|DRUG|Flavonoid|Can combine aescin and MPFF reduce bleeding in early hemorrhoid
223968796|NCT02514226|PROCEDURE|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
223968797|NCT02514226|PROCEDURE|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
223968798|NCT02514226|PROCEDURE|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
223968799|NCT02514226|OTHER|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
223968800|NCT02096809|PROCEDURE|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
223968801|NCT02096809|DEVICE|Cochlear Baha BI300/BA400 Implant System|
223968802|NCT02077153|BEHAVIORAL|Reminiscence therapy|
223968803|NCT02077153|BEHAVIORAL|Active participation in group setting|
223968804|NCT00640185|DRUG|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
223968805|NCT00640185|DRUG|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
223968806|NCT02358083|BEHAVIORAL|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
224291594|NCT02194023|DRUG|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
224291595|NCT02194023|DRUG|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
223968807|NCT02176356|BIOLOGICAL|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
223968808|NCT02176356|DRUG|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
223968809|NCT02176356|DEVICE|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
223968810|NCT02176356|DEVICE|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
223968811|NCT02176356|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
223968812|NCT02591706|DEVICE|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
223968813|NCT00996814|BEHAVIORAL|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
223968814|NCT00332488|DRUG|Technosphere Insulin|Inhalation, 15U/30U, prandial
223968815|NCT00332488|DRUG|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
223968816|NCT00332488|DRUG|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
223968817|NCT00066378|DRUG|anastrozole|
223968818|NCT00066378|DRUG|gefitinib|
224113247|NCT00090285|BIOLOGICAL|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
224113248|NCT00090285|BIOLOGICAL|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
224113249|NCT01109706|OTHER|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
224113250|NCT00907478|BIOLOGICAL|romiplostim|Romiplostim administered by subcutaneous injection
223968819|NCT00371462|BEHAVIORAL|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
223968820|NCT00371462|BEHAVIORAL|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
223968821|NCT02048683|DRUG|Short term sedation with sevoflurane in ICU|
223968822|NCT02459236|DRUG|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
223968823|NCT02459236|DRUG|Placebo|
223968824|NCT02841345|OTHER|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~* In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~* In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~* In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
223968825|NCT01165359|DRUG|ITX 5061|"For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days."
224291596|NCT02194023|DRUG|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
224291597|NCT02194023|DRUG|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
223968826|NCT01165359|DRUG|Placebo ITX 5061|"For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days."
223968827|NCT05163106|DRUG|Letrozole 2.5mg oral tablet; Ribociclib 600mg oral tablet|Patients will be given letrozole 2.5mg and ribociclib 600mg daily, per oral for a period of 21 days followed by 7 days of letrozole only.
223968828|NCT05163106|DRUG|Goserelin|Premenopausal women will be given goserelin 3.6 mg (subcutaneous) every 4 weeks in concert with their Letrozole and Ribociclib treatment.
223968829|NCT02507687|DRUG|Bimatoprost SR|Bimatoprost SR is a biodegradable, sustained-release, preservative-free bimatoprost implant, preloaded in an applicator for administration. The Bimatoprost SR implant is injected into the anterior chamber via the corneal limbus using the prefilled applicator.
223968830|NCT02507687|DRUG|Sham Bimatoprost SR|Sham bimatoprost SR performed using the same procedure as for Bimatoprost SR using an needleless applicator that touches the eye at the area of insertion but does not deliver an implant into the anterior chamber.
223968831|NCT02507687|PROCEDURE|Selective Laser Trabeculoplasty|"SLT is a laser procedure that targets the melanin, or pigment, in specific cells of the eye.~An ophthalmologist performed 360 degrees of SLT using a standardized method."
223968832|NCT02507687|PROCEDURE|Sham Selective Laser Trabeculoplasty|Sham SLT is performed on the contralateral eye using the same method as for SLT, with the exception that the laser is not switched to the active state.
223968833|NCT06214598|DIETARY_SUPPLEMENT|Supplement|Supplements of anti-inflammatory oils rich in omega-3 and gamma-linolenic acid
223968834|NCT06214598|DIETARY_SUPPLEMENT|AI diet|diet rich in whole grains, healthy oils and polyphenols,
223968835|NCT06214598|DIETARY_SUPPLEMENT|Placebo|Placebo caps with standard diet
223968836|NCT04927559|OTHER|Survey Administration|Complete survey
223968837|NCT01145859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
223968838|NCT05348642|DIETARY_SUPPLEMENT|pasteurized A. muciniphila|pasteurized A. muciniphila - oral daily dose
223968839|NCT05348642|DIETARY_SUPPLEMENT|placebo|Placebo = identical to verum regarding the form, size, taste, color and intake
223968840|NCT02156999|DEVICE|Ibandronic acid, vitamin D|
223968841|NCT02669888|DRUG|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
223968842|NCT02669888|DRUG|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
223968843|NCT03134976|DRUG|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
223968844|NCT06330857|PROCEDURE|Laparoscopic vaginorectopexy|Modified laparoscopic anterior rectopexy for multiple pelvic prolapses
223968845|NCT03229356|OTHER|Best Practices Advisory (BPA)|"1. BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~2. Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
223968846|NCT03229356|OTHER|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
223968847|NCT00853203|BEHAVIORAL|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
223968848|NCT00853203|BEHAVIORAL|Questionnaires|Written survey taking about 1 hour.
223968849|NCT00853203|OTHER|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
223968850|NCT00853203|BEHAVIORAL|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
223968851|NCT00853203|BEHAVIORAL|Written Materials|Written educational materials plus community resource information.
223968852|NCT00889733|DRUG|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
223968853|NCT00912054|DRUG|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
223968854|NCT00912054|DRUG|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
223968855|NCT05372913|DEVICE|Woebot for Adolescents (W-GenZD) Mobile Application|"Woebot for Adolescents (W-GenZD) is a mobile application program that delivers evidence-based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent called Woebot. It is a brief, self-guided 4 week-intervention that draws from cognitive behavioral therapy (CBT), interpersonal psychotherapy for adolescents (IPT-A), and elements of dialectical behavior therapy (DBT), depending on the presenting situation, to help the adolescent develop emotion regulation skills in the context of their everyday life. In this way, the mobile application is designed to be targeted, relevant, and integrated into the lived experience of adolescents, capable of delivering the appropriate technique for the problem at hand, at the time of need."
223968856|NCT05372913|BEHAVIORAL|CBT-Lite Teletherapy Group|The CBT-Lite teletherapy group is a brief, 4-week intervention held once weekly for an hour, and limited to those triaged into the Children's Hospital of the King's Daughters low-intensity track and participating in this protocol. An assigned study clinician will facilitate each teletherapy group with approximately 10 adolescents in each session. Each group begins with orientation and reviewing group rules, individual check-ins with each participant (rating stress level and hopefulness), followed by a guided mindfulness moment. Sessions are designed to draw from elements of cognitive behavioral therapy (CBT) and the 4 topics include: building a coping tool box, accepting your feelings, challenging negative thoughts, and problem solving.
223542785|NCT02527473|OTHER|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~1. Video self-instruction manikin practice (30 min), including a brief introduction to AED.~2. Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~3. Debriefing (15 min): Questions, answers and reflection~4. Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
223968857|NCT02194777|DRUG|BIBN 4096 BS - in single rising doses|
223968858|NCT02194777|DRUG|Placebo|
223968859|NCT02149576|PROCEDURE|Low Dose Computed Tomography Imaging|
223968860|NCT02149576|PROCEDURE|Chest Radiograph Imaging|
223968861|NCT02810483|DRUG|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
223968862|NCT02810483|DRUG|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
223968863|NCT03711825|DRUG|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
223968864|NCT03711825|PROCEDURE|Imaging Assessment (MRI)|Imaging assessments \[MRI\] will be performed on specified days according to protocol
223968865|NCT03711825|PROCEDURE|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
223968866|NCT05213559|OTHER|wheat biscuit enriched with plant proteins|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a biscuit enriched with plant proteins
224291598|NCT03256422|DRUG|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
224291599|NCT06293443|OTHER|Lower extremity unilateral amputee|To evaluate the functionality of lower extremity unilateral amputees, to ensure that the results of the Medicare Functional K Classification System, which provides subjective data for the evaluator, become an objective evaluation method and to determine the functional levels of unilateral amputees; To create an objective data set by applying one-leg standing test, Ten meter walking test, L test, figure-8 walking test, joint range of motion, amputee mobility estimator scale, Houghton scale and joint position sense evaluation tests.
224291600|NCT01058928|OTHER|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
224291601|NCT01996059|PROCEDURE|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
224291602|NCT01996059|PROCEDURE|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
224291603|NCT01688726|OTHER|SYSTANE® BALANCE eyedrops|
223968867|NCT05213559|OTHER|common wheat biscuit|Postprandial glucose and appetite-regulating hormone responses of subjects with overweight/obesity after a 12-week dietary intervention with a common wheat biscuit
223968868|NCT03275402|BIOLOGICAL|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
223968869|NCT00199992|PROCEDURE|application of autologous platelet gel|
223968870|NCT01282749|BEHAVIORAL|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
223968871|NCT01282749|BEHAVIORAL|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
223968872|NCT05135156|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After two weeks, participants will gain access to the publicly available website (attention control) and will have an additional two weeks of access to both of these resources.
223968873|NCT05135156|BEHAVIORAL|Publicly available transplant education resource (Attention Control)|Participants will access the publicly available education resource via their login to a secure website. After two weeks, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional two weeks of access to both of these resources.
223968874|NCT01724047|BEHAVIORAL|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
223968875|NCT01724047|BEHAVIORAL|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
223968876|NCT04741815|DEVICE|Forced Air Warming|It consists of the WarmAir® unit and FilteredFlo® blankets. FilteredFlo® blankets are a cover designed to cover the entire body and extremities with air channels that provide the appropriate distribution of patient warm. The WarmAir® warming device connected to the shroud via a pipe; it has three temperature settings, 32.2 C, 37.8 C, and 43.3 C.
223968877|NCT04741815|DEVICE|Peripheral Carbon Fiber Warming|It was developed by the researcher. Designed as gloves and socks, these warming materials have three layers. The first layer in contact with the patient and the third layer in contact with the external environment is a thermal material to maintain body temperature. The second floor consists of a USB-connected carbon fiber warmer and foil.
223968878|NCT02986659|DRUG|Metformin|
223968879|NCT02986659|DRUG|Placebo|
223968880|NCT00059735|DRUG|E7070|
223968881|NCT05600998|DRUG|Camrelizumab|Subjects will receive carilizumab every three weeks, with alozantinib 20 mg orally daily for 9 weeks
224113251|NCT03053089|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
224113252|NCT06034704|OTHER|Plantar fascia self massage with a magnetic fascia ball|Participants were asked to roll the magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
224291604|NCT01688726|OTHER|Minims® Saline 0.9% eyedrops|
224291605|NCT00279539|GENETIC|Vascular Endothelial Growth Factor (VEGF1)|
224113253|NCT06034704|OTHER|Plantar fascia self massage with a non-magnetic fascia ball|Participants were asked to roll the non-magnetic fascia ball on the sole of each foot for 3 minutes each, from the metatarsal heads towards the heel, concentrating on the medial longitudinal arch. Participants were informed that more intense pressure would be more beneficial and were asked to apply pressure in a way that would not cause pain.
224113254|NCT00002410|DRUG|Indinavir sulfate|
224113255|NCT00002410|DRUG|Lamivudine|
224113256|NCT00002410|DRUG|Zidovudine|
224113257|NCT01362712|RADIATION|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
224291606|NCT03499119|DRUG|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
224291607|NCT03499119|DRUG|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
224291608|NCT03499119|DRUG|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
224291609|NCT05296876|PROCEDURE|Carotid endarterectomy (CEA)|Surgeons follow the contemporary guideline combined with their experience and preference in order to perform CEA for patients. All patients will be assessed by SSPC evaluation system before CEA. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA and the type of CEA can be selected as conventional, eversion or a shunt or patch based on the discretion of the surgeon.
223968882|NCT02883140|OTHER|Three-dimensional sialography CBCT and MRI sialography|"1. MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~2. 3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
223968883|NCT00447629|DRUG|PPM-204|
223968884|NCT04405856|DEVICE|Intra Aortic Balloon Pump|Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle.
223968885|NCT00647998|DRUG|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
223968886|NCT00647998|OTHER|Standard care|
223968887|NCT03704571|DRUG|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
223968888|NCT02449993|DEVICE|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
223968889|NCT00647283|PROCEDURE|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
223968890|NCT00308841|DRUG|Lidocaine (drug)|
223968891|NCT03968536|BEHAVIORAL|fall prevention|Training in physiotherapy sessions and ergonomic home development
223968892|NCT05803902|DRUG|Experimental drug 9MW1911|Experimental drug administered with IV infusion
223968893|NCT05803902|DRUG|Placebo|Placebo administered with IV infusion
223968894|NCT04563247|DIAGNOSTIC_TEST|IgG SARS CoV 2 antibodies|The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies
224291610|NCT00003972|BIOLOGICAL|filgrastim|
224291611|NCT00003972|BIOLOGICAL|sargramostim|
224291612|NCT00003972|DRUG|busulfan|
223968895|NCT04904237|DRUG|Aza-Ven-allo-HSCT|aaa-ven treatment followed by allo-HCTS with reduced toxicity conditioning (RTC) of Fludarabine, Busulifan and Melphalan
223968896|NCT00694564|DRUG|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
223968897|NCT03378778|PROCEDURE|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
223968898|NCT02742792|OTHER|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
223968899|NCT02742792|OTHER|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
223968900|NCT01647152|DRUG|Ustekinumab|
223968901|NCT05004805|DRUG|Methylene Blue|MB administered topically as a 0.02% solution nasal spray in COVID-19 patients requiring hospitalization.
223968902|NCT05004805|DRUG|Saline nasal spray|Saline administered topically as nasal spray in COVID-19 patients requiring hospitalization.
223968903|NCT04392479|DRUG|Aflibercept-FOLFIRI|Aflibercept-FOLFIRI
223968904|NCT04392479|DRUG|Aflibercept-mFOLFIRI3|Aflibercept-mFOLFIRI3
223968905|NCT01763034|PROCEDURE|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
223968906|NCT06031870|DEVICE|Vaginal pessary|In the pessary group, all patients received a cube pessary, which was individually adapted to each patient. These pessaries exist in sizes 0 (25 mm edge length) to 9 (75 mm edge length). Patients were instructed by a physician or a trained nurse on how to autonomously manage the pessary, including daily changing and cleaning. After one week of treatment, all patients had an office visit to check if fitting was correct and if autonomous handling of the pessary was feasible. Treatment duration was 12 weeks.
223968907|NCT06031870|BEHAVIORAL|Standard care|Standard care consisted of a pelvic floor group exercise course led by a midwife, a physiotherapist, or an osteopath. Courses were in general once a week for a minimum of seven to a maximum of twelve weeks. The course was chosen by the patient, and the study team had no influence on the choice.
224291613|NCT00003972|DRUG|carboplatin|
224291614|NCT00003972|DRUG|cyclophosphamide|
224291615|NCT00003972|DRUG|melphalan|
224291616|NCT00003972|DRUG|paclitaxel|
224291617|NCT00003972|DRUG|tamoxifen citrate|
223968908|NCT06031870|PROCEDURE|Pelvic floor muscle training|Twelve pelvic floor physiotherapy sessions were prescribed by the study physician. Pelvic floor physiotherapy was performed in individual courses by trained physiotherapists. The patient was free to choose the physiotherapist and the study team had no influence on the choice.
223968909|NCT03294421|PROCEDURE|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
223968910|NCT03294421|PROCEDURE|standard closed tympanomastoidectomy|"1. Supine position and general anesthesia with orotracheal intubation~2. Antisepsis and placing of sterile fields~3. Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~4. Retroauricular incision~5. Removal of the temporal muscle fascia~6. Elevation of the surgical flap of the tympanic meatus~7. Visualization and exploration of the cholesteatoma~8. Exploration of the ossicular chain~9. Mastoid debridement~10. Conservation of the upper posterior wall of the auditory conduct~11. Removal of the cholesteatoma~12. Tympanoplasty with the temporal fascia~13. Retroauricular suture with vycril 3.0 and mononylon 4.0"
223968911|NCT04531371|DRUG|Dexmedetomidine injection|post surgical agitation prophylaxis
223968912|NCT02357719|DEVICE|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
223968913|NCT00220597|BEHAVIORAL|Trauma-focused group therapy|
223968914|NCT01059526|DRUG|ecallantide|30 mg SC
223968915|NCT02720081|DRUG|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
223968916|NCT02720081|DRUG|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
223968917|NCT02720081|DRUG|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
223968918|NCT02720081|DRUG|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
223968919|NCT03630523|BIOLOGICAL|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
223968920|NCT02766010|DEVICE|TensorTip|Non Invasive screening of various physiological and hematological parameters.
224291618|NCT00003972|DRUG|thiotepa|
223968921|NCT04632797|DEVICE|Hilotherm Chemo Care|Application of Hilotherm Chemo Care gloves for constant cryotherapy during chemotherapy application.
223968922|NCT01820221|PROCEDURE|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
223968923|NCT03738254|OTHER|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
223968924|NCT03738254|OTHER|Paper Survey|Paper version of daily survey
223968925|NCT03738254|OTHER|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
223968926|NCT03209050|DEVICE|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
223968927|NCT00251290|PROCEDURE|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
223968928|NCT05790187|OTHER|Presentation of differents face pictures|Test 1: Unmasked face vs. masked face Test 2: Unmasked face up vs. unmasked face down Test 3: Face masked right side vs. face masked reverse
223968929|NCT02005029|DRUG|Erythromycin|
223968930|NCT02005029|DRUG|placebo|
223968931|NCT00360750|DRUG|carboplatin|
223968932|NCT00360750|DRUG|cytarabine|
223968933|NCT00360750|DRUG|etoposide|
223968934|NCT00360750|DRUG|vincristine sulfate|
223968935|NCT00360750|OTHER|clinical observation|
223968936|NCT00360750|PROCEDURE|adjuvant therapy|
223968937|NCT00360750|RADIATION|radiation therapy|
223968938|NCT03743129|DRUG|Anlotinib|Anlotinib 12mg p.o, qd
223968939|NCT06120114|PROCEDURE|Modified percutaneous internal ring suturing|Laparoscopically guided percutaneous high ligation of indirect inguinal hernia in adults
223968940|NCT01011127|DRUG|pravastatin, rosuvastatin|
223968941|NCT03375840|BEHAVIORAL|Text-only PWL|Control condition
223968942|NCT03375840|BEHAVIORAL|Low-emot PWL|Pictorial warning
223968943|NCT03375840|BEHAVIORAL|High-emot PWL|Pictorial warning
223968944|NCT03375840|BEHAVIORAL|Immediate posttest|
223968945|NCT03375840|BEHAVIORAL|delay posttest|
223968946|NCT00743223|OTHER|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
223968947|NCT06006832|DRUG|Steroid Drug|Maintaining low-dose oral steroids
223968948|NCT06006832|OTHER|Withdraw all immunosuppresants|Withdraw all immunosuppresants
223968949|NCT05450640|OTHER|satisfaction survey|1 eQuestionnaire per patient completed during study
223968950|NCT02716857|DRUG|Oxycodone extended-release|
223968951|NCT02716857|DRUG|Placebo of oxycodone extended-release|
223968952|NCT03207698|PROCEDURE|Open flap debridement (OFD)|Open flap debridement (OFD) alone
223968953|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
223968954|NCT03207698|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
223968955|NCT03694119|DRUG|Phenelzine|Phenelzine
223968956|NCT03694119|DRUG|Tyramine|Tyramine
223968957|NCT03694119|DRUG|Phenelzine placebo|Phenelzine placebo
223968958|NCT03694119|DRUG|ozanimod placebo|ozanimod placebo
223968959|NCT03694119|DRUG|ozanimod|ozanimod
223968960|NCT06215625|OTHER|Robot-assisted therapy|The TIGER system provides assistance for activities of daily living. Continuous passive mode of TIGER system provides passive range of motion as warm-up. Functional mode TIGER system provides functional training.
223968961|NCT06215625|OTHER|Task-oriented training|The TOT group will practice sensorimotor techniques for warming up, and then they will practice various functional tasks based on task-oriented approach.
223968962|NCT05127590|DRUG|RBN-2397|Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
223968963|NCT02599090|DRUG|Temozolomide|"Groups 1 \& 2: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m\^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m\^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 \& 4: 75 mg/m\^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m\^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
223968964|NCT02599090|RADIATION|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
223968965|NCT02599090|DRUG|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
223968966|NCT00683397|OTHER|Blood sampling|Screening of thrombophilia
223968967|NCT02242799|DRUG|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
223968968|NCT02242799|DRUG|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
223968969|NCT02242799|DRUG|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
223968970|NCT04717713|DRUG|steroid injection|steroid injection at surgical location
223968971|NCT04717713|DRUG|placebo|saline injection at surgical location
223968972|NCT01370018|BIOLOGICAL|alpha-1-Proteinase Inhibitor|Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
223968973|NCT03739697|OTHER|spontaneous breathing|spontaneous breathing during induction of anesthesia in infants
223968974|NCT03497780|PROCEDURE|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
223968975|NCT02125656|OTHER|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
223968976|NCT03386214|DRUG|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.
223968977|NCT03386214|DRUG|Ruxolitinib|-Standard of care outside of protocol
223968978|NCT03386214|PROCEDURE|Peripheral blood draw|"* Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment"
223968979|NCT03386214|PROCEDURE|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
223968980|NCT03448289|BEHAVIORAL|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
223968981|NCT03809806|PROCEDURE|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
223968982|NCT03809806|DIAGNOSTIC_TEST|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
224113258|NCT03285217|DIETARY_SUPPLEMENT|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
224113259|NCT03285217|DIETARY_SUPPLEMENT|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL\&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
224291619|NCT00003972|PROCEDURE|peripheral blood stem cell transplantation|
224291620|NCT00003972|RADIATION|radiation therapy|
223968983|NCT03809806|DIAGNOSTIC_TEST|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
223968984|NCT03809806|DIAGNOSTIC_TEST|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
223968985|NCT03809806|DIAGNOSTIC_TEST|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
223968986|NCT03809806|DIAGNOSTIC_TEST|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
224113260|NCT06517849|BEHAVIORAL|Monetary Incentive for Take-Up of Cognitive Behavioral Therapy|Both treatment arms will be offered a monetary incentive (in form of a retail gift card) for undergoing a certain number of CBT sessions.
224113261|NCT05874986|OTHER|Resistance training|12-week resistance training intervention
224113262|NCT06424366|BEHAVIORAL|Ballet for All Kids|The intervention consists of 12 weeks of ballet classes that follow the structure and curriculum of Ballet for All Kids (BFAK). BFAK is a non-profit organization that has been tailoring ballet classes for children with autism spectrum disorder for over one decade. Ballet classes will be held once a week for 45 minute sessions and led by trained medical and graduate students who have successfully completed BFAK's training and certification. BFAK instruction is based on the Schlachte Method, which combines auditory, visual, vestibular, and emotional learning to individualize instruction to match each child's skill level. In classroom accommodations include, but are not limited to a visual schedule, personal dance areas demarcated by tape on the floor, and one-on-one volunteer assistance.
224113263|NCT05427851|PROCEDURE|pulpotomy|coronal pulp tissue removal followed by radicular pulp hemostasis them applying a pulp capping material
224113264|NCT05427851|DEVICE|Diode laser - fonalaser|diode laser beam application
224113265|NCT02639182|DRUG|AGS-16C3F|Intravenous (IV) infusion
224113266|NCT02639182|DRUG|Axitinib|Oral
224113267|NCT03640143|OTHER|venous blood lead|data about ve,nous blood lead
224291621|NCT03163433|BEHAVIORAL|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
224291622|NCT02870036|DRUG|Simmitecan|
224291623|NCT02870036|DRUG|5-fluorouracil and Leucovorin Calcium|
224291624|NCT02870036|DRUG|Thalidomide|
224291625|NCT04553913|DEVICE|cooling device|device placed on patient in recovery on non surgical side to determine resolution of spinal anesthetics.
224291626|NCT03003260|OTHER|CBD chewing gum|
224291627|NCT03003260|OTHER|Placebo|
224291628|NCT03036774|PROCEDURE|Ultrasonic measurement of antral area|"Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures."
224291629|NCT04216420|DEVICE|MERM-observed self-administered therapy|The MERM device has an electronic module and a medication container that records adherence, stores medication, emits audible and visual on-board alarms to remind patients to take their medications on time and refill, and enables providers to download the data and monitor adherence. It is manufactured by Wisepill Technologies, South Africa.
224291630|NCT02774486|DEVICE|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
224291631|NCT00128934|DRUG|levonorgestrel/ethinyl estradiol|
224291632|NCT04205396|BEHAVIORAL|Written emotional disclosure|Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
223968987|NCT00219869|DRUG|Galantamine|
223968988|NCT04584216|OTHER|Steam Eye Mask with acupoints stimulation|A participant needs to use SEM with acupoints stimulation once a day for 10 days and use hands to massage the acupoints on the eyebrows for the first 3 minutes, total application time at least for 20 minutes.
223968989|NCT04584216|OTHER|Steam Eye Mask|A participant needs to use SEM once a day for 10 days, total application time at least for 20 minutes.
223968990|NCT00761410|DEVICE|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
223968991|NCT01193062|DRUG|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
223968992|NCT01193062|DRUG|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
223968993|NCT01081119|BEHAVIORAL|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
223968994|NCT04213820|DEVICE|Transcranial magnetic stimulation|TMS (theta burst) will be administered consisting of bursts containing 3 pulses at 50 Hz and an intensity of 80% motor threshold repeated at 200 ms intervals (i.e., at 5 Hz) and a 10 s between burst triplet interval for a total for 190 s (600 pulses). The intervention will be given daily 5 times/week during 4 weeks.
223968995|NCT04213820|BEHAVIORAL|Body Image Intervention|Body image interventions delivered directly after TMS will include body exercises that target disturbed body image and psychoeducation about the body. Together with a therapist the participants with anorexia nervosa will explore and estimate their body size through feedback.
223968996|NCT04213820|BEHAVIORAL|Treatment as usual|Treatment as usual at the eating disorder unit, Child and adolescent psychiatric clinic and Psychiatric clinic is delivered during 4 weeks
224113268|NCT00775359|DRUG|Fenofibrate 160 mg tablets|
224113269|NCT04756635|OTHER|Experimental Group|This 3-year project will include two groups of participants: 1) young men accustomed to resistance training (study #1) and 2) young men accustomed to endurance training (study #2). Inclusion will be limited to healthy participants (i.e. nonsmokers, normotensive with systolic and diastolic values \<135/85 mmHg, non-obese, non-medicated, and free of any known disease as assessed by medical history) (Pickering, Hall et al. 2005). Month 1-3 will focus on literature review and month 4 to 8 will address experimental settings preparation and selection of participants to include in each study. Testing and data collection will be scheduled for months 9-14 and 13-18 (study # 1 and 2 related testing, respectively). Data processing, analysis and presentation will occur from month 21 to 33. All participants will read and sign an informed consent document with the description of the testing procedures. The Faculty's ethical committee will be asked to approve this document before testing.
223968997|NCT03964038|DRUG|gilteritinib|oral
223968998|NCT03964038|DRUG|gilteritinib mini tablet|oral
223968999|NCT00823446|DEVICE|Revera Wound Care|Revalesio Part Number MDW0060
223969000|NCT00823446|DEVICE|Normal Saline|Sodium Chloride for Irrigation
223724925|NCT06064604|DEVICE|Ankle Exoskeleton|The Dephy Exoboot is a lower limb exoskeleton which attaches to the user below the knee through a cuff at the proximal calf and a provided shoe. This investigational device is used to make it easier for able-bodied and impaired individuals to walk and run under a variety of conditions. The exoskeleton provides assistance at the ankle joint during movement. The purpose is to assist the user in lower limb movements such as ground level walking, climbing stairs/ramps, and sit-to-stand.
223724926|NCT05545930|PROCEDURE|Hand Wrung|Hand wrung refers to manually wringing surgical sponges by hand.
223969001|NCT01742650|PROCEDURE|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
223969002|NCT01742650|PROCEDURE|TightRope|TightRope transfixation of syndesmosis
223969003|NCT01974934|DRUG|Desvenlafaxine Succinate|
223969004|NCT03255915|DRUG|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
223969005|NCT03255915|OTHER|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
223969006|NCT02754310|OTHER|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
223969007|NCT02754310|OTHER|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
223969008|NCT01855997|DRUG|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
223969009|NCT04854616|BEHAVIORAL|CoSTED Intervention|Brief smoking cessation advice, the provision of an e-cigarette starter kit and training in its use, and referral to stop smoking services.
223969010|NCT02896218|OTHER|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
223969011|NCT03902145|OTHER|Egg|One egg per day for 6 months
223969012|NCT03612453|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
223969013|NCT03612453|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
223969014|NCT01550822|OTHER|HEALS|
224113270|NCT03585374|COMBINATION_PRODUCT|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
223969015|NCT01536535|DRUG|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
223969016|NCT01536535|DRUG|IV Corticosteroid|Treatment with IV Corticosteroid
223969017|NCT01536535|DRUG|Oral Corticosteroids|Treatment with oral corticosteroids
223969018|NCT01536535|OTHER|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
223969019|NCT01536535|PROCEDURE|Colectomy|Colectomy
223969020|NCT03315988|OTHER|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
223969021|NCT04545983|OTHER|Motion Analysis|Cinematographic recordings will be made. Participants are seated on a crutch, adjustable in height, with their neck, shoulders and head free. Before recordings are made, participants will be instructed to perform the prescribed flexion and extension movement in about 10 seconds with 7 frames per second. Participants are placed on the crutch with their shoulder's perpendicular to the image intensifier to obtain sagittal images from the occiput till C7. As soon as the recording is started, the participant is instructed to move his head in the sagittal plane from maximal extension to maximal flexion, without moving the upper part of the body. It is important that the participants shoulders are kept as low as possible while making the recordings to ensure that all the cervical vertebrae are visible. The movement of the cervical spine should be as fluent as possible to prevent for sudden large rotations and translations between consecutive frames.
223969022|NCT03571347|BEHAVIORAL|Self Help Plus|5-session psychosocial intervention
223969023|NCT03571347|OTHER|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
223969024|NCT00392314|OTHER|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
223969025|NCT04091919|DIAGNOSTIC_TEST|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
223969026|NCT03334773|BEHAVIORAL|Nutrition education|
223969027|NCT02788617|DEVICE|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
223969028|NCT03703141|DIETARY_SUPPLEMENT|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
223969029|NCT06350370|PROCEDURE|Natural orifice specimen extraction|We perform laparoscopic colorectal cancer resection, intracorporeal anastomosis and transanal or transvaginal specimen extraction
223969030|NCT05452837|PROCEDURE|FDFG|FDFG is applied to the parotidectomy bed after superficial parotidectomy
224113271|NCT03585374|DRUG|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
224113272|NCT03585374|DRUG|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
223969031|NCT05452837|PROCEDURE|SMAS|SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
223969032|NCT05738070|DIAGNOSTIC_TEST|Magnetic resonance imaging|MRI was done in 1.5T unit (Siemens, Magnetom, Essenza). Different parameters for SWI as follows at 1.5T: echo time (TE) = 40 ms, repetition time (TR) = 29 ms, slice thickness = 0.7 mm, flip angle = 25°, field of view (FOV) = 184 × 200, intersection gap = 0 mm, and matrix size = 322 × 225. MRA parameters were as follows: TR = 29 ms, TE = 7.15 ms, FOV = 168 × 200 mm, slice thickness = 0.7 mm, flip angle = 25°, with acquisition time of 3 minutes.
223969033|NCT03866434|DRUG|SPD422|Participants will receive 1 mg of SPD422 (2\*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
223969034|NCT03866434|DRUG|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
223969035|NCT01705951|OTHER|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
223969036|NCT01705951|BIOLOGICAL|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
223969037|NCT00519714|DIETARY_SUPPLEMENT|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
223969038|NCT00519714|DIETARY_SUPPLEMENT|Placebo|Placebo
223969039|NCT03623399|PROCEDURE|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
223969040|NCT04139239|DIAGNOSTIC_TEST|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
223969041|NCT00387907|DRUG|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
223969042|NCT00387907|DRUG|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
223969043|NCT00167323|BEHAVIORAL|Adherence therapy|
223969044|NCT00729885|DEVICE|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
223969045|NCT00729885|DEVICE|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
223969046|NCT04134455|PROCEDURE|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
223969047|NCT04134455|PROCEDURE|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
224113273|NCT03585374|DRUG|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
224113274|NCT02976493|OTHER|No Intervention|No Intervention
224113275|NCT03666260|PROCEDURE|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
224113276|NCT03666260|PROCEDURE|femoral block|femoral block with echography
224113277|NCT03069690|BEHAVIORAL|HABITpreg|"Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.~Due to COVID-19(coronavirus disease) restrictions and safety guidelines, HABIT pregnant treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
224113278|NCT03069690|BEHAVIORAL|HABITpost|"Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.~Due to COVID-19 restrictions and safety guidelines, HABIT post treatment sessions have been taking place virtually, using video chat or phone calls starting in March 2020."
224113279|NCT02445378|PROCEDURE|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
224113280|NCT02445378|OTHER|Placebo|Undergo placebo intervention using rose water
224113281|NCT02445378|OTHER|Questionnaire Administration|Ancillary studies
224113282|NCT03660371|PROCEDURE|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
224113283|NCT03660371|PROCEDURE|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
224113284|NCT00591227|DRUG|insulin aspart|"insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
224113285|NCT00591227|DRUG|insulin detemir|"insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating."
224113286|NCT05907967|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
224113287|NCT04050904|DEVICE|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
224113288|NCT02016742|DRUG|RDC5|
223969048|NCT02806596|DRUG|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
223969049|NCT02003664|DRUG|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
223969050|NCT02003664|DRUG|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
223969051|NCT05559164|DRUG|Lipitor 40mg Tablet|LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
224113289|NCT00575822|DEVICE|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
224113290|NCT00575822|DEVICE|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
223542786|NCT01641107|DRUG|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
223542787|NCT05165732|BIOLOGICAL|Experimental vaccine 1|Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
223542788|NCT05165732|BIOLOGICAL|Experimental vaccine 2|Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
223969052|NCT01445990|DEVICE|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
223969053|NCT01128777|BEHAVIORAL|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
223969054|NCT01128777|BEHAVIORAL|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
224113291|NCT06068725|BEHAVIORAL|Training videos|After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
224113292|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
224113293|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
224113294|NCT00858767|DIETARY_SUPPLEMENT|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
224113295|NCT01733069|DEVICE|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
223969055|NCT06345924|BEHAVIORAL|MERAKI_PC|"The three music therapy sessions focus on helping the patient to adjust to their situation. The aim is to provide emotional support and encourage communication between family members through music. In addition, the therapy will help the patient to appreciate their remaining abilities and encourage their involvement in the rehabilitation process. The second session focuses on living in the present through re-identification. The session aims to improve the symptoms associated with the illness by focusing on the present situation and encouraging expression.~The main aim of the final session, 'The Journey of Life - Leaving a Mark', is to recapitulate and provide support.~Songs are used during the session, taking into account musical preferences."
223969056|NCT03840278|DEVICE|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
223969057|NCT03840278|DEVICE|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
223969058|NCT03840278|DRUG|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
223969059|NCT05707689|BEHAVIORAL|Entertainment gaming|If needed, gaming schedule will be tailored based on the participants' individual needs (working, studying, family issues) as long as the total gaming hours will be achieved. Participants are encouraged not to play video games during the study period. Participants' gaming interventions will be monitored carefully and recorded after each gaming session in specific gaming diary.
223969060|NCT03805698|DEVICE|Platelet-rich Plasma (PRP)|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
223969061|NCT03805698|OTHER|Standard Arthroscopic Debridement|Standard arthroscopic debridement. No PRP injection.
224113296|NCT03268746|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
223542789|NCT05165732|BIOLOGICAL|Experimental vaccine 3|Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
223542790|NCT02890459|OTHER|Prize incentive - Low|Low expected prize value.
223542791|NCT02890459|OTHER|Prize incentive - High|High expected prize value.
223969062|NCT00926978|RADIATION|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is \< 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
223969063|NCT05651334|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active stimulation
223542792|NCT02890459|OTHER|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
223969064|NCT05651334|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham stimulation
223969065|NCT03547648|PROCEDURE|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
223969066|NCT06153901|PROCEDURE|endoloop mediated cardioplication (ECLC) procedure|The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
223969067|NCT05881161|BEHAVIORAL|Adherence self-efficacy-enhancing exercise|This exercise aims to increase self-efficacy to adhere to an internet intervention. It consists of a video and two text-based tasks. The contents are grounded in Social-Cognitive Theory.
223969068|NCT05881161|BEHAVIORAL|Med-Stress Student|Med-Stress Student is an intervention that spans over 4 weeks and aims to enhance resources to cope with job stress and promote well-being in medical students.
224113297|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation using surgical guide|The surgical procedure begins with securing a prefabricated guide firmly to the surgical site. Implant positions are marked, and after guide removal, a crestal incision is made 1 mm palatal to the marked point, extending with sulcular and vertical incisions. A full-thickness mucoperiosteal flap is reflected to expose the maxillary sinus and alveolar crest. After readapting the surgical guide to the bone, implant positions are marked, and cutting edges are tracked. The lateral window is formed by extending and connecting mesial and distal borders, created using piezotome. The sinus membrane is carefully reflected and elevated with a surgical curette to avoid iatrogenic perforation. Implant fixtures are then placed using the identical surgical guide, followed by graft material placement beneath the elevated sinus membrane. If the bony plate is preserved, the lateral window is covered with the plate.
224113298|NCT06130657|PROCEDURE|Lateral Maxillary Sinus Floor Elevation without surgical guide|The sinus's lateral wall is exposed through a crestal incision and a mucoperiosteal flap. A bony window is created, and upon its removability, the sinus floor is carefully elevated using sinus elevation curettes, taking care to avoid membrane perforation. In cases of perforation, a resorbable collagen membrane is applied to cover the hole. Implant osteotomies are then completed following the standard sequential placement protocol. Graft material, mixed with normal saline, is gently packed into the sinus to fill the cavity with bone substitute material and achieve the desired bone height. Finally, a resorbable membrane is placed on the outer surface of the window, and the flap is sutured for primary closure.
224291633|NCT04205396|BEHAVIORAL|Resilience training|Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.
224291634|NCT04205396|OTHER|No treatment|Participants will complete baseline and outcome assessments and no intervention will be conducted.
223969069|NCT00179478|DRUG|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
223969070|NCT00843245|OTHER|No intervention|No intervention
223969071|NCT03130127|DRUG|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
223969072|NCT06647290|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
223969073|NCT03604653|DEVICE|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
223969074|NCT03604653|DRUG|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
223969075|NCT03604653|DRUG|CDDP 50|50mg/m2@T0
223969076|NCT03604653|DRUG|CDDP 75|75mg/m2@T0
223969077|NCT03604653|DRUG|Doxorubicin|15mg/m2@T0
223969078|NCT00124137|DEVICE|Aquadex system|
223969079|NCT00124137|DRUG|IV diuretic|
223969080|NCT06645561|PROCEDURE|X-ray|defined radiographic semiological criteria to determine an analytical methodology to facilitate the dating of long bone fractures of infants under one year of age
223969081|NCT04474691|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract can be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available. Knowledge of performance feedback could describe either the desired articulator placement or the auditory quality of the target sound.
223969082|NCT04474691|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum generated by the staRt app. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3. Knowledge of performance feedback will typically involve reference to the location of the third peak or 'bump' on the visual display.
223542793|NCT02890459|OTHER|Travel Voucher|Travel voucher to assist with linkage to care.
223542794|NCT02890459|OTHER|Standard care|Includes HIV viral load and treatment adherence counseling.
223969083|NCT02970721|DRUG|Antipsychotic|Antipsychotic monotherapy
223969084|NCT02970721|DRUG|Antidepressant|Antidepressant monotherapy
223969085|NCT02970721|DRUG|Antipsychotic and Antidepressant|Polytherapy
223969086|NCT00139659|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
223969087|NCT00139659|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
223969088|NCT00924209|DRUG|Gemcitabine|1250 mg/m\^2 dose for two doses on days 1 and 8
223969089|NCT00924209|DRUG|Cisplatin|80 mg/m\^2 on day 1
223969090|NCT00924209|DRUG|Bevacizumab|7.5 mg/m\^2 on day 1 every 21 days for first two cycles only
223969091|NCT00924209|PROCEDURE|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
223969092|NCT00924209|DRUG|Etoposide|100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
224291635|NCT01699763|DEVICE|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
223969093|NCT02625922|DRUG|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
223969094|NCT02625922|DRUG|Placebo|Matching placebo i.v infusion
223969095|NCT06194786|BEHAVIORAL|Group D|Usual care
223969096|NCT01437384|DRUG|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
223969097|NCT02391116|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
223969098|NCT05492123|DRUG|Nivolumab 40 mg in 4 ml Injection|Nivolumab 1mg/kg every 3 weeks for 4 cycles prior to radiation and 240mg every 2 weeks with concurrent radiation
223969099|NCT05492123|DRUG|Ipilimumab 200 MG in 40 ML Injection|Ipilimumab 3mg/kg every 3 weeks for 4 cycles prior to radiation
223969100|NCT05492123|RADIATION|Chemoradiation|Radiation to a dose of 45Gy over 25 1.8Gyfractions and brachytherapy with concurrent weekly cisplatin 40mg/m2/w or carboplatin AUC 2/w
223969101|NCT00399659|DRUG|Tegaserod|
223969102|NCT06073444|DEVICE|Picterus JP|Picterus JP is a medical device consisting in a smartphone app which is use to take images of the skin of the newborn, a color calibration card that must be placed in the newborn chest to calibrate color and lighting in the images and a server to analyze data and estimate bilirubin level
223969103|NCT01747629|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
223969104|NCT01747629|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
224113299|NCT02149654|DEVICE|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
224113300|NCT03761953|DRUG|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
224113301|NCT01372878|DEVICE|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
224113302|NCT01372878|PROCEDURE|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
224113303|NCT03913949|DRUG|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
223724927|NCT05545930|DEVICE|ProCell Wrung|ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
223969105|NCT00794911|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
223969106|NCT00794911|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
223969107|NCT06398171|OTHER|Exercise|Participants will perform 8 sessions of 4 sets of knee extension exercises during 1 month
223969108|NCT03830515|DEVICE|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
223969109|NCT02260583|DEVICE|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
223969110|NCT05192226|BEHAVIORAL|Counterfactual Strategy|Participants in this intervention condition will think about their past and identify how a less than desirable physical activity event could have turned out better using counterfactual thinking (i.e., If only I... then....). After identifying actions they could have taken to reach a better outcome in their physical activity event, they will then apply those thoughts to the future upcoming week so they can be realized.
223969111|NCT05440578|DRUG|olaparib plus bevacizumab maintenance therapy|First-line olaparib plus bevacizumab maintenance therapy initiated from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required).
224113304|NCT03277573|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
224113305|NCT03277573|DRUG|Placebo|Inactive ingredient
224113306|NCT06517030|PROCEDURE|Tooth Extraction|After local anaesthesia, a buccal split-full-split-thickness envelope flap will be elevated, and the tooth will be extracted a-traumatically.
223969112|NCT01940692|DRUG|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
223969113|NCT01940692|DRUG|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
223542795|NCT02890459|BEHAVIORAL|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
223969114|NCT06293014|DRUG|TAS-102+bevacizumab|TAS-102 35mg/m2, PO, D1-5, repeated every 14 days; Bevacizumab 5mg/kg, IV, D1, repeated every 14 days; Q4w.
223969115|NCT06293014|DRUG|Standard chemotherapy+bevacizumab|Standard chemotherapy (chemotherapy regimen based on investigator's choice, including FOLFIRI, FOLFOX, or CAPEOX); Bevacizumab
223969116|NCT03100136|DRUG|[11C]PF-06809247|PET Tracer
223969117|NCT02419040|PROCEDURE|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
223969118|NCT02419040|PROCEDURE|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
223969119|NCT02419040|PROCEDURE|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
224113307|NCT06517030|PROCEDURE|Immediate Implant Placement|After providing that the extraction socket will meet the inclusion criteria, an implant will be immediately inserted with 1 mm of its transmucosal portion positioned under the interproximal bone crest.
224113308|NCT06517030|PROCEDURE|Socket reconstruction with DBBB+HA|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral with hyaluronic acid (DBBM+HA).
224113309|NCT06517030|PROCEDURE|Socket reconstruction with DBBB|The gap between the implant surface and the bone plates will be filled with deproteinized bovine bone mineral (DBBM).
224113310|NCT06517030|PROCEDURE|CTG placement|Once the appropriate healing abutments will be installed, a CTG will be utilized as a barrier membrane. Then, the buccal flap will be coronally advanced and will be adapted to the healing abutment.
224113311|NCT01863264|OTHER|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
224113312|NCT06553924|DRUG|Macitentan and Tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
224113313|NCT06553924|DRUG|PrOpsynvi® macitentan and tadalafil film-coated tablets|1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
224113314|NCT00117338|DRUG|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
224113315|NCT00117338|DRUG|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
224113316|NCT00404443|DEVICE|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
223969120|NCT04414397|DEVICE|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC injectable gel
224113317|NCT02910778|DRUG|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
223969121|NCT04414397|OTHER|No-treatment control|Participants received no treatment for 3 months during the Control Period.
224113318|NCT02910778|DRUG|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
224113319|NCT02910778|DRUG|Ticagrelor|
224113320|NCT02296346|DRUG|SoluMedrol|Infusion of drug subcutaneously, once a month.
224113321|NCT02296346|DEVICE|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
224113322|NCT04331301|PROCEDURE|Bipolar Vapo-Enucleation of the prostate|group A: Patient will be subjected to bipolar endoscopic enucleation of the prostate by vaporization electrode (vapoenucleation).
224113323|NCT04331301|PROCEDURE|Bipolar Needlescopic Enucleation of the prostate|group B: Patient will be subjected to bipolar endoscopic enucleation of the prostate by hot knife electrode (Needlescopic Enucleation ).
224113324|NCT01351519|DRUG|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
224113325|NCT01723501|DRUG|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
224113326|NCT01723501|DRUG|sterile water|Sterile water wipes (placebo)
224113327|NCT00002445|DRUG|IM862|
224113328|NCT01412242|OTHER|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
224113329|NCT05170191|BEHAVIORAL|Sleep Deprivation|The participants will stay awake for 24 hours.
224113330|NCT03920605|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
224113331|NCT03920605|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
224113332|NCT03920605|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
223724928|NCT02947503|DRUG|Metformin TEVA 850 mg|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
223724929|NCT03365687|DIETARY_SUPPLEMENT|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
223724930|NCT03365687|DIETARY_SUPPLEMENT|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
223969122|NCT02502487|PROCEDURE|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
223969123|NCT02502487|DRUG|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
223969124|NCT02502487|DRUG|Tetracaine|1% Tetracaine gel instilled into urethra
223969125|NCT01854372|DRUG|R-HCVAD and R-MC|
223969126|NCT01920178|DEVICE|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
224113333|NCT03333369|DRUG|200 mg levodopa/50 mg benserazide|
224113334|NCT03333369|DRUG|Dextrose|
224113335|NCT00865501|DRUG|spironolactone|25mg per oral once daily
224113336|NCT00865501|DRUG|placebo|placebo
224113337|NCT02240628|DEVICE|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
224113338|NCT02240628|DRUG|Saline|Patients in arm 2 will receive Saline with the Propofol.
224113339|NCT02240628|DRUG|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
224113340|NCT03450889|PROCEDURE|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
224113341|NCT05431465|OTHER|Vita Ambria|onlay restoration will be fabricated from Zirconia reinforced lithium disilicate glass ceramic(vita ambria)
224113342|NCT05431465|OTHER|IPs emax onaly|onlay restoration will be fabricated from lithium disilicate glass ceramic(IPS emax)
224113343|NCT01140542|DRUG|Roflumilast|500µg, once daily
223969127|NCT03944902|DRUG|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
223969128|NCT03944902|DRUG|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
223969129|NCT04366648|DRUG|JK-1201I|malignant solid tumor that has been confirmed by histopathology and/or cytology
223969130|NCT05000593|OTHER|normal saline|Intra-articular injection of normal saline
223969131|NCT05000593|OTHER|Cord Blood Mononuclear Cells (UCB-MNCs)|Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)
223969132|NCT02987088|DRUG|Sodium Nitrite|
223969133|NCT05343819|DRUG|AON-D21|AON-D21 is a PEGylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
223969134|NCT05343819|DRUG|Placebo|Isotonic glucose solution identical in appearance to AON-D21.
223969135|NCT01261793|DRUG|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
223724931|NCT04216875|PROCEDURE|Best Practice Diabetes Management in Primary Care|Practice adherence to best practice guidelines treating diabetes patients in different primary care practices is shown in this before- and after observational study
223969136|NCT01261793|DRUG|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
223969137|NCT01261793|DRUG|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
223969138|NCT06531811|DRUG|AZD8630 (test formulation) via test inhaler|Participants will receive AZD8630 via test inhaler.
223969139|NCT06531811|DRUG|AZD8630 (reference formulation) via Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
223969140|NCT06531811|DEVICE|Test inhaler|Participants will receive AZD8630 via test inhaler.
223969141|NCT06531811|DEVICE|Monodose inhaler|Participants will receive AZD8630 via Monodose inhaler.
224113344|NCT03408080|DRUG|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
224113345|NCT04476771|BEHAVIORAL|Feliz-Mente (third generation psychotherapy)|The intervention is delivered in a group format with a total of 12 sessions and a maximum of 10 patients per group. The protocol consists of specific exercises: 1: welcome and identification of emotions, 2: identification and amplification of positive emotions, 3: regulation of negative emotions, 4: gratitude, 5: forgiveness, 6: self-compassion, 7: personal strengths, 8: loving-kindness and positive interpersonal relationships, 9: values, 10: purpose of life, 11: resilience, 12: keeping the change and farewell party.
224113346|NCT02385123|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
223969142|NCT01972373|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
223969143|NCT01972373|DEVICE|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
223969144|NCT02961816|DRUG|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
223969145|NCT02961816|DRUG|Panobinostat|20 mg by mouth daily from Day -9 to -2.
223969146|NCT02961816|DRUG|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
224113347|NCT03626415|DRUG|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
224113348|NCT01070303|BIOLOGICAL|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
224113349|NCT02022423|BEHAVIORAL|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
224113350|NCT02022423|BEHAVIORAL|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals
223969147|NCT02961816|DRUG|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
223969148|NCT02961816|DRUG|Melphalan|60 mg/m2 by vein on Days -3 and -2.
223969149|NCT02961816|DRUG|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
223969150|NCT02961816|DRUG|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
223969151|NCT02961816|DRUG|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
223969152|NCT02961816|DRUG|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
223969153|NCT02961816|OTHER|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
223969154|NCT02961816|DRUG|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
223969155|NCT02961816|BIOLOGICAL|Stem Cell Infusion|Stem cells administered by vein on Day 0.
223969156|NCT02961816|DRUG|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
223969157|NCT02109718|DRUG|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
223969158|NCT02109718|DRUG|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
223969159|NCT02985086|DRUG|Cefoxitin|
223969160|NCT02985086|DRUG|oxytocin/misoprostol|
223969161|NCT03562117|DRUG|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
223969162|NCT03288480|DRUG|PT-112|This is a single arm study
223969163|NCT05807542|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
223969164|NCT05807542|DRUG|Paclitaxel-albumin|Paclitaxel-albumin will be administered on day 1 of each cycle at 260mg/m2 once every 21 days.
223969165|NCT05807542|DRUG|Carboplatin|carboplatin will be administered on day 1 of each cycle at AUC=5 once every 21 days.
223969166|NCT01884376|DEVICE|Neuromaix|
223969167|NCT06149533|DRUG|Edoxaban|Edoxaban, an oral selective factor Xa inhibitor, had been approved by the National Medical Products Administration in 2018. It is used for the treatment and recurrence prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults.
223969168|NCT05620199|PROCEDURE|Upfront resection|Resection of the primary tumor
224113351|NCT05978895|OTHER|Targeted canteen menus|"The nutritional intervention consisted in the development of targeted menus aiming at the needs of individuals with ASD and in assessing their acceptance of the targeted menus.~The revision of the standard menus was carried 1) balancing energy and macronutrient content, according to LARN 2014; 2) promoting adequate weekly food frequencies consumption and portions, to provide an adequate and sustainable menus according to CREA 2018; 3) adapting the sensory characteristics of the foods offered to the sensory needs of individuals with ASD.~The acceptance of the targeted menus by the enrolled population was evaluated through meal evaluation forms. These results were compared with the ones collected during the first observational phase (WP1). In fact, referring to the results of WP1, new canteen menus were drafted according to the nutritional and sensory needs of the population."
224113352|NCT02786459|DEVICE|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
224113353|NCT02786459|DEVICE|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
224113354|NCT02786459|DEVICE|SPECT-CT|Used as a comparative to ProxiScan.
224113355|NCT01355991|DRUG|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
224113356|NCT01355991|DRUG|Salmeterol|50mcg inhalation twice daily for two weeks
223969169|NCT05872906|DEVICE|Acupuncture|A 1.5-inch needle of 34 gauge (CASOON stainless steel acupuncture needles) is inserted. The physician will then locate the de qi location of the test subjects and elicit a de qi response accompanied by muscle twitch.
223969170|NCT00829517|OTHER|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
223969171|NCT00829517|OTHER|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
223969172|NCT01294358|DRUG|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
223969173|NCT00104364|DRUG|MK0731|
223969174|NCT00524693|DRUG|Montelukast|4mg sachets
223969175|NCT00524693|DRUG|Placebo granules|
223969176|NCT00848640|DRUG|Sorafenib|400 mg twice daily
223969177|NCT05662878|OTHER|Assessment of Hand Strength and Spasticity|Assessment of Hand Strength and Spasticity
223969178|NCT00001623|PROCEDURE|Allogeneic Bone Marrow Transplant|
223969179|NCT03554200|DRUG|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
223969180|NCT03554200|DRUG|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
223969181|NCT01083537|DRUG|Cisplatin|"1\) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~1. Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~2. Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
223969182|NCT01083537|DRUG|Paclitaxel|"2\) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~1. Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~2. Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~3. Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
223969183|NCT02646644|OTHER|Metastasized intestinal NET|This is an observational study
223969184|NCT05156216|OTHER|Patient education|Knowledge and beliefs about the condition and its management influences patient behavioural intentions, including treatment choices. Thus, patient education may play an important role in facilitating desirable behaviours with the aim of education being to develop accurate beliefs about treatment options and empower people to choose wisely for their current needs and circumstances.
223969185|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
223969186|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
223969187|NCT00117650|BIOLOGICAL|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
223969188|NCT00117650|OTHER|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
223969189|NCT04985071|PROCEDURE|Pancreaticoduodenectomy|Patient with periampullary cancer will be underwent pancreaticoduodenectomy in 2 types of pancreatic-jejunal anastomosis reconstructions. We describe the postoperative complications (pancreatic fistula and bleeding) and analysis the risk factors relate to those complications
223969190|NCT02684942|DRUG|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
223969191|NCT02684942|DRUG|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
223969192|NCT00659971|DRUG|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
223969193|NCT01796834|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
224113357|NCT06212895|OTHER|Survey|"A survey is handled out at the patient registration. Patients can fill it out during waiting for their appointment. The physician, who treats the patients is not aware aout the filling status or content. The Survy will not influence the treatment.~The Survey consists of 3 parts: patients attidude and expectations, and questionnaire about their usual physical activity and the validated Expectation Treatment Score."
224113358|NCT01897415|BIOLOGICAL|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
224113359|NCT02897635|BEHAVIORAL|Individualized Integrative Medicine Intervention|
224113360|NCT01782183|DEVICE|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
223969194|NCT02784535|DRUG|Atomoxetine|norepinephrine transporter inhibitor
223969195|NCT02784535|DRUG|Placebo|placebo
224113361|NCT02345434|OTHER|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
224113362|NCT00259259|BEHAVIORAL|SALATRIM|
224113363|NCT03824977|DIAGNOSTIC_TEST|Six minutes stepper test (6MST)|"The 6MST is done using a stepper (Stepper essential, Decathlon(TM), France), with a walking height of 20 cm, placed in front of a wall or parallel bars, so patients can hold on if necessary.~Patients are instructed to make the maximum number of steps possible in 6 minutes, and are given a time check at one minute intervals."
224113364|NCT03824977|DIAGNOSTIC_TEST|Sit to stand test (STST)|The STST is done using a chair measuring 47 cm in height. The patient are instructed to sit in the chair and then to do the maximum number of lifts possible from the chair, in 1 minute, with arms folded and without leaning against the chair.
224113365|NCT06469658|OTHER|The standard practice dietary supplements intervention|Participants receive supplements prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.
224113366|NCT06469658|OTHER|The AI-guided practice dietary supplements group|Participants receive DS prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
224113367|NCT02926573|DRUG|Gabapentin|
224113368|NCT02926573|DRUG|Placebo|
224113369|NCT00984464|BIOLOGICAL|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
223969196|NCT06116266|OTHER|Education and support for primary care providers (PCPS)|All PCPs in the EUC and Co-Care arms receive brief education on SUD treatment, including medications for OUD and AUD and contingency management for StUD, and recognizing and counteracting stigma while caring for patients with SUD.
223969197|NCT06116266|OTHER|Nurse Care Manager (NCM) visits|A full-time clinic-embedded nurse care manager who works with patients and their PCPs to facilitate and support patient engagement in evidence-based treatment for polysubstance use and management of associated health conditions
224291636|NCT01699763|DEVICE|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224291637|NCT01699763|DEVICE|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
224291638|NCT03046134|BIOLOGICAL|PCV13|Conjugated pneumococcal vaccine
224291639|NCT01522079|PROCEDURE|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
223969198|NCT06116266|OTHER|Addiction specialist consultant|An addiction specialist consultant who supports the nurse care manager and PCP in formulating and adjusting treatment plans
223969199|NCT06116266|OTHER|Health coaching sessions|Health coaches who use motivational interviewing and cognitive behavioral therapy to motivate and support patients in behavior change to reduce polysubstance use-related harms. Patients may receive up to 12 health coaching sessions in total. The sessions will occur via phone and/or HIPAA compliant video chat software.
223969200|NCT06116266|OTHER|Patient educational materials|Patient participants receive an educational pamphlet addressing overdose prevention, information about accessing naloxone, and local SUD treatment options.
223969201|NCT04047680|DRUG|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
223969202|NCT04047680|DRUG|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
223969203|NCT04047680|DRUG|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
223969204|NCT04047680|DRUG|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
223969205|NCT04047680|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
223969206|NCT04047680|DRUG|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
223969207|NCT03198416|DEVICE|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
223969208|NCT05066178|BEHAVIORAL|CAS Treatment for Minimally Verbal Children with Autism|Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
223969209|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
223969210|NCT01229527|DRUG|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
223969211|NCT01229527|DRUG|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
223969212|NCT04453306|DRUG|Topiramate|topiramate 25mg is coated in tablets in an independent laboratory
224291640|NCT02427984|OTHER|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
224291641|NCT02427984|OTHER|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
223724932|NCT04216329|DRUG|Selinexor|Selinexor will be administered orally at an initial dose of 80 mg. The first dose will be given on day 2 of radiation and will thereafter be administered weekly on the second day of weekly radiation on weeks 1, 2, 4, and 5. If this dose level is tolerated, the dose will be escalated to 60 mg twice a week (days 1 and 4) on weeks 1,2,4,5. The third and final dose level will also be 60mg administered twice weekly for 6 weeks starting on days 1 and 4 radiation.
223969213|NCT04453306|DRUG|Placebo|innocuous substance is coated in tablets in an independent laboratory
223969214|NCT01239056|PROCEDURE|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
223969215|NCT03071900|DIAGNOSTIC_TEST|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
223969216|NCT04198272|BEHAVIORAL|CyberRwanda|The CyberRwanda intervention consists of three primary components: 1. STORIES: The CyberRwanda curriculum empowers youth to learn about family planning and reproductive health and employment skills and to set goals for their futures through age-appropriate, interactive, digital and printed stories and activities. 2. LEARN: Q\&As and videos related to family planning and reproductive health. 3. SHOP: Youth can directly purchase health products, including menstrual hygiene and contraceptive products (emergency contraception, condoms, and oral contraceptive pills) online. The online health facility finder tool links youth to health facilities for longer-acting methods. All participating pharmacies will be trained to give unbiased, nonjudgmental information and services.
223969217|NCT03740919|DRUG|LY900014|Administered SC
223969218|NCT03740919|DRUG|Insulin Lispro|Administered SC
223969219|NCT03740919|DRUG|Insulin Glargine|Administered SC
223969220|NCT03740919|DRUG|Insulin Degludec|Administered SC
223969221|NCT02335242|DRUG|Sildenafil 20 mg tablets|
223969222|NCT02335242|OTHER|Placebo tablets (resembling Revatio)|
223969223|NCT02848898|DEVICE|Equistasi|
223969224|NCT02848898|OTHER|Placebo|
223969225|NCT04916340|BEHAVIORAL|Muscular Strength Training Group|"Week 1 3 days/week Bench Press - 1 set at 80% of one repetition maximum~(1RM) Bent Over Row - 1 set at 80% 1RM Back Squat - 1 set at 80% 1RM Romanian Deadlift - 1 set at 80% 1RM~Week 2 3 days/week Bench Press - 2 sets at 80% 1RM Bent Over Row - 2 sets at 80% 1RM Back Squat - 2 sets at 80% 1RM Romanian Deadlift - 2 sets at 80% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 80% 1RM Bent Over Row - 3 sets at 80% 1RM Back Squat - 3 sets at 80% 1RM Romanian Deadlift - 3 sets at 80% 1RM"
223969226|NCT04916340|BEHAVIORAL|Muscular Fitness Training Group|"Week 1 3 days/week Bench Press - 1 set at 65% 1RM Bent Over Row - 1 set at 65% 1RM Back Squat - 1 set at 65% 1RM Romanian Deadlift - 1 set at 65% 1RM~Week 2 3 days/week Bench Press - 2 sets at 65% 1RM Bent Over Row - 2 sets at 65% 1RM Back Squat - 2 sets at 65% 1RM Romanian Deadlift - 2 sets at 65% 1RM~Weeks 3-10 3 days/week Bench Press - 3 sets at 65% 1RM Bent Over Row - 3 sets at 65% 1RM Back Squat - 3 sets at 65% 1RM Romanian Deadlift - 3 sets at 65% 1RM"
223969227|NCT04763863|OTHER|Body Assessment Tool|Assessment tool to evaluate stoma to find proper ostomy products
224291642|NCT02427984|OTHER|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
224291643|NCT03377023|DRUG|Nivolumab|Intravenous nivolumab every 2 weeks.
224291644|NCT03377023|DRUG|Ipilimumab|Intravenous ipilimumab every 6 weeks.
223969228|NCT04763863|OTHER|Clinical usability evaluation of the Body Assessment Tool|"The stoma care nurses evaluated the clinical usability of the Body Assessment Tool, which included answering the following questions:~Does the tool offer value in clinical practice? Does it provide a good starting point when choosing ostomy product(s)? Does it help raise the quality of care? Participants provided their responses on a 6 point-scale (1-6), where 1 indicated the lowest satisfaction and 6 the greatest satisfaction with the tool."
223969229|NCT00690950|DRUG|Dutasteride|0.5mg capsule, taken once daily for 12 months
223969230|NCT03771534|DRUG|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
223969231|NCT03670199|OTHER|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
223969232|NCT03670199|OTHER|Physiotherapist intervention|Respiratory capacity Functional capacity
223969233|NCT03670199|OTHER|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
223969234|NCT03670199|OTHER|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
223969235|NCT04477954|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
223969236|NCT06564246|DRUG|Vonoprazan 20 mg versus Pantoprazole 40 mg|Patients divided into two arms First Arm administered vonoprazan Second arm administered pantoprazole
223969237|NCT01707914|DIETARY_SUPPLEMENT|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
224113370|NCT00984464|DRUG|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
224113371|NCT00984464|DRUG|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
224113372|NCT01241513|DRUG|NAC|NAC provided to determine if beneficial at altitude
223724933|NCT04216329|DRUG|Temozolomide|Temozolomide will begin on the first day or evening prior of radiation and be administered orally daily at a dose of 75 mg/m\^2 during the radiation treatment. Temozolomide will continue until the completion of radiation and then will be stopped. Beginning 1-month post-radiation therapy (RT), the adjuvant temozolomide will be given per standard of care.
223724934|NCT04216329|RADIATION|Generic Radiation therapy (RT)|Radiation therapy (RT) will be administered daily (Monday to Friday)
223969238|NCT01707914|DIETARY_SUPPLEMENT|placebo|
223969239|NCT00004171|DRUG|busulfan|
223969240|NCT00004171|DRUG|cyclophosphamide|
223969241|NCT00004171|PROCEDURE|peripheral blood stem cell transplantation|
224113373|NCT01241513|DRUG|Placebo|Placebo
224113374|NCT00858702|DRUG|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
224113375|NCT00858702|DRUG|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
224113376|NCT06121557|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
224113377|NCT06121557|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
223969242|NCT06026462|DIAGNOSTIC_TEST|Observation of clinical indicators related to asthma|Observe the severity of asthma, drug compliance, comorbidities, asthma control, pulmonary function, FeNO, and the number of acute episodes of asthma
223969243|NCT03873038|DRUG|MK-2060|"Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.~Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22."
223969244|NCT03873038|DRUG|Placebo|Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.
223969245|NCT02458274|OTHER|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
223969246|NCT02301104|DRUG|TAS-102|
223969247|NCT04222088|DRUG|Arthemeter-lumefantrine|"Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)"
223969248|NCT04222088|DRUG|Chloroquine|Chloroquine will be administered according to body weight at a total dose of 25 mg base/kg over 3 days (10 mg base/kg on Day 0; 10 mg base/kg on Day 1 and 5 mg base/kg on Day 2). Correct drug dosage will be determined using the dosing chart (in accordance with national treatment guidelines)
223969249|NCT04222088|DRUG|Primaquine|For Pf patients, primaquine at 0.75 mg base/kg body weight single dose will be given on Day 3 for Pf patients; For Pv patients primaquine will be withheld for 28 days and will be given after Day 28 follow-up, at 0.25 mg base/kg per day for 14 days.
223969250|NCT02467673|DRUG|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
223969251|NCT02467673|DRUG|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
223969252|NCT05749562|DEVICE|Cheneau-Toulouse-Munster brace|Full length, orthogonal anteroposterior and lateral X-rays will be taken with the Cheneau-Toulouse-Munster brace.
224113378|NCT06121557|DRUG|Fludarabine|Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
224113379|NCT06121557|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|In the dose-escalation portion, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).
224113380|NCT06121557|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
224113381|NCT06121557|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a dose of 200mg (3mg/kg for participants whose weight is below 50kg) IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
224113382|NCT06121557|DRUG|Chemotherapeutic drug, ADC or PARP inhibitor|Another anti-tumor drug chosen from chemotherapeutic drug, ADC, or PARP inhibitor will be administered at investigator's discretion.
224113383|NCT05503134|BIOLOGICAL|Universal Donor Natural Killer Cells|Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment
223969253|NCT00905255|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
223969254|NCT00905255|DEVICE|Pen auto-injector|
223969255|NCT05324748|DRUG|Methylprednisolone|Injection with prednisolon
224113384|NCT05570916|DEVICE|Zip-stitch(R)|Zip-stitch clips for vaginal cuff closure during laparoscopic hysterectomy
223969256|NCT05324748|DRUG|Saline solution|0,9%
223969257|NCT02270125|PROCEDURE|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
223969258|NCT02240836|OTHER|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
223969259|NCT05385991|BIOLOGICAL|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)|ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
223969260|NCT05850858|DIAGNOSTIC_TEST|ascetic fluid study|ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
223969261|NCT03735368|DRUG|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
223969262|NCT03735368|DRUG|Placebo oral capsule|placebo oral capsules
223969263|NCT03735368|DRUG|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
224113385|NCT05570916|DEVICE|Reference suture|Standard suture for vaginal cuff closure during laparoscopic hysterectomy
224113386|NCT02522962|BEHAVIORAL|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
224291645|NCT03377023|DRUG|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
223969264|NCT03735368|DRUG|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
223969265|NCT00471549|DRUG|Statin (simvastatin)|
223969266|NCT01657552|DRUG|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
223969267|NCT01657552|DRUG|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
223969268|NCT01657552|DRUG|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
223969269|NCT04528368|BIOLOGICAL|Convalescent plasma|The intervention group will receive 400 mL of convalescent plasma with a SARS-CoV-2 antispike antibody titer with a dilution ≥ 1: 320.
223969270|NCT05532319|COMBINATION_PRODUCT|HAIC sequential TAE combined with lenvatinib and tislelizumab|Patients with unresectable hepatocellular carcinoma will receive hepatic arterial infusion chemotherapy (HAIC) sequential transarterial embolization combined with lenvatinib and tislelizumab.
223969271|NCT04825210|BEHAVIORAL|Integrated Behavioral Health - Prevention|IBH-P consists of 15-30 minute visits with mothers as part of the 1, 2, 4, and 6 month well-child visits. The intervention is delivered by doctoral level pediatric psychologists that are an integrated member of the primary care team.
223969272|NCT04825210|BEHAVIORAL|Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 4th Edition|Bright Futures curriculum will be delivered by the pediatrician as part of the 1, 2, 4 and 6 month well-child visits.
223969273|NCT03588676|OTHER|Melatonin|5mg Melatonin
223969274|NCT03588676|OTHER|Placebo|5mg Placebo capsule
223969275|NCT00789399|DRUG|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
223969276|NCT00789399|OTHER|Placebo|subcutaneous equivolume isotonic saline
223969277|NCT00860522|DRUG|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
223969278|NCT00860522|DRUG|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
223969279|NCT02599376|DEVICE|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
223969280|NCT03662854|BIOLOGICAL|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
224113387|NCT02522962|BEHAVIORAL|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
224113388|NCT02728934|BIOLOGICAL|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
223969281|NCT03662854|OTHER|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
223969282|NCT05862779|DIETARY_SUPPLEMENT|Placebo Group|The placebo group will receive 4 g per day of corn oil and 40 g per day of maltodextrin.
223969283|NCT05862779|DIETARY_SUPPLEMENT|Whey Protein + Placebo|The whey protein + placebo group will receive 40g per day of whey and 4g per day of corn oil.
223969284|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Placebo|The omega 3 + placebo group will receive 4 g per day of fish oil and 40 g per day of maltodextrin.
223969285|NCT05862779|DIETARY_SUPPLEMENT|Omega 3 + Whey Protein|The omega 3 + whey group will receive 4g per day of fish oil and 40g per day of protein.
223969286|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day on a 21-day cycle
223969287|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed intermittently on a 21-day cycle
223969288|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
223969289|NCT04770246|DRUG|TAS-117|TAS-117 will be dosed orally every day or intermittently on a 21-day cycle
223969290|NCT02133131|DRUG|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
223969291|NCT02133131|DRUG|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
223969292|NCT02144194|DRUG|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
224291646|NCT04583163|DIAGNOSTIC_TEST|Transcranial Doppler|Transcranial Doppler is a non-invasive, painless, ultrasound technique that uses high frequency sound waves to measure the rate and direction of blood flow vessels in the brain.
223969293|NCT02144194|DRUG|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
223969294|NCT06197100|OTHER|Supportive care training|The program includes breastfeeding teaching, baby massage, managing gas issues (shaking, white noise), and nutrition for mothers.
224113389|NCT02728934|BIOLOGICAL|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
224113390|NCT02728934|BIOLOGICAL|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
224113391|NCT02875210|PROCEDURE|Laximeter measurement|
224291647|NCT03287908|DRUG|AMG 701|Subjects will receive IV infusions of AMG 701.
224291648|NCT03287908|DRUG|Pomalidomide|Subjects will receive oral capsules of pomalidomide.
224291649|NCT03287908|DRUG|Dexamethasone|Subjects will receive IV injections or oral dexamethasone.
224291650|NCT02553525|PROCEDURE|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
224291651|NCT02553525|PROCEDURE|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
223724935|NCT04216329|OTHER|Selective serotonin receptor (5-HT3) antagonists|Anti-emetic for breakthrough nausea.
223724936|NCT04216329|OTHER|Olanzapine|2.5mg to 5mg once a day if weight loss is rapid.
223969295|NCT06197100|OTHER|control grups|Mothers in this group will be given an educational brochure containing information about colic.
223969296|NCT01544153|BEHAVIORAL|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
223969297|NCT01544153|BEHAVIORAL|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
223969298|NCT01544153|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
223969299|NCT02127892|BIOLOGICAL|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
223969300|NCT02127892|BIOLOGICAL|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
223969301|NCT02127892|BIOLOGICAL|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
223969302|NCT02127892|DEVICE|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
223969303|NCT02249429|DRUG|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
224113392|NCT01738035|DRUG|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
224113393|NCT01738035|OTHER|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
223969304|NCT02600988|DRUG|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
223969305|NCT02600988|DRUG|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
223969306|NCT00884793|DRUG|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
223969307|NCT00884793|DRUG|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
223969308|NCT00884793|DRUG|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
223969309|NCT04783519|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
223969310|NCT04783519|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
223969311|NCT01032200|DRUG|Armodafinil|Given orally
223969312|NCT01032200|OTHER|placebo|Given orally
223969313|NCT01874470|DEVICE|renal denervation|
223969314|NCT01874470|OTHER|standard medication|
223969315|NCT02785900|DRUG|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
223969316|NCT02785900|DRUG|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
223969317|NCT02785900|DRUG|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
223969318|NCT02785900|DRUG|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
223969319|NCT00409500|DRUG|AQW051|
223969320|NCT05663541|DIAGNOSTIC_TEST|Lower extremity position test|Assessing proprioception of the lower extremity of individuals multiple sclerosis
223969321|NCT06088082|DRUG|Bupivacaine Hydrochloride|Patients will be randomly assigned to receive a TAP and PRS blocks with 34 mL of 0.25% bupivacaine (study group) or standard hospital analgesia protocol (control group).
223969322|NCT03373188|BIOLOGICAL|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
223969323|NCT03373188|BIOLOGICAL|Ipilimumab|Given IV
223969324|NCT03373188|BIOLOGICAL|Nivolumab|Given IV
224291652|NCT06956690|BIOLOGICAL|ENV-501|ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.
223969325|NCT03373188|PROCEDURE|Surgery|Undergo therapeutic conventional surgery
223969326|NCT06647147|OTHER|Aerobic training|For twelve weeks, the women in the study group will participate in aerobic training on cycle ergometer. Each session will consist of 30-45 minutes of cycling at a moderate intensity, accompanied by a workout heart rate ranging from 65% to 75% of the maximal heart rate and ranging between 12 and 14 on the Borg rating of perceived exertion 20-point scale. After ten minutes of warm-up, every session will end with a brief 3-minute period of cool-down.
223969327|NCT06647147|OTHER|Diaphragmatic breathing exercises|From the hook-lying position, the women will receive instructions to position their hands on the rectus abdominis muscle located under the anterior chest wall. They will be advised to inhale slowly and deeply, expanding their abdomen without causing any movement in their upper chest, while simultaneously relaxing their shoulders. Slowly, the women will expel every breath. Air will be inhaled via the nose, swelling the abdomen. After the breath ceased, the women will purse her lips and exhale from his mouth with half-opened lips and a hollow belly. A single respiratory cycle consists of a three-second intake, followed by a three-second pause, and concluding with a six-second expiration phase.
223969328|NCT02779127|OTHER|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
223969329|NCT02779127|OTHER|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
223969330|NCT02779127|OTHER|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
223969331|NCT02779127|OTHER|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
223969332|NCT02779127|OTHER|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
223724937|NCT04216329|DIETARY_SUPPLEMENT|Salt tablets|To treat hyponatremia, add salt tablets to participants diet per institutional guidelines.
223969333|NCT02249156|BEHAVIORAL|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
223969334|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 1 Creatine HCl|Creatine hcl
223969335|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 2 Creatine HCl|Creatine hcl
223969336|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 3 Creatine Ethyl ester|Creatine ethyl ester
223969337|NCT06660004|DIETARY_SUPPLEMENT|Dietary Supplement: Experimental 4 Placebo|Placebo
223724938|NCT04216329|OTHER|Anti-diarrheal|Treat diarrhea with an anti-diarrheal per institutional guidelines
223724939|NCT06805565|DRUG|ONO-1110|ONO-1110 tablets once a day
223724940|NCT06805565|DRUG|Placebo|Placebo tablets once daily
223724941|NCT06457178|BEHAVIORAL|Acceptance and Commitment Therapy-Based Intervention for Oncology Patients|An intervention program was prepared for oncology patients aiming to reduce psychological distress and increase participation in normal life.
223724942|NCT06457178|BEHAVIORAL|Psychoeducation for Oncology Patients|A program was prepared to support oncology patients in physical and psychological symptom management.
223724943|NCT01333826|BEHAVIORAL|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
223724944|NCT03857321|DRUG|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly \& Company)
223724945|NCT03857321|OTHER|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
223724946|NCT03857321|DEVICE|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
223969338|NCT03616314|DEVICE|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
224291653|NCT05854238|DEVICE|TIRA-VoM|"treat persistent atrial fibrillation~* The ablation temperature range is 50-60℃~* About 2 minutes per ablation"
223724947|NCT06193499|PROCEDURE|Platelet rich plasma (PRP)|Intra-articular injection of platelet rich plasma (PRP)
223724948|NCT06193499|OTHER|Placebo|Intra-articular Saline injection (0,6-1ml)
223969339|NCT03616314|DEVICE|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
223969340|NCT03616314|OTHER|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
223969341|NCT06597435|OTHER|Nicotine pouch|Participants will self-administer an experimenter-provided nicotine pouch
223969342|NCT06242184|PROCEDURE|Group A(Nano-fortified Adhesive)|Nano-fortified dentin adhesive
224291654|NCT06099769|DRUG|Enzalutamide|mouth once daily (160 mg/day)
224291655|NCT06099769|DRUG|Mifepristone|mouth once daily 300-mg tablet
224291656|NCT06099769|DRUG|TPC|"The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"
223969343|NCT06242184|PROCEDURE|Group B(Adhesive without nanoparticles)|Conventional adhesives without nanoparticles
223969344|NCT06261840|DRUG|Metronidazole 500 mg|Multi-dose oral MTZ (500 mg twice daily for 7 days) for the treatment of T. vaginalis infection in women and men
223969345|NCT06261840|DRUG|Secnidazole 2000 MG|Single-dose 2 g oral SEC for the treatment of T. vaginalis infection in women and men
223969346|NCT06329544|DIETARY_SUPPLEMENT|Fructose|12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
224291657|NCT06136741|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
224291658|NCT06136741|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
224291659|NCT05688475|DRUG|CC-122|Specified dose on specified days
224291660|NCT05688475|DRUG|Dexamethasone|Specified dose on specified days
224291661|NCT06511167|DEVICE|TIGR® Matrix|bioresorbable, synthetic, surgical mesh
224291662|NCT03943537|DRUG|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
224291663|NCT05897125|OTHER|Virtual at Home Medication Reconciliation Visit(s)|Patients will have their medications reviewed by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
224291664|NCT05897125|BEHAVIORAL|Virtual At Home Medication Education Visit(s)|Patients will be provided with inhaler education by the TELE-TOC interventionalist, a member of the pharmacy team (anticipated)
224291665|NCT05897125|OTHER|COPD advanced practice nurse Inpatient Consult|Patients will receive a COPD consult by an advanced practice nurse as part of standard of care
224291666|NCT05897125|OTHER|Inpatient Medication Reconciliation|Patients will have their medications reviewed by member(s) of the clinical care team as part of standard of care
223969347|NCT06329544|DIETARY_SUPPLEMENT|glucose|12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
223969348|NCT03993054|BEHAVIORAL|Culturally-tailored cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 10 weeks. This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
223969349|NCT03476551|DRUG|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
223969350|NCT06324188|OTHER|Early atrial fibrillation ablation|Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.
223969351|NCT06324188|OTHER|Usual Care|Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.
223969352|NCT03370861|BIOLOGICAL|Immunotherapy|Medications that increase the activity of the immune system.
223969353|NCT06672055|BIOLOGICAL|VXA-CoV2-3.1|Tablets for oral use.
223969354|NCT06672055|BIOLOGICAL|COMIRNATY®|Intramuscular (IM) injection.
223969355|NCT06672055|BIOLOGICAL|VXA-CoV2-3.3|Tablets for oral use.
223969356|NCT02648282|DRUG|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
223969357|NCT02648282|DRUG|GVAX Pancreatic Cancer Vaccine|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of 8 doses. In the extended treatment phase, eligible patients may receive 2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells administered one day after CY every 6 months for an additional 4 doses.
223969358|NCT02648282|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg as a 30 minute IV infusion every 21 days for an additional 9 doses.
223969359|NCT02648282|RADIATION|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX Pancreas Vaccine).
223969360|NCT06283693|OTHER|mindfulness-based stress reduction|Müdahale grubundaki kadınlara depresyon, anksiyete ve stres düzeylerini azaltmak için farkındalık temelli bir stres azaltma programı uygulanacaktır. Program, haftada bir seans olmak üzere haftada iki kez toplam 4 hafta boyunca 8 seanstan oluşacaktır. Müdahale grubu haftada 2 seans alacaktır. Her seans 80 dakika sürecektir. Çalışmadaki seanslar, katılımcıların iş yoğunluğu, hayattaki sorumlulukları ve 4 hafta boyunca düzenli olarak katılamama ihtimalleri göz önünde bulundurularak zoom programı üzerinden gerçekleştirilecektir. 4 hafta/8 oturumluk MBSR programı tamamlandıktan sonra müdahale grubundaki kadınlara veri toplama formları tekrar uygulanacak ve son test ölçümleri yapılacaktır. Son test ölçümlerinden sonra müdahale grubundaki kadınların takip ölçümleri ölçümlerden 8 hafta sonra yapılacaktır.
223969361|NCT07009067|BEHAVIORAL|Exercise-based Cardiac Rehabilitation|Participated will receive 36 individualized Exercise-based Cardiac Rehabilitation after enrollment in our Cardiac Rehabilitation Center.
223969362|NCT07009470|DRUG|Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar)|First, perform a single session of TACE. Followed by three cycles of neoadjuvant therapy with Finotonlimab combined with bevacizumab. Proceed with curative resection. Finally, initiate postoperative adjuvant targeted-immunotherapy . Finotonlimab: intravenously every three weeks ,200mg. bevacizumab：intravenously every three weeks , with a dosage based on body weight: 15 mg (≤60 kg) .
223969363|NCT07009470|PROCEDURE|TACE|Initial Perform a single session of TACE procedure.TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).
223969364|NCT07009587|PROCEDURE|Endoscopy|endoscopic procedure
223969365|NCT07008157|OTHER|1. IFC|IFC therapy was applied while the patient lay in a supine position with the knees slightly apart. Each treatment session involved four electrodes enclosed in lint cloth covers. Two electrodes were positioned bilaterally on the lower abdomen, just below the anterior superior iliac spines (ASIS), while the remaining two were placed on the inner surfaces of both thighs. To maintain hygienic standards, the cloth covers were replaced for each participant at every session. The intervention was administered three times weekly over an eight-week period. A frequency range of 0-10 Hz was used, and the current intensity was carefully adjusted based on each patient's comfort and tolerance. Each IFC session lasted 15 minutes, with the aim of modulating pelvic region activity to support improved bladder function. This protocol was implemented three times per week over an eight-week period
224113394|NCT02417623|BEHAVIORAL|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
224113395|NCT01933984|DRUG|Bronchodilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
223724949|NCT07131423|DEVICE|Standard extracorporeal shock wave therapy|ESWT was performed using the Swiss DolorClast Master ESWT device in accordance with the guidelines of the International Society of Medical Shockwave Therapy. The treatment was carried out by a physical therapist with at least 5 years of ESWT experience. The patient sat with the shoulder abducted at 45°, the elbow flexed at 90°, and the forearm supinated. The shock waves were delivered in a circular motion, targeting the 2-3 most painful tender points within a 3 cm radius centered on the lateral epicondyle. A total of 2,500 pulses were administered per session (0.2 to 2 bar, 8 Hz, 2,500 pulses, with intensity adjusted according to the patient's tolerance). All patients received a total of 4 ESWT sessions, once every 5 days, over a period of 3 weeks.
223724950|NCT07131423|DEVICE|CC points shock wave therapy|The assessment was conducted by a 5-year or more experienced FM therapist, following the standard procedure of the FM organization. The process included conducting interviews, filling out assessment forms, performing movement checks, and conducting palpation. Four CC points covering the entire upper limb, including the shoulder area, were selected. The points were ranked based on the severity of the dense touch. The blackboard pen was used to mark the points on the patient's body. The same ESWT therapist as in Group A used the same shock wave treatment instrument to treat the four CC points. The most severe point received 800 shocks, the second most received 700 shocks, and the remaining two points each received 500 shocks. A total of 2,500 pulses (with an intensity of 0.2 to 2 bar, a frequency of 8 Hz, and the intensity adjusted according to the depth of the point and the patient's tolerance) were administered. This treatment was performed once every 5 days for 3 weeks.
223724951|NCT07131423|DEVICE|Shock wave therapy for the CC points and the lateral epicondyle|Carry out the same process as Group B, but only select the three most severe CC points for shock therapy. Also, rank them according to the severity of the touch examination-induced densification. The most severe point receives 600 pulses, the second most severe receives 500 pulses, and the third most severe receives 400 pulses. At the same time, treat the lateral epicondylitis pain area in the same way as Group A. Apply 1000 pulses to the pain area. The total number of shocks for all treatments is 2500 (with an intensity of 0.2 to 2 bar, a frequency of 8 Hz, and the intensity is adjusted according to the depth of the point and the patient's tolerance). The therapist performing the treatment is the same as those in Group A and Group B. The treatment is carried out once every 5 days for 3 weeks.
223724952|NCT06607458|DRUG|Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab|Trifluridine-tipiracil plus Bevacizumab Alone
223724953|NCT06607458|DRUG|Trifluridine-tipiracil plus Bevacizumab Alone|Trifluridine-tipiracil plus Bevacizumab Alone
223724954|NCT05353985|DRUG|TAK-062|TAK-062 tablets.
223969366|NCT07008157|OTHER|2. Timed voiding.|The approach involved instructing participants to follow a fixed, scheduled voiding routine, typically every 3 hours, irrespective of the sensation to urinate. Additionally, patients were advised to adjust their toileting posture by sitting and leaning forward at an angle of approximately 45 degrees, allowing adequate time for complete bladder emptying. The technique also included practicing double voiding, where the individual would stand up and sit down again after the initial void to help ensure maximum bladder evacuation
223969367|NCT07008157|OTHER|motor imagery training|Prior to initiating MIT, participants watched a 10-minute instructional video in a quiet treatment space, illustrating proper PFM contractions through both visual and auditory cues. The therapist provided a detailed explanation, using a simple analogy of the bladder as a balloon filled with urine, connected by a tube (the urethra) to the outside, and controlled by the PFM. It was explained that contracting these muscles tightens the balloon, holding back urine, whereas weak or relaxed muscles may lead to leakage. Patients were then guided to mentally visualize contracting and holding these muscles until they reached a suitable time and place (the toilet), without physically performing the action. Following this explanation, patients were asked to sit comfortably with their eyes closed and spend 10 minutes visualizing the movement and control of their PFM while remaining physically relaxed. Throughout the session, the therapist used open-ended prompts to help maintain the patient's focu
223969368|NCT07008157|OTHER|pelvic floor muscles training|Before beginning each treatment session, participants were instructed to empty their bladders to promote comfort and relaxation during the exercises. All patients were taught a structured PFMT routine, to be performed daily in multiple positions such as lying, sitting, and standing. The program consisted of contracting the PFM for 10 seconds, followed by a 10-second relaxation period, with this sequence repeated 15 times in each session. To gradually enhance the endurance of the slow-twitch muscle fibers, both contraction and relaxation times were increased by one second each week. In addition, to activate and strengthen the fast-twitch muscle fibers, patients were directed to perform 20 quick, repetitive contractions and relaxations of the levator ani muscles - simulating the act of stopping urine flow, followed by a 10-second rest. This rapid contraction sequence was repeated for 2 to 4 sets in each session. This protocol was implemented three times per week over an eight-week period
223969369|NCT07008612|DIAGNOSTIC_TEST|Patients with a genetic syndrome linked to the MYT1L gene|"* Neuropsychological assessment by the neuropsychologist (lasting 1h30)~* Speech and language assessment (including language and prosody) by the speech therapist, lasting 1h30"
223969370|NCT07008612|DIAGNOSTIC_TEST|Patients with a neurodevelopmental disorder of genetic origin but not linked to MYT1L|Evaluation de la prosodie par l'orthophoniste (45 minutes)
224113396|NCT04385030|DEVICE|TRANSCRANIAL DIRECT CURRENT STIMULATION AND MIRROR THERAPY|The study will consist of 12 sessions, carried out over a period of 1 month, with 3 weekly sessions on consecutive days, where each patient will receive ETCC for 30 minutes concomitantly with ET. Outcome assessments will be performed before the beginning of the protocol on the base (T0) and immediately after the end of the 12 sessions (T1).
223724955|NCT05353985|DIETARY_SUPPLEMENT|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar|SIGE gluten bars.
223724956|NCT05353985|DRUG|TAK-062 Placebo|TAK-062 placebo-matching tablets.
223724957|NCT05353985|DIETARY_SUPPLEMENT|Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar|SIGE gluten-free bars.
224113397|NCT03667677|DRUG|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
223724958|NCT07002476|DRUG|guideline-recommended SoC|Guideline-recommended SoC, including but not limited to oral lipid-lowering drugs, antiplatelet aggregation drugs, anticoagulant drugs, antihypertensive drugs, etc. It is to be determined by the investigator based on the subject's treatment needs.
223724959|NCT07002476|DRUG|Recaticimab (intensive)|Recaticimab is added to the guideline-recommended SoC. After randomization and before endovascular interventional treatment, patients will receive a subcutaneous injection of Recaticimab. The specific method is: Recaticimab 450 mg (3 vials) as a single subcutaneous injection, until the end of the follow-up for this study.
223724960|NCT07131215|OTHER|Home-based multimodal exercise|Mobile Applications
223724961|NCT07131215|OTHER|Supervised multimodal exercise program|In laboratory
223724962|NCT07131215|OTHER|Education|Menopause education
223724963|NCT07131618|OTHER|cryocompression|"Cryocompression induces vasoconstriction in the applied area, thereby reducing blood flow. As a result, the delivery of the chemotherapeutic agent to peripheral nerves is limited, and it is aimed to protect nerve tissue from toxic effects. At the same time, low temperature slows down nerve conduction and cellular metabolism, helping to prevent damage to nerve cells.~30 minutes after the start of the paclitaxel infusion, cryocompression will be applied using ice gel gloves for the hands and socks for the feet, lasting 30 minutes. After paclitaxel ends, carboplatin will be infused intravenously in 250 cc isotonic solution over 1 hour. Cryocompression will again be applied 30 minutes after the start of the carboplatin infusion using the same method, for 30 minutes. This intervention will be performed weekly during each cycle of the 6-week carboplatin/paclitaxel protocol, for a total of 60 minutes per session."
223724964|NCT07002684|DRUG|Esketamine|nasal
223969371|NCT07008326|BEHAVIORAL|High Intensity Circuit Training|HICT: 3x/week high intensity circuit training for 12 weeks
223969372|NCT07008326|BEHAVIORAL|Moderate Intensity Continuous Training|3x/week moderate intensity continuous training for 12 weeks
223969373|NCT07009366|PROCEDURE|Sudden weaning of NCPAP|"NCPAP was taken off entirely when the neonate met the stability criteria and remained on oxygen or room air via a headbox or incubator with an aim to stay off NCPAP."
223969374|NCT07009366|PROCEDURE|Gradual weaning with increasing the time off NCPAP|The regimen adopted for this method was 1 hour off twice a day on the 1st day, then 2 hours off twice a day on the 2nd day, hence increasing the time off to 6 hours twice a day (or 12 hours per day), i.e., using a smaller period off. At this point, NCPAP was taken off completely.
223969375|NCT07009366|PROCEDURE|Pressure weaning of NCPAP|In this method the pressure was reduced in steps of 1 cm of H2O every 12 to 24 hours until 5 cm of H2O, and then if the child tolerated it well, NCPAP was removed, and the child was shifted to oxygen via incubator or room air according to the situation.
223969376|NCT07008365|DRUG|Furosemide 20 Milligrams|Decongestive therapy with e.v. furosemide +/- hydrochlorothiazide will be adjusted by intraabdominal pressure and/or point of care ultrasound
223969377|NCT07008443|DRUG|Bupivacaine + saline|25 ml of 0.5% bupivacaine combined with 5 ml of normal saline, administered via ultrasound-guided supraclavicular brachial plexus block as a control intervention
223969378|NCT07008443|DRUG|Bupivacaine + nalbuphine|25 ml of 0.5% bupivacaine combined with nalbuphine at a dose of 50 µg/kg, administered via ultrasound-guided supraclavicular brachial plexus block
223969379|NCT07008443|DRUG|Bupivacaine + morphine|25 ml of 0.5% bupivacaine combined with morphine at a dose of 50 µg/kg, administered via ultrasound-guided supraclavicular brachial plexus block
223969380|NCT07009106|OTHER|Educational video on postpartum care|Participants watched a short educational video on postpartum care during a regularly scheduled prenatal visit.
223969381|NCT07007715|OTHER|Flow of 40L/min|Setting flow rate at 40L/min
223969382|NCT07007715|OTHER|Peak tidal inspiratory flow (PTIF) guided|Setting HFNC flow at 5 L/min above the peak tidal inspiratory flow (PTIF), up to a maximum of 60 L/min.
223969383|NCT07007715|OTHER|PaO2/FiO2 ratio guided|Setting HFNC flow according to P/F ratio prior to extubation. Flow will be set at 60, 50 40 L/min if P/F ratio \<250 mmHg, 250-300 mmHg and \>300 mmHg, respectively.
223969384|NCT07007715|OTHER|Flow of 60L/min|Setting flow rate at 60L/min
223969385|NCT07009678|DIAGNOSTIC_TEST|intravenous access in greater saphenous vein compared to upper extremity site.|Ultrasound access of greater saphenous vein with placement of midline 4French catheter and use of sphygmomanometer to regulate valsalva maneuver, imaging with and without valsalva and injection of agitated saline.
223969386|NCT07007897|DEVICE|Optical Biometry|Biometric measurements of the eye used for surgical planning will be obtained.
223969387|NCT07007897|PROCEDURE|Cataract Surgery|A video recording of the surgical procedure will be obtained.
223969388|NCT03571100|DRUG|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
223969389|NCT03571100|DRUG|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
223969390|NCT07007741|OTHER|Software Group|"Download the Fatty Liver Data Analysis and Management Software, register and update your profile, connect to a scale, and associate with a researcher and dietitian. Upload meal charts and weight and body fat data every day, adjust recipes according to the patient's exercise and diet every week, and customise one-on-one Q\&A according to the patient's uploaded photos every day. After enrolment, w12 and w24 were required to follow-up to complete relevant examinations and scales and collect data."
223969391|NCT07007949|DRUG|Ivosidenib combined with venetoclax and azacitidine|• Ivosidenib (Ivo): The dosage is 500 mg, administered orally once daily (QD). Oral administration begins on Day 15 of Cycle 1 (C1D15) and continues on each subsequent day of the following cycles. Each cycle lasts 28 days (±2 days), with continuous dosing. • Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once daily (QD). For subsequent cycles, the dosage is 400 mg on Days 1-14, administered orally once daily (QD). • Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV). It is given during the first week (7 days) of each 4-week (28-day) cycle (or according to the 5-2-2 dosing schedule). Whenever possible, each subject should use the same dosing schedule throughout the treatment period.
224113398|NCT03667677|DRUG|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
224113399|NCT03667677|DRUG|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
224113400|NCT03667677|DRUG|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
223969392|NCT07007949|DRUG|Ivosidenib combined with venetoclax and azacitidine|• Ivosidenib (Ivo): The dosage is 500 mg, administered orally once daily (QD). Oral administration begins on Day 15 of Cycle 1 (C1D15) and continues on each subsequent day of the following cycles. Each cycle lasts 28 days (±2 days), with continuous dosing. • Venetoclax (Ven): The dosage is 100 mg on Day 1 of Cycle 1 (C1D1), 200 mg on Day 2 of Cycle 1 (C1D2), and 400 mg on Days 3-14 of Cycle 1 (C1D3-14), administered orally once daily (QD). For subsequent cycles, the dosage is 400 mg on Days 1-14, administered orally once daily (QD). • Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV). It is given during the first week (7 days) of each 4-week (28-day) cycle (or according to the 5-2-2 dosing schedule). Whenever possible, each subject should use the same dosing schedule throughout the treatment period.
223969393|NCT07008313|BEHAVIORAL|The enhanced recovery after surgery|Enhanced recovery after surgery (ERAS) refers to a series of optimal management measures which are proved to be effective by evidence-based medical evidence in order to reduce patients' psychological and physiological traumatic stress reaction
224113401|NCT05652192|RADIATION|SBRT|SBRT was added to systematic treatment (chemo+ PD-1 antibody)
224113402|NCT02544984|DRUG|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
223969394|NCT07008313|BEHAVIORAL|Traditional treatment methods.|Traditional treatment methods.
223969395|NCT06285383|OTHER|Music listening|Participants will listen to the music pieces Pachabel Canon in D major (30 minutes), free from external sounds (max 70 dB through headphones).
223969396|NCT06285383|OTHER|classic physical therapy|classic physical therapy
224113403|NCT02544984|DRUG|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
223969397|NCT07004465|DIETARY_SUPPLEMENT|cyanocobalamin|Group A will be given vitamin B12 tablets (1000 mcg) once daily.
223969398|NCT07004465|DEVICE|triamcinolone acetonide|Group B will be given Kenalog gel (triamcinolone acetonide 40 mg/ml). The other ingredients are benzyl alcohol, polysorbate 80, carmellose sodium, sodium chloride and water, by covering the area twice daily
223969399|NCT07006961|OTHER|Generative AI-based food chaining device|Our group has developed the only generative-AI tool that produces allergy-safe food-chaining recommendations, but it has not yet been clinically tested. This proposal builds on that proof of concept to evaluate its effectiveness in a broader pediatric ARFID population.
223969400|NCT07009327|PROCEDURE|ALA-PDT|use ALA\_PDT to treat the disease
223969401|NCT07008430|OTHER|No Intervention: Observational Cohort|There will be no intervention. Only archival data will be analyzed
223969402|NCT03586284|DRUG|Valganciclovir Hydrochloride|21 to 28 days of oral valganciclovir treatment
223969403|NCT03586284|DRUG|Ganciclovir Sodium|21 to 28 days of topical ganciclovir solution treatment
223724965|NCT07002021|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on dengue prevention and campus environmental governance, while the control group will continue with their standard school health education without any additional intervention. An health education including the knowledge of dengue fever, harm of mosquitoes, and measures of mosquito control, will be developed and reviewed by an expert group. The campus environmental governance includes organizing campus environmental cleaning once a week, focusing on removing mosquito breeding places such as water containers.
223969404|NCT03586284|DRUG|Placebo Oral Tablet|21 to 28 days of placebo pill treatment
223969405|NCT03586284|DRUG|Topical placebo|21 to 28 days of topical placebo treatment
223969406|NCT07009496|BEHAVIORAL|Tibialis Anterior Fatigue Protocol|Participants lie in a supine position with the ankle fixed at 100° dorsiflexion using a custom apparatus. They perform repeated isometric dorsiflexion contractions for 30 seconds followed by 15 seconds of rest. The protocol continues until a perceived exertion of ≥7 is reported on the Modified Borg Scale. Evaluations include joint position sense, balance, muscle elasticity, pain threshold, and performance metrics recorded at four time points: pre-, post-, 24h, and 48h.
223969407|NCT07009496|BEHAVIORAL|Gastrocnemius Fatigue Protocol|Participants lie in a prone position with their foot placed against a wall. They perform repeated isometric plantarflexion contractions for 30 seconds with 15 seconds of rest between repetitions. The exercise is continued until a Modified Borg score of ≥7 is reached. Measurements of neuromuscular and biomechanical parameters are conducted at the same four time points: before, immediately after, 24 hours, and 48 hours post-exercise.
223969408|NCT07009561|BEHAVIORAL|Motor Execution Typing Task|Participants will perform a 3-minute typing task using custom-designed text that emphasizes index finger use. This task is designed to actively engage the motor cortex and will be administered in a controlled environment using standard posture and equipment. The task aims to elicit changes in cortical excitability, which will be measured pre- and post-intervention using TMS.
223969409|NCT07009561|BEHAVIORAL|Action Observation of Typing Task|Participants will observe a 3-minute first-person video of an individual typing the standardized text. The video is designed to activate mirror neuron systems through visual engagement with a familiar motor task. It will be shown once in a controlled setting, and post-assessment of cortical excitability will follow immediately after.
223969410|NCT04142385|OTHER|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
223969411|NCT04142385|OTHER|Laboratory Biomarker Analysis|Correlative studies
223969412|NCT04142385|PROCEDURE|Medical Examination|Undergo anal and penile clinical exam
224291667|NCT05897125|OTHER|Post-discharge nurse 48 hour phone follow-up call|Patients will receive a post-discharge nurse 48 hour phone follow-up call as part of standard of care
223724966|NCT06792136|DRUG|ONO-1110|ONO-1110 tablets once a day
223724967|NCT06792136|DRUG|Placebo|Placebo tablets once daily
223969413|NCT04142385|PROCEDURE|Physical Examination|Undergo targeted physical exam
223969414|NCT04142385|PROCEDURE|Proctoscopy with Biopsy|Undergo HRA
223969415|NCT04142385|OTHER|Questionnaire Administration|Ancillary studies
223969416|NCT06095492|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
223969417|NCT06095492|DRUG|Linagliptin|linagliptin 5 mg once a day
223969418|NCT07008716|RADIATION|Radiation Therapy|Twice-daily (45 Gy/30 fractions) or once-daily (45 Gy/15 fractions) thoracic radiotherapy after 2-4 cycles of chemotherapy
223969419|NCT07008716|DRUG|Etoposide + carboplatin; Etoposide + cisplatin|Carboplatin IV (AUC=5) on day 1 combined with etoposide IV (100mg/m2) on days 1-3, or cisplatin IV (25mg/m2) on days 1-3 combined with etoposide IV (100mg/m2) on days 1-3. Treatment is repeated every 21 days for 4-6 cycles.
223969420|NCT07008716|RADIATION|Creating CTV for primary tumor|A margin of 0.8 cm beyond the gross target volume of primary tumor.
223969421|NCT07008716|RADIATION|prophylactic cranial irradiation (PCI)|Beginning 4-6 weeks after chemoradiotherapy completion, patients in both arms who achieve a complete or partial response without brain metastasis receive PCI at 25 Gy/10 fractions or 26 Gy/13 fractions, delivered once daily (5 days per week).
224291668|NCT05897125|OTHER|Post-discharge follow-up advanced practice nurse outpatient visit|Patients will be scheduled for a 1-2 week post-discharge visit with the COPD advanced practice nurse as part of standard of care
224291669|NCT03017820|PROCEDURE|Biopsy Procedure|Undergo tumor or lymph node biopsy
224291670|NCT03017820|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224291671|NCT03017820|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224291672|NCT03017820|PROCEDURE|Computed Tomography|Undergo SPECT/CT
224291673|NCT03017820|DRUG|Cyclophosphamide|Given IV
224291674|NCT03017820|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223969422|NCT06167330|OTHER|Progressive rehabilitation program|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes pain science education, sensory training, implicit and explicit motor imagery, and mirror therapy. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
223542796|NCT02890459|BEHAVIORAL|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
223969423|NCT06167330|OTHER|Stimulation devices|Twelve-week treatment program delivered via eight, up to 1-hour telehealth sessions. The first five sessions will be scheduled every week, and the final three sessions will be scheduled fortnightly. Participants will also be prescribed approximately 15-30 minutes of home activities daily. The treatment program includes transcutaneous electrical nerve stimulation and cranial electrical stimulation. Participants will complete activities at a self-directed pace following a standard progression protocol. Participant adherence will be measured via session attendance and self-report therapy diaries.
224291675|NCT03017820|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
224291676|NCT03017820|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
224291677|NCT03017820|BIOLOGICAL|Cemiplimab|Given IV
224291678|NCT03017820|DRUG|Ruxolitinib|Given PO
224291679|NCT03017820|BIOLOGICAL|ipilimumab|Given IV
224291680|NCT03017820|BIOLOGICAL|Nivolumab|Given IV
224291681|NCT03017820|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224291682|NCT03017820|PROCEDURE|Echocardiography Test|Undergo echocardiography
224291683|NCT03017820|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224291684|NCT06679374|DRUG|Placebo|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
224291685|NCT06679374|DRUG|Varenicline|Participants will take one pill (.5 milligrams) a day for days 1-3 and then one pill (.5 milligrams) in the morning and one pill in the evening days 4-30 and months 2-12. In month 13 participants will take one pill in the morning days 1-3. Participants will be off study drug month 13 days 4-30.
224291686|NCT01169259|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
224291687|NCT01169259|DRUG|omega-3 fatty acids (fish oil)|Omacor, one 1-gram capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
224291688|NCT01169259|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
224291689|NCT01169259|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
224291690|NCT06720415|DRUG|Oral methadone, immediately prior to transport|Patients will receive 0.4mg/kg PO methadone immediately prior to transport to the operating room
224291691|NCT06720415|DRUG|Intravenous methadone|Patients will receive 0.3mg/kg IV methadone after induction of general anesthesia
224291692|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autologous cartilage|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous auricular cartilage graft spacer.
224291693|NCT06679439|PROCEDURE|Surgical correction of lower eyelid retraction using autogenous dermis graft spacer.|Surgical correction of lower eyelid retraction (LER) was performed using transcanthal cantopexy along with the insertion of an autogenous dermis graft spacer.
224291694|NCT05599269|DEVICE|Examination of dentures with SR Phonares II teeth|The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
224291695|NCT06784752|RADIATION|[177Lu]Lu-DOTA-TATE|\[177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)
223969424|NCT06009861|DRUG|Tislelizumab|Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
223969425|NCT06009861|DRUG|Albumin-Bound Paclitaxel|Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
223969426|NCT06009861|DRUG|Cisplatin|Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
223969427|NCT06134986|OTHER|Time restricted eating|8-h eating window Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
223969428|NCT06134986|OTHER|Daily calorie restriction|25% energy restriction every day Diet counseling provided
224291696|NCT06784752|DRUG|Octreotide LAR|"Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W.~In the control arm Octreotide LAR will be administered Q4W."
223542797|NCT02890459|BEHAVIORAL|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
223969429|NCT06686888|DIETARY_SUPPLEMENT|SCFA|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
223969430|NCT06686888|DIETARY_SUPPLEMENT|microcristalline cellulose|On test days participants will ingest the capsules during a standard no fiber breakfast. Blood samples will be collected at regular time points for 8 hours. A visual analogue scale that questions hunger and satiety will be completed at regular time points.
223969431|NCT04387201|DRUG|Cyanocobalamin|Cyanocobalamin (vitamin B12) 1000 mcg subcutaneous weekly for 6 weeks.
223969432|NCT04387201|DRUG|Dulaglutide|Dulaglutide 0.75 mg subcutaneous weekly for 2 weeks, followed by 1.5 mg subcutaneous weekly for 4 weeks
224113404|NCT05197972|OTHER|cardiac coherence program coupled with hypnosis|"At home the patient will perform the cardiac coherence sessions between 7 days and a maximum of 15 days before the surgery through the application Respirelax: 3 sessions per day, lasting 5 minutes with a breathing frequency of 6 cycles/min for a period of 7 days minimum and maximum 15 days.~An audio tape read in a hypnotic tone can be listened to by the patient during the cardiac coherence program or at another time of the day (see the text of the audio tape)."
223969433|NCT06698276|OTHER|Alveolar Ridge Reconstruction|It will be used a combination of two biomaterials for alveolar ridge preservation
223969434|NCT04341584|DRUG|Anakinra|"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERET® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERET® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERET® 100mg (Total 100 mg) at day 5 (D5).~In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level \> 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter"
224291697|NCT04257578|DRUG|Acalabrutinib|Given PO
223969435|NCT06701149|DRUG|Rademikibart injection|300 mg administered subcutaneously on the first day
223969436|NCT06701149|DRUG|CBP-201 injection|300 mg administered subcutaneously on the first day
224113405|NCT02592304|DEVICE|Dual energy computed tomography|one extra scanning with a dual energy ct.
224113406|NCT02844582|DRUG|Cabazitaxel|Given IV
224113407|NCT02844582|DRUG|Prednisone|Given PO
224113408|NCT01419366|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
224291698|NCT04257578|BIOLOGICAL|Axicabtagene Ciloleucel|Given IV
224291699|NCT04340141|DRUG|Oxaliplatin|Given IV
223969437|NCT04320602|BIOLOGICAL|Eculizumab|Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.
223969438|NCT04320602|BIOLOGICAL|Ravulizumab|During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.
223969439|NCT06309368|DRUG|Primary Ostomy Closure with 0.1% Betaine/0.1% Polyhexanide Wound Irrigation|An elliptical transverse incision will be made extending 1-2 cm lateral and medial to the mucocutaneous junction. The mobilization, anastomosis and fascial closure will be performed as in the pursestring closure group. The incision will then be irrigated using direct stream into the wound with 350cc of Prontosan. After one minute the wound will be suctioned dry. The subcutaneous fat will be mobilized and approximated with interrupted 2-0 Vicryl. The skin will be approximated with deep dermal 3-0 Vicryl and a running subcuticular 4-0 Monocryl suture and Dermabond will be applied.
223969440|NCT06309368|PROCEDURE|Pursestring Closure|A circular incision will be made at the mucocutaneous junction of the ileostomy. After complete mobilization of the ileal limbs off the fascia and a stapled side to side functional end to end anastomosis, the fascia including the external and posterior rectus sheath will be closed with two running #0 PDS (Polydioxanone) suture. The wound will then be irrigated with saline and partially closed in the subcuticular plane with a 2-0 Monocryl suture in a pursestring fashion and packed in the middle with plain packing.
223969441|NCT00497198|DRUG|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
223969442|NCT00497198|DRUG|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
224113409|NCT00142103|DRUG|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
224113410|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
224291700|NCT04340141|DRUG|Irinotecan Hydrochloride|Given IV
224291701|NCT04340141|DRUG|Leucovorin Calcium|Given IV
224291702|NCT04340141|DRUG|Fluorouracil|Given IV
224113411|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
224113412|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
224291703|NCT04340141|PROCEDURE|Resection|Undergo surgical resection
223542798|NCT02890459|BEHAVIORAL|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
223542799|NCT02890459|BEHAVIORAL|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
223542800|NCT03383250|DIETARY_SUPPLEMENT|Normal meal|
224113413|NCT00142103|DRUG|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
224291704|NCT04340141|OTHER|Questionnaire Administration|Ancillary studies
224291705|NCT04963296|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
224291706|NCT04963296|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
224291707|NCT04963296|DRUG|Acetaminophen/Paracetamol|Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
224291708|NCT04963296|DRUG|Diphenhydramine hydrochloride|Diphenhydramine 50 mg will be administered as premedication prior to infusions.
224291709|NCT04963296|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
224291710|NCT04189445|DRUG|Futibatinib|Futibatinib tablets were dosed orally every day on a continuous 28-day cycle
223969443|NCT06702774|DIAGNOSTIC_TEST|Active case finding|Villagers will be informed through public announcements and social workers. Before the campaign, social workers and village doctors will recruit participants and obtain consent through door-to-door visits. A mobile van equipped with an AI-assisted digital radiography (DR) machine and a refrigerator will visit villages on agreed dates. Participants will complete a TB symptom questionnaire and undergo DR screening. Those with TB symptoms or abnormal DR results will provide on-site sputum samples and collect additional morning and night samples. Trained staff will ensure proper collection and offer nebulizer support if needed. Samples will be transported daily to hospitals for testing using smear, culture, and GeneXpert. Participants with negative bacteriological results but abnormal findings will be referred for further clinical assessment.
224113414|NCT00142103|DRUG|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
224113415|NCT05190575|DRUG|TST001|TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
224113416|NCT04376346|BEHAVIORAL|Native WYSE CHOICES|Native WYSE (Women, Young, Strong, and Empowered) CHOICES (Changing High-risk alcohOl use and Increasing Contraception Effectiveness Study) is an alcohol-exposed pregnancy prevention program that translates CHOICES, an evidence-based targeted intervention, into an mHealth universal intervention for young urban American Indian/Alaska Native (AI/AN) women ages 16-20.
224113417|NCT00002089|DRUG|Azithromycin|
224113418|NCT00443404|PROCEDURE|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
224113419|NCT01094964|BIOLOGICAL|BCG solution|
224113420|NCT01094964|BIOLOGICAL|recombinant interferon alfa|
224113421|NCT01094964|DRUG|epirubicin hydrochloride|
224113422|NCT01094964|DRUG|mitomycin C|
224113423|NCT01094964|OTHER|laboratory biomarker analysis|
224113424|NCT01094964|PROCEDURE|hyperthermia treatment|
224113425|NCT01094964|PROCEDURE|quality-of-life assessment|
224113426|NCT02416908|DRUG|Selinexor|
224113427|NCT02416908|DRUG|Cladribine|
224113428|NCT02416908|DRUG|G-CSF|
224113429|NCT02416908|DRUG|Cytarabine|
224113430|NCT02416908|PROCEDURE|Bone marrow biopsy|
224113431|NCT00349791|DRUG|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
224113432|NCT00349791|DRUG|Placebo patch|placebo patch replaced twice a week for two years
224113433|NCT02887105|OTHER|Standard neuropsychological assessment|
224113434|NCT02887105|OTHER|Brain MRI|
224113435|NCT04530812|OTHER|Best Practice|Maintain usual diet
224113436|NCT04530812|DIETARY_SUPPLEMENT|Kefir|Consume commercial kefir beverage
224113437|NCT04530812|OTHER|Quality-of-Life Assessment|Ancillary studies
224113438|NCT04530812|OTHER|Questionnaire Administration|Ancillary studies
224113439|NCT02974946|DEVICE|RenalGuard|
224291711|NCT06959095|DRUG|Depemokimab|Depemokimab as a sterile liquid formulation will be administered.
224291712|NCT06959095|DRUG|Placebo|Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.
224113440|NCT02575313|DIETARY_SUPPLEMENT|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
224113441|NCT04039828|DRUG|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for \> 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
224291715|NCT06837246|DIETARY_SUPPLEMENT|Cognitive Nutritional Supplement|Pills of cognitive nutritional supplement
224113442|NCT06532461|DEVICE|Mio Advanced infusions set|Insulin infusionsset fitting Medtronic 780 G insulin pump
224113443|NCT06532461|DRUG|Novorapid|Randomized to either Novorapid or Humalog
224113444|NCT06532461|DEVICE|Extended wear insulin infusion (EWIS)|Insulin infusionsset fitting Medtronic 780 G insulin pump
224113445|NCT06532461|DRUG|Humalog|Randomized to either Novorapid or Humalog
224113446|NCT00163553|DRUG|Pethidine|
224113447|NCT00163553|DRUG|Placebo|
224113448|NCT02157831|BIOLOGICAL|CP-870,893|
224113449|NCT02179307|BEHAVIORAL|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
224113450|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
224113451|NCT02634164|DIETARY_SUPPLEMENT|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
224113452|NCT02634164|DIETARY_SUPPLEMENT|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
224113453|NCT03120403|PROCEDURE|intrathecal morphine|
224291716|NCT06837246|OTHER|Placebo|Matching placebo to active
224291717|NCT06836232|DRUG|VTX2735|Dose A, daily
224291718|NCT06836232|DRUG|VTX2735|Dose B, Daily
224291719|NCT06836232|DRUG|VTX2735|Dose C, daily
223969444|NCT06879522|BEHAVIORAL|Maximizing Energy Intervention|A licensed occupational therapist will deliver the intervention. The Maximizing Energy program combines problem-solving therapy (PST) and energy conservation education. Participants will participate in 6 virtual once/week sessions for 30 minutes. The introductory session, they will track their fatigue and identify three key fatigue-related problems. In session 2, they will prioritize one problem and practice problem-solving steps. They then implement an action plan and review progress in the next session. If the solution is ineffective, the therapist helps modify it or create a new one. If successful, the participant moves to the next problem. A MAX workbook supports learning, covering intervention details, fatigue education, energy conservation strategies, and problem-solving worksheets. The goal is to help participants apply these strategies to improve daily life and return to work.
224113454|NCT02448901|DRUG|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
224113455|NCT02909296|PROCEDURE|Endoscopic drainage|
223542801|NCT05155124|DRUG|Cetuximab + trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
224113456|NCT01421290|PROCEDURE|Surgery|Knee surgery
224113457|NCT01421290|OTHER|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
224113458|NCT05775692|DRUG|fluconazole|According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
224113459|NCT03561285|DIAGNOSTIC_TEST|antiphospholipid Abs|Laboratory test
224113460|NCT01985685|DRUG|Thiamine|200 mg IV thiamine
224113461|NCT00940342|DRUG|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
224113462|NCT00940342|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly for four weeks
224113463|NCT01641016|DRUG|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
224113464|NCT03100435|DEVICE|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
224113465|NCT03100435|OTHER|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
224113466|NCT03330743|BEHAVIORAL|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
224113467|NCT03330743|BEHAVIORAL|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
224113468|NCT01830452|PROCEDURE|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
224113469|NCT03792750|DRUG|BMS-986205|Specified Dose on Specified Day
224113470|NCT03792750|BIOLOGICAL|Nivolumab|Specified Dose on Specified Day
224113471|NCT00615940|DRUG|WX-671|capsules taken per os once daily until progression or toxicity
224113472|NCT00615940|DRUG|placebo|capsule taken per os once daily until progression or toxicity
224113473|NCT00956475|BEHAVIORAL|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
224113474|NCT00956475|OTHER|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
224113475|NCT00956475|PROCEDURE|assessment of therapy complications|questionnaire via telephone
224113476|NCT00956475|PROCEDURE|fatigue assessment and management|questionnaire via telephone
224113477|NCT00956475|PROCEDURE|psychosocial assessment and care|questionnaire via telephone
224113478|NCT00956475|PROCEDURE|quality-of-life assessment|questionnaire via telephone
223969445|NCT06879522|BEHAVIORAL|Health Education|To control for the effects of interactions with an interventionist, participants in the attention control group will receive the Health Education intervention. The interventionists will review a workbook covering fatigue, energy conservation, healthy eating, exercise, and relaxation. Like the MAX intervention, Health Education will be delivered virtually in weekly 30-minute one-on-one sessions for six weeks. The interventionist provides education on breast cancer-related fatigue, diet, safe physical activities, and energy conservation strategies tailored to individual needs. A workbook will support learning.
223969446|NCT06695988|BEHAVIORAL|Time Restricted Eating|The intervention group will eat and drink in a prescribed daily feeding window of 8-hour between 6 a.m. to 8 p.m. for 8 weeks and follow their normal exercise and resistance training routines. We will allow +/-1 hour starting and ending times for the eating window while aiming for an 8-hour eating window
223969447|NCT06716970|DRUG|QR12000 75mg|QR12000 75mg QD
223969448|NCT06716970|DRUG|QR12000 75mg placebo|Matching placebo of QR12000 75mg QD
223969449|NCT06716970|DRUG|QR12000 150mg|QR12000 150mg QD
223969450|NCT06716970|DRUG|QR12000 150mg placebo|Matching placebo of QR12000 150mg QD
223969451|NCT06716970|DRUG|Sacubitril/valsartan 200mg|Sacubitril/valsartan 200mg QD
223969452|NCT06716970|DRUG|Sacubitril/valsartan 200mg placebo|Matching placebo of Sacubitril/valsartan 200mg QD
223969453|NCT06719895|BEHAVIORAL|web based education|experimental
224113479|NCT03479879|DRUG|Estradiol|Estradiol
224113480|NCT03479879|DRUG|Placebo Oral Tablet|Placebo
224291720|NCT06828861|DRUG|Placebo|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 10 weeks
223969454|NCT06720792|OTHER|EscapeCovid|Online Escape Game with 4 players and a game guide. The players, in a group, must solve enigmas to win.
223969455|NCT06721273|DIETARY_SUPPLEMENT|Iodine|In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
223969456|NCT06721273|DIETARY_SUPPLEMENT|Placebo|Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.
223969457|NCT06720766|DIAGNOSTIC_TEST|FibbroScan and biopsy|In individuals with obesity, a biopsy is performed within a week after undergoing an FibroScan examination.
223969458|NCT06720558|OTHER|Placebo probiotic|Three-week consumption of placebo probiotic capsules passed off as being actual probiotics
223969459|NCT06720558|OTHER|Open-Label Placebo probiotic|Participants of the Control group will be switched to this condition after three weeks and receive placebo probiotic capsules for the following three-weeks of no intervention. Specifically, they will be honestly informed that the capsules are inert placebos.
224113481|NCT03479879|DRUG|Misoprostol|Misoprostol
224113482|NCT00931957|DRUG|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
224291721|NCT06828861|DRUG|ARD-101|200 mg BID (twice per day) for 1 week, 400 mg BID for 1 week, 800 mg BID for 10 weeks
224291722|NCT06281509|PROCEDURE|Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.|Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)
224291723|NCT06281509|PROCEDURE|Ultrasound|A small mobile ultrasound device will be used to further asses the presence of the tendon.
224291724|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized clinician-led self-management telehealth sessions
224291725|NCT05075759|BEHAVIORAL|Behavioral Intervention|Receive personalized goal setting for daily steps and activity and dietary goals
224291726|NCT05075759|BEHAVIORAL|Behavioral Intervention|Remote sessions with a health coach
224291727|NCT05075759|OTHER|Survey Administration|Ancillary studies
224113483|NCT05277155|DIETARY_SUPPLEMENT|BEJO Red Ginger Extract|"BEJO Red Ginger Extract ingredients:~* Zingiber officinale var. rubrum (Rhizome extract) 80 mg~* Foeniculi vulgare Fructus (Fennel) 25 mg~* Menthae arvensis Folium (Mint) 5 mg~* Piper retrofractum Fructus (Javanese long pepper) 12.5 mg~* Honey 7500 mg"
224113484|NCT05277155|OTHER|Placebo|Placebo composition: Substance without active ingredient
224113485|NCT06453447|DRUG|Prednisone|40 mg PO once daily for 14 days starting day of surgery
224113486|NCT06453447|DRUG|Placebo|Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
224291728|NCT05075759|OTHER|Interview|Ancillary studies
224291729|NCT03959527|DRUG|zoliflodacin|Dose: 3g, oral administration
224291730|NCT03959527|DRUG|ceftriaxone|Dose: 500mg, Intra-Muscular (IM) administration
224291731|NCT03959527|DRUG|azithromycin|Dose: 1g, oral administration
224291732|NCT04095364|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224291733|NCT04095364|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224291734|NCT04095364|DRUG|Carboplatin|Given IV
224291735|NCT04095364|PROCEDURE|Imaging Procedure|Undergo medical imaging
224291736|NCT04095364|DRUG|Letrozole|Given PO
224291737|NCT04095364|DRUG|Paclitaxel|Given IV
223969460|NCT06720558|OTHER|Control-no treatment|For the first three weeks, the Control group will not be exposed to any intervention.
223969461|NCT06721286|DRUG|Teripalimab|240mg intravenous injection, D1, q3w, for 9 weeks (3 cycles)
223969462|NCT06721286|DRUG|Gemcitabine + Cisplatin|Gemcitabine 1000mg/m2 + cisplatin 25mg/m2, D1\&D8, q3w, for 9 weeks (3 cycles)
223969463|NCT06721286|PROCEDURE|Surgery|Radical resection
224113487|NCT05717920|DRUG|ADX-629 (Open-label)|ADX-629 (250 mg) administered twice daily for 90 days
223969464|NCT06719934|DRUG|Dienogest 2 mg orally|2 mg Dienogest orally
223969465|NCT06719934|PROCEDURE|UAE|under local anasthesia uterine artery embolizationwill be done
223969466|NCT06719687|DEVICE|Self-driving robotic-assisted bronchoscope|All procedures will be performed under general anesthesia with endotracheal intubation and mechanical ventilation. The self-driving robotic-assisted bronchoscope will automatically advance through airway to the target lesion according to the preoperative planning path under the guidance of electromagnetic navigation. After that, the bronchoscopist will use radial endobronchial ultrasound (rEBUS) to confirm the lesion localization. The choice of biopsy tools (eg. forceps, needles, brush, etc.) will be left to the discretion of the bronchoscopist.
223969467|NCT06720753|BEHAVIORAL|Opposite to emotion action|Participants will be taught the opposite action skill from Dialectical Behavior Therapy
223969468|NCT06720753|BEHAVIORAL|GIVE|Participants will be taught the GIVE skill from Dialectical Behavior Therapy
223969469|NCT06720194|DEVICE|Virtual therapy|Virtual therapy has been applied for four weeks, three times a week. We administered a total of twelve sessions with a duration of 30 minutes each. Prior to virtual therapy experimental group have received kinesitherapy for 15 minutes to improve and prevent muscle spasticity and joint contractures. Therapists recorded the order of the session and they have providen the same external aid to all patients. Two days a week the experimental group have received the conventional treatment for 45 minutes (kinesitherapy, strengthening exercises muscle, trunk control, transfers, standing and walking). In addition to physiotherapy treatment, participants have done occupational therapy 5 days a week (training to perform ADLs, tracking techniques and search, manipulation, reach and grasping of different utensils, etc.), for 30 minutes each session.
223969470|NCT06720194|OTHER|Usual treatment|Patients assigned to the control group have received the conventional treatment five days a week. They have done physiotherapy session and occupational therapy for 45 and 30 minutes a day each one.
223969471|NCT06721832|PROCEDURE|Erector spina plane block (ESP)|"The block will be performed in prone position under complete aseptic condition. The site to be blocked will be painted with 5% povidone iodine followed by 70% ethyl alcohol and draped. Linear high-frequency ultrasound probe (7 -15 mhz) (General Electric; GE, LOGIQ E) T1 transverse process will be approached with an 18 G Tuohy's needle in caudal-to-cranial direction. A total of 30 ml of 0.25% bupivacaine with 150 μg of clonidine and 8 mg dexamethasone was administered deep to erector spinae muscle (ESM) bilaterally."
223969472|NCT06720233|DRUG|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
224113488|NCT05248958|OTHER|Turkish Validity and Reliability of The CRAVE Scale|The aim of this study is to adapt the Cravings for Rest and Volitional Energy Expenditure (CRAVE) scale to Turkish society and to make its validity and reliability in Turkish.
224113489|NCT03949582|OTHER|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
224113490|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus multi-strain probiotic capsules|
224113491|NCT01887834|DIETARY_SUPPLEMENT|Kyodophilus Matching Placebo Capsules|
224113492|NCT00167908|DRUG|Ethyol (drug)|
224113493|NCT02902809|BIOLOGICAL|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
224113494|NCT05176678|DIETARY_SUPPLEMENT|1 gram of a protein hydrolysate|After 1 gram of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
223969473|NCT06721377|PROCEDURE|Novaloc attachment|upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region \& will be loaded by Novaloc attachment.
223969474|NCT06721377|PROCEDURE|Equator attachment|upper complete dentures and lower complete overdentures. The upper complete denture will be mucosa supported and the lower complete denture will be supported and retained for all patients by two dental implants in the inter-foraminal region\& will be loaded by Equator attachment.
223969475|NCT06723587|OTHER|Instep weights use|"Players will perform their scheduled training sessions while wearing a 150-gram instep weight. The use of instep weights in the intervention group will be introduced progressively and gradually, increasing both the frequency of sessions and the duration of their use.~During weeks 1-2, instep weights will be used in one training session per week. During weeks 3-5, will be used in two training sessions per week.~And during weeks 6-8, will be used in three training sessions per week.~The duration of instep weight usage within each session will increase by 5% weekly, starting at 40% in Week 1 and reaching 75% by Week 8."
223969476|NCT06717113|DRUG|18F-FDG|Prior to the examination, patients will be required to fast for at least 6 hours. 18F-FDG (0.05-0.1 mCi/kg) will be intravenously injected, and one hour after the injection, head and torso imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the upper third of the thigh. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
223969477|NCT06717113|DRUG|68Ga-BC1|The prepared and quality-controlled 68Ga-BC1 (0.05-0.1 mCi/kg) will be intravenously injected into the patient. Two hours after the injection, whole-body imaging will be performed using a Shanghai United Imaging uMI 780 PET/CT scanner, covering the region from the top of the head to the mid-thigh. If any indeterminate lesions are found during the routine imaging, delayed imaging will be performed for further differentiation. The patient will lie supine and breathe calmly during the procedure. After image acquisition, the data will be reconstructed using the OSEM method to generate coronal, sagittal, transverse, and PET/CT fusion images.
223969478|NCT06711458|BEHAVIORAL|AI-Generated Discharge Instructions|Patient-friendly hospital discharge instructions generated by GPT-4, an advanced natural language processing model.
223969479|NCT06711458|BEHAVIORAL|Standard of Care Discharge Instructions|Standard hospital discharge instructions.
223724968|NCT07061912|DEVICE|NSTI® HIV Self-Test|Each participant will be provided with the INSTI® HIV Self-Test(s) and asked to conduct self testing, unobserved. The participant will record their interpretation of the results. Subjects will perform the test without intervention or observation from the operator. The operator will then enter the room and also interpret the subject's self-test results then perform the comparator test. In the event of a discrepant result between the INSTI® HIV ST and comparator test, an additional venous blood sample will be collected from the subject and sent for discrepancy testing
223724969|NCT07070518|DRUG|GV20-0251|Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks
223724970|NCT05601453|PROCEDURE|Elective redo transcatheter aortic valve implantation (redo-TAVI)|Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)
223969480|NCT06721442|DRUG|Dapagliflozin (DAPA)|Patients randomized to receive a daily dose of 10 milligrams of dapagliflozin were evaluated to assess the medication's impact on electrocardiographic parameters of repolarization, with focus on its potential to reduce ventricular repolarization prolongation in individuals with type 2 diabetes.
224113495|NCT05176678|DIETARY_SUPPLEMENT|2 grams of a protein hydrolysate|After 2 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
223724971|NCT07132996|DIAGNOSTIC_TEST|POCUS-based Splenic Volume Measurement|Splenic volume was measured at baseline and at 72 hours using the Butterfly iQ+ handheld ultrasound (Butterfly Network, Inc.) in abdominal preset mode. Certified POCUS operators obtained spleen length, width, and depth in standard orthogonal planes. Volumes were calculated using the prolate ellipsoid formula (length × width × depth × 0.523), a validated method in ultrasound volumetric studies. ΔSpleen was defined as the 72-hour value minus the baseline value.
223724972|NCT07132086|DRUG|Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting|Daridorexant 50 mg is administered once daily at bedtime, either as monotherapy or as add-on therapy in patients with chronic insomnia. The intervention is evaluated in a naturalistic, real-world setting over a 3-month observational period. Both subjective (questionnaires, sleep diary) and objective (actigraphy) sleep parameters are collected at baseline, 1 month, and 3 months. Actigraphy is used to assess total sleep time, sleep efficiency, wake after sleep onset, and circadian rhythm parameters. Sleep misperception is calculated as the discrepancy between subjective and objective sleep metrics. The study also explores potential predictors of treatment response such as age, sex, BMI, insomnia duration, and comorbid sleep disorders.
223724973|NCT06922708|DIAGNOSTIC_TEST|Integrated PRS-Enhanced Breast Cancer Risk Assessment (CanRisk model)|Standard genetic counseling followed by a blood draw (0.5 mL) for DNA extraction. The sample is processed using a high-throughput SNP genotyping platform, and the PRS, based on 313 SNPs, is calculated and integrated into the CanRisk model for refined breast cancer risk stratification.
223724974|NCT07131722|DRUG|Trineumin|"Trineumin(Code name: PRG-N-01) is administered orally once daily. The study includes six dose levels.~Dose escalation decisions are based on observed DLTs."
223724975|NCT07131722|DRUG|Trineumin|Trineumin(Code name: PRG-N-01) is administered orally once daily at the lower dose selected from Phase 1 results.
223724976|NCT07131722|DRUG|Trineumin|Trineumin(Code name: PRG-N-01) is administered orally once daily at the higher dose selected from Phase 1 results.
223724977|NCT06927297|BIOLOGICAL|Engineered mitochondria vaccine|Participants were assigned to receive subcutaneous injections of the low dose, medium dose, or high-dose of the engineered mitochondrial vaccine. The regimen consisted of 3 doses of primary immunization, 1 dose of boost immunization and subsequent personalized treatment.
223724978|NCT07131826|OTHER|Observational study, non-interventional|Observational study, non-interventional
223724979|NCT07132294|BEHAVIORAL|Exercise Intervention|"Supramaximal Interval Running (SIR) This protocol was individualized based on each player's Maximal Aerobic Speed (MAS). Training intensities were prescribed at 100% to 110% of each player's MAS. Each session consisted of eight sets. During the first three weeks, each set involved a 2-minute maximal effort run followed by 2 minutes of passive recovery. In the final three weeks, the duration of each set was extended to a 3-minute maximal run with 3 minutes of passive rest, increasing intensity and volume. SIR sessions were designed to enhance anaerobic capacity and lactate tolerance.~Small-Sided Games (SSG) SSG sessions were implemented to develop agility, acceleration, tactical decision-making, and match-relevant conditioning. Training took place on regulation-size grass pitches, adjusted to maintain a consistent length-to-width ratio across all formats. Over the six-week intervention, game formats progressed from 4v4 to 7v7, with gradual increases in duration and pitch dimensions."
223724980|NCT06492330|DRUG|CS0159|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
223724981|NCT06492330|DRUG|CS0159 placebo|The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).
223724982|NCT01730833|BIOLOGICAL|pertuzumab|Given IV
223724983|NCT01730833|BIOLOGICAL|trastuzumab|Given IV
223724984|NCT01730833|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223724985|NCT01730833|OTHER|laboratory biomarker analysis|Optional correlative studies
224113496|NCT05176678|DIETARY_SUPPLEMENT|4 grams of a protein hydrolysate|After 4 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
223969481|NCT06721429|OTHER|dual task exercise group|Dual task exercise group Patients in the dual-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training. In addition, cognitive exercise training will be incorporated into each session, performed concurrently with the conventional physiotherapy. The cognitive exercises provided in this study are structured to target areas such as memory, verbal fluency, executive functions, calculation, and attentioN Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
223969482|NCT06721429|OTHER|single task group|Single task exercise group Patients in the single-task training group will undergo 60-minute conventional physiotherapy sessions three times a week for 8 weeks. Each physiotherapy session will consist of aerobic exercise, strengthening exercises, and balance training.
223542802|NCT03211819|PROCEDURE|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
223542803|NCT02649452|OTHER|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
223969483|NCT06887426|DRUG|Cladribine|To evaluate the clinical activity during the 2 years of follow-up in patients switching to cladribine and continuing current DMT
223969484|NCT06721182|DEVICE|REBOA|endovascular balloon occlusion of the aorta
223969485|NCT06721104|OTHER|Dual Task|"The dual-task abilities of individuals will be assessed by adding motor and cognitive tasks to the 10-Meter Walk Test. The tasks given to participants are as follows:~Single Motor Task (comfortable walking): The individual is asked to walk at a normal pace, and the time is recorded.~Motor-Motor Dual Task: The individual carries a half-filled water bottle in each hand while walking, and the time is recorded.~Motor-Cognitive Dual Task (mental): The individual counts backward from 10 in increments of one while walking, and the time is recorded.~Motor-Cognitive Dual Task (memory): The individual is asked to recall three previously mentioned words while walking, and the time is recorded."
224113497|NCT05176678|DIETARY_SUPPLEMENT|8 grams of a protein hydrolysate|After 8 grams of a protein hydrolysate is taken daily for 2 weeks, 1 blood draw will be taken.
224113498|NCT01771302|DEVICE|Bio-Oss|It is a bone substitute of bovine origin
223542804|NCT00052910|DRUG|cisplatin|Given IV
223542805|NCT00052910|DRUG|epirubicin hydrochloride|Given IV
223542806|NCT00052910|DRUG|fluorouracil|Given IV
223542807|NCT00052910|DRUG|leucovorin calcium|Given IV
223542808|NCT00052910|RADIATION|radiation therapy|Given 5 days a week for 5 weeks
223724986|NCT07090616|DEVICE|Arm 1-Kronos brace|Subjects randomized to the treatment group will be measured and fitted with the KRONOS knee brace at their initial clinic visit after study enrollment
223724987|NCT07090616|DEVICE|Arm 2-Breg T-Scope brace|Subjects randomized to Breg T-Scope Postoperative Brace will be placed in this standard postoperative hinged knee brace in the operating room that will be locked in full extension.
223724988|NCT07093411|BIOLOGICAL|LUCAR-E9D or LUCAR-E9K cells product|Prior to infusion of the LUCAR-E9D or LUCAR-E9K cells product subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
223724989|NCT07131553|OTHER|Wheelchair school|Wheelchair skills training with pysiotherapist and peer mentor
223724990|NCT07131553|OTHER|Comparison group, conventional rehabilitation|Conventional rehabilitation at the same unit of similiar length and intensity
223724991|NCT07132177|DRUG|Naltrexone (oral tablets)|All participants will receive 31 pills of 50 mg Naltrexone to take as needed over the month of January 2026.
223724992|NCT07131748|OTHER|Physical Exercise Session in heated Swimming Pool - HEx|Warm Up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise (following the same control parameter of the experimental session); Resistance exercises - 20 minutes of resisted exercises, which will be divided into 6 exercises with 2 sets of 10 to 15 repetitions (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
223724993|NCT07131748|OTHER|Physical Exercise Session in Land- LEx|Warm up - 5 minutes of stretching and heating of the joints and muscle groups to be worked; Aerobic exercise - 30 minutes of aerobic exercise performed on treadmill and / or exercise bike (following the same control parameter of the experimental session); Endurance Exercises - 20 minutes of exercises resisted, also divided into 6 exercises with 2 sets of 10 to 15 repetitions. The large muscle groups of the upper limbs, lower limbs and trunk will be exercised in fitness machine and with free weights (following the same control parameter of the experimental session); Calm back - 5 minutes of stretching.
223724994|NCT07131748|OTHER|Control Session Without Exercise- CON|Guidance to maintain the usual level of physical activity and not to enter physical exercise programs during the 12 weeks of follow-up.
223724995|NCT07101094|DRUG|xanomeline and trospium chloride (X/T) therapy|According to the product label
223969486|NCT06721104|OTHER|Functional Balance|"Functional balance will be assessed using the Timed Up and Go (TUG) test. The TUG test measures the time it takes for an individual to stand up from a chair upon the ready, go signal, walk a distance of 3 meters, turn around, walk back to the chair, and sit down again. The TUG test is a reliable and sensitive measure of balance and functional mobility in children.~At the beginning of the test, participants will be seated on an armless chair with their hips and knees flexed at approximately 90 degrees and their feet flat on the ground. The children will be instructed to stand up from the chair, walk as quickly as possible, touch a target on the wall, walk back, and sit down again."
224113499|NCT01771302|DEVICE|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
223542809|NCT00047502|DRUG|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
223542810|NCT00047502|DRUG|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
223542811|NCT04961138|PROCEDURE|Transhepatic Arterial Chemotherapy And Embolization (TACE)|Receiving TACE and lenvatinib before surgery.
223542812|NCT04961138|PROCEDURE|Surgery|Removing tumor by surgery.
223969487|NCT06721104|OTHER|Social Adaptation Assessment|Adaptive behavior will be evaluated using the Vineland Adaptive Behavior Scales. This is a parent interview designed to assess functionality in daily life. Specifically, adaptive behavior is evaluated in four domains: Communication, Daily Living Skills, Socialization, and Motor Skills. The Vineland scales are known for their reliability and up-to-date validity. They have been reported to be sensitive to the challenges faced by children with Autism Spectrum Disorder (ASD).
223969488|NCT06721104|OTHER|Cervical Posture Assessment:|"Cervical posture will be evaluated using the Android-based PostureScreen Mobile application (version 8.5, developed by Posture Co. Inc., USA). This application assesses the static posture of individuals. After determining reference points, the application draws reference lines and records postural deviations. At least two photos of each participant will be taken for the assessment. Participants should not wear clothing items that cover the neck (e.g., scarves, shawls).~While the primary focus of the application is to assess postural deviations, it also includes a dental evaluation feature. The validity and reliability of the application have been established in previous studies. In addition to using the application, the posture of individuals will also be evaluated through observational analysis, and the findings will be documented."
223969489|NCT06721104|OTHER|Temporomandibular Joint (TMJ) Assessment|"The TMJ will be evaluated using the Helkimo Clinical Craniomandibular Index. This index consists of five subcategories: pain during muscle palpation, pain during TMJ palpation, pain during mandibular functions, TMJ functions (sounds, gliding during maximum opening, dislocation and/or locking), and the mandibular range of motion. Each subcategory is scored as 0, 1, or 5, resulting in a total score ranging from 0 to 25.~As this index is based on performance measurements, there is no Turkish validity and reliability study for it. However, a prevalence study using this index was conducted in Turkey by Üner et al. to evaluate its applicability within the Turkish population."
223969490|NCT06721676|DEVICE|transcatheter aortic valve replacement in severe aortic stenosis|transcatheter aortic valve replacement with A² Flex and commissural alignment technology in severe aortic stenosis
223969491|NCT06719557|DRUG|MK-1084|Oral Tablet
223969492|NCT06719557|DRUG|Itraconazole|Oral solution
223969493|NCT06719557|DRUG|Phenytoin|Oral capsule (extended)
223969494|NCT06719739|DEVICE|Intraocular lens implantation|Cataract patients scheduled for surgery will be evaluated by OCT, and those diagnosed with macular epiretinal membrane will be implanted in different IOLs according to the patients' decision: monodical IOL or functional IOL.
223969495|NCT06720025|DRUG|SAL-0951 tablets|initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
223542813|NCT03313635|DIAGNOSTIC_TEST|Men presenting with low-T|Evaluation of prealbumin levels.
223542814|NCT05964491|OTHER|No intervention|No intervention studied
223969496|NCT06720025|DRUG|rHuEPO injection|Initial based on the original rHuEPO dose adjust the dose based on hemoglobin concentration level every 4 weeks
223969497|NCT02475707|BIOLOGICAL|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
223969498|NCT06474546|OTHER|Diet intervention|"A diet based on the principles of the Mediterranean Diet (MedDiet): consists of an abundance of plant foods - unrefined cereals, fruit, vegetables, and extra-virgin olive oil - a moderate consumption of poultry, dairy products, eggs, and low consumption of sweets and red meats.~All subjects will be instructed to follow the MedDiet for 8 weeks by the study team. Families will be given the option to continue for 12 weeks if they wish to do so."
224113500|NCT00532259|DRUG|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
224113501|NCT06367270|DRUG|Pressured Intraperitoneal Aerosol Chemotherapy|PIPAC cycles will be scheduled every 6-8 weeks and 2 weeks after the last systemic chemotherapy administration. The bidirectional program for the combination of intraperitoneal and systemic chemotherapy is designed as follows: systemic chemotherapy followed by PIPAC two weeks later, followed by a one-week interval, and then systemic chemotherapy once again until three PIPAC cycles have been completed. Up to a one-week delay in returning to systemic chemotherapy after PIPAC and vice versa were considered acceptable. Systemic drug choice was based on previous chemotherapy exposure and the medical oncologists' decision. The study ends after the 3rd cycle of PIPAC.
223542815|NCT01187095|BEHAVIORAL|Expressive writing|3 consecutive days of writing
223542816|NCT01187095|BEHAVIORAL|Active ctrl|Control
223542817|NCT05140135|BEHAVIORAL|Recovery Oriented Cognitive Therapy (CT-R)|The CT-R that will be implemented in the present study will focus on strengthening aspirations and focusing on activities that can bring about one's desired life. In CT-R, clinicians use techniques to engage the patient in the adaptive mode, which includes cognitions, affects, motivation, and behaviors that are activated when the individual is engaged in personally meaningful activities.
223542818|NCT05140135|OTHER|Treatment as Usual|All patients enrolled in the study who are randomized to the continued care as usual condition will continue to receive the treatments from their physician/treatment team at the Community Mental Health Center; however, they will not receive the adjunctive CT-R treatment.
223542819|NCT03549286|OTHER|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
223542820|NCT01559415|OTHER|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
223542821|NCT01559415|OTHER|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
223542822|NCT02420184|DEVICE|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
223542823|NCT02420184|OTHER|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
223724996|NCT06913660|BEHAVIORAL|MyGoals|"A smartphone game for ALHIV aged 15-21 yrs~MyGoals includes 3 components:~1. A role-playing narrative in which all players make decisions for male and female characters navigating scenarios from adolescence and early adulthood.~2. A series of mini-games to reinforce knowledge, skills and related self-efficacy, explored in the narrative.~3. A metanarrative component, My Story, where players will create an avatar and set personal goals."
223724997|NCT06913660|BEHAVIORAL|Standard of care|A minimum standard of care package will be identified prior to identification and recruitment of CCCs to ensure a comparable and adequate level of care is being offered to all control participants, since implementation of the range of support and care strategies recommended by the Kenya Ministry of Health differs by clinic.
223724998|NCT06831526|DRUG|Azeliragon|Provided by Cantex Pharmaceuticals
223724999|NCT06831526|DRUG|Temozolomide|Standard of care.
223725000|NCT06831526|RADIATION|Radiation therapy|Standard of care.
223725001|NCT06831526|PROCEDURE|Surgery or LITT|Standard of care surgical resection or laser interstitial thermal therapy (LITT).
223725002|NCT07121582|OTHER|Motor Brain Stimulation|For each grip trial (20 grip trials per block), participants will receive visual cues that signify the onset and offset of squeezing. Just prior to the start of the visual cue representing the onset of squeezing, participants will receive a burst of repetitive transcranial magnetic stimulation (rTMS) to their primary motor hotspot region. Motor brain stimulation will involve 3 bursts of 5 pulses/burst with a 20 Hz inter-pulse interval delivered at 90% of their resting or active motor threshold.
223725003|NCT07121582|OTHER|Visual Brain Stimulation|For each grip trial (20 grip trials per block), participants will receive visual cues that signify the onset and offset of squeezing. Just prior to the start of the visual cue representing the onset of squeezing, participants will receive a burst of repetitive transcranial magnetic stimulation (rTMS) to their ipsilesional occipital cortex region. Visual brain stimulation will involve 3 burst of 5 pulses/burst with a 20 Hz inter-pulse interval delivered at 90% of their resting or active motor threshold.
223725004|NCT07132801|DIETARY_SUPPLEMENT|Qualia NAD⁺ version 1|Qualia NAD+ version 1 manufactured by Qualia Life Sciences
223969499|NCT06897982|BEHAVIORAL|One-arm feasibility pilot of a nutrition intervention to recruit, engage, and retain DPP participants in the safety-net setting in Los Angeles|This clinical trial incorporates a behavioral intervention as the primary outcome of Aim 3 is to assess the feasibility and acceptability of adding an educational intervention using nutritional demonstrations aligned with the Diabetes Prevention Program (DPP) curriculum among patients who are at-risk for prediabetes. The purpose of this study is to assess if having a nutritional demonstration as part of the DPP would be accepted by clinic DPP patients and hear their perspectives about if this would help them in achieving DPP goals of achieving at least 5% weight loss and implementing sustainable lifestyle changes with healthy eating to reduce their risk of prediabetes. The intervention is designed to encourage healthier eating habits and encourage clinic DPP patients to incorporate this into their daily lives. This study will also determine if it is feasible to incorporate nutritional demonstrations to enhance the existing DPP curriculum
224113502|NCT04481100|DRUG|itraconazole|Oral administration of itraconazole twice daily concurrent with chemoradiation
224113503|NCT00793104|PROCEDURE|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
224113504|NCT00744367|DRUG|metformin|\>1500 mg/day or maximum tolerated dose (MTD)
224113505|NCT00744367|DRUG|pioglitazone|\>= 30 mg/day
223969500|NCT04731428|BEHAVIORAL|Progressive Relaxation Exercise|Progressive Relaxation Exercise involves stretching sixteen muscle groups while breathing in sequentially, relaxing while exhaling. Exercise can be from head to toe or from foot to head. In order for the technique to be effective, it is important to have affective (music, etc.) and visual aids. During the exercise, the patient should complete the processes of perceiving the tension in his body, maintaining control and getting into a state of relaxation. After the patient is informed about the exercise, the person starts with breathing exercises. A deep but relaxing breath is taken from the nose, and lips are given by contracting simultaneously with relaxation. During this application, the patient keeps contracting the muscle group that he exercises for 10 seconds; the nurse provides the patient to notice the temperature / warming felt in the muscle group.
223969501|NCT04269811|DRUG|Flu-Bu-Mel|5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)
223542824|NCT00288886|BEHAVIORAL|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
223542825|NCT00288886|BEHAVIORAL|Control arm|Routine residential treatment and orientation to continuing care.
223969502|NCT06898788|DRUG|Visbiome|"Visbiome® is an oral multi-strain probiotic which contains 8 strains: Lactobacillus (L.) paracasei, L. planatrum, L. acidophilus, L. helveticus, Bifidobacterium (B.) longum, B. infantis, B. breve, and Streptococcus (S.) thermophilus.~Participants will be instructed to consume the powder mixed in water."
223969503|NCT06898788|DRUG|Placebo|Participants will be instructed to consume the powder mixed in water (same instructions as the probiotic group).
223969504|NCT06313268|DRUG|Bevacizumab Biosimilar MB02|5 mg/kg to 15 mg/kg in combination with chemotherapy.
223969505|NCT05963854|OTHER|Survey Curbside|Observational. Waste will be collected on specific days for 2 consecutive weeks and surveys will be completed to coincide with the waste collections.
223969506|NCT04639960|DRUG|Risperdal|Twelve weeks of treatment with a gradual increase of dosage over one week and a gradual decrease over two weeks.
223542826|NCT03663855|DRUG|Tiopronin|Phase 1: No medication, Phase 2: 500mg PO daily x 7 days (total 500mg), Phase 3: 500mg PO BID x 7 days (total 1g), Phase 4: 1g PO BID x 7 days (total 2g)
223969507|NCT04639960|DRUG|Placebo|Twelve weeks of placebo treatment.
223969508|NCT04956094|DIAGNOSTIC_TEST|GGT/Uric Acid|Standard laboratory blood testing for GGT and uric acid levels.
223969509|NCT06539533|OTHER|pilates training|The Pilates that will be used in this study are articulating bridge, Hundreds, Plank , rolls up, one leg stretch, lift leg supine.
224113506|NCT00744367|DRUG|placebo|sc once weekly
224113507|NCT00744367|DRUG|taspoglutide|10 mg sc once weekly;
224113508|NCT00744367|DRUG|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
224113509|NCT03453086|PROCEDURE|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
224113510|NCT04535570|OTHER|Indirect Calorimetry|In the pre-transplant, before the conditioning regime, and also on the 10th and 17th post-transplant, the resting energy expenditure was measured by indirect calorimetry.
224113511|NCT00466752|DRUG|sorafenib tosylate|Given PO
224113512|NCT00466752|GENETIC|microarray analysis|Correlative studies
224113513|NCT00466752|OTHER|immunohistochemistry staining method|Correlative studies
224113514|NCT00466752|GENETIC|gene expression analysis|Correlative studies
224113515|NCT00466752|PROCEDURE|needle biopsy|Correlative studies
224113516|NCT00466752|PROCEDURE|therapeutic conventional surgery|Undergo prostatectomy
223542827|NCT05595850|BEHAVIORAL|Mindfulness|Online non-meditation mindfulness program
223542828|NCT05595850|BEHAVIORAL|Mindful Learning|Online learning program
224113517|NCT00466752|OTHER|laboratory biomarker analysis|Correlative studies
224113518|NCT00466752|GENETIC|western blotting|Correlative studies
224113519|NCT00466752|GENETIC|RNA analysis|Correlative studies
224113520|NCT01910506|DRUG|RDEA3170 10 mg|
224113521|NCT01920139|PROCEDURE|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
224113522|NCT01920139|PROCEDURE|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
223969510|NCT04822246|PROCEDURE|Control: Hand instrumentation for caries excavation|"An enamel hatchet will be used to create access to the carious lesion and then removal of soft carious tissue will be undertaken with excavators. Excavation will be stopped when some resistance to excavation will be felt and the cavity will be then conditioned with polyacrylic acid for 20 s, washed and dried with cotton pellets. A high-viscosity glass-ionomer cement will be used to restore the cavity. Moisture control will be achieved with the use of cotton wool rolls. A chair-side assistant will hand-mix the glass-ionomer according to manufacturers' instructions and it will be placed in the cavity using the press-finger technique whenever the type of cavity allows it. In the case of root restorations, a glove coated with petroleum jelly will be used similarly to the press-finger technique to better condense the material into the cavity. Excess material will be removed; the restoration will be coated with petroleum jelly. No local anaesthetic will be used to provide ART treatment."
224113523|NCT01920139|OTHER|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
224113524|NCT02349230|OTHER|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
224113525|NCT03057873|DIETARY_SUPPLEMENT|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
224113526|NCT03057873|DIETARY_SUPPLEMENT|Placebo|Dry powder to be mixed with 10 ounces of cold water
223542829|NCT01475721|DRUG|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
224113527|NCT03046238|DRUG|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
224113528|NCT03046238|DRUG|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
224113529|NCT00379730|DRUG|Prednisolone|
224113530|NCT06135818|DIAGNOSTIC_TEST|IRISA-TB|ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.
224113531|NCT05196698|OTHER|High Flow Oxygen Therapy|"HFOT will be delivered validated medical devices and established as follow:~* Patient will be acclimatized to HFOT which will aim to achieve a flow of air of 30L/min at a temperature of 34°C using dedicated nasal canula.~* Once patient acclimatized, oxygen will be entrained in the HFOT device at a flow that will aim to achieve a saturation \> 90%. An arterial blood gas will be performed with such oxygen delivery, flowrate and temperature to ensure a PaO2 ≥ 8kPa"
224113532|NCT05196698|OTHER|Long-term oxygen therapy|LTOT delivery will be performed according to French guidelines
224113533|NCT05609422|OTHER|Physical therapy program|"* Stretching exercises~* Strength Training Kneeling exercises~* Standing exercises~* Gait Training"
224113534|NCT05609422|OTHER|scooter board activities|"1. Scooter board bear walk.~2. Scooter board crab walk.~3. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~4. Cross sitting on scooter board, pulls along the rope using his/her hands~5. Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~6. Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items~7. Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8. Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~9. Supine flexion on scooter board, Clip clothespins to a rope hanging above."
224113535|NCT02928237|DEVICE|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
223969511|NCT04822246|PROCEDURE|Intervention 1: EMS Airflow device for caries excavation|An enamel hatchet will first be used to gain access into the cavity. Then the powder-water prophylaxis device will be used for the removal of soft carious tissue with the sodium bicarbonate powder-water jet. Excavation will be stopped when the colour of the lesion begins to darken and all the soft deposits are evacuated. The excavation will be done intermittently allowing sufficient time to check with hand instrument the surface hardness of the lesion. If the lesion is still soft excavation will be continued until the surface is hard suitable for restoring. The cavity will be then rinsed with copious water spray to evacuate all the powder-water material. The restoration procedure with a glass-ionomer cement will be done following the same procedures as in the control group.
223542830|NCT01475721|DRUG|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
223542831|NCT01475721|DRUG|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
223969512|NCT04822246|PROCEDURE|Intervention 2: Hand excavation + EMS Airflow device for caries excavation|The participants allocated to this group will have the caries excavated as described for the control group. Then prior to filling the excavated cavity, the procedure of sodium bicarbonate powder-water jet irrigation as described for the intervention group #1 will be performed to condition the prepared excavated cavity. Then the restorative procedure will be completed with the restorative material and procedures as described for the previous groups.
223969513|NCT02480283|PROCEDURE|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
223969514|NCT02480283|RADIATION|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
223969515|NCT02480283|PROCEDURE|Venipuncture|To collect blood cells and serum for analyses.
224113536|NCT05554900|PROCEDURE|preventive regenerative peripheral nerve interface reconstruction|Each RPNI unit consists of nerve stump and free autologous muscle graft that is cut off from healthy muscle of the amputated limb. The muscle graft is approximately 30×15×5 mm.The ends of the transected nerve are placed within the muscle belly of the free muscle grafts in an orientation that is parallel to the muscle fibers. Next, the nerve is secured distally with 6-0 non-absorbable monofilament sutures in an epimysial-to-epineurial fashion. The nerve is then wrapped around completely via muscle graft and epimysial securing sutures. All RPNI units are placed in areas remote from the surgical incision and from the weight-bearing surface of the limb.
223969516|NCT02480283|PROCEDURE|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
223969517|NCT04800978|BIOLOGICAL|BAVC-C+Durvalumab|"* Durvalumab Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for infusion after dilution.~* BVAC-C BVAC-C will be supplied in cyclic olefin co-polymer vials containing 1x10⁸ cells of suspension at a concentration of 5x10⁷ cells/mL infusion"
224113537|NCT00700752|DEVICE|senofilcon A|silicone hydrogel contact lens
224113538|NCT00700752|DEVICE|balafilcon A|silicone hydrogel contact lens
223542832|NCT01475721|DRUG|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
223542833|NCT01475721|DRUG|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
224113539|NCT01302769|DEVICE|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
223725005|NCT07132801|DIETARY_SUPPLEMENT|Qualia NAD⁺ version 2|Qualia NAD+ version 2 manufactured by Qualia Life Sciences
223542834|NCT01475721|DRUG|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
223542835|NCT04343092|DRUG|Ivermectin (IVM)|Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly
223725006|NCT07132801|DIETARY_SUPPLEMENT|Placebo|Rice Flour
223725007|NCT07131527|DRUG|Gabapentin|oral Gabapentin will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy
223969518|NCT06923007|DEVICE|Vagus Nerve Stimulation|After randomization, VNS is performed for 6 months. The stimulation parameters will be 30 Hz and 250 μs, the maximum tolerable current is selected according to the patients' adverse reactions (dizziness, palpitations, abnormal sensations, local pain, etc.), and the recommended treatment intensity is 0.8 mA.
223969519|NCT06923007|DEVICE|Sham Vagus Nerve Stimulation|After randomization, sham vagus nerve stimulation VNS treatment is performed for 6 months. The stimulation parameters will be 30 Hz, 250 μs, and the treatment intensity will be 0 mA.
223969520|NCT00801749|BEHAVIORAL|sleep|
223542836|NCT05382884|OTHER|Postpartumcare.ca (Web-Enabled Intervention)|Postpartumcare.ca is a web-enabled intervention accessible via computer, tablet or smartphone devices. The content and design of postpartumcare.ca were created based on the needs, opinions, and desires of birthing parents in British Columbia affected by postpartum depression and/or anxiety, which were solicited previously in phases 1 \& 2 of the SUPPORT study.
223969521|NCT04267393|DRUG|BMS-986263|Specified dose on specified days
223542837|NCT00803738|DRUG|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
223542838|NCT00803738|DRUG|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
223542839|NCT02377024|DIETARY_SUPPLEMENT|TF 600mg|
223542840|NCT02377024|DIETARY_SUPPLEMENT|TF 1200mg|
223969522|NCT04267393|OTHER|Placebo|Specified dose on specified days
223969523|NCT00701597|DRUG|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
223969524|NCT06914349|PROCEDURE|Antecolic gastrojejunostomy|Gastrojejunostomy in front of the transverse colon
223969525|NCT06914349|PROCEDURE|Retrocolic gastrojejunostomy|Gastrojejunostomy through the transverse mesocolon
223969526|NCT04994418|DIETARY_SUPPLEMENT|Recommended sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily recommended sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
223969527|NCT04994418|DIETARY_SUPPLEMENT|High sodium and low fructose diet|Upon completion of a 7 day dietary intervention of consuming the daily high sodium and low fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
223969528|NCT04994418|DIETARY_SUPPLEMENT|High sodium and high fructose diet|Upon completion of a 7 day dietary intervention of consuming the high sodium and high fructose contents we will investigate changes in ambulatory blood pressure, urinary sodium excretion, heart rate variability, secretion of inflammatory cytokines, and reactive oxygen species.
223969529|NCT06941311|BEHAVIORAL|Cognitive Behavioral Therapy for Suicide Prevention (CBT-SP)|Clinicians will provide this specialized evidence-based mental health care. The study focuses on the acute phase of CBT-SP, which is 12 sessions. CBT-SP's goals are to reduce suicide risk factors, enhance coping, and prevent future suicidal behavior. Identifying the emotional, cognitive, behavioral, or familial processes that precede a suicide crisis is a major focus, which yields an individualized treatment plan. Each session lasts one hour and can be completed either in person or via a secure telehealth platform. Most youths will attend sessions on a weekly basis and therapists typically like to be in contact with parents as well.
223969530|NCT06941311|BEHAVIORAL|Youth-Nominated Support Team|Youth will nominate up to 4 trusted adults. Following parental approval, Support Persons will attend an orientation session with their assigned intervention specialist, learn about the youth's difficulties, treatment plan, and receive ideas for supporting the youth. Support Persons will be asked to have contact with the youth each week for up to three months to offer emotional support, encourage participation in treatment, and support the youth's healthy behaviors. Support Persons will have weekly check-ins with their intervention specialist every week for the 3 months of the study. During these calls, Support Persons have an opportunity to discuss any questions or concerns they may have about the youth and how best to support them.
223969531|NCT00586430|DRUG|lorazepam|single 2 mg dose of lorazepam
223969532|NCT00586430|DRUG|placebo|single dose of placebo
223969533|NCT01801813|OTHER|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
223969534|NCT04641234|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|As prescribed by the treating physician
224113540|NCT03267095|BEHAVIORAL|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
224113541|NCT06152263|OTHER|Compare color information and mucosal microvascular density|To investigate the association between the color and mucosal microvascular density of CAG and EGC using linked color imaging.
224113542|NCT04983940|DRUG|Jatenzo|237 mg soft gel capsule taken twice a day by mouth with food.
224113543|NCT05346952|DRUG|TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection|PD-L1(programmed cell death-Ligand 1) may be expressed on tumor cells and/or tumor-infiltrating immune cells, which can inhibit the anti-tumor immune response in the tumor microenvironment. On T cells and antigen-presenting cells, PD-L1 binding to PD-1 (programmed cell death-1) and B7.1 receptors inhibits cytotoxic T cell activation, T cell proliferation, and cytokine production.
224113544|NCT06971185|DRUG|Luspatercept|As per product label
224113545|NCT06971185|DRUG|Erythropoiesis-stimulating agent (ESA)|As per product label
224291738|NCT03873467|BEHAVIORAL|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
223969535|NCT06951555|BEHAVIORAL|Online Individual Cognitive-Behavioral Therapy (CBT)|"12-session individual and online CBT treatment for online sexual compulsivity/cybersex addiction~Cognitive-behavioral psychological treatment program applied online and individually. The program consists of twelve sessions of approximately one hour's duration and weekly frequency~1. Psychoeducational module and motivational interviewing.~2. Environmental planning~3. Beginning of training in emotional self-regulation techniques.~4. Cognitive errors and cognitive discussion.~5. Self-talk, thought traps, responsibility vs. guilt and backpack of coping resources.~6. Self-esteem, stigma and life goals~7. Backpack of coping resources, mindfulness and slow breathing training for anxiety~8. Stress coping techniques~9. Lifestyle~10. and 11. Reduction of stimulus control and addressing previously unaddressed relevant issues.~12\. Relapse prevention"
223542841|NCT02377024|DIETARY_SUPPLEMENT|placebo|
223542842|NCT04858438|PROCEDURE|Insufflation during surgery|This is the amount of insufflation using during the surgical procedure.
223542843|NCT03910725|OTHER|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
223542844|NCT04861779|DRUG|HSK29116|Oral HSK29116
223542845|NCT01583114|DRUG|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
223542846|NCT01583114|DRUG|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
223542847|NCT03551613|DIETARY_SUPPLEMENT|honey supplementation|honey supplementation
223542848|NCT06045065|OTHER|Fresh tumor sampling|Patient samples will be collected during neurosurgical resection. .
223725008|NCT07131527|DRUG|Diclofenac Sodium|oral diclofenac sodium will be given 2 hours perioperative as postoperative analgesia patients undergoing laparoscopic cholecystectomy
223725009|NCT07132151|PROCEDURE|AI Controlled General Anesthesia|During painless abortion, anesthesia will be induced using ciprofol, and controlled by an AI model.
223969536|NCT03138629|DRUG|VAL-083|VAL-083 will be administered intravenously
223969537|NCT03723057|DRUG|AG-221|Oral AG-221 administered as directed by treating physician.
223969538|NCT03327025|BEHAVIORAL|Health education counseling|Health education counseling
223969539|NCT03542721|DRUG|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
224291739|NCT03873467|OTHER|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
224291740|NCT04663347|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|6 cycles (21-day cycles)
224291741|NCT04663347|DRUG|rituximab and lenalidomide|rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
223969540|NCT03542721|DRUG|Placebo of DA-5515|Placebo (three times a day)
224291742|NCT04663347|DRUG|rituximab and bendamustine|6 cycles (28-day cycles)
223969541|NCT02475499|DRUG|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969542|NCT02475499|DRUG|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969543|NCT02475499|DRUG|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969544|NCT02475499|DRUG|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969545|NCT02475499|DRUG|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969546|NCT02475499|DRUG|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969547|NCT02475499|DRUG|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
223969548|NCT02799745|DRUG|Enzalutamide|Oral
223969549|NCT02799745|OTHER|Active Surveillance|
223969550|NCT04826744|OTHER|Standard dermatology consultation|"with clinical examination, score filling such as SCORAD and DLQI~* Standard Allergy consultation, with clinical examination, research of atopic or allergic personal and familial history~* Allergy skin testing: patch tests with the Standard European Battery and with some products bring by the patient if necessary, skin prick tests with aero allergens. Two reading of the patch tests will be performed, at H48 and H72.~* ophthalmologic consultation with slit lamp examination and OSDI (self questionnaire)"
223969551|NCT05969119|DRUG|Pyridostigmine|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
223969552|NCT05969119|DRUG|Placebo|Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
223969553|NCT05172557|BEHAVIORAL|Wellness Program|Wellness Program involves participation in classes with topics involving resiliency, stress, physical activity, and nutrition to be completed within a few months of study participation
223969554|NCT05172557|BEHAVIORAL|Wellness Coaching|Wellness coaching sessions throughout 12 months of study participation
223969555|NCT06452043|OTHER|PARC program|Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature
223969556|NCT00153374|BEHAVIORAL|Women's health|
223969557|NCT05982847|DIAGNOSTIC_TEST|Blood pressure screening|Blood pressure and anthropometric measurements will be performed in children and adolescents between ages 5-18 years to develop South African nomograms that will aid in the development of clinical practice guidelines to optimise hypertension care in South Africa youth.
223969558|NCT04853238|OTHER|Prospective observational cohort study|Prospective observational cohort study. No study treatment was administered in this study.
223969559|NCT04688554|DIAGNOSTIC_TEST|fMRI and DTI|Neurologic imaging correlates
223969560|NCT04688554|BEHAVIORAL|Behavioral questionnaires|RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
224113546|NCT05852171|DRUG|Baricitinib|Baricitinib administered orally
224113547|NCT06443879|OTHER|Axillary brachial plexus nerve block: loss and return of sensation|Evaluating loss and return of sensation after axillary brachial plexus nerve block
224113548|NCT04803786|DRUG|Transition from Xyrem to Xywav|This is a single-group non-interventional study where participant's transitioning from Xyrem to Xywav will be observed. Investigational product (IP) or drug support or requested changes to their medication will not be provided to participants by Jazz Pharmaceuticals. The Xyrem and Xywav that the participants will take will be provided by the participant's health care provider.
224113549|NCT00950417|DRUG|Nimotuzumab|
224113550|NCT03378206|DEVICE|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
224113551|NCT03378206|DEVICE|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
224113552|NCT05760456|DRUG|DIDALA hard capsules|DIDALA is given orally with a dose of 2 capsules, 3 times per day for 12 weeks
224113553|NCT05760456|DRUG|Metformin|Metformin 500mg, 1 tablet twice a day, immediately after breakfast and dinner for 12 weeks
224113554|NCT06335940|OTHER|Videoregulation|"To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation."
224113555|NCT01288378|DRUG|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
224113556|NCT01645930|DRUG|Ixazomib|Ixazomib capsules
224113557|NCT01645930|DRUG|Lenalidomide|Lenalidomide capsules
224113558|NCT01645930|DRUG|Dexamethasone|Dexamethasone tablets
224113559|NCT02846675|BIOLOGICAL|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
224113560|NCT02846675|BIOLOGICAL|Placebo|a Placebo treatment without SVF cells
224113561|NCT01769521|DEVICE|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
223969561|NCT04688554|BEHAVIORAL|Disease-Specific Patient-Reported Outcomes|Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
223969562|NCT04688554|BEHAVIORAL|Behavioral tests|Behavioral tests may include one or more of the following procedures: Upper extremity testing, Perdue Peg Board testing, Hand tactile detection and discrimination test, Temperature and pain threshold testing, Lower extremity Testing, Myomotion Inertial Motion Testing.
224113562|NCT02522377|DRUG|Ketamine|inter venous injections
224113563|NCT02522377|DRUG|Midazolam|inter venous injections
224113564|NCT00946270|DRUG|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
224113565|NCT00946270|DRUG|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
224113566|NCT00946270|DRUG|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
223969563|NCT06082856|DRUG|Dexmedetomidine|Induction of general anesthesia by administration of dexmedetomidine 0.5µg/Kg (maximum dose 50 µg) in titration by bolus of 10µg intravenously over 5 minutes
223969564|NCT06082856|DRUG|Sufentanil|Induction of general anesthesia by administration of sufentanil 0.25µg/Kg (maximum dose 20 µg) intravenously at anesthetic induction.
223969565|NCT05652387|BEHAVIORAL|Father Inclusive Prenatal Care|Pregnant and parenting couples participate in co-parenting and parenting education, and job skills and education readiness
223969566|NCT06212622|DRUG|Alfentanil|Subcutaneous injection
223969567|NCT06212622|DRUG|Oxycodone|Oral solution
223969568|NCT01193023|OTHER|Pressure Support|Ventilation under pressure support
224113567|NCT02814214|DEVICE|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
224113568|NCT02263365|DRUG|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
224113569|NCT02367612|DIETARY_SUPPLEMENT|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
224113570|NCT02367612|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224113571|NCT06512324|DEVICE|Ampa One TMS System|Transcranial Magnetic Stimulation
223969569|NCT01193023|DEVICE|NAVA|Ventilation under NAVA
223969570|NCT01935193|DRUG|lysine acetylsalicylate|
223969571|NCT03868735|DEVICE|CleanSweep Closed Suction System|Device with balloon sweeping technology
223969572|NCT03549299|BIOLOGICAL|LSC2|Topical application of IMP on target eye
223969573|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
223969574|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
223969575|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
223969576|NCT00434577|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
223969577|NCT00434577|BIOLOGICAL|Placebo|Single intramuscular injection
223969578|NCT02821078|OTHER|4D flow imaging sequence|4D flow imaging sequence
223969579|NCT04826926|PROCEDURE|Procedure/Surgery: Non Surgical Periodontal Therapy|"Conventional staging debridement (CSD) according to the severity of periodontal disease in 2 to 4 appointments at day 0, 7, 14 and 21.~Supra and subgingival scaling and polishing will be performed by the use of manual and ultrasonic instruments and oral hygiene instructions will be given. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing."
223969580|NCT01216059|PROCEDURE|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
224113572|NCT06513364|DRUG|WH002|"Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles."
223542849|NCT06069180|DRUG|Busulfan|Conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
223969581|NCT03982875|DEVICE|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
223969582|NCT02846935|DRUG|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.
224113573|NCT06513364|DRUG|paclitaxel injection|"Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles."
224291743|NCT04663347|DRUG|rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin|3 cycles (21-day cycles)
223969583|NCT02846935|DRUG|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
223969584|NCT05982080|DRUG|FP002 Injection|Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
223969585|NCT04854278|OTHER|Massive Open Online Course (MOOC)|Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
223969586|NCT02924350|OTHER|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
224113574|NCT03115255|DRUG|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
224291744|NCT04663347|DRUG|gemcitabine and oxaliplatin|4 cycles (28-day cycles)
224291745|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
224113575|NCT04522752|OTHER|Size and pathological type of benign epithelial gastric polyp|All subjects will undergo gastroscopy and biopsy to determine the size and pathological type of benign epithelial gastric polyps.The correlation between polyp size and type and polyp development was observed at 6 months, 12 months and 18 months after inclusion.
224113576|NCT03078985|PROCEDURE|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
224113577|NCT03078985|DEVICE|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
224113578|NCT03048097|DRUG|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
224113579|NCT03048097|DRUG|Rubidium|used in PET scans
223542850|NCT06069180|DRUG|Flu/Cy/ATG or Cy/ATG|Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
223542851|NCT06080763|PROCEDURE|Physical Therapy Management|Physical therapy management is a routine intervention provided by physical therapists at Mahidol University's Physical Therapy Center for individuals with knee osteoarthritis.
223542852|NCT02364037|BEHAVIORAL|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
223969587|NCT02924350|OTHER|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
223969588|NCT00097708|DRUG|experimental anti-anxiety drug|
223969589|NCT01195740|BEHAVIORAL|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
224113580|NCT03048097|DIAGNOSTIC_TEST|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
224113581|NCT05313919|DIAGNOSTIC_TEST|Comprehensive functional diagnostics of coronary circulation|"Comprehensive functional diagnostics of coronary circulation in patients with INOCA (ischemia and no obstructive coronary arteries) including:~* echocardiography with assessment of diastolic function~* flow-mediated dilation of brachial artery~* coronary angiography~* functional coronary assessment (RFR, FFR, IMR, CFR, dp/dt, Tau)~* provocative test with acetylcholine (registration of symptoms, ECG and angiographic spasm)~* laboratory tests (full blood count, serum creatinine level, eGFR, lipidogram, serum CRP/hsCRP level, serum NT-proBNP level)~* serum level of inflammatory cytokines and chemokines"
224113582|NCT03940170|DEVICE|vistacam proof|Light fluorescence device
224113583|NCT03940170|OTHER|ICDASII|visual examination
224113584|NCT03940170|PROCEDURE|fissurotomy|histological validation
224113585|NCT02406872|DRUG|Remimazolam Tosilate|IV pumping for anesthesia
224113586|NCT02406872|DRUG|Propofol|IV bolus for anesthesia
224113587|NCT01765712|PROCEDURE|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
224113588|NCT01765712|BIOLOGICAL|Platelet Rich Plasma|
224291746|NCT04663347|DRUG|rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone|6 cycles (21-day cycles)
224113589|NCT05134298|DRUG|Piperacillin/tazobactam, Meropenem|This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
224113590|NCT06389370|OTHER|HU-DBI questionnaire|a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
224113591|NCT01341509|PROCEDURE|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
224291747|NCT04663347|DRUG|Lenalidomide|12 cycles (28-day cycles)
224291748|NCT04663347|DRUG|rituximab, ifosfamide, carboplatin, and etoposide phosphate|3 cycles (21-day cycles)
223725010|NCT07132151|PROCEDURE|General Anesthesia|Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.
223969590|NCT01195740|BEHAVIORAL|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
223969591|NCT01921114|DEVICE|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
223969592|NCT01921114|DEVICE|Bard® Dual-Lumen PowerPICC SOLO2®|
223969593|NCT04301700|BEHAVIORAL|mindfullness and relaxation|three arms: mindfullness and relaxation
223969594|NCT04605822|DEVICE|3D imaging Total Body Photography Vectra® WB360|3D Total Body Photography Vectra® WB360 (Canfield Scientific, Parsippany, New Jersey, USA) and its digital dermoscopic camera (VISIOMED® D200evo dermatoscope) and scoring of pigmented skin lesions. All participants of this study will undergo 3D TBP at baseline and the follow-up visits up to month 24.
223969595|NCT04605822|DEVICE|2D imaging FotoFinder ATBM® Master imaging system|2D imaging with FotoFinder® Mole Analyzer and scoring of pigmented skin lesions. All participants of this study will undergo 2D imaging FotoFinder ATBM® Master imaging system at baseline and the follow-up visits up to month 24.
223969596|NCT04605822|DEVICE|Smartphone application (SkinVision®)|Smartphone application for all dermatoscopically documented pigmented skin lesions in all study participations and record of risk assessment of the health application (low, medium or high risk) to compare the app's accuracy in risk assessment with the AI tools and the dermatologist. The SkinVision® smartphone app is CE certified.of skin lesions. All participants of this study will undergo Smartphone application (SkinVision®) at baseline and the follow-up visits up to month 12.
223969597|NCT04605822|OTHER|Standard-of-care clinical assessment of the skin|Clinical skin examination with dermatoscope by an experienced dermatologist and risk assessment of pigmented lesions (melanoma vs. naevus). All participants of this study will undergo Standard-of-care clinical assessment of the skin at baseline and the follow-up visits up to month 24.
224113592|NCT01341509|PROCEDURE|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
224113593|NCT01341509|PROCEDURE|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
224113594|NCT00002466|DRUG|cyclophosphamide|
224113595|NCT00002466|DRUG|doxorubicin hydrochloride|
224113596|NCT00002466|DRUG|etoposide|
224291749|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
224113597|NCT00002466|DRUG|ifosfamide|
224113598|NCT00002466|DRUG|vincristine sulfate|
224291750|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
224113599|NCT00002466|PROCEDURE|conventional surgery|
224113600|NCT00002466|RADIATION|radiation therapy|
224113601|NCT01182129|DRUG|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
224113602|NCT01182129|DRUG|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
224113603|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is made.
224113604|NCT04923412|PROCEDURE|Pulmonary branch of vagus nerve not preserved|During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
224291751|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1 and then every 8 weeks for a total of 2 years.
223969598|NCT01509937|DEVICE|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
223969599|NCT01509937|DEVICE|Device|participants in control arm will not receive BCM measurement.
223969600|NCT02615548|OTHER|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
223969601|NCT02615548|OTHER|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
223969602|NCT03966534|OTHER|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
223969603|NCT04744805|OTHER|face mask or not|long term face mask wear
223969604|NCT00300963|DRUG|Talnetant|
223969605|NCT01974453|RADIATION|Radiation dose|Radiation dose adsorbed by operators
223969606|NCT04082481|DRUG|TAK-988|TAK-988 tablets.
223969607|NCT04082481|DRUG|TAK-988 Placebo|TAK-988 placebo-matching tablets.
223969608|NCT03238456|BEHAVIORAL|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
223969609|NCT02580968|DEVICE|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
223969610|NCT02580968|DRUG|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
223969611|NCT03157492|BEHAVIORAL|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
224113605|NCT01367743|DRUG|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
223969612|NCT03157492|BEHAVIORAL|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
224113606|NCT01367743|DRUG|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
224291752|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
223969613|NCT00138918|BIOLOGICAL|OGX-011|See Detailed Description, Treatment Plan
223969614|NCT02854839|BIOLOGICAL|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
224113607|NCT02246270|DRUG|Intravesical Heparin|Heparin bladder instillation
224113608|NCT02246270|OTHER|Placebo|Intravesical saline
224113609|NCT03863496|PROCEDURE|Scoliosis surgery|All patients will be implanted Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control and standard anesthetic support.
223542853|NCT02364037|BEHAVIORAL|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
223542854|NCT02364037|DEVICE|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
223542855|NCT00619944|DRUG|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
224113610|NCT05798962|PROCEDURE|Biopsies|Biopsies from the pathological muscle and healthy, unaffected muscle
224113611|NCT02707757|DRUG|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
224113612|NCT02707757|DRUG|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
224113613|NCT04214795|OTHER|Observational study. Postnatal variables are recorded|Postnatal evolution is analyzed in both groups
224291753|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
224291754|NCT04663347|BIOLOGICAL|Epcoritamab|Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
223542856|NCT00619944|DRUG|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
223969615|NCT04005456|DIETARY_SUPPLEMENT|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
224113614|NCT05342831|OTHER|Biological Nutrition Technique|Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
224291755|NCT04663347|BIOLOGICAL|Epcoritamab|"Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules.~Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years.~In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years."
224291756|NCT04663347|DRUG|Rituximab and Lenalidomide|Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
223969616|NCT04005456|BEHAVIORAL|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
223969617|NCT04005456|OTHER|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
224113615|NCT05673135|DRUG|Anti-Hypertensive|For control of the blood pressure
224113616|NCT05673135|RADIATION|Ultrasound|For assessment of gestational age and fetal weight
224113617|NCT05673135|RADIATION|Doppler ultrasound|Umbilical artery Doppler assessment
224113618|NCT05673135|DIAGNOSTIC_TEST|complete blood count|For assessment of platelet count
224113619|NCT05673135|DIAGNOSTIC_TEST|Body mass index|for assessment of maternal weight during pregnancy
224113620|NCT04128592|DEVICE|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
223969618|NCT03380598|BEHAVIORAL|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
223969619|NCT03380598|BEHAVIORAL|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
223969620|NCT04675905|OTHER|no intervention (cohort study)|Explanatory variables include preoperative comorbidities, baseline disability, surgical risk, postoperative complications, sex, rural/urban area of residency, Oslo Social Support Scale; Clinical Frailty Scale in patients aged \>= 65 years
223969621|NCT01101464|DRUG|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
223969622|NCT01101464|DRUG|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
223969623|NCT06065709|BEHAVIORAL|Mindfulness breath awareness meditation|Mindfulness breath awareness meditation
223969624|NCT04279756|OTHER|Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch|Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
223969625|NCT01319825|DRUG|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
224113621|NCT01410591|DEVICE|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
224113622|NCT01410591|DEVICE|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
223969626|NCT01083407|DRUG|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
223969627|NCT01083407|OTHER|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
224113623|NCT00734929|DRUG|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
224113624|NCT00734929|DRUG|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
224113625|NCT02725385|OTHER|Laboratory Biomarker Analysis|Correlative studies
224113626|NCT02725385|OTHER|Physiologic Testing|Undergo Trier Social Stress Test
224113627|NCT02725385|OTHER|Questionnaire Administration|Complete questionnaire
224113628|NCT00330629|BEHAVIORAL|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
224113629|NCT00330629|BEHAVIORAL|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
224113630|NCT03516799|OTHER|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
223969628|NCT05463926|BEHAVIORAL|PDA mobile application|"Parentbot - a Digital healthcare Assistant (PDA):~A mobile application-based psychosocial parenting intervention with integrated chatbot features. It consists of multimedia educational materials (text files, audio files and videos), discussion forums, guided mindfulness-based meditation videos, guided reflection and gratitude journals and a chatbot."
223969629|NCT02189369|OTHER|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
223969630|NCT02189369|OTHER|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
223969631|NCT05851456|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
223969632|NCT03535077|OTHER|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
223969633|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with local anesthetic|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of 1% Lidocaine will be administered."
223969634|NCT05494281|PROCEDURE|Serratus Anterior Plane Block with saline solution|"A deep analgesic block of the Serratus anterior plane block (SAPB) type by echo-guided lateral approach will be performed by An 8-13 Mhz high frequency linear ultrasound probe witch will be located cranio-caudally, transversely to the 3rd and 4th intercostal space on the mid-axillary line while patients are supine with the ipsilateral upper limb raised to 90°.~Once the landmark anatomical structures have been identified (upper rib, lower rib, pleural line, Serratus muscle, superficial structures), the puncture will begin Under aseptic conditions, an 80 mm 22 gauge needle will be inserted into the in-plane view of the ultrasound probe. When the needle has reached the plane under Serratus between the Serratus muscle and the intercostal muscle opposite the lower edge of the upper rib, 30 ml of saline solution"
223969635|NCT01580111|BIOLOGICAL|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
224113631|NCT05101291|DRUG|Bupivacain|Interventional anaesthesia provided through an indwelling spinal catheter was administered according to protocol
224113632|NCT01687231|OTHER|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
224291757|NCT04663347|BIOLOGICAL|Epcoritamab|Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
224291758|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program A) intervention
224291759|NCT06386432|BEHAVIORAL|Smartphone App-delivered Smoking Cessation Intervention|Receive access to EQQUAL-NM (Program B) intervention
223542857|NCT04413916|DIAGNOSTIC_TEST|miRNA expression|Analysis of expression of selected miRNAs (miR-29c, miR-126, miR-146a, miR-150, miR-155, miR-223) by qPCR.
223969636|NCT03200236|BEHAVIORAL|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
223969637|NCT03200236|BEHAVIORAL|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
223969638|NCT01848262|PROCEDURE|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
224113633|NCT01883310|DEVICE|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
224113634|NCT01883310|DEVICE|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
224113635|NCT04838912|BEHAVIORAL|Cool Kids (Chilled) Anxiety program adapted to children and youths with autism and anxiety disorders.|CBT program for anxiety in teenagers with autism
224113636|NCT03004014|OTHER|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
224113637|NCT04599816|DRUG|levosimendan at a dose of 3 mcg/kg|levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction
224113638|NCT04599816|DRUG|levosimendan at a dose of 6 mcg/kg|levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
224113639|NCT04599816|DRUG|levosimendan at a dose of 12 mcg/kg|levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction
224113640|NCT03002493|DRUG|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
224113641|NCT03002493|DRUG|Eribulin mesylate|
224113642|NCT03002493|DRUG|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
224113643|NCT05066893|OTHER|telehealth visits|intensive visits with doctor
224113644|NCT03176966|DRUG|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
224113645|NCT03176966|DRUG|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
224113646|NCT03176966|OTHER|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
224113647|NCT02351037|DRUG|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
224113648|NCT02351037|DRUG|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
224291760|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program A)
223969639|NCT01848262|PROCEDURE|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
223969640|NCT03055923|DEVICE|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
223969641|NCT01410084|DIETARY_SUPPLEMENT|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
223969642|NCT01410084|DIETARY_SUPPLEMENT|Vitamin E|400 IU vitamin E once monthly for 5 months
223969643|NCT06277518|PROCEDURE|Surgery for malignant tumors of the digestive system|Related treatment or palliative surgery under general anesthesia for digestive system malignancies
224113649|NCT02351037|DRUG|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
223969644|NCT02108197|DEVICE|Continuous positive airway pressure (S9, ResMed)|
223969645|NCT00531063|DRUG|Everolimus (RAD001)|
223969646|NCT01249677|DRUG|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
224113650|NCT04036136|BEHAVIORAL|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
224113651|NCT04036136|BEHAVIORAL|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
224113652|NCT05476549|DIETARY_SUPPLEMENT|Lemon verbena|Lemon verbena supplement administered at an estimated daily dose of 15mg/kg
224113653|NCT05476549|DIETARY_SUPPLEMENT|Placebo|Placebo supplement containing carrier material only
224113654|NCT01267435|PROCEDURE|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
224113655|NCT04570449|DRUG|Fluoxetine|20 mg capsule
223969647|NCT05964751|DIAGNOSTIC_TEST|lipid profile|measuerments of lipid profile parameters to detect hyperlipidemia
223969648|NCT05964751|DIAGNOSTIC_TEST|fasting blood suger|measurment of fasting blood suger to detect hyprerglicemia
223969649|NCT01357109|DRUG|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
223969650|NCT01357109|DRUG|Placebo|Matched placebo bid
223969651|NCT03045055|DEVICE|Remote ischemic conditioning.|The RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 200 mmHg during the ischemia period. RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
224113656|NCT04570449|DRUG|Placebo|fluoxetine placebo capsule
224113657|NCT03245788|OTHER|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
224113658|NCT01696877|DRUG|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
224113659|NCT01696877|DRUG|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
223969652|NCT03045055|PROCEDURE|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
223969653|NCT03045055|DEVICE|Sham remote ischemic conditioning|The sham RIC procedure consists of four cycles of unilateral arm ischemia for 5 minutes, which was followed by reperfusion for another 5 minutes. The procedure is performed with an electric, autocontrol device with a cuff that inflated to a pressure of 30 mmHg during the ischemia period. Sham RIC is performed before recanalization of the occluded artery, immediately following successful recanalization, and once daily for the subsequent 7 days.
223969654|NCT02406274|OTHER|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
223969655|NCT00383630|BIOLOGICAL|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
223969656|NCT00383630|BIOLOGICAL|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
223969657|NCT00383630|DEVICE|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
223969658|NCT02612805|OTHER|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
223969659|NCT02612805|OTHER|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
223969660|NCT02612805|OTHER|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
223969661|NCT01589523|DRUG|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
223969662|NCT00709540|BIOLOGICAL|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
223969663|NCT02245464|DRUG|Telmisartan|
223969664|NCT00242164|DRUG|Dialysate Magnesium (Concentration)|
223969665|NCT04039555|DEVICE|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
223969666|NCT04039555|DEVICE|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
223969667|NCT04039555|DEVICE|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
223969668|NCT05591170|DRUG|Cholecalciferol 120 000 IU|single, oral administration of high dose of vitamin D
223969669|NCT01916642|DRUG|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
223969670|NCT01916642|DRUG|Lidocaine 1.5mg/kg|same as other
223969671|NCT01916642|DRUG|Lidocaine 2mg/kg|same as other
223969672|NCT01916642|DRUG|Lidocaine 2.5mg/kg|same as other
223969673|NCT06151847|PROCEDURE|Biospecimen Collection|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2
223969674|NCT06151847|DRUG|Cyclophosphamide|Given IV
223969675|NCT06151847|PROCEDURE|Echocardiography|Undergo echocardiography
223969676|NCT06151847|DRUG|Fludarabine|Given IV
223969677|NCT06151847|BIOLOGICAL|Interleukin-2|Given IV
223969678|NCT06151847|BIOLOGICAL|Lifileucel|Given IV
223969679|NCT06151847|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223969680|NCT06151847|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223969681|NCT06151847|PROCEDURE|Tumor Resection|Undergo tumor resection
223969682|NCT06176053|OTHER|Homebased stretching exercise and app supervision|The intervention group will perform a self-administered, home-based stretching program (a total of 6 minutes per day) and maintain their daily activities as identified at baseline. Exercises are to be performed daily for six weeks. Adherence will be supported, and weekly contact with each participant will be maintained via a mHealth application.
224113660|NCT01696877|DRUG|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
224113661|NCT01803802|BEHAVIORAL|Expressive writing|Five sessions of 30 minutes of expressive writing
224113662|NCT06396481|BIOLOGICAL|Vγ9Vδ2 T cell|The trial consisted of two phases: dose climbing phase and extension phase. At least 15 patients with malignant brain glioma (WHO Grade IV) were enrolled in the climbing phase. According to the 3+3 design, the amount of cells suitable for implantable Ommaya capsules for cell transfusion was increased according to the dose of 1x107, 3x107, 1x108 and 3x108 per dose, so as to observe its tolerability and safety. In the expansion phase, 10 patients with malignant brain glioma (WHO Grade IV) were enrolled, and dose expansion therapy was performed according to the optimal dose obtained in the climbing phase to observe its tolerability and safety. One course of treatment every 4 weeks, a total of 3 courses. Vγ9Vδ2 T cells were injected into the ventricle or ventricle once a week for the first three weeks and observed at the fourth week. In some patients, radiotherapy or other chemotherapy drugs (such as temozolomide) may be combined at week 4.
224113663|NCT02457052|DEVICE|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
224113664|NCT03562780|DRUG|Fortolin Tab 500mg|Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
224113665|NCT03562780|DRUG|Panadol Caplet 500mg|Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
224113666|NCT02961764|DRUG|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
224113667|NCT02961764|DRUG|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
224113668|NCT01422304|DRUG|Sugammadex|Sugammadex 4 mg/kg intravenously
223969683|NCT00449436|DRUG|TRIZIVIR|TRIZIVIR
223725011|NCT07131696|DEVICE|Transcutaneous Vagal Nerve Stimulation|Participants will receive up to 4 sessions per day of up to 20-minute stimulation, over the next 10 days of their inpatient hospital stay, following endovascular treatment. Stimulation will be provided by the tVNS device through a small electrode placed around the ear that will send low intensity, pulsed, electrical pulses the vagus nerve.
223969684|NCT00449436|DRUG|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
223969685|NCT00449436|DRUG|Boosted Protease Inhibitor|Boosted Protease Inhibitor
223969686|NCT03545178|BEHAVIORAL|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
223969687|NCT03545178|DIAGNOSTIC_TEST|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
223969688|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
223969689|NCT03844178|PROCEDURE|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
223969690|NCT03844178|DRUG|installation of Tetracaine 1%|installation of Tetracaine 1%
223969691|NCT03844178|PROCEDURE|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
223969692|NCT00961896|DRUG|Vehicle|Placebo cream
223969693|NCT00961896|DRUG|LDE225 0.25%|
223969694|NCT00961896|DRUG|LDE225 0.75%|
223969695|NCT03148483|OTHER|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
223542858|NCT03444545|DEVICE|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
223542859|NCT03444545|DEVICE|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
223542860|NCT01104402|DEVICE|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
223969696|NCT03148483|OTHER|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
223969697|NCT03148483|DIETARY_SUPPLEMENT|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
223969698|NCT03148483|DIETARY_SUPPLEMENT|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
223969699|NCT00174356|DRUG|CI 1033|
223969700|NCT00174356|DRUG|PACLITAXEL|
223969701|NCT00174356|DRUG|CARBOPLATIN|
223969702|NCT00506922|DRUG|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m\^2~Group 3 - Pentostatin 1 mg/m\^2~Group 4 - Pentostatin 1.5 mg/m\^2~Group 5 - Pentostatin 2 mg/m\^2"
223969703|NCT00506922|DRUG|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
223969704|NCT00506922|DRUG|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
223969705|NCT02674048|OTHER|Metvix|
223969706|NCT03948464|DRUG|Slow release oral morphine (SROM)|Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
223969707|NCT03948464|DRUG|Methadone|Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
223969708|NCT03659890|DIETARY_SUPPLEMENT|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
223969709|NCT03659890|DIETARY_SUPPLEMENT|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
223969710|NCT03659890|DIETARY_SUPPLEMENT|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
223969711|NCT05808062|PROCEDURE|Root canal obturation|Root canal dryness
223969712|NCT06319547|PROCEDURE|Thoracocentasis|patients will be submitted to diagnostic pleural fluid study, chest x-ray, liver function and blood picture
224113669|NCT01422304|DRUG|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
224113670|NCT01422304|DRUG|Placebo to neostigmine|Normal saline (NaCl 0.9%)
224113671|NCT01422304|DRUG|Placebo to sugammadex|Normal saline (NaCl 0.9%)
224113672|NCT01301612|DRUG|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
224113673|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
224291761|NCT06386432|OTHER|Health Promotion and Education|Receive text message reminders, motivational messages and prompts via SMS text messages (Program B)
224291762|NCT06386432|OTHER|Biospecimen Collection|Complete at-home saliva sample collection
223969713|NCT05584813|OTHER|Hypobaric Hypoxia|The Waggoner Computerized Color Vision Test (WCCVT) and the Waggoner D-15 (WC-D15) were performed by 54 healthy volunteers in a decompression chamber.
223969714|NCT02970357|OTHER|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~* what is diabetes~* Monitoring~* Hypoglycemia and Hyperglycemia~* Nutrition~* Insuline"
223969715|NCT02970357|BEHAVIORAL|WHO-5|5 item questionnaire of the World Health Organization about quality of life
223969716|NCT05592769|DEVICE|HealthBeacon Injection Care Management System (ICMS)|"All participants will receive access to the HealthBeacon ICMS to remotely monitor adherence to therapy in the home setting. The system includes the following items/services:~* The HealthBeacon Smart Sharps Bin~* The HealthBeacon Companion App~* HealthBeacon Care Team Support (including smart dose reminders and intervention calls)~* Waste Management Services~Participants will also be issued the following interventions to enable collection of the secondary endpoints:~-Participant Feedback Questionnaire (issued electronically upon study completion, to gather feedback on the HealthBeacon ICMS)"
224113674|NCT01301612|RADIATION|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
224113675|NCT01301612|DRUG|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
224113676|NCT01301612|RADIATION|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
224113677|NCT00469014|DRUG|Clofarabine|Day -6 to Day -3 for Arm 1 = 10 mg/m\^2 intravenous (IV) Daily; Arm 2 = 20 mg/m\^2 IV Daily; Arm 3 = 30 mg/m\^2 IV Daily; Arm 4 = 40 mg/m\^2 IV Daily
224113678|NCT00469014|DRUG|Busulfan|"Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily; Arm 4: 40 mg/m\^2 IV Daily.~Test dose Day -8 32 mg/ m\^2 IV over 45 min, rest on Day -7."
224113679|NCT00469014|DRUG|Fludarabine|Day -6 to Day -3 for Arm 1: 30 mg/m\^2 IV Daily; Arm 2: 20 mg/m\^2 IV Daily; Arm 3: 10 mg/m\^2 IV Daily
224291763|NCT06386432|OTHER|Questionnaire Administration|Ancillary studies
224113680|NCT00469014|OTHER|Stem Cell Infusion|Day 0 stem cell infusion (Bone marrow or peripheral blood progenitor cells (PBPC))
224291764|NCT06029959|DEVICE|Continuous positive airway pressure (CPAP)|Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist. The CPAP device includes an auto-titrator that adjusts the delivered pressure between 5 to 15 cm of water to eliminate obstructive events.
224291765|NCT06029959|BEHAVIORAL|CPAP technical support intervention|SCOUTS 3 sleep technologists (ST) will make mask type/size or device adjustments, as needed, and provide training to participants and CPAP partners to improve skills involved with mask placement and device maintenance. For participants with non-acceptance of CPAP over the first night, a standardized desensitization program will be implemented. Persistent problems with CPAP use or mask fit, or any high residual respiratory events will be discussed between the sleep technologist and the study's board-certified sleep medicine physician.
223969717|NCT02983877|BEHAVIORAL|iTAB-CV|"Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.~In the second stage for the following month, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1."
223969718|NCT02955706|DRUG|Acetyl-L-Carnitine|TID
223969719|NCT02955706|DRUG|Placebo of Acetyl-L-Carnitine|TID
223969720|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
223969721|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
223969722|NCT02956356|DIETARY_SUPPLEMENT|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
223969723|NCT02956356|DIETARY_SUPPLEMENT|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
223969724|NCT03721978|BIOLOGICAL|VGX-3100|1 milliliter (mL) VGX-3100 injected IM.
223969725|NCT03721978|BIOLOGICAL|Matched Placebo|1 mL of matched Placebo injected IM.
223969726|NCT03721978|DEVICE|CELLECTRA™-5PSP|CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
223969727|NCT02542410|DRUG|Cabergoline|
223969728|NCT02542410|DRUG|Norethindrone acetate|
223969729|NCT00256685|DRUG|DVS-233 SR|
223969730|NCT01782729|DRUG|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
223969731|NCT05244226|DRUG|Fentanyl/Hydromorphone|Per routine care
223969732|NCT05244226|DRUG|Methadone|Initial dosing 0.1mg/kg, potential to escalate to 0.15mg/kg following interim analysis
223969733|NCT06395922|DEVICE|Blockbuster LMA|The LMA was inserted using the recommended technique, with the patient's head in the sniffing position. The appropriate size was selected based on body weight (size 3 for 30-50 kg, size 4 for 50-70 kg)
223969734|NCT06395922|DEVICE|Baska Mask|The BM was inserted by opening the mouth, avoiding the tongue, and negotiating the palatopharyngeal curve using the hand-tab.
223969735|NCT05283356|DRUG|Ticagrelor 60mg|Ticagrelor 60mg BID after TAVI
223969736|NCT00272454|DRUG|Cilostazol|
223969737|NCT00272454|DRUG|Aspirin|
223969738|NCT03767972|DEVICE|Energy-based device|Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
223969739|NCT05611853|DRUG|BN301|BN301 will be administered intravenously on Day 1 of every 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, loss to follow-up, death, or other conditions in which patients are not suitable for study treatment, whichever occurs first. Since this is the first time BN301 will be used in Chinese patients, it is planned to enroll 1 subject at the first dose level of 3.5 mg/kg.
223969740|NCT03453424|PROCEDURE|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
223969741|NCT03453424|PROCEDURE|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
223969742|NCT02304562|BIOLOGICAL|UCB Mesenchymal Stem Cells treatment|reduce skin injury
223969743|NCT04632212|BEHAVIORAL|Explicit Tax|"To impose an explicit tax on food and beverage items that are eligible for red stop-sign food logos (explained in Intervention 2) as less healthy foods. Explicit tax shows pre-tax prices and a label indicating that the price includes a corresponding tax on the less healthy products.~Food and Beverages: we will impose a 20% tax on sales price of the food items"
224113681|NCT00469014|DRUG|Thymoglobulin (ATG)|Day -3 to Day -1 at 0.5 mg/kg IV on Day -3; 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
224113682|NCT00469014|DRUG|Filgrastim|Subcutaneous injection daily, starting 1 week after Stem Cell Transplant.
224113683|NCT00396227|DRUG|vildagliptin|vildagliptin as add-on to metformin
224113684|NCT00396227|DRUG|thiazolidinedione (TZD)|TZD add-on to metformin
224113685|NCT03153397|OTHER|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
224113686|NCT03153397|OTHER|Osmolite|non-prebiotic fiber containing formula (Osmolite)
224113687|NCT03515980|DRUG|BMS-986231|Intravenous (IV) administration
223969744|NCT04632212|BEHAVIORAL|Food Labels (with the summary of healthiness of shopping baskets & targets)|"To provide the green circle 'healthy choice' food label to items with Nutri-Score A and B, the amber circle 'in between healthy and unhealthy choice' food label to items with Nutri-Score C, and the red stop-sign 'less healthy choice' food label to items with Nutri-Score D and E.~In the presence of food labels,~* Video: subjects will watch a video briefly explaining the food labels on the store.~* My Cart Summary: subjects will be provided a live visual indicator of the healthiness of shoppers' current basket with the recommended healthy baskets goals."
223969745|NCT04632212|BEHAVIORAL|Ordering|To order food items by Nutri-Score (high to low).
223969746|NCT04632212|BEHAVIORAL|Within-Group Substitution|To provide substitutes within corresponding food categories that are better than the items that subjects chose in terms of Nutri-Score based on the similarities of price, primary ingredients, flavor, and other characteristics.
223969747|NCT00605995|DRUG|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
223969748|NCT05426447|OTHER|Dietary intervention of reduced protein intake|6-wk dietary intervention of reduced protein intake
223969749|NCT05426447|OTHER|Dietary intervention of normal protein intake|6-wk dietary intervention of normal protein intake
223969750|NCT03038945|OTHER|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
223969751|NCT03038945|OTHER|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
223969752|NCT02529371|DEVICE|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
224113688|NCT03977389|PROCEDURE|Total wrist denervation|Study of the files
224113689|NCT00866294|DRUG|paroxetine IR 10mg tablet|1 or 2 tablets once a day
224113690|NCT00866294|DRUG|paroxetine IR 20mg tablet|1 tablet once a day
223542861|NCT00118638|DRUG|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
223542862|NCT00118638|DRUG|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
224113691|NCT00866294|DRUG|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
224113692|NCT00866294|DRUG|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
224113693|NCT00866294|DRUG|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
224113694|NCT00866294|DRUG|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
224113695|NCT05457530|DRUG|DOR/3TC/TDF|100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF
224113696|NCT05457530|COMBINATION_PRODUCT|DOR + FTC/TAF|100 mg of doravirine + 200 mg emtricitabine (FTC) and 25 mg of tenofovir alefenamide fumerate (TAF)
223969753|NCT05684666|OTHER|Slow Breathing Exercise (SBE)|"Slow Breathing Exercise (SBE) delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to make six breaths per minute for 30 minutes per session, twice a week for 4 weeks."
223969754|NCT05684666|OTHER|Progressive Muscle Relaxation (PMR) Technique|"Progressive Muscle Relaxation (PMR) Technique delivered in a relaxed supine posture on a couch with keeping the feel flat and knee flexed to 90 degree.~Participants were instructed to complete all sixteen steps of PMR technique for 30 minutes per session, twice a week for 4 weeks."
223969755|NCT00298337|DRUG|Mixture of probiotic bacteria and prebiotic oligosaccharide|
223969756|NCT01304771|BIOLOGICAL|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).
223969757|NCT00815022|DRUG|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
223969758|NCT00522470|DRUG|rosiglitazone|
223969759|NCT00046683|DRUG|alemtuzumab|
223969760|NCT00004097|DRUG|fluorouracil|
223969761|NCT00004097|DRUG|gemcitabine hydrochloride|
223969762|NCT00004097|DRUG|paclitaxel|
223969763|NCT00004097|RADIATION|radiation therapy|
224113697|NCT05457530|DRUG|BIC/FTC/TAF|Bictegravir sodium 50 mg, emtricitabine 200mg, tenofovir alefenamide fumerate 25mg
223969764|NCT03209245|BIOLOGICAL|Purethal Mites|perennial allergren specific immunotherapy during 24 months
224113698|NCT00916721|DRUG|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
223725012|NCT06521294|OTHER|Mulligan SNAG mobilization tecnique|Mulligan SNAG mobilization tecnique
223725013|NCT06521294|OTHER|Conventional Physiotherapy|Conventional Physiotherapy
223969765|NCT03209245|OTHER|placebo injection|perrenial injection wich were administered in same protocol as Purethal
223969766|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
223969767|NCT03209245|DIAGNOSTIC_TEST|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
223969768|NCT01623206|DRUG|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
223969769|NCT01805206|OTHER|Assessment of urinary iFABP|
223969770|NCT01805206|OTHER|Administration of enteral feedings|
223969771|NCT01538225|DRUG|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
223969772|NCT01538225|DRUG|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
223969773|NCT06442163|DEVICE|AVAPS study was performed within 1 week of the CPAP titration attempt failure, using the auto-titrating EPAP (AE), the OmniLab Advanced +, System One device (Philips Respironics, Murrysville, PA, U.S.|"After attending an educational session (in the presence of a family member) with hands-on training, the AVAP -AE devices were provided to the patients.~During the study, one month after AVAPS -AE initiation, patients had direct immediate access to medical and technical support through phone contact during daytime working hours."
223969774|NCT01919346|DRUG|Eculizumab|
223969775|NCT01919346|DRUG|Normal Saline|
223969776|NCT01801423|DRUG|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at \~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
223969777|NCT01015378|PROCEDURE|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
223969778|NCT00175656|PROCEDURE|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
224113699|NCT00916721|DRUG|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
224113700|NCT04331730|DRUG|AKST4290|Oral AKST4290
223969779|NCT03385798|PROCEDURE|Endowrist|Anastomosis made by Endowrist
224113701|NCT04331730|DRUG|Placebo|Oral placebo
224113702|NCT04331730|DRUG|Aflibercept|Aflibercept intravitreal injection
223725014|NCT02700815|DRUG|Diclofenac|
223725015|NCT02700815|DRUG|Capsaicin|
223725016|NCT02700815|DRUG|Placebo|
223969780|NCT03385798|PROCEDURE|Endo-GIA|Anastomosis made by Endo-GIA
223969781|NCT05338112|DIAGNOSTIC_TEST|Tzanck smear|The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
223969782|NCT02490605|PROCEDURE|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
224113703|NCT01903434|DRUG|Evacetrapib|Administered orally
224113704|NCT01202110|DRUG|Propranolol|
224113705|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
223969783|NCT02490605|PROCEDURE|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
223969784|NCT04397614|OTHER|mHealth Assessments|Daily symptom tracker
223969785|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
223969786|NCT01964339|OTHER|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
223969787|NCT06544421|OTHER|Assigned Interventions|Assigned Interventions
223969788|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
223725017|NCT03249727|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
223969789|NCT00555997|DRUG|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
224113706|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
223542863|NCT01142440|BEHAVIORAL|behavioral intervention|"* Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups"
223542864|NCT01820806|DRUG|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
223725018|NCT05205421|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|Intravenous injection a single dose of RT-01
223725019|NCT03592199|DRUG|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
223969790|NCT00555997|DRUG|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
223969791|NCT01540578|OTHER|laboratory biomarker analysis|Correlative studies
223969792|NCT04930003|BIOLOGICAL|QazCoVac-P -COVID-19 Subunit Vaccine|QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
224113707|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
224113708|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
224113709|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
224113710|NCT01469052|DRUG|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
224291766|NCT06029959|BEHAVIORAL|Motivational Enhancement Therapy (MET)|In-person Motivational Enhancement Therapy (MET) sessions by a trained sleep coach will occur within a week of starting CPAP and, with permission, conducted with a CPAP partner, when available. The MET session recordings will be uploaded into the HIPAA compliant Lyssn platform for evaluation, including feedback to the sleep coach. The goal will be 5 total MET sessions, either in-person or by phone, spanning the inpatient and then outpatient settings.
223969793|NCT04930003|OTHER|Placebo|The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
223969794|NCT06260241|PROCEDURE|Traction Dressing|Traction dressing will be applied to one group for 24 hours and simple dressing to the other group.
223969795|NCT06260241|OTHER|Without Traction Dressing|Without Traction Dressing
224113711|NCT00530699|DRUG|AZD1152|intravenous
224113712|NCT05552599|PROCEDURE|woolen blanket|Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
224113713|NCT04390815|DRUG|Insulin|Adding insulin to conventional wound treatment
223969796|NCT04934241|OTHER|Self-Acupressure|Acupressure is a therapy method performed with an instrument or hand, fingertip, palm, elbow, knee, thumb relaxation and wrist bands on various points representing the waist organs in order to ensure the continuation and balance of the energy in our body
223969797|NCT05336981|RADIATION|Low-Level Light Therapy|The method consists of the application extraoral of low-intensity infrared laser in the major salivary glands-parotid, submandibular
223969798|NCT04210804|DIETARY_SUPPLEMENT|Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)|200mls Smoothie
223969799|NCT02684955|DEVICE|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
223969800|NCT02684955|DEVICE|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
223969801|NCT03698630|DRUG|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
223969802|NCT03698630|DRUG|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon\* on the other containing 2 mg dexamethasone."
224113714|NCT06511011|DRUG|Modified Suan ZaoRen Tang-TianWang BuXin Dan|Chinese medicine granules for 6 weeks
224113715|NCT06511011|DRUG|Placebo|Placebo granules for 6 weeks
224113716|NCT04372693|OTHER|impliminting Online Distance Learning|as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
224113717|NCT03201328|OTHER|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
224113718|NCT03201328|OTHER|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
224113719|NCT03201328|OTHER|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
224113720|NCT00075751|DRUG|gemcitabine hydrochloride|Given IV
224113721|NCT00075751|DRUG|carboplatin|Given IV
224113722|NCT00075751|DRUG|bortezomib|Given IV
223969803|NCT02475018|DIETARY_SUPPLEMENT|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
223969804|NCT02475018|DIETARY_SUPPLEMENT|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
223969805|NCT04996537|OTHER|Micro-video digiral learning|On the digital platform, you can accept courses anytime, anywhere, and repeat learning, answering, leaving messages, or interacting with lecturers.
223969806|NCT06250088|BIOLOGICAL|Emdogain (EMD) - test|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt the computer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. Extraorally, (Emdogain) EMD will be applied to the root surface of the donor tooth. Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
223969807|NCT06250088|PROCEDURE|Sham group|Initially, tooth sectioning of the hopeless tooth (receptor) will be carried out using fissure carbide burs, and the resulting two fragments will be extracted with a minimally invasive approach. A multiple drilling axis tooth-supported surgical guide will be used to prepare the recipient site in accordance with the 3D planning. Additional alveoloplasty procedures will be performed with round diamond burs if necessary to adapt thecomputer assisted rapid prototyping (CARP) model to the virtual planning position. The donor tooth will be extracted as atraumatically as possible, utilizing a piezoelectric surgical instrument if ostectomy is required, and avoiding the use of elevators or forceps over the root surface. No Emdodain (EMD). Sutures will be applied to closely adapt the soft tissues around the autotransplanted tooth. A semi-rigid orthodontic wire will be used to splint the tooth to the mesial and distal adjacent teeth
223969808|NCT02222883|GENETIC|Testing of BRCA status regarding germline and somatic mutation|
223969809|NCT00262249|DRUG|somatropin|
223969810|NCT04917263|DIAGNOSTIC_TEST|Immunohistochemistry, Flow citometry, Trascriptome analysis|we will perform immunohistochemistry, flow cytometry, transcriptomic analysis, mRNA microarray and mutational profiling
223969811|NCT02510222|DIETARY_SUPPLEMENT|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
223969812|NCT02510222|OTHER|Placebo|
223969813|NCT04596098|OTHER|Blood sampling|During a care-related blood sampling, patient will provide additional blood sample for research purpuse.
223969814|NCT02622256|BEHAVIORAL|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team \& may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
223969815|NCT04143906|DRUG|Vinorelbine|injection
223969816|NCT04143906|DRUG|Gemcitabine|injection
223969817|NCT04143906|DRUG|Carboplatin|injection
223969818|NCT01324739|DRUG|human BNP-32|3pmol/kg/min infusion
223969819|NCT03378947|OTHER|clinical and pathological data EBV-related GZL and DLBCL|"Invesrigators will retrospectively collect clinical and pathological data of all EBV-related GZL and DLBCL in immunocompetent patients diagnosed in the pathology department Centre Hospitalier Lyon Sud.~Investigators will analyze their clinical feature and prognosis."
223969820|NCT06255912|DRUG|LTC004 + MIL-97|Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
223969821|NCT06255912|DRUG|LTC004 + MIL-97+chemotherapy|LTC004 + MIL-97+chemotherapy
224113723|NCT03640897|DEVICE|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
223725020|NCT03021408|OTHER|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
224113724|NCT03640897|OTHER|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
223969822|NCT05285956|BEHAVIORAL|Calm app|Calm is a popular, subscription-based, meditation app accessible across web-based and smartphone platforms (iOS and Android) with over 100 million downloads and four million subscribers. The app offers a range of content rooted in mindfulness principles to help users incorporate mindfulness into their lives and generally promote wellbeing (e.g., a large library of guided meditations including the 10-minute Daily Calm, Sleep Stories, educational courses, mindful movement, music, and nature scenes and sounds). Calm also teaches users the basics of mindfulness, includes components to remind users to meditate, track user activity, and allow users to share their status with others. The feasibility of the app and its efficacy for improving mental health outcomes (i.e., stress, anxiety, and depressive symptoms), mindfulness, and sleep have been previously tested in various populations providing evidence that using Calm may improve wellbeing.
223969823|NCT03511573|PROCEDURE|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
223969824|NCT00130910|DRUG|Albendazole|Albendazole 400mg x 3 first dose observed
223969825|NCT00130910|DRUG|Placebo|Albendazole Placebo 400mg x 3 first dose observed
223969826|NCT02675998|DRUG|Tenapanor|
223969827|NCT02675998|DRUG|Placebo|
223969828|NCT00900406|GENETIC|gene expression analysis|blood collection
223969829|NCT00900406|GENETIC|microarray analysis|Blood collection
223969830|NCT00900406|GENETIC|polymorphism analysis|Blood collection
223725021|NCT03021408|OTHER|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
223725022|NCT03021408|OTHER|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
223969831|NCT00900406|GENETIC|proteomic profiling|Blood collection
223969832|NCT00900406|OTHER|flow cytometry|Blood collection
223969833|NCT00900406|OTHER|immunologic technique|Blood collection
223969834|NCT00900406|OTHER|laboratory biomarker analysis|Blood collection
223969835|NCT00900406|PROCEDURE|biopsy|Blood collection
223969836|NCT02197143|DRUG|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
223725023|NCT04953468|DIAGNOSTIC_TEST|expression level of ANXA2 protein|The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
223969837|NCT02197143|DRUG|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
223969838|NCT02197143|DRUG|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
223969839|NCT00275301|DRUG|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
224113725|NCT03640897|OTHER|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
224113726|NCT06511505|OTHER|TEMPUS AI-enabled ECG-based Screening Tool|The AI-enabled ECG-based screening tool, Tempus Next software, analyzes 12-lead ECG recordings to identify patients at increased risk for undiagnosed cardiovascular diseases, specifically atrial fibrillation (AF) and structural heart disease (SHD). Clinicians in the intervention group will receive a risk assessment for AF and SHD each time they order an ECG for their patients.
224113727|NCT05694078|OTHER|Hand Therapy Splinting Protocol|Relative motion splinting protocol
224113728|NCT05924360|OTHER|conventional exercise program|The conventional treatment program will be applied to all participants included in the study, consisting of wand, codman, active and passive stretching exercises. This program will be administered to all patients five days a week. Wand exercises will be applied in the directions of flexion, abduction, extension, internal and external rotation, and will consist of 10 repetitions. Codman exercises will be applied in the directions of flexion, abduction, and circular, and will also consist of 10 repetitions. Active and passive stretching exercises will be applied in the directions of flexion, abduction, and external rotation, and will consist of 10 repetitions.
224113729|NCT05924360|OTHER|Mulligan application|The mobilization with movement technique, a part of Mulligan applications, will be performed twice a week in the directions of flexion, abduction, and external rotation.
224113730|NCT05924360|OTHER|Maitland application|Maitland Group: The Maitland application will be applied in the anterior-posterior, posterior-anterior, and caudal directions. The Maitland application will be administered at grades 2-3. Patients in this group will receive the application in five sets of 30 seconds, twice a week.
224113731|NCT05924360|DEVICE|TENS|TENS application will be administered for 20 minutes at 100Hz
224113732|NCT04743882|OTHER||
224113733|NCT01753752|DRUG|Chitosan- N- Acetylcysteine eye drops|
224113734|NCT01753752|DRUG|Placebo|
224113735|NCT03595215|DEVICE|TENS|Transcutaneous electrical nerve stimulation
224113736|NCT05882162|PROCEDURE|Coronectomy|Removal of crown part of the mandibular third molar
224113737|NCT05882162|PROCEDURE|Pulp Capping with calcium silicate|Application of a pulp capping material (BiodentineTM, Septodont, St Maur-des-Fosses, France) on pulp tissue to preserve the vitality of the residual pulp and prevent inflammation
224113738|NCT00865462|DRUG|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
224113739|NCT00865462|DRUG|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
224113740|NCT00048906|DRUG|DRX005B|
224113741|NCT00764842|DEVICE|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
223725024|NCT02656121|DRUG|Vitamin D|6000 IU of vitamin D3
223725025|NCT02656121|DRUG|Ovulatory Agent|only Clomophine Citrate
223969840|NCT04219878|BEHAVIORAL|Know@Home|Participants randomly assigned to the Know@Home arm will access the features of Know@Home by downloading the app or accessing the website. The contents were developed to serve as a comprehensive mobile HIV prevention platform for MSM or TGW, with HIV prevention and care information and links to resources. This intervention arm provides an toolkit that allows users to access information about prevention services as their needs change. Participants will have access to Know@Home for the study period. The Know@Home arm will offer participants the opportunity to order free condoms and lubricant as well as an at-home sexually transmitted infection (STI) testing kit.
224113742|NCT05819632|OTHER|curcumin gel 2%|curcumin gel 2%
224113743|NCT05055661|OTHER|Pharmaceutical Teleconsultation|The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
223969841|NCT04219878|OTHER|Self-test Kit|All participants will be shipped two at-home HIV self-tests. They will also receive a link to a previously-produced video that fully describes the specimen collection process, pointing out common errors and providing tips for successful collection. Participants will interact with study staff through phone, email, or text. Information to schedule a video HIV testing and counseling session with study staff will be made available to participants in all arms via a website, email, and/or text.
223969842|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
223969843|NCT03087994|BEHAVIORAL|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
223969844|NCT05688098|DRUG|Irbesartan/Amlodipine High FDC|Irbesartan/Amlodipine High FDC
223969845|NCT05688098|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine High
224113744|NCT02101411|DIAGNOSTIC_TEST|PRU(Platelet reactivity unit)|measure by VeryfyNow.
223969846|NCT05688098|DRUG|Amlodipine High|Co-administration of Irbesartan and Amlodipine High
223969847|NCT02867111|DEVICE|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
223969848|NCT02867111|OTHER|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
223969849|NCT02867111|PROCEDURE|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
223969850|NCT02097849|DRUG|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
224113745|NCT05477966|OTHER|Medical records review|The clinical characteristics at the time of diagnosis of rifampin-susceptible pulmonary tuberculosis patients, the Xpert MTB/RIF assay Ct value, the tuberculosis activity score based on AI of the chest image, and treatment results will be collected retrospectively through medical records.
223969851|NCT02097849|BIOLOGICAL|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
223969852|NCT02097849|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
223969853|NCT02097849|BIOLOGICAL|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
223969854|NCT02097849|DRUG|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
223969855|NCT03822195|PROCEDURE|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
223969856|NCT00733226|DRUG|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
223969857|NCT00733226|DRUG|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
223969858|NCT05906901|OTHER|Cranial listening technique|5 minutes
224113746|NCT01662973|OTHER|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.
223969859|NCT05906901|OTHER|Suboccipital muscles inhibition technique|6 minutes
223969860|NCT01939210|OTHER|Educational Intervention|Participate in breathing training sessions
223969861|NCT01939210|OTHER|Meditation Therapy|Participate in breathing training sessions
223969862|NCT01939210|OTHER|Questionnaire Administration|Ancillary studies
224113747|NCT01662973|OTHER|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
224113748|NCT01784562|DRUG|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
224113749|NCT02595060|DRUG|inhaled molgramostim (rhGM-CSF)|
224113750|NCT02595060|DRUG|inhaled placebo|formulated as the active substance without molgramostim
224113751|NCT01519427|DRUG|Akt inhibitor MK2206|Given PO
224113752|NCT01519427|DRUG|selumetinib|Given PO
224113753|NCT01519427|OTHER|laboratory biomarker analysis|Correlative studies
223969863|NCT02482532|BIOLOGICAL|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
223969864|NCT02424019|DRUG|ILUVIEN 0.19 MG|
223969865|NCT02397343|DRUG|Hyperbaric oxygen|
223969866|NCT03964181|OTHER|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
223969867|NCT04596605|OTHER|T2309|Food for Special Medical Purpose / 4 capsules daily for 12 weeks
223969868|NCT04596605|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules daily for 12 weeks
223969869|NCT04981353|PROCEDURE|bilateral erector spinae plane block at T11|A real-time high-frequency linear ultrasound will be used to do the thoracic (ESP) at the level of T11 by visualizing the transverse process of T11 thoracic vertebrae and erector spinae muscle and injecting a 20 ml of bupivacaine 0.25% bilaterally using an in-plane technique, a 20-gauge, 70-mm needle (Tuoren, Henan, China) will be advanced into the plane below (ESM) after injecting lidocaine 1% 2ml at the site of injection, Needle will be advanced with a cranial to caudal directio
223969870|NCT02137499|DEVICE|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
223969871|NCT01814436|DEVICE|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
223969872|NCT02845310|PROCEDURE|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP \>65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP \> 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (\>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
223969873|NCT02845310|PROCEDURE|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
223969874|NCT00022607|BIOLOGICAL|bevacizumab|
223969875|NCT00022607|DRUG|thalidomide|
223969876|NCT01911923|PROCEDURE|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
223969877|NCT01911923|PROCEDURE|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
223969878|NCT05705336|DRUG|Tranexamic Acid Oral Product|Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.
223969879|NCT05705336|DRUG|Placebo pills|Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
223969880|NCT00848393|DRUG|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
224291767|NCT06029959|BEHAVIORAL|Mobile Health intervention|Study participants will be assisted in registering for and trained on the ResMed myAir app. Participants will also receive mobile health messages based on Self-Determination Theory.
223725026|NCT02499302|BEHAVIORAL|Mental training|
223969881|NCT00848393|DRUG|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
223969882|NCT00848393|DRUG|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
223969883|NCT02561078|DRUG|Human regular U-500 insulin (CSII)|Administered SC
224113754|NCT02540174|PROCEDURE|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
224113755|NCT02540174|PROCEDURE|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
223542865|NCT04868942|OTHER|Assisting to the event|"Participant will attend a concert respecting the Following measures :~* Individual protection kit: disposable FFP2 masks (3), Hydroalcoholic solution, disposable tissues, garbage bag, water bottle~* Health mediation, information on barrier measures~* Physical distancing (sitting participation)~* Person flow management"
223969884|NCT02561078|DRUG|Human regular U-500 insulin (MDI)|Administered SC
223969885|NCT00575367|DRUG|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
223969886|NCT00575367|DRUG|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
224113756|NCT00184912|DRUG|caffeine|
223969887|NCT02534753|DRUG|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
223969888|NCT03014817|PROCEDURE|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
223969889|NCT03014817|PROCEDURE|Electrocautery|Dissection with electrocautery
223969890|NCT02881021|OTHER|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
223969891|NCT02881021|DEVICE|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
224113757|NCT00184912|DRUG|Technetium-TC99m-labeled Annexin A5|
224113758|NCT00184912|PROCEDURE|ten minutes forearm ischemia|
223725027|NCT00955591|OTHER|Papanicolaou test|
224113759|NCT00184912|PROCEDURE|ischemic forearm exercise|
224113760|NCT03632512|DIETARY_SUPPLEMENT|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
223969892|NCT02475876|DRUG|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose =12 mg/kg;~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose =12 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose =12 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose =10 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose =10 mg/kg."
223969893|NCT02475876|DRUG|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~* Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~* Cohort 2; No. Subjects = 5; Age \>5 months to 1 year; Dose = 6 mg/kg.~* Cohort 3; No. Subjects = 5; Age \>1-2 years; Dose = 6 mg/kg.~* Cohort 4; No. Subjects = 4; Age \>2-6 years; Dose = 6 mg/kg.~* Cohort 5; No. Subjects = 4; Age \>6-12 years; Dose = 6 mg/kg.~* Cohort 6; No. Subjects = 4; Age \>12-16 years; Dose = 4 mg/kg."
223969894|NCT04164498|OTHER|music|exposure to music to investigate its effects on reducing noise adverse effects
223969895|NCT01750086|DRUG|Teriparatide 40-mcg subcutaneous injection|
223969896|NCT01750086|DRUG|Denosumab Injection|One-time Denosumab injection
224113761|NCT03632512|DIETARY_SUPPLEMENT|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
224113762|NCT04556331|BEHAVIORAL|Parenting programme (cognitive behavioural) aimed at reducing generational transmission of anxiety|'Psychoeducation' (psychologically informed information about the topic of transmitting anxiety) and cognitive-behavioural strategies aimed at reducing the transmission of anxiety from parent to young child. These will be shared with a group of maximum 8 remotely delivered, in a didactic format.
224113763|NCT02404831|OTHER|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
223725028|NCT01103011|DRUG|ND0611|Continuous delivery of ND0611
223969897|NCT01750086|DRUG|Alendronate Oral Tablet|weekly alendronate for 8 weeks
224291768|NCT04654689|DIETARY_SUPPLEMENT|Liposomed polyphenols resveratrol and curcumin|Combination of resveratrol (75mg) and curcumin (200mg) liposomed
223969898|NCT03015597|BEHAVIORAL|Contingency Management|Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
223969899|NCT00003133|BIOLOGICAL|filgrastim|
223969900|NCT00003133|DRUG|cisplatin|
223969901|NCT00003133|DRUG|doxorubicin hydrochloride|
223969902|NCT00003133|DRUG|gemcitabine hydrochloride|
223969903|NCT00003133|DRUG|paclitaxel|
223969904|NCT06383429|OTHER|forward head posture by using mobile application. And patients will fill out headache disability index.|forward head posture by using mobile application. And patients will fill out headache disability index.
223969905|NCT01984749|DRUG|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~1. The starting dose of the investigational product (febuxostat) will be 10 mg/day.~2. The dose will be increased to 20 mg/day at Week 4.~3. The aim is to increase the dose to 40 mg/day at Week 8."
223969906|NCT04252300|DRUG|Rosuvastatin|Single dose of 5 mg rosuvastatin is administered as tablet orally on Day 1 of Period 1 (total length = 5 days).
224113764|NCT02404831|OTHER|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
224113765|NCT03894904|DRUG|Papaverine|0.12 mg/mL papaverine administered as soon as the arterial catheter is placed and secured, and 0.12 mg/mL papaverine administered one hour after initial dose
224113766|NCT03894904|DRUG|Heparin|2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
224113767|NCT03894904|DRUG|Rescue papaverine, as needed|If the arterial catheter spasm/patency or waveform does not improve 10 minutes after the second papaverine plus heparin or heparin only dose, then the anesthesiology care team will consider treating clinically with 0.3 mg of papaverine.
224113768|NCT05032833|DRUG|5-MeO-DMT|A single dose of 5-MeO-DMT will be administered intranasally
224113769|NCT05032833|OTHER|Placebo|A single dose of placebo will be administered intranasally
223725029|NCT01103011|DRUG|ND0611|Solution of ND0611 delivered continuously
223969907|NCT04252300|DRUG|Rosuvastatin + BAY1817080|A single dose of 5 mg rosuvastatin tablets is administered on Day 8 of Period 2 (total length = 15 days). BAY1817080 is administered as tablets twice daily on Days 1 to 14 of Period 2.
223969908|NCT02288364|DRUG|1% Lidocaine|
223969909|NCT02288364|DRUG|1% Lidocaine plus sodium bicarbonate|
223969910|NCT03555708|OTHER|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
223969911|NCT00043186|DRUG|Placebo|Placebo subcutaneous injection
223969912|NCT00043186|DRUG|Denosumab|Denosumab for subcutaneous injection
223969913|NCT00043186|DRUG|Alendronate|Alendronate 70 mg tablets
224113770|NCT06338059|OTHER|Vitamin B12 Level|Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
223542866|NCT02053844|OTHER|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
223542867|NCT02053844|OTHER|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
224113771|NCT04272905|OTHER|Non-interventional study|The participants will be asked to complete a questionnaire on their knowledge of, and attitudes towards the recording of patient care by patients or relatives/friends in the maternity unit. An investigator will be immediately available to facilitate completion of the survey and assist with understanding of the questions. The data recorded will be a mixture of nominal data (selections from a number of options using a tickbox) or ordinal (as above, but graded e.g. yes / yes with qualifiers / no). Free text will be coded and presented as nominal data or presented verbatim to illustrate points that arise.
224113772|NCT02190435|DEVICE|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
224113773|NCT02190435|DEVICE|Conventional technique|Conventional Technique
223542868|NCT00387088|DEVICE|Respimat|
223542869|NCT00387088|DRUG|Tiotropium|
223542870|NCT03238989|OTHER|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
223542871|NCT02611102|DIETARY_SUPPLEMENT|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
223725030|NCT04398498|DIAGNOSTIC_TEST|Diagnostic Test: TruGraf® Testing|5 mL collection PAXgene blood sample
224113774|NCT05552586|DIETARY_SUPPLEMENT|Melatonin|patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
223969914|NCT04077385|BEHAVIORAL|Retrieval-extinction (R-E) Training|The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip.
223969915|NCT04077385|BEHAVIORAL|Extinction Training|The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion of high calorie snack foods such as a single M\&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
223969916|NCT03181919|DRUG|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
223969917|NCT05668000|OTHER|Bluetooth-connected monitoring devices and a feedback system|"AIDA/KT-app with devices and feedback:~The mobile application provide self-management interventions with devices including sphygomanometer and body water meter and a feedback system"
223969918|NCT05668000|OTHER|Mobile application|The mobile application provide only self-management interventions.
224113775|NCT05552586|OTHER|placebo|patients will receive capsules of the same size and color
224113776|NCT00005029|DRUG|topotecan hydrochloride|
223542872|NCT02830243|DRUG|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
223969919|NCT02246634|OTHER|Diffusion Weighted MRI scan|Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.
223969920|NCT03032640|OTHER|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
223969921|NCT03032640|OTHER|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
223969922|NCT03032640|OTHER|Stool sampling|Subjects will provide a stool sample.
224113777|NCT00202410|BIOLOGICAL|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
223542873|NCT02830243|DRUG|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
223542874|NCT05363488|DRUG|Bosutinib|Patients receiving bosutinib treatment
224113778|NCT00202410|OTHER|placebo|subcutaneous administration of physiologic solution
224113779|NCT05515549|OTHER|Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers|"The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group."
224113780|NCT03136211|BEHAVIORAL|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
224113781|NCT01781026|DRUG|Vemurafenib|Single arm trial
224113782|NCT06671444|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
224113783|NCT06672276|DRUG|TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.
223969923|NCT03032640|OTHER|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
224113784|NCT06673420|OTHER|No Interventions|This is an observational study
224113785|NCT06672952|DIETARY_SUPPLEMENT|400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention consists of 400 mg of glucosyl-hesperidin (CITRAPEAK®) in capsule form.
224113786|NCT06672952|DIETARY_SUPPLEMENT|Placebo|The placebo intervention consists of 400 mg/day of cellulose in capsule form, matching the appearance and dosage of active interventions.
224291769|NCT04654689|OTHER|Placebo for liposomed resveratrol and curcumin|Water with sucrose replacing the liposomed polyphenols
223969924|NCT03032640|OTHER|Placebo|Subjects in group 2 will be provided with placebo.
223969925|NCT03032640|OTHER|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
223542875|NCT02015403|DRUG|Standard Care + NAC (N -ACETYLCYSTEINE)|
224113787|NCT06672952|DIETARY_SUPPLEMENT|200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation|The active intervention includes 200 mg of glucosyl-hesperidin (CITRAPEAK®) and an additional 200 mg of cellulose in capsule form.
224113788|NCT06672848|DIAGNOSTIC_TEST|Numeretic rating scale (NRS)|NRS is a pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
224113789|NCT06672848|DIAGNOSTIC_TEST|Brief Pain Inventory (BPI)|BPI is a chronic pain intensity determination system based on the person being asked to describe their pain on a scale of 0 (none), 10 (unbearable pain) and a point between.
224113790|NCT06672848|DIAGNOSTIC_TEST|The S-LANSS Pain Score|The Leeds assessment of neuropathic symptoms and signs (LANSS) Pain Scale is based on analysis of sensory description and bedside examination of sensory dysfunction, and provides immediate information in clinical settings. It was developed in two populations of chronic pain patients.
224113791|NCT05910801|PROCEDURE|Biopsy|Undergo biopsy
224291770|NCT04654689|DIETARY_SUPPLEMENT|Isocaloric Diet|40% carbohydrates, 40% lipids and 20% proteins
223969926|NCT03722485|DEVICE|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
223969927|NCT03722485|BIOLOGICAL|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
223969928|NCT03477409|OTHER|plasticizers|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
224113792|NCT05910801|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224113793|NCT05910801|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224113794|NCT05910801|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223969929|NCT00349622|DRUG|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
223969930|NCT00349622|OTHER|placebo|an inactive substance
223969931|NCT00121446|DRUG|tenecteplase|
223969932|NCT00121446|DRUG|enoxaparin|
223969933|NCT00121446|DRUG|clopidogrel|
223969934|NCT00121446|PROCEDURE|percutaneous coronary intervention|
223542876|NCT02015403|DRUG|Standard Care (in control arm)|
223969935|NCT06478108|DEVICE|IRSW-MIM|IRSW-MIM collects patient's data and outputs a therapeutical strategy for treating advanced solid tumors.
223969936|NCT06292559|DEVICE|Bilateral STN deep brain stimulation|patients with Meige syndrome underwent bilateral subthalamic stimulation
223969937|NCT06292559|DEVICE|Bilateral GPi deep brain stimulation|patients with Meige syndrome underwent bilateral pallidal stimulation
224113795|NCT05910801|PROCEDURE|Computed Tomography|Undergo CT scan
224113796|NCT05910801|DRUG|Lenalidomide|Given PO
224113797|NCT05910801|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224113798|NCT05910801|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224113799|NCT05910801|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224113800|NCT05910801|BIOLOGICAL|Tafasitamab|Given IV
224113801|NCT05910801|DRUG|Venetoclax|Given PO
224113802|NCT03998735|DRUG|Herbal Snuff (Smokeless Tobacco)|4 levels of \[D4\]nornicotine in herbal snuff
224291771|NCT04654689|DRUG|G04CB02|G04CB02, in a single daily dose for 2 months
224291772|NCT04654689|OTHER|Placebo microcrystalline methylcellulose|Placebo replacing G04CB02
224291773|NCT06157879|DEVICE|WVI-MIS-01-2022|Microwave scans
224291774|NCT06161441|DRUG|Fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
224291775|NCT06161441|DRUG|Cemiplimab|Administered IV Q3W
224291776|NCT06161441|DRUG|Pemetrexed|Administered IV Q3W
224291777|NCT06161441|DRUG|Paclitaxel|Administered IV Q3W
224291778|NCT06161441|DRUG|Carboplatin|Administered IV Q3W
224291779|NCT06161441|DRUG|Cisplatin|Administered IV Q3W
224291780|NCT06161441|DRUG|Placebo|Administered IV Q3W
224291781|NCT04868682|BEHAVIORAL|Behavioral Education Intervention I|Manual-based education program provided in individual sessions.
224291782|NCT04868682|BEHAVIORAL|Behavioral Education Intervention II|Manual-based education program provided in individual sessions.
224291783|NCT06807268|DRUG|Abrocitinib|Abrocitinib administered as liquid oral suspension.
224291784|NCT06807268|OTHER|Placebo|Placebo administered as liquid oral suspension.
223969938|NCT04662736|OTHER|patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy|description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
223969939|NCT01013688|PROCEDURE|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
223969940|NCT01902381|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
223969941|NCT06201715|DRUG|Tofacitinib 5 MG|5mg tofacitinib tablet twice daily
223969942|NCT00942513|OTHER|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
223969943|NCT00942513|OTHER|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
223969944|NCT00942513|OTHER|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
223969945|NCT00942513|OTHER|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
223969946|NCT00942513|OTHER|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
223969947|NCT00942513|OTHER|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
223969948|NCT00942513|OTHER|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
223969949|NCT06632925|PROCEDURE|Catheter ablation|"The catheter ablation strategy is the same as the current treatment approach in patients with AF, according to the consensus of catheter ablation of AF. All procedures will be performed under local sedation or general anesthesia depending on the operator, and each patient will undergo an electrophysiological study and substrate mapping in the fasting state with adequate pre-ablation anticoagulation and transesophageal echocardiography to rule out LA thrombus. All antiarrhythmic drugs except amiodarone will be discontinued for at least 5 half-lives before the procedure.~Step I: Substrate mapping before ablation, Step II: Pulmonary vein isolation (PVI), Step III: Post-ablation mapping in SR immediately after ablation, Step IV: Inducibility after ablation, Step V: Remmaping 30 minutes after ablation"
223969950|NCT04100239|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
223725031|NCT03758274|BEHAVIORAL|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
223969951|NCT06170502|DEVICE|Using the mobile application and applying the survey|"In the study, The Form for Determining the Educational Needs of Parents Administering Medicines at Home, Introductory Information Form, Parental Drug Preparation Information Evaluation Form, Parent Evaluation Form in Suspension Drug Administration, Capsule Drug Application Parent Evaluation Form, developed by the researchers in line with the literature, Tablet Pharmaceutical Application Parent Evaluation Form, Mobile Application Usability Questionnaire, AkilMobil Expert Opinion Evaluation Form and STAI State Anxiety Inventory developed by Spielberger et al. will be used."
224113803|NCT05270694|BEHAVIORAL|Public Health Intervention Package|"The intervention package consists of two components:~1. At the time of study enrollment, participants will attend an in-person training on how to properly take an at-home COVID-19 test. Study staff will verbally walk through the steps of the test with the participant while the participant administers the test on themselves, with the opportunity to ask questions and receive corrective feedback, as needed.~2. To make COVID-19 testing more accessible, participants will be provided five at-home COVID-19 testing kits at the training and then every other month throughout the course of the year-long study for a total of 35 kits."
224113804|NCT05989477|OTHER|At-home Breast Oncology care Delivered with E-health solutions - ABODE|The development and implementation of the Breast Cancer Treatment Application (BCTA) will facilitate a secure approach to virtual care for Breast Cancer patients, provide patient specific treatment education and facilitate evaluation of Patient Reported Outcome Measures.
224113805|NCT01991977|PROCEDURE|Diffusion Weighted Imaging|Undergo DTI
224113806|NCT01991977|DRUG|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
224291785|NCT03981445|BEHAVIORAL|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
223969952|NCT02759887|PROCEDURE|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
224113807|NCT01991977|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224113808|NCT01991977|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo pMRI
224113809|NCT01991977|PROCEDURE|Positron Emission Tomography|Undergo 18F-DOPA-PET
224113810|NCT01991977|OTHER|Quality-of-Life Assessment|Ancillary studies
224113811|NCT01991977|DRUG|Temozolomide|Receive temozolomide
224113812|NCT02311712|DEVICE|Capsule sponge|Capsule sponge cytology examination coupled with H\&E staining analysed for the presence of atypia and p53 immunohistochemistry
224113813|NCT05155631|BEHAVIORAL|COGNITIVE BEHAVIORAL THERAPY|8-10 week self directed on line CBT program approved by FDA
224113814|NCT04868773|DRUG|Cabozantinib|Oral cabozantinib
224113815|NCT04868773|DRUG|TAS-102|Oral TAS-102 (trifluridine and tipiracil)
224113816|NCT02166840|PROCEDURE|Plastic stent (7-10Fr)|
224113817|NCT02166840|PROCEDURE|Self Expanding Metal Stent|
224113818|NCT01818622|DEVICE|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
224113819|NCT01818622|DEVICE|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
223969953|NCT02759887|OTHER|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
224113820|NCT05934799|DRUG|Clopidogrel film-coated tablet 75 mg|Clopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
224113821|NCT05934799|DRUG|Plavix® film-coated tablet 75 mg|Plavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
224113822|NCT00814073|DRUG|Masitinib|Masitinib 6 mg/kg/day
223969954|NCT02759887|OTHER|caregiver questionnaire|
223969955|NCT02759887|PROCEDURE|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
223969956|NCT02759887|PROCEDURE|MRI|Magnetic resonance imaging of the head and brain.
223969957|NCT02759887|PROCEDURE|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
223969958|NCT02759887|PROCEDURE|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
223969959|NCT02759887|PROCEDURE|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
223969960|NCT03065205|DEVICE|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
223969961|NCT02182583|DRUG|Ba253MDI|
223969962|NCT02182583|DRUG|Ba253BINEB|
223969963|NCT02999932|OTHER|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
223969964|NCT00157690|DRUG|Alendronate|70 mg 1x weekly for 12 months
223969965|NCT00157690|DRUG|Placebo|70 mg 1 x weekly for 12 months
223969966|NCT00887185|OTHER|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
223969967|NCT05382910|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
223969968|NCT05382910|DRUG|Placebo|Placebo
223969969|NCT02977780|DRUG|Temozolomide|Temzolomide capsules
223969970|NCT02977780|DRUG|Neratinib|Neratinib tablets
223969971|NCT02977780|DRUG|QBS10072S|QBS10072S administered intravenously
223969972|NCT01341444|DEVICE|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
223969973|NCT01341444|OTHER|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
223969974|NCT05311774|DRUG|Duloxetine 30 mg|tablet
223969975|NCT05311774|DRUG|Tramadol|tablet
223969976|NCT05311774|DRUG|Placebo|tablet
223969977|NCT06268431|OTHER|Oxytocin rest|60-minute oxytocin rest
223969978|NCT05138432|BEHAVIORAL|Fruit and Vegetable Prescription Voucher|Each participant will immediately (intervention group) or after a 6-month waiting period (delayed-intervention group) receive seven $15 vouchers (value $105 per month) for 12 months. Up to 4 vouchers ($60 total) can be redeemed at any one transaction for purchase of fresh fruits and vegetables, dried beans and legumes at participating Northgate Gonzalez markets. Both groups will continue to receive diabetes and nutrition education as is standard in their practice.
224113823|NCT00814073|DRUG|Placebo|Matching placebo
224113824|NCT00814073|OTHER|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
224113825|NCT01772342|OTHER|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
224113826|NCT01772342|OTHER|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
223969980|NCT05082233|DRUG|SHR7280 tablets|Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；
223969981|NCT00038298|DRUG|Placebo|Placebo given 3 times weekly
223969982|NCT00038298|DRUG|AMG 719|50 mg 3 times weekly
223969983|NCT00038298|DRUG|AGM 719|200 mg 3 times weekly
223969984|NCT00038298|DRUG|AMG 719|400 mg 3 times weekly
223969985|NCT00038298|DRUG|placebo to AMG 719|Placebo dose given 3 times weekly
223969986|NCT00755716|DRUG|Placebo (sugar pill)|patients receive
223969987|NCT00755716|DRUG|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
223969988|NCT00755716|DRUG|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
223969989|NCT02394509|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
223969990|NCT02762500|DRUG|LYC-30937-EC|
223969991|NCT02762500|DRUG|Placebo|
223969992|NCT04143737|BEHAVIORAL|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
223969993|NCT02312609|DRUG|Minocycline hydrochloride|extended release tablets 135 mg
223969994|NCT02763150|BEHAVIORAL|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
223969995|NCT02763150|OTHER|Health Promotion|The health promotion group will receive education on healthy eating and activity
223969996|NCT02609035|BEHAVIORAL|Telephonic prompt|
223969997|NCT05278065|OTHER|Nicotine|Participants will be provided with electronic cigarettes and 5% nicotine e-liquid cartridges for 8 weeks and encouraged at weekly assessments to use the electronic cigarette any time they would normally smoke. Participants will be able to choose commercially available e-liquid flavors (tobacco) at each weekly assessment.
223969998|NCT04598945|OTHER|Functionel MRI|During the activation fMRI sequences, the subject will perform target pointing tasks, that is to say that he will have to reach, by controlling a cursor using a non-magnetic joystick, targets projected onto a display screen. In each of the pointing tasks he will have to reach the target as quickly and as precisely as possible, and stay in the center of it for a long time times reached.
223969999|NCT02229396|DRUG|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
223970000|NCT02229396|DRUG|Exentide|2 mg
223970001|NCT02229396|DRUG|Dapagliflozin|10 mg once daily Dapagliflozin
223970002|NCT00349245|DRUG|Remifentanil|
223970003|NCT00349245|DRUG|Dexmedetomidine|
223970004|NCT00730847|BIOLOGICAL|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
223970005|NCT00333502|DRUG|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
223970006|NCT02733835|DRUG|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
223970007|NCT04767802|DRUG|PTG-300|Hepcidin mimetic
223970008|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily.
223970009|NCT04655183|DRUG|M4344|M4344 will be administered once daily or on an intermittent schedule in combination with niraparib.
223970010|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally once daily at the RDE as determined in Part 1 of this study.
223970011|NCT04655183|DRUG|M4344|M4344 will be administered at a dose and schedule that was determined as RDE in Part 1A in combination with niraparib.
223970012|NCT04655183|DRUG|Niraparib|Niraparib will be administered orally, once daily. Dose of niraparib will be escalated beyond the dose in Part 1A.
223970013|NCT04655183|DRUG|Niraparib|Niraparib will be administered as single agent at the approved dose.
223970014|NCT03460847|DRUG|Steroids|Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
223970015|NCT04514796|DRUG|Adalimumab|SB5 (adalimumab), 40 mg, single-dose
223970016|NCT01111136|BEHAVIORAL|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
224113827|NCT03260335|BEHAVIORAL|Anxiety management strategy|Anxiety management strategy as per standard care plan
223542877|NCT03401437|BEHAVIORAL|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
223542878|NCT03401437|BEHAVIORAL|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
223542879|NCT03401437|OTHER|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
223725032|NCT03758274|OTHER|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
223725033|NCT00822991|DEVICE|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
223725034|NCT00822991|DEVICE|B-mode US|screening by conventional B-mode US every 3-5 months
223725035|NCT00793403|OTHER|As per routinary clinical care|As per routine clinical care
224113828|NCT01053624|PROCEDURE|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
224113829|NCT02963727|BIOLOGICAL|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
224113830|NCT04160156|DEVICE|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
224113831|NCT04383977|DRUG|Apatinib and Etoposide capsule|Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
224113832|NCT04383977|DRUG|Apatinib|Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
223725036|NCT05058248|PROCEDURE|pudendal block|general anesthesia with an intravenous analgesic protocol then oral without anesthesia regional loco
223725037|NCT04081168|DEVICE|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
223725038|NCT04081168|DEVICE|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
223725039|NCT06125353|DIETARY_SUPPLEMENT|Melatonin|Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
224113833|NCT03766334|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
223970017|NCT03577756|OTHER|Neurodevelopmental assessments|Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
224113834|NCT05184296|PROCEDURE|Extracorporeal Membrane Oxygenation (ECMO)|All patients in cohort 1 will initiate ECMO as fast as possible. A maximum of 6 hours is allowed between enrollment and the actual initiation of ECMO. ECMO catheterization and management will be operated by an experienced ECMO team and carried out at the bedside. VA or VAV mode will be chosen according to the patient's condition.
224113835|NCT01240811|DRUG|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
224113836|NCT01240811|DRUG|Levonorgestrel IUD|
224113837|NCT01240811|DRUG|Copper T380A IUD|
223970018|NCT03022578|PROCEDURE|Laser Interstitial Thermal Therapy|Undergo LITT
223970019|NCT03022578|DRUG|Lomustine|Given PO
223970020|NCT06479551|OTHER|high intensity-low volume resistance training|13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
223970021|NCT06479551|OTHER|Moderate intensity-high volume resistance training|13 participants will be in control group giving them Moderate intensity-high volume resistance training of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
223970022|NCT02625129|OTHER|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
223970023|NCT06235385|OTHER|Intervention not provided|This study is purely observational
223970024|NCT00823004|DRUG|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
223970025|NCT00823004|DRUG|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
223970026|NCT00823004|DRUG|GnRH agonist (buserelin)|50 µg SC twice daily
223970027|NCT00823004|DRUG|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
224113838|NCT04907006|DRUG|SY-004 capsule|After fasting for 10 hours, subjects in group 1 took one SY-004 (80mg) orally on an empty stomach on the day of administration with 240ml warm water; Subjects in group 2 began to eat high-fat breakfast 30 minutes before administration , and took one SY-004 capsule（80mg） orally with 240ml warm water. The subjects in both groups were fasted within 4 hours after taking the medicine, and drinking water was forbidden within 1 hour before and after taking SY-004.
224113839|NCT03990766|DRUG|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
224113840|NCT03990766|DRUG|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
224113841|NCT05521685|PROCEDURE|Endoscopic Ultrasound (EUS) administration of cyanoacrylate tissue adhesive to control bleeding gastric varices|Subjects will have undergone treatment and been enrolled into the existing registry.
224113842|NCT00075244|DRUG|Replagal|
224113843|NCT01550718|BEHAVIORAL|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
223970028|NCT00823004|DRUG|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
223970029|NCT04656860|DIETARY_SUPPLEMENT|Juice Plus+|Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period
223970030|NCT04517877|BEHAVIORAL|Caring Response App|Participants will receive the Caring Light mobile app containing the coping skills training.
223970031|NCT04517877|BEHAVIORAL|Traditional Educational/Resources Program|Participants will receive a traditional educational/resources program, containing a workbook and online resources.
224113844|NCT01550718|BEHAVIORAL|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
224113845|NCT04437017|DRUG|Olanzapine+NK-1 RA+5-HT3 RA|On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
224113846|NCT04437017|DRUG|Dexamethasone+NK-1 RA+5-HT3 RA|On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
224113847|NCT02232672|DEVICE|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
224113848|NCT01543490|DRUG|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
224113849|NCT01543490|OTHER|Vehicle|Vehicle twice daily for 2 weeks
224113850|NCT06290830|BEHAVIORAL|Abdominal massage group|abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.
224113851|NCT06290830|BEHAVIORAL|Kegel Exercises group|Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles
223542880|NCT06563947|BIOLOGICAL|Oral enterobacterium capsules|Enterobacterium capsules (300 mg/per capsule) orally 6 capsules/day for 10 consecutive days.
223542881|NCT02665533|DRUG|Dexamethasone|Dexamethasone 8 mg
223542882|NCT02665533|DRUG|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
223970032|NCT00397137|PROCEDURE|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
223970033|NCT00397137|PROCEDURE|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
223970034|NCT05142072|DRUG|Vitamin D3|intranasal film
223970035|NCT04703868|DRUG|Rabeprazole Sodium 10mg|Part A: 1 tablet administered before the breakfast during 7 days
223970036|NCT04703868|DRUG|Rabeprazole Sodium 20mg|Part B: 1 tablet administered before the breakfast during 7 days
223970037|NCT03245762|DRUG|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
223970038|NCT03245762|DRUG|Placebo|4 IU/day of placebo administered via nasal spray device each morning
223970039|NCT05056701|OTHER|annual follow-up during 10 years|an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
223970040|NCT03498586|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
223970041|NCT03498586|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
223970042|NCT03474042|DRUG|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
223970043|NCT03474042|DRUG|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
223970044|NCT02773407|DRUG|Azithromycin|
223970045|NCT02773407|DRUG|Co-trimoxazole|
223970046|NCT04406142|DEVICE|VISUAL|thin catheter insertion between vocal cords under direct specially adapted videolaryngoscopy
223970047|NCT01304251|OTHER|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
223970048|NCT01304251|OTHER|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
223970049|NCT03681353|BEHAVIORAL|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
223970050|NCT00873561|DRUG|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
223970051|NCT00476918|DRUG|Intravitreal injection (triamcinolone acetonide)|
223970052|NCT03935932|DEVICE|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
223970053|NCT01997749|DIETARY_SUPPLEMENT|Ketocal 4:1 (Nutricia)|
223970054|NCT01997749|DIETARY_SUPPLEMENT|Control diet: Regular diet offered at the hospitals|
223970055|NCT01997749|DIETARY_SUPPLEMENT|Ketogenic meals|
223970056|NCT00002432|DRUG|Foscarnet sodium|
223970057|NCT01295775|DRUG|sulodexide|"A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
223970058|NCT00960284|DRUG|capecitabine|Given orally
223970059|NCT00960284|DRUG|cisplatin|Given IV
223970060|NCT00960284|DRUG|epirubicin hydrochloride|Given IV
223970061|NCT00960284|DRUG|fluorouracil|Given IV
223970062|NCT00960284|DRUG|gemcitabine hydrochloride|Given IV
223970063|NCT05065892|BIOLOGICAL|COVAX|2 doses of Covid-19 vaccine
223970064|NCT02358499|DRUG|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
223970065|NCT03113214|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
223970066|NCT03113214|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
223970067|NCT03113214|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
223970068|NCT03113214|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
223970069|NCT03113214|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
223970070|NCT03113214|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
224113852|NCT06290830|BEHAVIORAL|Both abdominal massage and kegel exercises to gether|with both exercises are performed to accelerate the peristalsis movement by mechanical movements
224113853|NCT05445622|OTHER|learning spinal mobilization with a force sensor|Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
224113854|NCT04435262|OTHER|Remote Monitoring|Remote Monitoring Follow-up
224113855|NCT03026504|DRUG|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
224113856|NCT05005559|BIOLOGICAL|SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant|SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
224113857|NCT05005559|BIOLOGICAL|Saline placebo|0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the deltoid muscle of the non-dominant arm
224113858|NCT01797276|DRUG|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
224113859|NCT06369675|DRUG|MOB015B|Topical formulation
224113860|NCT06369675|DRUG|0.2% SLS|Positive control
224113861|NCT06369675|DRUG|0.9% Saline|Negative control
224113862|NCT06369675|DRUG|MOB015B vehicle|Topical formulation
224113863|NCT05128435|DIAGNOSTIC_TEST|Blood sample|Blood sample taken 3 to 5 months after the infection
224113864|NCT04484779|DEVICE|IIM System|IIM System
224113865|NCT04484779|DRUG|Insulin Lispro and/or Insulin Glargine|Administered subcutaneously (SC)
224113866|NCT02219555|DRUG|Steroid Injection|volume and specific steroid drug will be based on the recommendation of the treating clinician
224113867|NCT02219555|PROCEDURE|Carpel Tunnel surgery|Standard of care carpel tunnel surgery
224113868|NCT05121727|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
224113869|NCT05121727|PROCEDURE|Deep and Superficial Serratus Anterior Plane Block|Combined Deep and Superficial Serratus Anterior Plane Block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position. 20 ml of 0.25% bupivacaine will be used in applications.
224113870|NCT01655264|BEHAVIORAL|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
224113871|NCT01655264|BEHAVIORAL|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
224113872|NCT03225781|DEVICE|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
224113873|NCT06255470|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
224113874|NCT06257498|PROCEDURE|MRI scan|MRI scan on open scanner and some questionnaires
224113875|NCT01458444|DEVICE|Non invasive ventilation (VNI)|BIPAP® vision
224113876|NCT01458444|DEVICE|Non invasive ventilation|OPTIFLOW system
223970071|NCT05092477|BEHAVIORAL|Integrated Intervention for Breast Cancer Survivors with Diabetes|"All pilot participants will be required to have a SMB target to be included in this study. A SMB target will be chosen by the participant after reviewing their 18mo follow-up responses with the Care Coach. Participants may endorse a maladaptive belief or emotional response; however, this is not required to participate in this intervention. At each follow-up session, the Care Coach will review the participant's SMB goal and progress, address participant's challenges and suggest alternatives, and correct further misinformation on the disease(s). Additionally, the Care Coach will reinforce or introduce techniques that could help overcome barriers to reaching SMB goal and recommend participants to continue improving on the same goal or begin action planning towards a new SMB goal.~1. Just SMB concern~2. SMB + maladaptive belief + emotional response~3. SMB + maladaptive belief~4. SMB + emotional response"
223970072|NCT05092477|BEHAVIORAL|Attention Control|Participants in the control arm will receive a brochure to discuss healthy lifestyle behaviors to improve DM management. To control for the potentially confounding effect of personalized attention from the care coach on the relationship between the intervention and outcomes, participants also receive 4 calls to discuss study progress, thoughts and feelings about study/illness/behaviors, remind them about returning their pill bottles, and about scheduling for their upcoming 24mo follow-up study interview.
223970073|NCT05439525|OTHER|mulligan technique|The patient will be in sitting and the therapist stands on the contralateral side of pain, stabilizing the scapula posteriorly with one hand. The head of the humerus is translated posteriorly and laterally with the other hand, along the plane of the glenoid fossa. While the glide is sustained, the patient actively elevates their arm through the plane of abduction or scaption (elevation). Apply 6-10 repetitions in a set, with 3-5 sets in a treatment session the perform mobilization on acromioclavicular and sternoclavicular joint
223970074|NCT05439525|OTHER|conventional therapy|"1. Flexibility exercises: enhance flexibility of the glenohumeral Posterior capsule, pectoralis muscle, and upper thoracic spine.~2. Strengthen the rotator cuff and scapular stabilizers.~3. Improve upper-quarter postural awareness"
223970075|NCT03630783|BEHAVIORAL|Combined Cognitive Bias Modification|
223970076|NCT00982540|DRUG|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
224113877|NCT03995238|BEHAVIORAL|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
224113878|NCT03995238|BEHAVIORAL|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
224113879|NCT03995238|BEHAVIORAL|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
224113880|NCT03546725|DEVICE|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
224113881|NCT05380297|DEVICE|Speech analysis|Speech analysis to detect and monitor mild cognitive impairment
224291786|NCT03981445|BEHAVIORAL|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
224113882|NCT04904653|DEVICE|Hemopatch|"HEMOPATCH Sealing Hemostat (HEMOPATCH) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).~Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.~HEMOPATCH is supplied in the following 3 sizes:~* HEMOPATCH 27 x 27 mm~* HEMOPATCH 45 x 45 mm~* HEMOPATCH 45 x 90 mm"
224113883|NCT04904653|OTHER|Control group|No sealant (liquid, gel or patch) + suction drain
224113884|NCT04043507|OTHER|Sample Collection|Blood and urine samples will be collected for research purposes along with the routinely collected blood and urine samples that are collected as part of the standard of care.
224113885|NCT01101568|DRUG|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
224113886|NCT01101568|DRUG|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
224113887|NCT01101568|DRUG|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
224113888|NCT05835752|DRUG|RAY1225|Administered SC
224113889|NCT05835752|DRUG|Placebo|Administered SC
224113890|NCT05835752|DRUG|RAY1225|Administered SC
223970077|NCT02456298|BEHAVIORAL|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
223970078|NCT02456298|BEHAVIORAL|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
223970079|NCT05135923|DIETARY_SUPPLEMENT|Randomized, controlled trial (RCT) with parallel arms and double blinded|Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
223970080|NCT00726388|DRUG|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
223970081|NCT02072798|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
223970082|NCT01924637|DRUG|Faster-acting insulin aspart|"A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
223970083|NCT01924637|DRUG|insulin aspart|"A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
223970084|NCT05415644|DRUG|hrx0701 tablets、Metformin hydrochloride tablets、Retagliptin phosphate tablets|"High-specification group: subject preparation: HRX0701 (50 mg/1000 mg) 1 tablet (to be taken after a meal); Reference preparation: 1 tablet of retagliptin phosphate (50 mg), 2 tablets of metformin hydrochloride (Glucophage®) (500 mg), taken twice after meals.~Low Specification Group:~Preparation: HRX0701 (50 mg/850 mg) 1 tablet (taken after a meal); Reference: 1 tablet of retagliptin phosphate (50 mg), 1 tablet of metformin hydrochloride (Glucophage®) (850 mg), taken twice after meals."
223970085|NCT05415644|DRUG|hrx0701 tablets|"High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach)."
223970086|NCT04105062|DRUG|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
223970087|NCT04105062|DEVICE|Cancer Vision Goggles|-Non-significant risk device
223970088|NCT01257412|DRUG|Dapagliflozin|5mg Oral dose od
223970089|NCT01257412|DRUG|Dapagliflozin|10 mg Oral dose od
224113891|NCT05835752|DRUG|Placebo|Administered SC
224113892|NCT05835752|DRUG|RAY1225|Administered SC
224113893|NCT05835752|DRUG|Placebo|Administered SC
224113894|NCT00004895|DRUG|octreotide acetate|
224113895|NCT01213433|DRUG|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
224113896|NCT01976819|DEVICE|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
224113897|NCT05055115|PROCEDURE|Balloon Eustachian Tuboplasty|Balloon Eustachian Tuboplasty of the cartilaginous part of ET. The procedure is performed endonasally under general anesthesia. It is believed that BET leads to micro-bleeding in the mucosa with subsequent scarring and expansion of ET.
224113898|NCT03789682|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
223970090|NCT01257412|DRUG|placebo|5/10 mg Oral dose od
223970091|NCT03207620|DIAGNOSTIC_TEST|using serum periostin and eotaxin-2 level|"collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity."
224113899|NCT03918642|BEHAVIORAL|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
223970092|NCT03207620|DIAGNOSTIC_TEST|airway corticosteroid sensitivity|each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
223970093|NCT02682004|OTHER|leptin, serotonin and adiponectin level|
223970094|NCT02682004|OTHER|leptin,serotonin, adiponectin level|
223970095|NCT00111839|DRUG|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
223970096|NCT00111839|DRUG|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
223970097|NCT04323111|PROCEDURE|metzenbaum's technique|surgical procedure for correction of caudal end nasal septal deviation
223970098|NCT04768751|DIAGNOSTIC_TEST|kidney assessment|Urea, BUN, and Creatinine BLOOD LEVELS
223970099|NCT00626158|DRUG|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
223970100|NCT00626158|DRUG|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
224113900|NCT03918642|BEHAVIORAL|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
224113901|NCT04349995|DEVICE|Amplatzer PFO Occluder|Percutaneous PFO closure using Amplatzer PFO Occluder
224113902|NCT06491823|BEHAVIORAL|Adaptation|Auditory adaptation in speech
224113903|NCT06491823|BEHAVIORAL|Adaptation baseline|Auditory baseline in speech
224113904|NCT06491823|DEVICE|Motor evoked potentials|motor evoked potentials will be obtained in each recording block
224113905|NCT06491823|DEVICE|Auditory evoked potentials|auditory evoked potentials will be obtained in each recording block
224113906|NCT06491823|DEVICE|Somatosensory evoked potentials|Somatosensry evoked potentials will be obtained in each recording block
223970101|NCT05971186|DRUG|Ibuprofen 400 mg|Dosage Form: Tablet Dosage: 1 tablet of Ibuprofen (400 mg) Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption
223970102|NCT05971186|OTHER|Young Coconut Water|Dosage Form: Liquid (coconut water) Dosage: 330 ml (milliliters) of young coconut water Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
223970103|NCT05971186|OTHER|Dark Chocolate Bar|Dosage Form: Solid (dark chocolate bar) Dosage: 35 grams of 70% dark chocolate Frequency: One-time consumption Duration: Pain intensity measured before consumption and two hours after consumption.
223970104|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
223970105|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
223970106|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
223970107|NCT01011049|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
223970108|NCT01532102|DRUG|AP611074|
223970109|NCT01532102|DRUG|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
223970110|NCT00478439|DIETARY_SUPPLEMENT|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
223970111|NCT00478439|DIETARY_SUPPLEMENT|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
223970112|NCT00382408|BIOLOGICAL|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
223970113|NCT00382408|OTHER|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
224113907|NCT03478124|BEHAVIORAL|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
224113908|NCT06513767|DEVICE|Zirconia Dental Ceramics|This investigation was conducted by enrolling subjects who met the enrolment criteria, using the investigational device (Zirconia Dental Ceramics) to perform dental prosthesess.
223970114|NCT05319002|BEHAVIORAL|Group EMDR|The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure \& future template: Strong closure with artwork. 8. Re-evaluation: if possible.
223970115|NCT06162637|DEVICE|femoral neck locking plate|femoral neck fractures fixation by femoral neck locking plate
223970116|NCT06162637|DEVICE|multiple cannulated cancellous screws|femoral neck fractures fixation by multiple cannulated cancellous screws
223970117|NCT01090232|OTHER|blood samples|
223970118|NCT01090232|OTHER|blood samples|
223970119|NCT03753750|DEVICE|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
223970120|NCT01347281|PROCEDURE|Injection of [18F]HX4|"Injection of \[18F\]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~\[18F\]HX4 PET scans; 444 MBq (12 mCi) \[18F\]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of \[18F\]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): \[18F\]FDG PET in treatment position"
223970121|NCT04589390|DRUG|Selexipag|treatment with selexipag
223970122|NCT05161143|DRUG|Donafenib|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,patients will receive TACE once."
223970123|NCT00871143|BEHAVIORAL|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
223970124|NCT00871143|BEHAVIORAL|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
223970125|NCT04835233|DRUG|Methyldopa 250 MG|maintaining postpartum the use of methyldopa 250 mg 01 tablet every 8 hours, being able to double the dose depending on pressure levels, up to 15 days postpartum
223970126|NCT01150019|OTHER|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
223970127|NCT05867550|DRUG|Rifaximin 550 MG|Rifaximin 550 MG Oral Thrice Daily for 2 weeks will be included in all three treatment regimes i.e A, B and C
223970128|NCT05867550|DRUG|Mebeverine 135 MG|Mebeverine 135 MG Oral Twice Daily for 2 weeks will be included in Group A Treatment Regimes
223970129|NCT05867550|DRUG|Psyllium Husk|Psyllium Husk 15-35 MG Oral Once Daily for 2 weeks will be included in Group C Treatment Regimes
224291787|NCT02027870|DEVICE|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
224113909|NCT03825042|DIETARY_SUPPLEMENT|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
224113910|NCT03825042|DIETARY_SUPPLEMENT|Placebo|Inactive compound in oral tablets
224113911|NCT02385032|DRUG|Ursodiol|
224291788|NCT06406569|DEVICE|H-Man Robot|The HMAN is certified as a CE class 2A upper limb rehabilitation robot suitable for hospital, clinic and home-based use in 2020 by Health Sciences Authority, Singapore. It has since been employed in post-stroke neurorehabilitation therapy and assessment of sensorimotor functions in stroke patients.
224113912|NCT02385032|DRUG|URSO Forte|
224113913|NCT00805883|PROCEDURE|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
224113914|NCT05801523|PROCEDURE|laparoscopic ethanol sclerotherapy|ethanol (96%) sclerapy of endometrioma - endometrioma is filled with ethanol via foley catether, left for 10 min and than aspirated, endometrioma is washed with saline
224113915|NCT05801523|PROCEDURE|laparoscopic cystectomy of endometrioma|cystectomy of endometrioma - removal of endometrioma from ovary surgically
224113916|NCT06352216|DIAGNOSTIC_TEST|Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)|Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
224113917|NCT05995522|DIETARY_SUPPLEMENT|Vitamin K2|100 µg per day for 90 days
224113918|NCT05995522|OTHER|Cornstarch|500 mg per day for 90 days
224113919|NCT01959555|OTHER|No treatment given|Patients will not be treated with any specific product. Data collection only.
224291789|NCT06406569|DEVICE|ReHandyBot|ReHandyBot is the portable version of ReHapticKnob a robot developed at ETH Zurich that provides neurocognitive therapy, focusing on hand opening and closing movements as well as prono-supination of the forearm.
224291790|NCT06406569|DEVICE|MyoPanda|MyoPanda is a passive wrist/hand device which patients use to train the hand and wrist function by controlling a virtual avatar with EMG activity measures.
223970130|NCT05867550|DRUG|Amitriptyline Hydrochloride 25 MG|Amitriptyline Hydrochloride 25 MG Oral Once Daily for 2 weeks will be included in Group B Treatment Regimes
223970131|NCT03686241|PROCEDURE|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
223970132|NCT03686241|DEVICE|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
223970133|NCT03198936|DIETARY_SUPPLEMENT|Cognizin® SynapsaTM|2 capsules to be taken twice a day with meals with a glassful of water
223970134|NCT03198936|DIETARY_SUPPLEMENT|Placebo|2 capsules to be taken twice a day with meals with glassful of water
223970135|NCT00352053|DRUG|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
223970136|NCT00352053|DRUG|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
223970137|NCT02591797|PROCEDURE|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~1. Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~2. Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~3. anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~4. Syringe: carpule syringe-conventional harpoon with suction system."
224113920|NCT01943630|DRUG|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
223970138|NCT05871918|DRUG|TCbHP VS ddEC-THP|The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
223542883|NCT05587660|PROCEDURE|Fully threaded cannulated screws|The most popular method in undisplaced neck of femur fracture include internal fixation by cannulated screws in which screws can be inserted relatively simply and atraumatically as compared to other methods. Screws can be used partially threaded or fully threaded; however studies on fully threaded screw fixation method are inconclusive.
223542884|NCT02178800|DRUG|GSK1265744 Tablets|30-mg tablets, taken orally
223542885|NCT02178800|DRUG|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
223970139|NCT01921777|DRUG|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
223970140|NCT01921777|DRUG|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
223970141|NCT04751461|OTHER|Product A|P0213420, a 1.8% nicotine ENDS product
223970142|NCT04751461|OTHER|Product B|P0213520, a 1.8% nicotine ENDS product
223970143|NCT04751461|OTHER|Product C|P0211220, a 1.8% nicotine ENDS product
223970144|NCT04751461|OTHER|Product D|P0211820, a 1.8% nicotine ENDS product
223970145|NCT04751461|OTHER|Product E|P0213417, a 2.4% nicotine ENDS product
223970146|NCT01828398|DEVICE|real-tDCS + UE robot-assisted therapy|
223970147|NCT01828398|DEVICE|sham-tDCS + UE robot-assisted therapy|
223970148|NCT03849521|DIAGNOSTIC_TEST|MRI|Enhanced carotid calcification presented by UTE MR.
223970149|NCT02969005|RADIATION|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
223970150|NCT05816577|DIETARY_SUPPLEMENT|EcN Colibactin knockout|E coli Nissle strain with ClbP-gene removed and therefore not producing colibactin
223970151|NCT05816577|DIETARY_SUPPLEMENT|E Coli Nissle|E Coli wildtype strain
224113921|NCT01943630|DRUG|Vehicle|Administration of Vehicle once a day (overnight)
224113922|NCT04366271|BIOLOGICAL|Mesenchymal cells|1 infusion of undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue
224113923|NCT04366271|DRUG|Standard of care|Best treatment option for COVID-19 according to investigator criteria
223970152|NCT06086405|DEVICE|Patients underwent cardiorespiratory support|Patients underwent cardiorespiratory support using the Oxyprime® ECMO Braile Biomédica® Membrane Oxygenator
223970153|NCT06188312|OTHER|Health education program|"A pretest questionnaire will be filled out, asking the participants about their knowledge, attitudes, and practices toward chemical hazards and the use of personal protective equipment (PPE) then analysis of the obtained pre-test data will be done.~we will apply a health education program. Development phase: developing the message of the health education program and preparing the materials (slide presentation, brochures, and an educational video).Implementation phase: A group health education session through face-to-face, one hour long, interactive lecture combined with slide presentation will be carried out by the researcher. Evaluation phase: A post-test will be done, after 6 months of the first session, to assess the changes of their knowledge and attitude after the intervention."
223970154|NCT04712500|DRUG|AND017|AND017 oral capsule
223970155|NCT02007421|PROCEDURE|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
223970156|NCT02007421|PROCEDURE|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
223970157|NCT01066897|DRUG|Pramipexole|Patients will received increasing dose of pramipexole
223970158|NCT02939859|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
223970159|NCT02939859|DEVICE|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
223970160|NCT02939859|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
223970161|NCT00764010|DIETARY_SUPPLEMENT|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
224113924|NCT05573594|OTHER|Muscle Energy Technique|"The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up."
224113925|NCT05573594|OTHER|conventional physical therapy and rehabilitation|In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
224113926|NCT01225393|DRUG|MLTA3698A|Subcutaneous repeating dose
224113927|NCT01225393|DRUG|adalimumab|Subcutaneous repeating dose
223542886|NCT02178800|DRUG|Placebo for GSK1265744 Tablets|Taken orally
223970162|NCT00764010|DIETARY_SUPPLEMENT|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
223970163|NCT00764010|DIETARY_SUPPLEMENT|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
224113928|NCT01225393|DRUG|leflunomide|Stable dose if not on methotrexate
224113929|NCT01225393|DRUG|methotrexate|Stable dose if not on leflunomide
224113930|NCT01225393|DRUG|placebo|Subcutaneous repeating dose
223970164|NCT05376735|BEHAVIORAL|Purrble intervention|"The intervention takes the form of an interactive plush toy, designed to be handed over to the child and support in-the-moment soothing.~The Purrble is introduced to the student as an anxious creature that may need kind attention from humans. When picked up, the Purrble emits a frantic heartbeat that slows down if the child uses calm stroking movements. If it's soothed for long enough, it transitions into a purring vibration indicating a calm, content state.~Logic model underlying the intervention:~Level 1: in-the-moment soothing support to students in emotional moments when they would attempt to practice emotion regulation (ER) strategies to calm down.~Level 2: mechanisms that facilitate long-term engagement with the intervention, building on positive subjective experience of Level 1.~Level 3: shift in students' ER practices and implicit beliefs about emotion, after repeated experience of Levels 1-2."
223970165|NCT05376735|BEHAVIORAL|Single Session Intervention|"The SSI has been co-produced with university students and clinical experts, combining the theories of ER with the qualitative experiences of students in open trial.~The result follows a traditional SSI structure (cf., Schleider et al 2020), including~* Initial guided reflection exercise (helping understand one's experience with Purrble in the 1st week).~* Short interactive psychoeducation, introducing the concept of window of tolerance, the Process Model of Emotions (Gross2015), and specific ways in which Purrble can help students down-regulate emotions within the context of the process model.~* Action plan to identify: moments when Purrble could be useful, what ER strategies they would like to use in those moments, what obstacles they may encounter, and how to overcome them.~The SSI will be accessible by students on a website and be both desktop and mobile browser friendly. The full process should not take students longer than 30 minutes."
224113931|NCT04488692|OTHER|Early intervention (Mobility functional training)|functional training focused on mobility (bed mobility, sitting balance, standing balance, and ambulation)
224113932|NCT04488692|OTHER|Sham intervention|friendly visit and education
224113933|NCT03569423|PROCEDURE|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
223970166|NCT02269033|BEHAVIORAL|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
223970167|NCT02269033|BEHAVIORAL|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged \> 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
223970168|NCT03942861|DRUG|Solu-Medrol|Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
223970169|NCT05240482|PROCEDURE|ST36 acupuncture|"ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed)."
223970170|NCT02635711|BEHAVIORAL|Adapted Taekwondo training|Adapted Taekwondo training for beginners
223970171|NCT02635711|BEHAVIORAL|Control|Daily jogging
223970172|NCT05946447|DEVICE|Ultrasound|The gastric antrum will be scanned using ultrasound.
223970173|NCT00393198|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
223970174|NCT00393198|DRUG|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
223970175|NCT00393198|DRUG|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
223970176|NCT00412828|DRUG|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
223970177|NCT02980198|BIOLOGICAL|IFN-Kinoid|IM administration
223970178|NCT02980198|OTHER|Placebo|IM administration
223970179|NCT02980198|OTHER|ISA 51|adjuvant
223970180|NCT02608697|DRUG|CAT-2054|
223970181|NCT02608697|DRUG|Placebo|
223970182|NCT02608697|DRUG|Atorvastatin|
223970183|NCT01723332|BEHAVIORAL|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
223970184|NCT01723332|BEHAVIORAL|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
223970185|NCT04912102|DEVICE|high flow nasal oxygen device (HFNO)|it is a novel technique by which heated humidified oxygen is supplied via nasal prongs at flow rates ranging from 40 to 70 L/minute. The Fio2 ranges from 0.21 to 1.0.
223970186|NCT04949789|OTHER|Placebo without Exercise|2 Capsules to be taken 30 minutes before breakfast.
223970187|NCT04949789|OTHER|Placebo with Exercise|2 Capsules to be taken 30 minutes before breakfast.
223725040|NCT03757897|DRUG|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
223970188|NCT04949789|OTHER|IP I|2 Capsules to be taken 30 minutes before breakfast.
223970189|NCT04949789|OTHER|IP II|2 Capsules to be taken 30 minutes before breakfast.
223970190|NCT04949789|OTHER|IP III|2 Capsules to be taken 30 minutes before breakfast.
223970191|NCT01661244|DRUG|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
223970192|NCT01661244|DRUG|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
223970193|NCT01661244|DRUG|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
223970194|NCT01661244|DRUG|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
223970195|NCT02503306|DRUG|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
223970196|NCT02503306|DRUG|placebo|Pharmaceutical form:tablets Route of administration: oral
223970197|NCT01137552|DRUG|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
223970198|NCT02842125|DRUG|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
223970199|NCT02842125|DRUG|Xeloda|Oral metronomic chemotherapeutic agent
223970200|NCT02842125|DRUG|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
223970201|NCT02842125|DRUG|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
223970202|NCT06036797|DRUG|Hydromorphone|For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
223542887|NCT02178800|DRUG|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
223970203|NCT06036797|DRUG|Sufentanil|For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
223970204|NCT06036797|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
223970205|NCT03857516|DEVICE|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
223970206|NCT02727647|DRUG|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
223970207|NCT02727647|DRUG|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
223970208|NCT02895854|RADIATION|Hypofractionated RT 5 x 7,25 Gy|
223970209|NCT02895854|RADIATION|LDR-brachytherapy with I125 seeds|
223970210|NCT02835937|OTHER|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
223970211|NCT02402465|DRUG|Placebo|Patients will be treated by placebo
223970212|NCT02402465|DRUG|Fluticasone propionate|Patients will receive fluticasone nasal spray
223970213|NCT02402465|DRUG|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
223970214|NCT02402465|PROCEDURE|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
223970215|NCT01296178|DRUG|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
223970216|NCT01296178|DRUG|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
223970217|NCT05537519|BIOLOGICAL|Phage Therapy|3-phage cocktail comprised of HP3, HP3.1 and ES19
223970218|NCT00288379|DRUG|formoterol|
223970219|NCT00288379|DRUG|budesonide/formoterol|
223970220|NCT03807700|DRUG|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
223970221|NCT05021965|PROCEDURE|different combined of tooth bleaching procedure|The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
223970222|NCT03211897|DRUG|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
223970223|NCT03211897|DRUG|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
223970224|NCT03211897|DRUG|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
223970225|NCT03211897|DRUG|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
223970226|NCT04189341|DRUG|Erector spinae plane block (Group E)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
223970227|NCT04189341|DRUG|Modified-thoracolumbar interfascial plane block|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
223970228|NCT00785850|DRUG|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
223970229|NCT00570557|OTHER|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
223970230|NCT03191214|DEVICE|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery \>30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
223970231|NCT00001666|DEVICE|Cadwell High-Speed Magnetoelectric Stimulator|
223970232|NCT00001666|DEVICE|Magpro High-Speed Magnetoelectric Stimulator|
223970233|NCT04180306|OTHER|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
223970234|NCT01675050|DRUG|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
223970235|NCT01675050|DRUG|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
223970236|NCT05615896|DEVICE|Imaging Session|Various scans will be captured on both devices
223970237|NCT03451526|PROCEDURE|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
223970238|NCT02520414|DEVICE|Symphion® Bipolar Hysteroscopic Tissue Resection System|
223970239|NCT04389944|OTHER|convalescent plasma application to SARS-CoV-2 infected patients|In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
223970240|NCT02580214|DIETARY_SUPPLEMENT|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
223970241|NCT02282917|DRUG|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
223970242|NCT05834361|DRUG|early vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
223970243|NCT05834361|DRUG|delayed vaginal administration of carboprost methylate|In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
223970244|NCT05469763|OTHER|Circuit training|"Mode : any rhythmical and aerobic activity using large muscle groups that can be maintained continuously.~* Intensity: 60% to 90% of maximum heart rate reserve or 50% to 85% of vO2 max.~* Duration: 25 to 30 minutes of continuous aerobic activity.~* Frequency: three to five days per week."
223970245|NCT04691336|BEHAVIORAL|Educational and Training with counselling|The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
223970246|NCT05183997|DIAGNOSTIC_TEST|complete blood count|laboratory test
223970247|NCT05183997|DIAGNOSTIC_TEST|prothrombin time|laboratory test
223970248|NCT05183997|DIAGNOSTIC_TEST|prothrombin concentration|laboratory test
224113934|NCT03569423|PROCEDURE|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
224113935|NCT04930640|DIETARY_SUPPLEMENT|SGF200 group|1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
224113936|NCT04930640|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
223970249|NCT05183997|DRUG|Verapamil|drug will be add to prolong the effect of regional block
223970250|NCT04136249|DIETARY_SUPPLEMENT|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
223970251|NCT01150500|DEVICE|MDT-4107 Zotarolimus-Eluting Coronary Stent|
223970252|NCT04350983|BEHAVIORAL|Increased physical activity|PAP and enhanced individual support by physiotherapist to increase physical activity
224113937|NCT04854265|OTHER|Mindfulness Meditation|Mindfulness meditation will include mindfulness based stress reduction program, Qigong, Tai Chi exercise, Yoga, and Pranayama breathing exercise.
224113938|NCT03348657|OTHER|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
224113939|NCT03566537|PROCEDURE|Thyroidectomy|Thyroidectomy
224113940|NCT02467452|DRUG|BDP/FF/GB|
224113941|NCT02467452|DRUG|FlF/VI + Tiotropium|
224113942|NCT02316470|BIOLOGICAL|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
224113943|NCT02316470|BIOLOGICAL|Placebo|phosphate buffered saline (PBS) solution
224113944|NCT04788303|OTHER|School meal, garden, education, and community workshops|"School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
224113945|NCT04788303|OTHER|Garden, education, and community workshops|"School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH."
224113946|NCT02505555|DEVICE|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
223542888|NCT05120700|BIOLOGICAL|Synovial Tissue and Fat Pad Stromal Vascular Fraction|Treatment of cartilage injury with a tissue engineering construct. It will be composed of stromal vascular fraction collected from the synovial membrane and infrapatellar fat of the injured knee, submitted to enzymatic processing in a single surgical time, associated with a collagen scaffold
223970253|NCT03962270|DEVICE|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
223970254|NCT04931199|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The standard of care procedures for children with clinically elevated anxiety, depression, and PTSD is traditional CBT from their mental health provider.
223970255|NCT04931199|BEHAVIORAL|CBT+App|Participants receive CBT as usual enhanced with a simple, HIPAA compliant, web-based application to help mental health providers implement homework during CBT with children with elevated PTSD, anxiety, and/or depression, and their caregivers. The three major components of the app help providers to (1) Practice interactive, digitized CBT exercises with patients in-session; (2) Remind patients to practice CBT exercises for homework, and (3) Review homework during the next session.
223970256|NCT06485830|PROCEDURE|Neural mobilization of the lower limb|"Static neural mobilization techniques will be performed for the lower limb. Static procedures will consist of two sets of 10 repetitions, with one minute rest between sets. Next, dynamic neural mobilization techniques will be performed, with each exercise lasting 5 minutes per set, with one minute rest between them. Therefore, dynamic procedures will consist of 10 minutes per mobilization technique (with one minute rest between exercises).~At the end of all dynamic mobilization exercises, static mobilizations of the sciatic nerve will be performed again in the same order and with the same duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
223970257|NCT06485830|PROCEDURE|Conventional physical therapy|"The intervention will include a first part in which active mobilizations, active-assisted mobilizations, and active stretches will be performed, followed by activities aimed at improving physical training, mobility training, and strength training oriented towards specific tasks. After this second part, the first part will be repeated in the same order and duration.~The intervention will consist of a total of 8 sessions (either twice a week for four weeks or once a week for a total of 8 weeks). This will depend on the participant usual attendance to his/her treatment center"
223970258|NCT04998032|BIOLOGICAL|supaglutide injection+metformin|supaglutide subcutaneous injection under RP3D dose combined with metformin treatment
223970259|NCT04998032|OTHER|placebo+metformin|placebo subcutaneous injection combined with metformin treatment
223970260|NCT05820815|DEVICE|in-bed self-exercises based on EMG-sensor feedback intervention|It presents the exercise method and amount of exercise for self-exercise and performs self-exercise while receiving feedback from muscle activity during self-exercise.
224113947|NCT01289392|DEVICE|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
224113948|NCT01289392|DEVICE|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
224113949|NCT01289392|BEHAVIORAL|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
224113950|NCT05318625|DEVICE|Gynaecological laparoscopic surgery (Sirius System)|"The laparoscopic procedures were done in the usual manner. The only difference was for the study participants, the Sirius System was used in place of the usual conventional laparoscope. All other procedures and instruments including the number of ports remained the same.~For every procedure using the Sirius System, a conventional laparoscope was on immediate standby to replace the Sirius System should there be an unanticipated equipment failure so that the procedure could be completed without delay."
224113951|NCT04056130|DRUG|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
224113952|NCT04056130|DRUG|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
224113953|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
223970261|NCT03467789|DRUG|Dietary Vitamin D3 pre-treatment|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is \> 31 ng/mL
223970262|NCT03467789|RADIATION|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
223970263|NCT03467789|DRUG|Serum Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
223970264|NCT03443752|OTHER|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
223970265|NCT03443752|OTHER|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
223970266|NCT03514745|DEVICE|GlideScope|Endobronchial intubation is performed using the GlideScope.
224113954|NCT04056130|DRUG|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
224113955|NCT02016417|DRUG|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
224113956|NCT02016417|DRUG|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
224113957|NCT05031325|DEVICE|Endoscopic submucosal dissection with Purastat|Purastat (peptidic gel) application
224291791|NCT02414269|GENETIC|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
224291792|NCT02414269|DRUG|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
224291793|NCT02414269|DRUG|pembrolizumab|Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
224291794|NCT06310213|DEVICE|Non-Invasive Pressure Monitor|Modified smart soft contact lens and cap with reader coil
223542889|NCT05994768|OTHER|18F-FDG PET/CT|Patients who underwent an 18F-FDG PET/CT examination and a labeled leukocyte scintigraphy before and after antibiotic therapy in the case of management of an EO.
223970267|NCT03514745|DEVICE|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
223970268|NCT02948205|PROCEDURE|3D group|infertility patient get TU-LESS by 3D Laparoscopy
223970269|NCT02948205|PROCEDURE|normal group|infertility patient get normal laparoscopic surgery
223970270|NCT01518517|DRUG|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
223970271|NCT01518517|DRUG|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
223970272|NCT04306549|OTHER|Bulk-Fill and Microhybrid Composite Resins|Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
223970273|NCT03724695|OTHER|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
223970274|NCT03639194|DRUG|ABBV-011|Intravenous
223970275|NCT03639194|DRUG|Budigalimab|Intravenous
223970276|NCT00702234|BIOLOGICAL|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
223970277|NCT00702234|BIOLOGICAL|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
223970278|NCT00702234|BIOLOGICAL|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
224113958|NCT00184639|DRUG|insulin detemir|
224113959|NCT02787512|DEVICE|Stent|Endoscopic biliary stent insertion
224113960|NCT00079612|DRUG|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
224113961|NCT00079612|DRUG|Placebo|2x 400mg tabs daily
223970279|NCT00702234|BIOLOGICAL|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
223970280|NCT00702234|DRUG|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
223970281|NCT00655668|DRUG|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
224113962|NCT02299908|DRUG|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
224113963|NCT02299908|DRUG|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
224291795|NCT06580704|DRUG|Lumbosacral Erector Spinae Plane Block|Patients will receive ultrasound-guided lumbosacral erector spinae plane block.
224291796|NCT06580704|DRUG|Psoas Muscle Compartment With Sciatic Nerve Block|Patients will receive ultrasound-guided psoas muscle compartment with sciatic nerve block.
223542890|NCT05511012|OTHER|motion control fault tests|Patients make 6 motion control fault tests, in the same order. Each test is performed three times
223542891|NCT03505333|PROCEDURE|conventional suture|we use Liga-sure device for hysterectomy
223970282|NCT03467997|BEHAVIORAL|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
223970283|NCT03467997|OTHER|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
223970284|NCT04783272|DIAGNOSTIC_TEST|Photoacoustic Computed Tomography (PACT) Imaging|PACT will be completed prior surgery.
223970285|NCT03231579|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
223970286|NCT00595764|BEHAVIORAL|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
224113964|NCT00667758|DRUG|Cetrorelix|3-5 mg s.c. on days 1-5
224113965|NCT00667758|DRUG|Placebo|3-5 ml NaCl s.c. on days 1-5
224113966|NCT00353847|DEVICE|Acupuncture|
224113967|NCT06482645|PROCEDURE|Perilesional/regional systematic biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
223970287|NCT00595764|BEHAVIORAL|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
223970288|NCT04741984|BIOLOGICAL|MT-201-GBM monocyte vaccine|monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)
223970289|NCT01338051|BIOLOGICAL|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
223970290|NCT04964609|DEVICE|EmbracePlus|"A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter."
223970291|NCT03229525|BEHAVIORAL|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
223970292|NCT03229525|BEHAVIORAL|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
223970293|NCT05457296|DRUG|Hydrocortisone (capsule)|salivary cortisol measurement at baseline and at one, two, and four hours after hydrocortisone intake.
223970294|NCT01894256|DRUG|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
224113968|NCT06482645|PROCEDURE|Combination of systematic biopsy and targeted biopsy|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
224113969|NCT03357822|DRUG|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
223725041|NCT05601258|OTHER|Age, gender, hospitalization and mortality rates will be compared|Age, gender, hospitalization and mortality rates will be compared
223970295|NCT03771209|DIAGNOSTIC_TEST|ultrasound examination|ultrasound assessment
223970296|NCT02691884|PROCEDURE|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
223970297|NCT00975078|PROCEDURE|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
223970298|NCT00975078|DRUG|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
223970299|NCT05939050|DEVICE|Powered toothbrush|Oral-B Powered toothbrush
223970300|NCT03145519|DEVICE|Vasofix Certo Catheter|Placement of IV-catheter
223970301|NCT03145519|DEVICE|OptiVein Catheter|Placement of IV-catheter
223970302|NCT00067808|DRUG|Decitabine|10 mg/m\^2 by vein over 1 hour daily for 10 days
224113970|NCT03357822|DRUG|Entecavir|0.5mg entecavir is orally taken every day
223970303|NCT00067808|DRUG|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
223970304|NCT00067808|DRUG|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
223970305|NCT02278822|OTHER|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
224113971|NCT03357822|DRUG|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
224113972|NCT04618692|OTHER|Surgical Loupes|Biliary reconstruction will be performed using surgical loupe
224113973|NCT04618692|OTHER|Microscope|Biliary reconstruction will be performed using microscope
224113974|NCT02372825|PROCEDURE|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
224113975|NCT01988012|BIOLOGICAL|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
224113976|NCT00788658|BEHAVIORAL|Diet modifications|Diet consultation
224113977|NCT00788658|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
224291797|NCT06226701|DEVICE|Cryolipolysis device|"-Cryolipolysis device~1max cool shaping device ( inform china korean technology).Is used for fat lipolysis ,with no harm to the skin.The device consist of Cool sculptor applicator head , cool gel pad its alarge gel pad it should be adherent to the area to be treated before applying the cool sculptor applicator to protect the skin from bruising or ecchymosis. The device uses vacuum suction which can be adjusted according to the patient tolerance. Duration of session 45min at each of treatment session ,1session every 2weeks for 3months."
224291798|NCT00576641|BIOLOGICAL|autologous dendritic cells|
223970306|NCT02278822|OTHER|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
223970307|NCT03594786|DEVICE|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
223542892|NCT05771532|BEHAVIORAL|Received the GS-SHEP|"The experimental group (n=33) received the GS-SHEP (a 10-15-minute individual sexual health education and a sexual health pamphlet). GS-SHEP effectiveness was examined using a self-report instrument to measure background information and three dependent variables: sexual knowledge, sexual attitudes, and sexual self-efficacy."
223542893|NCT00259844|BIOLOGICAL|TroVax|
223970308|NCT02338206|DRUG|Growth hormone|
223970309|NCT05566626|DEVICE|Hyperspectral retinal image|Hyperspectral image of both eyes
223970310|NCT05566626|DRUG|Mydriacyl Ophthalmic Product|Mydriatic drops before retinoscopy
223970311|NCT05160402|DRUG|IGM-6268|Active comparator
223970312|NCT05160402|DRUG|Placebo|Placebo comparator
224113978|NCT04842721|DRUG|Hypertonic Saturated Saline Mouth Rinse Active Arm|Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.
224113979|NCT04842721|OTHER|Placebo Plain Water Mouth Rinse Arm|Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
224113980|NCT02664285|OTHER|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
224113981|NCT02664285|OTHER|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
224113982|NCT04712578|DIETARY_SUPPLEMENT|Caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse caffeinated pre-workout supplement (Legion Athletics, Inc.).
224113983|NCT04712578|DIETARY_SUPPLEMENT|Non-caffeinated pre-workout supplement|The intervention will consist of consuming a standardized meal followed by one serving of the commercially available Pulse non-caffeinated pre-workout supplement (Legion Athletics, Inc.).
223970313|NCT00500539|DRUG|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
223970314|NCT02926495|DEVICE|eCoin System|Median nerve neurostimulator.
223970315|NCT03785418|BEHAVIORAL|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
223970316|NCT00645099|DRUG|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
223970317|NCT00645099|DRUG|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
223970318|NCT06472960|BEHAVIORAL|Moderate-intensity cycling|Moderate-intensity cycling on Ergoline Ergoselect 100
223970319|NCT06472960|BEHAVIORAL|Vigorous-intensity cycling|Vigorous-intensity cycling on Ergoline Ergoselect 100
223970320|NCT06472960|BEHAVIORAL|Uninterrupted sitting|Uninterrupted sitting in a quiet room
223970321|NCT06475092|OTHER|Tanita device|bioelectric impedance analysis
223542894|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
223970322|NCT05234008|OTHER|High intensity training at home|"A HIT exercise intervention is performed. Four sessions are performed at REVAL Research Center to educate participants on the exercise protocol. Eight exercise sessions are performed at home with support of Physitrack (a mobile application for participants and a software platform for researchers).~In-center program (2 weeks, 4 sessions): Participants perform a concurrent exercise protocol of 1h-1.5h, as published by our research team previously, consisting of cardiorespiratory, general resistance, and core muscle training, all at high intensity.~Home sessions (4 weeks, 8 sessions): Researchers provide participants with a fitness bike, smartwatch, and training mat. Using Physitrack, researchers formulate a personalized HIT program to be performed at home for each participant by selecting from \>3500 exercises or insert a new exercise to add to the library. This HIT program resembles the program performed in the rehabilitation center as much as possible."
223542895|NCT01343745|DRUG|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
223542896|NCT01343745|DRUG|Placebo|pressurised metered dose inhaler
223970323|NCT02061189|OTHER|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
223970324|NCT05510102|DEVICE|WHOOP strap 4.0 (full data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will have full remote monitoring data access throughout the entirety of the study (6 months).
223970325|NCT05510102|DEVICE|WHOOP strap 4.0 (partial data access)|The WHOOP strap 4.0 provides continuous physiologic data via remote monitoring. Subjects will be blinded to remote monitoring data for the first 3 months of the study followed by an unblinding and full access to remote monitoring data at the 3 month mark (continued for the remainder of the study).
223970326|NCT02076802|BEHAVIORAL|physical exercises|
223970327|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
223970328|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
223970329|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
223970330|NCT00729508|BIOLOGICAL|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
223970331|NCT00729508|BIOLOGICAL|Cat-PAD|Placebo
223970332|NCT01685307|DIETARY_SUPPLEMENT|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
224113984|NCT04712578|DIETARY_SUPPLEMENT|Placebo|The intervention will consist of consuming a standardized meal followed by a placebo beverage.
224113985|NCT01228071|DRUG|testosterone gel 2%|40 mg testosterone gel 2%
224113986|NCT00678509|BIOLOGICAL|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
224113987|NCT03487380|PROCEDURE|Fecal sample collection|Fecal sample collection
223970333|NCT04804228|OTHER|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
223970334|NCT04804228|OTHER|Ischemic compression, analytical stretching and postural habits educational dossier|The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
223970335|NCT03206489|DEVICE|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
224113988|NCT04586894|DIAGNOSTIC_TEST|Cardiac MRI|Gadolinium-enhanced magnetic resonance imaging of the heart before the first cycle of chemotherapy
224113989|NCT04586894|DEVICE|Smart cloth|A smart cloth recording cardiac and hemodynamic parameters will be worn by patients during 42 days. Replaced by a holter monitor if the smart cloth is refused or not tolerated by the patient.
224113990|NCT04586894|OTHER|Biobanking|Blood samples (plasma, serum, DNA, stem cells, immune cells) taken as part of the study will be stored in a biological sample collection. These samples may be used for further analysis not described in the initial protocol but which may be useful for investigation or in light of advances in scientific knowledge.
223970336|NCT03206489|DEVICE|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
223970337|NCT01201915|DRUG|Vismodegib|Vismodegib was supplied in gelatin capsules.
223542897|NCT03631264|DEVICE|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
223542898|NCT04199585|DRUG|Lu AF95245|solution, single dose, orally
223542899|NCT04199585|DRUG|Lu AF95245 14C radiolabelled spiked dosage|solution, single dose, orally
223542900|NCT04199585|DRUG|Placebo|solution, single dose, orally
223542901|NCT02044679|OTHER|Water|
223970338|NCT05734885|OTHER|Back and Sacral massage massage application|Massage will be applied to the pregnant woman in the position preferred by the pregnant woman. Circular movements are applied to the sacrum with the thumb. Pressure is applied to both sides of the spinal cord with the thumb. The thumb is moved towards the hip of the pregnant woman at 1.5 cm intervals, starting from the lower part of the pelvis and the sacrum. The palm is placed in direct contact with the mother's sacrum and pressure is applıed. The massage is completed by making a bunch of flowers from the sacrum upwards, towards the shoulder and around it.
224113991|NCT01543464|DRUG|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
224113992|NCT02969343|BEHAVIORAL|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
224113993|NCT04388657|DIAGNOSTIC_TEST|Echo-Doppler|Utrasound Doppler of the lower limbs
224113994|NCT00635531|OTHER|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
224113995|NCT00635531|DRUG|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
224113996|NCT00834002|BIOLOGICAL|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
224113997|NCT00161824|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
224113998|NCT06532019|OTHER|Targeted intervention based on risk factors|Correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
223970339|NCT04354623|OTHER|A 6-minute walk test|Each subject will perform a 6-minute walk test during which gait assessment will be obtained from the APDM system (Portland, OR). In addition there will be four video cameras (on the front, back and sides) that will measure raw video data for our gait analysis. The camera does not record any facial data (in fact, 'deepfake' software in the system deletes all facial details) and the patient's movements are converted to a 'stick figure' prior to being saved in the system.
223970340|NCT06653569|DRUG|Baloxavir Marboxil|"The antiviral baloxavir marboxil administered in one unique dose.~1 capsule (40 mg) if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg"
223970341|NCT06653569|DRUG|Placebo|Patients in the placebo group will receive one unique dose of placebo. 1 capsule if participant weighs \< 80 kg; 2 capsules (80 mg) if participant weighs ≥ 80 kg.
223970342|NCT01282918|DEVICE|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
223970343|NCT01282918|DEVICE|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
223970344|NCT00966641|DRUG|Naproxen|Single orally administered dose of 500 mg naproxen
223970345|NCT00966641|DRUG|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
223970346|NCT00370188|DRUG|Topiramate|
223970347|NCT04114279|PROCEDURE|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
223970348|NCT04493307|DIAGNOSTIC_TEST|Phlebotomy|Serial assessment of hemostasis by blood and urine collection
223970349|NCT02316171|BIOLOGICAL|CVA21|CAVATAK is a purified preparation of CVA21
223970350|NCT02316171|DRUG|Mitomycin C|Chemotherapy
223970351|NCT03537534|DRUG|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
223970352|NCT03537534|DRUG|Placebos|Applying surgilube following endourologic procedure
223542902|NCT02044679|OTHER|No intervention|
223970353|NCT01524887|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
223970354|NCT01524887|BIOLOGICAL|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
223970355|NCT02039596|OTHER|Diet|
223970356|NCT00002371|DRUG|Indinavir sulfate|
223970357|NCT00002371|DRUG|Lamivudine|
223970358|NCT00002371|DRUG|Stavudine|
223970359|NCT00002371|DRUG|Zidovudine|
223970360|NCT01596699|DRUG|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
223970361|NCT01596699|DRUG|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
223970362|NCT01596699|DRUG|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
223970363|NCT01596699|DRUG|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
223970364|NCT05081778|BEHAVIORAL|Obese patient following a medical course|Questionnaires for the assessment of dissociative disorders in obese patients : DES scale of Carlson and Putman, SDQ-20 of Nijenhuis, comorbidities, Dutch Eating Behaviour Questionnaire (DEBQ), questionnaire of Rosenberg
223970365|NCT03805685|PROCEDURE|Non-Cardiac Surgery|Non-cardiac surgery
223970366|NCT05667727|DRUG|nebulized epinephrine|we are using 1:1000 epinephrine into nebulization form
223970367|NCT05667727|DRUG|Salbutamol|Patient will receive salbutamol as 4th nebulization.
223970368|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
223970369|NCT04156685|DRUG|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
223970370|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
223970371|NCT04156685|DRUG|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
223970372|NCT07007624|OTHER|Basketball training (Sport and diet)|The intervention program will last for 3 years, and each year will be divided into two periods: a preseason, beginning in early September and lasting for the first 6 weeks, followed immediately by a 32-week season (until the end of the school year). The preseason will include 5 training sessions per week, each lasting 2 hours (Monday to Friday). The following season will include 3 training sessions per week, each lasting 2 hours (after school), and one match on the weekend. Each session will be divided into 2 periods separated by a 10-minute break: the first period will focus on individual skills with moderate to high-intensity exercises (60-85% of heart rate), and the second period will focus on gameplay (tactics and strategy). The trainers had a high level of professional training, ensuring the quality of the sessions. Dietary recommendations based on the Mediterranean diet will be given to the subjects.
223970373|NCT03920761|DEVICE|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
223970374|NCT03920761|DEVICE|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
223970375|NCT06493669|DIAGNOSTIC_TEST|Cognitive assessment|MoCA
223970376|NCT00421122|DRUG|budesonide/formoterol (Symbicort)|inhalation therapy
223970377|NCT00421122|DRUG|budesonide (Pulmicort)|inhalation
223970378|NCT00421122|DRUG|terbutaline sulfate (Bricasol)|inhalation therapy
223970379|NCT01557699|BIOLOGICAL|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
223970380|NCT01557699|BIOLOGICAL|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
223970381|NCT01557699|BIOLOGICAL|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
223970382|NCT03635437|DRUG|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
223970383|NCT03635437|DRUG|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
223970384|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
223970385|NCT01002547|DRUG|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
223970386|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
223970387|NCT01002547|DRUG|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
223970388|NCT01002547|DIETARY_SUPPLEMENT|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
223970389|NCT01002547|DRUG|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
224113999|NCT00598533|DEVICE|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
224114000|NCT00598533|DEVICE|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
224114001|NCT03252639|PROCEDURE|EVT for RAS & PBV acquisition protocol for target kidneys|
224114002|NCT00905879|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
224114003|NCT05429723|DRUG|HS-10383|HS-10383 administered as one 50 mg, 150 mg, 450 mg and 900 mg tablet once daily, depending upon randomization.
224114004|NCT05429723|DRUG|HS-10383 Placebo|Placebo for HS-10383
224114005|NCT05868642|PROCEDURE|subarachnoid block|subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
224114006|NCT01278680|BEHAVIORAL|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
224114007|NCT04141345|DIAGNOSTIC_TEST|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
224114008|NCT00426985|DRUG|Ketoprofen Topical Patch 20%|
224114009|NCT06483555|DRUG|Gemcitabine|1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
224114010|NCT06483555|DRUG|Nab paclitaxel|125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
224114011|NCT06483555|DRUG|Erlotinib|50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
223970390|NCT01516606|DRUG|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
223970391|NCT01039259|DEVICE|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
223970392|NCT03273283|BEHAVIORAL|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
223970393|NCT00710814|DRUG|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
223970394|NCT00710814|OTHER|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
223970395|NCT02275845|DRUG|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
223970396|NCT02275845|OTHER|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
223970397|NCT06023888|OTHER|Mapping strategy|The ablation strategy was based on the mapping results of periodicity.
223970398|NCT06023888|OTHER|Mapping strategy|PVI+ non-PV trigger
223970399|NCT05648448|DRUG|Oseltamivir|Oral oseltamivir 75mg BD for 5/7
223970400|NCT05648448|DRUG|Favipiravir|Oral favipiravir 1800mg BD D0 and 800mg BD for a further 4/7
223970401|NCT05648448|DRUG|Zanamivir|Inhaled zanamivir 10mg BD for 5/7
223970402|NCT05648448|DRUG|Baloxavir|"Oral baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
223970403|NCT05648448|DRUG|Molnupiravir|Oral molnupiravir 800mg BD for 5/7
223970404|NCT05648448|DRUG|Peramivir|Intravenous peramivir 600mg once only
223970405|NCT05648448|DRUG|Laninamivir|Inhaled laninamivir 40mg once only
223970406|NCT05648448|DRUG|Oseltamivir and Baloxavir|"Oseltamivir 75mg BD for 5/7 and~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
223970407|NCT05648448|DRUG|Oseltamivir and Favipiravir|"Oseltamivir 75mg BD for 5/7 and~favipiravir 1800mg BD D0 and 800mg BD for a further 4/7"
223970408|NCT05648448|DRUG|Favipiravir and Baloxavir|"favipiravir 1800mg BD D0 and 800mg BD for a further 4/7~Baloxavir:~* \<80kg- single dose of 40mg on D0~* ≥80kg- single dose of 80mg on D0"
223970409|NCT05823519|DEVICE|Endologix Ovation Alto Endograft|Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
223970410|NCT00672763|DRUG|Colecalciferol D3 (Vigantol Oil)|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
223970411|NCT00672763|DRUG|Medium chain triglycerides|"1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)"
223970412|NCT04528537|OTHER|questionnaire|16-item quality of recovery questionnaire for the postanesthesia care unit (QoR-PACU)
223970413|NCT02548754|DEVICE|Parasym device|
223970414|NCT03394183|OTHER|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
223970415|NCT04877132|DRUG|olipudase alfa (GZ402665)|Patients will receive intravenous (IV) infusion of olipudase alfa
223970416|NCT03159325|BEHAVIORAL|Healing Circles|See description in the arm description.
223970417|NCT02565888|DRUG|Daclatasvir|
223970418|NCT02565888|DRUG|Atazanavir|
223970419|NCT02565888|DRUG|Ritonavir|
223970420|NCT02565888|DRUG|Cobicistat|
224114012|NCT06483555|DRUG|NALIRIFOX|Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
224114013|NCT06483555|DRUG|Folfirinox|Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
224114014|NCT04454996|DRUG|tong-jiang granules|This is a kind of compound Chinese medicine granules, 1 bag each time, 3 times a day, treatment for 4 weeks.
223970421|NCT04792255|PROCEDURE|Carotid artery stenting with standard contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
223970422|NCT04792255|PROCEDURE|Carotid artery stenting with reduced contrast media protocol|Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.
223970423|NCT04792255|DIAGNOSTIC_TEST|Carotid Duplex Ultrasound|Pre- and postinterventional assessment of the treated internal carotid artery.
223970424|NCT00003212|DRUG|doxorubicin hydrochloride|
223970425|NCT00003212|DRUG|ifosfamide|
223970426|NCT03146754|OTHER|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
223970427|NCT04532983|PROCEDURE|fixation of mesh prosthesis|in the first group mesh was fixed in position with laparoscopic tacks
223970428|NCT04532983|PROCEDURE|mesh placement without fixation|mesh placement in preperitoneal space without fixation
223970429|NCT03838419|RADIATION|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
223970430|NCT03838419|RADIATION|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
223970431|NCT02093897|BIOLOGICAL|rVIII-SingleChain|
224114015|NCT04454996|DRUG|Chang 'an II Recipe|This is Chang 'an II Prescription granule, 1 bag each time, 3 times a day, treatment for 4 weeks.
224114016|NCT04454996|DRUG|The placebo of tong-jiang granules|This is a granule, containing 5% tongyu granule active drug,1 bag each time, 3 times a day, treatment for 4 weeks.
224114017|NCT04454996|DRUG|The placebo of Chang 'an II Recipe|This is a granule containing 5% chang 'an II,1 bag each time, 3 times a day, treatment for 4 weeks.
223970432|NCT00088452|DRUG|Ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
224114018|NCT06120478|OTHER|observe|observational study
223970433|NCT00088452|DRUG|Lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
223970434|NCT00088452|DRUG|Valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
223970435|NCT03429595|DRUG|ATx201|ATx201 GEL
223970436|NCT03429595|OTHER|ATx201 GEL Vehicle|Vehicle
223970437|NCT03377725|DRUG|Decitabine|20mg/m\^2,d1-5,ivgtt,28days as a duration
223970438|NCT03377725|DRUG|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
224114019|NCT04016493|PROCEDURE|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
224114020|NCT02829346|DRUG|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
224114021|NCT02829346|DRUG|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
224114022|NCT00553059|DRUG|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
224114023|NCT00553059|DRUG|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
224291799|NCT00678626|DRUG|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
224291800|NCT00678626|DRUG|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
223970439|NCT02264418|DRUG|ODM 203|ODM 203
223970440|NCT02264418|DRUG|ODM 203|ODM 203
223970441|NCT02596399|DRUG|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
223970442|NCT02596399|DRUG|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
223970443|NCT02629419|DRUG|Amphotericin B|Oral lipid nanocrystal formulation of amphotericin B
223970444|NCT02081196|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223970445|NCT02936492|DRUG|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
223970446|NCT02936492|DRUG|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
224114024|NCT00553059|DRUG|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
223970447|NCT02936492|DRUG|BAY1003803 0.01% ointment|Topical administration for 22 h per day
223970448|NCT02936492|DRUG|BAY1003803 0.1% ointment|Topical administration for 22 h per day
223970449|NCT02936492|DRUG|Lipophilic cream vehicle|Topical administration for 22 h per day
223970450|NCT02936492|DRUG|Ointment vehicle|Topical administration for 22 h per day
223970451|NCT02936492|DRUG|Clobetasol propionate|Topical administration for 22 h per day
223970452|NCT02055053|DRUG|0.5% Bupivicaine|Local anesthetic
223970453|NCT00399997|BEHAVIORAL|Exercise on Prescription|
223970454|NCT03018847|DEVICE|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
223970455|NCT03098797|DRUG|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
223970456|NCT03098797|DRUG|Placebo|daily subcutaneous injection for 12 weeks
223970457|NCT01176136|BEHAVIORAL|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
223970458|NCT04814615|DRUG|89Zr-daratumumab PET/CT|CD38-targeting imaging
223970459|NCT00888407|BEHAVIORAL|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
224114025|NCT00553059|OTHER|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
224114026|NCT03462004|BIOLOGICAL|HPIV3/ΔHNF/EbovZ GP vaccine|Administered intranasally
224114027|NCT03462004|BIOLOGICAL|Placebo|Administered intranasally
224114028|NCT05057988|BEHAVIORAL|Empowered Relief class|The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
224114029|NCT03283215|DIAGNOSTIC_TEST|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
223970460|NCT00888407|BEHAVIORAL|Nutrition - Small group educational session|Small group session with diet \& nutrition focused, topic related resources provided.
223970461|NCT00985634|DEVICE|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
223970462|NCT00985634|DEVICE|Control|Vessel loops
223970463|NCT04258215|DEVICE|Experimental: Routine positive pressure airway management.|The use of the PSA extraglottic airway for routine general anesthesia will be assessed for quality of airway management by measuring the seal pressure when using the device in 20 participants.
223970464|NCT05813535|DRUG|Sodium bicarb lock|8.4% sodium bicarb locks when off venous nutrition
223970465|NCT05964556|OTHER|Functional Movement Screen (FMS)|FMS is an analysis system that evaluates muscle strength imbalance and functional performances on the dominant-non-dominant side in athletes. It aims to detect stability and mobility that can be ignored in the asymptomatic active population and athletes. It consists of 7 basic parameters determined by Gray Cook (Deep Squat, Hurdle Step, -In-line Lunge, Shoulder Mobility, Active Straight Leg Raise, Trunk Stability, Rotatory Stability). The athletes were evaluated after giving verbal instructions to the athletes about the head, trunk, knee and foot positions. For each parameter, the athletes were given points between 0-3 values. The total score was determined as 21 points. Completing the movement completely and without compensation was given 3 points, and 2 or 1 points were given according to the activation of the compensation mechanism and balance disorders. In case of any pain during or at the end of the movement in the evaluated parameter, 0 points were given to the athletes.
224114030|NCT02061007|DRUG|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m\^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
224114031|NCT02061007|DRUG|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
224114032|NCT02061007|PROCEDURE|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
223970466|NCT05964556|OTHER|Isokinetic Muscle Evulation of Knee Muscles|The isokinetic knee flexor and extensor group muscle strengths of the athletes participating in the study were measured on the dominant and non-dominant sides. Measurements were performed with an ISOMED 2000 (D\&R Ferstl GmbH, Hemau, Germany) isokinetic measuring device. The test protocol was adjusted to be concentric/concentric. Measurements were made at angular velocities of 60°/sec and 180°/sec. At an angular speed of 60°/sec, the athlete was asked to perform 10 repetitions of voluntary knee flexion/extension at maximum strength. Then, after resting for 30 seconds, 30 repetitions of knee flexion/extension were performed at an angular velocity of 180°/sec. Before starting the test in both angular speeds, 3 repetitive attempts were made to learn the movement. The following parameters were evaluated at 60°/sec and 180°/sec angular speed.
223970467|NCT01868516|DRUG|dexmecamylamine|
223970468|NCT01868516|DRUG|Placebo|
223970469|NCT04410315|OTHER|Serum-lactate < 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
223970470|NCT04410315|OTHER|Serum-lactate >/= 2,2 mmol/L|Bloodgas analysis every hour from start surgery until recovery ward discharge
223970471|NCT02515656|DRUG|POLYGYNAX®|
223970472|NCT02515656|DRUG|GYNODAKTARIN®|
223970473|NCT02515656|DRUG|Placebo|
223970474|NCT04568356|DIAGNOSTIC_TEST|Direct Antigen Tests for COVID-19|Rapid Antigen diagnostic device performance comparative to RT-PCR
223970475|NCT05037721|OTHER|gargling with green tea|experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
223970476|NCT05037721|OTHER|gargling with water|using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
223970477|NCT03626025|OTHER|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
223970478|NCT02329223|BIOLOGICAL|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
223970479|NCT02329223|OTHER|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
223970480|NCT04196829|DRUG|silver diamine fluoride ⁄ potassium Iodide|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption . Then after SDF application KI will be applied using a separate microbrush which will be saturated by the solution and will be used to paint solution over carious lesion , no rinse will be performed and special instructions will be given following application
223970481|NCT04196829|DRUG|Silver Diamine Fluoride|The affected tooth surface will be gently cleaned and dried with cotton gauze. The gingival tissue of the tooth will be protected with petroleum jelly. An applicator will be dipped into the SDF and 3-4 mg applied to the lesion with microbrush which will be used to paint solution over carious lesion then we will wait for 1 minute till absorption .
223970482|NCT06157619|PROCEDURE|Oocyte Vitrification /Warming|In Vitro matured oocytes will be randomly assigned to any of the two Vitrification protocols
223970483|NCT06144788|DRUG|SGLT2 inhibitor|SGLT 1/2 dual inhibitor
223970484|NCT00174798|DRUG|SSR240600C|once daily
223970485|NCT00174798|DRUG|Placebo|oral
223970486|NCT00174798|DRUG|Tolterodine|once daily
223970487|NCT00306956|BEHAVIORAL|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
223970488|NCT06436495|OTHER|Hair Wash Shampoo|A standard marketed hair wash shampoo is to be used for the hair wash intervention post baseline evaluations of the scalp.
223970489|NCT01865500|DRUG|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
223970490|NCT01865500|DRUG|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
223970491|NCT01865500|DRUG|Metil prednisolone|
223970492|NCT00381888|DRUG|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
223970493|NCT04162236|DIAGNOSTIC_TEST|Ecocardiographyc ultrasound|"* Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~* Antropomethric measures~* Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~* Carotid Intima Thickness~* Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~* Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays."
223970494|NCT03308747|DIETARY_SUPPLEMENT|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
223970495|NCT03449134|DRUG|Placebo|Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
223970496|NCT03449134|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
223970497|NCT04120662|PROCEDURE|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
223970498|NCT04120662|DEVICE|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
223970499|NCT01330992|OTHER|Ocular light or darkness exposure|Ocular light or darkness exposure
223970500|NCT01504009|OTHER|Muscle training|12 weeks of strength training 2-3 times/week
223970501|NCT01397188|DEVICE|PiCCO|transpulmonary thermodilution technique
223970502|NCT01397188|OTHER|sham, no intervention|no intervention
224114033|NCT02383719|DEVICE|Oro-nasal Mask|
223542903|NCT02848092|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
223970503|NCT04700475|DEVICE|low level laser|"Laser will be performed with a GaAlAs diode laser at a wavelength of 808 nm, 100-mW output power, laser beam area of 0.03 cm2, and in continuous wave mode, three times a week, on alternate days. Laser therapy will be initiated before the first radiotherapy session and ended after the last session, totaling 21 sessions.~The total energy per session (56 J) will be divided into 14 irradiation points, as marked on the overlying skin (Fig.2). Each irradiation point received a dose of 4 J over an irradiation time of 40 s.~With exclusion of tumor area or area of removed tumor laser will be applied as following:~• Extra oral application: The laser will be used extraorally at eight points in the parotid glands (bilaterally, four points in each gland), at four points in the submandibular glands (bilaterally, two points in each gland~• Intraoral application: The will be used intraorally at two points in the sublingual glands bilaterally, one point in each gland ."
223970504|NCT04700475|DRUG|citric acid solution|citric acid solution applied as a mouth rinse
223970505|NCT06289023|RADIATION|HA-WBRT-SIB|A total dose of 30-36 Gy delivered in 18-20 fractions to the whole brain (CTV), while the dose to the GTV were boosted to 44 Gy-52 Gy in 18-20 fractions, ﬁve times a week.
223970506|NCT01997489|DRUG|Enzyme replacement|Observational study of current treatment and with no comparative groups
223970507|NCT03418181|PROCEDURE|Standard Haemodialysis|Thrice weekly dialysis.
223970508|NCT03418181|PROCEDURE|Incremental dialysis|Individualised dialysis dose according to native kidney function.
223970509|NCT00854971|BIOLOGICAL|TKCell|Biological/Vaccine: TKCell
223542904|NCT02848092|OTHER|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
223970510|NCT06478576|DEVICE|multibranched stent graft system|To evaluate the feasibility of multibranched stent graft system for Endovascular Treatment of Thoracoabdominal Aortic Aneurysm(TAAA)
223970511|NCT04513275|DRUG|non-medicine intervention|rating by MCCB only one time
223970512|NCT00957996|DRUG|Peramivir|300 mg twice daily
223970513|NCT00957996|DRUG|Peramivir|600 mg once daily
223970514|NCT02007811|BIOLOGICAL|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
223970515|NCT01268124|DRUG|HTC-867|
223970516|NCT00547053|DRUG|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
223970517|NCT00468507|DIETARY_SUPPLEMENT|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
223970518|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 3mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
223970519|NCT05222009|DRUG|PEG-rhG-CSF|PEG-rhG-CSF, 6mg, D1, Q3W, subcutaneous injection, until stop using PD-(L)1 inhibitor, progressive disease (PD) or unacceptable toxicity. Meanwhile, the original maintenance regimen--PD-(L)1 inhibitor ± VEGFR/EGFR TKI/Ab--continues.
223970520|NCT02383238|DRUG|Dapagliflozin|10 mg, oral for 6 weeks
223970521|NCT02383238|DRUG|Placebo|oral for 6 weeks
223970522|NCT04523298|PROCEDURE|Non-ablative vaginal Erbium YAG laser treatment|"There are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. If needed, 3 extra laser applications can be added to the treatment (ie. with a maximum of 6 applications). Each application lasts around 15 minutes. The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~Laser therapy is performed using a 2940 nm VEL (SP Spectro, Fotona, Slovenia(24)) with SMOOTH mode setting, which enables non-ablative, thermal-only operation(25). The parameters are selected based on extensive preclinical and clinical studies(26,27,28).~Each laser treatment session consists of a full vaginal canal irradiation (using a 360° circular adapter), followed by additional irradiation of the prolapsed anterior wall (using a 90° angular adaptor) and concluded with irradiation of the vestibule area."
224114034|NCT06390618|OTHER|Aerobic Exercise (AE) Group|"A total of 24 sessions of aerobic exercise will be performed in 8 weeks, 3 days a week.~For aerobic exercise, a moderate intensity (50-60%) aerobic exercise program will be applied using the karvonen method. According to the aerobic exercise intensity karvonen method, the formula (Maximal Heart Rate (220-years) - Resting Heart Rate) x 50-60% + Resting Heart Rate) will be used. 1-4. week 50%, 5-8. Exercise intensity will be increased by 60% per week."
224114035|NCT06390618|OTHER|Combined Exercise (CE) Group|"In the combined exercise group, biopsychosocial exercise will be performed in addition to aerobic exercise.~In the combined exercise group, in addition to aerobic exercise (3, 8 weeks, 24 sessions of aerobic exercise per week), 16 sessions of biopsychosocial-based group exercise treatment will be performed 2 days a week for a total of 8 weeks.~BETY approach will be used in group exercise treatment."
224114036|NCT02768909|DEVICE|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
224114037|NCT02768909|OTHER|Survey & Physical Exam|2\. Perform a oriented survey for risk factors and a complete physical exam.
224114038|NCT02768909|OTHER|Chest X-ray|Perform anteroposterior chest X-ray
224114039|NCT02768909|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
223542905|NCT00607802|BIOLOGICAL|leukocyte therapy|
223970523|NCT04523298|OTHER|Pelvic floor exercises (PFE)|Standard PFE in Belgium are 9 sessions with a pelvic floor physiotherapist of choice, which can be extended by another 9 sessions, if clinically indicated. There are different strategies, though that will be on discretion of the physiotherapist. We will register the type of physiotherapy (standard (PFMT) versus assisted pelvic floor muscles training (APFMT)), number of completed sessions and duration of therapy. What is exactly done by the patient is registered as a variable.
223970524|NCT01391676|PROCEDURE|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
223970525|NCT02123277|DEVICE|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
223970526|NCT01997437|DEVICE|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
224114040|NCT02768909|DEVICE|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
223542906|NCT00607802|GENETIC|polymerase chain reaction|
223970527|NCT01502306|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
223542907|NCT03345511|PROCEDURE|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
223542908|NCT01861847|DRUG|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
223542909|NCT01861847|DRUG|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
223542910|NCT01072721|OTHER|Elastometry|Fibrosis detection with FIBROSCANN
223542911|NCT01798381|DIETARY_SUPPLEMENT|Essential fatty acids|
223542912|NCT01639469|BEHAVIORAL|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
223970528|NCT01502306|DRUG|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
223970529|NCT01502306|BEHAVIORAL|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
223970530|NCT01019499|OTHER|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
223970531|NCT01019499|OTHER|control products|two portions daily
223970532|NCT01580995|DRUG|Valacyclovir|Valacyclovir 500 mg po bid
223970533|NCT01580995|DRUG|Placebo|Placebo tablet twice daily
223970534|NCT06545110|DRUG|Baricitinib Oral Tablet|Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
223970535|NCT05000411|DRUG|Compound Danshen Dropping Pills (CDDP)|The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
223970536|NCT05000411|DRUG|Placebo|The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
223970537|NCT02916706|DRUG|Teneligliptin 20mg|
223970538|NCT02916706|DRUG|Placebo|
223970539|NCT00361036|DEVICE|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
223970540|NCT00361036|DEVICE|Uterine fibroid embolization Embosphere®|Embosphere - control arm
223970541|NCT02874105|OTHER|Group C: physiotherapy protocol with Conventional physiotherapy.|
223970542|NCT02874105|OTHER|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
223970543|NCT00598871|DRUG|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
223970544|NCT00598871|OTHER|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
223970545|NCT01194271|DRUG|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
223970546|NCT01194271|DRUG|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
223970547|NCT01194271|PROCEDURE|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
223970548|NCT03376698|DRUG|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
223970549|NCT03376698|DRUG|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
223542913|NCT01639469|BEHAVIORAL|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
223970550|NCT03376698|DRUG|Placebo|oral administration of Placebo once daily for 12 weeks
223970551|NCT01983462|DRUG|Clonidine|
223970552|NCT01983462|DRUG|Hydrochlorothiazide|
223970553|NCT01983462|DRUG|Placebo|
223970554|NCT00381797|BIOLOGICAL|Bevacizumab|Given IV
223970555|NCT00381797|RADIATION|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
224114041|NCT02768909|DEVICE|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
224114042|NCT02768909|DEVICE|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
223970556|NCT00381797|DRUG|Irinotecan Hydrochloride|Given IV
224114043|NCT02768909|DEVICE|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
224114044|NCT01383044|PROCEDURE|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
223970557|NCT02151630|DRUG|Pyruvic acid|
223970558|NCT02151630|DRUG|Salicylic Acid|
223970559|NCT01430117|BIOLOGICAL|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
223970560|NCT01828359|DRUG|Amosartan® tab|comparison of different combination of anti-hypertension drug
223970561|NCT01828359|DRUG|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
223970562|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
223970563|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 48 weeks
223970564|NCT00443898|DRUG|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
223970565|NCT00443898|DRUG|Placebo|vehicle (placebo) applied once daily for 24 weeks
223970566|NCT00152399|DRUG|Somatostatin UCB (drug)|
223970567|NCT02763163|BEHAVIORAL|Sun exposure routine|
223970568|NCT03884062|DRUG|DAAs|lab, U/S, Fibroscan \& CT if needed
223542914|NCT02833883|DRUG|Enzalutamide|
223542915|NCT02833883|DRUG|CC-115|
223542916|NCT03092310|DEVICE|Artificial Pancreas Device|Artificial Pancreas Device
223542917|NCT03155139|DIAGNOSTIC_TEST|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
223542918|NCT03155139|DIAGNOSTIC_TEST|Confirmatory tests|Captopril challenge test, Saline infusion test
223542919|NCT03888014|DEVICE|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
223542920|NCT03888014|DRUG|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
223970569|NCT00958711|DEVICE|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
223970570|NCT00958711|OTHER|Saline and Gauze|gauze moistened with sterile saline
224114045|NCT01383044|DRUG|carvedilol|carvedilol 6.25mg-12.5 mg per day
224114046|NCT01020292|DRUG|Nelfinavir|
224114047|NCT02107391|BIOLOGICAL|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
224114048|NCT02107391|DRUG|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
224114049|NCT02107391|DRUG|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
223970571|NCT05965960|DEVICE|TUS Active|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 30 W/cm2 Isppa
223970572|NCT05965960|DEVICE|TUS Sham|Bilateral M1s/GPis will be sonicated using NeuroFUS device for two minutes per hemisphere with theta burst protocol and 0 W/cm2 Isppa
223970573|NCT00949793|DEVICE|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
223970574|NCT01929577|DRUG|ASP015K|oral tablet
223970575|NCT02836041|BEHAVIORAL|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
223970576|NCT02836041|DEVICE|actigraph|This device reliably measures sleep by monitoring the child's motion.
223970577|NCT05137405|PROCEDURE|Sleeve gastrectomy|An online survey format was administered to all obese patients on the waiting list for bariatric surgery in our Department of Medical and Surgical Sciences to obtain information about the COVID- 19 pandemic's impact on patients with obesity starting March 09, 2020 until May 18, 2020.
223970578|NCT00369603|DRUG|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
223970579|NCT00369603|DRUG|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
223970580|NCT02396446|OTHER|Abdominal acoustic measurement|Device meant to listen to the sounds of the gut to determine post op ileus.
223970581|NCT02344017|DRUG|ODM-204|co-administered with prednisone, orally daily
223970582|NCT02344017|DRUG|Prednisone|ODM-204 is co-administered with oral prednisone
223970583|NCT04859218|PROCEDURE|RBC transfusion|two consecutive transfusion episodes: an ABO identical product at one transfusion episode and an ABO non-identical product for the other episode. The number of RBCs given for each study transfusion episode will be identical 2 RBC units.
223970584|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
223970585|NCT01213992|DRUG|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
223970586|NCT00695370|DRUG|Pegfilgrastim (drug)|
223970587|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
223970588|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
223542921|NCT02156193|PROCEDURE|Prophylactic clip|Prophylactic clipping
223542922|NCT02156193|PROCEDURE|No prophylactic management|No prophylaxis
223542923|NCT00420381|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
223970589|NCT04049240|DEVICE|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
223970590|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
223970591|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
224114050|NCT02458651|OTHER|No intervention|No intervention administered in this study
224114051|NCT04003506|DRUG|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine + 10ml 0.5% standard bupivacaine
224114052|NCT04003506|DRUG|Bupivacaine Injection|LIA with ACB will be given using 20ml 0.5% standard bupivacaine
224114053|NCT01549847|DRUG|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
224114054|NCT01549847|DRUG|Placebo|Placebo PO BID
224114055|NCT02584569|DRUG|TAK-915|TAK-915 oral suspension
224114056|NCT05159232|PROCEDURE|hospital stay|hospital stay in in inguinal hernia repair
224114057|NCT06012604|BIOLOGICAL|allogeneic mesenchymal stromal stem cells|mesenchymal stromal stem cells injection under ultrasound guidance into parotid and submandibular glands
224114058|NCT06035380|OTHER|placebo group|aromatherapy
224114059|NCT06035380|OTHER|mint oil group|aromatherapy
224114060|NCT06035380|OTHER|rose oil group|aromatherapy
224114061|NCT03121352|DRUG|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
224114062|NCT03121352|DRUG|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
223970592|NCT04049240|DEVICE|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
223970593|NCT06413277|DEVICE|Saluda Evoke Smart SCS System|Surgical implantation of the Saluda Evoke Smart SCS System targeting the conus medullaris for stimulation
223970594|NCT00821119|DEVICE|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
224114063|NCT03121352|DRUG|Pembrolizumab|200 mg IV every 21 days
224114064|NCT02333240|OTHER|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
224114065|NCT05173272|DRUG|Neoadjuvant Therapy|Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
224114066|NCT05173272|RADIATION|CCRT|weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.
224114067|NCT05173272|RADIATION|Brachytherapy|The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.
224114068|NCT01825044|DRUG|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
224114069|NCT01825044|DRUG|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
224114070|NCT02467595|DRUG|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
224114071|NCT02467595|DRUG|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
224114072|NCT02467595|DRUG|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
224114073|NCT02467595|DRUG|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
224114074|NCT02467595|DRUG|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
224114075|NCT00859898|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
224114076|NCT00859898|DRUG|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
224114077|NCT00859898|DRUG|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
224114078|NCT00859898|DRUG|dapagliflozin matching Placebo|Tablets
224114079|NCT00859898|DRUG|metformin HCl Modified Release matching Placebo|Tablets
223970595|NCT06240377|DEVICE|Transcranial direct current stimulation (tDCS)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
223970596|NCT06240377|DEVICE|Ultrasound-guided percutaneous neuromodulation (NMP)|"EPTE Bipolar System is a medical device for health professionals that combines several techniques that extend the therapeutic variety of electrostimulation, for the treatment of different pathologies of the musculoskeletal system and peripheral and central nervous system.~It is a nationally manufactured device that meets all quality standards, being the perfect tool for the application of techniques such as tDCS. It is a versatile, compact, portable and easy to use equipment that has the ability to adapt the parameters to achieve any protocol established by scientific evidence to treat the various pathologies.~The EPTE® Bipolar System device has an CE Health Certificate."
223970597|NCT00243217|DRUG|SPM 936|
223970598|NCT02480244|BEHAVIORAL|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
223970599|NCT02480244|OTHER|Control|Control arm receives no health-related behavioral intervention
223970600|NCT03334799|DEVICE|sacroiliac belt|standing and walking with the belt on and with the belt off
223970601|NCT00550771|DRUG|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m\^2 IV push + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
223970602|NCT00550771|DRUG|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m\^2 IV over 60 minutes + cyclophosphamide 600 mg/m\^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m\^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
223970603|NCT01701271|OTHER|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
223970604|NCT04830761|BEHAVIORAL|Motivation|The key constructs targeted by the motivational module are attitudes towards the target behavior, risk perception, outcome expectancies and self-efficacy. The intervention includes the following techniques: information about health consequences, salience of consequences, goal setting (behavior), problem solving, verbal persuasion about capabilities, focus on past success (Michie et al., 2013)
223970605|NCT04830761|BEHAVIORAL|Habit|The goal of the habit module is to guide participants to perform correct hand hygiene at self-selected key times repeatedly. The aim is that the behavior will be translated into a habit. The intervention includes the following techniques: Information about antecedents, self-monitoring of behavior, action planning, prompts/cues, habit formation, behavioral practice/ rehearsal, prompts/cues (physical cue) (Michie et al., 2013).
224114080|NCT03789773|DEVICE|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
224114081|NCT02253667|DEVICE|HFONC|
224114082|NCT02253667|DEVICE|Conventional oxygen therapy|
224114083|NCT01302041|DRUG|Enzalutamide|Oral
224114084|NCT03697395|DIAGNOSTIC_TEST|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
224114085|NCT03697395|DRUG|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
224114086|NCT04718987|RADIATION|Low dose rate (LDR) brachytherapy|Low dose rate (LDR) brachytherapy is a type of radiation treatment where doctor places the radioactive implants (seeds) inside patient's prostate gland and these seeds emits low dose radiation over a certain period of time. During low-dose-rate brachytherapy, a continuous low dose of radiation is released over time -from several hours to several days.
224114087|NCT01150994|BEHAVIORAL|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
224114088|NCT03791983|OTHER|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
224291801|NCT03216694|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
223970606|NCT04830761|BEHAVIORAL|Social|The key constructs targeted by the social module are perceived norms including descriptive norms and injunctive norm. The intervention includes the following techniques: Monitoring of behavior by others, social incentive, social comparison, social reward, restructuring the physical environment, information about others approval, credible source, information about health consequences, feedback on behavior (Michie et al., 2013).
223970607|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 1: PH-10 with 544 nm LED light illumination.
223970608|NCT00555646|DRUG|PH-10 (rose bengal disodium 0.001%)|Treatment plaque area 2: PH-10 with ambient light illumination.
223970609|NCT00555646|DRUG|Control|No treatment control.
223970610|NCT02536885|PROCEDURE|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
223970611|NCT02536885|PROCEDURE|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
223970612|NCT00429078|GENETIC|2nd Generation Designer T Cells|
224114089|NCT03791983|OTHER|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
224291802|NCT02645344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
223725042|NCT04405986|PROCEDURE|Auditory Evoked Potentials (AEP)|Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
223725043|NCT04405986|PROCEDURE|Blink and Masseter Inhibitory Reflex|Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
223725044|NCT03912766|DIAGNOSTIC_TEST|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
223970613|NCT01855178|DEVICE|Emfit Movement Monitor|Factory settings
223970614|NCT05428241|BEHAVIORAL|Assigned Interventions|Behavioral: 6 sessions of Motivational Interviewing and 3-month follow-up. 6 sessions of Motivational Interview will be applied to the working group. All sessions will be in the form of face-to-face meetings. Each interview will take an average of 45-60 minutes. With this intervention, it was aimed to increase the levels of coping with motivational interviewing, functionality, adherence to treatment and quality of life in bipolar disorder patients. Study data consists of personal information form, Morisky Treatment Adherence Scale (MMAS), World Health Organization Quality of Life Scale, Short Form (WHOQOL-BREF), Assessment of Coping Attitudes Inventory (COPE), Bipolar Disorder Functioning Questionnaire (BDFQ). Data will be analyzed pre-intervention, post-intervention and 3 months post-intervention. A drug and device will not be administered to participants.
223970615|NCT02160678|DRUG|Vehicle|Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle
223970616|NCT02160678|DRUG|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product
223970617|NCT02160678|DRUG|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
223970618|NCT02605278|OTHER|Clinical program for pain and depression|Already described
223970619|NCT02605278|OTHER|Control|Care as usual
223970620|NCT02645773|DEVICE|non-ablative laser|non-abaltive laser pre, immediate and post wounding
223970621|NCT00003698|DRUG|fosbretabulin disodium|
223970622|NCT03666208|DEVICE|Sirolimus Coated Balloon|"Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution."
223970623|NCT02457442|DRUG|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
224291803|NCT02645344|BEHAVIORAL|Sensory Cueing (SC)|
224291804|NCT02645344|BEHAVIORAL|Conventional Rehabilitation|
224291805|NCT03898674|DRUG|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
224291806|NCT04299659|DIAGNOSTIC_TEST|Landolt C entry method|Four different methods for entering the Landolt C gap position are compared
224291807|NCT06136624|DRUG|Opevesostat|Administered orally
224291808|NCT06136624|DRUG|Abiraterone acetate|Administered orally
224291809|NCT06136624|DRUG|Enzalutamide|Administered orally
224291810|NCT06136624|DRUG|Hydrocortisone|Administered orally or IM as a rescue medication
224291811|NCT06136624|DRUG|Fludrocortisone acetate|Administered orally
224291812|NCT06136624|DRUG|Prednisone|Administered orally
224291813|NCT06136624|DRUG|Dexamethasone|Administered orally as rescue medication
224291814|NCT06072482|DRUG|Avacopan|Administered orally.
224291815|NCT06072482|DRUG|Placebo|Administered orally.
223970624|NCT02457442|DRUG|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
223970625|NCT02457442|DRUG|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
223970626|NCT02457442|DRUG|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
223970627|NCT02457442|DRUG|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
223970628|NCT02457442|DRUG|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
223970629|NCT01502605|DRUG|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
223970630|NCT04604951|DEVICE|Transcutaneous Spinal Cord Stimulation|This non-invasive therapeutic modality uses electrodes applied over the skin to deliver electrical stimulation. It is based on the same principles of ground-breaking work from the investigator's group and others, showing that stimulation of the spinal cord can promote motor and autonomic (cardiovascular, bladder, bowel) recovery in individuals with chronic SCI.
223970631|NCT02203045|OTHER|Total Knee Arthroplasty|
223970632|NCT02136342|DRUG|chlorogenic acid|
223970633|NCT06074445|OTHER|No intervention|No intervention
223970634|NCT00206505|DRUG|Taxotere|
223970635|NCT01520077|DRUG|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
224114090|NCT02367170|PROCEDURE|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation \>92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
224114091|NCT02367170|DRUG|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
224114092|NCT02367170|PROCEDURE|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
224291816|NCT06072482|DRUG|Standard of Care|All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
224291817|NCT04578834|DRUG|Placebo|Placebo to LNP023 200mg b.i.d
224291818|NCT04578834|DRUG|LNP023|LNP023 200mg b.i.d
224291819|NCT03997370|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223542924|NCT01201551|DRUG|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
223542925|NCT01201551|DRUG|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
223542926|NCT01201551|DRUG|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
223542927|NCT00173017|DEVICE|wearing N95 masks|
224291820|NCT03997370|DRUG|Carboplatin|Given IV
224291821|NCT03997370|DRUG|Iohexol|Given IV
223970636|NCT04915079|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"PRISM is a novel resilience resource intervention consisting of five, one-on-one sessions lasting 30-50 minutes targeting specific teachable resilience skills: stress management, problem solving, goal setting, benefit finding, and meaning making. Sessions will occur at a time convenient to the patient with the first session to occur within 1 week of enrollment either while inpatient or if the patient is discharged, in the outpatient setting in-person or by HIPPA-compliant Zoom. After completion, participants will receive weekly booster contacts (invitations to practice reviewing certain skills) until the occurrence of a planned patient-clinician conversation, facilitated and arranged by study staff during the 5th session. All participants will receive paper worksheets to practice skills between sessions, plus access to a free, digital PRISM app (available only for patients enrolled in PRISM)."
223970637|NCT04564859|DEVICE|Heated Humidified High-Flow Nasal Cannula|Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
223970638|NCT03142828|DRUG|Chlorhexidine|Healing abutment with Clorhexidine
223970639|NCT03142828|OTHER|Placebo|Healing abutment without any antiseptic
223970640|NCT04662606|BEHAVIORAL|Consumption of a standard meal prior to the fMRI data collection|Consumption of a standard meal prior to the fMRI data collection
223970641|NCT00560807|PROCEDURE|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
223970642|NCT03581344|DIAGNOSTIC_TEST|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
223970643|NCT02660047|DRUG|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
223970644|NCT02660047|DRUG|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
223970645|NCT06477237|BIOLOGICAL|HB0017 Q4W|HB0017 at W0,1,2,4,8+HB0017Q4W
223542928|NCT05001971|DRUG|Anlotinib Plus Penpulimab|Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
223970646|NCT06477237|BIOLOGICAL|HB0017 Q8W|HB0017 at W0,1,2,4,8+HB0017Q8W
223970647|NCT06477237|BIOLOGICAL|placebo|placebo at W0,1,2,4,8+HB0017Q4W
223970648|NCT05204316|OTHER|Digital Analysis of Speech|Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.
223970649|NCT04113928|DIETARY_SUPPLEMENT|Broccoli & mustard seed soup|200ml acute feed
223970650|NCT04113928|DIETARY_SUPPLEMENT|Broccoli soup|200ml acute feed
223970651|NCT01928407|DRUG|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
223970652|NCT01928407|DRUG|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
223970653|NCT04070729|OTHER|Placebo gel|Localized subgingival application
223970654|NCT04070729|DRUG|Hyaluronic acid gel|Localized subgingival application
223970655|NCT04070729|BIOLOGICAL|Platelet rich fibrin|Localized subgingival application
223970656|NCT01628289|OTHER|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
223970657|NCT01628289|OTHER|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
223970658|NCT03152500|DEVICE|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
223970659|NCT03152500|DEVICE|Acrysof SN60WF IOL|IOL in the bag
223970660|NCT02406040|OTHER|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
224291822|NCT06580314|BIOLOGICAL|Bevacizumab|Given IV
224291823|NCT06580314|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224291824|NCT06580314|PROCEDURE|Computed Tomography|Undergo CT
223725045|NCT00038207|DRUG|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
223970661|NCT00069628|DEVICE|GlucoWatch® G2™ Biographer (GW2B)|
223970662|NCT00069628|DEVICE|Continuous Glucose Monitoring System (CGMS)|
223970663|NCT00331851|DRUG|liraglutide|
223970664|NCT00331851|DRUG|insulin glargine|
223970665|NCT00331851|DRUG|metformin|
223970666|NCT00331851|DRUG|glimepiride|
223970667|NCT02303847|DRUG|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
224291825|NCT06580314|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224291826|NCT06580314|DRUG|Olaparib|Given PO
224291827|NCT03812705|BIOLOGICAL|fecal microbiome transplantation|"1. Stop antibiotics treatment 1 day before fecal microbiome transplantation;~2. Fasting food 6 hours before fecal microbiome transplantation;~3. Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~4. Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~5. Perform up to 4 times if patient response;~6. Stop if no response after twice fecal microbiome transplantation."
224291828|NCT05008848|BEHAVIORAL|Smoking Cessation Intervention|Participate in schedule gradual reduction program
224291829|NCT05008848|OTHER|Health Promotion and Education|Receive cessation support messages
224291830|NCT05008848|OTHER|Informational Intervention|Receive NCI's Clearing the Air booklet
223970668|NCT00002216|DRUG|Lamivudine/Zidovudine|
223970669|NCT00002216|DRUG|Abacavir sulfate|
223970670|NCT00002216|DRUG|Amprenavir|
223970671|NCT00002216|DRUG|Nelfinavir mesylate|
223970672|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
224291831|NCT05008848|OTHER|Questionnaire Administration|Ancillary studies
224291832|NCT06134167|DEVICE|Transdermal Compress Device|Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
224291833|NCT01758133|BEHAVIORAL|Exposure to medical clown activities|
224291834|NCT04742777|DRUG|rapamycin|Taken orally 1mg daily for 8 weeks
224291835|NCT05974267|DRUG|M5717 60 mg|Participants will receive single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition
224291836|NCT05974267|DRUG|Pyronaridine|Participants will receive Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition
224291837|NCT05974267|DRUG|Atovaquone-Proguanil|Participants will Receive Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.
224291838|NCT05974267|DRUG|M5717 200 mg|Participants will receive single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition
223970673|NCT01073215|BEHAVIORAL|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
223970674|NCT03135821|DIAGNOSTIC_TEST|TCM|
223970675|NCT05234645|OTHER|Kefir consumption|Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
223970676|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
223970677|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
223970678|NCT01494740|BIOLOGICAL|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
223970679|NCT02178397|DRUG|ERLOTINIB WITH CHEMOTHERAPY|
223970680|NCT02178397|DRUG|CHEMOTHERAPY ONLY|
223970681|NCT05225285|BIOLOGICAL|Inactivated Coronavac/Butantan vaccine|Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart
223970682|NCT05225285|BIOLOGICAL|BNT162b2 (Pfizer)|BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
223970683|NCT02206464|BIOLOGICAL|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
223970684|NCT02206464|BIOLOGICAL|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
223970685|NCT02312622|DRUG|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
223970686|NCT01648985|OTHER|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
223970687|NCT02361177|DRUG|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
223970688|NCT00936754|DIETARY_SUPPLEMENT|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
223970689|NCT00936754|DIETARY_SUPPLEMENT|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
223970690|NCT05475496|OTHER|Measurements of quality of life and burnout|"WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items)."
223970691|NCT03358303|DEVICE|Medly|Medly will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
224122719|NCT05980832|OTHER|Peer practitioner training - Peer Education Supported Psychosocial Skills Education|"Psychosocial skills training-practitioner training will be given to 4 patients diagnosed with chronic mental disorder by the research psychiatry nurse.~Educational content~1. Getting acquainted - briefing about the study~2. The Importance, Aims and Objectives of Psychosocial Skills Education~3. The importance of peer support~4. The importance, aims and objectives of peer education supported psychosocial skills training~5. Management of the meeting game, warm-up games and role plays~6. 1st and 2nd session peer education supported psychosocial skills training~7. 3rd and 4th session peer education supported psychosocial skills training~8. The last 5th and 6th sessions of peer education are supported by psychosocial skills training.~9. Key points and termination in group management. The training will be planned to last 10-13 hours in total. Trainer's booklet prepared by the researcher psychiatric nurse."
224291839|NCT05974267|DRUG|M5717 660mg|Participants will receive single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition
223970692|NCT02223507|DRUG|BIIR 561 CL|
224291840|NCT02158858|DRUG|Pelabresib|CPI-0610 is administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)
223970693|NCT02223507|DRUG|Placebo|
223970694|NCT03535480|DRUG|G-CSF|G-CSF subcutaneously during five days
223970695|NCT03535480|COMBINATION_PRODUCT|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
223970696|NCT05362513|DRUG|Ivermectin Tablets|Group B received a single dose of oral ivermectin 200 mcg per kg
223970697|NCT05362513|DRUG|Permethrin Cream|Group A received Permethrin 5% twice with a one-week interval.
223970698|NCT02299856|OTHER|Cardiac magnetic resonance scan|
223970699|NCT04165525|DEVICE|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
223970700|NCT01807936|PROCEDURE|Lymphadenectomy|
223970701|NCT01717547|BEHAVIORAL|Yoga-based treatment|
223970702|NCT05353621|BEHAVIORAL|VAS reported Stress|VAS reported Stress measurement during simulation
223970703|NCT00024570|DRUG|IL13-PE38QQR|
223970704|NCT00024570|PROCEDURE|targeted fusion protein therapy|
223542929|NCT04954534|BIOLOGICAL|human umbilical cord blood derived mesenchymal stem cells|High dose: 3 x 10\^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4-week intervals
223970705|NCT00024570|PROCEDURE|surgery|
223970706|NCT05291585|DEVICE|the dedicated venous sinus thrombectomy stent|the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.
223970707|NCT05291585|DEVICE|balloon catheter thrombectomy|Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
223970708|NCT02640326|OTHER|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
223970709|NCT02640326|OTHER|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
223970710|NCT05692414|DIETARY_SUPPLEMENT|Preoperative carbohydrate drink|Allocation will be performed using an alternating weeks scheme. Patients undergoing surgery in the first week will be included in the control group and follow a conventional fasting protocol. However, patients undergoing surgery the following week will be included in the intervention group and take 800 ml of CHO drink on the day before surgery and 400 ml on the surgery day no later than 6 hours before the procedure.
223970711|NCT00839306|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
223970712|NCT00839306|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
223970713|NCT03780699|PROCEDURE|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
223970714|NCT01697592|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
223970715|NCT01697592|DRUG|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
223970716|NCT05315076|OTHER|thoracic Manipulation Posterior anterior and conventional therapy|A high-velocity, end range force directed to both sides of the respective zygapophyseal joint as indicated by the segmental examination. This procedure will be performed for a maximum of two attempts. When a cracking sound occurred, the therapist will move on to the next segmental restriction from an upper level to a lower level.
223970717|NCT05315076|OTHER|Muscle Energy Technique (PIR) and conventional treatment|sustain the Isometric contraction for 7-10 and hold the breath. Then the patient will be asked to breathe out and relax while the therapist stretches further up to the neck barrier and hold this for 30 seconds.3 to 5 repetition
223970718|NCT05733000|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223970719|NCT05733000|PROCEDURE|Computed Tomography|Undergo CT
223970720|NCT05733000|DRUG|Devimistat|Receive IV
224291841|NCT02158858|DRUG|Ruxolitinib|Ruxolitinib is given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.
223970721|NCT05733000|DRUG|Fluorouracil|Receive IV
223970722|NCT05733000|DRUG|Gemcitabine Hydrochloride|Receive IV
223970723|NCT05733000|DRUG|Hydroxychloroquine|Receive PO
223970724|NCT05733000|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223970725|NCT01132222|DRUG|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
223970726|NCT00829647|DRUG|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
223970727|NCT06106789|DRUG|Tobramycin inhalation solution|"Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital."
223970728|NCT05325658|OTHER|FEES, treatment with modified diet, electrical swallowing muscle stimulation.|Endoscopic swallowing assessment (FEES) consists of three parts:1) assessment of mouth, throat anatomy and more; 2) the patient is given to swallow a certain amount and consistency of liquids and solid food. 3) evaluated: preparation of the bolus for swallowing, aspiration. An 8-point Penetration-Aspiration scale is described.Swallowing exercises. Swallowing exercises are also used in practice, which can help coordinate the swallowing muscles or stimulate the nerves involved in the swallowing reflex.Transcutaneous electrical stimulation is a method of treating dysphagia in which weak electrical impulses stimulate the muscles in the neck area associated with swallowing. In patients with oropharyngeal dysphagia, patients have great difficulty swallowing water of normal consistency or other non-thick liquids, so they should be thickened with special thickeners to such an extent that the patient does not experience discomfort and be able to swallow.
223970729|NCT01862679|OTHER|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
223970730|NCT01862679|PROCEDURE|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
223970731|NCT01039597|DRUG|ORE1001|Oral capsules containing 300 mg of the active, study drug
223970732|NCT01039597|DRUG|Placebo|placebo capsules
223970733|NCT00558220|PROCEDURE|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
223970734|NCT00558220|PROCEDURE|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
223970735|NCT00558220|PROCEDURE|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are \>20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
223970736|NCT00558220|PROCEDURE|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
223970737|NCT00558220|PROCEDURE|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
223970738|NCT00558220|RADIATION|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (\>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
223970739|NCT01126879|DIETARY_SUPPLEMENT|genistein|Given orally
223970740|NCT01126879|OTHER|placebo|Given orally
223970741|NCT01126879|PROCEDURE|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
223970742|NCT02024399|OTHER|Exercise|Strength training, aerobic exercise and core strengthening, running
223970743|NCT03715413|OTHER|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
223970744|NCT03715413|DRUG|Tamoxifen|received Tamoxifen 10 mg daily
223970745|NCT05221216|OTHER|Collect data of medical record|Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
223970746|NCT00498433|DRUG|Aliskiren|300 mg tablet once daily
223970747|NCT00498433|DRUG|Amlodipine|5 mg capsule once daily
223970748|NCT00498433|DRUG|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
223970749|NCT00498433|DRUG|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
223970750|NCT02536547|DEVICE|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
223970751|NCT01212952|DRUG|pomalidomide|Given orally
223970752|NCT01212952|DRUG|bortezomib|Given IV
223970753|NCT01212952|DRUG|dexamethasone|Given orally
223970754|NCT01212952|OTHER|laboratory biomarker analysis|Optional correlative studies
223970755|NCT01212952|OTHER|gene expression analysis|Optional correlative studies
223970756|NCT05973357|PROCEDURE|Sub-crestal implant|Patients receiving delayed implant placed 2mm sub-crestal level with immediate provisionalization
223970757|NCT05973357|PROCEDURE|Equi-crestal implant|Patients receiving delayed implant placed equi-crestal level with immediate provisionalization
223970758|NCT02117856|PROCEDURE|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
224291842|NCT05535361|DEVICE|Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome|The surgeon verifies the intestinal diameter and selects the appropriate device diameter size. The device is introduced into the lumen of the intestine and advanced about 5-10cm. The surgeon uses 4-0 chromic sutures placed in the seromuscular layer to secure the XL1 Coil within the intestine. The surgeon places metal clips on proximal and distal sutures and in the mesentery adjacent to the XL1 Coil ends to mark the location for radiologic evaluation. The surgeon releases the XL1 Coil and closes the enterotomy.
223970759|NCT02117856|PROCEDURE|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
223970760|NCT02117856|PROCEDURE|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
224114093|NCT02367170|DEVICE|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
224114094|NCT02367170|DEVICE|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
224291843|NCT06564896|DEVICE|CPAP Airsense 10 vs Air-Mini|Patients' satisfaction and CPAP efficacy
223970761|NCT02117856|DEVICE|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
223970762|NCT02117856|DEVICE|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
223970763|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
223970764|NCT02117856|PROCEDURE|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
223970765|NCT01641289|DRUG|Paracetamol|\>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate \<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
223970766|NCT01641289|DRUG|No Paracetamol|"No paracetamol + Intravenous Artesunate~* If temperature \> 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
223970767|NCT01538901|OTHER|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
223970768|NCT01538901|DRUG|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
223970769|NCT04208815|OTHER|Milk Polar Lipids|Effects of the addition of 5 g of milk polar lipids to 20 g milk fat.
223970770|NCT04208815|OTHER|Milk Fat|Effects of the addition of 20 g milk fat.
223970771|NCT00234221|BEHAVIORAL|Strengths Based Case Management|
223970772|NCT00234221|BEHAVIORAL|Motivational Enhancement Therapy|
223970773|NCT00234221|BEHAVIORAL|Brief Informational Feedback|
223970774|NCT03744741|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
223970775|NCT02543697|RADIATION|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
223970776|NCT00425906|DRUG|nicotine|
223970777|NCT00425906|OTHER|Placebo|
223970778|NCT00425906|PROCEDURE|Quality of life|
223970779|NCT04881396|BIOLOGICAL|Evaluation of the immunogenicity of the vaccine in haemodialysis patients|The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
224114095|NCT02367170|PROCEDURE|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
224114096|NCT02367170|OTHER|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
224114097|NCT00032019|BIOLOGICAL|filgrastim|Cycle 1: 300 ug (BW \< = 70 kg) or 480ug (BW \>70 kg) sub Q injection Day 6 until ANC \> 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
224114098|NCT00032019|BIOLOGICAL|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
224114099|NCT00032019|DRUG|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
223970780|NCT04498871|DRUG|Nilotinib|Nilotinib is recommended to be administered orally on a continuous schedule at a dose of 400 mg twice daily. The patient should be instructed to take each morning dose of nilotinib 2 hours after a light breakfast (e.g., toast and jam), with no oral intake other than water for 1 hour after dosing. It is recommended that the patient take nilotinib doses every 12 hours with a glass of water. The evening dose of nilotinib should be taken at least 2 hours after dinner with no oral intake other than water for 1 hour after dosing.
223970781|NCT03193216|DRUG|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
223970782|NCT05913583|DRUG|Immune checkpoint inhibitor|"Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1."
223970783|NCT01514864|DRUG|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
223970784|NCT06158971|DEVICE|Flexible Bronchoscopic Microwave Ablation|The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
223970785|NCT00271466|DRUG|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
224291844|NCT04609046|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
224114100|NCT00032019|DRUG|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
224114101|NCT00032019|DRUG|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
224114102|NCT00032019|DRUG|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
224114103|NCT00032019|DRUG|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
224114104|NCT01872741|PROCEDURE|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
224114105|NCT01872741|PROCEDURE|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
224114106|NCT01673724|DRUG|pramipexole|pramipexole
223970786|NCT02373605|OTHER|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
223970787|NCT02373605|OTHER|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
223970788|NCT02223871|DRUG|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
223970789|NCT02223871|OTHER|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
223970790|NCT02223871|DRUG|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
223970791|NCT02223871|DRUG|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
223970792|NCT02253147|DEVICE|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
223970793|NCT00004016|BIOLOGICAL|recombinant interferon gamma|
224114107|NCT01673724|DRUG|Bromocriptine|bromocriptine
224114108|NCT04504032|DRUG|Rivaroxaban|Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
224114109|NCT04504032|DRUG|Placebo|Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
224114110|NCT00771030|BIOLOGICAL|Brodalumab|Solution for subcutaneous or intravenous administration
224114111|NCT00771030|OTHER|Placebo|Solution for subcutaneous or intravenous administration
223970794|NCT00478322|DRUG|Placebo|Matching placebo of 100 mg BID
223970795|NCT00478322|DRUG|INCB013739|INCB013739 100 mg BID
223970796|NCT02924532|BIOLOGICAL|immediate post operative bioassay of Parathyroid Hormone|
224114112|NCT02734550|OTHER|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
224114113|NCT02734550|OTHER|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
224114114|NCT04693247|DEVICE|EQ103|Refraction device
224114115|NCT01842464|PROCEDURE|Anterior Sacro-Spinous|Anterior Sacro-Spinous
224114116|NCT01220752|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
224114117|NCT00956644|DRUG|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
224114118|NCT00956644|DRUG|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
224114119|NCT01198444|DRUG|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
224114120|NCT01450930|DRUG|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
224114121|NCT01450930|DRUG|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
224114122|NCT03341468|DEVICE|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
224114123|NCT00729118|DRUG|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
224291845|NCT04609046|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
224291846|NCT04609046|PROCEDURE|Echocardiography Test|Undergo ECHO
224291847|NCT04609046|DRUG|Lenalidomide|Given PO
223970797|NCT02641106|OTHER|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
223970798|NCT02641106|OTHER|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
223970799|NCT04978012|DRUG|Fluzoparib and Camrelizumab|Maintenance therapy of Fluzoparib and Camrelizumab, until disease progression or intolerable adverse effect.
223970800|NCT03965247|DRUG|Lithium|
223970801|NCT03965247|OTHER|Placebo - Rayotabs|
223970802|NCT03256370|PROCEDURE|milk collection|"* Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~* After completed informed consent, demographic data was collected and filled in case record form~* Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~1. Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~2. High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
223970803|NCT00371618|PROCEDURE|Fluoroscopy|
223970804|NCT00978497|DRUG|placebo|oral BID
223970805|NCT00978497|DRUG|ANA598|oral 200mg BID
223970806|NCT00978497|DRUG|ANA598|oral 400mg BID
223970807|NCT00978497|DRUG|Peginterferon|180 μg dose via subcutaneous injection weekly
223970808|NCT00978497|DRUG|Ribavirin|oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
223970809|NCT02054598|BEHAVIORAL|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
223970810|NCT05388864|BEHAVIORAL|Three-Tier Model|Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
223970811|NCT05915832|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
223970812|NCT05915832|PROCEDURE|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
223970813|NCT01181583|BEHAVIORAL|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
223970814|NCT01181583|BEHAVIORAL|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
223970815|NCT01181583|BEHAVIORAL|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
223970816|NCT02254681|DRUG|Gemcitabine|
223970817|NCT02254681|DRUG|Cisplatin|
223970818|NCT02254681|RADIATION|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
224114124|NCT00729118|DRUG|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
223970819|NCT02611375|OTHER|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
223970820|NCT02611375|OTHER|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
223970821|NCT02611375|OTHER|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
223970822|NCT05217290|BEHAVIORAL|transtheoretical model|The Transtheoretic Model is a conscious behavior change model and argues that behavior change is a process and that the attempts made in accordance with the change stage of the individual facilitate the change, otherwise resistance to behavior change is developed.
224114125|NCT03340077|OTHER|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
224114126|NCT03340077|OTHER|Standard of Care|Pharmacist review of ART medications
224114127|NCT00006386|DRUG|carmustine|
223970823|NCT04316221|DIETARY_SUPPLEMENT|Eggs plus standard of care|Eggs will be secured locally and delivered to families weekly.
223970824|NCT04316221|OTHER|Standar of care|frequent growth monitoring, general nutrition education, parasite treatment, and multiple micronutrient supplementation.
224114128|NCT00006386|RADIATION|radiation therapy|
224291848|NCT04609046|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224291849|NCT04609046|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223970825|NCT00207233|BEHAVIORAL|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
224114129|NCT00006386|RADIATION|stereotactic radiosurgery|
224114130|NCT05279469|OTHER|no intervention, just observational for D-Dimer level in blood|observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
224114131|NCT03340493|DRUG|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
224114132|NCT00114114|DRUG|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10\* gms topically each day
224114133|NCT00114114|DRUG|Goserelin acetate|3.6 gms sc every 4 weeks
224291850|NCT04609046|DRUG|Methotrexate|Given IV or PO
224291851|NCT04609046|BIOLOGICAL|Nivolumab|Given IV
224291852|NCT04609046|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224291853|NCT04609046|BIOLOGICAL|Rituximab|Given IV
224291854|NCT04609046|PROCEDURE|Ultrasound Imaging|Undergo testicular ultrasound
224291855|NCT05568680|BIOLOGICAL|SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR|Autologous T cells Transduced with Mesothelin KIR-CAR
223970826|NCT00207233|BEHAVIORAL|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
223970827|NCT00207233|PROCEDURE|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
223970828|NCT06149052|OTHER|SMART TRAINING|Patients in Group A received SMART training intervention. For sensory stimulation planter massage was given, and it was applied to entire planter surface. Grade III anterior to posterior talocrural joint mobilization was given (26). For balance, single and double leg stance was performed. For functional training, lateral hops and SEBT was performed. And at the end, for resistance training, theraband was used with normal ankle joint movement. There is a progress in focus between the five domains over the 3weeks, as described below: The domains S and M are present across the whole intervention. In week 1, the main focus is on the A domain, in week 2 on the R domain, and in week 3 on the T domain. During the 3-week intervention period, 3 training sessions was held per week each lasting approximately 45 - 60 min, including 10 min warm up
223970829|NCT06149052|OTHER|FIRE training|Patients in Group B was received foot intensive rehabilitation (FIRE).The FIRE intervention was include the progressive balance training, ankle and hip strengthening, range of motion exercises and foot massage. Plantar massage consisted of two, 1-min plantar massages with a 1-min rest between sets. Four previously established exercises were targeted the IFMs including the short-foot, toe-spread-out, hallux extension, and lesser-toe extension
223970830|NCT00212719|DRUG|ONO-5920|
223970831|NCT02846597|PROCEDURE|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
223970832|NCT01700114|DEVICE|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
223970833|NCT02880332|OTHER|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
223970834|NCT02880332|OTHER|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
223970835|NCT02880332|OTHER|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
223970836|NCT02762539|DRUG|omega-3 enriched SMOF lipid emusion|
224114134|NCT03081325|PROCEDURE|low-dose lymphocyte immunotherapy|Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
224114135|NCT00087204|DRUG|becatecarin|Given IV
224114136|NCT00087204|OTHER|laboratory biomarker analysis|Correlative studies
223725046|NCT03896776|BEHAVIORAL|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions, totaling \~1 hour of main content, plus 2 booster sessions at 6- and 12-week follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
223725047|NCT06089135|DEVICE|Intravascular Lithotripsy|Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
223725048|NCT06089135|DEVICE|Cutting Balloon|Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
223725049|NCT03339960|OTHER|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
224114137|NCT00957346|DRUG|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
223725050|NCT02597894|PROCEDURE|Biopsy of Prostate|Undergo biopsy
223725051|NCT02597894|OTHER|Laboratory Biomarker Analysis|Correlative studies
223970837|NCT04323332|DRUG|Traditional Chinese Medicine Prescription|Traditional Chinese Medicine Prescriptions have been recommended according to the Guidelines for the treatment of COVID-19 issued by National Health Commission of the PRC.
223970838|NCT02470611|DRUG|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% sodium alendronate gel
223970839|NCT02470611|OTHER|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% placebo gel
223970840|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via serratus anterior block|patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,
223970841|NCT05661253|DRUG|25 ml of bupivacaine 0.25% via modified serratus anterior palne block|patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
223970842|NCT01414556|OTHER|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
223970843|NCT01414556|OTHER|saline|
223970844|NCT02316847|DRUG|diazepam nasal spray|
224114138|NCT00957346|DRUG|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
223725052|NCT00842712|DRUG|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
223725053|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
223970845|NCT02621047|DRUG|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
223970846|NCT04621422|BIOLOGICAL|Subject carrying an amplification of nucleotide repeats in one of the following 9 genes FMR1, DMPK, ZNF9, SCA2, JPH3, HD, FXN, C9ORF72, RFC1|Biological/Vaccine: DNA Samples collection as part of usual care
223970847|NCT00397020|DRUG|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
223970848|NCT00397020|DRUG|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
223970849|NCT05546424|BEHAVIORAL|EMRESERVA|training program will be carried out in groups (up to 6 patients) who will meet one hour once a week for 5 months.
223970850|NCT04421313|DRUG|Dietary Fiber Supplementation|12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
224114139|NCT02125929|PROCEDURE|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
223725054|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m\^2) as intravenous infusion over 2 hours on Day 1.
223725055|NCT00842712|DRUG|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.
223725056|NCT00842712|DRUG|Cisplatin|Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
223725057|NCT00842712|DRUG|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
223970851|NCT03718819|OTHER|exercise|Pilates and aquaplyometric exercises will be done combinedly.
223970852|NCT03121729|PROCEDURE|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
223970853|NCT04675762|DRUG|Fingolimod|Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
224114140|NCT02125929|PROCEDURE|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
224114141|NCT02125929|PROCEDURE|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
223970854|NCT04675762|OTHER|Placebo|Patients randomized to fingolimod will also receive placebo once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
223970855|NCT05068271|BEHAVIORAL|Multi-Domain Exercise Program|The multi-domain exercise consisted of the main exercise (e.g., aerobic exercise, resistance exercise, flexibility training, and coordinative exercise), social interaction, and meditation. Participants are encouraged to engage in 150 min exercise per week consisting of one 90-min on-site session and multiple online sessions for 6 months.
223970856|NCT05068271|BEHAVIORAL|Control Group|"The usual physical activity group, as the control group, is informed to maintain their lifestyles. In addition, participants are invited to attend one 60-min online educational course per week. The logs of physical activity behavior will be obtained from the participants once per month during the intervention period."
223970857|NCT01746277|DRUG|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
223970858|NCT01746277|DRUG|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
223970859|NCT00735462|DRUG|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
223970860|NCT00735462|DRUG|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
224114142|NCT01205490|OTHER|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
224114143|NCT02307305|DRUG|Duloxetine|"1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)"
224114144|NCT02307305|DRUG|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
224291856|NCT03692312|DRUG|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
224291857|NCT03692312|DRUG|Placebo|Matching placebo formulation
224291858|NCT06352437|DRUG|BI 3034701|BI 3034701
224291859|NCT06352437|DRUG|Placebo matching BI 3034701|Placebo matching BI 3034701
223725058|NCT00842712|DRUG|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.
223725059|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
223725060|NCT00842712|DRUG|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
223970861|NCT00735462|DRUG|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
223970862|NCT00607256|DRUG|[S,S]-reboxetine|S\_S reboxetine dosed daily.
223970863|NCT02236598|DRUG|K+ supplement|
223970864|NCT02236598|DRUG|Placebo|
223970865|NCT04636957|DRUG|Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution|0.25mL/vial, each vial contains 0.75mg of ciprofloxacin and 0.0625mg of fluocinolone acetonide.
223970866|NCT04636957|DRUG|Ciprofloxacin 0.3% solution|0.4mL/vial, each vial contains 1.2mg ciprofloxacin
223970867|NCT06123364|DRUG|mirabegron 50 mg daily|Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
223970868|NCT06123364|DEVICE|Extracorporeal magnetic innervation (active treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
223970869|NCT06123364|DEVICE|Extracorporeal magnetic innervation (sham treatment)|Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
223970870|NCT01484314|DRUG|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
223970871|NCT01264887|DRUG|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
224114145|NCT05286398|PROCEDURE|Palatoplasty|Surgical closure of palatal defect
224114146|NCT05286398|DIAGNOSTIC_TEST|Addition silicone impression|diagnostic impression for maxillary arch
224114147|NCT06344520|BEHAVIORAL|pektoralis minor shortnes|One factor that is effective in acceleration during swimming is the force of the arm pulling the water. While the pectoralis minor muscle pulls the crocoid process forward, it pulls its posterolateral corner down, which helps the latismus dorsi to make an extension movement and the lower trapezius to depress the scapula. When the pectoralis minor muscle is short, it prevents maximum reach in the arm because its full function cannot be revealed. It is thought that depression of the scapula will directly affect acceleration in swimming, as it increases the backward thrust of the arm.
224291860|NCT05259501|OTHER|RMIST|"RMIST will involve:~1. A study automated visual recognition web-based platform accessible on the participant's smartphone web browser.~2. A supply of methadone in single use bottles and previously described packaging to be kept securely at the methadone clinic/lab setting."
224291861|NCT00338377|BIOLOGICAL|Dendritic Cell Immunization|1x10\^7 to 2.5x10\^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
224291862|NCT00338377|DRUG|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
224291863|NCT00338377|DRUG|Fludarabine|25 mg/m\^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
223725061|NCT00842712|DRUG|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m\^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
224114148|NCT06344520|BEHAVIORAL|Group in which the Pectoralis Minor stretching exercise was performed in a sham manner|In most cases, exercise practices also affect the person psychologically. In order to ignore the psychological effects of the exercises, they were made to perform exercises that were similar to pectoralis minor stretching exercises but did not activate the muscle
224291864|NCT00338377|BIOLOGICAL|T-Cells|On Days 0, up to 1.5 x 10\^11 T-cells by vein infusion over 30-60 minutes.
224291865|NCT00338377|BIOLOGICAL|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
223542930|NCT05404971|OTHER|Joint integrity exercises|patients with three strokes followed by 3 sec rest period. Kinaesthetic stimulations will be given to the patients to increase proprioception proprioception in neglected limb in sitting position, the limb on the affected side of the body is supported and moved by the examiner in various directions but movement is only at one joint at a time. Stereognosis by placing the object in the patient's hand for a maximum 30 seconds with close eyes. Identification is by naming, description or by pair matching with an identical set.
224291866|NCT00338377|DRUG|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
223725062|NCT00842712|DRUG|Chemotherapy|Cis 80 mg/m\^2 intravenous infusion on Day 1 + Vin 25 mg/m\^2 or Cis 75 mg/m\^2 intravenous infusion on Day 1 + Gem 1250 mg/m\^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
223970872|NCT00443677|DRUG|COPPEBVCAD vs BEACOPP vs ABVD|
223970873|NCT05482256|DIAGNOSTIC_TEST|Esophageal String Test (EST)|Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.
223970874|NCT05482256|OTHER|Colgate|2 grams of toothpaste (pea sized amount) for 2 minutes
223970875|NCT05482256|DIAGNOSTIC_TEST|High Resolution Esophageal Manometry (HREM)|Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
223970876|NCT00668512|BIOLOGICAL|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
223970877|NCT01586429|OTHER|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
223970878|NCT02726035|DRUG|Naltrexone|oral naltrexone 50 mg daily
224114149|NCT06344520|BEHAVIORAL|The group in which Pectoralis Minor stretching exercise was not applied|The Control Group was not given any exercise and they continued to do their own training.
224291867|NCT00338377|BIOLOGICAL|Intrathecal T-Cells|5.0x10\^9 T-cells administered on Day 1, and 10x10\^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
224291868|NCT00338377|BIOLOGICAL|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
223725063|NCT01539057|DRUG|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
223970879|NCT02726035|OTHER|Placebo|oral placebo (appearing identical to naltrexone) once daily
223970880|NCT02171130|DRUG|Nasal Glucagon|3 mg nasal glucagon powder
223970881|NCT04613622|DRUG|Venetoclax|This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
223970882|NCT00781417|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
223970883|NCT00781417|OTHER|Placebo|Matching Placebo
223970884|NCT02981537|DEVICE|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
223970885|NCT02981537|DEVICE|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
223970886|NCT04701528|DRUG|Voclosporin|Temporarily switching of tacrolimus maintenance immunosuppression to voclosporin maintenance immunosuppression with possible additional anti-viral activity
223970887|NCT04701528|DRUG|Tacrolimus|Comparator
224114150|NCT01660841|DRUG|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
224114151|NCT05452161|OTHER|Control group|All patients follow only the standard care of the department, which includes a preoperative group session of 1h30, with 15 to 30 participants, 6 to 8 weeks before the operation The objectives of these sessions are to inform the patients in a general way about the operation, its preparation and the postoperative process in order to standardize the information received. The content includes general information from the surgeon, explanations related to the course and management of patients by the various professionals (nurse, surgeon, anesthesist, physiotherapist, ergotherapist and liaison-nurse).
224291869|NCT06534892|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered at different timepoints (revaccination groups) or for the first time (crossover group)
224291870|NCT05579366|DRUG|Rina-S|Intravenous infusion of Rina-S
224291871|NCT05579366|DRUG|Carboplatin|Carboplatin intravenous infusion
224291872|NCT05579366|DRUG|Bevacizumab|Bevacizumab intravenous infusion
223970888|NCT03836742|PROCEDURE|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
223970889|NCT03553849|DIETARY_SUPPLEMENT|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
223970890|NCT02353455|PROCEDURE|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
223970891|NCT05022290|PROCEDURE|Single-syringe diluted with normal saline technique|Adenosine is mixed with normal saline up to 20 ml in a single syringe before administering to the patient by the IV bolus method.
223970892|NCT04757714|PROCEDURE|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius|The high-resolution peripheral scanner (HRpQCT) of the tibia and radius
223970893|NCT04757714|PROCEDURE|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)|a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)
223970894|NCT04757714|OTHER|Questionnaires|"* a physical activity questionnaire (PHAS instrument)~* a COPD quality of life questionnaire (St George Hospital)"
223970895|NCT04757714|OTHER|A search for sarcopenia by studying the strength of the grip (dynamometer)|A search for sarcopenia by studying the strength of the grip (dynamometer)
223970896|NCT03544229|DRUG|TAK-906 Maleate|TAK-906 maleate capsules.
223970897|NCT03544229|DRUG|Placebo|TAK-906 maleate placebo-matching capsules.
223970898|NCT04367363|BEHAVIORAL|Social media & news consumption|Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
223970899|NCT02143310|DEVICE|EVP|
223970900|NCT03187353|DRUG|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
224114152|NCT05452161|OTHER|Intervention group A|The day of the preparatory surgical consultation (CPC), the patient has a 30 minute patient-centered education session by a physiotherapist and a 30 minute patient-centered education session by a nurse. The physiotherapist's session addresses the technical skills to be mastered postoperatively (crutching, stairs, exercises), the course of postoperative rehabilitation, the patient's role in the rehabilitation process, the questions still remaining on this subject and the patient's perspective concerning the rehabilitation (degree and sources of anxiety, expectations of follow-up and results, degree of self-efficacy). The nursing intervention addresses the postoperative pain management, the patient's role in pain management, the care pathway, the organization of the return home and the postoperative follow-up.
223970901|NCT03187353|DRUG|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
224291873|NCT05579366|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion
224291874|NCT03373227|DRUG|Envarsus|Patients will take once daily Envarsus
223970902|NCT05183243|DRUG|GH21 Capsule|GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
223970903|NCT06541340|PROCEDURE|Modified strategy|Modified preoperative biliary drainage strategy with prealbumin as the main indicator
223970904|NCT06541340|PROCEDURE|Traditional strategy|Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
223970905|NCT01593865|PROCEDURE|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
223970906|NCT01593865|PROCEDURE|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
223970907|NCT01856010|OTHER|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
224291875|NCT05721222|BIOLOGICAL|GEN1160|IV infusion of GEN1160
224291876|NCT04967274|PROCEDURE|Startling acoustic stimulus|StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus (Transcranial magnetic stimulation).
224291877|NCT06476288|OTHER|Low-intensity resistance exercise training|The intervention protocol will consist of 60 minutes of low-intensity resistance exercise training 3x/week for 6 weeks.
223970908|NCT01856010|OTHER|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
223970909|NCT00510263|DRUG|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
223970910|NCT00510263|DRUG|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
223970911|NCT00510263|DRUG|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
223970912|NCT00510263|DRUG|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
224291878|NCT06476288|OTHER|High-Dose Remote ischemic conditioning (RIC)|Treatment dose of RIC- the RIC cuff will be inflated to 20 mmHg over the participant's systolic blood pressure. The treatment dose of RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
224291879|NCT06476288|OTHER|Low-Dose Remote ischemic conditioning (RIC)|This dose will be the control for the study. Low-dose RIC- the RIC cuff will be inflated to 10 mmHg below the participant's diastolic blood pressure. The low-dose RIC will be applied in 4 sets of cycles with inflating the cuff and leaving it pumped for 5 minutes then deflating the cuff for an off period of 5 minutes. Total treatment time will be 35 minutes.
224291880|NCT06315751|DRUG|Gemlapodect|Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.
224291881|NCT06315751|DRUG|Placebo|Administered in the form of oral capsules with inert ingredients.
223970913|NCT05560945|DRUG|0.32% Sodium Fluoride Dentifrice Toothpaste|Toothpaste
223970914|NCT05560945|DRUG|1.5% Arginine Dentifrice|Toothpaste
223970915|NCT05560945|DRUG|8.0% Arginine Dentifrice|Toothpaste
224291882|NCT06065540|DRUG|Cagrilintide|Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.
224291883|NCT06065540|DRUG|Semaglutide|Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.
224291884|NCT06065540|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
224291885|NCT06065540|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
223970916|NCT04915157|DEVICE|Spinal Cord Stimulator|All patients will receive an implanted spinal cord stimulator.
223970917|NCT01061775|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
223970918|NCT01816100|OTHER|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
223970919|NCT01816100|BEHAVIORAL|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
223970920|NCT05812209|PROCEDURE|Stellate Ganglion Block|Ultrasound guided block of the Stellate Ganglion with local anesthetics.
223970921|NCT04451031|BEHAVIORAL|LiFT Program|
223970922|NCT00162058|DRUG|Peflutren Lipid Microsphere Injectable Suspension|
223970923|NCT01933659|DRUG|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
223970924|NCT03303521|DRUG|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
223970925|NCT03303521|DRUG|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
223970926|NCT06233045|DRUG|Dapagliflozin-Test product|Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
224291886|NCT05282485|DIETARY_SUPPLEMENT|Synbiotic|Synbiotic (2'-FL HMO + B. infantis probiotics)
224291887|NCT05282485|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
223970927|NCT06233045|DRUG|Dapagliflozin-Reference product|Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
223970928|NCT02642159|DRUG|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
223970929|NCT02642159|DRUG|Statins|Statins at stable dose without other LMT as clinically indicated.
223970930|NCT02642159|DRUG|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
223970931|NCT02642159|DRUG|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
223970932|NCT02642159|DRUG|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
223970933|NCT02642159|DRUG|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
223970934|NCT02642159|DRUG|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
223970935|NCT02745184|BIOLOGICAL|Lung stem cells|Patients will receive 0.5-5x10\^6 (0.5-5 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
223970936|NCT00237900|DRUG|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
223970937|NCT02683356|OTHER|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
223970938|NCT02683356|OTHER|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
223970939|NCT01779427|BEHAVIORAL|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
223970940|NCT02840071|OTHER|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
223970941|NCT00640523|DRUG|forodesine HCl|2 x 100mg capsules daily
223970942|NCT05436145|BEHAVIORAL|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
223970943|NCT05204771|OTHER|Ultrasound exam|Ultrasound exam
223970944|NCT05204771|OTHER|Postnatal abdominal ultrasound|Postnatal abdominal ultrasound
223970945|NCT05204771|OTHER|Pediatric Follow up|Pediatric Follow up
223970946|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
223970947|NCT02205476|DRUG|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
223970948|NCT05261347|PROCEDURE|mulligan mobilisation|an active mobilisation with movement on elbow according to mulligan's protocol
223970949|NCT05261347|PROCEDURE|sham|a lateral glide
223970950|NCT01313299|BIOLOGICAL|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
223970951|NCT01313299|BIOLOGICAL|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
223970952|NCT01313299|DRUG|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
224122720|NCT05980832|OTHER|Peer Education Supported Psychosocial Skills Education|"It is a psychosocial skills training that will be given to both experimental groups in 6 sessions within 6 weeks. 2 of the 4 peer trainers who received the practitioner training will conduct the training. During the training period, the research psychiatric nurse will support.~Session titles are as follows:~1. Session:Preparation Session~2. Session: Understanding Mental Disorders~3. Session: Developing Communication Skills~4. Session: Developing Emotion Recognition and Expression Skills~5. Session: Dealing with Daily Living Activities and Problems~6. Session: Understanding the Stigma Experience~The duration of each session is determined as 90 minutes. Taking into account the patient's opinions breaks not exceeding 15 minutes will be given as needed."
224291888|NCT05142696|DRUG|[177Lu]Lu-DOTA-TATE|"Solution for infusion of \[177Lu\]Lu-DOTA-TATE will be administered as follows:~* 2 administrations during the induction period on either Day 3, 4 or 5 of Week 1 and on Week 7 Day 3~* 1 to 4 administrations during the maintenance period on Week 13 Day 1, Week 16 Day 1, Week 19 Day 1 and Week 22 Day 1, depending on the dose assessed"
223725064|NCT01539057|DRUG|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
223970953|NCT02773121|BEHAVIORAL|Physical Activity|Trainer-guided at-home behavioral intervention
223970954|NCT01907022|DEVICE|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
223970955|NCT05880459|DRUG|propofol and magnesium sulphate ,propofol and nalbuphine|"The patients will be randomly divided into 2 groups by using a computer-generated randomization tableAll patients will fast from solids for 8 h and from liquids for 2 h. After arrival at preoperative area an intravenous cannula will be placed in the peripheral vein of right hand for fluid infusion and medicine administration.~All of the patients will be interviewed by the patient sedation satisfaction assessment tool (PSSI) regarding their experience 1 hour after the operation."
223970956|NCT04764877|OTHER|Osteopathic Manipulative Medicine|Provided 15-20 minute long OMT session for patients in the OMT arm
224291889|NCT05142696|DRUG|Atezolizumab|Atezolizumab 1200 mg on Day 1 from Cycle 2 every 3 weeks in induction and maintenance period
223970957|NCT04341415|PROCEDURE|Auricular neuromodulation|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid"
224114153|NCT05452161|OTHER|Intervention group B|"In addition to intervention A, patients receive a interdisciplinary intervention of three 10-15 minute phone or video conferences between the patient, a physiotherapist and a nurse.~The aim of these interviews is to identify the patient's difficulties in the living environment, to detect possible postoperative complications and to provide advice on practical aspects (e.g. ability to perform activities), therapeutic aspects (e.g. exercises to be performed, medication), pain management, interpretation of symptoms and subjective needs (e.g. need for support). Advice on rehabilitation and care is individualized according to the results of the questionnaires administered on the day of the pre-surgical consultation and those administered at discharge, as well as the needs of the moment discussed with the patient. Any suspected complication is reported to the operating physician for appropriate management."
224114154|NCT05367804|DIETARY_SUPPLEMENT|Isolated pea protein|The subjects eligible to take part in this study will consume an isolated plant protein for 4 weeks (week 4 to 8), in each week the amount of protein supplementation will increase (0.25 to 1.0 g of protein per kg of body weight). The protein will be provided as a powder in opaque bags and participants will be instructed to dissolve the contained powder in liquids (as water) or on their food (e.g., yogurt, oat porridge). The baseline will consist of 4 visits (1 to 4) to see how stable are the baseline results.
224114155|NCT02221739|DRUG|Ipilimumab|
224114156|NCT02221739|RADIATION|Radiotherapy (IMRT or 3-D CRT)|
224114157|NCT01883245|DEVICE|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
224114158|NCT01883245|DEVICE|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
223725065|NCT05252000|DEVICE|mechanical debridement|subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque
224114159|NCT05743023|BEHAVIORAL|Ayurvedic lifestyle protocol|"Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique."
224114160|NCT02487745|BEHAVIORAL|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
223970958|NCT04341415|PROCEDURE|Control|"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid."
223970959|NCT02798276|PROCEDURE|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
223970960|NCT02798276|OTHER|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
223970961|NCT02391545|DRUG|Duvelisib|PI3K Inhibitor
223970962|NCT02391545|DRUG|Rituximab|monoclonal antibody
223970963|NCT02391545|DRUG|Obinutuzumab|monoclonal antibody
223970964|NCT04754594|BIOLOGICAL|BNT162b2|Intramuscular Injection
224114161|NCT02487745|BEHAVIORAL|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
224114162|NCT03988114|DRUG|Abemaciclib|Administered orally
224114163|NCT03988114|DRUG|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
224114164|NCT00114205|DRUG|docetaxel|
224114165|NCT00114205|PROCEDURE|therapeutic thoracoscopy|
224114166|NCT04370249|OTHER|pulmonary ultrasound|pulmonary ultrasound on admission
224291890|NCT05142696|DRUG|[68Ga]Ga-DOTA-TATE|2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
224291891|NCT05142696|OTHER|Carboplatin|Four cycles of carboplatin AUC 5 on Day 1 every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
223970965|NCT04754594|OTHER|Placebo|Intramuscular Injection
224291892|NCT05142696|OTHER|Etoposide|Four cycles of etoposide 100 mg/m2 on Day 1-3, every 3 weeks (Weeks 1, 4, 7 and 10) in induction period
224291893|NCT05673148|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SABR
224291894|NCT05673148|PROCEDURE|Resection|undergo surgical resection
224291895|NCT05673148|PROCEDURE|Microwave Ablation|undergo microwave ablation
223970966|NCT03386357|COMBINATION_PRODUCT|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
223970967|NCT03386357|DRUG|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
223970968|NCT05961228|OTHER|exercise|"Three different posture with and without correction according to the Schroth method"
223970969|NCT05486871|PROCEDURE|laparoscopic partial nephrectomy|"This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes."
223970970|NCT05789667|DRUG|Lenvatinib|Patients will be treated by lenvatinib as recommended by good clinical practice
223970971|NCT04896502|BEHAVIORAL|Standard of Care Education|Education regarding recognition and removal of in-home asthma triggers
223970972|NCT04896502|OTHER|Interactive Video (IAV) Telemedicine|Interactive video assessment of asthma triggers in the home.
224114167|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
224114168|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
224114169|NCT01583582|DIETARY_SUPPLEMENT|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
224114170|NCT03452150|DRUG|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
224114171|NCT02461732|BEHAVIORAL|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
224114172|NCT02461732|BEHAVIORAL|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
223725066|NCT05252000|DEVICE|adjunctive aPDT|Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.
223970973|NCT05820256|DIETARY_SUPPLEMENT|Milk Protein Isolate (MPI)|Study participants will consume two smoothies per day containing a milk protein isolate (MPI) for 31 days.
223970974|NCT05820256|DIETARY_SUPPLEMENT|Soy Protein Isolate (SPI)|Study participants will consume two smoothies per day containing a soy protein isolate (SPI) for 31 days.
223970975|NCT06090487|DIAGNOSTIC_TEST|myocardial function after surgery|This group includes (15) patients who will have 200 mg twice daily oral (5) sacubitril-valsartan 1 month before the operation. transthoracic echo will be done before and after surgery, also total dose if inoptropic drugs will be noted
224114173|NCT05436808|RADIATION|Partial Chest Wall Radiation Therapy|Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day
224114174|NCT03873350|OTHER|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
224291896|NCT05673148|DRUG|Chemotherapy|Receive SOC chemotherapy
224114175|NCT03873350|OTHER|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
224114176|NCT04841135|OTHER|Multiomics quantification|One time blood, stool and urine samples will be taken.
224291897|NCT05673148|PROCEDURE|Computed Tomography|Undergo CT scan
224291898|NCT05673148|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224291899|NCT05673148|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224291900|NCT05812807|BIOLOGICAL|Pembrolizumab|Given IV
224291901|NCT05812807|OTHER|Patient Observation|Undergo observation
224291902|NCT05812807|PROCEDURE|Biopsy|Undergo biopsy
224291903|NCT05812807|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224291904|NCT05812807|OTHER|Questionnaire Administration|Ancillary studies
224291905|NCT05812807|OTHER|Quality-of-Life Assessment|Ancillary studies
224291906|NCT04437888|DRUG|Ketamine|Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
223970976|NCT03340766|DRUG|Blinatumomab|Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
223970977|NCT03340766|DRUG|Pembrolizumab|One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
223970978|NCT02867371|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
223970979|NCT04473118|OTHER|Survey|An online-based questionnaire sent to participants via email
223970980|NCT05057078|BEHAVIORAL|mindfulness-based stress reduction program|groups of 10 people will be formed among the patients included in the mindfulness program group. A mindfulness-based stress reduction program will be done once a week for eight weeks and will take approximately 60-120 minutes. A plan will be made with the patients for the day and time of the session. During this process, no application will be made to the control group. Meetings will be held as an online session via Zoom Video Communications.
224291907|NCT00417404|DRUG|Aquasol A|IM Aquasol A 10,000IU three times weekly
224291908|NCT00417404|DRUG|aquasol A|10,000 IU three times weeks, by intramuscular injection
224114177|NCT04841135|OTHER|Polysomnography|Facultative polysomnography
224114178|NCT04877015|DEVICE|Active Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.
224114179|NCT04877015|DEVICE|Sham Vibrotactile Coordinated Reset (vCR)|Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. An inactive pattern of vibration to each fingertip is delivered which theoretically will not have the effects of active vCR.
224114180|NCT06138847|DIAGNOSTIC_TEST|electroencephalogram|Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
224291909|NCT00417404|OTHER|sham injection|sham injection
224291910|NCT00099268|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
224291911|NCT00099268|DRUG|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
224291912|NCT03894241|BEHAVIORAL|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
223542931|NCT05404971|OTHER|Mirror therapy|A 5 cm × 35 cm mirror will be placed vertically between the upper limbs on the table, with the reflecting surface facing the uninjured limb. Patients will be asked to observe the motion of the upper limb on the uninjured side and imagine that the limb on the affected side was in motion, imagine the motion of the affected limb the same as that observed on the uninjured side, and complete 6 movements including shoulder joint forward flexion, elbow joint flexion and extension, forearm forward and backward rotation, wrist joint flexion and extension, finger extension and grasping, and thumb abduction. The participants will be asked to perform each movement for 5 min and try to reach the maximum range of motion of the joints. Training will be completed for 30 min per day) Session will be 3 days per week. Per day session will be for 30 minutes.
223725067|NCT05252000|DEVICE|sham aPDT|subjects will receive saline and non-light emitting laser on the tooth
223725068|NCT04220450|DIAGNOSTIC_TEST|T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined
223970981|NCT03922295|PROCEDURE|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
223970982|NCT00581009|OTHER|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
223970983|NCT00581009|DRUG|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
223970984|NCT00581009|RADIATION|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
223970985|NCT05044078|OTHER|Autogenic Inhibition MET|If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
223970986|NCT05044078|OTHER|Reciprocal Inhibition MET|If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
223970987|NCT04389983|DIETARY_SUPPLEMENT|Medium Chain Triglyceride oil|Bulletproof Braine Octane MCT oil
223970988|NCT03823261|BEHAVIORAL|Cognitive Behavioral Therapy|HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
223970989|NCT00149071|DEVICE|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
223970990|NCT00149071|DEVICE|TMS|Transcraniel Magnetic Stimulation active and sham
223970991|NCT00149071|DEVICE|rTMS|active Transcranial Magnetic Stimulation
223970992|NCT00149071|DEVICE|rTMS|daily for three weeks
223970993|NCT00449488|DRUG|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
223970994|NCT03847389|DRUG|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
223970995|NCT02019238|OTHER|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
223970996|NCT00975130|BIOLOGICAL|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
223970997|NCT00975130|BIOLOGICAL|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
223970998|NCT03204318|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily.
223725069|NCT00875212|DRUG|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
223725070|NCT00875212|DRUG|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
223970999|NCT03204318|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.
223971000|NCT03204318|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
223971001|NCT03204318|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
223971002|NCT02599987|DEVICE|POWERbreathe® Classic Light|Inspiratory Muscle Training
223971003|NCT03792789|DEVICE|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
224122721|NCT01762657|DRUG|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
224122722|NCT01762657|DRUG|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
224122723|NCT02551367|DRUG|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
224122724|NCT02551367|DRUG|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
223725071|NCT00875212|DRUG|fluoride|use of a dentifrice containing fluoride (1500ppm) only
223725072|NCT00875212|DRUG|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
223725073|NCT02031666|DRUG|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
223971004|NCT03792789|DEVICE|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
223725074|NCT02031666|DRUG|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
223971005|NCT01018576|OTHER|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
223971006|NCT00795977|BIOLOGICAL|dendritic cells, OK-432|Single Group Assignment
223971007|NCT02815618|DEVICE|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
223971008|NCT06138834|DRUG|Low-dose Y-6 sublingual tablets|Take one Y-6 sublingual tablet (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), one placebo of Y-6 sublingual tablet (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
223971009|NCT06138834|DRUG|High-dose Y-6 sublingual tablets|Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
223971010|NCT06138834|DRUG|Low-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), one half Cilostazol tablet (each tablet contains 50 mg Cilostazol), and one half Cilostazol mimicry tablet(each tablet contains 0 mg Cilostazol) for 28 days continuously.
224114181|NCT03333785|BEHAVIORAL|eOncoNote|"* Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~* Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~* Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
224114182|NCT02341170|RADIATION|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
224114183|NCT04982432|DRUG|Orismilast|Orismilast is a next generation PD4 inhibitor with demonstrated broad anti inflammatory properties
224114184|NCT01364571|BIOLOGICAL|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
223971011|NCT06138834|DRUG|High-dose Cilostazol|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol tablet (each tablet contains 50 mg Cilostazol) for 28 days continuously.
223971012|NCT06138834|DRUG|Placebo|Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
223971013|NCT00260702|DRUG|Omalizumab (Xolair)|
223971014|NCT00734851|DRUG|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
224114185|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
223971015|NCT00734851|DRUG|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
223971016|NCT00734851|RADIATION|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
223971017|NCT05126537|OTHER|no intervention|prospective and observational study with no intervention
223971018|NCT04320472|OTHER|Follow up|Follow up up to day 90 (Glasgow outcome scale, Glasgow outcome scale extended, functionnal impairments : Barthel index, Disability Rating Scale)
223971019|NCT04374019|DRUG|Ivermectin|"Ivermectin:~Days 1-2: Weight \< 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight \> 75kg: 5 tabs (15 mg total daily dose)"
223971020|NCT04374019|DRUG|Camostat Mesilate|Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
223971021|NCT04374019|DIETARY_SUPPLEMENT|Artemesia annua|Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
223971022|NCT04374019|DRUG|Artesunate|Days 1-14:
223971023|NCT03899285|DRUG|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
223971024|NCT01963858|PROCEDURE|Functional relaxation|Functional relaxation during colonoscopy
223971025|NCT01963858|PROCEDURE|No relaxation|No relaxation during colonoscopy
223971026|NCT06292832|PROCEDURE|Ultrasound-guided pain block|Ultrasound-guided pain block after cesarean section
223971027|NCT06292832|DEVICE|Ultrasound Machine|Ultrasound machine used to guide the nerve block.
223971028|NCT02832830|RADIATION|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
223971029|NCT02832830|RADIATION|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
223971030|NCT01074034|DEVICE|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
223971031|NCT03474978|DEVICE|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
223971032|NCT01332318|DRUG|XP13512|XP13512 once daily for 16 days
223971033|NCT01332318|DRUG|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
223971034|NCT01332318|DRUG|Placebo|XP13512 placebo once daily for 16 days
223971035|NCT02820298|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
223971036|NCT03261934|OTHER|No intervention|No intervention
223971037|NCT01780584|DRUG|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
223971038|NCT01780584|DRUG|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
223971039|NCT01780584|DRUG|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
223971040|NCT04793555|OTHER|Monitoring by unobtrusive sensors|During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
223971041|NCT02750371|OTHER|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
223971042|NCT01464671|DRUG|Bivalirudin|Anticoagulation during percutaneous coronary intervention
223971043|NCT01464671|DRUG|Heparin|Anticoagulation during percutaneous coronary intervention
223971044|NCT04222335|OTHER|Blood samples|"Each participant will be followed-up regularly as part of the usual practice for imaging and medical consultations. During their visits, from inclusion (T0) to the end of study participation (T progression), each patient will have a blood sampling specifically for the research to analyze tumor DNA and circulating tumor cells: T0, T1month, T3 months, Tn months, T DNA C+, T progression.~This research does not include any other act or intervention specifically required for its purposes."
223971045|NCT01022671|DRUG|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
223971046|NCT03747159|DRUG|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
223971047|NCT02108496|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
223971048|NCT02108496|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
223725075|NCT05484518|BEHAVIORAL|Method of Levels Therapy|"Method of Levels (MOL) is a therapy that is the direct application of Perceptual Control Theory (PCT) (Powers, 2008) which proposes that psychological distress results from a person's reduced control over important life goals. A conflict between two or more goals can occur outside of a person's awareness (Carey, Mansell \& Tai, 2014) and the achievement of one goal leaves the other incompatible goal unachievable, leading to distress (Mansell, 2012). MOL therapy aims to help people develop awareness of important goals and conflicts between them, to increase their chances of developing potential solutions. Conflict can be resolved through reorganisation; a mechanism through which random change is continuously generated until control is restored (Tai, 2016).~Therapy uses a questioning style to help clients bring their attention to their problems long enough for them to restore control. In practice clients choose the number, frequency and duration of therapy sessions"
223725076|NCT03026452|PROCEDURE|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
223971049|NCT02108496|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
223971050|NCT02108496|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
223725077|NCT02310568|DRUG|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
223971051|NCT00861354|DEVICE|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
223971052|NCT03426332|OTHER|No intervention|No intervention
223971053|NCT03916159|PROCEDURE|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta \~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
223971054|NCT03916159|PROCEDURE|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
223971055|NCT01924468|DRUG|Oral methylphenidate and Oral haloperidol|
223971056|NCT02512107|DIETARY_SUPPLEMENT|Juice Plus+|Dried fruit and vegetable juice capsule.
223971057|NCT02512107|OTHER|Placebo|Placebo capsule
224114186|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
224114187|NCT01364571|BIOLOGICAL|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
224114188|NCT01364571|PROCEDURE|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
224114189|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
224114190|NCT01364571|BIOLOGICAL|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
224114191|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
224114192|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
224114193|NCT01364571|BIOLOGICAL|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
224114194|NCT01364571|PROCEDURE|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
224114195|NCT01364571|PROCEDURE|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
224114196|NCT05232097|BEHAVIORAL|Behavioral therapy|Diaphragmatic breathing exercises
224114197|NCT05232097|BEHAVIORAL|Physiotherapy|Body awareness aiming at the patient becoming aware of the tensed thoracic and abdominal muscles and to reduce the tension by relaxation exercises taught by the psychophysical physiotherapist
224114198|NCT05508360|DEVICE|PerQdisc Nucleus Replacement System|Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
224114199|NCT04494503|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
224114200|NCT04494503|DRUG|Rituximab|Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
224114201|NCT04494503|DRUG|Ibrutinib|Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
224114202|NCT04514367|DRUG|ANX005|Intravenous Infusion
224114203|NCT06443281|DIAGNOSTIC_TEST|Neurophysiology|Pain-related evoked potentials and nerve conduction studies
223542932|NCT02431546|BEHAVIORAL|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
224114204|NCT06443281|DIAGNOSTIC_TEST|Cardiovascular test|Blood pressure control, orthostatic intolerance test, baro-reflex sensitivity, heart-rate variability
224114205|NCT06443281|DIAGNOSTIC_TEST|Experimental pain paradigms|Temporal summation of pain, conditioned pain modulation
224114206|NCT06443281|DIAGNOSTIC_TEST|Quantitative sensory testing|Thermal and mechanical sensory testing
224114207|NCT06443281|DIAGNOSTIC_TEST|Clinical pain phenotype|Pain drawings, plus and minus signs of pain
224114208|NCT05182203|DRUG|biologic/targeted therapy|TNF inhibitors or the JAK inhibitors
224114209|NCT02392546|DRUG|elobixibat|
224114210|NCT02392546|DRUG|placebo|
224122725|NCT02551367|DRUG|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
224122726|NCT04695847|DRUG|M1231|M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
224122727|NCT04695847|DRUG|M1231|M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
224122728|NCT03421847|DIAGNOSTIC_TEST|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
223971058|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLActive® (hydrophilic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLActive® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
223725078|NCT01989078|DRUG|Losartan|"Adults and Children \>50 kg:~* Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~* Those with SBP \<100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children \<50 kg weight:~* Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
224114211|NCT01832311|DRUG|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
224114212|NCT03691012|DIAGNOSTIC_TEST|Circulating tumour DNA testing|Circulating tumour DNA testing
224114213|NCT01172288|DRUG|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
224291913|NCT05002413|DIAGNOSTIC_TEST|Resistell AST|The Resistell AST is intended for rapid antibiotic susceptibility testing of most common clinically relevant Gram-negative bacteria causing bloodstream infections (BSI) (bacteremia). In the scope of this study, the Resistell Phenotech device will be used to test the susceptibility of Gram-negative bacteria, in particular Escherichia coli and Klebsiella pneumoniae to ceftriaxone and ciprofloxacin.
224291914|NCT03892213|DRUG|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
223971059|NCT06460103|DEVICE|"Placement of a Straumann® Bone Level Tapered implant SLA® (hydrophobic surface)"|"Immediately after tooth extraction, patients will receive a Straumann® Bone Level Tapered SLA® mini-implant at the ideal prosthetic position of the final implant, and bone augmentation using bone graft maxgraft®  and dental membrane collprotect®membrane.~The mini-implant will be removed as a core trephine biopsy; the resulting osteotomies will be fine-prepared, and the final permanent implant will be placed after a healing period of 3 weeks post-augmentation."
224114214|NCT01172288|DRUG|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
224114215|NCT04048967|BEHAVIORAL|Professional development|professional development of preschool staff
224114216|NCT01327339|DRUG|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
223725079|NCT02085317|DRUG|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
224114217|NCT00813956|DRUG|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
224122729|NCT01201538|DRUG|Nilotinib|
223971060|NCT00727259|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
223971061|NCT00727259|DRUG|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
223971062|NCT01021683|DRUG|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
224122730|NCT04027465|DIETARY_SUPPLEMENT|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
224122731|NCT06671249|PROCEDURE|Laparoscopic breast-conserving surgery|Use laparoscopic surgery to treat breast cancer patients who want and have the opportunity to preserve their breast
224122732|NCT06671249|PROCEDURE|Traditional open breast-conserving surgery|Treat breast cancer patients who want and have the opportunity to preserve their breast with traditional open breast-conserving surgery.
224122733|NCT06672692|DIAGNOSTIC_TEST|LIAISON NES FLU A/B, RSV & COVID-19|The LIAISON® NES FLU A/B, RSV \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA RSV viral RNA, and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
224122734|NCT06671652|BEHAVIORAL|Duyugoda igalenisodi (Starting again the right way)|Participants in the intervention arm will receive training and resources to build community resources and programming
223971063|NCT01339156|DRUG|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
223971064|NCT01339156|DRUG|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
223971065|NCT02579941|PROCEDURE|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
224291915|NCT03892213|DRUG|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
224291916|NCT05723419|PROCEDURE|axillary block using 5 ml local anesthetics|ultrasoud guided axillary block
223971066|NCT02579941|PROCEDURE|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
223971067|NCT00471562|BIOLOGICAL|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
223971068|NCT06540248|DEVICE|Ialuadapter|minimally invasive syringe device for bladder catherization
223971069|NCT02921438|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
223971070|NCT03037814|DEVICE|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
224291917|NCT00999180|PROCEDURE|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
224291918|NCT00999180|PROCEDURE|Saline and Kinesiotherapy|Saline and Kinesiotherapy
224291919|NCT00046449|DRUG|Investigational Seasonal Affective Disorder (SAD) Drug|
224291920|NCT01237353|DIETARY_SUPPLEMENT|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
224114218|NCT05237882|OTHER|Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders|The offered treatment will be the Danish versions of the Swedish i-CBT programs for children. The child i-CBT program consists of 10 modules for the child and 10 for parents. The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents. Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group. Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises. The family needs to select one parent to participate in the parent program. The participants will be expected to use approximately 4 hours per week. The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
223971071|NCT03037814|DEVICE|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
223971072|NCT03037814|DEVICE|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
223971073|NCT03037814|DEVICE|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
223971074|NCT06040138|DIAGNOSTIC_TEST|End expiratory occlusion maneuver|An end expiratory occlusion maneuver will be performed during pressure support ventilation in patients with prolonged weaning.
223971075|NCT01914302|DEVICE|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971076|NCT01914302|DEVICE|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971077|NCT01914302|DEVICE|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971078|NCT01914302|DEVICE|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971079|NCT01914302|DEVICE|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971080|NCT01914302|DEVICE|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971081|NCT01914302|DEVICE|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971082|NCT01914302|DEVICE|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
223971083|NCT03149432|PROCEDURE|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
223971084|NCT03149432|DRUG|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
223971085|NCT03149432|PROCEDURE|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
224291921|NCT01237353|DRUG|Rabeprazole|rabeprazole po daily x 5 days
223971086|NCT03149432|OTHER|Local care|local care for directed healing of the stump.
223971087|NCT02095938|DRUG|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
223971088|NCT06477562|OTHER|Endoscopy|surveillance endoscopy was routinely performed to the patients with proximal gastrectomy with double tract reconstruction group.
223971089|NCT01601639|DEVICE|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
223971090|NCT01601639|DEVICE|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
223971091|NCT01121497|DRUG|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
223971092|NCT02089984|BEHAVIORAL|Internet Based CBT Training|
223971093|NCT00415025|PROCEDURE|adjuvant therapy|
223971094|NCT00415025|PROCEDURE|management of therapy complications|
223971095|NCT00415025|PROCEDURE|quality-of-life assessment|
223971096|NCT00415025|RADIATION|intensity-modulated radiation therapy|
223971097|NCT01971424|DIETARY_SUPPLEMENT|Mg oxide|
223971098|NCT01971424|OTHER|healthy diet|
223971099|NCT01863888|DRUG|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
223971100|NCT01863888|DRUG|cholestyramine|Pharmaceutical form:powder Route of administration: oral
223971101|NCT01863888|DRUG|charcoal|Pharmaceutical form:granule Route of administration: oral
223971102|NCT05024266|DRUG|Tislelizumab|Participants received 2 cycles Tislelizumab 200mg d1 + Albumin Paclitaxel 260mg/m2 d1 + Carboplatin AUC5 d1 every 3 weeks, and then were evaluated for surgery.
223971103|NCT00911014|OTHER|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
223971104|NCT03406507|BIOLOGICAL|Ravulizumab|Single intravenous (IV) loading dose on Day 1, followed by regular IV maintenance dosing beginning on Day 15, based on weight.
223971105|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
223971106|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
223971107|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
223971108|NCT01515202|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
223971109|NCT01515202|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
223971110|NCT00663923|PROCEDURE|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
223971111|NCT05248217|BEHAVIORAL|healthcare workers|healthcare
223971112|NCT05799040|DEVICE|Self-developed pulmonary lobar ventilation detector|The participants would evaluated by the self-developed pulmonary lobar ventilation detector.
223971113|NCT05799040|DEVICE|Chartis detection system|The participants would evaluated by the Chartis detection system.
223971114|NCT05020886|BEHAVIORAL|turning task|Several trials included bilateral turning in 30, 60, 90, 120, 150, 180 degree.
223971115|NCT03071341|DRUG|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
223971116|NCT01588379|BEHAVIORAL|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
223971117|NCT01588379|BEHAVIORAL|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
223971118|NCT01588379|OTHER|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
223971119|NCT02084589|OTHER|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
223971120|NCT02084589|OTHER|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
223971121|NCT05308342|PROCEDURE|transplantation of human UC-MSCs into ovaries of POI patients|UC-MSCs (GMP grade, from Clinical Center for Stem Cell Research of the Affiliated Drum Tower Hospital of Nanjing University Medical School, licensed by the China Food and Drug Administration) are injected into the ovary of patients under transvaginal ultrasonographic (TVUS)-guidance. A total number of 10×106 cells, 5×106 for unilateral ovarian injection) is immediately preserved and transferred for direct injection. After vaginal sterilization, TVUS-guided transplantation is performed by two senior-level medical physicians, using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcare Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The UC-MSC solution is injected into the ovary by using 21-G PTC needles (Hakko Medical Co, Japan) under TVUS guidance.
223971122|NCT05308342|DRUG|hormone replacement treatment|Routine estrogen progesterone replacement periodic therapy
223971123|NCT05149716|DIETARY_SUPPLEMENT|Taurine|Taurine supplementation in capsules of 500 grams of taurine powder, total dosage: 1.5 gram/day
223725080|NCT02085317|DRUG|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
223971124|NCT05149716|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation in capsules of 500 grams of starch powder, total dosage: 1.5 gram/day
223971125|NCT00522678|DRUG|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
223971126|NCT00522678|DRUG|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
223971127|NCT02832453|BEHAVIORAL|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
224114219|NCT02134314|DRUG|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
223725081|NCT01327105|DEVICE|TVU|Use of transvaginal ultrasound to determine location of micro-insert
223971128|NCT02832453|BEHAVIORAL|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
223971129|NCT02832453|BEHAVIORAL|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
223971130|NCT06585644|DRUG|Furmonertinib in combination with Anrotinib and chemotherapy|The enrolled patients are planned to receive preoperative treatment with a combination of furmonertinib and anrotinib, along with platinum-based doublet chemotherapy. Three weeks after the completion of this treatment, they will undergo curative lung lobe resection and systemic lymph node dissection. Postoperatively, they will continue taking furmonertinib for one year. In case of disease progression, they will be switched to comprehensive therapy.
223971131|NCT03313544|DRUG|Nivolumab|NIVOLUMAB
223971132|NCT03313544|DEVICE|MRI|Cardiac MRI 6 MONTHS
223971133|NCT03313544|BIOLOGICAL|BLOOD SAMPLES|biological (BNP and troponin)
223971134|NCT03313544|DEVICE|trans-thoracic echocardiography|1, 3 and 6 months
223971135|NCT00547300|DRUG|Metoprolol ER|Metoprolol ER once daily, oral administration
223971136|NCT00547300|DRUG|Nebivolol|Nebivolol once daily, oral administration
223971137|NCT02156089|OTHER|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
224114220|NCT02134314|DRUG|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
224114221|NCT03472482|DIAGNOSTIC_TEST|non-invasive retinal imaging|
224114222|NCT00428727|DRUG|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
224114223|NCT00428727|DRUG|placebo patch|daily application during 90 days
224114224|NCT00343304|DEVICE|Robot|
224114225|NCT00343304|DEVICE|Ergometer|
223971138|NCT04380688|DRUG|Acalabrutinib|Acalabrutinib administered orally
223971139|NCT06602206|OTHER|Conventional Treatment|Hot pack,TENS, ultrasound and exercises
223971140|NCT06602206|OTHER|shoulder mobilization|In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
223971141|NCT06602206|OTHER|neck mobilization|Bridge, lateral flexion movement combined with traction, anterior-posterior gliding with traction, and lateral gliding techniques will be applied in neck mobilization.
223971142|NCT06574724|OTHER|Visiting a green space|Participants are asked to visit a green space for a defined time period
223971143|NCT06606769|OTHER|Exercise|supervised exercise training; twice a week for 12 months
223971144|NCT07002320|DRUG|SX-682|SX-682 is supplied as 100mg film coated tablets.
223971145|NCT07002320|DRUG|Apalutamide|Apalutamide is supplied as 60mg film coated tablets.
223971146|NCT07000422|OTHER|Selected gait training program|All children in both groups will receive selected gait training (treadmill) sessions for five times per week over 6 successive months.
223971147|NCT07000422|OTHER|Eye movement exercise|All children in the experimental group will receive eye training exercises for five times per week over 6 successive months. The exercises include tasks to improve visual focus and tracking. Children search for a specific card among 20 while covering one eye, repeated 10 times. They follow a pencil moving vertically, horizontally, in circles, and in a figure 8, maintaining a 1m distance. Exercises include shifting gaze between two pencils, recognizing letters on a shaking card, and tracking a pencil from 5cm to 50cm. Tasks are done with each eye covered separately. Another task involves walking while focusing on a fixed target 1m away at eye level for 5 minutes.
223971148|NCT07009041|OTHER|Strength training program|Strength training was implemented for eight weeks, including full-body, core, and leg exercises.
224114226|NCT06176040|DRUG|TAVO101|TAVO101 IV Infusion.
224114227|NCT04925414|DRUG|oxygenotherapy|High concentration mask delivering 15L/min of oxygen
224114228|NCT04925414|DRUG|placebo air aerosol|High concentration mask delivering 15L/min of air
224114229|NCT05536453|DEVICE|Lumbar Interbody Fusion Devices|Posterior Lumbar Interbody Fusion device placed to treat symptoms associated with degenerative disc disease
224114230|NCT05741710|DRUG|Methylone|Methylone capsules, given orally, once a week for 4 weeks
224114231|NCT05741710|DRUG|Placebo|Placebo capsules to match methylone, given orally, once a week for 4 weeks. NOTE: Placebo is only in Part B
224114232|NCT02631187|DEVICE|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
224122735|NCT06920368|PROCEDURE|septoplasty with nasal packs|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then nasal packs in inserted at the end of operation for prevention of post operative complication
224291922|NCT00358748|DRUG|Hydrocortisone|See detailed description above.
223971149|NCT07009041|OTHER|Stretching exercises program|Stretching exercises were performed after strength training for the entire eight-week period. The training was administered exclusively to participants in the experimental group, following a consistent schedule and sequence. The program was conducted three days a week for eight weeks, separate from regular football training.
223971150|NCT07009041|OTHER|Plyometric exercises program|Plyometric exercises were included only one day per week, and a minimum one-day rest period was maintained between training sessions.Since this program was originally 6 weeks long, it was implemented in the first 6 weeks of the study's implementation process.
223971151|NCT07009041|DIAGNOSTIC_TEST|Demographic tests|Demographic tests were applied to determine the height, weight and BMI values for the identification of the participants.
223971152|NCT07009041|DIAGNOSTIC_TEST|Jump tests|Jump tests (CMJ, CMJ Free, SJ, DJ, Horizontal Jump). Three different measurements were taken at three different times.(Before starting, end of week 4 and after completion of week 8).
223971153|NCT07009041|DIAGNOSTIC_TEST|Knee Valgus tests|It was conducted to determine the right and left knee valgus values of the participants.Three different measurements were taken at three different times. (Before starting, end of week 4 and after completion of week 8).
223971154|NCT02160548|DRUG|Standard care|Standard management for OP poisoning
223971155|NCT02160548|DRUG|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
223971156|NCT02160548|DRUG|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
223971157|NCT07008274|PROCEDURE|surgery|laparoscopic sleeve gastrectomy
223971158|NCT07008131|DEVICE|Double J stent|Extravesical ureteroneocystostomy with double J-catheter placement
223971159|NCT07008131|PROCEDURE|No Double J stent|Extravesical ureteroneocystostomy with no Double J stent colocation
223971160|NCT07009262|OTHER|Inapplicable|Inapplicable
223971161|NCT06721923|DIETARY_SUPPLEMENT|Dietary protein|Beneprotein powder, a whey-based supplement, will be used in both arms. Intervention dose will be 1g/kg of dietary protein (or 1.2g/kg of the powder), provided to both arms with different modes of delivery.
224114233|NCT06404008|BEHAVIORAL|REST|After randomization, individuals will attend an in-person training session in the REST protocol. This is a 15 minute controlled breath protocol that includes 3 yoga breathing techniques: 3-part dirgha breath, alternate nostril breathing, and 2:1 breathing. Each technique will be completed for 5 minutes, for a total of 15 minutes. After the training session, participants will practice the REST protocol for 15 minutes twice a day with guidance from research staff over zoom (Days 1-7) with daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and exacerbation education. On Day 8, participants will attend the Trial Session where they will complete the REST protocol (15 minutes) while vitals, lung function, and ECG measurements are taken. Surveys will be administered before and after the REST protocol to document patient reported stress and dyspnea.
223971162|NCT06716281|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|a single intra-articular injection of IxCell hUC-MSC-O at a dose of 5.0×10\^7 cells with a volume of 2.0 mL
223971163|NCT06716281|BIOLOGICAL|Placebo|Sodium Chloride Injection
223971164|NCT06719999|DIETARY_SUPPLEMENT|B4HT Mediterranean Lunch box|lunch boxes developed in the PRIMA project (L-MedFood or F-MedFood, \~600 kcal)
223971165|NCT06720883|PROCEDURE|Major hepatectomy|All patients will undergo robotic major hepatectomy with S1 resection, hilar lymphadenectomy and biliary reconstruction
223971166|NCT06720428|DEVICE|dry eye acupoint therapy instrument|The dry eye acupuncture point treatment device treat dry eye through stimulating acupuncture points by low pulse current.
223971167|NCT06720428|DRUG|Artificial tear|0.3% Ali eye drops
224114234|NCT06404008|OTHER|Education|After randomization, individuals will attend an in-person education session led by a research coordinator. For the following 7 days, the research staff will call patients daily and provide daily COPD education including inhaler technique, nutrition, vaccinations, tobacco cessation counseling, and COPD exacerbation education. On Day 8, participants will attend the Trial Session where they will do spontaneous breathing (15 minutes) while vitals, lung function, and EKG measurements are taken. Surveys will be administered before and after the spontaneous breathing period to document patient reported stress and dyspnea. After the study, participants will be asked to complete a close out survey and interview over zoom.
224122736|NCT06920368|PROCEDURE|septoplasty with intra-nasal silicon splint|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then intra-nasal silicon splint is inserted at the end of operation for prevention of post operative complication
223971168|NCT06721858|OTHER|Emotion Focused Therapy application|Participants in the intervention group will first be given face-to-face individual interviews to establish the therapeutic environment and relationship (Individual interviews are designed as orientation, diagnosis and planning stages, 30-minute interviews). Then, three intervention stages (40-minute, group therapy) will be applied and the last session will be both intervention (post-test application) and termination stage (completion of emotion-focused therapy application). After the individual interviews, individuals will be included in 3 intervention sessions as group training. It is planned that each group will have at least 4 and at most 6 people. If the specified number cannot be reached, the study will continue until the specified number is reached.
223971169|NCT06721858|OTHER|scale form|Emotion-focused therapy contributes to the treatment compliance and functionality of psychiatric patients.
223971170|NCT06721364|BEHAVIORAL|Suicide prevention treatment|"Intervention I:RAAHI RAAHI is a suicide literacy module that is specially designed to provide individuals with essential knowledge and skills by equipping them with tools to navigate the complexities of mental health and suicide prevention. This module aims to empower people to recognize signs of suicidal ideation, engage in empathetic communication through open discussion, combat stigma, and connect individuals in crisis with appropriate support and resources. The duration of the module will be of three hours.~Intervention II: safeTALK The \&#34;safeTalk\&#34; program is a psychoeducational initiative designed for suicide prevention among adolescents, consisting of a 4-hour workshop that incorporates presentations, videos, discussions, and questions.The workshop is designed according to the standard practices of safeTALK, to assist participants in (a) identifying warning signs of suicide; (b) Avoiding frequent impulses to overlook, dismiss, or avoid discussions about suicide."
223971171|NCT05357066|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
223971172|NCT05357066|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
223971173|NCT03441659|PROCEDURE|ACL reconstruction|Surgical ACL reconstruction
223971174|NCT06720402|BEHAVIORAL|Sun protection knowledge|To increase knowledge and awareness about sun protection methods, a presentation will be implented to pediatricians and family physicians.
223971175|NCT06720337|DRUG|bupivacaine 0.5%|patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique
223971176|NCT06720337|DRUG|Dexmedetomidine|patients will receive plus 0.5 µg/kg of dexmedetomidine (Precedex® 100 µg/ml) diluted in 2 ml of normal saline at each side
223971177|NCT06720337|DRUG|MgSO4|patients will receive plus 1.5 mL (150 mg) MgSO4 and 0.5 mL normal saline at each side
223971178|NCT06868303|BEHAVIORAL|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
223971179|NCT06868303|BEHAVIORAL|New Life Psychiatric Rehabilitation Association electronic clinic for psychological service|The eClinic treatment spans eight to fourteen week and is designed for individuals with moderate to severe mental health issues. The service is provided in a hybrid format, incorporating an in-person initial screening using the Patient Health Questionnaire-9 and General Anxiety Disorder-7, followed by online self-learning resources and sessions with a therapist. Pre- and post-treatment assessments as well as follow-ups will be used to keep track of service users' progress.
223971180|NCT06868303|BEHAVIORAL|Integrated Community Centres for Mental Wellness|Integrated Community Centres for Mental Wellness (ICCMWs) are the main community-based mental health services in Hong Kong. However, their reach among young people is limited, as their broad target age range primarily focuses on middle-aged individuals. ICCMW offers comprehensive, district-based community support and social rehabilitation services, from early prevention to risk management, for people in mental recovery, those with suspected mental health issues, their families and carers, and residents within the service area, all accessible through a single-entry point.
223971181|NCT06868303|OTHER|General Practitioner|Services provided by genersl practitioner
223971182|NCT06868303|BEHAVIORAL|Hub Casework|Services provided during hub casework sessions
223971183|NCT04957251|PROCEDURE|anterior approach to the hip|anterior hip hemiarthroplasty
223971184|NCT04957251|PROCEDURE|posterior approach to the hip|posterior hip hemiarthroplasty
223971185|NCT05223647|PROCEDURE|Thoracic radiotherapy|30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.
223971186|NCT05223647|DRUG|Chemo-immunotherapy|Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
223971187|NCT06900998|DRUG|Nimodipine|Nimodipine will be administered orally beginning on the evening prior to the study lab session. 90mg doses will be administered at 6:00pm, 12:00am, 6:00am, and 12:00pm.
223725082|NCT01384760|BEHAVIORAL|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
223971188|NCT06905561|DRUG|Diclofenac Sodium Gel|Diclofenac Sodium Gel were applied to the skin of the irradiated site triple a day a day from the date of first radiotherapy until end of radiotherapy or until the test side skin developed ≥grade 3 RID.
223971189|NCT06905561|OTHER|Placebo gel|The placebo does not contain the active ingredients of Jalosome, only the co-formulants.
223971190|NCT05344352|DIETARY_SUPPLEMENT|Multistrain Probiotic|8-week daily administration
224291923|NCT02328222|DRUG|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
224291924|NCT01880125|DRUG|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
224291925|NCT03744871|OTHER|N95 Respirator|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
223971191|NCT05344352|OTHER|Placebo|8-week daily administration
223971192|NCT06620809|DRUG|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection（5×10\^9 particles）
224291926|NCT01953822|OTHER|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
224291927|NCT05033366|DIAGNOSTIC_TEST|Proov Test|Rapid response urine PdG, FSH, E1G and LH test strips, Proov
224291928|NCT01509742|DRUG|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
224291929|NCT01509742|DRUG|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
223971193|NCT06620809|DRUG|A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection|Extracellular vesicles placebo(5×10\^9 particles）
223971194|NCT03465644|DRUG|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
224291930|NCT03822507|DRUG|KHK7580|oral administration
224291931|NCT03822507|DRUG|Cinacalcet Hydrochloride|oral administration
224291932|NCT05589961|DRUG|TMZ|After enrollment, temozolomide 50mg/m2 was given orally for QD until progression, and radiotherapy and PF 0.2g/ time for TID were started one week later until progression. Pembrolizumab 200mg once every 3 weeks until progression; The radiotherapy regimen depends on the patient's recurrence and initial treatment.
223971195|NCT03465644|DRUG|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
223971196|NCT06926153|OTHER|TABAPSY|"The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.~The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur"
223971197|NCT06926153|OTHER|Usual Care|Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)
223971198|NCT04990973|BEHAVIORAL|Average American Diet (AAD)|"Participants will follow specified diet requirements.~Macronutrient targets for the AAD will be approximately 35-37% of energy from fat (13.5% from saturated fat), 15% from protein, and 48-50% from carbohydrates (10 g fiber/d for an average 2000 kcal/d diet)."
223971199|NCT04990973|BEHAVIORAL|Mediterranean Diet|"Participants will follow specified diet requirements.~Macronutrient targets for the Mediterranean diet will be approximately 40% of energy from fat (8.5% from saturated fat), 20% of energy from protein, and 40% from carbohydrates (40 g fiber/d for an average 2000 kcal/d diet)."
223971200|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined
223971201|NCT06515470|DRUG|Fulvestrant|500 mg intramuscular injections on Day 15 and then every 28 days
223971202|NCT06515470|DRUG|BTX-9341|Daily oral dose in 28-day cycles using dose determined in Part A
223971203|NCT02286245|OTHER|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
223971204|NCT02286245|OTHER|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
223971205|NCT03130816|BIOLOGICAL|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
223971206|NCT00564564|DRUG|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
223971207|NCT00564564|DRUG|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
223971208|NCT00000133|PROCEDURE|Trans-scleral Cryotherapy|
224114235|NCT04550507|BEHAVIORAL|Mindful sensory awareness intervention|The mindfulness sensory awareness exercise will be a brief (3-5 minutes), guided meditation focusing on sensory and interoceptive awareness developed by Co-I Price, modified slightly to meet the needs of this age group and targeted for attention to indicators of fatigue or a sense of overstimulation. Youth will be asked to use the exercise after ending media use but before trying to sleep. The meditation component will be delivered via an audio-guided MP3, along with illustrated instructions in both handout and video, and a guided workbook that coaches youth over the 8-week intervention period to practice their skills, reflect on their experiences, and maintain adherence.
224114236|NCT04550507|BEHAVIORAL|Mindful sensory awareness + mindful body awareness check-ins intervention|During the intervention period for Group B: Mindful Sensory \& Body Awareness(the second 8 weeks), they will receive the same mindful sensory awareness intervention, and also learn the mindful body awareness check-ins to guide media use choices strategy (referred to here as the check-ins component). We will coach youth to pause briefly every 30 minutes during media use to discern if they detect physical, cognitive, or emotional signs of escalated state arousal, and to make an intentional and real-time choice about possible changes in media use content or duration to help decrease state arousal levels before bed.
223971209|NCT05277818|PROCEDURE|Surgery lumbar disc herniation|Surgery for a degenerative or traumatic mono-segmental lumbar disc herniation
223971210|NCT04306913|DRUG|Esmolol|esmolol 250 mg in cardioplegia solution every 25 minutes
223971211|NCT04306913|DRUG|Potassium Cardioplegic Solution|15 meq potassium added to cardioplegia solution
223971212|NCT03561025|DIAGNOSTIC_TEST|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
223971213|NCT03561025|DIAGNOSTIC_TEST|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
223971214|NCT02895698|DEVICE|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
223971215|NCT02895698|OTHER|Stretching exercises|"* The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds."
223971216|NCT05087953|DIAGNOSTIC_TEST|Head-Up Tilt table test|Autonomic response assessment in the orthostatic head up tilt test.
223971217|NCT05087953|DIAGNOSTIC_TEST|Heart Rate Variability|Assessment of heart rate variability on 24-hour Holter monitoring..
223971218|NCT02476708|DIETARY_SUPPLEMENT|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
223971219|NCT02476708|DIETARY_SUPPLEMENT|Placebo|oral placebo capsule
223971220|NCT03683914|DRUG|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
223971221|NCT03683914|DRUG|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
223971222|NCT04734847|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Non-invasive magnetic stimulation of the brain
223971223|NCT04734847|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)|Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
223971224|NCT04145323|DIAGNOSTIC_TEST|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
223971225|NCT05664399|OTHER|Surprise events|Subjects will be subjected to 4 surprise events, two using Virtual Reality simulations of falling out of a boat, and 2 involving falling into dunk tanks of cool and thermoneutral water.
223971226|NCT03626311|DIETARY_SUPPLEMENT|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
223971227|NCT03626311|OTHER|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
224114237|NCT01388010|OTHER|1-Fermented Probiotic Dairy Product (test)|
224114238|NCT01388010|OTHER|2-Milk-based non-fermented dairy product(control)|
224114239|NCT05185232|OTHER|Impact of gaps in care/loss to healthcare follow-up|There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
224114240|NCT00239460|DRUG|Tiotropium|
223971228|NCT01967719|OTHER|mTHS 2.2|Single use of mTHS 2.2
223971229|NCT01967719|OTHER|mCC|Single use of subject's own mCC
223971230|NCT01967719|OTHER|NNS|Single administration of 1 mg of nicotine
223971231|NCT00761397|BEHAVIORAL|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
223971232|NCT00761397|BEHAVIORAL|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
223971233|NCT00761397|OTHER|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
223971234|NCT00761397|OTHER|Questionnaire|Day 1 of study, 10 weeks after starting study, \& 12 months after starting study
223971235|NCT04314570|PROCEDURE|Saphenous Nerve Block with Ropivacaine Treatment|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive ropivacaine through the catheter from the start of the nerve block.
224114241|NCT01851473|DRUG|cocaine|25 mg IV on days 1, 5, and 10
224114242|NCT01851473|DRUG|quinine|80 mg orally on days 7-10
224114243|NCT01851473|DRUG|acetazolamide|15 mg orally on days 2-5
224114244|NCT00988962|BEHAVIORAL|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
224114245|NCT05994651|BEHAVIORAL|Tidal Model improvement model|"1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process"
224114246|NCT05084547|OTHER|No intervention|No intervention
224114247|NCT04965714|BIOLOGICAL|Nivolumab|Given IV
224114248|NCT04965714|BIOLOGICAL|Pegargiminase|Given IM
224114249|NCT04965714|PROCEDURE|Resection|Undergo surgical resection
224114250|NCT01737164|BEHAVIORAL|Aerobic Exercise|
223971236|NCT04314570|PROCEDURE|Saphenous Nerve Block with Saline Control|Regional Anesthesia nerve blocks have become standard practice for several orthopedic surgeries for post-operative pain management, however concerns for compartment syndrome have prevented nerve blocks to become common practice for tibial plateau open reduction internal fixation pain management. Interestingly, saphenous nerve blocks do not cover the sciatic nerve, allowing for pain management while reducing concerns that it may possibly mask compartment syndrome. Patients will receive a loading dose of Normal Saline through the catheter. After one hour, the patient will receive their Ropivacaine infusions as per standard protocol.
223971237|NCT04759118|BEHAVIORAL|modified childbirth education program|The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
223971238|NCT03927677|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
223971239|NCT06058117|OTHER|No intervention|no intervention, this is an observational study
223971240|NCT00189683|PROCEDURE|Monitoring|
223971241|NCT00189683|PROCEDURE|Xeloda|
224114251|NCT02810002|DEVICE|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
224114252|NCT02810002|DEVICE|Control infantry boot|Training: infantry basic training in the control boots
224114253|NCT03072511|BEHAVIORAL|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
223725083|NCT01384760|BEHAVIORAL|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
223725084|NCT03379532|DEVICE|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
223725085|NCT03379532|DEVICE|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
223725086|NCT00000752|DRUG|Pseudoephedrine hydrochloride|
223725087|NCT00000752|DRUG|Guaifenesin|
223725088|NCT00000752|DRUG|Cefuroxime axetil|
223725089|NCT00000752|DRUG|Beclomethasone dipropionate|
223971242|NCT00286975|BEHAVIORAL|Leadership development program educational intervention|
223971243|NCT00796614|DRUG|tamsulosin hydrochloride|Oral
223971244|NCT00796614|DRUG|Placebo|Oral
223971245|NCT05182970|DRUG|Metformin|Individualised target dose of 2000 mg daily depending on tolerability.
223971246|NCT04103086|DRUG|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
223971247|NCT04103086|DRUG|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
223971248|NCT01231464|DRUG|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
223971249|NCT01231464|DRUG|placebo|placebo
223971250|NCT00985283|BEHAVIORAL|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
223971251|NCT00985283|BEHAVIORAL|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
223971252|NCT00319813|BEHAVIORAL|Education|
223971253|NCT05654298|DRUG|Sumatriptan|Sumatriptan 100 mg
224114254|NCT03072511|DRUG|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
224114255|NCT06480045|PROCEDURE|Performed PECS II block with AI integrated USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with AI-integrated USG.
224114256|NCT06480045|PROCEDURE|Performed PECS II block with conventional USG|A 4-year anesthesiology resident, under the supervision of two senior anesthesiologists, performed a PECS II block with conventional USG.
224114257|NCT02481518|DRUG|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
223971254|NCT05654298|DRUG|Ubrogepant|Ubrogepant 100 mg
223971255|NCT02604706|DEVICE|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
223971256|NCT02604706|DEVICE|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
224114258|NCT02481518|OTHER|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
224114259|NCT00590083|BIOLOGICAL|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
223971257|NCT02604706|BEHAVIORAL|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
223971258|NCT00993798|DRUG|SABER-Bupivacaine Treatment 1a|5.0 ml
223971259|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
223971260|NCT00993798|DRUG|Bupivacaine HCl Treatment 1c|20.0 ml
223971261|NCT00993798|DRUG|SABER-Bupivacaine Treatment 2a|7.5 ml
223971262|NCT00993798|DRUG|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
223971263|NCT00993798|DRUG|Bupivacaine HCl Treatment 2c|20.0 ml
223971264|NCT03787238|DEVICE|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
223971265|NCT04280679|DEVICE|Sonovein 2|Patient are treated with the HIFU device and the pysician is doing a compressive bandage
223971266|NCT00283777|DRUG|Chromium Picolinate|
223971267|NCT04635085|BEHAVIORAL|Empowerment-based Cognitive behavioral therapy for insomnia for MCI|Participants in the intervention group will participate in a 12-week empowerment-based CBT-I comprising face-to-face sessions supplemented with telephone follow-ups. In total, six face-to-face sessions (90 minutes/session) will be conducted in a small group format with 6-8 participants in a group.
223971268|NCT00000897|DRUG|Zidovudine|
223971269|NCT06229249|OTHER|Carpal ligament self-myofascial stretching|Carpal ligament self-myofascial stretching is a technique that involves applying pressure and stretching to the carpal ligaments and surrounding myofascial tissues of the wrist and hand. The objective is to release tension, improve flexibility, and alleviate discomfort or pain in the wrist and hand area.
224114260|NCT06269211|DRUG|Toripalimab|240mg IV, Q3W
223971270|NCT06229249|OTHER|Conventional physical therapy|In this technique, ultrasound therapy, nerve gliding exercise, tendon gliding exercise, and wrist splinting were performed.
224114261|NCT03244891|OTHER|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~1. baseline~2. after fluid shift induced by passive head down position at 15 degrees~3. after fluid challenge with Ringer acetate 15ml\*kg in head down position~A total of six steps will be considered for the analysis"
224114262|NCT03244891|OTHER|Ventilation mode|"Each previous step will be done in two respiratory conditions:~1. spontaneous breathing~2. noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
224114263|NCT00298610|DRUG|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
224114264|NCT00298610|DRUG|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
224114265|NCT02270398|BEHAVIORAL|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
224114266|NCT02270398|BEHAVIORAL|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
224114267|NCT02270398|BEHAVIORAL|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
224114268|NCT03077945|BEHAVIORAL|heart rate variability biofeedback and cognitive reappraisal|
224114269|NCT03077945|BEHAVIORAL|control tasks|
224114270|NCT04980183|DEVICE|Arthroscopic surgical robot|The surgeon performs cruciate ligament bone canal positioning and ligament reconstruction with the assistance of an arthroscopic surgical robot
224114271|NCT04980183|DEVICE|Conventional arthroscopic cruciate ligament reconstruction|The surgeon performs conventional arthroscopic cruciate ligament reconstruction surgery without other auxiliary equipment
224122737|NCT06920368|PROCEDURE|septoplasty with trans--septal quilting sutures|Septoplasty to all the patients will be done using general hypotensive anesthesia via cuffed oral endotracheal tube. The patient will be positioned in a slight reverse Trendelenburg position. Local hemostasis will be achieved by injection of lidocaine with epinephrine (1:100000) with placement of topical epinephrine soaked cotton (1:1000) then trans-septal quilting sutures is done at the end of operation for prevention of post operative complication
224114272|NCT05326893|OTHER|Femoral nerve neurodynamic mobilization|The mobilization was carried out with the patient lying on the non-dominant side in a total flexion position, and the therapist performed the hip extension movement with the knee joint kept in flexion till the patient felt soreness or pain. This position was held for three seconds and then released. This tensioning maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
224114273|NCT05326893|OTHER|Femoral nerve placebo neurodynamic mobilization|The individual was asked to lie on his non-dominant side and keep his head in the midline. In this position, while the pelvis was stabilized, the upper leg, which was in full knee extension, was grasped and the hip was abducted for 3 seconds. This maneuver was repeated in three sets of ten repetitions at each session and an interval of 2 min between series were performed. A total of nine sessions were performed within three weeks.
224114274|NCT04663867|DEVICE|AngioSafe Peripheral CTO Crossing System|The AngioSafe Peripheral CTO Crossing System is intended to facilitate the intraluminal placement of guidewires beyond stenotic lesions, including chronic total occlusions (CTOs) in the peripheral vasculature.
223971271|NCT04692376|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.
223971272|NCT04692376|DRUG|Glucocorticoids|Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.
223971273|NCT04692376|DRUG|cyclosporine|Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
223971274|NCT02072278|DRUG|Vortioxetine 10 mg|
223971275|NCT02072278|DRUG|Vortioxetine 20 mg|
223971276|NCT02072278|DRUG|Escitalopram 15 mg|
223971277|NCT02072278|DRUG|Placebo|
224114275|NCT03830801|DEVICE|IVLCM tethered capsule|Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
224291933|NCT03483207|DRUG|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
224291934|NCT03483207|PROCEDURE|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
223971278|NCT00020969|DRUG|arsenic trioxide|
223971279|NCT02503982|DRUG|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
223971280|NCT01960348|DRUG|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
223971281|NCT01960348|DRUG|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
223971282|NCT04274062|PROCEDURE|Integrated Nursing care of placenta previa|"Phase I :( preparation phase) Phase II: (Implementation phase) includes Preoperative care , intraoperative care and postoperative care by a nurse.~Phase III: (Evaluation phase)"
223971283|NCT01050361|PROCEDURE|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
223971284|NCT00599833|BIOLOGICAL|cetuximab|
223971285|NCT00599833|RADIATION|3-dimensional conformal radiation therapy|
223971286|NCT06426147|DIETARY_SUPPLEMENT|L-citrulline|1 or 2 sachets every 12 hours (200-300mg/kg/day depending on weight-band) for 28 days
223971287|NCT06426147|DIETARY_SUPPLEMENT|Placebo|1 or 2 sachets every 12 hours (depending on weight-band) for 28 days
223971288|NCT00197119|BIOLOGICAL|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
223971289|NCT00197119|BIOLOGICAL|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
223971290|NCT01335412|BIOLOGICAL|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
223971291|NCT02151643|DRUG|PT20|Modified ferric oxide adipate tablets
223971292|NCT02151643|DRUG|Placebo|Placebo tablets matched to each PT20 dose arm
223971293|NCT01907945|BEHAVIORAL|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
223971294|NCT01907945|BEHAVIORAL|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
223971295|NCT03619889|OTHER|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
223971296|NCT03619889|OTHER|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
223971297|NCT00383903|BIOLOGICAL|HRV vaccine|Two or three oral doses
223971298|NCT00508274|DRUG|lapatinib|Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.
223971299|NCT00508274|DRUG|capecitabine|Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.
223971300|NCT01179412|DRUG|2% povidone-iodine|apply 4 times a day for one week
223971301|NCT01179412|DRUG|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
223971302|NCT03296566|BEHAVIORAL|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
223971303|NCT02968823|OTHER|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
223971304|NCT02968823|OTHER|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
223971305|NCT06153030|OTHER|no intervention|No intervention
223971306|NCT04591262|DRUG|14C-PF-06826647-LR 600 mg PO|14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
223971307|NCT04591262|DRUG|PF-06826647 600 mg PO|Unlabeled PF-06826647 600 mg
223971308|NCT04591262|DRUG|14C-PF-06826647 100 ug IV|14C-PF-06826647 100 ug IV
223971309|NCT00197106|DRUG|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
223971310|NCT00197106|DRUG|fluticasone propionate 2 x 100 mcg|comparator
223971311|NCT01881152|OTHER|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
223971312|NCT01881152|OTHER|Usual care|Information on stroke usually delivered at the community level.
223971313|NCT01709123|DRUG|chromium niacinate|200ug or 500ug supplementation in pill form
223971314|NCT01709123|DRUG|placebo|Placebo pill for chromium niacinate
223971315|NCT06096376|DIAGNOSTIC_TEST|Diaphragm Ultrasound|Diaphragm ultrasound to assess respiratory muscle function and respiratory efficiency
223971316|NCT00791102|DRUG|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
223971317|NCT00791102|DRUG|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
223971318|NCT01187147|DIETARY_SUPPLEMENT|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
223971319|NCT01084239|RADIATION|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
223971320|NCT01872156|OTHER|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
224114276|NCT03995407|DIETARY_SUPPLEMENT|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
223971321|NCT01872156|OTHER|Control Group|The group control will act according to usual management.
223971322|NCT04163835|DRUG|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
223971323|NCT04163835|DRUG|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
223971324|NCT04163835|DRUG|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
223971325|NCT04163835|DRUG|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
223971326|NCT01774461|OTHER|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
223971327|NCT02861625|BEHAVIORAL|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
223971328|NCT06190184|COMBINATION_PRODUCT|VIOME Precision Nutrition Program|Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
223971329|NCT06190184|OTHER|Control arm|Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and/or supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.
223971330|NCT05501847|RADIATION|Patient with no ventricular hypertrophy|"Patients without LVH ≥ 12 mm will routinely receive a bone scan as part of the study.~In case of cardiac fixation on bone scan, the patient will be managed as part of routine care according to a standardized care protocol that follows Guillmor's algorithm: monoclonal abnormality testing on biological blood samples +/- genotyping, in order to specify the senile or mutated character of TTR cardiac amyloidosis and to give the genotype."
223971331|NCT02889783|OTHER|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
223971332|NCT01536873|DRUG|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
224114277|NCT03995407|OTHER|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
224114278|NCT05606822|OTHER|Observational|Collection of data from electronic health record
223971333|NCT03025555|OTHER|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
223971334|NCT03025555|OTHER|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
223971335|NCT02637258|OTHER|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
223971336|NCT00170417|BEHAVIORAL|Cognitive Behaviour Therapy|
223971337|NCT02335398|DRUG|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
223725090|NCT03487068|DEVICE|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
223971338|NCT05762081|PROCEDURE|Disposable Wipes for wiping baths|A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.
223971339|NCT05762081|PROCEDURE|Traditional bed bath|Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
223971340|NCT03911362|BEHAVIORAL|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
223971341|NCT03911362|BEHAVIORAL|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
223971342|NCT03532269|DEVICE|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
224114279|NCT05914220|DEVICE|AI Insights Application|Predictive AI Model Risk score
224114280|NCT05121597|DEVICE|HugeMed Videolaryngoscope|Macintosh laryngoscope
224114281|NCT04343573|RADIATION|Involved-field Photon Radiation Therapy|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions)
224114282|NCT04343573|RADIATION|Proton Craniospinal Irradiation (CSI)|Proton CSI (30Gy \[RBE\] in 10 fractions)
223971343|NCT04038320|DRUG|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
223971344|NCT05598606|DRUG|Denosumab Injection|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection plus intravenous placebo every 6 months (Q6M)
223971345|NCT05598606|DRUG|Zoledronate|Intravenous zoledronic acid 5 mg plus subcutaneous placebo every 12 months
223971346|NCT03987659|PROCEDURE|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
223971347|NCT03987659|PROCEDURE|Conventional Irrigation protocols|Conventional Irrigation protocols
223971348|NCT04933838|DEVICE|atelocollagen|"This collagen-contained product is used to supplement tendon, ligament, muscle, and (biological) membrane that is missing or damaged during internal/surgical treatment and surgery.~Patients with chronic low back pain are randomized after obtaining informed consent for the study.~Participants are divided into group A (atelocollagen) and group B (control). A physical examination for lumbar pain was performed and evaluated trigger points in multifidus, erector spinae, and quadratus lumborum muscles.~After physical exam, cross sectional area of each muscle is measured by ultrasound in both gorup.~Group A will receive atelocollagen mixture (atelocollagen 3 mL + 1% lidocaine 3 mL) and group B will receive local anesthetics only (Normal saline 3 mL + 1% lidocaine 3 mL).~Each participants will be injected 1 mL of injectate into each muscle on both sides (total 6 mL)."
224291935|NCT03483207|DRUG|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
224291936|NCT02006628|DRUG|Placebo|Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
223971349|NCT05579145|OTHER|5-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 5 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
223971350|NCT05579145|OTHER|10-Second Expiratory Pause|Patients on mechanical ventilation for more than 24 hours will be randomized for the first technique to be applied. This technique consists of closed system aspiration and expiratory pause with mechanical ventilator for 10 seconds. After randomization and before the application of the technique, all patients will be positioned in supine position with the headboard elevated at 30 degrees and will be aspirated once with closed aspiration system and with vacuum of -40 cm H2O.
223971351|NCT04715503|RADIATION|PET imaging, 18F-FDG|PET-MRI with 18F-FDG
223971352|NCT04715503|RADIATION|PET imaging, 68Ga-DOTANOC|PET-CT with 68Ga-DOTANOC
223971353|NCT02679079|DRUG|NBI-98854|
223971354|NCT02679079|DRUG|Placebo|
223971355|NCT05283525|DIETARY_SUPPLEMENT|Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches|0 - 90 Days of Treatment
223971356|NCT05283525|DIETARY_SUPPLEMENT|Oxygen Saturation|0 - 90 Days of Treatment
223971357|NCT05283525|DIETARY_SUPPLEMENT|Total Blood Chemistry|0 and 90 Days of Treatment
223971358|NCT05283525|DIETARY_SUPPLEMENT|Adverse Event Monitoring|Adverse Event Monitoring Throughout the Study
223971359|NCT05283525|DIETARY_SUPPLEMENT|Body Weight Monitoring|0 - 90 Days of Treatment
223971360|NCT05283525|DIETARY_SUPPLEMENT|Physical well-being including mood, energy, satiety level. sugar cravings, sleep, and overall health|0 - 90 Days of Treatment
223971361|NCT03361618|DIETARY_SUPPLEMENT|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
223971362|NCT04312971|DRUG|Placebo|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of Normal Saline 0.9% with a starting dose of 0.0025 ml/kg/min.
223971363|NCT04312971|DRUG|Norepinephrine|Patients undergoing different cardiac surgical procedures will receive a continuous intravenous infusion of norepinephrine (40 ug/ml) with a starting dose of 0.0025 ml/kg/min.
223971364|NCT04312971|OTHER|Increase infusion rate|Infusion rate will be increased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min increments
223971365|NCT04312971|OTHER|Decrease infusion rate|Infusion rate will be decreased as needed in order to maintain a MAP ≥65 mmHg during cardiopulmonary bypass period as per the discretion of the anesthesiologist using 0.00125 ml/kg/min decrements
223971366|NCT00616486|DEVICE|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
223971367|NCT00616486|DEVICE|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
223971368|NCT01437813|DRUG|Glimepiride/ Extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
223971369|NCT05655234|BEHAVIORAL|Music Breathing|"The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised."
224291937|NCT02006628|DRUG|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
223971370|NCT05655234|BEHAVIORAL|Control condition|The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
223971371|NCT01395498|OTHER|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
223971372|NCT05199441|DRUG|Dihydroxydibutylether group|This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.
223971373|NCT05199441|DRUG|Control group placebo|This group takes 1,500 mg/day of placebo for 8 weeks.
223971374|NCT00787683|DEVICE|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
223971375|NCT06478225|DRUG|BGT007H Cell Injection|"Intervention roughly goes through 3 phases (the day of cell infusion is defined as day 0, d0):~1. Apheresis and baseline period: Eligible subjects are enrolled for leukapheresis to prepare BGT007H cell injection solution, and baseline assessment is performed from after apheresis to before preconditioning.~2. Preconditioning (d-5\~d-3): Patients begin preconditioning (FC regimen) 5 days before BGT007H cell administration. A 2-day rest and observation period is conducted after preconditioning.~   The FC regimen is as follows:~  * Fludarabine: 25\~30mg/m2/d, intravenous infusion, once a day, for 3 consecutive days;~  * Cyclophosphamide: 250\~350mg/m2/d, intravenous infusion, once a day, for 3 consecutive days.~3. Cell infusion (d0) and DLT observation period (d0\~d28)."
223971376|NCT00520403|DRUG|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
223971377|NCT00520403|DRUG|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
223971378|NCT00520403|DRUG|Vinblastine|0.1mg/kg iv every 3 weeks
223971379|NCT04420741|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
224291938|NCT03982563|BEHAVIORAL|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
224291939|NCT03982563|BEHAVIORAL|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
224291940|NCT03982563|BEHAVIORAL|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
223971380|NCT04420741|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
223971381|NCT04239950|DRUG|Placebo|Placebo
223971382|NCT04239950|DRUG|Ethyl Icosapentate|Ethyl Icosapentate
223971383|NCT02125097|DEVICE|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
223971384|NCT05635955|DRUG|Remimazolam|"Total intravenous anaesthesia will be induced with 0.3mg/kg remimazolam and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.2 mg/kg remimazolam (IV) will be administrated."
223971385|NCT05635955|DRUG|Propofol|"Total intravenous anaesthesia will be induced with 2mg/kg propofol and 0.3mg/kg esketamine, slow injection.~During the painless abortion surgery, if the MOAA/S scores \> 1 or body movements occur, supplemental 0.25 mg/kg propofol (IV) will be administrated."
223971386|NCT05635955|DRUG|Esketamine|0.3mg/kg esketamine will be co-administrated in both arms
223542933|NCT05302310|OTHER|integrated care|"i) Screening of older people for risk of frailty using a frailty screening tool, to identify the appropriate care they will require:~* Older adults with low risk of frailty will receive health promotion and preventive care from the Information and Advice Center nurse and/or social worker.~* Older adults at risk will receive the following:~ii) a Comprehensive Geriatric Assessment (CGA) delivered by the Information and Advice Center nurse and social worker over the course of multiple appointments, to identify the health and social care needs and goals of the older person; iii) Development of an individualized care plan by a multidisciplinary team, which will include evidence-based interventions and be coordinated by the Information and Advice Center nurse and/or the social worker; and iv) follow-up depending on the situation of each older person, and adaptation of the individualized care plan, as needed."
223542934|NCT00912626|BEHAVIORAL|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
223971387|NCT00153556|BIOLOGICAL|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
223971388|NCT02435381|DRUG|Carisbamate|600mg Orally on days 2-4
223971389|NCT02435381|DRUG|Placebo|Placebo treatment only
223971390|NCT01065207|BIOLOGICAL|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
223971391|NCT02435797|DRUG|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
223971392|NCT02435797|DRUG|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
224291941|NCT03982563|BEHAVIORAL|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
224291942|NCT03893474|DIAGNOSTIC_TEST|OCT|Optical Coherence Tomography of study eye.
224291943|NCT03893474|DIAGNOSTIC_TEST|Visual Acuity|Visual acuity measured by ETDRS
223971393|NCT01490359|BEHAVIORAL|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
224291944|NCT06224166|DIAGNOSTIC_TEST|Collection and use of tissue samples, blood and saliva|"For tissue collection, tumor and surrounding tissues will be used healthy specimens taken during surgical removal, according to clinical practice. Blood and saliva sampling will be carried out at different times:~i) the day before surgery; ii) the day after surgery (only for blood); iii) at the time of patient discharge (approximately 15 days after surgery); iii) during the check-up visit scheduled to monitor the follow-up (FU)"
223971394|NCT01490359|BEHAVIORAL|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
223971395|NCT00946634|DRUG|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
223971396|NCT00946634|DRUG|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
224114283|NCT04343573|OTHER|Neurocognitive Assessment|All patients at MSKCC will complete a neurocognitive test battery at study entry (prior to RT), and approximately 3, 6 and 12 months and post -RT. The neurocognitive tests consists of standardized, validated and reliable measures of attention, executive functions, and memory, for which age- and education-matched healthy control published data are available. Patients will also complete self-report mood and fatigue scales at each of the same time points. This testing will only be done at MSKCC. Non-English-speaking patients and pediatric patients are exempt from completing the neurocognitive assessments. Neurocognitive assessments will be performed in person at MSK-Manhattan; an option to perform follow up assessments via telehealth will be available only for patients who are not able to go to Manhattan for these visits.
224114284|NCT04343573|OTHER|MDASI-BT and MDASI-SP|Using MDASI-BT and MDASI-SP questionnaires before, weekly during, at 3 months (+/- 4 weeks), 6 months (+/- 4 weeks), 9 months (+/- 4 weeks), and 12 months (+/- 4 weeks) after group assignment, and at CNS disease progression. Only one set needs to be completed. Non-English-speaking patients and pediatric patients are exempt from completing the patient-reported outcomes unless translated PRO assessment forms are available. Questionnaires will be completed via mail, in-person, or online (MSK Engage).
224114285|NCT01809366|PROCEDURE|seminal plasma insemination|
224291945|NCT04569448|DRUG|Brexpiprazole|Adjunctive variable dose (1-3 mg/day) Brexpiprazole
224291946|NCT00002922|DRUG|paclitaxel|
224291947|NCT00343239|DRUG|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
224291948|NCT00343239|DRUG|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
224291949|NCT00343239|DRUG|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
224291950|NCT01618136|DRUG|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
224291951|NCT01618136|DRUG|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
223971397|NCT00946634|DRUG|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
223971398|NCT04150341|DRUG|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
224114286|NCT01158950|DRUG|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
224114287|NCT01158950|OTHER|Placebo|Placebo (200mg) administered at study visit
224114288|NCT01757457|DRUG|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
224114289|NCT01757457|DRUG|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
224114290|NCT06511414|DEVICE|duramesh|Duramesh™ non-absorbable polypropylene suture is a hollow core, microporous, cylindrical suture made off in polypropylene filaments that are loosely braided and bonded to each other with heat and pressure
224114291|NCT06511414|DEVICE|Control|standard closure of fascia
224114292|NCT01811030|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
224114293|NCT04345939|DIAGNOSTIC_TEST|Detection method|Different methods for pathogen diagnosis
224291952|NCT01618136|DRUG|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
224291953|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, adjuvanted|
223542935|NCT03584347|BEHAVIORAL|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
223542936|NCT02213614|DIETARY_SUPPLEMENT|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
223542937|NCT02213614|DIETARY_SUPPLEMENT|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
223971399|NCT04150341|DRUG|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
223971400|NCT04977297|BEHAVIORAL|Move to Music Intervention (M2M)|The move to music (M2M) intervention pairs exercise with only music (no video), providing only audio stimulation. The intervention will be provided via an audio playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
224114294|NCT03047460|OTHER|multimodal evoked potentials|
224114295|NCT03591029|OTHER|blood samples|blood samples will be obtained from the superior vena cava (via centra venous catheter), from the pulmonary artery (via Swan Ganz catheter), and from a radial or femoral artery catheter
224114296|NCT06375330|DEVICE|PoliArt|PoliArt injections
224114297|NCT00510692|DRUG|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
224114298|NCT00510692|PROCEDURE|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
224114299|NCT00510692|PROCEDURE|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
224114300|NCT00510692|DRUG|Placebo|2 x 500mg placebo capsules twice daily for 6 months
224114301|NCT03358862|DEVICE|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
224291954|NCT00262041|BIOLOGICAL|MenACWY-CRM conjugate vaccine, unadjuvanted|
224291955|NCT00262041|BIOLOGICAL|MenACWY polysaccharide vaccine|
223971401|NCT04977297|BEHAVIORAL|Move to Music -Video (M2M-V) Intervention|The move to music video (M2M-V) intervention pairs exercise with both music and video, thus providing both audio and visual stimulation. The intervention will be provided via an audio and video playlist that can be played on a phone, tablet, or computer. Each session lasts 10-15 minutes.
223971402|NCT04735913|DRUG|Abiraterone acetate tablets|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach or after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
223971403|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
223971404|NCT01083446|OTHER|Nutritional Intervention|Cognitive and executive functions during fast
223971405|NCT00405912|DRUG|Placebo|Placebo (inactive drug) given 3 times per day
223971406|NCT00405912|DRUG|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
223971407|NCT00405912|DRUG|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
223971408|NCT04921748|PROCEDURE|Neurorehabilitation|All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
223971409|NCT03730662|DRUG|Tirzepatide|Administered SC.
223971410|NCT03730662|DRUG|Insulin Glargine|Administered SC
223971411|NCT01797562|DIAGNOSTIC_TEST|Panels 1.3, 2.2 and 3.2 experimental allergens|Three allergen panels will be applied to the upper backs of study subjects and will be worn for 48 hours. Allergen test sites will be evaluated at 3, 4, 7(±1) and 21(±2) days post application.
223971412|NCT03372577|BEHAVIORAL|Mindfulness-Based Sex Therapy|It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
223971413|NCT03372577|OTHER|Treatment as usual|Routine discharge counseling
223971414|NCT03892928|DRUG|Dexmedetomidine group|In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
224114302|NCT01478750|DIETARY_SUPPLEMENT|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
224114303|NCT01478750|PROCEDURE|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
223971415|NCT01309243|DRUG|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
223971416|NCT01309243|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
223971417|NCT05329233|DEVICE|Masimo Radical-7 Pulse CO-Oximeter|The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
223971418|NCT01458080|DRUG|eltrombopag|eltrombopag
223971419|NCT03930238|BEHAVIORAL|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
223971420|NCT03930238|BEHAVIORAL|Fitbit Only|Fitbit Only
223971421|NCT00062686|DRUG|GW572016|
223971422|NCT02721433|DRUG|Pamidronate|Bone-targeted agent as standard of care
223971423|NCT02721433|DRUG|Denosumab|Bone-targeted agent as standard of care
224114304|NCT05822999|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
224114305|NCT05822999|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
224114306|NCT01845077|DRUG|2x500 mg Metformin (Glumetza)|2 tablets
223542938|NCT02213614|OTHER|natural spring water|A group will drink natural spring water for 4 months
224114307|NCT01845077|DRUG|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
224114308|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
223971424|NCT02721433|DRUG|Zoledronate|Bone-targeted agent as standard of care
223971425|NCT00632931|DRUG|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
224291956|NCT01098864|DEVICE|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
224291957|NCT05483803|BEHAVIORAL|Adhera® Caring digital intervention for Type 1 Diabetes|The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
223971426|NCT00632931|DRUG|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
223971427|NCT04332679|DEVICE|Group A - control group|20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
223971428|NCT04332679|DEVICE|Group B - Test group|20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
224291958|NCT05841290|PROCEDURE|Primary local anesthesia|Tooth will be anaesthetized using Local anesthesia containing Articaine with epinephrine 1:100,000.
223971429|NCT03328845|DRUG|Toujeo SoloStar|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
223542939|NCT06305585|OTHER|Primal Reflex Release Technique (PRRT)|Primal Reflex Release Technique (PRRT) is a non-invasive complementary hands-on treatment method intended to help relax the central nervous system by gently stimulating innate protective reflexes. A certified practitioner applies light tactile stimulation to targeted areas in a structured sequence postulated to help release hypertonic muscles, restore regulation of automatic responses, and enable a calm, parasympathetic state.
223542940|NCT05608954|OTHER|Bobath Concept|Handling of the Bobath Concept
223971430|NCT03328845|DRUG|Tresiba|Basal insulin at 16.00h and optimization of this basal doses with objetives of glycaemia before breakfast betwen 80-130 mg/ dl.
223971431|NCT03328845|DRUG|Humalog Kwikpen|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
223971432|NCT03328845|DRUG|NovoRapid|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
223971433|NCT03328845|DRUG|Apidra|Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
223971434|NCT03227978|COMBINATION_PRODUCT|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
223971435|NCT03009019|DRUG|DFN-15 Active|
224114309|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
223542941|NCT05608954|OTHER|Pediasuit|Pediasuit
223542942|NCT05608954|OTHER|Locomotor training|Locomotor training
223971436|NCT03009019|OTHER|DFN-15 Placebo|
223971437|NCT04705402|DRUG|Mannitol|"Mannitol (Israeli Brand Name: Osmitrol) is in the osmotic diuretic pharmacologic categoryaccording to the American Hospital Formulary Service (AHFS) database. . During the procedure, volume of 2.8 cc / kg body weight of the solution bag (either mannitol or saline 0.9%) will be given. The bag itself will be covered so it cannot be identified which solution is in it and marked per patient.~Mannitol is injected by intravenous infusion using an I-vac pump and infused over 15 minutes."
224114310|NCT01845077|DRUG|3x500 mg Metformin (Glumetza)|3 tablets
223542943|NCT05608954|OTHER|Stretching|Active, passive, active-assisted stretching
224114311|NCT01845077|DRUG|5 mg Linagliptin (Tradjenta)|1 tablet
224114312|NCT01845077|DRUG|2 x 500 mg Metformin (Glumetza)|2 tablets
224114313|NCT01845077|DRUG|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
224114314|NCT01845077|DRUG|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
224114315|NCT05441150|DRUG|Low dose ketamine infusion|Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
224114316|NCT05441150|DRUG|0.9% NaCl infusion|Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
224114317|NCT00077233|DRUG|cetuximab|IV
224114318|NCT00077233|DRUG|5-FU|IV
224114319|NCT00077233|DRUG|irinotecan|IV
224114320|NCT00077233|DRUG|leucovorin|IV
224114321|NCT00077233|DRUG|oxaliplatin|IV
223542944|NCT05608954|OTHER|Psychomotricity|Psychomotor skills
223542945|NCT05608954|OTHER|Virtual reality|Virtual reality
223971438|NCT04705402|DRUG|Saline|Study participants randomized to this arm will receive a 0.9% saline solution at a dose of 2.8 cc / kg, infused within 15-30 minutes prior to renal artery reperfusion through an existing intravenous access catheter (either through an central or peripheral intravenous infusion).
223971439|NCT03758794|OTHER|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
223542946|NCT02654496|OTHER|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
223971440|NCT03758794|OTHER|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
223971441|NCT04095598|DIAGNOSTIC_TEST|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
223971442|NCT01965145|DRUG|Gevokizumab|Sterile solution administered subcutaneously
223971443|NCT01965145|DRUG|Placebo|Sterile solution administered subcutaneously
223971444|NCT01441583|DEVICE|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
224114322|NCT03095183|DEVICE|Grape flavored Puritan Junior tongue depressor|
223971445|NCT01441583|DEVICE|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
223971446|NCT00849745|PROCEDURE|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
224114323|NCT03095183|DEVICE|Traditional unflavored Puritan Regular Tongue Depressor|
224114324|NCT00392444|DRUG|sunitinib malate|Given orally
224114325|NCT04183257|DRUG|oral vitamin D|oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
223542947|NCT04739930|PROCEDURE|Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Autologous bone marrow aspirate will be processed and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to the site of operation in the treatment group
223542948|NCT04739930|PROCEDURE|Control group incision|0.5cm sham incision over the iliac crest
224114326|NCT04253301|DEVICE|InnoVein Valve Treatment|Subjects will have the InnoVein Valve implanted
223542949|NCT02433912|PROCEDURE|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
224114327|NCT05260931|DIAGNOSTIC_TEST|Fetal echocardiography|Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function. Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas at maximum distension at end of systole. Atria and ventricle to-heart ratios calculated. Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV. MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated. Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
224114328|NCT05665985|DRUG|Moringa Oleifera|Intervention with Dry Extract of Moringa Oleifera (trade name is Keloreena Ⓡ , registered number in National Food and Drug Registry: 193332021) The dose given is 1000 mg bi in day for 30 days.
223542950|NCT02433912|PROCEDURE|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
223971447|NCT04517968|OTHER|immediate implant with customized healing abutment|"* All patients will be operated under local anesthesia.~* Atraumatic extraction of the remaining root or tooth will be achieved.~* A careful curettage of the socket will be performed if any granulation tissue is present.~* Sequential drilling of the osteotomy site with copious irrigation will be done~* The Implant is secured in place using a torque wrench.~* Fabrication of the customized abutment with flowable composite by first placing a rubber dam between the abutment and the implant to prevent leakage of composite into the socket then start adding the composite in a manner to seal the socket.~* Finishing the composite outside the patient's mouth will be done to ensure the borders are smooth with no sharp ends.~* The abutment will be attached to the implant."
223971448|NCT03014908|OTHER|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
223971449|NCT00735228|DEVICE|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
223971450|NCT06375018|OTHER|Placebo Technique|In the control group, manual contact will be carried out without any therapeutic intention. This contact will be maintained for the same period of time as the experimental group.
223971451|NCT06375018|OTHER|Diaphragm Stretching|The participant will be in supine position and the researcher will be at the headrest of the examination table, placing his hands on the lower costal margin. Superior direction traction is performed during inspiration, remaining during expiration. The procedure is repeated for a maximum period of 4 minutes.
223971452|NCT03341312|BIOLOGICAL|LY900014|Administered SC
223971453|NCT03341312|BIOLOGICAL|Insulin Lispro|Administered SC
223971454|NCT06448845|PROCEDURE|Arm intravenous regional anesthesia|After placement of the upper arm and forearm tourniquets and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the arm tourniquet cuff is inflated to a pressure of 250 mmHg. The double arm cuff pneumatic pressure tourniquet is placed immediately above the elbow crease and on the top of a circumferentially placed cotton cast padding before inflation. Subsequently, tourniquet failure is ruled out by observing the absence of distal circulation and 40 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand. The tourniquet remained inflated for 60 minutes from injection of lidocaine to reduce the risk of local anesthetic systemic toxicity (LAST)
223971455|NCT06448845|PROCEDURE|Forearm IVRA block|After placement of the forearm double tourniquet and exsanguination of the limb distal to the cuff by applying an Esmarch's bandage starting from the fingertips, the forearm tourniquet cuff is inflated to a pressure of 250 mmHg. The forearm tourniquet will be placed 5 cm distal to the medial epicondyle of the humerus and on the top of a circumferentially placed cotton cast. Subsequently, tourniquet failure is ruled out by observing the distal circulation and 25 ml 0.5% lidocaine is slowly injected through the intravenous cannula on the dorsum of the hand.
223971456|NCT01812707|DRUG|Alirocumab|Two SC injections in the abdomen only
224114329|NCT06658951|BIOLOGICAL|Anti-HER2 CAR-T cells|All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
223971457|NCT01812707|DRUG|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
223971458|NCT01812707|DRUG|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
223971459|NCT05060237|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|"Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing."
223971460|NCT02982070|BEHAVIORAL|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
223971461|NCT00965302|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
224114330|NCT00787332|DRUG|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
224114331|NCT02528695|RADIATION|18F-FDG PET/CT|18F-FDG PET/CT
223542951|NCT02433912|DRUG|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
224114332|NCT02528695|DEVICE|euglycemic clamp|euglycemic clamp
224114333|NCT02528695|DEVICE|hypoglycemic clamp|hypoglycemic clamp
224114334|NCT02928640|DEVICE|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
224291959|NCT05841290|PROCEDURE|Supplemental local anesthesia|if needed
224291960|NCT05841290|PROCEDURE|Removal Of Caries and Access Cavity|• Access cavity will be performed using a carbide round steel bur and tapered diamond stone until complete deroofing.
224291961|NCT05841290|PROCEDURE|Rubber dam isolation of tooth|Rubber dam isolation of tooth using certain clamps .
224291962|NCT05841290|PROCEDURE|Bleeding control|bleeding is controlled by using excavator for the removing the pulp tissue . using a piece of cotton soaked with Sodium hypochlorite. using local anesthesia with vasoconstrictor if needed and if suitable for the patient.
224291963|NCT05841290|PROCEDURE|Canal negotiation|Coronal patency of the coronal and the Middle part of the canal using file #10 Apical patency of the apical part of the canal using #10
223542952|NCT02433912|DRUG|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
223542953|NCT02652910|DRUG|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
223542954|NCT00953810|OTHER|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
223542955|NCT01797757|DIETARY_SUPPLEMENT|Fish oil enriched with EPA|
223542956|NCT01797757|DIETARY_SUPPLEMENT|MAG-EPA oil|
223542957|NCT01797757|DRUG|Orlistat|
223542958|NCT02575729|DRUG|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
223542959|NCT00592631|DEVICE|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
223542960|NCT00592631|DEVICE|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
223971462|NCT00965302|BEHAVIORAL|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
223971463|NCT01819428|DRUG|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
223971464|NCT00001848|DRUG|Raloxifene|
224114335|NCT00768378|DEVICE|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
224114336|NCT01554215|BEHAVIORAL|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
224114337|NCT01554215|BEHAVIORAL|Mom Power Attentional Control Group|at home control, weekly mailings
224114338|NCT00248677|BEHAVIORAL|Behavioral Family-Based Intervention|Behavioral family intervention
224114339|NCT00248677|BEHAVIORAL|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
224114340|NCT05946330|BEHAVIORAL|NUTRITIONAL EDUCATIONAL INTERVENTION IN FATTY LIVER DISEASE NON-ALCOHOLIC (NAFLD).|The intervention group will receive educational actions in individual nutrition with nutrition consultation (in person at the beginning and at 180 days of the intervention and phone calls and text messages at 30, 60, 90, 120 and 150, 240 and 300 days of follow-up
224114341|NCT04631718|RADIATION|Magnetic Resonance Imaging (MRI)-based Quantitative Susceptibility Mapping (QSM)|"MRI-based QSM methods estimate the susceptibility of tissues based on measuring the magnetic field distortion produced by the tissues themselves.~Upon successful validation, MRI-based abdominal QSM will provide accurate, repeatable, and reproducible quantification of Liver iron concentration (LIC) that is independent of the distribution of iron and does not require calibration."
223542961|NCT02523989|OTHER|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
223542962|NCT04393038|DRUG|ABX464|ABX464 50mg QD for 28 days + Standard of Care
223542963|NCT04393038|DRUG|Placebo|Placebo 50mg QD for 28 days + Standard of Care
224291964|NCT05841290|PROCEDURE|Coronal flaring|Coronal flaring using Orifice opener of a certain Rotary system in and out motion first then brushing motion touching all the canal walls
223542964|NCT00437398|BIOLOGICAL|Islet Transplant|Purified pancreatic islets
223542965|NCT06401499|DRUG|etoricoxib 60mg|investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
223542966|NCT03102983|OTHER|MRI functional|vowels records and MRI session
223971465|NCT05999513|DRUG|casdatifan|Administered as specified in the treatment arm
223971466|NCT06363877|DRUG|Povidone-Iodine|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of dilute aqueous povidone-iodine solution allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the povidone-iodine solution then wash-out with 2L of normal saline followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL povidone-iodine solution, suctioned, then washed-out with 500 mL normal saline."
224291965|NCT05841290|PROCEDURE|Working Length Determination (W.L)|Working length determination (W.L) using #10 K File , working length is recorded using apex locator and confirmatory radiograph.
224291966|NCT05841290|PROCEDURE|Glide path|Glide path of the canal Using #10 ,15 ,20 ,25 K files till becoming Super-Loose Inside the Canal at the recorded w.l to create a path for the rotary file .
223971467|NCT06363877|DRUG|Normal Saline|"Peritoneal lavage: With the fascia open, the peritoneum will be washed out with 1L of normal saline allowing the solution to sit in the peritoneum for 2 minutes. This is followed by suctioning of the solution, wash-out with 2L of normal saline, followed by suctioning of the normal saline.~Wound Irrigation: With the fascia closed, the wound will be irrigated with 500mL normal saline solution, suctioned, then washed-out with 500 mL normal saline."
224291967|NCT05841290|PROCEDURE|Irrigation|Irrigation using 5.25% sodium hypochlorite introduced using side vented needle
223542967|NCT06471959|DRUG|Psilocybin|Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
223542968|NCT03486782|DEVICE|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
224291968|NCT05841290|PROCEDURE|Cleaning and shaping using rotary system|Cleaning and shaping using rotary system plus irrigation and apical patency between every rotary file .
224291969|NCT05841290|PROCEDURE|Second w.l determination|Second w.l determination using electronic apex locator before using final finishing rotary file .
223542969|NCT03486782|DEVICE|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
223542970|NCT03486782|BEHAVIORAL|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
223971468|NCT00218075|DRUG|Levodopa|
223971469|NCT00218075|DRUG|Carbidopa|
223971470|NCT00218075|BEHAVIORAL|Clinical Management|
223971471|NCT00218075|BEHAVIORAL|Relapse Prevention Therapy|
223971472|NCT00218075|BEHAVIORAL|Contingency Management|
223971473|NCT03221634|BIOLOGICAL|Pembrolizumab|IV infusion
223971474|NCT03221634|BIOLOGICAL|Daratumumab|IV infusion
223971475|NCT02396758|DEVICE|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
223971476|NCT02396758|BIOLOGICAL|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
223971477|NCT02312362|PROCEDURE|Combined sclerotomy ab interno and phaco|
224291970|NCT05841290|PROCEDURE|Apical gauging|"Establish the depth of apical constriction - this is the zero reading on your apex locator. your working length will be 0.5mm - 1mm short of this.~After cleaning and preparing the canal system to your working length, passively insert 02 taper hand files, starting from #15. If the file goes past the apical constriction (your working length + 0.5-1mm), then choose the next largest file and repeat.~When a file passively binds short of the apical constriction, that will be the upper limit of the apical constriction diameter. The smaller file before that would be the lower limit.~Apical gauging helps with:~Choosing the best master cone that closely matches canal length and taper Achieving true tug back - as opposed to false tug back! Minimising gutta percha extrusions during obturation"
224291971|NCT05841290|PROCEDURE|Activation of the irrigant|Activation of the irrigant using Manual Dynamic Agitation and Ultra x or eddy tips for activation
223971478|NCT02312362|PROCEDURE|Phacoemulsification with IOL implantation|
224291972|NCT05841290|PROCEDURE|Master cone check|Master cone check Clinically and confirmatory radiograph
224291973|NCT05841290|DRUG|application of resin based sealer inside the canal in the resin based sealer group|application done by inserting inside the canal by spreader or master cone
224291974|NCT05841290|DIAGNOSTIC_TEST|application of the sillicon based sealer inside the canal in the sillicon based group|application done by injection inside the canal
224291975|NCT05841290|PROCEDURE|Obturation|done by lateral condensation technique
224291976|NCT05841290|DIAGNOSTIC_TEST|Visual Analogue Scale (VAS)|"Pain is evaluated using visual analogue scale (VAS) which is a pain rating scale. Scores are based on measures that are self-reported of symptoms that are recorded through a single handwritten mark placed at one point along the length of a 10-cm line representing a continuum between the two ends of the scale; on the left end of the scale (0 cm) means no pain and the on the right end of the scale (10 cm) worst pain"
224291977|NCT05633108|OTHER|No Intervention|No intervention will be administered.
224291978|NCT06044532|OTHER|Experimental|At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.
224291979|NCT01421342|DRUG|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
223971479|NCT00111163|DRUG|sulfadoxine-pyrimethamine with artesunate|
223971480|NCT00111163|DRUG|amodiaquine with artesunate|
223971481|NCT00111163|DRUG|chlorproguanil-dapsone|
224291980|NCT01421342|DRUG|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
224291981|NCT01421342|DRUG|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
224291982|NCT03055442|OTHER|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
224291983|NCT03055442|OTHER|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
224291984|NCT00834652|DRUG|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
224291985|NCT00834652|DRUG|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
224291986|NCT06457399|DRUG|Heliox|Treatment for 30 minutes with Heliox from a commercial tank (Oxhelⓒ, Air Liquideⓒ) with a fixed mixture of 70% helium and 30% oxygen with non-rebreather mask or reservoir bag at a flow of 12-15 lpm.
223542971|NCT02432937|DRUG|Corever|Corever
224291987|NCT06457399|DRUG|Oxygen|Treatment for 30 minutes with oxygen at FiO2 of 31% with Venturi mask.
224291988|NCT05484453|DIAGNOSTIC_TEST|Complete Eye Examination by Ophthalmologist|complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
223542972|NCT03722381|DRUG|Amlodipine Besylate|Pharmacokinetics
223971482|NCT00485914|BEHAVIORAL|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
223725091|NCT05237531|BEHAVIORAL|Standardized Preoperative Education|"The standardized preoperative education includes a brief video, an interactive quiz, and a written handout.~The video will provide information on the proper use and common side effects of opioid pain medications, the expected effects of a peripheral nerve block, and the concept of multimodal postoperative pain management with non-opioid medications and non-pharmaceutical pain management strategies. The interactive quiz will reinforce the critical components of the video in a question-and-answer format which requires active participation. The written handout will summarize the educational content in a form which can be easily referenced by patients at home."
223971483|NCT00485914|BEHAVIORAL|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
223971484|NCT01095601|DRUG|Avanafil|"* Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~* Treatment B: 2x100 mg Formulation II avanafil tablet, fed~* Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~* Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
223971485|NCT00265096|BIOLOGICAL|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
223971486|NCT00265096|BIOLOGICAL|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
224291989|NCT03762551|OTHER|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
223971487|NCT00265096|BIOLOGICAL|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
223971488|NCT05611658|OTHER|MR, PET CT|diagnostic method
223971489|NCT00774306|DRUG|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
223971490|NCT00774306|DRUG|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
223971491|NCT00774306|DRUG|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
223971492|NCT05478200|BEHAVIORAL|physical exercise|Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).
223971493|NCT05478200|OTHER|Manual therapy|Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
223971494|NCT03126188|DRUG|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
223971495|NCT03126188|DRUG|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
223971496|NCT03126188|DRUG|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
224291990|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
223971497|NCT02261545|DIETARY_SUPPLEMENT|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
224291991|NCT03633448|DRUG|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
224291992|NCT00006472|DRUG|carboplatin|Carboplatin AUC 6 days 1 and 22
223542973|NCT00878592|BEHAVIORAL|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
223542974|NCT00285285|DEVICE|Point of Care Device; i-Stat Analyzer|
223725092|NCT05237531|BEHAVIORAL|Standard of care|Education per provider preference (no standardization, current standard of care)
223971498|NCT02261545|DIETARY_SUPPLEMENT|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
223971499|NCT01024829|RADIATION|Radiotherapy|Radiotherapy
224291993|NCT00006472|DRUG|fluorouracil|5FU 225mg/m2 continuous infusion on days 1-42 during radiation
224291994|NCT00006472|DRUG|paclitaxel|taxol
224291995|NCT00006472|PROCEDURE|conventional surgery|
224291996|NCT00006472|RADIATION|radiation therapy|The initial fields should be treated AP:PA when possible to a dose of 4500 cGy in 180 cGy fractions
224291997|NCT00044668|DRUG|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
224291998|NCT04214925|OTHER|Tai Chi|Home exercises will include warm-up and cool-down exercises, stretching for shoulder, hamstring and erector spinae muscles, strengthening exercises for abdominal and back muscles.
224291999|NCT06434922|DEVICE|Prevention Strategies|Data collection sessions lasted approximately 1 to 1.50 hours, with education and foot care provided once a month. Subsequently, patients underwent monthly follow-ups for three months, during which they received guidance on foot examination, foot care, dietary habits, physical exercise, and stress management.
223971500|NCT06434545|BEHAVIORAL|Palliative Reasoning methodology|Twenty nursing teams will be trained in the Palliative Reasoning methodology during a four hour training, split into two sessions. Additionally, teams receive a coaching session ones a month and practice with a real life case every week or two weeks during a one hour team meeting. This will be compared with 20 other nursing teams that will continue to provide care as usual.
223971501|NCT00666835|DRUG|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
223971502|NCT00666835|DRUG|ERYPO®, Janssen-Cilag|Solution for i.v. injection
223971503|NCT03897049|BEHAVIORAL|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
223971504|NCT03897049|BEHAVIORAL|General Health App|The control group will download a mobile app that addresses COVID and provides COVID resources.
223971505|NCT03978299|DIAGNOSTIC_TEST|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
223971506|NCT04903912|DIAGNOSTIC_TEST|Vascular ultrasound or other imaging methods according to current guidelines|Peripheral vascular ultrasound / ankle/brachial index / CT angiography / MR angiography / angiography
223971507|NCT04903912|DIAGNOSTIC_TEST|Laboratory tests|Metabolic profile and platelet reactivity
224292000|NCT06434922|DEVICE|Standard Strategiies|Group were educated about DM management, medication adherence, dietary practices, physical exercise routines, and foot care through pamphlets
224292001|NCT00349726|DRUG|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
224292002|NCT00349726|DRUG|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
224292003|NCT00349726|DRUG|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
224292004|NCT00349726|DRUG|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
224292005|NCT00273481|DRUG|dorzolamide 2%/timolol maleate 0.5% fixed combination|
224292006|NCT00273481|DRUG|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
224292007|NCT00273481|DRUG|timolol maleate 0.5%|
224292008|NCT00273481|DRUG|placebo|
224292009|NCT04095949|DIETARY_SUPPLEMENT|Artichokes|Approximately 200 g of cooked artichokes
224292010|NCT03053219|DRUG|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
224292011|NCT00788502|BEHAVIORAL|Healing Touch|
224292012|NCT00788502|BEHAVIORAL|Desensitization Therapy|
224292013|NCT04131543|DRUG|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
224292014|NCT04131543|DRUG|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
224292015|NCT04131543|DRUG|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
223971508|NCT04903912|DRUG|Medical treatment according to current guidelines|Antithrombotic drugs, lipid-lowering drugs, antihypertensive drugs, and pharmacotherapy to increase walking capacity according to current guidelines
223971509|NCT04903912|PROCEDURE|Endovascular od surgical peripheral revascularizations|Endovascular od surgical peripheral revascularizations according to current guidelines
223971510|NCT05295992|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
223971511|NCT04778683|PROCEDURE|Virtual Reality|The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
223971512|NCT03254992|DEVICE|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
223971513|NCT03254992|DEVICE|ASD - Tangible task|Experimental group using Keyboard with more real activity.
224114342|NCT01296386|BIOLOGICAL|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
224114343|NCT01797432|DRUG|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
224292016|NCT03625518|DRUG|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
224292017|NCT03625518|DEVICE|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
224292018|NCT01836406|DRUG|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
223725093|NCT05237531|BEHAVIORAL|Preoperative and postoperative questionnaires|Preoperative questionnaire: Demographic questions plus specific questions about chronic pain, prior opioid use, and mental health diagnoses Postoperative questionnaire: Questions about pain control after surgery, satisfaction with pain control, healthcare contact since surgery, opioid consumption since surgery, and satisfaction with education
223971514|NCT03254992|DEVICE|TD - Abstract task|Control group using Kinect with more virtual activity.
224292019|NCT00014625|DRUG|indisulam|
224292020|NCT03217396|PROCEDURE|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
223725094|NCT01942330|PROCEDURE|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
223971515|NCT03254992|DEVICE|TD - Tangible task|Control group using Keyboard with more real activity.
223971516|NCT00692445|DRUG|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
223971517|NCT00692445|DRUG|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
223971518|NCT01233492|DRUG|boron phenylalanine|
223971519|NCT01233492|DRUG|mannitol|
224114344|NCT01797432|DEVICE|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
224114345|NCT06037655|DRUG|Total Neoadjuvant Treatment|Adebrelimab (1200 mg) every three weeks intravenously; Mecapegfilgrastim (6 mg) every three weeks intravenously; Gemcitabine (1000 mg/m2) every three weeks on days 1 and 8 intravenously; Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously
224114346|NCT03403972|DRUG|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
224114347|NCT05478915|PROCEDURE|discectomy of the TMJ disc|removal of the TMJ disc
224114348|NCT05478915|PROCEDURE|TMJ discopexy|fixation of the TMJ disc
224114349|NCT00395785|DEVICE|Carotid Stent Implantation|
224114350|NCT00395785|DEVICE|Embolic Protection|
224114351|NCT05910593|DIAGNOSTIC_TEST|Dexterity Assessment Tool|Measures finger dexterity using pressure sensor pads.
224114352|NCT03322137|DRUG|SNA-120|Pegcantratinib ointment
224114353|NCT03322137|DRUG|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
224114354|NCT03994640|COMBINATION_PRODUCT|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
224114355|NCT03994640|COMBINATION_PRODUCT|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
224114356|NCT01539265|DRUG|silodosin|
224114357|NCT01539265|DRUG|silodosin|
224292021|NCT05515393|DRUG|XY03-EA|The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.
224114358|NCT01539265|DRUG|placebo|
224114359|NCT05446246|PROCEDURE|Bariatric surgery|Sleeve gastrectomy
224114360|NCT01666522|DRUG|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
224114361|NCT01666522|OTHER|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
224114362|NCT04701255|PROCEDURE|phacoemulsification with intraocular lens implantation|treatment of cataract by phacoemulsification procedure and implantation of different types of IOLs.
224114363|NCT04701255|DEVICE|ocular aberrometer assesment|evaluate total ocular wavefront, corneal wavefront \& internal wavefront (High order aberrations ) post operative by corneal tomography and aberrometer
224114364|NCT01379586|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
224114365|NCT01379586|DRUG|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
224114366|NCT02139410|PROCEDURE|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
224292022|NCT05515393|DRUG|XY03-EA Placebo|XY03-EA Placebo
224292023|NCT01087671|DRUG|tafluprost|prostaglandin analogue
224292024|NCT02264288|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
224292025|NCT02264288|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
223971520|NCT01233492|OTHER|biologic sample preservation procedure|
223971521|NCT01233492|RADIATION|radiation therapy treatment planning/simulation|
223971522|NCT02336113|BEHAVIORAL|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
223971523|NCT02718053|OTHER|L-stiff|spasticity measurement with Lokomat
223971524|NCT02718053|OTHER|Ashworth|spasticity measurement with Ashworth scale
223971525|NCT04385628|BEHAVIORAL|the patient' relatives satisfaction questionnaire|The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
223971526|NCT02801916|OTHER|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
224114367|NCT05249595|DEVICE|Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
224114368|NCT05249595|DEVICE|Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
224114369|NCT05249595|DEVICE|Surface electromypgraphy and ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices|The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by combining sEMG and ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
224114370|NCT01498510|BEHAVIORAL|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
224114371|NCT04640246|BIOLOGICAL|TBX-3400|Autologous transfusion
224114372|NCT06070610|DRUG|BI 1015550|BI 1015550
224114373|NCT06070610|DRUG|Nintedanib|Soft capsules
224114374|NCT06070610|DRUG|Pirfenidone|Film-coated tablets
223725095|NCT03376022|OTHER|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
223725096|NCT00963547|DRUG|MK-2206|\[Part 1\]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. \[Part 2\] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
223725097|NCT00963547|BIOLOGICAL|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
223971527|NCT02801916|OTHER|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
223971528|NCT02801916|OTHER|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
223971529|NCT02801916|OTHER|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
224114375|NCT02086773|BIOLOGICAL|Red blood cell transfusion|
224114376|NCT01916369|BIOLOGICAL|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
223971530|NCT03319719|DEVICE|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
223971531|NCT03319719|DEVICE|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
223971532|NCT02429232|DRUG|Pioglitazone|Pioglitazone 30mg/tablet once daily
223971533|NCT02429232|DRUG|Linagliptin|Linagliptin 5mg/tablet once daily
223971534|NCT04244708|DRUG|Radiotherapy plus temozolomide|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
223971535|NCT04244708|OTHER|Radiotherapy plus placebo|undergoing fractionated radiotherapy at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks, for a total dose of 54 Gy, plus placebo
223971536|NCT03139383|OTHER|dextrose solution|The patients received 5%D/N/2 during surgery
223971537|NCT03139383|OTHER|saline solution|The patients received NSS during surgery
223542975|NCT06386926|OTHER|Electro Therapy|radial shockwave 3 sessions one session per week for four consecutive weeks ,receive Ultrasound phonophoresis using diclofenac Na+ 12 session, 3 sessions per week and conventional physical therapy modalities in the form of 3 sessions every week for 8 weeks
223542976|NCT03292003|DEVICE|Journey II BCS Total Knee System|
223542977|NCT01162551|DRUG|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days."
223542978|NCT06284239|OTHER|Tell me about the game.|It is a game played with playing cards. On the game cards, there will be the word that the narrator student must explain to his group friends and five prohibited words right below this word. Prohibited words are synonyms, antonyms or close meanings of the word to be explained. According to the game rules, the student narrator will explain the word on the cards to his group friends without using prohibited words.
223542979|NCT04594629|DRUG|Nitroglycerin|Patients of nitroglycerine group received nebulized nitro glycerine (a vial contains 50 mg nitroclycerine ), its starting concentration was 200 mcg/ml with nitro glycerine was delivered at 2.5-5 mcg/kg/min (5 mg, 1 mg/ml) over 10 minutes by ultrasonic nebuliser connected to the inspiratory limb of the breathing circuit
223542980|NCT04594629|DRUG|PGI2|Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC) (60 ml syringe of PGI2 with concentration 20000 ng/ml was attached to an intravenous pump which delivers a titrating rate of 8 ml/h to the nebulizer compartment (MiniHEART nebulizer; Westmed, Tucson, Ariz) fixed to the inspiratory limb of the breathing circuit or to the face mask with venturi accessory for sprinkling. The nebulizer was filled with 15 ml PGI2 with nebulized oxygen flow rate 3 litres
223542981|NCT02424058|DEVICE|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
223971538|NCT04086719|DRUG|BMS-986165|Oral administration of tablet BMS- 986165
223971539|NCT04086719|DRUG|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
223971540|NCT00220116|DRUG|Capecitabine, Oxaliplatin|
223971541|NCT02764788|OTHER|Specific auriculotherapy|Specific auriculotherapy with needles
223971542|NCT02764788|OTHER|non-specific auriculotherapy|non-specific auriculotherapy with needles
223971543|NCT02764788|OTHER|seed auriculotherapy|non-specific auriculotherapy with seeds
223971544|NCT04077775|DIAGNOSTIC_TEST|assesment|assesment
223971545|NCT00295048|BEHAVIORAL|Computer Assisted Cognitive Remediation (CACR)|
223971546|NCT06204614|DEVICE|Implantable Micro-Device|The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
223971547|NCT06204614|DRUG|Methotrexate|Methotrexate will be placed in reservoir 1 of the implantable microdevice.
223971548|NCT06204614|DRUG|Carboplatin|Carboplatin will be placed in reservoir 2 of the implantable microdevice.
223971549|NCT06204614|DRUG|Avelumab|Avelumab will be placed in reservoir 3 of the implantable microdevice.
223971550|NCT06204614|DRUG|Paclitaxel|Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
223971551|NCT06204614|DRUG|Vinblastine|Vinblastine will be placed in reservoir 5 of the implantable microdevice.
223971552|NCT06204614|DRUG|Gemcitabine/Cisplatin I|Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
223971553|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
223971554|NCT06204614|DRUG|Gemcitabine/Cisplatin II|Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
223971555|NCT06204614|DRUG|Cisplatin|Cisplatin will be placed in reservoir 9 of the implantable microdevice.
223971556|NCT06204614|DRUG|Nivolumab|Nivolumab will be placed in reservoir 10 of the implantable microdevice.
223971557|NCT06204614|DRUG|Pembrolizumab|Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
224114377|NCT02585804|DRUG|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
223971558|NCT06204614|DRUG|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
223971559|NCT06204614|DRUG|Methotrexate/Vinblastine/Doxorubicin/Cisplatin|(Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
223971560|NCT06204614|DRUG|Gemcitabine/Cisplatin/Nivolumab|(Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
223971561|NCT06204614|DRUG|Erdafitinib|Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
223971562|NCT06204614|DRUG|Paclitaxel/Docetaxel/Ifosfamide|(Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
223971563|NCT06204614|DRUG|Gemcitabine|Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
223971564|NCT06204614|DRUG|Gemcitabine/Carboplatin/Nivolumab|(Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
223971565|NCT06204614|DRUG|Enfortumab|Enfortumab will be placed in reservoir 19 of the implantable microdevice.
223971566|NCT06204614|DRUG|Sacituzumab|Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
223971567|NCT06457347|PROCEDURE|Ultra early (<24 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in less than 24 hours after rupture to prevent early rebleeding.
223971568|NCT06457347|PROCEDURE|Early (24-72 hours) ruptured aneurysm clipping|Aneurysms are clipped with open surgery in 24 to 72 hours after rupture to prevent early rebleeding.
223971569|NCT00744796|PROCEDURE|DSAEK|Endothelial Keratoplasty
223971570|NCT00744796|DIAGNOSTIC_TEST|Anterior Segment Optical Coherence Topography (OCT)|Non-contact, high resolution, cross sectional imaging of the anterior segment of the eye.
224292026|NCT02264288|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
223971571|NCT00744796|DIAGNOSTIC_TEST|Best Spectacle Corrected Visual Acuity (BSCVA)|Visual acuity determined using a combination of detecting hand motion, counting fingers displayed and reading Snellen charts at specific distances.
224114378|NCT03927729|DRUG|Methoxyflurane|Pain will be treated with inhaled methoxyflurane (Penthrox®).
224114379|NCT02796989|DIETARY_SUPPLEMENT|Wheat bran|20 g each day
224114380|NCT02796989|DIETARY_SUPPLEMENT|Placebo|20 g each day
224114381|NCT03078491|OTHER|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
224114382|NCT01137435|BIOLOGICAL|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
224114383|NCT05315310|DEVICE|Soft Exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
224114384|NCT05058378|DEVICE|perfusion index measurement|Clip will be attached to the patient's toe for perfusion index measurement
224114385|NCT04630015|OTHER|Survey Administration|Participants will complete study specific survey
224114386|NCT05182515|DRUG|Therapeutic plasma exchange|"Plasma exchange techniques reported in COVID-19 vary from study to study. No consensus exists on the use of a specific technique.~The use of a central venous catheter will be left to the discretion of investigators. If so, central venous catheter will be inserted through the internal jugular or femoral route under ultrasound control by a trained operator. After radiographic control of the position of the catheter and the absence of complications in the placement of the catheter, plasma exchanges will be carried out.~Three plasma exchanges of 1.5 plasma volume will be carried out every 48 hours on D1, D3 and D5. Plasma volume will be assessed by this equation VP = (1-Hct)x70xweight Body(measured). The substitution volume will be 5% albumin as first intervention. The use of a hemofiltration or centrifugation technique will be left to the discretion of each center."
224114387|NCT03534271|DEVICE|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
224114388|NCT05431686|BEHAVIORAL|SMA visits|SMA visit once every 3 months over a 12 month period
224114389|NCT01048515|DRUG|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
224114390|NCT02334969|DRUG|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
224114391|NCT02334969|DRUG|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
224292027|NCT02264288|OTHER|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
224292028|NCT01642914|DRUG|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
223971572|NCT03682237|DEVICE|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
223971573|NCT03682237|DEVICE|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
223971574|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
223971575|NCT02537236|BEHAVIORAL|TLC nutritional intervention|nutritional orientation.
224292029|NCT01642914|DRUG|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
224292030|NCT01642914|DRUG|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
223971576|NCT02537236|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
223971577|NCT00994396|DIETARY_SUPPLEMENT|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
223971578|NCT00994396|DIETARY_SUPPLEMENT|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
224114392|NCT01363895|PROCEDURE|Percutaneous closure of LAA|Percutaneous closure of LAA
223542982|NCT02424058|BEHAVIORAL|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
223542983|NCT02383862|OTHER|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
223971579|NCT03134937|DEVICE|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
223971580|NCT01405521|BIOLOGICAL|Vaccine placebo (excipients only)|single oral dose,
223971581|NCT01405521|BIOLOGICAL|Ty21a|3 oral doses, alternate days
223971582|NCT01405521|BIOLOGICAL|M10ZH09 vaccine|single oral dose
223971583|NCT01444547|DRUG|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
224114393|NCT01363895|PROCEDURE|Catheter ablation of AF|Catheter ablation of AF
224114394|NCT04176822|OTHER|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
224292031|NCT06005597|COMBINATION_PRODUCT|Combination Therapy|tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
223971584|NCT03470103|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
223971585|NCT03342170|GENETIC|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
223971586|NCT00131183|DRUG|Nebido|
224292032|NCT06005597|DRUG|Monotherapy obicetrapib|tablet; 10mg obicetrapib
224292033|NCT06005597|DRUG|Monotherapy ezetimibe|capsule; 10mg ezetimibe
223542984|NCT01154491|DRUG|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
223542985|NCT01154491|DRUG|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
223542986|NCT01154491|DRUG|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
223542987|NCT01833494|DRUG|PA21|
223725098|NCT00963547|DRUG|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
223971587|NCT02921139|RADIATION|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
223971588|NCT02921139|PROCEDURE|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
223971589|NCT03146897|DIETARY_SUPPLEMENT|Supplementary Food|Supplementary food for treating MAM
223971590|NCT00129506|DRUG|methotrexate + misoprostol|
223971591|NCT00129506|DRUG|misoprostol|
224114395|NCT04176822|OTHER|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
224114396|NCT02896725|DEVICE|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
224114397|NCT02896725|DEVICE|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
224114398|NCT04668846|OTHER|non-invasive sample collection of skin tissue|Both lesional and non-lesional skin will be sampled with up to 24 adhesive patches.
224114399|NCT00125203|DRUG|Botulinum toxin type B (Myobloc)|
224114400|NCT00125203|PROCEDURE|Injection of salivary glands|
224292034|NCT06005597|OTHER|Combination Therapy placebo|tablet; no active ingredient
224292035|NCT06005597|OTHER|Obicetrapib Placebo|tablet; no active ingredient
224292036|NCT06005597|OTHER|Ezetimibe Placebo|capsule; no active ingredient
223971592|NCT06504212|OTHER||
223971593|NCT04772313|BIOLOGICAL|Pegloticase|Participants will receive pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
223971594|NCT04772313|DRUG|Methotrexate (MTX)|Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
223971595|NCT02005068|DRUG|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
223971596|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
223971597|NCT03228342|DIAGNOSTIC_TEST|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
223971598|NCT01836198|DRUG|LY2409021|
223971599|NCT01836198|DRUG|Gemfibrozil|
223971600|NCT01836198|DRUG|Ketoconazole|
223971601|NCT01836198|DRUG|Clarithromycin|
223971602|NCT02215954|DRUG|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
223971603|NCT02215954|DRUG|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
224292037|NCT03247088|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
223725099|NCT05367648|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
223725100|NCT05367648|OTHER|Placebo|Placebo comparator
223971604|NCT00203723|DRUG|Risperidone|
223971605|NCT05710198|DRUG|Citicoline eye drops 2%|Eye drops containing Citicoline 2%
223971606|NCT05710198|DRUG|Placebo|Eye drops containing placebo matching product
223971607|NCT05247476|DRUG|L-T4|Patients with refractory hypothyroidism continued to receive L-T4 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
223971608|NCT05247476|DRUG|L-T4+T3 (thyroid tablet)|Patients with refractory hypothyroidism changed to receive L-T4 +T3 therapy. The drug dose was adjusted so that FT4 did not exceed the normal range, and the TSH suppression target was achieved as far as possible.
223971609|NCT04060732|DEVICE|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
223971610|NCT02683213|DRUG|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
224292038|NCT03247088|DRUG|Busulfan|Given IV
224292039|NCT03247088|DRUG|Cyclophosphamide|Given IV
223542988|NCT04357561|BEHAVIORAL|Exercise group (Schroth best practice)|Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
223971611|NCT02683213|DRUG|Placebo|Matching placebo.
223971612|NCT02460562|DEVICE|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
223971613|NCT02460562|DEVICE|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
224292040|NCT03247088|BIOLOGICAL|Filgrastim|Given SC
224292041|NCT03247088|DRUG|Fludarabine|Given IV
224292042|NCT03247088|DRUG|Mycophenolate Mofetil|Given PO
224292043|NCT03247088|DRUG|Sorafenib|Given PO
224292044|NCT03247088|DRUG|Tacrolimus|Given PO
223542989|NCT05866692|DRUG|TY-2699a|"TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results"
224292045|NCT02664857|DRUG|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
224292046|NCT02664857|DRUG|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
223971614|NCT03441919|RADIATION|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
223971615|NCT03441919|DIAGNOSTIC_TEST|Blood drawn|Blood drawn
223971616|NCT00888394|PROCEDURE|chiropody|basic procedure of chiropody in podiatry
223971617|NCT00888394|PROCEDURE|basic orthesis|individual basic orthesis of foot
223971618|NCT00888394|PROCEDURE|advantage orthesis|advantage orthesis of foot with special material and design
223971619|NCT00888394|PROCEDURE|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
223971620|NCT04494243|DRUG|AD-214 10/600mg|1 tablet administered before the breakfast during 7 days
223971621|NCT04494243|DRUG|Rabeprazole 10mg|1 tablet administered before the breakfast during 7 days
223971622|NCT02728947|DRUG|ROTIGOTINE|1 week at each dose
223971623|NCT01654289|OTHER|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
224114401|NCT03830138|GENETIC|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
224292047|NCT02721836|BEHAVIORAL|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
224292048|NCT02721836|BEHAVIORAL|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
224292049|NCT05742698|DRUG|Nabilone|Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.
223971624|NCT01654289|OTHER|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
223971625|NCT04653571|OTHER|CASPR2 encephalitis|Defining the initial clinical symptoms and those leading to the diagnosis of CASPR2 antibody associated encephalitis. For that, we will investigate the initial cognitive status, the initial neuropsychological investigations the clinical presentation of the first seizures, and the prodromes assessed by patients at the beginning of their disease. We will also look at the initial EEG records, in order to acknowledge whether the initial cognitive symptoms may be due to unseen seizures.
223971626|NCT04194541|DEVICE|Cutimed Sorbact Hydroactive B wound dressing|Wound dressing applied and changed as needed.
223971627|NCT04194541|DEVICE|Cutimed Siltect wound dressing|Wound dressing applied and changed as needed.
223971628|NCT04194541|DEVICE|Sorbion Sana multi-star wound dressing|Wound dressing applied and changed as needed.
223971629|NCT00269126|DRUG|fluticasone propionate/salmeterol combination DISKUS|
223971630|NCT00269126|DRUG|salmeterol xinafoate|
224292050|NCT05742698|DRUG|Placebo|The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.
223971631|NCT03472859|DEVICE|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
223725101|NCT03767504|DIETARY_SUPPLEMENT|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
223725102|NCT00673569|DRUG|erlotinib hydrochloride|
223971632|NCT03472859|DEVICE|KTP|This is the traditional green laser (KTP)
223971633|NCT04431739|DEVICE|MRI including conventional MRI, DWI with multiple ADC values|The utility of apparent diffusion coefficient obtained in diffusion-weighted MR imaging for the differentiation between benign and malignant vertebral lesions
223971634|NCT02628613|DRUG|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
224292051|NCT05907330|DRUG|CU104|CU104 will administer the study drug once a day after a meal
224292052|NCT05907330|DRUG|Placebo|Placebo will administer the study drug once a day after a meal
224292053|NCT01009671|DRUG|ART 44|
224292054|NCT01009671|DRUG|ART 50|
224292055|NCT00754442|DRUG|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
224292056|NCT04479475|BEHAVIORAL|Supportive care through community support persons|The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
223971635|NCT02628613|DRUG|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
223971636|NCT03373500|OTHER|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
224114402|NCT05574543|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
224114403|NCT05574543|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
224292057|NCT05128032|DEVICE|Standard microcatheter|Small device used for mapping as part of radioembolization procedure
224292058|NCT05128032|DEVICE|PEDD device|Pressure enabled small device used for mapping as part of radioembolization procedure
224292059|NCT06407232|DRUG|Letermovir|480 mg taken orally once daily, for 84 days
223971637|NCT05615662|BEHAVIORAL|Meru Health Program|The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.
224114404|NCT04859803|PROCEDURE|Patients will be received rhomboid intercostal block under ultrasound guidance.|Following endotracheal intubation, patients allotted to the RIB group were positioned in the lateral decubitus position with the chest on the operating side lying superiorly. The ipsilateral arm was abducted from the chest to move the scapula laterally. The RIB was performed as described previously \[8\]. A high-frequency (6-12 MHz) linear ultrasound probe (LOGIQ e ultrasonic system, Deutschland GmbH \& Co. KG, Solingen, Germany) was placed medial to the medial border of the scapula in the oblique sagittal plane. The landmarks, i.e., the trapezius muscle, rhomboid muscle, intercostal muscles, pleura, and lung, were identified in the ultrasound. Under aseptic conditions, an 80-mm 21-gauge needle was inserted at the level of T6-7 in the ultrasound view. A single dose of 30 ml 0.25% bupivacaine will be injected in the interfascial plane between the rhomboid major and intercostal muscles. The spread of the local anesthetic solution under the rhomboid muscle was visualized by ultrasonography.
224114405|NCT04859803|DRUG|conventional intravenous analgesia|Following endotracheal intubation, patients will be received morphine sulfate (0.02 mg/kg) bolus doses were used to preserve MAP and HR within 20% of pre-induction readings
224114406|NCT04845776|DIETARY_SUPPLEMENT|ANRC Essentials Plus|a vitamin/mineral supplement designed for children and adults with autism
224114407|NCT02714946|DEVICE|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
224114408|NCT02714946|DEVICE|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
224114409|NCT00782080|DRUG|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
224114410|NCT00782080|DRUG|Placebo|Placebo
224292060|NCT05919264|DRUG|FOG-001|FOG-001 will be administered IV at assigned doses in continuous cycles of 28 days
224292061|NCT05919264|DRUG|mFOLFOX-6|mFOLFOX-6 will be administered per the prescribing information in combination with FOG-001
223725103|NCT00673569|GENETIC|gene expression analysis|
223971638|NCT05615662|BEHAVIORAL|Treatment as Usual|Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
223971639|NCT00030745|DRUG|cisplatin|
223971640|NCT00030745|DRUG|gemcitabine hydrochloride|
223971641|NCT00030745|PROCEDURE|conventional surgery|
223971642|NCT04448821|DRUG|Metformin|Single administration of metformin
223971643|NCT04448821|DRUG|Metformin + Nilotinib|Coadministration of metformin and nilotinib
223971644|NCT03746483|DRUG|MS1819|MS1819, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
223971645|NCT03746483|DRUG|Porcine PERT|Porcine PERT is being used as a comparator to MS1819 as a second drug/intervention
223971646|NCT05712850|PROCEDURE|SiJoin® Transfixing Sacroiliac Fusion Device|Sacroiliac Fusion
223971647|NCT05645744|BIOLOGICAL|Prior MB-102 CAR-T cell investigational product.|No investigational product will be administered.
223971648|NCT05645744|BIOLOGICAL|Prior MB-106 CAR-T cell investigational product.|No investigational product will be administered.
223971649|NCT00187135|DRUG|Fentanyl|"1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
223971650|NCT00187135|DRUG|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
223971651|NCT00187135|DRUG|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
223971652|NCT00187135|DRUG|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
223971653|NCT04349124|DRUG|Nifedipine Extended-Release Tablets|Antihypertensive
223725104|NCT00673569|GENETIC|protein expression analysis|
223971654|NCT06023745|GENETIC|genotyping|Genotyping. Measurement of SOD serum level. Measurement of IL-35 serum level.
223725105|NCT00673569|OTHER|immunoenzyme technique|
223971655|NCT00607737|DRUG|insulin detemir|3 cutaneous injections
223971656|NCT00607737|DRUG|saline|3 cutaneous injections
223971657|NCT01389609|DRUG|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
223971658|NCT01389609|DRUG|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
223971659|NCT01389609|DRUG|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
223971660|NCT03480945|DIAGNOSTIC_TEST|serotonin|Endothelium-dependent dilatation
224114411|NCT02263339|BEHAVIORAL|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
224292062|NCT05919264|DRUG|Nivolumab|Nivolumab will be administered per the prescribing information in combination with FOG-001
224292063|NCT05919264|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil will be administered per the prescribing information in combination with FOG-001
224292064|NCT05919264|DRUG|Bevacizumab|Bevacizumab will be administered per the prescribing information in combination with FOG-001
223725106|NCT00673569|OTHER|immunologic technique|
223725107|NCT00673569|OTHER|laboratory biomarker analysis|
223725108|NCT00673569|PROCEDURE|needle biopsy|
223725109|NCT03962920|DRUG|Tigecycline 50 MG|Local instillation of drug directly to the tumour tissue
223725110|NCT03962920|OTHER|Placebo|Local instillation of sterile water directly to the tumour tissue
223971661|NCT02949622|BEHAVIORAL|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
223971662|NCT02949622|OTHER|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
223971663|NCT01610622|DEVICE|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
223971664|NCT04796389|OTHER|Music|Preferred music of the participant administered using headphones.
223971665|NCT03512587|PROCEDURE|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
223971666|NCT03512587|PROCEDURE|Placebo|Headphones will be place in patients without playing quantum sonotherapy
223971667|NCT04785742|DRUG|Almonertinib|Almonertinib
223971668|NCT03841227|DEVICE|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
223971669|NCT03841227|DEVICE|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
223971670|NCT01951261|PROCEDURE|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
223971671|NCT00011778|DRUG|bortezomib|
223971672|NCT00011778|RADIATION|radiation therapy|
223971673|NCT03175835|DRUG|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1\~Day5
223971674|NCT03175835|DRUG|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9\~Day21
223971675|NCT03175835|DRUG|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22\~Day26
223971676|NCT02650934|PROCEDURE|Percutanous coronary intervention|
224114412|NCT02263339|BEHAVIORAL|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
224114413|NCT02263339|BEHAVIORAL|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
224114414|NCT03251976|BEHAVIORAL|video|informational video
224114415|NCT03251976|BEHAVIORAL|usual care|usual physician counseling on end of life care
224114416|NCT02955186|DRUG|Saracatinib|Saracatinib 125 mg once per day for 8 days
224114417|NCT02955186|DRUG|Placebos|Placebo once per day for 8 days
224292065|NCT04800484|DEVICE|Tall Soft|Tall heel wedge made of soft foam
224292066|NCT04800484|DEVICE|Tall Firm|Tall heel wedge made of firm foam
224292067|NCT04800484|DEVICE|Short Soft|Short heel wedge made of soft foam
224292068|NCT04800484|DEVICE|Short Firm|Short heel wedge made of firm foam
224292069|NCT05084521|DRUG|Famotidine 400 mg/50 mL|Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
224292070|NCT06400303|BIOLOGICAL|KYV-101|Anti-CD19 CAR-T cell therapy
224114418|NCT04792996|OTHER|No intervention|No intervention. case - control design.
224114419|NCT00757523|DRUG|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
224292071|NCT06400303|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
224292072|NCT04781140|DRUG|100mg SPN-812|100mg SPN-812 will be administered once daily and compared to Placebo
224292073|NCT04781140|DRUG|Placebo|Placebo will be administered once daily
223725111|NCT06352281|BIOLOGICAL|CAR-T cells|CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.
224114420|NCT00757523|DRUG|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
224114421|NCT05632250|DEVICE|ConvaFoam|ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. Patient's wounds will be assessed and a dressing from the above will be applied as part of their normal standard of care. The wounds will be assessed on a weekly basis for up to 12 weeks.
224114422|NCT04756089|DEVICE|Electronic breast pump|Participants randomized to the breast stimulation will use breast stimulation by hand or with an electronic breast pump (intervention) to stimulate labor.
224292074|NCT06568172|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or plasma
224292075|NCT06568172|BIOLOGICAL|Cemiplimab|Given IV
224292076|NCT06568172|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
224292077|NCT06568172|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
223971677|NCT00043407|DRUG|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
223971678|NCT05979402|OTHER|Training group Face-to-face pressure ulcer training|Face-to-face presure ulcer training
223971679|NCT05979402|OTHER|Control group|No intervention
224114423|NCT04756089|OTHER|Exogenous oxytocin intravenous infusion|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to stimulate labor.
224292078|NCT06568172|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224292079|NCT06568172|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224292080|NCT06568172|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224292081|NCT06568172|OTHER|Questionnaire Administration|Ancillary studies
224292082|NCT06568172|PROCEDURE|Surgical Procedure|Undergo surgery per SOC
224292083|NCT06568172|PROCEDURE|Surgical Procedure|Undergo response-adaptive surgery
224292084|NCT05279313|DRUG|Centanafadine Hydrochloride|Capsule
223725112|NCT01479517|DRUG|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
223971680|NCT06338254|OTHER|percussion massage therapy|Pregnant women included in this group received a total of 12 sessions of percussion massage therapy, applied to their bilateral lower extremities for four weeks. Percussion massage was applied to both extremities at separate times for 5 minutes each with the Hypervolt device. (Fig. 2) Four muscles in total were focused on; These muscles are medial gastrocnemius, lateral gastrocnemius, peronus longus, and tibialis anterior. Percussion massage was applied in the longitudinal direction of the muscle, from distal to proximal and back to distal, going from posterior to anterior muscle groups. Percussion massage started on the medial side and ended on the lateral side for each muscle. Equal pressure and duration were applied to each muscle.
223971681|NCT00309621|DRUG|alitretinoin|
223971682|NCT01138189|PROCEDURE|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
223971683|NCT01138189|PROCEDURE|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
223971684|NCT05533645|OTHER|Questionnaire|These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
223971685|NCT01924806|DEVICE|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
223971686|NCT01924806|DEVICE|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
223971687|NCT03284593|DRUG|intensive chemotherapy|
223971688|NCT03284593|DRUG|Azacitidine|
223971689|NCT02278133|DRUG|WNT974|
223971690|NCT02278133|DRUG|LGX818|
223971691|NCT02278133|BIOLOGICAL|Cetuximab|
223971692|NCT02025361|DRUG|intrarectal lidocaine gel|intrarectal local anesthetic application
223971693|NCT02025361|DRUG|periprostatic nerve blockade|periprostatic local anesthetic application
223971694|NCT05532683|BEHAVIORAL|Health Behaviors Group|The proposed intervention will include eight modules across nine weekly group sessions targeting psychoeducation of CHR-P symptoms, goal setting, physical activity, sleep, substance use, nutrition, and evidence-based strategies for stress management. Intervention facilitators will utilize motivational interviewing (MI; Miller \& Rollnick, 2012) strategies to engage youth in goal setting to target change in health promotion behaviors. Caregivers will be invited to join at the end of each session for a 10-minute check-out where an outline of content covered and patient goals for the week will be shared.
223971695|NCT00088075|DRUG|Risperidone|
223971696|NCT00184496|DRUG|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
223725113|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
223725114|NCT01479517|DRUG|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
223725115|NCT03751488|DRUG|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
223725116|NCT03751488|DRUG|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
223971697|NCT05106816|OTHER|skin surface vibration|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
223971698|NCT05106816|OTHER|light skin surface vibration- SHAM|This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
223971699|NCT02886234|BEHAVIORAL|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
223971700|NCT02886234|BEHAVIORAL|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
223971701|NCT00229190|PROCEDURE|Nasal lavage|
223971702|NCT00229190|PROCEDURE|Allergy skin testing|
223971703|NCT00229190|PROCEDURE|Peak nasal inspiratory flow|
223971704|NCT00229190|PROCEDURE|Acoustic rhinometry|
224114424|NCT04681846|PROCEDURE|Staged approach using antibiotic-cement impregnated PMMA spacer|It will be prepared in the following manner. the cement will be mixed with vancomycin in a ratio of 2 gm to each 40 gm of the spacer. The spacer should be shaped into a cylinder before its solidification. The spacer should be as big as possible to fill the whole defect, without compromising the soft tissue and skin closure. Also, cement should wrap the two ends of bone extremities on 2 or 3 centimeters.
224114425|NCT01483092|DIETARY_SUPPLEMENT|inulin|20g/day for 4 weeks
223971705|NCT00229190|PROCEDURE|Nasal examination|
223971706|NCT00229190|PROCEDURE|Quality of Life Questionnaire|
224292085|NCT05197777|DEVICE|tDCS associated to functional activities|The intervention will start by a pretest on the first day (day 0, baseline record). Tdcs will be applied associated functional task from an experimental workstation, consisting in a hairdressing dummy head fixed to a telescopic table, adjustable to each individual's height. Elbow angles will be adjusted in a static position with a manual goniometer (60 degrees). The task will be performed in a standing position inside a 1m2 perimeter during 30 minutes, undergoing repetitive movements. Performing a repetitive manual gesture. The cycle will be executed at a cadence of 30s/cycle with a metronome beat. The TCT - tDCS Stimulator Kit Research version, with 35 cm2 on M1 of the contralateral hemisphere for the rigth dominant hand. During the first 30 s of active tDCS, an initial period of ''ramping up'' is administered, in which the stimulator reaches the maximum programmed current (2 mA) to mimic cutaneous perceptions. A 2 mA intensity will be maintained during activity.
224292086|NCT05197777|OTHER|Conservative physiotherapy|Education and exercices for pain relief by usual tradicional physiotherapy in Hospital: walking, mobility, and transfert.
224292087|NCT00296491|DRUG|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
224292088|NCT00296491|DRUG|montelukast (MON)|montelukast capsule
223971707|NCT00229190|PROCEDURE|Physical examination|
224292089|NCT00296491|DRUG|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
223542990|NCT06167226|DRUG|Personalized Ayurveda treatment protocol|The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
223725117|NCT04610268|DEVICE|transcranial direct current stimulation|Depending on the location of sEEG electrode implanted in the patient's head, the tDCS electrode (5 cm×7 cm each) was placed on occipital-frontal lobe or bilateral temporal lobe. Current intensity: 2 mA and 4 mA, Stimulus time: 3 min (each stimulus session).
223971708|NCT05171361|PROCEDURE|Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique|To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
223971709|NCT03343288|DEVICE|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
223971710|NCT04783883|DEVICE|Vestal DM|Battery powered non-invasive neurostimulation device (1.5mA)
223971711|NCT00825214|DEVICE|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
223971712|NCT00825214|DEVICE|Inactivated zapperclick device|placebo
223971713|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~* 50 mg/m2 oral vinorelbine d1, d8, d15~* 20 mg/m2/d cisplatin from d1 to d4"
223971714|NCT00683514|DRUG|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~* 60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~* 80 mg/m2 cisplatin d1"
223971715|NCT00262769|DRUG|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
223971716|NCT00262769|DRUG|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
223971717|NCT04787900|DEVICE|iPhone measurement application|The iPhone measurement application will be used to ensure validity and reliability.
223971718|NCT04787900|DEVICE|Bubble inclinometer|Bubble inclinometer with proven validity and reliability will be used for this study.
223971719|NCT01802476|DRUG|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
223971720|NCT01802476|DRUG|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
223971721|NCT04034914|OTHER|Questionnaire administration|Ancillary studies
223971722|NCT05463835|DIETARY_SUPPLEMENT|RubusElite|Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
223971723|NCT05463835|DIETARY_SUPPLEMENT|'Protein rich' dairy beverage|This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
223971724|NCT05463835|DIETARY_SUPPLEMENT|'Low Protein' dairy beverage|This product also contains no polyphenols and negligible protein.
224292090|NCT00296491|DRUG|placebo nasal|vehicle placebo nasal spray
223971725|NCT04331015|DIAGNOSTIC_TEST|Pure tone audiometry|pure tone audiometry
223971726|NCT02811393|OTHER|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
223971727|NCT00487513|PROCEDURE|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
223971728|NCT03229096|DRUG|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
223971729|NCT04098497|BEHAVIORAL|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
223971730|NCT01325818|DRUG|pravastatin, rosuvastatin|"1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
223971731|NCT04960436|PROCEDURE|Meniscus Allograft Transplantation|patients received surgery of Meniscus Allograft Transplantation
223971732|NCT04960436|PROCEDURE|Meniscectomy|patients received surgery of Meniscectomy
224114426|NCT01483092|DIETARY_SUPPLEMENT|maltodextrin|20g/day for 4 weeks
224114427|NCT00205972|DEVICE|Humerus Nail or LC Plate|
224292091|NCT00296491|DRUG|ADVAIR DISKUS|ADVAIR DISKUS
224292092|NCT00296491|DRUG|placebo capsule|placebo capsule
223971733|NCT00556764|DRUG|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
223971734|NCT00556764|DRUG|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
223971735|NCT06425094|DIETARY_SUPPLEMENT|Microalgae Extract Capsules|Tetrasol extract
223971736|NCT06425094|DIETARY_SUPPLEMENT|Placebo|maltodextrin \& vegetable magnesium stearate
224114428|NCT02601781|PROCEDURE|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
224114429|NCT02601781|DEVICE|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
224292093|NCT00296491|DRUG|placebo DISKUS|placebo DISKUS
224292094|NCT01183325|DEVICE|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
224292095|NCT01300052|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
224292096|NCT01300052|DRUG|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
224292097|NCT04695756|OTHER|COVID-19 pandemic|The exposure of this observational study is the COVID-19 pandemic
224292098|NCT06969898|OTHER|Single Ultramarathon runners|All participants underwent the same protocol: two laboratory assessments, a 106 km race, and post-race physiological parameter evaluations at 24 hours and 48 hours.
223971737|NCT04957407|OTHER|pepsinogen|diagnostic value of pepsinogen for severe atrophy and gastric cancer
224292099|NCT06970665|DRUG|avacincaptad pegol|intravitreal injection
224292100|NCT06972251|BEHAVIORAL|TARDIS Photo Elicitation|Using visual-based qualitative methods to help identify and more robustly describe DD in Veterans.
224292101|NCT06972251|BEHAVIORAL|TARDIS Intervention|Design \& pilot test an innovative, tailored self-management information and supportive services intervention for Veterans with type 2 diabetes (T2D), to promote engagement in self-management behaviors.
224292102|NCT06541704|DRUG|Pozelimab|Subcutaneous (SC) injection
223971738|NCT00297778|DRUG|Pramipexole|Dopamine agonist
223971739|NCT00297778|OTHER|Placebo|
223971740|NCT01381458|DRUG|FSC|fluticasone propionate / salmeterol xinofoate combination
223971741|NCT01381458|DRUG|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
223971742|NCT00679549|DEVICE|CPAP Therapy|CPAP therapy is provided as an inpatient.
223971743|NCT04300322|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
224114430|NCT05087823|DIETARY_SUPPLEMENT|Lipid Challenge|For the lipid challenge, participants consume 100 grams of a long chain triglyceride emulsion in the form of liquid drink, which is the commercially available brand called Calogen, from Nutricia, Inc.
224114431|NCT05087823|DIETARY_SUPPLEMENT|Glucose Challenge|For the glucose challenge, participants consume 75 grams of glucose in 200 milliliters of water, which is the World Health Organization (WHO) recommended drink for the Oral Glucose Tolerance Test.
224114432|NCT05087823|DIETARY_SUPPLEMENT|Mixed Meal Challenge|For the mixed-meal challenge, participants consume 237 milliliters of the Ensure Enlive nutrition drink , which contains 11 grams of fat, 22 grams of sugar and 20 grams of protein.
224114433|NCT06512311|DIAGNOSTIC_TEST|CBMed Drug Screening Plattform|The main devices used within the drug screening process are purchased from PerkinElmer, Liconic Instruments, BioTek and Beckman Coulter Diagnostics.
224114434|NCT03461289|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
224292103|NCT06541704|DRUG|Cemdisiran|SC injection
224292104|NCT06541704|DRUG|Placebo|SC injection
223971744|NCT04300322|DRUG|Vaginal Progesterone|Vaginal progesterone (Cyclogest 200 mg) once a day will be used, from 16-22 to 37 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
223971745|NCT04700566|BIOLOGICAL|Renuva Allograft Adipose Matrix|Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
224114435|NCT04590729|BEHAVIORAL|3-min Exercise Per 30 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 30 minutes for 6 hours, totaling 36 minutes of cycling exercise.
224114436|NCT04590729|BEHAVIORAL|3-min Exercise Per 15 Min|This protocol involves 3 minutes of cycling on a stationary bike at 50 revolutions per minute and 1 kilopond every 15 minutes for 3 hours, totaling 36 minutes of cycling exercise.
224114437|NCT06085391|OTHER|REThink Game|REThink Game is the therapeutic game that uses psychological science to help youths find their superhero emotional strengths! It is composed of seven levels, each training a specific emotion regulation ability: emotion recognition, mindfulness and relaxation, cognitive change, positive bias, distinction between useful and useless thoughts, problem solving and compassion.
224114438|NCT06085391|OTHER|MoodWheel|Mood Wheel is a web and mobile-based app that uses experience sampling procedures for the assessment of current/previous distress and positive emotions. The aim of the app is to inquire about the valence, control and functionality of users' emotions.
224114439|NCT06085391|OTHER|PsyPills|"PsyPills is a self-help psycho-educational instrument intended to build stress resilience and to target (only) mild and transient negative mood states, alone or in combination with other methods/instruments.~Psychological Pills (PsyPills) are inspired by Rational-Emotive \& Cognitive-Behavioral Therapy (CBT/REBT), which has strong evidence for its efficacy/effectiveness in human development/health promotion and in the treatment of a variety of psychological conditions.~The PsyPills app was tested in a pilot study and showed positive effects on reducing distress."
224114440|NCT04806581|DRUG|Allogeneic Hepatocyte|Allogeneic hepatocyte with cell numbers L,M,H respectively.
224114441|NCT02890771|PROCEDURE|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
224114442|NCT02890771|PROCEDURE|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
224292105|NCT04590235|DRUG|Selumetinib|"All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m\^2. After a washout period of 2 days, oral selumetinib 25 mg/m\^2 twice daily will be administered continuously. Subjects will continue to receive selumetinib until disease progression or unacceptable drug-related toxicity, whichever occurs first.~10 mg and 25 mg capsules strengths available."
223971746|NCT06183905|DIAGNOSTIC_TEST|Prostate imaging|"Multiparametric ultrasound (mpUS) The mpUS examinations are performed in the order of greyscale imaging, elastography and contrast-enhanced ultrasound (CEUS), with the patients in the left lateral decubitus position.Greyscale imaging and elastography are evaluated by one radiologist. After standard step-sectional greyscale imaging, transverse elastic images are obtained from the base to the apex by manual compression. The amplitude and frequency of compression are adjusted according to the visual compression indicator on the screen to minimize interoperator variability. CEUS is performed using a bolus of 2.4 mL contrast agents (SonoVue, Bracco) using Contrast mode.~Multiparametric MRI (mpMRI) Prostate mpMRI images were acquired using a 3-T scanner with an external phased-array coil."
224114443|NCT02890771|PROCEDURE|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
224114444|NCT02963077|DRUG|A4250|
224114445|NCT02963077|DRUG|CRC (A3384)|
224114446|NCT02963077|DRUG|Questran|
224114447|NCT02963077|DRUG|Placebo|
224114448|NCT03991377|BEHAVIORAL|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~1. Patient history.~2. Patient preparation.~3. Patient assessment.~4. Memory desensitization.~5. Installing the positive cognition.~6. Body scan.~7. Closure.~8. Reevaluation."
223971747|NCT06183905|PROCEDURE|Prostate biopsy|All patients will undergo standard 12-core systematic biopsy (SB) within 1 week following the imaging protocol in conjunction with targeted biopsy (TB) for suspicious lesions on mpUS and/or mpMRI. First, 12-core SB is performed, followed by cognitive mpUS-TB with 2-3 cores for each suspicious lesion. The suspicious lesions on mpUS include hypoechoic lesion(s) on greyscale imaging, reproducible stiff lesion(s) on elastography, and hypoperfused area(s) with ill-defined boundaries or increased focal/asymmetric contrast enhancement on CEUS. Thereafter, MRI/US fusion TB is performed sampling 2-3 cores for each lesion with a Prostate Imaging Reporting and Data System (PI-RADS) version 2 score of 3 or above.Each biopsy sample is placed in the micro-cassette and labelled to identify the biopsy technique and location.
223971748|NCT03280108|DEVICE|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
223971749|NCT03280108|DEVICE|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
223971750|NCT02957162|DRUG|Atorvastatin|
223971751|NCT02957162|OTHER|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
223971752|NCT01717170|DRUG|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
223971753|NCT02511340|DRUG|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
224114449|NCT03991377|DRUG|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
224114450|NCT05299827|OTHER|The same evaluation methods were used for both groups.|No treatment applied to participants and same evaluation methods used in both groups. Trunk muscle strength, muscle endurance, posture, flexibility and pelvic floor muscle activity of participants was evaluated with stabilizer pressurized biofeedback unit, sit-ups and modified push-ups test; trunk flexors endurance test and Modified Biering Sorensen Test; Posture Screen Mobile And Foot Posture Index; sit-reach-test and Beighton Score; and NeuroTrac-Myoplus4Pro,
224114451|NCT01245894|DRUG|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
224114452|NCT01245894|DRUG|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
224114453|NCT00193310|DRUG|Paclitaxel|
224114454|NCT00193310|DRUG|Carboplatin|
224114455|NCT00649519|DRUG|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
224114456|NCT00649519|DRUG|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
224114457|NCT01177150|DRUG|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
224114458|NCT01177150|DRUG|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
224114459|NCT02333955|DRUG|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
224292106|NCT05901233|DEVICE|Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS)|tDCS is a type of non-invasive brain stimulation. 1.5 milliamp (mA) of current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. The stimulation will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
223725118|NCT01288066|PROCEDURE|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
223725119|NCT01288066|PROCEDURE|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
223971754|NCT04585568|OTHER|Biosensors|Measures of blood flow and preassures
223971755|NCT02716753|BIOLOGICAL|seminal plasma|
223971756|NCT02716753|BIOLOGICAL|Physiological NaCL solution|
223971757|NCT05050435|PROCEDURE|Early extubation|Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU
223971758|NCT02201771|DRUG|Aspirin|
223971759|NCT02201771|DRUG|Ticagrelor|
223971760|NCT01300078|DRUG|MF101|MF101 10 g/day MF101 15 g/day
223971761|NCT00218998|BEHAVIORAL|exercise training|
223971762|NCT05458830|BEHAVIORAL|Brief Barrier Reduction Intervention|After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
223971763|NCT05458830|BEHAVIORAL|Plain advisory text|Care as usual
223971764|NCT01999543|DIETARY_SUPPLEMENT|plant-based dietary supplement|
223971765|NCT01999543|OTHER|Placebo|
223971766|NCT04719819|PROCEDURE|Spinal anaesthesia for caesarean section|Descriptive questionnaire with open and closed questions, to be completed during the procedure
223971767|NCT01820637|DEVICE|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
223971768|NCT00264498|DRUG|Gefitinib|oral tablet
223971769|NCT00264498|DRUG|Gemcitabine|intravenous injection
223971770|NCT00264498|DRUG|Carboplatin|intravenous injection
223971771|NCT05534464|OTHER|Milk|Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.
223971772|NCT05534464|OTHER|Sorghum|Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.
224114460|NCT04988607|DRUG|Osimertinib|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle
224114461|NCT04988607|DRUG|Bevacizumab|osimertinib plus bevacizumab arm is dosed at osimertinib 80 mg orally once every day combined with bevacizumab 15mg/kg by intravenous drip infusion on day 1 of a
223725120|NCT05006911|DRUG|Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound|To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
223725121|NCT04813406|DRUG|Anlotinib + Sintilimab|"Anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Sintilimab: 200 mg/time, intravenous injection, every 3 weeks is one cycle."
223725122|NCT01206608|DRUG|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
223725123|NCT01206608|DRUG|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
223971773|NCT05534464|OTHER|Black beans|Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
223971774|NCT01378598|OTHER|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
223971775|NCT01767662|PROCEDURE|manipulation|home programme
223971776|NCT01767662|PROCEDURE|No intervention|observation
223725124|NCT00695487|DRUG|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
223971777|NCT04072666|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach \& Gysin-Maillart, 2017).
224114462|NCT04988607|DRUG|Osimertinib|Osimertinib is dosed orally at 80 mg once per day
224114463|NCT00081289|RADIATION|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
224114464|NCT00081289|DRUG|Capecitabine 1650 mg/m^2/day|825 mg/m\^2 q12 hours (1650 mg/m\^2/day) orally 5 days per week during radiotherapy.
224114465|NCT00081289|DRUG|Capecitabine 1200 mg/m^2/day|600 mg/m\^2 q12 hours(1200 mg/m\^2/day) orally 5 days per week during radiotherapy.
224114466|NCT00081289|DRUG|Irinotecan|50mg/m\^2 IV over 1 hour on days 1, 8, 22, and 29
224114467|NCT00081289|DRUG|Oxaliplatin|50mg/m\^2 IV over 2 hours on days 1, 8, 15, 22, and 29
224114468|NCT00081289|PROCEDURE|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
224114469|NCT00081289|DRUG|Folinic Acid|400 mg/m\^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
224114470|NCT00081289|DRUG|Fluorouracil|"5-fluorouracil bolus 400 mg/m\^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m\^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
223971778|NCT04072666|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
223971779|NCT04072666|BEHAVIORAL|Suicide Prevention Pathway (SPP)|The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, \& Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
223971780|NCT04205136|DRUG|Spironolactone|If tolerated and serum potassium \<5.0 meq/L, the dose will be increased to 50 mg (2 pills) after 4 weeks. If serum potassium is \>5.0 but less than 5.5 or creatinine \>4.0 mg/dL, the dose will be adjusted to 25 mg every other day; if potassium levels ≥5.5 in a non-hemolyzed blood sample, the medication will be discontinued.
223971781|NCT04205136|DRUG|Placebo|Subjects assigned to the placebo group will take one pill for the first 4 weeks and a second pill for the remaining 8 weeks.
223971782|NCT01800539|BEHAVIORAL|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
223971783|NCT04692883|PROCEDURE|Percutaneous suturing|
223971784|NCT05153785|DRUG|Lidocaine|Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
223971785|NCT05153785|DRUG|Normal saline|Placebo
224114471|NCT00081289|DRUG|Oxaliplatin|85 mg/m\^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
224114472|NCT03025191|BEHAVIORAL|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
224114473|NCT03025191|BEHAVIORAL|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
224114474|NCT03025191|BEHAVIORAL|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
223725125|NCT00988611|OTHER|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
223971786|NCT02419209|OTHER|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
223971787|NCT02046447|DRUG|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
223971788|NCT02046447|OTHER|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
223971789|NCT02046447|OTHER|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
224114475|NCT03025191|BEHAVIORAL|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
224114476|NCT01250067|PROCEDURE|Motor-related cortical potential (Procedure)|
224292107|NCT05901233|DEVICE|Remotely supervised sham tDCS (RS-sham-tDCS)|tDCS is a type of non-invasive brain stimulation. During sham stimulation 1.5 milliamp (mA) of current will be delivered for a brief period and then turned off. Current will be delivered via electrodes in saline-soaked sponges placed on the left side of the head and right upper arm. Sham will be delivered for 20 minutes, 5 times weekly, in the participant's home setting while the participant engages in computer-delivered speech-language training. Sessions are monitored by study personnel.
224114477|NCT03863392|DRUG|Misoprostol|induction of labor
224114478|NCT02886026|DEVICE|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
224114479|NCT02886026|DEVICE|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
224114480|NCT04099901|DRUG|Anakinra|Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
224114481|NCT04099901|DRUG|Placebos|Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
223725126|NCT00760578|DRUG|Placebo|Once daily, oral
223725127|NCT00760578|DRUG|Pioglitazone|Once daily, oral
223725128|NCT00760578|DRUG|MSDC-0160 90 mg|Once daily, oral
223971790|NCT02046447|OTHER|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
223725129|NCT00760578|DRUG|MSDC-0160 220 mg|Once daily, oral
223725130|NCT03432754|BEHAVIORAL|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
224114482|NCT04552236|DEVICE|Ultrasound ELastography|"A standardized liver Elastography is critical to obtain reliable and accurate results . The patient is imaged in supine or slight 30 degrees left lateral decubitus position, with the right arm elevated above the head to open the intercostal spaces and improve the acoustic window to the liver . it is recommended to sample measurements in the right lobe , which has shown the most reliable results. Transducer pressure on the skin should be similar to regular anatomical B-mode imaging.~When using SWE techniques, the acoustic radiation force push pulse should be applied perpendicular to the liver capsule, with measurements obtained 4-5 cm deep to the skin and within a minimum 1-2 cm of liver parenchyma to limit refraction of the pulse. The operator should verify that these areas are free of vascular and biliary structures and rib shadows."
223971791|NCT04230668|BEHAVIORAL|Cognitive Processing Therapy with Suicide Risk Management|CPT is an evidence-based treatment for PTSD. This first-line treatment for PTSD will be adapted and combined with SRM into 12 sessions, 60-90 minutes targeting both PTSD and BPD. Individuals assigned to this intervention will attend treatment sessions, and be asked to do treatment homework at home. The primary outcomes are PTSD and BPD severity.
223971792|NCT04230668|BEHAVIORAL|Treatment as Usual with Suicide Rick Management|In the Suicide Risk Management only condition, participants will receive 6 weekly sessions over the course of six weeks focused on suicide stabilization and management. Each SRM session will be variable lengths, depending on the participants' suicide risk and can be up to 60 minutes.
223971793|NCT05029271|DEVICE|InPen with Guardian 4 System|Subjects will receive the InPen™ and InPen™ Diabetes Management App combined with the Guardian™ 4 system.
223971794|NCT06379906|OTHER|Assessment|Baseline assessment
223971795|NCT06454071|OTHER|Blood test|Immunologic tests including Interleukin 6 were conducted before surgery, on the third day following surgery, and on the first outpatient visit day (approximately 21 days after surgery). The IL-6 tests and NK cells were carried out in our hospital.
224114483|NCT01628991|BEHAVIORAL|behavioural program|interventional behavioural program
223971796|NCT02176317|BIOLOGICAL|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10\^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
224114484|NCT01628991|DEVICE|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
224292108|NCT05901233|BEHAVIORAL|Lexical Retrieval Training (LRT)|Participants work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 3 times per week.
223971797|NCT01461343|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
224114485|NCT00855530|DRUG|amibegron (SR58611A)|oral administration of 300 mg twice daily
224114486|NCT04442620|OTHER|Physical activity and Mediterranean Diet (PA-MD)|Physical Activity plus caloric restricted Mediterranean diet
224114487|NCT04442620|OTHER|High meal frequency of Mediterranean Diet (HMF-MD)|High meal frequency of unaltered Mediterranean diet
224114488|NCT04442620|OTHER|Control diet (CD)|Control Diet
224114489|NCT04946110|DEVICE|Electromagnetic stimulation|Electromagnetic stimulation of the phrenic nerve
223971798|NCT05021757|DEVICE|Shockwave C2 Coronary IVL|PCI procedure using a Shockwave C2 coronary IVL catheter
223971799|NCT04255173|DIAGNOSTIC_TEST|Body mass index|Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
224114490|NCT05786261|DEVICE|experimental group MIRT|Task 1a: Assessing the effect of MIRT on cortical plasticity tested with rPAS Task 1b: Assessing the effect of MIRT on structural cortical plasticity and brain connectivity tested with MRI Task 1c: Assessing the effect of MIRT on movement-related beta modulation Task 1d: Assessing the effects of MIRT on motor skills formation with reaching tasks Task 1e: Assessing the effects of MIRT on EEG correlates of motor skills formation Task 2a: Assessing the effect of MIRT on muscle synergies during gait Task 2b: Assessing the effect of MIRT on muscle synergies during reaching movements Task 3a: Assessing the effect of MIRT on sleep microstructure
224114491|NCT05786261|DEVICE|EEG task rTMS, fMRI|EEG task rTMS, fMRI
224114492|NCT03845998|PROCEDURE|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
223971800|NCT04255173|DIAGNOSTIC_TEST|waist circumference|waist circumference is measured as cm
224114493|NCT03845998|PROCEDURE|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
224114494|NCT03403101|DRUG|S1|"Patients are planned to receive the SIRIOX regimen including S-1 (BSA \< 1.2m2, 40 mg/day; BSA = 1.2\~1.4 m2, 60 mg/day; BSA = 1.4\~1.6 m2, 80 mg/day; BSA \> 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle."
224114495|NCT03403101|DRUG|Oxaliplatin|"Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle"
223971801|NCT04255173|DIAGNOSTIC_TEST|hip circumference|hip circumference is measured as cm
223971802|NCT04255173|DIAGNOSTIC_TEST|height|height is measured as cm
223971803|NCT04255173|DIAGNOSTIC_TEST|Fat percentage|Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
223971804|NCT04255173|DIAGNOSTIC_TEST|Skeletal muscle index|Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height \[m2\].
223971805|NCT04255173|DIAGNOSTIC_TEST|A body shape index (ABSI)|ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
223971806|NCT04255173|DIAGNOSTIC_TEST|Dual energy x ray absorptiometry (DXA)|Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
224114496|NCT03403101|DRUG|Irinotecan|"Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle"
223971807|NCT04255173|DIAGNOSTIC_TEST|The Rapid Assessment of Physical Activity (RAPA) aerobic assessment|Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).
223971808|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
223971809|NCT03799289|BEHAVIORAL|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
224114497|NCT02749370|DRUG|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
224114498|NCT03242759|DRUG|nintedanib|Drug
224114499|NCT03242759|DRUG|pirfenidone|Drug
224114500|NCT01347918|DEVICE|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
224114501|NCT01347918|DIETARY_SUPPLEMENT|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
224114502|NCT00256828|DRUG|didanosine + lamivudine + efavirenz|
224292109|NCT05901233|BEHAVIORAL|Video Implemented Script Training in Aphasia (VISTA)|Participants work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 3 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
223971810|NCT04893785|DRUG|Cabozantinib and Temozolomide|"Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.~Patients will be required to attend clinic on Day 1, Day 8, Day 14 and Day 22 of every 4 week cycle.~Patients will return to clinic at 30 days (+/- 5 days) of their last dose of cabozantinib or temozolomide (whichever is discontinued last), for an end of treatment visit.~Following their end of treatment visit patients will be followed-up 3-monthly during routine clinic appointments to collect data on further anti-cancer treatment and survival. Follow-up will continue until 6 months after the last patient stops study treatment or up to 18 months after the last patient is randomised, whichever is sooner."
223971811|NCT04089332|OTHER|Oral Glucose Tolerance Test (OGTT)|Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
223971812|NCT04089332|DEVICE|3 Tesla MRI|A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
223971813|NCT04089332|DEVICE|Intravenous Catheter|A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
223971814|NCT04089332|OTHER|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
223971815|NCT05984147|DRUG|AUR108|3 Days dosing, and 4 days no dose in a week
223971816|NCT01026883|OTHER|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
223971817|NCT05250492|PROCEDURE|Prosthetic hip surgery|"Total hip prosthesis performed by an anterior approach with intra-articular infiltration of an anesthetic product intraoperatively.~OR~\- Total hip prosthesis performed by an anterior approach with infiltration of the same anesthetic product by ultrasound-guided PENG block intraoperatively."
223971818|NCT01923870|DRUG|Androxal 25 mg|
223971819|NCT06217497|OTHER|Foot massage|Patients in the experimental group were subjected to a foot massage with baby oil for 10 minutes during HD treatment three times a week for four weeks, 12 times in total. At the end of the second and fourth weeks after the foot massage, the second and third readings were recorded by repeating the PFS and PSQI
223971820|NCT04376255|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
223971821|NCT06015620|PROCEDURE|Mini gastric bypass surgery|Mini gastric bypass surgery is a common metabolic or bariatric surgery done world wide for patients suffering from morbid obesity not managed by non surgical modalities of treatment.
224114503|NCT03028025|DEVICE|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
224114504|NCT03028025|DEVICE|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
224114505|NCT03255525|OTHER|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
224114506|NCT03255525|OTHER|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
223971822|NCT05433129|PROCEDURE|Transient hyperemic response|The transient hyperemic response will be tested via carotid compression method. This test will consist of 5 carotid compressions lasting 5 seconds each with a 60 seconds interval between each compression to allow normalization of the CBF to precompression levels, and the total time for this block would be 6 minutes. The ipsilateral common carotid artery will be compressed for this method, and the response of the middle cerebral artery (MCA) blood flow velocity will be assessed using transcranial doppler (TCD) probe (EMS-9D, Delica). The carotid compressions will only be accepted when there is no further decrease in blood flow velocity can be achieved and stable conditions remained during the whole period of the compression. Otherwise, the compression will be terminated and repeated again after 60 seconds. Satisfactory compression is typically considered to result in a reduction in MCA velocity of 50%, at a minimum.
223971823|NCT05433129|PROCEDURE|Orthostatic challenge|The orthostatic challenge response will be evaluated by lying-to-sit and sit-to-stand methods 5 times where sitting and standing positions will be held for 3 minutes each for a total block time of 35 minutes. A baseline in lying position will be collected at the start of the block, then the position will be changed from lying to sit for 3 minutes and then position will be changed to standing for another 3 minutes.
223971824|NCT05433129|PROCEDURE|Vascular chemo-reactivity|vascular chemo-reactivity will be assessed by varying CO2 concentrations through slow and fast breathing exercises with Capnostream 35 Portable Respiratory Monitor (Medtronic Canada) to monitor EtCO2 through nose clip. The breathing trials will occur two times and each of them will have fast and slow trials along with an interval of normal breathing. First time, the normal, fast and slow breathing trials will be 2.5 minutes long while the second time, these breathing trials will be 1.5 minutes long. The normal respiratory rate for adults is 12 breaths/minute, the target slow respiratory rate will be 5 breaths/minute and fast respiratory rate will be 25 breaths/minute as set by metronome. It has been shown that the EtCO2 has a 10% increase during hypoventilation and almost 50% decrease during hyperventilation compared to normal breathing.
223542991|NCT02135068|DEVICE|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
223542992|NCT02135068|OTHER|Snacking|Up to 45 g of oral glucose via Gatorade
224114507|NCT03255525|OTHER|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
224114508|NCT04631471|DRUG|Ibudilast|Increasing dose of ibudilast from 60mg/6 capsules per day to 100mg/10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
224114509|NCT04631471|PROCEDURE|Cervical decompressive surgery|Surgical decompression of degenerate cervical myelopathy
224114510|NCT04631471|DRUG|Matching placebo|Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
224114511|NCT02660697|PROCEDURE|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
224114512|NCT03720080|DEVICE|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
224114514|NCT06671509|DRUG|YZJ-1139|Single oral dose, 20 mg tablet
224114515|NCT06671691|RADIATION|SBRT level I|20Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
223542993|NCT04403308|BIOLOGICAL|ONO-7913|ONO-7913 will be administered by intravenous continuous infusion during the designated time.
224114516|NCT06671691|RADIATION|SBRT level II|23Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
224114517|NCT06671691|RADIATION|SBRT level III|26Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
224114518|NCT06671691|RADIATION|SBRT level IV|28Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
224114519|NCT06671691|RADIATION|SBRT level V|30Gy in 1 fraction will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique
224114520|NCT06673355|OTHER|dental implant prosthesis|patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
224114521|NCT06672302|DIAGNOSTIC_TEST|ExoPred|Performing in vitro diagnostics with devices developed by EXoPERT
224114522|NCT06671769|DIETARY_SUPPLEMENT|Heart Health Supplement|This is a natural heart health supplement in powdered format, chocolate flavor where participants will take a daily dose.
224292110|NCT06059690|DIAGNOSTIC_TEST|pH Measurement of in vivo tissue|The investigator will identify multiple (2-5) 5-8mm diameter spherical targets on GI maps for use in stereotactic pH measurement and biopsy acquisition. All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target. After the pH probe is removed, the biopsy needle will be placed into the cannula and standard-of-care biopsy tissue will be obtained from the same area where pH measurements were recorded.
224114523|NCT04294784|DRUG|Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
224114524|NCT04294784|DRUG|Albumin-bound Paclitaxel|Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
223542994|NCT04708262|OTHER|Cognitive Analytic Therapy for Containing Self-Harm in Young People|The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
223542995|NCT04726891|BEHAVIORAL|Movement-2-Music + Social Networking Support|The primary goal of the proposed research is to conduct a 12-week pilot study of the SMART-HEALTH intervention in 30 individuals with SCI. There are several unique features of this study design, including a novel adapted exercise program (M2M), instructor-led, individualized training (M2M Live; described in D.2.1), individualized behavioral coaching, and social networking support.
223542996|NCT00234130|PROCEDURE|nocturnal vs conventional dialysis|
223542997|NCT01694433|DRUG|Calcipotriene|1g daily BID
223542998|NCT01694433|DRUG|Placebo|1g daily BID
223542999|NCT03071861|DRUG|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
223971825|NCT05433129|PROCEDURE|Neurovascular coupling|The fourth block will evaluate the neurovascular coupling using Automated Neuropsychological Assessment Metrics (ANAM) General Neuropsychological Screening (GNS) Clinical Toolkit which contains 5 tests explained as follows 1) Standard Continuous Performance test will assess sustained attention, concentration and working memory. 2) Manikin test will assess 3D spatial rotation ability, left-right orientation, problem solving and attention. 3) Pursuit Tracking test will measure the visuo-motor control. 4) Switching test will assess divided attention, mental flexibility, and executive function. 5) Stroop test will assess the processing speed, selective attention, interference, and executive functioning with three trial blocks.
223971826|NCT05955365|DRUG|P2Y12 inhibitor|The choice of P2Y12 inhibitor is left at investigator's discretion.
223971827|NCT05955365|DRUG|Aspirin|Aspirin is administered for up to 1 month after PCI at investigator's discretion
224114525|NCT04445077|OTHER|Dementia Competence Education for care home setting|The intervention is a competency-based education program for care home staff who provide dementia care in Mainland China.
224114526|NCT04445077|OTHER|Printed educational materials|The educational materials will be delivered to the participants in the control group for their self-study.
223971828|NCT05955365|DRUG|DOAC|The choice of DOAC is left at investigator's discretion.
223971829|NCT05383651|DEVICE|bellavista 1000|observational use of Bellavista 1000 ventilator in adult ventilated patients
223971830|NCT05383651|DEVICE|bellavista 1000 neo|observational use of Bellavista 1000 ventilator in neonatal ventilated patients
224114527|NCT06340555|OTHER|GUIA ATENCION MULTIDISCIPLINAR SANT BOI|Women with losses attended according to the multidisciplinary intervention proposed at the SJD Hospital de Sant Boi
224114528|NCT06340555|OTHER|USUAL CARE|Women with losses treated at the Hospital Comarcal del l'Alt Penedes.
224114529|NCT03932136|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
224292111|NCT03519451|OTHER|Internet-Based Intervention|Given KickAsh smartphone mobile application
224292112|NCT03519451|OTHER|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
224292113|NCT03519451|OTHER|Questionnaire Administration|Ancillary studies
224292114|NCT04889898|DEVICE|Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone|\[Patients only\] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.
223971831|NCT05657613|DRUG|CYP450 Cocktail and Transporter Substrates with Pacritinib|"Day 1: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, omeprazole 20 mg and metformin (transporter)~Day 3: Single oral dose of transporter substrates (digoxin 0.25 mg, rosuvastatin 5 mg)~Days 8-22: Oral doses of pacritinib 200 mg BID approximately 12 hours apart~Day 17: Single oral dose of transporter substrates (digoxin 0.25 mg and rosuvastatin 5 mg) will be coadministered with the AM dose of pacritinib 200 mg.~Day 21: Single oral dose of a cocktail of cytochrome P450 substrates (caffeine 100 mg, midazolam 2 mg, and omeprazole 20 mg) along with transporter substrate (metformin 500 mg) will be coadministered with the AM dose of pacritinib 200 mg."
223971832|NCT05657613|DRUG|Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of bosentan 125 mg BID"
223971833|NCT05657613|DRUG|Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib|"Days 1-7: Oral doses of pacritinib 200 mg BID~Days 8-14: Oral doses of pacritinib 200 mg BID, coadministered with an oral dose of fluconazole 200 mg QD."
223971834|NCT02720783|DRUG|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
223971835|NCT02720783|DRUG|Placebo plus Econazole nitrate 150 mg vaginal pessary|
223971836|NCT02720783|DRUG|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
223971837|NCT02720783|DRUG|Placebo vaginal pessary|
224114530|NCT03932136|COMBINATION_PRODUCT|Placebo|The placebo is safe, with no therapeutical effect, and has same appearance and similar smell and taste with active tablet.
224114531|NCT00328263|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
224114532|NCT00328263|DIETARY_SUPPLEMENT|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
224114533|NCT03531372|DEVICE|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
224114534|NCT03531372|DEVICE|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
224114535|NCT02325999|PROCEDURE|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
224114536|NCT02133014|PROCEDURE|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
223971838|NCT06288451|DRUG|Oral calcitriol with cinacalcet rescue|Participants will receive in-center oral calcitriol at a fixed dose of 0.5 mcg three times weekly at their dialysis treatment sessions regardless of their parathyroid hormone (PTH) concentrations over the 12-month trial period. Only if their serum PTH exceeds 800 pg/mL over 2 consecutive measurements will they be started on cinacalcet at 30 mg/d in order to protect against severe unremitting hyperparathyroidism.
223971839|NCT06288451|DRUG|IV activated vitamin D|Participants will continue to receive intravenously-administered activated vitamin D per the Northwest Kidney Center treatment protocol, dose-titrated to monthly to quarterly parathyroid hormone concentrations.
223971840|NCT06415747|OTHER|Observational pain and motor function assessments, and also comorbidities assessments with x-ray.|There was no intervention in our study, only observational and quantitative clinical evaluations.
223971841|NCT00207298|PROCEDURE|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
224114537|NCT02133014|DRUG|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
224114538|NCT01690962|OTHER|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
224114539|NCT01690962|DIETARY_SUPPLEMENT|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
224114540|NCT00677144|DRUG|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days
223971842|NCT02256488|BIOLOGICAL|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
223971843|NCT02256488|BIOLOGICAL|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
223971844|NCT02256488|BIOLOGICAL|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
223971845|NCT02256488|BIOLOGICAL|TIVf|Single IM administration dose of 0.5 mL of TIVf
223971846|NCT02108483|DRUG|dapsone gel|Patches containing dapsone gel will be applied to the skin.
223971847|NCT02108483|DRUG|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
224114541|NCT00677144|DRUG|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
224114542|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T4 dental implants in posterior mandible|Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
224114543|NCT05712031|PROCEDURE|Insertion of 1 Nucleoss T5 dental implants in posterior mandible|Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
224114544|NCT05712031|PROCEDURE|Insertion of 2 Nucleoss T4 dental implants posterior mandible|2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
224114545|NCT02309710|DEVICE|ShangRing|ShangRing administered to males seeking medical male circumcision
224114546|NCT01123304|DRUG|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
224114547|NCT02081469|OTHER|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
224114548|NCT03876340|OTHER|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
224114549|NCT03876340|OTHER|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
224114550|NCT01201369|DEVICE|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
224114551|NCT01201369|DEVICE|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
224114552|NCT00318201|DRUG|Erythromycin|
224114553|NCT00318201|DRUG|Diltiazem|
224114554|NCT03649776|OTHER|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
224114555|NCT04670146|DIAGNOSTIC_TEST|ultrasound of the masseteric muscle|Ultrasound of the masseteric muscle to evaluate the thickness and rigidity of the masseteric muscle before and after oral cancer treatment. There will be no invasive investigation of the muscle.
224292115|NCT04889898|RADIATION|Modified Barium Swallow Study (MBSS)|\[Patients only\] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.
224292116|NCT04889898|BEHAVIORAL|Speech Intelligibility Test (SIT)|\[Patients only\] The SIT is a standardized test for measuring speech intelligibility.
224292117|NCT04889898|BEHAVIORAL|SIT Scoring|\[Listeners only\] Listeners will judge the intelligibility of speech recordings made by patients in the study.
223543000|NCT03071861|DRUG|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
223971848|NCT05739799|PROCEDURE|IPL|Patients in Group A received intense pulse light (IPL) frequency of 690. A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by patients' were recorded.
223971849|NCT05739799|PROCEDURE|Diode|patients in Group B received diode laser treatment system. Diode laser was employed using triple wavelength (1064, 810 and 755 mm). A total of three sessions were carried out one month apart, and hair reduction was assessed by seeing thickness of hair and by counting the number of hair follicles in a 1cm2 area on each side of the face before the first session and at the 4th month. A consultant dermatologist assessed the reduction in hair count on the affected side of face at the end of last session. Patients' response and any adverse effects experienced by the patients were recorded.
223971850|NCT00240097|DRUG|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
223971851|NCT00240097|DRUG|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
223971852|NCT00303017|DIETARY_SUPPLEMENT|flavocoxid|flavonoid mixture
223971853|NCT00303017|DRUG|Naproxen|non-steroidal anti-inflammatory drug
223971854|NCT05603299|OTHER|Educational Materials on the Dawn test|Receive educational materials and sample test results replicating what physicians would receive in the real-world market as they learn about the probability of IO therapy response from the Dawn™ test.
223971855|NCT02973945|DEVICE|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
223971856|NCT02973945|DEVICE|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
223971857|NCT05590845|OTHER|Survey|"Patients, 65 and above, scheduled for elective total hip replacement surgery, will be invited to participate in a survey (consisting of 15 questions) testing their knowledge regarding PND.~After completion of the survey, patients will receive a standard preoperative brochure on anaesthesia-related topics and delirium.~T-MOCA scores will be collected (22 = perfect score; \<18 = cutoff for cognitive impairment) (through a pre-operative telephone call).~Six weeks post-operatively patients will once again be called for T-moca scores.~Initially a feasibility study for 1/3 of sample size will be done."
224292118|NCT06575075|DRUG|RR-HNK/Hydroxynorketamine|(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.
224292119|NCT06575075|DRUG|Placebo|Sterile Saline
223543001|NCT03021603|BEHAVIORAL|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
224114556|NCT01861340|DRUG|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
224114557|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
224114558|NCT00765869|OTHER|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
224114559|NCT00765869|OTHER|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
224114560|NCT06296264|DEVICE|Standard ultrasound|Placement of IV line using standard ultrasound.
224114561|NCT06296264|DEVICE|Ultra-portable ultrasound|Placement of IV line using ultra-portable ultrasound.
224114562|NCT06003816|BEHAVIORAL|Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI|The CHoBI7 program is during group sessions by a health promoter to those residing in a ring around a cholera patient reinforced through weekly voice and text messages from the CHoBI7 mHealth program over 12 months on the recommended water, sanitation, and hygiene behaviors.
224114563|NCT06003816|BEHAVIORAL|Standard message|Standard message given in the Democratic Republic of the Congo to diarrhea patients at health facility discharge on use of oral rehydration solution
224114564|NCT04267237|DRUG|Atezolizumab|Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.
224114565|NCT04267237|DRUG|RO7198457|RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
224114566|NCT05129839|DEVICE|lightened and musical baby mobile|Before going to sleep in the infant's room in the intervention group, a lightened and musical baby mobile was used.
224114567|NCT05061225|BEHAVIORAL|Physical activity counselling|Educational content on several topics regarding physical activity and its implementation in daily living
224114568|NCT02522481|DRUG|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography
224114569|NCT02524080|PROCEDURE|Triage to optimal healthcare level|Triage to optimal healthcare level
223543002|NCT01109186|OTHER|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
223543003|NCT03729986|OTHER|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
224114570|NCT03291782|DRUG|D-0120|oral, single dose
224114571|NCT03340805|DRUG|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
224114572|NCT03340805|DRUG|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
224292126|NCT01231373|DRUG|polidocanol injectable foam, 0.125%|active placebo for blinding
224292127|NCT01231373|DRUG|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
224292128|NCT01231373|DRUG|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
224292129|NCT01231373|DRUG|Vehicle|injection of vehicle comparator
224292130|NCT06620523|DRUG|CoQ10 1200 mg orally with Glutathione 1000 mg orally|This is the intervention to assess efficacy of CoQ10 and Glutathione in prevention of cardiac surgery associated acute kidney injury
224292131|NCT06620523|DRUG|Group B: Placebo CoQ10 orally and Placebo Glutathione orally|A placebo to exactly match the CoQ10 will be made with white gelatin empty capsules containing cellulose AND a placebo to exactly match the L-Glutathione will be made with white gelatin empty capsules containing cellulose.
223971858|NCT06645613|DEVICE|Transcranial Magnetic Stimulation Device|Transcranial magnetic stimulation uses FDA-approved coils to generate varying magnetic fields in the brain of the participant and induce an electric field in the underlying brain tissue. The standard intermittent Theta Burst Stimulation (iTBS) TMS protocol will be applied in this study. The same coil can be applied to generate sham stimulations that only generate sound and stimulations to the scalp without stimulating the brain.
224114573|NCT06123429|BEHAVIORAL|Mindfulness Based Stress reduction|"The MBSR course will consist of weekly sessions lasting two and a half hours, involving lecture, meditation, and self-reflection.~Mindfulness-Based Stress Reduction (MBSR) is a structured program designed to help individuals manage stress, increase self-awareness, and promote overall well-being. Developed by Dr. Jon Kabat-Zinn in the late 1970s, MBSR combines elements of mindfulness meditation and cognitive-behavioral techniques. MBSR is a comprehensive program that equips individuals with practical skills to better manage stress and enhance their mental and emotional well-being. Its emphasis on mindfulness, self-awareness, and the integration of these practices into daily life makes it a valuable resource for those seeking to reduce stress and improve their overall quality of life."
223971859|NCT00818519|DRUG|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
223971860|NCT00818519|DRUG|Placebo|Inert tablet
224114574|NCT00404768|DRUG|GSK221149A|6mg/h and 12 mg/h
223971861|NCT03899844|OTHER|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
224114575|NCT00404768|DRUG|Placebo|Matched Placebo to Drug
224114576|NCT01829789|BEHAVIORAL|Group Community Reinforcement Training for Parents|
224114577|NCT01829789|BEHAVIORAL|Individual Community Reinforcement Training for Parents|
224114578|NCT03123939|BIOLOGICAL|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10\^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10\^8 CTL019 transduced viable T cells (for patients \> 50 kg)
224114579|NCT04446234|DRUG|Risperidone|Use medicine according to patients condition
224114580|NCT04446234|DRUG|Aripiprazole|Use medicine according to patients condition
224292132|NCT05642169|BEHAVIORAL|HIIT|"The training sessions will have a frequency of 3 times per week (Monday, Wednesday and Friday) and the duration will be between 39 to 54 minutes, depending on the training week.~The training program will be developed with the own body weight of each participant. Therefore, a progression according to the needs of this population will be fulfilled. The session model could be multi-joint exercises with self-loads, where the difficulty of the exercises will be worked progressively. Throughout the main part of each workout, 30 seconds of work will be performed at the corresponding intensity and 30 seconds of rest. Halfway through the total repetitions, there will be 2 minutes of recovery."
223971862|NCT06585345|BIOLOGICAL|CD7 CAR-T cell|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]
223971863|NCT06584981|PROCEDURE|pectoral nerve block (PECS II), parasternal and serratus plane blocks|These block applications are performed under sterile conditions under the guidance of ultrasonography
223971864|NCT06584981|OTHER|analgesic|Analgesia needs of patients who do not receive blockade are met with intravenous drugs.
224114581|NCT04446234|DRUG|Ziprasidone|Use medicine according to patients condition
224114582|NCT04446234|DRUG|Amisulpride|Use medicine according to patients condition
224114583|NCT04446234|DRUG|Quetiapine|Use medicine according to patients condition
224114584|NCT01962636|DRUG|Fludarabine|25 mg/m\^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
224114585|NCT01962636|DRUG|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
224114586|NCT01962636|RADIATION|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
224114587|NCT01962636|DRUG|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
224292133|NCT05642169|BEHAVIORAL|HIIT+PA|In relation to the 2 groups that will perform HIIT, the HIIT+AF will have to complete 10.000 steps per day. In this way, they will be focusing on increasing their daily physical activity. In addition, this group will perform the same HIIT training programme as the other experimental group.
223971865|NCT04337502|DIAGNOSTIC_TEST|Machine learning model|Machine learning, such as logistic regression, random forest, and deep learning
224292134|NCT05642169|BEHAVIORAL|CON|This group will not suffer any changes in their lifestyle
224292135|NCT03446599|DRUG|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
223971866|NCT06171919|OTHER|Organizational Partnerships|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs and risks of formerly incarcerated individuals living with HIV. Component 3 includes the provision of legal support.
223971867|NCT06171919|OTHER|HIV Continuum Care|Participants will be included in the pilot trial. The investigative team will work with the staff at Hope and Help Inc. to identify and recruit those out of care through reviewing electronic medical records.
224292136|NCT03446599|DRUG|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
224292137|NCT03446599|DRUG|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
224292138|NCT06572800|DEVICE|DiviTum-TKa|Analyze blood samples by DiviTum-TKa
224114588|NCT01962636|DRUG|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
224114589|NCT01962636|BIOLOGICAL|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
224114590|NCT05836740|DRUG|Minocycline hydrochloride capsule|50 mg per capsule, containing 50mg of Minocycline Hydrochloride.
224114591|NCT05836740|DRUG|Placebo capsules of Minocycline hydrochloride capsules|50 mg per capsule, containing 0mg of Minocycline Hydrochloride.
224114592|NCT02717689|OTHER|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
224114593|NCT06864962|PROCEDURE|Renal sympathetic denervation|Under the guidance of the 3-dimensional navigation system, HFS was performed from the accessible branches to the proximal (the ostium of renal artery) segments of the bilateral renal arteries, and the target ablation sites were identified by HFS-induced SBP elevation \>5mmHg, and radiofrequency ablations were performed with a power setting of 8 to 12 Watts and a duration of 90 seconds. The endpoint of RSD was defined as the elimination or bluntness of HFS-induced SBP elevation response (≤5mmHg). If this was not achieved, ablation was repeated until the desired response was attained.
224114594|NCT06864962|PROCEDURE|Renal sympathetic denervation plus aorticorenal ganglion ablation|Following RSD, HFS was performed in the the junction area of abdominal aorta and renal arteries to recognize ARG. Radiofrequency ablations were performed with a power setting of 12 to 20 Watts and a duration of 90 seconds. The endpoint of ablation was defined as the elimination or bluntness of HFS-induced SBP elevation response (≤5mmHg). If this was not achieved, ablation was repeated until the desired response was attained.
224292139|NCT03451006|DRUG|Metformin|Oral metformin (up to 2gm) will be given in divided doses
224292140|NCT03451006|DRUG|Placebo|Oral Placebo will be given in divided doses
224292141|NCT03660215|OTHER|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
224292142|NCT02650141|DRUG|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
223543004|NCT00836394|DEVICE|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
223543005|NCT03925272|PROCEDURE|Collection of samples (blood, stool, etc.)|
223543006|NCT03925272|GENETIC|Genetic determinants analysis|
223543007|NCT03925272|PROCEDURE|Sample obtained after surgery performed in the context of care|
223543008|NCT04862559|DEVICE|NovaCross|A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
223543009|NCT00410189|DRUG|ZD6474|300 mg by mouth daily for 28 Days.
223971868|NCT05584397|PROCEDURE|Venipuncture|Draw of peripheral blood (about 20 ml and 40 ml, during the screening and procedure visits, respectively).
223971869|NCT05584397|PROCEDURE|Targeted physical medical exam|"Study participants will be undergoing a physical exam where vitals will be recorded (e.g. temperature, blood pressure, heart rate). The registered nurse (RN) will also perform auscultation of heart and lungs.~Study participants will be also asked to fill out a survey with questions related to his/her medical history, current use of medications, sexual history and substance abuse."
223971870|NCT05584397|PROCEDURE|Urine pregnancy test|Women of childbearing potential will be asked to run an urine pregnancy test during the second (procedure) visit. Pregnant women will not be allowed to participate in the study.
224292143|NCT02650141|DRUG|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
223971871|NCT05584397|PROCEDURE|Anoscopy|The anoscopy is an examination using a small, rigid, tubular instrument called anoscope (also called an anal speculum). This is inserted a few inches into the rectum in order to collect some small samples of mucosal tissue. We will collect 5 rectum biopsy samples and one cytobrush.
223971872|NCT05584397|PROCEDURE|Esophagogastroduodenoscopy (EGD)|The EGD involves looking at the esophagus, stomach, and first and second portion of the duodenum. This procedure involves the use of an endoscope to remove small tissue samples. This procedure uses conscious sedation drugs given by a vein in the arm. The procedure takes about 1½-2 hours, including time for recovery. We will collect 5 duodenal biopsies and one cytobrush.
223971873|NCT03427177|BEHAVIORAL|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
224114595|NCT03527901|DIAGNOSTIC_TEST|GCF collection with aMMP-8 chair side test|
223971874|NCT05472883|PROCEDURE|blood samples|\- Research blood sample: 2 additional tubes compared to the classic sample for the analysis of the 9 research molecules.
223971875|NCT05472883|PROCEDURE|collection of body tissues|removal of intra-abdominal fat and muscle tissue
224114596|NCT03527901|OTHER|Saliva collection|
224114597|NCT06318923|OTHER|Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment|"The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders.~The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study.~Affective disorders will be assessed using the following tests:~* The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression,~* State trait anxiety inventory-Y (STAI-Y) to assess anxiety,~* Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia,~* The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy,~* The Dot Probe Task to assess participants' emotional information processing style."
224114598|NCT06318923|OTHER|MS questionnaire|This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.
224114599|NCT06318923|OTHER|MONTREAL COGNITIVE ASSESSMENT (MoCA) test|The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).
223543010|NCT05290662|DRUG|oNKord®|Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
223543011|NCT05290662|DRUG|Cyclophosphamide/Fludarabine (Cy/Flu)|Lymphodepleting conditioning regimen
224114600|NCT04773041|PROCEDURE|Infinitome|All patients will have rs-FMRI images analyzed with the Infinitome cloud-based software processing program.
223543012|NCT05025410|DRUG|Remimazolam|Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
223543013|NCT03745768|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
223543014|NCT03745768|DEVICE|sham stimulation|Sham stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain for 6 weeks.
224114601|NCT01643915|BEHAVIORAL|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
224114602|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
224292144|NCT00004810|DRUG|-aminosalicylic acid|
224292145|NCT06651294|DIETARY_SUPPLEMENT|Neorenal Forte|This specialized formulation of phytotherapeutic extracts consists of proprietary Betula pendula leaves dry extract, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens. The product contains supplementary ingredients: microcrystalline cellulose, povidone, magnesium stearate, colorant film (brilliant blue FCF, iron dioxide).
224292146|NCT06651294|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical to the active form and will have the same composition but without the proprietary extract from Betula pendula, Herniaria glabra, Viburnum opulus, Elymus (Agropiren) repens.
223971876|NCT05472883|PROCEDURE|routine care procedure|"* Routine care blood sample: Full vitamin panel, CBC, liver panel, urea, creatinine, blood ionogram, blood calcium, phosphorus, magnesium at all visits, except the morning of surgery when only ß HCG (for women of childbearing age), HbA1c.~* clinical examination : weight, height, waist measurement, cardiovascular examination, digestive system examination.~* dosage of ß HCG for womens."
223725131|NCT03432754|BEHAVIORAL|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
223971877|NCT02817685|OTHER|3 months|
223971878|NCT02817685|OTHER|6 months|
223971879|NCT02817685|OTHER|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
223971880|NCT02804347|DEVICE|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
223971881|NCT02804347|DEVICE|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
223971882|NCT02804347|OTHER|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A \& B, RAVLT
224114603|NCT01643915|BEHAVIORAL|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
224292147|NCT00437190|DEVICE|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
224292148|NCT00437190|DEVICE|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
224292149|NCT03865537|PROCEDURE|Cold snare EMR|Participants will have their large polyp removed without electrocautery
224292150|NCT03865537|PROCEDURE|Hot snare EMR|Participants will have their large polyp removed with electrocautery
224292151|NCT03865537|PROCEDURE|Eleview injection|Participants will have their polyp submucosally injected with Eleview
224292152|NCT03865537|PROCEDURE|Placebo injection|Participants will have their polyp submucosally injected with placebo
224292153|NCT06052787|DRUG|Cerebrolysin|Cerebrolysin, a mixture of free amino acids and low molecular weight peptides, has a neurotrophic factor-like activity with immediate pleiotropic neuroprotective activity and long-term multimodal effects on endogenous post-lesional regulation. Cerebrolysin has been suggested to exert beneficial effects on neurobehavioural functions, cognitive performance , and neuro-motor recovery , as part of initial therapy in severe and moderate acute TBI.
224292154|NCT06052787|DRUG|amantadine sulfate|The dopaminergic agonist amantadine enhances presynaptic dopamine release and inhibits dopamine reuptake, resulting in an increased amount of dopamine in the synaptic cleft. Amantadine may also increase the density of postsynaptic dopamine receptors and alter the conformation of these receptors. Amantadine acts as an NMDA receptor antagonist, blocking glutamate, an NMDA channel activator. This effect may be responsible for amantadine's possible beneficial effect soon after TBI
223543015|NCT00443118|DEVICE|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
223543016|NCT00443118|DEVICE|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
223971883|NCT06135779|BEHAVIORAL|A Lust for Life|A Lust For Life (ALFL) is a universal teacher-led programme which aims to build resilience, increase wellbeing, and enhance emotional literacy of 8-13 year old school children. The programme spans ten 40-minute classes. The ALFL curriculum draws on multiple sources including contemporary positive psychology; traditional, second, and third wave cognitive behaviour therapy (CBT); and developmental, educational, and health psychology. In ALFL children learn the following specific self-regulation skills: naming and rating the intensity of emotions; linking thoughts, feelings and actions; mindfulness; breathing exercises; visualization exercises; progressive muscle relaxation; positive self-talk (gratitude, optimism, and cognitive restructuring); obtaining social support from adults and peers; assertiveness; managing bullying; and using the internet safely. Skills are learned through didactic instruction, video modelling, in-class experiential exercises, and homework practice.
223971884|NCT06135779|BEHAVIORAL|Waiting List Control|Control group placed on a 12-week waiting list for the A Lust for Life School programme.
223971885|NCT03356145|DRUG|12 mL paracervical block|Injection of 12 mL of lidocaine
223971886|NCT03356145|DRUG|20 mL paracervical block|Injection of 20 mL of lidocaine
223971887|NCT01446822|DEVICE|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
223971888|NCT01446822|DEVICE|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
223971889|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
223971890|NCT03613454|DEVICE|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
223971891|NCT06046976|PROCEDURE|piesosurgical extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
223971892|NCT06046976|PROCEDURE|conventional extraction|exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
223971893|NCT04885478|OTHER|Immune response monitoring , blood samples|"In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring"
224114604|NCT05314595|PROCEDURE|bilateral uterine artery ligation|"* Spinal anaethesia with intrathecal morphia~* Transverse skin incision~* Adequate dissection of the bladder.~* Incision of the uterus above placental edge.~* Delivery of the fetus.~* Delayed cord clamping (60 seconds) if the baby appears well.~* Exteriorization of the uterus.~* Start Oxytocin infusion and uterine massage to ensure good uterine contractions immediately after delivery of the fetus. No trials of placental delivery will be made at this point.~* At this point, a gentile trial to deliver the placenta is performed~* A catheter is placed in the cervix from above to secure the cervical opening~* Compression is applied to the site of bleeding from placenta site~* Placental pouch is marked by multiple allies and is closed down to the multiple-8 suture.~* Blood loss is measured using the suction device and coated socked towels. In modified PPC, Bilateral uterine artery ligation will be done after exteriorization of the uterus in order to minimize the blood loss."
224114605|NCT06257004|GENETIC|Saliva collection (screening of all participants)|All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis
224114606|NCT06257004|GENETIC|Bloodsampling|Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
224114607|NCT04811677|OTHER|radiology|image analysis
224114608|NCT04220047|PROCEDURE|Left Atrial Appendage Resection and Marshall Ligament Amputation|Left Atrial Appendage Resection and Marshall Ligament Amputation during the cardiac surgery
224114609|NCT03733678|BEHAVIORAL|Price discounts for SARCs|SARCs are offered free to the client
224114610|NCT03733678|BEHAVIORAL|Price discounts for LARCs|LARCs are offered at lower prices to the client
224114611|NCT03733678|BEHAVIORAL|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
224292155|NCT00638794|DEVICE|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
224292156|NCT01929395|DEVICE|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
224292157|NCT01863056|OTHER|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
224292158|NCT02547766|DRUG|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
224292159|NCT04491357|DRUG|Calcium Gluconate|Intravenous calcium gluconate within 4 hours of skin closure after total thyroidectomy
223971894|NCT01511744|BIOLOGICAL|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
223971895|NCT02963922|DRUG|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
224292160|NCT04491357|DRUG|Normal saline|Normal saline within 4 hours of skin closure after total thyroidectomy
223971896|NCT02963922|DRUG|Placebo|Injected subcutaneously (s.c., under the skin) once daily
223971897|NCT02420938|DRUG|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
223543017|NCT00443118|DEVICE|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
223543018|NCT04280575|PROCEDURE|Percutaneous coronary intervention|Coronary artery stenting for stable angina
223725132|NCT00173082|PROCEDURE|Glucose tolerance test|
223971898|NCT02420938|DRUG|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
223971899|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums with Fluoride|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.
223971900|NCT05623761|DRUG|BUCCOTHERM® Sensitive Gums Fluoride-Free|Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
224292161|NCT01643226|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
224292162|NCT01643226|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
224292163|NCT01643226|DEVICE|KXL System|30 mW/cm2
224292164|NCT00974948|PROCEDURE|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
224114612|NCT01118143|BEHAVIORAL|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
223971901|NCT06132906|PROCEDURE|Orthognathic surgery (lefort1)|"1. All patients will be treated under general anesthesia.~2. The surgical field will be scrubbed with povidone-iodine surgical scrub solution, followed by draping of the patient with sterile towels exposing only the area of surgery.~3. The surgical procedure of Le Fort I osteotomy will be performed which can be summarized as follows:~   1. External reference marking~  2. Incision and subperiosteal dissection~  3. Maxillary osteotomy~  4. Pterygomaxillary disjunction,~  5. Septal, vomerine, and lateral nasal osteotomies~  6. Down fracture~  7. Mobilization of the maxilla~  8. Application of stent in one group and the locating guide in the other group.~  9. Maxillary fixation~  10. Occlusal evaluation~  11. Wound debridement and closure"
224114613|NCT06294847|DRUG|Ursolvan|single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
224114614|NCT06294847|DRUG|Placebo|Patients will receive a single dose of placebo orally within 24 hours before the surgical intervention, followed by two doses per day for 30 days
224114615|NCT01378754|DRUG|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
223725133|NCT02989194|DRUG|VIS410 low dose|Single intravenous fixed low dose of VIS410
224114616|NCT01378754|DRUG|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
224114617|NCT01378754|DRUG|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
224292165|NCT03693534|DIAGNOSTIC_TEST|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
223543019|NCT03673540|BEHAVIORAL|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
223543020|NCT00476320|PROCEDURE|Magnetic Resonance Imaging|
223543021|NCT00476320|PROCEDURE|Revascularization|
223543022|NCT00476320|PROCEDURE|Echocardiography with myocardial deformation imaging|
223543023|NCT04361292|PROCEDURE|INTRAUTERINE INSEMINATION|Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
223543024|NCT01770405|DEVICE|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
224292166|NCT05802108|DRUG|Evolocumab combined with statins|The experimental group was treated with evolocumab combined with statin for lipid-lowering
224292167|NCT05802108|DRUG|Statin|the control group was treated with statin only for lipid-lowering
224292168|NCT06311669|PROCEDURE|iliac vein stenting|patients will undergo left common iliac vein stenting according to diameter measurements using balloon-mounted stents.
224292169|NCT06311669|PROCEDURE|pelvic vein embolization|embolization of pelvic veins by injection of left ovarian vein or parauterine veins pelvic escape points using sandwich technique of detachable or pushable coils and polidocanol 3 %.
223971902|NCT00908245|PROCEDURE|Control|Surgery without preconditioning surgery
223971903|NCT00908245|PROCEDURE|Preconditioning ischemia|Surgery with a preconditioning ischemia
223971904|NCT06195878|DEVICE|CPAP Therapy|Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
223971905|NCT04053517|OTHER|Medical Chart Review|Medical chart is reviewed
223971906|NCT04053517|OTHER|Quality-of-Life Assessment|Ancillary studies
223971907|NCT04053517|OTHER|Questionnaire Administration|Ancillary studies
223971908|NCT04835493|OTHER|Intervention|In the proposed study, we will conduct a randomized clinical trial of low-income, adult Latino(a)s with type 2 diabetes randomized at the individual level a telehealth-supported, integrated CHWs, medication-access, diabetes education program) (intervention) versus usual care (UC). Our research team will provide telementoring to local clinic teams (providers and CHWs) to initiate the 12-month the program into their clinics.
223971909|NCT04940780|OTHER|Acupuncture|Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms
224114618|NCT05104151|DIETARY_SUPPLEMENT|Nutritional bar|Protein-based nutritional bar, providing 155 calories per bar
224114619|NCT05104151|BEHAVIORAL|Healthy Habits Intervention|The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
224114620|NCT02409420|BEHAVIORAL|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
224114621|NCT05089864|OTHER|Stent Placement Timing - Early|Stent placement 5-7 weeks after STAR procedure
224114622|NCT05089864|OTHER|Stent Placement Timing - Late|Stent placement 12-14 weeks after STAR procedure
224114623|NCT02112448|DRUG|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
224114624|NCT02112448|DRUG|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
224114625|NCT02112448|DRUG|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
224292170|NCT03104348|DIAGNOSTIC_TEST|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
224292171|NCT03452618|DIAGNOSTIC_TEST|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
224292172|NCT04372290|OTHER|Product A|Usual brand (UB) filtered, combustible cigarette
223971910|NCT04940780|OTHER|Touch Therapies|Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch
223971911|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate high dose|
223971912|NCT03063346|DIETARY_SUPPLEMENT|Protein hydrolysate low dose|
223971913|NCT03063346|DIETARY_SUPPLEMENT|Placebo|
223971914|NCT04035863|DEVICE|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
223971915|NCT01865695|DRUG|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (\<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
223971916|NCT01865695|OTHER|Placebo|
223971917|NCT00585910|DRUG|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
224114626|NCT02112448|DRUG|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
224122660|NCT04323709|OTHER|Data collection|Clinical data are collected from the medical record of the institution. At admission, date were collected on age, gender, body mass index, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment, hypertension, diabetes, hypercholesterolemia, smoking, history of stroke or congestive heart failure, coronary or peripheral artery disease, renal failure with dialysis, Left Ventricular Ejection Fraction(LVEF), Tricuspid Annular Plane Systolic Excursion, mean arterial pressure, heart rate, central venous pressure, ScvO2, presence of an intra-aortic balloon pump and biochemical parameters. During hospitalization data were collected on reason for initiation of VA-ECMO and its characteristics (duration, type, flow L/min, RPM, FiO2), length of stay in ICU, catecholamines and inotropes maximal dose and length of administration, patients with heart transplantation or LVAD. In patients with levosimendan treatment, timing of administration regarding ECMO canulation was collected
224292173|NCT04372290|OTHER|Product B|Nicorette® White Ice Mint 2 mg nicotine gum
224114627|NCT05471297|OTHER|There is no intervention|There is no any intervention
224114628|NCT02100657|DRUG|Plitidepsin|
224114629|NCT02100657|DRUG|Bortezomib|
224114630|NCT02100657|DRUG|Dexamethasone|
224114631|NCT00409422|BEHAVIORAL|weight management program|
224114632|NCT02617732|DRUG|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
224114633|NCT02617732|DRUG|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
224114634|NCT02060201|DRUG|Saxagliptin|
224114635|NCT02060201|DRUG|Dapagliflozin|
224114636|NCT02060201|DRUG|Saxagliptin/Dapagliflozin FDC|
224292174|NCT04372290|OTHER|Product C|CSD1904-01, a nicotine pouch, 2 mg nicotine
224292175|NCT04372290|OTHER|Product D|CSD1904-02, a nicotine pouch, 4 mg nicotine
224292176|NCT04372290|OTHER|Product E|CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
223725134|NCT02989194|DRUG|VIS410 high dose|Single intravenous fixed high dose of VIS410
223725135|NCT02989194|DRUG|Placebo|Single intravenous infusion of placebo
223725136|NCT01033266|DIAGNOSTIC_TEST|CPET|CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
224114637|NCT02272621|PROCEDURE|Minimally invasive aortic valve replacement|
224114638|NCT02272621|PROCEDURE|Full sternotomy aortic valve replacement|
224114639|NCT00006360|DRUG|radioprotection|
224114640|NCT00006360|RADIATION|radiation therapy|
224114641|NCT02575794|DRUG|Terameprocol|Given PO
224114642|NCT02575794|OTHER|Pharmacological Study|Correlative studies
224114643|NCT00403117|DRUG|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
224114644|NCT00403117|DRUG|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
224292177|NCT02521818|OTHER|Modified Atkins Diet|
224114645|NCT00403117|DRUG|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
224114646|NCT00403117|DRUG|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
224114647|NCT00403117|DRUG|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
224114648|NCT00403117|DRUG|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
224292178|NCT02521818|OTHER|NIA Diet for Seniors|
223543025|NCT06455722|DRUG|[68Ga]Ga-P15-041|Intravenous injection of one dose of 111-148 MBq (3-4 mCi) \[68Ga\]Ga-P15-041. Tracer doses of \[68Ga\]Ga-P15-041 will be used to image lesions by PET/CT.
223543026|NCT01673659|DRUG|Mometasone furoate|
223543027|NCT01673659|DRUG|Nasonex Nasal Spray|
223543028|NCT01673659|DRUG|Placebo nasal spray|
223543029|NCT02825446|PROCEDURE|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
224114649|NCT00403117|DRUG|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
224114650|NCT00403117|DRUG|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
223971918|NCT00814554|BEHAVIORAL|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
224114651|NCT00403117|DRUG|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
224114652|NCT00403117|DRUG|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
224114653|NCT00119301|DRUG|leucovorin calcium|
224114654|NCT00119301|DRUG|methotrexate|
224114655|NCT00119301|DRUG|trimetrexate glucuronate|
224114656|NCT05392127|DRUG|SHR0302 Tablets|SHR0302 Tablets once daily
223971919|NCT00814554|BEHAVIORAL|Screening strategy|2\. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
223971920|NCT00814554|OTHER|Environmental strategy|3\. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
223971921|NCT04567745|DIAGNOSTIC_TEST|Retinal fundus photography|Fundus photographs
223971922|NCT00043368|DRUG|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
223971923|NCT00209053|PROCEDURE|Coronary Artery Bypass|
223971924|NCT02040532|DRUG|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
223971925|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
223971926|NCT03138356|DRUG|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
223971927|NCT03138356|DRUG|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
223971928|NCT03138356|DRUG|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
223971929|NCT03138356|DRUG|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
223971930|NCT03138356|DRUG|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
223971931|NCT03138356|DRUG|500 mg Glucophage XR®|Used in treatments C, F and I.
223971932|NCT02468882|DIETARY_SUPPLEMENT|Watercress|100g of watercress daily during radiation therapy
223971933|NCT03850847|OTHER|Step 1: Semi-structured Interviews|"1. Cover SDMs' experience around:~   * withdrawal of life sustaining therapies~  * organ donation among those who were approached (including with the medical team and the organ donation organisation)~  * understanding of the situation~  * views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~2. Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
223971934|NCT03850847|OTHER|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
223971935|NCT00755924|DIETARY_SUPPLEMENT|Vinegar|Apple cider vinegar 2 TBlsp/day
223971936|NCT00755924|OTHER|Placebo|Water placebo colored with balsamic vinegar
223971937|NCT03973437|DEVICE|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
224114657|NCT05392127|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
224114658|NCT05392127|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
224114659|NCT05392127|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
224114660|NCT05392127|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
224114661|NCT05392127|DRUG|Repaglinide Tablets|Repaglinide Tablets single dose
224114662|NCT05326399|BEHAVIORAL|renal biospy|Standard percutaneous biopsy has been performed in all participants. Modification of treatment will be jointly decided by hepatologists and nephrologists based on the pathological results. All participants will be followed up for 96 weeks.
224292179|NCT00850226|BEHAVIORAL|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
224292180|NCT00850226|BEHAVIORAL|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
224114663|NCT06348420|PROCEDURE|anti-reflux mucosal valvuloplasty (ARMV)|During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.
224114664|NCT00092586|DRUG|MK0653, ezetimibe|
224114665|NCT00092586|DRUG|Comparator: statins|
224114666|NCT04655950|OTHER|protocols and practices for the immobilization of vertebral osteomyelitis in different French hospitals and bone and joint infections Centers|"Evaluation of the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications.~We search for association between type and duration of spine immobilization and neurological status at the end of follow-up"
223971938|NCT03973437|DEVICE|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
223971939|NCT03956147|OTHER|Munich Shoulder Questionnaire|Validation and Reability study
223971940|NCT02287571|DEVICE|Derotation splint|This group is the actual intervention group.
224114667|NCT02075502|BEHAVIORAL|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
223725137|NCT05711953|OTHER|Egyfil Pain Lotion|"Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product."
223725138|NCT03529916|OTHER|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
224292181|NCT04963387|OTHER|Whole body vibration|Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.
224292182|NCT04963387|OTHER|Balance and Strengthening exercise|Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
223971941|NCT02287571|DEVICE|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
224114668|NCT02075502|PROCEDURE|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
224114669|NCT02075502|PROCEDURE|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
223971942|NCT06372756|DIAGNOSTIC_TEST|Deep learning image reconstruction|Deep learning image reconstruction (DLIR) is a newly developed artificial intelligence noise reduction algorithm in recent years. It trains massive high-quality FBP data sets to learn to distinguish noise and signal, so as to selectively reduce noise and reconstruct high-quality images with low-quality image data.
223971943|NCT02825849|BIOLOGICAL|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
224292183|NCT03786419|DRUG|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
223971944|NCT05985109|DRUG|KN046|KN046 is a recombinant humanized PD-L1/CTLA-4 bispecific single-domain antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
224292184|NCT03604341|DRUG|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
223725139|NCT06152978|DRUG|Sintilimab|Sintilimab (200mg) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
223971945|NCT05985109|DRUG|regorafenib|Regorafenib is a multi-target tyrosine kinase inhibitors and is one of the standard third-line therapy in mCRC
223725140|NCT06152978|DRUG|Chemotherapy|Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.
223971946|NCT01350388|DRUG|Febuxostat|80 mg/day of febuxostat for 24 weeks
223971947|NCT01350388|DRUG|Placebo|1 placebo tablet per day for 24 weeks
223971948|NCT02612363|DRUG|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~* Analgesia~* Propofol at lowest dosage.~* Dose range: 0.1- 0.7 u/kg/hour~* Target RASS score of -2 to +1~* Supplemental other sedatives at lowest effective dose"
223971949|NCT02767596|DRUG|Lixisenatide|
223971950|NCT02767596|DRUG|Basal insulins|patients are on basal insulin treatment
223971951|NCT00928876|DRUG|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
223971952|NCT00928876|DRUG|Placebo|placebo s/c daily for four weeks
223971953|NCT01266499|DRUG|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
224114670|NCT04297670|OTHER|Measurement of HPV types prevalence|Self collected genital samples to be tested for the presence of different HPV types.
224114671|NCT05684159|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.
224114672|NCT04723524|COMBINATION_PRODUCT|Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine|Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
224114673|NCT04723524|OTHER|Placebo Comparator|Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.
224292185|NCT03604341|OTHER|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
224292186|NCT05385848|PROCEDURE|Autologous Platelet-rich Plasma (PRP) Injection|PRP contains a high concentration of platelets which contains multiple vaso-active peptides and cytokines such as Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF) and Sphingosine-1-phosphate. Many of these cytokines have been implicated in important roles in ovarian function, follicular genesis and oocyte maturation. Intraovarian autologous PRP infusion was recently introduced in the context of addressing ovarian insufficiency, with several studies showing an increase in ovarian function and promising ART outcomes. Possible mechanisms include anti-inflammatory and mitogenic potentials in this growth factor rich fraction contributing towards tissues regeneration. Through being involved in the cell regeneration cycle, autologous PRP potentially gives women with premature ovarian insufficiency (POI) or diminished ovarian insufficiency (DOR) hope in achieving a healthy genetically related offspring.
224292187|NCT04375839|DEVICE|Zirconia implant|Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.
223971954|NCT01266499|DRUG|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
223971955|NCT01266499|DRUG|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
223971956|NCT01266499|DRUG|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
223971957|NCT05455554|DIAGNOSTIC_TEST|Flowmet-D|Flowmet-D is a non-invasive device that measures blood flow.
223971958|NCT05455554|DIAGNOSTIC_TEST|ABI|ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
223971959|NCT05106023|DRUG|SHR-1701|SHR-1701 combined with temozolomide
223971960|NCT05106023|DRUG|Temozolomide|SHR-1701 combined with temozolomide
223971961|NCT01740999|PROCEDURE|silicone arthroplasty|silicone arthroplasty
223971962|NCT01740999|PROCEDURE|arthrodesis|arthrodesis
223971963|NCT03274206|BIOLOGICAL|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
223971964|NCT03274206|DRUG|Placebo|BLS-ILB-E710c-placebo
223971965|NCT05079958|BEHAVIORAL|cognitive-behavioral education|four-week cognitive-behavioral education course
223971966|NCT05079958|BEHAVIORAL|12-week brisk walking|12-week brisk walking
223971967|NCT05272787|OTHER|TH Facial Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
223971968|NCT05272787|OTHER|TH Lip Moisturizer|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
223971969|NCT05272787|OTHER|Facial Moisturizer B (Control)|All subjects will receive all the products. There will be a supervised application at the site on the baseline visit of the study. Then subjects will use all the products at home.
224114674|NCT06203548|BEHAVIORAL|Lifestyle modification programme|All patients will attend sessions weekly in the first 2 months and monthly in the remaining 4 months. The programme focuses on reducing caloric intake and increasing energy expenditure. At the first visit, the dietitian will perform a complete behavioural assessment including the patient's eating and lifestyle patterns, specific eating-related behaviours, knowledge, concerns and feelings. A target body weight will be set. During follow-up visits, the dietitian will review the patient's dietary pattern and provide recommendations. Each patient will be given an individualised meal plan. The dietary component and portion size are based on recommendations by the American Dietetic. The patients will be taught techniques to cope with at-risk situations such as parties and festival celebrations. In addition, the patients will be encouraged to have a combination of aerobic exercise and resistance training with intensity and frequency following the Physical Activity Guidelines.
224114675|NCT06036433|DEVICE|Infrared laser photobiomodulation device|904 super pulsed Infrared laser PBM therapy for the treatment of the signs and symptoms associated with Parkinson's, such as improved motor, non-motor and Quality of Life.
224114676|NCT06036433|DEVICE|Infrared & Red LED photobiomodulation device|Infrared \& red LED therapy for the treatment of the signs and symptoms associated with Parkinson's, such as motor, non-motor and Quality of Life.
224114677|NCT02380352|DRUG|Amoxicillin|
224114678|NCT02380352|DRUG|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
224114679|NCT05216211|DRUG|Bupivacaine Hydrochloride|1 ml / kg, % 0.25 bupivacaine
224114680|NCT04868461|DIETARY_SUPPLEMENT|Unheated Whey Protein (UWP) beverage|The preload is made from whey protein powder. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
223971970|NCT05272787|OTHER|Sunscreen|Auxiliary product
223971971|NCT05272787|OTHER|Facial wash|Auxiliary product.
223971972|NCT03441152|DEVICE|tDCS|Transcranial direct current stimulation
223971973|NCT01039116|BEHAVIORAL|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
223971974|NCT01039116|BEHAVIORAL|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
224114681|NCT04868461|DIETARY_SUPPLEMENT|Heated Whey Protein (HWP) beverage|The preload is made from whey protein powder of 95% and it is heated for a certain amount of time. The energy load of the preload is 119.7 kcal and has banana flavor and sweetener.
223971975|NCT04486742|BEHAVIORAL|Itch CBT|Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.
223971976|NCT00447239|PROCEDURE|glucontrol (insulin therapy)|
223971977|NCT05318716|DEVICE|Fat grafting - Revolve device|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
223971978|NCT05318716|DEVICE|Fat grafting - Decantation|Standardized fat collection The donor areas previously agreed on by the patient and surgeon for fat harvesting will be injected with pre-standardized formulae and volume of tumescent fluid, and fat will be extracted using a standardized harvesting method between surgeons. Once the fat is collected. It will then be processed in one of two ways depending on the patient's group, using a Revolve system or via decantation. Fat will then be injected into the breast using a 10 or 20cc syringe in the standard retrograde manner to achieve the desired size and shape. A standard gauze-based dressing will be applied post-operatively, with no compression.
223971979|NCT05887479|DRUG|Botulinum toxin type A|Toxin of Clostridium Botulinum
224114682|NCT04868461|DIETARY_SUPPLEMENT|Casein (Cas) beverage|The preload is made from casein powder. The energy load of the preload is 105 kcal and has banana flavor and sweetener.
224114683|NCT04868461|DIETARY_SUPPLEMENT|Water|The preload is water acting as a control and contain the same banana flavor and sweetener to match the other three intervention - protein beverages.
224114684|NCT01840176|PROCEDURE|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
224114685|NCT01452776|DRUG|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
224114686|NCT01452776|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
224114687|NCT04168645|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 4 sessions of BCBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour.
224114688|NCT02343536|DRUG|Oral Azacitidine|
224114689|NCT02343536|DRUG|Rituximab|
224292188|NCT04375839|DEVICE|Titanium implant|Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
224292189|NCT03563846|DRUG|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
224292190|NCT05916521|DRUG|0.454% stannous fluoride|Brush two times daily
224292191|NCT05916521|DRUG|0.76% sodium monofluorophosphate|Brush two times daily
224292192|NCT05916521|DRUG|0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM|Brush two times daily
223971980|NCT05887479|DRUG|%0,9 NaCl|%0,9 NaCl
223971981|NCT04291716|DEVICE|Motor Seizure Detection Algorithm (mSDA)|A seizure detection algorithm installed on a propriety mobile application to be used on a commercially available watch with a gyroscope to detect movement.
223971982|NCT02516371|OTHER|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
223971983|NCT03392779|DRUG|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
223971984|NCT03392779|DRUG|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
223971985|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
223971986|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
223971987|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
223971988|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
224114690|NCT02343536|DRUG|cyclophosphamide|
224114691|NCT02343536|DRUG|Vincristine|
224114692|NCT02343536|DRUG|Prednisone|
224114693|NCT02155296|BEHAVIORAL|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
224292193|NCT01653613|GENETIC|DNA analysis|
224292194|NCT01653613|GENETIC|fluorescence in situ hybridization|
223971989|NCT03392779|DRUG|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
223971990|NCT03392779|DRUG|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
223971991|NCT03392779|DRUG|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
223971992|NCT03392779|DRUG|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
223971993|NCT03392779|DRUG|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
223971994|NCT03392779|DRUG|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
223971995|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
223971996|NCT03392779|DRUG|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
223971997|NCT03392779|DRUG|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
223971998|NCT03392779|DRUG|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
223971999|NCT03392779|DRUG|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
223972000|NCT03392779|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
223972001|NCT02330861|DEVICE|combowire and IVUS|
224114694|NCT06512415|DRUG|10 mcg Norepinephrine|The assigned dose (10 mcg) will be diluted with normal saline in a 10-cc syringe
224292195|NCT01653613|GENETIC|gene expression analysis|
223972002|NCT03298347|DRUG|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
223972003|NCT03298347|DRUG|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
224114695|NCT06512415|DRUG|15 mcg Norepinephrine|The assigned dose (15 mcg) will be diluted with normal saline in a 10-cc syringe.
223972004|NCT06219902|DRUG|Elinzanetant (BAY3427080)|Oral administration of multiple doses of elinzanetant.
223972005|NCT06219902|DRUG|Placebo to elinzanetant|Oral administration
223972006|NCT06219902|DRUG|Zopiclone|Oral administration
223972007|NCT06219902|DRUG|Placebo to zopiclone|Oral administration
223972008|NCT01579461|DRUG|mirabegron|oral
223972009|NCT05194631|OTHER|Quadriceps microbiopsy using a Tru-Cut biopsy needle|During surgery for a benign or malignant tumor of the liver a quadriceps microbiopsy will be performed. A 1 cm incision of the skin and fat planes will be made using a scalpel until contact with the quadriceps aponeurosis. The biopsy needle will be inserted superficially into the muscular part allowing, through a suction system, a micro biopsy of the quadriceps of approximately 25 mg.
223972010|NCT03433378|DRUG|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
223972011|NCT03433378|DRUG|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
224114696|NCT00108849|DRUG|estradiol, 10 mcg|
224114697|NCT03459131|DEVICE|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
224114698|NCT03459131|DEVICE|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
224114699|NCT02004054|OTHER|measure of pupil diameter|The measure will use infra-red cameras
224114700|NCT02049255|DRUG|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
224114701|NCT02049255|DRUG|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
224114702|NCT04703660|PROCEDURE|cervical mobilization|3 types of cervical mobilization at the level of C 5- 6
224292196|NCT01653613|GENETIC|microarray analysis|
224292197|NCT01653613|GENETIC|mutation analysis|
224292198|NCT01653613|GENETIC|polymorphism analysis|
224292199|NCT01653613|GENETIC|reverse transcriptase-polymerase chain reaction|
224292200|NCT01653613|OTHER|laboratory biomarker analysis|
223972012|NCT03433378|DRUG|Vehicle of the test product|Vehicle of the test product
223972013|NCT05723029|OTHER|Bowen Technique|A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position.
223972014|NCT05723029|OTHER|Post Isometric Relaxation|Post Isometric Relaxation is performed in supine position on treatment table. The therapist passively flexed the hip and knee at the 90 degrees and then passively extends the knee until the point of tissue resistance. Patient placed their leg on therapist shoulder and contracts his hamstring muscles by pushing down on the therapist shoulder for 10 seconds. After the contraction, patient is asked to relax, then therapist passively stretch to gain new range of muscles.
224114703|NCT04623190|BEHAVIORAL|Wait-List Control|-Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
223972015|NCT04248049|OTHER|Platelet rich fibrin|The roots of patients with diagnosis of gingival recessions will be covered with coronally advanced flap (CAF) and platelet rich fibrin (PRF) (CAF+PRF)
224114704|NCT04623190|BEHAVIORAL|PREVENT tool|-PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
223725141|NCT00928603|PROCEDURE|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
224114705|NCT03132805|BEHAVIORAL|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
224114706|NCT03132805|BEHAVIORAL|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
223725142|NCT00660023|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
223972016|NCT02515526|DRUG|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
224114707|NCT04708392|DEVICE|Spinal Cord Stimulator|A spinal cord stimulator is a surgically implanted device that delivers an electrical signal to a patient's spinal cord to reduce the perception of pain
224114708|NCT03517748|DEVICE|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
224114709|NCT03517748|DEVICE|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
223972017|NCT02515526|DRUG|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
223972018|NCT05347602|DIETARY_SUPPLEMENT|Gold Factor (Gold Nanoparticles, AuNPs)|AuNP used in the study is an aqueous suspension of clean-surfaced, faceted gold nanoparticles that have extraordinary catalytic capabilities. AuNP were 8 - 28 nm in diameter, with varying shapes from bipyramids to polyhedrons. To avoid contamination, AuNP was suspended in ultra-pure water, and were not coated with any proteins or molecules to avoid negative reactions within living tissues. This resulted in a rose-pink color due to the incident light inducing a specific resonance known as the localized surface plasmon resonance. The AuNP supplement used in this study contains elemental gold at 6 ppm. Study dosage is 1 oz per day, which is about 0.17 mg elemental gold per day.
223972019|NCT05347602|DIETARY_SUPPLEMENT|Placebo|For the Placebo, water and red dye were mixed to create a placebo liquid with the same rose-pink shade as the AuNP supplement, along with flavoring that matched the AuNP supplement.
223972020|NCT03640754|BIOLOGICAL|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
223972021|NCT03640754|OTHER|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
224114710|NCT04646980|DIETARY_SUPPLEMENT|Biobran/MGN-3|Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
223972022|NCT05729477|DEVICE|miCOR System|The miCOR system is a lens fragmentation device used to break up the cataract prior to IOL implantation during cataract surgery.
223972023|NCT05729477|DEVICE|Phaco Subject Cohort|Phaco Subject Cohort
223972024|NCT05075135|DEVICE|Swibrace 3D-splint|"The Swibrace 3D splint is a custom-made splint. For scanning of the forearms, the investigators will use the scanner HandySCAN300 and the therewith delivered software VXElements, the latter being necessary to create an accurate scan on the computer.~Printing of the splint will be done by Materialise, Belgium."
223972025|NCT05075135|DEVICE|Plaster cast|The conservative gold standard treatment of distal radius and scaphoid fractures is applying a plaster cast. Therefore, patients in the control group follow standard therapy procedures.
223972026|NCT05329402|DEVICE|Disposable Powered Articulating Endoscopic Linear Cutter Stapler|Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
223972027|NCT05329402|DEVICE|ECHELON Flex Powered Articulating Endoscopic Linear Cutters|Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
224114711|NCT04646980|OTHER|Placebo|Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
224114712|NCT00665496|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
224114713|NCT00665496|DRUG|Placebo|Matching Placebo
224114714|NCT04254289|BEHAVIORAL|Usual Care|Usual care
224114715|NCT04254289|BEHAVIORAL|Home-based exercise program|Home-based program determined by exercise physiologist
224114716|NCT01608789|DEVICE|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
223972028|NCT03249272|DRUG|Regadenoson|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
223972029|NCT03249272|DRUG|Adenosine|Microvascular disease will be considered present if regional perfusion defects are observed or global perfusion reserve is reduced. For the assessment of microvascular disease, the adenosine and regadenoson groups will be combined, as the medications are considered interchangeable.
223972030|NCT05858606|DIAGNOSTIC_TEST|Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation|"1. pre-inclusion consultation~2. inclusion consultation~   * personal history~  * height, weight, cranial perimeters, and spans of both parents~  * clinical examination of the child~  * photographs of the child~  * additional X-rays"
223972031|NCT05858606|PROCEDURE|analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team|"multidisciplinary team (geneticist, orthopedist, radiologist, pediatric endocrinologist) which will assign each patient an orientation:~* either to the non idiopathic short stature group (syndromic diagnostic orientation or to a constitutional bone pathology)~* or to the authentified idiopathic short stature group"
223972032|NCT05858606|GENETIC|Whole genome analysis for authentified idiopathic short stature|"For the first 30 patients included in the authentified idiopathic short stature group, a whole genome analysis in trio (child + parents) will be performed as part of the research.~For these 30 patients in the authentified idiopathic short stature group, the teleconsultation carried out for the submission of the multidisciplinary consultation meeting conclusions will make it possible to establish the family tree, to explain the interest and limits of the analysis, and to submit the consents dedicated to the genetic analysis."
223972033|NCT04314102|OTHER|No intervention will be made.|No intervention will be made. Only checks will be made
223972034|NCT00322764|DRUG|Uridine|
224114717|NCT06843889|DRUG|Toripalimab (240mg day1, Q3W*3cycle)|Phase 1: Toripalimab (240mg day1, Q3W\*2cycle) + investigator's choice of clinical conventional chemotherapy; Phase 2: Toripalimab (240mg day1, Q3W\*1cycle) + radiotherapy (intensity modulated radiotherapy, 40Gy/20F, 2Gy/F); Surgery was performed 4-6 weeks after completion, and subsequent treatment options were considered after surgery according to MDT discussion.
224114718|NCT04676464|DIAGNOSTIC_TEST|Ultra- sound|Ultrasound assessment of quadricep muscle layer thickness QMLT within 72hrs of initial CT scan
224114719|NCT03896399|PROCEDURE|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
224114720|NCT03950245|OTHER|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
224114721|NCT03950245|OTHER|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
224292201|NCT02312713|BEHAVIORAL|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
223725143|NCT03804047|OTHER|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
223725144|NCT04883502|BIOLOGICAL|Blood sample collection|A blood sample will be collected at enrollment.
223725145|NCT04883502|BIOLOGICAL|Other biological sample collection|"The following biological samples will be collected during the first surgery:~* 1 blood sample~* 3 fragments of induced membrane~* 1 fragment of periosteum"
223972035|NCT00825513|DEVICE|Akreos Toric IOL|Lens implant following cataract surgery
223972036|NCT00825513|DEVICE|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
223972037|NCT00233207|DRUG|IC14|
223972038|NCT02458794|PROCEDURE|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
223972039|NCT02458794|DEVICE|LMA SupremeTM|
223972040|NCT02458794|DEVICE|Ambu-Aura GainTM|
223972041|NCT03638700|DEVICE|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
223972042|NCT03638700|DEVICE|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
223972043|NCT03638700|DEVICE|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
224114722|NCT03950245|OTHER|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
224292202|NCT02312713|BEHAVIORAL|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
224292203|NCT02676713|DRUG|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
223725146|NCT04883502|DIAGNOSTIC_TEST|Surgical waste collection|The pieces of polymethylmethacrylate surgical cement will be collected during the second surgery.
223972044|NCT03638700|DEVICE|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
223972045|NCT03157414|DRUG|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
223725147|NCT04883502|DIAGNOSTIC_TEST|Radiological examination and functional exploration|A radiological examination and a functional exploration will be performed 6 weeks, 3 months and 6 months after the first surgery
224114723|NCT03950245|OTHER|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
224114724|NCT01520415|DRUG|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
224114725|NCT01520415|DRUG|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
224114726|NCT05453370|DEVICE|CALMA m-health app|CALMA is an app for smartphones that provides evidence-based tools to prevent suicide. Out of Crisis modality consists of 4 sections: Moments, Agenda, Profile and Tips. The I need help modality uses DBT skills presented in a card format. The Problem-solving Card is the first one showed and helps the user to know if the problem that triggered the crisis can be addressed through a problem-solving strategy. If not, the next step is to use the CALMA thermometer (to identify the intensity of the emotion) and the DBT Skills Cards. They are based fundamentally in two groups of DBT skills, emotional regulation and distress tolerance. If distress worsens or does not diminish the Emergency Card is activated, offering the user the option to make one or several calls to emergency contacts and providing the option to use the geolocation function to show all emergency services near the user's location so that he/she can consult personally. All participants will also receive mental health treatment.
224114727|NCT05453370|OTHER|Treatment As Usual (TAU)|Participants who do not receive the application will continue the usual mental health treatment (psychotherapeutic and/or psychopharmacological) by their usual treating professionals throughout the duration of the study.
224114728|NCT01654562|DRUG|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
224114729|NCT05382676|DEVICE|Eyeswift Pro|assessment of visual function parameters
224114730|NCT03080922|BIOLOGICAL|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
224114731|NCT04270851|DIAGNOSTIC_TEST|LiMAx test|The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
224114732|NCT04270851|DIAGNOSTIC_TEST|HepaT1ca magnetic resonance scan|The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
224114733|NCT04451434|DRUG|Danicopan|Oral tablet
224114734|NCT03475407|DRUG|Ozurdex intravitreal injection|"1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
224114735|NCT03475888|DEVICE|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
224114736|NCT00404404|BIOLOGICAL|bevacizumab|
224114737|NCT00404404|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
224114738|NCT03070457|OTHER|Early discharge|Patients randomised to early discharge or not
224114739|NCT03070457|OTHER|Conventional protocol|Discharge as usually done 48-72 hours after surgery
224114740|NCT04450355|DRUG|Nefopam 80mg/day|continuous nefopam infusion
224114741|NCT04450355|DRUG|Normal saline|continuous normal saline infusion
223725148|NCT04180488|DRUG|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
223725149|NCT04180488|DRUG|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
223972046|NCT03157414|OTHER|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
223972047|NCT03734614|DRUG|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
223972048|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
224114742|NCT01210950|BIOLOGICAL|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
224114743|NCT01856491|DEVICE|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
224114744|NCT04695730|OTHER|Active physical therapy (including both pain education and home exercises)|"One session (60 minutes). In this session, a physical therapist will explain and demonstrate the exercises to perform individually at home. Exercises will be performed daily. In addition, an education session will be provided, concerning pain mechanisms and management. To support patients during the treatment, a booklet will be created.~One booster session (30minutes) will be planned after 4 weeks. Patients will follow the active treatment for 8 weeks."
223972049|NCT01679613|DRUG|Nintedanib|low dose oral administration
223972050|NCT01679613|DRUG|Ketoconazole|oral administration
223972051|NCT01679613|DRUG|Nintedanib|low dose oral administration
223972052|NCT01679613|DRUG|Nintedanib|low or medium dose depending on pilot part
223972053|NCT01679613|DRUG|Ketoconazole|oral administration
224114745|NCT04695730|OTHER|Active physical therapy plus manual therapy|"Participants in the Group 2 will receive active intervention plus 8 Pompage technique sessions (1 session/week). In these sessions (30 minutes each), Pompage technique will be performed by a physical therapist."
224114746|NCT02823262|OTHER|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
224114747|NCT02823262|OTHER|Usual Care|
224114748|NCT06513325|OTHER|Canadian Occupational Performance Measure|It is a semi-structured scale that helps to identify problematic areas of performance experienced by individuals and to measure their perceived occupational performance and satisfaction. This scale assesses the level of performance of self-care, productivity and leisureoccupations and satisfaction with these performances as perceived by the individual.
224114749|NCT06534944|DRUG|Nicotinamide riboside|NR 1g daily for 4 weeks
224114750|NCT04082767|DRUG|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
224114751|NCT04082767|DRUG|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
224292204|NCT02676713|DRUG|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
223972054|NCT03169530|OTHER|Alcohol|\~15 gm daily of beer, wine, or spirits for \~6 years
223972055|NCT03087461|BEHAVIORAL|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
223972056|NCT04090788|DIETARY_SUPPLEMENT|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
223972057|NCT04090788|DIETARY_SUPPLEMENT|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
223972058|NCT03453177|DRUG|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
223725150|NCT04180488|DRUG|non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: oral administration
224114752|NCT05085392|BEHAVIORAL|Trauma-Informed Yoga|6 weeks of twice weekly trauma-informed yoga for 45 minutes per session
224114753|NCT01609959|DRUG|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
224114754|NCT01609959|DRUG|Valsartan|Valsartan 160 mg per day
224114755|NCT00058578|DRUG|Cyclophosphamide|
224114756|NCT00058578|DRUG|Mesna|
223725151|NCT04497805|BIOLOGICAL|ALLO-ASC-SHEET|Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
223972059|NCT03453177|PROCEDURE|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
223972060|NCT03453177|PROCEDURE|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
223972061|NCT05490368|DEVICE|Bed mattress sensor system|The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
223972062|NCT06269393|DRUG|Placebo|Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
223972063|NCT06269393|DRUG|IBI311|IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
223972064|NCT00355771|DRUG|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
223972065|NCT00355771|DRUG|Placebo|1 tablet OD in the morning for 8 weeks
224114757|NCT00058578|DRUG|G-CSF|
224114758|NCT00058578|PROCEDURE|Leukopheresis|
224114759|NCT00058578|PROCEDURE|Total Body Irradiation|
224114760|NCT01158534|DRUG|celecoxib|Given orally
224114761|NCT01158534|BIOLOGICAL|recombinant interferon alfa-2b|Given subcutaneously
224114762|NCT01158534|OTHER|polymerase chain reaction|Correlative studies
224114763|NCT01158534|OTHER|laboratory biomarker analysis|Correlative studies
224114764|NCT01158534|OTHER|reverse transcriptase-polymerase chain reaction|Correlative studies
224292205|NCT02676713|DRUG|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
223725152|NCT01003730|OTHER|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
223972066|NCT04753281|OTHER|Lifestyle counselling|brief psychological intervention, based on the behaviour change whee
224114765|NCT01158534|OTHER|immunologic technique|Correlative studies
223725153|NCT04056689|DRUG|DNL151|Oral repeating dose
223725154|NCT04056689|DRUG|Placebo|Oral repeating dose
223972067|NCT02173756|DRUG|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
223972068|NCT02173756|DRUG|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
223972069|NCT01540019|DRUG|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
224114766|NCT01158534|OTHER|immunohistochemistry staining method|Correlative studies
224114767|NCT01158534|OTHER|flow cytometry|Correlative studies
224114768|NCT01124058|DRUG|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
224114769|NCT01124058|DRUG|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
224114770|NCT02060617|BEHAVIORAL|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
224114771|NCT02060617|PROCEDURE|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
224114772|NCT02060617|PROCEDURE|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
224114773|NCT02060617|PROCEDURE|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
224114774|NCT00466128|DRUG|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
224114775|NCT05676320|DEVICE|V-Flex|Bone cement including Inossia Cement Softener. Treatment for vertebral compression fracture
224114776|NCT05676320|DEVICE|V-Steady|Bone Cement alone
224114777|NCT05158309|OTHER|8% Capsaicin patch|Cutaneous pain was induced using a (5x10 cm) 8% topical capsaicin patch (transdermal patch, 'Qutenza', Astellas) on the volar part of the dominant right forearm (5 cm from the wrist) of each participant.
224114778|NCT05158309|OTHER|placebo patch|A transparent patch with no formulation or effect but the same size of the capsaicin patch was applied to the same location.
224114779|NCT02857907|OTHER|Blood sample|A blood sample is performed one year after kidney transplantation.
224114780|NCT02115815|BIOLOGICAL|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
223972070|NCT01991678|DRUG|145 mg/m2 NKTR 102|
223972071|NCT01991678|DRUG|120 mg/m2 NKTR 102|
223972072|NCT01991678|DRUG|50 mg/m2 NKTR 102|
223972073|NCT02965599|DRUG|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
224292206|NCT02676713|DRUG|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
224292207|NCT03627234|BEHAVIORAL|Same Day Discharge|Patients will be randomized to same day discharge
224292208|NCT03627234|BEHAVIORAL|Overnight Stay|Patients will be randomized to stay overnight
224292209|NCT05880121|DIAGNOSTIC_TEST|MRI|brain MRI
224292210|NCT03153618|OTHER|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
224292211|NCT01829113|DRUG|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
224292212|NCT01829113|DRUG|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m\^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
224292213|NCT05294367|DRUG|Magnesium Chloride-based Lotion|Given topically
224292214|NCT05294367|OTHER|Quality-of-Life Assessment|Ancillary studies
224292215|NCT05294367|BEHAVIORAL|Special Diet Therapy|Consume magnesium rich foods
224292216|NCT04754334|DRUG|ORMD-0801|Oral Insulin
224292217|NCT04754334|OTHER|Placebo|Fish Oil
223972074|NCT02965599|DRUG|Placebo|Placebo is a white, opaque, gelatin capsule.
223972075|NCT05401669|PROCEDURE|Trans-radial access|Cerebral angiography performed by trans-radial access
223972076|NCT05401669|PROCEDURE|Trans-femoral access|Cerebral angiography performed by trans-femoral access
224292218|NCT00833352|DEVICE|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
224292219|NCT04118998|BEHAVIORAL|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
224292220|NCT04118998|BEHAVIORAL|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
223972077|NCT02840812|DRUG|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
223972078|NCT07007884|DEVICE|Active Transauricular Vagus Nerve Stimulation|Active taVNS application was performed by stimulating a sterile acupuncture needle (0.25x25 mm) placed on the left ear cymba choncae with a stimulator. Active taVNS group received for 10 days, 30 minutes with a current intensity of 1 mA, pulse width of 200 µs, frequency of 25 Hz and biphasic sinusoidal waveform. In the sham group, stimulation was applied to the lobulus auriculae of the left ear (which is not innervated by the vagus nerve) using the same current intensity and duration as the active group.
223972079|NCT07007884|DEVICE|Sham Transauricular Vagus Nerve Stimulation|Sham taVNS application was performed by stimulating a sterile acupuncture needle (0.25x25 mm) placed on the left lobulus auriculae of the left ear (which is not innervated by the vagus nerve) with a stimulator. Sham taVNS group received for 10 days, 30 minutes with a current intensity of 1 mA, pulse width of 200 µs, frequency of 25 Hz and biphasic sinusoidal waveform.
223972080|NCT07008924|OTHER|No intervention is provided. We monitor natural recovery to full sleep.|Return to normal sleep observation.
223972081|NCT02748902|DRUG|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
223972082|NCT03415347|PROCEDURE|Abscess de-roofing and curettage|Abscess de-roofing and curettage
223972083|NCT03415347|PROCEDURE|Abscess wide local excision|Abscess wide local excision
223972084|NCT03386305|DRUG|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
223972085|NCT03386305|DRUG|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
223972086|NCT03025997|DIETARY_SUPPLEMENT|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
223972087|NCT03025997|DIETARY_SUPPLEMENT|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
223972088|NCT00787813|DRUG|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
223972089|NCT00787813|DRUG|Placebo|
223972090|NCT01630395|PROCEDURE|protective ventilation|low tidal volume and PEEP
223972091|NCT01630395|PROCEDURE|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
223972092|NCT01628341|DRUG|insulin|Patients will be asked to complete 2 self-assessment questionnaires
223972093|NCT06076798|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
223972094|NCT05235841|OTHER|acupressure|Acupressure is a complementary and supportive approach used in symptom management.
223972095|NCT06309485|DRUG|WGI-0301 at MTD/RP2D dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
223972096|NCT06309485|DRUG|WGI-0301 at MTD/RP2D -1 dose IV infusion, QW|WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
223972097|NCT06309485|DRUG|Sorafenib 400 mg PO, BID continuously|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
223725155|NCT02056782|DRUG|Dociparstat sodium|"The following induction regimen was administered:~* Cytarabine (100 mg/m2/day) via continuous intravenous (IV) infusion 24 hours daily for 7 days.~* Idarubicin (12 mg/m2/day) IV on Days 1, 2, and 3.~* Dociparstat (4 mg/kg) given over 5 minutes IV, immediately after the idarubicin dose on Day 1, followed by a continuous IV infusion (0.25 mg/kg/hr for 24 hours daily) for a total of 7 days."
223972098|NCT06309485|DRUG|Sorafenib 400 mg PO, BID|Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
224292221|NCT03453840|DRUG|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
223972099|NCT02956278|DRUG|Allopurinol|
223972100|NCT02956278|OTHER|Placebo|lactose placebo pill
223972101|NCT04633213|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
223972102|NCT04633213|DRUG|Placebo|Ophthalmic Solution
224114781|NCT02115815|BIOLOGICAL|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
224114782|NCT02115815|BIOLOGICAL|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
224114783|NCT02115815|BIOLOGICAL|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
224114784|NCT02115815|BIOLOGICAL|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
224114785|NCT02115815|BIOLOGICAL|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
223725156|NCT04161989|DRUG|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% \& Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
223725157|NCT04161989|DRUG|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
223725158|NCT02069301|BEHAVIORAL|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
223725159|NCT02069301|OTHER|Treatment as Usual|National Guideline for antidepressant care
223972103|NCT04588519|DEVICE|Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System|Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
223972104|NCT03084198|PROCEDURE|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
223972105|NCT03084198|PROCEDURE|Standard care for ALF|A standard of care for subjects with acute liver failure.
223972106|NCT02782208|DRUG|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
223972107|NCT02782208|DRUG|Placebo|Placebo is administered 4 times previous to and during the investigation day.
223972108|NCT02782208|DRUG|GH substitution|GH substitution as usually
223972109|NCT02782208|OTHER|GH pause|GH substitution pause two days prior to the experimental day
224114786|NCT02115815|BIOLOGICAL|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
224114787|NCT00112099|PROCEDURE|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
224114788|NCT00112099|PROCEDURE|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
224114789|NCT05994794|DIETARY_SUPPLEMENT|Alpha-GPC, Creatine and Ashwagandha (Sensoril®)|Other Ingredients: Microcrystalline Cellulose, Rice Fiber, Maltodextrin, Silica, Vegetable Stearate
224114790|NCT05994794|OTHER|Placebo|Microcrystalline Cellulose
224114791|NCT04003155|DRUG|fezolinetant|Oral Tablet
224114792|NCT04003155|DRUG|placebo|Oral Tablet
224114793|NCT05347914|BEHAVIORAL|Mindfulness|Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
224114794|NCT04664660|OTHER|Retrospective analysis of obstetrics outcomes|Retrospective analysis of clinical records including general medical and gynecological history, pregnancy course, delivery mode and newborn conditions.
224114795|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus (ST) tendon only|ACL reconstruction with a ST tendon graft received a reconstruction according to the Tape Locking Screw technique (FH Industrie, Quimper, France) with a dedicated interference screw
224292222|NCT06477120|BEHAVIORAL|Time Restricted Eating|The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
224114796|NCT05464485|PROCEDURE|ACL hamstring reconstructions using semitendinosus and gracilis (ST/G) tendon|ACL reconstruction with a ST/G tendon graft received a reconstruction with the anteromedial portal technique with endobutton fixation (Smith \& Nephew, London, UK).
224114797|NCT05927246|DIAGNOSTIC_TEST|ECG|12 lead ecg for each participant
224292223|NCT06127316|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthoses (CDOs) used in this study will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee. The CDO will be modular in design which will allow three carbon fiber struts of the same stiffness and differing lengths to be used to implement 0cm, 1cm, and 2cm levels of heel distraction height. A longer posterior strut will move the carbon fiber footplate away from the participants foot to create the heel distraction height.
224292224|NCT06975787|DRUG|Vonsetamig|Administered as per the protocol
224292225|NCT06975787|DRUG|Odronextamab|Administered as per the protocol
224114798|NCT01912872|DRUG|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
224114799|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
224114800|NCT01912872|DRUG|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
223725160|NCT02069301|OTHER|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
224292226|NCT06208605|BEHAVIORAL|Transdiagnostic Network Informed Personalized Treatment|Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
224292227|NCT06208605|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy for Eating Disorders|Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
224292228|NCT06191744|DRUG|Epcoritamab|Subcutaneous (SC) Injection
224292229|NCT06191744|DRUG|Prednisone|Oral Tablet
224292230|NCT06191744|DRUG|Rituximab|Intravenous (IV) Infusion
224292231|NCT06191744|DRUG|Lenalidomide|Oral Capsule
224292232|NCT06191744|DRUG|Doxorubicin|IV Injection
224292233|NCT06191744|DRUG|Vincristine|IV Injection
224292234|NCT06191744|DRUG|Cyclophosphamide|IV Injection
224292235|NCT06191744|DRUG|Obinutuzumab|IV Infusion
224292236|NCT06191744|DRUG|Bendamustine|IV Infusion
224292237|NCT00232271|DRUG|Clexane|
224292238|NCT04134845|DRUG|Dantrolene/Ryanodex|muscle relaxant
224292239|NCT04134845|DRUG|Placebo|Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
224292240|NCT02010255|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
224292241|NCT02010255|DRUG|RBV|RBV tablets administered orally in a divided daily dose
223725161|NCT02554266|DEVICE|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
223725162|NCT01635101|DRUG|IV Acetaminophen|IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours
223725163|NCT01635101|DRUG|IV Control|IV Control q6h; 4 doses, in 24 hours
223725164|NCT02275650|RADIATION|nbUVB|2 SED nbUVB exposure will be given every other week
224114801|NCT01912872|DRUG|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
224114802|NCT01912872|DRUG|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
224114803|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 14 days
224114804|NCT01190657|DRUG|Selbex|50mg/day, 3 times/day, for 56 days
224292242|NCT04703543|DEVICE|Pilot evaluation study on use PSMA and Cu-PET/CT|This study aims at assessing the detection rate of both PSMA and Cu-PET/CT on tissue relapse, study whether this method is equivalent to mpMR
224292243|NCT01404052|DEVICE|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
224292244|NCT03226171|DRUG|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
223725165|NCT02659306|DRUG|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
224114805|NCT03089177|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year."
224114806|NCT02778867|OTHER|1 Food Elimination Diet Therapy|
224114807|NCT02778867|OTHER|6 Food Elimination Diet Therapy|
224114808|NCT02778867|OTHER|6 Food Elimination Diet (after 1FED failure)|
224114809|NCT02778867|DRUG|Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)|
224114810|NCT04492956|DRUG|Ecopipam|Oral tablet
224114811|NCT04492956|DRUG|Placebo|Oral tablet
224114812|NCT02394444|OTHER|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
224114813|NCT02884791|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
224114814|NCT06001372|DRUG|Ketamine|"Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)"
224114815|NCT05305118|PROCEDURE|TSCS Mapping|"Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention."
224292245|NCT00867048|DRUG|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
224292246|NCT02568709|DRUG|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
224292247|NCT02568709|DRUG|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
224292248|NCT05818982|DRUG|Afatinib|Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.
224292249|NCT05818982|DRUG|Irinotecan|Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
224292250|NCT01914172|OTHER|online questionairres|see group descriptions
224292251|NCT03405376|DRUG|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
224292252|NCT04528576|DEVICE|Dragonfly mitral valve repair system|With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
224292253|NCT03645382|DIETARY_SUPPLEMENT|baked barley powder|The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
223725166|NCT02569723|DRUG|Carbon C 14 Oxaliplatin|Intravenous infusion
223725167|NCT02569723|DRUG|Oxaliplatin|Intravenous infusion
224114816|NCT05305118|DEVICE|Transcutaneous spinal cord stimulation|"TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device)."
224114817|NCT06567106|OTHER|Ultrasound application|Apply ultrasound to the participant within a safe range.
224114818|NCT06567106|OTHER|No ultrasound application|No ultrasound application to the participant.
224114819|NCT03955848|BIOLOGICAL|Alloreactive NK cell infusion|Alloreactive NK cell infusion
224114820|NCT04917796|OTHER|Electroacupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
224114821|NCT04917796|OTHER|Sham Acupuncture|Real and sham acupuncture will be delivered by experienced licensed acupuncturists at MSK. The intervention includes 10 treatments of acupuncture over 8 weeks (i.e., twice per week for two weeks, then one treatment per week for six weeks).
224114822|NCT03336138|OTHER|AMA (Assistance for ambulatory patients)|telephone follow-up modality
224114823|NCT05226585|BEHAVIORAL|In-Person Cognitive Behavioral Therapy for Insomnia|Cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi). CBTi contains the following well-validated components of cognitive behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
224292254|NCT03645382|DIETARY_SUPPLEMENT|jeju steam onion|The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
224292255|NCT06318039|OTHER|Novel program|Applying new training method; the Nordic hamstring exercise
224114824|NCT05226585|BEHAVIORAL|Telehealth Cognitive Behavioral Therapy for Insomnia|Telehealth cognitive behavioral therapy is recommended as a first-line treatment for insomnia (CBTi) conducted via audio-video communication. tCBTi contains the following well-validated components of cognitive-behavioral treatment for insomnia: stimulus control, sleep compression, sleep hygiene, relaxation training, and cognitive restructuring.
224114825|NCT05226585|BEHAVIORAL|Internet Cognitive Behavioral Therapy for Insomnia|Sleep Healthy Using The Internet (SHUTi; aka iCBTi) is a self-guided, fully automated, online CBTi program that includes interactive features: personalized goal setting, graphical feedback based on inputted data, animations/illustrations to enhance comprehension, patient vignettes, and video-based expert explanations.
224114826|NCT00722345|BEHAVIORAL|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
224292256|NCT06318039|OTHER|Traditional program|Conventional rehabilitation training administered
223972110|NCT04755023|DRUG|Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide|Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
223972111|NCT01281215|BEHAVIORAL|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
223972112|NCT03067610|RADIATION|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
223972113|NCT03067610|DRUG|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
223972114|NCT02587013|PROCEDURE|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
223972115|NCT02587013|PROCEDURE|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
223972116|NCT01226485|DRUG|Taladegib|Administered IV
223972117|NCT04145609|BEHAVIORAL|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
223972118|NCT01795521|RADIATION|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
223972119|NCT00049335|DRUG|capecitabine|1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
223972120|NCT02125318|DRUG|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
223972121|NCT00509821|DRUG|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
223972122|NCT00509821|DRUG|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
223972123|NCT01165164|OTHER|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
223972124|NCT03436043|DEVICE|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
223972125|NCT05101083|DEVICE|New Receiver-in-Canal Device|Successor of previous device generation
223972126|NCT05101083|DEVICE|Legacy Receiver-in-Canal Device|Receiver-in-canal device available on the market
223972127|NCT00399503|PROCEDURE|Spectral T Wave Alternans|
224114827|NCT00722345|BEHAVIORAL|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current \& past activities; 2) reviewing the pros \& cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
224114828|NCT06077058|OTHER|Nicotine Replace Therapy (NRT) sampling|The intervention involves a Zoom/WhatsApp meeting or face-to-face session with a trained counselor who introduces NRT use, possible side effects, and patch dosage based on a previous RCT guide. An online intervention pack with a pamphlet and 1-week free NRT sample (14mg or 21mg patch) is mailed to participants. After 1 week, the counselor follows up. If participants need more patches, an additional pack is mailed, and they are advised to obtain further patches from smoking cessation services or pharmacies. NRT patch users may experience skin reactions, insomnia, or vivid dreams; if severe side effects occur, they are asked to stop using NRT.
223972128|NCT00399503|PROCEDURE|Modified Moving Average T Wave Alternans|
223972129|NCT00399503|PROCEDURE|Baroreceptor Sensitivity|
223972130|NCT00399503|PROCEDURE|Heart Rate Variability|
223972131|NCT00399503|PROCEDURE|Heart Rate Turbulence|
223972132|NCT00399503|PROCEDURE|Deceleration Capacity|
223972133|NCT00399503|PROCEDURE|Signal Averaged ECG|
223972134|NCT02967809|DEVICE|echography|cardiac and pulmonary echography
223972135|NCT01359683|DEVICE|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
223972136|NCT04438122|OTHER|Cabernet Sauvignon|Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
223972137|NCT04438122|OTHER|Tsipouro|Tsipouro is a greek spirit which contains 38% alcohol vol
223972138|NCT06171282|DRUG|Recombinant oncolytic herpes simplex virus type Ⅰ (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
223972139|NCT00932659|DEVICE|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
223972140|NCT02239081|DRUG|CTP-730|
223972141|NCT02239081|DRUG|Placebo for CTP-730|
223972142|NCT04137302|DRUG|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
223972143|NCT03647202|DRUG|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
223972144|NCT03647202|DRUG|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
223972145|NCT03647202|DRUG|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
223972146|NCT01722864|DRUG|COV155|COV155 tablets
223972147|NCT01520844|BIOLOGICAL|blood sampling|blood sampling
223972148|NCT02720185|DRUG|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
224114829|NCT06077058|BEHAVIORAL|Simple exercise education (SEE)|All participants will be given a handgrip at study enrolment. The SEE includes a Zoom/WhatsApp meeting or face-to-face session including 1) watching a 5-minute video (www.youtube.com/watch?v=mZex2Wwy3fU) showing a chair professor of public health demonstrating the 10s-E, including the simple exercises with and without handgrip. The video also encourages participants to 1) follow the exercise instructions during the video demonstration; 2) perform the exercises whenever they experience craving or an urge to smoke during the quitting process; and 3) increase their exercise frequency and intensity as much as possible, which may also increase their grip strength. Participants will also receive a leaflet with exercise instructions and motivational messages.
223972149|NCT02720185|PROCEDURE|Conventional Surgery|Undergo surgery
223972150|NCT02720185|OTHER|Laboratory Biomarker Analysis|Correlative studies
223972151|NCT03924128|DEVICE|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
223972152|NCT05172518|DRUG|Taxane plus Intermittent Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
224292257|NCT02466802|DRUG|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
224292258|NCT02466802|DRUG|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
223725168|NCT02263794|PROCEDURE|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
224292259|NCT00139438|BEHAVIORAL|Disease Management Assessment|
224292260|NCT02593487|DRUG|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
224292261|NCT02593487|DRUG|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
224292262|NCT03389087|DRUG|Apatinib and Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
224292263|NCT01897623|OTHER|ultrasound of aorta|
224292264|NCT03700645|DRUG|Allopurinol|Allopurinol
224292265|NCT04701034|DRUG|Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)|infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
224292266|NCT04701034|DRUG|Prednisolone Tablets|5 mg before ET and 10 mg after ET until gestational week 8+0
223972153|NCT05172518|DRUG|Utidelone plus Intermittent Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (1000 mg/ m2 twice daily D1-14 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
223972154|NCT05172518|DRUG|Taxane plus Metronomic Capecitabine|Eligible patients will receive treatment with taxane (paclitaxel, nab-paclitaxel or docetaxel , the dosage reference to related prescribing information or clinical practice by investigators) plus capecitabine ( 500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(For the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
223725169|NCT02263794|PROCEDURE|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
223972155|NCT05172518|DRUG|Utidelone plus Metronomic Capecitabine|Eligible patients will receive treatment with utidelone (30 mg/ m2 /day D1-5 Q3W) plus capecitabine (500 mg three times daily on days 1-21 Q3W) for 6 \~8 cycles(for the the patients with SD, PR or CR after 6\~8 cycles treatment could choose to receive continuous combination therapy or capecitabine maintenance mono therapy ), or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.
223972156|NCT04695821|DEVICE|Senti V1.0 Device|"This device class I, CE marked garment, with a similar form to a T-Shirt, embedded with ten sensor modules encased in silicone; the device comes with a charging stand in the form of a clothes hanger. Depending on the outcome of this feasibility study, the device may, in the future, form part of a class IIb medical device system, when accompanied by cloud-based software to listen to both current and historically recorded breath sounds for each Senti patient. The Senti Version One device will be labelled clearly to indicate the device version, on the inside of the garment, conforming to the MDR.~The garment itself will be made from textile composite, including cotton, elastase, micromodel, spandex, and polyester. All other components (including electronic and other plastic components) will be entirely encased in medical-grade silicone."
223972157|NCT02071680|OTHER|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
223972158|NCT04527783|OTHER|experimental group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
223972159|NCT04527783|OTHER|control group|Each subject will undergo 10 rehabilitation sessions 2-3 times a week, lasting around 30'.
223972160|NCT01957592|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
223972161|NCT03105778|DIAGNOSTIC_TEST|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
223972162|NCT02990923|DEVICE|High-Flow Needleless Valve|
223972163|NCT02990923|DEVICE|DualCap Disinfection Devices|
224114830|NCT06077058|OTHER|Chat-based instant messaging|Participants will receive individualized chat-based encouragement and support messages about motivation and preparation for quit attempts using WhatsApp for 8 weeks. A trained smoking cessation counsellor will have real-time (synchronous), one-to-one interaction with the participants and provide personalized motivational, behavioural support according to the participants' needs. The conversation intensity will be flexible and depends on the participant. The conversation will also be integrated with brief advice using the Behaviour Change Techniques (BCTs) (18) and the AWARD (Ask, Warn, Advise, Refer, Do-it-again) intervention model (11). The intervention protocol will be similar as that in our previous RCT on CBIM (19). For participants who receive the SEE and NRTS, the trained counsellor shall follow-up on their compliance and provide adequate advice in adhering to these interventions.
224114831|NCT06077058|OTHER|Chatbot for smoking cessation|The information and access to the chatbot will be introduced to participants. Through the chatbot service, participants shall access to practical information on smoking cessation 24 hours at any time, such as details on cessation services and skills for tackling cravings. By using the second-generation chatbot, participants could receive personalized risk information and recommendations for smoking cessation, as well as reach to a counsellor through WhatsApp live chat for urgently needed advice.
224114832|NCT01518582|DEVICE|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
224292267|NCT04701034|DRUG|Human Albumin Solution|Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
223725170|NCT01516931|PROCEDURE|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
223972164|NCT04240600|DIETARY_SUPPLEMENT|Experimental group|2 cans or bottles (200ml)per day, orally
223972165|NCT04240600|DIETARY_SUPPLEMENT|Control group|2 cans or bottles (200ml)per day, orally
223972166|NCT05937815|PROCEDURE|Sample collection|collection of sputum, stool and blood samples at baseline, 6 months and 1 year after baseline
223972167|NCT00348868|BEHAVIORAL|enhanced behavioral motivation counseling|
223972168|NCT00348868|BEHAVIORAL|Motivational counseling|
223972169|NCT00348868|BEHAVIORAL|Standard counseling|
224114833|NCT00628511|DEVICE|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
224292268|NCT04701034|DRUG|Placebo tablet|1 tablet before ET and 2 tablets after ET until gestational week 8+0
223972170|NCT06133686|DRUG|Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)|Group A will receive oral TDF-FTC PrEP (using either event-driven or daily) for 9-months. After 9-months, participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP
223972171|NCT06133686|DRUG|Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)|Group B will receive CAB-LA for 9-months. After 9-months participants will be offered choice of PrEP (either TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Those receiving oral PrEP will be able to choose between event-driven and daily PrEP with the emphasis on coital coverage by PrEP.
223972172|NCT01106365|DEVICE|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
223972173|NCT05493098|OTHER|dry needling|"The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more Dry needling:~The method of performing the dry needling technique will be based on the methods presented by Dommerholt and Fernandez-de-Las-Penas. One length of sterile, disposable 0.30 mm x 30 mm solid filament needle (Tony, China) will be used. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes."
223972174|NCT05493098|OTHER|sham (placebo) dry needling:|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
224114834|NCT02940054|OTHER|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
224114835|NCT03955107|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
224114836|NCT00480753|DRUG|Nitroglycerin|
224114837|NCT04405804|DRUG|Ivabradine 5Mg Tab|"Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg"
224114838|NCT00373971|BEHAVIORAL|Involving the patients in their own nutritional care|
224114839|NCT02653378|BEHAVIORAL|DIET|25% Energy Depletion by Diet only for 3 Days
224114840|NCT02653378|BEHAVIORAL|EX|25% Energy Depletion by Exercise only for 3 Days
224114841|NCT05264571|DIAGNOSTIC_TEST|calscreener|The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.
224114842|NCT05264571|OTHER|Metabolic profile|"The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria"
224114843|NCT05264571|OTHER|optical microscopy|To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture
224114844|NCT05264571|OTHER|RTqPCR|To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
224114845|NCT01626183|GENETIC|RNA analysis|
224114846|NCT01626183|GENETIC|proteomic profiling|
224114847|NCT01626183|OTHER|laboratory biomarker analysis|
224114848|NCT03090620|DRUG|Physostigmine|Administration of physostigmine bolus followed by an infusion
224114849|NCT03090620|DRUG|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
224114850|NCT00109317|DRUG|Raptiva (efalizumab)|
223725171|NCT01516931|BEHAVIORAL|counseling|Placebo monthly by general counseling for 12 months.
223725172|NCT01327885|DRUG|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
224114851|NCT00003750|BIOLOGICAL|hu14.18-IL2 fusion protein|
224114852|NCT04081883|OTHER|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
224114853|NCT02662777|DEVICE|Eso-SPONGE® vacuum treatment|
224114854|NCT05925114|DRUG|S-309309|Administered as oral capsules
224114855|NCT05925114|DRUG|Placebo|Administered as an oral capsule that looks identical to S-309309 capsule
224114856|NCT00003386|BIOLOGICAL|BCG vaccine|
224114857|NCT00003386|BIOLOGICAL|autologous tumor cell vaccine|
223972175|NCT04338230|OTHER|Progressive muscle relaxation exercise|"Relaxation Exercises CD Audio Records prepared by Turkish Psychological Association is used. Before starting the PMR exercises, the woman in the intervention group is provided to lie on a comfortable seat or bed, stretching the muscles of the face and all body for about 10 seconds starting from the hands to the foot in line with the sound recordings of the PKG exercises and then holding the deep breath while each muscle group is stretching, It is applied as a slow release of this breath during relaxation. In this way, the muscle groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, the face and the whole body are tensioned and relaxed, and the woman is relaxed. During the eight-week period, the women are called by the researcher once a week and the exercises are reminded. Home visit There are 2 home visits at week 1 and at week 8. In case of need, repeated home visits are provided to ensure the continuity of the application."
223972176|NCT03140566|DIAGNOSTIC_TEST|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index \>50% in addition to relief of symptoms and signs of congestion before discharge.
223972177|NCT03140566|DIAGNOSTIC_TEST|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
223972178|NCT01628406|PROCEDURE|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
223972179|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
224114858|NCT00003386|DRUG|carboplatin|
224114859|NCT00003386|DRUG|cisplatin|
224114860|NCT00003386|DRUG|cyclophosphamide|
224114861|NCT00003386|DRUG|paclitaxel|
224114862|NCT00003386|OTHER|dinitrophenyl|
223972180|NCT03924947|DRUG|Pancrelipase|Delayed release capsules
223972181|NCT03962764|BEHAVIORAL|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
223972182|NCT02674009|DRUG|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
224114863|NCT00003386|PROCEDURE|surgical procedure|
224114864|NCT00302237|DEVICE|RX ACCULINK, RX ACCUNET Embolic Protection System|1\) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
224114865|NCT00589472|DRUG|Bicalutamide|Given PO
224114866|NCT00589472|DRUG|Goserelin Acetate|Given SC
224114867|NCT00589472|OTHER|Laboratory Biomarker Analysis|Correlative studies
224114868|NCT00589472|DRUG|Leuprolide Acetate|Given IM
224114869|NCT00589472|PROCEDURE|Therapeutic Conventional Surgery|Undergo radical prostatectomy
224114870|NCT00589472|DRUG|Vorinostat|Given PO
224114871|NCT00330824|DRUG|antibiotic/steroid combination|1gtt, 4x/d, 15 days
224114872|NCT00330824|DRUG|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
224114873|NCT03469245|OTHER|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
224114874|NCT05000580|PROCEDURE|Surgical|Conservative vs surgical management
224114875|NCT02320799|BEHAVIORAL|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
224114876|NCT02320799|BEHAVIORAL|treatment as usual|Clinic psychosocial treatment as usual
224114877|NCT05876650|OTHER|Pilates exercises|Pilates exercises starts with warm up, followed by 6 main exercises that are Swan, Swimming, Prone press up, Dart, Arm arch and Scarecow. The session will end with the cool down exercises. Each exercise will be repeated 10 times for 5 sets. Patients will be treated 3 times per week for 4 consecutive weeks.
224114878|NCT05876650|OTHER|Yoga|Yoga will start with warm up followed by 6 yoga poses which are Warrior pose 1, Triangle pose, Child pose, Cow face pose, Bound angle pose, half bow poseThe session will end with a cool down pose. Each yoga pose will be held for 8-10 breathes Patients will be treated 3 times per week for 4 consecutive weeks.
224114879|NCT02968043|OTHER|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
224114880|NCT02968043|OTHER|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
224114881|NCT01667575|DRUG|Esomeprazole|antisecretary drug of the quadruple therapy
224114882|NCT01667575|DRUG|Amoxicillin|antibiotic of the quadruple therapy
224114883|NCT01667575|DRUG|Clarithromycin|antibiotic of the quadruple therapy
224114884|NCT01667575|DRUG|Bismuth Potassium Citrate|one of a component of a quadruple therapy
224114885|NCT01667575|OTHER|long duration (14 day)|
224114886|NCT04090931|PROCEDURE|Orthodontic treatment|leveling and aligning stage in orthodontics
224114887|NCT04534062|OTHER|PNF D2 technique|PNF D2 technique of bilateral upper limb will be performed
224114888|NCT03719560|DRUG|Methotrexate|Systemic methotrexate
224114889|NCT03719560|DRUG|Cytarabine|Systemic cytarabine
224114890|NCT01596842|DRUG|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
224114891|NCT01596842|OTHER|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
224292269|NCT01758341|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
224292270|NCT01758341|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
223972183|NCT03408223|RADIATION|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
224292271|NCT01758341|DEVICE|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
223972184|NCT03408223|RADIATION|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
223972185|NCT01907113|DRUG|BI 10773|oral administration
224292272|NCT04676815|PROCEDURE|NBI and interventional bronchoscopy|NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
223972186|NCT01907113|DRUG|BI 10773|oral administration
223972187|NCT01907113|DRUG|BI 10773|oral administration
223972188|NCT01907113|DRUG|BI 10773|oral administration
223972189|NCT01907113|DRUG|BI 10773|oral administration
223972190|NCT05173233|DEVICE|Transcatheter Annuloplasty|Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
224114892|NCT01596842|OTHER|cholecalciferol|if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
224114893|NCT06215898|OTHER|LSVT-BIG Group via Telerehabilitation|An aerobic supervised exercise protocol was implemented four times a week for four weeks in LSVT-BIG Group via a Tele-rehabilitation model.
224114894|NCT01967420|BEHAVIORAL|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
223972191|NCT01646528|PROCEDURE|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
223972192|NCT02869815|PROCEDURE|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
223972193|NCT01179906|BEHAVIORAL|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
223972194|NCT01179906|BEHAVIORAL|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
223972195|NCT00833898|DEVICE|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
223972196|NCT00833898|BEHAVIORAL|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development \& application of various stress-mgmt techniques such as effective problem-solving, identifying \& challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support \& goal setting.
224114895|NCT01967420|BEHAVIORAL|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
224114896|NCT06429683|OTHER|Sexually transmitted diseases training for young adolescents aged 17-21|Education
224114897|NCT05916677|OTHER|Virtual Reality-training in Theory of Mind|"Two social scenarios will be used in a virtual environement. Experimenter and subject participate in the scenario as friends of the main character, Nicolas. During the training session, experimenter asks structured questions about participant's awareness of a mental state. In the case of a wrong answer, a feedback-correction is provided via the avatar's thought bubbles. The participant has access to all avatars thought bubbles. In this way, he is able to compare the desires, beliefs or false beliefs of each story character.~Participants included in this condition will also have an eye-tracking assessment before and after the training procedure."
224292273|NCT05470933|DRUG|WJ01075|"Phase Ia: Dose Escalation Accelerated titration (the first two dose groups) and 3 + 3 combination (the subsequent dose group) were used for dose escalation.~Phase Ib: Dose Expansion and Cohort Expansion The actual dose, dosing schedule (including combination) and indication selection will be evaluated based on the results of existing trials."
223972197|NCT06446271|DIAGNOSTIC_TEST|Plasma biomarker levels|"This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.~Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines."
224292274|NCT00005119|PROCEDURE|Measures of calcium and bone turnover|
223972198|NCT00805285|DRUG|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
223972199|NCT00917462|DRUG|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
223972200|NCT00917462|PROCEDURE|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
223972201|NCT01402063|DRUG|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
223972202|NCT01402063|DRUG|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
223972203|NCT02080390|PROCEDURE|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
223972204|NCT05846438|OTHER|Showering 48 hours after surgery|The main intervention is allowing patients to shower 48 hours after surgery
223972205|NCT03879083|OTHER|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
223972206|NCT03879083|OTHER|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
223972207|NCT04482270|DRUG|fezolinetant|Oral
223972208|NCT00002878|DRUG|dexamethasone|
223972209|NCT00002878|DRUG|doxorubicin hydrochloride|
224292275|NCT02138981|PROCEDURE|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
223972210|NCT00002878|DRUG|valspodar|
223972211|NCT00002878|DRUG|vincristine sulfate|
223972212|NCT05698511|DRUG|Psilocybin|Multiple dosing of healthy volunteers with up to 25 mg psilocybin separated from each other by at least one week. Participants will be scanned before and after receiving psilocybin on each dosing day. Surveys will be performed on dosing days and after dosing.
223972213|NCT00255515|DRUG|Quetiapine fumarate|oral
223972214|NCT00255515|DRUG|conventional treatment for schizophrenia|various standard therapies
224292276|NCT02138981|PROCEDURE|Immediate Resection|patients received immediate surgical resection.
224292277|NCT00933283|DRUG|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
224292278|NCT00933283|DRUG|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
224114898|NCT05916677|OTHER|Traditional training in Theory of Mind|The same two social scenarios are presented to the participant in a story-telling form. Participant has access to thought bubbles via an illustrated book. These trainings will take place in the same number of sessions and took place for a duration equivalent to those used in low immersion Virtual Reality mode. Each training session (EFB, BE, SOFB, ERA, FP, EFP) will be illustrated via visual aids taken from screenshots of the two virtual environments and the target protagonists.
224114899|NCT02487628|DEVICE|HQ® Matrix Soft Tissue Mesh|
224114900|NCT02487628|DEVICE|ULTRAPRO® Partially Absorbable Lightweight Mesh|
224114901|NCT03075462|DRUG|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
224114902|NCT03075462|DRUG|Apatinib|Apatinib at 250mg once daily, tablet oral
224114903|NCT03808623|DEVICE|MAC with NOVOCART Basic|"NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called matrix associated chondrogenesis (MAC). It is a single-step procedure.~NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue."
224114904|NCT01640587|DRUG|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
224114905|NCT01640587|DRUG|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
224114906|NCT00149851|DRUG|Tegaserod|
224114907|NCT00904241|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224114908|NCT00904241|OTHER|Laboratory Biomarker Analysis|Correlative studies
224114909|NCT06027242|DIETARY_SUPPLEMENT|oral glutamine|10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
224114910|NCT06027242|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
224114911|NCT05357313|DEVICE|Bright light therapy|Exposure to 10,000lux bright light for 30minutes a day for six weeks
224292279|NCT01094028|DRUG|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
224292280|NCT02641002|DRUG|CC-90002|Monoclonal Ab to CD47
224292281|NCT04787770|OTHER|non-intervention|non-intervention
224292282|NCT04826068|BEHAVIORAL|Emotional Processing|Processing Emotions of others based on photographs of faces
224292283|NCT00308126|DRUG|Hydroxyethyl Starch 130/0.4 (Voluven)|
224292284|NCT04588688|DRUG|Mifepristone|Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
224292285|NCT04597489|PROCEDURE|Fractional flow reserve|Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.
224292286|NCT04597489|PROCEDURE|Angiography-only|Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.
224292287|NCT02346851|PROCEDURE|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
223972215|NCT00692523|OTHER|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
224292288|NCT05198388|DIAGNOSTIC_TEST|βeta endorphins, interleukin 6 and interleukin 38|"* \- Collection of peripheral blood samples in gel tube.~* \- Creparation of samples in centrifuge to obtain serum.~* \- Measurement of interleukin 6 and interleukin 38 and βeta endorphins using ELISA method."
224292289|NCT06502587|OTHER|blood flow restriction training|"we will apply blood flow restriction training with low intensity exercises like knee flexion ,knee extension and straight leg raise 10 repetitions 2 sets a day and 3 times/week a rest interval of 2 minutes between exercises, for 30 minutes of this whole procedure.~total 12 sessions given in 4 weeks each session of maximum 30 minutes"
224292290|NCT06502587|OTHER|ultrasound therapy|All subjects will be given Ultrasound therapy as per patient requirement with 1.5 Watts/cm\^2 in continuous mode around knee joint. Conservative exercises(quads isometric exercise, pillow squeeze, heel raise, straight leg raise and side leg raise) will be applied for 3 times per week (daily one set of 10 repetitions) They will be given this treatment for 3 times per week
224292291|NCT06616207|DRUG|Placebo|Placebo (Double distilled water matched in color and taste) will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
224292292|NCT06616207|DRUG|Povidone-iodine solution|Povidone-iodine solution will be applied topically by the graduate student to all tooth surfaces at the consultation appointment before the placement of fixed appliances and at 3, 6, and 9 months after appliance placement.
224292293|NCT06074302|DEVICE|RHA Redensity|RHA Redensity will be injected in a microdroplet technique to bilateral cheeks.
224292294|NCT04606836|DRUG|Bupivacaine Hydrochloride|See group descriptions
224292295|NCT05009732|DRUG|GT0918|300mg once daily orally
223972216|NCT00692523|OTHER|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
223972217|NCT03378895|BEHAVIORAL|online questionnaire|Risk assessment identified by online questionnaire
223972218|NCT00825643|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
224292296|NCT05009732|DRUG|Standard of care|Local standard of care per written policies or guidelines
224292297|NCT05009732|DRUG|Matching placebo|Matching placebo
223972219|NCT01535196|DRUG|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
223972220|NCT02375932|BEHAVIORAL|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
223972221|NCT02375932|BEHAVIORAL|Usual Care Control|Patients continue to receive usual care from their primary care provider
223972222|NCT01057888|OTHER|Autodialer|Autodialer telephone calls
223972223|NCT01057888|OTHER|Letters|Mailed reminder letters
223972224|NCT03794128|PROCEDURE|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
223972225|NCT03794128|PROCEDURE|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
223972226|NCT00076063|BIOLOGICAL|ALVAC-HIV (vCP1452)|experimental vaccine
223972227|NCT00076063|BIOLOGICAL|LIPO-5|experimental vaccine
223972228|NCT04845087|OTHER|Ozonized water|Irrigation of dental implants with ozonized water
223972229|NCT04845087|OTHER|Placebo|Irrigation of dental implants with water
223972230|NCT01631825|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
223972231|NCT05139576|DIAGNOSTIC_TEST|serum 25OHD testing|Subjects tested for serum 25OHD between April 2020 to March 2021 was reviewed daily and those with 25OHD levels \>150 ng/ml were contacted via telephone.
223972232|NCT02110225|DRUG|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
223972233|NCT02110225|DRUG|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
223972234|NCT02110225|DRUG|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
223972235|NCT01003379|DRUG|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
223972236|NCT01003379|DRUG|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
223972237|NCT02176018|DRUG|Dextromethorphan and quinidine|
223972238|NCT02176018|DRUG|Placebo|
223972239|NCT02982096|DEVICE|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
223972240|NCT02982096|OTHER|Standard of Care|Acellular burn wound management
223972241|NCT02157688|OTHER|no intervention : case control study|
224114912|NCT05357313|DEVICE|Inactive negative ion generator|Exposure to an inactive negative ion generator for 30 minutes a day for six weeks
224114913|NCT03233776|DRUG|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
224114914|NCT05527171|BEHAVIORAL|Virtual Reality Mindfulness Meditation|Participants will be immersed in a virtual environment of their choosing. While in the virtual environment, participants will follow a guided mindfulness meditation script. Participants will complete the intervention 3 times a week over the course of 8-weeks.
224114915|NCT05527171|BEHAVIORAL|Virtual Reality Sham|Participants will be immersed in a virtual environment of their choosing, such as at a beach, forest, or lake.
224114916|NCT01651052|PROCEDURE|Heart Valve Surgery|Implant of an aortic valve, Model 11000
224114917|NCT03819946|DEVICE|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
224114918|NCT03819946|OTHER|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
224114919|NCT03074448|DEVICE|Aquanet|Aquanet bowel cleansing devices
224114920|NCT03074448|DRUG|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
224114921|NCT04788199|OTHER|Closure of mesenteric defects using glue|Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
224114922|NCT06395142|OTHER|pedal walking|Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.
224114923|NCT06395142|OTHER|visual-deprivation walking|visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
224114924|NCT00012727|PROCEDURE|Matching Symptom Severity to Service Intensity|
224114925|NCT03100331|OTHER|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
224114926|NCT02898025|DEVICE|Active Interferential Current|Involves the application of medium frequency alternating currents
224114927|NCT02898025|DEVICE|Active Laser|Involves the application of low level laser over the knee
224114928|NCT02898025|DEVICE|Placebo Interferential Current|It is a sham interferential therapy
224114929|NCT02898025|DEVICE|Placebo Laser|It is a sham laser therapy
224114930|NCT01372111|DRUG|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
224114931|NCT01372111|RADIATION|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
223725173|NCT01327885|DRUG|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
223725174|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
223725175|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
223972242|NCT03967119|DEVICE|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/\[(PWmax+PWmin)/2\].
223972243|NCT03022045|DRUG|risankizumab|risankizumab administered by subcutaneous injection
223972244|NCT03436433|DRUG|Lacosamide|LCM 100mg twice a day.
223972245|NCT03436433|DRUG|Levetiracetam|LEV 1000mg twice a day.
223972246|NCT06143488|PROCEDURE|Endovascular therapy|"Drug: Best medical management All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.~Procedure: Endovascular therapy In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
223972247|NCT06143488|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
224114932|NCT04397393|DRUG|Midazolam|Dosage of Midazolam (in mg) needed to achieve satisfactory level of sedation to perform OPU
224114933|NCT06553378|OTHER|Geriatric Oncology Supportive Clinic|Subjects in the intervention arm will be seen within four weeks of recruitment. Clinical assessment involves a Comprehensive Geriatric Assessment (CGA) and Supportive Care Assessment conducted by a geriatric-oncologist. Both clinical assessments and targeted interventions are supported by a multi-disciplinary team comprising the geriatrician, geriatric trained nurse, physiotherapist, occupational therapist, speech therapist, pharmacist, dietician, and medical social worker. We will conduct an initial GOSC assessment, with a follow up review during oncology treatment. Subsequently, further GOSC clinic sessions duration of follow up will be determined by the subject's underlying disease, symptom burden and clinical course during treatment.
224114934|NCT05322863|DEVICE|High-definition Transcranial Direct Current Stimulation|The HD-tDCS will be administered by the program device called Starstim (Neuroelectrics). All participants will receive the treatment by using the same model of device. The HD-tDCS device can be portable and controlled wirelessly via computer software developed by the manufacturer. The montages will be a '4 × 1 ring set-up', which is the most commonly used HD-tDCS setting. The centre anode electrode is surrounded by four return cathode electrodes. The anode will be placed over the left dorsal lateral prefrontal cortex. Conductive electrode gel will be applied on the scalp at all designated electrode stimulation areas. A cap appropriate for each participants' head size will be used to ensure that the electrodes are secured in place. Impedance checks will be performed using the Starstim software before each treatment session.
224114935|NCT04770610|DRUG|OT-101 Ophthalmic Solution|Atropine 0.01%
224114936|NCT04770610|DRUG|Vehicle|Investigational Product minus active ingredient
224114937|NCT04795713|DRUG|MT-6402|Experimental Treatment
224114938|NCT03736083|DEVICE|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
224114939|NCT00057616|DRUG|CC-5013|
224114940|NCT02835638|DEVICE|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
224114941|NCT05490953|DRUG|Pentoxifylline|Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
224114942|NCT05490953|DRUG|Placebo|Patients will be treated with placebo during the first two chemotherapy cycles of their respective treatment.
224114943|NCT03249350|BEHAVIORAL|Standard Contingency Management (CM)|"CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
224292298|NCT02593227|BIOLOGICAL|Low dose FRα vaccine|165ug per peptide ID injection
224292299|NCT02593227|DRUG|Cyclophosphamide|IV infusion over 1 hour
224292300|NCT02593227|BIOLOGICAL|High dose FRα vaccine|500ug per peptide ID injection
224292301|NCT01671982|OTHER|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to \<50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
223972248|NCT01653171|DRUG|Water (Placebo)|Water 100 mL
223725176|NCT01027221|RADIATION|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
223725177|NCT02441777|DEVICE|Polarization-Sensitive OFDI|OCT Imaging of the eye
223972249|NCT01653171|DRUG|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
224114944|NCT03249350|BEHAVIORAL|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
224114945|NCT06004115|DRUG|Lorazepam|1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form
224114946|NCT06004115|OTHER|Placebo|placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form
223725178|NCT03015012|GENETIC|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
224292302|NCT00767520|DRUG|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
223972250|NCT01653171|DRUG|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
223972251|NCT01653171|DRUG|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
223972252|NCT02607345|DIETARY_SUPPLEMENT|Zusto|25gr
224114947|NCT01776268|OTHER|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
224114948|NCT00871858|DRUG|anastrozole|Given orally
224292303|NCT00767520|DRUG|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
224292304|NCT02172482|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
223972253|NCT02607345|DIETARY_SUPPLEMENT|Glucomedics®|25gr
223972254|NCT02499835|BIOLOGICAL|Pembrolizumab|Given IV
223972255|NCT02499835|BIOLOGICAL|pTVG-HP Plasmid DNA Vaccine|Given ID
223972256|NCT05109117|DRUG|CAP Unscented|Sunscreen lip balm.
223972257|NCT03972137|BEHAVIORAL|Cognitive-Behavioral Smoking Cessation|Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
223972258|NCT03972137|BEHAVIORAL|Heart Rate Variability Biofeedback (HRVB)|All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
223972259|NCT03972137|DRUG|Transdermal Nicotine patch|All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
224114949|NCT00871858|DRUG|fulvestrant|Given intramuscularly
224114950|NCT05533554|BEHAVIORAL|Brief Intervention Based on the Theory of Planned Behavior to Reduce Alcohol Consumption in University Students|Cognitive-behavioral intervention where the key concepts of the Theory of Planned Behavior were operationalized from which two intervention sessions were formed and the most appropriate techniques were chosen to influence the key concepts of the theory: behavioral beliefs, subjective norms, perceived behavioral control and self-efficacy. The program is made up of 3 evaluation sessions (pre and post a month later) and 2 intervention sessions with a duration of 120 minutes each.
224114951|NCT03758677|DRUG|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
224292305|NCT00722631|DRUG|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
224292306|NCT00722631|DRUG|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
223972260|NCT04481334|OTHER|Collaborative occupational therapy interactive vaulting group|Children will participate in a weekly 60 minute group that focuses on the devilment of social skills by incorporating activities that require team work. Part of the intervention will incorporate the equine to better understand non-verbal body language. It should be noted that each child will have two agreed upon goals developed that are agreed upon by the child and the parent and will be of emphasis during each group.
223972261|NCT01751451|DRUG|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
224114952|NCT01188798|DRUG|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
224292307|NCT06053762|BEHAVIORAL|Peer-facilitated tobacco cessation|Peer-facilitated tobacco cessation: Participants will be given the evidence-based N-O-T program curriculum for tobacco cessation classes and provided with virtual materials, information, and resources by their assigned peer facilitators. Virtual tobacco cessation peer motivation sessions will be offered using the digital online platform Zoom, and the peer facilitators will communicate with the participants in between the classes
223972262|NCT01751451|DRUG|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
224292308|NCT06053762|BEHAVIORAL|Self-navigated tobacco cessation|Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves. Self-navigated tobacco cessation: The participants in the self-navigated group will receive the same ALA N-O-T program curriculum and will complete the eight-week sessions, but it will be self-navigated and without peer facilitations. No peer facilitator will be assigned to this group and the participants will complete the curriculum by themselves.
224292309|NCT00841360|OTHER|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
224292310|NCT00841360|OTHER|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
224292311|NCT04729647|PROCEDURE|Mastectomy|Mastectomy for breast cancer Blood sample for Complete Blood Cell Count and other blood parameters (Delta Neutrophil Index, Immature Granulocyte Count)
224292312|NCT02777918|BEHAVIORAL|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
224292313|NCT00775541|DIETARY_SUPPLEMENT|Vitamin C|One IV infusion of 2 gm vitamin C
224292314|NCT01744119|DEVICE|Vascutek Anaconda™ Stent Graft System|
224292315|NCT00216645|DRUG|doxorubicin hydrochloride|
224292316|NCT04711720|DEVICE|"VTS surgical navigation system"|"TheVTS surgical navigation system can accurately match the preoperative and intraoperative image data with the patient's anatomical structure on the operating table, track the surgical instruments during the operation, and update the position of the surgical instruments on the patient's image in real time, so that the doctor can clearly understand the position of the surgical instruments relative to the patient's anatomical structure, and make the operation procedure more accurate and safer."
224292317|NCT00616174|PROCEDURE|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
224292318|NCT00416026|BEHAVIORAL|Educational/Counseling/Training|
224292319|NCT01882920|DRUG|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.
224292320|NCT01882920|DRUG|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
224292321|NCT01338987|PROCEDURE|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
224292322|NCT01338987|DRUG|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years
224292323|NCT01338987|DRUG|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
224292324|NCT01338987|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)
224292325|NCT01338987|DRUG|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
224292326|NCT01338987|DRUG|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
224292327|NCT01338987|RADIATION|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
224292328|NCT01338987|DRUG|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
224292329|NCT01338987|DRUG|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
224292330|NCT01338987|PROCEDURE|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
223972263|NCT01751451|DRUG|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
224114953|NCT01188798|DRUG|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
224114954|NCT02017249|DRUG|arginine in powder form|
224114955|NCT02017249|DRUG|Silica and cellulose placebo powder|
223972264|NCT00899379|DRUG|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
223972265|NCT00899379|DRUG|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
223972266|NCT02056600|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
224114956|NCT00999752|DRUG|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure \<140/90
224114957|NCT00999752|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
224114958|NCT06208709|DEVICE|carpal arch space augmentation (CASA)|A BOA brace with a balloon that is affixed internally. The device applies a small cyclic force of to the wrist. The cycles include a brief period of force applied, followed by a brief period of no force. The device is intended to be worn during hours of sleep.
224114959|NCT06208709|DEVICE|standard of care (SOC)|A BOA brace that can be adjusted to the arm of the participant.
223972267|NCT02056600|DRUG|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
223972268|NCT01906658|DRUG|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
224114960|NCT02795767|DRUG|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
224114961|NCT00199186|DRUG|imatinib|
224114962|NCT00199186|DRUG|vincristine|
224292331|NCT01700478|DRUG|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
224292332|NCT01700478|DRUG|Vasopressin|Vasopressin was used in all patients during surgery.
224114963|NCT00199186|DRUG|cyclophosphamide|
224114964|NCT00199186|DRUG|cytosine arabinoside|
224114965|NCT00199186|DRUG|dexamethasone|
224114966|NCT00199186|DRUG|idarubicin|
224114967|NCT00199186|DRUG|methotrexate (intrathecal)|
224114968|NCT00199186|DRUG|AraC (intrathecal)|
224114969|NCT00199186|DRUG|dexamethasone (intrathecal)|
224114970|NCT02553915|OTHER|Placebo|Soybean oil placebo
224114971|NCT02553915|DRUG|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
224114972|NCT02553915|DRUG|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
224114973|NCT02553915|DRUG|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
224114974|NCT01450371|DEVICE|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
224114975|NCT01450371|DEVICE|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
224114976|NCT04263922|DRUG|Huaiqihuang granules|Huaiqihuang granules, 2 bags at a time, 3 times a day. Valsartan capsule simulant, 80mg at a time, once a day. Oral administration.
224114977|NCT04263922|DRUG|Valsartan capsule|Valsartan capsule, 80mg at a time, once a day. Huaiqihuang granules simulant, 2 bags at a time, 3 times a day. Oral administration.
224114978|NCT02947139|DRUG|Co-administration of DWC20155/DWC20156|
224114979|NCT02947139|DRUG|DWC20161|
224114980|NCT04722133|DRUG|HERZUMA+mFOLFOX|Herzuma (Trastuzumab-pkrb) 4mg/kg after 6mg/kg loading D1 5FU 400mg/m2 bolus+2400mg/m2 infusion for 46 hrs D1 Leucovorin 200mg/m2 D1 Oxaliplatin 85mg/m2 D1 every 2 weeks
224114981|NCT01949493|DEVICE|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
224114982|NCT01949493|OTHER|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
224292333|NCT06205433|OTHER|IHSS Basic Training|The intervention is the Center for Caregiver Advancements 30-hour IHSS Basic training course.
223972269|NCT03865862|OTHER|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
223972270|NCT03865862|OTHER|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
224292334|NCT03166553|DRUG|Elemene|
224292335|NCT00757848|DRUG|AZD9668|60 mg, oral tablet, twice daily for 28 days
224292336|NCT00757848|DRUG|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
224292337|NCT00976794|DRUG|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
224292338|NCT00976794|DRUG|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
224292339|NCT00632086|DRUG|PA32540|
224292340|NCT00632086|DRUG|aspirin component of PA32540|The 325 mg aspirin component of PA32540
224292341|NCT00632086|DRUG|Ecotrin|325 mg Ecotrin
224292342|NCT02071953|DEVICE|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
224292343|NCT02071953|DEVICE|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
223972271|NCT02127814|DIETARY_SUPPLEMENT|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
223972272|NCT03220776|DRUG|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
223972273|NCT03220776|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
224292344|NCT06166784|DEVICE|Mectascrew B|reconstruction of ACL or PCL rupture
224292345|NCT02116517|DIETARY_SUPPLEMENT|green tea extract|500 mg three times per day
224292346|NCT02116517|DIETARY_SUPPLEMENT|Placebo|cellulose 500mg three times a day for 6 weeks
224292347|NCT06601621|COMBINATION_PRODUCT|electroacupuncture+ self-acupressure|"Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi; is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2/10Hz for 30 minutes. self-acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi; for three minutes."
223972274|NCT03220776|DRUG|Placebo Oral Tablet|5 day trial of matched placebo
223972275|NCT05939089|DIAGNOSTIC_TEST|ECG, Echocardiography, cTnI, NT-ProBNP|All pediatric cancer survivors are evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.
223972276|NCT05723289|DEVICE|MI-E Telemonitoring|Daily telemonitoring using a ad-hoc communicating device
223972277|NCT03362684|DRUG|Cetuximab|Cetuximab every 2 weeks
223972278|NCT03362684|DRUG|FOLFOX|FOLFOX-4 every 2 weeks
223972279|NCT05262439|DEVICE|New generation CPAP mask|All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
223972280|NCT01608958|DRUG|Oxytocin|10 IU oxytocin in 500 ml infusion
223972281|NCT01608958|DRUG|Oxytocin|10 IU oxytocin IM injection
223972282|NCT06244706|COMBINATION_PRODUCT|Opioid drug + CNS-acting add-on drug|Patients suffering from persistent pain (pain lasting for at least three months), already treated with an opioid medication (treatment A) and to whom the treating physician is about to prescribe a CNS-acting add-on drug such as an antiepileptic, an antidepressant, a benzodiazepine or an alpha2-agonist (treatment B: the combination treatment).
223972283|NCT06537141|PROCEDURE|selective embolization of thyroid arteries (SETA)|selective embolization of thyroid arteries
223972284|NCT03226353|DEVICE|somofilcon A|contact lens
223972285|NCT03226353|DEVICE|omafilcon A|contact lens
223972286|NCT01797822|DRUG|Dexamethasone|
223972287|NCT01797822|DRUG|Artificial tear|
223972288|NCT03441789|DRUG|Enstilar|Enstilar foam applied to affected areas daily
223972289|NCT03441789|DRUG|Vehicle|vehicle foam applied to affected areas once daily
223972290|NCT03441789|DRUG|Otezla|Otezla 30mg
223972291|NCT01659177|DRUG|LY2140023|Administered orally
223972292|NCT01780545|DRUG|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
223972293|NCT01780545|DRUG|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
223972294|NCT01367613|DRUG|SC Methylnaltrexone|
223972295|NCT03138616|DRUG|vitamin D|take 1600 units of vitamin D daily for nine months
223972296|NCT02821689|DRUG|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
223972297|NCT04318587|DIAGNOSTIC_TEST|Allosure|Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
223972298|NCT00215631|DRUG|tadalafil|
223972299|NCT04297839|DRUG|Citrate Anticoagulation Solution|Regional citrate anticoagulation in extended hemodialysis sessions compared to the standard of care actually performed in these therapies (heparin or continuous saline infusion)
223972300|NCT04297839|DRUG|Control Group (heparin or continuous saline)|Use of heparin in hemodialysis sessions. If there is any contraindication against the use of heparina, the investigators will perform saline flush of the dialysis system
223972301|NCT03192202|DRUG|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
223972302|NCT03696732|OTHER|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
224114983|NCT01571674|PROCEDURE|Manipulation + Exercise Group|"First 2 sessions~* High-velocity, low-amplitude manipulations to the thoracic spine.~* Low-velocity mid to end-range mobilizations to the cervical spine.~* Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
224292348|NCT06601621|COMBINATION_PRODUCT|sham electroacupuncture + sham self-acupressure|"Sham electroacupuncture: The sham electroacupuncture shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi; sensation. Sham self-acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
224292349|NCT00488813|DRUG|Third generation cephalosporins|
224292350|NCT00058214|DRUG|perifosine|Given orally
224292351|NCT00058214|OTHER|laboratory biomarker analysis|Correlative studies
224292352|NCT06616350|DEVICE|esTOCma: an app to fight stigma associated with OCD|The intervention consists of playing a serious game, called esTOCma, on a mobile phone. In the game, players must use their knowledge to battle the stigma monster of OCD, complete 10 missions, and release 10 individuals who have been afflicted by the esTOCma monster, a creature that feeds on false beliefs and misinformation in society.
224292353|NCT05279508|BEHAVIORAL|Make My Day - stroke prevention program|A stroke prevention program within primary healthcare
224292354|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
224292355|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.
224292356|NCT04352608|BIOLOGICAL|Two doses of placebo at the emergency vaccination schedule|Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
223972303|NCT03696732|OTHER|VAS questionnaire|verbal numerical scale (VNS) anxiety score
223972304|NCT02581189|DRUG|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
223972305|NCT02581189|DRUG|Dasabuvir|Tablet
223972306|NCT02581189|DRUG|Ribavirin|Tablet
223972307|NCT00004740|DRUG|isoniazid|
223972308|NCT04092621|DRUG|Amiodarone in Parenteral Dosage Form|Amiodarone IV
224114984|NCT01571674|PROCEDURE|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
224114985|NCT01534832|DEVICE|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
224114986|NCT05308485|OTHER|Events exposure questionnaire|Events exposure questionnaire that assess the occurrence of exposure to events and their severity over a limited period
224114987|NCT00233636|DRUG|Iressa (Gefitinib)|
224114988|NCT00233636|PROCEDURE|Radiotherapy|
223972309|NCT04092621|DRUG|Amiodarone Pill|Amiodarone tablet
223972310|NCT04092621|PROCEDURE|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
223972311|NCT04092621|DRUG|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
223972312|NCT04024371|BEHAVIORAL|Self-rating Questionnaires|"* Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~* Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~* Behavioral avoidance/inhibition Scales (BIS/BAS)"
223972313|NCT04024371|BEHAVIORAL|Measures of Reward processing/reinforcement learning|"* Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~* Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~* Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
223972314|NCT04024371|BEHAVIORAL|Additional Schizophrenia-specific Questionnaires and Interviews|"* Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~* Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
223972315|NCT04361916|OTHER|home care monitoring|home care active monitoring of patients with suspected of confirmed COVID-19
223972316|NCT03402321|DRUG|Gelatin Sponge Sheet|sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
223972317|NCT03402321|DRUG|Alvogyl|paste form with analgesic action to protect the palatal donor site and help to relief pain
223972318|NCT03845335|DEVICE|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
223972319|NCT02399683|BIOLOGICAL|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
224114989|NCT03662334|DRUG|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
224114990|NCT03662334|DEVICE|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
224114991|NCT03061968|BEHAVIORAL|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
224114992|NCT01564654|DEVICE|iTotal KRS|Total Knee Replacement System
223972320|NCT03487341|OTHER|Cord drainage|Cord drainage
223972321|NCT03487341|OTHER|Cord clamping|Cord clamping
223972322|NCT04836338|DEVICE|orotracheal intubation|orotracheal intubation
223972323|NCT01615107|DEVICE|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
223972324|NCT01615107|DRUG|PITOCIN|: Oxytocin infusion alone (Standard Protocol
223972325|NCT01615107|OTHER|double balloonand oxytocin|balloonand oxytocin
223972326|NCT01615107|OTHER|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
223972327|NCT01615107|PROCEDURE|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
223972328|NCT02874248|DRUG|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
223972329|NCT02874248|DRUG|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
223972330|NCT02874248|DRUG|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
223972331|NCT02874248|DRUG|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
224114993|NCT01016483|DRUG|Pimasertib|
224114994|NCT01016483|DRUG|Gemcitabine|
224114995|NCT01016483|DRUG|Placebo|
224292357|NCT04352608|BIOLOGICAL|Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.
223972332|NCT02874248|DRUG|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
224114996|NCT01379443|OTHER|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
224114997|NCT04135261|DRUG|HBM4003|Intravenous (IV) administration
224114998|NCT00898261|GENETIC|microarray analysis|
224114999|NCT00898261|GENETIC|reverse transcriptase-polymerase chain reaction|
224115000|NCT00898261|OTHER|flow cytometry|
224115001|NCT02805088|OTHER|Electroencephalographic recordings|
224115002|NCT02805088|OTHER|neuropsychological evaluation|
224115003|NCT02805088|OTHER|clinical evaluation of symptoms|
224115004|NCT00000711|DRUG|Zidovudine|
223972333|NCT01873573|PROCEDURE|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
223972334|NCT01873573|OTHER|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
223972335|NCT01873573|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
223972336|NCT03348969|DRUG|Mitomycin c|Neoadjuvant Mitomycin C
223972337|NCT00470171|DRUG|Ursodesoxycholic acid|
223972338|NCT02210611|PROCEDURE|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
224115005|NCT00000711|DRUG|Sargramostim|
224115006|NCT02305251|OTHER|Survey|Standard Gamble Survey
224115007|NCT01294254|DRUG|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
224292358|NCT04352608|BIOLOGICAL|Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ
224292359|NCT04352608|BIOLOGICAL|Two doses of placebo at the routine vaccination schedule|Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.
224292360|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
223972339|NCT02210611|PROCEDURE|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
223972340|NCT05065164|DRUG|Denosumab Only Product|denosumab subcutaneous injection /6 months, twice a year
224115008|NCT01294254|PROCEDURE|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
224115009|NCT03288584|DRUG|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
224115010|NCT03288584|DRUG|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
224115011|NCT03288584|DRUG|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
224115012|NCT00691197|DEVICE|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
224115013|NCT00691197|DEVICE|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
223972341|NCT04066400|OTHER|Nutritional Intervention|Dietary Counselling
223972342|NCT00937456|PROCEDURE|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
223972343|NCT03551197|DRUG|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
224115014|NCT05908383|DRUG|GMDTC for injection|GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
224292361|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42
223972344|NCT00465907|DRUG|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
224115015|NCT05908383|OTHER|Normal saline|0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
224115016|NCT00614003|BEHAVIORAL|Decision support skills building Intervention|Decision support skills
224115017|NCT06192446|DRUG|Survey using a questionnaire.|An observational study conducted in a cross-sectional manner using a questionnaire.
224292362|NCT04352608|BIOLOGICAL|Three doses of placebo at the emergency vaccination schedule|Three doses of placebo at the schedule of day 0,14,42
224292363|NCT04352608|BIOLOGICAL|Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
224292364|NCT04352608|BIOLOGICAL|Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
223972345|NCT02604485|DRUG|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
223972346|NCT02604485|DRUG|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
224115018|NCT02896426|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
224115019|NCT02896426|BEHAVIORAL|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
224115020|NCT00287833|OTHER|placebo|Given orally
223972347|NCT02604485|DRUG|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
223972348|NCT02604485|DRUG|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
223972349|NCT05845840|DRUG|BRII-297|Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
224115021|NCT00287833|DRUG|Bowman-Birk inhibitor concentrate|Given orally
224115022|NCT04209868|DRUG|Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL Injection|As per arm description
224115023|NCT04209868|DRUG|0.9% Sodium Chloride 20mL Injection|As per arm description
224115024|NCT03465852|BEHAVIORAL|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
224115025|NCT06109116|OTHER|Self myofascial release+ Conventional PT|The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility
224115026|NCT06109116|OTHER|Conventional PT|"Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins"
224115027|NCT03236350|DEVICE|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
223972350|NCT05845840|DRUG|Placebo|Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
223972351|NCT00797511|BIOLOGICAL|TdcP-IPV vaccine|0.5 mL, Intramuscular
223972352|NCT00979329|OTHER|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
223972353|NCT03471897|DIAGNOSTIC_TEST|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
223972354|NCT02666170|DRUG|Alpha-lipoic acid|
223972355|NCT00843115|OTHER|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
223972356|NCT04310527|DRUG|Enasidenib|Enasidenib
223972357|NCT02934542|DEVICE|AutoLap system|
224115028|NCT03236350|DEVICE|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
224115029|NCT03127202|DEVICE|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
224115030|NCT04981340|BEHAVIORAL|Diaphragmatic breathing|Same as previously described
223972358|NCT06460181|DIETARY_SUPPLEMENT|Astaxanthin|Manufactured by AstaReal Inc
223972359|NCT06460181|DIETARY_SUPPLEMENT|Placebo|Manufactured by AstaReal Inc
223972360|NCT01037413|DRUG|EXC 001|Multiple intradermal injections of EXC 001 and placebo
223972361|NCT01037413|DRUG|Placebo|Multiple intradermal injections of EXC 001 and placebo
223972362|NCT01593436|BEHAVIORAL|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
223972363|NCT04262778|DIAGNOSTIC_TEST|electrochemical skin conductance measurement|electrochemical skin conductance measurement
223972364|NCT06312995|DEVICE|T3DDY01|Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.
223972365|NCT06312995|DEVICE|PLASTER|Standard treatment plaster for fractures.
223972366|NCT05215418|DRUG|VI-0521|Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
223972367|NCT05215418|DRUG|Phentermine|Phentermine 30 mg capsule
223972368|NCT05215418|DRUG|Placebo|Inactive oral capsule
223972369|NCT01359878|DRUG|Fibrinogen Concentrate|2 gram intra venous
224115031|NCT04981340|BEHAVIORAL|Standard urotherapy|Same as previously described
223972370|NCT01359878|DRUG|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
224115032|NCT05387395|OTHER|NO intervention|no intervention
224115033|NCT02083445|OTHER|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
224115034|NCT02083445|OTHER|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
223972371|NCT02188277|DRUG|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
223972372|NCT02188277|DRUG|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
223972373|NCT04623359|DEVICE|High resolution manometry|High resolution manometry
223972374|NCT01002911|DRUG|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
223972375|NCT01002911|DRUG|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
223972376|NCT01218295|DEVICE|Spirotiger®|training session :10 minutes twice a day X 4 weeks
223972377|NCT05730517|DIETARY_SUPPLEMENT|CP5HA|Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
223972378|NCT05730517|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.
223972379|NCT05730517|DIETARY_SUPPLEMENT|CP5|Test group 2 will receive investigational product 2 containing collagen (5 g/ 15 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 16 weeks.
224115035|NCT02083445|DEVICE|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
224115036|NCT02083445|OTHER|Intermittent hypobaric hypoxia|
224115037|NCT05780853|DIAGNOSTIC_TEST|Tablet Game-based Assessment - YARN assessment service|Tablet game-based assessment to assess neurodevelopmental profile.
224115038|NCT05780853|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System, Third Edition (ABAS-3)|A parent-reported child behavioural assessment questionnaire used to diagnose and classify various developmental, learning and behavioural disabilities and disorders.
224115039|NCT05780853|OTHER|Demographic questionnaire|Parent/carer and child's demographic data such as age, ethnicity, employment status, household income, medical history and education status.
224115040|NCT04558645|OTHER|Online Survey|Online surveys will be applied to all participants
223725179|NCT03015012|OTHER|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
223972380|NCT00619983|DRUG|donepezil|Group 1: Will receive donepezil 5mg once a day
223972381|NCT00619983|DRUG|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
223972382|NCT00619983|DRUG|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
223972383|NCT00619983|DRUG|placebo|Group 4: Will receive placebo pills
223972384|NCT00619983|DRUG|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
223972385|NCT02798913|DRUG|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
223972386|NCT02798913|DRUG|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
223972387|NCT04546659|OTHER|Retrowalking|Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed
224115041|NCT02864745|DEVICE|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
224115042|NCT02864745|OTHER|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
224115043|NCT04163146|DIAGNOSTIC_TEST|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
224115044|NCT05764798|DRUG|Experimental group: Shugan Jieyu Capsule combined with zolpidem|Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
223972388|NCT04546659|OTHER|Conventional Therapy|Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
223972389|NCT02520596|OTHER|Bioavailability of Raspberry polyphenols|
223972390|NCT05765890|OTHER|No treatment given|No treatment given
223972391|NCT00497692|DRUG|Lactoserum|
223972392|NCT04326153|DRUG|Sintilimab Injection|"Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total."
224115045|NCT05764798|DRUG|Control group: Placebo combined with zolpidem|Placebo and zolpidem orally for 8 consecutive weeks
224115046|NCT03464058|DRUG|BOS172767 tablets|Oral tablets
224115047|NCT03464058|DRUG|BOS172767 liquid capsules|Oral capsules
223972393|NCT02406495|DEVICE|filcon IV 1|contact lens
223972394|NCT02406495|DEVICE|ocufilcon D|contact lens
223725180|NCT06276439|PROCEDURE|Surgical removal of breast cancer and lymph nodes|The patients will undergo a surgical procedure to remove tumor tissue in the breast and its associated lymph nodes. No clinical decision is based on the imaging device tested.
223725181|NCT02003612|OTHER|Not applicable - observational study|No intervention exists as this is a retrospective observational study
223972395|NCT01624597|BEHAVIORAL|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
223972396|NCT01624597|BEHAVIORAL|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
223972397|NCT05110014|OTHER|Primary Care Office Visits|mPATH iPad program that contains self-administered screening items for depression, fall risk, and intimate partner violence
223972398|NCT02271685|OTHER|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
223972399|NCT02271685|OTHER|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
223972400|NCT02271685|OTHER|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
224115048|NCT03464058|DRUG|BOS172767 micronized capsules|Oral capsules
224115049|NCT03464058|DRUG|BOS172767 immediate release capsules|Oral capsules
224115050|NCT03464058|DRUG|BOS172767 matching placebo capsules|Oral capsules
224115051|NCT03464058|DRUG|BOS172767 matching placebo tablets|Oral tablets
224115052|NCT03464058|DRUG|Rabeprazole|Oral tablets
224115053|NCT03658330|DRUG|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
224115054|NCT04937894|DRUG|Tigecycline|Efficacy and safety of Tigecycline
224115055|NCT00840645|DRUG|YM178|Oral
224115056|NCT04830995|DIETARY_SUPPLEMENT|moderate restricted diet (1800-2000 kcal/day) for four weeks|high intensity interval training 3 sessions for four weeks
224115057|NCT02998008|BEHAVIORAL|high intensity interval training|
224115058|NCT05037903|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive and behavioral interventions aimed at increasing behavioral activation, and reducing procrastination and inattentive symptoms.
223972401|NCT02271685|OTHER|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
223972402|NCT00703105|BIOLOGICAL|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
223972403|NCT00582959|OTHER|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
223972404|NCT05273177|OTHER|Chronic ankle instability|Persistent condition of ankle instability after a first ankle sprain episode.
223972405|NCT02228135|DRUG|Dexamethasone|
223972406|NCT03371485|BIOLOGICAL|AST-VAC2|Allogeneic dendritic cell vaccine.
223972407|NCT02723305|OTHER|No intervention|
223972408|NCT02204319|DEVICE|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
223972409|NCT03228277|DRUG|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
223972410|NCT05500898|DRUG|DWP16001|Tablets, Oral, multiple doses of DWP16001
223972411|NCT05500898|DRUG|DWC202204+DWC202205|Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination
223972412|NCT05500898|DRUG|DWP16001+DWC202204+DWC202205|Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination
223972413|NCT02046798|DRUG|ASP3652|oral
223972414|NCT05428592|BIOLOGICAL|LVRNA009|50μg /0.5 mL/Vial/person
223972415|NCT05428592|BIOLOGICAL|CoronaVac®|0.5 mL/Vial, 0.5mL per human dose containing 600SU of inactivated SARS-CoV-2 antigen
223972416|NCT03630692|DRUG|observance of oral drug treatment|Completion of questionnaires at 4 times during patient's oral route drug treatment
223972417|NCT02853305|BIOLOGICAL|Pembrolizumab|IV infusion
223972418|NCT02853305|DRUG|Cisplatin|IV infusion
223972419|NCT02853305|DRUG|Carboplatin|IV infusion
223972420|NCT02853305|DRUG|Gemcitabine|IV infusion
223972421|NCT02805985|DEVICE|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
223972422|NCT01947153|DRUG|Metformin|Free combination
223972423|NCT01947153|DRUG|Linagliptin|Fixed dose combination
224115059|NCT04742465|OTHER|Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.|"Augmented reality technological assistance for the movements of people with Alzheimer's disease or MCI in a controlled environment.~The ARIADE project will take place in a controlled and reproducible ecological environment (Ker Lann gymnasium) and will aim at assessing the effectiveness of Augmented Reality assistance, that of the devices for detecting wandering, the safety of the patient when traveling with an Augmented Reality headset, and his acceptance of the device.~Three routes each comprising seven intersections, i.e. a location requiring a decision on navigation, will allow us in 20 patients to objectively compare the three different visual aids offered in augmented reality, i.e. arrows, light path, animated companion."
224115060|NCT01097330|PROCEDURE|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
224115061|NCT01097330|DRUG|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
224115062|NCT00717418|DRUG|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
224115063|NCT03483688|BIOLOGICAL|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
224115064|NCT05868993|DRUG|Dose of 0.5% Ropivacaine|Dose varied by 5mL of 0.5% Ropivacaine
224115065|NCT02796690|OTHER|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
223972424|NCT01947153|DRUG|Metformin|Combination
223972425|NCT01947153|DRUG|Linagliptin|Free combination
223972426|NCT00644956|DRUG|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
223972427|NCT00644956|DRUG|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
224115066|NCT00174161|BEHAVIORAL|self-care, health behavior|
224115067|NCT06248320|PROCEDURE|Sigh ventilation|Sigh breaths were delivered from intubation to extubation. Intervention primarily conducted in the following three stages: 1. From intubation to surgical opening of the chest cavity; 2. From the surgical closure of the chest cavity close and continue unit the operating room exiting; 3. From Intensive Care Unit (ICU) arrival to Spontaneous breathing trial (SBT) start.
224115068|NCT05297539|OTHER|Point light display|Visualization of point-light human actions
224115069|NCT03309670|OTHER|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
223972428|NCT00280020|BEHAVIORAL|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
223972429|NCT00280020|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
223972430|NCT00280020|BEHAVIORAL|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
223972431|NCT02510053|DRUG|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
223972432|NCT03883698|DRUG|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
223972433|NCT03883698|DRUG|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
223972434|NCT05503693|DRUG|AP303 50 μg|AP303 tablet
223972435|NCT05503693|DRUG|AP303 150 μg|AP303 tablet
223972436|NCT05503693|DRUG|AP303 300 μg|AP303 tablet
223972437|NCT05503693|DRUG|AP303 600 μg|AP303 tablet
223972438|NCT05503693|DRUG|Placebo 50 μg|Placebo tablet
223972439|NCT05503693|DRUG|Placebo 150 μg|Placebo tablet
223972440|NCT05503693|DRUG|Placebo 300 μg|Placebo tablet
224115070|NCT05808088|OTHER|Hypnotherapeutic sound-files|The participants have access to hypnotherapeutic sound files which they can use as the please.
224115071|NCT01828827|DRUG|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
224115072|NCT04807946|PROCEDURE|lower third molar extraction|"All surgeries were performed by the same expert surgeon (RP), with the buccal approach using local anesthesia, and included the following maneuvers:~* luxation of the coronal portion of the tooth/root in an ipsilateral or parallel direction with respect to the IAN position and running, in order to minimize nerve compression;~* post-extraction residual bone cavity inspection using a Zeiss 4x300 magnification optical system to better identify intra-operative nerve exposure.~No material was inserted into the residual cavity, neither by regeneration nor by haemostasis.~After one week, sensitivity was tested on both sides with the tactile test using a 27-gauge needle tip and, if a difference was found, the patient was followed up once a week for the first month and every two weeks thereafter, until he/she reported to perceive the pin-prick test in the affected side the same way as the healthy side."
224115073|NCT00319618|DRUG|Gefitinib|
224115074|NCT00319618|DRUG|Docetaxel|
224115075|NCT01104818|BEHAVIORAL|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
224115076|NCT05887856|OTHER|comprehensive educational program for reduction of Pre-Operative Anxiety|"BSEP 1 makes use of modern media and aims to educate patients and their carers through educational videos comprising of various aspect of surgical treatment.~1. Introduction to surgery by consultant surgeon, Patient to receive video of their own surgeon.~2. Introduction to Anesthesia.~3. What are different type of breast surgeries in cancer patients (General Video)~4. Specific video pertaining to the type of surgery patient is undergoing (Mastectomy, Breast Conserving Surgery, Breast Re Construction surgery)~5. Explanation of Methicillin-resistant Staphylococcus aureus Decolonization protocol~6. What to expect on Surgery Day~7. Virtual tour of Holding bay and Operation Room~8. Post-Operative care including wound care, drain management and common post-operative complications."
224115077|NCT02967523|DEVICE|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
224115078|NCT06172543|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants were assigned to ingest a single serving daily of either A) a 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb); or B) a 25-gram dose of Whey Protein Isolate + 25-gram dose of carbohydrate powder + 5-gram dose of creatine monohydrate (Creatine) for a 17-21-day period.
224292365|NCT04352608|BIOLOGICAL|Three doses of placebo at the routine vaccination schedule|Three doses of placebo at the schedule of day 0,28,56
223972441|NCT05503693|DRUG|Placebo 600 μg|Placebo tablet
223972442|NCT02036255|DRUG|Taurolidine Urokinase|
223972443|NCT02036255|DRUG|Taurolidine Heparin|
224292366|NCT05283603|DIAGNOSTIC_TEST|ECG, Echocardiogram, Magnetic resonance|Clinical and instrumental follow-up
224292367|NCT01906359|OTHER|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
223972444|NCT04778787|DRUG|Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)|Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy
223972445|NCT03600649|DRUG|Seclidemstat|Twice daily administration of seclidemstat
223972446|NCT03600649|DRUG|Cyclophosphamide|250 mg/m2/day on Days 1 thru 5 of a 21-day cycle
223972447|NCT03600649|DRUG|Topotecan|0.75 mg/m2/day on Days 1 thru 5 of a 21-day cycle
223972448|NCT04561167|OTHER|Cuspal reduction in MOD cavity in endodontically treated teeth|Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.
223972449|NCT04561167|OTHER|No cuspal reduction in MOD cavity in endodontically treated teeth|In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
223972450|NCT03008304|DRUG|High-activity natural killer|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
224115079|NCT06172543|DIETARY_SUPPLEMENT|Control|A 25-gram dose of whey protein isolate + 25-gram dose of carbohydrate powder (ProCarb)
224115080|NCT00083824|DRUG|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
224115081|NCT00083824|DRUG|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
224115082|NCT00083824|DRUG|Placebo|2 pills/day QID for 3 years
224115083|NCT06858800|PROCEDURE|LTRI technique|"Hematoma distraction Artroplasty (HDA): A dorso-radial incision in the CMC joint was used in order to perform a trapezectomy. The thumb was displaced at its anatomical position (subtle opposition with 30º abduction) and fixed percutaneously with a 1.5mm K-Wire for three weeks along with a cast. This allowed to act the postoperative hematoma as an interposition between first-metacarpal and the scaphoid.~Ligament reconstruction with tendon interposition (LRTI): A complete removal of the trapezium bone with a radial-volar incision was made with posterior resection of the articular surface of the first metacarpal bone, and ligament transfer with a loop from hemi-tendonectomy of the flexor carpi radialis (FCR) was used to cushion the joint while occupying the space of the resected bone following modified Weilby Garcia-Elias technique"
224115084|NCT06858800|PROCEDURE|HDA technique|A dorso-radial incision in the CMC joint was used in order to perform a trapezectomy. The thumb was displaced at its anatomical position (subtle opposition with 30º abduction) and fixed percutaneously with a 1.5mm K-Wire for three weeks along with a cast. This allowed to act the postoperative hematoma as an interposition between first-metacarpal and the scaphoid
224115085|NCT05616390|DRUG|Sintilimab|200mg IV d1,Q3W
224115086|NCT05616390|DRUG|Bevacizumab|7.5mg/kg IV d1,Q3W
224115087|NCT05616390|COMBINATION_PRODUCT|Liver Protective Support Therapy|Medical treatment such as liver protection therapy, antiviral therapy, platelet and granulocyte upgrading therapy
224292368|NCT01906359|OTHER|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
224292369|NCT01906359|OTHER|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
224292370|NCT04608799|DRUG|Perampanel|Efficacy of epilepsy drugs
224292371|NCT00442754|BIOLOGICAL|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
224292372|NCT00121147|DRUG|Travatan|
224292373|NCT00121147|DRUG|Azopt|
224292374|NCT00121147|DRUG|Alphagan P|
224115088|NCT03945331|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
224115089|NCT03945331|DEVICE|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
224115090|NCT04663035|DRUG|Tislelizumab|200mg, iv. drip, Q3W. Tislelizumab will start within 3-7 days after ablation treatment. The longest course of treatment is 12 months.
224115091|NCT04663035|PROCEDURE|Ablation|After local anesthesia and intravenous sedative injection, the unipolar needle would be gradually inserted into the lesion and placed on the deepest edge of the lesion. The ablation electrode is a unipolar needle with a bare end of 2 or 3 cm (adjusted to tumor size). The ablation power is 150 watts (range from 100 to 200 watts). In general, the average ablation time for each lesion is about 12 minutes (ranging from 10 to 15 minutes).
224115092|NCT04512729|DIAGNOSTIC_TEST|Colonoscopy|"For all patients, either moderate sedation with intravenous midazolam or conscious sedation with intravenous propofol will be administered in a standard fashion prior to undergoing colonoscopy.~The colonoscope will be inserted and cecum will be intubated. Photo documentation of the cecum will be performed. The colonic mucosa will be carefully visualized upon withdrawal of the colonoscope.~The time spent in inspecting the mucosa during withdrawal of the colonoscope will be documented as the withdrawal time. Meticulous technique will be employed during the withdrawal phase with special efforts to visualize portions of colonic mucosa on the proximal aspects of haustral folds, flexures and valves.All polyps detected will be documented: size, location, and morphology. Photo documentation of the polyps will be performed."
224115093|NCT03531957|DRUG|ASN002|Daily dose of ASN002 for 12 weeks
224115094|NCT03531957|DRUG|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
224115095|NCT02095730|DRUG|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
224115096|NCT02095730|DRUG|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
224115097|NCT02095730|DEVICE|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
224115098|NCT02095730|DEVICE|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
224292375|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
224292376|NCT02191007|DRUG|Calcipotriol Betamethasone ointment|
224292377|NCT02191007|DRUG|Calcipotriol Betamethasone ointment and Urea Cream|
224292378|NCT00411398|DRUG|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
224115099|NCT03668548|DIETARY_SUPPLEMENT|Leucine|192 mg/kg body mass/day
224115100|NCT03668548|DIETARY_SUPPLEMENT|Placebo|A taste and calorie-matched placebo
224115101|NCT02467764|OTHER|Retrospective study|
224115102|NCT06085365|DRUG|Immunonutrition （Su yusu)|Immunonutrition （Su yusu） 250ml oral twice a day d1-d21
224115103|NCT06085365|DRUG|fluorouracil based chemotherapy regimens|fluorouracil based chemotherapy regimens
224115104|NCT02746679|OTHER|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
224115105|NCT02436798|DRUG|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
224115106|NCT06133010|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
224292379|NCT04478461|DRUG|PD-1 monoclonal antibody|"The enrollment mainly depends on 3+3 principle. A total of 3 or 4 dose groups will be evaluated during the dose escalation period: 1, 3, 10 mg/kg, and maybe an additional fixed dose (e.g., to evaluate 200 mg or other fixed dose as RP2D). The drug is scheduled to be administrated Q3W"
224292380|NCT02480582|OTHER|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\\kg
224292381|NCT02480582|OTHER|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
224292382|NCT02971982|DRUG|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
224292383|NCT02971982|DRUG|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
224292384|NCT05698927|PROCEDURE|Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)|Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
224292385|NCT04882982|BEHAVIORAL|Caria app|App to improve symptoms of menopause
224292386|NCT04882982|BEHAVIORAL|Menopause Education|Educational materials about symptoms of menopause
224292387|NCT00485927|BEHAVIORAL|stress|
224292388|NCT03757780|OTHER|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
224292389|NCT03313882|OTHER|no intervention is involved|
224115107|NCT06133010|BIOLOGICAL|Placebo|Sterile liquid for injection
224115108|NCT04125823|BEHAVIORAL|Video game-based physical activity training|"Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
224115109|NCT04125823|BEHAVIORAL|Conventional physiotherapy program|"A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
224115110|NCT00997412|DRUG|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
224292390|NCT06615791|BEHAVIORAL|FIT FIRST Teen|High intensity sports drills and games.
224292391|NCT01487382|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
224292392|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
224115111|NCT00997412|DRUG|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
224115112|NCT00501852|DRUG|NVA237|single-dose dry-powder inhaler (SDDPI)
224115113|NCT00501852|DRUG|Placebo|single-dose dry-powder inhaler (SDDPI)
224115114|NCT00501852|DRUG|Tiotropium|Handihaler inhaler
224115115|NCT00232570|DRUG|quetiapine|
224115116|NCT05153005|OTHER|examination methods|Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
224292393|NCT00958126|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
224292394|NCT00958126|BIOLOGICAL|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
223725182|NCT05346341|PROCEDURE|Minimally invasive techniques|"All patient will be treated under general anaesthesia An appropriate gland-preserving minimally-invasive surgical procedure will be performed for all patients according to the nature and extent of the disease for either submandibular or parotid ducts.~Minimally invasive techniques for ductal salivary gland pathologies include:~1. Sialolithotomy through a simple cutdown~2. Sialendoscopy~3. Transoral microscopic-assisted sialolithotomy."
223725183|NCT03232801|BEHAVIORAL|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
223725184|NCT03232801|BEHAVIORAL|general health education group|A general health and aging education group
223972451|NCT06550297|BEHAVIORAL|Medically Tailored Meals and Nutritional Counseling|God's Love We Deliver's current MTM program, which consists of weekly home-delivered MTMs and nutritional counseling by a Registered Dietitian Nutritionist for an 8-month period. The Food is Medicine Coalition Clinical Committee establishes and regularly updates the MTM Nutrition Standards, which catalogue the nutrition quality of this evidence-based intervention. Arms 1-3 will receive 10 MTMs per week for 8 months. Arm 4 will receive a distinct dosing down approach as follows: 10 MTMs/week in months 1-3, 9 MTMs/week in month 4, 8 MTMs/week in month 5, 7 MTMs/week in month 6, 6 MTMs/week in month 7, and 5 MTMs/week in month 8.
223972452|NCT06550297|BEHAVIORAL|Cardiovascular Health Promotion Educational Program|Culturally and contextually tailored cardiovascular health promotion program that consists of didactic sessions focused on lifestyle change and the American Heart Association's Life's Essential 8 framework, setting weekly specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, group coaching, cooking demonstrations, recipes and gift bags with healthy ingredients, and addressing social needs.
224115117|NCT00006452|DRUG|motexafin gadolinium|
223972453|NCT01746628|PROCEDURE|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
223972454|NCT00000922|DRUG|Indinavir sulfate|
224115118|NCT00006452|RADIATION|radiation therapy|
224115119|NCT02275572|PROCEDURE|Pharmacist Intervention|
224115120|NCT02602431|DEVICE|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
223725185|NCT05036551|DIAGNOSTIC_TEST|Kellgren Lawrence classification|The Kellgren Lawrence classification was used in the radiological evaluation. It is a classification method used in the staging of knee osteoarthritis. Five stages were defined according to the anteroposterior X-ray.(Stage 0-5)
224115121|NCT02602431|DEVICE|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
224115122|NCT02602431|DEVICE|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
224115123|NCT02602431|DEVICE|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
224115124|NCT05965206|BEHAVIORAL|Follow-up phone interview|Follow-up phone interview within 7 business days after receiving intravenous chemotherapy
224115125|NCT01631357|BIOLOGICAL|CIK cell|CIK cell injection
224115126|NCT01631357|DRUG|Gemcitabine Injection|Gemcitabine injection
224115127|NCT01631357|DRUG|Cisplatin injection|Cisplatin injection
224292395|NCT00720226|DRUG|Losartan|Losartan 100 mg daily
224292396|NCT00720226|DRUG|Placebo|Placebo pill daily
224292397|NCT04339426|DRUG|Atovaquone/Azithromycin|Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
223725186|NCT03824912|DRUG|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
223725187|NCT03824912|DRUG|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
223725188|NCT03824912|DRUG|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
223972455|NCT00000922|DRUG|Abacavir sulfate|
223972456|NCT00000922|DRUG|Nelfinavir mesylate|
223972457|NCT00000922|DRUG|Efavirenz|
223972458|NCT00000922|DRUG|Nevirapine|
223972459|NCT00000922|DRUG|Lamivudine|
223972460|NCT00000922|DRUG|Stavudine|
223972461|NCT00000922|DRUG|Didanosine|
223972462|NCT01287416|BEHAVIORAL|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
223972463|NCT01287416|BEHAVIORAL|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
223972464|NCT00728832|DRUG|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
223972465|NCT01643902|DRUG|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
224115128|NCT02679066|DEVICE|Sugar-tong splint|Plaster immobilization including the elbow
224115129|NCT02679066|DEVICE|Short forearm cast|Fiberglass immobilization with elbow free
224115130|NCT05101421|DIETARY_SUPPLEMENT|Rice ceramide supplementation|At the dosage of 40mg daily for 3 months
224115131|NCT00059761|DRUG|cisplatin|
224115132|NCT00059761|DRUG|irinotecan hydrochloride|
224115133|NCT00059761|RADIATION|radiation therapy|
224115134|NCT00004184|BIOLOGICAL|monoclonal antibody 4B5 anti-idiotype vaccine|
224115135|NCT00004184|BIOLOGICAL|sargramostim|
224115136|NCT00004184|DRUG|alum adjuvant|
224115137|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
224115138|NCT00632593|PROCEDURE|Laparoscopic Gastric Bypass|
224115139|NCT01221298|DRUG|ABT-450|tablets
224115140|NCT01221298|DRUG|ABT-072|tablets
224115141|NCT01221298|DRUG|Ribavirin|tablets
224115142|NCT01221298|DRUG|Ritonavir|capsules
224115143|NCT03176212|DIETARY_SUPPLEMENT|Milk fat globule membrane|
224115144|NCT00149929|DRUG|Mycophenolate sodium (enteric coated)|
224292398|NCT01497626|DRUG|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
224292399|NCT03401073|DRUG|Intravenous immunoglobulin|Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
223972466|NCT04714788|DEVICE|RECAP_MyLife mobile app|"The intervention will be the use of a mobile application for collecting data from cohorts participants, envisioning to engage participants and collect continuous unbiased records. Participants in the intervention group will install the mobile application on their smartphones on the beginning of the trial and will be asked to self-report information on mood every day. Simultaneously, physical activity (number of steps) will be passively tracked through real-time information.~Participants will complete baseline and post-intervention measures of mood status based on the Circumplex Mood Model and IPAQ-Short form. Following these measures, participants will be asked to complete questionnaires on usability (SUS scale) and acceptability of the intervention."
223972467|NCT04714788|OTHER|Usual data collection methods|Participants in this group will provide data through usual types of data collection methods (face-to-face assessments, mailed questionnaires, online questionnaires).
224115145|NCT05452746|DEVICE|Acupuncture|"Unilateral and bilateral acupuncture points:~Du 20 and GV 29,39 MS1, MS2, MS3 and MS4,40~Location of points:~Number of needles: 9~Depth of insertion:~MS1, MS2, MS3: insert the needle obliquely in the frontal direction for 1 cm Du 20: insert the needle obliquely in the frontal direction for 0.5 cm GV 29: insert the needle obliquely and downward for 0.5 cm Needles retained for 20 min Needle type: Han Yi 0.25x25 mm Treatment regimen: once per day for 2 weeks"
224115146|NCT05452746|OTHER|Treatment as usual|Inpatient psychiatric care for depression
224115147|NCT01511146|DRUG|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
224115148|NCT01511146|DRUG|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
224115149|NCT02891746|OTHER|non invasive sampling|
224115150|NCT01927562|DEVICE|Fractyl Duodenal Remodeling System|
224292400|NCT03401073|DRUG|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
224115151|NCT06316089|BEHAVIORAL|PrEPared for Release|A multilevel, behavioral and navigation intervention administered over two sessions to promote PrEP initiation, adherence and linkage to PrEP care in the community for incarcerated men with a history of injection drug use.
224115152|NCT00642616|DRUG|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
224292401|NCT00522340|BEHAVIORAL|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
224292402|NCT00733369|DEVICE|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
224292403|NCT00733369|DEVICE|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
223972468|NCT00741351|DRUG|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
223972469|NCT00741351|DRUG|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
223972470|NCT00741351|DRUG|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
223972471|NCT04260984|PROCEDURE|US-guided injection|For US-guided injection, a 22 MHZ linear array probe (Esaote MyLab™ClassC, Italy) will be used for guidance of injection via a transverse scan, in-plane approach. After sterilization, the probe will be placed at the radial styloid with maximal swelling or tenderness. Then a 2.5 cm 25-gauge needle will be placed into the tendon sheath via transverse scan, in-the-plane approach, and the injectate will be pushed into the tendon sheath. Care will be taken avoiding injury of vessels and the superficial branch of radial nerve during the injection.
223972472|NCT04260984|PROCEDURE|palpation-guided injection|Injectate: a mixture of 10mg triamcinolone acetonide (10mg/1ml) and 0.3ml 1% lidocaine. For palpation-guided injection, a 2.5cm 25-gauge needle will be inserted almost horizontally between APL and EPB tendons, just distal to the radial styloid, at the site of maximum tenderness. Then the mixture of triamcinolone and lidocaine will be pushed into the common tendon sheath.
223972473|NCT03126214|DRUG|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
223972474|NCT03164525|DIAGNOSTIC_TEST|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
223972475|NCT03052478|DRUG|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
223972476|NCT04289714|DEVICE|Novel Electronic Monitoring Device|Four Novel electronic Monitoring Devices were trialled
223972477|NCT05846308|BEHAVIORAL|Structured synchronous physical training|"The instructors and the participants will form a circle facing each other while doing the physical exercises. To facilitate interpersonal synchrony, the participants will be instructed to do the same physical exercises (spatial synchrony) together at the same pace (rhythmic synchrony). Each session will consist of four parts:~1. Warm-up (10 minutes)~2. Social Game (10 minutes)~3. Main training (30 minutes): Each session will contain two sets, each consisting of seven fixed exercises with a resting period of 10-15 seconds between each. Each exercise will be performed at one of three different paces: Slow - one movement cycle per 2 seconds, Medium - one movement cycle per 1 second and Fast - two movement cycles per 1 second.~4. Cool-down (10 minutes)"
223972478|NCT05846308|BEHAVIORAL|Structured non-synchronous physical training|The participants will do the same physical exercises as the participants in the synchronous group but in the form of circuit training with seven stations. The circuit training will require the participants to do a different physical exercise at a different pace at each station. A detailed description of the exercises will be provided for each station. The instructors will demonstrate all the exercises before the beginning of training. The participants will be instructed to do the exercise for a set period of time, the same duration used in the synchronous group. The circuit training stations will be in the form of a circle but will be set up so that the participants do not to face each other when doing the exercises to prevent spontaneous synchronization. Each session will consist of four parts, the same as in the synchronous intervention.
223972479|NCT02251197|DRUG|BIII 890 CL|
223972480|NCT02251197|DRUG|Placebo|
223972481|NCT04390893|DEVICE|ultrasound|Anesthesiologist would scan three planes of the neck to position the LMA
223972482|NCT04390893|DIAGNOSTIC_TEST|air leakage test|Anesthesiologist would use air leakage test to position the LMA
223972483|NCT04800133|BIOLOGICAL|Tozinameran|mRNA vaccine developed by BioNTech against COVID-19
223972484|NCT04800133|BIOLOGICAL|CoronaVac|Inactivated virus vaccine developed by SinoVac against COVID-19, intramuscular
223972485|NCT04800133|BIOLOGICAL|CoronaVac, intradermal|Inactivated virus vaccine developed by SinoVac against COVID-19, intradermal
223972486|NCT06280118|OTHER|Fatigue|Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track.
224115153|NCT00642616|DRUG|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
224115154|NCT05484063|OTHER|Multicomponent, mobility-focused intervention|The intervention group will receive early therapist review (within one working day of admission to HOME unit), to be mobilised at least three times a day. They will also receive additional group exercise therapy sessions, as well as nurse screening for geriatric syndromes. Besides that, they will be screened for 4Ms (Mobility, Mentation, Medication, What Matters) by doctor on admission.
224115155|NCT03183921|OTHER|No intervention|No Interventions
224115156|NCT00492921|DRUG|Cyclophosphamide|
224115157|NCT00350064|BEHAVIORAL|Exercise Training|16 weeks of aerobic exercise training at two different intensities
224115158|NCT00399802|DRUG|ZA|Single ZA 4 mg IV infusion at the start of treatment
224115159|NCT00399802|DRUG|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
224115160|NCT00399802|DRUG|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
224115161|NCT00399802|DRUG|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
224115162|NCT05743543|OTHER|Sphenopalatine ganglion block|The block is performed with a nasoscope and the administration of a local anesthetic.
223972487|NCT02694198|OTHER|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
224292404|NCT05223257|OTHER|AOT|Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
224292405|NCT02529202|DRUG|Dexmedetomidine|Dexmedetomidine infusion
224292406|NCT00286819|DRUG|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
223972488|NCT03439397|DEVICE|Ballon Technique|Ballon Technique
223972489|NCT03439397|DEVICE|SOAI|SOAI
223972490|NCT01406808|BEHAVIORAL|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
224292407|NCT01949714|PROCEDURE|Removal of adrenal tumor|
223972491|NCT02863913|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
223972492|NCT02863913|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
224292408|NCT01470612|DRUG|CP-690,550|5 mg tablets, BID, for at least 12 months
224292409|NCT01470612|DRUG|CP-690,550|10 mg tablets, BID, for at least 12 months
223972493|NCT02863913|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
223972494|NCT04832815|BEHAVIORAL|Equine Therapy|Aim 1: Six session equine interventions. Intervention will be provided one day per week for four weeks. During the first two weeks, each intervention day with consist of two sessions with a lunch break in between. Weeks four and five consist of one trail riding session per intervention day followed by lunch. Each session will be approximately 1.5 hours in length. Sessions 1-4 will occur at the USU Equine Education Center, and session 5-6 will occur on local trails. Optional transportation for participants will be provided from the VA to the intervention site.
223972495|NCT04832815|BEHAVIORAL|Therapeutic Horsemanship Program|Aim 2: Therapeutic Horsemanship program utilizes the USU Pathways to Horsemanship model and covers levels of equestrian training from basic groundwork to more advanced riding techniques. Training occurs in a three or six-session format with once weekly sessions over three or six weeks. Mindfulness and mindful self-compassion training may be included.
223972496|NCT00160979|PROCEDURE|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
223972497|NCT04512898|DRUG|Triple therapy for H.pylori|Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
223972498|NCT04786431|OTHER|Blood collection for lipid profiling by LC-MS|Blood withdrawal
223972499|NCT00524810|DRUG|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
223972500|NCT00524810|DRUG|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
223972501|NCT01130714|BEHAVIORAL|Exercise|Resistance training with resistance bands.
223972502|NCT00400959|PROCEDURE|cd133+cell intracoronary administration|
224115163|NCT04674137|DRUG|XC8 100 mg|1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
224115164|NCT04674137|DRUG|Placebo|1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
224115165|NCT00542815|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
224115166|NCT00542815|DRUG|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
224115167|NCT06468410|OTHER|long duration Hatha Yoga|60 min of Hatha yoga for 4 weeks. Week One:Participants begin with foundational breathing and yoga practicesOn the second day, Square Breathwork is introduced to foster calm and concentration. After a warm-up, the yoga flow focuses on heart openers to increase chest and shoulder flexibility, ending with a soothing cool-down. Week Two:Advanced breathing techniques and targeted yoga flows are introduced. The second session includes Nadi Shodhana to balance the nervous system. Week Three:The focus remains on heart openers with varied breathing exercises. The second day revisits Full Yogic Breath, followed by a warm-up and another heart opener sequence, concluding with a cool-down. Week Four:The final week integrates additional breathing techniques. The last session features Kapalabhati and Suddhi Pranayama to purify and energize the body. After a warm-up, participants engage in a well-rounded yoga flow combining various poses to enhance overall fitness, concluding with a final cool-down.
224115168|NCT06468410|OTHER|short duration Hatha Yoga|30 min of Hatha yoga for 4 weeks .
224115169|NCT06468410|OTHER|Control group|participants will receive information about physical activity guidelines but will not engage in any structured yoga exercise during the study period.
223972503|NCT02456675|DRUG|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
223972504|NCT02456675|DRUG|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
223972505|NCT02456675|DRUG|itacitinib|The dose of itacitinib will be given orally once daily (QD).
223972506|NCT05643443|OTHER|Gradual increase of force|steady force
223972507|NCT04402203|DRUG|Favipiravir|Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
223972508|NCT04402203|DRUG|Only Standard Treatment|Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
223972509|NCT00364221|DRUG|Rosiglitazone|
223972510|NCT01137123|DRUG|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
223972511|NCT01137123|PROCEDURE|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
223972512|NCT01137123|PROCEDURE|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
223972513|NCT01137123|PROCEDURE|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
223972514|NCT01645358|DEVICE|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
223972515|NCT01645358|DEVICE|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
223972516|NCT00857298|BEHAVIORAL|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
223972517|NCT03269513|BEHAVIORAL|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
223972518|NCT02494453|PROCEDURE|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
223972519|NCT02494453|PROCEDURE|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
223972520|NCT03271918|DRUG|Cabergoline|
223972521|NCT02262390|PROCEDURE|Partner Notification Reminders|"For all 3 arms, the following will be done:~* All participants will have an antenatal clinic visit every 4 weeks until delivery.~* All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~* Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
223972522|NCT02245750|DEVICE|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
223972523|NCT05654805|DIETARY_SUPPLEMENT|Drinking powder supplement|Drinking powder supplement, to be taken twice daily over 12 weeks
223972524|NCT00181532|DRUG|Celecoxib|
223972525|NCT01708005|DRUG|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
223972526|NCT01708005|DRUG|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
223972527|NCT03772600|DEVICE|Dexcom G6 CGM|Use of Dexcom G6
223972528|NCT02689752|DRUG|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
223972529|NCT03327077|OTHER|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
223972530|NCT00984399|DRUG|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
223972531|NCT04520581|OTHER|"group O"|"Endotracheal tube was made O shape by assistants."
223972532|NCT02506881|DRUG|Darbepoetin alfa|
223972533|NCT02369588|OTHER|Food portion size|
223972534|NCT05615480|OTHER|Controlled hypotension guided by cerebral oxygen saturation monitoring|In this group, intraoperative monitoring of cerebral oxygen saturation will be used. When the cerebral oxygen saturation decreased by 20% \~ 25% compared with the baseline for 300 seconds without improvement, or the cerebral oxygen saturation decreased by 25% \~ 30% compared with the baseline for 180 seconds without improvement, intervention would be carried out. When the cerebral oxygen saturation decreased by 30% compared with the baseline, immediate intervention would be carried out. The intervention measures were intravenous administration of deoxyepinephrine 50 \~ 100 μg or ephedrine 5 \~ 10mg, which can be administered multiple times until the cerebral oxygen saturation reaches more than 80% of the baseline.
223972535|NCT06279299|PROCEDURE|lateral pelvic lymph node dissection|Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
223972536|NCT02774564|DRUG|BIA 3-202|Nebicapone tablets 50 mg, oral administration
223972537|NCT02774564|DRUG|Placebo|Nebicapone matching placebo tablets
223972538|NCT02774564|DRUG|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
223972539|NCT01919398|DRUG|LY2940680|Administered orally
223972540|NCT00887380|DRUG|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
224115170|NCT02777463|OTHER|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
224115171|NCT02182037|DRUG|Single rising doses of BIBT 1011 BS|
224115172|NCT02182037|DRUG|BIBT 1011 BS placebo|
224115173|NCT01520922|BIOLOGICAL|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
224115174|NCT01520922|DRUG|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
223972541|NCT00887380|RADIATION|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
224115175|NCT03605134|DIAGNOSTIC_TEST|level of cardiac troponin|blood test
224115176|NCT03605134|DIAGNOSTIC_TEST|diastolic function assessment|transthoracic echocardiography
224115177|NCT00615706|OTHER|No intervention|no intervention
224115178|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
224115179|NCT01815437|DIETARY_SUPPLEMENT|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
224115180|NCT01815437|DIETARY_SUPPLEMENT|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
224115181|NCT01815437|DIETARY_SUPPLEMENT|Mushroom Extract|Same quantity of mushroom extract in a capsule
224115182|NCT01301911|DRUG|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
224115183|NCT00395122|DEVICE|Retinal nerve fiber layer and macular thickness measurements|
224115184|NCT03634046|PROCEDURE|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
224115185|NCT03634046|PROCEDURE|Radiofrequency ablation|The same as the descriptions in active comparator group.
224115186|NCT03424330|DEVICE|ReX-C intervention|Patients receive medication by the ReX-C device
224115187|NCT03424330|OTHER|Standard of Care|Patients receive medication as usual
224115188|NCT02213757|DRUG|Premarin vaginal estrogen cream|
224115189|NCT02213757|DRUG|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
224115190|NCT05197244|BEHAVIORAL|Culinary Medicine Intervention|A 2-hour practical culinary medicine program facilitated by a culinary dietitian at a hospital-based teaching kitchen, followed by 3 virtual group follow-up sessions occurring monthly, each lasting approximately 30 minutes. The follow-up sessions will be facilitated by a culinary dietitian and will be conducted using a secure telephone/video conference platform.
224115191|NCT04187001|OTHER|Content Validity|Use Delphi technique for achieve consensus
224115192|NCT04187001|OTHER|Cultural adaptation|Adapt the content to the target population
223972542|NCT00887380|DRUG|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
223972543|NCT01359722|DRUG|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
223972544|NCT01359722|DRUG|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
223972545|NCT01766414|DRUG|C1-esterase inhibitor|intravenously
223972546|NCT01766414|DRUG|Endotoxin|intravenously
223972547|NCT01044836|BIOLOGICAL|HD203|Injectable form
223972548|NCT01975636|DRUG|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
223972549|NCT00741468|DRUG|Proellex|2, 25 mg Proellex capsules administered daily
223972550|NCT00741468|DRUG|CYP1A2 probe|Caffeine (200 mg)
223972551|NCT00741468|DRUG|CYP2C9 probe|Tolbutamide (250 mg)
223972552|NCT00741468|DRUG|CYP2C19 probe|Omeprazole (20 mg)
223972553|NCT00741468|DRUG|CYP2D6 probe|Dextromethorphan (30 mg)
223972554|NCT00741468|DRUG|CYP3A4 probe|Midazolam (2mg)
223972555|NCT03997708|OTHER|Med-LFD|All participants of this group at phase 1 (elimination phase), will initially follow the Med- LFD (2-6 weeks). At phase 2 (reintroduction phase), patients will gradually reintroduce foods rich in FODMAPs (6-8 weeks) and test their tolerance. At phase 3 (maintenance phase), following the reintroduction of foods rich in FODMAPs, patients will follow an individualized diet based on their personal tolerance (a combination of high and low FODMAPs).
223972556|NCT03997708|OTHER|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will be informed to follow a diet based on the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS for 4 weeks.
223972557|NCT04834063|DIAGNOSTIC_TEST|Serum Zinc a level|Diagnostic test
223972558|NCT04834063|DIAGNOSTIC_TEST|serum selenium level|Diagnostic test
223972559|NCT04834063|DIAGNOSTIC_TEST|Fibroscan measurement|Diagnostic test
223972560|NCT02860299|DRUG|citrate 4%|
223972561|NCT02860299|DRUG|unfractionated heparin|
223972562|NCT02860299|BIOLOGICAL|blood sample|
223972563|NCT01077011|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
223972564|NCT01077011|OTHER|GenTeal Gel|1 drop in each eye, one time
223972565|NCT05110651|DRUG|Hydroxychloroquine|Oral Hydroxychloroquine 200mg once daily Dose tapered if blood-hydroxychloroquine levels \> 2000ng/ml
223972566|NCT01785771|DRUG|ITCA 650 (exenatide in DUROS)|
224115193|NCT00745264|DRUG|Diractin|100 mg Ketoprofen to 2 joints
224115194|NCT00745264|DRUG|Diractin|400 mg ketoprofen to 4 joints
224115195|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
224115196|NCT00745264|DRUG|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
224115197|NCT04076072|DEVICE|Utravit High-Speed 10000 cpm Beveled Probe|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
224115198|NCT04076072|DEVICE|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
224115199|NCT04910412|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation will be use for the intervention. Anodal and sham tDCS will be applied in 2 mA through a pair of saline-soaked surface sponge electrode 35 cm square for 20 minute over the primary motor area for modulating the cortical excitability before apply the rehabilitation training
224115200|NCT04372355|DRUG|WF10|WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
224115201|NCT03152864|BEHAVIORAL|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
224115202|NCT04770155|DIETARY_SUPPLEMENT|Dietary Nitrates 400 mg|The nitrates in the beetroot juice will be absorbed and reduced in the plasma to nitrite and nitric oxide, increasing endothelium-independent nitric oxide bioavailability.
224115203|NCT04770155|DIETARY_SUPPLEMENT|L-citrulline 3 g|Ingested L-citrulline becomes available in large quantities in the plasma for enzymatic conversion into L-arginine. The activity of the endothelial nitric oxide synthase converts L-arginine into nitric oxide, increasing endothelium-dependent nitric oxide bioavailability.
224115204|NCT04770155|DRUG|Sildenafil 100 mg|Sildenafil inhibits phosphodiesterase 5, an enzyme that degrades cyclic guanosine monophosphate in the vascular smooth muscle cells inactivating the nitric oxide-mediated signal; thus, Sildenafil will prolong the availability of cyclic guanosine monophosphate, enhancing the nitric oxide-mediated intracellular cascade.
224115205|NCT04770155|DRUG|Bosentan 125 mg|Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
224115206|NCT04044547|DRUG|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
223972567|NCT05438446|PROCEDURE|Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)|"The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney."
223972568|NCT04509583|DIETARY_SUPPLEMENT|PROFortil|Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months
223972569|NCT04509583|OTHER|Vitamin E|Only Vitamin E (Enat 400, once per day) in 3 months
223972570|NCT03887871|DRUG|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration after meal
223972571|NCT03887871|DRUG|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
224115207|NCT04044547|DRUG|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
223972572|NCT03106337|DEVICE|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
223972573|NCT02592928|OTHER|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
223972574|NCT04865510|PROCEDURE|Regional citrate anticoagulation|"The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6)."
223972575|NCT05026242|BEHAVIORAL|Almond intervention|Participants will follow their regular Western-style diet substituting unhealthy snacks by 2-daily servings of almonds
223972576|NCT05026242|BEHAVIORAL|Control|Participants will be provided with isocaloric snacks
224115208|NCT04281927|DEVICE|Monitoring with wearable (the tested device) and Holter ECG (eMotion Faros 90)|Participants will use the wearable (the tested device) to record at least 2 minutes of photoplethysmography and 6-lead ECG. In addition, each subject will be monitored with synchronous ECG Holter monitoring (with eMotion Faros 90).
224115209|NCT00864227|BIOLOGICAL|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~* Fludarabine: 40 mg/m\^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~* Cyclophosphamide: 50 mg/kg IV on Day -6~* Total body irradiation: 200 centigray (cGy) on Day -1"
223972577|NCT04923230|BEHAVIORAL|Cannabis Actions and Practices Resource for Parents|The Cannabis Actions and Practices (CAP) resource is a parent-focused approach to help MM parents address marijuana use and attitudes by their adolescents. CAP includes information about the effects of marijuana on adolescent behavioral health, brain development, and social functioning. CAP also integrates motivational strategies to foster The CAP intervention focuses on building parenting skills and teaching strategies to: (1) limit adolescent exposure to cannabis products and parent cannabis use at home, (2) improve parent communication about their MM use, expectations about youth marijuana use, and attitudes about the potential harms of adolescent cannabis use, (3) improve monitoring, and (4) increase positive reinforcement for youth abstinence. Parents meet with an interventionist for two individual 75-minute sessions involving presentations, discussions, and behavioral rehearsal of key parenting skills.
223972578|NCT04056117|BIOLOGICAL|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
223972579|NCT04056117|BIOLOGICAL|MenACWY|Control vaccine administrated to adults and infants
223972580|NCT04056117|BIOLOGICAL|Rabies|Control vaccine administrated to children
223972581|NCT04056117|BIOLOGICAL|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
223972582|NCT04056117|BIOLOGICAL|Placebo|Control administrated to adults
223972583|NCT05268822|OTHER|Home exercise|Movement control exercise with or without specific breathing techniques
223972584|NCT01888627|OTHER|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
223972585|NCT00596258|DRUG|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
223972586|NCT05042362|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
223972587|NCT05042362|DRUG|Placebo|Matching placebo orally once daily
223972588|NCT01372683|OTHER|Dietary Intervention|Comparison of oat based breakfast cereals
224115210|NCT00864227|BIOLOGICAL|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~* Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~* MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm\^3 for three consecutive measurements, each on different days."
224115211|NCT05359627|DRUG|Polymyxin B|Polymyxin B acts against gram-negative bacteria (GNB) only, via three known mechanisms of action: First, polymyxin B can electrostatically interact with the outer membranes of GNB to compete against and displace calcium and magnesium divalent cations from membrane lipids, thereby disrupting lipopolysaccharide (LPS) molecules on the outer membrane and triggering their release. This leads to changes in the permeability of the bacterial membrane and subsequently causes cell content leakage, cell lysis, and death. Second, polymyxin B can act as a surfactant, as it is amphipathic and contains both lipophilic and lipophobic groups; this allows it to penetrate cell membranes, interact with the phospholipids within, and rapidly disrupt membranes to kill bacteria. Third, polymyxin B can bind to the lipid A portion of bacterial endotoxin or LPS molecules, thus neutralizing their toxicity.
224115212|NCT02722577|PROCEDURE|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
223725189|NCT03965910|OTHER|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
224292410|NCT04649450|OTHER|Music|Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed just before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days at the neurosurgical ward they will receive music twice a day for 30 minutes.
224292411|NCT01166555|DRUG|PF-04236921|single subcutaneous dose
224292412|NCT01397708|BIOLOGICAL|INXN-2001|"* approximately 1.0 x 1012 viral particles (vp) per injection~* one intratumoral injection of INXN-2001 per study cycle~* maximum of 6 study cycles"
224292413|NCT01397708|DRUG|INXN-1001|"* 4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~* 7 oral daily doses of INXN-1001 per study cycle~* maximum of 6 study cycles~* 1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
224292414|NCT00065455|DRUG|Vitamin A|
224292415|NCT01343095|DEVICE|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
224292416|NCT01343095|DEVICE|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
224292417|NCT02510014|DRUG|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
224292418|NCT02510014|DRUG|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
224292419|NCT03314818|DEVICE|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
224292420|NCT02112721|DIETARY_SUPPLEMENT|Vitamin D|
224292421|NCT02112721|DIETARY_SUPPLEMENT|Placebo|
224292422|NCT01913236|OTHER|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
224292423|NCT04053413|OTHER|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
224292424|NCT03808870|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
224292425|NCT02332408|RADIATION|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
224292426|NCT02332408|RADIATION|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
224292427|NCT05470764|DRUG|PERINDOPRES® TRIO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide / 10 mg amlodipine tablets|Oral, generic fixed-dose combination of perindopril tert-butylamine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
224292428|NCT05470764|DRUG|TRIPLIXAM® 10 mg /2.5 mg/10 mg, 10 mg perindopril arginine / 2.5 mg indapamide / 10 mg amlodipine film-coated tablets|Oral, innovative fixed-dose combination of perindopril arginine (angiotensin-converting-enzyme inhibitor for the treatment of high blood pressure and heart failure), indapamide (thiazide-like diuretic used in the treatment of hypertension and decompensated heart failure) and amlodipine (calcium channel blocker used to treat high blood pressure and coronary artery disease).
224292429|NCT00247299|DEVICE|IPL Quantum Product manufactured by Luminis Ltd.|
224292430|NCT05451732|PROCEDURE|Nanofat grafting|Naofat grafting in the urethral stricture. The autologous adipose tissue is transferred by injection and in this way, the access to the urethral stricture is carried out with a minimal incision of the male urethra while in the female urethra is transferred exclusively with injections, without incision of urethral tissue.
224292431|NCT01464554|BEHAVIORAL|Usual care|alcohol and drug education
224292432|NCT01464554|BEHAVIORAL|Project Free Talk|motivational interviewing alcohol and drug program
224292433|NCT03182894|DRUG|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
224292434|NCT03083626|OTHER|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
224292435|NCT05012865|DRUG|avelumab|as provided in real world practice
224292436|NCT05012865|DRUG|axitinib|as provided in real world practice
223725190|NCT02511184|DRUG|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
223725191|NCT02511184|DRUG|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
223972589|NCT04230993|OTHER|Sea water solution|Administration of different sea water solution is performed and the rating of cold symptoms according to the Jackson scale, the fluidity of mucus and the ease of blowing will be evaluated.
223972590|NCT03888261|BEHAVIORAL|Mind-Body Approaches for Medical Conditions|"The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~1. Contemplative practices~2. Psychoeducation~3. Dialogue, including therapist-group dialogue as well as participant-participant dialogue."
223972591|NCT01683643|BEHAVIORAL|SBIRT|Screening, brief intervention, and referral to treatment.
223972592|NCT01683643|BEHAVIORAL|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
223972593|NCT05904288|DEVICE|Smartwatch Garmin Vivosmart [wearable sensor]|Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.
223972594|NCT05904288|DEVICE|Soturi™ [digital mobile app]|Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
223972595|NCT05904288|OTHER|Clinical Assessment|Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
223972596|NCT04817930|DEVICE|Polyetheretherketone patient specific implant|a customized peek patient specific implant is place to augment the chin
223972597|NCT04817930|DEVICE|Computer guided advancement genioplasty|advancement genioplasty using patient specific cutting and positioning surgical stents
223972598|NCT05664230|OTHER|osteopathy|five osteopathy sessions
223972599|NCT01270217|BEHAVIORAL|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
224115213|NCT03344328|DRUG|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
224115214|NCT03418662|DEVICE|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
223725192|NCT03657706|PROCEDURE|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
223725193|NCT03657706|PROCEDURE|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
223972600|NCT00261625|DRUG|alendronate|
223972601|NCT00050167|DRUG|Paclitaxel|80 mg/m\^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
223972602|NCT00050167|DRUG|Docetaxel|75 mg/m\^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
223972603|NCT00050167|DRUG|Capecitabine|1500 mg/m\^2 by mouth Twice Daily x 2 Weeks
223972604|NCT02085590|BIOLOGICAL|BCG vaccine|
223972605|NCT02085590|BIOLOGICAL|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
223972606|NCT06473272|OTHER|Cardiovascular and cerebrovascular diseases|Cardiovascular and cerebrovascular diseases
224115215|NCT05191329|DIAGNOSTIC_TEST|TPQue Greek version, NEI-VFQ-25 Greek version|Study participants with non surgical presbyopic correction will be evaluated with TPQue regarding their personality traits. Visual acuity will also be assessed. Study participants with pseudophakic presbyopic correction will be evaluated with the TPQue before surgery. They will also be visual acuity evaluation and NEI-VFQ-25 assessment six months after surgery.
224115216|NCT02812030|OTHER|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
224115217|NCT01950884|DRUG|Ezetimibe|Ezetimibe tablets
224115218|NCT01950884|BEHAVIORAL|Lifestyle|lifestyle
224115219|NCT00370656|DRUG|Pregabalin|capsule, 150mg bd, 300mg bd
224115220|NCT00370656|DRUG|Duloxetine|Capsule, 60mg on, 60mg bd
224115221|NCT00370656|DRUG|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
224115222|NCT03911570|DRUG|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
223725194|NCT05741320|OTHER|questionnaire|27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
224115223|NCT04083742|DEVICE|ANTERION|3 repeat angle measurements performed on each of the 3 Anterion devices and the 3 reference devices
224292437|NCT04768894|PROCEDURE|Second transurehral resection of bladder tumour|Remove of the bladder tumour as endoscopically
223725195|NCT04462003|DRUG|Apixaban|10 mg/12 h for 1 week followed by 5 mg/12 h
223725196|NCT04462003|DRUG|Enoxaparin|1mg/Kg/sc/12h
224115224|NCT02805699|DRUG|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
224115225|NCT02805699|DRUG|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
224115226|NCT00890968|DRUG|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
224115227|NCT00890968|DRUG|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
224115228|NCT00897559|GENETIC|gene expression analysis|
224115229|NCT00897559|GENETIC|mutation analysis|
224115230|NCT00897559|GENETIC|polymorphism analysis|
224115231|NCT00897559|GENETIC|protein analysis|
224115232|NCT00897559|OTHER|flow cytometry|
224115233|NCT00897559|OTHER|laboratory biomarker analysis|
224115234|NCT03540368|DRUG|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
224115235|NCT03540368|OTHER|Placebo|Administering placebo or sodium chloride 0,9% intravenously
224115236|NCT02575482|DRUG|SUVN-D4010|
224115237|NCT02575482|DRUG|Placebo|
223972607|NCT06049433|BEHAVIORAL|Maternal Mental Health Access for Postpartum Depression- Prevention and UPLIFT- intervention|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. We have adapted UPLIFT for this study, based on input from focus groups and in response to the ongoing pandemic, and under the direction of our team's mental health professionals. Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content),
224115238|NCT03870581|BEHAVIORAL|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
224115239|NCT03870581|BEHAVIORAL|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
224115240|NCT04526977|DIAGNOSTIC_TEST|Immune response study|"* ACE2 and CD26 receptor study~* Cytokine profile: Quantification of plasma cytokine levels~* SARS-CoV-2 CD4/CD8 T cell response~* TLR7/8 activation~* KIR characterization"
224115241|NCT00797927|DRUG|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
224115242|NCT00797927|OTHER|no intervention|keep the original conventional antipsychotic agent for 28 days
224115243|NCT04373980|DEVICE|phototherapy|estimate CD4 and CD8 subsets in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
224115244|NCT05044169|DRUG|Broncho-Vaxom|administration for 6 months after remmission
224115245|NCT04649710|BIOLOGICAL|BMS-986036|Specified dose on specified days
224115246|NCT04649710|OTHER|Placebo|Specified dose on specified days
224115247|NCT01765764|DRUG|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
223725197|NCT05012839|OTHER|impact of COVID-19 on Health-Seeking Behaviors|The impact of the coronavirus disease 2019 (COVID-19) pandemic on medical services is overwhelming due to limited medical resources. During its initial surge in 2020, Taiwan's government rapidly established diverse public actions, which helped maintain the medical supply without travel restrictions. However, whether the fear of being infected with COVID-19 interfered with health-seeking behavior (HSB) remains unclear. Therefore, this study aimed to elucidate whether acute complicated appendicitis (ACA) rates in adults were affected by the COVID-19 pandemic.
224115248|NCT01765764|DRUG|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
224115249|NCT04876664|DEVICE|measuring blood pressure with noninvasive blood pressure device|To measure blood pressure in different circumstances with noninvasive blood pressure device
224115250|NCT05113823|PROCEDURE|Simulation Training|Simulation Training using High and Low Fidelity Simulator
224115251|NCT03138850|DEVICE|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
224115252|NCT03138850|DEVICE|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
224115253|NCT03138850|DEVICE|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
224115254|NCT00547937|DEVICE|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
224115255|NCT01558089|DRUG|etanercept|according to SmPC and clinical practice
224115256|NCT01558089|DRUG|methotrexate|according to SmPC and clinical practice
223972608|NCT06049433|BEHAVIORAL|On-Demand + Discussion board (DB)|Adaptations include access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. a discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
223972609|NCT06049433|BEHAVIORAL|Arm 2|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings. MBCT can be delivered individually and in groups and via electronic platforms, in diverse populations. On-demand multi-media MBCT content (digital audio-video files and downloadable content)
223972610|NCT06049433|BEHAVIORAL|On Demand (OD) + Video Conference (VC)|on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC) reduced from 8 weekly one-hour sessions to 4 one-hour sessions every two weeks. A discussion board with the potential to build a sense of community in a similar way that synchronous VC groups provide.
223972611|NCT06049433|BEHAVIORAL|Arm 3|The intervention uses a standardized, manualized program (UPLIFT - Using Practice and Learning to Increase Favorable Thoughts) based on Mindfulness-Based Cognitive Behavioral Therapy (MBCT) in the prevention of depression in various populations and settings.
223972612|NCT06049433|BEHAVIORAL|On Demand (OD) + Video Conference (VC)|Access to asynchronous, on-demand multi-media MBCT content (digital audio-video files and downloadable content), as well as synchronous Videoconference (VC)
223972613|NCT04188119|DRUG|Avelumab|(Arm A) Avelumab + Proto Pump Inhibitor (PPI)
223972614|NCT04188119|DRUG|Aspirin|300mg tablets
223972615|NCT04188119|DRUG|Lansoprazole|30mg
223972616|NCT05783154|BIOLOGICAL|Autologous Adipose Tissue-Derived Mesenchymal Stem Cell|"After cleaning the knee with 10% povidone-iodine (Povidep10% solution, manufactured by Jayson Pharmaceuticals limited, Bangladesh) and draping it in a sterile manner, the injection site will be anesthetized with 0.5% bupivacaine (Inj. Bupi Heavy 0.5%, Manufactured by Popular Pharmaceuticals limited, Bangladesh) superficially outside of joint capsule.~Within one hour of preparation, the autologous AT-MSC will be injected into each knee joint through medial tibio-femoral compartment in group -I using a 38-mm 18- gauge needle"
223972617|NCT00743496|BIOLOGICAL|Anti-GD2 antibody|Anti-GD2 antibody
223972618|NCT05721378|PROCEDURE|Permissive Weight Bearing group|The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
224115257|NCT03021525|PROCEDURE|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in \<15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
224115258|NCT03021525|PROCEDURE|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate \<100 bpm, mean arterial pressure \>65 mmHg, SpO2\>94%, and core temperature \>36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
223725198|NCT03349112|BEHAVIORAL|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
223725199|NCT03349112|BEHAVIORAL|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
223725200|NCT00002990|BIOLOGICAL|BCG vaccine|
223972619|NCT05721378|PROCEDURE|Restricted Weight Bearing group|The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
223972620|NCT01880944|OTHER|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
223972621|NCT03277586|DRUG|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
223972622|NCT03277586|DRUG|Placebo|Identically formulated and packaged inactive substance
223972623|NCT05401149|DRUG|rt-PA|Recombinant Tissue Plasminogen Activator
223972624|NCT05043688|DRUG|Camrelizumab|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
223972625|NCT05043688|RADIATION|radiotherapy|The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
223972626|NCT03974997|DIAGNOSTIC_TEST|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
223972627|NCT00495612|DRUG|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
223972628|NCT00495612|DRUG|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
223972629|NCT00705042|DRUG|Etanercept|
223972630|NCT02766764|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
223972631|NCT02766764|DRUG|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
223972632|NCT02766764|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
223972633|NCT02766764|DRUG|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
223972634|NCT01489462|BEHAVIORAL|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
223972635|NCT01489462|BEHAVIORAL|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
223972636|NCT01489462|BEHAVIORAL|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
223972637|NCT00579657|OTHER|control diet, supported by dietary supplement twice daily|control diet, see above
223972638|NCT00579657|OTHER|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
224115259|NCT01797029|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
224115260|NCT01797029|BIOLOGICAL|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
224115261|NCT00472342|BEHAVIORAL|exercise prescription|
224115262|NCT01671436|BEHAVIORAL|Central Meditation and Imagery Therapy|
224115263|NCT01003587|BEHAVIORAL|District health information package|"The intervention package consists of:~* A report on disease burden, disease control priorities and health system performance in India~* Condensed fact sheet based on the report~* District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~* Customized speech for district level officials detailing key actions to reduce deaths~* Reminder materials including poster version of the DRCs and video on key points and actionable messages"
223972639|NCT00579657|OTHER|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
223972640|NCT00579657|OTHER|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
223972641|NCT00006099|BIOLOGICAL|Monoclonal antibody hu3S193|Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.
223972642|NCT06016127|DEVICE|iovera system|"The iovera° system consists of a reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The 190 Smart Tip will be used in this study."
223972643|NCT06016127|DEVICE|Radiofrequency ablation|The RFA system consists of a Cosman, G4 Generator. The needles used are 20-gauge, 10cm long with a 10mm active tip manufactured by Cosman. A grounding pad, also manufactured by Cosman, is placed on the upper thigh for each procedure and connected to the G4 Generator.
223972644|NCT05662215|DRUG|CK-3828136|CK-3828136
223972645|NCT05662215|DRUG|Placebo for CK-3828136|Placebo for CK-3828136
223972646|NCT05417555|DEVICE|Low-Intensity Focused Ultrasound Pulsation (LIFUP)|Low intensity focused ultrasound pulsation will be administered to the left entorhinal cortex at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 50%, duration 30s with 30s spacing between sonications, 6 sonications per dose (participants receive 0, 1, 2 or 3 doses depending on group assignment)
224115264|NCT01359826|DRUG|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
224115265|NCT01627756|OTHER|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
223725201|NCT01176669|DRUG|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
223972647|NCT06091969|DIETARY_SUPPLEMENT|Active multi-ingredient supplement (Fertility Enhancer, FE)|Consuming a multi-ingredient supplement targeting multiple cell pathways daily for 3 months.
223972648|NCT06091969|DIETARY_SUPPLEMENT|Inactive placebo (Placebo; PLA)|Consuming an inactive placebo that is calorie-matched to the active supplement daily for 3 months.
224115266|NCT01627756|OTHER|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
224115267|NCT01455727|OTHER|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
224115268|NCT01455727|OTHER|Usual care|Control patients received usual care directed by their physician.
223725202|NCT00053053|DIETARY_SUPPLEMENT|Juven|
223725203|NCT00053053|DIETARY_SUPPLEMENT|Non-Juven Supplement|
223725204|NCT05951062|BEHAVIORAL|behavior management for anti-hypertensive medication|five sessions of educational interview and home visiting to improve medication-related self-management skills
223725205|NCT05951062|OTHER|placebo group|treatment as usual
223972649|NCT02103426|DRUG|ASP0113|intramuscular injection
223972650|NCT02103426|DRUG|Placebo|intramuscular injection
223972651|NCT05889221|OTHER|Drug and medical device|Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
223972652|NCT02189122|DRUG|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
224115269|NCT02167204|PROCEDURE|Computed Tomography|Undergo 18F-FLT PET/CT
223725206|NCT01770626|OTHER|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
223725207|NCT05898555|DEVICE|Skiin garment and pods|"Participants will be asked to wear a Skiin smart garment over their own clothes.~Small motion capture markers will be placed on their body and pressure-sensitive insoles placed into their shoes to measure the pressure underneath their feet during the study tasks.~Once the sensors are ready for collection, participants will be asked to complete 5 tasks associated with their daily activities: 1. Locomotion; 2. Lower limb strength - repeated sit-to-stand-to-sit transitions; 3. Lower limb strength and locomotion - Timed Up and Go; 4. Free walking during a 2min walk; 5. Standing balance, postural control."
223725208|NCT05803057|DEVICE|TMS stimulation treatment|Using the TMS treatment coli to stimulation with high frequency
223972653|NCT02189122|DRUG|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
223972654|NCT02189122|DRUG|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
223972655|NCT02189122|DRUG|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
223972656|NCT02189122|DRUG|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
223972657|NCT02189122|DRUG|Placebo|Subjects will take matching placebo for five days.
223972658|NCT04026074|DRUG|Fentanyl|Weight adapted drug application
223725209|NCT05803057|DEVICE|TMS stimulation sham-treatment|Using the TMS sham-treatment coli to stimulation with high frequency
223725210|NCT02309879|DRUG|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
223725211|NCT02309879|DRUG|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
223972659|NCT04026074|DRUG|Remifentanil|Weight adapted drug application
223972660|NCT04026074|DRUG|Clonidine|Weight adapted drug application
223972661|NCT04026074|DRUG|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
223972662|NCT04026074|DRUG|Placebo iv|i.v. administration of 0,9% NaCl
223972663|NCT04026074|DRUG|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
223972664|NCT04593771|DRUG|BCG-PPD|BCG-PPD was used for skin test in 40 healthy people, and BCG-PPD was marketed in other 40 healthy people (as control)
223972665|NCT05572697|BEHAVIORAL|Digital Cognitive-behavioral therapy for insomnia (dCBT-I)|6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
223972666|NCT05572697|BEHAVIORAL|Usual care|Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
223972667|NCT02264353|DRUG|Donepezil|Donepezil 10mg before sleep
223725212|NCT02309879|DRUG|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
223972668|NCT02264353|DRUG|placebo|One piece of placebo before sleep
223972669|NCT06543407|BEHAVIORAL|SWITCH IT|"Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6."
223972670|NCT06543407|OTHER|E-cig Provision Only|Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
223972671|NCT04461938|OTHER|Fasting|The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
223972672|NCT04475497|OTHER|Blood management|The intervention will include pre-surgical optimization blood management referral based on pre-operative Hgb levels \<11.0 g/dL. Treatment will include PO iron, IV iron, B12 or folate per blood management algorithm.
223972673|NCT04475497|OTHER|Usual care|Usual care per surgeon preference can include iron by mouth or no iron therapy.
223972674|NCT05631379|OTHER|Measurement of body composition with computed tomography (CT)|The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
223972675|NCT05631379|DIAGNOSTIC_TEST|GLIM malnutrition criteria|GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
223972676|NCT05631379|DIAGNOSTIC_TEST|EWGSOP2 sarcopenia criteria|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia
223972677|NCT05631379|DIAGNOSTIC_TEST|ESPEN-EASO criteria for sarcopenic obesity|The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) consensus criteria from 2018 will be applied to assess sarcopenic obesity
223972678|NCT05631379|DIAGNOSTIC_TEST|Prognostic Nutritional Index (PNI)|Prognostic Nutritional Index is diagnostic test based on serum albumin level and total lymphocyte count
223972679|NCT05631379|DIAGNOSTIC_TEST|The high-sensitivity modified Glasgow prognostic score|The high-sensitivity modified Glasgow prognostic score (Hs-mGPS) is an inflammation-based score consisted of C-reactive protein level and serum albumin
224115270|NCT02167204|RADIATION|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
224115271|NCT02167204|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET/CT
224115272|NCT00391638|DRUG|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
223972680|NCT02656745|DEVICE|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones \& engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
223972681|NCT01948882|DEVICE|ESS505 (BAY1454033)|
223972682|NCT02574234|OTHER|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
223972683|NCT02574234|OTHER|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
223972684|NCT02574234|OTHER|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
223972685|NCT02574234|OTHER|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
223972686|NCT02574234|OTHER|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
223972687|NCT06241677|DRUG|alteplase or tenecteplase|Either alteplase (0.6 or 0.9mg/kg, maximum dosage 90mg) or tenecteplase (0.25mg/kg, maximum dosage 25mg) will be given
223972688|NCT02864147|DRUG|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
224115273|NCT00391638|BIOLOGICAL|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
224115274|NCT00016861|DRUG|irinotecan hydrochloride|
224115275|NCT02255786|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
224115276|NCT04064684|DRUG|Budesonide|Enrolled patients will be treated with Pulmicort Respules® (Budesonide inhalation suspension), at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator. The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
224115277|NCT04064684|DRUG|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
224115278|NCT04064684|DEVICE|Nebulizer|The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit.
224115279|NCT04180436|DRUG|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
224115280|NCT04014504|DIAGNOSTIC_TEST|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
224115281|NCT01946048|BIOLOGICAL|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
224115282|NCT04676139|DRUG|Fluoxetine|Fluoxetine 10 mg capsules once daily for 12 months
224115283|NCT04676139|DRUG|Placebo|placebo for 12 months
224115284|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 200mg PO is given
224115285|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 400mg PO is given
224115286|NCT02644525|DRUG|Imatinib Mesylate|A single dose of imatinib 600mg PO is given
224115287|NCT02644525|DRUG|Placebo|A single dose of placebo pill is given
223972689|NCT02864147|DRUG|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
224115288|NCT03412422|DIAGNOSTIC_TEST|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
224115289|NCT04848363|PROCEDURE|Quadratus lumborum block|QL block will be used for perioperative anesthesia. The blockade will be performed bilaterally by levobupivacaine (20ml) at concentration 0.25%.
223725213|NCT02309879|DRUG|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
223725214|NCT04219631|DEVICE|expiration mouthpiece used during breathing exercises to ensure a constant ventilatory flowrate.|women enrolled in WINNER-FLOW-URO-MG group will freely use the expiratory mouthpiece device during all their childbirth process.
223725215|NCT05922150|RADIATION|low level laser therapy|LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
223725216|NCT05922150|DRUG|ozone gel|ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
223972690|NCT01351883|DIETARY_SUPPLEMENT|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
223972691|NCT06546566|OTHER|Video Game-Based Breathing Exercises|The video game-based breathing exercises program will consist of 5 breathing games included in the BreathingLabs game kit and each game will be performed in 2 sets of 10 repetitions. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
224115290|NCT06313281|PROCEDURE|Preoperative Antiseptic preparation prior to transnasal skull base surgery|The patient received one of three antiseptic preparation before transnasal skull base surgery
224115291|NCT02222987|DRUG|Terbogrel|
224115292|NCT02222987|DRUG|Clopidogrel|
224115293|NCT06047431|DRUG|QL1706H|QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
224115294|NCT00624130|DRUG|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
223972692|NCT06546566|OTHER|Conventional Breathing Exercises|The conventional breathing exercises program will consist of routine breathing exercises. Breathing exercises will be given 2 times a day, 5 repetitions, 2 sets. The program will last for 8 weeks, 5 days a week, 30 minutes a day.
223972693|NCT02269917|DRUG|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
224115295|NCT00624130|DRUG|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
223972694|NCT02269917|DRUG|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.
224115296|NCT03686254|COMBINATION_PRODUCT|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
224115297|NCT03686254|DRUG|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
224292438|NCT01095419|OTHER|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
224292439|NCT01095419|OTHER|Control|no intervention
224292440|NCT05667636|RADIATION|salvage SBRT|steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
224292441|NCT02761213|DRUG|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
224292442|NCT02761213|DRUG|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
223725217|NCT06124612|DIAGNOSTIC_TEST|Thrombotic assessment|"GTT~The Global Thrombosis Test (GTT) (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~TEG Thromboelastography (TEG, Haemonetics Corporation, USA) is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Citrated plasma will be stored for subsequent evaluation of thrombosis and fibrinolysis markers (including but not restricted to D-dimer, PAI-1, hs-CRP, NETs)"
223725218|NCT03219294|DRUG|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
223725219|NCT03219294|DRUG|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
223972695|NCT02269917|DRUG|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
224115298|NCT02290639|BEHAVIORAL|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
224292443|NCT01997021|OTHER|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
224292444|NCT01997021|OTHER|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
223972696|NCT06105099|BEHAVIORAL|Motor-phonetic intervention|"Children will receive phonetic articulation therapy treating consonants in a phoneme-by-phoneme basis, emphasizing phonetic placement and shaping techniques.~Phonetic articulation therapy includes a progression of the target consonant from isolated level, syllable level, word level, sentence level, spontaneous speech level in five different steps:~identification of the target consonant using visual, tactile, and auditory feedback techniques, discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 90% of the time with minimal cues from the therapist."
223972697|NCT06105099|BEHAVIORAL|Phonological intervention|"The phonological approach consists of two phases. In the first phase, the child's attention is drawn to the contrastive features of the speech sound system which are relevant to the target consonants. Terms that describe the sound features will be introduced using words on the child's level, e.g. in the case of active nasal fricatives the words 'nose' and 'mouth' will be used. Child-friendly games will be played to illustrate the contrast between the concepts followed by activities that focus on the contrasts in non-speech sounds, in which child and therapist will alternate between being listener and speaker. At the end of this phase, minimal word pairs (e.g. tap/cap), only produced by the therapist, will be used to facilitate the child's awareness of sounds in words and meaningful differences based on distinctive features.~In the second phase, the child will produce minimal pairs providing the opportunity to monitor his/her speech and to make self-corrections."
223972698|NCT06105099|BEHAVIORAL|Combined phonetic-phonological intervention|Children will receive motor-phonetic articulation therapy supplemented with phonological principles. Therapy will be provided following the same five steps as the 'motor-phonetic group'. However, articulation errors will not be treated in a phoneme-by-phoneme basis. In contrast, multiple errors will be targeted simultaneously by focusing on a process. For example, if the child produces glottal stops for the /t/ and the /p/, these sounds will be treated simultaneously as sounds requiring oral front placements. Exercises will be embedded in meaningful language contexts such as minimal pairs
223972699|NCT02185586|PROCEDURE|laparoscopic cholecystectomy|
223972700|NCT05408156|OTHER|Insoles|semi-flexible non-moulded insole with a 2.5mm coverage with Shore A 28, a 5mm retrocapital bar with a Shore A 22 and a 2mm infracapital bar of the first metatarsal with a Shore A 35, produced in acetate ethylene vinyl (EVA)
223972701|NCT01596894|DRUG|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
223972702|NCT01596894|DRUG|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
223972703|NCT02769390|DRUG|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
223972704|NCT02769390|DRUG|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
224115299|NCT02290639|BEHAVIORAL|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
224115300|NCT00935220|DRUG|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
224115301|NCT00985881|DEVICE|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
224292445|NCT01997021|OTHER|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
223725220|NCT02187484|DRUG|BIBR 277|
223725221|NCT03224572|DRUG|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
223725222|NCT03224572|OTHER|normal saline|500ml normal saline, once per week, and total 4-week treatment
223972705|NCT02769390|DRUG|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
223972706|NCT02383927|DRUG|Tipifarnib|FTase inhibitor
224292446|NCT02556307|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
223972707|NCT03093597|OTHER|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
224115302|NCT00985881|DEVICE|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
224115303|NCT00798967|DRUG|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
224115304|NCT00798967|DRUG|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
224115305|NCT02474017|DRUG|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
224292447|NCT02556307|DRUG|Ribavirin|Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
224292448|NCT01510652|PROCEDURE|BiP Group|Implantation of standard Left Ventricular (LV) lead
223725223|NCT01160250|DRUG|vismodegib (GDC-0449)|Oral repeating dose
223725224|NCT04912050|DEVICE|Tablo Hemodialysis System|Renal Replacement Therapy between 12\< to ≤ 24 hours.
223725225|NCT00168688|DIETARY_SUPPLEMENT|multi micronutrient supplement|
223725226|NCT00168688|DIETARY_SUPPLEMENT|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
223972708|NCT03093597|OTHER|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
223972709|NCT03093597|OTHER|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
223972710|NCT03093597|OTHER|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
223972711|NCT01334905|DRUG|YM178|oral
223972712|NCT02259569|OTHER|Pressure-controlled ventilation|
223972713|NCT02259569|OTHER|Volume-controlled ventilation|
223725227|NCT00168688|DIETARY_SUPPLEMENT|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
223725228|NCT02329249|BEHAVIORAL|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
223972714|NCT06646211|DRUG|Zanubrutinib , Thiotepa|"First 1-4 cycle~Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 1 for up to 4 cycle Drug: Zanubrutinib~* Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
223972715|NCT06646211|DRUG|Methotrexate , Thiotepa and Zanubrutinib|"Cycle 5 - 10 Drug: Methotrexate~* Intravenous methotrexate at 3.5g/m2 for 6 hours will be given on day 1 each 21-day cycle 【Leucovorin Calcium (CF): 15mg/m², rescue begins 12 hours after the infusion of methotrexate (MTX) ends, administered every 6 hours until the MTX plasma concentration is ≤ 0.1 μmol·L-¹ at 48 hours; plasma concentration monitoring time points: 0, 6, 24, 48, 72 hours.】 Other Names: MTX Drug: Thiotepa~* 40mg/m2，d1 each 21-day cycle from cycle 5 for up to 10 cycle Drug: Zanubrutinib Zanubrutinib will be given at a dose of 160mg，bid，d1-d21"
224115306|NCT02474017|DEVICE|CRC749 inhaler|
224115307|NCT03515603|PROCEDURE|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
224115308|NCT03515603|PROCEDURE|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
224292449|NCT01510652|DEVICE|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
224292450|NCT04574115|DEVICE|Omega Refractive Capsule with an FDA approved Intraocular Lens|Omega refractive capsule in conjunction with an FDA approved Intraocular Lens
224292451|NCT04574115|DEVICE|FDA approved Intraocular Lens|FDA approved Intraocular Lens
224292452|NCT05941273|DEVICE|smaller incision, new generation implantable miniature telescope (SING-IMT)|The IMT (model SING) is an intraocular implant comprised of 2 micro lenses in a glass tube (optics) in a flexible silicone carrier (haptics)
224115309|NCT04348721|OTHER|online survey|"An online survey including 8 case-vignettes was sent to international liver transplant surgeons who had published on liver transplantation. The first part is related to surgeon's own experience. In the second part, the surgeons were asked to rate the difficulty of various situations in liver transplantation on a scale of 1 to 10 (level 1 was labeled as easier, and level 10 was labeled as difficult). In the third part, 8 case-vignettes corresponding to 8 clinical real-life situations are submitted to experts"
224115310|NCT01377467|DRUG|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
223725229|NCT02329249|OTHER|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
223725230|NCT01963403|DRUG|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
223972716|NCT06646211|DRUG|ASCT±Zanubrutinib|"Consolidation / maintenance treatment Patients who achieve a Complete Response (CR) or Partial Response (PR) after the ZT/ZMT treatment will enter consolidation/maintenance therapy.~Patients age ≤65 years old will undergo Autologous Stem Cell Transplantation (ASCT, with a recommended conditioning regimen that includes Thiotepa), followed by 6 months of maintenance treatment with zanubrutinib.~Patients age \> 65 will receive 6 months of maintenance treatment with zanubrutinib.~\*The study permits the prophylactic use of Granulocyte Colony-Stimulating Factor (G-CSF). For detailed usage, please refer to the guidelines from the National Comprehensive Cancer Network (NCCN) or the Chinese Society of Clinical Oncology (CSCO)"
223972717|NCT06646705|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
223972718|NCT04449133|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
223972719|NCT04449133|DRUG|Placebo|Oral administration of two capsules before sleep for 7 days.
223972720|NCT03600090|BIOLOGICAL|EOC202|EOC202 will be SC injection.
223972721|NCT03600090|DRUG|Paclitaxel|Paclitaxol will be IV injection
223972722|NCT03093233|OTHER|no intervention|only descriptive data analysis
223972723|NCT03876678|OTHER|Lactobacillus salivarius AP-32|Taking 1 probiotic capsule two times everyday for 7 days.
223972724|NCT03876678|OTHER|Bifidobacterium animalis subspecies lactis CP-9|Taking 1 probiotic capsule two times everyday for 7 days.
223972725|NCT03876678|OTHER|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
223972726|NCT04542551|PROCEDURE|Dilation 60-Fr non stricture|Dilation of patients with subjective dysphagia and normal endoscopy
223972727|NCT04542551|PROCEDURE|Sham|Sham dilator for patients with subjective dysphagia and normal endoscopy
224292453|NCT06048289|OTHER|Blood samples, tumor biopsy specimens will be collected|Blood samples, tumor biopsy specimens at baseline will be collected
223725231|NCT01963403|DRUG|Placebo|1 pill per day; daily during study participation (up to 84 days)
223725232|NCT05964244|DEVICE|Vela Investigational Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
223725233|NCT05964244|DEVICE|Nivairo Standard Mask|Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.
223725234|NCT03395886|DRUG|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
224115311|NCT00800761|DRUG|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
224115312|NCT00800761|DRUG|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
224292454|NCT02537873|DRUG|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
223725235|NCT03395886|DRUG|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
223725236|NCT01580189|DIETARY_SUPPLEMENT|Whey protein|18g protein, immediately after training, 9 weeks
224292455|NCT02537873|DRUG|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
224292456|NCT02537873|DRUG|Placebo comparator|Dextrose in gelatin capsule
224292457|NCT02199340|OTHER|iStep exercise test|newly developed submaximal exercise test
224292458|NCT02199340|OTHER|CPET exercise test|maximal gold standard exercise test
224292459|NCT01583517|PROCEDURE|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
223972728|NCT04542551|PROCEDURE|Non severe stricture - dilation with 60-Fr|Dilation of non severe stricture with 60-Fr dilator
223972729|NCT04542551|PROCEDURE|Non severe stricture - dilation with 46-Fr|Dilation of non severe stricture with 46-Fr dilator
224115313|NCT02838550|BEHAVIORAL|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
224115314|NCT02838550|BEHAVIORAL|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
224115315|NCT03040583|OTHER|No intervention|Patients data will be collected during their disease follow-up
224115316|NCT01415440|DRUG|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
224115317|NCT01415440|DRUG|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
224115318|NCT05340400|OTHER|ROME IV Criteria|Collaborators will use Rome IV criteria for diagnosing IBS by the presence of the abdominal pain at least once a week in the last 3 months, in addition to at least two of the following: abdominal pain related to defecation, change in stool frequency, or shape.
224115319|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
224115320|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
224292460|NCT01583517|PROCEDURE|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
223725237|NCT01580189|DIETARY_SUPPLEMENT|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
224115321|NCT00336492|BIOLOGICAL|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
224115322|NCT00336492|BIOLOGICAL|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
224115323|NCT05546788|PROCEDURE|scaling and root planing|subgingival Depridement
224115324|NCT05546788|DRUG|hydroxylated poly methoxy flavones|Received hydroxylated poly methoxy flavones extract solid dispersion incorporated into sodium carboxymethylcellulose gel
224115325|NCT05546788|DRUG|chlorhexidine|Received chlorhexidine gel
224115326|NCT05546788|DRUG|placebo|Received placebo gel
224115327|NCT04295304|DEVICE|Retinal surgery with implantation of epi-retinal device|Retinal surgery and implantation of epi-retinal prosthesis
224115328|NCT00620204|DRUG|atorvastatin|atorvastatin 40mg qd for 1 year
224292461|NCT01583517|PROCEDURE|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
224292462|NCT04652284|DRUG|Rifabutin|150 mg
224292463|NCT04652284|DRUG|Amoxicillin|1000 mg
224292464|NCT04652284|DRUG|Esomeprazole|40 mg
224292465|NCT04652284|DRUG|Clarithromycin|500 mg
224292466|NCT04652284|DRUG|Tinidazole|500 mg
223972730|NCT04542551|PROCEDURE|Severe stricture - dilation with 51-Fr|Dilation of a severe stricture with 51-Fr dilator
223972731|NCT04542551|PROCEDURE|Severe stricture - dilation with 42-Fr|Dilation of a severe stricture with 42-Fr dilator
223972732|NCT02671071|BEHAVIORAL|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
223972733|NCT03071874|DRUG|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
223972734|NCT01754545|DRUG|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
223972735|NCT01754545|DRUG|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
223972736|NCT05888142|BEHAVIORAL|in clinic pain VR reduction exercises|"During the in clinic training phase, participants will use commercially available VR during in clinic VR physical therapy exercises, to help reduce their pain and improve functionality. But this group will not take a VR system home until after completing the in clinic training phase."
223972737|NCT05888142|BEHAVIORAL|In clinic VRpain reduction exercises + VR homeworks|"During the training phase, participants will use commercially available VR during in clinic physical therapy exercises, and during the training phase, they will also receive a VR system they take home and will begin VR homeworks during the traininng phase, to help reduce their pain and improve functionality."
223972738|NCT00282009|BEHAVIORAL|Basic Internet|Basic Internet control intervention
223972739|NCT00282009|BEHAVIORAL|Enhanced Internet|enhanced Internet cessation intervention
223972740|NCT00282009|BEHAVIORAL|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
223972741|NCT01995149|BEHAVIORAL|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
223972742|NCT00593983|BEHAVIORAL|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
223972743|NCT00593983|BEHAVIORAL|Time-matched health education|Health education and standard of care treatment
223972744|NCT02942628|OTHER|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
224292467|NCT04729465|DRUG|Propofol|Propofol
224292468|NCT04729465|DEVICE|Bispectral Index Monitor|Bispectral Index Monitor
224292469|NCT00734201|DRUG|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
223725238|NCT01580189|DIETARY_SUPPLEMENT|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
223972745|NCT05473221|BIOLOGICAL|CD33 CAR-T|CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
224292470|NCT02059330|DRUG|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
223972746|NCT02502851|DEVICE|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
223972747|NCT02502851|DEVICE|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
223972748|NCT05966545|PROCEDURE|pars plana vitrectomy and intraocular foreign body removal|removal of vitreous body and attachment to foreign body then extraction of foreign body
223972749|NCT00139971|DRUG|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
223972750|NCT00139971|DRUG|UFT 250mg/m2, daily for 1 year|
223972751|NCT02893371|DRUG|Lithium Carbonate|Exposure to all dosages and delivery forms.
223972752|NCT02893371|DRUG|Lamotrigine|Exposure to all dosages and delivery forms.
223972753|NCT02893371|DRUG|Valproic Acid|Exposure to all dosages and delivery forms.
223972754|NCT02893371|DRUG|Oxcarbazepine|Exposure to all dosages and delivery forms.
223972755|NCT02893371|DRUG|Carbamazepine|Exposure to all dosages and delivery forms.
223972756|NCT02893371|DRUG|Ziprasidone|Exposure to all dosages and delivery forms.
223972757|NCT02893371|DRUG|Risperidone|Exposure to all dosages and delivery forms.
224115329|NCT01233219|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
224115330|NCT00001056|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
224115331|NCT00227877|BEHAVIORAL|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
224115332|NCT00227877|BEHAVIORAL|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
224115333|NCT03285009|OTHER|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
224115334|NCT02958137|PROCEDURE|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
224115335|NCT05707845|DRUG|Medical treatment.|Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
223972758|NCT02893371|DRUG|Quetiapine|Exposure to all dosages and delivery forms.
223972759|NCT02893371|DRUG|Olanzapine|Exposure to all dosages and delivery forms.
223972760|NCT02893371|DRUG|Aripiprazole|Exposure to all dosages and delivery forms.
223972761|NCT02893371|DRUG|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
223972762|NCT02893371|DRUG|Haloperidol|Exposure to all dosages and delivery forms.
223972763|NCT02893371|DRUG|Perphenazine|Exposure to all dosages and delivery forms.
223972764|NCT02893371|DRUG|Clozapine|Exposure to all dosages and delivery forms.
223972765|NCT02893371|DRUG|Asenapine|Exposure to all dosages and delivery forms.
223972766|NCT02893371|DRUG|Lurasidone|Exposure to all dosages and delivery forms.
223972767|NCT02893371|DRUG|Paliperidone|Exposure to all dosages and delivery forms.
223972768|NCT02893371|DRUG|Mirtazapine|Exposure to all dosages and delivery forms.
223972769|NCT02893371|DRUG|Bupropion|Exposure to all dosages and delivery forms.
223972770|NCT02893371|DRUG|Desvenlafaxine|Exposure to all dosages and delivery forms.
223972771|NCT02893371|DRUG|Duloxetine|Exposure to all dosages and delivery forms.
223972772|NCT02893371|DRUG|Venlafaxine|Exposure to all dosages and delivery forms.
223972773|NCT02893371|DRUG|Citalopram|Exposure to all dosages and delivery forms.
223972774|NCT02893371|DRUG|Escitalopram|Exposure to all dosages and delivery forms.
223972775|NCT02893371|DRUG|Fluoxetine|Exposure to all dosages and delivery forms.
223972776|NCT02893371|DRUG|Fluvoxamine|Exposure to all dosages and delivery forms.
223972777|NCT02893371|DRUG|Paroxetine|Exposure to all dosages and delivery forms.
223972778|NCT02893371|DRUG|Sertraline|Exposure to all dosages and delivery forms.
223972779|NCT02893371|DRUG|Vilazodone|Exposure to all dosages and delivery forms.
223972780|NCT02893371|DRUG|Doxepin|Exposure to all dosages and delivery forms.
223972781|NCT05733793|OTHER|NGS tests|"This study is an observational, the patients with have an available NGS report performed in context of clinical practice or collected in clinical trials.~Patients enrolled in the current study will be managed as for clinical practice and no additional genetic tests or other procedure will be required."
223972782|NCT00291863|DRUG|Simvastatin|
223972783|NCT00337922|DRUG|Lamivudine / Abacavir Sulfate|
223972784|NCT01954758|OTHER|personalized Embryo Transfer (pET)|
223972785|NCT01954758|OTHER|Frozen Embryo Transfer (FET)|
223972786|NCT01954758|OTHER|Fresh Embryo Transfer (ET)|
223972787|NCT03809871|BIOLOGICAL|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
223972788|NCT02865135|DRUG|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
223972789|NCT02865135|DRUG|Cyclophosphamide|Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
223972790|NCT02772445|BEHAVIORAL|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
223972791|NCT04935762|DRUG|CST-103, CST-107, matching placebo|CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
223972792|NCT05768321|DRUG|GEC255 tablets|"Part 1: Dose escalation After initial starting dose cohort, daily dosages in subsequent cohorts are determined by cohort review committee.~Part 2: Dose expansion Daily oral dosage RP2D based on data from Part 1"
223972793|NCT00456183|BIOLOGICAL|MVA 85A|
223972794|NCT05248425|OTHER|Nurse Monitoring|Questionnaire responses that indicate new or worsening symptoms will be monitored by a study nurse who will contact the participant for clinical assessment and develop a management plan following irAEs management guidelines.
223972795|NCT05483192|DIETARY_SUPPLEMENT|Oral Dyglomera|"Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin."
223972796|NCT06585436|PROCEDURE|partial caries removal|removal of all cavity caries except last layer related to the pulp
224115336|NCT05707845|BEHAVIORAL|weight reduction|weight reduction in the form low caloric diet program for 12 weeks.
224115337|NCT05707845|OTHER|exercise|aerobic exercise in the form of walking on treadmill for 30 minutes 3 times a week for 12 weeks.
224115338|NCT04346394|DRUG|Yohimbine HCl|Yohimbine hydrochloride will be used to manipulate the noradrenergic system during some of the assessments. By measuring the amounts of hormones the body produces before and after yohimbine hydrochloride administration, researchers can assess how well the noradrenergic system is functioning
224115339|NCT02517047|DEVICE|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
224122661|NCT04323709|OTHER|Data analysis|Continuous variables were presented as mean ± standard deviation and compared using Student's t-test or Mann-Whitney U-test depending on their normality. Categorical variables were presented as counts and percentages and compared using Pearson's chi-squared test or Fisher's exact test, as appropriate. Survival at day 28 was estimated using the Kaplan-Meier method and compared using the log rank test. Investigators conducted a multivariable logistic regression with propensity score matching, which was defined as the probability of exposure to levosimendan. Results were reported as odd ratios (ORs) together its 95%CI assuming a 5% level of statistical significance. All analyses were carried out using STATA 15.0 (Stata Corp, College Station, Texas 77845 USA).
224115340|NCT05629416|BEHAVIORAL|Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples|"1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation."
223972797|NCT01811823|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
224292471|NCT02059330|DRUG|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
223972798|NCT05076955|DRUG|vancomycin-tobramycin-itraconazole|Participants with diabetic foot ulcers will be treated with a compounded, anti-infective irrigation therapy daily until closure of the ulcer or up to a maximum of 3 months. This is an irrigating foot bath with a compounded medication of vancomycin-tobramycin-itraconazole. This medication with combined 3/4 gallon of water. Participant will soak foot in solution for 10 minutes per day. Daily until wound is healed for a minimum of 4 weeks and a maximum of 3 months.
223972799|NCT00523926|DRUG|TMC207|
223972800|NCT04106336|DEVICE|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
223972801|NCT04938739|OTHER|Cognitive Behavioral Therapy|"The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained."
224115341|NCT05208983|BIOLOGICAL|mRNA Vaccines or Viral vector-based vaccines for COVID|Participants receiving an approved COVID vaccine
224115342|NCT00633139|BIOLOGICAL|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
224115343|NCT01452425|DEVICE|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
224115344|NCT01452425|DEVICE|INVOS assessment|Near Infraread spectroscopy, non invasive
224292472|NCT02059330|DRUG|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
224292473|NCT02059330|DRUG|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
224292474|NCT02059330|DRUG|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
224292475|NCT01778153|BEHAVIORAL|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
224115345|NCT01452425|DEVICE|EMG assessment|Electromyography, non invasive
224115346|NCT04108767|BEHAVIORAL|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
224292476|NCT00331071|DRUG|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
224292477|NCT00331071|DRUG|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
223972802|NCT04938739|OTHER|Home program exercises|Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
223972803|NCT01442623|OTHER|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
223972804|NCT03311997|PROCEDURE|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
223972805|NCT01071317|DRUG|Naproxen|Naproxen 500mg PO bid prn headache
223972806|NCT01071317|DRUG|Sumatriptan|100mg po q day prn headache
223972807|NCT01071317|BEHAVIORAL|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
223972808|NCT01071317|BEHAVIORAL|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
223972809|NCT01071317|OTHER|Typical care|Care to be determined by attending physician
223972810|NCT01159756|DRUG|Travacom|Travacom ophthalmic solution (1 drop per day)
223972811|NCT01748851|DRUG|XELOX|capecitabine 1000mg/m2 bid po D1-D14
223972812|NCT01748851|DRUG|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
223972813|NCT04301518|OTHER|Multimodal intervention strategy|"* Once weekly nurse support~* 200 mg/daily micronized progesterone as vaginal suppository~* 81 mg/daily low dose aspirin~* two transvaginal ultrasounds~* cerclage placement if cervical length is less than or equal to 10 mm prior to 24 weeks gestation"
223972814|NCT03974308|OTHER|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
223972815|NCT03974308|OTHER|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
224122662|NCT01686022|OTHER|Immunoblot|serum specific IgE binds to grass extract by immunoblot
224122663|NCT04561388|PROCEDURE|Electrocochleography|"Electrocochleographic responses will be evoked using different pure tone sounds delivered through an insert placed in the external auditory duct. The responses will be recorded with the electrodes of the cochlear implant connected to a dedicated interface.~Electrocochleographic responses will be collected continuously during the electrode-array insertion at the implantation surgery using 500Hz pure tone and after suturing with 250, 500, 750 and 1000Hz pure tones. Then, electrocochleographic responses to pure tones from 125 to 8000HZ (according to the subject residual hearing) will be recorded 2 weeks, 1 month, 2 months and 4 months after implantation."
223972816|NCT03974308|OTHER|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
223972817|NCT06055400|DEVICE|AR-US|The ultrasound imagery is projected onto the glasses, and participants use the AR-US throughout the entire CVC placement procedure
223972818|NCT01555879|DRUG|Abatacept|As prescribed by a doctor for patient medical care.
223972819|NCT02154516|DEVICE|ODH Hip System|
224115347|NCT06671145|DIAGNOSTIC_TEST|catheter ablation|Catheter ablation after differentiating Atrioventricular Nodal Reentry Tachycardia from Orthodromic Atrioventricular Reentry Tachycardia during electrophysiological study.
224115348|NCT06671028|DRUG|Ropivacaine and Lidocaine|Popliteal sciatic block using Ropivacaine 100 mg and Lidocaine 100 mg in 20 mL
224292478|NCT01176110|DEVICE|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
224292479|NCT00234455|DEVICE|drug eluting-stent|PCI
224292480|NCT00234455|DEVICE|drug-eluting stent|PCI
224292481|NCT05793814|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri 3613|Daily for 6 month
223972820|NCT00000647|DRUG|CD4-IgG|
223972821|NCT00000647|DRUG|Zidovudine|
223972822|NCT00000647|DRUG|Interferon alfa-n1|
223972823|NCT00000647|PROCEDURE|Peripheral lymphocyte infusion|
223972824|NCT00000647|PROCEDURE|Bone marrow transplant|
224115349|NCT06671028|DRUG|Ropivacaine 0,5%|Popliteal sciatic block using ropivacaine 0.5% 20 mL
224115350|NCT06671288|OTHER|Balloon-blowing exercises with abdominal & lumbar core muscle activation position.|"Patients in this group will recieve Balloon-blowing exercises with abdominal and lumbar core muscles activation position Total 4 weeks protocol will be followed in which 3 sessions per week will be supervised by physical therapist.~FREQUENCY: 3 times a week, INTENSITY : Moderate, TIME: 4 sets of balloon-blowing with 1 min rest (30 mins) TYPE: Balloon-blowing with abdominal \& lumbar core muscle activation position, DURATION : 4 weeks"
223972825|NCT02827799|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
223972826|NCT02827799|BEHAVIORAL|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
224115351|NCT06671288|OTHER|Diaphragmatic breathing exercise|Participants in this group will only be receiving diaphragmatic breathing exercise for 4 weeks. FREQUENCY: 3 times a week , INTENSITY: Moderate, TIME: 4 sets of diaphragmatic breathing with 1 min rest, TYPE: Diaphragmatic breathing, DURATION: 4 weeks
224115352|NCT06671067|DEVICE|Remote dielectric sensing system|The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.
224115353|NCT06673030|BEHAVIORAL|Using Kaleidoscope glasses during pulpotomy procedures|Kaleidoscope is an instrument that shows an infinite number of fascinating geometric shapes in the form of a flower, repeating and reflecting images of coloured goggle fragments in the front section in a prism mirroring the inner surface.
224292482|NCT05793814|DIETARY_SUPPLEMENT|Placebo|Daily for 6 month
224292483|NCT00408564|BIOLOGICAL|cetuximab|
224292484|NCT00408564|DRUG|capecitabine|
224292485|NCT00408564|DRUG|oxaliplatin|
224292486|NCT00408564|PROCEDURE|conventional surgery|
224292487|NCT00408564|RADIATION|radiation therapy|
224292488|NCT00408564|DRUG|Gemcitabine|
224292489|NCT03525418|BIOLOGICAL|Longeveron Mesenchymal Stem Cells|Allogeneic bone marrow-derived mesenchymal stem cell
223972827|NCT04404699|DIAGNOSTIC_TEST|Stimulation TcPO2 test|"During measurement of TcPO2 in various angiosomes the stimulation test will be performed. We modify the Ratschow test (elevation of the lower limbs, rhythmic flexion and extension in talocrural joints for 2 minutes, then return to horizontal position). TcPO2 is measured continuously. Depending on the type of detected flows by DUS in the evaluated arteries supplying the relevant angiosome, in which TcPO2 values are measured, the patients and their angiosomes will be divided into 2 baseline groups - group M with monophasic flows or arterial obliterations and group T with triphasic flows.~We will compare macrocirculation parameters-systolic pressure on dorsalis pedis artery (DPA), posterior tibial artery (PTA) and their doppler indexes. The resting TcPO2, the minimal TcPO2 found during the stimulation test, their delta (resting TcPO2 - minimal TcPO2) and the percentage decrease in TcPO2 will be compared between the study groups, as well as the duration of TcPO2 recovery."
223972828|NCT05762978|DEVICE|In-Check Dial|Patient will have their NIF measured with In-Check Dial
223972829|NCT05762978|DEVICE|Inhaler Device|Children will use inhaler per standard of care.
223972830|NCT00090558|DRUG|nitroglycerin|
224115354|NCT06673030|BEHAVIORAL|The Play-Doh Doctor Drill 'n Fill toy set|Consists of a plastic human head with slots into which Play-doh molded teeth can be inserted. A battery operated toy drill is used to drill into and clean the black, cavitated tooth model and filled with white Play-Doh compound to simulate cavity preparation and restoration using tooth colored cement.
224115355|NCT06673030|OTHER|Group 1 (Tell-Show-Do)|"In which Tell-Show-Do technique was done in three stages:~* Tell: The dental procedures were explained to the children using language and expressions appropriate for their age.~* Show: This began with showing the child the instruments and the topical anesthetic gel, high-speed handpiece and explaining the purpose of using the handpiece. and how the water removed using the suction device.~* Do: Performing the dental procedure immediately."
224115356|NCT06672796|OTHER|Resisted Toe Spread Out Exercise|new resistance exercise phase in addition to the standard protocol
224115357|NCT06672796|OTHER|Toe Spread Out Exercise|Standart protocol of toe spread out exercise
224115358|NCT06672796|OTHER|Stretching exercise|Toe stretching
223972831|NCT06052683|RADIATION|Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant|Low-dose rate brachytherapy with Iodine-125 to a total dose of 144 Gy
224115359|NCT06671886|BEHAVIORAL|E-trigger|The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned.
224115360|NCT02160977|PROCEDURE|total knee arthroplasty|
224292490|NCT03261479|DIAGNOSTIC_TEST|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
223972832|NCT06052683|RADIATION|Stereotactic Body Radiation Therapy to the prostate|Prostate Stereotactic Body Radiation Therapy using 36.25 Gy in 5 fractions
224292491|NCT05040178|DRUG|Carglumic Acid|Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
224292492|NCT03347552|BEHAVIORAL|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
224292493|NCT03446352|OTHER|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
224292494|NCT03446352|OTHER|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
224292495|NCT02485821|DRUG|Estradiol|
224292496|NCT02485821|DRUG|Placebo|
223972833|NCT04999683|DIETARY_SUPPLEMENT|ITIS diet|anti-inflammatory diet for 14 days
224115361|NCT06672913|BEHAVIORAL|skin to skin contact care|Early and regular skin to skin contact in NICU GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured
223972834|NCT01919255|DRUG|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)\[Day-Prior\] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)\[Split-Dose\]
223972835|NCT01919255|DRUG|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) \[Day-Prior\] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)\[Split-Dose\]
223972836|NCT01693159|DEVICE|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
223972837|NCT01693159|OTHER|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
223972838|NCT00230971|DRUG|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
224292497|NCT02485821|DRUG|Misoprostol|
224292498|NCT06402682|PROCEDURE|Right approach|Right approach of the management of esophageal atresia with a right aortic arch
223972839|NCT00230971|DRUG|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
223972840|NCT01398345|BEHAVIORAL|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
223972841|NCT03216915|DRUG|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
223972842|NCT02710578|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
223972843|NCT02710578|DRUG|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
223972844|NCT03166397|DRUG|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
223972845|NCT03166397|DRUG|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
223972846|NCT03166397|BIOLOGICAL|TIL|TIL administration
223972847|NCT03166397|DRUG|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
223972848|NCT03166397|DRUG|Nivolumab|Nivolumab 480 mg fixed dose
224115362|NCT06672432|OTHER|CareMom (a mobile app-based 8-wekk cognitive behavioral therapy program)|The intervention is divided into daily tasks spread across eight weeks, with each day involving a variety of interactive elements such as videos, text-based content, guided reflections, and mental health check-ins. If the user misses a daily challenge, she can complete that challenge in the later days. Each week has a distinct focus that progressively builds the user's skills and understanding in managing emotional health. Tasks are designed to be short yet impactful, aiming to enhance engagement and adherence.
224115363|NCT06672432|OTHER|Matched Attention Control (a mobile app-based 8-week online relaxation training program)|This program is designed to mirror the structure and engagement level of the intervention group, providing participants with a similar amount of interaction and daily activities. Each day, participants in the control group will complete 1-2 daily tasks focused on relaxation techniques, such as breathing exercises, mindfulness meditation, and guided imagery. Each task is brief, approximately 3 minutes in duration, making it easy for participants to incorporate into their daily routine.
224115364|NCT05115461|DEVICE|Biodex Balance System™ SD|Postural stability index values (anteroposterior, mediolateral and overall) will be measured for static and dynamic conditions.
224115365|NCT05115461|OTHER|questionnaires and inventories|questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
224115366|NCT00004697|DRUG|choline chloride|
224115367|NCT06302322|PROCEDURE|Thin Tissues|Patients with thin tissues received implants 10 years ago and are now followed up after 10 years.
224115368|NCT06302322|PROCEDURE|Thick Tissues|Patients with thick tissues received implants 10 years ago and are now followed up after 10 years.
224115369|NCT06302322|PROCEDURE|Surgically augmented thin tissues|Patients with thin tissues received soft tissue augmentation and implants 10 years ago and are now followed up after 10 years.
224115370|NCT00259025|DRUG|lipid emulsion with a high content of n-3 fatty acids|
224292499|NCT06402682|PROCEDURE|Left approach|Left approach of the management of esophageal atresia with a right aortic arch
224292500|NCT03443518|PROCEDURE|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
224292501|NCT03443518|PROCEDURE|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
224292502|NCT03443518|DRUG|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
224292503|NCT03443518|DRUG|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
224292504|NCT00706992|BIOLOGICAL|ALVAC-MART-1 vaccine|Given subcutaneously
223972849|NCT03166397|DRUG|Ipilimumab|Ipilimumab 1 mg/kg up to 100 mg
223972850|NCT03166397|DRUG|FMT Protocol|"FMT given both directly into the colon via colonoscopy and orally using capsules (12 capsules each time).~FMT will be taken from melanoma patients treated with Anti PD-1 who achieved a durable response of more than 12 months."
223972851|NCT05350514|DRUG|PI-2620 tracer|Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.
223972852|NCT02045745|BIOLOGICAL|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
223972853|NCT00005088|DRUG|cisplatin|
223972854|NCT00005088|RADIATION|radiation therapy|
223972855|NCT05243498|OTHER|Assessment of the Allogenomic Mismatch Score (AMS)|Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
223972856|NCT05243498|OTHER|Assessment of the optimised Allogenomic Mismatch Score (AMS)|Optimised Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient, encountering only peptides that can be presented by the donors' MHC (using another layer of algorithm, NetMHCpan).
223972857|NCT03941587|DRUG|Aflibercept + reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
223972858|NCT03941587|DRUG|Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)|Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
223972859|NCT06605703|BEHAVIORAL|WW Clinic|Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
223972860|NCT06605703|DRUG|Bupropion-Naltrexone|Bupropion-Naltrexone
223972861|NCT06605703|DRUG|Bupropion-Naltrexone-Metformin|Bupropion-Naltrexone-Metformin
223972862|NCT04614194|DRUG|Letrozole|Oral. Tablets should be taken at the same times every day, with or without food.
223972863|NCT04614194|DRUG|Abemaciclib|Oral. Tablets should be taken at the same times every day, with or without food.
224292505|NCT00706992|BIOLOGICAL|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
224292506|NCT00706992|BIOLOGICAL|Aldesleukin|Given subcutaneously
224292507|NCT00706992|BIOLOGICAL|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
223972864|NCT06646861|OTHER|Exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included.
224292508|NCT00706992|BIOLOGICAL|incomplete Freund's adjuvant|Given subcutaneously
223972865|NCT00689195|DIETARY_SUPPLEMENT|Curcumin powder|oral capsules containing the investigational agent
223972866|NCT00689195|DIETARY_SUPPLEMENT|Ashwagandha extract|4.5% extract of ashwagandha
223972867|NCT03254524|OTHER|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
223972868|NCT05186493|PROCEDURE|robot-assisted total pelvic exenteration|Patients with locally advanced pelvic cancer that require pelvic exenteration considered eligble, are operated minimmally invasive robot-assisted
223972869|NCT06602128|BEHAVIORAL|Experimental: Breathing Exercise Application Group|The Effect of Breathing Exercise on Anxiety, Pain and Life Findings in Patients Undergoing Coronary Angiography
223972870|NCT01818453|BEHAVIORAL|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
224292509|NCT05970419|OTHER|high power laser acupuncture (HPLA)|High power laser therapy A Zimmer Opton pro, integrated High-power class IV laser device (serial N: 15200013306 \& REF: 4682, made in Germany, manufactured by Zimmer Medizin System). It emits radiation in the infrared range to deliver topical heating and raise tissue temperature. The simultaneous application of two wavelengths of laser light (810 and 980nm) provides the user with a huge variety of therapy options. The laser probe - with the small spacer (3.1cm2) , with parameters of 3 watts, 5Hz, 50% duty cycle, 20 joule/ point for 13 seconds with 6.4 j/cm2 . Although a maximum power of 8000 W was reported in two studies, the average power of the lasers used in t
224292510|NCT05970419|OTHER|conventional treatment|"Superficial heat (hot packs). Will be applied 10 - 15 minutes. Guideline-endorsed treatment is to stay active, return to normal activity, and to exercise. Different exercise types are used in the treatment of CLBP such as strength and aerobic training on land as well as specific exercises such as motor control exercises (MCE).~General exercises activating the extensor (paraspinals) and flexor (abdominals) muscle groups will be used."
224292511|NCT05970419|OTHER|Sham laser|sham laser (Not active)
224292512|NCT04900909|DEVICE|Aortic Valve Replacement|Surgical replacement of aortic valves
223972871|NCT01879085|DRUG|Docetaxel|75 mg/m2 IV given over 60 minutes on day 8 every 21 days (1 cycle)
223972872|NCT01879085|DRUG|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, given over 67.5 minutes at 10 mg/m2/min
223972873|NCT01879085|DRUG|Vorinostat|given orally at the specified dose levels (either 300 mg/daily or 200 mg twice per day) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle)
223972874|NCT01879085|DRUG|Pegfilgrastim|administered on day 9 subcutaneously at 6 mg
223972875|NCT01554345|DRUG|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
223972876|NCT01709071|DRUG|IPV|
223972877|NCT01709071|DRUG|Low dose Sabin-IPV|
224292513|NCT05982821|OTHER|Artificial Intelligent|Artificial intelligence assisted radiologists to extract ultrasound features of thyroid nodules.
223972878|NCT01709071|DRUG|Low dose adjuvanted Sabin-IPV|
223972879|NCT01709071|DRUG|Middle dose Sabin-IPV|
223972880|NCT01709071|DRUG|Middle dose adjuvanted Sabin-IPV|
223972881|NCT01709071|DRUG|High dose Sabin-IPV|
223972882|NCT01709071|DRUG|High dose adjuvanted Sabin-IPV|
223972883|NCT03285633|BEHAVIORAL|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
223972884|NCT06380049|DEVICE|EMG Analysis Software|Surface electromyography devices are non-invasive tools that measure electrical activity produced by skeletal muscles through sensors placed on the skin.
223972885|NCT04248881|BEHAVIORAL|Healthy Lifestyle Education|"Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling."
223972886|NCT06517706|COMBINATION_PRODUCT|Combination of tDCS (device) with cognitive training (behavioral)|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive two sessions of tDCS plus cognitive training with the Categorization Program
223972887|NCT06517706|BEHAVIORAL|Categorization Program|Participation in 15 one-hour sessions distributed over three weeks. During each session participants will receive cognitive training and sham tDCS
223972888|NCT03891433|DRUG|Meropenem|Carbapenems group intervention.
223972889|NCT03891433|DRUG|Ertapenem 1000 MG|Carbapenems group intervention.
223972890|NCT03891433|DRUG|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
223972891|NCT06607315|OTHER|physical properties of soft tissue|Using the Myoton Pro device, the physical properties such as elasticity and viscosity of the Achilles tendon, patellar tendon, gastrocnemius, quadriceps, and hamstring muscles will be measured.
223972892|NCT06607315|OTHER|Analysis of Running Form|High-speed camera systems will be used to analyze biomechanical parameters in detail, such as angular movements of the lower extremity joints (tibia, ankle, knee, hip), step length, and ground contact time during running. These analyses will allow us to objectively characterize different running forms.
224122664|NCT04561388|OTHER|Pure Tone Audiometry|"The perception thresholds to 125, 250, 500, 750, 1000, 2000, 4000 and 8000 Hz pure tones will be measured within the month preceding the implantation using the same insert t.~Pure tone audiometry with the same frequencies will be done 2 weeks, 1, 2 and 4 months after the implantation."
224122665|NCT04561388|OTHER|Speech audiometry|The speech perception will be assessed in silence and in noise in free field 1 and 4 months after implantation. The speech perception in silence will be assessed using monosyllabic words 60 dB SPL. Speech in noise will be assessed using an adaptative test with fixed noise level (60 dB SPL).
224122666|NCT00038259|DRUG|Aldesleukin|
223972893|NCT06377059|DEVICE|WARD|Heart rate and respiratory rate is measured using Isansys lifetouch (Isansys Lifecare, Oxfordshire, UK), single-lead ECG monitor. An ECG is recorded as a 10-second segment every minute. Heart rate is derived once per minute from the R-R interval, and similarly, the RF is calculated from the changes in thoracic impedance once per minute. Blood pressure is monitored with either Meditech BlueBP-05 (Meditech Ltd., Budapest, Hungary) or A\&D TM-2441 (A\&D company Ltd., Tokyo, Japan). Both are non-invasive oscillometric, cuff-based blood pressure monitoring devices. Peripheral oxygen saturation was measured with NonIn WristOx 3150 (Nonin Medical Inc., Minnesota, USA) pulse oximeter, which is a photoplethysmograph with a sampling frequency of 75 Hz.
223972894|NCT03741309|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
223972895|NCT03741309|OTHER|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
223972896|NCT03741309|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
223972897|NCT06673433|DIAGNOSTIC_TEST|obesity|Patients diagnosed with obesity (BMI ≥ 28kg/m2)
223972898|NCT06673433|DIAGNOSTIC_TEST|health|the health control group include paticipants with nomal BMI
223972899|NCT02676739|DRUG|Adderall XR|
223972900|NCT03019809|BIOLOGICAL|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
224115371|NCT06671808|OTHER|Examination of HIV Infection in Patients with Multi-Drug Resistant Tuberculosis (MDR-TB)|This meta-analysis examines the impact of HIV infection on the prevalence and outcomes of multi-drug resistant tuberculosis (MDR-TB) among affected populations. The analysis synthesizes data from multiple studies conducted across various countries, focusing on the correlation between HIV co-infection and MDR-TB rates, treatment outcomes, and demographic factors. The findings aim to enhance understanding of the complex interactions between HIV and MDR-TB, ultimately informing clinical practices and public health strategies.
224115372|NCT06673108|DEVICE|SoLa Pelvic Therapy|SoLa Pelvic Therapy laser emits near-infrared (810-980 nm wavelength) energy to the vaginal tissues. The device treats at 5-8 W for 3-6 minutes and delivers a fluence of 3,000 and 5,000 J/cm2 through a sterile vaginal probe. Specific treatment time is calculated based on vaginal length. Based on a code input, the device can cycle between emitting laser energy or sham which is visible light without focused laser energy.
224115373|NCT06672783|PROCEDURE|echocardiogrphy|"Transthoracic echocardiography~• Parameters assessed:~* Right ventricular dimensions and function~* Pulmonary artery pressure estimation~* Valvular function assessment~* Left ventricular dimensions (end-diastolic and end-systolic)o Left ventricular function (ejection fraction, fractional shortening) o"
223972901|NCT03019809|BIOLOGICAL|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
223972902|NCT07008794|DRUG|Atorvastatin 40 mg|Rosuvastatin 20 mg
223972903|NCT06721624|OTHER|Naturopathic medicine|Whole system naturopathic medicine
223972904|NCT06030440|RADIATION|Eliminating RT to the elective neck|Reduction of radiation volume by eliminating radiotherapy to the elective neck
223972905|NCT06030440|RADIATION|RT standard of care|postoperative radiotherapy of the head and neck region according to current standard including elective nodal irradiation
223972906|NCT06719830|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of the septal accessory pathway
223972907|NCT06721130|DIAGNOSTIC_TEST|FDG radiotracer|Pilot study evaluating the role of FDG PET/CT in Cavernous sinus syndrome
223972908|NCT06720740|DEVICE|RELIEF Ureteral Stent|The study intervention is placement of the RELIEF Ureteral Stent
223972909|NCT06720740|DEVICE|Standard of Care Ureteral Stent|The control product is the Ascerta stent by Boston Scientific.
223972910|NCT05505110|PROCEDURE|Vaginal Seeding|Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the intervention group will have their nasal cavity swabbed with maternal vaginal secretions.
223972911|NCT05505110|PROCEDURE|Sterile Swab|Following birth by C-section and immediately after the initial newborn care by the general pediatric team, children randomized to the control group will have their nasal cavity swabbed with a sterile swab.
223972912|NCT06777589|DEVICE|Monitoring of anesthesia depth|During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).
224115374|NCT06672744|OTHER|Exercise|Lumbar muscles (especially quadratus lumborum) and thoracolumbar fascia stretching exercises and strengthening exercises for the lumbar and abdominal muscles were described by the physiotherapist. Participants were asked to perform the exercises three times a day, five days a week
224115375|NCT06672744|OTHER|Myofascial release technique|Myofascial release technique was applied by the same researcher (YY) twice a week for four weeks.
224115376|NCT06672744|OTHER|Kinesiotaping|Kinesiotaping was performed by the same researcher (XX) for two sessions per week for four weeks with fascia correction technique
224115377|NCT06619990|BIOLOGICAL|XmAb942|Antibody
223972913|NCT06890923|DRUG|Foralumab TZLS-401 100 µg|Patients meeting the requirements of the dose escalation rules will receive nasal foralumab 100 µg three (3) days a week (Monday-Wednesday-Friday) for two weeks, followed by a one-week rest, comprising 3-week cycles.
223972914|NCT05368922|DEVICE|Virtual reality rehabilitation|"The virtual reality rehabilitation protocol will be based on two perceptual-motor tasks (e.g., visuomotor tracking task and pointing task) in a 3D environment. The visuomotor tracking task will consist in tracking a virtual target moving with an effector manipulated by a remote controller. The pointing task will consist in tapping targets that are in a cube as quickly as possible with an effector manipulated by a remote controller. Both tasks will be performed in a 3D virtual playful environment.~The rehabilitation protocol will follow a progression through the manipulation of the virtual environment and the constraints of the tasks."
223972915|NCT06919640|DRUG|Psilocybin|10mg oral psilocybin
224115378|NCT06619990|DRUG|Placebo|Placebo
224115379|NCT02977091|OTHER|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
224115380|NCT00221091|PROCEDURE|ventriculo-peritoneal shunt|
224115381|NCT00049413|BIOLOGICAL|rituximab|
224115382|NCT00049413|DRUG|cyclophosphamide|
224115383|NCT00049413|DRUG|pentostatin|
224115384|NCT01810991|DEVICE|Nd:YAG Laser|Nd:YAG 1440nm Laser
224115385|NCT00827268|BEHAVIORAL|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
224115386|NCT05687760|BIOLOGICAL|bromelain|is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication
224115387|NCT05687760|DRUG|Calcium hydroxide|calcium hydroxide
224115388|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
224115389|NCT00122772|RADIATION|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
224115390|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
224115391|NCT00122772|RADIATION|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
223725239|NCT05398211|BEHAVIORAL|Preferred Recorded Music (PRM)|Preferred Recorded Music (PRM) involves a credentialed music therapist in planning and administering, which qualifies it as music therapy, which is defined as a professional use of music and its elements to improve physical, social, communicative, emotional, intellectual, and spiritual health, optimize quality of life and wellbeing(Aigen, 2013; Bruscia, 2014). PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. During the PRM intervention the MT will start/stop the music and otherwise not engage with the participants during the listening session.
223972916|NCT06192537|BEHAVIORAL|A role-playing exercise by utilizing an obesity suit in a simulation scenario|All participants will be asked to wear an obesity simulation suit (Unisex obesity Simulation suit, Erler-Zimmer, Germany) and to participate in a standardized scenario that simulates meetings between a person with obesity and a 'registered dietitian'. The 'registered dietitian' will be presented by a professional role-player and the scenario will encompass different levels of weight bias through dialogue and the use of inappropriate equipment.
223972917|NCT04027491|BEHAVIORAL|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
223972918|NCT01618578|PROCEDURE|rubber hand illusion|"There were three consecutive trials of the RHI:~1. one control trial: asynchronous condition (3 Min.)~2. two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
223972919|NCT05862467|BEHAVIORAL|Written Exposure Therapy (WET) via telehealth|Written Exposure Therapy (WET) via telehealth
223972920|NCT03993561|OTHER|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
223972921|NCT00223561|DRUG|methylphenidate|
223972922|NCT01772147|DRUG|Umeclidinium bromide 62.5mcg|Inhalation powder
223972923|NCT01772147|DRUG|Umeclidinium bromide 125mcg|Inhalation powder
223972924|NCT01772147|DRUG|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
223972925|NCT04382768|DRUG|Inhaled Hypertonic ibuprofen|Standard of care plus lipid ibuprofen 50mg tid
223972926|NCT04950387|OTHER|Breathing exercises|Based in yoga, common load
223972927|NCT02972242|RADIATION|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
224115392|NCT03461692|DRUG|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
224115393|NCT01483573|OTHER|neural mobilization|stretch the nerve
224115394|NCT01483573|OTHER|straight leg raise|stretch the hamstring
223972928|NCT04572997|DRUG|Apremilast|Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
223972929|NCT03795935|OTHER|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
224115395|NCT03250520|DRUG|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
224115396|NCT05392322|OTHER|Self-help skills|Self-help skills were given to down's syndrome children 3 times per week upto 15 minutes.
224115397|NCT05392322|DEVICE|Virtual video reality gaming|Virtual video reality gaming was given to children with down's Syndrome 3 time per week upto 15 minutes.
224115398|NCT00410280|BIOLOGICAL|IMA-638 is a biologic|
224115399|NCT03344159|DRUG|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
224115400|NCT03344159|DRUG|Placebo|Placebo daily for a total of duration of 12 weeks
224115401|NCT03344159|RADIATION|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
224115402|NCT03344159|DIAGNOSTIC_TEST|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
224292514|NCT06347991|BEHAVIORAL|SelfBack|The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
224292515|NCT06918015|DRUG|ZGCVP|"Patients receive the ZGCVP regimen (zanubrutinib, obinutuzumab, cyclophosphamide, vindesine, prednisolone) for 6 cycles at the following dose:~1. Zanubrutinib: 160mg orally twice daily;~2. Obinutuzumab: 1000mg intravenously on days 1, 8, and 15 of cycle 1 and on day 1 of subsequent 5 cycles;~3. Cyclophosphamide: 750m/m2 intravenously on days 1 of every cycle;~4. Vindesine: 3 mg/m2 (maximum dose 4 mg) intravenously on days 1 of every cycle;~5. Prednisolone: 30mg orally three times daily on day 1-5 of every cycle. Patients achieving CR at stage II underwent observation directly; those at stage III/IV receive obinutuzumab maintenance every 8 weeks for 2 years (1000mg intravenously) until disease progression or withdrawal. Patients with disease progression during treatment switch to second-line therapy."
224292516|NCT01125020|DRUG|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
224115403|NCT03246035|BEHAVIORAL|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
223725240|NCT05398211|BEHAVIORAL|Preferred Live Music (PLM)|Preferred Live Music (PLM) involves a credentialed music therapist in planning and administering which qualifies it as music therapy, which is defined as professional use of music and its elements to improve physical, social, communicative, emotional, intellectual and spiritual health, optimize quality of life and wellbeing (Aigen, 2013; Bruscia, 2014).PRM intervention will be delivered for 30 minutes, once per day at the same time of the day, for three consecutive days. The intervention will consist of the previously assessed preferred songs/musical pieces. The MT will be more actively engaged in a musical interaction with the participants in the PLM interventions.
223725241|NCT06023823|OTHER|Toe spread out|toe-spread-out exercise.
223972930|NCT00435981|DRUG|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
223972931|NCT00018759|DRUG|paroxetine|
223972932|NCT00018759|BEHAVIORAL|ongoing psychological screening|
223972933|NCT00305097|DIETARY_SUPPLEMENT|Decaffeinated coffee|5 cups per day for 8 weeks
223972934|NCT00305097|DIETARY_SUPPLEMENT|Caffeinated coffee|5 cups per day for 8 weeks
223972935|NCT00305097|DIETARY_SUPPLEMENT|No coffee|
224115404|NCT03246035|OTHER|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
224115405|NCT04536415|DRUG|Oseltamivir Phosphate 75 mg capsules|Capsules, 75 mg, single, oral dose
223972936|NCT06479525|OTHER|Big Toe Flexor Strengthening Exercises|16 participants will be in experimental group A giving them Big Toe Flexor strengthening exercise protocol along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
223972937|NCT06479525|OTHER|Calf Strengthening Exercises|16 participants will be in experimental group B giving them calf strengthening exercises including towel curls and thera band exercises along with the sports training plan for eight weeks measuring all values before giving them protocol and after protocol.
223972938|NCT01765452|DRUG|Closone|75mg/100mg, 8weeks, PO
223972939|NCT01765452|DRUG|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
223972940|NCT04560777|OTHER|CO-OP intervention|"The general structure of the intervention will follow the original key principles of CO-OP, with some adjustments to adapt it to the specificities of the ABI population (14 CO-OP sessions vs 10 in the original protocol).~The global strategy will be taught to the participant at the first session. The following sessions will be consisted of an process of implementation of the global strategy in the context of guided discovery to identify domain specific strategies to overcome performance ''breakdowns the participant will be experiencing when performing the self-selected tasks. In addition, homework will be assigned to encourage the application and practice of the cognitive strategies discovered during the intervention sessions. Parents will be invited to attend the sessions if it will be possible for them. In any case, the global strategy, as well as the progress of the child, will be explained to the parents."
223972941|NCT05063123|DRUG|Flotetuzumab|Flotetuzumab will be given after at least 2 intensive chemotherapy cycles and before the start of the conditioning regimen prior to allo-HCT.
224115406|NCT04536415|DRUG|Tamiflu capsules 75 mg|Capsules, 75 mg, single, oral dose
224115407|NCT01522651|DRUG|Ranolazine|Tablets administered orally twice daily.
224115408|NCT01522651|DRUG|Dronedarone|Capsule administered orally twice daily
224115409|NCT01522651|DRUG|Ranolazine placebo|Tablets administered orally twice daily.
223725242|NCT06023823|OTHER|Dry needling+Toe spread out|The group will be given 3 sessions of dry needling with Seirin branded 0.6\*50 mm acupuncture needles for trigger pointe in the abductor hallucis muscle and additionally toe-spread-out exercise.
223972942|NCT00740597|GENETIC|gene expression analysis|
223972943|NCT00740597|GENETIC|polymerase chain reaction|
224115410|NCT01522651|DRUG|Dronedarone placebo|Capsules administered orally twice daily
223972944|NCT00740597|GENETIC|western blotting|
223725243|NCT02711540|PROCEDURE|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
223725244|NCT01868750|DIETARY_SUPPLEMENT|Calcitriol|1.0ug twice daily for 7 days before surgery
223725245|NCT01868750|DIETARY_SUPPLEMENT|Control Pill|placebo pill taken twice daily for 7 days before surgery
223972945|NCT00740597|PROCEDURE|neoadjuvant therapy|
223972946|NCT00740597|PROCEDURE|therapeutic conventional surgery|
223972947|NCT00740597|RADIATION|intensity-modulated radiation therapy|
223972948|NCT03955354|DRUG|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
224115411|NCT06513221|DRUG|Chemotherapy, Bevacizumab, Adebrelimab|Adebrelimab: 1200mg，q3w Bevacizumab: 7.5mg/kg，q3w Fruquintinib: 4mg po d1\~d14, q3w Chemotherapy: XELOX/mXELIRI: conventional dose
223972949|NCT03955354|DRUG|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
223972950|NCT04402983|OTHER|Physiotherapy|Program content Respiratory exercise (chest breathing, diaphragmatic breathing, basal expansion exercises), Breath control training, Active breathing techniques cycle Light aerobic exercise Posture exercises Self walking
223972951|NCT01181219|PROCEDURE|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
223972952|NCT01181219|PROCEDURE|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
223972953|NCT00841607|PROCEDURE|pancreaticojejunostomy vs pancreaticogastrostomy|
223972954|NCT00413075|DRUG|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
223972955|NCT01304108|OTHER|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
223972956|NCT01304108|OTHER|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
223972957|NCT01304108|OTHER|Usual Care|No addition to the baseline system for care
223972958|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
223972959|NCT03439098|DIETARY_SUPPLEMENT|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
223972960|NCT03439098|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 8 weeks
223972961|NCT03443063|DRUG|Lemborexant|oral tablet
223972962|NCT00552513|PROCEDURE|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) as soon as possible (and within 24 hours of randomisation).
223972963|NCT00552513|PROCEDURE|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention \[PCI\] or coronary artery bypass graft \[CABG\] surgery) any time after 36 hours after randomisation.
223972964|NCT00990262|RADIATION|Cardiac Computed Tomography|"1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
223972965|NCT02827578|DRUG|Tamsulosin|Tamsulosin
223972966|NCT02827578|DRUG|Solifenacin|Solifenacin
223972967|NCT02827578|DRUG|Solifenacin placebo|Solifenacin placebo
223972968|NCT02825277|DEVICE|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
223972969|NCT00514475|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
223972970|NCT04316520|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet 2:1
223972971|NCT05771597|OTHER|Home Biofeedback therapy|"Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~1. HBT for patients with constipation and dyssynergic defecation:~   Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~2. HBT for patients with FI:~   Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~3. HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well."
224115412|NCT02650778|PROCEDURE|Breast ultrasound|automated whole breast ultrasound
224115413|NCT01746602|DRUG|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
224115414|NCT01746602|DRUG|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
224115415|NCT01746602|DEVICE|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
224115416|NCT01746602|DEVICE|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
224115417|NCT01746602|DEVICE|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
224115418|NCT03699345|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
224115419|NCT00340327|DRUG|IMA-638|
224115420|NCT04644107|DRUG|Marizomib|Marizomib will be administered via IV
224115421|NCT06940635|DEVICE|closed-loop BCI-FES device|Closed-loop neurorehabilitation system that combines EEG-based brain-computer interface technology with functional electrical stimulation (FES) to facilitate neural and motor recovery.
224115422|NCT00302601|PROCEDURE|Scintigraphic interpretation|Not relevant
223972972|NCT05771597|OTHER|Office biofeedback therapy|"Patients will receive traditional office biofeedback, once weekly, over six weeks.~1. OBT for patients with constipation and dyssynergic defecation:~   The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~2. OBT for patients with FI:~   Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~3. OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training."
223972973|NCT01827098|PROCEDURE|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
224115423|NCT02658656|DEVICE|ReWalk 6.0|Exoskeletal Assisted Walking Device
224115424|NCT00284388|PROCEDURE|Simultaneous controlled power measurement|
224115425|NCT00284388|PROCEDURE|Surface EMG measurement|
223972974|NCT05418686|BIOLOGICAL|Capillary colchicine dosage in colchicine-resistant Familial Mediterranean Fever patients.|"* Adherence to colchicine therapy will be assessed by the Girerd questionnaire (6 questions ) completed by the patient at the inclusion visit.~* A blood sample (8ml) is taken, including a haemogram, CRP and creatinine and proteinuria.~* Standard on-site stool analysis for C. difficile toxin.~For research purposes, samples of:~* Stool. If the patient is unable to produce stools on the day of the visit, a collection kit with 2 tubes containing a preservative will be given to him/her as well as a stamped envelope to take the sample at home and send it by post within 10 days according to a validated procedure.~* A strand of hair with the diameter of a pencil and a minimum length of 2 cm, in the region of the posterior vertex.~* In patients with baldness or bleached hair only: pubic and/or axillary hair, a pencil-sized strand.~* Additional blood (5ml) and urine (2ml) samples for colchicine determination."
224115426|NCT00247390|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
224115427|NCT00247390|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
224115428|NCT05565677|DEVICE|micro-computed tomography scanning of lung tissue specimens|Micro-computed tomography will be utilized to scan surgically resected lung tissue specimens.
224115429|NCT05730439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224115430|NCT05730439|DRUG|Nicotine Oral Pouch|Receive ZYN brand NP
224115431|NCT05730439|DRUG|Nicotine Oral Pouch|Receive Rogue brand NP
224115432|NCT05730439|OTHER|Questionnaire Administration|Ancillary studies
224115433|NCT05730439|DRUG|Smokeless Tobacco|Receive usual SLT
224115434|NCT05482347|OTHER|Educational video|The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
224115435|NCT06055894|DIETARY_SUPPLEMENT|Omega-3|For 2 weeks, patients will receive omega 3 fatty acid supplements 1640 mg (2 capsules) twice daily
224115436|NCT06055894|DIETARY_SUPPLEMENT|Curcumin|For 2 weeks, patients in the curcumin arm will receive Curcumin C3 complex 1000 mg with 5 mg BioPerine twice daily
224115437|NCT06055894|DIETARY_SUPPLEMENT|Probiotic|For 2 weeks, patients in the probiotic arm will receive Ultra-50 probiotics with 50 billion CFU per capsule (one capsule) twice daily
224292517|NCT01125020|DRUG|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
224115438|NCT06055894|OTHER|Whole food, plant-based diet (WFPBD)|Daily Harvest once a week. The meals will have range from 2 breakfast, 11 lunch/dinners, 1 snack (provided Week 1), and whole grains items (provided Week 2).
224115439|NCT03624101|DRUG|Symdeko|CFTR modulator
224115440|NCT03624101|DRUG|Ivacaftor and Symdeko|CFTR modulator
224115441|NCT06519435|DEVICE|Mayo Dopplex ABIlity|Device used to measure lower extremity venous hemodynamic pressure
224115442|NCT06519435|DEVICE|Intermittent Pneumatic Compression (IPC)|Device used to measure lower extremity venous hemodynamic pressure
224115443|NCT06501872|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
223972975|NCT02867241|BEHAVIORAL|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
223972976|NCT02867241|BEHAVIORAL|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
223972977|NCT04899401|DIETARY_SUPPLEMENT|Standard of care + PediaFlù®|Standard of care: Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. PediaFlù®: During the 6 days of the clinical investigation, the subjects will administer PediaFlù® 5ml x3 times per day for children below 6 years and 10mlx3 times per day for children above 6 years.
223972978|NCT04899401|OTHER|Standard of care|Standard of care for acute tonsillitis / rhinopharyngitis is focused on symptomatic treatment. Standard of care Nasopharyngeal liberation through hydration with drinking fluids to support body fluid excretion, aspiration of secretions, NaCl solution for nasal irrigation, Nasal sprays with sea water, nasal spray with active compound (to be used only at special indication of the medical doctor) Throat spray with Benzydamine hydrochloride (Tantum Verde®), Pediatric use: children over 6 and below 12: 4 sprays 2 - 6 times a day. Children (under 6 years): 1 spray per 4 kg of body weight, a maximum of 4 sprays at once, 2-6 times a day according to the leaflet. Each spray equals 0.17 ml of solution. Acetaminophen (Paracetamol) per os: at need, as antipyretic (\>38,5C), 10 mg/kg/dose, per need every 6-8 hours or according to the leaflet, maximum dosage 80 mg / kg / day. A dosage of over 30 mg/Kg/dose will result in an IP failure;
223972979|NCT01816685|DEVICE|CPAP|
224115444|NCT03101891|PROCEDURE|Serial amnioinfusions with isotonic fluid|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
224115445|NCT03101891|DEVICE|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.
223972980|NCT01417702|DEVICE|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
224115446|NCT03101891|DRUG|Isotonic fluid|Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
224115447|NCT05180487|BEHAVIORAL|Family Check-Up|This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be provided.
224115448|NCT06256380|BEHAVIORAL|Enhanced Cognitive-behavior therapy for adolescents with an eating disorder|Psychotherapy
224115449|NCT06256380|BEHAVIORAL|Family-based therapy for adolescents with an eating disorder|Psychotherapy
224115450|NCT02934529|DRUG|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
223972981|NCT01157351|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
223972982|NCT01157351|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 15 months
223972983|NCT01157351|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
223972984|NCT01157351|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
224115451|NCT02934529|DRUG|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
224115452|NCT02934529|DRUG|5-FU|5-FU 400 mg/m² bolus day 1, q d15
224115453|NCT02934529|DRUG|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
224115454|NCT02934529|DRUG|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
224115455|NCT02934529|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
223972985|NCT01157351|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
223972986|NCT01157351|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
223972987|NCT01157351|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
223972988|NCT01157351|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
224115456|NCT02934529|DRUG|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
224115457|NCT02934529|DRUG|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
223972989|NCT00746785|DRUG|2.5 mg Olanzapine|2.5 mg
223972990|NCT00746785|DRUG|5mg Olanzapine|5 mg
223972991|NCT00746785|DRUG|placebo|placebo
223972992|NCT06250478|DIAGNOSTIC_TEST|Dynamic ultrasound of the calf muscles|Dynamic changes of the calf muscles during walking will be assessed in persons after stroke and compared to healthy controls
223972993|NCT06274450|COMBINATION_PRODUCT|skin care product|Subjects are uniformly using skin care products provided by the sponsor during the test. Skin care product include: WINONA sensitiveness relieving moisturizing cleansing foam, WINONA sensitiveness relieving moisturizing lotion, WINONA anti-sensitive tolerance-extreme moisturizing cream
223972994|NCT06274450|OTHER|Drinks with active ingredients Rosa Roxburghii and Pomegranate|Take drinks with active ingredients such as Rosa Roxburghii and Pomegranate. Drink every morning on an empty stomach, 20ml/2 sachets/day.
223972995|NCT00566839|PROCEDURE|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
223972996|NCT00566839|PROCEDURE|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
223972997|NCT03876002|DRUG|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
223972998|NCT02783053|DRUG|Metformin|Metformin vs no metformin
223972999|NCT02602353|DRUG|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
223973000|NCT02602353|DRUG|Placebo Patch|One Placebo Patch applied daily for 3 days
223973001|NCT02602353|DRUG|No Treatment|No Treatment for 3 days
223973002|NCT05549336|DRUG|PD-1 inhibitor|PD-1 inhibitor is defined as the exposure factor in our cohort study, for the tumor patients with the treatment of PD-1 inhibitor are allocated to the Exposure group whereas those tumor patients without the treatment of PD-1 inhibitor are allocated to the Non-exposure group.
223973003|NCT02485314|OTHER|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
223973004|NCT00263484|DRUG|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
223973005|NCT00263484|DRUG|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
223973006|NCT00263484|DRUG|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
223973007|NCT04244149|OTHER|Prolonged Exercise session|After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.
223973008|NCT04804059|DRUG|[14C]-APX001 Oral Solution|Total dose containing NMT 3.1 MBq (84.0 µCi) 14C
224115458|NCT02934529|DRUG|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
224115459|NCT02934529|DRUG|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
224115460|NCT06738797|DIAGNOSTIC_TEST|SPHERTEST test|The SPHERETEST is an in vitro model of heterotypic spheroids composed of commercial urothelial carcinoma tumor cells and leukocyte mononuclear cells from healthy donors.
224115461|NCT03656835|PROCEDURE|Molecular Nanotechnology|Undergo ILN biochip testing
224115462|NCT06278987|DRUG|PENG block and cryoablation|will receive an ultrasound guided PENG block with 20 mL of 0.5% bupivacaine followed by cryoablation of the PENG nerves.
223973009|NCT04804059|DRUG|[14C]-APX001 Solution for Infusion|Total dose containing NMT 3.4 MBq (93.0 µCi) 14C
223973010|NCT00356993|DRUG|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
223973011|NCT00356993|BEHAVIORAL|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
224292518|NCT05402982|DEVICE|Electrical Cardiometry (EC) ICON|Electrical Cardiometry (EC) ICON (Osypka Medical, Berlin, Germany) is an FDA approved device used for non-invasive measurement of some hemodynamic parameters as cardiac output,cardiac index, stroke volume,stroke volume variation, systemic vascular resistance, thoracic fluid content, ICON (index of contractility), variation of ICON,corrected flow time and systolic time ratio.The set data of EC are the height, weight,hemoglobin, Oxygen saturation(SPO2),age, gender ,blood pressure and heart rate(HR) of the patient
224292519|NCT05402982|OTHER|Rohrich formula|Rohrich formula and the intraoperative fluid ratio (subcutaneous infiltration fluid plus intravenous fluid divided by total aspirate volume) will be 1.2
224292520|NCT01293760|OTHER|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
224292521|NCT01293760|OTHER|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
223973012|NCT04947826|PROCEDURE|HAIC (Hepatic arterial infusion chemotherapy)|For the HAIC procedure, a 5F catheter was introduced using the Seldinger technique through the femoral artery or the radial artery. Then, angiographic surveys of the celiac trunk and superior mesenteric artery were performed. According to tumor size, location, and arterial supply, the catheter or a 2.7F microcatheter was advanced into the hepatic artery at the level of selective segmental, lobar, or whole liver. The catheter or microcatheter was connected to an external infusion pump. The following regimen of modified FOLFOX was administered: oxaliplatin, 85mg/m2 for 2 hours; leucovorin, 400mg/m2; and 5-fluorouracil, 2400mg/m2 for 44-46 hours. After HAIC treatment, the catheter or microcatheter, and the sheath were removed.
223973013|NCT04947826|DRUG|HLX10 (PD-1 antibody)|PD-1 antibody with proven efficacy in advanced hepatocellular carcinoma
224115463|NCT06278987|DRUG|fascia iliaca compartment block|will receive an ultrasound guided fascia iliaca compartment catheter with initial bolus of 20 mL of 0.5% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour
224115464|NCT04484220|DEVICE|Ellipsys Vascular Access System|The Ellipsys System is indicated for the creation of a proximal radial artery to perforating vein anastomosis via a retrograde venous access approach in patients with a minimum vessel diameter of 2.0mm and less than 1.5mm of separation between the artery and vein at the fistula creation site who have chronic kidney disease requiring dialysis.
224115465|NCT02026908|DEVICE|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
224115466|NCT06512363|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
224115467|NCT06512363|DRUG|Ramelteon placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
224292522|NCT01077882|BEHAVIORAL|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
223973014|NCT04947826|DRUG|HLX04 (VEGF antibody)|Combination of PD-1 antibody and VEGF antibody might promote the efficacy of HAIC in hepatocellular carcinoma with major portal vein thrombosis.
223973015|NCT04947826|DRUG|Placebo|Placebo
223973016|NCT06067022|OTHER|observation|Planned measurements and scales will be applied
223973017|NCT05188625|OTHER|Telesupport - Telehealth|Online self-paced dietary education videos; Dietary counselling via video consultation; Blood glucose monitoring via a specially-designed health app
223973018|NCT02517528|DRUG|ABT-450/r/ABT-267|Tablet
223973019|NCT02517528|DRUG|ABT-333|Tablet
224115468|NCT04005209|DRUG|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
224115469|NCT04005209|OTHER|Pain management|Pain management
224115470|NCT02811458|BEHAVIORAL|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
224115471|NCT05922423|BEHAVIORAL|MBSR|Week 1: Introduce mindfulness theory knowledge to participants and guide them to engage in mindfulness breathing training; Week 2: Sitting meditation, explaining the essence of meditation and practicing with music; Week 3: Explain the connotation of walking meditation, inform the participants of precautions, and guide them to practice; Week 4: Explain the connotation and requirements of body scanning, guide participants in practice; Week 5: Introduce the connotation of hatha yoga and guide participants to practice; Week 6: Explain the meaning of mindfulness sounds and thoughts, guide participants to practice; Week 7: Explain the characteristics of non selective perception, combined with music practice; Week 8: Emphasize mindfulness to promote health, encourage participants to practice internalization, and develop into their own patterns.
224115472|NCT05922423|BEHAVIORAL|health education|For cancer patients who have entered the comfort group, automatic tweets and health knowledge related to science popularization will be provided knowledge
224115473|NCT04742257|DEVICE|MyoRegulator® device|Trans-spinal DCS paired with peripheral DCS
224115474|NCT03083158|DRUG|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
224115475|NCT05776186|DRUG|Spinal anesthesia with heavy bupivacaine|Spinal anesthesia
224292523|NCT01077882|BEHAVIORAL|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
224292524|NCT01077882|BEHAVIORAL|Lifestyle factors and psycho-education|by dietician and psychiatrist
223973020|NCT02517528|DRUG|ribavirin|Tablet
224292525|NCT01077882|OTHER|no educational program|standard care without educational program
223973021|NCT02986750|DEVICE|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
223973022|NCT02986750|DEVICE|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
223973023|NCT02986750|DEVICE|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
223973024|NCT04315129|DIAGNOSTIC_TEST|Smart Catheter Biosensor|A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
223973025|NCT02361879|DRUG|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
223973026|NCT02361879|DRUG|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
223973027|NCT04764201|DRUG|HIP2001|Test drug
223973028|NCT04764201|DRUG|HGP2001|Reference drug
224292526|NCT01769274|DRUG|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
223973029|NCT04419805|DEVICE|Single Palatal TAD|A single mini-screw inserted in the mid-palate
223973030|NCT04419805|DEVICE|Two buccal TADs|Two buccal TADs inserted in the upper jaw
223973031|NCT00513058|DRUG|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
223973032|NCT00513058|DRUG|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
224115476|NCT05279794|OTHER|Jones Group (Strain Counterstrain)|No pain positioning technique with diaphragmatic breathing
224115477|NCT05279794|OTHER|Myofascial Induction Group|Myofascial Induction technique on the lumbar fascia
224115478|NCT05279794|OTHER|Placebo Group|No pain positioning of participants
224115479|NCT01937130|DRUG|IDN-6556|
224115480|NCT01937130|OTHER|Placebo|
224115481|NCT02618850|PROCEDURE|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
224115482|NCT02618850|DRUG|first-line chemotherapy|as prescribed by oncologist
224292527|NCT01769274|DRUG|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
224292528|NCT02059720|PROCEDURE|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
224292529|NCT03795831|DEVICE|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
224292530|NCT00949689|BEHAVIORAL|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
223973033|NCT04961242|DEVICE|Together for Wellness digital mental health website|The intervention is a digital mental health resources website that includes multiple, free resources for broad public use. Different categories of resources include information on COVID-19 from CDC, multi-language versions of the UCLA Mindfulness App and other meditation programs, resources for families and social connection, including addressing discrimination or equity, and resource links.
223973034|NCT05005286|OTHER|Past history of vaginal Infections|With or without vaginal infection during pregnancy
223973035|NCT05780216|DRUG|DMT + harmine|The intervention used in this study is a combination of the two main ingredients of ayahuasca, DMT (N,N-dimethyltryptamine) and harmine in purified form.
223973036|NCT05780216|DRUG|Placebo|The placebo consists of pharmaceutically inactive ingredients and additional flavors, and is organoleptically hardly distinguishable from the verum.
223973037|NCT00684203|DRUG|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
223973038|NCT00684203|DRUG|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
223973039|NCT00684203|DRUG|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
223973040|NCT00684203|DRUG|Clopidogrel|100 mg two or three times daily for 60 days.
223973041|NCT02759237|DEVICE|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK \& EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System \& EnVeo R Loading System - Used to load the TAV onto the delivery system"
224115483|NCT03158649|OTHER|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
224115484|NCT05402501|BEHAVIORAL|"Lifestyle intervention program Leef! met MS"|The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
224115485|NCT04861961|PROCEDURE|DS vs. SADI-S vs. OAGBP|Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
224115486|NCT04018963|PROCEDURE|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
224115487|NCT04018963|PROCEDURE|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
224115488|NCT02563288|DRUG|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
223973042|NCT04257422|OTHER|Intentional Rounding|"A new method of nursing care named Intentional Rounding. The intentional roundings are planned rounds, conducted at regular intervals by nursing staff to anticipate care, comfort, hospitality and psychological needs of hospitalized users."
223973043|NCT06483386|DRUG|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine|Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
223973044|NCT01699698|OTHER|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
223973045|NCT03418493|DRUG|LY3316531 - IV|Administered IV.
223973046|NCT03418493|DRUG|LY3316531 - SC|Administered SC.
223973047|NCT03418493|DRUG|Placebo - IV|Administered IV.
223973048|NCT05203809|DEVICE|TempTraq temperature monitor|All participants will wear both TempTraq temperature monitor and CORE temperature monitor.
223973049|NCT06063447|OTHER|Examination|Posture Evaluation, Scoliosis Examination, Pelvic Floor Assesments
223973050|NCT00485706|PROCEDURE|high calcium dialysate|
223973051|NCT04847310|OTHER|Group brief transdiagnostic cognitive-behavioral therapy|An adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) (Barlow et al., 2015) and the IAPT programme (Clark, 2018). It has been developed by Cano-Vindel (González-Blanch et al., 2018) and consists in seven 90-minute sessions, provided by a non-assessor clinical psychologist in 12-16 weeks, with 8-10 participants per group. Sessions are weekly or biweekly, reducing their frequency as the intervention advances. The activities and homework proposed are supported with materials such as theory documents, a CD for progressive muscle relaxation, self-recording sheets, and a therapy web (www.desordenesemocionales.es).
223973052|NCT04847310|OTHER|Individual brief transdiagnostic cognitive-behavioral therapy|An adaption of the group therapy, with the same phases. However, since it is an individual intervention, it is more flexible than group one and its contents and duration can be personalized. This intervention consists of a minimum of 6 and a maximum of 8 sessions of 30-60 minutes, provided by a clinical psychologist not involved in the assessments.
223973053|NCT04847310|OTHER|Treatment as usual|Participants in this group will be provided the common primary care treatment by the GP, in a face-to-face consultation that seldom exceeds 10 minutes. TAU usually consists in pharmacological treatment prescribed by the GP, however, it might also consist in practical advice or even non-treatment (Watts et al., 2015). The first consultation will count as part of the recruitment process and, if the patient accepts to participate in the trial, no therapeutic help will be provided to them until they are allocated. Once in the TAU intervention, if the practitioner recommended any psychological treatment as part of it (e.g., referral to specialized care), the participant would be excluded to avoid contamination between clusters. TAU has not a specific amount of sessions; it will finish when the GP considers the patient is recovered.
223973054|NCT00719212|BIOLOGICAL|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
223973055|NCT02454049|DIETARY_SUPPLEMENT|beetroot juice|6mmol nitrate
223973056|NCT02454049|DIETARY_SUPPLEMENT|sodium nitrate|6mmol sodium nitrate
223973057|NCT02454049|DIETARY_SUPPLEMENT|water|plain water
223973058|NCT03837236|OTHER|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
223973059|NCT05446714|DEVICE|CH 4 band|expansion of maxilla and observation improvement of the air way
223973060|NCT05446714|DEVICE|HH 2 bands|expansion of maxilla and observation improvement of the air way
223973061|NCT05446714|DEVICE|MSE 2 bands and 4|expansion of maxilla and observation improvement of the air way
223973062|NCT02106364|DRUG|Insulin Peglispro|Administered SQ
223973063|NCT02106364|DRUG|Insulin Glargine|Administered SQ
223973064|NCT06412536|OTHER|Blood work|Blood work on some participants to review eligibility for future clinical trials
223973065|NCT03253120|OTHER|Water|Patient/ Healthy volunteer will drink 5dl of Water
223973066|NCT02742532|DRUG|Oxytocin|Intranasal oxytocin 40 IU
223973067|NCT02742532|DRUG|Placebo|Intranasal saline solution
223973068|NCT03499561|DIAGNOSTIC_TEST|urine analysis|Intervention is (urine analysis ): of a mid stream urine sample will be taken
223973069|NCT02392663|OTHER|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
223973070|NCT02392663|OTHER|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
223973071|NCT02392663|OTHER|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
223973072|NCT04978428|DRUG|Cannabidiol|Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)
224115489|NCT02563288|DRUG|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
224115490|NCT00104494|DRUG|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
224115491|NCT02674997|BIOLOGICAL|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
224115492|NCT05072769|DIETARY_SUPPLEMENT|Date Fruit|Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
224115493|NCT00824499|OTHER|Complex regional intervention|"Components of the complex intervention:~* Introduction of a program coordinator~* Introduction of a self-management education program~* Bottom up development of a interdisciplinary care protocol~* Support program for the intiation of insulin therapy in primary care~* Regional audit"
223973073|NCT05045950|DRUG|Memantine -Twice Daily or Extended Release|"Both extended release memantine and twice daily memantine dosing will be allowed.~Twice daily dosing:~The target dose for memantine is 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg each week to a target of 10 mg twice daily (i.e., 5 mg a day on week 1, then 5 mg twice daily (BID) on week 2, then 10 mg in AM plus 5 mg in PM on week 3, followed by 10 mg in AM plus 10 mg in PM by week 4).~Extended Release Memantine:~The target dose for extended release memantine is 28 mg. Dose will be escalated by 7 mg per week to a target of 28 mg daily (i.e., 7 mg a day on week 1, then 14 mg a day on week 2, then 21 mg a day on week 3, followed by 28 mg a day by week 4)."
223973074|NCT05045950|RADIATION|WBRT utilizing the PRDR technique|The total dose of 3000 cGy (30 Gy) will be divided 10 fractions of 300 cGy (3 Gy); each fraction will be delivered as a series of 20 cGy (0.2Gy) pulses separated by 3 min time intervals. 20 cGy / 3 min = 6.67 cGy/min (or 0.0667 Gy/min). Total time is determined by the fractionated series and time intervals, meaning 300cGy/20cGy = 15 division x 3 minutes = 45 minutes. Including time to set up, approximate total time per treatment session will be 60 minutes.
223973075|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.5ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
223973076|NCT05645900|BIOLOGICAL|Quadrivalent influenza virus subunit vaccine|This vaccine（0.25ml） is produced by Ab\&b Biotechnology Co., Ltd.JS。Subjects will receive two doses of quadrivalent influenza virus subunit vaccine administered 28 days apart by intramuscular injection
223973077|NCT05645900|BIOLOGICAL|Quadrivalent split influenza virus vaccine|This vaccine（0.25ml） is produced by HUALAN BIO。Subjects will receive two doses of quadrivalent split influenza virus vaccine administered 28 days apart by intramuscular injection
224115494|NCT05179031|DIETARY_SUPPLEMENT|First Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
224115495|NCT05179031|DIETARY_SUPPLEMENT|Second Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
224115496|NCT05179031|DIETARY_SUPPLEMENT|Third Reference product (dextrose, containing 25 g of carbohydrates)|Reference dextrose solution containing 25 g of available carbohydrates
224115497|NCT05179031|DIETARY_SUPPLEMENT|High protein tube feed|Nutritional product containing 25 g of available carbohydrates
224115498|NCT05179031|DIETARY_SUPPLEMENT|High-protein tube feed with additional amino acid|Nutritional product containing 25 g of available carbohydrates
224115499|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients|Nutritional product containing 25 g of available carbohydrates
224115500|NCT05179031|DIETARY_SUPPLEMENT|Oral Nutritional Supplement for diabetes patients (new formula)|Nutritional product containing 25 g of available carbohydrates
224115501|NCT05179031|DIETARY_SUPPLEMENT|ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
224115502|NCT05179031|DIETARY_SUPPLEMENT|Plantbased ONS for disease related malnutrition|Nutritional product containing 25 g of available carbohydrates
224115503|NCT02829177|DRUG|Allopurinol|
224115504|NCT02829177|DRUG|Placebo|
223973078|NCT06146790|PROCEDURE|endovascular treatment|For the subjects randomized to endovascular treatment (EVT) treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well.Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
223973079|NCT06146790|OTHER|Standard medical management|Standard medical management
223973080|NCT04276636|DRUG|Caltrate Pill|Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
223973081|NCT01912183|BEHAVIORAL|Communication through PHR outside clinic|
223973082|NCT01912183|BEHAVIORAL|Monitoring device in PHR|
224292531|NCT05981248|BEHAVIORAL|Mindfulness Intervention for Emotional Distress|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
223973083|NCT01912183|DEVICE|Physical activity and sleep monitor|
223973084|NCT01912183|OTHER|PHR|Access to their PHR
224292532|NCT05818748|DEVICE|virtual reality|virtual reality distraction
223725246|NCT03495076|OTHER|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
223973085|NCT01878136|DRUG|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
223973086|NCT01859221|RADIATION|Stereotactic radiation|Stereotactic radiation
223973087|NCT05259397|DRUG|PF-07225570|PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.
223973088|NCT05259397|DRUG|sasanlimab|Sasanlimab will be administered SQ on day 1 of each 28 day cycle.
224115505|NCT05789264|DEVICE|Nasal Compression Device|Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.
224115506|NCT05789264|DIAGNOSTIC_TEST|Routine Care|Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
224115507|NCT00162396|DRUG|Albuterol|
224115508|NCT01104259|DRUG|veliparib|Given PO
224115509|NCT01104259|DRUG|cisplatin|Given IV
223973089|NCT03738098|BEHAVIORAL|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
223973090|NCT03738098|BEHAVIORAL|GUÍA|GUÍA for the ROR1 visit.
223973091|NCT01990313|DEVICE|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
224115510|NCT01104259|DRUG|vinorelbine tartrate|Given IV
224115511|NCT01104259|OTHER|laboratory biomarker analysis|Correlative studies
223973092|NCT01742234|PROCEDURE|Organ Donation|People in this study will donate either a lung or kidney
223973093|NCT02711813|DRUG|TAB08|biologic
223973094|NCT02711813|OTHER|Placebo|
223973095|NCT03426553|BIOLOGICAL|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
223973096|NCT03426553|BIOLOGICAL|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
223973097|NCT06168422|DEVICE|DES|drug eluting stent
223973098|NCT06168422|DEVICE|DCB|drug-coated balloon
223973099|NCT03511378|DRUG|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
223973100|NCT03511378|DRUG|Neulasta®|Administration of Neulasta®
223973101|NCT05992636|PROCEDURE|pneumoperitoneum insufflation (flow) rate|"Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)"
223973102|NCT06355128|OTHER|NOT|NOT
224115512|NCT01104259|OTHER|pharmacological study|Correlative studies
224115513|NCT02590445|DEVICE|deep brain stimulation system|
224115514|NCT04247932|BEHAVIORAL|Active labor market intervention|Behavior change intervention
224115515|NCT03710785|BEHAVIORAL|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
224115516|NCT02022683|DEVICE|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
224115517|NCT06169865|OTHER|cross sectional study|cross sectional study to explore magnitude of peripheral vascular diseases and presentations in patients with autoimmune diseases in sohag society.
224115518|NCT03723265|DEVICE|Cardiac Resynchronization Therapy|
224115519|NCT05644210|DRUG|Telitacicept|160mg once a week for 24 weeks
224115520|NCT05644210|DRUG|Rituximab|Patients received 200mg of rituximab intravenously at week 0 and week 2.
224115521|NCT05644210|DRUG|Aspirin|50-100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
224115522|NCT05644210|DRUG|Warfarin|Warfarin should be used in patients with arterial thrombosis, and rivaroxaban should be replaced if the patient cannot reach the standard or cannot tolerate it
224115523|NCT05644210|DRUG|Hydroxychloroquine|200mg, po, twice per day (Bid) prescribed，if tolerated by the patient， the dose should remain constant during the observation period
223973103|NCT00522717|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
223973104|NCT00522717|BEHAVIORAL|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
223973105|NCT06311747|BEHAVIORAL|Oculo-motor exercises|Oculo-motor exercises will be applied as an intervention. As oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (The eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (First eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (Horizontal, vertical, diagonal, circular, infinite eight).
223973106|NCT00837096|DEVICE|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
223973107|NCT00837096|DEVICE|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
223973108|NCT01026116|DRUG|Epirubicin|75 mg/m2 every-3-week for four cycles
223973109|NCT01026116|DRUG|Cyclophosphamide|600 mg/m2 every-3-week for four cycles
223973110|NCT01026116|DRUG|Paclitaxel|175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
223973111|NCT05249309|DRUG|Ketamine|The administration will be done subcutaneously, in the abdominal wall, using ketamine without dilution. The ketamine dose will be 0.5mg/kg, recommended for the first infusion. If there is no adequate response, according to psychiatric scales and clinical evaluation, the second infusion must be performed at least two days after the first, using 0.75mg/kg and the subsequent 1mg/kg. If the patient adequately responds to a dose (0.5 or 0.75mg/kg), it should be repeated after over twice weekly over a period of 4 weeks.
223973112|NCT03293472|DRUG|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml \> 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
224115524|NCT05644210|DRUG|Prednisone|5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
224115525|NCT04483362|BEHAVIORAL|Complex physical activity intervention|"Structured weekly sessions with a Physiotherapist over an 8 week period, including:~* Evaluation of current levels of physical activity and physical function - including discussion of results~* Education regarding the importance of physical activity~* Supervised physical activity session with a physiotherapist~* Structured weekly sessions applying behavioural change techniques which aim to increase participation in physical activity. Sessions include: provision of activity monitor (Fitbit Inspire), goal setting, monitoring, collaborative problem solving and action plan implementation. Intervention includes additional time allowance of 1 hour per week to assist in implementing action plan items"
224115526|NCT03591705|DRUG|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
224115527|NCT03591705|DRUG|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
224115528|NCT01139723|DRUG|MINT1526A|Intravenous escalating dose
224115529|NCT01139723|DRUG|bevacizumab|Intravenous repeating dose
224115530|NCT02992470|DIETARY_SUPPLEMENT|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
224115531|NCT02992470|DIETARY_SUPPLEMENT|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
224115532|NCT01847638|DRUG|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
224115533|NCT01847638|DRUG|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
224115534|NCT02528669|DEVICE|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
224115535|NCT05071781|DRUG|Corticotropin-release hormone|intravenous CRH (100 µg)
224115536|NCT05071781|DRUG|Corticotropin-release hormone|a bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)
224115537|NCT01437631|PROCEDURE|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
224115538|NCT00950612|BIOLOGICAL|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
224115539|NCT00950612|BIOLOGICAL|Placebo|Intramuscular injection, 2 doses
224115540|NCT05892783|OTHER|manual treatment|soft tissue mobilization applied by the therapist on the plantar fascia of both legs and self massage and stretching using foam roller and self stretching.
223973113|NCT03293472|DRUG|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
223973114|NCT05251857|BEHAVIORAL|Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients|Behavioral: Animation Education Program The investigators will apply Animation Education Program.
223973115|NCT04732247|DRUG|Oxytocin nasal spray|Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
224115541|NCT00900133|OTHER|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
224115542|NCT00900133|OTHER|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
224115543|NCT03935477|DEVICE|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
224115544|NCT05722899|OTHER|Football training|10-week progressive football training with small-sided games, 2x/week, 45min-1h sessions
224115545|NCT06440161|OTHER|Primary exposures were venous congestion defined by central venous pressure (CVP) and mean arterial pressure (MAP).|"After the induction of anaesthesia, a central venous or pulmonary artery catheter was positioned. Based on prior studies, thresholds for central venous pressure were set at 10, 12, 16, and 20 mm Hg. Venous congestion was quantified by time exceeding each CVP threshold and the area under the curve (AUC) surpassing each CVP threshold in mmHg × min. Assessments were limited to pre- and post-CPB periods, as the venous drainage cannulate generated negative CVP during CPB.~An arterial catheter was installed upon room admission. Continuous arterial blood pressure monitoring commenced after exposure to atmospheric pressure and calibration to zero. The MAP was determined using the formula: 2/3 × diastolic blood pressure + 1/3 × systolic blood pressure. Data were logged by automated software every minute. Established thresholds for MAP were 55, 65, and 75 mm Hg. Hypotension was quantified as (1) time under each MAP threshold in minutes and (2) the AUC below each MAP threshold in mmHg × min."
224115546|NCT06221605|DIETARY_SUPPLEMENT|Probiotic|The intervention lasted for 3 months and 3 visits (at 0 month, 3rd and 6th month respectively).
224115547|NCT05566197|DIETARY_SUPPLEMENT|Diet Nusantara|Diet Nusantara consists of 1700 kilocalories (or 500 kilocalories lower than basal energy expenditure) on first month and subsequent reduction for the following months (200 kilocalories). The participants should also limit the sodium intake not more than 2300 mg daily
223973116|NCT04732247|DRUG|Placebo nasal spray|Intranasal treatment with placebo via nasal spray
223973117|NCT01124214|PROCEDURE|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
223973118|NCT00035802|DRUG|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
224115548|NCT05566197|BEHAVIORAL|Nutrition Counseling|Nutrition counseling consists of the definition of balancing food, metabolic syndrome, exercise, and related health parameters.
224115549|NCT02485366|DRUG|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
224115550|NCT02485366|PROCEDURE|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
223973119|NCT00035802|DRUG|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
223973120|NCT04249518|BEHAVIORAL|Videoeducation|No drugs used. The only difference in the to arms is the way the extradition is.
223973121|NCT00280683|DRUG|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
223973122|NCT00280683|DRUG|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
223973123|NCT01243411|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
224292533|NCT03602040|BEHAVIORAL|PISICC|"PISICC consists of:~1. Standard disease-specific information leaflet~2. Personalised lifestyle consideration form~3. 1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
224292534|NCT01507974|DRUG|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
224292535|NCT01507974|DRUG|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
224292536|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
224292537|NCT01507974|DRUG|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
223973124|NCT02921152|PROCEDURE|bone marrow aspiration /trephine biopsy|
223973125|NCT00866164|DEVICE|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
223973126|NCT05495919|OTHER|Control|No intervention was perfomed to reduce anxiety in control group
223973127|NCT05495919|OTHER|video interaction|Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.
223973128|NCT05495919|OTHER|flipped training|Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
223973129|NCT03299127|BEHAVIORAL|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
223973130|NCT05221437|OTHER|antibiotic prescription|
224115551|NCT05443958|OTHER||
224292538|NCT01507974|DRUG|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
224292539|NCT01507974|DRUG|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
224292540|NCT01731717|BEHAVIORAL|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
224292541|NCT01731717|BEHAVIORAL|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
224292542|NCT01731717|BEHAVIORAL|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
224292543|NCT01731717|BEHAVIORAL|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
224292544|NCT01731717|PROCEDURE|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
224292545|NCT01731717|BEHAVIORAL|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
223973131|NCT00082641|BIOLOGICAL|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
224115552|NCT03245671|DRUG|Kenalog Injectable Product|80 mg of Kenalog will be used.
224115553|NCT03245671|DRUG|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
224115554|NCT03245671|PROCEDURE|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
224115555|NCT00211770|BEHAVIORAL|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
224115556|NCT06041529|DRUG|Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
224115557|NCT06041529|DRUG|Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg|PO, Once daily(QD), 8 weeks and 26 weeks if applicable
223725247|NCT03495076|OTHER|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
223725248|NCT00549302|DRUG|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
223973132|NCT02396953|DRUG|Lanreotide PRF|
224292546|NCT01731717|OTHER|Control group: treatment as usual|treatment as usual
224292547|NCT02377063|DIETARY_SUPPLEMENT|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
224292548|NCT02560441|OTHER|chemotherapy followed by radiotherapy|
223973133|NCT05019313|DEVICE|Evaluation of diaphragmatic contractility by ultrasound|Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
224292549|NCT02560441|OTHER|radiotherapy followed by chemotherapy|
224292550|NCT02560441|DRUG|IPGDP regimen chemotherapy|
223973134|NCT06426095|BEHAVIORAL|Group A (instructional video),|Participants in Group A received access to a specially prepared pre-recorded instructional video detailing the step-by-step process of porcelain-fused-to-metal tooth preparation for molars.
223973135|NCT06426095|BEHAVIORAL|Group B (live demonstration)|Participants in Group B were provided with live demonstrations of the same procedure conducted by the same experienced Prosthodontist to ensure consistency in teaching quality and technique
223973136|NCT06426095|BEHAVIORAL|Group C (hybrid)|Group C received a dual approach, combining instructional video guidance with live demonstrations.
223973137|NCT03404050|OTHER|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
224292551|NCT00702208|DEVICE|Delphi Screener|Self-sampling device for cervical vaginal lavage
224292552|NCT03257150|PROCEDURE|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die. Eligible patients will undergo in situ IRE performed via laparotomy surgery.
224292553|NCT03257150|DEVICE|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the tumor.
223725249|NCT00549302|DRUG|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
223725250|NCT02326376|DRUG|anakinra (Kineret)|
223973138|NCT00685425|DRUG|Levalbuterol HFA MDI|"1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI"
223973139|NCT00685425|DRUG|Racemic Albuterol|"1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI"
223973140|NCT02805036|DEVICE|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
223725251|NCT01442233|PROCEDURE|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
223725252|NCT01442233|PROCEDURE|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
223725253|NCT06043089|DIETARY_SUPPLEMENT|Beetroot juice supplementation or placebo|Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
223725254|NCT03585504|DRUG|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
223973141|NCT02805036|DEVICE|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
223973142|NCT06123949|DEVICE|Galvanic Vestibular Stimulation|Galvanic Vestibular Stimulation (GVS) is a non-invasive technique that uses low-level electrical currents to stimulate the vestibular system, affecting balance, posture, and eye movements. It has applications in research, clinical assessment, and rehabilitation of vestibular and balance-related issues, as well as potential applications in cognitive and motor function enhancement.
224115558|NCT04280601|DIETARY_SUPPLEMENT|vitamin D|Patients with insufficient and/or deficient vitamin D status (\<75 nmol/L) at study enrolment will be instructed to take a 12-month supply of vitamin D3 supplementation (to a maximum of 2,000 IU/day) vs. those with sufficient status will be observed for 12-months
224115559|NCT02669927|OTHER|Observational|
224115560|NCT03357276|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
223973143|NCT05748678|DEVICE|Compression pants|"Patients will have 3D photos taken each week of each buttock and thigh separately. A lymph scanner will also be used for each section to provide a percentage of water content. Weight will also be taken for each visit.~The first 2 weeks the patients will wear their regular pants, and from weeks 3-7 wear the compression pants provided. Weeks 8-9 the patients will be asked to resume to regular pants again"
223973144|NCT03866980|BIOLOGICAL|AK105|IV infusion
223973145|NCT03866980|DRUG|carboplatin|IV infusion
223973146|NCT03866980|DRUG|pemetrexed|IV infusion
224292554|NCT01783002|RADIATION|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
224292555|NCT01783002|RADIATION|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
223725255|NCT03632525|DRUG|Ferric carboxymaltose|Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin \<14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
223973147|NCT03866980|DRUG|placebo|IV infusion
223973148|NCT03866980|DRUG|Anlotinib|PO
223973149|NCT03957408|DEVICE|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
223973150|NCT00510198|DEVICE|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
223973151|NCT00510198|DEVICE|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
223973152|NCT03018223|DRUG|Fludarabine|Myeloablative conditioning: 40 mg/m\^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m\^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
223973153|NCT03018223|DRUG|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol\*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol\*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
223973154|NCT03018223|DRUG|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
223973155|NCT03018223|RADIATION|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
223973156|NCT03018223|PROCEDURE|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
223973157|NCT03018223|DRUG|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
223973158|NCT03018223|DRUG|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
223973159|NCT03018223|DRUG|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is \> 1,000/mm\^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
224115561|NCT05425238|OTHER|Blood flow restriction|"strengthening protocol but with Blood flow restriction technique~.Standard BFR Application: a standard pressure (used for all patients) for e.g. 180~mmHg; a pressure relative to the patient's systolic blood pressure, for e.g. 1.2 - or 1.5-fold greater than systolic blood pressure.40% cuff pressure as percentage of LOP.(4) And performing BFR-RE with low load exercises. So 30% of 1 RPM would be enough 4 times a week for 6 week"
224115562|NCT05425238|OTHER|Conventional physical therapy|Resistance exercise 75 repetitions across four sets of exercises, with30 repetitions in the first set and 15 repetitions in each subsequent set. 4 times a week for 6
224292556|NCT01783002|RADIATION|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
223973160|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
223973161|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
223973162|NCT00329550|BIOLOGICAL|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
224115563|NCT03233490|OTHER|web course|Web course Help Brain Heart was conducted Before CPR training.
224115564|NCT03233490|OTHER|CPR training|No web course was conducted
224115565|NCT03888300|OTHER|Physiotherapy|Chest Physiotherapy, physical exercises
224115566|NCT01005394|DEVICE|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
224115567|NCT02288767|DEVICE|Conventional arterial blood pressure monitoring|
224115568|NCT02288767|DEVICE|Stroke volume variation monitoring with arterial blood pressure monitoring|
224115569|NCT03393052|PROCEDURE|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
224115570|NCT00046319|DRUG|BSF 208075|
224115571|NCT06480305|DIETARY_SUPPLEMENT|Post dinner snack|one walnut, 2 cashews, 2 almonds, and 2 pistachios.
223973163|NCT00245245|DRUG|recombinant porcine coagulation factor VIII (OBI-1)|
224115572|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-1|Prepackaged dose of 25 peanuts.
224115573|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-2|Prepackaged dose of 25 raisins
223725256|NCT04841031|BEHAVIORAL|NET Treatment|Narrative Exposure Therapy (NET) aims to address PTSD symptoms among survivors of mass violence and torture (Onyut et al., 2004; Schauer, et al., 2005). Mainly, different from other psychosocial interventions which require the survivor to process a single traumatic event in his or her life at a given time, NET treatment recognizes that trauma survivors undergo multiple distressing events within their lifetime (Schauer et al., 2005). Focusing on the traumatic events, the patient constructs a chronological narrative of his or her life story and a coherent narrative is then structured with the assistance of the therapist. They received NET one to three months following their screening and randomization. The therapy involves 8 to 12 individual sessions of about 90 minutes each.
223973164|NCT00637247|DRUG|imexon in combination with gemcitabine|875 mg/m\^2 imexon IV + 1000 mg/m\^2 gemcitabine IV
223973165|NCT00637247|DRUG|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m\^2 gemcitabine IV
223973166|NCT02179853|DRUG|Anakinra|First two doses IV followed by SQ dosing
223973167|NCT02786290|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
223973168|NCT04838964|DRUG|MRG003|Administrated intravenously
223973169|NCT00562185|DRUG|carboplatin|
223973170|NCT00562185|DRUG|doxorubicin hydrochloride|
223973171|NCT04372537|BEHAVIORAL|hypnosis|use of hypnosis.
223973172|NCT04372537|BEHAVIORAL|standard care|standard clinical procedure
223973173|NCT00304668|DRUG|dapivirine (TMC120) vaginal gel|
223973174|NCT02762292|DEVICE|Measurement of work of breathing using indirect calorimeter|"1. Preparation:~   1. Patient baseline characteristics will be collected.~  2. Connection of the Indirect Calorimeter to the respiratory circuit.~  3. Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~2. Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~3. End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
223973175|NCT01530477|DEVICE|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
223973176|NCT01530477|DEVICE|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
223973177|NCT01530477|DEVICE|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
223973178|NCT06172998|DRUG|Phentolamine Injection|Under patient safety, Phentolamine will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent sympathetic overactivity. Under patient safety, Nitroglycerin will be pumped into the OSA patients equipped with PSG and ECG monitoring in a safe dose to prevent endothelial dysfunction.
223973179|NCT00146198|DRUG|ALGRX 4975|
223973180|NCT06402578|DIAGNOSTIC_TEST|HbA1c testing|Bloods will be take pre and post 12 week intervention.
224115574|NCT06480305|DIETARY_SUPPLEMENT|Pre-Breakfast-3|Prepackaged dose of 25 peanuts on one day and 25 raisins as a pre-breakfast.
224115575|NCT02695485|PROCEDURE|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
223725257|NCT04841031|OTHER|Alternative Intervention|Individuals in control group received non-NET psychosocial support in the interim that is provided to SGBV survivors as part of the Great Lakes SGBV project and will then receive NET after endline data has been collected.
224292557|NCT04363749|OTHER|hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint|the fraction of inspired oxygen is reduced from \~21% (room air) to 14.3 and 12.7% allowing the SpO2 to decrease to \~75%, rebreathing test allowing the PCO2 to rise to 65 mmHg, inspiratory mechanical constraint with 50 to 75% of maximum inspiratory pressure
224292558|NCT03596736|PROCEDURE|Elbow Hemiarthroplasty|
224292559|NCT03596736|PROCEDURE|Total Elbow Arthroplasty|
223973181|NCT06370117|BEHAVIORAL|Buzzy|Before the procedure; 60 seconds before starting the vascular access process, the Buzzy® tool was placed in the procedure area and cold and vibration application was started. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed to the middle part of the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
223973182|NCT06370117|BEHAVIORAL|Music video listening|Before the procedure; A music video was played 60 seconds before starting the intravenous access procedure.
223973183|NCT06370117|BEHAVIORAL|Buzzy+ Music video listening|60 seconds before starting the vascular access process, a music video was played and cold and vibration application was started with the Buzzy® tool. 60 seconds before the procedure began, the Buzzy® tool was placed on the procedure area and cold and vibration application was initiated. The tourniquet was tied 10-12 cm above the vein to be treated. The Buzzy® tool was fixed midway between the procedure area and the tourniquet, approximately 2 cm above the IV catheter entry site.
223973184|NCT02985047|OTHER|Brief Admission|Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
224292560|NCT06030349|DEVICE|Non-invasive ventilation|Non-invasive ventilation
223725258|NCT01414114|DRUG|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
224292561|NCT00644384|DRUG|acitretin|
224292562|NCT00644384|GENETIC|gene expression analysis|
224292563|NCT00644384|GENETIC|northern blotting|
224292564|NCT00644384|GENETIC|polymerase chain reaction|
224292565|NCT00644384|GENETIC|protein expression analysis|
224292566|NCT00644384|OTHER|laboratory biomarker analysis|
224292567|NCT04667702|BEHAVIORAL|Interviews|We will conduct a phone or virtual interview with patients with sickle cell disease or cancer, caregivers and their healthcare providers.
223973185|NCT05962515|PROCEDURE|ultrasound guided dry needling|Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
223725259|NCT05576714|OTHER|delineate its prognostic biomarker, host genetic factors, immunopathogenesis and viral pathogenesis|We will delineate the clinical and laboratory characteristics of COVID-19 associated encephalopathy and encephalitis, the role of immune, virology, genetics mechanism in pathophysiology, and will optimize the treatment algorithm based on the result of this study. We also expect that the important biomarkers and risk factors associated with clinical outcome and severity, the immunopathogenesis of MIS-C, host genetic factors and the viral pathogenesis and microbiota associated with MIS-C will be found.
223725260|NCT03787953|DRUG|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
223973186|NCT00000454|DRUG|nicotine replacement patch|
223973187|NCT06285227|BIOLOGICAL|CM313 injection|CM313
223973188|NCT02646735|DRUG|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
223973189|NCT02646735|DRUG|Exemestane 25 mg|Exemestane 25mg will be given once daily.
223973190|NCT00689520|DRUG|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
223543030|NCT02825446|PROCEDURE|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
223973191|NCT00689520|DRUG|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
223973192|NCT01549249|DEVICE|optical coherence tomography|spectral-domain optical coherence tomography
223973193|NCT00000137|PROCEDURE|Histocompatibility Matching|
223973194|NCT01154465|PROCEDURE|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~* Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~* Rinse with sterile water and then drying.~* First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~* Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
223973195|NCT01154465|DEVICE|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~\- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
223973196|NCT00344539|BIOLOGICAL|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
223973197|NCT00344539|BIOLOGICAL|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
223973198|NCT01565252|DIETARY_SUPPLEMENT|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
223973199|NCT02241278|DRUG|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
223973200|NCT02675803|BIOLOGICAL|VAY736|VAY736 treatment
223973201|NCT02675803|BIOLOGICAL|VAY736 placebo|VAY736 placebo
223973202|NCT05236140|DEVICE|Perineal electrical stimulation|Perineal electrical stimulation will be performed in lithotomy position via a stimulation device (Enraf Nonius Myomed 632) with perineal surface electrodes. Perineal electrical stimulation will be performed three days a week, 20 minutes a day, a total of 24 sessions for 8 weeks. The stimulation parameters are frequency at 50 Hz, a 5-10s work-rest cycle, and a 300ms pulse width. The symmetric biphasic pulse wave could be delivered over a range of 1-100mA (according to the patient's discomfort level feedback). In this application, three surface electrodes which had 2 cm diameters were used; two electrodes symmetrically at the perianal region (medial to ischial tuberosity); and one electrode at the leg (ground-neutral electrode). Surface electrodes will be used individually for each patient. Perineal electrical stimulation sessions will be performed by an experienced urogynecology rehabilitation nurse.
223973203|NCT05367752|OTHER|Myofascial release with TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
223543031|NCT01864083|PROCEDURE|Positron Emission Tomography (PET)|
223543032|NCT01864083|DRUG|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
223543033|NCT01864083|PROCEDURE|Positron emission mammography (PEM) When available|
223543034|NCT01864083|PROCEDURE|MR|
223973204|NCT05367752|OTHER|Myofascial release without TENS conductive glove|"Before each MR session, light massage and stretching was applied for five minutes as preparation for the manipulations. The massage included the effleurage technique followed by petrissage and kneading on the cervical and thoracic areas (on the upper three parts of the trapezius muscle, in the suboccipital area, and on the paraspinal cervical muscles). Stretching was applied to the following muscles: upper part of the trapezius, levator scapulae, and the sternocleidomastoid muscle.~Upper trapezius myofascial release, unilateral gross stretch, vertical gross stretch, focused stretch, cranial base myofascial release, gross release of the sternocleidomastoid muscle, and release of the suprahyoid and infrahyoid muscles."
223973205|NCT05367752|OTHER|Conventional TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
223973206|NCT05367752|OTHER|Sham TENS|Two 40\*50mm silicone electrodes were placed with the negative electrode on the trigger point of the trapezius muscle and the positive one on the acromion. The current frequency was 120Hz and pulse duration 80ms for 30 minutes. This protocol has been proposed by Ebadi et al. (2021)
223973207|NCT05097898|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (including the EVEREST, Ambrosy and ASCEND score) will be performed during day hospitalization or consultation
223973208|NCT05097898|PROCEDURE|Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardiac, vena cava, pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional/Cardiac echo is optional for patients included in consultation
223973209|NCT05097898|PROCEDURE|Blood and urine sample retrieved for biological assessment and biobanking|Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation/ Urine analysis is optional for patients included in consultation
223973210|NCT05097898|OTHER|Telephone follow-up|Telephone follow-up will be performed 3, 12 and 24
223973211|NCT05097898|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
223543035|NCT05879952|BEHAVIORAL|TAU + BTsN session|BTsN treatment session included exercises aimed at identifying, finding, chasing or moving objects, with the aim of improving the perceptual-cognitive skills of each patient, through audio-visual stimuli and feedback implementing visuo-spatial skills and spatial cognition, allowing at the same time motor coordination and balance improvement.
223543036|NCT05879952|BEHAVIORAL|TAU|neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
223543037|NCT01688297|BIOLOGICAL|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
223543038|NCT01688297|BIOLOGICAL|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
223543039|NCT02910141|DEVICE|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
223543040|NCT03657836|DIETARY_SUPPLEMENT|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
223543041|NCT03657836|DRUG|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
224292568|NCT00839059|DRUG|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
224292569|NCT04061642|DEVICE|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
224292570|NCT03237533|DRUG|Dexamethasone|Dexamethasone will be applied locally on the lesion
224292571|NCT04054128|DRUG|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
223543042|NCT02566811|PROCEDURE|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
223543043|NCT02566811|PROCEDURE|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
224292572|NCT04054128|DRUG|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
224292573|NCT01870245|DRUG|ACHN-975|Intravenous multiple dose
224292574|NCT01870245|DRUG|placebo|Intravenous multiple dose
224292575|NCT01940328|DEVICE|Transchoracic ultrasound Doppler|
224292576|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (low dose)|
224292577|NCT00794976|DRUG|Dexamethasone Iontophoretic Patch (high dose)|
224292578|NCT00794976|DRUG|Dexamethasone Passive Patch|
223543044|NCT03856359|DRUG|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
223543045|NCT04461353|DRUG|Aerolized Hydroxychloroquine Sulfate|sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
223973212|NCT00301041|OTHER|laboratory biomarker analysis|
223973213|NCT00301041|PROCEDURE|adjuvant therapy|
223973214|NCT00301041|RADIATION|radiation therapy|
223973215|NCT00419419|DRUG|Topical AmphiMatrix with nitroglycerin (MQX-503)|
223973216|NCT01932983|DEVICE|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
223973217|NCT02191527|DEVICE|PIMA® for quantitative analysis of CD4-count|
223973218|NCT02191527|DEVICE|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
223973219|NCT02191527|DEVICE|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
223973220|NCT00318981|DRUG|Concerta|
224292579|NCT00794976|DRUG|Placebo Patch|
224292580|NCT02746627|BEHAVIORAL|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
224292581|NCT02746627|BEHAVIORAL|Education|Educational materials on diabetes management
224292582|NCT04871516|OTHER|Quality-of-Life Assessment|Ancillary studies
224292583|NCT04871516|OTHER|Questionnaire Administration|Ancillary studies
224292584|NCT04871516|RADIATION|Radiation Boost|Undergo radiation therapy boost
224292585|NCT04871516|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard surgery
224292586|NCT04871516|RADIATION|Whole Breast Irradiation|Undergo standard WBI
224292587|NCT04871516|OTHER|Breast MRI|A baseline breast MRI
224292588|NCT02776514|DRUG|Triamcort|Fluoroscopic guided injection in the knee joint
224292589|NCT02776514|DRUG|Platelet-rich-plasma|
224292590|NCT02776514|DRUG|Suplasyn1|
224115576|NCT03504774|DRUG|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
223973221|NCT03713073|DEVICE|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
224292591|NCT02776514|DRUG|Placebo|
223543046|NCT04461353|OTHER|Placebo|The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
223973222|NCT03713073|DEVICE|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
223973223|NCT05648513|BEHAVIORAL|Motivational Interwiev|Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
223973224|NCT02483845|DRUG|Natalizumab|
223973225|NCT02958059|BIOLOGICAL|Pacetin® (cefoxitin)|1\~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
223973226|NCT02958059|BIOLOGICAL|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
224115577|NCT02344628|DRUG|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
224115578|NCT05738096|OTHER|TSEP + rhizotomy surgery|TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery. TSEPs will be measured at baseline prior to surgery. During the rhizotomy procedure, an electrode or balloon is placed through a metal sheath to then damage the nerve. A stylet is introduced to clear tissue from the sheath in preparation for the electrode or balloon. Prior to the final insertion of the RF electrode where the gasserian ganglion will be damaged, we will place a standard stereotactic EEG electrode (SEEG). Following damaging the nerve (clinical procedure), we will record again to measure differences in the TSEPs following cell body damage. The Neuralynx system will be used to record the potentials at 40 KHz.
224115579|NCT05738096|OTHER|TSEPs recording only|TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
224115580|NCT05074849|BEHAVIORAL|A 90-minute self-care education + bi-weekly 30-minute one-on-one follow-up phone discussion|A 90-minute group session to educate patients on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch). Follow-up Care: A biweekly 30-minute one-on-one follow-up phone discussion (i.e., daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch, addressing feedback and questions regarding the intervention and prevention of foot-related complications).
224115581|NCT04144881|DIAGNOSTIC_TEST|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
224115582|NCT01479088|DRUG|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value \<180 pg/mL as tolerated by the patient
224115583|NCT02065947|PROCEDURE|paravertebral block|catheter with 3-level-injection
224115584|NCT02065947|DRUG|fentanyl, propofol, atracurium|endotracheal intubation
224115585|NCT02065947|DRUG|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
224115586|NCT02065947|DEVICE|catheter with 3-level-injection|
224115587|NCT02065947|DRUG|sevoflurane and 50% oxygen in air|
224115588|NCT00916604|DRUG|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
224115589|NCT00916604|DRUG|Placebo|Placebo oral suspension, 8 days treatment
224115590|NCT04845698|DEVICE|i-Dashboard|i-Dashboard is a team-designed, patient-centered electronic medical record viewer, which retrieves data from multiple databases and provides a quick representation of essential metrics for each patient.
224115591|NCT03634215|DIAGNOSTIC_TEST|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
223973227|NCT03068793|DIAGNOSTIC_TEST|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
223973228|NCT05466188|DIAGNOSTIC_TEST|CPC|CPC
223973229|NCT04872634|BIOLOGICAL|SNK01 (Super Natural Killer Cells 01)|Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10\^9 or 6x10\^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.
223973230|NCT04872634|DRUG|GC|"Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min.~Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour."
223973231|NCT04872634|BIOLOGICAL|Cetuximab|"First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration\*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops.~400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes"
223973232|NCT03825614|BEHAVIORAL|training|plates and therapeutic exercises applied on young adults
223973233|NCT01906645|OTHER|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
223973234|NCT00003926|DRUG|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
223973235|NCT00003926|DRUG|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
223973236|NCT00003926|DRUG|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
223973237|NCT00003926|DRUG|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
223973238|NCT00003926|DRUG|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
223973239|NCT00003926|PROCEDURE|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
224115592|NCT01320579|DRUG|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
224292592|NCT06316713|BEHAVIORAL|One MORE (Spanish Adaptation)|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
223973240|NCT03168425|OTHER|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
223973241|NCT03168425|OTHER|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
223973242|NCT01292317|OTHER|application of intravenous volume|weight based intravenous application of volume
223973243|NCT01292317|OTHER|oral fluid application|oral fluid application
223973244|NCT04233983|PROCEDURE|Laparoscopic Endometriosis Surgery|Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
223973245|NCT00003402|DRUG|carmustine|
223973246|NCT00003402|DRUG|cisplatin|
224115593|NCT01320579|DRUG|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
224115594|NCT01320579|DRUG|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
223973247|NCT00003402|DRUG|cyclophosphamide|
223973248|NCT00003402|DRUG|dexamethasone|
223973249|NCT00003402|DRUG|etoposide|
223973250|NCT00003402|DRUG|melphalan|
224115595|NCT01320579|DRUG|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
224115596|NCT02393651|DEVICE|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
224115597|NCT04797013|DRUG|rt-PA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
224292593|NCT05649449|BEHAVIORAL|Self-Directed Care|Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
224292594|NCT05649449|BEHAVIORAL|Services as usual|Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
224292595|NCT03964610|DIAGNOSTIC_TEST|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
224292596|NCT05606588|BEHAVIORAL|Playful sensorimotor training|"For the max. duration of the first in-hospital phase (3weeks), all children will receive supervised training. When children go home they will be supplied with a manual, specific exercises and the necessary training devices. Regular supervision will allow to ensure that the training is performed at maximum benefit. Each session will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises chosen from a standardized pool of exercises according to the child's age, with increasing difficulty in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue."
224292597|NCT03126422|DRUG|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
224292598|NCT05654194|DRUG|Azacitidine Combined With Venetoclax and ATRA group|AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
224292599|NCT05361291|DRUG|Lidocaine Hydrochloride|Inferior alveolar nerve block
224292600|NCT02671682|PROCEDURE|Immunoadsorption|
224292601|NCT02671682|PROCEDURE|Plasmapheresis|
224292602|NCT03020719|DRUG|Oral Glutathione|Oral Glutathione oral powder
224292603|NCT03020719|DRUG|Placebo|Placebo oral powder
223973251|NCT00003402|DRUG|paclitaxel|
223973252|NCT00003402|PROCEDURE|bone marrow ablation with stem cell support|
224115598|NCT04797013|DRUG|rhTNK-tPA|Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
224292604|NCT02004184|DRUG|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
224292605|NCT02004184|DRUG|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
224292606|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
224292607|NCT00754468|DEVICE|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
224292608|NCT01965184|BEHAVIORAL|Cognitive-Behavioral Therapy for Anger and Aggression|
224292609|NCT01965184|BEHAVIORAL|Supportive Psychotherapy (SPT)|
224292610|NCT01392326|DRUG|Secukinumab (75 mg)|Secukinumab (75 mg)
224292611|NCT01392326|DRUG|Secukinumab (150 mg)|Secukinumab (150 mg)
223973253|NCT00003402|PROCEDURE|peripheral blood stem cell transplantation|
223973254|NCT00115986|BIOLOGICAL|Influenza A/H5N1 Vaccine|
223973255|NCT02892006|BEHAVIORAL|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
223973256|NCT03459521|BIOLOGICAL|Fendrix or HBVAXPRO 40|To administer hepatitis B virus vaccines in patients with chronic liver disease that have not been previously vaccinated.
223973257|NCT01591668|DRUG|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
224115599|NCT03527446|BEHAVIORAL|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
224115600|NCT03984760|DRUG|Ferric Citrate|Take the capsules with meals or immediately after meals.
224115601|NCT03984760|DRUG|Sevelamer Carbonate|Take the tablets with meals.
224292612|NCT01392326|DRUG|Placebo Comparator|Placebo Comparator
223973258|NCT01591668|DRUG|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
224115602|NCT03975972|OTHER|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
224115603|NCT04385797|OTHER|Telephone interview|Sociodemographic data. Clinical data. PMCI/MD quality of life, cognition, depression, technophilia and perceived stress and caregiver quality of life and burden assessments.
224115604|NCT00308542|DRUG|dexamethasone|
224115605|NCT06396039|DRUG|BMS-986374|Specified dose on specified days.
223973259|NCT02814097|DRUG|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
223973260|NCT02814097|DRUG|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
223973261|NCT04491006|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
224292613|NCT03527004|OTHER|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
223543047|NCT04406402|BEHAVIORAL|Acute dietary protocols and lifestyle modification|The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
223973262|NCT04491006|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
223973263|NCT01443546|DRUG|HCG|hCG Trigger
223973264|NCT01443546|DRUG|Lupron Trigger|leuprolide acetate 2 mg SQ
224115606|NCT04727112|DRUG|Usual care versus primary care|RCT study
224115607|NCT04737122|DRUG|LM-061|Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.
224115608|NCT04737122|DRUG|Toripalimab|For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
224115609|NCT00455546|DRUG|A-002|
224115610|NCT04410783|BEHAVIORAL|Education|Nurses and physicians will be engaged regarding the clinical outcome data on the importance of ED-based sedation, and the objectives of the research. Education will include in-services and lectures focused on the importance of sedation protocols on patient outcome. The use of sedation will be evaluated throughout the study in order to better understand providers' perception of and experience with ED-based sedation protocols.
224115611|NCT04410783|OTHER|Standard post intubation sedation practices|Usual care sedation provide in the ED
224115612|NCT00230581|DRUG|DDP225|
224115613|NCT05269134|DRUG|Bacteriophage|Phage Therapy
224115614|NCT05269134|DRUG|Placebo|Placebo
224115615|NCT02870452|BEHAVIORAL|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
224115616|NCT02870452|BEHAVIORAL|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
223973265|NCT01443546|DRUG|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
224292614|NCT03527004|OTHER|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
224292615|NCT05429697|DRUG|SMT-NK inj.+Pembrolizumab|"SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle."
223973266|NCT03146325|DRUG|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
223973267|NCT03146325|DRUG|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
224292616|NCT05429697|DRUG|Pembrolizumab|Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
224115617|NCT01198418|BEHAVIORAL|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
224115618|NCT02707094|DEVICE|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
224115619|NCT02707094|OTHER|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
224115620|NCT04151381|DRUG|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
224292617|NCT01972035|DRUG|Valacyclovir|Experimental Arm
224292618|NCT01972035|DRUG|Valganciclovir|Standard of care
223543048|NCT06151470|DRUG|Alpha-Agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223543049|NCT06151470|DRUG|α-adrenergic receptor agonist|An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223973268|NCT00700947|DRUG|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
223973269|NCT01639014|DRUG|F2695|75 mg OD in 2 capsules
223973270|NCT01639014|DRUG|placebo|2 capsules
223973271|NCT03287375|DRUG|PIPAC|
224115621|NCT04012268|DEVICE|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
224115622|NCT04012268|DRUG|Aspirin|patients will accept medication guided by neurologists
224115623|NCT00763685|DRUG|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
224115624|NCT00295399|DEVICE|The Jerusalem Telerehabilitation System|
224115625|NCT05603624|PROCEDURE|Cervical examination to assess labor|Patients were randomized to receive cervical examinations to assess progression in labor with either sterile or clean gloves.
223973272|NCT04838145|DRUG|Ribavirin + Pleconaril|Randomized to treatment with study drugs (ribavirin and pleconaril)
224292619|NCT00233987|DRUG|carmustine|150 mg/m\^2 IV over 2 hours 4, 5, and 6 days before transplant.
224292620|NCT00233987|DRUG|cyclophosphamide|100 mg/kg IV 2 days before transplant.
224292621|NCT00233987|DRUG|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
223973273|NCT04838145|DRUG|Placebos|Randomized to treatment with placebo
224292622|NCT00233987|DRUG|melphalan|150 mg/m\^2 IV 1 day before transplant.
224292623|NCT00233987|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10\^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
224292624|NCT00233987|RADIATION|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
224292625|NCT02508259|DRUG|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
224292626|NCT02508259|DRUG|Saline|50 ml IV over 30 minutes
224292627|NCT03743610|OTHER|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
224292628|NCT03743610|OTHER|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
224292629|NCT00518622|DRUG|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
224292630|NCT00518622|DRUG|Comparator: Placebo|MK7009 Placebo
223973274|NCT02302625|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
224115626|NCT00322595|DRUG|Quetiapine fumarate|
224115627|NCT00322595|DRUG|Paroxetine|
224292631|NCT01941108|BEHAVIORAL|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
224292632|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
224292633|NCT03284502|DRUG|HM95573, cetuximab|Regimen: twice daily (BID), continuous dosing for HM95573
224115628|NCT00780468|BEHAVIORAL|Existing diet plan|
224292634|NCT03284502|DRUG|HM95573, cobimetinib|Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1
224292635|NCT03284502|DRUG|HM95573, cetuximab|Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
224115629|NCT00780468|BEHAVIORAL|New diet plan|
224115630|NCT01148056|RADIATION|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
224292636|NCT06490887|OTHER|Use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing surgery or from pregnant women giving birth. Peripheral blood will be also collected from patients to conduct virological screening and isolate peripheral blood mononuclear cells.
224292637|NCT03567525|PROCEDURE|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
224292638|NCT03567525|PROCEDURE|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
223543050|NCT06178367|DRUG|Low molecular weight hyaluronic acid|Topical 0,1% low molecular weight (7 kDa) hyaluronic acid in vehicle
223543051|NCT06178367|DRUG|High molecular weight hyaluronic acid|Topical 0,1% high molecular weight (1.800 kDa) hyaluronic acid in vehicle
223973275|NCT00676429|DRUG|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
223973276|NCT00676429|DRUG|Placebo|Placebo as oral solution, individually titrated
223973277|NCT00639964|OTHER|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
223973278|NCT00639964|OTHER|diet questionnaire|questions about nutrition before and during pregnancy
224115631|NCT03493308|OTHER|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
224115632|NCT03493308|OTHER|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
224115633|NCT01902797|OTHER|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
224115634|NCT06334029|DIAGNOSTIC_TEST|Functional and structural Connectome|Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
224115635|NCT03293095|PROCEDURE|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
224115636|NCT00915005|RADIATION|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
224115637|NCT00915005|RADIATION|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
224115638|NCT00915005|DRUG|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
224115639|NCT00915005|DRUG|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
224115640|NCT03069339|DRUG|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
224115641|NCT03069339|PROCEDURE|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
224115642|NCT04761497|OTHER|Actice music therapy|active music therapy sessions for three months
224115643|NCT04761497|OTHER|Watching nature videos|nature videos sessions for three months
224115644|NCT04761497|OTHER|Passive music therapy|passive music therapy for three months
224292639|NCT03705949|DRUG|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
224292640|NCT03705949|DRUG|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
223973279|NCT00639964|OTHER|umbilical cord blood collect|collected at the delivery
223973280|NCT00639964|OTHER|placenta collect|collected at the delivery
224115645|NCT03070418|PROCEDURE|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
224115646|NCT00719576|BIOLOGICAL|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
224115647|NCT00719576|PROCEDURE|Microfracture|Microfracture performed by arthroscopic surgery
224115648|NCT06148233|RADIATION|[18F]CSF-23|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.
224115649|NCT01023399|DRUG|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
224115650|NCT03554005|DRUG|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
224115651|NCT03554005|DRUG|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
224115652|NCT00631488|DRUG|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
224115653|NCT00631488|DRUG|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
224115654|NCT00631488|DRUG|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
224115655|NCT00631488|DRUG|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
224115656|NCT00631488|DRUG|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
224115657|NCT00631488|DRUG|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
224115658|NCT02580487|PROCEDURE|appendicectomy|Appendix was removed either laparoscopically or open surgery
224115659|NCT03648476|BEHAVIORAL|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
224115660|NCT00103194|DRUG|lapatinib ditosylate|Given PO
224115661|NCT00103194|OTHER|laboratory biomarker analysis|Correlative studies
224115662|NCT02855411|DRUG|PF-04958242|Administered as specified in the treatment arm
224115663|NCT02855411|DRUG|placebo|placebo, twice daily (BID) for 12 weeks, capsule
224115664|NCT05634031|RADIATION|PET imaging|PET imaging visit, which will take approximately 1-2 hours.
223973281|NCT04686370|OTHER|laser treated implant surface|Better marginal bone stability is expected for this type
223973282|NCT00414219|BEHAVIORAL|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
223973283|NCT01960114|DRUG|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
223973284|NCT01960114|DRUG|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
223973285|NCT04108975|PROCEDURE|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
223973286|NCT04108975|PROCEDURE|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
223973287|NCT01858064|DRUG|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
224115665|NCT05634031|RADIATION|Coronary CT angiogram|A coronary CT angiogram if the participant has not had one recently.
224115666|NCT05634031|PROCEDURE|Functional Angiography|"A subset of patients with abnormal results on cardiac PET myocardial perfusion imaging study (estimated number of patients = 12) will be invited to participate in an invasive sub-study wherein they would undergo detailed invasive coronary physiology evaluation.~Functional Angiography (coronary reactivity test- CRT): is an angiography procedure done in the catheterization laboratory. It evaluates the coronary artery microcirculation and how the blood vessels respond to different medications."
224115667|NCT05634031|PROCEDURE|Treadmill exercise stress study|A treadmill exercise stress study
224115668|NCT03313505|BIOLOGICAL|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
224115669|NCT03313505|OTHER|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
224115670|NCT05909579|BEHAVIORAL|PelvicSense (R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
224292641|NCT00258375|DRUG|custirsen sodium|
224292642|NCT00258375|DRUG|docetaxel|
223973288|NCT03976778|OTHER|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
223973289|NCT01302301|PROCEDURE|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
223543052|NCT06178367|DRUG|Vehicle|Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
223973290|NCT03052283|DIAGNOSTIC_TEST|Questionnaire Patient Reported Outcome Measure (PROM)|non-interventional
223973291|NCT00572351|OTHER|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
223973292|NCT00572351|OTHER|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
223543053|NCT01773954|DRUG|Intravitreal Aflibercept Injection|Increased or decreased time between visits
223973293|NCT05753241|OTHER|no intervention|It's only observational study. No interventions.
224115671|NCT06018831|OTHER|Urine and Ultrasound Screening|When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
224115672|NCT03293199|PROCEDURE|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
224115673|NCT03293199|PROCEDURE|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
224115674|NCT05690412|PROCEDURE|Endoscopic Papillectomy|Endoscopic resection of ampullary neoplasm
224115675|NCT00856271|DRUG|olmesartan medoxomil|oral tablets, once daily for 8 weeks
224292643|NCT02456649|DEVICE|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to \< 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as \< 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
224292644|NCT03103074|DRUG|Botulinum B Toxin|Intradermal injections
224292645|NCT03103074|OTHER|Placebo Saline|Intradermal injections
223973294|NCT03650361|DRUG|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
223543054|NCT04021446|OTHER|Exercise|personalized exercise prescription
223973295|NCT03650361|DRUG|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
223973296|NCT03650361|DRUG|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
223543055|NCT03882593|PROCEDURE|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
223543056|NCT03125499|OTHER|Previous treated with TPX-100|No intervention, only observational
223973297|NCT02639078|DRUG|TD-0714|One time dosing in capsule formulation
223973298|NCT02639078|DRUG|Placebo Comparator|One time dosing in capsule formulation
223973299|NCT03116672|DRUG|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
223973300|NCT03116672|DRUG|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
223973301|NCT03116672|DRUG|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
223973302|NCT03248713|DRUG|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
223973303|NCT03248713|DRUG|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
223973304|NCT04486079|DIETARY_SUPPLEMENT|Nutricia PreOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
223973305|NCT02358213|PROCEDURE|Ultrasound|Ultrasound examinations are done 5 times
223973306|NCT02469077|BEHAVIORAL|6 week aerobic exercise intervention|"Participants randomly assigned to the 6 week aerobic exercise intervention will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks).~Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out."
223973307|NCT02469077|DRUG|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
223973308|NCT02469077|DRUG|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
223973309|NCT02469077|DRUG|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
223973310|NCT05212597|DRUG|Sacubitril-valsartan|50mg\~100mg twice daily
224115676|NCT00856271|DRUG|losartan potassium|capsules, once daily for 8 weeks
224115677|NCT04344405|DRUG|Vitamin D|vitamin D supplementation
223543057|NCT03399279|PROCEDURE|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
223543058|NCT03399279|OTHER|Perforated collagen membrane|Membrane perforations using dental needle
223543059|NCT03399279|OTHER|Occlusive membrane|Biotech collagen membrane
224115678|NCT04344405|DRUG|Steroid Drug|control
224115679|NCT06527378|DIAGNOSTIC_TEST|AI in implant planning|Assessment of Current Technology for Supporting Implant Planning
224115680|NCT03864237|BEHAVIORAL|Alcohol texts|A text message each day for 10 weeks, containing factual information about campus drinking norms.
223543060|NCT03399279|OTHER|Nanohydroxyapetite|Nanbone Particles
224115681|NCT03864237|BEHAVIORAL|Attention control|"A text message each day for 10 weeks, containing this day in history facts."
223543061|NCT00560092|DRUG|intrathecal magnesium sulfate|intrathecal magnesium sulfate
223543062|NCT00869635|DRUG|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
223543063|NCT00869635|PROCEDURE|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
223543064|NCT00869635|PROCEDURE|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
223543065|NCT06302465|DRUG|narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide|Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
223543066|NCT06302465|DRUG|doxorubicin、cisplatin、methotrexate、ifosfamide|doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
223973311|NCT05212597|DRUG|Amlodipine-losartan|amlodipine/losartan 2.5/25mg \~ 5/100mg once daily
223973312|NCT00996359|BIOLOGICAL|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
223973313|NCT00996359|RADIATION|total-body irradiation|100 cGy TBI
223973314|NCT01040403|DRUG|olodaterol (BI 1744) low|olodaterol (BI 1744) low
223973315|NCT01040403|DRUG|low tiotropium bromide|low tiotropium bromide
223973316|NCT01040403|DRUG|olodaterol (BI 1744) high|olodaterol (BI 1744) high
223973317|NCT01040403|DRUG|medium tiotropium bromide|medium tiotropium bromide
223973318|NCT01040403|DRUG|high tiotropium bromide|high tiotropium bromide
223973319|NCT01040403|DRUG|Placebo|Placebo
223973320|NCT01040403|DEVICE|Respimat|Respimat inhaler
223973321|NCT03925662|DRUG|Folfox with avastin|Folfox with avastin only
223973322|NCT03925662|DRUG|Mebendazole|Folfox with avastin with mebendazole
223973323|NCT02017132|DIETARY_SUPPLEMENT|Pomegranate extract|
223973324|NCT03228953|OTHER|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
223973325|NCT05773027|BEHAVIORAL|SAFE|SAFE includes a motivational interviewing session addressing alcohol use and risk for sexual aggression, a workshop addressing alcohol use and sexual aggression, and a booster session review.
223973326|NCT05773027|BEHAVIORAL|Mindfulness-Based Control Condition|The program includes the same amount of contacts as SAFE, including an individual session focused on mindfulness and stress, a group session, and a booster session review.
223973327|NCT01364441|DRUG|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
223973328|NCT01364441|DRUG|Placebo|Placebo dosed in the same manner as ONO-2952
224115682|NCT03952078|DRUG|CPI-818|Interleukin-2 inducible T-cell Kinase Inhibitor
224292646|NCT06412211|DEVICE|Photoacoustic finder|Sentinel lymph node detector using photoacoustic signal
223973329|NCT01885936|DRUG|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
223973330|NCT01885936|DRUG|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
224115683|NCT02546856|OTHER|Heart Failure (HF) nurse up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support."
224115684|NCT02546856|OTHER|Heart Failure (HF) cardiologist up-titration|"Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist."
224115685|NCT03735095|DRUG|Porfimer Sodium|Given IV
224292647|NCT04208269|OTHER|postcard campaign|Post card sent to parent only
224292648|NCT04208269|OTHER|Health Information Technology system|Accessed by adolescent and provider only
224292649|NCT01709994|DRUG|Aspirin|100 mg/day of aspirin
223973331|NCT01373333|DRUG|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
223973332|NCT03036150|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
223973333|NCT03036150|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
223973334|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant: A large majority of visits will be part of patients' usual care.~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
223973335|NCT05472519|BIOLOGICAL|blood samples|"Only one visit for each participant:~* Medical examination : weight, gender, blood pressure, medical history~* Blood samples : 1 EDTA tube (3 mL) for CBC, 3 heparin tubes (3 × 7 mL) for frozen PBMC, 1 EDTA tube (3 mL) for frozen plasma"
223973336|NCT02223013|DRUG|BIBV 308 SE solution|
223973337|NCT02223013|DRUG|BIBV 308 SE capsule L|
223973338|NCT02223013|DRUG|BIBV 308 SE capsule S|
223973339|NCT02991703|DEVICE|pOpmètre®|the pOpmètre® uses saturation sensors,
223973340|NCT02991703|DEVICE|Sphygmocor|the Sphygmocor uses applanation tonometry
223973341|NCT00637832|BIOLOGICAL|rituximab|
223973342|NCT00637832|DRUG|cyclophosphamide|
223973343|NCT00637832|DRUG|doxorubicin hydrochloride|
223973344|NCT00637832|DRUG|prednisolone|
223973345|NCT00637832|DRUG|vincristine sulfate|
223973346|NCT00637832|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223973347|NCT01347177|PROCEDURE|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
223973348|NCT01347177|PROCEDURE|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
223973349|NCT05324813|BEHAVIORAL|Domain-Specific Episodic Future Thinking|Individualized intervention that provides systematic prompts to enable creation and envisioning of positive future events across multiple life domains.
223973350|NCT02554552|DRUG|YY1201 2ml|YY1201 2ml
223973351|NCT02554552|DRUG|Placebo 2ml|phosphate buffered saline 2ml
223973352|NCT02554552|DRUG|YY1201 3ml|YY1201 2ml
223973353|NCT02554552|DRUG|Placebo 3ml|phosphate buffered saline 3ml
224115686|NCT03735095|PROCEDURE|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
224115687|NCT05346393|PROCEDURE|TIPS|A transjugular intrahepatic portosystemic shunt (TIPS) is implanted into the cirrhotic liver
224292650|NCT06882655|PROCEDURE|PIFB group|A pecto-intercostal-fascial plane block (PIFB) will be performed bilaterally in a supine position after induction of anaesthesia. The in-plane needle approach will be applied under the guidance of a high-frequency Hockey Stick Linear-Array US transducer probe (SONOSITE M-TURBO). Under strict aseptic precautions, the transducer will be placed 1-2 cm lateral to and parallel to the sternum to count the ribs from the second to the sixth rib. A 22-gauge, 50-mm short bevel echogenic needle will be advanced in a caudal-to-cranial direction until the tip of the needle will be in the targeted fascial plane, a test bolus of normal saline (1-2 mL) will be injected (in real-time) to confirm that the tip was correctly placed, as shown by separation of the fascial layers. After excluding intravascular, the dose of local anaesthetic (0.4 mL/kg 0.25% bupivacaine) will be deposited into the fascial plane visualised in real-time.
223973354|NCT00078234|DRUG|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
223973355|NCT03413540|OTHER|Jump|Drop jump from step
223973356|NCT02455284|DEVICE|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
223973357|NCT03528109|BEHAVIORAL|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
223973358|NCT06353009|OTHER|NOVA4 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 4 - Ultra-processed foods. They are the ones that use many ingredients including food additives that improve palatability, processed raw materials (hydrogenated fats, modified starches, etc.) and ingredients that are rarely used in home cooking such as soy protein or mechanically separated meat. These foods are mainly of industrial origin and are characterized by a good pleasantness and the fact that they can be stored for a long time."
224115688|NCT05346393|DRUG|Standard of Care|Terlipressin/Albumin treatment is the preferred standard of care treatment. In the case Terlipressin is not tolerated treatment with Noradrenaline may be considered following actual guidelines.
224115689|NCT05307289|OTHER|Biposy|Biopsy at inclusion visit and at disease progression if applicable
224115690|NCT02324530|DEVICE|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
223973359|NCT06353009|OTHER|NOVA1-3 meal|"NOVA (a name, not an acronym) is a food classification system divided into four groups, based on the level of processing.~Group 1 - Unprocessed or minimally processed foods (fruit, vegetables, eggs, meat, milk, etc.)~Group 2 - Foods processed in the kitchen with the aim of extending their shelf life. In practice, these are ingredients to be used in the kitchen such as fats, aromatic herbs, etc. to be kept in jars or in the refrigerator to be able to use them later.~Group 3 - Processed foods. These are the foods obtained by combining foods of groups 1 and 2 to obtain the many food products for domestic use (bread, jams, etc.) made up of a few ingredients"
223973360|NCT03646695|PROCEDURE|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
223973361|NCT03646695|PROCEDURE|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
223973362|NCT04719468|OTHER|Dance with ballet elements|Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
223973363|NCT02935777|DIETARY_SUPPLEMENT|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
223973364|NCT02935777|DIETARY_SUPPLEMENT|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
223973365|NCT05183321|PROCEDURE|periodontal therapy|periodontal cleaning
223973366|NCT00427778|DEVICE|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
223973367|NCT03068221|OTHER|anaerobic exercise|assessing anaerobic exercise status
223973368|NCT00439647|DRUG|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
223973369|NCT00439647|DRUG|Placebo|Placebo intravenous (i.v.) once a year
223973370|NCT01408875|DEVICE|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
223973371|NCT04883021|DEVICE|Dual Target Theta Burst Stimulation|"TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.~Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold."
223973372|NCT02845375|DRUG|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
224115691|NCT01097616|DRUG|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants \<65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
224115692|NCT01097616|DRUG|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants \<65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
224115693|NCT01097616|DRUG|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants \<65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
223543067|NCT05064046|BEHAVIORAL|LuCa + Health Disparity module|"The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making."
224115694|NCT03108755|DRUG|ASP7713|oral
224115695|NCT03108755|DRUG|Placebo|oral
224115696|NCT04446936|PROCEDURE|Flap covering for pressure ulcer|Flap covering for pressure ulcer
223973373|NCT02845375|DRUG|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
223973374|NCT02845375|DRUG|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
223973375|NCT02822209|BEHAVIORAL|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
223973376|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
223973377|NCT02822209|BEHAVIORAL|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
223973378|NCT02822209|BEHAVIORAL|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
223973379|NCT03679468|OTHER|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
223973380|NCT03679468|OTHER|Sham Exercise|Sets of balance and stretching exercises
223973381|NCT03679468|OTHER|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
223973382|NCT03679468|OTHER|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
223973383|NCT01265121|DEVICE|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
223973384|NCT01265121|OTHER|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
223973385|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
223973386|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
224115697|NCT00915811|DRUG|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
224115698|NCT00915811|DRUG|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
224115699|NCT00915811|DRUG|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
223543068|NCT02232971|DRUG|Glucagon|Glucagon is given in three different doses according to three research days.
223973387|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
223973388|NCT02621502|DIETARY_SUPPLEMENT|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
223973389|NCT02621502|DIETARY_SUPPLEMENT|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~* In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~* In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
223973390|NCT03287778|DIETARY_SUPPLEMENT|Pyridoxine|Max dose of 400 mg QD PO
223973391|NCT03287778|DIETARY_SUPPLEMENT|Placebo|Matching placebos will be administered.
223973392|NCT05296252|BEHAVIORAL|mind-wandering intervention|"Participants in this condition receive a brief introduction to the potential impact of mind-wandering (before learning, proactive), and are redirected to lesson if probe-caught mind-wandering are endorsed (during learning, reactive)"
223973393|NCT05296252|BEHAVIORAL|mind-wandering comparison|Participants in this condition receive no introduction, and only redirection, and the redirection is random, not in reaction to mind-wandering
223973394|NCT00221702|DRUG|PegIntron|100 mcg SC/week for 36 months
223973395|NCT00221702|DRUG|intron A|3mui TIWW SC for 18 months
223973396|NCT02127489|DRUG|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
223973397|NCT04304313|DRUG|Sildenafil citrate tablets|0.1g/day for 14 days
223973398|NCT00003597|BIOLOGICAL|recombinant human thrombopoietin|
223973399|NCT00003597|DRUG|carboplatin|
223973400|NCT00003597|DRUG|etoposide|
223973401|NCT00003597|DRUG|ifosfamide|
223973402|NCT00003597|BIOLOGICAL|G-CSF|
223973403|NCT03882996|DRUG|Ezetimibe|Ezetimibe 10 mg daily in the morning
223973404|NCT03882996|DRUG|Atorvastatin|Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
223973405|NCT02315053|OTHER|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
223973406|NCT01781013|OTHER|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
223973407|NCT00554944|PROCEDURE|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
223973408|NCT04651556|DRUG|Magnesium Sulfate & bupivacaine|intraperitoneal instillation of a combination of Magnesium sulphate with bupivacaine
224115700|NCT00915811|PROCEDURE|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
223973409|NCT04651556|DRUG|paracetamol & ketorolac|parenteral analgesics
223973410|NCT00586118|DRUG|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
223973411|NCT00586118|DRUG|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
224115701|NCT04430972|PROCEDURE|Aortic valve replacement|Open surgical replacement of aortic valve
224292651|NCT06882655|PROCEDURE|Intrathecal fentanyl(IT fentanyl)|IT fentanyl group (Group IT; n = 30) will be placed in lateral decubitus position immediately after intubation and catheterisation and receive an IT injection of 2 µg/kg of fentanyl in 0.2 mL/kg of normal saline through a 2-in., 25-gauge Quincke spinal needle inserted at L3-4 or L4-5. The dose of IT fentanyl will be based on a previous study. (15) with this route of fentanyl administration to provide intraoperative analgesia and blunt the stress response in pediatric cardiac anaesthesia. Successful dural puncture will be confirmed by observation of a free flow of cerebrospinal fluid, and the injection will be performed with the bevel of the needle oriented in the cephalic direction.
223543069|NCT02232971|OTHER|Isotonic saline solution|Placebo
223973412|NCT04683211|OTHER|Evaluation of iodine supplementation|survey of iodine supplementation
223973413|NCT02013895|DEVICE|99mTc-GSA|
223973414|NCT00383747|DRUG|transdermal nicotine patch|14mg transdermal nicotine application
223973415|NCT00383747|DRUG|Transdermal Nicotine Patch|14mg transdermal nicotine application
223973416|NCT00392886|DRUG|carboplatin|Given IV
224115702|NCT05834959|OTHER|An Educational and Training Program|Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
224115703|NCT05348850|DEVICE|Tensiomayography (TMG)|Quadriceps muscle contractile properties will be assessed using tensiomayography
223973417|NCT00392886|DRUG|cisplatin|Given IV
223973418|NCT00392886|DRUG|cyclophosphamide|Given IV
223973419|NCT00392886|DRUG|etoposide|Given IV and orally
223973420|NCT00392886|DRUG|methotrexate|Given IV
223973421|NCT00392886|DRUG|temozolomide|Given orally
223973422|NCT00392886|DRUG|thiotepa|Given IV
223973423|NCT00392886|DRUG|vincristine sulfate|Given IV
223973424|NCT00392886|PROCEDURE|autologous bone marrow transplantation|Given on day 0
223973425|NCT00392886|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
223973426|NCT00392886|PROCEDURE|peripheral blood stem cell transplantation|Given on day 0
223973427|NCT00392886|RADIATION|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
224292652|NCT06882655|PROCEDURE|IT + PIFB|Patients assigned to the combined IT fentanyl and PIFB (Group IT + PIFB; n = 30) will receive both a PIFB and IT fentanyl, with the use of the methods described for the other two groups.
223973428|NCT04168021|BEHAVIORAL|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
223973429|NCT03781947|DRUG|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
223973430|NCT01792596|OTHER|Pasta with protein|Pasta with Protein
223973431|NCT01792596|OTHER|Pasta with Fiber|Pasta with Fiber
223543070|NCT04738175|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
223543071|NCT04738175|DRUG|Placebo|Diluent solution
223543072|NCT04264923|OTHER|HyGIeaCare Prep|Each patient will have up to 5 stool specimens for evaluation by a lab for microbial contents.
223543073|NCT04790747|DRUG|CAR-T cells|Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion
223543074|NCT03525002|DRUG|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
223543075|NCT03525002|OTHER|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
223543076|NCT03982277|DRUG|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
223973432|NCT01792596|OTHER|Pasta|Pasta
223973433|NCT05334706|BIOLOGICAL|Nonavalent HPV vaccine (9vHPV/Gardasil-9™).|"Sterile suspension, 0.5 ml dose, intramuscular administration in a 3 dose-regimen (Day 1, Month 2, Month 6), prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from 9 HPV types: 6/11/16/18/31/33/45/52/58.~9vHPV is currently indicated in the EU in individuals from 9 years of age for the prevention of diseases caused by vaccine's 9 HPV types: genital warts (HPV6 and 11) and premalignant lesions and cancers affecting the cervix, vulva, vagina and anus (HPV16, 18, 31, 22, 45, 52 and 58). It was authorized for marketing in the EU on June 9th, 2015."
223973434|NCT00153023|DRUG|Telmisartan|
223973435|NCT00153023|DRUG|Valsartan|
223973436|NCT01448382|DEVICE|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
223973437|NCT01753596|DEVICE|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
223973438|NCT01753596|OTHER|Physiological Sodium Chloride solution (0,9%)|Placebo
223973439|NCT04673877|DRUG|Systemic IV Vancomycin|1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
223973440|NCT04673877|PROCEDURE|Bier Block|After exsanguination of the limb and elevation of the tourniquet in the prepped and draped patient, Vancomycin will be injected into a superficial vein in the hand, wrist or forearm.
223973441|NCT04673877|DRUG|Vancomycin|500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
223973442|NCT05321771|OTHER|Family caregiver application of HELP principles|The family caregiver will apply the principles of the HELP program in a structured manner following training by a nurse clinical specialist in geriatrics. These principles include engaging patients in conversation, particularly emphasizing orientation to time and place, encouraging eating and drinking, and assisting with early mobility.
223973443|NCT02099136|PROCEDURE|UV Light Therapy|Undergo UV-irradiation
224115704|NCT06804031|BEHAVIORAL|Nutrition and exercise education|Nutrition and exercise training was created as a result of literature review, and expert opinions (Public Health Nursing, Pediatric Nursing, Physical Therapy and Rehabilitation, Nutrition and Dietetics) were taken for the training content and finalized. The training program consists of six sessions. It is planned to have one session per week and each session will last 30-45 minutes on average. The times when the students are available will be determined by discussing with the school administration in advance. Computers and barcovisions in schools will be utilized for the training of students. Trainings will be conducted through verbal expression, power point presentations, brainstorming, exercises, games, written and visual materials, video screenings and question-answer methods. Adolescents will be given bookmarks, magnets and brochures prepared to prevent obesity.
223973444|NCT02099136|OTHER|Placebo|Given PO
223973445|NCT02099136|DRUG|Celecoxib|Given PO
223973446|NCT02099136|PROCEDURE|Biopsy|Undergo skin biopsy
223973447|NCT02099136|OTHER|Imaging Biomarker Analysis|Correlative studies
223973448|NCT03411928|DEVICE|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
223973449|NCT03140449|DRUG|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
223973450|NCT03140449|DRUG|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
223973451|NCT03140449|DRUG|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
223973452|NCT01177137|DEVICE|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
223973453|NCT01177137|DEVICE|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
223973454|NCT01177137|BEHAVIORAL|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
223973455|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
223973456|NCT01177137|BEHAVIORAL|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
223725261|NCT04298892|OTHER|clinical data and sample collection|Patients with hematologic malignancies and disorders will be asked to donate part of the samples collected as per clinical practice for the management of their disease for the aims of this study. In addition, patients will be asked to donate one oral swab sample, and urine samples. Collection of these additional samples is a non-invasive procedure with no associated risks for patients. Clinical data (demographics including ethnicity, stage of disease, concise treatment history, cytogenetic reports, and molecular data if available, as routinely performed during diagnosis procedures) will be collected.
223725262|NCT00105482|DRUG|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
223973457|NCT00866983|DRUG|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
224122667|NCT06671743|PROCEDURE|Root canal treatment|"History of presenting illness will be recorded and vitality testing will be done in addition to pre-operative radiograph.~Patient will read and sign the consent form. Pre-operative pain score will be recorded using visual analogue scale. The patient will take the preoperative medication 1 hour prior to the procedure.~The patient will receive 1 cartridge of LA with inferior alveolar nerve block (2% lidocaine 1:80000) and a rubber dam will be used for isolation.~Access cavity will be prepared and working length will be determined. Cleaning and shaping of the root canal system will be performed followed by obturation using a standardized protocol followed by final coronal restoration.~Postoperative pain score will be recorded at the 6, 12, 24, and 48 hours using visual analogue pain scale."
223973458|NCT05442073|OTHER|PEEP adjustment|adjusting PEEP about 3-5cmH2O (increase or decrease)
223973459|NCT06294483|DIAGNOSTIC_TEST|CBC|Is used to detect haematological indices (mean platelet volume, platelet lymphocyte ratio and neutrophil lymphocyte ratio) and its relation to disease activity
223725263|NCT00105482|DRUG|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
223725264|NCT00105482|BEHAVIORAL|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
223973460|NCT06294483|DIAGNOSTIC_TEST|Antinuclear Antibody tests (ANA)|To be tool in diagnosis of SLE
223973461|NCT06294483|DIAGNOSTIC_TEST|Rest of ANA profile|As tool of diagnosis of SLE
223973462|NCT06294483|DIAGNOSTIC_TEST|C3 and C4 complement level.|As method of detection of acute acivity of SLE
224115705|NCT05920096|OTHER|Diabetes specialist nurse-led multi-component smoking cessation intervention|"Aims to:~* inform participants on the association between smoking and diabetic complications;~* motivate and encourage smokers to quit;~* support participants in using the appropriate behavioural skills to quit smoking and avoid relapse.~In the first session, the participants will be supported to set a Target Quit Date (TQD) within two weeks. Participants will be followed up within a week (or two weeks max.) from their TQD. Those who report having not smoked (for ≥24 hours from the time of assessment) will be provided with a final follow-up session within five weeks from their set TQD (three sessions in total). Conversely, those who report still smoking will be encouraged to set another TQD and will be seen again in one (or two weeks max.) and five weeks from their new TQD (four sessions in total). The participants will also receive a six-week supply of Nicotine Replacement Therapy (NRT) nicotine patch and/or spray to use for a few days prior to their TQD and on quitting."
224115706|NCT05920096|BEHAVIORAL|Health Promotion and Disease Prevention Directorate's one-to-one smoking cessation service (standard care)|A behavioral smoking cessation intervention based on motivational interviewing and delivered by trained tobacco cessation facilitators within community health centres. Participants will be provided with 20-minute counseling sessions based on their needs.
224115707|NCT00677027|OTHER|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
224115708|NCT00677027|OTHER|placebo|Placebo
223725265|NCT04067895|PROCEDURE|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
223725266|NCT05620563|DRUG|LY3857210|Administered orally
223725267|NCT05620563|DRUG|Placebo|Administered orally
223973463|NCT06294483|DIAGNOSTIC_TEST|Anti phospholipid marker|To detect antiphospholipid syndrome if there is sign of thrombosis
223973464|NCT06294483|DIAGNOSTIC_TEST|Serum creatinine and Alb/create ratio|To detct complication of disease on kidney
223973465|NCT06294483|OTHER|2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.|Is criteria of diagnosis of SLE
223973466|NCT06294483|OTHER|SLEDAI scores|Is score to detect the activity of disease
224115709|NCT03253406|BEHAVIORAL|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
224115710|NCT03253406|BEHAVIORAL|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
223725268|NCT03578289|BEHAVIORAL|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
223725269|NCT02175888|DIETARY_SUPPLEMENT|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
223725270|NCT02175888|DIETARY_SUPPLEMENT|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
223973467|NCT05524415|DEVICE|Neurosteer EEG recorder|The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity.
223973468|NCT03783858|DEVICE|P200TE|OCT images
224115711|NCT03781193|OTHER|Questionnaires administration|Psychological and quality of life questionnaires
224115712|NCT03781193|OTHER|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
223973469|NCT02672397|BEHAVIORAL|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
223973470|NCT02314585|OTHER|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
223973471|NCT02314585|OTHER|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
223725271|NCT05314855|DEVICE|functional MRI|Subjects will undergo functional MRI at 4 time points in 24 hours.
223973472|NCT00700453|BEHAVIORAL|Control group with no video game play|Subjects will abstain from all video game play during study participation.
223973473|NCT00700453|BEHAVIORAL|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
223973474|NCT00700453|BEHAVIORAL|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
223973475|NCT00700453|BEHAVIORAL|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
223973476|NCT04724005|OTHER|No drug|No drug used
223973477|NCT05923398|BEHAVIORAL|Digital Intervention Group|"Participants will use a Digital Intervention Suite composed of a virtual reality (VR) scenario, a web-based platform, and a wearable device to assess their stress response in near-real time and in a hypothetical stressful scenario.~During the VR scenario, physiological signals such as Galvanic Skin Response (GSR), Electrocardiogram (ECG), Respiratory Independence (RI), and Photoplethysmography will be measured. Additionally, an educational intervention video on how to deal with stress and distress will be shown to participants. We will then request participants to practice the skills taught during the intervention video in the VR scenario.~The wearable device (Oura Ring) will measure sleep, activity, readiness information, heart rate, heart rate variability, body temperature (delta), and respiratory rate. Additionally, the web-based platform will, through questionnaires, assess stress-related symptoms such as loneliness, anxiety, depression, and moral injury."
223973478|NCT06452927|PROCEDURE|Endoscopic enucleation of the prostate|"Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3"
223973479|NCT01263990|DEVICE|NexFin|noninvasive finger cuff system
223973480|NCT00249730|DRUG|Sildenafil|
223973481|NCT05784077|DIAGNOSTIC_TEST|Polysomnography|Study of the sleep pattern
223973482|NCT05784077|BEHAVIORAL|Lifestyle counselling|Weight loss counselling
223973483|NCT05306522|OTHER|Spinal stabilization exercise|The effects of telerehabilitation based spinal stabilization exercise in chronic stroke patients will be investigated.
224115713|NCT03781193|OTHER|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
224115714|NCT03781193|OTHER|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
224115715|NCT03781193|OTHER|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
223973484|NCT02959177|DRUG|Galcanezumab|Administered SC
223973485|NCT02959177|DRUG|Placebo|Administered SC
224115716|NCT03781193|OTHER|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
224115717|NCT03781193|OTHER|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
223973486|NCT04970381|DRUG|Rivaroxaban|Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
223973487|NCT04009720|DEVICE|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area \[AVA\] \<1.0 cm2 or AVA index \<0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
224115718|NCT03781193|OTHER|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
223725272|NCT00597545|PROCEDURE|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
223973488|NCT01327027|DRUG|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
223973489|NCT01327027|DRUG|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
223973490|NCT03389451|DRUG|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
223973491|NCT04876768|PROCEDURE|Use of different concentrations of oxygen during ERCP|The endoscopic intervention will be conducted in the endoscopy suite located at UK Albert B. Chandler Hospital in Lexington, Kentucky. ERCP/EUS uses an endoscope which is a long flexible narrow tube with a camera at the end is passed through the mouth, esophagus, stomach and the first part of the duodenum. The goal is to access a small elevation in the duodenum called the papilla of Vater. This papilla drains the biliary and pancreatic ducts which brings digestive juices from the liver, gallbladder and the pancreas. The endoscopist will inject contrast dye through the papilla into the ducts and takes X-rays to show lesions such as stones, strictures or blockages. If appropriate these can be treated by passing instruments through a port in the endoscope. Immediately following the endoscopic intervention; complications (bleeding, aspiration, perforation) will be recorded by study personnel as either yes or no, which will be used to assess the overall success of the procedure.
223973492|NCT00108498|DRUG|mirtazapine|
223973493|NCT06236828|DEVICE|Mechanical Thrombectomy|The endovascular mechanical thrombectomy methods mainly include stent retriever thrombectomy, ADAPT thrombus aspiration technique, or their combination.
223725273|NCT00597545|DEVICE|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
223725274|NCT04298554|OTHER|CBD Oil|CBD PURE CBD OIL 20mg/1ml concentration
223725275|NCT04298554|OTHER|Hemp Oil|CBD PURE HEMP OIL
223973494|NCT05246384|DRUG|RP7214|RP7214 will be administered daily twice a day orally; Azacitidine will be administered from Days 1 to 7 of each 28-day cycle
223973495|NCT05168709|BIOLOGICAL|Tozinameran|Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
223973496|NCT06024135|DEVICE|NeoKidney|Progressive exposition to NeoKidney device starting with only one NeoKidney therapy on a mid-week day and 5 SDHD sessions with the usual device in week one, followed by 2 NeoKidney therapies and 4 SDHD sessions with the usual device in week 2, and only progressing to a full week on NeoKidney after a safety review.
224292653|NCT05711342|BEHAVIORAL|Aggression|"The intervention consists of 10 lessons:~1. Motivation - where are you now?~2. Where do you want to go?~3. Circle of aggression.~4. Thoughts.~5. Emotions.~6. Bodily sensations.~7. Techniques for self-control.~8. Asking for help.~9. Assertiveness.~10. Relapse-prevention. Each lesson consists of multiple components, i.e. written text, assignments and videos with therapists and/or experts by experience. After each lesson, the therapist sends written feedback on the assignments to the patient. Because 'Aggression' is a blended intervention, each lesson is briefly discussed in an in-person treatment session. Generally, participants work on one lesson per week."
223973497|NCT03044002|DEVICE|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
223973498|NCT03044002|DEVICE|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
223973499|NCT04097691|DRUG|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
223973500|NCT01860807|DRUG|Ibudilast|
223973501|NCT01860807|DRUG|Placebo|
224292654|NCT05711342|BEHAVIORAL|Treatment as usual|In-person aggression treatment as usual (TAU), as delivered by the organization. This refers to any form of psychotherapy that is delivered by a licenced psychologist to a patient. The main focus of treatment as usual should lie on aggression regulation.
223973502|NCT04531813|DRUG|Butenafine HCl 1% (BAY1896425)|Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
223973503|NCT04531813|DRUG|Positive Control-Sodium lauryl sulfate (SLS)|Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
223973504|NCT04531813|OTHER|Negative Control|A blank patch was applied to the Negative Control test site.
223973505|NCT00858507|BEHAVIORAL|RN Brief Intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
223973506|NCT00858507|BEHAVIORAL|Social Worker Outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
223973507|NCT00349388|DRUG|Asacol|Asacol is given once a day versus twice or three times a day
224115719|NCT03781193|OTHER|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
224115720|NCT01052168|OTHER|skills training|participants will train using different performance goals (based on different metrics)
224115721|NCT00179920|DRUG|Carboplatin|
224115722|NCT00179920|DRUG|VP-16|
224115723|NCT00179920|PROCEDURE|Local Surgery|
224115724|NCT00179920|PROCEDURE|Cryotherapy|
223725276|NCT05587205|BIOLOGICAL|EO2002|Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
223973508|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
223973509|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
223973510|NCT02381652|COMBINATION_PRODUCT|Cingal|Injection into the knee
223973511|NCT05896111|PROCEDURE|Physical therapy exercises.|Exercises to treat hemiparetic cerebral palsy
223973512|NCT01340300|BEHAVIORAL|Exercise training|Two supervised exercise sessions per week
223973513|NCT01340300|DRUG|Metformin|Oral metformin QD for two weeks, then BID
223973514|NCT01340300|OTHER|Educational information|educational information
223973515|NCT01656486|RADIATION|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
223973516|NCT02802150|DIETARY_SUPPLEMENT|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
223973517|NCT02802150|DIETARY_SUPPLEMENT|Soy Bean Oil;placebo(4g/day)|parallel design
223973518|NCT02222337|BEHAVIORAL|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
223973519|NCT03198351|DRUG|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
223973520|NCT04715919|DIAGNOSTIC_TEST|Chest Computed Tomography|Evaluation of Lung Structure
223973521|NCT04715919|DIAGNOSTIC_TEST|Pulmonary Function Tests|Respiratory Capacity
223973522|NCT04715919|OTHER|Six Minutes Walk Test|Exercise Capacity
223973523|NCT04715919|OTHER|Quality of Life|Physical disability assessment tool
223973524|NCT00375583|DRUG|DEC/Albendazole|
223973525|NCT02730676|OTHER|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
224115725|NCT00179920|PROCEDURE|Laser hyperthermia|
224115726|NCT02205970|DEVICE|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
224115727|NCT02205970|DEVICE|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
224115728|NCT01780558|OTHER|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
224115729|NCT01780558|DRUG|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
224115730|NCT00130208|DRUG|Sulodexide|100 mg sulodexide gelcaps
224115731|NCT00130208|DRUG|Placebo|0 mg gelcap
224115732|NCT04015297|DIAGNOSTIC_TEST|raman analysis|negative or pozitive
224115733|NCT03017586|DEVICE|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
224115734|NCT06330948|DIETARY_SUPPLEMENT|SugarCut® Unripe Guava Fruit Extract|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
224115735|NCT06330948|DIETARY_SUPPLEMENT|Placebo group|This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
223973526|NCT02730676|OTHER|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
223725277|NCT05587205|OTHER|Sham injection|Sham injection
223973527|NCT03013725|OTHER|No intervention|No intervention
224115736|NCT06570902|DEVICE|WCD|An FDA-approved, CE marked WCD will be prescribed for up to 3 months of use after hospital discharge, with the option for longer use under physician discretion
223973528|NCT04052932|DRUG|SHR4640 dose1|tablets，dose1，QD
223973529|NCT04052932|DRUG|SHR4640 dose2|tablets，dose2，QD
223973530|NCT04052932|DRUG|Placebo oral tablet|tablets，QD
224115737|NCT01586663|DEVICE|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
224115738|NCT01586663|DRUG|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
224115739|NCT03132246|DIAGNOSTIC_TEST|Blood draws|The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
223725278|NCT01170754|DRUG|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
223725279|NCT01170754|DRUG|Golytely 4 liters|Golytely 4 liters
223725280|NCT02085785|BEHAVIORAL|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
223973531|NCT04052932|DRUG|Allopurinol 300 MG|tablets，300mg，QD
223973532|NCT04785586|BEHAVIORAL|Healthy Weight Coaching|Lifestyle intervention based on Healthy Weight Coaching (HWC) is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
223973533|NCT04785586|BEHAVIORAL|Individual meetings|Individual sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
223973534|NCT04785586|BEHAVIORAL|Group meetings|Group sessions via video, offered to the participant at three (3) different time points during the 12 month intervention.
223973535|NCT01202669|OTHER|No intervention planned, observational study only.|No intervention planned, observational study only.
223973536|NCT02702739|DRUG|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
223973537|NCT00789932|BEHAVIORAL|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
224115740|NCT00225368|DEVICE|Insecticide treated bednets|
224115741|NCT03505697|OTHER|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
224122668|NCT06671418|PROCEDURE|Primary percutaneous stenting (PPS)|PPS bridging malignant hilar biliary obstruction with self-expandable uncovered metal stents without crossing the ampulla and without leaving an external drain. The procedure is performed by an interventional radiologist who has performed at least 5 PPS procedures.
224122669|NCT06671418|PROCEDURE|Endoscopic biliary drainage|EBD according to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines of 2021. The procedure is performed by a gastro-enterologist who is experienced in performing EBD in patients with a MHBO.
224122670|NCT00387387|DRUG|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
224122671|NCT00387387|DRUG|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
224122672|NCT00387387|DRUG|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
224122673|NCT03796156|DRUG|Aspirin|75mg low dose non enteric coated or dispersible
224122674|NCT02756715|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation.
224122675|NCT02756715|DRUG|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
224122676|NCT04356755|DRUG|AdMSC|At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
224122677|NCT04356755|DRUG|Placebo|At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
224122678|NCT03400696|BEHAVIORAL|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
224122679|NCT03400696|BEHAVIORAL|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
224122680|NCT03400696|BEHAVIORAL|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>
224122681|NCT02711761|DEVICE|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
223725281|NCT02085785|BEHAVIORAL|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group \[e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)\], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
223725282|NCT02085785|OTHER|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
223973538|NCT00789932|BEHAVIORAL|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
223973539|NCT05558098|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death
223973540|NCT05558098|OTHER|Standard of Care|Current standard of care for management of critically ill patients
223973541|NCT01954771|BEHAVIORAL|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
223973542|NCT01954771|OTHER|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
223973543|NCT04968015|DRUG|Cytarabine-Venetoclax Association|Consolidation treatment with cytarabine + venetoclax
223973544|NCT04968015|DRUG|Cytarabine-Idarubicin Association|Consolidation treatment with cytarabine + idarubicin
223973545|NCT02937051|OTHER|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
223973546|NCT03635775|DEVICE|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
223973547|NCT03635775|DEVICE|Sham tDCS|Sham-setting--no electrical current delivered.
223973548|NCT05542225|PROCEDURE|Strength training|Strength training will be performed with the patient in supine lying position as per FITT guidelines in which resistance will be given with the help of resistance bands on major muscle groups including shoulder flexors and extensors, hip and knee flexors and extensors, hip abductors and adductors,foot plantar flexors and dorsiflexors at an intensity of 8-15 repetitions, 2-3 times per week for 30 minutes.
223973549|NCT05542225|PROCEDURE|Flexibility training|Flexibility training will be performed with the patient in supine lying position as per FITT guidelines. Static stretching will be applied to the major muscle groups( trapezius, latissmus dorsi, gluteus maximus and medius, gastrocnemus, soleus, hamstrings and paraspinals( errector spinae and multifidi. Session will be completed in 10-15 minutes with a hold of 15 secs, 5 times per week. Stop before it becomes painful.
223973550|NCT05542225|PROCEDURE|Standard therapy|TENS at frequency of 2-125Hz for 30 minutes, pharmacological intervention
224115742|NCT03505697|OTHER|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
224292655|NCT05355038|BEHAVIORAL|lifestyle modification (dietary modification)|low glycemic index diet the researcher gave detail information about (importance of LGI diet, component of food, number of meals and snake, example of food taken in breakfast, lunch, dinner and snake in between, food allowed and not allowed). After that, the researcher required from the woman to make an example of food for one day according to her income level, if correction of the content of food needed, the researcher will explain this point again.
223543077|NCT02615977|BEHAVIORAL|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
223725283|NCT04245332|DIETARY_SUPPLEMENT|Fish oil|Fish oil-derived omega-3 polyunsaturated fatty acids (4g fish oil concentrate: 2g EPA+ 1g DHA)
223725284|NCT04245332|DIETARY_SUPPLEMENT|Coconut oil|Coconut oil (4g/d)
223973551|NCT05937971|OTHER|plantar sensitivity training|"Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)"
223725285|NCT00779467|DRUG|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
223725286|NCT00779467|DRUG|Bupivacaine|
223725287|NCT00779467|DRUG|fentanyl|fentanyl 2 mcg/ml
223725288|NCT00672867|DRUG|Clevudine|30mg
223725289|NCT00672867|DRUG|Adefovir dipivoxil|10mg
223725290|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
223973552|NCT05937971|OTHER|aerobic exercise training|Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
223973553|NCT00003359|DRUG|batabulin sodium|
224115743|NCT06297460|BEHAVIORAL|Systems Training for Emotional Predictability & Problem Solving (STEPPS)|STEPPS is based on a cognitive-behavioral and skills training approach divided into three major components. The first component (sessions: 1-2) teaches participants to replace misconceptions about the presented issues with greater awareness of thoughts, feelings, and behaviors that characterize them. It also helps them identify their own thought patterns driving their behaviors. The second (sessions 3-12) teaches skills to more effectively manage the cognitive and emotional effects of the issues, such as distancing, communication, challenging, distraction, and problem-solving. The third component (sessions 13-19) teaches behavioral skills where participants are encouraged to master habits of healthy eating, sleep hygiene, regular exercise, leisure activities, health monitoring, self-harm prevention, and interpersonal effectiveness. The therapeutic objectives of the three blocks are awareness of illness (1), emotional regulation (2), and behavioral regulation (3).
224115744|NCT00012337|DRUG|gefitinib|
223725291|NCT00612781|PROCEDURE|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
223725292|NCT02692703|DRUG|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
223725293|NCT04118166|DRUG|Ipilimumab|Ipilimumab 1 mg/kg, injection
224115745|NCT05141526|OTHER|Non-restrictive satiating intervention|Diet group containing satiating foods
224115746|NCT05141526|OTHER|Conventional restrictive intervention + non-restrictive satiating intervention|Diet group with a calorie deficit during the first phase followed by a diet containing satiating foods in the second phase
224115747|NCT05141526|OTHER|Control group|This group will receive minimal healthy guidelines
224115748|NCT05314348|DEVICE|High-density surface EMG|High-density surface EMG for fasciculation detection
223725294|NCT04118166|PROCEDURE|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
223725295|NCT04118166|DRUG|Nivolumab|Nivolumab 3 mg/kg, injection
223725296|NCT01148784|PROCEDURE|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
223973554|NCT01007721|DRUG|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
223973555|NCT01007721|DRUG|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
223973556|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
223973557|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
224115749|NCT05314348|DEVICE|Ultrasound|Ultrasound for fasciculation detection
224115750|NCT01541605|DRUG|methylphenidate|tablets for oral use
223725297|NCT00025766|DEVICE|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
223725298|NCT00025766|BEHAVIORAL|Optimal Medical Therapy|Participants will receive optimal medical therapy.
223725299|NCT03434275|DRUG|N1539|Once Daily
223725300|NCT03434275|DRUG|Placebo|Once Daily
223725301|NCT02455232|PROCEDURE|upper limb muscle block|
224115751|NCT01541605|DRUG|Placebo|tablets for oral use
224115752|NCT04310137|BEHAVIORAL|Therapist-Directed Re-loading|Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
223725302|NCT02455232|DRUG|4cc of lidocaïne®|
223725303|NCT02918175|BEHAVIORAL|mHealth|Personalized step count feedback and medication teaching tool.
223725304|NCT03900078|OTHER|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
223973558|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
223973559|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
223973560|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
223973561|NCT01007721|DRUG|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
223973562|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
223973563|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
223973564|NCT01007721|DRUG|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
223973565|NCT01007721|DRUG|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
223973566|NCT01007721|DRUG|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
223973567|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
223973568|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
223973569|NCT01007721|DRUG|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
223973570|NCT01007721|DRUG|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
223973571|NCT01007721|DRUG|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
224115753|NCT02876224|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
224115754|NCT02876224|DRUG|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
224115755|NCT02876224|DRUG|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
224115756|NCT01461031|DRUG|nefopam|nefopam infusion for postoperative 24 hours
224115757|NCT01461031|DRUG|normal saline (control)|normal saline infusion for postoperative 24 hours
224115758|NCT01618981|PROCEDURE|pace make active/inactive cross over|
223973572|NCT01007721|DRUG|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
223973573|NCT01007721|DRUG|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
223973574|NCT04171921|PROCEDURE|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
223973575|NCT04171921|PROCEDURE|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
223973576|NCT06223100|DRUG|Eravacycline|There is no other intervention.
223973577|NCT00999141|BIOLOGICAL|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
223973578|NCT01242033|DIETARY_SUPPLEMENT|red raspberries|single serving of one, two or four cups red raspberries
223973579|NCT01242033|DIETARY_SUPPLEMENT|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
223973580|NCT01990378|DRUG|Rabeprazole sodium 20 mg Delayed Release tablet|
223725305|NCT03900078|OTHER|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
223725306|NCT00284050|DRUG|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
224115759|NCT02242149|DRUG|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
224115760|NCT02242149|DRUG|Placebo|Sugar pill manufactured to mimic Diacerein
224115761|NCT02518178|DEVICE|NFC Necklace|
224115762|NCT02518178|DEVICE|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
224115763|NCT02518178|DEVICE|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
224115764|NCT01084499|DRUG|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
224115765|NCT01084499|DRUG|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
224115766|NCT01084499|DRUG|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
224115767|NCT01084499|DRUG|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
224115768|NCT05312905|OTHER|Mirror Therapy|Mirror Therapy applied alone
223725307|NCT00284050|DRUG|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
223973581|NCT02781077|PROCEDURE|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
223973582|NCT01641627|PROCEDURE|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
223973583|NCT05562583|BEHAVIORAL|SAGE LEAF|"SAGE LEAF covers 8 skills and each skill has related home-practice activities that unlock every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time."
223973584|NCT02113150|DRUG|remifentanil|renal function
223973585|NCT02113150|DRUG|Ketamine|renal function
224115769|NCT05312905|OTHER|Mirror Therapy + Cognitive Therapy|Mirror Therapy supported with Cognitive Exercises
224115770|NCT05670119|OTHER|Structured Training|Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
224115771|NCT06207175|BIOLOGICAL|Nonavalent HPV study vaccine|A 3-dose regimen administered at months 0, 2 and 6.
224115772|NCT06207175|BIOLOGICAL|GARDASIL® 9|A 3-dose regimen administered at months 0, 2 and 6.
224115773|NCT06513637|DIAGNOSTIC_TEST|12-Lead ECG and home sleep study (HST) diagnostics|"* 12-lead ECG hookup will be performed following standard placement procedures.~* The Home Sleep Study diagnostic device placement will be performed by study personnel following the manufacturer's instructions."
224115774|NCT01690949|DRUG|PUR118|inhaled PUR118, BID
224115775|NCT03968367|PROCEDURE|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
223725308|NCT00284050|DRUG|Sham injection|Non-treatment control for sham intravitreal injection.
223725309|NCT00038857|PROCEDURE|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
223725310|NCT00038857|DRUG|Melphalan|140 mg/m\^2 on day -8
223725311|NCT00038857|DRUG|Thiotepa|10 mg/kg on day -7
223725312|NCT00038857|DRUG|Fludarabine|160 mg/m\^2 over 4 days on days -6, -5, -4, -3
224292656|NCT05355038|BEHAVIORAL|lifestyle modification (physical activity)|health teaching about choose between two types of exercise to be selected according to the ability of GDM women to perform : brisk walking or seated arm exercise or selected both. Brisk walking should be performed for at least half an hour three time /week, while, seated arm exercise done three time after each meal for10 minute in each time. The researcher given a detail information about both types and its importance in decreasing blood glucose level, also how to perform and what should be done in case of appearance of fatigue manifestation during exercise, and the women have choice for perform both or selected one to perform according to your health condition.
223725313|NCT00038857|DRUG|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
223973586|NCT01262118|DRUG|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
223973587|NCT04101019|DRUG|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
223973588|NCT04101019|DRUG|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
223973589|NCT00694135|DRUG|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
223973590|NCT00694135|DRUG|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
223973591|NCT00694135|DRUG|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
223973592|NCT00694135|DRUG|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
223973593|NCT02046941|BEHAVIORAL|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
223725314|NCT02968251|BEHAVIORAL|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
223725315|NCT00899262|OTHER|immunohistochemistry staining method|
224115776|NCT02238405|OTHER|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
223725316|NCT00899262|OTHER|laboratory biomarker analysis|
223725317|NCT00899262|OTHER|sputum cytology|
224115777|NCT00816218|DRUG|Pioglitazone|pioglitazone, 45 mg daily
224115778|NCT00359814|DRUG|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
224115779|NCT00359814|DRUG|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
223725318|NCT00899262|PROCEDURE|Fourier transform infrared spectroscopy|
223725319|NCT00899262|PROCEDURE|diagnostic bronchoscopy|
223725320|NCT04771442|DRUG|Stromal vascular fraction|Single dose
223725321|NCT00742534|DRUG|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
224115780|NCT05920850|OTHER|Educational Video about LDCT lung cancer screening|A culturally tailored video that provides education about the process LDCT lung cancer screening
224115781|NCT05920850|OTHER|A culturally tailored shared decision-making tool|A culturally tailored shared decision-making tool that educates participants about the shared decision-making process
223973594|NCT04364750|DIETARY_SUPPLEMENT|L-Histidine|1 capsule (0.6g) twice daily
223973595|NCT04364750|DIETARY_SUPPLEMENT|High-FODMAP beverage|High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.
223973596|NCT04364750|DIETARY_SUPPLEMENT|Low-FODMAP beverage|Low-FODMAP beverage (10g glucose) consumed twice daily.
223973597|NCT04364750|DIETARY_SUPPLEMENT|Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.|Total of 50 billion CFU/capsule taken twice daily.
223973598|NCT04364750|OTHER|Placebo|Enteric coated capsule with no active ingredient, taken twice daily
223973599|NCT03178318|PROCEDURE|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
223973600|NCT00087477|DRUG|Pivanex|
223973601|NCT01823640|OTHER|placebo|
223973602|NCT01823640|OTHER|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
223973603|NCT00162552|DRUG|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
223973604|NCT00162552|DRUG|PLACEBO|Patients with severe cirrhosis treated with a placebo
223973605|NCT03807453|OTHER|Microbiota|The scalp microbiota
223973606|NCT00095017|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
223973607|NCT03545321|BEHAVIORAL|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
224115782|NCT05920850|OTHER|Flip chart|The use of a flip chart that reinforces the information provided in the video and shared decision-making tool
224115783|NCT05920850|OTHER|Navigation support|Navigation support for participants who express interest in LDCT and quitting smoking.
224115784|NCT01703819|DRUG|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
224115785|NCT01703819|OTHER|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
223973608|NCT03595137|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
223973609|NCT03595137|DEVICE|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
223973610|NCT06406868|OTHER|American Cancer Society|"After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down"
223973611|NCT00236483|DRUG|tramadol hydrochloride + acetaminophen|
223973612|NCT00404508|DRUG|Hydralazine and magnesium valproate|
223973613|NCT02414555|DRUG|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
224115786|NCT04230486|DEVICE|Cross-model Visual Auditory Rehabilitation|Subjects will put on a virtual reality rehabilitation system which will present sights and sounds.
224115787|NCT03215264|DRUG|hydroxychloroquine|600-1200mg daily
223973614|NCT02414555|DRUG|fluid bolus|
223973615|NCT02414555|DEVICE|oesophagus doppler (CardioQ)|
223973616|NCT02414555|DRUG|Normal Saline|
223973617|NCT02414555|DEVICE|arterial cannulation|
223973618|NCT02414555|DEVICE|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
224115788|NCT03215264|DRUG|entinostat|3-5mg weekly
224115789|NCT03215264|DRUG|regorafenib|160mg daily
224115790|NCT01598584|DRUG|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
224115791|NCT01598584|DRUG|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
224115792|NCT01977209|DRUG|Gossypol|
224115793|NCT01977209|DRUG|Placebo|
224115794|NCT00188500|BEHAVIORAL|atkins diet|
223973619|NCT02414555|DRUG|Elo-Mel Isoton (balanced acetat-based infusate)|
224115795|NCT00188500|BEHAVIORAL|ability to follow low carbohydrate diet|
224115796|NCT02145156|BEHAVIORAL|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
224292657|NCT05355038|BEHAVIORAL|lifestyle modification( self glucose monitoring)|self-glucose monitoring the researcher explain the important of monitoring blood glucose level and instruct the women about how to perform self- glucose measuring, recording way of the result in schedule and to bring this result in the next antenatal visit. The women who have digital blood glucose monitoring instructed to measure it at least 5 time/day. while, the women who didn't have digital blood glucose monitoring measure went to nearest pharmacy to measure blood glucose at least one time per day especially when the woman felt the signs and symptoms of hypo or hyperglycemia and recorded the result in paper or sent the result in whatsapp for the researcher if you have whatsapp application. In addition to give the woman instruction about sings symptoms of hypoglycemia and hyperglycemia and the proper ways for management
224292658|NCT06826365|DIAGNOSTIC_TEST|Percentage distribution of immune system cells in peripheral blood|Assessment of the percentage distribution of the immune system cell population in peripheral blood by flow cytometry
224292659|NCT06826365|DIAGNOSTIC_TEST|Percentage distribution of immune system cells in endometrium|Assessment of the percentage distribution of the immune system cell population in endometrium by flow cytometry
224292660|NCT06616662|PROCEDURE|MAF|use mucosal advancement flap to treat PAF
224292661|NCT06616662|PROCEDURE|LIFT|use LIFT surgery for treating PAF
224292662|NCT06928974|PROCEDURE|Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition|Bilateral Pedicled Vastus Lateralis Muscle Flaps Transposition to restore the function of underdeveloped or absent rectus abdomini muscles
224292663|NCT05087862|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After the ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between the iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% bupivacaine.
224292664|NCT05087862|PROCEDURE|Pericapsular local anesthetic infiltration of the hip|Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
224292665|NCT03821272|BIOLOGICAL|PepCan|50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
224292666|NCT03821272|BIOLOGICAL|Placebo|0.9% Saline solution per dose administered intradermally in the extremities
224292667|NCT05307328|DRUG|SPI-62|11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor
224292668|NCT05307328|DRUG|Placebo|Inactive tablets identical to SPI-62 tablets
224292669|NCT04702880|BIOLOGICAL|BMS-986012|Specified dose on specified days
224292670|NCT04702880|DRUG|Carboplatin|Specified dose on specified days
224292671|NCT04702880|DRUG|Etoposide|Specified dose on specified days
224292672|NCT04702880|BIOLOGICAL|Nivolumab|Specified dose on specified days
224292673|NCT05904769|DEVICE|LIFELEAF Smartwatch|Noninvasive wearable smartwatch/monitor that utilizes photoplethysmography (PPG) which is a set of measurements acquired from the light flashed from the back of the watch and measuring the intensity of the reflected light from the blood in the blood vessels just below the skin at the wrist. Provides a non-invasive method for measuring blood glucose as well as alternative method for measuring blood pressure, heart rate and rhythm, etc.
224292674|NCT06246526|DEVICE|Evoke|The Saluda Medical Evoke® CL-SCS System (Evoke System). The Evoke System measures and records spinal cord (SC) activation resulting from stimulation via evoked compound action potentials (ECAPs). The Evoke System can be programmed to provide ECAP-controlled, closed-loop SCS or open-loop, fixed-output (traditional) SCS; ECAPs may be measured and recorded in either stimulation mode.
224292675|NCT05835466|DRUG|reparixin|reparixin at 1200mg TID three times per day.
224292676|NCT06474195|BEHAVIORAL|Cue based intervention|The intervention arm will receive the cues in the form of daily repeating reminders for a time period of 30 days. The reminders will be set on participants' mobile phones to receive at least 1 hour prior to the prescribed oral antipsychotic medication. The same reminder will be repeated after 10 minutes duration to ensure that the participant does not miss the cue and the uniformity of the cue will be ensured by setting the same emoji or the same phrase on the participant's own mobile phone. The participant will also be asked a task of daily routine during the same time of medication.
224292677|NCT06474195|BEHAVIORAL|Treatment as Usual|This group will not get any intervention but the usual treatment all assessments will continue
224292678|NCT05206331|DEVICE|contrast enhanced mammography|Dual-energy contrast images; low-energy CEM images will be obtained with a kilovoltage below 35 kVp while the high-energy images will be obtained with 45-49 kVp.The average glandular dose of the CEM procedure is approximately 2.44 mGy per view
224292679|NCT05206331|DRUG|Iodinated Contrast Media (ICM)|standard FDA-approved low osmolarity Iodine contrast agent with 350-370 mg/ml
224292680|NCT06001320|DRUG|Letermovir 480 mg once daily|We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.
224292681|NCT06001320|OTHER|Historical/Control|The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.
223973620|NCT03653377|OTHER|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
223973621|NCT03336073|DRUG|Carfilzomib|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
223973622|NCT03336073|DRUG|Dexamethasone|dexamethasone oral at a dose of 20 mg (10 mg for patients \>75 years) days 1, 2, 8, 9, 15 and 16
224292684|NCT04551430|DRUG|Cabozantinib|Cabozantinib will be supplied by Exelixis.
224292685|NCT04551430|DRUG|Nivolumab|Nivolumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
224292686|NCT04551430|DRUG|Ipilimumab|Ipilimumab will be provided free of charge (as investigational supply) by Bristol-Myers Squibb.
224292687|NCT06785038|BEHAVIORAL|EMPOWER Strategy|The EMPOWER Strategy will: 1) identify women in primary care; 2) deliver understandable, actionable, and non-stigmatizing PrEP education, in multiple formats and languages, directly and securely to women via the patient portal; 3) enable women to discreetly self-schedule a visit to discuss PrEP options via the patient portal, with either their own PCP or with a female PCP who has years of experience in PrEP delivery; and 4) support PCP counseling via clinical decision support that provides standardized, patient-centered language to guide PrEP discussions and via 'smart sets' to facilitate PrEP prescribing, when desired and appropriate.
224292688|NCT06785038|BEHAVIORAL|Attention Control|Women in this arm will be sent, via the patient portal, a CDC patient education material on benefits of physical activity. The material will be in English or Spanish based on patient's language.
224292689|NCT03533283|DRUG|Glofitamab|Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
224292690|NCT03533283|DRUG|Atezolizumab|Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
224292691|NCT03533283|DRUG|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.
224292692|NCT03533283|DRUG|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
224292693|NCT03533283|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
224292694|NCT03533283|DRUG|89Zr-Df-IAB22M2C|Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
224292695|NCT04497779|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or nasopharyngeal swabs
224292696|NCT04497779|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
224292697|NCT04497779|OTHER|Electronic Health Record Review|Donors and recipients have their medical records reviewed.
224292698|NCT04497779|OTHER|Questionnaire Administration|Ancillary studies
224292699|NCT05980546|DRUG|Bupivacaine Injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
224292700|NCT05980546|DRUG|Dexamethasone injection|The genicular nerve block and anterior femoral cutaneous nerve blocks consists of bupivacaine with preservative-free dexamethasone injections.
224292701|NCT05980546|DRUG|Fentanyl|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
224292702|NCT05980546|DRUG|Mepivacaine|This is a drug that is given as part of the analgesia and sedation regime. This drug is not the study intervention.
224292703|NCT01688466|DRUG|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
224292704|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab Prefilled Syringe|Prefilled Syringe (PFS) for subcutaneous (SC) injection self-administration of rocatinlimab.
224292705|NCT06224192|COMBINATION_PRODUCT|Rocatinlimab AI|AI for SC injection self-administration of rocatinlimab.
224292706|NCT04939090|DRUG|Olanzapine|Given PO
224292707|NCT04939090|DRUG|Megestrol Acetate|Given PO
224292708|NCT04939090|OTHER|Questionnaire Administration|Ancillary studies
223973623|NCT03336073|DRUG|cyclophosphamide|cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
223973624|NCT02739490|PROCEDURE|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
224292709|NCT06770582|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224292710|NCT06770582|DRUG|Cisplatin|Given IV
224292711|NCT06770582|PROCEDURE|Computed Tomography|Undergo CT
224292712|NCT06770582|DRUG|Fluorouracil|Given IV
224292713|NCT06770582|DRUG|Gemcitabine|Given IV
223973625|NCT03128541|DIAGNOSTIC_TEST|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
223973626|NCT01537406|RADIATION|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
223973627|NCT01644825|DRUG|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
223973628|NCT01644825|DRUG|pazopanib|orally, 800 mg orally daily
223973629|NCT01018797|PROCEDURE|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
223973630|NCT02216578|DRUG|cabozantinib|Oral
223973631|NCT04531878|DRUG|4-Phenylbutyrate|4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB). In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
223973632|NCT00212797|DRUG|Org 34517|low dose Org 34517
223973633|NCT00212797|DRUG|Org 34517|high dose Org 34517
223973634|NCT00212797|DRUG|Placebo|placebo
223973635|NCT01865578|DEVICE|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
223973636|NCT01865578|DEVICE|Sham Stimulation|no electrical stimulation
224292714|NCT06770582|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224292715|NCT06770582|DRUG|Mitomycin|Given IV
224292716|NCT06770582|BIOLOGICAL|Pembrolizumab|Given IV
224292717|NCT06770582|OTHER|Questionnaire Administration|Ancillary studies
224292718|NCT06770582|RADIATION|Radiation Therapy|Undergo radiation therapy
224292719|NCT05353439|PROCEDURE|Biopsy Procedure|Undergo biopsy
224292720|NCT05353439|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223973637|NCT02996097|DEVICE|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
223973638|NCT02996097|DRUG|Intralesional Triamcinolone Acetonide|
223973639|NCT02852278|OTHER|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
223973640|NCT03412513|DRUG|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
224115797|NCT02145156|BEHAVIORAL|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
224115798|NCT02145156|BEHAVIORAL|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
224115799|NCT06317272|OTHER|DIBH using ABC technique|Deep breath inspiration hold (DIBH) using Active Breathing Control (ABC) technique
224115800|NCT06317272|OTHER|DIBH using VC technique|Deep breath inspiration hold (DIBH) using Voluntary Coaching (VC) technique
224115801|NCT03803540|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
224115802|NCT02819648|DRUG|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
224115803|NCT02819648|OTHER|Control|Milk Tablet
224292721|NCT05353439|PROCEDURE|Computed Tomography|Undergo CT scan
224292722|NCT05353439|BIOLOGICAL|Pembrolizumab|Given IV
224292723|NCT05353439|DRUG|Tazemetostat Hydrobromide|Given PO
224292724|NCT05353439|DRUG|Topotecan Hydrochloride|Given IV
224292725|NCT02960893|DRUG|Troriluzole|Randomization Phase: Neat (i.e., drug substance without excipients); loose filled capsule.
224292726|NCT02960893|DRUG|Placebo|Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
224292727|NCT02960893|DRUG|Troriluzole|OLE phase: Neat capsule or formulated capsule (i.e., drug substance with excipients).
224292728|NCT06581211|PROCEDURE|Aromatherapy and Essential Oils|Inhale LA
224292729|NCT06581211|OTHER|Electronic Health Record Review|Ancillary studies
224292730|NCT06581211|OTHER|Jojoba Oil|Inhale jojoba oil aromatherapy
223973641|NCT03412513|DRUG|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
223973642|NCT00583115|DRUG|Gleevec|260 mg/M2/day, given once daily by mouth
223973643|NCT05363605|DRUG|[225Ac]-FPI-1966|\[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
224115804|NCT01840020|PROCEDURE|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
223973644|NCT05363605|DRUG|[111In]-FPI-1967|\[111In\]-FPI-1967 is an imaging agent that consists of vofatamab, a bifunctional chelate and indium-111 radionuclide. Participants will receive \[111In\]-FPI-1967 Injection of 185 MBq for imaging.
224115805|NCT01840020|PROCEDURE|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
224292731|NCT06581211|OTHER|Lavender Oil|Inhale LAO
224292732|NCT06581211|OTHER|Questionnaire Administration|Ancillary studies
224292733|NCT06581328|DRUG|Vedolizumab IV|Vedolizumab IV infusion
224292734|NCT06581328|DRUG|Vedolizumab SC|Vedolizumab SC injection
224292735|NCT04704024|DRUG|Tenofovir Disoproxil Fumarate|oral TDF medication 300 mg daily
224292736|NCT04704024|DRUG|Lamivudine Oral Solution|Oral lamivudine with weight-based dosing BID from birth until 6 months of age
224292737|NCT05267106|DRUG|Pemigatinib|13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
224292738|NCT06004986|DRUG|Dupilumab|Administering Dupilumab 300 mg at different dosing intervals.
224115806|NCT02027688|OTHER|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
224115807|NCT02027688|OTHER|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
224292739|NCT04370587|BIOLOGICAL|T3011|T3011 will be administered up to 4mL as an intratumoral injection given Q2W.
224292740|NCT04370587|COMBINATION_PRODUCT|T3011 + pembrolizumab|T3011 will be administered up to 4mL as an intratumoral injection in combination with intravenous pembrolizumab given Q3W.
224292741|NCT05832151|DRUG|CIN-102 Dose 15mg or 10mg|2 capsules twice daily for 12 weeks
224292742|NCT05832151|DRUG|Placebo|2 capsules twice daily for 12 weeks
224292743|NCT04859699|BEHAVIORAL|COVID-19 Health Education Comic Books and Videos|Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
224292744|NCT05946941|DRUG|Deucravacitinib|Specified dose on specified days
224292745|NCT05946941|OTHER|Placebo|Specified dose on specified days
223973645|NCT05363605|BIOLOGICAL|vofatamab|Vofatamab is a Fibroblast Growth Factor Receptor 3 (FGFR3)-targeting human monoclonal antibody without a radioisotope. In Phase 1, the dose depends on cohort assignment. In Phase 2, if pre-dosing with vofatamab is indicated, the RP2D regimen will be administered.
223973646|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg Ferrous sulfate
223973647|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|60 mg ferrous sulfate
223973648|NCT01404533|DIETARY_SUPPLEMENT|Ferrous sulfate|6 mg ferrous sulfate
223973649|NCT01712295|DRUG|17% Salicylate with ethyl pyruvate|
223973650|NCT01712295|DRUG|Salicylates|
223973651|NCT03722498|DRUG|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223973652|NCT03722498|DRUG|Sorafenib|administration of Sorafenib
223973653|NCT03569475|DRUG|Levomilnacipran ER|Levomilnacipran extended-release oral capsules
223973654|NCT03569475|DRUG|Fluoxetine|Fluoxetine oral capsules
223973655|NCT03569475|DRUG|Placebo|Matching placebo oral capsules
223973656|NCT03638258|DRUG|Roflumilast Cream 0.3%|Applied once daily for 12 weeks
223973657|NCT03638258|DRUG|Roflumilast Cream 0.15%|Applied once daily for 12 weeks
223973658|NCT03638258|DRUG|Vehicle Cream|Applied once daily for 12 weeks
223973659|NCT04238533|OTHER|eADAPT training|eADAPT training for myoelectric prosthesis users is the comparator training.
223973660|NCT04238533|OTHER|Conventional training|Conventional training with Myoboy has been the only training available to users.
223973661|NCT04351100|DRUG|Diacerein|Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
224115808|NCT05447377|BIOLOGICAL|SII Yellow Fever Vaccine|"SII YF vaccine:~Live attenuated Yellow Fever Virus (17D-213 Strain) not less than 1000 IU/dose propagated in specific pathogen-free chick embryos.~SII-YFV contains the 17D-213 vaccine strain, a derivative of 17D-204 strain which is used in many currently produced yellow fever vaccines. SIIPL imported the YF WHO Primary Seed Virus lot 213-77 from National Institute for Biological Standards and Control (NIBSC) for preparation of the master seed virus, working seed virus and the vaccine.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-213 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 5 mg of sorbitol per dose."
224115809|NCT05447377|BIOLOGICAL|STAMARIL®|"STAMARIL® contains the 17D-204 vaccine strain, which is used in many currently produced yellow fever vaccines. STAMARIL® is specific pathogen free embryonated hen's egg based and is prepared by harvesting and stabilizing the virus collected from the homogenized chicken embryos infected with YF vaccine virus.~STAMARIL® will be used as a comparator in the study. It is a live, attenuated, freeze-dried (lyophilized) vaccine and is to be reconstituted with solvent.~After reconstitution, 1 dose (0.5 mL) contains:~* Yellow fever virus 17D-204 strain (live, attenuated) not less than 1000 IU propagated in specific pathogen-free chick embryos~* Excipients with known effects:~* This product contains approximately 8 mg of sorbitol (E420) per dose."
224115810|NCT00198341|PROCEDURE|Radiological Arm|Clinical Visit + X-Ray Chest
223973662|NCT03111849|OTHER|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
223973663|NCT03489837|DRUG|Levotuss|oral taken
224115811|NCT00198341|PROCEDURE|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
224122682|NCT06000722|OTHER|eDelphi method|This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
223973664|NCT00669292|BIOLOGICAL|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
223973665|NCT00360971|BIOLOGICAL|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
223973666|NCT00360971|DRUG|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
223973667|NCT00360971|OTHER|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
224122683|NCT06130696|OTHER|Clamshell exercises|Group A will receive treatment with Clamshell exercises Change sides and do 3 sets. Total of 6 session were given.
223973668|NCT00360971|PROCEDURE|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
223973669|NCT00360971|RADIATION|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
223973670|NCT03868098|DRUG|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
224115812|NCT04645459|OTHER|low phosphorus meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
224115813|NCT04645459|OTHER|control meals|All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
223973671|NCT03868098|DRUG|Placebo ointment|Placebo ointment (vehicle)
223973672|NCT01425541|DRUG|estrace|0.5-1 mg once a day PO for 7 days
223973673|NCT01425541|DRUG|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
223973674|NCT02088723|BEHAVIORAL|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
224115814|NCT00205504|DRUG|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
224115815|NCT04175197|DEVICE|Drug Coated Balloon|Legflow Drug Coated Balloon
224115816|NCT01335568|PROCEDURE|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
224115817|NCT03537768|DRUG|Ulipristal Acetate|UPA Tablet
224115818|NCT03537768|DRUG|Levonorgestrel|LNG Tablet
224115819|NCT03537768|DRUG|Levonorgestrel|LNG Tablet (x2)
224115820|NCT03709888|DRUG|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
224115821|NCT02234583|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
224115822|NCT02801097|DRUG|RRx-001|
224115823|NCT02801097|DRUG|Irinotecan|
224115824|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
224115825|NCT00895349|PROCEDURE|CT Abdomen and Pelvis scan|Pre-treatment scan
224115826|NCT03463694|OTHER|Na Cl solution|\~2.6% NaCl solution prepared from sea salt
223973675|NCT05253547|BEHAVIORAL|Healthy climate-friendly dietary guidelines|Personalised climate-friendly healthy dietary recommendations
223973676|NCT05253547|BEHAVIORAL|Healthy dietary guidelines|Personalised healthy dietary recommendations
224115827|NCT00086710|DRUG|Fuzeon|
224115828|NCT05178953|DRUG|Zinc Sulfate 220 mg Capsules|Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
224115829|NCT05178953|DRUG|Pentoxifylline|Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
224115830|NCT05498961|OTHER|Gallstone characteristics|stone size, number, the thickness
224115831|NCT03914287|OTHER|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
224115832|NCT00008294|DRUG|FOLFOX regimen|
224115833|NCT00008294|DRUG|dexamethasone|
224115834|NCT00008294|DRUG|floxuridine|
224115835|NCT00008294|DRUG|fluorouracil|
224115836|NCT00008294|DRUG|leucovorin calcium|
224115837|NCT00008294|DRUG|oxaliplatin|
224115838|NCT05635552|DIAGNOSTIC_TEST|Dynamic retinal vessel analysis (DVA)|DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.
224115839|NCT05635552|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.
224115840|NCT05635552|DIAGNOSTIC_TEST|Biochemistry and immune phenotyping|Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.
224115841|NCT05635552|DIAGNOSTIC_TEST|Handgrip strength test|Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.
224115842|NCT05635552|DIAGNOSTIC_TEST|Questionnaires (Patient reported outcomes)|The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
224115843|NCT00541086|DRUG|anastrozole|1 mg per day, orally
224115844|NCT00541086|DRUG|exemestane|25 mg per day, orally
223543078|NCT02615977|BEHAVIORAL|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
224115845|NCT00541086|DRUG|letrozole|2.5 mg per day, orally
224115846|NCT00541086|DRUG|tamoxifen citrate|20 mg per day, orally
224115847|NCT00386893|PROCEDURE|simultaneous EEG/fMRI|fMRI/EEG recordings
224115848|NCT00386893|DEVICE|fMRI|
224115849|NCT03378011|OTHER|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
224115850|NCT03032185|DEVICE|Transcutaneous Elevtrical Nerve Stimulation|
224115851|NCT00791440|BEHAVIORAL|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
224115852|NCT00791440|OTHER|Standard Psychiatric Treatment|Standard psychiatric treatment.
224122684|NCT06130696|OTHER|Isometric and muscle strengthen exercise|"group B will receive simple exercises also with clamshell 10 to 20 times. Change sides and do 3 sets.~Total 6 session were given"
224122685|NCT00942045|BIOLOGICAL|Biologic - Osteocel Plus|Osteocel Plus
224122686|NCT05618457|DRUG|Aminoglycoside dose adjustment|Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
224122687|NCT03063775|DEVICE|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
224122688|NCT03063775|OTHER|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
224122689|NCT03063775|OTHER|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
224122690|NCT03063775|DEVICE|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
224122691|NCT04775797|DRUG|AB-836|Capsules or Tablets
224122692|NCT04775797|DRUG|Placebo|Capsules of Tablets
224122693|NCT04775797|DRUG|AB-836|Tablets
224122694|NCT04775797|DRUG|Placebo|Tablets
224122695|NCT04775797|DRUG|Nucleos(t)ide Analogue|Tablets
224122696|NCT03839147|BEHAVIORAL|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
224122697|NCT03414840|DRUG|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
224122698|NCT01721408|DRUG|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
224122699|NCT01721408|DRUG|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
224122700|NCT03638947|DEVICE|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
224122701|NCT03987620|DRUG|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
224122702|NCT03987620|DRUG|Placebo|Matching Placebo
224122703|NCT04523844|DRUG|Brinzolamide-brimonidine Fixed Combination|In case group one drop of a fixed combination of brinzolamide-brimonidine will be instilled two hours before the injection
224122704|NCT06556056|OTHER|SesZen-Bio Serum|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liduid Frequency: Daily Night application. Route of administration: Topical"
224292746|NCT06265584|DRUG|ATG dosing platform when combined with standard tacrolimus and mini methotrexate|On Day -8, you will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). You will receive a steroids 3 hours before every ATG infusion. On day -7, you will receive a small dose of ATG as an intravenous (IV) infusion. ATG will be repeated on days -6, -5 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -7 to -3 as daily IV infusions. Melphalan, another routine transplant chemotherapy will be given on day -4 as IV infusion. Tacrolimus (standard immune suppression agent) will start on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate is another standard immune suppression medication which is given IV on day +1, +3, +6, and +11 post-transplant. We plan to draw blood on days -4,, -1, +3, +7, and +14 to measure ATG levels.
224292747|NCT06250985|OTHER|Timing of reimplantation|Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
224115853|NCT01742468|DIETARY_SUPPLEMENT|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
224115854|NCT01742468|DIETARY_SUPPLEMENT|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
224115855|NCT01221467|DEVICE|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
224115856|NCT04635696|DRUG|Ethyl chloride|Pressurized vapocoolant developed for acute, mild pain relief.
224115857|NCT04635696|OTHER|Tissue culture grade water|Pressurized water mist
224115858|NCT00908297|DIETARY_SUPPLEMENT|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~* 300 mg for two weeks~* 600 mg for two weeks~* 1200 mg for two weeks~* 1800 mg for final two weeks"
224115859|NCT02223221|PROCEDURE|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
224115860|NCT02223221|GENETIC|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
224115861|NCT02223221|OTHER|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
224115862|NCT02481037|OTHER|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
224115863|NCT02481037|OTHER|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
224115864|NCT02481037|OTHER|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
224115865|NCT04729088|DRUG|Isosorbide mononitrate|Intra-anal application performed by the study physician of 2 g of the study drug
224115866|NCT04998045|BEHAVIORAL|Screening and brief intervention for substance use|Screening will be done using the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST). The brief intervention will be delivered based on ASSIST risk scores: low risk - verbal positive reinforcement and brief advice on harmful consequences of substance use (ii) moderate risk - brief motivational interviewing (BMI) (iii) high risk - BMI and referral to child psychiatry out-patient clinic. The BMI will be delivered in a single session (approximately 15 minutes) using Feedback Listen Options model (15): (i) providing feedback on screening results (ii) exploring pros and cons of substance use, enquiring about importance of change (iii) exploring options for change.
224115867|NCT03002389|DRUG|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
224115868|NCT03002389|DRUG|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
224115869|NCT05912959|OTHER|photo biostimulation|the intervention is a type of wavelength around 820 nm. this method of treatment is totally safe. yet, it has many therapeutic effects on the cellular level as well as tissue and organ level. during treatment with laser, the patient does not feel any specific sensation.
224115870|NCT02805907|DRUG|Calcifediol|
224115871|NCT02805907|DRUG|Placebo|
224115872|NCT01595256|BEHAVIORAL|muscular strength|12-week moderate intensity walking program
224115873|NCT00000455|DRUG|naltrexone|
223973677|NCT04533334|PROCEDURE|FOB measurement|A FOB will be inserted after anesthesia induction and the distances will be measured by direct observation via the bronchoscope.
223973678|NCT02569944|PROCEDURE|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
224115874|NCT03408873|DRUG|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
224115875|NCT03408873|BEHAVIORAL|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
224115876|NCT02990481|BIOLOGICAL|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
224115877|NCT02990481|BIOLOGICAL|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
224292748|NCT06960187|BEHAVIORAL|Weyera Intervention|"Weyera intervention is an eight-week program featuring weekly, two-hour facilitated group sessions with 6-10 participants in each group, led by trained lay facilitators. Each session will address the weekly topic and introduce an evidence-based coping strategy (e.g., mindfulness, positive refocusing) that participants can practice over the following week. Within this outline, we will create intervention activities based on theory-based change methods and practical applications matched to objectives and determinants in the Logic Model of Change.~Outline of major modules for the eight weeks:~1. Introduction to mental health~2. Stress and family pressure~3. Self-exploration and critical reflection~4. Intersectional Identities~5. Family Relationships~6. Discussing mental health in the Ethiopian and Eritrean communities~7. Trauma and Abuse~8. Navigating mental health services"
224115878|NCT02990481|BIOLOGICAL|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
224115879|NCT01806870|DIETARY_SUPPLEMENT|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
223973679|NCT02569944|PROCEDURE|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
224115880|NCT06201572|OTHER|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared|The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
224115881|NCT03481764|GENETIC|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
224115882|NCT01264965|DRUG|long acting oxycodone|10mg twice daily
224115883|NCT01264965|DRUG|extra strength acetaminophen|1,000 mg twice daily
224115884|NCT00722592|DRUG|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
223973680|NCT00144716|DEVICE|Insect Repellent plus Insecticide Treated Net|
223973681|NCT05846048|OTHER|semi-structures questionaire|semi -structured questionnaire prepared by the researcher collect sociodemographic data , awareness ,attitudes about marital rape and health consequences
223973682|NCT04675671|OTHER|Preoperative and postoperative anxiety measurement [Spielberger's State Anxiety Scale (STAI-S)] and [ Spielberg's State-Trait Anxiety Inventory (STAI-T) ]|The postoperative pain is measured and evaluated by Visual Analog Scale (VAS= 0 = no pain to 10 = worst pain)
223973683|NCT04847908|OTHER|Single high-intensity interval exercise intervention|Study participants perform a single bout of exercise on a cycle ergometer (high-intensity interval exercise intervention) within the first and third cycle of chemotherapy. Following a 2 minute warm-up, the interval protocol comprises 10 intervals à 15 seconds with high intensity and 60 seconds low intensity in-between. Blood samples are taken at t0 pre-exercise (after a 10 minute rest) and at t1 immediately post-exercise via central catheter (Hickman/port).
223973684|NCT01905293|OTHER|Feeding Study|
223973685|NCT02429037|DRUG|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (VP) in a 21-days cycle.
223973686|NCT02429037|RADIATION|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
223973687|NCT02429037|DRUG|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
223973688|NCT05544539|DRUG|Ozone-Based Agent|In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
223973689|NCT05544539|DRUG|Placebo|In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
223973690|NCT02169245|OTHER|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
223973691|NCT02277587|DRUG|Plenadren|Oral Tablets: 20-25-30 mg
223973692|NCT02277587|DRUG|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
223973693|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|Daily supplementation with \~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
223973694|NCT03826147|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Daily supplementation with \~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
223973695|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl|injection of local anesthetic mixture(Bupivacaine +Fentanyl ) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
223973696|NCT06162806|PROCEDURE|ultrasound guided caudal epidural block using 50 mg of Magnesium sulfate added to(1ml/kg of Bupivacaine 0.25% + 0.5microgram/kg of Fentanyl)|injection of local anesthetic mixture(Bupivacaine +Fentanyl +magnesium sulfate) in the caudal epidural space under guidance of ultrasound, it is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space
223973697|NCT02109107|DEVICE|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
223973698|NCT04184856|DIAGNOSTIC_TEST|fMRI|(Imaging while) performing reward related tasks.
223973699|NCT02811042|DEVICE|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
223973700|NCT02811042|DEVICE|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
223973701|NCT02526771|PROCEDURE|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
223973702|NCT02526771|PROCEDURE|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
223973703|NCT04159051|DEVICE|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
224115885|NCT00722592|DRUG|pegylated liposomal doxorubicin (PLD)|50 mg/m\^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
224115886|NCT00722592|OTHER|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
224115887|NCT04561817|DRUG|Ipatasertib|400mg PO daily: day 1-21 of 28 day cycle
224292749|NCT06960187|BEHAVIORAL|Delayed intervention (waitlist control)|Wait-list control participants will be assigned to a group for initiation of the full intervention beginning at month 4 after their enrollment (i.e., beginning after they, and their corresponding intervention group, have completed their intervention and two follow-up surveys). Wait-list control participants will complete surveys at enrollment (baseline), 2 months (pre-intervention), 4 months (pre-intervention), 6 months (immediate post-intervention), and 8 months (post-intervention).
224292750|NCT06960213|DRUG|ADX-324|siRNA duplex oligonucleotide
224292751|NCT06960213|DRUG|Placebo|saline
224292752|NCT05947500|DRUG|Avelumab|Given IV
224292753|NCT05947500|PROCEDURE|Biopsy Procedure|Undergo biopsy
224292754|NCT05947500|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool
224292755|NCT05947500|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224292756|NCT05947500|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224292757|NCT05947500|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224292758|NCT05947500|DRUG|Tuvusertib|Given PO
223973704|NCT01001130|DRUG|fluticasone furoate group|patients who are administered fluticasone furoate at least once
223973705|NCT03090893|DRUG|ATryn continuous infusion|replenish serum thrombin levels
223973706|NCT02745314|OTHER|Frailty measurement|Frailty measurement under Fried at el criteria
223973707|NCT02745314|OTHER|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
224115888|NCT04561817|DRUG|Paclitaxel|80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
224292767|NCT05321719|BEHAVIORAL|Comparison Condition|In this Phase II project, BR2S will be evaluated for efficacy relative to a usual care control. Investigators expect BR2S to improve outcomes on behavioral change, self-efficacy, establishment of a dental home, knowledge, and attitudes in real settings relative to the usual care condition. The outcome measures include a direct clinical dental measure as well as observational measures of parental behavior. The study will also provide important information regarding the various types and combinations of BeReady2Smile product components for dissemination. The long-term goal of the program is to help parents provide the foundation for a lifetime free from preventable oral disease.
224292768|NCT05321719|BEHAVIORAL|BeReady2Smile video only|"The video will be viewed at the Head Start site after informed consent and T1 questionnaires and plaque assessment. The video will include concrete demonstrations and feature diversity in settings and actors in video content derived from actual peer-based parenting education sessions. Parents' ability to see themselves in the content makes them more likely to engage in discussions about dental health. Supporting these conversations has been identified as an important need. For example, in a recent environmental scan prepared by the Association of State and Territorial Dental Directors the lack of communication strategies was identified as a gap in oral health educational resources. Specifically mentioned was the lack of oral health curricula that support interactive communication between families and home visitors. Families struggle with such dialogues."
224292769|NCT05321719|BEHAVIORAL|BeReady2Smile video and BeReady2Smile app completely self-guided|In addition to the BeReady2Smile video as described above, the BeReady2Smile app includes: (a) presentation of concepts, behaviors, and examples via video and text, (b) electronically presented check-in questions recorded to a database for review, (c) capture of a 5-minute video of parent-child interactions uploaded for later review by the parent, using a mobile application, (d) daily dental activities (homework), and (e) program feedback recorded to the database. BeReady2Smile will be designed such that before the parent can go on to a new area of learning, the parent must complete the previous lesson. Participants can go back and review previous material in a non-linear format. The database and log-files record all computer activities to track use of each intervention component.
224292770|NCT05321719|BEHAVIORAL|"Complete BeReady2Smile video and BeReady2Smile app guided by a Coach"|"In addition to the BeReady2Smile video and BeReady2Smile app described above, the complete intervention includes support via phone and text from a trained facilitator/coach who builds supportive one-on-one relationships with the parent and gives feedback on parent-recorded videos of parent-child interactions of tooth-brushing, designed to facilitate learning and promote engagement with their oral health professional; and tools to create a long-term follow-up plan. Dental behaviors will be tailored for children's developmental level (e.g. twice daily tooth brushing for preschoolers and limiting sugar sweetened beverages or milk in bottles at bed for infants)."
223973708|NCT03525483|DIAGNOSTIC_TEST|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
223973709|NCT01630837|OTHER|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
224115889|NCT05922267|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUES|"The participants in group A will be given ACBT with conventional chest physiotherapy .~Instruction for patient~* Try to keep your chest~* Take a long, slow and deep breath in, through your nose if you can.~* At the end of the breath in, hold the air in your lungs for 2-3 seconds before breathing~* Breathe out gently and relaxed, like a sigh. Don't force the air out.~* Repeat 3 - 5 times.~* If the patient feels light-headed then it is important that they revert back to the breathing control phase of the cycle~* Huffing"
223973710|NCT04868318|OTHER|Very-high protein enteral formula|Peptamen® Intense VHP (37% protein)
223973711|NCT04868318|OTHER|Standard-high protein enteral formula|Peptamen® (16% protein)
224122705|NCT06556056|OTHER|Minoxidil hair serum (1%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
224292771|NCT06029270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224292772|NCT06029270|PROCEDURE|Bone Scan|Undergo bone scan
224292773|NCT06029270|DRUG|Carboplatin|Given IV
224292774|NCT06029270|DRUG|Cisplatin|Given IV
223973712|NCT02371161|DRUG|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
223973713|NCT05666063|DIAGNOSTIC_TEST|Ambulatory Urodynamic Study|Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
223973714|NCT04653207|OTHER|Glucose Solution 1|50g glucose dissolve in 300ml of water
223973715|NCT04653207|OTHER|Glucose Solution 2|50g glucose dissolve in 300ml of water
223973716|NCT04653207|OTHER|Glucose Solution 3|50g glucose dissolve in 300ml of water
223973717|NCT04653207|OTHER|Sucrose/Isomaltulose 100:0|50g sucrose dissolve in 300ml of water
223973718|NCT04653207|OTHER|Sucrose/Isomaltulose 0:100|50g isomaltulose dissolve in 300ml of water
223973719|NCT04653207|OTHER|Sucrose/Isomaltulose 50:50|25g sucrose and 25g isomaltulose dissolve in 300ml of water
223973720|NCT04653207|OTHER|Sucrose/Isomaltulose 60:40|30g sucrose and 20g isomaltulose dissolve in 300ml of water
223973721|NCT04653207|OTHER|Sucrose/Isomaltulose 70:30|35g sucrose and 15g isomaltulose dissolve in 300ml of water
223973722|NCT04653207|OTHER|Sucrose/Isomaltulose 80:20|40g sucrose and 10g isomaltulose dissolve in 300ml of water
223973723|NCT04848103|BEHAVIORAL|Radial extracorporeal shockwave therapy|Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation \[TENS\], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
223973724|NCT04903847|DRUG|Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]|Two-drug therapy
224115890|NCT05922267|OTHER|SLOW EXPIRATION WITH OPEN GLOTTIS IN LATERAL POSITION|The participants in group B will be given slow expiration with open glottis in lateral posture and conventional chest physiotherapy .In this technique, a patient adopts a lateral posture or a lateral decubitus posture. The affected lung is in the dependent position. A patient commences breathing normally, at tidal volumes. They are then instructed to perform a series of slow expirations with an open glottis. Expiration from functional residual capacity to the end of the expiratory reserve volume are encouraged to achieve maximum inflation . To assist in maintaining an open glottis, a mouthpiece may be used, to decrease the degree of airway compression A series of three ELTGOL may be performed, with each series composed of approximately 10 slow and deep expirations. In between each series of maneuvers, a rest period (around 1-2 minutes) is provided, with the patient staying in the same position. A typical treatment lasts for around 20 minutes
224115891|NCT03550716|PROCEDURE|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
224292775|NCT06029270|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223973725|NCT04903847|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Three-drug therapy
223973726|NCT05132530|BEHAVIORAL|yoga|yoga practice will be done two days a week for 10 weeks.
223973727|NCT05093023|GENETIC|Real-Time PCR|Genomic DNA was extracted from 2 ml of venous blood. ABCB1 1236 G\>A and 3435 G\>A were genotyped using predesigned TaqMan SNP genotyping assays on a stepOne PCR instrument in accordance with the manufacturer's protocol.
224292776|NCT06029270|DRUG|Gemcitabine|Given IV
223973728|NCT06337240|OTHER|Pelvic floor on COPD patients|"Group A (study group) :~This group will include 30 COPD patients with urinary incontinence , who will receive pelvic floor exercise for 3 days a week for a total of 3 months."
223973729|NCT06337240|OTHER|Pilates exercises on COPD patients|"Group B (study group):~This group will include 30 COPD patients with urinary incontinence , who will receive pilates for 3 days a week for a total 3 months."
223973730|NCT04760327|COMBINATION_PRODUCT|Electrochemotherapy with bleomycin or cisplatin|Electrochemotherapy with cisplatin or bleomycin of gynecological cancers
223973731|NCT05364645|DRUG|Carboplatin|Given IV
223973732|NCT05364645|DRUG|Pemetrexed|Given IV
223973733|NCT05364645|DRUG|Selpercatinib|Given PO
223973734|NCT01792206|DRUG|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
223973735|NCT01792206|DRUG|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
224115892|NCT03550716|PROCEDURE|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
224115893|NCT06109623|OTHER|observation|To observe the changes and differences of steroid hormones between stress urinary incontinence group and control group.
224115894|NCT06109623|OTHER|sex hormone|Six indicators of steroid hormones (estrogen, testosterone, follicle stimulating hormone, luteinizing hormone, pituitary prolactin, progesterone)
224115895|NCT03274336|BEHAVIORAL|questionnaire|questionnaire post preanesthetic interview
224115896|NCT03274336|BEHAVIORAL|face-to-face interview|Group A = face-to-face interview
224115897|NCT03274336|BEHAVIORAL|brochure|after reading a brochure a face to face interview will take place
224115898|NCT03274336|BEHAVIORAL|movie|after seeing a film about the procedure a face-to-face interview will take place
224115899|NCT00542685|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
224115900|NCT00542685|DRUG|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
224115901|NCT00542685|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
224115902|NCT00542685|DRUG|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
223973736|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
223973737|NCT01562821|DRUG|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
223973738|NCT01562821|DRUG|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
223973739|NCT01121185|BIOLOGICAL|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
223973740|NCT01121185|OTHER|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
223973741|NCT02991781|OTHER|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
223973742|NCT02991781|DRUG|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
224115903|NCT00299533|DRUG|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
224115904|NCT01797107|DRUG|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
224115905|NCT04197297|DIAGNOSTIC_TEST|CT and MRI Scans|CT and MRI scans will occur before and after radiation therapy.
224115906|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens with comfort additive|
224115907|NCT01797783|DEVICE|Nelfilcon A multifocal contact lens|
224115908|NCT00532883|DRUG|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
224115909|NCT00532883|DRUG|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
224115910|NCT00532883|OTHER|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
224115911|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
224115912|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
224115913|NCT00712114|DRUG|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
224115914|NCT03807999|DRUG|Nab-paclitaxel|
224292777|NCT06029270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224292778|NCT06029270|BIOLOGICAL|Nivolumab|Given IV
224292779|NCT06029270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224292780|NCT06029270|BIOLOGICAL|Relatlimab|Given IV
223973743|NCT02991781|OTHER|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
223973744|NCT02991781|OTHER|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
223973745|NCT03905213|DEVICE|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
223973746|NCT03905213|DEVICE|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
223973747|NCT03905213|DEVICE|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
223973748|NCT04950049|DRUG|Dexamethasone|receive 2ml dexamethasone (5mg/ml)
223973749|NCT04950049|OTHER|Diluted dexamethasone 5ml|receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
223973750|NCT04950049|OTHER|Diluted dexamethasone 10ml|receive 10ml dexamethasone (1mg/ml) diluted with 5% glucose
223973751|NCT04950049|OTHER|Diluted dexamethasone 20ml|receive 20ml dexamethasone (0.5mg/ml) diluted with 5% glucose
223973752|NCT04273854|DEVICE|OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®|The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
223973753|NCT05114902|DIAGNOSTIC_TEST|Nasopharyngeal swab|A sample obtained from the nasopharynx for detection of live pneumococci and pneumococcal respiratory carriage
223973754|NCT01478256|DRUG|Erythromycin|Topical erythromycin ointment twice a day
223973755|NCT01478256|DRUG|Besifloxocin|Topical Besifloxocin twice a day
223973756|NCT05254288|OTHER|Chlorhexidine|In-office and domiciliary use of chlorhexidine for 14 days.
223973757|NCT05254288|OTHER|Ozoral gels|In-office administration of Ozoral Pro and domiciliary use of Ozoral gel for 14 days.
223973758|NCT04299724|BIOLOGICAL|Pathogen-specific aAPC|The subjects will receive three injections of 5x10\^6 each Covid-19/aAPC vaccine via subcutaneous injections.
223973759|NCT00509925|DRUG|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
223973760|NCT00509925|DRUG|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
223973761|NCT00509925|DRUG|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
223973762|NCT06352034|BEHAVIORAL|Empathy Training|"The intervention contains five themes: 1) An overview of empathy and emotions. 2) Cognitive empathy and clarification technique. 3) Emotional empathy and reflection of feelings technique. 4) Awaring and dealing with the inner feelings while empathizing. 5) Empathy timing and emotional pendulum technique."
223973763|NCT00275678|PROCEDURE|Blood stem cell versus bone marrow transplant|"1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
223973764|NCT03171389|DRUG|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
223973765|NCT06650137|DIAGNOSTIC_TEST|diaphragmatic ultrasound|"The examination is performed with a phased array probe, also known as a cardiac probe. The technique used will be that described and validated in anterior studies: the patient is in the Fowler position: half-seated, at an angle of around 45 degrees. The patient is ventilating spontaneously, and no participation is required. The probe is positioned in the sub-costal region between the mid-clavicular and anterior axillary line on the right, and between the anterior and middle axillary line in the sub- or intercostal region on the left. The liver is used as an acoustic window for the right hemi-diaphragm. The probe is oriented medially, cranially and dorsally.~The operator switches to time-motion (TM) mode when an angle of over 70° is achieved between the upper part of the diaphragm and the analysis axis in the most cephalic part of the diaphragm. The image is frozen when 6 respiratory cycles have been measured."
224115915|NCT03807999|DRUG|Gemcitabine|
224115916|NCT01205191|BEHAVIORAL|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
224115917|NCT01205191|BEHAVIORAL|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
224115918|NCT01205191|BEHAVIORAL|CBT|CBT for anxiety disorders
224115919|NCT00601588|DRUG|Sertraline|
224115920|NCT00086840|DRUG|temsirolimus|Given IV
224115921|NCT00086840|OTHER|laboratory biomarker analysis|Correlative studies
224115922|NCT02508168|DRUG|Alogliptin|Alogliptin 12.5 mg tablets
224115923|NCT02508168|DRUG|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
224115924|NCT02508168|DRUG|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
224115925|NCT00495560|DRUG|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
224115926|NCT00658970|DRUG|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
224115927|NCT03799718|BIOLOGICAL|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
223973766|NCT04457011|DRUG|High dose Susu Xiao'er Zhike Granules 1 bag|High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
223973767|NCT04457011|DRUG|Middle dose Susu Xiao'er Zhike Granules 1 bag|Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
223973768|NCT04457011|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
224115928|NCT06250530|PROCEDURE|High tibial osteotomy using TOMOFIX|TOMOFIX: A guidepin is placed to determine the level and length of the osteotomy with an appropriate hinge position selected. The oscillating saw is then used along with osteotomes to complete the osteotomy under image intensifier guidance. This is opened to the desired width of correction with a trapezoidal gap noted when using laminar spreader in the posterior position to avoid slope change. The plate is then applied and secured as per manufacturers operative technique.
224115929|NCT06250530|PROCEDURE|High tibial osteotomy using BodyCAD|BodyCAD: The patient specific cutting block is applied to the proximal tibia and secured in placed. The osteotomy is then created with sequential drills and osteotome and opened to the predetermined correction as per the manufacturer's guidelines. The plate is applied and secured with the supplied screws.
224115930|NCT03593304|DRUG|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
224115931|NCT03593304|DRUG|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
224115932|NCT03593304|DRUG|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
224115933|NCT03593304|DRUG|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
224292781|NCT05925530|DRUG|Durvalumab|Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
224292782|NCT06094491|BEHAVIORAL|Virtual Group Visit|Group visits must have these core components: diabetes education, group social support and goal setting.
224292783|NCT05891613|DRUG|Bupivacaine Hydrochloride|20 ml of 0.25% Bupivacaine (50 mg) with 20 ml of injectable saline (total of 40 cc) as a subcutaneous infiltration along the inframammary fold incision on one breast
224292784|NCT05891613|DRUG|Liposomal Bupivacaine|20 ml of Liposomal (Exparel) Bupivacaine (266 mg/20 ml) on the contralateral breast
224292785|NCT05479981|DRUG|Placebo|Placebo will be administered by intravenous (IV) infusion.
224292786|NCT05479981|DRUG|AOC 1001|AOC 1001 will be administered by intravenous (IV) infusion.
224292787|NCT06180460|BEHAVIORAL|CALM|The CALM intervention is a supportive-expressive therapy that is administered by CALM trained clinicians in a particular style.
224292788|NCT06180460|BEHAVIORAL|Treatment as usual|Treatment as usual includes a list of local / national resources (e.g., psychologist, social worker, or other mental health providers) if an individual chooses to seek treatment for the distress they are experiencing.
224292789|NCT05477576|DRUG|RYZ101|RP3D as determined in Phase 1b
224292790|NCT05477576|DRUG|Everolimus|Everolimus
224292791|NCT05477576|DRUG|Sunitinib|Sunitinib
224292792|NCT05477576|DRUG|Octreotide|High-dose octreotide
224292793|NCT05477576|DRUG|Lanreotide|Lanreotide
224292794|NCT05831176|DRUG|Dupilumab|Administered as described in the protocol
223973769|NCT03302559|OTHER|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
223973770|NCT03302559|OTHER|Facial cleanser|Facial cleanser in the morning and in the evening.
223973771|NCT03302559|OTHER|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
223973772|NCT03302559|OTHER|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
223973773|NCT03302559|DEVICE|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
224115934|NCT02332356|DRUG|azathioprine or adalimumab and infliximab|
224115935|NCT02411227|BEHAVIORAL|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
224115936|NCT02028104|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
224115937|NCT04866420|BEHAVIORAL|The MenFAS Study|A cross over repeated exposure randomized design observational study
224115938|NCT05556382|RADIATION|radiation of brain tissue specimen and dna damage analysis|increasing doses of radiation on brain tissue specimen and analysis of related dna damage.
224292795|NCT02786277|OTHER|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
224292796|NCT01013649|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
224292797|NCT01013649|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
224292798|NCT01013649|DRUG|Capecitabine|Given PO
224292799|NCT01013649|DRUG|Chemotherapy|Given combination chemotherapy
224292800|NCT01013649|PROCEDURE|Computed Tomography|Undergo CT
224292801|NCT01013649|DRUG|Erlotinib Hydrochloride|Given PO
224292802|NCT01013649|DRUG|Fluorouracil|Given IV
224292803|NCT01013649|DRUG|Gemcitabine Hydrochloride|Given IV
224292804|NCT01013649|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
224292805|NCT01013649|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223973774|NCT05942183|DIAGNOSTIC_TEST|ONSD|ultrasound measurement of the optic nerve sheath diameter
223973775|NCT03925402|DRUG|Ertapenem|Ertapenem injection
223973776|NCT03925402|DRUG|Carbapenems|Other carbapenems injection
223973777|NCT06720285|PROCEDURE|nerve block with 0.5% ropivacaine|Compared to active comparator arm, the experimental arm received the same procedure except in the analgesia maintenance which was performed by nerve block of the scalp using 0.5% ropivacaine. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
223973778|NCT06720285|DRUG|General anesthesia and opioids (fentanyl, propofol, rocuronium)|Compared to experimental arm, the active comparator arm received the same procedure except in the analgesia maintenance which was performed through continuous fentanyl infusion. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
223973779|NCT06721052|DRUG|meta-Peng block|The convex transducer was positioned obliquely in a superolateral to inferomedial direction just above the femoral crest. Anatomical structures including AIIS, iliopubic eminence, sartorius muscle, iliopsoas muscle, psoas tendon, artery, vein, and iliac fascia were identified sono-anatomically. The AIIS was centered in the transducer image. To determine the insertion point of the rectus femoris tendon (RFT) on the AIIS, the transducer was rotated sagittally, and the level where the RFT ends cephalically was identified. After identifying the target, the transducer was obliquated again to visualize the IPE. The 22G x 100 mm block needle was advanced in-plane from lateral to inferomedial towards the potential space between the IPM and AIIS. After confirming the target plane with a few mL of saline, 30-40 mL of 0.25% bupivacain was applied to the area. The spread of injectate was observed beneath the IPM, below the psoas tendon, and around the iliacus muscle within the iliac fascia.
224115939|NCT02202031|BEHAVIORAL|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
223973780|NCT06721052|DRUG|Postoperative analgesia management|We ordered 400 mg intravenous ibuprofen for the patients every 8 hours during the postoperative period. We planned to perform 100 mg tramadol as a rescue analgesic if the patient's NRS score was above 4. We observed the patients for 24 hours in the postoperative period.
224115940|NCT02202031|BEHAVIORAL|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
224115941|NCT02087319|OTHER|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
224115942|NCT05645484|DRUG|18F-PFPN|18F-PFPN (dose: 3.0-5.4 MBq/kg) will be injected intravenously prior to imaging.
223973781|NCT06721039|DRUG|Bilateral QL block|sonovisible block needle will be inserted under ultra-sonographic monitoring between the iliac wing and rib at the midaxillary line for the TQL block in the lateral decubitus positioning of the patient. The space between the quadratus lumborum and psoas major muscles will be visualized with Ultrasound Guided and 0.25% bupivacaine will be injected after visualization of the tip of the needle reaching the plane, 2ml of anaesthetic solution will be instilled to view the hydro dissection, confirming the correct placement. Following this, the total volume of 40 ml of 0.25% bupivacaine will be instilled, creating a meniscus between the planes
223973782|NCT06721039|DRUG|Intraperitoneal and port sites infiltration|with 40 ml of 0.25% bupivacaine will be injected under the direct vision into the hepato-diaphragmatic space, near and above the hepato-duodenal ligament and above the gall bladder also injected at the port sites at the end of operation before removal of the probes
223973783|NCT06720506|DRUG|fentanyl|Fentanyl will be given intrathecal with dose 10-20ug
223973784|NCT06720506|DRUG|Nalbuphine|Nalbuphine will given IV as shot in Dose 1mg /kg
223973785|NCT06719622|DRUG|budesonide|1 mg budesonide ampoule twice daily for patients weighing ≤35 kg or 2 mg twice daily for patients weighing \>35 kg
223973786|NCT06719622|DRUG|omeprazole (proton pump inhibitor)|omeprazole 10 mg twice daily for patients weighing ≤35 kg or 20 mg twice daily for patients weighing \>35 kg
223973787|NCT06720805|DRUG|Pentabiocel|"This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires."
224115943|NCT05645484|DRUG|18F-FDG|18F-FDG (dose: 3.7-5.4 MBq/kg) will be injected intravenously prior to imaging.
224115944|NCT00000309|DRUG|Risperidone|
224115945|NCT03924024|DEVICE|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
224115946|NCT05832164|OTHER|Multifactorial intervention|"* Adherence to a Mediterranean diet.~* Progressive aerobic and anaerobic exercise program.~* Review of polypharmacy~* Group socialization activities"
224115947|NCT00748826|BIOLOGICAL|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
224292806|NCT01013649|OTHER|Quality-of-Life Assessment|Ancillary studies
224292807|NCT01013649|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224292808|NCT04285567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
224292809|NCT04285567|DRUG|Venetoclax|Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
223973788|NCT06720805|DRUG|Placebo|"This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires."
223973789|NCT04130061|BIOLOGICAL|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
223973790|NCT06374186|BEHAVIORAL|Behavioral Intervention with financial rewards and coaching|Participants will receive variable financial incentives based on their engagement with the continuous glucose monitor and meeting diabetes treatment goals. In addition, they will participate in three motivational interviewing sessions focused on their diabetes management. Participants will continue to receive their diabetes treatment as usual.
223973791|NCT06374186|BEHAVIORAL|Control|Participants will only receive a continuous glucose monitor, which they may engage with as desired and no further intervention. Participants in the control group will continue to receive their diabetes treatment as usual.
223973792|NCT06096506|BEHAVIORAL|Virtual Culinary Medicine|The virtual curriculum will include five 90-minute sessions (to be held weekly or bi-weekly). Participants will also be expected to shop for groceries ahead of the sessions to participate in the program. A gift card will be provided for groceries ($30 per class = $150 total).Asynchronous virtual educational content (cooking skills videos, animated nutrition education videos, and additional recipes) will be provided to engage and retain participants beyond initial sessions
223543079|NCT01128725|OTHER|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~* psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~* Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
223543080|NCT01739608|OTHER|Invitation to screening|Invitation to screening
223973793|NCT00647374|OTHER|this is an observational study|
224115948|NCT00819624|OTHER|Interactive Voice Response System (IVRS)|Telephone based system
224115949|NCT00819624|OTHER|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
224115950|NCT00000404|BEHAVIORAL|Patient education in self-care of knee OA|
224115951|NCT02039180|DRUG|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
224115952|NCT02039180|DRUG|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
224115953|NCT02039180|DRUG|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
224115954|NCT06058494|PROCEDURE|Anterior Cruciate Ligament Reconstruction|Reconstruction of the anterior cruciate ligament by means of the three reported techniques, namely single-bundle, single-bundle with extraarticular tenodesis and anatomic double-bundle.
224115955|NCT00076219|PROCEDURE|renal replacement therapy|renal replacement therapy
224292810|NCT04285567|DRUG|Fludarabine|Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
224292811|NCT04285567|DRUG|Cyclophosphamide|Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
223973794|NCT00989898|OTHER|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
223973795|NCT03747614|DRUG|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
223973796|NCT03747614|DEVICE|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
224115956|NCT02560701|OTHER|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
224115957|NCT05748925|DRUG|dapagliflozin|The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.
224115958|NCT05748925|DRUG|placebo|Control group: will be maintained on their medication
224115959|NCT04855877|DRUG|Oral tablet|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
223543081|NCT04176107|BEHAVIORAL|Informative video|Exposure to informative video before cesarean delivery
223543082|NCT02789462|PROCEDURE|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
223543083|NCT03302403|GENETIC|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
224292812|NCT04285567|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
224292813|NCT04285567|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
224292814|NCT05826535|DRUG|LYL314|CAR T-cell therapy
224292815|NCT05826535|DRUG|Fludarabine|Conditioning chemotherapy
224292816|NCT05826535|DRUG|Cyclophosphamide|Conditioning chemotherapy
224292817|NCT04888312|BIOLOGICAL|CD40 agonist mitazalimab in combination with chemotherapy|Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.
224292818|NCT03485209|DRUG|tisotumab vedotin|Given into the vein (IV; intravenously)
224292819|NCT03485209|DRUG|pembrolizumab|200mg or 400mg given by IV
224292820|NCT03485209|DRUG|carboplatin|AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV
223543084|NCT03302403|GENETIC|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
223543085|NCT03302403|GENETIC|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
224292821|NCT03485209|DRUG|cisplatin|100mg/m\^2 given by IV
224292822|NCT06508658|DRUG|Epcoritamab|Subcutaneous Injection
223543086|NCT03302403|GENETIC|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
223543087|NCT03302403|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223973797|NCT03140878|DIETARY_SUPPLEMENT|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
223973798|NCT03140878|DIETARY_SUPPLEMENT|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
223973799|NCT02282423|BEHAVIORAL|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
223973800|NCT02282423|PROCEDURE|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
223973801|NCT02282423|PROCEDURE|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
223973802|NCT02282423|PROCEDURE|VO2max.|VO2max.
223973803|NCT02282423|BEHAVIORAL|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
223973804|NCT02282423|PROCEDURE|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
223973805|NCT03389425|BEHAVIORAL|simplified intervention to modify physical activity, lifestyle, and eating behavior|16 week, behavioural weightloss intervention.
223973806|NCT04668521|OTHER|OVA360|Multifactorial Risk Assessment for Breast \& Ovarian Cancer Risk Detection
223973807|NCT02168621|PROCEDURE|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score \<30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
223973808|NCT02168621|PROCEDURE|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
223973809|NCT06102798|DEVICE|Acunpuncture|"For the bilateral BL25, sterile disposable steel needles (Hwato, China; 0.3 mm×75 mm) will be inserted through adhesive pads to a depth of 50-70mm until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Hwato, China; 0.3 mm×40 mm) will be inserted through adhesive pads to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi."
223973810|NCT06102798|DEVICE|Sham acupuncture|For all the points, the needles will be inserted into adhesive pads without skin penetration. Needles will be lifted, thrust and twirled for 3 times to mimic real acupuncture. No manipulation will be conducted during 30-minute maintenance.
223973811|NCT00890539|DRUG|Methacholine challenge|Clinical and research test used in asthma
223973812|NCT01257399|DRUG|Asacol®|400 mg tablets
223973813|NCT01257399|DRUG|Mesalazine|400mg tablets
223973814|NCT03226106|BEHAVIORAL|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
223973815|NCT03226106|OTHER|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
224292823|NCT06508658|DRUG|Rituximab|Intravenous (IV) Infusion
224292824|NCT06508658|DRUG|Lenalidomide|Oral Capsule
224292825|NCT06508658|DRUG|Oxaliplatin|IV Infusion
224292826|NCT06508658|DRUG|Gemcitabine|IV Infusion
224292827|NCT06807281|DRUG|Abrocitinib|Abrocitinib administered as liquid oral suspension.
224292828|NCT03917381|BIOLOGICAL|Acasunlimab|Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).
223543088|NCT03302403|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223543089|NCT06512688|OTHER||This is a cross-sectional study without intervention.
223973816|NCT06957353|PROCEDURE|oblique K-wire technique in controlling Calcaneal displacement during osteotomy in flatfoot correction|Under spinal Anaesthesia , patients will placed in lateral decubitus position. A standard lateral incision will be made over the calcaneus, and the osteotomy site will be exposed. An oblique K-wire will be inserted percutaneously into the posterior calcaneus under fluoroscopic guidance to facilitate the desired displacement. Cannulated screws will then be inserted across the osteotomy site to secure the calcaneal fragment. Post-operative care will include a non-weight bearing protocol for six weeks, followed by gradual weight bearing as tolerated.
223973817|NCT04349657|DEVICE|Supera Peripheral Stent System treatment group|Percutaneous endovascular stenting with the Supera Peripheral Stent System
223973818|NCT04349657|PROCEDURE|Endarterectomy treatment group|Surgical treatment through endarterectomy
223973819|NCT00721214|DRUG|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
223973820|NCT03067363|DRUG|MOR107|MOR107 solution for injection
223973821|NCT03067363|DRUG|Placebo|Solution for injection manufactured to match MOR107 solution for injection
223973822|NCT03067363|OTHER|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
223973823|NCT00333281|DRUG|tadalafil|
223973824|NCT00488319|DRUG|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
223973825|NCT02927899|OTHER|Survey Administration|Ancillary studies
223973826|NCT02927899|DIETARY_SUPPLEMENT|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
223543090|NCT04716608|OTHER|physiotherapy program|"physiotherapy program with Myofascial Release Massage, stretching, strengthening.~2 sessions per week (duration 30 minutes per session) for 8 weeks, supervised by a physiotherapist; complemented by a home training program."
223543091|NCT04716608|OTHER|usual care treatment|stretching,strengthening; 2 sessions per week (duration 30 minutes per session) for 8 weeks
223543092|NCT03957863|BIOLOGICAL|Plasma collection for EPO assay|Plasma collection for EPO assay
223543093|NCT01664247|DRUG|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
223543094|NCT01664247|DRUG|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
223543095|NCT01664247|DRUG|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
223543096|NCT01349205|DRUG|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
223543097|NCT01349205|DRUG|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
223543098|NCT01349205|DRUG|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
223543099|NCT01885650|OTHER|Airway Clearance Techniques|
223543100|NCT05113654|DIAGNOSTIC_TEST|Sleep study|Nocturnal polysomnography or polygraphy to assess sleep-related breathing disorder and other sleep disorders
223543101|NCT05915585|DEVICE|High-Intensity Laser Therapy|"The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session"
223973827|NCT05383105|PROCEDURE|Virtual bronchoscopic navigation|Virtual bronchoscopy navigation (VBN) calculates the access to a solitary pulmonary nodule via a trans-parenchymal route. In contrast to the gold Standard transthoracic approach, with this technique also very small lesions (7 mm diameter), and lesions which cannot be reached via the transthoracic route - located in the inner two thirds of the lung - can be approached.
223973828|NCT05501782|OTHER|questionnaire|A questionnaire consisting of seven parts was applied to the participants. In the first part, 20; demographic data and general health status of the participants; There were 11 questions including nutritional habits and anthropometric measurements (body weight and height). The other parts of the questionnaire were the Intuitive Eating Scale (IES-2), Power of Food Scale (PFS-Tr), Food Craving Questionnaire (FCQ-T), the Pittsburg Sleep Quality Scale (PUKI), Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) and Palatable Eating Motive Scale (PEMS), respectively contains. Consent from the participants was also obtained with the questionnaire form.
223973829|NCT04016350|BEHAVIORAL|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
223973830|NCT04016350|BEHAVIORAL|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
223973831|NCT04700488|DIAGNOSTIC_TEST|6D-MRI|Six-Dimensional Quantitative Dynamic Contrast Enhanced MRI
223973832|NCT02344056|OTHER|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
223973833|NCT02344056|OTHER|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
223973834|NCT00255671|OTHER|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
223973835|NCT02345915|OTHER|Blood sample|
223973836|NCT02345915|OTHER|Electrocardiogram|
223973837|NCT02209610|DEVICE|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
223973838|NCT02209610|DRUG|Intrathecal Fentanyl|Mu-opioid receptor agonist
224115960|NCT04855877|DRUG|Placebo|Oral administration of lactose tablet (placebo)
224292829|NCT03917381|BIOLOGICAL|Acasunlimab in combination with docetaxel (in a single expansion cohort)|Acasunlimab and docetaxel will be administered intravenously once every 21 days.
223973839|NCT04547621|DEVICE|Radiation|Intensity-modulated radiotherapy 20Gy/10fx
223973840|NCT04547621|DEVICE|Radiation|Hypofractionated Stereotactic Radiotherapy 30Gy/5fx
223973841|NCT04547621|DRUG|Temozolomide|Temozolomide 75 mg/m2 concurrently administered with RT.
224292830|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)|Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.
223973842|NCT04475237|OTHER|CT-scan evaluation and segmentation|CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.
223973843|NCT00414089|DRUG|90Y-ibritumomab tiuxetan (Zevalin)|
223973844|NCT00899145|OTHER|Laboratory Biomarker Analysis|Correlative studies
223973845|NCT02932553|DEVICE|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
223973846|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
224115961|NCT05942274|DIAGNOSTIC_TEST|We propose to validate these smartwatch ECG functions to support FDA submissions|1\) Obtain a simultaneous recording of a Lead I (RA-LA) ECG from the Smartwatch and a clinical standard device (GE Cardiosoft ECG). Subsequent recordings will be acquired from the other models of the Smartwatch as well as a recording utilizing the FDA-cleared KardiaMobile.
224115962|NCT06077630|OTHER|No intervention|There is no intervention, observational study
224115963|NCT01024465|DEVICE|ReShape Duo Balloon|ReShape Duo Balloon
224115964|NCT03384290|DRUG|PRS-060|Drug
224115965|NCT03384290|DRUG|Placebo|PRS-060 Matching Placebo
224115966|NCT02519751|DIETARY_SUPPLEMENT|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
223973847|NCT01551810|BIOLOGICAL|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
223973848|NCT06258954|OTHER|3D reconstruction|3D reconstruction based on CT data and It reconstructs the trachea and bronchus and compares them with the DLT, predicting the most suitable size of the DLT for lung isolation.
223973849|NCT06258954|OTHER|traditional method for selecting double lumen tube|In control group, the size of DLT is based on patient's sex and height.
224115967|NCT02519751|DIETARY_SUPPLEMENT|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
224115968|NCT05762185|DEVICE|nursing consultation|nursing consultation
223973850|NCT02020746|DRUG|EscharEx|
223973851|NCT02020746|DRUG|Gel Vehicle|
223973852|NCT01783158|PROCEDURE|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
223973853|NCT04393792|DRUG|Povidone-Iodine|0.23% three times daily (tds) for 3 days
223973854|NCT04393792|DRUG|Normal saline|0.9% three times daily (tds) for 3 days
224115969|NCT05607290|BEHAVIORAL|Cognitive-Behavioral Treatment|12 sessions of Cognitive-Behavioral Treatment for Alcohol Use Disorder
224115970|NCT03078608|BEHAVIORAL|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
223973855|NCT00387959|BIOLOGICAL|filgrastim|
223973856|NCT00387959|BIOLOGICAL|rituximab|
224115971|NCT03078608|BEHAVIORAL|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
224115972|NCT03811600|DIAGNOSTIC_TEST|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
224115973|NCT00723840|OTHER|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
224115974|NCT05848245|DEVICE|low suction|This group receives low-volume intraoral suction during procedures. Low suction typically refers to standard saliva ejectors, which provide minimal suction power and are commonly used in routine dental treatments.
223973857|NCT00387959|DRUG|cyclophosphamide|
223973858|NCT00387959|DRUG|cyclosporine|
223973859|NCT00387959|DRUG|fludarabine phosphate|
223973860|NCT00387959|DRUG|mycophenolate mofetil|
223973861|NCT00387959|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223973862|NCT00387959|PROCEDURE|umbilical cord blood transplantation|
223973863|NCT00387959|RADIATION|total-body irradiation|
224115975|NCT05848245|DEVICE|intraoral suction|This group receives conventional intraoral suction, likely using high-volume evacuators (HVE), which are more effective than low suction. This arm serves as the comparison or standard-of-care group against which other interventions are evaluated.
223973864|NCT03712449|DEVICE|JUVÉDERM®|Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8 (BELKYRA Treatment) and Month 0 to Month 2 (Non-BELKYRA Treatment).
223973865|NCT03712449|DRUG|BOTOX Cosmetic®|BOTOX Cosmetic, 20 U to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U injected to forehead lines at Month 9 and Month 10 (BELKYRA Treatment) and at Month 3 and Month 4 (Non-BELKYRA Treatment).
224115976|NCT05848245|DEVICE|high & low suction|Participants in this group receive both high-volume and low-volume intraoral suction simultaneously. The combined use aims to optimize fluid and aerosol control, with high suction capturing larger volumes and low suction assisting in continuous evacuation.
224115977|NCT05848245|DEVICE|extra-oral suction & low suction|This group receives a combination of extra-oral suction (a device placed outside the mouth to capture aerosols at the source) and low-volume intraoral suction. This setup is designed to reduce airborne particles during procedures by controlling both intraoral and environmental aerosols.
224115978|NCT05848245|DEVICE|Extra-Oral Suction and Intraoral Suction|This group is treated using both extra-oral suction and intraoral suction, likely high-volume. The dual approach targets aerosol containment both at the oral cavity level and in the surrounding air, representing a comprehensive strategy for infection control during aerosol-generating procedures.
224115979|NCT02853331|BIOLOGICAL|Pembrolizumab|Intravenous infusion
224115980|NCT02853331|DRUG|Axitinib|Oral tablet
224115981|NCT02853331|DRUG|Sunitinib|Oral capsule
224115982|NCT05176210|DRUG|PS1|PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.
224115983|NCT05176210|DRUG|Placebo|Placebo will be provided as a 120 mg tablet.
224115984|NCT03868553|OTHER|No intervention|observational study
224115985|NCT03477188|BEHAVIORAL|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
224292831|NCT03917381|BIOLOGICAL|Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)|Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.
224292832|NCT05640947|DEVICE|The Hot AXIOS™ Stent and Electrocautery-Enhanced Delivery System|EUS-guided gastro-gastrostomy using the Hot Axios device: Using a therapeutic endoscopic ultrasound endoscope with a working channel of 3.7mm and under fluoroscopic control, the excluded stomach will be identified and punctured with a 19G needle. Contrast injection will confirm the good position of the needle in the excluded stomach. If needed, the excluded stomach will be filled with blue-stained aqua (5% indigocarmine) until a sufficient distension is obtained for placement of the lumen-apposing metal stent. A lumen-apposing metal stent with a diameter of 20mm will be used according to the manufacterers' instructions to create a gastrogastrostomy. Position will be checked with fluoroscopy.
224292833|NCT04628494|BIOLOGICAL|Epcoritamab|Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.
224115986|NCT03477188|BEHAVIORAL|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
224292834|NCT04628494|DRUG|Investigator's Choice Chemotherapy|Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.
223973866|NCT03712449|DRUG|BELKYRA®|BELKYRA, subcutaneous injection for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose = 100 mg (10mL).
224115987|NCT05571150|BEHAVIORAL|Dyad-focused strategy training intervention|"The program consists of five critical ingredients: shared decision making, self-selected goals, self-evaluation of performance, strategy development and implementation, and therapeutic guided discovery.~Trained research therapists will deliver the intervention to the survivor-caregiver dyads on a one-to-two base at the participants' home or in a quiet room at our collaborative hospitals. The therapist will ask the dyad to identify 3 to 5 shared participation goals and provide them the global strategy (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
224115988|NCT05571150|BEHAVIORAL|Attention-control intervention|The topics of the education will cover: (1) secondary stroke prevention; (2) prevention and management of comorbidities; (3) managing emotions and behaviors; (3) medications and personal care; (4) finances and transportation; and (5) home and community-based participation.
224115989|NCT01079793|DRUG|ixabepilone|
224115990|NCT01079793|PROCEDURE|adjuvant therapy|
224115991|NCT01079793|RADIATION|intensity-modulated radiation therapy|
224115992|NCT05398874|COMBINATION_PRODUCT|Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)|120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily
224115993|NCT05398874|COMBINATION_PRODUCT|placebo in addition to the standard treatment|placebo in addition to the standard treatment
224115994|NCT00778323|PROCEDURE|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
224115995|NCT03511638|DEVICE|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
224115996|NCT03511638|DEVICE|Alcon VISCOAT®|Ophthalmic viscosurgical device
224115997|NCT02609477|DRUG|Istradefylline|Istradefylline 40, 80, 160 mg
224115998|NCT02609477|DRUG|Phentermine 45 mg|Phentermine 45 or 90 mg
224115999|NCT02609477|OTHER|Placebo|Placebo
223973867|NCT03712449|OTHER|SkinMedica|SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11 (BELKYRA Treatment) and Month 0 to Month 5 (Non-BELKYRA Treatment).
223973868|NCT05432518|DRUG|Afatinib|Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
223973869|NCT05432518|DRUG|Dasatinib|Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
223973870|NCT05432518|DRUG|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
223973871|NCT05432518|DRUG|Everolimus|Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
223973872|NCT05432518|DRUG|Olaparib|Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
223973873|NCT02224183|BEHAVIORAL|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
223973874|NCT02224183|BEHAVIORAL|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
223973875|NCT00226993|DRUG|CPG 7909|
223973876|NCT00808145|DRUG|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
223973877|NCT01592396|BIOLOGICAL|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
223973878|NCT04849377|RADIATION|RT 50 Gy|Radiation Therapy (RT) 50 GY
223973879|NCT04849377|RADIATION|RT 54 GY|Radiation Therapy (RT) 54 GY
223973880|NCT04849377|RADIATION|RT 60 GY|Radiation Therapy (RT) 60 GY
223973881|NCT04849377|OTHER|Induction Therapy|Induction Therapy: Cisplatin, Docetaxel, Fluorouracil
224116000|NCT02383329|DIETARY_SUPPLEMENT|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
224116001|NCT00004346|DRUG|chenodeoxycholic acid|
224116002|NCT00004346|DRUG|lovastatin|
223973882|NCT04849377|DRUG|Carboplatin|Carboplatin AUC 9.0
223973883|NCT04849377|DRUG|Cisplatin 200|200 mg/m2
223973884|NCT04849377|DRUG|Cisplatin 240|240mg/m2
223973885|NCT01984567|DIETARY_SUPPLEMENT|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
223973886|NCT01984567|DIETARY_SUPPLEMENT|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
223973887|NCT01984567|DIETARY_SUPPLEMENT|Control|Daily consumption of 3 placebo capsules
223973888|NCT03859817|OTHER|Comparison of eGFR values and ketonemia in diabetic patients|To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
223973889|NCT05376787|DEVICE|Medline NE Grounding Pad|Split Universal Grounding Pads
223973890|NCT01763645|DRUG|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
223973891|NCT01763645|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
224116003|NCT01812720|DRUG|carfilzomib|Given IV
224116004|NCT01812720|DRUG|dexamethasone|Given PO
224116005|NCT01812720|OTHER|laboratory biomarker analysis|Correlative studies
224116006|NCT06013787|BEHAVIORAL|"Nuestras Historias"|"Nuestras Historias is a digital story curriculum that is displayed on a small solar-powered tablet. The curriculum is a collection of 7 digital stories used to discuss health issues during pregnancy that the community identified as important. The digital stories are short videos that combine local photos and local voices sharing real-life narratives about experiences during pregnancy. The videos were made in collaboration with community health workers and local mothers."
224116007|NCT06143579|DRUG|FOLFOX-HAIC+Lenvatinib+Envolizumab|"FOLFOX-HAIC: Oxaliplatin 130 or 85 mg/m2; leucovorin 200 mg/m2; fluorouracil 400 mg/m2 intravenous bolus followed by fluorouracil 2400 mg/m2 continuous infusion over 23 hours, Q3W, 2 to 4 cycles;~Lenvatinib: 8 mg/day (BW \< 60 kg) or 12 mg/day (BW ≥ 60 kg), PO, 3-4 cycles;~Envolizumab: 300 mg, SC, Q3W, 3-4 cycles."
223973892|NCT01763645|DRUG|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
223973893|NCT02115178|OTHER|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
223973894|NCT06279208|BIOLOGICAL|Blood sample|Recovery of plasma from the bottom of a blood collection tube.
223973895|NCT00666198|DRUG|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
223973896|NCT04156178|BIOLOGICAL|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
223973897|NCT05153499|BIOLOGICAL|CP101|CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
223973898|NCT05153499|OTHER|Placebo|Placebo
223973899|NCT00793299|BEHAVIORAL|Video Illness Narrative|video
223973900|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
223973901|NCT02651961|PROCEDURE|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
223973902|NCT01369706|DEVICE|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
223973903|NCT04528953|BEHAVIORAL|Interval walking and Qigong exercise|"Interval walking: The subjects will be asked to complete daily 30 minutes of walking in two 15-minute bouts with the rest interval for at least 0.5 an hour and not more than 2 hours between each bout.~Qigong exercise: mind-body exercise using the six healing sound Qigong exercise will be used because it is easy to learn, requires minimal physical capability, and can be performed even in a sitting body position."
223973904|NCT02315079|OTHER|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
223973905|NCT02315079|OTHER|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
223973906|NCT04018547|DEVICE|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
223973907|NCT04461184|BEHAVIORAL|Internet Wellness Intervention for Aging|Internet technologies have emerged as a platform for performing wellness interventions that also have wide outreach. Previous studies that have used the internet for delivering health interventions have found that older adults valued this platform, used it for researching health information and social communications. Likewise, the effectiveness of delivering health-related information intended for behavior change through the internet is equal to that of print-based delivery, thereby lowering costs and expanding reach. Thus, the internet provides a unique platform for conducting interventions. The internet based wellness intervention will be a low cost method focused on older adults to help increase intrinsic motivation through autonomy, competence, and relatedness (Intrinsic Motivation) to help increase daily physical activity.
223973908|NCT04127019|DRUG|Paclitaxel|Paclitaxel chemotherapy (injection)
223543102|NCT01722344|BEHAVIORAL|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
223973909|NCT04127019|DRUG|Docetaxel|Docetaxel chemotherapy (injection)
223973910|NCT04127019|DRUG|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
223973911|NCT04127019|DRUG|Epirubicin|Epirubicin chemotherapy (injection)
223973912|NCT04127019|DRUG|5-fluorouracil|5-fluorouracil chemotherapy (injection)
223973913|NCT06477757|PROCEDURE|Minimally Invasive Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.
223973914|NCT06477757|PROCEDURE|Conventional Extracorporeal Circulation|Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.
223973915|NCT01046071|PROCEDURE|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
223973916|NCT01046071|PROCEDURE|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
223973917|NCT01552668|DRUG|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
223973918|NCT01552668|DRUG|Placebo|Receive Placebo twice daily
223973919|NCT03089502|OTHER|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
223973920|NCT05743114|DEVICE|Elemind Neuromodulation (ENMod)|The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.
223973921|NCT02599870|GENETIC|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
223973922|NCT02084355|DRUG|oral oxycodone|
224116008|NCT03854162|DEVICE|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
224116009|NCT05553379|DIAGNOSTIC_TEST|FeNO measurement|FeNO measurement at each visit
224116010|NCT03425799|DRUG|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
224116011|NCT03425799|DRUG|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
224116012|NCT03919110|DIAGNOSTIC_TEST|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
224122706|NCT06556056|OTHER|Placebo|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Dosage form: Liquid Frequency: Daily Night Application Route of administration: Topical"
224122707|NCT06556056|OTHER|Liposomal Form of SesZenBio|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical"
223973923|NCT02084355|DRUG|oral hydromorphone|
223973924|NCT02084355|DRUG|fentanyl patch|
223973925|NCT00546702|DRUG|Insuline Glulisine|
223973926|NCT05563428|PROCEDURE|Free gingival graft|A free gingival graft will be carried out for recession treatment.
223973927|NCT05563428|PROCEDURE|Connective tissue graft|The pouch technique with a connective tissue graft will be carried out for recession treatment.
223973928|NCT04073849|DRUG|EPOGEN® (epoetin alfa)|Active drug
223973929|NCT04073849|OTHER|Normal Saline|Placebo
223973930|NCT02694588|DRUG|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
223973931|NCT02694588|DRUG|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
223973932|NCT00996619|PROCEDURE|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
223973933|NCT05740969|DRUG|5Fluorouracil|Cream
223973934|NCT05740969|DRUG|Imiquimod|Cream
223973935|NCT05740969|DRUG|Melatonin|Cream
224122708|NCT06556056|OTHER|Minoxidil Hair Serum (5%)|"Mode of Usage: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical"
223973936|NCT03700463|OTHER|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
223973937|NCT02166047|DRUG|Vesatolimod|Vesatolimod tablet administered orally
224116013|NCT03241056|BEHAVIORAL|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
223543103|NCT01722344|BEHAVIORAL|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
223973938|NCT02166047|DRUG|Placebo|Placebo to match vesatolimod tablet administered orally
223973939|NCT03389321|DRUG|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
223973940|NCT03389321|DRUG|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
223973941|NCT00598286|DRUG|[18F]FMPEP-d2|
223973942|NCT01730742|BEHAVIORAL|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
223973943|NCT01730742|BEHAVIORAL|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
223973944|NCT01730742|PROCEDURE|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
223973945|NCT03296007|BEHAVIORAL|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
223725322|NCT05360511|DRUG|particulate xenograft + erythropoietin gel.|"1. Surgical sites will be anaesthetized using local anaesthesia.~2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~   * In Group A (test group):~Particulate xenograft will be mixed with EPO gel and applied to fill the whole defect."
223725323|NCT05360511|COMBINATION_PRODUCT|particulate xenograft|"* All surgeries will be performed by the same operator as follows:~  1. Surgical sites will be anaesthetized using local anaesthesia.~ 2. Intrasulcular incision will be done in the periodontal pocket as close as possible to the tooth surface with the deepest point being the alveolar crest.~ 3. The incisions will be extended to the mesial papilla of the tooth before the defect and the distal papilla of the tooth after the defect.~ 4. Both buccal and lingual/palatal mucoperiosteal flaps will be raised using blunt dissection.~ 5. Mechanical debridement of the infected tissue from the intrabony defect and root debridement will be done using Gracey curettes.~* In Group B (control group):~Particulate xenograft will be applied to fill the whole defect."
223725324|NCT03729960|OTHER|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
223725325|NCT00159536|DRUG|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
223973946|NCT04562714|DEVICE|FreeStyle Libre Flash Glucose Monitor|The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.
223973947|NCT04562714|OTHER|Diabetes self-management education|"The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."
223973948|NCT05141071|DRUG|Ivabradine 5mg Tab|Ivabradine will be administrated enterally
224116014|NCT03241056|OTHER|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
224116015|NCT02672839|DRUG|LGD-6972 Solution|15 mg of LGD-6972
224116016|NCT02672839|DRUG|LGD-6972 Capsules|15 mg LGD-6972
224292835|NCT05410158|DRUG|Ketamine in PECS block versus topical wound instillation|On arrival to the operating room, an intravenous line will be inserted in the contralateral upper limb to the side of surgery. Anesthesia will be induced for all participating patients with 2 μg/kg fentanyl, 2 - 3 mg/kg propofol and 1.5 mg/kg lidocaine. Endotracheal intubation will be facilitated by 0.15 mg/kg cis-atracurium.The patients will be randomly assigned into 2 groups ( pecs block group , topical instillation group) using a randomization-computer program . Anesthesia will be maintained by 1 - 1.5 MAC isoflurane in 50% oxygen/ air mixture and 0.03 mg/kg cisatrcurium, respectively, in ventilation parameters that maintain normocapnia. At the end of surgery, a reversal of the muscle relaxant will be done using neostigmine (0.04 mg/kg) and atropine (0.01 mg/kg). After extubation, all patients will be transmitted to the post anesthesia care unit (PACU) for follow up .
224292836|NCT04612517|DRUG|ZP7570|Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.
224292837|NCT04612517|DRUG|Placebo|Placebo; corresponding volume
223973949|NCT05141071|DRUG|Placebo|50 ml of saline will be administrated enterally
223973950|NCT04509414|DRUG|Dexmedetomidine|For dexmedetomidine group after ramdomization, an intranasal dose of 2ug/kg dexmedetomidine will be administrated.
224116017|NCT00480454|BIOLOGICAL|MVA 85A|intradermal vaccine
224116018|NCT04239274|DEVICE|transcranial direct current stimulation|Subjects in this arm will receive one session of tDCS for 20 minutes at 2.0 milliamps.
224116019|NCT04239274|DEVICE|transcranial pulsed current stimulation|Subjects in this arm will receive one session of tPCS for 20 minutes at 2.0 milliamps.
224116020|NCT04239274|DEVICE|Sham-no stimulation|Subjects in this arm will receive one session of sham for 20 minutes.
224116021|NCT01441167|BIOLOGICAL|PfSPZ|
224116022|NCT02289755|DRUG|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
224116023|NCT06030895|DRUG|Sorafenib Tablets|Sorafenib Tablets (200 -400 mg) twice daily
224116024|NCT02086565|BEHAVIORAL|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
224116025|NCT02086565|BEHAVIORAL|Portal training|training in use of patient portal
224116026|NCT01019408|DRUG|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
224292838|NCT06781385|DRUG|Intra-arterial Tenecteplase|One-time dose of intra-arterial tenecteplase post-thrombectomy
224292839|NCT06781385|DRUG|Intra-arterial Saline|One-time dose of intra-arterial saline post-thrombectomy
224292840|NCT04172519|OTHER|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
224292841|NCT04172519|OTHER|Unsupervised PMFT|intervention after surgery, unsupervised exercises
223973951|NCT04509414|DRUG|Midazolam|For midazolam group after ramdomization, an intranasal dose of 0.2mg/kg midazolam will be administrated.
223973952|NCT02538718|DRUG|MgSO4|
223973953|NCT02538718|DRUG|YTP(Ritodrine)|
223973954|NCT04059497|BEHAVIORAL|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
223973955|NCT04059497|BEHAVIORAL|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w\_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
223973956|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
223973957|NCT01176435|DRUG|Levodopa|Solution taken orally three times a day.
224116027|NCT01858428|DEVICE|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
224116028|NCT01858428|DEVICE|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
223543104|NCT05640362|OTHER|Natural enzymes mouthwash|Natural enzymes mouthwash contains numerous natural protein-enzymes, including lactoferrin, lysozyme, lactoperoxidase, glucose oxidase. These active ingredients were proposed to render this mouthwash to act as salivary substitutes by reinforcing the functions of available saliva, hence reinforcing the immune system in the oral cavity. It was expected to relieve the symptoms in xerostomia patients, and even more if the patients have salivary flow reduction by improving the functions of the limited amount of saliva. The potential mechanisms of action of the mouthwash to treat xerostomia may be related to: (1) lubrication effects to wet the oral mucosal surfaces; (2) antimicrobial properties that will reduce risks of mucosal irritation by infections; (3) absence of alcohol in the mouthwash Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
224116029|NCT00758303|DRUG|Low Dose TRIA-662|One Capsule 3 times a day
223543105|NCT05640362|OTHER|Benzydamine mouthwash|Subjects were instructed to rinse with the mouthwash 4 times per day at a specific period, for 2 weeks.
223725326|NCT00159536|DRUG|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
223973958|NCT01176435|DRUG|Placebo|Solution taken orally three times a day.
223973959|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
223973960|NCT01107106|DRUG|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
223973961|NCT03313583|PROCEDURE|Transfusion of blood products|
224116030|NCT00758303|DRUG|High Dose TRIA-662|3 Capsules 3 times daily
224116031|NCT00758303|DRUG|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
224116032|NCT03882840|BIOLOGICAL|ITNK cell therapy|Infusion of ITNK/CAR-ITNK cells
223973962|NCT02636751|BEHAVIORAL|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
223973963|NCT02636751|DEVICE|Walking aid adjustment|Walking aid adjustment
223973964|NCT02636751|BEHAVIORAL|Information about pain control|General information about pain control, such as ice application and medication usage
224116033|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
223973965|NCT03722797|PROCEDURE|Metabolic Cost Testing Procedures|"The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3."
223973966|NCT01940523|DRUG|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
223973967|NCT01940523|DRUG|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
223973968|NCT02676440|OTHER|Treatment|F13/T38
223973969|NCT02676440|OTHER|Comparator|M26
223973970|NCT02490878|DRUG|bevacizumab|IV
224116034|NCT02406781|DRUG|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
224116035|NCT02116972|DRUG|FX006 32 mg|Single 5 mL IA injection
224292842|NCT04172519|OTHER|Supervised PMFT|intervention after surgery and supervised exercise
224292843|NCT00618930|DRUG|Moviprep®|use of Moviprep®
223973971|NCT02490878|DRUG|corticosteroids|IV
223973972|NCT02490878|OTHER|placebo|IV
223973973|NCT05433311|OTHER|Exercises|Neutral position training, transversus abdominis/multifidius/abdominal/back extensors strengthening exercise, bridge exercise, cat-camel exercise, lumbal extensor/hamstring/gastrosoleus/latissimus dorsi/gluteal stretching exercises
224116036|NCT02116972|DRUG|Placebo|Single 5 mL IA injection
224116037|NCT02116972|DRUG|FX006 16 mg|Single 5 mL IA injection
224116038|NCT00784784|BIOLOGICAL|Fluviral|One dose
223973974|NCT04665778|OTHER|hospital bedroom booking|Patient in high risk of hospitalization group benefits a dedicated process to find and book a bedroom
223973975|NCT02541942|OTHER|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
223973976|NCT02994264|RADIATION|adjuvant concurrent chemoradiation|
223973977|NCT01020942|PROCEDURE|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
223973978|NCT01020942|PROCEDURE|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
224116039|NCT00784784|DRUG|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
224116040|NCT06258629|DIAGNOSTIC_TEST|Flowcytometry on bone marrow aspiration|Flowcytometry on bone marrow aspiration
224116041|NCT05713305|PROCEDURE|Online-based self-help psychological intervention|Daily members of the intervention group were thought to provide three different forms of daily sessions each day, averaging 10-20 minutes. These sessions included psycho-educational and cognitive-behavioral exercises, music therapy, sleep hygiene, stress relief methods. Weekly online lecture sessions presented by professional mental health therapists
224116042|NCT05713305|PROCEDURE|Provide online mental health knowledge|They will receive official mental health recommendations on how to cope mentally with the pandemic. These recommendations inform about the importance of a daily structure, social contact, acceptance of negative emotions and strengthening of positive emotions, and stimulus control to assimilate SARS-CoV-2 Omicron-related news
224292844|NCT00618930|DRUG|Fleet|Use of Fleet
224292845|NCT06803342|BIOLOGICAL|cAd3-Sudan Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-Sudan) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
224292846|NCT06803342|BIOLOGICAL|Placebo|0.9% NaCl solution for injection.
223973979|NCT03298633|OTHER|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
223973980|NCT03298633|OTHER|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
223973981|NCT05425173|OTHER|Conventional treatment|Chest Physical Therapy as required
223973982|NCT05425173|OTHER|Limb Range of Motion Exercises + Chest Physical Therapy|"Limb Range of Motion Exercises + Chest Physical Therapy~Frequency: 4 sessions Time: 5 to 10 minutes"
224116043|NCT02067312|OTHER|Thai massage|
224116044|NCT03663608|PROCEDURE|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
224116045|NCT04171128|BEHAVIORAL|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
224292847|NCT03659461|DRUG|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
224292848|NCT02018926|DRUG|Mocetinostat|Mocetinostat (a histone deacetylase \[HDAC\] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
223973983|NCT03962478|DEVICE|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
224116046|NCT01901471|DRUG|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
223973984|NCT03962478|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
223973985|NCT05195450|DRUG|Tenofovir alafenamide fumarate|• TAF 25 mg OD vs no treatment x 5 years and beyond
223973986|NCT03122483|DIAGNOSTIC_TEST|blood biomarker|
224116047|NCT01901471|DRUG|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
224292849|NCT02018926|DRUG|Azacitidine|Azacitidine (a hypomethylating agent \[HMA\]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
224292850|NCT06379789|DRUG|REGV131|Single dose administered via intravenous (IV) infusion before LNP1265
224292851|NCT06379789|DRUG|LNP1265|Single dose administered via IV infusion following REGV131
223543106|NCT03159546|DEVICE|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
223973987|NCT00451555|DRUG|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
223973988|NCT00451555|DRUG|placebo|oral, daily
223973989|NCT00451555|DRUG|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
223973990|NCT04017949|DRUG|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
223973991|NCT04929054|DIAGNOSTIC_TEST|imaging|ultrasound and contrast enhanced ultrasound for BI RADS4A breast modules
223973992|NCT03460496|BEHAVIORAL|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
223973993|NCT03460496|BEHAVIORAL|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
223973994|NCT03460496|BEHAVIORAL|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
223973995|NCT03460496|BEHAVIORAL|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
223973996|NCT03460496|BEHAVIORAL|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
223973997|NCT03460496|BEHAVIORAL|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
223973998|NCT03460496|BEHAVIORAL|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
223973999|NCT03460496|BEHAVIORAL|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
223974000|NCT03460496|BEHAVIORAL|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
223974001|NCT03988478|BEHAVIORAL|Detoxification & psychotherapeutic support|
223974002|NCT03430050|DRUG|Progesterone|Progesterone capsule
223974003|NCT03430050|DRUG|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
223974004|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #1|Main Hairfinity formulation
224116048|NCT04593498|DIAGNOSTIC_TEST|Holter recording|Holter recording with Zenicor Flex ECG during 14 days.
224292852|NCT06353971|DRUG|Briquilimab|Subcutaneous Injection
223543107|NCT06512610|OTHER|Middle Eastern or North Coast of Africa patients with newly AML|Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia in MENAFC patients
223974005|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #2|Variation to main formulation
223974006|NCT03106792|DIETARY_SUPPLEMENT|Hairfinity #3|Variation to main formulation
223974007|NCT03106792|DIETARY_SUPPLEMENT|Placebo|No active ingredients
223974008|NCT06047613|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 10 a.m. and fasting from midnight.
223974009|NCT06047613|OTHER|Hetero-questionnaires and auto-questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Heteroquestionnaires will be administrated during a clinical interview (1h) conducted by a psychiatrist or psychologist. Autoquestionnaires (45 min) will be completed by the participant himself."
223974010|NCT06047613|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be processed (at both visits for patients and at inclusion visit for healthy controls) to study between groups white matter microstructure and brain functional connectivity networks
223974011|NCT05514197|DRUG|Ascorbic acid 5000mg|Intravenous loading of 5000mg ascorbic acid with normal saline, totally 100ml Completed before surgical incision
223974012|NCT05514197|DRUG|Control Rx|Intravenous loading 100ml normal saline
223974013|NCT00922441|DRUG|Fimasartan 60 mg group|Fimasartan 60 mg
223974014|NCT00922441|DRUG|Fimasartan 120 mg group|Fimasartan 120 mg
223974015|NCT00922441|DRUG|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
224292853|NCT06406751|DEVICE|MI Paste|Sterile swabs will be used to collect plaque from under the subject's upper denture (when the denture is removed) and the subject's mouth tissues. This will be used for genomic DNA, bacteria analysis, and fungus analysis. Subjects will also apply 1 cubic centimeter of MI Paste to the fitting surface on a daily basis for 7 days. Afterward, subjects will return to the clinic for another sterile swab to be collected.
223974016|NCT06320327|OTHER|Cannabidiol cream|Group 1 will be administered the recommended quantity of CBD cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
223974017|NCT06320327|OTHER|Placebo cream|Group 2 will be administered the recommended quantity of placebo cream to be applied at various times throughout the study and used in a specific way instructed by the researcher (the cream is applied via massage through a standardized application method).
223974018|NCT05592236|OTHER|Dynamic compression garments|Dynamic compression garments for 2 hours a day in addition to standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
223974019|NCT05592236|OTHER|Standard therapy|Standard therapy twice a week (1 session of 45 minutes) for a total of 6 weeks
223974020|NCT03606850|DEVICE|Measurements of markers of cortical excitability by TMS|"In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle."
223974021|NCT03391583|OTHER|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
223974022|NCT05042713|OTHER|WaveOne Gold, One Curve, OneFlare|During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
223974023|NCT00563745|DEVICE|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
223974024|NCT02723383|DRUG|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
224116049|NCT04593498|DIAGNOSTIC_TEST|Echocardiography (Echo)|Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.
224116050|NCT04593498|DIAGNOSTIC_TEST|Blood sample|Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.
224116051|NCT04593498|DIAGNOSTIC_TEST|24 hour ambulatory blood pressure monitoring And Arteriograph|To assess artery stiffness.
224116052|NCT00292474|DEVICE|percutaneous coronary intervention|
224116053|NCT01461954|DRUG|FST-100|FST-100
224116054|NCT01461954|DRUG|FST-100 Vehicle|FST-100 Vehicle
224292854|NCT03414970|RADIATION|Radiation Therapy|Undergo RT
224116055|NCT03908788|DEVICE|Intplex test|Blood sample at each tumor assessment
224116056|NCT00854932|OTHER|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
224116057|NCT06286852|BEHAVIORAL|Administration of K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)|Administration of 1) K-SADS-PL- Kiddie-Schedule for Affective Disorder and Schizophrenia-Present and Lifetime version (Kaufmann, 2002)
224116058|NCT06286852|BEHAVIORAL|Administration of ChEDE- Child Version of the EatingDisorder Examination|Administration of ChEDE- Child Version of the EatingDisorder Examination
224116059|NCT00865254|BEHAVIORAL|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
224292855|NCT03414970|OTHER|Questionnaire Administration|Ancillary studies
224292856|NCT03414970|OTHER|Quality-of-Life Assessment|Ancillary studies
224292857|NCT03414970|OTHER|Laboratory Biomarker Analysis|Correlative studies
224292858|NCT03414970|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
224292859|NCT02494544|DEVICE|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith \& Nephew, or Stryker
224292860|NCT02494544|DEVICE|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
224292861|NCT05776004|DRUG|CAL02|CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
224292862|NCT05776004|DRUG|Placebo|Physiological 0.9% sodium chloride solution for iv administration
224292864|NCT05533697|BIOLOGICAL|mRNA-4359|Intramuscular Injection
224292865|NCT05533697|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223543108|NCT02281656|PROCEDURE|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
223543109|NCT02281656|PROCEDURE|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
224292866|NCT05533697|BIOLOGICAL|Ipilimumab|Intravenous infusion
224292867|NCT05533697|BIOLOGICAL|Nivolumab|Intravenous infusion
224292868|NCT02088190|PROCEDURE|Sleeve gastrectomy|Type of bariatric surgery
224292869|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
224292870|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
223974025|NCT02723383|DRUG|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
223974026|NCT00000398|BEHAVIORAL|Coping skills training|
223974027|NCT00000398|BEHAVIORAL|Physical exercise training|
223974028|NCT00000398|BEHAVIORAL|Coping skills training plus physical exercise training|
223974029|NCT05404698|OTHER|Aerobic exercise|EX: 30 min of aerobic exercise (3/10 Borg scale) during hemodialysis treatment (between 30 min and 3h of treatment).
223974030|NCT05404698|OTHER|Control|CONT: participants will receive hemodialysis treatment only (usual care)
223974031|NCT05255198|PROCEDURE|Anterior versus lateral approach to hip joint|
224292871|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
223543110|NCT03375931|BEHAVIORAL|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
223543111|NCT03375931|BEHAVIORAL|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
223543112|NCT01913847|DRUG|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
223543113|NCT01913847|DRUG|Placebo|Oral placebo TID for 12 weeks
223543114|NCT05224427|BEHAVIORAL|Near-Peer Coaching|Targeted coaching by near-peer medical students
223974032|NCT00543101|DRUG|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
223974033|NCT00543101|DRUG|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
223974034|NCT00828529|DRUG|TMC207|
223974035|NCT04664985|DEVICE|Mucogyne® ovule|hyaluronic acid, vaginal ovule
223974036|NCT00196118|DEVICE|Günther Tulip Vena Cava Filter|
224292872|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
224292873|NCT03607890|DRUG|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).
224292874|NCT03607890|DRUG|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).
224292875|NCT03118986|DRUG|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
224292876|NCT03118986|DRUG|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
224292877|NCT04235699|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
223725327|NCT02573350|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
223974037|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with an App with active therapeutic components|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a smartphone App with therapeutic components during the intervention (8 weeks) and follow-up period (time frame: one year)."
223974038|NCT04765813|BEHAVIORAL|Cognitive-behavioral treatment to quit smoking along with a control App|"Cognitive-behavioral smoking cessation treatment components will be: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem-solving training, change tobacco-related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Participants will use a control smartphone App (only to access session materials) during the intervention period (8 weeks)."
223974039|NCT05764590|DRUG|AP-306|A blood phosphorus lowering drug with a novel mechanism
223974040|NCT05764590|DRUG|Sevelamer Carbonate|A phosphate binder
224116060|NCT00865254|BEHAVIORAL|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
224292878|NCT04306237|DRUG|IMB-1018972|IMB-1018972 200 mg tablet for oral administration
224292879|NCT04306237|DRUG|Placebo oral tablet|Matched placebo tablet for oral administration
224292880|NCT05581303|DRUG|Placebo|Placebo given by subcutaneous injection once every 12 weeks (Q12W).
224292881|NCT05581303|DRUG|Olpasiran|Olpasiran given by subcutaneous injection Q12W.
223974041|NCT02973477|DRUG|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
223974042|NCT02973477|DRUG|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
223543115|NCT04867083|DRUG|ARV bitherapie|"1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day"
223974043|NCT02654457|PROCEDURE|Women with Breast Cancer|IVD Study
223974044|NCT06111443|DRUG|Dapagliflozin 10 mg [Farxiga]|Dapagliflozin 10 mg \[Farxiga\] for 3 months after catheter ablation of atrial fibrillation
223974045|NCT03500263|DRUG|PTI-808|Active
223974046|NCT03500263|DRUG|Placebo|Placebo
223974047|NCT03500263|DRUG|PTI-801|Active
223974048|NCT03500263|DRUG|PTI-428|Active
223974049|NCT03500263|DRUG|Placebo|Placebo
224292882|NCT03578237|DEVICE|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
223974050|NCT04857775|BEHAVIORAL|Attachment and Child Health (ATTACH) Parenting Program|ATTACH™ provides parent training to address Reflective Function (RF) of parents affected by a broad array of toxic stressors. RF, defined as the ability to have insight into one's own and one's child's mental states, feelings, thoughts and intentions, underpins parental sensitivity and responsiveness and is undermined by the experience of current or past stress. Parents require high RF to respond sensitively/appropriately to their children and thus promote secure parent-child attachments, essential for child MEB health. ATTACH™ consists of 10-12 \~45-minute clinic visits with dyadic (mother and infant) and triadic (mother, infant, and co-parent) elements, with a trained facilitator, who may be a nurse, social worker or other allied health professional.
223974051|NCT06400264|PROCEDURE|Biopsy|Undergo biopsy
223974052|NCT06400264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223974053|NCT06400264|PROCEDURE|Computed Tomography|Undergo CT scan
223974054|NCT06400264|PROCEDURE|Echocardiography|Undergo ECHO
223974055|NCT06400264|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223974056|NCT06400264|BIOLOGICAL|Nivolumab|Given IV
223974057|NCT06400264|BIOLOGICAL|Relatlimab|Given IV
223974058|NCT06208800|OTHER|Blend Aromatherapy|Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
223974059|NCT03109652|DRUG|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
223974060|NCT06339814|OTHER|Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol|An Eye Movement Desensitization and Reprocessing psychotherapist will hold the Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol sessions, dedicated to psychoeducation, imagery exercises, stabilization techniques and the reprocessing of traumatic events. The Eye Movement Desensitization and Reprocessing Integrative Group Treatment Protocol will be composed of 4 sessions of 120 minutes each.
223974061|NCT06339814|OTHER|Treatment As Usual|Treatment As Usual condition will receive only standard support.
223974062|NCT03322852|OTHER|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
223974063|NCT02619305|OTHER|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
223974064|NCT01834768|DRUG|Eplerenone|
223974065|NCT02690493|PROCEDURE|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
223974066|NCT02690493|OTHER|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
223974067|NCT02690493|OTHER|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
223974068|NCT01318538|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
223974069|NCT01318538|BEHAVIORAL|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
223974070|NCT03758703|OTHER|Pre-recorded music intervention group|Refer to the arm/group descriptions.
223974071|NCT03758703|OTHER|Pre-recorded soothing poetry group|Refer to the arm/group descriptions.
223974072|NCT00991029|DRUG|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
223974073|NCT00991029|DRUG|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
223974074|NCT00256347|DRUG|intramuscular injections of morphine|
223974075|NCT00317603|BIOLOGICAL|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
223974076|NCT02664025|PROCEDURE|vaginal examination simulator|
223974077|NCT00523549|DRUG|valsartan|160 mg or 320 mg tablets once a day
224116061|NCT00865254|BEHAVIORAL|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
224116062|NCT05664685|DRUG|Optimized bismuth quadruple therapy|Scheme that have high dosage of amoxicillin, metronidazole and omeprazole, with bismuth. The rationale of this scheme is that in Chile, amoxicillin resistance is low, clinical metronidazole is low in the doses used and the high doses ob Proton Pump Inhibitor enhanced the antimicrobial drugs
224116063|NCT05664685|DRUG|Control|Standard eradication therapy using omeprazole, clarithromycin and amoxicillin
224116064|NCT06415578|OTHER|ergonomics training|In this training; What is ergonomics, the importance of ergonomics, the purpose of ergonomics, risk factors for musculoskeletal disorders that can be seen in e-sports players, ergonomic arrangements that can be made in the working environment and methods of protection from musculoskeletal injuries, posture disorders and various ergonomic arrangements that can be made for posture disorders and chair selection, screen selection. selection and rest breaks were included. Participants will be trained twice in total, on the first day of the study and at the end of the 4th week. The training will be carried out interactively, supported by videos and visuals. Training will be done individually and will last approximately 2 hours.
224292883|NCT03578237|DEVICE|Sham cryoneurolysis procedure|"Mastectomy (subjects 1-18): Myoscience Iovera device: simulated full cryo cycle without administering gas to the probe.~Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature"
224292884|NCT04856124|DRUG|Intranasal esketamine|Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
223974078|NCT00523549|DRUG|amlodipine|5 mg or 10 mg tablets once a day
223974079|NCT05262465|BIOLOGICAL|microtransplantation, HLA-mismatched donor peripheral stem cell infusion|HLA-mismatched donor peripheral stem cell infusion
223974080|NCT05262465|DRUG|Azacitidine|azacytidine 50-75mg/m2
223974081|NCT05262465|DRUG|Venetoclax|Venetoclax 100-300mg/d ×3d，400mg 4-28d
223974082|NCT02359578|DRUG|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
223974083|NCT02487251|BEHAVIORAL|Mealtime Supports|Participants will receive or engage in a variety of supports for family mealtimes in Phase 1 (e.g., receipt of prepared meals, receipt of cookware, informational supports, classes). In Phase 2 of the study participants received two prepared meals per week for 12 weeks and received a comprehensive set of cookware at the beginning of the intervention period.
223974084|NCT02487251|BEHAVIORAL|Usual Exposure|Participants receive no supplemental information on family mealtimes beyond what is already currently received
223974085|NCT06247618|DEVICE|visor|The treatment will have a duration of 4 weeks, with the execution of two sessions per week with the use of a viewer positioned on the head that allows users to navigate and interact in real time with a three-dimensional (3D) environment
223974086|NCT05641714|OTHER|L test|The test includes standing up from a chair, walking in a straight line for 3 m, turning to the right, walking in a straight line for 7 m, turning around, walking back 7 m along the same line, turning to the left, walk 3 m in a straight line to the chair, and then sit down.
223974087|NCT05641714|OTHER|Timed Up and Go test|The test requires the individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.
223974088|NCT05641714|OTHER|10 meter walk test|In the test, the clinician measures the time taken to walk a distance of 10 m from a standing position. Participants are asked to walk along a 14 m long walkway.
223974089|NCT05641714|OTHER|Six Minute Walk Test|This test measures the distance (in m) that an individual is able to walk at a comfortable speed for 6 minutes. Starting from a standing position, participants walk continuously around two pylons placed 30 m apart for 6 minutes. The distance is recorded end of the test.
223974090|NCT05641714|OTHER|The timed 360° turn test|Each participant turns around in place in a standing position for both sides.
223974091|NCT02747719|BEHAVIORAL|Light and exercise|Exposure to light and exercise
223974092|NCT03987490|BEHAVIORAL|Text Message|Vaccine reminder notification sent via text
223974093|NCT03987490|BEHAVIORAL|PostCard|Vaccine reminder notification sent via standard mail
223974094|NCT03987490|BEHAVIORAL|Standard of Care|No additional information given to parents
224116065|NCT06415578|OTHER|Exercises|The exercise training program will be implemented for 8 weeks, 3 days a week, lasting an average of 45 minutes. All participants will be given information about the exercises before the exercise training. The exercise protocol was designed as 3 parts: warm-up, exercise and cool-down. Stretching exercises, mobility and strength exercises will be applied. A rest period of 30-45 seconds was given between sets and 2-3 minutes between exercises. Participants will be given dynamic and static stretching, nerve stretching, postural strength and functional exercises for the upper extremity. Relevant movements will be modified according to the exercise capacity of the participants. Exercise content will also include median, ulnar and radial nerve stretching, neck and thoracic mobility exercises, and functional strength exercises for the shoulder, arm, hand and wrist. Exercise tracking will be checked regularly through online conversations.
224116066|NCT01541592|OTHER|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.
223974095|NCT03987490|BEHAVIORAL|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
223974096|NCT00053352|PROCEDURE|conventional surgery|
224116067|NCT01455571|DRUG|HM781-36B|Q1DX14/2W for 3W HM781-36B
224116068|NCT02563184|BIOLOGICAL|Fluzone|
223543116|NCT01106157|DRUG|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
223974097|NCT00053352|DRUG|cisplatin|Given IV
223974098|NCT00053352|DRUG|etoposide|Given IV
223974099|NCT00053352|BIOLOGICAL|bleomycin sulfate|Given IV
223974100|NCT00053352|OTHER|laboratory biomarker analysis|Correlative studies
223974101|NCT02624505|DRUG|90 mcg Reference Product|Drug: 90 mcg Reference Product
223974102|NCT02624505|DRUG|180 mcg Reference Product|Drug: 180 mcg of Reference Product
223974103|NCT02624505|DRUG|90 mcg Test Product|Drug: 90 mcg of Test Product
223974104|NCT02624505|DRUG|Placebo|Placebo Product
223543117|NCT01106157|DRUG|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
223974105|NCT02494752|PROCEDURE|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
223974106|NCT02494752|PROCEDURE|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
223974107|NCT04112875|DIETARY_SUPPLEMENT|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
223974108|NCT04112875|DIETARY_SUPPLEMENT|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
223974109|NCT04959461|BEHAVIORAL|webCHAT|A self-guided, single session web intervention that utilizes a motivational interviewing style to prevent impaired driving
223974110|NCT04959461|BEHAVIORAL|Usual Care|6 hours of driver education
223974111|NCT00931918|DRUG|Bortezomib|Bortezomib IV
223974112|NCT00931918|DRUG|Rituximab|Rituximab IV
223543118|NCT01106157|DRUG|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
223543119|NCT01154335|DRUG|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
223543120|NCT01154335|DRUG|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
223974113|NCT00931918|DRUG|Cyclophosphamide|Cyclophosphamide IV
223974114|NCT00931918|DRUG|Doxorubicin|Doxorubicin IV solution
223974115|NCT00931918|DRUG|Vincristine|Vincristine IV
223974116|NCT00931918|DRUG|Prednisone|Prednisone tablet
224116069|NCT03974646|BEHAVIORAL|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
224116070|NCT03621969|OTHER|Physical exam and medical history|This will be completed by a medical doctor on the research team
224116071|NCT03621969|DIAGNOSTIC_TEST|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
223974117|NCT02694796|BEHAVIORAL|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
223974118|NCT00570921|DRUG|Everolimus|Everolimus tablets, two-5 mg tablets a day
223974119|NCT00570921|DRUG|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
223974120|NCT03442140|OTHER|Harmonica playing|Patients will play the harmonica for up to 6 months
223974121|NCT02380638|DEVICE|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
223974122|NCT06187597|DRUG|S-1|Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
223974123|NCT06187597|DRUG|Toripalimab|Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
223974124|NCT06187597|RADIATION|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 54 Gy in 27 fractions over 5-6 weeks.
223974125|NCT05573347|PROCEDURE|Rotator Cuff Repair|Surgical repair of one or more ligament(s) that form the rotator cuff shoulder complex (supraspinatus, infraspinatus, subscapularis, and teres minor)
224292885|NCT03471364|DRUG|Ketoconazole|Applied topically
223543121|NCT03084705|DEVICE|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
223974126|NCT05573347|PROCEDURE|Bone Marrow Harvest|Procedure in which bone marrow cells are extracted, or harvested, from a given location in the body
223974127|NCT03686618|DRUG|Secretin|Drug to stimulate pancreatic secretion
223974128|NCT05001997|DIETARY_SUPPLEMENT|Lactose free probiotic yogurt|Probiotics are non-pathogenic, live microbes that when eaten or administered In adequate amount, it confer health benefits to host. Only lactose free probiotic yogurt containing cultures such as Lactobacillus acidophilus and Bifidobacterium lactis will be selected.
223974129|NCT03616236|DRUG|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
223974130|NCT03616236|OTHER|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
223974131|NCT00131898|PROCEDURE|Surgical Resection|
223974132|NCT00131898|PROCEDURE|Intensity Modulated Radiation Therapy (IMRT)|
224292886|NCT03471364|OTHER|Laboratory Biomarker Analysis|Correlative studies
224292887|NCT03471364|OTHER|Placebo Administration|Applied topically
223974133|NCT02832284|DEVICE|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
223974134|NCT03493568|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
224292888|NCT03471364|OTHER|Quality-of-Life Assessment|Ancillary studies
224292889|NCT03471364|OTHER|Questionnaire Administration|Ancillary studies
224292890|NCT01400386|OTHER|Coffee bioavailability trial|Coffee bioavailability trial
224292891|NCT00973765|DRUG|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
224292892|NCT00973765|DRUG|placebo|placebo 2 pills po BID x 7 days
224292893|NCT00000396|BEHAVIORAL|Patient self-care education|
224292894|NCT02011113|DRUG|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
223543122|NCT01673646|DRUG|Pasireotide LAR|Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
223543123|NCT06049550|OTHER|no intervention|no intervention
223974135|NCT03493568|DRUG|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
223974136|NCT06118177|PROCEDURE|connective tissue harvesting|The subepithelial connective tissue graft was obtained in each patient using the single incision technique from the region between the mesial of canine and the mesial of first molar in the palate. Connective tissue dimensions were approximately 10 × 5 × 2 mm. Finally, the incision line was sutured with 5/0 synthetic, nonabsorbable, sterile monofilament suture
223974137|NCT06118177|DIAGNOSTIC_TEST|ultrasonography|A 6-18 MHz intraoral probe was used in intraoral USG examinations. Sterile gel was applied to the intraoral probe and covered with a stretch film. Then, it was placed directly on the mucosal surface of the donor site in the palatal area. Mucosal thickness was evaluated using the B-mode of the device, and vascularization was evaluated using the color doppler and pulsed wave doppler modes of the device. The following equation is used and calculated by US unit: Pulsality index (PI) = (Vmax-Vmin)/(Vmean) (Vmax is peak systolic flow velocity, Vmin is diastolic flow velocity and Vmean is mean flow velocity). The mean PI values of each patient were measured.
223974138|NCT06118177|OTHER|autolog platelet rich fibrin application|Leukocyte rich PRF (L-PRF) was obtained with the centrifugation of the two tubes at 2800 rpm for 12 minutes. After centrifugation, L-PRF clots were taken from the tubes using sterile tweezers, separated from the red blood cell base using scissors. Then L-PRF membrane was placed into the donor site.
223974139|NCT00280709|DEVICE|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
224292895|NCT02011113|DRUG|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
224292896|NCT02964949|DRUG|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
224292897|NCT02914093|OTHER|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
224292898|NCT00267943|DRUG|telmisartan 80 mg + hydrochlorothiazide 25 mg|
224292899|NCT03130218|OTHER|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
224292900|NCT05163314|DRUG|Soticlestat|Soticlestat mini-tablets or tablets
224292901|NCT04072952|DRUG|ARV-471|Parts A and B: ARV-471 administered QD or BID for 28 day cycles.
224292902|NCT04072952|DRUG|ARV-471 in combination with palbociclib (IBRANCE®)|Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
224292903|NCT04932447|BEHAVIORAL|Inspiratory Muscle Strength Training|30 breaths/ day, 5 days/week for 24 weeks.
224292904|NCT04363840|DRUG|Aspirin 81 mg|Aspirin 81 mg to be taken orally once daily for 14 days.
223543124|NCT01104480|DRUG|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
223543125|NCT01899781|DRUG|Antibiotic-Cefamezin|
223543126|NCT05504681|OTHER|Observational study|It takes the patient on average 15 minutes to complete the Brainlab Cognition app.
224292905|NCT04363840|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
224292906|NCT04692779|OTHER|Lung Ultrasound (LUS)|Enrolled subjects will undergo LUS 1 hour before and 1 hour after prone positioning by a trained clinician and will be assessed using a LUS score based on LUS pattern. LUS will then be performed again 1 hour before supination (16 hours) and assessed by a LUS score. This process will be repeated on the first 3 prone sessions. Patients will be enrolled in the study for 4 weeks in order to observe patient outcomes.
224292907|NCT02442674|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
224292908|NCT02442674|OTHER|Placebo|Placebo tablet matching active drug
223974140|NCT04300153|PROCEDURE|ESP Block|At the end of the skin closure, patients will be positioned in lateral decubitis with the involved site lying superiorly. A convex ultrasound probe will be placed over the transverse process of T12 vertebra in longitudinal axis and an 80- mm 21-gauge needle will be inserted in the plane view under aseptic conditions. A unilateral ESP block will be performed with 30 ml 0.25% bupivacaine into the interfascial plane between erector spinae muscle and T12 transverse process
223974141|NCT04300153|OTHER|Global Quality of Recovery-15 score|Global Quality of Recovery-15 score (QoR-15) will be recorded prior to the surgery and at the postoperative 24th hour.
224116072|NCT03621969|DEVICE|Patient Instruction and use of Device (RePlay)|"1. providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~2. improving assessment and evaluation of patients involved in future interventional studies,~3. producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
224116073|NCT00230386|DEVICE|MRI|
224116074|NCT00594152|DRUG|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
224116075|NCT02099799|BEHAVIORAL|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
224116076|NCT04942418|OTHER|Multicolor hybrid ceramic laminate veneers.|Multi shaded blocks have been recently introduced to the market, due to lack of evidence in clinical performance evaluating marginal adaptation and shade matching of the polychromatic newly introduced blocks comparing their different color gradient. Multicolor hybrid ceramic laminate veneers.
224116077|NCT04942418|OTHER|Multicolor fieldspathic ceramic laminate veneers.|the feldspathic ceramic blocks display the highest translucent properties of all ceramic blocks which make them the first choice in the esthetic zone. esthetic and translucency with polychromatic feature and resilience properties.
224116078|NCT03290300|DEVICE|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
224116079|NCT05985070|DIETARY_SUPPLEMENT|Oral Sucrosomial iron|30 mg capsule
224116080|NCT05985070|DIETARY_SUPPLEMENT|Oral Ferric maltol|30 mg capsule
224116081|NCT05189015|DRUG|Olmesartan|\- Olmesartan group: Olmesartan, 20 (40) mg once a day, oral administration
224292909|NCT00171301|DRUG|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
224292910|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
224292911|NCT00606359|BIOLOGICAL|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
224116082|NCT04416516|BIOLOGICAL|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
223974142|NCT04300153|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale score will be recorded at the 1.-2.-4.-6.-8.-12.-24.hours. If Numerical Rating Scale score will be equal to or over 4, iv dexketoprofen 50 mg will be applied as rescue analgesic. Numerical Rating Scale scores, the rescue analgesic need and the time for first mobilization of the patient will be recorded and kept in a statistical evaluation.
223725328|NCT02573350|DRUG|OBR|Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
223974143|NCT02513979|DRUG|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
223974144|NCT00784277|DRUG|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
223974145|NCT00784277|DRUG|oxycodone IR|10mg for 14 days
223974146|NCT00784277|DRUG|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
223974147|NCT00784277|DRUG|Tapentadol IR (CG5503)|50mg for 14 days
223974148|NCT00784277|DRUG|Tapentadol IR (CG5503)|75mg for 14 days
223974149|NCT00784277|DRUG|placebo|1 capsule for 14 days
223974150|NCT00784277|DRUG|placebo|Tablets and capsules 2 x a day for 28 days
223974151|NCT00598637|DEVICE|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
223974152|NCT00598637|DEVICE|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
223974153|NCT03857737|PROCEDURE|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
223974154|NCT03857737|PROCEDURE|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
223974155|NCT05315817|DEVICE|multiPlus dialysate|Treatment of acute kidney injury patients either with continuous veno-venous haemodialysis (CVVHD) or continuous veno-venous haemodiafiltration (CVVHDF) using the multiPlus dialysate.
223974156|NCT01585688|DRUG|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
223974157|NCT03230071|DRUG|TMBCZG|0.1g per pill which contains 14mg TMBCZG
223974158|NCT03230071|OTHER|placebo|0.1g per pill which contains 0mg TMBCZG
224116083|NCT00260000|DRUG|5,6,7,8-tetrahydrobiopterin|
224116084|NCT00764894|DEVICE|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
223974159|NCT00588341|DRUG|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
223974160|NCT00543166|DRUG|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
223974161|NCT01039558|DRUG|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
223974162|NCT01039558|DRUG|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
223974163|NCT01039558|DRUG|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
223974164|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
223974165|NCT02198716|PROCEDURE|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
223974166|NCT03121599|DEVICE|Diagnostic (18F-FLT PET/CT)|The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
223974167|NCT00983424|DRUG|Cyclosporins|dose escalation, administered orally twice a day
223974168|NCT00983424|DRUG|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
223974169|NCT05245084|DRUG|CKD-386(3)|QD, PO
223974170|NCT05245084|DRUG|D013, D326, D337|QD, PO
223974171|NCT01372202|DRUG|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
223974172|NCT01372202|DRUG|Cisplatin|"Paclitaxel and cisplatin:~* Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~* Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~* Cisplatin 75 mg/m² days 1, 29."
223974173|NCT01372202|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
223974174|NCT01372202|DRUG|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~* Oxaliplatin 85 mg/m2 days 1, 15, 29.~* 5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~* 5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~* Cisplatin 75 mg/m² days 1, 29."
223974175|NCT01372202|RADIATION|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
223974176|NCT01372202|PROCEDURE|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
223974177|NCT05662683|OTHER|Virtual Reality (VR)|Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
223974178|NCT05662683|OTHER|Distraction Cards Practice Group|It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
223974179|NCT05662683|OTHER|Virtual Reality (VR) Breathing Exercise Group|From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
223974180|NCT00658983|OTHER|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
223974181|NCT00658983|OTHER|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
223974182|NCT06277024|DRUG|Combination of Cardonizumab with Lenvatinib and SOX regimen|"Phase 1: Conduct a ramp up test on the dosage of lenvatinib according to the traditional 3+3 design; Phase 2: 6 cycles of treatment with candenizumab+lenvatinib+SOX regimen (Q3W); For patients who have not progressed, they will enter the third stage of maintenance treatment.~Phase 3: Maintenance therapy with candenizumab, lenvatinib, and tigio (Q3W)."
224116085|NCT03809546|DRUG|Dronabinol|THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
223974183|NCT04433286|OTHER|Questionnaire|"This is a cross-sectional survey which will be distributed online between surgeons. The survey was proposed by a consensus of consultants of surgery and revised by an improvement consultant. It consists of a semi-structured questionnaire that is provided in English language. A subsequent translation in different Language will provided based on geographical distribution. The survey will be conducted online through an online survey development cloud-based software (SurveyMonkey®; San Mateo, CA, USA). Participants will be aware of the nature of the survey and informed that they will be listed as co-authors. Collected data will be confidential and anonymous.~The first sector of the questionnaire includes trainee demographics and baseline characteristics. Then the questionnaire aims to compare the trainee experience before and after the pandemic with focus on research activities, clinical, and surgical practice."
223974184|NCT00948103|DRUG|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
224116086|NCT03809546|DRUG|dextrose|We are administering dextrose to health volunteers for our placebo group
224116087|NCT03618225|DRUG|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
224116088|NCT03618225|DRUG|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
224116089|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
224116090|NCT00844246|OTHER|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
224116091|NCT00487279|DEVICE|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
224116092|NCT00487279|OTHER|Control|No Intervention
224116093|NCT05328843|DRUG|PB119|"Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration."
224116094|NCT01986205|COMBINATION_PRODUCT|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen \>99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
223974185|NCT00948103|DRUG|Oxygen|oxygen
224116095|NCT01986205|COMBINATION_PRODUCT|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
224116096|NCT00444210|DEVICE|DL6049 (injectable poly-L-lactic acid)|
224116097|NCT05888714|DEVICE|Experimental FES cycling|Using the experimental, new FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
224116098|NCT05888714|DEVICE|Comparator FES cycling|Using the comparator, marketed FES cycling device, provide neuromuscular electrical stimulation of the gluteal, quadriceps and hamstring muscles at sufficient intensity to cause muscle contraction and push the cycle ergometer pedals for 30 minutes, for 16 treatment sessions (twice a week, for 8 weeks), in addition to conventional physical therapy for muscle strengthening.
224116099|NCT05888714|OTHER|Conventional physical therapy|Conventional physical therapy for muscle strengthening, for 16 treatment sessions (twice a week, for 8 weeks).
224116100|NCT02606786|OTHER|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
224116101|NCT03852212|OTHER|Manipulation|Thrust technique application
224116102|NCT05599217|OTHER|Dietary and nutritional questionnaire|Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
224116103|NCT05599217|OTHER|Neurological function, cognitive function, and life quality assessment|Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
224116104|NCT05599217|OTHER|Peripheral blood test|Collect peripheral blood samples from patients.
224116105|NCT05599217|OTHER|Metabonomic test|Collect urine and stool samples from patients.
223974186|NCT02057302|DRUG|Xuezhikang capsule|
224116106|NCT05599217|OTHER|Hematoma test|Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
224116107|NCT04740866|RADIATION|Adjuvant Radiotherapy|Irradiation of both the bladder tumor bed and pelvic lymph nodes using Intensity-Modulated Radiation-Therapy (IMRT) technique. (\[50Gy in 25 fractions conventional fractionation including tumor bed \& pelvic lymph nodes\]
224116108|NCT06508996|DIAGNOSTIC_TEST|Xpert HCV|Detection of HCV RNA by Xpert HCV test
224116109|NCT05662358|DRUG|Denosumab|1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection
224116110|NCT05662358|DRUG|Alendronate|oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
223725329|NCT03702946|OTHER|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
224116111|NCT05662358|DRUG|Placebo|oral placebo weekly
224292912|NCT04319159|COMBINATION_PRODUCT|BF-200 ALA and red light LED lamp|Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
223725330|NCT04815161|BEHAVIORAL|Adherence|Adherence to medication using an electronic pillbox
223974187|NCT05784649|OTHER|health education|"The health education program will be conducted on the WeChat platform. The contents of health education include 1) knowledge about how to prevent anemia during pregnancy; 2) self-care education videos such as breastfeeding; 3) online courses on how to manage weight during pregnancy, and how to keep good emotions, etc.; 4) Nutrition and lifestyle guidance; 5) knowledge about recognition and prevention of risk factors or diseases: abortion, toxic substances, premature birth. The contents of health education will be totally shared 5 times from 12 weeks to 36 weeks in the pregnancy and once a month on the platform. Every participant should reply read after learning the contents. if they have any questions, they can reply for help for further connection with health professionals."
223974188|NCT05784649|BEHAVIORAL|individual counsel|The participants will receive the same health education as the control group. The pregnant women will have one routine checkup a month from 12 weeks to 36 weeks in the hospital. And they will receive counseling with a midwife and a doctor after every routine checkup. The counseling will have a total of 5 times and once a month, 45 minutes per time. The professionals will evaluate health-promoting behaviors such as nutrition and physical activity based on the procedure of the health promotion model. The model includes four continued parts: prior behaviors; personal influences; interpersonal Influences; commitment to a plan of action. Finally, the professionals will give person-centered advice to help the participants practice the content of health education, keep health-promoting behaviors, and achieve a healthy lifestyle.
223974189|NCT04998097|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
223974190|NCT04998097|DEVICE|sham repetitive transcranial magnetic stimulation (rTMS)|no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
223974191|NCT03994341|DIAGNOSTIC_TEST|A FLIR Thermovision a320M thermal IR camera|"1. Clothing removed if necessary~2. ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~3. Axillary temperature prior to starting the thermographic imaging.~4. Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~5. After surface cooling, thermal imaging will be recorded for \~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~6. After \~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~7. Axillary temperature to ensure temperature stability, any clothes will be put back on."
223974192|NCT02929316|DRUG|Vedolizumab|IV infusion week 0, 2 and 6
224292913|NCT05822687|BEHAVIORAL|Education|This is a constant component; all participants will get a psychoeducation digital module.
223725331|NCT00958152|DRUG|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
223974193|NCT03719118|GENETIC|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
223974194|NCT03719118|OTHER|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
223974195|NCT06329271|BEHAVIORAL|Early-Weight bearing|The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
223974196|NCT00913783|DRUG|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
223974197|NCT00913783|DRUG|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
224116112|NCT03713723|DEVICE|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
224116113|NCT04379518|OTHER|Best Practice|Receive standard of care
224116114|NCT04379518|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
224116115|NCT04379518|DRUG|Rintatolimod|Given IV
223543127|NCT03064074|DRUG|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
224116116|NCT01088815|DRUG|Gemcitabine, nab-Paclitaxel, GDC-0449|"1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
224292914|NCT05822687|BEHAVIORAL|Reappraisal Coping|This digital module will teach reappraisal coping skills.
223725332|NCT00958152|DRUG|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
223725333|NCT00958152|DRUG|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
224292915|NCT05822687|BEHAVIORAL|Distraction Coping|This digital module will teach distraction coping skills.
224292916|NCT05822687|BEHAVIORAL|Relaxation Coping|This digital module will teach relaxation coping skills.
224292917|NCT01346124|RADIATION|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
223974198|NCT00033189|DRUG|Coenzyme Q10|
223974199|NCT05235776|OTHER|observation|observation
223974200|NCT03041701|DRUG|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
223974201|NCT03041701|DRUG|Dasatinib|Twice daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
223974202|NCT03041701|DRUG|Ganitumab|Once every 2 weeks beginning on day 0.
224116117|NCT04509856|BEHAVIORAL|Teach-back educational method|In the teach-back method, after teaching new information to the patient, the patients were asked to explain that new information in their own words. Then the patients' knowledge and the adequateness of their explanations were determined. The patient should repeat the instructions in their own words. In this way, the healthcare professional can evaluate how the patient understands the information. If the patient repeated the information correctly, the teach-back phase for that information was completed, and progression for new information was resumed. However, if there was a deficiency or error in the information, it was corrected and repeated by the healthcare professional.
223543128|NCT03190798|DRUG|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
223543129|NCT03190798|DRUG|Placebo|Placebo for Canagliflozin
224116118|NCT01346137|DRUG|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
224116119|NCT02658162|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
224116120|NCT02658162|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
224116121|NCT02434887|DEVICE|KL029 Intimate Lubricant Gel|
224116122|NCT01032785|DEVICE|no interventions|no interventions
224116123|NCT02172222|DRUG|BI 10773|
224116124|NCT02172222|DRUG|Linagliptin|
223543130|NCT00885183|PROCEDURE|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
223974203|NCT02865759|BEHAVIORAL|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
223974204|NCT00745121|DEVICE|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
223974205|NCT03709485|OTHER|rectal swab for microbial culture.|Rectal swab and culture.
223974206|NCT00989313|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
223974207|NCT04577976|DEVICE|SMBG|Subjects and/or their caregivers will utilize capillary SMBG for managing diabetes for 6 months.
223974208|NCT05625568|DRUG|VYNT-0126|Liquid for oral administration once daily
223974209|NCT05625568|DRUG|Placebo|Liquid for oral administration once daily
223974210|NCT01527903|DRUG|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
224116125|NCT01618656|DRUG|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
224116126|NCT01618656|DRUG|Placebo|Sugar pill
224116127|NCT00477529|DRUG|ABI-008|nab-docetaxel
224116128|NCT01899144|DRUG|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
224116129|NCT01899144|DRUG|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
224116130|NCT01899144|DRUG|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
224116131|NCT03312673|OTHER|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
223725334|NCT00958152|DRUG|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
224116132|NCT02711748|DEVICE|electrostimulation|Electrostimulation using manual defibrillator
224116133|NCT02711748|DEVICE|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
224116134|NCT01175239|GENETIC|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
224116135|NCT04665544|PROCEDURE|SLN side-specific detection rate using radioactive tracer with/without blue dye and ICG tracer.|"The primary objective of this study is to compare SLN detection rate using two types of intracervical tracers (radioactive tracer with or without blue dye vs. ICG).~The null hypothesis is that the detectionrate does not differ between the two techniques."
223974211|NCT01527903|DRUG|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
224116136|NCT03865069|OTHER|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
224116137|NCT03865069|OTHER|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
224116138|NCT05805969|OTHER|Accommodating variable-resistance training|"The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise."
224116139|NCT05805969|OTHER|Standard physical therapy|The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
223543131|NCT02287194|DEVICE|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
223543132|NCT03191942|DEVICE|Modified ortho-k lenses|KETT MC lens
223974212|NCT04761341|DRUG|NUTROF TOTAL|1 per day over a course of 3 months
223974213|NCT05143879|DIETARY_SUPPLEMENT|Citrulline|3 g/day during 9 weeks
223974214|NCT05143879|DIETARY_SUPPLEMENT|Nitrate|300 mg/day during 9 weeks
223974215|NCT05143879|DIETARY_SUPPLEMENT|Nitrate plus Citrulline|3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks
223974216|NCT05143879|DIETARY_SUPPLEMENT|Placebo|3 g/day during 9 weeks
223974217|NCT05866341|DIETARY_SUPPLEMENT|nitrate-rich lettuce juice|Consumption of a daily dosage of 200 mg nitrate via the consumption of a 300mö of a nitrate-rich lettuce juice
223974218|NCT05866341|DIETARY_SUPPLEMENT|nitrate-depleted lettuce juice|Daily consumption of 300 ml of a nitrate-depleted lettuce juice
223974219|NCT03598725|DRUG|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
223974220|NCT03598725|DRUG|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
223974221|NCT03598725|DRUG|Rituximab|375mg/Square meter for consecutive 4 months
224116140|NCT03049540|DRUG|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
224116141|NCT03049540|DRUG|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
224116142|NCT00751881|DRUG|Placebo|"Film-coated tablet~Oral administration"
224116143|NCT00751881|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
224122709|NCT06556056|OTHER|SesZen-Bio Serum + SesZen-Bio 350 mg extract|"Mode of Usage of serum: Dispense a small amount of serum directly onto your fingertips and gently massage it into the roots and scalp using circular motions to ensure even distribution and absorption. Continue this process across your entire scalp, focusing on areas that need the most attention. Avoid rinsing the serum out; instead, allow it to absorb fully.~Frequency: Daily Night Application Rout of administration: Topical Mode of Usage of Capsule: Swallow the capsule whole with a full glass of water without chewing, crushing, or opening it.~Frequency: One time daily after meal Rout of administration: Oral"
223974222|NCT04967586|OTHER|No intervention, questioner only|questioner only
223974223|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
223974224|NCT01650883|DIETARY_SUPPLEMENT|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
223974225|NCT04723732|DRUG|Myrrh mouthwash|1% mouthwash solution of commiphora myrrha, made from Commiphora Myrrha resin extract.
223974226|NCT04723732|DRUG|Chlorhexidine mouthwash|0.2% mouthwash solution of chlorhexidine gluconate.
223974227|NCT04723732|DRUG|Normal saline|0.9% solution of sodium chloride, containing 9 g/L Sodium Chloride (154 mEq/L sodium and 154 mEq/L chloride)
223974228|NCT01187407|DRUG|LY2216684|
223974229|NCT01187407|DRUG|Placebo|
223974230|NCT01187407|DRUG|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
223974231|NCT04491084|DRUG|FLT3 Ligand (CDX-301)|Fms-like tyrosine kinase 3 (FLT3) ligand is a potent hematopoietic growth factor that mobilizes stem cells and greatly increases the number of circulating dendritic cells (DCs) in blood and organs.
223974232|NCT04491084|BIOLOGICAL|anti-CD40 antibody (CDX-1140)|CD40 is a key molecule in the regulation of immune responses whose activity can be modulated using antibodies. CD40 is a tumor necrosis factor receptor superfamily member expressed on antigen presenting cells, including dendritic cells, as well as a host of other cell types, including a wide range of tumor cells
223974233|NCT04491084|RADIATION|SBRT|For subjects on Arm 1, SBRT will be delivered concurrently with FLT3 ligand during Week 1 of study therapy. If only one lesion is being treated, SBRT should be completed during week 1 (e.g., with daily treatments for a 5-fraction course of treatments every other day for a 3-fraction course). In cases where multiple lesions are being treated with SBRT (Arm 1 or Arm 2) or if treatment is interrupted due to technical issues or intercurrent illness, SBRT may extend beyond Week 1.
223974234|NCT02873325|OTHER|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
223974235|NCT06245161|DEVICE|Quicksleeper5|intraosseous anesthesia for dental treatment
223974236|NCT06245161|DEVICE|conventional anesthesia|inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars
223974237|NCT04878575|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
223974238|NCT04878575|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
223974239|NCT00238498|DRUG|vildagliptin|
223974240|NCT03951012|PROCEDURE|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
223974241|NCT06162065|DRUG|Oxybutynin Pill|pharmacological antimuscarinic treatment
223974242|NCT06162065|DIETARY_SUPPLEMENT|Boldo supplement|treatment supplemented with boldo
223974243|NCT04233502|DRUG|Melatonin|prolonged release 1 mg and 5 mg mini-tablets coated odorless and tasteless to facilitate swallowing
223974244|NCT04233502|DRUG|Placebo|Placebo melatonin
223543133|NCT03191942|DEVICE|Ortho-k lenses|KATT BeFree lens
223543134|NCT04590599|DRUG|IBI310|IBI310 3 mg/kg,Q3W, for a total of 4 cycles
223543135|NCT04590599|DRUG|Placebo|Placebo Q3W, for a total of 4 cycles
223543136|NCT04590599|DRUG|Sintilimab|Sintilimab 200mg,Q3W
223543137|NCT02052869|PROCEDURE|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
223974245|NCT03644706|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
223974246|NCT03644706|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
223974247|NCT04260399|OTHER|Lavender Aromatherapy|Participants in the experimental group will be passively exposed to lavender essential oil
223974248|NCT04260399|OTHER|Placebo Aromatherapy|Participants in the control group will be passively exposed to saline water aromatherapy
223974249|NCT02785445|DEVICE|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
223974250|NCT02785445|DEVICE|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
223974251|NCT02719925|OTHER|Mg(+)|"* 1,5 L per day during 30 days~* No livestyle counseling"
223974252|NCT02719925|OTHER|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
223974253|NCT02831998|DRUG|ZuraPrep|Apply topically.
224116144|NCT05028023|BIOLOGICAL|Apneic oxygenation - supplemental high flow oxygen administration by an apneic way|In pediatric patients undergoing tracheal balloon dilatation, oxygenation maintenance is essential, while induction in anesthesia, cessation of spontaneous ventilation by neuromuscular relaxant and pediatric i-gel placement are necessary for access to trachea. After i-Gel placement controlled ventilation with 100% oxygen is initiated. Pediatric bronchoscope and balloon dilatation catheter are advanced into trachea to the stenotic area. Overall dilatation duration is 2,5-3minutes, while the balloon is inflated for 60sec. Every dilatation cession consists of three dilatations. First dilatation is performed without oxygen enrichment. During second and third dilatation, a nelaton catheter, connected with high oxygen flow, is advanced into i-Gel canal, together with bronchoscope and balloon catheter. Effects of no oxygenation and apneic oxygenation in regional cerebral oxygen saturation rSO2, pulse oximetry SpO2, arterial blood gases and haemodynamics are recorded and compared.
224116145|NCT01566838|DRUG|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
224292918|NCT04438213|DRUG|Ertugliflozin|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
224292919|NCT04438213|DRUG|Metolazone|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
224292920|NCT04438213|DRUG|Placebo|Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo
224292921|NCT05219500|DRUG|FPI-2265|Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
223974254|NCT02831998|DRUG|ChloraPrep|Apply topically.
223974255|NCT02831998|DRUG|ZP Vehicle|Apply topically.
223974256|NCT02028468|PROCEDURE|hemiarthroplasty|
223974257|NCT00488228|BEHAVIORAL|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
223974258|NCT00177385|BEHAVIORAL|Modest sleep deprivation with sleep hygiene education|
224292923|NCT02796937|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
224292924|NCT06249386|BEHAVIORAL|Behavioral Activation (BA)|BA reduces alcohol use and posttraumatic stress symptoms and increases psychosocial functioning via psychoeducation, activity monitoring, values clarification, and activity scheduling.
224292925|NCT06249386|BEHAVIORAL|Relapse Prevention (RP)|RP reduces alcohol use via increasing awareness and avoidance of high-risk situations, enhancing drink refusal skills, improving assertiveness, and other strategies.
224292926|NCT05461573|DRUG|Drospirenone|LPRI-CF113 consists of 24 active white tablets containing drospirenone (DRSP) 4 mg followed by 4 active pink tablets containing DRSP 2.8 mg, taken orally once daily for 28 consecutive days, in consecutive cycles for 12 months (13 medication cycles) without a break in daily tablet intake.
223543138|NCT04312503|DRUG|Lurasidone|Patients are treated with dosages according clinical practice
223974259|NCT02892864|OTHER|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
224292927|NCT06290141|DRUG|riliprubart|Pharmaceutical form: Solution Route of administration: IV solution
224292928|NCT06290141|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: IV solution
224292929|NCT06290141|DRUG|riliprubart|Pharmaceutical form: Solution Route of administration: SC solution
224292930|NCT06290141|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: SC solution
223974260|NCT02892864|OTHER|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
223974261|NCT02109861|DRUG|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
223974262|NCT02109861|DRUG|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
223974263|NCT02109861|DRUG|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
223974264|NCT01677949|DRUG|Clofarabine|Days 1-5: Clofarabine 30 mg/m\^2 for 0-30 years of age or 20 mg/m\^2 for \> 30 years of age intravenously (IV) over 2 hours
223974265|NCT01677949|DRUG|Etoposide|Days 1-5: Etoposide 100mg/m\^2 IV over 2 hours
223974266|NCT01677949|DRUG|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m\^2 as a 30-60 minute infusion
223974267|NCT01677949|BIOLOGICAL|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
223974268|NCT05324007|OTHER|Basic Science|This is a basic science experiment to test whether infants' looking time to video stimuli differ according to the race of the individuals shown.
223974269|NCT00123019|BEHAVIORAL|Exercise and diet|Advice and measurement only
223974270|NCT00123019|BEHAVIORAL|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
224116146|NCT01566838|DRUG|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
223974271|NCT00123019|BEHAVIORAL|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
223974272|NCT00123019|BEHAVIORAL|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
223974273|NCT06485648|BIOLOGICAL|Umbilical cord mesenchymal stem cells|Treatment: G(glucocorticoid) + i.v. uc-MSC (1×106 cells/Kg)
223974274|NCT06485648|DRUG|Normal saline|Control: G(glucocorticoid) + i.v. Normal saline
223974275|NCT02630706|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
223974276|NCT02630706|DRUG|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
223974277|NCT02630706|DRUG|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
223974278|NCT02630706|DRUG|Metformin|Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
224116147|NCT03798561|DRUG|ASN008 TG|ASN008 TG
223974279|NCT02630706|DRUG|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
223974280|NCT05122078|DEVICE|ANI|Investigators will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
223974281|NCT05122078|OTHER|Control|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
223974282|NCT04410549|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|To perform OCT in pulmonary artery of patient with COVID-19
223974283|NCT00216788|DRUG|Esomeprazole (Nexium) 40 mg/day|
223974284|NCT00221156|DRUG|Acarbose|
223974285|NCT00915460|DRUG|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
223974286|NCT00752999|DRUG|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
223974287|NCT00752999|DRUG|Placebo|Placebo tablet, oral, twice-a-day
223974288|NCT06453304|DRUG|Calcium Hydroxide|Intracanal medication
223974289|NCT06453304|DRUG|Leddermix|Intracanal medication
223974290|NCT06453304|DRUG|Glycirrhizin|Intracanal medication
223974291|NCT05888558|DEVICE|Body fluid diagnosis|miRNAs derived from exosomes in the serum
223974292|NCT00224809|DRUG|Angiotensin-Converting Enzyme Inhibitors|
223974293|NCT00224809|PROCEDURE|Coronary Artery Bypass Graft|
223974294|NCT00224809|DRUG|Angiotensin Receptor Blockers|
223974295|NCT00224809|DRUG|Spironolactone|
223974296|NCT00224809|DRUG|Aspirin|
223974297|NCT00224809|DRUG|Clopidogrel|
223974298|NCT00224809|PROCEDURE|Surgical Ventricular Restoration|
223974299|NCT00640042|DRUG|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
223974300|NCT00549042|DRUG|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
223974301|NCT00549042|DRUG|Placebo|Placebo
223974302|NCT04471480|DRUG|TC/PD-1 inhibitor/anlotinib|chemotherapy and immunotherapy plus antiangiogenic therapy
224116148|NCT03798561|DRUG|Placebo TG|Placebo TG
224116149|NCT03509753|DIETARY_SUPPLEMENT|High Fiber|See intervention description.
224116150|NCT03509753|DIETARY_SUPPLEMENT|Low Fiber|See intervention description.
224116151|NCT05547555|DIAGNOSTIC_TEST|embryo selection|The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A
224116152|NCT05845164|DEVICE|tDCS|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~tDCS: The anode and cathode are two large 5 cm by 5 cm gel-based pads which are placed on the scalp. This reduces the risk of burn or irritation and increases conduction. The 2 electrodes are connected to the tKIWI device which delivers a low intensity electrical current (\</=2A), thereby polarizing membrane potential of neurons in the stimulated area. Current that flows from the cathode to the anode has an inhibitory effect on the stimulated area, while current that flows from the anode to the cathode is typically excitatory. We will be initiating bilateral stimulation of the Dorsolateral pre-frontal cortex (DLPFC), which has been shown in the literature to elicit a significant decrease in ambiguous risk-taking behavior in healthy human subjects and a decrease in impulsivity on a non-ambiguous risk task."
223543139|NCT04312503|DRUG|aripiprazole, olanzapine, quetiapine or risperidone|Patients are treated with dosages according clinical practice
223543140|NCT03177018|DIAGNOSTIC_TEST|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
223974303|NCT04521933|OTHER|Survey|"Each participant completes a questionnaire. In the questionnaire, he performs a subjective qualitative evaluation of Point-of-Care ultrasound records of the heart.~Each participant will complete a questionnaire in which they perform a subjective qualitative evaluation of ultrasonographic recordings of the heart."
223974304|NCT03535493|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
223974305|NCT03535493|BEHAVIORAL|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
223974306|NCT03535493|BEHAVIORAL|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
223974307|NCT00703599|PROCEDURE|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
223974308|NCT02631616|DRUG|Somatostatin|Monthly injections of Somatostatin
223974309|NCT01527500|DRUG|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
223974310|NCT01527500|DRUG|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
223974311|NCT01527500|DRUG|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
223974312|NCT04782596|PROCEDURE|Posterium nasal septum resection|Posterium nasal septum resection is required to ensure approach during transnasal endoscopic pituitary surgery in patients with pituitary adenoma.
223974313|NCT00672347|DRUG|Clonidine|1 mcg/kg
223974314|NCT00672347|DRUG|Morphine|20 mcg/kg
223974315|NCT00672347|DRUG|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
223974316|NCT00672347|DRUG|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
223974317|NCT00003924|BIOLOGICAL|recombinant interferon alfa|
223974318|NCT03521206|BEHAVIORAL|ACP+ programme|Training program for nursing home staff.
223974319|NCT00010270|BIOLOGICAL|LMB-9 immunotoxin|
223974320|NCT04355052|DRUG|hydroxychloroquine in combination with camostat mesylate|Two drugs which may act as antivirals against SARS CoVid 2 (Hydroxychloroquine may also act as an immunomodulator, Camostat mesylate is a protease inhibitor)
223974321|NCT04355052|DRUG|Hydroxychloroquine in combination of Azithromycin|Hydroxychloroquine 400 mg BID on day 1 and than 200 mg BID on days 2-5 + Azithromycin 500 mg QD on day 1 and 250 mg QD on days 2-5
223974322|NCT03039088|OTHER|Follow-up after 12 weeks after TNF alpha blockers initiation|
223974323|NCT03790878|BEHAVIORAL|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
223974324|NCT03790878|BEHAVIORAL|Habituation|An exposure procedure that reduces emotional distress through habituation
223974325|NCT03790878|BEHAVIORAL|Control|No emotion regulation intervention, placebo
224116153|NCT05845164|DEVICE|tDCS Sham|"EEG: The tKIWI uses sensors placed on specific locations of the head for the EEG reading.~The sham group will receive ramped up current from 0.0mA to no more than 0.5mA for the first minute at the initiation of each of the three ramp ups, after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle. The current delivered by tDCS is not strong enough to trigger an action potential in a neuron; instead its sub-threshold changes the pattern of already active neurons."
223974326|NCT04851171|PROCEDURE|Flexible Ureteroscopy|Flexible ureteroscopy is the use of flexible ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
223974327|NCT04851171|PROCEDURE|Semi-rigid Ureteroscopy|Semi-rigid ureteroscopy is the use of the semi-rigid ureteroscope for the treatment of stone in the upper ureter with the aid of laser lithotripsy.
224116154|NCT04918940|BIOLOGICAL|Determination of COVID-19 vacciantion efficacy|Samples will be taken after each vaccine injection to perform Sars-Cov-2 serology and Elispot interferon gamma and 3 months after the first vaccine injection
224116155|NCT04077203|BEHAVIORAL|Biofeedback / No biofeedback|Biofeedback / No biofeedback
223543141|NCT01580410|DRUG|mitomycin C|Given by HIPEC
223543142|NCT01580410|DRUG|oxaliplatin|Given by HIPEC
223543143|NCT01580410|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223543144|NCT01580410|OTHER|quality-of-life assessment|Ancillary studies
223543145|NCT01580410|DRUG|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
224116156|NCT01072279|OTHER|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
224116157|NCT01072279|OTHER|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
223974328|NCT03657537|DRUG|Ketone infusion|β-hydroxybutyrate is infused intravenously.
223974329|NCT03657537|DRUG|Saline infusion|saline is infused intravenously.
223974330|NCT00895089|DRUG|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
223974331|NCT00895089|DRUG|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
223974332|NCT00655083|DRUG|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
224116158|NCT03851679|DIAGNOSTIC_TEST|B-Type natriuretic peptide (BNP) serum values|"evaluation BNP serum values:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
224116159|NCT03851679|DEVICE|Pulmonary echography|"Pulmonary echography:~* pre- Cesarean Section (30 minutes before surgery)~* post- Cesarean Section (6 hour and 24 hour after surgery)"
224116160|NCT03851679|OTHER|urine collection|6 hour and 24 hour urine collection after Cesarean Section
223543146|NCT06011317|DRUG|EDG-7500|EDG-7500 is administered orally once daily
223543147|NCT06011317|DRUG|Placebo|Placebo is administered orally once daily
223543148|NCT03417466|DEVICE|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
223543149|NCT01397227|BIOLOGICAL|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
223974333|NCT00655083|DRUG|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
223974334|NCT02686671|OTHER|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
224116161|NCT06440590|PROCEDURE|suprapectineal quadrilateral buttress plating|15 cases will undergo anatomical supra-pectineal quadrilateral plate
224116162|NCT06440590|PROCEDURE|Infra-pectineal plating|15 cases will undergo conventional manually contoured infra-pectineal plate
223974335|NCT04383834|DEVICE|NobelActive® TiUltra™ implants and On1™ Base/Xeal™ along with On1 components|"The NobelActive® TiUltra™ implant is an ultra-hydrophilic multi-zone anodized implant surface. NobelActive® TiUltra™ features a gradual change in topography, from a minimally rough non-porous nanostructured implant collar to a moderately rough porous apex: more than roughness. NobelActive® TiUltra™ collar features surface chemistry and topography that promote early osseointegration and are designed to support bone stability. In addition, the Protective Layer preserves the pristine surface chemistry and hydrophilicity.~The second new product is the Base/Xeal™ new surface, which is covered by a titanium oxide layer, created by electrochemical anodization of a titanium machined component, resulting in a yellow hue nano-structured surface."
223974336|NCT00484172|PROCEDURE|blood draws|
223974337|NCT02541799|PROCEDURE|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
224292931|NCT06290141|DRUG|IVIg|Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution
224292932|NCT06290141|DRUG|Placebo|Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution
224292933|NCT02100319|DRUG|Azilsartan|Azilsartan tablets
223974338|NCT02541799|PROCEDURE|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
223974339|NCT03524547|DEVICE|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
224292934|NCT02485002|DEVICE|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
224292935|NCT02485002|DEVICE|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
224292936|NCT01913379|DRUG|MDV3100|Oral
223974340|NCT03524547|DEVICE|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
223974341|NCT03644784|DIAGNOSTIC_TEST|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
223974342|NCT03083093|DIAGNOSTIC_TEST|The initial CTPA will be reviewed|The initial CTPA will be reviewed
224292937|NCT01913379|DRUG|Gemfibrozil|Oral
224292938|NCT01913379|DRUG|Itraconazole|Oral
224292939|NCT03875014|DEVICE|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
224292940|NCT00675636|OTHER|study of socioeconomic and demographic variables|database, no intervention
224292941|NCT00675636|PROCEDURE|evaluation of cancer risk factors|database, no intervention
224292942|NCT00675636|PROCEDURE|study of high risk factors|database, no intervention
224292943|NCT03113448|DRUG|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
224292944|NCT03113448|DRUG|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
223974343|NCT00806299|DRUG|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
223974344|NCT00806299|DRUG|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
223974345|NCT00806299|DRUG|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
223974346|NCT01845558|DRUG|Wobenzym® plus|
223974347|NCT01845558|OTHER|Placebo|
223974348|NCT04559516|BEHAVIORAL|Exercise Intervention|"The Ethica mobile app will provide a daily alert accompanied by a short educational statement about PAH, disease self-management tips, dietary and nutritional advice, goal setting, and a motivational statement to encourage patients.~Participation with each session will be assessed by a mobile app-embedded survey administered at the end of the day. Patients will be presented with weekly alerts to complete validated patient-reported quality of life questionnaires using the EmPHasis-10 and the Living with Pulmonary Hypertension Questionnaire, as well as the PRAISE self-efficacy score for pulmonary rehabilitation. The app will also ask patients to report their WHO/NYHA functional class every week. Using in-app buttons, participants can log adverse events associated with each exercise session."
223974349|NCT04559516|BEHAVIORAL|Standard Care|Participants will be provided usual care administered at the PH clinic at the University of Calgary and no supervised exercise session will be performed.
223974350|NCT01212484|DRUG|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
224292945|NCT02349971|DEVICE|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
223974351|NCT01212484|DRUG|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
224116163|NCT04133779|PROCEDURE|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
224116164|NCT04133779|PROCEDURE|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
224292946|NCT03375320|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224292947|NCT03375320|DRUG|Cabozantinib S-malate|Given PO
223974352|NCT01170923|DEVICE|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
223974353|NCT01170923|DEVICE|CT|CT performed after 3 cycles of chemotherapy
224292948|NCT03375320|PROCEDURE|Computed Tomography|Undergo CT
224292949|NCT03375320|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224292950|NCT03375320|OTHER|Placebo Administration|Given PO
223974354|NCT05895110|BIOLOGICAL|Recombinant Novel Coronavirus vaccine (CHO Cells)|The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
223974355|NCT03697083|OTHER|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
223974356|NCT03697083|OTHER|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
224292951|NCT03375320|OTHER|Quality-of-Life Assessment|Ancillary studies
224292952|NCT03375320|PROCEDURE|X-Ray Imaging|Undergo x-ray
224292953|NCT06283979|COMBINATION_PRODUCT|STIMULAN VG|Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.
224292954|NCT06283979|PROCEDURE|Standard of Care|Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.
224292955|NCT05552755|DRUG|REC-4881|REC-4881 4mg capsules
224292956|NCT05552755|DRUG|Placebo|Placebo capsules
223974357|NCT03697083|OTHER|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
223974358|NCT04919044|OTHER|Motor Imagery Training|The number of imagined contractions were 34 trials, each trial was 10 seconds with 5seconds rest between each trial and 2 minutes' rest was given after first 17 trials.
223974359|NCT05561296|PROCEDURE|Femtosecond laser assisted cataract surgery with astigmatism management|The alignment would be guided by preoperatively obtained iris registration using Cassini Ambient. Patients will undergo femtosecond laser-assisted cataract surgery with Catalys femtosecond laser.
223974360|NCT03078751|DRUG|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib was supplied in the form of 200 mg film-coated tablets taken by mouth."
223974361|NCT03078751|DRUG|Adjuvant endocrine therapy|Letrozole 2.5 mg by mouth daily, or anastrozole 1 mg by mouth daily, exemestane 25 mg by mouth daily, tamoxifen 20 mg by mouth daily, for a total duration of at least 60 months. In premenopausal women, a GnRH agonist administered every 28 days.
223974362|NCT03078751|DRUG|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Placebo was supplied in the form of 200 mg film-coated tablets taken by mouth."
223974363|NCT05666271|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation will be performed by using the Octopus MP electrodes. It is a method of directly measuring the temperature near the surrounding tissue of the target tumor using the Octopus MP electrode, and stopping ablation when the temperature rises above 60 degrees to prevent adjacent organ (gallbladder, gastrointestinal tracts, diaphragm, and heart). If the shape of the tumor is elliptical or irregular rather than circular, using an adjustable tip that can change the length of the active tip of the electrode according to the size of the tumor has the advantage of tailoring the ablation zone.
223974364|NCT06117761|OTHER|Attention Placebo|Telephone follow-up focused on information provision and brief counselling relating to their health conditions. They will also receive routine care from the healthcae system, including medical follow-ups with the clinical team, without structured out-patient rehabilitation services.
223974365|NCT06117761|OTHER|Home-based exercises combined with cognitive training|An 8-week, home-based, exercise with cognitive training intervention. 3 sessions per week, and 80 minutes per session.It comprises of 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.A blended training platform with supervised in-person home visits and a real-time supervised online and unsupervised selfpractice approach will be used to deliver the intervention, with the platform gradually shifted from home visits to unsupervised self-practice according to participants' physical functioning level. Family caregivers will be involved in the intervention, so that they can facilitate home-based training. Each intervention session will last for 80 minutes and comprise 45 minutes of exercise training, a 5-minute break and 30 minutes of cognitive training.
223974366|NCT06117761|OTHER|Home-based exercises|An 8-week, home-based, exercise-only intervention. Weeks 1 and 2 will be the induction phase, all sessions will be supervised with two home visit sessions and one online session in real-time. Weeks 3 to 6 will be the maintenance phase. For participants with a higher functional performance level (Level 3 or 4), the mode of delivery will change to one home visit and two online training sessions. Weeks 7 and 8 will be the consolidation phase, consisting of two online sessions and one unsupervised self-practice session. They will not receive any structured cognitive training.
223974367|NCT02093117|PROCEDURE|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
223974368|NCT02093117|PROCEDURE|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
223974369|NCT02960334|DEVICE|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
223974370|NCT00198198|DRUG|Aripiprazole|
223974371|NCT04934124|DRUG|ITI-333|ITI-333 oral solution
223974372|NCT04934124|OTHER|Placebo|Matching placebo
223974373|NCT02900222|PROCEDURE|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
223974374|NCT03212950|DRUG|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
223974375|NCT03212950|DRUG|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
223974376|NCT00607789|DRUG|Duloxetine|30 mg/day - 120 mg/day
223974377|NCT00607789|DRUG|Placebo|identical to study drug
223974378|NCT01174485|PROCEDURE|exercise|combined resistance and aerobic training
223974379|NCT02947581|DRUG|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
223974380|NCT02947581|DRUG|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
223974381|NCT02650206|DRUG|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
223974382|NCT02650206|OTHER|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
223974383|NCT02174159|DRUG|Ulonivirine|MK-8507 administered as a single oral dose
223974384|NCT01845311|DEVICE|ReZolve2 Scaffold|
223974385|NCT01209286|BIOLOGICAL|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
223974386|NCT05257252|BEHAVIORAL|"Persons With Disability Friendly Nursing Education Program"|Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
223974387|NCT02496143|DRUG|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
224116165|NCT04133779|PROCEDURE|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
224116166|NCT05496803|OTHER|routine education plus digital video disk|Parents receiving routine education plus digital video disk before their children receiving congenital heart disease catheterization. The DVD content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
224116167|NCT05496803|OTHER|routine education|Parents receiving routine education before their children receiving congenital heart disease catheterization
224116168|NCT02804802|OTHER|questionnaire|dietary habits and physical activity questionnaire
224122710|NCT01433627|OTHER|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
223543150|NCT01397227|BIOLOGICAL|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
223543151|NCT01397227|BIOLOGICAL|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
223974388|NCT02496143|DRUG|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
223974389|NCT04865614|DRUG|Etomidate|Use of etomidate
224116169|NCT05347589|OTHER|Post isometric relaxation of quadratus lumborum and gluteus Gluteus maximus activation exercises|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range.
224122711|NCT01433627|OTHER|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
223974390|NCT04865614|DRUG|Sevoflurane|Use of sevoflurane
224122712|NCT01433627|OTHER|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
223543152|NCT02137642|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
223543153|NCT02137642|DRUG|Placebo|Double blind placebo will be delivered once by injection during study procedure.
223543154|NCT00572416|BEHAVIORAL|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
223543155|NCT00572416|BEHAVIORAL|Healthy Eating Control|Equal time and attention and information about healthy eating
223543156|NCT02141672|DRUG|Voclosporin High Dose|
223543157|NCT02141672|DRUG|Voclosporin Low Dose|
223543158|NCT02141672|DRUG|Placebo|
223974391|NCT02950688|BIOLOGICAL|Seasonal LAIV|10\^7.0 fluorescent focus units (FFU); administered by intranasal spray
223974392|NCT02950688|BIOLOGICAL|Placebo|Administered by intranasal spray
223974393|NCT02950688|BIOLOGICAL|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10\^6 TCID50; administered intranasally
223974394|NCT04136964|OTHER|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
223974395|NCT04255654|OTHER|Brief Intervention for Food Insecurity|2 item screening tool (brief intervention)
223974396|NCT05095714|OTHER|Liver ultrasound and fast-MRI|Half-yearly liver ultrasound and fast-MRI
223974397|NCT05095714|OTHER|Liver ultrasound|Half-yearly liver ultrasound
223974398|NCT02108847|DRUG|.2% Ropivacaine|
223974399|NCT02108847|DRUG|Saline|
224122713|NCT01433627|OTHER|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
223974400|NCT02108847|PROCEDURE|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
223974401|NCT01068223|DRUG|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
223974402|NCT01068223|DRUG|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
223974403|NCT01068223|DRUG|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
223974404|NCT04271566|BEHAVIORAL|Education program|A mobile application plus short message service (SMS) program to deliver disease-related health education and reinforcement to experimental group patients and see its impact on their health related quality of life, physical activity and Body mass index
223974405|NCT01705314|DIETARY_SUPPLEMENT|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
223974406|NCT01705314|DIETARY_SUPPLEMENT|placebo|7mls of placebo drops per week for 8 months.
223725335|NCT02708121|BEHAVIORAL|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
223974407|NCT05127018|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
223974408|NCT02199249|DEVICE|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
223974409|NCT02199249|DEVICE|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
223974410|NCT05414006|DRUG|S-ketamine|S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
224292957|NCT05973838|BEHAVIORAL|"Peer-Delivered Behavioral Activation (Peer Activate)"|"The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention."
224292958|NCT04109586|BEHAVIORAL|Personalized nutritional therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
223974411|NCT06478056|PROCEDURE|pancreatectomy|patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
223974412|NCT00457171|DRUG|GI-270384|
224122714|NCT01433627|OTHER|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
223974413|NCT05014906|DRUG|Minocycline 45 MG|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
223974414|NCT05014906|DRUG|Azelaic acid|45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
223974415|NCT03121040|DIETARY_SUPPLEMENT|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
223974416|NCT05150002|DEVICE|Spinal cord stimulation|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
224116170|NCT05347589|OTHER|post isometric relaxation of the Quadratus lumborum|Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
224116171|NCT00092144|DRUG|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
224116172|NCT00092144|DRUG|Comparator: placebo / Duration of Treatment: 4 weeks|
224116173|NCT06480474|DEVICE|Deprexis|The internet-based self-help program used in this study, Deprexis, contains 10 modules ( based on different psychotherapeutic approaches, consistent with a cognitive-behavioral perspective) and accessible at any time via regular internet browsers on laptops, computers, tablets, or smartphones through a secure website. Participants can repeat all modules as often as they wish after completing the full sequence once.
224292963|NCT05599022|DEVICE|Magnetic Stimulation|Transcutaneous Magnetic Stimulation
224292964|NCT02523014|DRUG|Vismodegib|Given PO
224116174|NCT06480474|DEVICE|Deprexis with online forum|Those in this group will have access to deprexis ( same as the first group) as well as an online forum built for the study. This forum will feature a general discussion page where participants can ask and answer questions, and they will be divided into groups of 10 to share experiences if they wish. Additionally, there will be subforums related to specific modules of the program. Participants can share their experiences and ask questions related to the modules. A moderator will regularly check to ensure no personal or sensitive information is disclosed and will ask questions weekly to encourage contributions to the forum.
224116175|NCT05325138|OTHER|Interview|Parents of girls aged 9-14yearsold will undergo an interview to determine their knowledge, attitudes and beliefs concerning HPV vaccination
224292965|NCT02523014|DRUG|FAK Inhibitor GSK2256098|Given PO
224292966|NCT02523014|DRUG|Capivasertib|Given PO
224292967|NCT02523014|DRUG|Abemaciclib|Given PO
224292968|NCT00692471|DEVICE|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
224292969|NCT05976763|DRUG|Zanubrutinib|Given PO
224292970|NCT05976763|BIOLOGICAL|Rituximab|Given IV
224292971|NCT05976763|OTHER|Patient Observation|Undergo observation
224292972|NCT05976763|PROCEDURE|Bone Marrow Biopsy|undergo bone marrow biopsy
224292973|NCT05976763|OTHER|Fludeoxyglucose F-18|Given IV
224292974|NCT05976763|PROCEDURE|Positron Emission Tomography|Undergo PET
224292975|NCT05976763|PROCEDURE|Computed Tomography|Undergo CT
224292976|NCT05976763|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223974417|NCT06105996|BEHAVIORAL|Interoceptive training|There will be 6 interoceptive training sessions carried out over two months. Each training session will comprise two blocks, between which participants will undergo a self-paced, light physical activity that aims to enhance heartbeat perception and lasts 2 to 3 minutes. During the pre- and post-exercise block, each participant will complete cardiac interoceptive tasks, and for each trial, note their confidence in their answer on a visual analogue scale and then be given accurate feedback about their objective heartbeat perception accuracy and the accuracy of their subjective confidence rating, relative to their objective accuracy.
223974418|NCT05756348|DEVICE|Marathon® XL No Sting Cyanoacrylate Skin Protectant and 3M™ Cavilon™ Advanced Skin Protectant|All participants will receive both device interventions listed above.
223974419|NCT05845099|DEVICE|Polymethyl Methacrylate-Based Complete Removable Dentures.|The patients will receive Complete Removable Dentures processed by Heat cured acrylic resin.
223974420|NCT05845099|DEVICE|Photopolymerized Methacrylate- Based Complete Removable Dentures.|The patients will receive a 3D-printed removable denture digitally manufactured using a 3d printer device with light polymerized resin.
223974421|NCT00000441|DRUG|lorazepam (Ativan)|
223974422|NCT00000441|DRUG|carbamazepine (Tegretol)|
223974423|NCT03915951|DRUG|encorafenib|self-administered orally
223974424|NCT03915951|DRUG|binimetinib|self-administered orally
223974425|NCT03928678|PROCEDURE|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
223974426|NCT00613132|DRUG|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
224116176|NCT03020524|BIOLOGICAL|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
224116177|NCT04739124|OTHER|Follow-up questionnaires|"The patient normally follows the education program as usual but research specific data is collected:~* Biological sampling at the start and end of the education program (glycated hemoglobin).~* Retrieval of usage and glycemic balance data from the Libreview online platform (at one week, one month and three months of use)~* Iterative questionnaires allowing the study of factors of acceptance, appropriation and use (at the start of the study, at 4 weeks, at 12 weeks)"
224292977|NCT05976763|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
224292978|NCT05976763|PROCEDURE|Colonoscopy|Undergo colonoscopy
224292979|NCT05976763|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224292980|NCT05976763|OTHER|Questionnaire Administration|Ancillary studies
223974427|NCT00985530|DRUG|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast \& dinner) during each 6 week cycle
223974428|NCT00985530|DRUG|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
224292981|NCT06415344|DRUG|GTX-102|Antisense Oligonucleotide
224292982|NCT04940286|BIOLOGICAL|Durvalumab|Given IV
224292983|NCT04940286|DRUG|Gemcitabine|Given IV
223725336|NCT02708121|OTHER|Comparator Intervention|Participants informed that they have access to weight loss treatment.
223725337|NCT05000476|OTHER|eye mask and earplugs|Materials similar to those offered on long commercial flights
223725338|NCT05000476|OTHER|Nurse Education and Environmental Regulation|providing orientation to the patient (frequent orientation of the patient to the place, time and person), cognitive stimulation (objects such as clocks and calendars in the patient's field of view), reducing noise and light (minimizing monitors and fluid infusion pump alarms at night), providing early mobilization ( passive-active joint movements, sitting and walking in bed), reducing social deprivation (receiving visitors, telephone calls)
223725339|NCT02383277|OTHER|Stretching|Stretching of the rib cage muscles
223974429|NCT02033499|BEHAVIORAL|SMBG|Blood glucose levels are tested once daily.
223974430|NCT04242342|RADIATION|Adaptative MR-Guided Stereotactic Body Radiotherapy|"If lesion near organs at risk:~* Prescription of 50 Gy in 5 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy and daily adaptive treatment~If lesion far of organs at risk:~* Prescription of 60 Gy in 6 fractions of 10 Gy~* 3 sessions per week, with MRI guided stereotactic radiotherapy without daily adaptive treatment"
224116178|NCT04739124|OTHER|Interviews|Semi-structured interviews will be carried out during the visits, either face-to-face or remotely.
224292984|NCT04940286|DRUG|Nab-paclitaxel|Given IV
224292985|NCT04940286|BIOLOGICAL|Oleclumab|Given IV
224292986|NCT03994796|DRUG|Abemaciclib|Given PO
224292987|NCT03994796|DRUG|PI3K Inhibitor paxalisib|Given PO
223974431|NCT04313036|DRUG|Defibrotide|25 mg/kg/day at 4 divided doses of 6.25 mg/kg, 2-h infusion given for 5 days, if not in CR treatment continued for \>/= 21 days or per discretion of enrolling physician.
223974432|NCT03716583|DRUG|Melatonin|25 mg
223974433|NCT03716583|DRUG|Dimethyl Sulfoxide|150 mg
223974434|NCT03716583|DRUG|Placebos|1 g
223974435|NCT03835403|OTHER|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
223974436|NCT02880124|DIETARY_SUPPLEMENT|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
223974437|NCT02880124|BEHAVIORAL|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
223974438|NCT02880124|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
223974439|NCT02880124|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
223974440|NCT02880124|OTHER|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
223974441|NCT02880124|OTHER|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
223974442|NCT02880124|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
223974443|NCT02880124|BEHAVIORAL|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
223974444|NCT05999344|OTHER|commercially available cannabis administered prior to commercially available alcohol|Self administration of cannabis prior to researcher administered alcohol
223974445|NCT05999344|OTHER|commercially available alcohol administered prior to commercially available cannabis|Researcher administered alcohol prior to self-administration of cannabis
223974446|NCT03519477|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
223974447|NCT01196741|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
223974448|NCT01196741|DRUG|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
223974449|NCT01196741|DRUG|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
223974450|NCT00690534|DRUG|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
223974451|NCT00690534|DRUG|L-NMMA|variable rate for 3 hours
223974452|NCT00690534|DRUG|Sodium Nitroprusside|variable rate for 3 hours
223974453|NCT00690534|OTHER|mixed meal|mixed meal
223974454|NCT02851394|DRUG|Levobupivacaine|
224292988|NCT03994796|DRUG|Entrectinib|Given PO
224292989|NCT03994796|DRUG|Adagrasib|Given PO
223974455|NCT02851394|DRUG|levobupivacaine|
223974456|NCT02851394|DRUG|tramadol|
223974457|NCT05944133|OTHER|No intervention, observational retrospective study|No intervention
223974458|NCT02465775|DEVICE|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
223974459|NCT02150109|DEVICE|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
223974460|NCT02150109|DEVICE|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
223974461|NCT06111183|BIOLOGICAL|AUP1602-C|AUP1602-C is topically applied on chronic wounds and covered by wound dressing.
223974462|NCT06111183|OTHER|Placebo|Placebo is topically applied on chronic wounds and covered by wound dressing.
223974463|NCT00984347|DRUG|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas \[6th delivery and up\] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
223974464|NCT00984347|PROCEDURE|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
223974465|NCT04560192|BEHAVIORAL|Mindfulness based Emotion regulation therapy (MBERT) - Treatment as usual (TAU)|"1. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation.~2. Waiting period with TAU."
223974466|NCT04560192|OTHER|Treatment as usual (TAU) - Mindfulness based Emotion regulation therapy (MBERT)|"1. Waiting period with TAU.~2. In each of 8 sessions (allocated over 4 weeks) the patient brings an (actual) topic that induces rumination. After identifying the underlying affect, the patients are instructed (1) to concentrate on it, (2) to accept and tolerate it (considering the personal situation and experiences), (3) to give it a new interpretation so the patient can look at it with a more generous view, and (4) to dissociate from it, so the patient can perceive it as one of many affects and as one that hasn't the power to influence one's thoughts and actions that much (as it does through rumination). These steps are gradually instructed and trained throughout 20 trials (à 40 seconds) in each session. After each trial there is room to talk about the trial, possible barriers and helpful strategies to overcome those. Between-sessions the patients are encouraged to train the strategies in their daily life and do some homework like a protocol of ruminative thoughts and meditation."
223725340|NCT02383277|OTHER|Control|Rest without stretching (sham)
223974467|NCT00273650|DRUG|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
224116179|NCT04766424|BEHAVIORAL|Sleep extension intervention|Participants will receive a fitbit and 8 weekly sleep-related educational materials via email and telephone coaching to review their sleep tracker data, set goals, trouble shoot any problems, and increase motivation.
224116180|NCT04766424|BEHAVIORAL|Health education|Participants will receive 8 weekly health education newsletters delivered via email.
224116181|NCT01209208|DRUG|Budesonide|9 mg per day
223725341|NCT02383277|OTHER|Exercise|Constant load exercise on a bike
223725342|NCT01833520|DRUG|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
224116182|NCT01209208|DRUG|Mesalamine|3 g per day
224116183|NCT01209208|OTHER|Placebo|0 g per day
224116184|NCT02617121|DRUG|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
224116185|NCT02617121|DRUG|Ramosetron|ramosetron 0.3 mg iv at end of surgery
224116186|NCT02617121|DRUG|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
224116187|NCT02273323|OTHER|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
224116188|NCT02273323|OTHER|Placebo|Placebo: tea flavour, colouring and sugar
224116189|NCT04788719|OTHER|Gait analysis|Gait analysis
223974468|NCT00273650|OTHER|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
224116190|NCT03836118|PROCEDURE|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E\&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
223974469|NCT01064856|BIOLOGICAL|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
223974470|NCT01064856|BIOLOGICAL|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
223974471|NCT02831751|BIOLOGICAL|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
223974472|NCT02831751|BIOLOGICAL|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
223974473|NCT02831751|BIOLOGICAL|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
223974474|NCT02831751|BIOLOGICAL|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
223974475|NCT04115956|DRUG|Melphalan-Flufenamide (Melflufen)|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
223974476|NCT04115956|DRUG|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
223974477|NCT03427606|PROCEDURE|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
223974478|NCT03302871|DRUG|Botulinum toxin type A|
223974479|NCT03302871|DEVICE|transcranial direct current stimulation|
223974480|NCT03302871|OTHER|hybrid training model of CIMT and BIT|
223974481|NCT03302871|OTHER|usual care|
223974482|NCT04870814|DEVICE|Tactical tourniquet set up|The tactical tourniquet will be set up to the upper limb and the lower limb during a maximum of 2 minutes.
223974483|NCT04870814|DIAGNOSTIC_TEST|Medical ultrasound|The efficacy of tactical tourniquet set up will be assessed by medical ultrasound.
223974484|NCT04870814|OTHER|Questionnaire|"The participants will have to fill a questionnaire assessing pain (for the receiver), ease of use, stability and rusticity (for the fitter)."
223725343|NCT03649698|BEHAVIORAL|Home-based training program|Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.
223974485|NCT03323814|DEVICE|Slow-wave optimization|employing sensory stimulation to enhance slow waves
223974486|NCT02223299|DIETARY_SUPPLEMENT|L-tyrosine|6g/d daily for 30 days
223974487|NCT02223299|DIETARY_SUPPLEMENT|L-Tryptophan|2g/d daily for 30 days
223974488|NCT02223299|DRUG|deplin|15mg daily for 30 days
223974489|NCT02223299|OTHER|Placebo A|a sugar-pill that looks like a real medication
223974490|NCT02223299|OTHER|Placebo B|a sugar-pill that looks like a real medication
223725344|NCT03649698|DIETARY_SUPPLEMENT|High-quality protein supplement|The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
223725345|NCT03649698|DIETARY_SUPPLEMENT|Omega-3 fatty acid|Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
223974491|NCT02062671|PROCEDURE|renal denervation|
223974492|NCT05532618|PROCEDURE|Adductor canal block|Before anterior cruciate ligament surgery an adductor canal block will be placed using ultrasound.
223974493|NCT05532618|DRUG|Levobupivacaine|Levobupivacaine
223974494|NCT05532618|DRUG|Placebo|10 ml of sodium chloride 0.9%
223974495|NCT05709886|DEVICE|EUS-LA by LaserPro Diode Laser System|This trial is a prospective, single-arm, multi-center clinical trial. Four hospitals with national medical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive endoscopic ultrasound (EUS)-guided laser ablation (LA) by LaserPro Diode Laser System according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the procedure will be made according to groups.
223974496|NCT03465670|DEVICE|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
223974497|NCT03465670|DEVICE|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
223974498|NCT01204775|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
223974499|NCT01204775|DRUG|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
223974500|NCT01204775|DRUG|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
223974501|NCT01204775|DRUG|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
223974502|NCT01204775|DRUG|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
223974503|NCT05270889|DRUG|Tislelizumab+Zanidatamab|"Zanidatamab will be administered at a flat dose as follows:~* Subjects with body weight \<70 kg: 1800 mg IV on Day 1 of each 21-day cycle~* Subjects with body weight ≥70 kg: 2400 mg IV on Day 1 of each 21-day cycle Tislelizumab will be administered at a dose of 200 mg IV on Day 1 of each cycle."
223974504|NCT00860899|DRUG|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine \[Catapres®, Boehringer Ingelheim, Germany\], 7 mL of 0.25% levobupivacaine \[Chirocaine®, Abbott S.p.A., Italy\] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
223974505|NCT02008539|DRUG|MSC_apceth_101|
224116191|NCT03117049|DRUG|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
223974506|NCT02567786|PROCEDURE|Surgery with CPB|
223974507|NCT02567786|OTHER|Fresh Frozen Plasma|
223974508|NCT02567786|OTHER|Plasmalyte|
223974509|NCT04090216|DEVICE|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
224116192|NCT03117049|DRUG|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
224116193|NCT03117049|DRUG|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
224116194|NCT03117049|DRUG|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
224116195|NCT03117049|DRUG|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
224116196|NCT00651118|DRUG|Placebo|placebo
224116197|NCT00651118|DRUG|azelastine Hcl|azelastine Hcl 548 mcg
224116198|NCT00651118|DRUG|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
224116199|NCT00651118|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
223974510|NCT01690286|DRUG|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
223974511|NCT01690286|DRUG|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
223974512|NCT01690286|DRUG|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
223974513|NCT01690286|DRUG|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
223974514|NCT01427231|DIETARY_SUPPLEMENT|glucose|The effect of a glucose solution on cognitive performance will be measured.
223974515|NCT01427231|DIETARY_SUPPLEMENT|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
223974516|NCT01427231|DIETARY_SUPPLEMENT|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
223974517|NCT03148301|OTHER|Survey|Survey
224116200|NCT03215888|PROCEDURE|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
224116201|NCT00042185|BEHAVIORAL|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
224116202|NCT00042185|BEHAVIORAL|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
223974518|NCT04135469|OTHER|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
223974519|NCT04135469|OTHER|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
223974520|NCT03165344|OTHER|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
223974521|NCT03165344|OTHER|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
223974522|NCT03165344|OTHER|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
223974523|NCT05938959|DRUG|Sham block|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0,9% normal saline
223725346|NCT03649698|DRUG|Placebo protein powder|Isocaloric maltodextrin powder. Amount based on food diary.
223725347|NCT03649698|DRUG|Placebo omega-3|Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
223974524|NCT05938959|DRUG|ESPB|Bilateral ESPB under ultrasound guidance bi-level Th3-6 and Th9-L1(adjusted to the incision line): 0.3-0.5ml/kg 0.2% Ropivacaine (max 2.5mg/kg)
223974525|NCT05466968|DRUG|Suxiao Jiuxin Pills|Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian).
223974526|NCT05466968|DRUG|The placebo of Suxiao Jiuxin Pills|The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
223974527|NCT05793827|BEHAVIORAL|Adapted Hatha Yoga|Yoga includes breath work (pranayama), gentle stretching and holding of postures (asanas), and meditation (dhyana). Modifications/adaptations are incorporated so all participants can successfully complete the yoga intervention. Yoga is delivered in a standardized progression, including: focused, slow breath with movement and breathwork throughout every session; mantras, progressively challenging yoga postures (sitting, standing, and floor); and meditation
223725348|NCT02834507|DRUG|Placebo|Matching placebo capsules
223974528|NCT05793827|BEHAVIORAL|Low-Impact Exercise|This includes low-intensity exercise, which is matched to the estimated metabolic costs of yoga, 2.5 Metabolic Equivalent of Task (MET). Sessions include warm up, cool down, and five, 10-minute exercise stations, (e.g., walking, balance, resistance bands, weight-bearing exercise, and core work). Control exercise will be prescribed between 2.0 to 3.0 METs, equating to 30 to 40% heart rate reserve. Heart rate zones are calculated for each participant and monitored to ensure proper intensity
224116203|NCT00042185|BEHAVIORAL|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
223725349|NCT02834507|DRUG|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
223725350|NCT02834507|DRUG|Comtan®|Capsules containing entacapone 200 mg
223725351|NCT02834507|DRUG|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
223725352|NCT06171763|OTHER|Telemedicine|The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
223725353|NCT03489447|OTHER|ICU care|exposure to ICU treatment with or without diagnosed sepsis
223725354|NCT00913042|OTHER|sample blood|"* Early culture~* Bacterial DNA tests in blood"
223725355|NCT00000534|DRUG|calcium|
223725356|NCT00000534|BEHAVIORAL|dietary supplements|
223725357|NCT03928574|PROCEDURE|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
223725358|NCT03928574|PROCEDURE|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
223725359|NCT01264588|OTHER|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
223725360|NCT03729505|PROCEDURE|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
223725361|NCT03729505|PROCEDURE|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
223725362|NCT00489021|PROCEDURE|sub-acute hospitalization|
223725363|NCT00004760|BEHAVIORAL|Exercise|
223725364|NCT03287661|BEHAVIORAL|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
223725365|NCT03454776|DEVICE|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
223974529|NCT04021147|BEHAVIORAL|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
223974530|NCT04021147|BEHAVIORAL|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
223974531|NCT04021147|BEHAVIORAL|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
223974532|NCT04021147|BEHAVIORAL|Exercise|Orofacial exercises
223974533|NCT01702155|DRUG|DFP-10917|
223974534|NCT01138137|DRUG|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles"
223974535|NCT01138137|DRUG|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg"
223725366|NCT03454776|DEVICE|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
223974536|NCT01138137|DRUG|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles"
223974537|NCT06128434|OTHER|zinc carbonate nano-hydroxyapatite toothpaste|Participants will brush their teeth with zinc carbonate nano-hydroxyapatite toothpaste twice daily.
223974538|NCT06128434|OTHER|8% arginine toothpaste|Participants will brush their teeth with 8% arginine toothpaste twice daily.
223974539|NCT06128434|OTHER|Fluoride toothpaste|Participants will brush their teeth with Fluoride toothpaste twice daily.
223974540|NCT02368366|BEHAVIORAL|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
223974541|NCT02368366|BEHAVIORAL|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
223974542|NCT02368366|BEHAVIORAL|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
223974543|NCT04266366|OTHER|Face-to-Face Rehabilitation program|In each hospital, two trained therapists will carry out a face-to-face rehabilitation program consisting of electroanalgesia and an exercise program that follows the Mckenzie method. The physiotherapists place the electrodes in the patients, for this they use 5x9 cm electrodes, which they place at the bilateral paravertebral level, in the patients who present with radicular pain, the electrodes will be placed in the path of the affected nerve. The duration will be sufficient to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal periarticular components of the spine.
223974544|NCT04266366|OTHER|Telemedicine program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
223974545|NCT06141772|OTHER|Measure of the circulating tumor DNA|Blood assessment to measure the kinetics au circulating tumor DNA
224116204|NCT00839098|OTHER|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
223725367|NCT00935597|BIOLOGICAL|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
223725368|NCT02547649|BIOLOGICAL|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
223725369|NCT02547649|BIOLOGICAL|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
223725370|NCT02547649|BIOLOGICAL|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
223725371|NCT04267367|BEHAVIORAL|Dietitian-led dietary approach to management of diabetes|In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
223725372|NCT03030924|DEVICE|Solace|Noninvasive physiologic monitor
223725373|NCT00002144|DRUG|Foscarnet sodium|
223725374|NCT06200233|DRUG|Rivoceranib|700mg once daily
223725375|NCT03857243|DEVICE|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
223725376|NCT01432860|BEHAVIORAL|In-person counseling|The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
223725377|NCT01432860|BEHAVIORAL|Workbook|Participants will read a workbook and perform skills training exercises.
223974546|NCT05465486|DEVICE|Brain-Computer Interface control of robotic arms with augmented reality|"The participants will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement). BCI will be used to control the arms in physical space as well as in an Augmented Reality Environment. Each participant will take part in 3 sessions~Device: robotic arms MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics \& Digital Innovation Lab."
223725378|NCT01432860|BEHAVIORAL|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
223725379|NCT03765918|BIOLOGICAL|Pembrolizumab 200 mg|200 mg administered IV infusion on Day 1 of each 21-day cycle
223725380|NCT03765918|RADIATION|Radiotherapy 60 Gray|Low risk participants administered 2 Gray in 30 fractions. Administered using intensity modulated radiation therapy.
223725381|NCT03765918|RADIATION|Radiotherapy 66 Gray|High risk participants administered 2 Gray in 33 fractions. Administered using intensity modulated radiation therapy.
223725382|NCT03765918|RADIATION|Radiotherapy 70 Gray|Participants with gross residual disease administered 2 Gray in 35 fractions. Administered using intensity modulated radiation therapy.
223725383|NCT03765918|DRUG|Cisplatin 100 mg/m^2|100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
223725384|NCT06637501|DRUG|Sonrotoclax|Administered orally
223725385|NCT06637501|DRUG|Zanubrutinib|Administered orally
223725386|NCT00134251|DRUG|SLV308|
223725387|NCT00006903|DRUG|Fulvestrant|Given intramuscularly
223725388|NCT03143413|OTHER|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
223725389|NCT02552771|PROCEDURE|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
223725390|NCT02552771|PROCEDURE|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
223725391|NCT05999032|BEHAVIORAL|CASE in person version (High Intensity Package)|Controlling Asthma in Schools Effectively (CASE) is a multi-level school-based asthma management program delivered by a Community Health Worker (CHW) that includes 1) staff training involving education on asthma management in school, 2) child-based asthma management education with an emphasis on control of symptoms in the school setting provided in a group setting during the school day, 3) caregiver education after school involving supporting children's asthma control in the school setting, 4), and provision of an Asthma Action Plan (AAP) to the school for child enrollees.
223725392|NCT05999032|BEHAVIORAL|CASE-V remote version (Low Intensity Package)|CASE-V, the low intensity version of CASE, includes similar child and caregiver-based asthma management education that is provided in a remote format with adaptation to integrate technological feature of Zoom. All CASE-V components (for staff, children, and parents) have been adapted to promote engagement (e.g., use of chat and polling function).
223974547|NCT05465486|DEVICE|Serious game with augmented reality|"The participants will don wearable robotics and use them as input to play a dojo-themed immersive serious game intended at tracking participants movement and presenting them with motor tasks to perform. The game wiil be played in a computer screen, as well as in an Augmented Reality Environment. Each participant will take part in 10 sessions~Device: Wearable robotics The NeuroSuitUp wearable robotics jacket \& gloves are non-commercial wearable devices, equiped with inertial motion units, electromyography and electrical muscle stimulation, built and developed by the Medical Physics \& Digital Innovation Lab"
224116205|NCT00839098|OTHER|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction \& Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
224116206|NCT03078673|OTHER|training intervention, motor skill training|cross country specific motor skill strength training
224116207|NCT03078673|OTHER|training intervention, maximal strength training|general maximal strength training
224116208|NCT03078673|OTHER|control group|regular training
224116209|NCT00121810|DRUG|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
223543159|NCT05757180|BEHAVIORAL|Positive Events Training (PET)|PET is a group-based training program combining Memory Specificity Training (MEST; Raes, 2007) and Future Event Specificity Training (FEST; Dutch version of Hallford et al. (2020): Changing the Future: An initial test of Future Specificity Training). It comprises four sessions of 50 minutes each. The training is delivered in a standardized manner, using the Positive Event Training Manual developed for this study (content adapted from our MEST and FEST manuals). Following brief psychoeducation on the rationale, participants practice generating detailed specific memories and future events using neutral and positive cue-words. Participants are maximally supported and challenged by the trainer and by the other group-members to generate very specific and highly detailed memories and future events using mental imagery and drawing upon visual, olfactory, auditory and emotional elements of the events, including both contextual and sensory-perceptual details.
223543160|NCT05757180|BEHAVIORAL|CREAtive writing Training (CREAT)|CREAT follows the exact same format and length as the PET training (i.e., delivered by a trainer in group over 4 x 50-minute sessions, including homework exercises). Following brief psychoeducation on the (bogus\*) rationale behind PET, participants complete a series of creative writing exercises using funny and thought-provoking writing prompts. Just as in PET, participants are maximally supported and challenged by the trainer and by the other group-members, in this case to generate completions that are as creative and funny as possible. The investigators used CREAT successfully before in an online format as a bogus control training for a memory specificity training. (\*) The investigators tell participants that these creative writing exercises have been found to be beneficial for mental wellbeing, as creative writing exercises cultivate creativity and stimulate participants' imagination skills.
223543161|NCT02733549|OTHER|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
223543162|NCT06183151|DEVICE|Entia Liberty System|See arm/group description
223543163|NCT02512289|DEVICE|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
223543164|NCT00422188|DRUG|Deoxycholic Acid Injection|Administered via intralipomal injection.
224116210|NCT00121810|DRUG|Corticosteroids|As prescribed
224116211|NCT00121810|DRUG|Calcineurin inhibitors|As prescribed
224116212|NCT00121810|DRUG|Sirolimus|As prescribed
224116213|NCT01340287|DIETARY_SUPPLEMENT|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
224116214|NCT01340287|DIETARY_SUPPLEMENT|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
223974548|NCT05300217|OTHER|Strategies for promoting mental health|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding strategies for promoting mental health"
223974549|NCT05300217|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants in this intervention group will only be shown parts of the website regarding general information about depression"
223974550|NCT02273180|DRUG|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
224116215|NCT02286011|BIOLOGICAL|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
224116216|NCT02286011|OTHER|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
223974551|NCT02273180|DRUG|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
224116217|NCT05329688|PROCEDURE|novel nutrition program|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
224116218|NCT00003369|DRUG|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
223543165|NCT00422188|DRUG|Placebo|Administered via intralipomal injection.
223543166|NCT01887964|OTHER|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
223543167|NCT01887964|OTHER|Control flour|Wheat flour without resistant starch (type-4)
223543168|NCT01798095|BIOLOGICAL|Aplisol@ PPD material|Determine equivalency of materials
224116219|NCT00003369|DRUG|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
224116220|NCT04490668|BIOLOGICAL|Human albumin|Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
224116221|NCT00365976|DRUG|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
224116222|NCT00365976|DRUG|Placebo|Placebo nightly over duration of double blind study phase
224116223|NCT04993027|DRUG|Vancomycin Powder|Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.
224116224|NCT05840289|OTHER|fractionated first dose rituximab|Patients at high-risk to develop tumor lysis syndrome received a initial fractionated dose of rituximab over 2 or 3 days
224116225|NCT01485679|OTHER|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
224116226|NCT03749993|OTHER|Screening|Use of bpMRI for opportunistic prostate cancer screening.
224116227|NCT02942550|DRUG|Methylnaltrexone bromide (Relistor®).|
223974552|NCT02273180|DRUG|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
223974553|NCT06410625|DIAGNOSTIC_TEST|FLT PET imaging|Evaluation of response to chemotherapy with FLT PET imaging
223543169|NCT01798095|BIOLOGICAL|Reference Standard|Reference standard material for comparison to newly produced materials.
223974554|NCT06069596|COMBINATION_PRODUCT|Natalis Obstetric Lubrican Gel|The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
223543170|NCT04633395|OTHER|Music|The participant can choose between 5 different soothing playlists
223974555|NCT02801747|BEHAVIORAL|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
223974556|NCT02297529|DRUG|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
223974557|NCT05056675|PROCEDURE|PENG block|All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
223974558|NCT05056675|PROCEDURE|Placebo|ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
223974559|NCT02722122|DRUG|AIR DNase™|
223974560|NCT00247117|DRUG|Metformin|
223974561|NCT05657132|DRUG|herbal intracanal medication paste|study the effect of costus herbal paste on enterococcus faecalis bacteria
223974562|NCT05657132|DRUG|Meta paste|compare the effect of Costus paste with meta paste in reducing the number of enterococcus faecalis
223974563|NCT00494208|DRUG|Testosterone|Testosterone ester
223974564|NCT02709798|DRUG|Shenfu Injection|
223974565|NCT02709798|DRUG|5% Glucose Injection|
223974566|NCT05173506|OTHER|Computer decision support for physician|The Child Health Improvement through Computer Automation - Child Neurology (CHICA-CN) system will screen patients for needed services and provide reminders to physicians to provide the needed services.
223974567|NCT02946788|DRUG|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
224116228|NCT02942550|DRUG|Sodium Chloride 9mg/mL|
224116229|NCT00984802|DRUG|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
224116230|NCT00984802|DRUG|Placebo control|Vehicle solution for IV administration single dose.
223543171|NCT04633395|BEHAVIORAL|Sleep hygiene|These are behavioural guidelines to help establish a better sleep pattern
223543172|NCT02909660|OTHER|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
223974568|NCT06658704|BEHAVIORAL|Supervised exercise in a group setting|Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16.
223543173|NCT01725802|DRUG|Levodopa/carbidopa solution for SC administration|
223543174|NCT01725802|DRUG|Placebo|
223543175|NCT06374680|PROCEDURE|laminectomy at C3 level|laminectomy at C3 level
223543176|NCT01118780|DRUG|Duloxetine|Administered by mouth, daily for 10 weeks
223543177|NCT01118780|DRUG|Placebo|Administered by mouth, daily for 10 weeks
223543178|NCT06289946|DRUG|NitroBid|We will apply nirobid to the wrist prior to left heart catheterization.
223543179|NCT06289946|DRUG|Placebo|We will apply placebo moisturizing cream to the wrist
223543180|NCT02318836|DRUG|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
223543181|NCT06140368|BEHAVIORAL|virtual reality|During the trigger point injection, patients will be shown videos that the patient wants to watch, such as nature and seaside walks, underwater videos, with music background, through virtual reality glasses for 10 minutes.
223543182|NCT00984776|OTHER|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
223543183|NCT00272831|DRUG|Cilostazol|Cilostazol 100 mg twice daily
223543184|NCT00272831|DRUG|Placebo|1 tablet twice daily
223543185|NCT01531582|DRUG|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
223543186|NCT03947268|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
223543187|NCT03885154|DRUG|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
223725393|NCT05999032|BEHAVIORAL|CASE and HARP in person (High Intensity package)|"Children with poorly controlled asthma will receive both the CASE and HARP programs. HARP is a home-visiting program that includes individualized asthma management education and strategies and supplies for environmental remediation. All 3 visits can be conducted by a CHW. The first includes a walk-through to identify triggers. Asthma education and self-management strategies are provided using a structured protocol and low-literacy flip-book (English or Spanish). Referrals and advocacy are offered to address asthma management barriers (e.g., communication with landlord/housing re: code violation). The 2nd and 3rd visits include delivery of supplies (e.g., HEPA vacuum, pest gels, mattress covers), instruction for use, review of AAP, and follow-up on environmental control recommendations provided during the 1st visit."
223725394|NCT05999032|BEHAVIORAL|CASE-V and HARP-V remote version (Low Intensity package)|"HARP-V replicates the content delivered in HARP in a remote format. The first session includes a virtual walk-through in which the educator uses a structured script and checklist to guide the caregiver through the home and show specific components of the environment (e.g., carpeting, area under the kitchen sink, exhaust fan in bathroom) to identify asthma triggers. Asthma education and self-management strategies are provided using a structured protocol and slide overview based on the HARP flip-book. Supplies for environmental remediation are delivered prior to the 2nd visit. The 2nd and 3rd visit include instruction for use of supplies, review of AAP, and follow-up on recommendations and referrals."
223725395|NCT01864811|BEHAVIORAL|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
223725396|NCT01864811|BEHAVIORAL|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
223725397|NCT00187369|PROCEDURE|Method of Delivery|CS or VB
223974569|NCT06658704|BEHAVIORAL|Usual care (Physical activity on Prescription)|Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks.
223725398|NCT01506128|OTHER|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
223725399|NCT02197000|DIETARY_SUPPLEMENT|DIM-Avail 100mg|DIM 100 mg\*1 daily for 2 years
223725400|NCT01484197|DRUG|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
223725401|NCT01484197|DRUG|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
223725402|NCT01484197|DRUG|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
223725403|NCT01484197|DRUG|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
223974570|NCT02046057|PROCEDURE|PNB of SLN|Percutaneous biopsy of sentinel node
223974571|NCT06608459|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010 is a capsule for oral administration that contains the drug substance PYEX.
223974572|NCT06608498|BEHAVIORAL|SPARK Coping|SPARK Coping is a single-session intervention providing psychoeducation and structured practices related to stigma reduction, cognitive restructuring, behavioral activation, and effective coping. It is a self-guided website powered by research data capture software.
223974573|NCT06593275|PROCEDURE|Protection of the palatal donor area with flowable resin|Use of fluid resin for protection of the palatal donor area to assess postoperative pain generated during14 days
223974574|NCT06593275|PROCEDURE|Protection of the palatal donor area with a self-adhesive dressing|Use of a self-adhesive dressing for protection of the palatal donor area to evaluate postoperative pain generated for 14 days
223974575|NCT03582917|DRUG|Alphacalcidol|Alphacalcidol 0,5mg tablet
223974576|NCT03749616|DRUG|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
223974577|NCT03749616|DRUG|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
223974578|NCT02207322|OTHER|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
223974579|NCT07000318|GENETIC|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by ex vivo base editing technique
223974580|NCT07000344|DRUG|Cohort 1 (triple-drug group)|"Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Fluzoparib: 100 mg orally twice daily, with a 4-week continuous treatment cycle.~Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Treatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred."
223974581|NCT07000344|DRUG|Cohort 2 (dual-drug group)|Apatinib: 250 mg orally once daily, with a 28-day treatment cycle. Letrozole: 2.5 mg orally once daily, with a 4-week continuous treatment cycle. Treatment continued until disease progression, intolerable toxicity, or other protocol-specified reasons occurred.
224116231|NCT06102161|PROCEDURE|Wedge resection|Wedge resection is a surgical procedure that is done to remove a wedge-shaped section of lung tissue, usually for treating lung cancer. A wedge resection is less invasive than some of the other surgical options used to remove lung cancer.
224116232|NCT03138915|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
224116233|NCT03138915|PROCEDURE|CTA|Radiomic features were extracted from CTA images.
224116234|NCT01354691|DRUG|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
224116235|NCT06672640|BEHAVIORAL|Remote Exercise Program|Participants in this group will engage in an eight-week exercise program conducted via video conferencing software. The sessions, which focus on balance, lower limb strength, and gait function, will be held twice weekly for 50 minutes each. Licensed physical therapists will supervise the sessions, and participants will exercise at home, with assistance from caregivers if necessary. The program aims to evaluate the effectiveness of remote exercise interventions in improving physical function and reducing the risk of falls in pre-frail older adults.
224116236|NCT06672640|BEHAVIORAL|In-Person Exercise Program|Participants in this group will take part in an eight-week in-person exercise program at a senior welfare center. The sessions will be held twice weekly for 50 minutes and will be led by a licensed physical therapist. The exercise program, which includes balance, lower limb strength, and gait training, is identical to that of the remote exercise group, with the primary difference being the mode of delivery (in-person at the welfare center). This group aims to assess the effectiveness of direct supervision in a controlled environment.
224116237|NCT06672640|OTHER|Physical Activity Education|Participants in this group will receive educational materials about physical activity, including a booklet and one educational session. They will not participate in any structured exercise program but will be encouraged to maintain their usual activities. The control group serves as a baseline to compare the outcomes of exercise interventions against no structured exercise, focusing on evaluating usual care versus targeted exercise programs.
224116238|NCT05938738|DEVICE|PEP-buddy|PEP-buddy
224116239|NCT06796946|DRUG|Deprescription of Antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram)|Deprescription of Antidepressants Reduction or elimination of the dose of antidepressants (fluoxetine, citalopram, sertraline, paroxetine, and escitalopram) taken by patients
223725404|NCT01484197|DRUG|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
223725405|NCT00811798|BIOLOGICAL|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
223725406|NCT00586001|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
223725407|NCT05741632|DRUG|Moxifloxacin Ophthalmic Solution|Moxifloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
224116240|NCT05695911|BEHAVIORAL|Limb Load Biofeedback Training Intervention|Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.
224116241|NCT05695911|OTHER|Attention Control|The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).
224116242|NCT02620332|DRUG|MultiPepT1De injection|A mix of peptides
224116243|NCT02620332|OTHER|Placebo|Water for injection
224116244|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
224116245|NCT03630614|DRUG|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
224116246|NCT03630614|DRUG|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
224116247|NCT04207853|OTHER|whole body vibration em DM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
224116248|NCT04207853|OTHER|"Vibration sham em DM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
224116249|NCT04207853|OTHER|whole body vibration em NDM|The vibrating platform is a new biophysical modality of exercise. The individual exercises on a plate that oscillates up and down movements at a specific frequency and amplitude, and the exercises are performed static and / or dynamic. Vibration is supposed to activate muscle spindles and evoke contractions, which are induced by the complex spinal and supraspinal neurophysiological mechanism known as the tonic vibration reflex.
224116250|NCT04207853|OTHER|"Vibration sham em NDM"|Sham vibration will be performed with the platform disconnected. A sound device will be connected producing a noise similar to the connected platform for a time equivalent to the treatment protocol, as it will not be possible to visibly distinguish the vibratory stimulus. Participants who will undergo false vibration will not have contact with those who will perform the protocol effectively.
224116251|NCT03408574|DRUG|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
224116252|NCT01073345|PROCEDURE|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
224116253|NCT01073345|PROCEDURE|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
224116254|NCT01073345|PROCEDURE|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
223543188|NCT03885154|DRUG|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
223543189|NCT04841785|DIAGNOSTIC_TEST|mailer-based finger-prick|All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
223543190|NCT02110849|RADIATION|Proton|Proton Therapy for Prostate Cancer
223543191|NCT01715688|DRUG|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
223543192|NCT01715688|DRUG|Saline|Administration of saline in the endotracheal tube cuff
224116255|NCT00928616|DIETARY_SUPPLEMENT|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
224116256|NCT00928616|DIETARY_SUPPLEMENT|margarine (placebo)|non-sterol ester supplemented margarine
224116257|NCT01437670|DRUG|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
224116258|NCT05493865|BEHAVIORAL|The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)|This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
224292990|NCT04136951|OTHER|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co-morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut-off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
224292991|NCT06422273|DRUG|Tranexamic Acid|Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients
224292992|NCT06422273|OTHER|Saline (placebo)|Topical Saline (placebo) administered as endobronchial topical application prior to performing transbronchial biopsies in lung transplant recipients.
224292993|NCT06706362|DRUG|Bactrim or Macrobid|Participants will be assigned to Bactrim or Macrobid depending on participants' allergies
224292994|NCT06706362|DRUG|Placebo|Participants will be assigned to identical appearing placebo
224292995|NCT05796570|DRUG|Decitabine|Nucleoside metabolic inhibitor, via IV infusion.
223543193|NCT00407615|DEVICE|Flex Pad/Static Magnet|
224292996|NCT05796570|DRUG|Filgrastim|Recombinant granulocyte colony-stimulating factor (G-CSF), via subcutaneous injection.
224292997|NCT02589522|DRUG|Berzosertib|Given IV
224292998|NCT02589522|OTHER|Quality-of-Life Assessment|Ancillary studies
224292999|NCT02589522|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224293000|NCT02589522|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
224293001|NCT03587311|BIOLOGICAL|Anetumab Ravtansine|Given IV
223543194|NCT03162133|OTHER|Baduanjin exercise|
224293002|NCT03587311|BIOLOGICAL|Bevacizumab|Given IV
223543195|NCT06196151|BEHAVIORAL|Antenatal training|"Training hours: Training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be given online via Zoom application. The training will consist of a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Pregnant women in both the control and intervention groups will be asked to fill out the Women's Introductory Information Form. The data of the intervention group will be filled out before the first Antenatal education lesson and after all six-hour Antenatal education lessons are completed. The data of the control group will be filled in parallel with the intervention group.~Group to receive the training: Healthy pregnant women who are at the 20th gestational week at the earliest will be included in the training. Trainings will be carried out in closed groups."
224293003|NCT03587311|DRUG|Paclitaxel|Given IV
223543196|NCT01127984|DRUG|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
223543197|NCT01127984|PROCEDURE|drainage system|application of vacuum drainage system
223543198|NCT05474287|PROCEDURE|SJOV|SJOV is conducted using a Wei nasal jet tube (WNJ, Well Lead Medical Co. Ltd, Guangzhou, China) which is connected to a manual jet ventilator (Well Lead Medical Co. Ltd, Guangzhou, China) via its jet port. The initial settings of SJOV were as follows: driving pressure (DP) 15 psi; respiratory rate (RR) 20 bpm; inspiratory-to-expiratory (I/E) ratio 1:2, and gas supply, 100% oxygen.
223543199|NCT05474287|PROCEDURE|HFNO|HFNO is conducted. Oxygen supplementation is delivered at 35 liters min-1 with a fraction of inspired oxygen (FiO2) of 100%.
224293004|NCT05032820|DRUG|Lenalidomide|Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression
224293005|NCT05032820|BIOLOGICAL|bb2121|Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\^6 cells.
224293006|NCT05032820|DRUG|Cyclophosphamide|300 mg/m\^2/day for 3 consecutive days prior to the CAR T infusion
224293007|NCT05032820|DRUG|Fludarabine|30 mg/m\^2/day or 3 consecutive days prior to the CAR T infusion
224293008|NCT05032820|PROCEDURE|leukapheresis|Placement of central line catheter and leukapheresis
224293009|NCT05660967|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.
224293010|NCT05660967|DRUG|Lenalidomide|Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
224293011|NCT05611996|BEHAVIORAL|Peers plus|Peer support intervention in which peer mentors who have experiential knowledge of depression deliver social support through video chats and texts to older adults with depression.
223974582|NCT06600815|PROCEDURE|preemptive stepwise infiltration anaesthesia(PSIA)|For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.
223974583|NCT06600815|PROCEDURE|postoperative local infiltration analgesia(PLIA)|Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.
224116259|NCT02471248|DEVICE|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
224116260|NCT02471248|DEVICE|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 \* 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
224116261|NCT04955145|DRUG|RUTA C 60|Rutin known as vitamin p or rotoside and C-retard is Ascorbic acid
224116262|NCT04636008|DRUG|Sintilimab|Sintilimab+Hypofractionated radiotherapy
224116263|NCT04636008|RADIATION|Hypofractionated Radiotherapy|Hypofractionated Radiotherapy
224116264|NCT03700008|DIAGNOSTIC_TEST|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
224116265|NCT03700008|DIAGNOSTIC_TEST|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
224293012|NCT05524493|DIAGNOSTIC_TEST|Structural MRI|We will examine migraine and epilepsy patients as well as healthy controls using conventional structural MRI in the brain and spinal cord including T1-, T2-, and T2\*-weighted sequences
224293013|NCT05524493|DIAGNOSTIC_TEST|Quantitative MRI|We will examine migraine and epilepsy patients as well as healthy controls using quantitative MRI in the brain and spinal cord. This includes multi-parameter mapping (MPM) and quantitative susceptibility mapping (QSM).
224293014|NCT05524493|DIAGNOSTIC_TEST|Diffusion MRI|We will examine migraine and epilepsy patients as well as healthy controls using diffusion MRI in both brain and spinal cord.
224293015|NCT05524493|DIAGNOSTIC_TEST|fMRI|We will examine migraine and epilepsy patients as well as healthy controls using resting-state and task fMRI (including sensory stimulation using pain stimulus) in both brain and spinal cord.
223725408|NCT05741632|DRUG|Levofloxacin Ophthalmic|Levofloxacin solution 0.1 cc undiluted, self preserved, injected into intracamera at the end of cataract surgery
223725409|NCT00622245|DRUG|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
223725410|NCT00622245|DRUG|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
223725411|NCT00622245|DRUG|Placebo|per oral doses, twice daily as capsules during 13 weeks
224116266|NCT04496791|DEVICE|RIC (Receiver in Canal) hearing aid/ hearing instrument (HI)|HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
223974584|NCT04435522|DRUG|Maraviroc|Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
223974585|NCT02661581|BEHAVIORAL|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
223974586|NCT01874522|DRUG|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
224116267|NCT00479804|DEVICE|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
224293016|NCT05524493|DIAGNOSTIC_TEST|MR Spectroscopy|We will examine migraine and epilepsy patients as well as healthy controls using MR Spectroscopy in both brain and spinal cord.
224293017|NCT05230732|DEVICE|neuromodulation device|Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks
224293018|NCT05230732|DEVICE|SHAM|Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
224293019|NCT06457503|DRUG|Toripalimab|Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.
224293020|NCT06457503|DRUG|Cisplatin|Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
224293021|NCT06457503|DRUG|Gemcitabine|Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.
223725412|NCT01980394|PROCEDURE|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
223725413|NCT02170597|DRUG|BIBR 1048 MS HPMC capsule|
223974587|NCT01874522|DRUG|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
223974588|NCT07009444|BEHAVIORAL|Psychoeducation|Providing information about social anxiety, role of safety and avoidance behaviors in maintaining social anxiety, rationale for exposure to feared social situations
223974589|NCT07009444|BEHAVIORAL|Prospective Mental Imagery|A standard imagination script is recounted in which participants have successfully mastered the socially feared situation
223974590|NCT06611657|DRUG|Antirotinib hydrochloride|Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
224293022|NCT06457503|DRUG|Carboplatin|In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.
223725414|NCT02170597|DRUG|BIBR 1048 MS gelatine capsule|
224116268|NCT00479804|DEVICE|spirometry|spirometry for testing the ventilatory function
224116269|NCT00479804|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
224116270|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-L|Low dose: 2x1010 CFU/day
224116271|NCT04893746|DIETARY_SUPPLEMENT|Maltodextrin|0x1010 CFU/day
224116272|NCT04893746|DIETARY_SUPPLEMENT|Lactobacillus plantarum TWK10-H|High dose: 6x1010 CFU/day
224116273|NCT01253512|DRUG|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
224116274|NCT01253512|DRUG|Placebo|Intravenous
224116275|NCT00246038|DEVICE|Boston Scientific ENOVUS AAA Endograft|
223974591|NCT05430074|DEVICE|HM Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of HM casts.
223974592|NCT05430074|DEVICE|Fibreglass Cast|Subjects assigned to this arm will be treated via cast immobilisation with the use of Fibreglass casts.
223974593|NCT06274892|OTHER|Remote monitoring PROs|Attendance at RT review appointments triaged based on remotely monitored PROs
223974594|NCT03770338|DRUG|Teriparatide|20ug dosage daily injection, 1-month preoperative
223974595|NCT06715787|BEHAVIORAL|FEAST Perinatal Support Program|The intervention will include the core perinatal support program (PSP) with $15 weekly grocery gift cards for healthful food (fruit, vegetables, whole grains), The PSP will be completed during weekly group sessions over 16 weeks. The core PSP includes the two primary behavior change techniques: group-based nutrition education based on current United States Department of Agriculture (USDA) national guidelines for pregnant individuals and guided group sharing and engagement.
223974596|NCT06721078|BEHAVIORAL|Peer navigation effectiveness|To determine the effectiveness of peer navigation on viral suppression and retention in care among adolescents living with HIV in South Africa.
223974597|NCT06721325|BEHAVIORAL|THERAPEUTIC EDUCATION IN PHYSIOTHERAPY|Educational program of physiotherapy for women survivors of sexual violence and female genital mutilation.
223974598|NCT06721325|BEHAVIORAL|Psychotherapy and legal advice|Usual psychological and legal advice therapy for this population
223974599|NCT06719596|DRUG|Bifidobacterium Bifidum Oral Capsule|enteral nutrition+Pre-operative + one week post-operative Oral Bifidobacterium bifidum live triple capsule, 4 capsules Oral BID
224116276|NCT00219336|BEHAVIORAL|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
224116277|NCT00219336|BEHAVIORAL|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
223974600|NCT06721650|OTHER|Perturbation-Based Balance Training|Perturbation-based balance training (PBT; or reactive balance training or perturbation training) is balance training that uses repeated, externally applied mechanical perturbations to trigger rapid reactions to regain postural stability in a safe and controlled environment
223974601|NCT06721650|OTHER|the selected physical therapy exercise program|trunk control therapeutic exercise, static and dynamic balance treaining exercises
223974602|NCT06728774|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD)|8-week manualized group-based behavioral intervention including compensatory cognitive training for difficulties with learning, memory, processing speed, executive functioning, verbal functioning, concentration, and attention.
223974603|NCT06728774|BEHAVIORAL|Goal-focused Supportive Contact|8-week group-based behavioral intervention primarily focused on setting and achieving short or long-term goals. Does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement.
223974604|NCT06724562|OTHER|Anti-IL1 Therapy|Anti-IL1 is a rescue therapy for FOP patients that is hypothesized to reduce flare activity and subsequent ossification in these patients
224116278|NCT01869829|DRUG|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
224116279|NCT02547077|PROCEDURE|Wound Closure with 2-octylcyanoacrylate|
224116280|NCT02547077|PROCEDURE|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
224116281|NCT04592380|DRUG|Stage 1: Clevidipine (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
223974605|NCT06721533|DEVICE|Cerebellar rTMS|Cerebellar rTMS applied to pharyngeal area of right hemisphere
223974606|NCT06721195|DRUG|Remimazolam for Gastrointestinal Endoscopy Sedation|"This intervention involves the use of remimazolam, a short-acting benzodiazepine, for sedation during gastrointestinal endoscopy procedures (gastroscopy, colonoscopy, or both). Remimazolam is administered intravenously at an initial dose of 0.2-0.3 mg/kg, followed by additional doses of 2.5 mg as needed to maintain adequate sedation (MOAA/S score ≤ 2).~Unlike other benzodiazepines, remimazolam is rapidly metabolized by plasma esterases, resulting in a quick onset and recovery with minimal respiratory and cardiovascular depression. The study specifically evaluates the euphoria-inducing potential of remimazolam, using the ARCI-MBG scale pre- and post-procedure to assess its effect on patient comfort and satisfaction."
223974607|NCT06721117|OTHER|Grip strength assessment|Jamar hand dynamometer, recommended by the American Hand Therapists Association and accepted as the gold standard in many studies due to its high validity and reliability, will be used to measure hand grip strength. Pinchmeter (Baseline Mechanical Pinch Gauge) will be used to measure fine grip strength. Hand grip and finger grip strength measurements will be made in the recommended standard position of sitting, shoulder adduction and neutral rotation, elbow 90 degrees flexed, forearm in mid-rotation and supported, wrist in neutral. In the test procedure, 3 measurements will be taken for hand grip and finger grip strengths with one-minute intervals between each measurement and the averages will be recorded.
223974608|NCT06721117|OTHER|Forearm muscle strength assessment|Wrist isometric muscle strength assessment will be performed with a handheld dynamometer (Lafayette Instrument Company, Lafayette, Indiana, USA). Patients will be placed in the supine, prone and sitting positions using the positions required for the fine muscle test method defined by Lovett and will be performed without compensatory movements. Wrist flexor and extensor muscles will be assessed. The values obtained with isometric contraction will be recorded in kg. Muscle strength measurements will be assessed bilaterally, in three repetitions for 5 seconds. The average value of the three repetition results will be recorded.
224293023|NCT05169073|PROCEDURE|Virtual Reality training|In the Virtual Reality (VR) study arm, a VR software (Specto VRTM, version 4.0, Diffuse Ltd, Heimberg, Switzerland) will be used to display volumetric MRCP data using a tethered head-mounted display (HMD) prior to the operation. Specto uses volume rendering at 180 frames/sec to visualize the medical data in an immersive fashion in the VR environment and allows for viewing of the 3D reconstructed 3D imaging with 360° free movement. Each participant will perform a procedure with VR training and one with conventional preparation (MRCP).
224293024|NCT05169073|PROCEDURE|Conventional training|In the conventional study arm, the participants will view the preoperative MRCP.
224293025|NCT01979367|DEVICE|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
224293026|NCT05469737|DRUG|Oral Azacitidine|Specified dose on specified days
224293027|NCT05469737|DRUG|Placebo for Oral Azacitidine|Specified dose on specified days
224293028|NCT05560763|DEVICE|FlowTriever2 Catheter|The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism via mechanical thrombectomy of thrombus in the pulmonary arteries.
224293029|NCT06237309|DRUG|REGN5381|Single dose intravenous (IV) infusion
224293030|NCT06237309|DRUG|Placebo|Single dose IV infusion
224293031|NCT06221969|DRUG|Cagrilintide|Cagrilintide will be administered subcutaneously.
224293032|NCT06221969|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
224293033|NCT06221969|DRUG|Tirzepatide|Tirzepatide will be administered subcutaneously.
224293034|NCT06966700|BIOLOGICAL|Sacituzumab tirumotecan|IV infusion
224293035|NCT06966700|BIOLOGICAL|Pembrolizumab|IV infusion
224293036|NCT06966700|DRUG|Rescue Medication|Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).
224293037|NCT06966700|DRUG|Carboplatin|IV infusion
224293038|NCT06966700|DRUG|Paclitaxel|IV infusion
224293039|NCT06966700|DRUG|Doxorubicin|IV infusion
224293040|NCT06966700|DRUG|Epirubicin|IV infusion
224293041|NCT06966700|DRUG|Cyclophosphamide|IV infusion
224293042|NCT06966700|DRUG|Capecitabine|Oral tablet
224293043|NCT06966700|DRUG|Olaparib|Oral tablet
224293044|NCT06967805|BIOLOGICAL|MTX-463|MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
224293045|NCT06967805|OTHER|Placebo|Placebo
224293046|NCT06107361|DEVICE|B. Braun 6.35cm 20 gauge ultralong intravenous catheter|B Braun Medical Inc, 6.35cm 20 gauge ultralong intravenous catheter
224293047|NCT06107361|DEVICE|BD 5.71 cm 20 gauge Accucath|Bard Access Systems, Inc, BD 5.71 cm 20 gauge ultralong intravenous catheter with guide wire
224293048|NCT05689151|DRUG|Abrocitinib|Study Drug for Observational Data Collection
224293049|NCT06265285|OTHER|Home Health Encounter|Receive in-home visits by a home health nurse
224293050|NCT06265285|BIOLOGICAL|Nivolumab|Given SC
224293051|NCT06265285|PROCEDURE|Patient Monitoring|Undergo remote patient monitoring
224293052|NCT06265285|OTHER|Questionnaire Administration|Ancillary studies
224293053|NCT03228537|DRUG|Atezolizumab|Given IV
224293054|NCT03228537|DRUG|Cisplatin|Given IV
224293055|NCT03228537|PROCEDURE|Extrapleural Pneumonectomy|Undergo EPP
224293056|NCT03228537|DRUG|Pemetrexed Disodium|Given IV
224293057|NCT03228537|PROCEDURE|Pleurectomy|Undergo PD
224293058|NCT03228537|RADIATION|Radiation Therapy|Undergo RT
223974609|NCT06721117|OTHER|Pain threshold assessment|"Pain sensitivity to pressure will be assessed with a pain measuring device called an algometer. The Baseline Dolorimeter brand algometer will be used in the assessment. 3 measurements will be taken from the midpoint of the upper trapezius muscle and C7 points between the lateral edge of the acromion and C7. The areas will be marked before the measurement. The algometer will be placed perpendicular to these points. The patients will be asked to report the moment they first felt the pain and 30 seconds of rest will be given between the measurements. The value on the display will be read and the pain threshold will be recorded in pounds (1kg=2.2 pounds)."
223974610|NCT06721117|OTHER|Anxiety level assessment|"The anxiety level will be determined with the Beck Anxiety Inventory. The Beck Anxiety Inventory is a scale developed by Aaron T. Beck (1988). This scale consists of 21 questions. For each item, the patient is asked to report how he/she has felt during the past week.~The items are scored as 0, 1, 2 or 3. The score range is between 0-63. For the total score, \< 21 is considered mild, 22-35 is considered moderate, and \> 36 is considered severe. The Turkish validity study of the Beck anxiety scale was conducted by Ulusoy et al (1996)."
224116282|NCT04592380|DRUG|Stage 1: Placebo (double-blinded)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the double-blinded placebo infusion, an oral antihypertensive agent may be administered. The placebo infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
224116283|NCT04592380|DRUG|Stage 2: Clevidipine (open-label)|Patients may be transitioned to an oral antihypertensive medication as necessary. When such a transition is required, then approximately 1 hour prior to the anticipated cessation of the clevidipine infusion, an oral antihypertensive agent may be administered. The clevidipine infusion may be down-titrated or terminated at any time following administration of the oral agent, in order to achieve the desired BP level.
224116284|NCT04592380|DRUG|Stage 2: Standard of Care (open-label)|Transition to oral antihypertensive medication from SOC IV antihypertensive is per institutional practice.
224116285|NCT04220489|DRUG|Ketamine|Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
224116286|NCT04220489|DRUG|Placebo Comparator|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
224116287|NCT06224699|DRUG|Toothpaste Product|Use of toothpaste with or without sodium carbonate at 67%
224293059|NCT05101746|DRUG|Nitric Oxide (NO) 20 part per million (ppm)|Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
224116288|NCT02338076|DRUG|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
224116289|NCT01841424|BEHAVIORAL|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
224293060|NCT05101746|OTHER|Standard of care cardiopulmonary bypass|Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
224293061|NCT06283550|DRUG|Abrocitinib 200 mg|Abrocitinib will be available in 100 mg strength tablet
224293062|NCT06283550|DRUG|Abrocitinib 100 mg|Abrocitinib will be available in 100 mg strength tablet
224293063|NCT06283550|DRUG|Placebo|Placebo tablet
224293064|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 1|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
224293065|NCT05742802|COMBINATION_PRODUCT|Tozorakimab 2|Participants randomised to either dose regimen in the predecessor studies will be assigned to a single Tozorakimab dose regimen in the PROSPERO study.
224293066|NCT05742802|COMBINATION_PRODUCT|Placebo|Participants previously randomised to placebo in one of the predecessor studies will be re-randomised in a 1:1 ratio to the active dose of Tozorakimab or placebo.
224293067|NCT05317078|DRUG|AMG 794|Short-term intravenous (IV) infusion.
224293068|NCT06822049|DRUG|Combination Nicotine Replacement Therapy (patch and lozenge)|All participants receive 8 weeks of combination nicotine replacement therapy - long-acting transdermal patch and short-acting lozenge.
224293069|NCT06823713|DRUG|RTX001|RTX001 is an autologous engineered regenerative macrophage cell therapy
224116290|NCT00408421|DRUG|Duloxetine|
224116291|NCT00408421|DRUG|placebo|
224293070|NCT00581321|DIETARY_SUPPLEMENT|water|water 500 ml x 1
224293071|NCT04572243|DRUG|Placebo|Placebo matching to lorcaserin oral tablet, administered as oral suspension.
224293072|NCT04572243|DRUG|Lorcaserin|Lorcaserin oral tablet, administered as oral suspension.
224116292|NCT00457054|DRUG|Lithium|starting dose 600 mg increase as tolerated
224293073|NCT05425641|BEHAVIORAL|Goal Setting|"Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?."
223543200|NCT06199804|BEHAVIORAL|Toy Hygiene Training|The training was given to the mothers in 2 sessions (morning and afternoon), each lasting approximately 30 minutes, accompanied by the Toy Hygiene Guide. The sessions were presented face to face in the mother's room in the form of explaining, showing, question and answer and power point, at a time convenient for the mother and the child, outside the morning and afternoon treatment and care hours. After the first session was completed, an appointment was made with the mother for the afternoon session. In the second session, the information in the book that was not given in the first session was presented to the mothers face to face in the mother's room, outside the treatment and care hours, at a time convenient for the mother and the child. After the training was completed, a final five-minute discussion was held with the mothers in the form of a general question and answer session. The training book was given to the mothers in the experimental group on the first day.
224293074|NCT05425641|BEHAVIORAL|Action Planning|"Individuals will receive daily text messages that include the Action Planning behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Action Planning BCT is Take one minute and plan for today how, where and when you can walk an extra 1,000 steps more than your baseline average. Have you planned for today?"
223974611|NCT06719843|BEHAVIORAL|ACT-based intervention|"Participants in the intervention group will receive the face-to-face ACT-based intervention weekly for 4 weeks (each session lasting approximately 90 minutes), with each group consisting of 6-8 older adults. The intervention consists of 4 sessions:~Session 1 (acceptance and cognitive fusion) Session 2 (contact with the present moment and self-as-context) Session 3 (values) Session 3 (committed action)"
223974612|NCT00951171|PROCEDURE|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
223974613|NCT00951171|PROCEDURE|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
223974614|NCT06525753|OTHER|Weaning off Parenteral Nutrition|pediatric intestinal failure patients who have been weaned off parenteral nutrition
224293075|NCT05425641|BEHAVIORAL|Self-Monitoring of Behavior|"Individuals will receive daily text messages that include the Self-Monitoring behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Self-Monitoring BCT is Check your fitbit for yesterday. Type in the number of steps you did yesterday."
223543201|NCT03541278|PROCEDURE|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
223974615|NCT00919061|DRUG|Gemcitabine|Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
223974616|NCT00919061|DRUG|Cisplatin|20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
223974617|NCT00919061|DRUG|Sorafenib|400 mg PO once a day continuously.
223974618|NCT00767286|DRUG|flutamide|
223974619|NCT00767286|DRUG|goserelin acetate|
223725415|NCT05502757|OTHER|Fruit and vegetable provision|Fresh fruits and vegetables are provided to families at no cost
223725416|NCT02706691|DRUG|BGJ398|Given by mouth (oral)
223974620|NCT00767286|RADIATION|low-LET cobalt-60 gamma ray therapy|
223974621|NCT00767286|RADIATION|low-LET photon therapy|
223974622|NCT05820451|DEVICE|Impella CP, 2.5, 5.0 and 5.5 with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed left sided hemodynamic support devices (Impella) will be included.
224116293|NCT04628403|OTHER|massage|clinical interventions, of mechanophysiological origin for the treatment of symptoms corresponding to DOMS, after exercise
223725417|NCT05746949|PROCEDURE|oxygenization techniques|to compare the effects of high-flow nasal oxygen and jet ventilation on oxygenation in patients who will receive general anesthesia for endolaryngeal surgery.
223725418|NCT03647982|DRUG|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
223974623|NCT05820451|DEVICE|Impella RP with Sodium Bicarbonate used as purge solution|US commercially approved Abiomed right sided hemodynamic support devices (Impella) will be included.
223974624|NCT02868788|DIETARY_SUPPLEMENT|dietary fiber|Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal
223974625|NCT02868788|OTHER|HFHC meal|910 Calorie HFHC meal
223974626|NCT04769895|DRUG|MaaT013|MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
223725419|NCT03647982|DRUG|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
223725420|NCT04382339|DRUG|SOF/RBV/PegINFα-2|SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
224116294|NCT04628403|DEVICE|lasertherapy|lasertherapy
224116295|NCT04628403|DEVICE|shock waves|shock waves
224116296|NCT01979796|DEVICE|Ecig 24 mg nicotine|Cigalike
224116297|NCT01979796|DEVICE|Ecig 0 mg nicotine|Cigalike
224116298|NCT01979796|DEVICE|Nicotine free inhalator|Plastic CIG a Like
224116299|NCT01445743|BIOLOGICAL|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
223974627|NCT06317259|BEHAVIORAL|Hypoxic breathwork plus music and messaging|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. The audio track also includes dynamic music that accompanies the different stages as well as positive messaging encouraging self-determination.
223974628|NCT06317259|BEHAVIORAL|Hypoxic breathwork only|Hypoxic breathwork consists of about 5 min of rhythmic breathing in a 4-in/4-out pattern followed by a breath hold on the exhale for about 1-2 min. This is repeated 1-2 times with increasing breath rate up to 2-in/2-out. Other than breathing instructions and pacing, the audio track is silent.
223974629|NCT06317259|BEHAVIORAL|Music and messaging meditation|Music and messaging meditation consists of dynamic music that is engaging and aids focus, as well as positive messaging encouraging self-determination.
223974630|NCT03127618|DRUG|Lorlatinib|
223974631|NCT04967677|DIAGNOSTIC_TEST|Nine Hole Peg Test, Purdue Pegboard Test, Box and Block Test|At first, each person will be asked to fill in the questionnaire. Than he/she will be tested by the Nine Hole Peg Test, Purdue Pegboard Test and the Box and Block Test according to the Czech version of extended manuals for those tests. Audio recording of verbal instructions will be used.
224293076|NCT05425641|BEHAVIORAL|Feedback on Behavior|"Individuals will receive daily text messages that include the Feedback behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Feedback BCT is Your goal is to walk 1000 steps more than your baseline average. Yesterday you did not meet your goal. If you think this is incorrect you can check your step count from yesterday on your Fitbit app to confirm. "
223543202|NCT03541278|PROCEDURE|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
223543203|NCT05255692|DIAGNOSTIC_TEST|invasive urodynamic evaluation|Invasive urodynamic evaluation to define maximum cystometric capacity. By means of catheterisation the bladder gets filled and volumes en pressures are measured.
223543204|NCT05255692|DIAGNOSTIC_TEST|functional magnetic resonance imaging during bladder filling|Functional MRI is used to capture brain activity during tasks. The task in the current study is bladder infusion and withdrawal by means of the INFSYS-2 infusion/withdrawal pump (Leitner et al. 2017)
223543205|NCT00003262|BIOLOGICAL|bleomycin sulfate|
223543206|NCT00003262|BIOLOGICAL|filgrastim|
223543207|NCT00003262|DRUG|Stanford V regimen|
223543208|NCT00003262|DRUG|doxorubicin hydrochloride|
223543209|NCT00003262|DRUG|epirubicin hydrochloride|
223543210|NCT00003262|DRUG|etoposide|
223543211|NCT00003262|DRUG|mechlorethamine hydrochloride|
223543212|NCT00003262|DRUG|prednisone|
223543213|NCT00003262|DRUG|vinblastine sulfate|
223543214|NCT00003262|DRUG|vincristine sulfate|
223543215|NCT03279887|DIAGNOSTIC_TEST|Lung Ultrasound|
223725421|NCT01980992|DRUG|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
223725422|NCT03018509|DRUG|JTE-451|Active drug tablets containing JTE-451
223725423|NCT03018509|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
223974632|NCT03658694|PROCEDURE|Conventional rTMS - study 1|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
223974633|NCT03658694|PROCEDURE|Sham rTMS - study 1|Patients will be undergoing to sham transcranial magnetic stimulation session
223974634|NCT03658694|PROCEDURE|Conventional rTMS - study 2|Patients will be undergoing to 10Hz transcranial magnetic stimulation session
223974635|NCT03658694|PROCEDURE|Patterned rTMS - stage 2|Patients will be undergoing to theta-burst transcranial magnetic stimulation session
224293077|NCT04075916|DRUG|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
223543216|NCT01605422|OTHER|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
223543217|NCT03186092|OTHER|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
223543218|NCT03186092|OTHER|sham muscle training|sham comparator
223543219|NCT04992026|PROCEDURE|robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection|Robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection will be performed.
223974636|NCT02270463|DRUG|Tagraxofusp-erzs|Tagraxofusp-Erzs administered by IV infusion at doses of 7, 9, and 12 µg/kg/day
223974637|NCT03579680|BEHAVIORAL|ADT ORDER CHECK ATTESTATION (OR)|Order restrictions (Or) operate as an organizational constraint, widely perceived as a forcing function giving providers little leeway to exercise judgment but have a strong evidence-base for changing provider behavior.
223974638|NCT03579680|BEHAVIORAL|PROVIDER SCRIPT (SC)|The provider script (Sc) is a communication aid to be used and documented as an accountable justification in the electronic medical record. This strategy also has a strong evidence-base for changing provider behavior.
223974639|NCT05589584|DRUG|N acetyl cysteine with weight reduction|high dose 2400mg/day
223974640|NCT02896153|OTHER|Questionnaire|
223974641|NCT05294328|DRUG|Aceclidine+Brimonidine combination ophthalmic solution|LNZ101-combination ophthalmic solution
223974642|NCT05294328|DRUG|Aceclidine ophthalmic solution|LNZ100- aceclidine ophthalmic solution
223974643|NCT05294328|DRUG|Vehicle Proprietary Ophthalmic Solution|Proprietary Vehicle Ophthalmic Solution
223974644|NCT00442026|DRUG|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
223974645|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
223974646|NCT00442026|DRUG|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
223543220|NCT04992026|DRUG|1.Abiraterone Acetate Tablets|1000mg(4 tablets, 250mg per tablet) daily for 6 cycles
223543221|NCT04992026|DRUG|Prednisone Acetate Tablets|5 mg oral low dose prednisone taken along with Abiraterone Acetate Tablets
223974647|NCT01319175|OTHER|Hip flexion strength training|
223974648|NCT05926232|DRUG|Repotrectinib|Repotrectinib
223974649|NCT04225234|OTHER|Financial incentives|"Depending on their level of participation or weight loss outcomes, participants will have the opportunity to receive between $60-$120 (over 12 months), on average, regardless of program assignment.~Regardless of which incentive program that participants are randomized to, they will receive the incentaHEALTH weight loss program intervention. incentaHEALTH is an technology-supported multi-component coaching intervention for weight loss includes a website, objective weight assessment using HIPAA-compliant kiosks, daily social cognitive theory-based email and text message support, and online access to health coaches. The intervention encourages increased intake of fruit, vegetables, lean protein, and complex carbohydrates while monitoring portion sizes."
224116300|NCT02772965|DRUG|Methotrexate|"1. Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to \<40 kg, and 10 mg for children 20 to \<30 kg.~2. A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
224116301|NCT02772965|OTHER|Sugar pill (placebo)|"1. Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~2. Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~3. A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
224116302|NCT05365620|DEVICE|Mechanical In-Line Inexsufflation|In-line mechanical inexsufflation (IL-MIE) is a new method for performing MIE in intubated patients, which overcomes the drawbacks of MIE for ICU use . IL-MIE devices are integrated in-line with the patient's ventilator circuit, and do not themselves perform insufflations. Rather, the regular inspiration provided by the ventilator serves as the insufflation phase of each simulated cough, and the IL-MIE device performs only exsufflation, timing the onset of each exsufflation to the beginning of passive exhalation. Figure 1 demonstrates the setup and mode of operation of an IL-MIE device. The concept of IL-MIE was first developed by one of the authors (EB) in the Department of Respiratory Rehabilitation of ALYN Hospital in Jerusalem, Israel.
224116303|NCT05365620|PROCEDURE|catheter suction|catheter suction is the standard, routine method for clearing secretions from the airway of a ventilated subject, by means of inserting a catheter into the endotracheal tube.
224116304|NCT05855928|DIAGNOSTIC_TEST|Mime Therapy|electrical stimulation with the MIME therapy and protocol
224116305|NCT05855928|DIAGNOSTIC_TEST|PNF Technique|electrical stimulation with the PNF technique with the routine physical therapy
223543222|NCT04992026|DRUG|Luteinizing Hormone-Releasing Hormone Analog|Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.
223543223|NCT03715725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
223543224|NCT03715725|DRUG|Apixaban (Eliquis)|Administration according to clinical practice
223543225|NCT03715725|DRUG|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
223974650|NCT02056873|DEVICE|Continuous DBS|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
223974651|NCT02056873|DEVICE|Responsive Brain Stimulation (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
223974652|NCT05327725|OTHER|Fatigue Reduction Diet|Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
223974653|NCT05089981|DRUG|N acetyl cysteine|Intravenous use of N acetyl cysteine in prescribed doses
223974654|NCT05089981|DRUG|Placebo of N acetyl cysteine|Intravenous Placebo of N Acetyl cysteine in look alike form (Normal saline)
223543226|NCT03715725|DRUG|Warfarin (Marevan)|Administration according to clinical practice
223974655|NCT02003690|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical Behavior Therapy
223543227|NCT05947916|DEVICE|Real-time Continuous Glucose Monitoring System|The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.
223543228|NCT02630069|DRUG|CDP-choline|CDP-choline 500mg once a day for 12 weeks
223543229|NCT02630069|DRUG|Placebo|Placebo 500mg once a day for 12 weeks
223543230|NCT02630069|BEHAVIORAL|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
223974656|NCT02003690|BEHAVIORAL|Standard of Care Psychotherapy|Standard of Care Psychotherapy
223974657|NCT02003690|OTHER|Pharmacotherapy|Standard of Care Pharmacotherapy
223543231|NCT00083460|DRUG|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
223543232|NCT00083460|DRUG|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
223543233|NCT00083460|DRUG|Dexamethasone|A dose of 20mg for cylces 3-8.
223543234|NCT05796258|DIAGNOSTIC_TEST|NTRK fusion assessment|To evaluate NTRK fusion presence by MCG, Immunohistochemistry or NGS
223725424|NCT05104229|DRUG|Aspirin 81Mg Ec Tab|Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
223974658|NCT03480919|DEVICE|Shen Men acupuncture|20-minute acupuncture session
223974659|NCT03480919|PROCEDURE|Epidural injection|Epidural injection for the relief of back pain
223974660|NCT02628964|DEVICE|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
223974661|NCT01704066|OTHER|Training and education|
223974662|NCT04243122|DRUG|Apixaban 2.5 MG Oral Tablet [ELIQUIS]|2.5mg twice per day for 6 months Then treated \& followed up as per standard of care
223974663|NCT04243122|DRUG|Aspirin 81 mg|81mg once per day for 6 months Then treated \& followed up as per standard of care
223725425|NCT05104229|DRUG|Standard of Care|Standard of Care VTE prophylaxis
223974664|NCT04860856|DRUG|0.5% ropivacaine|The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
223974665|NCT04860856|DRUG|Normal Saline|20ml of normal saline
223974666|NCT02137395|DRUG|Dexamethasone|dexamethasone administration, intravenously
223974667|NCT02137395|DRUG|Placebo|saline administration intravenously
223974668|NCT02752217|OTHER|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
223974669|NCT02752217|OTHER|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
223974670|NCT00196378|DRUG|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
223974671|NCT00196378|OTHER|Placebo|1 tablet daily
223974672|NCT00002721|DRUG|doxorubicin hydrochloride|
223974673|NCT00002721|DRUG|estramustine phosphate sodium|
223974674|NCT00002721|PROCEDURE|drug resistance inhibition treatment|
223974675|NCT02645539|DEVICE|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
223974676|NCT02450617|BEHAVIORAL|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
223974677|NCT02450617|BEHAVIORAL|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
223974678|NCT02450617|BEHAVIORAL|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
223974679|NCT05849324|DEVICE|Straight needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, straight needle is going to be used.
223974680|NCT05849324|DEVICE|Bent needle|Lumbar transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of lumbar radicular pain. During lumbar transforaminal epidural steroid injection, bent needle is going to be used.
223974681|NCT00120185|DRUG|Interleukin-2|
223974682|NCT00344253|DRUG|Interferon beta|
223974683|NCT00344253|DRUG|Methotrexate|
223974684|NCT03015870|BEHAVIORAL|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
223974685|NCT03015870|BEHAVIORAL|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
223974686|NCT01533558|DRUG|caspofungin|normal dosage for caspofungin, not adapted for the study
223974687|NCT00012636|PROCEDURE|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
223974688|NCT01145820|DIETARY_SUPPLEMENT|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
223974689|NCT00318786|DRUG|biphasic insulin aspart|
223974690|NCT00791297|DRUG|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
223974691|NCT01016223|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
223974692|NCT01016223|DRUG|placebo|Matched placebo swallowed two puffs twice daily
223974693|NCT04085705|DIAGNOSTIC_TEST|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
223974694|NCT01754532|BIOLOGICAL|Hair Sample|Analysis of hair cortisol levels
223974695|NCT05162196|RADIATION|SBRT|24Gy/3F
223974696|NCT05162196|DRUG|Toripalimab|Toripalimab 240mg, ivgtt, d1, q3w.
223974697|NCT05162196|DRUG|Niraparib|200mg qd
223974698|NCT04302649|DRUG|peritoneal dialysate at 37°C temperature|during a PET test, patients received peritoneal dialysate warmed at 37°C before infusion
223974699|NCT00113269|DRUG|basiliximab|IV
223974700|NCT00113269|DRUG|rabbit anti-thymocyte globulin|IV
223974701|NCT00113269|DRUG|tacrolimus|oral
223974702|NCT00113269|DRUG|alemtuzumab|Intravenous (IV)
223974703|NCT00113269|DRUG|mycophenolate mofetil|oral
223974704|NCT00113269|DRUG|steroids|IV and/or oral
223974705|NCT05052502|OTHER|Case Management and Follow-up|"Individuals will be told of their test result and a positive test result on either RDT will prompt treatment as per the national treatment guidelines.~* Individuals with P. falciparum infection will be treated with an age-appropriate course of dihydroartemisinin/piperaquine (DHAP) or artesunate-pyronaridine (Pyramax) and PQ.~* At all study sites in Thailand, patients with a P. vivax infection identified by the standard combination RDT will be tested by the VMV and Health Promotion Hospital (HPH) staff member using the quantitative G6PD RDT. G6PD normal individuals will be treated with Chloroquine (CQ) and a 14-day course of primaquine (PQ). G6PD deficient individuals will receive CQ alone and referred to the nearest health facility for further primaquine management decisions."
224116306|NCT05608317|DEVICE|ALLEVYN Non-Adhesive|"ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer"
224116307|NCT04054778|BEHAVIORAL|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
224293078|NCT05112965|DRUG|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study at the time of participant discontinuation from the parent study closure.
224293079|NCT05112965|DRUG|Bevacizumab|Bevacizumab will be administered as directed per the parent study.
224293080|NCT05112965|DRUG|Pemetrexed|Pemetrexed will be administered as directed per the parent study.
224293081|NCT05112965|DRUG|Paclitaxel|Paclitaxel will be administered as directed per the parent study.
224293082|NCT05112965|DRUG|Enzalutamide|Enzalutamide will be administered as directed per the parent study.
224293083|NCT00262470|DRUG|Acetazolamide|250 mg PO x 1
224293084|NCT00262470|DRUG|Atomoxetine|10-40 mg PO x 1 dose
224293085|NCT00262470|OTHER|NO Drug|No intervention - just monitoring
224293086|NCT00262470|DRUG|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
224293087|NCT00262470|DRUG|Entacapone|Entacapone 200-400 mg PO x 1 dose
224293088|NCT00262470|DRUG|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
224293089|NCT00262470|DRUG|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
224293090|NCT00262470|DRUG|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
224293091|NCT00262470|DRUG|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
224293092|NCT00262470|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
224293093|NCT00262470|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg PO x 1 dose
224293094|NCT00262470|DRUG|Midodrine|midodrine 2.5-10 mg PO x 1 dose
224293095|NCT00262470|DRUG|Modafinil|modafinil 100-200 mg PO x 1 dose
224293096|NCT00262470|DRUG|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
224293097|NCT00262470|RADIATION|Placebo|lactose tablet x 1 pill
224293098|NCT00262470|DRUG|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
224293099|NCT00262470|DRUG|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
224293100|NCT00262470|DRUG|Sertraline|sertraline 25-50 mg PO x 1 dose
224293101|NCT00262470|PROCEDURE|IV Saline|1 liter IV over 2 hours
224293102|NCT00262470|OTHER|Drinking Water|16 fluid ounces
224293103|NCT00262470|DEVICE|Breathing Device|Breathing through a dead space tube
224293104|NCT00262470|DRUG|memantine|memantine 5-20 mg PO x 1 dose
224293105|NCT00262470|DEVICE|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
224293106|NCT05421858|DRUG|Fosmanogepix|IV infusion
224293107|NCT05421858|DRUG|Fosmanogepix|Oral tablet
224293108|NCT05421858|DRUG|Caspofungin|IV infusion
224293109|NCT05421858|DRUG|Fluconazole|Fluconazole oral capsule
224293110|NCT05421858|DRUG|Placebo|Matching placebo for caspofungin (IV infusion)
224293111|NCT05421858|DRUG|Placebo|Matching placebo for fluconazole (oral capsule)
224293112|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (IV infusion)
224293113|NCT05421858|DRUG|Placebo|Matching placebo for fosmanogepix (oral tablet)
224293114|NCT06672510|DEVICE|ATC|The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute P
224293115|NCT05853367|DRUG|MK-0472|Oral Administration
224293116|NCT05853367|BIOLOGICAL|Pembrolizumab|IV infusion
224293117|NCT05853367|DRUG|MK-1084|Oral Administration
224293118|NCT05240898|DRUG|RO7623066|Administered orally in capsule
224293119|NCT05240898|DRUG|Olaparib|"Administered orally.~Dose levels and schedules will be selected based on integration of preclinical data as well as clinical PK, safety, efficacy, and PD/biomarker data (as appropriate) from the dose escalation cohorts."
224293120|NCT05240898|DRUG|Carboplatin|Administered intravenously.
224293121|NCT06976372|DRUG|AMG 133|AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.
223974706|NCT05052502|OTHER|Reactive focal mass drug administration (rfMDA)|"Reactive focal mass administration (rfMDA) will be implemented around the index case household and to forest co-workers/co-travelers in Thailand. The VMV will conduct the investigation visit within 7 days after the notification of the index case. All members of the index case's household as well as all members of the nearest five households around the index case's household, including temporary visitors will be invited to participate in the study and to be treated for malaria without a malaria test. After obtaining participants' or parents/guardians' consent, the VMV will proceed with the participant questionnaire, and all consenting household members will be tested for G6PD using the G6PD quantitative test prior to administration of antimalarials.~For rfMDA, all eligible participants will be offered artesunate-mefloquine (AS-MQ). Per national policy, a 14-day course of primaquine will be administered to G6PD non-deficient study participants."
224116308|NCT04054778|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
224116309|NCT03919916|PROCEDURE|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
224116310|NCT03919916|OTHER|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
224293122|NCT06649084|BEHAVIORAL|Multicomponent Lexical Retrieval Training (Multi-LRT)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing names of personally relevant target in multiple communication modalities. Treatment focuses on the use of strategies which capitalize on residual linguistic ability and autobiographical memory to support word retrieval. The participant completes two one-hour-long sessions per week plus daily homework. The participant also meets 4 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
223974707|NCT05812586|BIOLOGICAL|SCB-2019/Clover|SCB-2019/Clover Vaccine
223974708|NCT05812586|BIOLOGICAL|AstraZeneca/Fiocruz|AstraZeneca/Fiocruz Vaccine
223974709|NCT05812586|BIOLOGICAL|Pfizer/Wyeth|Pfizer/Wyeth Vaccine
223974710|NCT01796223|BEHAVIORAL|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
223974711|NCT01796223|BEHAVIORAL|Control|
223974712|NCT01317823|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
223974713|NCT01744743|PROCEDURE|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
223974714|NCT04289259|OTHER|TMB assessment|Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).
223974715|NCT01821729|DRUG|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
223974716|NCT01821729|DRUG|Losartan|Taken orally every day during Phase I for all 8 cycles
223974717|NCT01821729|RADIATION|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
223974718|NCT04278495|DRUG|Cozaar (Losartan Potassium 25mg)|Cozaar (Losartan Potassium 25mg)
223974719|NCT04278495|DRUG|Placebo|Placebo
223974720|NCT04813432|DIAGNOSTIC_TEST|Computed Tomography of the Abdomen|"Multi-phasic CT scan of the abdomen: 1 low dose unenhanced scan + 10 low dose arterial perfusion scans + 1 portal-venous phase scan + 1 delayed phase scan.~Bolus-tracking threshold in abdominal aorta = 160 HU. Delay of first arterial scan 5 sec after bolus-tracking threshold has been reached; and then 1 scan every 3 sec until 35 sec after threshold.~Contrast media (CM) protocol: fixed injection duration: 25 sec, body weight-adjusted CM volume: 750 mgI/kg bodyweight (max 80 kg women, 100kg men), Iomeron 400mgI/ml.~Image-reconstruction: Motion-correction, noise-reduction and fusion of the best arterial time points to reconstruct one optimally timed early and one optimally timed late arterial phase."
223974721|NCT06201871|DRUG|Lidocaine Hydrochloride|Patients will receive an inferior alveolar nerve block injection using 1.8 mL of 2% lidocaine with 1: 80 000 epinephrine using a direct Halsted approach.
224116311|NCT01477151|DRUG|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
223543235|NCT06199232|DRUG|HAIC+targeted therapy+PD-1 inhibitor|"HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w."
223543236|NCT00002811|DRUG|liposomal T4N5 lotion|
223543237|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose)|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
223543238|NCT05254236|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
223543239|NCT06026280|BEHAVIORAL|DRIVEN Application|Participants will complete the six-week DRIVEN program, which includes a smartphone application and job coaching.
223974722|NCT03441945|OTHER|magnetic steering|magnetic steering
223974723|NCT03120598|BEHAVIORAL|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
223974724|NCT03120598|BEHAVIORAL|ISF strategy|Implementation \& Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
223543240|NCT06026280|OTHER|Career Resources|Participants will receive weekly information about job-searching skills and resources from a study coordinator for six weeks.
223974725|NCT00467298|BEHAVIORAL|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
223974726|NCT00467298|BEHAVIORAL|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
223974727|NCT00467298|BEHAVIORAL|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
223974728|NCT01672398|OTHER|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
223974729|NCT00461643|DRUG|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
223974730|NCT01093599|BEHAVIORAL|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
223974731|NCT01093599|BEHAVIORAL|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
223974732|NCT01703845|DRUG|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
224116312|NCT03323229|DIAGNOSTIC_TEST|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
224116313|NCT00664092|OTHER|Residential|living in a democratic, resident-run setting
223974733|NCT01703845|DRUG|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
223974734|NCT01644188|DRUG|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
223974735|NCT01644188|DRUG|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
223974736|NCT01644188|DRUG|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
223974737|NCT01644188|DRUG|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
224116314|NCT00664092|OTHER|Residential|Professionally-run substance abuse recovery setting
224293123|NCT06649084|BEHAVIORAL|Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)|In person or via teletherapy: A multi-component treatment incorporating elements of restitutive, compensatory, and care-partner focused interventions. Participants work on producing personally relevant scripts of 3-5 sentences in length. Length and complexity of scripts are individually tailored. The participant completes 30 minutes per day of home practice, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts. Biweekly (one hour each) sessions with a clinician are held which target clear and accurate script production, script memorization, and conversational usage of the script and multimodal communication. The participant also meets 6 times during the course of treatment with a study partner (e.g., spouse) for communication counseling, education, and practice of communication strategies.
223974738|NCT01644188|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
223974739|NCT01087749|DRUG|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
223974740|NCT01087749|DRUG|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
224116315|NCT04339569|DIAGNOSTIC_TEST|Biomechanical analysis|3D analysis of landing manoeuvres.
223543241|NCT05554302|DRUG|18F-Fluciclovine|Patients will receive 5-mCi dose (+/- 20%) of 18F-Fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-Fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-Fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
223543242|NCT05018689|OTHER|Aevidum curriculum|The Aevidum curriculum will be delivered to 9th grade students at participating high schools in both study arms. All school staff who plan to deliver the curriculum will participate in a web-based training workshop with the Aevidum Executive Director.
223725426|NCT06354400|OTHER|Core stabilization training|Isometric exercises of the abdominal muscles in the supine, prone, and squatting positions; isotonic exercises in the supine, prone, squatting, and side-lying positions; isotonic exercises in coordination with the extremity movements in the supine, prone, and crawling positions; and trunk rotation exercises in the sitting position will be performed. The Swiss ball will be used for dynamic exercises. It will include isometric and isotonic exercises of the abdominal muscles. Exercises will start with 3 sets of 20 repetitions, gradually increase in intensity on static and dynamic surfaces, and progress towards difficulty. Each exercise will be performed in coordination with breathing control. Breathing control will be coordinated with every exercise.
223974741|NCT01087749|DRUG|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
223974742|NCT05827770|DRUG|Toripalimab combined with Temozolomide|Toripalimab combined with Temozolomide
224116316|NCT04339569|OTHER|Fatigue protocol|A circuit of different tasks (e.g. jumping, sprinting forward and backward, side-stepping exercise) was performed to induce fatigue.
224116317|NCT01228266|BIOLOGICAL|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
224116318|NCT02685384|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
224116319|NCT02254668|OTHER|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
224116320|NCT02254668|OTHER|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
224116321|NCT02322892|DRUG|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
223974743|NCT05651113|OTHER|SCID Screening|The addition of newborn bloodspot screening for severe combined immunodeficiency
223974744|NCT05076188|DIAGNOSTIC_TEST|Emergency radiography|The intervention is to determine how the radiographer classify emergency radiography.
223974745|NCT02028247|BEHAVIORAL|Personalized Cognitive-behavioral therapy|
223974746|NCT02028247|BEHAVIORAL|Standard Practice Cognitive-behavioral therapy|
223974747|NCT02028247|BEHAVIORAL|Treatment as Usual|
223974748|NCT06546358|DRUG|Trazodone|Participants will be randomized to receive either quetiapine or trazodone.
223974749|NCT06546358|DRUG|Quetiapine|Participants will be randomized to receive either quetiapine or trazodone.
223974750|NCT05411874|DRUG|Chidamide|5mg po biw for 24 weeks
223974751|NCT05411874|DRUG|HD-DXM|40mg po qd for 4days
223974752|NCT00966979|DEVICE|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
223974753|NCT00092326|DRUG|MK0966, rofecoxib|
223974754|NCT00092326|DRUG|Comparator: oxycodone with acetaminophen, placebo|
224116322|NCT02322892|DRUG|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
224116323|NCT03802838|DEVICE|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
224116324|NCT03802838|DRUG|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
224116325|NCT03478878|DRUG|Vitamin A Palmitate|Provide vitamin A to participants with pre/post assessments of vision.
224116326|NCT00943293|DRUG|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
223974755|NCT02993536|OTHER|Biospecimen Collection|
224116327|NCT00943293|DRUG|Melphalan|Melphalan 140 mg/m2 IV on day -2.
224116328|NCT00943293|DRUG|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
223974756|NCT04735783|DIETARY_SUPPLEMENT|Placebo breakfast|Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.
224293124|NCT06649084|BEHAVIORAL|Multicomponent Communication Partner Training (Multi-CPT)|In person or via teletherapy: A multi-component treatment incorporating elements of compensatory and care-partner focused interventions. Biweekly (one hour each) sessions with a clinician are held which target use of communication strategies including multimodal communication for the participant and study partner (e.g., spouse). The participant also completes regular assignments meant to increase generalization of communication strategies and progress on personal goals.
224293125|NCT05611450|OTHER|disease self-management application|The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
224293126|NCT04934150|DEVICE|navigated repetitive Transcranial Stimulation|High frequency nrTMS over 13 sessions (1800-2000 pulses per session) over DLPFC and M1 cortical areas.
224293127|NCT05039619|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
223543243|NCT05018689|OTHER|Club|Schools will identify ten students interested in participating in an Aevidum club. Following training of interested students, schools are asked to commit to running two Aevidum club activities during the school year.
223725427|NCT03296358|DRUG|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
223974757|NCT04735783|DIETARY_SUPPLEMENT|Typical whole-food breakfast|Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.
223974758|NCT04735783|DIETARY_SUPPLEMENT|Water-only control|Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
224293128|NCT05039619|DRUG|Placebo|Placebo matching obinutuzumab will be administered by IV on Day 1, Day 14, Week 24, Week 26 and Week 52.
223725428|NCT03296358|DRUG|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
223974759|NCT02718547|DRUG|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
223974760|NCT00636480|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
223974761|NCT00636480|DRUG|ChloraPrep One Step|Administer topically
223974762|NCT00636480|DRUG|Sterile saline|0.9% NaCl solution
223974763|NCT01542554|OTHER|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
223974764|NCT01542554|OTHER|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
223974765|NCT04140266|DRUG|Dapivirine (DPV) Vaginal Ring (VR)-004|Vaginal ring containing 25 mg of DPV
223974766|NCT04140266|DRUG|Truvada Tablet|Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
223974767|NCT02024659|DRUG|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
224116329|NCT01345877|PROCEDURE|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
224116330|NCT01570400|BEHAVIORAL|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
223974768|NCT02024659|OTHER|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
223974769|NCT04924088|BEHAVIORAL|Medical-legal partnership|Treatment group will receive the MLP intervention through the Connecticut Veterans Legal Center in partnership with the VA Connecticut Healthcare System. The MLP intervention can be categorized into seven activity components: initial in-person and subsequent in-person interviews; discussions with clients by phone; research and review of relevant documents; consultations with clinicians or other attorneys; interactions with opposing parties; time appearing at formal hearings; and travel time.
223974770|NCT04924088|BEHAVIORAL|Referral to pro-bono lawyer|Control group will receive outside legal aid, i.e., control participants will be referred to pro-bono lawyers in the state.
224116331|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
223725429|NCT01599767|DEVICE|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
223974771|NCT05431998|PROCEDURE|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement|the use of demineralized autogenous tooth graft in the jumping gap during immediate implant placement
223974772|NCT05431998|PROCEDURE|the use of autogenous bone graft in the jumping gap during immediate implant placement|the use of autogenous bone graft in the jumping gap during immediate implant placement
223974773|NCT01318317|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
223974774|NCT01318317|BIOLOGICAL|Filgrastim|Given IV
223974775|NCT01318317|BIOLOGICAL|Genetically Engineered Lymphocyte Therapy|Receive ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR
223974776|NCT01318317|OTHER|Laboratory Biomarker Analysis|Correlative studies
223974777|NCT01318317|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
223974778|NCT01318317|DRUG|Plerixafor|Given IV
223974779|NCT01318317|BIOLOGICAL|Rituximab|Given IV
223974780|NCT04234945|DRUG|Doxycycline Capsule|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding.
223974781|NCT04234945|DRUG|Multivitamins W/Iron Tab|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7. She will be instructed to commence the medication on day 7 of her next menstrual cycle and hysterosalpingogram will be done within the proliferative phase (Day 10) of the same menstrual cycle after cessation of bleeding
223974782|NCT06784310|BEHAVIORAL|Medically Tailored Meals|Dare to Care will provide meals each week for 12 weeks tailored for comorbidities. Meals will be provided to both the adult and the child(ren). Meals have been developed with a Registered Dietitian and have been approved through Food Is Medicine Coalition (FMIC). Meals are delivered via Door Dash each week.
224116332|NCT01570400|BEHAVIORAL|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (\< or \>) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
224116333|NCT05443672|DEVICE|Yizhun BUSMS|During the breast scanning, Yizhun BUSMS uses different color box to identify the breast lesion, and the box color indicates the risk grade of the lesion.
224293129|NCT05039619|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
223725430|NCT05984966|BEHAVIORAL|Supported Employment|PeerC2T is part of a supported employment program where PWID are trained and supported to provide PWID with job skills to be able to act as Peer Health Worker to facilitate distribution of rapid SARS-CoV-2 testing to other PWID. The effect of the training on the Peer Health Worker themself will be evaluated (Aim 1). In addition, in Aim 2 they will distribute the rapid test kits in places of residence such as tents, shelters, apartments, trailers, or houses or locations where other PWID frequently engage with services such as syringe exchange. The kit is the BinaxNOW COVID-19 Antigen Self Test, which is approved to be used as a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. PWID community members will be offered a free test kit, and the Peer Health Worker will record whether the community member elected to take the test (yes/no), and they will also collect administrative demographic data on the PWID.
223974783|NCT06784310|BEHAVIORAL|Grocery Prescription|Instacart Fresh Funds (for those that need delivery) or Kroger Grocery Rx cards will be issued to each participant per month to be spent on eligible healthy food items (lean protein, lean dairy, fruits, vegetables, eggs, and nuts). For each participating child in the household, they will receive additional funds/per child loaded on their grocery Rx card
223974784|NCT06784310|BEHAVIORAL|Medically Tailored Meals and Grocery Prescription|will receive both tailored MTM meals per week for adult and child(ren) and the GP monthly grocery funds
223974785|NCT06784310|BEHAVIORAL|Nutritional Counseling|30 minutes per week of nutrition counseling and assistance.
223974786|NCT03378037|PROCEDURE|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
223974787|NCT05835076|DIAGNOSTIC_TEST|Stool antigen test|Antigen test in the stool analysis
223974788|NCT01050387|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
223974789|NCT06308731|DIETARY_SUPPLEMENT|Caffeine-Based Energy Drink|Energy drink with 200 mg caffeine
223974790|NCT06308731|OTHER|Placebo|Placebo
224293130|NCT05039619|DRUG|Acetaminophen/paracetamol|Acetaminophen 1000 mg will be administered as pre-medication prior to infusions.
224293131|NCT05039619|DRUG|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
223725431|NCT03500952|OTHER|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
223974791|NCT05484895|BEHAVIORAL|WeTest-WeLink|"WeTest-WeLink application on the WeChat platform provides videos on HIV self-testing and linkage to care; informational articles on HIV, sexually transmitted infections (STI), testing, antiviral treatment (ART), and care; online behavioral self-assessments; linkage to providers; local data reports; stories about coping, wellness, and social support; two-way communication with NGO; and free, additional HST."
223974792|NCT05484895|BEHAVIORAL|Control condition|Contact information of local NGO for emergency referrals; free additional HST.
223974793|NCT04782700|OTHER|Steroid Taper (Prednisone)|The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
223974794|NCT01307917|DIETARY_SUPPLEMENT|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
223974795|NCT02750553|DRUG|SHR0534|
223974796|NCT02750553|DRUG|Placebo|
223974797|NCT05540418|OTHER|lavender oil inhalation|Two drops of lavender (2%) essential oil were dripped onto a 2 x 2 cm cotton gauze cloth attached to the front of the clothes of the experimental group patients, approximately 12 inches below their noses. They were asked to inhale 2% lavender essential oil for 20 minutes. They were directed to breathe normally after inhalation. Vital signs of the patients were checked before and after the procedure. After the process, the forms were filled again, the final test process was completed.
223974798|NCT04018885|DRUG|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
223974799|NCT04018885|DRUG|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
223725432|NCT03500952|OTHER|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
223725433|NCT02637739|DEVICE|hysteroscope|Women of PUL with β-hCG \> 1000 IU/L or abnormal β-hCG trend (increase \< 66% or decrease \< 15%) were offered HSC.
223974800|NCT04018885|DRUG|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
223974801|NCT05493228|DRUG|Precedex Injectable Product|Precedex activates 2-adrenoceptors, and causes the decrease of sympathetic tone, with attenuation of the neuroendocrine and hemodynamic responses to anesthesia and surgery; it reduces anesthetic and opioid requirements; and causes sedation and analgesia. it is used before and/or during surgical
223974802|NCT05493228|DRUG|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
224116334|NCT02125331|PROCEDURE|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
224116335|NCT02159391|BEHAVIORAL|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
224116336|NCT05528003|PROCEDURE|Commercialized single-access port devices|Two kinds of commercialized single-access port devices were used.
224293132|NCT05039619|DRUG|Methylprednisolone|Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
223974803|NCT03171532|PROCEDURE|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
223974804|NCT03119688|OTHER|Test Product|Micellar cleanser (0.09 ml)
223974805|NCT03119688|OTHER|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
223974806|NCT03119688|OTHER|Reference Product|Sterile Water (0.09 ml)
223974807|NCT03119688|OTHER|No Treatment|Unwashed area of the forearm
223974808|NCT05188547|DEVICE|Video education|Participants will be shown a video educating them on anesthesia and perioperative instructions.
224116337|NCT06848153|OTHER|Plantar Vibration|The patients in the study group will receive plantar vibration intervention with a frequency of 100 Hz on the affected plantar region for 30 minutes each day over 3 consecutive days.
223974809|NCT03692689|BIOLOGICAL|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
223974810|NCT02446379|DRUG|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
223974811|NCT02446379|DEVICE|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
223974812|NCT02446379|DEVICE|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
223974813|NCT03433183|DRUG|Selumetinib|Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
224116338|NCT06848153|OTHER|Placebo Plantar Vibration|The patients in the placebo group will receive placebo plantar vibration intervention with a frequency of 100 Hz on the affected plantar region, without touching the skin, for 30 minutes each day over 3 consecutive days.
224116339|NCT05627934|DIAGNOSTIC_TEST|qICG|Evaluation of bowel fluorescence by pixel software, qICG
224116340|NCT05336266|DRUG|Ketorolac Tromethamine|Trial treatment of ketorolac 10mg orally four times a day for 5 consecutive days
224116341|NCT03867669|OTHER|Open Bay Unit|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
223725434|NCT02602496|OTHER|Fruits and Vegetables|5 servings of fruits or vegetables
223725435|NCT02602496|OTHER|Whole Grain|3 servings of whole grain
223974814|NCT03433183|DRUG|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
223974815|NCT00629317|OTHER|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
223974816|NCT00629317|DRUG|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
224116342|NCT03867669|OTHER|Single patient room|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
224116343|NCT00873769|DRUG|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
223725436|NCT02602496|OTHER|Control|3 servings of refined grain
223974817|NCT04648111|DIAGNOSTIC_TEST|Vital sign measurement|Vital signs measurement will be obtained by the research staff using hospital standard medical devices and the Anura Research App will also be used to measure vital signs. Measurement will take place before surgery and post surgery (1 ±2hrs and 2 ±4hrs after surgery).
224116344|NCT03785886|BEHAVIORAL|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
224116345|NCT03785886|BEHAVIORAL|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
223725437|NCT05965154|DRUG|Carrilizumab, bevacizumab,capecitabine|"1. Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~2. Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~3. Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment."
223974818|NCT03823274|DRUG|Aspirin, Clopidogrel|to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
223974819|NCT01649557|DRUG|OPC-34712|oral administered once daily
223974820|NCT04361968|OTHER|Animal-assisted placebo condition|Participants receive the same verbal information as in the Placebo condition. Additionally, participants will receive the same verbal information as in the Dog only condition.
224293133|NCT05039619|DRUG|Prednisone|Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
223725438|NCT05025241|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
223974821|NCT04361968|OTHER|Placebo condition|"Participants receive verbal information that they are receiving an analgesic cream (i.e. Antidolor, containing Lidocain), which has been shown to produce significant pain reduction in previous clinical trials. However, they will receive an inert cream."
223974822|NCT04361968|OTHER|Dog only condition|"Participants will get a therapeutic rationale for the presence of the dog. The rationale is supported in the literature and therefore not invented for the purpose of this study. Participants will be told that: Studies have shown the presence of an animal can affect pain perception because the presence and the interaction with an animal can increase our Oxytocin level. Therefore, the investigators want to examine if the presence of a dog has an impact on your pain perception. While participants have to wait for the action time of the cream they are allowed to pet the dog. The intensity of interaction will be documented and be rated on a scale from 1-5 (1=very low degree of interaction, 5=very high degree of interaction). During the experiment the dog will be lying in the room with some distance to participants to avoid further physical interaction. The dog will always be lying at the same spot. Participants will still be able to see the dog."
224116346|NCT03785886|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
223725439|NCT05510804|COMBINATION_PRODUCT|ALISA|assisted self-help smartphone application featuring virtual reality within a structured CBT programme / low-frequency scheduled therapist assistance
223725440|NCT06158594|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
223725441|NCT03981211|DRUG|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
223974823|NCT04361968|OTHER|Control Condition|Participants in this condition will receive no intervention. All instructions will be conveyed in a standardized manner to ensure that the participant-experimenter relationship is comparable in terms of friendliness and attention across all four conditions.
224116347|NCT02309164|PROCEDURE|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
223725442|NCT03981211|DRUG|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
223725443|NCT06359067|OTHER|Treated by bispecific antibodies, teclistamab or elranatamab in usual care|Treated by bispecific antibodies, teclistamab or elranatamab in usual care
223725444|NCT06359067|OTHER|Not treated by bispecific antibodies in usual care|Not treated by bispecific antibodies in usual care
223725445|NCT04069494|OTHER|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
223725446|NCT04921371|OTHER|Colgate® Cavity Protection Toothpaste|Participants will use Colgate® Cavity protection toothpaste for brushing teeth twice daily.
223725447|NCT04921371|OTHER|Listerine® Cool Mint®|Participants will use 20 mL of Listerine® Cool Mint® mouth rinse for 30 seconds after brushing twice daily.
223725448|NCT04921371|OTHER|Concept Curve Winter Series Toothbrush|Participants will brush twice daily for 1 minute with the toothpaste and soft bristled toothbrush provided.
223725449|NCT04921371|OTHER|5% Hydroalcohol Mouthrinse|Participants will use 20 mL of 5% Hydroalcohol Mouthrinse for 30 seconds after brushing twice daily.
223974824|NCT02444351|DRUG|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
223974825|NCT02444351|OTHER|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
223974826|NCT06478134|DRUG|Trimix tear substitutes|Patients were instructed to instill 1 drop of TriMix tear substitute into each eye 3 times per day for 6 months.
224116348|NCT02309164|BEHAVIORAL|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
223725450|NCT04921371|OTHER|Mouthrinse Prototype 1|Participants will use 20 mL of Mouthrinse Prototype 1 for 30 seconds after brushing twice daily.
223725451|NCT04921371|OTHER|Mouthrinse Prototype 2|Participants will use 20 mL of Mouthrinse Prototype 2 for 30 seconds after brushing twice daily.
223725452|NCT03091634|DRUG|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
223725453|NCT03091634|DRUG|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
223725454|NCT01318304|OTHER|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
223725455|NCT03128554|OTHER|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
223725456|NCT05113472|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Patients who were administered any dose of the Pfizer-BioNTech COVID-19 vaccine.
223725457|NCT01619774|DRUG|GSK2118436|Starting dose 150 mg by mouth twice a day.
223725458|NCT01619774|DRUG|GSK1120212|2 mg by mouth daily.
223725459|NCT00426907|PROCEDURE|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
223725460|NCT01115634|BIOLOGICAL|Fibroblast|20 million cell in three injection
223725461|NCT01115634|BIOLOGICAL|fibroblast and gel|20 million cell in three injection plus filler
224293134|NCT05132361|DEVICE|SELUTION SLR™ 018 DEB|a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
223725462|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
223725463|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
223725464|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
223725465|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
223725466|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
223974827|NCT06478134|DRUG|Hyaluronic acid tear substitute|Patients were instructed to instill 1 drop of 0.15% HA tear substitute into each eye 3 times per day for 6 months.
223974828|NCT00870532|DRUG|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
223974829|NCT00870532|DRUG|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
223974830|NCT00715637|DRUG|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
224293135|NCT05132361|DEVICE|Plain (Uncoated) Balloon Angioplasty (PTA)|a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up above the-knee arteries that have been narrowed due to peripheral arterial disease.
223725467|NCT02603419|DRUG|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
223725468|NCT01092104|DRUG|TBR-652|TBR-652 25 mg
223725469|NCT01092104|DRUG|TBR-652 Matching Placebo|Matching Placebo
223725470|NCT01092104|DRUG|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
223725471|NCT01092104|DRUG|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
223725472|NCT01092104|DRUG|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
223725473|NCT01092104|DRUG|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
223725474|NCT03537898|OTHER|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
223725475|NCT03537898|OTHER|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
223725476|NCT02231723|DRUG|BBI608|Administered continuously twice daily with doses separated by 12 hours
223725477|NCT02231723|DRUG|Nab-paclitaxel|Nab-paclitaxel 125 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
223725478|NCT02231723|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
223974831|NCT00715637|DRUG|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
223974832|NCT00286962|DEVICE|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
223974833|NCT00286962|DEVICE|continuous subcutaneous insulin infusion (CSII) or MDI|
223974834|NCT02335333|OTHER|No treatment|
223974835|NCT03097302|PROCEDURE|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
223974836|NCT05668442|BEHAVIORAL|Online exercise and group meetings|"The intervention consists of 8 weeks of 30 minutes of online supervised high intensity physical exercise followed by 30 minutes of online group meeting once a week in Microsoft Teams. The program consist of a short warm-up, followed by interval.-based physical activity including bodyweight aerobic and strength training, followed by stretching.~Following the online exercise session, participants will be sent out in smaller break-out rooms in Microsoft Teams. The online group meeting sessions are intended to serve as a platform for group discussion evaluation of weekly physical acitvity.~Each online group will be facilitated by a participant. All participants will be encouraged to set physical activity goals to increase habitual physical activity As a part of the intervention, participants will wear a Garmin Vivofit 4 activity watch or a Garmin 245 watch."
223974837|NCT03317899|PROCEDURE|Hematopoietic Cell Transplantation|Undergo auto HSCT
223974838|NCT03317899|DRUG|Tbo-filgrastim|Given subcutaneously
223974839|NCT03317899|OTHER|Laboratory Biomarker Analysis|Correlative Studies
223974840|NCT01091844|PROCEDURE|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
223974841|NCT02747121|BEHAVIORAL|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
223974842|NCT00042302|PROCEDURE|Chemotherapy|
223974843|NCT00042302|DRUG|tariquidar + paclitaxel/carboplatin|
223974844|NCT00042302|DRUG|placebo + paclitaxel/carboplatin|
223974845|NCT03029234|DRUG|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
223974846|NCT03029234|DRUG|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
223974847|NCT03638401|PROCEDURE|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
223974848|NCT02812628|PROCEDURE|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
223974849|NCT02812628|PROCEDURE|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
223974850|NCT06407947|DRUG|Chimeric antigen receptor modified T cells Infusion|chimeric antigen receptor T cells
223974851|NCT02324309|DRUG|BIOD-531|
223974852|NCT02324309|DRUG|Humalog Mix 75/25|
223974853|NCT02324309|DRUG|Humulin R U-500|
223974854|NCT02324309|DRUG|BIOD-531|
223974855|NCT01359514|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
224293136|NCT05420012|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
223725479|NCT02231723|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
223725480|NCT02231723|DRUG|Leucovorin|Arm C, D: Leucovorin 400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
223725481|NCT02231723|DRUG|Irinotecan|Arm B: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
223725482|NCT02231723|DRUG|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m\^2 I.V. bolus followed by 2400 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
223725483|NCT02231723|DRUG|MM-398|MM-398 70 mg/m\^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
223725484|NCT01233440|BIOLOGICAL|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
223725485|NCT01233440|BIOLOGICAL|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
223725486|NCT03008681|DEVICE|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
223725487|NCT01709890|DEVICE|YO2(R) catheter|
223974856|NCT01359514|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
223974857|NCT01165502|DRUG|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
223974858|NCT01165502|DRUG|Placebo|Placebo for compound CM3.1-AC100 s.c.
223974859|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
223974860|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
223974861|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
223974862|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
223974863|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
223974864|NCT01649297|DRUG|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
223974865|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
223974866|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
223974867|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
223974868|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
223974869|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
223974870|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
224116349|NCT03009539|BEHAVIORAL|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
224116350|NCT03151148|BIOLOGICAL|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
223725488|NCT02214524|DEVICE|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
223974871|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
223974872|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
223974873|NCT01649297|DRUG|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
223974874|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
223974875|NCT01649297|DRUG|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
223974876|NCT01649297|DRUG|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
223974877|NCT01649297|DRUG|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
224116351|NCT03151148|DRUG|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
224116352|NCT01986218|DRUG|BMS-986115|
224116353|NCT00710034|OTHER|Oral tobacco|Snus
224116354|NCT00710034|DRUG|Nicotine Gum|4 mg Nicotine gum
223974878|NCT01649297|DRUG|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
224116355|NCT00482872|GENETIC|gene expression analysis|
224116356|NCT00482872|GENETIC|mutation analysis|
223974879|NCT04995406|DIAGNOSTIC_TEST|ISIT-TB prototype|Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour
223974880|NCT02413554|DRUG|Rivastigmine patch|acetylcholine esterase inhibitor
223974881|NCT03230110|DIAGNOSTIC_TEST|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
223974882|NCT05009147|OTHER|Home-based massage by caregivers for dementia|A total of 40 patients with dementia and their family caregivers will be included and randomly allocated to experiment (n=20) or control group (n=20). The experiment and control group will receive whole body manual massage and placebo intervention (30 minutes once per week for 8 continuous weeks), respectively.
223974883|NCT00507975|DRUG|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
223974884|NCT01839383|OTHER|different dialysate calcium concentration|
223974885|NCT00465478|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
223974886|NCT03228654|PROCEDURE|Unipolar Electrocautery sealing of vessels|"1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
223974887|NCT03228654|PROCEDURE|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
224116357|NCT00482872|GENETIC|polymerase chain reaction|
224116358|NCT00482872|GENETIC|polymorphism analysis|
224116359|NCT00482872|OTHER|flow cytometry|
224116360|NCT00482872|OTHER|laboratory biomarker analysis|
224116361|NCT04710524|DRUG|Placebo|Placebo BID for 13 weeks
224116362|NCT04710524|DRUG|FM101 150 mg BID|FM101 (150 mg) BID for 13 weeks
224116363|NCT04710524|DRUG|FM101 300 mg BID|FM101 (300 mg) BID for 13 weeks
224116364|NCT05239897|DEVICE|Continuous theta burst stimulation (cTBS)|Patients assessed for postoperative delirium will be treated by consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions.
223974888|NCT05908578|OTHER|High Frequency Exercise Training|Two sessions per week of high-intensity interval training (30 min each) and two sessions per week of continuous endurance exercise (30 min each). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
224116365|NCT03338751|DIAGNOSTIC_TEST|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
223974889|NCT05908578|OTHER|Low Frequency Exercise Training|One session per week of high-intensity interval training (60 min) and one session per week of continuous endurance exercise (60 min). All exercise sessions will be performed on a stationary bike under supervision by an investigator.
223974890|NCT00540384|DRUG|Placebo|Placebo
223974891|NCT00540384|DRUG|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
224116366|NCT03338751|DIAGNOSTIC_TEST|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
224116367|NCT00494871|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
223974892|NCT02778334|OTHER|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
223974893|NCT01529541|DRUG|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
223974894|NCT01529541|DRUG|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
223974895|NCT05452421|DIETARY_SUPPLEMENT|Isotonic carbohydrate beetroot juice drink|An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.
223974896|NCT05452421|DIETARY_SUPPLEMENT|Beetroot juice drink|A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
223974897|NCT00282698|DRUG|Insulin infusion with a goal|
223974898|NCT02544113|DRUG|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
223974899|NCT02544113|DRUG|Placebo|Normal transplant immunosuppression
223974900|NCT06379555|PROCEDURE|Walanpoigne|Intervention will combine WALANT anesthesia with arthroscopy to reduce a joint fracture of the wrist
223974901|NCT00317759|BIOLOGICAL|therapeutic autologous lymphocytes|
223974902|NCT00317759|DRUG|fludarabine phosphate|
223974903|NCT01750177|BEHAVIORAL|Television Viewing before mealtime|
223974904|NCT01750177|BEHAVIORAL|Video Game Playing|
223974905|NCT01750177|BEHAVIORAL|Computer Use|
223974906|NCT01750177|BEHAVIORAL|Sitting quietly|
223974907|NCT04205214|BEHAVIORAL|Integrative Cognitive Behavioural Therapy|This intervention involves the psychological intervention of Cognitive Behavioural Therapy. This intervention also includes third wave psychological interventions of Mindfulness and Narrative Therapy which has been found to be helpful for people with chronic health conditions and chronic skin conditions.
223974908|NCT06259513|PROCEDURE|omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO|Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
223974909|NCT02950714|OTHER|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
223974910|NCT02950714|OTHER|LIN_WAIT|Usual care for three months prior to access to the LIN
223974911|NCT00902226|DRUG|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
223974912|NCT01661530|DIETARY_SUPPLEMENT|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
223974913|NCT01661530|DIETARY_SUPPLEMENT|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
223974914|NCT01457833|DEVICE|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
224116368|NCT00494871|DRUG|Warfarin|Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
223974915|NCT01457833|DEVICE|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
223974916|NCT02847637|DRUG|Emicizumab|Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
223974917|NCT02847637|DRUG|Factor VIII (FVIII)|FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
223974918|NCT02648113|PROCEDURE|Restrictive transfusion|Transfusions are withheld unless Hb is \<= 8 g/dL, with a target Hb of 8 to 10 g /dL
223974919|NCT02648113|PROCEDURE|Liberal transfusion|transfusions are allowed as soon as Hb \<= 10 g/dL with a target of 11 g /dL
223974920|NCT02648113|BIOLOGICAL|red blood transfusion|
223974921|NCT04435405|OTHER|Observational|video footage analysis of group and individual behavioral processes.
223725489|NCT04334161|COMBINATION_PRODUCT|Administration of glucose and controlled induction of hypoglycaemia.|Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
223725490|NCT04081974|OTHER|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
223725491|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron)|Ferrous fumarate syrup 2.5ml/70mg (22.5mg elemental iron) daily for 8 weeks (N=10).
223974922|NCT03742817|OTHER|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
223725492|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg(45mg elemental iron)|Ferrous fumarate syrup 5ml/140mg (45mg elemental iron) daily for 8 weeks (N=10).
223974923|NCT05908305|DRUG|articaine@ (4% 1:100000 epinephrine) dental anesthesia|Administration, calculation and adjustment of dental local anesthesia doses.
223725493|NCT06321887|DRUG|Ferrous fumarate syrup 2.5ml/70mg (90mg elemental iron)|Ferrous fumarate syrup 5ml/140mg twice daily (90mg elemental iron) for 8 weeks (N=10).
223974924|NCT04177628|BEHAVIORAL|Shared decision making supported by an in-consultation patient decision aid|After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
223974925|NCT00026013|DRUG|hypericum perforatum|
223974926|NCT06354192|BEHAVIORAL|Precision Nudging for Hypertension Management|The hypertension digital health intervention under study combines behavioral science theory with a type of machine learning called reinforcement learning to enable precision nudging: the selection, assembly, and delivery of behavioral science-based messages created to address barriers to, and promote, management of hypertension. The behavioral design process used for the hypertension DHI intentionally includes research on traditionally underserved populations, such as racial and ethnic minorities and people with lower incomes or educational attainment. By including the right ingredients to meet a diverse set of needs and by effectively personalizing the content each individual sees based on their own reactions, the intervention aims to improve health equity by matching each individual to the right behavioral approach.
223974927|NCT06050018|OTHER|YesMilkdiet|In the YesMilkdiet the participants will consume Milk and dairy products
223974928|NCT06050018|OTHER|NoMilkdiet|In the NoMilkdiet the participants will not consume milk or dairy products only another sources of proteins
223974929|NCT04232800|DRUG|Riboflavin|The intervention will consist of 100mg riboflavin (vitamin B2) given in three time daily dosing.
223974930|NCT04232800|OTHER|Placebo|An inert, standard placebo in identical capsules to primary intervention.
223725494|NCT02152033|BEHAVIORAL|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
223974931|NCT04765553|DRUG|NI-0501|emapalumab single i.v infusion (1 mg/kg)
223974932|NCT04765553|DRUG|Saline|Saline single i.v infusion
223974933|NCT03106298|DRUG|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
223974934|NCT01746108|BIOLOGICAL|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
223974935|NCT01328808|DRUG|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
223974936|NCT02690415|PROCEDURE|Antibiotics Given|Patients who's treating physician prescribed antibiotics
223974937|NCT02690415|PROCEDURE|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
223974938|NCT02685007|OTHER|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
223974939|NCT00169585|DRUG|Levofloxacin oral tablets|
224116369|NCT00494871|DRUG|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
224116370|NCT00494871|DRUG|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
224116371|NCT06123208|OTHER|Whole cooked pinto bean|Meal comprised of whole cooked pinto beans
224116372|NCT06123208|OTHER|Pinto bean flour|Meal comprised of pinto bean flour
223725495|NCT02152033|BEHAVIORAL|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
223725496|NCT02850965|DRUG|BI 695501|
223725497|NCT02850965|DRUG|Humira|
223725498|NCT03682666|DEVICE|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
223974940|NCT01887990|DRUG|Ketamine|single dose IV 0.2 mg/kg ketamine
223974941|NCT01887990|DRUG|placebo|saline infusion
223974942|NCT04126122|DIAGNOSTIC_TEST|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
223974943|NCT00005797|DRUG|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
223974944|NCT00005797|DRUG|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
223974945|NCT00005797|DRUG|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.
223974946|NCT00005797|RADIATION|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
223974947|NCT06090019|BEHAVIORAL|Routine PICU nursing care for children on mechanical ventilator.|Nursing interns students learned the routine PICU nursing care for the children on mechanical ventilator.
224116373|NCT06123208|OTHER|Control|Control meal
224116374|NCT01829802|DRUG|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
223974948|NCT06090019|BEHAVIORAL|Self-instructional module for VAP care bundle prevention|Nursing interns students learned about VAP care bundle prevention self-instructional module through assessment, preparation, implementation and evaluation phases.
223974949|NCT01486511|PROCEDURE|Liver resection|Hepatectomy including both minor and major.
223974950|NCT01486511|RADIATION|Computed Tomography|Computed Tomography +/- pulmonary angiography
223974951|NCT02274623|DRUG|CTAP101 Capsules|escalating doses
223974952|NCT02987322|DIETARY_SUPPLEMENT|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
223974953|NCT01829828|BEHAVIORAL|No intervention|This is an observational study with no investigational drug administered.
224116375|NCT01829802|DRUG|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
224116376|NCT01829802|DRUG|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
224116377|NCT01908621|DRUG|G-CSF (filgrastim)|
224116378|NCT01908621|DRUG|Cytosine arabinoside + G-CSF (filgrastim)|
224116379|NCT00688168|BEHAVIORAL|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
224116380|NCT00688168|BEHAVIORAL|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
224116381|NCT00688168|BEHAVIORAL|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
223725499|NCT03682666|BEHAVIORAL|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
223974954|NCT01304628|DRUG|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
223974955|NCT04068285|OTHER|Aerobic Exercise|Participants will be making aerobic exercise
223974956|NCT06479226|DRUG|cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash|mouthrinse
223974957|NCT04228900|DIETARY_SUPPLEMENT|Individualized plan for improvement of nutrition|For each participant we will make a plan, describing different items the can improve their nutritional status: enrichment of food, dental care,
223974958|NCT04228900|DRUG|Systematic drug review|Consider altering medication list if the patient has symptoms that may be attributed to adverse drug effects, in particular side effects as nausea, dry mouth or loss of appetite, and if drug-drug interactions or drug-disease interactions are likely to occur. Recommended changes in patient's medication list will be presented for the family physician who will hold the final decision to implement the suggested adjustments.
223974959|NCT01396200|DRUG|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
223974960|NCT01396200|DRUG|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
223974961|NCT02845713|DRUG|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
223974962|NCT00932555|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
223974963|NCT04137718|OTHER|nonIntervention|nonIntervention
224116382|NCT04543955|DRUG|Telotristat (Low-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
224116383|NCT04543955|DRUG|Telotristat (High-Dose)|Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
224116384|NCT02084836|OTHER|Functional Magnetic Resonance Imaging|
223974964|NCT04301115|OTHER|attachment|unilateral attachment from rehine 83
223974965|NCT04301115|OTHER|bridge|tooth implant supported bridge
223974966|NCT04301115|OTHER|CONVENTIONAL|conventional metalic partial denture
224116385|NCT03825289|DRUG|Hydroxychloroquine|Given PO
224116386|NCT03825289|DRUG|Trametinib|Given PO
224116387|NCT05345886|BEHAVIORAL|Hippotherapy|Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
223725500|NCT03682666|DEVICE|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
223725501|NCT02788357|DRUG|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
223974967|NCT05282641|DIETARY_SUPPLEMENT|10 g of collagen hydrolysate|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 10-gram collagen protein hydrolysates + 5-gram erythritol and it has to be dissolved in 250 ml of water.
223974968|NCT05282641|DIETARY_SUPPLEMENT|Placebo|Before breakfast, participants consume 1 sachet every day for 4 weeks. The sachet contains 5-gram erythritol (placebo) and has to be dissolved in 250 ml of water.
223974969|NCT01388478|DRUG|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with the physician prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
223974970|NCT04150185|PROCEDURE|Donor hepatectomy|
223974971|NCT01990664|DEVICE|senofilcon A|
223974972|NCT01990664|DEVICE|senofilcon A for Astigmatism|
224116388|NCT00218855|DRUG|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
224116389|NCT00218855|DRUG|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
224116390|NCT05436899|OTHER|LapSim training|Complete 4 courses, each of 12 weeks, of virtual reality simulation on LapSim surgical simulator.
224116391|NCT05436899|OTHER|LapSim exam|Completed at the beginning and at the end of each of the 4 courses the corresponding exam task.
224116392|NCT05502471|DIAGNOSTIC_TEST|Zonulin|Serum zonulin level
224116393|NCT05502471|DIAGNOSTIC_TEST|Occludin|Serum occludin level
223974973|NCT05767814|OTHER|Phenotyping of synovial immune and stromal cells|Generate a comprehensive cellular and molecular atlas of PsA by CITE-Seq (single cell protein and transcriptomics) and spatial transcriptomics of synovium of PsO at risk of developing PsA and PsA patients across different disease stages.
223974974|NCT03433209|DEVICE|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
224116394|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
224116395|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
224116396|NCT03799926|DRUG|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
224116397|NCT03799926|DRUG|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
224116398|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
223725502|NCT02788357|DRUG|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
223974975|NCT03433209|DEVICE|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
223974976|NCT02764177|DIETARY_SUPPLEMENT|Protein drink|The protein drink was administered during this trial
223974977|NCT02764177|DIETARY_SUPPLEMENT|Carbohydrate drink|The carbohydrate drink was administered in this trial
223974978|NCT01019798|DRUG|sunitinib, docetaxel, cisplatin|"1. Sunitinib given 10 days within 14 days of each cycle。~2. Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~3. Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~4. Overall 12 cycles (24 weeks)"
224116399|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
224116400|NCT03799926|DRUG|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
224116401|NCT03799926|DRUG|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
224116402|NCT05824845|PROCEDURE|Hip/Knee Replacement|Hip/Knee Replacement
224116403|NCT04631458|OTHER|standard of care.|Observational trial.
224116404|NCT04031170|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
223974979|NCT05887206|OTHER|Collection of datas|The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).
223974980|NCT02629276|OTHER|neurodynamic testing|
223974981|NCT02246218|DRUG|RAVICTI|
223974982|NCT04603833|DRUG|SHR3680+Docetaxel|Participants will receive SHR3680 combined with Docetaxel
223974983|NCT04603833|DRUG|SHR3680|Participants will receive SHR3680
223974984|NCT04603833|DRUG|Docetaxel|Participants will receive Docetaxel
223974985|NCT04362098|BEHAVIORAL|Home visiting Program for Young Pregnant Women|The visitation program was elaborated based in the following theoretical principles: a) Albert Bandura's self-efficacy theory; b) Urie Brofenbrenner's bioecological theory, which recognizes the importance of the insertion of individuals in families in varied contexts of life in society; c) John Bowlby and Mary Ainsworth's attachment theory. The basic premises of the intervention are health care, environmental health, life course development, development of parenting ability, relationship with friends and family, and social service support.
223974986|NCT00301561|PROCEDURE|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :~* some clinical consultations will be performed by nurses under the physicians' responsibility ;~* the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~* the biologic assessment for tolerability will be limited"
223974987|NCT00301561|PROCEDURE|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :~* all clinical consultations will be performed by physicians ;~* the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~* the biologic assessment for tolerability will be available as needed"
223974988|NCT06544252|DIETARY_SUPPLEMENT|Low glycaemic index rice-based mixed meal (GI value = 47)|The mixed meal consisted of Basmati rice, chicken, and green-leafy vegetables. The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
223974989|NCT06544252|DIETARY_SUPPLEMENT|High glycaemic index rice-based mixed meal (GI value = 80)|The mixed meal consisted of fragrant rice, chicken, and green-leafy vegetables.The energy content of the mixed meal was based on the body mass of the participant. The amount of CHO was 1.3 g.kg-1 body mass (Burke et al. 2019), and the amount of protein given was 0.5 g.kg-1 per meal (Witard, Garthe and Phillips 2019).
223725503|NCT03425747|DRUG|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
223974990|NCT02762305|OTHER|RSVP Bone Builders Group Exercise|
223974991|NCT03891641|BEHAVIORAL|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
224116405|NCT04031170|OTHER|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
224116406|NCT03913286|DEVICE|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
224116407|NCT00186238|PROCEDURE|high dose chemotherapy then autologous hematopoietic cell transplant|
224116408|NCT04153812|DEVICE|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
224116409|NCT01997567|DRUG|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
224116410|NCT01997567|DRUG|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
224116411|NCT01115946|DRUG|ASP1585|oral
223725504|NCT03425747|DRUG|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
223725505|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
223974992|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of SOCS3 gene|Detection of expression of SOCS3, in each samples using Real-Time PCR
223974993|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-α gene|Detection of expression of IFN-α gene in each samples using Real-Time PCR
223974994|NCT05781841|DIAGNOSTIC_TEST|Detection of expression of IFN-β gene|Detection of expression of IFN-β gene in each samples using Real-Time PCR
224116412|NCT01115946|DRUG|enalapril|oral
224116413|NCT03120338|DIAGNOSTIC_TEST|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
224116414|NCT02601001|DRUG|Omecamtiv mecarbil|Omecamtiv mecarbil tablets for oral administration
224116415|NCT02601001|DRUG|Placebo|Matching placebo tablets
223974995|NCT00941109|DRUG|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
223974996|NCT00941109|DRUG|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
223974997|NCT00941109|DRUG|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
223974998|NCT00941109|DRUG|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m\^2 1-hour IV infusion on Days 2-5 of Cycle 1.
223974999|NCT03756922|DRUG|FDL169|CFTR corrector
223975000|NCT03756922|DRUG|FDL176|CFTR potentiator
223975001|NCT02535962|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
223975002|NCT02535962|OTHER|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
223975003|NCT06183827|PROCEDURE|Emergency Medical Service intervention|"Facing an Acute Respiratory Failure, emergency medical service must rapidly choose between oxygen supply by face mask (15Liters/minutes), Mechanical Ventilation or non-invasive ventilation.~Mechanical Ventilation as non-invasive ventilation present interest and side arms as oxygen supply by face mask (15Liters/minutes) for hypoxemia control."
223975004|NCT00614588|DEVICE|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
223975005|NCT03577925|DIAGNOSTIC_TEST|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
223975006|NCT00564252|DRUG|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
223975007|NCT05449847|BIOLOGICAL|Blood Sampling|Blood sampling under a complete aseptic conditions
223975008|NCT01961921|DRUG|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
223975009|NCT02362347|DEVICE|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
223975010|NCT02362347|OTHER|exercise|exercise
223975011|NCT00075283|DEVICE|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
223975012|NCT00418418|PROCEDURE|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
223975013|NCT00418418|PROCEDURE|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
223975014|NCT00418418|BIOLOGICAL|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
223975015|NCT00418418|BIOLOGICAL|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
223975016|NCT00120822|DRUG|Folic acid|
223975017|NCT01650935|BEHAVIORAL|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate\>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
223975018|NCT01156402|BEHAVIORAL|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
224116416|NCT03319992|DEVICE|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
224116417|NCT04157660|PROCEDURE|Oxygen application|Oxygen application Supplemental oxygen via mask
223725506|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
223725507|NCT00632242|DRUG|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
223975019|NCT03800485|DEVICE|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
223975020|NCT05024409|DEVICE|Upper Extremity Orthotic|3D printed orthotic which uses elbow motion to facilitate finger extension
223975021|NCT05024409|OTHER|Occupational Therapy|6 weekly sessions of occupational therapy, without use of an assistive orthotic device
224116418|NCT04157660|PROCEDURE|Sham room air|Room air will be applied via mask
224116419|NCT02292381|OTHER|Isometric exercise|
224116420|NCT02951546|DIETARY_SUPPLEMENT|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.
224116421|NCT02951546|DIETARY_SUPPLEMENT|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
224116422|NCT02951546|OTHER|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
223975022|NCT00604513|OTHER|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
223975023|NCT00604513|OTHER|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
223725508|NCT00632242|DRUG|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
223975024|NCT03195049|DIAGNOSTIC_TEST|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
223975025|NCT00003478|PROCEDURE|conventional surgery|
223975026|NCT00003478|RADIATION|iodine I 131 monoclonal antibody 81C6|
223975027|NCT00003478|RADIATION|radiation therapy|
223975028|NCT05774171|OTHER|no intervention|no intervention
223975029|NCT04202016|PROCEDURE|Piezocision Surgery|After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
223975030|NCT00325546|DRUG|Rimonabant (SR141716)|
223975031|NCT00325546|DRUG|Placebo|
223975032|NCT03153098|BEHAVIORAL|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
223975033|NCT05725733|OTHER|Physical Therapy|The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
224116423|NCT01945931|OTHER|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
223975034|NCT02949076|BEHAVIORAL|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
223975035|NCT01713998|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223975036|NCT04788966|DEVICE|the translation tool BabelDr|Doctors use a speech-enabled fixed-phrase translation tool to help communicate with an allophone patient.
224116424|NCT02815631|DEVICE|Cardiogoniometry (CGM)|
224116425|NCT02815631|DEVICE|Fractional Flow Reserve (FFR)|
224116426|NCT00733512|DEVICE|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
224116427|NCT01823822|DIETARY_SUPPLEMENT|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
223975037|NCT02287740|BEHAVIORAL|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
223975038|NCT02287740|BEHAVIORAL|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
224116428|NCT01823822|DIETARY_SUPPLEMENT|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
223975039|NCT02287740|BEHAVIORAL|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
223975040|NCT02101268|DRUG|Momelotinib|Momelotinib tablet administered orally once daily
223975041|NCT02101268|DRUG|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
223975042|NCT00740870|DEVICE|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
223975043|NCT01092988|DEVICE|Exablate 2100|MR guided focused ultrasound
223975044|NCT01659047|DRUG|GS-1101|150 mg taken twice daily by mouth
223975045|NCT02222961|DRUG|BIIR 561 CL|
223975046|NCT02222961|DRUG|Placebo|
223975047|NCT04970693|DRUG|Furmonertinib|The different dose of furmonertinib will be given according to the generation of EGFR-TKI used as the first-line therapy. The doses and target volume of radiotherapy will be decided according to the oligoprogressive sites.
223975048|NCT05447728|DIAGNOSTIC_TEST|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
223975049|NCT05447728|DIAGNOSTIC_TEST|PRESTO|The PRESTO study is a group of 8 pre-hospital stroke scales used to detect large vessel occlusion strokes.
224116429|NCT03564665|DIETARY_SUPPLEMENT|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
223975050|NCT02965053|DRUG|EOS789|
224116430|NCT03564665|OTHER|Placebo|Placebo BID for 8 weeks.
223975051|NCT02965053|DRUG|Placebo|
223975052|NCT02965053|DRUG|Renvela|
223975053|NCT00946205|PROCEDURE|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
223975054|NCT00946205|PROCEDURE|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
224116431|NCT06259955|OTHER|Mindfulness|In the hybrid education process, the group that received their first year education online realized their first face-to-face clinical practice this year. In the fall semester, internal medicine nursing course and practice, and in the spring semester, surgical diseases nursing course and practice. These two practice areas, which have a high tendency to make medical errors, require clinical decision-making skills and increase stress levels, constitute the beginning of clinical practice. Studies show that the most stressful period for students is the second year of their education (Alzayyat \& Al- Gamal, 2014; White, 2011; Coram, 2015). This is because their professional knowledge and skills are not yet fully developed and they are not sufficiently prepared to meet the demands for higher level knowledge and skills (Alzayyat \& Al- Gamal, 2014; Coram, 2015). Based on the results of these studies, our study group consisted of second-year students.
224116432|NCT02433210|DEVICE|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
224116433|NCT02433210|DEVICE|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
224116434|NCT02433210|DEVICE|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
223975055|NCT01252056|DRUG|Probucol|250mg,Bid
223975056|NCT01252056|DRUG|Probucol and Cilostazol|50-100mg,Bid
223975057|NCT00414583|OTHER|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
223975058|NCT03247361|OTHER|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
223975059|NCT03247361|OTHER|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
223975060|NCT03247361|OTHER|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
224116435|NCT00747890|PROCEDURE|Modified tonsillectomy|"* Tonsillectomy~* Uvulectomy~* Soft palatal resection~* Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
223975061|NCT00607997|DRUG|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
223975062|NCT01606891|BEHAVIORAL|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
223975063|NCT03046381|DRUG|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
223975064|NCT05074771|DEVICE|ARC intellicare|ARC is a system that allows home motor and respiratory rehabilitation. The system includes 5 inertial measurement units for limbs and neck, a tablet with a dedicated app installed, to acquire and monitor the exercises performed by the patient in his/her daily rehab activity. Sensors and tablet can be charged on the base station. ARC allows the therapist to tailor the individual rehab project, with the support of a monitoring dashboard. The artificial intelligence engine analyses data coming from sensors positioned on the limbs, providing real-time feedback to the patient on the correct number of repetitions performed for each exercise. ARC allows therapists to create new exercises and/or select exercises from the ARC library to customize treatment (including tutorials and tips) based on condition-specific validated protocols and best practice. Patients can safely perform home rehabilitation sessions by wearing sensors and following video tutorials and tips from the ARC library.
223975065|NCT03975296|PROCEDURE|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
223975066|NCT03975296|PROCEDURE|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
223975067|NCT03975296|DRUG|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
223975068|NCT03558282|OTHER|Recession Observation|Soft tissue measurements
223975069|NCT03558282|DIAGNOSTIC_TEST|Crown Contour Observation|Ultrasound measures of implant crown contour.
223975070|NCT04350112|OTHER|Clinical assessment|Clinical assessment (history, examination) is gold standard for diagnosing constipation - gold standard will be compared with simple question about constipation, Rome IV diagnostic criteria for OIC, and common definitions of constipation for constipation / OIC
223975071|NCT02350855|DIETARY_SUPPLEMENT|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
223975072|NCT02350855|OTHER|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
223975073|NCT02350855|BEHAVIORAL|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
224116436|NCT00747890|OTHER|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
224116437|NCT05055739|DEVICE|Rigid plate X steel wires|Compare the sternal alignment between the fixation with rigid plate X steel wires.
224116438|NCT02731040|DRUG|Bisphosphonate|
224116439|NCT04171544|DEVICE|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
224116440|NCT03206944|DRUG|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
224116441|NCT03206944|DRUG|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
224116442|NCT02298517|PROCEDURE|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
224116443|NCT02298517|PROCEDURE|inspiratory load equipment|Threshold and Power breathe
223725509|NCT00632242|DRUG|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
223725510|NCT03900351|PROCEDURE|Wii fit protocol of virtual reality games|the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .
223725511|NCT03900351|PROCEDURE|Regular exercise rehabilitation protocol|It will be according to the criterion of Adams et al. (2012).
223725512|NCT02231333|DRUG|S-adenosylmethionine (SAMe)|
223725513|NCT02231333|DRUG|pentoxiphylline (PTX)|
223725514|NCT01377532|DRUG|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
223725515|NCT04946188|DEVICE|Opuz NICGM|A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
223975074|NCT06447298|OTHER|Satisfaction questionnaires|Use of a post-laparoscopy satisfaction questionnaire designed to be adapted to the context of laparoscopic surgery. This post-laparoscopy questionnaire was inspired by the PedsQL generic care satisfaction questionnaire, a standardised and validated questionnaire.
223975075|NCT00839332|DRUG|LY2603618|
223975076|NCT00839332|DRUG|Gemcitabine|
224116444|NCT03574896|OTHER|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
224116445|NCT03046472|OTHER|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
224116446|NCT02099916|DRUG|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
224116447|NCT02099916|DRUG|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
224293137|NCT05420012|DRUG|Placebo|A starting dose of vericiguat 2.5 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Subjects will be up-titrated in a blinded fashion to 5 mg and then to the target dose of 10 mg of vericiguat or matching placebo using titration criteria based on mean systolic blood pressure(SBP) evaluation and clinical symptoms at 2 week intervals. Titration to 10 mg in subjects who have not yet reached the target dose is intended at every visit/phone call throughout the study duration based on mean SBP measurement and safety considerations, at the discretion of the investigator.
223725516|NCT04038684|BEHAVIORAL|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 12 group-based sessions with weekly home practice (e.g., mindfulness exercises, dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Sessions will include BWC and mindfulness components. BWC components include: 1) a dietary plan based on a balanced, caloric deficit diet; 2) increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g., breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of emotions and their relation to emotional eating.
223725517|NCT04038684|BEHAVIORAL|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 12 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). All components of this telehealth intervention will be delivered via HIPAA-compliant videoconferencing software. Group sessions will include SBWC component, including: 1) a balanced, caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
223725518|NCT00719420|DRUG|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
223725519|NCT00719420|DRUG|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
223725520|NCT04229563|DEVICE|AURYON™ System|"The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system."
223725521|NCT02364752|PROCEDURE|Blood Draw|
223725522|NCT02364752|PROCEDURE|Loop Diuretic Withdrawal/Salt Load|
223725523|NCT03231605|BIOLOGICAL|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
223725524|NCT01848691|OTHER|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
223725525|NCT05157230|BEHAVIORAL|exercise|volunteers in the exercise arm instructed to do three basic deltoid muscle exercises 3 times daily at least 20 repetitions for each exercise for five days. exercises were side lateral shoulder raises, front shoulder raises with hyperextension and mid range arm circles.
223725526|NCT02205632|DEVICE|MPS II|
223725527|NCT03560232|DRUG|Ceftriaxone|See arm description
223725528|NCT03560232|DRUG|Ampicillin/sulbactam|See arm description
223725529|NCT03560232|DRUG|Piperacillin/tazobactam|See arm description
223725530|NCT03560232|DRUG|Cefazolin + Gentamicin|See arm description
223725531|NCT03560232|DRUG|Clindamycin + Gentamicin|See arm description
223725532|NCT00923247|DRUG|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
223725533|NCT00923247|DRUG|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
223725534|NCT02071914|DRUG|CT-P27|Influenza A treatment drug.
223725535|NCT02071914|DRUG|Placebo|Placebo.
223725536|NCT03438344|BIOLOGICAL|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
223725537|NCT03438344|OTHER|Laboratory Biomarker Analysis|Correlative studies
223725538|NCT03438344|OTHER|Placebo|Given IM
223725539|NCT05469828|DRUG|Crizanlizumab|patients will be started on 5mg/kg of body weight to be initiated at week 1 with follow up dosing at week 3 and week 7 then q4weeks until week 23, which will be the last dose given (7 total doses).
223725540|NCT05469828|OTHER|control|Standard of care
223725541|NCT00903799|DEVICE|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
223725542|NCT02746744|DRUG|Rituximab|Infusion of Mabthera/Rituximab every 6 months
223725543|NCT02746744|DRUG|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
223975077|NCT00433797|DIETARY_SUPPLEMENT|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
223725544|NCT02746744|DRUG|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
223975078|NCT01200485|DRUG|Rasburicase|"Cycle 1: 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
223975079|NCT01200485|DRUG|Allopurinol|Arm B: 300 mg/day by vein, as standard of care, over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
223975080|NCT06080438|DRUG|Botulinum toxin|15 units of botulinum toxin administered one time to the eye via eye drops
223975081|NCT00915577|DRUG|Interferon beta-1a|30mcg, IM once-a-week
223975082|NCT00915577|DEVICE|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
223975083|NCT03589300|DEVICE|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
223975084|NCT01376297|DRUG|Netupitant and Palonosetron|
223725545|NCT00251485|DRUG|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
223975085|NCT01376297|DRUG|Aprepitant|
224116448|NCT03823937|OTHER|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
223975086|NCT01376297|DRUG|Palonosetron|
223975087|NCT01376297|DRUG|Dexamethasone|
224116449|NCT01614769|DRUG|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
223725546|NCT06504823|OTHER|Light level|light application
223725547|NCT06505655|DIAGNOSTIC_TEST|trehalase levels|We think that in surgical patients requiring hypotensive anesthesia, acute kidney injury, which may occur due to intraoperative renal hypoperfusion, can be diagnosed early by evaluating the urine trehalase value using the ELISA method
223725548|NCT04932278|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment (OMT) is hands-on care provided by an osteopathic physician (D.O.). During osteopathic manipulative treatment, an osteopathic physician may move participants' muscles and joints using osteopathic techniques including stretching, gentle pressure and resistance, as well as thrust techniques that apply a quick, therapeutic force of brief duration that travels a short distance.
224116450|NCT01614769|DRUG|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
224116451|NCT01614769|DRUG|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
223725549|NCT04932278|PROCEDURE|Usual care|Routine concussion management with healthcare professionals.
223725550|NCT05540405|DIETARY_SUPPLEMENT|Low-dose bitter melon|Subject will receive 1 Insumate bitter melon capsule/d (300 mg) and 1 placebo capsule/d (300 mg)
223975088|NCT03134547|DRUG|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
223975089|NCT03134547|DRUG|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
223975090|NCT03341858|OTHER|no intervention-strictly observational|
223975091|NCT01678898|DRUG|PRX-102|
223975092|NCT03029611|DRUG|Carboplatin|Given IV
223975093|NCT03029611|PROCEDURE|Gynecological Surgical Procedure|Undergo cytoreductive surgery
223975094|NCT03029611|OTHER|Laboratory Biomarker Analysis|Correlative studies
223975095|NCT03029611|DRUG|Paclitaxel|Given IV
223975096|NCT03029611|BIOLOGICAL|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
223975097|NCT00002388|DRUG|Abacavir sulfate|
223975098|NCT06646601|OTHER|Intervention of prevention|A 6-month multidisciplinary preventive intervention for each patient: gardening, adapted physical activity, nutritional workshops.
224293138|NCT02684201|DEVICE|Boston Scientific Stimulator Lead|A Boston Scientific (PMA P030017) spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
223975099|NCT05104957|OTHER|Dynamic tape|The experimental group will use a special dynamic patch made of cotton, coated with a hypoallergenic acrylic heat-activated adhesive arranged in sinusoidal-shaped layers. The tape will be applied using the muscle technique with a Y-shaped cut patch directly to the dried and non-greased skin. The application will be performed in a standing position, with the participant's lower extremities straight. The therapist will place the beginning of the tape (the base) on the participant's sacrum and then, asking them to bend 45 degrees forward, tape the tails of the tape along the spine on the extensor muscles of the lumbar region, without changing the tension of the tape, keeping the base in the initial position.
223725551|NCT05540405|DIETARY_SUPPLEMENT|High-dose bitter melon|Subject will receive 2 Insumate bitter melon capsules/d (300 mg each)
223725552|NCT05540405|DIETARY_SUPPLEMENT|Placebo|Subject will receive 2 placebo capsules/d (300 mg each)
223975100|NCT05104957|OTHER|Sham tape|In the control group, a plain paper patch will be used to conduct the study, which, like the dynamic patch, will be applied using the same form of tape cutting and the same application technique. The entire method of applying the patch will also take place in the participant's standing position with forward bending. The paper patch will be placed at the levels from the L3 segment to the sacrum, along the spine on the lumbar extensor muscles.
223975101|NCT06647186|PROCEDURE|Non Incised Papillae Surgical Approach|Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. A single horizontal or oblique incision was made in the mucosa located on the cortical bone tissue, apical to the intrabony defect. The mesiodistal extension of the incision was sufficient to allow access to the defect. Tissue coronal to the incision was raised to full thickness from the incision line to expose the bone peaks delimiting the intrabony defect. The granulation tissue was removed from the bone walls of the defect. Dental plaque and calculus deposits were removed from the root surface with ultrasonic scaler tips and micro-minicurettes. A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with horizontal internal mattress sutures then simple interrupted sutures.
224116452|NCT01614769|PROCEDURE|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
224116453|NCT04655495|DIETARY_SUPPLEMENT|Low FODMAPs /balanced gluten free diet|Dietary Supplement: Balanced low FODMAPs /gluten free diet
224116454|NCT03960138|DEVICE|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
224116455|NCT03960138|DEVICE|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
224116456|NCT03123354|DEVICE|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
224293139|NCT05027789|BEHAVIORAL|Self-Guided|People in this arm will come to 15 information sessions. These sessions will provide training and education on memory support strategies and healthy lifestyles. You will decide how you want to implement this information into your daily life.
223725553|NCT06504797|DEVICE|automatic massage|automatic massage
223725554|NCT03193203|DRUG|Etanercept|50 mg/mL PFS and AI
223725555|NCT01105728|PROCEDURE|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
223725556|NCT02711592|GENETIC|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
223725557|NCT00023504|BIOLOGICAL|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
223975102|NCT06647186|PROCEDURE|Conventional flap design|"Ten patients were included in this group, phase I therapy (scaling, root planing and oral hygiene measures) was performed. Intrasulcular incision was made splitting the buccal papilla from the palatal papilla. All defects were approached by elevating a flap only on the buccal side and leaving the oral portion of the interdental supracrestal soft tissues undetached. The full-thickness elevation of the marginal portion of the flap was performed with a microsurgical periosteal elevator.~After removal of granulation tissue from the bone walls of the defect, root and defect debridement was performed with manual and mechanical (ultrasonic) instruments with tips for subgingival instrumentation.~A solution of 24% Ethylenediaminetetraacetic acid (EDTA) was applied to the root surface for 2 min, irrigation with saline solution then allograft bone material was packed into the periodontal defect. The incision was sutured with simple interrupted sutures."
223725558|NCT00023504|BIOLOGICAL|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
223725559|NCT00023504|BIOLOGICAL|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
223725560|NCT00023504|BIOLOGICAL|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
223725561|NCT05373368|BEHAVIORAL|multi purpose activities|
223725562|NCT05410691|DEVICE|Handheld US device|Handheld US-guided AVF/AVG cannulation
223725563|NCT03039140|OTHER|Educational Intervention|Attend weekly educational sessions
223725564|NCT03039140|BEHAVIORAL|Exercise Intervention|Participate in CR program
223725565|NCT03039140|OTHER|Quality-of-Life Assessment|Ancillary studies
223725566|NCT03039140|OTHER|Questionnaire Administration|Ancillary studies
223975103|NCT06646809|DIETARY_SUPPLEMENT|Alpha-ketoglutarate|Alpha-ketoglutarate supplements
223975104|NCT06646809|DIETARY_SUPPLEMENT|Placebo|Placebo tablets
223975105|NCT06646809|OTHER|Standard care|Standard care
223975106|NCT06647199|PROCEDURE|the plaque index (PI)|Peri-implant soft tissue changes as regards plaque was assessed employing the modiﬁed plaque index (PI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
223975107|NCT06647199|PROCEDURE|the bleeding index (BI)|Peri-implant tissue changes as bleeding score was assessed employing the bleeding index (BI) . Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD).
224293140|NCT05027789|BEHAVIORAL|Structured Group|People in this group will come to 15 information sessions. The study will provide recommended behavior targets (like how much exercise you should have each week). Participants in this group will either receive an iPad or have a special application installed on their own personal device. They will receive training on how to use the application, and will be asked to use the application to record their activities and receive reminders.
223975108|NCT06647199|PROCEDURE|simpliﬁed gingival index(GI),|Peri-implant soft tissue changes as regards gingival scores was assessed simpliﬁed gingival index(GI). Patients were evaluated clinically at the time of mandibular overdenture insertion (T0), 6 months (T1), 12 months (T2) and 3 years (T3) after denture insertion. Both plaque index (PI) and bleeding index (BI) were evaluated according to the Mombelli index , and gingival index (GI) according to the modified Silness and Loe index. Measurements were taken from the buccal, lingual, mesial, and distal aspects of each implant. All the clinical parameters were measured from the four aspects using a graduated periodontal probe (Hawe Perio-Probe, Kerr), and the sum total of the four readings was divided by four to obtain the mean value. The distance between the marginal border of the peri-implant mucosa and the tip of the probe was measured and considered as pocket depth (PD
223725567|NCT01356108|DEVICE|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
223725568|NCT04766398|DRUG|KHK7791|oral administration
223725569|NCT04766398|DRUG|Placebo|oral administration
223975109|NCT01073774|BEHAVIORAL|Side by side|
223975110|NCT01073774|BEHAVIORAL|couples control condition|
223975111|NCT00352391|OTHER|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
223975112|NCT05246618|DRUG|TUM012|Ex-vivo infusion
223975113|NCT05246618|DRUG|Placebo|Ex-vivo infusion
223975114|NCT05278442|OTHER|LaserArc|LaserArcs.com is an online arcuate incision nomogram calculator initially developed on the basis of 12 months of data tabulation of patients undergoing femtosecond surgery with arcuate incisions
223975115|NCT04934878|BIOLOGICAL|Referral information|first visit to our hospital/transfer from another hospital
224116457|NCT06022913|BEHAVIORAL|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
223975116|NCT03235401|OTHER|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
223975117|NCT06646874|BEHAVIORAL|VR game|Each participant in the VR group completed a five-minute familiarization session with the VR game before the experimental session. Following the familiarization session, participants in the VR group were instructed to complete the Montreal Cognitive Assessment (MoCA) Arabic version (pre-test: Arabic version 8.1 and post-test: Arabic version 8.2)
223975118|NCT06244693|OTHER|No intervention|No intervention
224116458|NCT06173492|PROCEDURE|Dental extraction|After local anesthesia (mepivacaine 2%), the tooth is extracted atraumatically with levers and forceps taking care to preserve the cortex. The roots of multi-rooted teeth are separated before extraction. The pocket epithelium and granulation tissue inside the socket are removed.
224116459|NCT06173492|DEVICE|Platelet Rich Fibrin|The clot obtained by centrifugation is made into PRF cylinders and inserted into the socket and compacted.
224116460|NCT03903029|DRUG|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
224116461|NCT01818791|BEHAVIORAL|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
224293141|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days, (except Cycle 1 for high-dose cohorts = 35 days).
224293142|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 21 days and 28 days.
224293143|NCT04623541|DRUG|rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone|R-CHOP will be administered intravenously (prednisone may be administered orally) in cycles of 21 days.
224293144|NCT04623541|DRUG|Venetoclax|Venetoclax tablets will be administered orally once daily during the 5-week ramp up period in cycles of 28 or 35 days each.
224293145|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
224293146|NCT04623541|DRUG|Lenalidomide|Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days.
224293147|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
224293148|NCT04623541|DRUG|Pirtobrutinib|Pirtobrutinib tablets will be administered in cycles of 28 days.
224293149|NCT04623541|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered subcutaneously in cycles of 28 days.
224293150|NCT05322837|OTHER|Clinical and technological-aided assessments and questionnaires|Assessments and questionnaires related to upper limb function and quality of life will be used
224293151|NCT03253744|DRUG|18F-DCFPyL|Participants will receive 2-(3-{1-carboxy-5-\[(6-18F-fluoro-pyridine-3-carbonyl)-amino\]-pentyl}-ureido)-pentanedioic acid at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 6-6.5 mCi.
223725570|NCT02427022|OTHER|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
223725571|NCT03714867|DRUG|Pregabalin 150mg|150 mg concealed pregabalin capsule
223975119|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
224293152|NCT03253744|RADIATION|Tumor Irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy.
223725572|NCT03714867|OTHER|Placebo|Concealed placebo capsule
223543244|NCT05282667|PROCEDURE|Reconstructive therapy of peri-implantitis by means of bone graft (and barrier membrane in the test group)|"A full-thickness flap was raised to ensure sufficient access. Debridement of granulation tissue was subsequently conducted using a mini-five curette (Hu-Friedy) and site-specific Gracey curettes (Hu-Friedy). The surgical approach was tailored to the clinical scenario. Specifically, resective therapy by means of implantoplasty was performed for supracrestal defects (Meisinger LLC, Nauss, Germany). Surface detoxification was performed with 3% hydrogen peroxide during 2 minutes and irrigation with 0.12% chlorhexidine. The intraosseous compartment was grafted using mineralized and demineralized bone graft (LifeNet Health, Virginia, USA). The graft was compartmentalized in the test group with a collagen porcine resorbable membrane (RTM, Cytoplast, California, USA) adapted to the defect morphology. Nylon 5.0 (Resorba Sutures, Osteogenics Biomedical, Lubbock, Texas) was used for suturing, ensuring primary wound closure"
223543245|NCT01170052|DRUG|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
223975120|NCT04041024|OTHER|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
223975121|NCT04104724|OTHER|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
223543246|NCT01170052|DRUG|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
223975122|NCT04713878|OTHER|Mesenchymal stem cells|Intravenous infusion of Mesenchymal stem cells
224116462|NCT01818791|BEHAVIORAL|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality-i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
224116463|NCT02169635|PROCEDURE|macular buckle|macular buckle with a three-armed silicone capsule
224116464|NCT04524936|DIAGNOSTIC_TEST|blood sample|
224116465|NCT00976768|DRUG|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
223543247|NCT01170052|DRUG|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
223543248|NCT02557451|OTHER|Surgery|
223543249|NCT02557451|OTHER|Intravitreal injections of gas|
223975123|NCT00126061|DRUG|Tedisamil sesquifumarate|
224116466|NCT01958671|DRUG|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
224116467|NCT01958671|DRUG|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
224116468|NCT01958671|DRUG|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
224116469|NCT01958671|DRUG|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
224116470|NCT01958671|DRUG|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
224116471|NCT01958671|DRUG|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
223975124|NCT02134249|DRUG|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
223975125|NCT02134249|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
223975126|NCT03240458|DEVICE|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
224116472|NCT04813237|OTHER|n a|the participants are not subjected to any type of intervention
224116473|NCT00348972|DRUG|Lantus® (insulin glargine)|
223975127|NCT03237598|OTHER||
223975128|NCT05753358|OTHER|Total Worker Health for Wildland Firefighters|The program is structured as 30-minute modules that can be done individually, with a partner, as a group or in a classroom setting. The six core modules are supplemented with eight elective modules. The program can be accessed on a smartphone, tablet or computer, and if needed can be downloaded as a pdf.
223975129|NCT01424176|DRUG|Dexpramipexole (dose 1)|
223975130|NCT01424176|DRUG|Dexpramipexole (dose 2)|
224116474|NCT00711399|DEVICE|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
224116475|NCT06438913|DRUG|Tezepelumab|Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.
224116476|NCT00587418|DIETARY_SUPPLEMENT|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
223543250|NCT02557451|PROCEDURE|injections of an antiangiogenic|
223543251|NCT03962855|DRUG|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
223543252|NCT03962855|DRUG|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
223975131|NCT01841645|DIETARY_SUPPLEMENT|CLA depletion-repletion|
224116477|NCT00587418|DIETARY_SUPPLEMENT|Placebo|Placebo powder 9.2g bid for 7 days
224116478|NCT02388529|DRUG|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
224116479|NCT02388529|DRUG|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
223543253|NCT06331156|COMBINATION_PRODUCT|HRV PCV-free|2 doses of HRV PCV-free vaccine are administered orally at Month 0.5 and Month 1.5 (Co-administration Group) and at Day 1 and Month 1 (Staggered Group), according to the immunization schedule for HRV vaccine licensed outside of China. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
223975132|NCT01953471|OTHER|Allergic rhinitis|Questionnaire
223975133|NCT03377959|OTHER|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
223975134|NCT03377959|OTHER|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
224116480|NCT02388529|DRUG|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
224116481|NCT02388529|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
224116482|NCT06034834|DIAGNOSTIC_TEST|Near-infrared fluorescence imaging of perfusion|Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
224116483|NCT00559052|DRUG|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
224116484|NCT04760314|DRUG|Lebrikizumab|Administered SC
224116485|NCT04760314|DRUG|Placebo|Administered SC
224116486|NCT04760314|DRUG|Topical Corticosteroid|Self-applied
224116487|NCT04279561|PROCEDURE|Computed Tomography|Undergo 68Ga-PSMA-11 PET/CT
223543254|NCT06331156|COMBINATION_PRODUCT|IPV|3 doses of IPV vaccine are administered intramuscularly at Month 0.5, Month 1.5 and Month 2.5 (Co-administration Group and Staggered Group), according to the recommended schedule for vaccination against poliovirus in China.
223975135|NCT00464217|DRUG|ARA-C|
223975136|NCT00464217|DRUG|Idarubicin|
223975137|NCT00464217|DRUG|Leucomax|
224116488|NCT04279561|DRUG|Gallium Ga 68 Gozetotide|Given IV
224116489|NCT04279561|PROCEDURE|Positron Emission Tomography|Undergo 68Ga-PSMA-11 PET/CT
224116490|NCT01290484|DRUG|Sildenafil|Sildenafil oral tablet three times daily
224116491|NCT03883022|DRUG|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
224116492|NCT03883022|DRUG|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
224116493|NCT03572543|DEVICE|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
224116494|NCT03435991|OTHER|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
224116495|NCT03952897|OTHER|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
224116496|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
224116497|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
223543255|NCT04469088|OTHER|Dry needling|Twenty-three patients with TJD will be allocated in Dry Needling Group. They will receive 3 sessions of dry needling separated for 4 days. This treatment will consist of puncturing the active myofascial trigger points (PGM) of the aforementioned muscles. Sterile acupuncture needles of 0.26 mm in diameter by 40 mm in length, guided with a plastic cannula of the Ener-qi brand, will be used. The area will be cleaned with alcohol and a deep puncture of the PGM will be performed, triggering local spasm responses. Needle through the muscle following the technique described by Hong (Hong et al. 1994). After the procedure, the area is compressed with cotton for 90 seconds.
223725573|NCT03558178|PROCEDURE|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
223975138|NCT05207449|OTHER|Questionnaire|"The questionnaire will include:~1. The demographic data of the patients~2. Chronic disease related questions~3. Assessment of adherence to treatment by using Arabic validated version of Medication Adherence Report Scale (MARS)~4. Patients' beliefs about medication will be assessed using Arabic validated version of Beliefs about Medicines Questionnaire (BMQ)~5. Disease acceptance will be evaluated using: Arabic validated version of Acceptance to Illness Scale (AIS)~6. Assessment of health-related quality of life (HRQoL) using the Arabic version of the Pediatric Qualify of Life Inventory Generic Core Scale (PedsQL) 4.0 GCS~7. Assessment of readiness for transition to adult health care settings using The Transition Readiness Assessment Questionnaire (TRAQ)"
223975139|NCT02284802|PROCEDURE|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
224116498|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
224116499|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
224116500|NCT00960440|DRUG|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
224116501|NCT00960440|DRUG|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
224116502|NCT05396066|DIAGNOSTIC_TEST|Muscle evaluation|Repeated maximal voluntary contraction
224116503|NCT00428506|DRUG|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
224116504|NCT00428506|DRUG|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
224116505|NCT02461914|DRUG|PEX168|200µg,injected subcutaneously,once a week.
224116506|NCT02461914|DRUG|Warfarin|5mg,oral,two times.
224116507|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
224116508|NCT01635751|DRUG|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
224116509|NCT01635751|DRUG|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
224116510|NCT04202562|PROCEDURE|Ab interno trabeculectomy|Ab interno trabeculectomy performed after pupil contraction and 90 degrees ablation of the nasal trabecular meshwork
224116511|NCT04202562|PROCEDURE|Cataract|Cataract surgery with minimal clear cornea incision and phacoemulsification
224116512|NCT01279538|DRUG|bleselumab|Intravenous (IV) infusion
224116513|NCT01279538|DRUG|Placebo|Intravenous (IV) infusion
224116514|NCT03601416|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
224116515|NCT03601416|DRUG|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
224116516|NCT04442958|OTHER|Convalescent Immune Plasma|One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
223543256|NCT04469088|OTHER|Manual Therapy Treatment|Twenty-three patients will be allocated in Manual Therapy (MT) Group for three sessions during 30 minutes. MT treatment will consist in the application of neuromuscular techniques of the temporal, masseter and sternocleidomastoid muscles and Jones techniques in the external pterygoid muscle. Neuromuscular techniques are performed with the index and major fingers to apply a transverse friction with enough pressure to feel vertical fibers of each muscle or produce a medium discomfort level. To perform the Jones technique on the external pterygoid muscle, the patient will be asked to open the mouth and deviate the jaw slightly towards the treated side in order to make room for the finger to be located between the upper jaw and the coronoid process. Once the trigger point is located, we press to trigger the pain and we look for neurological silence and we maintain the pressure for 90 seconds. Over time, we slowly withdraw the pressure and return to the position passively.
223543257|NCT02864264|DRUG|BMS-986184|
223543258|NCT02864264|DRUG|Placebo matching BMS-986184|
223725574|NCT03558178|DEVICE|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
223725575|NCT03791489|DEVICE|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
223725576|NCT03572062|BIOLOGICAL|Formulation A|RSV vaccine
223725577|NCT03572062|BIOLOGICAL|Formulation B|Adjuvanted RSV vaccine
223975140|NCT02857309|DEVICE|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
223975141|NCT02857309|DRUG|Optimal medical therapy|OMT using standard heart failure (HF) drugs
223975142|NCT02134899|DRUG|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
223975143|NCT02134899|DRUG|Calcineurin inhibitors maintenance|Usual treatment
223975144|NCT01849679|OTHER|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
223975145|NCT00000904|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
223975146|NCT00000904|BIOLOGICAL|gp160 MN/LAI-2|
223725578|NCT03572062|BIOLOGICAL|Formulation C|RSV vaccine
223725579|NCT03572062|BIOLOGICAL|Placebo|Placebo
223725580|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
223725581|NCT01858389|DRUG|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
223975147|NCT00000904|BIOLOGICAL|ALVAC(1)120(B,MN)GNP (vCP1433)|
223975148|NCT00000904|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223975149|NCT00000904|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
223725582|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 1|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223725583|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 2|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223725584|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 3|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223725585|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 4|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223725586|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 5|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223975150|NCT02146729|PROCEDURE|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
223975151|NCT02146729|PROCEDURE|Open Treatment|Midline posterior incision with instrumentation.
223975152|NCT00068835|BEHAVIORAL|Lindamood-Bell training for dyslexia|
223975153|NCT04665349|DIETARY_SUPPLEMENT|Nutricia Pre-op, 400 milliliters, per os|After 10 hours of fasting participants will receive per os 400 milliliters of Nutricia Pre-op
223975154|NCT01395706|PROCEDURE|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
223543259|NCT01158755|DRUG|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
223975155|NCT06205576|DEVICE|DCB catheter|Trade name of DCB catheter：Acoart Orchid＆Dhalia
223975156|NCT01174498|DEVICE|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
223975157|NCT01174498|DEVICE|t-VNS Sham stimulation|t-VNS Sham stimulation
223725587|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 6|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223975158|NCT04748471|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccine
223975159|NCT02264717|PROCEDURE|SPECT|Patients are randomized to either SPECT or Cardiac MRI
223975160|NCT02264717|PROCEDURE|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
223975161|NCT02864342|DEVICE|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
224116517|NCT01803399|DRUG|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
223975162|NCT02864342|DEVICE|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
223975163|NCT00776984|DRUG|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
223975164|NCT00776984|DRUG|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
223975165|NCT03353155|BEHAVIORAL|Usual Care|
223975166|NCT03353155|BEHAVIORAL|CareHub|
223975167|NCT00006137|DRUG|enalapril|
223975168|NCT02672137|BEHAVIORAL|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
223975169|NCT01971034|DRUG|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
223975170|NCT01971034|DRUG|Metformin|850mg, PO, every 8 hours, daily.
223975171|NCT01192672|BEHAVIORAL|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
223975172|NCT01192672|BEHAVIORAL|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
223975173|NCT00661466|DRUG|Bupivacaine Collagen Sponge|
223975174|NCT00661466|DRUG|Placebo|placebo
223975175|NCT03852875|OTHER|Education|Same
223975176|NCT03852875|OTHER|Control|Same
223975177|NCT03609671|BEHAVIORAL|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
223975178|NCT03609671|OTHER|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
223975179|NCT03709316|DRUG|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
223975180|NCT03709316|DRUG|Placebo Comparator|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
223975181|NCT04369300|BEHAVIORAL|Registery Data Collection|Observational Data Collection
223975182|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
223975183|NCT03596099|DIETARY_SUPPLEMENT|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
224116518|NCT01803399|DRUG|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
223975184|NCT01570621|PROCEDURE|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
223975185|NCT02311985|OTHER|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR \>1.5 or PTT \>50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
223975186|NCT02311985|OTHER|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex \>40 mm, then no blood transfusion is performed; when CTex \>80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib \>10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
223975187|NCT02311985|OTHER|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR \>5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
223975188|NCT00009789|RADIATION|accelerated conformational radiotherapy|
224116519|NCT01803399|DRUG|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
223975189|NCT05687318|DEVICE|DeFrame|DeFrame can analyze colonoscopy medical images generated by electronic digestive endoscopy equipment to automatically identify, label and screen capture polyps in the colon.
223975190|NCT04040283|PROCEDURE|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
223975191|NCT00502983|BEHAVIORAL|Interview|Interview lasting approximately 50 minutes.
223975192|NCT06039943|DEVICE|Wheeze measurement|Acoustic breath sounds will be measured during tidal breathing prior to spirometry and during a spirometry attempt.
223975193|NCT02958813|BEHAVIORAL|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
223975194|NCT02958813|BEHAVIORAL|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
223975195|NCT03298555|BEHAVIORAL|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
223975196|NCT00890214|DRUG|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
223975197|NCT00890214|DRUG|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
224293153|NCT03253744|RADIATION|Prostate + tumor irradiation|Stereotactic body radiation therapy (SBRT) will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate.
224293154|NCT03253744|RADIATION|Tumor Irradiation|External beam radiation therapy (EBRT): Participants with locally recurrent prostate cancer after treatment with EBRT. These participants cannot have had permanent brachytherapy as part of their treatment.
224293155|NCT05536830|OTHER|Nutrition Status|Participants will be examined by a registered dietitian to assess nutrition status.
224293156|NCT06522893|OTHER|Electrical Dry Needling and Therapeutic exercise|The group receiving dry needling combined with therapeutic exercise (n=35) will receive up to 6 sessions of stimulation at the active trigger points in the cervical region, according to Travell and Simons: occipitofrontalis, sternocleidomastoid, splenius capitis, anterior, middle, and posterior scalene muscles, upper, middle, and lower trapezius, and multifidus at the C6 level, bilaterally, once a week for 3 weeks. Using ultrasound guidance, 0.25 mm x 25 mm needles will be inserted into the active trigger points. The needles will be connected to a TENS (transcutaneous electrical nerve stimulation) device (TensMed S82-Enraf Nonius), applying an asymmetric biphasic square wave current, low frequency (2 Hz), pulse duration of 250 μs, for 30 minutes. In addition, this group will perform a protocol of specific therapeutic exercises for the cervical spine during the same electropuncture session and immediately afterward.
224116520|NCT01803399|DRUG|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
224116521|NCT03799003|DRUG|ASP1951|Intravenously (IV)
224116522|NCT03799003|DRUG|pembrolizumab|Intravenously (IV)
224116523|NCT05062161|BEHAVIORAL|Sleep hygiene/extension intervention|The 60-minute sleep hygiene/extension educational session include the following: This session will consist of questionnaires, handouts, videos, and a discussion. Topic examples include information on establishing a comfortable sleep environment, including strategies on how to extend sleep duration by a maximum of 1 hour over the duration of the 8-week trial for an average of 7.5 minutes per week, not to exceed 15 minutes per week. Participants will also receive educational brochures and a sleep diary.
224116524|NCT05062161|BEHAVIORAL|Control care|The 60-minute educational session will address sleep physiology but not sleep hygiene. This session will consist of questionnaires, handouts, videos, and a discussion. Participants will receive an educational brochure.
224116525|NCT05401773|OTHER|Real-time Quaking-Induced Conversion (RT-QuIC)|RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies.
224116526|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with vincristine and prednisone|After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
223975198|NCT04595526|PROCEDURE|Forced expiratory technique and induced sputum|The intervention is based on the patient's own attempt to deliver a sputum sample after instructions of proper huff forced exhalation and coughing technique. After an attempt to deliver a sputum sample the patient will receive a 0,9% isotonic saline by an inhalation mask to induce the sputum, thereafter the patient will again make an effort to expectorate a sputum sample repeating the forced expiratory technique.
223975199|NCT04595526|PROCEDURE|Tracheal suction|Tracheal suction is often used on intubated patients at the intensive care unit to collect sputum, and this method has become the standard procedure at several emergency departments.
223975200|NCT04892602|DIAGNOSTIC_TEST|Serum vitaminDlevel|Investigate about fibromyalgia in psoiaritic and rheumatiod arthritis patients ...and assesment of seum vitamin D level
223975201|NCT02573883|DEVICE|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
223975202|NCT02573883|DRUG|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
223975203|NCT01544309|DRUG|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society \[JAS\] Guidelines \[GL\] after 3 months, had the atorvastatin \[ATV\] dose of 20 mg.)"
223975204|NCT01544309|DRUG|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)"
223975205|NCT02410317|DRUG|Ropivacaine|
223975206|NCT02410317|DRUG|Morphine|
223975207|NCT05292170|OTHER|Heat acclimation|10 consecutive days of heat acclimation
223975208|NCT02671864|OTHER|1: incretin-based therapy|
223975209|NCT02671864|OTHER|2: other antidiabetic|
223975210|NCT04959825|DRUG|Melatonin 5 mg|study the effect of preoperative oral melatonin 5mg on isoflurane consumption and postoperative pain
223975211|NCT04959825|DRUG|Sugar Coated Tablets|the control group patients will receive placebo tablets one hour before induction of anesthesia
223975212|NCT05113485|BEHAVIORAL|Diabetes Prevention Program-based lifestyle change intervention (DPP)|The DPP condition consists of 11 health education sessions over 12 weeks, including 2 virtual home visits, two virtual group education sessions and 7 telephone coaching calls. These sessions will teach DPP-based lessons on how to lose excess body fat through calorie restriction and increased physical activity. All dietary and physical activity recommendations are intended to be consistent with federal nutrition and physical activity guidelines.
223975213|NCT05113485|BEHAVIORAL|Highly Microbiota-Accessible Foods (HMAFs) intervention|The Highly Microbiota-Accessible Foods (HMAFs) intervention approach includes 11 health education sessions, including two virtual home visits, two virtual group education sessions, and 7 telephone coaching sessions. These sessions are designed to help study participants to identify and consume optimally 6 daily instances of minimally processed, fiber-rich food sources, drawn from all four of the MyPlate.gov categories: vegetables, fruits, whole grains and plant-based protein-rich foods (e.g., legumes, nuts and seeds). Increased physical activity is also recommended as a way to optimize the microbial conversion of fiber-rich food sources to short chain fatty acids, which are then expected to reduce excess low-grade inflammation.
223975214|NCT04087070|DEVICE|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)"
223975215|NCT01290783|DRUG|Irintoecan|"* Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks.~* 8 months of treatment."
223975216|NCT01290783|DRUG|HA-Irinotecan solution for Infusion|"* HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients \> 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~* Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~* 5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~* Repeat every two weeks~* 8 months of treatment."
223975217|NCT01412632|DRUG|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
223975218|NCT02036606|BEHAVIORAL|questionary|
223975219|NCT00183183|BEHAVIORAL|Screening and Brief Intervention|
223975220|NCT01990911|DEVICE|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
223975221|NCT01990911|DRUG|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
223975222|NCT04695314|DEVICE|Massage|Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
223725588|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 7|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223975223|NCT04695314|PROCEDURE|Experimental insert|Raised shoe insert, insert used for massage
224116527|NCT05026229|DRUG|dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine|After induction therapy, the patients in the 'Dasatinib, Methotrexate and Cytarabine' group will receive dasatinib and consolidation chemotherapy with high-dose methotrexate and cytarabine.
223725589|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 8|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223725590|NCT06358716|DIETARY_SUPPLEMENT|Complete Oral Nutrition Supplement 9|Liquid formula produced by several food ingredients to provide a balance nutrient intake
223725591|NCT06358716|DIETARY_SUPPLEMENT|Glucose|25 mg of glucose dissolved in 200 mL
223725592|NCT00534391|DRUG|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
223725593|NCT00534391|DRUG|Artificial tear|4 times daily
223975224|NCT04695314|PROCEDURE|Sham insert|Flat shoe insert, insert used for massage
224116528|NCT06031467|DEVICE|Er, Cr: YSGG laser-assisted non-surgical mechanical therapy|The laser group received mechanical therapy followed by Er;Cr;YSGG laser. Laser application was performed using the bottom-up technique. Therefore, the tip was retracted about 1 mm after it was placed on the bottom of the pocket and slowly moved in the coronal direction to the parallel to the implant surface.
224116529|NCT06031467|DEVICE|Non-surgical mechanical therapy|Traditional non surgical mechanical therapy Mechanical instrumentation in all groups was made with titanium curettes.The curette was gently inserted into the peri-implant pocket and the mechanical therapy was completed with threads felt.
223975225|NCT01584271|DEVICE|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
223975226|NCT01422083|PROCEDURE|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
223975227|NCT00118703|DRUG|GW685698X|
223975228|NCT00087113|DRUG|pemetrexed disodium|
223975229|NCT03410095|DIAGNOSTIC_TEST|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment-R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
223975230|NCT05067543|DEVICE|Tornier Perform Humeral - Stem|The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
223975231|NCT00953212|DRUG|beta blockers|metoprolol 25mg by mouth every 6 hours
223975232|NCT00953212|DRUG|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
223975233|NCT00953212|DRUG|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
223975234|NCT00115817|DRUG|Atorvastatin|
223975235|NCT04646135|DRUG|Lorazepam 4 mg/ml|Lorazepam will be administered intravenously according to the scheduled sequences.
223975236|NCT00004090|DRUG|cisplatin|
223975237|NCT00004090|DRUG|gemcitabine hydrochloride|
223975238|NCT03688022|DRUG|MT-7117|MT-7117
223975239|NCT03688022|DRUG|PPI|Proton pump inhibitor
223975240|NCT03688022|DIETARY_SUPPLEMENT|Acidic beverage|Acidic beverage
223975241|NCT04514172|DEVICE|Passive industrial exoskeleton for back support|The goal is to compare the human response to the simulated industrial tasks
223975242|NCT04514172|OTHER|The protocol will be performed without exoskeleton|The protocol will be performed without exoskeleton
223975243|NCT05205252|DRUG|Tazemetostat|Orally, twice daily in continuous 28-day cycles.
223975244|NCT05205252|DRUG|Tafasitamab|Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
223975245|NCT05205252|DRUG|Lenalidomide|Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
223975246|NCT05205252|DRUG|Acalabrutinib|Orally, 100 mg, twice daily.
223975247|NCT05205252|DRUG|Daratumumab (Intravenously)|Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
224116530|NCT02421120|DRUG|Ceftolozane/Tazobactam|1 hour intravenous infusion
224116531|NCT02207530|DRUG|MEDI4736|MEDI4736 monotherapy
224116532|NCT02996695|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
224116533|NCT02996695|DRUG|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
223975248|NCT05205252|DRUG|Mosunetuzumab|Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
223975249|NCT05205252|DRUG|Daratumumab (Subcutaneously)|Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
223975250|NCT05205252|DRUG|Hyaluronidase-Fihj|Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
223975251|NCT05205252|DRUG|Pomalidomide|Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
224293157|NCT06522893|OTHER|Therapeutic exercise|The therapeutic exercise group (n=35) will perform progressive exercises for the cervical flexor and extensor muscles, once a week for 6 weeks (12 sessions in total). The protocol includes activation and recruitment of the deep cervical flexor muscles, isometric co-contraction exercises for both deep and superficial flexors, and eccentric and isokinetic exercises for both flexors and extensors. Each week's session will include the exercises for that week, along with the exercises from previous weeks, as detailed in the specific cervical spine exercise table, which indicates sets, repetitions, contraction time, and rest periods.
224293158|NCT05245201|OTHER|Standard of care|Two control clinics will be selected based on a set of matching criteria, e.g., urbanity and the sex, race, and age distributions of the patient population. Control clinics will not participate in study activities.
224293159|NCT05245201|OTHER|Clinical decision support for PrEP|Healthcare providers at 2 intervention clinics (total of approximately 60 providers anticipated) will be prompted by an EHR-based tool to discuss PrEP with patients whose demographics and clinical history indicate increased predicted HIV risk. Providers will be offered clinical decision support tools to guide sexual health discussions and support PrEP prescribing.
224293160|NCT04736108|DRUG|Abiraterone acetate|1000 mg orally daily for 24 weeks before radical prostatectomy
223975252|NCT05205252|DRUG|Dexamethasone 20mg|Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
223975253|NCT00067548|DRUG|EKB-569|
223975254|NCT01933529|DRUG|ARA 290|ARA 290 is injected s.c. once daily during the study period
223975255|NCT02723513|OTHER|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
223975256|NCT00053768|BIOLOGICAL|filgrastim|
223975257|NCT00053768|DRUG|EPOCH regimen|
223725594|NCT02447042|PROCEDURE|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
223975258|NCT00053768|DRUG|cyclophosphamide|
223975259|NCT00053768|DRUG|doxorubicin hydrochloride|
223975260|NCT00053768|DRUG|etoposide|
223975261|NCT00053768|DRUG|prednisone|
223975262|NCT00053768|DRUG|vincristine sulfate|
223975263|NCT00053768|RADIATION|radiation therapy|
223975264|NCT06039592|DRUG|Captopril Tablets|0.3mg/kg, tid
223975265|NCT06039592|DRUG|Metoprolol Oral Tablet|0.2mg/kg, bid
223975266|NCT06039592|DRUG|Spironolactone Tablets|2-4mg/kg, bid
223975267|NCT06039592|DRUG|Torsemide Tablets|0.2-0.5mg/mg, bid
223975268|NCT06039592|DRUG|Potassium citrate powder|0.06g/kg, tid
223975269|NCT02970786|DRUG|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c\[RGDyK\])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
223975270|NCT00953511|GENETIC|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
223975271|NCT01808521|DRUG|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
223975272|NCT00326703|PROCEDURE|Hypobaric hypoxia|
223975273|NCT04469452|DEVICE|Apollo Device|Comparisons will be made between the Apollo EE Device (Sable Systems International, Las Vegas, NV) and the TrueOne 2400 metabolic cart (Parvo Medics, Salt Lake City, UT)
223975274|NCT02780739|BEHAVIORAL|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
223975275|NCT02780739|BEHAVIORAL|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills \& Skills; and Cool-down/stretch.
223975276|NCT02780739|BEHAVIORAL|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
223975277|NCT02780739|DEVICE|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
223975278|NCT02780739|DEVICE|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
224116534|NCT02996695|BIOLOGICAL|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
224116535|NCT02996695|OTHER|Placebo|Placebo
224116536|NCT01523119|DRUG|Ondansetron|Orally Disintegrating Tablets 8 mg
224116537|NCT04099056|DEVICE|Neurostimulation|"Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Participants will receive neurostimulation in the form of Transcranial Magnetic Stimulation (TMS) or Temporal Interference (TI).~TMS: Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.~TI: Either during, or just before, any of the above tasks, participants will receive stimulation with TI. To do so, commercially available gel-based electrodes will be placed on the scalp to target the relevant brain region. The position targeted by the electrodes will be guided by previously defined coordinates."
224116538|NCT03962049|DRUG|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
224116539|NCT05034783|DRUG|[68Ga]Ga-HBED-CC-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
224116540|NCT05034783|DRUG|[68Ga]Ga-NOTA-exendin-4|Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
224116541|NCT02345161|DRUG|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
224293161|NCT04736108|DRUG|Prednisolone|5 mg oral low dose prednisone, once daily
223975279|NCT02780739|BEHAVIORAL|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
223975280|NCT01764698|BEHAVIORAL|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
224116542|NCT02345161|DRUG|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
224116543|NCT02345161|DRUG|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
224116544|NCT02345161|DRUG|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
224116545|NCT02345161|DRUG|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
224116546|NCT04364074|DIETARY_SUPPLEMENT|Goodbelly|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
224293162|NCT04736108|DRUG|Goserelin|10.8 mg goserelin hypodermic once per 12 weeks
224116547|NCT04364074|DIETARY_SUPPLEMENT|Placebo|To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
223725595|NCT02447042|DEVICE|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
223725596|NCT02165969|PROCEDURE|endoscopic endonasal surgery with UPSIT|
224116548|NCT00003264|DRUG|cisplatin|
224116549|NCT00003264|DRUG|gemcitabine hydrochloride|
224116550|NCT01573208|DEVICE|Custom guides|Symbios custom guides for TKA
223975281|NCT01764698|BEHAVIORAL|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
223975282|NCT01915992|OTHER|blood samples|
223975283|NCT00634218|BEHAVIORAL|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
223975284|NCT00634218|BEHAVIORAL|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
223975285|NCT00634218|BEHAVIORAL|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
223543260|NCT03749824|DIETARY_SUPPLEMENT|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
223543261|NCT03749824|DIETARY_SUPPLEMENT|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
223975286|NCT00634218|BEHAVIORAL|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
224116551|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
224116552|NCT03555279|BEHAVIORAL|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
224116553|NCT02636764|OTHER|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
224116554|NCT02636764|DEVICE|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (\<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
224116555|NCT02636764|DEVICE|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
223975287|NCT05484713|DIAGNOSTIC_TEST|Cardiac imaging|Baseline - 2D transthoracic echocardiography, 128-multislice CT coronary angiography, CCTA of peripheral lower limbs vessels 12-months follow-up - 128-multislice CT coronary angiography with transthoracic echocardiography
223543262|NCT04209374|DEVICE|THA with SYMBOL CUP DM HA|
223543263|NCT03952403|DRUG|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
223543264|NCT03952403|DRUG|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
223975288|NCT05484713|DEVICE|3D printing of the aortic valve|3D printing of the aortic valve based on CCTA image acquisition
223975289|NCT00306878|DRUG|Abatacept|
223975290|NCT01707706|OTHER|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
223975291|NCT04158973|OTHER|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
223975292|NCT04158973|OTHER|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
223975293|NCT00686088|DRUG|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
223975294|NCT04192539|DIAGNOSTIC_TEST|Taurine|Serum taurine was determined by High Performance Liquid Chromatography (HPLC) according to the pre-column extraction and derivatization methodology of McMahon et al. In the present work, we use Shimadzu HPLC model LC-10AT
223975295|NCT04915547|OTHER|Group-Based Exercise|"Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor."
223975296|NCT01560585|DRUG|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
223975297|NCT02725008|DRUG|Dexamethasone|
223725597|NCT01740947|DRUG|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
223975298|NCT02725008|DRUG|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
223975299|NCT04303871|DIAGNOSTIC_TEST|Invasive blood pressure assessment by radial artery canulation|radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
223975300|NCT05750277|OTHER|Evening Time-Restricted Eating|Eating between 8am-6pm.
223975301|NCT04631588|DRUG|Botox|Intradermal (ID) injection
223975302|NCT04631588|DRUG|Placebo|Intradermal (ID) injection
223975303|NCT01837589|OTHER|QCT|
223975304|NCT01837589|OTHER|DXA|
223975305|NCT05188898|OTHER|MINSD and Hyaluronic acid|After local anesthesia, MINSD will be performed using an ultrasonic scaler with fine tips and micro-curette; then, a hyaluronic acid-based gel will be applied to the intraosseous periodontal pockets.
223975306|NCT05188898|OTHER|MINSD|Only subgingival mechanical debridement (MINSD) will be performed with an ultrasonic scaler with fine tips and micro-curette.
223975307|NCT05456308|PROCEDURE|Hydrodistention during cystoscope|Hydrodistention for treatment of interstitial cystitis will be performed. Participants will be randomly selected to one of the arms described. There are three variables that they will be assigned: the pressure of fluid in the bladder that will be filled, the duration of time that the fluid will be held in the bladder, and the number of times the procedure is completed.
223975308|NCT01240252|DRUG|Human insulin|U100 Humulin at a rate of 80 mU/m\^2 surface area per minute one time over 4 hours
223975309|NCT06546761|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
224116556|NCT02636764|DEVICE|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
224116557|NCT02636764|DEVICE|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
224116558|NCT02045277|DRUG|IDP-118 Lotion|Lotion
224116559|NCT02045277|DRUG|IDP-118 Monad HP Lotion|Active Comparator
224116560|NCT02045277|DRUG|IDP-118 Monad Taz Lotion|Active Comparator
224116561|NCT02045277|DRUG|IDP-118 Vehicle Lotion|Vehicle
224116562|NCT00824486|BEHAVIORAL|Injury prevention education (TIPP)|using TIPP materials
224116563|NCT00824486|BEHAVIORAL|Injury prevention education (safe home)|using safe home model
224116564|NCT03468283|OTHER|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
223975310|NCT01363297|DRUG|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2."
223975311|NCT02515097|DRUG|IDP-122 Lotion|Medicated topical lotion
223975312|NCT02515097|DRUG|IDP-122 Vehicle Lotion|Vehicle topical lotion with no active ingredient
223975313|NCT01624012|DEVICE|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
223975314|NCT01624012|DEVICE|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
223975315|NCT05813132|DRUG|BEAM Protocol|BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)
223975316|NCT05813132|DRUG|CEM protocol|CEM (Carboplatin, Etoposide, Melphalan)
223975317|NCT05383053|DEVICE|NeuroAI|"NeuroAI is an artificial brain diagnostic software that determines whether to perform amyloid PET tests for Alzheimer's by specialists through the detection of amyloid PET positive rates based on brain MR images (T1 weighted MRI, T2 FLAIR MRI) and clinical information (age, gender, and APOE) genotype.~When using this product, input gender, birth year, and apolipoproteinE (APOE) genotype and upload T1 MR image and T2 Flair image, input data and image analysis result data are integrated to infer the positive rate of amyloid PET by PET positive prediction model. The result report provides image analysis results and amyloid PET positive prediction results compared to normal groups."
223975318|NCT01914458|PROCEDURE|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
223975319|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
223975320|NCT02453802|DRUG|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
224116565|NCT05424900|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
224116566|NCT03642015|BEHAVIORAL|Music listening|listening the music 15 min
223725598|NCT04765956|DEVICE|Drug-eluting balloon treatment|Drug-eluting balloon (DEB) treatment of lipid-rich plaque
223725599|NCT03191994|BEHAVIORAL|Exercise|a structured, supervised eight week moderate intensity exercise intervention
223725600|NCT01022229|DIETARY_SUPPLEMENT|Compound Natural Health Product|"* 15-35 mg zinc citrate~* 150-350 mg magnesium lactate~* 30-70 mg pyridoxine hydrochloride~* 150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
223725601|NCT01022229|DIETARY_SUPPLEMENT|Placebo|Placebo
223725602|NCT03748888|BEHAVIORAL|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
223725603|NCT03390816|OTHER|Nutritional assessment|Observational
223725604|NCT00958750|DRUG|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
223725605|NCT01082991|OTHER|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
223975321|NCT02453802|DRUG|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
223975322|NCT02453802|DRUG|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
223975323|NCT02453802|DRUG|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
223975324|NCT05621746|DRUG|Esperoct|Participants will be treated with commercially available Esperoct for a total study duration of 24 months according to the local label and local routine clinical practice at the discretion of the physician. The decision to switch to Esperoct will be made prior to and separate from the decision to enrol in the study.
223975325|NCT04751019|DEVICE|Amber Glasses|It is hoped that the use of amber glasses to complement the natural sleep-wake by inducing a perceived 'physiological darkness' to aid the secretion of melatonin should help sleep and reduce the use of hypnotic medication
223975326|NCT02709447|BEHAVIORAL|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
223975327|NCT02709447|BEHAVIORAL|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
223975328|NCT03601949|DEVICE|SInergy Cooled Radiofrequency|ablation of low back pain
224116567|NCT04366986|OTHER|Tested for SARS-CoV-2 (regardless of the result)|This is an observational study with no intervention
224116568|NCT04366986|OTHER|Clinical diagnosis of COVID-19 by a health care professional|This is an observational study with no intervention
224116569|NCT03066817|DRUG|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
224116570|NCT03066817|DRUG|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
224116571|NCT02238028|BEHAVIORAL|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
224116572|NCT05367687|DRUG|Camrelizumab、Rivoceranib|Camrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.
223975329|NCT03601949|OTHER|Medical Management|physical therapy, medications, lifestyle changes
223975330|NCT00025545|DRUG|cyclophosphamide|
223975331|NCT00025545|DRUG|methotrexate|
223975332|NCT00025545|PROCEDURE|peripheral blood stem cell transplantation|
223975333|NCT00025545|RADIATION|radiation therapy|
223975334|NCT02411214|OTHER|survey|questionnaire survey sent by regular mail for 3 groups
223975335|NCT01393314|DEVICE|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
223975336|NCT06264661|BEHAVIORAL|Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia|Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR.
223975337|NCT02269683|PROCEDURE|Robot-assisted distal pancreatectomy|
223975338|NCT02269683|PROCEDURE|Laparoscopic distal pancreatectomy|
223975339|NCT00574171|DRUG|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
223975340|NCT00574171|DRUG|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
223975341|NCT00405002|PROCEDURE|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
223975342|NCT02026505|DRUG|Bortezomib|
223975343|NCT00404599|DRUG|atrorvastatin 10mg|Atorvastatin 10 mg once a day
223975344|NCT00404599|DRUG|simvastatin 40mg|simvastatin 40mg once a day
223975345|NCT06140485|DIETARY_SUPPLEMENT|NW Low-Glu®|One NW Low-Glu® capsule contains Mas Cotek powdered Extract 300 mg (from leaves of Ficus deltoidea Jack by aqueous solvent extraction) + Cinnamomum cassia L. powdered Extract 100 mg + Black seed powdered extract 250 mg (from seeds of Nigella sativa L. by 70% hydro-alcoholic extraction).
223975346|NCT06140485|DRUG|Metformin|Patients in the active comparator arm will receive a total of 2000 mg of metformin per day.
224116573|NCT05367687|DRUG|Camrelizumab|Camrelizumab: 200 mg, intravenous infusion.
224116574|NCT05217979|DEVICE|Transcutaneous pulsed radiofrequency|single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
223975347|NCT05240664|BEHAVIORAL|Have A Say Programme|Each dyad of participants will receive a 4-session ACP programme, which consists of 2 group-based sessions and 2 dyadic sessions, one hour for each session. The group-based sessions are led by nurse which include didactic educational components, guided reflection, videos, and group sharing. Dyads of participants will be provided with information about ACP, the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are facilitated by trained ACP facilitators and guided by an ACP booklet. Dyads of participants will be supported to have an individualized ACP discussion guided by an ACP booklet. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
223975348|NCT05240664|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 4-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health, and healthy diet.
223975349|NCT03652870|DRUG|Nortriptyline|A medication used to treat conditions such as depression
223975350|NCT03652870|DRUG|Escitalopram|A medication used to treat conditions such as depression
223975351|NCT03652870|DRUG|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
223975352|NCT06116942|DEVICE|Active rTMS|"The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil.~In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas."
223975353|NCT06116942|DEVICE|Sham rTMS|To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.
223975354|NCT05765838|DIAGNOSTIC_TEST|(NPS right - Nasal swab left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975355|NCT05765838|DIAGNOSTIC_TEST|(NPS left - Nasal swab right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
224116575|NCT05217979|DEVICE|Sham|Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
223725606|NCT06318195|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
223725607|NCT03585998|DRUG|Durvalumab|Concurrent radiotherapy Maintenance therapy
223975356|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - NPS left - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975357|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - NPS right - OPS)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975358|NCT05765838|DIAGNOSTIC_TEST|(NPS right - OPS - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975359|NCT05765838|DIAGNOSTIC_TEST|(NPS left - OPS - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975360|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab right - OPS - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975361|NCT05765838|DIAGNOSTIC_TEST|(Nasal swab left - OPS - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
224116576|NCT04875819|DRUG|Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine|One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.
223725608|NCT05422196|PROCEDURE|Platelet-rich fibrin|Addition of platelet-rich fibrin into the cleft site.
223725609|NCT05742100|DRUG|Darvadstrocel|expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas
223725610|NCT00764647|BEHAVIORAL|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
223725611|NCT00458211|DRUG|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
223975362|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS right - Nasal swab left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975363|NCT05765838|DIAGNOSTIC_TEST|(OPS - NPS left - Nasal swab right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975364|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab left - NPS right)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975365|NCT05765838|DIAGNOSTIC_TEST|(OPS - Nasal swab right - NPS left)|Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
223975366|NCT04407533|OTHER|Diet tracking and survey|Mobile AI-based food diary application and online questionnaires
223975367|NCT01547182|BEHAVIORAL|Caloric restriction|Caloric restriction
223975368|NCT01547182|BEHAVIORAL|Aerobic Training|Walking
223975369|NCT01547182|BEHAVIORAL|Resistance Training|Lifting weights
223975370|NCT03505918|OTHER|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
223975371|NCT03927742|BEHAVIORAL|Shade + app with messaging|Shade wearable device and application with UV messaging activated
223975372|NCT03927742|BEHAVIORAL|Shape + app without messaging|Shade wearable device and application without UV messaging activated
223975373|NCT04027673|BEHAVIORAL|TMW ECE Curriculum|The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
223975374|NCT04340466|OTHER|No intervention|No intervention
223975375|NCT04238130|DIAGNOSTIC_TEST|Perioperative ctDNA Dynamic Monitoring|To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
223975376|NCT02611921|DRUG|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
223975377|NCT02611921|DRUG|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
223975378|NCT03456635|OTHER|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
223975379|NCT05404126|OTHER|exercise|• Static exercises and dynamic exercises to group 2; Hearing impaired children in group 3 will be given motor-motor double-task and motor-cognitive double-task exercises in addition to conventional balance exercises.
223975380|NCT04713813|OTHER|Therapeutic exercise program via hippotherapy mechanical stimulator|Patients were planned to complete hippotherapy exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
223975381|NCT04713813|OTHER|Therapeutic home exercise program|Patients were planned to complete home exercises sessions 3 times a week for 12 weeks, each lasting 35 minutes per sessions.
223975382|NCT00005968|DRUG|irofulven|
223975383|NCT01169571|DRUG|Dexmedetomidine|
223975384|NCT06584747|DIAGNOSTIC_TEST|PET scan|18F-FDG PET scans will be performed to assess cerebral vascular reserve. For exams involving stimulation with Acetazolamide (DIAMOX®), the radiopharmaceutical injection (18F-FDG or 99mTc-HMPAO) will start exactly 15 minutes after the Acetazolamide (DIAMOX®) injection.
223975385|NCT05583734|DEVICE|Portomar(TM) Device|Portomar(TM) access device for bone marrow biopsy
223975386|NCT03291873|PROCEDURE|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
223975387|NCT00523133|DRUG|naltrexone|50 mg naltrexone daily for 3 months
223975388|NCT00523133|DRUG|naltrexone|50 mg of naltrexone daily for 6 months
223975389|NCT00523133|BEHAVIORAL|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
223975390|NCT00523133|BEHAVIORAL|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
223975391|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
224116577|NCT04875819|DRUG|13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine|One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
224116578|NCT02196142|DRUG|Cortisol 20mg|Drug: Cortisol 20mg
224116579|NCT02196142|DRUG|Placebo Mannitol|Drug: Placebo Mannitol
223975392|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
223975393|NCT01180790|DRUG|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
223975394|NCT01180790|DRUG|Placebo|Powder in capsule once daily
223975395|NCT01180790|DRUG|Pegylated Interferon alpha-2a|180 micrograms (ug) once a week by subcutaneous injection
223975396|NCT01180790|DRUG|Ribavirin|400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily
223975397|NCT02789098|OTHER|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
223975398|NCT01885377|OTHER|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
223975399|NCT01885377|OTHER|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
223975400|NCT01628783|DRUG|escitalopram 10 mg|orally once daily
223975401|NCT01628783|DRUG|Placebo|once daily
224116580|NCT03777579|DRUG|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
224116581|NCT03777579|DRUG|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
224116582|NCT03777579|DRUG|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
224116583|NCT02834052|DRUG|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
224116584|NCT02834052|DRUG|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
224116585|NCT00305006|PROCEDURE|Constraint-Induced Movement Therapy (CIMT)|90 hours
224116586|NCT00305006|PROCEDURE|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
224116587|NCT02484196|BEHAVIORAL|Questionnaires|Questionnaires
224116588|NCT06472700|OTHER|No intervention|No intervention
224116589|NCT03793816|DEVICE|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
224116590|NCT03071224|DRUG|[18F] MNI-946|Subjects will undergo PET imaging using \[18F\]MNI-946, a PET radioligand for imaging tau.
223975402|NCT04263883|DEVICE|Study or Experimental Group|3D PCO to make mirror image therapy (reverse posture training) during the patient walking on motorized treadmill, This way of functional training will deliver via the use of the adjustable cervicothoracic orthosis during the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image traction.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill based on Harrison et al., approach, this program will be repeated 2-3 times /week for 10weeks.
223975403|NCT02517476|DIETARY_SUPPLEMENT|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
223975404|NCT02332434|OTHER|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
223725612|NCT06505317|DIAGNOSTIC_TEST|AI-based PAD screening intervention|"Providers will receive alerts for a patient that is flagged by model as being high risk for PAD. This will allow the provider to review the alert, check the patient's previous history, develop additional questions to assess the risk of PAD, and initiate orders prior to seeing a patient. Depending on their assessment during the patient visit the provider may choose to order an ABI test (or perform one at bedside) and/or initiate other secondary prevention measures. All patients for which an alert is triggered will be included for secondary analysis."
223975405|NCT03379909|DRUG|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
224116591|NCT03071224|DRUG|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-946.
223725613|NCT04403477|BIOLOGICAL|Convalescent plasma|Apheretic convalescent plasma from a COVID-19 survivor
223725614|NCT00052689|DRUG|bortezomib|Given IV
223725615|NCT00052689|DRUG|gemcitabine hydrochloride|Given IV
223725616|NCT03854305|DRUG|PRV-6527|Treatment
223725617|NCT03854305|DRUG|Placebo|Comparator
223725618|NCT05276193|OTHER|Observational health care register - no applicable intervention at present|Observational health care register - no applicable intervention at present
223975406|NCT00263783|DRUG|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]
223975407|NCT05905445|DRUG|ozone gel|the activity of omega-3 in the ozone gel may be advantageous as a host-modulating agent in the supplemental treatment of periodontitis
224116592|NCT05348187|DIAGNOSTIC_TEST|therascreen® KRAS RGQ PCR Kit|The primary objective is to utilize a clinical trial assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 2 of Amgen clinical trial, in order to identify patients (with NSCLC and CRC) with KRAS G12C mutation positive tumors
223975408|NCT01189136|DEVICE|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
223975409|NCT01189136|OTHER|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
223975410|NCT06593288|OTHER|Pressure Support Ventilation|Conduct the Spontaneous breathing trial with pressure support
223975411|NCT06593288|OTHER|continuous positive airway pressure (CPAP)|Conduct the spontaneous breathing trial with CPAP
223975412|NCT05264649|DEVICE|acupuncture|"The acupuncture group were consisted of twelve 30 minutes sessions 2 times per week sessions for 6 weeks. The acupoints were included full body protocol (LI4, LR3, and PC7) and joint-specific protocol tailored as many as three of the patient's most painful joint areas. After 20 minutes De Qi reported by patients, needles were restimulated manually and removed after an additional 10 minutes."
223725619|NCT03322878|DRUG|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
223725620|NCT00662805|DRUG|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
223975413|NCT05264649|DRUG|Guizhi-Shaoyao-Zhimu decoction|The patients consumed GZSD (4g paper bagged medicine) three times per day (total daily dose was 12 g/day) continuously during the 6-week intervention period.
223975414|NCT06589453|DEVICE|Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants|This is a unique nasal elevator aiming to improve nasolabial esthetics in conjunction with digital nasoalveolar molding appliance when used in bilateral cleft lip and palate infants.
223975415|NCT06589453|DEVICE|Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants|Nasal stent that is used in conjunction with digital nasoalveolar molding in bilateral cleft lip and palate infants
223975416|NCT04601090|OTHER|ICU treatment|This is an observational study, so all patients will undergo a variation of ICU treatment, and we will record that information (e.g., time on ventilator, time in ICU, SAPS score at admission)
223725621|NCT03206528|DEVICE|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
223725622|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
223725623|NCT03991572|DEVICE|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
223725624|NCT03761524|PROCEDURE|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
223725625|NCT03761524|PROCEDURE|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
223725626|NCT04984083|DIETARY_SUPPLEMENT|vitamin k|patients will take vitamin k 10 mg/ml once daily orally or IM between four and 96 hours before elective cesarean section
223725627|NCT01207869|BIOLOGICAL|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
223725628|NCT01207869|OTHER|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
223725629|NCT04080414|BEHAVIORAL|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
223725630|NCT04080414|BEHAVIORAL|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
223725631|NCT03781596|DIAGNOSTIC_TEST|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
223725632|NCT03781596|OTHER|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
223725633|NCT03781596|OTHER|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
223975417|NCT01379989|DRUG|Carboplatin|Carboplatin AUC 5
223975418|NCT01379989|DRUG|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
223975419|NCT01379989|DRUG|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
223975420|NCT05085808|DRUG|Trazodone|Trazodone will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the trazodone arm.
223975421|NCT05085808|DRUG|Quetiapine|Quetiapine will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the quetiapine arm.
223975422|NCT05085808|DRUG|Placebo|Placebo will be administered to ICU patients who need pharmacological intervention for delirium, if they are randomized to the placebo arm.
223975423|NCT02074878|DRUG|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
223975424|NCT02074878|DRUG|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
223975425|NCT02074878|DRUG|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
223975426|NCT06620432|PROCEDURE|Low segment hysterotomy|A low segment hysterotomy is a surgical procedure in which an incision is made in the lower segment of the uterus, typically during a cesarean section or other uterine surgeries. This approach is preferred because the lower uterine segment is thinner and less vascular, reducing the risk of bleeding and complications during and after the procedure. The incision is typically horizontal.
223975427|NCT06620432|PROCEDURE|High segment hysterotomy|A high segment hysterotomy is a surgical procedure involving an incision in the upper segment of the uterus.
223725634|NCT03781596|DIAGNOSTIC_TEST|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
223725635|NCT03781596|OTHER|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
223725636|NCT03781596|DRUG|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
223725637|NCT03781596|DRUG|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
223725638|NCT03781596|DRUG|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
223725639|NCT01655472|DEVICE|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
223725640|NCT01655472|DEVICE|imaging follow up: Ultrasonographic examination|
223725641|NCT05778916|PROCEDURE|5 year follow up on patients operated for hallux valgus deformity|Clinical and radiological control of patients operated for hallux valgus deformity between 2016-2018.
223975428|NCT06620432|PROCEDURE|Crossed hysterorrhaphy|Crossed hysterorrhaphy is a surgical technique used to close the uterine incision following a hysterotomy, particularly during cesarean sections. In this method, the sutures are placed in a crossed or X-shaped pattern, which helps to evenly distribute tension across the incision site.
223975429|NCT06620432|PROCEDURE|Non-Crossed hysterorrhaphy|Non-crossed hysterorrhaphy is a surgical technique used to close a uterine incision, typically after a hysterotomy, such as during a cesarean section. In this method, the sutures are placed in a linear, parallel fashion rather than in a crossed or X-shaped pattern
223975430|NCT03713437|DIAGNOSTIC_TEST|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
224116593|NCT02606045|DRUG|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
223975431|NCT07007767|DRUG|sintilimab|"Sintilimab (anti-PD-1 monoclonal antibody) Specification: 100 mg/10 mL (10 mg/mL concentrated solution)~Administration:~Dose: 200 mg (fixed dose) Route: Intravenous (IV) infusion over 30-60 minutes Schedule: Day 1 of each 21-day cycle (Q3W)"
223975432|NCT07007767|DRUG|Bevacizumab Biosimilar|"Bevacizumab biosimilar (anti-VEGF monoclonal antibody) Specification: 100 mg/4 mL (25 mg/mL concentrated solution)~Administration:~Dose: 7.5 mg/kg (body weight-adjusted) Route: IV infusion Schedule: Day 1 of each 21-day cycle (Q3W)"
223725642|NCT05881915|DRUG|Phenylephrine|phenylephrine infusion at rate of 0.4 mcg/Kg/min. (10 mg /1 mL) will be diluted to reach a final concentration of 10 mcg/mL
223725643|NCT05881915|DRUG|Epinephrine|epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
223725644|NCT00346112|PROCEDURE|psycho-educational|
223725645|NCT03721601|DEVICE|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
223725646|NCT03721601|DEVICE|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
223975433|NCT07007767|DRUG|Decitabine|"Decitabine (hypomethylating agent) Specification: 10 mg lyophilized powder per vial~Administration:~Dose: 10 mg/m²/day (body surface area-adjusted) Route: IV infusion over 1 hour Schedule: Days 1-5 of each 21-day cycle (Q3W)"
223975434|NCT03386799|DEVICE|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
223975435|NCT01996397|PROCEDURE|Cardiac resynchronization therapy device implantation|
223975436|NCT06719648|DEVICE|Acellular dermal matrix + L-Prf|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
223975437|NCT06719648|PROCEDURE|Connective Tissue graft + L-Prf|"Incisions: Incisions were made in the gums using a specialized scalpel. Flap Elevation: The gum tissue was lifted away from the underlying bone using a dental elevator.~Partial Thickness Dissection: The tissue was cut to release tension and allow for easier repositioning.~Interdental Papilla Elevation: The gum tissue between the teeth was partially lifted.~Flap Extension: The flap was extended to cover more teeth for better coverage. Tissue Separation: The flap was carefully separated from underlying tissues to allow for proper positioning.~Root Preparation: The exposed root surfaces were smoothed and cleaned."
223975438|NCT06720571|DEVICE|Auricular vagal neuromodulation therapy (aVNT)|The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.
223975439|NCT06720571|DEVICE|Sham Auricular vagal neuromodulation therapy (aVNT)|The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.
223975440|NCT06720480|DIAGNOSTIC_TEST|Homglobin Electrophoresis|To diagnose thalassaemia \&amp;best method to control disease progress
223975441|NCT06719921|PROCEDURE|AF ablation|"The primary ablation strategy for both groups will be pulmonary vein isolation (PVI).~Other additional ablation, including but not limited to linear ablation, complex fractionated atrial electrogram (CFAE) ablation, or superior vena cava (SVC) isolation is not recommended unless necessitated by one of the following:~* Documented atrial flutter (AFL) or atrial tachycardia (AT) observed during the procedure, or~* Arrhythmias originating from the specific region requiring intervention."
223975442|NCT06719921|OTHER|AF ablation in a non-fluoroscopic EP lab|This procedure will take place in a non-fluoroscopic lab.
223975443|NCT06719921|OTHER|AF ablation in a fluoroscopic lab|This procedure will take place in a fluoroscopic lab.
223975444|NCT06720532|DIAGNOSTIC_TEST|characterization of renal function.|Blood and urine sample collection
223975445|NCT06720532|DIAGNOSTIC_TEST|Handgrip strength test|Assess the peak isometric strength of the hand and forearm muscles, as well as their susceptibility to fatigue.
223975446|NCT06720532|DIAGNOSTIC_TEST|Questionaires|The questionnaires evaluate quality of life, psychological distress, fear of progression, frailty, pain, decision regret and treatment expectations.
223975447|NCT06720779|OTHER|TRAK physio knee prosthesis protocol|The exercise protocol designed for knee conditions is carried out through TRAK, the digital rehabilitation tool.
223975448|NCT06720779|OTHER|Knee conventional rehabilitation program|Exercise protocol with the methodology of conventional clinical practice.
223975449|NCT01029678|DRUG|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
223975450|NCT01029678|DRUG|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
223975451|NCT01029678|RADIATION|Radiotherapy|66Gy, 33 fractions, 6 week
223975452|NCT00938288|DRUG|KW-3357|50IU/mL, IV single dose
223975453|NCT00202332|PROCEDURE|Coronary artery bypass|
223543265|NCT03952403|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
223543266|NCT03952403|DRUG|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
223543267|NCT04064476|DRUG|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
223543268|NCT02590107|DIETARY_SUPPLEMENT|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
223543269|NCT02590107|DIETARY_SUPPLEMENT|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
223543270|NCT02590107|DIETARY_SUPPLEMENT|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
223543271|NCT02590107|OTHER|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
223975454|NCT06090760|BEHAVIORAL|Mindfulness|"Mindfulness is paying attention in a particular way: on purpose, in the present moment, and non-judgmentally (Kabat-Zinn 1994, 4) and has five facets: awareness, nonjudgement, nonreactive, observe, and describe (Baer et al., 2006)."
223975455|NCT00153348|BEHAVIORAL|Women's health|
223975456|NCT01568112|DRUG|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
223975457|NCT01568112|DRUG|BG00012 placebo|Placebo matching BG00012
223975458|NCT01568112|DRUG|ASA|325 mg microcoated aspirin (ASA)
223975459|NCT01568112|DRUG|ASA placebo|Placebo matching aspirin
223975460|NCT06098443|OTHER|Acupressure|Acupressure is effective on anxiety and depression management. acupressure therapy at K1, ST36, and SP6 acupoints significantly reduced anxiety \& depression in patients with ESRD.
224116594|NCT02606045|DRUG|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
224116595|NCT00907881|DRUG|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
223543272|NCT03893981|OTHER|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
223543273|NCT03893981|OTHER|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
223543274|NCT04660734|PROCEDURE|Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.|Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
223543275|NCT02184065|DRUG|Meloxicam|
223725647|NCT04367636|BEHAVIORAL|Behavioral: OCAT-sham|Placebo version of the online contingent attention training preceded by psycho-education movieclip.
223725648|NCT04367636|BEHAVIORAL|Behavioral: OCAT|Online contingent attention training preceded by psycho-education movieclip.
223975461|NCT06098443|DEVICE|Transcutaneous electrical nerve stimulation|TENS lead to meaningful reduction of pain in patients suffering from difficult to treat phantom limb pain. This treatment has a high success rate and is associated with high satisfaction rates and no reported adverse events. The suggested duration of treatment is at least 30 minutes and may be extended up to 45 minutes. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extra segmental analgesia. TENS delivers pulsed electric currents across the intact surface of the skin to stimulate peripheral nerves and the spinal cord, resulting in segmental and extrasegmental analgesia. (Vathakul et al., 2022).
223975462|NCT06401096|PROCEDURE|Preoperative respiratory exercises|The Triflo Exerciser
223725649|NCT04367636|OTHER|psycho-education video|Both groups get to see a psycho-education video before the smartphone training starts.
223975463|NCT03390933|DRUG|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
223975464|NCT03371706|BEHAVIORAL|Communication Bridge™|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
223975465|NCT03371706|BEHAVIORAL|Evidence-Based Impairment Focused|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
223725650|NCT01647620|DRUG|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
223725651|NCT01647620|DRUG|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
223725652|NCT01118221|BEHAVIORAL|pulmonary rehabilitation|structured exercise program
223975466|NCT00832364|DRUG|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
224116596|NCT01391312|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
223975467|NCT00832364|DRUG|Placebo|Placebo capsules
223975468|NCT00832364|BIOLOGICAL|Etanercept|Injectable Biologic
223975469|NCT00560313|BIOLOGICAL|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
223975470|NCT00560313|BIOLOGICAL|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
224116597|NCT01391312|DRUG|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
224116598|NCT06642337|OTHER|Educational program +Oral Iron therapy|The Nutritional Education Program is a structured intervention designed to enhance caregivers' understanding of nutrition and improve dietary practices for children suffering from iron deficiency anemia. The program comprises six weekly workshops lasting 1.5 hours each, focusing on essential topics such as the importance of iron in child development, identifying and preparing iron-rich foods, and practical meal planning strategies. Participants will engage in hands-on cooking demonstrations and receive educational materials, including recipe cards and meal planning tools, to support their learning. Knowledge assessments will be conducted at the beginning and end of the program to measure improvements in caregivers' nutritional knowledge.
224116599|NCT03440372|DRUG|Ozanimod|Specified dose on specified days
224116600|NCT03440372|OTHER|Placebo|Specified dose on specified days
224116601|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
223975471|NCT04786483|OTHER|Laughter Theraphy|"Laughter therapy will be applied for 60 minutes, 10 sessions, 2 days a week. The therapy, which starts with the stimulation of the acupuncture points in the palm and acquaintance with hand clapping for an average of 10 minutes, continues with deep breathing and breathing exercises that include diaphragmatic breathing. The childish games section, which is played to reveal and trigger simulated laughter, is the section where laughter starts as if and turns into reality. The last part is the part where the group makes eye contact for no reason and for no reason, and laughs for at least 3 minutes unconditionally. In the last part, wish meditation and relaxation sessions are performed."
223975472|NCT05750342|DIETARY_SUPPLEMENT|Experimental Product Caqui|Supplement extracted from persimmon
223975473|NCT05750342|DIETARY_SUPPLEMENT|Control product placebo|Product with identical characteristics to the experimental product.
223975474|NCT00315666|DRUG|memantine|
223975475|NCT04290611|DRUG|Enzalutamide|Enzalutamide for the treatment of prostate cancer or other solid tumors
223975476|NCT06462274|OTHER|body sample collection and imaging scan|
223975477|NCT06400797|OTHER|estimation of patient outcome by health care providers|On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.
223725653|NCT03069547|OTHER|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~\- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
223975478|NCT00747695|DRUG|Rabeprazole sodium|
223975479|NCT00835510|DRUG|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
223975480|NCT00835510|DRUG|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
223975481|NCT00835510|DRUG|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
223975482|NCT05140707|OTHER|Virtual Reality Distraction|The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
223975483|NCT04926441|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
223975484|NCT04578587|DEVICE|MicroFET 2|Lumbar Flexor and Extensor Strength Measurement
223975485|NCT05817474|DRUG|lidocaine (2 %) 2 ml and tranexamic acid|lidocaine (2 %) 2 ml and tranexamic acid 2 ml in each tonsillar bed
223975486|NCT03300609|BIOLOGICAL|Panitumumab|Given IV
223975487|NCT03300609|DRUG|Oxaliplatin|Given IV
223975488|NCT03300609|DRUG|Leucovorin Calcium|Given IV
223975489|NCT03300609|DRUG|Fluorouracil|Given IV
223975490|NCT03300609|DRUG|Capecitabine|Given PO
223975491|NCT03300609|OTHER|Quality-of-Life Assessment|Ancillary studies
223975492|NCT03300609|OTHER|Laboratory Biomarker Analysis|Correlative studies
223975493|NCT03090971|DRUG|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
223975494|NCT03090971|DRUG|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
224116602|NCT02965898|DIETARY_SUPPLEMENT|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
224116603|NCT02972723|DRUG|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
224116604|NCT02950662|OTHER|Overdenture|Active comparator will be metal housing and peek housing
224116605|NCT02298270|BEHAVIORAL|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
224116606|NCT01996319|DRUG|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
223975495|NCT05238155|DRUG|antimetabolite|When OLT recipients are discharged following transplantation, they are typically prescribed a triple immunosuppression maintenance regimen, consisting of a calcineurin inhibitor, an antimetabolite, and a corticosteroid. Over the last several years, there have been changes made to this protocol, and the current protocol now suggests
223975496|NCT04166110|DRUG|Predetermined treatment duration|Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
223975497|NCT04166110|DRUG|Variable treatment duration|"Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment."
223975498|NCT04083937|RADIATION|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
223975499|NCT04083937|RADIATION|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
223975500|NCT04083937|RADIATION|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
223975501|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
223975502|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
223975503|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
224116607|NCT01996319|DRUG|Placebo|Placebo once a day via Breezhaler® device
224116608|NCT03627455|OTHER|Percutaneous coronary intervention|Percutaneous coronary intervention
224293163|NCT06823518|BEHAVIORAL|Thrive Initiative Parent-Education Programming|The Thrive Initiative Parent-Education programs are universal prevention programs designed to support parents as they raise their children. There are four programs that correspond to specific child developmental periods. The programs include: Take Root for parents/caregivers of 0-3-year-old children; Sprout for parents/caregivers of 3-5-year-old children; Grow for parents/caregivers of 5-10-year-old children; and Branch Out for parents/caregivers of 10-18-year-old children. Each program focuses, in developmentally appropriate ways, on three primary dimensions: positive parenting, stress management, and healthy lifestyles. Each program is available in either an online-only format or a hybrid format, which includes group meetings in addition to the online program components.
223975504|NCT01442077|DEVICE|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
223975505|NCT01011699|DRUG|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
223975506|NCT01011699|DRUG|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
224116609|NCT01820689|OTHER|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
224116610|NCT04787809|BEHAVIORAL|Living Well|Living Well is a single session digital intervention that aims to decrease experiential avoidance and increase engagement in values-consistent behavior.
224116611|NCT03229746|DRUG|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
224116612|NCT03229746|DRUG|vincristine|1mg intravenous weekly for 4 weeks
224116613|NCT03229746|DRUG|azathioprine|dose 100mg daily for at least 3 weeks
224293164|NCT05730907|DRUG|Levosimendan|examine whether levosimendan could improve in-hospital survival with good neurological outcomes in patients with cardiac arrest supported by E-CPR
224116614|NCT00050349|DRUG|EPO906 epothilone B|
224116615|NCT00483249|DEVICE|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
224116616|NCT03552705|DRUG|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
224116617|NCT03552705|DRUG|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
224116618|NCT05772650|BEHAVIORAL|e-Health Program|Lifestyle modification for health and disease management using digital solutions
224116619|NCT01671085|DRUG|LY3015014|Administered SQ
224116620|NCT01671085|DRUG|Placebo|Administered SQ
224116621|NCT00637273|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
224116622|NCT00637273|DRUG|sitagliptin|oral tablet, 100mg, once a day
224116623|NCT00637273|DRUG|pioglitazone|oral tablet, 45mg, once a day
224116624|NCT00637273|DRUG|placebo tablet|oral tablet, once a day
224116625|NCT00637273|DRUG|placebo once weekly|subcutaneous injection, once a week
224116626|NCT05240950|DRUG|Anti-CEA CAR-T Cells|"The study will evaluate the safety of intravenous infusion of anti-CEA CAR-T (+) cells in humans at doses of 1×10\^6/kg, 3×10\^6/kg, and 6×10\^6/kg using a standard 3+3 design and preliminarily observe the efficacy."
223725654|NCT03069547|OTHER|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~\- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
223725655|NCT02943278|BEHAVIORAL|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
223975507|NCT01011699|DRUG|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH \> 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH \< 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be \< 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia \< 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
223975508|NCT03631303|DEVICE|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
224116627|NCT01266707|BIOLOGICAL|antiangiogenic paptide vaccine|for drugs include administration time frame
224116628|NCT02733692|BEHAVIORAL|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
224116629|NCT03471845|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
224116630|NCT01762293|DRUG|Famitinib|Famitinib 25 mg p.o. qd
224293165|NCT03736759|BEHAVIORAL|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
224293166|NCT03250390|DEVICE|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
224293167|NCT05102019|DEVICE|Arm 1: treatment with Shockwave Reducer|Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
223975509|NCT00668330|DRUG|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
224116631|NCT01762293|OTHER|placebo|p.o. qd
224293168|NCT05102019|OTHER|Arm 2 (control): Implantation procedure with no device implanted|No device is implanted
224293169|NCT05102019|DEVICE|Arm 3 (unblinded, non-randomized): Single arm registry|Shockwave Reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
223975510|NCT00668330|DRUG|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
223975511|NCT02257229|PROCEDURE|Surgical|Surgery only
223975512|NCT02257229|PROCEDURE|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
223975513|NCT02257229|PROCEDURE|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
223975514|NCT01939561|DRUG|Lamotrigine|
223975515|NCT01939561|DRUG|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
223975516|NCT00238953|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223975517|NCT06956326|BEHAVIORAL|Intensive rehab|Frequent moderate-to-high intensity physical therapy, provided by local physiotherapists.
223975518|NCT06956326|BEHAVIORAL|Usual care|Usual care physiotherapy
223975519|NCT06957613|PROCEDURE|Revascularization/Conservative management|Percutaneous Transluminal Angioplasty of Coronary Chronic Total Occlusions via Dedicated Drug Eluting Stents and/or Balloons.
223975520|NCT01966198|OTHER|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
223975521|NCT03629899|DEVICE|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
223975522|NCT06084676|DRUG|Immunotherapy|Organoid samples will be collected at time of biopsy and cultured in the lab. The samples will then receive the same standard of care immunotherapy treatment as the patient.
223975523|NCT00526097|DRUG|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
223975524|NCT00526097|DRUG|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
223975525|NCT02139462|OTHER|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
223975526|NCT02139462|OTHER|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
223975527|NCT00855725|OTHER|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
223975528|NCT00855725|OTHER|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
223975529|NCT00855725|OTHER|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
223975530|NCT00855725|OTHER|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
223975531|NCT01625676|OTHER|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
224293170|NCT03551951|DIAGNOSTIC_TEST|Test for circulating tumor cells, DNA alterations|
224293171|NCT06979375|DRUG|CDR132L|Administered intravenous infusion of CDR132L once every 4 weeks for 48 weeks.
223975532|NCT01625676|OTHER|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
223975533|NCT06238050|PROCEDURE|introduction of oxygen therapy or not|During hospitalisation, surgeon decides if patient needs and will have an oxygen therapy during this hospitalisation and at home.
223975534|NCT00004316|DRUG|capsaicin|
223975535|NCT00004316|DRUG|Placebo|
223975536|NCT06957717|COMBINATION_PRODUCT|cow's milk kefir|group given cow's milk kefir and blood supplement tablets (TTD)
223975537|NCT06957717|COMBINATION_PRODUCT|pasteurized cow's milk|group given pasteurized cow's milk and blood supplement tablets (TTD)
223975538|NCT06951932|DIETARY_SUPPLEMENT|Mediterranean-type diet with MCT supplementation|The treatment arm will follow a Mediterranean diet supplemented by daily intake of MCT (30 mL)
223975539|NCT06951932|OTHER|Mediterranean-type food regimen using extra virgin olive oil|The arm will follow a Mediterranean diet with an indication to take extra virgin olive oil as the main fat in the diet daily
223975540|NCT06048133|DRUG|Gemcitabine|Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days
223975541|NCT06048133|DRUG|Cisplatin|Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.
223975542|NCT06048133|DRUG|Zimberelimab|Zimberelimab IV: Day 1 and 22 every 42 days
223975543|NCT06048133|DRUG|Quemliclustat|Quemliclustat IV: Day 1, 15, 29 every 42 days
223975544|NCT00943618|DRUG|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
223975545|NCT00943618|DRUG|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
223975546|NCT00943618|OTHER|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
223975547|NCT00943618|BEHAVIORAL|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
223975548|NCT06178718|DRUG|TNP-2092 capsules|Administered orally, 100 to 1200 mg
223975549|NCT06178718|DRUG|TNP-2092 placebo capsules|Administered orally
223975550|NCT03713281|DEVICE|Toric Multifocal etafilcon A with PVP|Investigational
224293172|NCT06979375|DRUG|Placebo|Administered intravenous infusion of placebo once every 4 weeks for 48 weeks.
223975551|NCT05566886|DEVICE|Continuous measurement of photoplethysmography at the wrist|Patients receive a wristband that uses multi-color LEDs to measure pulsations at the wrist.
223975552|NCT01355978|DEVICE|Noninvasive Open Ventilation System|Noninvasive ventilation system
223975553|NCT03206268|DEVICE|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
223975554|NCT03515447|OTHER|Non interventional study|
223975555|NCT02230293|OTHER|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
223975556|NCT02230293|OTHER|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
223975557|NCT00184197|DRUG|Botulinum toxin|
223975558|NCT00184197|DRUG|Placebos|
223975559|NCT05006417|DRUG|Botox|reconstituted at 100 units/mL, dosage will be based upon the affected muscles
223975560|NCT00536081|DRUG|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
223975561|NCT04678713|DIETARY_SUPPLEMENT|investigate the nutritional determinants of MFO in moderate to well-train individuals|The participants will receive a 3-day fat rich or a carbohydrate rich diet. The participants will perform a maximal fat oxidation test before and after the diet intervention to evaluate the effect of the two diets on MFO.
223975562|NCT04678713|OTHER|Investigate the physiological determinants of MFO in moderate to well-train individuals|Muscle biopsies will be obtained at baseline to compare muscle characteristics between well-matched train individuals with a high compared to a low maximal fat oxidation.
223975563|NCT00038155|PROCEDURE|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
223975564|NCT00195884|BEHAVIORAL|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
223975565|NCT01830764|DRUG|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
223975566|NCT01058525|PROCEDURE|median nerve block|median nerve block performed using ultrasound guidance
224116632|NCT00986258|DRUG|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~* if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~* if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~* if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
224116633|NCT04585945|DIAGNOSTIC_TEST|Positive for SARS-CoV-2 infection|Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
224293173|NCT07124598|DEVICE|VR Headset Device - Meta Quest 3|The VR sessions will be conducted using hardware and software developed by AugMend Health Company. The AI-guided sessions will be administered using the commercially available Meta Quest 3 headset, which delivers high-resolution VR images and spatial audio through a standalone, wireless system.
224293174|NCT03609216|DRUG|Gemcitabine Hydrochloride|Given IV
223725656|NCT02943278|BEHAVIORAL|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
223725657|NCT01096901|BEHAVIORAL|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
223725658|NCT05805904|DRUG|BMS-986278|Specified dose on specified days.
223975567|NCT01058525|PROCEDURE|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
223975568|NCT04950036|DIAGNOSTIC_TEST|Diagnostic Test|The results of hip arthroscopy were taken as the gold standard and MRI examination was taken as the research object.
224293175|NCT03609216|DRUG|Cisplatin|Given IV
224293176|NCT03609216|BIOLOGICAL|Pegfilgrastim|Given SC
223975569|NCT06454201|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
223975570|NCT06454201|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
223975571|NCT00883636|OTHER|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
223975572|NCT00883636|OTHER|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
223975573|NCT00883636|OTHER|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
223975574|NCT03553485|DEVICE|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
223975575|NCT03553485|DEVICE|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
223975576|NCT03553485|RADIATION|Radiotherapy|Standard treatment for included patients
223975577|NCT04047771|DRUG|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
223975578|NCT02041221|DRUG|SPARC1316 Dose 1|The subjects will receive SPARC1316.
223975579|NCT02041221|DRUG|Placebo|
223975580|NCT02041221|DRUG|SPARC1316 Dose 2|
224293177|NCT03609216|PROCEDURE|Conventional Surgery|Undergo bladder sparing
224293178|NCT03609216|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
223975581|NCT02041221|DRUG|SPARC1316 Dose 3|
223975582|NCT02041221|DRUG|SPARC1316 Dose 4|
223975583|NCT02041221|DRUG|SPARC1316 Dose 5|
223975584|NCT04342598|OTHER|Serum Vitamin D|Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
223975585|NCT05220956|BEHAVIORAL|Intermittent fasting|One arm will undergo a TRF diet (Time-Restricted Feeding) for 12 weeks while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
223975586|NCT05220956|BEHAVIORAL|DGE diet|The control arm is not a subject to any time restrictions concerning eating while both arms undergo a training according to the 10 rules of healthy nutrition of the DGE.
224293179|NCT03609216|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
224293180|NCT06600425|DRUG|RCT1100|RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
223725659|NCT05805904|DRUG|Placebo|Specified dose on specified days
223975587|NCT02716688|DRUG|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
223975588|NCT02716688|RADIATION|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
223975589|NCT02830009|OTHER|Urines samples|24-hour urines will be collected
223975590|NCT02830009|OTHER|Blood sample|
223975591|NCT01982786|RADIATION|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
223975592|NCT01982786|RADIATION|Brachytherapy|Brachytherapy boost
223975593|NCT00144378|DRUG|Irinotecan|
223975594|NCT01871168|PROCEDURE|TAP block|Infusion of 0.5-1% lidocaine
223975595|NCT01871168|PROCEDURE|Sham TAP block|Infusion of saline
223975596|NCT02253745|DRUG|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
223975597|NCT02253745|DRUG|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
223975598|NCT04747821|BIOLOGICAL|Adsorbed COVID-19 (Inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
223975599|NCT00875615|DRUG|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
223975600|NCT00875615|DRUG|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
223975601|NCT00875615|DRUG|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
223975602|NCT00002796|DRUG|fluorouracil|Given IV
223975603|NCT00002796|DRUG|sodium phenylbutyrate|Given IV
223975604|NCT00002796|DRUG|indomethacin|Given orally
223975605|NCT00002796|BIOLOGICAL|recombinant interferon gamma|Given subcutaneously
223975606|NCT01772823|BEHAVIORAL|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
223975607|NCT01772823|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
223975608|NCT01772823|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
223975609|NCT02176382|DRUG|denosumab|denosumab subcutaneous injection
223975610|NCT02176382|DRUG|teriparatide|teriparatide daily subcutaneous injection
223975611|NCT02176382|DRUG|Zoledronic acid|zoledronic acid infusion
223975612|NCT05786521|DRUG|Semaglutide Injectable Product|Semaglutide will be started at 0.25mg once a week for 4 weeks followed by 0.5mg once weekly for 4 weeks followed by 1.0mg once a week for 12 weeks.
223975613|NCT05786521|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling will be provided throughout study intervention
223975614|NCT03650374|OTHER|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
223975615|NCT03650374|OTHER|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
223975616|NCT00935714|OTHER|Exercise|
223975617|NCT00935714|OTHER|Exercise|
223975618|NCT04287634|OTHER|Segmental Mobilization|Hot fermentation =10 minutes Soft tissue mobilization =5 minutes Targeted segmental mobilization= 3 sets of 10 repetitions Home plan exercise= cervical muscles stretching, postural care.
223975619|NCT04287634|OTHER|Entire Spine Mobilization|Hot fermentation=10 minutes Soft tissue mobilization=5 minutes Entire spine mobilization =3 sets of 10 repetitions Home plan exercises=cervical muscles stretches, postural care.
223975620|NCT02064309|DEVICE|Beta-Air device for encapsulation of transplanted human islets|
223975621|NCT04458987|BEHAVIORAL|Expert patient in addictology|"EP's Intervention, with patients hospitalized for addiction withdrawal. These are weekly individual interviews, in room, proposed by the EPs to inpatients.~The content of the intervention will be defined trough the results of step one of the study."
223975622|NCT02160561|OTHER|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
223975623|NCT00104975|BIOLOGICAL|alemtuzumab|
223975624|NCT00104975|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223975625|NCT00104975|DRUG|fludarabine phosphate|
223543276|NCT05180513|BEHAVIORAL|Teleconference Mindfulness Intervention|The teleconference intervention is administered by a trained interventionist via Zoom and is based on a manual adapted from a traditional MBSR version. Practices and activities include meditations, mindful breathing exercises and movements, discussions, and reflections, which participants learn at weekly sessions and practice on their own throughout the week. To adapt the traditional MBSR program for the target community population, intervention materials were reviewed for feedback from community stakeholders, and modified according to their feedback.
223975626|NCT00104975|DRUG|melphalan|
223975627|NCT00104975|DRUG|tacrolimus|
223975628|NCT00104975|DRUG|thiotepa|
223975629|NCT00104975|PROCEDURE|peripheral blood stem cell transplantation|
223975630|NCT04570254|DRUG|Vitamin C|Vitamin C. Tablet of 1 gr. A dose of 1 gr every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient. Protect from light at all times, as it is photosensitive.
223975631|NCT04570254|DRUG|Vitamin E|Vitamin E. 800 mg tablet. 800 mg dose every 24 hours. Dissolve the capsule in 30 ml of hot water. The administration of vitamin E is recommended during or after meals since its absorption depends on pancreatic enzymes' presence.
223975632|NCT04570254|DRUG|Melatonin|"Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast."
223975633|NCT04570254|DRUG|N-acetyl cysteine|N-acetylcysteine. Tablets, 600 mg. 600 mg dose every 12 hours. Dissolve one tablet in a volume of 30 ml of water and administer it immediately, then rinse the glass with 10 ml of water and administer it to the patient.
223975634|NCT04570254|DRUG|Pentoxifylline|Pentoxifylline. 400 mg tablets. 400 mg dose every 12 hours. The tablet is dissolved in 30 ml of water and is administered orally or nasogastric tube.
223975635|NCT06008340|DEVICE|Dual chamber Pacemaker|Anti bradycardia device implanted in patients with complete heart block, the device has 2 leads, one in the RT atrium and the other in RV. The RV lead positioned either apical or septal
223975636|NCT00249119|DRUG|risperidone|
223975637|NCT02396498|DRUG|HIPEC|Using cisplatin in HIPEC plus oral S-1
223975638|NCT00468858|OTHER|Placebo|"Lyophilized, single dose vials and sterile water for~\> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
223975639|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
223975640|NCT00468858|BIOLOGICAL|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
223725660|NCT04100265|DEVICE|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
223725661|NCT04100265|DEVICE|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
223725662|NCT04753060|PROCEDURE|Waxing|Donor sites of patients skin grafts are waxed prior to surgery for donor harvesting.
223725663|NCT02876354|DRUG|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
223725664|NCT05028478|DRUG|CN202|Participants will receive CN202 by IV infusion on Day 1 of each cycle (once every 2 weeks). The 4 planned dose levels are 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg
223725665|NCT01950507|DRUG|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
223725666|NCT01950507|DRUG|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
223725667|NCT01950507|DRUG|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
223725668|NCT01950507|DRUG|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
223975641|NCT05738447|BIOLOGICAL|HBV mRNA vaccine|With 20ug as the starting point, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose, and the intramuscular injection was administered again every 7 days, and after 4 doses, the 5th dose was given after 1-month interval.
223975642|NCT02497196|DEVICE|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
223975643|NCT02497196|DEVICE|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
223725669|NCT01773785|DRUG|SPI-1620|SPI-1620 11 μg/m2 will be given intravenously over 1 minute.
223975644|NCT02497196|DEVICE|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
224116634|NCT04465370|DEVICE|Hemosphere Advanced Monitoring System, ClearSight 1.5, Swan-Ganz Catheter, Flotrac, Foresight|A Swan-Ganz catheter, FloTrac transducer, ClearSight finger cuff and ForeSight Elite sensors will be placed prior to the start of the catheterization procedure. Intermittent cardiac output and other hemodynamic parameters will be collected throughout the duration of the procedure and analyzed according to the Statistical Analysis Plan.
224116635|NCT05919784|BEHAVIORAL|Cognitive behavioural therapy|The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
224116636|NCT05361018|OTHER|Whole Body Vibration exercise - WBV|participants will be randomised to two different training interventions
224293181|NCT06652815|BEHAVIORAL|Suicide ideation or suicide attempt|Individuals with high suicide ideation or suicide attempts visiting ABVIMS -Dr. RML Hospital for treatment will be screened for this study. socio- demographics details will also be gathered. Following this Depression, Anxiety and Stress Scale (DASS-21), Wisconsin Card Sorting Test (WCST), Metacognitions Scale (MCQ-30) and Stigma of Suicide Scale (SOSS) will be administered.
224293182|NCT04542824|BIOLOGICAL|Epcoritamab (monotherapy)|Epcoritamab will be administered subcutaneously in cycles of 4 weeks (i.e. 28 days)
224293183|NCT04542824|BIOLOGICAL|Epcoritamab|Epcoritamab will be administered in combination with the respective SOC chemotherapy followed by epcoritamab monotherapy.
224293184|NCT04542824|DRUG|Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone|21-day cycles
224293185|NCT04542824|DRUG|Gemcitabine and oxaliplatin|28-day cycles
223725670|NCT01773785|DRUG|Docetaxel|Docetaxel 75 mg/m2 infusion will be administered per standard of care 10 (±2) minutes after SPI-1620.
223975645|NCT02497196|DEVICE|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
223975646|NCT03645005|BEHAVIORAL|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
224116637|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
224116638|NCT04059133|DEVICE|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
223543277|NCT05180513|BEHAVIORAL|Smartphone App Mindfulness Intervention|The smartphone app intervention is administered through the app. The smartphone app aligns with the traditional MBSR format, but training and practice is done individually and independently by members of this group. To adapt the traditional MBSR program for the target community population, the app was tested by community stakeholders and modified according to their feedback.
223543278|NCT02132286|DRUG|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
224116639|NCT02616029|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
223543279|NCT02007304|BEHAVIORAL|Eccentric exercise training|12 weeks of lower leg eccentric training
224116640|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
223543280|NCT00127855|BIOLOGICAL|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
224116641|NCT03486535|DRUG|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
224116642|NCT06316661|DIAGNOSTIC_TEST|stress perfusion cardiac magnetic resonance|stress perfusion cardiac magnetic resonance according to guidelines, with quantitative evaluation for microvascular dysfunction assessment
224116643|NCT06316661|DIAGNOSTIC_TEST|cardiopulmonary exercise test|bike exercise with ECG and non invasive respiratory gas exchange monitoring
224293186|NCT04542824|BIOLOGICAL|Epcoritamab (maintenance)|28-day cycle for Cycle 1 and then 56-day cycle from Cycle 2 through 13
223543281|NCT00127855|BIOLOGICAL|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
223543282|NCT00127855|BIOLOGICAL|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
223543283|NCT00127855|BIOLOGICAL|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
223543284|NCT00127855|BIOLOGICAL|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
223543285|NCT00127855|BIOLOGICAL|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
223543286|NCT00127855|BIOLOGICAL|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
224116644|NCT03453749|DIETARY_SUPPLEMENT|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
224116645|NCT06099054|DEVICE|Pigtail catheter|Pigtail catheter will be inserted using Seldinger technique under US guidance to drainage exudative pleural effusion by a trained radiologist
224116646|NCT06099054|DEVICE|Intercostal tube|Chest tube will be inserted according to BTS guideline for insertion of ICT by a trained thoracic surgeon
224293187|NCT04542824|DRUG|Rituximab and lenalidomide|28-day cycles.
224293188|NCT06815965|DRUG|neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules.
223543287|NCT01686113|OTHER|NEFA|
223543288|NCT01686113|OTHER|Sucrose|
223725671|NCT02480023|RADIATION|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
223725672|NCT03130361|DEVICE|Non-Invasive Ventilation|
223975647|NCT03645005|BEHAVIORAL|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
223975648|NCT03022383|DEVICE|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
223975649|NCT00004403|DRUG|albendazole|
223975650|NCT00004403|DRUG|dexamethasone|
223975651|NCT00004403|DRUG|phenytoin|
223975652|NCT04853134|DRUG|Proxalutamide|200 mg q.d.
223975653|NCT04853134|OTHER|Standard of Care|Standard of care as determined by the PI
223975654|NCT05213325|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
223975655|NCT00581464|BEHAVIORAL|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
223975656|NCT00581464|BEHAVIORAL|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
223975657|NCT05132660|DRUG|Sinemet CR|25 mg carbidopa/100 mg levodopa
224116647|NCT02599467|OTHER|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
224116648|NCT01278628|OTHER|exercise training|exercise class once a year
224116649|NCT02832804|DEVICE|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
223975658|NCT05132660|DRUG|placebo|Placebo pill of similar size/shape
223975659|NCT05194475|OTHER|Thermogenic Ready-to-drink Beverage|Thermogenic ready-to-drink beverage, which will be ingested by the participant.
223975660|NCT05194475|OTHER|Placebo Ready-to-drink Beverage|Placebo ready-to-drink beverage, which will be ingested by the participant.
223975661|NCT00001359|DRUG|Penicillin or Placebo|
223975662|NCT05254717|OTHER|counselling|intervention groups will receive counselling on improving quality of complementary feeding by soaking complementary foods flours and basic methods of soaking complementary flours.
223975663|NCT04938622|OTHER|Sedentary Control|Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
224116650|NCT01611077|DRUG|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
224116651|NCT01611077|DRUG|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
224116652|NCT01611077|DRUG|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
224116653|NCT00013039|BEHAVIORAL|Computer reminders|
224116654|NCT01648608|DRUG|Exemestane|Exemestane for neoadjuvant chemotherapy
224116655|NCT05827146|DRUG|Hepalatide|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
224116656|NCT05827146|DRUG|Hepalatide Placebo|Either the placebo or hepalatide (2.1 mg, 4.2 mg, or 6.3 mg) will be given for 4 consecutive weeks. s.c., once daily.
223543289|NCT02343302|DEVICE|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
223543290|NCT02343302|DEVICE|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
223975664|NCT04938622|OTHER|Exercising control|Exercise: Participants engaged in supervised exercise training in Noll Laboratory Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories sufficient to maintain body weight and additional calories to remain in energy balance. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein.
224116657|NCT01497314|OTHER|Low Lactose Infant Formula|Low Lactose Infant Formula
223543291|NCT04660760|DRUG|Paclitaxel|Given IV
223543292|NCT04660760|OTHER|Quality-of-Life Assessment|Complete questionnaires
223543293|NCT04660760|BIOLOGICAL|Ramucirumab|Given IV
223543294|NCT04660760|DRUG|Trifluridine and Tipiracil Hydrochloride|Given PO
223725673|NCT03440021|DRUG|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
223975665|NCT04938622|OTHER|15 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 15 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
223975666|NCT04938622|OTHER|30 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had calories to meet metabolic needs (before 30 percent deficit exercise). Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
224116658|NCT06203145|DRUG|Bortezomib|A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
224116659|NCT05275218|PROCEDURE|Implementation of the KDIGO bundle)|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"
224116660|NCT03887637|DRUG|DAAs|Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
224116661|NCT01423240|DRUG|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
224116662|NCT01423240|DRUG|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
223725674|NCT03440021|DRUG|Placebo|Identical in appearance to experimental drug, not psycho-active
223725675|NCT03949504|PROCEDURE|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
223725676|NCT00646776|DRUG|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
223725677|NCT00646776|DRUG|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
223725678|NCT02590848|DIETARY_SUPPLEMENT|Walnut intake|Nutritional intervention: 30g walnut kernels per day
223725679|NCT01867268|DRUG|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
223975667|NCT04938622|OTHER|30 percent energy deficit (15/15)|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 15 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 15 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
223975668|NCT04938622|OTHER|60 percent energy deficit|"Exercise: Participants engaged in supervised exercise training in Noll Laboratory that was equal to 30 percent of the participants' daily caloric needs.~Diet: Participants consumed meals in the General Clinical Research Center metabolic kitchen that had 30 percent less calories than those needed to meet metabolic needs. Diet composition was 55 percent carbohydrates, 30 percent fat, and 15 percent protein."
223975669|NCT03234842|RADIATION|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
223975670|NCT03234842|RADIATION|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
223725680|NCT01867268|OTHER|prone positioning|prone positioning the patient for 10 days following the surgery
223725681|NCT01867268|OTHER|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
223975671|NCT03234842|DRUG|Chemotherapy|Concurrent weekly chemotherapy at standard doses
223975672|NCT03403556|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
223975673|NCT03403556|DRUG|Monorova|Rosuvastatin 20mg qd for 24 weeks
223975674|NCT02969629|DRUG|Apomorphine|
223975675|NCT02969629|DRUG|Normal Saline|
223975676|NCT01093222|DRUG|Erlotinib Hydrochloride|Given PO
223975677|NCT01093222|DRUG|Sorafenib Tosylate|Given PO
223975678|NCT02388399|PROCEDURE|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex\> cap thickness, spotty calcification)
223975679|NCT02388399|PROCEDURE|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
223975680|NCT06051097|DIAGNOSTIC_TEST|sleep study|over-night polysomnography
223975681|NCT04696926|OTHER|Edwards Intuity TM Valve implantation|aortic valve replacement with an Edwards Intuity TM bioprosthesis
223975682|NCT03941990|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
223975683|NCT03941990|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
223975684|NCT03435809|PROCEDURE|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
223975685|NCT00347802|DRUG|Bimatoprost 0.03%, Travoprost 0.004%|
223975686|NCT05527509|BEHAVIORAL|Emotional Resilience Skills Training (ERST)|"The ERST training is designed as a train the trainer model. Sauer-Zavala, a co-developer of the UP, personally trained a group of RCMP trainers during a week-long interactive workshop. The trainers continue to have access to Sauer-Zavala for optional follow-up consultation and support related to delivery of the ERST training for questions or to address any issues that arise during training. Having consultation and support available for the trainers should help to offset concerns raised about ensuring training fidelity subsequent to other mental health programs. Participants have ongoing access to ERST to support skill retention after training is completed, which should help to offset previous indications of problems with skill development for mental health programs."
223975687|NCT05527509|BEHAVIORAL|Active Monitoring|Participants in the STC will be assessed for at least 66 months, via full assessments (i.e., self-report surveys, clinical interviews), monthly assessments (i.e., \~20 minute self-report surveys), daily assessments (i.e., \~1 minute self-report surveys), and biometric assessments. The self-monitoring and feedback should be inherently beneficial and should facilitate earlier access to evidence-based care, which is why the STC is considered an active comparator.
223975688|NCT01033279|OTHER|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
223975689|NCT03578419|DEVICE|Small-Volume Blood Collection Tubes|Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
223975690|NCT03578419|DEVICE|Standard-Volume Blood Collection Tubes|Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
223975691|NCT01670188|DEVICE|Pneumatic SCD - VenaFlow System (DJO Global)|
223975692|NCT00836914|DRUG|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
223975693|NCT00836914|DRUG|Placebo|Placebo capsules administered orally BID for 7 days
223975694|NCT05924048|OTHER|Reducing the Oxygen Concentration From 5% to 2%|Effect of Reducing the Oxygen Concentration From 5% to 2% in arm 1.
223543295|NCT03201120|BEHAVIORAL|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
223975695|NCT02696863|BEHAVIORAL|questionnaire|
223975696|NCT00078858|DRUG|fludarabine phosphate|Given IV
223975697|NCT00078858|RADIATION|total-body irradiation|Undergo TBI
223975698|NCT00078858|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
223975699|NCT00078858|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
223975700|NCT00078858|DRUG|cyclosporine|Given PO
223975701|NCT00078858|DRUG|mycophenolate mofetil|Given PO or IV
223975702|NCT00078858|OTHER|laboratory biomarker analysis|Correlative studies
223975703|NCT02115334|BEHAVIORAL|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
223975704|NCT02115334|BEHAVIORAL|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
223975705|NCT02115334|BEHAVIORAL|health education|health education of the children with DD.
223975706|NCT00065819|BEHAVIORAL|HIV Symptom Education Program|
223975707|NCT01575483|DRUG|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
223975708|NCT03504371|DEVICE|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
223975709|NCT03504371|DEVICE|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
224293189|NCT06820281|DRUG|Tirzepatide 2.5mg weekly|"Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)~Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses."
223975710|NCT01104064|DEVICE|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
223975711|NCT01104064|DEVICE|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
223975712|NCT06276101|BIOLOGICAL|NWRD08 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
224116663|NCT01423240|DRUG|Placebo|Placebo once daily orally in the evening
224116664|NCT02633072|DEVICE|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
224293190|NCT06820281|DRUG|Placebo injection (normal saline)|Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.
224116665|NCT02754778|BEHAVIORAL|conditional workout|6 month of regular conditional workout 1-3 times a weak
224116666|NCT06521008|DRUG|anti muscarinic drugs|a selective anti muscarinic drugs (5-10mg) once per day for 12 weeks.
224116667|NCT06521008|OTHER|Instructions including bladder training|The program teaches women skills and strategies to prevent incontinence, including bladder irritants like caffeine and discussing bowel habits to prevent constipation. It also teaches them how to respond adaptively to urgency, such as pause, sit down, relax, and contract pelvic muscles to diminish urgency and prevent urine loss. Once urgency subsides, they can proceed to the toilet at a normal pace. The program emphasizes the importance of educating patients about bladder irritants and bowel habits.
224116668|NCT06521008|OTHER|pelvic floor muscle training (PFMT)|The training program teaches bladder control through contracting the striated skeletal pelvic floor muscles (PFM). The women are instructed to empty their bladder, lie in a lithotomy position, and tighten their pelvic floor muscles. The duration of contraction and repetitions is gradually increased, totaling 20-30 minutes. The program is 3 sessions per week under supervision for 12 weeks, and each woman is instructed to perform exercises at home until they can do 300 contractions per day.
224293191|NCT06177639|DEVICE|WiSLO|Imaging with the research WiSLO device in non-contact mode (4 images from each eye)
224293192|NCT06177639|DEVICE|Volk Pictor Plus™|Imaging with the commercial handheld fundus camera, Volk Pictor Plus™ (4 images from each eye)
223975713|NCT05596149|OTHER|Toothpaste without fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste without fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
223975714|NCT05596149|OTHER|Toothpaste with sodium fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
223975715|NCT05596149|OTHER|Toothpaste with sodium monofluorophosphate|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with sodium monofluorophosphate and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
224116669|NCT06521008|OTHER|abdominal exercise|Women will engage in transverse abdominis exercises, focusing on drawing the lower abdominal wall towards the spine and pressing the lumbar region downward, repeated for 15 minutes per session, three times per week.
224116670|NCT06521008|OTHER|Diaphragmatic Training|The therapist will instruct each woman to lie on her back with knees bent, place one hand on her upper chest and the other on her belly. They will breathe in slowly, tighten abdominal muscles, and exhale through pursed lips. Expiration should be relaxed and lightly controlled, and not forceful. Expiration should not be prolonged, and the woman should not initiate inspiration with accessory muscles or upper chest. The session will be repeated 3-4 times, lasting 5-10 minutes, and repeated three times per week for 12 weeks.
224116671|NCT03232424|DEVICE|NovoTTF-200A|"* Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~* Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
224293193|NCT05647265|BIOLOGICAL|Nivolumab|Given IV
224293194|NCT05647265|BIOLOGICAL|Ipilimumab|Given IV
224293195|NCT05647265|PROCEDURE|Surgical Procedure|Undergo surgery
224293196|NCT05647265|PROCEDURE|Computed Tomography|undergo CT
223975716|NCT05596149|OTHER|Toothpaste with amine fluoride|A sample of cells from the area of the buccal mucosa of each of the subjects will be taken with a cytological brush just before the start of using the toothpaste with amine fluoride and 30, 45 and 60 days after the start of use. Cell suspension is applied on a microscopy slide. Slides will be stained with Fast Green FCF dye and analyzed with an epifluorescence microscope. After using each tested toothpaste, the respondents will be given a specially designed questionnaire with questions related to their opinion about the used oral hygiene product.
223975717|NCT03936075|BEHAVIORAL|the Guided Imagery and Music method|the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
223975718|NCT03936075|BEHAVIORAL|standard care and verbal counselling|the participants receive their usual cancer treatment and two individual counselling sessions
223975719|NCT02212301|DEVICE|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
224116672|NCT03232424|DRUG|Temozolomide|"Concomitant phase:~* 75 mg/m2 per day for 42 days concomitant with radiotherapy.~* Begins 1 day prior to XRT start.~Maintenance phase:~* Begins 4 weeks after concomitant phase completion (+/- 1 week).~* Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~* Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~* Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
223975720|NCT02212301|DEVICE|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
223975721|NCT06298968|DRUG|combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab|"Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years."
224116673|NCT03232424|RADIATION|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
223975722|NCT02825719|DRUG|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
223975723|NCT02825719|OTHER|Placebo pills|Placebo pills will be prescribed
223975724|NCT02825719|DRUG|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
223975725|NCT02825719|DRUG|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
223975726|NCT03047902|OTHER|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
223975727|NCT03047902|OTHER|Group 2- Parents will not be present for the Questionnaire|
223975728|NCT03277417|OTHER|Echocardiography|Imaging of fetal heart and amniotic fluid
223975729|NCT03927222|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
223975730|NCT03927222|DRUG|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
223975731|NCT03927222|BIOLOGICAL|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
223975732|NCT03927222|BIOLOGICAL|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
224116674|NCT06554938|DEVICE|water pik|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
224116675|NCT06554938|DEVICE|Super floss|One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
224116676|NCT01009996|PROCEDURE|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
224116677|NCT01038284|BEHAVIORAL|Patient education|Pharmaceutical care of patients with PAH
224116678|NCT01038284|OTHER|Data collection|Clinical and biological data, treatment, medication errors and ADEs
224116679|NCT04332341|DRUG|Nicotinamide riboside (NR)|Nicotinamide riboside, PO, 500mgtwice daily for 21, 28, and 35 days
224116680|NCT02191917|PROCEDURE|Respiratory muscle strength measurements by different techniques.|
224116681|NCT01313104|PROCEDURE|colposcopy|Undergo colposcopy
224116682|NCT01313104|OTHER|cervical Papanicolaou test|Undergo cervical Pap smear
224116683|NCT01313104|PROCEDURE|screening method|Undergo anal Pap smear
224116684|NCT01313104|PROCEDURE|screening method|Undergo high resolution anoscopy
224116685|NCT05828238|DRUG|[18F]SF-DEVD-2|Patients will receive a tracer dose of 18F (2-4mCi) labelled SF-DEVD-2
224116686|NCT05828238|DRUG|[18F]-FDG|Patients will receive a tracer dose of 18F (5-10mCi) labelled FDG
224293197|NCT05647265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223975733|NCT03927222|BIOLOGICAL|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10\^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10\^7 DCs) prior to injection.
223975734|NCT06464614|DRUG|Adebrelimab|Adebrelimab 1200mg，d1，q3w, until disease progression or unacceptable toxicity
223975735|NCT06464614|DRUG|Apatinib|Apatinib 250mg，d1-21，q3w, until disease progression or unacceptable toxicity
223975736|NCT06464614|DRUG|Investigator chosen chemotherapy (ICC)|"Nab-paclitaxel: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles;Intravenous infusion of 100 mg, D1, qw is used at the same time as radiotherapy.~Ilinotecan: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles; Capecitabine, 625 mg/m2 orally, d1-14, q3w; continued until disease progression, intolerable toxicity, or withdrawal due to other reasons; when synchronized with radiotherapy, 625mg/m2, bid, oral, d1-5, qw."
223975737|NCT06464614|RADIATION|Radiotherapy|Radiotherapy mode: IMRT for the primary lesion and SBRT for the metastasis; If the patient has symptoms of dysphagia, the radiation dose is 1.8 Gy×28 F or 2 Gy×25 F, d1-5 5 times a week; If oligometastatic lesions occur in the body: the radiation dose is 8 Gy×5F, d1-5; If oligometastatic lesions occur in the brain, the radiation dose is 7 Gy×5F, d1-5.
223975738|NCT03986983|DEVICE|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
223975739|NCT03986983|OTHER|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
223975740|NCT06389929|BEHAVIORAL|Education|In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
223975741|NCT01099683|DRUG|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
224116687|NCT02717871|DEVICE|PACK-CXL|"Local anesthesia~\- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~\- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
224116688|NCT02717871|DRUG|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
224116689|NCT02717871|DRUG|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
224116690|NCT02717871|DRUG|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
224293198|NCT05647265|PROCEDURE|Positron Emission Tomography|Undergo PET
224293199|NCT06824649|BIOLOGICAL|Biologic Agents|Evidence by way of phase III clinical trials has shown efficacy of dupilumab, omalizumab, and mepolizumab to placebo, leading to regulatory approval and widespread clinical use. However, data from these clinical trials does not show universal improvement and ideal control of disease across all patients with Chronic Sinusitis with Nasal Polyps (CRSwNP). Successful completion of this trial will help answer some of the most pressing clinical questions related to biologics and CRSwNP. Specifically, findings will inform whether any one biologic has superior outcomes to another and whether clinicians can identify patients at baseline who are most likely to improve on biologic therapy.
224295251|NCT05253274|DEVICE|Virtual Reality Glasses|In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
224116691|NCT02717871|DRUG|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
224116692|NCT04964921|OTHER|Device: ANSiScope Plus|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
223975742|NCT01099683|DRUG|Placebo|All subjects will receive rectal suppository containing placebo
223975743|NCT00273351|DRUG|[123I]B-CIT|Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
223975744|NCT00030303|BIOLOGICAL|recombinant 70-kD heat-shock protein|
223975745|NCT03305471|DRUG|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
223975746|NCT03305471|DRUG|Placebo|Placebo matching stock solution in bottle
224116693|NCT05257239|OTHER|no intervention|National University Health System,
224116694|NCT01530399|DRUG|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
224116695|NCT01530399|DRUG|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
224116696|NCT01530399|DRUG|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
224116697|NCT01530399|DRUG|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
224116698|NCT01530399|DRUG|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
224116699|NCT01530399|DRUG|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
224116700|NCT00653835|DRUG|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
224116701|NCT00653835|DRUG|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
224116702|NCT02307019|OTHER|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
224116703|NCT02307019|OTHER|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
224116704|NCT00193440|DRUG|Rituximab|
224116705|NCT00193440|DRUG|CHOP|
224116706|NCT00193440|DRUG|CVP|
224295252|NCT03112980|DEVICE|Transcatheter aortic valve implantation|(TAVI)
223975747|NCT03305471|DRUG|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
223975748|NCT03305471|DRUG|DS-2330b Tablet|DS-2330b as tablet formulation
223975749|NCT00000701|DRUG|Zidovudine|
223975750|NCT01580007|DRUG|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
223975751|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
223975752|NCT01580007|DRUG|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
223975753|NCT01580007|DRUG|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
223975754|NCT03122405|DEVICE|RAM sensors|Noninvasive acoustic monitoring device
223975755|NCT00804414|DRUG|SBG|Solution for topical use
223975756|NCT00804414|DRUG|Placebo Comparator|Solutin for topical use
223975757|NCT00866827|OTHER|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
224116707|NCT00193440|DRUG|Ibritumomab Tiuxetan|
224295253|NCT03112980|PROCEDURE|Surgical aortic valve replacement|(SAVR)
223975758|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
223975759|NCT00413634|DRUG|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; participants will be stable on an anagrelide regimen and will take capsules from their own prescription except on the PK day when the participant specific anagrelide dose will be administered from a controlled study specific supply.
223975760|NCT01561885|OTHER|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
223975761|NCT02025985|DRUG|Selinexor|"Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles."
223975762|NCT00585208|DRUG|Ramelteon|Ramelteon 8mg daily
223975763|NCT00585208|DRUG|Placebo|matching placebo for ramelteon 8mg daily
223975764|NCT04148521|BEHAVIORAL|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
223975765|NCT01539408|DRUG|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
223975766|NCT01539408|PROCEDURE|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
223975767|NCT05167513|DRUG|Metformin / Sitagliptin Oral Tablet|"Metformin and sitagliptin are oral diabetes medicines that help control blood sugar levels.~Metformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Sitagliptin works by regulating the levels of insulin your body produces after eating.~Metformin and sitagliptin is a combination medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. metformin and sitagliptin is not for treating type 1 diabetes."
223975768|NCT03628456|DEVICE|International Biophysics AffloVest|High-frequency chest wall oscillation vest
224295254|NCT00750126|DRUG|Fludarabine, Busulfan, Thymoglobulin|"study :~* acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~* the effectiveness of the protocol on tumor response~* overall survival"
223975769|NCT03628456|DEVICE|Hill-Rom Monarch|High-frequency chest wall oscillation vest
223975770|NCT01723514|DRUG|Erenumab|Administered by subcutaneous injection once a month
223975771|NCT01723514|DRUG|Placebo|Administered by subcutaneous injection once a month
224295255|NCT01843348|DRUG|Everolimus|
224295256|NCT01843348|DRUG|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
224295257|NCT01843348|DRUG|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
224116708|NCT05632133|DRUG|Lacosamide 50 MG Oral Tablet|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
224116709|NCT05632133|DRUG|Ibuprofen 400 mg|We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.
223725682|NCT03673553|OTHER|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
224116710|NCT04313335|DRUG|Duloxetine|Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
224116711|NCT05924100|DRUG|Luspatercept Injection [Reblozyl]|"Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit."
224116712|NCT05456100|BEHAVIORAL|Expressive Helping|Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
224116713|NCT05456100|BEHAVIORAL|Expressive Writing|Expressive writing involves emotional disclosure writing over four weeks.
224116714|NCT05456100|BEHAVIORAL|Factual Writing|Factual writing involves writing facts about cancer treatment and experiences over four weeks.
224116715|NCT05789446|BEHAVIORAL|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action
224116716|NCT00511082|DRUG|OPB-31121|100-mg tablet Dose: OPB-31121 50, 100, 200, 400, 600, 800, and 1000 mg Dosage regimen: ingestion with water after breakfast Treatment period: 4 weeks Mode of Administration: oral administration of OPB-31121 once daily
224116717|NCT04057963|OTHER|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
224116718|NCT04057963|OTHER|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
224295258|NCT01843348|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
224295259|NCT01843348|DRUG|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
224116719|NCT05394545|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
224116720|NCT04392011|DRUG|Midazolam HCl|Oral syrup, 2 mg/mL
224116721|NCT04392011|DRUG|Dextromethorphan HBr|Oral liquid capsules, 15 mg
224295260|NCT01843348|DRUG|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
224295261|NCT01843348|DRUG|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
223975772|NCT04961983|BEHAVIORAL|Comprehensive Travel Health Education Model|"The comprehensive travel health education model consists of:~1. Online training: 10 hours (2 days) online education via Zoom. The topics that will be delivered during the training includes:~   * The potential roles of tour guides in tourists' health,~  * The importance of travel health information for tourists,~  * Assessment of tourist's health risks,~  * Prevention and first aid of various travel health problems Topics related to tour guides will be delivered by the tourism experts, while topics related to travel health will be provided by travel medicine experts, Faculty of Medicine, Udayana University. Participants will also receive a travel health guide book.~2. Weekly travel health Information sharing through WhatsApp group for 2 months."
223975773|NCT03723915|BIOLOGICAL|Pembrolizumab|Given IV
223975774|NCT03723915|BIOLOGICAL|Wild-type Reovirus|Given pelareorep IV
223975775|NCT01336387|DRUG|retinoid 9cUAB30|Given PO
223975776|NCT01336387|OTHER|placebo|Given PO
223975777|NCT01336387|OTHER|pharmacological study|Correlative studies
223975778|NCT01336387|OTHER|laboratory biomarker analysis|Correlative studies
223975779|NCT01336387|OTHER|cancer prevention|Disease prevention
223975780|NCT00799136|DRUG|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
223975781|NCT04612478|BEHAVIORAL|Self-Directed Exercise Program|The full SDEP program, which will be developed by physical therapists, orthopaedic trauma surgeons, and investigators with experience in health behavior change, will be designed to maximize adherence/compliance with the program
223975782|NCT04612478|BEHAVIORAL|Clinic-Based Physical|Patients will be referred to PT by the orthopaedic surgeon for enrollment into a clinic-based PT program per usual referral patterns at the surgeon's center. Patients will receive services based on their health care benefits defined by his or her insurance plan.
223725683|NCT03673553|OTHER|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
223725684|NCT03627624|OTHER|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
223725685|NCT01654029|BEHAVIORAL|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
223975783|NCT03497221|BEHAVIORAL|Education intervention|The same description of arm Education intervention.
223975784|NCT03497221|BEHAVIORAL|Visual identity campaign|The same description of arm Visual identity campaign.
223975785|NCT03510377|OTHER|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
223975786|NCT03510377|OTHER|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
223725686|NCT03752580|DEVICE|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
223975787|NCT03510377|OTHER|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
223975788|NCT01576913|OTHER|Music listening|Listening to tempo music while cycling in an exercise test
223975789|NCT04677933|DRUG|A: OLP-1002|10 patients will receive 5 µg OLP-1002 twice-weekly (BIW) OLP-1002
223975790|NCT04677933|DRUG|B: OLP-1002|10 patients will receive 10 µg OLP-1002 BIW OLP-1002
223975791|NCT04677933|DRUG|C: Placebo|10 patients will receive Placebo BIW
223975792|NCT05742659|OTHER|A mobile-based interactive simulation scheme (MISS)|A mobile-based interactive simulation scheme (MISS) was proposed and developed to investigate its effects on facilitating hands-on learning of NG insertion in undergraduate medical students.
223975793|NCT01558778|PROCEDURE|management of therapy complications|Undergo mechanical stimulation
223975794|NCT01558778|PROCEDURE|musculoskeletal complications management/prevention|Undergo mechanical stimulation
223975795|NCT03557450|DEVICE|PET/CT Scan|PET/CT scanning with sodium fluoride
223975796|NCT00873678|BIOLOGICAL|Whole blood sample|Whole blood sample (10 ml)
223975797|NCT01744756|DRUG|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
223975798|NCT00335374|DRUG|Pardoprunox|12 -42 mg
224116722|NCT04392011|DIETARY_SUPPLEMENT|Kratom|Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two g of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Subjects will drink the tea within 10 minutes of administration.
224116723|NCT04490954|DEVICE|brain biological electrical impedance tomography|Patients diagnosed with brain supratentorial tumors through MRI/CT are evaluated with brain biological electrical impedance tomography. And the brain biological electrical impedance tomography is used to monitor the cerebral edema situation of patients with brain edema
224116724|NCT04490954|DEVICE|MRI/CT|Patients diagnosed with brain supratentorial tumors through MRI/CT
224116725|NCT01765647|OTHER|AGY|AGY is a natural health product produced in egg yolks
224116726|NCT03964415|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
224295262|NCT06188130|OTHER|active rTMS|Participants recevied 20 Hz high frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed dominant side abductor pollicis brevis (APB).The patient received robotic therapy for lower extremity just after each active TMS sessions.
223975799|NCT05092776|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
223975800|NCT05092776|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
224116727|NCT03964415|BIOLOGICAL|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
224116728|NCT03964415|BIOLOGICAL|Placebo|Participants will receive matching placebo.
224116729|NCT02192710|PROCEDURE|electronic tab|classic use of an electronic tab with age specific games
224116730|NCT02192710|DRUG|Midazolam oral intake|
223975801|NCT01673295|DRUG|RTX infusions|RTX + Standard of Care
223975802|NCT01673295|OTHER|Standard of Care|Standard of Care only
223975803|NCT03023852|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2\*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
224116731|NCT02295098|OTHER|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
224116732|NCT02295098|OTHER|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
224116733|NCT05463679|DRUG|Enzastaurin|500 mg QD orally in the form of four 125 mg tablets with background standard of care
224116734|NCT05463679|DRUG|Placebo|Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
224116735|NCT03747172|DIETARY_SUPPLEMENT|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
224116736|NCT00596518|DRUG|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
224116737|NCT06361745|BIOLOGICAL|T cell injection targeting CD19 chimeric antigen receptor|Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
224116738|NCT01734993|DRUG|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
224116739|NCT02096393|DEVICE|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
224116740|NCT02096393|DEVICE|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
224116741|NCT00506051|DRUG|ZD6474 (vandetanib) 100mg|once daily oral tablet
224116742|NCT00506051|DRUG|pemetrexed|intravenous infusion
224116743|NCT00506051|DRUG|ZD6474 (vandetanib) 300mg|
224116744|NCT01257646|OTHER|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
223975804|NCT03023852|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg (1\*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
223975805|NCT01978236|DRUG|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
223975806|NCT01978236|DRUG|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
224116745|NCT01848964|DEVICE|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
224116746|NCT03411213|DEVICE|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
224293200|NCT05151575|BEHAVIORAL|supervised group-based walking and non-supervised individual-based walking interventions|Group exercise interventions tended to be systematic and supervised by professionals. The current intervention is proposing to conduct a randomized control trial that is not only examining the nature of walking on older adults' well-being but also involving the elements of group-based and professional supervision intervention, aiming at comparing with the individual-based intervention without professional supervision. Qualified professional fitness trainers (1 male and 1 female separately for male and female groups, respectively) will be involved in the group-based intervention programs in order to provide appropriate guidance and supervision to the participants. Whereas, the non-supervised individual-based intervention will be conducted by a research assistant (males and females) to ensure the attendance and general safety, but without providing professional advice or supervision.
224293201|NCT05423470|BEHAVIORAL|Intermittent hypoxia|The intermittent hypoxia protocol will consist of three 4-minute hypoxic cycles (arterial oxygen saturation of 80%) interspersed with 4-minute normoxic cycles.
224293202|NCT05423470|BEHAVIORAL|Intermittent normoxia|The intermittent normoxia protocol will consist of three 4-minute normoxic cycles (compressed air) interspersed with 4-minute normoxic cycles (room air).
223725687|NCT01745172|PROCEDURE|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
223725688|NCT04464356|DEVICE|mechanical circulatory support|mechanical circulatory support: cardiopulmonary bypass, extracorporeal membrane oxygenation(ECMO), left ventricular assist device
223975807|NCT01120288|DRUG|EZN-2968|
224293203|NCT01606852|DRUG|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
224293204|NCT00455442|DRUG|Mifepristone|
224293205|NCT04223999|PROCEDURE|Skullremodeling surgery|"Strategically placed cranial burrholes in order to improve the TTField dose focally in the tumor."
223975808|NCT02906696|DRUG|Bosutinib|Given PO
223975809|NCT02906696|OTHER|Laboratory Biomarker Analysis|Correlative studies
223975810|NCT02785276|DEVICE|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
223975811|NCT02785276|DRUG|Ropivacaine|Commonly used local anaesthetic drug
223975812|NCT02785276|OTHER|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
223975813|NCT01728688|OTHER|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
223975814|NCT01728688|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
223975815|NCT02879799|OTHER|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
224116747|NCT00733356|DRUG|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
223975816|NCT02148653|OTHER|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
223975817|NCT02148653|OTHER|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
223975818|NCT02643745|PROCEDURE|Nephrology Intervention|"1. pre-operative study:~   * Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~  * Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~2. optimise the patient' s overall condition with a pre-operative strategy:~   * Obesity control~  * Control protein, caloric, salt intake~  * Stop smoking~  * Good glycemic control~  * Start ACEI/ARA II if there is proteinuria~  * Start additional antihypertensive drug if required~  * Start hypolipemic treatment if required~  * Start hyperuricemia treatment if required~  * Start AAS, clopidogrel if it is necessary (prophylaxis)~  * Phosphate control~  * Anemia control~  * Metabolic acidosis correction"
223975819|NCT00634920|DRUG|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
223975820|NCT00634920|DRUG|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
223975821|NCT00634920|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
224116748|NCT00004284|DRUG|potassium citrate|
224116749|NCT00004284|DRUG|potassium phosphate|
224116750|NCT02836990|DEVICE|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
224116751|NCT02836990|DEVICE|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
224116752|NCT03917719|DRUG|Edasalonexent|100 mg/kg/day
224116753|NCT05967988|DEVICE|Immersive atmospheric projection|Projection of computer-generated videos or videos of real moving landscapes on the walls of the examination room
224116754|NCT05967988|DEVICE|Minimal atmospheric projection|Projection of a colors on the walls on the walls of the examination room
224116755|NCT04506606|PROCEDURE|Afferent block|Block sensory feedback to evaluate hemodynamic and fatigue consequence of group III/IV muscle afferents
224116756|NCT04770142|DEVICE|TIRA catheter|treat hypertrophic obstructive cardiomyopathy
224293206|NCT04223999|OTHER|Control|Tumor treating fields combined with best medical treatment.
224293207|NCT04954378|DIAGNOSTIC_TEST|radiomics|
224293208|NCT02159937|OTHER|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
224116757|NCT05814770|DRUG|Finerenone|The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
223975822|NCT00634920|DRUG|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
223975823|NCT00634920|DRUG|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
223975824|NCT01068106|DEVICE|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
223975825|NCT01068106|DEVICE|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
223725689|NCT01717560|OTHER|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
223725690|NCT00126568|DRUG|sorafenib tosylate|Given orally
223975826|NCT04232878|DRUG|CVL-936|CVL-936
224116758|NCT05814770|DRUG|Spironolactone|The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
224116759|NCT02277132|DRUG|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
224293209|NCT03856593|BEHAVIORAL|Standard letter|The standard letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 morphine milligram equivalents (MME) per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking \> 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
223725691|NCT06381882|PROCEDURE|Pancreatic resection|Any kind of pancreatic resection will be included
223975827|NCT04232878|DRUG|Matching Placebo|Placebo matching CVL-936
223975828|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
223975829|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
224116760|NCT02277132|DRUG|Placebo|Placebo tablets three times daily orally from randomization until delivery
224116761|NCT06095973|DRUG|GB-6002|Depending on the cohort, volume will be varied to administer.
224293210|NCT03856593|BEHAVIORAL|Comparator letter|"The comparator letter includes all the details in the standard letter plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
224293211|NCT04299451|OTHER|Open dialogue about CAM|1-hour dialogue about CAM with a nurse specialist as an integrated part of conventional oncology care
224293212|NCT06148545|DRUG|Elemental iron|Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
224293213|NCT06148545|DRUG|Elemental iron and Vit D|Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
224293214|NCT03014414|BEHAVIORAL|Fun First|Learn key enjoyable maintenance skills before losing weight
224293215|NCT03014414|BEHAVIORAL|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
223975830|NCT00819013|BIOLOGICAL|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
223975831|NCT00819013|BIOLOGICAL|Saline placebo|0.5 mL, Intramuscular
224116762|NCT06095973|DRUG|Placebo|Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
224116763|NCT06095973|DRUG|Naropin injection|Single dose of Naropin s.c. injection.
223975832|NCT04082377|PROCEDURE|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905\*((height in cm)-152.4) for men, and = 45.5+0.905\*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
223543296|NCT03201120|BEHAVIORAL|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
223975833|NCT04082377|PROCEDURE|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
223975834|NCT01299298|DRUG|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
224293216|NCT01129453|BIOLOGICAL|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10\^6, 10\^7, 10\^8, or 10\^9 CFU per mL. Route: oral.
223975835|NCT01299298|DRUG|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
223975836|NCT04037306|BEHAVIORAL|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
223975837|NCT04037306|BEHAVIORAL|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
223975838|NCT05091554|PROCEDURE|intraoral ice pack application|Tap water was filled into plastic ice molds and kept in the freezer in the clinic until the application was made. The ice packs used were weighed with digital pocket scale (Knmaster CT1000, Turkey) as 6-8 grams. In the cryotherapy groups, at the end of the first appointment ice packs were removed from the freezer, wrapped in sterile gauze and placed on the vestibular mucosa of the teeth.
224293217|NCT01129453|OTHER|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
224293218|NCT02350374|OTHER|carbohydrate counting|"patients must fill their logbook with the following data:~* cho amount at breakfast, lunch, snack and dinner~* insulin amount at breakfast, lunch, snack and dinner"
224293219|NCT01949116|DRUG|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
223975839|NCT04885634|DRUG|Semaglutide Injectable Product|Subcutaneous injection of Semaglutide 2.4 mg once weekly
223975840|NCT04885634|DRUG|Placebo|Subcutaneous injection of volume-matched placebo once weekly
223975841|NCT00112710|DRUG|carboplatin|
223975842|NCT00112710|DRUG|cisplatin|
223975843|NCT00112710|DRUG|gemcitabine hydrochloride|
223975844|NCT00979745|DRUG|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
224293220|NCT01949116|DRUG|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
224293221|NCT01949116|DIETARY_SUPPLEMENT|Folic acid|1-mg tablet of folic acid by mouth once a day
224293222|NCT03383419|DRUG|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
224293223|NCT05926596|DEVICE|Wearable Robotic Exoskeleton|"* Participant preparation, placement of wearable sensors and monitoring, and wearable device fitting.~* Lower-limb joint rotations and leg stretching protocol (40-60 minutes). The wearable exoskeleton and its control algorithm are evaluated to rotate leg joints and apply stretching similarly to the forces applied by nurses and caregivers when providing manual forces. Joint rotation and limb stretching is conducted while participants sit down (e.g., in a wheelchair, on a chair, on one side of a bed, or on a clinical mat) or lay down on a bed/mat. The protocol involves ankle plantarflexion and dorsiflexion, knee extension, hip flexion with the knee flexed, and toe flexion and extension (bilaterally) assisted by the exoskeleton, and each movement is repeated at a low-to-moderate rate of 10-30 cycles/minute.~* Treadmilll and Overground Walking (60-90 minutes including rest periods)~* Cool down (5-10 minutes)"
223543297|NCT02448147|BEHAVIORAL|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
223543298|NCT02448147|BEHAVIORAL|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
223543299|NCT01564342|PROCEDURE|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
223975845|NCT00979745|DRUG|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
223975846|NCT02468310|OTHER|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
223975847|NCT02870751|BIOLOGICAL|TW11681 or TW10722|
223975848|NCT00868764|DRUG|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
223725692|NCT02520076|DRUG|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~* Pre-transplant Day -1~* Post-transplant Day 3~* Post-transplant Day 7~* Post-transplant Day 14"
224116764|NCT04617340|OTHER|Multifaceted clinical pharmacy intervention|"1. Assessing patient and caregiver preferences~2. Medication reconciliation on admission~3. Performing a comprehensive medication review before discharge~4. Promoting safe transition~4.a. Compiling a patient friendly medication list~4.b.Optimizing communication with healthcare providers in primary care:~4.b.i.Providing a copy of the medication list for the community pharmacist~4.b.ii. Contacting the general practitioner by phone~4.b.iii. Contacting, if applicable the home care nurse or the nurse from the nursing home by phone.~5.A motivation interview will take place before discharge with patients and caregivers~6.Post-discharge follow-up: 6.a.Follow-up call to discuss potential drug therapy issues, therapy adherence and to resolve any pending issues 6.b.A telepharmacology service will be provided to primary healthcare professionals as a means to consult the ward-based clinical pharmacists and/or research team after discharge."
224116765|NCT04156646|DRUG|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
224116766|NCT04156646|DRUG|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
224116767|NCT04485169|PROCEDURE|Therapeutic Plasma Exchange|a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
224116768|NCT05692193|BEHAVIORAL|pain education|Pain education was given to the experimental group for 20-30 minutes on the day of hospitalization.
224116769|NCT00036205|DRUG|sumanirole|
224116770|NCT05700240|DEVICE|orthokeratology|rigid contact lenses
224116771|NCT05700240|DEVICE|single-vision spectacle correction|simple wear of spectacle
224116772|NCT03989063|BEHAVIORAL|Instructions to perform a motor task (external vs. internal focus instructions)|During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
224116773|NCT03383367|BEHAVIORAL|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
224116774|NCT03322683|PROCEDURE|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
224116775|NCT03322683|PROCEDURE|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
224116776|NCT00469235|DRUG|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
224116777|NCT00477451|DRUG|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
224116778|NCT00477451|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
224116779|NCT00477451|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
224116780|NCT00477451|DRUG|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
224293224|NCT06992427|DRUG|Gabapentin|Given PO
224116781|NCT03682588|OTHER|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
224293225|NCT06992427|DRUG|Placebo|Given PO
224293226|NCT06992427|DRUG|Chemotheraphy|Receive standard of care chemotherapy
224293227|NCT06992427|RADIATION|Radiation Therapy|Undergo standard of care radiation
224293228|NCT06992427|DRUG|Analgesic Agent|Receive standard of care pain medication
224293229|NCT06992427|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293230|NCT06992427|OTHER|Survey Administration|Ancillary studies
224293231|NCT06992999|DRUG|Low Dose Psilocybin|10mg dose of psilocybin
224116782|NCT04847830|DEVICE|Er:YAG laser (Waterlase)|The WaterLase iPlus tissue cutting system is a unique device with diverse, hard- and soft-tissue dental applications. It utilizes advanced laser and water atomization technologies to safely and effectively cut, shave, contour, roughen, etch, and resect oral hard-tissue, and direct laser energy to perform oral soft-tissue removal, incision, excision, ablation and coagulation.
224293232|NCT06992999|DRUG|High Dose Psilocybin|30mg dose of psilocybin
224293233|NCT06608901|DRUG|REGN7544|Administered per the protocol
224293234|NCT06608901|DRUG|PB|Administered per the protocol
224293235|NCT06997016|DIETARY_SUPPLEMENT|pre-operative carbohydrate drink|50 g of carbohydrate drink 2 hours before surgery
224116783|NCT04847830|PROCEDURE|root surface dbridement|root surface debridement under local anaesthesia
224116784|NCT00785746|OTHER|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
224293236|NCT06997016|DRUG|Acetaminophen|650mg acetaminophen 30 minutes prior to surgery
224293237|NCT06997016|DRUG|Gabapentin|300 mg gabapentin 30 minutes prior to surgery
224293238|NCT06997016|DRUG|Bupivacaine|intraoperative local anesthetic
223725693|NCT02048787|DRUG|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
223725694|NCT01658670|BEHAVIORAL|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
224116785|NCT01964365|DRUG|Cresto 20mg|tablet, rosuvastatin 20mg
224116786|NCT01964365|DRUG|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
224116787|NCT01964365|DRUG|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
224116788|NCT00882869|DRUG|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
224116789|NCT00882869|DRUG|Sorafenib|Sorafenib will be administered at 400 mg BID every day
223975849|NCT04394312|OTHER|Parent PLAYSHOP|"The Parent PLAYSHOP includes:~1. Educational Training- the 75 min workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities. Parents will be provided with modifications to perform activities 'at home'.~2. Distribution Education and Activity Resources- At the workshop conclusion parents are given education Resources (e.g. Canada's 24-hour movement guidelines for the early years, activity idea booklet, and a physical literacy handout) and inexpensive activity resources (ball, bean bag, scarves, balloons etc.).~3. Provide Follow-up Support- Research staff will send parents a follow-up email with key workshop messages (e.g., rationale and importance of physical literacy); support and encouragement for parents to engage in purposeful play with their child; and an opportunity for parents to provide feedback and/or seek further support."
223975850|NCT04866706|DEVICE|Visiol|VISIOL is a 2.0% (m/v) SH viscoelastic solution used for ocular surgery.
223975851|NCT00067093|DRUG|SanOrg34006|
223975852|NCT00067093|DRUG|LMW heparin|
223975853|NCT00067093|DRUG|Unfractionated heparin|
224293239|NCT06997016|OTHER|Ambulation|Assisted ambulation 12 hours after surgery
223725695|NCT01658670|BEHAVIORAL|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
223725696|NCT00230997|DRUG|Galantamine|
223975854|NCT00067093|DRUG|Vitamin K antagonist (VKA)|
224116790|NCT04110834|DRUG|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
224116791|NCT04110834|DRUG|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
224116792|NCT04110834|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
224293241|NCT04623801|PROCEDURE|Percutaneous Laser Ablation (PLA)|Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.
224293242|NCT06863402|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293243|NCT06863402|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223975855|NCT06083610|OTHER|miRNA levels analysis from saliva samples|Each participant will be given two 50-mL Falcon tubes and will be asked to expectorate a small amount (about 1 mL) of saliva before and immediately after the end of exercise. Part of each saliva sample will be mixed with an equal volume of denaturing solution included in the mirVanaTM PARISTM kit from Ambion, Foster City, CA, in order to inactivate ribonucleases. Serum samples will be separated by centrifugation at 4000 rpm from the saliva samples taken into the biochemistry tubes of the participants and controls and will be raised to -80 centigrade degrees until the study day. Micro RNA will be isolated from serum samples on the working day. Determination of microRNA expression levels (micro RNA-1 and micro RNA-133a) will be determined by reverse transcriptase polymerase chain reaction (RT-PCR) (Applied Biosystems 7500 Fast Real-Time PCR).
223975856|NCT00576823|DRUG|Alfuzosin|"Dose: 0.2 mg/kg/day~Route: oral"
223975857|NCT00409591|DRUG|Maternal and infant nevirapine|"* In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately"
223975858|NCT00409591|DRUG|Maternal placebo and infant nevirapine|"* In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded."
223975859|NCT00409591|DRUG|Maternal lopinavir+ritonavir|\- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
223975860|NCT00409591|DRUG|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
223725697|NCT03032315|DRUG|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
223725698|NCT03032315|DRUG|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
224116793|NCT02396407|BEHAVIORAL|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children \< 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
224293244|NCT06863402|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
223725699|NCT03032315|DRUG|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
224116794|NCT00940927|DRUG|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
224116795|NCT04440241|PROCEDURE|regenerative treatment periimplantitis|"Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps."
223725700|NCT05735132|PROCEDURE|Conventional Line-blocking|Participants will receive a 2 cm subcutaneous 1% lidocaine local infiltration injection parallel to the arm at the puncture site.
223725701|NCT05735132|PROCEDURE|Bar-blocking|Participants will receive a bar-shaped subcutaneous 1% lidocaine local infiltration injection in the vertical arm, 2 cm away from the puncture site.
224293245|NCT06863402|PROCEDURE|Echocardiography|Undergo ECHO
224293246|NCT06863402|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223725702|NCT05735132|PROCEDURE|V-blocking|Participants will receive a V-shaped subcutaneous 1% lidocaine local infiltration injection at a 90-degree angle 2 cm away from the puncture site.
223543300|NCT02374541|BEHAVIORAL|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
224293247|NCT06863402|DRUG|Nemtabrutinib|Given PO
224116796|NCT03687034|DRUG|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
224293248|NCT06863402|BIOLOGICAL|Pembrolizumab|Given IV
224293249|NCT06863402|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223543301|NCT04163939|OTHER|Vista Therapy Collar|The patient will wear the cervical collar
223543302|NCT04163939|OTHER|Placebo|The patient will not wear the cervical collar
223543303|NCT01258673|DRUG|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
223543304|NCT01258673|DRUG|Fimasartan|Fimasartan 60mg, 120mg
223543305|NCT06135584|DRUG|Pioglitazone metformin tablets|Drug intervention for 24 weeks and follow-up for another 72 weeks (fasting blood glucose was controlled below 7.0mmol/l throughout the study)
224293250|NCT06863402|OTHER|Questionnaire Administration|Ancillary studies
224293251|NCT06863961|DRUG|Afimkibart|Afimkibart will be administered as SC injection.
223543306|NCT06135584|DRUG|Other drugs|Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
223543307|NCT06135584|OTHER|Drug-free|Drug-free
223543308|NCT02655887|DEVICE|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
223543309|NCT05518006|DIETARY_SUPPLEMENT|PreMama Balance|Premama Balance is a blend of the following: Vitex (Chasteberry Extract), commonly used to help regulate hormones; Antioxidants, Selenium, and Magnesium, also help support the cleansing of hormonal birth control from the liver and help strengthen the uterine lining.
223725703|NCT02345694|DEVICE|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
224116797|NCT03687034|DEVICE|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
224293252|NCT06863961|DRUG|Placebo|Placebo will be administered as SC injection.
224293253|NCT00608725|RADIATION|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
224293254|NCT00608725|PROCEDURE|QSweat|Quantitative Sweat Testing
223543310|NCT05518006|DIETARY_SUPPLEMENT|Placebo Drink|Blended Placebo drink
223725704|NCT02345694|DEVICE|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
223725705|NCT00615758|DRUG|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
224293255|NCT00608725|DRUG|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
224293256|NCT06746506|BEHAVIORAL|Amigurumi toy|A toy prepared using anti-allergic yarn to suit children's developmental stages.
224293257|NCT06671912|DRUG|Anastrozole|Given PO
224293258|NCT06671912|DRUG|Letrozole|Given PO
224293259|NCT06671912|DRUG|Exemestane|Given PO
224293260|NCT06671912|DRUG|Tamoxifen|Given PO
224293261|NCT06671912|PROCEDURE|Mammogram|Undergo mammogram
224293262|NCT06671912|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224293263|NCT06671912|BIOLOGICAL|Dual X-ray Absorptiometry|Undergo DEXA
224293264|NCT06671912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293265|NCT06671912|OTHER|Questionnaire Administration|Ancillary studies
223543311|NCT01306695|BEHAVIORAL|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
223725706|NCT00705653|DRUG|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
223725707|NCT03833115|OTHER|vaginal gel containing or not sodium lauryl sulfate|Prevention
224116798|NCT02769260|OTHER|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
224293266|NCT04804553|DRUG|Apremilast|Participants will receive apremilast orally.
224293267|NCT04804553|DRUG|Placebo|Participants will receive the matching placebo orally.
224293268|NCT06588634|DEVICE|FlowTriever System|Mechanical thrombectomy for pulmonary embolism
224293269|NCT06588634|PROCEDURE|Standard of Care|Standard of care treatment for pulmonary embolism
223543312|NCT01306695|OTHER|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
223725708|NCT05229380|DRUG|Saccharin test|Saccharin is a nonnutritive sweetener. It has property of being inert to respiratory epithelium that is it does not hamper physiological mucus clearance of sino-nasal mucosa. Methylene blue is a chemical compound. It can be used to check patency of (ET). The dye, because of its liquid form, gravitates through the ET to the nasopharynx.
224116799|NCT03762252|OTHER|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
224116800|NCT03762252|OTHER|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
224116801|NCT01747330|DRUG|Pancreatin|Doses of Pancreatin \<2500 lipase u/kg/feed or \<4000 lipase U/g fat/intake or \<10000 lipase U/kg/day given orally are used
224116802|NCT00026468|DRUG|exisulind|
224116803|NCT04554030|BEHAVIORAL|Evaluate sperm count before and after immunotherapy|Evaluate sperm count before and after immunotherapy
224116804|NCT00863928|DRUG|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
224116805|NCT05534555|DIAGNOSTIC_TEST|FebriDx|Testing of finger-prick blood sample using FebriDx
224116806|NCT03750110|OTHER|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~* For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~* For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
224116807|NCT03750110|OTHER|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
224116808|NCT05016128|DRUG|S-ketamine|S-ketamine is used for preventing postoperative hyperalgesia,thus reducing the patient's acute postoperative pain
224116809|NCT05016128|DRUG|saline|saline is used for control
224116810|NCT04460287|DIETARY_SUPPLEMENT|DHA Wet Mixing method|Children will drink milk contain 100 mg DHA wet mixing daily for 30 days
224116811|NCT04460287|DIETARY_SUPPLEMENT|DHA Dry Blending Method|Children will drink milk contain 100 mg DHA dry blending daily for 30 days
224116812|NCT04460287|DIETARY_SUPPLEMENT|Fish Oil|Children will have this intervention every day for 30 days
224116813|NCT06539845|BEHAVIORAL|Outbreak Preparedness Intervention for the Orang Asli|"The chosen villages will be given the intervention package, which includes a workshop, simulation exercises, and a card game, in addition to educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This entire package will be delivered once, during the workshop, after they have answered the survey at T0."
224116814|NCT06539845|BEHAVIORAL|Educational Brochures for the Orang Asli|"The chosen villages will be given educational brochures on communicable disease prevention sourced from the Ministry of Health Malaysia Info Sihat website. This will be given once during the first encounter with the participant, after they have answered the survey at T0."
224116815|NCT02354391|DRUG|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
224116816|NCT02354391|DRUG|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
224293270|NCT06865079|DRUG|TPX-100 200mg, Once weekly for 4 weeks|"TPX-100 (200 mg per dose) will be administered once-weekly (Week 1, 2, 3 \& 4) to a single target knee of the subject for 4 injections.~TPX-100 can be administered by conventional methods such as subcutaneous or intra-articular injection."
224293271|NCT06865079|OTHER|PBS|PBS / placebo for intra-articular injection administered once-weekly (Week 1, 2, 3 and 4) to a single target knee of the subject for 4 injections
224293272|NCT03141684|DRUG|Atezolizumab|Given IV
223543313|NCT03119168|DRUG|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
223543314|NCT03119168|OTHER|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
223543315|NCT03332121|BIOLOGICAL|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
223543316|NCT03565172|DIAGNOSTIC_TEST|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
223543317|NCT03565172|OTHER|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
223543318|NCT03565172|DIAGNOSTIC_TEST|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
223543319|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
223543320|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
223543321|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
223543322|NCT03966040|BIOLOGICAL|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
223543323|NCT01750125|DEVICE|measure ascending aortic blood flow with pulse wave Doppler|
223543324|NCT04300387|BEHAVIORAL|multidisciplinary care|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
223543325|NCT04643847|DRUG|Almonertinib|110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment). For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
223543326|NCT01107067|DRUG|Sustanon|250 mg/21 days
223543327|NCT02020590|DRUG|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
223543328|NCT03069508|DRUG|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
224293273|NCT03141684|BIOLOGICAL|Bevacizumab|Given IV
224293274|NCT03141684|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine
224293275|NCT03141684|PROCEDURE|Computed Tomography|Undergo CT
224293276|NCT07000084|BIOLOGICAL|BCG Solution|Given intravesically
224293277|NCT07000084|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
224293278|NCT07000084|PROCEDURE|Cystoscopy|Undergo cystoscopy
224293279|NCT07000084|PROCEDURE|Computed Tomography|Undergo CT Scan
223543329|NCT02308761|DRUG|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
224293280|NCT07000084|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223975861|NCT00907946|PROCEDURE|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
223975862|NCT03360110|DEVICE|Phoebe test lens|Daily disposable contact lens
224293281|NCT07000084|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223975863|NCT03360110|DEVICE|stenfilcon A lens (control)|Daily disposable contact lens
223975864|NCT00510146|DRUG|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
223975865|NCT00510146|DRUG|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
223975866|NCT00005064|DRUG|bortezomib|Given IV
223975867|NCT03470792|DEVICE|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
223975868|NCT00166881|DRUG|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
223975869|NCT05101915|DRUG|RESP301|Inhaled IMP delivered via nebulisation
224293282|NCT07000084|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
224293283|NCT07000084|DRUG|Gemcitabine|Given intravesically
223543330|NCT05979961|RADIATION|IMRT and concurrent cisplatin|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated radiotherapy (IMRT)
223975870|NCT03188536|OTHER|No Intervention|As it was an observational study, no intervention was administered in this study.
223975871|NCT03260803|DRUG|Oligopin|Oligopin ,150 mg ,once daily, 12 week
223975872|NCT03260803|DRUG|Placebo|Placebo,150 mg ,once daily, 12 week
223975873|NCT04189510|DEVICE|Artificial Pancreas|The Artificial Pancreas will delivery insulin in place of Multiple Daily Injections after a kidney transplant.
223975874|NCT04189510|OTHER|Multiple Daily Injections|Multiple Daily Injections as standard of care post kidney transplant.
223975875|NCT03041298|PROCEDURE|MR mammography with Dotarem|
223975876|NCT00134147|DRUG|Inhaled Insulin|
223975877|NCT01930214|DEVICE|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
223975878|NCT04207645|DIAGNOSTIC_TEST|Modified RIPASA score|Clinical Prediction Rules consist of clinical and laboratory parameters to aid diagnosis of acute appendicitis
223975879|NCT06201637|OTHER|Performance Test|Performance Test
224293284|NCT05514509|DRUG|APRETUDE|Available as intramuscular injection.
223975880|NCT04311047|DIAGNOSTIC_TEST|USPIO-enhanced MRI|Administration of USPIO contrast 24-36 hours before MRI scan of the abdomen to detect lymph node metastases.
223975881|NCT02132117|DRUG|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
223975882|NCT02132117|DRUG|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
223975883|NCT04075786|OTHER|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
223975884|NCT02550912|DRUG|Vitamin D3|vitamin D drops for paediatrics
223975885|NCT02550912|OTHER|Placebo|glucose syrup with same taste and color to vitamin D3 drops
223975886|NCT02885792|OTHER|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
223975887|NCT02885792|OTHER|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
223975888|NCT02885792|OTHER|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
223975889|NCT02885792|PROCEDURE|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
223975890|NCT02569632|BIOLOGICAL|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
224116817|NCT02354391|PROCEDURE|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
224116818|NCT06821256|DEVICE|Anodal transcranial direct current stimulation (a-tDCS)|tDCS is delivered by a battery-driven constant current stimulator throught a pair of saline soaked surface sponge electrodes. The active electrode (anode) is placed on the scalp over the over the cerebellum area (2 cm under the inion, using a 7 × 5 cm sponge electrode), with the cathode being applied either to the right deltoid muscle (arm 1: cerebellar stimulation) or over the spinal lumbar enlargement (2 cm under T11; arm 2: cerebellar-spinal stimulation) using a sponge electrode of the same size as the anode. Durng real stilumation a costant current of 2mA is applied for 20 minutes.
224116819|NCT06821256|DEVICE|Sham stimulation|For the sham condition the electrode placement is the same of active tDCS but the electric current is ramped down 5 seconds after the beginning of the stimulation
224116820|NCT05753761|BEHAVIORAL|Behaviour- & Imaging-Guided Stepping Training Early Post-Stroke (BIG STEPS) intervention|Using baseline accelerometry data, personalized goals of replacing sedentary time with stepping time will be developed.
224116821|NCT03392519|OTHER|Chronic stroke|MRI data acquisition and behavioral test
224116822|NCT06663358|DRUG|Pegunigalsidase-alfa|Administered via intravenous (IV) infusion under conditions of routine clinical care
224116823|NCT01373645|DEVICE|Yinyi stent|subjects with Yinyi stent implantation
223543331|NCT05979961|DRUG|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
223543332|NCT04133025|OTHER|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
224116824|NCT00539721|DRUG|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
223543333|NCT01186250|DRUG|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
223543334|NCT01186250|DRUG|Placebo|placebo taken daily for one year
223543335|NCT05490758|OTHER|sensorimotor training|sensorimotor training include activities like play with dough, peg games, puzzles for 5 days a week for 4 week.
223543336|NCT05490758|OTHER|constraint induced movement therapy|constraint induced movement therapy in which arm was constraint for 6 hours a day for 5 days a week for 4 week.
224293285|NCT05514509|DRUG|Cabotegravir tablet|Available as marketed orally administered tablets.
224293286|NCT07012395|DRUG|SPY001|Experimental
224293287|NCT07012395|DRUG|SPY002|Experimental
224293288|NCT07012395|DRUG|SPY003|Experimental
224293289|NCT07012395|OTHER|Placebo|Placebo
223543337|NCT02273102|DRUG|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
224293290|NCT06685835|DRUG|Brensocatib|Film-coated Oral tablet
224293291|NCT06685835|DRUG|Placebo|Film-coated Oral tablet
223975891|NCT04692090|OTHER|Yoga|"Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks."
224293292|NCT07011771|DRUG|gene therapy|IV gene therapy
224293293|NCT07011771|DRUG|gene therapy|IV gene therapy
224293294|NCT04263428|BEHAVIORAL|Irregular sleep|Experimental-induced sleep variability
224293295|NCT06685068|DRUG|GEN1286|Specified dose on specified days
224293296|NCT01783652|BEHAVIORAL|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
224293297|NCT01038037|DRUG|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
224293298|NCT01038037|DRUG|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
224293299|NCT01038037|DRUG|panitumumab|i.v. day 1: 9 mg/kg q3w
224293300|NCT03653494|PROCEDURE|phrenic block|phrenic block by 1% ropivacaine 5ml
224293301|NCT03653494|PROCEDURE|no phrenic block|no phrenic block
224295263|NCT06188130|OTHER|sham rTMS|Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for lower extremity just after each sham TMS sessions.
224116825|NCT00539721|DRUG|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
224116826|NCT00539721|DRUG|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
224116827|NCT00539721|DRUG|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
224116828|NCT00539721|DRUG|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
224116829|NCT00539721|DRUG|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
224116830|NCT03078101|DRUG|Empagliflozin 10 MG [Jardiance]|administered orally once daily
224116831|NCT03078101|DRUG|Placebo Oral Tablet|administered orally once daily
224116832|NCT05114863|OTHER|Product A1|Usual Brand (UB) filtered, non-menthol cigarette
224116833|NCT05114863|OTHER|Product B|40007388, A Non-Combusted Cigarette Variant and product use Mode A
224116834|NCT05114863|OTHER|Product C|40007388, A Non-Combusted Cigarette Variant and product use Mode B
224116835|NCT05114863|OTHER|Product D|40007386, A Non-Combusted Cigarette Variant and product use Mode B
224116836|NCT05114863|OTHER|Product A2|Usual Brand (UB) filtered, menthol cigarette
224116837|NCT05114863|OTHER|Product E|40007385, A Non-Combusted Cigarette Variant and product use Mode A
224116838|NCT05114863|OTHER|Product F|40007385, A Non-Combusted Cigarette Variant and product use Mode B
224116839|NCT05114863|OTHER|Product G|40007387, A Non-Combusted Cigarette Variant and product use Mode B
224116840|NCT05114863|OTHER|Product H|40007386, A Non-Combusted Cigarette Variant and product use Mode B
224116841|NCT05114863|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
224116842|NCT04804852|OTHER|sarcopenia assessment|evaluation of sarcopenia by CT san at the C3 vertebrae
224116843|NCT02648035|BIOLOGICAL|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
224116844|NCT04031378|RADIATION|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
224116845|NCT04031378|DRUG|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
224116846|NCT02046915|DRUG|Imnovid (pomalidomide)|
224116847|NCT02046915|DRUG|Dexamethasone|
224116848|NCT02046915|DRUG|Endoxan (Cyclophosphamide)|
224116849|NCT02247206|BEHAVIORAL|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
224116850|NCT01237548|OTHER|Smoking Narghile for 30 min|No Other intervention will be used
224116851|NCT04671680|DEVICE|LiDCO CNAP Monitoring Equipment|A continuous non-invasive arterial blood pressure monitor for rapidly changing hemodynamics.
224116852|NCT02446366|OTHER|Laboratory Biomarker Analysis|Correlative studies
224116853|NCT02446366|OTHER|Quality-of-Life Assessment|Ancillary studies
223975892|NCT04107597|OTHER|Core stabilization exercises|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
223975893|NCT04107597|OTHER|Core stabilization exercises and paced breathing training|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
223975894|NCT04107597|OTHER|Myofascial trigger point release|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
223975895|NCT04107597|OTHER|Myofascial trigger point release and paced breathing training|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
223975896|NCT04869150|PROCEDURE|radial access coronary angiography|The right radial artery was cannulated with a 6-f radial sheath after local infiltration with 2% lidocaine.All patients received 5000 units of unfractionated heparin, 100 - 200 μg (depending on blood pressure) of nitroglycerin and 5 mg of diltiazem unless there was an absolute contraindication to diltiazem and anticoagulants.Coronary angiography was performed using the standard Judkins' technique via right radial access with a 5-f diagnostic catheter
223975897|NCT00673127|DRUG|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
223975898|NCT02548676|DEVICE|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
223975899|NCT02420405|PROCEDURE|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
223975900|NCT02420405|PROCEDURE|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
223975901|NCT03779321|OTHER|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
223975902|NCT03719378|OTHER|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
223975903|NCT03856814|DEVICE|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
223975904|NCT02841176|OTHER|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
223975905|NCT02841176|BIOLOGICAL|Golimumab|Participants will start monthly Golimumab after their baseline visit
223975906|NCT02113540|DRUG|Atorvastatin|
223975907|NCT04615715|BEHAVIORAL|CMV Risk-Reduction Intervention|CMV Risk-Reduction Intervention
223975908|NCT04615715|BEHAVIORAL|Stress Reduction Messaging|Stress Reduction Messaging
223975909|NCT01309113|DRUG|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
223975910|NCT01267058|BIOLOGICAL|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
224116854|NCT02446366|RADIATION|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
224116855|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
224116856|NCT01399346|DRUG|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
224116857|NCT05770414|BEHAVIORAL|Make the Connection® Online Program|"Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment."
224116858|NCT04946344|BEHAVIORAL|Diet & Exercise|Participants will attend exercise and diet classes.
223725709|NCT04703335|DRUG|Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation|Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.
223975911|NCT01267058|BIOLOGICAL|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
223725710|NCT02793934|OTHER|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
223725711|NCT02793934|OTHER|New model of rehabilitation|
223725712|NCT02793934|OTHER|Old model of rehabilitation|
223725713|NCT02793934|OTHER|ICF reader|
223725714|NCT03031678|DEVICE|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
223725715|NCT00948129|OTHER|Laboratory Biomarker Analysis|Correlative studies
223725716|NCT00948129|BEHAVIORAL|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
223725717|NCT00948129|BEHAVIORAL|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
223725718|NCT00948129|OTHER|Tobacco Cessation Counseling|Undergo smoking cessation counseling
223725719|NCT03944460|DRUG|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
223725720|NCT01753856|DRUG|Teriparatide|Administered SC
223725721|NCT01753856|DRUG|Denosumab|Administered SC
223975912|NCT01267058|BIOLOGICAL|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
224116859|NCT04946344|BEHAVIORAL|Attention Control|Participants will attend healthy living classes and receive phone calls/emails/texts.
223975913|NCT05734742|OTHER|Educational video|"There were two videos including the first video Sleep apnea Syndrome Driving Safety Picture Scroll and the second video Sleep apnea Syndrome and Traffic Accidents. The first video was approximately 3 minutes long. This video was suitable for all ages. It was an easy-to-understand video explaining the characteristics of OSA and its relationship with traffic accidents. The second video was the detailed video, which is approximately 20 minutes in duration. This video was suitable for those who desire to learn more about OSA. It can be used in various educational settings, including internal training and traffic safety workshops. Participants must watch at least the first video."
223975914|NCT05857514|DRUG|Rectal Indomethacin|Prophylactic Rectal indomethacin 100mg for prevention of post ERCP pancreatitis
223975915|NCT05857514|PROCEDURE|Prophylactic Pancreatic duct stenting|Prophylactic pancreatic duct stenting with rectal indomethacin 100 mg for prevention of post-ERCP pancreatitis
223975916|NCT05762471|DRUG|GSBR-1290|Patients will receive GSBR-1290 or matching Placebo
223975917|NCT05762471|DRUG|Placebo|Patients will receive GSBR-1290 or matching Placebo
224116860|NCT04172831|DRUG|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
224116861|NCT04172831|DRUG|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
224116862|NCT01041573|BIOLOGICAL|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
224116863|NCT01041573|BIOLOGICAL|Havrix®720|0.5 ml im. at day 0 and month 7
224116864|NCT01041573|BIOLOGICAL|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
224116865|NCT02365532|DRUG|GS-6615|GS-6615 tablets administered orally
224116866|NCT02365532|DRUG|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
224116867|NCT02365532|DRUG|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
223975918|NCT06396923|DIAGNOSTIC_TEST|Wingate test|Wingate Anaerobic Power Test is based on maximal pedaling on a bicycle ergometer against a predetermined constant load to provide the highest mechanical power for 30 seconds. During the test, measurements are made automatically at intervals of five seconds and six equal intervals. As a result of these measurements, some data are obtained that allow us to obtain information about anaerobic performance.
223975919|NCT03292497|PROCEDURE|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle \>=25 degrees, or repaired if the posterior leaflet tethering angle \<25 degrees.
223975920|NCT03292497|PROCEDURE|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
223975921|NCT02517125|DEVICE|Transoral robotic-assisted surgery with Da Vinci Xi|
223975922|NCT01246219|DRUG|GH treatment (Genotropin)|4 years treatment with GH
223975923|NCT01246219|DRUG|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
223975924|NCT02301364|DRUG|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
223975925|NCT02901483|DRUG|PEP503|PEP503 will be administered by intratumoral route as slow injection
223975926|NCT02901483|DRUG|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.
223975927|NCT02901483|RADIATION|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
223975928|NCT01497340|OTHER|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
223975929|NCT01497340|OTHER|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
223975930|NCT00328380|DRUG|Rifaximin|
223975931|NCT00308919|DRUG|WST09|Treatment with WST09 Vascular Photodynamic therapy
223975932|NCT01612767|DEVICE|PRO-Kinetic Energy Stent|Coronary artery stent implant
223975933|NCT02218775|DRUG|LY2456302|Mood and Anxiety Disorders
223975934|NCT05861778|DRUG|89Zr-Girentuximab|A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
223975935|NCT03796208|BEHAVIORAL|Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)|Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
224116868|NCT02365532|DRUG|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
224116869|NCT02832492|BEHAVIORAL|pupil near response|
224116870|NCT03148171|OTHER|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
223725722|NCT01753856|DRUG|Demeclocycline|Administered orally
224116871|NCT02234115|DRUG|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
224116872|NCT01276847|DRUG|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing \> 100 kg on Day 1, and Weeks 4 and 16
224116873|NCT01276847|DRUG|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
223725723|NCT01753856|DRUG|Tetracycline|Administered orally
223975936|NCT03796208|BEHAVIORAL|Treatment As Usual|Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
223725724|NCT01753856|DRUG|Calcium Supplement|Administered orally
223975937|NCT00287157|DRUG|Sublingual Tizanidine HCl|
223975938|NCT00312234|BEHAVIORAL|Aerobic exercise|
223725725|NCT01753856|DRUG|Vitamin D|Administered orally
223975939|NCT00312234|BEHAVIORAL|Qigong exercise|
223975940|NCT04717947|PROCEDURE|Interval between NAT and surgery|Evaluate three groups according to the interval between the end of neoadjuvant therapy and surgery.
223975941|NCT00519285|DRUG|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
223975942|NCT00519285|DRUG|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
223975943|NCT00519285|DRUG|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
223975944|NCT00519285|DRUG|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
223975945|NCT04343859|DRUG|IMMH-010|After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
223975946|NCT01149876|OTHER|Nu Skin Product|Thin layer of Nu Skin product applied to face.
223975947|NCT01149876|OTHER|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
223975948|NCT01149876|DRUG|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
223975949|NCT01149876|OTHER|CeraVe moisturizer|Thin layer of CeraVe applied to face.
223975950|NCT04658654|DRUG|Roflumilast|chronic intervention (24 weeks): roflumilast capsule
223975951|NCT04658654|DRUG|Placebo oral tablet|Pill with inactive ingredients to mimic same appearance of roflumilast capsule
223975952|NCT04400799|DRUG|Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml|daily incetion s.c. for 14 days
223975953|NCT02997683|DEVICE|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
223975954|NCT02997683|OTHER|exercises at home on the floor|exercises at home on the floor
223975955|NCT02990364|DRUG|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
223975956|NCT02990364|DRUG|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
223975957|NCT02990364|DRUG|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
223975958|NCT01020747|DRUG|Avastin® (bevacizumab)|Bevacizumab injections (\~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
223975959|NCT01020747|DRUG|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
223975960|NCT03443011|RADIATION|Low dose CT without intravenous contrast|participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
223543338|NCT02273102|DRUG|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
223543339|NCT00002170|DRUG|Nelfinavir mesylate|
223975961|NCT04206709|PROCEDURE|aerobic effort|Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
223975962|NCT04206709|OTHER|passive pedaling|20 minutes passive pedaling by upper limbs.
223975963|NCT01222078|BIOLOGICAL|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
224295264|NCT06188130|OTHER|active tDCS|Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the Cz central (International 10/20 Electroencephalogram System) area, corresponding to the location of the dominant hemisphere lower extremity motor cortex and cathodal to the contralateral supraorbital region. The patient received robotic therapy for lower extremity just after each active tDCS sessions.
223725726|NCT01385553|BEHAVIORAL|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
223725727|NCT01385553|BEHAVIORAL|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
223543340|NCT05295264|OTHER|Moderate exercise program|"Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy."
223543341|NCT05497661|OTHER|448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population.|448kilohertz Capacitive Resistive Radiofrequency Stimulation on Patellar tendon in a Sporty Population.
223543342|NCT05497661|OTHER|Placebo comparator|To simulate a 448kilohertz capacitive resistive monopolar radiofrequency application on the non dominant patellar tendon
223725728|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
223725729|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
223725730|NCT00864214|DRUG|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
223725731|NCT00864214|DRUG|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
223725732|NCT04386252|BIOLOGICAL|AV-COVID-19|Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
223725733|NCT05778097|DRUG|Apalutamide 60mg Tab|Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle
223725734|NCT05778097|DRUG|Androgen deprivation therapy(ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
223725735|NCT05307068|OTHER|No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)|No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
224293302|NCT06236256|DEVICE|MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system|The MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system consists of the following devices: MiniMed 780G insulin pump, Guardian Link (4) transmitter and the Guardian Sensor (4). It is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed 780G system includes SmartGuard technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values. Study participants will be connected to the system and glucose data will be collected throughout the 12 month study period.
224295265|NCT06188130|OTHER|sham tDCS|Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for lower extremity just after each sham tDCS sessions
223543343|NCT03465722|DRUG|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
223543344|NCT03465722|DRUG|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
223543345|NCT02965066|DEVICE|Coloplast Test Catheter|Newly developed intermittent catheter
223543346|NCT02965066|DEVICE|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
223543347|NCT02745873|DRUG|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
223543348|NCT04144114|DIETARY_SUPPLEMENT|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
223543349|NCT04144114|DIETARY_SUPPLEMENT|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
223543350|NCT04144114|DIETARY_SUPPLEMENT|Placebo|Placebo
223543351|NCT01476410|DRUG|brentuximab vedotin|Given IV
223543352|NCT01476410|DRUG|doxorubicin hydrochloride|Given IV
223543353|NCT01476410|DRUG|vinblastine|Given IV
223543354|NCT01476410|DRUG|dacarbazine|Given IV
223543355|NCT01476410|PROCEDURE|quality-of-life assessment|Ancillary studies
223543356|NCT01476410|GENETIC|DNA analysis|Optional correlative studies
223975964|NCT04890886|DIAGNOSTIC_TEST|Thermal imaging|Use of a thermal imaging cameral to measure brown and white adipose tissue function
223975965|NCT04890886|DIAGNOSTIC_TEST|Echocardiogram|Echocardiographic imaging of the fetal heart to assess ventricular function
223975966|NCT04890886|DIAGNOSTIC_TEST|ECG|ECG of the fetus and the neonate to look at the cardiac electrical activity
223975967|NCT04890886|DIAGNOSTIC_TEST|MRI scan|MRI scan of the neonate to assess adipose tissue, liver architecture and cardiac structure and function
223975968|NCT04890886|DIAGNOSTIC_TEST|Serum blood markers|Serum sample taken from mother before birth and umbilical cord or neonatal blood spot at birth to assess glucose levels / lipid levels and lipidomics and cardiac function (using NTproBNP) as a marker
223975969|NCT02576327|DRUG|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
223975970|NCT02576327|DRUG|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
223725736|NCT03942848|DRUG|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
223975971|NCT02576327|DRUG|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
224116874|NCT01732263|DRUG|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
224293303|NCT06236256|OTHER|MDI/CSII|Participants in the control group with continue their routine procedures that include eighter Multiple daily insulin injections (MDI) treatment or different kinds of Continuous subcutaneous insulin infusion (CSII) pumps depending on their treatment before the study. The participants will be connected to a standalone sensor at the start, middle and end of the study and glucose data will be collected.
224293304|NCT06697353|DRUG|vericiguat (BAY 1021189)|2.5 mg initiating dose
223975972|NCT03447574|OTHER|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
223975973|NCT03592823|DRUG|Hydroxychloroquine Sulfate 200 Mg Tablet|200 mg, bidpo.
223975974|NCT02175745|DRUG|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
223975975|NCT02175745|PROCEDURE|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
223975976|NCT02175745|PROCEDURE|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
223975977|NCT02175745|PROCEDURE|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
224116875|NCT00164424|DRUG|Acyclovir|
224116876|NCT02064218|DRUG|Anti-hypertensive drugs|
224116877|NCT00493389|DRUG|Adrenocorticotrophic hormone|
224116878|NCT00695994|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
224293305|NCT02858726|DRUG|CR845 0.5 mcg/kg|IV medication delivered three times/week
224293306|NCT02858726|DRUG|CR845 1 mcg/kg|IV medication delivered three times/week
224293307|NCT02858726|DRUG|CR845 1.5mcg/kg|IV medication delivered three times/week
224293308|NCT02858726|DRUG|Placebo|IV medication delivered three times/week
224295266|NCT02823730|OTHER|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
223975978|NCT02220777|DRUG|ASP8477|oral
223975979|NCT02220777|DRUG|omeprazole|oral
223975980|NCT02220777|DRUG|Placebo|oral
223975981|NCT01438515|DRUG|Rifampin|600mg po once daily x 7 days
223975982|NCT01438515|DRUG|Doxycycline|100mg po twice daily x 7 days
223543357|NCT01476410|GENETIC|RNA analysis|Optional correlative studies
223543358|NCT01476410|RADIATION|fludeoxyglucose F 18|Correlative studies
223543359|NCT01476410|PROCEDURE|positron emission tomography|Correlative studies
223543360|NCT01476410|OTHER|laboratory biomarker analysis|Optional correlative studies
223543361|NCT01476410|OTHER|immunohistochemistry staining method|Optional correlative studies
223543362|NCT01476410|GENETIC|polymorphism analysis|Optional correlative studies
223543363|NCT03154671|OTHER|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
223543364|NCT03650868|PROCEDURE|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
223543365|NCT03962959|DEVICE|TBS|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
223543366|NCT01293136|PROCEDURE|Femoral nerve block|Ropivacaine
223543367|NCT01293136|DRUG|Intravenous opioids|Whatever opioids prescribed
223975983|NCT01438515|OTHER|2% mupirocin ointment|\~ 1cm applied to the anterior nares twice daily for 7 days
223975984|NCT01438515|OTHER|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
224295267|NCT02046525|BIOLOGICAL|Autologous fecal microbiota therapy|
224295268|NCT02046525|OTHER|Placebo|Saline enema
223725737|NCT03942848|DRUG|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
223725738|NCT03689478|OTHER|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
223725739|NCT00989378|BEHAVIORAL|baseline study|normal bedtimes
223725740|NCT04140591|DRUG|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
223725741|NCT04140591|DRUG|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure \>90mmHg) PPI: Pariet EC 20mg/QDAC
223725742|NCT05944874|DEVICE|high definition transcranial direct current stimulation|Transcranial direct current stimulation, in recent decades, has been identified as a non-invasive tool for transiently modulating human brain activity. The technique consists of the application of a low-intensity continuous electric current, through electrodes applied to the scalp, acting in a regulatory way on the frequency of triggered action potentials, however, without interacting directly with the neurons.
223725743|NCT02706340|OTHER|No intervention - observational study only|
223725744|NCT00935753|DRUG|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
223725745|NCT04008615|OTHER|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
223725746|NCT04274842|OTHER|observation by D-OCT|observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
223725747|NCT03592108|OTHER|CSR remote monitoring|The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
223725748|NCT03793933|PROCEDURE|Liver resection|Surgery for the liver
223975985|NCT06017336|OTHER|Inspiratory Muscle Training Group|Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.
223975986|NCT06017336|OTHER|Control Group (breathing exercises)|Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
223975987|NCT01729923|DRUG|Capecitabine|Given PO
223975988|NCT01729923|DRUG|Celecoxib|Given PO
223975989|NCT01729923|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223975990|NCT01729923|OTHER|Laboratory Biomarker Analysis|Correlative studies
223975991|NCT01729923|OTHER|Quality-of-Life Assessment|Ancillary studies
223975992|NCT01729923|RADIATION|Radiation Therapy|Undergo radiation therapy
223975993|NCT01729923|RADIATION|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
223975994|NCT01729923|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223975995|NCT04661514|DRUG|Psilocybin|Psilocybin-assisted psychotherapy
223975996|NCT00808899|DRUG|Temsirolimus|Temsirolimus
223975997|NCT00808899|DRUG|Irinotecan|Irinotecan
223975998|NCT00808899|PROCEDURE|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
223975999|NCT00808899|DRUG|Cyclophosphamide|Cyclophosphamide
223976000|NCT00808899|DRUG|Doxorubicin|Doxorubicin
223976001|NCT00808899|DRUG|Etoposide|Etoposide
223976002|NCT00808899|DRUG|Cisplatin|Cisplatin
223976003|NCT00808899|DRUG|Topotecan|Topotecan
224122715|NCT01433627|OTHER|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
223976004|NCT00808899|PROCEDURE|PBSC|Peripheral Blood Stem Cell Harvest
223976005|NCT00808899|RADIATION|Radiation Therapy|Radiation Therapy
223976006|NCT00808899|DRUG|13-cis-retinoic acid|13-cis-retinoic acid
223976007|NCT01252511|PROCEDURE|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
223976008|NCT00450398|DRUG|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
223976009|NCT00450398|DRUG|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
223976010|NCT03284528|OTHER|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
223976011|NCT03529084|DRUG|EFG816|It will be administered orally daily.
223976012|NCT03529084|DRUG|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
223976013|NCT04615910|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
223976014|NCT04466410|BIOLOGICAL|XT-150|Single bolus intrathecal injection
223976015|NCT04466410|BIOLOGICAL|Placebo|Placebo is a sterile phosphate-buffered saline
223976016|NCT04987034|DEVICE|EchoTip® Insight™|Patients will undergo procedure where HVPG is obtained under mild sedation, next the patients will undergo anesthesia and mechanical intubation where HVPG measurements will be obtained simultaneously with the EchoTip Insight measurement. For patients receiving a transjugular intrahepatic portosystemic shunt (TIPS), direct portal vein pressure measurements will be obtained by the EchoTip® Insight™ and compared to the transjugular direct portal vein measurement obtained during the interventional radiology (IR) procedure.
223976017|NCT03373955|DRUG|pembrolizumab|anti-programmed death 1 (PD-1) antibody
223976018|NCT04093466|DRUG|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg,125mg,150mg,175mg
223725749|NCT00242489|DRUG|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
224122716|NCT05319535|OTHER|Implementation Strategy: Foundational REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators propose that low intensity implementation support that promotes adapting Caregivers FIRST for context and provides tools for ongoing Caregivers FIRST evaluation (defined as foundational REP), will be sufficient for some but not all sites to successfully incorporate Caregivers FIRST into routine practice.
224295269|NCT03313648|PROCEDURE|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
223725750|NCT00242489|DRUG|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
223976019|NCT06135675|DRUG|TNP-2092 capsules|Administration orally.
223976020|NCT06135675|DRUG|Placebo|Administration orally.
223976021|NCT05335343|OTHER|no intervention|no intervention
223976022|NCT05459025|BEHAVIORAL|Aromatherapy yoga|The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
223976023|NCT05459025|BEHAVIORAL|Yoga|The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
223976024|NCT04116242|OTHER|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
223976025|NCT04116242|OTHER|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
224295270|NCT03313648|PROCEDURE|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
223976026|NCT04116242|OTHER|Health-related Questionnaires|Health-related Questionnaires (Questionnaire\_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
223725751|NCT01154764|DRUG|CG100649|I period: CG 100649 II period: Ketoconalzole + CG100649 at the same time
224116879|NCT00695994|DRUG|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
224116880|NCT01203462|OTHER|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
224116881|NCT01203462|OTHER|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
223725752|NCT01154764|DRUG|Ketoconazole|I period: ketoconazole + CG100649 II period: CG 100649
224293309|NCT05976724|OTHER|TENS, exercise|"TENS: The patients were sat in a chair positioned next to a treatment table. The hand to be treated was placed on the treatment table with the forearm in the supine position. Electrodes were then placed on the transverse carpal ligament and palmar surface of the hand. Conventional TENS was applied, with the current transition time set to 50-100 µs, and performed at a frequency of 100 Hz for a period of 20 minutes at an amplitude that did not cause muscle contraction or any feeling of numbness or tingling.~The supervised exercises were performed by the patients in a seated position. Strengthening exercises were performed with both hands by means of Digi-Flex hand exerciser (IMC Products Corp, Hicksville, New York), modeling mass and elastics. The patients were tasked with performing these exercises 10 times in each session and three times daily."
223725753|NCT03462264|DEVICE|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
223725754|NCT03462264|OTHER|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
223976027|NCT04116242|OTHER|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
223976028|NCT05022927|DRUG|ERY974|ERY974 vial
224116882|NCT02813330|OTHER|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
224116883|NCT02813330|OTHER|saline injection|Saline injection in two points of low back pain
223976029|NCT05022927|DRUG|Tocilicumab|Tocilizumab vial
223976030|NCT05022927|DRUG|Atezolizumab|Atezolizumab vial
223976031|NCT05022927|DRUG|Bevacizumab|Bevacizumab vial
223976032|NCT04382807|BEHAVIORAL|Counseling|Online delivered group counseling session, providing insights into the tinnitus symptoms
224116884|NCT02564822|PROCEDURE|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
224116885|NCT04471740|PROCEDURE|CSF shunt diversion|Clinical response to a CSF shunt insertion
224116886|NCT01738139|DRUG|Imatinib Mesylate|Given PO
224116887|NCT01738139|BIOLOGICAL|Ipilimumab|Given IV
224116888|NCT03321929|COMBINATION_PRODUCT|LUM Imaging System|Drug: LUM015 Device: LUM 2.6 Imaging Device
224116889|NCT03453463|OTHER|exercise|3x week predominately resistance exercise for 18 months
224116890|NCT00707018|DEVICE|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
223725755|NCT06559033|BIOLOGICAL|Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS|Estimation of the frequency of variants in the PSAP/GBA genes in patients with MM or MGUS, then comparison with a reference frequency from databases such as the Exome Aggregation Consortium, the Exome Sequencing Project, the 1000 Genomes Project and the dbSNP.
224293310|NCT05976724|OTHER|Mulligan mobilisation|Each participant was tested with sustained manual glides in each of the possible directions during active wrist flexion and extension from the seated position. For the lateral glide, the therapist stabilises the lateral aspect of the distal radius using the first web-space. And glides the proximal row of carpal bones laterally (towards the thumb) using the first web-space of the other hand, following the joint line. For the medial glide, the therapist stabilises the medial aspect of the distal ulna using the first web-space. And glides the proximal row of carpal bones medially (away from the thumb) using the first web-space of the other hand, following the joint line.
224116891|NCT00707018|DEVICE|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
224116892|NCT01065129|DRUG|G-CSF|
223725756|NCT01402791|OTHER|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
224116893|NCT01065129|DRUG|Plerixafor|
224116894|NCT01065129|DRUG|Azacitidine|
224116895|NCT05679726|BEHAVIORAL|massage|reflexology foot massage
224116896|NCT03538392|DEVICE|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
223725757|NCT05471778|BEHAVIORAL|Watching comedy movie|A 25-minute comedy film created by the researchers was watched.
223725758|NCT05471778|BEHAVIORAL|listening to music|25 minutes of music created by the researchers was played.
224116897|NCT03787004|DRUG|CNTX-6970|Oral dose CNTX-6970
224116898|NCT03787004|OTHER|Placebo|Oral dose placebo
224116899|NCT02868125|RADIATION|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
224116900|NCT03311685|DEVICE|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
223725759|NCT04880525|OTHER|Dietary intervention|In accordance with Turkey Dietary Guidelines, these diet plans were designed to provide 45-60% of energy from carbohydrates, 10-20% from protein, and 20-35 percent from fat.
223725760|NCT05600491|DRUG|Temozolomide|Two weeks after surgery, temozolomide was administered orally at 200 mg·m-2 ·d -1 for 5 days. From day 29, patients were treated with a standard therapy regimen (Stupp).
223725761|NCT04718051|DRUG|Shen Pu Yang Gan Wan|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; in addition, it has a high dose.
223725762|NCT04718051|DRUG|Placebo|Shen Pu Yang Gan Wan is Traditional Chinese Medicine; however, it has a very low dose.
223725763|NCT02305056|DRUG|C13 N15 Valine|C13 N15 Valine administration
223725764|NCT01447095|DRUG|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
224116901|NCT01742962|PROCEDURE|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
224116902|NCT02222129|DRUG|Bupivacaine|
224116903|NCT02222129|DRUG|liposomal bupivacaine|
224116904|NCT00991172|DRUG|REGN475|Single Subcutaneous injection dose level 1
224116905|NCT00991172|DRUG|REGN475|Single subcutaneous injection dose level 2
224116906|NCT00991172|DRUG|Placebo Injection|Placebo Subcutaneous injection
224116907|NCT04073823|DEVICE|Flexitouch Plus|Flexitouch Plus full arm and core treatment
224116908|NCT04073823|DEVICE|Flexitouch Plus FT with software modification|Flexitouch Plus full arm and trunk/chest treatment
224116909|NCT04522427|DEVICE|Use Multifocal and Extended Depth-of-Focus Intraocular Lenses(IOLs)|IOLs include AT LISA tri 839MP, AcrySof IQ PanOptix IOL, TECNIS Symfony EDOF
224116910|NCT04522427|DEVICE|Use Monofocal intraocular lenses(IOLs)|Monofocal IOLs include 409(Zeiss), AcrySof, TECNIS IOLS
224116911|NCT00196495|DEVICE|Polypropylene Mesh|
224116912|NCT00627640|DRUG|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
224116913|NCT00627640|DRUG|Matching Placebo|Matching Placebo
224116914|NCT05811572|DEVICE|measurement of pelvic floor muscle with perinometer|Questions the person's perceptions about low back pain and related disability VAS questions the person's perceptions about low back pain severity
223725765|NCT01447095|DRUG|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
223725766|NCT01447095|DRUG|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
223725767|NCT04928040|DIAGNOSTIC_TEST|Measurement of optic nerve sheath diameter|The fluid challenge effects of optic nerve sheath diameter
224116915|NCT02662686|OTHER|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
224116916|NCT02662686|OTHER|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
224116917|NCT01752517|DRUG|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
224116918|NCT04660903|PROCEDURE|Autologous fat cell transplantation|Up to 75 ml of fatty tissue mixture fluid
224116919|NCT03005535|OTHER|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
224116920|NCT03005535|OTHER|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
224116921|NCT01553539|DRUG|therapeutic angiotensin-(1-7)|Given SC
224116922|NCT01553539|OTHER|laboratory biomarker analysis|Correlative study
224116923|NCT00530712|DEVICE|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
224293311|NCT03358043|DEVICE|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
224293312|NCT00190879|DRUG|Atomoxetine hydrochloride|
224293313|NCT00190879|DRUG|placebo|
223976033|NCT05632016|PROCEDURE|erector spinae block (ESP)|the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
224116924|NCT02573805|DEVICE|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
224116925|NCT03837756|DRUG|Saline|Placebo
224116926|NCT03837756|DRUG|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
224116927|NCT03837756|DRUG|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
224116928|NCT00800033|BEHAVIORAL|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
224116929|NCT00800033|DIETARY_SUPPLEMENT|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
224116930|NCT02948192|OTHER|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
224116931|NCT03174860|DRUG|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
224116932|NCT03174860|DRUG|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
224116933|NCT03832868|BEHAVIORAL|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
224293314|NCT03856905|OTHER|Physical therapy program|It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
223976034|NCT04688086|DIAGNOSTIC_TEST|Thermalytix|Thermalytix is an Artificial intelligence based automated breast screening solution that analyzes thermal distribution on the breast to generate a breast health score automatically. Thermal imaging was performed by a trained technician to capture thermal images of the participant in five views. These thermal images were uploaded to Thermalytix software on the cloud where it was automatically analyzed by AI-based Thermalytix computer-aided detection (CADe) engine. This CADe engine analyzes uploaded thermal images and outputs an interpretation report for each participant with quantitative scores corresponding to computed probability of malignancy based on the structural, vascular, areolar, thermal properties of the observed abnormality. Thermalytix also generates annotated images with markings of abnormal regions and an overall Thermalytix score suggesting likelihood of breast malignancy. The locked AI model Thermalytix algorithm version 3, dated December 2018 was used for the analysis.
224116934|NCT03832868|BEHAVIORAL|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
224116935|NCT04830748|OTHER|Mechanical knee traction|Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
224122717|NCT05319535|OTHER|Implementation Strategy: Enhanced REP|Among Caregivers FIRST sites that do not meet implementation adoption benchmarks, the goal is to test implementation intensification approaches, specifically Foundational REP vs. Enhanced REP. The investigators posit that higher intensity strategies (defined as Enhanced REP) that directly influence teams' capacity and skills to effectively self-organize and problem-solve will lead to higher implementation adoption, penetration, fidelity, and value.
224295271|NCT01633502|DEVICE|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
224295272|NCT01633502|DEVICE|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
224293315|NCT03856905|DEVICE|Extracorporeal shock wave therapy|It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
224293316|NCT03856905|DEVICE|Functional electrical stimulation|It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
223976035|NCT01090700|DRUG|TMC435|TMC435 150 mg daily for 7 days
223976036|NCT01090700|DRUG|Escitalopram|Escitalopram 10 mg daily for 7 days
223976037|NCT01090700|DRUG|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
223976038|NCT03786003|PROCEDURE|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
223976039|NCT03786003|PROCEDURE|Thoracotomy|Standard thoracotomy
223976040|NCT03509142|DEVICE|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
223976041|NCT00988117|DRUG|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
223976042|NCT06224335|DIAGNOSTIC_TEST|intra-abdominal pressure with Femfit® device during (jumps on the ground, jumps on a trampoline, weightlifting, slow running, fast running|Change in intravaginal and intra-abdominal pressure assessed by Femfit® , leakage of urine in grams assessed by inovative pad test during 5 sports activities.
223976043|NCT02292641|PROCEDURE|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
223976044|NCT05955547|OTHER|Prognosis Scoring|To determine the prognosis of patients admitted to ICU with a scoring system that includes inflammation and nutritional status
224122718|NCT06350344|DEVICE|mobile venous thromboembolism application (mVTEA)|mVTEA will assist in the management of patients with high-risk of VTE during the post-hospitalization follow-up phase. The mVTEA's doctor terminal automatically sends VTE-related health education materials in different frequencies and contents based on the patient's knowledge of VTE prevention and treatment, as well as their risk of thrombosis and bleeding during follow-up. In addition, thrombosis physicians on the mVTEA's doctor terminal can deliver health education to patients based on their condition. This can be done through the mVTEA doctor-patient communication module, which includes text, voice, and video communication.
224293317|NCT01358149|OTHER|cocoa-based food|single intake of cocoa-based food
224293318|NCT01358149|OTHER|cocoa-based food|Single intake of cocoa-based food
224293319|NCT06632327|PROCEDURE|Surgical Procedure|undergo surgery
224293320|NCT06632327|DRUG|Cisplatin|Give cisplatin
223725768|NCT00064844|BEHAVIORAL|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
223976045|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
223976046|NCT04928482|BEHAVIORAL|Backward Walking Training|Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
224293321|NCT06632327|DRUG|Carboplatin|Give Carboplatin
224293322|NCT06632327|DRUG|Pemetrexed|Give Pemetrexed
224293323|NCT06632327|DRUG|Gemcitabine|Give Gemcitabine
224293324|NCT06632327|DRUG|Docetaxel|Give Docetaxel
224293325|NCT06632327|DRUG|Vinorelbine|Give Vinorelbine
223976047|NCT00702273|DRUG|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
223976048|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223976049|NCT00702273|DRUG|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
224293326|NCT06632327|DRUG|Nivolumab|Give Nivolumab
224293327|NCT06632327|DRUG|Pembrolizumab|Give Pembrolizumab
224293328|NCT06632327|DRUG|Atezolizumab|Give Atezolizumab
224293329|NCT06632327|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
224293330|NCT06632327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224293331|NCT06632327|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223976050|NCT00702273|DRUG|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
223976051|NCT00702273|BIOLOGICAL|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
223976052|NCT00702273|DRUG|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
224293332|NCT01594359|OTHER|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
224293333|NCT01594359|OTHER|BEAN|Placebo
223543368|NCT00532701|DRUG|Peg-IFN + WB RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 5-16"
223725769|NCT00064844|DRUG|Nicoderm CQ nicotine patch|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy.
223976053|NCT00702273|BIOLOGICAL|hCG|When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
223976054|NCT00702273|BIOLOGICAL|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
223976055|NCT03483597|OTHER|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
224293334|NCT02008708|BEHAVIORAL|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
223976056|NCT05683886|DRUG|KC1036|Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
223976057|NCT00513461|DRUG|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
223976058|NCT00513461|OTHER|placebo|Given PO
223976059|NCT00513461|OTHER|laboratory biomarker analysis|Correlative studies
223976060|NCT00513461|OTHER|immunoenzyme technique|Correlative studies
223976061|NCT00513461|OTHER|high performance liquid chromatography|Correlative studies
223976062|NCT00853021|BIOLOGICAL|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
223976063|NCT00853021|BIOLOGICAL|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
224293335|NCT02008708|OTHER|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
224295273|NCT01048216|RADIATION|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
224295274|NCT05895734|DEVICE|NDS-Powerball®,|Rehabilitation using the Powerball system
223976064|NCT01196247|DRUG|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
223976065|NCT01329419|DRUG|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
223976066|NCT05166798|BEHAVIORAL|Cognitive control training|The five intervention groups will receive either 1, 5, 10, 15 or 20 training sessions with the Adaptive Paced Auditory Serial Addition Task (aPASAT).
223976067|NCT05370547|DRUG|Chidamide|"1. Chidamide monotherapy mode: Chidamide was administered for at least 6 times after leukapheresis, 10mg oral D1-4, 20mg oral D7 every 3 days to the beginning day of FC conditioning.~2. Chidamide combination mode: The combination of one or more of the following drugs in addition to chidamide is permitted: glucocorticoids, BTK inhibitors, chemotherapy, other previously used resistance drugs, etc."
223976068|NCT05370547|DRUG|Fludarabine and cyclophosphamide|Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
223976069|NCT05370547|BIOLOGICAL|Anti-CD19 CAR-T cells|A single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 100 × 10\^6 for Relma-cel or 2 × 10\^6/kg for Axi-cel. Other commercial CAR-T doses are determined by specific drug infusion instructions. The dose of experimental CAR-T was determined by the investigator. Infusion volume was calculated based on CAR-T cell density and recommended dose.
223976070|NCT05258877|OTHER|Plasma samples|Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.
223976071|NCT06348498|DRUG|Jia Shen Tablet|Jia Shen Tablets contain 4 tablets (0.47 g per tablet), take orally, 2 times a day for 12 weeks
223976072|NCT06199206|OTHER|Theraputic Play|Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
223976073|NCT02972814|DEVICE|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
223976074|NCT02972814|DEVICE|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
223976075|NCT02972814|DEVICE|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
223976076|NCT00317447|DRUG|Oral Prednisone|
223725770|NCT00064844|DRUG|Placebo gum|Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
223976077|NCT01536613|DRUG|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
223976078|NCT02201147|PROCEDURE|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
223976079|NCT02201147|PROCEDURE|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
223976080|NCT02201147|DEVICE|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
223976081|NCT02201147|DEVICE|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
223976082|NCT01220856|DRUG|Reparixin|Reparixin + immunosuppression
223976083|NCT02580019|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
223976084|NCT02814461|DRUG|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
223976085|NCT02814461|RADIATION|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
223976086|NCT03600922|PROCEDURE|the patella was resurfaced.|Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
223976087|NCT04088500|BIOLOGICAL|Nivolumab|Specific dose on specific days
223976088|NCT04088500|BIOLOGICAL|Ipilimumab|Specific dose on specific days
223976089|NCT05765409|OTHER|TIMCA|"TIMCA is an individual therapy that will include the parents at certain points in the therapy .~It will consist of two sessions of MI, two sessions of CBT, five sessions of ABI and one final session of summary to conclude the therapy.~Out of 10 sessions, there will be three with the parents and the adolescent together."
223976090|NCT05765409|OTHER|Treatment as Usual|"TAU will consist of several approaches including analytical, cognitive-behavioral , intepersonal psychotherapy.~Each therapist will be asked to specify the approach used as well as the therapeutic axes."
223976091|NCT03421171|OTHER|no intervention|Qualitative research through semi-structured interviews
223976092|NCT00981578|DEVICE|ExAblate 2100|Conformal Bone System
223976093|NCT00806741|DRUG|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
223976094|NCT00806741|DRUG|Phenylephrine|1μg/kg/min, infusion period 20 minutes
223976095|NCT00806741|DRUG|Physiological saline solution (as placebo)|infusion period 20 minutes
224116936|NCT04830748|OTHER|Therapeutic exercises|"Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force."
224116937|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
224116938|NCT03884348|DRUG|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
224116939|NCT00002195|DRUG|Amprenavir|
224116940|NCT00002195|DRUG|Lamivudine|
224116941|NCT00002195|DRUG|Zidovudine|
224116942|NCT03415464|OTHER|Exercise|neuromuscular training
224116943|NCT02241850|OTHER|High intensity training|9 weeks of supervised high intensity training
224116944|NCT04936139|BEHAVIORAL|Art Therapy|"During the 12 planned sessions, different artistic disciplines will be used: visual arts, music, play, narrative, dramatization, movement and body expression.~Each session is structured in 3 phases:~i. A first part of encounter and contextualization, to make contact with oneself, with the art therapist and with the group through a relaxation or meditation activity (35 minutes).~ii. A second part, where the session continues with the work of artistic elaboration and production with the different materials and the different artistic languages (50 minutes).~iii. A third part where the participants will be invited to make a closing, a moment to welcome and share whoever wishes, the experiences that have been experienced. A dialogue is created between Work-Patient-Art Therapist (35 minutes)."
223976096|NCT00806741|DEVICE|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
224116945|NCT01835990|DEVICE|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
224116946|NCT01835990|DEVICE|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
224116947|NCT05074095|OTHER|retrospective analysis|
224295275|NCT05895734|OTHER|Conventional treatment|Rehabilitation by conventional treatment
223976097|NCT00806741|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements
223976098|NCT00806741|OTHER|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
223976099|NCT05310344|COMBINATION_PRODUCT|Albumin-bound paclitaxel and bevacizumab|Patients will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles.
223543369|NCT00532701|DRUG|Peg-IFN + LD RBV for 16 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-6~2. Rapid virologic response (RVR) at week 4 of therapy: achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
223976100|NCT05130502|OTHER|Foam roller|The investigators use Foam roller to 3 muscle groups per leg then conduct a dynamic warm up program and conduct performance tests
223976101|NCT05130502|OTHER|Kinesiotape|The investigators use Kinesiotape to 3 muscle groups per leg, wait 45 minutes for bring out the effects then conduct a dynamic warm up program and conduct performance tests
223976102|NCT04206384|DEVICE|Ultrasound|Ultimate Contour Body Sculpting Device
223976103|NCT02212197|DRUG|leuprolide acetate FluidCrystal® injection depot|
223976104|NCT02212197|DRUG|leuprolide acetate|
223543370|NCT00532701|DRUG|Peg-IFN + WB RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
223976105|NCT03705988|DEVICE|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA\~2mA.
223976106|NCT03705988|DEVICE|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
223976107|NCT04030988|DRUG|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
223976108|NCT04030988|DRUG|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
223976109|NCT01600235|DRUG|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
223976110|NCT00321529|DEVICE|motion analysis by durometer|
223976111|NCT03015181|BIOLOGICAL|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
223976112|NCT00346177|BIOLOGICAL|Autologous Stem Cells|Intramyocardial injections
223976113|NCT06454799|BEHAVIORAL|Akupressur|The application will be carried out on 3 body points. These; Pericardium 6, Yintang and Shen men points. Acupressure will be applied to each of these acupressure points for 1 minute.
223543371|NCT00532701|DRUG|Peg-IFN + WB RBV for 48 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (\< 75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) from weeks 1-4~2. Rapid virologic response (RVR) at week 4 of therapy: not achieved~3. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
223543372|NCT00532701|DRUG|Peg-IFN + LD RBV for 24 weeks|"1. Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~2. Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
223543373|NCT04940130|BIOLOGICAL|Sanaria® PfSPZ Vaccine|non-adjuvanted, live (metabolically active), radiation-attenuated, non-replicating, whole sporozoite (SPZ) vaccine designed to prevent malaria infection caused by Plasmodium falciparum (Pf).
223976114|NCT01911936|DRUG|LM716|
223976115|NCT04641416|DIAGNOSTIC_TEST|Routinely performed echo, ECG and hemodynamic monitoring|The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
223976116|NCT02703402|OTHER|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
224293336|NCT01742559|PROCEDURE|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman \& Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
223976117|NCT02703402|OTHER|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
223976118|NCT02551692|DRUG|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
223976119|NCT02551692|DRUG|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
223976120|NCT02551692|DRUG|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
223976121|NCT02551692|DRUG|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
224116948|NCT03114241|BEHAVIORAL|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
224116949|NCT00002221|DRUG|Peripheral blood stem cells|
223543374|NCT04940130|OTHER|Normal Saline|placebo control- saline
223543375|NCT03141255|DEVICE|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
224116950|NCT04195074|DRUG|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
224116951|NCT04195074|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
223543376|NCT03141255|DEVICE|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
223543377|NCT02329093|PROCEDURE|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
224116952|NCT04195074|DRUG|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
224116953|NCT03625219|DRUG|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
224116954|NCT03625219|DRUG|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
223543378|NCT00295282|DRUG|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
223543379|NCT02240121|DRUG|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
223543380|NCT02240121|DRUG|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
223976122|NCT03711799|BEHAVIORAL|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
223976123|NCT01091519|OTHER|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
223976124|NCT01091519|OTHER|Toviaz(fesoterodine) without educational materials|No educational materials
223976125|NCT00621946|DRUG|Placebo|Placebo Matching Escitalopram
223976126|NCT00621946|DRUG|Escitalopram|Active Escitalopram
223976127|NCT03030599|DRUG|JZP-258|JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
223976128|NCT03030599|OTHER|Placebo|Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
223976129|NCT00598858|DRUG|Docetaxel|Given IV
223976130|NCT00598858|DRUG|Prednisone|Given PO
223976131|NCT01177228|DRUG|Vedolizumab|Vedolizumab for intravenous infusion
223976132|NCT01177228|DRUG|Placebo|Placebo intravenous infusion
223976133|NCT05360342|DRUG|Vitamin K supplement|Single dose of vitamin K supplement
223976134|NCT02900313|OTHER|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
223976135|NCT01592383|DRUG|erlotinib hydrochloride|Given PO
223976136|NCT03861585|OTHER|Semantic group|"The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial."
223976137|NCT03861585|OTHER|Emotional group|"The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial."
223976138|NCT06053047|DEVICE|Bluedrop Monitoring Service (BMS)|Remote use of ThermoVisual monitoring
223976139|NCT05832944|DEVICE|ultrasound guided hyomental distance|measuring the hyomental distance by ultrasound guidance
223976140|NCT06516692|DIAGNOSTIC_TEST|Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment|Assessment of hydration status in critically ill patient recruited to this arm will be intervened through an ultrasound guided calculation of collapsibility and distensibility index of Inferior Vena Cava. This method of intervention will be continued and repeated as needed throughout the stay of the participant in intensive care unit.
223976141|NCT06288256|OTHER|No Intervention|No Intervention
223976142|NCT04292925|OTHER|New treatment protocol|The new treatment protocol focuses on training of executive processes using remedial strategies and on promoting the use of meta-cognitive strategies. Goal directed activities are used to improve the underlying cognitive process and transfer of the learned skill to everyday function will be encouraged.
223976143|NCT04292925|OTHER|Conventional therapy|conventional therapy
223976144|NCT05018949|PROCEDURE|Lower limb angioplasty|Patients who have undergone LL angioplasty are enrolled in study for a medical records review.
224116955|NCT00962923|BIOLOGICAL|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10\^6 cells/kg body weight).
223543381|NCT02274961|DRUG|S-pantoprazole 10mg|
223543382|NCT02274961|DRUG|Placebo|
223976145|NCT04472442|PROCEDURE|Intermittent hypoxia|"Acute intermittent treatment (AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. AIH (using 9% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
223976146|NCT04472442|PROCEDURE|Sham hypoxia|"Sham acute intermittent treatment (sham AIH) will be initiated using an oxygen generator (Model HYP-123, Hypoxico Inc, New York, NY, and participants will be seated comfortably and fitted with a non-rebreather mask. Sham AIH (using 20% O2) will be provided in 60 s intervals and repeated 15 times with alternating 60 s intervals of normoxia (21% O2). Continuous pulse oximetry (Masimo 7, Irvine CA) will be monitored to ensure oxygen saturation of 82-85%. Signs and symptoms of distress with AIH exposure will be noted throughout, with HR and blood pressure taken every 3-5 minutes and documented.~High-intensity training will then be performed (40 min of walking training up to 70-80% maximum heart rate within 1 hr)."
223976147|NCT04582864|DRUG|Flotetuzumab|Will be provided by MacroGenics Inc.
223976148|NCT04582864|PROCEDURE|Donor lymphocyte infusion|DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
223976149|NCT02657018|DEVICE|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
223976150|NCT02657018|OTHER|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
223976151|NCT02860559|BIOLOGICAL|TBX-1400|Hematopoietic stem cells transplantation
224116956|NCT05348005|DEVICE|Ovira Transcutaneous Electrical Nerve Stimulation Unit|TENS units have a wide application from treatment of chronic back pain, chronic abdominal pain, cancer pain, perioperative pain, and labor pain.19-24 TENS units have been shown to be well-tolerated with minimal side effects and have been successful in reducing pain as well as pain medication use in patients with primary dysmenorrhea, which excludes pathology such as endometriosis. 11-18 Certain TENS units have also been FDA approved for the general indication of pelvic pain.
223976152|NCT04975932|OTHER|TACE+ICIs|TACE plus ICIs ( with or without molecular targeted therapies)
223976153|NCT04975932|PROCEDURE|TACE|TACE without combination of ICIs ( with or without molecular targeted therapies)
223976154|NCT05580783|OTHER|Test meal labelled with 54Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 54Fe
223976155|NCT05580783|OTHER|Test meal labelled with 57Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 57Fe
223976156|NCT05580783|OTHER|Test meal labelled with 58Fe|Each participant will receive 2 test meals containing 4mg each of isotopic tracer 58Fe
224116957|NCT03785197|OTHER|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
223976157|NCT04167085|DRUG|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
223976158|NCT04167085|OTHER|Placebo|Matching placebo, twice a day for 2 months
224116958|NCT02111824|DEVICE|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
224116959|NCT02111824|DRUG|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
224116960|NCT02986958|OTHER|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
224116961|NCT02986958|OTHER|Usual care|routine primary care
224116962|NCT02257814|BEHAVIORAL|Incredible Years Teacher Training|
224116963|NCT02257814|BEHAVIORAL|Preschool PATHS|
224116964|NCT02257814|BEHAVIORAL|Tools of the Mind|
223725771|NCT00064844|DRUG|Nicotine gum - Nicorette®|Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
223725772|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
223725773|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
223725774|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
223976159|NCT02618785|PROCEDURE|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
223976160|NCT01890499|DIETARY_SUPPLEMENT|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
223976161|NCT04177732|DIAGNOSTIC_TEST|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
223976162|NCT04177732|DIAGNOSTIC_TEST|Probing depth|Williams SE manual probe will be used to measure the probing depth
223976163|NCT04177732|DIAGNOSTIC_TEST|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
223976164|NCT04177732|DIAGNOSTIC_TEST|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
223976165|NCT04177732|DIAGNOSTIC_TEST|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
223976166|NCT03307083|OTHER|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
223976167|NCT02367742|BEHAVIORAL|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
223976168|NCT02367742|BEHAVIORAL|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~* Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~* Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
223976169|NCT06574633|BEHAVIORAL|In-person therapy|Participants will be referred to in-person therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
223976170|NCT06574633|BEHAVIORAL|Telehealth therapy|Participants will be referred to telehealth therapy services when facilitating referral resources by a dedicated behavioral mental health specialist (BMHS).
223976171|NCT01299441|DEVICE|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
223976172|NCT03314389|DEVICE|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
223976173|NCT01361789|DRUG|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
224116965|NCT02820610|DRUG|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
224116966|NCT02820610|DRUG|Magnesium Sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
224293337|NCT01742559|PROCEDURE|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
223976174|NCT01361789|DRUG|Dexamethasone|8 mg IV
223976175|NCT01361789|DRUG|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
223976176|NCT05016778|DRUG|GPRC5D-CAR-T|After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
223976177|NCT06326281|PROCEDURE|unilateral external oblique intercostal plane block group|USG guided external oblique intercostal plane block will perform unilateral with Bupivacaine 25 patient included and patients were observed for pain for 24 hours
223976178|NCT06326281|PROCEDURE|unilateral oblique subcostal transversus abdomınıs plane block group|USG guided oblique subcostal transversus abdomınıs plane block block will perform unilateral with Bupivacaine. 25 patient included and patients were observed for pain for 24 hours
223976179|NCT06326281|PROCEDURE|Local anesthetic infiltration group|Bupivacaine infiltration will be performed to trocar insertion sites. 25 patient included and patients were observed for pain for 24 hours
224116967|NCT02820610|DRUG|Normal saline 0.9 %|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
224116968|NCT01950481|DRUG|LDK378|Oral LDK378 750 mg once
224116969|NCT02399475|DRUG|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
224116970|NCT02399475|DRUG|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
224116971|NCT02399475|DRUG|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
224293338|NCT02056067|BEHAVIORAL|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
224295276|NCT02689063|DRUG|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
223976180|NCT06326281|DRUG|Control group|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol patient controlled analgesia. Tramadol at a concentration of 5 mg/mL is included in our patient controlled analgesia protocol (total volume 100 mL.) patient controlled analgesias were set to no basal infusion and 10 mg bolus doses with a 20 min lock time 25 patient included and patients were observed for pain for 24 hours
223976181|NCT01958047|DRUG|ASP3652|Oral
223976182|NCT03440580|DEVICE|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
223976183|NCT03379311|DRUG|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
223976184|NCT01396733|DRUG|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
223976185|NCT00328276|DRUG|Sarcosine|
223976186|NCT03594045|DRUG|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
223976187|NCT03002233|DRUG|TRK-820|
223976188|NCT04601883|DRUG|Colchicine 0.5 MG|"The intervention tablets are commercially available Colchicine Tiofarma"
223976189|NCT04601883|DRUG|Placebo|Encapsulated placebo tablets. Placebo is identical to the active intervention.
223976190|NCT03427879|DRUG|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
223976191|NCT03427879|DRUG|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
223976192|NCT04685018|DEVICE|fMRI acquisition|Participants from the two groups will perform an avoidance-relief task inside an MRI scanner
224116972|NCT02237807|DRUG|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
224116973|NCT02237807|DRUG|DYNABAC 250 MG ENTERIC COATED TABLET|
224116974|NCT05328778|DRUG|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
224116975|NCT02260193|DRUG|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224116976|NCT02260193|DRUG|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224116977|NCT02260193|DRUG|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
224116978|NCT02154854|DRUG|Tacrolimus targeted half-dose|
224116979|NCT02154854|DRUG|Tacrolimus targeted plain dose|
224116980|NCT03141801|DEVICE|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
223976193|NCT01297452|DRUG|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
223976194|NCT01297452|DRUG|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
224116981|NCT03141801|OTHER|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
224116982|NCT03141801|OTHER|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
224116983|NCT00744146|BIOLOGICAL|Protexia|Single 50 mg IM dose
224116984|NCT00744146|BIOLOGICAL|Protexia|Single 100 mg dose
224116985|NCT00744146|BIOLOGICAL|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
224116986|NCT00744146|BIOLOGICAL|Protexia|Single 500 mg dose, IM
224116987|NCT00744146|BIOLOGICAL|Protexia|Single 750 mg dose, IM
224116988|NCT03393013|DRUG|KZR-616|Subcutaneous Injection of KZR-616
224116989|NCT00013403|PROCEDURE|Blindness|
224116990|NCT01009385|PROCEDURE|cervical epidural steroid injection|"* After aseptic preparation and skin infiltration with 1% lidocaine~* 20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~* identification of the epidural space confirmed by injection of contrast medium under fluoroscope~* injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~* Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
223725775|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, \>100 to 150 Units/kg/week, or \>150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
223976195|NCT01297452|DRUG|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
224116991|NCT01009385|PROCEDURE|epidural pressure measurement|"* The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~* Identification of the epidural space and measurement of EP was performed with a closed measurement system."
224116992|NCT02416687|DEVICE|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
224116993|NCT02133378|DEVICE|Hemopatch|Baxter Hemopatch
224116994|NCT02133378|BEHAVIORAL|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
224116995|NCT02532868|DRUG|MK-0457|
224116996|NCT01963117|RADIATION|Combined hyperthermia and radiation therapy|
224116997|NCT00403702|DRUG|Oxane HD [oil-RMN3-mixture]|
224116998|NCT00403702|DRUG|Densiron [(F6H8)|
224116999|NCT00886132|DRUG|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
224295277|NCT02689063|DRUG|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
224295278|NCT02689063|DRUG|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
223725776|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
223725777|NCT00434330|DRUG|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
223725778|NCT04461730|DEVICE|deep brain stimulation|Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
223725779|NCT00263133|DRUG|Sertraline|
223725780|NCT00708006|DRUG|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
223725781|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
223976196|NCT01297452|DRUG|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
223976197|NCT02811302|DEVICE|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
223976198|NCT02413502|BIOLOGICAL|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10\^8 CFUs.
224117000|NCT05606354|OTHER|Intervention group|Experimental
224117001|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation)|"Patients will benefit from screening for refractory pain, neuropathic or not, with myofascial syndrome, between 3 and 12 months after surgery.~The healthcare professional will determine 4 trigger points. TENS is applied twice 45 min every day for 2 months. Pain treatment will be done by using the P6 program in alternative mode: 2hz / 100Hz.~The time between 2 electrostimulations will be a minimum of 4 hours and a maximum of 15 hours."
224117002|NCT04936451|DEVICE|TENS (transcutaneous electrical nerve stimulation) ECOMODYN|"TENS ECOMODYN® is applied to 4 treatment points, 5 minutes per point 2 times a day for 2 months.~A minimum rest period of 4 hours between 2 sessions on the same point must be respected Stimulation is performed directly with the bipolar probe of the TENS ECOMODYN® device on the painful area by fixed stimulation of 4 active pain points in 77Hz mode."
224295279|NCT02689063|DRUG|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
224295280|NCT04719234|DEVICE|lung ultrasonography|Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)
224117003|NCT02082067|PROCEDURE|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
224117004|NCT02082067|PROCEDURE|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
223976199|NCT03650244|DEVICE|REMEEX implantation|Device implantation
223976200|NCT05809726|OTHER|Manual lymph drainage|one session 20 minutes
223976201|NCT05744791|BEHAVIORAL|Active Play planned movement program|Teachers will implement an addition two physical activity opportunities that incorporate active play each day for a potential dose of 20-30 minutes per day and 100-150 minutes per week.
223976202|NCT02826759|OTHER|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
223976203|NCT06240403|DRUG|Digoxin 0.125 MG|One capsule containing digoxin per day for three months
223976204|NCT04557865|DIAGNOSTIC_TEST|18F-PMPBB3 (APN-1607) PET imaging|"1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical"
223976205|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
223976206|NCT00702520|DRUG|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
223976207|NCT00702520|DRUG|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
223976208|NCT00702520|BIOLOGICAL|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
223976209|NCT00702520|BIOLOGICAL|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
223976210|NCT06646588|DRUG|Fruquintinib|Fruquintinib: Oral, once daily, 2 weeks on and 1 week off. The product can be taken with food or orally on an empty stomach, and needs to be swallowed whole. It is recommended that the dose be taken at the same time each day; if the patient vomits after taking the dose, no refill is needed; a missed dose should not be added the next day, but the next prescribed dose should be taken as usual.
223976211|NCT06646588|DRUG|Tislelizumab|Tislelizumab: intravenous drip 200mg，day1，once every three weeks.
223976212|NCT06646588|RADIATION|Radiotherapy|Radiotherapy synchronised with drugs.
223976213|NCT03196622|DEVICE|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
223976214|NCT03597997|DRUG|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
223976215|NCT03597997|DRUG|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
223976216|NCT06290557|DRUG|HY_133|A recombinant chimeric bacteriophage endolysin HY-133
223976217|NCT06290557|DRUG|Placebo|Placebo
223976218|NCT05876286|OTHER|Neurological examinations|Neurological, neuropsychological, polysomnography examinations and multiple sleep latency test. The protocol is divided into three visits.
223976219|NCT03460132|DEVICE|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
223976220|NCT00860301|OTHER|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
223976221|NCT02481934|PROCEDURE|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
223976222|NCT02481934|DRUG|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
223976223|NCT02481934|DRUG|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
223725782|NCT00615095|OTHER|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
223725783|NCT00615095|OTHER|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
223725784|NCT04567433|DRUG|Hydroxyethyl starch|Hydroxyethyl starch compared to 0.9% saline
223725785|NCT04567433|DRUG|Hydrocortisone|Hydrocortisone compared to Placebo
223725786|NCT04567433|PROCEDURE|Early Goal Directed Therapy|Early Goal Directed Therapy compared to Usual Care
223725787|NCT02733068|BIOLOGICAL|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
223976224|NCT04459949|DEVICE|Sharkskin|Use of Sharkskin ILM forceps
223976225|NCT04459949|DEVICE|Grieshaber|Use of Grieshaber ILM forceps
223976226|NCT04547101|DRUG|AK104|AK104，6 mg/kg IV，every 2 weeks (Q2W)
223725788|NCT02733068|BIOLOGICAL|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
223976227|NCT03044834|OTHER|PPB|Global current care
223725789|NCT00016016|DRUG|cytarabine|Given IV
223725790|NCT00016016|DRUG|mitoxantrone hydrochloride|Given IV
223725791|NCT00016016|DRUG|alvocidib|Given IV
223725792|NCT00016016|OTHER|pharmacological study|Correlative studies
223725793|NCT00016016|OTHER|laboratory procedure|Correlative studies
223725794|NCT03278613|DEVICE|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
223725795|NCT04777071|PROCEDURE|Computed Tomography|Undergo PET/CT scan
223725796|NCT04777071|DRUG|Gallium Ga 68 Gozetotide|Given IV
223725797|NCT04777071|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
223725798|NCT04777071|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR scan
223725799|NCT04777071|PROCEDURE|Bone Scan|Undergo bone scan
223725800|NCT04777071|OTHER|Electronic Health Record Review|Ancillary studies
223725801|NCT05459038|DIAGNOSTIC_TEST|C-Arm Rotational View (CARV)|CARV includes predefined fluoroscopy landmarks of the uninjured side to correct for rotational malalignment of the injured side in which the rotation of the C-Arm Image Intensifier is used
223976228|NCT06310278|DIAGNOSTIC_TEST|Ossicular mobility measurement|Measurements of ossicular mobility i.e. the dynamic velocity of middle ear structures (umbo of malleus and incus at the incudostapedial joint) normalized to sound pressure incident on the tympanic membrane.
223976229|NCT04907344|DRUG|Camrelizumab|IV infusion
223976230|NCT04907344|DRUG|Nab-Paclitaxel|IV infusion
223976231|NCT04907344|DRUG|Carboplatin|IV infusion
223976232|NCT05025553|DIETARY_SUPPLEMENT|Gut mobilization|Polyethylene Glycol (PEG) at the Dose of 6.9 g/d Once a Day for 6 Month. Children were observed and tested at baseline (T0), 1 month (T1) and 6 months (T2) after gut mobilization.
223976233|NCT03152474|DRUG|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
223976234|NCT03152474|DRUG|Vitamin A 100,000 IU|Dosed Intramuscular once daily
223976235|NCT03152474|OTHER|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
223976236|NCT03750500|DEVICE|Biofeedback device|12-week exercise program performed through the device
223976237|NCT03750500|BEHAVIORAL|Education on falls risk|Education on falls risk factors and how to minimize them
223725802|NCT06678074|DRUG|Atibuclimab (IC14), 20 mg/kg intravenously, once|monoclonal antibody against CD14
223725803|NCT06678074|OTHER|Placebo, 150 mL intravenously, once|sterile normal saline for injection
223725804|NCT07015138|RADIATION|TRT|"Comprehensive metastasis-directed radiotherapy:~* Targets: Primary prostate tumor + all metastatic lesions (≤10 sites confirmed by PSMA PET)~* Concurrent therapy: Standard systemic treatment (ADT + novel hormonal agents)"
223725805|NCT07015138|RADIATION|NTRT|"Standard primary radiotherapy:~* Targets: Prostate primary tumor only~* Concurrent therapy: Same systemic treatment as experimental arm"
223976238|NCT03750500|OTHER|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
223976239|NCT03750500|DIAGNOSTIC_TEST|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
223976240|NCT04675086|DRUG|alpha1-proteinase inhibitor|Alpha1-Proteinase Inhibitor (Human), AralastÔ, is a sterile, stable, lyophilized preparation of purified human alpha1-proteinase inhibitor (a1-PI), also known as alpha1-antitrypsin.
223976241|NCT04675086|DRUG|Antiviral Agents|a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
223976242|NCT00942188|DRUG|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
223976243|NCT00942188|DRUG|Placebo|Participants received 2 SC injections weekly for 12 weeks.
223976244|NCT06012877|BEHAVIORAL|Health Friendly Program|"The intervention, known as the Health-Friendly Programme, took place at the Clinical Skills and Simulation Centre of the Public University of Navarre. The intervention consisted of showing the children different scenarios that simulated various medical contexts, letting them experiment with the material and ask questions.~The structure and content of the intervention were intended to address two main issues. First, the health contexts with which school-age children may come into contact with; these are a consultation at a health centre and a hospital room. Second, the concerns, in relation to intrapersonal, procedural, environmental and interpersonal aspects, experienced by children when they interact with health care professionals or they are sick.~As reference material, the intervention is described in detail in the guide about the Health-Friendly Programme (Escalada-Hernández et al., 2021)."
223976245|NCT00276016|DRUG|phenylephrine|immediate-release 12 mg capsules for oral administration
223976246|NCT00276016|DRUG|pseudoephedrine|60 mg immediate-release tablets for oral administration
223976247|NCT00276016|DRUG|placebo|placebo capsules
223976248|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
223725806|NCT07018297|COMBINATION_PRODUCT|Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor|Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.
223976249|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
223976250|NCT03656445|DRUG|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
223976251|NCT00390936|DRUG|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
223976252|NCT04818047|BEHAVIORAL|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
223976253|NCT05181891|BEHAVIORAL|Contingency Management|Incentives for submitting negative-alcohol urine samples
223976254|NCT05181891|BEHAVIORAL|Non-contingent control|Incentives for submitting urine samples
223976255|NCT01374971|DRUG|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
224117005|NCT02082067|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
223725807|NCT01461941|DRUG|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
223976256|NCT01374971|PROCEDURE|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
223976257|NCT01378481|DRUG|Vorinostat|Given PO
223976258|NCT01378481|RADIATION|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
223976259|NCT01378481|OTHER|Laboratory Biomarker Analysis|Correlative studies
224117006|NCT02082067|PROCEDURE|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
224117007|NCT02082067|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
224117008|NCT02082067|DRUG|Ropivacaine 0,75%|
224117009|NCT02082067|DRUG|Levobupivacaine 0,5%|
224117010|NCT02082067|DRUG|Levobupivacaine 0,125%|
224117011|NCT02082067|DRUG|Ketorolac 30mg|
224117012|NCT02082067|DRUG|Morphine|
223725808|NCT01461941|DRUG|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
223976260|NCT01378481|OTHER|Pharmacological Study|Correlative studies
224117013|NCT02082067|DEVICE|stimulong sono, Pajunk, Germany|
224117014|NCT03637868|DRUG|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
224117015|NCT06270940|PROCEDURE|Pulsed Radiofrequency (PRF) Treatment|PRF treatment maintains a temperature below 42°C and does not produce structural tissue damage around the needle. PRF exposure to the Dorsal Root Ganglion (DRG) induces c-Fos gene expression in the dorsal horn, which suggests a cellular response to the electric forces generated within the DRG. PRF has been found to relieve neuropathic pain by inducing long-term depression of synaptic transmission in the spinal cord, leading to a decrease in allodynia and hyperalgesia. It also modulates the inflammatory response in the injured area by decreasing the expression of pro-inflammatory cytokines, such as TNF-α, in the peripheral nerve and spinal cord, which is a major player in the development and maintenance of neuropathic pain. PRF is characterized by a 500 kHz current applied for 2 pulses per second, with each pulse lasting 20 milliseconds.
224117016|NCT05232591|DIAGNOSTIC_TEST|The teeth diagnosed with chronic apical periodontitis|GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
224117017|NCT04126369|OTHER|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
224117018|NCT04126369|OTHER|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
224117019|NCT00619931|DRUG|APD791|APD791 or matching placebo in escalating doses
224117020|NCT01938820|DRUG|entecavir|anti-viral therapy
223725809|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group I: A total of 20 mL will be injected: 10 mL Ropiclobet (1 ampoule) + 10 mL of 0.9% isotonic saline"
223725810|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group II: A total of 20 mL will be injected: 15 mL Ropiclobet (1.5 ampoules) + 5 mL of 0.9% isotonic saline"
223725811|NCT07131657|DRUG|Ropivacaine + Clonidine + Betamethasone|"Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)~Group III: A total of 20 mL will be injected: 20 mL Ropiclobet (2 ampoules)"
223725812|NCT01937559|BIOLOGICAL|Tranexamic acid (TXA)|1.5g of TXA in 100ml normal saline solution
223725813|NCT01937559|DRUG|Normal saline|
223725814|NCT07031895|COMBINATION_PRODUCT|a bovine-derived graft/xenograft enriched with hyaluronic acid|In study group a bovine-derived graft/xenograft enriched with hyaluronic acid will be placed in the extraction socket after tooth removal.
223725815|NCT07031895|COMBINATION_PRODUCT|a standart bovine-derived graft/xenograft|In comparison group a standard bovine-derived graft/xenograft will be placed in the extraction socket after tooth removal.
223725816|NCT06718348|OTHER|Use of the Exoskeleton JAPET.W|Phsysiotherapy sessions with the support of the Exoskeleton JAPET.W
223725817|NCT06741657|DRUG|Litifilimab|Administered as specified in the treatment arm.
223976261|NCT01378481|PROCEDURE|Therapeutic Conventional Surgery|Undergo neurosurgery
223976262|NCT03735147|BIOLOGICAL|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
223976263|NCT05213117|BEHAVIORAL|Co-Localization with Nursing|Co-localize 15 residents to one of 6 general medical floors to complete all 8 weeks of general medicine on this floor
223976264|NCT05878249|PROCEDURE|wound lavage with normal saline|After removing caries and achieving hemostasis after removing caries and achieving hemostasis, wound lavage of the exposed pulp will be done with 5 ml of Normal saline for 30 seconds
223976265|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5% sodium hypochlorite (NaOCl) for 30 seconds,Subsequently the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets
224117021|NCT01938820|DRUG|Thymosin-α|antiviral and antifibrosis therapy
224117022|NCT05186181|BEHAVIORAL|In situ fenestration|Interventional therapy of aortic dissection. In situ needle fenestration of left subclavian artery.
224117023|NCT03604614|DRUG|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
224117024|NCT03604614|DRUG|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area \<1.25m2 40mg/time, 1.25-1.50m2 50mg/time, \>1.50m2 60mg/time.
223725818|NCT06741657|DEVICE|AI|Administered as specified in the treatment arm.
223725819|NCT06741657|DEVICE|OBI|Administered as specified in the treatment arm.
223725820|NCT06741657|DEVICE|PFS|Administered as specified in the treatment arm.
223725821|NCT07064200|OTHER|TAP Block|the TAP block is a regional anesthesia technique that targets the somatic nerves supplying the anterior abdominal wall.
223725822|NCT07073417|DRUG|XW003 injection|Subcutaneous injection
223725823|NCT07073417|DRUG|semaglutide injection|Subcutaneous injection
224117025|NCT04430582|OTHER|Cognitive Assessment (not diagnostic)|Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
223725824|NCT07071363|DRUG|Depigmenting Cosmetic Serum (Applied Morning and Evening)|Participants in Group 1 receive a depigmenting cosmetic serum with non-drug actives applied morning and evening, plus a placebo cream without hydroquinone applied in the evening. Group 2 receives a placebo serum (no active depigmenting ingredients) applied morning and evening, and a hydroquinone 4% cream applied in the evening. All participants apply an SPF50+ sunscreen in the morning throughout the 84-day study. The cosmetic serum is the investigational product; hydroquinone serves as the active comparator. Placebo products are visually matched to their respective actives to ensure blinding. The study distinguishes each intervention by active ingredients, timing of application (morning/evening), and role (test vs. reference vs. supportive care). All products are applied topically, and the regimen remains fixed across the study duration.
223543383|NCT05459441|BIOLOGICAL|Autologous progenitor expansion -T|After the completion of RAK cell culture, RAK cells were slowly injected into the tumor cavity through Ommaya capsule for no less than 10 minutes, each time about 1.0-4.0 108/4 mL, once a week,3 times as a course of treatment. Il-2 (500,000 units/capsule) was injected into the tumor cavity through Ommaya reservoir every other day after the injection of RAK cells In other words, the day of RAK cell injection was the first day, and the third and fifth days were respectively injected. Then, about LML of sac fluid was pumped back before each injection to observe the growth of RAK cells in the tumor cavity. Il-2 was dissolved with LML normal saline, and the fluid storage sac was pressed 3-5 times after injection to make the sac fluid and IL-2 fully mixed.
223725825|NCT06755060|COMBINATION_PRODUCT|AI-associated strategy|The intervention in this study involves an AI system that leverages multimodal data fusion to support the clinical decision-making and evaluation of ophthalmic diseases. Patients in the intervention group will undergo standard ophthalmic examinations, with clinical decisions guided by the recommendations generated by the AI system. In contrast, patients in the control group will receive only standard ophthalmic examinations and treatment, without the support of AI-assisted decision-making tools.
223725826|NCT06904469|OTHER|Access to a digital clinic|This intervention grants access to a digital clinic that provides chat-based primary care consultations via phone application and website.
223725827|NCT07090655|DRUG|Budoprutug|Subcutaneous or IV administration
223976266|NCT05878249|PROCEDURE|wound lavage with Ethylenediaminetetraacetic acid(EDTA)|after removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 12% Ethylenediaminetetraacetic acid for 5minutes ,Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
223976267|NCT05878249|PROCEDURE|wound lavage with sodium hypochlorite followed by Ethylenediaminetetraacetic acid|fter removing caries and achieving hemostasis wound lavage of the exposed pulp will be done with 5 ml of 2.5%sodium hypochlorite (NaOCl) for 30 seconds followed by 12%Ethylenediaminetetraacetic acid(EDTA) for 5 minutes.Subsequently, the cavity will be flushed with saline for 10 s and blotted dry using sterile cotton pellets.
224117026|NCT04430582|DIAGNOSTIC_TEST|ECG|ECG will take place during screening visit.
223725828|NCT07090655|DRUG|Placebo|Placebo comparator
223725829|NCT06734468|BEHAVIORAL|Lifestyle Management|"Each subject will receive a personalized intervention plan, comprised of:~1. An individualized exercise plan guided by a mobile phone app.~2. Healthy diet and nutrition recommendations.~3. Theriome metabolomics testing and individualized recommendations that include dietary supplements.~4. Guidance on healthy sleep patterns, stress management, and maximizing social engagement, as appropriate."
223725830|NCT06918041|DEVICE|FiberLocker® System (encompassing FiberLocker® Instrument SN & SpeedPatch® PET)|The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue.
223725831|NCT07114055|DRUG|ebastine|Tab. Ebastine 20mg once daily at night
224117027|NCT00031577|DRUG|paclitaxel|
224117028|NCT00031577|RADIATION|radiation therapy|
223725832|NCT07114055|DRUG|Placebo|Tab. Placebo once daily at night
224117029|NCT06287125|DEVICE|Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147|"Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI"
224117030|NCT00204633|DRUG|Darbepoetin alfa|
224122738|NCT07007195|DEVICE|Ad Libitum Use followed by Instructed Use of the Inspire Device|Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will then be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™. When urges above 0 are reported, the app will instruct participants to use the Inspire device. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Instructed Use condition. Participants will then be instructed to use the Inspire device only when participants report a cigarette craving about 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™.
223976268|NCT05803525|OTHER|Intra-canal medication protocol|"Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points."
223976269|NCT03761407|DRUG|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
223976270|NCT03761407|DRUG|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
223976271|NCT03761407|DRUG|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
223976272|NCT03761407|DRUG|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
223976273|NCT03761407|DRUG|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
224295281|NCT04997655|DIAGNOSTIC_TEST|Ultrasound measurement|In the patient group who will undergo elective laparoscopic cholecystectomy, the diaphragmatic thickness values measured and recorded routinely at the pre-operative, post-extubation and post-operative 30th minute, at the end of inspiration and expiration, and the inspiratory amplitude in m-mode in the ultrasound measured from the right anterior axillary line subcostal area were observed as observational data. will be saved in our file.
224295282|NCT00350155|DRUG|Lumiracoxib|
223725833|NCT07114536|DIETARY_SUPPLEMENT|Calcium-a-ketoglutarate|Description: Participants in the intervention group will receive oral calcium alpha-ketoglutarate (CaAKG) in granular tablet form. Each tablet contains 0.5 grams of CaAKG.Participants will take two tablets twice daily (morning and evening). The total daily dose is 2 grams. The intervention period will last for 12 weeks. CaAKG is a stabilized form of alpha-ketoglutarate that enhances bioavailability and provides supplemental calcium. The tablets are identical in appearance and texture to those in the placebo group to maintain blinding.
223725834|NCT07114536|OTHER|Placebo(starch)|Participants in the placebo group will receive oral tablets identical inappearance and texture to the CaAKG tablets, but containing starch with no active calciumalpha-ketoglutarate. Each tablet weighs 0.5 grams. Participants will take two tablets twicedaily (morning and evening), for a total daily intake of 2 grams. The placebo tablets arepackaged and administered in the same manner as the CaAKG tablets to ensure blindingthroughout the 12-weekintervention period.
223725835|NCT04847557|DRUG|Tirzepatide|Administered SC
223725836|NCT04847557|OTHER|Placebo|Administered SC
223725837|NCT06932952|DRUG|BYON4228 + Pembrolizumab|BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every three weeks until disease progression or unacceptable toxicity. Different doses. Pembrolizumab IV infusion (200 mg) every three weeks from the second treatment cycle onwards.
223725838|NCT07132710|OTHER|Semi-structured interviews|Patients and caregivers will be interviewed about the barriers and facilitators to the use of VR masks in the management of pain and anxiety, in order to propose organizational changes that encourage their use.
223725839|NCT02384408|PROCEDURE|Endometrial Biopsy|Histological assessment
223976274|NCT04127383|DEVICE|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient completes the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, diabetes type 2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a score on that domain. If a patient and healthcare provider select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
223976275|NCT00016237|BIOLOGICAL|tucotuzumab celmoleukin|
223976276|NCT05980975|OTHER|Coffee|4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.
223976277|NCT05980975|OTHER|Hot water|hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
223976278|NCT05382871|BIOLOGICAL|BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
223976279|NCT05382871|BIOLOGICAL|WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell)|intramuscular injection in the deltoid muscle
223976280|NCT05382871|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|intramuscular injection in the deltoid muscle
223976281|NCT04577586|OTHER|oral contrast|negative oral contrast utilization in PET/CT studies
223976282|NCT00033462|DRUG|erlotinib hydrochloride|Given orally
223976283|NCT00033462|OTHER|laboratory biomarker analysis|Correlative studies
223976284|NCT00223132|DEVICE|Absorbable sutures|
223976285|NCT04946097|OTHER|gross Myofascial Release|Gross Myofascial Release : is amanual technique in form of Stretch of the Posterior Cervical Musculature and Gross stretch of gross Myofascial Release upper quarter: Arm Pull for duration of 10-15 min per session each stretch position was healed for 90sec
224117031|NCT01255397|PROCEDURE|Male Infertility Protocol|"1. Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~2. Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~3. When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~4. 35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~   1. If the follicle has collapsed than IUI will be performed~  2. It the total motile sperm count is above 5 million sperm/ml then IUI will be done~  3. If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6\) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
224117032|NCT06896604|DEVICE|Ocular Ultrasonography for measuring Optic Nerve Sheath Diameter|In the study, the investigators measured the optic nerve sheath diameter to observe its effects on intracranial pressure and used ocular ultrasonography for this measurement.
224117033|NCT06896032|OTHER|physical therapy intervention|retro-walking and forward-walking underwater treadmill training
223725840|NCT02384408|DEVICE|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
223725841|NCT02384408|PROCEDURE|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
223976286|NCT04946097|OTHER|conventional selected exercise program|stretching exercises for cervical muscles and pectoralis major and source of heat in form of hot packs for 15 minutes
223976287|NCT04946097|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is a method of pain relief involving the use of electrical current, the electrode placement on the course of pain for 15 minutes
223976288|NCT02885883|DEVICE|MRI 3T|
223976289|NCT01182272|DRUG|sorafenib tosylate|
223976290|NCT01182272|OTHER|laboratory biomarker analysis|
223976291|NCT01182272|PROCEDURE|neoadjuvant therapy|
223976292|NCT01182272|PROCEDURE|therapeutic conventional surgery|
223543384|NCT05459441|DRUG|pemetrexed|For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
223543385|NCT03152123|DRUG|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
223543386|NCT03152123|DRUG|Placebos|tablets over-capsuled
223725842|NCT02154490|DRUG|Docetaxel|Given IV
223976293|NCT00749671|DEVICE|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
223976294|NCT00749671|OTHER|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
223976295|NCT03973047|DRUG|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
223976296|NCT03973047|DRUG|Zofran|8 mg tablet (over-encapsulation in a capsule)
223543387|NCT03152123|DRUG|Phentermine|Phentermine 60 mg (capsule over-capsuled)
223543388|NCT04581785|BIOLOGICAL|hLB-001|hLB-001 via IV infusion
223543389|NCT03117959|DEVICE|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
223543390|NCT03117959|DEVICE|Stryker Triathlon Custom Fit Knee|
223725843|NCT02154490|BIOLOGICAL|Durvalumab|Given IV
223725844|NCT02154490|DRUG|Erlotinib Hydrochloride|Given PO
223725845|NCT02154490|DRUG|FGFR Inhibitor AZD4547|Given PO
223725846|NCT02154490|BIOLOGICAL|Ipilimumab|Given IV
223725847|NCT02154490|OTHER|Laboratory Biomarker Analysis|Correlative studies
223725848|NCT02154490|BIOLOGICAL|Nivolumab|Given IV
223725849|NCT02154490|DRUG|Palbociclib|Given PO
223725850|NCT02154490|OTHER|Pharmacological Study|Correlative studies
223725851|NCT02154490|BIOLOGICAL|Rilotumumab|Given IV
223725852|NCT02154490|DRUG|Talazoparib|Given PO
223725853|NCT02154490|DRUG|Taselisib|Given PO
223976297|NCT03973047|DRUG|Placebo|capsule
223976298|NCT00068718|BIOLOGICAL|Therapeutic Allogeneic Lymphocytes|Given IV
223543391|NCT03278548|DRUG|Volulyte 6%|Solution for infusion
223976299|NCT05517577|BEHAVIORAL|Behaviour Change Communication and Male involvement intervention|For the integration of the intervention, it is planned to deliver both service at the same time a by the same means to the women and the men. Pregnant women who fail to take one of the intevetion will not be considered as the participant who received integrated intervention. The intervention will be provided through Women Developmental army (WDA) leaders imparted through gatherings and home visits whereas the Broadcast will be used to strengthen and as a frequent remidinng of the conveyed messages.
223976300|NCT01431105|DRUG|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
223976301|NCT00960505|OTHER|Alternate day fasting|
223976302|NCT00960505|OTHER|Calorie restriction|
223976303|NCT00960505|OTHER|Control diet|
223976304|NCT03572998|DRUG|Indocyanine Green (ICG)|Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
223976305|NCT06042270|DIETARY_SUPPLEMENT|Betaine|3 grams per day for \~4 weeks
223976306|NCT06042270|DIETARY_SUPPLEMENT|Placebo|3 grams per day for \~4 weeks
223543392|NCT03278548|DRUG|Ionolyte|Solution for infusion
223543393|NCT02156024|DRUG|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
223976307|NCT06310226|DEVICE|Epidural electrical spinal cord stimulator|Epidural electrical spinal cord stimulator turned on vs. turned off
223976308|NCT05152706|OTHER|Aerobic training|Cycling at the aerobic intensity
223976309|NCT05152706|OTHER|Photobiomodulation|Photons therapy
223976310|NCT02807961|DRUG|ELX-02|Synthetic aminoglycoside
223543394|NCT00334568|DRUG|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
223976311|NCT02807961|DRUG|Placebo|Placebo comparator
223976312|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
223976313|NCT01605786|BIOLOGICAL|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
224117034|NCT02875522|OTHER|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
224117035|NCT03725046|OTHER|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
223543395|NCT00334568|DRUG|Placebo|Placebo
223543396|NCT02228161|BEHAVIORAL|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
224117036|NCT01292772|PROCEDURE|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
224117037|NCT01292772|RADIATION|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
224117038|NCT01059604|DRUG|Sumatriptan|Sumatriptan
224117039|NCT01059604|DRUG|Naratriptan|Naratriptan
223543397|NCT05939752|OTHER|ophthalmological examination|OCT-retinal angiography At inclusion, 3 months and 6 months
223543398|NCT05939752|BIOLOGICAL|blood test|"a 2-mL tube of blood will be taken to test for blood markers predisposing to cardiovascular complications.~At inclusion"
223543399|NCT02989181|DEVICE|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
223543400|NCT05724082|OTHER|Clean Air Intervention|"Based on findings from preliminary focus groups/in-depth interviews, staff will introduce various components of established clean air interventions to each household. Each household will receive interventions, depending on their known risk factors, exposures, and willingness to trial the intervention.~Study staff will ask the primary cook to complete a time-activity diary during the intervention period that includes cooking episodes, duration of cooking, stove(s) used, type of food cooked, and number of people for whom the meal was cooked. Staff will continuously monitor use of the LPG/pellet stove and any other stoves owned by the household with the Berkeley Stove Use Monitoring System, a temperature logger attached to the stove to quantify the number of stove uses / time of use . Study staff will use similar loggers to monitor use of other devices installed including the air purifiers, lighting etc."
223543401|NCT04419467|BIOLOGICAL|CSL346|VEGF-B antagonist monoclonal antibody
223543402|NCT04419467|DRUG|Placebo|Normal saline
223543403|NCT00981903|DRUG|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
223543404|NCT01925768|DRUG|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
223543405|NCT01925768|DRUG|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
223543406|NCT05490316|DRUG|IBI353 (Orismilast)|dose 1 or dose 2
223976314|NCT01605786|OTHER|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
223976315|NCT01222533|DRUG|Tiotropium medium|Tiotropium inhalation solution medium dose
223976316|NCT01222533|DRUG|Tiotropium low|Tiotropium inhalation solution low dose
223976317|NCT01222533|DRUG|Tiotropium high|Tiotropium inhalation solution high dose
223976318|NCT01222533|DRUG|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
223976319|NCT01222533|DRUG|Tiotropium placebo|Placebo inhalation solution
223976320|NCT02960945|DRUG|CTP-543, 16 mg (2 x 8 mg tablet)|
223976321|NCT02960945|DRUG|Jakafi 15Mg Tablet|
223976322|NCT01947517|DEVICE|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
223976323|NCT01947517|DEVICE|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
223976324|NCT01692145|DRUG|KCT-0809|
223976325|NCT01692145|DRUG|Placebo|
223976326|NCT02743988|DRUG|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
224117040|NCT01059604|DRUG|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
223976327|NCT04698798|PROCEDURE|Muscle Biopsy|Patients will be treated for SARS-CoV-2 symptoms on the intensive care unit. During this treatment two muscle biopsies will be obtained with an interval of seven days between them.
223976328|NCT05382598|PROCEDURE|Renal replacement therapy|Renal replacement therapy (RRT) will be initiated in the early group for patients who have stage 2 AKI according to KDIGO classification. The late group will have RRT when they develop any of the absolute indications for RRT
223976329|NCT02276638|DEVICE|Specular Microscope Nidek CEM-530|Nidek CEM-530
223976330|NCT02276638|DEVICE|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
223976331|NCT06957262|PROCEDURE|Surgical correction of nasal obstruction|Surgical intervention to correct anatomical nasal obstruction, specifically septal deviation, performed under general anesthesia. The procedure involved the repositioning and reshaping of the deviated nasal septum to improve nasal airflow. The surgery was conducted by an otolaryngologist with experience in nasal airway procedures. No additional medications or postoperative interventions beyond standard care (e.g., saline irrigation, analgesics) were administered. Postoperative assessments occurred 2-3 months after surgery, including evaluations of nasal patency, sleep quality, and aerobic performance using treadmill-based gas exchange measurements.
223976332|NCT06956378|BEHAVIORAL|Instruction Emphasis|The study team will emphasize the questionnaire instructions when asking the second time.
223976333|NCT06957015|DEVICE|EndoAIM|EndoAIM will be used during the withdrawal process of the colonoscopy
223976334|NCT06701019|OTHER|Semi-structured interview/focus group discussion|"All participants will be asked via email for their medical history/status and demographic information.~Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option."
223976335|NCT05683912|DRUG|Aflibercept|Intravitreal aflibercept as used in the routice clinical practice
223976336|NCT01630005|BEHAVIORAL|talk therapy|Psychotherapy
223976337|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 20mg
223976338|NCT00600847|DRUG|desloratadine|single dose for 7 days, oral, 5 mg
223976339|NCT00600847|DRUG|placebo|single dose for 7 days, oral
223976340|NCT06122454|DRUG|Hepenofovir Fumarate Tablets|Each subject received multiple doses of the test drug/control drug and completed safety, efficacy, and PK evaluations
224117041|NCT04083040|PROCEDURE|transcatheter aortic valve implantation|"1. Tilt angle.~2. Depth of implantation of the valve.~3. Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
223543407|NCT05490316|DRUG|placebo|placebo
223543408|NCT01730612|DRUG|TF2 - 68 Ga-IMP-288:|ImmunoTEP
223976341|NCT00141362|DRUG|Pregabalin|
223976342|NCT01662037|DRUG|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
223976343|NCT00460564|DRUG|GSK1358820|botulinum toxin type A
223976344|NCT00460564|DRUG|Placebo|Placebo
223976345|NCT05955963|OTHER|Abdominal auscultation|spectral analysis of Bowel sounds
223976346|NCT04087564|OTHER|music intervention|"The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session"
223976347|NCT06031961|DRUG|melatonin|We will premedicate the children whom involved in the 1st group with 0.5 mg/kg oral melatonin in the midnight before surgery and the dose will be repeated at morning before getting in the catheterization room
223976348|NCT04795206|OTHER|No Intervention|Administered as specified in the treatment arm.
224117042|NCT02407574|DEVICE|External Pacing Box|Atrial pacing using an external pacing box
224117043|NCT04963179|DEVICE|Womed Leaf|"Womed Leaf™ device is composed of a uterine anti-adhesion film pre-loaded inside a flexible inserter.~Womed Leaf™ is inserted in the uterine cavity by the gynecologist surgeon as a film folded into a 5 mm diameter flexible inserter. Once released, the film will unfold and swell into the uterine cavity to keep uterus walls separated. It is degraded and discharged naturally through the cervix and vagina."
224117044|NCT04749862|OTHER|Online symptom reporting|Online symptom reporting questionnaire with linked self-management advice
223976349|NCT04458220|OTHER|photo and voice obtained|The 3D face scanner and camera is used to obtain 3D or 2-dimensional portrait images of patients in different positions and from different angles.The Hi-Fi Recorder is used to obtain sound samples of patients in different word.
223976350|NCT03362034|DEVICE|double transfer trays|double trays one soft and one hard
223976351|NCT03362034|DEVICE|single transfer tray|single soft tray
223976352|NCT06957197|DRUG|Hydrogel with xenograft|vehicle to hold xenograft
223976353|NCT06957197|DRUG|Xenograft|to maintain the socket
223725854|NCT02154490|BIOLOGICAL|Tremelimumab|Given IV
223976354|NCT04742062|DRUG|ApTOLL|ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
223976355|NCT04742062|OTHER|Placebo|100 mL 0.9% Sodium Chloride solution
223976356|NCT05931445|OTHER|e-PRO monitoring|"The e-PRO monitoring will concern treatment of each predefined type of cancer or characteristic symptoms of the condition. PRO-CTCAE (Patient-Reported Outcome-Common Terminology Criteria for Adverse Events) will be used as the scale for monitoring symptoms. The patient and (sub)investigator will share the monitoring results during examinations and use them to determine treatment strategies, etc. Threshold values will be predefined for a diagnosis of severe for individual symptoms. When it is reported that a threshold value has been exceeded, an alert notification will be sent to the study staff member assigned to the patient. The (sub)investigator who receives the notification will assess the information in the notification and take the best course of action."
223976357|NCT06951386|DIETARY_SUPPLEMENT|with short-chain fatty acids enriched drink|Oat-based drink enriched with 15 g/L short-chain fatty acids
223976358|NCT06951386|DIETARY_SUPPLEMENT|unenriched oat drink|Oat-based drink
223976359|NCT06956534|OTHER|Questionnaire and Physical Exam|online digital questionnaire
223976360|NCT03919955|DRUG|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
223976361|NCT03919955|DRUG|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed. Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
223976362|NCT03919955|DRUG|Placebo|Placebo, per mouth, before bed.Participants will take the intervention nightly for one month. Half doses will be given on the first three nights.
223976363|NCT04584333|BEHAVIORAL|Brief intervention|Group 1 (intervention group): depending on the willingness to change evaluated with the RCQ at each visit, the characteristics of the intervention to be performed will be established. Prochaska and DiClemente (1983) proposed a transtheoretical model of change in which different stages of change are identified that have been found to be predictive of adherence to treatment and its efficacy (Prochaska, Norcross and DiClemente, 1994). The RCQ includes three of the stages of change: Precontemplation, Contemplation and Action. In the Precontemplation stage, the person does not consider that he has a problem and has no intention of changing, in the Contemplation stage, he begins to contemplate that he has a problem and the possibility of change is raised and in the action stage, he has already started actively make a change in your behavior.
223976364|NCT06142578|DEVICE|Dermal Filler Device|Injection of device by investigators according to the Instruction For Use (IFU)
223725855|NCT02336711|RADIATION|dose escalation|molecular imaging based radiotherapy dose escalation
224117045|NCT03079739|DIAGNOSTIC_TEST|fractional flow reserve|assessment with FFR in at least one coronary lesion
224117046|NCT04975269|DRUG|Acetazolamide|Target dose: 500 mg / day
223725856|NCT01157949|DRUG|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
224117047|NCT04975269|DRUG|Placebo|Placebo
224117048|NCT06541730|DRUG|DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
223725857|NCT03853265|BEHAVIORAL|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
223725858|NCT03675607|OTHER|Complementary feeding behaviours|Any kind of complementary feeding practice
223976365|NCT05120596|DRUG|Pembrolizumab+T3P-Y058-739|intravenous infusion or intratumoural injection
223976366|NCT05120596|DRUG|T3P-Y058-739 (IV)|Intravenous infusion
223976367|NCT05120596|DRUG|T3P-Y058-739 (IT)|Intratumoral use
223976368|NCT06712693|DEVICE|Phonak Audeo Infinio Hearing Aid|Receiver-In-Canal hearing aid type that is coupled with either a custom earmold or a dome.
223976369|NCT06509945|OTHER|allogeneic peripheral blood stem cell transplantation|Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
223976370|NCT02010983|OTHER|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
223976371|NCT01660919|DRUG|placebo|
223976372|NCT01660919|DRUG|rosuvastatin|
223976373|NCT00320814|DRUG|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
223976374|NCT03736278|OTHER|No intervention|We group the patients according to the outcome (survival vs mortality)
223976375|NCT04573556|DRUG|Lemborexant|Lemborexant oral tablets.
223976376|NCT02724293|DRUG|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
223976377|NCT02724293|DRUG|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
223976378|NCT02724293|DRUG|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
223976379|NCT02724293|DRUG|placebo|patients received placebo
223976380|NCT03371277|OTHER|Medical visit for specific questionnaires|Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
223976381|NCT00320398|DRUG|Fondaparinux|
223976382|NCT00573456|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
223976383|NCT00517842|DRUG|ViNeuro|
223976384|NCT06316245|OTHER|DASI questionnaire|All patients will answer the DASI questionnaire before surgery. According to their scores, they will be divided into two groups. A score of 34 and below will be considered poor, and above 34 will be considered to have good functional capacity.
223976385|NCT00630552|OTHER|Placebo|Inactive dummy of AMG 655.
224295283|NCT02994355|OTHER|Systems Analysis and Improvement Approach|"1. Understanding the cascade from FP clinic enrollment to HIV testing~2. Use process mapping to identify modifiable bottlenecks~3. Define and implement workflow adaptations to eliminate modifiable bottlenecks~4. Monitor change in performance~5. Repeat the analysis and improvement cycle (steps 1-4)"
223725859|NCT02483728|OTHER|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
223976386|NCT00630552|DRUG|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
223976387|NCT00630552|DRUG|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
223976388|NCT04349644|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention that involves 10 sessions of approximately 3 hours each that culminates in a public performance.
223976389|NCT04221958|DEVICE|Electrocardiogram|"An electrocardiogram measures the electrical activity of the heartbeat. This intervention will be used on healthy adult volunteers whom are part of the staff at the institution."
223976390|NCT00522509|DRUG|Floxuridine FUDR|
223976391|NCT04150913|DRUG|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
223976392|NCT04150913|DRUG|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
223976393|NCT01245803|DRUG|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
223976394|NCT01245803|DRUG|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
223976395|NCT05124002|DRUG|Recombinant Human Adenovirus Type 5|H101 will be intratumorally injected 3 days before HAIC. Dosage of H101: 1 vial (5.0 × 10\^11 vp) if the maximum diameters of lesion ≤ 5 cm, 2 vials (1.0 × 10\^12 vp) if the maximum diameters of lesion ≤ 10 cm, 3 vials (1.5 × 10\^12 vp) if the maximum diameters of lesion is \> 10 cm.
223976396|NCT05124002|DRUG|HAIC of FOLFOX|Oxaliplatin 50 mg + 5-FU 1.5 g + leucovorin calcium. The infusion will be continued for 2-3 days according to patients' tolerance and tumor conditions. The standard treatment for HAIC consists of 4-6 cycles, with the second cycle being 3 weeks after the end of the first HAIC cycle and the subsequent cycles being 4 weeks after the end of the previous HAIC.
224117049|NCT06541730|DRUG|Placebo of DA-302168S|Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.
224117050|NCT05551299|DRUG|Photosensitizer|A photosensitizer, which is absorbed preferentially by tumour cells, is administered 24 - 48 hours prior to PDT. Light of a particular wavelength is then applied during endoscopic retrograde cholangiopancreatography (ERCP) to kill primarily cancer cells locally within the stenosis. Immediately after PDT treatment, new stents are inserted into all treated segments if needed.
224295284|NCT00003014|DRUG|carboplatin|
224295285|NCT00003014|RADIATION|radiation therapy|
223976397|NCT05633056|BEHAVIORAL|Adherence support intevention|Compare the effects of adherence support interventions on clinical and biological endpoints using an adaptive randomized platform.
223976398|NCT03472976|OTHER|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
223976399|NCT03472976|DRUG|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
223976400|NCT03472976|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
223976401|NCT00799747|DRUG|AZD4017|ascending single doses (start dose 2 mg), oral suspension
223976402|NCT00799747|DRUG|Placebo|placebo
223976403|NCT02546505|OTHER|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
223976404|NCT02546505|OTHER|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
223976405|NCT04826991|DEVICE|Active UV Device|Active water treatment system
223976406|NCT04826991|DEVICE|Inactive UV Device|Inactive water treatment system
223976407|NCT02428218|DRUG|dimethyl fumarate|enteric-coated microtablets
223725860|NCT02012998|BIOLOGICAL|HBVAXPRO 5µg|0.5mL intramuscular injection
223976408|NCT02428218|DRUG|Placebo|enteric-coated microtablets
223976409|NCT00983905|DRUG|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
223976410|NCT00983905|DRUG|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
223976411|NCT04488861|OTHER|Non-interventional cohort study|Non-interventional cohort study
223976412|NCT06134583|PROCEDURE|Superior cervical sympathetic block group|5 ml bupivacaine 0.5% will be injected around the internal carotid artery at the level of carotid bifurcation
223976413|NCT06134583|PROCEDURE|Stellate ganglion block group|5 ml bupivacaine 0.5% will be injected between the common carotid artery and longus capitis muscle at the level of C7 vertebra
223976414|NCT00215722|DRUG|Cetuximab|
223976415|NCT02250768|BIOLOGICAL|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
223976416|NCT04077697|DIAGNOSTIC_TEST|RT-PCR for influenza|influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
223976417|NCT01389414|DRUG|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
223976418|NCT01389414|DRUG|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
223976419|NCT01284309|DRUG|Mirabegron|oral
223976420|NCT01284309|DRUG|Placebo|oral
223976421|NCT02743299|DEVICE|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
223976422|NCT03788122|OTHER|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
223976423|NCT00321321|DRUG|Sulfonylurea|
223976424|NCT05807425|PROCEDURE|Polidocanol foam sclerotherapy|The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
223976425|NCT02154477|DRUG|intranasal insulin|insulin
223976426|NCT02154477|DRUG|placebo (intranasal saline)|saline
223976427|NCT06146413|DRUG|Double trigger|GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) and hCG ( 10000 IU) are administered 40 and 34 h before ovum pick-up
223725861|NCT05924204|RADIATION|Photobiomodulation|Application of photobiomodulation
223725862|NCT05924204|OTHER|Simulation of Photobiomodulation|Simulation of photobiomodulation
223725863|NCT04638023|DEVICE|Arabin pessary|Arabin pessary was inserted intravaginally electively in women with cervical insufficiency (history based) or as emergency in those with short cervix on ultrasound.
223725864|NCT01113983|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transapical and transfemoral approach
223976428|NCT06146413|DRUG|HCG trigger|hCG ( 10000 IU) is administered 36 h before ovum pick-up
223976429|NCT01510002|PROCEDURE|Total thyroidectomy|Extracapsular total thyroidectomy
223976430|NCT01510002|PROCEDURE|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
223976431|NCT02741713|PROCEDURE|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
223976432|NCT02741713|PROCEDURE|Interscalene Block|An interscalene block will be performed on the subjects.
223976433|NCT02741713|PROCEDURE|Sham Block|
223976434|NCT02741713|DRUG|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
223976435|NCT02741713|DRUG|Solution for Injection in Sham Block|Lidocaine 1%
223976436|NCT02741713|DRUG|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
223976437|NCT02081118|DRUG|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
223976438|NCT02081118|DRUG|Placebo|Placebo for HM11260C
223976439|NCT04458181|BEHAVIORAL|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve subjective wellbeing in recovery and reduce relapse. PPJ uses journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Good wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
223976440|NCT04668534|DEVICE|taVNS 10|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
223976441|NCT04668534|DEVICE|taVNS 25|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
223976442|NCT04668534|DEVICE|Control|"Patients were given taVNS (by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 10 Hz; current intensity: minimal pain threshold; pulse width: 500 μs)"
224293339|NCT02056067|BEHAVIORAL|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
223976443|NCT05047497|DIAGNOSTIC_TEST|questionaire and ventilatory function test|we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
224117051|NCT05551299|PROCEDURE|Radiofrequency ablation (RFA)|RFA is also carried out as part of an ERCP. The RFA-probe is placed within the tumour stenosis and electrical current is applied. New stents are inserted into all treated segments if needed.
223976444|NCT00809341|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.
223976445|NCT00809341|DRUG|Cyclophosphamide|750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
223976446|NCT00809341|DRUG|Doxorubicin|50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
223976447|NCT00809341|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
223976448|NCT00809341|DRUG|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
224117052|NCT04061980|DRUG|Binimetinib|Given PO
224117053|NCT04061980|DRUG|Encorafenib|Given PO
224117054|NCT04061980|BIOLOGICAL|Nivolumab|Given IV
224117055|NCT03484299|PROCEDURE|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
224117056|NCT03484299|DRUG|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
224117057|NCT03484299|DRUG|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
224117058|NCT04267562|DEVICE|Minitouch System|The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
224293340|NCT04873180|DIAGNOSTIC_TEST|sectioning and staining of renal neoplasms after nephrectomy operation|nephrectomy operations will be done to patients diagnosed as having renel tumors
224293341|NCT05045313|DRUG|Warfarin sodium tablets|Drug: Warfarin sodium, tablet, oral
224117059|NCT06830980|DEVICE|intermittent theta burst stimulation (iTBS)|iTBS is an excitatory TMS paradigm that delivers 1800 pulses to the left dlPFC. Participants will receive 2 iTBS sessions separated by 50 minutes.
224117060|NCT06830980|DEVICE|continuous theta burst stimulation (cTBS)|cTBS is an inhibitory TMS paradigm that delivers 1800 pulses to the frontal pole. Participants will receive 2 iTBS sessions separated by 50 minutes.
223543409|NCT00188617|DRUG|GEFITINIB|250 mg once a day for 28 days before surgery
223543410|NCT00815048|DRUG|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
223543411|NCT00815048|DRUG|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
223543412|NCT03468777|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
223543413|NCT03468777|DRUG|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
223543414|NCT03468777|DRUG|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
224117061|NCT06830980|DEVICE|Sham TMS|Sham TMS delivered with the MagVenture B65 A/P coil
224117062|NCT06831968|DIAGNOSTIC_TEST|Enlighten|"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."
223976449|NCT00809341|DRUG|Ifosfamide|2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
223725865|NCT05725811|OTHER|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
223725866|NCT03276884|OTHER|Experimental Infant Formula|amino acid-based infant formula powder
223976450|NCT00809341|DRUG|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
224117063|NCT06313164|DIETARY_SUPPLEMENT|enhanced glutathione|L-glutathione (in combination with tannin, low molecular weight chitosan and polyethylene glycol)
223725867|NCT03276884|OTHER|Control Infant Formula|amino acid-based infant formula powder
223725868|NCT05066594|DEVICE|Transoral incisionless fundoplication|The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.
224117064|NCT06313164|OTHER|placebo comparator|placebo group
223725869|NCT00254813|DRUG|Quetiapine|
223725870|NCT02518828|OTHER|High SpO2|SpO2 range ≥96%
223725871|NCT02518828|OTHER|Low SpO2|SpO2 range 90-92%
223725872|NCT02584335|DRUG|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
224117065|NCT06249503|DRUG|platelet rich plasma|The patients hand will be facing upwards and slightly extended, the Median nerve will be identified at the inlet of the carpal tunnel. Ultrasound guided injection will be done with the use of the ulnar in-plane technique. with a 25-gage needle will be introduced from the ulnar side of the wrist between carpal tunnel and median nerve.
223725873|NCT02584335|DRUG|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
223976451|NCT00809341|DRUG|Etoposide|100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
224117066|NCT05060991|DRUG|Reduction in antimetabolite immunosuppression|Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
224117067|NCT04755543|DRUG|LP002|600mg or 900 mg by intravenous (IV) infusion on Day 1, every 2 weeks (Q2W).
223976452|NCT00809341|DRUG|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
223976453|NCT00809341|PROCEDURE|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
223976454|NCT04011397|OTHER|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
223976455|NCT04011397|BEHAVIORAL|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
223976456|NCT01709955|DIETARY_SUPPLEMENT|Glucomannan|750 MG of Glucomannan in capsule form
223976457|NCT01709955|OTHER|Placebo|750 mg of Cellulose powder in a capsule form
223976458|NCT05197114|OTHER|summerlunch+ At Home Food Skills Program|The summerlunch+ At Home program a virtual eight-week food skills program that teaches cooking, nutrition and environmental sustainability to children. The program has been adapted for those with Type 1 Diabetes to teach important food skills specific to diabetes management.
224117068|NCT04755543|DRUG|Cisplatin|50mg/m2 IV on Day 1, Q2W
224117069|NCT04755543|DRUG|Fluorouracil|2000 mg/m2 IV continuous infusion over 48 hours from Day 1, Q2W
224117070|NCT04755543|BIOLOGICAL|OH2 oncolytic virus|106 or 107 or 108 CCID50/mL by intra-tumoral injection, Q2W
223725874|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
223976459|NCT04311385|DIAGNOSTIC_TEST|CT imaging|CT scan reported as 1-2 pericolic bubbles, but no free distant bubbles in the abdomen or abscess.
223976460|NCT01579110|DRUG|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
223976461|NCT01579110|DRUG|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
223976462|NCT05226247|PROCEDURE|Spontaneous breathing trial|To perform cardiac and lung echography before and during a spontaneous breathing trial
224117071|NCT01850563|DEVICE|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
224117072|NCT04359823|DRUG|Lovastatin 2%, 2% Cholesterol Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
223725875|NCT01616524|BIOLOGICAL|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
223725876|NCT01616524|BIOLOGICAL|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
223725877|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
223725878|NCT01616524|DRUG|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
223725879|NCT01616524|DRUG|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
223725880|NCT01616524|DRUG|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
223725881|NCT02961751|DRUG|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
224117073|NCT04359823|DRUG|Lovastatin 2% Cream|Patients selected to the study will be randomly assigned to this arm. They will have a 50% chance of being placed in this arm compared to the other arm.
223725882|NCT05816512|DRUG|Gold Nano particle from Pelargonium Graveolens Mouthwash|Gold Nano particle from Pelargonium Graveolens Mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
223725883|NCT05816512|DRUG|Chlorhexidine gluconate mouthwash .|Chlorhexidine gluconate mouthwash will be applied by using 15ml of it for one minute, two times daily for three weeks and then follow up after three weeks the clinical parameters as ( plaque index, gingival index and calculus index ) and microbiological aspect will be assessed .
223725884|NCT00939250|BEHAVIORAL|Diabetes and depression intervention|Disease self management for diabetes and depression
223725885|NCT00939250|BEHAVIORAL|Diabetes intervention|Disease self management for diabetes
223725886|NCT02298803|DEVICE|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
223725887|NCT02500888|RADIATION|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
223725888|NCT02326961|DEVICE|Celution Device|ADRCs Prepared using the Celution Device
224293342|NCT05045313|DRUG|Digoxin tablet|Drug: Digoxin, tablet, oral
224293343|NCT05045313|DRUG|Probenecid tablets|Drug: Probenecid, tablet, oral
224293344|NCT05045313|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
224293345|NCT05668013|DRUG|TEV-48574 Dose Regimen A|Subcutaneous (sc) administration using a commercial sc infusion system
223725889|NCT02326961|OTHER|Placebo|Inactive Placebo
223725890|NCT04078477|OTHER|Body positioning|Comparison lateral tilt bed to standard patient´s body positioning in the bed.
223976463|NCT03694626|DEVICE|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
223976464|NCT03694626|DEVICE|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
224117074|NCT03900559|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
224117075|NCT00021697|DRUG|AVP-923|
223725891|NCT01617174|BEHAVIORAL|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
224293346|NCT05668013|DRUG|TEV-48574 Dose Regiment B|Subcutaneous (sc) administration using a commercial sc infusion system
224293347|NCT02029781|PROCEDURE|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
223725892|NCT03615976|PROCEDURE|high tibial osteotomy with or without arthroscopic circumpatellar denervation with or without arthroscopic circumpatellar denervation|"Arthroscopy will be done in all cases before osteotomy to assess lat. Comp and grade of patellofemoral O.A Arthroscopic patellar denervation with vaper or diathermy will be done plus open wedge high tibial osteotomy in one group and other group OWHTO only will be done comparing the rustles of two groups to assess the efficacy of this procedure~followed by an average follow up to 12 months. And follow up( 6th weeks ,3rd month ,6th month , 12th month)~By clinical examinationan and x-ray and knee scores~1. Scoring of patellofemoral disorders( Kujala) score~2. Knee Injury and Osteoarthritis Outcome Score (KOOS)"
223976465|NCT03694626|DEVICE|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
224117076|NCT04582734|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy intervention
224117077|NCT04463329|PROCEDURE|conventional two-operator versus single operator using Jedi grip axillary brachial plexus blockage|on goup C, operator used the probe and needle with different hands while an assistant controlling the syringe to aspirate or inject local anesthetic. On Group J single operator controlled the probe with one hand while controlling the needle and the syringe on the other hand with the Jedi technique. The needle was held between the index finger and the middle phalanx of the middle finger, and the syringe was held with fingers 4 and 5, with the plunger part to the thumb in the palm.
224117078|NCT02370849|DRUG|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
224117079|NCT02370849|DRUG|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
224117080|NCT02370849|DRUG|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
224117081|NCT05029115|DRUG|SGLT2 inhibitor|Dapagliflozin, Empagliflozin
224117082|NCT00269074|DRUG|IDEA-070|
224117083|NCT05047640|BIOLOGICAL|BNT162b2 vaccine|Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
224117084|NCT05047640|BIOLOGICAL|JNJ-78436735 Vaccine|Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
224117085|NCT02391844|DRUG|Oxycodone|Oxycodone with Acetaminophen Extended Release
224117086|NCT04634058|DRUG|PD-L1 antibody combined with CTLA-4 antibody|After 4 cycles of PD-L1 monoclonal antibody combined with CTLA-4 monoclonal antibody treatment, PD-L1 monotherapy was maintained until the disease progressed or intolerable toxicity and adverse reactions or the medication was used for two years.
224117087|NCT04527224|DRUG|AstroStem-V|Allogenic adipose tissue-derived mesenchymal stem cells (AdMSCs)
224117088|NCT02306772|DRUG|TP05 Coating A|One radio-labelled tablet given to subjects
224117089|NCT02306772|DRUG|TP05 Coating B|One radio-labelled tablet given to subjects
224117090|NCT00926055|DRUG|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
224117091|NCT00926055|DRUG|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
223543415|NCT03388762|DIETARY_SUPPLEMENT|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
223543416|NCT03388762|OTHER|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
223543417|NCT04494828|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
223543418|NCT04494828|DRUG|Normal saline group|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
223976466|NCT03694626|DEVICE|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
223976467|NCT03694626|DEVICE|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
223976468|NCT02243761|OTHER|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
223976469|NCT02954796|DRUG|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
224117092|NCT04220528|DRUG|Capecitabine/Tiggio|"Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2)."
223543419|NCT03579069|OTHER|Ductus venosus Doppler|Ductus venosus Doppler
223543420|NCT00004927|DRUG|ixabepilone|
223543421|NCT05740046|DEVICE|INTORUS|INTERVENTION PROTOCOL WITH INTORUS
223976470|NCT01219777|DRUG|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
223976471|NCT01219777|DRUG|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
223976472|NCT01219777|DRUG|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 \& 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
223976473|NCT02678364|DIETARY_SUPPLEMENT|Control eggs|Control eggs containing no additional vitamin D beyond norm
223976474|NCT02678364|DIETARY_SUPPLEMENT|Vitamin D3 eggs|Vitamin D3-biofortified eggs
223976475|NCT02678364|DIETARY_SUPPLEMENT|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
223976476|NCT02975297|DRUG|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
223976477|NCT02975297|DRUG|NRT|Nicotine Patch (21mg) / 24 hours.
224117093|NCT01806077|DRUG|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
224117094|NCT03018782|OTHER|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
224117095|NCT00773760|OTHER|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
223976478|NCT02975297|BEHAVIORAL|Counseling|Brief individual behavioral smoking cessation counseling.
223976479|NCT02975297|DRUG|Placebo|Normal saline.
223976480|NCT03937037|PROCEDURE|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
223976481|NCT02106637|DRUG|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
223976482|NCT02106637|DRUG|placebo|placebo
223976483|NCT05501496|PROCEDURE|intramedullary nailing|Flexible intramedullary nailing using 2 nails
223976484|NCT05501496|PROCEDURE|casting|casting with long leg cast
223976485|NCT05864885|DRUG|Minoxidil|Topical formulation applied once a day.
223976486|NCT01655992|DRUG|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
224293348|NCT07029737|DRUG|Acalabrutinib + R-CHOP standard of care|Acalabrutinib will be administered 100 mg twice per day (BID) orally (PO) until disease progression if medically appropriate, along with R-CHOP standard of care up to six 21-day cycles of the induction phase.
224293349|NCT07029737|DRUG|Acalabrutinib combination with Rituximab|If the subject achieves response during the induction phase, acalabrutinib will be administered 100 mg BID PO until disease progression and rituximab 375 mg/m2 on Day 1 of every other 28-day cycle for a maximum of 12 additional doses.
224293350|NCT07029737|DRUG|Acalabrutinib monotherapy|If the subject does not achive response during the induction phase, monotherapy acalabrutinib will be administered 100 mg BID PO until disease progression.
224293351|NCT06693531|DRUG|dupilumab|No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
224293352|NCT04465643|DRUG|Nivolumab|Nivolumab 4.5 mg/kg Q3W x 2
224293353|NCT04465643|DRUG|Ipilimumab|Ipilimumab 1 mg/kg Q3W x 2
224293354|NCT06868368|OTHER|Biospecimen Collection|Undergo blood sample collection
224293355|NCT06868368|OTHER|Survey Administration|Complete Surveys
224293356|NCT06868368|BEHAVIORAL|Vaping Topography|Use e-cigarette connected to a topography device
223976487|NCT01655992|DRUG|S1 generic|40mg／m2 bid four weeks on two weeks off
223976488|NCT05291806|OTHER|Reference Product|This intervention is based on white rice.
223976489|NCT05291806|OTHER|Wholegrain product Dose A|This wholegrain intervention contains whole cereal kernels.
223976490|NCT05291806|OTHER|Wholegrain product Dose B|This wholegrain intervention contains whole cereal kernels.
223976491|NCT05291806|OTHER|Wholegrain product Dose A, cut kernels|This wholegrain intervention contains cut cereal kernels.
223976492|NCT00225277|DRUG|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
223976493|NCT00225277|DRUG|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
223976494|NCT06468267|DRUG|Thiotepa|The reduced intensity conditioning regimen is composed by thiotepa (5mg / kg / d-7d (1d)), fludarabine (30mg / m2 / d, -6d--2d (5d)), Ara-C (1g / m2 / d, -6d--2d (5d)), and busulfan (3.2mg / kg / d, -4d-3d (2d)).
223976495|NCT03432650|DRUG|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
223976496|NCT03432650|DEVICE|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
223976497|NCT00276900|DRUG|Sertraline|
223976498|NCT01961674|DIETARY_SUPPLEMENT|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
223976499|NCT03772509|OTHER|CATI|The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
223976500|NCT00822666|DRUG|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
223976501|NCT02923609|BIOLOGICAL|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
223976502|NCT03220165|DRUG|MGL-3196|oral, 100 mg
223976503|NCT00711997|BIOLOGICAL|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
224293357|NCT06868368|OTHER|Participant's Own Preferred E-cigarette|Participant vapes their own preferred e-cigarette for 30 minutes
224293358|NCT06868368|OTHER|Nicotine E-cigarette|Participant vapes a commercially available nicotine e-cigarette for 30 minutes
224293359|NCT06868368|OTHER|6-methyl-nicotine (metatine) e-cigarette|Participant vapes a commercially available metatine e-cigarette for 30 minutes
224117096|NCT02941107|DRUG|Rotarix (RV1)|ROTARIX™ (RV1) is a live-attenuated human monovalent oral vaccine containing attenuated G1P\[8\] human rotavirus strain sponsored and distributed in Australia by GlaxoSmithKline Biologicals where it is licensed for the prevention of rotavirus gastroenteritis.
223976504|NCT00945763|DRUG|N1539|30 mg
223976505|NCT00945763|DRUG|placebo|tablets
223976506|NCT00945763|DRUG|N1539|15 mg
223976507|NCT00945763|DRUG|N1539|60 mg
223976508|NCT00945763|DRUG|Motrin|400 mg
223976509|NCT04731675|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
224117097|NCT02941107|DRUG|Placebo|The placebo for this trial will be Viscosweet, a clear and flavoured solution used as a pharmaceutical excipient repackaged into a labelled syringe identical to the active and firmly sealed with an end cap.
224117098|NCT02269111|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
224117099|NCT02269111|PROCEDURE|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
223976510|NCT00511186|DRUG|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
223976511|NCT00511186|DRUG|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
223976512|NCT02735356|DRUG|Itraconazole|Applied topically
223976513|NCT02735356|OTHER|Placebo|Applied topically
223976514|NCT04356638|DRUG|Midazolam|Oral Midazolam and intranasal placebo
223976515|NCT04356638|DRUG|Dexmedetomidine|Intranasal Dexmedetomidine and oral placebo
223976516|NCT04356638|OTHER|Placebo|Placebo orally and intranasally
223976517|NCT04582669|DRUG|Intralesional Triamcinolone 10 mg/mL|Injection of 1 mL intralesional triamcinolone 10 mg/mL in up to 3 anatomic areas.
223976518|NCT04582669|DRUG|Intralesional Triamcinolone 20 mg/mL|Injection of 1 mL intralesional triamcinolone 20 mg/mL in up to 3 anatomic areas.
223976519|NCT04582669|DRUG|Intralesional Triamcinolone 40 mg/mL|Injection of 1 mL intralesional triamcinolone 40 mg/mL in up to 3 anatomic areas.
223976520|NCT04582669|DRUG|Placebo|Injection of 1 mL sodium chloride 0.9% in up to 3 anatomic areas.
224117100|NCT02269111|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
224117101|NCT02269111|PROCEDURE|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
224117102|NCT02401750|DRUG|Oxycodone Naltrexone (a)|
224117103|NCT02401750|DRUG|Oxycodone Naltrexone (b)|
224117104|NCT02401750|DRUG|Placebo|Matches both experimental drugs
224117105|NCT01560546|DRUG|Testosterone|50 mg/dose/day for 24 weeks
224117106|NCT01560546|DRUG|Placebo|placebo on the skin for 24 weeks
224117107|NCT01924546|OTHER|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
223976521|NCT05700578|BEHAVIORAL|Safety Behavior Elimination for Traumatic Stress (SBETS)|This intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used trauma-related safety behaviors to reduce or eliminate over the coming month.
223976522|NCT05700578|BEHAVIORAL|Modifiable Behavior Intervention (MoBI)|The intervention took 30 minutes to complete. At the end of the intervention, participants were instructed to select two of their most commonly-used unhealthy behaviors to reduce or eliminate over the coming month.
223976523|NCT04853407|DRUG|LY03005 extended-release tablet|orally once a day
223976524|NCT04853407|DRUG|Placebo|orally once a day
223976525|NCT04693845|BEHAVIORAL|Collaborative Assessment and Management of Suicidality|"CAMS is a suicide-focused intervention that stabilizes the suicidal patient and identifies, targets, and treats patient-defined suicidal drivers-the problems (e.g., trauma, financial issues, relationship loss) that compel a patient to consider suicide. CAMS is theoretically agnostic, patient-centered, and can be used across different suicidal populations and clinical settings."
223976526|NCT04693845|BEHAVIORAL|Treatment as Usual|Treatment as Usual was based on the staff, policies, and procedures of the community mental health center Next Day Appointment clinic (CMHC) affiliated with our university. Research therapists and the research psychiatrist were hired from the CMHC staff who followed standard CMHC policies and procedures.
223976527|NCT06511518|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioural therapy (CBT) is a therapy that can help you manage your problems by changing the way you think and behave.
223976528|NCT04052035|PROCEDURE|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
223976529|NCT00353093|PROCEDURE|Ultrasonography of the deep vein system of the legs|
223976530|NCT05277090|DRUG|2L of polyethyleneglycol|2L of polyethyleneglycol
223976531|NCT05277090|DIETARY_SUPPLEMENT|inulin|15g inulin per day
223976532|NCT05277090|COMBINATION_PRODUCT|probiotic combination product|"participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals."
223976533|NCT00591409|DRUG|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
223976534|NCT00591409|DRUG|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
223976535|NCT01430078|DRUG|ASP015K|oral tablet
223976536|NCT01430078|DRUG|ASP015K|solution via oral capsule
223976537|NCT02209727|DRUG|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
223976538|NCT03544437|PROCEDURE|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
223976539|NCT00677092|DRUG|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
223725893|NCT05323942|OTHER|Education and Exercise Therapy Group|"82 children were evaluated. Among those, 37 volunteered children were trained and demonstrated in practice about bruxism, parafunctional oral habits, sleep hygiene education, and 5x5 therapeutic exercises. Therapeutic exercises program 5x5 included breathing exercises, head-neck, and scapular posture exercises which included jaw muscle and neck muscle stretching and strengthening exercises. They were asked to repeat each exercise with 5 set and 5 times a day for 8 weeks.~Sleep hygiene education was given to parents and children with explanation of the parafunctional oral habits to raise awareness about being conscious about the oral habits. Sleep hygiene education includes routines about bedtime, sleeping room environment, and timing for exercise."
223725894|NCT02137733|DRUG|Bisoprolol|
223725895|NCT02137733|DRUG|Carvedilol|
223976540|NCT00502164|DRUG|AZD2171|
223976541|NCT06371430|DEVICE|Dental Implant insertion and tooth extraction|"The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment."
223976542|NCT05245305|OTHER|Mindfulness Based Stress Reduction Program|The intervention was structured as 11 weeks, taking into account the group. The program takes 2-2.5 hours per week. The program includes raisin exercise, body scanning meditation, breath awareness meditation, sitting meditation, mindfull movement, walking meditation, vision meditation, compassion meditation,mindfulness communication and day of silence.
223976543|NCT01795729|DEVICE|Stent|Coronary revascularization
223976544|NCT01795729|DRUG|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
223976545|NCT04737005|PROCEDURE|Nano-ceramic hybrid (Grandio Blocs) Endo-crown|Nano-ceramic hybrid
223976546|NCT02716077|RADIATION|FDG PET/CT imaging|
223976547|NCT01175564|DRUG|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
223976548|NCT01175564|DRUG|Placebo|Placebo tablet, single dose and 6 days repeated dose
223976549|NCT03401723|OTHER|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
223976550|NCT03401723|OTHER|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~1. Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~2. Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~3. Loop Management - The management of a standard alfa-loop.~4. Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
223976551|NCT03401723|OTHER|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
223976552|NCT02554422|DEVICE|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
223976553|NCT05047653|DIAGNOSTIC_TEST|RALE score vs. severity score|RALE score vs. severity score and CORADS
223976554|NCT02673307|BEHAVIORAL|1 chewing gum over 45 minutes|
223976555|NCT02273700|DRUG|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
223976556|NCT06213519|DRUG|S-1, Oxaliplatin sintilimab HIPEC|"1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity."
223976557|NCT02714699|DRUG|diclofenac potassium|patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
223976558|NCT02714699|DRUG|hyoscine butyl bromide|patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
223976559|NCT02714699|DRUG|placebo|patients will take oral placebo; 2 tablets one hour before the procedure
223976560|NCT02716298|DEVICE|fanfilcon A|contact lens
223976561|NCT02716298|DEVICE|lotrafilcon B|contact lens
224293360|NCT02420418|DIETARY_SUPPLEMENT|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
224293361|NCT02420418|OTHER|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
224293362|NCT03373136|DEVICE|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
224293363|NCT07041385|DRUG|Aspirin 75 mg|"This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition.~Eligible women attending the antenatal clinic were screened by history, physical exam, and uterine artery Doppler. Risk assessment was entered into the Fetal Medicine Foundation software. Participants were randomized:~Group A: 75 mg aspirin nightly. Group B: 150 mg aspirin nightly."
224293364|NCT07041385|DRUG|Aspirin 150 mg|"This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition.~Eligible women attending the antenatal clinic were screened by history, physical exam, and uterine artery Doppler. Risk assessment was entered into the Fetal Medicine Foundation software. Participants were randomized:~Group A: 75 mg aspirin nightly. Group B: 150 mg aspirin nightly."
223725896|NCT02938689|OTHER|Exercise|
223725897|NCT00574509|RADIATION|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
223725898|NCT00574509|DRUG|BEAM|Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
223725899|NCT02371109|OTHER|selftaken versus clinically taken swabs|
224293365|NCT07043426|OTHER|THRIVE-DM|Low-SS and High-SS will be referred by the CHW to appropriate community-based organizations through the THRIVE Directory. High-SS participants will also receive additional support from a patient navigator (PN), who will follow up to facilitate service connection and address barriers to engagement. CHWs and PNs will coordinate care to ensure services are aligned with the patient's assessed needs.
223725900|NCT00999583|DRUG|EPOETINE ALPHA|5 injections of 40000 UI of EPO
223725901|NCT00999583|OTHER|Control arm|Usual take care of cardiac arrest
223725902|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo strength training classes
224293366|NCT07043426|OTHER|Standard of care|Standard of care may include support from the primary care team, health related social needs (HRSN) screening via the THRIVE screener, printed resource guides, and referrals to community-based organizations initiated at the discretion of clinic staff using the THRIVE Directory.
224293367|NCT06829914|DEVICE|Shockwave Catheter|Shockwave™ IVL + DCB procedure
224293368|NCT06829914|PROCEDURE|CFA Endarterectomy|Standard CFA endarterectomy
224293369|NCT03812653|DEVICE|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
224293370|NCT06887647|OTHER|Physical Therapy Using Hippotherapy and the Equine Environment|"Subjects will be mounted on a horse for 15-30 minutes. Therapeutic activities will include movements like reaching, throwing, and bilateral coordination tasks in addition to assuming various positions on the horse during equine movement, per the tolerance of individual participants. Remaining treatment time will involve participation-based functional motor activities in the equine environment, such as feeding and grooming horses.~Treatment will include the following active ingredients:~1. Encourage use of both upper extremities during therapeutic activities.~2. Design therapeutic activities with equines to guide practice of functional motor skills.~3. Design therapeutic activities with the equines to practice participation (ie. activities involved in life situations).~4. Utilize the presence of the equines to optimize patient mood and engagement in the therapeutic activities. (Design activities around patient strengths and preferences; use the equines as positive reinforcement)"
224293371|NCT06887647|OTHER|Standard Play-Based Physical Therapy|"The treatment will focus on encouragement of functional play activities, such as reaching, throwing, and catching games. Treatment will incorporate the following active ingredients:~1. Encourage use of both upper extremities during therapeutic activities.~2. Design therapeutic activities using play and games to guide practice of functional motor skills.~3. Design therapeutic activities with play and games to practice participation (ie. activities involved in life situations).~4. Utilize play and games to optimize patient mood and engagement in the therapeutic activities. (Design activities around patient strengths and preferences; use play and games as positive reinforcement)"
223543422|NCT01280786|DRUG|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
223543423|NCT00224081|DRUG|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
223543424|NCT00255216|DRUG|Policosanol supplement (oral capsule) vs. placebo|
223543425|NCT04944147|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA)
223543426|NCT04944147|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants
223543427|NCT04944147|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions
223543428|NCT04944147|BEHAVIORAL|Progressive muscle relaxation (PMR)|Standardized instructed PMR training, 9 sessions
223543429|NCT02779777|DRUG|Tipifarnib|Oral tablet
223725903|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo tai chi classes
223725904|NCT01635413|BEHAVIORAL|Exercise Intervention|Undergo stretching and relaxation classes
223543430|NCT02217813|DRUG|Tafamidis|20 mg of current commercial formulation
223543431|NCT02217813|DRUG|Tafamidis|20 mg of new formulation
223725905|NCT01635413|OTHER|Questionnaire Administration|Ancillary studies
223725906|NCT06382584|PROCEDURE|Femoral fracture surgery|Hip fracture surgery
223725907|NCT04550390|DIAGNOSTIC_TEST|Saliva collection|2 saliva samples are self-collected by participants
223725908|NCT00765050|BIOLOGICAL|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
223725909|NCT00686192|DIETARY_SUPPLEMENT|Calcium Carbonate|1500 mg per day
223725910|NCT06334471|OTHER|no intervention needed|no intervention needed
223725911|NCT02550249|DRUG|Nivolumab|Intravenous administration of nivolumab
223725912|NCT01439191|DRUG|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
223725913|NCT01439191|DRUG|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
223725914|NCT04022902|OTHER|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
223725915|NCT01549860|DEVICE|MIST Therapy|Non-contact low frequency ultrasound therapy
223725916|NCT03742934|OTHER|Short peptide|Short peptide formula during bowel preparation
223725917|NCT03742934|OTHER|Liquid diet|Liquid diet during bowel preparation
223725918|NCT00275184|DRUG|Senna|
223725919|NCT00275184|DRUG|Citramag powder|
223725920|NCT00275184|DRUG|Metoclopramide|
223725921|NCT01129609|DEVICE|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
223725922|NCT00275769|DEVICE|Pacemaker|
223725923|NCT03125343|PROCEDURE|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~* PET-CT is optional, but can be performed at inclusion~* Pelvic MRI including diffusion weighted imaging according to appendix C.~* Clinical examination~* Endoscopy (flexible sigmoidoskopy) with photodocumentation~* CEA~After two years the patients will be followed every six month with:~* Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~* Clinical examination~* Endoscopy with photodocumentation~* CEA"
223725924|NCT03125343|PROCEDURE|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
223725925|NCT03125343|DEVICE|MRI|
223725926|NCT04432194|DIETARY_SUPPLEMENT|Nutritional supplementation and Pulmonary Rehabilitation|Nutritional supplementation (HMB 4g) or Nutritional supplementation (citrulline 3g) with Pulmonary Rehabilitation
223725927|NCT04937491|DEVICE|New medical device (ReBalans)|Body worn, battery powered bioimpedance measuring patch device.
223725928|NCT01148823|OTHER|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
223725929|NCT01148823|OTHER|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
223725930|NCT02588807|DRUG|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
223976562|NCT00550446|DRUG|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
223976563|NCT00550446|DRUG|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
223976564|NCT00550446|DRUG|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
223976565|NCT00550446|DRUG|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
223976566|NCT00550446|DRUG|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
223976567|NCT00550446|DRUG|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
223976568|NCT00550446|DRUG|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
223976569|NCT05524285|DEVICE|Intracranial Support Catheter|Endovascular procedure using the intracranial support catheter which approved by NMPA
223976570|NCT05524285|DEVICE|Guide Catheter|Endovascular procedure using the guide catheter which approved by NMPA
224117108|NCT01989546|DRUG|BMN 673|Poly (ADP-ribose) polymerase (PARP) inhibitor; has been shown to cause single-agent synthetic lethality in breast cancer 1 and breast cancer 2 (BRCA1/2)- and phosphatase and tensin homolog (PTEN)-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in deoxyribonucleic acid (DNA) repair pathways.
224117109|NCT03252704|OTHER|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
224117110|NCT03252704|OTHER|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
224117111|NCT00624572|DRUG|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
224117112|NCT02654704|BIOLOGICAL|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
224117113|NCT00002572|BIOLOGICAL|aldesleukin|
224117114|NCT00002572|BIOLOGICAL|muromonab-CD3|
224117115|NCT00002572|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
224117116|NCT00002572|PROCEDURE|conventional surgery|
224117117|NCT02392039|DRUG|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
224117118|NCT02392039|DRUG|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
224117119|NCT02392039|OTHER|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
223976571|NCT04052945|PROCEDURE|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4) within first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6 )."
224117120|NCT02392039|BEHAVIORAL|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
223725931|NCT05067829|DEVICE|Train of four(TOF)|Train of four(TOF) monitoring after anesthesia induction
223725932|NCT00458198|BEHAVIORAL|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
223725933|NCT00088985|BIOLOGICAL|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
224117121|NCT01488825|BEHAVIORAL|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
224117122|NCT02454218|DEVICE|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
223725934|NCT00088985|BIOLOGICAL|trastuzumab|4 mg/kg intravenously, every 14 days
224117123|NCT04811521|BEHAVIORAL|Primary care follow-up|Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.
224117124|NCT04811521|BEHAVIORAL|Online Self-Administered Anxiety Management Program plus Peer Support Guidance|Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.
223725935|NCT00088985|DRUG|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
223725936|NCT01595698|OTHER|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
223725937|NCT01595698|OTHER|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
223725938|NCT02775721|OTHER|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
224117125|NCT04811521|BEHAVIORAL|Therapist-Administered Cognitive Behavioral Therapy|Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
224117126|NCT01180413|DRUG|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
224117127|NCT01180413|DRUG|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
224117128|NCT01180413|DRUG|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
224117129|NCT01180413|DRUG|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
224117130|NCT04417088|DRUG|Carboplatin|Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
224117131|NCT04417088|DEVICE|Exablate BBBD|BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
224293372|NCT06752928|DEVICE|Dexcom G7 rtCGM|The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 CGM System or G7) is a glucose monitoring system that continuously measures glucose in the interstitial fluid. It aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments
223725939|NCT02775721|OTHER|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
224293373|NCT06752928|DIAGNOSTIC_TEST|Capillary Blood glucose Testing (POC)|POC glucose meters measure whole blood and convert the results to plasma glucose concentrations, which is the standardized form used in clinical practice.
224293374|NCT06241573|DRUG|Spesolimab|Spesolimab
224293375|NCT06872125|DRUG|zorevunersen|Zorevunersen group will receive study drug by intrathecal (IT) administration on Day 1 (after the 8-week Baseline Period), Day 57 (Week 8), Day 169 (Week 24), and Day 281 (Week 40) at a dose level of 70 mg on Day 1 and Day 57, and 45 mg on Day 169 and Day 281.
223976572|NCT04052945|PROCEDURE|sham acupuncture|"For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4) with first two weeks, and then followed-up for a further 2 weeks (visit 5 and visit 6)."
224293376|NCT06872125|OTHER|Sham Comparator|Sham group will not have drug administered. Sham group will have a lumbar puncture with CSF withdrawal.
223725940|NCT02775721|OTHER|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
223725941|NCT02775721|OTHER|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
224117132|NCT04388735|BEHAVIORAL|Questionnaire|Series of questions covering quality of life, physical and psychological symptom burden, mood, and illness and prognostic understanding administered in person or remotely.
224117133|NCT01873664|BEHAVIORAL|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
224117134|NCT00909987|DRUG|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
224117135|NCT00909987|DRUG|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
224117136|NCT00909987|DRUG|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
223725942|NCT02775721|OTHER|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
223725943|NCT03208855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
223725944|NCT04946838|DEVICE|DS5 electrical stimulator|TENS
223725945|NCT00720434|DRUG|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
223725946|NCT00720434|DRUG|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
223725947|NCT00720434|DRUG|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
223976573|NCT03503162|DEVICE|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
224117137|NCT00909987|RADIATION|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
224117138|NCT00909987|DRUG|Capecitabine during all Radiotherapy period|825 mg/m2 bid
223976574|NCT03230045|DEVICE|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
223976575|NCT03230045|DEVICE|no treatment|electrodes are attached, but no stimulation is given
223976576|NCT04134715|DRUG|PF-06826647|100 mg tablet
223976577|NCT04134715|DRUG|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
223976578|NCT04566198|OTHER|Questionnaire|The participants will have to filled out a questionnaire about their working conditions and their lifestyle habits.
223725948|NCT00720434|DRUG|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
223725949|NCT03132376|DIETARY_SUPPLEMENT|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
223725950|NCT03132376|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
223725951|NCT03132376|DIETARY_SUPPLEMENT|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
224117139|NCT00909987|PROCEDURE|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
223725952|NCT03132376|DIETARY_SUPPLEMENT|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
223725953|NCT03132376|DIETARY_SUPPLEMENT|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
223725954|NCT01586676|BEHAVIORAL|SAU|Supervision-as-usual
223725955|NCT01586676|BEHAVIORAL|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
223976579|NCT04952701|DEVICE|Control lenses|Control Multifocal lenses
224117140|NCT05884788|OTHER|free interview, and questionnaires in a second time|"After inclusion in the study, patients will be met for a free interview. The interview will be conducted using an open-ended interview method with the patients to allow free expression of their life history, using open and broad questions to avoid the influence of the interviewer as much as possible.~Each interview will be conducted by the same person to allow for better interpersonal reproducibility.~After the interview, the patients will be seen again to complete two questionnaires:~* An attachment questionnaire: Relationship Scales Questionnaire~* A questionnaire on symptoms: Distress thermometer"
224117141|NCT06045546|PROCEDURE|5-5-5-8 technique|the new technique of 5-5-5-8 for laparoscopic cholecystectomy
223725956|NCT00031057|DRUG|Thiamine hydrochloride|
223725957|NCT00031057|DRUG|Riboflavin|
223725958|NCT04818281|BIOLOGICAL|SARS-CoV-2 VLP Vaccine|VLP adjuvanted vaccine
223725959|NCT04818281|BIOLOGICAL|Placebo|0.9% NaCl
223725960|NCT05187715|DRUG|Simvastatin 40mg|Simvastatin 40mg OD
224117142|NCT06045546|PROCEDURE|10-10-5-5 technique|the standard technique of 10-10-5-5 for laparoscopic cholecystectomy
224117143|NCT03965988|DRUG|DHA|Docosahexaenoic acid
224117144|NCT03965988|DRUG|Placebo|Placebo
223725961|NCT05187715|OTHER|Placebo|Placebo
223725962|NCT05187715|OTHER|Standard medical Treatment|Standard medical Treatment eccluding pentoxiphylline
223725963|NCT03611764|BEHAVIORAL|Body Scan|-All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
223976580|NCT04952701|DEVICE|Test lenses|Test Multifocal lenses
223976581|NCT06295042|OTHER|BREAST-Q Questionnaire|Patient-reported outcome measure
223976582|NCT03330717|PROCEDURE|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
223976583|NCT03330717|PROCEDURE|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
223976584|NCT03330717|PROCEDURE|General anesthesia with preoperative session of hypnosis|Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
223976585|NCT00818870|DRUG|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
223976586|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
223976587|NCT00818870|DRUG|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
223976588|NCT06054919|DRUG|Cholecalciferol|vitamin D3
223976589|NCT02051985|OTHER|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
223976590|NCT02051985|OTHER|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
223976591|NCT01789619|DRUG|Extended release tacrolimus (Advagraf®)|
223976592|NCT01013064|DRUG|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
223543432|NCT06186583|DRUG|Pimicotinib（ABSK021）|A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
223976593|NCT05820321|DIETARY_SUPPLEMENT|Beetroot juice rich in nitrate|The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
223976594|NCT05820321|OTHER|Beetroot juice NO3 depleted|The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
224117145|NCT05520996|BEHAVIORAL|Cyberball|Social exclusion or ostracism can be measured by the Cyberball 5 task. The principle of Cyberball is based on the creation of a situation of exclusion through a computerized task. During this task, the participant passes a ball to 2 other players controlled by Artificial Intelligence (AI). The ball-passing method of AI-controlled players is determined in advance in the computer program code. A series of ball passing is carried out with initially an equal passing between the three participants and then an exclusive passing between the players controlled by an artificial intelligence
224117146|NCT06286098|DRUG|Alpha lipoic acid|THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA
224117147|NCT06286098|OTHER|Placebo|Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.
224117148|NCT01848821|DEVICE|OASIS Ultra|Porcine derived intestinal submucosa
224117149|NCT01848821|DEVICE|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
224117150|NCT01495546|OTHER|Early loading|Patients stepping down immediately after THA
224117151|NCT01495546|OTHER|Late loading|Patients stepping down after three weeks of HTA
224117152|NCT00019513|DRUG|fluorouracil|
224117153|NCT00019513|DRUG|gemcitabine hydrochloride|
224117154|NCT00019513|DRUG|leucovorin calcium|
224117155|NCT06031480|DRUG|Anlotinib and TQB2450|"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."
224117156|NCT04438603|DRUG|Intervention for incipient patients at low risk of disease progression|Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
224117157|NCT04438603|DRUG|Intervention for patients at high risk of disease progression|"BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks."
224117158|NCT04205370|DEVICE|Deactivated Pregnancy Coach|Naturalistic monitoring of their typical sleep patterns and behaviors
224117159|NCT04205370|DEVICE|Active Pregnancy Coach|The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
223543433|NCT01117194|DEVICE|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
223976595|NCT04499014|DEVICE|ultrasound|5 days a week, a total of 10 sessions
223976596|NCT04456049|DRUG|Enzalutamide|40 mg oral tablets once daily for a maximum of 28 days.
223976597|NCT06011928|OTHER|MOPEX Exercise|"Exercises to be done in order:~1. Pelvic tilt in supine position~2. Bridge building~3. Pelvic stretching~4. Ball spin~5. Cat-camel exercise~Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds"
223976598|NCT06011928|OTHER|Relaxation Exercise|Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened.
223976599|NCT06011928|OTHER|Combine Exercise|"Exercises to be done in order:~Pelvic tilt in supine position Bridge building Pelvic stretching Ball spin Cat-camel exercise Exercise program 8 weeks, 3 days a week, 3 sets of 10 repetitions of each movement and between sets It is planned to rest for 10 seconds.~Progressive muscle relaxation exercises, respectively, facial muscles, neck and shoulders, right-left arm, right-left hand, back muscles, chest muscles, abdominal muscles, hip, right-left leg, right-left foot muscles are contracted while breathing deeply and slowly, and relaxing when exhaling. will be displayed. Each muscle is contracted for 5 seconds and relaxed for 10 seconds. will be held. Before moving on to the new muscle group in intermuscular contraction and relaxation, several times in between Slow and deep breathing will be practiced. After all the muscles are contracted and relaxed in sequence, Then, while inhaling, all the muscles contract simultaneously and while exhaling, will be loosened."
223976600|NCT00375778|DRUG|memantine (drug)|
223976601|NCT03690284|DEVICE|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
223976602|NCT03690284|DEVICE|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
223976603|NCT02574949|RADIATION|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
223976604|NCT02574949|RADIATION|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
223976605|NCT02574949|RADIATION|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
223976606|NCT01929564|OTHER|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
223976607|NCT01929564|OTHER|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
223976608|NCT02997397|PROCEDURE|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
223976609|NCT02997397|PROCEDURE|tourniquet(-)|
223976610|NCT03231761|OTHER|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
223976611|NCT03231761|OTHER|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
223976612|NCT05240547|OTHER|Spinal Manipulation|Spinal manipulative therapy delivered to the cervical spine by a chiropractor
223976613|NCT05240547|OTHER|Placebo|Sham manipulative treatment delivered to the cervical spine by a chiropractor
223976614|NCT00001440|PROCEDURE|Autologous T cells|
223976615|NCT00001440|DRUG|Interleukin-2|
224117160|NCT04162964|BEHAVIORAL|Virtual Chair Yoga|8-week virtual chair yoga program for one hour per week. Chair yoga is an effective way to offer modified yoga postures and relaxation techniques to individuals with limited mobility and/or advanced age for whom mat-based classes may not be accessible. The weekly yoga classes will be lead on the software Zoom by a certified instructor in English and French.
223976616|NCT04659200|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing.|For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
223976617|NCT05062837|DRUG|Hepatectomy Combined With Camrelizumab and Apatinib|Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.
223976618|NCT03455218|DRUG|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
223976619|NCT03455218|DRUG|Placebo|INOmax device connected to oxygenator, but no gas is delivered
223976620|NCT03455218|DEVICE|INOmax|All patients will have the INOmax device connected to the oxygenator
223976621|NCT01705223|BIOLOGICAL|DNA vaccine|4mg/dose, three doses at week 0,4,8
223976622|NCT01705223|BIOLOGICAL|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
223976623|NCT01705223|BIOLOGICAL|rTV boost|at week 16
223976624|NCT01705223|BIOLOGICAL|rTV boost|at week 24
223976625|NCT01705223|BIOLOGICAL|rTV boost|at week 32
224117161|NCT05653778|DEVICE|Scrambler therapy|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
224117162|NCT05653778|DEVICE|TENS treatment|Superficial electrocardiogram (ECG) electrodes are placed on the dermatomes involved with pain, above the area of pain itself. Each treatment lasts 30-40 minutes or until pain relief is obtained.
224293404|NCT06770101|BEHAVIORAL|Behavioral: Enhanced Friendship Bench + Safety Planning|The protocol will include six sessions, starting with the development of the SP during the first session. Each of the following sessions will include SIBs and suicide risk assessments, SP check-ins and revisions, as well as FB problem-solving to address SIBs and suicide risk. SP+FB will be delivered by selection of young counselors (mixed genders, aged 20-35) who are motivated to work with young people. Counseling sessions will take place in a discrete location within the HIV clinic and be available on weekends. Each structured session lasts 30-45 minutes and conducted in the participant's local language (Chichewa). After 4 sessions of individual therapy, the counselor can refer participants not improving or with suicidal ideation to a supervisor trained in mental health to reassess and manage the case. Case management may include additional counseling or pharmacotherapy, at the discretion of the managing clinician. Participants may also receive text message support and peer-support.
224293405|NCT06770101|BEHAVIORAL|Augmented usual care|Care for suicidality in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic's psychiatric nurse, or, for acute cases or crises, referral to the psychiatric units at tertiary care hospitals (Bwaila Hospital in Lilongwe District). Nurses and clinicians at the study sites have been specifically trained to use the Tool for Assessment of Suicide Risk for Adolescents (TASR-A) to assess ALWH considered at elevated risk for suicide. For this study, usual care will be augmented by a trained study nurse who will provide mental health evaluation, brief supportive counseling, information, education and support on SIBs, and (if indicated) facilitation of referral to the clinic's psychiatric nurse or to Bwaila Hospital.
224293406|NCT06105541|DEVICE|Transcutaneous Auricular Neurostimulation|Transcutaneous Auricular Neurostimulation (tAN) is a wearable, electrical stimulation device that delivers electricity to specific parts of the human ear.
223976626|NCT00204516|BIOLOGICAL|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
223976627|NCT00204516|DRUG|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
223976628|NCT00052325|DIETARY_SUPPLEMENT|mistletoe extract|
223976629|NCT06369857|PROCEDURE|Pectopexy|Suspension of apical organs
223976630|NCT00578318|BEHAVIORAL|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
223976631|NCT00841477|BIOLOGICAL|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
223976632|NCT00841477|BEHAVIORAL|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
224117163|NCT06036446|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 24 0/7 - 26 6/7 weeks of gestation.
224117164|NCT06036446|DRUG|Vaginal Suppository Progesterone|Continuing or initiation of vaginal progesterone 200mg daily until 36 weeks of gestation.
223976633|NCT01340040|DRUG|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
223543434|NCT04257643|OTHER|aquatic based exercise.|exercise under water with the patient standing in a swimming pool, for 60 minswith water to the neck and then practice the arm exercise plus the diaphragmatic breathing exercise. The duration of the exercise programs was selected to be 60 minutes, 3 days per week for 8-week intervention
223976634|NCT00866918|DRUG|Arsenic Trioxide|Given IV
223976635|NCT00866918|DRUG|Cytarabine|Given IT or IV
223976636|NCT00866918|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223976637|NCT00866918|DRUG|Idarubicin|Given IV
223976638|NCT00866918|DRUG|Mercaptopurine|Given orally
223976639|NCT00866918|DRUG|Methotrexate|Given orally
223976640|NCT00866918|DRUG|Mitoxantrone Hydrochloride|Given IV
223976641|NCT00866918|DRUG|Tretinoin|Given orally
223976642|NCT04031118|DEVICE|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
223976643|NCT02053064|GENETIC|SAF-301|
223976644|NCT02486159|DRUG|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
224293407|NCT06391775|BIOLOGICAL|GEN1055|Intravenous (IV) administration.
223725964|NCT03611764|OTHER|Rotterdam Symptom Checklist|"* 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent"
224293408|NCT06391775|BIOLOGICAL|Pembrolizumab|IV administration
224293409|NCT06391775|DRUG|Standard Chemotherapy|IV administration
224293410|NCT06115499|DRUG|Nab paclitaxel|Given IV
224293411|NCT06115499|DRUG|Gemcitabine|Given IV
224293412|NCT06115499|DRUG|Cisplatin|Given IV
223976645|NCT02486159|PROCEDURE|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
224293413|NCT06115499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224293414|NCT06115499|PROCEDURE|Computed Tomography|Undergo CT
224293415|NCT06115499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293416|NCT06895174|DEVICE|Titanium miniplates|Titanium miniplates are used for open reduction and internal fixation in mandible fractures according to Champy's principle of osteosynthesis
223976646|NCT04611724|DRUG|FOLFIRINOX|oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
223976647|NCT04069429|RADIATION|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
224293417|NCT06895174|OTHER|Arch Bar|Arch bars are used for intermaxillary fixation in facial fractures as a mean of closed reduction.In this study arch bars placed in tension zone will be combined with single miniplate placed at inferior border of mandible and this modality efficacy will be compared with two miniplate group.
224293418|NCT06435429|DRUG|Zanidatamab|Administered by intravenous infusion
224293419|NCT06435429|DRUG|Trastuzumab|Administered by intravenous infusion
224293420|NCT06435429|DRUG|Eribulin|Administered by intravenous infusion
224293421|NCT06435429|DRUG|Vinorelbine|Administered by intravenous infusion
224293422|NCT06435429|DRUG|Gemcitabine|Administered by intravenous infusion
223725965|NCT03611764|OTHER|Practice Logs|-Describe frequency of the Zen Den
223976648|NCT04069429|RADIATION|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
224293423|NCT06435429|DRUG|Capecitabine|Given orally
223976649|NCT04069429|DRUG|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
223976650|NCT04069429|RADIATION|Planar Images|2 dimensional imaging - whole body planar scans
223976651|NCT04069429|PROCEDURE|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
223976652|NCT00527514|DRUG|Amlodipine|Tablets
223976653|NCT00527514|DRUG|Olmesartan medoxomil plus amlodipine|Tablets
223976654|NCT03775278|DRUG|PHP-303|Investigational drug
223976655|NCT03775278|OTHER|Placebo|Matching placebo
223976656|NCT01842919|OTHER|Kinesthetics tests|
223976657|NCT01842919|OTHER|Psychological questionnaires|
223976658|NCT01842919|OTHER|structural Magnetic ResonanceImaging (MRI)|
223976659|NCT00027963|DRUG|gabapentin|
223976660|NCT00027963|OTHER|placebo|
224293424|NCT06769126|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
224293425|NCT06769126|DRUG|Ceralasertib|Given PO
224293426|NCT06769126|PROCEDURE|Computed Tomography|Undergo CT scan
224293427|NCT06769126|BIOLOGICAL|Durvalumab|Given IV
224293428|NCT06769126|DRUG|Etoposide|Given etoposide
224293429|NCT06769126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224293430|NCT06769126|BIOLOGICAL|Monalizumab|Given IV
224293431|NCT06769126|DRUG|Platinum Compound|Given platinum compound
224293432|NCT06769126|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224293433|NCT06769126|DRUG|Saruparib|Given PO
224293434|NCT06769126|RADIATION|Thoracic Radiation Therapy|Undergo thoracic radiation
224293435|NCT06834373|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293436|NCT06834373|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224293437|NCT06834373|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224293438|NCT06834373|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Undergo standard of care CAR-T therapy
224293439|NCT06834373|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224293440|NCT06834373|DRUG|Golcadomide|Given PO
224293441|NCT06834373|PROCEDURE|Leukapheresis|Undergo leukapheresis
224293442|NCT06834373|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223976661|NCT05644236|OTHER|mouthwash|After obtaining baseline information and randomizing the participants into two groups, dental scaling was performed, followed by clinical treatment. The participants were instructed to gargle twice daily for 7 days. All the participants were instructed not to eat or drink anything for at least 4 hours before the experiment. Oral hygiene, such as gargling and tooth brushing, was prohibited for 8 hrs before the visit.
223976662|NCT04045522|DRUG|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
223976663|NCT01636830|DEVICE|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
223976664|NCT03230409|BEHAVIORAL|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents \>12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
223976665|NCT03230409|BEHAVIORAL|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
223976666|NCT03230409|BIOLOGICAL|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
223976667|NCT03230409|BEHAVIORAL|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
223976668|NCT05854771|OTHER|Single bout of yoga before eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend before the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition maximum of each participant will be calculated first, and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
224117165|NCT04809727|PROCEDURE|Cervical biopsy|4 quadrant biopsy
224117166|NCT02538237|DRUG|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
224117167|NCT02538237|DRUG|Ibuprofen 2% mouthwash|
224117168|NCT03808272|DEVICE|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
224117169|NCT05870007|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg
224117170|NCT05870007|DRUG|Sodium Bicarbonate 600 Mg Oral Tablet|Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
224293443|NCT06834373|BIOLOGICAL|Rituximab|Given IV
223976669|NCT05854771|OTHER|Single bout of yoga after eccentric exercise|The participants will perform a single bout of the following 5 yoga poses; Child's pose, Thread the needle pose, Eagle arms, Cow face pose, Hands overhead in wide-legged forward bend after the eccentric exercise designed to induce delayed onset muscle soreness for a total time duration of 20-30 minutes. The participants will be asked to breathe and hold each yoga pose for 6-8 breaths. For induction of delayed onset muscle soreness, one repetition of each participant will be calculated first and on the basis of one repetition maximum the participants will perform 6 sets of 10 repetitions of the eccentric drills of elbow and knee flexors and extensors with 3 minutes rest period between each set.
223976670|NCT04850859|OTHER|measure various dimensions of the glenoid|measurement of Superior-Inferior glenoid diameter ,Anterior-Posterior glenoid diameter and study shape of the glenoid cavity .
224117171|NCT05897138|DRUG|Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle|"Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle"
224117172|NCT02184416|OTHER|observational|The study is non interventional. All drugs will be prescribed
223725966|NCT05084274|BEHAVIORAL|Lifestyle program|If the patient is allocated to the interventional group, the lifestyle modification program will be planned/started immediately after the intake at the fertility clinic. The lifestyle modification program has a duration of 12 weeks in which the subject will receive follow-up by the endocrinologist/diabetologist and dietitian to re-ceive an active dietary intervention plan, follow-up by the physiotherapist where sessions to start with physical exercise will be given. Monthly follow-up visits with the coordinating PCOS-midwife will be planned to enhance the subject's knowledge about PCOS and give emotional support. At the moment of randomization, the PCOS coordinating midwife will immediately plan all necessary appointments, with the endocrinologist and dietitian, physiotherapist and PCOS-coordinator, for the 12-week lifestyle program. This way, patients will have a clear overview of the following 12 weeks.
223725967|NCT06036667|PROCEDURE|"28Fr coaxial smart drain chest tube"|"To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies."
223976671|NCT04850859|OTHER|measure various dimensions of the acetabulum|measurement of transverse diameter of the acetabulum ,vertical diameter of the acetabulum, depth of the acetabulum ,Width of acetabular notch and study shape of anterior acetabular ridge and ends of lunate surface .
223976672|NCT02643953|BEHAVIORAL|Incentives|1\) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
223976673|NCT02643953|BEHAVIORAL|Community|1\) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
223976674|NCT03106935|DRUG|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
223976675|NCT00812838|DRUG|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
223725968|NCT05744154|BEHAVIORAL|Audit & feedback with educational outreach and facilitation|As in arm descriptions
223725969|NCT05744154|BEHAVIORAL|Simple audit & feedback (usual practice)|As in arm descriptions
223976676|NCT00812838|OTHER|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
223976677|NCT00812838|DRUG|100 units Botulinum Toxin A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
223976678|NCT01562483|DRUG|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
223976679|NCT01562483|DRUG|Placebo|Identical to the Namisol arm.
224117173|NCT00478660|DRUG|adalimumab (Humira)|
224117174|NCT06035432|OTHER|Bluesky software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
224117175|NCT06035432|OTHER|3D slicer software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
224117176|NCT06035432|OTHER|OnDemand software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
223976680|NCT06117202|OTHER|music therapy|The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
223976681|NCT04933162|DIETARY_SUPPLEMENT|High Protein and Low Fiber Diet|Protein intake will be increased to be \>40% calories from protein, and the fiber intake will remain \<15gm/day.
223976682|NCT04933162|DIETARY_SUPPLEMENT|Low Protein and High Fiber Diet|Increase fiber intake up to 40gms of fiber with a requirement to increase at least 15gms above baseline fiber, with 50-75% of total fiber intake from psyllium husk. Subjects will be allowed to slowly increase fiber every two days to reach goal by end of week 1. The total protein will be reduced to \<10% total calories from protein.
223976683|NCT04064723|DEVICE|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
224117177|NCT06035432|OTHER|Mimics software|Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
224117178|NCT04594408|DRUG|Epinephrine|1 mL of 1:1000 mixed into irrigation bag.
224117179|NCT04594408|DRUG|Tranexamic acid|1 g IV x 1 dose to be administered intraoperatively.
224117180|NCT04594408|DRUG|Epinephrine and Tranexamic Acid|1 mL of 1:1000 epinephrine mixed into irrigation bag, and 1 g tranexamic acid x 1 dose to be administered intraoperatively.
224117181|NCT02369978|DRUG|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
224117182|NCT02369978|DRUG|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
224117183|NCT02369978|DRUG|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
224117184|NCT06342297|DEVICE|Dermatoscopy|Dermatoscopy used in decision of surgical margin before resection of basal cell carcinoma or cutaneous squamous cell carcinoma
224117185|NCT05360732|DRUG|FOLFIRINOX|Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
224117186|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
223976684|NCT01245335|DEVICE|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
224117187|NCT03661073|BEHAVIORAL|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
223976685|NCT01245335|DEVICE|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
223976686|NCT01334762|DRUG|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
223976687|NCT01334762|DRUG|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
223976688|NCT01793298|DRUG|ASM-024|Ascending doses of ASM-024
223976689|NCT00557336|DRUG|somatropin|
223976690|NCT01530659|DRUG|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
224117188|NCT02005653|DRUG|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
224117189|NCT02005653|DRUG|Albendazole|Experimental
224117190|NCT02005653|DRUG|Doxycycline|Experimental
224117191|NCT05451121|DRUG|Propofol|patient sedation with a propofol (sedative agent) after cardiac surgery
224117192|NCT05451121|DRUG|Dexmedetomidine|patient sedation with dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist) after cardiac surgery
224117193|NCT05451121|DRUG|Propofol and dexmedetomidine|Patients sedation with a drug combination: propofol and dexmedetomidine (selective α2-adrenergic receptor (α2-AR) agonist)
224117194|NCT03938376|DIAGNOSTIC_TEST|Micro-Ultrasound guided biopsy|High-resolution imaging device
224117195|NCT04328064|DRUG|Rosuvastatin calcium 40mg|Active drug -Rosuvastatin
223976691|NCT01530659|PROCEDURE|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
223976692|NCT01880697|BIOLOGICAL|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
223976693|NCT00920699|DRUG|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
223976694|NCT00632723|DRUG|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
224117196|NCT04328064|DRUG|Placebo oral tablet|40 mg placebo for 12 months
224117197|NCT02758886|BEHAVIORAL|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
224117198|NCT02758886|BEHAVIORAL|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
224117199|NCT02758886|BEHAVIORAL|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
224117200|NCT00227279|BIOLOGICAL|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
223976695|NCT00953862|DRUG|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
223976696|NCT03696602|DIAGNOSTIC_TEST|bronchial provocation test|
223976697|NCT01329185|DRUG|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
223976698|NCT01329185|DRUG|Placebo|1 capsule twice a day for 14 days prior to transplant date
223976699|NCT00001941|BIOLOGICAL|daclizumab|
223976700|NCT04112277|DRUG|Cumulative morphine consumption|morphine equivalent \[mg\] 24 hours after the procedure
223976701|NCT02241161|OTHER|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
223976702|NCT02241161|OTHER|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
224117201|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
224117202|NCT01505491|DRUG|BI695501|BI 695501 single s.c injection
224117203|NCT01505491|DRUG|adalimumab|40mg adalimumab single s.c. injection
224117204|NCT00002206|DRUG|Adefovir dipivoxil|
224117205|NCT05415956|BEHAVIORAL|Walking exercise therapy|Moderate-to-high intensity walking exercise therapy (7 weeks, 14 session) with progression in duration and intensity.
224117206|NCT00695084|BEHAVIORAL|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
224117207|NCT02597842|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
223976703|NCT02241161|OTHER|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
224117208|NCT06410781|OTHER|Radial Extracorporeal Shockwave|Treatment procedure will be initiated by palpation to locate the painful area around the lateral femoral condyle and the lateral side of the thigh. The therapist uses the principle of clinical focusing where the patient guides the therapist to the most painful area. The area will be treated in a circumferential pattern, starting at the point of maximum pain. At each of the session a total of 4600 pulses will be applied. RESWT will start with 500 pulses at (2 Bar) with the frequency of 15 Hz to the lateral femoral condyle to adjust to treatment.An additional 2000 pulses will be applied at (2- 4 Bar), 15 Hz, depending on pain tolerance. in addition,stretching exercise, manual therapy, and ultrasound on the iliotibial band.
224117209|NCT06410781|OTHER|traditional therapy|the patients will receive traditional therapy in the form of stretching exercise, manual therapy and ultrasound on iliotibial band.
224117210|NCT05601999|BIOLOGICAL|GNR-060|GNR-060 will be administered in an individual dose depending on body weight as a single intravenous bolus
224117211|NCT05601999|BIOLOGICAL|Metalyse|Metalyse will be administered in an individual dose depending on body weight as a single intravenous bolus
224117212|NCT02759146|OTHER|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
224117213|NCT02759146|OTHER|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
224117214|NCT01515982|BEHAVIORAL|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
224117215|NCT01515982|BEHAVIORAL|Control Group|All participants were asked not to commence any new exercise regimen.
224117216|NCT03237832|DRUG|ARN-6039|Ascending doses per Cohort
224117217|NCT03237832|OTHER|Placebo|Placebo to match ARN-6039
223976704|NCT06124183|BEHAVIORAL|The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals|The program is based on the emotional intelligence skills model (Mayer \& Salovey, 1997; Salovey \& Mayer, 1990), which suggests that emotional intelligence consists of four hierarchical branches or components: (a) perception of emotions, (b) facilitating thinking using emotions, (c) understanding emotions, and (d) managing and handling emotions. The program comprises 12 sessions and additional activities to be carried out after each session, alongside counseling from the program's leading professionals. The sessions follow a similar structure, involving session framing, motivation on the central theme, group activity for sharing ideas and experiences, individual activities, review, and task assignment. The first and second sections focus on analyzing the personal reality and current emotional conditions of the participants, while the final session is designed for both celebration and program evaluation. The remaining nine sessions address the four branches of the skill model.
223976705|NCT03964922|BIOLOGICAL|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
223976706|NCT03964922|BIOLOGICAL|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
223976707|NCT01723007|OTHER|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
223976708|NCT05270473|PROCEDURE|uterine compressive sutures|uterine compression sutures comaprison
223976709|NCT05725044|DIETARY_SUPPLEMENT|Ginsengberry concentrate|Ginsengberry concentrate
223976710|NCT05725044|DIETARY_SUPPLEMENT|Placebo|Placebo
223976711|NCT01222702|DRUG|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
223976712|NCT01222702|DRUG|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
223976713|NCT01222702|DRUG|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
223976714|NCT01222702|DRUG|Placebo-matching vancomycin|Placebo of vancomycin capsules
223976715|NCT06357936|PROCEDURE|nano-fat grafting in chronic limb ischaemia|The nano fat grafting procedure in the clinical trial involves the collection of adipose tissue under tumescent anesthesia, which is a technique to swell and firm the targeted area, through a separate puncture in the anterior abdominal wall. Following the collection, the adipose tissue undergoes a process of cannulation to prepare the nano fat. This prepared material is then injected into the tissues of the foot and leg using standard intramuscular injection needles. The injections are performed in various directions to ensure proper distribution of the nano fat. This method does not require additional drug therapy. It leverages the natural growth factors and stem cells present in adipose tissue, aiming to improve blood flow and tissue regeneration in limbs affected by critical ischemia. The unique aspect of this treatment is its focus on using autologous materials, minimizing the risk of rejection and side effects associated with foreign substances.
223976716|NCT06357936|PROCEDURE|sham comparator|For the clinical trial, a sham procedure would be designed to mimic the nano fat grafting without providing the actual therapeutic intervention. This involve the patient undergoing a similar process with tumescent anesthesia and making a puncture on the anterior abdominal wall. However, instead of harvesting adipose tissue and preparing nano fat, a placebo solution (such as saline) would be injected using the same intramuscular injection technique. The aim of this sham comparator is to assess the psychological and physiological effects of the nano fat grafting procedure itself, by eliminating the potential therapeutic benefits of the nano fat.
223976717|NCT04913623|PROCEDURE|Hip Replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
224117218|NCT01829035|OTHER|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
224117219|NCT04906239|PROCEDURE|Erector Spinae Plane Block|A high-frequency ultrasound linear probe, covered with a sterile sheath, will be placed approximately 2 cm to the right or left of the T 4-5 spinous process. After showing the T 4-5 transverse process and the erector spinae muscle on top of it, a 22-gauge, 80 mm insulated quincke type needle will be inserted into the skin at an angle of approximately 30 degrees from cranial to caudal, using the in-plane technique. When the transverse process is touched, the needle will be pulled out and after a negative aspiration test with 0.5 mL of normal saline and after the demonstration of a hypo-echogenic image and hydro dissection, a local anesthetic solution will be applied to the fascia beneath the erector spinae muscle. A 20 mL dose of 0.25% bupivacaine, which has been shown to spread both above and below the T 4-5 level, will be injected.
224117220|NCT00679159|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
224117221|NCT00679159|BIOLOGICAL|Prevenar|Streptococcus pneumoniae vaccine
224117222|NCT01204840|DRUG|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
223976718|NCT00865813|PROCEDURE|Punch Biopsy|"1. Instillation of anesthetic eye drops.~2. Asepsis~3. Placement of surgical cloths and drapes~4. Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~5. Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~6. Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
223976719|NCT01311414|DRUG|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
223976720|NCT03462498|DRUG|1-months DAPT|1-month DAPT followed by 59-month monotherapy
223976721|NCT03462498|DRUG|12-month DAPT|12-month DAPT followed by 48-month monotherapy
223976722|NCT01547247|DEVICE|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
223976723|NCT01547247|PROCEDURE|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
223976724|NCT03416621|BEHAVIORAL|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
223976725|NCT03416621|BEHAVIORAL|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
223976726|NCT03416621|DRUG|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
223976727|NCT02388113|BEHAVIORAL|accumulated exercise|
223976728|NCT02388113|BEHAVIORAL|traditional exercise|
223976729|NCT03618836|OTHER|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
224117223|NCT01204840|DRUG|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
224117224|NCT01397071|OTHER|Avocado|Fresh Avocado
224117225|NCT03397797|DRUG|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
223976730|NCT00626613|DRUG|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
223976731|NCT01281917|DRUG|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
223976732|NCT01281917|DRUG|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
224293444|NCT06858787|DEVICE|Continuous glucose monitor|Device is a remote sensor applied to the upper extremity that continuously samples glucose of interstitial fluid and uploading results to a mobile application.
223725970|NCT06369376|DIAGNOSTIC_TEST|New nerve conduction protocol|We opted for three different recording sites, each mimicking distinct parts of the pectoral muscle, allowing for a comprehensive assessment of nerve conduction across various regions.
223725971|NCT03916198|DRUG|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
223725972|NCT03916198|DRUG|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
223976733|NCT04647318|BEHAVIORAL|Compassion focused imagery, relaxation imagery and control task|Participants will engage in three tasks (control task, relaxation imagery, and CFI) every three days on a total of 3-4 occasions. Audio-recordings of scripts will be used for both relaxation and compassion imagery. The 4-minute relaxation imagery will involve the following components (i) breathing deeply and bringing mindful awareness to the breath, (ii) relaxing the body, (iii) multisensory mental imagery of a beach or a forest, (iv) noticing feelings that arise. The 4-minute self-compassion imagery scripts will involve the following components: (i) informing participants that showing ourselves self-compassion is an effective emotional-regulation tool, (ii) breathing deeply and attending mindfully to the breath, (iii) imagining oneself embodying the four characteristics of compassion according to Gilbert5, (iv) imagine wishing oneself free of suffering using a warm voice tone and (v) noticing feelings that arise. The control task will involve reading a local city culture magazine.
224117226|NCT06286787|OTHER|Intervention|The training programme will consist of a 3-hour lecture. The contents of the lecture will include knowledge of mountaineering in Hong Kong, country codes and care for the environment, environmental awareness when undertaking outdoor activities, hiking skills, knowledge and choice of hiking equipment and clothing, trip planning, mountain safety, map reading, the use of a compass, mountain safety, basic first aid, methods of calling for help in an emergency and sources of weather data. After completing the lecture, participants will be required to join a 6-day hiking training programme on weekends within a 3-month period (each training will be at least 5 kilometres and the duration will be at least 4 hours).
224117227|NCT06286787|OTHER|Placebo|Control participants will be asked to join six day-time leisure activities on weekends within a 3-month period. Leisure activities will be organised by the Asbury Methodist Social Service and will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and eating a healthy diet, and day visits to a museum and theme park. Children in the placebo control group will receive free access to leisure activities, including visits to museums and theme parks as an incentive for his/her participation.
224117228|NCT02629601|BEHAVIORAL|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
224117229|NCT02629601|BEHAVIORAL|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
224117230|NCT02629601|BEHAVIORAL|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
224117231|NCT02629601|BEHAVIORAL|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
224117232|NCT02629601|BEHAVIORAL|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
223725973|NCT02940145|OTHER|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
223725974|NCT00894569|DRUG|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
223725975|NCT00894569|DRUG|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
223725976|NCT01224431|DRUG|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
223725977|NCT00004224|DRUG|cyclophosphamide|
223725978|NCT00004224|DRUG|etoposide|
223725979|NCT00004224|DRUG|vincristine sulfate|
223725980|NCT00004224|PROCEDURE|adjuvant therapy|
223725981|NCT00004224|PROCEDURE|conventional surgery|
223725982|NCT00004224|RADIATION|radiation therapy|
223725983|NCT02705495|OTHER|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
223725984|NCT02705495|DRUG|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
223725985|NCT00827424|BEHAVIORAL|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
223725986|NCT05212649|DIAGNOSTIC_TEST|cardiopulmonary exercise test|CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
223725987|NCT02938871|DIETARY_SUPPLEMENT|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
223976734|NCT00096109|DRUG|tanespimycin|Given IV
223976735|NCT00096109|OTHER|laboratory biomarker analysis|Correlative studies
223976736|NCT00646711|DRUG|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
223976737|NCT00646711|DRUG|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
223976738|NCT01801462|OTHER|Simulation-based training|
223976739|NCT04266002|OTHER|Validation of Charter score for the CNS diffusion of antiretroviral drugs|IHFB001 (Neuroplustrois) is a pilot study, phase IV, open-label, multicenter in Ile-de-France region, trying to demonstrate the improvement of cognitive change after treatment characterized by its better diffusion in the central nervous system. The characteristics of the change in treatment are (Cn - Ci) ≥ 3 and Cn ≥ 9, where Cn is the Charter score of the new treatment and Ci the Charter score of the initial treatment.
223976740|NCT01074697|DRUG|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
223976741|NCT01074697|DRUG|Placebo|Saline water
223976742|NCT04054453|COMBINATION_PRODUCT|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
223976743|NCT06035185|PROCEDURE|apical shaping size|24 patients will randomly be assigned to two groups according to the apical shaping size during root canal treatment: 25/.04 and 35/.04. Microbiological sampling of the teeth will be done with paper cones in three steps during the root canal treatment: 1. Sterility control samples (SR1) from the tooth surface after cavity preparation, 2. The first microbiological sample (S1) from the root canal after the initial file reaches the working length. 3. The second microbiological sample (S2) from the root canal after the shaping and irrigation of the root canal is finished. 4. The third microbiological sample (S3) from the root canal after the irrigation activation in the root canal is finished.The samples will be sent to the genetic analysis laboratory for further analysis in the cold chain using a Droplet Digital PCR.
224117233|NCT02680223|DEVICE|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
224117234|NCT02680223|DEVICE|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
224117235|NCT04723108|OTHER|Destek V4 Virtual Reality Headset|The DESTEK V4 is a smartphone VR headset made by DESTEK, a manufacturer based in the US. This mobile virtual reality headset is compatible with most iOS and Android smartphones, as long as their screen size is between 4.5 and 6.
224117236|NCT01740440|DEVICE|BMR Face|BMR Face used in accordance with manufacturer IFU
223976744|NCT05892822|OTHER|Amyotrophic Lateral Sclerosis|All ALS patients included in this group.
223976745|NCT04857047|DRUG|BR9003 2mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003 tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it.
223976746|NCT04857047|DRUG|BR9003A 1mg|After fasting for at least 10 hours from 10:00 p.m. the previous day, one BR9003A tablet will be administered orally with 150mL of water around 8:30 a.m. after starting breakfast 30 minutes before the scheduled time of administration and finishing it. Another BR9003A tablet will be administered orally with water 150mL around 20:30 after dinner between 18-19:00.
223976747|NCT04007146|DIAGNOSTIC_TEST|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
223976748|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
223976749|NCT02001077|BEHAVIORAL|Cognitive Behavioral Therapy for Pain (CBT-P)|
223976750|NCT02134613|OTHER|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
223976751|NCT02960126|DRUG|Aspirin|
223976752|NCT02960126|DRUG|Clopidogrel|
223976753|NCT05867914|DEVICE|Inhaled Nitric Oxide (iNO)|eNOfit system delivering iNO
223976754|NCT00504413|DRUG|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
223976755|NCT00504413|DRUG|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
223976756|NCT00504413|DRUG|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
223976757|NCT03382288|DEVICE|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
223976758|NCT03331432|DIETARY_SUPPLEMENT|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
223976759|NCT03331432|DIETARY_SUPPLEMENT|Placebo|Taking daily placebo capsules for 4 weeks.
223976760|NCT05993520|OTHER|Assessment|Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
224117237|NCT06504173|PROCEDURE|diced cartilage|In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.
224117238|NCT03862079|OTHER|Best Practice|Given standard of care
224293445|NCT05607004|DRUG|(Z)-endoxifen|(Z)-endoxifen capsules. Doses of (Z)-endoxifen to be evaluated include 20 mg (two x 10 mg capsules), 40 mg (one 40 mg capsule) and 80 mg (two x 40 mg capsules).
224293446|NCT05607004|DRUG|goserelin|goserelin 3.6 mg subcutaneous implant
224293447|NCT02655016|DRUG|Niraparib|Niraparib will be administered.
224293448|NCT02655016|DRUG|Placebo|Placebo will be administered.
224293449|NCT06929273|DRUG|KarXT|Specified dose on specified days
223976761|NCT04124783|DEVICE|Cooling Bolero|A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
223976762|NCT00363649|BIOLOGICAL|GM-K562 cell vaccine|Given by injection
224117239|NCT03862079|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
223976763|NCT00363649|BIOLOGICAL|Interferon alfa|Given by injection
223976764|NCT00363649|BIOLOGICAL|Sargramostim|Given by injection
223976765|NCT06350708|OTHER|Virtual reality (VR) tracheostomy educational tool|This is an unsupervised VR training packaged designed to train healthcare professionals and their students the management of the paediatric tracheostomy emergency.
224117240|NCT03862079|DRUG|Nystatin|Given PO
224117241|NCT03862079|DRUG|Piperacillin-Tazobactam|Given PO
224117242|NCT00367640|DRUG|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
224117243|NCT00367640|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
223976766|NCT01271023|DEVICE|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
223976767|NCT01432522|DRUG|Epinephrine|"1. Intranasal epinephrine 5 mg /spray~2. Intramuscular epinephrine 0.3 mg~3. Intranasal saline spray"
223976768|NCT03290222|OTHER|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
224117244|NCT00367640|DRUG|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
224117245|NCT00367640|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
224117246|NCT01695057|DRUG|vorinostat|Given PO
224117247|NCT01695057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224117248|NCT01695057|OTHER|laboratory biomarker analysis|Correlative studies
224293450|NCT06895070|DEVICE|Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)|Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
224293451|NCT05180474|BIOLOGICAL|GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.|GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
224293452|NCT06828835|OTHER|Reach for Equity in Pediatric Obstructive Sleep Evaluation (REPOSE)|The REPOSE intervention consists of a centralized patient navigator who (1) identifies and addresses dynamic individual barriers, (2) provides support for parent-child dyads, and (3) facilitates bidirectional SDB care coordination between clinical teams and parents to achieve evidence-based care. The goals of the REPOSE intervention are to systematically address barriers to care, develop parental self-efficacy to enhance healthcare utilization (e.g., receipt of recommended care and adherence to evidence-based care), and to improve symptom severity and quality of life.
224293453|NCT06828835|OTHER|Usual Care|Usual care is defined by standard clinical care delivered without a protocolized intervention (e.g., the ordinary course of care).
224293454|NCT06906562|DRUG|Pemigatinib|Pemigatinib will be taken orally with a targeted starting does of 13.5 mg
224293455|NCT06906562|PROCEDURE|Computed Tomography (CT)|Undergo CT scan
224293456|NCT06906562|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224293457|NCT06906562|PROCEDURE|Optical Coherence Tomography|Undergo OCT
224293458|NCT06906562|PROCEDURE|Bone Scan|Undergo whole body bone scan
224293459|NCT06906562|PROCEDURE|Ophthalmoscopy|Undergo dilated ophthalmoscopy
223725988|NCT02938871|DIETARY_SUPPLEMENT|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
223725989|NCT01571427|BEHAVIORAL|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
223725990|NCT01571427|BEHAVIORAL|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
223725991|NCT05919381|DRUG|Gentuximab Injection|Gentuximab Injection 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
223725992|NCT05919381|DRUG|Gentuximab Injection Placebo|Gentuximab Injection Placebo 8 mg/kg, D1, 15 intravenous drip, a cycle every 28 days.
223725993|NCT01499550|DEVICE|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
223725994|NCT01499550|OTHER|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
223725995|NCT04337606|DRUG|Chidamide|Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
223725996|NCT04337606|DRUG|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
223725997|NCT04337606|DRUG|Camrelizumab|Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
223725998|NCT05830851|OTHER|real tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with therapeutic parameters
224293460|NCT06127264|DEVICE|Carbon Fiber Custom Dynamic Orthosis (CDO)|The carbon fiber custom dynamic orthosis (CDO) will consist of a semi-rigid carbon fiber footplate, a carbon fiber posterior strut, and a proximal cuff that wraps around the leg below the knee that is fastened to different tightness's
223725999|NCT05830851|OTHER|sham tDCS and aerobic exercise|Walking on a treadmill at 60-80% of HRmax while wearing a head tDCS device with sham tDCS
223726000|NCT04493281|DRUG|MT-1186|Oral suspension
223726001|NCT04493281|DRUG|MCI-186|Intravenous formulation
223726002|NCT02144051|DRUG|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
223726003|NCT02694874|DRUG|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
223726004|NCT02694874|DRUG|Placebo|This is the placebo control
223726005|NCT03933189|OTHER|Physical Therapy|Physical therapy modalities to treat chronic pain
223976769|NCT03781245|OTHER|All the Right Moves for Subcontractors|"All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change."
223976770|NCT02940210|DEVICE|Mediclore® (adhesion barrier)|
223726006|NCT05877833|OTHER|Vibrancy Assessment|Additionally, important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAEs when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above.
223976771|NCT04164862|DEVICE|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
223976772|NCT05655039|OTHER|Rehabilitation|Stroke Rehabilitation Program
223976773|NCT00006010|DRUG|docetaxel|
223976774|NCT00006010|DRUG|gemcitabine hydrochloride|
224293461|NCT01000350|DRUG|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
223976775|NCT04610632|DIAGNOSTIC_TEST|home pregnancy test|use of home pregnancy test
223976776|NCT04114097|DRUG|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
223976777|NCT04114097|DRUG|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
223976778|NCT05051215|OTHER||
224293462|NCT01000350|OTHER|Placebo|Placebo x1 lactose tablet
223726007|NCT02041286|DEVICE|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
223726008|NCT02985554|DRUG|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
223726009|NCT04534023|DRUG|Idebenone|trial group
223726010|NCT04534023|DRUG|Placebo|control group
223726011|NCT01824901|DRUG|docetaxel|Given IV
223726012|NCT01824901|DRUG|AZD4547|Given PO
223726013|NCT02520050|BEHAVIORAL|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
223726014|NCT02520050|BEHAVIORAL|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
223976779|NCT01913626|BEHAVIORAL|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
224117249|NCT01680419|BEHAVIORAL|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
224117250|NCT01680419|BEHAVIORAL|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
224117251|NCT02409784|DIETARY_SUPPLEMENT|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
224117252|NCT02409784|DIETARY_SUPPLEMENT|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
223726015|NCT02520050|BEHAVIORAL|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
223976780|NCT03183180|DIAGNOSTIC_TEST|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
223976781|NCT02620956|OTHER|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
223976782|NCT04991688|DRUG|BOTOX-A|10 injections of 20 U of toxin will be made into the rectum 5, 10 and 15 cm above the pectinate line. At each level, 3 injections of 20 U will be performed in the submucosa, circumferentially.The last injection is made 20 cm above the pectinate line. Total does not exceed 200U of Botox-A
223976783|NCT01748045|DRUG|inhaled nitric oxide|
224117253|NCT05808348|OTHER|Scales and questionnaires|"We will ask participants about their age, gender, height, weight, education level, medical history, number of falls in the last 1 year, status and length of COVID-19-related hospitalizations, and whether they have gotten the COVID-19 vaccine. The participants will be interviewed in person as part of the evaluation process.~The Modified Baecke Physical Activity Questionnaire, the Fall Efficacy Scale-International, and the Numerical Pain Rating Scale will be used to assess the participants' levels of pain, fear of falling, and physical activity, respectively."
223726016|NCT00662610|DRUG|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
223726017|NCT00662610|DRUG|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
223726018|NCT01685931|DRUG|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
223726019|NCT02257788|BIOLOGICAL|PRO 140|Humanized monoclonal antibody to CCR5
223726020|NCT03211689|OTHER|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
223976784|NCT01748045|DRUG|Placebo Comparator - nitrogen gas|
223976785|NCT04947436|DEVICE|High Frequency Chest Wall Oscillation|The HFCWO aims to mobilize the secretions to the pharynx to allow the patient to expel the secretions. However, many ALS patients are unable to expel their secretions due to atrophied expiratory muscles. The HFCWO device uses a small air compressor with a vest that wraps around the chest to induce airflows that pull secretions from the walls of the airways, thin the secretions and move them up the airways towards the larger airways and pharynx.
224293463|NCT07094906|DEVICE|Isometric handgrip exercise training|Maximum voluntary contraction (MVC) will be assessed first in both hands using a hand dynamometer with a digital display (Handexer HFEH20); the participant squeezes the hand dynamometer as hard as they can for 3 to 5 attempts to obtain the MVC. The intervention is an 8- week training protocol that consists of handgrip exercises performed by the participant at home. Each cycle of sustained handgrip exercise consists of sustained squeezing of the hand dynamometer at 30% of MVC for 2 minutes (i.e. isometric) followed by 1 minute of rest.
223976786|NCT04947436|DEVICE|Mechanical insufflation/exsufflation|A noninvasive therapy, removes secretions in patients who have an ineffective cough because their peak cough flows are less than 270 L/min. This device applies a positive pressure to the airway and rapidly switches to a negative pressure applied to the airway. The rapid switch between the two types of pressure simulates a natural cough, thus assisting with expulsion of the secretions.
223976787|NCT00413855|PROCEDURE|laparoscopic appendectomy or not (surgery)|
223976788|NCT06570434|DRUG|budoprutug|monoclonal antibody
223976789|NCT05268185|BEHAVIORAL|Moderna Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Moderna vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, Moderna booster (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
224117254|NCT04362579|DEVICE|wearable vital signs sensor|vital signs monitoring during maternal non-stress testing or in the home setting
224117255|NCT05631327|DRUG|JZP341|JZP341 will be administered as a single, intravenous infusion over 2 hours.
224117256|NCT03329040|OTHER|No Intervention.|No intervention.
224117257|NCT00139854|DRUG|Alprazolam orally disintegrating tablets|
224117258|NCT01512641|OTHER|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
224117259|NCT01512641|OTHER|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
224117260|NCT03389061|DRUG|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
224117261|NCT03389061|DRUG|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
224117262|NCT04279912|DEVICE|Focused Ultrasound (MRgFUS) for the Management of Tremor in Patients With Multiple Sclerosis|The intervention is MRIgFUS thermal ablation of the ventral intermedius (Vim) thalamus contralateral to the most affected side of the body.
224117263|NCT02003560|RADIATION|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
224117264|NCT03121872|PROCEDURE|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
224117265|NCT03121872|PROCEDURE|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
224293464|NCT07094906|DEVICE|Sham Training|Each cycle of sustained handgrip exercise consists of sustained squeezing of the hand dynamometer at 3 - 5% of MVC rather than 30%.
224293465|NCT06911944|DRUG|Donanemab|Donanemab will be administered as an IV infusion every 4 weeks using an up-titration regimen that will allow participants to reach a target dose of 1400 mg within 24 weeks.
223976790|NCT05268185|BEHAVIORAL|Pfizer Booster Vaccine|Participants assigned to this intervention will be given the recommendation to receive the Pfizer vaccine for their Covid-19 booster shot. The study team will not be administering vaccines to the participants; participants must have equal access to both the Pfizer and Moderna booster vaccines to be eligible for this study. According to current FDA recommendations, the Pfizer booster (0.30 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.
223976791|NCT01213615|DEVICE|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
223976792|NCT00359385|DRUG|Alendronate 70mg weekly|70mg weekly
223976793|NCT02681445|DEVICE|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
223976794|NCT04754191|DRUG|Enfortumab vedotin|Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months.
223976795|NCT04655742|DEVICE|VitaFlow™ Transcatheter Aortic Valve System|VitaFlow™ Transcatheter Aortic Valve System contains a valve stent-VitaFlow™ Aortic Valve, a delivery system-VitaFlow™ Delivery System,loading tools, a balloon dilatation catheter, and an introducer set
223726021|NCT02634684|DRUG|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
223976796|NCT00466089|DRUG|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
223976797|NCT00142038|DRUG|Docetaxel|
223976798|NCT00142038|DRUG|Capecitabine|
223976799|NCT03352882|DIAGNOSTIC_TEST|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
223976800|NCT04622371|OTHER|Moderate exercises|Group 1 received 30 minutes of aerobic exercise at 40-60% of maximum heart rate. Group 2,Treated by walking30 minutes daily divided into 5minutes every 2 hours to break sedentary position for 12 hours daily.
223976801|NCT05652790|PROCEDURE|Enhanced Rehabilitation Programme|"The ERP would be offered at least two sessions, each lasting 60-120 minutes per week, delivered in the Manchester Institute of Health and Performance. Interventions may include a combination of the following depending on the individual patient needs.~Manual Therapy Hydrotherapy Exercise Strength and Conditioning Programmes Gait re-education Pilates/ Yoga Cognitive and Vocational Rehabilitation Occupation Therapy Interventions eg. Anxiety Management, Pacing, Cognitive Behavioural Therapy"
224117266|NCT02000986|BEHAVIORAL|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
223726022|NCT02634684|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
223976802|NCT05652790|PROCEDURE|Standard Care|Standard care received at usual NHS facility
223726023|NCT00774150|BEHAVIORAL|Cognitive Behavioral Therapy|16 sessions of CBT
223976803|NCT00006104|BIOLOGICAL|trastuzumab|
223976804|NCT00006104|DRUG|docetaxel|
224117267|NCT00077805|DRUG|Enoxaparin sodium|
224117268|NCT04453839|DRUG|ZYESAMI (aviptadil acetate)|Patients will be treated with 12 hour infusions of ZYESAMI at ascending doses of 50/100/150 pmol/kg/hr on 3 or more successive days
223976805|NCT04573257|OTHER|Echocardiography and pulse wave velocity measurement|Echocardiography(Conventional ultrasonic imaging,tissue Doppler imaging and non invasive myocardial work) and pulse wave velocity measurement
223976806|NCT02161185|DRUG|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
223976807|NCT01545778|DRUG|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
223976808|NCT01545778|DRUG|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
223976809|NCT06646380|BEHAVIORAL|Multicomponent Training|The multicomponent training (MCT) program comprised aerobic, resistance, flexibility, and balance exercises, following recommendations by Carvalho et al. (23). Sessions lasted 50 to 60 minutes, including warm-up, aerobic exercise, resistance training, balance training, and cool-down. Training intensity gradually increased over time. The experimental group will have three 60-minute sessions weekly for 32 weeks, while the control group will not participate in any exercise program, but they will maintain the daily physical activity. Both groups will be evaluated at two time points: initial assessment (M1) at the start of training and final assessment (M2) after 32 weeks
223976810|NCT06646380|OTHER|Maintenance|Participants were instructed to maintain daily life activities regarding physical activity.
223976811|NCT04655014|OTHER|High Intensity Circuit Training|The High Intensity Circuit Training comprises of 7 full body exercises as per recommendation of ACSM Where the participants shall be given total of 18 sessions of their respective protocol, comprising of 20 minutes, 3 times/ week for duration of six weeks
223976812|NCT02447380|DRUG|AZD6094|AZD6094 600MG qd
224117269|NCT01524445|OTHER|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
224117270|NCT04220632|DRUG|Itacitinib|at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
224117271|NCT04220632|DRUG|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
224117272|NCT04220632|DRUG|Methylprednisolone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
224117273|NCT00614666|DRUG|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~* 50 mg BID (n=4) vs placebo capsule BID (n=1)~* 50 mg BID (n=4) vs 250 mg BID (n=4) vs Placebo capsule BID (n=2)~* 250 mg BID (n=4) vs 500 mg BID (n=4) vs Placebo capsule BID (n=2)~* 500 mg BID (n=4) vs Placebo capsule BID (n=1)~At least 4 subjects complete lower dose before randomization includes next higher dose.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
224117274|NCT00614666|DRUG|Placebo|Placebo comparator
224117275|NCT00013598|DRUG|Pioglitazone|
223976813|NCT02447380|DRUG|Docetaxel|Docetaxel 60 mg/m2
223976814|NCT03612492|DRUG|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
223976815|NCT03612492|DRUG|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
224117276|NCT02065440|DRUG|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
223976816|NCT05153642|PROCEDURE|Microsurgical intervention|The EC-IC bypass distal to the occlusion will be prepared in patients with a failure to pass the lesion using microwire and subjects with a failure to reach the occlusion. Middle cerebral artery exploration and eventual embolectomy will be performed before the bypass. A transverse arteriotomy will be used in the M1 segment occlusion, while a longitudinal arteriotomy with optional subsequent lesion retrieval using a Fogarty catheter will be used in the upper or lower M2 trunk occlusions. Minimally invasive and rapid surgical embolectomy technique will be used in cases with atrial fibrillation as the suspected source of emboli. In cases with successful passage using a microwire or catheter, but with failure of thrombus retrieval, a calcified cerebral embolus can be an example of failure. In cases with suspected occlusion due to intracranial atherosclerosis, the superior temporal artery will be always dissected and EC-IC bypass was performed.
224117277|NCT02065440|DRUG|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
223976817|NCT00372255|BIOLOGICAL|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
224117278|NCT02739334|BEHAVIORAL|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
224293466|NCT06911944|DRUG|Placebo|The control product (placebo) will be supplied in vials containing 350 mg/20 mL of donanemab Placebo for donanemab is supplied to the clinical site to match the active study intervention and contains only inactive ingredients. Normal sterile saline solution (0.9% sodium chloride) will be used for dilution.
224117279|NCT02739334|BEHAVIORAL|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
224293467|NCT07100080|DRUG|Iza-bren|Specified dose on specified days
224293468|NCT07100080|DRUG|Carboplatin|Specified dose on specified days
223726024|NCT00774150|BEHAVIORAL|Client Centered Therapy|16 sessions of CCT
223726025|NCT03704454|DIETARY_SUPPLEMENT|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
224293469|NCT07100080|DRUG|Cisplatin|Specified dose on specified days
223726026|NCT03704454|DIETARY_SUPPLEMENT|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
223726027|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
223726028|NCT03704454|DIETARY_SUPPLEMENT|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
223726029|NCT01053728|DRUG|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
224293470|NCT07100080|DRUG|Pemetrexed|Specified dose on specified days
224293471|NCT05777941|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied.
223726030|NCT01053728|DRUG|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
224117280|NCT03253198|DRUG|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
223726031|NCT02630550|DEVICE|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
223726032|NCT02630550|DEVICE|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
223726033|NCT03836612|OTHER|No intervention|Observation of routine clinical practice
223726034|NCT06017440|BEHAVIORAL|EXERCISE|Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
224117281|NCT03253198|DRUG|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
224293472|NCT07104474|OTHER|RESTORE|RESTORE is a process intervention that combines systems analysis and human-centered design (HCD) approaches to directly engage hospital nursing staff in ongoing organizational redesign to address burnout. Specifically, RESTORE is comprised of multiple in-person sessions with hospital unit design teams. In these sessions, hospital nurses are guided through using a well-known systems analysis model to understand their unit, including what factors act as drivers of burnout, what can be modified, and/or what constraints might be in place regarding system changes. Then, using HCD, nursing staff design, develop, and implement a system redesign solution to address the unique drivers of burnout in their unit that works within their constraints.
223976818|NCT04461314|BEHAVIORAL|peer-led counselling|"About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence."
223976819|NCT00086021|PROCEDURE|Acupuncture|
223976820|NCT04602039|DIETARY_SUPPLEMENT|Bovine Colostrum|Bovine colostrum (Neovite)
223976821|NCT04248036|BEHAVIORAL|Circle of Security - Parenting, COS-P|Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
223976822|NCT00107081|DRUG|ciprofloxacin and amoxicillin|
224117282|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
224117283|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
224117284|NCT01166412|DRUG|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
224117285|NCT01166412|DRUG|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
223726035|NCT06017440|BEHAVIORAL|CONTROL|Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
223726036|NCT04894773|OTHER|Imaginary Resistance Exercises|In imaginary resistance exercises, resistive force is assumed to get applied by the patient after demonstrating some resistive objects and the kind of force exerted by them.
223726037|NCT04894773|OTHER|Physical Resisted Exercises|In physical resistance exercises, resistive force is applied to the targeted region by using different and appropriate resistive objects.
224117286|NCT03474133|DRUG|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
224293473|NCT07096193|DRUG|GS-4321|Administered subcutaneous (SC) or intravenously IV
224293474|NCT07096193|DRUG|GS-4321 Placebo|Administered SC
224293475|NCT07096193|DRUG|GS-4321|Administered SC
223726038|NCT02069990|DRUG|Cholecalciferol|
223726039|NCT05743179|DRUG|Zoledronate|Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
223976823|NCT00107081|PROCEDURE|Outpatient management|
223976824|NCT00107081|DRUG|i.v. antibiotics|
223976825|NCT00107081|PROCEDURE|inpatient management|
223976826|NCT03987464|BEHAVIORAL|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
223976827|NCT03987464|BEHAVIORAL|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
223976828|NCT03987464|BEHAVIORAL|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
223976829|NCT03987464|BEHAVIORAL|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
224117287|NCT01807507|DEVICE|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
224117288|NCT03542240|DIETARY_SUPPLEMENT|Curcumin|500 milligram daily supplement
224117289|NCT03939130|DIETARY_SUPPLEMENT|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
224117290|NCT03939130|DIETARY_SUPPLEMENT|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
224117291|NCT03939130|OTHER|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
224117292|NCT06329362|PROCEDURE|Minimally invasive implantation|Specially designed ridge splitting instrumentation by Champions Implant GmbH which is implant shaped expanders.
224117293|NCT06329362|PROCEDURE|Open flap procedure for ridge expansion.|Mucoperiosteal elevation and ridge splitting using conventional ridge expanders.
224293476|NCT07105722|BIOLOGICAL|Pn-MAPS30plus|The Pn-MAPS30plus vaccine will be administered intramuscularly.
224293477|NCT07105722|COMBINATION_PRODUCT|PCV20|The PCV20 vaccine will be administered intramuscularly.
224293478|NCT07105709|DRUG|GSK4527226|GSK4527226 will be administered.
223976830|NCT03987464|BEHAVIORAL|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
224117294|NCT04860713|DRUG|aspirin and ketamine|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
223976831|NCT01940783|RADIATION|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
223543435|NCT04257643|OTHER|land-based exercise.|land-based exercise session for 60 minutes for 8 weeks in the form of warm-up, strengthening, and cooling down exercise.Land-based exercise program: Supervised program consisted of 60-min sessions, three times a week, over 8 weeks. The exercise program consisted of the first 10 minutes for warm-up exercise with a small softball, fit -ball, mobility and stretching exercise. Then 30-40 minutes for strength development with different materials and positions, that require more body control and increase joint motion. Then the last 10 minutes for cooling down for stretching exercise for the arm muscles \[14\]. Women were asked to exercise continuously for 60 mins, by performing the arm exercises by repeating the session, and were instructed to exercise at moderate intensity .
223543436|NCT01364129|PROCEDURE|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
223543437|NCT04571060|DRUG|Zavegepant|One dose of zavegepant
224117295|NCT04860713|DRUG|Nurtec (Rimegepant)|Drug: 75 mg of ODT
224293488|NCT07107945|DRUG|Empagliflozin|Empagliflozin
224293489|NCT07107945|DRUG|Placebo|Placebo
224293490|NCT06635824|DRUG|Acasunlimab|IV infusion
224293491|NCT06635824|DRUG|Pembrolizumab|IV infusion
224293492|NCT06635824|DRUG|Docetaxel|IV infusion
223543438|NCT04571060|DRUG|Placebo|One dose of matching placebo
223976832|NCT01940783|DEVICE|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
223976833|NCT00944892|DRUG|REGN475|2 Administrations of REGN475 within 24 weeks.
223976834|NCT00944892|OTHER|Placebo|Placebo to match REGN475 doses
223976835|NCT00131547|BEHAVIORAL|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
223976836|NCT01692132|DRUG|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (\>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
223976837|NCT02149732|BIOLOGICAL|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
223976838|NCT03752489|DIAGNOSTIC_TEST|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
223976839|NCT03752489|DIAGNOSTIC_TEST|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
223976840|NCT05211453|PROCEDURE|atrioventricular node ablation|atrioventricular node ablation
224293502|NCT06408259|DRUG|Ozanimod|Specified dose on specified days
224293503|NCT06408259|DRUG|Fingolimod|Specified dose on specified days
224293504|NCT06408259|OTHER|Placebo|Specified dose on specified days
224293505|NCT00687115|BEHAVIORAL|Weight Loss|liquid diet at 50% of weight maintaining intake
224293506|NCT00687115|BEHAVIORAL|Overfeeding|Overfeeding at 150% of weight maintaining intake
224293507|NCT00687115|BEHAVIORAL|Overfeeding Low Pro|Overfeeding 150% of normal intake at \<5% protein
223976841|NCT02341599|DRUG|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
224293508|NCT04459715|DRUG|Xevinapant (Debio 1143)|Xevinapant (Debio 1143) administrated as oral solution from Day 1 to 14, every 21-day cycle.
224293509|NCT04459715|DRUG|Cisplatin|Cisplatin administered as an IV infusion every 3 weeks (Q3W).
224293510|NCT04459715|RADIATION|Intensity Modulation Radiation Therapy (IMRT)|70 Gy given in 35 fractions over 7 weeks.
224293511|NCT04459715|DRUG|Placebo|Matched placebo administrated as oral solution from Day 1 to 14, every 21-day cycle.
224293512|NCT06915727|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
224293513|NCT06915727|PROCEDURE|Near Infrared Imaging|Undergo NIR fluorescent imaging
224293514|NCT06915727|DRUG|Pafolacianine Sodium|Given IV
224293515|NCT06915727|PROCEDURE|Surgical Procedure|Undergo SOC surgery
224293516|NCT07103941|DEVICE|AM Aligner|"Intervention Name: AM Aligner (Interocclusal Aligner) Type: Device Manufacturer: (AM Aligner; TAP Sleep Care, Texas, USA)~Description:~The AM Aligner is a prefabricated, commercially available thermoplastic appliance designed to help patients return their mandible to a normal resting position after nighttime use of a Mandibular Advancement Device (MAD). In this study, the aligner will be used each morning immediately after removing the MAD. The participant will bite into the warmed aligner for 2-5 minutes to promote realignment of the mandible and occlusion. This approach aims to minimize or prevent occlusal changes, including posterior open bite and anterior shift, associated with prolonged MAD therapy.~This intervention is distinct from the alternative study arm, which uses a set of guided jaw exercises instead of a physical appliance to achieve the same goal.~The AM Aligner used in this study is a standard-of-care option and is FDA-cleared for this use. It is not investigational."
224293517|NCT07103941|BEHAVIORAL|Exercise|"Participants in this arm will perform a standardized set of jaw exercises for 5 minutes each morning immediately after removing their Mandibular Advancement Device (MAD). The exercises are intended to assist in reestablishing the natural occlusal relationship following overnight mandibular advancement.~This routine includes the following movements:~Side-to-side jaw movements Backward pressure to the chin (similar to a thinker's pose) Gentle simulated clenching~The exercises are performed once daily and take approximately 2-3 minutes to complete. This approach represents a standard-of-care method for minimizing occlusal changes associated with MAD therapy."
223726040|NCT05513079|BEHAVIORAL|Positive Psychotherapy Based Counseling|The main purpose in Positive Psychotherapy is to develop the individual's main capacities. and to maintain balance in the four areas of life (body, success, relationships and future) in daily life. to help provide. The essence of Positive Psychotherapy is a five-step process: 1. Observation/distance phase, 2. Inventory phase, 3. Situational encouragement phase, 4. Verbalization phase, 5. Expanding the objectives phase. Shaping five-step model therapy It is a helpful guide.
223726041|NCT03181087|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
223726042|NCT00869206|DRUG|zoledronic acid|Given IV
223726043|NCT04376372|DIAGNOSTIC_TEST|Functional testing, Magnetic resonance imaging, Electromyography|Electromyography only for cases (F-Lefthanders), not for controls (TD-lefthanders)
223976842|NCT02360813|BEHAVIORAL|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
223976843|NCT02360813|OTHER|Treatment as usual|Keep getting usual care.
223976844|NCT00264823|BEHAVIORAL|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
224293518|NCT06531499|DRUG|AAA617|\[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.
224293519|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) analogues|Anatomical Therapeutic Chemical \[ATC\] code L02AE
223976845|NCT02638233|DRUG|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
223726044|NCT01781403|DRUG|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
223726045|NCT00546845|DEVICE|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
223976846|NCT05925062|BEHAVIORAL|QActual|QActual is a phone-based app that offers peer-to-peer support, tracks mental wellness self-assessments, and provides support to users who are in crisis.
223976847|NCT04777097|OTHER|Blood sample|Two blood sample will be drawn. On the day of operation and the first postoperative day.
224293520|NCT06531499|DRUG|Gonadotropin-releasing hormone (GnRH) antagonists|Degarelix, Relugolix
223976848|NCT04885426|DRUG|low-dose metformin|Metformin Pill 250mg/day
223976849|NCT04885426|DRUG|high-dose metformin|Metformin Pill 500mg/day
223976850|NCT04885426|DRUG|Placebo|Placebo
223976851|NCT01540812|DRUG|Vincristine in induction|
224117296|NCT02226094|DEVICE|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
223976852|NCT01540812|DRUG|Daunorubicin in induction|
223976853|NCT01540812|DRUG|Prednisone in induction|
223976854|NCT01540812|DRUG|Metotrexato in induction|
223976855|NCT01540812|DRUG|Cytarabine in induction|
223726046|NCT00546845|DEVICE|Use of self-expanding Expert stent|Nitinol stent
223726047|NCT04106986|COMBINATION_PRODUCT|Pulsed electromagnetic field and Progressives resistance exercise|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
224117297|NCT02226094|DEVICE|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
224117298|NCT02226094|DEVICE|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
224117299|NCT02226094|DEVICE|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
224117300|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
224117301|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
223976856|NCT01540812|DRUG|Hydrocortisone in induction|
224117302|NCT02391623|DRUG|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
224117303|NCT02391623|DRUG|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
223976857|NCT01540812|DRUG|Idarubicin in induction-2|
223976858|NCT01540812|DRUG|Fludarabine in induction-2|
223976859|NCT01540812|DRUG|Ara-C in induction-2|
223976860|NCT01540812|DRUG|G-CSF in induction-2|
223976861|NCT01540812|DRUG|Dexamethasone in consolidation-1|
223976862|NCT01540812|DRUG|Vincristrine in consolidation-1|
223976863|NCT01540812|DRUG|Metotrexato in consolidation-1|
223976864|NCT01540812|DRUG|PEG-ASP in consolidation-1|
223976865|NCT01540812|DRUG|Dexamethasone in consolidation-2|
223976866|NCT01540812|DRUG|ARA-C in consolidation-2|
223976867|NCT01540812|DRUG|PEG-ASP in consolidation-2|
223976868|NCT01540812|DRUG|Dexamethasone in consolidation-3|
223976869|NCT01540812|DRUG|Vincristine in consolidation-3|
223976870|NCT01540812|DRUG|Metotrexato in consolidation-3|
223976871|NCT01540812|DRUG|PEG-ASP in consolidation-3|
223976872|NCT01540812|PROCEDURE|allogeneic HSCT|
223976873|NCT01540812|PROCEDURE|Allo HSCT with reduced-intensity conditioning|
224117304|NCT03813563|DRUG|RL|lactated Ringer's
224117305|NCT03813563|DRUG|PLA|PlasmaLyte
224117306|NCT02786355|OTHER|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
224293521|NCT06919016|BIOLOGICAL|DV700P-RNA|Intramuscular (IM) injection
223726048|NCT04106986|OTHER|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
223726049|NCT01349790|DRUG|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
223726050|NCT00002942|PROCEDURE|autologous bone marrow transplantation|
223726051|NCT00002942|PROCEDURE|peripheral blood stem cell transplantation|
223726052|NCT01250405|DRUG|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
223726053|NCT01250405|DRUG|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
223976874|NCT05727488|OTHER|Exercise|Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
223976875|NCT05640973|OTHER|Evaluation|Evaluation of ease of use
223726054|NCT06299033|DRUG|hNPC01|hNPC01, human forebrain neural progenitor cell product, intracerebral injection
223976876|NCT00246610|DRUG|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
224117307|NCT05015400|OTHER|Plain Water|To increase water fluid intake, an additional 1.89 L, during phase 1 of the menstrual cycle (days 1-5).
224117308|NCT00023985|BIOLOGICAL|autologous tumor cell vaccine|
224117309|NCT00023985|BIOLOGICAL|therapeutic autologous dendritic cells|
224117310|NCT00023985|PROCEDURE|conventional surgery|
224117311|NCT01792622|OTHER|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
223976877|NCT06252090|OTHER|Short term mentalization-based treatment for adolescents (MBT-A)|The general framework of intervention corresponds to the Mentalization-Based Treatment model for adolescents (MBT-A). In this study, the model was adapted to a brief, time-limited format (12 sessions) aimed at both the adolescent and their family. The model retains the main characteristics of Mentalization-Based Therapy, such as the therapist's basic attitude toward actively promoting patients' mentalization, uncertainty of mental states, focus on the here and now, and the use of affect as a mechanism for change.
223976878|NCT03021278|OTHER|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
223976879|NCT03021278|OTHER|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
223976880|NCT00456417|DRUG|123-I MNI-187 Injection and Imaging Procedures|
223976881|NCT01510132|DRUG|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
223976882|NCT01040923|DEVICE|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
223976883|NCT01792778|DEVICE|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
223976884|NCT01792778|DEVICE|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
223976885|NCT00136682|DRUG|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
223976886|NCT00136682|DRUG|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
223976887|NCT02970305|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
223976888|NCT02970305|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
223976889|NCT00006005|DRUG|thalidomide|
223976890|NCT00983892|BEHAVIORAL|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
223976891|NCT04338347|BIOLOGICAL|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Extracellular Vesicles (EVs) from Cardiosphere-Derived Cells (CDCs)
224293522|NCT06919016|BIOLOGICAL|DV701B1.1-RNA|IM injection
223976892|NCT02894905|DRUG|AL-335|Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
224293523|NCT07114510|OTHER|OPTI-VENT Bundle|"Provider Education: During a brief (\<2 minute) bedside education, the educator will 1) review the CPR ventilation rate targets for age, and 2) ensure the provider has a cue card of current rate recommendations on his/her person. Compliance will be defined as performance of at least 30 trainings per unit per month. We will record provider discipline and time since last training as a surrogate of training spread. Educators will leverage these two-minute trainings to review the patient's current ventilator settings as an initial target during CPR to ensure adequate chest rise.~Additionally, a focus on CPR ventilation rates will be integrated into resuscitation education or quality meetings for all disciplines. Report cards detailing unit-level performance will be generated by the study team for review during site monthly presentations.~Point-of-Care Guidance: A metronome will be deployed to all cardiac arrests using a smart phone application."
223976893|NCT02968121|DRUG|Brexpiprazole, OPDC-34712|
223976894|NCT04124016|DIETARY_SUPPLEMENT|Inulin|Powder of inulin fractions dissolved into 250 ml of water
223976895|NCT04124016|DIETARY_SUPPLEMENT|green tea extract|Powder of green tea extract dissolved into 200 ml of water
223976896|NCT04124016|DIETARY_SUPPLEMENT|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
223976897|NCT04124016|DIETARY_SUPPLEMENT|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
224293524|NCT07114510|OTHER|Transition|There will be a 2-month transition period for study sites beginning study enrollment using standard ICU practices as they onboard to the study intervention.
224293525|NCT07114510|OTHER|None - control|Control - no intervention
224293526|NCT07117162|OTHER|ADRD Care Delivery Protocol|1\. Included in arm/group descriptions
224293527|NCT06923527|DRUG|Elacestrant|"Administration of elacestrant will follow the FDA approved dose and schedule for patients with ER+ metastatic breast cancer. Elacestrant 345 mg will be administered orally once daily for 12 cycles or until disease progression or unacceptable toxicity. The pills shall be administered with food (to reduce nausea and vomiting) at approximately the same time each day, and the prescription will be provided with the standard Swallow tablets whole; do not chew, crush, or split warning label."
224293528|NCT03704662|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224293529|NCT03704662|RADIATION|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
224293530|NCT07134777|DIAGNOSTIC_TEST|MRI|Functional MRI scan
224293532|NCT07141914|OTHER|No treatment given|No treatment given
224293533|NCT07141914|OTHER|No treatment given|No treatment given
223976898|NCT02582034|RADIATION|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve \> 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
224293534|NCT06935357|DRUG|Felzartamab|Administered IV
224293535|NCT06935357|DRUG|Placebo|Administered IV
224293536|NCT06508463|PROCEDURE|Biopsy|Undergo tumor biopsy
224293537|NCT06508463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293538|NCT06508463|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224293539|NCT06508463|PROCEDURE|Computed Tomography|Undergo SPECT/CT
224293540|NCT06508463|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224293541|NCT06508463|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Given IV
224293542|NCT06508463|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
224293543|NCT06508463|BIOLOGICAL|Cemiplimab|Given IV
224293544|NCT06508463|BIOLOGICAL|Ipilimumab|Given IV
224293545|NCT03900845|DEVICE|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
223726055|NCT06071091|DEVICE|Intracranial stenting|"In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible.~Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication."
223976899|NCT02582034|RADIATION|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments."
223726056|NCT06071091|OTHER|Optimal medical care, without additional endovascular procedures|"The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts.~In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion.~The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list):~* Nursing~* Nursing care~* Symptomatic treatments: analgesics for example~* Systematic clinical monitoring and control imaging if necessary~* Rehabilitation if necessary)"
223976900|NCT03120949|DRUG|Olokizumab 64 mg SC q4w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS).PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
223976901|NCT03120949|DRUG|Olokizumab 64 mg SC q2w|160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial with target volume of 0.4 mL or in the pre-filled syringe (PFS). PFS is composed of a 1 mL clear Type I glass barrel vial with target volume of 0.4 mL.
223726057|NCT05321732|DRUG|DWP16001|DWP16001 A mg
223726058|NCT05321732|DRUG|DWP202010|DWP202010 B mg
223726059|NCT03290898|BEHAVIORAL|High Intensity Interval Training|Training (HIIT)
223726060|NCT04813445|DRUG|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
223726061|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
223726062|NCT00885105|BIOLOGICAL|Influenza Virus Vaccine|0.25 mL, Intramuscular
223976902|NCT03120949|DRUG|Concomitant treatment|"Methotrexate 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses). (Subject maintained their stable dose and route (oral, SC, or IM) during the core study and for ≥ 12 additional weeks of OLE.)~Folic acid ≥ 5 mg per week or equivalent"
223976903|NCT03466229|DIETARY_SUPPLEMENT|Androferti|
223976904|NCT03466229|DIETARY_SUPPLEMENT|Placebo|
223976905|NCT04522778|DEVICE|Wearable Central Line Securement Device (Vest)|The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.
224117312|NCT01792622|OTHER|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
224117313|NCT02183025|DRUG|Meloxicam 7.5 mg|
224117314|NCT02183025|DRUG|Meloxicam 15 mg|
223726063|NCT05792891|OTHER|Collecting biological material from frail patients, with or without COVID-19|The study planned to collect demographic information, disease history, COVID-19 symptomatology, COVID-19 molecular test details, COVID-19 serological test results, and biobanking of biological specimens (PBMCs, sera, plasma). In addition, clinical analyses, anamnestic data, and pharmacological treatment pieces of information were collected.
223726064|NCT05714813|BEHAVIORAL|High-Speed Circuit Resistance Training|Performance of 24 weeks of high-speed concentric and low-speed eccentric lift across three circuits on eleven pneumatic machines. Each training session will be in person and will last between 45 minutes and one hour.
224117315|NCT02183025|DRUG|Mefenamic acid 500 mg|
224117316|NCT02183025|DRUG|Placebo matching 7.5 mg meloxicam|
224117317|NCT02183025|DRUG|Placebo matching 15 mg meloxicam|
224117318|NCT02183025|DRUG|Placebo matching 500 mg mefenamic acid|
224117319|NCT03140800|DEVICE|intrauterine device|a method of contraception inserted in the uterus
223976906|NCT04522778|OTHER|Traditional Securement Dressing|All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
223976907|NCT02824497|OTHER|No intervention. It's a description study|
223976908|NCT00688077|DRUG|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
224293546|NCT03900845|DEVICE|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (\~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
223726065|NCT05714813|BEHAVIORAL|Lecture on Diet, Exercise and Cognition|Lectures on diet, exercise, and cognition. Lectures will be provided in person or online and will last approximately one hour.
223976909|NCT00688077|DRUG|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
223976910|NCT02920021|DRUG|Etokimab|Humanized monoclonal antibody, administered by intravenous infusion
223976911|NCT02920021|DRUG|Placebo|Administered by intravenous infusion
223976912|NCT03127878|OTHER|Exercise|
223976913|NCT01225159|DRUG|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
223976914|NCT01225159|DRUG|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
223976915|NCT02010398|OTHER|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
223976916|NCT02010398|OTHER|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
223976917|NCT02010398|OTHER|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
223976918|NCT02996318|DEVICE|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
223976919|NCT02996318|DEVICE|Sirolimus coated balloon|Sirolimus coated balloon
223976920|NCT00316498|DRUG|OGT918|
223976921|NCT04786756|DRUG|Bupivacaine 0.25% Injectable Solution|1 mg/kg Bupivacaine (0.25%)
223976922|NCT04001998|DRUG|BLD-2660|Randomized to active product
223976923|NCT03974698|PROCEDURE|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
223726066|NCT03519932|DEVICE|comfilcon A toric lens|Contact lens
223726067|NCT03519932|DEVICE|samfilcon A toric lens|Contact lens
223726068|NCT04745429|OTHER|breathing exercises, cold exposure and meditation|It is a combination of exercises that include breathing exercises, cold exposure and meditation
223976924|NCT03010345|DEVICE|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
223976925|NCT03010345|OTHER|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
223976926|NCT02927652|OTHER|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
223976927|NCT04257942|PROCEDURE|carotid endarterectomy|carotid endarterctomy that is being used for carotid stenosis disease
223976928|NCT03630965|OTHER|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
223976929|NCT05400226|DRUG|VGT-309|VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.
223976930|NCT00930683|DRUG|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
223976931|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
223976932|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
223976933|NCT00930683|DRUG|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
223976934|NCT00930683|DRUG|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
223976935|NCT00930683|DRUG|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
223976936|NCT00930683|DRUG|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
223976937|NCT00930683|DRUG|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
223976938|NCT00930683|DRUG|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
223976939|NCT01145547|DEVICE|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
223976940|NCT04410354|DRUG|Merimepodib|400 mg (total daily dose of 1200 mg) for 10 days
223543439|NCT06364397|PROCEDURE|ERCP|Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.
223976941|NCT04410354|DRUG|Matching Placebo|0 mg (total daily dose of 0 mg) for 10 days
224293547|NCT03900845|DEVICE|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
223543440|NCT06364397|COMBINATION_PRODUCT|Health education and conservative management of clinical routines|Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
223976942|NCT04410354|DRUG|Remdesivir|200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
223976943|NCT05971017|DIETARY_SUPPLEMENT|Control Group|Lettuce without any biostimulation was assigned to each participant belonging to the control group which ate 100gr every day for 15 days
224117320|NCT01321996|PROCEDURE|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
224117321|NCT02273154|DRUG|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
223976944|NCT05971017|DIETARY_SUPPLEMENT|Biostimulated group|Intervention biostimulated group 100gr of biostimulated lettuce were assigned to each participant belonging to the intervention group which ate 100 grams every day for a total of 15 days
223976945|NCT05011617|DEVICE|Non-intubation and monitoring anesthesia care (MAC)|Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
224117322|NCT02273154|DRUG|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
224117323|NCT01449019|DRUG|exendin(9-39)amide|intravenous infusion of exendin(9-39)
224117324|NCT01449019|DRUG|saline|intravenous infusion of saline
224117325|NCT01449019|OTHER|duodenal meal|duodenal perfusion of a meal
224117326|NCT01449019|OTHER|duodenal saline|duodenal perfusion of saline
224117327|NCT04730986|BEHAVIORAL|ED GOAL Nursing|A brief (\<7minutes) interview by an emergency department nurse to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
224117328|NCT00200278|BEHAVIORAL|PROJECT STRIDE|
224293548|NCT06951711|DRUG|KarXT|Specified dose on specified days
224293549|NCT06951711|OTHER|Placebo|Specified dose on specified days
223976946|NCT00312845|DRUG|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
223976947|NCT00312845|DRUG|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
223976948|NCT05509283|BEHAVIORAL|Risk Reduction|Letter, patient portal, SMS and/or another modality
223543441|NCT05834985|PROCEDURE|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches|endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
223543442|NCT00442416|DRUG|Epoetin alfa|As prescribed, SC
223976949|NCT02659384|DRUG|Bevacizumab|
223976950|NCT02659384|DRUG|atezolizumab|
223976951|NCT02659384|DRUG|acetylsalicylic acid|
223976952|NCT02659384|DRUG|placebo|
223976953|NCT04345783|DRUG|Camrelizumab for injection, apatinib mesylate and tegio|Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
223976954|NCT01770314|BEHAVIORAL|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
223543443|NCT00442416|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
223543444|NCT03184883|PROCEDURE|single conventional denture|mandibular conventional denture with soft liner
223543445|NCT03184883|PROCEDURE|single flexible denture|mandibular flexible compete denture
223976955|NCT00453934|DEVICE|h-Patch|
223976956|NCT06129045|BEHAVIORAL|One-time educational video|Sleep hygiene educational tips provided through a video participants watch on their own.
224117329|NCT04412954|BEHAVIORAL|Smartphone + Text Messaging with Health Coach|The program includes (1) use of a free commercially available smartphone application program for 12 months, (2) a wearable Fitbit Charge device that will be provided by the study to monitor active minutes, and (3) one 45-minute behavioral counseling session focused on healthy eating and exercise and (4) personalized text messaging for 6 months by a health coach. The health coach will not send feedback during months 6-12. The intervention will be fully self-directed in these months, as there will be no contact between the 6 months visit and 12-month visit.
224117330|NCT00848692|DRUG|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
224117331|NCT00848692|DRUG|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
224117332|NCT02405052|OTHER|No intervention|Validation of the Panic Screening Score
224117333|NCT03238144|OTHER|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
224117334|NCT06373081|BIOLOGICAL|Anti-CD19-CD3E-CAR-T cells|The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.
224117335|NCT01142219|DRUG|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
224117336|NCT01142219|DRUG|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
224117337|NCT03235570|DRUG|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
224117338|NCT01615224|DRUG|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
224117339|NCT02214186|OTHER|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
223976957|NCT06129045|BEHAVIORAL|Educational video plus repeated education|Sleep hygiene educational tips are provided first through a video participants watch on their own and then tips are repeated through daily automated text messaging for an additional 4 weeks.
223976958|NCT02091297|DRUG|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
223976959|NCT02091297|DRUG|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
223976960|NCT02091297|DRUG|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
223976961|NCT02091297|DRUG|Morphine|
224117340|NCT04554849|OTHER|Gender dysphoria psychosocial health|Retrospective analysis of medical records
224117341|NCT05870644|OTHER|Cycling exercise in room temperature at 25 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 25 degree Celsius.
224117342|NCT05870644|OTHER|Cycling exercise in room temperature at 34 degree Celsius.|The participants received a aerobic exercise of cycling for 60 minutes in room temperature at 34 degree Celsius.
224117343|NCT01525849|DEVICE|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
224117344|NCT01525849|PROCEDURE|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
224117345|NCT03868007|DEVICE|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
224117346|NCT03868007|DEVICE|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
224117347|NCT02754934|OTHER|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
223543446|NCT00932074|DRUG|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
223543447|NCT02154165|OTHER|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
223543448|NCT01705340|DRUG|Akt inhibitor MK2206|Given PO
223543449|NCT01705340|BIOLOGICAL|trastuzumab|Given IV
223543450|NCT01705340|DRUG|lapatinib ditosylate|Given PO
223543451|NCT01705340|OTHER|laboratory biomarker analysis|Optional correlative studies
223543452|NCT00087698|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
223543453|NCT00087698|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
223543454|NCT05753514|OTHER|ESWT|ESWT
223543455|NCT02357199|OTHER|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
223543456|NCT03139032|DRUG|APD334|APD334 active treatment for 12 weeks.
223543457|NCT03411018|OTHER|Mechanical ventilation exposure|
223543458|NCT01233024|DIETARY_SUPPLEMENT|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
223543459|NCT01233024|DIETARY_SUPPLEMENT|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
223543460|NCT01233024|DIETARY_SUPPLEMENT|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
223543461|NCT01233024|DIETARY_SUPPLEMENT|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
223543462|NCT01233024|DIETARY_SUPPLEMENT|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
223543463|NCT06440603|DIAGNOSTIC_TEST|PCR|"Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System"
223726069|NCT01658891|DRUG|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
223726070|NCT01658891|DRUG|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
223726071|NCT03099421|PROCEDURE|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
223726072|NCT02254486|DRUG|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
223726073|NCT02254486|DRUG|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
223726074|NCT01612481|PROCEDURE|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
223726075|NCT01612481|PROCEDURE|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
223726076|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 D contains 400 mg of ESIT12
224117348|NCT05631015|OTHER|AI recongnize disease and generate recommendations|According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.
224117349|NCT06250127|DEVICE|Modified 3D printed facemask|modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
224117350|NCT06250127|DEVICE|Conventional facemask appliance|Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
223976962|NCT03582150|DEVICE|Remote Monitoring with Ambulatory Detox|"* Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~* Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~* Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~* Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~* If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~* The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
223976963|NCT06646718|PROCEDURE|Close kinetic chain exercise group|●Close kinetic chain exercise group: group A will receive forward step-ups, lateral step-ups, squats, sit-to-stand, and stoop-and-recover exercises. session will be initiated with a 10 min warm-up period, including stretching of the major muscles and muscle groups, then 40 min different exercises and terminated with a 10 min cool-down period in the form of aerobic exercises.
223976964|NCT06646718|PROCEDURE|Traditional physical therapy.|●Traditional physiotherapy: group B will receive stretching for the lower extremity muscles, namely hip flexors and adductors, hamstrings, and calf muscles; and strengthening exercises for core muscles, hip extensors, flexors and abductors, internal and external rotators of the hip, flexors and extensors of the knee, ankle dorsi flexors, kneeling exercises, and standing and gait training
223976965|NCT06646770|PROCEDURE|Segmentectomy|Pulmonary anatomic segmentectomy with mediastinal nodal dissection via VATS, RATS or open approach.
223976966|NCT06646770|PROCEDURE|Lobectomy|Pulmonary lobectomy with mediastinal nodal dissection via VATS, RATS or open approach.
223976967|NCT06646497|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow|"1. Conditioning regimen Thymoglobulin (0.5/mg/kg à D-9, 2 mg /kg at D-8 and 2.5 mg/kg à D-7), Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant, Cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day -1).~2. Stem cell source Bone Marrow only. Target of 4 × 10\^8 nucleated cells/kg recipient body weight. Granulocyte colony stimulating factor is given subcutaneously starting on day +5 at 5 mg/ kg/day until the absolute neutrophil count is greater than 1.5 × 10\^9/L for 3 days.~3. GVHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4. Tacrolimus (0,2 à 0,3 mg/kg/day per os divided into 2 doses or 0.05 to 0.1 mg/kg/d IVSE) and mycophenolate (MMF) will begin from D+5. In absence of GvHD, MMF will be stopped between D35 and D45 and Tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT (except patients and their donor with EBV serology and EBV PCR negative)."
223976968|NCT04155333|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
223976969|NCT05950776|BIOLOGICAL|MVA-SARS-2-S|Vaccination with MVA-SARS-2-S
223976970|NCT05950776|OTHER|Placebo|Placebo
223976971|NCT03581253|OTHER|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
223976972|NCT03581253|OTHER|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
223976973|NCT03512288|BIOLOGICAL|Multivalent|Pneumococcal conjugate vaccine
223976974|NCT03512288|BIOLOGICAL|13vPnC|Pneumococcal conjugate vaccine
223726077|NCT06062511|DIETARY_SUPPLEMENT|ESIT12 4D|ESIT12 is a poplar-type propolis powder extract containing phenolic compounds from flavonoids and phenolic acids family. ESIT12 4D contains 1600 mg of ESIT12
223726078|NCT06062511|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of the carriers of ESIT12 : arabic gum, sucrose and silicon dioxide mix
223726079|NCT00468182|DRUG|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
223726080|NCT01911871|BIOLOGICAL|Blood sample|a blood sample was taken on the day of inclusion
223726081|NCT02263989|DRUG|Telmisartan film coated tablet|
223726082|NCT02263989|DRUG|Telmisartan conventional tablet|
223726083|NCT01350414|DEVICE|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
223976975|NCT00601471|OTHER|proximal tibiofibular manipulation|proximal tibiofibular manipulation
223976976|NCT00601471|OTHER|distal tibiofibular manipulation|distal tibiofibular manipulation
223976977|NCT00601471|OTHER|no intervention|no intervention / control
223976978|NCT02946827|DIETARY_SUPPLEMENT|Balanced low FODMAPs /gluten free diet|
223976979|NCT02946827|DIETARY_SUPPLEMENT|Balanced gluten free diet|
223976980|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram on visit 5 single dose
223976981|NCT01257048|DRUG|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
223976982|NCT01257048|DRUG|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
224117351|NCT02353351|DEVICE|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
224117352|NCT00339183|DRUG|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
224117353|NCT00339183|DRUG|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m\^2, leucovorin 400 mg/m\^2 racemate (or 200 mg/m\^2 I-leucovorin), 5-FU bolus 400 mg/m\^2, 5-FU infusion 2400 mg/m\^2.
224117354|NCT00793819|DRUG|silodosin|α1-adrenergic antagonist
223976983|NCT03953378|OTHER|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
224117355|NCT00004880|BIOLOGICAL|dendritic cell vaccine therapy|
224117356|NCT00004880|PROCEDURE|conventional surgery|
224117357|NCT02446054|DIETARY_SUPPLEMENT|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
224117358|NCT00078962|BIOLOGICAL|GTI-2040|Given IV
224117359|NCT00078962|DRUG|gemcitabine hydrochloride|Given IV
223726084|NCT01177592|DEVICE|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19\*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
223726085|NCT01247740|DRUG|NuTRIflex Lipid peri|parenteral nutrition
224117360|NCT00078962|OTHER|laboratory biomarker analysis|Correlative studies
223726086|NCT01247740|DRUG|compounded monobag|parenteral nutrition
223726087|NCT01374620|DRUG|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90"
223726088|NCT01374620|DRUG|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
223726089|NCT01374620|DRUG|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
224117361|NCT00078962|OTHER|pharmacological study|Correlative studies
224117362|NCT03407924|OTHER|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
224117363|NCT03407924|OTHER|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
224117364|NCT00446446|DRUG|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
224117365|NCT05944991|OTHER|Olive oil message|Message of olive oil 2 times daily
224117366|NCT04520022|DRUG|Human Umbilical Cord Blood-derived Mesenchymal Stem Cells|3.0 x 106 cells/kg, IV, Total of 3 doses every 2weeks
224117367|NCT00639301|BEHAVIORAL|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
223726090|NCT01374620|BIOLOGICAL|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
223726091|NCT01445561|DRUG|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
223543464|NCT03491033|DRUG|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
223726092|NCT03795987|DEVICE|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
223543465|NCT04970069|OTHER|Video on analgesic education|A four minute video informing the patient about opioids.
223543466|NCT04970069|OTHER|Video on general perioperative education|A four minute video informing the patient about general perioperative process.
223543467|NCT01484457|DEVICE|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose \< 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
223726093|NCT02333877|OTHER|Skinlink|suture using Skinlink
223726094|NCT02333877|OTHER|Nylon|conventional suture using nylon
223726095|NCT03116893|DRUG|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
223976984|NCT00688051|OTHER|My Life with CF game|Play the game My Life with CF
223976985|NCT03910296|BEHAVIORAL|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
224117368|NCT02997020|OTHER|EDSPD|The equipment \& conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
223543468|NCT06406244|DEVICE|TEAS group|Transcutaneous electrical acupoint stimulation (TEAS) is a contemporary modification of traditional acupuncture that sends electrical impulses into acupoints through electrodes on the skin surface. In the TEAS group, patients will receive TEAS 30 min before anesthesia until be discharged from the post-anaesthesia care unit (PACU). The same treatment will be performed on the 1st, 2nd and 3rd days after surgery. The stimulation intensity will be adjusted in accordance with the maximal level tolerated by each patient.
223543469|NCT06406244|DEVICE|sham group|Patients in the sham group will receive electrode attachment but without stimulation.
223543470|NCT04750863|OTHER|diagnosis criteria performance|
223543471|NCT01992224|OTHER|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate \> 28 per minute serum lactate \> 3 mmol/L PaO2/FiO2 Index \<300 mmHg SvO2 \< 65% lung infiltration or atelectasis, pleural exudation"
223543472|NCT01992224|OTHER|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate \> 28 bpm dyspnea PaO2/FiO2 Index \<200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
223976986|NCT05317299|OTHER|3 different type of exercise|Group 1: Resistance Exercise Group 2: Plyometric Exercise Group 3: Hight Intensity Interval Training
223976987|NCT02108418|DRUG|TG-2349 as the original formulation|single oral dose under fed condition
223976988|NCT02108418|DRUG|TG-2349 as a new capsule formulation|single oral dose under fed condition
223976989|NCT02274519|OTHER|Tai Chi|Arm 1
223976990|NCT02274519|OTHER|Education|Arm 2
223976991|NCT00148616|DRUG|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
223976992|NCT00148616|DRUG|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
223976993|NCT06369883|DIAGNOSTIC_TEST|Spine radiography|Posterior-anterior and lateral spine radiography
223976994|NCT02145195|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
223976995|NCT00866502|DRUG|sNN0031|Continuous ICV infusion for two weeks
223976996|NCT00866502|DRUG|Placebo|Continous ICV infusion
223976997|NCT05218421|DIAGNOSTIC_TEST|Carotid ultrasound|Carotid ultrasound with flow and elastography (strain and shear wave) measurements will be performed maximally 2 weeks prior to the CEA. Ultrasound-based flow imaging will be repeated six weeks after the CEA to assess the hemodynamic consequences of the CEA procedure.
223976998|NCT05218421|OTHER|Biospecimen collection and examination|The plaque excised during CEA will be histologically examined to assess the plaque composition, and therefore plaque vulnerability.
223543473|NCT04550897|DRUG|BM7PE|BM7PE immunotoxin is supplied as a liquid solution and is diluted in 0.9% saline to a total volume of 250 ml.
223976999|NCT05218421|OTHER|Blood sample collection|In the first 20 included patients in the Radboudumc, a 10 mL blood sample will be collected during surgery via the arterial line that is applied for regular care.
223977000|NCT03726983|OTHER|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
224293550|NCT07148973|PROCEDURE|Transcatheter Aortic Valve Replacement|The TAVR surgery mainly involves attaching an artificially-made aortic valve to a special catheter, and then using the catheter to deliver the valve to the affected area and release it. This surgery replaces the original aortic valve with an artificial one, thereby restoring the valve function. Compared with traditional open-chest surgery, it causes less trauma, has lower risks, and enables faster recovery. It is particularly suitable for patients who cannot tolerate open-chest surgery, have poor cardiac function, or are older.
223977001|NCT01355471|DRUG|CD07805/47 Gel|applied topically once daily
223977002|NCT01355471|DRUG|Placebo|applied topically once daily
223977003|NCT02345707|DRUG|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
224293551|NCT07148206|DRUG|Dronabinol Capsules|Dronabinol is a synthetic form of THC. Dronabinol is eliminated in a biphasic manner, with an initial half-life of 25-36 hours.
224293552|NCT07148206|DRUG|Epidiolex 100 mg/mL Oral Solution|Epidiolex is an oral solution (100 mg/mL) which rapidly appears in plasma, reaches peak plasma concentration in 3-4 hours and has a half-life of 18-32 hours.
223977004|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
223977005|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
223977006|NCT02345707|DRUG|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
223977007|NCT02345707|DRUG|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
223977008|NCT01102387|DRUG|LAS41003|Once daily, topically
223977009|NCT01102387|DRUG|LAS189962|Once daily, topically
224293553|NCT07148206|OTHER|Placebo Dronabinol|Placebo capsules
224293554|NCT07148206|OTHER|Placebo Epidiolex|Placebo oral solution
224293555|NCT07155213|BEHAVIORAL|Virtual reality exergaming|High-intensity active video gaming using head-mounted display.
223977010|NCT01102387|DRUG|LAS189961|Once daily, topically
223977011|NCT01594697|DRUG|Metformin|
223977012|NCT01208870|BEHAVIORAL|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
223977013|NCT01208870|BEHAVIORAL|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
223977014|NCT05402618|OTHER|No intervention|This is an observational study without any intervention.
223977015|NCT01086878|DRUG|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
223977016|NCT01133925|DEVICE|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
224117369|NCT03454139|PROCEDURE|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
224117370|NCT00153634|DRUG|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
224117371|NCT00153634|DRUG|PO azithromycin|250 mg once daily
224117372|NCT00153634|DRUG|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
224117373|NCT00153634|DRUG|PO ciprofloxacin|500 mg every 12 hours if weight \<50 kg 750 mg every 12 hours if weight ≥50 kg
224117374|NCT00153634|DRUG|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
224117375|NCT00153634|DRUG|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
224117376|NCT00153634|DRUG|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
224117377|NCT00153634|DRUG|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
224293556|NCT07164131|DRUG|Doxycycline|Subjects will receive Doxycycline (orally or intravenously) in combination with beta-lactam therapy within 12 hours of hospital admission. Treatment duration will be 5-7 days.
224293557|NCT07164131|DRUG|Azithromycin|Subjects will receive Azithromycin (orally or intravenously) in combination with beta-lactam therapy within 12 hours of hospital admission. Treatment duration will be 5-7 days.
224293558|NCT07161700|DRUG|SPT-300|A prodrug of allopregnanolone, a small molecule drug
224293559|NCT07167875|BEHAVIORAL|Personalized Digital Oral Health Coaching|All participants will use an electronic toothbrush and mobile app to record brushing behavior throughout the study. However, only the intervention arm will receive personalized digital coaching through the Oralytics app, including tailored feedback, educational messages, and motivational prompts.
223977017|NCT01133925|DEVICE|Sirolimus Eluting Stent|Cypher stents implanted in overlap
223543474|NCT02578160|PROCEDURE|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
223977018|NCT01133925|DEVICE|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
223977019|NCT01133925|DEVICE|Zotarolimus eluting stent|Endeavor stents implanted in overlap
223977020|NCT01123512|DEVICE|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
223543475|NCT04190823|DRUG|RC98|Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.
223977021|NCT06028399|OTHER|Concurrent Training|The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise \& toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.
223977022|NCT06028399|OTHER|Aerobic Training|The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
224117378|NCT00611130|DRUG|vigabatrin|Tablets twice a day for 9 weeks
223977023|NCT06034964|DRUG|Tislelizumab|Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity
223977024|NCT04022603|DEVICE|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
223977025|NCT06479252|OTHER|Sit-to-Stand Test (STS)|The 30-s and 1-min STS tests are reliable, valid, and responsive tests for measuring functional exercise capacity in patients with lung disease. For the STS tests that are centre-based or supervised remotely, investigators will collect the total number of repetitions on the 30-s and 1-min STS tests, as well as the number and duration of rests within and between tests.
224293560|NCT07164209|PROCEDURE|"Excision of the mesentery: the mesentery is fully dissected and excised to the limit of macroscopic fat wrapping, where mesenteric fat is inflamed and extends beyond its normal anatomical distribut"|The resection of mesentery could take off the inflammatory tissue who may increase the risk of anastomotic recurrence The Kono anastomosis achieves a column of support (made with the bowel ) located immediately behind the posterior wall of the anastomosis providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lumen of the anastomosis being a barrier between anastomosis and mesentery
224293561|NCT07164209|PROCEDURE|Kono S Anastomosis|ono-S anastomosis: the mesentery is not removed but cutted close to the bowel. The bowel is then divided transversely by placing a linear stapler perpendicular to the intestinal lumen and the mesentery. The corners of the two staple lines are reinforced and the two stumps are approximated using 5-7 sutures to create the column. If the caliber of the two intestinal segments differs significantly, the sutures should be spaced to evenly distribute the surplus tissue of the larger segment, in order to achieve good approximation and stable support for the anastomosis. To create the anastomosis, an antimesenteric longitudinal enterotomy (or colostomy) is performed on each stump to allow a transverse lumen of 7 cm in diameter for the small bowel or closer to 8 cm for the colon. In this way the supporting column is located immediately behind the posterior wall of the anastomosis providing a rigid and stable support to prevent mechanical deformation and functional constriction of the lum
224293562|NCT07174856|DRUG|Misoprostol-only medication abortion regimen|This intervention is an updated misoprostol-only regimen that involves being counseled on and receiving medications for a medication abortion using 3-4 doses of 800μg misoprostol administered sublingually every 3 hours.
223977026|NCT05645809|DEVICE|MONOFIX® PGCL|An absorbable suture made of polyglycapron (PGCL) used for soft tissue suture.
223977027|NCT05645809|DEVICE|Quill Monoderm™|An absorbable suture made of polyglactin used for soft tissue suture.
223977028|NCT00816153|OTHER|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
223977029|NCT04976283|DRUG|Pioglitazone|Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.
223977030|NCT04976283|DRUG|Empagliflozin|Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.
223543476|NCT02074943|BIOLOGICAL|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
223726096|NCT03116893|DRUG|Itraconazole|Administration of itraconazole together with BI 685509
223726097|NCT03116893|DRUG|Rifampin|Administration of rifampicin together with BI 685509
223977031|NCT04976283|DRUG|Pioglitazone + Empagliflozin|Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).
223977032|NCT00402636|DEVICE|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
223977033|NCT00402636|DEVICE|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
223977034|NCT05787171|DEVICE|WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
223977035|NCT05787171|DEVICE|WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
224117379|NCT00611130|DRUG|placebo|tablets twice daily for 9 weeks
224117380|NCT03195634|DRUG|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate \>55 beats per minute, or up to 12.5 mg/day
224117381|NCT01704248|DEVICE|Eye Drop Guide technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~5. Then place the upper lip down to cover the whole orbital rim area.~6. Tilt the head back if seated or standing.~7. Insert the bottle in the device all the way. Hold the bottle gently.~8. Look upward.~9. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~10. Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
223543477|NCT05229809|DRUG|Yiqi Wenyang Jiedu prescription|The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
223726098|NCT03116893|DRUG|BI 685509 Fasted Conditions|BI 685509, given alone
223726099|NCT03943134|OTHER|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
223726100|NCT03943134|OTHER|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
224117382|NCT01704248|BEHAVIORAL|Routine self-instillation technique|"1. Wash the hands.~2. Shake and then uncap the bottle.~3. Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~4. Lie down or tilt the head back if seated or standing.~5. Using the other hand, pull the lower lid down.~6. Hold the bottle over the eye and look up.~7. Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~8. Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
224117383|NCT03883048|OTHER|Observation of bronchiectasis with pulmonary hypertension|
224117384|NCT06322823|PROCEDURE|direct thawing|Vitrified blastocysts will be thawed directly into 1ml G-TL medium
224117385|NCT06322823|PROCEDURE|Vitrification|Vitrified blastocysts will be thawed using commercially available one-step media.
224117386|NCT01252797|RADIATION|Stereotactic Radiosurgery (15 Gy)|"Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy"
224117387|NCT01252797|RADIATION|Stereotactic Radiosurgery (12 Gy)|Group B will start at Dose Level I: 12 Gy
224117388|NCT06275971|DEVICE|Dexcom G6|Glycemic control was monitored using CGM data for seven days following cardiac surgery
224117389|NCT06275971|DEVICE|SMBG or venous/arterial blood glucose|Glycemic control was monitored using SMBG or venous/arterial blood glucose data for seven days following cardiac surgery
224117390|NCT05309226|OTHER|Cannabis use in pregnancy or cannabis exposure in utero|Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).
223977036|NCT05787171|DEVICE|WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）|The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
223977037|NCT01058083|DRUG|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
223977038|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
224117391|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS training|After the PSS and TBW are calculated with the standard TOJ paradigm, 100 training trials are provided where the SOA is set to a PSS slightly greater than what was the mean calculated for normal subjects, with the goal of shifting the PSS in a direction associated with better clinical vestibular parameters and vestibular precision measurements (e.g. standard rotational testing VOR time constant, lower DHI, higher FGA score) . Then the TOJ task will be repeated but every 10 testing trials will be followed by 10 training trials (SOA = PSS desired or mean normal PSS), and this pattern will be repeated 10 times to 100 more training trials interspersed with the Post TOJ data. Subjects will respond after all trials and testing and training will not be distinguished. After this is completed, the new PSS and TBW are calculated. Sham PSS training will be identical to the above except that the 'training' period will consist of random SOAs rather than a series of fixed SOAs.
224117392|NCT04196933|BEHAVIORAL|Temporal Binding Adaptation - PSS adaptation with VI stimulation|The adaptation will utilize the same approach used in non-implanted patients. The investigators will provide a repeated, fixed SOA with either the CI or VI leading the other stimulus by 220 ms. After the training period, which will match the number of stimuli pairs provided to our normal vestibular-auditory control subjects undergoing PSS adaptation, the TOJ study is repeated to recalculate the PSS and TBW.
224117393|NCT04196933|BEHAVIORAL|Chronic Motion-modulated Stimulation|To provide 8 hours of 'physiologic' CI and VI inputs during normal activities, the investigators will employ standard motion-modulated stimulation with the VI. This requires pre-adaptation to a 200 pps tonic stimulation rate (to emulate the push-pull design of the native vestibular system allowing modulating stimulation upward or downward with opposite directions of motion). The three electrodes are connected to the head-mounted prosthetic circuit, which consists of three angular velocity sensors (one aligned with the sensitive axis of each canal) such that head rotations in the plane of the given canal modulate the stimulation rate of the corresponding electrode, upward (for ipsi) or downward (for contralateral) head rotations, thereby simulating normal canal-mediated modulations.
224117394|NCT05772715|OTHER|orthosis + exercise therapy|The orthosis + exercise group receives the same orthosis and instructions as the orthosis group (see next section), supplemented by exercise therapy. This includes weekly 25-30-minute physical therapy sessions with a total of 12 sessions. Sessions include patient education on thumb positioning, functional training and home exercise instructions to improve CMC-1 stability during pinch in extension/abduction, as instability and degeneration occurs in flexion/adduction(17,19,28-31). The first phase (week 0 - week 6) comprises coordination exercises for the thumb intrinsics (except adductor pollicis), extensor pollicis brevis and first dorsal interosseous to support CMC-1 extension/abduction. The second phase (week 6 - month 3) comprises reduced orthosis usage and thenar muscle strengthening exercises(except adductor pollicis).
224117395|NCT05772715|OTHER|Orthosis|The orthosis group receives a custom-made thermoplastic orthosis immobilizing the first carpometacarpal joint (CMC-1) in extension/abduction and the metacarpophalangeal joint in flexion. Orthosis usage is 24/7 in the first two weeks, thereafter only during activities with high load until three months. Two appointments take place: one for orthosis fabrication and one for a one-week checkup.
224117396|NCT03433287|DIAGNOSTIC_TEST|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
223977039|NCT01058083|DRUG|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
223977040|NCT01058083|DRUG|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
223977041|NCT01058083|DRUG|Placebo|Placebo, Oral, 0 mg, daily, 28 days
223977042|NCT05157568|BEHAVIORAL|Exercise Streaming (ES)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. No equipment is required. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
223977043|NCT05157568|BEHAVIORAL|Exercise Streaming + Equipment (ES+E)|Participants will complete 8 weeks (1 class per week) of supervised exercise online. Each participant will have a stationary exercise bike delivered to their home for use during their live classes. They will follow a pre-recorded exercise video and at the same time, get instruction, feedback and support from their coach. Each class will be held as a teleconference.
223726101|NCT02743520|DEVICE|The Lifestar Act III|The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
223726102|NCT02280785|DRUG|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
223977044|NCT05157568|BEHAVIORAL|Control|Participants will complete 8 weeks (1 class per week) of in-person supervised exercise.
223977045|NCT03069014|DRUG|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
223726103|NCT01749514|DRUG|Luspatercept|Participants receive luspatercept up to 1.75mg/kg subcutaneously (SC) every 3 weeks for up to 5 cycles (each cycle length = 21 days).
223977046|NCT03069014|DRUG|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
224117397|NCT03422991|OTHER|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
224117398|NCT05033444|DRUG|PRV-002|"SAD portion: Eligible participants will be randomized to receive a single ascending dose of PRV-002 on study Day 1. Dose escalation will be conducted in a total of 3 cohorts. Within each cohort, 6 participants will be randomized to receive a single dose of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.533 mg/kg (based on a 60kg participant) will be investigated.~MAD portion: Eligible participants will be randomized to receive a multiple (one dose per day for 5 consecutive days). Dose escalation will be conducted in a total of 2 cohorts. Within each cohort, 6 participants will be randomized to receive of PRV-002. The starting dose, dose increments and dose range to be evaluated are based on available nonclinical data. PRV-002 dose levels in the range of 0.133 to 0.266 mg/kg (based on a 60kg participant) will be investigated."
223726104|NCT03066089|DRUG|Fenfuro|
223726105|NCT00447460|PROCEDURE|Mesenchymal stem cell (MSC)|
223726106|NCT04456660|DIAGNOSTIC_TEST|Markers of ultrasound|CRL, HR, and other ultrasound measurements.
223726107|NCT04456660|DIAGNOSTIC_TEST|Immunologic factors|Measurement of NK cells subpopulations types in the maternal serum
223977047|NCT03069014|DRUG|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
223977048|NCT06158178|DIAGNOSTIC_TEST|Diagnostic accuracy|The PET CT study with choline, being part of the normal standard diagnostic work-up of the patients, was performed following the normal clinical protocol. By analyzing the data retrospectively, the time elapsed following the prostatectomy operation and the follow up time after the choline PETCT study will be evaluated.
224117399|NCT05033444|DRUG|Placebo|Placebo used is hydroxypropyl beta cyclodextrin (HPβCD)
224117400|NCT06649903|BEHAVIORAL|Chiropractic|high speed low amplitude neck manipulation
224117401|NCT06649903|BEHAVIORAL|Osteopathy|the stomach and liver technique was applied
223726108|NCT04456660|DIAGNOSTIC_TEST|Serum factors|Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.
223726109|NCT03088982|OTHER|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
223726110|NCT06564441|DRUG|Survodutide|Survodutide
223726111|NCT06564441|DRUG|Bupropion|Bupropion
223726112|NCT06564441|DRUG|Caffeine|Caffeine
223726113|NCT06564441|DRUG|Midazolam|Midazolam
223726114|NCT02851758|OTHER|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
223977049|NCT00747045|OTHER|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
223977050|NCT00733564|DRUG|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
223977051|NCT00733564|DRUG|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
223977052|NCT00733564|DRUG|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
223977053|NCT03030105|DRUG|BPN14770|investigational drug
223977054|NCT03030105|DRUG|BPN14770 placebo|placebo
223977055|NCT03030105|DRUG|Donepezil|comparator
224117402|NCT06284928|OTHER|Gut Microbiota Analysis|This refers to the procedure of collecting fecal samples from both the hypertension group and the control group, followed by analyzing these samples to assess and compare the gut microbiota composition using methods like gene sequencing.
223543478|NCT05229809|DRUG|Simulation agent of Yiqi Wenyang Jiedu prescription|It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
224117403|NCT05545813|DIETARY_SUPPLEMENT|Probiotic|Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
224117404|NCT05545813|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
224117405|NCT03735693|DIAGNOSTIC_TEST|Ulstrasound|measurement of right femoral cross-section
224117406|NCT01455428|DRUG|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
224117407|NCT01455428|DRUG|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
224117408|NCT04906005|DRUG|gadopiclenol|administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
224117409|NCT04906005|DRUG|Placebo|intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
223543479|NCT02849834|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
223543480|NCT01840488|DRUG|Irosustat (BN83495)|"Three parts (A, B \& C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
223726115|NCT04648631|DEVICE|antibiofilm surfactant wound gel (ABWG)|ABWG is a hydro-gel applied topically using a tongue depressor
223977056|NCT03030105|DRUG|Donepezil placebo|placebo
223977057|NCT03030105|DRUG|Scopolamine 0.6 MG/ML|cognition impairment
223977058|NCT03030105|DRUG|Scopolamine placebo|placebo
224117410|NCT02948595|OTHER|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
224117411|NCT02948595|OTHER|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
224117412|NCT02806765|DIETARY_SUPPLEMENT|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months
224117413|NCT02806765|OTHER|Control|Placebo in Softgel form
223977059|NCT05253079|OTHER|subcostal transversus plane block|Patient in TAP block group will receive oblique subcostal TAP while in supine position using a linear 6-13 MHz ultrasound transducer. The operator will place the ultrasound probe obliquely on the upper abdominal wall along the subcostal margin near the xiphisternum of the sternum in the midline of the abdomen. The landmarks, which included the rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin and xyphoid. The probe will be then moved laterally until the aponeurosis of the external, internal oblique, and transversus abdominis are seen, and then the probe will be moved further laterally until the transversus abdominis muscle is identified. The operator will direct the needle toward the transversus abdominis, and the local anesthetic solution will be injected after negative aspiration between the rectus abdominis and transversus abdominis muscles along the subcostal line (in-plane superomedial to inferolateral)
223977060|NCT05253079|OTHER|erector spinae plane block|Patients in ESPB group will be turned to the lateral position and receive ESPB at the level of the 7th thoracic (T7) transverse process using a linear 6-13 MHz ultrasound transducer. The transducer will be positioned vertically 3 cm to the side of the midline to visualize the muscles of the back, the transverse process, and the pleura between the two transverse processes. Then, a 22G 10-mm needle will be introduced in the cranial-caudal direction toward the transverse process (T7) using the in-plane method till the needle tip crosses all the muscles. The tip of needle should be in the plane between the transverse process and the erector spinae muscle. After ensuring negative aspiration, the local anesthetic solution will be injected below the muscle. the procedure will be repeated on the other side
223977061|NCT04785573|DIETARY_SUPPLEMENT|Mastiha oil|1 soft gel capsule of Mastiha oil every day for 3 months
223977062|NCT03065439|DIAGNOSTIC_TEST|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
223977063|NCT06543550|DRUG|Implantable gestrinone|1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.
223977064|NCT06543550|DRUG|Oral Dienogest|Administered orally at 2 mg daily
223977065|NCT00016978|DRUG|FOLFOX regimen|
223977066|NCT00016978|DRUG|fluorouracil|
223977067|NCT00016978|DRUG|leucovorin calcium|
224117414|NCT00828386|PROCEDURE|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
224117415|NCT00818142|BEHAVIORAL|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
223977068|NCT00016978|DRUG|oxaliplatin|
223977069|NCT06585319|DRUG|Collagen-polyvinylpyrrolidone|2 ml intramuscular q24 h
223977070|NCT06585319|DRUG|Pirfenidone 1200 mg|1,200 mg of oral q12 h
224117416|NCT03303339|DRUG|Onvansertib|Onvansertib orally
224117417|NCT03303339|DRUG|Cytarabine|subcutaneously
223977071|NCT05613504|OTHER|Acupuncture treatment|"Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
224117418|NCT03303339|DRUG|Decitabine|intravenously
224117419|NCT05394272|OTHER|Energy Therapy - Pranic Healing|Energy therapy - Non invasive non touch and non pharmacological - 100% natural complementary therapy
223726116|NCT01979016|DRUG|Dupilumab|
223726117|NCT01979016|DRUG|Placebo|Matching placebo
223977072|NCT05613504|OTHER|Sham acupuncture treatment|"Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
223977073|NCT04743453|DRUG|Dapagliflozin|Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
223977074|NCT04743453|DRUG|Placebo|Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
223977075|NCT02722759|OTHER|hemoglobin measurement|
223977076|NCT02044341|DRUG|AR01|drops administered an needed for pain
223977077|NCT02044341|DRUG|Glycerin ear drops|placebo drops administered for ear pain
223977078|NCT00660764|DRUG|Rosuvastatin|Oral
224117420|NCT06324487|OTHER|Progressive Exercises|Electrotherapy, stretching of the capsules, strengthening, ROM exercises, proprioceptive exercises
224117421|NCT06324487|OTHER|Blood Flow Restriction Therapy|Strengthening exercises performed by using cuff surrounding proximal part of the arm.
223977079|NCT01314014|DRUG|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
223977080|NCT00006436|BIOLOGICAL|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
223977081|NCT00006436|BIOLOGICAL|Filgrastim|Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle
223977082|NCT00006436|DRUG|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
223977083|NCT00316589|BIOLOGICAL|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
223977084|NCT05262504|DEVICE|İntraocular lens implantation|Each participant underwent bilateral sequential cataract surgery and bilateral implantation of a novel non-diffractive EDOF IOL (n=26) or a trifocal IOL (n=26). The interval between the first and second-eye surgeries was 1 to 3 weeks. The patients selected the IOL model after they were fully informed regarding the advantages and disadvantages of each IOL, by their surgeon. Their degree of interest in greater spectacle freedom at far, intermediate, and near distances, as well as their daily activities such as frequency of night driving or reading habits were discussed. The possibility of photic disturbances was described and explained as well.
223977085|NCT01482819|DEVICE|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
223977086|NCT01482819|DEVICE|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
224117422|NCT06079476|DRUG|Romosozumab|Single-use prefilled syringe for SC injection.
224117423|NCT03718104|OTHER|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
224117424|NCT03718104|OTHER|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
223977087|NCT01482819|DEVICE|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
223977088|NCT01482819|DEVICE|polymacon|contact lenses worn bilaterally for 8-12 hours
223977089|NCT01482819|OTHER|spectacles|habitual spectacles owned by subject, non-specific manufacturer
223977090|NCT00562484|BIOLOGICAL|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
223977091|NCT00562484|BIOLOGICAL|Placebo|Placebo
223977092|NCT05306730|DEVICE|ECHOcardiography, Point-of-Care UZ|Emergent echocardiography is reproducible method providing clinically significant information during primary survey of acute cardiovascular diseases. Possible benefit is the risk stratification of acute non-stemi coronary syndromes and differentiation from other serious conditions, such as pulmonary embolism or aortic dissection. The aim of interest is to consider riscs and benefits of the ultrasound of heart done by non-cardiologist after standardized course.
223977093|NCT05119166|DIETARY_SUPPLEMENT|Vitamin B3|ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.
223977094|NCT05119166|BIOLOGICAL|Azithromycin|"ELICIT Study: Factorial design RCT of nicotinamide (vitamin B3) to mothers and infants, and antimicrobial prophylaxis (Azithromycin) to infants.~VITAL Pakistan Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant."
223977095|NCT05119166|DIETARY_SUPPLEMENT|Fortified food supplement|"VITAL Study: 3-arm RCT of fortified food supplement (protein energy) during lactation, with or without azithromycin prophylaxis for infant.~MISAMEIII Study: 2x2 cross-over efficacy RCT of fortified food supplement (folic acid/iron +/- peanut spread) during pregnancy and/or lactation; unmasked (open label)."
223977096|NCT06092684|DRUG|BT-KTM-I|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
223977097|NCT06092684|DRUG|Ketanest®S|The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
223977098|NCT04671251|DRUG|AEVI-007|50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
223977099|NCT05450822|DRUG|Levetiracetam|"Healthy subjects and patients in Cohort III will undergo a 120 min. \[11C\]-UCB-J PET-MR brain scan followed by intravenous administration of levetiracetam after approx. 60 min. in a displacement paradigm. Before, during and after the intervention arterial spin labeling and resting-state functional MRI will be acquired.~To measure the radiolabelled tracer's arterial input function, including its radiolabelled metabolites, blood samples will be drawn during the PET scan from an arterial catheter.~The selected regions for the primary analyses are the epileptogenic lesion(s) (patients) and the neocortex, hippocampus, entorhinal cortex, fusiform gyrus, dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, orbitofrontal cortex, striatum, anterior cingulate cortex and amygdala. \[11C\]-UCB-J binding, volume of distribution and SV2A occupancy will be quantified by analyzing the PET images with well-validated kinetic models."
223977100|NCT05450822|DRUG|Levetiracetam Tablets|Patients in Cohort II will be randomized to treatment with an ASM (levetiracetam) in accordance with standard treatment procedures. The patients will enter a 4 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to lamotrigine arm.
223726118|NCT01979016|OTHER|Background treatment|Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).
223977101|NCT05450822|DRUG|Lamotrigine tablet|Patients in Cohort II will be randomized to treatment with an ASM (lamotrigine) in accordance with standard treatment procedures. The patients will enter a 6 weeks titration period receiving increasing doses. During weeks 5-30, patients will enter an evaluation period where the dose can be increased (continued seizures) or decreased (adverse reactions). In cases of unacceptable seizure control and/or intolerable adverse reactions; shift to levetiracetam arm.
223977102|NCT01507753|DRUG|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
223977103|NCT01507753|BEHAVIORAL|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
223977104|NCT01507753|OTHER|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
223977105|NCT01552642|BEHAVIORAL|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
224117425|NCT03718104|GENETIC|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
224117426|NCT03718104|OTHER|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
224117427|NCT02857023|BEHAVIORAL|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
224117428|NCT02062151|OTHER|Acupuncture|Acupuncture
224117429|NCT04004507|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
224117430|NCT04004507|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
224117431|NCT01058174|DRUG|micafungin|intravenous infusion
224117432|NCT01058174|DRUG|fluconazole|intravenous infusion
223543481|NCT02138812|DRUG|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
223543482|NCT02138812|DRUG|Paclitaxel|75 mg/m\^2 (initial dose escalation) or 90 mg/m\^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
224117433|NCT01058174|DRUG|liposomal amphotericin B|intravenous infusion
224117434|NCT01058174|DRUG|caspofungin|intravenous infusion
223977106|NCT05041439|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 6 months.
223977107|NCT03648684|BEHAVIORAL|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
223977108|NCT03648684|BEHAVIORAL|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
223977109|NCT05992519|DIAGNOSTIC_TEST|¸FeNO|FeNO measured with a NIOX VERO device after the methacholine challenge
223977110|NCT07000266|PROCEDURE|Percutaneous Coronary Intervention (PCI)|Standard PCI intervention
223977111|NCT07000266|DIAGNOSTIC_TEST|Diagnostic Imaging|Cardiac Magnetic Ressonance (CMR) and hospital discharge
223977112|NCT07000266|DEVICE|Device Treatment|SSO2 therapy
223977113|NCT07000266|PROCEDURE|Follow-up at 30 days|Remote (phone) follow-up at 30 days
223977114|NCT07000266|PROCEDURE|Follow-up at 60 days|In person follow-up at 60 days
223977115|NCT07000266|PROCEDURE|Follow-up at 12 months|Remote (phone) follow-up at 12 months
223977116|NCT06632340|PROCEDURE|TUR-BT|Transurethral resection of bladder tumor
223977117|NCT01718613|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
223977118|NCT01718613|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
223977119|NCT06908486|BEHAVIORAL|Cognitive Bias Modification for Interpretation|"Cognitive Bias Modification involves administering the Ambiguous Scenarios paradigm. This is a series of ambiguous scenarios which could be resolved to be associated with pain. The task consists of 30 unique scenarios and an associated comprehension question (pertaining to the pain-relatedness of the scenario), which are presented in a random order to participants.~Each scenario presents an ambiguous sentence, ending with a word fragment which the participant must complete. The statement remains ambiguous until the completion of the word fragment, which resolves the statement as either pain-related or benign. For example, the statement You are bush walking. Suddenly, you trip over and fall onto your knees. Your knees feel all wet, and you look down to see... can be followed by le\_v\_s \[leaves\] for a benign resolution, or bl\_\_d \[blood\] for a pain-related resolution. In the intervention group, all 30 scenarios will be followed with the benign word fragment."
223977120|NCT06908486|BEHAVIORAL|Placebo|The Ambiguous Scenarios paradigm described previously will be used for the placebo intervention. The same 30 scenarios will be presented to participants, however 50% (15) trials will be followed by the benign word fragment, ad 50% (15) trials will be followed by the pain-related word fragment.
223543483|NCT00556803|PROCEDURE|radiofrequency ablation|radiofrequency ablation
223543484|NCT00556803|PROCEDURE|TACE after RFA|TACE after RFA within one month
223543485|NCT06176846|BEHAVIORAL|Immersive Virtual Reality Exergaming Program|"Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games."
223543486|NCT06176846|BEHAVIORAL|Home-Based Exercise Program|In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
223543487|NCT04650997|BEHAVIORAL|Eccentric exercise|Knee eccentric exercise with sham or focused extrocorporeal shockwave therapy for 12 weeks
223543488|NCT02099825|DRUG|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
223543489|NCT00400855|DRUG|Fluticasone propionate|Study drug
223543490|NCT06163196|OTHER|acupressure|Before the blood collection procedure, pressure will be applied to the acupressure points determined by the researcher for 2 minutes and then blood collection will be performed.
223543491|NCT05851885|DIAGNOSTIC_TEST|AI-based reporting system|AI-based reporting system is a software platform for real-time analysis and records of abnormalities and landmarks during endoscopy.
223543492|NCT02855658|DRUG|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
223543493|NCT02855658|DRUG|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
224117435|NCT03774017|PROCEDURE|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
224117436|NCT03774017|PROCEDURE|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
224117437|NCT03268174|OTHER|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
224117438|NCT03268174|OTHER|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~* LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~* RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
224117439|NCT00832715|PROCEDURE|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
224117440|NCT02481960|PROCEDURE|CM-BC2 Irinotecan drug-eluting bead|
224117441|NCT00478972|DRUG|Rimonabant|Tablet, oral administration
224117442|NCT00478972|DRUG|placebo (for Rimonabant)|Tablet, oral administration
224117443|NCT00478972|OTHER|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
224117444|NCT00941772|OTHER|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
224117445|NCT02020343|BEHAVIORAL|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
223543494|NCT03154021|COMBINATION_PRODUCT|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
223977121|NCT05831995|DRUG|ABM-168|Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration
223977122|NCT04807023|BIOLOGICAL|blood sampling|blood sampling
223543495|NCT03154021|COMBINATION_PRODUCT|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
223543496|NCT01862081|DRUG|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
223543497|NCT01862081|DRUG|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
223543498|NCT01862081|DRUG|Paclitaxel|Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
223543499|NCT04096105|DRUG|CC-93538|a single dose CC-93538 SC
223977123|NCT05546736|BEHAVIORAL|iCanWork Intervention|Participants will receive RTW support from the VRC and OT.
223977124|NCT04417569|DRUG|hCG|human chorionic gonadotropin
223977125|NCT04417569|DIAGNOSTIC_TEST|Ultrasound|Endometrial thickness monitoring
223977126|NCT04417569|OTHER|Blood test|Progesterone, Luteinizing Hormone, Estradiol
223977127|NCT02809807|OTHER|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
223977128|NCT02809807|DEVICE|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
224293563|NCT07174856|DRUG|Combined regimen|This intervention will involve participants being counseled on and receiving medications for a medication abortion regimen of mifepristone (200mg orally) followed 24-48 hours later by misoprostol (800μg b/v) with a second dose of misoprostol (800μg b/v) taken 3 hours later only for those 64-77 days.
224293564|NCT07191327|DEVICE|HD-tDCS sessions|This project translates decades of observational neuroimaging research into a biologically plausible stimulation target (i.e., DAN) and uses functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) to plan personalized brain stimulation and to ensure target engagement. When available; those not MRI compatible will receive a standard montage with per channel amplitudes of up to 5 milliamperes (mA) or a montage derived from other imaging methods. Participants will receive 4 days of HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.
223977129|NCT01491542|DEVICE|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
224293565|NCT07191327|DEVICE|Sham HD-tDCS sessions|Participants will receive 4 days of sham HD-tDCS sessions in person. During these sessions participants will have electrodes placed on different areas of the head and held in place with headgear. Participants may also have memory and thinking tests during and after the sessions as well as questionnaires about the experience. Additionally, on the fourth day participants may have repeat immersive virtual reality (iVR) as well as other study activities.
223977130|NCT01491542|DEVICE|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
223977131|NCT02306447|DEVICE|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
223977132|NCT02236663|BEHAVIORAL|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
223977133|NCT02236663|BEHAVIORAL|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
223977134|NCT06413264|PROCEDURE|Ultrasonography guided Veress needle insertion for creating pneumoperitoneum|A real-time visualisation of the path of the Veress needle entry by the use of high frequency (13-6 MHz) probe ultrasonography.
223977135|NCT06413264|PROCEDURE|Veress needle will be inserted blindly as a closed technique for creating pneumoperitoneum|The Veress needle is inserted blindly and guided by the resistance of tissues and the click sounds of layers of abdominal wall.
223977136|NCT05248698|BEHAVIORAL|lifestyle change|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, plus Mediterranean Diet for 6 months
223977137|NCT05248698|OTHER|exercise|30 older patient who will complain from dry eye will receive 3-time interval exercise per the week, applied for 30 min with high intensity, for 6 months
223977138|NCT01904136|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
223977139|NCT01904136|PROCEDURE|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
223977140|NCT01904136|DRUG|Cyclophosphamide|Given IV
223977141|NCT01904136|DRUG|Fludarabine|Given IV
223977142|NCT01904136|OTHER|Laboratory Biomarker Analysis|Correlative studies
223543500|NCT04618588|PROCEDURE|Low Window Sinus Lift technique|"Preoperative CBCT of surgical site and Fabrication CAD/CAM surgical stent, Sinus elevation using Low Window Sinus Lift technique, Implant, bone graft and membrane placement"
223977143|NCT01904136|DRUG|Melphalan|Given IV
223977144|NCT01904136|DRUG|Mycophenolate Mofetil|Given PO
223977145|NCT01904136|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
223977146|NCT01904136|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
223977147|NCT01904136|DRUG|Tacrolimus|Given IV and PO
223977148|NCT01904136|RADIATION|Total-Body Irradiation|Undergo TBI
223977149|NCT01742845|OTHER|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
223977150|NCT01742845|OTHER|landmark based superfical ropivacaine 4.75 mg/ml injection|
223977151|NCT00370370|DRUG|bevacizumab|Injection of intravitreal bevacizumab
223543501|NCT02271061|DEVICE|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
223977152|NCT00370370|DRUG|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
223977153|NCT00349739|DRUG|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
223977154|NCT04334447|OTHER|Improved primary care HF diagnostics|Reimbursement of natriuretic peptide testing for participating general practitioners (GPs) Audit and feedback in GPs EHR
223977155|NCT04334447|OTHER|Heart Failure education|Reimbursement of heart failure education for patients at risk. Web-based training for participating general practitioners
223977156|NCT04334447|OTHER|Structured transitional protocol planning post-discharge care|Checklist-supported discharge protocol for HF patients including telephone contact with patients' general practitioners and a contact with the HF educator
223977157|NCT04950062|OTHER|High Intensity Interval Training|"1. Warming up period for 5 min at an intensity corresponding to 65-75% of heart rate maximum (HRmax).~2. Training phase for 30 min divided into four sets of 4-min length each at intensity equals 80-90% of HRmax interspersed by 3 minutes low intensity walking at the level of 65-75% of HRmax.~3. Cooling down period for 5 min of at 50-60% of the HRmax. All subjects will be trained at the lower intensity limit for the first 2 weeks of the program before increasing the intensity levels toward the upper limit."
223977158|NCT04950062|OTHER|Intermittent Fasting 16/8 Protocol|Every subject will be instructed to fast a fixed 16 hours followed by 8 hours of eating every day through the whole study period based on their life and sleeping style. During fasting, zero-calorie coffee, tea and water intake will be permitted. Beverages containing calories were consumed during the feeding hours each day. All subjects will be instructed about their optimum caloric requirement based on their basal metabolic rate that will be calculated in advance to avoid over consumption of food on severe caloric restriction as we like to investigate the effect of this way of fasting on reducing weight and improving functional capacity.
223977159|NCT05218746|PROCEDURE|Serratus anterior plane block|High-frequency linear transducer will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, Then, using ultrasound guidance, the needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib . one millileter normal saline will be injected to confirm placement and to hydro-dissect the fascial layers and open the potential space.
224117446|NCT05616065|OTHER|Blinding to academic performance of candidate|Each candidate applying to our program will be interviewed by three core faculty. One of them will be selected, a priori, to be asked not to view a candidate's academic performance (medical school transcripts, standardized test scores). This will not be randomized. Instead, it shall be set up so that each assessor has two blinded candidates to interview each day scheduled. Given that different faculty will be scheduled each day, it may end up that certain faculty will be blinded more than others.
224117447|NCT05616065|OTHER|Usual Interview methodology|Each candidate applying to our program will be interviewed by three core faculty. Two of them will be selected, a priori, to be asked to interview their candidates as they see fit.
224293566|NCT07191327|DEVICE|HD-tDCS sessions - Open-label (after randomized treatment)|Optional 26 weeks of additional HD-tDCS sessions. Participants can complete up to 5 days per week, but most people will complete about 3 days per week. The study team may also collect audio recordings of these sessions. Participants can complete this in person or at-home via using a secure, HIPAA-compliant videoconferencing with the supervision of a research staff member. Participant's that decide to complete the additional sessions at home, a research staff member will train a study partner during the first 4 HD-tDCS sessions in the office. This option may not be available or appropriate for all participants and the study team member will discuss this with participant's and study partners.
223726119|NCT00494078|DEVICE|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
223726120|NCT00494078|DRUG|intensive insulin therapy|intensive insulin therapy according to an algorithm
223726121|NCT01676389|OTHER|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
224117448|NCT03809065|DRUG|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
224117449|NCT03809065|DRUG|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
224293567|NCT07184086|DRUG|CagriSema (Cagrilintide B + semaglutide I)|Cagrilintide and semaglutide will be administered subcutaneously.
224293568|NCT07184086|BEHAVIORAL|Low Energy Diet|Participants will receive dietary intervention as per diet intervention manual.
224293569|NCT07187362|BIOLOGICAL|Use iliac bone graft|
223726122|NCT01676389|OTHER|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
223977160|NCT05218746|PROCEDURE|Erector spinae block|A high-frequency linear ultrasound probe will be placed in a longitudinal orientation 3 cm from the midline. Once the erector spinae muscle and the transverse processes is identified, spinal needle will be inserted in a caudad-to-cephalad direction until the tip lay in the interfacial plane deep to the erector spinae muscle.
223977161|NCT00489528|DRUG|Somatropin; Recombinant human growth hormone (r hGH)|
223977162|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
223977163|NCT00088543|BIOLOGICAL|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
223977164|NCT03785626|PROCEDURE|CEA surgery|patients with carotid artery severe (70-99%) stenosis or occlusion received CEA surgery
223977165|NCT01346462|BEHAVIORAL|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
223543502|NCT02271061|DEVICE|Control tape|Apply tape in same technique without tension.
223543503|NCT00142792|DEVICE|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
223543504|NCT02826408|DRUG|Rabeprazole sodium|WIll study effect of the medication on palpittions
223977166|NCT02925234|DRUG|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
223977167|NCT02925234|DRUG|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
223977168|NCT02925234|DRUG|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
223977169|NCT02925234|DRUG|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
223977170|NCT02925234|DRUG|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
223977171|NCT02925234|DRUG|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
224117450|NCT00751101|DRUG|Nicotine patch|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
224117451|NCT03591952|PROCEDURE|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
224117452|NCT03591952|PROCEDURE|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
224117453|NCT01206595|DRUG|SKY0402|Single dose of SKY0402 administered as a nerve block
224117454|NCT01206595|DRUG|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
223543505|NCT02826408|DRUG|Pacebo|Placebo comparison to active treatment
223543506|NCT04796038|DEVICE|Balloon dilatation|Patient will be treated with balloon dilatation either stand-alone (POBA) or followed by stent implantation.
223543507|NCT01409408|DRUG|Aliskiren|300 mg of aliskiren daily for 8 weeks.
223543508|NCT01409408|DRUG|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
223543509|NCT02771405|DRUG|Sofosbuvir|Sofosbuvir 400 mg orally once daily
223543510|NCT02771405|DRUG|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223543511|NCT02771405|DRUG|Simeprevir|Simeprevir 150 mg orally once daily
223543512|NCT02771405|DRUG|daclatasvir|Daclatasvir 60 mg orally once daily
223977172|NCT02925234|DRUG|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
223977173|NCT02925234|DRUG|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
223726123|NCT03679936|DIAGNOSTIC_TEST|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC). At the same time, evaluating the ability of 18 F-FDG PET/CT dynamic imaging to differentiating multiple primary lung cancer from intrapulmonary metastases.
223977174|NCT02925234|DRUG|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
223977175|NCT02925234|DRUG|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
223977176|NCT02925234|DRUG|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
224117455|NCT03332004|DRUG|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
223977177|NCT02925234|DRUG|Afatinib|Afatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Afatinib might be expected based on their molecular tumor profile.
223977178|NCT02925234|DRUG|Dabrafenib and trametinib|Dabrafenib + trametinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Dabrafenib + Trametinib might be expected based on their molecular tumor profile.
223977179|NCT02925234|DRUG|Ribociclib|Ribociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Ribociclib might be expected based on their molecular tumor profile.
224117456|NCT03327922|DEVICE|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
224117457|NCT02850614|BEHAVIORAL|gaming application to encourage physical activity|
224117458|NCT02850614|DEVICE|FitBit|
224117459|NCT06074822|OTHER|Residual neuromuscular biopsy|recovery of residual neuromuscular biopsy (nerve ans muscle)
224117460|NCT05183581|DEVICE|Feeling Hot sensor system|The Feeling Hot sensor system consists of two temperature probes placed on the penis and outer thigh of the test subject to measure skin temperature during erection.
224293570|NCT07187362|BIOLOGICAL|use bone morphogenetic protein|
224293571|NCT07187362|BIOLOGICAL|use bone derived allograft MSCs|
223726124|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
224117461|NCT02956174|DEVICE|Co-Cr single crown|
224117462|NCT02956174|OTHER|Periodontal parameters|
224293572|NCT07187362|BIOLOGICAL|Use adipose tissue derived MSCs|
224293573|NCT07187362|BIOLOGICAL|Use amnion/placental derived MSCs|
224293574|NCT07192133|DIAGNOSTIC_TEST|CT scan|Dynamic contrast-free chest CT scan
224293575|NCT07191964|PROCEDURE|Supra-Sartorial Subcutaneous Infiltration (SSSI)|20 mL ropivacaine or saline infiltrated lateral-to-medial subcutaneously above sartorius at femoral triangle apex using inject-as-you-advance technique, avoiding hyperechoic nerves.
224293576|NCT07191964|PROCEDURE|intermittent adductor canal block (iACB)|An adductor canal catheter is inserted proximal-to-distally over a distance of 6-10 cm at femoral triangle apex, with an initial bolus of 10 mL of 0.3% ropivacaine administered in PACU. The following doses start at 9:00 PM on the day of surgery and are repeated every 12 hours,
223977180|NCT02925234|DRUG|Lenvatinib|Lenvatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Lenvatinib might be expected based on their molecular tumor profile.
223977181|NCT02925234|DRUG|Pembrolizumab|Pembrolizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Pembrolizumab might be expected based on their molecular tumor profile.
223977182|NCT02925234|DRUG|Durvalumab|Durvalumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Durvalumab might be expected based on their molecular tumor profile.
223977183|NCT02925234|DRUG|Rucaparib|Rucaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Rucaparib might be expected based on their molecular tumor profile.
223977184|NCT02925234|DRUG|Axitinib|Axitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Axitinib might be expected based on their molecular tumor profile.
223977185|NCT02925234|DRUG|Palbociclib|Palbociclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Palbociclib might be expected based on their molecular tumor profile.
223977186|NCT02925234|DRUG|Crizotinib|Crizotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Crizotinib might be expected based on their molecular tumor profile.
223977187|NCT02925234|DRUG|Sunitinib|Sunitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Sunitinib might be expected based on their molecular tumor profile.
223977188|NCT02925234|DRUG|Cabozantinib|Cabozantinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Cabozantinib might be expected based on their molecular tumor profile.
223977189|NCT02925234|DRUG|Abemaciclib|Abemaciclib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Abemaciclib might be expected based on their molecular tumor profile.
223977190|NCT02925234|DRUG|Alectinib|Alectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Alectinib might be expected based on their molecular tumor profile.
224117463|NCT01905397|DEVICE|Conventional wound therapy|Sterile bandages and wound coverings
223543513|NCT02771405|DRUG|Ledipasvir|Ledipasvir 90 mg orally once daily
223543514|NCT01328743|BEHAVIORAL|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
223543515|NCT00299364|DRUG|Black Cohosh (iCR) or tibolone|
223726125|NCT00938639|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
224117464|NCT01905397|DEVICE|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
224117465|NCT04024683|PROCEDURE|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
223543516|NCT05105321|DRUG|Berberine|The tablet of berberine and placebo are both coated with white sugar and had the same appearance. Berberine tablet will be orally taken with a dose of 500mg twice daily
223977191|NCT02925234|DRUG|Atezolizumab and Bevacizumab|Atezolizumab + Bevacizumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Atezolizumab + Bevacizumab might be expected based on their molecular tumor profile.
223977192|NCT02925234|DRUG|Ipilimumab and nivolumab|Ipilimumab+nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of ipilimimab + nivolumab might be expected based on their molecular tumor profile.
223977193|NCT02925234|DRUG|Entrectinib|Entrectinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of entrectinib might be expected based on their molecular tumor profile.
223977194|NCT02925234|DRUG|Talazoparib|Talazoparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of talazoparib might be expected based on their molecular tumor profile.
223977195|NCT02925234|DRUG|Dacomitinib|Dacomitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dacomitinib might be expected based on their molecular tumor profile.
223977196|NCT02925234|DRUG|Lorlatinib|Lorlatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of lorlatinib might be expected based on their molecular tumor profile.
223977197|NCT02925234|DRUG|Erdafitinib|Erdafitinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erdafitinib might be expected based on their molecular tumor profile.
223977198|NCT02925234|DRUG|Alpelisib|Alpelisib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of alpelisib might be expected based on their molecular tumor profile.
223977199|NCT02925234|DRUG|Niraparib|Niraparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of niraparib might be expected based on their molecular tumor profile.
223977200|NCT02925234|DRUG|Pemigatinib|Pemigatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of pemigatinib might be expected based on their molecular tumor profile.
223977201|NCT02925234|DRUG|Selpercatinib|Selpercatinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of selpercatinib might be expected based on their molecular tumor profile.
223977202|NCT02925234|DRUG|Tepotinib|Tepotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of tepotinib might be expected based on their molecular tumor profile.
223977203|NCT05096078|OTHER|Diet|Special diet program for gestational diabetes
223977204|NCT05096078|OTHER|Exercise|The circuit exercise program will consist of a medium-intensity circuit training for 50 minutes, 3 days a week, detailing the main muscle groups of the patients (chest, back, biceps, triceps, deltoid, quadriceps, thigh and calf muscles). Exercise intensity will be monitored using Borg's scale of perceived exertion, with a target intensity of 12 to 14. 8 exercises will be given in a continuous, circuit-type manner with short 1-minute rests.
223977205|NCT00033943|DRUG|deligoparin|
223977206|NCT01130311|DRUG|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223726126|NCT00468689|DRUG|SB-751689 oral tablets (100 and 400 ng)|
223977207|NCT01130311|DRUG|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
223543517|NCT05105321|BEHAVIORAL|Healthy lifestyle intervention|"Healthy lifestyle intervention will be launched according to the Chinese guidelines on prevention of cardiovascular and metabolic diseases by Chinese Preventive Medical Association in 2019, including health lectures, health information promotion, health manual and so on."
223543518|NCT02481258|DRUG|Ataciguat (HMR1766)|
223543519|NCT02481258|OTHER|Placebo Comparator: Matching Placebo|
223977208|NCT01049386|OTHER|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
223977209|NCT01049386|PROCEDURE|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
223977210|NCT00071877|DRUG|Replagal|
223977211|NCT01028755|DRUG|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
224117466|NCT02535949|DRUG|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
224117467|NCT02535949|OTHER|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
224117468|NCT04766203|BEHAVIORAL|Treatment of REDS using a holistic treatment arm|This arm aims to treat athletes with REDS symptoms by implementing a holistic, individualized nutrition intervention to improve energy availability and thus restore impaired body function due to REDS.
224117469|NCT00002056|DRUG|Pentamidine isethionate|
224117470|NCT00455858|DRUG|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
224117471|NCT00138125|DRUG|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
224117472|NCT00138125|BIOLOGICAL|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
223543520|NCT05106348|DIAGNOSTIC_TEST|Aerobic Fitness Test|aerobic fitness test to assess wheelchair rugby players capacity
223726127|NCT00468689|DRUG|Ketoconazole (NIZORAL) oral tablets (200 mg)|
223726128|NCT04953546|OTHER|No Intervention|This is an observation study, with no intervention
223977212|NCT04298099|DRUG|Ropivacaine|Given the reproducible efficacy of the erector spinae plane block for thoracic procedures, this pilot study will recruit patients scheduled to undergo thoracic surgery with the adjunct of an erector spinae plane block for perioperative pain. Participants will be assigned sequentially to either ropivacaine 0.2% at 0.3ml/kg or ropivacaine 0.5% at 0.3ml/kg.
223977213|NCT02572635|BIOLOGICAL|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
223977214|NCT02572635|BIOLOGICAL|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
224117473|NCT01654497|DRUG|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
223726129|NCT00653250|DRUG|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
223726130|NCT00653250|PROCEDURE|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
223726131|NCT00653250|PROCEDURE|therapeutic conventional surgery|surgery to remove the lung tumor
223977215|NCT04338906|DRUG|Camostat Mesilate|400 mg tid, d1-d7
223977216|NCT04338906|DRUG|Placebo|Instead of Camostat Mesilate, tid, d1-d7
223977217|NCT04338906|DRUG|Hydroxychloroquine|400 mg bid on day 1, 200 mg bid d2-d7
223977218|NCT00000545|BEHAVIORAL|exercise|
223977219|NCT00000545|BEHAVIORAL|diet|
224117474|NCT05468450|DRUG|Ultrasound-guided-foam sclerotherapy (UGFS) using Polidocanol sclerosant|Direct injection Foam sclerotherapy
224117475|NCT05468450|DEVICE|Endovenous Laser Ablation (EVLA)|EVLA using a 1470nm generator and 600-micron radial fibres (Biolitec® Biomedical Technology, Jena, Germany), under tumescent local anaesthesia (TLA)
224117476|NCT04429425|PROCEDURE|epidural anesthesia|epidural anesthesia through epidural injection of a local anaesthetic combined with an opioid
223726132|NCT02509156|BIOLOGICAL|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
223977220|NCT04388696|BEHAVIORAL|Sisterhood 2.0|The Sisterhood 2.0 curriculum was adapted from Program M, created in 2006 by Promundo to address health and empowerment of young women aged 15-24. The curriculum engages young women in questioning rigid and non-equitable stereotypes about masculinity and femininity and how they affect both women's and men's health and well-being.
224293577|NCT07191964|PROCEDURE|posterior capsule local infiltration analgesia (PC-LIA)|PC-LIA consists of two 10 mL injections of 0.3% ropivacaine delivered intraoperatively to the posteromedial and posterolateral aspects of the posterior capsule before cementation. The target injection plane is the potential space between the posterior capsule and the popliteal artery.
223726133|NCT02509156|BIOLOGICAL|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
223977221|NCT01055210|DEVICE|Optimisation of VV delay|Programmed VV delay altered on device
223977222|NCT06037239|DRUG|Linperlisib in combined with Chidamide|"Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly.~Phase 2：dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle"
223977223|NCT01584011|OTHER|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
224293578|NCT07189897|DRUG|Enoxaparin|For DVT prophylaxis
224293579|NCT07189897|DRUG|Apixaban|For DVT prophylaxis
223726134|NCT01790256|DEVICE|Cereve Sleep System at 30 degrees C|
223726135|NCT01790256|DEVICE|Cereve Sleep System at 14-16 degrees C|
223726136|NCT04326231|DEVICE|Usability assessment of Cognoa ASD Therapeutic Device|Usability assessment of Cognoa ASD Therapeutic Device
224293580|NCT07192614|DRUG|AZD6621|A T Cell-engaging Antibody that targets STEAP2, CD3, and CD8
224293581|NCT07197983|DEVICE|Automated Vitrification|The PRESERVE-CR system performs automated vitrification (ultra-rapid freezing) of human oocytes and embryos using robotic manipulation and computer-controlled timing.
224293582|NCT07197983|DEVICE|Manual Vitrification|Control specimens are vitrified by standard vitrification protocol.
223726137|NCT01936688|DRUG|MK-3222 200 mg|MK-3222 200 mg administered SC.
223726138|NCT01936688|DRUG|MK-3222 100 mg|MK-3222 100 mg administered SC.
223726139|NCT01936688|DRUG|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
223726140|NCT01936688|DRUG|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
223726141|NCT01936688|DRUG|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
223977224|NCT01584011|OTHER|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
223543521|NCT01402960|DEVICE|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~* For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~* For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~* For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
223543522|NCT04617080|PROCEDURE|SUPRACOR Regular|SUPRACOR algorithm with regular (100%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
223543523|NCT04617080|PROCEDURE|SUPRACOR Strong|SUPRACOR algorithm with strong (130%) ablation profile. SUPRACOR is a presbyopic algorithm that consists of a pre-calculated pulse pattern combined to the refractive pattern to combine near, intermediate and distance vision correction.
223543524|NCT02908581|DRUG|Placebo|Administered orally once daily
223543525|NCT02908581|DRUG|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
223977225|NCT01584011|BEHAVIORAL|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
223977226|NCT01584011|OTHER|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
224293583|NCT07203079|DRUG|Acetaminophen Oral Tablet|Participants take 1000mg by mouth every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
224293584|NCT07203079|DRUG|placebo oral tablet|Participants take one placebo tablet (matchable to tylenol) by mouth every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
223543526|NCT05573139|DIAGNOSTIC_TEST|Assessment of muscle strength by manual dynamometry|The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
223543527|NCT00038844|DRUG|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
223977227|NCT06544447|DEVICE|taVNS|"taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water.~The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution."
223977228|NCT06544447|DRUG|Hyaluronic acid eye drops|Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
223977229|NCT04145388|OTHER|online cancer risk assessment|Electronic surveys to collect family cancer history information.
224293585|NCT07203079|DRUG|Acetaminophen infusion|Participants take 1000mg by intravenous infusion over 15 minutes every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
224293586|NCT07203079|DRUG|Placebo infusion|Participants take 1000mg placebo by intravenous infusion over 15 minutes every 6 hours for a total of 8 doses (48 hours total) starting within 2 hours after their spine surgery.
223977230|NCT04145388|OTHER|Usual care|Family cancer history captured by provider during a clinical encounter
223977231|NCT05726266|OTHER|Music|Patients will listen daily to a musical playlist for 30 - 60 minutes in a row; the psychologist will set up a music playlist according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
223977232|NCT05726266|OTHER|Audiobook|Patients will listen daily to an audiobook for 30 - 60 minutes in a row; the psychologist will set up a list of audiobooks according to the patient's individual interests. Patients will be asked to focus on this activity, that is, without performing any other activity simultaneously.
223977233|NCT00687245|DRUG|esomeprazole magnesium|capsules, oral, qd, one day
223977234|NCT00970320|OTHER|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
223977235|NCT02311777|DRUG|Pregabalin|Pregabalin will be given orally during preoperative period
223977236|NCT02311777|DRUG|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
223977237|NCT02311777|DRUG|Placebo|Placebo will be given orally during preoperative period
223977238|NCT03345147|OTHER|High Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
224293587|NCT07198074|BIOLOGICAL|Bevacizumab|Given IV
223543528|NCT00038844|DRUG|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
223977239|NCT03345147|OTHER|Normal Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
223977240|NCT03587779|DRUG|Sevoflurane|Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
223977241|NCT03587779|DRUG|Desflurane|Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
223543529|NCT00038844|DRUG|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
223543530|NCT00038844|DRUG|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
223543531|NCT05948189|OTHER|exercise program|The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
223977242|NCT05995847|BEHAVIORAL|Harmonica playing program plus basic PR care with routine follow-up|The intervention will last for a total of six months. During this period, patients are expected to play the harmonica daily for 30 minutes, five days a week. Additionally, patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months.
223977243|NCT05995847|BEHAVIORAL|Basic PR care with routine follow-up|These patients will receive basic pulmonary rehabilitation (PR) care, which includes self-management education, exercise training, and breathing training, as well as routine follow-up. All training sessions are home-based and will take place five days per week for the duration of six months
224117477|NCT05979129|OTHER|zero PEEP|zero end-expiratory pressure during face mask ventilation
224117478|NCT05979129|OTHER|low PEEP|4 cmH2O PEEP during mask ventilation
224117479|NCT05979129|OTHER|high PEEP|8 cmH2O PEEP during mask ventilation
224117480|NCT00123526|BEHAVIORAL|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
224117481|NCT00123526|BEHAVIORAL|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
223543532|NCT01650454|OTHER|2 night polysomnography|Polysomnography
223543533|NCT01650454|OTHER|battery of neuropsychological tests|
223543534|NCT01650454|OTHER|virtual reality test|
223543535|NCT01650454|OTHER|subjective evaluation of sleep and somnolence|
223543536|NCT00490581|OTHER|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
223543537|NCT00882024|DRUG|Tranilast|150 mg tranilast tablets, bid, 12 weeks
223543538|NCT00882024|DRUG|Tranilast|75 mg tablets, bid, 12 weeks
223543539|NCT00882024|DRUG|Placebo|Placebo tablets, bid, 12 weeks
223543540|NCT02804061|BEHAVIORAL|NELIP|
223543541|NCT03061292|PROCEDURE|Pectoral Nerve Block|
223543542|NCT03061292|PROCEDURE|Without Pectoral Nerve Block|
223543543|NCT02965989|PROCEDURE|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
223543544|NCT02057926|DRUG|The effect of tetracycline in degradation and permeability of collagen membranes.|
223543545|NCT01913327|DRUG|Aripiprazole|
223543546|NCT01913327|DRUG|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
223543547|NCT01913327|DRUG|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
223543548|NCT05317598|OTHER|Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)|It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
224293588|NCT07198074|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223543549|NCT02605408|DEVICE|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
223543550|NCT02605408|PROCEDURE|Phacoemulsification|Removal of the cataractous lens
223543551|NCT01381770|BIOLOGICAL|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
223543552|NCT00672230|DIETARY_SUPPLEMENT|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
223977244|NCT02376647|OTHER|Driving pressure limited ventilation|"Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment."
223977245|NCT02376647|OTHER|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
223977246|NCT04721899|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks
223977247|NCT03921242|DRUG|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
223977248|NCT03921242|DRUG|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
223977249|NCT03921242|DRUG|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
223977250|NCT03921242|DRUG|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
223977251|NCT03921242|DRUG|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
223977252|NCT00206739|DRUG|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
223977253|NCT02491710|DEVICE|Training on low-cost box trainer|
223977254|NCT02491710|DEVICE|Training on standard box trainer|
223977255|NCT03756168|DEVICE|1060nm Diode laser|"All subjects received a single treatment with Venus Bliss' 1064 nm laser administered to the flanks~Venus Bliss is a non-invasive medical aesthetic device designed for body contouring. The device contains four 1060 nm diode laser applicators which are 60x60 mm in size. It has a separate RF/PEMF applicator, but this was not used in this study. There is a belt included with the system to allow for the secure attachment of the applicators to the treatment area."
223977256|NCT00936962|BIOLOGICAL|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
223977257|NCT01929876|DRUG|Cobimetinib|10 milligram (mg) (2\* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
223977258|NCT01929876|DRUG|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
223977259|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
223977260|NCT00779064|DRUG|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
223977261|NCT01542398|BEHAVIORAL|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
223977262|NCT02043834|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
223977263|NCT04037345|BIOLOGICAL|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
223977264|NCT04037345|BIOLOGICAL|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
223977265|NCT04037345|BIOLOGICAL|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
223977266|NCT01845649|DRUG|WC3011 Estradiol Vaginal Cream|Daily for 14 days followed by 3 times per week for 10 weeks
223977267|NCT01845649|DRUG|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
223977268|NCT05162898|DRUG|toripalimab|240mg,ivgtt, every three weeks as a cycle, the first day of each cycle.
223977269|NCT05162898|DRUG|Lenvatinib|12mg (weight ≥60kg) or 8mg (weight \<60kg) orally, once a day
223977270|NCT05162898|DEVICE|Radiofrequency ablation|ultrasound-guided percutaneous radiofrequency ablation of recurrent hepatocellular carcinoma
223977271|NCT01893853|OTHER|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at \~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
223977272|NCT03988998|DRUG|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
223977273|NCT03988998|DRUG|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
223977274|NCT03991988|DRUG|Montelukast|"Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events."
223977275|NCT03991988|DRUG|Placebo oral tablet|Participants in this arm will take a matched placebo pill daily
223977276|NCT04224259|PROCEDURE|Ultrasound pre-scan|Before cannulation, use ultrasound to mark the position of right internal jugular vein
223977277|NCT04224259|PROCEDURE|Landmark guidance|The traditional landmark-guided technique for internal jugular vein cannulation, including recognizing the sternocleidomastoid muscle and palpating the carotid artery
223977278|NCT05243615|BEHAVIORAL|Guided internet delivered cognitive behavioural therapy|A 10-week internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a stroke. In addition to the online program, a Guide with experience delivering ICBT will provide support by email or phone call once a week. The Guide will spend approximately 15 minutes per week/per client.
223977279|NCT05243615|BEHAVIORAL|Stroke rehabilitation mental health education|A 10-week stroke-specific rehabilitation education program for stroke patients in usual care at specialized stroke rehabilitation units. The lessons will include information on spinal cord injury rehabilitation: 1)stroke basics, 2)mental health after stroke, 3)pain after stroke, 4)understanding rehabilitation 5)summary of lessons through an online platform. A Guide will check in with participants once a week to answer any content-related questions. The Guide will spend approximately 15 minutes per week/per client.
223977280|NCT05000099|OTHER|video calls|A tablet for video-calls will be available for patients and families. Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time
223977281|NCT00476112|DRUG|Vernakalant Injection 20 mg/mL|
223977282|NCT00003693|DRUG|Dolastatin 10|IV bolus once every 3 weeks.
223977283|NCT05986084|DRUG|Cabotegravir Injection [Apretude]|Injection
223977284|NCT04649671|BEHAVIORAL|Mobile health|"Perform exercise daily with mobile application and wearable device (warm-up, stretching, aerobic, and strengthening).~Mobile application: Hepatocellular carcinoma by Second Doctor Wearable device: Dofit"
223977285|NCT02412111|DRUG|Ivacaftor|
223977286|NCT02412111|DRUG|Tezacaftor/Ivacaftor|
223977287|NCT00487552|DEVICE|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
223977288|NCT01543334|BIOLOGICAL|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
224117482|NCT01242020|DRUG|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
223726142|NCT04473014|BEHAVIORAL|Heat Pain Paradigm|A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
223977289|NCT06064045|BEHAVIORAL|Simulation-based team training intervention|"Participants in the intervention group will aim to participate in simulation at a higher quantity and frequency.~Moreover, the intervention group:~1. Enrolled 15 healthcare professionals in a 3-day training program to become simulator facilitators, enabling an increase in the utilization of simulation within the group (October 2022).~2. Organized a 2-day workshop for all pediatric simulation facilitators with the objective of establishing a more robust and standardized foundation for implementing simulation within their respective departments (March 2023).~3. Procured essential equipment, including mannequins, SimPads, and monitors (before the intervention period).~4. Provide simulator facilitators with access to an online repository where they can access scenarios for conducting simulations (during the intervention period)."
224117483|NCT01695980|PROCEDURE|ETT with non modified retractor|adenotonsillectomy
224293589|NCT07198074|DRUG|Carboplatin|Given IV
224293590|NCT07198074|PROCEDURE|Computed Tomography|Undergo CT
224293591|NCT07198074|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224293592|NCT07198074|DRUG|Paclitaxel|Given IV
224293593|NCT07198074|BIOLOGICAL|Pembrolizumab|Given IV
224293594|NCT07204158|DEVICE|Spray pompe nasal confort|Seawater solution with hyaluronan
224293595|NCT07203326|BIOLOGICAL|Alloderm|Alloderm is a ready to use tissue graft, made from donated allograft human dermis, processed to remove cells while preserving biologic components and structure of the dermal matrix.
224293596|NCT07203326|BIOLOGICAL|MicroDerm|MicroDerm is an acellular dermal matrix sourced from donated human tissue. Cytoplast™ MicroDerm is micro-surfaced.
224293597|NCT07212699|OTHER|KneeApp|"Our app collects patient-authorized mobility data that are already stored on the patient's smartphone and those that will be recorded in the future, and analyzes these data with respect to their temporal patterns. Each study participant can decide individually which data they wish to share.~In addition, participants are prompted at regular intervals to perform and document functional tests, such as gait assessments (once per month) and knee function tests (weekly).~Furthermore, subjective health data are regularly collected using standardized PROMs: KOOS and SF-36 every three weeks, patient-reported satisfaction with health status on a monthly basis, and user satisfaction with the app every three months.~The collected data can be accessed both by the patient and the study team and can be downloaded and stored as a PDF file if needed.~Participation in the study requires a single on-site visit at the Department and Outpatient Clinic of Orthopedics and Sports Orthopedics. No further in-pe"
224293598|NCT07212933|BIOLOGICAL|RetroNectin active Killer cells|RetroNectin-Activated Killer (RAK) cells, derived from autologous peripheral blood mononuclear cells (PBMCs), are induced in vitro by RetroNectin along with anti-CD3 monoclonal antibody and Interleukin-2 (IL-2). These cells consist of various cytotoxic effectors, primarily CD8+ T (cytotoxic T, Tc) cells and natural killer T cells, which exhibit minimal cytotoxicity to normal cells but substantial specificity to tumor cells, thereby demonstrating both safety and potent anti-tumor activity.
224117484|NCT01695980|OTHER|LMA with modified retractor|LMA with modified retractor
224117485|NCT03418402|DEVICE|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
224117486|NCT03418402|DEVICE|Standard insufflator|Standard insufflator
224117487|NCT02402192|DRUG|Corifollitropin alfa|
224117488|NCT04521959|PROCEDURE|Blood flow restricted and normal aerobic exercise and resistance exercise|Interventions of the same duration and intensity will be applied to two groups.
224117489|NCT02865044|OTHER|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
224117490|NCT02865044|OTHER|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
224117491|NCT00379938|BIOLOGICAL|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
224117492|NCT00379938|DRUG|Placebo|Saline control
224117493|NCT00379938|BIOLOGICAL|MF-59|Adjuvant
223977290|NCT06845735|DEVICE|Non-Absorbable Sutures|Non-Absorbable Sutures
223977291|NCT06845735|DEVICE|Absorbable Suture|Absorbable suture
223977292|NCT03170947|DEVICE|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
223977293|NCT03170947|DEVICE|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
223977294|NCT01169636|DRUG|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
223977295|NCT01169636|DRUG|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
224117494|NCT00339079|DRUG|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
223977296|NCT01169636|DRUG|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
223977297|NCT01169636|DRUG|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
223977298|NCT01169636|DRUG|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
223977299|NCT01169636|DRUG|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
223977300|NCT03088098|DEVICE|LAAO|Left atrial appendage occlusion for stroke prevention
223977301|NCT00039117|BIOLOGICAL|oblimersen sodium|Given IV
223977302|NCT00039117|DRUG|cytarabine|Given IV
223977303|NCT00039117|DRUG|daunorubicin hydrochloride|Given IV
223977304|NCT00039117|OTHER|laboratory biomarker analysis|Correlative studies
223977305|NCT00039117|OTHER|pharmacological study|Correlative studies
223977306|NCT04111900|BEHAVIORAL|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
223977307|NCT03745378|OTHER|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
224117495|NCT00339079|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
223977308|NCT02705625|DRUG|MIV-711|MIV-711 administered orally once daily
223977309|NCT02705625|DRUG|Placebo|Placebo manufactured to mimic MIV-711 capsule.
223977310|NCT02719262|DEVICE|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
223977311|NCT02168231|PROCEDURE|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
223977312|NCT01565317|OTHER|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
223977313|NCT04071509|DEVICE|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
223977314|NCT03680963|PROCEDURE|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
224117496|NCT00339079|OTHER|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
224117497|NCT00339079|DRUG|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
223543553|NCT01352286|GENETIC|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
224117498|NCT02764866|OTHER|Sleep testing|Home sleep testing
224117499|NCT01011062|PROCEDURE|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
224117500|NCT01011062|DRUG|Losartan|Acute administration of losartan 200mg total prior to clamp
224117501|NCT01011062|DRUG|Saline|Infusion of Saline as a volume control intervention
224117502|NCT00231062|DEVICE|Sinuplasty|
224117503|NCT02277210|OTHER|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
224117504|NCT00502710|DRUG|Placebo|Placebo po daily.
224293599|NCT07212933|DRUG|TAS-102 (trifluridine and tipiracil, Lonsurf®)|Based on the results of the RECOURSE \[16\] and TERRA \[17\] studies, TAS-102 (Trifluridine/Tipiracil Hydrochloride) will be administered orally at a dose of 35mg/m², twice daily, Days 1-5, with each cycle lasting 3 weeks.
224293600|NCT07212751|DIAGNOSTIC_TEST|CTCA|"Patient who is ≥ 18 years old presented with chest pain and has undergone CTA between 01-Jan-2012 and 31-Dec-2022 before treatment~\- If multiple CTAs are taken, the most updated one before treatment commencement will be chosen."
224293601|NCT07212296|PROCEDURE|Conventional total knee replacement|Knee replacement without robotic technology
224293602|NCT07212296|PROCEDURE|Robotic TKR|Total knee replacement WITH robotic technology
224117505|NCT00502710|DRUG|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
224117506|NCT01052012|DRUG|SABER-Bupivacaine|Injectable Extended Release Solution; SABER-Bupivacaine /Once
224117507|NCT01052012|DRUG|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
224117508|NCT01052012|DRUG|SABER-Placebo|Injectable Solution; SABER-Placebo/Once
224117509|NCT02228512|DRUG|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
224117510|NCT02228512|DRUG|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
224117511|NCT02228512|DRUG|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
224117512|NCT02228512|DRUG|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
224117513|NCT02228512|DRUG|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
224117514|NCT02228512|DRUG|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
224117515|NCT02228512|DRUG|Cyclophosphamide|Part B: 750 mg/m2 Day 5
224293603|NCT07212634|DEVICE|Transcranial Direct Current Stimulation|"Different experimental groups received tDCS stimulation at the following distinct sites: bilateral cerebellar hemispheres, bilateral cortical areas corresponding to the suprahyoid muscles, and combined bilateral cerebellar hemispheres alongside bilateral cortical areas corresponding to the suprahyoid muscles.~Stimulation parameters: 2 mA constant current, 20 minutes per session Treatment regimen: 5 sessions per week for 2 consecutive weeks"
224293604|NCT07212634|OTHER|Sham tDCS|The patients in this group will receive sham stimulation applied to the same area for the same duration.
223726143|NCT00571987|DEVICE|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
223726144|NCT00426855|DRUG|Bendamustine|starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w
223977315|NCT03680963|PROCEDURE|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
223977316|NCT00494026|DRUG|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
223726145|NCT00426855|DRUG|Bortezomib|weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w
223726146|NCT06327867|DEVICE|Oro Tracheal Intubation by DL|DL
223977317|NCT00494026|DRUG|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
223977318|NCT00494026|PROCEDURE|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
223977319|NCT04366362|PROCEDURE|Individualised ACL reconstruction|ACL reconstruction based on anatomical and functional distinctiveness of each patient separately
223977320|NCT04366362|PROCEDURE|Conventional ACL reconstruction|ACL reconstruction based on surgeons experience without taking into account any other patients characteristics
223977321|NCT03423368|DEVICE|Libramed|Policaptil Gel Retard
224117516|NCT06274346|OTHER|Multiangular Isometric exercise|already were described in arm descriptions
224117517|NCT04100070|BEHAVIORAL|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
224117518|NCT05386433|DRUG|Paxlovid|"Paxlovid contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir \[PF-07321332\] is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.~Ritonavir is co-administered with nirmatrelvir to help slow its metabolism in order for it to remain active in the body for longer periods of time at higher concentrations to help combat the virus."
223726147|NCT06327867|DEVICE|Oro Tracheal Intubation by VL|VL
223726148|NCT05740761|OTHER|Gene editing in vitro|Testing of gene editing efficiency in vitro in human cellular models derived from patients
223726149|NCT01287689|OTHER|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
223726150|NCT03012347|DRUG|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
224117519|NCT05386433|DRUG|standard-of-care|standard-of-care of COVID-19
224117520|NCT05757999|DRUG|Magnesium Sulphate|A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
224117521|NCT05757999|DRUG|Saline|The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
224117522|NCT00388752|PROCEDURE|Acupuncture|
223726151|NCT03012347|DRUG|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
223726152|NCT06030557|DRUG|Truvada|Participants will receive either Truvada or Descovy (based on prescription guidelines).
223726153|NCT06480747|OTHER|Resistance exercise training|Participants will strength train via linear periodization resistance exercise training.
223726154|NCT04202965|DRUG|PTG-300|Active treatment with PTG-300 injected subcutaneously.
223726155|NCT05380804|DIAGNOSTIC_TEST|cutaneous silent period (CSP) measurement|CSP recordings are performed in the upper extremities using the same surface bar recording electrodes. Filters are set at 2 Hertz (Hz) to 10 kilo Hz, sensitivity is 200 microVolts (µV) and sweep speed is set at 200 milliseconds (ms). Stimulating electrode is placed on the index finger and recording bar electrode is placed on the abductor pollicis brevis (APB) muscle. During steady submaximal (50% of the maximal contraction) thumb abduction, 10 consecutive painful electrical stimuli of standard 80-milli Ampere (mA) intensity and 0.5-ms duration are applied to the index finger and responses are superimposed. CSP latency and duration are calculated and recorded. CSP latency is defined as the time between the stimulation and the onset of the silent period. CSP duration is calculated as the time interval between the beginning and end of the CSP.
223726156|NCT04819074|PROCEDURE|Microsurgery|Microsurgery for unruptured intracranial aneurysm
223977322|NCT03423368|DEVICE|Placebo|Placebo-comparator
223977323|NCT00187499|DRUG|Inhaled fluticasone 500 ug BID for 8 weeks|
223977324|NCT00002647|DRUG|verteporfin|
223977325|NCT00002647|PROCEDURE|conventional surgery|
223977326|NCT03507153|PROCEDURE|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
223977327|NCT03507153|PROCEDURE|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
224117523|NCT04500288|DEVICE|LEFT Device|LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
224117524|NCT00883428|OTHER|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
224117525|NCT06022679|OTHER|CBCT|CBCT examination in supine position A computerized 3D-analysis using Dolphin Imaging 11.95 software was performed in each CBCT.
223543554|NCT04892186|DRUG|Myo-inositol|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used myo-inositol 2g + folic acid 200mcg twice daily for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
223543555|NCT04892186|DRUG|Metformin|"30 women with polycystic ovary syndrome and insulin resistance or glucose intolerance will used metformin 850 mg twice a day for 6 months, having a re-evaluation every 3 months.~Evaluation will be made by transvaginal ultrasound, abdominal ultrasound, inflammatory tests, hormonal tests, glycemic curve with insulin curve, lipid profile, body mass index, evaluation of abdominal and hip circumference."
223543556|NCT03069066|DEVICE|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
223977328|NCT05972304|DEVICE|Nasal positive airway System by Vyaire Medical|Incidence of Hypercarbia and Hypoxia in interventional group and its monitoring using transcutaneous (SpO2) and (tCO2) Sensor
223977329|NCT00518856|OTHER|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
224293605|NCT07212283|BEHAVIORAL|Wise Intervention LGB-TNB|The intervention will be designed to reduce aggressive behaviors based on sexual orientation and gender identity and to promote prosocial behaviors toward these individuals. This intervention will include three components: (1) reading scientific studies about people's ability to change. In addition, they will read other studies about how thoughts and emotions influence behavior through brain pathways, and that these pathways can be modified under certain circumstances; (2) reading testimonials that support the idea that people can change. These testimonials include accounts of people who were victims or perpetrators based on sexual orientation and gender identity, including important components of empathy and prosocial behaviors toward the victims. To give credibility to the intervention, they will be informed that these stories were written by other young people who previously participated; and (3) self-persuasion exercises that involve an active commitment to change.
224293606|NCT07212283|BEHAVIORAL|Values alignment wise intervention|This intervention will be based on the same strategies as the experimental intervention, but it will not address aspects related to prosocial behaviors or aggression toward LGB-TNB individuals; instead, it will be applied to improve adolescents' eating habits.
224293607|NCT07212127|DEVICE|Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture theory（TENS-WAA)|Based on the theory of wrist and ankle needles, transcutaneous electrical nerve stimulation is a kind of analgesic treatment device that combines wrist and ankle needles with transcutaneous electrical nerve stimulation, and can be worn on the human wrist and ankle. Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture Theory uses low-frequency electronic pulses to stimulate the entry point of the wrist-ankle needle, which has the advantages of easy to wear, concentration of the treatment site, safety of the treatment, and no needles.
224117526|NCT04850911|DRUG|Ketamine Hydrochloride|Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who have failed to respond to conventional monoaminergic agents.
224117527|NCT04850911|OTHER|No intervention (placebo)|Placebo injection (0.9% sodium chloride)
223543557|NCT05272189|BEHAVIORAL|Simulated Second Reader AI|In this experiment, in some conditions, the participant makes their decision in the presence of information about a simulated artificial intelligence decision.
223543558|NCT05272189|BEHAVIORAL|Target Prevalence|The frequency with which targets are presented varies from 10% to 90%
223726157|NCT01277263|DEVICE|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
223726158|NCT04833881|OTHER||
223726159|NCT02490332|DEVICE|Ventilation tube treatment|Tympanostomy
223977330|NCT00518856|OTHER|Standard of care|continued with current standard of care for birth attendants
224117528|NCT02973646|DRUG|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
224117529|NCT02973646|DRUG|Peginterferon Alfa-2B|
224117530|NCT00398528|DRUG|Glatiramer acetate, (Copaxone®)|
224117531|NCT00398528|DRUG|IFN-β-1a, (Avonex®)|
224117532|NCT03514472|DIETARY_SUPPLEMENT|Dried Moringa oleifera leaves|
224117533|NCT02152423|DRUG|LOVENOX|LMWH
224117534|NCT02152423|DRUG|ENOXAMED|LMWH
223977331|NCT05557071|BEHAVIORAL|Digital Health Behaviour Change Platform|"Participants will gain access to 6 weekly lessons.~A series of 6 weekly educational modules including information on psychosocial determinants of physical activity engagement, adherence and maintenance, as well as corresponding behaviour change techniques and a number of other tools and strategies, such as reflection activities, quizzes, and worksheets. Mini podcasts are available to supplement the concepts introduced in the modules. The content is tailored for early career professionals. There will be an emphasis on tactics (e.g., mindfulness, acceptance, emotion regulation) to assist with overcoming incidental affect."
223977332|NCT00489645|DRUG|placebo|placebo SC during euglycemia
223977333|NCT00489645|DRUG|pramlintide|pramlintide SC during eglycemia
223977334|NCT00489645|DRUG|placebo|placebo during hyperglycemia
223977335|NCT00489645|DRUG|pramlintide|pramlintide SC during hyperglycemia
223977336|NCT06149143|DEVICE|Cardiac Performance System (NSR)|Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function.
223977337|NCT00364390|DRUG|Anginera, a human tissue replacement therapy|
223977338|NCT03298529|OTHER|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
223977339|NCT03298529|OTHER|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
223977340|NCT03298529|OTHER|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
223977341|NCT03298529|OTHER|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
223977342|NCT03298529|OTHER|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
223977343|NCT03298529|OTHER|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
223977344|NCT03238222|BEHAVIORAL|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 \& 2) and 2 x 20-minute follow-up telephone calls (weeks 6 \& 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
223977345|NCT00004039|BIOLOGICAL|recombinant interferon alfa|
223977346|NCT00004039|BIOLOGICAL|rituximab|
223977347|NCT00004039|DRUG|cyclophosphamide|
223977348|NCT00004039|DRUG|doxorubicin hydrochloride|
223977349|NCT00004039|DRUG|prednisone|
223543559|NCT03037762|PROCEDURE|Flexible Endoscopic Evaluation of Swallowing|
223543560|NCT01465035|BIOLOGICAL|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
223543561|NCT01465035|BIOLOGICAL|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
223977350|NCT00004039|DRUG|vincristine sulfate|
223977351|NCT06230133|BEHAVIORAL|MBSR intervention|In our study, it is the same to arm description.
223977352|NCT01916798|DRUG|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
223977353|NCT04937205|BEHAVIORAL|MOVE|The MOVE physical activity support program is based on the Self-Determination Theory and targets autonomous motivation for physical activity by encouraging 1) choice in physical activity type (e.g. walking, household chores, yoga), 2) a meaningful, value-based rationale for engaging in physical activity, and 3) physical activity that is intrinsically enjoyable. MOVE was delivered during two, 60-75 minute group-based classes and one, 45 minute individualized 1:1 support session to enhance adherence to physical activity recommendations within a lifestyle weight loss program. The group-based classes included a combination of PowerPoint slides, participant handouts, and group-based discussions. All MOVE content was delivered by trained study staff.
223977354|NCT02866071|DRUG|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
223977355|NCT02866071|DRUG|Placebo-Comparator|50mg IN Placebo
223977356|NCT06332300|DRUG|Adebelimumab+Famitinib + FOLFIRI+Ariely|Adebelimumab in combination with famitinib and lateral ventricular chemotherapy in patients with non-squamous NSCLC with soft meningeal metastases who have failed EGFR-TKI therapy
223977357|NCT04296422|DRUG|NSAIDs or oral contraceptives treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
223977358|NCT04296422|DEVICE|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
223977359|NCT04296422|DEVICE|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner
224117535|NCT00740506|BEHAVIORAL|Frequency of Intercourse|
223543562|NCT04546919|OTHER|sepsis|Body temperature higher than 38°C or lower than 36°C; Heart rate higher than 90/min; Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg; White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.
223543563|NCT02862886|OTHER|myometrium biopsy|
223977360|NCT04865783|PROCEDURE|Saline spray|The saline spray will be applied twice for 1-2 seconds.
223977361|NCT04865783|PROCEDURE|Cryospray|The cryospray will be applied twice for 1-2 seconds.
223977362|NCT03946098|BEHAVIORAL|iCBT|A newly developed iCBT protocol targeting problem gambling.
223977363|NCT04673799|DRUG|MV088 injection|MV088 injection (60mg) by subcutaneous injection once on the first day
223977364|NCT04673799|DRUG|Prolia® injection|Prolia® injection (60mg) by subcutaneous injection once on the first day
223977365|NCT03765515|DEVICE|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
223977366|NCT03765515|DEVICE|Q-Fix|Q-Fix
224117536|NCT02384369|DRUG|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
224117537|NCT05164276|OTHER|Head position|Before nasotracheal intubation, patient's head is positioned to one of three positions according to assigned group: sniffing, neutral or flexed position.
223977367|NCT05858801|DEVICE|PRIMUS|PRIMUS system
223977368|NCT03284125|OTHER|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
223977369|NCT02190552|DEVICE|EmboTrap® Revascularization Device|
223977370|NCT04787289|DRUG|Bevacizumab|Low standard dose of bevacizumab, combined with single agent chemotherapy (7.5mg/kg IV Q3w or 5mg/kg IV Q2w)
223977371|NCT01620307|DRUG|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
223977372|NCT02637856|DRUG|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
223977373|NCT02637856|DRUG|Ocrelizumab|Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
223977374|NCT03677245|OTHER|Strider Balance Bike|Learning to ride a Strider balance bike
223977375|NCT03343210|DIAGNOSTIC_TEST|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
223977376|NCT00814411|BEHAVIORAL|group family planning counseling|group family planning counseling for gynecological patients with unmet need
223977377|NCT00814411|BEHAVIORAL|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
223977378|NCT00440388|DRUG|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
223543564|NCT05238415|DIAGNOSTIC_TEST|Psychological and Physiological Assessments|About N = 60 patients admitted to the study receive a 3-day assessment (a further examination) at the Kiliani-Klinik Bad Windsheim which considers physical and psychological parameters relevant for the diagnosis of a Post-/ Long-COVID Syndrom.
223543565|NCT00921050|DRUG|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
223543566|NCT00921050|DRUG|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
223977379|NCT00440388|DRUG|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
224117538|NCT03596125|DRUG|N-acetylcysteine|N-acetylcysteine supplementation
224117539|NCT03596125|DRUG|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
223977380|NCT04615598|BEHAVIORAL|Action observation|The idea is to show some videos with the aim of improving patients' tongue strength.
224117540|NCT05938439|DEVICE|MAGUS placement|"An upper endoscopy will be performed with the use of fluoroscopy under general anaesthesia with orotracheal intubation. The delivery system will be placed over a guidewire, under fluoroscopy. The main steps are the following:~* Placement through the endoscope of a soft guidewire through the upper GI tract;~* Insertion of the MAGUS system on the guidewire;~* Advancement of the MAGUS system until proximal magnet reach the top of the septum;~* Release and placement of the proximal magnet at the bottom of the septum, pouch side;~* Meeting of the distal and proximal magnet on both sides of the septum, by pulling on the delivery system;~* Release of the distal magnet and activate the retractable wire;~* Insure that wire is not blocked and unblocked it if applicable.~Endoscopy and contrast injection will be performed before and after placement to ensure the correct positioning of the magnets."
223726160|NCT01195558|OTHER|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
223977381|NCT04615598|BEHAVIORAL|Placebo group|The idea is to show some videos of vegetation with the aim of having an intervention time but ineffective.
223977382|NCT05596747|DRUG|LY3209590|Administered SC.
223977383|NCT05596747|DRUG|Insulin Glargine|Administered SC.
223977384|NCT05722405|DRUG|Ixazomib plus low-dose lenalidomide|Whether Ixazomib combined with low-dose lenalidomide improves the outcome and prognosis of patients with high-risk multiple myeloma as a maintenance treatment option compared to ixazolomib alone
223977385|NCT05722405|DRUG|Ixazomib|Ixazomib alone
223977386|NCT00980577|DEVICE|NUUS|Sonosite Micro Maxx
223977387|NCT05097937|OTHER|Sham intervention|The needle will be inserted into the right common extensor tendon of the epicondyle for 90 seconds without galvanic current.
223977388|NCT05097937|OTHER|Low intensity percutaneous electrolysis|A single impact of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 0.3 mA for 90 seconds.
223977389|NCT05097937|OTHER|High intensity percutaneous electrolysis|Three impacts of galvanic current will be applied in the common extensor tendon of the epicondyle (right side) with an intensity of 3 mA and a duration of 3 seconds each.
223726161|NCT00904644|DRUG|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
223977390|NCT03049098|BEHAVIORAL|Simulation|A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
223977391|NCT00907192|BEHAVIORAL|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
223977392|NCT00907192|BEHAVIORAL|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
223977393|NCT05479188|DEVICE|Cerebral oximetry|Cerebral oximetry monitoring with near-infrared spectroscopy.
223977394|NCT05479188|DEVICE|Peripheral oximetry|Tissue perfusion monitoring with somatic near-infrared spectroscopy.
223977395|NCT05479188|DEVICE|Cerebral autoregulation|Cerebral autoregulation monitoring with COx.
223977396|NCT05479188|DEVICE|Sublingual microscopy|Evaluation of microcirculation with sublingual microscopy.
223977397|NCT01674920|BEHAVIORAL|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
223977398|NCT04544865|DEVICE|Staple Line Reinforcement|ENDOPATH ECHELON Staple Line Reinforcement is used for reinforcement of staple lines during lung resection and bariatric surgical procedures, according to instructions for use.
223977399|NCT04231162|DIETARY_SUPPLEMENT|Active product|Bifidobacterium lactis HN019 (probiotic powder). One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
223977400|NCT04231162|DIETARY_SUPPLEMENT|Control product|Placebo. One capsule to consume orally with still water (not sparkling) at room temperature once a day at least 15 minutes before breakfast time.
223977401|NCT04358536|DEVICE|CovX|Convolutional neural network for classification of COVID-19 from chest X-rays
223977402|NCT04731974|DRUG|Melatonin 3 MG|Participants in the melatonin group will be instructed to take 3-mg liquid melatonin pill 1 hour prior to their habitual fall asleep time daily for 30 days.
223977403|NCT04731974|OTHER|Placebo|Participants in the placebo group will be instructed to take liquid placebo pill 1 hour prior to their habitual fall asleep time daily for 30 days.
223543567|NCT03829592|DRUG|misoprostol in a neutral media|giving misoprostol in a neutral media
223543568|NCT03829592|DRUG|misoprostol in an acidic media|giving misoprostol in an acidic media
223543569|NCT03829592|DRUG|misoprostol in an alkaline media|giving misoprostol in an alkaline media
223543570|NCT01336816|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
223543571|NCT01336816|OTHER|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
223543572|NCT03816176|DRUG|Isavuconazonium sulfate|Intravenous (IV) infusion
223543573|NCT03816176|DRUG|Isavuconazonium sulfate|Oral capsule
223543574|NCT05178784|DEVICE|External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation|Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
223543575|NCT02530177|OTHER|Clinical Assessments|
223543576|NCT02530177|BEHAVIORAL|Questionnaires|
223543577|NCT02530177|OTHER|Saliva sample|(only once, preferably at baseline)
223543578|NCT02267889|PROCEDURE|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
223543579|NCT02267889|DEVICE|D-SPECT dedicated cardiac nuclear camera|
223977404|NCT02740205|OTHER|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
223977405|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
223977406|NCT00175045|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
223977407|NCT03320642|DRUG|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
223977408|NCT03320642|DRUG|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
223977409|NCT04912700|BIOLOGICAL|COVID-19 vaccine|Full or partial reception of vaccine
224117541|NCT01955174|DRUG|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
223977410|NCT02815735|DEVICE|comfilcon A|contact lens
224117542|NCT01955174|OTHER|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
224117543|NCT00863629|DRUG|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
223726162|NCT05306301|DRUG|Ponatinib|Ponatinib is a novel, synthetic, orally-active TKI discovered using a computational and structure based drug design approach. Ponatinib was specifically designed to inhibit all clinically relevant variants of BCR-ABL1, including the T315I mutant (15-17). In vitro assays have demonstrated that Ponatinib potently inhibits the kinase enzymatic activity of the T315I ABL kinase domain, as well as that of the native (unmutated) enzyme. In leukemia cell lines expressing these BCR-ABL1 variants, Ponatinib potently inhibited BCR-ABL1 signaling, leading to the reduction of cellular proliferation and induction of apoptosis. Ponatinib also inhibits the proliferation of cell lines expressing other major clinically-observed Imatinib-resistant mutants of BCR-ABL1.
223726163|NCT02798575|DEVICE|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
223726164|NCT01238471|DRUG|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
223977411|NCT02815735|DEVICE|lotrafilcon B|contact lens
223977412|NCT01508832|DRUG|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
223977413|NCT01508832|DRUG|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
223977414|NCT04065516|PROCEDURE|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
223977415|NCT02306083|DRUG|Placebo three times a day|
223977416|NCT02306083|DRUG|glucosamine sulfate 1500 mg three times a day|
223977417|NCT03820570|PROCEDURE|hernia repair|inguinal hernia repair
223977418|NCT00397202|DEVICE|Diva Cup TM|See Detailed Description.
223977419|NCT00334139|DRUG|Zoledronic Acid|every 4 weeks for 4 months
223977420|NCT02221999|DRUG|Paclitaxel|
223977421|NCT02221999|DRUG|Cisplatin|
223977422|NCT02221999|DRUG|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
223977423|NCT02221999|DRUG|Letrozole|
223977424|NCT01501747|DRUG|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
223977425|NCT01501747|DRUG|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
223977426|NCT04608032|OTHER|[Eco-Sz] Ecological Cognitive training program for schizophrenia spectrum disorder|The first group will have \[Eco-Sz\] Ecological Cognitive training program for schizophrenia spectrum disorder
223977427|NCT04608032|OTHER|Recovery-Oriented Therapy|The second group will have \[THoR\] Recovery-Oriented Therapy
223977428|NCT02973802|BIOLOGICAL|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
223977429|NCT00610818|OTHER|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
223977430|NCT03357471|DRUG|e-Device|"* Active Substance: Certolizumab Pegol~* Pharmaceutical form: Solution for injection~* Route of administration: subcutaneous injection by e-Device"
224117544|NCT00233220|BEHAVIORAL|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
223726165|NCT01238471|DRUG|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
223977431|NCT04841070|OTHER|Ages & Stages Questionnaires®, Third Edition (ASQ3)|Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.
223726166|NCT03042624|DIETARY_SUPPLEMENT|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
223977432|NCT02668627|PROCEDURE|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
224117545|NCT00233220|BEHAVIORAL|Usual Care|Patients will receive usual care.
224117546|NCT01105338|BEHAVIORAL|Green tea drink|Green tea drink
224117547|NCT01105338|DIETARY_SUPPLEMENT|green tea capsules|green tea capsules
224117548|NCT01105338|OTHER|Green tea placebo capsules|Green tea placebo capsules
224117549|NCT01105338|DIETARY_SUPPLEMENT|Lycopene capsules|Lycopene capsules
224117550|NCT01105338|OTHER|Lycopene placebo capsules|Lycopene placebo capsules
224117551|NCT01105338|OTHER|Tomato rich diet|Tomato rich diet
224117552|NCT04246229|DIAGNOSTIC_TEST|Transcutaneous bilirubinometry|use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels
223726167|NCT03042624|DIETARY_SUPPLEMENT|Maltodextrins|7 g of maltodextrins powder
223726168|NCT02232165|OTHER|Hypotension avoidance|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP \>= 65 mmHg is not inferior to induced hypertension.
223726169|NCT02232165|OTHER|Induced hypertension|Induced hypertension with MAP \>= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
223977433|NCT03457974|OTHER|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
223977434|NCT00392535|RADIATION|conventional radiotherapy 74 Gy delivered in 37 fractions|
223977435|NCT00392535|RADIATION|hypofractionated radiation therapy 60 Gy in 20 fractions|
223977436|NCT00392535|RADIATION|hypofractionated radiation therapy 57 Gy in 19 fractions|
223977437|NCT03364478|PROCEDURE|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
223977438|NCT03364478|PROCEDURE|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
223977439|NCT02943707|PROCEDURE|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
223977440|NCT02943707|DRUG|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
223977441|NCT02609152|DRUG|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
224117553|NCT04246229|DIAGNOSTIC_TEST|Serum bilirubin|use of blood draws to measure serum bilirubin level
224117554|NCT04632329|DEVICE|Negative Pressure Treatment via the Mercury Multi-Pressure Dial|Negative Pressure Treatment via the Mercury Multi-Pressure Dial
224117555|NCT04822922|GENETIC|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|The hUC-MSCs were injected intravenously on the 1, 4, 7 and 10 days after patients recruitment. The treatment doses include low dose: 4\*10\^5 cells/kg/each time, and medium dose: 8\*10\^5 cells/kg/each time, high dose 12\*10\^5 cells/kg/each time. After 3 groups of patients were enrolled, the group with appropriate safety and effectiveness was selected and the other 4 subjects were included.
224117556|NCT00818038|DRUG|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
224117557|NCT00668525|DRUG|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
223977442|NCT02609152|DRUG|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
223977443|NCT05187247|DEVICE|Virtual Reality glasses|use of virtual reality glasses to reduce anxiety and pain levels
223977444|NCT01903083|DRUG|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
223977445|NCT01903083|DRUG|Gemcitabine|Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
223977446|NCT01903083|RADIATION|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
224117558|NCT00668525|DRUG|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
224117559|NCT00668525|DRUG|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
224117560|NCT02147938|DRUG|Tacrolimus|oral
224117561|NCT03468023|PROCEDURE|Short arm cast|Application of a below-elbow cast
223543580|NCT02904174|BEHAVIORAL|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 \& 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 \& 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 \& 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question \& answer session were included in the group education.
223977447|NCT01903083|PROCEDURE|Pancreaticoduodenectomy|Surgical resection.
223977448|NCT03017313|DRUG|LHRH analogues|3-or 6-month formulations
223977449|NCT02787811|DEVICE|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
223977450|NCT02476747|OTHER|EMR|performing EMR for patients with small polyp
223977451|NCT02476747|OTHER|CSP|performing CSP for patients with small polyp
223977452|NCT04241809|DIAGNOSTIC_TEST|Bioaerosol Sampling|Cyclone collection of exhaled bioaerosol
223977453|NCT02932085|DEVICE|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
224117562|NCT03468023|PROCEDURE|Long arm cast|Application of an above-elbow cast
224117563|NCT00492401|DRUG|decitabine|Given IV
224117564|NCT00492401|OTHER|laboratory biomarker analysis|Correlative studies
224117565|NCT00492401|OTHER|pharmacological study|Correlative studies
224117566|NCT00492401|OTHER|high performance liquid chromatography|Correlative studies
224117567|NCT00492401|GENETIC|microarray analysis|Correlative studies
224117568|NCT00492401|GENETIC|RNA analysis|Correlative studies
224117569|NCT00492401|OTHER|mass spectrometry|Correlative studies
224117570|NCT00492401|GENETIC|DNA methylation analysis|Correlative studies
224117571|NCT00492401|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
224117572|NCT02088944|DRUG|Infliximab|
224117573|NCT02119104|DRUG|Prevenar (13v)|Prevenar (13v)
224117574|NCT05730608|OTHER|18F-FDG PET/CT|Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
224117575|NCT00050713|DRUG|Sirolimus|
223977454|NCT05897983|OTHER|Rocabado exercises plus TENS device|Rocabado exercises form of 2 parts , 6×6×6 exercises part are repeated 6 times a day for 20 minutes for each repetition and mobilization exercises exercises is done by the therapist 3 times a week for 20 min ,each mobilization is performed for 10-15 times and repeated for 5-6 times. TENS is used, with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 mA and the pulse width is between 50-200 microseconds, The TENS will be applied for 20 min 3 sessions/week for 8 weeks, Traditional exercises are passive , active Rom exercises and massage, these exercises are performed for 30 minutes and repeated 2 times daily
223543581|NCT01415583|DRUG|Dexamethasone|0.5mg/kg (max dose 20mg)
223977455|NCT01850823|DRUG|placebo|
223977456|NCT01850823|DRUG|Mometasone Nasal Spray|
223977457|NCT01850823|DRUG|Mometasone nasal spray|
223977458|NCT02652195|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
223977459|NCT02652195|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
223977460|NCT01751165|BIOLOGICAL|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
223977461|NCT05663164|DRUG|Vitamin B|vitamin B1 (100mg) will be diluted in 50 ml 0.9% NACL(normal saline) and administered IV every 6 hours for 3 days
223977462|NCT05663164|DRUG|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
223977463|NCT02830048|DRUG|Glibenclamide|
223977464|NCT06202911|DRUG|oral n-acetyl cysteine|the active participants will receive oral N-acetyl cysteine with dose 20mg/dose every 6 hours for 10 days or until reaching full feeding or resolution of feeding intolerance
223977465|NCT06202911|OTHER|placebo|the control group will receive placebo
224117576|NCT02828319|DRUG|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
224117577|NCT02229149|DRUG|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
224117578|NCT02229149|DRUG|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
223543582|NCT04600726|OTHER|no intervention|no interventioni
223543583|NCT00003421|BIOLOGICAL|bleomycin sulfate|
223543584|NCT00003421|DRUG|ABVD regimen|
223543585|NCT00003421|DRUG|chlorambucil|
223543586|NCT00003421|DRUG|dacarbazine|
223543587|NCT00003421|DRUG|doxorubicin hydrochloride|
223977466|NCT00511277|DRUG|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
223543588|NCT00003421|DRUG|etoposide|
223977467|NCT05865171|DRUG|IXP|Tablets for oral administration.
223977468|NCT02573649|DEVICE|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
224117579|NCT02229149|DRUG|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~* Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~* Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~* Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~* Docetaxel 75 mg/m2 IV every 3 weeks; OR~* Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
224117580|NCT00282490|DEVICE|Nerve stimulator|
224117581|NCT02698423|DEVICE|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
224117582|NCT02698423|OTHER|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
223977469|NCT02573649|DEVICE|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
223977470|NCT00828893|DEVICE|navigation station|navigation station for gestures (carried out under CT) guidance
223977471|NCT03182296|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
223977472|NCT03100955|DRUG|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
223977473|NCT03100955|DRUG|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
223977474|NCT06125899|BEHAVIORAL|emhGAP-Age|"* Adapted emhGAP-IG;~* Adapted Problem-Solving Therapy (PST-PC)~* Support/supervision of lay providers~* Links to social support resources."
223977475|NCT02656849|DRUG|BAY 1000394|
223977476|NCT01852188|OTHER|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
223977477|NCT01752764|OTHER|Test product: Salad with a high dosage fat|
223977478|NCT01752764|OTHER|Control product: Salad with low dosage fat|
223977479|NCT02895360|DRUG|BAL101553|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 (study days 15-21)
223977480|NCT02895360|DRUG|BAL101553 at MTD|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
223977481|NCT03177109|DRUG|5% fluoride varnish|Applied topically as a coating at single point in time
223977482|NCT03177109|DRUG|8% arginine containing paste|Applied topically as a coating at single point in time
223977483|NCT03177109|DRUG|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
223977484|NCT02149524|DRUG|Herceptin (trastuzuamb)|Intravenous administration
224117583|NCT06133777|OTHER|Respiratory variability monitoring|Respiratory variability will be measured using a belt equipped with an external sensor allowing automatic and continuous analysis of thoracic movement by frequency analysis
224117584|NCT03826953|OTHER|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
224117585|NCT01373905|PROCEDURE|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
223543589|NCT00003421|DRUG|prednisolone|
223543590|NCT00003421|DRUG|procarbazine hydrochloride|
223977485|NCT02149524|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
223977486|NCT00307164|DRUG|NucleomaxX|36 g sachet taken orally three times daily
223977487|NCT00307164|DRUG|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
223977488|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
223977489|NCT05656612|OTHER|Written, Oral and Visual Education|Before the training, state anxiety levels were measured with a questionnaire. The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale.
223977490|NCT05656612|OTHER|Written, Oral and Visual Education|"Before the initial training was given, state anxiety levels were measured with a questionnaire.~The pre-process measurement was repeated. Post-procedure pain and satisfaction levels were measured using a scale."
223977491|NCT01416935|OTHER|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
223977492|NCT01457274|OTHER|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (\<60) than those in the light sedation group (BIS 70-80)."
223977493|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
223977494|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
223977495|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
224117586|NCT01373905|PROCEDURE|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
224117587|NCT00538382|DRUG|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
224117588|NCT02466269|PROCEDURE|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
224117589|NCT05126225|BEHAVIORAL|Stigma reduction|The intervention is modularized to have eight weekly sessions of 2-hour group discussions, led by a trained facilitator. The facilitator applies the principle of CBT and provides psychoeducation to promote the awareness and understanding of HIV stigma as well as training to help participants acquire alternative coping skills, such as relaxation techniques.
223543591|NCT00003421|DRUG|vinblastine sulfate|
223543592|NCT00003421|DRUG|vincristine sulfate|
223543593|NCT00003421|RADIATION|radiation therapy|
223543594|NCT00428181|BEHAVIORAL|Brief alcohol intervention|Brief alcohol intervention
223543595|NCT00428181|BEHAVIORAL|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
223543596|NCT00236288|DRUG|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
223543597|NCT03680833|PROCEDURE|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
223543598|NCT03611881|BEHAVIORAL|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
224117590|NCT03693365|PROCEDURE|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
224117591|NCT03211130|BEHAVIORAL|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
223977496|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
223977497|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
224117592|NCT03211130|BEHAVIORAL|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
224117593|NCT01187212|DRUG|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
223726170|NCT05775874|DRUG|AZD4547|Initiation dose: 80mg BID,po.
223726171|NCT05775874|DRUG|Tislelizumab|Tislelizumab:200mg Q3W
223726172|NCT05698797|OTHER|Hip strengthening exercises|Hip abductor and external rotator strengthening exercises were performed for 4 weeks.
223726173|NCT05698797|OTHER|Proprioceptive training|Proprioceptive training consisted of eight exercises was performed for 4 weeks.
223977498|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
223977499|NCT01913977|DEVICE|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
223977500|NCT03740178|DRUG|MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
224117594|NCT01187212|DRUG|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
224117595|NCT03279510|DEVICE|hearing aids|Subjects are fit with hearing aids.
224117596|NCT03950102|RADIATION|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
223977501|NCT03740178|DRUG|Placebo to MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
223977502|NCT03740178|DRUG|Donepepzil|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
224117597|NCT00929578|DRUG|Fluphenazine|Intralesional injection of Fluphenazine
224117598|NCT00929578|DRUG|Placebo|Intralesional injection of placebo
224117599|NCT01893593|OTHER|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
224117600|NCT01893593|OTHER|Control|Guideline summary and data feedback from a baseline medical record review
224117601|NCT04761380|DIAGNOSTIC_TEST|balloon-based tongue pressure measurement device|The probe was inflated at a baseline pressure of 19.6 kilopascal (kPa). To measure MTP, the balloon was positioned on the anterior palate with the lips closed. Subjects raised their tongue and compressed the balloon onto the palate with maximal voluntary muscular effort for approximately 7s. The measurement was taken three times with a 1-min interval. The maximum value was recorded as the MTP.
223726174|NCT05698797|OTHER|Conventional physical therapy|Conventional physical therapy included interferential therapy and two types of knee-strengthening exercises.
223726175|NCT05719766|OTHER|education ,psycological support and social support|we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
223726176|NCT01666574|OTHER|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
223977503|NCT02876848|OTHER|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~* Contact you over the phone or in person to provide medical advice on how to better take your pills,~* Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
223977506|NCT05286242|BIOLOGICAL|COVID19 vaccine|All participants receive one or more FDA-authorized COVID19 vaccinations according to standard of care and current medical recommendations. The intervention is not specifically administered as part of the study.
223977507|NCT01963442|RADIATION|Chest X-ray|at Day 0, Day 30 and relapse
223977508|NCT01963442|BIOLOGICAL|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
223977509|NCT01963442|DRUG|Augmentin|2 tablets 3 times a day for 5 days from Day 3
223977510|NCT01963442|DRUG|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
223977511|NCT01963442|DRUG|Beta-Lactams|administered from Day 0 to Day 3
223977512|NCT02298855|BEHAVIORAL|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
223977513|NCT02648711|DRUG|CRLX101|infusion CRLX101 weekly
223977514|NCT02648711|DRUG|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
223977515|NCT02648711|DRUG|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
223977516|NCT02601105|OTHER|Placebo Vehicle Cream|Lipoderm Cream alone
223977517|NCT02601105|OTHER|Centella Asiatica Cream|1% Centella Asiatica in lipoderm
223543599|NCT03611881|DRUG|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
223543600|NCT03611881|BEHAVIORAL|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
223543601|NCT04504539|BIOLOGICAL|mOPV|mOPV (monovalent oral polio vaccine) is an oral polio vaccines which consists of only attenuated virus of serotypes 1
223543602|NCT04504539|BIOLOGICAL|bOPV|bOPV (bivalent oral polio vaccine) is an oral polio vaccines which consists of attenuated virus of serotypes 1and 3
223543603|NCT04504539|BIOLOGICAL|Full dose IPV|FIPV (full dose injectable polio vaccine)
223543604|NCT04504539|BIOLOGICAL|fractional IPV|fIPV (fractional dose injectable polio vaccine)
223543605|NCT03180112|GENETIC|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
223543606|NCT01427218|OTHER|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
223977518|NCT03693040|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
223977519|NCT04551378|OTHER|Quality-of-Life Assessment|Ancillary studies
223977520|NCT04551378|OTHER|Survey Administration|Complete survey
223977521|NCT02652715|OTHER|Laboratory Biomarker Analysis|Correlative studies
223977522|NCT02652715|OTHER|Quality-of-Life Assessment|Ancillary studies
223977523|NCT02652715|OTHER|Questionnaire Administration|Ancillary studies
223977524|NCT02652715|DIETARY_SUPPLEMENT|Salvia hispanica Seed|Given PO
223977525|NCT00132951|DRUG|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
223977526|NCT00132951|DRUG|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
224117602|NCT04115397|DRUG|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
223543607|NCT01427218|BEHAVIORAL|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
223977527|NCT00742898|OTHER|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
224117603|NCT04115397|DRUG|Placebo|Placebo
224117604|NCT00991627|DRUG|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
224117605|NCT00991627|DRUG|Morphine|200 µg of a 100 µg/ml solution, intrathecally
224117606|NCT00991627|DRUG|Lactated Ringer's solution|25 ml/min intravenously
223543608|NCT01427218|BEHAVIORAL|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
223543609|NCT01427218|OTHER|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
223543610|NCT00102986|DRUG|Lopinavir/ritonavir|
223977528|NCT01732926|DRUG|Idelalisib|150 mg tablet administered orally twice daily
223977529|NCT01732926|DRUG|Rituximab|375 mg/m\^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
223977530|NCT01732926|DRUG|Bendamustine|90 mg/m\^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
223977531|NCT01732926|DRUG|Placebo|Tablet administered orally twice daily
223977532|NCT00384098|DRUG|CTA018 cream|
223977533|NCT02018471|BEHAVIORAL|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
224117607|NCT00991627|DRUG|Ephedrine, continuous infusion|37.5 mg/h intravenously
224117608|NCT00991627|DRUG|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
224117609|NCT00991627|DRUG|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
224117610|NCT05138120|BEHAVIORAL|Common Elements Toolbox|An unguided online single-session intervention with four modules: behavioral activation, cognitive restructuring, gratitude, and self-compassion.
224117611|NCT06858124|OTHER|Mulligan+TE|"Mulligan Mobilizations plus Home Therapeutic Exercise~The protocol will last 25 minutes (Mulligan protocol: 5 minutes and Home Therapeutic Exercise protocol: 20 minutes) and will include the application of the following mulligan techniques and home exercises:~* Mulligan sustained natural apophyseal glide SNAG mobilizations with overpressure with the patients in seated position.~* 4 home-based therapeutic exercises: isometric exercises for cervical regions, head retractions, thoracic spine rotation mobility exercise and diagonal cervical mobility exercise pattern."
223977534|NCT05498077|PROCEDURE|Body scan meditation|Subject is placed through a brief body scan meditation to determine whether this intervention affects a person's pain experience
223977535|NCT04868981|DRUG|GST-HG141 tablets|Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
223726177|NCT01666574|OTHER|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
223977536|NCT04868981|DRUG|Matching Placebos for GST-HG141 tablets|Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
223977537|NCT00583050|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
224117612|NCT06858124|OTHER|Maitland+TE|"The participants of this group will perform the same 4 home-based therapeutic exercises as the first group. In addition, they will receive a 5-minute maitland mobilization protocol.~Maitland mobilizations will include posterioranterior glides with oscillations with the patients in prone position."
224117613|NCT06858124|OTHER|Control|Participants in this group will only perform the same 4 home-based therapeutic exercises as the first group.
224117614|NCT03271008|DEVICE|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
224117615|NCT03271008|DEVICE|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
224117616|NCT03271008|DEVICE|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
224117617|NCT01651260|OTHER|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
223977538|NCT00676897|DRUG|Simvastatin|Simvastatin 40mg PO or NGT
223977539|NCT00676897|DRUG|Placebo|Corn Starch
223977540|NCT03552237|DIETARY_SUPPLEMENT|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
223977541|NCT02262364|BIOLOGICAL|APS|See above
223977542|NCT01049984|DRUG|Rasagiline|1mg tablet daily for 18 weeks
223977543|NCT01049984|DRUG|Placebo|one tablet daily for 18 weeks
223977544|NCT02651883|BEHAVIORAL|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
223977545|NCT02651883|BEHAVIORAL|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
223977546|NCT04574661|OTHER|Static Stretching|In Control group all the individuals will be asked to perform static stretching for 10 mints, 1 set . Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual.
223977547|NCT04574661|OTHER|Intermittent Occlusion|Individuals of Interventional group will be asked to lay down in supine position, apply proximal thigh cuff, 220mg for 12 minutes for intermittent occlusion. During this procedure discomfort will be checked on numeric pain rating scale, if we get 6 on scale, will stop the occlusion. Vitals will be monitored from every individual. On 3rd day to this protocol leg circumference, ROM of planter and dorsal flexion and numeric pain rating scale (NPRS ) will be measured alone with all the Vitals from every individual
223726178|NCT02817100|DRUG|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
223977548|NCT03128788|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
223977549|NCT04308642|OTHER|blood test for renal biomarkers|blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)
223726179|NCT02817100|DRUG|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
223977550|NCT04308642|OTHER|urine test for renal biomarkers|urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)
224117618|NCT02144220|OTHER|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
224117619|NCT04863287|BIOLOGICAL|2217LS|Fully Human Monoclonal Antibody
223726180|NCT02817100|DRUG|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
223726181|NCT03978338|DIETARY_SUPPLEMENT|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
223726182|NCT03978338|OTHER|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
223977551|NCT00772655|DRUG|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 \[if platelets are below 150000/µl only 11 MBq/kg are administered).
224117620|NCT04863287|OTHER|0.9% Sodium Chloride (NaCl)|Subcutaneous injection
224117621|NCT00935233|GENETIC|DNA analysis|
224117622|NCT00935233|GENETIC|polymorphism analysis|
224117623|NCT00935233|GENETIC|protein analysis|
224117624|NCT00935233|OTHER|laboratory biomarker analysis|
224117625|NCT00935233|OTHER|questionnaire administration|
224117626|NCT00935233|OTHER|survey administration|
224117627|NCT01952015|BIOLOGICAL|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
224117628|NCT04570891|PROCEDURE|Ultrasound-guided fascia iliaca compartment block|Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.
224117629|NCT04570891|PROCEDURE|Control|No regional block is provided at the end of surgery.
224117630|NCT05275829|OTHER|Tele simulation|Interactive tele simulation sessions utilising web-based video-conferencing technology (WebEx platform).
224117631|NCT02239094|DRUG|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
224117632|NCT01568580|DRUG|GreenGene|Dose : 10 \~ 50IU/kg Administration method : intravenous infusion or bolus
223977552|NCT00772655|DRUG|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
224117633|NCT02008240|PROCEDURE|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
223977553|NCT06435741|DIAGNOSTIC_TEST|99mTc-3PRGD2 Spect-CT scan|Before the operation，SPECT-CT imaging of lymph nodes was performed by integrin αvβ3-specific 99mTc-3PRGD2 probe. The locations of 99mTc-3PRGD2 SPECT-CT were determined by preoperative CT scan. During the operation, D2 lymph node dissection of gastric cancer was performed under the guidance of fluorescent laparoscopy。
223726183|NCT00456560|DRUG|AV650|
223726184|NCT00456560|DRUG|Fluvoxamine|
223726185|NCT00456560|DRUG|Paroxetine|
223977554|NCT03523325|OTHER|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
223977555|NCT06454318|DIAGNOSTIC_TEST|Wellue O2 ring|Wellue O2 ring wore when doing the polysomnography
223977556|NCT00997932|DRUG|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
223977557|NCT02730000|PROCEDURE|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
223977558|NCT02730000|PROCEDURE|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
223977559|NCT01228721|DEVICE|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
223977560|NCT02801500|DEVICE|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
223977561|NCT02801500|PROCEDURE|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
223977562|NCT00003423|DRUG|asparaginase|
223977563|NCT00003423|DRUG|cyclophosphamide|
223977564|NCT00003423|DRUG|cytarabine|
223977565|NCT00003423|DRUG|daunorubicin hydrochloride|
223977566|NCT00003423|DRUG|dexamethasone|
223977567|NCT00003423|DRUG|etoposide|
223977568|NCT00003423|DRUG|mercaptopurine|
223977569|NCT00003423|DRUG|methotrexate|
224117634|NCT02008240|PROCEDURE|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
223977570|NCT00003423|DRUG|prednisolone|
224117635|NCT01597193|DRUG|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
223977571|NCT00003423|DRUG|thioguanine|
223977572|NCT00003423|DRUG|vincristine sulfate|
223977573|NCT04921878|DRUG|Mitoxantrone Hydrochloride Liposome injection|Mitoxantrone hydrochloride liposome injection will be administered intravenously once every 3 weeks (a cycle) for a maximum of 6 cycles.
223977574|NCT01086332|DRUG|Nelfinavir|1250 mg twice daily
223977575|NCT01086332|DRUG|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
224117636|NCT01597193|DRUG|anastrozole|1 mg/day
224117637|NCT01597193|DRUG|exemestane|The exemestane dose is 25mg daily.
224117638|NCT01597193|DRUG|fulvestrant|500 mg every 28 days
224117639|NCT01597193|DRUG|enzalutamide|160 mg (4 capsules) taken orally daily.
224117640|NCT01597193|DRUG|exemestane|The exemestane dose is 50 mg daily.
224117641|NCT00296283|BEHAVIORAL|integrative behavior couples therapy|
223977576|NCT06347770|DRUG|Probiotic Blend Oral Tablet|In our study, forty pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 #106 CFU) by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered four tablets three times a day (2 g/d) for seven days before surgery until the fourth day after surgery.
223726186|NCT06311201|OTHER|Abdominal belt|This was used for all women in both groups (A and B) for 8 weeks starting from the 7th days after delivery. The women was asked to wear the abdominal belt throughout the day except when bathing, eating and sleeping. The binder was worn over the skin directly or on a thin layer of clothing. The side of the abdominal binder without the straps was pulled over by the woman's stomach with one hand. The side of the binder with straps was stretched across the stomach and pulled to the center of the abdomen. The straps then was fitted into the buckles. Women were instructed not to wear the binder too tight or too loose as it might irritate the skin and produce difficulty in breathing creating discomfort. They were asked to inspect their skin regularly for any signs of sensitivity.
223726187|NCT06311201|OTHER|Pilates exercises|"The Pilates exercise program for the study group (B) consisted of a 10-minute warm-up with low-intensity exercises, followed by a 40-minute central part with floor exercises like leg circles, kicks, and stretches. It included the classic hundred exercise, performed with proper form. Each exercise had two sets of 10 repetitions. The session ended with a 10-minute cool-down of stretching exercises, supervised by a physical therapist. The program was conducted three times per week, one hour per session, for eight weeks, starting from the 7th day after delivery."
223726188|NCT00000793|DRUG|Mexiletine hydrochloride|
223977577|NCT01650727|DRUG|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.
223977578|NCT01650727|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
223977579|NCT06480253|DEVICE|Helmet Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on inspired fraction of oxygen (FiO2)= 21% with the Helmet interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
223726189|NCT00000793|DRUG|Benztropine mesylate|
223726190|NCT00000793|DRUG|Amitriptyline hydrochloride|
223726191|NCT02922556|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
223726192|NCT02922556|OTHER|Commercially available computerized training|
224295286|NCT06166316|DEVICE|overdenture retained by locator attachments.|"• Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing."
223726193|NCT05299281|DEVICE|Micropulse transscleral cyclophotocoagulation (MP-TSCPC)|"patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively."
223726194|NCT04694417|OTHER|Compression stocking|Please see the description of the intervention in another section
223726195|NCT04694417|DIETARY_SUPPLEMENT|Magnesium tablet|Please see the description of the intervention in another section
223726196|NCT04694417|OTHER|Placebo tablet|Please see the description of the intervention in another section
223726197|NCT01931124|BEHAVIORAL|High Intensity Training|
223726198|NCT01931124|BEHAVIORAL|Moderate Intensity Training|
223726199|NCT00453882|DEVICE|flostat (TM) System|
223726200|NCT04943094|OTHER|Urodynamic examination|A urodynamic examination is performed in all patients four to six weeks following TURBT and repeated six months later in order to obtain bladder function and possible changes.
223726201|NCT02810860|PROCEDURE|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
223726202|NCT01366209|DRUG|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
223977580|NCT06480253|DEVICE|Oronasal Mask Continuous Positive Airway Pressure|Partecipants will be started on Continuous Positive Airway Pressure at 10 cmH2O on Inspired fraction of oxygen (FiO2)= 21% with the oronasal mask interface for a duration of 5 minutes while laying down on a stretcher with head elevated at 60°
223977581|NCT00237614|DRUG|intravenous and oral N-acetylcysteine|
223977582|NCT06546514|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
224117642|NCT01819220|DRUG|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
223726203|NCT01366209|DRUG|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
223977583|NCT02090998|PROCEDURE|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
223977584|NCT02090998|DRUG|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
223977585|NCT00085111|BIOLOGICAL|bevacizumab|Given IV
223977586|NCT04267471|BEHAVIORAL|Tai Chi|Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
223977587|NCT04267471|BEHAVIORAL|Walking|Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
223977588|NCT03623477|BEHAVIORAL|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
223977589|NCT03623477|BEHAVIORAL|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
223977590|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
224117643|NCT01819220|DRUG|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
224117644|NCT01144689|BEHAVIORAL|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
223726204|NCT02670837|DEVICE|Cellutome Epidermal Harvesting System|
223726205|NCT01053221|DRUG|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
223726206|NCT01053221|DRUG|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
224117645|NCT01144689|BEHAVIORAL|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
224117646|NCT02508701|BEHAVIORAL|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
224295287|NCT03661606|OTHER|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
223977591|NCT04031573|DRUG|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
223977592|NCT04031573|DRUG|Placebo|Placebo will be administered via the enteral route, every 12 hours.
223977593|NCT04262609|RADIATION|hypofractionated radiotherapy|volumetric modulated moderately fractionated arc therapy
223977594|NCT04683328|BIOLOGICAL|SCTA01|Recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
223726207|NCT04201860|DIAGNOSTIC_TEST|Arterial blood gas analyses and haemostasis measures|Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
223977595|NCT04683328|BIOLOGICAL|SCTA01 Placebo|The excipients of SCTA01
223977596|NCT03478046|OTHER|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
224117647|NCT03391440|DRUG|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
223977597|NCT03354234|OTHER|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
223977598|NCT03354234|OTHER|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
223977599|NCT03354234|OTHER|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
223977600|NCT03354234|DEVICE|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
223977601|NCT03354234|DEVICE|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
224117648|NCT06403774|DRUG|Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)|A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.
224117649|NCT06403774|DRUG|Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )|An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
224117650|NCT03475394|OTHER|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket
224117651|NCT03475394|OTHER|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket
224117652|NCT03475394|OTHER|Placebo|0.1 ml of Placebo gel was administered into the periodontal pocket
224117653|NCT03177876|PROCEDURE|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
224117654|NCT03177876|PROCEDURE|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
224117655|NCT00607360|BEHAVIORAL|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
224117656|NCT05295160|BEHAVIORAL|weight loss by very low energy diet intake which may differ in protein or carbohydrate content|The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
224117657|NCT04579068|BEHAVIORAL|Screening and Brief Intervention of Problematic Alcohol Use|Provide/enhance knowledge, screening and detection, modify attitudes, motivate and provide skills and resources to reduce alcohol related risk and consumption.
224117658|NCT02917486|OTHER|blood sample|
224117659|NCT04051567|DRUG|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
224117660|NCT03792269|DRUG|Irinotecan|intraperitoneal
224117661|NCT03792269|DRUG|Oxaliplatin|intravenous
224117662|NCT03792269|DRUG|Capecitabine|
224117663|NCT02134704|OTHER|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
224117664|NCT03184701|OTHER|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
223726208|NCT01856413|DRUG|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
223726209|NCT04419584|DRUG|Modified Qing-Ying Decoction|Herbal granules
223726210|NCT04419584|DRUG|Identical looking placebo|Placebo granules
223977602|NCT04588675|DIAGNOSTIC_TEST|MRI|the patients will underwent dobutamine stress cardiac MRI
223977603|NCT01977183|DIETARY_SUPPLEMENT|MSPrebiotic|Potato Resistant Starch
223977604|NCT01977183|DIETARY_SUPPLEMENT|Placebo|Placebo - Corn Starch
223977605|NCT00889837|DRUG|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
223977606|NCT00889837|DRUG|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
223977607|NCT01584323|DIETARY_SUPPLEMENT|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
223726211|NCT05228262|OTHER|Cohort follow-up|"* Inclusion medical consultation,~* Inclusion clinical examination,~* Collection of biological samples (bone biomarkers, epigenetic biomarkers (microRNA)) and analysis of microbiota and genotyping,~* Calculation of the Kauppila score on profile spine radiographs by the rheumatologist,~* Cardiovascular investigations (FMD, Flow-Mediated Dilation); measurement of digital volume increase (RHI, Reactive hyperhemia index); measurement of microcirculatory perfusion of the skin at the hand (FLD, Flow Laser Doppler) ; measurement of the stiffness of the main arteries (aorta) by the Pulse Wave Velocity (PWV),~* Exploration of sarcopenia: questionnaires and tests: SARC-F, SPPB, muscle strength,~* Quality of life component questionnaires Pittsburgh Sleep (PSQI), Numerical Scale (NS), Brief Pain Inventory (BPI), Hospital Anxiety and Depression scale (HADs), and 36-Item Short Form Survey (SF-36) Quality of Life Questionnaire."
223977608|NCT01584323|DIETARY_SUPPLEMENT|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
223977609|NCT04167228|DRUG|Ceftazidime-Avibactam|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with ceftazidime-avibactam.
223977610|NCT04167228|DRUG|Best Available Therapy|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
223977611|NCT02560389|DRUG|Placebo|Sugar pill packaged to resemble levodopa
223977612|NCT02560389|DRUG|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
223977613|NCT06392893|COMBINATION_PRODUCT|Meat product without additives and allergens|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of meat products without additives and allergens (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
223977614|NCT06392893|COMBINATION_PRODUCT|Commercial meat product|"Baseline time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine.~Consumption of commercial meat products (6 days a week; 5 weeks).~Final time: Measurement of anthropometric parameters and inflammatory and oxidative markers in blood, faeces and urine."
223977615|NCT01217619|DRUG|erlotinib|erlotinib 150mg/d continuously for 56 days
223977616|NCT04226937|OTHER|Not Applicable as this is a translational, sample collection study.|"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."
223977617|NCT02856490|DEVICE|vSculpt|A genital vibration device that operates in two modes, vibration only or vibration and light, to help tone and tighten pelvic floor muscles.
223977618|NCT02856490|DEVICE|InTone|A genital device using electric muscle stimulation to treat incontinence.
223977619|NCT06325345|BEHAVIORAL|Gut-directed hypnotherapy|Eight session gut-directed hypnotherapy for IBS symptoms adapted from the evidence-based Manchester protocol for treatment of IBS.
223977620|NCT06325345|OTHER|Standard Medical Therapy|Standard medical treatment will be administered by board certified gastroenterologists
223977621|NCT04703257|DRUG|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
223977622|NCT04703257|DRUG|Placebo|Patients in the control group will be instructed to take a placebo tablet three times a day for four days and patients will be instructed to take 1000 mg paracetamol orally four times a day for four days.
223977623|NCT06101472|DEVICE|ASQELIO Toric Biaspheric Monofocal Lens|Intraocular lens implantation in cataract surgery
223977624|NCT03359226|PROCEDURE|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
223977625|NCT02205541|DRUG|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
223977626|NCT02205541|DRUG|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
224295288|NCT04704349|RADIATION|Scintigraphy|The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
223977627|NCT01537185|OTHER|Placebo|3 cohorts of normal saline injection
223977628|NCT01537185|BIOLOGICAL|SPWCV+Alum 100 mcg|3 injections 28 days apart
223977629|NCT01537185|BIOLOGICAL|SPWCV+Alum 600 mcg|3 injections 28 days apart
223977630|NCT01537185|BIOLOGICAL|SPWCV+Alum 300 mcg|3 injections 28 days apart
223977631|NCT04074343|DRUG|TAS-102|Given PO
223977632|NCT04074343|DRUG|Irinotecan|Given IV
223977633|NCT01211444|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
223977634|NCT00687947|DRUG|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
223977635|NCT00484601|DRUG|Ifosfamide|
223977636|NCT00484601|DRUG|Doxorubicin|
223977637|NCT06157528|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients were treated with abarelix prior to the examination
224295289|NCT00506818|OTHER|Multifactorial vascular-risk-factor-intervention|
223977638|NCT05018897|BEHAVIORAL|To Share or Not to Share|Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met. Six one-hour virtual sessions conducted weekly.
223977639|NCT05018897|BEHAVIORAL|Peer Support|Peer-led support group for mood disorders. Six one-hour virtual sessions conducted weekly.
223977640|NCT03131349|DIAGNOSTIC_TEST|serum zinc and iron|history ,examination,investigations
223977641|NCT00965120|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
223977642|NCT00965120|DRUG|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
223977643|NCT00965120|DRUG|Placebo (saline)|Systemic infusion of placebo (saline).
223977644|NCT03052712|BEHAVIORAL|social cognition|battery of tests of social cognition
223977645|NCT05117879|PROCEDURE|Cold snaring polypectomy/ Cold EMR/Hot EMR|"Cold snaring polypectomy: The technique of cold snare polypectomy is used to remove \[small colonic polyps\] without diathermy, which implies that a polyp is transected by a snare along with a rim of surrounding normal mucosa.~Cold EMR: Cold EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal cold snare resection of target polyp with a margin of normal tissue.~Hot EMR: Hot EMR technique comprising submucosal injection of succinylated gelatin and dilute methylene blue before piecemeal electrocautery snare resection of target polyp with a margin of normal tissue."
223977646|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
223543611|NCT03370211|OTHER|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
223543612|NCT04714866|BEHAVIORAL|Cognitive behavioral therapy for ADHD|CBT is a time-limited and structured approach that influences change in thoughts, feelings and behavior, leading to symptom changes.
223977647|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose with placebo capsules to match as required
223977648|NCT05875441|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg tablet over encapsulated capsules will be administered as a single dose.
223977649|NCT05875441|DRUG|Placebo|16 placebo capsules will be administered as a single dose.
223977650|NCT05549999|DIAGNOSTIC_TEST|North Star Ambulatory Assessment|North Star Ambulatory Assessment is an ambulatory assessment developed specifically for Duchenne Muscular Dystrophy.
223977651|NCT00251888|DRUG|campto (irinotecan)|
223977652|NCT00251888|DRUG|cisplatin (cisplatyl)|
223977653|NCT04016402|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
223977654|NCT00005946|BIOLOGICAL|filgrastim|
223977655|NCT00005946|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223977656|NCT00005946|DRUG|cyclophosphamide|
223977657|NCT00005946|DRUG|etoposide|
223977658|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
223977659|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
223977660|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 0
223977661|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
223977662|NCT01264445|BIOLOGICAL|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
223977663|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Month 4
223977664|NCT01264445|BIOLOGICAL|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
223977665|NCT01264445|BIOLOGICAL|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
224295290|NCT02546349|DRUG|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
224295291|NCT03347513|DRUG|triple attack therapy|eradication of H-pylori using triple attack therapy.
223977666|NCT04617236|BEHAVIORAL|Cultivando La Salud|"A lay health worker delivered educational intervention for breast and cervical cancer screening.~In total, the Intervention Group subject participation will take approx. up to four hours (1 hour for interview, 1 hour for the second interview, and 1-2 hours for the CLS intervention) and Control Group up to four hours (One hour for interview, one hour for the second interview, up to two hours for educational intervention after the second interview).~Follow-up data was collected 4-6 months post education session (intervention group) or post-baseline survey (control group)."
223977667|NCT02938897|BEHAVIORAL|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
223977668|NCT02938897|BEHAVIORAL|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
223977669|NCT02938897|BEHAVIORAL|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
223977670|NCT06278337|GENETIC|genetic restrospective study|it is not an interventional study but observational
223977671|NCT05891652|PROCEDURE|modified thoracoabdominal nerve block through perichondrial approach|Following sterile conditions for bilateral M-TAPA block application, the transducer was inserted on the chondrium in the sagittal plane at the 9-10th rib level. Subsequently, a deep angle was created with the probe for visualization of the underside of the costochondrium. The sonovisible needle tip was placed just below the chondrium and saline (5 ml) was injected for site confirmation. After the confirmation, 20 ml of 0.25% bupivacaine was administered for each group for a total of 40 ml of local anesthetic. Blocks were applied using an 80 mm sonovisible needle with a 6-10 MHz linear probe under the guidance of a portable ultrasound. Same procedure applied to the contralateral side.
223543613|NCT02173405|DRUG|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
223543614|NCT02173405|DRUG|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
223543615|NCT05607602|OTHER|Comparison of blood samples between the two groups|In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
223543616|NCT01206829|BEHAVIORAL|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
223726212|NCT00280631|DRUG|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
223977672|NCT00663273|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
223977673|NCT00827775|DRUG|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
224117665|NCT05690594|OTHER|Self or straight administered questionnaire|"Self or straight administered questionnaire with 5 parts:~* General questionnaire (to collect socio-demographic data)~* ICIQ score to evaluate urinary continence~* FLQI score to evaluate fecal continence~* FSFI score to evaluate sexuality in women or IIEF-5 score to evaluate sexuality in men~* SF-12 score to evaluate quality of life The questionnaire will be sent to patients by email and/or mail. Patients will be able to either complete the questionnaire alone and return it to the primary investigator, or to request a telephone interview to help them to complete the questionnaire. The questionnaire is administered only once and the estimated response time to the questionnaire is between 30 minutes and one hour."
224117666|NCT01863563|DEVICE|QuickClot|1 application of treatment to each tonsil/adenoid removal area
224117667|NCT00734409|DEVICE|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
223726213|NCT04173078|BEHAVIORAL|Computerized Distress Intolerance Intervention|
224117668|NCT01259297|DRUG|Aliskiren|Aliskiren 150/300 mg once daily
224117669|NCT01259297|DRUG|Amlodipine|Amlodipine 5 mg
223977674|NCT00479843|BEHAVIORAL|Nutritional programme|
223977675|NCT02151578|OTHER|home/community case management|
223977676|NCT04912154|PROCEDURE|Rehabilitation protocol|Rehabilitation protocol after open surgery for Achilles tendon rupture
223977677|NCT00414258|PROCEDURE|breastfeeding|See detailed description.
224293608|NCT07211698|OTHER|Qualitative study|"Semi-structured interviews will enable an in-depth conversation between the researcher and the participant, delving deeply into personal and sometimes sensitive issues that participants are unable to talk about in a focus group.~Focus groups allow participants to share their thoughts and experiences as part of a group, bouncing off each other instead of answering questions alone. People can discuss with each other and the researcher can learn not just what people think, but also how and why they think that way.~Both semi-structured interviews and focus groups will be audio recorded with participants consent, which may influence what participants say or do not say during the conversations. This could also make people uncomfortable, and therefore, they may decide not to participate in the study.~Therefore, an informal conversational interview is needed as an option. Informal conversations will not be recorded, creating a more friendly and comfortable atmosphere for people to share their"
224117670|NCT01259297|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
224117671|NCT01259297|DRUG|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
223543617|NCT01206829|BEHAVIORAL|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
223977678|NCT03980132|DRUG|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
223977679|NCT02767518|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
223977680|NCT05624697|PROCEDURE|sticky bone housed in PEEK Shell|Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
223977681|NCT00000725|DRUG|Interferon alfa-2a|
223543618|NCT00666081|DRUG|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
223543619|NCT02497222|DRUG|RNS60|
223543620|NCT02497222|DRUG|Normal Saline|
223543621|NCT00756275|DRUG|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
223543622|NCT00756275|DRUG|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
223543623|NCT00756275|BEHAVIORAL|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
223543624|NCT01466465|DRUG|Cholecalciferol|given orally, once daily, before grass pollen season
223543625|NCT01466465|OTHER|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
223543626|NCT03819387|DRUG|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
223543627|NCT02268110|OTHER|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
223543628|NCT02268110|OTHER|Abdominal binding|Wearing an abdominal binder for 12 weeks
223543629|NCT04380623|BEHAVIORAL|Mobile Phone-Based Web-Page: HPV vaccine|Website to be accessed via mobile phone to deliver tailored educational material
223977682|NCT00000725|DRUG|Zidovudine|
223977683|NCT00000725|DRUG|Interferon alfa-n1|
223977684|NCT05243537|OTHER|ECG (diagnostic)|ECG collection (once, at rest), in both cases and controls
223977685|NCT02600585|BIOLOGICAL|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
223977686|NCT02600585|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
224117672|NCT01259297|DRUG|Placebo for Amlodipine|Placebo for Amlodipine
224117673|NCT01259297|DRUG|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
224117674|NCT03290638|PROCEDURE|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
224117675|NCT00126464|DRUG|fulvestrant|
224117676|NCT00126464|DRUG|tamoxifen citrate|
224117677|NCT00126464|PROCEDURE|conventional surgery|
223726214|NCT04173078|BEHAVIORAL|Computerized Healthy Behaviors Intervention|
223977687|NCT03828877|OTHER|Group A ( Group Acupuncture)|Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
223977688|NCT04440930|OTHER|White tea|Mouthwash with white tea five to six times a day for nine weeks
223977689|NCT04440930|OTHER|Salt water with soda|Mouthwash with salt water and soda eight to ten times a day for nine weeks
223977690|NCT01811628|BEHAVIORAL|Questionnaire|Questionnaire completion taking about 10-15 minutes.
223977691|NCT01811628|BEHAVIORAL|Interview|Audio-recorded interview that will last about 1 hour.
223977692|NCT05896540|BEHAVIORAL|ENFOCATE|ENFOCATE is a comprehensive program of sexual education for adolescents. Its design follows the guidelines of the Intervention Mapping Approach and the orientations proposed by the Framework for Gender-Transformative Health Promotion. The intervention has a participative focus, thus the activities are designed to promote processes of knowledge, understanding, application and reflection in the adolescents. The activities aim to improve the capacity for critical thinking, increase the motivation to listen and learn actively, and to improve interpersonal abilities. The execution of the intervention uses three pillars: (i) preventive sexual behavior; (ii) gender equity; and (iii) mental health. The intervention consists of ten weekly sessions, each lasting one hour. The teams that will perform the intervention will be composed of at least two professionals of the psychosocial area (mainly psychologists, social workers and/or guidance counsellors) of the schools included in the study.
223977693|NCT03989583|OTHER|Infrared thermography|Temperature observation in foot and footwear in healthy children
223977694|NCT00141908|DRUG|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
224117678|NCT00126464|PROCEDURE|neoadjuvant therapy|
223726215|NCT00382460|DRUG|PRAVASTATIN SODIUM|
224117679|NCT04927988|OTHER|Ringer's Lactated|Using of Ringer's Lactated In Autologous Blood Cell Transfusion
224117680|NCT01051388|DRUG|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
224117681|NCT01051388|DRUG|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
223543630|NCT05940506|DRUG|KX-826-2.5 mg (0.25%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
224117682|NCT01051388|DRUG|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
223726216|NCT01929434|OTHER|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
224117683|NCT02014532|DRUG|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
224117684|NCT02014532|DRUG|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
223726217|NCT01929434|BIOLOGICAL|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
223726218|NCT02408640|BEHAVIORAL|Cannabishjalpen.se|
223726219|NCT00876629|DEVICE|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
223726220|NCT03053414|DIETARY_SUPPLEMENT|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
223726221|NCT01624454|OTHER|Laxabon|4 l PEG solution split dose cleansing
223726222|NCT01624454|OTHER|CitraFleet|Small volume osmotic bowelcleansing
223977695|NCT00141908|DRUG|Castor oil|weekly IM injections
224117685|NCT00279500|DEVICE|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
224117686|NCT01527604|OTHER|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
224117687|NCT01527604|OTHER|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
224117688|NCT01429012|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
224117689|NCT01429012|OTHER|Culture medium without MSC.|2 ml of culture medium.
224293609|NCT07209462|DRUG|Low dose of MRM-3379|Oral capsule
224293610|NCT07209462|DRUG|Middle Dose of MRM-3379|Oral capsule
224293611|NCT07209462|DRUG|High dose of MRM-3379|Oral capsule
223977696|NCT05550714|DRUG|general anesthesia|The patients did not use any preoperative sedative drugs and were given sufentanil citrate 0.1-0.2 µg/kg, cisatracurium 0.2 mg/kg and propofol 1.5-2.0 mg/kg during anesthesia induction. After the patients were unconscious, oral endotracheal intubation was performed. Anesthesiologists should continuously monitor PetCO2 and maintain PetCO2 at 30-35 mmHg. During the operation, patients are treated with remifentanil, cisatracurium, and desflurane inhalation at 0.5-1.0 minimum alveolar concentration (MAC). In the MER process, the desflurane concentration is adjusted to maintain 0.5-0.6 MAC. If the desflurane concentration needs to be adjusted to less than 0.5 MAC during MER for various reasons, remedial measures will be implemented.
223977697|NCT05550714|DRUG|Conscious sedation|A loading dose of DEX 0.5 µg/kg was infused intravenously at a constant speed within 15 min after the patients entered the operating room, and the DEX maintenance dose was infused at 0.2-0.5 µg/kg/h until the end of the first stage (deep-brain stimulation implantation) of the operation. Maintain the BIS value at 60-80.
223977698|NCT00014222|BIOLOGICAL|epoetin alfa|40,000 IU
223977699|NCT00014222|BIOLOGICAL|filgrastim|5 mg/kg/d - days 2-13
223977700|NCT00014222|DRUG|cyclophosphamide|75, 600 and 830 mg/m2
223977701|NCT00014222|DRUG|doxorubicin hydrochloride|60 mg/m2
223977702|NCT00014222|DRUG|epirubicin hydrochloride|60 mg/m2
223977703|NCT00014222|DRUG|fluorouracil|500mg/m2
223543631|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL QD|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.
223726223|NCT04737343|DRUG|Leflunomide|Patient will be treated with Leflunomide(Tuoshu, the commericial name) 30mg QD for 18 months
223726224|NCT04737343|DRUG|Azathioprine Tablets|Patients included into this study will be treated with Azathioprine tablets 100mg QD for 18 months.
223977704|NCT00014222|DRUG|paclitaxel|175 mg/m2
223977705|NCT00591604|DRUG|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
223977706|NCT05090475|BEHAVIORAL|Academic detailing intervention|Academic detailing or educational outreach is a method based on scientific data with the help of educated A-team members in the form of direct (face-to-face) interactions, prescribing practices change and adherence improves according to the application of currently valid therapeutic guidelines
223977707|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock 360 app.|"Visit 5, during week 4.~Randomization will be applied:~Active group will use all functionalities of Insulclock 360. They will have reminders, all their information and statistics at the disposition of the patient and healthcare providers, they have the assistance if desired of an ally or caregiver, a bolus calculator and the rest of functionalities described in the protocol."
223977708|NCT04847778|DEVICE|Use of Insulclock system, both Insulclock device and Insulclock app on masked mode.|"Visit 5, during week 4.~Randomization will be applied:~Masked group will remain with the masked system, without functionalities."
223977709|NCT01209741|DRUG|telcagepant potassium|\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
223977710|NCT01209741|DRUG|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
223977711|NCT01209741|DRUG|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
223977712|NCT02287883|OTHER|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
223977713|NCT00002621|BIOLOGICAL|recombinant interferon alfa|
223977714|NCT04322916|DEVICE|RM Pressfit vitamys|Implantation of a RM Pressfit vitamys hip cup
223977715|NCT02679547|OTHER|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
223977716|NCT06222775|BEHAVIORAL|Group session 1|"This session will have 3 editions in which the 50 participants of the experimental group will be distributed, with about 16 to 17 participants per edition.~Its objective is to know the group and their expectations, in addition to providing basic knowledge about diabetes and a healthy lifestyle."
223977717|NCT06222775|BEHAVIORAL|Group session 2|"The sessions for the 5 groups will take place within 2 weeks. Two weeks after the 1st session, the 2nd session-workshop will be scheduled with no more than 10 participants. For this, 5 groups will be made. An attempt will be made to ensure that the participants in the groups remain stable.~Its objective is to pave the way for the change to a healthy eating lifestyle and provide patients with sufficient knowledge so that with theory they can prepare a daily group menu according to the caloric needs of each of the participants."
223977718|NCT06222775|BEHAVIORAL|Group session 3|Its general objective is to motivate the change towards healthy eating. And the specific ones develop a weekly menu according to calorie needs.
223977719|NCT06222775|BEHAVIORAL|Group session 4|Its general objective is to reinforce a healthy lifestyle-eating, and the specific ones are to learn to read labels, preparing a weekly menu in a group.
223543632|NCT05940506|DRUG|KX-826-5 mg (5%)/60 mL BID|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.
223543633|NCT05940506|OTHER|Placebo|Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
223977720|NCT06222775|BEHAVIORAL|Group session 5|Its general objective is to reinforce lifestyle-physical activity. And the specific objectives are to recognize that it is a moderate physical activity and the goal to achieve of recommended physical activity per week and plan a week of physical activity.
223977721|NCT06222775|BEHAVIORAL|Group session 6|Its general objective is to reinforce a lifestyle-healthy eating and physical activity. And the specific ones are to reinforce the concept of physical activity in diabetes, what to do with hypoglycemia and adjust diet and exercise to current weight and needs.
223543634|NCT00376636|DRUG|SPP635 (drug)|
223977722|NCT06222775|BEHAVIORAL|Group session 7 to 8|The objective will be to maintain a healthy lifestyle and adjust menus and physical activity to current caloric needs, in addition to sharing experiences.
223977723|NCT06222775|BEHAVIORAL|Group session 9|"In the final session, a certificate of adherence to healthy living will be delivered, reminding you to continue with the acquired habits and attend scheduled consultations and tests.~The days of the sessions are indicative, but they must be held in the week when the specified period of time between session and session is met."
223977724|NCT06222775|BEHAVIORAL|Control Intervention 1|They will be given written information about the convenience of moderate physical activity and they will be informed of the importance of following an appropriate diet for diabetes and we will encourage weight loss.
223977725|NCT06222775|BEHAVIORAL|Control Intervention 2|Your controls will be carried out according to the usual diabetes protocol established in the individual scheduled diabetes consultation reviews.
223977726|NCT06222775|BEHAVIORAL|Control Intervention 3|These patients will also be given a written document about living with diabetes, advice on physical activity, and a pre-established diet will be given according to the number of calories needed previously calculated
223977727|NCT06222775|BEHAVIORAL|Control Intervention 4|In addition to verbal recommendations. This document will be made after the act of assigning the control or experimental group.
224117690|NCT03281226|DRUG|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
224117691|NCT03281226|DRUG|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
224117692|NCT04805021|OTHER|no intervention|no intervention
224117693|NCT00780000|DRUG|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
224117694|NCT02832726|DIETARY_SUPPLEMENT|Vitamin B12|
224117695|NCT06020859|DEVICE|undergo NaviEC-2000Pro Gastro Scan mode|Patients undergo NaviEC-2000Pro Gastro Scan mode.
224117696|NCT06020859|DEVICE|NaviEC-2000Pro Routine gastric examination|Patients undergo NaviEC-2000Pro Routine gastric examination mode.
224117697|NCT06020859|DEVICE|NaviEC-1000 Routine gastric examination|Patients undergo NaviEC-1000 Routine gastric examination mode.
224117698|NCT03611400|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10\^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10\^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
224293612|NCT07209462|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
224293613|NCT07209462|DRUG|Low dose of MRM-3379 Open-Label|Oral capsule
223543635|NCT01683136|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
224293614|NCT07213258|BEHAVIORAL|CHAMPION Intervention|MHealth intervention to enhance PrEP adherence, combined with computer-administered cognitive behavioral therapy for a 6-month period for the intervention arm.
223977728|NCT02728375|OTHER|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
223977729|NCT02728375|OTHER|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
223977730|NCT03144778|BIOLOGICAL|Durvalumab|Given IV
223977731|NCT03144778|BIOLOGICAL|Tremelimumab|Given IV
223977732|NCT05077241|DEVICE|Inspiratory muscle training|Individuals will be instructed to perform a rapid contraction of the inspiratory muscles against a load and sustain it for 2 seconds in each maneuver.
224117699|NCT03611400|DIETARY_SUPPLEMENT|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
223977733|NCT04317001|DRUG|Modafinil|Treatment will be with 100mg of modafinil for the two week primary phase of the study
223977734|NCT04317001|DRUG|Placebo|placebo
224293615|NCT07213258|BEHAVIORAL|Delayed CHAMPION Package|Informational resources for first 3-months of study, followed by CHAMPION intervention for final 3-months.
224293616|NCT07212335|BIOLOGICAL|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells: intravenous infusion, 2×10⁶ cells/kg body weight/week (once weekly), with 1 to 4 administrations based on different dosage groups.
224293617|NCT07211880|DRUG|Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin|7 days therapy
224293618|NCT07211880|DIAGNOSTIC_TEST|Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer)|Endoscopic examinations were conducted using a GIF-150 endoscope in combination with the CV150 system (Olympus Co., Tokyo, Japan).
224293619|NCT07211880|DEVICE|Urea Breath Test for the prevalence of H pylori|After eradication of the H pylori with drug success of the therapy was assessed 6 to 8 weeks after treatment using the UBT(C13 Urea Breath Test: Beijing Richen-Force Science \& Techinology Co. Ltd.)
224293620|NCT07211451|PROCEDURE|Breast conserving surgery with axillary surgery|In this study, all patients received breast conserving surgery with axillary surgery.
223543636|NCT02849002|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
223543637|NCT00566046|DRUG|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
223543638|NCT00566046|DRUG|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
223543639|NCT01242631|DRUG|Everolimus|Everolimus 10 mg orally per day.
223543640|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
223543641|NCT03487484|BEHAVIORAL|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
223543642|NCT03487484|BEHAVIORAL|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
223977735|NCT05089604|DRUG|Tacrolimus, Immediate Release, Oral|Twice Daily Tacrolimus
224117700|NCT03653715|DEVICE|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
224293621|NCT07212322|DRUG|CD19 UCAR-T cells|CD19 UCAR-T cells treatment
224293622|NCT07212101|BEHAVIORAL|Sleep and diet|Participants will be asked to increase their fruit and vegetable consumption, time in bed, and modify light exposure across the day
224295292|NCT03347513|DRUG|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
223977736|NCT05089604|DRUG|Tacrolimus Extended Release Oral Tablet|Once Daily Tacrolimus
224117701|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
223977737|NCT05648136|BIOLOGICAL|blood sample|"Blood sampling by venipuncture will be performed :~* for patients and controls: between the 20th and 24th day of the menstrual cycle (implantation window) preceding the following IVF+/-ICSI cycle~* for patients receiving an endometrial biopsy: on the same day as the endometrial biopsy~* for patients and controls receiving follicular stimulation for ovarian puncture: the day of the oocyte puncture~* for patients and controls undergoing embryo transfer: on the day of embryo implantation"
224117702|NCT03653715|DEVICE|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
223543643|NCT05646225|OTHER|chest physiotherapy and early mobilization|"Chest Physiotherapy: Each session included a series of exercises, lasting a total of 15 minutes and including positioning self-conscious breathing control, diaphragmatic breathing control, and exercises for the chest wall and abdominal muscle walls.~Early mobilization: Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes"
223543644|NCT05646225|OTHER|early mobilization|Each session included abdominal and upper and lower limb exercises, shoulder and full arm circling, lying to sit, sit to stand, walk and other exercises. This training has been described previously and used in other clinical trials. Each exercise was repeated 8-10 times over 30 minutes
223543645|NCT00938912|DRUG|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
223977738|NCT01476124|DRUG|morphine Placebo|Morphine Placebo
223977739|NCT01476124|DRUG|GEn 600 mg|Gabapentin enacarbil 600 mg
223977740|NCT01476124|DRUG|Morphine|morphine extended release 60 mg
223977741|NCT01476124|DRUG|GEn Placebo|Gabapentin enacarbil placebo
223977742|NCT00372177|RADIATION|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
223977743|NCT02110511|OTHER|blended lentils|blended lentils burritto breakfast
223977744|NCT02110511|OTHER|whole lentils|whole lentils breakfast burritto
223977745|NCT02110511|OTHER|no lentils|No lentils control breakfast burritto
223977746|NCT03436030|OTHER|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
223977747|NCT02234635|OTHER|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
223977748|NCT00402584|DRUG|sibutramine|
223977749|NCT00802438|BIOLOGICAL|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
223977750|NCT00151697|DRUG|Novomix 30|
223977751|NCT00151697|DRUG|Novorapid and Amaryl|
223977752|NCT00151697|DRUG|Lantus|
223977753|NCT00245440|DRUG|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
223977754|NCT00245440|DRUG|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
224295293|NCT01592136|DRUG|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
223543646|NCT00938912|DRUG|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
223543647|NCT04103112|DEVICE|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
223543648|NCT02827812|OTHER|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
223977755|NCT03705364|OTHER|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
223977756|NCT06308185|OTHER|observational study|Observational retrospective study on infants with neonatal seizures
223543649|NCT02827812|OTHER|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
223543650|NCT02827812|OTHER|Home-Based telemedicine program|"1. A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~2. A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
223543651|NCT05448729|DIAGNOSTIC_TEST|Elastography EUS|Comparison between the values of strain ratio and shear wave in concordance with the final diagnosis
224117703|NCT03653715|DEVICE|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
224117704|NCT00021853|BEHAVIORAL|constraint-induced movement therapy|
224117705|NCT02527876|BEHAVIORAL|High Intensity Interval Training|High Intensity Interval Training
224117706|NCT02527876|BEHAVIORAL|Moderate Intensity|Moderate Intensity Training
223726225|NCT05520944|DRUG|ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray|Patients will have received treatment with ClorNovir® as prescribed by their physician at the approved dose per local prescribing information, as part of their COVID-19 clinical recovery.
223726226|NCT06219850|OTHER|No intervention|The study sample is divided into the six intervention groups of the EDUGUTION study (ClinicalTrials.gov Identifier: NCT05261373), although participants do not receive intervention in the present study, as only a description of the sample is made one year after the EDUGUTION study from a longitudinal perspective.
223726227|NCT01564381|DIETARY_SUPPLEMENT|ResA|90mg of resveratrol conjugated with arginine.
223726228|NCT01564381|DIETARY_SUPPLEMENT|Resveratrol|90mg of resveratrol.
223726229|NCT01564381|DIETARY_SUPPLEMENT|Placebo|Made up of cellulose.
223726230|NCT05193864|DEVICE|Device: JVPHome and ultrasound|Remote clinician assessment of JVP height using the JVPHome, and ultrasound based assessment of JVP height in the same patients.
223726231|NCT01230905|RADIATION|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
223726232|NCT02774525|BEHAVIORAL|Reinforcement for drug & alcohol abstinence|
223726233|NCT02774525|BEHAVIORAL|Parenting intervention|
223726234|NCT02774525|BEHAVIORAL|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug \& alcohol screening plus support for personal goal setting
223726235|NCT02660502|DRUG|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
223977757|NCT03175198|DRUG|Prazaxa® Capsules|Dosage of Dabigatran etexilate approved in Japan: 300 milligram (mg) daily (150 mg \[as 2 capsules of 75 mg\] twice a day (b.i.d)) or 220 mg (110 mg \[as 1 capsule of 110 mg\] b.i.d) for a treatment duration of 52 weeks.
223977758|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
224117707|NCT02527876|BEHAVIORAL|Delayed Control|Delayed Control
224117708|NCT02527876|DEVICE|FitBit Flex|Use to measure increase in Physical Activity
224117709|NCT00897520|BIOLOGICAL|recombinant interferon alfa|
224117710|NCT00897520|GENETIC|proteomic profiling|
224117711|NCT00897520|OTHER|immunoenzyme technique|
224117712|NCT00897520|OTHER|laboratory biomarker analysis|
224117713|NCT02776280|OTHER|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
224117714|NCT01417780|DRUG|AB103|AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
224117715|NCT01417780|DRUG|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
224117716|NCT00828867|DRUG|100 mg GSK investigational drug|
224117717|NCT00828867|DRUG|200 mg GSK investigational drug|
224117718|NCT00828867|DRUG|400 mg GSK investigational drug|
224117719|NCT00828867|DRUG|800 mg GSK investigational drug|
224117720|NCT00828867|DRUG|2000 mg GSK investigational drug|
224117721|NCT00828867|DRUG|1500 mg GSK investigational drug|
224117722|NCT00828867|DRUG|800mg fed GSK investigational drug|
224117723|NCT00828867|DRUG|3000mg GSK investigational drug|
224117724|NCT00828867|DRUG|4000mg GSK investigational drug|
224117725|NCT05975567|OTHER|Three-dimensional imaging of the collected cardiac specimens|The cadaveric coronary artery segments will first be scanned with intravascular imaging modalities, namely optical coherence tomography (OCT) and intravascular ultrasound (IVUS), and then with micro-computed tomography (micro-CT) and light sheet fluorescence microscopy (LSFM). The thrombotic specimens aspirated from patients with ST-elevated myocardial infarction, will also be scanned using micro-CT. The surgically removed aortic valves will undergo scanning with micro-CT and LSFM. Traditional histopathological assessment will also be performed on the scanned specimens.
224117726|NCT02145767|DRUG|Progesterone|
224117727|NCT02145767|DRUG|Placebo|
224117728|NCT01345786|DRUG|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
224117729|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
224117730|NCT01345786|DRUG|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
224295294|NCT04439084|OTHER|Prospective Chart Review|Collected data will include demographic features, clinical characteristics, clinical outcome, medication use, COVID-19-related complications in patients with chronic liver disease.
223977759|NCT01512914|DRUG|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
223977760|NCT01512914|DRUG|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
223977761|NCT01512914|DRUG|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
223977762|NCT03903523|DEVICE|Lumen apposing metal stent (LAMS)|Stent positioning
223977763|NCT05434715|PROCEDURE|Thyroidectomy|removal of the thyroid gland
223977764|NCT00302497|DRUG|basiliximab|
224117731|NCT03179098|OTHER|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
224117732|NCT03179098|OTHER|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
223726236|NCT02660502|DRUG|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
223977765|NCT03367910|DRUG|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
223977766|NCT00275145|BEHAVIORAL|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
223977767|NCT00275145|BEHAVIORAL|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
223977768|NCT00275145|BEHAVIORAL|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
223977769|NCT00275145|BEHAVIORAL|Continued Sedentary lifestyle|No changes
223977770|NCT01603771|OTHER|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
223977771|NCT02790112|OTHER|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
223977772|NCT00187343|DEVICE|Breast IMRT|
223977773|NCT04183244|PROCEDURE|Erector spinae block|A 5-cm needle prick in the back of the patient 3 cm lateral to mid-line under sterile conditions, with ultrasound guidance.
223977774|NCT04183244|PROCEDURE|Infraclavicular subomohyoid (ISO) block|Under complete aseptic precaution, 12 cm needle will be inserted 2cm superior to the clavicle and advanced retroclavicular, with ultrasound guidance.
224117733|NCT03179098|OTHER|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
224117734|NCT01891747|DRUG|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I \& phase II)
224117735|NCT01891747|DRUG|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I \& Phase II)
224117736|NCT01891747|DIETARY_SUPPLEMENT|Vitamin C|250 mg vitamin C once a day (oral) - Phase I \& Phase II
224117737|NCT03555539|DRUG|Danicopan|Oral tablet.
224117738|NCT00063648|BIOLOGICAL|EBV-specific autologous CTL|
224117739|NCT01974674|PROCEDURE|Allogeneic transplantation of intrahepatic islet|
224117740|NCT01185535|PROCEDURE|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
224117741|NCT03058458|DRUG|PIN201104|IV or SC administration
224117742|NCT03058458|DRUG|Placebo|IV or SC administration
224117743|NCT04037358|DRUG|Radium-223|Radium-223 plus SABR will be within two weeks.
224117744|NCT04037358|RADIATION|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
224117745|NCT01217658|BEHAVIORAL|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
224117746|NCT01217658|BEHAVIORAL|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
224117747|NCT05420519|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
224117748|NCT04436510|DRUG|Matching Placebo|"Drug: Matching Placebo~Administration: Oral~Dose: two tablets twice daily"
224117749|NCT04436510|DRUG|Verdiperstat|"Drug: Verdiperstat~Administration: Oral~Dose: 600mg twice daily"
224117750|NCT06113354|DEVICE|Transcatheter mitral valve repair (MRace Implant and Delivery System)|"The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr"
223726237|NCT02660502|DRUG|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
223726238|NCT02660502|DRUG|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
223726239|NCT00013429|PROCEDURE|Visual|
223977775|NCT01138761|BEHAVIORAL|Nurse instruction|"The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group."
224117751|NCT01775046|DEVICE|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
224117752|NCT03574467|BEHAVIORAL|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
224117753|NCT01959308|OTHER||
223543652|NCT03724279|DEVICE|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
223977776|NCT04444219|OTHER|Breakfast meals|Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
223977777|NCT03389997|DIAGNOSTIC_TEST|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
224117754|NCT01050179|OTHER|carbon dioxide|sinusoidal carbon dioxide delivery
224117755|NCT01147731|BIOLOGICAL|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
224117756|NCT02313935|OTHER|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
224117757|NCT02313935|OTHER|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
224117758|NCT02313935|OTHER|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
224293623|NCT07211724|OTHER|MUD Management (contingency management +/- adjunctive MUD pharmacotherapy)|Management of MUD will be individualized for each study patient. All patients will receive behavioral counseling utilizing motivational interviewing and education and offered a contingency management (CM) plan incentivizing abstinence from meth. Several pharmacotherapies are recommended for the treatment of MUD: mirtazapine, bupropion and naltrexone, or bupropion monotherapy. If required, adjunctive MUD pharmacotherapy will be added to the CM guided by comorbid conditions, patient characteristics, and characteristics of use.
224293624|NCT07211724|OTHER|HF GDMT management|As per standard clinical care, patients will be followed by a cardiologist for HF management including assessment for GDMT optimization.
224293625|NCT07212413|PROCEDURE|Snow-plow restorative technique|The snow-plow technique involves placing a thin layer of uncured flowable bulk-fill resin on the gingival floor of a Class II cavity, immediately followed by placement of a packable bulk-fill composite. Both materials are light-cured simultaneously, allowing the flowable resin to fill voids and improve marginal adaptation.
223726240|NCT06021145|DRUG|Empagliflozin|26-week use of automated insulin delivery system with empagliflozin (2.5 mg daily) in individuals with suboptimal time in range.
223726241|NCT06021145|DRUG|Placebo|26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
223726242|NCT04059978|DRUG|CBD|1600mg cannabidiol, single oral dose (8 ml oily solution)
223726243|NCT04059978|DRUG|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
223726244|NCT04059978|DRUG|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
223726245|NCT05252117|DRUG|Articaine Hydrochloride 40 MG/ML|Analysis of uterovaginal plexus block with articain for intrauterine device placement
223977778|NCT06465615|DEVICE|Self-education with dichoptic reading on tablet|"Intervention 25 min/day, 5 days a week for 6 weeks at home (125-minute weekly load), under the supervision of a parent, on a dichoptic reading application on a loaned digital tablet, wearing anaglyph glasses provided and the patient's optical correction (if applicable).~During the first half of treatment (first 3 weeks), dichoptic separation takes place at the word level, and during the second half of treatment (last 3 weeks), it takes place at the individual letter level to promote precise eye alignment. This shift from dichoptic separation at word level to letter level increases the difficulty of the task. The text is freely chosen by the child and parent from a bank of age-appropriate books."
223977779|NCT06465615|PROCEDURE|Conventional orthoptic rehabilitation|Conventional orthoptic rehabilitation consisting of 12 x 25-minute sessions twice a week over 6 weeks, carried out with an orthoptist from Montpellier University Hospital, combined with reinforcement exercises to be carried out at home for 15 minutes a day under parental supervision, 5 days a week (125-minute weekly load). This is the standard orthoptic treatment offered in France to patients with symptomatic convergence insufficiency, according to orthoptic procedures (10-15 sessions of the order of 20-25 minutes and 10-15 minutes of daily reinforcement exercises at home).
224117759|NCT02313935|OTHER|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
224117760|NCT02639117|DRUG|Vismodegib|Vismodegib 150 mgs po qd for 3 months
224117761|NCT03204838|GENETIC|IDH mutation test performed at diagnosis|Observation of the test result
224117762|NCT01070784|DRUG|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
224295295|NCT03977701|BEHAVIORAL|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
223726246|NCT05252117|DRUG|Mepivacaine|Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement
223726247|NCT00006361|DRUG|semaxanib|
223726248|NCT01699282|BEHAVIORAL|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
223726249|NCT01699282|BEHAVIORAL|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
223726250|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
223726251|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
223726252|NCT00752232|BIOLOGICAL|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
223977780|NCT06048939|OTHER|moderate intensity aerobic training and body weight resistance training|"Bodyweight Resistance exercises Frequency: twice a week Intensity: moderate Time: 40 Minutes Warm up: 10mins Rotations and Dynamic stretches Body weight resistance Exercises: 20mins Calf raises (1 x 10-15 Reps) Squats (1 x 10-15 Reps) Lunges (1 x 10-15 Reps on each side) Modified push-ups (1 x 10-15 Reps) Bridging (1 x 10-15 Reps) Plank hold (10 Seconds) Side planks (10 Seconds each side) Cool down: 10 mins Slow marching and static stretches for next 6 weeks progression will be made by adding one more set of same exercises Aerobic training: Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Exercise Protocol Warm up: 10mins Rotations and Dynamic stretches~Aerobic exercises will be same as given to control group"
223977781|NCT06048939|OTHER|moderate intensity aerobic training|"Aerobic Exercises Frequency: 2 Days per week Intensity: 60% of maximum heart rate. Time: 45 Minutes Warm up: 10mins Rotations and Dynamic stretches Aerobic exercises: 25 mins~(1 minute of each exercise with 60 seconds rest and repeating the same sequence for 1 minute.) Exercises will be performed at slow pace Marching, Single step touch, Step touches front and back, Double step touch, V step, knee lift, leg curl , forward walk, reach outs, lunge side and back, L Step, jumping jacks Cool down: 10 mins Slow marching and static stretches for next 6weeks progression will be made by increasing speed of same exercises"
223977782|NCT00002061|DRUG|Inosine pranobex|
223977783|NCT03526471|DEVICE|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
223977784|NCT02966418|PROCEDURE|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
223977785|NCT02966418|PROCEDURE|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
223977786|NCT05764577|PROCEDURE|DIEP flap surgery|Removal off the DIEP flap followed by closure of the rectus sheath and abdominal skin.
223977787|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
223977788|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
223977789|NCT01260142|DRUG|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
223977790|NCT05712655|OTHER|Measurement of bilateral electromyographic activity of Masseter and Anterior Temporalis muscles.|Assessment was done by surface electromyography (sEMG) device.
223977791|NCT03822377|DRUG|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
223977792|NCT03822377|DRUG|Ticagrelor standard tablets|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
223977793|NCT03792893|OTHER|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
223726253|NCT00752232|OTHER|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
223726254|NCT00752232|OTHER|PBS|IM injection, Day 1, month 3, 6, 9, 12
223726255|NCT01103648|DRUG|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
223726256|NCT01103648|DRUG|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
223726257|NCT01103648|DRUG|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
223726258|NCT01919723|DRUG|Ticagrelor|Ticagrelor loading dose
223977794|NCT03792893|OTHER|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
223726259|NCT01919723|DRUG|Eptifibatide|i.v. infusion
223726260|NCT05787457|OTHER|Clinical examination|
223726261|NCT05787457|OTHER|Blood testing|
223726262|NCT05787457|OTHER|MRI|
223726263|NCT04938193|DIAGNOSTIC_TEST|68Ga-citrate PET/CT|PET/CT Imaging with 68Ga-citrate PET/CT injection
223726264|NCT03234686|DRUG|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
223726265|NCT03234686|DRUG|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
223726266|NCT04502589|DRUG|Perampanel Tablet|Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
223977795|NCT06032273|BEHAVIORAL|Investigator-designed lung transplant education website|Caregiver participants assigned to the intervention will access the investigator-designed educational resource via their login to a secure website.
223977796|NCT03161223|DRUG|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
223977797|NCT03161223|DRUG|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
223977798|NCT03161223|DRUG|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
223977799|NCT03161223|DRUG|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
223977800|NCT02872519|DRUG|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
223977801|NCT02872519|PROCEDURE|Positron Emission Tomography|Undergo scan
223977802|NCT02872519|OTHER|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
223977803|NCT02112578|DRUG|Meclizine|25 mg, 3 times per day up to 30 days
224117763|NCT01070784|DRUG|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
223977804|NCT02112578|DRUG|Dimenhydrinate|50 mg, 3 times per day up to 30 days
224117764|NCT05769803|DIAGNOSTIC_TEST|Nasal and mouth swab|"Whinin 7 days from diagnosis, the subjects will be requested to sample another two specimens i.e. nasal swab and mouth swab, that will be tested for the presence of SARS-CoV-2 RNA. Results, expressed as cycle threshold will be then compared to analyze viral loads from the two different sites.~Moreover, an aliquot will be retro-transcribed into cDNA and sequenced by Next Generation Sequencing (NGS) to obtain the virus entire genome sequence or evaluated by RT-PCR for variantdetermination."
224117765|NCT03693287|DRUG|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
223543653|NCT03336190|BEHAVIORAL|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
223543654|NCT02259725|DRUG|regorafenib|Given PO
223543655|NCT02259725|OTHER|laboratory biomarker analysis|Correlative studies
223543656|NCT00610792|DRUG|bortezomib|1.3 mg/m2 on Days 1, 4, 8 \& 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
223543657|NCT00610792|DRUG|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
223543658|NCT00456755|DRUG|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
223543659|NCT00456755|OTHER|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
223543660|NCT06164691|DEVICE|Blue light|Participants undergoing this intervention will be exposed to blue (442nm) light.
223543661|NCT06164691|DEVICE|Amber light|Participants undergoing this intervention will be exposed to amber (617nm) light.
223543662|NCT06164691|OTHER|Ambient White Light|This cohort will be exposed to usual, ambient white lighting of the environment during chemotherapy and radiation treatments
223543663|NCT01594840|DEVICE|Changing chat|Diapers with tips
223543664|NCT00879723|DIETARY_SUPPLEMENT|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
223543665|NCT05179278|OTHER|Post-surgical nurse follow-up|Follow-up face-to-face consultation or follow-up telephone consultation a month after the intervention and telephone consultation at one year
223543666|NCT03533699|DRUG|Propranolol|
223543667|NCT03533699|DRUG|Placebo Oral Tablet|oral tablets with no active drug
223543668|NCT02970136|DEVICE|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
223977805|NCT06291584|OTHER|Exercise|In the exercise program, the first 5 minutes are for heating, and the last 5 minutes are for cooling. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. At the end of respiratory exercises, resistance exercise training will be started. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, hip extrudy, squat, and cat-decrease. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
224117766|NCT03693287|DRUG|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
223726267|NCT04502589|DRUG|Disulfiram|Disulfiram will be kept at 250mg daily
224117767|NCT00797459|DEVICE|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
224117768|NCT02682888|BEHAVIORAL|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
224117769|NCT02682888|DRUG|Oxytocin|intranasal administration of oxytocin
224117770|NCT02682888|DRUG|Placebo|intranasal administration of placebo
224117771|NCT03502759|BEHAVIORAL|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
224117772|NCT01888354|DRUG|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
224117773|NCT02515591|OTHER|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
224117774|NCT06276972|OTHER|no intervention|there's no intervention. it's a cross sectional study correlation study
224117775|NCT01031758|OTHER|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
224117776|NCT01636869|DRUG|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
224117777|NCT02309736|DEVICE|ReSure Sealant|
224117778|NCT00000849|DRUG|Aldesleukin|
223543669|NCT02970136|DEVICE|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
223543670|NCT02970136|DEVICE|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
223543671|NCT02970136|OTHER|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
223543672|NCT02970136|DEVICE|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
223543673|NCT02970136|OTHER|Home Based Screening Tests|Patients will provided screening tests and instructed by Community Health Worker on how to perform home screening tests
223543674|NCT05587179|OTHER|recovery position|A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
224117779|NCT01000064|DRUG|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
224117780|NCT01000064|PROCEDURE|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
224117781|NCT01000064|DRUG|Placebo|Placebo capsules taken every morning for 6 weeks.
223543675|NCT02248896|DRUG|Telmisartan|
223543676|NCT02248896|DRUG|Other angiotensin-receptor blockers (ARBs)|
223543677|NCT02248896|DRUG|Angiotensin-converting enzyme inhibitors (ACEIs)|
223543678|NCT02248896|DRUG|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
223543679|NCT03561155|DEVICE|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
223543680|NCT03561155|OTHER|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
223543681|NCT01684670|BEHAVIORAL|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
223543682|NCT02280993|DRUG|DHAP|DHAP
223543683|NCT02280993|DRUG|Brentuximab Vedotin|Brentuximab Vedotin
223543684|NCT02280993|OTHER|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
223726268|NCT04541550|DRUG|AMP-001 Low Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
223977806|NCT00496834|DRUG|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
223977807|NCT00496834|DRUG|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
223977808|NCT00496834|DRUG|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
223977809|NCT00496834|DRUG|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
223977810|NCT00721825|DRUG|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
223977811|NCT00721825|DRUG|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
223977812|NCT01227928|DRUG|Pazopanib|Pazopanib 800 mg daily for 24 months
223977813|NCT01227928|DRUG|Placebo comparator|Placebo 800 mg daily for 24 months
223977814|NCT01993628|OTHER|Rey figure test|
223726269|NCT04541550|DRUG|AMP-001 Medium Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
223726270|NCT04541550|DRUG|AMP-001 High Dose|AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
223726271|NCT00555321|DRUG|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
224117782|NCT02518620|BIOLOGICAL|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
224117783|NCT00176566|DRUG|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
223726272|NCT00555321|DRUG|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
223726273|NCT00555321|DRUG|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])"
223726274|NCT00555321|DRUG|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
223726275|NCT00555321|DRUG|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
223977815|NCT01993628|OTHER|MRI|
223977816|NCT01042145|DRUG|Prednisone|2 mgs/kg for 3 days
224117784|NCT00876174|PROCEDURE|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
224117785|NCT00876174|PROCEDURE|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
224117786|NCT00085540|DRUG|depsipeptide|Given IV
224117787|NCT02389946|DEVICE|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
224293626|NCT07212413|PROCEDURE|Resin coating restorative technique|The resin coating technique involves applying and light-curing a thin layer of flowable bulk-fill resin after adhesive application to create a stress-absorbing layer on dentin (resin coating), followed by restoration with packable bulk-fill composite. This approach aims to protect the dentin, enhance bond stability, and reduce postoperative sensitivity
223726276|NCT02235480|DRUG|Experimental Tazarotene Gel|
223977817|NCT01042145|DRUG|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
223977818|NCT04721405|DEVICE|Observational Study: No intervention|Observational Study: No intervention
224117788|NCT02389946|DEVICE|Xience DES|
224117789|NCT01518192|DRUG|doxycycline|100 mg bid; 15 days
224117790|NCT01518192|DRUG|cefuroxime axetil|500 mg bid; 15 days
223726277|NCT02235480|DRUG|Placebo|
223726278|NCT03178981|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
223726279|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
224117791|NCT00759512|OTHER|Therapeutic Touch|
223977819|NCT04501978|BIOLOGICAL|LY3819253|Participants are no longer being randomized to this intervention.
223977820|NCT04501978|DRUG|Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion
223977821|NCT04501978|BIOLOGICAL|Remdesivir|Provided to all study participants as SOC unless contraindicated for an individual patient.
223977822|NCT04501978|BIOLOGICAL|VIR-7831|Participants are no longer being randomized to this intervention.
223543685|NCT00551096|DRUG|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
223543686|NCT00551096|DRUG|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
223977823|NCT04501978|BIOLOGICAL|BRII-196/BRII-198|Participants are no longer being randomized to this intervention.
223543687|NCT00551096|DRUG|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
223543688|NCT04794738|DRUG|SHR8554|SHR8554 Injection; high dose
223977824|NCT04501978|BIOLOGICAL|AZD7442|Participants are no longer being randomized to this intervention.
223977825|NCT04501978|DRUG|MP0420|Participants are no longer being randomized to this intervention.
224117792|NCT03911544|DEVICE|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
223543689|NCT04794738|DRUG|SHR8554|SHR8554 Injection; low dose
223977826|NCT04501978|DRUG|PF-07304814|250 mg per day for 5 days. Administered as a constant rate intravenous infusion. Suspended: Participants are not currently being randomized to this intervention.
224117793|NCT00161304|DRUG|Testosterone Enanthate|Testosterone Enanthate
224117794|NCT00161304|OTHER|Placebo|placebo
224117795|NCT02619240|PROCEDURE|bronchoscopy|performance of bronchoscopy with BAL
223977827|NCT04887701|DEVICE|Non-hormonal vaginal device therapy|Experimental Active Therapy
223977828|NCT04887701|DEVICE|Sham vaginal device therapy|Sham Comparator
223977829|NCT05699967|OTHER|data collection|Participants wear a wristband with a Photoplethysmography (PPG), heart rate and respiratory rate sensor continuously for 3 days. Once gateway and device are linked, all data will be transmitted continuously via Bluetooth to an in-house database. The Device Hub allows to control data availability and signal quality of the wearables, but no scores will be calculated and visualized. The data obtained for calculating the NEWS2 is solely observational and for the study staff. It has no clinical consequence on the treatment of the patient. It is analyzed whether the score with values form the wearables and Electronic Health Record (EHR) corresponds to the conventionally calculated NEWS2 score with values coming only from the EHR.
223543690|NCT04794738|DRUG|Saline Solution|Saline Solution
223543691|NCT04794738|DRUG|Morphine|Morphine
223977830|NCT00768209|DRUG|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
224117796|NCT01175070|DRUG|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen \[TM\]) 0.3mg every 6 weeks over a 30 week period.
224117797|NCT00978445|OTHER|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
224295296|NCT03977701|BEHAVIORAL|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
224295297|NCT05240131|DRUG|GB1211|GB1211 is a galectin 3 inhibitor an orally available small molecular anti-fibrotic. It is administered orally twice a day.
224295298|NCT05240131|DRUG|Placebo|Placebo is administered orally twice a day.
223977831|NCT01128140|BEHAVIORAL|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
223977832|NCT01128140|BEHAVIORAL|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
223977833|NCT03819842|DIAGNOSTIC_TEST|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
223977834|NCT03462368|PROCEDURE|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
223977835|NCT03462368|PROCEDURE|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
223977836|NCT03462368|PROCEDURE|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
223977837|NCT02930837|DRUG|alteplase|
223977838|NCT06561256|DRUG|Janus Kinase Inhibitor|Janus Kinase Inhibitor in combination with corticosteroids
224117798|NCT00903461|BIOLOGICAL|EGFR Antisense DNA|"* Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~* EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
224117799|NCT02380430|OTHER|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
224117800|NCT04722393|OTHER|Exercise|Exercise training
224117801|NCT02681887|DRUG|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
224117802|NCT02681887|DRUG|Placebo|placebo tablet identical to circadian
224295299|NCT05240131|DRUG|Atezolizumab|Atezolizumab is an PD-L1 inhibitor administered as an intravenous infusion every three weeks at a dose of 1200mg
223726280|NCT01066533|OTHER|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
223726281|NCT04993092|OTHER|muscle energy technique|Post facilitation stretch Patient perform isometrics for 15 seconds then therapist rapidly move the shoulder to the end range
223726282|NCT04993092|OTHER|mulligan mobilization technique|Sustain Posterolateral glide with belt and then told Patient to move in following pattern (internal rotation, external rotation, abduction, wall sliding)
223726283|NCT04014842|DEVICE|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
223726284|NCT03782272|DIETARY_SUPPLEMENT|Enterade|enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
223977839|NCT05708976|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a behavioral (psychotherapeutic) intervention for major depressive disorder (MDD). A highly trained masters' or PhD-level clinician will administer 8 weekly CBT sessions (\~50 minutes each), following the standard cognitive behavioral therapy for depression protocol.
223977840|NCT05708976|DEVICE|Active Whole-Body Hyperthermia (Active WBH)|Active whole-body hyperthermia (active WBH) will be administered by trained research assistants. Preparation for the active WBH session, the active WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the active heating phase will last until the participants has achieved a core (rectal) temperature of 38.5 C.
224117803|NCT02207192|OTHER|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
224117804|NCT02131467|DRUG|Perampanel|oral drug
224117805|NCT03670862|OTHER|CT|Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
223726285|NCT03782272|DIETARY_SUPPLEMENT|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
223726286|NCT02277301|BEHAVIORAL|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
223726287|NCT02055014|DRUG|Liraglutide|
223726288|NCT02055014|DEVICE|Duodenal-jejunal bypass liner - Endobarrier device|
223726289|NCT02840370|DEVICE|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
224117806|NCT03141307|BEHAVIORAL|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
224117807|NCT03141307|BEHAVIORAL|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
224117808|NCT03141307|BEHAVIORAL|Control|Standard of care, paper-based brochure
224117809|NCT03090737|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
224117810|NCT06671080|DIAGNOSTIC_TEST|Closed Kinetic Chain Upper Extremity Stability Test|All of these tests planned to be used in the study will be applied to adolescent amateur soccer players who meet the inclusion criteria.
224117811|NCT03458000|DEVICE|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
224117812|NCT03458000|OTHER|Standard of Care|Patient was admitted to hospital for care and received in-patient EGD.
223977841|NCT05708976|DEVICE|Sham Whole-Body Hyperthermia (Sham WBH)|Sham whole-body hyperthermia (sham WBH) will be administered by trained research assistants. Preparation for the sham WBH session, the sham WBH session, and cool down will last 3.5 hours, with heating lasting approximately 90-100 minutes (and no longer than 140 minutes). The treatment will take place in an infrared sauna dome, and the sham WBH session will minimally impact core body temperature.
223977842|NCT05463445|OTHER|Only observation|No intervention is needed.
223977843|NCT01919177|DIETARY_SUPPLEMENT|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
223977844|NCT01919177|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
223977845|NCT04636879|OTHER|Positive expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding message.
223977846|NCT04636879|OTHER|Neutral expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
223977847|NCT04636879|OTHER|Negative expectation AND dry needling in the upper trapezius fibers, at the most painful point|The subjects will received the same treatment, using dry needling in the upper trapezius fibers, at the most painful point after receiving the corresponding
223977848|NCT05335577|DIAGNOSTIC_TEST|Urinary Claudin-2|A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
223977849|NCT05335577|DIAGNOSTIC_TEST|Urinary Caveolin-1|A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
223977850|NCT05335577|DIAGNOSTIC_TEST|Urinary EGF|A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
223977851|NCT01393613|DRUG|OPC-34712|Higher dose tablet, once daily, for six weeks,
223977852|NCT01393613|DRUG|OPC-34712|Middle dose tablet, once daily, for six weeks
223977853|NCT01393613|DRUG|OPC-34712|Lower dose tablet, once daily, for six weeks
223977854|NCT01393613|DRUG|Placebo|Placebo, once daily, for six weeks
223977855|NCT03821064|OTHER|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
223977856|NCT01618227|DEVICE|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
223977857|NCT01618227|PROCEDURE|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
223977858|NCT03945851|PROCEDURE|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
223977859|NCT02187445|DRUG|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
223977860|NCT03209297|OTHER|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
223543692|NCT02663154|DRUG|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
224295300|NCT00453817|DRUG|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
223543693|NCT02663154|DRUG|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
223726290|NCT02840370|DEVICE|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
223726291|NCT04243681|COMBINATION_PRODUCT|CD 34 and MSC infusion|Combination of stem cells
223726292|NCT04243681|DRUG|Standard of care for Cirrhosis management|Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
223726293|NCT00582166|DRUG|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
223726294|NCT02792972|OTHER|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
223977861|NCT00110955|DRUG|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
223977862|NCT00110955|DRUG|Placebo|Q3W dosing of placebo
223977863|NCT02489721|DEVICE|PICC and Midline|Peripherally inserted central venous catheter
223977864|NCT03955952|PROCEDURE|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
223977865|NCT01794650|DIETARY_SUPPLEMENT|Meal composition|
223977866|NCT03847220|DIAGNOSTIC_TEST|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
223977867|NCT00951574|DRUG|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
224117813|NCT06672211|OTHER|video-supported training|Patients with stomas were provided with video-supported training in addition to standard stoma care training.
224295301|NCT00453817|PROCEDURE|Islet transplantation|intraportal percutaneous islet transplantation
223543694|NCT04882865|DEVICE|assist|A custom designed patient wrap will envelope the patient. This will be coupled to a mechanical lift system to facilitate repositioning of the patient (AMMP) Commercially available repositioning sheets will be used for the general care of some study patients
223543695|NCT02477527|DRUG|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
223543696|NCT05988736|DEVICE|MaCintosh Laryngoscope (DL)|A conventional Laryngoscope. It is battery powered, with a detachable MaCintosh blade that contains a light source.
223543697|NCT05988736|DEVICE|McGrath Laryngoscope (VL)|A video Laryngoscope that has a high-resolution video camera, and a light source at the cone end of the blade allowing for direct and indirect viewing of the glottis
223977868|NCT00951574|DRUG|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
223977869|NCT00525200|DRUG|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
223977870|NCT00525200|DRUG|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
223977871|NCT06212765|DRUG|L-citrulline|to take 1 pod a day for 45 days
223977872|NCT02592486|BIOLOGICAL|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
224117814|NCT02858388|DEVICE|Sinuclean Nebules 45|Nebulization of solution
224117815|NCT02858388|OTHER|Saline solution|Nebulization of solution
224117816|NCT06123416|BEHAVIORAL|Expressive Writing|Caregivers complete three 20-min writing sessions in which they write about an assigned topic - emotional or non-emotional.
224117817|NCT04654325|DIAGNOSTIC_TEST|conjunctival swab|Patients will have conjunctival swab for SARS-CV-2 genome detection
223726295|NCT02792972|OTHER|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
223726296|NCT05063604|DRUG|Citalopram|20 mg tablet one or twice daily for 12 weeks
223726297|NCT05063604|BEHAVIORAL|Psychotherapy|One session weekly for 12 weeks
223726298|NCT05675397|DIETARY_SUPPLEMENT|donor human milk|Pasteurized preterm donor milk (PDM) versus term donor milk (TDM) will be provided to the study population following randomization, as supplementary to mother's own milk (MOM) or as alternative feeding
223726299|NCT00005571|DRUG|h5G1.1-mAb|
223977873|NCT02592486|BIOLOGICAL|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
223977874|NCT02978846|OTHER|Clinical Observation|Undergo side effects evaluation using cards
223977875|NCT06453161|OTHER|Post-operative acute kidney injury|"Serum creatinine increase by 0.3 mg/dl within 48 h OR Serum creatinine ≥ 1.5-1.9 times baseline within 7 days~Baseline creatinine is defined as the last pre-operative value available in the medical file"
223977876|NCT01283971|DRUG|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
223977877|NCT01283971|DRUG|adalimumab|Adalimumab 40 mg SC every 2 weeks.
223977878|NCT01283971|DRUG|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
223977879|NCT01283971|DRUG|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
223977880|NCT01283971|DRUG|methotrexate|Methotrexate 10-25 mg weekly.
224117818|NCT04019496|DRUG|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
224117819|NCT03953638|DIAGNOSTIC_TEST|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
223977881|NCT01283971|DRUG|folate|Folate at least 5 mg weekly.
224117820|NCT06722352|BEHAVIORAL|Palliative Care Training|Teaching about caring for individuals with
224117821|NCT01770353|DRUG|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
224295302|NCT00453817|PROCEDURE|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
223977882|NCT02511171|OTHER|Cranial osteopathic manipulative therapy|
223977883|NCT00427245|DRUG|cyclophosphamide|
223977884|NCT00427245|DRUG|goserelin acetate|
223977885|NCT00427245|PROCEDURE|adjuvant therapy|
223977886|NCT00427245|PROCEDURE|fertility assessment and management|
223977887|NCT00427245|PROCEDURE|neoadjuvant therapy|
223977888|NCT02617667|DRUG|Cyclosporine A|topical ocular, eye drops
223977889|NCT02617667|DRUG|Placebo|topical ocular, eye drops
223977890|NCT01108484|BEHAVIORAL|Exercise|Supervised exercise: Three 90-minutes sessions per week.
224117822|NCT01770353|DRUG|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
224117823|NCT02556645|OTHER|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
224117824|NCT02556645|OTHER|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
224117825|NCT06736483|DRUG|Dexmedetomidine|Intravenous administration of 1 µg /kg of dexmedetomidine in 10 ml of 0.9% sodium chloride at the time of incision.
223977891|NCT01108484|BEHAVIORAL|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
223977892|NCT01108484|BEHAVIORAL|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
223977893|NCT02791126|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
223977894|NCT02791126|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
223977895|NCT03777553|BEHAVIORAL|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
224117826|NCT06736483|DRUG|Placebo administration|Intravenous administration of 10 ml sodium chloride 0.9% at the time of incision
224117827|NCT06736483|OTHER|Face Legs Activity Cry Consolability scale|The pain will be assessed on admission and every 15 minutes until discharge from the PACU
223977896|NCT06196229|OTHER|Action Observation Therapy|"During each training session, participants were asked to observe a specific object-directed daily action presented on a computer screen, and afterward they performed what they have observed, 5 repetitions of each task, time duration was noted .~16 motor tasks related to their daily living that were performed with their own hands which are following~1. Folding a towel~2. Cutting a toilet roll~3. Using scissors~4. Tightening shoelaces~5. Opening and closing a square airtight container~6. Opening a bottle top~7. Turning a faucet~8. Using a field of billfold~9. Drinking water~10. Setting a seal~11. Changing batteries~12. Opening and closing a zipper~13. Turning over pages of a book~14. Plugging the outlet~15. Spraying water with a sprayer~16. Sorting chopsticks and spoons and putting them in a box • The participants were advised to keep focusing on their affected arm/hand action observational tasks"
223977897|NCT06196229|OTHER|Action Observation Therapy combined with Virtual Reality|"In the VRT group, participants will execute VR-based activities conducted by the same therapist.~* 16 tasks will be assigned in each session. VR SHINECON 3D Glasses will be used~* The virtual environment was set in a 6 m2 physical space~* At the beginning of each session, the participant will sit in the center of the set zone and will be assisted to wear the VR glasses~* After the participant will confirm that the sight and sound is clear and comfortable, the tasks mentioned in action observation therapy will be done using virtual reality videos~* The Extrinsic feedback will be provided, including the time left, number of repetitions, and record number of repetitions"
224117828|NCT06736483|OTHER|Post-Hospitalization Behavior Questionnaire|The Post-Hospitalization Behavior Questionnaire will be completed at day 1 and at day 7
224117829|NCT06736483|OTHER|Postoperative pain measure|The Postoperative pain measure will be completed by parents at day 1, day 7, 3 months and 6 months
224117830|NCT06736483|OTHER|Post-operative quality of life questionnaire|The Post-operative quality of life questionnaire pedQL will be completed at 3 and 6 months
224117831|NCT03466320|BIOLOGICAL|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
224117832|NCT06738836|DRUG|[14C]-EDG-7500|Oral liquid suspension
224117833|NCT05574504|DRUG|avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin|"Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.2 mg/m2 administered as a 1-h intravenous infusion once every 3 weeks (day 1 and 22 every 6 week cycle )~1 cycle= 6 weeks~Premedication for lurbinectedin:~* Corticosteroids (dexamethasone 8 mg intravenously or equivalent)~* Serotonin antagonists (ondansetron 8 mg intravenously or equivalent) Granulocyte-colony stimulating factor (G-CSF) or equivalent per ASCO guidelines per investigator discretion"
224117834|NCT06757140|DRUG|Alprazolam|Participants will receive varying non-therapeutic experimental doses of oral alprazolam, alone and in combination with oral oxycodone
224117835|NCT06757140|DRUG|Oxycodone|Participants will receive varying non-therapeutic experimental doses of oral oxycodone, alone and in combination with oral alprazolam
224117836|NCT06757140|DRUG|Placebo|Participants will receive inactive oral doses
224295303|NCT04648124|DEVICE|IRMf-r (séquence resting state)|Functional MRI of functional brain networks
224295304|NCT02577341|DRUG|Nimotuzumab|Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
223977898|NCT06045871|PROCEDURE|Corticotomy followed by compression osteogenesis|Surgical corticotomy supra apical in anterior maxilla then application of the compression osteogenesis concept via traction on miniscrews implanted above the corticotomy line
224117837|NCT06768268|PROCEDURE|Voluven-assisted Indocyanine green fluorescence guided sentinel lymph node biopsy for breast cancer|The procedure includes: (1) preparation of specific formula of ICG:Voluven solution (2) injection of ICG solution at subarelar area or peri-tumoral area (3) observation of fluorescent lymphatic drainage and retrieval of sentinel lymph nodes
224117838|NCT06768268|DRUG|Mannitol (20%)|Adding Mannitol into Voluven and used as solvent of ICG
224117839|NCT06801314|OTHER|aerobic exercise using cycle ergometer in addition to usual care|"aerobic exercise group):Patients in this group will be received usual care and cycle ergometer aerobic exercise Mood of exercise: continuous aerobic exercise~* Modality of exercise: cycle ergometer~* Intensity of exercise: low to moderate intensity and HR (calculated as recommended by the American College of Sports Medicine (ACSM) and tolerated up to 20-30 bpm above the resting HR), BP, SpO2 and rate of perceived exertion through the Borg Scale (10-13) will be monitor during cycling~* Duration: 15-20 min including 5 min warm up and 5 min cool down and working phase from 5-10 min~* Frequency: daily until discharge aerobic exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guide and stop exercise when there is any adverse events will occur."
224117840|NCT06801314|OTHER|resisted exercise using weights and dumbbells in addition to usual care|"resisted exercise group): Patients in this group will be received usual care and resisted exercise~* Mode: resisted exercise~* Modality: dumbbells or sand bags tied around main groups of muscles for upper and lower limbs Intensity of exercise: the load that the patient can lift for 10-12 repetition at RPE of 10-13 and 1-2 sets resisted exercise group guided by wearable artificial intelligence ECG monitor to real-time support, guided and stop exercise when there is any adverse events will occur."
223726300|NCT02532972|DEVICE|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
223977899|NCT02864199|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
224117841|NCT06801314|OTHER|usual care using mobilization and breathing exercise|mobilization and breathing exercise
224117842|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
224117843|NCT02574312|DEVICE|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
224117844|NCT06930430|PROCEDURE|Non-Surgical Periodontal Therapy (NSPT)|Scaling and root planing was performed using hand instruments under local anesthesia, if necessary. Oral hygiene instructions were provided using the modified Bass technique. GCF samples were collected from the same sites at baseline, 1 month, and 3 months to measure levels of IL-1β and S1P using ELISA.
224117845|NCT06929858|OTHER|cognitive-behavioral strategies training|"A structured training program focused on cognitive-behavioral strategies tailored to the challenges of caring for children with ASD. Examples include:~Techniques to manage stress (e.g., relaxation exercises). Cognitive reframing to address negative thoughts. Coping skills to enhance resilience in a demanding work environment."
224117846|NCT06929650|PROCEDURE|Radiofrequency ablation|"Radiofrequency energy is delivered to the thyroid nodule via the medical device. This device is a system consisting of 3 main components:~1. VIVA combo RF system (generator and pump)~2. single foot switch~3. electrode (5mm, 7mm, 10mm, or adjustable)."
224117847|NCT06930508|BEHAVIORAL|Patient participant screening|Patient participants will be provided with the standardized PrEP screening and initiation protocol.
224117848|NCT06930508|BEHAVIORAL|Physician participant training|Physician participants will be trained in the investigators' standardized PrEP screening and initiation protocol.
223977900|NCT02864199|DRUG|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
223977901|NCT04421118|OTHER|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient|a non-invasive technology to evaluate hepatic venous pressure gradient and portal pressure gradient based on three-dimensional modeling and fluid dynamics simulation
223977902|NCT03216252|BIOLOGICAL|samples|Blood samples, oral smear and urine
224117849|NCT06930287|OTHER|250 mg Nimbus shoe|lightweight shoe
224117850|NCT05091489|OTHER|Qualitative assessment about PrEP acceptability|Qualitative research among key-populations, community and healthcare workers, and decision and policy makers, including focus group and semi-directive interviews
223726301|NCT01308671|DRUG|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
223726302|NCT01308671|BEHAVIORAL|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
223977903|NCT01554371|DRUG|Eribulin|"Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only"
223726303|NCT01606436|DRUG|LY2140023|Administered orally.
223726304|NCT01606436|DRUG|Placebo|Administered orally.
223726305|NCT01606436|DRUG|Moxifloxacin|Administered orally.
223726306|NCT02279381|DRUG|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
223726307|NCT02279381|OTHER|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
223977904|NCT01554371|DRUG|Cyclophosphamide|Given IV
223977905|NCT02598934|DRUG|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
223977906|NCT01618071|DIETARY_SUPPLEMENT|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
223977907|NCT03441737|BEHAVIORAL|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
223726308|NCT02279381|OTHER|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
223977908|NCT03441737|BEHAVIORAL|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
223977909|NCT02672514|DEVICE|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
223977910|NCT02672514|DEVICE|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
223977911|NCT00002855|DRUG|Bicalutamide|
223977912|NCT00002855|DRUG|Doxorubicin hydrochloride|
223726309|NCT02859454|DRUG|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
223726310|NCT06139029|DRUG|3% normal saline|nebulization
223726311|NCT06139029|DRUG|steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline|nebulization
223977913|NCT00002855|DRUG|Estramustine Phosphate Sodium|
223726312|NCT03626883|PROCEDURE|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
223726313|NCT03626883|PROCEDURE|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
223726314|NCT05938972|BIOLOGICAL|Mepolizumab|Monoclonal antibodies
223726315|NCT01596400|DRUG|granisetron transdermal system|patch
223726316|NCT01596400|DRUG|Granisetron IV|IV
223726317|NCT01656473|OTHER|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
223726318|NCT01656473|OTHER|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
223977914|NCT00002855|DRUG|Flutamide|
224117851|NCT02444637|DRUG|Rivastigmine|
223977915|NCT00002855|DRUG|Ketoconazole|
223977916|NCT00002855|DRUG|Nilutamide|
224117852|NCT06100432|DRUG|DLBS5055 200mg|1x1 caplet
224117853|NCT06100432|DRUG|Placebo DLBS5055|1x1 caplet
223726319|NCT02003820|BEHAVIORAL|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
223977917|NCT00002855|DRUG|Therapeutic Hydrocortisone|
223726320|NCT03577691|OTHER|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
223726321|NCT03577691|OTHER|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
223726322|NCT03577691|OTHER|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
223726323|NCT03577691|OTHER|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
223726324|NCT05459675|OTHER|Very low-calorie diet|Meal replacement (800 kcal/day, protein 90 g/day)
223726325|NCT05459675|PROCEDURE|Bariatric surgery|Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
223726326|NCT00877253|DRUG|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
223726327|NCT00877253|DRUG|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
223726328|NCT00877253|DRUG|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
223726329|NCT01596868|DRUG|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
223977918|NCT00002855|DRUG|Vinblastine|
223977919|NCT00002855|PROCEDURE|Conventional Surgery|Surgical castration
223977920|NCT02409121|BEHAVIORAL|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
223977921|NCT05313815|RADIATION|Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)|External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes
223977922|NCT03212183|BEHAVIORAL|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
223977923|NCT03212183|OTHER|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
223977924|NCT02456259|PROCEDURE|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
223977925|NCT02579278|OTHER|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
223977926|NCT02579278|OTHER|Blood sample (mrEMVI negative patient)|
223977927|NCT03325608|OTHER|POISED Care|Program of dementia care management.
223977928|NCT03352661|OTHER|Collect retrospectively data|Collect retrospectively data
223977929|NCT03600519|DEVICE|NOTAL OCT V2.5|AMD Patients
223977930|NCT04205500|OTHER|Specific carbohydrate diet|Specific carbohydrate diet (see arm description)
223977931|NCT02188784|DRUG|Polysaccharide Iron Complex 150 mg|Oral Iron
223977932|NCT02188784|DRUG|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
223977933|NCT05634083|DIETARY_SUPPLEMENT|Uremic pateints with itching|Activated charcoal
223977934|NCT00884884|DRUG|Double Placebo|1 capsule daily
223977935|NCT00884884|DRUG|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
223977936|NCT00884884|DRUG|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
223977937|NCT00884884|DRUG|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
223977938|NCT00884884|DRUG|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
223977939|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
223977940|NCT00884884|DRUG|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
223977941|NCT00884884|DRUG|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
223977942|NCT00884884|DRUG|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
223726330|NCT01596868|DRUG|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
223977943|NCT00884884|DRUG|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
223977944|NCT01356121|DRUG|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
224117854|NCT06100432|DRUG|Multivitamin (Vitamin C 500mg + Vitamin E 100IU + Beta Carotene 10000IU)|1x2 caplets
224117855|NCT06100432|DRUG|Placebo Multivitamin|1x2 caplets
224117856|NCT05396456|PROCEDURE|Muscle Fiber Fragment (MFF) Injections|The participant will be treated with an injection of muscle fiber fragments into the external anal sphincter at 3, 6, 9 and 12 o'clock using a 21-gauge needle to a depth of 1-2 cm from the external skin using equal amounts in each quadrant.
224117857|NCT06226285|DEVICE|TechQoL4Carers Platform|"The TechQoL4Carers platform is a technological solution that has been designed and developed by the research team in collaboration with the end users. A website and a mobile application integrate the platform. The services offered are: summary of the person's state of health; training content, advice and personalised recommendations based on their situation in terms of quality of life, provision of care, occupational balance, self-management of health and empowerment. It also allows synchronisation with the Xiaomi Smart Band 7/8 activity wristband.~The intervention has a duration of three months. Participants will use the services of TechQoL4Carers and wear the Xiaomi Smart Band 7/8 wristband on a regular basis.~It is expected that caregivers will access and use the TechQoL4Carers platform, at least once a week, to answer the weekly questionnaire and they will consult, at least once a month, the training contents for self-care and for the provision of care."
224117858|NCT03920410|OTHER|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
224117859|NCT03920410|OTHER|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
223977945|NCT01356121|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
223977946|NCT00204100|DEVICE|Surface Functional Electrical Stimulation|
223977947|NCT02503488|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
223977948|NCT02503488|BEHAVIORAL|Treatment as Usual|See arm description
223977949|NCT03527758|DEVICE|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
223977950|NCT01889771|DRUG|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
223977951|NCT01497951|OTHER|Aminolaevulinic acid|Photodynamic therapy
223977952|NCT01497951|OTHER|Methylcellulose Placebo|Methylcellulose
223977953|NCT04365738|OTHER|Rehabilitation|Chest and diaphragm respiration, in-house mobilization, joint range of motion exercises was performed to the patients as breathing exercises.
223977954|NCT05753319|OTHER|Physiotherapy in the emergency department after a fall|Realization of a physiotherapy assessment.
223977955|NCT06415071|OTHER|No intervention|Exposures of interest would be clearly defined according to a specific research question and identified from the database
223977956|NCT02724163|DRUG|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
223977957|NCT02724163|DRUG|Liposomal daunorubicin|"Anthracycline~(Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug."
223977958|NCT02724163|DRUG|Mitoxantrone|DNA-reactive agent
223977959|NCT02724163|DRUG|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
223977960|NCT02724163|DRUG|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
223977961|NCT02724163|DRUG|Busulfan|Alkylsulfonate
223977962|NCT02724163|DRUG|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
223977963|NCT05442593|OTHER|Plyometric training|Participants will perform: 8 sets of 10 maximal countermovement jumps
223977964|NCT04944784|DRUG|Reldesemtiv|Reldesemtiv Oral Tablet
224295305|NCT02577341|DRUG|docetaxel and cisplatin|Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
223726331|NCT03687489|DEVICE|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
223726332|NCT03703765|DEVICE|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
223726333|NCT03944954|DEVICE|Placebo TMS Sham|Individuals will receive placebo dose and sham TMS.
223726334|NCT03944954|DRUG|Marinol 10Mg Capsule TMS Sham|Individuals will receive 10mg dose and sham TMS.
223726335|NCT03944954|DRUG|Marinol 30Mg Capsule TMS Sham|Individuals will receive 30mg dose and sham TMS.
223726336|NCT03944954|DEVICE|Placebo TMS Real|Individuals will receive placebo and real TMS.
223726337|NCT03944954|OTHER|Marinol 10Mg Capsule TMS Real|Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
223726338|NCT03944954|OTHER|Marinol 30Mg Capsule TMS Real|Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)
223977965|NCT04944784|DRUG|Placebo|Placebo Oral Tablet
223977966|NCT03836170|PROCEDURE|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
223977967|NCT04322760|DRUG|Lidocaine 5% patch with Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
223977968|NCT04322760|DRUG|Dexmedetomidine Bupivacaine|10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%
223977969|NCT06094335|DEVICE|Virtual reality rehabilitation|Children in this group received Virtual Reality Rehabilitation plus traditional physical therapy
223977970|NCT06094335|OTHER|Traditional physical therapy|Flexibility exercises, strengthening exercises, endurance exercises, and postural stability exercises
223977971|NCT00853372|DRUG|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
223977972|NCT00853372|DRUG|Trebananib|Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
223977973|NCT05348668|DRUG|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors|Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
223977974|NCT01268098|DRUG|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
224295306|NCT02577341|RADIATION|daily RT to the chest|Patients received daily RT to the chest
224295307|NCT04744324|BEHAVIORAL|Self-supporting Care|Individualized self-supporting care with four principals (i.e., drinking water, exercise, excretion, and nutrition)
224295308|NCT04744324|BEHAVIORAL|Home health education|Individualized home health education
223726339|NCT03223246|OTHER|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
223726340|NCT05350111|BEHAVIORAL|lifestyle education|education on healthy lifestyle through group sessions and telemedicine tools
223726341|NCT00469183|DRUG|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
223726342|NCT02268084|DEVICE|Magnetic EEG/ECG-guided Resonance Therapy|A coil delivers a pulsed magnetic field to the cortex of the brain
223726343|NCT02268084|DEVICE|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
223726344|NCT05227027|BEHAVIORAL|Game Module|Receive access to the the game module through the free, 'Smoke Free' smartphone application
223977975|NCT05439473|DIETARY_SUPPLEMENT|Curalin|Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
223977976|NCT00665132|DEVICE|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
223977977|NCT04311190|OTHER|Family engagement|Physical exercises and simple care tasks
223977978|NCT01727206|DRUG|Tocilizumab|
223977979|NCT06385613|BEHAVIORAL|Mobile-based stoma care education group|Individuals included in the intervention group will be given mobile-based stoma care trainings before surgery, on the 3rd postoperative day, on the day of discharge, and on the 1st and 3rd months after discharge, and their effectiveness will be measured using data collection forms.
223977980|NCT00523068|DRUG|Tolterodine|
223977981|NCT00523068|PROCEDURE|tension free vaginal tape|
223977982|NCT03215342|BEHAVIORAL|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
223977983|NCT03215342|BEHAVIORAL|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
223977984|NCT00085878|DRUG|SB-485232|
223977985|NCT00228098|BEHAVIORAL|Smoking cessation|
223977986|NCT01059188|DRUG|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
223977987|NCT01059188|DRUG|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
223726345|NCT05227027|BEHAVIORAL|Smoke Free smartphone application|Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
223726346|NCT05989750|DEVICE|Ultrasonic scaler|Ultrasonic scaling for subgingival cleaning every 6 months for 2 years according to the manufacturer's procedures.
223726347|NCT05989750|DEVICE|Air-Flow Prophylaxis Master|AIR-FLOW PROPHYLAXIS MASTER with erythritol powder (AIR FLOW Powder Plus) will be used every month for 2 years for subgingival cleaning according to the manufacturer's procedures.
223726348|NCT03415217|OTHER|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
223726349|NCT01890551|OTHER|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
223726350|NCT03817307|DIAGNOSTIC_TEST|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
223726351|NCT00248989|DRUG|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
223726352|NCT00248989|DRUG|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
223977988|NCT01059188|DRUG|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
223977989|NCT01059188|RADIATION|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
223977990|NCT01059188|PROCEDURE|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
223977991|NCT02432170|DEVICE|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
223977992|NCT01347268|PROCEDURE|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
223977993|NCT01347268|PROCEDURE|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
223977994|NCT05507398|DRUG|Placebo, metformin and atorvastatin|comparing the anti-tumor effects of metformin and atorvastatin
223977995|NCT00093288|DRUG|bupropion XL|
223977996|NCT01310712|DRUG|Oxybutynin|5 mg every 12 hours for 6 weeks
223977997|NCT01310712|DRUG|placebo|placebo twice a day for 42 days.
223977998|NCT05186896|OTHER|Risk perception questionnaire|A questionnaire for risk perception will be developed and administered
223977999|NCT00048503|DRUG|ZARNESTRA, tipifarnib, R115777|
223978000|NCT00148252|DRUG|Mycophenolate mofetil withdrawal|
223978001|NCT00148252|DRUG|Cyclosporione A withdrawal|
223978002|NCT00248534|BIOLOGICAL|rituximab|given IV days 1,8, 15 and 22
223978003|NCT00248534|DRUG|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
223978004|NCT00248534|DRUG|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
223978005|NCT06956248|OTHER|Off-label or non-standard systemic therapies|Off-label systemic treatments and/or relevant clinical trials recommended by the NCCS Molecular Tumour Board (MTB).
223978006|NCT02418845|DRUG|SYM-1219|
223978007|NCT02418845|DRUG|Placebo|
223978008|NCT06385847|DRUG|Zoladex|Patients received 3.6 mg subcutaneous Zoladex
223978009|NCT06385847|DRUG|LY01005|Patients received 3.6 mg intramuscular LY01005
224295309|NCT00337441|DRUG|Epoetin Alfa (drug)|
223978010|NCT06957561|DRUG|Disitamab Vedotin Injection|Participants will receive Disitamab Vedotin at a dose of 2.0 mg/kg. In the neoadjuvant phase, it will be administered every 2 weeks for 6 cycles (12 weeks total). In the postoperative adjuvant phase, it will be administered every 3 weeks for 4 cycles, starting 4-8 weeks after surgery.
223978011|NCT06957561|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|Participants will receive Ivonescimab at a dose of 20 mg/kg. In the neoadjuvant phase, it will be administered every 3 weeks for 4 cycles (12 weeks total). In the postoperative adjuvant phase, it will be administered every 3 weeks for 9 cycles, starting 4-8 weeks after surgery.
223978012|NCT06957561|PROCEDURE|Radical Cystectomy with Pelvic Lymph Node Dissection|Participants will undergo radical cystectomy with pelvic lymph node dissection 4-6 weeks after the last dose of neoadjuvant treatment.
224295310|NCT00869024|BIOLOGICAL|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
223978013|NCT05707715|DEVICE|XSensor|"A pressure mapping system (X3 SENSOR PX 100:64.160.02, X-Sensor®, Calgary, Canada) was used to record the pressure distribution in mmHg of the head and shoulder section \[18,19\]. Pressure distribution was recorded for 1 minute for each lying position. The purpose of these measurements was to describe the pressure distribution created by the participants in the pillow and the supported areas, as well as to find out the differences that may occur between the pillows. Lower pressure values measured by the device were defined as high comfort, while more contact of the head area with the pillow was accepted as high support."
223978014|NCT03367598|GENETIC|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T\>C polymorphism.
223978015|NCT00389688|DRUG|cisplatin|
223978016|NCT00389688|DRUG|pemetrexed disodium|
223978017|NCT00389688|PROCEDURE|adjuvant therapy|
223978018|NCT00389688|PROCEDURE|conventional surgery|
223978019|NCT00389688|PROCEDURE|neoadjuvant therapy|
223978020|NCT03669198|DIAGNOSTIC_TEST|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
224117860|NCT05885997|BEHAVIORAL|Supported HBPM program plus multifaceted implementation strategy|"Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices"
224117861|NCT05885997|OTHER|Usual care|Usual care
223726353|NCT04542785|OTHER|Rate control|Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.
223726354|NCT03648268|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
223726355|NCT04405947|PROCEDURE|Reverse Shoulder Arthroplasty|implantation of a reversed shoulder prostheses through two different surgical approaches
223726356|NCT02911753|OTHER|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
223726357|NCT02911753|OTHER|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
223978021|NCT02603705|DRUG|Oxycodone extended-release|
223978022|NCT02994784|DRUG|Propylene Glycol-Free Melphalan Hydrochloride|Intravenous Propylene Glycol-Free Melphalan Hydrochloride
223978023|NCT05282238|DIAGNOSTIC_TEST|Nasal pressure assessment|Once the patient is enrolled nasal pressure will be measured through a dedicated pressure line located at the nostril entrance and connected to a dedicated pressure transducer (OptiVentTM, SIDAM, Mirandola, Italy). Measured nasal pressure will be the result of the variation between inspiratory and expiratory pressure (DeltaPnose). The measurement of DeltaPnose will be obtained considering the average of 3 values registered during 3 breath after at least 3 minutes of stable and constant respiratory pattern. Pnose values will be measured before extubation (T0) and 30 minutes (T1), 2 hours (T2), 4 hours (T3), 12 hours (T4) , 24 hours (T5) and 48 hours (T6) after extubation.
223978024|NCT00805597|RADIATION|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
223978025|NCT00805597|RADIATION|no radiation|no radiotherapy
223978026|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 75 mg/capsule|Take 2 capsules per day at any time.
224293627|NCT07213024|BEHAVIORAL|Facilitated group-structured active play at the hospital|"The hospital-based part of the intervention includes daily facilitated group-structured active play sessions during the weekdays (i.e., Monday-Friday) at the hospital for 40 weeks. All sessions will be 45 minutes long and structured using the RePlay Model following four core principles: 1) ritual practices; 2) reinforcement of movement through repetition; 3) devel-opment through appropriate challenges; and 4) adjusting activities to accommodate treat-ment-related side effects. All activities are performed together, where healthcare pro-fessionals, parents, and children all participate to support social development.~The group-structured active play sessions will take place at the pediatric oncology ward and will be facilitated by a health professional (i.e., an exercise professional or physiother-apist)."
223978027|NCT05803083|DIETARY_SUPPLEMENT|Hyaluronic acid 50 mg/capsule|Take 2 capsules per day at any time.
223726358|NCT02911753|OTHER|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
223726359|NCT01503944|DRUG|18F-AV-133|185 MBq
223726360|NCT01503944|DRUG|18F-AV-45|185-370 MBq
223726361|NCT03504150|BEHAVIORAL|SPHERE|Comprehensive Internet-based CBT program with no human support
223726362|NCT03504150|BEHAVIORAL|PRISM|Brief Internet-based CBT program with no human support
223726363|NCT04464915|OTHER|Isopropyl alcohol swab|Treatment will be administered by taking one deep inhalation of an isopropyl alcohol swab held 1-2cm below the nares. Intervals of administration will be every 10 minutes or every 20 minutes for a total of one hour.
223726364|NCT03334448|DRUG|LY900014-U200|Administered SC
223726365|NCT03334448|DRUG|LY900014-U100|Administered SC
223726366|NCT01504945|OTHER|RBC transfusion|1 bag of packed red blood cells
223978028|NCT05803083|DIETARY_SUPPLEMENT|Placebo|Take 2 capsules per day at any time.
223978029|NCT02363998|DRUG|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
223726367|NCT01504945|OTHER|Normal saline infusion|500 mL of normal saline infusion
223726368|NCT04919850|DIETARY_SUPPLEMENT|Saccharomyces boulardii and SOD|A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
223726369|NCT04919850|COMBINATION_PRODUCT|Placebo|A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
223726370|NCT04940689|DRUG|Dexmédétomidine 0.5 g/kg + lidocaine 1.5 mg/kg|The patient will be anesthetized with Dexmedetomidine 0.5 g / kg + lidocaine 1.5 mg / kg for the induction instead of morphin.
223726371|NCT04940689|DRUG|Remifentanil|The patient will be anesthetized with morphin.
223978030|NCT04248907|OTHER|0 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
223978031|NCT04248907|OTHER|2 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
223978032|NCT04248907|OTHER|4 pound tension|A digital fish scale will be attached to the distal strap of a gel liner to measure the distraction values while casting. A digital fish scale can measure in pounds or kilograms depending on how you set it. The digital fish scale will be held in place while casting to maintain a consistent tension between the scale and the residual limb.
223978033|NCT04834492|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty in Crowe type 4 developmental dysplasia of the hip.
223978034|NCT02466243|DRUG|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
223978035|NCT02466243|DRUG|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
223978036|NCT03347266|DRUG|VVZ-149 injections|•VVZ-149 injection
223978037|NCT03347266|DRUG|Placebo|water for injection
223978038|NCT04106570|OTHER|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
223978039|NCT02803671|DEVICE|TFU-NIRS|
223978040|NCT02803671|DEVICE|NIRS|
223978041|NCT02803671|DEVICE|EEG|
223978042|NCT00477464|DRUG|Lapatinib|1250mg once daily
223978043|NCT00477464|DRUG|capecitabine|2000mg/m\^2 twice daily (14 days out of 21 days)
223726372|NCT03613012|DIAGNOSTIC_TEST|Pain index|Record the patients' EEG and extract pain index before and after pain treatments
223978044|NCT03664206|DIAGNOSTIC_TEST|MRS, conventional TMS and treshold tracking TMS|"Using~* two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~* SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
223726373|NCT03775629|DRUG|Polmacoxib and Tramadol combination|Tramadol hydrochloride , Polmacoxib
224117862|NCT05529706|OTHER|Brain Health Program|The Brain Health Program employs 1-hour/week group-based training and education regarding modifiable Alzheimer's disease dementia risk factors delivered over a 12-week period. Participants will be assigned into a group of up to 20 participants, and participants will engage the Brain Health Program collaboratively, as administered by the program content leader (instructor), while also being monitored and supported by the tech leader (in accordance with the Diabetes Prevention Program model).
224117863|NCT06794437|OTHER|Questionnaire|Translate and culturally adapt the original English version of the Mobile Device Proficiency Questionnaire
224117864|NCT05547438|DRUG|NTS-104 TRIS|Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
224117865|NCT05547438|DRUG|Placebo|Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
224293628|NCT07213024|BEHAVIORAL|Parents educational program|"The parent educational program consists of two educational sessions within the first three months of the child's treatment trajectory. The sessions have the aim of providing the par-ents with knowledge and skills to facilitate structured active play at home:~1. A 30-60-minute session with general information on gross motor function development, common physical side effects of cancer treatment, and the importance of physical activity and active play.~2. A 60-minute practical, interactive introduction to structured active play and the RePlay Model - including inspiration for active play activities they can do at home that challenge different gross motor skills.~The parents will receive practical material on gross motor development stages and skills as well as descriptions of active play activities that target gross motor functions."
223726374|NCT03775629|DRUG|Polmacoxib|Polmacoxib
223726375|NCT03775629|DRUG|Tramadol hydrochloride|Tramadol hydrochloride (HCl)
223726376|NCT02988843|DRUG|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
224117866|NCT05158452|PROCEDURE|Discussion|Attend a focus group
224293629|NCT07213024|BEHAVIORAL|Online facilitated structured active play at home|The online facilitated structured active play sessions at home are provided daily during the weekdays (i.e., Monday-Friday) in the afternoon (e.g., 16.00-17.00). A healthcare profes-sional (i.e., an exercise professional or physiotherapist) facilitates these sessions, guiding the families through active play activities following the RePlay Model structure. When the families log on for the online sessions, a healthcare professional will instruct them through different play activities. Each family will receive basic essential home-structured active play equipment (e.g., bean bags, balls, bingo games, items for an obstacle course) for the online sessions. The sessions will be conducted through video connections (Teams or Skype). Families who do not have an iPad or suitable computer will receive an iPad from the research group for the nine-month intervention.
223726377|NCT02988843|DRUG|Bevacizumab|15 mg/kg every 21 days
223726378|NCT01683383|DEVICE|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
223726379|NCT01683383|OTHER|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
224117867|NCT04550793|DRUG|Botulinum toxin injection|Botulinum toxin injection at affected brachialis and/or biceps brachials.
224117868|NCT01012193|DRUG|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
224117869|NCT06552442|DRUG|Methylprednisolone|High-dose intracoronary glucocorticoid methylprednisolone to abrogate no-reflow: a unique study for restoration of infarct-related artery patency and reduction of ischemia-reperfusion injury
224117870|NCT05294822|PROCEDURE|Autologous regenerative islet transplantation for insulin-dependent diabetes mellitus|Islet transplantation was completed using percutaneous transhepatic portal vein puncture. After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
224293630|NCT07211750|OTHER|integrated care intervention tailored to the needs of older adults leaving at home with mood disorders and multimorbidity in Leuven|The six guiding principles are translated into practice through a structured six-step care model. Each step operationalizes one or more principles, ensuring that the model is consistently applied across patient trajectories. The program takes 12 months, with flexible contacts depending on patient's needs.
224293631|NCT07213388|BEHAVIORAL|VRPA|Effects of virtual reality physical activity on outcomes
224293632|NCT07213388|BEHAVIORAL|Treadmill|Effects of treadmill walking with music on outcomes
224293633|NCT07213388|BEHAVIORAL|Control|Effects of music while sitting on outcomes
223726380|NCT05204238|DIAGNOSTIC_TEST|Transthoracic Echocardiography|LV dimensions, LV mass and indices of LV function LA area and volume Indices of diastolic function (E/A ratio, E/e' ratio) Heart valve assessment according to GL RV dimensions and indices of RV function PAPs (RV-RA gradient and vena cava dimensions and collapsibility) B-lines at lung ultrasounds (comet lung score) Speckle Tracking analysis of LV (GLS), LA (PALS) and RV (LS of free wall) Optional 3D analysis of left and right ventricle
223726381|NCT06068478|DRUG|Qingzhu Granules|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.
223726382|NCT06068478|DRUG|Qingzhu Granules Placebo|During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
223726383|NCT00855920|DRUG|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
223726384|NCT00855920|DRUG|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
224117871|NCT02160379|OTHER|standard test meal|
223726385|NCT00855920|OTHER|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
223726386|NCT00855920|OTHER|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
223726387|NCT05362097|OTHER|The reliability and validity of the Chinese version of CC-QoL|Cc-qol, LCQ, and VCD were repeated 1-2 times before and 1-13 weeks after treatment.
223726388|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
223978045|NCT04952779|DRUG|Xultophy® (insulin degludec/liraglutide)|"Xultophy® is a fixed ratio combination of the long-acting basal insulin, insulin degludec, and the glucagon-like peptide 1 receptor agonist (GLP-1 RA), liraglutide, administered under the skin.~Patients will be treated according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS.~The assignment of the patient to Xultophy® is not decided in advance by the protocol but falls within current practice and the prescription of Xultophy® is clearly separated from the decision to include the patient in the study."
223978046|NCT01921907|DRUG|AD17137 topical treatment|
223978047|NCT01921907|DRUG|Placebo|
223978048|NCT04329546|OTHER|NA (no intervention)|NA (no intervention)
223978049|NCT03647384|DRUG|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
223978050|NCT03647384|DRUG|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
224117872|NCT01446952|DRUG|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
223726389|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
223726390|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
223726391|NCT00996307|BIOLOGICAL|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
223726392|NCT03262909|DEVICE|GelrinC|Patients will undergo GelrinC implantation.
224117873|NCT00625521|DRUG|ASF 1096 0.5 % cream applied twice daily|
224117874|NCT00625521|DRUG|Cream vehicle for ASF 1096 cream applied twice daily|
224117875|NCT02078713|BEHAVIORAL|Contraceptive Decision Support Tool|"The decision support tool:~* Provides an educational session about different aspects of contraception~* Elicits patient preferences about different aspects of contraception~* Identifies potential contraindications to certain contraceptive methods~* Allows the patient to view details about and compare available contraceptive methods~* Suggests methods most appropriate based on the patient's preferences~* Collects questions the patient may have for her provider~* Generates a printout the patient can bring to her contraceptive counseling visit"
224117876|NCT00094341|DRUG|Etanercept|
224117877|NCT02096861|BIOLOGICAL|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
224117878|NCT02096861|BIOLOGICAL|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
224293634|NCT07212205|OTHER|Visual & Auditory Cueing Walker|"Intervention Name:~Visual \& Auditory Cueing Walker~Other Intervention Names (varsa):~Cueing Walker Walker with Visual \& Auditory Cues~Intervention Description:~Participants in this arm were assessed under two within-subject conditions: walking on a 7-meter path without cues (control condition) and walking on the same path using a visual and auditory cueing walker (intervention condition). Each participant completed both conditions in a single session. Pre- and post-walking evaluations were conducted for walking speed (Timed Up and Go Test), fall risk (Tinetti Balance and Gait Assessment), and gait adaptation (Dynamic Gait Index). The 'no cues' condition represents a repeated-measures control within the same arm. Participants were included based on the presence of freezing of gait.~Planned Enrollment: 18"
224293635|NCT07211425|DRUG|BI 3031185|BI 3031185
224293636|NCT07211425|DRUG|Itraconazole|Itraconazole
223726393|NCT03262909|OTHER|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
223978051|NCT00639769|DRUG|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
223978052|NCT00639769|DRUG|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
223978053|NCT00072683|DRUG|tolvaptan|
223978054|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
223978055|NCT00863798|DRUG|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
223726394|NCT05886829|COMBINATION_PRODUCT|Chlorpheniramine Maleate 0.4% Nasal Spray|Chlorpheniramine Maleate 0.4% Nasal Spray
223726395|NCT05886829|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
223726396|NCT05409456|OTHER|mild aerobic exercise|mild aerobic exercise given to group A on treadmill
223726397|NCT05409456|OTHER|moderate aerobic exercise|moderate aerobic exercise given to group B on treadmill
223978056|NCT00863798|DRUG|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
223978057|NCT02418715|OTHER|Water Aerobics Training|
223978058|NCT04238520|BEHAVIORAL|Functionally Tailored Oral Care Intervention|Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
223726398|NCT04603690|DIETARY_SUPPLEMENT|Complementary therapy|A daily supplementation of 168 mg curcumin, 260 mg quercetin and 360 IU of vitamin D3 (cholecalciferol) for 14-days
223726399|NCT04603690|DRUG|Standard of care|This arm will receive standard of care as per the hospital guidelines
223978059|NCT04238520|BEHAVIORAL|Control Intervention|Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
223978060|NCT01470599|DRUG|CP-690,550|ORAL TABLET, TWICE DAILY
223978061|NCT01470599|DRUG|CP-690,550|ORAL TABLETS, TWICE DAILY
223978062|NCT00195442|DRUG|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223978063|NCT00847132|BEHAVIORAL|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
223978064|NCT00847132|BEHAVIORAL|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
223978065|NCT02413606|OTHER|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
223978066|NCT01057251|DRUG|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
223978067|NCT01057251|DRUG|Placebo|5 mg or 20 mg once daily, oral administration
223978068|NCT04651309|OTHER|Transperineal Ultrasound|The ultrasound examination will be conducted using the technique described by Hassan et al (2013). Briefly, transperineal ultrasound images are obtained by placing a covered transducer between the labia below the symphysis pubis. Small lateral movements of the probe are then made to align the ultrasound beam in a midsagittal orientation to include the whole cervical length after which the probe is rotated 90 degrees in order to measure the cervical dilatation. The probe is rotated up and down until the echogenic circle of the cervix is seen. Please note that this technique is widely used within the delivery room and that the ultrasound machine that will be used is frequently used within the delivery room.
224293637|NCT07211958|DRUG|Revumenib|Participants will receive revumenib orally.
224293638|NCT07211958|DRUG|Placebo|Participants will receive placebo (non-active agent) orally.
224293639|NCT07211958|DRUG|Intensive Chemotherapy Regimen|Participants will receive an intensive chemotherapy regimen of cytarabine and daunorubicin by intravenous (IV) infusion.
224293640|NCT07212361|DIETARY_SUPPLEMENT|Probiotic|Specific infant-adapted commercially available strains or strains isolated from the infant's mother.
224293641|NCT07212361|OTHER|Placebo|Infant formula without bacteria.
224293642|NCT07212803|DIETARY_SUPPLEMENT|Energy Drink A + Placebo Capsule|1000 mL caffeine- and taurine-containing commercially available beverage (Formula A) consumed with placebo capsule
224293643|NCT07212803|DRUG|Placebo Drink + Moxifloxacin Capsule|Placebo drink with 400 mg moxifloxacin capsule
223726400|NCT04891874|RADIATION|Stereotactic radiotherapy|Radiation using stereotactic radiotherapy device.
223726401|NCT01845493|DIETARY_SUPPLEMENT|Alpha Sprout Homogenate|Alpha Sprout Homogenate
223726402|NCT01845493|DIETARY_SUPPLEMENT|Sulforaphane Homogenate|Active
223978069|NCT00784147|DRUG|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
223978070|NCT00784147|DRUG|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
223978071|NCT03596242|OTHER|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
223978072|NCT03596242|BEHAVIORAL|blood pressure control education|standard blood pressure control education given during visits
223978073|NCT02509312|DRUG|Ketorolac|Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
224293644|NCT07212803|DIETARY_SUPPLEMENT|Placebo Drink + Caffeine Capsule|Placebo drink with 320 mg caffeine capsule
224293645|NCT07212803|OTHER|Placebo Drink + Placebo Capsule|Placebo drink with placebo capsule
224293646|NCT07212803|DIETARY_SUPPLEMENT|Energy Drink B|568 mL caffeine- and taurine-containing commercially available beverage (Formula B)
224293647|NCT07212803|DIETARY_SUPPLEMENT|Control Product + Taurine|Control product with 4000 mg taurine powder
224293648|NCT07212803|DIETARY_SUPPLEMENT|Control Product + Caffeine + Taurine|Control product with 320 mg caffeine + 4000 mg taurine powder
224293649|NCT07212803|DIETARY_SUPPLEMENT|Lower Dose Energy Drink A|591 mL caffeine- and taurine-containing commercially available beverage (Formula A)
224293650|NCT07212998|BIOLOGICAL|Plasma|urgent release early plasma resuscitation following burn/thermal injury
224293651|NCT07212998|BIOLOGICAL|Standard care|Standard resuscitation as dictated by institutional protocol
224293652|NCT07212270|PROCEDURE|periodontal flap surgery|Open flap debridement with intra-sulcular incisions or flaps with para-marginal incisions were performed by lifting the mucoperiosteal flap and debriding the periodontal defect under visual control.
224293653|NCT07212270|PROCEDURE|gingivectomy and gingivoplasty|surgical methods for the excision of hyperplastically enlarged gingiva.
223978074|NCT02509312|DRUG|Placebo|Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
223978075|NCT04492137|PROCEDURE|Cannulation technique|"Participants in the ultra early NKF group will be submitted to 2 standard cannulation attempts (2 contacts with the papilla) before starting NKF. If any of these 2 attemps is successful, NKF won't take place. If NKF is indeed performed and cannulation is not achieved within 8 minutes, the endoscopist is free to perform techniques other than NKF. On the other hand, participants in the standard cannulation group in which cannulation is not achieved within 8 minutes can cross-over to other advanced cannulation techniques (e.g. NKF). For ethical reasons we choose to exclude flat and intradiverticular/diverticular border papillas.~During ERCP all participants will be submitted to PEP prophylaxis with rectal indomethacin. A pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct.~For the purposes of the study, a dedicated form (attached) will be created with the various variables to be analyzed"
223978076|NCT01705405|DEVICE|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
223978077|NCT03616860|DEVICE|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
223978078|NCT06521424|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
223978079|NCT06521424|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
223978080|NCT05419310|OTHER|Rehabilitation - core strengthening|Physical rehabilitation based on core strengthening
223978081|NCT05419310|OTHER|Rehabilitation - rehabilitation pilates|Physical rehabilitation based on rehabilitation pilates
223978082|NCT05419310|OTHER|Elastic taping application|Application of elastic taping
223978083|NCT02162017|OTHER|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
223978084|NCT02162017|OTHER|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
224117879|NCT05050409|BEHAVIORAL|Brief mindfulness|A 15-minute guided mindfulness practice that includes focused attention on breath and body sensations and open monitoring and acceptance of thoughts, emotions, and pain.
223978085|NCT01939951|DIETARY_SUPPLEMENT|Activation Energy Serum|7 drops or 21 drops twice daily
223978086|NCT03412578|PROCEDURE|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
223978087|NCT01297699|DRUG|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
223978088|NCT01297699|DRUG|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
223978089|NCT05131711|COMBINATION_PRODUCT|Combined stereotactic radiosurgery and enhanced immunotherapy|Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
223978090|NCT03046797|DEVICE|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
223978091|NCT03046797|DEVICE|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
223978092|NCT04418180|DRUG|Fenofibrate|Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
223978093|NCT04418180|DRUG|Placebo|oral distilled water
224117880|NCT05050409|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|An 8-session intervention. Sessions involve: 1) mindfulness training to reduce pain and increase self-regulation over opioid use, 2) cognitive reappraisal to decrease psychological distress, and 3) savoring to augment natural reward processing, positive emotion, and esprit de corps.
224293654|NCT07211711|DEVICE|Stabilizing occlusal splint|Maxillary stabilizing occlusal splint, made of acrylic with 2mm thickness in the posterior region. Installed and evaluated monthly for 4 months.
224293655|NCT07211711|DEVICE|placebo splint|Maxillary placebo non-occlusal splint, installed and evaluated monthly for 4 months.
224293656|NCT07211633|BIOLOGICAL|Ublituximab|Administered as an IV infusion.
223978094|NCT00064428|DRUG|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
223978095|NCT00064428|OTHER|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
223978096|NCT00064428|DRUG|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
223978097|NCT00064428|DRUG|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
223978098|NCT04561583|DEVICE|LED light source system for endoscope|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
223978099|NCT04561583|DEVICE|Pinpoint Endoscopic Fluorescence Imaging System|"This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period."
224117881|NCT05050409|OTHER|Standard care|Preoperative Standard Care. Patients will attend a 2-hour preoperative class involving pain coping education and are offered prehabilitation services. Postoperative standard care includes (1) pain medications to minimize opioid use, including acetaminophen, lyrica, meloxicam/naproxen and celebrex, and (2) anticoagulants for 3-6 weeks postoperatively, as well as (3) ambulatory care with assistive devices 1-6 weeks after surgery. Patients see their surgeon postoperatively 2-6 weeks after surgery, 3-6 months, and yearly.
224117882|NCT03383718|PROCEDURE|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
224117883|NCT03383718|OTHER|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
224117884|NCT03544554|BEHAVIORAL|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
224117885|NCT00696657|DRUG|semaglutide|0.1 mg, once weekly, s.c. injection
224117886|NCT00696657|DRUG|semaglutide|0.2 mg, once weekly, s.c. injection
223978100|NCT02906995|DRUG|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"* One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~* The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
223978101|NCT04771962|DRUG|DESFLURANE AND SEVOFLURANE|COMPARING THE EFFICACY IN MAINTAINANCE OF SPONTANEOUS GENERAL ANAESTHESIA USING AMBU AURA GAIN IN PEDIATRIC PATIENTS
223978102|NCT00706914|DRUG|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
223978103|NCT00706914|DRUG|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
223978104|NCT00706914|DRUG|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
223978105|NCT00706914|DRUG|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
223978106|NCT04832581|BEHAVIORAL|The Self-Care Behavior Development Program|This program, which is based on the Orem Self Care Model, includes anatomical, physiological and hormonal changes, urinary system infections and preventive measures during pregnancy. The program is different from other researches in that it is based on a methodological theory and is created with up-to-date information.
223978107|NCT04010383|DIAGNOSTIC_TEST|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
223978108|NCT00087997|DRUG|STA-4783|
223978109|NCT04214275|OTHER|pulmonary rehabilitation|Simple breathing techniques, secretion-removal techniques, airway-cleaning techniques, mobilization techniques and use of an incentive spirometer
223978110|NCT02025478|DIETARY_SUPPLEMENT|Breastmilk|"* A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
224117887|NCT00696657|DRUG|semaglutide|0.4 mg, once weekly, s.c. injection
223978111|NCT06220812|DEVICE|low level laser ,pulsed electromagnetic field .|"LLL ,ASA via Alessandro Volta, 9 .36057 Arcugnano- Italy. With 905-nm wavelength, and maximum power output of 500 mW, laser spot of approximately 1 cm2 .~PEMF, ASA, Easy teraza serie (ETS), Italy 2011, its code F9020087 and 230 its voltage."
223978112|NCT04868253|DRUG|EMB-01|EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
223978113|NCT05338541|DRUG|Tucidinostat and etoposide|Tucidinostat: 3+3 design，14 mg/m2，17.5 mg/m2，23 mg/m2 etoposide: 50mg/m2,
223978114|NCT02122549|DEVICE|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
223978115|NCT03505255|DRUG|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
223978116|NCT03505255|OTHER|Normal saline|Normal saline 0.9 % is given in the control group
223978117|NCT01159483|DRUG|PF-04958242|Administered as specified in the treatment arm
223978118|NCT01159483|DRUG|Placebo|Administered as specified in the treatment arm
224117888|NCT00696657|DRUG|semaglutide|0.8 mg, once weekly, s.c. injection
224117889|NCT00696657|DRUG|semaglutide|0.8 mg with titration, once weekly, s.c. injection
224117890|NCT00696657|DRUG|semaglutide|1.6 mg with titration, once weekly, s.c. injection
224117891|NCT00696657|DRUG|placebo|0.1 mg, once weekly, s.c. injection
224117892|NCT00696657|DRUG|placebo|0.2 mg, once weekly, s.c. injection
224117893|NCT00696657|DRUG|placebo|0.4 mg, once weekly, s.c. injection
224117894|NCT00696657|DRUG|placebo|0.8 mg with titration, once weekly, s.c. injection
224117895|NCT00696657|DRUG|placebo|1.6 mg, once weekly, s.c. injection
224117896|NCT00696657|DRUG|liraglutide|1.2 mg with titration, once daily, s.c. injection
224117897|NCT00696657|DRUG|liraglutide|1.8 mg with titration, once daily, s.c. injection
224117898|NCT04914832|BIOLOGICAL|AZD1222|AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
224117899|NCT00649376|DRUG|Fexofenadine Tablets 180 mg|180mg, single dose fasting
223978119|NCT02352077|BIOLOGICAL|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
223978120|NCT00702650|DRUG|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
223978121|NCT05987644|DRUG|Alectinib|600mg taken orally, twice daily for 25 Cycles Cycle = 4 weeks (28 days)
223978122|NCT05987644|RADIATION|Stereotactic Radiosurgery|SRS dose varies by brain met size and location
223978123|NCT03669328|PROCEDURE|locoregional anesthesia|Both groups received locoregional anesthesias
223978124|NCT02156388|BIOLOGICAL|GW003|freeze-dried powder；single SC injection
223978125|NCT03954223|BEHAVIORAL|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)
223978126|NCT03954223|BEHAVIORAL|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
223978127|NCT03954223|DEVICE|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
223978128|NCT05380102|DEVICE|Telemetry monitoring|All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
223978129|NCT05380102|DEVICE|Continuous monitoring through Earlysense|EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
223978130|NCT05380102|DEVICE|Continuous monitoring through Dozee VS|Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
223978131|NCT00005569|DRUG|SLPI (Secretory Leukocyte Protease Inhibitor)|
223978132|NCT02200978|DRUG|ATO|Given IV
223978133|NCT02200978|DRUG|RIF|Given orally
223978134|NCT02200978|DRUG|ATRA|Given orally
223978135|NCT02200978|DRUG|mitoxantrone|Given IV
223978136|NCT02200978|DRUG|Ara-C|Given IV
223978137|NCT02200978|DRUG|MTX|Given orally
223978138|NCT02200978|DRUG|6MP|Given orally
223978139|NCT02200978|OTHER|intrathecal injection|Ara-C and dexamethasone
223978140|NCT04026399|OTHER|peripheral vibration stimulation|wearing a wristband that delivers imperceptible vibratory stimulation.
223978141|NCT04026399|BEHAVIORAL|therapy|practice of daily living tasks
223978142|NCT00239096|DRUG|losartan (drug)|
223978143|NCT03626077|OTHER|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
223978144|NCT03626077|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
223978145|NCT03626077|COMBINATION_PRODUCT|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
223978146|NCT02431455|DEVICE|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
223978147|NCT02431455|DEVICE|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
223978148|NCT00988533|DRUG|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
223978149|NCT02888223|BIOLOGICAL|SCT800|
223978150|NCT02888223|BIOLOGICAL|Xyntha|
223978151|NCT05184777|DIAGNOSTIC_TEST|Determination of progesterone and oestradiol|Blood and saliva samples will be taken for determination of progesterone and oestradiol hormones.
223978152|NCT05105568|BEHAVIORAL|Process-based therapy|Process-based therapy (PBT) is a meta-theoretical model of evidence-based therapies that organizes adaptive and maladaptive processes of change using complex and dynamic networks based on an evolution science framework. Depending on the participant's presentation, PBT would be shaped by different evidence-based techniques. Examples of evidence-based procedures include: behavioral activation, exposures, mindfulness, self-compassion, values exploration, and contingency management.
223978153|NCT00675792|DRUG|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
223978154|NCT00675792|DRUG|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
224117900|NCT00649376|DRUG|Allegra® Tablets 180 mg|180mg, single dose fasting
223978155|NCT00675792|DRUG|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
223978156|NCT05413863|BIOLOGICAL|Biocon's Human Insulin R U-500|Biocon's Human Insulin R U-500 (Insulin Human Injection 500 units/mL), 3 mL cartridges (containing 1,500 units of insulin).
223978157|NCT05413863|BIOLOGICAL|Humulin® R U-500 (US Reference Product)|Humulin® R U-500 (US Reference Product), 3 mL single-patient-use KwikPen® (containing 1,500 units of insulin)
223978158|NCT05219578|DRUG|RTX-224|RTX-224 monotherapy
223978159|NCT00943722|BIOLOGICAL|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
223978160|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment exercise targeting expectancy violation|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet with questions aimed at enhancing the processing of what was learned during treatment in terms of expectancy violation. For example, they are asked if what they were most worried about occured and what actually happened compared to what they predicted to happen. This should highlight the discrepancy between anticipated and actual outcomes. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
223978161|NCT04790864|BEHAVIORAL|Online large-group one-session treatment with post-treatment control exercise|The treatment is aimed at reducing public speaking anxiety by using cognitive and behavioral techniques. Following a psychoeducation phase, different speaking tasks are conducted to expose the individuals to their feared situation on the one hand and to address common cognitive processes characterizing public speaking anxiety, e.g. self-focused attention, on the other hand. The exercises will be conducted in smaller groups. After treatment, participants receive a worksheet that addresses basic contentual information concerning the treatment without a specific attempt to highlight the discrepancy between anticipated and actual outcomes. For example, participants will be asked how they would explain public speaking anxiety and exposure therapy to a friend and what advantages they see in conducting treatments like this in groups. The intervention is conducted in an online group format via videoconference with a duration of approximately 5 hours.
223978162|NCT03993457|DRUG|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
223978163|NCT03993457|DRUG|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
223978164|NCT03613636|DIAGNOSTIC_TEST|Enzyme-linked immunospot (ELISpot) assay [Blood]|The ASC ELISpot will be developed based on the improved methods recently described \[Nat Protoc 2013;8:1073-87\]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described \[Nat Protoc 2009;4:461-9\].
223978165|NCT01117129|DRUG|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
223978166|NCT01117129|DRUG|placebo|i.v. infusion on day 1 and 15
223978167|NCT01117129|DRUG|methotrexate|10-25 mg weekly
223978168|NCT01117129|DRUG|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
223978169|NCT00037115|DRUG|interferon beta 1a|
223978170|NCT00037115|DRUG|methotrexate|
223978171|NCT00037115|DRUG|methylprednisolone|
224117901|NCT04470492|COMBINATION_PRODUCT|Doctormate®+Medical Management|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
223726403|NCT05639426|BEHAVIORAL|Culturally Responsive Practices (CRP)|The CRP component of the intervention targets pedagogy, curriculum, and potential teacher biases and discriminatory behavior. This component will consist of two intensive 4-hour workshops delivered by Morton and Billingsley in each school's first intervention year as well as one-hour annual boosters (Backpacks for Success and Culturally Relevant Pedagogy). All teachers and school administrators will participate in the workshops. The purpose of Backpacks for Success is to increase participants' awareness of structural racism, empathy for students, and motivation to change, while identifying equity targets and strategies to reach those targets. Culturally Relevant Pedagogy comprises classroom based strategies to promote equity, including use of culturally responsive curriculum, language, attitudes, and actions, with the goal of reducing interpersonal and cultural racism. Ongoing group coaching sessions will provide a space for peer support and learning around increasing CRP.
224117902|NCT04470492|DRUG|Medical Management|Patients will be treated with conventional medication for 3 months.
224117903|NCT01368731|PROCEDURE|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
224117904|NCT01790438|DRUG|LY2605541|
224117905|NCT01790438|DRUG|Human Insulin NPH|
224117906|NCT01790438|DRUG|Oral Antihyperglycemic Medications (OAM)|
224117907|NCT00962065|DRUG|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
224117908|NCT00962065|DRUG|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
224117909|NCT00962065|DRUG|Placebo|Matching placebo dosing with daily oral intake for 28 days
224117910|NCT05137522|DRUG|Chidamide combines with VP-16 and methylprednisolone|Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21
223978172|NCT04240028|OTHER|Data Collection|The NuAge study has been designed to investigate nutrition as a determinant of successful aging in older men and women in Quebec. This study is based on a population-based observational cohort design that initially recruited healthy community-dwellers with age ranged from 67 to 82 years (51.8% women) between January 2004 and April 2005. All participants lived in the areas of Montreal, Laval, and Sherbrooke in the Province of Quebec, Canada. After recruitment, they have been followed for 3 years with one clinical follow-up assessment each year (i.e.; 4 data collection time). A previous analysis performed on the NuAge study database has shown a significant decline of physical and cognitive performances with time (respectively an average of 10% and 2%), participants with lower physical performance showing lower cognitive performance.
223726404|NCT05639426|BEHAVIORAL|Culturally-Responsive Schoolwide Positive Behavior Interventions and Supports (C-SWPBS)|We will implement SWPBS according to the equity-focused framework established by the Center on PBIS, with an increased emphasis on community integration. SWPBS involves creating a school team of 6-10 people, including at least one administrator, teachers, and staff members. We will include at least three community stakeholders on each C-SWPBS team to integrate the culture of the community, reducing institutional and cultural racism. Community stakeholders may be parents or other invested members of the local community not employed by the school district. The school climate specialists serve on the C-SWPBS team and provide consultation for the management of violence incidents and mental health concerns.
223726405|NCT02496611|DRUG|Weight loss with pharmacotherapy|Participants randomized to the drug intervention group will receive Exenatide extended-release.
223978173|NCT04640818|DRUG|Cladribine Oral Tablet|Treatment according to the label and medical prescription
223978174|NCT04640818|DRUG|Rituximab|Treatment according to the label and medical prescription
223978175|NCT04640818|DRUG|Ocrelizumab|Treatment according to the label and medical prescription
223978176|NCT04410809|BIOLOGICAL|TA-46|Decoy protein of the fibroblast growth factor receptor 3, 50 mg/mL (Parts A, B and C) and 120 mg/mL (Part C and Part D), sc solution for injection/infusion
223978177|NCT04410809|OTHER|Placebo|The same composition as the active medication but without the active substance TA-46
223978178|NCT02580175|PROCEDURE|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
223978179|NCT02580175|PROCEDURE|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
223978180|NCT04330378|OTHER|Hospital-at-home|As per experimental arm
223978181|NCT04330378|OTHER|Usual in-hospital care|As per control arm
223978182|NCT02378636|DEVICE|600S|Monofocal Aspheric Intraocular Lens (IOL)
223978183|NCT01036165|DEVICE|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
224117911|NCT02025972|PROCEDURE|Allogeneic umbilical cord blood therapy|
224117912|NCT03762525|RADIATION|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
223978184|NCT00048776|DRUG|Pletal|
223978185|NCT01840449|DRUG|Somatuline Autogel® 60, 90 or 120 mg|
223978186|NCT04423172|DEVICE|the new tissue containment system|Using the new tissue containment system during Laparoscopic hysterectomy. The divice is a soft specimen bag in which the uterus tissue is sealed and quickly morcellation and removed through vagina. The divice is named the new tissue containment system.
223978187|NCT04434118|DRUG|Traditional antirheumatic drugs|Hydroxychloroqine, Methotrexate, Glucocorticoids, Leflunomide, and Sulphasalazine
223978188|NCT01276613|DRUG|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
223978189|NCT01276613|DRUG|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
223978190|NCT03468179|DIETARY_SUPPLEMENT|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
223978191|NCT03701633|DIAGNOSTIC_TEST|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
223978192|NCT04485299|DRUG|Bifluorid 10 ,VOCO|NaF and CaF 10 %
223978193|NCT04485299|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
223978194|NCT06486675|OTHER|education|breastfeeding consultant training
223978195|NCT02958241|OTHER|MRI|Supine and weight bearing MRI
223978196|NCT05423431|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
223978197|NCT04592497|PROCEDURE|AF ablation|Prospective, single-center, non-randomized, open label, two arm study. After informed consent, 60 consecutive subjects who are scheduled to undergo AF ablation will be enrolled in the study in two equally sized groups of 30 subjects each. One group will undergo the procedure with assistance THERMOCOOL SMARTTOUCH SF-5D QDOT system and the other with the standard Thermocool Smartouch SF system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Data will be anonymized by removing patient protected health information, only initials will be used.
223978198|NCT03293836|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
223978199|NCT03293836|PROCEDURE|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
223978200|NCT03543605|BEHAVIORAL|PROA Experimental|PROA Control plus clinical advice
223978201|NCT03543605|OTHER|PROA Control|PROA Control
224117913|NCT03275883|PROCEDURE|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
224293657|NCT07211633|BIOLOGICAL|Ublituximab|Administered as an SC injection.
223978202|NCT01339624|DRUG|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
223978203|NCT01339624|DRUG|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
224117914|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY DORSAL APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . LISTER TUBERCULA WITH 3 CM PROXIMAL AND 3 CM DISTAL IN INCISION MADE UNDER THE SKIN. 2,3 EXTENSOR COMPARTMENTS RADIAL 4. THE EXTENSON COMPARTMENT IS EARTHED TO ULNAR A AND THE WRIST JOINT CAPSULE IS REACHED. THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision ON DISTAL UNDER RADIUS metaphyseal area of 2CM. 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
223726406|NCT02496611|DRUG|Weight loss without pharmacotherapy|Participants randomized to the placebo group will receive a placebo.
223726407|NCT04226001|OTHER|Quality of life questionnaire|Quality of life questionnaire
223726408|NCT00524784|BIOLOGICAL|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
223978204|NCT02470923|DRUG|Nicotine replacement therapy|
223978205|NCT02470923|BEHAVIORAL|Intensive counseling|
223978206|NCT02470923|BEHAVIORAL|Medical advice|
223978207|NCT04456647|OTHER|Parenteral nutrition|Parenteral nutrition treatment in palliative care
223978208|NCT03082898|DEVICE|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
223978209|NCT03752242|DRUG|BMX-010 0.3%|Safety and efficacy of BMX-010 in topical treatment of acne.
223978210|NCT01387815|BIOLOGICAL|Adalimumab|Adalimumab administered by subcutaneous injection.
224117915|NCT04892862|PROCEDURE|SCAHOİD GRAPHONAGE WITH AUTOGRAPH FROM DİSTAL RADİUS BY VOLAR APPROACH|ON GENERAL OR LOCAL ANESTESİA PATİENT N SUPİNE POSTİON EFFECTED WRİST ON ARM TABLE . İNCİSİON STARTS 2 CM RADİAL TO SCAPHOİD TUBERCULE EXTENTS ITS 3 CM PROXİMAL . AFTER PASİNG SUBCUTANEOUS TİSSUE , FCR AND RADİAL ARTERY ARE İDENTİFİED AND DİVİDED SEPERATLY THEN THE CAPSULE IS OPENED AND THE SCAPHOLID PROXIMAL AND MIDDLE POLE IS VIEWED. THE PERSODOARTHOSIS FIELD IS REGENERATED WITH THE TURRET AND TURR ENGINE. Following the same incision WİTH PASSİNG PRONATOR QUADRATUS MUSCLE , ON DISTAL UNDER 2 CENTİMETER OF RADIUS metaphyseal area . 2X2 centimeter WINDOW opened to get spongios bone GREFt, greft added in to field of pseudoarthrosis.After scaphoid HEIGHT AND anatomy recovered it has fixated one headless mini acuttrack screw under fluoroscopy guidance .skin and subcutaneous tissue closed with non absorbabl sutures.
224117916|NCT03119038|DRUG|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
224117917|NCT03119038|DRUG|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
224117918|NCT03119038|DRUG|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
224117919|NCT03119038|DRUG|Ketorolac|Intraoperative periarticular injection of 30 mg
224117920|NCT03119038|DRUG|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
223726409|NCT02551978|OTHER|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
223978211|NCT05803148|PROCEDURE|Cardioneuroablation|The left atrium model was established under the guidance of three-dimensional mapping. Atrial septum puncture、left atrium mapping and right atrium mapping will be performed according to standard EP lab protocol. The location of GPs will be detected with HAFE potential (duration ≥ 50ms， deflections ≥ 4 times， amplitude ≥ 0.7mV) and high frequency stimulation (HFS; 30 Hz, 20 mV, pulse width 2ms) through positive vasovagal response (transient ventricular asystole, atrioventricular block, or R-R interval increased by 30%) . Saline Irrigated-tip catheter with pressure monitoring will be applied for the procedure, and radiofrequency energy is limited to 40W and 43℃ for at least 30s at each site. The ablation endpoint for each GP is defined as the complete elimination of all targeted HAFE potential and elimination of positive vasovagal response. The endpoint of the procedure was that the heart rate reach 75% of the maximum heart rate in atropine test.
223978212|NCT05803148|DRUG|Midodrine Oral Tablet|Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
223978213|NCT02389322|BIOLOGICAL|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
223978214|NCT02389322|BIOLOGICAL|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
223726410|NCT01767155|DRUG|AEZS-108 / zoptarelin doxorubicin|267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
224293658|NCT07212777|PROCEDURE|Medial Open Wedge Hight Tibial Osteotomy using patient-specific instrumentation|Medial Open Wedge Hight Tibial Osteotomy using 3D printed patient-specific instrumentation as a guide for the osteotomy
224293659|NCT07212777|PROCEDURE|Medial Open Wedge Hight Tibial Osteotomy using conventional surgery techniques|Conventional Medial Open Wedge Hight Tibial Osteotomy
223726411|NCT01767155|DRUG|doxorubicin|60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
223978215|NCT02389322|BIOLOGICAL|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
223978216|NCT02389322|BIOLOGICAL|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
223978217|NCT00913523|DEVICE|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
223978218|NCT00913523|DEVICE|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
223978219|NCT00483353|PROCEDURE|Intra-nasal allergen challenge with Phleum pratense.|
223978220|NCT00483353|PROCEDURE|Collection of nasal effluent using filter paper.|
223978221|NCT00483353|PROCEDURE|Measurement of nasal congestion using acoustic rhinometry.|
223978222|NCT06164808|DEVICE|HeartWatch|The HeartWatch is indicated for the extended diagnostic evaluation of patients with symptomatic and transient symptoms such as light-headedness, syncope, and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. It is an armband consisting of the main body of the device with an additional sensor located on the band. It is worn around the upper left arm to obtain heart electrical signals. The device is paired with the HelpWear application on a smartphone where the signals are stored and then will be uploaded to a secure network for analysis.
223978223|NCT01844726|DRUG|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
223978224|NCT01844726|DRUG|Placebo|Single injection of placebo (saline)
223978225|NCT00916305|OTHER|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
223978226|NCT00916305|OTHER|Unmodified audio video|An audio video with unaltered music
223978227|NCT05781165|OTHER|Augmented reality|Step-by-step 3D models displayed with augmented reality guiding the self-test procedures
223726412|NCT03928600|COMBINATION_PRODUCT|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
223726413|NCT03928600|DRUG|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
223726414|NCT03928600|DRUG|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
223726415|NCT02518750|DRUG|Dexamethasone|Given orally (PO).
223726416|NCT02518750|DRUG|Panobinostat|Given PO.
223726417|NCT02518750|DRUG|Liposomal vincristine|For intravenous (IV) use only.
223726418|NCT02518750|DRUG|Mitoxantrone|Given IV.
223726419|NCT02518750|DRUG|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
223726420|NCT02518750|DRUG|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
223978228|NCT01688817|OTHER|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
223978229|NCT01688817|OTHER|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
223978230|NCT02717741|DRUG|tafetinib|
224117921|NCT00399269|DRUG|Recombinant Human Erythropoietin alpha|
224117922|NCT02090114|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
223726421|NCT02518750|DRUG|Intrathecal Triples|Given IT as ITMHA.
223726422|NCT02518750|DRUG|High-dose methotrexate|Given intrathecally (IT) or IV.
223726423|NCT02518750|DRUG|6-Mercaptopurine|Given PO at consistent time each day.
223726424|NCT02518750|DRUG|High-dose cytarabine|Given IT or IV.
223726425|NCT02518750|DRUG|Nelarabine|Given IV
223978231|NCT04264546|BIOLOGICAL|sIPV|The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
223726426|NCT02518750|DRUG|Cyclophosphamide|Given IV.
223726427|NCT02518750|DRUG|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
223726428|NCT02518750|DRUG|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
223726429|NCT02747589|PROCEDURE|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
223726430|NCT01365910|DRUG|linifanib|Given PO
223726431|NCT01401270|BEHAVIORAL|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
223726432|NCT00371137|DRUG|Xyrem®|two doses
223726433|NCT00371137|DRUG|Placebo|Oral Solution
223978232|NCT00777998|PROCEDURE|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"\*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> 2 months later: Melphalan plus allogeneic PBSCT~* -\> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~* -\> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10\^6 (MRD) or 5 x 10\^5 (MUD) CD3+ cells per kg BW)~* -\> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Further DLI depending on MRD-measurement"
223978233|NCT00777998|PROCEDURE|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"\*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~* -\> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
223726434|NCT05950932|DIETARY_SUPPLEMENT|Melissa phytosome|Melissa phytosome® is composed of dry extract of Berberis aristata root (550mg/cpr), complexed with phospholipids (soy lecithin), Pisum sativa proteins, and proanthocyanidin oligomers from Vitis vinifera. 2 tablets of 200 mg Melissa phytosome will be provided to participants, to be taken 30 minutes before bedtime for 14 days.
223978234|NCT00583271|DRUG|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
223978235|NCT00583271|DRUG|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
223978236|NCT00190099|DEVICE|Dexamethasone-Eluting Stent|
223978237|NCT05574751|OTHER|Titanium tacker|Mesh fixation with Titanium tacker
223726435|NCT05950932|OTHER|Placebo|2 tablets with an equivalent form, color, flavor, and coating as the experimental product, to take 30 minutes before bedtime.
223726436|NCT00691821|OTHER|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
223978238|NCT05574751|OTHER|Polypropylene 0|Mesh was sutured and fixed with polypropylene 0
223978239|NCT02520700|DEVICE|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
223978240|NCT02325362|DRUG|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
223978241|NCT02325362|DRUG|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
223978242|NCT00000677|DRUG|SCH 39304|
223978243|NCT03729427|PROCEDURE|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
223978244|NCT05098015|BEHAVIORAL|Game Changers|8-session group intervention that uses didactic instruction, role plays and experience sharing to empower participants to engage in HIV prevention advocacy.
223978245|NCT04183023|GENETIC|Collection of a salivary sample|"Volunteers who agreed to participate will have to collect their saliva with the self-collection device. They will then send back their saliva sample and a dated and signed copy of the informed consent form in the pre-paid return envelope.~All DNA of the saliva samples will be automatically extracted, then DNA samples will be genotyped and 4,000 of them will be sequenced.~The genotyping will consist of measurement of general genetic variation, including the Single Nucleotide Polymorphisms. The SNP genotyping will be carried out using Illumina high density chips, in CNRGH production platform.~A subset of 4,000 individuals will be selected to provide a homogeneous geographic coverage and to avoid inclusion of related individuals who will share large genomic regions. Sequencing will be performed in order to reach a mean coverage of 30X for each sample and a minimum of 25X mean coverage.~Finally, a bioinformatics analysis will be performed on sequencing data."
223978246|NCT03565302|DRUG|Formoterol|Subjects are treated with daily inhalation of formoterol
223978247|NCT03565302|DRUG|Terbutaline|Subjects are treated with daily inhalation of terbutaline
223978248|NCT03565302|OTHER|Placebo|Subjects are treated with placebo
223978249|NCT00212277|DRUG|Norethindrone,Ethinyl Estradiol|
223726437|NCT00691821|DEVICE|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
223726438|NCT00480298|DRUG|Administration of oral methylprednisolone|
223726439|NCT05466877|DRUG|MG-K10|MG-K10 Humanized Monoclonal Antibody Injection
223726440|NCT05466877|DRUG|Placebo|MG-K10 Humanized Monoclonal Antibody Injection
223726441|NCT05954806|DRUG|Antivenom Snakes|No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
223726442|NCT02015871|DRUG|Degarelix|
224117923|NCT02090114|DRUG|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
224117924|NCT02090114|DRUG|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
224117925|NCT02090114|DRUG|Enzalutamide|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
224117926|NCT02782455|DRUG|Flavonoids|Daflon is administered
223726443|NCT01780818|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
223978250|NCT06477991|DRUG|Tireilizumab（PD-1 inhibitor）|"Neoadjuvant immunotherapy phase :~1. Pharmaceuticals: Tireilizumab: 200mg, intravenous infusion, Q3W, at least 4 cycles, the number of specific neoadjuvant immunotherapy cycles was determined according to the results of MRD dynamic monitoring.~2. MRD dynamic monitoring time node: dynamic monitoring at the initial diagnosis and after the fourth cycle of neoadjuvant immunotherapy. Blood monitoring points were 1-2 weeks after immunotherapy. If the two consecutive MRDs were negative, the watch and wait strategy was adopted. If the MRD was still positive after 8 cycles of neoadjuvant immunotherapy, surgical treatment was performed."
223978251|NCT04658550|OTHER|Remote Behaviour Modification Program|The standard of care behaviour modification program for weight loss will be offered virtually due to the COVID-19 pandemic (prospective).
223978252|NCT04658550|OTHER|In Person Behaviour Modification Program|The standard of care behaviour modification program for weight loss was offered in person prior to the COVID-19 pandemic (retrospective).
223726444|NCT01780818|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
223726445|NCT01780818|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
223978253|NCT02753764|DRUG|AZD7624|
223978254|NCT02753764|DRUG|prednisone|oral prednisone 20 mg bid for one week
223726446|NCT00536198|DRUG|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
223726447|NCT00536198|DRUG|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
224117927|NCT02782455|DRUG|CDobi|Calcium dobesylate is administered
223726448|NCT02013791|DRUG|Vehicle|Vehicle of cyclosporine administered as per protocol
223978255|NCT02753764|DRUG|Placebo|
223978256|NCT02968654|PROCEDURE|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
223978257|NCT02968654|PROCEDURE|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is \< 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
223978258|NCT03496337|OTHER|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
223978259|NCT02181998|DRUG|Full dose tenecteplase|
223978260|NCT02181998|DRUG|Unfractioned heparin|
223978261|NCT02181998|DRUG|Enoxaparin|
223978262|NCT00000578|DRUG|theophylline|
223978263|NCT00000578|DRUG|beclomethasone|
223978264|NCT04550286|BEHAVIORAL|Smartphone Use Reduction in Academic Context|"Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation). This refers to the behavior change techniques (BCT 4.1, instructions on how to perform the behavior; Michie et al.; 2013).~In the next step, participants in the intervention group complete planning sheets. Each student has to develop up to three action plans (BCT 1.4) including when, where, and for how long the smartphone will be put away during the daily exam preparation period (cf. Radtke et al., 2018). In addition, each participant should try to anticipate possible barriers to engaging in the planned behavior and plan what he or she could do to overcome these possible barriers (i.e., coping planning; BCT 1.2; Michie et al., 2013)."
224117928|NCT03161639|OTHER|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
224122739|NCT07007195|DEVICE|Instructed Use followed by Ad Libitum Use of the Inspire Device|Participants in this condition will use the novel olfactory stimulation delivery system (Inspire), to smell a specific order designed to assist with smoking cessation for 7 days. Participants will be instructed to use the Inspire device only when participants report a cigarette craving about 0 at each of the surveys prompted from the smartphone-based smoking cessation app, Insight™. On day 8, participants will receive a notification on the smartphone-based smoking cessation app, Insight™, to switch to the Ad Libitum condition. Participants will then control how often they use Inspire and will be instructed to record every urge to smoke and report times when they think they might smoke in the smartphone-based smoking cessation app, Insight™.
223978265|NCT04550286|BEHAVIORAL|Control|Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
223543698|NCT04741932|OTHER|Dementia Care Management (DCM)|"A computerized Information and Care Management System (IMS) will identify unmet nursing, medical, psychosocial and social needs of the PwD and its informal caregiver. Based on this data, the IMS generates suggestions for interventions: The DCM in cooperation with the general practitioner (GP) develops an individual treatment and care plan that is tailored to the needs of the PwD and its caregiver. The DCM will initiate the implementation of respective actions and monitor the status of implementation. Therefore, the DCMs are supposed to take on activities that were previously usually performed by doctors (redistribution of tasks between physicians and qualified nurses in primary care)."
223543699|NCT05233514|OTHER|Aerobic exercise in addition to Metformin treatment|The aerobic exercises were walking on the treadmill for 30 minutes at a 0% slope, including three phases: the warming-up phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of Maximum Heart Rate, MHR), the actual phase, which consisted of walking on the treadmill for 20 min at moderate intensity (60 -70% of MHR) and the cooling phase, which consisted of walking on the treadmill for five minutes at low intensity (30% of MHR). The MHR was calculated according to the equation (210- age in years). Both the AEM and M groups received metformin 1,500 mg daily for a further 12 weeks.
223543700|NCT00059631|DRUG|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
223726449|NCT02013791|OTHER|Sham|Sham administered to non-study eye as per protocol on Day 1
223978266|NCT01681199|DRUG|Fluvastatin extended release tablet|
223978267|NCT05154240|DRUG|INS018_055|INS018\_055 is a small molecule compound. INS018\_055 has good solubility in water and was chemically and physically stable at different temperatures.
223978268|NCT05154240|DRUG|Placebo|Placebo
223978269|NCT01743521|DRUG|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
223978270|NCT04510610|DRUG|Camrelizumab and Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function. Camrelizumab is a humanized anti-PD-1 monoclonal antibody.
223978271|NCT00382798|DRUG|RO5024048|
223978272|NCT03510806|DIETARY_SUPPLEMENT|Supplement|dietary supplement contain protein from milk and fruit extract
223978273|NCT03510806|OTHER|Placebo|color, taste, and calorie-matched placebo
223978274|NCT03060213|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
223978275|NCT03016949|BIOLOGICAL|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
223978276|NCT03016949|BIOLOGICAL|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
223978277|NCT00664183|DRUG|Vitreosolve|Intravitreal injection
223978278|NCT04761692|BEHAVIORAL|Full VEPMP Intervention|Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
223978279|NCT04761692|BEHAVIORAL|Partial VEPMP Intervention|Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)
223978280|NCT04761692|BEHAVIORAL|Delayed VEPMP Intervention|Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
223978281|NCT04191148|DRUG|LBP-EC01|crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
223978282|NCT04191148|DRUG|Placebo|Lactated Ringers Solution for Injection dosed BID by intraurethral administration
223978283|NCT01637285|BIOLOGICAL|PF-04856883|Dose A
223978284|NCT01637285|BIOLOGICAL|PF-04856883|Dose B
223978285|NCT01637285|BIOLOGICAL|PF-04856883|Dose C
223978286|NCT01637285|BIOLOGICAL|PF-04856883|Dose D
224117929|NCT01290172|DRUG|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
223978287|NCT05410119|BEHAVIORAL|8-week Resilience Group Psychotherapy|Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
223978288|NCT05410119|OTHER|Usual care|Usual care means treating as usual, such as regular home visit.
223543701|NCT00059631|DRUG|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
223543702|NCT01176760|DRUG|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
223543703|NCT01176760|OTHER|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
223543704|NCT02837718|PROCEDURE|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
223726450|NCT02013791|DRUG|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
223978289|NCT03696888|BEHAVIORAL|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
223978290|NCT03696888|BEHAVIORAL|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
223978291|NCT04156347|DRUG|Episcleral Topotecan|Transscleral Topotecan
223978292|NCT01148498|DRUG|solanezumab|400mg administered once intravenously
223978293|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
223978294|NCT00755898|DRUG|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
223978295|NCT02282306|BEHAVIORAL|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
223978296|NCT01274559|DRUG|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
223978297|NCT01274559|DRUG|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
223978298|NCT03757078|DRUG|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
224117930|NCT01290172|DRUG|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) \>= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) \>= 90 ml/min \* 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
224117931|NCT01152008|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
224117932|NCT01241851|BEHAVIORAL|Aerobic exercise|
224117933|NCT01241851|BEHAVIORAL|Resistance exercise|
224117934|NCT03750032|PROCEDURE|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
224117935|NCT03750032|PROCEDURE|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
224117936|NCT03750032|PROCEDURE|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
224117937|NCT06239909|OTHER|24-h pad-weight test|The patients will be asked to perform the 24-h pad-weight test
224117938|NCT06239909|OTHER|Patient Global Impression - Improvement Questionnaire|The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
224117939|NCT04688346|DRUG|HemeRX epinephrine pellets|Racemic Epinephrine Pellet
224117940|NCT01589068|DRUG|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
223978299|NCT03757078|DRUG|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
223978300|NCT01013506|DRUG|IGF-1R inhibitor OSI-906|Given orally
223978301|NCT01013506|DRUG|erlotinib hydrochloride|Given orally
223978302|NCT01013506|DRUG|goserelin|Given subcutaneously
223726451|NCT03798483|OTHER|Individualised exercise|The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
223978303|NCT01013506|DRUG|letrozole|Given orally
223726452|NCT02923960|OTHER|Standard ONS|One serving (237 ml) standard oral nutritional beverage
223978304|NCT00069381|BEHAVIORAL|Psychotherapy treatment|
223978305|NCT00678977|DRUG|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
223978306|NCT00678977|DRUG|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
223978307|NCT00678977|DRUG|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
223978308|NCT01339962|OTHER|Non-interventional|Non-interventional (retrospective chart reviews)
223978309|NCT01003145|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
223978310|NCT05416411|BEHAVIORAL|Inspiratory muscle training|Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
223978311|NCT03231969|DRUG|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
223978312|NCT03231969|DRUG|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
223978313|NCT03231969|DRUG|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
224117941|NCT01589068|DRUG|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
224117942|NCT04645472|DEVICE|CT-Ultrasound|For patients with kidney stones who are planning to undergo PCNL, perform a preoperative simulated CT-ultrasound fusion examination to further clarify the condition of the kidney stones and simulate and optimize the puncture route. Apply CT- Ultrasound fusion precise positioning to guide the intraoperative PCNL puncture process.
223726453|NCT02923960|OTHER|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
223726454|NCT02923960|OTHER|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
223726455|NCT00450684|DEVICE|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
223726456|NCT00450684|DEVICE|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
223726457|NCT01678430|DRUG|Ofatumumab|
224117943|NCT00157092|DRUG|Aerosolized, Recombinant Alpha 1-Antitrypsin|
223726458|NCT01678430|DRUG|Chlorambucil|
223726459|NCT01678430|DRUG|Bendamustine|
223978314|NCT03231969|DRUG|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
223978315|NCT00498615|DRUG|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
223978316|NCT00220909|DRUG|Lansoprazole|
223978317|NCT01401114|DRUG|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
223978318|NCT03774212|DEVICE|Active noise cancelling headphones|The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
223978319|NCT03700372|DEVICE|IOWA Approach Cardiac Ablation System|Epicardial ablation using the IOWA Approach Cardiac Ablation System
223978320|NCT00030537|DRUG|erlotinib hydrochloride|
223978321|NCT03409731|DEVICE|ABSORB GT1 BVS|Patients receiving Absorb GT1 BVS
223978322|NCT04171947|DEVICE|Matuzalem ovule|vaginal ovule with 2 mg tea extract
223978323|NCT04171947|DEVICE|Vehicle ovule|polyethylene glycol vaginal ovule
223978324|NCT00892944|DRUG|AZD2516|Fractionated single oral dose
223978325|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
223978326|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
224117944|NCT00541892|OTHER|Medium with no human serum albumine added|See above
224117945|NCT00541892|OTHER|Conventional medium|See above
224117946|NCT06291181|DIAGNOSTIC_TEST|antibiotic sensitivity test|"Disc diffusion method using modified Kirby-Bauer technique on Muller Hinton agar (MHA) will be carried out for antimicrobial susceptibility of S. aureus isolates. The following antibiotics will be tested: cefoxitin (30 µg ), Tetracyclin 30 µg (TE), Chloramphenicol 30 µg (C), Gentamycin 10µg (CN), Erythromycin 15µg(E),Clindamycin 2 µg (DA), Ciprofloxacin 5 µg (CIP), Trimethoprim/sulphamethoxazole 1.25/23.75 µg (SXT), Rifampin 5µg (RA), Linezolide 30µg (LZD); cefoxitin disc (FOX 30 g)~zone diameters interpretation will be done according to Clinical and Laboratory Standard Institute (CLSI 2018),"
223978327|NCT02452099|PROCEDURE|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
223978328|NCT04933799|DRUG|PF-06650833|"PF-06650833 is an investigational, highly potent and selective, reversible inhibitor of IRAK4. IRAK4 is a serine, threonine kinase that is a key intracellular signaling node downstream of the myddosome-associated Toll-Like Receptors (TLR) 1, 2, 4, 5, 6, 7, 8, 9 and 10, and the interleukin (IL)-1 family receptors (IL-1R, IL-18R and IL-33R) that mediate much of the innate immune signaling.~As an inhibitor of TLR signaling, PF-06650833 targets a different part of the immune system from the Janus kinase (JAK) inhibitors. Given the partial redundancy of innate immune signaling through IRAK4-independent TLR pathways and the lack of direct suppression of T- and B-cell signaling, PF-06650833 is unlikely to lead to exaggerated immunosuppression."
223978329|NCT04933799|DRUG|Matching Placebo|Placebo will match the study drug in dose, formulation, route and frequency.
223978330|NCT00784745|DRUG|Dexamethasone|2mg morning and night for 5 days.
223978331|NCT05863013|OTHER|ADL-Glittre Test|They will receive standard care described plus perioperative pulmonary rehabilitation, with 20 preoperative sessions and 60 postoperative sessions. Preoperative sessions will be held 2X/week, in addition to home sessions 3X/week. Each outpatient session will last 2 hours and will consist of therapeutic education, aerobic exercises, resistance training of lower limbs, upper limbs and abdominal wall and respiratory muscle training (RMT), which will include breathing pattern, positive expiratory pressure and training of inspiratory and respiratory muscles. home will last 1h, unsupervised and personalized MRT plus 30 min of aerobic walking at 60-80% of maximum HR intensity. Participants will receive a portable pedometer and HR monitor. Postoperative rehabilitation will be offered only to the IG, from 1 month after surgery, with 60 sessions divided into 24 outpatient sessions performed 2X/week and 36 home sessions 3X/week. The postoperative program will last 12 weeks.
223978332|NCT05188313|DRUG|Trastuzumab|Intravenous administration of study drug
223978333|NCT05188313|DRUG|Pertuzumab|Intravenous administration of study drug
223978334|NCT05188313|DRUG|Paclitaxel|Intravenous administration of study drug
223978335|NCT05188313|DRUG|Carboplatin|Intravenous administration of study drug
223978336|NCT02568878|DRUG|Creatine monohydrate|
223978337|NCT02833623|BEHAVIORAL|Short-message-based Re-education|
223978338|NCT02833623|BEHAVIORAL|conventional education|
223978339|NCT04016805|DRUG|Ublituximab|"* recombinant chimeric anti-CD20 monoclonal antibody~* administered as an IV infusion"
224117947|NCT04739657|DEVICE|Insight Lifetech IVUS System|The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
223543705|NCT02817178|OTHER|Additional biological samples|blood and tumor tissue samples
223543706|NCT00253916|BEHAVIORAL|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
223543707|NCT00253916|BEHAVIORAL|Resistance Exercise Program|Resistance Exercise Program
223543708|NCT05361265|OTHER|fetal movement counting|pregnant women were trained about fetal movements and fetal movement counting was taught. Pregnant women were asked to perform ten fetal movements by counting once a day. In the application of the study, it was ensured that the pregnant women in the experimental group performed fetal movement counting for at least four to six weeks. In this context, pregnant women were called every week to monitor and to motivate them to continue the counting.
223543709|NCT03613155|OTHER|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
223978340|NCT04016805|DRUG|Umbralisib|"* Phosphoinositide-3-kinase (PI3K) delta inhibitor~* Tablet form, to taken orally on a daily basis"
223978341|NCT04016805|DRUG|Ibrutinib|"* Bruton Tyrosine Kinase (BTK) inhibitor~* Tablet form, to taken orally on a daily basis"
223978342|NCT04016805|DRUG|Venetoclax|"* BCL-2 inhibitor~* Tablet form, to be taken orally"
223978343|NCT04016805|DRUG|Acalabrutinib Oral Capsule|Kinase inhibitor, capsule form, to be taken orally
224117948|NCT04739657|DEVICE|Boston Scientific IVUS System|The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.
224117949|NCT04243135|DEVICE|ESWT|Extracorporeal shock wave therapy
224117950|NCT05465603|DEVICE|ETDNO (Elastic Tension digital neoprene orthosis)|A bespoke orthosis created from neoprene.
224117951|NCT00059215|DRUG|Prasugrel (CS-747)|Administered orally
224117952|NCT00059215|DRUG|Clopidogrel|Administered orally
223543710|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 1|\[¹⁴C\] BI 685509 formulation 1
223978344|NCT03240497|BEHAVIORAL|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\]."
223978345|NCT03240497|BEHAVIORAL|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
224117953|NCT02645656|DRUG|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
224117954|NCT04439838|DRUG|BI 1595043|BI 1595043
224117955|NCT04439838|DRUG|Placebo|Placebo
224117956|NCT03169829|DIETARY_SUPPLEMENT|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~* Animal only Protein~* Refined only Grains~* Limit Dairy~* Low-k only"
224117957|NCT03169829|DIETARY_SUPPLEMENT|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~* Limit Dairy, provide Soymilk Dairy~* Low-k only Fruit and Vegetables"
224117958|NCT03169829|DIETARY_SUPPLEMENT|Standard|"•¼ Animal, ¾ Plant Proteins~* Refined, ½ Whole Grain~  •Limit Dairy, provide Soymilk Dairy~* Low-k, Fruit and Vegetables~* High-k Fruit and Vegetables"
224117959|NCT03898336|OTHER|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
223726460|NCT04602455|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a week webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
224117960|NCT03898336|OTHER|placebo|daily intake of capsules
223543711|NCT05515328|DRUG|[¹⁴C] BI 685509 formulation 2|\[¹⁴C\] BI 685509 formulation 2
223726461|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, three weeks for one cycyles;Carboplatin 500mg/m2 d1,Pemetrexed Disodium AUV＝5 d1,Q3W;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
224117961|NCT02668107|OTHER|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
224117962|NCT03174717|BEHAVIORAL|Music performance|residents of LTC will learn and perform songs with musicians from the community
223543712|NCT05515328|DRUG|BI 685509 formulation 3|BI 685509 formulation 3
223543713|NCT04967066|DIAGNOSTIC_TEST|Serum Levels of Adipocytokines|Serum leptin and adiponectin: venous blood samples (3 ml) will be obtained from children with FS (within 3 hours of seizures) as well as the two control groups. The serum will be obtained by centrifugation at 3,500 rpm for 5 min at 4 ℃. The serum will be immediately separated and stored at -70 ℃. Serum leptin and adiponectin will be assessed through enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions.
223543714|NCT03815747|DEVICE|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
223726462|NCT06208033|DRUG|SMET12|"1. platinum-containing two-drug chemotherapy：Carboplatin plus Pemetrexed Disodium, administrated for 2-4 cycles, 3 weeks for one cycle.cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15;~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
224117963|NCT04494633|OTHER|Clinical Encounters Medical School 3D Simulation|A 3D simulation related to coping with the stresses of medical school and burnout.
223726463|NCT06208033|DRUG|SMET12|"1. chemotherapy：Docetaxel 60-75 mg/m2 d1, administrated for 2-4 cycles, 3 weeks for one cycle.~2. Toripalimab, IV, 3mg/kg，Q2W；~3. SMET12: IV，60μg，Q2W，injected the day after toripalimab ；"
223726464|NCT03985514|DRUG|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
223543715|NCT00959426|DRUG|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
223543716|NCT00959426|DRUG|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
223726465|NCT03985514|OTHER|Active observation|In-hospital observation without antibiotics
223978346|NCT00545571|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
224293660|NCT07212842|DRUG|Methylene Blue|"This protocol was designed to perform intraoperative blood lavage with methylene blue at the end of surgery, with a duration of 20 minutes. A low dose of 1 mg/kg of body weight was administered. The objective was not to elicit hemodynamic effects, which require higher doses, but rather to exploit the anti-inflammatory and antioxidant properties of methylene blue.~Methylene blue was diluted in 1000 mL of 0.9% saline. An equivalent volume of fluid was removed simultaneously by zero-balance ultrafiltration, maintaining a fluid-equilibrium state throughout the 20-minute procedure. For this purpose, a dedicated circuit was developed to enable concurrent blood lavage and ultrafiltration. Blood was withdrawn through a dedicated port integrated into the SORIN oxygenator and directed by a centrifugal pump to a small reservoir containing the methylene blue solution. From this reservoir, the blood passed through a hemoc"
223543717|NCT00913510|DEVICE|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
223726466|NCT01784159|DRUG|Aspirin|Aspirin administration for 7 days
223726467|NCT03002766|PROCEDURE|Breast conservative surgery|
223726468|NCT03695120|OTHER|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
223726469|NCT03932110|DIAGNOSTIC_TEST|omentin, visfatin|diagnostic blood test
223726470|NCT01666782|BIOLOGICAL|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
223726471|NCT01666782|BIOLOGICAL|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
223726472|NCT02704871|OTHER|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
223726473|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
223726474|NCT02933047|PROCEDURE|Total laparoscopic hysterectomy|
223726475|NCT03971214|DRUG|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
223978347|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
224117964|NCT05764018|DIETARY_SUPPLEMENT|Caffeine|Negligible amount of maltodextrin in flavoured drink solution containing 6 mg/kg body mass caffeine provided 45 minutes before exercise
224117965|NCT05764018|OTHER|Hypoxia|Participants will be breathing from a hypoxic gas mixture (13% O2) for the duration of the exercise bout. This will simulate an altitude of approximately 3500 m.
224117966|NCT05764018|OTHER|Placebo|Negligible amount of maltodextrin in flavoured drink solution provided 45 minutes before exercise.
224117967|NCT05764018|OTHER|Normoxia|Participants will be breathing from ambient air (\~21% O2) for the duration of the exercise bout. This will provide no hypoxic stimulus as the laboratory is located relatively near sea level (295 m)
223978348|NCT00751205|DRUG|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
223978349|NCT03092245|DRUG|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
223978350|NCT03092245|DRUG|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
223978351|NCT01540903|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
223978352|NCT01540903|BIOLOGICAL|Saline|Saline
223978353|NCT05999019|PROCEDURE|robotic surgery|robotic surgery
223978354|NCT04255121|DRUG|2% adrenaline lidocaine associated with 4.2% sodium bicarbonate|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an alkalinization of adrenaline lidocaine solution
223978355|NCT04255121|DRUG|2% adrenaline lidocaine|conversion of epidural analgesia into epidural anesthesia during an emergency caesarean using an adrenaline lidocaine solution
223978356|NCT01491763|DRUG|Imatinib|600 mg p.o. from day 1 until consolidation
223978357|NCT03722693|DEVICE|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
223978358|NCT02765386|DEVICE|Hybrid fittings for cochlear implant recipients|
223978359|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
223978360|NCT04033770|OTHER|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
223978361|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Video Game Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during watching video game.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
224117968|NCT03196271|DIETARY_SUPPLEMENT|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
224117969|NCT06491628|BEHAVIORAL|Avoiding the risk factors|Exercise, Salt and lipid reduction in diet, smoking cessation
223978362|NCT05191836|BEHAVIORAL|Evaluation of the effectiveness of Audio Video Distraction in the management of anxious pediatric patients during dental treatment|"The child will be provided dental treatment during audio video distraction.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
223978363|NCT05191836|OTHER|Evaluation of the anxiety in pediatric patients during dental treatment without using any type of distraction aids|"The child will be provided dental treatment without using any type of distraction aids.The Behavior Rating Scale HOUPT will be measured four times: directly when the patient seated comfortably on the dental chair, after anesthesia, after pulpotomy, and when the treatment completed.~The child will be provided dental treatment during watching video game. All child patients will ask to choose a face that describe their status from one of the Simplified Wong Baker faces scale in the same four times."
224117970|NCT00414310|DRUG|Decitabine|20 mg/m\^2 IV over 1 hour daily for 5 days.
224117971|NCT00414310|DRUG|Valproic Acid|50 mg/kg orally daily for 7 days
224117972|NCT06467305|DEVICE|continuous theta-burst stimulation (cTBS)|Non-invasive brain stimulation, evoked potentials and fMRI will be used to identify brain regions involved in speech motor learning and retention.
224117973|NCT06467305|BEHAVIORAL|Adaptation|Auditory adaptation in speech
224117974|NCT06258525|RADIATION|Standard of care oxaliplatin-based chemotherapy|mFOLFOX6 or CAPOX
224117975|NCT06258525|DIETARY_SUPPLEMENT|S-adenosylmethionine (SAMe) supplement|(400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection
224117976|NCT06258525|PROCEDURE|Surgery|At 1-Month
224117977|NCT03862534|PROCEDURE|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
223978364|NCT05632718|OTHER|Exercise|Resistance and endurance supervised exercise-training. The training programme will last for 16 weeks. Training sessions will be held at Porto Faculty of Sports, 3 times per week with the duration of 1 hour.
223978365|NCT01684618|PROCEDURE|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
223978366|NCT02599493|DRUG|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
223978367|NCT04863638|BIOLOGICAL|3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 42
223978368|NCT04863638|BIOLOGICAL|3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 111
223978369|NCT04863638|BIOLOGICAL|3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated|the schedule of Day 0, 21, 171
223978370|NCT04863638|BIOLOGICAL|2 doses of vaccine|the schedule of Day 0, 21
223978371|NCT04578899|DEVICE|Transvertebral magnetic stimulation|Continuous theta-burst with a frequency of 5 Hz, lasting 20 minutes 3 times a week for 5 weeks, the total number of procedures is 15
223978372|NCT01800578|DEVICE|monitor for depth of hypnosis|"evaluation of depth of hypnosis~\--------------------------------------------------------------------------------"
223978373|NCT00177684|DRUG|Amphotericin B|
223978374|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
223978375|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
223978376|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
223978377|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
223978378|NCT01193218|DRUG|BI 10773|BI 10773 tablets low dose once a day
223978379|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
223978380|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
224117978|NCT03862534|PROCEDURE|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
224117979|NCT05687201|DIAGNOSTIC_TEST|Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)|Non-surgical patients were followed up by CT on days 1 and 5-7 after ICH, and by CT or MRI on day 5-7. Surgical patients were followed up by CT before surgery and then transferred to the operating room. The first postoperative follow-up CT scan was performed on the second day after surgery, and the second postoperative CT scan was performed on the third day after surgery. Some patients need a third or even a fourth CT follow-up after surgery. The CT scan can be repeated at any time if the patient has neurologic deterioration.
223978381|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
223978382|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-high dose once a day
223978383|NCT01193218|DRUG|BI 10773|BI 10773 tablets high dose once a day
223978384|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
223978385|NCT01193218|DRUG|Placebo (high dose)|Placebo tablets once a day
223978386|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
223978387|NCT01193218|DRUG|Placebo (low dose)|Placebo tablets once a day
223978388|NCT01193218|DRUG|BI 10773|BI 10773 tablets mid-low dose once a day
223978389|NCT01193218|DRUG|Placebo (mid dose)|Placebo tablets once a day
223978390|NCT00037895|PROCEDURE|Ambulation training|
223978391|NCT05088538|OTHER|Patient Education|After completing the necessary forms, it is planned to give the QR-coded education booklet prepared by the researcher to the patients and to inform the patients and their relatives about the use of QR codes. At that time, it is planned that the teaching will be carried out using various training methods such as lecture, question-answer, demonstration and practice. It is thought that the teaching will be divided into 3 parts: pre-operative, post-operative and discharge. According to the physical conditions of the clinic, it is planned to provide patient education in an suitable area for teaching as much as possible. Patients will be reminded that they can access the information whenever they want and as many times as they want by scanning the QR code from their phone.
223978392|NCT04071093|OTHER|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
223978393|NCT03168698|DRUG|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
223978394|NCT03168698|DRUG|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
223978395|NCT06104579|OTHER|Person-level linkage of both databases looking for concordance in the diagnosis of organ-space surgical site infection|Concordance between the two registers was analysed using Cohen´s Kappa.
223978396|NCT00238719|DRUG|Venlafaxine ER|
223978397|NCT00796393|DIETARY_SUPPLEMENT|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
223978398|NCT00796393|DIETARY_SUPPLEMENT|Starch of potato|1 pill per day for 12 weeks
223978399|NCT01013740|DRUG|Vinorelbine|Vinorelbine
224293661|NCT07212842|PROCEDURE|Conventional ultrafiltration|Conventional ultrafiltration (CUF). CUF during cardiopulmonary bypass (CPB) is performed to remove excess fluid and solutes from the patient's blood during cardiac surgery, thereby limiting fluid accumulation and attenuating pro-inflammatory effects. This technique increases hematocrit, improves cardiopulmonary function, and reduces the need for blood transfusions. Unlike modified ultrafiltration (MUF), which is performed after weaning from CPB, CUF is carried out simultaneously with CPB while the heart-lung machine remains in operation.
223978400|NCT01013740|DRUG|Lapatinib|Lapatinib
223978401|NCT01013740|DRUG|Capecitabine|Capecitabine
223978402|NCT03159078|DRUG|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
223978403|NCT02725398|DRUG|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
223978404|NCT02725398|DRUG|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
223978405|NCT02725398|DRUG|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
224117980|NCT04864535|DIAGNOSTIC_TEST|Recordings of cough sounds from adults|Smartphone recordings of the cough sounds of participants who enrol in the study and obtain a COVID-19 rt-qPCR result.
224117981|NCT00914199|PROCEDURE|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
224117982|NCT03955887|BIOLOGICAL|bronchoalveolar lavage fluid (BAL)|Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
224293662|NCT07212842|PROCEDURE|Zero-balance ultrafiltration|Zero-balance ultrafiltration (Z-BUF). Z-BUF is performed during cardiopulmonary bypass (CPB) to maintain fluid equilibrium by removing plasma water and solutes while simultaneously infusing an equal volume of replacement fluid, thereby achieving a net zero fluid balance. This technique has been shown to decrease urine output, reduce tissue edema and the inflammatory response, improve arterial oxygenation (PaO₂), and lower the need for postoperative blood transfusions.
223978406|NCT04773730|PROCEDURE|Posterior transversus abdominus plane block|Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
223978407|NCT04773730|PROCEDURE|Quadratus lumborum block type 2|Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side
223978408|NCT00338949|DRUG|Switch|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
223978409|NCT00338949|DRUG|Control|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
223978410|NCT03232034|DIETARY_SUPPLEMENT|Calcium Citrate|1000 mg calcium as calcium citrate
223978411|NCT03232034|DIETARY_SUPPLEMENT|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
223978412|NCT03232034|DIETARY_SUPPLEMENT|Whey Protein Hydrolysate|50 g whey protein hydrolysate
224117983|NCT03955887|BIOLOGICAL|Venous blood|Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
224117984|NCT03743662|RADIATION|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
224117985|NCT03743662|DRUG|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
223978413|NCT05168137|DRUG|Low-dose colchicine|prescribed colchicine 0.6 mg/day
223978414|NCT05168137|DRUG|Placebo|Placebo of colchicine
223978415|NCT03302442|OTHER|Non interventional study|Not applicable - Non interventional Study
223978416|NCT03811834|DRUG|Mobocertinib|Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
223978417|NCT02819219|DIETARY_SUPPLEMENT|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
224117986|NCT03743662|DRUG|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
223726476|NCT03657511|BEHAVIORAL|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
223726477|NCT01116583|DRUG|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
223726478|NCT01116583|DRUG|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
223978418|NCT02819219|OTHER|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
223978419|NCT03643757|PROCEDURE|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
224117987|NCT03743662|PROCEDURE|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
224117988|NCT05741944|OTHER|Care with the use of PERSARC|PERSARC is a personalized risk assessment tool which provides patients and STS professionals insight into the personalized risks and benefits of each treatment option based on patient's age, tumor size, tumor depth and histology. PERSARC will be used in multidisciplinary tumour boards to guide treatment advice and in consultation in which the oncological/orthopaedic surgeon informs the patient about his/her diagnoses and discusses the benefits and harms of all relevant treatment options
224117989|NCT05741944|OTHER|standard care|All patients in control condition receive usual care.
224117990|NCT04598581|RADIATION|Low Dose Radiation Therapy (LD-RT)|Low Dose Radiation Therapy (LD-RT) of both lungs with 1 Gray
224117991|NCT04598581|OTHER|Sham irradiation|Sham irradiation
224117992|NCT01781429|DRUG|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
224117993|NCT03740607|DEVICE|Virtual reality|Healthcare virtual reality software implemented during peripheral intravenous catheter placement
224117994|NCT03740607|PROCEDURE|Peripheral intravenous catheter placement|Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
224117995|NCT03533140|DEVICE|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
223726479|NCT01918930|BIOLOGICAL|MGA271|MGA271 anti-B7-H3 monoclonal antibody
223978420|NCT03643757|DRUG|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
223978421|NCT01419938|DEVICE|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
223978422|NCT01419938|DEVICE|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
223978423|NCT04550559|PROCEDURE|Endoscopic ureterolitotripsy|Endoscopic ureterolithotripsy
223978424|NCT01230762|DRUG|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
223978425|NCT01242371|DIETARY_SUPPLEMENT|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
223978426|NCT01242371|DIETARY_SUPPLEMENT|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
223978427|NCT06189989|BEHAVIORAL|The group to which a care package was applied in addition to the clinical routine care protocol)|"Intervention Group:~* Immediately after the newborn's admission to the intensive care unit, mechanical ventilation mode, physiological parameters, blood gas results and descriptive characteristics of the baby were recorded in the Data Collection and Daily Monitoring Form.~* In addition to the routine care practices of the clinic (every 3 hours / 8 times a day), the newborn's temporary tachypnea care package was applied. Postural drainage, percussion and vibration were applied 4 times a day for an average of 10-15 minutes.~* Mechanical ventilation mode and physiological parameters were recorded one hour after 4 daily maintenance applications.~* Blood gas parameters were evaluated immediately before and 1 hour after the newborn was separated from mechanical ventilation.~* Physiological parameters were recorded again 1 hour after the first routine nursing care after the newborn was separated from mechanical ventilation."
224117996|NCT03533140|DEVICE|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
224117997|NCT04397406|DRUG|levobupivacaine|The patients will receive 15 ml of 0.125% levobupivacaine.
223978428|NCT00947141|DRUG|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR \>200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
223978429|NCT00947141|OTHER|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased \> 3,000. If treated (and monitored) treat until \<200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
223978430|NCT00947141|DRUG|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
223978431|NCT00947141|OTHER|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load \> 3,000 copies/ml. Participants are randomised to treat until \< 3,000 copies/ml on 2 occasions or treat until \<200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
224117998|NCT04397406|DRUG|Dexmedetomidine|The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
224117999|NCT04397406|DRUG|Fentanyl|The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
224118000|NCT01368289|PROCEDURE|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
224118001|NCT00034970|BEHAVIORAL|Mindfulness-based at therapy|
224118002|NCT02205567|DIETARY_SUPPLEMENT|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
224118003|NCT02797366|RADIATION|Proton radiotherapy|
224118004|NCT01686984|OTHER|Altered breath|
224293663|NCT07211659|BIOLOGICAL|THEO-260|Oncolytic virus
224293664|NCT07213336|OTHER|Exercise, massage|trigger point massage and stretching exercise
223726480|NCT06094595|DIAGNOSTIC_TEST|MAS-p administration|Each patient will be assessed the first time at mealtime by two experienced speech therapists, and scores obtained on the MAS-p will be recorded independently and blinded to each other. The two scales selected for comparison will also be administered at the same time. The assessment with the MAS-p scale will be repeated 48 hours apart, a time considered optimal in order to avoid possible bias related to the clinical improvement of the patient undergoing rehabilitation treatment, by one of the two speech therapists.
223726481|NCT04764903|OTHER|No intervention|There is no intervention in this study
223726482|NCT03809052|DRUG|GB1211|Hard capsules for oral use
223726483|NCT03809052|DRUG|Placebo|Hard capsules for oral use
223726484|NCT01798511|PROCEDURE|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
223726485|NCT01798511|OTHER|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
223726486|NCT01691781|DRUG|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
223726487|NCT00655044|DRUG|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
223726488|NCT05725967|PROCEDURE|Primary Obesity Endoscopic Procedures|Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
223726489|NCT05725967|PROCEDURE|Endoscopic Revision of Bariatric Surgical Procedures|Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
223726490|NCT05725967|PROCEDURE|Bariatric Surgery Procedures|Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
223978432|NCT02382523|DRUG|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
223978433|NCT01491906|BEHAVIORAL|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
223978434|NCT01108042|DRUG|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
223726491|NCT05725967|DEVICE|Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction|Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
223978435|NCT00025662|DRUG|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
223726492|NCT05725967|DEVICE|Intragastric Balloon|An endoscopic bariatric procedure involving the placement of an intragastric balloon.
224118005|NCT06097195|DEVICE|BioEP|When a consenting participant has their first electroencephalogram (EEG), they will be assigned with a unique participant study identifier before being uploaded. The centre will convert the EEG to European Data Format (EDF) format (or upload the total file) and upload this to the Neuronostics platform. The EEG will be stored on the Neuronostics database management system, within which the computational and mathematical analysis will be carried out. This study involves data analysis and mathematical modelling of the EEG recordings of each patient individually to generate a computational analysis score (BioEP).
224118006|NCT00956241|PROCEDURE|j-pouch coloanal anastomosis|
224118007|NCT00956241|PROCEDURE|side-to-end coloanal anastomosis|
224118008|NCT02021123|DRUG|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
223726493|NCT05725967|DEVICE|Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal|Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
224118009|NCT00041236|DRUG|exatecan mesylate|
223726494|NCT05725967|DEVICE|Argon Plasma Coagulation, Gastroplasty with Endoscopic Myotomy, Bariatric Endoscopic Antral Myotomy, Pylorus Sparing Antral Myotomy|Electrosurgical interventions for obesity. Use of electrosurgical devices, such as electrocautery for the primary treatment of obesity or obesity related complications.
223726495|NCT05725967|DEVICE|Aspiration Therapy|Placement of an aspiration therapy device for the treatment of obesity.
223726496|NCT01605877|DEVICE|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
223726497|NCT02818569|DRUG|Dexmedetomidine|Oral form
223978436|NCT00025662|DRUG|Isolex system|CD34 selection/ T cell depletion used this system
223978437|NCT01686490|BEHAVIORAL|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
224118010|NCT00390780|DRUG|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
224118011|NCT00390780|DRUG|Clotrimazole|10mg troches administered Five Times a Day for 14 days
224118012|NCT05054933|OTHER|ultrasound capsule endoscopy|Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
224118013|NCT01710228|DRUG|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
224118014|NCT03360981|DRUG|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
224118015|NCT01070550|DRUG|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
224118016|NCT05469932|DEVICE|Rexon device|Rexon device for 20 minutes each session. A total of 4 sessions with one week apart from each other.
224118017|NCT05228652|OTHER|Questionnaire|Three different questionnaires have been developed. They consist of multiple-choice questions and some open-ended questions.
224118018|NCT05152160|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell Therapy|Umbilical Cord Mesenchymal Stem Cell Therapy
224118019|NCT04971044|BEHAVIORAL|COACH|Multi-Level Behavioral Intervention
223726498|NCT02818569|OTHER|Saline Placebo|Saline Placebo
223726499|NCT02088281|DRUG|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
223726500|NCT01918085|OTHER|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
223726501|NCT01918085|OTHER|Strata strip|An adhesive strip made of the Strata adhesive
223726502|NCT03637114|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
223726503|NCT03637114|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
223726504|NCT00388778|DRUG|Doxycycline|
223726505|NCT05930977|PROCEDURE|total thyroidectomy followed by thyroid auto transplantation|"All studied cases received general endotracheal anaesthesia, and all underwent total thyroidectomy.~Frozen section will be done intraoperative to exclude malignancy and obtain piece of healthy tissue part .~Most healthy-looking part of gland was selected after complete excision. Thyroid tissue to be transplanted weighed between two and five grammes. This section was finely split into ten-fifteen fragments with scalpel. Small pocket was created in sternomastoid muscle, into which these minor fragments were implanted, and this pocket was closed with absorbable sutures to prevent displacement of implanted fragments and was marked with metallic stables, as well as good hemostasis of thyroid bed and skin was closed with subcuticular sutures using absorbable three-zero Vicryl sutures."
223726506|NCT00148018|DRUG|Bortezomib|
223726507|NCT00148018|DRUG|Dexamethasone|
223726508|NCT02535988|RADIATION|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
223726509|NCT02535988|DRUG|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
223726510|NCT04085809|OTHER|AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
224118020|NCT04971044|BEHAVIORAL|School Readiness Intervention|Multi-Level Language and School Readiness Intervention (Control Group)
224118021|NCT00028366|DRUG|Fosamprenavir|
224118022|NCT00028366|DRUG|Lopinavir/Ritonavir|
224118023|NCT00028366|DRUG|Ritonavir|
224118024|NCT00028366|DRUG|Tenofovir disoproxil fumarate|
224122740|NCT07007195|DEVICE|Smart-T Smoking Cessation App with the Inspire Device Condition|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks. Participants will also use the Inspire device.
223726511|NCT05609006|DIETARY_SUPPLEMENT|High-Energy, Low-Volume ONS|2 bottles/day of a High-Energy, Low-Volume ONS
223726512|NCT05609006|DIETARY_SUPPLEMENT|High-Energy Standard ONS|2 bottles/day of a High-Energy Standard ONS
223978438|NCT01686490|BEHAVIORAL|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
223978439|NCT05097183|PROCEDURE|Accurate Commissural Alignment (ACA)|Software based, computed tomography analysis that allows planification of accurate commissural alignment of TAVR by inserting the delivery system in a patient-specific degree of rotation.
224293665|NCT07212387|PROCEDURE|Sacral neurostimulation|Sacral neurostimulation (SNS), or sacral neuromodulation (SNM), is a minimally invasive, reversible treatment for bladder and bowel control problems, including overactive bladder and fecal incontinence.
223978440|NCT00169949|DRUG|aripiprazole|
223978441|NCT05052749|OTHER|High Intensity Resistance Training (HIRT)|High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
223978442|NCT05052749|OTHER|Low-moderate Resistance Exercise Training|Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
223978443|NCT04518761|PROCEDURE|Elective surgery|Any patient who needs to undergo an elective surgery.
223978444|NCT01043198|GENETIC|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~* Standardized screening with :~* radiological (hands, feet, spine ; and renal ultrasonography)~* biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
223978445|NCT06647251|PROCEDURE|Q-MODE : radiofrequency ablation up to 50W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W."
223978446|NCT06647251|PROCEDURE|Q-MODE+ : radiofrequency up to 90W|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W."
224118025|NCT06478758|DRUG|Ibuprofen 400 mg|The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
223978447|NCT06647251|PROCEDURE|Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part|"The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part."
223978448|NCT06647329|BIOLOGICAL|CAR-T Therapy|CAR-T Technology for the Treatment of Recurrent/Refractory Malignant Hematological Lymphomas
223978449|NCT06646081|PROCEDURE|Greater Occipital Nerve Block|The patient is placed prone with the head neutral or slightly flexed. After sterile preparation, a high-frequency linear probe is positioned transversely at the upper nuchal line in the occipital region. The Greater Occipital Nerve, exiting from the posterior root of C2, is located near the occipital artery. Using an in-plane technique, a 25-gauge needle is inserted into the fascial plane around the artery. After confirming no intravascular placement by negative aspiration, 5 mL of a mixture of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
223978450|NCT06646081|PROCEDURE|Stellate Ganglion Block|The patient lies supine with a pillow under the shoulders, and the head slightly extended, neck gently turned opposite to the blockade. After sterile preparation, a high-frequency linear probe is placed transversely at the C6 vertebra (Chassaignac's tubercle). Ultrasound identifies the C6 vertebra, Longus colli muscle, carotid artery, and internal jugular vein. The Stellate Ganglion is located within the prevertebral fascia over the Longus colli. Using an in-plane technique, a 25-gauge needle is inserted and advanced into the prevertebral fascial plane. After confirming no intravascular placement by negative aspiration, 5 mL of 50 mg lidocaine and isotonic saline is injected. The fascial plane opening confirms the site. The area is dressed, and the patient is monitored for one hour for side effects.
223978451|NCT02661503|DRUG|Bleomycin|
223978452|NCT02661503|DRUG|Etoposide|
223978453|NCT02661503|DRUG|Doxorubicin|
223978454|NCT02661503|DRUG|Cyclophosphamide|
223978455|NCT02661503|DRUG|Vincristine|
223978456|NCT02661503|DRUG|Procarbazine|
223543718|NCT00913510|DRUG|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
223978457|NCT02661503|DRUG|Prednisone|
223978458|NCT02661503|DRUG|Brentuximab Vedotin|
224118026|NCT06478758|DRUG|Acetaminophen 100 MG/ML|The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of \> 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of \> 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
224118027|NCT03532945|DEVICE|Bioactive Glass-Ceramic Spacer|
224118028|NCT03532945|DEVICE|Titanium cage|
224118029|NCT01585961|DEVICE|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
224118030|NCT01670513|DRUG|IDP-118 Low Strength|8 weeks
224118031|NCT01670513|DRUG|IDP-118 High Strength|8 weeks
223726513|NCT03640130|BEHAVIORAL|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
223726514|NCT06370650|PROCEDURE|platelet rich plasma, narrow band UVB|Role of PRP in treating stable vitiligo
223978459|NCT02661503|DRUG|Dacarbazine|
223978460|NCT02661503|DRUG|Dexamethasone|
224118032|NCT00935142|DRUG|[18F]VM4-037|Bolus IV injection of \[18F\]VM4-037
224118033|NCT02704728|OTHER|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
223543719|NCT05074823|DRUG|Ketamine 0.1 mg|Patients will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.1 mg/kg
223978461|NCT02068196|PROCEDURE|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
223978462|NCT02068196|DRUG|Ipilimumab|
223978463|NCT02934815|OTHER|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
223543720|NCT05074823|DRUG|Ketamine 0.2 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.2 mg/kg
223543721|NCT05074823|DRUG|Ketamine 0.3 mg|will receive 3mL of bupivacaine (heavy) 0.5% in addition to 0.5 ml of a preservative-free ketamine 0.3 mg/kg
223543722|NCT05160363|DRUG|Pyronaridine Tetraphosphate|A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.
223543723|NCT05160363|DRUG|Piperaquine tetraphosphate|A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.
223543724|NCT05160363|DRUG|Placebo|Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
223978464|NCT00478998|DRUG|Tamsulosin|
223978465|NCT02640222|DRUG|VKA|
223978466|NCT02640222|DRUG|Apixaban|
223978467|NCT02640222|DRUG|dabigatran|
223978468|NCT02640222|DRUG|rivaroxaban|
223978469|NCT05848453|DRUG|BAP5191|Placebo
224118034|NCT02704728|OTHER|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
223726515|NCT01914198|OTHER|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
223978470|NCT06088797|OTHER|METRIC COMPARISON Tasks : Tactile PVSE test|"Tactile PVSE test The tests are presented in 6 independent booklets, each of which tests a distinct skill: comparison of lengths, comparison of sizes, comparison of obliques, perception of environments, comparison of relative positions in relation to a frame and comparison of relative positions with distractors.~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
223978471|NCT06088797|OTHER|METRIC COMPARISON Tasks : Classic PVSE test|"Classic PVSE test Use of the standardized PVSE test printed on thick white paper in 6 separate booklets each containing a subtest (length, size, oblique, middle, relative position and relative position with distractor)~The assessment sheet presented in a table with the expected answers will allow you to note whether the answers are correct (rating 1) or not (rating 0). A total of the correct answers from all the sub-tests will give a total score."
223978472|NCT06088797|OTHER|Mental imagery task|This involves answering questions concerning the position or identity of 2 or 3 objects on the basis of the mental representation of a grid by auditory guidance. Each grid must be constructed mentally with the verbal description of the path and the objects encountered.
223978473|NCT06088797|OTHER|Proprioceptive spatial representation tasks|"16 configurations of 3 objects with direct or indirect passive exploration of their relative positions.~Each grid is presented 3 times with the following 3 questions to which the subject answers yes or no by forced choice~a single measure of the number of correct answers which will be the sum of the correct answers obtained to each of the 3 questions in the direct vs indirect condition"
223978474|NCT06088797|OTHER|Tasks assessing number sense based on relative positions or lengths|"Pointing exercises on a digital line of 50 cm paper tape: the participant points with his finger to a position on the tape, according to the verbal request of the experimenter~Measures the intermanual gap during requests for evaluation of 5 times the wand, subtracting the length of a wand, then dividing this length by 2."
224118035|NCT02902016|DRUG|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
224122741|NCT07007195|DEVICE|Smart-T Smoking Cessation App Without the Inspire Device Condition|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempts. Smart-T app contains multiple components, including an EMA delivery and data transfer system, automated messages based on EMA responses, and on-demand content. Participants will use Smart-T for 13 weeks.
224122742|NCT07007195|DRUG|Nicotine replacement therapy (NRT)|NRT patches will be provided to assist with cravings and withdrawal symptoms following the quit attempts.
223726516|NCT03340532|OTHER|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
223726517|NCT03340532|OTHER|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
223726518|NCT03340532|OTHER|Sleep hygiene video|Contain information on better sleep hygiene
223726519|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
223726520|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
223726521|NCT01382095|BIOLOGICAL|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
223726522|NCT01382095|BIOLOGICAL|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
223726523|NCT01064713|DRUG|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
223726524|NCT01897402|BIOLOGICAL|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
223726525|NCT01897402|BIOLOGICAL|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
223726526|NCT00795314|DRUG|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
223726527|NCT00795314|DRUG|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
223726528|NCT03920579|DRUG|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
223726529|NCT03920579|DRUG|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
223726530|NCT03920579|DRUG|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
223726531|NCT02260700|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
223978475|NCT06088797|OTHER|WISC V Similarity and Span Test|The Wechsler Intelligence Scale for Children - Fifth Edition, Australian Standard (WISC-V) is an individually administered and comprehensive clinical instrument used to assess the general thinking and reasoning skills of children aged six years to 16 years. Test results include a Full-Scale Intelligence Quotient (IQ) score as well as age-equivalent rankings and scores for Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory and Processing Speed composites
224293666|NCT07213154|PROCEDURE|Quantitative Oblique Back-Illumination Microscopy|Undergo qOBM
224293667|NCT07213154|RADIATION|Radiation Therapy|Undergo SOC RT
223978476|NCT06088797|OTHER|WISC V Arithmetic subtest|The WISC-V is an individually administered, comprehensive clinical instrument for assessing the intelligence of children. The primary and secondary subtests are on a scaled score metric with a mean of 10 and a standard deviation (SD) of 3. These subtest scores range from 1 to19, with scores between 8 and 12 typically considered average.
223726532|NCT02260700|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
223726533|NCT02260700|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
223726534|NCT01157260|DRUG|Kremezin|AST-120 2g three times a day
223726535|NCT04557878|DRUG|Hypertonic Dextrose Solution|Patients in this group will receive an intra-articular injection of 12.5% hypertonic dextrose solution, once every month for three consecutive months, in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.The point of needle entry will be 1 cm below the apex of the zygomatic arch and guided by ultrasound to ensure intra-articular injection in the superior joint space.
223726536|NCT04557878|BIOLOGICAL|Liquid Phase Concentrated Growth Factor (LPCGFs)|Patients in this group will receive single intra-articular injection of LPCGF in conjugation with a maxillary CAD/CAM full-arch hard clear acrylic stabilization appliance.
223726537|NCT01183156|BEHAVIORAL|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
223726538|NCT01183156|BEHAVIORAL|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
223726539|NCT03405129|BEHAVIORAL|Phoenix|Phoenix cessation app
223726540|NCT03405129|BEHAVIORAL|NRT order button|Ability to order NRT through smartphone app
223726541|NCT03405129|BEHAVIORAL|Factoid|Factoid app
223726542|NCT02071121|DRUG|BIIB061|BIIB061 capsules for oral administration
223978477|NCT06213064|BEHAVIORAL|Study Product, THC Product, Placebo|Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
223978478|NCT01398644|OTHER|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
223978479|NCT04225000|OTHER|Exercise Group|Control group included 6 different exercises to treat participants having PFPS. These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. These all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This exercise protocol was for 4 weeks and 3 sessions per week.
223978480|NCT04225000|OTHER|Mobilization Group|"Experimental group included Anterior-Posterior (AP) tibiofemoral joint mobilization and all 6 exercises suggested controlled group for treating participants having PFPS; 3 sessions of mobilizations per week and total 4 weeks.~These exercises included Semi squat with hip adduction and internal rotation, Quads isometrics, Straight Leg Raise (SLR) Hamstring Stretch, Terminal knee extension with elastic band , Adductor squeeze in crook lying (squeeze the ball), Hip abduction in standing with elastic band. Theses all exercises were advised to perform 3 x 15 Repetitions with 10 sec hold. This protocol was for 4 weeks and 3 sessions per week."
223978481|NCT01349036|DRUG|PLX3397|Capsules administered once or twice daily, continuous dosing
223978482|NCT00600301|DRUG|Triamcinolone Acetonide and Bevacizumab|
223978483|NCT04003961|OTHER|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
223978484|NCT05499143|OTHER|Online questionnaire|Online questionnaire impact for DCD - Belgian version
223978485|NCT04012099|DRUG|BMT101|Intradermal injection to each of 3 dose-groups.
223978486|NCT05930002|DRUG|Ivermectin Tablets|oral tablets (0.2 mg/kg/day) single dose on an empty stomach for three successive days.
223978487|NCT05930002|DRUG|Colchicine 0.5 MG|0.5mg tablets (3times/day after meal for 3 days then twice daily for 4 days)
223978488|NCT05930002|DRUG|Standared managment|(Vitamin C 500mg tablet twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75mg tablet once daily for two weeks
223978489|NCT00281502|DRUG|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
223978490|NCT00119795|BEHAVIORAL|Exercise|Increase Physical Activity to 150 min/wk
223978491|NCT00119795|BEHAVIORAL|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
223978492|NCT00119795|BEHAVIORAL|Health Education Control|Lectures on information relevant to successful aging
224118036|NCT05973994|DEVICE|intravascular lithotripsy with Shockwave coronary system|OCT acquistion is performed at baseline. Then the IVL catheter will be passed across the lesion over the guidewire. Atherectomy or cutting/scoring balloons is not permitted per protocol. The IVL procedure is considered successful when a residual stenosis \<50% by visual estimate after IVL alone is achieved. After IVL procedure, one OCT imaging acquisition must be performed. If the residual stenosis is ≥50% following IVL, noncompliant balloon dilatation will be performed prior to stenting and OCT images repeated accordingly. Subsequent stent implantation will be performed per local standard of care at the discretion of the operator. Following stent implantation, high pressure post-dilatation is recommended and OCT imaging acquisition must be performed to assess stent apposition for secondary end point.
223726543|NCT02071121|DRUG|Placebo|BIIB061 matching placebo capsules
223726544|NCT02071121|DRUG|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
223726545|NCT00687323|DRUG|temozolomide|
223726546|NCT04691505|DRUG|Methotrexate|Methotrexate is used as the reference group.
223726547|NCT04691505|DRUG|Hydroxychloroquine|Hydroxychloroquine is used as the exposure group.
223978493|NCT05207631|OTHER|Systematic and standardised assessment of inhalers and implementation of a prescribing guide|Participants included in the intervention cohort receive a systematic and standardised assessment of their inhalers on admission to our department. The assessment is carried out by a physiotherapist and aims to assess inhalation technique, peak inspiratory flow and ability to use the inhaler after targeted teaching. Based on this information and a prescription guide provided, the patient's doctor can select the most appropriate inhaler.
223978494|NCT05300997|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
223978495|NCT02196168|DRUG|Cisplatin|Given IV
223978496|NCT02196168|OTHER|Laboratory Biomarker Analysis|Correlative studies
223978497|NCT02196168|OTHER|Pharmacological Study|Correlative studies
223978498|NCT02196168|OTHER|Placebo|Given PO
223978499|NCT02196168|DRUG|WEE1 Inhibitor AZD1775|Given PO
223978500|NCT01215032|DRUG|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
223978501|NCT00961610|BEHAVIORAL|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
223978502|NCT06002321|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' \> 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR \> 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.
223978503|NCT06002321|DIAGNOSTIC_TEST|Laboratory Test|BNP, NT-proBNP and renal function.
223726548|NCT01209260|DEVICE|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
223726549|NCT01209260|DEVICE|Mechanical Needle|Mechanical needle for transseptal access
223543725|NCT02126319|BEHAVIORAL|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
223543726|NCT02126319|BEHAVIORAL|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
223978504|NCT01125566|DRUG|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
223978505|NCT01125566|DRUG|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
223978506|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
223978507|NCT01125566|DRUG|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
223978508|NCT02041312|OTHER|No intervention|No intervention will be needed.
223978509|NCT03002922|DRUG|BAY987517|Sunscreen formula Y65-158
223978510|NCT03420898|OTHER|Quality Improvement Intervention, prescription reduction|The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
223978511|NCT01818609|BEHAVIORAL|Step reduction|taking less than 1500 steps/d
223978512|NCT03156205|BEHAVIORAL|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
223978513|NCT03156205|BEHAVIORAL|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
223978514|NCT03156205|BEHAVIORAL|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
223978515|NCT06180863|DRUG|oral azacitidine (CC-486)|Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
223978516|NCT03087331|OTHER|medication reviews, assessment, recommendations, education.|
223978517|NCT06342245|RADIATION|Radiofrequency coblation micro-tenotomy|Radiofrequency micro-tenotomy with low-temperature controlled ablation will be performed with the TOPAZ (Smith and Nephew) wand, which has a 1mm tip, and full thickness 1mm RF tendon debridement at 5mm intervals will be performed.
223978518|NCT04477356|PROCEDURE|SU|Aliquot 1.2 ml Ferticult Flushing media (Fertipro, Belgium) into 14 ml tube and then gently add 1 ml semen sample to the bottom of the tube (in case of larger semen volume, use multiple 14 ml tubes). The tubes then will be hold at an angle of 45 degrees for 45-60 minutes at 37C. Collect 1 ml of supernatant and then wash with 2 ml Ferticult Flushing media by centrifugation at 1200 RPM for 10 minutes. Keeping 0.3 ml washed semen for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
224118037|NCT03751995|BEHAVIORAL|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
224118038|NCT00003982|DRUG|sabarubicin|
224118039|NCT00819533|DEVICE|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
224118040|NCT03452553|DEVICE|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
224118041|NCT04387058|DEVICE|TIPS|TIPS (Transjugular Intrahepatic Portosystemic Shunt) is an interventional radiology method that creates an anastomosis between the portal venous network and the hepatic venous network.
224118042|NCT03466489|DEVICE|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
224118043|NCT01090089|DRUG|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
223543727|NCT05480176|OTHER|Comprehensive intervention and management Ⅰ|Mainly health advisory.
223543728|NCT05480176|OTHER|Comprehensive intervention and management Ⅱ|Health advisory and regular follow-ups.
223543729|NCT05480176|OTHER|Comprehensive intervention and management Ⅲ|Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
223543730|NCT00917319|OTHER|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
223543731|NCT03816787|PROCEDURE|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
223726550|NCT02555072|BIOLOGICAL|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
224118044|NCT01090089|DRUG|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
224118045|NCT03928834|BEHAVIORAL|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
223978519|NCT04477356|PROCEDURE|DG|Add 1.5 ml Sil-select 90% first and then 1.5 ml Sil-select 45% (Fertipro, Belgium) into centrifuge tube, then gently add 1 - 1.5 ml semen on the top of Sil-select layer and centrifuge at 1200 RPM for 15 minutes. Discard upper layer, collect 0.5 ml lower layer into new tube and then wash with 2 ml Ferticult Flushing media at 1200 RPM for 10 minutes. Discard upper layer then collect 0.3 ml lower layer for IUI, sperm density counting. Prepared sperms will be transferred into uterus by soft catheter (Gynétics, Belgium).
223978520|NCT02886169|OTHER|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
223978521|NCT02886169|OTHER|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
223978522|NCT02643511|RADIATION|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
223978523|NCT00739076|BEHAVIORAL|Virtual Reality|Using Virtual Reality for pain control
223978524|NCT03618706|RADIATION|Involved-field radiotherapy|After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
223978525|NCT05934656|OTHER|Latent class analysis|"The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation."
223978526|NCT03998501|BEHAVIORAL|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
223978527|NCT01454232|OTHER|stools sampling|stools sampling at baseline, 1, 3 and 12 months
223978528|NCT01454232|OTHER|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
223978529|NCT01810276|OTHER|Saline|400 mL of Saline will be given intravenously over 2 hours once
223978530|NCT01810276|OTHER|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
224118046|NCT04050007|OTHER|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
224118047|NCT04050007|OTHER|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
224118048|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
223543732|NCT03037866|BEHAVIORAL|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
223978531|NCT03936764|OTHER|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing."
223978532|NCT03028012|DRUG|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
223543733|NCT02540590|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
223543734|NCT02540590|DEVICE|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
223543735|NCT04157699|DRUG|TDF tablet|TDF tablet 300mg QD
223543736|NCT04157699|DRUG|QL-007|QL-007 tablet
223543737|NCT02656836|OTHER|Home tonometry, diagnostic study|Evaluating intraocular pressure
223543738|NCT00728156|DRUG|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
223543739|NCT00728156|DRUG|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
223543740|NCT02462187|DRUG|NVN1000 8% Gel|once and twice daily
223543741|NCT02462187|DRUG|NVN1000 16%|once daily
223543742|NCT02462187|DRUG|Vehicle|placebo comparator
223543743|NCT02462187|DRUG|NVN1000 24%|once daily
223543744|NCT02011269|BIOLOGICAL|Trichuris Suis Ova|
223543745|NCT05036161|OTHER|Nasal high flow|Newborns with respiratory distress treated with NHF.
223543746|NCT05036161|OTHER|Continuous Positive Airway Pressure|Newborns with respiratory distress treated with CPAP.
223543747|NCT05927116|OTHER|Mobile phone app-based intervention for supporting and empowering parents of children with autism spectrum disorder (ASD)|TRIP is a mobile app-based intervention comprises of a 6-week structured training on mindfulness and educational modules on ASD parenting skills.
223543748|NCT01428219|DRUG|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
223543749|NCT05010083|BEHAVIORAL|diet and lifestyle program|See description of main arm.
223543750|NCT04624516|OTHER|self-structured foot exercise|The exercise was done 3 times a week (15x/until they tired x 2set). The exercise used a flexible band with difference thickness (0,5 mm in the first 12 weeks and 0,65 mm in the second 12 weeks)
223543751|NCT04144283|BEHAVIORAL|NAP|"For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold during stage 2 and stage 3 of NREM sleep."
223543752|NCT04144283|BEHAVIORAL|WAKE|For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.
223978533|NCT03028012|DRUG|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
223978534|NCT03028012|DRUG|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
223978535|NCT00099203|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
223978536|NCT00099203|DRUG|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
223978537|NCT00270647|DIETARY_SUPPLEMENT|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
223978538|NCT00270647|DIETARY_SUPPLEMENT|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
223543753|NCT01291108|DRUG|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
223543754|NCT01291108|DRUG|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
223543755|NCT01291108|DRUG|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
223543756|NCT01333410|DRUG|tacrolimus ointment|2 applications per days for 6 months
223543757|NCT01333410|DRUG|Mometasone furoate|2 applications per day for 6 months
223543758|NCT05592821|PROCEDURE|dental implant placement|In both groups, dental implants of the same brand will be placed into the bone with the same protocol.
223543759|NCT01762683|OTHER|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
223543760|NCT02458872|BEHAVIORAL|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
223543761|NCT05894057|OTHER|Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB|On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.
223978539|NCT00270647|DIETARY_SUPPLEMENT|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
223978540|NCT00270647|DIETARY_SUPPLEMENT|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
223978541|NCT03020056|DRUG|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
223978542|NCT03020056|PROCEDURE|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
223726551|NCT01772108|DEVICE|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
223726552|NCT00088517|DRUG|[11C]NNC-112|
223978543|NCT02624375|DRUG|Zoster Vaccine Live|
223978544|NCT02606097|DRUG|regorafenib|
223978545|NCT04897685|BEHAVIORAL|Flow with Nature|Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
223726553|NCT04984720|BEHAVIORAL|Smartphone based digital application|Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
223726554|NCT00439660|BIOLOGICAL|Oral Rotavirus Vaccine 116E Live Attenuated|
223726555|NCT00078637|DRUG|E7820|
223726556|NCT02568085|DEVICE|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
223726557|NCT00679302|DRUG|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
223978546|NCT00569010|DRUG|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m\^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m\^2 IV Over 20-30 minutes Daily for 7 days
224118049|NCT00109733|BIOLOGICAL|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
223726558|NCT00679302|DRUG|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
223726559|NCT06177587|OTHER|Assesment of biomarkers in acute coronary syndromes|Collection of 20ml of blood from peripheral vein.
223726560|NCT06112262|DRUG|Heparin|Comparison between heparin and hirudin
223726561|NCT06046391|BIOLOGICAL|LP-003 dose 1|Liquid in vial
223978547|NCT00569010|DRUG|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m\^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m\^2 Daily CIV for 4 days (age\<65 years) or 3 days (age\>=65 years)"
223978548|NCT04525456|DIETARY_SUPPLEMENT|Reduxium|Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
224118050|NCT02829086|OTHER|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
224118051|NCT02829086|OTHER|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
224118052|NCT02829086|OTHER|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
224118053|NCT03904446|DRUG|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
224118054|NCT03904446|DRUG|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
223726562|NCT06046391|BIOLOGICAL|LP-003 dose 2|Liquid in vial
223726563|NCT06046391|BIOLOGICAL|Placebo|Liquid in vial
224118055|NCT03271931|BEHAVIORAL|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
223978549|NCT06194812|OTHER|Pain Catastrophizing scale|"Participants' fear and avoidance behaviors will be evaluated with the Fear Avoidance Beliefs Questionnaire (KKBS) (Appendix 2).~Participants' fear of movement will be evaluated with the Tampa Kinesiophobia Scale (TKS) (Appendix 3).~Pain Catastrophizing Scale (PAS) (Appendix 4) will be used to evaluate the participants' pain-related thoughts and feelings.~The amount of improvement in symptoms perceived by the participants will be evaluated at the end of the treatment with the Global Perceived Impact Scale (GAES) (Appendix 5). Participants were asked How would you describe your current situation compared to the beginning of treatment? question will be asked."
223726564|NCT05013593|DIETARY_SUPPLEMENT|Red Clover Extract (RCE)|Red clover extract containing isoflavones Formononetin and biochanin A together with a heterogenous culture of probiotic lactic acid bacteria, and a natural sugar free raspberry/orange flavor. Isoflavone amount is 57.45 mg isoflavones daily (55.84 mg aglycones daily), in 70 ml red clover extract (35 ml twice daily, morning and evening together with a meal)
223726565|NCT05013593|OTHER|Placebo (PL)|Placebo containing water, brown coloring, and natural sugar free raspberry/orange flavor.
224118056|NCT03271931|BEHAVIORAL|Passive choice|EHR passive alert to cardiologists about prescribing a statin
223978550|NCT00331708|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
223726566|NCT05544916|DRUG|XC221|200 mg/day, for 5 days
223726567|NCT05544916|DRUG|Placebo|2 tablets/day, for 5 days
223726568|NCT02789202|OTHER|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
223978551|NCT03745586|DRUG|Tocilizumab|Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
223978552|NCT03745586|DRUG|Glucocorticoids|Day0-day2: methylprednisolone 500mg i.v.
224118057|NCT05857202|DRUG|Analgesics, Opioid|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
224118058|NCT05857202|DRUG|Analgesics, Non-Narcotic|Drugs were given immediately after the surgery, and correlation between analgesic use and parameters of oxidative stress and inflammation was assessed.
224118059|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
223726569|NCT02789202|OTHER|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
223726570|NCT05950490|DRUG|Intravitreal injection of methotrexate|"Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years"
223726571|NCT00462267|BEHAVIORAL|Enriched lifestyle intervention|Multi-component lifestyle intervention
223726572|NCT00844688|DRUG|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason."
224118060|NCT00678275|DRUG|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
224118061|NCT01218932|DRUG|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
223726573|NCT00844688|DRUG|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
223726574|NCT06445192|OTHER|Best Practice|Receive usual care
223978553|NCT00148135|DRUG|Carboplatin|
223978554|NCT00148135|DRUG|Gemcitabine|
223978555|NCT00148135|DRUG|Capecitabine|
223978556|NCT02508597|OTHER|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
223726575|NCT06445192|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223726576|NCT06445192|OTHER|Exercise Counseling|Attend group counseling
223726577|NCT06445192|OTHER|Exercise Intervention|Receive aerobic and resistance exercise intervention via telehealth
223726578|NCT06445192|OTHER|Medical Device Usage and Evaluation|Wear Fitbit
223726579|NCT06445192|OTHER|Physical Performance Testing|Ancillary studies
223978557|NCT02484547|DRUG|Aducanumab (BIIB037)|Low dose
223726580|NCT06445192|OTHER|Questionnaire Administration|Ancillary studies
223726581|NCT06445192|OTHER|Telemedicine|Receive aerobic and resistance exercise intervention via telehealth
223726582|NCT04542135|DRUG|Sulindac Pill|Randomized participants will receive either 150 mg oral sulindac twice daily.
223726583|NCT04542135|DRUG|Placebo|placebo pills twice daily
223726584|NCT04356274|OTHER|Participatory System Dynamics (PSD)|Participatory system dynamics is a facilitated health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff running simulations of clinic improvement strategies to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
223726585|NCT04356274|OTHER|Audit and Feedback (AF)|Audit and feedback is a health care quality improvement or evidence-based practice implementation strategy that includes frontline addiction and mental health staff reviewing clinical care team data to find the best approaches for improving the reach of evidence-based psychotherapy and evidence-based pharmacotherapy.
223726586|NCT01731392|DIETARY_SUPPLEMENT|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
223726587|NCT01731392|DIETARY_SUPPLEMENT|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
223978558|NCT02484547|DRUG|Aducanumab (BIIB037)|High dose
223978559|NCT02484547|DRUG|Placebo|Placebo
223978560|NCT04287140|OTHER|Bolus fluid administration|1000 ml of 0.9% normal saline bolus over one hour
223978561|NCT00001123|DRUG|Ribavirin|
223978562|NCT02924558|OTHER|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
223978563|NCT02924558|OTHER|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
223726588|NCT01731392|DIETARY_SUPPLEMENT|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
223726589|NCT02176876|DRUG|GS-5745|GS-5745 400 mg administered intravenously
223726590|NCT02176876|DRUG|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
223978564|NCT01813305|DRUG|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
223978565|NCT01813305|DRUG|CSTC1 Matched vehicle|
223978566|NCT01515722|BEHAVIORAL|Health education intervention (HEI)|"* \<Part 1\> Understanding OAB~* \<Part 2\> Behavioral/lifestyle modification~* \<Part 3\> Bladder training~* \<Part 4\> Understanding antimuscarinics"
223978567|NCT02736955|DRUG|Valbenazine|
223978568|NCT05337488|OTHER|questionnaire with interview|They will be invited to complete a questionnaire and an individual semi-structured interviews.
223978569|NCT05050526|BEHAVIORAL|Real-time videoconference-based Exercise program|12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
223978570|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
223978571|NCT02590471|PROCEDURE|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
223978572|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
223978573|NCT01474421|DRUG|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
223978574|NCT01474421|DRUG|Placebo|Patients will receive placebo once daily orally for 28 days.
223726591|NCT05319145|BEHAVIORAL|Intervention group|1\) Multi-component exercise intervention program based on Vivifrail©. It consists of 1 daily-30 minutes session, twice a week, for 10 consecutive weeks supervised by an experienced exercise specialist. Exercises (resistance, gait retraining, balance training) are personalized depending on the person's functional capacity (evaluated by the SPPB and a walking speed test) and the risk of falling. Between sessions, individual, unsupervised training by the own patient, supported in the case by the caregiver, will be stimulated, through the recommendations of ViviFrail©. 2) Nutrition. Personalized recommendations according to nutritional and medical status (active oncologic treatment, remission, or palliative stage) will be offered according to the ESPEN recommendations for cancer patients, aimed at compensating for inadequate energy intake, improving patients' malnutrition risk stage (assessed by means of the MNA-SF).
223726592|NCT05319145|OTHER|Control group|General recommendations (written and videos) will be offered.
223978575|NCT01665599|DRUG|Testosterone gel (FE 999303)|
223978576|NCT03953209|DRUG|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
223978577|NCT03953209|DRUG|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
223726593|NCT05505903|DIAGNOSTIC_TEST|Temerature measurement|Temerature measurement on admission to WBN or NICU
223978578|NCT03953209|DRUG|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
224118062|NCT01218932|DRUG|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
224118063|NCT02519075|OTHER|No intervention|Observational study
223726594|NCT02726646|DRUG|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
223726595|NCT02726646|PROCEDURE|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
223726596|NCT02726646|DRUG|Placebo|The application of 1 mg of microspheres placebo
223978579|NCT00949221|DEVICE|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"* group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
223978580|NCT04548297|OTHER|Assessment|Assessments of foot sole sensation, joint position sensation, attention, fatigue, body awareness, and physical activity level
223978581|NCT03878290|BEHAVIORAL|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
223978582|NCT00897754|GENETIC|gene expression analysis|
223978583|NCT00897754|GENETIC|protein expression analysis|
223978584|NCT00897754|GENETIC|reverse transcriptase-polymerase chain reaction|
223978585|NCT00897754|OTHER|immunoenzyme technique|
223978586|NCT00897754|OTHER|immunohistochemistry staining method|
223978587|NCT00897754|OTHER|immunologic technique|
223978588|NCT02876003|DRUG|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
223978589|NCT02668770|DRUG|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
223978590|NCT02668770|DRUG|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
223978591|NCT01262742|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
223978592|NCT01262742|DRUG|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
224118064|NCT06360874|DRUG|ND-003 40mg|Participants receive 40mg ND-003 tablets once.
224118065|NCT06360874|DRUG|ND-003 placebo 40mg|Participants receive placebo tablet matching to receive 40mg of ND-003.
224118066|NCT06360874|DRUG|ND-003 80mg|Participants receive 80mg ND-003 tablets once.
224118067|NCT06360874|DRUG|ND-003 placebo 80mg|Participants receive placebo tablet matching to receive 80mg of ND-003.
224293668|NCT07212257|PROCEDURE|Gait analysis with surface electromyography (EMG)|Each participant undergoes a standardized gait analysis session. After skin preparation, 28 surface electrodes are placed bilaterally on seven lower limb muscles according to SENIAM recommendations. The child completes 10 walking trials (five round trips of 10 meters) at a comfortable, self-selected speed while being recorded by synchronized cameras. Data collected include EMG signals and video recordings. This procedure is non-invasive and performed in a single session lasting approximately one hour
223726597|NCT06198868|PROCEDURE|Operable|Enrolled patients capable of surgical treatment
223726598|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
223978593|NCT01262742|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
223978594|NCT01262742|DRUG|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
223978595|NCT01262742|DRUG|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
223978596|NCT06500858|OTHER|Exercise Intervention|Receive a welcome package with exercise equipment
223978597|NCT06500858|OTHER|Exercise Intervention|Participate in virtual-exercise sessions
223978598|NCT06500858|OTHER|Exercise Intervention|Receive access to optional drop-in classes
223978599|NCT06500858|OTHER|Health Promotion and Education|Receive monthly newsletters
223978600|NCT06500858|OTHER|Internet-Based Intervention|Receive access to online fitness buddy matching program
223978601|NCT06500858|OTHER|Physical Activity|Participate in a walking program
223978602|NCT06500858|OTHER|Questionnaire Administration|Ancillary studies
224118068|NCT06360874|DRUG|ND-003 160mg|Participants receive 160mg ND-003 tablets once.
224118069|NCT06360874|DRUG|ND-003 placebo 160mg|Participants receive placebo tablet matching to receive 160mg of ND-003.
224118070|NCT06360874|DRUG|ND-003 240mg|Participants receive 240mg ND-003 tablets once.
224118071|NCT06360874|DRUG|ND-003 placebo 240mg|Participants receive placebo tablet matching to receive 240mg of ND-003.
224118072|NCT06360874|DRUG|ND-003 300mg|Participants receive 300mg ND-003 tablets once.
224118073|NCT06360874|DRUG|ND-003 placebo 300mg|Participants receive placebo tablet matching to receive 300mg of ND-003.
224118074|NCT06360874|DRUG|MAD_ND003_Dose 1|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
224118075|NCT06360874|DRUG|MAD_placebo_Dose 1|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 1
224118076|NCT06360874|DRUG|MAD_ND003_Dose 2|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
224118077|NCT06360874|DRUG|MAD_placebo_Dose 2|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 2
224118078|NCT06360874|DRUG|MAD_ND003_Dose 3|Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
224118079|NCT06360874|DRUG|MAD_ placebo_Dose 3|Participants will orally administrated the placebo tablets matching to the MAD\_ND003\_Dose 3
224293669|NCT07212231|DIETARY_SUPPLEMENT|GI Product Placebo Control|Participants will use their GI Product Placebo Control as directed for a period of 6 weeks.
223726599|NCT01317030|DEVICE|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
223978603|NCT00357318|DRUG|sunitinib malate|Given PO
223978604|NCT00357318|BIOLOGICAL|bevacizumab|Given IV
223978605|NCT00357318|OTHER|pharmacological study|Correlative studies
223978606|NCT00357318|OTHER|laboratory biomarker analysis|Correlative studies
223978607|NCT03524950|DRUG|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
223978608|NCT04270656|PROCEDURE|Insulin pump therapy|5-day hospitalization in case of randomization in the insulin pump group (insulin pump establishing in according to the recommendations of the HAS)
223978609|NCT04270656|PROCEDURE|Multi-injection treatment ( MDI ).|Corresponds to an outpatient visit if the patient is randomized into the multi-injection group
223978610|NCT04547166|DRUG|HLX10|a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
223978611|NCT04547166|DRUG|HLX04、|7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
223978612|NCT00269841|DRUG|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
223978613|NCT00269841|DRUG|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
223978614|NCT00269841|DRUG|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
223978615|NCT01424189|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
223978616|NCT01424189|DEVICE|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
223978617|NCT06009445|DIAGNOSTIC_TEST|Renal resistive index|"The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity \_ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged."
223978618|NCT06197113|DEVICE|Magstim Rapid2 Magnetic Stimulator|For TMS, the Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK) device, available in our center, was used.
223978619|NCT05201170|DRUG|Vehicle Ophthalmic Solution|Ophthalmic Solution
223978620|NCT05201170|DRUG|PL9643 Ophthalmic Solution|Ophthalmic Solution
223978621|NCT05745181|BIOLOGICAL|CAR-T Cell Infusion|Peripheral blood mononuclear cells were isolated, amplified and cultured in vitro, pretreated with FC regimen, and Anti-CD1a CAR-T cells were transfused.
223978622|NCT01705145|DRUG|Ivacaftor|
223978623|NCT00221481|DRUG|divalproex or olanzapine|
223978624|NCT04682340|DIAGNOSTIC_TEST|Serum BPA|Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
223978625|NCT05253911|DRUG|TUKYSA®|tucatinib/trastuzumab/capecitabine according to TUKYSA® SmPC.
223978626|NCT03937232|BEHAVIORAL|Cross-Education|Home exercise program + usual care
223726600|NCT01317030|OTHER|Non-Contact Lens Wear|No intervention
223726601|NCT04525989|RADIATION|Radiation therapy|5 x 5 Gy external radiation therapy
223726602|NCT06130579|DRUG|IFN-Α|Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
223726603|NCT04204668|PROCEDURE|TMR|Surgical procedure to connect injured proximal nerve stumps to motor nerve branches directly innervating a muscle
223726604|NCT04204668|PROCEDURE|RPNI|Surgical procedure to wrap the ends of injured nerves in small muscle grafts
223978627|NCT03937232|BEHAVIORAL|Mirror Visual Feedback|Home exercise program + usual care
223978628|NCT03937232|OTHER|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
223978629|NCT03955861|BIOLOGICAL|adalimumab|Subcutaneous injection
223978630|NCT03955861|BIOLOGICAL|Certolizumab|Subcutaneous injection
223978631|NCT03955861|BIOLOGICAL|Etanercept|Subcutaneous injection
223978632|NCT03955861|BIOLOGICAL|Golimumab|Subcutaneous injection
224293670|NCT07212231|DIETARY_SUPPLEMENT|Active Product 1|Participants will use their GI Active Product 1 as directed for a period of 6 weeks.
223978633|NCT03955861|BIOLOGICAL|Secukinumab|Subcutaneous injection
223978634|NCT02480777|BIOLOGICAL|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
223978635|NCT04092959|BEHAVIORAL|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
224118080|NCT06360874|DRUG|Food effect_Cohort 1|Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
224118081|NCT06360874|DRUG|Food effect_Cohort 2|Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
223978636|NCT04092959|BEHAVIORAL|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
223978637|NCT04092959|BEHAVIORAL|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
223978638|NCT00069277|DRUG|E7389|
223978639|NCT00175370|DRUG|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
223978640|NCT02933307|DEVICE|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
223978641|NCT02933307|DEVICE|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
223978642|NCT02442245|DIETARY_SUPPLEMENT|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
223978643|NCT02442245|OTHER|Placebo: Microcrystalline Cellulose|
223978644|NCT02442245|OTHER|Control: No supplementation|
223978645|NCT00004758|DRUG|carbamazepine|
223978646|NCT00004758|DRUG|corticotropin|
223978647|NCT00004758|DRUG|nitrazepam|
223978648|NCT00004758|DRUG|pyridoxine|
223978649|NCT00004758|DRUG|valproic acid|
223978650|NCT00004758|PROCEDURE|Surgery|
223978651|NCT00051103|DRUG|Investigational Cancer Drug|
224118082|NCT04776356|DEVICE|QuickFix Small Staple (Arthrex)|The Arthrex QuickFix Small Staple enables the surgeon to perform a wedge osteotomy of the first phalanx (Akin). The device is made of stainless steel and designed with barbed leg tips. The staple sizes are 8 and 10 mm wide with a 1 mm diameter.
224118083|NCT02795351|DRUG|Sildenafil|Single oral administration of active or placebo one week apart
223978652|NCT00136175|DRUG|Paclitaxel|
223978653|NCT00136175|DRUG|Carboplatin|
224118084|NCT02795351|DRUG|Placebo|
224118085|NCT00423410|DRUG|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
224118086|NCT05721950|DRUG|Brigatinib|Brigatinib Tablets
224118087|NCT03616080|BEHAVIORAL|soccer play program|once a week for an hour of a soccer program for 8 weeks
223978654|NCT00136175|DRUG|Gemcitabine|
224118088|NCT02261870|DEVICE|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
224118089|NCT04143542|PROCEDURE|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
224118090|NCT06094296|DRUG|BMS-986315|Specified dose on specified days
224118091|NCT06094296|DRUG|Nivolumab|Specified dose on specified days
224118092|NCT06094296|DRUG|Pemetrexed|Specified dose on specified days
224118093|NCT06094296|DRUG|Cisplatin|Specified dose on specified days
224118094|NCT06094296|DRUG|Carboplatin|Specified dose on specified days
224118095|NCT06094296|DRUG|Paclitaxel|Specified dose on specified days
224118096|NCT04794699|DRUG|IDE397|IDE397 dosed orally
224118097|NCT04794699|DRUG|Docetaxel|Intravenous infusion
224118098|NCT04794699|DRUG|Paclitaxel|Intravenous infusion
223978655|NCT04801784|PROCEDURE|Increased net ultrafiltration with advanced hemodynamic monitoring|A net ultrafiltration rate of 100 ml/h or more will be applied during the first 72 hours of study participation. To insure the hemodynamic security of the intervention, it is associated with an advanced hemodynamic monitoring protocol which encompasses cardiac index, preload dependence assessment (using postural maneuvers), lactate levels and central venous pressure evaluation. The hemodynamic monitoring protocol allows the decrease or suspension of the neutral ultrafiltration rate in case of hemodynamic instability or of hemodynamic status considered at risk of worsening if net ultrafiltration rate is maintained.
223978656|NCT04801784|PROCEDURE|Zero or near-zero net ultrafiltration|The active control group aims to represent the present standard of care of net ultrafiltration management in the first 72 hours of study participation in patients with critical illness. This will be performed by setting the net ultrafiltration rate to 0 up to 25 ml/h.
223978657|NCT01006447|BEHAVIORAL|Instructor contact|
223978658|NCT01006447|BEHAVIORAL|Instructor contact|
223978659|NCT04373356|DEVICE|Resin Infiltration|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with a rubber dam and ICON will be applied following the manufacturer's instructions. After that, the rubber dam will be removed and 5% NaF Varnish will be applied.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
223978660|NCT04373356|DEVICE|Sodium Fluoride Varnish|"Patients will be instructed about enhancing their oral hygiene, and will be asked to brush their teeth twice a day with fluoride toothpaste, and use dental floss daily. In short, teeth will be isolated with cotton roll and 5% NaF varnish will be applied following the manufacturer's instructions.~Standardized digital bitewing radiograph will be taken at baseline and one year after treatment for caries lesion progression comparison."
224118099|NCT04794699|DRUG|Sacituzumab govitecan|Intravenous infusion
224118100|NCT06323356|DRUG|TAK-279|Specified drug on specified days.
224118101|NCT05280704|PROCEDURE|Volar digital block with lidocaine|Volar digital block with lidocaine
224118102|NCT05280704|PROCEDURE|Volar digital block with saline|Volar digital block with saline
224118103|NCT05280704|PROCEDURE|Dorsal digital block with lidocaine|Dorsal digital block with lidocaine
224118104|NCT05280704|PROCEDURE|Dorsal digital block with saline|Dorsal digital block with saline
223726605|NCT04204668|PROCEDURE|VDMT|Surgical procedure that creates a small muscle graft that is both denervated and vascularized, which will then receive the damaged nerve ending
223726606|NCT06423911|DRUG|olverembatinib|olverembatinib QOD
223726607|NCT06423911|DRUG|Bosutinib|Bosutnib QD
223978661|NCT06385314|OTHER|Collecting data with oral health related quality of life, dental anxiety and state anxiety|Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
223978662|NCT00801450|DRUG|Triamcinolone acetonide|4 mg
223978663|NCT00801450|DRUG|Triamcinolone acetonide|40 mg
224118105|NCT03439865|DRUG|Ivacaftor|150 mg tablet PO BID x 14 days
224118106|NCT03439865|DRUG|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
224118107|NCT03332667|RADIATION|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
224118108|NCT03332667|DRUG|Dinutuximab|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
224118109|NCT03332667|DRUG|Vorinostat|Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
224118110|NCT03332667|DRUG|Sargramostim|Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
224118111|NCT03332667|DRUG|Potassium Iodide|Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
224118112|NCT03508752|RADIATION|Stereotactic Radiosurgery|Stereotactic Radiosurgery dose is based on the largest tumor size
224118113|NCT05893537|DRUG|Active Comparator CT1812|123 participants will receive a single daily dose of CT1812 (200 mg)
224118114|NCT05893537|DRUG|Placebo Comparator|123 participants will receive a single daily dose of placebo
224118115|NCT05551351|DIAGNOSTIC_TEST|Cardiac CT with photon counting detector|Cardiac CT including the coronary arteries. The cardiac CT is performed in routine care for the included patients.
224118116|NCT04964063|OTHER|Potassium Nitrate + Sodium Fluoride|Potassium Nitrate 5% weight/weight (w/w) and Sodium Fluoride 0.15% weight/volume (w/v) fluoride ion.
223978664|NCT01172899|PROCEDURE|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
223978665|NCT01172899|BEHAVIORAL|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
223978666|NCT00361842|DRUG|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
223978667|NCT06585748|DRUG|Lidocaine spray|4 puffs of lidocaine spray was applied to the glans penis and urethral meatus, and after 5 minutes, the appropriate method and sterilization were used to apply a catheter gel, and a Foley catheter was placed in the bladder. After bladder catheterization, pain scores were evaluated by a neutral emergency medicine physician at 0 minutes (during the procedure), and at 15, 30, and 60 minutes post-procedure. The Face Legs Arms Cry Consolability Pain Scale (FLACC) and Wong-Baker pain scales were used for this evaluation.
224118117|NCT04160286|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
224118118|NCT06255977|DRUG|CN-105|Injection every 6 hours, up to a maximum of 13 doses within 72 hours.Each dose of CN-105 will be administered as a slow IV bolus over 30 minutes.
224118119|NCT04958564|DEVICE|DCP|"1. Dynamic compression plating to compress the fracture~2. Intramedullary device to share the load."
223726608|NCT06227910|DRUG|Vedolizumab|Vedolizumab IV infusion.
223726609|NCT06227910|DRUG|Upadacitinib|Upadacitinib over-encapsulated tablets.
223978668|NCT06585748|OTHER|Placebo|No medication/application will be administered as placebo.
224118120|NCT02310958|PROCEDURE|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
223726610|NCT06227910|DRUG|Placebo|Upadacitinib matched placebo capsules.
223726611|NCT05109442|DRUG|AFM24|intravenous infusion
223726612|NCT05109442|DRUG|Atezolizumab 840 MG in 14 ML Injection|intravenous infusion
223726613|NCT04853225|OTHER|Prospective observational cohort study|Prospective observational cohort study
223978669|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 10gM|"* 140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
223978670|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 20gM|"* 280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
224118121|NCT02771808|OTHER|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
224118122|NCT00003753|DRUG|dexamethasone|
224118123|NCT00003753|DRUG|floxuridine|
223726614|NCT04553523|DEVICE|Hydrus Microstent|Crescent-shaped nitinol device intended as a permanent implant to provide an outflow pathway for aqueous humor. The device is placed through the trabecular meshwork into Schlemm's canal immediately following placement of a monofocal IOL.
223726615|NCT04553523|PROCEDURE|Cataract surgery|Cataract surgery performed using standard anesthesia and phacoemulsification techniques
223978671|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 20gNoM|"* 280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
223978672|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement, 40gM|"* 560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
223978673|NCT00945698|DIETARY_SUPPLEMENT|Lipid-based Nutrient Supplement, 40gNoM|"* 560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
223978674|NCT00945698|DIETARY_SUPPLEMENT|Maize-soy flour|"* No food supplement during the primary trial period (6 to 18 months of age)~* 1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~* Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
224293671|NCT07212231|DIETARY_SUPPLEMENT|Active Product 2|Participants will use their GI Active Product 2 as directed for a period of 6 weeks.
223726616|NCT04553523|DEVICE|Monofocal IOL|Commercially available monofocal intraocular lens as determined by the investigator
223726617|NCT05659641|DEVICE|PerMed Stent Graft System In Surgical Operation|PerMed Branch Stent Graft
223978675|NCT05680285|DEVICE|diode lazer|diode laser was applied during the pulpotomy procedure
223978676|NCT05680285|DEVICE|low level diode laser|Low-dose diode laser was applied during the pulpotomy procedure
223978677|NCT06176378|OTHER|traditional pulpotomy|After complete deroofing, the coronal pulp was amputated to the level of the orifice using a high-speed size #2 round bur followed by rinsing the pulp chamber thoroughly with 5ml 0.9% saline solution.Hemostasis was then achieved by placing a sterile cotton pellet moistened with saline in the access cavity for 6 min.Retro MTA capping material was then applied,
223978678|NCT06176378|DEVICE|diode laser pulpotomy|after establishing hemostasis, low-level laser energy at (970nm, power .5W, duty cycle 50%, and frequency 5H) was applied to each pulp stump for 10 sec. through 320 microns optical fiber tip . The laser was used in pulsed non-contact mode at the level of the occlusal surface of the tooth.Retro MTA capping material was then applied,
223978679|NCT01077622|DRUG|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
223978680|NCT00424177|DRUG|eltrombopag|experimental
223978681|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
224293672|NCT07212231|DIETARY_SUPPLEMENT|Active Product 3|Participants will use their GI Active Product 3 as directed for a period of 6 weeks.
224293673|NCT07212231|DIETARY_SUPPLEMENT|Active Product 4|Participants will use their GI Active Product 4 as directed for a period of 6 weeks.
224293674|NCT07212231|DIETARY_SUPPLEMENT|Active Product 5|Participants will use their GI Active Product 5 as directed for a period of 6 weeks.
224293675|NCT07211984|DEVICE|Dalia Monitoring|All patients consulting psychiatrists and general practitioners in participating centers, meeting all eligibility criteria and agreeing to participate in the study, will be consecutively selected and randomized into one of the two groups. For iInterventional arm: Patients will benefit from Dalia telemonitoring, in addition to conventional care.
224293676|NCT07211984|OTHER|Conventional healthcare|All patients consulting psychiatrists and general practitioners in participating centers, meeting all eligibility criteria and agreeing to participate in the study, will be consecutively selected and randomized into one of the two groups. For Control arm: Patients in this group will benefit from the conventional care pathway.
224293677|NCT07213206|DRUG|CDK 4/6 inhibitor combined therapy (omit chemo)|CDK 4/6 inhibitor and endocrine therapy combined with Trastuzumab ( without chemotherapy)
224293678|NCT07213206|DRUG|standard of care|four cycles of docetaxel and cyclophosphamide or four cycles of weekly paclitaxel Combined with Trastuzumab followed by standard endocrine therapy( aromatase inhibitors or tamoxifen，Ovarian function suppression agents may be added if premenopausal)
224293679|NCT07212816|DEVICE|Sauti|Investigational, software-only device that acquires short voice samples during automated phone calls and analyzes cardiopulmonary signals to estimate heart rate (HR), heart-rate variability (HRV), and rhythm status (regular vs irregular). In this study, three calls are initiated via the Vital Audio web platform (pre-, post-cardioversion, and 1-month follow-up). Results are available only to study staff and are compared with ECG obtained at the same time points. The device is used for data collection/assessment only and does not guide clinical care. IDE: G230147.
224293680|NCT07211529|PROCEDURE|Paravertebral Block (PVB)|Participants in this arm will receive a paravertebral nerve block (PVB) performed intraoperatively under ultrasound guidance prior to the thoracic surgical procedure. The block will target the relevant thoracic vertebral levels corresponding to the surgical site. Standard local anesthetic agents will be administered according to institutional protocols. This intervention aims to provide perioperative analgesia, reduce postoperative pain, and potentially decrease the incidence of postoperative complications. All participants will also receive standard intraoperative monitoring and anesthesia management as per routine clinical practice.
224293681|NCT07213063|OTHER|Nutrition education|Participants and their families will also take part in nutrition education sessions to promote healthy eating and lifestyle habits.
224293682|NCT07212738|OTHER|Delayed mobilization (DeM)|Delayed mobilization (group 1): active therapy beginning ≥3 days from symptom onset.
223726618|NCT05659641|DEVICE|Endovastec CRONUS® Intraoperative stent system|CRONUS® Branch Stent Graft
223978682|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
223978683|NCT00778518|DRUG|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
223978684|NCT03614286|DIAGNOSTIC_TEST|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at -70°C until tested.
223978685|NCT04159805|DRUG|TAK-079|TAK-079 subcutaneous injection
223978686|NCT04159805|DRUG|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
223978687|NCT03328910|DEVICE|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
223978688|NCT01379261|PROCEDURE|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
223726619|NCT00005794|DRUG|perifosine|
223726620|NCT05073120|OTHER|Piqray Prescriber's/HCP guide for hyperglycemia|oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
223726621|NCT06071377|OTHER|Biologic Specimen Collection|Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
223726622|NCT05664737|BIOLOGICAL|Luspatercept|Specified dose on specified days
223726623|NCT05664737|DRUG|Placebo|Specified dose on specified days
223726624|NCT03918447|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
223726625|NCT03918447|DRUG|Placebo oral capsule|Capsule containing an inert placebo
223726626|NCT01405456|DRUG|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
223726627|NCT01405456|OTHER|placebo and lifestyle|placebo pill daily and lifestyle counseling
223726628|NCT06501833|OTHER|FIFA 11+ KIDS PROGRAM|The experimental group will perform eight weeks of FIFA 11+ kids program (3/week).
223726629|NCT06501833|OTHER|REGULAR TRAINING|The control group will be continuing their regular training
223726630|NCT01163045|PROCEDURE|thyroidectomy|total thyroidectomy and lobectomy
223726631|NCT00000350|PROCEDURE|radioactive substance|
223726632|NCT07001761|RADIATION|Ultrasound/ x rays|"* The MSK Ultrasound (US) will be performed using a General Electric LOGIQ P9 unit / Toshiba Applio 500 unit using a 7-13 MHz linear array transducer.~* Conventional Radio-graphic examination bi-plane weight-bearing semi-flexed (15) radiograms will be taken of the target knee; one in the posteroanterior view, and one in the lateral medial view"
223726633|NCT07001098|DRUG|Amino Acids|The participants receive a continuous infusion of a balanced mixture of amino acids (Trophamine) in a dose of 2g/kg/day (max 100g/day) starting at the time of cardiac surgery up to 3 days
223726634|NCT07001098|DRUG|Placebo|The participants receive a continuous infusion of a lactated ringers (placebo), equivalent volume to amino acids, starting at the time of cardiac surgery up to 3 days
223726635|NCT07000617|DRUG|DAPT regimen plus radiotherapy|Patients receive 6 cycles of DAPT regimen plus concurrent radiotherapy. The DAPT regimen is administered as follows: dexamethasone 10mg intravenously on days1-3, azacitidine 100mg subcutaneously on days 1-5, pegaspargase 2500IU/m2 intramuscularly on day 1, and tislelizumab 200mg intravenously on day 6, repeated every 21 days. Concurrent radiotherapy given to the tumor sites is started after 2 cycles of DAPT regimen. The specific doses and methods of radiotherapy are in accordance with the clinical guidelines for NK/T-cell lymphoma.
223978689|NCT05159778|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
223978690|NCT05159778|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
223978691|NCT00654615|DEVICE|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
224118124|NCT00003753|DRUG|irinotecan hydrochloride|
224118125|NCT00003753|PROCEDURE|adjuvant therapy|
224118126|NCT00003753|PROCEDURE|conventional surgery|
223978692|NCT00654615|PROCEDURE|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
223978693|NCT00115284|BEHAVIORAL|ABIM asthma practice improvement module|
224118127|NCT04316689|BIOLOGICAL|S-488210|S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
224118128|NCT04316689|BIOLOGICAL|S-488211|S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
223726636|NCT07001722|OTHER|TÜBSİS Web-based Psycho-education Programme|The theoretical infrastructure of the TÜBSİS Program, which consists of a total of 8 modules lasting 1 month, is supported by the integration of two different frameworks: Mindfulness Approach and HAPA Health Action Approach. While the progress process in the TÜBSİS Program was created with the HAPA Model, the module contents of it were created within the framework of the Mindfulness Approach. Each participant receives reminder emails during this asynchronous and distance learning process and can open each new module at least 3 days later. Participants in the intervention (as well as control group) were asked about sociodemographic and tobacco use characteristics at baseline. Health Action Process Approach (HAPA) Model Change Question Form, Warwick Edinburgh Mental Well-Being Scale, Fagerström Nicotine Dependence Test and Informed Consent Form were administered to the intervention group at the beginning, in the middle and at the end of the intervention study.
223726637|NCT07000799|BEHAVIORAL|CBT|The EMOTION Intervention is based on cognitive-behavioral therapy, which has been shown to be effective in both the treatment and prevention of anxiety and depression in children. The EMOTION intervention has been developed as a school-based program and consists of an intensive course lasting eight weeks, using a hybrid model with eight face-to-face group meetings at school and eight hours of digital sessions completed by the child at home. Additionally, it is desirable for parents to support their children; hence, guardians will be offered the opportunity to attend an informational meeting. They will also receive a brochure detailing how they can support and assist their child. A group leader manual and a workbook for the children have been developed (Martinsen et al., 2017).
223726638|NCT07002164|PROCEDURE|Immediate coronary angiography|Immediate coronary angiography ≤2 hours after randomization
223726639|NCT07002164|PROCEDURE|Delayed coronary angiography|Delayed coronary angiography after stabilization
223726640|NCT07000890|DIAGNOSTIC_TEST|Synovial Biopsy|Synovial tissue and blood samples will be collected and processed for bulk and scRNAseq; serum, plasma, DNA, RNA and PBMCs as per below flow chart. Biomarker exploratory analysis will be performed.
223726641|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days."
223726642|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days."
223726643|NCT07001501|DRUG|Azvudine tablets(FNC) and Itraconazole Capsules (ICZ)|"This study consisted of 3 cycles, each cycle was administered orally for 10 consecutive days, and the washout period between each cycle was 14 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 10 consecutive days; ICZ: 200 mg (2 capsules) each time, 1 time a day, orally, for 10 consecutive days; FNC 3 mg (1 tablet)+ICZ 200 mg (2 capsules) (taken at the same time), 1 time a day, orally, for 10 consecutive days."
223726644|NCT07132528|DRUG|SOX plus PD-1 inhibitor|SOX or XELOX plus PD-1 inhibitor
223726645|NCT07132528|DRUG|SOX Chemotherapy|SOX or XELOX
223978694|NCT02623686|OTHER|Aroma Therapy Massage and Inhalation Patch|
224118129|NCT02148458|OTHER|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
224118130|NCT02148458|OTHER|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
224118131|NCT01035606|BEHAVIORAL|training in goal-directed attention regulation|training in goal-directed attention regulation
224118132|NCT01035606|BEHAVIORAL|brain health education|brain health education workshops
224118133|NCT01035606|BEHAVIORAL|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
224118134|NCT02120651|PROCEDURE|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
224118135|NCT02120651|PROCEDURE|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
224118136|NCT06116461|DRUG|Nivolumab|Participants receive three reduced doses of 240 mg every four weeks
224118137|NCT03370081|DEVICE|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
224118138|NCT01809262|DRUG|single dose of 5 mcg|solution for inhalation
224118139|NCT01809262|DRUG|single dose of placebo|solution for inhalation
223978695|NCT00701506|DEVICE|Patterned Electrical Neuromuscular Stimulation|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* PENS for 20 minutes:~  * Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~ * Minimal twitch for 5 minutes.~ * Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~* Electrodes placed on quadriceps and hamstrings"
223978696|NCT00701506|DEVICE|Placebo PENS|"* 20-minute session, to each affected knee, 3 times per week for 12 weeks.~* Placebo PENS for 20 minutes:~* Electrodes placed on quadriceps and hamstrings."
223978697|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
223978698|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
223726646|NCT07132411|BEHAVIORAL|Patients in Talk With Me Baby Clinics|Parent-child participants in TWMB clinics will attend their regular WCC visits (scheduled per routine clinic processes) following the AAP Periodicity Schedule.
223726647|NCT07132411|BEHAVIORAL|Patients in Care-As-Usual Clinics|Parent-child participants in Care-As-Usual clinics will attend their regular WCC visits (scheduled per routine clinic processes) following the AAP Periodicity Schedule. Measures will be completed at five time points.
223726648|NCT03773692|BEHAVIORAL|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
223726649|NCT07021976|DRUG|HRS-1893 Tablets|HRS-1893 tablets.
223978699|NCT01502371|DRUG|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
223978700|NCT01502371|DRUG|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
223726650|NCT07021976|DRUG|HRS-1893 Placebo Tablets|HRS-1893 placebo tablets.
223726651|NCT04315909|DRUG|PRP-Fibrin Glue|Platelet-Rich Plasma-Fibrin Glue
223726652|NCT04315909|DIETARY_SUPPLEMENT|Vitamin E and C|Vitamin E and vitamin C
223726653|NCT04315909|OTHER|Placebo|Placebo
223726654|NCT07031219|OTHER|provider order set/order panel|Triple testing order panels will be built specifically for this study. An order for a screening blood test for any of the three bloodborne viruses (BBVs; i.e. HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)) will be coupled with orders for the respective screening blood tests for the other two BBVs to be selected by default in a single order panel. These order panels will only be available to participating providers during their participation in the intervention arm.
223726655|NCT06880263|DEVICE|use 360 degree VR training|Participants will use Virtual Reality (VR) training
223726656|NCT07030673|DRUG|antibiotic withdrawal|stop antibiotics on viral or negative results
223726657|NCT07030673|DRUG|Antibiotics|"standard of care~Antibiotics are :~Amoxicilline-acide clavulanique : 1g x3/j, 7j or Ceftriaxone : 1g/j, 7j or Pipéracilline-Tazobactam : 4g x3/j, 7j or Pristinamycine : 1g x 3/j, 7j"
223978701|NCT01502371|DRUG|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
223978702|NCT01502371|DRUG|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
224118140|NCT01809262|DRUG|single dose of 40 mcg|solution for inhalation
224118141|NCT01809262|DRUG|single dose of 20 mcg|solution for inhalation
224118142|NCT01809262|DRUG|single dose of 2 mcg|solution for inhalation
224118143|NCT01809262|DRUG|single dose of 10 mcg|solution for inhalation
223726658|NCT07133035|DIAGNOSTIC_TEST|Pulmonary function test|Participants' respiratory functions will be assessed in different positions with the Cosmed Pony Fx Digital Spirometer (11). Forced vital capacity (FVC), forced expiratory volume in one second (FEV1), the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC), and peak expiratory flow rate (PEF) will be determined during the pulmonary function test.
223726659|NCT07133035|DIAGNOSTIC_TEST|Fonseca Anamnestic Index|The questionnaire consists of 10 questions covering headaches, neck pain, temporomandibular joint pain, pain during chewing, parafunctional habits, malocclusion, and stress, and is scored as 10 (yes), 5 (sometimes), and 0 (no). The total score ranges from 0 to 100. A higher total score indicates an increased risk of temporomandibular joint problems.
224118144|NCT03802422|DRUG|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
224118145|NCT03802422|DRUG|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
224118146|NCT00779727|PROCEDURE|Placement of drainages|
223978703|NCT02552693|OTHER|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
223978704|NCT02154347|DRUG|KAD-1229|
223978705|NCT02154347|DRUG|Placebo|
223978706|NCT02154347|DRUG|Insulin|
223978707|NCT04643496|PROCEDURE|Laparoscopic or open Ileocolic resection|Laparoscopic or open Ileocolic resection
223978708|NCT01568021|OTHER|No Intervention|No intervention was administered in this study.
223978709|NCT02473913|DRUG|Milk Thistle|
223978710|NCT02473913|DRUG|Placebo|
223978711|NCT04160000|DEVICE|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
223978712|NCT04160000|DRUG|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
224118147|NCT06041672|BEHAVIORAL|Warm Water Hand Baths|"1. Patients in the experimental group receive warm water hand baths as an intervention on the evening before surgery.~2. The intervention is carried out in the patient's room, room temperature was adjusted to 26°C and the timing is determined based on the patient's preference.~3. The study utilizes a foldable water bucket with temperature maintenance capability.Patients in the experimental group have their hand immersed in warm water (40°C) for ten minutes in a comfortable lying position."
224118148|NCT00906022|DEVICE|Astron Pulsar Stent|Stenting with Astron Pulsar
224118149|NCT00906022|DEVICE|PTA alone|Balloon angioplasty alone
224118150|NCT02629523|DRUG|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
224118151|NCT01518608|DRUG|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
224118152|NCT02610556|DRUG|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
224118153|NCT02610556|DRUG|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
224118154|NCT02610556|DRUG|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
224118155|NCT02610556|RADIATION|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
224118156|NCT06101394|DRUG|Cetuximab-IRDye800|Infusion of the study drug will be performed 2-5 days before the surgery: the patients will receive 100 mg of cetuximab intravenously over 30 minutes and a dose 50 mg of cetuximab-IRDye800 over 30 minutes to 1 hour.
224118157|NCT02013024|OTHER|cryopreservation technique|
224118158|NCT03695523|BEHAVIORAL|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
224118159|NCT00331786|DRUG|nitric oxide-releasing acetylsalicylic acid derivative|
224118160|NCT00331786|OTHER|laboratory biomarker analysis|
224118161|NCT00331786|PROCEDURE|biopsy|
223726660|NCT07133035|OTHER|Jenkins Sleep Scale|The Jennkis Sleep Scale consists of four questions that assess sleep problems over a 4-week period. Each question is scored from 0 to 5. The total score ranges from 0 to 20 and indicates increasing sleep disturbance.
223978713|NCT04160000|DEVICE|Insertion of CardioMems Hemodynamic monitor|Insertion of wireless hemodynamic monitor to provide hemodynamic data to guide heart failure therapy to achieve heart failure improvement.
223978714|NCT04160000|DRUG|Empiric heart failure drug therapy|Administration of heart failure drug therapy based on clinical evaluation to achieve heart failure improvement.
223978715|NCT01789229|OTHER|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
223978716|NCT01789229|OTHER|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
224118162|NCT02942095|DRUG|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
224118163|NCT02942095|DRUG|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
224118164|NCT02021500|DRUG|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
224118165|NCT02432001|PROCEDURE|Image-Guided Biopsies|
224118166|NCT04419064|DIAGNOSTIC_TEST|Point of care ultrasound|Tracheal and lung ultrasonography
224118167|NCT02404155|DRUG|Clozapine|
224118168|NCT01815892|DRUG|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
224118169|NCT01815892|DRUG|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
224118170|NCT02064439|DRUG|BAY 59-7939|10 mg tablet once daily for 12 months
224118171|NCT02064439|DRUG|BAY 59-7939|20 mg tablet once daily for 12 months
224118172|NCT02064439|DRUG|ASA|100 mg tablet once daily for 12 months
224118173|NCT02433288|OTHER|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
223726661|NCT07133035|OTHER|Berlin Questionnaire|Berlin Questionnaire: The Berlin Questionnaire is a three-part assessment tool that assesses individuals' predisposition to sleep apnea. The first part contains five questions investigating snoring, the second part contains four questions investigating daytime sleepiness, and the third part contains two questions investigating hypertension and obesity. Each section is evaluated independently. Individuals who score 2 or higher in the first and second sections, and those who score 1 in the third section, are considered predisposed to sleep apnea. If two or more categories are positive, the participant is considered high risk for obstructive sleep apnea. If the participant scores two or more in the first and second categories, they are considered high risk. If blood pressure is high or BMI is above 30 kg/m2, the participant is considered high risk.
223726662|NCT07133035|OTHER|Headache Impact Test-6|"Headache Impact Test-6: The Headache Impact Test-6 (HIT-6) is administered to identify activities individuals are unable to perform due to headaches and to determine the extent to which headaches impact daily life. This six-question questionnaire includes columns with increasing scores, from never to always. Participants are asked to mark the box closest to their response. A high total score indicates that headaches negatively impact daily life."
223726663|NCT07033364|OTHER|Functional liver imaging using hepatobiliary scintigraphy (HEBIS)|The Hepatobiliary scintigraphy (HEBIS) or HIDA scan is a nuclear imaging technique that uses \[99mTc\]Tc-mebrofenin, a iminodiacetic acid (IDA) agent, which is a lidocaine analogue that is taken up by hepatocytes and is eliminated in the biliary tract (Arntz, 2023). This functional liver scan quantitatively assesses liver function of which the potential will be tested to measure liver function before and after radiotherapy.
223726664|NCT06925984|RADIATION|SBRT|SBRT of all oligoprogressive metastases (or other local therapy if SBRT not advisable), followed by continuation of the same systemic therapy.
223978717|NCT01789229|OTHER|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
223978718|NCT01789229|OTHER|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
223978719|NCT01789229|OTHER|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
223978720|NCT01789229|OTHER|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
223978721|NCT01789229|OTHER|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
223978722|NCT01772381|DRUG|Dexamethasone|Long acting corticosteroid
223978723|NCT02177435|DRUG|Telmisartan|
223978724|NCT02177435|DRUG|Telmisartan/Hydrochlorothiazide|
223978725|NCT02177435|DRUG|Placebo|
223978726|NCT04145089|DEVICE|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
223978727|NCT03614351|DIETARY_SUPPLEMENT|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
223978728|NCT03614351|OTHER|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
223978729|NCT05051683|PROCEDURE|combined endoscopic & radiologic intervention for management of acute perforated peptic ulcer|endoscopic management using stent , clipping and sewing combined with radiologic interventional drainage was used. For duodenal ulcer only metallic stent was used due to narrow space while for gastric ulcer either stent , clipping and sewing were used due to capacious space.
223978730|NCT05116865|BIOLOGICAL|HH-120 Dose 1|Dose level 1 of HH-120
223978731|NCT05116865|BIOLOGICAL|HH-120 Dose 2|Dose level 2 of HH-120
223978732|NCT05116865|BIOLOGICAL|HH-120 Dose 3|Dose level 3 of HH-120
223978733|NCT05116865|DRUG|Placebo|Placebo to match
223978734|NCT04531852|OTHER|CALSTI - Complex Active Lifestyle Intervention|"A group-based exercise (EX) and health empowerment program (HEP) conducted in the local area.~Structured, progressive resistance (55-60%), balance (10-15%), endurance (10-15%) exercise was delivered twice weekly for 12 weeks under supervision of a trained instructor.~HEP consists of 8 group sessions aiming to facilitate long-term behaviour change, by empowering older citizens to act on current risk behaviours (i.e. low physical activity/exercise, high sedentary behaviour, social isolation, poor dietary habits, incontinence). Four sessions were conducted during the exercise intervention period (phase 1 - intensive), and four sessions in the following 12 weeks (phase 2 - maintenance)."
223978735|NCT04531852|BEHAVIORAL|SEMAI - Self-Management Intervention|A low-cost enhancement of the existing preventive service where citizens are information about relevant health resources. Citizens allocated to SEMAI intervention are offered the health-empowerment program as outlined above, including four extra sessions dedicated to practical experiences with exercising. 24 weeks duration in total, with eight sessions in phase 1 and four sessions in phase 2
223978736|NCT06291597|OTHER|Vaping|Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.
223978737|NCT00871455|DRUG|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
223978738|NCT00038961|DRUG|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
223978739|NCT00038961|OTHER|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
223978740|NCT01399502|BEHAVIORAL|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
223978741|NCT06283563|OTHER|Physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
224118174|NCT02433288|OTHER|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
224118175|NCT03350750|DEVICE|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
224118176|NCT06018584|OTHER|Tooth extraction|Tooth extractions were performed by a single physician. Topical anesthesia (Xylo-caine, Astra, Södertalje, Switzerland) was applied to the dried mucosa in the area to be lo-calized with the help of an ear stick for 1 minute. Posterior-superior-alveolar nerve block anesthesia and palatal anesthesia were applied for the upper primary molars; Inferi-or-alveolar nerve block anesthesia and lingual anesthesia (Ultracain, Aventis Pharma, Is-tanbul, Turkey) were applied for the lower primary molars. After anesthesia control was achieved, a randomly selected tooth was extracted. Tooth extraction on the other side was performed two weeks later. During the shootings, attention was paid to the traumatic ap-proach. After the control of bleeding was achieved, data were recorded for each group.
224118177|NCT05858294|BEHAVIORAL|Cognitive Behavioral Therapy programme|This mobile application comprised CBT-based therapy for social anxiety based on the Clark and Wells model
224118178|NCT04314167|DRUG|Lowering cholesterol concentrations by PCSK-9 inhibitor|Patients will receive the PCSK9-inhibitor Evolocumab as part of routine clinical management within the indication of this drug.
224118179|NCT02615535|DEVICE|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
223726665|NCT06840444|BEHAVIORAL|Firefly Mobile App: A Digital Health Solution for Healthy Sleep in Teens|A six week cognitive behavioral therapy for insomnia program delivered via a mobile app.
223726666|NCT06820476|DRUG|NNC0487-0111|Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
223978742|NCT06283563|OTHER|No physical activity tracking|At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
223978743|NCT00035061|DRUG|pemetrexed|
223978744|NCT02094547|DIETARY_SUPPLEMENT|New infant formula|New infant formula
224118180|NCT02615535|DEVICE|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
224118181|NCT00985855|DRUG|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
223726667|NCT06820476|DRUG|Placebo (NNC0487-0111)|Participants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.
223978745|NCT02094547|DIETARY_SUPPLEMENT|Standard infant formula|Standard infant formula
223978746|NCT02094547|DIETARY_SUPPLEMENT|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
223978747|NCT04939324|BIOLOGICAL|Blood samples at 2 sites: peripheral vein and tumor-draining vein|"D0: surgery (inclusion): oncological lung resection~* Blood samples at 2 sites: peripheral vein and tumor-draining vein~* Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)"
224118182|NCT00985855|DRUG|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
224118183|NCT01073956|PROCEDURE|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
224118184|NCT01073956|PROCEDURE|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
224118185|NCT01073956|PROCEDURE|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
223726668|NCT06858150|DIAGNOSTIC_TEST|Ultrasound-Guided Needle Depth and Angle Measurement|This study utilizes ultrasound imaging to measure the needle insertion depth at Jianzhongshu (SI15) and an electronic goniometer to assess insertion angles. The aim is to collect anatomical reference data for acupuncture needling precision, focusing on the relationship between SI15 and the insertion point of the levator scapulae muscle. This is an observational study designed to collect anatomical reference data for acupuncture needling, without evaluating therapeutic effects.
223726669|NCT07133243|OTHER|testicular ultrasound|each patient will receive an testicular ultrasound to confirm diagnostic of testicular torsion
223978748|NCT06538519|PROCEDURE|total hip replacement using lateral approach|In the lateral approach partial detachment of the anterior one-third of the gluteus medius muscle.
223978749|NCT06538519|PROCEDURE|total hip replacement using anterior approach|the anterior approach using an internervous plane between the tensor fascia latae and the sartorius muscle.
223978750|NCT06538519|DEVICE|gait analysis at 6wks, 3 months and 18 months|gait analysis done in the gait lab at the mentioned postoperative periods
223978751|NCT00938132|DRUG|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
223978752|NCT05399082|DEVICE|Cryoprobe biopsy|A 1.1mm disposable cryoprobe that is passed through the working channel of the Ion Robotic bronchoscope to collect biopsy tissue
223978753|NCT05399082|PROCEDURE|Forceps biopsy|Biopsy forceps used to collect tissue
224118186|NCT05428748|OTHER|1 serving of test product|Participants will consume 1 serving/day of the test product for 28 days
224118187|NCT05428748|OTHER|2 servings of test product|Participants will consume 2 servings/day of the test product for 28 days
224118188|NCT05428748|OTHER|3 servings of test product|Participants will consume 3 servings/day of the test product for 28 days
224118189|NCT05428748|OTHER|Placebo|Participants will consume 1 serving/day of the placebo for 28 days
224118190|NCT00002452|DRUG|L-756423|
224118191|NCT00002452|DRUG|Indinavir sulfate|
224118192|NCT01834144|OTHER|Exercise Training|
224118193|NCT01120093|DRUG|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
224118194|NCT01120093|DRUG|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
223726670|NCT02633644|DEVICE|Harmony System|Percutaneous neuromodulation of the aortic wall
223726671|NCT04827550|OTHER|STUDY|Fibromyalgia Patient
224118195|NCT01120093|DRUG|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
224118196|NCT01120093|DRUG|Placebo|Placebo via inhalation in the morning and evening for 7 days
223726672|NCT03494309|PROCEDURE|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
223726673|NCT03494309|PROCEDURE|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars \& guided elastics
223726674|NCT03108833|DRUG|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
223978754|NCT03188809|PROCEDURE|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
223978755|NCT03188809|PROCEDURE|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
223978756|NCT05795309|DEVICE|Hybrid Automated Insulin Delivery|Consists of an insulin pump and real-time continuous glucose monitoring (CGM)
223978757|NCT05773209|DEVICE|RLRL device|Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
223978758|NCT01190449|BIOLOGICAL|ofatumumab|Given IV
223978759|NCT04186884|OTHER|Quality-of-Life Assessment|Ancillary studies
223978760|NCT04186884|OTHER|Questionnaire Administration|Complete questionnaires
224118197|NCT01120093|DRUG|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
224118198|NCT01880268|DEVICE|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
223978761|NCT03216941|DRUG|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
223978762|NCT05187000|DEVICE|individualized repetitive transcranial magnetic stimulation|During the rTMS-active stage, treatment will be given for 10 consecutive sessions (one session daily). The participants will be placed in the semi-reclining position on either a normal chair or a wheelchair and each stimulation session will last 20 minutes with a frequency of 10 Hz (train duration: 1s; inter-train interval: 5s; 200 effective stimulation series; 2000 pulses at 90% of RMT).
223978763|NCT05187000|DEVICE|Sham repetitive transcranial magnetic stimulation|The sham coil will be used which has no magnetic field to send to the cerebral cortex while appearing to be the same shape as the active coil, with good approximation of auditory feedback.
223978764|NCT00601133|OTHER|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
223978765|NCT00601133|OTHER|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
223978766|NCT00601133|BEHAVIORAL|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
224118199|NCT01880268|BEHAVIORAL|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
224118200|NCT01849250|DRUG|Docosahexaenoic Acid|Given PO
223978767|NCT00601133|BEHAVIORAL|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
223978768|NCT02209688|DRUG|ESR 1150 CL|
223978769|NCT02209688|DRUG|Placebo|
223978770|NCT03282799|DRUG|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
223978771|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic extension exercises|"Thoracic Extension Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic spine extension and trunk muscle flexibility. A specialized program of thoracic extension in sitting, in prone lying, in quadruped position, on foam roller, wall angle stretch, corner stretch + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks.~Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week."
224118201|NCT01849250|OTHER|Placebo|Given PO
223543762|NCT00835458|PROCEDURE|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
224118202|NCT00003636|DRUG|carboplatin|
224118203|NCT00003636|DRUG|cisplatin|
224118204|NCT00003636|PROCEDURE|conventional surgery|
224118205|NCT00003636|PROCEDURE|neoadjuvant therapy|
224118206|NCT04116814|DIAGNOSTIC_TEST|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
224118207|NCT02631135|DRUG|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
224118208|NCT02631135|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation
224118209|NCT02631135|DRUG|Dexmedetomidine|0.5 microgram/kg infusion, no changes
224118210|NCT02631135|DRUG|Rocuronium|0.5 mg/kg iv for intubation, no changes
224118211|NCT05288634|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
224118212|NCT02772354|PROCEDURE|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
224118213|NCT02772354|DRUG|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
223978772|NCT05395078|OTHER|Conventional physical therapy treatment along with thoracic stabilization exercises|Thoracic Stabilization Exercises (2 sets of 10 reps each/day). This exercise program will target thoracic musculature, static and dynamic thoracic posture. A specialized program of Draw- in and chin tucks in crook lying, prone, sitting and standing, prone chin- tuck elevation exercises with arm at sides, arms behind head or overhead (4) + hot pack (10 min) + Trapezius and Levator Scapulae stretching + Myofascial Release + Thoracic spinal mobilization (3 sets of 3 reps each/day). A total of 45 minutes session three times a week on alternate days for 3 weeks. Assessment will be done at baseline, on the end of 3rd week and for long term effects at the end of 6th week.
223978773|NCT00637325|DRUG|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
223726675|NCT03108833|DRUG|Alteplase|The drug is used for intravenous thrombolysis therapy
223726676|NCT03909295|DRUG|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
223726677|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
223726678|NCT04672447|DIETARY_SUPPLEMENT|L-Citrulline|Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
223726679|NCT04672447|DIETARY_SUPPLEMENT|Placebo|Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
223726680|NCT04672447|DIETARY_SUPPLEMENT|Glutathione|Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.
223726681|NCT01640145|DIETARY_SUPPLEMENT|Protein|Whey protein intake
223726682|NCT01640145|OTHER|Exercise|Unilateral low intensity exercise
224118214|NCT02772354|DRUG|Verapamil|Verapamil 20-240 mg
224118215|NCT02772354|DEVICE|NAVI-STAR® RMT ThermoCool|
224118216|NCT03306134|DIAGNOSTIC_TEST|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire \[4\]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
224118217|NCT00851734|DRUG|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
224118218|NCT02529761|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
224118219|NCT02529761|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
224118220|NCT03174821|DEVICE|Insulin pump|Blood glucose management device
224118221|NCT06641323|OTHER|Ozonized gel|Administration of Ozonized Gel GeliO3
224118222|NCT06641323|DEVICE|Ozonized water|Admininstration of Gaseous ozone (Healozone X4)
224118223|NCT05581589|PROCEDURE|Lymphadenectomy|Undergo pelvic lymph node dissection
224118224|NCT05581589|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
224118225|NCT05581589|BIOLOGICAL|Sacituzumab Govitecan|Given IV
224118226|NCT02731391|PROCEDURE|Pelvic floor reconstruction（with or without mesh）|
224118227|NCT02541838|OTHER|Muscle power|
224118228|NCT02541838|OTHER|balance perturbation|
224118229|NCT02541838|OTHER|aerobic exercise|
224118230|NCT00828087|DRUG|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
224118231|NCT00828087|DEVICE|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
223978774|NCT02127983|BEHAVIORAL|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
223978775|NCT02127983|BEHAVIORAL|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
223978776|NCT02585141|DEVICE|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
223978777|NCT02585141|PROCEDURE|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
223978778|NCT02585141|DRUG|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
223978779|NCT04438369|PROCEDURE|Erector Spinae Plane Block|Cathether based Erector Spinae Plane Block for postoperative pain management.
223978780|NCT03972397|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
223978781|NCT03972397|DRUG|Bupivacaine liposomal injectable suspension|Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
223978782|NCT03972397|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
223978783|NCT01649037|DRUG|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h."
223978784|NCT01649037|DRUG|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
223978785|NCT00788047|DRUG|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
223978786|NCT00788047|DRUG|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
223978787|NCT04633785|OTHER|No Intervention|There are no interventions in this study. The mercury sphygmomanometer and the wrist sphygmomanometer will be used in this study to collect blood pressure values from the study subjects.
223978788|NCT06355037|DRUG|Quercetin|quercetin 1000mg d1-d3, qw
223726683|NCT03147365|BEHAVIORAL|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
223978789|NCT06355037|DRUG|Dasatinib|Dasatinib 50mg d1-d3, qw
223978790|NCT06355037|DRUG|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum|Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
223978791|NCT05335668|PROCEDURE|Clinical Testing|Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
223978792|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
224118232|NCT02688842|DEVICE|Rapamycin target-eluting coronary stent systems (38mm)|
224118233|NCT02812433|DRUG|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
224118234|NCT02812433|DRUG|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
223978793|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
223978794|NCT00731588|BIOLOGICAL|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
223978795|NCT06632834|DRUG|simvastatin therapy|Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
224118235|NCT03982771|DRUG|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
224118236|NCT03982771|DRUG|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
224118237|NCT03982771|DRUG|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
224118238|NCT03252496|PROCEDURE|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
224118239|NCT03252496|DRUG|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
224293683|NCT07212738|OTHER|Standard Care (in control arm)|"Standard care (group 2): allied health assessment by 48 hours post-stroke followed by initiation of therapy at routine intensity (approximately 20 minutes/day of occupational and 20 minutes/day of physiotherapy). Therapy will depend on the level of disability of the participant, but will include working on standing, stepping, walking, balancing, self-care (i.e., grooming, dressing), functional task training (i.e., self-feeding), and addressing any cognitive and/or perceptive deficits.~Active therapy will be conducted by the Foothills Medical Centre stroke unit (Calgary, AB, Canada) certified physiotherapists and occupational therapists. The allied health team will not be blinded to the randomization of participants."
224293684|NCT07213245|OTHER|Meal high in energy density, high in ultra-processed food|Meal high in energy density, high in ultra-processed food
224293685|NCT07213245|OTHER|Meal high in energy density, low in ultra-processed food|Meal high in energy density, low in ultra-processed food
224293686|NCT07213245|OTHER|Meal low in energy density, high in ultra-processed food|Meal low in energy density, high in ultra-processed food
224293687|NCT07213245|OTHER|Meal low in energy density, low in ultra-processed food|Meal low in energy density, low in ultra-processed food
224293688|NCT07211568|DRUG|Pancreatic Enzyme Replacement Therapy|Enteric coated pancreatic enzyme preparation
224293689|NCT07211568|DRUG|Placebo|Similar appearing glucose capsules
224293690|NCT07211373|DEVICE|Jaspr|With assistance from a research staff, the subject will complete self-administered suicide risk assessment on the tablet via Jaspr app, then the subject will engage with suicide-related coping skills and resources that the app provides. Subjects will continue to have access to the coping skills and videos via a mobile app.
224293691|NCT07211373|BEHAVIORAL|Behavioral support|"Jaspr conversations will be augmented human-driven behavioral support. Conversations will be guided by motivational interviewing principles. Subjects can sign up to receive JAH mobile app.~Subjects will be prompted with their personalized goals as reminders to use the Jaspr app."
224293692|NCT07213323|DIETARY_SUPPLEMENT|Probiotics (Natural product)|"Participants will be instructed to daily take, during 26 weeks (that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment) one capsule of a probiotic with water at room temperature with the first meal.~Dosage levels: 1 capsule Digestive Quality of life during the study will be assessed."
224118240|NCT03252496|DRUG|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
224118241|NCT03252496|PROCEDURE|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
224118242|NCT03252496|RADIATION|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
224118243|NCT03252496|DRUG|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
224118244|NCT03252496|DRUG|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
224118245|NCT03252496|DRUG|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
224118246|NCT03252496|DRUG|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
224118247|NCT03252496|DRUG|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
224118248|NCT03252496|DRUG|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
224293693|NCT07213323|OTHER|Placebo|"Participants will be instructed to daily take, during 26 weeks (that will begin 2 weeks before the initiation of semaglutide or tirzepatide treatment) one capsule of PLACEBO with water at room temperature with the first meal.~Digestive Quality of life during the study will be assessed."
224293694|NCT07213440|PROCEDURE|lumbar puncture|After information and consent by the investigator, clinical data will be collected using a CRF and biological samples (Blood sampling, Urine sample, cephalo spinal fluid), lacrimal fluid sampling, and a smell test will be taken from all subjects at baseline and at 12 months.
224293695|NCT07212491|OTHER|Non-Interventional Study|Non-interventional study
223978796|NCT06332391|DEVICE|Exercise-similar cardiac pacing|Cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
223978797|NCT06332391|DEVICE|Sham cardiac pacing|Simulated (rates selected using programmer but not initiated) cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
223978798|NCT00420147|DEVICE|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
223978799|NCT00420147|DEVICE|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
223978800|NCT00610805|OTHER|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
224293696|NCT07213401|DEVICE|ComfTech HOWDY BABY|The Comftech HOWDYBABY medical device is a device for monitoring vital physiological parameters, in particular for monitoring heart rate and respiratory rate, consisting of a sensor-equipped belt. Blood oxygen saturation can also be monitored using a compatible accessory.
224293697|NCT07212088|BIOLOGICAL|ALC01 therapy|Bilateral implantation
223978801|NCT00610805|OTHER|Usual Care|Participants will receive usual care per their primary care physician.
223978802|NCT00771238|DEVICE|P500 Mattress|Study mattress
223978803|NCT02007759|DEVICE|VitalStim|This group will receive active VitalStim treatment.
223978804|NCT02007759|DEVICE|Sham VitalStim|This group will receive a sham VitalStim intervention.
223978805|NCT01601717|DRUG|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
223978806|NCT01601717|DRUG|Placebo|Matching placebo pill administered once per day for 10 days.
223978807|NCT00005058|PROCEDURE|ultrasound imaging|
223978808|NCT03754764|BIOLOGICAL|Specificity CD38 CAR-T Cells|1\) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
223978809|NCT01531907|OTHER|Study visit procedures|"Anthropometric measurements to include:~* Weight, height, and BMI.~* Waist and hip circumference~* Triceps skinfold thickness~* Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
223978810|NCT06014970|BEHAVIORAL|Health and Wellness Curriculum|The curriculum includes instructions, activities, and lessons on mindfulness, neurobiology, meditation, positive thinking, movement, and nutrition.
223978811|NCT06107049|DIETARY_SUPPLEMENT|BLa80|During the experiment, the subjects took a packet of probiotics every day, and the sleep condition, anxiety level and memory level of the subjects were evaluated by questionnaires and ability tests. The questionnaire included PSQI Pittsburgh Sleep Quality Index scale, ISI Insomnia Severity Index Scale and GSRS gastrointestinal symptom Score scale.
223978812|NCT00945113|BEHAVIORAL|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
223978813|NCT04185038|BIOLOGICAL|SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel|Autologous CD4+ and CD8+ T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
223978814|NCT03717077|PROCEDURE|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
223978815|NCT04596176|OTHER|Program Supportive Housing Services|The existing statewide SH model that included routine access to housing (voucher) and case management
223978816|NCT04596176|OTHER|Intensive Supportive Housing Services|an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
223978817|NCT02210208|DEVICE|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
223978818|NCT02210208|DEVICE|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
223978819|NCT00004478|DRUG|droxidopa|
223978820|NCT01171183|DRUG|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
223978821|NCT01171183|DRUG|Placebo|Placebo
223978822|NCT01718431|OTHER|test meal|
223978823|NCT01718431|OTHER|reference meal|
223978824|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets bonded using smile arc protection bonding strategy|female patients with mild crowding will recieve orthodontic brackets bonding using smile arc protection bonding strategy
223978825|NCT05277506|DEVICE|18 inch slot MBT orthodontic brackets boned using MBT placement guide|female patients with mild crowding will recieve orthodontic brackets bonding using MBT placement guide bonding strategy
223978826|NCT03840356|OTHER|Postoperative|No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
223978827|NCT01726049|DRUG|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
223978828|NCT01726049|DRUG|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
223978829|NCT04410939|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction|PCR test is performed from the oropharyngeal and nasal swab samples taken before admission to each pregnant to prevent contamination from the pregnant women hospitalized in this clinic. In addition, the same test is done before each operation and before the operation. The aim of the study is to scan these tests retrospectively and to determine the rate of positive COVID-19 cases in asymptomatic pregnant women. The results will determine the importance of the measures to be taken in the pregnant and undergoing pregnant women.
223978830|NCT04502043|OTHER|Exercise therapy|"* Education~* Hip-specific strengthening exercises~* Functional lower limb strengthening exercises~* Core stability exercises~* Postural balance exercises"
223978831|NCT03371121|OTHER|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
223978832|NCT03416569|DRUG|Placebo|placebo skin patch + placebo capsule
223978833|NCT03416569|DRUG|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
223978834|NCT03416569|DRUG|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
223978835|NCT03416569|DRUG|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
223978836|NCT01811498|DRUG|Bevacizumab|
223978837|NCT05885269|DRUG|Group A applied topical Clobetasol Propionate|Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months
223978838|NCT05885269|DRUG|Group B applied topical Tacrolimus|Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.
223978839|NCT02531399|DEVICE|FDOCT|Measurement of retinal blood velocities
223726684|NCT03147365|BEHAVIORAL|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
224118249|NCT03252496|DRUG|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
223726685|NCT00001008|DRUG|Methadone hydrochloride|
223726686|NCT00001008|DRUG|Zidovudine|
223726687|NCT00845689|DRUG|placebo|NaCl 0,9 %
223726688|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0, 2 %
223726689|NCT00845689|DRUG|adenosine|intravenous infusion of adenosine 0,2 %
223978840|NCT02531399|DEVICE|LDV|Measurement of retinal blood velocities
223978841|NCT02531399|DEVICE|DVA|Measurement of retinal vessel diameters
223978842|NCT02531399|DEVICE|LSFG|Imaging of retinal blood flow
223978843|NCT05955677|DRUG|[68Ga]Ga-PSMA-D5|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-D5, and undergo PET/CT imaging within the specificed time.
223978844|NCT05955677|DRUG|[68Ga]Ga-PSMA-11|Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
223978845|NCT00349570|DEVICE|Xtract Aspiration Catheter|
223978846|NCT00817245|DRUG|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
223978847|NCT02135822|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
223978848|NCT02135822|DRUG|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
223978849|NCT03602248|OTHER|Speed endurance training protocol A|1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)
223978850|NCT03602248|OTHER|Speed endurance training protocol B|1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
223978851|NCT04334668|DIETARY_SUPPLEMENT|Oral Sodium Chloride|Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days
223978852|NCT04334668|OTHER|Placebo|Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.
223978853|NCT02416713|DEVICE|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
223978854|NCT02416713|OTHER|Education Only|No active intervention, educational materials will be provided
223978855|NCT05787145|BEHAVIORAL|Let's Discuss Health Group|Use of the Let's Discuss Health website to prepare four medical encounters with the radiation oncologist throughout the radiation care trajectory.
223978856|NCT04317534|DRUG|Pembrolizumab|Pembrolizumab 400mg IV
223978857|NCT00207402|DRUG|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
223978858|NCT04853498|DRUG|TQB3720|This is an androgen receptor antagonists.
223978859|NCT00034853|DRUG|meloxicam oral suspension|
223978860|NCT00034853|DRUG|naproxen oral suspension|
223978861|NCT04470843|DRUG|Acetazolamide|Being that adequate pain control is essential to recovery in the post-operative setting, efforts have been made to address this pain at its root. Prior studies have demonstrated that preoperative administration of acetazolamide decreased post-operative referred pain in the immediate post-surgical period.
223978862|NCT04470843|OTHER|Placebo|Group 2 (placebo): Patients undergoing RALP with the peri-operative use of 10 mL normal saline as placebo.
224118250|NCT01063751|DEVICE|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
224118251|NCT05083780|DRUG|Chlorphenesin Carbamate, Hydroxychloroquine|In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
224118252|NCT05895279|OTHER|Media Intervention|Watch MiCaP Research Digest video
223978863|NCT04156399|OTHER|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
223726690|NCT00845689|PROCEDURE|Liver resection|Liver resection with Pringle maneuver
223978864|NCT03440047|DEVICE|Fuji Flim Processor VP-7000, Light Source BL-7000|Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
223978865|NCT01181609|DRUG|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
223978866|NCT03953456|DRUG|elafibranor 120mg|elafibranor 120mg is a coated tablet for oral administration, once daily
223978867|NCT03953456|DRUG|Placebo|Placebo is a coated tablet for oral administration, once daily
223978868|NCT01722045|DRUG|Intravitreal Aflibercept Injection (IAI)|
223978869|NCT05720377|DEVICE|continuous glucose monitor (Freestyle Libre|15 minute phone interview by health care provider to assess health goals set at clinic visits.
224118253|NCT05895279|OTHER|Media Intervention|Watch alternate video
224118254|NCT05895279|OTHER|Survey Administration|Complete survey
224118255|NCT02998892|BEHAVIORAL|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 6 weeks. This intervention corresponds to the current recommendations.
224118256|NCT02998892|BEHAVIORAL|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 9 hours, 5 days/week, by brisk walking for 6 weeks.
224293698|NCT07212543|OTHER|Routine anesthesia care (desflurane at different low-flow rates: 0.5, 1.0, 1.5 L/min); no intervention assigned as part of the study.|Routine anesthesia care (desflurane at different low-flow rates: 0.5, 1.0, 1.5 L/min); no intervention assigned as part of the study.
223726691|NCT00221728|DEVICE|Radiofrequency|
223726692|NCT00221728|PROCEDURE|conservative surgery|
223726693|NCT06144489|DIETARY_SUPPLEMENT|Tart Cherry|Tart cherry supplementation in two doses
223726694|NCT06144489|DIETARY_SUPPLEMENT|Placebo|Control group
223726695|NCT01728701|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
223978870|NCT05158283|DEVICE|chocolate balloon|chocolate balloon dilatation
223978871|NCT05158283|DEVICE|plain balloon|plain balloon dilatation
223978872|NCT04332432|DRUG|belapectin|intravenous
223978873|NCT04813497|DIAGNOSTIC_TEST|Serology to determine SARS-CoV-2 infection|Each participant accept to have two blood tests on a dry tube of maximum 8 ml of whole blood
223978874|NCT03080818|DIETARY_SUPPLEMENT|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
223978875|NCT03080818|OTHER|Placebo|2 placebo capsules per day for 90 days
224293699|NCT07211607|DRUG|selonabant|Intravenous infusion of selonabant
223726696|NCT01728701|BIOLOGICAL|Normal Saline (NS)|Normal saline
223726697|NCT03848650|DEVICE|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
223978876|NCT06103643|OTHER|Using High Reality Simulator|Using High Reality Simulator will perform emergency breech birth.
223978877|NCT01339299|DRUG|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
224118257|NCT04018014|OTHER|CT angiography|CT angiography in detection of pulmonary embolism
224293700|NCT07211607|DRUG|placebo|Placebo infusion which looks the same as the selonabant infusion
223978878|NCT01339299|DRUG|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
223978879|NCT02471456|OTHER|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
223978880|NCT02471456|OTHER|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
223978881|NCT02267265|OTHER|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
223978882|NCT02267265|OTHER|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
223978883|NCT00002492|DRUG|cisplatin|
223978884|NCT00002492|DRUG|doxorubicin hydrochloride|
223726698|NCT03848650|PROCEDURE|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
223726699|NCT00075179|DRUG|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
223978885|NCT00002492|DRUG|isolated limb perfusion|
223978886|NCT00002492|PROCEDURE|conventional surgery|
223978887|NCT00002492|RADIATION|brachytherapy|
223978888|NCT00002492|RADIATION|radiation therapy|
223726700|NCT00075179|PROCEDURE|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
223726701|NCT04202692|DEVICE|Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
223726702|NCT04202692|DEVICE|Placebo 1100 mg, identically-looking melt in mouth tablet|1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
223726703|NCT02942394|DEVICE|sinus-Obliquus Stent System|
223726704|NCT05859789|PROCEDURE|kegel exercise|"* Each female will be asked to Try to squeeze her pelvic floor muscles as much as possible. She was instructed that the numbers she saw at the top of screen indicated the activity of the muscle (electrical activity), in microvolt (mv).~* The therapeutic session will be repeated 3 sessions /week for 12 weeks for each female in both groups (A\&B).~* Each female will be instructed to Tighten her pelvic floor muscles. Hold tight and count 3 to 5 seconds, relax the muscles and count 3 to 5 seconds, then repeat 10 times, 3 times a day at least three sets of 10 to 15 repetitions a day as a home program~* They will be instructed not to use abdomen, thighs or buttock muscles during the contraction, avoid holding breath. Instead, breathe freely during the exercises."
223978889|NCT05649189|DIAGNOSTIC_TEST|telomere length measure|length of telomere between two groups
223978890|NCT04256369|COMBINATION_PRODUCT|Parenteral Nutrition (PN) Premixed Olimel N9E|Parenteral nutrition
223978891|NCT02697838|DRUG|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
223978892|NCT02697838|DRUG|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~1. The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~2. The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~3. Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~4. other paclitaxel-based regimens"
223978893|NCT02594046|OTHER|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
223978894|NCT00384865|DRUG|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
223978895|NCT00384865|DRUG|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
223978896|NCT00384865|DRUG|Placebo|Placebo, taken orally, once a day for 6 months
223978897|NCT02607202|DRUG|nab-paclitaxel|
223978898|NCT02607202|DRUG|Carboplatin|
223978899|NCT02607202|DRUG|Gemcitabine|
223978900|NCT00327353|DRUG|formoterol (TURBOHALER)|
223978901|NCT00327353|DRUG|Salmeterol (DISKUS)|
224122743|NCT07007195|DEVICE|Inspire Device|The Inspire Device is a novel olfactory stimulation delivery system. It is a self-contained system with seven sealed chambers, with six gel matrix's that contain a distinct odor and one odorless gel matrix. Participants will press a button on the device to release an odor for participants to smell.
224122744|NCT06622005|DRUG|Cxcr1/2 Inhibitor SX-682|Given PO
223726705|NCT05859789|OTHER|Mediterranean diet regimen for 12 weeks.|kegel ex in addition to mediterrian diet . The recommended composition of the dietary regimen was the following: carbohydrates 50-60%, proteins 15-20%, total fat o30%, saturated fat 10% and less than 300 mg of cholesterol consumed per day. Moreover, subjects Will be advised to consume at least 250-300 g of fruits, 125-150 g of vegetables and 25-50 g of nuts per day.
223978902|NCT02727257|PROCEDURE|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
223978903|NCT02582398|OTHER|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
223978904|NCT02582398|OTHER|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
223978905|NCT01095159|DEVICE|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
223978906|NCT01095159|DEVICE|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
223978907|NCT00485550|DRUG|Atomoxetine Hydrochloride|
223978908|NCT00485550|DRUG|Methylphenidate Hydrochloride|
223978909|NCT00485550|DRUG|Placebo|
223978910|NCT00006145|DRUG|Valganciclovir|
223978911|NCT02854371|DRUG|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
223978912|NCT02854371|DRUG|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
223978913|NCT06018688|DRUG|Osimertinib|Osimertinib is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
223978914|NCT06018688|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation.
223978915|NCT03089736|BEHAVIORAL|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
223978916|NCT03089736|BEHAVIORAL|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
223726706|NCT00260494|OTHER|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
223978917|NCT03089736|OTHER|Treatment as usual (TAU)|pharmacological treatment + advices
223978918|NCT00607178|BIOLOGICAL|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
223978919|NCT00607178|BIOLOGICAL|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
223978920|NCT02077205|BEHAVIORAL|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
223978921|NCT00482898|DRUG|MK0359|
223726707|NCT00260494|OTHER|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
223978922|NCT01572298|DEVICE|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
223978923|NCT01572298|DEVICE|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
223978924|NCT01935596|DRUG|ropivacaïne|spinal anesthesia.
223978925|NCT01935596|DRUG|lévobupivacaïne|
223726708|NCT01705184|DRUG|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
223978926|NCT04467346|DRUG|Ped-TMZ|Ped-TMZ will be administered using the provided dosing oral syringes and followed by a glass of 240 ml of water (for mouth rinsing) in sitting position and under fasting condition for at least 8 hours before dosing
223978927|NCT05280743|DRUG|Oxycodone|exposure to opioids after Cesarean Section
223978928|NCT06302595|DEVICE|MRI-guided prostate biopsy using the needle holder frame.|A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.
223978929|NCT04333732|DRUG|MR or M-M-R II ® vaccine|Education and surveillance plus MR or M-M-R II ® vaccine
223978930|NCT04333732|DRUG|Placebo|Placebo injection
223978931|NCT03893006|DEVICE|Level of vehicle automation|From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
223978932|NCT00816647|PROCEDURE|Patellofemoral stabilizing surgery|Comparison of surgical techniques
223978933|NCT06547385|DRUG|ONO-4578|Specified dose on specified days
223726709|NCT01705184|DRUG|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
223726710|NCT01705184|DRUG|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
223726711|NCT02670954|DRUG|Dexmedetomidine, tramadol and flurbiprofen|
223726712|NCT02670954|DRUG|tramadol and flurbiprofen|
223726713|NCT01720992|OTHER|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
223978934|NCT06547385|DRUG|ONO-4538|Specified dose on specified days
224118258|NCT01600131|BEHAVIORAL|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
223726714|NCT01832376|PROCEDURE|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
223726715|NCT05340608|OTHER|Smart, non-invasive shirt - Physiological parameters|Observation Group One and Control Group - Participants in these groups will be asked to wear a smart, non-invasive shirt while watching two different five-minute videos. One video will show relaxing images and will emit relaxing music (relaxing video). The second video will present impressive human body deformities accompanied by anxious music (disturbing video). Both videos will be presented with the participant in a sitting position. The duration of the entire session will be approximately 15 minutes. For the whole duration of the session, the smart shirt will collect data on participants' physiological parameters (electrocardiogram, heart rate, heart rate variability, respiration rate, minute ventilation, and body movement). Collected data will be used to develop an ad-hoc algorithm to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
223978935|NCT06547385|DRUG|Capecitabine|Specified dose on specified days
223978936|NCT06547385|DRUG|Oxaliplatin|Specified dose on specified days
223978937|NCT06547385|DRUG|Fluorouracil|Specified dose on specified days
223978938|NCT06547385|DRUG|Calcium Levofolinate Hydrateb|Specified dose on specified days
223978939|NCT06547385|DRUG|Bevacizumab|Specified dose on specified days
223978940|NCT03923686|PROCEDURE|EUS-guided drainage using LAMS with DPS|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
223978941|NCT03923686|PROCEDURE|EUS-guided drainage using LAMS alone|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
223978942|NCT05328310|DRUG|Nebivolol|Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
223978943|NCT02459405|PROCEDURE|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
223978944|NCT02459405|DEVICE|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
223978945|NCT04634955|PROCEDURE|tranforaminal epidural injection|tranforaminal epidural injection which is performed by fluoroscopic guidance
223978946|NCT01937195|DEVICE|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
224118259|NCT01600131|OTHER|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
223726716|NCT05340608|OTHER|Smart, non-invasive shirt - Relation with challenging behaviors|Observation Group Two - Each participant in this group will be asked to wear the smart, non-invasive shirt for seven consecutive days during waking hours, performing his usual daily activities. During the same seven days, the caregivers who care for the participant will be asked to accurately report the participant's status in a behavioral diary. Each evening, the data collected by the smart shirt will be uploaded to an online cloud along with the behavioral diary of the day. Collected data will be used to develop an ad-hoc algorithm able to anticipate the challenging behavior of participants with autism spectrum disorder based on physiological data collected by the smart shirt.
223726717|NCT05340608|OTHER|Smart, non-invasive shirt - Proof of Concept|Proof of Concept - The participant with autism spectrum disorder enrolled in the proof-of-concept phase of this study will wear the smart, non-invasive shirt for seven days during all hours of attendance at the special school. At the end of the seven days, the healthcare professional and teacher who interacted with the developed system at the special school will participate in a focus group to analyze their experiences and opinions related to the system use.
223726718|NCT03445572|OTHER|Best Practice|Receive standard supportive care
223978947|NCT05354713|DRUG|NVP-1805|NVP-1805 (80/10/20.8mg)
223978948|NCT05354713|DRUG|NVP-1805-R1 and NVP-1805-R2|coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)
223978949|NCT05594004|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
223978950|NCT05594004|DEVICE|Sonic electric toothbrush|Sonic electric toothbrush used twice daily
223978951|NCT05594004|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
223978952|NCT01097499|DEVICE|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
223978953|NCT03834623|DRUG|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
223978954|NCT03834623|DRUG|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
223726719|NCT03445572|PROCEDURE|Meditation Therapy|Perform MSB
223978955|NCT05316909|OTHER|Breastfeeding Simulation|In Period 1, one group will begin a simulated session with the NORALSim and the second group will begin with either the Mother's Own Milk Lactessa or Laerdal NeoNatalie, depending on the study date. Baseline level of breastfeeding experience and clinical lactation skills self-efficacy will be collected. Nursing students will teach a mock patient wearing the LSM and holding a newborn simulator how to position and attach the newborn at the breast and identify effective breastfeeding by differentiating between suckling patterns. In Period 2, each group will crossover to complete the same session with a different newborn simulator. After Period 1, each group will debrief to discuss their performance and engagement and use a Qualtrics survey (6-point Likert scale) to rate satisfaction, engagement, simulator fidelity, and self-efficacy. The same quantitative and qualitative data collection protocol will follow Period 2.
223978956|NCT00867178|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
223978957|NCT00867178|DRUG|Carboplatin|Given IV
223978958|NCT00867178|DRUG|Cisplatin|Given IV
223978959|NCT00867178|DRUG|Cyclophosphamide|Given IV
223726720|NCT03445572|PROCEDURE|Meditation Therapy|Perform IK meditation
223978960|NCT00867178|DRUG|Etoposide Phosphate|Given IV
223978961|NCT00867178|DRUG|Isotretinoin|Given PO
223978962|NCT00867178|OTHER|Laboratory Biomarker Analysis|Correlative studies
223978963|NCT00867178|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
223978964|NCT00867178|DRUG|Thiotepa|Given IV
223978965|NCT00867178|DRUG|Vincristine Sulfate|Given IV
223978966|NCT00867178|DRUG|Vorinostat|Given PO
223978967|NCT02813083|OTHER|No intervention (observational)|No intervention (observational)
223978968|NCT01338974|GENETIC|gene expression analysis|
223978969|NCT01338974|GENETIC|proteomic profiling|
223978970|NCT01338974|OTHER|flow cytometry|
223978971|NCT01338974|OTHER|laboratory biomarker analysis|
223978972|NCT00384605|DRUG|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
223978973|NCT00384605|DRUG|placebo|Placebo capsule once daily. Treatment for 52 weeks.
223978974|NCT06424730|OTHER|Feasibility Interview|One audio-recorded interview with the participants lasting about 30-minutes
223978975|NCT06424730|BEHAVIORAL|Team Based Equity Conscious Telemedicine Hypertension Intervention|Will provide blood pressure monitor connected to a telehealth application. Patients will be asked to measure home blood pressure once daily. Will intensify medications as needed based on blood pressure measurement. Trained nurses or pharmacists will provide 4 self-management telephone calls (up to 30 minutes per call) to patients to address hypertension knowledge, medication adherence, healthy eating, physical activity, weight management, stress management, tobacco and alcohol use, and sleep apnea (with referrals if needed). Will support needs relevant in blood pressure control using locally available resources via community health worker and social workers.
223978976|NCT06424730|BEHAVIORAL|Usual Care|Usual clinic based hypertension care using routinely available clinic services including community health worker/social worker. Clinicians can offer self-management support (e.g., dietician referral) or recommend a home blood pressure monitor. These activities mirror current primary care practice.
223978977|NCT06787482|DIETARY_SUPPLEMENT|ACE Retino|1 ml sublingually self administer / 4 times/day for 6 months
223726721|NCT03445572|OTHER|Questionnaire Administration|Ancillary studies
223978978|NCT06956404|DEVICE|Transcranial photobiomodulator (tPBM)|The tPBM-2.0 device consists of a therapeutic laser console (that produces laser energy as NIR), and an optical delivery system consisting of a flexible, double-sheathed optical fiber connected to a custom helmet (cap). tPBM will be administered via continuous, 808 nm wavelength laser delivery to the forehead at the standard scalp location \~12 minutes per day, 3 days per week, for 6 weeks (18 total sessions).
223978979|NCT06956404|DEVICE|Transcranial photobiomodulator (tPBM) in sham mode|The tPBM-2.0 device consists of a therapeutic laser console (which will be in sham mode, which does not produce laser energy), and an optical delivery system consisting of a flexible, double-sheathed optical fiber connected to a custom helmet (cap).
223978980|NCT06957132|DEVICE|Audiogram|"Either the patient can be proposed to perform the audiogram during their long-term consultation, or they will be contacted by the physician to come especially for the project and realize the audiogram.~iAudiogram is an Artificial Intelligence (AI) - automated audiometry platform (https://iaudiogram.com/), certified CE (European conformity).~This examination will be performed once within the study."
223978981|NCT06956885|DRUG|Discontibuation of oral ULT|Patients will stop the ULT at D0. They will have an US scan to look for urate deposits at each visit.
223978982|NCT06956885|DRUG|Maintenance of ULT|Patients will continue their ULT according to the recommendations of the Eular and French Society of Rheumatology, to maintain their SUA levels below 60 mg/l.
224118260|NCT04772365|DRUG|SHR-1819|SHR-1819 will be subcutaneously administered with different dose levels;
224118261|NCT04772365|DRUG|Placebo|Placebo will be subcutaneously administered with different dose levels;
224122745|NCT06622005|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
224122746|NCT06622005|DRUG|Carfilzomib|Given IV
223726722|NCT04980690|BIOLOGICAL|IBC0966|IBC0966 is an investigational product.
223978983|NCT06956820|DEVICE|Medication Management Center|The MMC that provides patient centred information on drug-drug interactions and pharmaco-genetics affecting personal polytherapy. The MMC will show a selection of high quality publicly available information such as details on different types of medications, including their uses, side effects and instructions for use, in the language of the patient. This information is targeted at an individual patient's medication profile to inform patients to better understand and deal with their personal health information, with regard to drug therapy. Patients in the Netherlands, Slovenia and Greece also will receive their PGx profile to further personalise the MMC experience.
224118262|NCT02961647|PROCEDURE|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
223543763|NCT02102958|BEHAVIORAL|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
223978984|NCT03479125|DIAGNOSTIC_TEST|Ultrasound|Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
223543764|NCT02102958|BEHAVIORAL|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
223543765|NCT01882335|BEHAVIORAL|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
223978985|NCT03447275|OTHER|Type 2 diabetes|Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
223978986|NCT04363619|DIAGNOSTIC_TEST|OCT and OCTA|Fundoscopy, OCT and OCTA will be performed 4 times in patients
223978987|NCT04865055|OTHER|cyclic merocyanine|long-UVA absorber
224118263|NCT02519244|DEVICE|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
223543766|NCT00848458|OTHER|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
223543767|NCT00848458|OTHER|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
223543768|NCT01435174|DRUG|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
223543769|NCT01435174|PROCEDURE|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
223978988|NCT04865055|OTHER|placebo|placebo
223978989|NCT03238807|DRUG|Human Chorionic Gonadotropin|500 IU of human Chorionic Gonadotropin
223978990|NCT04827589|DRUG|Tirabrutinib|Tablets administered orally
223978991|NCT04827589|DRUG|Placebo|Tablets administered orally
223978992|NCT05397366|DIAGNOSTIC_TEST|Task Specific Training|"Group A will be given Task Specific protocol with routine physical therapy treatment for 45 mins on the upper limb for 3 days a week for a period of 12 weeks.~This Task Specific protocol will include different exercises like, do the polishing of the table top , can perform arm cradling, can supinate and pronate the cylindrical object with arm , while pushing the cylindrical object can extend the wrist , can reach forward to touch or to pick an object , can bend side ways to pick the object and place it on the table in front , can pour the 1/2cup of water to the wide jar that is held by the patient in other hand , patient can comb his hair , patient can drink and eat independently , can lift the jar and bring it close to lips , can pick up pen by using thumb and two fingers , can do the stacking checkers , can throw a ball into the basket , can push the ball on wall from front and side."
224118264|NCT03534258|DEVICE|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
224118265|NCT02713581|BIOLOGICAL|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
224118266|NCT00406315|DRUG|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
224118267|NCT01312428|DEVICE|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
224118268|NCT01312428|DEVICE|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
224122747|NCT06622005|DRUG|Dexamethasone|Given PO
224122748|NCT06622005|PROCEDURE|Biospecimen Collection|Undergo Blood sample collection
223978993|NCT05397366|DIAGNOSTIC_TEST|Neurodevelopmental Training|"Group B will receive the Neurodevelopmental protocol with the routine physical therapy for 45 mins on the upper limb 3 times a week for period of 12 weeks. The intervention will be performed by the trained physical therapist.~This Neurodevelopmental protocol will include different exercises like , patient should sit while bearing weight , patient can do self-overhead movements with hand clasped , while holding the gymnastic ball reach forward and overhead position while sitting , weight bearing while plantigrade or quadruped position , while sitting or standing can move the ball in forward , backward and sideways."
223978994|NCT03046368|BEHAVIORAL|Targeted cover letter|The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
223978995|NCT00478647|BIOLOGICAL|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
223978996|NCT01741389|DRUG|"Melatonin (Circadin)"|
223726723|NCT06122129|PROCEDURE|Flexible ureteroscope with ureteral access sheath|The flexible ureteroscope either directly or via an access sheath, depending on the size of the ureter, a 9.5/11.5 Fr or a 12 Fr access sheath will be used.
223978997|NCT04378647|DRUG|Induction with Brentuximab vedotin (BV)|3 cycles ESHAP plus antibody-drug conjugate brentuximab vedotin (BV) at a dose of 1.8 mg/kg IV
223978998|NCT04378647|DRUG|Induction without Brentuximab Vedotin|3 cycles of ESHAP as a standard of care therapy for those patients with primary refractory cHL and those patients relapsing after first-line therapy
223978999|NCT04378647|DRUG|Consolidation with Brentuximab Vedotin|Up to 13 or 16 cycles of antibody-drug conjugate brentuximab vedotin (BV) at doses of 1.8 mg/kg iv every 21 days)
223543770|NCT01435174|PROCEDURE|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
223543771|NCT00114725|PROCEDURE|Laser-assisted intracytoplasmic sperm injection|
223979000|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract|207 mg curcumin
223543772|NCT01482195|BIOLOGICAL|Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.
223543773|NCT00083980|DRUG|Venlafaxine ER|75 to 225 mg daily
223979001|NCT03530436|DIETARY_SUPPLEMENT|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
223979002|NCT03530436|DIETARY_SUPPLEMENT|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
223979003|NCT03530436|DIETARY_SUPPLEMENT|Cyclodextrin complex of curcuminoids|207 mg curcumin
223979004|NCT03530436|DIETARY_SUPPLEMENT|Turmeric oleoresin|207 mg curcumin
223979005|NCT03530436|DIETARY_SUPPLEMENT|Liposomal curcumin|207 mg curcumin
223979006|NCT03530436|DIETARY_SUPPLEMENT|Phytosomal curcumin|207 mg curcumin
223979007|NCT03530436|DIETARY_SUPPLEMENT|Micellar turmeric extract|207 mg curcumin
223979008|NCT01489917|OTHER|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
223979009|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
223979010|NCT03448705|BIOLOGICAL|4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
224118269|NCT04191278|DRUG|Varenicline|All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
223543774|NCT00083980|DRUG|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
223726724|NCT06122129|PROCEDURE|Flexible ureteroscope without ureteral access sheath|Ureteroscopy will be carried out without a ureteral access sheath
223726725|NCT00844051|BIOLOGICAL|School-based influenza vaccination program|School-based influenza vaccination program
223726726|NCT00462774|PROCEDURE|Intramyocardial injection of autologous CD133+ marrow cells|
223726727|NCT03736317|DEVICE|sham TBS|Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
223726728|NCT03736317|DEVICE|real mPFC cTBS|Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
223726729|NCT03736317|DEVICE|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
223726730|NCT03736317|DEVICE|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
223979011|NCT03448705|BIOLOGICAL|3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
223979012|NCT01522703|DRUG|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
223543775|NCT00083980|DRUG|Kava|140 to 280 mg per day
223979013|NCT01522703|DRUG|Placebo|Alfalfa Sprouts
223979014|NCT05758987|BEHAVIORAL|Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)|A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.
223979015|NCT05758987|BEHAVIORAL|Prolonged exposure|A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.
223979016|NCT02525081|DRUG|Ramipril (ACE-inhibitor)|up to 10 mg
223979017|NCT02525081|DRUG|placebo|up to 10 mg
223979018|NCT06956261|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
223979019|NCT06956261|DRUG|Drug: NW-301D|TCR-T T cell targeting KRAS G12D mutation
223979020|NCT06957093|OTHER|artificial intelligence|The platform will also monitor the medical and lifestyle data of the patients every two weeks,offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform.
223979021|NCT06957093|OTHER|Routine diagnosis and treatment group for diabetes|There is no limit to the number of outpatient visits for the control group; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team (endocrinologist and nutritionist) objectively conducttheir diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level.
223979022|NCT03176901|BEHAVIORAL|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
224118270|NCT04191278|DEVICE|Mobile phone application|Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.
223979023|NCT03176901|BEHAVIORAL|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
223979024|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (apical position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position
223979025|NCT05140681|PROCEDURE|FibReORS with apically positioned flap (crestal position)|Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
223979026|NCT00511836|DRUG|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
223979027|NCT00511836|DRUG|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
223979028|NCT01540604|DRUG|CRD007|
223979029|NCT03003598|OTHER|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
223979030|NCT03003598|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
224118271|NCT04191278|BEHAVIORAL|Contingency management|Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
223979031|NCT05500781|BEHAVIORAL|Coaching HER|The CoachingHER coach education program is a six-module online program aimed at upskilling coaches in \[the effectiveness, feasibility, and acceptability of the Coaching HER; the first online program aimed at reducing gender stereotypes for coaches\]. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
223979032|NCT00721812|DRUG|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
223979033|NCT05650541|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
223979034|NCT01936324|DRUG|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
223979035|NCT01936324|OTHER|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
223979036|NCT01755546|DRUG|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
223979037|NCT05359055|DRUG|SPH3127 tablet|100mg once daily on Day 1 and Day 8
223979038|NCT05359055|DRUG|Itraconazole|200mg once daily from Day 3 to Day10.
223979039|NCT05359055|DRUG|SPH3127 tablet|200mg once daily on Day 1 and Day 12.
223979040|NCT05359055|DRUG|Rifampin|600mg once daily from Day 3 to Day13.
223979041|NCT05611541|BEHAVIORAL|Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group|The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.
223979042|NCT05611541|BEHAVIORAL|The group who received diet therapy and practiced their daily activities.|The group who received diet therapy and practiced their daily activities.
223979043|NCT04127071|PROCEDURE|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
224118272|NCT03143582|OTHER|Running|A 13-week running program where youth run for 30 minutes twice weekly.
224118273|NCT05508776|DRUG|LEO 152020|"Film-coated tablet~Route of administration: Orally~50 mg tablets"
223979044|NCT04127071|PROCEDURE|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
223979045|NCT04820647|BEHAVIORAL|KF-STRIDE|KF Stride works to improve identification (awareness) of personal character strengths and 2) express them in a socially appropriate way during a job interview
223979046|NCT02187367|BIOLOGICAL|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
223979047|NCT04957329|DRUG|Xalatan|Eye drop
223979048|NCT04957329|DRUG|Monoprost|Eye drop
223979049|NCT00362375|BEHAVIORAL|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
223979050|NCT00362375|BEHAVIORAL|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
223979051|NCT00884559|OTHER|instruction|Debriefing
223979052|NCT01674517|DRUG|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
223979053|NCT06469567|OTHER|Patient Counselling|Doctor's counselling using Culturally-responsive pamphlet
223979054|NCT04984239|BEHAVIORAL|Acceptance and Commitment Therapy for aphasia|The intervention will consist of Acceptance and Commitment Therapy modified to meet the needs of stroke survivors with aphasia, combined with communication strategy training.
224118274|NCT05508776|DRUG|Moxifloxacin|"Tablet (may be film-coated depending on brand)~Route of administration: Orally~400 mg tablet"
224118275|NCT05508776|DRUG|Placebo|"Film-coated tablet~Route of administration: Orally~No active ingredient"
224118276|NCT01262261|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
224118277|NCT02512263|PROCEDURE|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
224118278|NCT05921006|DRUG|RJ4287|Oral，tablets，Once daily for 14 days
224118279|NCT05921006|DRUG|Placebo|Oral，tablets，Once daily daily for 14 days
223979055|NCT03166046|DEVICE|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
223979056|NCT03166046|DEVICE|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
223979057|NCT05142930|OTHER|Intermittent ultrasound|Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region
223979058|NCT05142930|OTHER|Continuous ultrasound|Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region
223979059|NCT02083601|BEHAVIORAL|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
223979060|NCT02083601|BEHAVIORAL|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
224118280|NCT04075201|BIOLOGICAL|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd.
223979061|NCT00460018|BEHAVIORAL|Diet, Exercise, and Breastfeeding Intervention|"Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)"
224118281|NCT04075201|BIOLOGICAL|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
224118282|NCT04075201|BIOLOGICAL|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research \& Development Co., Ltd. on the schedule of month 0,1,2
224118283|NCT04075201|BIOLOGICAL|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
224118284|NCT03421002|DRUG|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
224118285|NCT04912570|PROCEDURE|Manual Thrombus Aspiration|Manual thrombus aspiration using one of the FDA approved aspirators will be done.
223543776|NCT06227533|PROCEDURE|Endodontic regeneration using concentrated growth factor compared with Platelet rich fibrin|regeneration of mature necrotic teeth with periapical abscess using concentrated growth factor compared with Platelet rich fibrin to allow healing of periapical lesion and regaining sensibility
223543777|NCT04144738|DIAGNOSTIC_TEST|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
224118286|NCT04912570|PROCEDURE|Standard PCI|Standard PCI according to the most recent guidelines
224118287|NCT00539630|DRUG|Docetaxel|
224118288|NCT00151762|DRUG|Colesevelam hydrochloride|
224118289|NCT00397228|DRUG|ALTROPANE®|ALTROPANE® SPECT imaging
224122749|NCT06622005|PROCEDURE|Bone Marrow Aspiration|Undergo Bone Marrow Aspiration
224122750|NCT06622005|PROCEDURE|Echocardiography|Undergo ECHO
224122751|NCT06622005|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224122752|NCT06622005|PROCEDURE|Computed Tomography|Undergo PET/CT
224122753|NCT06622005|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224122754|NCT07008677|OTHER|online questionaire|The online questionnaire includes demographic data: age, gender, instrument, professional background, and oral health behavior
223979062|NCT06956716|BIOLOGICAL|individualized anti-tumor new antigen iNeo-Vac-R01 injection|The individualized anti-tumor new antigen iNeo-Vac-R01 injection was commissioned by Hangzhou Nuanjin Biotechnology Co., Ltd., and all patients were admitted into the therapeutic intervention group. According to the results of previous non-clinical studies, the individualized mRNA injection of 100 μ g was a tolerable dose.
223979063|NCT06956716|DRUG|Gemcitabine + cisplatin (GP)|As standard chemotherapy (D1, D8 gemcitabine 1000mg/m², intravenous drip for 30 minutes, cisplatin 25mg/m², intravenous drip), once every 3 weeks
223979064|NCT06956716|DRUG|Sintilimab injection|Sintilimab Injection, 200mg, intravenous infusion
223979065|NCT03851380|BEHAVIORAL|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
223979066|NCT03851380|OTHER|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
223979067|NCT03851380|DEVICE|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
223979068|NCT03851380|DEVICE|Transcranial Electrical Stimulation (tES)|Home-based Transcranial Direct Current Stimulation
223979069|NCT03902509|DRUG|Pirfenidone|pirfenidone capsule made in China
223979070|NCT03902509|DRUG|basic treatment|glucocorticoid and expectant treatment etc.
223979071|NCT06045000|DRUG|DC-806|Oral tablets
223979072|NCT06045000|DRUG|[14C]-DC-806|Oral capsules
224118290|NCT03524365|PROCEDURE|RYGB|Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
223979073|NCT05880225|BEHAVIORAL|Reciprocal Imitation Training|As a naturalistic developmental behavioral intervention (NDBI), Reciprocal Imitation Training (RIT) utilizes contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities.
223979074|NCT05880225|BEHAVIORAL|music-enhanced Reciprocal Imitation Training|Music-enhanced imitation training uses music and rhythm to enhance the predictability and salience of the strategies utilized within the Reciprocal Imitation Training platform (i.e., contingent imitation, linguistic mapping, modeling, prompting, and contingent reinforcement to train object and gesture imitation during play activities).
224118291|NCT03524365|PROCEDURE|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
224122755|NCT05605327|DEVICE|EUS-guided gastroenterostomy|EUS-guided gastroenterostomy using the Hot-Axios and the WEST approach.
224122756|NCT05605327|OTHER|Laparoscopic gastroenterostomy|Laparoscopic gastroenterostomy
223979075|NCT04038697|PROCEDURE|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
223543778|NCT04144738|DIAGNOSTIC_TEST|FIT test|Stool samples will be collected by the subject for the FIT test.
223543779|NCT04144738|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
223543780|NCT04884503|DRUG|Clonazepam tablets|Dosing of clonazepam was as follows: in the first week, 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning), in the second week, 1 mg to be sucked for 2 minutes, and then swallowed (twice a day in the morning and one hour before falling asleep), in the third week, 1 mg to be sucked for 2 minutes and in the fourth week 1 mg to be sucked for 2 minutes, then swallowed (once a day in the morning)
223543781|NCT04884503|DEVICE|tongue pads|wearing a tongue pad 3 times a day for 20 minutes for 4 weeks
223543782|NCT03111004|OTHER|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
223979076|NCT04038697|PROCEDURE|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
223979077|NCT04038697|PROCEDURE|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
223979078|NCT04578288|PROCEDURE|INDIVIDUALIZED BLOOD PRESSURE MANAGEMENT DURING ENDOVASCULAR TREATMENT OF ACUTE ISCHEMIC STROKE UNDER PROCEDURAL SEDATION|The individual target range is defined as: bSBP ± 10 mmHg. The lowest possible SBP target range is 100-120 mmHg. The highest SBP target range is determined on the basis of whether patients receive concurrent IV fibrinolytic therapy or not. In patients where IV fibrinolytic therapy is applied, the highest SBP range is 160-180 mmHg, in patients without concurrent fibrinolytic therapy the highest SBP range is 180-200 mmHg.
223979079|NCT06389721|DIAGNOSTIC_TEST|Electroencephalogram (EEG)|Measure the electrical activity of your brain before you receive chemotherapy treatment and once monthly for a maximum of 6 measurements.
223979080|NCT06830772|OTHER|Experimental|Virtual Reality Exergame (VR) Participants will engage in a 5-minute fully immersive Virtual Reality (VR) exergame session using the PowerBeatsVR application. This intervention takes place in a virtual environment where participants perform rhythm-based physical activities such as punching targets and dodging obstacles. The VR session isolates participants from their real-world surroundings, offering a highly immersive experience designed to promote physical activity and assess its physiological and psychological effects.
223979081|NCT06830772|OTHER|Active comparator|Mixed Reality Exergame (MR) Participants will engage in a 5-minute Mixed Reality (MR) exergame session using PowerBeatsVR in MR mode. Unlike VR, this intervention integrates virtual elements into the real-world environment, allowing participants to maintain awareness of their physical surroundings while interacting with digital content. This hybrid experience reduces the risk of cybersickness while providing a practical approach for workplace settings.
224118292|NCT03524365|OTHER|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF."
223726731|NCT03921086|DRUG|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
223979082|NCT06956222|OTHER|Hybrid Tele-rehabilitation|"In-person session: participants attend the session in physiotherapy clinic.They will receive exercises (attached in the study protocol document) under the physiotherapist's supervision, including watching and correcting exercise techniques.~Video session: participants attend video session via Zoom platform (Zoom Video Communications, inc., USA), an accessible internet-based platform from any laptop or mobile device that offers a real-time video and audio communications. Participants will receive a Zoom link with a unique password. During the video session, the physiotherapist accesses from the clinic using a laptop, while participants are based at their home. Participants will receive exercises (attached in the study protocol document) with real time instructions from the physiotherapist. Instructions on downloading and accessing Zoom platform will be given to the participants in the first in-person session to ensure their readiness to access the Zoom platform."
223979083|NCT06956222|OTHER|Standard Rehabilitation|In-person session: participants attend the session in physiotherapy clinic.They will receive exercises (attached in the study protocol document) under physiotherapist's supervision, including watching and correcting exercise techniques.
223979084|NCT06735807|BEHAVIORAL|Generated AI-based intervention (Emohaa)|Participants will complete the intervention process by interacting with the Wechat applet. Participants will be required to complete a 6-week self-help therapy. Participants will be required to have a 30-minute dialogue including input and reflection time with Emohaa each week simultaneously with group ACT. Participants are free to dialogue with Emohaa for the rest of the week. An independent research assistant will monitor the intervention process from the platform. If the corresponding dialogue is not completed on time each week, the participant will be reminded via WeChat to complete this session before the start of the next session in the following week.
223979085|NCT06735807|BEHAVIORAL|group ACT|A 6-week group ACT intervention. Each group has 6-10 participants. Each session is one hour.
223979086|NCT06735807|BEHAVIORAL|wailist (delayed intervenion)|During the intervention period, participants in the WLG were only required to complete the appropriate assessments without receiving any intervention. Upon completion of the 15-day follow-up assessment, participants in the WLG could be free to choose to receive one of the two interventions. The intervention will be the same as the corresponding experimental group.
223726732|NCT05281445|BEHAVIORAL|Tic suppression task|Tic Suppression Task (TST, administered to Tourette syndrome participants only): At the beginning of the task, the child participant will be seated alone in front of a computer monitor with a countdown timer visible on the screen. For the first 10 minutes (baseline condition) they will be asked to tic freely and not to try to suppress their tics. For the second 10 minutes children will be asked to suppress their tics and will receive points for successful suppression. Participants will then be asked to sit alone in the room and tic freely for an additional 10-minutes.
223979087|NCT04606199|BEHAVIORAL|Mindfulness-based intervention, up to 5 minutes 0-3 times/day|The intervention consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3 minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
223979088|NCT05213429|OTHER|non interventional study|non interventional
223979089|NCT04478838|DRUG|Risperidone|0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets
223979090|NCT04478838|DRUG|Olanzapine|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
223979091|NCT04478838|DRUG|paliperidone|3 mg, 6 mg, 9 mg Tablets
223979092|NCT06328140|DRUG|Lurasidone|Daily medication treatment
223979093|NCT06328140|DRUG|FDA Approved antidepressant treatment|Daily treatment with an FDA approved antidepressant
223979094|NCT04190225|BEHAVIORAL|Digital/social media intervention|Participants will receive individual counseling, access to an individually tailored website, guided goal setting via texts, access to a study Instagram account, and a wearable tracker (Fitbit)
223979095|NCT05145439|DEVICE|VibratoSleeve Therapeutic Ultrasound Device|The VibratoSleeve is compromised of a 16-transducer array that is mounted within a wrap that conforms to the posterior calf.
224118293|NCT00257192|DRUG|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
224118294|NCT00257192|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing \<45 kg, the doses will range from 20 mg BID to 40 mg BID.
224118295|NCT00004081|DRUG|docetaxel|
224118296|NCT01120327|DRUG|Placebo|Placebo
224118297|NCT01120327|DRUG|Amlodipine|Amlodipine
224118298|NCT00570739|DRUG|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
224118299|NCT00570739|DRUG|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
224118300|NCT00570739|DRUG|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
224118301|NCT00570739|DRUG|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
224118302|NCT04256746|OTHER|Boiled Rice|
224118303|NCT04256746|OTHER|Boiled Rice+0.37 gr mulberry fruit powdered extract|
224118304|NCT04256746|OTHER|Boiled Rice+0.75 gr mulberry fruit powdered extract|
224118305|NCT04256746|OTHER|Boiled Rice+1.12 gr mulberry fruit powdered extract|
224118306|NCT04256746|OTHER|Boiled Rice+1.50 gr mulberry fruit powdered extract|
224118307|NCT04256746|OTHER|Rice Porridge|
224118308|NCT04256746|OTHER|Rice porridge+1.50 gr mulberry fruit powdered extract|
224118309|NCT00599430|DIETARY_SUPPLEMENT|Placebo|Inert excipient
224118310|NCT00599430|DIETARY_SUPPLEMENT|Lactobacillus acidophilus NCFM|1e10 CFU/day
224118311|NCT00599430|DIETARY_SUPPLEMENT|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
223979096|NCT06439641|OTHER|Ulcerative colitis Disease Activity Index|QUESTIONNAIRE - Score between 0 to 12, the higher is the worse
223979097|NCT04668365|DRUG|Rituximab|375mg/m2, Intravenous administration on day 0 of each 3-week cycle.
223979098|NCT04668365|DRUG|Zanubrutinib|160mg twice daily continuous oral administration.
223979099|NCT04668365|DRUG|Cyclophosphamide|750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223979100|NCT04668365|DRUG|Epirubicin|70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223979101|NCT04668365|DRUG|Vincristine|1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223979102|NCT04668365|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, disease progression after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223726733|NCT04359433|BEHAVIORAL|Exercise programme|"Exercise programme includes 8 anaerobic movements choosen from Tabata. This exercise programme workout is aimed at body fat reduction, and the structure is as follows:~* 8 anerobic movements in 20 seconds is a set~* Rest for 10 seconds before another set~* Finish 4 sets every time, it shall take you 4 minutes~* Do 4 sets 2 to 3 times a week"
223543783|NCT02666313|BEHAVIORAL|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
223726734|NCT03258151|GENETIC|detection of genotype|detection of genotype by next generation sequencing
223726735|NCT05851781|DRUG|Lacosamide tablet|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
223979103|NCT04294524|OTHER|Sleep apnea treatment|Sleep apnea treatment as decided according to routine practice. This may be Continuous positive airway pressure (CPAP) or wearing a mandibular advancement device (MAD).
223979104|NCT04669002|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
223979105|NCT04669002|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor)
223979106|NCT06028217|OTHER|prognosis status|observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
223979107|NCT04695886|OTHER|Community-delivered Integrated Malaria Elimination (CIME) intervention model|"Malaria: Malaria Diagnosis using RDT, treatment, referral and reporting; Prevention interventions (Behavioral Change Communication, net and repellent distribution); assisting in case and foci investigation and larval source management.~Dengue: Assisting in dengue prevention; Referral of cases. Tuberculosis (TB): Detection and referral of suspected cases; Contact tracing; Directly observed treatment, short-course (DOTS) providers; defaulter tracing; follow-up sputum examinations; assisting in TB health education talks and active case detection activities.~Childhood diarrhea: Prevention; Health education and Water, sanitation and hygiene (WASH) promotion; Diagnosis and dehydration assessment; Treatment and referral; Rehydration therapy using Oral Rehydration Solution (ORS) and oral Zinc tablet; assisted referral.~RDT-negative fever: Prevention and health education; Symptomatic treatment with antipyretics and immediate assisted referral."
223979108|NCT01114139|DRUG|Ferumoxytol|IV Ferumoxytol
223979109|NCT01114139|OTHER|Placebo|IV Placebo
223979110|NCT03371537|PROCEDURE|Liver debit measure|Mesure of liver debit during hepatectomy
224118312|NCT04738045|DRUG|Remdesivir|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
224118313|NCT04738045|DRUG|Lopinavir/ Ritonavir and Remdesivir combination|Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
223543784|NCT01760577|DRUG|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
223979111|NCT05671978|PROCEDURE|back-up head elevated position|The patient was then placed in the back-up head elevated position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table
223979112|NCT05671978|PROCEDURE|neutral position|The patient was then placed in the netural position
224118314|NCT04440917|DRUG|Camrelizumab|200mg, iv, on day 1, 15, 29, 43
223979113|NCT03728959|OTHER|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
224118315|NCT04440917|DRUG|Apatinib Mesylate|250 mg po, qd, 28 days as a cycle, 2 cycles in total
224118316|NCT05203302|OTHER|Single-Electrode Pulse Train|AIM 2 - Stimuli will be presented on one of three electrodes (apical, middle, and basal) at an amplitude between 10 and 100% dynamic range in µAs in 10% dynamic range steps. Stimulation will be delivered at a rate of 1000 pps. The process will be repeated in random order until 20 loudness estimates are obtained for each stimulus (3 electrodes x 2 rates x 10 amplitudes) for each subject. The dynamic range will be determined by measuring the maximum acceptable loudness (MAL) and threshold for each of the stimuli. MAL will be measured by slowly raising the current level for each stimulus until the subject reports that it is as loud as they are willing to accept without becoming uncomfortably loud.
224118317|NCT05203302|OTHER|Modulation Detection Threshold (MDT) and Gap Detection Tasks|AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
223726736|NCT05851781|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
223726737|NCT03498690|BEHAVIORAL|Integrative|Stakeholder groups: a-b
223726738|NCT03498690|BEHAVIORAL|Role specific|Stakeholder groups: a or b
223726739|NCT03498690|BEHAVIORAL|Consecutive|Stakeholder groups: a=\> b
223726740|NCT00119002|DRUG|dexamethasone|1mg/kg dexamethasone
223726741|NCT00119002|DRUG|Placebo|1mg/kg placebo
223979114|NCT03728959|OTHER|GIP|Subcutaneous injected GIP
224118318|NCT05203302|OTHER|Sound coding strategy.|Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL
224118319|NCT05203302|OTHER|Electric-only spectral resolution|Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
224118320|NCT03145129|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
224118321|NCT01595750|DRUG|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
223726742|NCT02950025|DEVICE|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
223726743|NCT02950025|DEVICE|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
223979115|NCT03728959|OTHER|GLP-2|Subcutaneous injected GLP-2
223979116|NCT03728959|OTHER|Placebo (saline)|Subcutaneous injected Placebo (saline)
223979117|NCT02995382|PROCEDURE|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
223979118|NCT00963443|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
223979119|NCT00963443|DRUG|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
223979120|NCT00963443|DRUG|Placebo|Matching Placebo
223979121|NCT06091839|OTHER|suturing technique in arteriovenous fistula creation for hemodialysis|End-to-side AV anastomosis was created in upper limb between cephalic vein and brachial or radial artery
224118322|NCT01595750|DRUG|Placebo|Placebo 500 mcg , 12 weeks of treatment
224118323|NCT01623778|DRUG|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
223979122|NCT05471804|DIETARY_SUPPLEMENT|Sceletium tortuosum|Zembrin® is a proprietary low-alkaloid extract of Sceletium tortuosum, often consumed by healthy humans in order to decrease anxiety and stress and improve cognitive function under stressful situations
223979123|NCT02813213|PROCEDURE|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
223979124|NCT02813213|PROCEDURE|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
223979125|NCT00974389|BIOLOGICAL|bevacizumab|
223979126|NCT00974389|DRUG|tegafur-gimeracil-oteracil potassium|
223979127|NCT00632385|DRUG|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose
223979128|NCT00771095|BEHAVIORAL|podcasting|
223979129|NCT01275768|PROCEDURE|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
223979130|NCT06371469|BEHAVIORAL|PHeBAC|Multi-interventions to health behaviour against cancer in mothers of Intellectual Disabled Children
223979131|NCT06371469|BEHAVIORAL|Control Group|Providing brochures from the Ministry of Health, answering questions and providing the researcher's phone number
223979132|NCT03376555|DIETARY_SUPPLEMENT|Low sodium no cheese|Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese 8 days
223979133|NCT03376555|DIETARY_SUPPLEMENT|Low sodium cheese|Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day 8 days
223979134|NCT03376555|DIETARY_SUPPLEMENT|High sodium no cheese|Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese 8 days
223979135|NCT03376555|DIETARY_SUPPLEMENT|High sodium cheese|Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day 8 days
223979136|NCT01435707|OTHER|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
223979137|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
223979138|NCT01435707|OTHER|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
223979139|NCT01435707|OTHER|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
224118324|NCT04687202|OTHER|follow up and record|None additional intervention was applied to the subjects.
224118325|NCT00325442|DRUG|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
224118326|NCT00325442|DRUG|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
224118327|NCT01729598|DRUG|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
224118328|NCT01729598|DRUG|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
224118329|NCT00875784|DRUG|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
224118330|NCT00875784|DRUG|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
224118331|NCT00875784|DRUG|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
224118332|NCT00875784|DRUG|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
224118333|NCT01623817|DRUG|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intravenous infusion during 2 or 3 hours.~Maintenance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
224118334|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal bupivacaine. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a 22 Gauche 80 mm block needle. Subsequently, intrathecal bupivacaine will be administered at the L3-L4 intervertebral level with 10-15 mg bupivacaine while the patient is in a sitting position.The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
224118335|NCT06298370|DRUG|Intrathecal bupivacaine and morphine|Patients will receive intrathecal bupivacaine and morphine without Pericapsular Nerve Group block. Intrathecal drugs will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
224118336|NCT06298370|DRUG|Pericapsular nerve group block plus intrathecal bupivacaine and morphine|Patients will undergo ultrasound-guided block using a linear or convex ultrasound probe in the supine position before intrathecal drugs. The block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone) and a S22 Gauche 80 mm block needle. Subarachnoid block will be administered at the L3-L4 intervertebral level by adding 10-15 mg bupivacaine with 100 μg of morphine. The patient controlled analgesia device with morphine will be adjusted as infusion: 0 ml/h, bolus: 1 mg/h, lockout period: 10 min.
224118337|NCT05427071|DEVICE|Magnetic seed localization|Magnetic seed guided localization
223979140|NCT03637647|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
223979141|NCT01917006|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
224118338|NCT05329181|BEHAVIORAL|Integrated cognitive behavioral treatment|Integrated cognitive behavioral treatment adapted specifically for homeless individuals and developed to treat substance use and depressive symptoms simultaneously
224118339|NCT00724035|DRUG|Midazolam|"Procedural sedation before the execution of the block.~* 0.03 mg/kg iv bolus"
224118340|NCT00724035|DRUG|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
223543785|NCT01760577|DRUG|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
223543786|NCT02443701|OTHER|Exercise|Warmup program, maximum isometric strengthening, and jump training
224118341|NCT00724035|DRUG|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
223543787|NCT02443701|OTHER|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
223543788|NCT02443701|OTHER|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
223543789|NCT04014426|OTHER|Blood sample|"Exposed group:~* 15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~* 2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~\- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
223979142|NCT01917006|DRUG|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
223979143|NCT00624013|DRUG|sertraline|50 mg up to 100 mg daily for 6 months
223979144|NCT00624013|DRUG|Placebo|50 mg up to 100 mg daily for 6 months
224118342|NCT00724035|PROCEDURE|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
224118343|NCT00724035|PROCEDURE|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
223543790|NCT04014426|OTHER|Urinary sample|"Exposed group:~* 15 to 30 min before the PIPAC procedure (T0)~* 2hours after the end of the procedure (T1)~* The next morning after the procedure (T2)~Non-exposed group:~\- During the morning (8 to 10 a.m) (T0)"
224118344|NCT00724035|PROCEDURE|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
224118345|NCT02676349|DRUG|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
223726744|NCT02950025|OTHER|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"* 30 questions~* 28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~* 1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~* 1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
223543791|NCT02735057|DRUG|Carboplatin|
223543792|NCT03432494|DEVICE|Transcaval closure device (TCD)|Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
223726745|NCT04590261|OTHER|Blood sampling|Peripheral Blood sampling, 25 mL
223726746|NCT04590261|OTHER|Nasal Brushing|Nasal Brushing, facultative
224118346|NCT02676349|RADIATION|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
223543793|NCT00185237|DRUG|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
223543794|NCT00185237|DRUG|Placebo|Placebo patch
223543795|NCT00644943|DRUG|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
223726747|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
223726748|NCT03989557|DEVICE|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
223726749|NCT03989557|DRUG|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
224118347|NCT02676349|PROCEDURE|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
224118348|NCT02676349|DRUG|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
224118349|NCT03700476|DRUG|Sintilimab|Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
224118350|NCT03700476|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
224118351|NCT03700476|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
223979145|NCT05548413|BEHAVIORAL|FamLit|The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide, including both spoken and printed materials written at a 4th-grade reading level for HF patients and their primary CPs.Three constructs guide the intervention, based on the Theory of Planned Behavior (TPB): 1) develop patient and CP positive attitudes through HF instruction and teach-back; 2) form positive subjective norms through coaching to improve patient and CP communication, support, and teamwork; and 3) increase perceived behavioral control through coaching and role-playing to empower patients and CPs to overcome individual barriers to adherence. This intervention also includes use of the SimpleMed+ electronic pillbox.
223979146|NCT05548413|BEHAVIORAL|Attention Control|Participants in this group will talk with an interventionist to discuss general health. This intervention also includes use of the SimpleMed+ electronic pillbox.
223979147|NCT02142634|DRUG|Budesonide granules 9 mg|per day
223979148|NCT02142634|DRUG|Placebo granules|per day
223979149|NCT05305677|DIETARY_SUPPLEMENT|NMN intervention|NMN capsules (total of 600mg/day) for 8 weeks
223979150|NCT05305677|OTHER|Placebo|NMN-free placebo capsules for 8 weeks
223979151|NCT00812721|OTHER|Preservative Free Saline|One drop will be instilled into each eye once
223979152|NCT00812721|OTHER|Optive|One drop will be instilled into each eye once
223979153|NCT00812721|OTHER|Refresh Moderate/Severe|One drop will be instilled into each eye once
223979154|NCT00812721|OTHER|Systane|One drop will be instilled into each eye once
223979155|NCT00812721|OTHER|Systane Ultra|One drop will be instilled into each eye once
223979156|NCT04797598|OTHER|Virtual reality group|This will receive Virtual reality sessions and both group will receive conventional physical therapy as base line treatment
223979157|NCT04797598|OTHER|Cyclic training group|This will receive cyclic training session. both group will receive conventional physical therapy as base line treatment
223979158|NCT01733589|DRUG|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
223979159|NCT01733589|DRUG|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
223979160|NCT01733589|DRUG|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
223979161|NCT01733589|OTHER|laboratory biomarker analysis|
223979162|NCT01733589|OTHER|CT perfusion imaging|
223979163|NCT00969969|DEVICE|Arthrodesis|arthrodesis using screws and/or a plate
223979164|NCT00969969|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
223979165|NCT05987098|DIAGNOSTIC_TEST|BBPA PET examination|A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.
223979166|NCT06114485|BEHAVIORAL|VIPA Treatment Program|Participants will receive and Alexa device with a behavioral activation program, along with a detailed guidebook about how to utilize the Alexa device and the VIPA program
223543796|NCT00644943|DRUG|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
223979167|NCT06114485|BEHAVIORAL|Alexa with Guidebook|Participants will receive an Alexa device with a detailed guidebook on how to use the device.
223979168|NCT01721174|PROCEDURE|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
223979169|NCT01721174|PROCEDURE|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
223979170|NCT05897528|OTHER|No Intervention|Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
223979171|NCT06418399|OTHER|cancer patients|Patients aged between 18 and 80 years with cancer-related pain lasting for more than 3 months will be included.
223979172|NCT01913899|OTHER|Occupational/ physical therapy|
223979173|NCT01913899|OTHER|Mirror therapy|\- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
223979174|NCT04949854|DEVICE|B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter|control Arm 1 (6.35 cm 20 Gauge ultralong intravenous catheter without guidewire
223979175|NCT04949854|DEVICE|B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter|Experimental Arm B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter with guide wire
223979176|NCT01377792|DRUG|Hypertonic saline|comparison of different dosages of drug
223979177|NCT04291209|DRUG|N-Acetyl Cysteine|One ear will be randomly chosen for the experimental treatment of intratympanic NAC. The other ear will serve as the control ear which will not receive any injection.
223979178|NCT05616598|DRUG|Sofosbuvir +daclatasvir+ simeprevir+Ribavirin|Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months
223979179|NCT03219177|BEHAVIORAL|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
223979180|NCT03219177|OTHER|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
223726750|NCT03542968|PROCEDURE|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
223726751|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
223726752|NCT03138889|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
223979181|NCT02171884|OTHER|Sample of cord blood|
223979182|NCT02171884|OTHER|Sample of placenta|
223979183|NCT04067843|PROCEDURE|Photodynamic treatment|Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
223726753|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
223726754|NCT03138889|DRUG|NKTR-214|NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
223726755|NCT03138889|DRUG|Cisplatin|Cisplatin will be dosed per the pharmacy manual
223726756|NCT03138889|DRUG|Carboplatin|Carboplatin will be dosed per the pharmacy manual
223726757|NCT03138889|DRUG|Nab paclitaxel|Nab-paclitaxel will be dosed per local practice and label
223726758|NCT03138889|DRUG|Paclitaxel|Paclitaxel will be dosed per local practice and label
223979184|NCT01354249|DIETARY_SUPPLEMENT|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
223979185|NCT05710237|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with either risperidone 1 mg or place. It will also be administered in conjunction with supportive therapy.
224118352|NCT03700476|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
224118353|NCT04381819|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 E gene
224118354|NCT00277472|DRUG|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
224118355|NCT00277472|DRUG|HCTZ|25 mg taken once daily orally
224118356|NCT01165801|PROCEDURE|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
223979186|NCT05710237|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with either psilocybin 25 mg or placebo. It will also be administered with supportive therapy.
223979187|NCT05710237|DRUG|Placebo|The placebo will be administered once during the trial in combination with either risperidone 1 mg or psilocybin 25 mg.
223543797|NCT00912574|DRUG|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
223979188|NCT02518347|DIETARY_SUPPLEMENT|FDS-Strawberry|Natural frozen and dried strawberries
224118357|NCT05438485|OTHER|Registry|Observational (Registry)
224118358|NCT00884182|BIOLOGICAL|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
224118359|NCT02883582|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
224118360|NCT02883582|DEVICE|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
224118361|NCT02718794|PROCEDURE|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
224118362|NCT02718794|PROCEDURE|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
224118363|NCT05379426|OTHER|Impact COVID-19 pandemic|Battery of screening tests and the semi-structured interview focusing on the difficulties experienced by the older adult during the pandemic period.
224118364|NCT05774457|BEHAVIORAL|Voice training|Traditional vs. virtual reality
223979189|NCT02518347|DIETARY_SUPPLEMENT|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
223979190|NCT05758103|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)|Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
223979191|NCT05936008|BEHAVIORAL|Exercise MICT|Standard of care, exercise recommendations for people with stroke
223979192|NCT05936008|BEHAVIORAL|Exercise HIIT|The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
223979193|NCT06224400|DRUG|ENC1018 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
223979194|NCT06224400|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort A1-A6) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally as a single dose.
223979195|NCT06224400|DRUG|ENC1018 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
223979196|NCT06224400|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (cohort B1-B3) to receive either ENC1018 or placebo. The investigational product (ENC1018 or placebo) will be administered orally for a total of 14 days.
223979197|NCT01475461|DRUG|Placebo|double-dummy placebo tablets administered once-daily for 84-days
223979198|NCT01475461|DRUG|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
223979199|NCT01475461|DRUG|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
223979200|NCT01475461|DRUG|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
223979201|NCT01475461|DRUG|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
223979202|NCT01475461|DRUG|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
223979203|NCT04184349|DRUG|LA group|In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
223979204|NCT04184349|DRUG|B Group|In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
223979205|NCT04151706|DRUG|CD8+ Memory T Cell Infusion|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
223726759|NCT03138889|DRUG|Pemetrexed|Pemetrexed will be dosed per the pharmacy manual
223979206|NCT04151706|DRUG|Thiotepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
223979207|NCT04151706|DRUG|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
223979208|NCT04151706|RADIATION|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
223979209|NCT04151706|DRUG|Busulfan|6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg
223979210|NCT04151706|DRUG|Cyclophosphamide|60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
223979211|NCT04672499|DRUG|Miricorilant 300 mg tablets|Miricorilant 300 mg tablets for oral administration
223979212|NCT04672499|DRUG|Miricorilant 150 mg tablets|Miricorilant 150 mg tablets for oral administration
223979213|NCT04672499|DRUG|Placebo 150 mg tablets|Placebo to match miricorilant 150 mg tablets for oral administration
223979214|NCT05259358|OTHER|exercise|exercises that increase muscular endurance
223979215|NCT01522677|DRUG|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
223979216|NCT06282185|OTHER|Physiotherapy|supervised training program for twelve weeks + usual care + advice about exercise
223726760|NCT03138889|DRUG|Atezolizumab|Atezolizumab will be dosed per current label indication
223726761|NCT00551733|DRUG|carboplatin|Given IV
223979217|NCT02434523|DRUG|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
223979218|NCT02434523|OTHER|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
224118365|NCT01921270|DRUG|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
224118366|NCT00216606|DRUG|topiramate|
223979219|NCT03487653|BIOLOGICAL|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
223979220|NCT04676633|DRUG|STP705|Investigational Product
223979221|NCT03911908|COMBINATION_PRODUCT|Cerebral oximetry (near infrared) based CPR-Algorithm|If NIRS values do not increase over time until ROSC (target: \>40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
223979222|NCT01271036|DEVICE|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
223726762|NCT00551733|DRUG|paclitaxel|Given IV
223726763|NCT00551733|DRUG|paclitaxel poliglumex|Given IV
223979223|NCT01093170|DRUG|RNA-144101|Intravitreous administration of RNA-144101
223979224|NCT02512861|DRUG|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients \> 50 kgs"
224118367|NCT04579055|OTHER|1-min STS test: adjusted|Individually adjusted chair seat height of 90° knee joint flexion
224118368|NCT04579055|OTHER|1-min STS test: standardized|Standardized chair seat height of 46 cm
224118369|NCT02427594|DRUG|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
223979225|NCT02512861|DRUG|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs"
223979226|NCT02347969|DIETARY_SUPPLEMENT|X34|Dietary supplement named X34
223979227|NCT03180554|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
223979228|NCT03180554|OTHER|Motivational nondirective resonance breathing (MNRB)|Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
223979229|NCT01362283|OTHER|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
223979230|NCT02107547|PROCEDURE|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
223979231|NCT02107547|PROCEDURE|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
223979232|NCT03891498|DRUG|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
224118370|NCT02427594|OTHER|Controlled diet|Diet without sodium bicarbonate supplementation
224118371|NCT01883128|DEVICE|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
224118372|NCT01883128|PROCEDURE|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
224295311|NCT06138119|BEHAVIORAL|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/ she belongs. Stereotype threat manipulation will be performed on the male and female participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare fiberoptic intubation performance between male and female anesthesiologists. Additionally, we are investigating whether the high inclination of males towards computer games has any impact on their fiberoptic intubation success. The other participants (Control Group) will not be given any prior information."
223979233|NCT04774783|DEVICE|Low-Level Laser Therapy|The TheraTouch LX2 device includes a 9-diode cluster probe which emits a combination of LED and laser light. The cluster probe includes four 650 nm LED diodes capable of delivering a total of 40 mW and five 850 nm laser diodes capable of delivering a total of 1000 mW of power. LLLT will the applied with the cluster probe directly in contact with the subject's skin. LLLT dosages will vary according to the location of the subject's pain and may require multiple applications during a session. Each individual application will typically range from 4-16 Joules.
223979234|NCT03206476|BEHAVIORAL|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
223979235|NCT03206476|BEHAVIORAL|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
223979236|NCT03104777|BEHAVIORAL|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
223979237|NCT02883179|DRUG|lidocaine injection|anhydrous solution
223979238|NCT02883179|DRUG|lidocaine-prilocaine cream|topical cream
224118373|NCT01883128|PROCEDURE|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
224118374|NCT00844428|DRUG|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
223979239|NCT02179710|BEHAVIORAL|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
223979240|NCT06642363|DRUG|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"|"Subjects in the intervention group will receive one capsule containing 10 mg Astaper day made by the Zyest Technology Tarawat Zendig institute in Iran. The dosage of ASX is determined based on the s"
223979241|NCT06642363|DRUG|Placebo|The placebo group will take one capsule containing corn starch in a wrapped and covered form and the appearance of ASX supplementation (blinding).
224118375|NCT01933191|BEHAVIORAL|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
223979242|NCT05985083|DRUG|IMM47|IMM47 is humanized mAb targeting CD24 to be administered via intravenous infusion every 2 weeks in 28-day treatment cycles.
223979243|NCT00694733|DRUG|Placebo injection|Normal saline injection IM monthly for 4 months
223979244|NCT00694733|DRUG|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
223979245|NCT00694733|DRUG|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
223979246|NCT00694733|DRUG|placebo|Placebo Cream 1ml applied twice daily for four months
223726764|NCT05948254|PROCEDURE|Triple function scan body|The scan bodies were used to scan the implant position, Jaw registration and facial scan alignment, First of all scan bodies were selected according to vertical dimension of occlusion, then the emergence profile together with the selected scan body were scanned,All scan bodies were then removed from the patient mouth except one or even two that were scanned in the jaw scan step, this scan body was utilized as a stopper, the patient was asked to bite until the scan body came in contact with the lower or upper teeth in case of edentulous upper or lower arch respectively, scan body in place (in the same orientation of the previous jaw scan ) provided that at least the tip of the scan body appeared when the patient is asked to smile which would be used as a common area so that the intra oral scanner can relate the jaw scan to the lips and face.
224118376|NCT01933191|BEHAVIORAL|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
224118377|NCT06333470|OTHER|Primary angle closure diseases|Primary angle-closure suspect (PACS), which is characterized by appositional angle closure, is the earliest stage of primary angle closure diseases and can finally progress to primary angle-closure glaucoma (PACG).
224118378|NCT04263662|OTHER|Analgesia-Sedation algorithm|The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
224118379|NCT06300970|DRUG|Amodiaquine-artesunate (ASAQ)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
223979247|NCT00694733|DRUG|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
223979248|NCT03214250|DRUG|APX005M|Administer intravenously once every 28-day Cycle
223979249|NCT03214250|DRUG|Nivolumab|Administer intravenously twice every 28-day cycle
224118380|NCT06300970|DRUG|Artemether+Lumefantrine (AL)|Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
224118381|NCT03766750|DRUG|LIMA association|1 coated tablet, oral, once a day.
223979250|NCT03214250|DRUG|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
223979251|NCT03214250|DRUG|Gemcitabine|Administer intravenously 3 times every 28-day cycle
223979252|NCT04503837|PROCEDURE|Personalized Mobile Phone Video Recording|Subjects will be asked to perform inhaler technique while on video recording. The video will be shown to subjects immediately during technique education session and mistakes (if any) will be pointed out to subject.
223979253|NCT00848068|OTHER|FID 114657|artificial tears
223979254|NCT00848068|OTHER|OPTIVE Lubricant Eye Drops|artificial tears
223979255|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
223979256|NCT02264964|PROCEDURE|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
223979257|NCT02264964|DEVICE|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
223979258|NCT02264964|PROCEDURE|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
223979259|NCT02428816|OTHER|MRI acquisition|MRI acquisitions
223979260|NCT02428816|BEHAVIORAL|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
223979261|NCT03065478|DIETARY_SUPPLEMENT|OnLife|Daily dosing of dietary supplement OnLife
223979262|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
223979263|NCT00616577|DRUG|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
223979264|NCT00616577|DRUG|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
223979265|NCT03801681|DIAGNOSTIC_TEST|ECG holter monitoring|patients will be monitored using ECG-holter
224118382|NCT03766750|DRUG|Tradjenta|1 coated tablet, oral, once a day.
224118383|NCT03766750|DRUG|Forxiga|1 coated tablet, oral, once a day.
224118384|NCT00088582|DRUG|Pasireotide (SOM230), Octreotide (Sandostatin)|
224118385|NCT00694512|DIETARY_SUPPLEMENT|Low fat diet|20% fat diet
224293701|NCT07213219|OTHER|PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).|"The PET-MRI will be performed using a Siemens Biograph mMR hybrid PET-MRI scanner. A 60-minute dynamic PET acquisition will begin following the intravenous injection of \\\[¹¹C\]raclopride (a radiotracer agonist of dopamine D2/D3 receptors) synthesized in the radiopharmaceutical laboratories of CERMEP. Simultaneously with the PET acquisition, brain MRI sequences will be acquired: 3D anatomical T1 and 3D T2, SWI, diffusion MRI (DTI), resting-state functional MRI, and arterial spin labeling (ASL) perfusion MRI.~Patients will undergo two PET-MRI scans on two consecutive days under two pharmacological conditions: Off and On dopamine:~* Day 1:\*\* The first PET-MRI session (TEPDopaOff) will be performed after a 12-hour withdrawal from usual dopaminergic treatment (Off dopamine).~* Day 2:\*\* The second PET-MRI session (TEPDopaOn) will be similar to the first, except it will take place 1 hour after administration of immediate-release Levodopa"
223726765|NCT05571241|BEHAVIORAL|Fast rehabilitation program|1-2 weeks (first post-op visit): Long thumb spica splint removed; Staples/stitches removed; Short hand-based thumb spica fitted for the patient Start Active Range of Motion Exercises (AROM) for thumb Add active assisted rang of motion exercises (AAROM) if no significant progress 6 weeks: Gradually wean off of splint during the day; wear for protection and/or more strenuous daily activities 6-8 weeks: Passive Range of Motion Exercises (PROM) (ie. stretching), if needed - (ie. No significant changes in ROM of thumb) 8-10 weeks: Resisted exercises/activities without splint on
223726766|NCT00004443|DRUG|NTBC|
223726767|NCT01514812|DRUG|YM150|oral - modified release formulation of YM150
223726768|NCT01514812|DRUG|placebo|oral
223726769|NCT01514812|DRUG|digoxin|oral
223726770|NCT04120831|DRUG|Abatacept Injection|Drug
223979266|NCT00292981|DRUG|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
223979267|NCT05755217|DIETARY_SUPPLEMENT|Dark chocolate|Single oral dose of 1g/kg of dark chocolate (70% cocoa).
223979268|NCT05755217|DIETARY_SUPPLEMENT|White chocolate|Single oral dose of 1g/kg of white chocolate (4% cocoa).
223979269|NCT00594178|DEVICE|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
223979270|NCT03080662|DEVICE|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
223979271|NCT03080662|DEVICE|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
223979272|NCT03738306|OTHER|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
223979273|NCT03738306|OTHER|Conventional Physiotherapy|therapeutic exercise; physical agents
223979274|NCT00016445|DRUG|growth hormone|
223979275|NCT00374088|DRUG|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
223979276|NCT00374088|DRUG|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
223979277|NCT01799109|DRUG|Magnesium Sulfate & albuterol|
223979278|NCT01799109|DRUG|albuterol|
223979279|NCT01799109|DRUG|magnesium|
223979280|NCT06416332|OTHER|group A: in face to face live therapeutic exercise|"In group A: in face to face live therapeutic exercise the program and its progressivity will be determined and performed for life according to the progress of the patient, with a frequency of sessions twice a week, session duration 45 minutes, following the recommended dosage of exercise according to clinical guidelines, while the total duration of the intervention will be eight weeks. You will be instructed to perform the program at home, 3 times a week. The standardized exercise program to be followed by this group will include :~1. Exercises to strengthen the hip and knee muscles through isometric contractions and resistance exercises using elastic bands.~2. Balance and neuromuscular coordination exercises."
224118386|NCT00694512|DIETARY_SUPPLEMENT|High fat diet|40% fat diet
224118387|NCT00694512|DIETARY_SUPPLEMENT|MCT diet|Medium chain triglyceride diet
224118388|NCT00789477|PROCEDURE|Laser Photocoagulation|laser every 16 weeks as needed
224118389|NCT00789477|DRUG|Intravitreal Aflibercept Injection|
224118390|NCT04891250|DRUG|Ivermectin|Treatment of SARS Cov-2 patients with Ivermectin
224118391|NCT04891250|OTHER|Prophylaxis|Treatment of high risk population with Ivermectin as prophylaxis
223726771|NCT04700982|OTHER|Based on the length of hospital stay|Based on the length of hospital stay, patients were divided into two groups: hospital stays ≤ 3 months (Group 1) and \> 3 months (Group 2).Clinical features and functional output will be then compared between the groups.
223726772|NCT03171623|DRUG|globalagliatin hydrochloride|orally administration, single dose
223726773|NCT03171623|DRUG|placebo|orally administration, single dose
223979281|NCT06416332|OTHER|group B: telerehabilitation program|In group B: telerehabilitation program, the therapeutic exercise program will follow the same structure, which was mentioned above. The differentiation in the intervention of this group will be that the explanation of the exercises, their presentation, monitoring and information of the participants will be done through the telerehabilitation platform and special data processing software. The intervention time remains the same, with the physical therapist during these 45 minutes of the session , to evaluate the data on the patients progress by receiving the information through the software and to inform the patient of any changes in the progressivity of the exercise program. The other parameters of the intervention remain the same, as in person exercise.
223979282|NCT03535805|BEHAVIORAL|Mind My Mind (MMM)|"Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (\>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks."
223979283|NCT03535805|BEHAVIORAL|Treatment as Usual (TAU)|The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
223979284|NCT00429442|DRUG|Simvastatin|80 mg once daily
223979285|NCT00429442|DRUG|placebo|calcium tablets once daily
223979286|NCT04223128|PROCEDURE|Ultrasound guided transversus abdominis plane block|Using an 18 G Tuohy needle (80 mm Smiths medical Portex®) and the layers of the abdominal wall will be identified guided by superficial high-frequency 45 mm linear array ultrasound probe (13 MHz) as described by McDonnell and colleagues.(1) Twenty millilitre of 0.25% bupivacaine will be injected slowly after careful aspiration to ensure no vascular injury has occurred. Successful injection will produce an echo-lucent space between the muscle layers (internal oblique and transversus abdominis). All TAP blocks will be performed by the same anesthetist.
223979287|NCT00171418|DRUG|Tegaserod|
223979288|NCT05554783|DIAGNOSTIC_TEST|Trendelenburg position|Positioning the patient with head 15 degrees down
223979289|NCT02361398|OTHER|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
223979290|NCT00375765|DRUG|Dutasteride|
224118392|NCT06321744|OTHER|adapted physical activity program (APA Program)|"Content of the APA program:~* Strengthening of the lower limbs: Exercises alternating different regimes of muscular contractions (eccentric, concentric and isometric), with the use of elastics, balls or even body weight. These exercises will mainly work the quadriceps and hamstrings.~* Upper limb strengthening: Exercises focused on eccentric and concentric contraction regimes, in a global movement approach (as opposed to a segmental approach), with the use of elastics, dumbbells, weighted balls, etc. These exercises will work the muscles of the biceps, triceps, pectorals, deltoids and lats.~* Walking: In the room and/or in the corridor, with technical assistance (cane/walker, etc.) or human work~* Balance and proprioception: Balance work in a bi- and uni-pedal situation, statically and dynamically (eyes open and closed) will be offered with the use of proprioception boards and/or mats combining if possible work in dual task."
224118393|NCT04232891|DIAGNOSTIC_TEST|liquid biopsy|detection of tumor DNA alteration in cf-DNA
224293702|NCT07211464|BEHAVIORAL|Acceptance and commitment therapy (ACT)|Each 1.5-hour session will consist of a 1-hour ACT intervention and 30 minutes of exercise training. The ACT group was led by a trained ACT counsellor and a trained exercise trainer.
223726774|NCT02557698|OTHER|Balneum oil bath|
224118394|NCT00808691|OTHER|Critical care|Standard care for each group of patients
224118395|NCT03575520|DRUG|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
224118396|NCT03575520|DRUG|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
224118397|NCT05535673|DRUG|ThisCART19A|In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.
224118398|NCT00806780|PROCEDURE|on table cholangiography|x-ray imaging of common bile duct
224293703|NCT07211464|BEHAVIORAL|back exercise|30-minute exercise class
223726775|NCT00948623|BEHAVIORAL|physical activity counseling program|
223726776|NCT00948623|BEHAVIORAL|sham counseling program|
223726777|NCT01779739|PROCEDURE|Perineorrhaphy|Procedure to build up the vaginal opening
223726778|NCT03963362|DRUG|GLA5PR tablet 75 mg|GLARS-NF3 tablet
223726779|NCT03963362|DRUG|GLA5PR tablet 150 mg|GLARS-NF3 tablet
223726780|NCT01693926|BEHAVIORAL|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
223726781|NCT01693926|BEHAVIORAL|placebo|
223726782|NCT01681732|OTHER|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
223726783|NCT01681732|OTHER|Control Standard Care|This is the standard care arm
223726784|NCT00403442|DEVICE|Verteporfin Therapy/ Drug: Bevacizumab|
223726785|NCT03244345|BEHAVIORAL|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
223726786|NCT05791266|DEVICE|Sticker pads containing lavender and ylang ylang oil|Sticker pads , size 160 mm2, were produced by a certified ISO 9001 manufacturer and contained 0.3% lavender oil and 0.7% ylang ylang oil. The sticker pad was attached to the shirts of healthy volunteers for 2 hours. The outcomes were evaluated before, during and 30 minutes after removal of the pad.
223726787|NCT02742584|PROCEDURE|Cough Stress Test|Varying bladder volumes during cough stress test.
223726788|NCT02289690|DRUG|Veliparib|Capsules administered orally twice a day according to the dosing schedule.
223726789|NCT02289690|DRUG|Carboplatin|Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
223726790|NCT02289690|DRUG|Etoposide|Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
223726791|NCT02289690|DRUG|Placebo|Placebo to veliparib administered orally twice a day according to the dosing schedule.
223726792|NCT04416464|OTHER|COVID-19 Pneumonia|Pneumonia due to proven or suspected SARS-Cov-2 infection
223726793|NCT04763798|OTHER|Straight-leg-raise (SLR)|The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the SLR, the knee was kept in full extension and then, hip flexion was performed until a marked resistance. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.The stretch lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes
223726794|NCT04763798|OTHER|Passive Knee extension test (PKE)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For the PKE, the hip was kept in 90º flexion and then, knee extension was performed. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
223726795|NCT04763798|OTHER|Maximum hip flexion (MHF)|"The stretched lower limb was on a mobile support and the contralateral limb was stabilized with a belt on the bench. For MHF, a maximal hip flexion was performed and then, knee extension was applied. All stretching modalities were applied until a marked resistance was felt by the physical therapist (end-feel) or until the point of maximal tolerance referred by subjects.~The stretches lasted 30 seconds followed by 15 seconds rest period and the procedure was repeated 5 times. Each stretching was applied for 5 minutes"
223726796|NCT03687853|DEVICE|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
223726797|NCT01427504|DRUG|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
223726798|NCT04166435|DRUG|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
223726799|NCT01327521|DEVICE|CyberKnife|Standard of Care
223726800|NCT01327521|PROCEDURE|TACE|Standard of Care
223726801|NCT01327521|DRUG|CT Contrast|Standard of Care
223726802|NCT01327521|DRUG|doxorubicin|Standard of Care
223726803|NCT01327521|DRUG|Epirubicin|Standard of Care
223726804|NCT01327521|DRUG|5-fluorouracil|Standard of Care
223726805|NCT01327521|DRUG|Mitomycin C|Standard of Care
223726806|NCT01327521|DRUG|Gemcitabine|Standard of Care
223726807|NCT01327521|DRUG|Cisplatin|Standard of Care
223726808|NCT01327521|DEVICE|SMANCS|Standard of Care
223726809|NCT01073709|DRUG|Acetaminophen|
223726810|NCT00449020|DRUG|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
223726811|NCT00449020|DRUG|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
223726812|NCT00449020|DRUG|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
224118399|NCT04311476|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy|Evaluate Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
224118400|NCT04311476|DRUG|0.9% Sodiun Chloride|0.9% Sodiun Chloride in control group
224118401|NCT05986539|OTHER|Observational|This study is only observational in nature and will not include an intervention.
224118402|NCT05930925|DRUG|[phenyl-14C]ARV-471|Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
223726813|NCT00449020|RADIATION|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
223726814|NCT03262818|DEVICE|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
223726815|NCT03262818|DEVICE|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
223726816|NCT01391559|DRUG|arformoterol|15 mcg administered via nebulizer
223726817|NCT01391559|DRUG|salmeterol|50 mcg delivered vis Diskus
223726818|NCT00267046|DRUG|Palifermin|180 mcg/kg 3 days prior to chemotherapy
224118403|NCT05930925|DRUG|[oxoisoindolin-14C]ARV-471|Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
224118404|NCT00198159|DRUG|ZD1839 Iressa|
224118405|NCT04539301|DIAGNOSTIC_TEST|Estimated anticoagulant level (conversion factor x anti-Xa activity)|Estimated anticoagulant level (conversion factor x anti-Xa activity)
224118406|NCT01844700|DRUG|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
223726819|NCT00267046|DRUG|Placebo|Single dose 3 days prior to chemotherapy
223726820|NCT00267046|DRUG|Adriamycin (Doxorubicin)|30 mg/m\^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m\^2).
223726821|NCT00267046|DRUG|Ifosfamide|2.5 g/m\^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m\^2); for patients receiving the AI Regimen.
223726822|NCT00267046|DRUG|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
223726823|NCT00267046|DRUG|Cisplatin|120 mg/m\^2 on day 0, for patients receiving the AP Regimen.
223726824|NCT05485597|DEVICE|Myosuit-based gait training|In a period of four weeks participants will undergo eight individual task-specific overground gait training sessions with the Myosuit. The sessions will be started with a therapist, and if possible and as soon as possible, the patient will train with an assistant. During the therapy sessions, the patient will be asked to perform various task-specific exercises with the Myosuit, such as Sit-to-stand-, Balance- and walking exercises. Depending on the individual skill level of the participant, a higher level of difficulty in task-specific exercises can be performed. The training sessions are set to last 45 minutes. All training sessions will be accompanied by a certified (physio)therapist or trained assistant and a study investigator.
223726825|NCT03421392|OTHER|non interventional study|non interventional study
223726826|NCT05277740|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
223726827|NCT06315439|PROCEDURE|Endoscopic ultrasound fine needle biopsy|"EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging."
224118407|NCT01844700|DRUG|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
223726828|NCT00865124|DRUG|Spironolactone|25 mg capsule daily for 6 months
223726829|NCT00865124|DRUG|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
223726830|NCT00865124|OTHER|Placebo|Placebo capsule daily
223726831|NCT00853801|BEHAVIORAL|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
223726832|NCT01380873|DRUG|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
223726833|NCT01380873|DRUG|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
223726834|NCT01380873|DRUG|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
223726835|NCT02212392|DRUG|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
223726836|NCT03287440|BEHAVIORAL|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
223979291|NCT05629247|DIAGNOSTIC_TEST|Systematic screening of immune deficiency|Systematic screening of immune deficiency with blood tests
223979292|NCT04889859|PROCEDURE|long Roux limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and 50 cm-long biliopancreatic limb.
223979293|NCT04889859|PROCEDURE|long biliopancreatic limb Roux-en-Y reconstruction|After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 50 cm-long Roux limb and 100 cm-long biliopancreatic limb.
223979294|NCT00721032|PROCEDURE|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
223979295|NCT00721032|DRUG|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -\> new dose 100 once daily (QD) -\> 200 QD; 200 QD -\> 400 QD; 300 QD -\> 600 QD; 400 QD -\> 600 QD"
223979296|NCT02066610|OTHER|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
223979297|NCT02066610|OTHER|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
223979298|NCT02066610|OTHER|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
223979299|NCT02066610|OTHER|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
223979300|NCT02971228|DRUG|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with type 1 diabetes mellitus (T1DM), but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
223979301|NCT02971228|DRUG|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
223979302|NCT02971228|DRUG|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
223979303|NCT02971228|DEVICE|iPhone-based bionic pancreas|An experimental device.
223979304|NCT02971228|DEVICE|iLet-based bionic pancreas|An experimental device.
223979305|NCT03315234|GENETIC|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
223979306|NCT05260554|DRUG|Fosfomycin|In this group with urinary tract inflammation; Fosfomycin was prescribed for 7 days (3 doses, 2 days apart). There are 80 patients in total.
223979307|NCT05260554|DIETARY_SUPPLEMENT|Cranberry|In this group with urinary tract inflammation; 7 days (used every day) cranberry tablet was given. There are 80 patients in total.
223979308|NCT03895502|DRUG|12-month Edoxaban|Prescription of Edoxaban for 12 months
223979309|NCT03895502|DRUG|3-month Edoxaban|Prescription of Edoxaban for 3 months
223979310|NCT00024323|DRUG|cisplatin|
223979311|NCT00024323|DRUG|triapine|
223979312|NCT00047177|DRUG|Oxaliplatin|
223979313|NCT05913986|DIETARY_SUPPLEMENT|LUDLEV®300 mg/46.2 mg|LUDLEV®300 mg/46.2 mg once day
223726837|NCT03287440|BEHAVIORAL|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
223726838|NCT02657174|DEVICE|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
223979314|NCT05913986|OTHER|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
223979315|NCT06499688|BIOLOGICAL|Rcombinant botulinum neurotoxin type A for injection (YY001)|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
224118408|NCT03554538|BEHAVIORAL|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
223979316|NCT06499688|BIOLOGICAL|OnabotulinumtoxinA|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
223979317|NCT06499688|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.
223979318|NCT03569605|BEHAVIORAL|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
223979319|NCT03569605|BEHAVIORAL|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
223979320|NCT02670499|DEVICE|CPM|Used to aid in recovery from TKR
223979321|NCT02670499|DEVICE|GAPFLEX|Used to aid in the recovery of TKR
223979322|NCT04875897|DEVICE|keepMED PAP device|The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.).
223979323|NCT02080377|DRUG|Glibenclamide|
223979324|NCT02080377|DRUG|Insulin|
224118409|NCT03554538|BEHAVIORAL|Exercise program|Exercise on an evidence based program for shoulder pain
224118410|NCT06255561|DEVICE|active rTMS stimulating|Two sessions of active rTMS would be delivered, with 1800 pulse/session and 50 min inter-session intervals.
224293704|NCT07211464|BEHAVIORAL|back care education|1-hour interactive lesson on back care
223726839|NCT02657174|DEVICE|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
223726840|NCT04983264|DRUG|GBT021601|Tablets and capsules which contain GBT021601 drug substance
223726841|NCT04022044|BEHAVIORAL|Observational group|
223726842|NCT03571152|OTHER|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
223726843|NCT04579185|DEVICE|Transcranial Photobiomodulation|Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
223726844|NCT05519410|DRUG|Sintilimab and Lenvatinib|Tislelizumab, 200mg, ivd,q3w; Lenvatinib,8mg/kg,po,qd.
223726845|NCT05519410|DRUG|HAIC-FOLFOX|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
223726846|NCT04661540|DRUG|CM4620-IE (Injectable Emulsion)|Auxora is an injectable emulsion containing 1.6mg/ML of the active pharmaceutical ingredient CM4620. Auxora will be administered intravenously as a continuous infusion
223726847|NCT04661540|DRUG|Placebo|Matching placebo is an injectable emulsion containing no active pharmaceutical ingredient. Placebo will be administered intravenously as a continuous infusion
223726848|NCT03752632|DEVICE|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
223726849|NCT03752632|DEVICE|Tourniquet|A tourniquet alone will be used.
223726850|NCT01690208|OTHER|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
223726851|NCT01690208|OTHER|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
224118411|NCT02680847|DRUG|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
223726852|NCT02344485|PROCEDURE|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
223726853|NCT06193720|DRUG|Arnica montana|Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
223726854|NCT06193720|OTHER|Placebo|Patients will take placebo drug after surgeries
223726855|NCT00184691|DRUG|somatropin|
223979325|NCT04540562|OTHER|COPD app|The COPD app consisted of an 8 week self-management program. The app had three views: timeline, information page, and contact page. The timeline was classified in 8 weeks, and each week included the lung exacerbation plan, daily and extra medication, information and education and questionnaires. The first week also included a video of a pulmonologist explaining the purpose of the app and additional information about the functionalities of the COPD app. A video consultation was planned after after 4 weeks and a face-to-face consultation after 8 weeks.
223979326|NCT01743105|PROCEDURE|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
223979327|NCT01743105|PROCEDURE|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
223979328|NCT03632005|DEVICE|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
223979329|NCT03632005|OTHER|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
223979330|NCT06015906|DEVICE|Plenum® Guide|Plenum® Guide is a white, absorbable synthetic regenerative membrane composed of poly(dioxanone), which will be installed on the tooth extraction sockets.
223979331|NCT06015906|DEVICE|Plenum® Oss|Plenum® Oss is a synthetic bone graft based on biphasic calcium phosphate, which will be used to fill the tooth extraction sockets.
223979332|NCT06015906|PROCEDURE|Tooth extraction|Tooth extraction and subsequent surgical procedure of guided bone regeneration.
223979333|NCT06511375|OTHER|sprint training|sprint training involves 20 meters sprint power training involve countermovement jump, squat jump and broad jump
223979334|NCT06511375|OTHER|Power Training|"GROUP 2 will perform POWER TRAINING for 4 weeks, 3 sessions per week Participants will perform Countermovement jump 2 trials, with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform squat jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week.~Participants will perform broad jump 2 trials with 1-minute recovery between each trial for four weeks, three times per week."
223979335|NCT05566392|DIAGNOSTIC_TEST|Brain MRI|Brain MRI including diffusion spectrum image, and functional MRI Interview with questionnaires for neuropsychiatric evaluation Near infrared spectroscopy and resting-state connectivity evaluation
223979336|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
223979337|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
223979338|NCT01582503|DRUG|MEMP1972A|Subcutaneous repeating dose
223726856|NCT02875483|OTHER|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
223979339|NCT01582503|DRUG|placebo|Subcutaneous repeating dose
223726857|NCT02875483|OTHER|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
223979340|NCT05840562|DRUG|Capsaicin|Application of capsaicin patches 179 mg
223979341|NCT05840562|DRUG|Duloxetine|Administration of duloxetine
223979342|NCT01321723|DRUG|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
223979343|NCT01321723|DRUG|Placebo|
223979344|NCT01321723|DRUG|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
223979345|NCT00025506|OTHER|Laboratory Biomarker Analysis|Correlative studies
223979346|NCT00025506|DRUG|Thalidomide|Given orally
223979347|NCT05623371|BEHAVIORAL|Training leaders in leading well-being and the psychosocial working environment|"The intervention comprises five training modules with practice in small groups in between. Training will take place over 5 months. The training will be received in groups of 20 and the training will be facilitated by 2 facilitators. Central themes of the training are:~1. Self-care and well-being of the manager and how to cope with stress as a manager.~2. Employee well-being and reducing risk-factors in the psychosocial working environment of employee mental health problems~3. Enhancing protective factors social social support and a healthy team climate~4. Responding to employees at risk and how to handle difficult conversations and procedures on return to work~5. Managing well-being in employees during organizational change and final reflections~The training will comprise video material and in person training of competencies and behaviors in group settings.~The waitlist control group will receive an offer of a webinar and written information."
223979348|NCT05623371|BEHAVIORAL|The offer of a webinar and written material|The offer of a webinar plus written material
223726858|NCT04519684|DRUG|Mesenchymal stem cells|Allogeneic bone marrow derived mesenchymal stem cells
223726859|NCT04519684|OTHER|Placebo|Normal Saline
223726860|NCT01690247|DRUG|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
223726861|NCT01690247|DRUG|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
223979349|NCT02250690|DEVICE|experimental group - tDCS|
223979350|NCT02250690|DEVICE|Control group (tDCS sham)|
223979351|NCT05223972|OTHER|Schroth Treatment|Schroth exercises consist of passive and active postural auto-correction exercises done repeatedly and based on kinesthetic and sensorimotor principles. The ultimate goal of the Schroth method is to enable the patient to consciously maintain correct posture in their daily living activities. To achieve this requires repeating corrective movements performed to improve postural motor control. Schroth exercises also include strength and endurance training of postural muscles in order to improve the curve, raise the patient's self-image, and reduce pain. In this study, the Schroth exercises progressed from more to less passive support, from more to less feedback, and from lying to sitting or standing positions, according to the patient's ability to perform the specific exercise
223979352|NCT03331926|DRUG|Xiapex|Follow-up of effect of treatment
223979353|NCT04310683|OTHER|natural cycle for endometrium preparation|patients will not use oral contraceptive drugs
223979354|NCT04310683|OTHER|hormone replaced cycle for endometrium preparation|patients will receive oral contraceptive drugs for menstruation before embryo transfer
223979355|NCT02947841|OTHER|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
223979356|NCT02947841|OTHER|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
223979357|NCT02011217|OTHER|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
223979358|NCT02011217|OTHER|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
223979359|NCT02011217|OTHER|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
223979360|NCT05623813|OTHER|Postoperative education|provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
223979361|NCT03551431|DIAGNOSTIC_TEST|Video EEG with verbal suggestion|Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
223979362|NCT00713206|DEVICE|Dental Implant (Osseotite)|Root form titanium dental implant
223979363|NCT00347399|DRUG|bevacizumab intravitreal injection|
223979364|NCT00347399|PROCEDURE|verteporfin photodynamic therapy|
223979365|NCT05336617|PROCEDURE|colonoscopy|A colonoscopy is an exam used to examine the colon and rectum. During a colonoscopy, a long, flexible tube is inserted into the rectum. A tiny video camera at the tip of the tube allows the doctor to view the inside of the entire colon.
223979366|NCT02182232|DRUG|BIBF 1120|
223979367|NCT02182232|DRUG|Paclitaxel|
223979368|NCT02182232|DRUG|Carboplatin|
223979369|NCT01838486|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
223979370|NCT00276666|DRUG|cisplatin|
223979371|NCT00276666|DRUG|lomustine|
223979372|NCT00276666|DRUG|vincristine sulfate|
224293706|NCT07211685|BIOLOGICAL|BAY 3401016|BAY 3401016
224293707|NCT07211685|OTHER|Placebo|Placebo to BAY 3401016
223979373|NCT00276666|PROCEDURE|adjuvant therapy|
223979374|NCT00276666|RADIATION|radiation therapy|
223979375|NCT02737111|BEHAVIORAL|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
223979376|NCT02737111|BEHAVIORAL|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
224293708|NCT07211542|DRUG|SHR-1905 Injection|SHR-1905 injection.
224293709|NCT07211542|DRUG|SHR-1905 Injection Blank Preparation|SHR-1905 injection blank preparation.
224295312|NCT06231719|OTHER|Cold Spray|Using cold spray for injection site before the Anti-D immunglobulin injection. 2 sprays of cold spray are applied from a distance of 25 cm.
224295313|NCT06231719|OTHER|Manuel Pressure|Using manuel pressure ( about 10 second ) before the Anti-D immunglobulin injection.
224295314|NCT06231719|OTHER|Standard Injection Procedure|Using any special method for injection
223979377|NCT02737111|BEHAVIORAL|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
223979378|NCT02737111|BEHAVIORAL|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
223979379|NCT02737111|BEHAVIORAL|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
223979380|NCT01377168|DRUG|oral naltrexone|
223979381|NCT01377168|DRUG|Placebo pill|
223979382|NCT05158023|DRUG|Placebo Comparator|Sterile solution for subcutaneous injection
223979383|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
223979384|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
224293710|NCT07211841|DEVICE|MRS study|"Thirty patients newly diagnosed with GBM will be included in this study. The study will be conducted without any major modification of the standard management of GBM.~The MRS study will be performed at the time of the initial MRI examination (morphological MRI sequences performed on 3T Philipps). The MRS will be performed on the most agressive part of the tumor : monovoxel PRESS MRS sequence with 3 echo times : 35, 144 and 288 ms. Spectra processing with Philipps software returns relative quantifications \> 7 ratios (choline/creatin, Glucose/creatin, glutamine/creatin, N-Acetyl aspartate/creatin, myoinositol/creatin, phsopholipids/creatin, lactate/creatin, acetate/creatin). With this experimental design, the additional time required for MRS acquisition is 10 min /patient."
224293711|NCT07211841|BIOLOGICAL|blood samples|Routine basic clinical and biological analyses will be collected during the project. In addition, 2 blood samples (5 mL each time) will be obtained at the time of inclusion (pre-therapeutic) and one month after completion of the initial therapeutic cycle (surgery + radiochemotherapy). The plasma samples will be used to measure fibrinogen, lactate and choline concentrations. In addition, a metabolomic study of plasma will be performed w
223543798|NCT00912574|DRUG|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
223979385|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
223979386|NCT05158023|BIOLOGICAL|ASLAN004|Sterile solution for subcutaneous injection
223979387|NCT05075512|DRUG|anlotinib, fulvestrant|anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
223979388|NCT06040047|OTHER|Proprioceptive neuromuscular facilitation|Contract relax technique for each neck motion for three repetitions.
223979389|NCT06040047|OTHER|Passive mobilization|To restore normal joint play, postero-anterior passive joint mobilization of cervical spine segments and cervicothoracic junction in limited motion will be applied.
223979390|NCT02561806|DRUG|Ixekizumab|Administered SC
223979391|NCT02561806|DRUG|Ustekinumab|Administered SC
223979392|NCT02561806|DRUG|Placebo|Administered SC
223979393|NCT04314388|OTHER|Intervention: Outdoor Walking Rehabilitation Programme|Participants in the intervention group will take part in an instructor led outdoor walking rehabilitation programme which will last for 3 months. Alongside this participants will also be asked to complete a home exercise programme.
223979394|NCT04314388|OTHER|Control: The light Stretches Programme|Participants in the control group will be asked to keep to their normal activities of daily living, and given 10 targeted active stretches of the upper and lower body.
224293712|NCT07211763|OTHER|No Interventions|No intervention, solely data collection
224293713|NCT07213089|BIOLOGICAL|Combined Diphtheria-Tetanus-recombinant acellular pertussis (DTaP) vaccine|A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml will be given by intramuscularly at Day 0
224293714|NCT07213089|BIOLOGICAL|Licensed DTaP|A single dose of Acellular pertussis (DTaP) vaccine 0.5 ml. will be given by intramuscular as at Day 0
224118412|NCT02375698|BIOLOGICAL|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
223979395|NCT05887141|BEHAVIORAL|Double Standards|We created a VR intervention based on the Cognitive Behavioral Therapy (CBT) technique 'double standards'. In the intervention the participants have to respond to a virtual character they imagine as their friend, who expresses similar self-criticism as they struggle with themselves. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with the virtual friend (second person perspective).
224118413|NCT02375698|BIOLOGICAL|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
223726862|NCT02606604|DEVICE|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
223726863|NCT03966703|BEHAVIORAL|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
223726864|NCT03435744|DRUG|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
223726865|NCT03435744|OTHER|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
223979396|NCT05887141|BEHAVIORAL|Self-criticism avatar|We created a VR intervention called 'Self-criticism avatar' that has common ground with two-chair dialogue. Participants have to assertively respond to their inner critic who criticizes them using their own self-critical thoughts. After responding assertively (for example: 'Go away, I don't need you', 'Good is good enough'), the virtual character becomes weaker until they give up. Two role-plays are played in Virtual Reality (either with or without perspective change after the role-plays). In the perspective change condition, the perspective is changed with a bystander (third person perspective).
223979397|NCT02062112|OTHER|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
223979398|NCT01427049|DEVICE|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
223979399|NCT00941642|DRUG|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
223979400|NCT00941642|DRUG|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
223979401|NCT04038749|DRUG|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
223979402|NCT04038749|DRUG|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
223979403|NCT04038749|OTHER|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
223979404|NCT02547441|DRUG|CLS001 (Omiganan)|Topical gel
224118414|NCT06219928|PROCEDURE|Control Group|After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline
224118415|NCT06219928|PROCEDURE|Ketamine Group|After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.
224118416|NCT06219928|PROCEDURE|Dexmedetomidine|After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
224118417|NCT06661265|PROCEDURE|adjuvant tomotherapy +- chemotherapy after the reconstructive surgery with flaps|adjuvant treatment in locally-advanced head and neck cancers submitted to upfront surgery with flap reconstruction, evaluation of toxicity and flap status performed at San Raffaele Hospital between December 2017-December 2022.
223726866|NCT00523354|DRUG|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
223726867|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with multimodal feedback (VRET-M)|The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
223726868|NCT05939986|BEHAVIORAL|Virtual reality-based exposure treatment with bimodal feedback (VRET-B)|The VRET-B group will experience visual and auditive cues in the exposure sessions.
223726869|NCT05939986|BEHAVIORAL|Imagery exposure treatment (IET)|The IET group will experience its own subjective imagined environment without any external stimulation.
223726870|NCT03905187|BEHAVIORAL|Modified CR|Stress management involved modified cardiac rehabilitation
223726871|NCT03905187|BEHAVIORAL|Traditional CR|Traditional cardiac rehabilitation
224118418|NCT00890630|PROCEDURE|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
223726872|NCT03905187|BEHAVIORAL|Education|Education
223726873|NCT00002079|DRUG|Butyldeoxynojirimycin|
223726874|NCT00002079|DRUG|Zidovudine|
223726875|NCT04579731|DRUG|Lactitol Monohydrate|Patients with lower urinary tract dysfunction and assumed to have constipation were placed on lactitol monohydrate 10 g for 8 weeks, and had re-evaluated.
224118419|NCT00890630|DRUG|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
224118420|NCT03786692|DRUG|Arm A|Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
224118421|NCT03786692|DRUG|Arm B|Carboplatin + Pemetrexed + Bevacizumab
224118422|NCT06598007|DRUG|CT3001|CT3001 is an Oral Solution, with active pharmaceutical agent, a small molecule inhibitor of GPR35, formulated with PEG 400, strawberry flavor, and anhydrous ethanol.
224293715|NCT07212686|DRUG|Angiotensin-II|Angiotensin-II will be given per the titration protocol.
223979405|NCT02547441|DRUG|Vehicle|Vehicle Gel
223979406|NCT04128800|DRUG|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
223979407|NCT01859611|DEVICE|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
223979408|NCT03039881|DEVICE|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
223979409|NCT00229710|DRUG|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
223979410|NCT05739110|BEHAVIORAL|tumor micronecrosis|whether HCC patients have tumor micronecrosis or not
223979411|NCT02735590|DRUG|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
223979412|NCT02735590|DRUG|Rifapentine|Rifapentine based on body weight (\>32kg - 50kg: 750 mg; \>50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
223979413|NCT01322009|DRUG|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
223979414|NCT01322009|DRUG|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
223979415|NCT04169451|DRUG|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
223979416|NCT02934945|DRUG|budesonide 160μg/formoterol 4.5μg|SMART regimen
223979417|NCT05361382|DRUG|18F-Flortaucipir radiopharmaceutical|Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.
223979418|NCT05361382|DRUG|18F-MK-6240 radiopharmaceutical|MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.
223979419|NCT05361382|DRUG|Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)|"The clinical sites will use either PiB, Florbetaben, Florbetapir, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques.~Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical.~Participants will receive a bolus intravenous injection of approximately 10 millicuries of the Florbetapir radiopharmaceutical."
223979420|NCT01241006|DRUG|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
223979421|NCT01241006|DRUG|Prednisone|Prednisone 60mg PO q day for 5 days
223726876|NCT02309489|BEHAVIORAL|Partner involvement|Partner is involved in maternity care
223979422|NCT00905034|DRUG|Methotrexate|200 mg/m\^2 by vein on days 1 and 15.
223979423|NCT00905034|DRUG|Vincristine|1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
223979424|NCT00905034|DRUG|PEG-l-asparaginase|2500 International units/m\^2 by vein on days 2 and 16
223979425|NCT00905034|DRUG|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
223979426|NCT00905034|DRUG|Rituximab|Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
223979427|NCT00394589|DRUG|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
223979428|NCT00394589|DRUG|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
223979429|NCT00394589|DRUG|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
224118423|NCT06609616|DEVICE|Motion Sensor|The motion sensor is the 10-axis Bluetooth Gyro Inclinometer by Wit Motion and is marketed for rehabilitation exercises, workplace injury prevention, patient care, and healthy shortrange wireless motion measurements.
224118424|NCT06609616|DEVICE|Incentive Spirometer|a device that measures the volume of the air inhaled into the lungs during inspiration.
223726877|NCT03042533|DEVICE|Conventional Compression|Method of Nail fitting
223979430|NCT00004265|DRUG|paclitaxel|
223979431|NCT04081389|DRUG|Celecoxib|Given PO
223979432|NCT04081389|DRUG|Cyclophosphamide|Given IV
223979433|NCT04081389|DRUG|Doxorubicin|Given IV
223979434|NCT04081389|DRUG|Doxorubicin Hydrochloride|Given IV
223979435|NCT04081389|DRUG|Paclitaxel|Given IV
223979436|NCT04081389|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
223979437|NCT04081389|DRUG|Rintatolimod|Given IV
223979438|NCT03707847|DRUG|Crizotinib|250mg, BID, PO
223979439|NCT03707847|DRUG|Etoposide Capsule|50mg, QD, PO, d1-10，21days for one cycle
223979440|NCT03707847|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who have achieved CR or VGPR.
223979441|NCT02134366|DRUG|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
223979442|NCT02134366|DRUG|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
223979443|NCT02134366|DRUG|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
223979444|NCT01089309|DRUG|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
223979445|NCT02173145|DRUG|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
224293716|NCT07211412|OTHER|Cryotherapy|A cold (-5°C) cold-pack for 15 minutes every 24 hours for 5 days
223979446|NCT02173145|DRUG|placebo|Placebo will be given 3 times a wek over a period of 3 months.
223979447|NCT04191876|OTHER|Wellth - Financial Incentives|Patients who are willing to participate will be offered financial incentives for medication adherence through an app (Wellth) over 10 weeks.
223979448|NCT05914415|OTHER|Supportive care and education before surgery|we will give supportive and informative education before surgery in order to increase patient' recovery rates
223979449|NCT02582385|OTHER|in-situ cytokine expression|
223979450|NCT03411993|DIAGNOSTIC_TEST|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
223979451|NCT00900783|DRUG|valacyclovir|1 gram, three times a day for seven days
223979452|NCT00900783|DRUG|FV-100|400 mg, once daily, for seven days
223979453|NCT00900783|DRUG|FV-100|200 mg, once daily, for seven days
223979454|NCT00900783|DRUG|Valacyclovir placebo|three times a day, for seven days
223979455|NCT00900783|DRUG|FV-100 placebo|once daily, for seven days
223979456|NCT00341471|PROCEDURE|Risk Behavior Prevention Intervention Program|
223979457|NCT00144846|DRUG|albuterol sulfate inhalation aerosol|
223979458|NCT00498095|PROCEDURE|Renal biopsy|
224118425|NCT02273310|BEHAVIORAL|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
224118426|NCT01288040|BEHAVIORAL|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
224118427|NCT00489983|DRUG|pemetrexed|
224118428|NCT00489983|DRUG|gemcitabine|
224118429|NCT02621268|DRUG|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
224118430|NCT00555945|PROCEDURE|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
224118431|NCT00555945|PROCEDURE|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
224118432|NCT05837260|OTHER|Sample collection only|Sample collection only
224118433|NCT04819425|DEVICE|Elastic Adhesive Strips|Securement of Endotracheal tube with Elastic Adhesive Strips
224118434|NCT04819425|DEVICE|Lace in A Protective Sheath|Securement of Endotracheal tube with Lace in A Protective Sheath
224118435|NCT03611309|OTHER|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
224118436|NCT03611309|OTHER|Surgeon team alone management|The surgeon and surgical team will manage
223726878|NCT03042533|DEVICE|Standard Backslapping|Method of Nail fitting
223726879|NCT03042533|DEVICE|Dynamic Locking with Backslapping|Method of Nail fitting
223726880|NCT06159712|OTHER|Blood samples|Extra blood samples
223726881|NCT01126853|BIOLOGICAL|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
223979459|NCT02780505|DRUG|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
223979460|NCT02780505|DRUG|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
223979461|NCT00480155|BIOLOGICAL|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
223979462|NCT00480155|OTHER|Placebo|
223979463|NCT03818243|BEHAVIORAL|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
224118437|NCT00363025|PROCEDURE|Two post-remission strategies|
224118438|NCT00363025|DRUG|Idarubicin versus daunorubicin|
224293717|NCT07211412|OTHER|Eccentric exercise-induced muscle damage|3 sets of 15 repetitions of eccentric contractions at 80% of 1RM. This is to induced a controlled muscle damage in 2 of the 3 arms.
224293718|NCT07213141|OTHER|Data extraction|Data extraction from medical records
223979464|NCT00830609|DRUG|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)
223979465|NCT00830609|DRUG|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks
224118439|NCT06611631|PROCEDURE|Hyaluronic acid pulpotomy|"1. After complete hemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder to reach suitable consistency (1:1 ratio by volume) then gentle condensation in the pulp chamber will be done by a moistened cotton pellet and then the rest of the pulp chamber will be filled by glass ionomer restoration .~2. Tooth will be restored with stainless steel crown."
223726882|NCT03578029|DRUG|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
223726883|NCT03578029|DRUG|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
223726884|NCT04421729|BEHAVIORAL|Group sessions over 3 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 6 sessions.
223726885|NCT04421729|BEHAVIORAL|Group sessions over 6 weeks|Informational and educational group-mediated program for family members caring for a person living with dementia; 3 sessions.
223726886|NCT01266954|DRUG|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
223726887|NCT05693246|DRUG|Glycopyrrolate|At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
223726888|NCT05693246|OTHER|normal saline|At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
223726889|NCT01550640|DRUG|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
223979466|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 24 weeks
223979467|NCT00830609|DRUG|ribavirin|ribavirin 800 mg/day for 24 weeks
223979468|NCT00830609|DRUG|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
223979469|NCT00830609|DRUG|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
223979470|NCT05425225|OTHER|Low level LASER therapy|Three consecutive treatments will be given in a session, with 5 seconds break in between, giving a total irradiation time of 90 seconds. Two sessions will be given per week for total of 6 weeks.(20)
223979471|NCT05425225|OTHER|Conventional physical therapy|Hot pack for 15 to 20 minutes followed by 10 repetitions of sustained stretching (10 seconds hold), for 3 days a week for 6 week
223979472|NCT02108626|DRUG|Nicotine|E-Cigarette with nicotine cartridge
223979473|NCT02108626|DRUG|Placebo|E-Cigarette with 0mg nicotine cartridge
223979474|NCT02025855|DRUG|Methadone|
223979475|NCT02025855|DRUG|Placebo|
223979476|NCT04982627|BEHAVIORAL|BNI Chatbot|The BNI Chatbot is a web application that guides participants through a brief motivational intervention that motivates them to engage in treatment for opioid use disorder.
224118440|NCT06611631|PROCEDURE|mineral trioxide aggregate pulpotomy|"1. After complete hemostasis, MTA+ saline will be manipulated in the ratio of 3:1 (powder: liquid) to obtain a putty mix. This mix will be placed over the radicular pulp with the help of a suitable sterile amalgam carrier. Gentle condensation of the mix will be done in the pulp chamber with a moistened cotton pellet, followed by the application of glass ionomer restoration.~2. Tooth will then be restored with stainless steel crown."
224118441|NCT02021422|DRUG|anakinra|Dosage Route Administration 100 mg SC Every Other Day
224118442|NCT02021422|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
224118443|NCT02021422|DRUG|Irinotecan|Irinotecan 180 mg/m2 90 minutes
224118444|NCT02021422|DRUG|fluorouracil|fluorouracil 2400 mg/m2 48 hours
224118445|NCT03213639|DRUG|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
224118446|NCT03213639|DRUG|Placebo Oral Tablet|once daily oral tablets
224118447|NCT00775372|DRUG|Clarithromycin 250mg/5mL|
224293719|NCT07211776|DRUG|ZL-1109 (VRDN-003)|ZL-1109 subcutaneous injection
224293720|NCT07211776|DRUG|Placebo|Matching placebo subcutaneous injection
224293721|NCT07211854|OTHER|Anticoagulant Treatment|Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023.
223979477|NCT04982627|BEHAVIORAL|OUD Education & Treatment Resources|The OUD Education \& Treatment Resources intervention is a web application that provides OUD education and treatment resources.
224118448|NCT00772967|DRUG|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
224118449|NCT00772967|DRUG|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
223726890|NCT01096524|OTHER|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
223979478|NCT04777825|OTHER|Heart rate variability biofeedback training (Symbiocenter)|12 sessions of thirty minutes. Patients will participate through several serious game associated with HRV biofeedback training
223979479|NCT04777825|OTHER|psychoeducation session|Each patient will therefore be presented individually with a Powerpoint consisting of 35 slides divided into 4 sub-sections explaining in a fun and educational format the physiological model of stress, the respiratory function and its benefits, presentation of various relaxation techniques and recommendations for reading (stress management, letting go, mindfulness meditation) and other tools to help relaxation (smartphone applications).
224118450|NCT00772967|DRUG|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
224118451|NCT02185599|DEVICE|DySIS|Colposcopy performed with the DySIS digital colposcope
224118452|NCT02612714|DRUG|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
223543799|NCT00912574|BIOLOGICAL|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
223979480|NCT01388062|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
224118453|NCT01070355|DRUG|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
224293722|NCT07212985|PROCEDURE|Autogenous Bone Block + Xenograft + Collagen Membrane|Autogenous chin bone block graft combined with particulate bovine xenograft (Bio-Oss, Geistlich Pharma AG) and covered with an absorbable collagen membrane (Bio-Gide).
224293723|NCT07212595|DRUG|Amino Acid infusion|Amino acid infusion of 2 grams/kilogram of participant weight/day for up to 72 hours
224293724|NCT07212595|DRUG|Lactated ringers solution|Placebo infusion to match the volume of the amino acid infusion in grams/kilogram/day
224293725|NCT07211828|DRUG|high dose of alfentanil|The initial dose is alfentanil cet 10ng/mL and propofol 1ug/mL. Dose of alfentanil will be increased by 10ng/mL each until PSI reach to 25-50. If alfentail has been adjusted to 50 but PSI is still too high, increase propofol cet by 0.5-1ug/mL till target PSI is reached. If propofol is adjusted to 0 but PSI is still too low, decrease alfetanil by 10ng/mL The range of dosage of alfentanil is 0-50ng/mL while propofol is 0-5ug/mL.
224118454|NCT01070355|DRUG|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
224118455|NCT03307447|DRUG|Secukinumab|Secukinumab 300 mg subcutaneous injection
224118456|NCT00294593|DRUG|folinic acid|
223979481|NCT04216485|BEHAVIORAL|Intensive Lifestyle Intervention|Dietary intervention combined with healthy lifestyle counseling
223543800|NCT00912574|DRUG|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
223726891|NCT01096524|DEVICE|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
223726892|NCT03294057|BEHAVIORAL|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
223726893|NCT03294057|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
223726894|NCT03294057|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
223726895|NCT03927664|OTHER|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
223726896|NCT05098925|OTHER|Biological testing|Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
223726897|NCT01971411|DRUG|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
223726898|NCT01971411|PROCEDURE|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
223726899|NCT01971411|BEHAVIORAL|Usual sun exposure documentation|
223726900|NCT01971411|BEHAVIORAL|Dietary intake of calcium, vitamin D, magnesium|
223726901|NCT02099357|DIETARY_SUPPLEMENT|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
223726902|NCT02099357|DIETARY_SUPPLEMENT|Placebo|
223726903|NCT02099357|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
223726904|NCT03629067|DRUG|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
223726905|NCT03629067|DRUG|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
223726906|NCT03231865|DIAGNOSTIC_TEST|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
223726907|NCT00240903|BIOLOGICAL|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
223726908|NCT01148758|DRUG|RO5323441|cohorts receiving multiple doses iv
223726909|NCT01443754|PROCEDURE|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~* use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~* minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
223726910|NCT01443754|PROCEDURE|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
223726911|NCT04075058|RADIATION|Hypofractionated Radiation therapy|
223726912|NCT01203150|OTHER|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
223726913|NCT01716351|BEHAVIORAL|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
223726914|NCT00774319|RADIATION|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
223979482|NCT04216485|BEHAVIORAL|Standard Care|Standard prenatal care on diet, nutrition and physical activity
223979483|NCT00992719|BIOLOGICAL|Inactivated H1N1 Vaccine|H1N1 vaccine \[Influenza A (H1N1) 2009 Monovalent Vaccine\] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
223979484|NCT04400344|OTHER|No intervention|No intervention
223979485|NCT05903677|OTHER|magnesium levels|Detection of the relationship between cardiac surgery associated AKI and preoperative magnesium levels.
223979486|NCT04241783|OTHER|descriptive|correlation
223979487|NCT06072963|DRUG|Semaglutide|The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
223979488|NCT06072963|DRUG|Intranasal insulin|The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
223979489|NCT06072963|OTHER|Semaglutide placebo|Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
223979490|NCT06072963|OTHER|Intranasal insulin placebo|The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
223979491|NCT02806817|DRUG|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
223979492|NCT02806817|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
223979493|NCT02806817|OTHER|Normal saline|Use saline as placebo
223979494|NCT00257764|BEHAVIORAL|behavioral swallowing exercises/ strategies|
223979495|NCT06478810|OTHER|Domomedicine and dedicated nursing care for a close and secure monitoring after an ambulatory hepatectomy|For patient who need a minor hepatectomy under laparoscopy for the standard of care, the follow-up will be an ambulatory follow-up. This ambulatory follow-up will be made possible thanks to the integration of Domomedicine and dedicated nursing care for a close and secure monitoring.
223979496|NCT00383864|DRUG|Pegylated interferon and ribavirin|
223979497|NCT06479200|BEHAVIORAL|VR-guided mindfulness|The VR-guided mindfulness intervention is a 6-week home-based program delivered through an Oculus Quest 3 (or equivalent) headset. Participants practice 10-15 minutes of guided mindfulness exercises daily in immersive virtual environments. The program includes various mindfulness techniques such as body scans, breath awareness, and loving-kindness meditation, designed to reduce stress and improve well-being.
223979498|NCT06479200|OTHER|Sham VR|The sham VR intervention is a 6-week home-based program that involves viewing relaxing nature videos without any mindfulness content. Participants use the same VR headset as the experimental group and engage with the sham content for 10-15 minutes daily, matching the duration of the experimental intervention. This sham intervention controls for the effects of using VR technology and engaging in a relaxing activity.
223979499|NCT04827186|PROCEDURE|Spleen Transplantation/Removal|Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
224295315|NCT04054284|DIETARY_SUPPLEMENT|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
223979500|NCT00241969|BEHAVIORAL|Behavioral and Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
223979501|NCT00241969|BEHAVIORAL|Education and Attention Control|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
224118457|NCT04111822|DRUG|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
223979502|NCT02186314|DEVICE|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
223979503|NCT02186314|DEVICE|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
223543801|NCT05068986|BEHAVIORAL|Asthma education|All the study participants were subjected to an educational asthma program for 3 months for providing parents and children with information and skills to manage their asthma ,which was presented from the the first session, through providing a written asthma action plan, information about avoiding triggers, training in the correct use of medicines, including inhaler technique, information and support to maximize adherence . All patients were followed up by a phone call every 2 weeks and follow up visit monthly to confirm compliance to the educational program
223979504|NCT02604797|DRUG|Nalbuphine|patient-controlled intravenous analgesia
223543802|NCT06301308|DRUG|Intraurethral lidocaine gel alone|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
223979505|NCT02604797|DRUG|Sufentanil|patient-controlled intravenous analgesia
223979506|NCT02604797|DRUG|flurbiprofen axetil|patient-controlled intravenous analgesia
223979507|NCT02604797|DRUG|ramosetron|patient-controlled intravenous analgesia
224118458|NCT04111822|DRUG|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
224118459|NCT01100021|DRUG|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
224118460|NCT01100021|DRUG|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
224118461|NCT03836638|DRUG|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
224118462|NCT03836638|DRUG|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
223543803|NCT06301308|DRUG|Intraurethral lidocaine gel + lidocaine 2% injection|participants received 10 ml of intraurethral lidocaine gel at a concentration of 2% and using the injection of lidocaine 2% to irrigate the urethra using a 20 ml syringe.
223979508|NCT02427958|DRUG|Leuprorelin|Suspension for injection.
223979509|NCT00322140|DRUG|CDDO|
223979510|NCT00001383|DRUG|PSC 833|
223979511|NCT00001383|DRUG|paclitaxel|
223979512|NCT00854152|DRUG|GDC-0980|Escalating repeating dose
223979513|NCT03847922|DRUG|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
223979514|NCT03847922|DRUG|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
223979515|NCT03847922|OTHER|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
223979516|NCT04758546|DIAGNOSTIC_TEST|Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial|Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
223979517|NCT03696641|OTHER|glazed lithium disilicate crowns|glazing of IPS e.max crowns
223979518|NCT03696641|OTHER|polished lithium disilicate crowns|polishing of IPS e.max crowns
223979519|NCT02236702|OTHER|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
223979520|NCT04080063|OTHER|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
223979521|NCT01009138|BEHAVIORAL|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~* Problem Analysis and Definition~* Problem Solving Intervention~* Cognitive Restructuring~* Activation of personal and social Resources~* Goal Definition and Agreement"
223979522|NCT01009138|BEHAVIORAL|Standard Diabetes Education|"Standard Diabetes Education Lesson including~* Health Care and specific Topics (e. g. Blood Pressure)~* Social Aspects of Living with Diabetes~* Diabetes Complications~* Sports, Activities and Exercise~* Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~* Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
223543804|NCT06301308|DRUG|intraurethral lidocaine gel + liquid paraffinl|Liquid paraffin were used to lubricate hte cystoscopy tube AND participants received 10 ml of intraurethral lidocaine gel at a concentration of 2%
223543805|NCT02733744|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
223543806|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess myofibrillar protein synthesis rates|Amino acid dose = 0.25g/kg bodyweight
223543807|NCT04887727|DIETARY_SUPPLEMENT|Crystalline amino acids to assess whole-body protein turnover, amino acid oxidation, and net protein balance|Amino acid dose = 0.25g/kg bodyweight
223543808|NCT01411423|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
223979523|NCT04973514|PROCEDURE|Cardiac surgery in grown-up congenital heart disease patients|Analysis of patient blood management, influence on 30 day and 6 month outcome
223979524|NCT05557149|DEVICE|Virtual Reality Exposure to Neutral Cues|Virtual reality exposure to neutral stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
223979525|NCT05557149|BEHAVIORAL|Respiratory Relaxation|Respiratory relaxation practise. No interaction with the investigator during the relaxation practise.
223979526|NCT05557149|DEVICE|Virtual Reality Exposure to Cocaine-Related Cues|Virtual reality exposure to cocaine-related stimuli (360 degrees visual and audio immersion with Oculus Quest 2 virtual reality headset). Participants stay sitted on chair and can tilt, rotate and move forward and backward upper body members. No interaction with the investigator during the virtual reality immersion.
223979527|NCT02384278|BEHAVIORAL|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
223979528|NCT02114983|OTHER|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
224118463|NCT02090582|OTHER|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
224118464|NCT02090582|OTHER|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
224118465|NCT05198167|OTHER|Hyperoxygenated fatty acids|Application of hyperoxygenated fatty acids in pressure zones for prevention of prone position pressure ulcers
224118466|NCT05198167|OTHER|Hydrocolloid dressings|Protection of pressure areas with hydrocolloid dressings for the prevention of prone pressure ulcers
223979529|NCT06310798|BEHAVIORAL|Inter-professional team test|"Digital Platform Support is used to improve communication and collaboration between the different stakeholders involved in the care of older adults. This platform allows for the sharing of oral health assessments, plans, and recommendations, ensuring all parties have access to the same information and can contribute to the care planning process.~Person-Centered, Three-Step Model:~Initial oral health assessments conducted by dental professionals, A person-centered planning process where the needs and preferences of the older adults are prioritized, The implementation of tailored oral health care plans, emphasizing shared decision-making and the active involvement of older adults in their care.~Educational Component: An important element of the intervention is the provision of a two-day course for nursing and dental staff."
223979530|NCT04733898|OTHER|SamenSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to elicit personal interaction.
223979531|NCT04733898|OTHER|FijnSpelen.app|An app designed to play simple, social games in a chat environment. These games are designed to not elicit personal interaction.
223979532|NCT00251264|PROCEDURE|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
223979533|NCT00251264|PROCEDURE|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
223979534|NCT01113164|DRUG|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
223979535|NCT00525018|DEVICE|contact heat evoked potential stimulator|
223979536|NCT00582114|DRUG|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
223979537|NCT00582114|DRUG|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \<140/90 mm Hg.
223979538|NCT05388097|OTHER|Managed Services|coordination of care and assistance with community resources (food, transportation)
223543809|NCT04455828|DEVICE|WHOOP strap 3.0|WHOOP strap 3.0, a photodiode-based device that tracks heart rate, respiratory rate, sleep, and heart rate variability.
223979539|NCT02604342|DRUG|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
223979540|NCT02604342|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
224118467|NCT01595646|DRUG|Saline|Saline, administered intranasally twice per day for a 16 week duration
223543810|NCT05160506|DRUG|Hydrocortisone|Hydrocortisone is a steroid (corticosteroid) medication.
223543811|NCT05160506|DRUG|Placebo|50ml of 0.9% NACL will serve as the placebo
223543812|NCT02971319|DEVICE|Tc-99M-Tetrofosmin SPECT|
223543813|NCT02971319|DEVICE|F-18 FDG PET|
223543814|NCT04751227|DRUG|Modafinil|100-200 mg oral daily for for Wakefulness in the Critical Care Units
223543815|NCT00094562|DRUG|Fish oil supplement|
223543816|NCT03811522|OTHER|carbon dioxide insufflation|Receives CO2 insufflation
223543817|NCT03811522|OTHER|Air insufflation|Receives air insufflation
223543818|NCT03440073|OTHER|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
223543819|NCT03440073|OTHER|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
223543820|NCT01696773|OTHER|Tangerine tomato juice|Post-prandial feeding study
223979541|NCT02604342|DRUG|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
223979542|NCT00130728|DRUG|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
223979543|NCT00130728|DRUG|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
223979544|NCT00130728|DRUG|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
223979545|NCT05230030|BEHAVIORAL|Improvisation Workshop|Each improvisation workshop will involve a series of exercises derived from an improvisation game book previously developed by study investigators, followed by a reflective debrief of the experience.
223979546|NCT01027663|DIETARY_SUPPLEMENT|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
223979547|NCT05582590|DRUG|Fludarabine|Lymphodepletion Chemotherapy on Days -5, -4, and -3 before Cycle 1 ONLY
223979548|NCT05582590|DRUG|Cyclophosphamide|Lymphodepletion Chemotherapy administered on Days -5, -4, and -3 before Cycle 1 ONLY
223979549|NCT05582590|BIOLOGICAL|NEXI-003 T cells|Adoptive Cell Therapy specified dose on specified day(s)
224118468|NCT01595646|DRUG|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
224118469|NCT01595646|DRUG|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
224118470|NCT00881829|DEVICE|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
223543821|NCT01696773|OTHER|Red tomato juice|Post-prandial feeding study
223543822|NCT02631291|BEHAVIORAL|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
223543823|NCT02631291|BEHAVIORAL|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
223543824|NCT00088491|DRUG|Intramuscular Olanzapine Depot|
223543825|NCT00088491|DRUG|Oral Olanzapine|
223543826|NCT03729635|PROCEDURE|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
223543827|NCT01486355|BIOLOGICAL|Measles vaccine|Edmonston-Zagreb measles vaccine
223979550|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
223979551|NCT00746356|DEVICE|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
223979552|NCT05729204|OTHER|Hypertonic seawater solution|Nasal irrigations with hypertonic seawater solution
223979553|NCT00032747|DRUG|Vasopressin V2 Receptor Antagonist|
223979554|NCT01449747|DRUG|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
223979555|NCT01825317|DEVICE|NeuroAD|synchronized TMS+COGNITIVE TRAINING
224118471|NCT05600712|DEVICE|REDAPT Sleeved Stem|The REDAPT Sleeved Stem is designed to provide secondary proximal support to the distal fixation and enhance implant stability.
224118472|NCT00693355|OTHER|Sodium butyrate|sodium butyrate
223979556|NCT01825317|DEVICE|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
223979557|NCT00511498|DRUG|Sildenafil|50 mg daily at bedtime
223979558|NCT03703843|DEVICE|ARTUS MONO|Temporarily implant and activation of the medical device
223979559|NCT04538222|OTHER|physical activity|aerobic exercise, muscle strength and stretching, nutrition education
223979560|NCT02595606|DRUG|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
223979561|NCT02881047|DEVICE|CO2 Laser|Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
223979562|NCT02881047|RADIATION|Ultrasound|Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
223979563|NCT02881047|DIAGNOSTIC_TEST|Skin Biopsy|standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
223979564|NCT01687868|DRUG|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
223979565|NCT02895321|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
223979566|NCT02895321|OTHER|Colgate, Protection Caries|a fluorine-based toothpaste gels
223979567|NCT02895321|OTHER|Placebo gel|a glycerin and water gel
224118473|NCT00693355|OTHER|NaCl|NaCl
224118474|NCT00693719|DRUG|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
224118475|NCT00693719|DRUG|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
224118476|NCT01221545|DRUG|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
224118477|NCT01221545|DRUG|Placebo|Placebo
224118478|NCT01418768|OTHER|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
224118479|NCT05615714|OTHER|Paresthesia-free Peripheral Nerve Field Stimulation|High frequency and sub-paresthesia threshold intensity parameters will be used for paresthesia-free stimulation of trigeminal nerve branches.
224118480|NCT05615714|OTHER|Sham stimulation|Stimulation will be turned off.
223979568|NCT03181282|BEHAVIORAL|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
223979569|NCT05959018|DEVICE|Arrow Three-Lumen Central Venous Catheter|Participants in the Non-impregnated CVC arm will receive Arrow Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
223979570|NCT05959018|DEVICE|Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter|Participants in the Antimicrobial-impregnated CVC arm will receive Arrowg+ard Blue Plus® Three-Lumen Central Venous Catheter inserted by healthcare personnel for critical care use
223979571|NCT00308399|DRUG|Itopride|
223979572|NCT05288504|DRUG|AVTX-002|Dose of 600 mg administered subcutaneously three times during the study.
223979573|NCT05288504|DRUG|Placebo|Placebo sourced as normal saline administered subcutaneously three times during the study.
223979574|NCT05455684|DRUG|Aticaprant|Aticaprant will be administered orally as tablets.
223979575|NCT05455684|OTHER|Placebo|Placebo will be administered orally as tablets.
223979576|NCT01664897|DRUG|Erlotinib Hydrochloride|Given PO
223979577|NCT01664897|OTHER|Laboratory Biomarker Analysis|Correlative studies
223979578|NCT01203956|DEVICE|SmartFlex|Device used with smartflex engaged.
223979579|NCT01203956|DEVICE|Standard|
223979580|NCT06015685|OTHER|Embedded Clinic|Once a week, a Primary Care clinic half-day will be dedicated to multi-disciplinary, team-based DM care. The inter-professional team will include an Internal Medicine attending physician, an Internal Medicine resident, a DM educator, a nurse trained in professional CGM, a behavioral health provider, and a social worker to assist in finding resources for housing, food, and patient assistance programs.
223979581|NCT06015685|OTHER|Routine Care|Researchers will use a 2:1 ratio of control to intervention patients. Using the CDW, researchers will identify a control population \[patients who receive routine care (i.e., referral to subspecialty care)\], who will be a propensity-matched cohort of individuals with similar age, gender, race/ethnicity, zip codes, insurance type, visit dates, and co-morbidities (Charlson Comorbidity Index) as the intervention group.
223979582|NCT02230306|DRUG|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
223979583|NCT02230306|DRUG|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
223979584|NCT04150471|OTHER|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
223979585|NCT04854902|PROCEDURE|Free gingival graft|1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region
223543828|NCT04694118|OTHER|rebound therapy|3 days a week in 12 weeks
223979586|NCT04854902|PROCEDURE|Cyanoacrylate|N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound
223979587|NCT04854902|PROCEDURE|Suture|The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
223979588|NCT06646133|DIAGNOSTIC_TEST|3D camera weight estimate|Weight estimation using 3D camera system
223979589|NCT06646133|DIAGNOSTIC_TEST|Standard methods of weight estimation|Standard methods of weight estimation will be used
224293726|NCT07211828|DRUG|low dose of alfentanil with propofol|Adjust dose of propofol to the upper limit before adjusting dose of alfentanil. Increase dose of propofol 0.5-1 ug/mL in order to have PSI valued 25-50. The initial dose of propofol is 1ug/mL, alfentanil 10 ng/mL. If propofol was adjusted to cet=5 ug/mL but PSI is still too high, increase alfentanil by 10 ng/mL instead. If alfentanil was adjusted to 0 but PSI is still too low, decrease propofol by 0.5-1 ug/mL instead . The range of dosage of propofol is 0-5 ug/mL while alfentanil is 0-50ng/mL.
223543829|NCT00641108|DRUG|ADAM SPECT plus Cognitive Therapy|
223543830|NCT00641108|DRUG|ADAM SPECT plus No Therapy|
223726915|NCT00774319|RADIATION|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
223979590|NCT06647316|OTHER|Physiotherapy|The subjects will receive the first physiotherapy session : early mobilization, postural and joint ergonomics, sensory stimulation, temporal-spatial orientation and health education for the patient and the main caregiver are carried out.The plan will progress with postural control in a seated position, head and trunk control, re-education of transfers, balance, standing and walking, depending on the subject's abilities.The second physical therapy session incorporates taste and preference-based elements into the therapy itself. The third physiotherapy session is planned to take place in the physiotherapy unit. Following the individualized session, group interaction is encouraged, whether with other patients, the rehabilitation team and/or the patient's primary caregiver.In the fourth physiotherapy session, it is promoted therapeutic compliance.
223979591|NCT04528290|DRUG|Ozanimod|Ozanimod capsule formulation of 0.92mg
223979592|NCT04528290|DRUG|Ozanimod|Ozanimod, granule formulation of 0.92mg
223979593|NCT04815785|DEVICE|TaurusOne® transcatheter aortic valve replacement system|The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
223979594|NCT06086119|DIAGNOSTIC_TEST|to assess the voice perception of the patient undergoing phonatory prosthesis placement surgery by evaluating the optimal score (>30) in terms of VHI.|Prospective, multicenter observational study involving patients who will undergo total laryngectomy surgery and placement of phonatory prosthesis
223979595|NCT04520841|DEVICE|Prevena TM|A Prevena Plus DuoTM Dressing Kit (KCI) is applied on the surgical wound at the end of surgery.
223979596|NCT04520841|DEVICE|Dry dressing|A standard dry sterile dressingwith non-adherent absorbent pad is applied on the surgical wound at the end of surgery
223979597|NCT00468065|DEVICE|VeinViewer|Veinveiwer is used to view veins subQ
223979598|NCT00468065|DEVICE|Veinviewer|near infrared light reveals veins subcutaneously
223543831|NCT05926063|OTHER|Comparison short vs extended EBAT treatment group|This study compares two management strategies of patients undergoing treatment with chemotherapy or a stem cell transplantation. One strategy is to treat these patients at the time of febrile neutropenia with a fixed 72 hours course of EBAT. The other, more commonly followed strategy is a longer minimum EBAT duration of 5 days as well as other variables like neutrophil recovery and defervescence. In both arms, definitive treatment is given when an infectious cause of the fever is found according to local guidelines (e.g. pneumonia or mucosits with bacteremia).
223543832|NCT00347932|DRUG|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
223543833|NCT00347932|DRUG|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
223543834|NCT00521677|PROCEDURE|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
223979599|NCT05819775|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
223979600|NCT02928809|DEVICE|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
223979601|NCT02928809|OTHER|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
224118481|NCT03029962|BEHAVIORAL|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
224118482|NCT02946229|DEVICE|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
224118483|NCT01161524|DRUG|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
224118484|NCT01161524|DRUG|Placebo|Matching Placebo taken once daily.
224118485|NCT02227407|DEVICE|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
224118486|NCT02688010|BEHAVIORAL|Noise reduction and cycled light|Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
224118487|NCT04211545|DRUG|Rabeprazole|Rabeprazole
224118488|NCT04211545|DRUG|CC-92480|CC-92480
224118489|NCT04089124|PROCEDURE|surgery of zone II cut flexor repair|we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
224118490|NCT03177577|DEVICE|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
224118491|NCT03177577|DEVICE|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
224118492|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
224118493|NCT01556633|DRUG|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
224118494|NCT03210285|DIAGNOSTIC_TEST|Whole exome sequencing|Whole exome sequencing
224118495|NCT03336840|DRUG|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
223543835|NCT00521677|PROCEDURE|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
223543836|NCT05650463|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
224118496|NCT03336840|DRUG|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
223543837|NCT04512001|DRUG|MSB11456|Participants will receive MSB11456 subcutaneously, once a week.
223726916|NCT00138476|DRUG|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
223726917|NCT00138476|BIOLOGICAL|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
223726918|NCT00340080|DRUG|Abacavir|
224118497|NCT03336840|DRUG|1. Metformin tablets; 2. ProMetS probiotics powder|"1. 0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night"
223726919|NCT02461563|DRUG|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
223726920|NCT02461563|DRUG|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
223726921|NCT02461563|DRUG|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
223726922|NCT03535870|DRUG|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
223726923|NCT03535870|DRUG|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
224118498|NCT02430792|BEHAVIORAL|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
223543838|NCT04512001|DRUG|EU-approved RoActemra|Participants will receive EU-approved RoActemra® subcutaneously, once a week.
223543839|NCT02776683|DRUG|BI 695502|
223543840|NCT02776683|DRUG|Avastin|
223543841|NCT01029912|DEVICE|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
223726924|NCT03535870|DRUG|Placebo|placebo dry powder administered via the LOMI inhaler device
223543842|NCT05236322|DEVICE|soft tissue laser|Surgical laser used in excision purpose
223543843|NCT01431898|DRUG|GS-9669 tablets|
223543844|NCT01431898|DRUG|Placebo to Match GS-9669 tablet|
223543845|NCT02019953|OTHER|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
224118499|NCT04346823|DRUG|Sevoflurane|"Each participant started by preoxygenation of 100% oxygen for 3minutes. Then, parturients breath 1% of sevoflurane in a mixture of oxygen and air (FIO2 0.5) by tight face mask with a gas flow of 6 L/min.~Thirty seconds after stating inhalation sedation, the obstetrician will be asked to start the procedure.The duration of ECV in addition to the level of difficulty estimated by obstetricians will be recorded. Usually, the duration of ECV does not exceed 10 minutes.~The intervention will be stopped if the woman reported severe pain, if version could not be achieved readily, or if prolonged fetal bradycardia, uterine bleeding or placental abruption occurred.~Parturient will be kept in Post Anesthesia Care Unit (PACU) for 45minutes. CTG will be monitored during PACU stay."
224118500|NCT00950781|PROCEDURE|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
224118501|NCT03224637|PROCEDURE|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
224118502|NCT03224637|DRUG|Paracetamol (conventional)|
224118503|NCT03224637|DRUG|Ketorolac Tromethamine (conventional)|
223726925|NCT01111149|OTHER|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
223726926|NCT01111149|DRUG|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
223726927|NCT01111149|DRUG|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
223726928|NCT04539847|DEVICE|High-end hearing aid|hearing aid with premium level of technology
223726929|NCT04539847|DEVICE|Basic hearing aid|hearing aid with basic level of technology
224118504|NCT03467022|DRUG|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
223979602|NCT06219161|DIETARY_SUPPLEMENT|NAD3|NAD3 supplement (per capsule): 344 mg microcrystalline cellulose,156 mg of a proprietary blend of Wasabia japonica (freeze-dried rhizome) cultivar, standardized to NLT 12,000 ppm isothiocyanates, 97.0% Theacrine, Copper Nicotinic Acid chelated complex (17-20% Copper by ICP-Mass spectroscopy)
224293727|NCT07212790|BEHAVIORAL|REAL-Fam Occupational Therapy Family Coaching|The REAL-Fam draws on the expertise of occupational therapy in evaluating the fit between the demands of everyday activities and the skills and abilities of the parent-child dyads. The dyad and the occupational therapist will be equipped to co-develop personalized strategies to enable participation in these meaningful occupations. It facilitates the family's consistent, habitual, and effective performance of their child's diabetes management tasks into their personalized daily routines. Emphasis is on the creation or modification of family-centered diabetes management and routines and catered to the child's developmental needs. Due to the complexity of diabetes management cares and the child's age, the caregiver will be present for all sessions. When working towards a caregiver-centered outcome, the caregiver will participate with little child involvement. When working toward a child-centered outcome, the child will be the focus of that session.
224293728|NCT07212179|DEVICE|AID + InsuLearn-SMA|Automated insulin delivery (AID) system with InsuLearn simplified meal announcement bolus calculator
224293729|NCT07212179|DEVICE|AID + CC|Automated insulin delivery (AID) system using usual carbohydrate counting bolus calculator
223726930|NCT01348945|OTHER|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
223979603|NCT00618917|GENETIC|Manganese Superoxide Dismutase Plasmid Liposome|15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
224293730|NCT07212348|BEHAVIORAL|Laughter Yoga|Students in the experimental group will participate in laughter yoga sessions conducted twice a week (Thursday and Friday) for four weeks, outside of class hours and in an indoor setting.
223726931|NCT00126841|PROCEDURE|CT and MR fusion|
223726932|NCT00061880|DRUG|forodesine hydrochloride|
223726933|NCT01366560|DRUG|Active|GSK962040 125mg
223726934|NCT01366560|DRUG|Placebo|Matching Placebo
223726935|NCT00332033|DRUG|Pirfenidone|
223979604|NCT00618917|DRUG|carboplatin|Chemotherapy to stop the growth of tumor cells.
223979605|NCT00618917|DRUG|paclitaxel|Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.
223979606|NCT00618917|RADIATION|Radiation Therapy|1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
223979607|NCT01012596|BEHAVIORAL|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
223979608|NCT04882748|OTHER|ADAMO|Physical therapy provided with or without the help of a robot
223979609|NCT00528710|DIETARY_SUPPLEMENT|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
224293731|NCT07209358|DEVICE|EDX110|EDX110 wound dressing system EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
224295316|NCT04054284|DIETARY_SUPPLEMENT|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
223726936|NCT03748160|OTHER|Letter|Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
223726937|NCT01890850|OTHER|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
223726938|NCT05975515|PROCEDURE|Connective tissue graft /Bone graft/ Customized HA|Soft tissue management and augmentation
223726939|NCT02368431|DRUG|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
223726940|NCT02368431|DRUG|Placebo|Placebo
223726941|NCT05460117|DEVICE|Radiofrecuency|he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
223726942|NCT05550402|DRUG|Salbutamol|Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
223726943|NCT05550402|DRUG|Ipratropium Bromide|Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
223726944|NCT05550402|DRUG|Salbutamol plus Ipratropium Bromide|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
223726945|NCT05550402|OTHER|Placebo|Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).
223726946|NCT04827329|OTHER|Questionnaire|Patients will complete a questionnaire regarding their anesthesia history, course and possible complications, and Questions about their treatment for their sleep disorder.
223726947|NCT01189214|DRUG|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
224295317|NCT01079884|DRUG|esomeprazole 40 mg|40 mg daily for 4 weeks
223726948|NCT05337007|OTHER|high protein diet|48 hours intervention with a 'high protein' ad libitum diet (30 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
223726949|NCT05337007|OTHER|moderate protein diet|48 hours intervention with a 'moderate protein' ad libitum diet (13 % protein; 80 % commercially available ultraprocessed foods) to measure energy balance in a metabolic chamber at physical activity level of 1.45
223726950|NCT03835611|OTHER|Game based treadmill Platform|"The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)"
223979610|NCT05481398|OTHER|Negative Pressure Wound Therapy|The wound is dressed using negative pressure wound therapy comprising of a single layer of sterile gauze followed by placement of a 18 Fr nelaton catheter and the wound further covered with 4 more layers of sterile gauze over the nelaton catheter. The wound is then covered with opsite dressing making it airtight. The nelaton catheter is attached to the wall suction port once the patient is shifted to the bed with pressure set at - 25 mm Hg.
223979611|NCT01503164|DEVICE|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
223979612|NCT01503164|BEHAVIORAL|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
223979613|NCT05404217|OTHER|LN-OS-22|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
224295318|NCT04248348|DRUG|Low Molecular Weight Heparin|Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
223726951|NCT03835611|OTHER|Control Group|"* Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes)."
223726952|NCT05039645|BEHAVIORAL|Patient specific, clinician determined Intervention|Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
223979614|NCT05404217|OTHER|Maltodextrin|2 capsules orally once a day to be taken with a glass of milk after breakfast for 56 days
223979615|NCT01211223|DRUG|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
223979616|NCT00472069|PROCEDURE|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
223979617|NCT01308047|DRUG|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
223979618|NCT06348745|DEVICE|ultrasound|5\. Transthoracic ultrasound for both right and left diaphragm during inspiration and expiration.
223979619|NCT00547183|DRUG|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
223979620|NCT00547183|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
223979621|NCT00547183|DRUG|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
223979622|NCT03591432|DEVICE|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
223979623|NCT03591432|DEVICE|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
223979624|NCT04168996|BEHAVIORAL|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
223979625|NCT05173259|BEHAVIORAL|F|The participant will be asked to chew the two-coloured chewing gum naturally.
223979626|NCT05173259|BEHAVIORAL|R|The participant will be asked to chew the two-coloured chewing gum on the right-side.
223979627|NCT05173259|BEHAVIORAL|L|The participant will be asked to chew the two-coloured chewing gum on the left-side.
223979628|NCT05173259|BEHAVIORAL|G05|The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
223979629|NCT05173259|BEHAVIORAL|G15|The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.
223726953|NCT01313936|DRUG|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
223726954|NCT05560997|DIAGNOSTIC_TEST|10-year ASCVD risk estimation|High CVD risk was defined as a history of CVD or a 10-year ASCVD risk ≥10%. The 10-year ASCVD risk estimation was carried out according to 2016 Chinese guidelines for the management of dyslipidemia in adults.
223726955|NCT05808491|RADIATION|online resilience intervention|online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
223979630|NCT05173259|BEHAVIORAL|G25|The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
223979631|NCT02480751|DRUG|Beraprost|
223979632|NCT02480751|DRUG|Placebo|
224118505|NCT01965548|PROCEDURE|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~* splenectomy~* splenic artery embolisation~* non-operative management~* any combination of the three treatments mentioned"
224118506|NCT02242539|BEHAVIORAL|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
224118507|NCT02242539|BEHAVIORAL|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
224118508|NCT05102201|DEVICE|Paro (social robot) intervention|Participants in the Paro group will receive a group (6-8 people as a group), facilitated, and 30-minute weekly session Paro intervention for 6 weeks
223979633|NCT05372471|OTHER|mHealth|ClouDi is a telemedicine platform that was developed for the remote monitoring of patients with diabetes in Colombia. It incorporated the recommendations that were published in a usability pilot study that was conducted previously with an open-source cloud platform. The platform consists of a web version, a version for mobile devices and a desktop application, which is installed on the patient's personal computer, thereby allowing glucose measurements taken through the Optium Neo glucometer (Abbott Diabetes Care, Alameda, CA, USA) to be uploaded automatically to the cloud. In this trial, the glucose measurements that were uploaded to the ClouDi website, were reviewed weekly by the members of the research group who were responsible for adjusting the therapy to the insulin titration scheme prescribed for the patient. The patients were informed about these adjustments by text messages sent from the web version of ClouDi to the patient's mobile phone via pop-up notifications.
223979634|NCT05372471|OTHER|Usual Care|They will have a regular visit after 3 months where the capillary glucose data will be evaluated in person by the clinical team, the insulin dose will be titrated according to the type of insulin and the presence of hypoglycemia.
223979635|NCT03074045|DRUG|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
223979636|NCT03074045|DRUG|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
223979637|NCT05087329|BEHAVIORAL|Virtual Mindfulness Meditation|Four week virtual mindfulness meditation course composed of four weekly group Zoom webinars during which participants will listen to a 15-20 minute pre-recorded meditation, facilitated by a study provider
223979638|NCT00282061|DRUG|Melatonin|
223979639|NCT01607099|PROCEDURE|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
223979640|NCT00584376|DRUG|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
223979641|NCT00584376|DRUG|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
223543846|NCT02019953|OTHER|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
223979642|NCT03159065|OTHER|Bilberry|Fruit beverage with bilberry and fermented oatmeal
223979643|NCT03159065|OTHER|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
223979644|NCT03159065|OTHER|Mango|Fruit beverage with mango and fermented oatmeal
223979645|NCT03159065|OTHER|Beetroot|Fruit beverage with beetroot and fermented oatmeal
223979646|NCT03159065|OTHER|Rose hip|Fruit beverage with rose hip and fermented oatmeal
223979647|NCT03159065|OTHER|Glucose drink|A reference glucose drink
223979648|NCT01199445|DIETARY_SUPPLEMENT|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
223979649|NCT01420900|DEVICE|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
223979650|NCT01420900|DEVICE|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
223979651|NCT04106453|PROCEDURE|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
223979652|NCT04106453|PROCEDURE|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
223979653|NCT04438330|OTHER|Nickel sulfate hexahydrate|Patch test
223979654|NCT02960256|DEVICE|ekocardiogram test|ekocardiogram test
223979655|NCT00092521|BIOLOGICAL|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
223979656|NCT00092521|BIOLOGICAL|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
224118509|NCT02696512|DRUG|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
223543847|NCT02019953|OTHER|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
223979657|NCT00092521|BIOLOGICAL|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
224118510|NCT02696512|DEVICE|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
224118511|NCT02696512|DIETARY_SUPPLEMENT|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
224118512|NCT02696512|OTHER|Standard of Care|Standard of Care treatment
224118513|NCT02688114|PROCEDURE|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
224118514|NCT02688114|PROCEDURE|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
224118515|NCT02688114|PROCEDURE|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
224118516|NCT02688114|PROCEDURE|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
224118517|NCT02688114|PROCEDURE|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
223979658|NCT03464383|DRUG|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
223979659|NCT03464383|OTHER|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
224118518|NCT05522114|PROCEDURE|TMJ injection using patient specific guide|Prefabricated patient specific guide used to guide the needle into the superior joint space of TMJ while real time MSCT evaluate the accuracy of needle position. Sodium hyaloronate injected within the superior joint space.
224118519|NCT03952312|BEHAVIORAL|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
224118520|NCT03952312|BEHAVIORAL|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
224118521|NCT00878228|DRUG|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
223979660|NCT03464383|OTHER|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
223979661|NCT03304613|BEHAVIORAL|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
223979662|NCT03304613|BEHAVIORAL|Promoting Resilience through Innovative Self-Management|Already noted.
223543848|NCT02507596|BIOLOGICAL|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
223543849|NCT02507596|PROCEDURE|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
223979663|NCT00605566|DRUG|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
223979664|NCT00605566|DRUG|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
223979665|NCT06090175|OTHER|Projector colleyscope group|Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.
223979666|NCT06090175|OTHER|Matching card group|Matching card will be used in children aged 3-6 who are administered inhaler medication.
223979667|NCT04505345|BEHAVIORAL|Cognitive training using the Systemic Lisbon Battery|The Systemic Lisbon Battery comprises exercises for cognitive rehabilitation developed to describe diverse activities of daily living.
223979668|NCT04505345|BEHAVIORAL|Treatment-as-usual|Treatment as usual for alcohol use disorder from Casa de Saúde do Telhal is delivered according to the Minnesota Model.
223979669|NCT05308277|DEVICE|Leo device monitoring|After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
223979670|NCT01921361|DRUG|Levobupivacaine|Intrathecal 3ml (15 mg)
223979671|NCT01921361|DRUG|Dexmedetomidine|Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
223979672|NCT01921361|DRUG|Dexmedetomidine|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
223979673|NCT01921361|DRUG|sodium chloride|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
223979674|NCT04361383|OTHER|control group|the patient will receive general anesthesia
223726956|NCT04035928|DEVICE|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
223726957|NCT06493721|PROCEDURE|Clear Aligner Treatment|Clear aligner therapy to treat incisors crowding
223979675|NCT04361383|PROCEDURE|quadratus lumborum block type 3|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
223979676|NCT04361383|PROCEDURE|erector spinae plane block|patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
223979677|NCT00837590|DRUG|Chronic salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
223979678|NCT00837590|DRUG|Acute Salsalate|Subjects will receive a single oral dose of 2 gram of oral salsalate
223979679|NCT02332304|PROCEDURE|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
223979680|NCT05470270|DRUG|Hydroxycarbamide|Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
223979681|NCT01709396|RADIATION|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
223979682|NCT04260464|DRUG|PF-06700841|A single dose of 30 mg PF-06700841 will be administered on Day 1
223979683|NCT06465992|DRUG|Exparel 266 MG Per 20 ML Injection|20 mL Liposomal bupivacaine (Exparel, 266 mg) will be administered in the popliteal and saphenous block
223979684|NCT06465992|DRUG|Bupivacaine Hcl 0.75% Inj|10 mL of 0.75% bupivacaine will be administered in popliteal and saphenous block
223979685|NCT06465992|DRUG|Dexamethasone|1 mL of 10 mg Dexamethasone will be administered in the popliteal and saphenous block
223979686|NCT03344016|OTHER|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
223979687|NCT06310083|PROCEDURE|Submucosal Resection Turbinoplasty Versus Partial Inferior Turbinectomy|The study's Participants Were Randomly classified in two groups Interventional Group, applied for Submucosal Resection Turbinoplasty and the controlled group who were applied for Partial Inferior Turbinectomy
223979688|NCT05390996|OTHER|dental implant placement|dental implant placement by using a different drilling techniques
223979689|NCT02895243|OTHER|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
223979690|NCT03353142|OTHER|Equal Breathing|"* Blood pressure recorded at baseline, immediately pre- and post-trial~* Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~* PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~* TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
223979691|NCT04390412|RADIATION|Low Dose Radiotherapy|0.5 Gy radiation to both lungs in an AP/PA treatment plan
223979692|NCT03384147|DIETARY_SUPPLEMENT|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
223979693|NCT03384147|OTHER|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
223979694|NCT03901443|OTHER|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
223979695|NCT04724096|DIAGNOSTIC_TEST|Oxygen Enhanced MRI scan|Dynamic MRI scanning switching from breathing room air to high concentration oxygen part way through the scan.
223979696|NCT01395849|DRUG|Salmeterol and Fluticasone|
223979697|NCT06351462|OTHER|Spermogram|Spermogram will be proposed to men
223979698|NCT06351462|OTHER|Hospital Anxiety and Depression Scale (HADS)|Anxiety and depression will be evaluated 10 years after HSCT
223979699|NCT06351462|OTHER|SF36 Quality of life questionnaire|Quality of life will be evaluated 10 years after HSCT
223979700|NCT06351462|OTHER|Psychologist interview|During a follow-up visit
223979701|NCT06351462|OTHER|Optional sera banking|One in the study
223979702|NCT06351462|OTHER|Optional DNA banking|Once in the study
223543850|NCT04998500|BIOLOGICAL|Growth hormone, saline and GH receptor blockade (Pegvisomant)|This study aims to uncover physiological effects of growth hormone (GH). The intervention with GH and GH receptor blockade (Pegvisomant) will therefore be used as tools to activate a well-known physiological response. Thus, this study is not a drug trial.
223979703|NCT03607617|OTHER|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
223979704|NCT00695136|DRUG|Donepezil hydrochloride|
223979705|NCT00695136|BEHAVIORAL|Increase REM sleep percentage|
223979706|NCT03469492|DRUG|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
223543851|NCT05234918|DEVICE|Pediatric Rotary File Systems|"* Kedo S plus (p1 molar file ) (A1 anterior file)~* Kidzo-file system 25/4 30/4 30/6"
223979707|NCT03469492|BEHAVIORAL|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
223979708|NCT03469492|DIETARY_SUPPLEMENT|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
223979709|NCT03912974|DRUG|Escitalopram|see 'arm description'
223979710|NCT03912974|DRUG|Placebo oral capsule|see 'arm description'
223979711|NCT02925936|OTHER|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
223979712|NCT02925936|OTHER|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
223979713|NCT06198699|DIETARY_SUPPLEMENT|Jing Si Herbal Tea|Consuming Jing Si Herbal Tea for three months; twice per day with each time 14 g of Jing Si Herbal in 600 ml water
223979714|NCT06198699|DIETARY_SUPPLEMENT|Barley Tea|Consuming Barley Tea for three months; twice per day with each time 600 ml barley tea consumption
223979715|NCT02331810|DRUG|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223979716|NCT02331810|DRUG|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223979717|NCT04067349|OTHER|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
223979718|NCT03184597|DIAGNOSTIC_TEST|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
223979719|NCT04249050|DIETARY_SUPPLEMENT|Oral Impact powder|Oral nutritional supplement containing fish oil, arginine and RNA
223979720|NCT01597583|BEHAVIORAL|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
223979721|NCT04710186|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, arterial tissues were excised, homogenized using a motor driven homogenizer and total RNA was isolated using Trizol reagent (Invitrogen, Milan, Italy), in accordance with the manufacturer's instructions. The expression of Androgen Receptor (AR), insulin receptor (IR) and the IGF-I receptor (IGF-IR) will be quantified by real-time PCR using platform Quant Studio7 Flex Real-Time PCR System (Thermo Fisher Scientific, Milan, Italy), following the manufacturer's instructions.
223979722|NCT04927962|OTHER|Questionnaires|For youth: self-reported questionnaires (on oral quality of life, bullying and cyberbullying, dental anxiety) and routine clinical examination for adolescents. For one parent: self-reported questionnaires (on perceived oral quality of life of their child and on their own dental anxiety).
223979723|NCT00542932|OTHER|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
223979724|NCT01138371|PROCEDURE|LDL Apheresis|LDL Apheresis
223979725|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
224118522|NCT00878228|DRUG|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
223543852|NCT00412581|DRUG|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
223979726|NCT02654899|OTHER|Placebo|Placebo
223979727|NCT02654899|DRUG|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
223979728|NCT02826798|DRUG|VBI-1501A 0.5 μg|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
223979729|NCT02826798|DRUG|VBI-1501A 1.0 μg|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
223979730|NCT02826798|DRUG|VBI-1501A 2.0 μg|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
224295319|NCT02213952|DRUG|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
223543853|NCT00412581|DRUG|Dacarbazine|600 mg/m\^2 intravenously on Day 1 of every study cycle.
223543854|NCT02385006|BIOLOGICAL|Blood sample|
223543855|NCT02973139|OTHER|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
223543856|NCT02973139|OTHER|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
223543857|NCT04873440|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d twice a week
223979731|NCT02826798|DRUG|VBI-1501 1.0 μg|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
223979732|NCT02826798|DRUG|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
223979733|NCT00008320|DRUG|ceramide|
223979734|NCT05932706|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
223979735|NCT05932706|DEVICE|sham high definition transcranial alternating current stimulation|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 30-minute intervention.
224293732|NCT07212725|BEHAVIORAL|Solving SCI Pain: Peer-Led Pain Self-Management Pain Tools Program|Solving SCI Pain Tools is a 7-week, peer-led, neuroscience-informed pain self-management program uniquely designed for individuals with spinal cord injury (SCI) and chronic pain. It integrates cognitive and body-based tools not commonly combined in other interventions, such as red light therapy, percussion massage, Graston technique, and guided movement, alongside education on pain neurobiology and behavior change. The program is delivered virtually and emphasizes participant autonomy, optionality, and personal relevance. Distinctively, it includes multiple individualized coaching sessions led by a peer with lived experience of SCI and pain. The program does not prescribe a fixed protocol but encourages flexible, self-paced exploration supported by structured check-ins. The integration of optional, non-clinical somatic tools with behavior-change coaching and SCI-specific education distinguishes this intervention from traditional rehabilitation or pain management programs.
224293733|NCT07213037|DRUG|Dexmedetomidine|patients will receive dexmedetomidine(D) in dose 0.2 μg/kg/h infusion via syringe pump during surgery
224293734|NCT07213037|DRUG|Magnesium sulfate|patients will be given intravenous dose 30mg/kg.
224293735|NCT07213037|DRUG|lidocaine|patients will be given in one dose 1.5 mg/kg.
224293736|NCT07211503|OTHER|blood sampling|The study involves the collection of an additional aliquot of cord blood and an additional aliquot of maternal venous blood.
224293737|NCT07211906|OTHER|Control Group: oral hygiene education standard|oral hygiene education Standard care: oral hygiene education standard care, which involved providing participants with printed oral health education leaflets without additional personalized instruction or digital support. Specifically, participants were assessed at baseline, and then, at one-month intervals, they received printed oral care instructions and completed follow-up assessments. This group was not provided oral education or interactive guidance via digital platforms during the study period.
223543858|NCT04873440|RADIATION|Radiotherapy|Measurable lesions were targeted for radiotherapy at the discretion of the treating physician.Standard-of-care radiotherapy or SBRT were both allowed.
223543859|NCT04873440|DRUG|Chemo-immunotherapy|The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
223543860|NCT05040646|OTHER|Delphi exercise|"During the Delphi exercise both patients and experts will participate in two anonymous online survey rounds where different items/outcomes will be presented that are possibly related to rectal cancer and the W\&W program. Both groups are asked to rate each item on a 9 point likert scale with respect to the importancy of the item.~After the two subsequent rounds, participants will be invited to attend a consensus meeting, where final consensus about the most important outcomes will be reached."
223543861|NCT03110484|DRUG|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
223543862|NCT03110484|DRUG|Erlotinib|Erlotinib 100mg once daily
223543863|NCT01285024|DEVICE|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
223979736|NCT03887247|BEHAVIORAL|E-mail Alert|Encrypted email to the following providers: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. If there is more than one provider, they are copied together on the same message. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. When multiple providers are involved, the message encourages the providers to coordinate with each other and provides provider contact information to facilitate this communication.
223979737|NCT05528822|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
224293738|NCT07211906|OTHER|oral hygiene education program|"Oral hygiene education program:~The oral hygiene education program includes a Line-based oral care guidance program, which involves personalized, one-on-one oral health education facilitated through the Line communication platform. The process began with an initial pre-test assessment, including interviews and questionnaire evaluations. Then, the participants engaged in the Line-guided oral care intervention, where they received tailored guidance and demonstrated"
223543864|NCT01698931|DRUG|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
223726958|NCT06493721|PROCEDURE|Low level laser|Apply clear aligner therapy with low level laser application on incisors
223726959|NCT02551731|DRUG|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
223726960|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in
223979738|NCT05528822|PROCEDURE|ultrasound-guided pericapsular nerve group (PENG) block|A low-frequency curvilinear transducer was placed in the transverse plane over the anterior inferior iliac spine (AIIS) and moved over inferiorly to visualize the pubic ramus. The femoral artery and ilio pubic eminence (IPE) were then visualized (Figure 1). Using in-plane technique 10 cm echogenic 21 gauge needle was advanced from lateral to medial direction, and 20 ml of local anesthetic 0.5% ropivacaine was deposited between the psoas tendon anteriorly and pubic ramus posteriorly.
223979739|NCT03320395|DEVICE|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
223979740|NCT06114134|DIETARY_SUPPLEMENT|Fenobet|receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)
223979741|NCT06114134|DIETARY_SUPPLEMENT|Placebo|Placebo
223979742|NCT02806505|DRUG|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
223979743|NCT04387045|BEHAVIORAL|Guilty feelings|Participants write for 20 minutes about situations that have caused them feelings of guilt throughout their lives.
224118523|NCT02159092|BEHAVIORAL|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
224118524|NCT02151539|OTHER|medical chart review|Ancillary studies
223543865|NCT01698931|DRUG|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
223543866|NCT01698931|DRUG|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
223543867|NCT01059006|PROCEDURE|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
223543868|NCT05196373|DRUG|STP705|STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.
223543869|NCT05502003|OTHER|High Intensity Interval Training|Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
223979744|NCT02377323|OTHER|MACFIMS|Cognitive evaluation of 50 participants
224118525|NCT02151539|OTHER|quality-of-life assessment|Ancillary studies
224118526|NCT02021812|DEVICE|GORE® TAG® Thoracic Branch Endoprosthesis|
224118527|NCT03634072|PROCEDURE|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
224118528|NCT06106425|DIAGNOSTIC_TEST|EEG|diagnostic tool
224118529|NCT01193725|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
224118530|NCT01193725|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
224118531|NCT01193725|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
224118532|NCT04016363|OTHER|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
224118533|NCT04016363|OTHER|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
224118534|NCT02307526|DRUG|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
224118535|NCT02307526|DEVICE|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
223979745|NCT02377323|OTHER|MSQoL-54|Quality of life questionnaires
223979746|NCT06410339|DIAGNOSTIC_TEST|Ultrasound|ultrasound of flexor tendons on hands
223979747|NCT06338436|DEVICE|Proton Radiation Therapy System (ProBeam)|All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.
223979748|NCT06049069|DIAGNOSTIC_TEST|physical activity in stroke|physical activity in stroke
223979749|NCT02979171|DEVICE|Laryngeal Mask Airway Classic|
224118536|NCT04390698|PROCEDURE|paravertebral block|Paravertebral block will be performed at T2,T4 level on the surgical side using out-of-plane approach under ultrasound-guided, with 0.4% ropivacaine 20ml at each injection site.
224118537|NCT04390698|DRUG|opioid free anesthesia|propofol, lidocine and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained.
224118538|NCT04390698|PROCEDURE|sham block|Local infiltration at the same site of paravertebral block will be performed, with 1% lidocaine 3ml on each injection site.
224118539|NCT04390698|PROCEDURE|opioid general anesthesia|propofol, sufentanil and muscle relaxant will be used for induction, after laryngeal mask airway insertion, general anesthesia will be maintained .
224118540|NCT06667284|PROCEDURE|Roux en y procedure|subtotal gastrectomy en bloc with Roux-en-Y reconstruction, using TA 90 and GIA staplers. The length of the biliopancreatic limb was 50 cm, while the alimentary limb was 80 cm
224118541|NCT06667284|PROCEDURE|Omega brown procedure|Gastrojejunal anastomosis with jejunojejunal anastomosis
223543870|NCT05502003|OTHER|Moderate Exercise Training|The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
223543871|NCT04702386|BEHAVIORAL|Focus groups|Groups of 3 to 8 children led by the study psychologist lasting 1 hour for the 8-11-year-old children and up to 2 hours for the children of at least 12 years old, about being the child of a parent with CF
223543872|NCT04702386|BEHAVIORAL|Individual interviews|Interview led by the psychologist about being the child of a parent with CF
223543873|NCT01379807|DRUG|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
224118542|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
224293739|NCT07212309|BEHAVIORAL|Board Game-Based Hydration Education Program|A six-week educational program delivered through board games, designed to improve hydration knowledge, practices, and status among school children. The program includes interactive sessions, quizzes, and games that teach the importance of adequate water intake. It is integrated into regular school activities and monitored for engagement and adherence.
224293740|NCT07211490|DEVICE|Repetitive Transcranial Magnetic Stimulation|1 Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.
223979750|NCT03550053|DEVICE|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
223979751|NCT04831047|DRUG|Oxymetazoline hydrochloride 0.1% ophthalmic solution|One drop of Upneeq (Oxymetazoline hydrochloride 0.1% ophthalmic solution) will be applied to the ocular surface of each eye.
223979752|NCT04831047|DRUG|Placebo|One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
223979753|NCT02219698|DRUG|Ibuprofen|
223979754|NCT02219698|DRUG|Paracetamol|
223979755|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
223979756|NCT01333111|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
223979757|NCT01333111|DRUG|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
223979758|NCT05141227|PROCEDURE|Two-stage Open reduction and internal fixation ( ORIF) using plates & screws|Two stage ORIF using initially temporary spanning fixator then conversion to plates \& screws
223979759|NCT05141227|PROCEDURE|single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed|Single stage Ex.Fix. Using illizarov \& minimal fixation of the articular surface using cannulated screws through mini open approaches
223979760|NCT01955759|DRUG|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
223979761|NCT01955759|DRUG|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
224118543|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
224118544|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
224293741|NCT07211490|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham Hz rTMS for 20 minutes, followed by 1.5 hours of motor training.
224293742|NCT07211581|PROCEDURE|total thyroidectomy|both lobes removed and observe the calcemic level
223543874|NCT04232943|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (IPV)|"IMOVAX® Polio is a highly purified, inactivated poliovirus vaccine. Each 0.5 mL dose contains:~* Type 1 (Mahoney) 40 D-antigen units~* Type 2 (MEF1) 8 D-antigen units~* Type 3 (Saukett) 32 D-antigen units"
223543875|NCT04232943|BIOLOGICAL|E.coli Double Mutant Heat-Labile Toxin (dmLT) (adjuvant)|"LT (R192G/L211A), or dmLT, is a protein toxoid derived from wild-type enterotoxigenic Escherichia coli (ETEC) labile toxin (LT). The LT toxin has been shown to have inherent mucosal adjuvant properties for co-administered antigens and thus has potential as a mucosal adjuvant for different co-administered vaccines. LT has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites, which are critical for activation of the secreted toxin molecules."
223979762|NCT01955759|DRUG|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
223979763|NCT02161406|DRUG|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
223979764|NCT02161406|DRUG|Placebo|125 mg of Placebo
223979765|NCT00846508|DRUG|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
223979766|NCT03888222|DRUG|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
223979767|NCT03888222|DRUG|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
224293743|NCT07213011|OTHER|Neck static stretching|The neck static stretching (SS) protocol consisted of four sets, each lasting 45 seconds, interspersed with 45-second recovery periods (total intervention time: 3 minutes). While seated on a chair, participants performed the stretch by gently inclining the head forward and to the left in an antero-lateral direction and assisting the movement with the contralateral (left) hand to specifically elongate the right posterolateral neck region.
224293744|NCT07213011|OTHER|Neck self-myofascial release|For the self-myofascial release (SMR) intervention, a Theraband® roller massager was employed. The device consists of a rigid plastic core surrounded by dense foam, designed with a grooved surface to facilitate both superficial and deeper tissue stimulation. The SMR protocol comprised four sets (total intervention time: 3 minutes), during which participants executed 45 rhythmic rolling movements per set at a cadence of one roll per second. The tempo was standardized using a metronome application. For the SMR condition, the protocol included 45-second recovery intervals between sets. Participants, seated on a chair, were instructed to perform self-administered rolling on the right posterolateral neck region using the massage roller and to cover the largest possible area of the posterolateral neck region during the rolling, with the head gently inclined forward and to the left in an antero-lateral direction.
224293745|NCT07212647|OTHER|Home Exercise Group|Patient education + structured, video-based home exercise program Participants instructed to perform exercises 5 days per week for 6 weeks Adherence monitored via logs and telephone follow-up at week 3
223543876|NCT04232943|BIOLOGICAL|Bivalent Oral Polio Vaccine (bOPV)|"Polio Sabin™ One and Three (oral) is a bivalent, live attenuated poliomyelitis virus vaccine of the Sabin strains Type 1 (LSc, 2ab) and Type 3 (Leon 12a, 1b), propagated in MRC5 human diploid cells.~Each dose (0.1 mL) contains not less than 10⁶ 50% cell culture infectious dose (CCID₅₀) of Type 1 and 10⁵·⁸ CCID₅₀ of Type 3."
224293746|NCT07212647|OTHER|Topical Therapy Group|Patient education + 1.5% diclofenac sodium gel Participants applied gel to anterior, medial, and lateral aspects of the knee, once daily, without massage techniques, for 6 weeks
223543877|NCT06070818|OTHER|Healthy Body & Mind Program|12-week physical activity and lifestyle education program
223543878|NCT06004206|DEVICE|nPSV and PSV|Ventilation with neurally adjusted modes or pressure support modes
223543879|NCT05976659|DEVICE|Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)|Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
223543880|NCT02695914|DRUG|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
223543881|NCT00435630|OTHER|LapSim training|complete curriculum training on LapSim surgical simulator
223543882|NCT00484341|DRUG|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
223543883|NCT00484341|DRUG|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
223543884|NCT00484341|DRUG|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
223543885|NCT03101319|DRUG|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
223543886|NCT03101319|DRUG|B Complex Oral Tablet|As mentioned in the description of the study arm
223543887|NCT02575443|DRUG|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
223543888|NCT02575443|DRUG|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
223543889|NCT01312727|OTHER|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
223543890|NCT04164810|OTHER|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
223543891|NCT04164810|OTHER|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
223543892|NCT00000226|DRUG|Buprenorphine|
223543893|NCT00484783|PROCEDURE|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
223543894|NCT00484783|PROCEDURE|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
223543895|NCT04891913|DRUG|SY-007/ Placebo 15mg|15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
223543896|NCT04891913|DRUG|SY-007/ Placebo 30mg|30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
223543897|NCT04891913|DRUG|SY-007/ Placebo 60mg|60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
223543898|NCT02448134|BEHAVIORAL|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
223543899|NCT01718522|DEVICE|sensor augmented pump (SAP)|
223543900|NCT01623505|DRUG|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
223979768|NCT00664105|DRUG|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
223979769|NCT00664105|DRUG|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
223979770|NCT00664105|RADIATION|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
223979771|NCT01612247|DRUG|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
223979772|NCT01875341|DEVICE|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
223979773|NCT01875341|DEVICE|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
223979774|NCT05155891|DEVICE|Embosphere Microspheres|The SOC PAE procedure will be performed by attempting to embolize prostatic arteries of both sides in a single session with 300-500 um Embosphere Microspheres. The microspheres will be mixed with a contrast agent and will be delivered to the arteries supplying the prostate via a microcatheter.
223979775|NCT05155891|PROCEDURE|HoLEP Procedure|The SOC PAE procedure will be performed with the SOC HoLEP as per standard institutional guidelines. The HoLEP procedure involves passing a telescope through the urethra and removing the central part of the prostate gland using a laser.
223979776|NCT04732871|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
223979777|NCT03339271|BEHAVIORAL|Technology-Enhanced Support|The study nurse will meet with the caregiver daily until patient is discharged from the hospital. The caregiver will take home an iPad upon discharge, and will have an initial video chat with the study nurse within 24-48 hours of hospital discharge and weekly for 8 weeks after that.
223979778|NCT03339271|BEHAVIORAL|Usual Care Support|The patient's doctor and nurses with input from the Palliative Care service will help the caregiver make a plan for discharge of the patient, and for taking care of the patient upon discharge. Someone from the study team will call the caregiver once a month for the duration of the study after the patient discharges from the hospital.
223979779|NCT06134947|OTHER|Echocardiographic examination|"Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~* Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE \<-2 Z Score is considered abnormal .~* Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler \<-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś)."
223979780|NCT02034162|DRUG|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
224118545|NCT01800604|BEHAVIORAL|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
224118546|NCT02112604|DEVICE|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
224118547|NCT02112604|DEVICE|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
224118548|NCT02112604|OTHER|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
224118549|NCT02112604|OTHER|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
223726961|NCT05951790|DEVICE|Inspiratory Muscle Training (IMT) + Air Stacking|Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity
224118550|NCT02112604|OTHER|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
223726962|NCT00971854|PROCEDURE|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
223726963|NCT00817024|DRUG|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
223726964|NCT00817024|DRUG|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
223979781|NCT02034162|DRUG|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
223979782|NCT02450695|DEVICE|rTMS|
223979783|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use supplementary food (RUSF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf
223979784|NCT06056089|DIETARY_SUPPLEMENT|ready-to-use therapeutic food (RUTF)|standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
223726965|NCT00817024|DRUG|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
223979785|NCT04556409|DEVICE|low intensity pulsed ultrasound plus static abdominal and pelvic floor exercises.|Ultrasonic irradiation was employed with parameters of current use in clinical practice, including lower potency (0.16 W/cm2), which is more adequate for stimulation of nerve regeneration, according to results obtained in investigations in which the irradiation was applied at the lesion site 32, 33.
223979786|NCT04556409|DEVICE|low level LASER plus static abdominal and pelvic floor exercises.|Application of laser irradiation (Ga-As laser) in the site of the anastomosis inhibits the degeneration process, accelerate remyelination, and nerve function recovery 27, 28
223979787|NCT04556409|OTHER|static abdominal and pelvic floor exercises only.|static abdominal and pelvic floor exercises., 3 times/week for 4 weeks.
223979788|NCT03379545|DIAGNOSTIC_TEST|3-dimensional (3D) magnetic resonance (MR) imaging|MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.
223979789|NCT03379545|DIAGNOSTIC_TEST|3D computed tomography (CT) imaging|The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
223979790|NCT01445795|DRUG|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
223979791|NCT01445795|DRUG|Placebo QD Fasted|Placebo capsule QD fasted x7 days
223979792|NCT01445795|DRUG|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
223979793|NCT01445795|DRUG|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
223979794|NCT01445795|DRUG|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
223979795|NCT01445795|DRUG|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
223979796|NCT01445795|DRUG|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
223979797|NCT01445795|DRUG|Placebo BID Fasted|Placebo BID fasted x7 days
223979798|NCT01445795|DRUG|ribavirin|
223979799|NCT04224454|OTHER|Questionnaire|"Questionnaire was adapted from questionnaires used by the French national agency Institut de Veille Sanitaire to study vaccination coverage and were completed with the assistance of one fellow to limit missing data."
223979800|NCT05380128|GENETIC|Genotype analysis for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms|Genomic DNA was extracted from peripheral blood samples using a Wizard Genomic DNA Purification Kit (Promega, Madison,Wisconsin, USA) as per the product instruction. VDR (rs731236, rs1544410, rs7975232, rs2228570) polymorphisms were genotyped by the improved Multiple Ligase Detection Reaction (iMLDR) developed by Genesky Biotechnologies Inc. (Shanghai, China).
223979801|NCT00097838|BIOLOGICAL|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
223979802|NCT00097838|OTHER|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
223979803|NCT03990142|DIAGNOSTIC_TEST|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
224118551|NCT02112604|DRUG|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
224118552|NCT03959618|OTHER|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
223979804|NCT03271749|OTHER|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
224118553|NCT02077049|DEVICE|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
224293747|NCT07212166|OTHER|Patient-Reported Outcome Surveys|PRO-AYA , Patient-Reported ECOG PS, EORTC QLQ-C30, Demographic/Clinical Characteristics
224293748|NCT07212166|OTHER|Spanish version of PRO-AYA and the cognitive interview|Revised Spanish PRO-AYA, Demographic/Clinical Characteristics
224293749|NCT07211438|DRUG|Psilocybin|25 mg Psilocybin
224293750|NCT07212855|PROCEDURE|Professional oral hygiene with glycine powder|Professional removal of hard and soft deposits using titanium curettes, spongy interdental floss, and air-polishing with glycine powder. The glycine powder used had a particle size of 25 μm and was applied using a supragingival nozzle positioned 3 mm from the prosthetic restoration, with particular attention given to the areas in direct contact with the mucosa.
224293751|NCT07212855|DEVICE|Domiciliary oral hygiene with angle toothbrush|Patients were motivated and instructed to use an angled-handle toothbrush (Specialist Implant, Curasept S.p.A., Saronno, Italy), in addition to a standard toothbrush and implant floss. The specific design of the angled handle was intended to facilitate access to areas that are difficult to clean. In patients rehabilitated with full-arch implant-supported prostheses, these areas typically include distal cantilevers and surfaces in direct contact with the mucosa.
224293752|NCT07213167|OTHER|None-placebo|No interventions.
223726966|NCT05446467|COMBINATION_PRODUCT|pembrolizumab+cisplatin + 5-FU|ivgtt, pembrolizumab 200mg d1+cisplatin20 mg/m2 qd d1-d3 + 5-fluorouracil 3000mg/m2 last for 120hours, six circles. Subjects will undergo surgery after receiving neoadjuvant chemotherapy within 3 weeks, followed by adjuvant therapy and pembrolizumab alone maintenance treatment.
223979805|NCT03458728|DRUG|Copanlisib (BAY806946)|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
223726967|NCT00968656|RADIATION|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
223726968|NCT00968656|OTHER|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
223726969|NCT00968656|OTHER|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
223726970|NCT00968656|OTHER|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
223726971|NCT00968656|DRUG|F-18-ISO|Patients receive F-18-ISO-1 i.v.
223726972|NCT00729989|PROCEDURE|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
223726973|NCT05259696|BIOLOGICAL|E-602|Subjects will receive E-602 (administered weekly, via IV infusion).
223726974|NCT05259696|BIOLOGICAL|Cemiplimab|Subjects will receive cemiplimab (administered once every 3 weeks, via IV infusion).
223726975|NCT06468397|DEVICE|iSeelr™|The iSeelr™ device will be used to deliver 1940nm laser output along with low airflow to seal a retinal tear
223726976|NCT06412848|DRUG|Avelumab|This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
223726977|NCT04771520|DRUG|Avapritinib|Given PO
223726978|NCT05149807|DRUG|SHR-1701 injection|SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
223726979|NCT05149807|DRUG|Placebo|Placebo Tegafur Gimeracil Oteracil Potassium Oxaliplatin
223726980|NCT04696445|DRUG|Morphine & Oxycodone|Morphine and Oxycodone are used in daily practice as part of standard care. Morphine and Oxycodone will be acquired through the clinical pharmacy of St Antonius and administered according to the standard postoperative pain protocol.
223726981|NCT01589744|DEVICE|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
223726982|NCT01678911|DRUG|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
223726983|NCT04697524|BEHAVIORAL|Support Group Therapy|Virtual group meetings
223726984|NCT04697524|BEHAVIORAL|Symptom Management Service (SMS) Consultation|Virtual individual meetings with symptom management service (SMS) over 5 minutes
223726985|NCT04697524|OTHER|Quality of Life (QOL) Questionnaires|Administered at each study visit
223726986|NCT04697524|OTHER|Interview|Virtual exit interview at end of study
223726987|NCT05460845|BEHAVIORAL|Low-Carbohydrate Diet|Using a meal delivery service and a list of prepared meals and recipes, foods/meals will be delivered to participants weekly to maintain daily net carbohydrate intake to less than 40 grams.
223726988|NCT03628560|DEVICE|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
223726989|NCT03628560|DEVICE|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
223979806|NCT04453163|PROCEDURE|Vertebroplasty|Patient will undergo a surgery in percutaneous vertebroplasty
223979807|NCT02999737|BIOLOGICAL|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
223726990|NCT03628560|DEVICE|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
223726991|NCT03628560|DEVICE|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
223726992|NCT03628560|DEVICE|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
223726993|NCT01073891|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
223726994|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
223979808|NCT02999737|BIOLOGICAL|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
223979809|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
223979810|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
223979811|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
223979812|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
223979813|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
223979814|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
223979815|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
223979816|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
223979817|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
223979818|NCT00848848|BIOLOGICAL|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
224118554|NCT02077049|OTHER|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
224118555|NCT06359249|BEHAVIORAL|change of habits|change of habits
224118556|NCT06359249|OTHER|change of habits + auto abdominal massage|change of habits + auto abdominal massage
224118557|NCT04052958|DEVICE|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
224118558|NCT05604612|PROCEDURE|Corticision|Incisions in the cortical plate of maxillary bone
224118559|NCT06295510|OTHER|No interventions.|It's only observational study.
224118560|NCT03207828|BEHAVIORAL|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
223979819|NCT00640744|DRUG|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
223979820|NCT00077597|DRUG|epoetin|3 times a week iv, as prescribed.
223979821|NCT00077597|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
223979822|NCT04729842|PROCEDURE|Axillary Brachial plexus block|Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
223979823|NCT05451797|DEVICE|Implant of WiSE-CRT with intracardiac pacemaker|Implant of two cardiac devices
223979824|NCT01501292|OTHER|Fixation and staining|Fixation and staining by MitiTracker Green FM
223979825|NCT01501292|OTHER|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
223979826|NCT01042717|DRUG|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
223979827|NCT03787420|OTHER|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
223979828|NCT01788475|DRUG|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
223979829|NCT00908349|DRUG|Oxcarbazepine XR|Open Label Study
223979830|NCT00458354|DEVICE|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
223979831|NCT00458354|PROCEDURE|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
223979832|NCT04028817|DEVICE|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
223979833|NCT04028817|DEVICE|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
223979834|NCT06957067|BEHAVIORAL|CPT Skills|CPT trainings recommend that if an individual is experiencing challenges with the CPT protocol (e.g., ambivalence about continuing treatment or struggling with completing homework), the provider can apply the skills of CPT to that particular problem. Those skills include problem solving and cognitive restructuring to identify and alter maladaptive underlying beliefs. The purpose of this work is to address the individual's underlying problem or problematic beliefs to improve the individual's attitudes about CPT and/or improve the individual's compliance with treatment activities. The therapist's end-goal is to keep the individual moving forward in the CPT protocol.
223979835|NCT06957067|BEHAVIORAL|Cognitive Processing Therapy|"CPT is a 12-session, cognitive-behavioral treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to prior trauma. The goal is to build a new understanding of prior trauma in order to limit the negative influence trauma and it's reminders have on individuals' daily lives. The treatment involves education about PTSD and skill building to identify and challenge maladaptive, trauma-related thinking through Socratic questioning and worksheets that teach individuals to challenge this thinking themselves. Later sessions focus on specific themes that are difficult for individuals with PTSD and can keep individuals stuck in their symptoms. Themes include safety, trust, control, self-esteem, and intimacy.~Although the skills utilized in CPT may be used to respond to challenges individuals have with participating in CPT, the effectiveness of these strategies has not been explicitly tested."
223979836|NCT06957067|BEHAVIORAL|Present Centered Therapy|"PCT was developed as a comparator for active TFT, so protocol length typically matches the comparator. PCT focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to life difficulties and stress, and emotional support and validation. Its hypothesized mechanisms are increased interpersonal connection and mastery in managing life stressors. Therapist skills include validation, support, and reflective listening. The first 2 sessions provide an overview and rationale for PCT. Subsequent sessions focus on topics participants choose and are less structured. Participants use a daily diary to record any concerning problems or issues they experience during the week. These diaries are used to select session topics."
223979837|NCT06957067|BEHAVIORAL|Shared Decision Making|Shared decision making (SDM) is widely considered the best model for achieving patient-provider agreement on treatment plans and an ethical imperative for decision making. SDM is a communicative process in which patients and their provider personalize treatment approaches to the individual, their situation, and the problems that they are experiencing. Providers and patients engage in a shared deliberation of meaningful treatment alternatives, including pros and cons, how choices align or misalign with values, and patients' abilities to complete the plans under consideration.
223979838|NCT06957067|BEHAVIORAL|Measurement Based Care|"Investigators will compare methods of identifying individuals experiencing challenges in CPT. Investigators will use self-report measures administered each week during treatment to identify individuals who may be struggling in during CPT and compare two approaches to cut scores on these measures to classify individuals as in need of intervention. Investigators will also use behavioral indices to determine if veterans are in need of intervention, including homework compliance and session attendance. One approach will liberally classify many individuals as in need of intervention (Catchall), while the other will take a more targeted approach (Targeted)."
223726995|NCT01073891|DRUG|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
223979839|NCT06957340|DEVICE|Low-Intensity Transcranial Ultrasound Stimulation|"LITUS is conducted using the UE880C model from RuAo Medical Technology Co., Ltd. (Beijing). The parameters are set as follows:Frequency: 800(1+10%) kHz,Pulse repetition period: 25 ms,Duty cycle: 50%,Output power: 1.2 W,Maximum output power duration: 0.6 W,Effective sound intensity: 0.4 W/cm².During treatment, the patient is placed in a quiet room and asked to relax in a seated position. Three ultrasound probes are coated with a coupling agent and positioned on the patient's forehead.The total treatment duration is 20 minutes.~The upper limb rehabilitation virtual training is used by the EM-BURT02-01 model from Eston.The affected limb is fixed to the robotic arm. Each treatment session consists of two virtual games (such as Airplane Battle, Mosquito Smasher, and other motion-based games).Each game lasts for 10 minutes, totaling 20 minutes of treatment. Treatment is administered 5 times a week."
223979840|NCT06957340|DEVICE|sham TUS|In the sham group, the machine only operates for 30 seconds, then stopping. Due to the physical characteristics of ultrasound, this stimulation cannot be perceived.Treatment is administered 5 times a week.
223979841|NCT06957288|OTHER|Mindfulness-based psychoeducation|The aim of psychoeducation is to reduce the death anxiety of nurses and to increase their awareness of death by providing them with information about the death experience they are secondarily exposed to (1- Death process and death anxiety, 2- Effects of the death process on the individual and family, 3- Coping with the death process, 4- Effects of the death process on caregiving nurses, 5- Awareness of death, 6- Nursing care and emotional competence during the death process). Therefore, it will be evaluated whether the implemented psychoeducation program reduces the intended death anxiety and creates awareness about death. This study will be conducted to examine the effect of a 6-week, 12-session mindfulness-based group psychoeducation program given to nurses on death anxiety and death awareness levels.
223979842|NCT06956196|BIOLOGICAL|Stapokibatrt|Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)
223543901|NCT01623505|DRUG|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter."
223979843|NCT06956196|OTHER|Placebo|Placebo of matching volume，Subcutaneous injection(SC)
224118561|NCT03207828|OTHER|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
224118562|NCT04791397|PROCEDURE|Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from control group undergo 15 procedures of IHHT, 5 procedures per week for 3 weeks, 1 procedure lasts 40 minutes. IHHT is a protocol which employs passive (the patient is at rest), short (several minutes) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia, and repeated for 40 minutes. During the initial pretreatment test, the patient inhales air with low oxygen content at atmospheric pressure in a continuous mode through a mask. In the interval therapeutic mode that follows, periods of hypoxia (10-14% O2) are interrupted by periods of reoxygenation by hyperoxia (up to 35% O2). Automatic switching of gas flows (SRT technology). Built-in intelligent software automatically identifies and suggests key treatment parameters for the individual treatment program, by adjusting the starting parameters based upon the results of the pretreatment hypoxic test.
223726996|NCT00356369|BIOLOGICAL|meningococcal ACWY (vaccine)|One intramuscular dose.
223726997|NCT00356369|BIOLOGICAL|Mencevax™ ACWY|One subcutaneous dose.
223726998|NCT04674384|DIETARY_SUPPLEMENT|Optifast meal replacement shakes|Optifast® is provided as 53g sachet. Each sachet replaces one meal. It is available in 5 flavours: vanilla, strawberry, chocolate and coffee shakes and vegetable soup.
223726999|NCT01910090|DRUG|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
223727000|NCT01910090|DRUG|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
223727001|NCT02521610|DRUG|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
223727002|NCT02521610|DRUG|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
223727003|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (one day)|Participants will engage in 40 minutes of cycling at 70-75% maximum heart rate (MHR).
223727004|NCT05972265|BEHAVIORAL|Placebo - Light Intensity Exercise (one day)|Control participants will engage in 40 minutes cycling at 40-50% maximum heart rate (MHR).
223727005|NCT05972265|BEHAVIORAL|Moderate Intensity Exercise (9 wks)|Participants will be asked to engage in moderate-intensity activity four days each week, 40 minutes each time, and will wear an activity monitoring device to assess their fidelity to the intervention.
223727006|NCT05972265|OTHER|Day 1 Assessments|Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), Life Events Checklist (LEC-5), and neuropsychological testing: approximately 1.50 hours
223727007|NCT05972265|OTHER|Symptom Measures and Neuropsychological Tests|Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), and neuropsychological testing: approximately 1.25 hours
223727008|NCT05972265|OTHER|Day 36 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
223727009|NCT05972265|OTHER|Day 57 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
223979844|NCT05119634|OTHER|whole body vibration training|participants will receive whole body vibration training 3 days in a week and for 8 weeks
223979845|NCT05119634|OTHER|home based exercises|participants will receive a home based exercise program for 8 weeks
223979846|NCT03099408|DRUG|Metronidazole Oral|Oral metronidazole 400 mg BID for 7 days at first month.
223979847|NCT03099408|DRUG|"Metronidazole and Lactobacillus"|Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
223979848|NCT01045863|DRUG|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
223727010|NCT05972265|OTHER|Day 78 Assessments|Activity monitoring device charged and data downloaded, questions regarding fidelity to activity as usual or moderate-intensity exercise and any difficulties, Cognitive complaints interview, Center for Epidemiological Studies Depression Scale Revised (CESD-R), Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5), neuropsychological testing, and activity monitoring device returned to participant: approximately 2.00 hours
223727011|NCT02749071|PROCEDURE|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
223727012|NCT02749071|DEVICE|EndoStim stimulation for first six months of study|Lower esophageal stimulation
223727013|NCT02749071|DEVICE|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
223727014|NCT02749071|DEVICE|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
223727015|NCT03545165|DRUG|177Lu-PSMA-617|\[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)\]
223979849|NCT01045863|DRUG|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
223979850|NCT01045863|DRUG|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
223979851|NCT01045863|DRUG|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
223979852|NCT01045863|DRUG|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
223979853|NCT05634798|OTHER|no intervention|There is no intervention in this study.
223979854|NCT06142981|BIOLOGICAL|PRP and PBD-VSEL Stem Cell therapy|The intervention began with the administration of three PRP sessions, where the patients received intravenous injections at four acupuncture points (stomach 36 and GB 34 on both sides) at the 1st, 2nd, and 3rd month.
223979855|NCT06546540|DRUG|Telitacicept|160mg，once weekly
223979856|NCT00303927|DRUG|capecitabine|
223727016|NCT03545165|DRUG|177Lu-J591|\[1.35 GBq/m2 or 36.5 mCi/m2\]
223727017|NCT03545165|DRUG|68Ga-PSMA-HBED-CC|\[185 ±74MBq or 5 ±2 mCi\]
223727018|NCT05916014|DIAGNOSTIC_TEST|Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists|Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
223979857|NCT03061604|DEVICE|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
223979858|NCT03061604|DRUG|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
223979859|NCT03061604|BIOLOGICAL|Blood transfusion|Blood transfusion will be administered to all patients if needed
223979860|NCT03061604|DRUG|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
224118563|NCT04791397|PROCEDURE|Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.|Every patient from group control undergo simulating procedures of interval hypoxic-hyperoxic training, 15 procedures, 5 procedures per week for 3 weeks. 1 procedure lasts 40 minutes, in normoxia. Before the start of the course, each patient undergoes a test procedure for 10 minute (in normoxia) for simulate procedures IHHT.
223727019|NCT05549570|DRUG|Sitagliptin/Metformin HCl 50/850 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/850 mg film-coated tablet
223979861|NCT05869045|OTHER|Diaphragm shortening fraction measurement by point-of-care ultrasound.|A noninvasive and feasible method to assess diaphragmatic function and predict the prognosis of patients with respiratory failure presenting to the emergency department. The method consists of measuring the diaphragmatic thickness at the end of inspiration and expiration using a linear probe placed in the subcostal region and calculating the percentage of change using the formula: diaphragmatic thickness at the end of inspiration - diaphragmatic thickness at the end of expiration/diaphragmatic thickness at the end of expiration×100. A value lower than 10% indicates diaphragmatic dysfunction and a higher risk of adverse outcomes.
223979862|NCT06957184|PROCEDURE|bladder dissection in placenta accreta spectrum|"All caesarean sections will be performed by a surgeon who has experience in performing caesarean hysterectomy in both groups.~* Scrubbing the abdomen as usual.~* Subumblical midline skin incision versus Pfannenstiel incision will be chosen according to site of the placenta and previous surgeries.~* In group A careful bladder dissection will be done before uterine incision with ensuring hemostasis, uterine incision will be done above the placenta, after delivering the baby awaiting for placental separation if not proceeding for caesarean hysterectomy.~* In group B uterine incision will be done above the placenta and after delivering the baby awaiting for placental separation if not proceeding to caesarean hysterectomy and dissecting bladder just before clamping uterine artery."
223979863|NCT06399991|BEHAVIORAL|Champion strategy|The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
223979864|NCT06399991|BEHAVIORAL|Adapted LOCI leadership and climate alignment strategy plus champion strategy|The LOCI strategy involves engaging with district health leadership through data and feedback, leadership development trainings, coaching, and alignment strategy activities to align leadership and climate in support of implementing the evidence-based mental health package. The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
223979865|NCT01009762|BIOLOGICAL|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
223727020|NCT02116296|BEHAVIORAL|ToyBox-intervention|
223979866|NCT00244907|DIETARY_SUPPLEMENT|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
223979867|NCT02624869|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224118564|NCT05022992|OTHER|Resistance Training|Both groups will perform a resistance training session consisted of 10 reps x 3 set of upper- and lower-body resistance exercises.
223979868|NCT02341586|OTHER|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
223979869|NCT02341586|DIETARY_SUPPLEMENT|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
224118565|NCT01276015|DRUG|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
224118566|NCT02644083|DRUG|Dimethyl fumarate|
224118567|NCT00004865|BIOLOGICAL|cetuximab|
224118568|NCT00004865|DRUG|cisplatin|
224118569|NCT00004865|DRUG|fluorouracil|
224118570|NCT00004865|DRUG|paclitaxel|
224118571|NCT01810146|OTHER|Digestive functions investigations|
224118572|NCT03335631|BEHAVIORAL|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
224118573|NCT00898144|OTHER|Papanicolaou test|
224118574|NCT00898144|OTHER|laboratory biomarker analysis|
224118575|NCT01856946|DIETARY_SUPPLEMENT|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
224118576|NCT01219244|BEHAVIORAL|caloric restriction|6 months of caloric restriction (15 %)
223727021|NCT03639298|DEVICE|Intendu|intensive training with Motion Based Cognitive Video Games Software
224118577|NCT01219244|BEHAVIORAL|omega-3 supplementation|6 months of omega-3 supplementation
223727022|NCT02408315|DRUG|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
224118578|NCT01219244|BEHAVIORAL|resveratrol supplementation|6 months of resveratrol supplementation
224118579|NCT01219244|BEHAVIORAL|Placebo|6 months of placebo intake
224118580|NCT01219244|BEHAVIORAL|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
224118581|NCT01219244|BEHAVIORAL|2nd step: intervention + control|most effective dietary intervention plus control
224118582|NCT01746667|BEHAVIORAL|Exposure in vivo|
224118583|NCT01746667|BEHAVIORAL|Virtual Reality Exposure Therapy|
224118584|NCT00592501|RADIATION|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
223979870|NCT02341586|OTHER|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
223979871|NCT03660397|PROCEDURE|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
223979872|NCT03660397|DRUG|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
223979873|NCT05417347|OTHER|Low-fat dairy products|Milk: low fat (less than 2% M.F.) Yogurt: less than 2% M.F. Cheese: less than 20% M.F.
223979874|NCT05417347|OTHER|Full-fat dairy products|Milk: full-fat milk Yogurt: 2% and more M.F. Cheese: Regular cheese products
223979875|NCT03801187|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
223979876|NCT03801187|PROCEDURE|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
223979877|NCT03801187|PROCEDURE|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
223979878|NCT04867707|DRUG|Zanamivir|5 days of treatment with 10mg zanamivir inhaler BID
223979879|NCT01620970|DRUG|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
223979880|NCT05231278|DEVICE|nCLE aided RANB biospy|nCLE aided RANB biopsy procedure using the Monarch® robotic-assisted navigational bronchoscopy platform and Cellvizio® I.V.E. system with AQ-Flex™ 19 Confocal Miniprobe™ used in combination with Fluorescein.
223979881|NCT05815823|OTHER|robotic exercise therapy|Functional exercise programs such as collecting rain in a glass, grating vegetables, goalkeeper, cleaning the stove, watering flowers, wiping windows, catching fish, and exploring landscapes were applied by robotic games to the patients
223979882|NCT05815823|OTHER|conventional therapy|streching, range of motion, strengthening, balance and walking exercise
223979883|NCT00163007|PROCEDURE|Nutritional support|
223979884|NCT00514800|BEHAVIORAL|Intervention - a validated home BP monitor and support from the specialist nurse|
223979885|NCT00514800|BEHAVIORAL|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
223979886|NCT03917537|GENETIC|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
223979887|NCT04871347|DRUG|TWP-101|IV infusion
223979888|NCT06788691|DRUG|Luspatercept|Administered at 1 mg/kg once every 3 weeks
223979889|NCT03373851|DEVICE|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
223979890|NCT03204500|COMBINATION_PRODUCT|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
223979891|NCT03204500|DRUG|Placebos|Administered orally under the same conditions
223979892|NCT01626729|BEHAVIORAL|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
223979893|NCT01626729|BEHAVIORAL|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
224118585|NCT00592501|DRUG|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
224118586|NCT00592501|DRUG|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
223979894|NCT01626729|BEHAVIORAL|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
223979895|NCT01626729|BEHAVIORAL|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
223979896|NCT01626729|BEHAVIORAL|No label control group|No label control group
223979897|NCT04441827|OTHER|breathing exercise|Pranayama Group Breathing Exercises Step One:Focusing on breathing (1 minute) Step Two: Alternative nasal breathing (3 minutes) Step Three: Refreshing breath (3 minutes) Step Four: Humming bee breath (2 minutes) Step Five: Focusing on breathing (1 minute)
223979898|NCT02703753|BEHAVIORAL|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
223979899|NCT04308213|DEVICE|Marrow Cellution System|The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
223979900|NCT03294941|COMBINATION_PRODUCT|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
223979901|NCT03277677|DRUG|Normal saline|for resuscitation in sepsis patients
223979902|NCT03277677|DRUG|Ringer's Acetate|for resuscitation in sepsis patients
223979903|NCT02732002|PROCEDURE|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
223979904|NCT06190288|OTHER|Transitional care model|A newly developed care model to support frail older adults during their transition from hospital to home.
223979905|NCT05264272|OTHER|Prospective serological assays|"1. Investigators will measure the levels of hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, and HDV RNA genotype at the enrollment of the study.~2. BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
224118587|NCT00053846|DRUG|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
224118588|NCT00053846|DRUG|Placebo|Placebo
224118589|NCT01563588|BEHAVIORAL|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
224118590|NCT02892851|DEVICE|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)"
224118591|NCT02033551|DRUG|Veliparib|
224118592|NCT02033551|DRUG|Carboplatin|
224118593|NCT02033551|DRUG|Paclitaxel|
224118594|NCT02033551|DRUG|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
224118595|NCT02692053|BIOLOGICAL|blood sampling|additional blood sampling (volume: 18 mL)
223979906|NCT05264272|OTHER|Retrospective serological assays|"1. Investigators will measure hemogram, AST, ALT, Bilirubine-total,Platelet, ALP, rGT, Albumin, GluAC, HBA1C, Albumin, INR, AFP, Creatinine, eGFR, HBsAg, quantitative HBsAg, anti-HBc, HBeAg, anti-HBe, HBV DNA, HBV genotype, anti-HDV, HDV RNA, HDV RNA genotype BMI data, and Child-Pugh score (in cirrhotic patients) at the enrollment of the study.~2. The smoking status, alcohol, coffee and green tea consumption, diabetes, family history of HCC will be collected."
223979907|NCT05051423|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes."
223979908|NCT03927690|DRUG|LKA651|LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
223979909|NCT03927690|DRUG|Lucentis|Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
223979910|NCT04601597|DEVICE|Shu Bei Kang (China) Midline Catheters|The procedures ① evaluation and selection of blood vessels: select the puncture vein in the middle of the patient's upper arm, ② Skin disinfection and towel laying: take the supine position, extend the upper limb to be punctured 45 \~ 90 °, disinfect the pre punctured upper limb with 75% alcohol and 5% povidone iodine. ③ Puncture vein: tie a tourniquet to fill the vein. Before puncture, use 0.2 \~ 0.4 ml of 2% lidocaine for local anesthesia. Under the guidance of ultrasound, use the puncture needle in the improved sedinger assembly for puncture. After successful puncture, insert the guide wire. ④ Delivery and confirmation of catheter position: after successful puncture, insert the dilator catheter sheath assembly, withdraw the setinger guide wire, deliver the catheter, after catheter placement, flush and seal the catheter with normal saline, and fix the catheter with sterile dressing.
223979911|NCT04759846|DRUG|Encorafenib + Binimetinib|The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
223979912|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
223979913|NCT04759846|DRUG|Encorafenib + Binimetinib|A smaller dose than the dose approved for patients with normal hepatic function has been defined
223979914|NCT00694798|BIOLOGICAL|Mycobacterium w|Immunomodulator
223979915|NCT05469412|DEVICE|iPad®|Use of Technology.
223979916|NCT05469412|DRUG|Midazolam|Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
223979917|NCT03248141|DRUG|Hemophilia B standard half-life|Benefix
223979918|NCT03248141|DRUG|Hemophilia B extended half-life|Alprolix
223979919|NCT03248141|DRUG|Hemophilia A standard half-life|Xyntha and other standard half-life agents
223979920|NCT03248141|DRUG|Hemophilia A extended half-life|Eloctate and Adynovate
223979921|NCT00661544|DRUG|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
223979922|NCT00661544|DRUG|Melphalan|Dose Levels 1, 2, \& 3: 100 mg/m2 IV Days -4, -3.
223979923|NCT00661544|DRUG|Ascorbic Acid|Dose Levels 1, 2, \& 3: 1000 mg IV Days -9 to -3.
223979924|NCT03871621|DRUG|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
223979925|NCT03871621|DRUG|Dapagliflozin|Dapagliflozin tablet (10 mg)
224118596|NCT04134104|PROCEDURE|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
224118597|NCT05777434|PROCEDURE|Conventional Physical Therapy for Chronic Neck Pain|Conventional physical therapy for Chronic Neck Pain will include hot pack and TENS for pain relief, axial elongtion exercises to correct posture, cervical isometrics and cervical stabilization exercises. After 2 weeks, functional training will be added. Sets and repetitions will be increased progressively.
223727023|NCT06124144|DRUG|Oleylphosphocholine|The trial is a dose escalation trial that follows a 3+3 approach. The sample size is determined by a decision-making algorithm and by the tolerability of the study drug in the study participants. This design follows predetermined rules that help identify notable toxicities in time with a reasonable degree of accuracy. The initial dose will be 50mg OlPC (1 capsule) and participants in subsequent cohorts will receive 100mg (2 capsules), 150mg (3 capsules), 200mg (4 capsules), 250mg (5 capsules), or 300mg (6 capsules) if the previous doses are tolerated. The study ends when the last cohort is completed or when it is determined that a dose (within a cohort) is not tolerable.
224118598|NCT05777434|PROCEDURE|Scapulothoracic Stabilization Exercises|• Scapulothoracic stabilization exercises in addition to conventional physical therapy will include scapular adduction and shoulder external rotation, B/L shoulder extension with scapular retraction, Eccentric scapular retraction, Brügger exercise and Forward punch. Exercises would be given using latex Thera-Band, or acc. to patient strength for mild to moderate resistance. After 2 weeks, functional training will be added. Sets aand repetitions will be increased progressively.
224118599|NCT03008590|DRUG|Naltrexone|One 4.5 mg capsule each evening
223979926|NCT01605656|BEHAVIORAL|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
223979927|NCT01605656|BEHAVIORAL|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
223979928|NCT01605656|BEHAVIORAL|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
223979929|NCT04331132|DRUG|Tolvaptan 15 MG|vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
223979930|NCT06456606|PROCEDURE|before prone position|It was evaluated with transesophageal echocardiography
223979931|NCT06456606|PROCEDURE|the first hour of prone position|It was evaluated with transesophageal echocardiography
223979932|NCT06456606|PROCEDURE|the first hour of returning to the supine position|It was evaluated with transesophageal echocardiography
223979933|NCT02148510|DEVICE|Monobloc|Construction fitted to upper and lower jaw
223979934|NCT02148510|DEVICE|Bibloc|Biblock construction
223979935|NCT04674254|DRUG|Bevacizumab Injection|Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.
223979936|NCT04674254|PROCEDURE|Targeted retinal photocoagulation|Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.
223979937|NCT04674254|PROCEDURE|Standard pan-retinal photocoagulation|Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
223979938|NCT00072605|DRUG|VRC-EBODNA012-00-VP|
223979939|NCT03234998|DEVICE|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
224118600|NCT03008590|DRUG|Placebo|One capsule each evening
224118601|NCT01696409|DIETARY_SUPPLEMENT|400 IU vitamin D3|Take 400 IU once/day for 2 months
224118602|NCT01696409|DIETARY_SUPPLEMENT|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
224118603|NCT03469193|PROCEDURE|internal PUC implanted with mechanical ancillary|The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.
223727024|NCT02117648|DRUG|Abemaciclib|Administered orally
223727025|NCT02117648|DRUG|Clarithromycin|Administered orally
223979940|NCT03234998|DEVICE|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
223979941|NCT01520337|DEVICE|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
223979942|NCT01851707|DRUG|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
223979943|NCT01851707|DRUG|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
223979944|NCT00002716|DRUG|dexamethasone|
223979945|NCT00002716|DRUG|floxuridine|
223979946|NCT00002716|DRUG|fluorouracil|
223979947|NCT00002716|DRUG|leucovorin calcium|
223979948|NCT00002716|PROCEDURE|laparotomy|
223979949|NCT00002716|PROCEDURE|conventional surgery|
223979950|NCT04692805|DEVICE|coils|EUS-guided injection of coils
223979951|NCT04692805|DRUG|cyanoacrylate glue|EUS-guided injection of cyanoacrylate glue
223979952|NCT02582268|DEVICE|intrauterine device TCu 380A|
223979953|NCT02582268|RADIATION|Trans-abdominal sonography|
223979954|NCT00005997|DRUG|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
223979955|NCT05463731|DRUG|Remternetug (IV)|Administered IV
223979956|NCT05463731|DRUG|Remternetug (SC)|Administered SC
223979957|NCT05463731|DRUG|Placebo|Administered IV or SC
223979958|NCT01617798|DRUG|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
223979959|NCT01617798|DRUG|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
223979960|NCT04582305|DRUG|Bleomycin|Intralesional bleomycin treatment administered with an electronic pneumatic jet injector
223979961|NCT04582305|DRUG|Normal saline|Intralesional placebo treatment of normal saline administered with an electronic pneumatic jet injector
223979962|NCT04051242|DEVICE|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
223979963|NCT01984762|PROCEDURE|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
223979964|NCT01984762|PROCEDURE|sleeve gastrectomy|SG = sleeve gastrectomy
223979965|NCT01848067|DRUG|Alisertib|Given PO
223979966|NCT01848067|DRUG|Abiraterone acetate|Given PO
223979967|NCT01848067|DRUG|Prednisone|Given PO
223979968|NCT00000770|DRUG|Nevirapine|
223979969|NCT00000770|DRUG|Zidovudine|
223979970|NCT00000770|DRUG|Didanosine|
223979971|NCT05507190|OTHER|Self-management of post COVID-19 respiratory outcomes|Intervention: using the participants' initial assessment, personal characteristics, main complaints/needs and goals, the therapist will adjust the exercise plan and personalize the recommendations (e.g. maximum heart rate) as well as instruct the patients about safety precautions (how to pace themselves, when to seek professional or emergency care). Participants will be encouraged to wear the smart shirt as much as they want during the 6 weeks (29), but at a minimum of 1-hour a day (M-F) including while performing the recommended exercises (30-45 min/3 times a week). They should self-monitor their biometric values trying to reach/stay within the target values while wearing the shirt using Hexoskin app installed on an iPad provided by the research team or on the participants' personal device if preferred.
223979972|NCT06315426|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
223979973|NCT06315426|BIOLOGICAL|Placebo|Placebo
223979974|NCT00093132|DRUG|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
223979975|NCT01202409|DRUG|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
223979976|NCT05917548|DEVICE|Teledentistry oral health promotion|Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
223979977|NCT05917548|BEHAVIORAL|Face-to-Face oral health promotion|Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
223979978|NCT05781997|DIAGNOSTIC_TEST|cycloplegic refraction|Cycloplegic autorefraction will be attempted on all children using a table-mounted autorefractor . Cycloplegia will be achieved with three drops of 1% cyclopentolate administered 5 min apart and autorefractive measurements will be performed 30 min after the instillation of the last drop. Auto refraction readings of three consecutive measurements will be obtained and the average will be computed automatically in each eye. Each child will be reexamined until three measurements fell within 0.50 diopters (D) if any two measurements varied by \>0.50D.
223979979|NCT03171116|OTHER|none intervention|it is not an interventional study; it is an observational study
223979980|NCT01061853|DRUG|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE\*)1mg/ml bid during 3 months
223979981|NCT01061853|DRUG|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE\*)0.05% bid during 3 months
223979982|NCT00141713|DRUG|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
223979983|NCT05375383|DIETARY_SUPPLEMENT|Streptococcus salivarius K12 lozenge|In this study, a lozenge will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
223979984|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
223979985|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
223979986|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 lozenges containing prebiotics A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
223979987|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder|In this study, a powder will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
223979988|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic A|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
223979989|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotic B|In this study, a powder containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
223979990|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius K12 powder containing prebiotics A and B|In this study, a powder containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity
223979991|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges|In this study, a lozenge containing will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223979992|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic A|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223979993|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 lozenges containing prebiotic B|In this study, a lozenge containing a prebiotic will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223979994|NCT05375383|DIETARY_SUPPLEMENT|Probiotic S. salivarius M18 + lozenges containing prebiotic A and B|In this study, a lozenge containing two prebiotics will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223979995|NCT03194854|BEHAVIORAL|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
223979996|NCT01269255|DRUG|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy"
223979997|NCT05286086|BEHAVIORAL|prehabilitation|Control of the physical, nutritional and psychological preparation of the patient who will undergo rectal cancer surgery
223979998|NCT00176475|BIOLOGICAL|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
223727026|NCT06237660|PROCEDURE|Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsy|These children who will be having a bronchoscopy (a long thin tube, with a camera at the end, which is put inside the lung to look at and collect samples) as part of their standard clinical management, determined by their own consultants or treating physicians. They will be having lung samples (washings from the lung and a tiny piece of tissue taken from the breathing tubes) taken as part of their usual medical management. The research team will ask for consent to use the leftover samples for the bronchoscopy, for the study
223727027|NCT06237660|DIAGNOSTIC_TEST|Skin prick test|To identify children with allergies. This test will not be done if the child has had allergy testing in the last 6 months
223727028|NCT06237660|DIAGNOSTIC_TEST|Finger prick blood test|Finger prick testing will be used for blood samples, and it is the same technique used by children with diabetes, to test their blood sugar levels, and therefore is regularly used in this age group successfully. The research team will be obtain the results within minutes, using a point-of-care device. A few more drops of blood, from the same finger prick sample, will be taken to look at how one of the blood cells work, in more detail, in the laboratory. There is no additional finger prick required for this lab test, and the drops of blood will be collected at the same time, from the same prick, as the point of care test.
223727029|NCT06237660|DIAGNOSTIC_TEST|Forced oscillation technique (FOT)|Breathing test will be performed using forced oscillation technique (FOT), to see how the child's lungs work and to detect airway inflammation. The test will be explained to the child and completed using our established protocols. This test will only require the child to breathe in and out normally, and therefore can be done in preschool aged children. The current test that is used to check lung function called spirometry cannot be used in preschool children, as it involves following complicated instructions. The aim is to assess how well this newer lung function test is tolerated, in children aged 1-5 years.
223979999|NCT00176475|BIOLOGICAL|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
223980000|NCT00337285|DRUG|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
223980001|NCT04008056|OTHER|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
223980002|NCT01774019|DEVICE|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
223980003|NCT01115283|BEHAVIORAL|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
224295320|NCT02213952|OTHER|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
224295321|NCT00377936|DRUG|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
224295322|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
223980004|NCT01115283|BEHAVIORAL|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
223980005|NCT01115283|BEHAVIORAL|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
223980006|NCT00553605|DRUG|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
224118604|NCT03469193|PROCEDURE|Internal PUC implanted with robotic assistance|Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
224118605|NCT03902405|BEHAVIORAL|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
224118606|NCT03902405|BEHAVIORAL|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
224118607|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
223980007|NCT00553605|DRUG|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
223980008|NCT05146661|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body.
223980009|NCT05671744|OTHER|Cell-based non-invasive prenatal testing|Blood sampling
223980010|NCT06443424|DEVICE|ultrasound device|usage of ultrasound device in pediatric airway asessment
224118608|NCT00835094|DEVICE|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
223980011|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
224118609|NCT00002191|DRUG|Albendazole|
224295323|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
223980012|NCT02160470|BEHAVIORAL|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
223980013|NCT02160470|BEHAVIORAL|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
223980014|NCT02160470|BEHAVIORAL|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
223980015|NCT00448773|BEHAVIORAL|Online education|
223980016|NCT00003185|BIOLOGICAL|autologous tumor cell vaccine|
223980017|NCT00003185|BIOLOGICAL|sargramostim|
223980018|NCT00003185|BIOLOGICAL|tumor-draining lymph node lymphocyte therapy|
223980019|NCT00003185|DRUG|cyclophosphamide|
223980020|NCT00003185|PROCEDURE|conventional surgery|
223980021|NCT02949856|DEVICE|Mallinckrodt, COVIDIEN|
223980022|NCT02949856|DEVICE|Endotracheal tube, Unomedica|
223980023|NCT04208347|DRUG|Apatinib 250mg|Apatinib 250mg
223980024|NCT04208347|DRUG|Camrelizumab|Camrelizumab 200mg
223980025|NCT04208347|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
223980026|NCT04208347|DRUG|Apatinib 500mg|Apatinib 500mg
223980027|NCT00145483|DRUG|Sildenafil|
223980028|NCT02226497|DEVICE|Health Telemonitoring|Use home telemonitoring device
223980029|NCT02226497|OTHER|Quality-of-Life Assessment|Ancillary studies
223980030|NCT02226497|OTHER|Questionnaire Administration|Ancillary studies
223980031|NCT02226497|PROCEDURE|Supportive Care|Receive standard outpatient supportive care
223980032|NCT04567797|DEVICE|Laevo 2|The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
223980033|NCT04567797|DEVICE|backX|"backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2."
223980034|NCT04567797|DEVICE|FLx ErgoSkeleton|The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
223980035|NCT04567797|DEVICE|V22 ErgoSkeleton|"Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons."
223980036|NCT01004185|DRUG|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM \& 2 Asacol 400mg PM; 33-\<54kg = 5 Asacol 400 mg AM \& 4 Asacol 400mg PM; 54-\<90kg = 6 Asacol 400mg AM \& PM
223980037|NCT01004185|DRUG|Asacol 400 mg|17-\<33kg = 2 Asacol 400mg \& 1 placebo AM, 1 Asacol 400mg \& 1 placebo PM; 33-\<54kg = 3 Asacol 400mg \& 2 placebo AM, 2 Asacol 400mg \& 2 placebo PM; 54-\<90kg = 3 Asacol 400mg \& 3 placebo AM \& PM
223980038|NCT00574483|DRUG|quinacrine|100 mg day
223980039|NCT03503487|OTHER|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
223980040|NCT02788526|PROCEDURE|Adjuvant TACE|1\~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
223980041|NCT02788526|PROCEDURE|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
223980042|NCT00508534|DRUG|SB-751689|
223980043|NCT04747210|BEHAVIORAL|contextual one-on-one coaching|Training workshop and coaching one-on-one
223980044|NCT04747210|BEHAVIORAL|Trainig workshop|Ten-hour training workshop.
223980045|NCT05923502|DRUG|Duvelisib|This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.
223980046|NCT04157023|DEVICE|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
223980047|NCT03643497|DRUG|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
223980048|NCT03962517|DEVICE|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
223980049|NCT03962517|OTHER|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
223980050|NCT02217488|DRUG|DG3173|
223980051|NCT02217488|DRUG|Placebo|
223980052|NCT01649505|DRUG|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
223980053|NCT01649505|PROCEDURE|breast reconstruction|Undergo sharp dissection technique
223980054|NCT01649505|PROCEDURE|breast reconstruction|Undergo electrocoagulation dissection technique
223980055|NCT00931008|DRUG|SID530, Taxotere|75mg/m2
223980056|NCT05203224|DRUG|Dornase Alfa|Intravenous Dornase alfa
223980057|NCT03396211|DRUG|Apatinib|Apatinib tablets
223980058|NCT03396211|DRUG|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
223980059|NCT02239861|BIOLOGICAL|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
223980060|NCT02652377|DRUG|EDP-494|10, 100 and 200 mg capsules
224118610|NCT04222127|OTHER|EUS guided injection of gastric varices by CYA|EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate \& lipidol using 19G EUS-FNA needle
224118611|NCT04222127|OTHER|Direct endoscopic injection of gastric varices by CYA|Direct endoscopic injection of gastric varix by CYA
223727030|NCT06237660|PROCEDURE|Sputum induction|Sputum induction is a test of obtaining phlegm after inhalation of salt water mist (saline nebuliser) and this will allow the research team to look for any relationships between infection in the lungs and the accuracy of the less invasive, nose and throat swabs. The research team will obtain phlegm samples, with a quick suction after patients have inhaled the salty mist (saline nebuliser) which will help loosen up their phlegm. If the child can cough it up, they will be encouraged to do it.
223727031|NCT06237660|DIAGNOSTIC_TEST|Oropharyngeal swab|Swabs from children's nose and throats (similar to swab tests that are done for Covid tests), that will be used to test for bacterial infection
223727032|NCT05268900|DEVICE|Volume control ventilation group|Volume control ventilation mode
223727033|NCT05268900|DEVICE|Pressure control ventilation-volume guaranteed group|Pressure control ventilation-volume guaranteed mode
223727034|NCT00247091|BIOLOGICAL|standard-titer measles vaccine|
223727035|NCT03406572|DEVICE|HFHO Group|"* Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2"
223727036|NCT03406572|DEVICE|Standard O2|Standard oxygen therapy
223727037|NCT01985867|DIETARY_SUPPLEMENT|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10\^8 CFU, twice daily, orally for 4 weeks)
223727038|NCT01985867|DIETARY_SUPPLEMENT|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
223727039|NCT01813591|DRUG|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
223727040|NCT03546192|BIOLOGICAL|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
223727041|NCT03658655|BIOLOGICAL|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
223727042|NCT00553514|DRUG|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
223727043|NCT00553514|DRUG|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
223727044|NCT00553514|DRUG|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
223727045|NCT00553514|DRUG|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
223727046|NCT00553514|DRUG|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
223727047|NCT00553514|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to \[=\<\] 3 follicles with a mean diameter of greater than or equal to \[\>=\] 14 millimeter \[mm\], and one or two of these follicles with a diameter of \>= 17 mm).
223727048|NCT04564729|OTHER|Shared Decision Making|The intervention group will receive a shared decision-making intervention including a decision aid and conversation with a study investigator. The intervention group will have the opportunity to choose the number of opioid pills they receive at discharge from hospital after total knee arthroplasty.
224118612|NCT03880227|DEVICE|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
224118613|NCT03880227|DEVICE|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
224118614|NCT03698240|BEHAVIORAL|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
224118615|NCT03292627|DEVICE|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
224118616|NCT03567499|DRUG|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
223727049|NCT04464889|DRUG|MDG1021 dose 1|3 patients to receive dose1: target dose of 0.3x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
223980061|NCT02652377|DRUG|Placebo|placebo to match EDP-494
223980062|NCT04932226|DEVICE|cloth mask|Buff bandana double layer worn over nose and mouth
223980063|NCT04932226|DEVICE|surgical mask|standard surgical mask
223980064|NCT04932226|DEVICE|FFP2 respirator|filtering facepiece 2 respirator
223980065|NCT02292485|BEHAVIORAL|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
223980066|NCT03526978|BIOLOGICAL|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
223980067|NCT03526978|BIOLOGICAL|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
223980068|NCT02296203|DRUG|cetuximab|
223980069|NCT02296203|DRUG|irinotecan|
224118617|NCT03567499|DRUG|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
224118618|NCT02229864|DEVICE|Coronary artery stenting: Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm"
224118619|NCT00002442|DRUG|Indinavir sulfate|
224118620|NCT00002442|DRUG|Nelfinavir mesylate|
224118621|NCT00002442|DRUG|Lamivudine|
223727050|NCT04464889|DRUG|MDG1021 dose 2|3 patients to receive dose 2: target dose of 1x10\^6 HA-1H TCR transduced T cells/kg BW ±20% in 100 mL
223727051|NCT04464889|DRUG|MDG1021 dose 3|3 patients to receive dose 3: target dose of 3x10\^6 HA-1H TCR transduced T cells/kg BW +20% in 100 mL
223727052|NCT04464889|DRUG|MDG1021 optimal dose|20 patients to receive the selected optimal dose
223727053|NCT05303636|DRUG|LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet|LF111 (drospirenone 4 mg tablet orally daily on days 1-24, followed by placebo tablet orally daily on days 25-28) or drospirenone (DRSP) 3.5 mg chewable tablet chewed daily on days 1-24, followed by placebo tablet chewed daily on days 25-28) (USA only). Subjects in the USA who choose to use the hormonal contraceptive method may choose between LF111 and DRSP 3.5 mg chewable tablets. The DRSP 3.5 mg chewable tablets are not available to subjects in Europe. Subjects in Europe who choose to use the hormonal contraceptive method will only receive LF111.
223727054|NCT04219553|BEHAVIORAL|Antimicrobial stewardship|The multifaceted AMS intervention includes pharmacist education, a clinical decision support tool, a parent/guardian questionnaire, and individualized monthly audit and feedback with each pharmacist.
223727055|NCT04219553|OTHER|Comparator (no intervention)|No active intervention
223980070|NCT01376050|DEVICE|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
223980071|NCT01376050|DEVICE|Placebo Laser|Placebo Laser has no therapeutic output emitted.
223980072|NCT06235853|DIAGNOSTIC_TEST|Blood serum: sUPAR, PAI-1, IL-8.|The concentration of described biomarkers were measured in serum.
223980073|NCT06235853|DIAGNOSTIC_TEST|Urine: IL-8, APOE, VEGF.|The concentration of described biomarkers were measured in urine.
223980074|NCT01553227|DEVICE|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
223980075|NCT03481556|DRUG|Melphalan flufenamide (Melflufen)|Intravenous infusion
223980076|NCT03481556|DRUG|Dexamethasone|Oral tablets
223980077|NCT03481556|DRUG|Bortezomib|Subcutaneous administration
223727056|NCT03767816|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
223980078|NCT03481556|DRUG|Daratumumab|Intravenous infusion
223980079|NCT03463577|OTHER|Safety assessment following routine immunization with Boostrix|Subject-level data was collected for pregnant women and their infants through the Electronic Health Records.
223980080|NCT02440737|OTHER|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
223980081|NCT02440737|OTHER|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
223980082|NCT02440737|PROCEDURE|Psychosocial Assessment and Care|Undergo the NEST intervention
223980083|NCT02440737|OTHER|Questionnaire Administration|Ancillary studies
223980084|NCT05694533|DRUG|INDV-2000|Capsules administered orally twice a day
223980085|NCT05694533|DRUG|Midazolam|Midazolam syrup administered orally on Days 1 and 15
223980086|NCT00171366|DRUG|amlodipine/benazepril|
223980087|NCT04546022|DRUG|Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.|
223980088|NCT00188825|OTHER|placebo|
223980089|NCT00188825|DRUG|basiliximab|
224118622|NCT00002442|DRUG|Stavudine|
224118623|NCT03298854|DEVICE|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
224118624|NCT00006346|PROCEDURE|psychosocial assessment and care|
224118625|NCT00006346|PROCEDURE|quality-of-life assessment|
224118626|NCT01531218|DRUG|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
224118627|NCT01531218|DRUG|Placebo|
224295324|NCT00377936|DRUG|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
223980090|NCT06483685|DRUG|Radiopharmaceuticals drugs|radiopharmaceuticals drugs included in the Anatomical Therapeutic Chemical (ATC) classification system.
223980091|NCT01797133|PROCEDURE|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
223980092|NCT01797133|PROCEDURE|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
223980093|NCT05470959|OTHER|ACTIVA bioactive|bioactive ionic resin composite
223980094|NCT05470959|OTHER|Riva LC|resin-modified glass ionomer
223980095|NCT02073253|OTHER|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
223980096|NCT05008263|DIAGNOSTIC_TEST|Liver elastography (2D-SWE)|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
223980097|NCT05008263|DIAGNOSTIC_TEST|Liver scintigraphy with 99mTc-mebrofenin|All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.
223980098|NCT01085812|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
223980099|NCT01085812|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily.
223980100|NCT01101997|DEVICE|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
223980101|NCT03334877|DIAGNOSTIC_TEST|β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
223980102|NCT04709978|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study|Participants enrolled in supplemental study will swallow different barium containing liquid and food boluses types that are captured on fluoroscopic imaging in real time.
223980103|NCT04709978|DIAGNOSTIC_TEST|Nuclear medicine pulmonary aspiration study|Participants enrolled in supplemental study will be administered radiotracer (Tc-99m-Sulfur Colloid) orally and static images of the chest will then be obtained at specified intervals over the next 2 hours to determine location of the radiotracer.
223980104|NCT04709978|DIAGNOSTIC_TEST|TOR-BSST and 3 oz Water Swallow|"The research specialist will conduct ten 1 tsp water swallows, one cup sip of water and a 3 ounce water swallow test with the patient. After each swallow, the participant is asked to say ah so that their voice quality can be assessed."
223980105|NCT04709978|DIAGNOSTIC_TEST|Sputum Culture|Patients will have sputum collected during stay (ED participants only)
223980106|NCT04709978|DIAGNOSTIC_TEST|MeMed BV®|A blood test to help determine if the infection is viral or bacterial (ED participants only)
223980107|NCT04709978|DIAGNOSTIC_TEST|Lung Ultrasound|To image the lungs (ED participants only)
223980108|NCT04709978|DIAGNOSTIC_TEST|Respiratory Function Tests|To measure respiratory pressures.
223980109|NCT00610025|PROCEDURE|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
223980110|NCT00002971|DRUG|O6-benzylguanine|
223727057|NCT03767816|DRUG|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
223727058|NCT03957720|DRUG|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
223727059|NCT03957720|DRUG|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
223727060|NCT03957720|DRUG|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
223727061|NCT03957720|DRUG|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
223727062|NCT04021940|PROCEDURE|ULOD|ULOD
223980111|NCT02953028|DEVICE|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
223980112|NCT02953028|DEVICE|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
223980113|NCT00496626|BIOLOGICAL|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
223980114|NCT00496626|BIOLOGICAL|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
223980115|NCT02541045|DRUG|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
223980116|NCT02541045|OTHER|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
223980117|NCT00727415|DRUG|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
223980118|NCT00727415|DRUG|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
223980119|NCT00727415|DRUG|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
223727063|NCT02755558|BEHAVIORAL|Low energy density|Low energy density milk served
223727064|NCT02755558|BEHAVIORAL|High energy density|High energy density milk served
223980120|NCT02005393|DEVICE|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
223980121|NCT00165334|DRUG|Cetuximab|
223980122|NCT00165334|DRUG|Vinorelbine (Navelbine)|
223980123|NCT00853229|DRUG|pregabalin|pregabalin 150mg twice daily for 4 weeks
223727065|NCT02755558|BEHAVIORAL|Small portion|Small portion of milk served
223727066|NCT02755558|BEHAVIORAL|Large portion|Large portion of milk served
223727067|NCT01694589|DRUG|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
223727068|NCT00967772|DRUG|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
223727069|NCT05145530|PROCEDURE|selective anterior cervical discectomy and fusion (ACDF)|selective anterior cervical discectomy and fusion (ACDF)
223980124|NCT00466713|DRUG|Rosiglitazone therapy|
223980125|NCT00264563|BEHAVIORAL|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
223980126|NCT00264563|BEHAVIORAL|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
223980127|NCT01700322|PROCEDURE|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
223980128|NCT01700322|DRUG|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
223980129|NCT01700322|DRUG|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
223980130|NCT01700322|DRUG|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
223980131|NCT01006499|DRUG|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
223980132|NCT02208037|DRUG|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
223980133|NCT02208037|DRUG|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
223727070|NCT05145530|PROCEDURE|SNRB+ selective anterior cervical discectomy and fusion (ACDF)|US-guided selective nerve root block (SNRB) + selective anterior cervical discectomy and fusion (ACDF)
223980134|NCT02208037|DRUG|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
223980135|NCT02208037|DRUG|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
223980136|NCT02208037|DRUG|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
223980137|NCT02208037|DRUG|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
223980138|NCT02208037|DRUG|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
223980139|NCT02208037|DRUG|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide \[50 mg/kg ideal body weight (IBW); if ABW \< IBW, use ABW\] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
223980140|NCT03201900|DRUG|E2007|Oral tablet
223980141|NCT05195892|DRUG|Treatment A|Single oral dose of alpelisib film-coated tablet at 50 mg in fed state
223980142|NCT05195892|DRUG|Treatment B|Single oral dose of alpelisib granule at 50 mg in fed state
223980143|NCT05195892|DRUG|Treatment C|Single oral dose of alpelisib granule at 50 mg in fasted state
223980144|NCT02790775|DRUG|Anti-VEGF in quadrant 1|
223980145|NCT02790775|DRUG|Anti-VEGF in quadrant 2|
223980146|NCT02790775|DRUG|Anti-VEGF in quadrant 3|
223980147|NCT02790775|DRUG|Anti-VEGF in quadrant 4|
223980148|NCT02673554|DRUG|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
223980149|NCT02673554|DRUG|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
223980150|NCT02673554|PROCEDURE|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
224295325|NCT04293549|DRUG|Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops|"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"
223543902|NCT01623505|DRUG|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
223980151|NCT02673554|PROCEDURE|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration \~ 8.5 mmol/l)
223980152|NCT03634306|DEVICE|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
223980153|NCT03634306|PROCEDURE|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
223980154|NCT01292577|BEHAVIORAL|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
223980155|NCT01292577|BEHAVIORAL|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
223980156|NCT00776659|OTHER|Aromasin|Non-Interventional study design.
223980157|NCT04185987|OTHER|Leone slide low friction elastomeric ligature|Leone slide low friction elastomeric ligature application
223980158|NCT04185987|OTHER|RMO tough - o energy elastomeric ligature|RMO tough - o energy elastomeric ligature application
223980159|NCT04185987|OTHER|Dentsply sili tie elastomeric ligature|Dentsply sili tie elastomeric ligature application
223980160|NCT04185987|OTHER|AO twisted ended ligature wire|AO twisted ended ligature wire application
223980161|NCT05090605|GENETIC|DNA analysis|GWAS
223980162|NCT02192723|DRUG|Typical antipsychotic|Haloperidol (6\~20mg/day) and perphenazine (16\~64mg/day), twice per day, 8 weeks
223980163|NCT02192723|DRUG|Risperidone|2\~6mg/day, twice per day, 8 weeks
223980164|NCT02192723|DRUG|Olanzapine|Olanzapine, 400\~750mg/day, twice per day, 8 weeks
223980165|NCT02192723|DRUG|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
223980166|NCT02192723|DEVICE|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
223980167|NCT02192723|DRUG|Ziprasidone|Ziprasidone 80\~160mg/day, twice per day, 8 weeks
223980168|NCT06215287|OTHER|Physician survey|Survey to assess physicians' knowledge of Exjade posology and biological monitoring recommendations as described in the Educational Materials
223980169|NCT01667172|DEVICE|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
223980170|NCT06287086|DRUG|BRL-101 autologous hematopoietic stem and progenitor cells injection|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
223980171|NCT06456086|BIOLOGICAL|stimulation with EB virus|stimulation with EB virus
223980172|NCT03409562|BEHAVIORAL|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
223980173|NCT03409562|BEHAVIORAL|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
224295326|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
223543903|NCT05265858|PROCEDURE|Total Hip Arthroplasty|Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
223543904|NCT06426446|DEVICE|Withings Body Comp Pro|Withings Body Comp Pro from which the following features will be used: body weight, body composition (fat, muscle and bone mass, cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), nervous health (electrochemical skin conductance)
223980174|NCT02602795|BEHAVIORAL|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
223980175|NCT02602795|BEHAVIORAL|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
223980176|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
223980177|NCT02308098|DRUG|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
223980178|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
223980179|NCT02308098|DRUG|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
223980180|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
223980181|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
223980182|NCT02308098|DRUG|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
223980183|NCT02308098|DRUG|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
223980184|NCT00726713|OTHER|Metanx (a medical food)|Metanx one tablet twice a day
223980185|NCT00726713|OTHER|Metanx placebo|Metanx placebo one tablet twice a day
224295327|NCT01828710|DIETARY_SUPPLEMENT|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
223980186|NCT06258733|BEHAVIORAL|Lay-led FL workshops|Groups of women recruited by trained lay-leaders will receive an 8-session lay-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the lay workshop facilitator. Lay-leaders will receive an incentive to collect surveys from workshop participants. A member of the research staff will be present at the time of the survey collection to ensure data are collected according to protocol. Monthly phone calls with lay-leaders will take place to ensure implementation in the community, including problem solving and help maintaining motivation. To help ensure implementation in the lay-led arm, lay leaders will be required to complete one workshop in the community before receiving a graduation certificate.
223980187|NCT06258733|BEHAVIORAL|Expert-led workshops|Matching groups of women recruited by research staff will receive the same 8-session expert-led FL workshop. Workshop participants will receive a self-report baseline survey at the first session, and post surveys at the last session and 3 months after the last session. The surveys will be anonymous and will be conducted and collected by the expert workshop facilitator.
223980188|NCT01940406|PROCEDURE|Stimulation procedure|Device
223980189|NCT01233999|DRUG|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
223980190|NCT01721083|PROCEDURE|Procedure: Z-track|Subject received immunization by z-track
224118628|NCT03102775|OTHER|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
223727071|NCT02461303|OTHER|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
224118629|NCT03102775|OTHER|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
224118630|NCT02096939|PROCEDURE|Adrenal extirpation|
224118631|NCT02096939|DRUG|Antihypertensive medication|
224118632|NCT00141635|BEHAVIORAL|physio,pain,psychotherapy;social,nutrit.counselling&sports|
224118633|NCT01145027|OTHER|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
223980191|NCT01721083|PROCEDURE|Procedure: Bunch|Subject receives immunization by bunch method.
223980192|NCT05350124|DRUG|Ascorbic acid|vitamin C (200 mg) capsule
223980193|NCT05350124|DRUG|Tocopherol|vitamin E (400 IU) capsule
223980194|NCT05350124|DRUG|Placebo capsule|Placebo one pill only
223980195|NCT05350124|DRUG|Placebo capsule|Placebo two pills only
223980196|NCT03771222|BIOLOGICAL|Prophylactic DLI|The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10\^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
223980197|NCT01167192|DRUG|Cisplatin|
223980198|NCT01167192|DRUG|Carboplatin|
224118634|NCT03575091|OTHER|Non-individualized|Comparing two experimental interventions with standard care
223980199|NCT01167192|RADIATION|Radiation therapy|
223980200|NCT01167192|PROCEDURE|Mastectomy (recommended but not mandatory)|
224118635|NCT03575091|OTHER|Individualized|Comparing two experimental interventions with standard care
224118636|NCT02755740|OTHER|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
224118637|NCT01929044|DRUG|654-II (anisodamine)|10mg injection
223980201|NCT01001962|DRUG|empagliflozin|ACTIVE TREATMENT FOR DIABETES
224118638|NCT01929044|DRUG|Buscopan® (hyoscine butylbromide)|20mg injection
224118639|NCT06191354|GENETIC|SKG0201 Injection|SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
223980202|NCT01001962|DRUG|Metformin|ACTIVE TREATMENT FOR DIABETES
223980203|NCT03109509|BEHAVIORAL|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
223980204|NCT03109509|BEHAVIORAL|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
223980205|NCT03247738|DRUG|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
223980206|NCT03247738|OTHER|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
223980207|NCT03184506|OTHER|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
223980208|NCT03184506|OTHER|no warming|patients were covered only with two layers of cotton blanket
224295328|NCT01828710|DIETARY_SUPPLEMENT|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
224295329|NCT03023514|DIETARY_SUPPLEMENT|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
224295330|NCT03023514|DRUG|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
223980209|NCT03613324|DIAGNOSTIC_TEST|Pad test|20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
223980210|NCT00129649|BEHAVIORAL|Telephone reminder call|
223980211|NCT02314104|DRUG|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
223980212|NCT04055415|BIOLOGICAL|adipose derived mesenchymal stem cells|The MSCs of 1×10\*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
223980213|NCT04055415|DRUG|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
223980214|NCT03516045|DRUG|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
223980215|NCT05209724|BEHAVIORAL|Provider supervision/ feedback|Provider supervision/ feedback provided before and after walking sessions
223980216|NCT01135082|BIOLOGICAL|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
223980217|NCT01710800|DRUG|Esomeprazole|
223980218|NCT01710800|DRUG|placebo|
223980219|NCT01672593|PROCEDURE|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
223980220|NCT01672593|DRUG|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
224295331|NCT02216019|OTHER|Whole blood|preoparatoire whole blood and postoperative whole blood
224295332|NCT01023295|DRUG|fosbretabulin|single dose, intravenous infusion
223543905|NCT02938247|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
223980221|NCT01672593|DIETARY_SUPPLEMENT|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
223980222|NCT01672593|PROCEDURE|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
223980223|NCT01756144|DEVICE|rhBMP-2|
223980224|NCT03451409|OTHER|Tasked based functional MRI (fMRI)|2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
223980225|NCT03451409|OTHER|Eye Tracking Device|Camera aimed at eyes to record eye movements during tasks
223980226|NCT00511797|DRUG|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
224295333|NCT01023295|DRUG|Saline|single dose, intravenous infusion
224295334|NCT00703508|DRUG|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
223980227|NCT00511797|DRUG|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
223980228|NCT00511797|DRUG|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
223980229|NCT00511797|DRUG|Placebo|Placebo
223980230|NCT00056329|DRUG|Vitamin E|1,000 international units twice daily for three years
224295335|NCT03657108|RADIATION|Civasheet 60 Gy|implantable proposed doses of Civasheet are 60 Gy
223980231|NCT00056329|DRUG|multivitamin|once daily for three years
223980232|NCT00056329|DRUG|Placebo|Placebo twice daily for three years
223980233|NCT03974100|BIOLOGICAL|GP2411|60 mg /mL subcutaneous injection every 6 months
223980234|NCT03974100|BIOLOGICAL|EU-Prolia (EU-authorized Prolia®)|60 mg /mL subcutaneous injection every 6 months
223980235|NCT04024514|OTHER|low dose CT contrast media|CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
224118640|NCT04316572|BEHAVIORAL|mental health specialist video consultation|"The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner"
224118641|NCT06499753|OTHER|high molecular weight HA-based artificial tears|use of high molecular weight HA-based artificial tears three times per day
224118642|NCT02815397|DRUG|Metformin|given in addition to standard of care treatment
224118643|NCT01605396|DRUG|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
224118644|NCT01605396|DRUG|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
224118645|NCT01605396|DRUG|Exemestane|Exemestane 25 mg tablet administered PO QD.
224118646|NCT03819803|BIOLOGICAL|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
224118647|NCT01360164|BIOLOGICAL|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
224118648|NCT02285764|OTHER|Nutritional Supplement|Modified carbohydrate
224118649|NCT02285764|OTHER|Standard of Care|As determined by the study site
224118650|NCT05174052|DRUG|Dapagliflozin 10Mg Tab|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily.
224118651|NCT05174052|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
224118652|NCT02025738|DEVICE|MAGNET APPLICATION|
224295336|NCT03657108|RADIATION|Civasheet 75 Gy|implantable proposed doses of Civasheet are 75 Gy
223980236|NCT04024514|OTHER|Standard dose CT contrast media|CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
223543906|NCT00537160|BEHAVIORAL|Behavior modification, Nutrition Education, Exercise|
223543907|NCT03516578|OTHER|Cardiac magnetic resonance imaging|
223543908|NCT06511960|OTHER|Astaxanthin (12 mg/day) intervention|12 mg/day astaxanthin was administrated to all participants in the astaxanthin 12 mg/day groupfor 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
223980237|NCT01980524|DRUG|acipimox|
223980238|NCT01980524|DRUG|Placebo Oral Capsule|
223980239|NCT05297253|DEVICE|telescopic overdenture|fixed implant retained prostheses
223980240|NCT02878421|DEVICE|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
223980241|NCT02878421|OTHER|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
223980242|NCT02878421|OTHER|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
224118653|NCT02025738|DEVICE|REPROGRAMING|
224118654|NCT02025738|DEVICE|NO ACTION|
224118655|NCT02058199|DRUG|rivaroxaban|Single dose pharmacodynamic study
224118656|NCT03124615|DRUG|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
224118657|NCT06671431|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy with or without radiotherapy
224118658|NCT06671158|BEHAVIORAL|Psychotherapy|Individual psychotherapy for weekly 12-sessions
224295337|NCT03657108|RADIATION|Adjuvant external beam radiation therapy|45 Gy in 25 fractions
224295338|NCT00922558|OTHER|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
224295339|NCT05070702|DRUG|CT-1500|Hard Capsule
224295340|NCT05070702|DRUG|Placebo|Hard Capsule
223980243|NCT00680147|BEHAVIORAL|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
223980244|NCT02941419|BIOLOGICAL|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
223980245|NCT01401036|DEVICE|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
223980246|NCT01401036|PROCEDURE|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
223980247|NCT00373022|BEHAVIORAL|exercise intervention|
223980248|NCT00373022|OTHER|flow cytometry|
223980249|NCT00373022|OTHER|laboratory biomarker analysis|
223980250|NCT00373022|PROCEDURE|management of therapy complications|
223980251|NCT00373022|PROCEDURE|psychosocial assessment and care|
223980252|NCT00373022|PROCEDURE|quality-of-life assessment|
224295341|NCT01064323|DEVICE|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
223980253|NCT05184621|OTHER|Eyesing Redlight Instrument|Eyesing Instrument developed by Suzhou Industrial Park Zoguan Medical Equipment Co. and conventional optometry.
223980254|NCT04356625|DIAGNOSTIC_TEST|MEPic|"* patient in the supine position sitting 45° to 60°,~* closed suction catheter was removed~* a 90° elbow was placed and a bacterial filter in series with endotracheal tube~* adapter was also coupled to the aneroid pressure gauge~* in series an inspiratory unidirectional valve was placed that did not allow expiration~* 2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough"
223980255|NCT04692298|OTHER|pulses|kidney beans, pinto beans, lentil, black-eyed pea and chickpea
224295342|NCT00831623|RADIATION|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
224295343|NCT00831623|RADIATION|Proton|As above
224295344|NCT01252849|DEVICE|iStent|Implantation of One iStent through a small temporal clear corneal incision.
223980256|NCT06112522|DRUG|Tirbanibulin|Subjects will be given one study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days. Subjects with unresolved lesion at d28 or d56 or d72 or d84 will be given an additional study kit containing single-dose packets of Tirbanibulin Ointment 1% and instructed to topically apply to the treatment area once daily for 5 consecutive days.
223980257|NCT05853692|DEVICE|Zinc Gluconate|Three times a day (spray)
223980258|NCT05853692|DEVICE|Sodium Bicarbonate|Five times a day (rinse)
223980259|NCT01560871|BEHAVIORAL|High-intensity IMT plus walking|"The IMT intensity was set at 60% of PImax which was reassessed weekly. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, it was the same as the one for the control group."
223980260|NCT01560871|BEHAVIORAL|Low-intensity IMT plus walking|"The IMT training was 3 sets of 10 repetitions, or when the participant felt tired. Participants returned to our facility every week to reassess PImax.~For the walking program, each participant was given a pedometer and a heart rate monitor to track daily step counts and heart rate. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion scale. Participants began at least 10 to 15 minutes, once to twice a day, for 7 days a week, and eventually progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
223980261|NCT06480435|OTHER|Chest physical Therapy|Chest Percussion is a conventional method to clear airway and mobilize the thick mucus from the chest wall. Percussion can be applied by both manually and mechanically, but the mechanical percussion is more useful
223980262|NCT06480435|OTHER|Lungs squeezing technique|"It improves the oxygen saturation and lung volumes better than percussion.~This technique has two phases:~1. Squeezing phase~2. Release phase"
223980263|NCT01010997|DEVICE|Foresee Home|using the Foresee home device
223980264|NCT00548002|DRUG|trovafloxacin and levofloxacin|Trovafloxacin: \<60 kg 200 mg iv/orally once daily and \>60 kg 300 mg iv/orally once daily Levofloxacin: \< 60 kg 500 mg iv/orally once daily and \>60 kg 500 mg iv/orally bid
224293753|NCT07212920|DIAGNOSTIC_TEST|Physiotherapy digital assessment|This study involves three types of knee assessments to evaluate diagnostic reliability and validity: (1) a video-based function-based examination without specific knee tests, (2) traditional in-person function-based examination without specific knee tests and to control with (3) a traditional in-person examination including specific knee tests. The video-based assessment includes standardized history taking and functional evaluation conducted via clinic software, with the physiotherapist and participant in separate rooms. Physiotherapists provide diagnostic judgments after each assessment phase. All procedures follow standardized protocols, pilot-tested and conducted at a public rehabilitation clinic in Västra Götaland.
223543909|NCT06511960|OTHER|36 mg/day astaxanthin intervention|36 mg/day astaxanthin was administrated to all participants in the astaxanthin 36 mg/day group for 4 weeks. Following this supplementation protocol, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
223980265|NCT02869906|OTHER|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
223980266|NCT02830828|OTHER|Investigation of precision pinch grip control|
223980267|NCT00616330|DRUG|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
224118659|NCT06672367|PROCEDURE|Balance training group|"It includes participants receiving balance training for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously."
223980268|NCT00616330|DRUG|clindamycin phosphate|semi solid, single dose
223980269|NCT00616330|DRUG|butoconazole nitrate|semi solid, single dose
223980270|NCT01137747|DRUG|Carfilzomib|
223980271|NCT03108976|OTHER|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
223980272|NCT03108976|OTHER|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
223980273|NCT03108976|OTHER|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
223980274|NCT02950181|DEVICE|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
223980275|NCT05377645|OTHER|Cyriax mobilization + traditional physiotherapy|TENS, US, exercise
223980276|NCT05527743|OTHER|Invasive Physiotherapy|They will receive an invasive physiotherapy protocol of 3 sessions of percutaneous electrolysis and percutaneous neuromodulation guided by ultrasound, with a time margin of one week between the first and the second session and two weeks between the second and the third. Each session will last approximately 30 minutes. Each treatment session will consist of the application of 3 impacts of 3 seconds of 1.5mA intensity (1.5:3:3) (34), in a needle placed in an echoguided manner in the carpal tunnel in relation to the median nerve over the area of fibrosis or entrapment. Subsequently, a second needle will be placed ultrasound-guided at the level of the elbow crease in relation to the median nerve. A symmetric biphasic current with a frequency of 2Hz and a pulse width of 250µs (22,35) will be applied for 17 minutes (36), increasing the intensity of the current until a slight tolerable discomfort is produced in relation to the patient's symptomatology.
223980277|NCT05527743|OTHER|Sham|"The participants of the study corresponding to the sham group will receive the application of the transcutaneous electrical stimulation sham technique (37), placing the patches in the same points where the needles are located in the percutaneous electrolysis and percutaneous neuromodulation technique, remaining in the supine position for the necessary time after the technique is performed, until 30 minutes are completed, thus ensuring that the evaluator does not know to which group each patient has been assigned (37). This technique has been studied as a sham technique for electrolysis and neuromodulation interventions (37).~Once the study is completed and if the results are better in the IF group, the subjects in the sham group will be offered to receive this treatment. The reason for this is to ensure that the entire sample ends up receiving a treatment that, a priori, should improve their functional capacities, thus guaranteeing one of the ethical principles of research."
223980278|NCT05417464|OTHER|Use of flowchart|Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
223980279|NCT03245177|BIOLOGICAL|Pembrolizumab|Anti-PD-1 antibody
223980280|NCT03245177|RADIATION|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
224295345|NCT01252849|DEVICE|iStent|Implantation of Two iStents through a small temporal clear corneal incision
224295346|NCT01252849|DEVICE|iStent|Implantation of Three iStents through a small temperal clear corneal incision
224295347|NCT00004313|DRUG|dehydroepiandrosterone|
223543910|NCT06511960|OTHER|Placebo|12 mg/day placebo was administrated to all participants in the placebo group for 4 weeks. Following the placebo supplementation, we assessed the muscle damage markers (creatine kinase and lactate dehydrogenase), total antioxidant status (malondialdehyde and uric acid), and muscle pain levels were evaluated using the Numerical Visual Pain Scale0-10.
223543911|NCT02298868|DRUG|Baclofen|
223980281|NCT04281693|DIAGNOSTIC_TEST|Standard screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.
223980282|NCT04281693|DIAGNOSTIC_TEST|New screening strategy|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.
223980283|NCT01944449|DIETARY_SUPPLEMENT|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
223980284|NCT01944449|DIETARY_SUPPLEMENT|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
223980285|NCT01944449|DIETARY_SUPPLEMENT|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
223980286|NCT01501227|DEVICE|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
223980287|NCT01501227|OTHER|Conventional endotracheal tube|Sham Comparator
223980288|NCT04785716|DRUG|Niraparib|Niraparib provided through the patient access program
224293754|NCT07212920|DIAGNOSTIC_TEST|Physiotherapy assessment - only functional tests|This study involves three types of knee assessments to evaluate diagnostic reliability and validity: (1) a video-based function-based examination without specific knee tests, (2) traditional in-person function-based examination without specific knee tests and to control with (3) a traditional in-person examination including specific knee tests. The in-person assessments (2 and 3) includes the same functional tests plus specific tests targeting knee structures (ligaments, meniscus etc). Physiotherapists provide diagnostic judgments after each assessment phase. All procedures follow standardized protocols, pilot-tested and conducted at a public rehabilitation clinic in Västra Götaland.
223980289|NCT06140914|DIAGNOSTIC_TEST|Proteomics, miRNA studies and studies of blood cells from blood samples|This is an observational study where we follow patients and save blood samples and biopsies for analysis as described above.
223980290|NCT05217355|DRUG|MBA-P01 (Botulinum toxin A)|MBA-P01 will be injected into the Glabellar line
223980291|NCT05217355|DRUG|Placebo|Placebo will be injected into the Glabellar line
223980292|NCT02958475|BEHAVIORAL|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
223980293|NCT02958475|BEHAVIORAL|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
223980294|NCT02958475|BEHAVIORAL|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
223543912|NCT01000506|BIOLOGICAL|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
223543913|NCT01000506|BIOLOGICAL|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
223727072|NCT04090450|RADIATION|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
223980295|NCT05432700|OTHER|LactApp|"LactApp® provides personalised answers that can be arrived at through different pathways, which vary according to the profile of the user and the options she selects, allowing data sampling through an Ecological Momentary Assessment.~The app will remind of:~The first month: baby's breastfeeding position, frequency of feeds, number and consistency of stools, general breast care, average weight gain; in mothers who gave some supplementation, advice and support for them to try re-breastfeeding.~From the second to the third month: advice on expressing milk to create a reserve just in case they went back to work or had to be absent from home for a day, instructions on how to handle and preserve milk.~From the fourth to the sixth month: indications to use the stored milk (if it was created) and techniques for administering it to the infant, the importance of maintaining the EBF and the inadvisability of offering other types of milk or food."
224118660|NCT06672367|PROCEDURE|Balance training combined with gaze stability exercises|"It includes participants receiving balance training combined with gaze stability exercises for mild cognitive impairment.~Balance training~Walking on a flat surface at the beginning of each session for 5-10 minutes Perform different static and dynamic balance exercises along with cognitive tasks.~Static standing with feet together with eyes open and closed Semi-tandem stand and tandem stand Forward and backward weight shift exercises Counting backwards by threes, Naming object or animals, Recalling a short sequence of numbers or words.~Side stepping, marching, forward and backward walking Hip extension and abduction Cognitive task includes word association or simple math problems. Standing on one leg Relaxation and breathing exercises including deep inhaling and exhaling or walking slowly at the end of each session for 5-10 minutes During training sessions, balance activities and cognitive tasks will be implemented simultaneously.~Gaze stability exercises~Visual tracking exercises"
224118661|NCT01723280|DRUG|Oxygen|During and 2 hrs after surgery
223980296|NCT05643313|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
223980297|NCT03053635|DRUG|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
223980298|NCT02024750|BEHAVIORAL|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
223980299|NCT04807283|DEVICE|Left Atrial Appendage Closure|Closure or occlusion of the left atrial appendage to reduce the risk of thromboembolism in patients with NVAF
224118662|NCT06920485|PROCEDURE|Third molar surgery|Effects of different gargles/mouth rinses/antiseptic agents applied after impacted surgical tooth extraction on postoperative wound healing and total bacterial load
223543914|NCT01000506|BIOLOGICAL|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
223543915|NCT01000506|DRUG|Placebo saline|Placebo saline every four weeks by i.v.
223543916|NCT00905190|DRUG|Ondansetron|24 mg one time
223543917|NCT05363592|DRUG|CT-L01 12.5/500 mg|FDC tablet, 2 tablets at a time, oral administration
223543918|NCT05363592|DRUG|Alogliptin Benzoate 12.5 mg|Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
223543919|NCT05363592|DRUG|Metformin HCl XR 500 mg|Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
223543920|NCT02379052|DRUG|Dupilumab|
223543921|NCT02379052|DRUG|Placebo|
223727073|NCT00279240|DRUG|Metformin|
223543922|NCT00308334|DRUG|Domperidone|10 mg po TID X 14 days
223543923|NCT00308334|DRUG|Placebo- Sugar pill|placebo po TID x 14 days
223543924|NCT00405249|DRUG|elvucitabine|
223543925|NCT01734824|DRUG|Denosumab|sc RANKL-inhibitor
223727074|NCT03041402|OTHER|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
223727075|NCT03041402|OTHER|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
223980300|NCT05457322|BEHAVIORAL|Behavioral intervention one|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
223980301|NCT05457322|BEHAVIORAL|Behavioral intervention two|Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
223980302|NCT01561456|DRUG|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
223980303|NCT01561456|DRUG|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
223543926|NCT01734824|DRUG|Teriparatide|daily subcutaneous injection of teriparatide
223543927|NCT01734824|DRUG|Placebo Denosumab|one subcutaneous injection denosumab placebo
223980304|NCT04830878|DRUG|Methotrexate|Systemic and intraoperative intravitreal injection of methotrexate
223980305|NCT00000636|DRUG|Isoniazid|
224118663|NCT06920485|DIAGNOSTIC_TEST|Pain Medicine|After the extraction, patients will be given two separate forms with VAS scales for pain to mark every day for 7 days. The patient will be asked to mark the level of pain they feel on the scale. The amount of analgesic use on the home assessment form will also be recorded as part of the pain assessment. On the 7th day, healing in the wound area will also be assessed.
224118664|NCT06920485|DIAGNOSTIC_TEST|Wound healing|The degree of healing of the wound area will be checked using Landry scoring.
224118665|NCT06920485|OTHER|Total bacterial load|Total bacterial load will be evaluated by microbiological analysis of sutures obtained from all groups.
223543928|NCT01734824|DRUG|Placebo Teriparatide|daily subcutaneous placebo injection
223543929|NCT00532844|DRUG|Sapropterin Dihydrochloride|Sapropterin Dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
223980306|NCT00000636|DRUG|Pyrazinamide|
223980307|NCT00000636|DRUG|Pyridoxine hydrochloride|
223980308|NCT00000636|DRUG|Rifampin|
223980309|NCT04218552|DRUG|AD209|PO, Once daily(QD), 8weeks
223980310|NCT04218552|DRUG|Amlodipine low|PO, Once daily(QD), 8weeks
223980311|NCT04218552|DRUG|Amlodipine high|PO, Once daily(QD), 8weeks
223980312|NCT04218552|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
223980313|NCT02787759|OTHER|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
224118666|NCT05894993|DEVICE|transient elastograghy|is a non-invasive method proposed for the assessment of hepatic fibrosis in patients with chronic liver disease by measuring liver stiffness. It can be easily performed at the bedside or in the outpatients clinic with immediate results and good reproducibility.
224118667|NCT00308295|DRUG|Fish oil capsules|
223980314|NCT02787759|OTHER|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
223980315|NCT01582412|DRUG|Isavuconazole|oral
223980316|NCT01582412|DRUG|digoxin|oral
223980317|NCT00383591|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
223980318|NCT00383591|BIOLOGICAL|Engerix-B|
223980319|NCT03075098|DEVICE|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
223980320|NCT02896101|DRUG|Pimecrolimus Cream, 1%|
223980321|NCT02896101|DRUG|Elidel® (pimecrolimus) Cream|
223980322|NCT02896101|DRUG|Placebo of Pimecrolimus Cream, 1%|
224118668|NCT00308295|DRUG|matched placebo capsules|
224118669|NCT00360022|OTHER|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
223727076|NCT03041402|OTHER|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
223727077|NCT01887873|DEVICE|Hyaluronan Thiomer i.o. implant|
223727078|NCT00697762|DRUG|RWJ-333369|200 mg tablet twice daily for 12 weeks
223727079|NCT00697762|DRUG|RWJ-333369|100 mg tablet twice daily for 12 weeks
223727080|NCT00697762|DRUG|Placebo|Placebo tablet twice daily for 12 weeks
223727081|NCT03530098|DEVICE|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
223727082|NCT00150722|DRUG|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
223727083|NCT05825521|OTHER|MRI|During management, patients with hydrocephalus will be subjected to flow MRI and diffusion MRI. Flow parameters and diffusion parameters will be measured and compared to those found in control subjects receiving the same type of imaging
223980323|NCT00998829|OTHER|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
223980324|NCT00702546|DRUG|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
223980325|NCT00702546|BIOLOGICAL|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
223980326|NCT00702546|DRUG|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
223980327|NCT00702546|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
223980328|NCT00702546|BIOLOGICAL|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
224118670|NCT02944799|DRUG|Placebo|Discontinuation of alendronate treatment
224118671|NCT02944799|DRUG|Alendronate|
224118672|NCT02944799|DRUG|Calcium|Daily dietary supplement of 800mg calcium
224118673|NCT02944799|DRUG|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
224118674|NCT04151017|OTHER|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
224118675|NCT04151017|OTHER|Suture|Graft fixation using 10.0 mononylon
224118676|NCT04075227|DRUG|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
224118677|NCT04075227|DRUG|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
224118678|NCT02559232|DRUG|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
223980329|NCT00702546|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
223980330|NCT00702546|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
223980331|NCT00702546|BIOLOGICAL|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
223980332|NCT00053378|DRUG|paricalcitol injection (Zemplar)|
223980333|NCT00053378|BEHAVIORAL|Effects on calcium regulation|
223980334|NCT00053378|BEHAVIORAL|Administration of elemental Ca during hypocalcemic ICU pts.|
223980335|NCT03714542|OTHER|Pre- and postoperative MRI|
223980336|NCT03779477|BEHAVIORAL|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
224118679|NCT02457351|DRUG|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
224118680|NCT02457351|DRUG|Itraconazole (Sporanox)|Part 1 \& Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
224118681|NCT04207112|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
224118682|NCT04207112|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
224118683|NCT04207112|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
224118684|NCT04207112|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
223980337|NCT05768737|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
223980338|NCT04303546|DEVICE|arterial stiffness measurements|We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB
223980339|NCT04886817|BEHAVIORAL|Pilot Intervention to reduce SSB consumption in children and families|"A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors"
223980340|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
223980341|NCT00640198|BEHAVIORAL|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
223980342|NCT00640198|DRUG|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
223980343|NCT00640198|DRUG|placebo|Placebo
223980344|NCT02914171|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
223980345|NCT02914171|DEVICE|Insertable cardiac monitor|Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
223980346|NCT03705533|DRUG|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
223980347|NCT03705533|DRUG|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
223980348|NCT06448104|OTHER|Dry needling and immersive virtual reality|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~The procedure will be carried out simultaneously with the use of immersive virtual reality distraction software, applied through MetaQuest 2 virtual reality glasses. This procedure consists of immersive visualization (video and sound images that represent scenes related to relaxation).~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
223980349|NCT06448104|OTHER|Dry needling|"The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue."
223980350|NCT01993576|DRUG|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
223980351|NCT03011905|DRUG|Dexamethasone|4 ml DexaGalen 4 mg/ml
223980352|NCT03011905|DRUG|NaCl (Control)|4 ml NaCl 9 mg/ml
223980353|NCT03011905|DRUG|Paracetamol|Premedication and as needed after operation
223980354|NCT03011905|DRUG|EtoriCoxib|Premedication and first 2 postoperative days.
223980355|NCT03011905|DRUG|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
223980356|NCT03011905|DRUG|Ropivacaine|In brachial plexus block
223980357|NCT04209998|DIAGNOSTIC_TEST|transcutaneous oximetry|Analysis of transcutaneous oximetry (Tcpo2) in terme of variability at rest and of response to oxygen inhalation
223980358|NCT02026245|DEVICE|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~* 5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~* New 'Tyndall/UU' developmental dataglove"
223980359|NCT00626015|BIOLOGICAL|PEP-3-KLH conjugate vaccine|Given intradermally
223980360|NCT00626015|BIOLOGICAL|daclizumab|Given IV
223980361|NCT00626015|DRUG|temozolomide|Given by mouth.
223980362|NCT00626015|OTHER|placebo|Given IV
223980363|NCT00626015|BIOLOGICAL|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
223980364|NCT02657954|BEHAVIORAL|CCT|10-week Compensatory Cognitive Training
224118685|NCT04207112|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
224118686|NCT04207112|DRUG|Standard Drugs|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
223980365|NCT02657954|BEHAVIORAL|HCE|10-week Holistic Cognitive Education
223980366|NCT00953199|DRUG|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
223980367|NCT00953199|DRUG|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
223980368|NCT01574014|BEHAVIORAL|CBGT|Cognitive-behavioral group therapy
223980369|NCT01574014|DRUG|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
223980370|NCT01574014|DRUG|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
223980371|NCT03795402|DEVICE|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
224118687|NCT05688267|OTHER|Continuous Mobility Training|The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
224118688|NCT05688267|OTHER|Usual Care|Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
224118689|NCT01271478|DRUG|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
224118690|NCT01271478|DRUG|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
224118691|NCT01271478|DRUG|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
224118692|NCT01271478|DRUG|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
223980372|NCT06353802|DIAGNOSTIC_TEST|Chronic non-specific neck pain and lumbar reposition sense|"In order to evaluate the lumbar joint repositioning error using the Joint Positioning Sense, the following guidelines were followed: (I) The participants were to stand with their arms at their sides, their feet externally rotated (about 20 degrees).~(II) With the feet flat on the floor and the arms resting on the front of the thighs, the person was seated in a height-adjustable seat that measured the length of the shank. (III) With a belt fastened, the iPhone® was positioned upright just above the iliac crest, (IV) the inclination of the inclinometer was 0°; (V) The inclinometer's 0° point was set as the initial position. (VI) The individual was passively guided by the assessor to a 30° flexion within the range of 0 to 30°; (VII) the subject was to memorize this position for 10 s; (VIII) the subject actively returned to the initial position. (IX) Subsequently, the participant was required to actively replicate the position three times."
223980373|NCT03704649|BEHAVIORAL|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
223980374|NCT02214771|DRUG|Fidaxomicin|oral
224118693|NCT06925438|PROCEDURE|Computer-guided zygomatic implant system|Preoperative digital planning (DICOM data) to fabricate guides with metal sleeves for drill alignment
223980375|NCT02214771|DRUG|Treatment for CDI other than fidaxomicin Type|Oral
223980376|NCT03185585|OTHER|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
223543930|NCT00532844|DRUG|Sapropterin Dihydrochloride and Vitamin C|Sapropterin Dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
223543931|NCT03637491|DRUG|Avelumab|IV treatment
223543932|NCT03637491|DRUG|Binimetinib|Oral treatment
223543933|NCT03637491|DRUG|Talazoparib|Oral treatment
223543934|NCT02077231|DRUG|Vitamin A|use one drop in the eye
223543935|NCT02077231|DRUG|carbomer eye gel|use one drop in the eye
223543936|NCT03335202|DIAGNOSTIC_TEST|analysis of microbiome|microbial profiling by next generation sequencing
224118694|NCT06925438|PROCEDURE|free-hand zygomatic implant placement|Standard placement using sequential drills (2.8-3.6mm) under saline irrigation
224118695|NCT03607682|PROCEDURE|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
224118696|NCT03607682|DEVICE|NovoTTF-200A Device|Undergo TTF therapy
224118697|NCT03607682|OTHER|Quality-of-Life Assessment|Ancillary studies
224118698|NCT00376688|OTHER|Laboratory Biomarker Analysis|Correlative studies
224118699|NCT00376688|DRUG|Temsirolimus|Given IV
224118700|NCT02202681|DEVICE|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
224118701|NCT05519761|DEVICE|Implantation of veinous access ports|"The surgeon, anaesthetist and interventional radiologist should be thoroughly familiar with the surgical procedure, instruments, and device characteristics prior to performing the implantation.~The nurse has also to be familiar with the implantable port since he/she intervenes in it at the time of the Huber needle puncture and solution injection."
223980377|NCT03185585|OTHER|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
223980378|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m\^2 on Day 1 plus gemcitabine 1250 mg/m\^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
223980379|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m\^2 plus pemetrexed 500 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
223980380|NCT02083679|DRUG|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute \[mg/mL/min\] plus paclitaxel 225 mg/m\^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
223980381|NCT02083679|DRUG|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m\^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
224118702|NCT05419154|PROCEDURE|Early pain dependent weight-bearing without immobilization|Patients are advised to conduct pain-dependent full weight-bearing starting at the day of study inclusion. In case of severe swelling, a splint or below knee cast can be applied until the initial swelling subsides, but no longer than 14 days. Otherwise, no immobilization is applied. The use of crutches is allowed per the individual patients demands. The physiotherapists at the individual study centers are informed prior to study initiation and are briefed about each patient enrolled in the study. Each patient is handed an information sheet for their outpatient physiotherapist.
224118703|NCT01395485|DRUG|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
224118704|NCT03334578|DRUG|Gastrografin|Gastrografin group
224118705|NCT06488326|DRUG|Mulberry leaf extract 6 mg capsule|Take one capsule of the sample one time.
224118706|NCT06488326|DRUG|Mulberry leaf extract 12 mg capsule|Take one capsule of the sample one time.
224118707|NCT06488326|DRUG|Mulberry leaf extract 18 mg capsule|Take one capsule of the sample one time.
224118708|NCT06488326|DRUG|Placebo capsule|Take one capsule of the sample one time.
224118709|NCT03660904|BIOLOGICAL|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
223543937|NCT02162654|PROCEDURE|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
223543938|NCT02162654|PROCEDURE|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
223543939|NCT06546475|DRUG|N-Acetylcysteine|regular dose or high dose add-on
223543940|NCT02861287|OTHER|Economic evaluation|
223727084|NCT05577481|COMBINATION_PRODUCT|sham iTBS combined with antidepressants|Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
223727085|NCT05577481|COMBINATION_PRODUCT|iTBS combined with antidepressants|Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
223980382|NCT04814992|BEHAVIORAL|Computer-Assisted Preoperative CBT Intervention (PAINTrainer)|Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
223980383|NCT02542085|PROCEDURE|Laparoscopic repair|operative method
223980384|NCT02542085|PROCEDURE|Hybrid repair|operative method
223980385|NCT00113997|DRUG|REG1|
223980386|NCT05699369|OTHER|Digital health interventions|Described in arm descriptions.
223980387|NCT02618863|DEVICE|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
223980388|NCT00691678|DRUG|Chondroitin|400mg chondroitin three times a day (TID) for twenty-four weeks
223980389|NCT00691678|DRUG|Glucosamine|500mg glucosamine TID for twenty-four weeks
223727086|NCT03455920|OTHER|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
223727087|NCT03455920|OTHER|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
223727088|NCT03483051|DRUG|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals \[610 mg, corresponding to 6.03 mmoles of NO3-\] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
223727089|NCT03483051|DRUG|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
223980390|NCT00554086|DRUG|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
224118710|NCT03660904|BIOLOGICAL|commercially made vitrification & thawing kit|commercially available vitrification \& thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
224118711|NCT05523063|OTHER|Quality of life questionnaire|"The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator."
224118712|NCT00668655|DRUG|Metronidazole Gel|Topical, Once daily for 2 weeks
223727090|NCT02592174|OTHER|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
223980391|NCT05772481|OTHER|PET-MRI|"Each patient will have a pre-treatment PET-MRI (PET-MRI 1) within 21 days before the start of treatment.~Induction chemotherapy may be performed at another center than the investigating center.~After 3 cycles of induction chemotherapy and before the 4th cycle, a second PET MRI (PET MRI 2) will be performed. In patients who have received less than 3 cycles of induction chemotherapy, this mid-therapy PET-MRI will not be performed.~A 3rd PET-MRI will be performed prior to radiation therapy (PET-MRI 3). A final MRI PET (MRI PET 4) will take place before surgery.~A total of 4 PET MRI scans will be performed."
223980392|NCT01458964|DRUG|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
223980393|NCT02277067|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
223980394|NCT02277067|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
223980395|NCT02348372|DRUG|GSK1278863A Placebo|Matching size, shape and color
223980396|NCT02348372|DRUG|GSK1278863A|A round, biconvex, white film coated tablet
223980397|NCT01462825|DIETARY_SUPPLEMENT|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
223980398|NCT01462825|DIETARY_SUPPLEMENT|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
223980399|NCT02279992|DRUG|Vardenafil|
223980400|NCT02279992|DRUG|Carboplatin|
223980401|NCT01831726|DRUG|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
223980402|NCT01716923|BIOLOGICAL|S-303 Red Blood Cells (RBCs) - Test|
223980403|NCT01716923|BIOLOGICAL|Conventional, untreated red blood cells (RBCs) - Control|
223980404|NCT03463538|PROCEDURE|arthroscopic capsular release|surgical release of shoulder joint capsule
223727091|NCT02592174|OTHER|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
223727092|NCT02592174|RADIATION|cerebral images sub-study|Standard magnetic resonance imaging
223727093|NCT03856164|DRUG|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
223727094|NCT03856164|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
223727095|NCT00913367|DRUG|glimepiride + insulin glargine (Amaryl + Lantus)|"* Amaryl® 4 mg at breakfast + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
223980405|NCT03463538|PROCEDURE|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
223980406|NCT03049306|DRUG|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
224118713|NCT00000728|DRUG|Zidovudine|
223980407|NCT03049306|DRUG|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
223980408|NCT02001467|OTHER|Simulation-based training|
223980409|NCT05363098|OTHER|Mechanically ventilated neurosurgical patients|Observational study where respiratory variables and intracranial pressure will be measured during assisted mechanical ventilation. No intervention is planned.
223980410|NCT06140576|DRUG|Sindilimab|Sindilimab, 200mg, Intravenous，every three weeks
223980411|NCT06140576|DRUG|Nab-paclitaxel|Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
223980412|NCT06140576|DRUG|Lenvatinib|Lenvatinib 8mg, 12mg, 16mg everyday
223980413|NCT03151551|DRUG|Ixekizumab|Administered SC
223980414|NCT03151551|DRUG|Adalimumab|Administered SC
223980415|NCT01669720|DRUG|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
223980416|NCT04458012|DIAGNOSTIC_TEST|Oculus Keratograph. Schirmer test. Tear fluid sample.|Objective measurements of the ocular surface using Oculus 5 keratograph. Slit lamp examination and tear fluid sample using Schirmer strips.
223980417|NCT02934893|OTHER|Medication Management Clinic|referral to medication management clinic from primary care
223980418|NCT02934893|OTHER|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
223980419|NCT04013932|BEHAVIORAL|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions \[\~30 to 45 minutes each\] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions \[\~1.5 hours each session\] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
223980420|NCT00356213|PROCEDURE|sleeve gastrectomy|laparoscopic sleeve gastrectomy
223980421|NCT00356213|PROCEDURE|Roux-Y-gastric bypass|laparoscopic gastric bypass
223980422|NCT05859009|PROCEDURE|EUS-Guided Therapy of Glue and Coil|This clinical trial aims to evaluate the effectiveness and safety of endoscopic ultrasound (EUS)-guided therapy of glue and coil in the management of gastrointestinal bleeding due to varices. The procedure involves the insertion of a catheter through an endoscope to deliver glue and/or coils to the bleeding site, under EUS guidance. Patients who meet the inclusion criteria will undergo EUS-guided therapy of glue and coil, followed by follow-up assessments to evaluate the outcomes of the procedure, including bleeding recurrence and adverse events.
223980423|NCT05859009|DRUG|Non-Selective Beta Blockers (Propanolol)|Participants in this arm will receive a daily oral dose of a non-selective beta blocker (such as propranolol) for the duration of the study. Participants will be monitored for side effects and efficacy of the medication.
224118714|NCT00000728|DRUG|Aldesleukin|
224118715|NCT03671824|OTHER|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
223543941|NCT01428310|DIETARY_SUPPLEMENT|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
223543942|NCT01428310|DIETARY_SUPPLEMENT|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
223543943|NCT00198328|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
223980424|NCT04131699|DEVICE|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output \& stroke volume measured and recorded with every change in intrathoracic pressure.
223980425|NCT00730210|DRUG|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
223980426|NCT00730210|DRUG|b:placebo|100 microgram placebo subcutaneous a day for 6 months
224118716|NCT02867345|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
224118717|NCT02867345|DRUG|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
223980427|NCT04739189|BEHAVIORAL|Con : control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at dinner time. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
223980428|NCT04739189|BEHAVIORAL|Def-EX : Condition with an exercise-induced energy deficit|Condition with an exercise-induced energy deficit The adolescents will be asked to complete an acute exercise set at 65% of their capacities (cycling) during the afternoon, inducing an energy expenditure of 400 kcal. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
224118718|NCT02867345|DRUG|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
224118719|NCT03027817|PROCEDURE|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
223543944|NCT00198328|PROCEDURE|Surgical Excision|Patients have their tumor surgically removed.
223543945|NCT03542019|DEVICE|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
223543946|NCT03542019|DEVICE|Dental crown|Replacement og missing tooth structure using monolithic zirconia
223543947|NCT03542019|DEVICE|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
223543948|NCT06270238|DEVICE|High-Frequency1|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
223980429|NCT04739189|BEHAVIORAL|Def-EI : Condition with an energy-restriction energy deficit|Condition with an energy-restriction energy deficit The adolescents will be asked to remain quiet during the whole day (no physical activity). They will receive a calibrated breakfast reduced from 400 kcal compare to their CON and Def-EX conditions. Dinner will be served ad libitum. Their food reward will be assessed before dinner. Their appetite feelings will be assessed at regular intervals.
223980430|NCT04337034|BEHAVIORAL|Mobile phone supported and family-centred rehabilitation|Participants in the intervention group will receive an eight-week mobile phone supported and family-centred rehabilitation intervention (F@ce 2.0).The participants will be introduced to a problem-solving strategy intended to facilitate the learning and problem-solving process to be used during the intervention. The strategy will provide a structure for healthcare professionals delivering the intervention. Three targets (goals) in daily activities will be formulated that the person wants and needs to do within the home environment. Each activity will be practiced together with the healthcare professionals and family members. Family members will be informed about the participant's target activities and the planned strategies for reaching the targets. The participants will practice the target activities in their home environment supported by mobile phone calls and SMS. In addition they will be given information about stroke and their blood pressure will be measured.
223980431|NCT04337034|PROCEDURE|Information and blood pressure measurement|Control group participants will be given information about stroke and their blood pressure will be measured.
223980432|NCT02785575|OTHER|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
223980433|NCT03604289|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
223980434|NCT03604289|DRUG|Saline|Saline will be used as the placebo comparator
223980435|NCT00514813|DRUG|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
223980436|NCT03043170|DEVICE|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
223980437|NCT02979613|DRUG|TAF|25 mg tablet administered orally once daily
223980438|NCT02979613|DRUG|TDF|300 mg tablet administered orally once daily
223980439|NCT02979613|DRUG|TAF Placebo|Tablet administered orally once daily
223980440|NCT02979613|DRUG|TDF Placebo|Tablet administered orally once daily
223980441|NCT02923817|BIOLOGICAL|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
223980442|NCT05590806|OTHER|Direct composite build-ups|Direct composite build-ups application
223980443|NCT01202383|BEHAVIORAL|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
223980444|NCT01202383|BEHAVIORAL|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
223980445|NCT02626689|OTHER|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
223980446|NCT02626689|OTHER|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
223980447|NCT03369314|DRUG|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
223980448|NCT02746237|DRUG|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
223980449|NCT02746237|DRUG|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
223980450|NCT01138098|BIOLOGICAL|Engerix™-B|Intramuscular, single dose
223980451|NCT01550783|OTHER|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
223980452|NCT01550783|OTHER|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
223980453|NCT01550783|OTHER|Questionnaire Administration|Ancillary studies
223980454|NCT01550783|PROCEDURE|Screening Method|Undergo standard of care Pap test screening
223980455|NCT01550783|PROCEDURE|Screening Method|Undergo home-based HPV screening
223980456|NCT04029792|COMBINATION_PRODUCT|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
223980457|NCT04029792|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
223980458|NCT00655369|DRUG|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
223980459|NCT00655369|DRUG|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
223980460|NCT00655369|DRUG|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
223980461|NCT00655369|DRUG|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
223980462|NCT00655369|DRUG|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
223980463|NCT00655369|DRUG|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
223980464|NCT03194945|DRUG|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
223980465|NCT03194945|DRUG|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
223980466|NCT03194945|DRUG|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
223980467|NCT03194945|DRUG|CSII alone|No OHA is given after short-term intensive CSII
223980468|NCT03501888|BEHAVIORAL|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
223980469|NCT03501888|BEHAVIORAL|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
223980470|NCT02546778|DEVICE|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
223980471|NCT03379428|DRUG|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
223980472|NCT03379428|DRUG|Ibrutinib 560 mg|560 mg by mouth daily
223980473|NCT03379428|DRUG|Ibrutinib 840 mg|840 mg by mouth daily
223980474|NCT03379428|DRUG|Ibrutinib 420 mg|420 mg by mouth daily
223980475|NCT06591767|DIETARY_SUPPLEMENT|Quercetin|200 mg supplemental Quercefit®
223980476|NCT06591767|COMBINATION_PRODUCT|Berberol K®|"Berberine Phytosome® 730 mg~\+ MonakoPure® containing 2.9 mg of monacolin K and KA from red yeast rice extract"
223980477|NCT04229706|DRUG|High dose Xiang Ju Ru Pi Ning capsule|xingjurupining capsule,8 capsule,tid,3 months.
223980478|NCT04229706|DRUG|Low dose Xiang Ju Ru Pi Ning capsule|xiangjurupining capsule,4 capsules , and xiangjurupining capsule placebo,4 capsules,tid,3 months.
223980479|NCT04229706|DRUG|Xiang Ju Ru Pi Ning capsule placebo|xiangjurupining capsule,8 capsule,tid,3 months.
223980480|NCT04981184|DEVICE|Gait and balance measurement|Virtual gait training procedures are included. Balance training procedures with Biodex Balance system are included too.
223980481|NCT05079906|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) for all enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
223980482|NCT05079906|DEVICE|High Definition Intravascular Ultrasound (HD-IVUS)|High Definition Intravascular Ultrasound (HD-IVUS) in addition to FFR for last 50 enrolled subjects. All interventional procedures, including FFR and HD IVUS, will be conducted in accordance with current approved User Guides and Instructions for Use.
223980483|NCT02169778|BEHAVIORAL|Intermittent energy restricted diet|
223980484|NCT02169778|BEHAVIORAL|Continuous energy restricted diet|
223980485|NCT05908539|BEHAVIORAL|Equipment box|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction only.
223980486|NCT05908539|BEHAVIORAL|Equipment box with briefing|Participants receive a box of exercise equipment containing dumbbell, elastic band, hand cycle machine, and booklet of exercise instruction, and they are given verbal briefing on how to use the equipment.
223980487|NCT05908539|BEHAVIORAL|Exercise training|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises.
224118720|NCT03781882|PROCEDURE|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
224118721|NCT03781882|PROCEDURE|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
224118722|NCT03238586|BEHAVIORAL|WELL Program|
224118723|NCT02826733|DEVICE|Electroencephalogram (EEG)|
224118724|NCT02826733|DEVICE|Near Infra Red Spectroscopy (NIRS)|
224118725|NCT02826733|DEVICE|magnetic resonance imaging (MRI)|
224118726|NCT03877120|DRUG|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
224118727|NCT03877120|DRUG|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
224118728|NCT01044238|DRUG|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
224118729|NCT01044238|DRUG|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
224118730|NCT00244699|BEHAVIORAL|MI Alone or Plus Mindfulness-Based Skills Training|
224118731|NCT04789642|OTHER|blood pressure measurement whatsapp educational program|educational
224118732|NCT00743600|OTHER|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
224118733|NCT00743600|OTHER|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
224293755|NCT07213128|OTHER|Training|"home-based inspiratory muscle training (IMT) will be delivered using a portable IMT device connected via Bluetooth to a smartphone application that provides real-time feedback, adherence monitoring, and telemonitoring by the study team. Patients will train for 365 days following hospital discharge due to an acute exacerbation of COPD:~* Intensive phase (Day 0-90): 2 daily sessions, each consisting of 30 breaths against an inspiratory load set by thetelemonitor, with regular online supervised IMT sessions, 7 sessions in total~* Maintenance phase (Day 91-180): One daily session of 30 breaths, with sporadic online supervised IMT sessions, 2 sessions in total.~* Follow-up phase (Day 181-365): Participants may continue IMT unsupervised. Supervision includes both in-person sessions at hospital visits and online sessions with telemonitors."
223980488|NCT05908539|BEHAVIORAL|Exercise training with behavioral modification|Participants receive al box of exercise equipment. They attend an 8-week group exercise training program for 1 hour /session and 1 session/ week, and are supervised by a physical fitness training. The exercise program includes a combination of aerobic, resistance, balance and flexibility exercises. After finishing the exercise training program, a 6-week behavioral modification is provided. Two home visits and four telephone visits are conducted to empower the participants for exercise at home.
223980489|NCT05264142|DRUG|Voriconazole 200mg|Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
223980490|NCT05264142|DRUG|FluvoxaMINE 50 Mg Oral Tablet|Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
223980491|NCT05264142|DRUG|Omeprazole 10 MG Oral Tablet|Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
223980492|NCT06625645|COMBINATION_PRODUCT|Modified triple antibiotic paste (TAP) mixed with chlorehexidine|M-TAP with CHX 2%
223980493|NCT06625645|COMBINATION_PRODUCT|Modified Triple Antibiotic Paste mixed with saline|M-TAP mixed with saline
223980494|NCT06625645|COMBINATION_PRODUCT|Calcium Hydroxide mixed with chlorohexidine Intracanal medication|calcium hydroxide powder mixed with CHX 2% solution as intracanal medication
223980495|NCT06625645|COMBINATION_PRODUCT|calcium hydroxide mixed with saline as intracanal medication|calcium hydroxide mixed with saline as intracanal medication for necrotic primary molars
223980496|NCT05958147|BIOLOGICAL|C-PRF|thorough scaling and root planing is performed followed by withdraw of 5ml of blood from antecubital vein of patient with consent . Following C-PRF protocol of 3000rpm for 8 min centrifugation is performed. 1ml of plasma is drawn from the test tube just above the red blood cell layer and allowed to clot and the formed clot is placed in the periodontal pocket after scaling and root planing
223980497|NCT00143598|DEVICE|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
223980498|NCT00143598|DEVICE|Knee-length, placebo stocking|Worn daily for two years
223980499|NCT05576012|BIOLOGICAL|SOL-116|Participants will receive SC injection in a double-blind manner
223980500|NCT05576012|BIOLOGICAL|Placebo|Participants will receive SC injection in a double-blind manner
223980501|NCT05241197|OTHER|Low Load Training with Blood Flow Restriction|A 12-cm-wide pneumatic nylon tourniquet will be proximally positioned with a snug fit on each thigh. Previously, arterial occlusion pressure (AOP) will be determined using a handheld Doppler Ultrasound in a standing position for each participant. For training routines, cuff pressure will be set to 50% of each individual´s AOP and will be keep inflated during the entire session including the interset rest period of 1 minute. Between the two exercises, the cuff will be deflated for 3 minutes.
224118734|NCT02736292|BEHAVIORAL|Mindfulness Practices for Healthcare Professionals|
223980502|NCT05241197|OTHER|High Load Training|All participants in this arm will do two exercises, unilateral dynamic standing and sitting calf-raises, with a training load of 70% 1RM, being progressively increased by 5% every four weeks from 70% to 80%. This protocol will consist of three sets of 6-12 repetitions with a interset rest period of 1 minute and 3 minutes rest between exercises.
223980503|NCT04817657|BIOLOGICAL|Ad26.COV2.S|Participants will be administered 0.5 milliliter suspension of Ad26.COV2.S 1\*10\^11 virus particles per milliliter (vp/ml) as intramuscular injection.
223980504|NCT03751553|DRUG|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson\&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that have purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child manually or using the sterile obstetric gel applicator without any manipulation or massage.
223980505|NCT01878383|DEVICE|Genexpert assay|
223980506|NCT05706636|DRUG|oral mini pulse|5mg / week oral dexamethasone
223980507|NCT05706636|DRUG|Topical cream|topical fluticasone cream for body lesions and topical tacrolimus for face lesions
223980508|NCT05706636|DEVICE|targeted phototherapy|twice weekly targeted excimer light sessions
223980509|NCT02185677|OTHER|Clinical evaluation|
223980510|NCT02185677|OTHER|neuropsychological battery test|
223980511|NCT02185677|OTHER|MRI|
223980512|NCT02185677|OTHER|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
224118735|NCT04542798|DEVICE|Radiofrequency COSMAN|Radiofrequency ablation and neuromodulation
224118736|NCT01254604|DRUG|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
224118737|NCT01254604|DRUG|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
224118738|NCT03074162|DRUG|Diclofenac Sodium|twice daily
224118739|NCT03074162|DRUG|Diclofenac & Capsaicin|twice daily
224118740|NCT03074162|DRUG|Diclofenac Sodium Topical Gel|twice daily
223980513|NCT03475056|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
223980514|NCT04396847|DRUG|Lorcaserin Oral Tablet|Lorcasering 10mg Oral Tablet (BID)
223980515|NCT04396847|DRUG|Placebo oral tablet|Placebo Oral Tablet (BID)
223980516|NCT04415827|DIAGNOSTIC_TEST|bicycle ergometry test with spiroergometry|"The 1st testing will be carried out on the 28-31th day of the disease, which corresponds to the period of the expected normalization of temperature, improvement of well-being, positive dynamics of radiological (with community-acquired pneumonia) and laboratory data, the 2nd test - after 3 months, the 3rd - after 6 months and IV - after 12 months.~Load testing will be carried out on a bicycle ergometer with an initial power of 25 watts with a further increase of 25 watts every 3 minutes. The cessation of the load will be carried out upon the appearance of signs set forth in the recommendations of the World Health Organization Expert Committee (1970)"
223980517|NCT01988298|DRUG|Ibuprofen|Ibuprofen 400 mg each 8 hours
223980518|NCT01988298|DRUG|Acetaminophen|Control group
223980519|NCT04678908|DRUG|HB0025|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
223980520|NCT01833208|OTHER|Laboratory Biomarker Analysis|Correlative studies
223980521|NCT01833208|RADIATION|Radiation Therapy|Undergo single-fraction radiation therapy
224118741|NCT02692820|DIETARY_SUPPLEMENT|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
223980522|NCT02331199|DEVICE|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
223980523|NCT02331199|DEVICE|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
223980524|NCT01699737|DRUG|JTT-851|
223980525|NCT01699737|DRUG|Glimepiride|Encapsulated Glimepiride tablets
223980526|NCT01699737|DRUG|Placebo for Active|
223980527|NCT01699737|DRUG|Placebo for comparator|
223980528|NCT01932762|DRUG|Grazoprevir|100 mg every day (QD) orally
223980529|NCT01932762|DRUG|Elbasvir|50 mg QD orally
224118742|NCT02692820|OTHER|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
224118743|NCT04964024|DIAGNOSTIC_TEST|SARS-CoV-2 antibodies|Analysis of the results of the serological response to COVID-19 and/or Vaccine
224118744|NCT03800706|DRUG|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
224118745|NCT03532971|OTHER|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
224118746|NCT03532971|DIAGNOSTIC_TEST|BK polyomavirus PCR|quantitative PCR testing
224118747|NCT03532971|OTHER|quality of life questionnaires|Standard questionnaires validated for HCT recipients
224118748|NCT05299203|DRUG|Sapropterin dihydrochloride tablets|dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
224118749|NCT01993329|DRUG|Gefapixant 50 mg|Gefapixant 50 mg tablet administered orally
224118750|NCT01993329|DRUG|Gefapixant 300 mg|Gefapixant 300 mg tablet administered orally
224118751|NCT01993329|DRUG|Placebo to mimic 50 mg tablets|Sugar pill manufactured to mimic gefapixant 50 mg tablets
224118752|NCT01993329|DRUG|Placebo to mimic 300 mg tablets|Sugar pill manufactured to mimic gefapixant 300 mg tablets
224118753|NCT05814393|DRUG|Treatment Period(JW0201)|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
224118754|NCT05814393|DRUG|Treatment Period(Placebo)|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)
224118755|NCT05814393|DRUG|Extension Period(JW0201)|JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
224118756|NCT05070429|OTHER|Clinic-based audiological rehabilitative service delivery|Participants will have scheduled clinic-based visits at 6 and 12 months post-randomization to reinforce self-management strategies and perform hearing aid checks.
223727096|NCT00913367|DRUG|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"* Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~* The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
223727097|NCT00331279|DRUG|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
223727098|NCT00331279|DRUG|Placebo|Placebo pills in likeness of the cinnamon extract
223727099|NCT04181502|PROCEDURE|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
223980530|NCT01932762|DRUG|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
223980531|NCT00390078|BIOLOGICAL|MVA-mBN32|3 immunizations: 1x 10E8\_TCID50 MVA-mBN32
223980532|NCT00390078|BIOLOGICAL|IMVAMUNE|3 immunizations: 1x 10E8\_TCID50 IMVAMUNE
223727100|NCT04181502|OTHER|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
223727101|NCT00226161|PROCEDURE|Inguinal herniorrhaphy|
223727102|NCT05940207|DEVICE|e-Bandages|A hydrogen-peroxide generating e-bandage for wound infection and treatment and prevention. Each e-bandage is composed of three electrodes - a working, a counter, and a reference electrode. Cotton fabric physically separates electrodes. Constant (regulated) generation of low-concentrations of hydrogen peroxide happens on the working electrode, which is in contact with the skin covered with a hydrogel layer.
223980533|NCT01333553|DEVICE|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
223980534|NCT00345709|BEHAVIORAL|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
223980535|NCT06322147|DRUG|Doublet or triplet chemotherapy combined with cetuximab|"chemotherapy+cetuximab combination therapy，chemotherapy regimens include FOLFOX, FOLFIRI, XELOX, or mFOLFOXIRI.~Cetuximab first dose 400 mg/m2, followed by cetuximab 250 mg/m2 every 2 weeks;~mFOLFOX6: oxaliplatin 85 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h) for up to 12 cycles;~XELOX (biweekly): oxaliplatin 85 mg/m2 (day 1), capecitabine 1000 mg/m2, bid, d1-10;~FOLFIRI: irinotecan 180 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h), Up to 12 cycles;~mFOLFOXIRI: oxaliplatin 85 mg/m2 (day 1), irinotecan 150 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1) and 5-FU 2400 mg/m2 CIV (46 h)."
223980536|NCT05876169|PROCEDURE|Orthognathic surgery|Surgical corrections of the maxilla and/or the mandible. Integrated jaw-neck movement patterns, muscle activity, bite force and occlusal contact area will be registered and mapped with quantitative objective functional variables. The state-of-the-art core equipment to evaluate jaw-neck motor function in detail is located in the Movement Lab (Department of Odontology, Umeå University).
223980537|NCT05648396|OTHER|FFRangio|Assessing the physiologic significance of an intermediate coronary lesion/lesions using FFRangio - a non invasive method to calculate the fractional flow reserve (FFR) of the assessed lesion.
223980538|NCT00541671|DRUG|Saline|10 c of saline
223980539|NCT00541671|DRUG|Phenergan|Physician ordered dose
223980540|NCT03993496|DIAGNOSTIC_TEST|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~1. Prior to EVAR deployment~2. After EVAR deployment, but before balloon affixation to the aortic wall~3. After EVAR deployment and after affixation"
223980541|NCT02153190|DEVICE|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
223980542|NCT02153190|DEVICE|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
223980543|NCT04604470|OTHER|Decision tool|no intervention.
223980544|NCT03588819|RADIATION|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
224118757|NCT05070429|OTHER|Telehealth audiological rehabilitative service delivery|Participants' scheduled clinic-based visits will be complemented with asynchronous and synchronous telehealth that will allow for routine troubleshooting of communication challenges, hearing aid technical issues, and reinforcement of self-management support strategies. At an initial session, participants will be instructed in the use of a study-provided, internet-enabled tablet device for telehealth sessions, re-introduced to the hearing loss toolkit for self-management and C2Hear Reusable Learning Objects within the context of the telehealth platform, re-evaluated on the Client Oriented Scale of Improvement (COSI) goals. Two remote follow-up sessions will be scheduled 3 and 6 weeks later to confirm participants' comfort with the telehealth platform and then completed every 6 months, in addition to scheduled 6-month clinic-based visits.
223980545|NCT05041725|DRUG|Remimazolam Injection [Byfavo]|Remimazolam injection and continuous infusion for postoperative sedation, 0.2 mg/kg for 1 min and continuous infusion of 1-2 mg/kg/hour
223980546|NCT06042023|DEVICE|Lifesignals Wearable Sensor|"The participants will wear the patch for 3-5 days and be provided with the mobile device, which records data transmitted wirelessly directly from the biosensor patch. During the monitoring period, participants can continue their normal activities.~Remote monitoring will be undertaken using the CE-marked LifeSignals wearable biosensor. The biosensor communicates with a commercially available mobile device, which relays data to a secure Cloud server (GDPR compliant data transfer).~Participants will subsequently undergo their planned surgery in the usual way. Data captured from the remote monitoring will not be used or made accessible to inform decisions about clinical care.~There will be no clinical intervention from the researchers if abnormalities in vital signs are picked up by the monitoring patch, as all data will be analysed retrospectively after the participant's operation. Any clinical concerns about the device that arise will be reported to the relevant clinical team."
223980547|NCT04427878|PROCEDURE|biopsies of subcutaneous adipose tissue|Two 4mm punch biopsies of subcutaneous abdominal or thight adipose tissue
223980548|NCT00509457|BIOLOGICAL|GV 1001 Telomerase peptide|
223980549|NCT02943642|BIOLOGICAL|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
223980550|NCT02943642|DRUG|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
223980551|NCT01172639|DRUG|Methotrexate|Methotrexate tablet
223980552|NCT01172639|DRUG|Sulfasalazine|Sulfasalazine tablet
223980553|NCT01172639|DRUG|Leflunomide|Leflunomide tablet
224118758|NCT02948777|DRUG|Evolocumab|
223727103|NCT06406283|BEHAVIORAL|High-Intensity Functional Training (HIFT)|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The training protocol will be designed based on Cross-Training workouts, emphasizing high-intensity interval training combined with functional resistance-training movements."
223980554|NCT01172639|DRUG|Prednisone|Prednisone tablet
223980555|NCT00070343|BIOLOGICAL|oblimersen sodium|
223980556|NCT00070343|DRUG|dacarbazine|
223980557|NCT01272323|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
223980558|NCT01272323|BIOLOGICAL|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
224118759|NCT03908138|DRUG|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
224118760|NCT03908138|DRUG|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
224118761|NCT05272917|OTHER|Sensorial tests|Patients will be included in the study between 3 to 6 months after the end of treatment and go to the Paul Bocuse Research Institute to perform several sensorial tests. The same sensorial tests will be completed by healthy volunteers to compare.
224293756|NCT07213427|OTHER|data collection|Collection of relevant medical data (clinical data, imaging, treatment, follow-up, toxicities), performed locally by investigators or authorized members of the medical team.
223980559|NCT01272323|BIOLOGICAL|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
223980560|NCT00126139|DRUG|Abciximab|
223980561|NCT03110263|OTHER|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
223980562|NCT03110263|OTHER|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., \& Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
223980563|NCT05469113|DRUG|Repaglinide|Administered orally.
223980564|NCT05469113|DRUG|Selpercatinib|Administered orally.
223980565|NCT01516853|DEVICE|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
223980566|NCT05708300|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
223980567|NCT00495872|DRUG|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
223980568|NCT00495872|DRUG|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
223980569|NCT00495872|DRUG|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
223980570|NCT00495872|DRUG|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
223980571|NCT00495872|DRUG|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
223980572|NCT00495872|DRUG|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
223980573|NCT00495872|DRUG|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
223980574|NCT03500666|DEVICE|Robot|Robot lateral neck lymph node dissection
223980575|NCT03500666|DEVICE|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
223980576|NCT04745377|DIAGNOSTIC_TEST|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus|IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
223980577|NCT02172950|BIOLOGICAL|rVIII-SingleChain|Recombinant single-chain coagulation factor VIII
223980578|NCT00469456|DRUG|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
223980579|NCT00469456|DRUG|placebo|Placebo oral administration twice daily for 12 weeks
223980580|NCT01196585|PROCEDURE|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
223980581|NCT01196585|PROCEDURE|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
223980582|NCT02880683|DEVICE|NeuroTronik CANS Therapy System|
223980583|NCT00269997|DRUG|epoetin alfa|
223980584|NCT00503217|DRUG|Tryptorelin|
223980585|NCT05560750|PROCEDURE|Frenotomy|Releasing the tongue-tie with scissors
223980586|NCT05560750|PROCEDURE|Oral physiotherapy|Gentle parental activation of the mouth area and the tongue for 1 month
223980587|NCT04379817|DIAGNOSTIC_TEST|Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT|Assess somatostatin receptor expression
223980588|NCT04367077|BIOLOGICAL|MultiStem|intravenous infusion
223980589|NCT04367077|BIOLOGICAL|Placebo|intravenous infusion
223980590|NCT01136447|PROCEDURE|Ultrasound|Block catheter will be introduced using ultraosound
223980591|NCT03565692|BIOLOGICAL|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~* Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~* Separation of the pellet and supernatant, stored at -20 ° C until testing~* Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~* Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~* Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~* Pseudomonas aeruginosa load measured by qPCR"
223980592|NCT03565692|BIOLOGICAL|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
223980593|NCT05139823|PROCEDURE|geriatric follow-up home visit after discharge|An appointment for a geriatric follow-up home visit is made with the patient and the municipal home care (community) nurse 2-4 days after discharge and only on weekdays. Relatives are informed about the visit and are welcome to join with the patient's acceptance. The local home care team as well as the patient's PCP receives the same digital discharge plan and discharge summary, respectively, as in the control group. While a follow-up visit is scheduled with the home care nurse, the PCP is invited to join too if available, either in person or by a video link. Administratively, the patients are treated as geriatric outpatients, with an in-home follow up instead of a visit in the Geriatric outpatient clinic.
223980594|NCT03453203|OTHER|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
223980595|NCT02163798|BEHAVIORAL|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
223980596|NCT02163798|BEHAVIORAL|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led \& self-practice).
223980597|NCT01487902|DRUG|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
223980598|NCT01487902|DRUG|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
223980599|NCT02795715|DEVICE|tDCS|
223980600|NCT02795715|BEHAVIORAL|training|
223980601|NCT02606383|DRUG|Dapaconazole|
223980602|NCT02606383|DRUG|Ketoconazole|
223980603|NCT05307263|PROCEDURE|Combination therapy of atherectomy and DCB|The target lesion in femoropopliteal artery will be treated with atherectomy folloewd by DCB. The choice of atherectomy devices (HawkOne, Jectstream, or Rotarex)and DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
223980604|NCT05307263|PROCEDURE|DCB alone|The target lesion in femoropopliteal artery will be treated with DCB. The choice of DCBs (IN.PACT or Ranger) will be left to the operator's decision. In presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of bare nitinol stents is recommended. Implantational of drug-eluting stents is not allowed.
223980605|NCT05964361|BIOLOGICAL|IL15-transpresenting WT1-targeted Dendritic Cell Vaccine|IL15/IL15Ra/WT1 DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered every 2 weeks (+- 3 days) for a total of 6 administrations.
223980606|NCT03336697|DIAGNOSTIC_TEST|Nasal swab|a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
223980607|NCT00291239|BEHAVIORAL|partial sleep deprivation|
223980608|NCT01035047|OTHER|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
223980609|NCT03752255|OTHER|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
223980610|NCT00611715|DRUG|erlotinib hydrochloride|OSI-774 150 mg/day
223980611|NCT00611715|DRUG|letrozole|Letrozole 2.5 mg/day
223980612|NCT00611715|GENETIC|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
224118762|NCT05272917|BEHAVIORAL|food preferences questionnaires|Patients will be included in the study between 3 to 6 months after the end of treatment and go at Institut Paul Bocuse to complete food preferences questionnaires. The same questionnaires will be completed by healthy volunteers to compare.
224118763|NCT02311478|DEVICE|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
223543949|NCT06270238|DEVICE|cTBS1|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
223543950|NCT06270238|DEVICE|High-Frequency2|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral premotor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
223543951|NCT06270238|DEVICE|cTBS2|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
223980613|NCT00611715|OTHER|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
223980614|NCT00611715|OTHER|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
223980615|NCT00000850|DRUG|Indinavir sulfate|
223980616|NCT00000850|DRUG|Sargramostim|
224118764|NCT06512818|DIETARY_SUPPLEMENT|Psiguavin|A purified guava extract will be used, enriched in psiguavin
224118765|NCT06512818|DRUG|Placebo|Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
224118766|NCT03242928|DRUG|AFQ056|50 mg and 100 mg tablets taken orally
223980617|NCT02003378|DEVICE|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
223980618|NCT02003378|DEVICE|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
223980619|NCT00107978|DRUG|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
223980620|NCT00107978|DRUG|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
223980621|NCT04061863|DRUG|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
223980622|NCT01016418|DIETARY_SUPPLEMENT|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
223980623|NCT04731142|DEVICE|Huma|Digital remote patient monitoring using blood pressure and blood sugar devices in combination with a smartphone app ('the Huma app'). Participants are provided with home monitoring devices and download the Huma app. Data recorded via the Huma app is self-reported and includes activity data, diet information, blood glucose measurements, blood pressure measurements, weight, and the Diabetes Distress Scale.
223980624|NCT04731142|BEHAVIORAL|Video group consultations|"Each patient is invited to attend a total of three VGCs during the 12-weeks lasting approximately one hour and 15 minutes each. Each session is facilitated by a Practice Nurse (PN) and consists of 6-10 people with T2DM. The self-reported Huma app (see below) and patient EPR data are used to populate a Discussion Dashboard which is used in each VGC to facilitate discussion. During the first VGC session, patient goals are discussed and adjusted in a group setting with topics relevant to their condition covered by the PN. Between each VGC session, patients spend time working on their goals and continuing to enter self-reported metrics into the Huma app. During the second and third VGC sessions, each patient is discussed, along with their performance against agreed goals."
223980625|NCT04731142|BEHAVIORAL|KNOW Diabetes|Each patient is signed up to a series of educational email campaigns to complement the VGC sessions and provide broader education around diabetes management. Patients receive two emails per week during the 12-week service on a variety of topics.
223980626|NCT04731142|OTHER|Standard of care|Normal primary care service provided to matched control group.
223980627|NCT02669407|PROCEDURE|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
223980628|NCT02669407|DRUG|regional nerve block with a local anesthetic (Lidocaine)|
223980629|NCT00611299|DIETARY_SUPPLEMENT|BB-12 and CRL 431|
223980630|NCT05538416|PROCEDURE|Posterior Lumbar Interbody Fusion (PLIF)|Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
223980631|NCT04864717|DRUG|Doxycycline 100mg po once daily x 6 months|active intervention
223980632|NCT04864717|DRUG|Isotretinoin 40 mg po once daily x 6 months|active intervention
223980633|NCT05512078|PROCEDURE|bone positioning surgical guide|patient specific surgical positioning guide made from acrylonitrile butadiene styrene (ABS) plastic material.
223980634|NCT03892551|OTHER|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 35 symptoms
223980635|NCT03892551|OTHER|Reason for patient presentation at ED|Exploratory interview assessing reason for patient presentation at ED
223980636|NCT03892551|OTHER|physicians rating of severity of illness|numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
223980637|NCT03892551|DIAGNOSTIC_TEST|Assessment of vital signs|Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
223980638|NCT03892551|OTHER|Clinical Frailty Scale|Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
223980639|NCT03892551|OTHER|Impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
223980640|NCT03892551|OTHER|Assessment of suspected diagnosis and differential diagnoses|Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
223980641|NCT05371145|BIOLOGICAL|Carnosine|Determine whether carnosine supplementation (2 g/day) for 3 months in peripheral arterial disease patients improves 6MWT ability.
223980642|NCT02316288|BEHAVIORAL|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
223980643|NCT02316288|BEHAVIORAL|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
223980644|NCT01391429|BEHAVIORAL|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
223980645|NCT00791739|DRUG|trazodone, pregabalin|"* phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~* phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
223980646|NCT02785731|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
223980647|NCT02785731|PROCEDURE|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
224118767|NCT03242928|DRUG|Placebo|Matching placebo tablets taken orally BID
223980648|NCT02785731|PROCEDURE|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
223727104|NCT06406283|BEHAVIORAL|Mindfulness-Based Stress Reduction Program (MBSR)|This intervention follows the official MBSR program designed by Jon Kabat-Zinn with some adaptations, as we did in Bermudo-Gallaguet, et al. (2022). The intervention will occur three days a week, including one 120-minute online synchronous session and two 20-40 min individual practices. The intensity of physical exercise will be adjusted to personal baseline characteristics.
223727105|NCT06406283|BEHAVIORAL|Qigong|"This intervention will include three sessions per week: two group 60-minute zoom online synchronous sessions guided by experts and one individual autonomous session (a repetition of a chosen session of that week).~The program includes the Baduanjin sequence, considered one of the most ancient and beneficial forms for physical and mental health within the Qigong tradition."
223727106|NCT00395369|DRUG|intraoperative aprotinin administration|
223727107|NCT06261203|DRUG|Aspirin|To investigate the efficacy of low dose aspirin for prevention of early pregnancy loss in women at high risk of preeclampsia.
223727108|NCT05769439|OTHER|No intervention in an observational study|This study is an observational study only.
223727109|NCT00492908|DEVICE|Helistent Titan2 (Titanium coated stent)|Titan2
223727110|NCT00492908|DEVICE|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
223727111|NCT01442675|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
223727112|NCT00220870|BEHAVIORAL|Decision aid|
223727113|NCT03640845|OTHER|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~* the transmission, the collection and the organization of the data,~* the analysis of the data and their confrontation with the referential and recommendations~* the writing of a Personalized Pharmaceutical Plan"
223727114|NCT02324894|PROCEDURE|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
223980649|NCT00910325|PROCEDURE|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
223980650|NCT00878293|DRUG|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
223980651|NCT00878293|DRUG|MS Continus®|60 mg, capsule, once daily
223980652|NCT00878293|DRUG|Placebo|liquid formulation and capsule, once daily
223980653|NCT02840916|PROCEDURE|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
223980654|NCT02840916|PROCEDURE|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
223727115|NCT02764515|DRUG|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
223727116|NCT02764515|DRUG|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
223727117|NCT05776589|DEVICE|The mechanical ventilation mode|Changing the mechanical ventilation mode
223727118|NCT06501482|DRUG|Postoperative reintroduction of FOLFIRI based chemotherapy|Postoperative reintroduction of FOLFIRI: irinotecan 180 mg/m2 + leucovorin 400 mg/m2 at day 1 then 5-FU 400 mg/m2 bolus followed by 2400 mg/m2 continuous infusion over 46 h biweekly. For a total of 12 cycles of perioperative chemotherapy including the preoperative chemotherapy
223980655|NCT02259062|OTHER|Music with brief mindfulness intervention|Music listening with mindfulness therapy
223980656|NCT02259062|OTHER|Music listening alone|
223980657|NCT02259062|OTHER|Audiobook listening|
223980658|NCT02121743|DEVICE|strattice|use of a strattice
223980659|NCT02121743|PROCEDURE|No strattice|no use of a strattice
223980660|NCT00739609|DRUG|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
223980661|NCT04716218|PROCEDURE|back up head elevated position|The patient was then placed in the back-up position to align the external auditory meatus and sternal notch, which was achieved by breaking the operating table at the hips to prevent patients from sliding off the table.
223980662|NCT01832454|OTHER|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
223980663|NCT00345800|DRUG|Sodium Oxybate (Xyrem)|"* Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral"
223980664|NCT03135613|PROCEDURE|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
223980665|NCT00704171|PROCEDURE|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
223980666|NCT00704171|DEVICE|PleuraSeal Lung Sealant System|
223980667|NCT00142545|DRUG|apomorphine HCl injection|
224118768|NCT00830661|PROCEDURE|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
223980668|NCT00135577|DRUG|alvimopan|
223980669|NCT00135577|DRUG|placebo|
223980670|NCT06386445|OTHER|Serum metabolomics sequencing|Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks，4 weeks，8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
223980671|NCT01874665|DRUG|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
223980672|NCT00237354|DRUG|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
223980673|NCT04988399|OTHER|Reiki|Reiki is a wellness practice of energy healing that began in Japan and is now practiced throughout the world. The principle of Reiki is that everything in the universe consists of energy including the human body, and deviations of this energy can lead to disease (Doğan 2018). Reiki does not have a religious doctrine and is accepted by people of all backgrounds and belief systems (McManus, 2017, p. 1056). Reiki is considered by practitioners to be a great tool for stress reduction and relaxation (International Association of Reiki Practitioners). Many people use Reiki for wellness. Reiki is not a cure for a disease or illness, but it may assist the body in creating an environment to facilitate healing. According to the Center for Reiki Research, Reiki is an effective approach for reducing pain, depression, and anxiety. Tinnitus is a pain percept, and it is likely Reiki may reduce pain and anxiety in patients with tinnitus.
223980674|NCT01113671|DRUG|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
223980675|NCT01113671|DRUG|Placebo|includes inactive Ingredients
223980676|NCT06215417|PROCEDURE|Rotator cuff repair|Arthroscopic rotator cuff repair augmented with graft.
223980677|NCT00408798|DRUG|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
223980678|NCT06133868|DRUG|Lavender and Chamomile Essential Oils|essential oils
223980679|NCT03277885|OTHER|chronic pain|work related chronic pain
223980680|NCT00078728|BEHAVIORAL|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
223980681|NCT00078728|BEHAVIORAL|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
223980682|NCT00350298|BIOLOGICAL|GS-CDA1/MDX-1388|One Intravenous dose
223980683|NCT00350298|BIOLOGICAL|normal saline|One Intravenous dose
224118769|NCT00830661|PROCEDURE|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
224118770|NCT00854529|DRUG|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
224118771|NCT00200525|DRUG|apomorphine HCl injection|
224118772|NCT01399801|PROCEDURE|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
224118773|NCT01399801|PROCEDURE|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
223727119|NCT00911053|DRUG|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
223727120|NCT00911053|BEHAVIORAL|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
223727121|NCT00911053|BEHAVIORAL|Light|Subjects will be exposed to light.
223980684|NCT03634839|DRUG|Flavoring Agents|Flavor of e-liquid - sweet or tobacco
223980685|NCT03634839|DRUG|Nicotine|Nicotine level (36 mg/ml)
223980686|NCT05763654|DEVICE|Linovera emulsion|Apply Linovera emulsion in clinical routine
223980687|NCT05969405|PROCEDURE|Laparoscopic staging|Laparoscopic staging
223727122|NCT00137046|DRUG|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
223727123|NCT00137046|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
223727124|NCT01214811|DEVICE|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
223727125|NCT03298594|DIAGNOSTIC_TEST|specific cervicograph|
223727126|NCT02345382|DRUG|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
223727127|NCT05571098|BEHAVIORAL|individualized colorectal cancer education|"Subjects taught within the scope of individualized colorectal cancer education:~* Common symptoms and management related to disease and treatment,~* Importance of nutrition in the treatment process."
223727128|NCT05571098|BEHAVIORAL|psycho-oncological counseling|"Topics discussed within the scope of psycho-oncological counseling:~* Psychological state (anxiety, depression, etc.),~* Coping strategies about the process,~* Presence of fear about the disease and/or treatment,~* Lifestyle changes/problems,~* Changes in body image,~* Family/friendship/work-related concerns,~* Additional issues, comments he wishes to convey"
223727129|NCT05571098|BEHAVIORAL|telephone support hotline service|Within the scope of the NNP, a telephone support hotline service was provided to the participants, where they could consult at any time about the subject they wanted.
223980688|NCT05969405|PROCEDURE|Robotic staging|Robotic staging
223980689|NCT05969405|PROCEDURE|Laparotomic staging|Laparotomic staging
223980690|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
223980691|NCT02447432|BIOLOGICAL|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
223980692|NCT02447432|BIOLOGICAL|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
223980693|NCT02647788|DRUG|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
223980694|NCT02647788|DRUG|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
223980695|NCT04198948|DRUG|Omeprazole|Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.
223980696|NCT04198948|DRUG|Placebo oral tablet|Placebo will be administered orally once daily for 5 days in one of the two treatment periods.
223980697|NCT04198948|DRUG|Gliclazide|Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.
223980698|NCT06224010|OTHER|Respiratory drive and effort assessment|The use of a neurally-adjusted ventilatory assist catheter, the measurement of electrical activity of the diaphragm, ∆Pocc, P0.1, and other ventilatory parameters to assess respiratory drive and effort in three cohorts of patients
223980699|NCT00607061|PROCEDURE|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
223980700|NCT04961632|DRUG|Tamoxifen|Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
223980701|NCT04961632|DRUG|Tamoxifen|Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
223980702|NCT06438692|PROCEDURE|VOM ethanol chemical ablation and 2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation，anhydrous alcohol ablation of VOM
223980703|NCT06438692|PROCEDURE|2C3L|Annular pulmonary vein ablation, mitral isthmus line ablation, tricuspid isthmus line ablation, apex line ablation
223980704|NCT00130078|DRUG|1.0% C31G SAVVY vaginal gel|
223980705|NCT00233389|DRUG|Rebamipide|
223980706|NCT03740477|DIAGNOSTIC_TEST|ECG|Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
224118774|NCT04531319|DIAGNOSTIC_TEST|Flow cytometric analysis|Flow cytometric analysis of T helper, T cytotoxic cells, NK cells and monocytes
224293757|NCT07212764|OTHER|mobile application|Patients will be instructed to record any symptoms suggestive of infectious diseases-such as fever, cough, nasal discharge, or myalgia-directly into the mobile application whenever they occur. The app will provide simple checklists and entry fields, allowing patients (or their caregivers) to promptly log these symptoms in real time. By systematically documenting infection-related manifestations alongside routine follow-up data, we will be able to prospectively evaluate whether infectious episodes act as potential triggers for Familial Mediterranean Fever (FMF) attacks. The collected data will then be analyzed to determine temporal and clinical associations between infection symptoms and subsequent disease flares, thereby clarifying whether infections precipitate or overlap with FMF attacks.
224293758|NCT07213375|DRUG|Dexamethasone|Patients will receive either low dose (8mg) or high dose (1mg/kg)
223727130|NCT03959566|DRUG|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
223980707|NCT01127321|OTHER|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
223980708|NCT01127321|BIOLOGICAL|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
223980709|NCT01127321|BIOLOGICAL|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
223980710|NCT01127321|BIOLOGICAL|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
223980711|NCT01127321|BIOLOGICAL|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
223980712|NCT02107742|PROCEDURE|Normal speed lidocaine injection|30 seconds
223980713|NCT02107742|PROCEDURE|Slow lidocaine injection|speed 45 seconds
223980714|NCT02107742|PROCEDURE|Fast lidocaine injection|speed 15 seconds
224118775|NCT00004735|BIOLOGICAL|Tetanus toxoid|
224118776|NCT00004735|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
224118777|NCT01031524|BIOLOGICAL|PfCS102|Antigen of the sporozoite protein
224118778|NCT01031524|BIOLOGICAL|Montanide ISA 720|adjuvant alone
224118779|NCT01099839|DRUG|ASP1941|oral
224118780|NCT01099839|DRUG|Miglitol|oral
224118781|NCT01742624|DRUG|Advagraf|oral
224118782|NCT01742624|DRUG|Prograf|oral
224118783|NCT01742624|DRUG|Corticosteroid|oral
224118784|NCT01742624|DRUG|Mycophenolate mofetil|oral
224118785|NCT03381924|OTHER|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
224118786|NCT03381924|OTHER|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
224118787|NCT05257720|DIAGNOSTIC_TEST|GFAP, S100B|It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
224118788|NCT02908958|BIOLOGICAL|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
224118789|NCT02908958|BIOLOGICAL|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
224118790|NCT03276936|DRUG|FMX103 1.5%|FMX103 1.5% minocycline foam
224118791|NCT04953949|DEVICE|NU-MAX®|Topical Hemostat
224293759|NCT07212907|DIETARY_SUPPLEMENT|Symbiosys® Stomalex (commercial name)|One oral capsule per day for 8 weeks. Each capsule contains Bacillus coagulans MY01, Bacillus subtilis MY02, and ginger root extract (50 mg, titrated to 20% gingerols).
224293760|NCT07212140|BEHAVIORAL|Adapted STAIR-NT|An adapted version of STAIR-NT that utilizes components from GMT in order to treat PTSD and TBI.
224293761|NCT07213453|DEVICE|Digital Smile Design|Digital Smile Design workflows used for virtual planning and fabrication of laminate veneer restorations.
223980715|NCT02800447|DRUG|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1\~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1\~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1\~14
223980716|NCT02800447|DRUG|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
223980717|NCT04963946|DRUG|Stop ACA|discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
223980718|NCT04963946|DRUG|ACA Continuation|continuation of acalabrutinib at the same dose
223980719|NCT00913068|PROCEDURE|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
223980720|NCT00913068|PROCEDURE|standard post op pain control|opiates
223980721|NCT02874573|DRUG|Tocilizumab|Investigational agent
223980722|NCT02874573|DRUG|Normal saline|Placebo
223727131|NCT03959566|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
223980723|NCT01849445|PROCEDURE|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
223980724|NCT01849445|OTHER|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
224118792|NCT04211610|DIAGNOSTIC_TEST|Blood and urine sampling|"* Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin."
224118793|NCT02697955|DRUG|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
224293762|NCT07212894|OTHER|DemensiaKITA mobile health application|A mobile health application developed to support dementia caregivers. It provides structured educational modules, attitude-shaping content, and practical caregiving tips, along with self-monitoring features to reduce caregiver stress and burden. Participants in the intervention group will use the app regularly during the study period.
223727132|NCT03959566|DRUG|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
223727133|NCT05451160|DEVICE|steep pulse therapy system|The steep pulse therapy system is produced by Zhejiang CuraWay Medical Technology Co., Ltd. for liver tumor ablation
223727134|NCT05451160|DEVICE|RF Ablation System|RF Ablation System
224118794|NCT02697955|OTHER|Placebo|9 mg sodium chloride pr. ml (0,9 %)
224118795|NCT05372068|OTHER|Concrete household floor|Household soil floors will be replaced with concrete floors
224118796|NCT05640713|DRUG|ThisCART19A|ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .
224118797|NCT05640713|DRUG|Fludarabine Pill|Fludarabine is used for lymphodepletion.
224118798|NCT05640713|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
224118799|NCT05640713|DRUG|VP-16 Protocol|VP-16 is used for lymphodepletion.
224118800|NCT01560728|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
223727135|NCT05083364|DRUG|ARO-C3|ARO-C3 for sc injection
223727136|NCT05083364|DRUG|Placebo|sterile normal saline (0.9% NaCl) for sc injection
223980725|NCT00003912|DRUG|carboplatin|
223980726|NCT00003912|DRUG|cisplatin|
223980727|NCT00003912|DRUG|doxorubicin hydrochloride|
223980728|NCT00003912|PROCEDURE|conventional surgery|
223980729|NCT04622475|BIOLOGICAL|Fecal Microbiota Transplant (FMT) Capsule|When enrolled in the study, subjects will ingest 20 FMT capsules/day orally for 3 consecutive days. If the syndrome is not completely recovered or relapse 14 days after the first administration, the subject will receive a booster dose (20 capsules/day for 3 consecutive days).
224118801|NCT01893944|OTHER|virtual reality|customized applications using virtual and augmented reality to be developed.
224118802|NCT00835887|DIETARY_SUPPLEMENT|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
224118803|NCT03041116|DRUG|Fosmetpantotenate|Daily dosing
223727137|NCT05279443|OTHER|yoga-based exercises therapy|Accompanied by a certified yoga instructor, and under the supervision of an PMR specialist and a Sports Medicine specialist, YBEs were administered to our patients included in the study for 8 weeks, 2 sessions a week, and with sessions of 60 minutes, using personal mats and equipment in a 2475 m3 (18mx25mx5.5m) gym area that belonged to our hospital, in the form of group therapy for 5 (five) people and in accordance with the social distancing rules. The exercises program was applied as a exercise program consisting of physical postures (asana) to improve the body's muscle strength and flexibility, breathing exercises (pranayama) to increase respiratory function, and relaxation and meditation (dhyana) techniques.
223727138|NCT00495183|DRUG|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
223727139|NCT00495183|DRUG|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
223727140|NCT00495183|DRUG|Placebo|Placebo
223727141|NCT06505369|DRUG|Daratumumab|Daratumumab will be administered by SC injection
223727142|NCT06505369|DRUG|Bortezomib|Bortezomib will be administered by SC injection
223980730|NCT03948399|DEVICE|Duplex scanning of carotid arteries|Measurement of carotid arteries
223980731|NCT03948399|DEVICE|ABI measurement|ankle brachial index (ABI) assessment
223727143|NCT06505369|DRUG|Lenalidomide|Lenalidomide will be administered by oral route
223727144|NCT06505369|DRUG|Dexamethasone|Dexamethasone will be administered by oral route
223727145|NCT06505369|DRUG|Talquetamab|Talquetamab will be administered by SC injection
223980732|NCT01588366|DRUG|Placebo|Administered orally
223980733|NCT01588366|DRUG|LY2409021|Administered orally
223980734|NCT06344806|BEHAVIORAL|Gamified Breastfeeding Education|Breastfeeding education content will be integrated into the game program designed with the gamification technique. A training program will be applied to the women in the experimental group in the last trimester. Women in the control group will receive the standard breastfeeding training in the hospital. Measurement tools will be applied to all participants before and after the training.
223980735|NCT05333575|BEHAVIORAL|Lullaby|The mothers in this group were asked to sing a lullaby while their babies were fed with an orogastric tube. Mothers were released on lullabies. They were encouraged to sing the lullaby they knew or loved the most. The mother was given a sound decibel meter. Mothers were asked to do an application before going to the baby. It was taught that the number of sound decibels should not exceed 40 decibels while singing a lullaby. Later, the mother was taken to the baby's incubator at feeding time. She was seated in a chair. The working status of the decibel meter was checked and given to the mother. When the feeding started, the mother started singing lullabies and continued to sing until the feeding was finished. Attention was paid to aseptic techniques during all procedures. A single mother was asked to sing a lullaby at each feeding, and the baby of the mother who sang only a lullaby was included in the study.
223980736|NCT05333575|BEHAVIORAL|Classic music|The babies in this group were given classical music recitals during feeding. The classical music piece Mozart-Baby Smart was preferred because it was seen to be used in the literature (Keidar 2014). Mozart-Baby Smart was loaded into the music player by the researcher before the feeding process. Before feeding, the decibel meter was disinfected by surface disinfectant and placed on sterile sponge in an incubator 10 cm away from the baby's head. The music player was turned on, not exceeding 40 decibels, by adjusting the decibel meter at the time of starting the feeding, and classical music was continued during the feeding. When the feeding was finished, the music player was turned off and the incubator was taken out. Attention was paid to acetic techniques during all procedures. Ambient sounds were tried to be controlled as much as possible so that the baby would not be affected by different sounds when listening to classical music.
223980737|NCT00719043|BIOLOGICAL|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
223980738|NCT00719043|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
223980739|NCT00719043|BIOLOGICAL|Placebo|Administered as an intramuscular (IM) injection
223727146|NCT06505369|DRUG|Teclistamab|Teclistamab will be administered by SC injection
223727147|NCT04686071|OTHER|PNF method|Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
223980740|NCT03520062|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for \~6 weeks
223980741|NCT00302159|PROCEDURE|adjuvant therapy|
223980742|NCT00302159|DRUG|Temozolomide|Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
223980743|NCT00302159|DRUG|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
223980744|NCT00302159|RADIATION|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
223980745|NCT02780102|OTHER|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
224118804|NCT03041116|DRUG|Placebo|Daily dosing
223727148|NCT04686071|OTHER|Standard rehabilitation|In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
223727149|NCT03067168|DRUG|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
223727150|NCT03067168|DRUG|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
223727151|NCT02658929|BIOLOGICAL|bb2121|bb2121
223980746|NCT02780102|DRUG|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
223980747|NCT02780102|OTHER|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
223980748|NCT06009744|DRUG|Low-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d
223727152|NCT00222794|DRUG|Atomoxetine (Strattera)|
223727153|NCT02312661|DRUG|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
223727154|NCT02312661|DRUG|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
223727155|NCT02312661|DRUG|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
223980749|NCT06009744|DRUG|High-dose vitamin C and zinc|This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
223980750|NCT04991636|PROCEDURE|Angioscan|"La procédure d'étude prévoit de prendre des images pendant une inspiration profonde ainsi que pendant une expiration profonde. Cette deuxième mesure ne nécessite pas l'administration d'une quantité supplémentaire de produit de contraste. Cependant, le temps d'exposition aux rayonnements ionisants est doublé. L'examen utilise une acquisition hélicoïdale en mode rapide. La durée de l'hélice est de l'ordre de 2 secondes en phase d'inspiration, puis il y a un délai de 5 secondes de machine ( demi-tour ) et à nouveau 2 secondes d'exposition en phase d'expiration, soit 4 secondes d'exposition effective aux rayonnements ionisants, le temps de la prise d'image et 9 secondes le temps total de l'examen. l'image et 9 secondes la durée totale de l'examen."
223980751|NCT04077814|DEVICE|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
223980752|NCT04077814|DEVICE|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
223980753|NCT00000447|DRUG|naltrexone (Revia)|
224293763|NCT07212894|OTHER|Usual Care|Participants assigned to the control group will continue with usual caregiving practices and community-based resources available to dementia caregivers. They will not be given access to the DemensiaKITA mobile health application during the study period. This group provides a comparator for evaluating the added benefit of th
223727156|NCT02268604|DRUG|BIIB 722 CL|
223727157|NCT02268604|DRUG|Placebo|
223727158|NCT04913402|OTHER|Sufentanil administered by paramedics after the phone call consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
223727159|NCT04913402|OTHER|Sufentanil administered by paramedics based on their competency, without consultation of medical doctor.|Administration of sufentanil to patients with acute injury by paramedics with competency to administer sufentanil without medical doctor consultation.
223727160|NCT00642876|DEVICE|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
223980754|NCT00000447|DRUG|nicotine replacement patch|
223980755|NCT03019198|DRUG|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
223980756|NCT03019198|DRUG|Placebo - Concentrate|
223980757|NCT04021225|DEVICE|Ectoin® Allergy Eye Drops 2%|A one-time application of 1-2 drops in the more affected eye will be investigated.
223980758|NCT04021225|DEVICE|Ectoin® Eye Spray Colloidal|A one-time application of 1-2 drops in the more affected eye will be investigated.
223980759|NCT04021225|DEVICE|Tears Again® eye spray|A one-time application of 1-2 drops in the more affected eye will be investigated.
223980760|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
223980761|NCT01895049|DRUG|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
223980762|NCT02754336|BEHAVIORAL|Cogmed Robomemo, working memory training|
223980763|NCT02754336|BEHAVIORAL|Othmer, neurofeedback|
223980764|NCT04212975|OTHER|joint lavage with dextrose|joint lavage with dextrose
223980765|NCT04758676|OTHER|Nutritional and physiotherapy protocol, BIA|Study subjects will be treated using the nutritional and physiotherapy protocol, based upon the results of measurements, using bioimpedance analysis.
223980766|NCT04758676|OTHER|Standard of care|Study subjects will receive the current standard of care.
223543952|NCT06270238|DEVICE|High-Frequency3|"rTMS intervention: 20 sessions of 10-Hz rTMS at 90% RMT, 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
223980767|NCT06009172|OTHER|Auricular point acupressure (APA)|Auricular point acupressure (APA) is a method derived from Traditional Chinese Medicine. PCOS women in the APA group began to apply pressure on the first day of enrollment. Patients were instructed to press each acupuncture point 3 times a day for 30 times. The PCOS woman is then trained to go to the outpatient clinic every 5-7 days to change the auricular acupressure sticker. The intervention period was 4 weeks.
223980768|NCT03245619|DRUG|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
223980769|NCT03245619|DRUG|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
223980770|NCT02794714|DRUG|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
223980771|NCT02794714|DRUG|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
223980772|NCT03202485|DEVICE|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
223980773|NCT03202485|DEVICE|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
224293764|NCT07212972|OTHER|Hemodialysis or peritoneal Dialysis|Hemodialysis or peritoneal Dialysis
224293765|NCT07213115|PROCEDURE|Gastrectomy+ chemotherapy|
223543953|NCT06270238|DEVICE|cTBS3|"rTMS intervention: 40 seconds of cTBS at 70% RMT, totaling 600 pulses.~rTMS target: contralateral primary motor cortex.~Total rTMS sessions: once a day, 5 days per week, for 2 weeks, totaling 10 sessions.~Additional treatment: inpatient conventional rehabilitation therapy, consisting of occupational and physical therapy for 30 minutes each, twice daily, for 2 weeks, as well as the routine pharmacotherapy based on the guidelines for management of patients with stroke."
223543954|NCT01768910|OTHER|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
223543955|NCT01768910|OTHER|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
223543956|NCT01768910|OTHER|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
223980774|NCT03463434|DEVICE|Air Fluidized Therapy|AFT bed used for pressure injury treatment
223980775|NCT03463434|DEVICE|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
223980776|NCT02471482|OTHER|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
223980777|NCT01380288|DRUG|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
223980778|NCT05225207|OTHER|Non-interventional|No intervention will be administered.
223980779|NCT05238363|DRUG|HLX07|HLX07 1500mg ivgtt Q3W
223980780|NCT04269434|OTHER|No Screening|the STI Laboratory will only process the samples/report the results from the non-screening arm at the end of the study.
223980781|NCT05098691|DIAGNOSTIC_TEST|serum marker levels|two groups comparisons
223980782|NCT04129047|DRUG|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
223980783|NCT04129047|DRUG|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
223980784|NCT03548493|DRUG|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
223980785|NCT03548493|DRUG|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
223980786|NCT03548493|DRUG|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
223980787|NCT05595811|OTHER|outcome following surgery|
223980788|NCT01685125|DRUG|abiraterone acetate|Given PO
223980789|NCT01685125|DRUG|dasatinib|Given PO
223980790|NCT01685125|DRUG|prednisone|Given PO
223980791|NCT02928471|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
223980792|NCT00277199|DRUG|Abatacept|
223980793|NCT04485754|OTHER|Telemedicine FU|Participant will get telemedicine follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
223980794|NCT04485754|OTHER|Office FU|Participant will get office follow-up visit at 1, 3, and 6 months or 1 and 6 months after discharge from hospital.
223980795|NCT04962698|BEHAVIORAL|Visual motor imagery (MI)|Subjects will relax their muscles and perform conventional visual motor imagery (MI). With the guidance of audio instruction, the subjects will imagine the grasp and release motions with the right arm for 2 s in each motion in their mind. There will be no proximal muscle contraction.
223980796|NCT04962698|BEHAVIORAL|Kinesthetic MI|The same MI procedure as Visual MI will be performed, except that the subjects will focus on the kinesthetic sensation that they would feel with the imagined motions.
223980797|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction with MI|Subjects will perform robotically augmented mental practice for grasp and release motions with the activation control of the proximal muscles. During this task, subjects will also imagine the kinesthetic sensation that they would feel with the corresponding motions with the right arm.
223727161|NCT00642876|DEVICE|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
223980798|NCT04962698|BEHAVIORAL|Robotic-Hand Interaction without MI|Subjects will perform the Robot-Hand Interaction without MI.
223980799|NCT04962698|BEHAVIORAL|Virtual-Hand Interaction|Subjects will interact with visual feedback of virtual robot actions on a monitor.
223980800|NCT04962698|BEHAVIORAL|Robotic Action Observation|Subjects will relax their muscles and focus on observing the computer-controlled grasp and release actions of the robotic hand.
223980801|NCT04962698|BEHAVIORAL|Rest|Subjects will rest without a task.
223980802|NCT02906280|DEVICE|EBUS-TBNA needle|tissue sampling
223980803|NCT05660330|BEHAVIORAL|Holistic semi-tailormade well-being intervention|The holistic well-being intervention consists of a mandatory basic package that will take 2 half days and 1 full day to complete. In the first half day, the conclusion of the baseline measurement will be discussed, as well as the specific outline of the well-being thay. On the well-being day, three trained professionals from an HR service company, called Liantis, will guide these interventions (consisting of training and workshops) in the workplace. Only a small proportion of the company employees, called the ambassadors, will attend the well-being day. In the second half day, the ambassadors will be coached to disseminate the obtained information to the entire workplace. This information will be personalized according to the problems, needs and context of each company. Besides the basic package, an optional expertise package will be offered during this second half day. In the period afterwards, the ambassadors are followed every 2 months by means of a semi-structured interview.
223980804|NCT04477993|DRUG|Janus Kinase Inhibitor (ruxolitinib)|5 mg P.O. b.i.d. for 14 days. Dose reduction will occur if neutrophils \< 500/mm3 or platelets \<50,000/mm3.
223980805|NCT04477993|OTHER|Placebo|Placebo tablets P.O. b.i.d. for 14 days.
223980806|NCT02815059|DRUG|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
223980807|NCT02815059|DRUG|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
223980808|NCT02815059|DRUG|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
223980809|NCT05953831|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
223980810|NCT05953831|DRUG|Placebo|Placebo to CDR132L
223980811|NCT02125136|DRUG|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
223980812|NCT02125136|DRUG|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
223980813|NCT04752033|DRUG|Morphine|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a morphine dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
223980814|NCT04752033|DRUG|Hydromorphone|Dose titration utilizing will be done using sequential up and down design using biased coin method. All participant will receive a hydromorphone dose that is within the range of doses currently utilized clinically and no participant will receive placebo only.
223980815|NCT05352971|OTHER|Biomarker quantification|Patient blood samples will be tested on 2 different platforms
223727162|NCT02063360|DRUG|BMS-663068|BMS-663068
223727163|NCT02063360|DRUG|Darunavir (DRV)|Darunavir (DRV)
223727164|NCT02063360|DRUG|Ritonavir (RTV)|Ritonavir (RTV)
223727165|NCT02063360|DRUG|Etravirine (ETR)|Etravirine (ETR)
223980816|NCT05326698|PROCEDURE|Medtronic NIM Eclipse for evoked potentials recording|Recording of somesthetic and motor evoked potentials during endoscopic posterior cervical foraminotomy.
223980817|NCT01043445|DIETARY_SUPPLEMENT|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
223980818|NCT01043445|DIETARY_SUPPLEMENT|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
223980819|NCT01043445|DIETARY_SUPPLEMENT|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
223980820|NCT00119938|BEHAVIORAL|Access to online patient portal|
223980821|NCT02909309|DEVICE|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
223980822|NCT03104283|DRUG|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
223980823|NCT03413215|BEHAVIORAL|Intensive|"Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects."
223980824|NCT05498454|BEHAVIORAL|Breathworks Mindfulness (Health or Stress Arm)|As for previous descriptions
223980825|NCT00995384|PROCEDURE|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
224118805|NCT00003546|DRUG|gemcitabine hydrochloride|given IV
223727166|NCT06374641|DIETARY_SUPPLEMENT|Mitochondrial Substrate Supplement|Mitochondrial Substrate supplement, 2xdaily 65 mL drink
223727167|NCT06374641|DIETARY_SUPPLEMENT|Placebo Supplement|Placebo supplement, 2xdaily 65 mL drink
223727168|NCT05602181|BEHAVIORAL|ALL Phonics Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech.
223727169|NCT05602181|BEHAVIORAL|ALL Sight Word Instruction|The Accessible Literacy Learning (ALL) App is available in the app store and created by TobiiDynavox (an AAC device company). The ALL app is evidence informed and includes pre-made lessons in early phonics/phonological skills including: letter-sounds, sound blending, decoding, phoneme segmentation, sight words, and encoding. The materials made in the app are adapted and created for children with minimal or no speech. This group will only use the sight word lessons, as well as the library for sight word books. No phonics instruction will be provided through the app.
223980826|NCT04339023|DRUG|Open-Label Placebo|in addition to Treatment as usual, patients receive placebos without concealment (open-label placebo, OLP)
223980827|NCT04339023|OTHER|treatment as usual|usual medication intake following minimally invasive TLIF. TAU consists of 3 gram Paracetamol per os a day, a patient-controlled morphine pump (Maximum of 2 milligram (mg) every 12 minutes) and rescue medication (1000 mg of Metamizol, maximum every 6 hours)
223980828|NCT05082623|OTHER|Music|Music medicine
223980829|NCT05082623|OTHER|Earplug|Earplug with noise cancelling
223980830|NCT04863820|DIAGNOSTIC_TEST|cutaneous silent period|form of Nerve conduction studies
223980831|NCT01903369|DEVICE|Shear Wave Elastography|Shear wave elastography
223980832|NCT00470405|DRUG|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
223980833|NCT00470405|DRUG|pemetrexed disodium|a novel antifolate with multiple targets.
223980834|NCT01411449|DRUG|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
223980835|NCT03789812|DEVICE|Manual toothbrush|Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
223980836|NCT03789812|DEVICE|Electric Toothbrush|Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
223980837|NCT03789812|DEVICE|Superfloss|Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
223980838|NCT03789812|DEVICE|Dental Water Jet|Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
223980839|NCT01664923|DRUG|Enzalutamide|160 mg, daily, by mouth.
223980840|NCT01664923|DRUG|Bicalutamide|50 mg, daily, by mouth
223980841|NCT03626831|DRUG|Evolocumab Prefilled Syringe|Injection of study drug
223980842|NCT03626831|DRUG|Placebos|Injection of placebo
223980843|NCT00117897|DRUG|pegfilgrastim|
223980844|NCT00117897|DRUG|Filgrastim|
223980845|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
223980846|NCT00376012|DRUG|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
223980847|NCT02367105|DRUG|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
223980848|NCT02367105|OTHER|Lifestyle Therapy|Weekly behavioral diet to induce \~10% weight loss in combination with supervised aerobic and exercise training three times a week
223980849|NCT02367105|DRUG|Placebo|Placebo gel for testosterone
224118806|NCT00003546|RADIATION|radiation therapy|1.8 Gy to tumor bed
224118807|NCT01555112|DRUG|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
224118808|NCT03279783|DEVICE|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
223980850|NCT02684799|DRUG|Cenicriviroc|
223980851|NCT02684799|DRUG|Omeprazole|
223980852|NCT02684799|DRUG|Famotidine|
223980853|NCT03840109|BEHAVIORAL|Questionnaire 1a|Participants will be randomly shown two versions of messages in which the last 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980854|NCT03840109|BEHAVIORAL|Questionnaire 1b|Participants will be randomly shown two versions of messages in which the first 20% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
224118809|NCT05078333|OTHER|dry needle|dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
224118810|NCT05078333|DEVICE|high intensity laser therapy|High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
224118811|NCT02822339|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
223980855|NCT03840109|BEHAVIORAL|Questionnaire 2a|Participants will be randomly shown two versions of messages in which the last 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980856|NCT03840109|BEHAVIORAL|Questionnaire 2b|Participants will be randomly shown two versions of messages in which the first 40% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980857|NCT03840109|BEHAVIORAL|Questionnaire 3a|Participants will be randomly shown two versions of messages in which the last 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980858|NCT03840109|BEHAVIORAL|Questionnaire 3b|Participants will be randomly shown two versions of messages in which the first 60% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980859|NCT03840109|BEHAVIORAL|Questionnaire 4a|Participants will be randomly shown two versions of messages in which the last 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980860|NCT03840109|BEHAVIORAL|Questionnaire 4b|Participants will be randomly shown two versions of messages in which the first 80% of the message consists of negative statements of criticism and rate of the effectiveness of the message.
223980861|NCT04811898|BIOLOGICAL|LNA-i-miR-221|LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)
223980862|NCT05477303|OTHER|taking a picture of a painful facial expression|Immediately after surgery, the patient's facial expression and the NRS score and ANI score reported by the patient are checked together.
223980863|NCT05073549|BEHAVIORAL|Collaborative Antimicrobial Stewardship Program (ASP)|"The collaborative ASP interventions will be implemented from October 1st, 2021 to September 30th, 2023 in all participating NICUs.~The collaborative ASP interventions include two levels of interventions that will be delivered at the NICU level: the NICU-targeted ASP program and collaborative quality improvement interventions to facilitate implementation of the ASP.~The core elements of the NICU-targeted ASP program include the establishment of ú ASP leader and team, development of the facility-specific antibiotic guidelines, checklist-led audit and feedback, and staff education.~The collaborative quality improvement interventions include data feedback and benchmarking, a potential 'better practice' list on neonatal antibiotic use, implementation using Plan-Do-Study-Act cycles and collaborative learning."
224118812|NCT04987541|DEVICE|intermittent theta burst stimulation|stimulatory protocol
224118813|NCT05741723|DEVICE|OCS Heart|Transplanted with OCS preserved heart.
224118814|NCT00683956|DEVICE|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
224118815|NCT00683956|DRUG|Propofol|
224118816|NCT00055822|BIOLOGICAL|oblimersen sodium|
224118817|NCT00055822|DRUG|fluorouracil|
224118818|NCT00055822|DRUG|leucovorin calcium|
224118819|NCT00055822|DRUG|oxaliplatin|
224118820|NCT00943319|DRUG|Busulfan|Daily intravenous dosing to target AVC
224118821|NCT00943319|DRUG|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
223727170|NCT05524155|DRUG|HAIC|hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
224118822|NCT00943319|DRUG|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
224118823|NCT00943319|PROCEDURE|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
224118824|NCT02379234|OTHER|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
224118825|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
224118826|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
224118827|NCT02043301|BIOLOGICAL|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
224118828|NCT00151060|DRUG|Estramustine|
224118829|NCT00151060|DRUG|Etoposide|
224118830|NCT00151060|DRUG|Paclitaxel|
224118831|NCT06103695|DRUG|Tapinarof|Add on Vtama (tapinarof) to biololgic therapy
224118832|NCT04804722|DEVICE|18F-FDG PET-CT (fluorodesoxyglucose positron emission tomography)|18F-FDG PET-CT exams during 30 minutes with injection of radiopharmaceutical product
224118833|NCT02734589|OTHER|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
224118834|NCT02734589|OTHER|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
224118835|NCT02734589|OTHER|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
224118836|NCT01798134|DEVICE|TANDEM™|
224118837|NCT02023164|DRUG|JDP-205 Injection|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
223727171|NCT05524155|DRUG|Sintilimab|200mg IV d1,Q3W
223980864|NCT03961997|DRUG|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
223980865|NCT03961997|DRUG|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
223980866|NCT03961997|DRUG|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
223980867|NCT02835092|OTHER|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 \& 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
223980868|NCT02835092|OTHER|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 \& 2 \& 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
223980869|NCT02835092|OTHER|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
223980870|NCT03530462|DRUG|rituximab|375 mg/m2 weekly for 4 weeks
223980871|NCT03530462|DRUG|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
223980872|NCT03530462|DRUG|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
223980873|NCT03530462|DRUG|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
223980874|NCT02767609|DEVICE|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
223980875|NCT05603065|DRUG|Tislelizumab + cisplatin + paclitaxel|Tislelizumab 200mgD1 + cisplatin 75mg/m\^2D1 + paclitaxel 150mg/m\^2D1 Q3W 3 cycles
223980876|NCT05603065|DRUG|Tislelizumab + radiotherapy|Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
223980877|NCT03630263|OTHER|Raw Corn Starch|Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.
223980878|NCT03630263|OTHER|No Raw Corn Starch|200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
223980879|NCT04805047|BEHAVIORAL|education and monitoring|regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback
223980880|NCT00047749|DRUG|Prialt (ziconotide)|
223980881|NCT03197077|PROCEDURE|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
223980882|NCT03197077|PROCEDURE|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
223980883|NCT03197077|PROCEDURE|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
223980884|NCT03197077|DRUG|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
223980885|NCT03197077|DRUG|Follitropin beta|Daily injection (three days) of follitropin beta
223980886|NCT03197077|DRUG|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
224118838|NCT02023164|DRUG|Diphenhydramine|Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
223727172|NCT05524155|DRUG|Regorafenib|80mg/day,PO,QD,d1～21,Q4W
223980887|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
224118839|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
223727173|NCT00254449|DRUG|NGX-4010|
223727174|NCT01849224|OTHER|Pelvic and lower extremity exercise|
223727175|NCT02684266|DRUG|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
223727176|NCT01202292|BEHAVIORAL|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
223980888|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
223980889|NCT01280747|OTHER|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
223980890|NCT01280747|OTHER|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
224118840|NCT02436577|DRUG|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
224118841|NCT02436577|DRUG|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
224118842|NCT06552585|OTHER|12-weeks weight prevention program|Twice a week, over 12-weeks, the weight program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with two weights Domyos with 1, 2, 3, 4, or 5 kg.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
223980891|NCT02901236|PROCEDURE|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
223980892|NCT02901236|DRUG|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
223980893|NCT02901236|DRUG|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
223980894|NCT06311643|OTHER|Postpartum back massage in study group|Effleurage massage from shoulders toward lower back
223980895|NCT00458146|DRUG|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
223980896|NCT05765747|DRUG|Yunnan Baiyao|Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks.
223980897|NCT05765747|DRUG|Celecoxib 200mg|The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.
223980898|NCT02671214|OTHER|Control|100 g high fibre flour
223980899|NCT02671214|OTHER|Active 2|98 g high fibre flour + 2 g guar gum
223980900|NCT02671214|OTHER|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
223980901|NCT02671214|OTHER|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
223980902|NCT02671214|OTHER|Active 5|96 g high fibre flour + 4 g guar gum
223980903|NCT02671214|OTHER|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
223980904|NCT02671214|OTHER|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
223980905|NCT02671214|OTHER|Active 8|94 g high fibre flour + 6 g guar gum
223980906|NCT02671214|OTHER|Active 9|98 g high fibre flour + 2 g konjac mannan
223980907|NCT02671214|OTHER|Active 10|96 g high fibre flour + 4 g konjac mannan
223980908|NCT02671214|OTHER|Active 11|100 g low fibre flour
223980909|NCT02671214|OTHER|Active 1|85 g high fibre flour + 15 g legume flour
223980910|NCT03712592|OTHER|Pre and post running evaluations|"Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage."
223980911|NCT01657877|DRUG|Calcium sodium phosphosilicate|CSP high percentage weight by weight
223980912|NCT01657877|DRUG|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
223980913|NCT01657877|DRUG|Placebo|No CSP and no fluoride
223980914|NCT05573100|DRUG|CU06-1004|CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
223980915|NCT01532635|RADIATION|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
223980916|NCT01532635|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
223980917|NCT01532635|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
224118843|NCT06552585|OTHER|12-weeks elastic band prevention program|Twice a week, over 12-weeks, the elastic band program group carried out a strength program with the 5 open kinetic chain exercises most often reported in the literature to prevent swimmer's shoulder - internal rotation at 90°, external rotation at 90°, scapular punches, T's, and Y's - with an elastic band Bodytone Power Band with 10, 15, 20, 25, or 30 kg weights Domyos.The load used to perform the programs with weights were previously assessed and adjusted for each swimmer, corresponding to 75% of one repetition maximum. After 6 weeks of program execution, each swimmer carried out another one repetition maximum test assessment, to verify the possibility of a load instrument progression.
223543957|NCT01768910|OTHER|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
223543958|NCT02002988|PROCEDURE|endomyocardial BT injection|
223543959|NCT01559545|DRUG|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
223543960|NCT01559545|DRUG|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
223543961|NCT01559545|DRUG|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
223543962|NCT03511001|OTHER|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
223543963|NCT01746446|OTHER|Care team|Provides additional support to patients, family, and friends.
223543964|NCT02558062|OTHER|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
223543965|NCT01807325|PROCEDURE|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
223543966|NCT02214069|DEVICE|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
223543967|NCT02141165|DEVICE|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
223980918|NCT01532635|DRUG|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
223727177|NCT02725710|DRUG|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
224293766|NCT07212218|BEHAVIORAL|Health Promotion Model-Based Education and Motivational Interviewing|Structured education sessions based on the Health Promotion Model will be delivered, followed by motivational interviewing techniques to enhance parental engagement and support diabetes management and quality of life.
223727178|NCT02725710|DRUG|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
223727179|NCT00941785|DRUG|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
223727180|NCT00941785|DRUG|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
223727181|NCT01462097|BEHAVIORAL|Aerobic exercise training|12 months of aerobic exercise
223727182|NCT01462097|BEHAVIORAL|Health Education|12 months of health education sessions
224293767|NCT07212192|DRUG|Lidocain spray|Applying 3 spray of 10% Lidocaine to the IV insertion site in women before their C-section
224293768|NCT07212192|COMBINATION_PRODUCT|Sterilized saline solution|Participants will be given three sprays sterilized saline solution 3 minutes before the interventionist performed the insertion of a catheter into their vein
224293769|NCT07211737|GENETIC|i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells|Dose Level 1: 3 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7/m\^2 of C7R.GD2.CAR T cells given 5 days later.
224293770|NCT07211737|GENETIC|i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells|Dose Level 2: 6 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
224293771|NCT07211737|GENETIC|i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells|Dose Level 3: 12 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
224293772|NCT07212608|DEVICE|Soft robotic exosuit|A soft robotic exosuit is a textile-based system worn on the waist and paretic lower limb that provides assistive torques via cables connecting the front and back of the ankle to anchor points on the shank. The exosuit provides dorsiflexion assistance during swing phase for foot clearance and plantarflexion assistance during stance phase for propulsion delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
223727183|NCT06387095|PROCEDURE|1. no block|After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
223727184|NCT06387095|PROCEDURE|2. superficial parasternal block|After induction, the patient will undergo an ultrasound-guided superficial parasternal plan block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
223727185|NCT06387095|PROCEDURE|3. deep parasternal block|After induction, the patient will undergo an ultrasound-guided deep parasternal plane block. . After extubation, patient-controlled analgesia will be applied for 24 hours (with PCA infusion pump device). During the follow-up of the patients in intensive care, extubation times, additional analgesic needs, pain scores; intensive care and hospital discharge times will be recorded.
223727186|NCT06296966|DRUG|VSJ-110|ophthalmic solution
223727187|NCT06296966|DRUG|Placebo|ophthalmic solution
223727188|NCT03228927|OTHER|comparison of twin A to twin B|Comparison of Twin A to Twin B
223727189|NCT04031391|OTHER|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
223980919|NCT01532635|DRUG|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
223980920|NCT01532635|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
223980921|NCT06428877|OTHER|analyzed on the post-operative scanner|analyzed on the post-operative scanner
223980922|NCT00197223|BIOLOGICAL|Influenza vaccine|
223980923|NCT01114672|DRUG|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
223980924|NCT01114672|DRUG|Placebo|oral placebo once weekly
223980925|NCT04693910|OTHER|Multimedia-Based Hormone Therapy Information Program|The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
224118844|NCT06552585|OTHER|sham intervention|The control group performed a sham intervention, twice a week, for 12-weeks. This intervention consisted of 2 sets of 10 repetitions of 5 shoulder mobility exercises, without preventive aim, normally carried out in warm-up before training: shoulder maximum flexion and extension, horizontal abduction and adduction starting from 90º of shoulder abduction, maximum internal/external rotation starting from 90º of shoulder abduction, circumduction of the shoulder in a clockwise direction and circumduction of the shoulder in a counterclockwise direction. There was no progression after 6-weeks of this sham intervention. The coach of the respective team checked the execution of the exercises, but there was no individualized monitoring with a regular exercise technique correction by a physiotherapist.
224118845|NCT03284619|DEVICE|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
224293773|NCT07212608|DEVICE|Propulsion neuroprosthesis|A neuroprosthesis is a textile-based, surface electrical stimulation system worn on the waist and paretic lower limb that delivers stimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides coordinated dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
224293774|NCT07213297|OTHER|clinical assessments and complementary examinations|"Evaluation Plan~Comprehensive Examination: Complete medical history and physical examination of all body systems, including height and weight measurements.~Clinical Parameters: Pulse/heart rate, respiratory rate, and SpO2 will be monitored. The NYHA classification will be used to assess heart failure if applicable.~Neurological Examination: Includes motor strength testing, sensory testing (pinprick, light touch, temperature, proprioception), deep tendon reflexes, and gait assessment.~Electrocardiogram (ECG): A 12-lead ECG will be performed with the subject at rest for at least 5 minutes in a supine position.~24-hour Holter Monitoring: Conducted in cases of suspected arrhythmias or echocardiographic findings indicating arrhythmias.~Color Dosments and complementary examinations"
224118846|NCT03219749|BEHAVIORAL|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
224293775|NCT07212452|DRUG|Tranexamic Acid (TXA)|In this study we are comparing the effect of tranexamic acid on hemoptysis when given through IV route and nebulization
224118847|NCT00169494|BIOLOGICAL|HPV-16/18 L1/AS04|
224118848|NCT03333057|DRUG|NOV03|Perfluorohexyloctane
224118849|NCT03333057|DRUG|Placebo|Saline solution (0.9% sodium chloride solution)
223543968|NCT04728646|DRUG|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
223543969|NCT04728646|DEVICE|Regular dissolvable intracanalicular plug|Inserted During Screening/Baseline: Day Zero in either the right or left eye (depending on randomization)
223543970|NCT01337193|OTHER|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
223543971|NCT01337193|OTHER|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
223543972|NCT00457678|DRUG|Visudyne|
223543973|NCT00457678|DRUG|Lucentis|
223543974|NCT00457678|DRUG|Dexamethasone|
223543975|NCT02852798|DRUG|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
223980926|NCT02053883|DRUG|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
223980927|NCT02053883|DRUG|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
223980928|NCT03371745|PROCEDURE|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
223980929|NCT03371745|PROCEDURE|Cryopreservation|Rapid freezing using vitrification
223980930|NCT03371745|PROCEDURE|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
223980931|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
223980932|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
223980933|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
223980934|NCT04885647|DRUG|YPEG-rhEPO|YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
223980935|NCT06226298|DEVICE|Xiaxi postural hammock|Lie in the Xiaxi postural hammock for 10 minutes for 5 days.
223980936|NCT06226298|BEHAVIORAL|Yoga mat|Lie in the Yoga mat for 10 minutes for 5 days.
223980937|NCT04672798|BEHAVIORAL|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
223980938|NCT04672798|BEHAVIORAL|Treatment As Usual (TAU)|Participants in this group will receive usual care from their mental health care provider.
223980939|NCT03304756|DRUG|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
223980940|NCT02550483|OTHER|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
223980941|NCT02550483|OTHER|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
223980942|NCT02550483|OTHER|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
223980943|NCT00934414|DRUG|Technosphere Insulin Inhalation Powder|30U
223980944|NCT04472988|BEHAVIORAL|Eye Movement Desensitization and Reprocessing|"The first session will be assigned to the assessment and the exploration of the personal history and for presenting the method to the client. Then, each case will be conceptualized according to the Model of Two Method Approach and the protocol for the treatment will be used. The procedure will be organized around targeting the most ten disturbing memories which happened before the illness debut, including stressful or traumatic memories from childhood. The rationale behind this approach is that adverse events leave traces in the neural network of an individual in such a way that these cause a variety of emotional or cognitive symptoms. If we consider the illness as being also a symptom of a traumatic past, then we expect that by accessing the dysfunctionally stored memory and stimulating the innate processing system, the symptoms of the illness diminish."
223980945|NCT04472988|OTHER|Placebo|The participants randomised in this group will receive a protocol focused only on present and future (present symptoms, daily problems, future projects). The psychologist will lead the discussion anywhere except for the past.
223980946|NCT04472988|DRUG|Treatment as Usual|The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
223980947|NCT03091582|BEHAVIORAL|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
223980948|NCT03091582|BEHAVIORAL|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
223980949|NCT03091582|BEHAVIORAL|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
223980950|NCT00019695|DRUG|alendronate sodium|
223980951|NCT00019695|DRUG|ketoconazole|
223980952|NCT01963715|DRUG|IMGN289|
223980953|NCT04520074|DRUG|Etoposide, Cyclophosphamide, Carboplatin/Cisplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5) d1/CDDP 30mg/m2 d1-d2+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
223980954|NCT03040609|BEHAVIORAL|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
223980955|NCT03040609|BEHAVIORAL|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
223980956|NCT03040609|BEHAVIORAL|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
223980957|NCT06486727|DEVICE|Redtouch|675-nm laser
223543976|NCT00446329|DRUG|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
223543977|NCT00581022|PROCEDURE|Polysomnography|Overnight Sleep Study
223543978|NCT00366210|BEHAVIORAL|Constraint-Induced Movement (CI) Therapy|
223980958|NCT02146092|PROCEDURE|Incentive spirometry|
223543979|NCT00366210|BEHAVIORAL|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
223543980|NCT00943631|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
223543981|NCT03396627|DIAGNOSTIC_TEST|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
223980959|NCT02146092|OTHER|Physiotherapy|Standard of care exercise training and supervision
223980960|NCT04745936|OTHER|Style curve similar to natural curvature of endotracheal tube|Stylet curvature is made similar to the natural curvature of endotracheal tube for intubation using C-MAC videolaryngoscope.
223980961|NCT04745936|OTHER|Style curve similar to hockey stick shape|Stylet curvature is made similar to hockey stick shape for intubation using C-MAC videolaryngoscope.
223980962|NCT00696553|OTHER|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
223980963|NCT00696553|BEHAVIORAL|Nutrition plus Exercise|Nutrition plus Exercise
223980964|NCT04383145|DEVICE|endovascular repair|Endovascular repair of thoracoabdominal aneurysm using stent grafts.
223980965|NCT04240236|PROCEDURE|Scalp block|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
223980966|NCT04240236|OTHER|Control Group|Patients will be randomly divided into two groups using a computer generated random number chart. Group S received scalp block with 20 ml of 0.5% bupivacaine, whereas Group C will not receive any intervention and will be considered as control group.
223980967|NCT03854019|DRUG|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
223980968|NCT03854019|DRUG|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
223980969|NCT00060437|DRUG|perifosine|
223980970|NCT06538467|OTHER|Hip extension exercise with inertial load|Hip extension exercise with inertial load
223980971|NCT06538467|OTHER|Hip extension exercise with gravitational load|Hip extension exercise with gravitational load
223980972|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-PreF-A vaccine|B/HPIV3/HMPV-PreF-A is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-PreF-A vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.7 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
223543982|NCT02069977|DRUG|Aripiprazole|
223980973|NCT06546423|BIOLOGICAL|B/HPIV3/HMPV-F-B365 vaccine|B/HPIV3/HMPV-F-B365 is a live-attenuated vaccine candidate. The B/HPIV3/HMPV-F-B365 vaccine is provided in a sterile 2.0-mL cryovial, each containing 0.6 mL of vaccine with a titer of approximately 10\^6.3 PFU/mL. The vaccine virus concentrate is diluted with Lactated Ringer's Solution for Injection to a dose of approximately 10\^5.6 PFU in a 0.2 mL volume.
223543983|NCT04240106|DRUG|Niraparib|Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
223980974|NCT06546423|DRUG|Placebo|Lactated Ringer's Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It will be drawn up in a sterile syringe to a volume of 0.2 mL.
223980975|NCT05143112|BIOLOGICAL|Allogeneic CD19 CR-T cell|Allogeneic CD19 CR-T cell infusion
223980976|NCT02586415|PROCEDURE|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
223980977|NCT02586415|DEVICE|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
223980978|NCT02586415|DEVICE|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
223980979|NCT02586415|DEVICE|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System \[026, 032, 041\] Penumbra System Separator Flex \[026, 032, 041, 054\] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 \& ACE68"
223980980|NCT02586415|DEVICE|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
223980981|NCT04811326|RADIATION|NB-UVB|radiation
223980982|NCT04811326|DRUG|Latanoprost|eye drops
223980983|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
223980984|NCT00538356|DEVICE|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
223980985|NCT00561899|DRUG|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
224118850|NCT02038296|PROCEDURE|transarterial chemoembolization|
224118851|NCT06552520|DRUG|TQH2722 injection|Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody
224118852|NCT06552520|DRUG|Placebo of TQH2722 injection|Placebo without drug substance
224118853|NCT03703375|DRUG|Azacitidine|Azacitidine
224118854|NCT03703375|DRUG|Romidepsin|Romidepsin
224118855|NCT03703375|DRUG|Gemcitabine|Gemcitabine
224118856|NCT06553339|DRUG|Oral HS-10516|Oral HIF-2α inhibitor
224118857|NCT03851276|RADIATION|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
224118858|NCT05679687|DRUG|Treatment|In this study, allogeneic anti-CD19 CAR T cells (ThisCART19A) infusion is used as a bridge therapy to hematopoietic stem cell transplantation to treat patients with refractory or relapsed CD19 positive B cell acute lymphoblastic leukemia. Lymphodepletion conditioning before CAR T cell infusion consists of fludarabine, CTX and VP-16.
224118859|NCT05160077|DIAGNOSTIC_TEST|Multispectral optoacoustic tomography (MSOT)|MSOT Acuity Echo, iThera medical, Munich
223727190|NCT00041483|DRUG|Anecortave Acetate 15 mg sterile suspension|
223727191|NCT00041483|OTHER|Photodynamic Therapy (PDT)|
224118860|NCT01815333|DRUG|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
224293776|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (30 minutes per session, 3 sessions per week, for a 12-week period)
223980986|NCT00561899|DRUG|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
223980987|NCT00561899|DRUG|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
224293777|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (45 minutes per session, 3 sessions per week, for a 12-week period)
224293778|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (60 minutes per session, 3 sessions per week, for a 12-week period)
223980988|NCT00429897|DRUG|Bendroflumethiazide 2.5mg - 5mg|
223980989|NCT00429897|DRUG|Amiloride 20-40mg|
223980990|NCT00429897|DRUG|Spironolactone 50-100mg|
223980991|NCT00429897|DRUG|Frusemide 20-40mg|
223980992|NCT00429897|DRUG|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
224293779|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (30 minutes per session, 5 sessions per week, for a 12-week period)
223980993|NCT00639899|PROCEDURE|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
223980994|NCT00329563|DRUG|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
223980995|NCT00000349|DRUG|Flupenthixol|
223980996|NCT01189422|DRUG|teplizumab or placebo|infusion or injection
224118861|NCT01815333|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
224293780|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (45 minutes per session, 5 sessions per week, for a 12-week period)
224293781|NCT07213362|DEVICE|Computerized Cognitive Training|Computerized Cognitive Training (60 minutes per session, 5 sessions per week, for a 12-week period)
223543984|NCT04240106|DRUG|Aromatase Inhibitors|Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
223543985|NCT04292197|DRUG|18-MC Compound|18-MC
223543986|NCT02881736|OTHER|electroencephalographic,magnetic resonance imaging|
223727192|NCT04923191|OTHER|Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care|percutaneous coronary intervention
223727193|NCT03758352|PROCEDURE|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
223727194|NCT03758352|OTHER|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
223980997|NCT04056793|OTHER|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
223980998|NCT03708705|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
223980999|NCT01423708|DRUG|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of \>5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels \<5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
223981000|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring and weight loss|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring and weight loss
223981001|NCT04770909|BEHAVIORAL|Incentives for dietary self-monitoring|Participants can earn up to $300 during the trial for achieving adequate dietary self-monitoring
223981002|NCT04770909|BEHAVIORAL|Incentives for weight loss|Participants can earn up to $300 during the trial for achieving weight loss
223981003|NCT00196534|DRUG|Human Thrombin|
224118862|NCT01336179|PROCEDURE|Salvadora persica|twice daily use, two minutes interval
224118863|NCT01336179|PROCEDURE|Toothbrush|Twice daily use two minutes interval
224118864|NCT04006899|DEVICE|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
223981004|NCT00196534|DRUG|Bovine Thrombin|
223981005|NCT01037062|DRUG|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
223981006|NCT03521518|DIAGNOSTIC_TEST|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
223981007|NCT03913169|OTHER|Educational Implementation of Interprofessional Curriculum|The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
223981008|NCT04662437|DIAGNOSTIC_TEST|Venous blood was collected for biochemistry testing|From the people in the healthy control group, 10 ml of venous blood was collected from the venous vein in the forearm of all individuals in the study. Parathyroid hormone, calcium, phosphorus, alkaline phosphatase levels were measured from this blood.
223981009|NCT02872311|BIOLOGICAL|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
223981010|NCT02872311|BIOLOGICAL|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
223981011|NCT02872311|BIOLOGICAL|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
223981012|NCT02872311|BIOLOGICAL|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
223981013|NCT03385577|BEHAVIORAL|Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer|'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
223981014|NCT04718233|DRUG|Sildenafil 25Mg Tablet|Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss
223981015|NCT04718233|DRUG|Placebo Oral Tablet|placebo will be administered orally in patients with recurrent pregnancy loss
223981016|NCT03171935|DEVICE|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
223981017|NCT03171935|DEVICE|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 \>92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 \>96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
223981018|NCT03171935|DEVICE|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
223981019|NCT03579238|PROCEDURE|CV4|The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.
223981020|NCT03579238|PROCEDURE|touching|the clinician allows the participant's head to rest quietly upon his open palms on a table.
223981021|NCT00316368|DEVICE|Ethicon TPW32 60 cm (pacing wires x 2)|
223981022|NCT03991598|OTHER|Exercise program|Exercise program in communities / Exercise program at home
223981023|NCT04721288|OTHER|Active communication through Reboot application|Access to active communication with the transplant care team through Reboot application based asynchronous messaging for non-urgent issues, as well as personalized clinical notifications.
223981024|NCT04721288|OTHER|Generic communication through Reboot application|Access to generic messaging through Reboot application, and communication with the transplant care team through standard of care communication system.
223981025|NCT03094962|OTHER|Motion capture|Capture kinematics of finger movements
223981026|NCT03094962|DIAGNOSTIC_TEST|MR scan|Capture MR images of hand and fingers in three postures
223981027|NCT03094962|DIAGNOSTIC_TEST|CT scan|Capture CT images of hand and fingers in three postures
223981028|NCT05072262|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml
223981029|NCT05072262|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex)
223981030|NCT05132855|BIOLOGICAL|BNT162b2|BNT162b2 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
223981031|NCT05132855|BIOLOGICAL|mRNA-1273|mRNA-1273 is an mRNA vaccine to prevent COVID-19 infection and is approved by the emergency use of authorization (EUA) by the Taiwan FDA.
223981032|NCT05132855|BIOLOGICAL|MVC-COV1901|MCV COVID-19 vaccine is a protein subunit vaccine containing S2P S-protein which passes the EUA by Taiwan FDA.
223981033|NCT04131010|DEVICE|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
223981034|NCT04707456|OTHER|Training operator|"After recruitment, the participants were divided into two groups to perform first-trimester ultrasound scan by two different levels of proficiency.~First group : operator has experience more than 3 years in NT scan and second trimester ultrasound scan Second group : operator has experience less than 3 years in NT scan and second trimester ultrasound scan"
223981035|NCT06115239|OTHER|Questionnaires|The patients will fulfill the EORTC-LC29 and HADS questionnaires in 5 different moments.
223981036|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Head.|One layer of APIS® will be applied to the post-operative wound on the head covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
223981037|NCT04545476|DEVICE|Participants in this group will receive the experimental APIS Biomaterial on the Lower Extremities.|One layer of APIS® will be applied to the post-operative wound on the lower extremities covered by petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
223981038|NCT04545476|OTHER|Standard Secondary Intention Healing on the Head|Participants in this group will receive standard secondary intention wound healing post-operative care on the Head. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
223981039|NCT04545476|OTHER|Standard Secondary Intention Healing on the Lower Extremities|Participants in this group will receive standard secondary intention wound healing post-operative care on the Lower Extremities. Post-operative wound will heal via conventional secondary intention. Application of petrolatum impregnated gauze, a non-stick Telfa pad, gauze, and Opsite tape.
223981040|NCT03143296|OTHER|Simulated reverberant environment|Reverberant environments simulate real-life situations mimicking a living room, classroom and auditorium. Each simulation lasts up to 2 hours.
223981041|NCT04161547|DRUG|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
223981042|NCT04161547|DRUG|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
223981043|NCT04161547|DRUG|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
223981044|NCT04161547|DRUG|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
223981045|NCT03904875|OTHER|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
223981046|NCT04620031|DRUG|HSK3486|Loading Dose：0.1 mg/kg, infused with 4 min ± 30 s； Maintenance Dose：Maintenance is started at 0.3 mg/kg/h, and the dose can be adjusted up and down by 0.05-0.1 mg/kg/h. Range of maintenance dose: 0.06-0.8 mg/kg/h
223981047|NCT04620031|DRUG|Propofol|"Loading Dose：0.5 mg/kg, infused with 4 min ± 30 s~Maintenance Dose：Maintenance is started at 1.5 mg/kg/h, and the dose can be adjusted up and down by 0.25-0.5 mg/kg/h. Range of maintenance dose:~0.3-4 mg/kg/h"
223981048|NCT02206945|BEHAVIORAL|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
223981049|NCT02206945|BEHAVIORAL|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
223981050|NCT02768077|DRUG|Melatonin(Circadin®)|
223981051|NCT02768077|DRUG|Placebo|
223981052|NCT04237714|BEHAVIORAL|Smiling is fun|"Smile is Fun is a self-applied program that combines elements of prevention and psychological treatment for emotional disorders. It is delivered via the Internet and it is based on CBT technics. The program consists of 8 therapeutic modules and includes 3 transversal tools (activity report, calendar, how am I?) to provide feedback and accompany patients during the intervention. The program requires 8 to 10 weeks to complete in its entirety.~The intervention, initially developed in Spain, will be adapted to the Ecuadorian culture including elements of the local population, such as, dialect, personal stories, examples and activities. The Ecuadorian version will be evaluate by health professional and users of public health system of Ecuador."
223981053|NCT00114543|PROCEDURE|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
224293782|NCT07212374|OTHER|Graduation|"Graduation is a multifaceted approach that aims to support ultra-poor households in permanently escaping poverty traps. The standard version of Graduation tested in this study includes: a one-time asset transfer; monthly cash transfers; life skills coaching on topics like health and nutrition; technical skills training on topics like financial literacy; and access to savings services."
224293783|NCT07211971|DIAGNOSTIC_TEST|retrospective study including neonates who underwent flexible fiberoptic bronchoscopy over a period of 10 years from January 2015 to January 2025.|retrospective study including neonates who underwent flexible fiberoptic bronchoscopy over a period of 10 years from January 2015 to January 2025.
224293784|NCT07211399|DRUG|Opioid-free anesthesia|Each patient will be pre-oxygenated receive IV-acetaminophen (1 g), and IV-lidocaine (60 - 100 mg). and dexmedetomidine (12-20 mcg IV) and ketamine (25-50 mcg) prior to intubation. Induction of anesthesia will be achieved with IV-propofol (1 - 2 mg/kg; 150 - 200 mg). Patient air ways will be secured with an intratracheal tube or LMA. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC). During surgery, dexmedetomidine and ketamine will be administered as needed. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC).
224293785|NCT07211399|DRUG|Opioid-based anesthesia|Each patient will be pre-oxygenated receive IV-acetaminophen (1 g), and IV-lidocaine (60 - 100 mg). and fentanyl 50-100 mcg IV prior to intubation. Induction of anesthesia will be achieved with IV-propofol (1 - 2 mg/kg; 150 - 200 mg). Patient air ways will be secured with an intratracheal tube or LMA. Anesthesia will be maintained by either propofol (100 - 150 mcg/kg/hour; TIVA), or sevoflurane (0.5-1 MAC). During surgery, each patient in the opioid group will receive IV-fentanyl (50 - 100 mcg) as needed.
223981054|NCT00114543|PROCEDURE|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
223981055|NCT00114543|PROCEDURE|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
223981056|NCT00114543|PROCEDURE|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
223981057|NCT03440983|DEVICE|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
223981058|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
223981059|NCT01183715|DRUG|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
223981060|NCT00690378|DRUG|NXL104/ceftazidime|125mg/500mg TID
223981061|NCT00690378|DRUG|Imipenem/Cilastatin|4 x daily
223981062|NCT02169921|DEVICE|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
223981063|NCT01355822|DRUG|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
223981064|NCT01355822|DRUG|Placebo control|orally, twice daily
223981065|NCT01051102|DRUG|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
223981066|NCT01051102|DRUG|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
223981067|NCT05426161|DRUG|Botulinum Toxin A|Botulinum Toxin A (10 units per cm2 wound areal) will be injected subcutaneously around the wound (1-2 cm from wound edge) maximum 200 units at each injection time.The total dose of BoNTA is maximum 400 units. Patient will receive one or two treatments in total.
223981068|NCT01154270|RADIATION|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
223981069|NCT02878460|OTHER|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
223981070|NCT02878460|OTHER|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is \< lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
223981071|NCT04011423|OTHER|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
223981072|NCT04011423|OTHER|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
224118865|NCT05248087|DEVICE|The bonded McNamara-type appliance|The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
224118866|NCT05248087|DEVICE|The removable palatal expansion appliance|The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
224118867|NCT01003561|PROCEDURE|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
224118868|NCT01324583|DRUG|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
224118869|NCT01324583|DRUG|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
224118870|NCT00003243|BIOLOGICAL|aldesleukin|
224118871|NCT00003243|BIOLOGICAL|filgrastim|
224118872|NCT00003243|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224118873|NCT00003243|DRUG|cyclophosphamide|
224118874|NCT00003243|DRUG|etoposide|
224118875|NCT00003243|DRUG|pegylated liposomal doxorubicin hydrochloride|
223981073|NCT05564546|PROCEDURE|FeNO (fractional exhaled nitric oxide)|"FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment."
223981074|NCT05564546|PROCEDURE|Spirometry|"Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment."
223981075|NCT05564546|OTHER|Physical examination|"A pulmonary clinical examination will be carried out by the investigator, including:~* Cough,~* Sputum,~* Vesicular murmur (MV),~* Added noises (BSA),~* Vocal vibrations (VV),~* Tympanism,~* Dullness,~* Signs of acute respiratory distress (ARD),~* …"
223981076|NCT05564546|OTHER|Interrogation|"Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc."
223981077|NCT04247269|OTHER|Enteral Tube Feeding|Enteral tube feeding
223981078|NCT00878553|DRUG|placebo|tablet at bedtime
223981079|NCT00878553|DRUG|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
223981080|NCT00912223|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~* Rituxan 375 mg/m\^2 on Day -13~* Rituxan 1000 mg/m\^2 on Days -6, +1, and +8~* Fludarabine 30 mg/m\^2 on Days -5 to -3~* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
223981081|NCT03980197|OTHER|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
223981082|NCT03980197|OTHER|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
223981083|NCT05784766|DIAGNOSTIC_TEST|30-second ECG using the Kardia Mobile|30-second ECG using the Kardia Mobile
223981084|NCT05784766|OTHER|routine care|medical review
223981085|NCT00592462|PROCEDURE|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
223981086|NCT03253068|DRUG|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
223981087|NCT03866447|DRUG|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
223981088|NCT03866447|DRUG|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
223981089|NCT05009381|DEVICE|Stylage XXL at enrollment|Injection in the chin at enrollment
223981090|NCT05009381|DEVICE|Stylage XXL at Month 6|Injection in the chin 6 months after randomization
223981091|NCT02504749|PROCEDURE|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated ."
224118876|NCT04860284|DRUG|Hydroxychloroquine tablets|Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
224118877|NCT05126368|OTHER|Cataract surgery|During cataract surgery the Eyhance toric II intraocular lens will be implanted in one eye of the patient
224118878|NCT06128005|BEHAVIORAL|knowledge translation in nursing for pressure injury care|Pressure injury's knowledge and healing of wound.
224118879|NCT04022811|DRUG|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
224118880|NCT05149794|OTHER|Calisthenic Exercises|Bunny Jumps, Bear Crawls, Bear Crawls, Bird Dog . these intervention were used
224118881|NCT01622920|OTHER|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
223543987|NCT06062381|PROCEDURE|Abdominal Massage|"The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles."
223981092|NCT01226836|OTHER|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
223981093|NCT05792761|DRUG|Peginterferon alfa-2b combined and ETV|"Child patients are assigned to one of the 3 treatment regimens according to their illness state and treatment desire of their parents/guardians, and the number of patients in each group is expected to limited to 300.~1. NA monotherapy group : received entecavir (ETV) for 96 weeks.~2. Combination therapy group: received peginterferon alfa-2b combined with ETV for 96 weeks.~3. Pulse therapy group :received peginterferon alfa-2b pulse treatment combined with ETV for 144 weeks."
223981094|NCT03288077|OTHER|Tryptophan|Beverage including tryptophan
223981095|NCT03625453|DRUG|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
223981096|NCT03625453|DRUG|Placebo|Part 1: 8 weeks with daily administration
223981097|NCT01341847|PROCEDURE|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
223981098|NCT01341847|PROCEDURE|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
223981099|NCT04276298|DRUG|Metronidazole cream|10% metronidazole applied rectally
223981100|NCT04276298|DRUG|Metronidazole and Diltiazem cream|Combination Metronidazole and Diltiazem applied rectally
223981101|NCT04276298|DRUG|Metronidazole and Lidocaine cream|Combination metronidazole and lignocaine applied rectally
223981102|NCT04276298|DRUG|Metronidazole, Diltiazem and Lidocaine cream|Combination of all active agents tested applied rectally
223981103|NCT03739333|OTHER|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
223981104|NCT00461123|DRUG|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
223981105|NCT00461123|DRUG|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
223981106|NCT03834207|DEVICE|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
223981107|NCT02692287|DEVICE|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
223981108|NCT04377412|OTHER|Pandemic control measures|Population of different countries are exposed to different pandemic control measures, and everyday lives of pregnant women are affected on different levels. Investigators will measure influence their influence on mental health.
223981109|NCT01100918|DEVICE|BiV ICD|Biventricular ICD
223981110|NCT01100918|DEVICE|ICD|Implantable Defibrillator
223981111|NCT00177372|DRUG|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
223981112|NCT05955755|OTHER|butterfly vacuum blood collection set|Blood collection from the children in the experimental group will be performed with a butterfly vacuum blood collection set.
223981113|NCT03299413|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
223981114|NCT00927901|DRUG|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
223981115|NCT00927901|DRUG|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
223981116|NCT00927901|DRUG|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
223981117|NCT00927901|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
223981118|NCT00483080|DRUG|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
223981119|NCT05012943|BIOLOGICAL|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine|ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
223981120|NCT05012943|OTHER|Placebo (normal saline)|Normal saline with the same volume as of ARCT-154
223981121|NCT05012943|BIOLOGICAL|Astra Zeneca COVID-19 vaccine|Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
223981122|NCT04252170|DEVICE|Rehabilitation Therapy, Experimental on the BrightArm Compact device|Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
223981123|NCT01306006|BIOLOGICAL|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
223981124|NCT03989921|OTHER|no intervention. observational study|no intervention. observational study
223981125|NCT02882841|OTHER|Biopsies, stool and blood collection|
223543988|NCT01731847|PROCEDURE|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
223981126|NCT03739255|DEVICE|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
223981127|NCT03739255|DEVICE|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
223981128|NCT00040820|DRUG|oxaliplatin|
223981129|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
223981130|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~* Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
223981131|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~* Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~* Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
224293786|NCT07212153|DIETARY_SUPPLEMENT|Oral Carbohydrate Drink (Maltodextrin)|Participants receive 400 mL of a clear beverage containing 50 g of maltodextrin (carbohydrate) 2 hours before anesthesia induction. The drink is used to lower insulin resistance and improve perioperative recovery.
224293787|NCT07212153|OTHER|Placebo (Water)|Participants receive 400 mL of plain water 2 hours before anesthesia induction, following the same protocol and timing as the carbohydrate drink group.
224293788|NCT07212426|DRUG|Biological/Vaccine: LP-005|Participants were administered LP-005 as an IV infusion every 4 weeks.
224293789|NCT07212426|DRUG|Biological/Vaccine: LP-005|Participants were administered LP-005 as an IV infusion every 4 weeks.
224293790|NCT07212426|DRUG|Biological/Vaccine: LP-005|Participants were administered LP-005 as an IV infusion every 4 weeks.
224293791|NCT07212062|DRUG|X/T + X-EC|Xanomeline and Trospium Chloride Capsules
223543989|NCT03800277|DIETARY_SUPPLEMENT|Cranberry|Supplementation of polyphenols from cranberry extract
223543990|NCT03800277|DIETARY_SUPPLEMENT|Agaves|Supplementation of inulin from Agaves powder
223543991|NCT03800277|DIETARY_SUPPLEMENT|Placebo|Supplementation with placebo
224293792|NCT07212062|DRUG|Placebo|Placebo
224293793|NCT07212062|DRUG|Lecanemab 10 mg/kg|Participants will continue their current Lecanemab infusions while in the study receiving the study drug or placebo.
223727195|NCT04597788|OTHER|Protein supplemented very low calorie diet program|"Protein supplemented very low calorie meal is a shake-type meal replacement with total calories of 600 to 800 calories per day and proteins provided at 1.2g of ideal body weight per day. The four-month, very low calorie diet program schedule will be as follows. In the first two weeks, all three meals are replaced, followed by two meals replaced and one meal in food in the next six weeks, and one meal replacement is recommended for the next eight weeks. For the next eight months, the intermittent very low calorie meal replacements will be provided regularly for one week a month. If a subject gains weight more than 2kg, he or she will have an additional 1 week of two meal replacements, and if a subject gains weight more than 4kg, he or she should have an additional 2 weeks of replacement.~Individual sessions will be held 11 times during the study. Mobile counseling with dietitians or nurses will be offered to help subjects lose weight and maintain weight loss."
223981132|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~* Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~* Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
223727196|NCT04597788|OTHER|Conventional low calorie diet program|Low calorie diet consists of 1200 to 1500 calories will be educated and lifestyle modification will be encouraged for participants in control group. Educational materials as well as recipes for low calorie diet will be provided in individual sessions. Mobile counseling will also be offered for sticking to the diet program.
223727197|NCT03273595|DRUG|Lapatinib|
223543992|NCT03506139|RADIATION|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
223543993|NCT02393820|DRUG|pazopanib|treatment will be given until progression or unacceptable toxicity .
223543994|NCT02634242|OTHER|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
223727198|NCT03273595|BIOLOGICAL|Trastuzumab|
223727199|NCT03273595|DRUG|Paclitaxel|
223727200|NCT03273595|DRUG|Epirubicin|
223981133|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~* Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~* Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
223543995|NCT02634242|OTHER|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
223543996|NCT02342353|DRUG|Pacritinib|
223543997|NCT02342353|DRUG|Erlotinib|
223727201|NCT03273595|DRUG|Cyclophosphamide|
223727202|NCT06417294|OTHER|3D health education model|explanation combined with 3D printed health education model
223727203|NCT06417294|OTHER|traditional education|Regular education
223727204|NCT01322178|DRUG|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
223727205|NCT05745584|DRUG|Mirabegron (beta3-adrenoceptor agonist), Anticholinergics|Administration of Mirabegron (beta3-adrenoceptor agonist) for 8 weeks, and followed by subsequent administration of anticholinergics for 8 weeks
223727206|NCT02090244|DRUG|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
223727207|NCT02868320|OTHER|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
223981134|NCT00830102|DRUG|fluticasone propionate, formoterol fumarate|"* Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~* Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~* Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~* Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
223981135|NCT05804682|PROCEDURE|Fascial Neck Dissection|Central and lateral neck dissection with the fascial technique
223981136|NCT05804682|PROCEDURE|Standard Neck Dissection|Central and lateral neck dissection with the standard technique
223981137|NCT03029819|BEHAVIORAL|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
223981138|NCT03029819|BEHAVIORAL|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
223981139|NCT03029819|BEHAVIORAL|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
223981140|NCT03029819|DRUG|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke \>10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
223981141|NCT01989923|OTHER|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
223981142|NCT01989923|DEVICE|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
223981143|NCT05436210|OTHER|foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test|Patients will be evaluated only observationally without intervention by foot posture index, north star ambulation assessment, timed performance tests, 6 minute walk test
223981144|NCT03536702|OTHER|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
223981145|NCT03536702|OTHER|Independent Writing - Control Group|This group will receive a book for a self writing session.
223981146|NCT05818995|DRUG|angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker|Drug types: angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blockers Treatment prescription: medication alone or in combination Dose used: \<standard dose, standard dose, \>standard dose Frequency of administration: once a day, twice a day, three times a day.
223981147|NCT02998619|RADIATION|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
223981148|NCT04344665|OTHER|Virtual Care and Remote Automated Monitoring|Patients will measure daily vitals (blood pressure, heart rate, respiratory rate, oxygen saturation, temperature, weight) with remote monitoring technology and complete recovery surveys daily in home after discharge from hospital. Patients will interact with a virtual nurse daily on days 1-15 and every other day from days 16-30. If the patient's RAM measurements exceed predetermined thresholds, the patient reports specific symptoms (e.g., shortness of breath), a drug error is identified, or the virtual nurse has concerns about the patient's health that they cannot resolve, the virtual nurse will escalate care to a pre-assigned and available physician. Physicians will add or modify treatments as needed, and if required, they will have the patient come to an outpatient facility for evaluation or management. Via secure video or text messaging, patients will also have access to a virtual nurse at night, for any urgent issues.
223981149|NCT03605368|BEHAVIORAL|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
223543998|NCT00974155|DRUG|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
223543999|NCT00974155|DRUG|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
223544000|NCT03941418|DIETARY_SUPPLEMENT|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
223544001|NCT03941418|DIETARY_SUPPLEMENT|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
223544002|NCT00525434|DEVICE|Seraffix LTB|wounds closure by using laser and albumin
223727208|NCT02868320|OTHER|Instruction booklet|General detailed instructions addressing the same SMS categories.
223981150|NCT03605368|BEHAVIORAL|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
223981151|NCT03605368|BEHAVIORAL|No intervention|Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
223981152|NCT05046106|DRUG|MLC1501|Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
223981153|NCT05046106|OTHER|Placebo|Caramel, chocolate brown, flavor (E\_1982648), dextrin
223981154|NCT02690337|DRUG|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
223981155|NCT03559829|DEVICE|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
223981156|NCT00698555|BIOLOGICAL|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
223981157|NCT00698555|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
223981158|NCT05694962|RADIATION|Low-Dose Radiation Therapy|1.5Gy single treatment of whole-lung radiation therapy
223981159|NCT01982175|BIOLOGICAL|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3\~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~\--------------------------------------------------------------------------------"
223544003|NCT04793282|BEHAVIORAL|Telephone Follow-up|Telephone Follow-up within 72 hours to discuss psycho education, discharge planning and clarify any questions they may have.
223544004|NCT04410159|DRUG|Povidone-Iodine|Gargle
223544005|NCT04410159|DRUG|Essential oils|Gargle
223544006|NCT04410159|OTHER|Tap water|Gargle
223981160|NCT05639998|BIOLOGICAL|COVAXIN(BBV152)|COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2
223727209|NCT03240614|DEVICE|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
223981161|NCT05639998|BIOLOGICAL|BBV154 Intranasal Vaccine|BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
223981162|NCT00876499|BEHAVIORAL|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
223981163|NCT05566509|PROCEDURE|Breast excision|some patient had minimal excision, some had maximal excision.
223981164|NCT01962311|PROCEDURE|lumbar puncture|lumbar puncture at enrollment in study
223981165|NCT01475422|BEHAVIORAL|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
224118882|NCT02215421|BEHAVIORAL|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
224118883|NCT04302610|DEVICE|Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,|A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments
223727210|NCT03240614|DEVICE|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
223727211|NCT03240614|DEVICE|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
223981166|NCT01475422|BEHAVIORAL|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
223981167|NCT04234503|BEHAVIORAL|Ethics Quarter|"In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~1. Developing of own ethics knowledge,~2. Influencing ethical issues,~3. Conducting/implementing ethics research,~4. Identifying and~5. Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory."
223981168|NCT02675218|OTHER|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
223981169|NCT00037661|DRUG|INS365 Ophthalmic Solution|
223981170|NCT00249171|DRUG|risperidone|
223981171|NCT02483598|DRUG|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
223981172|NCT02483598|DRUG|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
223981173|NCT02650466|DEVICE|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
223981174|NCT03633864|BIOLOGICAL|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
223981175|NCT02741258|DEVICE|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
223981176|NCT02741258|DRUG|skin cream|cream to treat skin erythema due to radiotherapy
223981177|NCT05886946|OTHER|ABG|ABG
223727212|NCT02589756|OTHER|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
223727213|NCT02589756|OTHER|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (\~1400 kcal \~100 grams walnuts, \~50 grams hazelnuts and \~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
223981178|NCT02547597|DRUG|Carvedilol|
223727214|NCT02589756|OTHER|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
223981179|NCT02547597|DRUG|Atenolol|
223981180|NCT04972539|DRUG|AJU-A51 Tab.|Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
223981181|NCT04972539|DRUG|A51R1 Tab. and A51R2 Tab.|Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
223981182|NCT03682198|DEVICE|NIRS measurements on skin, skull and dura|During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
223981183|NCT03682198|DRUG|Phenylephrine's effect on brain oxygenation|With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
223981184|NCT03682198|DRUG|Normal vs. high inspired oxygen|By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
223981185|NCT05160571|DEVICE|Ion Endoluminal System|Ion Endoluminal Procedure for pulmonary nodule
223981186|NCT00927550|DRUG|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
223981187|NCT00927550|DRUG|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
223981188|NCT01837797|DRUG|Placebo|Once daily, tablets, orally
223981189|NCT01837797|DRUG|Brexpiprazole 1 mg|once daily dose, tablets, orally
223981190|NCT01837797|DRUG|Brexpiprazole 3 mg|once daily dose, tablets, orally
223981191|NCT03797989|BIOLOGICAL|P. vivax infected inoculum (parasitised red blood cells)|In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
223981192|NCT04700397|DIAGNOSTIC_TEST|Nitroglycerine|We aim to test the repeatability of NTG-Pd/Pa with different dosages of nitroglycerine injection.
223981193|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
223981194|NCT00396214|DRUG|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
223981195|NCT00396214|DRUG|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
223981196|NCT06584825|DEVICE|Enhanced Vitals Monitoring|"For participants in the intervention group, they will receive the enhanced continuous vital sign monitoring, on top of the standard of care monitoring as prescribed per the care team. The enhanced monitoring will be provided during the entire time period of hospitalization (up to 30 days after surgery), using the Philips monitor (i.e. heart rate and oxygen saturation continuously and blood pressure once an hour while awake). Participants and caregivers will be educated how to put on and off the devices by the study coordinator.~When participants return home, they will perform thrice-daily monitoring using the Cloud DX Inc. Home kit and daily questionnaires at home 7 days after discharge (or 30 days after surgery, whichever occurs first)."
223981197|NCT04032119|PROCEDURE|Endoscopic submucosal dissection|Endoscopic submucosal dissection
223981198|NCT04032119|DRUG|Epinephrine|Epinephrine
224118884|NCT04302610|DEVICE|Sham treatment|Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
224118885|NCT04221906|DRUG|BOS-475|topical cream
224118886|NCT04221906|DRUG|Active ingredient-free vehicle cream|topical cream
223981199|NCT05930132|PROCEDURE|submucosal conchoplasty|Regarding the submucosal conchoplasty technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000. The mucosa was incised by blade 15 starting from the axilla posteriorly up to the attachment with the basal lamella. The mucosa covering the lateral lamella was dissected using the freer dissector. The lateral lamella was removed using a through cut forceps then the mucosa was repositioned. The bony skeleton of the medial lamella was preserved
223981200|NCT05930132|PROCEDURE|classic lateral lamellectomy|"Regarding the lateral lamellectomy technique, the concha was locally infiltrated with adrenaline with a concentration of 1:200,000; the sickle knife was used to open the concha then the scissor was used to remove the lateral lamella with its covering mucosa in one block.~No middle meatus packing was applied. Systemic antibiotics and steroids (0.5 mg / kg prednisolone) were given for two weeks after the surgery. The patients were instructed to use local nasal irrigations (2 ml of budesonide 0.5 mg / ml mixed with 250 ml of normal saline) two times daily for a month postoperatively. Patients were followed up at the end of each month throughout the six months follow-up period."
223981201|NCT03628690|DEVICE|BandGrip|Topical skin closure device
223981202|NCT03628690|DEVICE|Suture|Wound closure
223981203|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
223981204|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
223981205|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
223981206|NCT01319578|OTHER|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
223981207|NCT05261230|BEHAVIORAL|Vedic Counselling|Trauma focused Vedic Counselling intervention was delivered by trained and experienced therapist of Yoga and Vedanta.12-week sessions were provided on one to one bases on personalised approach.
223981208|NCT05261230|BEHAVIORAL|Standard Care|The active control group received standard psychosocial care provided by the participating psychologists and psychiatrists.
223981209|NCT02176837|DRUG|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
223981210|NCT03965221|BEHAVIORAL|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
223981211|NCT03965221|BEHAVIORAL|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
223981212|NCT05971277|DEVICE|Halo Wearable data device|A wrist-worn tracker with heart-rate monitor and pedometer (step counter), as well as a mobile app.
223981213|NCT03397316|PROCEDURE|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
223981214|NCT04318314|DIAGNOSTIC_TEST|COPAN swabbing and blood sample collection|COPAN swabbing of nostrils and/or oropharynx and blood sample collection
223981215|NCT01032356|DEVICE|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
223981216|NCT00159549|BEHAVIORAL|education and training program|
223981217|NCT04766047|DRUG|Dexmedetomidine|Administration of dexmedetomidine intraoperatively
224118887|NCT04221906|DRUG|Daivonex cream (calcipotriol 0.005%)|topical cream
224118888|NCT04221906|DRUG|Betnesol-V cream (betamethasone 0.1%)|topical cream
224118889|NCT02969317|DRUG|Tiotropium|Fixed dose combination
224118890|NCT02969317|DRUG|Olodaterol|Fixed dose combination
224118891|NCT04417777|GENETIC|Blood Test|Blood analysis
224118892|NCT02678741|DRUG|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
224118893|NCT00903032|BEHAVIORAL|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
224293794|NCT07212517|BEHAVIORAL|benson relaxation exercise|BRT is one of the behavioural intervention techniques developed by Herbert Benson in 1975. BRT is based on the principle of deep breathing and relaxing all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it. This exercise, which has no side effects on patients and can be applied for patients of all age groups, is more widely used because it is a simple and easy-to-learn method compared to other relaxation methods all the muscles in the body by choosing a word that is meaningful for the individual and focusing on it.
224118894|NCT00903032|BEHAVIORAL|Usual care|Usual care following ACS hospital discharge.
224118895|NCT05886244|DRUG|Eculizumab|Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
224118896|NCT04750070|DRUG|Blood and Dopamine|Children in this group will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. They will also receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
224118897|NCT04750070|DRUG|Blood and adrenaline|Children in this group will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. They will also receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
224118898|NCT02678156|DEVICE|Lyoplant Onlay|
224118899|NCT03500133|RADIATION|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
224118900|NCT03500133|DRUG|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
223981218|NCT02053740|DRUG|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
223981219|NCT02053740|DRUG|Routine western medicine|
223981220|NCT00604188|DRUG|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
223981221|NCT00604188|DRUG|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
223981222|NCT00592735|PROCEDURE|laparoscopic gastric banding|standard surgical procedure
223981223|NCT00248079|DEVICE|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
223981224|NCT04360434|DRUG|NI006|NI006 will be administered intravenously
223981225|NCT04360434|DRUG|Placebo|Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
223981226|NCT06170229|BEHAVIORAL|eHIIT|"Education and High intensity Interval Training (Aerobic Exercise)~The focus of the one educational session is rationale for aerobic exercise, expected physiological effects of aerobic exercise, diet when performing an exercise program, how the knee accommodates to exercise (including potential experience of muscle soreness and how that is different from joint pain), and management of potential knee OA symptom flares.~HIIT is an aerobic exercise form. The eHITT protocol consist of eight 2-minute intervals of high intensity training (with the goal to train at a heart rate of at least 80% of HRmax) followed by 2 minutes of moderate training intensity (with the goal to train at a heart rate of at least 60% of HRmax).~There will be several types of exercise modalities for aerobic exercise available (treadmills, cross-trainers, row- and cycle ergometers) and participants may choose whichever they prefer."
223981227|NCT06170229|BEHAVIORAL|NEMEX-e|"Education and Neuromuscular Exercise~The focus of the two educational sessions is on providing knowledge of OA and treatment options to the participants, with a special focus on knee OA, diet, and exercise and its benefits. Furthermore, advice about self-management is given.~The exercises are based on neuromuscular principles to improve sensorimotor control and achieve compensatory functional stability. Sensorimotor control is the ability to coordinate muscle activity and maintain functional stability during movement allowing for joint stability during physical activity. Various positions (sitting, lying, standing) are used to achieve the desired postural activity. The overall goal is to obtain muscle control and stability in situations resembling daily life and/or more strenuous activities. The focus is on achieving good quality of the performance in each exercise with appropriate postural orientation (e.g., joint positioned appropriately in relation to each other)."
223981228|NCT04452409|DEVICE|low level laser|The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
223981229|NCT04452409|OTHER|Mediterranean diet|recommend healthy diet component evaluated periodically by 24 hour recall
223981230|NCT01849913|OTHER|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
223981231|NCT01849913|OTHER|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
223981232|NCT00857740|BEHAVIORAL|Education|Education about the neurophysiology of pain
223981233|NCT01218425|DRUG|Methylphenidate 40 mg|Oral dose 40 mg
223981234|NCT01218425|DRUG|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
223981235|NCT01218425|DRUG|Domperidon 10 mg|Domperidon 10 mg
223981236|NCT01214681|DIETARY_SUPPLEMENT|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
223981237|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
223981238|NCT01214681|DIETARY_SUPPLEMENT|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
223981239|NCT01214681|DIETARY_SUPPLEMENT|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
223981240|NCT03167047|PROCEDURE|Caudal block|Caudal epidural
223981241|NCT03167047|PROCEDURE|Nerve Block|Peripheral nerve block
223981242|NCT03167047|DRUG|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
223981243|NCT01684111|DRUG|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
223981244|NCT01684111|DRUG|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
223981245|NCT05850182|BEHAVIORAL|Lifestyle intervention|12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
223981246|NCT04017637|BEHAVIORAL|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
224118901|NCT03500133|DRUG|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
223981247|NCT06153498|DRUG|Remimazolam besylate|After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
223981248|NCT05980819|OTHER|Sustainability lecture and opportunity to create a project|Pure education
223981249|NCT05822128|OTHER|Test of an alternative Epworth Sleepiness Scale ESS-ALT in French|Seniors recruited into the study will test the Epworth Alternate Sleepiness Scale -ALT
223981250|NCT04666376|OTHER|evaluation of the effectiveness of vitrification technique on ovarian tissue quality|there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
223981251|NCT02111720|BEHAVIORAL|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
223981252|NCT02111720|BEHAVIORAL|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
223981253|NCT05226039|BEHAVIORAL|Moderate intensity acute exercise bout|The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.
223981254|NCT02277392|BIOLOGICAL|Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells|
224118902|NCT03500133|RADIATION|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
224118903|NCT03500133|DRUG|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
224118904|NCT03500133|DRUG|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
224118905|NCT03500133|DRUG|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
224118906|NCT03500133|DRUG|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
224118907|NCT03500133|DRUG|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
224118908|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
224118909|NCT01482026|OTHER|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
224118910|NCT06723028|BEHAVIORAL|Regulation of craving training|"Participants randomized into the active mROC-T intervention (mROC-T+ or mROC-Tc) will: 1. Read a brief essay about either the social justice benefits of eating healthy foods (POSITIVE, mROCT+) or critical of social justice aspects of unhealthy foods (CRITICAL, mROC-Tc). 2. Participants complete six free-response questions to ensure that they understood the essays.~3\. Participants are instructed to use the information from the essay. They are shown a cue matching the essay they read either: Think Positive or Think Critically.~4\. They are shown an image of a healthy food (no added sugar and \< 2g/serving saturated fat) OR an image of an unhealthy food (contain added sugar and/or \>4.5g/serving saturated fat). 5. Finally, the participant is asked to rate how strong their craving is for the pictured food. The participant indicates their craving on a VAS from 1 (No craving at all) to 5 (Very high craving)"
224293795|NCT07213349|DRUG|Daridorexant 50 mg|Study drug (Daridorexant 50 mg) taken orally each night 30 minutes before bedtime, for the 1 year duration of the study
224293796|NCT07213349|DRUG|Placebo|Study drug (Placebo) will be taken orally each night, 30 minutes before bedtime, for the 1 year duration of the study
224118911|NCT01990521|PROCEDURE|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
224293797|NCT07213271|OTHER|Dance classes|Participants will attend supervised sessions three times per week, each lasting 60 minutes. Classes were instructed by certified professional dancers and incorporated structured choreographies from three dance genres: folkloric, Latin American, and contemporary.
224293798|NCT07211802|DRUG|Sotagliflozin Low Dose|200 mg Sotagliflozin, once daily for 6 weeks
224293799|NCT07211802|DRUG|Sotagliflozin High Dose|400 mg Sotagliflozin, once daily for 6 weeks
223981255|NCT02277392|BIOLOGICAL|SB---485232 (Human recombinant Interleukin---18)|
223981256|NCT00281047|DRUG|FP-10|
223981257|NCT04088136|BEHAVIORAL|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
223981258|NCT04088136|BEHAVIORAL|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
223981259|NCT01260207|OTHER|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
223981260|NCT04643093|DRUG|Pitavastatin|Pitavastatin, QD
223981261|NCT04643093|DRUG|Ezetimibe|Ezetimibe, QD
223981262|NCT04643093|DRUG|1PC111|1PC111, QD
223981263|NCT00356759|DRUG|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
223981264|NCT03750526|BEHAVIORAL|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
223981265|NCT03750526|BEHAVIORAL|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
223981266|NCT03750526|BEHAVIORAL|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
223981267|NCT03750526|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
223981268|NCT00934700|OTHER|Xenon gas|30% Xenon gas inhaled for 24 hours
223981269|NCT05027880|BEHAVIORAL|Web-based single-session growth mindset intervention for adolescent anxiety|This proposed study uses a four-arm, parallel group, cluster randomized controlled trial design to evaluate the efficacy of SIGMA compared to a web-based growth mindset SSI (SSI-GP) and an active web-based control programme. The concurrent parallel group structure assures that the different groups take part in their respective intervention at the same time.
223981270|NCT00566345|BIOLOGICAL|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
224118912|NCT01990521|DEVICE|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
224118913|NCT05951972|OTHER|nutritional|participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
224118914|NCT05041218|OTHER|Neural Interfaces Electroencephalogram measurement on Operators|Electroencephalogram based neural interfaces acquired during the interventional procedure and during alpha attenuation protocols (AAP) and psychometric questionnaires. AAP and psychometrics are acquired at the beginning of the shift, before and after each procedure performed.
224118915|NCT00135434|DRUG|Atazanavir/Ritonavir/Lopinavir/ritonavir|
224118916|NCT06226883|DRUG|Placebo|Matching placebo (identical appearance to MORF-057) administered orally.
224118917|NCT06226883|DRUG|MORF-057|MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
223981271|NCT00566345|OTHER|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
223981272|NCT05577663|OTHER|Routine treatment of the extraction socket|Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
223981273|NCT05577663|PROCEDURE|Socket seal technique by a free gingival graft|Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
223981274|NCT05577663|PROCEDURE|Socket seal technique using a synthetic resorbable membrane|Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
223981275|NCT05182671|OTHER|Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion|"Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:"
223981276|NCT04133259|DRUG|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
224118918|NCT05673603|DRUG|Brensocatib|Oral tablet
223981277|NCT04133259|DRUG|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
223981278|NCT04364503|DEVICE|Multiple interventions depending on diagnostic test being run.|Remnant samples and corresponding data from multiple diagnostic tests will be stored for future research and development.
223981279|NCT03799354|OTHER|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~1. MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~2. ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
223981280|NCT03799354|OTHER|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
223981281|NCT05105425|DIETARY_SUPPLEMENT|NUTRIOSE®|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of active formula (NUTRIOSE®) during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
223981282|NCT05105425|DIETARY_SUPPLEMENT|GLUCIDEX® IT21 (Placebo)|"After randomization (V2 visit), the subjects will consume per os, from V2 to V3, 1 sachet of 15g per day, in the morning, of placebo during 4 weeks.~They will consume 1 sachet in the morning. Powder will have to be mixed with usual beverage of the subject (whatever the type of drink, cold or hot)."
223981283|NCT03129971|PROCEDURE|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
223981284|NCT03129971|PROCEDURE|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
223981285|NCT02130271|DRUG|Radioactive dye|The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
223981286|NCT02130271|RADIATION|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
223981287|NCT02130271|OTHER|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
223981288|NCT04634812|DRUG|KBP-5074|a single oral dose of \[14C\]-KBP-5074
224118919|NCT05586581|DRUG|SV2A PET|SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
224118920|NCT05586581|DRUG|TSPO PET|TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
224118921|NCT05817773|DEVICE|breastfeeding cradle|Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
224293800|NCT07211802|DEVICE|Dual Continuous Glucose and Ketone Monitor|Abbott Libre X dual continuous glucose and ketone monitor (DGK) device.
224118922|NCT05716607|DRUG|OD dual-release Hydrocortisone|Treatment with once-daily dual-release hydrocortisone
224118923|NCT05716607|DRUG|TID Hydrocortisone|Treatment with thrice-daily conventional immediate-release hydrocortisone
224293801|NCT07212712|DRUG|GnRH antagonist|blockade of hormone production
224293802|NCT07212712|DRUG|Estradiol (E2)|Estrogen add-back in females
224293803|NCT07212712|DRUG|Testosterone|testosterone add-back in males
224293804|NCT07212712|DRUG|Anastrozole (Arimidex)|Prevention of testosterone conversion to estrogen in males
224293805|NCT07213193|PROCEDURE|colon-rectal resection|The patients who underwent colon rectal resection, would be evaluated for stomia or not.
223981289|NCT06289855|OTHER|MDS-UPDRS|"Movement disorder society- unified Parkinson disease rating scale (MDS-UPDRS) for Parkinson's disease.~Movement disorder society- non motor rating scale (MDS-NMS) Cognitive assessment using Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog)~Using Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale:~Timed up and go: originally aimed to clinically evaluate dynamic balance in elderly people during the performance of a task MR imaging of the brain will be performed with a 1.5T MR imaging scanner Assessment of Cortical excitability and unhibition by NIHON KOHDEN- neuropack2"
223981290|NCT05095233|BEHAVIORAL|Young Adults Culturally Adapted Manual Assisted Psychological Therapy (YA-CMAP)|"YA-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behavior Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the suicide risk mainly suicidal ideation, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking, relapse prevention strategies, training on interoceptive awareness, mood management and behavior."
223981291|NCT05095233|DEVICE|Min Plan Tool|Self-help Tool are common evidence-based methods to help deal with mental health problems.The 'MIN PLAN APP' aims to support people at risk of suicide by letting them create a safety plan based on cognitive therapeutic intervention and behavioral techniques.
223981292|NCT02756299|OTHER|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
223981293|NCT02756299|OTHER|Standard Support|General information about OSA and PAP treatment at baseline
223981294|NCT06304597|DRUG|Imfinzi|Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
223981295|NCT06304597|DRUG|Opdivo|Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
223981296|NCT00609323|DRUG|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
223981297|NCT00609323|DRUG|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
223981298|NCT02224352|DEVICE|Functional neuromuscular electrical stimulation|
223981299|NCT03134274|DEVICE|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
223981300|NCT00169962|DRUG|rhDNAse (pulmozyme)|
223981301|NCT05320861|DRUG|[14C]SJP-0008|Single oral dose of \[14C\]SJP-0008
223981302|NCT05308199|OTHER|thoracic manipulation|thoracic manipulation for unlocking of facet joints
223981303|NCT05308199|OTHER|muscle enegy technique|to release muscle spasm of cervical musces
223981304|NCT01075100|DRUG|Ixabepilone|20 mg/m2 on Days 1 and 8
223981305|NCT01075100|DRUG|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
223981306|NCT02250183|DEVICE|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
223981307|NCT02250183|DEVICE|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
223981308|NCT01497678|DEVICE|Extracellular Matrix|Extracellular Matrix
223981309|NCT03096977|DIAGNOSTIC_TEST|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
223981310|NCT03096977|DEVICE|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
223981311|NCT03096977|DEVICE|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
223981312|NCT03096977|DEVICE|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
223981313|NCT03096977|DEVICE|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
223981314|NCT03862105|OTHER|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
223981315|NCT04599387|OTHER|Remote Exercise Prescription|Exercise sessions will follow the recruitment meeting as prescribed by the BioGradient system, and will be tailored to the patient progress and limitations. In the beginning of each exercise session safety criteria will be collected and will allow participation . In addition, every 8 weeks and during the first exercise session outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect session data and discuss progress and limitation with the participant.
223981316|NCT04599387|OTHER|Usual Care|Exercise sessions will be initiated by the patient only. In the beginning of each exercise session safety criteria will be collected and will allow participation . Every 8 weeks and once after recruitment outcome measurements will be collected . The study coordinator will initiate a phone call every 8 weeks to collect outcome session data
224118924|NCT05076851|OTHER|placebo|placebo+ADT（Androgen Deprivation Therapy） ，Route of placebo administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
223727215|NCT06372002|BEHAVIORAL|Cognitive Stimulation Therapy (CST)|"The intervention will consist of the Spanish adapted version of Cognitive Stimulation Therapy (CST) followed by the Maintenance CST program.~CST is a cognitive intervention for treating mild to moderate dementia consisting of fourteen 45-minute group sessions that take place twice a week for 7 weeks. Each session follows a main topic (reminiscing about the person's life, current events, word games…) and is led by two group facilitators. The same structure is followed in every CST session: 1. Introduction (5 minutes). 2. Main Activity (25 minutes). 3. Closing (5 minutes).~The Maintenance CST program follows the principles and structure of the original CST program and consists of 24 sessions, one per week, that will be administered after the original program.~The topic, activities, and materials required for each session are specified in the CST-ES manuals, which also provide the key principles that should guide the intervention and other information necessary for its implementation."
223727216|NCT01525368|BEHAVIORAL|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
224118925|NCT05076851|DRUG|Proxalutamide|Proxalutamide +ADT（Androgen Deprivation Therapy） ，Route of Proxalutamide administration: tablet, dosage：300mg , dosage form oral , frequency of administration：QD
224118926|NCT00931892|DIETARY_SUPPLEMENT|Gluten|3g
224118927|NCT00931892|DIETARY_SUPPLEMENT|Gluten|10g
224118928|NCT04933006|DIAGNOSTIC_TEST|Pulsevelocity|arterial stiffness evaluation with pulsewave velocity
223981317|NCT02453477|GENETIC|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
223981318|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat|
223727217|NCT03623802|OTHER|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
223981319|NCT01811329|DIETARY_SUPPLEMENT|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
223981320|NCT01811329|DIETARY_SUPPLEMENT|Palm fat|
223981321|NCT01811329|DIETARY_SUPPLEMENT|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
223981322|NCT05088733|DRUG|Yang Yin Fu Zheng Jie Du therapy|Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
223981323|NCT05088733|OTHER|Routine medical care|Routine medical care
223981324|NCT01068405|DRUG|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
223981325|NCT01068405|DRUG|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
223981326|NCT05970783|DRUG|Jincaopian Tablets|Jincaopian Tablets 0.2g tid p.o.
223981327|NCT05970783|OTHER|Placebo|Placebo 0.2g tid p.o.
223981328|NCT05797883|DRUG|FOLFOX/FOLFIRI|mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
223981329|NCT06817993|BEHAVIORAL|Rejection and Acceptance Feedback|Participants will be administered cues of peer acceptance and rejection from virtual peers during an fMRI task. In the CHAT-I task, they will be chosen or not chosen to discuss various topics with a virtual peer. In the TBO Task, they will receive a high or low number of likes relative to the other photos displayed of peers. They will also view comments on their posts from peers, which may have positive, negative, or neutral content.
223981330|NCT03769077|DEVICE|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
223981331|NCT00498758|DEVICE|APOS System - biomechanical wedge shoe|
223981332|NCT06055972|OTHER|Educational Letter Post CT Examination|"Patients randomized to the CAC-based educational intervention will receive an educational letter within 8 weeks of CT examination which will include the following:~1. Their calcium score, brief educational content explaining what the calcium score means and how the presence of coronary calcifications is associated with an increased risk of a cardiac event.~2. Guidance on what actions could be taken to decrease the risk of a heart event, including blood cholesterol management, smoking cessation, weight loss, dieting, exercise, and blood pressure control.~3. For patients with CAC\>0, the letter will encourage the patient to pursue a shared decision- making discussion with his/her primary care physician or cardiologist regarding risk reduction strategies.~4. Links to American Heart Association (AHA) and phone number for study research coordinator."
223981333|NCT05896696|DEVICE|BeShape One|Single treatment with the BeShape One device. Participants will receive treatment on at least 4 abdomen/flanks treatment areas and up to 6 treatment areas, at the discretion of the investigator. The subject will receive one treatment on each treatment area.
223981334|NCT03900715|DRUG|Luspatercept|Luspatercept
224118929|NCT01876732|DRUG|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
224293806|NCT07212530|BEHAVIORAL|EmoTIChealth|The EmoTIChealth technological platform intervenes in users through a serious game, i.e. a video game whose main purpose is to teach or provide the player with certain skills that serve to achieve a higher purpose than the game itself. The game is composed of 6 areas, each of which refers to one of the variables that are analysed or considered important in promoting health related quality of life and adaptation to chronic illness: Area 1. Psychoeducation; 2. Emotional awareness and expression; 3. Emotional regulation; 4. Problem solving; 5. Self-esteem and identity;6. Social skills and communication.
224293807|NCT07212114|DRUG|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension) is formulated as a sterile, non-pyrogenic, white to off-white, preservative-free homogenous suspension of bupivacaine encapsulated into multivesicular liposomes (pMVL drug delivery system). For this study, EXPAREL will be provided in 20 mL (266 mg) EXPAREL single-use, clear glass vials.
223981335|NCT00406406|DRUG|SKI-606|
224118930|NCT03704597|OTHER|cryotherapy|Cooling of oral mucosa
224293808|NCT07212114|DRUG|0.25% bupivacaine (HCl): 50 ml|The reference product is 50 mL (125 mg) 0.25% bupivacaine HCl administered via a combined sciatic (in the popliteal fossa) and saphenous nerve block (in the adductor canal)
224293809|NCT07212114|DRUG|0.25% bupivacaine (HCl): 30 ml|EXPAREL admixed with 30 mL (75 mg) 0.25% bupivacaine HCl
223981336|NCT04510948|BEHAVIORAL|Patient Priorities Care|"Patient Priorities Care (PPC) is an innovative approach to shared decision-making that draws from existing professional training.~PPC requires the elicitation and documentation of patient health outcome goals and care preferences and the alignment of clinical care with health goals and healthcare preferences. This information will be collected and documented in the EHR by facilitators and shared with the clinicians who will then use the PPC approach with patients to inform and guide treatment decisions.~The PCPs will be trained in decisional strategies that have been shown to help align care with patients' health priorities. While encouraged to use these decisional strategies, PCPs will be free to make the recommendations they feel most appropriate for each patient.~This intervention has been developed to be integrated seamlessly into usual care."
223981337|NCT04597970|DRUG|cTACE-HAIC|transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
223981338|NCT03455205|DRUG|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
223981339|NCT03455205|DRUG|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
223981340|NCT02080403|DRUG|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
223981341|NCT03795168|DEVICE|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
223981342|NCT03795168|DEVICE|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
223981343|NCT02861196|PROCEDURE|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
223981344|NCT02851849|DRUG|LGD-6972-5 mg|5 mg LGD-6972 QD
223981345|NCT02851849|DRUG|LGD-6972-10 mg|10 mg LGD-6972 QD
223981346|NCT02851849|DRUG|LGD-6972-15 mg|15 mg LGD-6972 QD
223981347|NCT02851849|OTHER|Placebo|Placebo QD
223981348|NCT02250599|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
223981349|NCT02250599|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
223981350|NCT02250599|DRUG|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
223981351|NCT03533777|PROCEDURE|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
223981352|NCT03533777|OTHER|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
223981353|NCT03533777|DEVICE|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
223981354|NCT03533777|DRUG|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
223981355|NCT01101334|DRUG|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
223981356|NCT01101334|DRUG|erlotinib|Erlotinib; One 150mg tablet administered once daily
223981357|NCT05550597|DRUG|Fentanyl HCl|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia
223981358|NCT05550597|DRUG|Bupivacaine 0.25% Injectable Solution|Intrathecal additive Fentanyl with Hyperbaric Bupivacaine during Spinal Anesthesia Ultrasound-guided Transversus Abdominal plane block using Bupivacaine 0.25% Injectable Solution
223981359|NCT00940654|OTHER|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
223981360|NCT01384383|DRUG|GS-5885|GS-5885 30 mg tablet administered orally once daily
223981361|NCT01384383|DRUG|GS-9451|GS-9451 200 mg tablet administered orally once daily
223981362|NCT01384383|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223981363|NCT01384383|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
223981364|NCT01004029|DRUG|Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
223727218|NCT03623802|OTHER|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
223727219|NCT01755013|PROCEDURE|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
223727220|NCT04451239|DRUG|topical steroids and cyclosporin-A|All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
223727221|NCT00044278|DRUG|lamotrigine|
223727222|NCT01929915|PROCEDURE|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
223727223|NCT01929915|DRUG|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
223727224|NCT01927367|OTHER|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
223727225|NCT01997632|BIOLOGICAL|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
223727226|NCT01997632|BIOLOGICAL|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
223727227|NCT03331003|DEVICE|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
223727228|NCT03331003|DEVICE|non-LLLT wavelength group|A LED light device is non-curative for the patients.
223727229|NCT01422317|DRUG|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
223727230|NCT01422317|DRUG|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
223727231|NCT03251300|DRUG|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
223727232|NCT03251300|DRUG|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
223727233|NCT01152242|DRUG|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
223727234|NCT01152242|DRUG|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
223727235|NCT01161862|DEVICE|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
223727236|NCT00598832|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
223727237|NCT00598832|DRUG|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
223727238|NCT02310061|PROCEDURE|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
223727239|NCT02310061|OTHER|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
223727240|NCT05138497|OTHER|HILIT|A total of 92 men and women 65 years old, distributed in an experimental group that will receive a 12-week of HILIT program (n = 46); and a control group (n = 46) that will only receive general recommendations on the benefits of physical exercise. The variables will be measured for both groups with the same validated tools and the same researcher to avoid information biases and differential incorrect classification.
223727241|NCT01429753|OTHER|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
223727242|NCT01429753|DEVICE|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
223727243|NCT05381116|DEVICE|Avation System|Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.
223727244|NCT05381116|DEVICE|Sham Avation System|Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.
223727245|NCT02760069|DRUG|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
223981365|NCT01004029|DRUG|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
223981366|NCT05084599|DRUG|Metaraminol 2.7μg/kg/min|After spinal anesthesia, the patient was placed in a supine position until the fetus was delivered, and metaraminol was given at an initial rate of 2.7μg/kg/min throughout the process.
223981367|NCT05084599|DRUG|Metaraminol 2μg/kg/min|After spinal anesthesia, the patient was placed in left-tilt position until the fetus was delivered, and metaraminol was given at an initial rate of 2μg/kg/min throughout the process.
223981368|NCT03864341|BEHAVIORAL|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
223981369|NCT03864341|BEHAVIORAL|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
223981370|NCT03864341|BEHAVIORAL|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
223981371|NCT04069533|BIOLOGICAL|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
223981372|NCT00154427|DRUG|activated recombinant human factor VII|
223981373|NCT00514488|DRUG|STI571 (400 mg/day; or 800 mg/day)|
223981374|NCT05279534|DIETARY_SUPPLEMENT|Probiotic|Combination of strains Lactobacillus plantarum CECT30292, Lactobacillus plantarum CECT7484, Lactobacillus plantarum CECT7485, and Pediococcus acidilactici CECT7483, twice daily for 15 days
223981375|NCT05279534|OTHER|Placebo|Combination of maltodextrin (E1400, qs) in a vegetable hydroxymethylpropyl-cellulose capsule (HPMC) of size 0, twice daily for 15 days
223981376|NCT01338805|DRUG|BGG492|
223981377|NCT04325009|DRUG|Lipitor 80mg Tab → Dong-A Atorvastatin 80mg Tab|"1. st period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab"
223981378|NCT04325009|DRUG|Dong-A Atorvastatin 80mg Tab → Lipitor 80mg Tab|"1. st period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~2. nd period: single oral administration of 1 tablet of Lipitor 80mg Tab washout period: 7days~3. rd period: single oral administration of 1 tablet of Dong-A Atorvastatin 80mg Tab washout period: 7days~4. th period: single oral administration of 1 tablet of Lipitor 80mg Tab"
223981379|NCT04780984|DRUG|Tiotropium bromide inhalation solution|Tiotropium bromide inhalation solution
223981380|NCT04780984|DRUG|Placebo|Placebo comparator
224118931|NCT01134887|OTHER|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
224118932|NCT01134887|BEHAVIORAL|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
224118933|NCT01134887|OTHER|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
224118934|NCT01134887|BEHAVIORAL|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor \[Coaching\]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
224293810|NCT07211620|OTHER|Kinetics|Initiation of the AB therapy is recommended for the clinician if PCT ≥ 0.5 ng/ml and PCT elevation ≥100% from the previous day's value.
224293811|NCT07211620|OTHER|Absolute|According to the antibiotic protocol, starting ABs is recommended if PCT ≥ 0.5 ng/ml.
223981381|NCT00127400|BEHAVIORAL|anger management therapy|
223981382|NCT05064644|OTHER|Product that contains plant stanol ester|Product with active ingredient
223981383|NCT05064644|OTHER|Placebo product|Product without active ingredient
223981384|NCT00143026|DRUG|carbidopa, levodopa, entacapone|
223981385|NCT04595942|DRUG|Midodrine Hydrochloride Tablets|Patients will be started on 5 mg Midodrine three times a day and after one week the dosage will be up-titrated to 10 mg three times a day and continued for 12 months. They will receive the medication at four-hour intervals upon rising in the morning (the last dose should not be taken later than 6 PM). In case of intolerance, the dosage will be reduced to 2.5 mg three times a day. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting).
224118935|NCT01134887|OTHER|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
224118936|NCT06438276|BEHAVIORAL|Psychiatric outreach nurse service|Mental health service provided by psychiatric outreach nurses for 12-16 year old students in secondary schools
224118937|NCT03664986|DRUG|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
224118938|NCT03218293|DEVICE|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
224118939|NCT04997837|DRUG|PD-1 inhibitor|Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
224118940|NCT04997837|DRUG|Oxaliplatin|"CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off."
224118941|NCT04997837|DRUG|Capecitabine|CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
224118942|NCT04997837|DRUG|Tegafur-gimeracil-oteracil potassium|SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
224293812|NCT07211646|OTHER|sham tES|short 30s sham stimulation
223981386|NCT04595942|DRUG|Fludrocortisone Acetate Tablets|Patients will be started on 0.05 mg of fludrocortisone twice daily and after one week the dosage will be up-titrated to 0.1 mg fludrocortisone twice daily taken for 12 months. Patients will also receive recommendations for lifestyle modifications including drinking 2 to 3 liters of fluid per day, daily consumption of 10 grams of salt, and practicing counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting). In this arm, potassium levels will be checked 7-14 days after dose stabilization.
223981387|NCT04595942|BEHAVIORAL|Lifestyle modification|Patients will be recommended to drink 2 to 3 liters of fluid per day, consume 10 grams of salt per day, and practice counter-pressure maneuvers (handgrip, arm-tensing, leg crossing and squatting) for 12 months.
223981388|NCT01688453|BEHAVIORAL|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
224293813|NCT07211646|OTHER|Fixed tES|Fixed stimulation parameters for all participants
223981389|NCT01688453|BEHAVIORAL|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
223981390|NCT02668198|DEVICE|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
223981391|NCT02668198|DEVICE|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
223981392|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
223981393|NCT02668198|DEVICE|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine the area of prior EMR site.
224118943|NCT04997837|DRUG|5-FU|FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
224118944|NCT04997837|RADIATION|Radiotherapy|1.8 Gy/Fx, 45-50.4 Gy
224118945|NCT04997837|DRUG|Chemotherapy|Capecitabine 625mg/m2 bid orally with radiotherapy; ORegafur-gimeracil-oteracil potassium combination drug 40-60mg bid orally with radiotherapy
224118946|NCT01258348|DRUG|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
224293814|NCT07211646|OTHER|Personalized tES|Stimulation parameters personalized for each participant
224293815|NCT07212582|DRUG|Human Albumin 20% Solution|Intravenous 20% human albumin solution (50 mL per vial). In the experimental arm, patients receive 50 mL over 2 hours on admission, followed by additional doses for up to 72 hours, titrated to maintain serum albumin \>3.5 g/dL. If albumin is 2.5-3.4 g/dL, 1 vial every 12 hours is given; if \<2.5 g/dL, 1 vial every 6 hours is given. Infusion is withheld if there is fluid overload, pulmonary edema, or severe hypernatremia.
223981394|NCT02668198|PROCEDURE|Biopsy|Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
223981395|NCT02202109|BEHAVIORAL|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
224118947|NCT01258348|DRUG|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
224118948|NCT03685799|DIAGNOSTIC_TEST|Pathological revision|Pathological revision
224118949|NCT04367116|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
224118950|NCT04065230|DRUG|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
224118951|NCT05822895|DEVICE|CADe enabled programme (GI Genius)|CADe enabled programme (GI Genius)
224118952|NCT01286844|DRUG|GSK2190915A 5mg|Oral powder for dispersion in water
223981396|NCT02202109|BEHAVIORAL|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
223981397|NCT01361958|DRUG|NOMAC|
223981398|NCT04634370|BIOLOGICAL|Natural Killer Cells infusion|"Each patient will receive on dose of intravenous natural killer cell in following levels:~Level 1 : 1x106 cells/kg body weight (patients 1 to 3) Level 2: 5x106 cells/kg body weight (patients 4 to 6) Level 3: 1x107 cells/kg body weight (patients 7 to 24)"
223981399|NCT01798862|PROCEDURE|Endometrial injury by hysteroscopy or pipelle sampling|
223981400|NCT01798862|PROCEDURE|Proceed to COH directly|
223981401|NCT03163706|BEHAVIORAL|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
223981402|NCT04460729|DRUG|Capmatinib|400 mg administered orally twice daily
223981403|NCT00997711|DEVICE|Cypher|Sirolimus-eluting stents
223981404|NCT04431245|DRUG|Entecavir|Study subjects will stop the antiviral therapy. Patients will be closely monitored every 6-8 weeks for virological flare and/or biochemical flare.
223981405|NCT00902798|BEHAVIORAL|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
223981406|NCT00902798|BEHAVIORAL|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
223981407|NCT04505475|PROCEDURE|Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)|single and multiple teeth extraction, surgical tooth extraction, third molar surgery, gingivectomy, soft-tissue biopsy
223981408|NCT00612352|DRUG|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
223981409|NCT04531306|OTHER|Kinesio® Tape|Fascial taping technique for myofascial trigger points on the iliotibial band
223981410|NCT01979289|OTHER|computerized cognitive remediation|
223981411|NCT01979289|OTHER|computerized cognitive remediation:Control|
224118953|NCT01286844|DRUG|GSK2190915A 10mg|Oral powder for dispersion in water
224118954|NCT01286844|DRUG|GSK2190915A 25mg|Oral powder for dispersion in water
224118955|NCT01286844|DRUG|GSK2190915A 50mg|Oral powder for dispersion in water
224118956|NCT01286844|DRUG|GSK2190915A 100mg|Oral powder for dispersion in water
224118957|NCT02774759|DEVICE|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
224118958|NCT02774759|BEHAVIORAL|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
224118959|NCT02774759|BEHAVIORAL|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
224118960|NCT02774759|BEHAVIORAL|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
224118961|NCT02774759|BEHAVIORAL|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
224118962|NCT02774759|BEHAVIORAL|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
223981412|NCT05747612|OTHER|Counseling and Coaching|"Counseling is the art of helping yourself, that is, a helping relationship based on a series of interventions and stimuli for creativity, aimed at pursuing and maintaining an ever better relational, social and existential quality of life. Coaching is a fundamentally action-oriented method, aimed at concrete changes, the improvement of performance and the achievement of objectives."
223981413|NCT06240429|DIETARY_SUPPLEMENT|Collagen|Daily doses of 10 g collagen peptide supplementation
223981414|NCT06080360|OTHER|Patient-Reported Outcome Measures|Functional Independence Measurement-FIM, Barthel Index and European Quality of Life-5 Dimensions Questionnaire-EQ-5D, which are self-report based evaluation methods, were applied to patients who received routine treatment and met the inclusion criteria.To determine the patients' level of participation in the treatment, Hopkins was scored by the physiotherapist applying the treatment.
223981415|NCT05068921|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
223981416|NCT01969045|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
223981417|NCT01969045|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
223981418|NCT00263211|DRUG|Plavix|
223981419|NCT00263211|DRUG|Aspirin|
223981420|NCT03624387|OTHER|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
223981421|NCT00760513|DRUG|OMACOR|4 grammes daily, oral capsule
223981422|NCT00760513|DRUG|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
223981423|NCT03969576|PROCEDURE|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
223727246|NCT02760069|DRUG|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
223727247|NCT02760069|DRUG|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
223981424|NCT03969576|PROCEDURE|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
223981425|NCT05828849|BEHAVIORAL|Navigation, compensation, and personalization|The study intervention is composed of navigation, compensation, and personalization. Navigation refers to reducing barriers posed by fragmentation of health and social systems. Compensation refers to reimbursement of out-of-pocket expenses to offset dependent care, time costs, and travel expenditures necessary to access care for the different conditions and goals of the intervention. Personalization refers to preventative interventions that are personalized based on individual for potential benefit.
223981426|NCT01042249|OTHER|Pelvic Floor Muscle training|12 week training program including home exercises
224118963|NCT02774759|BEHAVIORAL|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
224118964|NCT04212494|PROCEDURE|Thrombus aspiration|Percutaneous Coronary Intervention with manual aspiration thrombectomy
224118965|NCT04212494|PROCEDURE|PCI Alone|Percutaneous Coronary Intervention without manual aspiration thrombectomy
223981427|NCT06118242|OTHER|Use of oral care solutions|Oral care solutions to be used: Chlorhexidine Gluconate, Sodium Bicarbonate, Ozonated Water and Hypochlorous Acid
223727248|NCT02760069|DRUG|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
223981428|NCT00571077|DEVICE|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
223981429|NCT00263497|DEVICE|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
223981430|NCT02619214|DRUG|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
223981431|NCT02619214|DRUG|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
223981432|NCT00749242|OTHER|orthopedic brace|antalgic drugs and orthopedic brace
223981433|NCT00749242|DEVICE|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
223981434|NCT01508637|OTHER|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
223981435|NCT01508637|OTHER|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
223981436|NCT01508637|DRUG|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
224118966|NCT05423899|BEHAVIORAL|Grace Robot|The Grace robot was designed by Awakening Health/Hanson Robotics for healthcare settings and to interact with the elderly and those isolated by the COVID-19 pandemic. Grace is a robot with a human-like appearance, which can move, actively listen, engage in conversation and react appropriately to human emotions. Intervention activities will mostly consist of active listening and general discussions about topics of interest (e.g. hobbies, music). The participant will also have the option of other types of interactions with the robot, including robot-led meditation, robot-led light exercise, listening to music and singing. Because loneliness is a subjective experience and does not have a standardized solution, this is a personalized intervention approach. We anticipate that each older adult participant will have different needs and wishes when interacting with the robot, which will allow for a more natural interaction with the robot.
224118967|NCT05423899|BEHAVIORAL|Treatment as Usual|The treatment as usual active control group will not receive the robot intervention. The investIgators have deliberately chosen the participating long-term care (LTC) homes due to their high frequency of social interactions for their clients as part of their routine care (e.g. one-on-one and group activities, family interaction, exercise groups) compared to most LTC homes settings, making TAU an active control.
223981437|NCT01508637|DRUG|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
223981438|NCT01122875|DRUG|MFGR1877S|Intravenous repeating dose
223981439|NCT03132662|DIETARY_SUPPLEMENT|Omega-3|3 gr/day of Omega-3
223981440|NCT03132662|DIETARY_SUPPLEMENT|Very Low Calorie Diet|4 servings/day Optifast
223981441|NCT01789840|DEVICE|Embosphere Microspheres|
223981442|NCT01789840|PROCEDURE|TURP|
223981443|NCT04199468|DRUG|Active Delta-9-THC|Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)
223981444|NCT04199468|DRUG|Placebo Delta-9-THC|A placebo dose given intravenously (IV)
223981445|NCT04199468|DRUG|Active Ketamine|Active Ketamine (0.2 mg/kg) given intravenously (IV)
223981446|NCT04199468|DRUG|Placebo Ketamine|A placebo dose given intravenously (IV)
223981447|NCT03006185|DEVICE|Ablative Fractional Carbon Dioxide (CO2) Laser|One 50 cm2 test area was randomized to pretreatment using a fractional 2940 nm Er:YAG laser (Joule®; Sciton Inc., Palo Alto, CA, USA). To remove hyperkeratosis, a fully-ablative 4 mm handpiece was optionally applied, followed by a single pass of a fractional Profrax 430 handpiece for all AKs. Subsequent field treatment consisted of a single pass of the Profrax 430 handpiece over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
223727249|NCT04995991|BEHAVIORAL|RRT rhythm only|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the RRT activities comprise only a rhythm accompaniment and no visual cue.
223981448|NCT03006185|DEVICE|Microdermabrasion|Another adjacent 50 cm2 test area was exposed to microdermabrasion using an MD pad with 58.5 µm-diameter particles (Ambu® Skin Prep Pads 2121M; Ambu A/S, Ballerup, Denmark). Lesion-directed treatment consisted of an increasing number of swipes concentrated to AK lesions. During field treatment, multiple swipes were applied in perpendicular directions over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
223981449|NCT01306539|PROCEDURE|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
223981450|NCT02828397|DRUG|REGN2222|
223981451|NCT00883974|BEHAVIORAL|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
223981452|NCT03984513|BEHAVIORAL|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
223981453|NCT03984513|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
223981454|NCT02169557|DRUG|Fexinidazole|
223981455|NCT02234947|PROCEDURE|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
223981456|NCT01468077|DRUG|Tocilizumab|8 mg/kg infusion
223981457|NCT04843579|DRUG|Selinexor|Given as 60 mg oral capsule
223981458|NCT04843579|DRUG|Clarithromycin|Given as 500 mg oral capsule
223981459|NCT04843579|DRUG|Pomalidomide|Given as 4 mg oral capsule
223981460|NCT04843579|DRUG|Dexamethasone|Given as 40 mg oral capsule
223981461|NCT01755910|OTHER|Left thoracic paravertebral block|
223981462|NCT01755910|OTHER|Right thoracic paravertebral block|
223981463|NCT05327036|OTHER|collect information about all participants|collect information On age,pregnancy history,Height, weight,Gestational weeks of umbilical artery embolism,Gestational week of delivery, mode of delivery, newborn birth weight, birth height, Apgar score, umbilical cord length, umbilical cord placental insertion point, placental weight, pregnancy complications, coagulation function,after obtaining the consent of all participants.
223981464|NCT03921489|PROCEDURE|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
223981465|NCT00761956|DEVICE|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
223981466|NCT00761956|DEVICE|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
223981467|NCT03617068|DRUG|Cocos Nucifera Whole|Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
223981468|NCT03617068|DRUG|Cocos Nucifera Whole|For dermatopharmacokinetic evaluation using tape/ skin stripping
223981469|NCT02825186|DRUG|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
223981470|NCT02825186|DRUG|Dexamethasone 0.1%|
223981471|NCT03189147|PROCEDURE|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
223981472|NCT03189147|PROCEDURE|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
223981473|NCT03008109|DRUG|EGFR-TK Inhibitor|
223981474|NCT03437135|DIAGNOSTIC_TEST|Glasgow Hearing Status Inventory questionnaire|"This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no."
223981475|NCT00004146|RADIATION|radiation therapy|Undergo radiotherapy
223981476|NCT00004146|DRUG|carboxyamidotriazole|Given orally
223981477|NCT00004146|OTHER|pharmacological study|Correlative studies
223981478|NCT00525928|DRUG|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
223981479|NCT03421977|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
223981480|NCT06789965|PROCEDURE|SADI-S|In the case of SADI-S, the complete dissection of the antrum and the first portion of the duodenum is performed up to the limit of the gastroduodenal artery. The right gastric artery is dissected, clipped, and sectioned at its root. A vertical gastrectomy is created using a 38F Foucher tube with staplers. Next, the duodenum is sectioned with a stapler, and the resection of the greater gastric curvature is completed. Then, from the left side of the patient, 250 cm is measured from the ileocecal valve, where the duodenoileal anastomosis will be performed. This anastomosis is carried out with the surgeon positioned again between the patient's legs. A manual end-to-side anastomosis with two layers of monofilament is performed. Finally, the vertical gastrectomy and the duodenoileal anastomosis are verified using intraoperative endoscopy or a methylene blue and air test. The gastrectomy specimen is removed through the left pararectal trocar incision. A drain will only be placed in cases of s
223981481|NCT06789965|PROCEDURE|RY-GBP|In the case of RY-GBP, first, the lesser gastric curvature is dissected between the cardia and the angular incisura, accessing the gastric transcavity. A horizontal gastric transection is performed using the first firing of a stapler. A gastric reservoir is created through successive firings with a 38F Foucher tube stapler. Next, 100 cm of the biliopancreatic limb is measured, where the manual or semi-mechanical gastrojejunostomy will be performed, with an end-to-side anastomosis using a stapler and manual closure of the loop. Then, 150 cm of the alimentary limb is measured, and a side-to-side jejunojejunostomy is created. A section is made between the two anastomoses. The mesenteric opening and the Petersen space are closed with a continuous non-absorbable suture. The anastomosis is verified using intraoperative endoscopy or a methylene blue and air test. A drain will only be placed in cases of special technical difficulty or intraoperative complications.
223981482|NCT06956313|DEVICE|Hydraulic Pressure Lifting Technique|Hydraulic Pressure Lifting Technique
223981483|NCT06956313|DEVICE|Piezo-Surgical Lifting Technique|Piezo-Surgical Lifting Technique
223981484|NCT06957470|PROCEDURE|Total Intravenous Anesthesia|It is a general anesthesia technique performed through a combination of intravenous agents administered intravenously by various methods.
223981485|NCT03024996|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
223981486|NCT03024996|OTHER|Placebo|Placebo matching to atezolizumab q3w
223981487|NCT00372346|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
224118968|NCT05770505|BEHAVIORAL|Exercise training using an e-health tool|Experimental: Exercise training will be guided by using the e-health tool MIA Health, with the possibility for digital communication between the participants and study personnel The participants will receive wearables that record heart rate. Participants will be encouraged to achieve 100 Personal Activity Intelligence (PAI) equivalents per week Control: No follow-up
224118969|NCT04964830|DEVICE|Orthodontic treatment with functional appliance (MAD)|Expansion plate and z-activator (MAD)
224118970|NCT02791789|OTHER|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
224293816|NCT07212582|OTHER|Standard Care (in control arm)|Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.
224293817|NCT07213102|OTHER|Integrated Whole-Household Programming|Treatment participants receive both Compassion International's Survival and Early Childhood Program (holistic child development through health support, educational programming, social development, and spiritual formation via local community partners) plus International Care Ministries' Transform + Family Academy intervention. The Transform component is a 15-week household-level program including health education covering malnutrition prevention, sanitation, respiratory infections, infant care; livelihood training focused on income diversification and business development with savings group formation; and values formation addressing personal character, family relationships, and decision-making. The Family Academy component provides home-based early numeracy and phonics instruction (one hour per topic) to children aged 3-5 with concurrent caregiver capacity building for school readiness support, delivered over 8 weeks.
224293818|NCT07213102|OTHER|Standard Child-Focused Programming|Compassion International's Survival and Early Childhood Program provides holistic child development through health support, nutritional assistance, educational programming, social development, and spiritual formation delivered via local community partners.
224293819|NCT07212673|BEHAVIORAL|CBT-based Mindful Courage|Self-guided online intervention
224293820|NCT07212673|BEHAVIORAL|Coached Self-Monitoring|Participants will log meals in recovery record
224293821|NCT07212959|OTHER|CXCR4-PET/CT|CXCR4-PET/CT for the detection of inflammatory activity in patient with active systemic sclerosis
224293822|NCT07213050|PROCEDURE|Radiofrequency|achieve a target temperature of 90-110°C for 4-12 minutes, ensuring an ablative margin of at least 0.5-1.0 cm around the tumor.
224293823|NCT07213050|PROCEDURE|Microwave|Antennas will be placed under imaging guidance, and ablation will be performed for 5-10 minutes per antenna activation to achieve the desired margin.
224293824|NCT07211555|DEVICE|LARC Robotic System (Micromate™ Version 3.0)|The LARC Robotic System (Version 3.0) is an investigational configuration of the Micromate™ robotic platform by iSYS Medizintechnik GmbH (Austria). It uses fluoroscopy-based surgical navigation to assist urologists in obtaining precise renal access during percutaneous nephrolithotomy (PCNL). This version is not FDA-cleared and is being evaluated for feasibility, safety, and potential clinical benefit.
224293825|NCT07212660|DEVICE|Fast curing mode|Composite restoration is cured with Turbo mode (5 seconds with 2000 mW/cm²).
224293826|NCT07212660|DEVICE|Conventional curing mode|Composite restoration is cured with High mode (10 seconds with 1200 mW/cm²).
224293827|NCT07213310|DRUG|DWP16001|Tablets, Oral
223981488|NCT01452737|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
223981489|NCT01452737|DRUG|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
223981490|NCT03362541|BEHAVIORAL|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
223727250|NCT04995991|BEHAVIORAL|RRT rhythm + visual cue|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. In this condition, the rhythmic accompaniment is synchronize with a visual cue (the verbal stimuli are highlighted using a red font in synchrony with the rhythm).
223727251|NCT01164982|DEVICE|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
223981491|NCT03362541|BEHAVIORAL|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
223981492|NCT06956911|DEVICE|traditional cardiac rehabilitation with early low resisted exercise with blood flow restriction|Traditional cardiac rehabilitation and early low resisted exercise with 0.5 kilogram in form of bilateral upper limb exercise (elbow flexion and extension,wrist flexion and extension ) with external pressure applied with pressure cuff which determined by 40% of systolic blood pressure which applied on the proximal part of the arm,the frequency of exercise is once per day for 14 consecutive day and intensity determined by rate of perceived exertion scale
223981493|NCT06956911|DEVICE|traditional cardiac rehabilitation|Diaphragmatic and costal breathing exercise, active assisted to active range of motion,percussion,splinted cough,early mobility, upper limb exercise with breathing and incentive spirometer
223981494|NCT06957678|DIAGNOSTIC_TEST|Artificial Intelligence-Based Predictive Model for Lymph Node Metastasis|The intervention is an artificial intelligence-based predictive model developed using preoperative multimodal data, including contrast-enhanced CT images, preoperative histopathological findings, and clinical features. The model is designed to predict (1) the presence or absence of lymph node metastasis, (2) the specific lymph node stations involved, and (3) the individual lymph nodes involved. Each lymph node's metastatic status is confirmed by serial pathological sectioning of surgically retrieved nodes, ensuring a highly accurate reference standard for model training and validation. This distinguishes the intervention from traditional imaging-based assessments and from other AI models that do not use individually validated lymph node pathology.
223981495|NCT02263040|BIOLOGICAL|Fluzone High-Dose|Influenza vaccine
223981496|NCT02263040|BIOLOGICAL|Fluzone (standard dose)|Influenza vaccine
223981497|NCT02828345|OTHER|Specimen Collection|
223981498|NCT04553445|BEHAVIORAL|Chronotype|Participants screened using the Morningness/Eveningness Questionnaire. Chronotype categorized as either Definite Morning/Morning, or Evening/Definite Evening. Participant will exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) either in sync or not in sync with chronotype for one month in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in the alternate chronotype for one month.
223981499|NCT04553445|BEHAVIORAL|Green exercise|Participants will be randomly assigned to four weeks of moderate intensity aerobic exercise (60-70% estimated heart rate max, 2 x per week, 30-min/session) in either natural or indoor environments in a randomized cross-over design. There will be a one-month wash out period, and then participant will complete training in alternate environment for one month.
223981500|NCT04157192|OTHER|Real acupuncture|The patient will be treated for migraine with real acupuncture.
223981501|NCT04157192|OTHER|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
223981502|NCT04027959|DIETARY_SUPPLEMENT|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
223981503|NCT06956365|PROCEDURE|Group-C|100 iu carbetosin administered to carbetocin group
223981504|NCT06956365|PROCEDURE|Group-O|In cesarean surgery, 5 IU of oxytocin will be administered after the baby delivered.
223981505|NCT06956872|OTHER|Counseling|Subjects in the both arms will receive individualized dietetic counseling as the standard dietetic care in Malaysia
224118971|NCT00166010|DRUG|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
224118972|NCT06518109|OTHER|Zarit Caregiver Burden Scale|The Zarit Caregiver Burden Scale (ZCBS) is a widely used instrument for assessing the burden experienced by caregivers of individuals requiring long-term care. It consists of 22 items and the total score ranges from 0 to 88 (low/no burden to severe burden)
224118973|NCT06012760|DRUG|Iron sucrose, Human Erythropoietin Injection, Vitamin C|The participants were administered a combined iron supplementation regimen consisting of iron sucrose,Human Erythropoietin Injection, and vitamin C, three times throughout the preoperative week.
224118974|NCT06012760|DRUG|Standard Medical Care|Standard Medical Care (SMC) for the treatment of IDA. SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
224118975|NCT01572532|OTHER|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
223727252|NCT02465216|OTHER|Placebo|Placebo
223727253|NCT02465216|BIOLOGICAL|ID93 + GLA-SE|ID93 + GLA-SE
223981506|NCT06956872|OTHER|Renal Diet App|Individualized dietetic counseling aided with a newly developed renal diet app for educative purpose and aiding tool to enhance the dietary adherence among CKD patients. Training on the use of the app will be provided to the subjects prior to the commencement of the intervention. Subjects will be trained on the use of the home screen, icons, feedback screens, the process of entering dietary and fluid intake data and selecting portion sizes. Subjects are considered as competent users when they could correctly record the foods and drinks with correct portion size eaten in the past 24 hours and successfully save the data.
224118976|NCT04436627|DEVICE|Amadeo-assisted training-1|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes active assistive training mode, followed by 20 minutes RT functional games (grasp and release) and 20 minutes RT finger coordination training.
224118977|NCT04436627|DEVICE|Amadeo-assisted training-2|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 10 minutes continuous passive motion mode followed by 20 minutes active assistive training mode, and 30 minutes RT functional games (grasp and release).
223727254|NCT04830774|DEVICE|ILR, PMK, ICD|"* Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~* Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions"
223727255|NCT04606082|DRUG|Granulocyte Colony Stimulated Factor|GCSF was intrauterine injected once at ovum pick up day
223727256|NCT04606082|DRUG|Human Chorionic Gonadotropins|500 IU of HCG was injected intrauterine once at ovum pick up day
223727257|NCT05015465|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for juvenile SLE patients and compare them with normal subjects
223727258|NCT02292602|BEHAVIORAL|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
223727259|NCT02733939|DEVICE|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~* leaves the home without notice, since this might occur in a moment of disorientation;~* leaves a water tap open;~* forgets something on the stove;~* gets out of bed during the night and doesn't come back within a certain time interval;~* never goes to the bathroom in 24 hours;~* never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~* automatically turn on a light to help avoid a fall during the night;~* alert the caregiver when the temperature in the house falls or rises excessively;~* act as burglar alarm in some areas of the home."
223727260|NCT01414010|DIETARY_SUPPLEMENT|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
223727261|NCT01414010|DIETARY_SUPPLEMENT|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
223727262|NCT01414010|DRUG|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
223727263|NCT05950009|OTHER|No intervention (observational studies)|No intervention (observational studies)
223727264|NCT06074315|DEVICE|Nail Genesis DLSO Product|Nail fungus is difficult to treat with topical drugs because of the thickness of the nails (Murdan, 2002). Nail Genesis DLSO Product does not contain a drug or antifungal agent and so is not designed to have a direct action on the microorganism, but instead will act by changing the conditions that allow growth of the fungus (i.e., keeping the nail plate and underlying nail bed dry and inhibiting secondary infection).
223727265|NCT06074315|DEVICE|Nail Genesis DLSO Product (vehicle only)|The Nail Genesis DLSO product poly-urethane vehicle
223981507|NCT06956872|OTHER|Printed Nutrition Pamphlet|After the counseling session, a standardized renal nutrition pamphlet prepared by dietitians from Universiti Putra Malaysia and Hospital Serdang will be given for patient's educative purpose. Since the mobile application is intended for patient's education and self-monitoring (food diary) purposes, and thus, to ensure the comparability between intervention and control groups, the patients in control group will be trained to record their diet intakes manually using the recommended approach 3-day diet records. Nutritional feedback or advices on the diet records will be given to the participants during follow up sessions.
223981508|NCT04581408|DRUG|Lumacaftor / Ivacaftor, Orkambi® Oral Tablet|"Total daily dose: 800 mg of Lumacaftor and 500 mg of Ivacaftor.~Duration of treatment: according to the clinical conditions of the patient and based on the response to the drugs: up to a maximum of 7 days"
223981509|NCT05097209|DRUG|Camrelizumab|Camrelizumab 200mg will be given every 3 weeks for 3 cycles started on day 1 of induction chemotherapy and every 2 weeks for 9 cycles thereafter.
223981510|NCT05097209|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation
223981511|NCT05097209|DRUG|Induction Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation
223981512|NCT05097209|RADIATION|intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
223727266|NCT02350790|PROCEDURE|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
223727267|NCT02350790|PROCEDURE|Robotic excision|Robotic excision of endometriosis
223727268|NCT03466008|BEHAVIORAL|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
223981513|NCT05097209|DRUG|Concurrent cisplatin|Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
223981514|NCT04633954|DRUG|Brimonidine Tartrate 0.15% Oph Soln|One drop of Brimonidine Tartrate 0.15% Oph Soln prior to FLACS
223981515|NCT04472845|RADIATION|1 week RT|RT will be delivered over 1 week
223981516|NCT04472845|RADIATION|2 week RT|RT will be delivered over 2 week
223727269|NCT00461162|BEHAVIORAL|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
223981517|NCT05764551|DIAGNOSTIC_TEST|Serum DNA methylation|Serum DNA methylation
223981518|NCT05559879|DRUG|Cabo + Dostarlimab|Combination of standard dose of cabozantinib and 500 mg dostarlimab for first 4 cycles followed by standard dose of cabozantinib and 1000 mg of dostarlimab until 2 years of treatment
223727270|NCT00461162|BEHAVIORAL|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
223981519|NCT06956898|OTHER|Mindfulness Training|Primiparous pregnant women in the experimental (mindfulness) group will be given training for 8 weeks starting from the 28th week.
223981520|NCT06956898|OTHER|Haptonomy Training|Primiparous pregnant women in the experimental (mindfulness) group will be given training for 8 weeks starting from the 28th week.
223981521|NCT05611749|DRUG|Duloxetine 60 MG|Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
223981522|NCT05611749|OTHER|Placebo|Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
223981523|NCT02948569|DRUG|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
223981524|NCT00522743|DRUG|growth hormone and gonadotropin-releasing hormone agonist|GH \& GNRHa treatment
223981525|NCT00522743|DRUG|growth hormone|GH treatment
223981526|NCT06573346|OTHER|Cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
223981527|NCT06548217|DRUG|ONO-4538HSC|ONO-4538HSC will be administered subcutaneously once every 4 weeks.
223727271|NCT00461162|BEHAVIORAL|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
223981528|NCT01951378|DEVICE|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS \> 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
224118978|NCT04436627|DEVICE|Amadeo-assisted training-3|Participants will receive 12-15 intervention sessions for about 3 consecutive weeks in a clinical setting (1 hour per session, 4-5 sessions per week). For each intervention session, participants will first receive 20 minutes continuous passive motion mode followed by 20 minutes active assistive training mode. After 40 minutes of RT, 20 minutes functional tasks without robot.
224118979|NCT03677687|BEHAVIORAL|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
224118980|NCT02469831|DRUG|Rocuronium|
224118981|NCT01943734|BEHAVIORAL|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
224118982|NCT02235116|OTHER|Survey|
223727272|NCT02142959|DRUG|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
223727273|NCT02142959|DRUG|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
223727274|NCT02142959|DRUG|Vehicle Lotion|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
223727275|NCT02142959|RADIATION|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
223727276|NCT04495348|DRUG|Doravirine|Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.
223727277|NCT04742296|DEVICE|low level laser therapy|We will use laser light that has continuous wave mode, power of 100 mW, energy density of 7,5 joule/cm2, treatment time as 300 seconds.
224118983|NCT04175704|DRUG|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
224293828|NCT07211672|DEVICE|Multichannel functionnal electrical stimulation|"The participants completed 24 gait rehabilitation sessions over the course of 8 to 12 weeks. Each session lasted between 30 minutes and 1 hour. A minimum of 2 days seperated two consecutive sessions. The number of sessions was used for standardization of the protocol instead of duration of treatment.~Four evaluations were completed throughout the protocol. Baseline evaluation(V1) was completed between 2 and 7 days before the first rehabilitation session. Intermediate evaluation(V2) was completed between 2 and 7 days after the 12th rehabilitation session, in other words 4 to 6 weeks after the baseline evaluation (V1) . Post-treatment evaluation(V3) was completed between 2 and 7 days after the 24th rehabilitation session, in other words 8 to 12 weeks after the baseline evaluation (V1). Follow-up evaluation(V4) was completed 2 months(60 days) after the 24th rehabilitation session, in other words 16 to 20 weeks after the baseline evaluation (V1)."
223727278|NCT00088478|DRUG|Intramuscular Olanzapine Depot|
224293829|NCT05544032|DRUG|axatilimab|Treatment with axatilimab includes receiving intravenous (IV) doses of axatilimab every 2 weeks
224293830|NCT04301076|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
224293831|NCT04301076|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224293832|NCT04301076|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
224293833|NCT04301076|DRUG|Cyclophosphamide|Given IV
224293834|NCT04301076|DRUG|Doxorubicin Hydrochloride|Given IV
224293835|NCT04301076|DRUG|Etoposide|Given IV
224293836|NCT04301076|DRUG|Lenalidomide|Given PO
223727279|NCT00088478|DRUG|Placebo|
224293837|NCT04301076|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224293838|NCT04301076|DRUG|Prednisone|Given PO
224293839|NCT04301076|DRUG|Vincristine Sulfate|Given IV
224293840|NCT05236192|BEHAVIORAL|Take Root Home Visitation (TRHV)|TRHV is a home-visiting, standardized program that home visitors can use to structure their time spent with families during home visits.
224293841|NCT05236192|BEHAVIORAL|Services as Usual (SAU)|SAU includes an installation's current NPSP home visiting practice, which may vary across the installations participating in this study.
224293842|NCT02386800|DRUG|ruxolitinib|ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
223981529|NCT01951378|DEVICE|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
223981530|NCT01951378|DRUG|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
223981531|NCT00487318|DRUG|standard of care|peginterferon/RBV
223981532|NCT00487318|DRUG|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
223981533|NCT03163043|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
223981534|NCT01854736|DRUG|Grazax|GRAZAX
224293843|NCT02386800|DRUG|panobinostat|panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
224293844|NCT04870762|OTHER|Best Practice|Receive standard of care
223981535|NCT01854736|OTHER|Placebo|Placebo
223981536|NCT06177899|PROCEDURE|Splitting of bone and fixation of bone laminae differ between the 3 groups.|In split-box technique, all osteotomies were made using with piezoelectric surgery. Horizontal and vertical osteotomies were performed 1.5 mm away from adjacent teeth. Lower border osteotomy of the vestibular cortical bone was performed. A chisel osteoma was used to separate completely and mobilize the segmented bone. This separated, corticocancellous block was stabilized on the distance to the native alveolar crest with micro screws. The space between the block and the alveolar crest was filled with allograft. In reverse split box technique, differs from the split-box technique as follows: it involves reversing the separated corticocancellous bone block before fixation. In sliding split box technique, differs from the split-box technique as follows: horizontal osteotomy is performed at the level where the bone thickness reaches at least 3 mm. Separated corticocancellous bone block is slid toward the coronal of alveolar crest and fixed in line with the native alveolar bone.
223981537|NCT00385099|DRUG|GW876008|
223981538|NCT05735743|BEHAVIORAL|Motivational interviewing|In this trial, motivational interviewing (MI) is the intervention. The MI sessions will embody the spirit of MI (PACE - Partnership, Acceptance, Compassion and Evocation) and the use of MI strategies (OARS - Open-ended questions, Affirmations, Reflections and Summaries) and MI communication processes (engagement, focusing, evoking and planning).
223981539|NCT02585297|OTHER|no intervention|
223981540|NCT06078566|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
223981541|NCT01122563|DRUG|Solifenacin|oral
223981542|NCT05032404|DEVICE|BNT103|BNT-103™ is a prescription digital therapeutic specifically designed to treat the symptoms of anxiety and depression related to cancer. There are 10 sessions provided over approximately 10 weeks.
224293845|NCT04870762|OTHER|Medical Device Usage and Evaluation|Wear 3D printed oral stent
224293846|NCT05047172|DRUG|Ticagrelor + Aspirin|ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
224293847|NCT05047172|DRUG|Rivaroxaban + Aspirin|low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
224293848|NCT05047172|DRUG|Clopidogrel + Aspirin|clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
224293849|NCT05047172|OTHER|Risk Factor Management|Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
224293850|NCT06604871|DEVICE|Insulin Pump with Continuous Glucose Monitoring|MiniMed™ 780G insulin pump in combination with the DS5 CGM
224293851|NCT06444412|PROCEDURE|Computed Tomography|Undergo PET/CT
224293852|NCT06444412|OTHER|Electronic Health Record Review|Ancillary studies
224293853|NCT06444412|DRUG|Ga 68 PSMA-11|Contrast dye given IV
224293854|NCT06444412|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224293855|NCT05886036|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224118984|NCT04778267|DRUG|Bupivacaine Hydrochloride|We hypothesize that combined ESPB and PIPB are as effective as TPVB in controlling perioperative pain in patients undergoing modified radical mastectomy (MRM) with lesser complications using bupivacaine hydrocloride
223981543|NCT04943354|BEHAVIORAL|Taking a person's venous blood|Collection of 5 ml of the patient's venous blood, carried out according to standard rules.
223981544|NCT00464945|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
223981545|NCT03831854|DRUG|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P\<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P\<.05).
223981546|NCT03831854|DRUG|Placebo|300 mg of oral Placebo
223981547|NCT03831854|DRUG|Ketamine|1mg/kg bolus at induction followed by 5 microgram/kg/min infusion till the end of the surgery
223981548|NCT01642953|DIETARY_SUPPLEMENT|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
223981549|NCT00021047|DRUG|capecitabine|
223981550|NCT00021047|DRUG|carboplatin|
224293856|NCT05886036|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223981551|NCT00021047|DRUG|epirubicin hydrochloride|
223981552|NCT05253859|OTHER|No intervention|Registry study: No intervention
223981553|NCT03067545|OTHER|Step rate increase|increase the step rate during running by 10% steps per minute
224118985|NCT04778267|DRUG|Dexamethasone phosphate|used as additive to bupivacaine
224293857|NCT05886036|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224293858|NCT05886036|PROCEDURE|Computed Tomography|Undergo PET/CT
224293859|NCT05886036|OTHER|Fludeoxyglucose F-18|Receive FDG
224293860|NCT05886036|BIOLOGICAL|Mosunetuzumab|Given SC
223981554|NCT04654962|PROCEDURE|Anesthetic nerve block|iliac fascia block is an analgesic technique that uses local anesthesia, is effective and relatively safe in preoperative management. The target of this block is the femoral and lateral femoral cutaneous nerves; which innervate the anterior aspect of the thigh, as well as the muscle and periosteum that covers the femoral head, neck and proximal femur.
223981555|NCT04293952|OTHER|Balance, Resistance, Aerobic, Cognition Exercises (BRACE)|BRACE is a combination of different exercises including Balance, Resistance, Aerobic, Cognition for fall risk reduction and to mobility in the elderly.
223981556|NCT04293952|OTHER|Balance Resistance Exercise (BRE)|this is the simple conventional treatment for the elderly in balance problems including warm-up, resistance exercises and cool-down exercises.
223981557|NCT06624839|BIOLOGICAL|Human papillomavirus (HPV) vaccine, 9-valent|0.5 ml intramuscular injection
223981558|NCT03925077|OTHER|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
224118986|NCT04310150|DRUG|Collastat|hemostatic agent that combine porcine-derived collagen thrombin
224118987|NCT04310150|DEVICE|Floseal|hemostatic agent that combine bovine-derived gelatin
224118988|NCT02709434|BEHAVIORAL|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
224118989|NCT02709434|OTHER|Standard care|Usual IBD management
224118990|NCT00415714|DEVICE|Portable Biofeedback|
224118991|NCT02184143|BEHAVIORAL|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
224118992|NCT02184143|OTHER|Education|Patient education
224118993|NCT04506827|PROCEDURE|Maxillary Sinus Augmentation|Biomaterial Graft into the Maxillary Sinus
224118994|NCT04506827|DEVICE|Maxillary Sinus Graft with ABBM|The maxillary sinuses in the control group are grafted with ABBM
224118995|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP|The maxillary sinuses in the test1 group are grafted with TCP
224118996|NCT04506827|DEVICE|Maxillary Sinus Graft with TCP + HA|The maxillary sinuses in the test1 group are grafted with TCP + HA
224118997|NCT03491722|OTHER|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
224118998|NCT00602316|DRUG|gadolinium-chelate|
224118999|NCT00602316|PROCEDURE|conventional surgery|
224119000|NCT00602316|PROCEDURE|magnetic resonance imaging|
224293861|NCT05886036|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224293862|NCT05886036|BIOLOGICAL|Rituximab|Given IV
224293863|NCT05886036|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
224293864|NCT06067828|DRUG|Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BGF MDI via oral inhalation twice daily (BID).
223981559|NCT03925077|OTHER|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
223981560|NCT01134471|DEVICE|Ostene|applied to sternal surface
223727280|NCT03547687|DEVICE|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
223981561|NCT01134471|DEVICE|Bonewax|applied to sternal surface
223981562|NCT02851875|OTHER|Registry|
223981563|NCT03065933|DRUG|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
223981564|NCT02536742|DRUG|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
223981565|NCT02536742|DRUG|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
223981566|NCT03559790|DRUG|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
223981567|NCT05444036|DRUG|Ketamine|compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
223981568|NCT04173702|DIAGNOSTIC_TEST|balance analysis|Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
223727281|NCT03547687|DEVICE|Neuromuscular Electrical Stimulation Treatment|"If a muscle contraction is not produced with the Intelect NMES portable device, the Vectra Neo Clinical Therapy System (Chattanooga Group) device will be used instead. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 10 seconds on, 30 seconds off Ramp up and down time: 2 seconds each"
223981569|NCT04629443|DRUG|S 64315 (also referred as MIK665) and azacitidine|"The combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) administered via intravenous (IV) infusion over at least 2 hours.~During the combination treatment period S64315 will be administered according to a dose escalation scheme starting at 50 mg up to 250 mg might be explored. The schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen of azacitidine administered at 75 mg/m² via subcutaneous (SC) injection for 7 days from D1 to D7 of each cycle followed by a rest period of 21 days."
223981570|NCT06553807|OTHER|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes.|The intervention group, which was randomly selected by randomisation and accepted to participate in the study, is planned to receive 3-week training sessions between 30-45 minutes. Pre-test and post-test will be applied to the participants after 4 weeks. Follow-up test data will be collected from the intervention and control groups after 3 months.
223981571|NCT00258362|DRUG|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
223981572|NCT00258362|DRUG|docetaxel|75 mg/m\^2 on Day 1 of each course
223981573|NCT00258362|RADIATION|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
223981574|NCT01547117|RADIATION|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called CO rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
223981575|NCT01547117|RADIATION|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 microcuries of radiation, blood samples are drawn before and 30 minutes after injection.
223981576|NCT01547117|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
223727282|NCT01691001|DRUG|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
223727283|NCT01691001|DRUG|normal saline|
223544007|NCT01361217|DRUG|Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan|"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."
223544008|NCT05110573|PROCEDURE|pancreatoduodenectomy|Patients included in the cohorts all underwent pancreatoduodenectomy, open or laparoscopic
223544009|NCT04256473|DRUG|mutant pro-urokinase|Intravenous administration
223544010|NCT04256473|DRUG|Alteplase|Intravenous administration
223544011|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
224119001|NCT00602316|PROCEDURE|magnetic resonance spectroscopic imaging|
224119002|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
223544012|NCT01050751|DRUG|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
223544013|NCT04314245|OTHER|Active Comparator: Pathology|Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
223981577|NCT01547117|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
223981578|NCT06301347|BEHAVIORAL|Learning through Play Plus|Combination of two interventions: Learning through Play and Cognitive Behaviour Therapy
223981579|NCT03437941|DRUG|CORT125281|CORT125281 is supplied as capsules for oral dosing
223981580|NCT03437941|DRUG|Enzalutamide (Xtandi)|Enzalutamide will be taken orally
223981581|NCT03437941|DRUG|Placebo|Placebo capsules to match the appearance of the CORT125281
223981582|NCT05907317|DEVICE|Cerebral oximetry monitoring device|Participants in the experimental group will be monitored with cerebral oximetry, if possible before or, as soon as possible and within six hours after initiation of invasive mechanical ventilation. Cerebral oximetry will be continued until 1) the cardio-pulmonary function has been stabilised as indicated by the need for respiratory and circulatory support and evaluated by the responsible physician, 2) extubation, 3) until 28 days after birth, or 4) until death. Randomisation will only direct the use of cerebral oximetry during the first invasive mechanical ventilation episode. Cerebral oximetry will be used to minimise cerebral hypoxia by modifying clinical care according to the SafeBoosC treatment guideline and monitoring as usual.
223981583|NCT05907317|OTHER|Usual care|Treatment as usual
223981584|NCT04481646|DIAGNOSTIC_TEST|Face mask sampling|Mask sampling consists of a modified face mask (flat surgical, duckbilled or FFP1) which contains up to strips of 3D printed Polyvinyl alcohol (PVA). As outlined in our previous work (ref lancet). These PVA strips are manufactured by the University of Leicester and measure approximately 50mm x 500mm and are fixed into place by adhesive pads. Mask assembly is conducted at the University of Leicester and are sterilised prior to use. Figure 3 and 4 shows examples of the inside of the mask with 4 strips placed inside and of how it is worn by study participants. The mask sampling system has been approved for previous studies in the UK, South Africa and The Gambia and has current approval for service improvement work at University Hospitals of Leicester NHS Trust for respiratory pathogens. It is awaiting approval as a medical device with the Medicines and Healthcare products Regulatory Agency.
223981585|NCT03239418|DEVICE|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
223981586|NCT03239418|DEVICE|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
223981587|NCT02024295|DRUG|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
223981588|NCT02024295|DRUG|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
223981589|NCT02024295|DRUG|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
223981590|NCT03563625|PROCEDURE|Caudal block|Caudal block/bupivacaine 0.25%
223981591|NCT03563625|PROCEDURE|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
223981592|NCT03563625|DRUG|Bupivacaine|bupivacaine
223981593|NCT04340765|DRUG|18F-fluorocholine|Dual phase 18F-fluorocholine PET/CT
223981594|NCT02367430|BEHAVIORAL|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
223981595|NCT03234712|DRUG|ABBV-321|Intravenous infusion
223981596|NCT00568698|DRUG|Hydroxyurea|
223981597|NCT00568698|DRUG|Placebo to match hydroxyurea|
223981598|NCT01759147|PROCEDURE|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
223981599|NCT02904785|DEVICE|Extracorporeal Shock Waves|
223981600|NCT02904785|DEVICE|Sham Extracorporeal Shock Waves|
223544014|NCT04314245|OTHER|Active Comparator: Clinical Diagnosis|Routine clinical diagnosis and treatment of benign disease of the urinary system
223981601|NCT02904785|OTHER|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
223981602|NCT04285047|OTHER|Advancing Patient Experience (APEX) in COPD|Involves both EMR and PRIO data
223981603|NCT05421156|PROCEDURE|Subtotal Laparoscopic Hysterectomy|Subtotal laparoscopic hysterectomy involves removing the main body of the uterus and leaving the cervix in place by laparoscopy.
223981604|NCT05421156|PROCEDURE|Total Laparoscopic Hysterectomy|Total laparoscopic hysterectomy involves removing the whole uterus and cervix by laparoscopy
223981605|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
223981606|NCT01038453|OTHER|placebo tablet|placebo 2 tablet, once a day,
223981607|NCT01038453|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
223981608|NCT05328024|DRUG|Immunotherapy|anti-PD1
223981609|NCT06027229|BIOLOGICAL|NVX-CoV2372|Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
223981610|NCT03491215|DRUG|Ruxolitinib|All enrolled pediatric participants received ruxolitinib as a 5 mg tablet (adult and adolescent formulation) or an oral pediatric formulation (administered as oral solution or capsule dispersed in liquid).
223981611|NCT01855347|DEVICE|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
223981612|NCT05384145|OTHER|COAST-AL|This combination intervention includes three CDC evidence based interventions: (1) a data-driven approach to direct Community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART Start program, all in MCHD jurisdictions in Alabama
223981613|NCT04456244|OTHER|Evaluation of the static posture|Photographing from the back, front and side with ADIBAS posturography in standing position
223981614|NCT04585737|DRUG|Dolutegravir / Lamivudine Pill|Experimental
223981615|NCT04585737|DRUG|Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill|Active comparator
223981616|NCT06512220|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with or without risperidone 1 mg. It will also be administered in conjunction with supportive therapy.
223981617|NCT06512220|DRUG|Risperidone 1 MG|The risperidone is encapsulated using a cellulose capsule and contains 1 mg of risperidone. The risperidone will be administered once during the trial in combination with psilocybin 25 mg. It will also be administered with supportive therapy.
223981618|NCT00058942|DEVICE|home drinking water treatment device|
223981619|NCT05031468|BIOLOGICAL|Licensed or EUA SARS-CoV-2 vaccine|Several SARS-CoV-2 vaccines utilizing different platforms (e.g., mRNA, viral vector, etc.), are available under EUA (and soon to be licensed) and are being administered to individuals who are pregnant or postpartum who belong to high-risk priority groups for vaccination. Participants will receive the SARS-CoV-2 vaccine of their choice or the type that is available to them. The researchers anticipate including up to 3 vaccines, whether given as part of the primary series or additional doses, as part of this non-interventional study.
223981620|NCT05648318|DRUG|Lactulose oral solution|In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
223981621|NCT05648318|DRUG|PEG|patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
223981622|NCT00500981|PROCEDURE|Volume challenge|
223981623|NCT00500981|PROCEDURE|Ultrasound evaluation of internal jugular vein|
223981624|NCT03096197|DEVICE|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
223981625|NCT03096197|DEVICE|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
223981626|NCT02913170|DIETARY_SUPPLEMENT|Nattokinase|
223981627|NCT02913170|DIETARY_SUPPLEMENT|Placebo|
223981628|NCT00210678|BEHAVIORAL|No intervention|No treatment is given to the patients as this is an observational study.
223981629|NCT06433440|BIOLOGICAL|PVRV|Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
223981630|NCT06286878|DRUG|Placebo|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
223981631|NCT06286878|DRUG|Dapagliflozin|Patients will be randomized to use dapagliflozin or placebo in a double-blind way
223981632|NCT03596463|OTHER|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
223981633|NCT06407583|BEHAVIORAL|ProMIO2.0 program|"ProMIO2.0 is a lifestyle intervention carried out by physiotherapy and dietetics. They guide and encourage the participants to achieve the following behavioral goals:~* moderate/intensive exercise (e.g. walking) for 150-300 minutes per week~* Muscle-strengthening exercises 2x a week~* Supplemented with balance and flexibility exercises~* 1.2 grams of protein per kilogram of body weight per day (\~25-30 grams of protein per meal, 4x/day) The combination of consultations, information sessions and on-site training at the physiotherapist should ensure that participants acquire the necessary knowledge, awareness and skills to adopt the health behavior in daily life. Materials such as posters, pedometers and videos are used for support.~The intervention is divided into 2 phases, which indicate the degree of professional guidance:~1. intensive guidance (month 0 - 3)~2. average guidance (months 4 - 6)"
223981634|NCT04067908|OTHER|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
223981635|NCT01046591|PROCEDURE|Polysomnography|Overnight sleep studies will be performed on all children.
223981636|NCT02176564|DRUG|inhaled bronchodilator|
223981637|NCT05789550|DIAGNOSTIC_TEST|ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY|"1. Full clinical history with detailed history about T2DM (its duration and treatment).~2. Full medical examination, including BMI using the formula: weight (kg)/height (m2).~3. Laboratory investigation, including the following:~   1. Complete blood picture.~  2. Fasting blood sugar (FBS).~  3. Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).~  4. HbA1c.~  5. Kidney function tests (serum creatinine and blood urea).~  6. Liver function tests (serum albumin, ALT, and AST).~  7. Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool"
223981638|NCT05130346|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|Participants will be asked to attend group meetings for mindfulness training. Each meeting will last approximately one hour and will take place online via Zoom. The meetings will occur on a weekly basis, over an 8-week period.
224119003|NCT00321984|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
224119004|NCT00321984|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
223727284|NCT02892071|DRUG|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
223981639|NCT06007105|BEHAVIORAL|SUCCEED Community-Based Intervention|"The main components of the intervention are peer support, case management and livelihoods activities, delivered by a peer support worker and a community support worker. The peer support worker has lived experience of psychosis and draws on a variety of manualised tools and techniques adapted from previous studies. The community support worker mobilises families and communities to activate resources in support of participants (e.g., education and employment, social and recreational activities), drawing on established models of mental health case management and community-based inclusive development. The peer support worker and community support worker also run self-help groups for people with lived experience and their family members, respectively. Self-help group meetings are also used as an opportunity for group livelihoods activities taking an ABCD (asset-based community development approach."
223981640|NCT01168245|DEVICE|Sham-NICE-System|sham TMS and sham cognitive training
223981641|NCT01168245|DEVICE|NICE-System|TMS combined with cognitive training
223981642|NCT00595647|DEVICE|Drug eluting stent|Implantation of stent
223981643|NCT00595647|DEVICE|Bare metal stent|Implantation of stent
223981644|NCT01624298|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
223981645|NCT01168336|DRUG|Betahistine standard formulation|betahistine 24 mg tablets
223981646|NCT01168336|DRUG|Betahistine Extended Release formulation|betahistine 32 mg tablets
223981647|NCT01168336|DRUG|Placebo|matching placebo
223981648|NCT03807817|OTHER|Alcohol administration|Amount of alcohol to be administered.
223981649|NCT03807817|OTHER|Placebo|Placebo Alcohol
223981650|NCT03807817|OTHER|No Alcohol|No Alcohol
223727285|NCT02892071|DEVICE|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
223981651|NCT02571998|DRUG|Omiganan (CLS001) Topical Gel|
223981652|NCT02571998|DRUG|Vehicle Topical Gel|
223981653|NCT04409522|DRUG|Melatonin|Participants in this group, in addition to receiving the usual treatment of COVID-19, will receive a 9 mg dose of melatonin for seven to ten nights.
223981654|NCT04409522|DRUG|The usual treatment|Participants in this group will receive the usual treatment of COVID-19
223981655|NCT04678765|PROCEDURE|Ultrasound-guided distal peripheral nerve block|"To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease."
223981656|NCT04678765|PROCEDURE|Ultrasound-guided quadruple-injection axillary nerve block|"The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited."
223981657|NCT00639977|OTHER|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
223981658|NCT00639977|OTHER|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
223981659|NCT03723122|BEHAVIORAL|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
223981660|NCT03862209|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
223981661|NCT03635840|DEVICE|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
223981662|NCT02627898|DRUG|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
223981663|NCT02627898|DRUG|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
223981664|NCT05159986|PROCEDURE|Group that received aplication of Diadynamic currents associated to Exercise during eight weeks with three sessions a week|Diadynamic currents was performed followed by exercises (divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week).
223981665|NCT05159986|OTHER|Group that received exercise during eight weeks with three sessions a week|The intervention was divided into Phase-1, Phase-2 and Phase-3 during eight weeks with three sessions a week. Each session lasted 45 minutes.
223981666|NCT00120575|PROCEDURE|hemofiltration|
223981667|NCT02869945|GENETIC|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
223981668|NCT02869945|OTHER|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
223981669|NCT02869945|OTHER|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
223981670|NCT02414347|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223981671|NCT04991350|DRUG|Intravitreal ranibizumab|Intravitreal injection of 0.3 mg/0.05 ml ranibizumab will be performed monthly for 3 months.
223981672|NCT04991350|DRUG|Intravitreal bevacizumab|Intravitreal injection of 1.25 mg/0.05 ml bevacizumab will be performed monthly for 3 months.
223981673|NCT01558323|DRUG|LCQ908|Participants will receive a single oral dose of LCQ908
223981674|NCT00766402|DRUG|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
223544015|NCT04314245|OTHER|Active Comparator: Clinical diagnosis|Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
223981675|NCT00766402|DRUG|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
223544016|NCT04314245|OTHER|Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay|A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
223981676|NCT04205656|BIOLOGICAL|Leukocyte-Poor Platelet Rich Plasma (LP-PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the vein.
223981677|NCT04205656|BIOLOGICAL|Bone Marrow Concentrate (BMC)|Participants will have a knee injected with BMC stem cells harvested from the iliac crest
223981678|NCT04205656|OTHER|Control group (Placebo)|Participants will undergo ACLR surgery with no injection into their knee.
223981679|NCT03619798|DEVICE|HemoTypeSC|Point-of-Care Rapid Test for Detection of Sickle Cell Disease-Relevant Hemoglobin Phenotypes in Whole Blood
223981680|NCT01007006|DEVICE|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
223981681|NCT01238393|DRUG|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
223981682|NCT03984175|PROCEDURE|Implementation of Processes|Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
223727286|NCT02892071|DEVICE|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
223727287|NCT01033591|BEHAVIORAL|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
223727288|NCT01033591|BEHAVIORAL|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
223727289|NCT03972553|PROCEDURE|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
223727290|NCT03972553|PROCEDURE|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
223981683|NCT05605561|OTHER|Digital Story|It is the standard of care given according to the hospital's policies and procedures.
223981684|NCT04456712|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution|antibiotic
223981685|NCT04456712|DRUG|Levofloxacin 750 MG|antibiotic
223981686|NCT05370729|DRUG|N-acetyl cysteine|Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
223981687|NCT05975632|DEVICE|Device: Self testing Potassium device|"Calibration Phase (1 visit) (Hemodialysis patients and subjects not on dialysis) Each patient will have one venous blood collection. Among them, one 30 patients one capillary sample is collected. In this phase, the HCP is the user of the device.~Comparison Phase~For subject not on dialysis (total 2 visits):~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test~For Hemodialysis patients (total 1 visit) :~Each patient will have one venous blood collection per visit Each patient will be equipped with CardioRenal device and trained to do the self-test"
223981688|NCT01336205|DRUG|NKTR-118|25 mg oral tablet once daily
223981689|NCT01336205|DRUG|Usual care|As prescribed by the investigator
223981690|NCT03629470|OTHER|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
223981691|NCT03629470|OTHER|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
223981692|NCT01006616|DRUG|Navarixin|Navarixin 10 mg and 30 mg capsules
224119005|NCT03560193|DRUG|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
224119006|NCT03560193|DRUG|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
223981693|NCT01006616|DRUG|Placebo|Placebo to navarixin capsules
223981694|NCT01006616|DRUG|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
223981695|NCT00462111|DRUG|Indometacin|
223981696|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
223981697|NCT01008163|DRUG|YY-351/Placebo|comparison of different dosages of drug
223981698|NCT01008163|DRUG|YY-351|comparison of different dosages of drug
223981699|NCT01008163|DRUG|Placebo|comparison of different dosages of drug
223981700|NCT03943836|BEHAVIORAL|Music|Patients in the music group will listen to classical music during their dental procedure.
223981701|NCT01061190|DRUG|Propranolol|oral application of 160 mg Propranolol for 30 days
223981702|NCT00089830|DRUG|MSI-1256F (Squalamine Lactate)|
224119007|NCT01593683|BEHAVIORAL|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
224119008|NCT05888428|DEVICE|MyoTrain|MyoTrain is a virtual prosthesis control training system. From a hardware perspective it consists of an Apple iPad tablet computer and an eight-channel EMG armband, based on the Element electrode platform, which interfaces with the tablet via Bluetooth™. From a software perspective, MyoTrain was developed in the cross-platform Unity 4.0 game development environment.
224119009|NCT05888428|BEHAVIORAL|Motor Imagery|Motor imagery describes the process by which a prosthesis user mentally simulates the execution of a desired limb movement and activates the musculature of the residual limb that would generate the desired movement.
224119010|NCT01488318|DRUG|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
224119011|NCT01488318|DRUG|Dasatinib|Dasatinib 150 mg po
224119012|NCT00003342|BIOLOGICAL|filgrastim|
224119013|NCT00003342|DRUG|carboplatin|
224119014|NCT00003342|DRUG|doxorubicin hydrochloride|
224119015|NCT00003342|DRUG|gemcitabine hydrochloride|
224119016|NCT00003342|DRUG|paclitaxel|
224119017|NCT05545267|PROCEDURE|Angioplasties|Transluminal angioplastie
224119018|NCT02946879|BIOLOGICAL|AAV OPTIRPE65|comparison of different doses of AAV RPE65
223727291|NCT01112241|DRUG|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
223727292|NCT00400751|BEHAVIORAL|FAMCON (Family Consultation)|
223981703|NCT02482935|DRUG|Abemaciclib|Administered orally
223981704|NCT05383625|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|intralesional 0.1 ml every two weeks
223981705|NCT05383625|DRUG|Bivalent Human Papilloma Virus Vaccine|Intralesional 0.1 ml every two weeks
223981706|NCT05383625|DRUG|Saline|intralesional into the largest warts every two weeks
223981707|NCT00270036|DRUG|epoetin alfa|
223981708|NCT04360798|OTHER|Unilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants exercises will only be done for 60 minutes with the affected lower extremities.
223981709|NCT04360798|OTHER|Bilateral Exercise Group|Exercise programs will be practiced 60 days, 2 days a week for 4 weeks. The entire exercise protocol will be carried out under the supervision of a physiotherapist. During the treatment session, participants will complete their exercises with both lower extremities for 30 minutes.
223981710|NCT03421405|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
223981711|NCT01163955|OTHER|Time to fatigue|5 minutes while playing video games
223981712|NCT02000128|DEVICE|bioimpedance monitoring|To assess the body composition using Multi-frequency bioelectrical impedance analysis
223981713|NCT02000128|OTHER|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
223981714|NCT00229762|BEHAVIORAL|phone call from nurses - informational only|
223981715|NCT01341249|DRUG|Experimental DW224aa|DW224aa tablet, single dose
223981716|NCT01341249|DRUG|Experimental DW224a|DW224a capsule, single dose
223981717|NCT03562429|DRUG|TGF|TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
223981718|NCT03562429|DRUG|TGFP|TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
223981719|NCT01187745|OTHER|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
223981720|NCT00156923|DRUG|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
223981721|NCT00156923|DRUG|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
223981722|NCT01585298|DRUG|FTY720|
223981723|NCT04699097|DRUG|Azithromycin|250 mg tablet, 5 ml / 200 mg 30 ml suspension
223981724|NCT06064370|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy for pheochromocytoma
223981725|NCT05294718|PROCEDURE|Internal shunt|glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.
223981726|NCT05294718|PROCEDURE|External shunt|Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
223981727|NCT00757978|DRUG|memantine|memantine 10mg twice a day
224119019|NCT06484530|DRUG|N acetyl cysteine|1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
223544017|NCT02701244|RADIATION|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
223981728|NCT00757978|DRUG|placebo|1 capsule of placebo twice a day
223981729|NCT02625571|BEHAVIORAL|Phase-based treatment of sexual behavior problems of children|
223981730|NCT00519064|BIOLOGICAL|Adjuvanted influenza vaccine|
224293865|NCT06067828|DRUG|Treatment B: Budesonide and Formoterol Fumarate|Randomized participants will receive 2 inhalations of BFF MDI via oral inhalation BID.
224293866|NCT06067828|DRUG|Treatment C : Placebo|Randomized participants will receive 2 inhalations of placebo MDI via oral inhalation BID.
223544018|NCT02325024|DRUG|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
223544019|NCT03940989|OTHER|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
223981731|NCT02508779|BEHAVIORAL|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
223981732|NCT02508779|OTHER|Routine Care|Participants will continue to receive care from their clinician.
223981733|NCT03306693|BEHAVIORAL|Emotional skills|2-hour 3 group sessions
223981734|NCT03306693|BEHAVIORAL|Relaxation and talking group|2-hour 3 group sessions
223981735|NCT05029349|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
223981736|NCT03262155|BIOLOGICAL|Blood test|
223981737|NCT01898442|DRUG|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
223727293|NCT01550302|PROCEDURE|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
223981738|NCT01898442|DRUG|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
223981739|NCT01898442|DRUG|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
223981740|NCT05178979|BEHAVIORAL|Training for HIV care providers (effect on provider outcomes)|This training program integrates evidence-based strategies to reduce provider bias, adapted to address gender bias in the context of HIV care in Uganda. The content aims to increase providers' knowledge, motivation, skills, and empathy to equitably deliver Ugandan Ministry of Health ART program guidelines to male and female patients (e.g., increasing awareness of HIV gender disparities, increasing empathy/skills to counsel men and women's gendered barriers to care, promoting shared decision-making). The intervention is delivered in a series of group training sessions with HIV providers.
223981741|NCT00611728|DRUG|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 \& 1/2 hrs on 1st day of each cycle \& then again on days 14 \& 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 \& continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height \& weight. Irinotecan will be given intravenously over 90 min on days 1, 14 \& 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, \& then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, \& then within 1 week prior to completion of every other cycle."
224119020|NCT05164861|DIETARY_SUPPLEMENT|kombucha-based beverage|"kombucha-based beverage: drinking water, black tea, kombucha, inulin, vitamins (B1, B2, B6, niacin, folic acid). Nutritional value in 100 ml: carbohydrates - 2.57 g (including sucrose - 0.22 g, glucose - 1.32 g, fructose - 1.03 g), inulin - 1.15 g (46%\*), vitamin B1 - 0.4 mg (29%\*), B2 - 0.21 mg (13%\*), B6 - 0.48 mg (24%\*), niacin - 2.74 mg (15%\*), folic acid - 24.0 mcg (12%\*). Energy value/Caloric content - 54 kilojoules/13 kcal (\* - % of the recommended daily allowance, according to the Technical regulations of the Customs Union #022/2011). Flavours, identical by nutrient's content and nutrients density: black currant berries \& juniper berries, or strawberries \& lime leaves, or passion fruit \& mango.~Portion's volume - 220 ml. Daily intake: 1 portion"
223727294|NCT01550302|DRUG|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
224119021|NCT06114953|DRUG|Mizoribine|Mizoribine+glucocorticoid+tacrolimus after kidney transplantation
224119022|NCT06114953|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil+glucocorticoid+tacrolimus after kidney transplantation
224119023|NCT00002887|DRUG|cisplatin|
224119024|NCT00002887|DRUG|etoposide|
224119025|NCT00002887|DRUG|hydroxyurea|
224119026|NCT00002887|DRUG|vinblastine sulfate|
224293867|NCT05864287|BEHAVIORAL|Bodies in motion intervention program|Intervention groups will be offered separately to male- and female-identifying athletes; each group will consist of six to eight athletes and multiple groups may be run each academic term. Facilitators will use the gender-specific programs in their delivery. Intervention athletes will receive a participant workbook as well as be invited to join a BIM-specific, private social media platform that will allow them to share, connect, and support each other through out their involvement in the program. As part of our mixed-methods design, we will also conduct qualitative interviews to explore the student athletes' experiences of the BIM program. Following intervention, we will invite 12-16 male and 12-16 female identifying athletes who completed the BIM program to participate in the structured interviews. Interviews will be semi-structured and are expected to last 60-90 minutes
224293868|NCT06529016|DEVICE|Luminopia, a virtual reality headset|Subjects will be provided with the equipment to use in their homes for six hours usage per week (1 hour 6 days a week), for 12 weeks.
224293869|NCT06529016|OTHER|Paper pre- survey|Pre-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
224293870|NCT06529016|OTHER|Paper Survey|Post-survey to be completed by the parent and child. Questions may be skipped. Survey developed by the study team
224293871|NCT06229912|DRUG|Revumenib|Given by PO
223727295|NCT02547454|DRUG|Methoxy polyethylene glycol-epoetin beta|
223727296|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy with proctoring|Implementation standardised laparoscopic right hemicolectomy with proctoring
224119027|NCT00002887|DRUG|vindesine|
224119028|NCT00002887|DRUG|vinorelbine tartrate|
224119029|NCT00002887|PROCEDURE|drug resistance inhibition treatment|
224119030|NCT03388125|DRUG|Injection Sclerotherapy|5% ethanolamine oleate group
224119031|NCT03388125|DRUG|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
224119032|NCT04713358|DRUG|Nalmefene|Immediately Intravenous injection of Nalmefene (0.25 g/kg, plus normal saline to 1ml) after surgery
224293876|NCT05497219|DIAGNOSTIC_TEST|Videofluoroscopic Swallowing Study (VF)|A videofluoroscopy (VF) is a dynamic radiological evaluation of swallowing in which the participant swallows liquid or food boluses of different consistencies prepared with barium contrast. The x-rays are recorded at 30 frames per second.
224293877|NCT03422822|DRUG|Abrocitinib 100 mg|In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
223981742|NCT03788954|OTHER|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
223981743|NCT03124550|BEHAVIORAL|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
223727297|NCT04889456|PROCEDURE|Implementation standardised laparoscopic right hemicolectomy without proctoring|Implementation standardised laparoscopic right hemicolectomy without proctoring
223727298|NCT00240162|DRUG|PTK787/ZK 222584|
223727299|NCT04203784|OTHER|Plasma concentration measurements|Plasma concentration measurements
223727300|NCT04104945|RADIATION|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
223981744|NCT05394883|BEHAVIORAL|Supervised Exercise|Women randomized to Supervised Exercise group will attend two to three exercise classes/week. Each session will consist of: 5-min flexibility warm-up and cool-down; 40 min of moderate intensity calculated as 40-59% Heart Rate Reserve (HRR) along with Rating of Perceived Exertion (RPE) between 13-14; and 20 minutes of resistance with an additional 30 minutes of unsupervised home aerobic activity per week. The women will be given their choice of aerobic equipment or walking either track/ treadmill to achieve a total of 40 minutes of moderate intensity exercise. The Supervised Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
223981745|NCT05394883|BEHAVIORAL|Home Exercise|Women assigned to Home Exercise group will receive instructions for their home walking program including tips for walking indoors and outdoors, exercise handouts for warm-up/cool-down activities, demonstrations for resistance training activities and an exercise log. Women assigned to Home Exercise group will be contacted once per week to discuss their progress, barriers/challenges faced, ask questions, and strategies to achieve the exercise guidelines. The Home Exercise group will receive exercise counseling during their first meeting in addition to materials on the benefits of exercise, a log to record additional activity completed each week, goal setting, making time for exercise/making exercise a habit and exercise behavioral strategies.
223981746|NCT02735798|DRUG|MM-302|
223981747|NCT02735798|DRUG|Trastuzumab|
223981748|NCT04157218|DEVICE|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
223981749|NCT04157218|DEVICE|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
223981750|NCT05579665|BIOLOGICAL|Platelet-rich Plasma|Research participants own blood will be used to prepare the platelet rich plasma injectate.
224119033|NCT04713358|DRUG|normal Saline|Immediately Intravenous injection of normal saline 1ml after surgery
223727301|NCT05196165|OTHER|No Intervention|No investigational product (IP) will be administered in this study
223727302|NCT02740764|OTHER|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
223727303|NCT03806140|BEHAVIORAL|text messages|receive about one health-related text message a day for 16 weeks
223727304|NCT01411111|DRUG|Rosuvastatin 10 mg|days 1-14
223727305|NCT01411111|DRUG|GSK2190915 30mg|1x30mg tablet, days 8-14
223727306|NCT01411111|DRUG|GSK2190915 100mg|1x100mg tablet, days 8-14
223727307|NCT01331798|DEVICE|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
223727308|NCT01331798|PROCEDURE|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
223981751|NCT05579665|BIOLOGICAL|Conditioned Medium From Umbilical Cord Mesenchymal Stem Cell Culture (MSCs) Secretome|Conditioned Medium UC-MSCs Secretome which will be injected into the affected knee using ultrasound guidance.
223981752|NCT05579665|DRUG|Low Molecular Weight Hyaluronic Acid|low molecular weight hyaluronic acid which will be injected into the affected knee using ultrasound guidance.
223981753|NCT02836054|PROCEDURE|lumbar puncture (LP)|
223981754|NCT02836054|PROCEDURE|brain MRI|
223727309|NCT03945578|OTHER|Pelvic Floor muscle training - PFMT|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
223981755|NCT00010842|DRUG|Ginkgo biloba|
223981756|NCT00010842|DRUG|Alpha-lipoic acid|
223981757|NCT00010842|DRUG|Vitamin E/Selenium|
223981758|NCT00010842|DRUG|Essential fatty acids|
223981759|NCT04207697|BIOLOGICAL|Beltavac® Polymerized with cat dander|Adminstration of Beltavac® Polymerized with cat dander according to the routine clinical practice
223981760|NCT05168514|OTHER|Massage|"Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days."
224119034|NCT02137772|DRUG|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
223981761|NCT02032108|BEHAVIORAL|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
223981762|NCT01603342|DRUG|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
223981763|NCT01603342|DRUG|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
223981764|NCT01481519|DRUG|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
224119035|NCT02137772|DRUG|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
224119036|NCT05785117|DEVICE|Vagal Stimulation|ear clips were placed in the ear region (auricular concha) at the stimulation site. The following stimulation settings were used: 1) density wave set to 20 Hz with a wave width of less than 1 ms; 2) intensity tuned to the patient's tolerance (4-6 mA)
223981765|NCT01481519|DRUG|Artificial Tears|artificial tears 1 drop, 4 times per day
223981766|NCT04522583|DIAGNOSTIC_TEST|Diagnosis of Myocardial Ischemia|Discharge diagnosis of myocardial ischemia
223981767|NCT06192719|OTHER|None, observational study.|Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.
223981768|NCT03671239|BEHAVIORAL|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
224119037|NCT05785117|OTHER|Circuit training program|The training regimen included ten different forms of resistance and aerobic exercise that were done three times a week for four weeks. The resistance training program included push-ups, squats, crunches, lunges, and a superman exercise program that included light jumping, jogging on the spot, foot stomping, steps, and jumping jacks
224293878|NCT03422822|DRUG|Abrocitinib 200 mg|In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
224293879|NCT03422822|DRUG|Placebo|For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
224293880|NCT03422822|DRUG|Abrocitinib 100 mg|For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
224293881|NCT03422822|DRUG|Abrocitinib 100 mg|In the secondary treatment period, Abrocitinib 100 mg, administered as one tablet to be taken orally once daily.
224293882|NCT03422822|DRUG|Abrocitinib 200 mg|In the secondary treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
224293883|NCT05506930|DRUG|Intrathecal Morphine|One group of subjects will receive intrathecal morphine: spinal (neuraxial) dose of preservative free morphine (Duramorph), usually about 4-5mcg/kg. This is injected into the cerebrospinal fluid under sterile technique by a pediatric anesthesiologist while the subject is already under general anesthesia. This procedure is well-described in the pediatric population and used regularly for postoperative pain relief for a variety of procedures including ureteral reimplantation.
223727310|NCT03945578|OTHER|Visceral Manual Therapy - VMT|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
223981769|NCT03671239|BEHAVIORAL|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
223981770|NCT03671239|BEHAVIORAL|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
224293884|NCT05506930|DRUG|Quadratus lumborum block|The second group of subjects will have bilateral quadratus lumborum blocks: peripheral nerve block utilizing ropivacaine 0.2%, usually about ½ mL per/ kg per side (total dose approximately 1mL/kg). This is injected in the subject's flank in the fascial plane between the quadratus lumborum muscle and the psoas muscle. Ultrasound guidance is used for needle and structure localization and this procedure is done by a pediatric anesthesiologist while the subject is already under general anesthesia. Quadratus lumborum blocks are regularly used in clinical practice for postoperative pain relief for a variety of abdominal procedures.
224293885|NCT04107402|OTHER|Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay|Blood sample Urine Sample Pulmonary, hepatic and cardiac tissue from biopsy and autopsy
224293886|NCT02631876|DRUG|Mirvetuximab soravtansine|Mirvetuximab Soravtansine will be administered per dose and schedule specified in the arm.
224293887|NCT02631876|DRUG|Paclitaxel|Paclitaxel will be administered per dose and schedule specified in the arm.
224293888|NCT02631876|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
224293889|NCT02631876|DRUG|Topotecan|Topotecan will be administered per dose and schedule specified in the arm.
223981771|NCT02019641|OTHER|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
223981772|NCT02019641|OTHER|Education|Weekly education
223981773|NCT02044614|OTHER|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
223981774|NCT03318783|DRUG|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
223981775|NCT03318783|DRUG|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
224119038|NCT00146705|PROCEDURE|blood samples are taken once|
224119039|NCT03404414|DRUG|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
224119040|NCT05416931|DRUG|ACD440 Gel 14mg/g|Topical application to painful area
224119041|NCT05416931|DRUG|Placebo Gel|Topical application to painful area
224119042|NCT03471091|DEVICE|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
223981776|NCT02238964|DEVICE|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
223981777|NCT02238964|PROCEDURE|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
223981778|NCT04019249|BEHAVIORAL|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
223727311|NCT03945578|OTHER|Manual Sham Therapy - MST|The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine
223981779|NCT00001677|DRUG|Methotrexate|
223981780|NCT00001677|DRUG|Fludarabine|
223981781|NCT02949232|DRUG|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
223981782|NCT02949232|DRUG|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
223981783|NCT01246050|OTHER|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
223981784|NCT01246050|OTHER|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
223981785|NCT01335321|DRUG|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
223981786|NCT01335321|DRUG|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
223981787|NCT04560023|OTHER|Exposition to multimedia content|Video and images watched on a tablet. Patient could decide which information want to watch.
223981788|NCT03271177|DEVICE|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
223981789|NCT03271177|DEVICE|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
223981790|NCT03410108|DRUG|Brigatinib|Brigatinib tablet
223981791|NCT00216957|PROCEDURE|Coronary bypass surgery without cardiopulmonary bypass|
223981792|NCT03398421|DRUG|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
223981793|NCT03398421|DRUG|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
223981794|NCT06173232|DEVICE|Camera Imaging|Camera Imaging
223981795|NCT05269927|DIAGNOSTIC_TEST|EEG|resting state EEG
223981796|NCT05269927|DIAGNOSTIC_TEST|DNA samples|genotypings of twelve CNTNAP2 SNPs from DNA obtained by saliva samples
223981797|NCT05269927|DIAGNOSTIC_TEST|clinical data|"standardized scales measuring the infants' cognitive, motor and linguistic development administered at 6, 12 and 18. Measures available at 6 and 12 months: a) Bayley Scales of Infant and Toddler Development- Third Edition; b) Griffiths mental development scales (0-2) (GMDS-R); Measures available at 18 months: c) Language Development Survey (LDS); d) Il PRIMO VOCABOLARIO DEL BAMBINO (PVB); e) CHILD BEHAVIOR CHECKLIST (CBCL); (f) Modified Checklist for Autism in Toddlers (M-CHAT)."
223981798|NCT05269927|OTHER|environmental data|questionnaires administered to parents related to the following environmental factors: a) information about the presence of a clinical diagnosis of neurodevelopmental disorders within first-degree relatives; b) gestational age; c) birth weight; d) parental age and education; e) socio-economic status
223981799|NCT05644535|DIAGNOSTIC_TEST|Cerebrospinal fluid densitometry|After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
223727312|NCT06969651|BEHAVIORAL|Black-Food|Ads featuring a Black person with a food product
223981800|NCT05644535|DIAGNOSTIC_TEST|blood routine examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.
223981801|NCT05644535|DIAGNOSTIC_TEST|Blood electrolyte examination|After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
223981802|NCT01463514|PROCEDURE|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
223981803|NCT01463514|PROCEDURE|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
223981804|NCT03770052|DRUG|duvie|take the intervention drug once daily according to the randomized groups
223981805|NCT05717517|DEVICE|anterior segment oct|ant segment oct before and after corneal collagen cross-linking
223981806|NCT05689281|BEHAVIORAL|Peer PrEP Navigation|Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
223981807|NCT05167032|BEHAVIORAL|Cognitive Multisensory Rehabilitation (CMR)|The goal of CMR is to restore proprioception (i.e., sense of joint position and movement), body awareness, and awareness of the paralyzed limbs and trunk in space, in order to improve sensory and motor function. For example, CMR tasks will have the participant solve exercises related to: (i) where the legs are situated in space; where the legs are in relation to the pelvis and the upper part of the body (ii) the dimensions and length of the legs, the dimension of the pelvis, and sensation of the pelvis as a central body reference. (iii) the relationship between the left and right side of the body, and the relationship between the pelvis and the feet. Further, improvements in touch and pressure sensation are obtained with (v) texture discrimination tasks, and (vi) discrimination of sponges with varying resistance. Given the importance of sensory feedback for movement, sensory improvements create the opportunity for motor recovery to occur.
223981808|NCT05167032|BEHAVIORAL|Adaptive fitness|The Courage Kenny Rehabilitation Institute centers provide access to state-of- the-art adaptive gym equipment in their fitness center to promote fitness and recreation. Equipment includes treadmills, elliptical, NuSteps, SciFit upper body ergometers, Ski Erg and Rowing Machine, Upright and recumbent stationary bicycles, chest press, rear row, leg extension, leg curl, leg press, uppertone, free weights, and kettlebells. The equipment is spaced to allow for movement and is accessible for use from a wheelchair. They allow for transfers and caregiver assistance.
223981809|NCT04006236|OTHER|Experimental Infant Formula|Feed Ad Libitum
223981810|NCT04006236|OTHER|Control Infant Formula|Feed Ad Libitum
223981811|NCT02801409|DRUG|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
223981812|NCT02801409|DRUG|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
223981813|NCT06406998|OTHER|Pre-existing atherosclerotic cardiovascular disease|Presence of pre-existing atherosclerotic cardiovascular disease
223981814|NCT04593706|DRUG|Betamethasone acetate + Betamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
223981815|NCT04593706|DRUG|Dexamethasone sodium phosphate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
223981816|NCT04593706|DRUG|Methylprednisolone acetate|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
223981817|NCT04593706|DRUG|Triamcinolone acetonide|"the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar"
223981818|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part one|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. In patients who will accept an arterial line will be placed and blood gas will be analyzed.
223981819|NCT04650659|DIAGNOSTIC_TEST|6-minute walk test part two|Measurement of: 6-minute walk distance, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured continuously on three anatomical location: the forehead, an earlobe and a finger. No arterial line will be placed.
223981820|NCT04650659|DIAGNOSTIC_TEST|1-minute sit-to-stand test|Measurement of: Number of repetitions, the modified Borg scale before and after testing and continuous measure of peripheral oxygen saturation and heart rate. The peripheral oxygen saturation will be measured on the three anatomical locations mentioned above.
224119043|NCT02607969|OTHER|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
223727313|NCT06969651|BEHAVIORAL|White-Food|Ads featuring a White person with a food product
223981821|NCT04650659|DIAGNOSTIC_TEST|4-meters gait speed test|Measurement of: Time to complete the 4 meters course and calculation of the 4-meters-gait-speed.
223981822|NCT04650659|DIAGNOSTIC_TEST|Nailfold videocapillaroscopy|"Capillary density measurement of: The finger with the probe and the average of all the fingers.~NVC with 200 x magnification will be performed on the 2nd to 5th finger on both hands."
223981823|NCT04650659|DIAGNOSTIC_TEST|HR-pQCT|Imaging: One arm is scanned in a 9 mm-long volume of the distal radius (110 slices), and the distal part of the 2nd to 5th finger on both hands are scanned in a 36,08 mm-long volume (440 slices) at baseline and after 1 year.
223981824|NCT04650659|DIAGNOSTIC_TEST|Hand x-ray|Imaging: Hand x-ray was performed on patients scanned with HR-pQCT, unless images were already available (≤ 1 year).
223981825|NCT04650659|DIAGNOSTIC_TEST|DEXA|Imaging: A bone density (DEXA) scan was performed on patients scanned with HR-pQCT, unless it was already available (≤ 2 years).
224119044|NCT01669369|DRUG|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
223981826|NCT03420261|BIOLOGICAL|0.9% saline|Fluid administration
223981827|NCT03420261|BIOLOGICAL|HES 130/0.4|Fluid administration
223981828|NCT04647305|OTHER|Closed face shield with Surgical face mask use|Use of a closed face shield with a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and proper use of the closed face shield and the surgical face masks.
223981829|NCT04647305|OTHER|Surgical face mask use only|Use of a surgical face mask during daily activities. The educational intervention will provide recommendations on COVID-19 prevention and the proper use of surgical face masks.
223981830|NCT02415283|DEVICE|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
223981831|NCT05808855|PROCEDURE|two-component skin adhesive Glubran Tiss 2®|After subcutaneous stitches with 4-0 Coated VicrylTM Plus PS-2, 3/8 (Ethicon Inc., USA); a two-component skin adhesive, 0.35 mL of Glubran Tiss 2® (GEM S.r.l., Viareggio, Italy), will be applied in the open wound. Before bandaging, subjects will rest for 20 seconds for a polymerization process.
223727314|NCT06969651|BEHAVIORAL|Black-Non Food|Ads featuring a Black person with a non-food product
224293890|NCT05200624|DEVICE|2RT subthreshold nanosecond laser|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
224293891|NCT05646316|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224293892|NCT05646316|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging
223727315|NCT06969651|BEHAVIORAL|White-Non Food|Ads featuring a White person with a non-food product
224293893|NCT05646316|PROCEDURE|Excisional Biopsy|Undergo sentinel lymph node excision
224293894|NCT05646316|DRUG|Indocyanine Green Solution|Given via injection
224293895|NCT05646316|PROCEDURE|Minimally Invasive Surgery|Undergo minimally invasive hysterectomy
224293896|NCT05646316|PROCEDURE|Pelvic Lymphadenectomy|Undergo pelvic lymphadenectomy
224293897|NCT05646316|OTHER|Questionnaire Administration|Ancillary studies
224293898|NCT05646316|PROCEDURE|Sentinel Lymph Node Mapping|Undergo sentinel lymph node mapping
224293899|NCT05315492|BEHAVIORAL|Community Care Consortium (CCC)|The intervention will train community health workers to take an active role in the drug control and addiction service delivery in the community.
224293900|NCT06488430|BEHAVIORAL|Multidomain intervention package for preventing cognitive decline|Participants with mild cognitive impairment will be identified and they will participate in a pilot study for one-month duration. During pilot study they will be subjected to a multidomain intervention including nutritional advice, physical activity, cognitive stimulation training, social support and engagement and management of vascular risk factors.
224293901|NCT04212377|BIOLOGICAL|Dendritic Cells for endometrial cancer|Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
223727316|NCT06969651|BEHAVIORAL|Food-Many Likes|"Ads with Many likes featuring a food product"
223727317|NCT06969651|BEHAVIORAL|Non Food-Many Likes|"Ads with Many likes featuring a non-food product"
223727318|NCT06969651|BEHAVIORAL|Food-Few Likes|"Ads with Few likes featuring a food product"
223727319|NCT06969651|BEHAVIORAL|Non Food-Few|"Ads with Few likes featuring a non-food product"
223981832|NCT05808855|PROCEDURE|skin stitched with transcutaneous nylon suture|The skin is stitched with transcutaneous nylon sutures (polypropylene-polyethylene monofilament, non-absorbable surgical suture) 4-0
223981833|NCT03100864|DRUG|Spesolimab|12 weeks treatment
223981834|NCT02101658|OTHER|clinic-based weight measurements|
223981835|NCT01648036|DRUG|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
223981836|NCT01648036|DRUG|Dalteparin|Dose 5000 IU, subcutaneous, daily
223981837|NCT05810441|OTHER|Evaluation of diagnostic accuracy of anti-ttg-m|Mucosal anti-ttg evaluated in intestinal biopsy samples
223981838|NCT04469062|DRUG|Mirikizumab IV|Administered IV
223981839|NCT04469062|DRUG|Mirikizumab SC|Administered SC
223981840|NCT04469062|DRUG|Vedolizumab IV|Administered IV
223981841|NCT04469062|DRUG|Placebo IV|Administered IV
223981842|NCT04469062|DRUG|Placebo SC|Administered SC
223981843|NCT05612841|OTHER|data collection|data collection from drug-drug interaction between anti-cancer treatment and and other medications
223981844|NCT06471907|PROCEDURE|erector spinae plane block|fascial plane injection using ultrasound
223981845|NCT02749136|DRUG|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"* Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~  * Oxaliplatin IV 85 mg/m2 Day (D) 1~ * Irinotecan IV 180 mg/m2 D1~ * 5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~ * Leucovorin IV 400 mg/m2 D1~* Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
224119045|NCT01669369|DRUG|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
224119046|NCT03339648|BEHAVIORAL|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
224119047|NCT02053220|BIOLOGICAL|Colo-Ad1|Oncolytic virus
224119048|NCT00326105|DRUG|Quetiapine fumarate|
224119049|NCT04107012|DEVICE|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
224119050|NCT04706546|OTHER|Hemodynamic effect of exercise under Sildenafil|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under SIldenafil."
223981846|NCT02277197|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
223981847|NCT02277197|DRUG|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
223981848|NCT04035577|BEHAVIORAL|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
223981849|NCT01233414|BEHAVIORAL|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
223981850|NCT01233414|OTHER|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
223981851|NCT00639314|PROCEDURE|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
223981852|NCT00639314|PROCEDURE|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
223981853|NCT02056002|OTHER|Usual Care|\- Standard CPAP educational training
223981854|NCT02056002|OTHER|Peer-Buddy System|"* Two 30-minute in person sessions with Peer Buddy~* Standard CPAP educational training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~\- Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy"
223981855|NCT02056002|OTHER|Usual Care|\- Educational Brochures
223981856|NCT02056002|OTHER|Usual Care|\- Educational DVD videos mailed to participant
223981857|NCT03713697|BEHAVIORAL|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
223981858|NCT03713697|BEHAVIORAL|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
223981859|NCT03713697|BEHAVIORAL|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
223981860|NCT02368899|OTHER|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
223981861|NCT02368899|OTHER|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
223981862|NCT02115919|DRUG|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
223981863|NCT02115919|DRUG|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
223981864|NCT05413837|DIAGNOSTIC_TEST|anotomy and variation of venous sinus|Contrast enhanced-magnatic resonance venography（CE-MRV）and other magnetic resonance imaging methods are used to estimate the anatomy of cerebral venous sinus.
223981865|NCT05413837|DIAGNOSTIC_TEST|the level of biomarker in bood|Elisa or omics analysis is used to test the level of biomarker in blood.
223981866|NCT01344499|PROCEDURE|Carbon dioxide|standard pneumoperitoneum with 100% CO2
223981867|NCT01344499|PROCEDURE|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
223981868|NCT01344499|DRUG|Adept|instillation of 1 liter of fluid at the end of laparoscopy
223981869|NCT01344499|DRUG|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
223981870|NCT03269695|DRUG|PF-06687234|SC QW
223981871|NCT03269695|DRUG|Placebo|SC QW
223981872|NCT00705562|OTHER|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
223981873|NCT02591862|DRUG|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
223981874|NCT00104637|DRUG|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
223981875|NCT00104637|DRUG|Placebo|25 mg po tid
223981876|NCT01313624|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
223981877|NCT01313624|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
223981878|NCT01619462|BIOLOGICAL|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
223981879|NCT00505414|DRUG|Tapentadol in the Titration Phase|
223981880|NCT00505414|DRUG|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
223981881|NCT00505414|DRUG|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
223981882|NCT00505414|DRUG|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
223981883|NCT00505414|DRUG|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
223981884|NCT04660578|PROCEDURE|ACCSS|A. Chohan Continuous Squeezing Suture (ACCSS)
223981885|NCT02715427|OTHER|Conventional care|
223981886|NCT02715427|OTHER|Enhanced recovery|
223981887|NCT03411798|DRUG|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
223981888|NCT02931578|OTHER|Glucose100|
223981889|NCT02931578|OTHER|Glucose50|
223981890|NCT02931578|OTHER|Glucose42|
223981891|NCT02931578|OTHER|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
223981892|NCT04012658|OTHER|No intervention|No intervention
224119051|NCT04706546|OTHER|Hemodynamic effect of exercise|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
224119052|NCT00003139|DRUG|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
223981893|NCT00846768|DRUG|BI 1744 CL|
223981894|NCT00527150|DRUG|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
223981895|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
223981896|NCT00527150|DRUG|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
223981897|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
224119053|NCT00003139|OTHER|Placebo|
224119054|NCT05846386|BEHAVIORAL|Resistance training|moderate-intensity resistance training: three sessions per week for one month. Participants had been instructed to perform exercises at a 4:2:4 tempo; that is, four sets of concentric contraction, two sets of isometric hold, and four sets of eccentric contraction. Participants had been instructed to complete a single set until volitional fatigue or been instructed to stop by the physiotherapist when the technique falters
224119055|NCT05846386|BEHAVIORAL|Aerobic training|"The exercise program consisted of ten minutes warm-up, 45 minutes of moderate aerobic exercises upper extremity aerobic bulk muscles training and arm ergometer and cool-down in five minutes, respectively. That was done as 3 sessions/week for 4 weeks."
223981898|NCT00527150|DRUG|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
224119056|NCT05504330|DRUG|Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin|First of all, ICAS patients were given health education to exhort them to reduce the risk factors of exposure to stroke and get rid of their unhealthy lifestyles. Secondly, for patients in need, standardize their dosage and course of treatment, mainly including antiplatelet drugs and statins. In addition, patients with diabetes and hypertension urge rational medication to control blood pressure and blood glucose level.
224119057|NCT00803244|DRUG|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
224119058|NCT00803244|DRUG|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
224119059|NCT03488810|OTHER|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
224119060|NCT03488810|DRUG|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
224119061|NCT03488810|DRUG|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
224119062|NCT03488810|DRUG|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
224119063|NCT00024297|DRUG|warfarin|
224119064|NCT01253460|DRUG|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
223981899|NCT05060835|OTHER|Virtual assistants offering medical recommendations to health care profesionals|the project will interconnect, following a federated approach, large, distributed cancer imaging repositories, currently used for AI tools training and validation, with patient registries and EHRs of cancer-related data and supports exploitation of relevant unstructured data through novel Natural Language Processing (NLP) tools
223981900|NCT05318235|OTHER|No intervention|No intervention
223981901|NCT04158271|DEVICE|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
223981902|NCT04158271|DEVICE|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
223981903|NCT04158271|DEVICE|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
223981904|NCT00746109|PROCEDURE|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
223981905|NCT00746109|PROCEDURE|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
223981906|NCT02187289|DEVICE|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
223981907|NCT02187289|DEVICE|Compression Sleeve, daytime wear|
223981908|NCT02187289|DEVICE|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
223981909|NCT01003262|OTHER|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
223981910|NCT01003262|OTHER|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
223981911|NCT00644878|DRUG|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
224119065|NCT01253460|DRUG|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
224119066|NCT01253460|DRUG|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
223981912|NCT03591627|DIAGNOSTIC_TEST|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
223981913|NCT01328210|PROCEDURE|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
223981914|NCT02625753|DRUG|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
223981915|NCT02625753|DRUG|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
224119067|NCT00200148|PROCEDURE|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
224293902|NCT02785653|DRUG|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
223981916|NCT02625753|DRUG|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
223981917|NCT00630136|BEHAVIORAL|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
223981918|NCT05879562|DIAGNOSTIC_TEST|MoCA-Xpresso|MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.
223981919|NCT04389346|PROCEDURE|Periapical surgery using autologous platelet aggregate|PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
223981920|NCT04389346|PROCEDURE|Periapical surgery without autologous platelet aggregate|Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
223981921|NCT00948610|DRUG|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
224119068|NCT00200148|PROCEDURE|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
223727320|NCT04997434|BEHAVIORAL|Art-therapy in the emergency department|"The intervention will begin with a 5-10 minute interview with the patient to define his or her tastes and contraindications to certain techniques. Since the art-therapeutic intervention that will be proposed seeks to generate pleasant feelings, it will be important to rely on the patient's tastes. At the end of the interview, modern art therapy will be presented to the patient and several artistic activities will be proposed (origami, drawing, creative writing).~Once the activity has been chosen, the patient will have 15 to 20 minutes to carry it out, accompanied by the art therapist according to his/her needs. During the activity, verbal exchanges will continue. After the 15 to 20 minutes of the session, 5 minutes will be devoted to the patient's self-evaluation of the past moment, of his level of anxiety, of the intensity of his pain and of his feelings in relation to his passage in the Emergency Department and the art therapy session."
223727321|NCT01756547|DRUG|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
223727322|NCT01756547|DRUG|Placebo|
223727323|NCT04107610|DEVICE|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
223727324|NCT03329950|DRUG|CDX-1140|CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3.
223727325|NCT03329950|DRUG|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
223727326|NCT03329950|DRUG|pembrolizumab|pembrolizumab will be administered every 3 weeks.
223727327|NCT03329950|DRUG|Chemotherapy|Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.
223981922|NCT00516828|DRUG|cytarabine|subcutaneously twice daily from Day 1 to 10
223727328|NCT02164812|DRUG|Moxifloxacin|
223981923|NCT05549167|DRUG|Sirolimus|Sirolimus 0,8 mg/m2, but \<2 mg per day, once a day (QD), per os, oral solution, 1mg/ml, 60 ml Optimal individual dosage of sirolimus will be determined under control of concentration in blood serum. Therapeutic concentration - 5-15 ng/ml. Blood samples will be collected until therapeutic concertation will be achieved in 2 consecutive samples, but no more than 4 samples (on the 4th, 7th, 10th, 14th days of admission).
223981924|NCT04310176|DRUG|Bevacizumab|5 mg/m2 as 20-to-30 minute intravenous (i.v.) infusion every two weeks. Maintenance treatment (both arms): 5 mg/m2 every 2 weeks (in combination with 5-Fluorouracil) or 7.5 mg/m2 every 3 weeks (in combination with capecitabine)
223981925|NCT04310176|DRUG|mFOLFOX6 regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two week
223981926|NCT04310176|DRUG|mOXXEL regimen|Oxaliplatin 85 mg/m2 as 2-3 hours i.v. infusion on day 1 plus oral capecitabine 1000 mg/m2 twice daily on days 1 to 10, every 2 weeks
223981927|NCT04310176|DRUG|Valproic acid|given orally from 500mg-1500mg daily and an intra-patient titration for a target serum level of 50-100µg/ml
223981928|NCT04310176|DRUG|Capecitabine|Maintenance treatment (both arms): 1250 mg/m2 twice daily on days 1 to 14, every 3 weeks or 1250 mg/m2 twice daily on days 1 to 10, every 2 weeks
223727329|NCT02164812|DRUG|Placebo|
223727330|NCT02164812|DRUG|Efavirenz|
223727331|NCT05633420|DRUG|Pyramax|"Participant body weight~* ≥65 kg (Pyramax 4 tablets)~* ≥45 kg and \<65 kg (Pyramax 3 tablets)"
223727332|NCT05174897|BEHAVIORAL|emotional liberation technique|experimental group; The child, to whom an intravenous catheter will be applied, is placed on a stretcher. pain ve score fear will be evaluated before the procedure. Then, the emotional liberation technique (EFT) will be applied for 10 minutes and an intravenous catheter will be applied to evaluate the pain and fear scores during and after the procedure.
223727333|NCT05333146|PROCEDURE|Cardiac Surgery|Cardiac surgery (e.g. coronary bypass surgery, cardiac valve surgery, ascending aortic surgery)
223727334|NCT01747798|DRUG|auranofin|Given PO
223727335|NCT01747798|OTHER|laboratory biomarker analysis|Correlative studies
223727336|NCT02888444|DRUG|Varenicline|Two 0.5mg tablets taken twice daily
224119069|NCT00616239|DRUG|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
224119070|NCT00616239|DRUG|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
224119071|NCT00299884|DRUG|Lipitor 20 mg|A/A for 6 weeks
224119072|NCT00299884|DRUG|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
224119073|NCT02873715|BEHAVIORAL|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
224119074|NCT02873715|BEHAVIORAL|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
224119075|NCT02138578|RADIATION|SBRT|
224119076|NCT02138578|RADIATION|RFA|
224119077|NCT00754429|DRUG|losartan|losartan 50mg qd for 30 weeks.
223544020|NCT03810846|BEHAVIORAL|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
223544021|NCT02804633|DRUG|IV Acetaminophen|1 gram every 6 hours
223727337|NCT02888444|BEHAVIORAL|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
223727338|NCT02888444|DRUG|Placebo|Two 0.5mg tablets taken twice daily
224119078|NCT00754429|DRUG|amlodipine|amlodipine 5 mg q.d for 30 weeks.
223544022|NCT02804633|DRUG|Placebo|100 ml of normal saline every 6 hours
223727339|NCT00018200|DRUG|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
223727340|NCT00018200|DRUG|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
223727341|NCT00018200|DRUG|Benztropine|Daily dose 0.125 to 0.5mg
223727342|NCT04316923|DIAGNOSTIC_TEST|ECG|ECG will be performed during each visit in the study group.
224119079|NCT02856789|OTHER|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
224119080|NCT02856789|OTHER|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
224119081|NCT02856789|OTHER|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
224119082|NCT02856789|OTHER|Specialized hemostasis tests|Coagulation factors
224119083|NCT03241173|DRUG|INCAGN01949|In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
224119084|NCT03241173|DRUG|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
223981929|NCT04310176|DRUG|5-fluorouracil|Maintenance treatment (both arms): Levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus. 5-fluorouracil 400 mg/m2, and a 46-hour i.v. infusion of 5-fluorouracil 2400 mg/m2 every two weeks
223981930|NCT01395511|DEVICE|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 \* 40 (mm) / SJ 0.18 \* 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
223981931|NCT02649361|DRUG|Anlotinib|Anlotinib p.o. qd
223981932|NCT02649361|DRUG|Placebo|Placebo p.o. qd
223981933|NCT03889054|BEHAVIORAL|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~1. Plan of action in an exacerbation.~2. Education related to COPD.~3. Information on pharmacological medication.~4. Management of the exacerbation.~5. Management of stress and / or anxiety.~6. Nutritional recommendations.~7. Physical exercise recommendations.~8. Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
223981934|NCT04891471|RADIATION|Stereotactic RadioTherapy|To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).
223727343|NCT04316923|DIAGNOSTIC_TEST|24-hour ECG monitoring|24-hour ECG monitoring will be performed during each visit in the study group.
223727344|NCT04316923|DIAGNOSTIC_TEST|Cardio-pulmonary exercise test (CPET)|CPET will be performed during the first and the last visit in the study group.
223727345|NCT04316923|DIAGNOSTIC_TEST|Cardiac biomarkers|Cardiac biomarkers will be assessed during each visit in the study group.
224119085|NCT03241173|DRUG|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
224119086|NCT00564629|DRUG|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
223727346|NCT03181568|DEVICE|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
223727347|NCT03181568|PROCEDURE|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
223727348|NCT03694821|DRUG|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
223727349|NCT03694821|DRUG|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
223727350|NCT03694821|DRUG|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
223981935|NCT04891471|RADIATION|Whole Brain Irradiation|To irradiate the entire brain, site of at least 5 parenchymal metastasis.
223981936|NCT00591591|DEVICE|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
223981937|NCT03121612|DEVICE|CPAP|CPAP therapy
223727351|NCT00540826|DRUG|Atomoxetine|in-label use
223727352|NCT00540826|DRUG|stimulants (any approved ADHD medication)|in-label use
223727353|NCT02805101|DRUG|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
223727354|NCT02805101|DRUG|MTA|MTA is going to be used as the sealing agent for the perforation.
223981938|NCT05809336|DRUG|Inosine 0.2g orally 3 times/day|inosine + PD-1/PD-L1 inhibitor ± chemotherapy/targeting,
223981939|NCT05809336|DRUG|PD-1/PD-L1 inhibitor ,chemotherapy/targeting|PD-1/PD-L1 inhibitor ± chemotherapy/targeting
223981940|NCT00579449|BEHAVIORAL|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
224119087|NCT00564629|DRUG|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
224119088|NCT00564629|BIOLOGICAL|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
224119089|NCT03094936|PROCEDURE|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
223981941|NCT00579449|BEHAVIORAL|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
223981942|NCT01270698|DRUG|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
223981943|NCT02085902|DRUG|Ropivacaine|
223981944|NCT05028946|DRUG|Foralumab|Foralumab will be administered per dose and schedule specified in the arm description.
223981945|NCT04455685|OTHER|anonymised data collection|The population of the present study corresponds to a sample of previous market research. Data from participants from the five main regions of Brazil (North, Northeast, Midwest, South, Southeast) will be selected at random and according to the sample size calculation.
224119090|NCT03094936|DEVICE|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
224119091|NCT04967755|DRUG|Jing-Si-Herbal-Tea|Eligible patients were randomized to receive routine treatment alone based on the Novel Coronavirus Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (Eleventh edition 2021) (control group) or the combination of routine treatment and JSHT (1 drink thrice daily for 7 days) (JSHT group) at the discretion of the attending clinicians. Routine treatment generally consisted of the supportive treatment such as oxygen therapy, antiviral medications and symptomatic therapies. Adherence to the study medications, clinical outcomes, the use of concomitant medications and adverse events were recorded. The following data were collected at admission: demographics, body mass index, smoking history, comorbidities, CURB-65 Score for pneumonia. Hemogram, laboratory testing, chest X-ray, and nucleic acid assays of SARS-CoV-2 were evaluated at admission and after randomization and on 7th day.
223981946|NCT02447276|DRUG|REGN475|
223981947|NCT02447276|DRUG|Placebo|
223981948|NCT03949712|DEVICE|Transcranial Static Magnetic Field Stimulation (tSMS)|tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
223981949|NCT03949712|DEVICE|Sham Transcranial Static Magnetic Field Stimulation (tSMS)|Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
223981950|NCT01419977|DRUG|Placebo|Normal saline solution, administered by nursing staff once daily
223981951|NCT01419977|DRUG|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
223981952|NCT03530488|DRUG|Lidocaine|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
223981953|NCT03530488|PROCEDURE|Office hystroscopy|A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
223981954|NCT00137020|DRUG|ziprasidone|
223981955|NCT03040830|DRUG|Progesterone 100 IM/day|Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
223981956|NCT00332826|DRUG|Technosphere Insulin|
223981957|NCT02812875|DRUG|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
223981958|NCT03579433|DEVICE|ORA with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
223981959|NCT03579433|OTHER|Alcon Barrett Toric Calculator|Web-based software application that utilizes an algorithm (Barrett Formula) to estimate the amount of post-operative corneal astigmatism in order to optimize IOL model selection and axis placement, with interoperative axis alignment done manually.
223981960|NCT03579433|DEVICE|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery (Model SN6AT3, SN6AT4, Model SN6AT5, Model SN6AT6)
223981961|NCT00468130|DRUG|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
223981962|NCT00468130|DRUG|Placebos|"Inactive tablet made to resemble active tablet~Subjects under 40 kg will be started on 2.5mg per day of placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects"
223981963|NCT05330052|DEVICE|Agilik|The Agilik is a leg orthosis device supporting the knee joint, and is intended to be worn on one or both the legs. The device is customized for single patient use. It is composed of custom-fabricated polypropylene leg shells (thigh, calf and foot components) with joint supports, actuator, sensors, cabling and a battery waist pack. The Agilik is attached to the patient using straps - two on the thigh and two on the shank. A rotational linkage connects the thigh and calf portions of the device, is placed lateral to the knee joint, and is aligned with the knee center of rotation.
223981964|NCT00436956|PROCEDURE|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
223981965|NCT00436956|DRUG|AZD2171|20 mg oral daily for 28 days
223981966|NCT00436956|DRUG|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
223981967|NCT01316965|BEHAVIORAL|Multifaceted prevention program HELP(Hospital Elder Life Program)|"* A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~* B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~* C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
223727355|NCT05045014|OTHER|Balance assessment|Romberg test and one-leg standing test will be used.
223981968|NCT02038998|DEVICE|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
223981969|NCT05082844|RADIATION|MRI assessment|Evaluation of the clinical-radiological results from the case series of patients surgically treated for cuff rotator lesions from 2009 to 2020 at the Shoulder-Elbow Department . At 12 months the result is considered stabilized, so we will proceed to collect all case histories that have passed this follow-up period.
223981970|NCT02542423|OTHER|Endocan blood test samples|
223981971|NCT05674292|DEVICE|Erchonia Violet Zerona Z6|405nm violet diode low level laser device
223981972|NCT03399838|DRUG|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
223981973|NCT03399838|DRUG|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
223727356|NCT05045014|OTHER|Unterberger test|During 50 steps, he will count in place with 45 degrees of hip flexion, and after 50 steps, the angle of rotation between the first position and the final position of the right foot will be measured with the help of a goniometer and the displacement distance.
224119092|NCT03005782|DRUG|REGN3767|
224119093|NCT03005782|DRUG|cemiplimab|
223727357|NCT05045014|OTHER|Corsi Block Tapping (mobıl app)|Spatial memory will be evaluated.
223981974|NCT04228406|DRUG|GST-HG161|There are 7 dose cohorts, including60mg, 150mg, 300mg, 450mg, 600mg, 750mg, 900mg QD in the dose escalation stage and GST-HG161 will be administered orally to patients once daily for each dose cohort. Recommended dose in the dose expansion stage will be determined by the results in the dose escalation stage .
224119094|NCT00300872|DEVICE|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
224119095|NCT00300872|DEVICE|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
223727358|NCT05045014|OTHER|Navigation performance|Two triangles (one equilateral, one oblique triangle, at 30°, 60° and 90° angles respectively) with route segment lengths between 150 and 300 cm will be marked on the floor and the participants will be asked to complete the task with their eyes closed. The final deviation amount will be recorded.
223727359|NCT05045014|OTHER|Cobb angle measurement|It will be evaluated with the help of X-ray.
223727360|NCT05045014|OTHER|Scolio Detector (mobıl app)|The degree of rotation will be measured with the mobile application called Scolio Detector.
223727361|NCT02554487|DEVICE|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI \> 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI \< 5) following stroke serve as a control group
223727362|NCT00203996|DEVICE|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
223727363|NCT00203996|DRUG|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
223727364|NCT00203996|DRUG|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
223727365|NCT00203996|PROCEDURE|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
223727366|NCT00203996|PROCEDURE|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
223727367|NCT04074460|DRUG|Propofol|General Anaesthesia
223727368|NCT04074460|DRUG|isoflurane, sevoflurane or desflurane|General Anaesthesia
223727369|NCT04358120|DEVICE|Hyaluronic Acid Combined With Chondroitin Sulfate|"Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection"
223981975|NCT04324658|DEVICE|Lactiplus|capsules containing L. gasseri LA806
223981976|NCT02838576|DRUG|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
223981977|NCT02838576|DRUG|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
223981978|NCT00177762|BEHAVIORAL|behavior weight loss|
224119096|NCT03648996|OTHER|Low-fructose diet, isocaloric|6 month of consumption a low fructose diet
224119097|NCT03648996|DRUG|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
224119098|NCT03648996|DRUG|Placebo|6 months of placebo treatment
224119099|NCT03648996|OTHER|Low-fructose, hypocaloric|6 month of consumption a low fructose diet with a 500 Calorie/day energy restriction
224119100|NCT01930734|DRUG|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
224119101|NCT01930734|DRUG|Normal Saline|Normal Saline solution 0.9% Placebo Arm
224119102|NCT02260414|DRUG|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
224119103|NCT02260414|OTHER|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
223981979|NCT01841112|DRUG|Placebo|Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
223981980|NCT01841112|DRUG|BI-409306 25 milligram (mg) SD|Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
223981981|NCT01841112|DRUG|BI-409306 50 mg SD|Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
223981982|NCT01841112|DRUG|BI-409306 100 mg SD|Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
223981983|NCT01841112|DRUG|BI-409306 100 mg MD|Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9
223981984|NCT04114812|OTHER|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
223981985|NCT04114812|OTHER|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
223981986|NCT06319651|OTHER|Lower Limb Resistance Band Exercises|"* Extending thighs~* Closing thighs~* Opening thighs~* Bending thighs~* Bending ankles~* Ankle opening"
223981987|NCT06319651|OTHER|Routine Phase 1 cardiac rehabilitation|Routine Phase 1 cardiac rehabilitation only.
223727370|NCT03064451|PROCEDURE|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
223727371|NCT02551276|DRUG|Salbutamol|
223727372|NCT02551276|DRUG|Placebo|
223727373|NCT02551276|OTHER|Resistance training|
223727374|NCT02401438|OTHER|5D ultrasound|
223981988|NCT03219671|DRUG|Nivolumab|nivolumab 240mg every 2 weeks
223981989|NCT03219671|DRUG|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
223981990|NCT03981718|PROCEDURE|Fat grafting|Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
223981991|NCT05851664|DEVICE|intubation by direct laryngoscopy|intubation using a direct laryngoscopy type macintosh
223981992|NCT05851664|DEVICE|Intubation by videolaryngoscopy|Intubation using a videolaryngoscope type McGrath
223981993|NCT02680197|DRUG|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
224119104|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject
224119105|NCT00317941|DRUG|Rebif|44ug administered with Rebiject II
224119106|NCT00317941|DRUG|Betaferon/Betaseron|250ug administrated with Betaject light
224119107|NCT00590681|DRUG|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
224119108|NCT03961919|DRUG|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
224119109|NCT03961919|DRUG|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
223727375|NCT02401438|OTHER|2D ultrasound|
223727376|NCT06350825|PROCEDURE|Cytoreductive prostatectomy or brachytherapy|local treatment+SOC for metastatic prostate cancer
223727377|NCT06350825|DRUG|ADT+second-generation antiandrogens ± chemotherapy|SOC(Triplet or doublet therapy) for mHSPC
223727378|NCT06472063|OTHER|pre- or perioperative treatment and D2 gastrectomy|pre- or perioperative treatment and D2 gastrectomy
223727379|NCT03839745|OTHER|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
224119110|NCT03961919|DRUG|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
224119111|NCT03961919|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
223727380|NCT04305483|PROCEDURE|Laser Bleaching|Content; There are 35% hydrogen peroxide, potassium nitrate, sodium fluoride, sodium hydroxide, thickener, glycol derivative. The way of application; Gingival protection is applied. The gel is applied to the labial surfaces of the teeth with a thickness of 1-2 mm. The use of laser increases the effectiveness of the gel. Operator and patient use protective glasses during laser application. The gel shows its effectiveness in about eight minutes. Then the gel is removed with the help of saliva absorber. The procedure is repeated until the desired degree of whitening is achieved. Then it is checked with a color scale.
223981994|NCT05760911|BEHAVIORAL|Outdoor activities motivation with smartwatches|Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
223981995|NCT02188394|DRUG|Anesthetic blockades with bupivacaine|
224119112|NCT01095952|DEVICE|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
223981996|NCT02188394|DRUG|Isotonic saline injection|
223981997|NCT01729845|DRUG|Cytarabine|Given IV
223981998|NCT01729845|DRUG|Decitabine|Given IV
223981999|NCT01729845|DRUG|Etoposide|Given IV
223982000|NCT01729845|OTHER|Laboratory Biomarker Analysis|Correlative studies
223982001|NCT01729845|DRUG|Mitoxantrone Hydrochloride|Given IV
223982002|NCT01576198|GENETIC|DNA analysis|
223982003|NCT01576198|GENETIC|nucleic acid amplification|
223982004|NCT01576198|OTHER|diagnostic laboratory biomarker analysis|
223982005|NCT01576198|OTHER|medical chart review|
223982006|NCT02294097|PROCEDURE|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
223982007|NCT01726517|DRUG|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
223982008|NCT01726517|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223982009|NCT00398723|DEVICE|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
223982010|NCT01674803|DEVICE|Orsiro|biodegradable polymer sirolimus eluting stent
224119113|NCT06096233|OTHER|Bouts of Exercise|The participants will run on the treadmill for 10 minutes (short) or 30 minutes (prolonged).
224119114|NCT03543891|OTHER||
224119115|NCT01750476|DRUG|Mirena|
224119116|NCT01750476|DRUG|Oral contraception|
224119117|NCT01750476|DRUG|Depo-Provera|
224119118|NCT02991820|DEVICE|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
224119119|NCT02991820|DEVICE|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
223982011|NCT01674803|DEVICE|Synergy|biodegradable polymer everolimus eluting stent
223982012|NCT01674803|DEVICE|Resolute Integrity|durable polymer zotarolimus-eluting stent
223982013|NCT03455777|DRUG|AKCEA-ANGPTL3-LRX|Single open-label cohort
223982014|NCT01695447|PROCEDURE|duct-to-mucosa|
223982015|NCT01695447|PROCEDURE|invagination|
223982016|NCT01695447|DEVICE|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
223982017|NCT03765164|DIAGNOSTIC_TEST|GlycoMark 1-5-AG|Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
223982018|NCT03765164|OTHER|Clinical Performance and Value Vignettes|Simulated diabetic patients cared for online
223982019|NCT03843398|PROCEDURE|Colorectal cancer resection via minilaparotomy|According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
223982020|NCT03843398|PROCEDURE|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
223982021|NCT05115292|BIOLOGICAL|BJ-005|dosed with intravenous infusion
223982022|NCT05168098|OTHER|board game comparison|The group used 24 board games popular among the elderly population in Taiwan, including Noah's Ark, Splash Attack, Pengoloo, Speedy, and Zingo. Because some games were too complicated for the participants to play, some game rules were modified into more simple and directive thinking.
223982023|NCT05168098|OTHER|olfactory stimulation intervention|The group used 15 flavors of essential oil (i.e., lavender, rosemary, sweet orange, lemongrass, mint, and hinoki) and essence (i.e., lemon, coffee, peach, magnolia, chocolate, jasmine, strawberry, pomelo, and passion fruit), purposefully selecting two to three flavors for each session. Because some flavors are familiar to the participants and some are not, the familiar flavors were initially used to trigger memory. The unfamiliar flavors (i.e., lavender, rosemary, sweet orange, and lemon) were used in later sessions because those were recognized as having potential effects on cognitive function
223982024|NCT05630378|BEHAVIORAL|outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients|Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.
223982025|NCT05630378|OTHER|waiting group|Patients receive no intervention
224119120|NCT02991820|DEVICE|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
224119121|NCT02991820|DEVICE|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
223982026|NCT01029236|OTHER|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
223982027|NCT01351337|PROCEDURE|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
223982028|NCT04149587|DRUG|Brodalumab|Brodalumab will be administered per dose and schedule specified in the arm.
223982029|NCT05266625|BEHAVIORAL|BT-001|"Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily."
223982030|NCT05266625|OTHER|Control App|The app asks patients brief questions about their health but does not include any behavioral therapy.
224119122|NCT00443430|DRUG|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
223982031|NCT03448536|DRUG|Naproxen Sodium, (Aleve, BAY117031)|220 mg \*2 tablets, orally, single dose
223982032|NCT03448536|DRUG|Acetaminophen (Tylenol Extra Strength)|500 mg \*2 caplets, orally, single dose
223982033|NCT00592189|PROCEDURE|blood draw|blood collection
223982034|NCT05476510|DRUG|Postoperative management|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
223982035|NCT05006222|DRUG|Enzyme Replacement Agent|Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
224119123|NCT00443430|DRUG|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
224119124|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
224119125|NCT00690937|DRUG|Enteric coated sevelamer|Drug treatment
223982036|NCT04137861|OTHER|Bioceramics|root repair material
223982037|NCT04016116|DRUG|Pembrolizumab|Pembrolizumab IV every 3 weeks
223982038|NCT04016116|DRUG|Ruxolitinib|Ruxolitinib po days 1-21
223982039|NCT03421639|DRUG|GnRH analog (11.25mg Leuprolide acetate)|11.25 Leuprolide acetate only one administration
223982040|NCT03421639|DRUG|Aromatase inhibitor and GnRH analog|1mg/day of Anastrazole for 3 months
223982041|NCT03421639|DRUG|Aromatase and GnRH analog (11.25mg Leuprolide acetate)|Leuprolide acetate 11.25mg only one
224119126|NCT00690937|DRUG|Colesevelam Cholestagel|Drug comparator
224119127|NCT00690937|DRUG|Placebo|Placebo
224119128|NCT00690937|DRUG|Placebo|Placebo
224119129|NCT06511856|DEVICE|ARROW|Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
224119130|NCT03074175|RADIATION|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 \<25%, lung V30 \<18%, spinal cord \<36 Gy.
223982042|NCT03747627|DIAGNOSTIC_TEST|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
223982043|NCT02528851|PROCEDURE|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
223982044|NCT01191554|DRUG|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
223982045|NCT03783546|DEVICE|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
223982046|NCT03783546|OTHER|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
224119131|NCT00418262|DRUG|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
224293903|NCT02785653|DRUG|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
224293904|NCT01805635|OTHER|No intervention|No intervention
224293905|NCT00785096|OTHER|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
224293906|NCT03877341|PROCEDURE|posterolateral fusion|Instrumented posterolateral fusion is a spinal surgery that combines bone graft fusion with the use of hardware like screws and rods to stabilize the spine, correct alignment, and promote successful fusion. It's used for various spinal conditions.
224293907|NCT03877341|PROCEDURE|posterior lumbar interbody fusion|Posterior lumbar interbody fusion (PLIF) is a spinal surgery that involves removing problematic discs, inserting bone graft material, and sometimes a spacer, to promote fusion and stabilize the spine.
224293908|NCT05704972|OTHER|the operating room environment risk|in determining the risks they face in the operating room environment.
224293909|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
224293910|NCT05227586|PROCEDURE|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation|Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
224293911|NCT06651333|DIAGNOSTIC_TEST|fMRI|Participants will be performing tasks while undergoing fMRI. Tasks include Stroop task, Emotion-regulation task and an Ambiguity reward task, Drug cue task, and Cognitive behavioral therapy task. Participants are not presented with any specific stimulus.
224293912|NCT05580952|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement system
223544023|NCT04233528|DIAGNOSTIC_TEST|Evaluation of systemic skin microvascular endothelial function|Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
223982047|NCT05128734|DRUG|Temozolomide|Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.
223982048|NCT05128734|DRUG|Olaparib|Olaparib will be administered orally twice daily in treatment arm 2.
223982049|NCT05338151|BEHAVIORAL|Brief Negotiated Interview (BNI)|Brief Negotiated Interview (with referral and telephone booster) alone
223982050|NCT05338151|BEHAVIORAL|BNI+facilitated provision of MAUD|Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)
223982051|NCT05338151|BEHAVIORAL|Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT|Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
223982052|NCT05275023|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously.
224119132|NCT00064662|PROCEDURE|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
224119133|NCT00064662|PROCEDURE|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
224119134|NCT01300780|DRUG|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
224119135|NCT01300780|OTHER|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
224119136|NCT04954469|BIOLOGICAL|CoVAC-1|Peptide vaccination should be started as soon as possible after the screening visit.
224119137|NCT02987673|PROCEDURE|MGB/OAGB|
224119138|NCT02987673|PROCEDURE|LSG|
224119139|NCT04067531|DRUG|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
223982053|NCT05275023|DRUG|PD-1 inhibitor|PD-1 inhibitor will be administered as IV infusion.
223982054|NCT05275023|DRUG|Tenofovir Disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
223982055|NCT05275023|DRUG|Tenofovir Alafenamide|TAF film-coated tablets will be administered orally.
223982056|NCT05275023|DRUG|Entecavir|ETV film-coated tablets will be administered orally.
223982057|NCT05107752|BEHAVIORAL|Cognitive Processing Therapy (CPT)|Cognitive processing therapy (CPT) is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of PTSD that have developed after experiencing a variety of traumatic events including child abuse, combat, rape and natural disasters. CPT is generally delivered over 12 sessions and helps patients learn how to challenge and modify unhelpful beliefs related to the trauma. In so doing, the patient creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life. This treatment is strongly recommended for the treatment of PTSD.
223982058|NCT05107752|DRUG|Stellate Ganglion Block|SGB is a procedure that has demonstrated efficacy for the reduction of PTSD symptoms. SGB is performed using real-time ultrasonography with an in-plane technique, and consists of 7-10 mL of ropivacaine 0.5%, which is injected around and into the site of the ganglion at the level of the C4 and C6 anterior tubercle (Mulvaney, Curtis et al., 2020). Ropivacaine is a long-acting amide local anesthetic agent and a pure S-enantiomer with a high pKa and relatively low solubility. Patients are not sedated during the procedure. Successful sympathetic blockade is confirmed by the presence of Horner's syndrome, which is characterized by constriction of the pupil (miosis) and drooping of the upper eyelid (ptosis). If Horner's syndrome is not observed within 20 minutes of the first injection, the right-sided SGB is repeated one hour later using the same technique. If Horner's syndrome is not confirmed after the second injection, no additional injections are provided.
223982059|NCT04500847|DRUG|Emtriva Capsule|200mg daily oral dose
223982060|NCT04500847|DRUG|Placebo|200mg daily oral dose
223982061|NCT01820910|DRUG|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
223982062|NCT04243798|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark)."
223982063|NCT04243798|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223982064|NCT06188624|DRUG|TQB2922 for injection|TQB2922 for injection is administrated to patients with advanced cancers, 28 days as a treatment cycle
223982065|NCT02852811|OTHER|Group education|Intervention involving two education session with topics common in menopause transition.
223982066|NCT04052997|DRUG|Camidanlumab Tesirine|Intravenous Infusion
223982067|NCT01653249|BIOLOGICAL|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
223982068|NCT00287547|DRUG|CTLA4Ig / Abatacept|
223982069|NCT04652011|PROCEDURE|Minimally Invasive Gynecologic Surgery|Minimally Invasive Surgery for gynecologic disease (laparoscopy, robotic surgery, vaginal surgery)
223982070|NCT04652011|PROCEDURE|osteopathic manipulative treatment|Osteopathic manipulative treatment
223727381|NCT04305483|PROCEDURE|Chemical Bleaching|"Total Blanc Office Teeth Whitening System (H35) will be used as chemical whitening agent. Content; There are 35% hydrogen peroxide, thickener, plant extracts, amide, release agent, glycol, paint and water. Method of Application; Gingival protection is applied. A 1 mm thick layer of gel is applied to all of the labial surfaces of the tooth. The whitening agent remains on the tooth surface for 20 minutes. At the end of this period, the gel is removed with saliva absorber and the surface is cleaned with a moist gauze."
223982071|NCT04652011|DRUG|Pain killer|Common pain killer (paracetamol, Ibuprofen, ketoprofen)
223982072|NCT05959161|PROCEDURE|DBS|We observed the prognostic changes of patients after DBS surgery
223982073|NCT05971628|PROCEDURE|RAPID procedure|RAPID procedure stands for Resection And Partial Liver Transplantation with Delayed Hepatectomy for hepatocellular carcinoma
223982074|NCT05212311|DEVICE|Chitosan Phonophoresis|Therapeutic pulsed ultrasound using EMS physio Ltd ultrasound device in presence of chitosan gel will be applied over the elbow. The following parameters will be used: US treatment was applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2.
223982075|NCT05212311|DEVICE|Therapeutic Ultrasound|US treatment will be applied for 5 min per session at a frequency of 3 MHz and an intensity of 0.5 W/cm2 in pulsed mode with a transducer area of 5 cm2 using aquasonic gel.
223982076|NCT05212311|DEVICE|Splinting|"Splinting the elbow in comfortable flexion (40-70), forearm and wrist in neutral (slight forearm pronation and wrist flexion if symptoms are severe), can allow the nerve and surrounding supporting structures the rest and relief from compression and traction.~The elbow portion of the splint should be well padded or ''bubbled out'' to provide pressure relief for the area of the cubital tunnel. It may be necessary to splint the ulnar digits of the hand to prevent contracture, maintain passive and active range of motion, and improve hand function. If the motor branch of the nerve is sufficiently involved to cause muscle denervation, a hand-based intrinsic plus splint or the use of finger-based splints to prevent clawing of the ring and small fingers will provide balanced positioning of the affected structures."
223727382|NCT03081065|DIETARY_SUPPLEMENT|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
223982077|NCT05212311|OTHER|Neural mobilization exercises of the ulnar nerve|Nerve mobilization exercises Inflammation or adhesions anywhere along the ulnar nerve path can cause the nerve to have limited mobility and essentially get stuck in one place. These exercises help stretch the ulnar nerve and encourage movement through the cubital tunnel
223982078|NCT03560414|PROCEDURE|simple plasma exchange|simple plasma exchange treatment
223982079|NCT03560414|PROCEDURE|conventional PDF treatment group|conventional PDF treatment group
223982080|NCT03560414|PROCEDURE|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
223982081|NCT02942368|DEVICE|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
223982082|NCT02453516|PROCEDURE|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
223982083|NCT02453516|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
223982084|NCT02453516|DRUG|ropivacaine|Drug indicated for regional anesthesia
223982085|NCT02453516|DRUG|epinephrine|Drug indicated to prolong the action of regional anesthesia
223982086|NCT02453516|OTHER|sterile saline|Neutral injection (no drug involved)
223982087|NCT01939821|BEHAVIORAL|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
223982088|NCT01939821|BEHAVIORAL|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
223982089|NCT01024036|DRUG|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
223982090|NCT01024036|DRUG|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
224119140|NCT02471131|DEVICE|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
223982091|NCT01024036|DRUG|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
224119141|NCT06139380|DRUG|Ketamine|This is medication which is commonly used for sedation in the emergency department. At the analgesic dose, this medication can be used to reduce the pain via other routes such as intranasal.
224293913|NCT04661592|DEVICE|NeuroCatch Platform|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch™ Platform version 2.0, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. Version 2.0 of the NeuroCatch™ Platform consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
224293914|NCT00726102|OTHER|Meat|2 0z of locally available meat per day
224293915|NCT00726102|OTHER|Cereal|Daily provision of cereal to infants from 6-18 mos
224119142|NCT06139380|DRUG|Sterile water|Intranasal sterile water was administered via syringe.
224119143|NCT04384640|OTHER|Change of posture after Intra Tympanic injection|Seating position after Intra Tympanic injection
224119144|NCT03731416|PROCEDURE|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
224119145|NCT03855917|DRUG|Sofosbuvir 400mg [Sovaldi]|Four weeks.
224119146|NCT03855917|DRUG|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
224119147|NCT03242096|COMBINATION_PRODUCT|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
223982092|NCT05230095|BEHAVIORAL|social cognition tests|"The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene.~Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery.~Healthy volunteers will be evaluated only one time."
223982093|NCT05230095|BEHAVIORAL|Quality of life self-questionnaire|Quality of life will be assessed using a self-administered questionnaire in the patients group only.
223982094|NCT03246399|DRUG|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
223982095|NCT03282578|DEVICE|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
223982096|NCT03282578|DEVICE|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
223982097|NCT04017897|DRUG|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
223982098|NCT02570256|BEHAVIORAL|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
223982099|NCT02570256|BEHAVIORAL|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
223727383|NCT00750204|DEVICE|APRV|"APRV Protocol~* Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~* Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~* Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~* P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~* Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~* If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
223727384|NCT00750204|DEVICE|Conventional MV|Low tidal-volume mechanical ventilation
223727385|NCT02701439|DEVICE|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention will be administered to both arms"
223727386|NCT06463327|DRUG|TCB008|TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
224119148|NCT03242096|COMBINATION_PRODUCT|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
223982100|NCT02570256|BEHAVIORAL|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
223982101|NCT04130581|OTHER|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
223982102|NCT04440059|DRUG|ICP-022|ICP-022 at a dose of 150mg PO QD
224119149|NCT04292119|DRUG|Lorlatinib|"Lorlatinib will be taken orally once daily for 28 days when combined with crizotinib or binimetinib. Lorlatinib will be taken orally once daily for 21 days when combined with TNO155.~Crizotinib taken orally twice daily for 28 days."
224119150|NCT04292119|DRUG|Crizotinib|"Crizotinib will be taken orally twice daily for 28 days.~Binimetnib taken orally twice daily for 28 days."
224293916|NCT00726102|OTHER|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
224119151|NCT04292119|DRUG|Binimetinib|Binimetinib will be taken orally twice daily for 28 days.
224119152|NCT04292119|DRUG|TNO155|TNO155 will be taken orally once daily for 14 days.
224293917|NCT00567437|OTHER|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
224293918|NCT00784524|BIOLOGICAL|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
223727387|NCT05188950|DEVICE|depression screening test App|The participants' use of the depression screening test App of 6 modules for 12 weeks, at least once a week, 20 minutes per once.
224119153|NCT02512016|OTHER|Study Procedures|"* Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~* Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~* Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~* Measures of strength and body habitus:~  8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~  1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~* Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
224293919|NCT00784524|BIOLOGICAL|aldesleukin|Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
223727388|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
223727389|NCT01092754|PROCEDURE|MRI|contrast enhanced MRI
223727390|NCT01092754|DRUG|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
224293920|NCT03570450|DRUG|Adipose derived Stem Cell|4 doses
224293921|NCT03570450|OTHER|placebo|placebo
224293922|NCT00494624|DRUG|prednisolone|
223982103|NCT06215703|BEHAVIORAL|Music Playing Task|For the music playing task, participants will tap on an MRI compatible MIDI drum in response to music, while following directions to either (1) maintain the beat of the music or (2) improvise a beat along with the music. Piano accompaniment for drum playing will be provided either (1) with a recording or (2) by a live music therapist. Participants will complete all four combinations of these music playing tasks following the sequence of experimental order 3. Each of the four tasks will be repeated with four one-minute songs, resulting in a total of 16 minutes of drum playing required to complete the study procedures. Participants will repeat the same task order with each song to facilitate task comprehension and task completion accuracy. Song order will be randomized for all participants.
223727391|NCT03405506|DEVICE|Quantitative Flow Ratio (QFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
223982104|NCT06254300|BEHAVIORAL|Exercise Training|The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
223982105|NCT03900429|DRUG|MGL-3196|Tablet
223982106|NCT03900429|DRUG|Placebo|Matching Tablets
223982107|NCT03900429|PROCEDURE|Liver Biopsy|A procedure in which a needle is inserted into the liver to collect a tissue sample
223982108|NCT00557349|DRUG|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
223982109|NCT00557349|DRUG|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
223982110|NCT02850718|DRUG|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
223982111|NCT02850718|DRUG|Oral Sildenafil|50 mg oral sildenafil (Viagra)
223982112|NCT02291809|BIOLOGICAL|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
223982113|NCT04303442|PROCEDURE|TEP|Total extraperitoneal laparoendoscopic hernia repair with one or three skin incisions.
223982114|NCT03524768|DIAGNOSTIC_TEST|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
224119154|NCT04615390|BEHAVIORAL|Early rehabilitation|The intervention is primarily focused on the recovery of mobility and functional autonomy. The treatment sessions are dependent on the patient's exercise tolerance.
223982115|NCT01817712|BEHAVIORAL|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
223727392|NCT06265727|DRUG|CRB-701|Nectin-4 targeted Antibody Drug Conjugate (ADC)
223727393|NCT06265727|DRUG|Anti-PD-1|checkpoint inhibitor
223982116|NCT01817712|BEHAVIORAL|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
223982117|NCT04498988|OTHER|Observational study without interventions|
224119155|NCT04615390|BEHAVIORAL|Subacute rehabilitation|Comprehensive intensive rehabilitation in the hospital
224119156|NCT04615390|BEHAVIORAL|Mindfulness training|The home mindfulness training consists of 2 parts: 1) explanation and reflection of the Mindfulness practice 2) formal and informal practice.
224119157|NCT04615390|BEHAVIORAL|Personalized ambulatory training|Low-intensity walking exercises at home
224119158|NCT05181917|BEHAVIORAL|STUDIA app|STUDIA application has two functions, an insulin bolus calculator that estimates the amount of insulin according to the amount of carbohydrates that the patients compute, the insulin sensitivity factor, and the insulin/carbohydrate ratio provide by their treating physician. The application has a graphical interface that shows a glucose curve four hours after the meal. . This graph is built using the estimations made by an MSBF based on some characteristics of the patient previously recorded in the same application, the amount of carbohydrates entered to calculate the insulin bolus, and an estimate of the fat and protein content of the meal.
224119159|NCT01243606|BEHAVIORAL|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
223982118|NCT05904756|DEVICE|framework for implant supported prosthesis, fabricated from metal of polyetherketoneketone|evaluation of patient satisfaction and oral healty related quality of life
223982119|NCT03094455|OTHER|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
223982120|NCT03111797|DRUG|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
224119160|NCT01243606|BEHAVIORAL|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
223727394|NCT06122207|DIETARY_SUPPLEMENT|Probiotic|"* Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy:~  * Women: 1 capsule of probiotic per day for 12 weeks.~* Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months."
223982121|NCT03111797|OTHER|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
223982122|NCT01190722|DRUG|etoricoxib|120 mg once daily for the 1st 6 postoperative days
223727395|NCT06122207|DIETARY_SUPPLEMENT|Placebo|"* Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy:~  * Women:1 capsule of placebo per day for 12 weeks.~* Men: 1 capsule of placebo per day for 6-months."
223727396|NCT06562894|DRUG|SYHX1901|Administered orally, once daily (QD)
223727397|NCT06562894|DRUG|Placebo|Administered orally, once daily (QD)
223727398|NCT06119685|DRUG|IDP-023|NK cell therapy
223727399|NCT06119685|DRUG|Rituximab|Anti-CD20 antibody therapy
223982123|NCT01190722|DRUG|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
223982124|NCT00102271|DRUG|Oxypurinol|
223982125|NCT00102271|DRUG|Sodium Nitrite|
223727400|NCT06119685|DRUG|Daratumumab|Anti-CD38 antibody therapy
223727401|NCT06119685|DRUG|Interleukin-2|Immune cytokine
223727402|NCT06119685|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy
223727403|NCT06119685|DRUG|Fludarabine|Lymphodepleting chemotherapy
223727404|NCT06119685|DRUG|Mesna|Chemoprotectant
223727405|NCT06119685|DRUG|Isatuximab|Anti-CD38 antibody therapy
223727406|NCT03567304|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
223727407|NCT04180579|DEVICE|PAXMAN Scalp Cooler|Scalp cooling will occur with each dose of chemotherapy.
223727408|NCT04783480|OTHER|Birthly|Women will receive a code to sign up for 3 free interactive childbirth education classes through the Birthly platform. They will be enrolled in 3 courses: Prenatal Education, Childcare and Breastfeeding. They will be encouraged to complete all courses prior to 36 weeks gestational age.
223727409|NCT04783480|OTHER|Standard of care|Subjects will participate in childbirth education at their own discretion.
224119161|NCT04674852|DEVICE|Research Marker|The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
224119162|NCT04895059|DRUG|Rosuvastatin (20mg) /Ezetimibe (10mg) in fixed dose|Form: Tablets Dosage: 20 mg Adminstration way: Oral
224119163|NCT04895059|DRUG|Rosuvastatin 20mg|Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration way: Oral
224119164|NCT04895059|DRUG|Ezetimibe 10mg|Pharmaceutical Form: Tablets Dosage: 10 mg Adminstration way: Oral
224119165|NCT00023907|DRUG|paclitaxel|
224119166|NCT00504166|DRUG|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
223727410|NCT03529851|OTHER|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
223727411|NCT00850564|DRUG|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
223727412|NCT02303301|DIETARY_SUPPLEMENT|Probiotics|Cultures from the oropharynx
223982126|NCT03115229|BEHAVIORAL|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
223982127|NCT06010550|RADIATION|Magnetic resonance imaging|Brain magnetic resonance imaging
223982128|NCT06320847|DIAGNOSTIC_TEST|rPPG|A pulse oximeter and blood pressure cuff will be applied on the study patient by the study team member (research coordinators). At the same time, vital signs from Nervotec's rPPG technology will be recorded via the laptop and webcam. Synchronous measurement process of heart rate, respiration rate, pulse oximetry, heart rate variability and blood pressure estimates using Nervotec rPPG technology will take place for a duration of 3 minutes.
223982129|NCT05648604|BEHAVIORAL|Mentored Community Gardening|This arm will consist of gardening at least once per week, meeting with a master gardening mentor twice monthly, and attending a gardening informational workshop once monthly.
223982130|NCT05588947|OTHER|Take Charge session|A 'talk therapy' session designed to harness the person's self-determination, re-establishing purpose, identity, autonomy, and skills to Take Charge of their recovery after stroke
223982131|NCT05588947|OTHER|Active Control|Life After Stroke educational video
223544024|NCT02073162|PROCEDURE|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
223544025|NCT01669746|BIOLOGICAL|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
223544026|NCT05137691|OTHER|Adapted NHS weight management 1:1 programme|Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
223544027|NCT05137691|OTHER|NHS 1:1 weight management programme|NHS 1:1 weight management programme
223982132|NCT04214327|BEHAVIORAL|Strengthening Families Program Online eLearning Game|Families (parent/caregiver and children) are to play-test a highly interactive online gamified version of the Strengthening Families Program called SFP Online, with 10 lessons that utilize three 10-minute mini-sessions and games that teach parents evidence-based parenting and family relationship skills and teach youth social, life, and alcohol and drug refusal skills. Skills are reinforced through gaming. Game points are achieved by right answers to self-correcting mini-quizzes for low-stakes failure and through actual reported home practice of the skills. The SFP parenting skills have been shown to reduce risk factors and increase protective factors that prevent youth substance abuse.
223982133|NCT04214327|BEHAVIORAL|SFP Home-use DVD|Family views an 11-session SFP video series online or at home using a DVD that contains the same program and lesson content as the online condition; however, the lesson material is more static without the interaction required in the gamified version of SFP Online.
223982134|NCT04214327|BEHAVIORAL|Wait-Listed Control|Families receive no active intervention for 22 weeks; however, during this wait time, participants receive weekly email reminders that contain riddles and puzzles for youth and parents receive nutritional information and food preparation recipes. Following conclusion of the initial trial the wait-listed control sites are then administered the 10-session SFP Online intervention
223727413|NCT02303301|DIETARY_SUPPLEMENT|Placebo|Cultures from the oropharynx
224119167|NCT00504166|OTHER|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
224119168|NCT04736524|OTHER|Rapid antibody test|Serial serology tests on day 21, 90, 180 and 365 following the first dose of the COVID-19 vaccine to detect the temporal trend of the IgM and IgG production in response to the vaccination.
224119169|NCT05537324|OTHER|Brazil nut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 50g Brazil nuts
224119170|NCT05537324|OTHER|Coconut|Blood lipids are measured at baseline and 3h, 6h, 24h, 7d and 14d after ingestion of 46g coconut flakes
224119171|NCT06070623|DEVICE|US|We use elastography and color Doppler from US machine and compare results with CT
224119172|NCT05941884|DIAGNOSTIC_TEST|Immunohistochemistry staining,|"Tissue samples:~* Histopathological examination: Hematoxylin and Eosin slides will be prepared and examined.~  * The only dependable criterion for the diagnosis of bilharzial infestation is the microscopic detection of Bilharzia ova in pathological sections.~ * Pathology (cystitis- cancer and its grade staging will be reported in accordance with the 2022 World Health Organization Classification of Tumors of the Urinary System (17).~* To quantify levels of Nuclear factor kappa B and protein kinase c α:~  * Immunohistochemistry according to the manufacturer's instructions."
224119173|NCT05941884|DIAGNOSTIC_TEST|microscopic examination of urine|"Urine samples:~* Mic roscopic examination (detection of S. haematobium egg - egg counting)~* Detection of HSP 70 Measurements: indirect ELISA will be used to quantify HSP concentrations in urine."
224119174|NCT04743414|DRUG|CTP-543|Itraconazole in solution dosage form
223727414|NCT06440408|DRUG|Ferumoxytol|Ferumoxytol will be used as a contrast agent for the cMRI
223727415|NCT06087107|OTHER|High Intensity Spinal Decompression Exercises|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes with 8-10 repetitions of each exercise.
224119175|NCT00192517|DRUG|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
223727416|NCT06087107|OTHER|Eldoa|The duration of the intervention will be 4 weeks, 3 sessions a week, and a total of 12 sessions will be given to the study participants. Each session will last for 40 minutes.
224119176|NCT00192517|OTHER|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
224119177|NCT04499508|DEVICE|Optima Coil System|Patients who have qualified for endovascular coiling in effort to treat intracranial aneurysms were treated with
224119178|NCT02665442|DEVICE|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
224119179|NCT04254237|PROCEDURE|Infraumbilical Hasson trocar incision|Infraumbilical Hasson trocar incision
224119180|NCT04254237|PROCEDURE|Supraumbilical Hasson trocar incision|Supraumbilical Hasson trocar incision
224119181|NCT01713400|DRUG|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
223727417|NCT07131449|OTHER|This is observational studies, participants are not assigned an intervention as part of the study.|This is observational studies, participants are not assigned an intervention as part of the study.
223727418|NCT07132697|DRUG|L-Amino acid mixture|Continuous infusion of a L-amino acids mixture in a dose of 2 g/kg dry body weight/day (to a maximum 100 g/day) after induction of anesthesia and insertion of CVP line till 72 hours after treatment initiation
223727419|NCT07132697|OTHER|Standard of care|Standard peri tranplant care as per out institution including intra operative and post operative care. Its includes starting of immunosuppression after serial blood investigation monitoring.
224119182|NCT01713400|DRUG|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
224119183|NCT01713400|DRUG|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
224119184|NCT01713400|DRUG|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
224119185|NCT01227915|DRUG|Tobracort|tobramycin 0.3% + dexamethasone 1%
224119186|NCT01227915|DRUG|Tobradex|tobramycin 0.3% + dexamethasone 1%
224119187|NCT03172546|GENETIC|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
223727420|NCT07131397|DEVICE|Inspiratory Muscle Traing|IMT will be performed by applying resistance at 40% of the maximum inspiratory pressure (1 set of 30 repetitions 30 breaths per session). Each week there will be a gradual increase in resistance by 10% of the initial maximum inspiratory pressure.
223727421|NCT07131397|DEVICE|Sham Inspiratory Muscle Training|Inspiratory muscle training will be applied with a constant resistance load of 7cmH20
223727422|NCT07131098|OTHER|Early Enteral Feeding Protocol|Early enteral nutrition was initiated within 24-48 hours of ICU admission based on a structured protocol aligned with ASPEN and ESPEN guidelines. The protocol defined target caloric goals, methods of tube feeding initiation, rate advancement, and monitoring procedures. Nurses and ICU staff were trained in protocol implementation. The goal was to optimize nutrition early in critical illness to improve clinical outcomes such as ICU length of stay, ventilator dependence, and physiological stability.
223982135|NCT05901155|DEVICE|MedAL-mentor|MedAL-mentor is a near real-time monitoring and benchmarking dashboard based on data collected through ePOCT+, providing direct feedback on several clinical indicators (antibiotic prescription, performance of key measurements, signs, and diagnostic tests).
223982136|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
223982137|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
223982138|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
223982139|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
223982140|NCT01999972|DRUG|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
223982141|NCT01999972|DRUG|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
223982142|NCT06105762|OTHER|Ketogenic Diet|The ketogenic diet intervention, administered as a Modified Atkins Diet, involves a significantly reduced daily carbohydrate intake, typically less than 20 grams of net carbs. This approach primarily relies on higher fat consumption to induce ketosis, a metabolic state characterized by elevated ketone body production, serving as an alternative brain fuel source.
223982143|NCT00103532|BEHAVIORAL|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
223982144|NCT00103532|BEHAVIORAL|Standard care|Participants will receive standard care plus referrals at three months post-baseline
224119188|NCT03704792|DEVICE|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
223982145|NCT00803777|DEVICE|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
223982146|NCT00002463|DRUG|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
223982147|NCT00002463|DRUG|Leucovorin Calcium|
223982148|NCT00002463|DRUG|Mechlorethamine Hydrochloride|
223982149|NCT00002463|DRUG|Methotrexate|
224119189|NCT05527704|DRUG|Salbutamol|Patients assigned to the active group will be treated with 0.15 mg/kg body weight (diluted in 3 mL 0.9% NaCl) nebulized salbutamol (Ventolin®, GlaxoSmithKline, Dublin, Ireland) for 30 min.
224119190|NCT05527704|DRUG|0,9% Chloride Sodium|3 mL nebulized 0.9% NaCl administered for 30 min.
224119191|NCT02796404|DEVICE|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
224119192|NCT02796404|OTHER|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
224119193|NCT01581112|BIOLOGICAL|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
224119194|NCT05090410|DRUG|filgotinib 200mg/day|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
224119195|NCT05090410|DRUG|subcutaneous tocilizumab 162mg/biweekly|Patients will be randomized in a 1:1 ratio to the administration of filgotinib 200mg/day or subcutaneous tocilizumab 162mg/biweekly switched from MTX ± other csDMARDs throughout the study period.
223727423|NCT07131098|OTHER|Standard Nutritional Care|Patients in the control group received standard nutritional care per routine hospital practices. Initiation and progression of feeding were left to the discretion of the attending physician and nursing staff, without the use of a structured protocol or defined early feeding timeline.
223982150|NCT00002463|DRUG|Prednisone|
224119196|NCT06512038|RADIATION|DEXA Scan|If the participant consents to take part in the trial, they will have an additional DEXA scan.
224119197|NCT02650284|DEVICE|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
223982151|NCT00002463|DRUG|Procarbazine Hydrochloride|
223982152|NCT00002463|DRUG|Vincristine Sulfate|
223982153|NCT00002463|PROCEDURE|Conventional Surgery|
223982154|NCT01861639|DEVICE|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
224119198|NCT02650284|DEVICE|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
224119199|NCT06314906|DEVICE|Electroacupuncture|Participants in this arm will undergo electroacupuncture sessions once daily from day 1 to day 4. Electrical stimulation will be administered for 30 minutes at alternating frequencies of 2/10Hz
224293923|NCT01852734|PROCEDURE|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
223982155|NCT01861639|DEVICE|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
223982156|NCT01861639|DEVICE|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
223982157|NCT01861639|DEVICE|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2\*-weighted echo-planar imaging sequence
223982158|NCT01861639|DEVICE|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
223982159|NCT01861639|DEVICE|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
223982160|NCT02369861|DRUG|ST266|Topical ocular application 4 times per day
223982161|NCT02369861|DRUG|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
223982162|NCT05731505|BEHAVIORAL|theory-based education-consulting|Parents in the study groups were provided with training and support in line with their needs in the educational issues specified in the Family Education-Support Booklet for a Child with Cerebral Palsy. The control group was not trained. Research data were collected using the Child and Parent Information Form, Needs Determination Form, Relaxed Behavior Checklist (KDKL), Quality of Life for Children Parent Form (PIDQ) and Self-Efficacy Scale. The comfort and quality of life of the children in the study group and the self-efficacy of the parents were evaluated before the education, 1 month and 3 months after the education.
223982163|NCT01986114|DRUG|SM-13496|
223982164|NCT00438178|DRUG|Obatoclax mesylate (GX15-070MS)|
223982165|NCT02450890|DRUG|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
223727424|NCT07132398|DRUG|Slow-tapering glucocorticoids + Inebilizumab|Slow-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab. The prednisone dose will be tapered as follows: a reduction of 5 mg every 2 weeks until reaching 20 mg/day(Week 16); thereafter, a reduction of 5 mg every 4 weeks until discontinuation (a total duration of 32 weeks for combined inebilizumab and glucocorticoids therapy).
223982166|NCT02450890|DRUG|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
223982167|NCT00220545|PROCEDURE|Laparoscopic ovarian diathermy|
223982168|NCT02185105|DEVICE|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
223982169|NCT02185105|DEVICE|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
223982170|NCT02808975|DRUG|Placebo|Subcutaneous injections administered as described in arm description
223982171|NCT02808975|DRUG|Adalimumab|Subcutaneous injections administered as described in arm description
223982172|NCT01672138|PROCEDURE|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
223982173|NCT01672138|PROCEDURE|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
223982174|NCT01672138|PROCEDURE|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
224119200|NCT06314906|DRUG|Antiemetic Therapy|Participants will receive oral olanzapine at a dose of 5 mg per day on days 1 through 4, along with NK1 receptor antagonist, 5HT3 receptor antagonist, and intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.
224119201|NCT06314906|DEVICE|Sham electroacupuncture|Participants assigned to this arm will receive sham electroacupuncture sessions daily from day 1 to day 4, mirroring the schedule of the experimental group
224119202|NCT06314906|DRUG|Antiemetic Therapy|They will also receive the same antiemetic medications as the experimental group.
224119203|NCT05296421|PROCEDURE|Biopsy|Undergo biopsy
224119204|NCT05296421|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223982175|NCT03234361|DIETARY_SUPPLEMENT|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
223982176|NCT03234361|DIETARY_SUPPLEMENT|Low Phosphate Phase|2 capsules of sodium chloride.
223982177|NCT06956729|PROCEDURE|Proximal Femoral Guided Growth.|"Proximal Femoral Guided Growth (PFGG) is performed under general anesthesia with the patient in a supine position on a radiolucent table. The surgical field is prepared from the abdomen to the feet. Anatomical landmarks on the femur and femoral neck are marked to guide the procedure.~A smooth guidewire (4.0-7.0 mm) is introduced parallel to the table and advanced to the lateral quarter of the femoral neck.~A 1-2 cm incision is made along the lateral femur, allowing access to the vastus lateralis muscle.~Fluoroscopic control is used to ensure precise guidewire placement in the proximal femoral epiphysis in both anteroposterior (AP) and lateral views.~The lateral cortex is drilled, and a fully threaded cannulated screw is inserted, ensuring at least three threads reach the epiphysis for effective growth modulation.~Final fluoroscopic verification is performed to confirm proper screw placement and rule out joint penetration. Continuous fluoroscopy is used if necessary.~The guidewire is r"
224119205|NCT05296421|OTHER|Uniformly-labeled [13C]glucose|Given IV
224119206|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement by subject|blood glucose measurement by subject using finger tip capillary blood
224119207|NCT06037538|DIAGNOSTIC_TEST|blood glucose measurement with reference|blood glucose measurement with reference method using finger tip capillary blood
223982178|NCT06956729|PROCEDURE|Standard prophylactic treatment for Hips at Risk of Dislocation.|"Both groups will receive standard prophylactic treatment for HRD, which consists of soft tissue release procedures based on clinical indication and functional level (GMFCS classification):~Adductor Tenotomy - Percutaneous or open technique, depending on contracture severity.~Psoas Tenotomy - Intrapelvic approach for GMFCS levels I-III and IV (ambulatory). Lesser trochanter approach for GMFCS levels IV-V (non-ambulatory). Additional tenotomies may be performed as needed, targeting muscles contributing to hip displacement and contractures.~Botulinum toxin type A may be administered to specific muscle groups if clinically indicated.~Postoperative immobilization includes:~Hip abduction wedge Knee immobilizers in extension Ankle-foot orthoses (AFOs), based on individual patient needs~The goal of this intervention is to reduce spastic muscle imbalance, improve hip stability, and delay or prevent hip dislocation in children with spastic CP and HRD."
223727425|NCT07132398|DRUG|Rapid-tapering glucocorticoids + Inebilizumab|Rapid-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab, with a tapering schedule of 5 mg reduction per week until discontinuation (a total duration of 12 weeks for combined inebilizumab and glucocorticoids therapy).
224119208|NCT03711552|OTHER|ObsQoR-11|Quality of recovery questionnaire
223727426|NCT07125521|OTHER|GERCCare mobile app|Using the smartphone application GERDCare (with detailed instructions provided during recruitment)
224119209|NCT03711552|OTHER|QoR-15|Quality of recovery questionnaire
224119210|NCT04523285|DRUG|TQB3728|TQB3728 tablets is a small molecule oral drug.
224119211|NCT06115577|DIAGNOSTIC_TEST|endometrial tissue and peripheral blood mononuclear cells receptivity|Participants investigated the expression level of estrogen and progesterone receptors (ERα, ERβ, GPER, PRA, PRB, mPR, PGRmC1) by RT-PCR in pathological endometrial tissue and peripheral blood mononuclear cells. GABDH was used as a comparison gene.
224293924|NCT01852734|PROCEDURE|embolizations|comparison between the two microspheres
223982179|NCT06957704|DRUG|ketamine|Ketamine will be administered as adjunctive therapy at an initial dose of 0.5 mg/kg via subcutaneous injection, twice weekly for four weeks, under double-blind conditions. Dose adjustments between 0.5 and 1.0 mg/kg will be based on depressive symptoms, efficacy, and tolerability. All procedures will occur at the Ketamine Clinic of Federal University of São Paulo.
223982180|NCT06957704|DRUG|Midazolam|Midazolam will be administered subcutaneously twice weekly for four consecutive weeks, also under double-blind conditions. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
223982181|NCT01885923|DEVICE|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
224119212|NCT06339229|OTHER|proteinuria|dipstick proteinuria values negative, trace, 1+, and ≥2+
224119213|NCT00509873|DRUG|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
224119214|NCT00509873|DRUG|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
224293925|NCT01751542|BEHAVIORAL|Mindfulness + Residential Treatment|
223727427|NCT07133217|DEVICE|Root canal preparation with Hand Files (Dentsply Sirona)|Root canal treatments were performed with hand files
223727428|NCT07133217|DEVICE|Root canal preparation with the WaveOne Gold file system (Dentsply Sirona, Ballaigues, Switzerland)|Root canal treatments were performed with WaveOne Gold Files
223727429|NCT07133217|DEVICE|Root canal preparation with the ProTaper Ultimate file system (Dentsply Sirona)|Root canal treatments were performed with ProTaper Ultimate Files
223982182|NCT03060382|DEVICE|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
223982183|NCT03060382|BIOLOGICAL|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
223982184|NCT00030823|BIOLOGICAL|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
223982185|NCT00030823|BIOLOGICAL|QS21|
223982186|NCT01488955|DRUG|Ibuprofen|400 mg oral once a day from day 0 for 3 days
224293926|NCT01751542|BEHAVIORAL|Residential treatment alone|
224293927|NCT00107718|DRUG|SB-485232|
224293928|NCT03993249|BIOLOGICAL|Nivolumab|standard of care chemoradiotherapy + Nivolumab
224293929|NCT03993249|OTHER|chemoradiotherapy|standard of care chemoradiotherapy
224293930|NCT00419549|DRUG|Glyceryl - trinitrate|Transdermal Patch once only
224293931|NCT00419549|DRUG|Valdecoxib|Single parenteral administration
224293932|NCT02277704|DRUG|TNX-102 SL|
224293933|NCT02277704|DRUG|Placebo|
223982187|NCT01488955|DRUG|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
223982188|NCT03102489|DRUG|BP101|Nasal spray
223982189|NCT03102489|DRUG|Placebo|Nasal spray
223982190|NCT05019170|BEHAVIORAL|Smartphone-based Financial Incentives|Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
223982191|NCT05019170|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
223982192|NCT00706771|DRUG|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
223982193|NCT00706771|DRUG|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
223982194|NCT06456476|DIAGNOSTIC_TEST|ERCP|ERCP used only if needed in some patients
223982195|NCT03513744|DIETARY_SUPPLEMENT|human milk oligosaccharides|mixture of five different human milk oligosaccharides
223982196|NCT01509261|DRUG|Ilaprazole|20mg/Tap, QD
223982197|NCT01509261|DRUG|Lansoprazole|30mg/Tap, QD
223982198|NCT01083199|DEVICE|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
223982199|NCT00269932|DRUG|levofloxacin|
223982200|NCT04415645|DRUG|[14C]-VVZ-149|A single IV infusion of radio-labeled VVZ-149
224293934|NCT00474604|PROCEDURE|diffusion-weighted magnetic resonance imaging|A scan will be performed.
224293935|NCT00474604|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
224293936|NCT00474604|PROCEDURE|magnetic resonance spectroscopic imaging|A scan will be performed.
224293937|NCT05421104|OTHER|Ruxolitinib|PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
224293938|NCT01408563|DRUG|Fludarabine|30 mg/m2/day IV x 6 days
223982201|NCT04333147|BIOLOGICAL|Otilimab (GSK3196165)|GSK3196165 solution in vial/pre-filled syringe (PFS) and auto injector (AI) to be administered SC.
223982202|NCT04333147|DRUG|csDMARD(s)|Stable dose of csDMARD(s) as standard of care (SoC).
223982203|NCT02106195|DRUG|Belumosudil|
223982204|NCT05498922|PROCEDURE|Peak pressure when mechanical ventilation was switched around a reasonable range|The research protocol was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consents were obtained from all patients. After induction of anesthesia, Rb patients were transorally intubated and mechanically ventilated. The inspiratory time, ventilation rate, positive end-expiratory pressure, and oxygen concentration were set consistently among patients. When anesthesiologist switch the peak pressure around a reasonable range, indices including tidal volume, lung compliance, mean airway pressure on ventilator screen changed and were recorded when stable. All the ventilator setting parameters followed the guidance of mechanical ventilation in neonates and children (https://doi.org/10.1007/978-3-030-83738-9\_8). All the anesthesia and ventilation performance were conducted by a fully qualified senior anesthesiologist to assure standardized and safe anesthesia, ventilation and operation procedure.
223982205|NCT03215953|DEVICE|cast shoe|ankle-high, custom-made, well-moulded cast shoe
223982206|NCT03215953|DEVICE|removable walker|Prefabricated especially designed for relieving load on the foot
224119215|NCT04174131|DEVICE|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
224119216|NCT04174131|DEVICE|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
224119217|NCT03753568|DEVICE|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
224119218|NCT04877548|OTHER|Fermented orange flour|Volunteers will have to consume a standardized breakfast including fermented orange flour and presenting 50g of available carbohydrates
224119219|NCT04877548|OTHER|Fermented grape flour|Volunteers will have to consume a standardized breakfast including fermented grape flour and presenting 50g of available carbohydrates
224293939|NCT01408563|DRUG|Melphalan|100 mg/m2/day IV x 1 day
224293940|NCT01408563|RADIATION|Total Body Radiation|200 cGy on Day 0
224293941|NCT01408563|BIOLOGICAL|Cord Blood|2 cord blood units IV
224293942|NCT03142516|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
223982207|NCT06957522|OTHER|face to face rehabilitation|"The face-to-face rehabilitation program will be delivered in a clinical setting to infants aged 0-6 months with congenital muscular torticollis (CMT). It is based on neurodevelopmental treatment (NDT) principles and consists of:~Passive range of motion (ROM) exercises for the neck~Active ROM exercises for the neck and trunk~Activities to promote the development of symmetrical movement~Environmental modification suggestions for the home setting~Parent/caregiver education and training~Sessions will be conducted twice per week, 30 minutes per session, over a total of 8 weeks.~In addition, an individualized home exercise program will be prescribed for each infant based on their specific needs. Frequency and duration of the home exercises may vary accordingly."
224293943|NCT03142516|DRUG|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
223982208|NCT06957522|OTHER|telerehabilitation|"The telerehabilitation program provides the same therapeutic content as the face-to-face rehabilitation group but will be delivered remotely via the Zoom video conferencing platform. The program will be applied to infants aged 0-6 months with congenital muscular torticollis (CMT) and is based on neurodevelopmental treatment (NDT) principles, including:~Passive range of motion (ROM) exercises for the neck~Active ROM exercises for the neck and trunk~Activities for symmetrical movement development~Environmental modification suggestions~Parent/caregiver education and guidance~Sessions will be conducted via live video calls, twice per week, 30 minutes per session, for 8 weeks.~Each family will also receive an individualized home exercise program, with its frequency and duration adapted to the infant's needs."
223982209|NCT06957041|PROCEDURE|Intertransverse process block|The patient(s) will receive a pre-induction Intertransverse process block as pilot study
223982210|NCT06957054|OTHER|Any|Any
223982211|NCT04182633|COMBINATION_PRODUCT|vancomycin, Miralax, intestinal microbiota|vancomycin for 14 days, then Miralax for 1 day, then intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
223982212|NCT04182633|COMBINATION_PRODUCT|placebo vancomycin, Miralax, placebo intestinal microbiota|placebo vancomycin for 14 days, then Miralax for 1 day, then placebo intestinal microbiota (high dose for 2 days, then maintenance dose for 12 weeks)
223982213|NCT06529718|DRUG|Ivonescimab|20 mg/kg IV infusion every 3 weeks
223982214|NCT06529718|DRUG|FOLFOX regimen|oxaliplatin 85 mg/m² IV, leucovorin 200 mg/m² IV (or folinic acid 400 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m² as a 46 hour continuous IV infusion, every 2 weeks
223982215|NCT06633757|DRUG|RCT1100|mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
223982216|NCT03939182|DRUG|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
224293944|NCT03142516|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
224293945|NCT03142516|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
223982217|NCT03939182|DRUG|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
223982218|NCT04743934|DRUG|Flibanserin 100 MG|Flibanserin 100mg tablets taken by mouth daily at bedtime
223982219|NCT04743934|DRUG|Placebo|Visually identical placebo tablets taken by mouth daily at bedine
223982220|NCT04743934|DRUG|Androgen deprivation therapy|Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
223982221|NCT03062449|DRUG|L-Serine|Gummy containing L serine dose
223982222|NCT03062449|OTHER|Placebo Gummy|Gummy with no dosing of L Serine
223982223|NCT03765398|BEHAVIORAL|VR Cognitive-motor-balance training|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
223982224|NCT02168283|COMBINATION_PRODUCT|treatment arm|Hypertonic peritoneal dialysis cycles
223982225|NCT02168283|BEHAVIORAL|Control arm|Dietary counseling
223982226|NCT02578888|OTHER|Palliative Therapy|Palliative Therapy
223982227|NCT02578888|OTHER|Palliative Therapy + idiographic|Ancillary studies
223982228|NCT05013515|DRUG|Surufatinib|"Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator."
223982229|NCT04702893|DRUG|Nintedanib|150 or 100 milligrams (mg) of nintedanib, when 150 mg is not tolerated, twice daily, administered 12 hours apart, according to the approved label.
223982230|NCT05900180|BEHAVIORAL|Speech Therapy|Delivery of speech therapy services
223982231|NCT06140901|DIAGNOSTIC_TEST|Study morphological and functional of respiratory epithelium|The working's investigators hypothesis is that the morphology and functional of the epithelium of children with ADV or RV respiratory infection is different between those who progress to PIBO and those who do not.
223982232|NCT06013865|DRUG|Empagliflozin|SGLT2 Inhibitor
224293946|NCT03030716|DIETARY_SUPPLEMENT|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
224293947|NCT05753670|DRUG|Tamsulosin|Subjects randomized to the experimental arm will receive a single dose of 0.4mg Tamsulosin tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
223982233|NCT06956183|OTHER|Control (Standard treatment)|In control group participants will take one hour conventional physiotherapy including stretching, strengthening, balance and gait exercises in each session.
224293948|NCT05753670|DRUG|Placebo|Subjects randomized to the control arm will receive a single dose of a placebo tablet in the preoperative holding area prior to their scheduled mid-urethral sling placement in the operating room.
223727430|NCT04692571|DEVICE|PSICON Measurement Apparatus|Test apparatus acquires 16 sEMG channels, measure four DoFs of force/moment at the hand-wrist \[hand open-close (Opn-Cls); wrist extension-flexion (Ext-Flx), radial-ulnar deviation (Rad-Uln) and pronation-supination (Pro-Sup)\]. sEMG system used 16 custom encased bipolar electrodes. A commercial LTI EMG amplifier (BE328) conditioned each EMG signal before A/D conversion on a PC. A thermoplastic hand cuff secured the wrist to a six-axis load cell (AMTI, model MC3A-100) for force/moment measurement. A separate hand-grasp one-axis load cell (Omega Engineering Inc., model LCR-150) was Velcro-secured between the fingers and the thumb, to measure power grip forces. The PC acquired and stored the sEMG and load cell data, and commanded a triangular screen target. The subject controlled a second triangular cursor. Left-right movement of the cursor was controlled by wrist Ext-Flx, up-down movement by Rad-Uln deviation, cursor rotation by Pro-Sup and cursor size by hand Opn-Cls forces.
223727431|NCT02044705|BEHAVIORAL|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
224293949|NCT02104336|DRUG|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
223727432|NCT00054145|DRUG|perifosine|
223727433|NCT01378078|DEVICE|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
223727434|NCT01378078|DEVICE|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
223982234|NCT06956183|OTHER|Vestibular exercise|In vestibular group (study group) participant will take 40 minutes conventional physiotherapy including stretching, strengthening, balance and gait exercises, and 20 minutes vestibular exercises including head and gaze stabilization, occulomotor, head turning and balance exercises in different postures.
223982235|NCT02988297|DRUG|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
224293950|NCT04227938|DRUG|ALPN-101|A single dose of ALPN-101 will be administered via intravenous infusion.
224293951|NCT00380692|DRUG|Atomoxetine|
224293952|NCT00380692|DRUG|Placebo|
224293953|NCT00219583|DRUG|UK-390,957|
223982236|NCT02988297|DRUG|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
223982237|NCT06956924|DIAGNOSTIC_TEST|CCTA|The data acquisition protocol was tailored to each patient's heart rate and rhythm. Specifically, a prospectively ECG-triggered volume scan was used to account for heart rates and rhythms, capturing predefined scanning areas during R-R intervals, especially in instances of frequent ectopic beats or irregular heart rates noted during pre-scan ECG monitoring. Imaging system parameters included a gantry rotation time of 0.275 seconds, collimation of 0.5 mm, tube voltage settings ranging from 100 kV to 120 kV, and a tube current-time product between 200 mAs and 450 mAs, with adjustments based on the patient's BMI.
223982238|NCT05854667|DRUG|Treatment as Usual plus Placebo|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
223982239|NCT05854667|DRUG|Treatment as Usual plus Placebo plus Contingency Management|Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
223982240|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01)|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15)."
223982241|NCT05854667|DRUG|Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management|"Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13."
223982242|NCT06630624|DRUG|IP-001|Intra-tumoral injection of IP-001 following ablation (MWA or IRE).
223982243|NCT00408928|DRUG|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
223982244|NCT06309576|BEHAVIORAL|Fasting-refeeding cycle|Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
223982245|NCT06155903|PROCEDURE|Selective Spinal Anesthesia|Selective Spinal Anesthesia will be performed at the L2-L3 or L3-L4 interspace with the patients lying in the lateral position (fractured side up). Anesthesiologists will determine the needling point for spinal anesthesia with reference to Tuffier's line, a virtual line connecting the tops of the iliac crests of a patient. A small dose of LA (4 ml of 1% lidocaine) will be injected into the skin and soft tissues at the planned site of spinal needle insertion. The correct path for spinal needle placement will be identified with the needle infiltration. The technique will be performed aseptically in the subarachnoid space after observing clear Cephalo-Spinal Fluid (CSF) in the spinal needle 25 Gauge, and without releasing the CSF. Selected patients will receive Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg and will maintain the lateral position for 15 min. At the end of these they will be gently placed in supine position.
223982246|NCT06155903|PROCEDURE|Peripheral nerve blocks|"In this group, four nerve blocks will be associated to ensure adequate anesthesia and analgesia during surgery.~Sciatic nerve blocks with para sacral approach will be performed with a needle connected to an electrical nerve stimulation. The needle will be advanced until contraction of the related muscles. Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.~Lateral femoral cutaneous, femoral and obturator nerve blocks, femoral will be performed with the ultrasound technique. After identifying the nerves, a needle will be inserted with an in plane approach and will be injected.~The anesthesia mixture will consist for all of :Ropivacaine 0.375% plus Mepivacaine 1% plus dexamethasone 4 mg.~The volumes of the 3 anesthesia mixtures will be respectively: 1ml, 15ml,5ml."
223982247|NCT06155903|DRUG|Anesthesiological mixtures (Spinal anesthesia)|The anesthesia mixtures will be injected into the subarachnoid space for spinal anesthesia. It will consist of the following local anesthetics and adjuvants: Hypobaric Bupivacaine 0.5% 7.5 mg and Sufentanil 5 µg.
223982248|NCT06155903|DRUG|Anesthesiological mixtures (Peripheral nerve block)|The anesthesia mixtures will be injected into selected peripheral nerves . It will consist of the following local anesthetics and adjuvants: Ropivacaine 0.375% plus Mepivacaine 1% and Dexamethasone 4 mg.
223982249|NCT03391973|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
223982250|NCT04469465|DRUG|Danicopan|Oral tablet
223982251|NCT04469465|DRUG|Placebo|Oral tablet
223982252|NCT04469465|DRUG|C5 Inhibitor|Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
223982253|NCT03212677|DIETARY_SUPPLEMENT|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
224119220|NCT04877548|OTHER|Control|Volunteers will have to consume a standardized breakfast without fermented flour but also presenting 50g of available carbohydrates
224119221|NCT05639920|COMBINATION_PRODUCT|Scoreing|Validation of Emergency surgery score in predicting mortality and mortality in Egyptian patients undergoing Emergency laparotomy
224119222|NCT00053820|BIOLOGICAL|aldesleukin|
224119223|NCT00053820|BIOLOGICAL|recombinant interferon alfa|
224119224|NCT00053820|DRUG|fluorouracil|
224119225|NCT03953586|DIAGNOSTIC_TEST|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
224119226|NCT06549686|BIOLOGICAL|CLS2901C (human [allogeneic] chondrocyte sheets)|CLS2901C (human \[allogeneic\] chondrocyte sheets)
224119227|NCT00246883|PROCEDURE|Exercise|
223982254|NCT03212677|DIETARY_SUPPLEMENT|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
223982255|NCT03212677|DIETARY_SUPPLEMENT|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
223982256|NCT03212677|OTHER|Placebo|Cornstarch
223982257|NCT06255626|DRUG|CD40.RBDv vaccin (SARS-Cov2 Vaccin)|1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))
223982258|NCT03480295|DEVICE|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
223982259|NCT03480295|DEVICE|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
223982260|NCT06130059|DRUG|Low Dose Colchicine|Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
223982261|NCT06130059|DRUG|Placebo|Placebo
223982262|NCT00314418|PROCEDURE|Colonoscopy in the prone position|
223982263|NCT04214613|PROCEDURE|non-cardiac non-neurologic surgery|non-cardiac non-neurologic surgery
223982264|NCT02976168|OTHER|12° head down tilt|supine head down tilt
223982265|NCT05435989|DIAGNOSTIC_TEST|Reduced extended high-frequency audibility|This study examines the effects of low-pass filtering speech on speech perception.
224119228|NCT05725798|DRUG|Sitagliptin|Group 1 who regularly takes Sitagliptin due to diabetes mellitus type 2 continues the treatment perioperatively. Group 2 and group 3 do not take Sitagliptin.
224119229|NCT04149327|DRUG|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
224119230|NCT04149327|PROCEDURE|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
224119231|NCT01080989|OTHER|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~1. mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~2. albendazole(400 mg bid \* 7days) or Ivermectin(200 mcg/kg/day \* 2 days) (For Strongyloidiasis).~Behavior:~1. Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~2. Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
224119232|NCT00554294|BEHAVIORAL|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
224119233|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
224119234|NCT01391091|PROCEDURE|Radiofrequency catheter ablation|PVAI
224119235|NCT01877330|PROCEDURE|Interscalene block for shoulder arthroscopy|
224119236|NCT06171880|DRUG|JLP-1901|administration of JLP-1901
224293954|NCT03695848|DEVICE|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
224119237|NCT06171880|DRUG|JC-001(active comparator)|administration of JC-001(tenofovir)
224119238|NCT03907722|OTHER|Long pentraxin 3|Primary PCI
224119239|NCT03268304|OTHER|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
223982266|NCT03194867|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223982267|NCT03194867|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223982268|NCT01828086|BIOLOGICAL|CJM112|Monoclonal antibody
223727435|NCT05570760|DEVICE|Adaptos®Ortho Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
223727436|NCT05570760|PROCEDURE|OWHTO without bone grafting|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation, without bone grafting. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
223982269|NCT01828086|BIOLOGICAL|Secukinumab|Monoclonal antibody
223982270|NCT01828086|OTHER|Placebo|Liquid for subcutaneous injection without active drug.
223982271|NCT01547624|OTHER|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
223982272|NCT03813732|PROCEDURE|orbital fracture|using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
223982273|NCT02161198|DIETARY_SUPPLEMENT|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
223982274|NCT02161198|DIETARY_SUPPLEMENT|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
223982275|NCT02941848|DRUG|HGP0816|
223982276|NCT02941848|DRUG|HGP1404|
223982277|NCT02941848|DRUG|HCP1306|
223982278|NCT03305809|DRUG|LY3154207|Administered orally.
223982279|NCT03305809|DRUG|Placebo|Administered orally.
223982280|NCT00816556|DRUG|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
223982281|NCT00816556|DRUG|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
223982282|NCT00816556|DRUG|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
223982283|NCT02438371|DRUG|Nifedipine|
223982284|NCT02438371|DRUG|Indomethacin|
223982285|NCT03546816|DRUG|5mg Serlopitant Tablets|Serlopitant Tablets
223982286|NCT03546816|DRUG|Placebo Tablets|Placebo Tablets
223982287|NCT04847245|DRUG|Pregabalin 75mg tid + Duloxetine|Pregabalin capsules were administered orally (75 mg, 3 times a day), combined administration of duloxetine (60-120 mg/day）.
223727437|NCT05570760|DEVICE|chronOS® Wedge (bone grafting surgery)|After screening and enrollment, subjects will undergo medial knee open wedge high tibial osteotomy (OWHTO) with load bearing locking plate fixation. A synthetic bone graft will be used as a bone void filler in the osteotomy defect. Follow-up visits will be at 6 weeks, 3 months, 6 months, and 12 months.
223982288|NCT04847245|DRUG|Intravenous administration of esketamine 0.125 mg/kg+Duloxetine|Intravenous administration of esketamine 0.125 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
223982289|NCT04847245|DRUG|Intravenous administration of esketamine 0.25 mg/kg +Duloxetine|Intravenous administration of esketamine 0.25 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
223982290|NCT04847245|DRUG|Intravenous administration of esketamine 0.50 mg/kg+Duloxetine|Intravenous administration of esketamine 0.50 mg/kg （2 times per week)， combined oral administration of duloxetine (60-120 mg/day）
223982291|NCT01161446|BEHAVIORAL|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
223982292|NCT01161446|DEVICE|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
223982293|NCT01124071|BEHAVIORAL|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
223982294|NCT01124071|BEHAVIORAL|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
223982295|NCT04183010|BEHAVIORAL|Physical activity coaching|"Interventions will be delivered via smartphone and will consist of physical activity coaching. Once randomized to the Coaching arm, individuals will be presented with seven broad categories of physical activity. They will receive a daily notification on their phone indicating that they have study activities to complete. They will then click on this notification and will be offered five options:~1. A low intensity activity from one of the categories they selected upon start of coaching~2. A moderate-to-vigorous endurance activity~3. The participant will be linked to video content with exercise tutorials/video coaching~4. Option to skip exercise that day~5. Option to fill in a different activity that the participant completed (free text entry)~The participant will then select one of these options and complete the chosen activity. They will be presented with the question Did you completed the exercise with three options:~1. Yes~2. No~3. Give me a different exercise"
223982296|NCT06468189|DEVICE|transcranial direct stimulation|Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
223982297|NCT06468189|DEVICE|Sham treatment|The same device used for stimulation will be used, but no stimulation will be given.
223982298|NCT02878369|PROCEDURE|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
223982299|NCT04959578|DRUG|Recombinant human erythropoietin|Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
223982300|NCT04959578|DRUG|Darbepoetin Alfa|Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
223982301|NCT00360477|PROCEDURE|Floseal|Bioglue that seals the kidney
223982302|NCT00360477|PROCEDURE|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
223982303|NCT00360477|PROCEDURE|Fascial Stitch|Stitch that closes the kidney
223982304|NCT00207818|DEVICE|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
223982305|NCT03916822|DIAGNOSTIC_TEST|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
223982306|NCT02349945|DRUG|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage \> 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
223982307|NCT05952947|BIOLOGICAL|HRYZ-T101 Injection|On day 1, the TCR-T cells will be administered intravenously.
223982308|NCT05952947|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
224119240|NCT04408092|DRUG|Granulocyte Macrophage Colony Stimulation Factor|Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
223982309|NCT04751682|BIOLOGICAL|BBV154 Vaccine|Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.
223982310|NCT04751682|BIOLOGICAL|Placebo|Placebo
223982311|NCT03450668|DEVICE|mOm incubator|24 hour usage of test incubator
223982312|NCT03450668|DEVICE|standard incubator|standard incubator
223982313|NCT05933889|GENETIC|Molecular Analysis|Germline and circulating tumour DNA analysis of buccal/ blood samples and molecular analysis of primary and recurrent tumour tissue samples
223982314|NCT05933889|OTHER|Radiomic/ Morphological analysis|Radiomic analysis and assessment of morphological features of pre-operative CT/ MRI imaging in patients who have undergone TORS for primary oropharyngeal cancer.
223982315|NCT04338789|OTHER|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
223982316|NCT01656213|DEVICE|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
223982317|NCT00844337|DRUG|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
223982318|NCT00844337|DRUG|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
223982319|NCT00844337|DRUG|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
223982320|NCT04301570|DEVICE|Ultrasound device|"The measurement of bone age is performed via ultrasound with the Ultrasound System for Bone Age Assessment (BAUS) from Sonic Bone (SonicBone Medical Ltd., Rishon Lezion, Israel)."
223982321|NCT04301570|RADIATION|XR|The measurement of bone age is performed via imaging procedure via X-ray (Röntgengerät, Stadler SE 4600, Littau, CH) of the left hand.
223982322|NCT05719402|PROCEDURE|non-interventional prospective cross-sectional observational study|to investigate the feasibility of using intestinal motility quantified by intestinal ultrasound (US) to evaluate disease activity. The outcomes of intestinal motility detected by ultrasound will be compared with endoscopic and histopathological reference standards in adult patients with IBD
223982323|NCT06488638|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days|commercially available beetroot juice dietary nitrate supplement
224119241|NCT05022004|DRUG|Brinzolamide ophthalmic suspension|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
224119242|NCT05022004|DRUG|Azopt®|dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
224119243|NCT04185324|BEHAVIORAL|Standard zippering vest|Standard zippering vest used to teach zippering
223982324|NCT01265043|OTHER|Oral hygiene intervention|Oral health promotion intervention
223982325|NCT02412449|DRUG|AKB-6548 tablet, reference formulation given in the fasted state|
223982326|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fasted state.|
223982327|NCT02412449|DRUG|AKB-6548 tablet, test formulation given in the fed state|
224119244|NCT04185324|BEHAVIORAL|Modified zippering vest|Modified zippering vest used to teach zippering, along with related story
224119245|NCT02456116|DEVICE|acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
224119246|NCT02456116|DEVICE|sham acupuncture/PCA/NSAID|"standard program with defined points:~1. Ear acupuncture needles bitten once (day 0-5)~2. Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
224119247|NCT02456116|OTHER|PCA/NSAID|standard boli of morphine by pressing a button of PCA
224119248|NCT02788916|OTHER|No Intervention|
224119249|NCT02807454|DRUG|Daratumumab|
224119250|NCT02807454|DRUG|Durvalumab|
224119251|NCT02807454|DRUG|Pomalidomide|
224119252|NCT02807454|DRUG|Dexamethasone|
224119253|NCT05474040|DRUG|Morphine versus multimodal analgesia for post elective craniotomy pain|To compare the effectiveness of opioid- sparing multimodal analgesia and opioid analgesia in the treatment of post-craniotomy pain
224119254|NCT02769572|OTHER|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
224119255|NCT02769572|DRUG|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
224119256|NCT02769572|DRUG|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
224119257|NCT02769572|OTHER|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
224119258|NCT03739944|PROCEDURE|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
224119259|NCT03739944|PROCEDURE|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
224119260|NCT03739944|PROCEDURE|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
224119261|NCT03739944|PROCEDURE|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
224119262|NCT05182502|DEVICE|Tixel|Subjects will receive 3 monthly treatments with the Tixel device to treat the signs of photodamage
224293955|NCT03181698|DIAGNOSTIC_TEST|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
224293956|NCT04525638|DRUG|177Lu-Dotatate|7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion
223982328|NCT01777126|OTHER|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
223982329|NCT01777126|OTHER|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
223982330|NCT03042364|OTHER|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
223982331|NCT02751047|OTHER|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
223982332|NCT02751047|OTHER|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
223982333|NCT02977247|OTHER|Non-Interventional|Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
223982334|NCT02977247|DEVICE|Automated Whole Breast Ultrasound|Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
223982335|NCT01660256|DRUG|OPC-12759|Instillation, 4 times/day for 4 weeks
223982336|NCT01660256|DRUG|Placebo|
223982337|NCT05601427|PROCEDURE|aACB|The patient will undergo a pre-operative single-shot, ultrasound-guided ACB performed by an anaesthesiologist skilled in regional anaesthesia techniques. The ACB will be performed in a dedicated block room, immediately prior to administration of a spinal anaesthetic.
223982338|NCT05601427|PROCEDURE|sACB|The patient will undergo an intraoperative single-shot ACB performed by the treating surgeon following placement of the TKA components.
223982339|NCT01184885|DRUG|Hyper-CVAD|"* Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are \< 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~* Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
223982340|NCT01184885|DRUG|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
223982341|NCT06374082|OTHER|WhatsApp message|"Participants in the intervention group will receive 3 WhatsApp messages per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205). These messages are about the core content of the course, including (1) Knowledge Themes: harmfulness of smoking and benefits of quitting, the fundamentals of nicotine addiction, smoking cessation counselling with the 5A model, and pharmacotherapy for smoking cessation; (2) Attitude Themes: nurses' role in smoking cessation and the importance of smoking cessation; and (3) Practice Themes: practical advice on counseling techniques, communication skills by motivational interviewing, local smoking cessation resources for referral.~Participants in the control group will receive 3 WhatsApp messages about generic mental health information per week for six weeks after attending the standardized course training Tobacco Dependency Nursing Intervention and Management (NURS8205)."
223982342|NCT01162135|DRUG|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
223982343|NCT02088554|DEVICE|Model 400 aortic valve bioprosthesis|
224293957|NCT04525638|DRUG|Nivolumab|240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
223982344|NCT06331104|GENETIC|gene expression levels|12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
223982345|NCT01896180|DRUG|ALZ-1101|ALZ-1101 Ophthalmic Solution
223982346|NCT01896180|DRUG|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
223982347|NCT05407987|DRUG|Ferric derisomaltose|Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.
223982348|NCT05407987|DRUG|Placebo|Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
223982349|NCT02002962|PROCEDURE|radiofrequency ablation|
223982350|NCT02002962|DRUG|Botulinum Toxin Type A injection|
223982351|NCT04411134|BIOLOGICAL|E7 TCR|Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)
223982352|NCT04398901|OTHER|Neurodevelopmental assessments|The investigators will evaluate multiple domains of neurodevelopment at age 3, 4, 5 and 7 years using parental questionnaires and child exams. At age 7 years, the children will have a non-sedated quantitative brain MRI.
223982353|NCT05204069|DRUG|Instillation of cyclopentolate|Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
223982354|NCT00551135|DRUG|Pregabalin|150 mg BID
223982355|NCT00551135|DRUG|placebo|Placebo
223982356|NCT00551135|DRUG|Pregabalin|75 mg BID
224119263|NCT01193790|PROCEDURE|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
224119264|NCT04637659|PROCEDURE|Root Canal Treatment|Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
223982357|NCT00551135|DRUG|Pregabalin|25 mg BID
223982358|NCT00858247|DIETARY_SUPPLEMENT|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
223982359|NCT00951964|DRUG|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
223982360|NCT00951964|DRUG|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
223982361|NCT04205955|OTHER|Best Practice|Receive healthy living education via phone call
223982362|NCT04205955|DIETARY_SUPPLEMENT|Dietary Intervention|Receive diet modification coaching via phone call
223982363|NCT04205955|OTHER|Message|Receive motivational messages via email and/or text message
223982364|NCT04205955|OTHER|Quality-of-Life Assessment|Ancillary studies
223982365|NCT04205955|OTHER|Questionnaire Administration|Ancillary studies
223982366|NCT03898960|DEVICE|NIMBUS Device|NIMBUS Geometric Clot Extractor
223982367|NCT00548847|BIOLOGICAL|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
223982368|NCT00548847|BIOLOGICAL|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
223982369|NCT01325597|OTHER|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
223982370|NCT01325597|OTHER|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
223982371|NCT01325597|OTHER|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
223982372|NCT01325597|OTHER|Control group|No intervention
223982373|NCT04866433|PROCEDURE|Real-time binaural sound|Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.
223982374|NCT04866433|PROCEDURE|Music|Play the same music in both ears through headphones during sedation
223982375|NCT04866433|PROCEDURE|Control|Just wear headphones during sedation
223982376|NCT04059887|DRUG|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
223982377|NCT02271659|RADIATION|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
223982378|NCT02271659|RADIATION|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
223982379|NCT04199455|DRUG|Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)|"Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day."
223982380|NCT04199455|DRUG|Placebo|"Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day."
223982381|NCT04347785|PROCEDURE|carotid endarterectomy|shunt
223982382|NCT02902653|DRUG|Oral misoprostol|hourly titrated misoprostol
223982383|NCT02902653|DRUG|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
223982384|NCT02902653|DRUG|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
223982385|NCT05054465|DRUG|Navitoclax|P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD
223982386|NCT05054465|DRUG|Venetoclax|P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD
223982387|NCT00252018|BEHAVIORAL|Daily intake of broccoli sprouts|
223982388|NCT00237861|DRUG|risperidone|
223982389|NCT00237861|DRUG|olanzapine|
223982390|NCT00237861|DRUG|quetiapine|
223982391|NCT00151905|DRUG|3 % hypertonic saline|
223982392|NCT03689439|DIAGNOSTIC_TEST|bone scintigraphy|bone scintigraphy
223982393|NCT00250640|DRUG|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
223982394|NCT05225636|PROCEDURE|thrombectomy|Extraction of intracranial thrombus in an acute large vessel occlusion
223982395|NCT02142998|OTHER|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
223982396|NCT02142998|OTHER|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
223982397|NCT01316887|DRUG|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
223982398|NCT01316887|DRUG|125mcg once-daily GSK573719|GSK573719
223982399|NCT01316887|DRUG|Placebo once-daily|inactive
223982400|NCT00720369|DRUG|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
223982401|NCT01470729|OTHER|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
223982402|NCT03121495|DIAGNOSTIC_TEST|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
223982403|NCT04092049|OTHER|lollipop|chewing lollipop for 10 minutes
223982404|NCT00813098|DRUG|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
223982405|NCT00813098|DRUG|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
223982406|NCT00813098|DRUG|Placebo|Matching placebo dosing with daily oral intake
223982407|NCT03732976|OTHER|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
223982408|NCT03732976|OTHER|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
223982409|NCT04517383|PROCEDURE|post-operative sedation|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. After the ET surgery is done, patients in POS group will be sedated for 6hrs before extubation.
223982410|NCT04517383|PROCEDURE|routine recovery|Patients with ischemic stroke will undergo endovascular thrombectomy (ET) under general anesthesia. Patients in Con group will be routinely recovered and extubated after the ET surgery is done.
223982411|NCT02876029|OTHER|Reference|the reference product used
223982412|NCT02876029|OTHER|Test product|The test Product used
223982413|NCT03564834|PROCEDURE|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
223982414|NCT03564834|PROCEDURE|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
223982415|NCT01809899|BEHAVIORAL|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
223982416|NCT01809899|BEHAVIORAL|Consent as Usual|Routine informed consent procedures
223982417|NCT02462343|OTHER|walk tests|
223982418|NCT02089412|DRUG|E2006|
223982419|NCT01068288|PROCEDURE|Laparoscopic or open appendectomy|
223982420|NCT01068288|PROCEDURE|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
223982421|NCT03361098|DRUG|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
223982422|NCT03361098|DRUG|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
223982423|NCT03361098|OTHER|placebo exenatide|placebo b.i.d. exenatide
223982424|NCT03361098|OTHER|placebo dapagliflozin|placebo tablets dapagliflozin
223727438|NCT06657235|OTHER|Transitional Care Program|Participants will receive personalized risk-factor management stroke care from a multidisciplinary team trained by our neurologists to understand the needs of stroke survivors and the nuances of stroke care. Risk factor data from in-home devices, health records, and self-reports will be collected along with functional status and behavioral data obtained through validated questionnaires and an occupational therapy evaluation. Syntrillo's neurology provider will review this data, assess the participant through a telemedicine encounter, and create a comprehensive secondary prevention plan to supplement the participant's care plan at discharge. Data generated through these clinical encounters will be de-identified and used for subsequent development of Syntrillo's stroke management technology.
223727439|NCT00321945|PROCEDURE|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
224119265|NCT04559906|OTHER|Spray and Stretch technique (Ethyl chloride)|"Group A receive spray and stretch technique (Ethyl chloride) with conventional treatment.~The upper trapezius muscle stretches on the basis of the Technique originally described by Simons. The subject is seated in a relaxed position on their homolateral hand for anchoring the distal end of the studied muscle. Initially, 3 to 5 parallel sweeps of ethyl chloride spray is applied covering the Upper trapezius muscle. Then, the muscle are positioned in a maximal but tolerable stretch and lengthened until the Physical Therapist felt the muscle tension barrier. This procedure repeated 2 or 3 times."
224119266|NCT04559906|OTHER|Sustain pressure release|"Group B receive sustain pressure release with conventional treatment. Progressive pressure release are considered in two stages. The initial step is to recognize and find the trigger in upper fiber of trapezius, utilizing trigger point palpation. Trigger point felt as firm and restricted hyperirritable knots with in gut of the muscle.~The second step is to applying pressure release ranging from eight to twelve second for each pressure, then it increases gradually for maximum of twenty seconds. The total duration of pressure is five minutes or more until the discharge is felt by the fingers."
223727440|NCT06591741|DIETARY_SUPPLEMENT|Oral PCA|PCA 1,000 mg BID until surgery, held until anticoagulation, and resumed at 1,000 mg daily for 4 years
224119267|NCT01165203|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
224119268|NCT01165203|BIOLOGICAL|Placebo|intramuscular injection
223727441|NCT06590896|DRUG|Cenobamate|Cenobamate will be orally administered once daily.
223727442|NCT01774968|DRUG|Human Regular U-500 Insulin|
223727443|NCT04322461|DIETARY_SUPPLEMENT|Betaquik MCT supplement|50g/day divided in 3. Breakfast, lunch and dinner
223727444|NCT06990009|BEHAVIORAL|exercise|In line with the Puerperium and Newborn Care Guide, an exercise implementation protocol will be prepared by obtaining the opinion of a group of 10 experts on the appropriateness of the exercises and when they should be started. In this direction, a brochure and a video will be created for the participants to practice the exercises. A pilot study will be conducted in a group of 10 people on the use of the brochure and video, and the brochure and video will be finalized. Participants will be asked to do these exercises for 30 minutes a day, five days a week for eight weeks. A reminder message will be sent to the exercise group by the researchers to remind them of the exercises and provide motivation for eight weeks.
223727445|NCT02044393|DRUG|itraconazole|multiple doses of itraconazole given as capsules
223727446|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
223727447|NCT02044393|DRUG|BI 691751|single dose BI 691751 given as tablet
223982425|NCT02298049|OTHER|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
223982426|NCT02298049|DEVICE|MRI|
223982427|NCT05155488|OTHER|No Intervention|This is a non-interventional study.
223727448|NCT05965505|DRUG|AXT-1003|AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
223727449|NCT06995014|BEHAVIORAL|Retrieval-based word learning: Standard retrieval practice schedule|Novel nouns and their meanings are practiced on 2 consecutive days. At the beginning of each learning session, a retrieval trial will immediately follow hearing the word and what it likes (a study trial). In the standard condition, the remaining retrieval trials for each word will be spaced - occurring only after 3 other words have intervened. This practice schedule is repeated the next day (Day 2).
223982428|NCT01143545|BIOLOGICAL|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
223982429|NCT01143545|DRUG|Celecoxib|400 g po bid
223982430|NCT01143545|DRUG|cyclophosphamide|50 mg po bid
223982431|NCT03470545|DRUG|mavacamten|mavacamten capsules
223982432|NCT03470545|DRUG|Placebo|placebo oral capsule
223982433|NCT01301703|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
223982434|NCT03354910|BEHAVIORAL|House Call|60 to 90 minute home based educational intervention which will be administered by a health educator.
223982435|NCT03354910|BEHAVIORAL|Peer Mentorship|A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
223982436|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Test Drug tablet|Investigational Medicinal Product
223982437|NCT05332106|DRUG|Estradiol Valerate and Dienogest 2 mg/ 2 mg Reference Product tablet|Climodien (Bayer plc.)
223982438|NCT00002547|DRUG|busulfan|
223982439|NCT00002547|DRUG|cyclophosphamide|
223982440|NCT00002547|DRUG|cyclosporine|
223982441|NCT00002547|DRUG|cytarabine|
223982442|NCT00002547|DRUG|methotrexate|
223982443|NCT00002547|PROCEDURE|allogeneic bone marrow transplantation|
224119269|NCT00374907|DRUG|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
224119270|NCT00374907|DRUG|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
224119271|NCT00374907|DRUG|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
224119272|NCT00374907|DRUG|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
224119273|NCT01629485|BEHAVIORAL|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
223982444|NCT00002547|PROCEDURE|syngeneic bone marrow transplantation|
223982445|NCT04674878|OTHER|METs|The isometric contraction of 7 sec will be applied followed by a stretching of 30 sec in painless range. This treatment will be given to the both sides of the neck targeting the three major accessory muscles of respiration.
223982446|NCT04674878|OTHER|Breathing exercise group|Three exercises will be performed in a circuit, 2 circuits in every session. It will include diaphragmatic breathing exercise in which patient will be in supine position inhaling through nose and expiration through moth with half closed lips. Second exercise pursed lip breathing also in supine position with the hands on abdomen and then inspiration through nose and expiration through mouth with half closing of lips. Third exercise resisted diaphragmatic breathing also in same pattern as second exercise with an addition of 1 kg weight on abdomen.
223982447|NCT01154062|DRUG|Pazopanib|Pazopanib tablet
223982448|NCT00585975|DRUG|bromfenac ophthalmic solution|sterile opthalmic solution
224119274|NCT01629485|BEHAVIORAL|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
224119275|NCT01629485|BEHAVIORAL|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
224119276|NCT02205385|PROCEDURE|Targeted Muscle Reinnervation|
224119277|NCT02205385|PROCEDURE|Traction Neurectomy|
223982449|NCT06547671|OTHER|Employment of a confort room to help in anxiety and agitation moments.|Use of the sensory comfort room located in the unit itself, decorated in soft and relaxing tones with motifs inspired by nature. It has relaxation sofas, rocking chair, aromatherapy, chromotherapy, projector, music of the user's choice, weighted blanket mats, balls of various sizes......... to teach people admitted to the area alternatives to cope and control anxiety and prevent the escalation of agitation, as well as to guide them in strategies to help them relax.
223982450|NCT02049112|DEVICE|Salivary equivalent|14-day treatment with salivary equivalent sticks
223982451|NCT02049112|DEVICE|Aequasyal|14-day treatment with Aequasyal oral spray
223982452|NCT02049112|DEVICE|Biotene|14-day treatment with Biotene oral spray
223982453|NCT03672175|DRUG|SAGE-217|SAGE-217 hard gelatin capsules.
223982454|NCT03672175|DRUG|Placebo|SAGE-217 matched placebo hard gelatin capsules.
223982455|NCT03675412|DIETARY_SUPPLEMENT|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
223982456|NCT06284434|DRUG|Liposomal Bupivacaine|Patients will receive liposomal bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
223982457|NCT06284434|DRUG|Bupivacain|Patients will receive standard bupivacaine mixed with epinephrine (ratio of 1:100,000) for pain management after surgery.
223982458|NCT06284434|DRUG|Epinephrine|Patients will receive epinephrine (ratio of 1:100,000) mixed with the appropriate drug assigned to them based on their arm.
223982459|NCT03414047|DRUG|Prexasertib|Administered IV
223982460|NCT02813993|OTHER|Health educational video|
223982461|NCT01337375|DRUG|peginterferon alfa 2a [Pegasys]|sc weekly
223982462|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv weekly
223982463|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|sc twice weekly
223982464|NCT01337375|DRUG|peginterferon alfa-2a [Pegasys]|iv twice weekly
223982465|NCT00438139|DRUG|Dronabinol|
223982466|NCT05921487|BEHAVIORAL|Time Restricted Eating|Time Restricted Eating Protocol: Subjects will be instructed to limit caloric consumption to a 10-hour TRE window. The window start-time will be self-selected (individualized). During the eating window, subjects will not be restricted on types or quantities of food consumed, and will be advised to continue their usual diets. Subjects will not be required to monitor their caloric intake. During the fasting period, subjects will be encouraged to stay hydrated and drink ample water. Outside the designated eating window, subjects are only permitted to consume medication, water, or zero-calorie herbal drinks such as unsweetened tea or black coffee.
223982467|NCT04312412|PROCEDURE|Controlled active motion (CAM)|Rehabilitation, post-surgery protocol
223982468|NCT01772563|DRUG|volasertib|Solution for infusion
223982469|NCT01772563|DRUG|itraconazole|capsules
224119278|NCT03070977|OTHER|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
223982470|NCT00510939|DRUG|Tipifarnib plus Bortezomib|
223982471|NCT04380428|OTHER|No Intervention. Observational study.|No Intervention. Observational study.
223982472|NCT03449862|OTHER|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
223982473|NCT01192776|PROCEDURE|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
223982474|NCT04974723|DRUG|Abaloparatide|Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)
223982475|NCT04974723|DRUG|Teriparatide|Teriparatide subcutaneous (TPTD; Forteo®)
223982476|NCT02181907|DRUG|UH-AC 62 XX tablet|
223982477|NCT02181907|DRUG|UH-AC 62 XX capsule|
223982478|NCT03107507|DRUG|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
223982479|NCT03107507|DRUG|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
223982480|NCT04374383|DRUG|Phthalocyanine Dye|following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
223982481|NCT04374383|DRUG|LASER assisted SRP|LASER assisted SRP will be carried
223982482|NCT04614571|DIETARY_SUPPLEMENT|Gluten Powder|Administered orally daily for 14 days
223982483|NCT05138250|DRUG|Mepolizumab 100 MG|participants will receive 100mg of mepolizumab every 4 weeks for 52 weeks
223982484|NCT05793307|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
223982485|NCT00000983|DRUG|Zidovudine|
223727450|NCT06995014|BEHAVIORAL|Retrieval-based word learning: Adaptive retrieval practice schedule|Novel nouns and their meanings are practiced on 2 consecutive days. At the beginning of each learning session, a retrieval trial will immediately follow hearing the word and what it likes (a study trial). For the remainder of the session, there will be spaced retrieval trials for each word - occurring after 3 words have intervened. In the Adaptive condition, children will have additional retrieval opportunities throughout. These will be provided whenever the child does not remember the word form, whether it is an immediate (initial) or space retrieval trial. This practice schedule is repeated the next day (Day 2).
223982486|NCT00353886|PROCEDURE|TONI-3|
223982487|NCT00353886|PROCEDURE|WRAT-3|
223727451|NCT05355805|DRUG|Izokibep|"Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)"
223727452|NCT05355805|DRUG|Placebo to izokibep|"Form: Solution for injection~Route of administration: Subcutaneous (SC)"
223982488|NCT00353886|PROCEDURE|Connor's Rating Scales PRS & TRS|
223982489|NCT00353886|PROCEDURE|Peabody Picture Vocabulary Test|
223982490|NCT00353886|PROCEDURE|Children's Memory Scale|
223982491|NCT00353886|PROCEDURE|WISC-3|
223982492|NCT00353886|PROCEDURE|Behavioral Assessment System for Children PRS & TRS|
223982493|NCT02897089|DEVICE|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
223982494|NCT03666195|COMBINATION_PRODUCT|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
223982495|NCT01896453|PROCEDURE|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
223982496|NCT01896453|PROCEDURE|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
223982497|NCT01636622|DRUG|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
223982498|NCT01636622|DRUG|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
223982499|NCT01636622|DRUG|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
223982500|NCT02493465|DRUG|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
223982501|NCT01086384|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
223982502|NCT01086384|DRUG|Fluticasone furoate|Inhaled corticosteroid
223982503|NCT04295018|DRUG|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
223982504|NCT01689467|DIETARY_SUPPLEMENT|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
223982505|NCT01689467|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
223982506|NCT02777242|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
223982507|NCT00001234|GENETIC|human glucocerebrosidase cDNA|
223982508|NCT00247702|DRUG|warfarin|
223982509|NCT04627441|DEVICE|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
223982510|NCT04627441|DEVICE|Epidural spinal cord stimulator system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
223982511|NCT03035318|DEVICE|DePuy Global® Anchor Peg Glenoid Instrumentation|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Glenoid Instrumentation.
223982512|NCT03035318|DEVICE|DePuy Global® Anchor Peg Instrumentation with SmartBone™|Placement of glenoid component will be performed using DePuy Global® Anchor Peg Instrumentation with SmartBone™.
223982513|NCT03035318|DEVICE|IRI with SmartBone™|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBone™.
223982514|NCT03035318|DEVICE|RTI with SmartBone™|Placement of glenoid component will be performed using Real Time Instrumentation (RTI) with SmartBone™.
223982515|NCT03035318|DEVICE|IRI with SmartBase|Placement of glenoid component will be performed using Intelligent Reusable Instrumentation (IRI) with SmartBase.
223982516|NCT02929706|GENETIC|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
224119279|NCT02572661|RADIATION|radiation in Squamous Head and Neck Cancer|
224119280|NCT06361277|DRUG|Reference Drug or Test Drug|Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
224119281|NCT01652378|DRUG|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
224119282|NCT06069557|OTHER|Respiratory exercise|This group will undergo intervention. The participants will be assessed in terms of abdominal distension and shoulder pain in preoperative period. Respiratory exercise training will be given in the preoperative period. At the 1st, 2nd, 3rd, 4th, 5th, 4th, 5th, and 6th hours postoperatively, 10 deep breathing exercises will be performed in semi fowlers 45º position. During this 6-hour period, the patient will be asked to give 10 deep breaths into the incentive spirometer every 2 hours. Patients will be evaluated for abdominal distension and shoulder pain at the 1st, 2nd, 3rd, 4th, 5th, and 6th hours postoperatively and mobilization times will be measured in the first 6 hours.
224119283|NCT06554626|DRUG|Dexamethasone|Glucocorticoids
224119284|NCT06554626|DRUG|Blinatumomab|Bi-specific anti CD19/CD3 antibody
224119285|NCT06554626|DRUG|Venetoclax|BCL-2 inhibotor
224119286|NCT06554626|DRUG|Inotuzumab ozogamicin|a humanized monoclonal antibody-drug conjugate targeting CD22
224119287|NCT06554626|DRUG|Methotrexate|antifolate antineoplastic drug
224119288|NCT06554626|DRUG|Pegaspargase|antitumor drug
223727453|NCT07002580|PROCEDURE|IPACK and adductor canal block with Bupivacaine 0.25%|iPACK block is infiltration between the Popliteal Artery and the Capsule of the Knee. iPACK and adductor canal blocks are performed with ultrasound guidence under sterile conditions.
223727454|NCT07002580|PROCEDURE|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia is a basic anesthesia method used for years to grant anesthesia for surgeries for lower extremities and lower torso surgeries.
223727455|NCT07000773|BEHAVIORAL|Bilateral Scapular Retraction with Shoulder External Rotation (BSR-SER) Exercise|Participants perform the Bilateral Scapular Retraction with Shoulder External Rotation (BSR-SER) exercise using a resistance band. The exercise is conducted under various conditions including stable and unstable surfaces (using BOSU® balance trainer) and in three different lower limb positions: standing, lunge, and squat. Each condition is randomized, and participants complete all conditions in a crossover design. The intervention aims to evaluate trapezius muscle activation patterns during these exercises using surface electromyography (EMG).
223982517|NCT04826497|DRUG|nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg nicorandil was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
223982518|NCT04826497|DRUG|Placebo（normal saline）|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the radial artery using the Seldinger method.The guidewire was passed into the culprit lesion.If the blood flow of culprit vessel reaches TIMI2-3 after balloon dilatation,6mg placebo was then administrated before stent implantation, A minimum 5-min interval occurred between the first and second doses of placebo to reduce adverse effects, subsequently , 6mg/h ivgtt. up to 48h after coronary intervention
223727456|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days; TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
223727457|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days; TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
223982519|NCT04152395|OTHER|EVAR|Patients undergoing EVAR
223982520|NCT06478732|OTHER|health services|Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
223982521|NCT04244422|OTHER|PIEZOSURGERY VERSUS CONVENTIONAL SURGERY|Piezosurgery: SATLEC ACTEON peizotome 2 (A company of ACTEON Group, France) was used. Conventional surgery with rotary instruments
223982522|NCT04237675|PROCEDURE|surgery and anesthesia|patients with MS who received general or regional anesthesia for a surgery or labor
223982523|NCT02987998|DRUG|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
223982524|NCT02987998|DRUG|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
224119289|NCT06554626|DRUG|Cytarabine|Pyrimidine, antimetabolites
223982525|NCT02987998|DRUG|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
223982526|NCT02987998|DRUG|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
223982527|NCT01627470|DEVICE|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
223982528|NCT03990298|DIAGNOSTIC_TEST|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
223982529|NCT05771025|PROCEDURE|Hepatectomy|Patients in the hepatectomy group receive liver resection.
223982530|NCT02828163|OTHER|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
223982531|NCT02828163|DRUG|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
223982532|NCT02945371|BEHAVIORAL|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
223982533|NCT02945371|BEHAVIORAL|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
223982534|NCT05066919|PROCEDURE|Open plantar fasciotomy|In the surgical treated group, the plantar fascia is defined percutaneously (medial and lateral margin). An incision is then made just distal to the heel pad medially over the plantar fascia. A resection is performed 1 cm in length with a width corresponding to 50% of the medial band. The skin is sutured with nylon/nonresorbable suture. Postoperatively, the operated foot is elevated for the first 24 hours. Then free mobilization in postoperative shoe (ProCare shoe) is allowed. The dressing is left untouched for 3-5 days, after which it can be changed to a patch. After 14 days the sutures are removed and the patient allowed using regular shoes.
223982535|NCT05066919|OTHER|Conservative treatment|In the conservative treatment group, patients are instructed in performing stretching exercises with plantar fascia specific stretching exercises 10 x 10 seconds, 3 times daily and high load strength training are every other day for 3 months. Each high load strength exercise consists of 3 seconds of concentric phase (lifting up with the heel) and 3 seconds of eccentric phase (lowering the heel) with 2 seconds of isometric pause (pause at maximum lifted heel). 12 repetitions max (RM) are performed, defined as the maximum (over) weight the patient can lift 12 times with full range of motion while performing the exercise correctly. 3 x 12 exercises are performed per workout. After 2 weeks, the load is while the number of repetitions is reduced to 10 RM with an increase to 4 repetitions per workout. After 4 weeks the intensity is increased to 8RM with 5 set. Patients are instructed to increase the load throughout the training period.
224119290|NCT00698126|DRUG|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
224119291|NCT00698126|DRUG|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
224119292|NCT05427682|DRUG|pyroglutamate rongliflozin capsules|Subjects will receive one 50mg capsule on Day 1
224119293|NCT05913557|BEHAVIORAL|Radically Open Dialectical Behavior Therapy (RO DBT)|Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
224119294|NCT05077917|DRUG|Cromolyn Sodium|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
224119295|NCT05077917|OTHER|Placebo|Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
224119296|NCT01293396|DRUG|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
223727458|NCT07002268|DRUG|Azvudine tablets(FNC) and Tenofovir Alafenol Fumarate Tablets (TAF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~TAF: 25 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3 mg (1 tablet)+TAF 25 mg (1 tablet) (taken at the same time), 1 time a day, orally, for 7 consecutive days."
224119297|NCT01293396|DRUG|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
224119298|NCT01293396|DRUG|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
223982536|NCT06234813|OTHER|Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen|"TTAS (single measurements)~Clot formation in whole blood under flow (2000 s-1) in a microfluidic flow chamber coated with tissue factor and collagen (T-TAS with AR chip)~1. 500 µL of whole blood for each point;~2. 7 points for each condition;~3. Around 4 mL of whole blood will be needed for each patient or healthy subject;~4. Values for Area Under the Curve (Aritrary Unit), Occlusion Starting Time (min), Occlusion Time (min.) will be reported."
223982537|NCT06234813|OTHER|: PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM|"ROTEM (single measurements)~1. ROTEM cups will be added~   * 20 µL calcium reagent (STARTEM)~  * 20 µL of 2,940-fold prediluted r-ExTEM reagent (50,000 fold dilution relative to 340 µL in the cup) added~  * 300 µL spiked PRP at 250 G/L (2.5 mL of PRP/patient)~2. Values for clot time (CT sec, clot formation time (CFT) sec, maximum clot formation (mm) will be reported."
223982538|NCT06234813|OTHER|Thrombin Generation Assay (TGA) in PRP using TF trigger|"TGA (single measurements)~1. The following will be added to well:~   * 20 uL of PRP-Reagent~  * 80 uL of spiked PRP (600 µL/patient at 100 G/L)~  * 20 uL FluCa~2. Values for thrombin activity versus time and the derived parameters incl. lag-time (min), time to peak (min), time to peak (min), ETP (Arbitrary Unit) will be reported."
223727459|NCT07002138|DEVICE|Digital Dental Impression|Digital dental impressions were performed using the Medit i700 intraoral scanner (Medit, Seoul, South Korea). The scanner utilizes 3D-in-motion video technology with UV-C and LED light sources and adaptive anti-fogging. Scans were taken of both upper and lower arches following manufacturer-recommended protocols. Two tip sizes were used (normal and small), and scanning included occlusal, lingual, and buccal surfaces. Moisture control was maintained with cheek retractors and saliva ejectors. Impression time was recorded using a chronometer. This procedure was used to evaluate patient comfort, anxiety, and preference.
224119299|NCT03721081|DRUG|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
224119300|NCT03721081|OTHER|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
224119301|NCT04885244|PROCEDURE|Index or spine revision surgery for complex adult spinal deformity|Surgical interventions will be patient specified by treating surgeon.
224119302|NCT00231985|BEHAVIORAL|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
224119303|NCT00231985|BEHAVIORAL|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
224119304|NCT01266798|BEHAVIORAL|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation"
224119305|NCT04790006|DRUG|TG103|Administered SC
224119306|NCT04790006|DRUG|Placebo|Administered SC
224119307|NCT05971290|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure administered by face mask
224119308|NCT05971290|DEVICE|Ambient air|Air (fraction of inspired oxygen) at 14000 feet in elevation
224119309|NCT01149278|DRUG|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
224119310|NCT01149278|OTHER|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
224119311|NCT04072237|BIOLOGICAL|MarzAA (marzeptacog alfa [activated])|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)
224119312|NCT00002141|DRUG|Abacavir sulfate|
224119313|NCT00907140|PROCEDURE|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
224119314|NCT00354549|DRUG|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
224119315|NCT00354549|DRUG|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
224119316|NCT04420481|DRUG|Somatropin|Dose: 1,4 mg (4,2 IE) every other day Dosage: 9 month treatment period and a 3 month follow-up period Administration: One subcutaneous injection of somatropin or corresponding placebo in the thigh or abdomen given in the evening given every other day.
224119317|NCT04420481|DRUG|Placebo|Placebo
224119318|NCT03431675|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
224119319|NCT03511261|DRUG|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
224119320|NCT03511261|DRUG|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
223982539|NCT06234813|OTHER|Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis|Global fibrinolytic capacity (Lysis Timer) in 100 µL of PRP (250 G/L) using reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA). Around 1 mL of PRP in total Lysis time in min
223982540|NCT06234813|OTHER|Concizumab|Thrombin generation assay (TGA), microchip flow-chamber assay (T-TAS, rotational thromboelastometry and global fibrinolytic capacity to investigate and compare the effects of mixing concizumab (200, 1000 and 4000 ng/mL) with the main bleed treatment options for persons with GT
223982541|NCT03503383|BEHAVIORAL|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
223982542|NCT03503383|BEHAVIORAL|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
223982543|NCT05609799|OTHER|Blood sample|Quantifying the volume of leucocyte subsets: NK-cells, B-cells, and T-cell subsets, including Treg, Th1, Th2 and Th17 in EDTA
223982544|NCT04116281|OTHER|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
223982545|NCT01317706|OTHER|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
223982546|NCT02261298|DRUG|ONO-4538|
223982547|NCT06192030|OTHER|Prediction model|We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.
223982548|NCT01005368|GENETIC|fluorescence in situ hybridization|
223982549|NCT01005368|GENETIC|mutation analysis|
223982550|NCT01005368|GENETIC|nucleic acid sequencing|
223982551|NCT01005368|GENETIC|polymerase chain reaction|
223982552|NCT01005368|GENETIC|western blotting|
223982553|NCT01005368|OTHER|flow cytometry|
223982554|NCT01005368|OTHER|laboratory biomarker analysis|
223982555|NCT01721746|BIOLOGICAL|BMS-936558|
223982556|NCT01721746|DRUG|Dacarbazine|
223982557|NCT01721746|DRUG|Carboplatin|
223982558|NCT01721746|DRUG|Paclitaxel|
223982559|NCT05428111|DIAGNOSTIC_TEST|flow cytometric immunophynotyping|Expression of programmed death-1 (PD-1) \& programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
223982560|NCT04358068|DRUG|Hydroxychloroquine (HCQ)|Administered orally
223982561|NCT04358068|DRUG|Azithromycin (Azithro)|Administered orally
223982562|NCT04358068|DRUG|Placebo for Hydroxychloroquine|Administered orally
223982563|NCT04358068|DRUG|Placebo for Azithromycin|Administered orally
223982564|NCT00237211|DRUG|Letrozole|
223982565|NCT03849768|DRUG|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223982566|NCT03849768|DRUG|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223982567|NCT03133078|OTHER|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
223982568|NCT03133078|OTHER|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
223982569|NCT00945399|PROCEDURE|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
223982570|NCT00945399|PROCEDURE|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
223982571|NCT01293799|BEHAVIORAL|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
223982572|NCT03712384|OTHER|Semi structured face to face interview|Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
223982573|NCT04502836|BEHAVIORAL|Preliminary psychological intervention|psychological intervention including providing knowledge and tools for problems solving according to the Choice - Agenda - Resilience - Emotional support (CARE) model . After intervention session patients and their parents will be asked to complete questionnaires
223982574|NCT03827850|DRUG|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
223982575|NCT04128462|DRUG|MNK-6105|L-Ornithine Phenylacetate for IV infusion
224293958|NCT03898518|OTHER|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
224293959|NCT05017974|BEHAVIORAL|Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement|MBSR+PS
224293960|NCT05017974|OTHER|Treatment as Usual|TAU
223727460|NCT07002138|PROCEDURE|Conventional Dental Impression|Conventional impressions were taken using extra-fast setting flavored alginate (Hydrogum 5, Zhermack SpA, Italy) for both upper and lower arches. The impression material was manually mixed according to the manufacturer's instructions and applied using standard perforated plastic trays suitable for pediatric arches. Children were seated upright, and the impression sequence followed lower arch first, then upper arch. Comfort was evaluated using VAS scores and anxiety using the Venham Clinical Anxiety Scale (VCAS). The procedure was timed with a chronometer.
223982576|NCT04128462|DRUG|Placebo|Matching placebo for IV infusion
223982577|NCT04128462|DRUG|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
223982578|NCT02174614|BEHAVIORAL|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
224293961|NCT04104555|OTHER|Birthday card|Birthday card sent to participants in the post
224293962|NCT04104555|DEVICE|Prefabricated orthoses|Prefabricated insole
224293963|NCT04104555|OTHER|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
223982579|NCT02174614|BEHAVIORAL|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
224293964|NCT04104555|OTHER|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
223982580|NCT02174614|BEHAVIORAL|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
223982581|NCT05809102|PROCEDURE|repair of flexor tendon in Zone II|Repair of Zone II flexor tendon of the hand using minimal incisions instead of whole tendon exposure
224293965|NCT05727072|DRUG|LY3848575|Administered IV.
223982582|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
224293966|NCT05727072|DRUG|LY3848575|Administered SC.
224293967|NCT05727072|DRUG|Placebo|Administered IV.
224293968|NCT05727072|DRUG|Placebo|Administered SC.
224293969|NCT00446836|DRUG|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
224293970|NCT00396799|DRUG|bazedoxifene/conjugated estrogens|
223982583|NCT02455999|DRUG|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
223982584|NCT02455999|DRUG|Placebo|Placebo eye drops administration for 10 consecutive days
223982585|NCT03384771|BEHAVIORAL|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
223982586|NCT05267678|OTHER|No intervention|This is an observational study without any intervention
223982587|NCT01036243|DIETARY_SUPPLEMENT|test formula 1|hydrolyzed formula with probiotics
223982588|NCT01036243|DIETARY_SUPPLEMENT|test formula 2|acidified hydrolyzed formula
223982589|NCT01036243|DIETARY_SUPPLEMENT|test formula 3|hydrolyzed formula without probiotics
223982590|NCT01036243|DIETARY_SUPPLEMENT|reference formula|standard infant formula
223982591|NCT03494465|PROCEDURE|PHACOEMULSIFICATION|"Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group"
223982592|NCT03494465|DRUG|MEDICAL GLAUCOMA TREATMENT|The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
224293971|NCT03715998|DRUG|Ramipril|1 or 2 capsules administered orally, twice daily
224293972|NCT03715998|DRUG|Firibastat|1 or 2 capsules administered orally, twice daily
224293973|NCT02177136|DRUG|Obeticholic Acid (OCA)|
224293974|NCT02177136|DRUG|Placebo|
224293975|NCT03641391|PROCEDURE|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
224293976|NCT03641391|PROCEDURE|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
224293977|NCT01660191|DRUG|Pitavastin 4mg|
224293978|NCT01660191|DRUG|Atorvastatin 20mg|
224293979|NCT01660191|DRUG|Rosuvastatin 5mg|
224293980|NCT00120536|DRUG|vildagliptin|
224293981|NCT02512536|DRUG|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
223982593|NCT01095133|DRUG|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
223982594|NCT01095133|DRUG|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
224119321|NCT03511261|DRUG|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
224119322|NCT03511261|DRUG|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
224119323|NCT00918528|PROCEDURE|Internal urethrotomy|
223727461|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 7 days. Subjects were administered the drug as follow:~FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days."
223982595|NCT02509988|DIETARY_SUPPLEMENT|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
223982596|NCT02509988|DIETARY_SUPPLEMENT|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
223982597|NCT02206932|DRUG|Sofosbuvir + Simeprevir|
223982598|NCT03467698|DEVICE|Active tDCS|Real stimulation
223982599|NCT03467698|DEVICE|Sham tDCS|Sham stimulation
223982600|NCT02143063|BEHAVIORAL|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
223982601|NCT02143063|BEHAVIORAL|prize contingency management on a variable interval schedule for cocaine abstinence|
223982602|NCT02143063|BEHAVIORAL|standard care|
223982603|NCT03245463|OTHER|Educational handout|The educational handout will include information on self-management strategies.
223982604|NCT03245463|OTHER|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
223982605|NCT03245463|DRUG|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
224119324|NCT00918528|DRUG|Mitomycin C - local injection|
224119325|NCT05493956|RADIATION|chemoradiation|Radiation dose of 54 Gy will be given alongwith concurrent capecitabine
224119326|NCT02371733|OTHER|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
224119327|NCT02371733|OTHER|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
224119328|NCT00004778|DRUG|betamethasone|
224119329|NCT00004778|DRUG|dexamethasone|
224119330|NCT00004778|DRUG|thyrotropin-releasing hormone|
224119331|NCT01328288|DRUG|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
223727462|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet) +RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days; RIF: 600 mg (4 capsules) each time, 1 time a day, orally, for 7 consecutive days."
223727463|NCT07002255|DRUG|Azvudine tablets(FNC) and Rifampicin Capsules (RIF)|"This study consisted of 3 cycles, each cycle was administered orally for 7 consecutive days, and the washout period between each cycle was 10 days. Subjects were administered the drug as follow:~RIF: 600 mg (4 capsules), 1 time a day, orally, for 7 consecutive days; FNC: 3 mg (1 tablet) each time, 1 time a day, orally, for 7 consecutive days; FNC 3mg (1 tablet)+RIF 600 mg (4 capsules) (taken at the same time), 1 time a day, orally, for 7 consecutive days."
223727464|NCT07002541|PROCEDURE|PECS II block|The PECS-II block is an ultrasound-guided interfascial plane block designed to provide analgesia for surgeries involving the anterolateral chest wall, particularly breast surgery. It is an extension of the PECS-I block, which targets the medial and lateral pectoral nerves. In the PECS-II technique, a high-frequency linear ultrasound probe is used to identify the fascial planes. A 22G, 50 mm regional block needle is advanced in-plane under sterile conditions. A total of 30 mL of 0.25% bupivacaine is administered: 10 mL is injected between the pectoralis major and minor muscles (targeting the pectoral nerves), and 20 mL between the pectoralis minor and serratus anterior muscles (to block the lateral branches of intercostal nerves and intercostobrachial nerve).
223982606|NCT03582345|PROCEDURE|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1\. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
223982607|NCT04482192|COMBINATION_PRODUCT|Thoracic paravertebral block|After ending pulmonary procedure, a pleural pouch created beside vertebral column, a catheter is inserted to the pouch for continuous infusion of 1% lidocaine for 3 postoperative days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
223982608|NCT04482192|DRUG|Systemic analgesia|Systemic analgesia (SA) group receive 1gm paracetamol and 30 mg ketorolac by intravenous infusion every 6 hours for 3 days. Intravenous morphine sulfate (0.05mg/kg) was given as a rescue medication if the VAS ≥ 4.
223982609|NCT05343208|DIAGNOSTIC_TEST|EFP Psychometric assessment to determine level of afflication|Patients were asked to complete a psychometric assessment in relation to their psychological wellbeing. Results were presented to the patient and validdated by the patient.
223982610|NCT05172986|BEHAVIORAL|Follow-up patient program|An additional paramedical visit will be carried out before the surgery. The interview is carried out by the healthcare team. An organization within the service has been set up so that a nurse can be totally seconded for the RAAC mission. The consultation lasts 30 to 45 minutes.
223982611|NCT01140282|OTHER|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
223982612|NCT01140282|PROCEDURE|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
223982613|NCT01140282|PROCEDURE|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
223982614|NCT01140282|BEHAVIORAL|exercise intervention|12 week exercise intervention
224119332|NCT01780389|DRUG|Open-label flexibly dosed milnacipran|
224119333|NCT03715569|DIAGNOSTIC_TEST|Vestibular function|Vhit, Caloric test
224119334|NCT03715569|DIAGNOSTIC_TEST|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
224119335|NCT03715569|DIAGNOSTIC_TEST|Biomarker|Biomarker examination
224119336|NCT03715569|DIAGNOSTIC_TEST|MOCA, eGOS|Cognitive tests
224119337|NCT03715569|DIAGNOSTIC_TEST|Audiometry|Hearing test
223982615|NCT01473615|BEHAVIORAL|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
223982616|NCT02138656|OTHER|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
223982617|NCT02138656|OTHER|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
223982618|NCT06402214|OTHER|Lombard test|In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.
223982619|NCT03962322|OTHER|Weaning TDI|"Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation."
223982620|NCT03499262|BEHAVIORAL|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
223982621|NCT04120142|OTHER|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
223982622|NCT04120142|OTHER|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
223982623|NCT04115852|BEHAVIORAL|fmri|functional magnetic resonance imaging
223982624|NCT02584036|BIOLOGICAL|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
223982625|NCT02584036|BEHAVIORAL|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
224119338|NCT02778776|DRUG|Metformin|Metfomin in tablet presentation of 500 mg
223982626|NCT02584036|BEHAVIORAL|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
223982627|NCT00869271|PROCEDURE|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
223982628|NCT00869271|PROCEDURE|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
223982629|NCT01719588|DRUG|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
223982630|NCT03065998|DRUG|Opipramol|PO
223982631|NCT03065998|DRUG|Baclofen|PO
223982632|NCT01991145|PROCEDURE|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
223982633|NCT01991145|BIOLOGICAL|Erythropoietin alfa|
223982634|NCT01991145|OTHER|Rehabilitation|Active rehabilitation
223982635|NCT01991145|PROCEDURE|Placebo UCB|
223982636|NCT01991145|BIOLOGICAL|Placebo EPO|
223982637|NCT01099579|DRUG|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to \<10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to \<15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to \<25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
223982638|NCT01099579|DRUG|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
223982639|NCT01099579|DRUG|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to \<20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to \<40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
223982640|NCT01099579|DRUG|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
223982641|NCT04022577|BEHAVIORAL|Adherence Therapy|Motivational interviewing-based AT in this study was based on Chien et al., (2016) and Gray et al., (2010) eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
223982642|NCT04022577|BEHAVIORAL|control group|The control group received routine care
223982643|NCT06345326|OTHER|Greater occipital nerve block|The nerve block will be done by ultrasound guidiance at the C2 level with a 22 gauge 5 cm needle inplane direction. The pulse radiofrequency will be done as defined with a radiofrequency cannula- 5 cm with an active tip of 2mm.
224119339|NCT02778776|DIETARY_SUPPLEMENT|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
224119340|NCT02778776|OTHER|Placebo of agave inulin|Calcinated magnesia powder
224119341|NCT02778776|OTHER|Metformin placebo|Calcinated magnesia tablet
223982644|NCT04063046|DRUG|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 \~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
223982645|NCT04063046|DRUG|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
223982646|NCT00066846|BIOLOGICAL|bevacizumab|
223982647|NCT00066846|DRUG|fluorouracil|
223982648|NCT00066846|DRUG|leucovorin calcium|
224119342|NCT00607646|DRUG|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
224119343|NCT00607646|DRUG|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
223727465|NCT07002541|PROCEDURE|ESP block|The erector spinae plane (ESP) block is a fascial plane block performed under ultrasound guidance to provide multimodal analgesia for thoracic and abdominal surgeries, including breast procedures. In this technique, a high-frequency linear ultrasound probe is used to visualize the transverse process of the thoracic vertebra, typically at the T4-T5 level. With the patient in a seated position and under standard sterile conditions, a 22G, 50 mm regional block needle is inserted in-plane until the tip reaches the fascial plane between the erector spinae muscle and the transverse process. After negative aspiration, 1-2 mL of test dose is injected to confirm correct needle placement by observing separation of fascial layers. Then, 20 mL of 0.25% bupivacaine is injected incrementally.
223982649|NCT04188756|OTHER|Exercise|High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
223982650|NCT00909532|DRUG|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
223727466|NCT07001813|DEVICE|socket preserved|(8 cases): was treated by immediate socket preservation with S1-XB xenograft augmentation after extraction.
223982651|NCT00909532|DRUG|Placebo|Tablet given orally q12h for up to 48 weeks
223982652|NCT01130168|DRUG|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
223982653|NCT01130168|DRUG|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
223982654|NCT01130168|DRUG|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
223982655|NCT02868671|OTHER|acupuncture|
223982656|NCT02868671|OTHER|sham acupuncture|
223982657|NCT04767334|DEVICE|Anti-Gravity Treadmill|"Each participant will started with a 5 - 10 minute warm-up on a standard cycle ergometer, manual and therapeutic therapy for upper extremity, and gait training using LBPP. Manual and therapeutic therapy will consist of passive and active ROM, joint mobilization, passive and active stretch, manual resistance exercise, and activities of daily life (ADL). All participants will walk in Alter G one session a day (for 40 min), three days a week, for six weeks. On session one, the Alter G pressure chamber will be set to unload 50% of patient's body weight. On the following sessions, the percentage of unload patient's body weight will be decrease depends on the patient's comfort.~The physical therapist assistance and treadmill speed will be evaluated and altered based on the patient's capacity. The participants can take a rest whenever his/her need during walking. The rest time will be measured and documented."
223982658|NCT05438134|BEHAVIORAL|SMART-3RP Group Intervention|"Nine 1.5 hour group sessions focusing on developing:~1. An understanding of stress physiology and the physiology of the relaxation response;~2. A regular practice of eliciting the relaxation response; and~3. Cognitive behavioral and positive psychology/resilience skills.~Participants receive a copy of the SMART-3RP session manual and audio recorded guided meditations for independent relaxation practice. Participants are encouraged to practice eliciting the relaxation response daily throughout the study, using the audio recordings or other mind body techniques. Participants will use a practice log to track their practice."
223982659|NCT02900235|DRUG|MT-3995|
223982660|NCT03715868|OTHER|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
223982661|NCT00444262|PROCEDURE|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
223982662|NCT00444262|DRUG|VOLUVEN and others solute|VOLUVEN and others solute
223982663|NCT00220480|DRUG|escitalopram|10 to 30 mg / day
223982664|NCT00607464|DEVICE|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
223982665|NCT01438840|DRUG|Avatrombopag|
223727467|NCT07001813|DEVICE|non preserved socket|(8 cases): was not exposed to any type of socket preservation after the extraction procedure.
223727468|NCT07002606|OTHER|medication errors reporting guidelines|the intervention is designed to reduce the medication errors and develop the culture of reporting the Medication errors in clinical settings.
223727469|NCT07000500|DIETARY_SUPPLEMENT|Nutritional Supplement|Participants in this arm will receive a daily dose of a nutritional supplement for 90 consecutive days. The supplement is administered orally and aims to improve cognitive performance in older adults with signs of cognitive decline. Participants will also complete cognitive assessments before and after the intervention.
223727470|NCT07000500|OTHER|Placebo|Participants in this arm will receive a daily dose of an inert placebo that matches the supplement in appearance, taken orally for 90 consecutive days. The placebo is used as a control to compare the effects of the nutritional supplement on cognitive performance. Participants will undergo the same cognitive assessments as the experimental group.
223982666|NCT01438840|DRUG|Placebo|
223982667|NCT01438840|DRUG|Standard of care|"Permitted ITP concomitant background therapies are as follows:~* Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~* Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~* Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
223982668|NCT01711398|DRUG|Drug|
223982669|NCT00750451|DRUG|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
223982670|NCT00750451|DRUG|crinone 8% gel|routine luteal phase support with progesterone gel
223982671|NCT01020214|DRUG|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
223982672|NCT01020214|DRUG|Benicar HCT® Tablets 40 mg/25 mg|
223982673|NCT02942342|PROCEDURE|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
224119344|NCT05641376|DRUG|Nebulized Dexmedetomidine|Children will receive a nebulized dexmedetomidine 2 mic/ kg diluted in 3 ml of 0.9% saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. Treatment will be stopped when the nebulizer began to sputter. At end of nebulizer administration, they will be observed for 30 min before induction of general anaesthesia. then the children will be transferred to the operation room and will receive intravenous (IV) normal saline 0.9% in 10 ml volume over 10 minutes after anesthesia induction.
224293982|NCT02350244|BEHAVIORAL|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
224293983|NCT00870649|BIOLOGICAL|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
223727471|NCT07001878|DRUG|Metformin|Metformin will be prescribed, reaching 1000mg/day (a standard dose). This will be done under the principal investigator's care and the patient's clinical team, including assessment of metformin adherence. Metformin will be prescribed for 6 months. Antipsychotic treatment will continue as per standard of care (metformin as adjunct therapy), as well as routine follow up.
223982674|NCT00932295|OTHER|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
224119345|NCT05641376|DRUG|Intravenous Dexmedetomidine|Children will receive nebulized 3 ml of 0.9% normal saline 1 h before induction of anaesthesia by standard hospital jet nebulizer via a mouthpiece with a continuous flow of 100% oxygen at 6 L /min for 10-15 min. then the children will be transferred to the operation room and will receive intravenous (IV) dexmedetomidine 1mic/kg diluted in 10 ml of 0.9% saline over 10 minutes after anesthesia induction.
223727472|NCT07002411|OTHER|Innovative hospital reception service with social robot NAO|The robot NAO welcomes the user and asks how it can assist them. At this point, the user responds, and the robot, in turn, replies in two possible ways: If it has not understood the request, it prompts the user to rephrase it, and the process returns to the previous point. If it has understood the request, it explains the route the user needs to follow. Once the interaction has been successful or two consecutive attempts have failed, the robot asks the user if the necessary information has been provided. If yes, the robot dismisses the user. If no, the interaction resumes from the point where the robot asks for the department to reach or the exam to take.
223727473|NCT07002411|OTHER|Innovative hospital reception service with social robot PEPPER|"The robot PEPPER welcomes the user and asks how it can assist them, stating the following phrase: Good morning and welcome to INRCA. I am PEPPER and I am here to provide directions to help you reach your desired location within the hospital. Which department do you need to reach or which exam do you need to take?  At this point, the user responds, and the robot, in turn, replies in two possible ways: If it has not understood the request, it prompts the user to rephrase it, and the process returns to the previous point. If it has understood the request, it explains the route the user needs to follow. Once the interaction has been successful or two consecutive attempts have failed, the robot asks the user if the necessary information has been provided. If yes, the robot dismisses the user as follows: Thank you for your participation. Have a good day. If no, the interaction resumes from the point where the robot asks for the department to reach or the exam to take."
223727474|NCT07000487|BEHAVIORAL|Yoga|Hatha yoga will be applied in this study. Yoga practice will be carried out by the researcher for 6 weeks, 1 day face-to-face and 1 day online, and each practice will be 60 minutes, in total 12 sessions, considering the studies done. It will be applied by a researcher with a yoga certificate. Pre-test and post-test nausea and pain measurements will be made.
223727475|NCT07001267|PROCEDURE|Anesthesia drugs during the surgery|During treatment for acute ischemic stroke, patients will be given either inhalation or intravenous anesthesia.
223727476|NCT04828304|DEVICE|PLASOMA|Treatment with cold plasma device
223727477|NCT07048756|BEHAVIORAL|Imagery Rescripting|Imagery Rescripting (Regular)
223727478|NCT07048756|BEHAVIORAL|Imagery Exposure|Imagery Exposure
223727479|NCT07048756|BEHAVIORAL|Imagery Rescripting with Disruption of Reconsolidation|Imagery Rescripting with Disruption of Reconsolidation
223727480|NCT07048756|BEHAVIORAL|Compassion-Focused Therapy Imagery Rescripting|Imagery Rescripting in Compassion-Focused Therapy
223727481|NCT02167893|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
223727482|NCT06729294|OTHER|Binaural beat music recital|Binaural beats music is therapeutic music that provides auditory stimuli at different frequencies to each ear. However, the maximum sound levels are 60 dB, which helps to relax and reduce stress.
223727487|NCT06890338|DRUG|Carboplatin|Intravenous (IV) infusion
223727488|NCT06890338|DRUG|Mirvetuximab Soravtansine|Intravenous (IV) infusion
223727489|NCT06890338|DRUG|Bevacizumab|Intravenous (IV) infusion (per investigator's discretion)
223727490|NCT06745388|DRUG|Magnesium sulfate|Receive intravenous magnesium intra-operatively
223727491|NCT06745388|DRUG|Ketamine|Receive IV push ketamine intra-operatively
223727492|NCT06745388|DRUG|Placebo|Receives no additional medication or infusion
223727493|NCT06555328|DRUG|CSU lower dose treatment|CSU lower dose treatment
223727494|NCT06555328|DRUG|CSU high dose treatment|CSU high dose treatment
223727495|NCT06555328|DRUG|CSU non responders IgE - high dose treatment|CSU non responders IgE - high dose treatment
223727496|NCT06555328|DRUG|HS low dose treatment|HS low dose treatment
223727497|NCT06555328|DRUG|HS medium dose treatment|HS medium dose treatment
223727498|NCT06555328|DRUG|HS high dose treatment|HS high dose treatment
223982675|NCT00932295|OTHER|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
223982676|NCT00932295|OTHER|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
223982677|NCT00932295|OTHER|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
223982678|NCT00859976|DEVICE|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
223982679|NCT00859976|DEVICE|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
224119346|NCT04985773|DEVICE|Lacrosse NSE ALPHA coronary dilatation catheter|The Lacrosse NSE ALPHA is a rapid exchange percutaneous transluminal coronary angioplasty balloon catheter with non-slip element nylon threads that focus dilatation force to reduce balloon slippage during inflation.
223727499|NCT07062159|OTHER|the psychoeducation intervention program|The content of the psychoeducation intervention program based on the Watson Human Caring Model will consist of the postpartum process and care, maternal blues, postpartum psychosis, postpartum depression, frequency, causes, predisposing factors, symptoms, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support, adaptation to the role of motherhood, mother and baby bonding, practices that will strengthen mother-baby bonding, breast milk and breastfeeding, nutrition and baby care, problems encountered in baby care and solution suggestions.
223727500|NCT07062159|OTHER|routine care|routine care
223727501|NCT06777485|PROCEDURE|Procedure/Surgery treatment|Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC
223727502|NCT06777485|DRUG|Anti-Tumor Drugs|Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
223727503|NCT06442397|BEHAVIORAL|Anti-Inflammatory Lifestyle Intervention|Content includes training in empirically-supported strategies to improve psychological function (e.g., restructuring negative thoughts, distress tolerance), with a focus on changing discrete behaviors linked to inflammation (e.g., sleep, processed foods, physical activity), all intertwined with evidence-based behavior change content adapted to meet the needs of EACS. Participants will also receive digital tools to facilitate daily self-monitoring (Fitbit activity monitor, wireless scales, self-monitoring app) and generate information for tailored weekly e-coaching
223727504|NCT04818840|DEVICE|Resurfaced Patella|JOURNEY II CR Total Knee System was used for Total Knee replacement
223727505|NCT04818840|PROCEDURE|Un-resurfaced Patella|JOURNEY II CR Total Knee System was used for Total Knee replacement
223727506|NCT07131592|DRUG|IV TXA|Patients randomized to the IV TXA group will receive intravenous Tranexamic acid during the procedure. The dose will be 1g IV infused over approx. 10 minutes prior to skin closure (dosing of approx. 15 mg/kg, capped at 1 g, which is within safe limits).
223727507|NCT07131592|DRUG|Topical TXA|Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized topical TXA intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the TXA to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
223727508|NCT07131592|DRUG|Topical saline|Before wound closure, one 15mm round Jackson-Pratt (JP) drain is placed in each breast pocket, exiting through a lateral chest wall stab incision. The randomized saline intervention is then applied through the drain into the breast after skin closure. The drains will then be temporarily clamped for 20 minutes to allow the saline to dwell in the tissue and exert local effect. After this the clamp is released, the excess fluid sucked off and the drain connected to a drainage bottle.
223982680|NCT01912989|BEHAVIORAL|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
223982681|NCT00192426|BIOLOGICAL|CAIV-T|
223982682|NCT01362647|PROCEDURE|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
223982683|NCT01362647|PROCEDURE|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
223982684|NCT03763149|BIOLOGICAL|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
223982685|NCT05549947|DRUG|SHR1819|Treatment group A：SHR-1819 injection dose 1， Treatment group B：SHR-1819 injection dose 2， Treatment group C：SHR-1819 injection dose 3，
223982686|NCT05549947|DRUG|Placebo|Treatment group D：placebo
223982687|NCT03679897|DRUG|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
223982688|NCT03679897|DRUG|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
223982689|NCT01398462|DRUG|CWP232291|IV Infusion
223982690|NCT04500028|DRUG|INH|3 vaginal tablet of isonicotinic acid hydrazide (900mg) inserted by the study nurse 4 hours before IUD insertion.
223982691|NCT04500028|DRUG|Placebo Comparator|3 tablet of placebo inserted by the study nurse 4 hours before IUD insertion.
223982692|NCT06078098|OTHER|Clinical Information|We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
223982693|NCT04810897|OTHER|Exercise|Exercise programme is reported in the clinical trial registration number is NCT03473834.
223982694|NCT03873454|DEVICE|Sennheiser non-occlusive headphones|Patients listened to music of their choice using non-occlusive headphones
223982695|NCT03873454|DEVICE|Sennheiser non-occlusive headphones without music|Patients wore non-occlusive headphones but had no music playing
223982696|NCT03873454|OTHER|No Sennheiser non-occlusive headphones|Patients did not wear non-occlusive headphones and did not listen to music
223982697|NCT01774305|DRUG|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
223982698|NCT01774305|DRUG|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
223982699|NCT00322686|DRUG|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
223982700|NCT00322686|DRUG|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
223982701|NCT04797117|DIAGNOSTIC_TEST|blood sample|"The blood samples for the study for each patient will be collected in the form of additional tubes.~* either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~* either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization."
223727509|NCT07131137|BEHAVIORAL|The Life Balance Training Intervention|The Life Balance Training intervention is administering as an individualized, therapist-guided program over a period of eight weeks, comprising two 45-minute sessions per week conducted via videoconferencing platforms. The program's objective was to enhance engagement in meaningful daily activities, promote a sense of life balance, and improve participation in instrumental activities of daily living (IADLs). Each session focused on fundamental components, including goal setting, skills training, activity planning, and problem solving. Caregiver involvement is encouraging when appropriate to support the generalization of skills to the home environment. The sessions commenced with a collaborative goal-setting process, centred on participants' desired modifications to their daily routines and occupational balance. The curriculum encompassed a range of pertinent subjects, including meal preparation, financial management, and time management.
223727510|NCT01804075|DRUG|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
223982702|NCT04627454|PROCEDURE|Discectomy and insertion of dynamic cervical implant in cervical disc herniation|The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
223982703|NCT00603083|DRUG|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
223982704|NCT00603083|DRUG|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
223982705|NCT02001142|OTHER|Exercise|single session of exercise
223982706|NCT04246853|DEVICE|Transcranial direct current stimulation (tDCS) of the resting state motor network|Transcranial direct current stimulation (tDCS) delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
223982707|NCT00333190|DEVICE|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
223727511|NCT01804075|DRUG|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
223727512|NCT02175498|DRUG|Homoeopathic medicines|4 pills once a week of the indicated Similimum
223727513|NCT07132346|OTHER|AGING ANXIETY SCALE|This study was conducted as descriptive research to determine the mediating role of aging anxiety in the relationship between maternal ambivalence and pregnancy avoidance in women.
223982708|NCT02394249|BEHAVIORAL|Physical activity regime|Information already included in arm descriptions
223982709|NCT04042025|BIOLOGICAL|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
223982710|NCT00840671|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
223982711|NCT00840671|DRUG|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
223982712|NCT00456378|DEVICE|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
223982713|NCT00456378|PROCEDURE|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
223982714|NCT03428464|DRUG|Sodium Bicarbonate|Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
223982715|NCT03428464|OTHER|Placebo|Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
223982716|NCT04089072|DRUG|Methylene Blue|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
224119347|NCT05663086|BIOLOGICAL|One dose group|The vaccines are to be administrated at day 0. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
224119348|NCT05663086|BIOLOGICAL|Two doses group|The vaccines are to be administrated at day 0 and 28. Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
224293984|NCT00870649|BIOLOGICAL|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
223982717|NCT04089072|DRUG|Phenylephrine|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of \>65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
223982718|NCT03623373|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m\^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
223982719|NCT03623373|DRUG|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m\^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
223982720|NCT03623373|DRUG|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
223982721|NCT03623373|DRUG|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
223982722|NCT03623373|PROCEDURE|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
223982723|NCT03623373|PROCEDURE|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
223982724|NCT03623373|PROCEDURE|Oral rinse|-Baseline
224119349|NCT05663086|BIOLOGICAL|Aged 18-59 years|The vaccines are to be administrated in the population of 18-59 years.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
224119350|NCT05663086|BIOLOGICAL|Aged 60 years old and above|The vaccines are to be administrated in the population of 60 years old and above.Low dose or high dose LYB001 or positve-controlled group will be randomly assigned to receive in a 1:1:1 ratio.
224119351|NCT03037957|DEVICE|ARIES Group A Strep Assay|
224119352|NCT05725369|BEHAVIORAL|Combined Lifestyle Intervention (CLI)|In the Netherlands, the combined lifestyle intervention (CLI, in Dutch: gecombineerde leefstijlinterventie (GLI)) is available for all Dutch citizens with a BMI ≥ 30 mg/kg2 or a BMI between 25 and 30 mg/kg2 and an increased risk of diabetes or cardiovascular disease. The CLI aims to realize health benefits for people with a moderate weight-related health risk and consists of a two-year program with advice and counseling to improve health-related behavior such as physical activity and diet.
224119353|NCT00620620|DRUG|Inhaled placebo|Inhaled Staccato Placebo
224119354|NCT00620620|DRUG|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
223982725|NCT03623373|PROCEDURE|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
223982726|NCT01157377|DRUG|AGN-214868|AGN-214868 injected into the bladder.
223982727|NCT01157377|DRUG|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
223982728|NCT05833776|PROCEDURE|spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with fentanyl (25ug)|group I (30 patients) received spinal anesthesia using hyperbaric bupivacaine 0.5% (3ml) with IPACK Block using plain bupivacaine 0.5% (15ml).
223982729|NCT05160311|DRUG|Optimized Medical Treatment (OMT)|Optimized Medical Drug Treatment
223982730|NCT05160311|DEVICE|Drug Eluting Stent (DES) Coronary Angioplasty|Percutaneous Angioplasty with DES
224119355|NCT00620620|DRUG|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
224119356|NCT00620620|DRUG|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
224119357|NCT00620620|DRUG|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
224119358|NCT03921281|OTHER|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~1. Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~2. Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~3. Treatment course: three times a week, 12 weeks in total."
224119359|NCT03921281|OTHER|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
224119360|NCT02058355|BEHAVIORAL|Consequences List Feedback|
223982731|NCT00193596|DRUG|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
223982732|NCT00193596|DRUG|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
223982733|NCT00193596|DRUG|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
223982734|NCT00193596|DRUG|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
223982735|NCT00193596|DRUG|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
223982736|NCT03935061|OTHER|Mulberry juice|On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
223982737|NCT03220997|DIETARY_SUPPLEMENT|Vitaflow Preload|Carbohydrate loading drink
223982738|NCT00641836|PROCEDURE|Transplantation of autologous endothelial progenitor cells|
223982739|NCT04186052|BIOLOGICAL|BCMA-CART cells|Target BCMA chimeric antigen receptor T cell infusion
223727514|NCT05305105|DRUG|Psilocybin|Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.
223727515|NCT07124624|DEVICE|AI-Assisted CTA Interpretation|A locked, independently validated deep learning model was used to assist radiologists in interpreting head CTA scans. The model was trained on 16,546 CTA cases and externally validated on an independent set of 900 DSA-verified CTA cases, achieving a patient-level sensitivity of 0.943 and an average of 0.187 false positives per case.
223982740|NCT04959500|DRUG|Anlotinib Hydrochloride|Drug: Anlotinib Hydrochloride Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
223982741|NCT04959500|DRUG|Placebo|Drug: Placebo Placebo will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
223982742|NCT04959500|RADIATION|Radiation Therapy|Radiation: Radiation therapy Radiation therapy will be delivered in daily fractions of 1.8-2.0 Gy given 5 days a week for a total of 54-60 Gy.
223727516|NCT07124624|DIAGNOSTIC_TEST|Standard CTA Interpretation|Head CTA interpretation performed by radiologists using local routine diagnostic workflows without AI support.
223727517|NCT07124949|OTHER|No intervention|no intervention
223727518|NCT07126834|BEHAVIORAL|VIH|During the experimental session, they additionally performed a 5-minute VIH session (20 breaths/minute) after 1 hour of hypoxic exposure. Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc., Kelowna, British Columbia, Canada) equipped with 6-liter breathing bags were employed to perform VIH. The accompanying Isocapnic mobile app was used to guide breathing rhythm and monitor session duration.
223727519|NCT07131501|PROCEDURE|Radical surgery|Radical surgery
223727520|NCT07131501|PROCEDURE|TACE treatment|TACE treatment (cTACE, Idarubicin): Preoperative: 1 session; Postoperative: 1 session.
223982743|NCT04959500|DRUG|Temozolomide|Drug: Temozolomide Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
223982744|NCT01949883|DRUG|CPI-0610|
223982745|NCT01228305|OTHER|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
223982746|NCT00080041|DRUG|Motexafin Gadolinium Injection|
223982747|NCT06401785|DIETARY_SUPPLEMENT|Hydrogen capsules|In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
223982748|NCT02261285|DRUG|ONO-4538|
223982749|NCT01430208|PROCEDURE|resectoscopy|hysteroscopy for myomas G0 and/or polyps
223982750|NCT05157737|OTHER|Electrophysiological detection of KCNQ2 mutation|Electrophysiological detection of KCNQ2 mutation performed using patch clamp technique in an in vitro cell model. Analyze the association between phenotype and genotype.
223982751|NCT05157737|OTHER|Multi-modal brain image and EEG|Multi-modal brain image include brain magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). The electroencephalogram (EEG) incuding video electroencephalogram (VEEG) and sleep electroencephalogram (SEEG).
223982752|NCT05157737|OTHER|Omics testing|Omics testing include proteomics, metabolomics, transcriptomics.
223727521|NCT07131501|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706)|Iparomlimab and Tuvonralimab Injection (QL1706): 7.5 mg/kg, intravenous infusion, Day 1 of each cycle, Q3W. Neoadjuvant: 2 cycles; Adjuvant: up to 17 cycles.
223727522|NCT07131501|DRUG|Lenvatinib|Lenvatinib: 8mg (body weight \<60kg) or 12mg (body weight ≥60kg), orally (PO), once daily (QD), Q3W. Consistent daily timing. Neoadjuvant: 2 cycles.
223982753|NCT01702519|DRUG|nicotine|nicotine transdermal patch
223982754|NCT03738397|BIOLOGICAL|Upadacitinib|Extended release tablet
223982755|NCT03738397|BIOLOGICAL|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
223982756|NCT03738397|DRUG|Placebo to dupilumab|Placebo administered as a subcutaneous injection
224119361|NCT02058355|BEHAVIORAL|Personalized Normative Feedback|
223727523|NCT07132229|OTHER|Cervical High-Intensity Resistive Exercises|The patient will wear a neck harness, and a weight equivalent to 90% of the patient's measured maximum voluntary isometric contraction (MVIC) will be attached to it.
223727524|NCT07132229|OTHER|Conventional physical therapy|Conventional physical therapy consisting of TENS for pain control, soft tissue release for the cervical and associated muscles, activation and strengthening exercises for the deep neck flexors, extensors, and scapular muscles, as well as diaphragmatic breathing exercises.
223982757|NCT03738397|DRUG|Placebo to upadacitinib|Tablet
224119362|NCT02582749|DRUG|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
224119363|NCT02582749|DRUG|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
224119364|NCT02582749|RADIATION|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
224119365|NCT00228488|DRUG|Gefitinib|
224119366|NCT01519570|OTHER|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
224119367|NCT01452074|OTHER|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, \~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
224293985|NCT02054130|DRUG|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
223727525|NCT07131150|BIOLOGICAL|SC01009 injection|Menstrual Blood-Derived Mesenchymal Stem Cell (Product Code: SC01009) Injection is a cell therapy product developed by Zhejiang Sinocord Precision Medicine Technology Co., Ltd. The active component consists of mesenchymal stem cells (MSCs) derived from menstrual blood.
223727526|NCT07131150|BIOLOGICAL|Placebo Group(Vehicle)|The placebo consists of the SC01009 Injection formulation solution, containing all components identical to the active product except for the absence of mesenchymal stem cells.
223727527|NCT07132554|OTHER|Combined 1:1 MICT and HIIT aerobic cardiac rehabilitation|Combining 1:1 MICT and HIIT in short (4 weeks) high-volume (32 sessions) early-to-very-early phase program post heart transplantation
223727528|NCT07131774|OTHER|Filling in a symptom diary|"Each patient will receive a diary form in which they are asked to record their symptoms, body temperature, and body weight on a daily basis. This approach is intended to provide a comprehensive overview of the disease course and the impact of treatment over time.~Depending on hospitalization status, disease severity, treatment progress, and national treatment guidelines, clinical, microbiological, and radiological follow-up assessments will be performed as part of routine care at intervals ranging from weekly to monthly. No additional study visits or microbiological or radiological diagnostics outside of standard clinical care will be conducted."
223982758|NCT01795859|DRUG|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
223982759|NCT01795859|DRUG|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
223982760|NCT04530877|BIOLOGICAL|Infliximab|Infliximab, a monoclonal antibody-targeting tumor necrosis factor (TNF), is one of the primary treatment strategies for active pediatric CD
223982761|NCT04530877|DIETARY_SUPPLEMENT|Exclusive Enteral Nutrition|the administration of a liquid formula diet with the exclusion of all other regular food for 6-8 weeks， the volume was determined according to the energy needs of the patient. All patients received high energy intakes (\>110%-120% of the average requirement).
223982762|NCT04429035|DIETARY_SUPPLEMENT|Vitamin K2|Administration of 300 μg Vitamin K2 (MQ7) daily p.o
224119368|NCT01452074|OTHER|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
224119369|NCT05652374|DEVICE|Ialuril 50ml Prefill|50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
224119370|NCT05652374|DRUG|Nitrofurantoin|nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
224119371|NCT02089386|DRUG|Tamoxifen|
224119372|NCT02089386|PROCEDURE|Endoscopy|
224119373|NCT03015350|DRUG|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
224119374|NCT03015350|DRUG|Desflurane|Measurement of blood desflurane level during one lung ventilation
224293986|NCT02054130|DRUG|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
224293987|NCT02054130|DRUG|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
224293988|NCT02054130|DRUG|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
223982763|NCT04429035|DIETARY_SUPPLEMENT|Placebo|Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
223982764|NCT06480877|DIAGNOSTIC_TEST|Taking a swab from periodontal pockets or gingival sulci|Swabs for next generation sequencing were taken with paper points as described earlier.
223727529|NCT06947577|OTHER|pulsed electromagnetic field (PEMF) therapy and a tailored exercise program (TEP)|pulsed electromagnetic field (PEMF) therapy for addressing chemotherapy-induced peripheral neuritis in the lower limb, patients were first prepared by ensuring they were in a relaxed state, free from distractions, and instructed to remove any metallic items while wearing comfortable clothing. The treatment utilized the ASA Easy Terza series PEMF device from Italy, with each patient positioned comfortably in a supine posture. The device was connected to a 220 V electrical supply, and the solenoid was placed over the lower leg, operating at a frequency of 50 Hz and an intensity of 20 G for a duration of 20 minutes. Patients were situated in a position between sitting and lying, with their lower legs and feet positioned within the solenoid. The setup adhered to the manufacturer's guidelines to ensure effective delivery of the magnetic oscillations, with treatment parameters meticulously adjusted
223982765|NCT00279877|PROCEDURE|Kyphoplasty|kyphoplasty
223982766|NCT02383407|DEVICE|Medtronic Deep Brain Stimulation|
223982767|NCT01938898|OTHER|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~1. Male \& Study \& Confidentiality~2. Male \& Study~3. Male \& Project \& Confidentiality~4. Male \& Project~5. Female \& Project \& Confidentiality~6. Female \& Project~7. Female \& Study \& Confidentiality~8. Female \& Study~9. Neutral \& Study \& Confidentiality~10. Neutral \& Study~11. Neutral \& Project \& Confidentiality~12. Neutral \& Project"
223982768|NCT01143883|OTHER|Silverlon|Silverlon dressings are gauze impregnated with silver ions
223982769|NCT01143883|OTHER|Standard of Care Dressing|Standard dry gauze dressing
223982770|NCT00984698|BEHAVIORAL|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
223982771|NCT00984698|BEHAVIORAL|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
223982772|NCT03515200|DRUG|Palbociclib Oral Capsule|Given orally or nasogastrically (NG).
223982773|NCT03515200|DRUG|Intrathecal Triple Therapy|Given intrathecally (IT).
223982774|NCT03515200|DRUG|Dexamethasone|Given orally, nasogastrically (NG) or intravenously (IV).
223982775|NCT03515200|DRUG|Bortezomib|Given intravenously (IV) or subcutaneously (SC).
223982776|NCT03515200|DRUG|Dasatinib|Given orally or nasogastrically (NG).
223982777|NCT03515200|DRUG|Doxorubicin|Given intravenously (IV).
224119375|NCT04330235|OTHER|Healthy Default Kids' Beverage Policy|The healthy default kids' beverage policy requires that all restaurants serve only healthy beverages (water, milk, or 100% juice) instead of sugary beverages as the default beverage with children's meals. The policy has been enacted in New York City and Philadelphia and will go into effect in April 2020.
224119376|NCT02013193|DEVICE|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
224119377|NCT02013193|DEVICE|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
223982778|NCT03515200|DRUG|Ruxolitinib|Given orally or nasogastrically (NG).
223982779|NCT06076824|DRUG|Methylprednisolone|The intervention group will recieve 7 mg/kg/day (or a maximum of 500 mg/day) of intravenous Methylprednisolone an hour before TAVR followed by 15 mg / 12h of Prednisone during 5 days after the intervention (starting 24h after the administration of Methylprednisolone).
223982780|NCT06076824|OTHER|Placebo|Saline solution
223982781|NCT05076136|OTHER|Regional treatment|In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.
223982782|NCT05076136|OTHER|Standard physiotherapy treatment|In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
224119378|NCT00778752|DRUG|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
224119379|NCT00003771|BIOLOGICAL|therapeutic estradiol|
224119380|NCT00003771|DRUG|norethindrone acetate|
224119381|NCT01323673|DRUG|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
223982783|NCT01263925|DRUG|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
223982784|NCT01263925|DRUG|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
223982785|NCT01263925|DRUG|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
223982786|NCT01263925|DRUG|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
224119382|NCT01323673|DRUG|Vehicle / Placebo|2 times a day, 14 total days of study treatment
224119383|NCT04598165|BEHAVIORAL|Interactive two-way SMS dialogue|We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
224119384|NCT04013581|DRUG|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
224293989|NCT02060474|DRUG|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
223544028|NCT04217707|BEHAVIORAL|Pre- and Post-Surgical Transgender Therapeutic Support Group|Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
223544029|NCT04342091|DEVICE|SOL Nova Device|A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
223544030|NCT04646577|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous) prime with anodal Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint induced movement therapy. Each session will last 20 minutes.
223544031|NCT04646577|DEVICE|Transcranial Direct Current Stimulation (tDCS|Subjects will either undergo sham Transcranial Direct Current Stimulation (tDCS) on the affected side combine with Constraint-induced movement therapy.
223727530|NCT06947577|OTHER|Tailored Exercise Program|This TEP has been meticulously designed to address the rehabilitation needs of patients dealing with lower limb issues. The program encompasses a comprehensive approach, integrating various types of exercises aimed at enhancing strength, functional mobility, balance, coordination, flexibility, and pain management. The sequence of exercises begins with strengthening exercises targeting key muscle groups such as the gastrocnemius and tibialis anterior, followed by functional training activities that simulate daily movements. This is complemented by balance and coordination drills, coordination drills that challenge stability, and flexibility and stretching exercises to improve range of motion. Additionally, pain management techniques and therapeutic modalities like hot packs are incorporated to alleviate discomfort and enhance relaxation. Finally, the program concludes with low-impact aerobics, such as walking programs, to promote cardiovascular fitness. Prior to commencing the exercise
223544032|NCT05065073|DRUG|Iodixanol|Iso-osmolar Contrast Media
223544033|NCT05065073|DRUG|Iohexol|Low-Osmolar Contrast Media
223982787|NCT01137877|OTHER|Milk based infant formula powder|milk based infant formula ad lib
223982788|NCT01137877|OTHER|Investigational Infant Formula #1|Milk based infant formula ad lib
223982789|NCT01137877|OTHER|Investigational Infant Formula #2|Milk based infant formula powder ad lib
223544034|NCT00736112|OTHER|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
223982790|NCT01137877|OTHER|Human Milk|Human milk ad lib
224293990|NCT06125574|OTHER|Osteopathic Manipulative Medicine|Individuals in the experimental cohort will undergo a systematic osteopathic manipulative treatment protocol encompassing paraspinal inhibition, rib raising, and condylar decompression techniques.
224293991|NCT04146311|DRUG|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
224293992|NCT04146311|DRUG|isotonic saline|A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
223544035|NCT00736112|PROCEDURE|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
223544036|NCT00736112|PROCEDURE|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
223982791|NCT04833244|BEHAVIORAL|Triangular Forearm Support|The intervention, the Triangular Forearm Support requires drawing the shoulders away from the subject's head and neck. This requires at least a mild force that this action can oppose. The most-favored maneuver is to have patients stand 2 feet away from a wall, interlock their fingers, and place their forearms to form two sides of an equilateral triangle against the wall. They then place their heads within the triangle, the backs of their heads close to or in on contact with the heels of their hands. Then, pressing against the wall with their elbows and forearms, they draw their shoulders as far away from the wall as possible, retaining contact between the wall and the tops of their heads. Subjects remain in this position for 45 seconds, at which time they stand erect and repeat the abduction and flexion maneuver.
223982792|NCT04833244|BEHAVIORAL|Placebo|Patients will be asked to raise arms overhead for 45 seconds.
223982793|NCT05021822|PROCEDURE|Erector spinae plane block|Bilateral erector spinae plane block will be performed preoperatively under ultrasound guidance using 15 ml bupivacaine on each side
223982794|NCT00904709|DRUG|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
223982795|NCT03185702|GENETIC|Research genetic tests|DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
223982796|NCT04583462|DRUG|Metformin|Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
223982797|NCT04583462|DRUG|Placebo|Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
223982798|NCT05851040|OTHER|Observation study|Looking to find the role of wheatgrass and tulsi give separately or with allopathic drug
223982799|NCT05799521|DRUG|Optate|Alkaline Buffer
223982800|NCT05799521|DRUG|Placebo|Normal Saline
223982801|NCT05865925|DRUG|LY010616|IV infusion was 90min (±5min), with an interval of 3 weeks between the first administration and the second administration, and once every 2 weeks thereafter
224293993|NCT04146311|OTHER|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
223727531|NCT00221273|PROCEDURE|ACL surgery|
223544037|NCT00599352|DIETARY_SUPPLEMENT|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
223727532|NCT02367677|OTHER|Method comparison|
223727533|NCT03542981|DEVICE|Interferential Current|
223727534|NCT03542981|DEVICE|Sham Interferential Current|
223982802|NCT00806598|DRUG|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~* Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~* MDS patients \<55 years receive 3.5 mg/kg/day for 5 days~* MDS patients \>55 years receive 2.5 mg/kg/day for 5 days"
223982803|NCT00806598|DRUG|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
223982804|NCT00806598|DRUG|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
223982805|NCT00806598|DRUG|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
223982806|NCT03539133|OTHER|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
223982807|NCT03540290|PROCEDURE|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
223982808|NCT04896684|BIOLOGICAL|blood and intestinal biopsy sampling|24 mL of blood and 10 intestinal biopsies will be sampled
223982809|NCT01536197|PROCEDURE|Gastric bypass|Roux-en-Y gastric bypass
223982810|NCT01536197|PROCEDURE|Gastric banding|Laparoscopic adjustable gastric banding
223982811|NCT01536197|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy surgery
223982812|NCT04507633|BEHAVIORAL|ROMA therapy(reminiacence therpy, orientation, music, and art)|An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
223982813|NCT03478410|PROCEDURE|Epicardial fat biopsy|A 1 cm (\~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
223982814|NCT04522206|DRUG|Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone|"The study subjects will be assigned to the defined pre-op MMA regimen with standard postop oxycodone based pain control regimen given on an as needed basis. The treatment group outcomes will be compared to patients outside of the study including a historical control group (receiving only post-op pain regimen) prior to the implementation of the new regimen. The studied treatment group will receive within 3 hours before surgery an oral MMA regimen consisting of:~Acetaminophen 975 mg Celecoxib 200 mg Gabapentin 300 mg Oxycodone 10 mg Extended Release"
223982815|NCT00520871|DRUG|Blueberry juice|
223982816|NCT03180008|BEHAVIORAL|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
223982817|NCT03180008|BEHAVIORAL|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
224119385|NCT04013581|DRUG|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
223727535|NCT04784949|PROCEDURE|portland cement|pulpotomy with PRF and white Portland cement
223982818|NCT03055546|DRUG|Oxytocin|intranasal administration of oxytocin
223982819|NCT03055546|DRUG|Placebo|intranasal administration of placebo
223982820|NCT05200325|OTHER|Educational materials for TissueCypher|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
223982821|NCT04665362|DRUG|Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib|"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
223982822|NCT05563090|OTHER|Questionnaires+Tongue diagnosis+Pulse diagnosis|Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools
223982823|NCT00890890|DRUG|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
223982824|NCT00890890|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
224119386|NCT00692900|DRUG|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
223727536|NCT04784949|PROCEDURE|Mineral trioxide aggregate|pulpotomy with PRF and white Mineral trioxide aggregate
223982825|NCT02759926|DRUG|Denatonium benzoate|
223982826|NCT02759926|DRUG|Quinine hydrochloride|
223982827|NCT02759926|DRUG|Tap water|
223982828|NCT01588210|OTHER|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
223982829|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
223982830|NCT01588210|OTHER|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
223982831|NCT00573651|OTHER|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
223982832|NCT01779453|DRUG|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
223982833|NCT01779453|DRUG|Placebo|Placebo once daily for 8 weeks
223982834|NCT01779453|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
223982835|NCT03242668|PROCEDURE|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
223982836|NCT03242668|PROCEDURE|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
223982837|NCT03242668|DRUG|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
224119387|NCT00692900|DRUG|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
224119388|NCT00175175|BEHAVIORAL|"Allied health professional-run osteoporosis service (case-management)"|
223982838|NCT00812123|DRUG|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
223982839|NCT00812123|DRUG|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
223982840|NCT00812123|DRUG|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
223982841|NCT00812123|DRUG|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
223982842|NCT00812123|PROCEDURE|Protocol biopsies|protocol kidney biopsies at month one and three
223982843|NCT04562896|DEVICE|Custom Carbon Fiber Dynamic Orthosis (CDO)|The custom carbon fiber dynamic orthoses will consist of a semi-rigid foot plate, a posterior carbon fiber strut, and a proximal cuff below the knee.
224119389|NCT03014661|OTHER|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
223982844|NCT03909282|PROCEDURE|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
223982845|NCT03909282|RADIATION|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
223982846|NCT05376371|OTHER|CJC-TraC|CJC-TraC utilizes a nurse case manager (NCM) to coordinate the participant's transitional care through release from a correctional facility. The NCM will visit either in person or via telehealth with the participant up to 4 times while incarcerated, and up to 4 times after release.
223982847|NCT04958941|BEHAVIORAL|Experimental: Intervention group|During 2 months participants will be able to asses their mood and practice in real time their emotional regulation skills with an ecological momentary interventions APP.
223982848|NCT06416319|DEVICE|Daily Activity Goal and Feedback|The daily activity target is a fixed number of steps. The exact number of steps is determined beforehand as part of the case number planning in a pilot study with ten participants and adjusted if necessary. The activity target we suggest is 8000 steps. In addition, the participants receive feedback several times a day about the steps needed to reach the goal and whether they have ultimately reached the daily goal.
223982849|NCT05103098|DRUG|misoprostol 400 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 400 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 400 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
223982850|NCT05103098|DRUG|misoprostol 800 mcg|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as an analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
223982851|NCT00968006|DRUG|Sitagliptin|100 mg once daily for 4 weeks
223982852|NCT03769298|DRUG|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
223982853|NCT00644735|DRUG|Esomeprazole|
223982854|NCT00644735|DRUG|Lansoprazole|
223982855|NCT03459612|DRUG|Lasmiditan|Administered orally
223982856|NCT03459612|DRUG|Placebo|Administered orally
223982857|NCT03459612|DRUG|Diphenhydramine|Administered orally
223982858|NCT03979547|BEHAVIORAL|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
223982859|NCT05511558|DRUG|[14C]-Fosgonimeton|Carbon-14 Radiolabeled Fosgonimeton
224119390|NCT03736837|DRUG|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
223544038|NCT04904029|OTHER|Digital Assessment Routing Tool [DART]|"DART is a first contact web-based and mobile health system that uses clinical algorithms to triage patients and recommend management pathways. Participants complete an online web-based questionnaire that follows a clinical reasoning process commonly observed in face-to-face physiotherapy consultations. Based on the participant's answers, the clinical algorithm generates sets of questions, leading up to a triage disposition with recommended management pathway. The triage outcomes with management pathways are classified;~1. Medical care~   * A\&E referral~  * Urgent GP~  * Routine GP~  * Consultant review~2. Physiotherapy care~   * Post-fracture or surgery physiotherapy~  * Physiotherapy referral~  * Physiotherapy referral plus psychosocial support~3. Self-management~   * Self-management with SOS~  * Continue self-management advice"
223544039|NCT04904029|OTHER|Physiotherapy-led remote triage (usual care)|Participants will receive usual physiotherapy-led remote triage services by a registered health care professional. This service is either a telephone or video consult and includes any diagnostic procedure (e.g. patient history, remote assessments) and treatment, such as management advise or home-based exercise therapy. Participants may seek help elsewhere or opt-out the study at any point, which will not affect their usual physiotherapy-led remote care
223544040|NCT00003869|DRUG|carboxyamidotriazole|Given PO
223544041|NCT00003869|OTHER|placebo|Given PO
223544042|NCT00003869|PROCEDURE|quality-of-life assessment|Ancillary studies
223544043|NCT00003869|OTHER|laboratory biomarker analysis|Correlative studies
223544044|NCT04364555|DRUG|Clobetasol Propionate|Klobetasol APL oral gel 0.025% is a topical steroid for rinsing the oral cavity. Manufactured by APL, Sweden.
223544045|NCT04364555|DRUG|Placebo/Klobetasol APL oral gel 0.025%|Placebo/active
223727537|NCT04784949|PROCEDURE|Biodentine|pulpotomy with PRF and Biodentine
224119391|NCT00400933|BEHAVIORAL|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
224119392|NCT01796353|OTHER|sexual rehabilitation|exercise plus psycho-education
224119393|NCT01796353|OTHER|Usual care|usual care
223544046|NCT04364555|DRUG|Placebo|Placebo/placebo
223982860|NCT04344756|DRUG|Tinzaparin or unfractionated heparin|Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
223982861|NCT05940831|BEHAVIORAL|Support-Moms|Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).
223982862|NCT05940831|BEHAVIORAL|Control|Routine care/ information giving
223982863|NCT03427008|OTHER|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
223982864|NCT03477825|DIETARY_SUPPLEMENT|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day"
223982865|NCT03477825|DIETARY_SUPPLEMENT|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet."
223982866|NCT03477825|DIETARY_SUPPLEMENT|Triphala|"Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
223982867|NCT04956614|DEVICE|immobilisation duration|immobilisation duration of 2,4,6 week after suture of Achilles tendon
223982868|NCT05571306|OTHER|four core components care|"The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills."
223982869|NCT05554926|DRUG|AEF0117|2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
223982870|NCT03674762|DEVICE|Microgrooved dental implants|Dental Implant placement
223982871|NCT05988034|DRUG|Avacopan|Administered orally.
223982872|NCT05988034|DRUG|Moxifloxacin|Administered orally.
223982873|NCT05988034|DRUG|Placebo for avacopan|Administered orally.
223982874|NCT05988034|DRUG|Placebo for moxifloxacin|Administered orally.
224119394|NCT03682796|DRUG|TRPH-222|administered by IV, 21-day Cycle
224119395|NCT01554202|BEHAVIORAL|assessment of memory|
224119396|NCT01554202|BIOLOGICAL|circulating tPA dosage|
224119397|NCT01554202|GENETIC|ApoE4|
223982875|NCT00352378|DRUG|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
223982876|NCT01752010|OTHER|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
224119398|NCT01554202|OTHER|Brain imaging examination MRI and PET examinations|
224119399|NCT04708964|DRUG|Flurbiprofen|Flurbiprofen solution will be administered, through the subglottic intake door of the endotracheal tube.
224119400|NCT04708964|DRUG|saline solution|Saline solution will be administered, through the subglottic intake door of the endotracheal tube.
224119401|NCT01200511|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
224119402|NCT00540722|DRUG|R-(-)-gossypol acetic acid|Given PO
224119403|NCT00540722|OTHER|laboratory biomarker analysis|Correlative studies
224119404|NCT03785717|PROCEDURE|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
224119405|NCT03785717|PROCEDURE|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
224119406|NCT03388177|BEHAVIORAL|Yoga-based therapy|
224119407|NCT03388177|OTHER|Treatment as usual|
223544047|NCT01474785|DRUG|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
223544048|NCT01474785|OTHER|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
223544049|NCT01474785|PROCEDURE|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
223544050|NCT04930146|OTHER|acupuncture and bloodletting|bloodletting at the well points of both hands and feet and acupuncture in DU26, DU24 3 times per week for 4 weeks, total 12 treatments.
223544051|NCT03573388|DEVICE|Optical coherence tomography (OCT)|Lesion OCT assessment
223544052|NCT01619761|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
223982877|NCT01752010|DEVICE|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
224119408|NCT01593748|DRUG|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
224119409|NCT01593748|DRUG|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
224119410|NCT02124850|DRUG|Motolimod|
224119411|NCT02124850|DRUG|Cetuximab|
224119412|NCT02124850|DRUG|Nivolumab|
224119413|NCT03664817|BEHAVIORAL|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
224119414|NCT03664817|BEHAVIORAL|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
224119415|NCT03549624|OTHER|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
224119416|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
224119417|NCT00096746|DRUG|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
223544053|NCT01619761|DRUG|Cyclophosphamide|Given IV
223544054|NCT01619761|DRUG|Fludarabine Phosphate|Given IV
223544055|NCT01619761|OTHER|Laboratory Biomarker Analysis|Correlative studies
223544056|NCT01619761|DRUG|Lenalidomide|Given PO
223544057|NCT01619761|DRUG|Melphalan|Given IV
223544058|NCT01619761|DRUG|Mycophenolate Mofetil|Given IV or PO
223544059|NCT01619761|BIOLOGICAL|Natural Killer Cell Therapy|Given IV
223544060|NCT01619761|BIOLOGICAL|Rituximab|Given IV
223544061|NCT01619761|DRUG|Tacrolimus|Given IV or PO
223544062|NCT01619761|RADIATION|Total-Body Irradiation|Undergo TBI
223544063|NCT01619761|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
223544064|NCT03364231|DRUG|Umbralisib|Oral Daily Dose
223544065|NCT03168893|DEVICE|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
223544066|NCT03168893|DEVICE|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
223544067|NCT04068922|BEHAVIORAL|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
223544068|NCT03542266|DRUG|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
223544069|NCT03542266|DRUG|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
223544070|NCT03269773|BIOLOGICAL|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
223544071|NCT03269773|OTHER|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
223544072|NCT02272946|DRUG|Canakinumab|150mg Canakinumab received subcutaneously
223544073|NCT02272946|DRUG|Placebo|150mg Placebo received subcutaneously
223544074|NCT01015755|BEHAVIORAL|combined therapy treatment|mouth care
223982878|NCT01752010|DEVICE|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
223982879|NCT03269747|DRUG|Prednisone|2 tablets of Prednisone 20 Mg in the morning
223982880|NCT03269747|DRUG|Placebo|2 Placebo tablets in the morning
223982881|NCT02316392|DRUG|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
223982882|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative dexmedetomidine sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
223982883|NCT04817033|PROCEDURE|Spinal anesthesia with intraoperative midazolam sedation|Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
223982884|NCT04817033|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
223982885|NCT04817033|DRUG|Midazolam|Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
223982886|NCT04702399|DEVICE|GEL GROUP|Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
223982887|NCT01965041|DRUG|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
223982888|NCT01134718|DRUG|TMC435 (G006)|one morning dose of 150 mg
223982889|NCT01134718|DRUG|TMC435 (F021)|one morning dose of 150 mg
224119418|NCT04229446|BEHAVIORAL|Music based caregiving|The intervention (MBC) consists of daily individualized prerecorded music integrated with activity with about 30 minutes duration, combined with a one hour active session in groups twice weekly. The music will be selected based on individualized preferences from the patients or their family. The music will also be adapted to the day rhythm; awakening in the morning, support activities during the day, or for sleep in the evening. The healthcare worker will bring playback equipment e.g. a CD-player to the patient room. In addition will two weekly sessions in groups be performed (each on one hour) with music and movement.
224119419|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
224119420|NCT00911664|DRUG|No supplementation|Control
224293994|NCT05506410|DRUG|Rituximab|Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
223982890|NCT01134718|DRUG|TMC435 (G007)|one morning dose of 150 mg
224293995|NCT04882631|DRUG|PBI-100 Topical Cream|A dose of approximately 560 ug (approximately 0.4 mL of each of the three concentrations to 3 different sites) of PBI-100 was applied daily (excluding weekends) to the skin test sites.
223544075|NCT00720577|DRUG|Simvastatin|40 Mg. tablet, 1 tablet daily
223982891|NCT04236245|DEVICE|Venclose RF System|Treatment of great saphenous vein (GSV) using Venclose RF System
223982892|NCT00474383|DRUG|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
223982893|NCT00474383|DRUG|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
223544076|NCT00720577|DRUG|Losartan|50 mg., tablets, 1 tablet once daily
223544077|NCT00720577|DRUG|Pioglitazone|30 mg, tablet, 1 tablet once daily
223982894|NCT04151771|OTHER|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
224119421|NCT00911664|DIETARY_SUPPLEMENT|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
224119422|NCT03366740|OTHER|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
223544078|NCT04273165|DRUG|Etravirine Tablets|Daily etravirine BID with 100 or 200 tablets for 4 months
223544079|NCT05164315|PROCEDURE|Tailored surgery|Procedure: Tailored surgery based on intraoperative local excision/biopsy
223544080|NCT05164315|PROCEDURE|Total mesorectal excision (TME)|Procedure: Total mesorectal excision for all allocated patients
223544081|NCT04780529|BIOLOGICAL|gucy2c cart cells|Patients with advanced malignant gastrointestinal tumors were injected with CART cells
223544082|NCT00838812|DRUG|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
223544083|NCT00585637|DRUG|Vitamin D|Taken orally every day for three months
224119423|NCT03366740|OTHER|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
223982895|NCT04151771|OTHER|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
223982896|NCT00926302|DRUG|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
224119424|NCT03366740|OTHER|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
224119425|NCT00002263|DRUG|Zidovudine|
224119426|NCT00002263|DRUG|Sargramostim|
224119427|NCT02284334|OTHER|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
223982897|NCT00926302|DRUG|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
223982898|NCT00977795|DRUG|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
223982899|NCT02998918|DIETARY_SUPPLEMENT|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
223982900|NCT02998918|DIETARY_SUPPLEMENT|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
223982901|NCT05910697|OTHER|MyProstateScore 2.0 Results|Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
223982902|NCT03500835|BEHAVIORAL|App|"1. 6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~2. Daily Weigh In~3. App based reminders~4. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months."
224119428|NCT03156556|BEHAVIORAL|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
224119429|NCT06671522|OTHER|Survey|It is a qualitatative research. Only a survey.
224119430|NCT06671639|DEVICE|da Vinci Xi Robotic Surgery System|"The da Vinci Xi Surgical System is a software-controlled, electro-mechanical system designed for surgeons to perform minimally invasive surgery. It consists of a Surgeon Console, a Patient Cart, and a Vision Cart, and is used with a Camera Instrument and EndoWrist Xi instruments and accessories.~The surgeon seated at the surgeon console controls all movement of the EndoWrist Xi instruments and Camera Instrument using two master controls and a set of foot pedals. The surgeon views the three-dimensional endoscopic image on a high-resolution stereo viewer (3D viewer), which provides him/her/they a view of patient anatomy and instrumentation, along with icons and other user interface features. The Vision Cart includes the supporting electronic and video processing equipment for the system."
224293996|NCT04882631|DRUG|Positive Control - Sodium laurel sulfate (SLS)|Approximately 0.4 mL of 0.25% SLS was applied daily (excluding weekends) as a positive control test site.
223544084|NCT00585637|DIETARY_SUPPLEMENT|Placebo|Placebo pill taken once daily for 3 month
223544085|NCT04308018|PROCEDURE|S2alar-iliac screws|Caudal end of the instrumentation at iliac bone via S2alar-iliac screws
223544086|NCT04308018|PROCEDURE|S1 screws|Caudal end of the instrumentation at S1
223544087|NCT04060004|OTHER|Dry needling|Dry needling is a technique used by physiotherapists.
223544088|NCT04060004|OTHER|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
223544089|NCT04060004|OTHER|Electrotherapy + therapeutic exercise|Standard care of neck pain.
223544090|NCT00382317|DRUG|Iobitridol|
223544091|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,25%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume."
223544092|NCT05921110|PROCEDURE|Pericapsular nerve group block 0,16%|"Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume"
223544093|NCT03040089|DEVICE|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
223544094|NCT03040089|DRUG|Neoquine Cream 2%|2% hydroquinone cream
223544095|NCT01059747|OTHER|no intervention applied|no intervention applied
223544096|NCT05853588|OTHER|training|On-the-job (toolbox) training given to the experimental group and containing brief information, lasting at most 10 minutes
223544097|NCT01514721|DRUG|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
223544098|NCT04892030|BEHAVIORAL|Whole Food Plant-Based Behavioral Weight Loss Treatment|Over the course of 12-weeks, participants will be prescribed a non-energy-restricted whole food plant-based diet and will learn behavioral weight loss strategies through an e-learning platform. Each week, participants will also complete a 15-minute coaching call to provide positive reinforcement and problem-solving support.
223544099|NCT04170920|DEVICE|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
223982903|NCT03500835|BEHAVIORAL|Coaching|"1. 6 month addiction based intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction.~2. Daily Weighing~3. Daily Text messages from Coach~4. Weekly 15 minute phone meetings with Coach~5. Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months post consent"
223982904|NCT03500835|BEHAVIORAL|Clinic: Modified KidsNFitness|"1. 6 month in-clinic, evidence-based, multi-disciplinary intervention~2. 90 minute sessions, in clinic that occur every month for 6 months~3. Follow Up: Face-to-face clinic visits Monthly x 6 months followed by face-to-face visit at12 and 18 months."
223982905|NCT02364609|DRUG|Afatinib Dimaleate|Given PO
223982906|NCT02364609|BIOLOGICAL|Pembrolizumab|Given IV
223982907|NCT00487799|DRUG|Ularitide|
223982908|NCT03393065|OTHER|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
224293997|NCT04882631|OTHER|PBI-100 Topical Cream, Vehicle|Approximately 0.4 mL of 0% placebo cream was applied daily (excluding weekends) as a positive control test site.
224293998|NCT04882631|OTHER|Negative Control|A blank patch was applied daily (excluding weekends) as a negative control test site.
224293999|NCT04047524|OTHER|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
224294000|NCT02783430|DRUG|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
224294001|NCT02783430|DRUG|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
224294002|NCT02783430|DRUG|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
224294003|NCT00094458|BIOLOGICAL|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
224294004|NCT00094458|OTHER|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
224294005|NCT00094458|DRUG|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
224294006|NCT02322619|DRUG|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
224294007|NCT05881902|BEHAVIORAL|HEALTH FAITH MODEL GUIDED IN CANCER FREQUENTLY SEEN IN WOMEN EARLY DIAGNOSIS AND SCREENING METHODS EDUCATION|"A total of 4 home visits and 2 phone calls will be made by giving awareness training based on the Health Belief Model to the participants in the Intervention 1 group in order to eliminate the lack of information about the common female cancers in women and to increase their awareness. For 3 months, intervention 1 group will be given applications to reinforce their awareness in the education based on the Health Belief Model (for BSE and KKVM, erasable calendar magnets, booklets, phone cases and accessories themed as common cancers awareness in women as a reminder, phone call) will be made"
224294008|NCT05881902|BEHAVIORAL|STANDART CANCER EDUCATİON|The participants in the intervention 2 group will be given the standard training applied by the Ministry of Health in KETEM for women's cancers during home visits, and a total of 4 home visits and 2 SMS reminders will be made.
224294009|NCT00170794|DRUG|Everolimus (RAD001)|
224294010|NCT04161846|BEHAVIORAL|Virtual Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
224294011|NCT04161846|BEHAVIORAL|In Person Training|The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
224294012|NCT03557359|DRUG|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
224294013|NCT03265288|DRUG|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
224294014|NCT03265288|DRUG|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
223544100|NCT01371058|DRUG|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
223544101|NCT01371058|DRUG|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
223982909|NCT03642288|DRUG|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
223982910|NCT00443599|DRUG|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
224294015|NCT03197558|COMBINATION_PRODUCT|Tymbion Iontophoresis and Tube Delivery System (TDS)|Subjects will receive active Tymbion iontophoresis and tube insertion using the Tube Delivery System in all ears indicated for tube placement.
224294016|NCT01046552|PROCEDURE|preoperative ERCP and LC|preoperative ERCP followed by LC
224294017|NCT01046552|PROCEDURE|Intraoperative ERCP and LC|LC and intraoperative ERCP
224294018|NCT05695872|PROCEDURE|subtarsal approach|surgical approach
224294019|NCT05695872|PROCEDURE|conventional transconjunctival approach|surgical approach
224294020|NCT05695872|PROCEDURE|transconjunctival approach with Y- modification|surgical approach
224294021|NCT01618188|DRUG|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
223982911|NCT00443599|OTHER|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
223982912|NCT03110692|BEHAVIORAL|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
223982913|NCT01952106|OTHER|play computer game|
223982914|NCT06336941|DEVICE|Ultrasound|Ultrasonographic scan with a 70 MHz probe
223982915|NCT00615355|RADIATION|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
223982916|NCT00615355|DEVICE|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
223982917|NCT01119534|DRUG|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
223982918|NCT01119534|DRUG|guaiacol suppository|2 times per day
223982919|NCT01119534|DRUG|Guaifenesin syrup|4.19 mL - 4 in 4 hours
223982920|NCT03594578|BEHAVIORAL|Episodic future thinking|Prospective thinking intervention
223982921|NCT03594578|BEHAVIORAL|Episodic recent thinking|Sham episodic thinking
223982922|NCT00220571|DEVICE|Coronary Angioplasty (PTCA)|
223982923|NCT01974661|BIOLOGICAL|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
223982924|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale|Assessment of the severity of hirsutism using the visual modified Ferriman-Gallwey scale in 9 body regions rated from 0 (no growth of terminal hair) to 4 (extensive hair growth), thus with a score ranging from 0 (the lowest score - no hirsutism) to 36 points (the highest score - the greatest severity of hirsutism)
223982925|NCT06530498|DIAGNOSTIC_TEST|Assessment of the severity of endogenetic alopecia using the visual Ludwig Scale|"Visual assessment of baldness on the Ludwig scale from I (least severe baldness) to III (most severe baldness):~Type I - minimal thinning of the mid-line parting in the hair; Type II - gradual thinning and noticeable widening of the mid-line parting in the hair; Type III - Heavy to total thinning of the mid-line"
223982926|NCT01286376|DIETARY_SUPPLEMENT|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
223982927|NCT01286376|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
223982928|NCT05655624|OTHER|Pursed lip Breathing along Mat Pilates|Experimental Group: will be treated with Pursed lip Breathing along Mat Pilates Training.
223982929|NCT05655624|OTHER|pursed lip breathing without Mat Pilates Training|Control Group will be treated pursed lip breathing without Mat Pilates Training
223982930|NCT05197153|BIOLOGICAL|Half dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
223982931|NCT05197153|BIOLOGICAL|Full dose of MVC-COV1901|Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
223982932|NCT05197153|BIOLOGICAL|AZD1222|Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
223982933|NCT05197153|BIOLOGICAL|Half dose of mRNA-1273|Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.
223544102|NCT01371058|DRUG|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
223544103|NCT02691026|DRUG|Pembrolizumab|
223544104|NCT01070979|DRUG|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
223982934|NCT02540343|OTHER|questionnaires|fill out all questionnaires twice
223982935|NCT00833183|DRUG|MAL|80 mg/g cream one administration with incubation for 90 minutes
223982936|NCT00057044|BEHAVIORAL|education and reminder|
223982937|NCT04836234|OTHER|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum|Wrigley Extra Strawberry Flavour Sugar Free Chewing Gum 65g 40 pieces
223982938|NCT04811339|DRUG|Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable|Pepto bismol (bismuth subsalicylate)
223982939|NCT04811339|OTHER|Placebo oral tablet without BSS|Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)
223982940|NCT04228354|DRUG|Semaglutide|Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
223982941|NCT05928858|DRUG|Premixed Bio-ceramic MTA|Partial caries removal will be carried out then Premixed Bio-ceramic MTA will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
223544105|NCT01070979|DRUG|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
223544106|NCT01070979|DRUG|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
223544107|NCT00123825|DRUG|Gemcitabine|
223544108|NCT00123825|DRUG|Cisplatin|
223544109|NCT01900886|OTHER|Peginterferon alfa-2a|Treatment as usual clinical practice
223544110|NCT01900886|DRUG|Ribavirin|Treatment as usual clinical practice
223544111|NCT02636387|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
223544112|NCT01474304|DRUG|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
223544113|NCT04796129|OTHER|the patients with hip osteoarthritis and their inflammatory status|The participants in the experimental group will be evaluated for the hip osteoarthritis. They will take and X-ray for hip joints and also hemogram for the excluding the inflammatory diseases.
223982942|NCT05928858|DRUG|Calcium hydroxide|Partial caries removal will be carried out then calcium hydroxide will be applied as indirect pulp capping agent followed by Glass ionomer filling and composite restoration
223982943|NCT01517607|OTHER|Mesalazine|Patient's treated with oral Mesalazine
223982944|NCT02827032|DEVICE|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
223982945|NCT05068947|DRUG|GV101|GV101 administered once orally.
223982946|NCT05068947|DRUG|Placebo|Matched placebo
223982947|NCT03700905|PROCEDURE|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
223982948|NCT03700905|RADIATION|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
223982949|NCT03700905|DRUG|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
223982950|NCT03700905|DRUG|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
223982951|NCT03700905|DRUG|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
223982952|NCT02444780|PROCEDURE|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
223982953|NCT06251999|DRUG|fospropofol sedation|Fospropofol sedation for same-day bidirectional endoscopy in elderly patients
223982954|NCT06251999|DRUG|Propofol|propofol
223982955|NCT06391437|DIAGNOSTIC_TEST|Extraction of blood sample|Blood samples will be collected from all patients during the first 24 h of admission before enteral nutrition and/ or parenteral nutrition.
223982956|NCT03755973|DRUG|CFA|Long-acting exogenous ovarian stimulation
223982957|NCT03755973|DRUG|rFSH|Daily rFSH
223982958|NCT03755973|PROCEDURE|Fixed daily rFSH dosing protocol of 200-300 IU|The dose of daily rFSH is fixed at 200 or 300 IU
223982959|NCT03755973|PROCEDURE|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
223982960|NCT01749267|PROCEDURE|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
223982961|NCT00497874|BEHAVIORAL|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
223982962|NCT03020953|OTHER|Exercise + Estrogen|12 weeks resistance training and estrogen patches
223982963|NCT03020953|OTHER|Exercise + Placebo|12 weeks resistance training and placebo patches
223727538|NCT00524368|DRUG|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
223727539|NCT00524368|DRUG|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
223727540|NCT02148692|PROCEDURE|Higher PEEP|
223982964|NCT02382562|BEHAVIORAL|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
223544114|NCT03376464|DEVICE|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
223544115|NCT01881815|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
223982965|NCT00548756|PROCEDURE|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
224294022|NCT01618188|DRUG|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
223727541|NCT02148692|PROCEDURE|Lower PEEP|
223727542|NCT01876160|OTHER|Transcutaneous electrical nerve stimulation|
223727543|NCT05194592|DRUG|Dapagliflozin|The patients assigned to the Dapagliflozin group will take Farxiga Pill 10mg for 6 months.
223727544|NCT05194592|DRUG|Gemigliptin|The patients assigned to the Gemigliptin group will take Zemiglo Pill 50mg for 6 months.
223727545|NCT05891262|DRUG|BMS-986196|Specified dose on specified days
223727546|NCT05891262|DRUG|Loestrin|Specified dose on specified days
223727547|NCT00793598|DRUG|Placebo|
223727548|NCT00793598|DRUG|Brincidofovir|
223727549|NCT01759030|DRUG|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
223982966|NCT00548756|OTHER|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
223982967|NCT00548756|BEHAVIORAL|Questionnaire|Questionnaire taking 40 minutes to complete.
223982968|NCT04759430|OTHER|Supervised Group|Individuals will apply ten different stabilization exercises in company with a physiotherapist.
223982969|NCT04759430|OTHER|Telerehabilitation group|Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
223982970|NCT00927524|DRUG|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
223982971|NCT00927524|DRUG|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
223982972|NCT00683059|DRUG|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
223982973|NCT04171245|OTHER|Laughie laughter prescription|Creation of a Laughie; laughing with their Laughie 3x a day
223982974|NCT04171245|DEVICE|Sleep tracking equipment|Tracking sleep using equipment
223982975|NCT04212780|DEVICE|Medtronic Summit Rechargable (RC)+S|Dual channel closed-loop pulse generator with connection to both new DBS leads for deep stimulation of VIM vs VO
223982976|NCT04212780|PROCEDURE|ipsilateral thalamic (VIM+VO) DBS|Implantation of two new ipsilateral thalamic (VIM+VO) DBS
223982977|NCT04212780|PROCEDURE|standard ET DBS|Single Lead VIM
223982978|NCT04212780|PROCEDURE|ipsilateral VO|second lead in the ipsilateral VO
223982979|NCT06085053|DRUG|TQA3038 injection|TQA3038 is an injection.
223982980|NCT06085053|DRUG|TQA3038 injection matching placebo|Placebo injection contains no active substance.
223982981|NCT04154800|DRUG|BMS-986209|Specified Dose on Specified Days
223982982|NCT04154800|OTHER|BMS-986209 Placebo|Specified Dose on Specified Days
223982983|NCT04154800|DRUG|Itraconazole|Specified Dose on Specified Days
223982984|NCT04154800|DRUG|Diltiazem|Specified Dose on Specified Days
223982985|NCT06956807|COMBINATION_PRODUCT|VB-C01 cellularised patch|surgical epicardial implantation of a membrane seeded with allogeneic adipose tissue derived stem cells in patients scheduled to undergo coronary revascularisation surgery and at high risk of developing heart failure
223982986|NCT04996368|DRUG|Tranexamic acid injection|Randomized comparison of two doses of tranexamic acid as prophylactic before start of incision in open heart surgery use for prevention of bleeding.
223727550|NCT02773355|DRUG|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
223727551|NCT04085068|OTHER|cranioscaral treatment|dural release
223727552|NCT04386421|OTHER|Video on oral hygeine instructions|A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.
223727553|NCT04386421|DRUG|Plaque disclosing tablets|"Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %"
223727554|NCT02652520|PROCEDURE|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
223982987|NCT03292445|PROCEDURE|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
223982988|NCT03292445|DRUG|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover \>10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
223982989|NCT02713971|DEVICE|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
223982990|NCT02713971|OTHER|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
223982991|NCT03819751|PROCEDURE|MRI-targeted prostate biopsy|All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
223982992|NCT01792388|DIETARY_SUPPLEMENT|Vitamin D|Capsule Form
223982993|NCT01792388|DIETARY_SUPPLEMENT|Soya Bean oil|Capsule form
223982994|NCT01382498|DRUG|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
223982995|NCT01382498|DRUG|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
223982996|NCT04564521|DRUG|Nitroglycerin|Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.
223982997|NCT04564521|DRUG|Normal saline|Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
223982998|NCT01479270|DRUG|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
223727555|NCT04508868|BEHAVIORAL|Brief Behavioral Activation with Mental Imagery|"Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary."
223727556|NCT04508868|BEHAVIORAL|Minimal Attention Control Intervention|Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
223727557|NCT00797472|DRUG|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
223982999|NCT03570151|OTHER|no intervention|no intervention will be done
223983000|NCT01459146|DRUG|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
223983001|NCT01459146|DRUG|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
223983002|NCT01459146|DRUG|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
223983003|NCT01830062|OTHER|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
223983004|NCT01830062|OTHER|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
223983005|NCT00891046|DRUG|Canakinumab|Canakinumab
223983006|NCT05828758|DRUG|Amoxicillin|Amoxicillin 10 mg/kg (50 mg/ml concentration) by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
223983007|NCT05828758|OTHER|Placebo|Distilled water 0.2 ml/kg by nasogastric tube 3 times daily (8 hours apart) 10 minutes before bolus gastric feeding for 7 days.
223983008|NCT04525599|BIOLOGICAL|ASP3772|Intramuscular (IM) injection
223983009|NCT04525599|BIOLOGICAL|PCV13|Intramuscular injection
223983010|NCT05337098|OTHER|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either aspartame, sucralose, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
223983011|NCT02034019|DRUG|Dexamethasone|
223983012|NCT02034019|DRUG|Punctum Plug|
223983013|NCT06956976|PROCEDURE|Dissection of Inferior Mesenteric Artery Root Lymph Node|Patients underwent robotic radical resection for rectal cancer, adhering to the principles of Total Mesorectal Excision (TME) or Tumor-Specific Mesorectal Excision (TSME), and dissecting the lymph nodes at the root of the inferior mesenteric artery (IMA).
223983014|NCT06956976|PROCEDURE|Preservation of Inferior Mesenteric Artery Root Lymph Node|Patients underwent robotic radical resection for rectal cancer, adhering to the principles of Total Mesorectal Excision (TME) or Tumor-Specific Mesorectal Excision (TSME), but preserving the lymph nodes at the root of the inferior mesenteric artery (IMA).
223983015|NCT06956573|OTHER|aorta imaging|Retrospective analysis of imaging data (echocardiography and/or cardiac MRI) in adult patients with Fabry disease to assess ascending aortic diameters.
223727558|NCT00797472|DRUG|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
223983016|NCT06956599|DRUG|test toothpaste|A commercially available fluoride toothpaste
223983017|NCT06956599|DRUG|Control toothpaste|A commercially available fluoride toothpaste
223983018|NCT03113383|DEVICE|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
223983019|NCT02122172|DRUG|afatinib dimaleate|Given PO
223727559|NCT04716569|DRUG|intranasal ivermectin spray|usage of ivermectin as intranasal spray for treating early covid patiens
223727560|NCT01850550|BEHAVIORAL|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
223727561|NCT02233816|BIOLOGICAL|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
223727562|NCT02233816|BIOLOGICAL|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
223983020|NCT02122172|OTHER|laboratory biomarker analysis|Correlative studies
223727563|NCT02233816|BIOLOGICAL|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
223727564|NCT02233816|BIOLOGICAL|Placebo|A single dose of placebo
223983021|NCT02849405|DEVICE|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
223983022|NCT06956846|DRUG|insulin eye drops|Use of topical insulin eye drops following a standard excimer laser photo-refractive keratecotmy in myopic/astigmatic patients, in order to examine its efficacy in promoting corneal epithelial healing and patient comfort
223983023|NCT06956846|DRUG|Artificial tears eye-drops|The other arm receiving only artificial tears
223983024|NCT03568812|DRUG|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
223983025|NCT03568812|OTHER|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
223983026|NCT06640296|DRUG|Liposomal Amphotericin B (LAmB)|collect data on tolerability and effectiveness of liposomal amphotericin B prophylaxis
223983027|NCT05624788|OTHER|No Intervention|Participants who self-identify as American Indian or Alaska Native with any indication requiring referral to a specialist after a primary care provider standard of care visit will be observed to collect data, using several surveys at 6 and 12 months. No additional specialty care visits will be added for the purpose of this study given the intent to observe medical care received following primary care provider referral. Referral to a specialist will be based on local clinical practice.
223727565|NCT04351321|PROCEDURE|Totally Laparoscopic Total Gastrectomy|Totally laparoscopic total gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
223727566|NCT04351321|PROCEDURE|Laparoscopy-Assisted Total Gastrectomy|Laparoscopy-Assisted Total Gastrectomy will be performed in patients with gastric or esophagogastric junction adenocarcinoma of preoperative clinical stage I (T1N0M0, T1N1M0, T2N0M0) with D1+/D2 lymph node dissection.
223727567|NCT04907721|DIAGNOSTIC_TEST|Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon|"The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD."
223727568|NCT03048565|BEHAVIORAL|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
223983028|NCT01863797|OTHER|Early induction|
223983029|NCT01863797|OTHER|Expectant mamagement|
223983030|NCT05418413|DEVICE|CTB|conventional Twin-block (CTB) will be comprised of maxillary and mandibular removable appliances having the labial bows, adam's clasps, and with no incisal capping.
223983031|NCT05418413|DEVICE|ETB|will be comprised of maxillary and mandibular removable 1.5-mm biocryl sheet will be adapted separately on maxillary and mandibular casts with help of vacuum machine, and Acrylic bite blocks with the inclined plane will be fabricated on biocryl sheets sim
223983032|NCT06242938|PROCEDURE|Early intensive antihypertensive treatment|"1. Treatment starts within 1 hour after randomization~2. SBP target:130-140 mmHg within 1 hour after treatment~3. The researchers can independently select oral + intravenous antihypertensive medications. Any type of antihypertensive drugs can be selected (eg. β-blokers, α-blockers, CCBs, ARBs/ACEIs, diuretic, etc.)."
223983033|NCT02720211|DEVICE|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
223983034|NCT02720211|DEVICE|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
223983035|NCT05245227|DRUG|Sublingual Misoprostol|Misoprostol 400 mcg sublingual
224294023|NCT03421756|DRUG|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
224294024|NCT03421756|RADIATION|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
224294025|NCT03421756|DRUG|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
224294026|NCT00001007|DRUG|Zidovudine|
224294027|NCT00822393|DRUG|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
224294028|NCT00822393|DRUG|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
224294029|NCT04660890|DRUG|ALXN2050|ALXN2050 will be administered orally twice daily as powder-in-capsule.
224294030|NCT04660890|DRUG|ALXN2050-matching Placebo|ALXN2050-matching placebo will be administered orally twice daily as placebo powder-in-capsule.
224294031|NCT04660890|DRUG|Moxifloxacin|Moxifloxacin will be administered as a single oral dose.
223983036|NCT05245227|DRUG|IV Oxytocin|40 units IV Oxytocin in 1000 mL normal saline
223983037|NCT01010204|DRUG|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
223983038|NCT01010204|DRUG|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
223983039|NCT02330562|DRUG|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2. Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
224294032|NCT04660890|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo will be administered as a single oral dose.
223983040|NCT02330562|DRUG|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
223983041|NCT00051038|DRUG|Entecavir|
223983042|NCT00882076|DRUG|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
223983043|NCT00882076|DRUG|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
223983044|NCT00882076|DRUG|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
223983045|NCT01755676|DRUG|Orlistat 60 mg|1 tablet 3 times a day
223983046|NCT01755676|OTHER|Placebo|1 tablet 3 times a day
223983047|NCT04700059|BEHAVIORAL|Virtual perinatal home visiting|10 perinatal home visits
223983048|NCT03082612|BEHAVIORAL|Faith-Based African American Cancer Survivorship Storytelling Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
223983049|NCT02719041|OTHER|Immunohistochemistry staining method|
224119431|NCT03067766|PROCEDURE|Art Therapy|Participate in a comic art creation workshop
224119432|NCT03067766|OTHER|Interview|Undergo qualitative interviews
224119433|NCT03067766|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224119434|NCT03067766|OTHER|Questionnaire Administration|Ancillary studies
224119435|NCT02960932|DEVICE|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
224119436|NCT05021536|OTHER|Placebo|Matching Placebo Comparator
224119437|NCT05021536|DRUG|AMX0035|Proprietary formulation of taurursodiol and sodium phenylbutyrate
224119438|NCT05185752|PROCEDURE|SIFP Block Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
223727569|NCT03746873|BEHAVIORAL|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
223727570|NCT05236569|DRUG|Tranexamic acid injection|The tranexamic acid injection was given intradermally to the facial skin
223727571|NCT05236569|DRUG|Injection Water|The 0.9% normal saline injection was given intradermally to the facial skin
223727572|NCT01252108|DRUG|SQ109|300 mg SQ109 daily for 14 days
224119439|NCT05185752|PROCEDURE|PECS II block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
224119440|NCT05185752|PROCEDURE|ESP block: Locoregional Interfascial Anesthesic Technique|"Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles."
224119441|NCT03026543|PROCEDURE|Pulmonary Recruitment Maneuver|
224119442|NCT03026543|PROCEDURE|Laparoscopic cholecystectomy|
224119443|NCT03026543|DEVICE|Ventilator|
224119444|NCT06011005|OTHER|Ethyl Chloride spray (group A)|Cold test spray
224119445|NCT06011005|OTHER|Benzocaine gel 20% (group B)|Topical analgesia
224119446|NCT02566525|DEVICE|CytoSorb|Cytosorb device use during cardiopulmonary bypass
223983050|NCT01938313|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~7. Epidural patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~10. Perioperative High content Oxygen therapy~11. No drain insertion~12. No Levin tube~13. Patients will be discharged at POD#4 if there's no problem."
223983051|NCT01938313|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Routine drain insertion~12. Levin tube insertion if needed"
223983052|NCT03225976|DEVICE|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
224119447|NCT00337467|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
224119448|NCT04035135|DRUG|ANX005|investigational drug
223727573|NCT02422511|GENETIC|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
223727574|NCT02422511|OTHER|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
223727575|NCT05160220|DRUG|Psilocybin|0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
223727576|NCT05160220|DRUG|Placebo|0.5 g dried edible non-psychoactive mushroom material.
224119449|NCT04035135|DRUG|Intravenous immunoglobulin|investigational drug
224119450|NCT01881035|PROCEDURE|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
224119451|NCT04341844|DRUG|Methylene Blue|2mg/kg MB diluted with normal saline into total 50 ml volume intravenous administration after induction of anesthesia within one hour.
224119452|NCT04341844|DRUG|Placebo|normal saline in total 50 ml volume intravenous administration after induction of anesthesia within one hour.
223727577|NCT03770442|DEVICE|Cycling with FES|As described already
223727578|NCT03770442|OTHER|Routine physiotherapy|As described already
223727579|NCT03281681|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
223983053|NCT03225976|DEVICE|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
223727580|NCT06087666|PROCEDURE|FICare|The Family Integrated Care (FICare) programme has been developed in a multicenter cluster randomised controlled trial, with 26 tertiary NICUs from Canada, Australia and New Zealand, comparing standard NICU care (which was mainly care by nurses) (891 infants) to FICare programme (895 infants). FICare model and showed that the involvement of parents in the direct care improved weight gain and increased breastfeeding rates in the preterm infants. In addition, their parents had lower rates of stress and anxiety. These results were confirmed in a cluster-randomised controlled trial. Subsequent studies carried out so far have shown promising positive effects on a variety of domains. Maturation profiles have been shown to accelerate with the FICare intervention as a shorter time to achieve exclusive enteral nutrition as well as oral nutrition has been shown in the preterm infants included in FICARE programmes compared to control babies
223727581|NCT00822250|OTHER|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
223983054|NCT06019065|DRUG|AJA001|AJA001
223983055|NCT06019065|OTHER|Placebo|Placebo
223983056|NCT06356623|OTHER|1|this is not an intervention study
223983057|NCT00380965|DRUG|Cesamet™ (nabilone)|
223983058|NCT02077725|OTHER|interdisciplinary polypharmacy clinic visit|
223983059|NCT01196819|DEVICE|Firehawk|Implantation of Firehawk drug eluting stent
223983060|NCT01196819|DEVICE|Xience V|Implantation of Xience V drug eluting stent
223983061|NCT06062615|PROCEDURE|Total knee replacement using Omnibot Knee System|total knee replacement with robotic assistance
223983062|NCT06062615|PROCEDURE|Conventional Total knee replacement|Conventional total knee replacement without robotic assistance
223983063|NCT06062615|DEVICE|Omnibot Robotic Knee System|utilizes an active motorized knee spacer to measure ligament tension and gap balance after the tibia has been cut during surgery
223983064|NCT02632812|DRUG|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
223983065|NCT02632812|DRUG|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
223983066|NCT02632812|DRUG|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
223983067|NCT01998971|DRUG|Daratumumab|Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
223983068|NCT01998971|DRUG|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
223983069|NCT01998971|DRUG|Pomalidomide|Administered orally in accordance with product labeling and local standards.
223727582|NCT06037291|DIETARY_SUPPLEMENT|Coriander Seed Oil|The study foresees the intake of 1 capsule per day during 56 days
223727583|NCT06037291|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 1 capsule per day during 56 days
223727584|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
223983070|NCT01998971|DRUG|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
223983071|NCT01998971|DRUG|Melphalan|Administered orally in accordance with product labeling and local standards.
223727585|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
223727586|NCT02526745|BIOLOGICAL|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
223727587|NCT02526745|BIOLOGICAL|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
223983072|NCT01998971|DRUG|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
223983073|NCT01998971|DRUG|Thalidomide|Administered orally in accordance with product labeling and local standards.
223983074|NCT01998971|DRUG|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
223983075|NCT01998971|DRUG|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
223983076|NCT01998971|DRUG|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
223983077|NCT01998971|DRUG|Lenalidomide|Administered orally in accordance with product labeling and local standards.
223983078|NCT01998971|DRUG|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
223983079|NCT04988776|OTHER|ultrasUltrasound-guided Intercostobrachial nerve block supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 m|patients recieved ultrasound-guided Intercostobrachial nerve block with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl ) .
223983080|NCT04988776|OTHER|ultrasound-guided pectoral nerves block type II supplemental to supraclavicular block|Patients received ultrasound-guided pectoral nerves block type II with 10 ml 0.25% bupivacaine (5 ml 0.5% bupivacaine will be added to 5ml 0.9% normal saline ) supplemental to supraclavicular block with 30 ml 0.25% bupivacaine (15 ml 0.5% bupivacaine will be added to 15 ml of 0.9 %Nacl )
223983081|NCT03416413|PROCEDURE|Ambulatory phlebectomy|Minor surgery to remove varicose vein tributaries
223983082|NCT03416413|DRUG|Foam sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
223983083|NCT03732820|DRUG|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
223983084|NCT03732820|DRUG|abiraterone acetate|1000 milligrams (mg) once daily
223983085|NCT01776359|DIETARY_SUPPLEMENT|High Protein|2.4g/kg of protein
223983086|NCT01776359|DIETARY_SUPPLEMENT|Low Protein|1.2g/kg of protein
223727588|NCT02526745|BIOLOGICAL|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
223727589|NCT02526745|BIOLOGICAL|placebo|
223727590|NCT01069107|OTHER|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
223727591|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
223983087|NCT00590525|PROCEDURE|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
223727592|NCT00694213|BIOLOGICAL|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
223727593|NCT00694213|BIOLOGICAL|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
223727594|NCT00694213|BIOLOGICAL|PBS|IM, 1 mL, 2 injections, 0 and 21 days
223983088|NCT06254755|DEVICE|mechanical thrombectomy|mechanical thrombectomy of acute ischemic stroke caused by major vessel occlusion of the anterior circulation has become an accepted procedure in the last decade.
223983089|NCT00451828|DRUG|Simvastatin|40mg/day
223983090|NCT03683550|PROCEDURE|SLNE with preoperative hybrid SPECT/CT|Single-photon emission computed tomography/computed tomography (SPECT/CT) provides complementary functional and anatomical information and has been shown to be superior to planar imaging in a number of indications. It can provide valuable information before sentinel lymph node biopsy and advocate its use in a range of tumors such as truncal and head and neck melanomas.
223983091|NCT03683550|PROCEDURE|Standard SLNE|"The current gold standard for detection and targeted extirpation of the sentinel lymph node (SLN) is preoperative lymphoscintigraphy.~Lymphoscintigraphy (sentinel lymph node mapping) is an imaging technique used to identify the lymph drainage basin, determine the number of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel node in an unexpected location, and mark the sentinel node over the skin for biopsy."
223983092|NCT00992992|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
223983093|NCT01804010|DRUG|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
223983094|NCT05399368|DRUG|RPT193|RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
223983095|NCT05399368|OTHER|Placebo|Nonactive placebo tablet
223983096|NCT02398045|OTHER|Computerised CBT for OCD|Computerised CBT for OCD
223983097|NCT01130649|DEVICE|HealthBuddy|Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
223983098|NCT04236232|DIAGNOSTIC_TEST|Thyroid function|Thyroid function,Lipid Profile, systolic Blood pressure ,diastolic blood pressure .Body Mass Index ,CRP,Echocardiography،ECG, Ultrasonography of Carotid artery
223983099|NCT03716388|BIOLOGICAL|Fecal Microbiota Transplantation|Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
223983100|NCT03716388|DRUG|Mesalamine Granules|Mesalamine granules 4 grams a day
223983101|NCT03716388|OTHER|Placebo infusion|Water with food grade colour to resemble fecal slurry
223983102|NCT03716388|OTHER|Placebo granules|Granules resembling mesalamine granules, 4 grams a day
224119453|NCT06671860|OTHER|Exercise|"Individuals were randomly assigned to the REP (Routine Exercise Program) group and the OHP group. The REP group received the traditional exercise protocol and the OHP group received oculomotor exercises and myofascial release techniques in addition to the traditional exercise. The groups were evaluated before the treatment and at the end of the 6-week treatment sessions. Patient education was given to the patients before both programs. Patient education included information about nonspecific chronic neck pain, symptoms, and complications, as well as assessment methods, parameters, tests, and exercises.~The first group, the REP group (n=19), received routine exercises, and the second group, the OHP group (n=19), received oculomotor exercises and myofascial relaxation techniques in addition to the routine exercise program. The treatments were applied for six weeks, three sessions per week, under the supervision and guidance of a physiotherapist in the clinic."
223983103|NCT04576845|OTHER|Survey|The children's eating behavior will be evaluated with Turkish validated Children's Eating Behavior Questionnaire - (CEBQ) by interviewing mothers face to face. The CEBQ is a Likert type, parent-report rating scale measuring the variation in eating behavior in children. The CEBQ consists of 35 items comprising eight subscales, each containing 3 to 6 items. Parents will be asked to rate their child's eating behavior on a five-point scale (never, rarely, sometimes, often, always; 1-5, respectively).
223983104|NCT03197025|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
223727595|NCT02324374|DEVICE|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
223727596|NCT02324374|DEVICE|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
223727597|NCT02373202|DRUG|Sarilumab|Pharmaceutical form:solution
223727598|NCT02373202|DRUG|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
223727599|NCT02373202|DRUG|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
223983105|NCT03197025|BIOLOGICAL|E6 T Cell Receptor (TCR)|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
223983106|NCT04044703|DRUG|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
223983107|NCT03527498|DEVICE|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
223727600|NCT02373202|DRUG|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
223983108|NCT03527498|BEHAVIORAL|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
223983109|NCT01854307|PROCEDURE|Pneumoperitoneum and SVV/PPV|
223983110|NCT02804451|DEVICE|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
223983111|NCT02804451|DEVICE|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
223727601|NCT02373202|DRUG|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
223727602|NCT02373202|DRUG|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
223727603|NCT00147888|PROCEDURE|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
224119454|NCT04581681|BEHAVIORAL|Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA)|"The 6-session group CBT intervention for perinatal anxiety has been formalized with session guides for the facilitators and a workbook, Overcoming Anxiety in Pregnancy and Postpartum (Furer \& Reynolds, 2015), developed by members of our Anxiety Disorders Clinic. There are 6 core modules covered over the 6 treatment sessions, including: (1) Understanding anxiety during pregnancy and postpartum, (2) self-care, (3) setting goals and facing fears, (4) nurturing the developing relationship with baby, (5) coping with negative thoughts and worries, and (6) relapse prevention. Content is based on general principles of CBT for anxiety but specific themes and examples are geared towards the pregnancy and postpartum periods. Distorted cognitions are also explored, with an additional focus on beliefs about motherhood and perfectionism. Due to the COVID-19 pandemic, the intervention will be conducted via a hospital-approved video-conferencing platform."
223983112|NCT02804451|DEVICE|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
223983113|NCT02804451|DEVICE|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
223983114|NCT01806935|DEVICE|DC086|
223983115|NCT01806935|DEVICE|Placebo|
223983116|NCT02305745|OTHER|Observational|
223983117|NCT00832000|DRUG|Mexiletine|200 mg three times a day; in pill form
223983118|NCT00832000|DRUG|Placebo|Placebo three times a day; in pill form
223983119|NCT05730998|DIETARY_SUPPLEMENT|ANTHOCRAN FITOSOMA|The product (Anthocran phytosome or placebo) will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
223983120|NCT05730998|DIETARY_SUPPLEMENT|PLACEBO|Placebo will be taken in the quantity of 1 capsule of 120 mg, 1 times a day, for 6 months
223983121|NCT03045809|DIAGNOSTIC_TEST|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
223983122|NCT02505893|BIOLOGICAL|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
224119455|NCT04581681|OTHER|No treatment (waitlist control)|Patients in this condition are randomly assigned to a waitlist control condition before receiving treatment.
223727604|NCT02884674|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
223983123|NCT02505893|DRUG|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
223983124|NCT02505893|DRUG|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
223983125|NCT02505893|DRUG|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
224119456|NCT01418222|DRUG|5-FU|Intravenous repeating dose
224119457|NCT01418222|DRUG|FOLFOX regimen|Intravenous repeating dose
224119458|NCT01418222|DRUG|Placebo|Intravenous repeating dose
224119459|NCT01418222|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
223727605|NCT02884674|DEVICE|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
223727606|NCT03936543|OTHER|Position change|Different position during central line catheterization
223983126|NCT02725567|DRUG|IVA|Granules in sachet for oral administration.
223983127|NCT05780905|DRUG|Semaglutide Auto-Injector|"Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration."
223983128|NCT05780905|OTHER|Placebo|Placebo
223983129|NCT02198261|DRUG|5% minoxidil topical foam|5% minoxidil topical foam
223983130|NCT03974789|DIAGNOSTIC_TEST|Blood test|Plasma cortisol level test
223983131|NCT03974789|DIAGNOSTIC_TEST|24-hour Urine test|Urinary free cortisol test
223983132|NCT03974789|DIAGNOSTIC_TEST|Saliva swab|salivette® for salivary cortisol quantification
223983133|NCT03974789|DIAGNOSTIC_TEST|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
223983134|NCT02929719|DRUG|Test.|gel
223983135|NCT02929719|DRUG|Aczone Gel 5%|gel
223983136|NCT02929719|DRUG|Placebo|gel
223983137|NCT00255944|BEHAVIORAL|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
223983138|NCT00255944|BEHAVIORAL|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
223983139|NCT01129115|BEHAVIORAL|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
224119460|NCT01418222|DRUG|leucovorin|Intravenous repeating dose
224119461|NCT01418222|DRUG|onartuzumab [MetMAb]|Intravenous repeating dose
224119462|NCT04083222|DRUG|Placebo|ISIS 757456-matching placebo solution administered as SC injection.
223983140|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
223983141|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
223983142|NCT01129115|BEHAVIORAL|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
223983143|NCT04626271|DEVICE|"ACR | U.S. Urine Analysis Test System"|"Each study participant will test their urine sample using the ACR \| U.S. test device - a home-use device intended for the semi-quantitative measurement of ACR in the urine (albumin and creatinine ratio) and used to aid in the management of kidney health."
223983144|NCT04626271|DEVICE|URiSCAN Optima Urine Analyzer|"Upon completion of the test using the ACR \| U.S. device, each urine sample will be provided to a professional user for further urine analysis test using the comparator device, the URiSCAN Optima Urine Analyzer."
223983145|NCT04597099|DRUG|Micronized progesterone|oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
223983146|NCT04597099|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
223983147|NCT04597099|DRUG|Flutamide|Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
223983148|NCT04597099|DRUG|Estradiol patch|Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
223983149|NCT06240546|DRUG|LPM6690176|Administered orally
223983150|NCT03877952|DRUG|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
224119463|NCT04083222|DRUG|ISIS 757456|ISIS 757456 administered as SC injection.
224119464|NCT06673251|OTHER|motor and sensory assessments, surveys|It does not include any intervention. Only evaluation will be made.
224119465|NCT06809361|BEHAVIORAL|Obesity prevention program|The Obesity Prevention Program was developed based on a literature review. Expert opinions (Public Health Nursing, Pediatric Nursing, Physical Therapy and Rehabilitation, Nutrition and Dietetics) were obtained for the educational content, and the final version was formulated. The training program is planned in eight sessions. The program will be scheduled at times convenient for students after prior discussion with the school administration. Two sessions per week will be conducted, with each session expected to last approximately 30-40 minutes. Students will utilize school computers and projectors during the training. The program will include verbal presentations, PowerPoint slides, brainstorming, exercises, games, written and visual materials, video screenings, and Q\&A sessions. Adolescents will try on weighted T-shirts of different weights, fruit plates will be distributed during sessions, and bookmarks, magnets, and brochures will be provided at the end of the sessions.
224119466|NCT06809361|BEHAVIORAL|Social media messages|In addition to the program, a total of 36 short messages will be sent three times a week to the Education + Social Media Supported group.
224119467|NCT05710874|OTHER|CPP-ACP paste|Daily application of CPP-ACP (Casein phosphopeptide amorphous calcium phosphate) paste (Tooth Mousse®) in addition to twice daily use of conventional toothpaste.
223727607|NCT03936543|OTHER|Conventional position|Conventional position during central line catheterization
223727608|NCT04992455|OTHER|Older Patients Receiving Chemotherapy|No Intervention
223727609|NCT00055263|DRUG|DN-101|
223983151|NCT01747837|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
223983152|NCT01728207|DRUG|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
223727610|NCT06024057|DRUG|LX101|LX101 (Containing recombinant human adeno-associated virus serotype 2, AAV2-RPE65 encoding human RPE65 gene).Specification: 0.2mL/bottle.Route of administration: subretinal injection, injection volume 0.3 mL/ eye
223983153|NCT00751634|DEVICE|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
223983154|NCT04730076|PROCEDURE|Standard Balloon Dilation|The standard approach involves a gradual balloon dilation where the balloon is inflated then held at each balloon size for 30-60 seconds then inflated to the next largest balloon diameter size and repeated to the maximum diameter size of that catheter. The dilation session will be repeated as frequently and as many times as needed to achieve the balloon diameter size of 18mm at the discretion of the endoscopist.
223983155|NCT04730076|PROCEDURE|Progressive Balloon Dilation|In the progressive approach, the balloon is continuously inflated over the course of 3-5 minutes starting at the smallest to the largest balloon diameter depending of the balloon catheter used. The dilation will be repeated every 2-3 weeks (total of 2-3 sessions). At the next endoscopic procedure, the balloon diameter used will be the next size up based on previous session.
223983156|NCT00001083|DRUG|Indinavir sulfate|
223983157|NCT00001083|DRUG|Ritonavir|
223983158|NCT00001083|DRUG|Nevirapine|
223983159|NCT00001083|DRUG|Lamivudine|
223983160|NCT00001083|DRUG|Stavudine|
223983161|NCT00001083|DRUG|Zidovudine|
223983162|NCT03184818|OTHER|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
223727611|NCT05611879|DRUG|Tislelizumab|Tislelizumab: 200mg, IV, day 1 of each 21-day cycle, Neoadjuvant therapy : 3 cycles
223983163|NCT01171300|OTHER|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
223983164|NCT01171300|OTHER|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
223983165|NCT02338427|OTHER|Immunohistochemistry|
223983166|NCT02338427|OTHER|Proteomic analysis|
223983167|NCT00155883|DRUG|Taxteral|
223727612|NCT05611879|DRUG|Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Paclitaxel: 60-75mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles. Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
223727613|NCT05611879|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion Q3W, given on cycle day 2.
223983168|NCT00155883|DRUG|5-Fluorouracil|
223983169|NCT00155883|DRUG|Leucovorin|
223983170|NCT05674383|PROCEDURE|Axillary plexus nerve block|Axillary plexus nerve block: an ultrasound-guided axillary plexus nerve block with a single injection of lidocaine 1%.
223983171|NCT05674383|PROCEDURE|Fracture hematoma block|Fracture hematoma block: a blinded single injection into the fracture with lidocaine 1%.
223983172|NCT02162914|DRUG|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
223983173|NCT02162914|DRUG|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
223983174|NCT03450148|OTHER|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
223727614|NCT04055142|PROCEDURE|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
223727615|NCT04055142|DRUG|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
223727616|NCT04055142|DRUG|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
223727617|NCT00042770|OTHER|talc|Given intrapleurally
223727618|NCT00042770|PROCEDURE|dyspnea management|No talc
223727619|NCT03316664|BEHAVIORAL|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
223727620|NCT03316664|BEHAVIORAL|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
223727621|NCT03316664|OTHER|COGPACK|Information already included in arm/group description.
223727622|NCT03019302|DEVICE|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
223727623|NCT06479798|DIAGNOSTIC_TEST|Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)|Endo bronchial ultrasound enables visualization of parabronchial structures throughout a bronchoscopic procedure. EBUS-TBNA, which is considered a less invasive diagnostic tool for nodal staging compared to mediastinoscopy, allows real-time, direct sampling of hilar \& MLNs under sonograghic guidance with concurrent cytological and histopathological examination
223727624|NCT00829946|BEHAVIORAL|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of \~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
223983175|NCT03450148|OTHER|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
223983176|NCT01435798|DRUG|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
223727625|NCT02036463|DRUG|Prednisone|
223983177|NCT04048798|OTHER|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
223983178|NCT04048798|OTHER|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
223983179|NCT01253447|DRUG|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
224119468|NCT05710874|OTHER|CPP-ACPF paste|Daily application of CPP-ACPF (Casein phosphopeptide amorphous calcium phosphate in combination with fluoridepaste) (MI Paste Plus®) in addition to twice daily use of conventional toothpaste.
224119469|NCT05710874|OTHER|1.25% fluoride gel|Weekly application of 1.25% fluoride gel (Elmex Medical Gel®) in addition to twice daily use of conventional toothpaste.
224119470|NCT05710874|OTHER|Conventional|Twice daily use of conventional toothpaste.
223727626|NCT02036463|DRUG|Placebo|
223727627|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
223727628|NCT02020395|DIETARY_SUPPLEMENT|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
223727629|NCT03566927|COMBINATION_PRODUCT|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
223727630|NCT02406976|OTHER|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
223727631|NCT02406976|BEHAVIORAL|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
223983180|NCT01253447|OTHER|laboratory biomarker analysis|Correlative studies
223983181|NCT00817336|DRUG|D Serine|60 mg/kg/day
223983182|NCT00817336|DRUG|Placebo|oral
223983183|NCT02299427|BEHAVIORAL|dog safety|use of dog safety website at home for about 2 weeks
223983184|NCT02299427|BEHAVIORAL|transportation safety|use of transportation safety website at home for about 2 weeks
223983185|NCT02449083|PROCEDURE|MRI|MRI
224119471|NCT02832440|OTHER|Exercise programmes|
224119472|NCT03580577|DEVICE|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
224119473|NCT02816762|DEVICE|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
223983186|NCT02449083|PROCEDURE|coronary angiography|coronary angiography
223983187|NCT04187430|BEHAVIORAL|Retrospective|Those patients with a positive sample for ICD will be randomly selected from the microbiology database.
223983188|NCT04187430|BEHAVIORAL|Prospective|After the routine identification of a case of DCI by the microbiology laboratory, those new cases will be included in the study.
223983189|NCT03123419|BEHAVIORAL|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
223983190|NCT01554293|DRUG|Matching placebo|Matching Placebo, single dose
223983191|NCT01554293|DRUG|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
223983192|NCT02108652|DRUG|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
223983193|NCT01095913|DRUG|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
223983194|NCT03311269|DEVICE|ClariVein RES|ClariVein system
223983195|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
223983196|NCT03311269|DRUG|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
223727632|NCT02406976|OTHER|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
223983197|NCT05241054|DRUG|Bupivacaine|With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
223983198|NCT05241054|DRUG|Nitroglycerine|This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
223983199|NCT05241054|DRUG|Propofol|General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
223983200|NCT05241054|DRUG|Fentanyl|fentanyl 1 microgram.kg
223983201|NCT05241054|DRUG|Atracurium Besylate|Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
223983202|NCT05241054|PROCEDURE|Mechanical ventilation|Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
223983203|NCT05241054|DRUG|Sevoflurane|Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
223983204|NCT05241054|DRUG|Lactated Ringers|Intravenous infusion of Lactated Ringers will be given per body weight and according to intraoperative loss
223983205|NCT05241054|OTHER|Head-up tilt|The patient is placed on the operating table with a head-up tilt to reduce venous congestion at the operative site
223983206|NCT05241054|DRUG|Paracetamol|paracetamol infusion (15 mg/kg) will be given by IV infusion in both groups
223983207|NCT04151823|DRUG|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
223983208|NCT04151823|DRUG|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
223983209|NCT04151823|OTHER|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
223983210|NCT04151823|OTHER|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
223727633|NCT01075204|DRUG|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
223727634|NCT02855216|OTHER|Manual technique of sub-occipital inhibition|
223727635|NCT02855216|OTHER|Self-treatment by way of Occipivot®|
223983211|NCT05756049|OTHER|compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.
223983212|NCT04760197|OTHER|no intervention|no intervention
223983213|NCT01940289|DEVICE|Algometric meter readings for perception of pain|
223983214|NCT03756064|DRUG|Pyrotinib|Pyrotinib: 400mg orally daily
223983215|NCT03756064|DRUG|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
223983216|NCT03756064|DRUG|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
223983217|NCT03756064|DRUG|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
223727636|NCT01411228|DRUG|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
223727637|NCT02177045|DRUG|Sonovue, Bracco|Intravenous injection
223727638|NCT00004984|DRUG|Parenteral Insulin|Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.
223727639|NCT00004984|OTHER|Close Observation|Study visits every 6 months including an oral glucose tolerance test
223983218|NCT03756064|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
223727640|NCT00004984|DRUG|Oral Insulin|Capsules oral insulin, 7.5 mg of recombinant human insulin crystals
223983219|NCT06128213|DRUG|NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))|oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days
223983220|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
223983221|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
223727641|NCT00004984|DRUG|Placebo|Placebo for oral insulin
223727642|NCT02569216|DEVICE|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
223983222|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
223983223|NCT01121913|DRUG|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
223983224|NCT01086618|DRUG|systemic chemotherapy|
223983225|NCT01086618|PROCEDURE|adjuvant therapy|
223983226|NCT01086618|PROCEDURE|quality-of-life assessment|
223983227|NCT01086618|PROCEDURE|therapeutic conventional surgery|
223983228|NCT00000232|DRUG|Buprenorphine|
224294033|NCT03648242|BEHAVIORAL|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~* One-click addition of elevated BMI to problem list~* Reminder to utilize Suggested PowerPlan~* One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~* Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~* Links to existing, evidence-based childhood obesity screening and management guidelines"
223983229|NCT03758456|BIOLOGICAL|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
223983230|NCT00143741|DRUG|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
223983231|NCT02610621|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
223983232|NCT04815473|PROCEDURE|Valvulotomy|Valvulotomy of the venous valves
224294034|NCT03056261|PROCEDURE|Combined general and epidural|Combined general and epidural anaesthesia
223983233|NCT04307641|BEHAVIORAL|2 Page Information Sheet|2 page information sheet about medication abortion
223983234|NCT05065697|OTHER|Brain MRI|Brain MRI will be scheduled within three days before the procedure and within seven days after the procedure, as well as at 1-year follow-up. MRI will be preferably performed using a 3.0-Tesla system unless patients are pacemaker-dependent after the procedure. In such case, a 1.5-Tesla system will be used. The MRI protocol consists of standardized conventional diffusion-weighted MRI (DW-MRI), T2-FLAIR (fluid-attenuated recovery inversion) and SWI (susceptibility-weighted imaging) parameters.
224294035|NCT03056261|PROCEDURE|General anaesthesia|General anaesthesia
224294036|NCT02276898|DRUG|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
224294037|NCT02276898|DRUG|Isotonic Saline 0.9% (Placebo)|
224294038|NCT03499418|OTHER|modified Silverman scale|Clinical assessment of severity of respiratory failure
223983235|NCT05940714|BEHAVIORAL|Video participants|Showing a video of oral hygiene intructions
223983236|NCT03028259|OTHER|lab results|Comparison of lab results
223983237|NCT04679740|DEVICE|Magmaris|MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.
224294039|NCT03499418|DIAGNOSTIC_TEST|echocardiography|echocardiographic evaluation of haemodynamic problems
224294040|NCT01956617|OTHER|lumbar plexus block|
224294041|NCT03735134|DRUG|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
223983238|NCT03101033|DEVICE|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
223983239|NCT03101033|DRUG|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
223983240|NCT03101033|DRUG|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
223983241|NCT03101033|DRUG|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
223983242|NCT02597036|DRUG|LY3127804|Administered IV
223983243|NCT02597036|DRUG|Ramucirumab|Administered IV
223727643|NCT01619345|DRUG|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
223983244|NCT02597036|DRUG|Paclitaxel|Administered IV
223983245|NCT00938990|DRUG|Etomidate|
223983246|NCT00938990|DRUG|Midazolam|
223983247|NCT04964778|DEVICE|SKED©|A SKED device is lightweight plastic stretcher used for moving patients through difficult terrain.
223983248|NCT02830256|OTHER|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
223727644|NCT01974375|DRUG|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing \<40 kg)
223727645|NCT01974375|DRUG|Fluconazole|Fluconazole 100\~200mg/day, IV care until oral medication becomes possible
223983249|NCT05458154|OTHER|questionnaires|Participants were recruited from the Baheya Centre for Early Detection and Treatment of Breast Cancer institution. Patients were eligible if they had a previously post-mastectomy pain syndrome (PMPS), and were presented with pain within the surgical area lasting more than 3 months. They were evaluated by questionnaires and methods of pain assessment then received their physiotherapy program specific for pain relief for six sessions, and so re-evaluation. All women gave informed written consent in Arabic and English forms.
223983250|NCT02767102|OTHER|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
223983251|NCT02767102|OTHER|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
224294042|NCT03735134|DRUG|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
224294043|NCT02262793|DRUG|telmisartan|
223727646|NCT02141282|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water within 30 minutes after the completion of breakfast or the participant's first meal of the day.
223727647|NCT02566083|DEVICE|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
223727648|NCT02566083|DEVICE|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
223983252|NCT02564718|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
223983253|NCT02283021|OTHER|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
223983254|NCT05393622|DEVICE|INTRACALVARIAL PREFRONTAL CORTICAL STIMULATION (IpCS) IN SEVERE TREATMENT-RESISTANT DEPRESSION|Subjects will have the neurostimulation device placed in the skull and continuous stimulation will be applied to relieve symptoms of depression.
223983255|NCT02654613|OTHER|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
223983256|NCT00935259|DRUG|Simvastatin|40 mg once daily for 2 weeks
224119474|NCT02816762|DRUG|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
224119475|NCT02816762|OTHER|Diet|Conventional anti-diabetic diet recommendations
224119476|NCT02411812|DEVICE|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
224119477|NCT02411812|DEVICE|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
224119478|NCT02411812|DEVICE|Twin-Block appliance|Group treated with Twin-Block appliance
224294044|NCT02262793|DRUG|ASA/ER-DP|
223727649|NCT05670392|DEVICE|laser and High intensity Tesla magnetic stimulation|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals followed by Eight (8) HITS therapies) Patients will receive two (2) HITS treatments per week for four (4) weeks(.
223727650|NCT05670392|DEVICE|laser (without HITS treatment)|Three (3) non-ablative Er:YAG laser treatments will be applied at monthly intervals as described above.
223727651|NCT02786147|OTHER|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
223727652|NCT02786147|OTHER|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
223727653|NCT02786147|OTHER|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
223983257|NCT00935259|DRUG|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
223983258|NCT02539238|OTHER|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
223983259|NCT04795583|DRUG|Prednisone|Prednisone 25 mg capsules
223983260|NCT04795583|DEVICE|Point of Care testing device for C-reactive protein|Determination of C-reactive protein blood levels by point of care testing device
223983261|NCT00904683|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
223983262|NCT00904683|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
223983263|NCT02757313|DRUG|Low dose THC marijuana|
223983264|NCT02757313|DRUG|High dose THC marijuana|
223983265|NCT02757313|DRUG|Placebo marijuana|
223983266|NCT00992121|DRUG|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
223983267|NCT00992121|DRUG|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
223983268|NCT00992121|DRUG|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
223983269|NCT05531890|DRUG|GTX-102 medium dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 fast
223983270|NCT05531890|DRUG|GTX-102 medium dose slow Period 1 and Period 2|GTX-102 Betamethasone oral spray medium dose (0.05 mg/kg) administered in Period 1 and Period 2 slow
223983271|NCT05531890|DRUG|GTX-102 high dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.1 mg/kg) administered in Period 1 and Period 2 fast
223983272|NCT05531890|DRUG|GTX-102 low dose fast Period 1 and Period 2|GTX-102 Betamethasone oral spray high dose (0.025 mg/kg) administered in Period 1 and Period 2 fast
223983273|NCT05531890|DRUG|Betamethasone solution as intramuscular injection Period 1 and Period 2|reference product 0.1 mg/kg betamethasone solution as an intramuscular injection
223983274|NCT05531890|DRUG|Betamethasone Oral Solution Period 1 and Period 2|Comparator product 0.1 mg/kg betamethasone oral drops solution
223983275|NCT02877264|DRUG|vapendavir 132 mg capsule|
223544116|NCT06094309|DRUG|Botulinum toxin type A injection|The BT injection will be performed by a doctor with experience in this therapy, with 100 Units (U) of type A BT, bilaterally, in the flexor muscle of the thigh, once, with replacement of the same ampoules with saline in controls. To the Patient assessments will take place over 4 months, weekly by telephone using a questionnaires on freezing and the notion of clinical improvement (FOGQ and SCGIC, respectively) and monthly in person with objective assessments using the MDS-UPDRS scales - part III motor assessment, Timed Up \& Go and Two Minute Walk.
223983276|NCT02877264|DRUG|vapendavir 264 mg tablet|
223983277|NCT02877264|DRUG|vapendavir 24 mg/mL oral suspension|
223544117|NCT02269696|DRUG|Metoprolol|Intraoperative metoprolol infusion.
223544118|NCT02269696|DRUG|Normal saline|Equal of volume compared to metoprolol.
223983278|NCT02951169|OTHER|No intervention|No intervention. Treatment are accordance with clinical practice.
223983279|NCT06801171|OTHER|cognitive stimulation|12 sessions (one per week for 12 weeks) in group of cognitive stimulation
223983280|NCT06801171|OTHER|mixed intervention|12 sessions (one per week for 12 weeks) in group of mixte stimulation (yoga, cognitive behavioral therapy, mindfullness meditation, positive psychology)
223983281|NCT05354310|COMBINATION_PRODUCT|VOILA|Participants will be given dietary supplement powder containing protein, galactooligosaccharide (GOS), vitamin D, and calcium throughout the twelve weeks of intervention. This will be accompanied with a resistance training regime whereby participants will train three times a week for the three months. A variety of measurements will be carried out at baseline and at endline.
223983282|NCT01860547|DIETARY_SUPPLEMENT|Bilberries|Frozen bilberries, 100 g/d
223983283|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
223983284|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
223983285|NCT01860547|DIETARY_SUPPLEMENT|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
223983286|NCT00000370|BEHAVIORAL|Cognitive behavior therapy|
224119479|NCT01168804|DRUG|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
223544119|NCT02832102|PROCEDURE|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
223544120|NCT05231876|OTHER|Recording of pathology-related information on the Wilson Register|Age, gender, date of diagnosis, clinical symptoms, ethnic charateristics and family tree will be collected and recorded on the Wilson Register during routine clinical care
223544121|NCT05160701|OTHER|Medherent|Medherent is a telehealth adherence intervention platform designed for individuals with Serious Mental Illness living in the community. It is currently being used to dispense medication and monitor consumer adherence. It is a fully supported digital hub that is always on network connection and provides a cost- effective mechanism for increased care coordination through the Electronic Medication Record (EMR). The enhanced intervention will add collection of health data though Bluetooth connected devices, Telehealth medical visits and integrated algorithms that provide feed back to providers and consumers about health status.
223983287|NCT00000370|BEHAVIORAL|Performance-based exposure therapy|
224119480|NCT01782599|OTHER|Dual nicotine patch and electronic cigarette|
223727654|NCT02786147|OTHER|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
223983288|NCT00000370|BEHAVIORAL|Psychosocial intervention|
223983289|NCT00673556|DRUG|alefacept|Intramuscular (IM)
223983290|NCT00673556|DRUG|placebo|Intramuscular (IM)
223983291|NCT03599336|PROCEDURE|Reverse Total Shoulder Arthroplasty (rTSA)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components as per standard surgical care and routine postoperative rehabilitation.
223983292|NCT03599336|OTHER|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
223983293|NCT02089438|DRUG|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
223983294|NCT02089438|DRUG|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
223983295|NCT02089438|DRUG|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
223983296|NCT02734186|DRUG|Praziquantel|Anthelminthic
223983297|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation I
223983298|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation II
223983299|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation III
223983300|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation IV
223983301|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation V
223983302|NCT00937521|BIOLOGICAL|Meningococcal B vaccine|Vaccine candidate formulation VI
223983303|NCT00937521|BIOLOGICAL|Control|Control
223983304|NCT00937521|BIOLOGICAL|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
223983305|NCT02713737|DEVICE|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.
223983306|NCT02713737|DEVICE|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.
223983307|NCT02205099|DRUG|SKL15508|
223983308|NCT02205099|DRUG|Placebo|
223983309|NCT00171795|DRUG|Rivastigmine|
223983310|NCT03322241|OTHER|overall wellness|Wellness lab testing
223983311|NCT02419963|PROCEDURE|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
223983312|NCT02419963|OTHER|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
223983313|NCT02419963|OTHER|Stool Sample|Stool sample to evaluate microbiome fingerprint.
223983314|NCT02609802|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
223983315|NCT02609802|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
223983316|NCT03494855|DEVICE|SyMRI Software|The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
223983317|NCT02023905|DRUG|Everolimus|everolimus at 10 mg daily continuously
223983318|NCT02023905|DRUG|Temozolomide|Temozolomide will be dosed initially at 150 mg/m2/day for 5 days out of a 28-day cycle. TMZ will be stopped after 12 cycles
223983319|NCT01135030|PROCEDURE|Total knee|Primary Total knee
223983320|NCT00487526|PROCEDURE|duodenal jejunal bypass|
223983321|NCT02878759|DEVICE|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
223983322|NCT00198302|DRUG|Aurexis®|
223983323|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
223983324|NCT02144168|DIETARY_SUPPLEMENT|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
223983325|NCT05234775|DRUG|lerodalcibep|300 mg of each drug given SC as single dose
223983326|NCT01732341|DEVICE|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
223983327|NCT01732341|DEVICE|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~\--------------------------------------------------------------------------------"
223983328|NCT04346485|PROCEDURE|SP TFL RIRS with 145 mcm fiber|retrograde intrarenal surgery
223983329|NCT04346485|PROCEDURE|SP TFL RIRS with 200 mcm fiber|retrograde intrarenal surgery
223983330|NCT04346485|PROCEDURE|Ho:YAG RIRS with 200 mcm fiber|retrograde intrarenal surgery
223983331|NCT00874497|DRUG|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
223983332|NCT00874497|DRUG|placebo|Placebo for 104 weeks (2 years)
223983333|NCT04842409|RADIATION|Whole breast irradiation|Whole breast irradiation using an ultra-hypofractionated schedule (26 Gy in 5 fractions)
223983334|NCT05181397|DRUG|Tocilizumab|Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
223983335|NCT02792647|DRUG|Placebo|Administered orally
223983336|NCT02792647|DRUG|IX-01|Administered orally
223983337|NCT01017263|DRUG|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
223983338|NCT05918393|BEHAVIORAL|functional communication training|During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
223983339|NCT03235362|DRUG|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
223983340|NCT03235362|DRUG|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
223983341|NCT03235362|DRUG|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
223983342|NCT05736731|BIOLOGICAL|A2B530|Autologous logic-gated Tmod CAR T-cells
223983343|NCT05736731|DIAGNOSTIC_TEST|xT-Onco with HLA-LOH Assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
223983344|NCT05177783|BEHAVIORAL|Tuune health questionnaire|Participants complete the Tuune contraceptive decision aid health questionnaire.
223983345|NCT05177783|BEHAVIORAL|Control health questionnaire|Participants complete a standard physician intake health questionnaire.
223983346|NCT00455845|DEVICE|Levonorgestrel IUD|levonorgestrel IUD
223983347|NCT03949465|DEVICE|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
223983348|NCT02276209|DRUG|Dasotraline|Dasotraline 4 mg once daily
223983349|NCT02276209|DRUG|Dasotraline|Dasotraline 6 mg once daily
223983350|NCT02276209|OTHER|Placebo|Placebo once daily
223983351|NCT05997459|DRUG|Pemigatinib|Pemigatinib,13.5mg ,QD,po, 2 weeks / 1 week;Q 3W
223983352|NCT01675310|DRUG|medical nutrition therapy + metformin|
223983353|NCT01675310|BEHAVIORAL|Medical nutrition therapy|medical nutrition therapy
223983354|NCT00506272|PROCEDURE|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
223983355|NCT00506272|PROCEDURE|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
223983356|NCT03820869|OTHER|Family Training|Family Training
223983357|NCT03820869|OTHER|Occupational Therapy|Occupational Therapy
223983358|NCT02004106|DRUG|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
223983359|NCT02980705|DRUG|SUNPG1622 I dose|Injection
223983360|NCT02980705|DRUG|Placebo dose|Injection
223983361|NCT01659671|PROCEDURE|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
223983362|NCT05803642|DRUG|Olanzapine|intramuscular injection, 10 mg/dose, first dose and an optional second or third dose.
223983363|NCT05803642|DRUG|Haloperidol|intramuscular injection, 7.5 mg/dose, first dose and an optional second or third dose.
223983364|NCT04515628|DRUG|Rosuvastatin|Specified dose on specified days
223983365|NCT04515628|DRUG|Branebrutinib|Specified dose on specified days
223983366|NCT06301971|DRUG|Emraclidine|Oral solution/suspension
223983367|NCT00263575|DRUG|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
223983368|NCT04560062|OTHER|Spontaneous changes in diabetes-related health care|The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
223983369|NCT00224978|DRUG|Chloroquine|
223983370|NCT04353817|DRUG|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration qd in the morning.
223983371|NCT04353817|DRUG|IVA|Tablet for oral administration qd in the evening.
223983372|NCT04353817|OTHER|Placebo (matched to ELX/TEZ/IVA)|Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.
223983373|NCT04353817|OTHER|Placebo (matched to IVA)|Placebo matched to IVA for oral administration qd in the evening.
224119481|NCT04652492|DRUG|Tislelizumab in combination with cTACE|On-demanded cTACE in combined with tislelizumab (200mg q3w ivgtt on day 4 of each 21-day cycle)
223983374|NCT01438762|BEHAVIORAL|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
223983375|NCT01438762|OTHER|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
223983376|NCT02411708|DRUG|SANGUINATE|Single two-hour infusion of SANGUINATE
223983377|NCT02411708|DRUG|Placebo|Single two-hour infusion of placebo
223983378|NCT05605288|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Coronary angiography +/- percutaneous coronary intervention
223983379|NCT05474898|OTHER|Magnesium Sulphate Iontophoresis +conventional therapy|will receive Mgso4 Iontophoresis in addition to conventional therapy twice a week/4 weeks
223983380|NCT05474898|OTHER|High- Power Pain Threshold Ultrasound +conventional therapy|will receive HPPT-US on the upper trapezius in addition to conventional therapy twice a week/4 weeks
223983381|NCT05474898|OTHER|conventional theapy|will receive postural correction exercise-stretching and strengthening twice a week/4weeks
223983382|NCT03887169|DRUG|Methionine|Administration of methionine from D1 to D60
223544122|NCT03870048|DEVICE|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
223544123|NCT05462899|OTHER|Purpose in life, goals, and expectations|There is no intervention. This is a cross-sectional study.
223544124|NCT05914194|DRUG|NLS-2|Participants will receive NLS-2 tablets orally.
223544125|NCT05914194|DRUG|Placebo|Participants will receive NLS-2 matching placebo tablets orally.
223544126|NCT03484429|DEVICE|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
223983383|NCT03887169|DRUG|Vitamin B12, B9, B6, C supplementation|In case of hyperhomocysteinemia
223983384|NCT03887169|DIAGNOSTIC_TEST|Methionine/homocysteine Dosage|Plasma concentration control of methionine and homocysteine from D0 to D75
223544127|NCT03484429|OTHER|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
223983385|NCT03887169|DIAGNOSTIC_TEST|Thoracic CT scan|At D60
223983386|NCT03887169|DIAGNOSTIC_TEST|Abdominal and liver ultrasound.|At D60
223983387|NCT03887169|DIAGNOSTIC_TEST|Brain MRI|In case of abnormal neurological examination
223983388|NCT03655665|DRUG|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
223983389|NCT02032264|OTHER|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
223983390|NCT02032264|OTHER|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
223983391|NCT02868372|DRUG|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
223983392|NCT02781298|DIETARY_SUPPLEMENT|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
223983393|NCT02781298|DIETARY_SUPPLEMENT|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
223983394|NCT04749498|OTHER|White Bread|Test breakfast with white bread was served after 12-hours of fasting and participants were asked to consume the meal in full, within 15 minutes.
223983395|NCT04749498|OTHER|Whole Wheat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
223983396|NCT04749498|OTHER|Barley Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
223983397|NCT04749498|OTHER|Oat Bread|In a crossover design, this bread was served with a standard breakfast to compare other breads.
223983398|NCT06382571|DRUG|Renin-Angiotensin System Inhibitor|
223983399|NCT00774423|DRUG|Riluzole|50 mg per day during 24 months
223983400|NCT00831012|BIOLOGICAL|rDEN3delta30/31-7164|A live attenuated, recombinant DEN3 candidate vaccine virus
223544128|NCT03447392|BEHAVIORAL|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
223544129|NCT03533010|DIETARY_SUPPLEMENT|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
223544130|NCT03533010|DIETARY_SUPPLEMENT|VitD800IU|subjects receive a daily dose of 800IU VitD3
223983401|NCT05005325|OTHER|Experimental group(Male)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
223983402|NCT05005325|OTHER|Experimental group(Female)|Hurdle steps Deep squats Inline lunges Shoulder Clearing Active straight leg raise Trunk stability pushup Rotary stability Spinal extension exam Spinal flexion exam
223983403|NCT02886598|DRUG|degarelix|
223983404|NCT04340856|PROCEDURE|colon surgery|There are no guidelines to direct surgical therapy in patients with chronic megacolon. Historically, it is the surgeons individual choice to use one of the above mentioned surgical treatments. Therefore, the aim of this study is to analyze the success and downsides of the different surgical approaches.
223983405|NCT04340856|DRUG|Laxatives|There are no guidelines to direct laxative measures in patients with chronic megacolon. Historically, it is the gastroenterologists individual choice to use one of the above mentioned laxative measures. Therefore, the aim of this study is to analyze the success and downsides of the different Laxative measures.
223983406|NCT04055610|DEVICE|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
223983407|NCT00239681|DRUG|Rosuvastatin|Oral
223983408|NCT00239681|OTHER|Placebo|Oral
223983409|NCT02447718|BIOLOGICAL|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
223983410|NCT02447718|BIOLOGICAL|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
223983411|NCT02447718|BIOLOGICAL|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
223983412|NCT00984438|DRUG|BCNU Wafer|Implantable during surgical resection into the tumor bed
223983413|NCT00984438|DRUG|Irinotecan|IV every 2 weeks for up to one year
223983414|NCT00984438|DRUG|Bevacizumab|IV every 2 weeks for up to one year
223983415|NCT06108453|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
223983416|NCT06108453|DRUG|Rifampicin|Co-administration of methotrexate and rifampicin
223544131|NCT03533010|OTHER|Placebo|subjects receive placebo tablet
223983417|NCT05192564|OTHER|Exercise for bilateral or unilateral vestibular hypofunction patients|Physical Activity intervention with balance exercises, multidirectional displacements, and strength with postural control, implementing 8-10 exercises integrating the main muscle groups and motor patterns, aerobic exercise on bicycle (15 min) developed progressively in intensity (R1-mild, R2-moderate, R3-vigorous) implementing an intervallic design in low volume.
223983418|NCT05192564|OTHER|Conventional rehabilitation treatment|Vestibular rehabilitation exercises counseling
223983419|NCT00716547|DRUG|ketoprofen in Diractin®|50 mg (b.i.d.)
223983420|NCT00716547|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
223983421|NCT00716547|DRUG|Placebo|b.i.d.
223983422|NCT00716547|DRUG|celecoxib|100 mg (b.i.d.)
223983423|NCT01818427|BIOLOGICAL|infusion of 2 units of plasma|infusion of 2 units of plasma
223983424|NCT02420041|PROCEDURE|Active comparator: Fluoroscopic Guided SIJ injection|"* Needle entry point is in the lower one-third of the SIJ~* Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~* Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~* 1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~* Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~* Patient observed in recovery bay for 20 minutes and then discharged home"
223983425|NCT02420041|PROCEDURE|Ultrasound Guided Sacroiliac Joint Injection|"* Sterile preparation (with chlorhexidine) and drape~* Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~* 3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~* Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~* After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~* Patient observed in recovery bay for 20 minutes and then discharged home"
223983426|NCT02420041|DEVICE|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
223983427|NCT02420041|DEVICE|SonoSite S-nerve|
223983428|NCT02420041|DEVICE|iohexol|
223983429|NCT02420041|DRUG|triamcinolone/lidocaine|
223983430|NCT03599622|DRUG|BMS-986165|Specified dose on specified days
223544132|NCT04276025|OTHER|Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome|Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
223544133|NCT05595928|OTHER|position|To compare whether there is a difference between maternal and fetal effects of Supine, 15-degree left tilt, and 30-degrees left tilt.
223544134|NCT04933500|DEVICE|Whitacre spinal needle|25G Whitacre spinal needle
223983431|NCT03599622|OTHER|Placebo|Specified dose on specified days
223983432|NCT01518088|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to study foods
223983433|NCT04011293|BIOLOGICAL|CNCT19|0.5 to 4 x 10\^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10\^8 autologous CNCT19 transduced cells via intravenous infusion.
223983434|NCT04226898|BIOLOGICAL|Synbiotic Supplement|Synbiotic supplement 1 powder stick by mouth daily
223983435|NCT04226898|BIOLOGICAL|Inert Compound|Synbiotic supplement identical placebo 1 powder stick by mouth daily
224119482|NCT04227977|DEVICE|JuxtaFlow System|The JuxtaFlow System consists of proprietary ureteral catheters deployed endoscopically over the wire to deliver mild controlled negative pressure into the renal pelvis.
224119483|NCT05106972|DRUG|UC-MSC infusion|UC-MSC infusion by introvenus
223983436|NCT00142688|BEHAVIORAL|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
223983437|NCT00142688|BEHAVIORAL|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
223983438|NCT03049345|PROCEDURE|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
223983439|NCT03049345|DRUG|Radioactive Tracers|see above
223983440|NCT03049345|DRUG|Methylene Blue 20 MG/ML|see above
223983441|NCT00770588|DRUG|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
223983442|NCT00770588|DRUG|Placebo|To match Gefitinib
223983443|NCT01114308|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
223983444|NCT01114308|DRUG|placebo implant|Implant contains ethylene vinyl acetate
223983445|NCT01114308|DRUG|Buprenorphine|sublingual buprenorphine/naloxone tablets
223983446|NCT02622711|BEHAVIORAL|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
223983447|NCT02622711|BEHAVIORAL|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
223983448|NCT02622711|BEHAVIORAL|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
223983449|NCT02622711|BEHAVIORAL|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
223983450|NCT06176898|DEVICE|Neurostimulating device|"A trained practitioner will apply the neurostimulator to the patient's ear. The patient will wear the neurostimulator for a period of three week with the position of the neurostimulator moving from one ear to the other on a weekly basis. After 3 weeks the neurostimulator will be removed and the patient will then undergo further clinical assessment at week 8.~At the 8 week clinical assessment, the patient will undergo the same assessments, namely:~* Six minute walking test (6MWT)~* Quality of life assessment using both generic (Short form 12) and disease specific (Vascuqol) questionnaires"
224119484|NCT03103750|PROCEDURE|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
224119485|NCT03103750|DRUG|PHNO|Used as a tracer for in vivo imaging.
223544135|NCT05910047|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
223544136|NCT05910047|DIETARY_SUPPLEMENT|Placebo|Inert substance
223983451|NCT04620369|DRUG|Placebo Administration|Instill isotonic nasal saline intranasally
223983452|NCT04620369|OTHER|Questionnaire Administration|Ancillary studies
223983453|NCT04620369|DRUG|Rose Geranium in Sesame Oil Nasal Spray|Instill intranasally
224119486|NCT03103750|DIETARY_SUPPLEMENT|calcitriol|three 0.5 mcg capsules
224119487|NCT03103750|DRUG|Placebo oral capsule|three 0.5 mcg capsules
224119488|NCT03103750|PROCEDURE|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
224119489|NCT03103750|DRUG|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
224119490|NCT05657977|OTHER|nonpharmacologic intervention (swaddling)|Swaddling method;The newborn will be placed on a square fabric blanket in the flexion and abduction position and will be loosely swaddled with a blanket.
223727655|NCT04329169|OTHER|Virtual Implant Planning|According to the virtual implant plan, a CAD/CAM tooth supported surgical guide will be fabricated to place the dental implant with a fully guided surgical protocol.The surgical guide will be manufactured from a photopolymer resin using a 3D printing machine. A hex- shaped metal sleeve will be inserted in the surgical guide with the flat surface located buccally so that it will help in orientation of the implant hex during the implant placement.
223727656|NCT05605392|OTHER|Deinstitutionalization process|"Phase 1: Comprehensive geriatric assessment to evaluate who might be a candidate for deinstitutionalization.~Phase 2: Intervention:~1. Support plan: design a plan agreed upon with the participant to provide resources to the person's needs and which guarantees support during the transition and beyond.~2. Transition process: progressive withdrawal of support in the institution and implementation of support and adaptation in the community, with different types of accommodation depending on the needs and preferences of each participant. Coordination with primary care teams, social services, and other community resources.~3. Case follow-up and gradual withdrawal of the project team. If the process does not go as the person expects, or difficulties are encountered that cannot be resolved, the participant will have the option and choice, if desired, to return to the residence at any time during the process."
223983454|NCT05294406|DRUG|Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine|Pregnant women attending routine antenatal care visits in their second and third trimester are given monthly IPTp consisting of a treatment dose of dihydroartemisinin-piperaquine (3 tablets per day for 3 days, 9 tablets total)
223983455|NCT01711346|BIOLOGICAL|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
223983456|NCT01711346|BIOLOGICAL|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
223983457|NCT00665223|DRUG|ACR16|Capsules will be swallowed whole with water.
223727657|NCT06392503|DIAGNOSTIC_TEST|different diagnostic models|the patients were screened by different diagnostic models
223544137|NCT06138171|OTHER|Psychological self-reported measures assesment (questionnaire)|The study involves the administration of a protocol of self-report questionnaires consisting of two parts: the main (about 25 minutes for the administration) and the optional one (additional 20 minutes). This decision stems from the realization of the length of the protocol, to increase the collection of data in pursuit of the main objective of the study (cluster analysis).
223544138|NCT05508126|DIAGNOSTIC_TEST|DECT examination|DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).
223544139|NCT05508126|DIAGNOSTIC_TEST|mpMRI examination|The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).
223727658|NCT01752907|OTHER|General Education DVD|A general chemotherapy side effects education DVD
223727659|NCT01752907|OTHER|Bone Pain Education DVD|
223983458|NCT00665223|DRUG|Placebo|Capsules will be swallowed whole with water.
223983459|NCT01657643|DIETARY_SUPPLEMENT|Probiotics|
223983460|NCT01657643|DIETARY_SUPPLEMENT|placebo|
223983461|NCT04195932|OTHER|Exercise training|
224119491|NCT03331172|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
224119492|NCT03158545|DIETARY_SUPPLEMENT|Olive oil Placebo|olive oil
224119493|NCT03158545|DIETARY_SUPPLEMENT|EPA-rich|EPA-rich omega-3 oil
224119494|NCT03158545|DIETARY_SUPPLEMENT|DHA-rich|DHA-rich omega-3 oil
224119495|NCT00807547|BIOLOGICAL|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
223983462|NCT06545578|OTHER|low-level laser therapy|The Low-level laser (LLL) pain-relief instrument RG-300IB (code E22), manufactured in China, was utilized for low-level laser therapy (LLLT) in Group A . The therapy employed a wavelength of 830 nm (near infrared) and involved careful skin contact hygiene at specified positions, 2.5 and 3.5 cm laterally from the spinous process (L4, L5, or S1) and one distal level segment. The laser operated at a repetition rate of 5,000, with a power density of 300 mW/cm2 and a power output of 10 mW. Each point received 3 J of energy, resulting in a density of 3 J/cm2, with four points. The spot size was 1 cm, and each point received a 30-second treatment. The energy was administered three times per week for four weeks
224119496|NCT00517686|OTHER|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
223727660|NCT06142045|DEVICE|RespirACT RA-MR System|RespirAct RA-MR™ is a computer-controlled gas blender to implement precise control of blood gases for a consistent and repeatable stimulus.
223727661|NCT02024633|DRUG|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
223727662|NCT02024633|DRUG|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
223727663|NCT01950650|BEHAVIORAL|No treatment given|Survey conducted through computer-assisted telephone interviewing.
223727664|NCT01950650|BEHAVIORAL|survey|Survey conducted via the Internet.
223727665|NCT04371991|DIAGNOSTIC_TEST|blood test|blood test (serum samples) for biochemical examination
223727666|NCT00113217|DRUG|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
223727667|NCT02165774|DEVICE|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
223727668|NCT02165774|DEVICE|Turning ON the neuromodulator|
224119497|NCT06693427|PROCEDURE|Peripheral Nerve Block|Femoral and Sciatic Nerve Blocks
224119498|NCT06692413|OTHER|Questionnaire|Users who consent to the study will receive a questionnaire every 3 months
224119499|NCT01128972|DRUG|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
223727669|NCT02696473|DIETARY_SUPPLEMENT|Carrot|
223727670|NCT00107445|DRUG|EF5|Given IV
223727671|NCT03912285|DRUG|Amlodipine10mg|Amlodipine 10mg will be administered orally twice a day for 9 days
223727672|NCT03912285|DRUG|Losartan potassium 100mg|Losartan 100mg will be administered orally once a day for 9 days
223727673|NCT03912285|DRUG|Amlodipine plus Losartan|"Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan"
223727674|NCT00187876|PROCEDURE|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
223727675|NCT00187876|PROCEDURE|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
223727676|NCT00333814|DRUG|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
223727677|NCT00333814|DRUG|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
223727678|NCT00333814|DRUG|Sham injection|Sham injection at Day 0
223727679|NCT02670083|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
223727680|NCT02670083|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
223727681|NCT03223597|DRUG|Radium-223 dichloride|Registry of patients who receive Radium-223.
224119500|NCT01128972|DRUG|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
224119501|NCT01128972|DRUG|Sterile water|Sterile water rinse
224119502|NCT01795040|DIETARY_SUPPLEMENT|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
224119503|NCT04624932|BEHAVIORAL|RR Digital Tool|This is the intervention condition. Participants in this condition will take the RR digital tool available at https://outsideplay.ca.
223727682|NCT00713050|BEHAVIORAL|Imitate Therapy|Imitation-based computer therapy
224119504|NCT04624932|BEHAVIORAL|Position Statement on Active Outdoor Play|This is the control condition. Participants in this condition will read the position statement that summarizes the issues and research regarding children's access to outdoor play.
223727683|NCT04982887|OTHER|Exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
223727684|NCT04687878|DRUG|Insulin|20 IU twice a day, intranasally, every day for 12 weeks
224119505|NCT01663740|DRUG|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
224119506|NCT01958034|DIETARY_SUPPLEMENT|Bilberry extract|
224119507|NCT04446585|DEVICE|Automated External Defibrillator (AED)|Deployment of AEDs
224119508|NCT04446585|OTHER|Training in cardiopulmonary resuscitation and AED use|Residents will undergo 30-minute courses at study start and if needed during the trial period. During the course they will also be recruited as citizen responders
223727685|NCT04687878|DRUG|Normal saline|twice a day, intranasally, every day for 12 weeks
223727686|NCT01279278|OTHER|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
223727687|NCT01279278|OTHER|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
224119509|NCT04446585|OTHER|Activation of citizen responders|Citizen responders will be activated in case of suspected cardiac arrest through the heart runner app.
224119510|NCT05254522|OTHER|not aplicable since it is a Registry|not aplicable since it is a registry
224119511|NCT06711835|OTHER|Whole-body vibration and Jumping|The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between.
224119512|NCT03397485|DIETARY_SUPPLEMENT|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
223727688|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
223983463|NCT06545578|OTHER|TENS|TENS Intelect Advanced device (Chattanooga, Mouguerre, France). The parameters for TENS stimulation included a frequency range of 60-80 Hz, a pulse width of 50-80 ms, and an intensity of 10-30 mA. Before commencing therapy, patients were provided information regarding the therapeutic approach and any potential adverse effects. During the procedure, two channels (four electrodes) were employed, with one set placed on the right and one on the left paraspinal muscles at the level of L2-L4. Active electrodes from the other channels were affixed 1.5 cm laterally to the spine, while passive electrodes were positioned 3 cm away. TENS therapy was utilized for 30 minutes in Group B, and the intensity of the pain and discomfort was adjusted to the patient's tolerance level.
223983464|NCT06545578|OTHER|motor control exercises|Training in coordinated trunk muscle action, including decreasing overactive superficial muscles and independent activation of deep muscles (such as transversus abdominis and multifidus). Exercises for the pelvic floor muscles, controlling respiration, and regulating the position and movement of the spine were added to these exercises.
223983465|NCT00012662|BEHAVIORAL|Diabetes Self Management Education|
223983466|NCT01003171|DRUG|MCS-2 soft-gel capsule|MCS-2 30 mg/day
223983467|NCT02136771|DIETARY_SUPPLEMENT|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
223983468|NCT02136771|DIETARY_SUPPLEMENT|Placebo|
223983469|NCT00239447|DRUG|Tiotropium|
223983470|NCT00239447|DEVICE|HandiHaler|
223983471|NCT00239447|DEVICE|Respimat SMI|
223727689|NCT02558140|BIOLOGICAL|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
223983472|NCT03967912|BEHAVIORAL|MOVE UP|Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
223983473|NCT00002597|DRUG|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
223727690|NCT05531084|DEVICE|Surgeon-Modified fenestrated stent grafts using Cook Zenith Platform (Zfen, TX2, Alpha Thoracic Endovascular Graft and Zenith Flex)|Depending on the location of the aneurysm, patients with failed EVAR and complex aortic pathology requiring fenestrated and branched endovascular repair will be treated with physician-modified Cook Zenith devices (Zenith Flex, Zenith Fenestrated stent graft (Zfen), Cook Alpha Thoracic Endovascular Graft, Cook dissection TX2), and their associated commercially approved ancillary components.
223727691|NCT00603993|BIOLOGICAL|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
223983474|NCT00002597|DRUG|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
223983475|NCT00002597|DRUG|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
223983476|NCT00002597|RADIATION|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
224119513|NCT03397485|DIETARY_SUPPLEMENT|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
224119514|NCT00906256|DRUG|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
224119515|NCT00906256|DRUG|Placebo|Placebo
223544140|NCT02525926|PROCEDURE|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
223544141|NCT02525926|PROCEDURE|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
223544142|NCT04519931|OTHER|Stress ball|The stress ball is a toy, usually no larger than 7 cm. It is used to relieve stress and muscle tension. Stress ball is one of the cognitive and behavioral therapy methods used in pain control. Stress ball is used as a method of diverting attention during painful procedures. It appears to reduce pain and anxiety.
223544143|NCT03934866|RADIATION|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
223544144|NCT06073704|PROCEDURE|antimicrobial photodynamic therapy (aPDT)|Scaling and root planing followed by antimicrobial photodynamic therapy
223544145|NCT06073704|PROCEDURE|Control|Treatment of scaling and root planing
223544146|NCT03669887|BEHAVIORAL|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
223544147|NCT02991339|DRUG|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
223983477|NCT00146510|BEHAVIORAL|HealtheLifestyle Program|
223983478|NCT00146510|BEHAVIORAL|step counters with monthly feedback on logs|
223983479|NCT05665322|PROCEDURE|Thermoablation with standard CT guidance|Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
223983480|NCT05665322|PROCEDURE|Thermoablation with porto-scanner guidance with Angio-CT|Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
223983481|NCT01073319|OTHER|Placebo|Administration of placebo pill
223983482|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
223983483|NCT01073319|DRUG|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
223983484|NCT01426113|DRUG|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
223983485|NCT01426113|DRUG|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
223983486|NCT01426113|DRUG|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
224119516|NCT03697967|PROCEDURE|supine or prone position|"Before delivery, a sealed enveloppe is opened by the physician or nurse present at delivery. Immediately at birth the team in charge of delivery place the newborn in skin to skin contact on the mother's chest where he is dried. Umbilical cord clamping is delayed in both intervention arms to 1 minute after birth.~The newborn is placed in the prone or in the supine position depending on allocation. The nurse in charge of the newborn uses a stopwatch to check the time at which clamping was accomplished.~All subsequent nursery care are conducted according to hospital protocol."
224294045|NCT00815256|PROCEDURE|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
223983487|NCT01682746|DRUG|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
223727692|NCT05954026|DEVICE|ExVent|ExVent Accessory (inserted into the O2Vent Optima device) for treatment of sleep apnea
223727693|NCT03268720|OTHER|FODMAP low diet|2 week FODMAP low diet
223727694|NCT03268720|OTHER|gluten-free diet|2 week gluten-free diet
223727695|NCT05118503|BEHAVIORAL|Customized education|Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
223727696|NCT05118503|BEHAVIORAL|Standard of care discharge education|Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
223727697|NCT03500627|DRUG|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
223727698|NCT06410820|DEVICE|Procedure/Surgery: Ultrasound method group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
223727699|NCT06410820|DEVICE|Landmark method group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
223983488|NCT01682798|DIETARY_SUPPLEMENT|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
223983489|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
223983490|NCT01682798|DIETARY_SUPPLEMENT|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
223544148|NCT05653700|DEVICE|Arena Strive|This second-generation platform provides frontline clinicians with a comprehensive journey to access the tools, training, and technology used by other high-pressure fields to increase performance and enhance resilience. The experimental intervention employed in this study will be a 12-week, multi-phased approach involving an asynchronous learning and coaching experience (6 weeks), and exploration phase (6 weeks).
223544149|NCT05653700|OTHER|Control Cohort|Participants randomized into the control cohort - survey at baseline and end of the study
223544150|NCT06128057|OTHER|Blood products|Massive blood transfusion
223544151|NCT02317692|BEHAVIORAL|Parent training|
223544152|NCT03424395|OTHER|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
223727700|NCT01761331|OTHER|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
223727701|NCT05534997|OTHER|intensive combined rehabilitation therapy|graded exercise therapy and cognitive behavioral therapy
223727702|NCT04218305|DIAGNOSTIC_TEST|Serum Level Of Fetuin A|
223544153|NCT05180968|DRUG|Nabilone 0.5 MG Oral Capsule|This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
223983491|NCT05874778|DRUG|6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy|All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone) and conduct evaluation about treatment effects (i.e. efficacy evaluation) once every 2 cycles, and after their completion of the 6th cycle, they will receive maintenance treatment . After the end of 6th cycle of treatment or after their leaving the group, efficacy evaluation is conducted every three months to obtain relevant data regarding the 2-year Progression-Free Survival(PFS) and survival of the subjects.
223983492|NCT05874778|RADIATION|Radiotherapy beyond standard R-CHOP Chemotherapy|Radiotherapy: after completion of the standard R-CHOP treatment, enrolled patients will be divided into radiotherapy group and non-radiotherapy group. In radiotherapy group, further consolidation radiotherapy targeting patients' pre-treatment large masses or extranodal affected areas will be given, with routine segmentation of 30-36Gy/15-18f.
224119517|NCT06929377|OTHER|IPPON warm-up programme|The IPPON intervention is an injury prevention programme designed specifically to reduce injuries in judo athletes. The trainer-supervised IPPON intervention mainly focuses on preventing musculoskeletal injuries of the shoulder, knee and ankle. The IPPON intervention consists of 36 exercises divided into (1) flexibility and agility, (2) balance and coordination and (3) strength and stability. Each category consisted of 12 exercises with 3 levels of difficulty. Athletes performed 4 exercises per category and thus 12 exercises at the start of the training at least two times per week.
224294046|NCT06204211|DIAGNOSTIC_TEST|ophthalmologic examinations|All the included personnel underwent routine ophthalmologic examinations on binoculus, including slit lamp microscope observation, intraocular pressure, diopters of refractive error, best corrected visual acuity, AL measurement, fundus photography and optical coherence tomography, adhering to the established and normalized principles.
224294047|NCT03361384|DRUG|Alcohol|
223727703|NCT01779102|BIOLOGICAL|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
223727704|NCT01779102|BIOLOGICAL|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
223983493|NCT01447199|BEHAVIORAL|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
223983494|NCT02485899|BIOLOGICAL|BMN 190|300 mg Intracerebroventricular (ICV) infusion administered every other week for up to 240 weeks
223983495|NCT02485899|DEVICE|Intracerebroventricular (ICV) access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
223983496|NCT06014047|PROCEDURE|No-touch vein graft|Two No-touch saphenous vein grafts anastomose to the right coronary and left coronary system. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
223983497|NCT06014047|PROCEDURE|Radial artery graft|One radial artery graft and one conventional saphenous vein graft anastomose to the right coronary or left coronary system basing on surgeons' decision. All participants also acquired Left intrathoracic artery(LITA)-left anterior decending artery(LAD) anastomosis to complete the revascularization.
223983498|NCT04933981|DIAGNOSTIC_TEST|Nasopharyngeal swab for SARS-CoV-2|in the interventional group, regular, i.e. twice to three times weekly, SARS-CoV-2 testing was offered to health-care workers and visitors of nursing homes
223983499|NCT00103636|PROCEDURE|Extending peripheral intravenous (IV) cannula dwell times|
224294048|NCT03361384|OTHER|Placebo (non-alcoholic beverage)|
224294049|NCT02816866|OTHER|empowered primary care model|mode of survivorship care
223983500|NCT02782572|OTHER|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
224294050|NCT02816866|OTHER|specialty survivor clinic|mode of survivorship care
224294051|NCT01251029|DRUG|N-acetylcysteine|1200 mg orally; 600mg i.v.
224294052|NCT01251029|DRUG|Siran (N-acetylcysteine)|
224294053|NCT01507155|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
224294054|NCT00017719|DRUG|Lamivudine|
224294055|NCT00017719|DRUG|Lamivudine/Zidovudine|
224294056|NCT00017719|DRUG|Nelfinavir mesylate|
223727705|NCT01779102|BIOLOGICAL|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
224294057|NCT00017719|DRUG|Nevirapine|
224294058|NCT00017719|DRUG|Zidovudine|
224294059|NCT00169819|DRUG|Abciximab|
224294060|NCT00468728|DRUG|PAR-101/OPT-80|capsules
223727706|NCT00275054|DRUG|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
223727707|NCT00275054|DRUG|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
223983501|NCT02460536|BEHAVIORAL|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
223983502|NCT02460536|BEHAVIORAL|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
223983503|NCT02460536|BEHAVIORAL|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
223983504|NCT02460536|BEHAVIORAL|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
224294061|NCT00468728|DRUG|Vancomycin|Capsules
224294062|NCT01168206|DIETARY_SUPPLEMENT|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
224294063|NCT01168206|DIETARY_SUPPLEMENT|1 capsule, 3 times per day|Placebo
224294064|NCT04648332|DRUG|Bupivacaine Hydrochloride|compartment psoas block
224294065|NCT00140621|DRUG|Agalsidase beta|
224294066|NCT06134362|DRUG|CAB LA|Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
224294067|NCT03418961|DRUG|Carvedilol|Given PO
224294068|NCT03418961|OTHER|Laboratory Biomarker Analysis|Correlative studies
224294069|NCT03418961|OTHER|Patient Observation|Undergo observation
224294070|NCT03463993|DRUG|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
223727708|NCT00275054|BIOLOGICAL|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
223983505|NCT00000902|DRUG|Ritonavir|
223983506|NCT00000902|DRUG|Nelfinavir mesylate|
223983507|NCT00000902|DRUG|Nevirapine|
223983508|NCT00000902|DRUG|Lamivudine|
223983509|NCT00000902|DRUG|Stavudine|
223983510|NCT00000902|DRUG|Zidovudine|
223983511|NCT00000902|DRUG|Zalcitabine|
223983512|NCT00000902|DRUG|Didanosine|
223983513|NCT05336513|OTHER|Diet Control|Diet following mediterranean principles, for 15 weeks
223983514|NCT05336513|OTHER|Diet anti-inflammatory|Diet combining food items with anti-inflammatory potential, following the principles described in Rondanelli, Clinical Nutrition, 2021 Mar;40(3):661-689. doi: 10.1016/j.clnu.2020.08.020.
223983515|NCT01918371|DRUG|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
224119518|NCT06930313|BEHAVIORAL|Brief Compassion-Based Intervention (BCI)|"The intervention program is based on Compassion-Focused Therapy (CFT) and incorporates evidence-based compassion exercises.Drawing on insights from the literature, the program includes:Session 1: Introduction to caregiving challenges and emotional systems. Includes a soothing breathing exercise and group discussion on caregiving stress.~Session 2: Cultivating self-compassion. Includes reflecting on emotions, guided meditation, and a compassionate body scan practice.~Session 3: Transforming self-criticism into self-compassion. Caregivers explore self-critical thoughts, practice reframing, and engage in compassionate dialogue.~Session 4: Building resilience and connections. Focuses on gratitude, setting boundaries, and loving-kindness meditation, ending with daily intention setting."
224119519|NCT06930313|BEHAVIORAL|Telephone-Based Support and Education (TSE)|The session will address their questions and concerns, provide psychological support for managing difficult emotions (e.g., anxiety, fear, sadness, and guilt), and emphasize the importance of self-care, encouraging them to take time for themselves and seek support when needed.
224119520|NCT06834815|DRUG|Probiotic with Prebiotic|"After assigning the patients , all patients will submit an unstimulated salivary sample of 1ml will in sealed test tubes then stored in a deep freezer until microbiological evaluation, then they'll receive an oral prophylaxis session.~* The patients will receive probiotics for 14 days given to them in a sealed box.~* All patients will be followed up after 14 days and another salivary sample will be collected and sent for microbiological assessment."
224119521|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
223983516|NCT00406900|PROCEDURE|Treatment of metastatic disease|
224119522|NCT04878640|PROCEDURE|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
224294071|NCT03463993|DRUG|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
223983517|NCT04683341|DRUG|Tenofovir Alafenamide Tablets|Approximately 100 adults, cirrhotic or non-cirrhotic (capped at 50), CHB patients with hepatic decompensation, will receive initial treatment (Arm A) with or switch (Arm B) to TAF 25 mg/day for 144 weeks. For Initiation Arm (Arm A), CHB patients with hepatic decompensation, who are currently not under HBV antiviral treatment will be enrolled. For Switch Arm (Arm B), CHB patients who are currently with hepatic decompensation and virally suppressed under HBV NUC treatment (HBV DNA \< 20 IU/mL) will be enrolled.
223983518|NCT01006889|DRUG|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
223727709|NCT02737189|PROCEDURE|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
223727710|NCT02737189|DRUG|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
223727711|NCT04817371|DEVICE|Volatile Organic Compounds analysis (e-noses)|VOC analysis in exhaled air with e-noses.
223727712|NCT04817371|OTHER|Canine odor detection of Volatile Organic Compounds|VOC analysis in sweat by trained dogs.
223983519|NCT01177995|BEHAVIORAL|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
223983520|NCT03595423|PROCEDURE|Surgical AVR with bioprosthetic or mechanical prosthesis|Surgical AVR with bioprosthetic or mechanical prosthesis
223727713|NCT04817371|DEVICE|Volatile Organic Compounds analysis (mass spectrometry)|VOC analysis in exhaled air with mass spectrometry.
223727714|NCT04817371|DEVICE|Volatile Organic Compounds analysis in sweat (mass spectrometry)|VOC analysis in sweat with mass spectrometry.
223727715|NCT01564797|BEHAVIORAL|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
223727716|NCT00836290|BEHAVIORAL|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
223727717|NCT00836290|BEHAVIORAL|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
223727718|NCT02562794|BEHAVIORAL|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
223983521|NCT01642095|OTHER|Laboratory Biomarker Analysis|Correlative studies
223983522|NCT04783103|DEVICE|a Magstim Rapid2 Plus1 Magnetic Stimulator connected to a Brainsway H1 coil|3 weeks home use
223983523|NCT03415399|BIOLOGICAL|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
223983524|NCT00479219|DRUG|GSI-953|
223983525|NCT00479219|OTHER|Placebo|
223983526|NCT02787447|DRUG|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
223983527|NCT02787447|RADIATION|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
223983528|NCT02787447|DRUG|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
223983529|NCT03336099|OTHER|Spa Treatment|"* Bath with immersion shower~* Overall shower, penetrating shower~* Multiple local application cataplasm~* Single local application cataplasm~* Inhalation or collective steam bath~* Individual physiotherapy technique"
223983530|NCT03297476|DIAGNOSTIC_TEST|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
223983531|NCT05752045|DEVICE|Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device|Double ophthalmological imaging capture of eye fundus with different fundus camera to screen patient for various eye diseases.
223983532|NCT00238992|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
223983533|NCT06307067|DIAGNOSTIC_TEST|Urine dipstick|Urine dipstick is a point of care test that can be performed on the urine in the public health center.
223983534|NCT06029985|DIAGNOSTIC_TEST|Hysteroscopic Follow Up|Office hysteroscopy was carried out to detect the scar site, performed with a 4-mm, continuous-flow operative hysteroscope by vaginoscopic approach, without analgesia or anesthesia. Distension of the uterus was obtained using a normal solution as distension medium, dispensed by an electronic suction/irrigation pump. This can maintain a constant intrauterine pressure of around 30-40 mmHg, balancing an irrigation flow of 200 mL/min with a vacuum of 0.2 bars, necessary to avoid overdistension of the muscle fibers and patient discomfort. The use of this distension medium allows blood or mucus to be washed out from the pouch if necessary.
223983535|NCT02782611|BEHAVIORAL|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
223983536|NCT02001909|DRUG|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
223983537|NCT02001909|DRUG|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
223983538|NCT00623363|DRUG|piclozotan|piclozotan, intravenous (IV) infusion
223983539|NCT00623363|DRUG|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline) intravenous (IV) infusion
223983540|NCT02332083|DEVICE|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
223983541|NCT02332083|DEVICE|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
223983542|NCT02332083|OTHER|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
223983543|NCT02332083|DEVICE|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
223983544|NCT00435955|PROCEDURE|High dose chemotherapy with autologous transplantation|
223983545|NCT00435955|DRUG|Rituximab|
223983546|NCT01514955|RADIATION|Gold seeds insertion to detect movements at pelvis|
223983547|NCT01514955|RADIATION|Image guided MRI based RT (IMRT+Brachytherapy)|
223983548|NCT06105112|DEVICE|Hyaluronic acid|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Application of cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) hyaluronic acid (hyaDent BG, Regedent, Germany) through a syringe over a bone xenograft (Smartgraft, Regedent, Germany). The mixture will be then compacted within the intrabony component of the defect.
223983549|NCT06105112|DEVICE|Enamel matrix derivatives|Minimally invasive flap elevation and debridement of the intrabony defect with micro-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Enamel matrix derivatives gel (Emdogain, Straumann, Switzerland) will be applied on the dry root surfaces and left in place for at least 1 minute avoiding blood contamination. Subsequently, a bone xenograft (Smartgraft, Regedent, Germany) will be compacted within the intrabony component of the defect.
224294072|NCT03725865|BIOLOGICAL|Induction of neural stem cells|Brain injection iNSC
224294073|NCT03659474|OTHER|compression|compression by Game Ready
224294074|NCT03659474|OTHER|ice pack|cryotherapy for ice pack
223983550|NCT04581252|DEVICE|Non-invasive cardiac system|Non-invasive cardiac system
223983551|NCT00511771|DRUG|Tegaserod|Tegaserod maleate
223983552|NCT05376904|DRUG|HR18034|HR18034 low dose
223983553|NCT05376904|DRUG|HR18034|HR18034 midium dose
223983554|NCT05376904|DRUG|HR18034|HR18034 high dose
223983555|NCT05376904|DRUG|ropivacaine HCl.|ropivacaine HCl.
223983556|NCT04848376|DEVICE|(1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L|As long as there are patients using the above device, conduct questionnaire interview.
223983557|NCT04751136|DRUG|cerebrolysin|Infants of the treatment group were given Cerebrolysin in a dose of 0.1 ml / kg body weight once weekly intramuscular injection for 12 month (total of 48 injections).Each selected infant, in both treatment and control group, was assessed as regard: Socioeconomic status, Nutritional status and feeding practice, assessed for neurocognitive development
224294075|NCT03659474|OTHER|immersion|immersion therapy
224294076|NCT04486378|DRUG|RO7198457 intravenous (IV)|RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.
224294077|NCT04486378|OTHER|Observational group (no intervention)|watchful waiting
223983558|NCT04919733|DEVICE|Fluoroscopy reduction|To decrease, using 3-D mapping systems, the amount of fluoroscopy needed to implant a CIED
223983559|NCT00718471|DRUG|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
223983560|NCT00718471|DRUG|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
223544154|NCT05180968|DRUG|Placebo Nabilone|This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
223983561|NCT05655455|BEHAVIORAL|walking group: 1.group|In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
223983562|NCT05655455|BEHAVIORAL|dance and movement therapy group: 2.group|In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
223983563|NCT06263439|DIAGNOSTIC_TEST|Throat/buccal swab sample|The study involves the genome detection of enteroviruses in throat or mouth swabs taken from children with a diagnosis of HFMD or herpangina. If positive, the precise type of enterovirus responsible will be identified by sequencing a viral genomic region.
223983564|NCT00179257|DRUG|sertraline (Zoloft)|
223983565|NCT00460668|BEHAVIORAL|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
223983566|NCT02572115|BEHAVIORAL|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
223983567|NCT02572115|BEHAVIORAL|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
223544155|NCT02148848|DRUG|Risedronate|Take risedronate 35 mg orally every week
223727719|NCT00099853|DRUG|Vildagliptin|Vildagliptin 50 mg tablets
223727720|NCT00099853|DRUG|pioglitazone|pioglitazone 45 mg qd
223983568|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
223983569|NCT01069328|DRUG|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
223983570|NCT01069328|DRUG|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
223983571|NCT01069328|DRUG|Bevacizumab|Bevacizumab 5 mg/kg intravenously
223983572|NCT01069328|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
223983573|NCT01069328|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenously
223727721|NCT00099853|DRUG|Placebo|Vildagliptin matching placebo
223983574|NCT01069328|DRUG|Paclitaxel|Paclitaxel 200 mg/m² intravenously
223983575|NCT01069328|DRUG|Carboplatin|Carboplatin AUC 6 intravenously
223983576|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
224119523|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
223983577|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
223983578|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
223727722|NCT02399501|PROCEDURE|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
223983579|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
223983580|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
223983581|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
223983582|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
223983583|NCT01195207|BIOLOGICAL|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
223983584|NCT04470570|OTHER|Cross-Education|1\) Cross-Education: The effect that exercising the uninvolved upper extremity will have a positive effect on the involved upper extremity.
223983585|NCT04470570|OTHER|Blood-Flow Restriction Training|1\) Blood Flow Restriction: A type of resistance training using a blood-pressure like cuff that partially occludes venous blood flow to induce various neurohormonal effects and allows strength gains to be achieved at very low loads of resistance.
223983586|NCT02867098|DRUG|XmAb5871|
223983587|NCT00001509|DRUG|IFN-alpha with retinoic acid|
223983588|NCT02669615|DRUG|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
223983589|NCT00823836|DRUG|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
223544156|NCT05962255|DRUG|Furosemide intravenous infusion|"At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics."
223544157|NCT05962255|DRUG|Continous intravenous infusion of 0.9% Sodium Chloride solution|Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
223544158|NCT05962255|DRUG|Continous intravenous infusion of 5% Glucose solution|Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
223544159|NCT02573948|OTHER|no intervention is assessed|
223544160|NCT00076440|DRUG|Leuprolide acetate|
223983590|NCT00823836|DRUG|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
223983591|NCT02801864|DEVICE|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
223983592|NCT02801864|DEVICE|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
223983593|NCT02801864|OTHER|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
223983594|NCT04967183|DIAGNOSTIC_TEST|Annual FIT|"Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~* After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~* After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas)."
223727723|NCT02399501|DEVICE|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
224119524|NCT00644540|BIOLOGICAL|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
223983595|NCT04967183|PROCEDURE|Endoscopic surveillance.|First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
223983596|NCT03903497|DEVICE|NBI|optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
223983597|NCT04065126|BEHAVIORAL|Physical activity intervention|Ten sessions (two hours each) with physical activity and psycho-educational components.
223983598|NCT04065126|BEHAVIORAL|Brief psycho-education|Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
223983599|NCT05513183|PROCEDURE|Intraoperative blood and peritoneal fluid samplings during HIPEC|"\- Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)"
223983600|NCT01551069|DRUG|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
223983601|NCT01551069|DRUG|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
223983602|NCT00503503|DRUG|Enbrel (etanercept)|
223983603|NCT02109666|DRUG|Abatacept|
223983604|NCT00530998|PROCEDURE|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
223983605|NCT00530998|PROCEDURE|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
223983606|NCT02271230|DRUG|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
223983607|NCT02271230|DIETARY_SUPPLEMENT|Fish oil (EPA/DHA) alone|1 g/d fish oil
223983608|NCT02271230|DRUG|Vitamin D alone|2000 IU vitamin D
223983609|NCT02271230|OTHER|Placebo|Vitamin D placebo and fish oil placebo
223983610|NCT00004922|DRUG|irinotecan hydrochloride|
223983611|NCT02505477|DRUG|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
223727724|NCT02399501|DEVICE|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
223727725|NCT02399501|DEVICE|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
223727726|NCT02057406|DRUG|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
223727727|NCT02057406|DRUG|High EPA|
223727728|NCT02057406|OTHER|Placebo|
223727729|NCT00756860|DRUG|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
223983612|NCT02505477|OTHER|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
223983613|NCT06102564|BEHAVIORAL|Group schematherapy|Brief group schematherapy for mothers with young children (age 0-5) focused on attachment relations between mother and child
223983614|NCT02238106|DRUG|Salmeterol medium dose|
223983615|NCT02238106|DRUG|Salmeterol low dose|
223983616|NCT02238106|DRUG|Salmeterol high dose|
223983617|NCT02238106|DRUG|Serevent® Diskus®|
223983618|NCT02238106|DRUG|Placebo HandiHaler®|
223983619|NCT02238106|DRUG|Placebo Diskus®|
223983620|NCT03874936|DRUG|Dexamethasone 24mg Solution for Injection|Administrated i.v.
223983621|NCT03874936|DRUG|Saline Solution for Injection|administrated i.v.
224119525|NCT05117086|BEHAVIORAL|DASH diet|Nutrition education and counseling on DASH diet, behavioral and lifestyle modifications
223983622|NCT04243642|DEVICE|IntelliSpace Cognition|Philips IntelliSpace Cognition (ISC) is a digital assessment platform that supports Healthcare Professionals (HCP) in assessing the cognition of individuals. It consists of two interfaces connected to the DCDx-module in the cloud. ISC is hosted on the Philips Health Suite Digital Platform (HSDP). The first interface is the patient's interface and is presented via a tablet to collect data on how the patient performs a series of tests. The second interface is the clinician's interface and can be used on any PC or tablet. It allows for assessments to be selected and administered, observations made, data analytics performed and the generation of a report.
223983623|NCT02087215|DRUG|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
223983624|NCT02087215|DRUG|Placebo|
223983625|NCT05367206|DRUG|Albumin-Bound Paclitaxel|260mg/m2 q3w \*2 circles
223983626|NCT05367206|DRUG|Carboplatin|AUC 5-6 q3w \* 2 circles
223983627|NCT03191071|DIAGNOSTIC_TEST|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
223983628|NCT03191071|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
223983629|NCT03191071|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
223983630|NCT03191071|DIAGNOSTIC_TEST|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
223983631|NCT04370535|DEVICE|cellulose|The subjects of group A and group C receive boxes containing placebo for supplementation for a total of 12 weeks.
223983632|NCT04370535|DEVICE|PMA-zeolite|The subjects of group B and group D receive boxes containing PMA-zeolite for supplementation for a total of 12 weeks.
223983633|NCT02725528|DRUG|collagenase injection|injection
223983634|NCT02725528|PROCEDURE|limited palmar fasciectomy|surgery
223983635|NCT04850235|DRUG|Nab paclitaxel|Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
223983636|NCT05442346|BIOLOGICAL|γ-globin reactivated autologous hematopoietic stem cells|gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
224119526|NCT05664971|BIOLOGICAL|Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection|200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
224119527|NCT05664971|BIOLOGICAL|Toripalimab|240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
224119528|NCT05664971|DRUG|Docetaxel|60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression
223727730|NCT00756860|DRUG|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
223727731|NCT02425046|BEHAVIORAL|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
224119529|NCT05664971|DRUG|Pemetrexed|500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed
224119530|NCT05664971|DRUG|Cisplatin|75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
224119531|NCT05664971|DRUG|Carboplatin|AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
224119532|NCT05664971|DRUG|Paclitaxel|175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles
224119533|NCT05664971|DRUG|Etoposide|100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
223983637|NCT03672799|BEHAVIORAL|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
223727732|NCT02425046|BEHAVIORAL|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
223727733|NCT01514929|DRUG|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
223983638|NCT03672799|OTHER|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
223983639|NCT01477736|DRUG|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
223983640|NCT01477736|DRUG|Botulinum toxin A|300 U intradetrusor injection
223983641|NCT05252936|OTHER|COVID-19 vaccine social media campaign exposure|A series of animated video clips will be promoted through Facebook Ads and randomized at the individual level across Facebook users throughout the entire country. To investigate the effectiveness of Mayan language content, we are testing three treatment arms - visually identical videos in the 1) Spanish, 2) K'iche', and 3) Kaqchikel languages. The videos are visually identical and follow the same audio script, translated into the three focal language. Local voiceover artists were used to record the scripts in the three languages. A control group that is not exposed to any of the social media campaign content will serve as active comparator to allow for comparison of outcomes with treatment arms.
223983642|NCT01410864|DEVICE|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
223983643|NCT01410864|OTHER|Control|Devices or drugs used to seal the dura (other than DuraSeal)
223983644|NCT01283022|DRUG|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
223983645|NCT03042299|DRUG|TAK-536|TAK-536 granules.
223983646|NCT03042299|DRUG|TAK-536|TAK-536 tablet.
223727734|NCT01514929|DRUG|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
223727735|NCT01514929|DRUG|Moxifloxacin|400mg oral pill given once
223983647|NCT01085383|DRUG|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
223983648|NCT05401383|DEVICE|Lumevis (IIa class)|intake of Lumevis 30 minutes before EGDS
223727736|NCT01514929|DRUG|Placebo|Placebo oral pill given once
223727737|NCT00891254|DEVICE|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
223727738|NCT03958721|DRUG|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
223727739|NCT03958721|RADIATION|Radiotherapy|Once daily (Monday through Friday) for six weeks
223727740|NCT04998474|BIOLOGICAL|FRAME-001 personalized vaccine|Patients will receive personalized peptide vaccine FRAME-001 based on frame-shift mutations (Frames) detected by Whole Genome Sequencing (WGS)/Ribonucleic Acid sequencing (RNAseq) in a tumor biopsy. FRAME-001 vaccine will be administered in four sequential cycles at 3-week interval (Q3W), along standard maintenance monotherapy of pembrolizumab (administration Q3W or Q6W). Each cycle will be consisting of up to four subcutaneous injections at up to four different sites in the upper and lower limbs.
223727741|NCT05552950|BIOLOGICAL|BioBlock® antiviral nasal spray|SARS-CoV-2 BioBlock is a natural preparation derived from bovine colostrum, where animals have an immune response against the SARS-CoV-2 spike protein in addition to conventional vaccines. The antiviral colostrum preparation was made from colostrum of cows immunized with SARS CoV-2 spike protein. Pregnant cows were immunized during the third trimester of gestation using a non-infectious recombinantly produced and purified SARS CoV-2 spike protein. Colostrum, which is milked after calving, concentrates most of the antibodies produced in the cow's body at very high concentrations, including neutralizing antibodies to SARS CoV-2 produced as a result of immunization.
223983649|NCT01874509|BEHAVIORAL|Check Your Drinking|
223983650|NCT01874509|BEHAVIORAL|Alcohol Help Centre|
223983651|NCT03062345|OTHER|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
223983652|NCT03062345|OTHER|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
223983653|NCT04686292|DIAGNOSTIC_TEST|urine flow cytometry|Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
223983654|NCT00430742|DRUG|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
223983655|NCT00430742|DRUG|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
223983656|NCT02062645|DRUG|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
224119534|NCT05895513|DRUG|Pimavanserin 34 mg|5HT-2a receptor antagonist
224119535|NCT05895513|DRUG|Placebo|Inactive Comparator
223727742|NCT04189211|DRUG|BAT8001|IV infusions.
223983657|NCT01372007|DRUG|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
223983658|NCT01372007|DRUG|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
223983659|NCT05247697|DRUG|Mirtazapine 7.5 MG Oral Tablet once daily at bedtime|Mirtazapine 7,5 mg capsule
223983660|NCT05247697|DRUG|Placebo oral tablet once daily at bedtime|Matching placebo
223727743|NCT02175589|OTHER|Colchicine Cessation|Colchicine Cessation
223727744|NCT03386682|DEVICE|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
223727745|NCT03696511|DEVICE|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
223727746|NCT05634304|BEHAVIORAL|A mobile app self-management (mSM) program|The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
223727747|NCT05855460|DIAGNOSTIC_TEST|Skin biopsy|biochemical assessment for measurement IL35 by ELISA (Enzyme linked immunosorbent assay) technique in tissue and serum samples of all thirty patients and healthy controls.
223727748|NCT02508402|DRUG|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
223727749|NCT02508402|DRUG|Placebo|two milliliters of normal saline given to placebo group .
223727750|NCT05784064|BEHAVIORAL|Survey|This is a nationalwide survey developed in order to know the management of patients diagnosed of acute uncomplicated diverticulitis.
223727751|NCT01994460|DRUG|Linezolid|
223727752|NCT01994460|DRUG|Ethambutol|
223983661|NCT03553290|DEVICE|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
223983662|NCT03553290|PROCEDURE|Control|Mechanical debridement alone
223983663|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (Low dose)|One Capsule to be consumed twice a day
224119536|NCT04838275|BEHAVIORAL|12-week mHealth home exercise prescription|3x/week home walking protocol, 2x/week resistance exercise program
223727753|NCT00353561|DRUG|Boric|Gelatin capsules filled with 600 mg of boric acid
223727754|NCT00353561|DRUG|Fluconazole|150 mg oral fluconazole gives once in 14 days
223727755|NCT05162131|DRUG|Bentracimab (PB2452) 100 mg or Placebo|"Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
223727756|NCT05162131|DRUG|Bentracimab (PB2452) 300 mg or Placebo|"Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion"
223727757|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo|"Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion"
223983664|NCT05825222|DIETARY_SUPPLEMENT|E-PR-01 (High Dose)|One Capsule to be consumed twice a day
223983665|NCT05825222|DIETARY_SUPPLEMENT|Placebo|One Capsule to be consumed twice a day
223983666|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
223983667|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
223983668|NCT00798304|BIOLOGICAL|meningococcal B rLP2086 vaccine|vaccination
223983669|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
224119537|NCT04307134|DRUG|Inotuzumab ozogamicin|R/R ALL who treated with Inotuzumab ozogamicin
224119538|NCT05579704|BEHAVIORAL|Web-based wellness platform|A web-based wellness platform is based on preventive self-care and contains tools to monitor nutrition, physical activity, and mental wellbeing.
223983670|NCT00798304|BIOLOGICAL|Routine age appropriate childhood vaccines|vaccination
223983671|NCT04211389|DRUG|ARQ-151 0.3% cream|ARQ-151 0.3% cream
223983672|NCT04211389|DRUG|ARQ-151 vehicle cream|ARQ-151 vehicle cream
223983673|NCT03850275|DIETARY_SUPPLEMENT|Intervention/treatment|Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
223983674|NCT00692458|DRUG|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
223983675|NCT00692458|DRUG|Comparator: placebo|placebo; oral, once daily for approximately 60 months
223983676|NCT00953316|OTHER|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
223983677|NCT04999605|DRUG|AK112 low dose|AK112 injection low dose+ olaparib (Lynparza®) PARP inhibitor
223983678|NCT04999605|DRUG|AK112 medium dose|AK112 injection medium dose+ olaparib (Lynparza®) PARP inhibitor
223983679|NCT04999605|DRUG|AK112 high dose|AK112 injection high dose+ olaparib (Lynparza®) PARP inhibitor
223983680|NCT01791777|BEHAVIORAL|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
223983681|NCT06540885|DRUG|Palonosetron (Group P)|Group P will be receiving palonosetron 1.5mcg/kg before the commencement of general anaesthesia
224119539|NCT05579704|BEHAVIORAL|Healthcare professional-facilitated online support group|Participants will take part in weekly group video conferencing sessions with various health professionals (registered dietitian, mental health therapist, and exercise professional). The sessions will occur once per week for 1 hour each. The group sessions will contain cohorts of approximately 10 individuals.
224119540|NCT05983146|DRUG|HRS-7053 Injection|HRS-7053 is administered by intravenous (IV) infusion once a week (QW) for one treatment cycle every 4 weeks
223983682|NCT06540885|DRUG|Granisetron (Group G)|Group G participants will receive IV Granisetron 1mg at the start of wound closure
223983683|NCT02964546|OTHER|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
223983684|NCT04009109|DRUG|Lenalidomide|Induction and Maintenance
223983685|NCT04009109|DRUG|Ixazomib|Induction and Only Maintenance Arm B
223983686|NCT04009109|DRUG|Daratumumab Injection|Induction and Only Maintenance Arm B
224119541|NCT05647811|DRUG|NM8074|NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
224119542|NCT04400318|DRUG|Dupilumab|solution for injection subcutaneous
224119543|NCT04400318|DRUG|Placebo|Solution for injection subcutaneous
223727758|NCT05162131|DRUG|Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
223727759|NCT05162131|DRUG|Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
223983687|NCT04009109|DRUG|Dexamethasone|Induction and Only Maintenance Arm B
223983688|NCT02357264|DEVICE|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
223983689|NCT05528263|DEVICE|Acupuncture|Standardized acupuncture protocol 1-2 times a week for 12 weeks (a total of 14 sessions).
223983690|NCT05528263|OTHER|Nature scenery with a relaxation exercise|Watch nature scenery videos with a relaxation exercise guide 1-2 times a week for 12 weeks (a total of 14 sessions)
224119544|NCT01893840|DEVICE|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
224119545|NCT01752569|DRUG|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
223727760|NCT05162131|DRUG|Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
223983691|NCT03793322|DRUG|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
223983692|NCT00020709|DRUG|cisplatin|Given IV
223983693|NCT00020709|DRUG|docetaxel|Given IV
223983694|NCT00020709|DRUG|etoposide|Given IV
223983695|NCT00020709|DRUG|gefitinib|Given orally
223983696|NCT00020709|RADIATION|radiation therapy|Undergo radiation therapy
223983697|NCT00020709|OTHER|placebo|Given orally
223983698|NCT04797520|DEVICE|Eko CORE Stethoscope|Eko CORE stethoscope will be used as a visual and auditory means of confirming placement of ETT
223983699|NCT04797520|DEVICE|Point of care ultrasound|"Point of care ultrasound will be used as a means of confirming placement of ETT. This is the gold standard used in standard of care"
223983700|NCT02856061|BEHAVIORAL|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
223983701|NCT00620633|BIOLOGICAL|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
223983702|NCT01062971|DRUG|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
223983703|NCT04823364|OTHER|Neurotransmitters evaluation by MRS|Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment
223983704|NCT01759238|DRUG|Capecitabine|825mg/m2 per os bid
223983705|NCT01759238|DRUG|Bevacizumab|7.5 mg/kg
223983706|NCT01759238|RADIATION|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
223983707|NCT01530087|DEVICE|CASTLE barrier|Prototype barrier to be used in place of current two piece device
223983708|NCT04882189|DIAGNOSTIC_TEST|Imaging|Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
223983709|NCT02760485|DRUG|itacitinib|Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
223983710|NCT02760485|DRUG|ibrutinib|
223544161|NCT04421404|BIOLOGICAL|COVID-19 Convalescent Plasma (CCP)|COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.
223983711|NCT05427019|PROCEDURE|Distal adductor canal block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
224119546|NCT02995343|PROCEDURE|Hypogastric and/or uterine artery ligation|
224119547|NCT00747617|DRUG|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
224119548|NCT00518219|DRUG|TW|TW,120mg/d
223983712|NCT05427019|PROCEDURE|Distal adductor canal block and Periarticular block|All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
223983713|NCT01748123|DRUG|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
223983714|NCT01748123|DRUG|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
223983715|NCT02592681|PROCEDURE|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
223983716|NCT02592681|PROCEDURE|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
223983717|NCT02592681|PROCEDURE|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
223983718|NCT00904722|DRUG|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
223983719|NCT00904722|DRUG|Rituximab|Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
223983720|NCT03862261|OTHER|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~* Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~* Improvement of diagnosis capacities and their integration in all levels of care and all services."
223983721|NCT00855322|OTHER|Gym exercise group intervention|Gym based circuit class
223983722|NCT00855322|OTHER|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
223544162|NCT04421404|BIOLOGICAL|Placebo|Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
223544163|NCT00707993|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
223544164|NCT00707993|DRUG|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
223544165|NCT06058962|DRUG|Suramin Sodium|Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.
223544166|NCT04795401|DEVICE|FRAME FR IFU|The surgeon will use the medical device FRAME to perform the plication procedure. The device will be selected and implanted according to the product IFU.
223544167|NCT06274983|DEVICE|IVR platform trial|8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform. Patients will receive device training and then use the VR device at home for 12 weeks. Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
223544168|NCT01070342|DEVICE|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
223983723|NCT00855322|OTHER|Control group|No intervention
223983724|NCT04759950|BEHAVIORAL|Multicomponent Physical Activity Program|The proposed physical exercise intervention follows the American College of Sports Medicine (ACSM, 2017) and the American Stroke Association (Billinger et al., 2014) recommendations for stroke patients. The five weekly 45-minute sessions are divided into (1) three sessions guided and supervised telematically by a physical exercise specialist and a physiotherapist; (2) and two autonomous exercise sessions. The supervised sessions include exercises to work aerobic capacity, muscle strength and endurance, flexibility, agility, and balance. The intensity of these exercises is prescribed individually according to each participant's initial level and are gradually increased as the program progresses. Participants are encouraged to walk at a similar intensity on autonomous physical exercise days as performed in the guided sessions (moderate intensity), based on the Borg scale of perceived exertion (Borg, 1982).
223983725|NCT04759950|BEHAVIORAL|Mindfulness-Based Stress Reduction Program|This intervention follows an adaptation of the scheme and instructions of the official Mindfulness-Based Stress Reduction (MBSR) program designed by Jon Kabat-Zinn. It includes body scanning, sitting meditation, and gentle hatha yoga techniques. An accredited mindfulness instructor leads the 12-week online program, which comprises a presentation session, followed by eight intervention sessions (once a week, lasting 2.5 hours) and an intensive practice session interspersed between sessions six and seven. Apart from the supervised session, the therapist asks participants to carry out some independent practice daily.
223983726|NCT04759950|BEHAVIORAL|Computerized Cognitive Training|An accredited neuropsychologist programs and supervises the computerized cognitive training through the Guttmann Neuropersonal Trainer (GNPT®) platform. The 12-week program consists of five sessions a week (45 minutes each) that include personalized activities planned to stimulate executive functioning, attention, processing speed, and memory.
223983727|NCT00296023|BIOLOGICAL|anti-thymocyte globulin|
223983728|NCT00296023|BIOLOGICAL|filgrastim|
223983729|NCT00296023|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223983730|NCT00296023|DRUG|busulfan|
223983731|NCT00296023|DRUG|fludarabine phosphate|
223983732|NCT00296023|DRUG|methotrexate|
223983733|NCT00296023|DRUG|tacrolimus|
223983734|NCT00296023|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223983735|NCT00296023|PROCEDURE|peripheral blood stem cell transplantation|
223983736|NCT04241887|PROCEDURE|thoracic paravertebral blockade|Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.
223983737|NCT04241887|PROCEDURE|local anaesthesia|Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
223983738|NCT04360083|OTHER|Collected data from Rhône RéPPOP database|BMI Z-scores at the start and the end of RéPPOP care programs.
223983739|NCT04360083|OTHER|telephonic questionnaire|Collected data though the telephonic questionnaire : current declared BMI Z-score.
223983740|NCT02251340|BEHAVIORAL|Eczema Care Plan|
223983741|NCT01413022|DRUG|Oxaliplatin|
223983742|NCT01413022|DRUG|Irinotecan|
223727761|NCT05162131|DRUG|Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)|"Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo"
223983743|NCT01413022|DRUG|Leucovorin|
223983744|NCT01413022|DRUG|Fluorouracil|
223983745|NCT01413022|OTHER|laboratory biomarker analysis|Correlative studies
223983746|NCT01413022|OTHER|flow cytometry|Correlative studies
223983747|NCT01413022|OTHER|immunohistochemistry staining method|Correlative studies
223983748|NCT01413022|OTHER|pharmacological study|Correlative studies
223983749|NCT01413022|DRUG|PF-04136309|
223983750|NCT03880825|DRUG|Metformin 500 mg Oral Tablet|single dose
223983751|NCT03880825|DRUG|Levoketoconazole 150 - 600 mg (BID)|escalating dose from 150 mg to 600 mg (BID)
223983752|NCT00567983|DRUG|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
223983753|NCT00567983|DRUG|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
223983754|NCT01187810|DRUG|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
223983755|NCT01187810|DRUG|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
223983756|NCT01187810|DRUG|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
223983757|NCT02702336|BEHAVIORAL|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
223983758|NCT05980962|PROCEDURE|Inferior oblique anteriorization|symmterical anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion
223983759|NCT05980962|PROCEDURE|Inferior oblique anteriorization together with unliateral resction|asymmterical surgery, anteriorization the the inferior oblique muscle 1 mm behind and lateral to the inferior rectus insertion in one eye, and an additional 3-5 mm resction of the inferior oblique in the eye with the larger devation
223544169|NCT04326062|OTHER|Main Study|The pharmacist will participate in the management of repeat prescribing and undertake medication reviews (which will address high risk prescribing and potentially inappropriate prescribing, deprescribing and cost-effective and generic prescribing) with adult patients. Pharmacists will also provide prescribing advice regarding the use of preferred drugs, undertake clinical audits, join practice team meetings and facilitate practice-based education. Throughout the six-month intervention period, anonymised practice-level medication (e.g. medication changes) and cost data will be collected.
223983760|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
223983761|NCT03179059|DIAGNOSTIC_TEST|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
223983762|NCT00631397|DEVICE|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
223983763|NCT01087814|DRUG|Efavirenz|Subject will take efavirenz for 5 days.
223983764|NCT01087814|DRUG|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
223983765|NCT04319614|DRUG|Tranexamic Acid Injectable Product|A single dose of tranexamic acid, corresponding to 20 mg/kg in 100 ml saline, will be administered in the beginning of procedure.
223983766|NCT04319614|DRUG|Placebos|100 ml of saline will be administered in the beginning of the procedure.
223983767|NCT00334971|PROCEDURE|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
223983768|NCT02050698|PROCEDURE|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
223983769|NCT02050698|PROCEDURE|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
223983770|NCT01891890|DRUG|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
223983771|NCT01891890|DRUG|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
223727762|NCT04566211|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
223983772|NCT01891890|DRUG|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
223983773|NCT05665413|DEVICE|TENS|strocking technique, HOT PACK and Ergon instrument
223983774|NCT05685953|BIOLOGICAL|DNA vaccine OC-007|Plasmid DNA vaccine
223983775|NCT05685953|OTHER|Placebo|0.9% NaCl solution
223983776|NCT01891656|BEHAVIORAL|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
223544170|NCT04326062|OTHER|PROM Study|For this, a sub-set of patients (n=200) aged ≥65 years on ≥10 repeat medicines will be recruited and invited to a medication review with the pharmacist. PROMs and healthcare utilisation data will be collected using patient questionnaires and a six-week follow-up review with these patients will also be conducted.
223544171|NCT05907811|PROCEDURE|Neuromuscular blocker usage|The patients were followed up, the total amount of muscle relaxant used was determined, intraoperative effects and postoperative analgesic usage
223544172|NCT04303975|OTHER|clinical measurements|Only clinical parameters were recorded, no intervention was made.
223544173|NCT03041935|PROCEDURE|Ilioinguinal/iliohypogastric nerve block|See arm description
223544174|NCT03041935|PROCEDURE|Caudal-epidural nerve block|See arm description
223544175|NCT03041935|DRUG|Acetaminophen|See arm description
223727763|NCT04566211|DRUG|pantoprazole+bismuth+amox+clar|pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
223727764|NCT03654651|DRUG|Peanut|Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
223983777|NCT01891656|BEHAVIORAL|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
223983778|NCT04842526|DRUG|Anlotinib and irinotecan combined with temozolomide|Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
223983779|NCT04201704|OTHER|Balanced crystalloid solution volume administration|Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
224119549|NCT02279524|DRUG|Aramchol|"Subjects will be administered Aramchol as follows:~* One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~* One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~* Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
223983780|NCT04201704|OTHER|Packed Erythrocytes Units, Blood Product Unit volume|For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
224119550|NCT06177054|BEHAVIORAL|Rotation guided by ultrasound|Instruction to avoid areas with hyperechogenicity - after two weeks observation
224119551|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day,|
224119552|NCT00200694|DRUG|ramipril 10 mg + valsartan 160 mg/day,|
224119553|NCT00200694|DRUG|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
224119554|NCT03165591|BIOLOGICAL|V3-P|one tablet of V3-P given once daily for 2 months
223544176|NCT03041935|DRUG|Sevoflurane|See arm description
223544177|NCT03041935|DRUG|Remifentanil|See arm description
224119555|NCT01182623|OTHER|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
224119556|NCT01697527|BIOLOGICAL|aldesleukin|Given SC
223544178|NCT03041935|DRUG|Propofol|See arm description
223544179|NCT03041935|DRUG|Morphine|See arm description
223544180|NCT03041935|DRUG|Ondansetron|See arm description
223544181|NCT03041935|DRUG|Dexamethasone|See arm description
223544182|NCT03041935|DRUG|Ketorolac|See arm description
224119557|NCT01697527|DRUG|fludarabine phosphate|Given IV
224119558|NCT01697527|DRUG|cyclophosphamide|Given IV
224119559|NCT01697527|OTHER|laboratory biomarker analysis|Correlative studies
224119560|NCT01697527|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
224119561|NCT01697527|BIOLOGICAL|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
224119562|NCT01697527|RADIATION|fludeoxyglucose F 18|Undergo PET scan using \[18F\] FDG tracer
224119563|NCT01697527|PROCEDURE|positron emission tomography|Undergo fludeoxyglucose F18 PET
224119564|NCT00738543|OTHER|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
224119565|NCT03609658|BEHAVIORAL|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
224119566|NCT03609658|BEHAVIORAL|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
224119567|NCT02726932|OTHER|No intervention, merely observational|
223983781|NCT04201704|OTHER|Plasma volume|For patients designated as Bleeding, where International Normalized Ratio (INR) \> 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
223983782|NCT04201704|OTHER|Platelets volume|For patients designated as Bleeding, where platelets \< 50,000 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
223983783|NCT04089839|OTHER|Non-Interventional|Non-Interventional
223983784|NCT01161628|DRUG|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
223983785|NCT03436550|PROCEDURE|mpMRI|Multiparametric MRI
223983786|NCT03436550|PROCEDURE|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
223983787|NCT06413017|DRUG|Nimotuzumab|Nimtuzumab：400mg,i.v.,once a week,until tumor progression、Death or untalerable toxicity
223983788|NCT06413017|DRUG|ICIs(Immune checkpoint inhibitors)|Use it as it is describe in the instructions from the specification
223983789|NCT05832619|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.
223983790|NCT05832619|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
223983791|NCT05832619|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
223983792|NCT06172114|PROCEDURE|Alveolar ridge preservation using sticky bone|In the test group the xenograft will be mixed in with the L-PRF then placed into the socket.
223983793|NCT04605744|BEHAVIORAL|Smoking cessation counseling|"Patients will be given a briefing on the benefits of smoking cessation in the peri-procedural period around their interventional pain procedure. They will also be provided an informational sheet from the American Society of Anesthesiologists promoting cessation. The sheet will contain the 1-800-QUITNOW national hotline phone number.~Additional an enrollment folder will provided that contains referral information to Cooper's Tobacco Cessation program. This service, free of charge to Cooper Health patients consists of 5 tobacco cessation counselors who use personalized cessation plans, individual and group counseling cessations, Chantix, and education to promote smoking cessation."
223983794|NCT01589549|BIOLOGICAL|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
223983795|NCT02778906|DRUG|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
223983796|NCT02778906|DRUG|Placebo|Administration of the comparator s.c. weekly in comparable to verum
223983797|NCT05656963|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
223544183|NCT03041935|DRUG|Ropivacaine|See arm description
223544184|NCT01127620|DRUG|Bilastine|20 mg encapsulated tablets
223983798|NCT04363710|OTHER|Low Calorie Diet|800-1000 Kcal/day
223983799|NCT04641117|OTHER|Exercise|Walking and Power Training
223983800|NCT01232400|DRUG|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~1. Heart rate less than 70 bpm.~2. Systolic blood pressure less than 120 mmHg~3. Maximum dose of esmolol of 200 mcg/kg/minute is reached."
223983801|NCT00865137|DRUG|Tacrolimus, modified release|Oral
223544185|NCT01127620|DRUG|Cetirizine|10 mg encapsulated tablets
223544186|NCT01127620|DRUG|Placebo|encapsulated tablets
223544187|NCT02619747|DRUG|Compound Sodium Alginate Oral Suspension sachet|
223544188|NCT02619747|DRUG|Matched placebo|
223983802|NCT02240797|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
223983803|NCT00321490|DRUG|Quetiapine fumarate|
224294078|NCT06464497|BEHAVIORAL|Whole Foods MyPlate Group|Families will receive 4-weeks of rotating menus that have been designed as a part of our preliminary work and will be adapted to support adherence with the adolescent in mind (e.g., school lunch options, on-the-go snacks). Menus and diet recommendations will align with the current macronutrient nutritional goals outlined by the 2020-2025 DGA for age-sex groups. Participants will be encouraged to eat ad libitum (i.e., as desired until full) without calorie restrictions. MyPlate will be used by participants to implement the diet. During the study, adolescents and adults in the intervention group will receive a MyPlate Plan to support daily food group and macronutrient goals that align with the whole foods diet per caloric needs.
223983804|NCT00321490|DRUG|Duloxetine|
223983805|NCT00523952|DRUG|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
224119568|NCT06384924|DEVICE|Raman Spectroscopy handheld probe (EmVision, FL, USA)|The probe is approximately the size of a pen or pencil. The handheld probe is connected to the laser source using a cable. The probe is placed in light contact with the skin. The features of the laser light after it bounces off the skin is collected. This measurement can allow us to see tissue characteristics. This is a single session that will take approximately 15 minutes.
224119569|NCT06384924|DEVICE|Raman Spectroscopy laser source (Hubner Photonics Inc, CA, USA)|This light source will create the laser light that will pass through the cable and through the handheld probe onto the skin.
223727765|NCT03654651|DRUG|High carbohydrate snack|Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
223727766|NCT03982927|OTHER|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
223983806|NCT05819047|DEVICE|Functional test with a haptic device|Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
223983807|NCT01458847|DRUG|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
223983808|NCT01458847|DRUG|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
224294079|NCT00004230|DRUG|captopril|
224294080|NCT00004230|DRUG|cyclophosphamide|
224294081|NCT00004230|PROCEDURE|autologous bone marrow transplantation|
223727767|NCT00846131|DRUG|Sorafenib|Randomized to Y-90 ± Sorafenib
223983809|NCT01458847|DRUG|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
223983810|NCT00383409|DRUG|multivitamins|
223983811|NCT00383409|DRUG|placebo|
223983812|NCT03051893|DRUG|Chronocort|Modified formulation of hydrocortisone
223983813|NCT05176691|DRUG|HMPL-760|Administered orally QD for 28-day cycles
223983814|NCT05154032|OTHER|Traditional Float-REST Therapy|Traditional Float-REST therapy uses sensory deprivation tanks that consist of a very large warm water enclosure with a high concentration of Epsom salt to create a completely buoyant environment. This, along with a combination of temperature that is kept equal to skin temperature (94 degrees), allows the participant to eliminate the gravitational effects on the body, and along with lack of sound and low to no light (depending on comfort) allows the brain and body to completely relax for augmented physical and mental recovery. The room will contain an intercom that allows participants to communicate with study personnel in the event they need assistance. Participants will undergo 60 minute sessions three times a week for 3 weeks.
223983815|NCT04680637|DRUG|Efavaleukin Alfa|Administered as a subcutaneous (SC) injection.
223983816|NCT04680637|DRUG|Placebo|Administered as a subcutaneous (SC) injection.
224119570|NCT04765800|BEHAVIORAL|weekly, biweekly, or twice a week sessions of face-to-face outpatient psychotherapy|according to the German Psychotherapy Guidelines (Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie)
224294082|NCT00004230|PROCEDURE|peripheral blood stem cell transplantation|
224294083|NCT00004230|RADIATION|radiation therapy|
223983817|NCT04680637|OTHER|Standard of Care|Standard of care procedures and therapies for managing active systemic lupus erythematosus will be carried out according to each investigator's standard procedures.
223983818|NCT06276517|OTHER|questionnaire|self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.
223983819|NCT06276517|OTHER|SS-QoL|49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).
223983820|NCT06276517|OTHER|SF-36|multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment
223983821|NCT06276517|OTHER|CIQ-R|16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration
223983822|NCT06276517|DIAGNOSTIC_TEST|BREFF|rapid frontal efficiency battery, 6 tests from 0 to 3 on each side
223983823|NCT06276517|DIAGNOSTIC_TEST|MoCA|MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.
223983824|NCT06276517|OTHER|IADL|8 questions rated from 0 to 1 to assess functional outcome
223983825|NCT06276517|OTHER|mMRS|mMRS score from 0 to 4 to assess functional outcome
223983826|NCT06276517|OTHER|PCL-5|To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.
223983827|NCT06276517|OTHER|Brief-Cope|28-question self-questionnaires to study patients' coping strategies
223727768|NCT00846131|DRUG|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
223727769|NCT06066658|DEVICE|cranial electrotherapy stimulation (Alpha-Stim AID)|Alpha-Stim AID
223727770|NCT02068833|PROCEDURE|Gastrectomy|
223983828|NCT01822145|DEVICE|ICD|
223983829|NCT00097669|DRUG|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo|multivitamin
223983830|NCT00097669|OTHER|Placebo|
223983831|NCT05250960|DEVICE|SCD|Patient will receive 1L of LR and have SCDs applied 15 minutes before epidural placement and will be removed 1 hour after epidural placement
223983832|NCT00951678|OTHER|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
223983833|NCT01837498|DRUG|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
223983834|NCT01837498|DRUG|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
223983835|NCT01828385|DRUG|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
223983836|NCT01828385|DRUG|Saline|Saline + rocuronium + sugammadex
224119571|NCT00912015|DRUG|Tramadol OAD|
223727771|NCT02068833|PROCEDURE|BPD-DS|
223983837|NCT04544592|DRUG|CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells|The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF-19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
223727772|NCT04981743|DIETARY_SUPPLEMENT|Nigella Sativa capsule twice daily|investigate the safety and efficacy of Nigella Sativa versus Vitamin D3 versus Nigella Sativa / vitamin D3 combination as supplement for management of COVID-19 .
223983838|NCT06187064|OTHER|Mobile Van Clinic|The investigators will implement a pilot clinic one evening per week, with the primary goal of measuring a community-based extension of SHE Clinic's impact on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). The clinic will be dispatched with a driver, nurse, physician, and research assistant. The van clinic will be outfitted with space to obtain a confidential history and physical exam and include a space for sample collection. In addition to standard of care, the investigators will provide participants with rapid point-of-care HIV and STI testing, and HIV PrEP and MOUD counseling and prescriptions.
223983839|NCT02917421|RADIATION|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
223983840|NCT04551222|DRUG|probenecid|1 gr. orally of probenecid twice daily for 180 days
223983841|NCT04551222|DRUG|Placebo|identical tablets to probenecid
223983842|NCT01547221|DRUG|clotrimazole|single application of 1%clotrimazole ear drop
223983843|NCT01547221|DRUG|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
223983844|NCT05834023|DRUG|Bupivacaine-Lidocaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml
223983845|NCT05834023|DRUG|Bupivacaine|Infraclavicular block with 35 ml of the following anesthetic solution: Bupivacaine 0.5% + dexamethasone 4 mg + epinephrine 5 mcg/ml
223983846|NCT04099485|OTHER|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
223983847|NCT04055259|BEHAVIORAL|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
223983848|NCT04055259|BEHAVIORAL|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
223983849|NCT00206856|DEVICE|Triage® B-Type Natriuretic Peptide (BNP) Test|
223983850|NCT02336256|PROCEDURE|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
223983851|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-LAMax|Interventional device, LAMax left atrial appendage closure system
223983852|NCT04429646|DEVICE|Percutaneous left atrial appendage closure-Watchman|Interventional device, Watchman® LAA Closure Device
223983853|NCT06782217|BIOLOGICAL|VENOX|Treatment with allergy vaccine againts Vespula spp. (wasp) or Apis mellifera (bee), as per clinical indication.
223727773|NCT03274401|DEVICE|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
223727774|NCT03274401|DEVICE|5 day ECG patch|Selection of device for monitoring clinicians' choice
223727775|NCT00224315|DRUG|ziprasidone|
223727776|NCT00224315|DRUG|risperidone|
223727777|NCT05641051|DRUG|Metoclopramide|Cases will receive 10 mg intravenous metoclopramide every 6 hours.
223727778|NCT05641051|DRUG|Placebo|Cases will receive the same volume of IV placebo / 6 hours.
223983854|NCT04385758|OTHER|Diabetes-REM Program|A comprehensive community paramedicine management program designed to support adults with uncontrolled diabetes and a recent emergency department visit or hospitalization
224119572|NCT00912015|DRUG|Tramadol OAD|
223727779|NCT02000973|DRUG|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
223727780|NCT02000973|DRUG|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
223727781|NCT02000973|DRUG|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
223983855|NCT04360785|DRUG|Methotrexate|Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual
223983856|NCT00930956|DIETARY_SUPPLEMENT|Resistant Starch|30 g of carbohydrate per Arm
223544189|NCT03730610|BEHAVIORAL|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
223727782|NCT02000973|DRUG|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
223983857|NCT05258591|DEVICE|Axem Home|Rehabilitation system comprised of functional near-infrared spectroscopy headband (measuring from the motor cortex), as well as tablet-based software application (guiding stroke survivors through rehabilitation exercises for their hands/arms).
223983858|NCT05401292|DRUG|Hibiclens|antiseptic/antimicrobial skin cleanser for skin wound and general skin cleansing
223983859|NCT05401292|DRUG|Isopropyl Alcohol 70% Topical Application Solution|First aid antiseptic
224119573|NCT00912015|DRUG|Tramadol OAD|
224119574|NCT00912015|DRUG|Tramadol OAD 100mg|
223544190|NCT04593550|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223544191|NCT04593550|BEHAVIORAL|BrainCheck Cognitive Assessment|Undergo cognitive function assessment BrainCheck
223544192|NCT04593550|PROCEDURE|Cognitive Assessment|Undergo 3D-Confusion assessment
223544193|NCT04593550|PROCEDURE|Electroencephalography|Undergo EEG
223544194|NCT00004227|BIOLOGICAL|cetuximab|
223544195|NCT00004227|PROCEDURE|conventional surgery|
223544196|NCT00004227|RADIATION|radiation therapy|
223544197|NCT05659849|OTHER|Manual therapy techniques|Passive joint mobilization techniques are applied to the affected knee joint. For the first week (three sessions), the joint mobilization exercises included grade I or II rhythmic oscillations. During the following weeks, grade III or IV oscillation techniques were applied, depending on the level of tolerance and pain of each patient. In knee distraction, the patients are in a prone position with 50° knee flexion, and the physical therapist applies the techniques. The dorsal and ventral glides was performed with the patient in a supine position.
223983860|NCT05089747|BIOLOGICAL|Blood sampling for biomarker analysis (microRNA, circulating DNA…)|From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
224119575|NCT03550326|PROCEDURE|airway management|patients will be intubated or will be placed an airway device
223544198|NCT05659849|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) therapy treats pain using low-voltage electric currents. A small device administers the electrical current to or near nerves. TENS treatment inhibits or changes pain perception.
223544199|NCT04500457|BEHAVIORAL|Exposure-based Treatment for Perfectionism (ETP)|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
223544200|NCT02558101|BEHAVIORAL|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling"
224119576|NCT05647057|COMBINATION_PRODUCT|A: gelofusine + ringers|750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
224119577|NCT05647057|COMBINATION_PRODUCT|B: albumine + ringers|200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)
223544201|NCT02558101|BEHAVIORAL|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
223544202|NCT02243683|DRUG|AX-024.HCl|
223544203|NCT02243683|OTHER|Placebo|
223544204|NCT03302143|PROCEDURE|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
223544205|NCT03302143|PROCEDURE|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
223544206|NCT00000134|DRUG|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
223544207|NCT00000134|DRUG|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
223544208|NCT01079325|DRUG|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
223544209|NCT01079325|OTHER|Saline|
223544210|NCT02459561|DEVICE|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
223544211|NCT02459561|OTHER|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
223983861|NCT04287283|OTHER|Hyperbaric Oxygen|40-60 daily hyperbaric sessions, 5 days per week. Each session consists of 90 minutes exposure to 100% oxygen at 1.5-2 ATA.
223983862|NCT05475847|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection|C-TIL052A injection followed by injection of IL-2
223983863|NCT00014287|DRUG|gemcitabine hydrochloride|
223983864|NCT03061058|DRUG|Docetaxel|intraperitoneal and/or intravenous
223983865|NCT03061058|DRUG|Oxaliplatin|intravenous
224119578|NCT05647057|COMBINATION_PRODUCT|C: ringers + retrograde autologous priming|"1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol."
224119579|NCT01109901|PROCEDURE|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
224119580|NCT01109901|PROCEDURE|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
224294084|NCT04323098|BIOLOGICAL|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
223983866|NCT03061058|DRUG|Cisplatin|intraperitoneal
223983867|NCT03061058|DRUG|Irinotecan|intraperitoneal and/or intravenous
223983868|NCT03061058|DRUG|Pemetrexed|intraperitoneal and/or intravenous
223983869|NCT03061058|DRUG|S1|oral
223983870|NCT05606198|OTHER|Exposed to a SARS-CoV-2 infection|The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
223983871|NCT02435576|RADIATION|Radiotherapy (primary or postoperative)|
223983872|NCT02330276|DRUG|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
223983873|NCT04486976|DEVICE|Cornea/Anterior Segment OCT CASIA2|Cornea/Anterior Segment OCT CASIA2 The Tomey Cornea/Anterior Segment OCT CASIA2 is a non-contact, high resolution tomographic and biomicroscopic device indicated for the in vivo imaging and measurement of ocular structures in the anterior segment, such as corneal thickness. The Tomey Cornea/Anterior Segment OCT CASIA2 is indicated as an aid in the visualization of anterior segment findings.
223983874|NCT04486976|DEVICE|Optovue RTVue XR Avanti|Optovue RTVue XR Avanti The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
223983875|NCT01256671|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
223983876|NCT02246881|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
223983877|NCT05175469|DIAGNOSTIC_TEST|Flow cytometric analysis of neutrophil myeloperoxidase expression|"Performance of flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed on the same day of collection.~Blood samples will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8/12-color flow cytometer and analyzed using flow cytometry software. Myeloperoxidase expression in the peripheral blood neutrophil population within an individual subject will be expressed as intra-individual robust coefficient of variation (RCV)."
223983878|NCT00564148|DRUG|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
223983879|NCT02295176|DIETARY_SUPPLEMENT|Armolipid Plus|
223983880|NCT02295176|DIETARY_SUPPLEMENT|Placebo|
224119581|NCT04114994|DIAGNOSTIC_TEST|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
224119582|NCT03978494|DRUG|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
224119583|NCT03978494|DRUG|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
223544212|NCT06184191|OTHER|Robotic hand rehabilitation|Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
223544213|NCT00207220|PROCEDURE|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
223983881|NCT03718377|PROCEDURE|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
223983882|NCT03718377|PROCEDURE|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
223983883|NCT04587986|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
223983884|NCT05099289|DEVICE|AtaCor EV-ICD Lead|Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.
223983885|NCT04009629|BEHAVIORAL|Moderate Intensity Aerobic Exercise|Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
223983886|NCT05879003|DEVICE|novel brace with neuromuscular electrical stimulation|The symptomatic rotator cuff tear subjects had NMES on scapular muscles and adductor muscle
223983887|NCT05879003|BEHAVIORAL|scapular and adductor exercise|The symptomatic rotator cuff tear subjects conduct scapular and adductor exercise
223983888|NCT04398368|DRUG|Gemcitabine Hydrochloride|Given intravesically
223983889|NCT03414528|DIAGNOSTIC_TEST|Diagnostic Test|Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
223983890|NCT02421549|DEVICE|Unpaired remote monitoring transmitter|
223983891|NCT06957301|PROCEDURE|Intrathecal Fentanyl Group (F)|Group fentanyl (F), an injection of bupivacaine 0.5% (3.5 ml) + fentanyl 0.5 ml (25 μg) will be administered intrathecally.
224119584|NCT01356602|DRUG|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
223983892|NCT06957301|PROCEDURE|intrathecal dexmedetomidine group(D)|Group dexmedetomidine( D), dexmedetomidine will be first diluted in normal saline to obtain a dose of 5 μg in 0.5 ml. Then, an injection of bupivacaine 0.5% (3.5 ml) + dexmedetomidine 0.5 ml (5 μg) will be administered intrathecally. Drug will be administered over 10 seconds (s) using 5 cc syringes with cephalad orientation of the spinal needle bevel.
223983893|NCT06957665|DEVICE|T-scan Assisted Occlusal Adjustment with Stabilization Splint|Participants were treated with a custom-fabricated stabilization splint (Michigan-type) whose occlusion was adjusted using the T-scan system (Tekscan, Norwood, MA, USA) to measure and optimize occlusal force distribution. The T-scan system was used in conjunction with articulating paper to guide occlusal refinement until bilateral force balance was achieved.
223983894|NCT05258955|OTHER|Natural honey|Natural Sidr honey based mouthwash used as intervention group B (Arm Group B) for the reduction of plaque index
223983895|NCT05258955|DRUG|Chlorhexidine mouthwash|Chlorhexidine gluconate 0.12% mouthwash is used as intervention in Group A (Arm Group A) for the comparison of plaque reduction among group A and B
223983896|NCT03602586|DRUG|Epacadostat|Given PO
223983897|NCT03602586|BIOLOGICAL|Pembrolizumab|Given IV
223983898|NCT02371720|BEHAVIORAL|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
223983899|NCT03372590|OTHER|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
223983900|NCT03372590|OTHER|Standard of care|Standard NICU care
223544214|NCT00207220|PROCEDURE|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
223544215|NCT02264613|DRUG|ALRN-6924|ALRN-6924 will be administered as an IV infusion
223544216|NCT05476081|DRUG|Aspirin|Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
223544217|NCT05476081|DRUG|Clopidogrel|Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
223544218|NCT05476081|DRUG|Ticagrelor|Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
223544219|NCT03463837|OTHER|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
223544220|NCT03463837|OTHER|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
223544221|NCT03463837|OTHER|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
223983901|NCT04721782|OTHER|smoking|to assess the effect of smoking of fetal liver circulation with prenatal Doppler Ultrasonography
223983902|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
223544222|NCT03463837|OTHER|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
223544223|NCT03463837|OTHER|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
223544224|NCT03463837|OTHER|Smoking Cessation|No smoking for 5-days in confinement.
223544225|NCT03888248|DEVICE|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
223544226|NCT03888248|OTHER|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
223544227|NCT05414175|DRUG|Mavacamten|Specified dose on specified days
223544228|NCT04183712|DRUG|gemcitabine and oxaliplatin.|GEMOX Conventional chemotherapy:gemcitabine and oxaliplatin.
223544229|NCT04183712|DRUG|Afatinib|Target therapy Drug: afatinib
223544230|NCT03490929|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
223544231|NCT03490929|DEVICE|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
223544232|NCT04895371|OTHER|Tele-physiotherapy group|Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
223983903|NCT01175759|DRUG|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)"
223983904|NCT03257098|BIOLOGICAL|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
223983905|NCT03691545|BEHAVIORAL|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
223983906|NCT02627768|DRUG|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
223983907|NCT03232710|DRUG|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
223983908|NCT03232710|DRUG|abilify|Aripiprazol orodispersible tablets 10mg
223983909|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate.|Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF
224119585|NCT01356602|DRUG|Canakinumab lyophilized powder|Canakinumab lyophilized powder
224119586|NCT01356602|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide
224119587|NCT01356602|DRUG|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
223983910|NCT06130072|DRUG|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil|iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)
223983911|NCT00682227|BIOLOGICAL|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
223983912|NCT02646709|DRUG|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
223983913|NCT02646709|DRUG|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
223983914|NCT02646709|DRUG|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
224119588|NCT05232942|OTHER|Headache calendar completion|The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
224119589|NCT02146807|DEVICE|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
224119590|NCT05904405|OTHER|quationaire|"Data will be collected through a semi-structured interview administered questionnaire which includes:~1. Socio-demographic characteristics of women~2. Family planning practice: This will include number of living children, current use of FP method and its type, and suggested causes of discontinuation of FP, previous contraceptive use, and reason for the visit 3-Facility factors such as gender of providers, qualification of providers, type of the health facility.~4-Quality of contraceptive counseling (QCC) scale: it is a 22-item scale which measures the quality of care received by women during family planning visits. It includes : 1) information exchange, 2) interpersonal relations, and 3) disrespect and abuse in contraceptive counseling. The information exchange subscale consists of ten items, the interpersonal relationship subscale consists of seven items, and the disrespect and abuse subscale consists of five items."
224119591|NCT00887718|BIOLOGICAL|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
223544233|NCT04895371|OTHER|Control group|Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
223544234|NCT06669455|BEHAVIORAL|Personalized and combined lifestyle approach|In the SENSS approach five different and complementary lifestyle domains (self-management, exercise, nutrition, sleep and stress) are combined. The process will be guided by a lifestyle coach. The intervention is personalised for each participant. The personal goals are decided based on 'shared decision making' together with the lifestyle coach after using a Parkinson lifestyle decision aid. The level of guidance needed throughout the intervention is based on a 'stepped care approach'.
223544235|NCT05599100|BEHAVIORAL|STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)|For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
223544236|NCT03081689|DRUG|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
223544237|NCT03081689|DRUG|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
223544238|NCT03081689|DRUG|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
223544239|NCT05969275|BIOLOGICAL|Allogeneic umbilical cord-derived human mesenchymal stromal cells|Intravenous infusion of 300 million allogeneic, cryopreserved, umbilical cord-derived human mesenchymal stromal cells
223544240|NCT05969275|OTHER|Placebo|Intravenous infusion of placebo, with excipients
223544241|NCT06333496|DIETARY_SUPPLEMENT|GLP-1 Booster (GB)|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
223544242|NCT06537791|BEHAVIORAL|Home-Based Rehabilitation Program|Physical Therapy: 32 sessions, 60 minutes each Occupational Therapy: 8 sessions, 60 minutes each Nutrition Counseling: 4 sessions, 60 minutes each Psychological Support: 8 sessions, 60 minutes each Nursing and Podiatry Care: 4 sessions, 60 minutes each Total Duration: Approximately 4 months
223983915|NCT02646709|DRUG|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
223983916|NCT00848510|BIOLOGICAL|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease \[SD\], complete response \[CR\], or partial response \[PR\]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
223983917|NCT01399762|DEVICE|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
223983918|NCT04523207|DRUG|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
223983919|NCT04523207|DRUG|ADT|Participants will receive ADT intramuscular or subcutaneously during the main study.
223983920|NCT04523207|DRUG|Relugolix|Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
223983921|NCT06954194|BEHAVIORAL|Explicit intervention (Shape Coding+syntactic priming)|For explicit intervention, a syntactic priming task will be preceded by explicit teaching of the target structure using the Shape Coding scheme adapted to be age- and language (Cantonese)-appropriate. A different set of 10 sentences will be used for teaching in each explicit intervention session, with five sentences used as exemplars for the experimenter to explain the target structure, and the remaining five sentences for children to practice. The syntactic priming session will be presented as a game to sustain the children's interest and to disguise the purpose of the study. Each intervention session will contain 40 pairs of prime-target pictures, 40 pairs of control-target pictures, and 20 pairs of filler pictures, randomly presented to the experimenter and child and controlled by the experimenter. In total, there are 500 doses of SRC-O sentences (50 sentences x10 sessions).
223983922|NCT06954194|BEHAVIORAL|Implicit intervention (syntactic priming only)|For implicit intervention, the same 10 sessions of syntactic priming will be provided to the children without explicit instruction of the SRC-O structure using the Shape Coding System. Nonetheless, to make the exposure and dosage as comparable as possible between the two groups, children in the implicit intervention group will also receive 10 listening sessions before the syntactic priming sessions. During the listening sessions, the same sets of sentences used in the explicit instruction sessions will be presented and the children will be instructed to listen closely as the tutor reads aloud the SRC-O sentence. Each listening session will be followed by a syntactic priming session that is identical to that of the explicit intervention group. In total, there are also 500 doses of SRC-O sentences (50 sentences x10 sessions).
223983923|NCT02738957|BEHAVIORAL|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
223983924|NCT01439854|DRUG|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
223983925|NCT01439854|DRUG|Placebo|Patients are treated with placebo
224119592|NCT04990245|DIAGNOSTIC_TEST|endoscopic biopsies|patients with planned endoscopy for ulcerative colitis have endosocpic data recorded aswell as biopsy sampling and blood tests
224119593|NCT01115569|DRUG|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
223727783|NCT02198742|DEVICE|Miller blade|To participate in the study the subjects must have \>500 intubations with the miller blade.
223727784|NCT02198742|DEVICE|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
223983926|NCT05095428|BEHAVIORAL|PARTS Program|The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
223983927|NCT05095428|BEHAVIORAL|NBSR-T Program|The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.
224119594|NCT01707069|BIOLOGICAL|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
224119595|NCT04346134|PROCEDURE|mini-PNL|Percutaneous nephrolithotomy using miniature nephroscope. The procedure will be performed under general or spinal anesthesia under fluoroscopy guidance.
224119596|NCT04346134|PROCEDURE|SWL|Extracorporal shockwave lithotripsy using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
224294085|NCT01478828|DRUG|Lovastatin|oral qd varying dose escalations/de-escalations
223544243|NCT05762432|DEVICE|Wound Dressing|RTD Wound Dressing that is being investigated
223544244|NCT05762432|DEVICE|NHS Standard Dressing|This is the standard dressing used by NHS staff when currently dealing with a diabetic foot ulcer
223544245|NCT03549780|DEVICE|Stomal Occlusion Device|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
223544246|NCT03899415|BIOLOGICAL|TCR redirected T cells|HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.
223544247|NCT05124353|DRUG|Cerebrolysin|Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
223983928|NCT03020030|DRUG|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
224119597|NCT03830008|BEHAVIORAL|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
223983929|NCT03020030|DRUG|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
223983930|NCT03020030|DRUG|Cyclophosphamide|Standard of Care
224294086|NCT00328679|DEVICE|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
223727785|NCT02198742|DEVICE|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
223983931|NCT03020030|DRUG|CYTARABINE|Standard of Care
223983932|NCT03020030|DRUG|DASATINIB|Standard of Care
223983933|NCT03020030|DRUG|DEXAMETHASONE|Standard of Care
223983934|NCT03020030|DRUG|Dexrazoxane|Standard of Care
223983935|NCT03020030|DRUG|Doxorubicin|Standard of Care
223983936|NCT03020030|DRUG|ETOPOSIDE|Standard of Care
223983937|NCT03020030|DRUG|HYDROCORTISONE|Standard of Care
223983938|NCT03020030|DRUG|LEUCOVORIN CALCIUM|Standard of Care
223544248|NCT00361465|OTHER|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
223544249|NCT06073678|OTHER|Photobiomodulation|Irradiation with red laser on palate wound each 48h for 4 sessions.
223727786|NCT00856284|DRUG|Alogliptin|Alogliptin tablets
223727787|NCT00856284|DRUG|Metformin|Metformin tablets
223727788|NCT00856284|DRUG|Glipizide|Glipizide tablets
223983939|NCT03020030|DRUG|MERCAPTOPURINE|Standard of Care
223983940|NCT03020030|DRUG|METHOTREXATE|Standard of Care
223983941|NCT03020030|DRUG|NELARABINE|Standard of Care
224119598|NCT02427256|DEVICE|Topcon Specular Microscope SP-1P|
224119599|NCT02427256|DEVICE|Konan Specular Microscope CELLCHEK XL|
224119600|NCT05623904|PROCEDURE|Carotid Revascularization|Carotid Artery Stenting/Carotid Endarterectomy
223983942|NCT03020030|DRUG|Vincristine|Standard of Care
223983943|NCT00328562|DRUG|ZD1839 (Iressa)|
223983944|NCT00328562|RADIATION|Thoracic Radiotherapy|
223983945|NCT03509961|DIAGNOSTIC_TEST|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
223983946|NCT03509961|DRUG|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
223983947|NCT04014790|DRUG|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
223983948|NCT04014790|DRUG|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
223983949|NCT04608136|BEHAVIORAL|Diet intervention|Volunteers will be instructed on dietary recommendation throughout the research program to achieve a stable daily energy intake.
223983950|NCT01411098|RADIATION|3-dimensional conformal radiation therapy|Undergo 3D-CRT
223983951|NCT01411098|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
224294087|NCT04867187|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|20 minutes of high frequency (20Hz) rTMS.
224294088|NCT04867187|OTHER|Mirror therapy using virtual reality|active mirror-based therapy
224294089|NCT04867187|OTHER|Mirror therapy using sham mirror|20 minutes of sham mirror-based therapy
224294090|NCT06346340|DRUG|Miebo|Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
224294091|NCT06567041|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
223983952|NCT01411098|DRUG|cisplatin|Given IV
224294092|NCT06567041|DRUG|Placebo|Placebo will be administered subcutaneously.
223983953|NCT01411098|DRUG|etoposide|Given IV
223983954|NCT05311553|PROCEDURE|Zona pellucida thinning|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through thinning. The laser thinning will be performed by making 2-3 holes without reaching the inner membrane at a depth of60-80% of the Zona pellucida thickness.
223983955|NCT05311553|PROCEDURE|Zona pellucida drilling|Laser-assisted hatching will be conducted using a Laser System with a 1.48-μm diode laser at 300 m W through drilling. The laser opening will be made from the outside to the inside of the Zona pellucida.
223983956|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg (intravitreal) Personalized regimen arm: 1\~3 x 4-week loading injections and one 8-week injection, followed by Treat-and-extend (T\&E) regimen up to Week 56
224294093|NCT03817502|DRUG|Cariprazine|Cariprazine capsules, oral administration, once daily.
224294094|NCT03817502|DRUG|Placebo|Matching placebo capsules, oral administration, once daily.
223983957|NCT05666804|DRUG|Brolucizumab 6mg|Brolucizumab 6mg(intravitreal) Standard q12w/q8w regimen arm: 3 x 4-week loading injections and disease activity assessment at week 16 followed by q12w/q8w up to Week 56
223983958|NCT05061199|PROCEDURE|approach of anastomosis|The approach of anastomosis
224294095|NCT06315309|DRUG|ATG Combined with Tacrolimus and Mini Methotrexate|On Day -7, subjects will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). Subjects will receive a steroid injection 3 hours before every ATG infusion. On day -6, subjects will receive a small dose of ATG as an IV infusion. ATG will be repeated on days -5,-4 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -6 to -2 as daily IV infusions. Busulfan, a routine transplant chemotherapy will be given on days -5 to -2 as IV infusion. Subjects with lymphoblastic leukemia will receive an alternative regimen of cyclophosphamide, a routine chemotherapy on days -6 and -5, followed by total body radiation on days -3 to -1. Tacrolimus (standard immune suppression agent) starts on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate a standard immune suppression medication which is given IV on day +1,+3,+6, and +11 post-transplant. Blood draws on days -4,-1,+3,+7,+14 to measure ATG levels.
224294096|NCT02056704|DEVICE|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
223544250|NCT06073678|OTHER|Protection with surgical dressing|Protection of the palatal wound with surgical dressing for 7 days
223544251|NCT00994903|DRUG|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
223544252|NCT00994903|DRUG|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
223983959|NCT01610960|DEVICE|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
223983960|NCT01610960|DEVICE|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
223983961|NCT01240889|DRUG|Fluticasone|nasal spray
223983962|NCT01240889|DRUG|Fluticason|2 sprays per day in each nostril
223983963|NCT04849689|BEHAVIORAL|Whole-food, plant-based lifestyle|"The WFPB lifestyle program included:~1. Nutrition/plant-based food (energy intake: at least 90% of whole-food, plant-based diet and ≤ 10% of energy intake from plant-based meal replacements (PBMR) and dietary supplements (e.g., vitamin B12, D, and EPA and DHA omega-3 fatty acids).~2. Physical activity (habitual; organized and other).~3. Support system (lectures, workshops and individual nutrition counselling, grocery shopping assistance, cooking classes, regular measurements body composition, food logging, regular medical monitoring)."
223983964|NCT00976690|DRUG|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
223983965|NCT01793636|DRUG|AZD2014|AZD2014 vs Everolimus
223983966|NCT01793636|DRUG|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
223983967|NCT05875454|DIAGNOSTIC_TEST|Histopathological examination of tru-cut needle biopsy|Renal biopsies fixed in formalin from patients with suspected medical renal disease will be processed and examined for histopathological diagnosis.
224294097|NCT06091280|DEVICE|Respiratory Muscle Strength Trainers|Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
224294098|NCT05677490|DRUG|Fluorouracil|Given IV
224294099|NCT05677490|DRUG|Leucovorin Calcium|Given IV
224294100|NCT05677490|DRUG|Oxaliplatin|Given IV
224294101|NCT05677490|DRUG|Irinotecan|Given IV
224294102|NCT05677490|BIOLOGICAL|Nivolumab|Given IV
223544253|NCT01527994|DRUG|Aprepitant|Aprepitant 125 mg oral tablets
223544254|NCT01527994|DRUG|Placebo pill|Placebo oral pill- inactive compound
223983968|NCT01519778|DRUG|TR701 FA|1 tablet 200 mg once daily
223983969|NCT01603433|DEVICE|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
223983970|NCT01592812|DEVICE|electrical muscle stimulation|Duration of the stimulation 20 minutes
223983971|NCT04486313|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
223983972|NCT04486313|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
223983973|NCT04486313|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
223983974|NCT01704443|BEHAVIORAL|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
224294103|NCT05677490|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224294104|NCT05677490|PROCEDURE|Computed Tomography|Undergo a CT Scan
224294105|NCT05677490|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224294106|NCT05677490|OTHER|Questionnaire Administration|Ancillary studies
224294107|NCT05312229|BEHAVIORAL|Critical Time Intervention|An evidence-based, structured, and time-limited case management practice
224294108|NCT05312229|OTHER|External Facilitation|Site-specific support to help sites develop tailored plans to implement CTI.
223983975|NCT01704443|OTHER|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
223983976|NCT04476836|OTHER|Animal-Assisted Therapy|Animal-Assisted Therapy is when animals are used in goal-directed treatment sessions. These goals can be physical, mental, emotional or social.
223983977|NCT01657799|DRUG|Veliparib|Veliparib capsules for oral administration
223983978|NCT01657799|DRUG|Placebo|Placebo to veliparib capsules for oral administration
223983979|NCT01657799|RADIATION|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
223983980|NCT06011278|OTHER|Community Supported Videos|"Volunteers will be asked to create a maximum of three minutes of content that will psychosocially strengthen and motivate pediatric oncology patients. In the videos, information will be given about not using words such as cancer/oncology/tumor and not including private and personal information. Videos will be created in such a way that they can be edited, merged or deleted accordingly. The applications of volunteer individuals will be made through social media (Instagram), the collection of these videos will be followed in accordance with the voluntary consent forms, and the volunteers will be informed in detail about the use of visual and verbal data.~Children will be sent videos featuring different volunteers each week. The content of the videos will be controlled by the child clinical psychologist and researchers. Inappropriate videos will not be included in the research."
223983981|NCT05963009|DRUG|baxdrostat (formerly CIN-107) oral solution|5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study
223983982|NCT03021551|DEVICE|Rainbow sensor|Masimo Radical-7 and Root System with ORi parameter in all subjects are enrolled in the test group and receive an Rainbow sensor during their elective surgery.
223983983|NCT02449057|OTHER|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
223983984|NCT05142579|OTHER|ENDOTRAKEAL TUBE HOLDER|During this process, the tube detection of endotracheal tube holder was changed every 24 hours, and the tubes were repositioned every 4 hours. On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale. In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
223983985|NCT05142579|OTHER|BANDAGE|On the first day of the study, the oral mucosa of patients in this group was evaluated by the eliers oral evaluation guide.Then, with the Braden pressure wound risk diagnostic scale, patients ' Pressure Wound risk assessment was performed. Patients in this group were monitored for four days for oral pressure wound as of the day they were intubated. During this process, patients ' tube holder was changed every 24 hours and the tube was repositioned every 4 hours. At the end of the fourth day, wound evaluation of patients who developed pressure wounds was performed using the international pressure wound staging system and pressure ulcer Recovery Assessment Scale.In addition, pressure wounds of patients who developed pressure wounds were treated in accordance with the recommendation of a plastic surgeon.
224294109|NCT05312229|OTHER|Replicating Effective Programs|A stakeholder-informed training and technical assistance implementation strategy
223983986|NCT00947232|BEHAVIORAL|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
223983987|NCT00947232|BEHAVIORAL|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
223983988|NCT00765154|DRUG|darunavir|two 400mg tablets (800mg) once daily
223983989|NCT00765154|DRUG|ritonavir|one 100mg capsule once daily
223983990|NCT03084276|OTHER|High-fat meal|High-fat meal
223983991|NCT03084276|OTHER|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
224294110|NCT04442451|OTHER|Control Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
224294111|NCT04442451|OTHER|Blood Flow Restriction Exercise|Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
223544255|NCT06292819|DEVICE|Bright light|Bright light will use a 5000-10,000 Lux LED light source. Exposure is for 60 minutes daily, between 7pm and 9pm.
223544256|NCT06292819|DEVICE|Near-infrared light|Near-infrared light will use a wavelength of 850nm and a dose range of 1 - 6.5 joules/cm2. It is fixed on the neck with a band, the light source contacts the back of the neck, and is used for 60 minutes before going to bed.
223544257|NCT06292819|DEVICE|Bright light+ near-infrared light|After using the bright light device, then use the near-infrared light device on the back of the neck before going to bed.
223983992|NCT04597346|DEVICE|Bronchoscopic Transparenchymal Nodule Access|Bronchoscopic Transparenchymal Nodule Access (BTPNA) is locating the lesion in the lung tissue guided by the bronchoscope navigation system (LungPro) in the natural lumen (bronchus), and automatically calculates the best point of entry (POE) and the best route to avoid blood vessels. An opening is made from the POE under the endoscope, and is extended with a balloon dilator. Combined with X-ray fluoroscopy, a sheath with a blunt-tip core is used in the lung parenchyma to reach the lesion site, and then biopsy diagnosis or treatment.
223983993|NCT02871583|PROCEDURE|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
223983994|NCT02871583|PROCEDURE|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
223983995|NCT01765738|DEVICE|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
223983996|NCT02543099|DRUG|policosanol|Patients will receive policosanol 20mg Qd
223983997|NCT02543099|DRUG|placebo|Patients will receive placebo 20mg Qd;
223983998|NCT05147337|DRUG|E2511|E2511 tablets.
223983999|NCT05147337|DRUG|Placebo|E2511 matched placebo tablets.
223984000|NCT04212754|OTHER|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
223984001|NCT06487143|DRUG|Triptorelin pamoate（15mg）|Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.
223984002|NCT06487143|DRUG|Triptorelin acetate （3.75mg）|Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.
223727789|NCT02043249|OTHER|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
223727790|NCT04862364|OTHER|Endo Patients with Endometriosis Health Profile -30 (EHP-30) Test|The appointment of the patients consists of patients who were surgically diagnosed with Endometriosis in our clinic.
223727791|NCT05277701|DRUG|Lazertinib|Lazertinib 240mg daily (1 cycle of 21 days) will be applied to the all patients until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. However, beyond disease progression is allowed based on the investigator's decision. Doses should be taken approximately 24 hours apart at the same time point each day before eating meal under fasting. If it is more than 12 hours after the dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time.
223727792|NCT00664976|PROCEDURE|Electroconvulsive therapy|Electroconvulsive therapy
223727793|NCT00664976|OTHER|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
223727794|NCT03063554|PROCEDURE|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
224119601|NCT05623904|DRUG|Medical Treatment|"Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment."
224119602|NCT03648281|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
223727795|NCT03063554|PROCEDURE|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
223727796|NCT00617045|DRUG|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
223727797|NCT02266745|DRUG|PT-112 Injection|
224119603|NCT01913249|PROCEDURE|LIFT|Ligation of intersphincteric fistula tract
224119604|NCT01419275|DRUG|Xenon contrast agent|
224119605|NCT01419275|DEVICE|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
223727798|NCT02904512|DEVICE|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
223727799|NCT02904512|OTHER|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
223984003|NCT00412880|DRUG|BI 2536|Intravenous Infusion
223984004|NCT05995652|PROCEDURE|elastography|elastography
223984005|NCT00589537|OTHER|questionnaire administration|
223984006|NCT00589537|PROCEDURE|computed tomography|
223984007|NCT00589537|PROCEDURE|magnetic resonance imaging|
223984008|NCT00589537|PROCEDURE|quality-of-life assessment|
223984009|NCT01496365|DRUG|DS-5565 tablet|5mg and 10mg tablets
223984010|NCT01496365|DRUG|pregabalin capsule|75mg and 150mg over-encapsulated
223984011|NCT01496365|DRUG|Placebo tablet|
223984012|NCT01496365|DRUG|placebo capsule|
223984013|NCT01288209|DRUG|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
223984014|NCT01288209|DRUG|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
224119606|NCT03478319|DRUG|ACE-2494 or placebo|Recombination fusion protein
224119607|NCT01274442|OTHER|anamnesis|To update the anamnesis.
224119608|NCT01274442|PROCEDURE|oral examination|A brief clinical oral examination will be performed.
224119609|NCT01274442|PROCEDURE|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
224119610|NCT02523664|DRUG|Hydrocortisone|effects of hydrocortisone on memory while fMRI
224119611|NCT02523664|DRUG|Placebo|
223984015|NCT01288209|DRUG|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
223984016|NCT00565266|DRUG|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
223984017|NCT00565266|DRUG|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
223984018|NCT00565266|DRUG|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
223984019|NCT01015677|DRUG|MK-6913|
223984020|NCT01015677|DRUG|17-β estradiol|
223984021|NCT01015677|DRUG|Placebo to MK-6913|
223984022|NCT01015677|DRUG|Placebo to 17-β estradiol|
223984023|NCT01015677|DRUG|MK-6913 25 mg|
223984024|NCT02131727|BEHAVIORAL|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
223984025|NCT02131727|BEHAVIORAL|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
223984026|NCT06464952|DIETARY_SUPPLEMENT|Resistant potato starch|Prebiotic
223984027|NCT06464952|DIETARY_SUPPLEMENT|Powdered cellulose|Active comparator
223984028|NCT02830542|DRUG|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
223984029|NCT02830542|DRUG|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
223984030|NCT06296004|DEVICE|Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S|"Complete blood count (CBC) Erythrocyte sedimentation rate (ESR) measured by standard westergren method (mm/h).~Serum C-reactive protein (CRP) Liver function tests: aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~Renal function tests: serum creatinine and blood urea. Complete urine analysis.~Optical coherence tomography angiography (OCTA): . Bilateral common femoral vein (CFV) Doppler US"
223984031|NCT00814008|DRUG|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
223984032|NCT00814008|DRUG|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
223984033|NCT04623762|OTHER|Yoga|yoga application
223984034|NCT03265015|BEHAVIORAL|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
223984035|NCT03265015|OTHER|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas.
223984036|NCT00751322|OTHER|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
224119612|NCT06072001|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
224119613|NCT06072001|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
224119614|NCT01449552|DRUG|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
223984037|NCT00751322|OTHER|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
223984038|NCT03064152|DEVICE|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
223984039|NCT05317455|DRUG|Dichloroacetate|Dichloroacetate has a long safety record of administration to humans with a rare metabolic disorder for over 40 years. It has been given orally to patients with T2DM for up to a week without any problems and other laboratory or significant clinical adverse effects were not noted. It activates mitochondrial PDH flux, a key regulator of glucose oxidation.
223984040|NCT00209664|DRUG|irinotecan|
224119615|NCT01449552|PROCEDURE|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
224119616|NCT01449552|OTHER|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
223984041|NCT00209664|DRUG|S-1|
223984042|NCT04083924|OTHER|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
223984043|NCT00601432|DRUG|levofloxacin oral solution|
223984044|NCT06001151|DRUG|Cadonilimab|Patients receive cadonilimab (10mg/kg) every 3 weeks.
223984045|NCT06001151|DRUG|Pemetrexed|Patients receive pemetrexed (500mg/m2) every 3 weeks.
223984046|NCT06001151|DRUG|Carboplatin|Patients receive carboplatin (AUC=5) every 3 weeks for 4 cycles.
223984047|NCT01986296|DEVICE|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
223984048|NCT05759286|BEHAVIORAL|Aromatherapy|Aroma therapy will apply before 5 minutes and during IANB injection in children, aromatherapy will apply through a nasal mask similar to one that uses when applying nitrous oxide after putting a 3d printed perforated box on the mask's circular halo on its surface, in this box cotton bolls impregnated with 3 drops of a 15% lavender-neroli oils blend are placed and then the child will smell the scent of aromatic oil blend from the box's perforated bottom surface which faces child's nose
223984049|NCT05759286|BEHAVIORAL|Music|Music will be played from a speaker in the treatment environment and will start 5 minutes before anesthesia and will be played through the whole anesthesia process, the music used will be chosen by the child from his favourite cartoon
223984050|NCT05759286|BEHAVIORAL|Control|using a tell-show-do approach and children will put on a nasal mask without the box that contains an aromatic oil blend for the placebo effect
223984051|NCT03017937|DEVICE|Q-collar|capture ultrasound images at each pressure point
224294112|NCT02488031|BEHAVIORAL|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
224119617|NCT01449552|OTHER|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
224294113|NCT02488031|BEHAVIORAL|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
223984052|NCT05558436|DIAGNOSTIC_TEST|Genome-wide methylation profiling|Detection for colorectal tumor-specific ctDNA methylation biomarkers
223984053|NCT04487353|OTHER|Labor mechanism application developed with virtual reality technology (VRT-LMA)|"In phase I: VRT-LMA application was developed. (Female in lithotomy position, bony pelvis, flexion of the coccyx back about 2 cm and the Hodge plane were modeled as lines. The theory training to be given to the control group was prepared in accordance with the curriculum.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~II. In the first stage: Pre-test was applied to both groups. After the pretest, theory training was given to the control group and the posttest was applied. VRT-LMA was applied to the experimental group, and the posttest, sense of presence scale, and cognitive load scale were administered.~III. In the second stage: the post-test and analyzes were performed after 5 weeks in both groups."
223984054|NCT05471440|DRUG|Direct boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
223984055|NCT05471440|DRUG|Direct boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
223984056|NCT05471440|DRUG|Post-poned boost mRNA|Participants will be boosted with a covid-19 vaccin after priming with mRNA
223984057|NCT05471440|DRUG|Post-poned boost adeno|Participants will be boosted with a covid-19 vaccin after priming with adeno
223984058|NCT01646385|DRUG|etanercept|use as per routine clinical practice
224119618|NCT00344617|DRUG|Bevacizumab (tradename: Avastin)|
224119619|NCT03044015|BEHAVIORAL|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
224119620|NCT03044015|BEHAVIORAL|as usual|
224119621|NCT04489485|BEHAVIORAL|Teen Depression Module used for care|All teens coming for routine well child care to the enhanced group PCPs will have depression screening with strengths and goals and a depression screen with follow up suggestions for activities to help any depression symptoms, and treatment using the Teen Depression Module and offered a depression chabot. Suicide screening will be conducted.
224119622|NCT05055232|DRUG|XZP-3621|tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
224119623|NCT05862792|DRUG|Liposomal bupivacaine|We will inject liposomal bupivacaine into the surgical bed.
223544258|NCT02112656|DRUG|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
223544259|NCT02112656|DRUG|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
223544260|NCT06675461|BEHAVIORAL|Gold Card Intervention|A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.
223544261|NCT06675461|BEHAVIORAL|Treatment as usual|Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
224119624|NCT04940871|DRUG|Favipiravir HU 200 mg hard capsules|Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
224119625|NCT04940871|DRUG|Placebo HU|Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
224119626|NCT02304783|DRUG|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
224119627|NCT02304783|DRUG|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
224119628|NCT02304783|DRUG|paracetamol|Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
223984059|NCT01646385|DRUG|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
223984060|NCT01843777|BEHAVIORAL|Standard-of-Care|the standard of care in audiologic practice
223984061|NCT01843777|BEHAVIORAL|Treatment|motivational interviewing
223984062|NCT04324190|BEHAVIORAL|Guided online support program|"Guided online support program consisting of several modules; Module General information ... is an unspecific control module (providing general information on hygiene etc. with no expected effect on outcomes)"
223984063|NCT04324190|BEHAVIORAL|WHO recommendations (waiting condition)|"During the waiting period, a german translation of the WHO recommendations Coping with stress during the 2019-nCoV outbreak is provided"
223984064|NCT05145699|DEVICE|VR-based post-stroke hemineglect evaluation system|Evaluation system applied with virtual environment using Pico Neo 2 eye
223984065|NCT01821105|PROCEDURE|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
223984066|NCT01821105|PROCEDURE|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
223984067|NCT01821105|RADIATION|fludeoxyglucose F 18|Given IV
223984068|NCT01821105|PROCEDURE|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
224294114|NCT02488031|BEHAVIORAL|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
223727800|NCT01577329|BEHAVIORAL|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
223727801|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
223727802|NCT02642289|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
223727803|NCT02642289|OTHER|Placebo|Innocuous substance
223984069|NCT02978677|RADIATION|Radiotherapy 68 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton
223984070|NCT02978677|RADIATION|Radiotherapy 72 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton
223984071|NCT02978677|RADIATION|Radiotherapy 60 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton
224294115|NCT02488031|BEHAVIORAL|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
223727804|NCT00568074|DRUG|repaglinide|
223727805|NCT00568074|DRUG|Glurenorm®|
223727806|NCT00568074|DRUG|Glucobay®|
223984072|NCT04977115|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
223984073|NCT04977115|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
224294116|NCT02488031|BEHAVIORAL|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
224294117|NCT02488031|BEHAVIORAL|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
224294118|NCT02488031|BEHAVIORAL|Brief Test of Attention|A cognitive test assessing focus and attention.
223727807|NCT04140799|DEVICE|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
223727808|NCT00166673|DEVICE|FreeStyle Navigator Continuous Glucose Monitoring System|
223984074|NCT02846064|PROCEDURE|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
223984075|NCT04883060|DEVICE|midline localizer|a midline localizer device with a laser pointer is used to localize where the midline is likely to be located on the patient head prior to the surgery.
223984076|NCT03539068|BEHAVIORAL|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive::~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider)."
223984077|NCT05888844|DRUG|INCB099280|Administered as specified in the treatment arm description.
223984078|NCT05500833|OTHER|Multidimentional observation scale (MDP)|Upon arriving to the hospital (for an hospitalization or a consultation), a trained and declared investigator will inform the patients and their parents of the study, orally and using a written information note. Participation to the study will also be proposed to under aged children in an adequate language and a specific information note will be handed to them. If they wish, they will have a 20 min reflexion time before deciding on participating to the study.One the patient is included, the study will unfold as follows. First, Evaluation of acute dyspnea: general data and dyspnea scores will be collected upon inclusion, and dyspnea score will be collected once again 30 min later, and subsequently one a day until the end of hospitalization (test-retest). Data from clinical examination and treatment modifications will also be collected daily. Second, Evaluation of chronic dyspnea: general data and dyspnea scores will be collected upon inclusion and 1 to 1.5h later
223984079|NCT03672019|BEHAVIORAL|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
223984080|NCT04488666|DEVICE|npSIMS|incisional NPWT
223984081|NCT00520624|DEVICE|inspiratory muscle strength training|
223984082|NCT00520624|PROCEDURE|Surgery|
224119629|NCT05545527|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
224294119|NCT02488031|BEHAVIORAL|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
224294120|NCT02488031|BEHAVIORAL|Hand Grip Dynamometer|This tests measures hand grip strength.
224294121|NCT02488031|BEHAVIORAL|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
223984083|NCT03546387|OTHER|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
223984084|NCT03546387|OTHER|California Verbal Learning Test, Children's Version|Used to assess verbal learning and memory in children and adolescents
224294122|NCT02488031|BEHAVIORAL|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
223984085|NCT03546387|OTHER|Beery Developmental Test of Visual Motor Integration, 6th edition|Helps assess visual-motor skills in children and adults.
223984086|NCT03546387|OTHER|Grooved Pegboard Test|Measures dexterity
224119630|NCT05545527|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
224294123|NCT02488031|BEHAVIORAL|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
224294124|NCT02488031|BEHAVIORAL|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
223727809|NCT03103633|PROCEDURE|mean artery pressure|mean artery pressure declined with less than 20% of baseline
223727810|NCT03103633|PROCEDURE|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
224119631|NCT05545527|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
224119632|NCT03395171|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
224119633|NCT06579170|BEHAVIORAL|Cyanobacteria exposure during water contact|Cyanobacteria levels in beach water among participants who report water contact in the beach survey
223727811|NCT03103633|PROCEDURE|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
223984087|NCT03546387|OTHER|Behavior Assessment System for Children/Parent Report|The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
223984088|NCT03359564|PROCEDURE|micro endoscopic discectomy|the patients receive micro endoscopic discectomy surgery therapy
223984089|NCT05896189|BEHAVIORAL|Arm 1: Computerized Cognitive Training-Global Stimulation Games|The program will includes 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku. These games are well matched for time on task, novelty, and progression across levels. These are strategy-based games without adaptive, speeded, or accuracy-based algorithms underlying their personalization.
223984090|NCT05896189|BEHAVIORAL|Arm 2: Computerized Cognitive Training-Neuroplasticity Games|Cognitive training exercises include Double Decision (targets visual speed of processing and useful field of view), Target Tracker (targets visuospatial working memory capacity), Visual Sweeps (targets speed of processing), Syllable Stacks (targets auditory memory), Eye for Detail (targets eye movement speed and visuo-spatial working memory), Mind Bender (targets mental flexibility), Divided Attention (a shape-color-pattern inhibitory control exercise that focuses on rapidly determining whether flashing colors, shapes, or patterns meet a pre-specified rule), Right Turn (targets spatial reasoning).
223984091|NCT06214624|BEHAVIORAL|Two types of exercise interventions|"* HIIT. 3 times/week. This consists of a 4x4 HIIT (preferably in treadmill), 4 intervals of 4min at high intensity (85-95% HRmax) and 3 intervals of 3min of active resting at \~70% HRmax in between. All sessions including 10 min of warming-up and 10min of cooling down, resulting in 45min sessions. The first 2 weeks will progress from moderate-intensity training to HIIT for a better adaptation and acceptability of the program.~* HIIT + resistance. 3 times/week. The aerobic part consists of a 3x4 HIIT (preferably in treadmill), 3 intervals of 4min at high intensity (85-95% HRmax) and 2 intervals of 3min of active resting (\~70% HRmax) in between. The resistance part consists of 2 series of an 8-exercise circuit (combination of upper and lower body exercises using elastic bands and body weight) with a ratio of 20sec of effort - 40sec of resting. Sessions will have 5min of warming up in the treadmill and 5min of cooling down walking in the gym, comprising a total of 45min sessions."
223984092|NCT06962020|DRUG|first-line biologic：IFX|IFX is administered intravenously at a dose of 5-10mg/kg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg/kg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg/time, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.
223984093|NCT06962020|DRUG|first-line biologic:VDZ|IFX is administered intravenously at a dose of 5-10mg/kg, once at weeks 0, 2, and 6 (or 0, 1, and 5), and then every 8 weeks at a dose of 5mg/kg for maintenance treatment. VDZ is administered intravenously at a dose of 300mg/time, once at weeks 0, 2, and 6, and then every 8 weeks at a dose of 300mg for maintenance treatment.
223984094|NCT06531304|DEVICE|Lokomat Robot Assisted Gait Training|Patients will underwent 12 RAGT training sessions (3 times/week for 4 consecutive weeks, 45 min each including the time for wearing the harness and the exoskeleton) with the Lokomat device as add-on to conventional regimen (5 times/week, 80 min each). The Lokomat is a technologically advanced robot-assisted gait training device. Patients are supported in a harness above a treadmill while the robotic device assists the movements of their legs to provide physiological gait. As treatment progresses, weight bearing is increased and assistance from the robotic legs is reduced, requiring the patient to gradually assume greater responsibility for movements needed during walking.
224294125|NCT02488031|BEHAVIORAL|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
223984095|NCT04685447|PROCEDURE|Expanded Hemodialysis for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
223984096|NCT04685447|PROCEDURE|Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients|After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
224294126|NCT00111358|BEHAVIORAL|Lifestyle Modification|
224294127|NCT00111358|OTHER|No lifestyle modification|
224294128|NCT02278718|DRUG|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
224294129|NCT02278718|PROCEDURE|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
224294130|NCT03645499|DRUG|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
224294131|NCT03645499|DRUG|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
224294132|NCT03645499|DRUG|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
224294133|NCT03645499|DRUG|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
223984099|NCT04599855|DRUG|Esketamine 56 mg|Esketamine 56 mg will be self administered as nasal spray.
223984100|NCT04599855|DRUG|Esketamine 84 mg|Esketamine 84 mg will be self administered as nasal spray.
223727812|NCT03103633|OTHER|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
223984101|NCT04599855|DRUG|Placebo|Matching placebo will be self administered as nasal spray.
223984102|NCT06134622|DRUG|Intravenous thrombolysis plus tirofiban|Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.
223984103|NCT06134622|DRUG|Intravenous thrombolysis plus placebo|placebo (saline)
223984104|NCT02165397|DRUG|Ibrutinib|Participants will receive 420 mg of Ibrutinib orally.
223984105|NCT02165397|DRUG|Placebo|Participants will receive placebo capsules orally.
223984106|NCT02165397|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV.
223984107|NCT01836016|DRUG|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
224119634|NCT01568190|BIOLOGICAL|AVANZ MITE|Immunotherapy Dermatophagoides mix
224119635|NCT03402867|PROCEDURE|Deep dry needling|Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
224119636|NCT02776696|DEVICE|Advanced Hybrid Closed Loop System|
224119637|NCT02776696|DEVICE|Hybrid Closed Loop System|
224119638|NCT00159744|DRUG|Asenapine|Asenapine, 3 weeks
224119639|NCT00159744|DRUG|Olanzapine|Olanzapine, 3 weeks
223984108|NCT01836016|DRUG|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
223984109|NCT01836016|DRUG|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
223984110|NCT01836016|DRUG|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
223984111|NCT01836016|DRUG|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
223984112|NCT01836016|DRUG|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
223984113|NCT01836016|DRUG|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
223984114|NCT01836016|DRUG|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
224119640|NCT00159744|DRUG|Placebo|placebo, 3 weeks
223727813|NCT03372811|DRUG|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
223984115|NCT04799418|DEVICE|Open Label Extension Study|This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
223984116|NCT05387837|DRUG|D-4517.2|D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
223984117|NCT03297398|DRUG|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
223984118|NCT03297398|DRUG|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
224119641|NCT03175393|DEVICE|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
223727814|NCT03372811|DRUG|Vehicle|Vehicle
223727815|NCT03828357|OTHER|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
223727816|NCT06197854|PROCEDURE|Hernioplasty|Surgical hernioplasty
224119642|NCT02752867|DRUG|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
224119643|NCT02752867|OTHER|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
224294134|NCT03645499|DRUG|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
224294135|NCT04440449|BEHAVIORAL|Lifestyle App|A mobile app used to assist with lifestyle changes
223984119|NCT03297398|OTHER|Placebo|Placebo
223984120|NCT06555770|BEHAVIORAL|müzik müdahalesi|One group of patients will be listening to music for 15 minutes during the surgery, while the other group will be applied a stress ball.
223984121|NCT00424554|DRUG|temozolomide|"Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
223984122|NCT04106713|BEHAVIORAL|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
223984123|NCT04106713|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven \[behaviours\] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing \[behavioural\] and emotional awareness, and situational and interoceptive exposure to emotion cues."
223984124|NCT04106713|BEHAVIORAL|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
223984125|NCT02988349|OTHER|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
223984126|NCT02772718|DRUG|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
223984127|NCT02772718|DRUG|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
223984128|NCT02772718|DRUG|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
223984129|NCT02772718|DRUG|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
223984130|NCT02956083|OTHER|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
223984131|NCT02956083|OTHER|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
223984132|NCT02956083|OTHER|saline|Saline - no brand name
223984133|NCT04335747|OTHER|COVID-19 infection|Hospitalisation due to a confirmed COVID-19 infection
223984134|NCT02895334|BEHAVIORAL|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
224294136|NCT04440449|BEHAVIORAL|Look AHEAD behavior lifestyle intervention|A modified Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
223984135|NCT04431752|RADIATION|Magnetic Resonance Imaging Scan|The selection of patients with different level of OA will be made using the existing Kellgren-Laurence grading systems. The recruited patients will receive MRI exams with our enhanced sequencing. The OA level of each patient will be determined objectively through our quantitative OA grading system on MRI, which will be compared to Kellgren-Laurence grading results to evaluate the clinical performance of the MRI.
223984136|NCT00000177|DRUG|Estrogen|
223984137|NCT05965739|OTHER|BrainHQ/Active Comparator Activity|BrainHQ platform provides a set of cognitive activities, like puzzles and games, that are cognitively stimulating and actively engage participants but do not continuously and adaptively challenge them. These activities are designed to be a face-valid, active comparison approach to cognitive therapy, thus participants are blinded, attention time is matched, and overall user experience is identical to the active arms.
223984138|NCT05965739|OTHER|BrainHQ|BrainHQ is an online cognitive training program, and has been used to improve cognitive function among persons with cognitive impairment based on principles of neuroplasticity.
223984139|NCT05965739|OTHER|PASC CoRE|PASC CoRE is a manualized, adaptable cognitive rehabilitation intervention adapted from Goal Management Training and other evidence based programs that improve attention and executive functions, among other cognitive domains.
223984140|NCT05965739|DEVICE|tDCS-active|"Transcranial direct current stimulation (tDCS) will use a device specifically for home-based use. This device delivers a weak electrical current of 2.0 mA passed through two electrodes placed on the scalp to target the dorsolateral prefrontal cortex region of the brain. The electrodes are single-use for each session and can be attached to a headset by snapping into place.~The device has a user-friendly interface and a large-button keypad, making it is easy to use at home."
223984141|NCT05965739|DEVICE|tDCS-sham|tDCS devices used in the sham arm will be pre-programmed to deliver the same ramp up/down at the beginning/end of the 30-minute period as the active arm, except with no current otherwise delivered during the session.
223984142|NCT06105931|BIOLOGICAL|Hyperinsulinemic-euglycemic clamp|Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.
223984143|NCT06105931|OTHER|High Fat Mixed Meal Tolerance Test|After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.
223984144|NCT03587519|PROCEDURE|Early|Early ileostomy closure
223984145|NCT03587519|PROCEDURE|Late|Late ileostomy closure
223984146|NCT03431480|BIOLOGICAL|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
223984147|NCT04493697|DEVICE|Experimental 1|A ThermoNeuroModulation device will be worn by the participant that delivers warm waveforms in one ear (42 °C) and cool waveforms (17 °C) in the other ear.
223984148|NCT04493697|DEVICE|Experimental 2|A ThermoNeuroModulation device will be worn by the participant that will neither warm nor cool.
223984149|NCT05185297|OTHER|Recreational Futsal|Participants will participate in 2-3 weekly one hour sessions of Recreational Futsal, during 3 months, while maintaining standard care provided by the family physician.
223984150|NCT00236184|DRUG|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
223984151|NCT00236184|OTHER|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
223984152|NCT06380647|DRUG|Intravenous Acyclovir|Patients were observed for developing signs of eczema herpeticum and Tzanck smear was done every 10th day and first follow up at OPD after 7days of discharge following ward management protocol. If prophylactic acyclovir was efficacious then no eczema herpeticum developed. Patients who develop eczema herpeticum were isolated and were treated with injection acyclovir 15 to 30 mg/kg/day into three divided doses for 10 to 14 days.
223984153|NCT01397500|DRUG|Genotropin|Genotropin administered sc once a day by patient or caregiver.
223984154|NCT01397500|DRUG|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
223984155|NCT04768868|DRUG|IMP7068|To evaluate the safety tolerability, pharmacokinetics, and anti-tumor activity of the WEE1 inhibitor IMP7068 monotherapy in patients with advanced solid tumors
223984156|NCT01579721|PROCEDURE|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
223984157|NCT03211585|DEVICE|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
223984158|NCT02394964|OTHER|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
223984159|NCT01984671|BEHAVIORAL|Mobile Pain Coping Skills Training|
223984160|NCT00643435|BEHAVIORAL|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
224294137|NCT04440449|BEHAVIORAL|Abbreviated Look AHEAD behavior lifestyle intervention|An abbreviated Look AHEAD behavior lifestyle intervention with smartphone-based self-monitoring of diet and physical activity
224119644|NCT04040062|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
224119645|NCT02844101|DEVICE|GT3X Actigraph accelerometer.|
224119646|NCT01798784|BEHAVIORAL|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
223984161|NCT00643435|BEHAVIORAL|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
223727817|NCT03578991|DEVICE|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
223984162|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
223984163|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
223984164|NCT01476813|DRUG|Glycopyrrolate|comparison of different dosages of drug
223984165|NCT01476813|DRUG|Comparator|comparison of different dosages of drug versus comparator
223984166|NCT05580198|DIAGNOSTIC_TEST|Transcranial sonography.|Transcranial sonography examination to determine the brainstem raphe echogenicity.
223984167|NCT00000319|DRUG|Buprenorphine|
223984168|NCT04874623|OTHER|Collection of peripheral blood mononuclear cells|Analysis of specific memory B cells in CDI patients
223984169|NCT04696133|OTHER|fine motor skills|stretching and strengthening exercises in addition to exercises to enhance fine motor skills
223984170|NCT04696133|OTHER|sensory integration|"* Tactile stimulation~* Proprioceptive stimulation"
223984171|NCT02205775|DRUG|Atorvastatin|80 + 40 mg pre PCI
224119647|NCT01798784|BEHAVIORAL|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
224119648|NCT01798784|BEHAVIORAL|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
224119649|NCT03282201|OTHER|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
223984172|NCT02205775|DRUG|Rosuvastatin|40 + 40 mg before PCI
223984173|NCT02205775|DRUG|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
224119650|NCT03613090|DRUG|Collagen-hydroxyapatite scaffold (Syn-Oss)|The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
224119651|NCT03613090|DRUG|Collagen Scaffold (Colla-Plug)|Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
224119652|NCT00779090|PROCEDURE|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
224119653|NCT04769583|DRUG|metronidazole based quadriple therapy|patient randomized in QC will be treated by a double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), metronidazole (500 mg x 2 per day) and clarithromycin (500 mg x 2 per day)
224119654|NCT04769583|DRUG|placebo based quadriple therapy|patient randomized in TT will be treated by double dose PPI (esomeprazole: 40 mg x 2 per day) in combination with amoxicillin (1 g x 2 per day), clarithromycin (500 mg x 2 per day) and a placebo of metronidazole.
224119655|NCT02725892|OTHER|NIS observational stud|NIS observational study : Epidemiologic registry
223984174|NCT02205775|DRUG|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
223984175|NCT02205775|DRUG|placebo|twice before PCI
223984176|NCT04049370|OTHER|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
223984177|NCT05142839|PROCEDURE|EUS-CD|EUS-guided choledochoduodenostomy
223984178|NCT05142839|PROCEDURE|EUS-GEA|EUS-guided gastroenterostomy
223984179|NCT02584881|OTHER|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
223984180|NCT02875002|DRUG|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m\^2, is schedule to increase to 100mg/m\^2, and be administered on days 1 and 8 of each 28-day cycle.
223984181|NCT02875002|DRUG|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m\^2 , is scheduled to increase to 1000 mg/m\^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
223984182|NCT00133055|BEHAVIORAL|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
223984183|NCT00133055|BEHAVIORAL|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
223984184|NCT02312206|DRUG|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
224119656|NCT00592150|DRUG|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
224119657|NCT00592150|DRUG|Placebo|Placebo infusion for 3 hours
224119658|NCT04339946|DIAGNOSTIC_TEST|Three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
223984185|NCT02312206|OTHER|Placebo|Placebo
223984186|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
224119659|NCT04339946|DIAGNOSTIC_TEST|Two-dimensional rectal water contrast transvaginal ultrasonography (2D-RWC-TVS)|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution.
224119660|NCT04541849|OTHER|Critical Care|Critical care in the intensive care units
224119661|NCT01270672|DRUG|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
224119662|NCT01270672|DRUG|carvedilol|50 mg per os, single dose
223984187|NCT01144962|PROCEDURE|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
223984188|NCT00507156|PROCEDURE|Standard primary PCI|Acute re-opening of the occluded coronary artery
223984189|NCT00507156|PROCEDURE|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
223984190|NCT02196805|DRUG|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
224119663|NCT01270672|DRUG|placebo|capsules identical to MDMA or carvedilol
224119664|NCT00708604|PROCEDURE|Islet Transplantation|Islet Transplantation
224119665|NCT00708604|BIOLOGICAL|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
223984191|NCT02196805|DRUG|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
223984192|NCT00364377|DRUG|Sitagliptin|100 mg once daily
223984193|NCT00364377|OTHER|Placebo|once daily for duration of the study
224119666|NCT00742443|DRUG|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
224119667|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
224119668|NCT00742443|DRUG|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
224119669|NCT03025048|BEHAVIORAL|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
224119670|NCT01935908|DRUG|levetiracetam|
223727818|NCT03578991|OTHER|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
223727819|NCT06398535|DEVICE|magenetic resonance and ultrasound|examination of patient using magentic resonace coil for imaging of knee and comapring the results obtaines by ultrasound examination using the ulatrsound tarsnsducer .
223727820|NCT06167044|OTHER|thoracic mobilization|Thoracic mobilization will be performed for the thoracic spine mobilization group, thoracic mobilization therapy will be performed for five minutes.
223727821|NCT00607412|BEHAVIORAL|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
223727822|NCT00607412|BEHAVIORAL|12-step based supportive therapy|supportive psychotherapy based on 12-step model
223984194|NCT04502602|DRUG|Neratinib 160 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
223984195|NCT04502602|DRUG|Neratinib 200 mg|Determined RP2D dose
223984196|NCT04502602|DRUG|Neratinib 240 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
223984197|NCT04502602|DRUG|Niraparib 100 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
223984198|NCT04502602|DRUG|Niraparib 200 mg|Escalating doses to determine recommended phase 2 dose (RP2D)
224294138|NCT04664868|PROCEDURE|Sphinkeeper™|Sphinkeeper™ prostheses are self-expandable solid prostheses, made of inert Hyexpan (polyacrylonitrile) and are inserted into the intersphincteric anal groove.
223984199|NCT04502602|DRUG|Niraparib 300 mg|Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)
223984200|NCT04502602|DRUG|Niraparib at RP2D|Phase 1b: Determined dose
223984201|NCT04502602|DRUG|Neratinib at RP2D|Phase 1b: Determined dose
223984202|NCT02333266|OTHER|Candidemia|
223984203|NCT03157908|DEVICE|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
223984204|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
224119671|NCT05255055|OTHER|Physical Therapy|A manual therapy protocol and a therapeutic exercise protocol
224119672|NCT03144141|OTHER|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
224119673|NCT03125746|DRUG|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
224294139|NCT02439632|DRUG|prulifloxacin|
223984205|NCT00974181|DEVICE|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
223984206|NCT00336817|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
223984207|NCT00336817|DRUG|CellCept|CellCept 500mg or 1000mg BID for 90 days
223984208|NCT01028612|RADIATION|thermal ablation with external beam radiation|thermal ablation with external beam radiation
224119674|NCT03125746|DRUG|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
224119675|NCT01825590|OTHER|Dialysate and serum sodium concentration aligned|
223727823|NCT06255314|PROCEDURE|ventral hernia repair|"Laparoscopic transabdominal retromuscular repair is a minimally invasive approach to the open Rives Stoppa retromuscular sublay repair for ventral hernia.~In ventral hernia repair, it relies on initiation of dissection in one retrorectus space and then crossover to the contralateral retrorectus space The sublay mesh technique is an open surgical procedure for ventral and incisional hernias"
223727824|NCT01816633|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
223727825|NCT05076526|BIOLOGICAL|Hyaluronic acid (Synolis VA)|"Synolis VA harbours the following characteristics:~* NaHA (Sodium hyaluronate): 20mg/mL, biofermantative and pharmaceutical grade origin.~* Sorbitol: 40mg/mL~* Molecular weight of 2MDa, sterilized in moist heat"
223727826|NCT05076526|BIOLOGICAL|Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)|"The CM-PRP-HA tube is under vacuum containing the following:~* 2mL of hyaluronic acid gel in phosphate buffer (Sodium chloride, Dipotassium hydrogenphosphate, Potassium dihydrogenphosphate, Potassium chloride and water for injection). Not crosslinked Hyaluronic Acid (40mg per tube) is obtained from fermentation~* 3g of inert cell-selector gel~* 0.6mL of anticoagulant (sodium citrate 4%)"
223727827|NCT01524510|RADIATION|CT scan|low dose radiation scan without contrast without and with MRA
223727828|NCT01524510|DEVICE|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
223727829|NCT04945902|BEHAVIORAL|Synchronous Intervention|Weekly one-hour support groups. These support groups will meet virtually using a restricted WebEx channel and will be recorded. In this support group, students will discuss the weekly activities and build connection and support with each other. This group will be led by advanced doctoral students in counseling psychology and overseen by a counseling psychology faculty member, who is also a licensed psychologist.
223727830|NCT04945902|BEHAVIORAL|Asynchronous Intervention|The asynchronous intervention will provide access to information and resources for mental health support via Brightspace. The intervention will be six weeks long and each week will have a topic. The weekly topics include: (1) identifying feelings; (2) biology of emotions; (3) mindfulness; (4) recognizing and responding to stress; (5) mental health stigma; and (6) self-care/self-advocacy. Each week, you will be required to complete four types of activities: education, reflective exercises, an activity, and a short assessment. All of these resources will be provided on Brightspace to be completed on your own time but the activities must be completed during the week they are assigned. You will not have to interact with other international students if you are in the asynchronous intervention group.
223727831|NCT00358228|DRUG|Rimonabant|
223727832|NCT02480842|OTHER|Alloplastic free ROM|
223727833|NCT02480842|OTHER|Alloplastic limited ROM|
223727834|NCT02480842|OTHER|Oncoplastic free ROM|
223984209|NCT01846403|DEVICE|Semi-quantitative urine pregnancy test|
224119676|NCT00461955|PROCEDURE|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
223727835|NCT02480842|OTHER|Oncoplastic limited ROM|
223727836|NCT06520852|OTHER|Group using artificial intelligence tools in addition to traditional tools in preparing educational materials|Students in the intervention group used AI tools in addition to tools such as books, journals, and websites.
223727837|NCT04107194|DRUG|Pantoprazole 40mg|Proton pump inhibitor
223727838|NCT04107194|DRUG|Amoxicillin 1000 MG|Antibiotic
223984210|NCT04668703|PROCEDURE|Conbercept intravitreal injection|intravitreal injection of 0.5 mg conbercept at the conclusion of cataract surgery
223984211|NCT04068051|DRUG|AXS-07|AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
223984212|NCT02542098|DRUG|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
224294140|NCT02439632|DRUG|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
223984213|NCT01946555|DRUG|Morphine|
223984214|NCT01946555|DRUG|Fentanyl|
223984215|NCT01946555|DRUG|Methadone|
223984216|NCT01946555|DRUG|Buprenorphine|
223984217|NCT01946555|DRUG|Oxycodone|
223984218|NCT01946555|DRUG|Hydromorphone|
223984219|NCT01946555|DRUG|Tapentadol|
223984220|NCT03003806|DEVICE|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
223984221|NCT03003806|OTHER|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
224294141|NCT02439632|DRUG|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
223727839|NCT04107194|DRUG|Clarithromycin 500mg|Antibiotic
223984222|NCT04817605|OTHER|Therapeutic Exercise|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
223984223|NCT05779917|BIOLOGICAL|CAR-T cells|Transfer CAR-T cells into patients for anti-ancer therapy.
223984224|NCT00026182|BIOLOGICAL|rituximab|Given IV
223984225|NCT00026182|BIOLOGICAL|recombinant interleukin-12|Given SC
223984226|NCT00026182|OTHER|laboratory biomarker analysis|Correlative studies
223984227|NCT00026182|OTHER|questionnaire administration|Ancillary studies
223984228|NCT00026182|PROCEDURE|quality-of-life assessment|Ancillary studies
223984229|NCT00736125|DEVICE|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
223984230|NCT00736125|DEVICE|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
223984231|NCT02905409|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
223984232|NCT03757871|DEVICE|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
224119677|NCT04949880|DEVICE|Neurovascular Drug-Eluting Balloon Dilatation Catheter|The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
224119678|NCT03097328|DRUG|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
224119679|NCT03272854|OTHER|No intervention performed, the study is observational|
224119680|NCT02653976|DRUG|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
224119681|NCT02932722|OTHER|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
224119682|NCT02932722|DRUG|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
224294142|NCT02439632|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
223727840|NCT04107194|DRUG|Metronidazole|Antibiotic
223727841|NCT04107194|DRUG|Tetracycline 125 MG|Antibiotic
223727842|NCT04107194|DRUG|Bismuth Subcitrate|Antibiotic adjuvant
223984233|NCT03251612|DRUG|Based on sensitivity analysis|"* 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin"
223984234|NCT02567305|OTHER|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
223984235|NCT02877732|DEVICE|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
223727843|NCT04107194|DRUG|Rifabutin 150 MG|Antibiotic
223727844|NCT04107194|DRUG|Levofloxacin 500mg|Antibiotic
223984236|NCT02877732|OTHER|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
223984237|NCT02877732|OTHER|DEM|Participant will be asked to read list of numbers out loud from a card
223984238|NCT02877732|OTHER|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
224119683|NCT02932722|DRUG|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
224119684|NCT00883558|DRUG|Insulin Lispro|
224119685|NCT00883558|DRUG|regular human insulin|
224119686|NCT00883558|DRUG|recombinant human hyaluronidase PH20|
224119687|NCT00883558|DRUG|Insulin glargine|
224119688|NCT04772183|DEVICE|SpO2 and SaO2 comparison|"Several pulse oximeter will be place on patient find few minutes before arterial blood gases.~During an arterial blood sample, all SpO2 will be recorded"
224119689|NCT01598857|DRUG|Blisibimod|
224119690|NCT01598857|DRUG|Placebo|
224294143|NCT04546932|PROCEDURE|Lung-protective mechanical ventilation|Patients were provided with a tidal volume of 7 ml/kg IBW and an intraoperative 10 cmH2O in PEEP. Simultaneously, the alveoli were recruited applying a stepwise increase in PEEP (from 4 to 10 cmH2O for 3 breaths, 10 to 15 cmH2O for 3 breaths, and 15 to 20 cmH2O for 10 breaths) with maximum PIP = 50 cmH2O \[24\]. The recruitment maneuvers were performed right after intubation, 30 minutes after CO2 insufflation, then every hour, and finally before extubation.
223984239|NCT02877732|OTHER|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
223727845|NCT03256214|PROCEDURE|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
223984240|NCT06194682|PROCEDURE|Anterior cruciate ligament reconstruction|Anterior cruciate ligament arthroscopic reconstruction
223984241|NCT03292523|OTHER|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
223984242|NCT03790904|OTHER|Co.|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
223984243|NCT03790904|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
223984244|NCT03790904|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
224119691|NCT01133210|DRUG|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
224119692|NCT01133210|OTHER|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
224119693|NCT00625365|DRUG|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
223727846|NCT03256214|PROCEDURE|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
223727847|NCT00642577|DRUG|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
223727848|NCT00642577|DRUG|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
223727849|NCT00642577|DRUG|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
223727850|NCT00642577|DRUG|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
223727851|NCT02908555|OTHER|No intervention|This is a descriptive study with no intervention
223727852|NCT02715414|BEHAVIORAL|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
223727853|NCT02715414|BEHAVIORAL|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
223984245|NCT03231332|OTHER|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
223984246|NCT01927107|DIETARY_SUPPLEMENT|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
223984247|NCT03815864|DIAGNOSTIC_TEST|Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation|Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
223984248|NCT02119949|BEHAVIORAL|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
223984249|NCT02119949|BEHAVIORAL|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
224119694|NCT06186882|BEHAVIORAL|Action Video-Game|Thanks to their specific characteristics (presentation of multiple peripheral, rapidly moving, spatio-temporally unpredictable stimuli), Action Video-Games improve reading skills through their effects on the Magnocellular-Dorsal stream. Training will consist of 20 days of Action Video-Games sessions of 1 hour each, three times per week.
223727854|NCT00460408|DRUG|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
223727855|NCT01674270|DRUG|Degarelix|
224119695|NCT02673593|DRUG|DS102|
224119696|NCT02673593|DRUG|Placebo|
224119697|NCT06424873|RADIATION|PET/CT with FDG or FES|The study consists of an additional 50 minutes of imaging during the radiotracer's uptake phase prior to their clinical scan (standard of care).
224119698|NCT01152333|DRUG|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
224119699|NCT01152333|DRUG|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
224119700|NCT01766297|RADIATION|Proton Radiotherapy|
224119701|NCT02481336|OTHER|Questionnaires|EORTC CIPN20 and EQ-5D-3L
224119702|NCT02481336|PROCEDURE|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
223984250|NCT04919070|BEHAVIORAL|Connect for Caregivers|The intervention being studied is a single session guided behavioral intervention to improve social connectedness in caregivers of individuals with ADRD. The intervention, Connect for Caregivers, provides psychoeducation on the importance of social connectedness for health and well-being, includes a card-sort process to identify and prioritize barriers to connectedness, and provides personalized resources and strategies for caregivers to use to increase their social connectedness.
223984251|NCT01648595|DRUG|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
223984252|NCT01550432|DIETARY_SUPPLEMENT|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
223984253|NCT01550432|DIETARY_SUPPLEMENT|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
223984254|NCT01550432|OTHER|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
223984255|NCT02466698|PROCEDURE|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
223984256|NCT02466698|DRUG|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
223984257|NCT02466698|DRUG|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
223984258|NCT02466698|DRUG|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
223984259|NCT00890799|DEVICE|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
223984260|NCT00890799|PROCEDURE|surgery|Patient in this group received open surgical repair of pmVSD.
223984261|NCT05350488|OTHER|Informational Interview|Interview topics will fall in the broad categories of assessing medical knowledge and understanding of stroke, knowledge of medical and community resources, understanding and experience of post-stroke rehabilitation barriers faced upon reintegrating back home and ability to continue management of stroke diagnosis and suggestions for improvement.
223984262|NCT05350488|OTHER|Focus Group|Focus group topics will fall into the same broad categories as the informational interviews, however will be asked from a caregiver's perspective
223984263|NCT03211728|DRUG|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
223984264|NCT03211728|DRUG|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
223984265|NCT01694888|OTHER|lecture|Teaching documentation skill using lecture method
224119703|NCT02481336|GENETIC|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
224119704|NCT04523064|DRUG|Empagliflozin 25 MG|Patients with diabetes waiting for surgery will receive empagliflozin for at least three months.
223727856|NCT01674270|DRUG|Casodex|
223727857|NCT01674270|DRUG|LHRH Agonist|
223727858|NCT06507982|DEVICE|EWL|the working length determination with EAL method
223984266|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with polyvinylsiloxane transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
223984267|NCT05483114|PROCEDURE|Accuracy of indirect bonding of self-ligating brackets made with thermal glue transfers|The uppethat consists of positioning brackets on a study model and they will be extended to the patient's mouth. .r hemiarch of each patient will be randomly placed to be cemented with a transfer tray made of polyvinylsiloxane thermal glue, by means of the indirect technique
223984268|NCT02244268|DRUG|ALNA®|
224119705|NCT04906993|DRUG|camrelizumab； famitinib malate|Camrelizumab intravenously ; Famitinib Orally
224119706|NCT04906993|DRUG|platinum-based chemotherapy|Physician's choice chemotherapy
224119707|NCT04510194|DRUG|Metformin|Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
224119708|NCT04510194|DRUG|Placebo|placebo; appearance and size are exact matching to the three study drugs.
224119709|NCT04510194|DRUG|Fluvoxamine|An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
224119710|NCT04510194|DRUG|Ivermectin|An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
224119711|NCT05588674|DIETARY_SUPPLEMENT|Probiotic Supplement|8.5 week supplementation period. One capsule daily.
224119712|NCT05588674|OTHER|Placebo Capsule|8.5 week supplementation period. One capsule daily.
224119713|NCT05968352|DEVICE|Sacral Anterior Root Stimulation (SARS)|Comparison of High frequency versus low frequency stimulation
223984269|NCT03381469|PROCEDURE|Comprehensive periodontal treatment|The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs \> 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
223984270|NCT03381469|PROCEDURE|single visit supragingival scaling|The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
223984271|NCT06317402|OTHER|malnutrition questionary|At the patient's bed, using a questionnaire, evaluators take anthropometric measurements (weight, height, muscle strength) and collect biological data (albumin, pre-albumin, CRP, if available in the medical record) to establish nutritional status according to HAS criteria for undernutrition 2019-2021 and 2003-2007.
223984272|NCT02250534|OTHER|Very low nicotine content cigarettes|
223984273|NCT03840265|PROCEDURE|carotid endarterectomy|In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
223984274|NCT00217022|OTHER|Placebo|Placebo, 3 tablets daily
223984275|NCT00217022|DRUG|Budesonide|9 mg daily (three tablets)
223984276|NCT00850486|DEVICE|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
223984277|NCT02592499|DEVICE|HM III|
223984278|NCT02592499|OTHER|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
223984279|NCT01383239|OTHER|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
223984280|NCT01383239|OTHER|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
223984281|NCT00115947|DRUG|Terlipressin|
223984282|NCT04397146|DIETARY_SUPPLEMENT|Oral Nutrition Supplement (ONS)|Consumption of a portion of 300-320kcal (based on a standard single serve for ONS products) with a two hour follow-up. Products include: 2 Prototype Oral Nutrition Supplements (ONS) with 2.4kcal/ml and respectively 9.6% protein and 14.4% protein; 6 Commercially available Oral Nutrition Supplements with varying energy and protein levels.
223984283|NCT00945451|DEVICE|CK|Cyberknife Irradiation
223984284|NCT05951621|OTHER|Qigong|An ancient Chinese system of postures, exercises, breathing techniques, and meditations designed to improve and enhance the body's QI.
224119714|NCT06648161|OTHER|Labor Mirror|The labor mirror used in the second stage of labor allows the mother and midwife to observe the descent and birth of the baby during vaginal delivery and provides instant visualization of progress for the mother and midwife, especially in water births or water births
224119715|NCT04903548|PROCEDURE|SIRT with Y-90 resin microspheres|Selective internal radiation therapy (SIRT) with Y-90 resin microspheres (Y-90 resin SIRT) is an intra-arterial, catheter-based locoregional therapy that has been used to treat patients with unresectable HCC
223984285|NCT05951621|BEHAVIORAL|guidance of nutrition and exercise|Provide health promotion and guidance to participants on diet and physical exercise
223984286|NCT03120299|DRUG|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
223984287|NCT03120299|DRUG|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
223984288|NCT01963572|OTHER|SG will be screened every time when they visit the clinics.|
224294144|NCT04583696|DIETARY_SUPPLEMENT|The Investigation of effect on Blood Lipid parameters with walnut addition of Diet|Participants were asked to consume 30 g of walnuts daily for 21 days. Individuals have consumed walnuts on an empty stomach in the morning or with breakfast.
224294145|NCT00343434|BEHAVIORAL|behavioral dietary intervention|
223984289|NCT00005845|DRUG|tipifarnib|Given PO
223984290|NCT00005845|OTHER|laboratory biomarker analysis|Correlative studies
223984291|NCT00005845|OTHER|pharmacological study|Correlative studies
224119716|NCT05730829|OTHER|pain informed movement|group classes twice weekly for 8 weeks of neuromuscular exercise in combination with mind-body techniques such as breath regulation, muscle tension regulation, relaxation, mindfulness, awareness of pain related thoughts and emotions.
224119717|NCT05730829|OTHER|standard neuromuscular exercise|group classes twice weekly for 8 weeks of neuromuscular exercise.
224294146|NCT00343434|BEHAVIORAL|exercise intervention|
224294147|NCT00343434|DIETARY_SUPPLEMENT|soy isoflavones|
224294148|NCT00343434|DIETARY_SUPPLEMENT|soy protein isolate|
224294149|NCT00343434|OTHER|counseling intervention|
224294150|NCT00343434|OTHER|educational intervention|
224294151|NCT00343434|PROCEDURE|psychosocial assessment and care|
223984292|NCT01797978|DRUG|Intravenous methylene blue administration|Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
223984293|NCT01797978|DRUG|Placebo|
223984294|NCT01768741|PROCEDURE|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
223984295|NCT01768741|PROCEDURE|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
224119718|NCT05730829|OTHER|Pain Neuroscience Education (PNE)|The pain neuroscience education (PNE) will be delivered in videos addressing concepts such as the purpose of pain, neurophysiological changes of pain, movement guidelines when pain persists, and self-care techniques to impact neurophysiology and support moving with ease that include breath awareness and regulation, muscle tension regulation, awareness of pain related thoughts and emotions, relaxation, and body awareness.
224119719|NCT05730829|OTHER|Standard osteoarthritis (OA) education|The standard osteoarthritis (OA) education will address the following topics, OA prevalence, risk factors, symptoms, diagnosis, treatment, role of exercise, surgery, self-management
223984296|NCT05431725|BIOLOGICAL|Influenza Vaccine (Split Virion), Inactivated, Quadrivalent|The influenza vaccines (Split Virion), inactivated, quadrivalent are developed by Sinovac Biotech Co., Ltd.15 μg hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride,disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region.
223984297|NCT05431725|BIOLOGICAL|Control Quadrivalent influenza virus vaccine|The Control Quadrivalent influenza virus vaccines are manufactured by Sanofi and are purchased by Pontifical Catholic University of Chile.15μg HA of each of the four influenza strains in 0.5 mL of solution per injection.The routine of administration is intramuscular injection into deltoid region.
223984298|NCT02189577|DRUG|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
223984299|NCT02189577|DRUG|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
223984300|NCT02815137|OTHER|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
223984301|NCT01182181|DRUG|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
223984302|NCT01182181|DRUG|Anastrozole (Arimidex®)|1 mg Tablets
223984303|NCT01280383|DEVICE|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
223984304|NCT03845075|DRUG|Tesofensine/Metoprolol|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
223984305|NCT03845075|DRUG|Placebo|During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
224119720|NCT02880319|DRUG|Stereotactic Body Radiation Therapy (SBRT)|
224119721|NCT02880319|DEVICE|Stereotactic Linear Accelerator|
224119722|NCT05919108|PROCEDURE|Endocrine Therapy|Undergo endocrine therapy
224119723|NCT05919108|PROCEDURE|Biopsy of breast|Undergo breast biopsy
224119724|NCT05919108|DRUG|Neratinib|Taken by mouth
224119725|NCT05919108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224119726|NCT05919108|PROCEDURE|Mammogram|Undergo Mammogram
224119727|NCT05919108|PROCEDURE|Magnetic Resonance Imaging|Undergo breast Magnetic Resonance Imaging
224119728|NCT05919108|PROCEDURE|Breast Surgery|Undergo Breast Surgery
224119729|NCT05919108|PROCEDURE|Ultrasound|Undergo Ultrasound
224119730|NCT06828796|DRUG|Tacrolimus|Begins Day -1 and continues to Day +90 or Day +180 after transplant
224119731|NCT06828796|DRUG|Cyclophosphamide|Given Days +3 and +4 after transplant
223727859|NCT06507982|DEVICE|SWL|In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.
223984306|NCT02400814|DRUG|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
223984307|NCT02400814|RADIATION|Stereotactic Body Radiation Therapy|Undergo SAR
223984308|NCT02798692|BIOLOGICAL|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
223984309|NCT02798692|BIOLOGICAL|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
223984310|NCT02798692|BIOLOGICAL|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
223984311|NCT02798692|BIOLOGICAL|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
223984312|NCT02605096|PROCEDURE|MRI|Magnetic Resonance Imaging Scan
223984313|NCT02605096|PROCEDURE|X-ray|X-ray exam (conventional radiography)
223984314|NCT03585283|OTHER|Myofascial Group|Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
223984315|NCT03585283|OTHER|Sham Group|Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
223984316|NCT03856047|DRUG|NNC0174-0833|Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
224119732|NCT06828796|DRUG|Mycofenolate mofetil|Given Day 0 to Day +35 after transplant
224119733|NCT06301373|DRUG|Methotrexate Combined With Tofacitinib|Methotrexate Combined With Tofacitinib
224294152|NCT00343434|PROCEDURE|quality-of-life assessment|
224294153|NCT00287300|DRUG|Sulfadoxine-Pyrimethamine|
224294154|NCT00287300|DRUG|Azithromycin|
224294155|NCT00287300|DRUG|Artesunate|
224294156|NCT04579315|OTHER|Intervention group; NNRD group|The intervention is a whole food approach, meaning that the participants in the intervention group receives all daily food elements that they should consume
224294157|NCT02430805|OTHER|dna extraction and genotyping|blood and urine sample
224294158|NCT01264549|DEVICE|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
224294159|NCT00897949|DRUG|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
224294160|NCT00897949|DRUG|Comparator: placebo|Placebo to rizatriptan
224294161|NCT01763918|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223984317|NCT03856047|DRUG|Placebo (NNC0174-0833)|Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
223984318|NCT03856047|DRUG|Liraglutide 3.0 mg|Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
224119734|NCT06301373|DRUG|Methotrexate|Methotrexate
224119735|NCT05014776|DRUG|Tadalafil|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Tadalafil (20 mg) will be administered orally every day on days 3-21 for cycles 1-6.
224119736|NCT05014776|DRUG|Pembrolizumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Pembrolizumab (200 mg) will be administered IV on Day 1 of cycles 1-6.
224119737|NCT05014776|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (50mg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
224119738|NCT05014776|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 \[1 × 10\^9 colony forming units (CFU) in 100ml NS\] will be administered IV on Day 2 of Cycles 1-6.
224119739|NCT06275126|OTHER|CONSYDER decision aid|Web-based breast cancer surgery decision aid
224119740|NCT02983981|DRUG|Topicort Topical Spray|open label Topicort spray
224119741|NCT04650321|DRUG|Ocrelizumab at home|Patients will receive ocrelizumab infusion at home.
224294162|NCT01763918|DRUG|Placebo|Administered by subcutaneous injection
224294163|NCT01553747|DRUG|Eluxadoline|Oral tablets twice daily
224294164|NCT01553747|DRUG|Placebo|Oral tablets twice daily
224294165|NCT00114621|DRUG|Anthrax Vaccine|
224294166|NCT00114621|PROCEDURE|Blood Chemistry|
224294167|NCT00114621|PROCEDURE|Hematology|
224294168|NCT00114621|PROCEDURE|Urinalysis|
224294169|NCT01712919|RADIATION|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
224294170|NCT01712919|DRUG|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
224294171|NCT01712919|BIOLOGICAL|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
224294172|NCT06301061|DEVICE|Equistasi®|Four devices will be attached to the skin according the indication of the investigators for 6 hours/day every day except Thursday and Sunday
224294173|NCT06301061|DEVICE|Sham|Four devices similar to the active one but not able to deliver the microvibration will be applied to the patients
223984319|NCT03856047|DRUG|Placebo (Liraglutide 3.0 mg)|Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
223984320|NCT05506215|DEVICE|SynPath Acellular Dermal Matrix plus Off-loading Device|Application of SynPath
223984321|NCT05506215|DEVICE|Wound Dressing composed of 90% collagen and 10% Alginate plus Off-loading Device|Application Wound Dressing composed of Collagen and Alginate
223727860|NCT06507982|DEVICE|RWL|Radiographic method was used for determining the working length
223727861|NCT02829515|PROCEDURE|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
224119742|NCT04449068|OTHER|Neurological and neuropsychological Follow-up after deep brain stimulation|Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
224294174|NCT06301061|DRUG|Gabapentin; Pregabalin; Duloxetine; Amitriptyline|Patients will be treated with drugs (gabapentinoids, Serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, opioids) according to guidelines.
224294175|NCT06097793|BIOLOGICAL|KSD-101|Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
224294176|NCT06242561|BEHAVIORAL|Data collection from sepsis management|observational study
224294177|NCT04574128|PROCEDURE|No retransfusion of cardiotomy blood|No retransfusion of cardiotomy blood via heart- and lung mashine
224294178|NCT01570348|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
223984322|NCT00227123|DRUG|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
223727862|NCT03028714|BEHAVIORAL|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
223984323|NCT00176410|DRUG|fluvastatin|40mg fluvastatin daily
223984324|NCT01200927|OTHER|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
223984325|NCT06330987|DEVICE|electrocardiograph|Ten standard derivation electrodes were used to acquired FANTE registrations. The peripheral electrodes (Left (L), Right (R) and Foot (F)) were placed on the maternal abdomen in a triangle around the navel (orange) with lower apex, while the precordial ones (C1, C2, C3, C4, C5, C6) were put on an external circle. The Neutral electrode was on the right side of the patient abdomen. The software was configured so that the system acquired and wrote on disk 8 signals (2 bipolar and 6 referenced to the centroid of the three L, R and F leads) at 1000 sps with a resolution of 0.763uV. This high resolution is needed to resolve the very small voltage changes related to fetal cardiac activity.
223727863|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
223727864|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
223727865|NCT03971370|BIOLOGICAL|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
223727866|NCT01986985|DEVICE|PET/MRI system|Compared to PET CT
223727867|NCT00125801|DRUG|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
223984326|NCT03324971|OTHER|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines."
224119743|NCT04462848|BIOLOGICAL|anti-SARS-CoV-2 human convalescent plasma|Single transfusion. The total volume (mL) to be transfused will be based on participant weight (kg) and will be calculated as 5 mL/kg. The maximum volume to be transfused will be 500 mL.
224119744|NCT00964548|DRUG|Dantrolene|1.25 mg/kg IV once over 60 min
224119745|NCT00964548|DRUG|Dantrolene|2.5 mg/kg IV once over 60 min
224119746|NCT06381518|OTHER|Switch to SC CT-P13.|all patients in the study will switch from IFX to SC CT-P13
224294179|NCT01570348|DRUG|Cyclophosphamide|Given IV
224294180|NCT01570348|DRUG|Fludarabine Phosphate|Given IV
224294181|NCT01570348|OTHER|Laboratory Biomarker Analysis|Correlative studies
224294182|NCT01570348|DRUG|Mycophenolate Mofetil|Given PO
224294183|NCT01570348|DRUG|Mycophenolic Acid|Given PO
224119747|NCT05804305|DRUG|Misoprostol|Misoprostol is a prostaglandin E1 analogue
224294184|NCT01570348|OTHER|Quality-of-Life Assessment|Ancillary studies
224294185|NCT01570348|DRUG|Tacrolimus|Given IV or PO
224294186|NCT01570348|RADIATION|Total-Body Irradiation|Undergo TBI
224294187|NCT02011750|DRUG|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
224294188|NCT02011750|DRUG|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
224294189|NCT05166681|PROCEDURE|surgical wound suturing|single layer surgical wound suturing in comparison with the traditional multi-layer wound suturing
224294190|NCT03100734|BIOLOGICAL|Benepali|As specified in the treatment arm
224294191|NCT03100734|BIOLOGICAL|Enbrel|As specified in the treatment arm
224294192|NCT03295695|DIAGNOSTIC_TEST|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-\[18F\]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
223727868|NCT00182377|DRUG|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
223727869|NCT05442320|DEVICE|Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)|Toothpaste with 500 or 1000 ppm of fluoride
223727870|NCT04384328|OTHER|Early Support Programme in Orthophony|Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
223727871|NCT01354951|OTHER|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
223727872|NCT04130126|BEHAVIORAL|Taking cold showers|Showering behaviour
223727873|NCT06135701|DIAGNOSTIC_TEST|One-legged knee-extensor exercise with Doppler measurements|Doppler ultrasound is used while participants exercise according to the one-legged knee-extensor exercise model
223727874|NCT02734446|DRUG|Reuterin D3 drops|5 drops/day for 3 months
223727875|NCT02734446|OTHER|Placebo|5 drops/day for 3 months
223727876|NCT02288559|OTHER|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
223727877|NCT02288559|DRUG|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
223727878|NCT00054314|DRUG|ortataxel|
223727879|NCT00525460|BEHAVIORAL|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
223727880|NCT04597827|OTHER|Metacognition tests|Test on episodic or semantic memory
223727881|NCT04728581|DRUG|Mirtazapine|Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.
223727882|NCT04728581|DRUG|Quetiapine|Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.
223727883|NCT04728581|DRUG|Placebo|a gelatinous capsule without an active ingredient
223727884|NCT00909116|PROCEDURE|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
223727885|NCT03303079|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
223727886|NCT03303079|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
223727887|NCT03303079|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
223727888|NCT02005445|DEVICE|CPAP|Continuous positive airway pressure
223727889|NCT02005445|BEHAVIORAL|HLSE|Healthy living and sleep education
224119748|NCT05804305|DRUG|Placebo|Placebo contained substance that has no therapeutic value.
224119749|NCT00536731|DRUG|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
224119750|NCT00536731|DRUG|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
224119751|NCT00536731|DRUG|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
224119752|NCT06382974|PROCEDURE|Cyst enucleation and bone grafting|cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.
224119753|NCT03899194|DIETARY_SUPPLEMENT|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
223984327|NCT02660268|OTHER|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
223984328|NCT01902498|DRUG|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
223984329|NCT01902498|DRUG|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
223984330|NCT01902498|DRUG|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
223984331|NCT04587583|BEHAVIORAL|WeCareAdvisor|Tailored, internet-based software intended to assess, manage and track behavioral symptoms and their contributing factors and to instruct dementia caregivers in problem solving approaches (tailored strategies for in-home, medication-free behavior management) to address difficult or disruptive behaviors exhibited by the person with dementia. During the testing period participants will refer to the WeCareAdvisor when behavioral challenges occur.
223984332|NCT01278615|OTHER|Laboratory Biomarker Analysis|Correlative studies
223984333|NCT01278615|DRUG|Selumetinib|Given PO
223984334|NCT00040898|DIETARY_SUPPLEMENT|Sho-saiko-to|
223984335|NCT03602222|BEHAVIORAL|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
223984336|NCT03602222|BEHAVIORAL|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
223984337|NCT05188872|DIAGNOSTIC_TEST|68Ga-Pentixafor|Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
224119754|NCT03899194|DRUG|escitalopram|escitalopram 10-20 mg/d
224119755|NCT00152815|DRUG|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
223984338|NCT00905359|PROCEDURE|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
223984339|NCT00905359|PROCEDURE|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
223984340|NCT00749359|DRUG|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
223984341|NCT02138253|DRUG|IDN-6556|
223984342|NCT02138253|DRUG|Placebo|Placebo control
223984343|NCT00027976|DRUG|celecoxib|
223984344|NCT00027976|DRUG|Placebo|
223984345|NCT00809913|DRUG|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
223984346|NCT06454305|OTHER|Active cycle of breathing technique|Breathing control, thoracic expansion and forced expiratory training are the three components of ACBT. The purpose of the thoracic expansion phase is to facilitate the release of secretions, enhance ventilation, and supply the necessary volume for forced expiratory breathing. Secretions are moved into the central airways during the forceful expiratory exercise that follows The three stages of ACBT
223984347|NCT06454305|OTHER|Blow Bottle Technique|A 1-liter plastic bottle was filled with water to a height of 10 centimeters for this intervention. The water in the bottle was filled using a 30-cm-long tube that was placed 8 cm down. The participants were instructed to sit on a bed with comfortable position, Hold the bottle with one hand and the tube with the other Blowing Technique, Put the tube in mouth by holding lips firmly, Breath in through nose and out through mouth, Blowing enough water is bubbled, Short Breaks for 2 to 3 mints, When mucus rises up get out of it by coughing or huffing
224119756|NCT00152815|BEHAVIORAL|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
224119757|NCT01675531|DRUG|Targin|Single arm for Targin
224294193|NCT03295695|BIOLOGICAL|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-\[18F\]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
224294194|NCT03295695|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
224294195|NCT01408095|DRUG|LY2608204|Administered orally
223984348|NCT02654132|DRUG|Elotuzumab|
223984349|NCT02654132|DRUG|Pomalidomide|
223984350|NCT02654132|DRUG|Dexamethasone|
223984351|NCT03201536|DEVICE|conventional Suture|Sutures
223984352|NCT03201536|DEVICE|Zip3|wound closure device
223984353|NCT02572440|PROCEDURE|Sorin XTRA/Sorin Group,|
223984354|NCT06270277|DIAGNOSTIC_TEST|Pediatric Quality of Life Inventory (PedsQL)|Questionnaire
223984355|NCT06270277|DIAGNOSTIC_TEST|Strengths and Difficulties Questionnaire (SDQ)|Questionnaire
223984356|NCT02739776|DEVICE|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
223984357|NCT00894998|BIOLOGICAL|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
223984358|NCT00894998|BIOLOGICAL|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
223984359|NCT00157898|DRUG|MK0826; ertapenem sodium|
223984360|NCT00157898|DRUG|Comparator: ceftriaxone + metronidazole|
223984361|NCT00083330|DRUG|VRC-HIVADV014-00-VP|
223984362|NCT05612451|PROCEDURE|Regenerative Endodontic Procedures|Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology
223984363|NCT05612451|OTHER|non-setting calcium hydroxide|non-setting calcium hydroxide
223984364|NCT05612451|OTHER|modified triple antibiotic paste|modified triple antibiotic paste
224294196|NCT01408095|DRUG|Glimepiride|Administered orally
223984365|NCT01494545|DEVICE|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
223984366|NCT03379558|DRUG|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
223544262|NCT06681649|BEHAVIORAL|Intervention|"The intervention group will receive follow-up care through the specialized post-ICU follow-up clinic at KHSC at approximately 1- and 3-months following ICU discharge. Caregivers will also be invited to participate in the follow-up clinic along with the ICU survivor participant.~In addition to receiving specialized follow-up clinical care, ICU survivor participants and their caregivers will also receive the following additional items as part of a bundled care intervention program (see Appendix):~* Informational pamphlet on critical illness and expectations following ICU discharge~* Flyer on critical illness and expectations following ICU discharge (brief version, which may be placed on the participant's refrigerator or other location at home as a consistent reminder)~* Diaries in which the healthcare team, family members, and the patient themselves are able to journal their experiences, updates, progress, and barriers in the ICU and following discharge"
223544263|NCT05852327|OTHER|Observation only|Observation only
223984367|NCT01031849|DRUG|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
223544264|NCT04486040|PROCEDURE|Drainage|Use of the suction drainage after hip revision arthroplasty
223984368|NCT06210061|DRUG|Propofol-Fentanyl|Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery. Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation.
223984369|NCT06210061|DRUG|Propofol-Fentanyl-Dexmedetomidine|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition patients will receive Dexmedetomidine (0.5ug.kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr). Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation."
223984370|NCT06210061|DRUG|Propofol-Fentanyl-Sevoflurane|"Anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 ug/kg). Anesthesia will be maintained with propofol and fentanyl infusion, commenced at 10 mg/kg/hr and 0.5 ug/kg/hr respectively and adjusted to keep BIS between 40 \& 50 during surgery.~In addition the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 \& 50 . Minimal dose of atracurium 0.1 mg/kg will be given at induction to facilitate intubation"
223984371|NCT04758052|OTHER|Timing of placement|Simultaneous placement of tracheostomy and gastrostomy
223984372|NCT05441098|OTHER|Neoadjuvant therapy|Preoperative systemic therapy for breast cancer patients
223984373|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
223984374|NCT05238649|BIOLOGICAL|Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
224294197|NCT06367595|DRUG|Magnesium sulfate|IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
223984375|NCT05238649|BIOLOGICAL|SARS-Cov-2 Vaccine Inactivated|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
223984376|NCT05715736|DRUG|APB-R3|APB-R3 is formulated as a sterile solution containing APB-R3 as the active substance administered intravenously.
223984377|NCT05715736|DRUG|Placebo|0.90% Normal Saline only
224294198|NCT04666519|DIAGNOSTIC_TEST|Zonulin Biomarker|During revision hip and knee surgery, discarded fluid/blood will be tested for the presence of zonulin biomarkers
223544265|NCT04486040|PROCEDURE|No-drainage|Patients without drainage after surgery
223727890|NCT06476457|BEHAVIORAL|STAIR Coach|STAIR is a brief, low-intensity intervention targeting difficulties in affective and interpersonal regulation that tend to be a significant problem for those exposed to traumatic events.
223727891|NCT01010386|PROCEDURE|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
223984378|NCT02872012|DEVICE|Cryoanesthesia device|The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.
223984379|NCT02872012|DRUG|Lidocaine|Lidocaine applied to the non-cryoanesthesia eye.
223984380|NCT00741832|DEVICE|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
224294199|NCT04560348|OTHER|adventure-based cognitive behavioral intervention|The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
224294200|NCT01969292|OTHER|Colometer|Real time software based image analysis tool.
223984381|NCT00741832|OTHER|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
223984382|NCT04855357|BEHAVIORAL|Resident counselling|One hour, one-on-one counseling for residents
223984383|NCT04855357|BEHAVIORAL|Staff Training|A two-hour training for PSH staff on how to provide referrals to smoking cessation programs using materials previously developed from UCSF's 'Rx for change' curriculum for service providers, directed toward empowering PSH staff to provide referrals to local cessation services using the ask, advise, and refer approach. The training will address nicotine addiction, tobacco use among PSH residents, pilot data, brief cessation counseling (ask, advise, and refer), and local resources for cessation. Because PSH resident-PSH staff encounters will take place as part of routine care, the study team will request permission from a random sample of staff and resident dyads (n=40) to record these interactions to assess fidelity.
223984384|NCT01728623|DRUG|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
223984385|NCT02219399|DIETARY_SUPPLEMENT|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
223984386|NCT02219399|DIETARY_SUPPLEMENT|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
223984387|NCT02219399|DIETARY_SUPPLEMENT|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
223984388|NCT03842631|DRUG|Timolol Maleate 0.5% Oph Soln|External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
223984389|NCT05559632|PROCEDURE|osteotomy for implant placement|preparing the bone for implant placement
223984390|NCT00672282|DRUG|Bicalutamide|150mg p.o. daily
223984391|NCT00672282|DRUG|Placebo|
223984392|NCT01382862|OTHER|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
223984393|NCT02957695|DEVICE|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
223984394|NCT02957695|DEVICE|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
223984395|NCT00243022|DRUG|Boswellia serrata extract|given orally
223984396|NCT00243022|DIETARY_SUPPLEMENT|cyanocobalamin|given orally
223984397|NCT02085473|BIOLOGICAL|Tralokinumab 300 mg|Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
224119758|NCT05602441|BEHAVIORAL|VALID - diabetes supportive clubs|"The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities."
223984398|NCT01380977|BEHAVIORAL|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
223984399|NCT03517111|BEHAVIORAL|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
223984400|NCT03517111|BEHAVIORAL|Substance use prevention only|Parenting program focusing only on substance use prevention
223984401|NCT03517111|BEHAVIORAL|Academic success program|Program focusing on academic success and college acceptance
223984402|NCT04901845|OTHER|No intervention provided|Study is provided in the usual daily practice of the physicians without interventions made in their practice
223984403|NCT00853736|DRUG|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
223984404|NCT00853736|DRUG|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
223984405|NCT06171035|OTHER|3D-printed high-fidelity craniofacial manikin model education|Slide-based presention plus 3D printed model
223984406|NCT06171035|OTHER|Traditional model education|Slide-based presention plus traditional model
223984407|NCT00088647|DRUG|MST-997|
223984408|NCT00887029|DRUG|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
223984409|NCT00887029|DRUG|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
224119759|NCT04415216|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
224119760|NCT00623467|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
224119761|NCT02874690|DRUG|Methylphenidate|single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg
223984410|NCT03272529|OTHER|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
223984411|NCT03272529|OTHER|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
223984412|NCT03272529|OTHER|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
223984413|NCT04711486|DRUG|Contraloid acetate|Oral administration of drug substance capsules
223984414|NCT04711486|DRUG|Placebo|Oral administration of placebo without any exipients.
223984415|NCT06302725|PROCEDURE|Vaginal self sampling detecting HPV|IMIDs patients who are not up to date with CCS be included into the study to perform a vaginal self-screening (VSS) A positive VSS will be confirmed by a standard HPV test and management of the results of standard HPV test or VSS will be performed as planned following HAS guidelines. For women with a positive VSS, follow-up results (HPV test and cytology, biopsy, etc.) will be collected according to the usual procedures of the screening facility and in accordance with the recommendations of the Health authorities
224119762|NCT02874690|DRUG|Placebo|Placebo pill identical in appearance to methylphenidate
224119763|NCT02597673|OTHER|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
224119764|NCT02597673|DEVICE|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
224119765|NCT02597673|DEVICE|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
223727892|NCT01010386|PROCEDURE|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
223727893|NCT01174927|DRUG|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
223984416|NCT03592004|OTHER|neoadjuvant chemotherapy|neoadjuvant chemotherapy
223984417|NCT02944396|DRUG|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
223984418|NCT02944396|DRUG|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
223984419|NCT02944396|DRUG|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
223984420|NCT02944396|DRUG|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
223984421|NCT02944396|DRUG|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
223984422|NCT00621192|DRUG|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
223984423|NCT04769375|OTHER|Evaluation of pain|The presence of pain localization pelvic girdle pain will be questioned in the body chart. Inaddition to this, the level of the pelvic girdle pain will be evaluated by visual analog scale.
223984424|NCT04769375|OTHER|Application of pelvic girdle pain tests|The tests will be applied sequentially to investigate the presence and severity of the pain (Tests: Posterior Pelvic Pain Provocation, Patriarch FABER, Long Dorsal Sacroiliac Ligament Pain Provocation, Simpsis Palpation, Modified Trendelenburg and Active Straight Leg Raise)
223984425|NCT04769375|OTHER|Application of pelvic girdle questionnaire|Pelvic girdle questionnaire will be filled by pregnant women with pelvic girdle pain.
223984426|NCT05445063|BIOLOGICAL|Autologous iPSC-derived RPE|Autologous transplantation of iPSC-derived RPE
223984427|NCT04426435|DRUG|honey based (HB) syrup|"honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO)."
223984428|NCT06401837|BEHAVIORAL|Circadian based acupressure application|Acupoints include three points in hand: PC6 Neiguan, LI4 Hegu, HT7 Shenmen; two points in leg: SP6 Sanyinjiao \& ST36 Zusanli; and one point in back: DU14 Dazhui will be selected. The nurse will also teach patients and their caregiver how to apply acupressure on these acupoints. Self-administered acupressure application on the above acupoints will be performed and followed in the second week. A rehabilitation program and routine care will be scheduled as usual except for acupressure.
223984429|NCT04706793|DRUG|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
223984430|NCT04706793|DRUG|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
223984431|NCT05457166|DEVICE|KASPARD system for fall prevention in nursing homes|"All subjects will be monitored for 2 periods of 100 nights each. Recordings will be made continuously at night for the duration of the study Period 0: set-up, adjustment, recording (without alarm); This is a preparatory phase which is part of the usual use of the device.~Duration: 10 days Before period: The BEFORE period runs for 100 nights during which the device alarm is not activated, but the device records events.~After period: The AFTER period is 100 nights during which the device alarm is activated: Monitoring with recording + alarm activated (usual care + action if alarm is triggered)"
223984432|NCT01580683|DRUG|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
223727894|NCT01174927|OTHER|Placebo|Saline
223984433|NCT01580683|OTHER|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
223984434|NCT04416932|PROCEDURE|Ultasound|Evaluation of post-operative patients who have had total shoulder arthroplasty and will assess the integrity of the rotator cuff using ultrasound.
223984435|NCT01398098|DRUG|Sodium phosphate|32 tablets
223984436|NCT04438382|BIOLOGICAL|Infliximab|Given IV
223984437|NCT04438382|BIOLOGICAL|Intravenous Immunoglobulin Therapy|Given IV
223984438|NCT04438382|DRUG|Prednisone|Given IV or PO
223984439|NCT04438382|DRUG|Methylprednisolone|Given IV or PO
224119766|NCT05483816|COMBINATION_PRODUCT|VR+TENS|The subjects will receive a therapy that combines electrical pleasant stimulation of the nerves, synchronised with event in virtual reality
223727895|NCT01626560|DRUG|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
223727896|NCT01626560|DRUG|Vancomycin|Vancomycin 1g q12h 10 - 14 days
223727897|NCT03055351|BEHAVIORAL|Stop&Go Intervention|Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
223727898|NCT00759954|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
223727899|NCT00759954|DRUG|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
223984440|NCT04215315|OTHER|Retrospective observation|Case note and imaging review
223984441|NCT02844530|DRUG|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
224119767|NCT04109625|DIAGNOSTIC_TEST|Demonstrator MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
223984442|NCT02844530|DRUG|chemotherapy/ immunotherapy|
223984443|NCT03654768|DRUG|Bosutinib|Given PO
223984444|NCT03654768|DRUG|Dasatinib|Given PO
223984445|NCT03654768|OTHER|Laboratory Biomarker Analysis|Correlative studies
223984446|NCT03654768|DRUG|Nilotinib|Given PO
223984447|NCT03654768|DRUG|Ruxolitinib|Given PO
223984448|NCT03654768|DRUG|Imatinib|Given PO
223984449|NCT00499928|DRUG|SB-751689|
223984450|NCT04454099|DIAGNOSTIC_TEST|4 kind of FOBT and colonoscopy with pathological examination|Detect Hb in stool by 4 kind of FOBT and detect colon lesion using colonoscopy and pathological examination.
223984451|NCT00087945|DRUG|Abacavir sulfate|
223984452|NCT00087945|DRUG|Abacavir sulfate, lamivudine, and zidovudine|
223984453|NCT03713320|DRUG|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
223984454|NCT03713320|DRUG|Vorinostat|Daily doses of vorinostat throughout study treatment period
223984455|NCT01492621|DRUG|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
223984456|NCT01880437|DRUG|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
223984457|NCT01880437|DRUG|vismodegib|Cohorts 1 and 2: 150 mg orally daily
223984458|NCT04421339|DIETARY_SUPPLEMENT|Melatonin|Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
223984459|NCT04421339|OTHER|Placebo|Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
223984460|NCT02168322|DEVICE|collagen membrane|bovine collagen membrane used for selective tissue regeneration
223984461|NCT02168322|DEVICE|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
223984462|NCT02418962|BIOLOGICAL|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
223984463|NCT02418962|OTHER|Normal Saline|0.9% Sodium chloride solution for injection
223984464|NCT04181489|DRUG|Sintilimab|Sintilimab 200mg d0
223984465|NCT04181489|DRUG|Rituximab|Rituximab 375 mg/m2 d0
223984466|NCT04181489|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
223984467|NCT04181489|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
223984468|NCT04181489|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
223984469|NCT04181489|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
223984470|NCT01284712|BIOLOGICAL|blood sample|blood sample coming from therapeutic bleeding in hospital
223984471|NCT00027703|DRUG|gemcitabine hydrochloride|Given IV
223984472|NCT00027703|DRUG|cisplatin|Given IV
223984473|NCT00027703|BIOLOGICAL|bevacizumab|Given IV
223984474|NCT00027703|OTHER|placebo|Given IV
223984475|NCT00027703|OTHER|laboratory biomarker analysis|Correlative studies
224119768|NCT02676076|DRUG|CHF 5993 100/6/12.5 µg|
224119769|NCT02676076|DRUG|CHF 1535 100/6 µg|
224119770|NCT06351748|DRUG|Semaglutide|Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
224119771|NCT01430429|DRUG|NI-0801|
224119772|NCT04143971|OTHER|intermittent fasting diet|intermittent fasting diet
224119773|NCT04143971|OTHER|low calorie diet|continuous low calorie diet
224119774|NCT02795988|BIOLOGICAL|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
224294201|NCT01969292|OTHER|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
224294202|NCT02255682|DRUG|Simvastatin|
224294203|NCT02255682|DIETARY_SUPPLEMENT|Q10|
223984476|NCT06497790|DIAGNOSTIC_TEST|BJH-SDS Screenint Test|The test includes the assessment of a sufficient level of consciousness (Glasgow Coma Scale over 13 points), a check for facial paresis, soft palate paresis and tongue paresis followed by a water swallow test with 90 ml of water if the previous points are assessed as normal. The water swallow test checks for signs of aspiration (throat clearing, coughing or a change in voice quality)
224119775|NCT02795988|DRUG|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
224119776|NCT05501444|OTHER|Topical antiperspirant|The participants will be instructed to use topical antiperspirant (aluminum chloride, 15 percent every evening for four weeks. The PI will contact the participants every week. If the participant experiences that antiperspirant have an effect, the use of antiperspirant will be reduced from daily use to 3 times a week.
224119777|NCT03819244|DEVICE|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
224119778|NCT03819244|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
224119779|NCT05678790|OTHER|Passive Stretching|Sustained passive stretching of hamstring, tendo-achilles, and adductors 10 (30 s, with three repetitions, five times per week)
224119780|NCT05678790|OTHER|Mobilization|Grade four mobilizations is a stretching motion performed at the talocrural joint with anterior-posterior gliding. Mobilization was performed once a day, 6 times a day, and 5 times a week, only on both deformed feet of the older sibling
224119781|NCT05678790|OTHER|Muscle strengthening|Abdominal muscle strengthening exercises were given to both siblings once a day, 10 times a day, 5 times a week. In the supine position, the patients were asked to lie on their knees with the knees flexed. The hip extensors were trained in the prone position on the bed by resisting hip extension
224119782|NCT05678790|OTHER|Balance and Coordination|"The following exercises were applied 5 times a week, with 1o repetition once a day.~* Standing on one leg in front of the mirror,~* Tandem walking,~* Rhythmic Dynamic Stabilization,~* Swiss ball sitting (eyes open and closed),~* Counting the alphabet or numbers while marching"
223727900|NCT03852355|DRUG|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
223727901|NCT03852355|DRUG|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
223984477|NCT06497790|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|The FEES evaluates anatomical changes, functional disorders of the visible structures (e.g. recurrent paresis), saliva management, penetration and aspiration of food boluses in order to draw conclusions about the underlying pathomechanism of dysphagia. It is an established standard diagnostic procedure for stroke patients and, in addition to the diagnosis of dysphagia, also enables pathomechanism-guided therapy by speech therapists
223984478|NCT05395923|PROCEDURE|Suture|The pressure application will be applied before the incision on the palate.
223984479|NCT05395923|PROCEDURE|No Suture CTG -Control|A graft will be taken from the palate before the procedure is applied.
223984480|NCT02121327|OTHER|disease management|disease management program include self management education
223984481|NCT02121327|OTHER|usual care|usual care group receive regular outpatient treatment
223984482|NCT03260933|OTHER|No intervention given. This is a qualitative interview study|This is a qualitative interview study
223984483|NCT00336336|DRUG|n-3 PUFA|1 g die per os
223984484|NCT00336336|DRUG|Rosuvastatin|10 mg die per os
223984485|NCT00336336|DRUG|Placebo|1 gram c. per os
223984486|NCT00336336|DRUG|Placebo|10 mg c. per os
223727902|NCT03251820|DRUG|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
223727903|NCT01586390|OTHER|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
223727904|NCT01586390|OTHER|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
223727905|NCT02093481|OTHER|Test meal|
223727906|NCT02093481|OTHER|Reference|
223727907|NCT02093481|OTHER|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
223727908|NCT02093481|OTHER|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
223984487|NCT04909671|DEVICE|Gi Genius, Medtronic|GI geniusTM (Medtronic) is an artificial intelligence device designed and validated on a dataset of white-light endoscopy videos from high-quality randomized controlled trials for the detection of colorectal lesions during colonoscopy. Based on a deep learning system using convolutional neural networks, GI genius works in real-time side-to-side with the gastroenterologist during colonoscopy highlighting the presence of precancerous lesions with a visual marker (green box) in real time and designed to be integrated with the majority of colonoscopies.
223984488|NCT04909671|OTHER|White light standart colonoscopy|High definition white light endoscopy will be used during the scope withdrawal
224119783|NCT02834403|DRUG|L-NMMA|Nitric oxide synthase inhibitor
224119784|NCT02834403|DRUG|Docetaxel|Mitotic inhibitor, cytotoxic
224119785|NCT02834403|DRUG|Amlodipine|Long-acting calcium channel blocker
223727909|NCT01291758|DIAGNOSTIC_TEST|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
223727910|NCT00914524|DRUG|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
223727911|NCT03892109|OTHER|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
223727912|NCT03892109|DEVICE|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
223984489|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on conventional coronary angiography|Revascularized coronary arteries are decided based on conventional coronary angiography (quantitative coronary angiography)
223984490|NCT06028165|PROCEDURE|Coronary artery bypass grafting based on cardiac computed tomography-derived fractional flow reserve.|Revascularized coronary arteries are decided based on cardiac computed tomography-derived fractional flow reserve.
223984491|NCT02960971|PROCEDURE|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
223984492|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
223984493|NCT02569957|DRUG|Topotecan Hydrochloride|Given IV
224119786|NCT02834403|DRUG|Pegfilgrastim|Colony-stimulating factor
224119787|NCT02834403|DRUG|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
224119788|NCT03808714|BEHAVIORAL|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
224119789|NCT03808714|BEHAVIORAL|Control Group|Alabama Quitline
224119790|NCT02438436|DIETARY_SUPPLEMENT|simo decoction|
224119791|NCT02438436|OTHER|gum chewing|
224119792|NCT02341014|DRUG|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
224119793|NCT02341014|DRUG|Romidepsin|
224119794|NCT02341014|DRUG|Lenalidomide|
224119795|NCT00004297|DRUG|diazepam|
224119796|NCT00004297|DRUG|lorazepam|
224119797|NCT01157871|DRUG|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
224119798|NCT01157871|DRUG|placebo|"Pharmaceutical form:solution~Route of administration: intramuscular"
224119799|NCT04667195|OTHER|Clinical assessment|"Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results"
223984494|NCT02569957|DRUG|Acetylcysteine|Given IV and PO
223984495|NCT03990636|DRUG|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
223984496|NCT00177021|DRUG|Aldara Cream 5%|
223984497|NCT03276390|BEHAVIORAL|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
223984498|NCT02864823|PROCEDURE|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
223984499|NCT02893098|DRUG|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
223984500|NCT02893098|DRUG|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
223984501|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR and i-PRF|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with i-PRF
223984502|NCT05010785|PROCEDURE|Immediate implant placement and alveolar ridge splitting with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
223984503|NCT03537235|DEVICE|Libramed|
223984504|NCT03537235|DEVICE|Placebo|
223984505|NCT04839055|DRUG|Coenzyme A Combined With Abiraterone|Abiraterone 4 pieces per day. Coenzyme A 200U
223984506|NCT04839055|DRUG|Abiraterone|Abiraterone
223984507|NCT02468908|DRUG|Molgramostim|
223984508|NCT02468908|DRUG|Placebo|
223984509|NCT04226092|DEVICE|GPSkin Barrier Pro|This study is a pilot study to determine if this device produces similar readings than Aquaflux AF200 for TEWL/skin barrier on patients with and without atopic dematitis (AD).
223984510|NCT04226092|DEVICE|Aquaflux AF200|This study is a pilot study to determine if this device produces similar readings than GPSkin Barrier Pro for TEWL/skin barrier on patients with and without atopic dematitis (AD).
223984511|NCT01993277|DEVICE|Nexalin Brain Stimulator|
223984512|NCT01993277|DEVICE|Fischer Wallace Stimulator|
223984513|NCT01993277|DEVICE|David Delight Stimulator|
223984514|NCT01993277|BEHAVIORAL|Relaxation Therapy|
223984515|NCT04354168|BEHAVIORAL|mHealth Application|Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
223984516|NCT02530788|DRUG|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
223984517|NCT02530788|DRUG|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
223984518|NCT01781832|DEVICE|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
223984519|NCT02920255|OTHER|Diagnostic|Measurement of spinal tilt
223984520|NCT05820113|DEVICE|Deep learning based reconstruction of T2-TSE sequence|A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.
223984521|NCT05710289|BIOLOGICAL|Immune Responses|To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510\_004 study.
223984522|NCT03062085|OTHER|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
223984523|NCT02719743|BIOLOGICAL|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
223984524|NCT02461862|BEHAVIORAL|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
223984525|NCT02461862|PROCEDURE|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
224119800|NCT03241797|PROCEDURE|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
224119801|NCT03384849|DIAGNOSTIC_TEST|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
224119802|NCT05222347|DIETARY_SUPPLEMENT|Olive Leaf Tea|Olive-leaf tea (OLT) is widely used in the traditional medicine in the Mediterranean region. Due to the high concentration of phenolic compounds, of which most abundant is oleuropein, interest in olive leaf has increased recently \[22, 23\]. The components of the olive leaves are known for their immune-modulatory, anti-inflammatory, antioxidant, hypoglycemic, antihypertensive, antimicrobial, and anti-atherosclerotic effects \[24, 25\]. Although its antiviral mechanism of action is not fully known, many studies have been conducted on the antiviral effects of olive leaf extract .
224119803|NCT04705597|DRUG|BGE-175|Drug
224119804|NCT04705597|OTHER|Placebo|Placebo
224119805|NCT03691623|DRUG|EDP-938 Dose 1|Oral suspension for 5 days
224119806|NCT03691623|DRUG|EDP-938 Dose 2|Oral suspension for 5 days
223984526|NCT02461862|PROCEDURE|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
223984527|NCT01440010|RADIATION|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
223984528|NCT01209598|DRUG|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
224119807|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
224119808|NCT03691623|DRUG|EDP-938 Dose 3|Oral suspension for 5 days
224119809|NCT03691623|DRUG|EDP-938 Dose 4|Oral suspension for 5 days
224119810|NCT03691623|DRUG|Placebo|Oral suspension for 5 days
224119811|NCT02816710|DRUG|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
224119812|NCT03797950|BEHAVIORAL|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
224119813|NCT03797950|BEHAVIORAL|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
224119814|NCT02136823|DRUG|sugar pill|
224119815|NCT02136823|DRUG|Riluzole|
224119816|NCT02136823|DRUG|Isradipine|
223727913|NCT03892109|OTHER|Gingitrac|packed into the sulcus
223727914|NCT02232633|DRUG|BBI503|
223727915|NCT00434655|PROCEDURE|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
223727916|NCT04431648|DRUG|DEFINITY|MRI-guided ultrasound-stimulated microbubble-treatment
223984529|NCT01209598|DRUG|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
223984530|NCT01971281|DEVICE|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
224119817|NCT02136823|DRUG|Memantine|
224119818|NCT02136823|PROCEDURE|Therapeutic muscle stretching|
224119819|NCT02284399|OTHER|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
224119820|NCT05413499|OTHER|Biomarkers research|For a part of the included population, the children with a mTBI and without indication of CT scan, a non-routine blood sample will be planned
224119821|NCT00005999|DRUG|arsenic trioxide|
224119822|NCT01511289|DRUG|Imatinib|400mg/Tab, QD
223984531|NCT01971281|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
223984532|NCT01971281|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
223984533|NCT01582373|BEHAVIORAL|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
223984534|NCT04606147|PROCEDURE|Serratus Anterior Plane Block|The block is performed with full aseptic precautions.in lateral position \&arm abduction. US probe placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib.With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, the skin and subcutaneous tissue can be topicalized. Then, using ultrasound guidance, A regional block needle is advanced in-plane at an angle of approximately 45 degrees towards the fifth rib.Correct location of the needle tip in the fascial plane deep to serratus anterior muscle will be confirmed by injecting 0.5-1 ml normal saline and seeing hydrodissection of fascial plane between SAM and 5th rib. After aspiration to avoid intravascular injection 30 ml of levobupivacaine 0.25% is injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.
223984535|NCT04606147|PROCEDURE|Erector spinae plane block|The block is performed with full aseptic precautions at T5 level. T5 transverse process is identified by us as flat, squared-off acoustic shadows with only a very faint image of the pleura.In longitudinal us view following layers will be visible superficial to transverse processes: skin and subcutaneous tissue, trapezius, erector spinae muscle.Skin is topicalised , then echogenic block needle inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% was injected and separation was seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm was used
223984536|NCT02846493|DRUG|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
224119823|NCT01511289|DRUG|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
224119824|NCT00273858|OTHER|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
224119825|NCT01564290|DIETARY_SUPPLEMENT|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
224119826|NCT01564290|DRUG|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
224119827|NCT00682825|BEHAVIORAL|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
224119828|NCT00682825|BEHAVIORAL|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
224119829|NCT03652415|DEVICE|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
224119830|NCT04302883|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE)|Ultrasound of heart chambers via esophagus
224119831|NCT04302883|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopical swallowing study
224119832|NCT02232516|DRUG|romidepsin|Given IV
224119833|NCT02232516|DRUG|lenalidomide|Given PO
224119834|NCT02232516|OTHER|laboratory biomarker analysis|Correlative studies
224119835|NCT01279135|RADIATION|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
223727917|NCT04431648|DEVICE|Sonalleve Focused Ultrasound Device|Sonalleve Focused Ultrasound Device
223984537|NCT02846493|DRUG|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
223984538|NCT02601209|DRUG|Pazopanib|Given PO
223984539|NCT02601209|DRUG|Pazopanib Hydrochloride|Given PO
223984540|NCT02601209|DRUG|Sapanisertib|Given PO
223984541|NCT02594410|DEVICE|stent|patients receiving renal artery stenting for renal artery atherosclerosis
223984542|NCT02594410|DRUG|Aspirine|100mg Qd
223984543|NCT02594410|DRUG|Clopidogrel|75mg Qd
223984544|NCT02594410|DRUG|Lercanidipine|10-20mg Qd
223984545|NCT03004586|DEVICE|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
223984546|NCT03004586|DEVICE|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
224119836|NCT01279135|RADIATION|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
224119837|NCT05552378|DEVICE|Multi-Gyn FloraFem|Vaginal gel packed in 5 single use plastic tubes.
223984547|NCT03004586|PROCEDURE|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
223984548|NCT03439618|OTHER|time-restricted feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.
223984549|NCT03439618|OTHER|continuous feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
223984550|NCT02599922|BIOLOGICAL|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
224119838|NCT02567344|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
224119839|NCT02567344|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
223984551|NCT01390142|PROCEDURE|Control|Deflated blood pressure cuff placed on upper arm for 30min
224119840|NCT03389126|DRUG|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
224119841|NCT03845036|BEHAVIORAL|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
223984552|NCT01390142|PROCEDURE|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
223984553|NCT01390142|PROCEDURE|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
223984554|NCT02912754|DRUG|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
223984555|NCT02912754|DRUG|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
223984556|NCT02804399|DRUG|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
223984557|NCT02804399|DRUG|rifampin|600 mg QD from day 1 to day 12 in period 2.
223984558|NCT02970097|DRUG|20ml bolus of 0.5% ropivicaine|local anesthetic
223984559|NCT02970097|DRUG|10 ml of 0.5% ropivicaine|local anesthetic
223984560|NCT02970097|DRUG|Midazolam|1-2 mg of medication given intravenously before nerve block
223984561|NCT02970097|DRUG|Fentanyl|50-100 mcg of medication given intravenously before nerve block
223984562|NCT05995093|OTHER|no intervention|no intervention
224119842|NCT03845036|BEHAVIORAL|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
224119843|NCT00748059|PROCEDURE|Standing or upright tilt|stand upright or tilt table test
224119844|NCT00748059|PROCEDURE|Microneurography|Recording from sympathetic nerve
224119845|NCT00748059|PROCEDURE|QSweat|quantitative sweat testing
224119846|NCT00748059|DEVICE|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
224119847|NCT00748059|DRUG|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
224119848|NCT00748059|DRUG|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
224119849|NCT00748059|PROCEDURE|BodPod|Determination of body composition
224119850|NCT00748059|PROCEDURE|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~1. 0.5% proparacaine (Alcaine, Allergan, Inc)~2. Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~3. 0.5%, 1% tropicamide (Mydriacyl, Alcon)~4. Over-the-counter preservative-free artificial tears~5. 0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~6. 1% cyclopentolate hydrochloride (Alcon)"
224119851|NCT00748059|PROCEDURE|Sleep study|Recording of sleep pattern overnight
223727918|NCT03271112|OTHER|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
223727919|NCT01359449|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
223984563|NCT01314599|DRUG|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
223984564|NCT03636373|DRUG|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
224119852|NCT00748059|PROCEDURE|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
224119853|NCT00748059|PROCEDURE|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
224119854|NCT00748059|PROCEDURE|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
224119855|NCT00748059|PROCEDURE|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
224119856|NCT00972244|DRUG|Dapagliflozin|once daily, 12 weeks
223727920|NCT01359449|BIOLOGICAL|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
224119857|NCT00972244|DRUG|Placebo|once daily, 12 weeks
224119858|NCT02871180|DIETARY_SUPPLEMENT|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
224119859|NCT02871180|OTHER|No late night snack|Patient consumed no nutrients at late night.
223727921|NCT05678309|OTHER|Blood samples|"At inclusion :~* 52.5 ml of blood :~* 24 ml plasma~* 20 ml serum~* 6 ml DNA~* 2.5 ml RNA"
223727922|NCT05678309|OTHER|skin swab sample|At inclusion a skin swab sample will be collected
223727923|NCT05678309|OTHER|skin biopsy sample|At inclusion a skin biopsy sample will be collected
223984565|NCT03636373|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
223727924|NCT05678309|OTHER|Questionnaires|At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
223727925|NCT04464629|DRUG|Dextenza|Intracanalicular sustained release dexamethasone insert 0.4 mg
223984566|NCT02150395|OTHER|music therapy|
223984567|NCT01313169|OTHER|EMR Reminder|EMR reminders displayed
224119860|NCT00366730|DRUG|Nitazoxanide|
224119861|NCT00038688|BEHAVIORAL|Peer HIV Education Program|
224119862|NCT06144528|OTHER|QT robot|In a single session each child will be video-recorded while performing the task. The participant subjects will perform the same task at two different times, once with the human operator and once with the Qt robot. Both tasks will have a duration of approximately 4 minutes. During the first minute, both the operator and the Qt will introduce themselves and ask four questions to the child to deepen the acquaintance. In the second minute, the operator/Qt will tell a story. In the third minute, the operator/Qt will ask to imitate 4 motor movements, while in the fourth minute, the operator/Qt will ask to imitate 4 facial expressions.
224119863|NCT03566524|DIETARY_SUPPLEMENT|Citrulline|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
224119864|NCT03566524|DIETARY_SUPPLEMENT|Alanine|Ketosis prone diabetes patients (n=10) will be randomly assigned to receive either dietary supplement of citrulline or alanine as placebo. They will then cross over to the other supplement.
224119865|NCT05582811|DRUG|Dose Riociguat 2,5 or 5mg|A selective stimulator of soluble guanylate cyclase (sGC)
224119866|NCT05582811|DRUG|Riociguat|A selective stimulator of soluble guanylate cyclase (sGC)
224119867|NCT05582811|DRUG|Placebo|Placebo
224119868|NCT05201859|DRUG|Sintilimab|Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
224119869|NCT05201859|DRUG|Capecitabine|An oral anticancer agent that can be converted into 5-Fu in vivo.
224119870|NCT05897346|OTHER|'Learning while serving' training program|The training program will involve training workshops, hands-on sessions, and a smoker referral competition.
224119871|NCT05897346|OTHER|Usual care|A 3-hour training workshops in the control group are regarded as usual care since the training workshops are also conducted regularly to other secondary or tertiary schools.
224294204|NCT05331157|DEVICE|ultrasound|the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
224294205|NCT01524250|DRUG|corticosteroids|1250mg of oral prednisone daily for 3 days
223984568|NCT01313169|OTHER|EMR Reminder + Panel management|EMR Reminder + Panel management
223984569|NCT06148402|DRUG|Fruquintinib plus camrelizumab and capecitabine|fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
223984570|NCT00572533|OTHER|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
223984571|NCT00572533|OTHER|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"|"Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm"
223984572|NCT02830529|BEHAVIORAL|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
223984573|NCT02830529|BEHAVIORAL|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
223984574|NCT05889962|PROCEDURE|Pudendal nerve block|Patients who are randomized in the pudendal block group will receive bilateral pudendal nerve block with ropivacaine.
223984575|NCT05889962|PROCEDURE|Placebo block|Patients who are randomized in the placebo group will receive bilateral pudendal block with normal saline.
223984576|NCT04228198|PROCEDURE|Radical cystectomy|Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
223984577|NCT00557531|DEVICE|BL-1040|2 mL of BL-1040
223727926|NCT04464629|DRUG|Prednisolone Acetate|Topical Prednisolone acetate 1% ophthalmic suspension
223727927|NCT03125317|OTHER|Music|a kind of music which the participant likes will be listened using speakers
223727928|NCT03125317|OTHER|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
223727929|NCT03125317|OTHER|control|No intervention
223984578|NCT04196543|OTHER|écho-doppler with ultrasonar Sonovue® injection|"During this unique visit they will benefit from 2 imaging exams performed by two different operators:~* Echo-doppler without standard method contrast injection (common practice)~* An echo-doppler with Sonovue® ultrasound injection Ultra\_evar method (2.5 ml bolus 2-3 seconds) During this examination, the endoprosthesis and the aneurysm sac will be scanned according to the 4 incidences described above in order to objective whether or not there is a endoleak.~The patient then performs the control CT-scan prior to discharge from hospital.~The results of the medical imaging exams will be communicated to them before the hospital discharge, once the CT-scan has been performed.~A cross-review of the studies will be performed later."
223984579|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
223984580|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
223727930|NCT04388202|DRUG|Sertraline|FDA approved antidepressant
223727931|NCT04388202|DRUG|Escitalopram|FDA approved antidepressant
223984581|NCT00528671|DRUG|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
223984582|NCT02313337|OTHER|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
223984583|NCT02313337|OTHER|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
223984584|NCT02313337|OTHER|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
223984585|NCT02313337|OTHER|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
223984586|NCT02313337|DRUG|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
223984587|NCT02313337|PROCEDURE|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
223984588|NCT02313337|DRUG|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
223984589|NCT03201237|OTHER|Action observation training|Each child observed a task video and then performed a task
223984590|NCT03720223|DRUG|Liposomal Bupivacaine|20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
223984591|NCT02807610|DRUG|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.
223984592|NCT02807610|DRUG|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
223984593|NCT02807610|DRUG|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
223984594|NCT02961478|DRUG|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
223984595|NCT05928949|OTHER|pilates exercises|Pilates is a system of repetitive exercises performed on a yoga mat or other equipment to promote strength, stability, and flexibility. Pilates exercises develop the body through muscular effort that stems from the core.
223984596|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid|
223984597|NCT02209103|DIETARY_SUPPLEMENT|Lozenge containing citrus flavonoid formulation|
223984598|NCT02209103|DIETARY_SUPPLEMENT|Identical looking placebo|
223984599|NCT05608031|OTHER|Pittsburgh sleep quality index (PSQI) scale|Pittsburgh Sleep Quality Index (PSQI) (6), a self-report questionnaire comprising seven component scores (subjective sleep quality, sleep latency, duration of sleep, sleep efficiency habits, sleep disturbances, use of sleeping medication, and daytime dysfunction), was used to evaluate sleep quality over the last month.
223984600|NCT01773876|DRUG|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
223984601|NCT01773876|DRUG|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
224119872|NCT03480282|OTHER|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
223727932|NCT02209389|DEVICE|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
223727933|NCT01296620|DRUG|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
223984602|NCT01560195|DRUG|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
224119873|NCT01966562|BEHAVIORAL|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
224119874|NCT01966562|BEHAVIORAL|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
223984603|NCT01560195|DRUG|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
224119875|NCT01947049|OTHER|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
224119876|NCT00285298|DRUG|Pentoxifylline|
224119877|NCT00285298|DRUG|Placebo|
223984604|NCT01560195|DRUG|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
223984605|NCT05226988|DEVICE|robot-assisted|Participants received the 18-session robot-assisted intervention 3 sessions a week for 6 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
223984606|NCT05226988|DEVICE|Conventional rehabilitation intervention|Participants received the 18-session conventional rehabilitation intervention 3 sessions a week for 6 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
223984607|NCT05551936|DRUG|Bendamustine|90 mg/m\^2 IV Days 1-2, Cycles 1-3
223984608|NCT05551936|DRUG|Rituximab|375 mg/m\^2 IV Day 1 Cycles 1-6
223984609|NCT05551936|DRUG|Tazemetostat|RP2D (400, 600, or 800 mg) orally twice daily Cycles 1-6
223984610|NCT00230945|BEHAVIORAL|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
223984611|NCT03896074|DRUG|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
223984612|NCT03896074|DRUG|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
223984613|NCT03772613|DRUG|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
223984614|NCT02478385|OTHER|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
223984615|NCT01182207|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
223984616|NCT01182207|DRUG|YAZ®|3 mg/0.02 mg Tablets
224119878|NCT02077075|BEHAVIORAL|Web-based weight loss program|A 4-week web-based wellness program.
224294206|NCT01524250|DRUG|corticosteroids|1000mg IV methylprednisolone daily for 3 days
223984617|NCT05698862|DIETARY_SUPPLEMENT|Probiotic|Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)
223984618|NCT05698862|DIETARY_SUPPLEMENT|Placebo|Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
223984619|NCT00371995|DRUG|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
223984620|NCT01427738|DRUG|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
223984621|NCT01427738|DRUG|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
223984622|NCT00661713|BIOLOGICAL|rMenB+OMV NZ|
223984623|NCT00661713|BIOLOGICAL|Placebo|
223984624|NCT00571337|DRUG|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
223984625|NCT03310398|BEHAVIORAL|NeuroImaging|standard anatomical and functional imaging
223984626|NCT03310398|BEHAVIORAL|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
223984627|NCT04250688|DEVICE|Ekso Training with FES|
223984628|NCT03462537|DEVICE|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
223984629|NCT03462537|DEVICE|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
223984630|NCT03462537|DEVICE|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
223984631|NCT05585736|DRUG|Cycloplegics|they are drugs that paralyze the ciliary muscles and cause relaxation of accommodation.
224119879|NCT02077075|BEHAVIORAL|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
224119880|NCT03897270|PROCEDURE|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
224119881|NCT01163162|DRUG|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
224294207|NCT04710511|OTHER|Child and Youth Resilience Measure - Revised (CYRM-R)|(CYRM-R): questionnaire , answered by the child (PMK): questionnaire, answered by the parent
224294208|NCT02563717|DEVICE|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
224294209|NCT02563717|DEVICE|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
223984632|NCT02658175|DRUG|Volanesorsen|300 mg volanesorsen administered via SC injection.
223984633|NCT01743976|DRUG|Donepezil|donepezil 5 mg once daily for 6 weeks
223984634|NCT01743976|DRUG|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
223984635|NCT01985646|PROCEDURE|surgery treatment|one staged pull-through left-colectomy
223984636|NCT01985646|BEHAVIORAL|anal dilation|anal dilation
223984637|NCT01985646|BEHAVIORAL|colonic lavage|colonic lavage
223984638|NCT01985646|DRUG|oral probiotic|oral probiotic
223984639|NCT02072421|PROCEDURE|PCI|
223984640|NCT06360952|DEVICE|Tasso+ CBC|Novel blood collection device
223984641|NCT03906604|PROCEDURE|Carpal Tunnel Procedure (open)|Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
223984642|NCT00503607|DRUG|BLI-800|
224119882|NCT06231199|OTHER|gastrocnemius release|The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non\_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller
224119883|NCT06231199|OTHER|conventional treatment|the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
224119884|NCT05394584|BEHAVIORAL|Cognitive Stimulation Therapy|Cognitive stimulation therapy is a non-pharmacological intervention for people with dementia at mild to moderate stages. Group cognitive stimulation therapy is a 14-session intervention delivered twice every week for 7 weeks. In each session, mentally stimulating activities are conducted around a specific themed, such as current affairs, word association, categorising objects, and number game. Each group consists of eight people with similar levels of cognitive impairment, facilitated by two group leaders who lead the activities according to 18 key principles of the therapy, including new associations, opinions rather than facts, implicit learning, and person-centred.
224119885|NCT03615547|DRUG|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
223727934|NCT01296620|DRUG|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
223984643|NCT00503607|DRUG|Polyethylene glycol 3350 based bowel preparation|
223984644|NCT00250978|DRUG|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
223984645|NCT04342312|PROCEDURE|Pulmonary vein isolation|Participation in this study does not influence the choice of ablation technique. Usually, cryoballoon ablation is chosen for patients with paroxysmal AF and no previous ablations. Radiofrequency ablation is often used for redo procedures or for patients with persistent AF. Hybrid ablations are most applied in persistent AF patients. However, physicians may deviate from these standard approaches for a variety of reasons, including personal experience or preference.
223984646|NCT01594645|PROCEDURE|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
223984647|NCT06394609|OTHER|double loaded knotted suture anchor|arthroscopic bankart repair by using double loaded knotted suture anchor
223984648|NCT06394609|OTHER|double grand knot|arthroscopic bankart repair by using double grand knot
223984649|NCT02460055|DEVICE|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
223984650|NCT02460055|DRUG|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
223984651|NCT02460055|DRUG|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
223984652|NCT02460055|DRUG|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
223984653|NCT02460055|DRUG|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
223727935|NCT01296620|DRUG|5% dextrose in water|Placebo
223984654|NCT02460055|DRUG|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
223727936|NCT03293589|PROCEDURE|open revascularization|surgical revascularization (i.e. Bypass surgery)
223727937|NCT03293589|PROCEDURE|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
223727938|NCT03949374|DRUG|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
223727939|NCT03949374|DRUG|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
223727940|NCT00372112|DRUG|GW642444|GW642444H
223727941|NCT00372112|OTHER|Placebo|Placebo administered twice daily
223984655|NCT05714423|PROCEDURE|Mini-PCNL|Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
223984656|NCT05714423|PROCEDURE|RIRS|RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
223984657|NCT05888610|BEHAVIORAL|Digital Outpost|A mobile application that allows caregivers of patients diagnosed with Alzheimer's Disease and Related Dementias to report patient symptom remotely to their clinical team.
223984658|NCT04996940|DEVICE|E-cigarette product|"Participants will be randomized 1:1 to e-cigarette flavor order either:~1. tobacco e-cigarette~2. menthol e-cigarette"
223984659|NCT03277560|OTHER|No Intervention as it is an observational study|No Intervention as it is an observational study
223984660|NCT02530398|DRUG|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
223984661|NCT02037256|DRUG|bortezomib|Given IV
223727942|NCT04785976|PROCEDURE|Surgical clipping and endovascular coiling|Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.
223984662|NCT02037256|BIOLOGICAL|filgrastim|Given SC
223984663|NCT02037256|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
223984664|NCT03190629|DEVICE|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
223984665|NCT03190629|DEVICE|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
223984666|NCT04783987|OTHER|Walking asessments|Gait parameters will be evaluated in single and dual task conditions with 10 Meter Walk Test and wireless digital miniature portable walking and movement analyzer.
223984667|NCT04169191|DRUG|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
223984668|NCT03614676|PROCEDURE|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
223984669|NCT03614676|PROCEDURE|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
223984670|NCT03614676|OTHER|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
223984671|NCT03614676|PROCEDURE|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
223984672|NCT03614676|OTHER|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
223984673|NCT02807974|DRUG|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
223984674|NCT00986596|DIETARY_SUPPLEMENT|vitamin D3|4000 IU once daily by mouth for 4 months
223984675|NCT00986596|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
223984676|NCT02089139|DEVICE|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
223984677|NCT02089139|OTHER|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~* medications (analgesics, NSAIDs, muscle relaxants),~* physical therapy,~* manual techniques,~* transcutaneous electrical nerve stimulation (TENS),~* blocks"
223727943|NCT04176978|DRUG|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
223727944|NCT04176978|OTHER|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
223984678|NCT02977299|DRUG|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
223984679|NCT02977299|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
223984680|NCT02977299|DRUG|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
223984681|NCT05616377|OTHER|Surgery or Radiotherapy|Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group
223984682|NCT05616377|OTHER|before or after target therapy|Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.
223984683|NCT00309647|BIOLOGICAL|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
223984684|NCT00309647|BIOLOGICAL|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
223984685|NCT02867683|OTHER|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
223984686|NCT01928693|DRUG|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
223544266|NCT06324656|PROCEDURE|crystallized phenol + platelet rich plasma application|"At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.~For enhanced healing, crystallized phenol + platelet-rich plasma application patients will receive platelet-rich plasma injections to minimize infection risk and promote tissue regeneration, all under strict sterilization to maintain cleanliness and efficacy."
223544267|NCT06324656|PROCEDURE|crystallized phenol|At our pilonidal care clinic, patients will undergo a comprehensive treatment regimen starting with manual or laser hair removal to reduce hair by over 90%. For pilonidal abscesses, we will perform incision, drainage, and antibiotic therapy. Treatments will include local anesthesia with lidocaine and epinephrine, thorough disinfection with povidone-iodine, and wound irrigation. Sinuses will be treated by removing hair and curettage, followed by protective ointment application and crystallized phenol to fill the cavity, ensuring precise dosing and safety.
223727945|NCT02875756|PROCEDURE|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
223984687|NCT01928693|DRUG|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
223984688|NCT01928693|DRUG|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
223984689|NCT03037047|DRUG|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
223984690|NCT03037047|DRUG|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
223984691|NCT05744102|DIAGNOSTIC_TEST|MRI Image|MRI sequences
223984692|NCT04194047|OTHER|Transfusion|RBC transfusion (1 unit)
223984693|NCT04194047|OTHER|Crystalloids infusion|Infusion of 500 ml of balanced crystalloids
223984694|NCT05395364|BEHAVIORAL|Intervention program BeE-school|The intervention program will be co-developed and directed to school professionals. It will be based on the promotion of health literacy and lifestyles.
223984695|NCT00848796|DRUG|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
223984696|NCT01226732|DRUG|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
223984697|NCT01226732|DRUG|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
223727946|NCT02875756|PROCEDURE|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
223984698|NCT01347372|BEHAVIORAL|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
223984699|NCT06421077|DEVICE|transauricular auricular vagus nerve stimulation|transauricular auricular vagus nerve stimulation
223984700|NCT02166970|DEVICE|Metallic stent deployment in hilar obstruction|Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
223984701|NCT06072040|COMBINATION_PRODUCT|AUR-201|Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
223984702|NCT02166476|DRUG|Meropenem-Vaborbactam|Meropenem-vaborbactam
223984703|NCT02166476|DRUG|Piperacillin-Tazobactam|Piperacillin-tazobactam
223984704|NCT02166476|DRUG|Levofloxacin|Levofloxacin
223984705|NCT02166476|DRUG|Saline|Saline
223984706|NCT00942747|DRUG|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
223984707|NCT00004060|DRUG|exatecan mesylate|
223984708|NCT05869695|OTHER|OSPRO-ROS Questionnaire|Completion of questionnaires
223984709|NCT05869695|OTHER|OSPRO-YF Questionnaire|Completion of questionnaires
223984710|NCT06164535|DRUG|Control group|35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
223984711|NCT06164535|DRUG|DPP-4 inhibitor group|35 T2DM patients will be given DPP-4 I once or twice daily
223984712|NCT06164535|DRUG|DPP-4 inhibitor + metformin group|35 T2DM patients will be given DPP-4 I + metformin once or twice daily
223984713|NCT01618370|DRUG|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
223984714|NCT01076244|PROCEDURE|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
223984715|NCT03687008|BEHAVIORAL|Cognitive Computer Based Intervention|25 sessions \[each 30-45 minutes, 5 days a week / for 5 weeks\], supervised by trained coaches
223984716|NCT00166946|PROCEDURE|foreskin from healthy adults for organotypic culture|
223727947|NCT01025791|DRUG|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
223984717|NCT01561677|DEVICE|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
223984718|NCT01561677|DEVICE|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
223984719|NCT03024892|PROCEDURE|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
223984720|NCT03024892|PROCEDURE|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
223984721|NCT03024892|PROCEDURE|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
224119886|NCT03615547|OTHER|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
224119887|NCT04719065|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|Subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/ m2, IV, on day 1 of each cycle for a maximum of 8 cycles.
223984722|NCT03024892|PROCEDURE|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
223984723|NCT00524186|DRUG|fluorouracil|Given IV
223984724|NCT00524186|DRUG|irinotecan hydrochloride|Given IV
223984725|NCT00524186|DRUG|leucovorin calcium|Given IV
223984726|NCT00524186|DRUG|sunitinib malate|Taken Orally
223984727|NCT00524186|OTHER|flow cytometry|Correlative Study
223984728|NCT00524186|OTHER|pharmacological study|Correlative Study
223984729|NCT04351698|DRUG|Montelukast|Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.
223984730|NCT04351698|OTHER|Oral Placebo|Inert chewable tablet with no therapeutic value
223984731|NCT00419302|DRUG|Technosphere/Insulin|
223984732|NCT03832972|OTHER|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
223984733|NCT02939846|DRUG|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
223984734|NCT01780454|DRUG|MEDI-507|T-Cell Depleting Agent
223984735|NCT01780454|DRUG|Rituximab|B-Cell Depleting Agent
223984736|NCT01780454|RADIATION|Total Body Irradiation|Bone Marrow Depletion
223984737|NCT01780454|RADIATION|Thymic Irradiation|
223984738|NCT04385576|DEVICE|Aerosol Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
223984739|NCT04385576|DEVICE|Intubation Box|Usage of an Intubation Box to minimize intubator and environment contamination during intubation and extubation. Time taken for first-pass success if also expected to be reduced with the usage of the Intubation Box.
223984740|NCT03651557|DRUG|Neu2000KWL High-dose group|1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
223984741|NCT03651557|DRUG|Neu2000KWL Low-dose group|1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
223984742|NCT03651557|DRUG|Placebo|1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
223984743|NCT06956482|DRUG|N-Acetylcysteine (NAC) Treatment|N-acetylcysteine for five days (day 1 to day 5) at a daily dose of 300mg/Kg
223984744|NCT06956482|DRUG|Prednisolone|prednisolone 40 mg/day for a total of 30 days
223984745|NCT06956482|DRUG|Placebo of N-acetylcysteine|Placebo of N-acetylcysteine for five days (day 1 to day 5)
224119888|NCT03685019|RADIATION|Valgus Stress|Valgus stress radiograph
224119889|NCT03685019|RADIATION|Varus stress|Varus stress radiograph
223727948|NCT01025791|DRUG|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
223984746|NCT06956482|DRUG|Placebo of Prednisolone|Placebo of prednisolone for 30 additional days
223984747|NCT06956482|DRUG|Prednisolone|prednisolone (tapering dose) for 30 additional days
223984748|NCT01808131|DRUG|Lesinurad|Tablets, 200 mg QD
223984749|NCT01808131|DRUG|Lesinurad|Tablets, 400 mg QD
223984750|NCT00672685|DIETARY_SUPPLEMENT|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
223984751|NCT00672685|BEHAVIORAL|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
224119890|NCT03685019|RADIATION|0 degree flexion radiograph|0 degree flexion radiograph
224119891|NCT03685019|RADIATION|20 degree flexion radiograph|20 degree flexion radiograph
224119892|NCT03685019|RADIATION|45 degree flexion radiograph|45 degree flexion radiograph
224119893|NCT04289129|DIAGNOSTIC_TEST|Myotonometric evaluation|Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
223984752|NCT00672685|DRUG|Placebo|OMEGA-3 placebo
223984753|NCT05833841|DIAGNOSTIC_TEST|Surface Electromyography and Video fluoroscopy|Surface EMG of three muscle groups (masseter, submental, and infrahyoid) and video fluoroscopy with Omnipaque
223984754|NCT05262010|BIOLOGICAL|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
223984755|NCT05262010|BIOLOGICAL|placebo|According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
224119894|NCT04126603|DRUG|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
223727949|NCT01025791|DRUG|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
223727950|NCT04470674|DRUG|Durvalumab|Durvalumab 1500 mg
223984756|NCT06956274|OTHER|Preoperative Telehealth|Conduct a preoperative telehealth consultation with a Certified Wound, Ostomy, and Continence Nurse (WOCN) to provide patient education on post-surgical care expectations.
223984757|NCT06956274|OTHER|Measure Ostomy Output|Patients will be sent home with a measuring container (graduated container) and will measure their ostomy output every 12 hours and record it in a pad that will be provided to them.
223984758|NCT06956859|BEHAVIORAL|Paternal Skin to skin applicated to newborns|Paternal Skin to skin applicated to newbornsin the intervention group for 45 minutes. Routine care will be applied to the newborns in the control group. Father Descriptive Information Form, Newborn Descriptive Information Form, Skin-to-Skin Contact Monitoring Form (Newborn/Father), Newborn Comfort
223984759|NCT06360926|DEVICE|SuperSonic® Ultrasound System|SuperSonic® Ultrasound System equipped with new software iterations used with a new probe and CE marked probes. The new software and probe are the new study investigational device not CE marked
223984760|NCT05427526|PROCEDURE|intraocular lens implantation|Lens surgery during or before vitrectomy surgery.
223984761|NCT00330356|BEHAVIORAL|Low Salt Diet versus High salt diet|
223984762|NCT06145789|OTHER|standing powered wheelchair evaluation|standing powered wheelchair evaluation
223984763|NCT02989571|DRUG|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
223984764|NCT02989571|DRUG|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
223984765|NCT05688683|OTHER|use of a theremin-type musical instrument|The patient will perform the task of reproducing sounds by manipulating an object. The settings of the object will be changed and the patient will have to reproduce the sounds a second time by manipulating the object.
224119895|NCT04126603|DRUG|Placebos|Placebo injection
223544268|NCT05342298|OTHER|prediction model|Data will be pre-processed prior to final analysis, including data cleaning, imputation of missing values, dimensionality reduction, and removal of outliers. Data will be utilized as Xi and Yi where Xi presents input (features) and Yi presents dependent variables (outcomes). Different classification algorithms will be tested for accuracy to build the final model including logistic regression, SVM, XGboost and random forest algorithms. Data will be split at 0.8:0.2 for model training and testing, respectively.
223544269|NCT04576494|OTHER|Monthly assessments of functional motor abilities by a trained therapist|Monthly assessments of functional motor abilities in adult 5q-SMA type 2 and type 3 patients by a trained therapist
223544270|NCT04576494|DRUG|Nusinersen|nusinersen
223727951|NCT04470674|DRUG|Carboplatin|carboplatin AUC 5
224119896|NCT03871517|DRUG|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
224119897|NCT03871517|DRUG|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
224119898|NCT05945290|PROCEDURE|Biospecimen Collection|Undergo blood and leftover tissue sample collection
224119899|NCT05945290|OTHER|Electronic Health Record Review|Medical records are reviewed
224119900|NCT03667664|DIAGNOSTIC_TEST|Multidimensional assessments|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 following the exercise program including:~1. Clinical assessment by a geriatrician~2. Nutritional assessment~3. Physical capacity assessment~Following initial assessment (T0), older adults are included in the multicomponent exercise program if they present mobility disability risk factors including :~* At least pre-frailty regarding Fried frailty criteria AND/OR~* At least probable sarcopenia regarding EWGSOP2 algorithm AND/OR~* The presence of at least an intermediate fall risk AND/OR~* The presence of a fear of falling Following the exercise program (T3), all participants are re-assessed in the same way as T0. Investigators then set goals in physical activity with participants to maintain benefits and foster self-engagement in an healthy lifestyle. Additionnally, participants are orientated to exercise facilities and received an individualized booklet of exercises for home-based training."
224119901|NCT03667664|OTHER|Multicomponent group-based and supervised exercise program|The intervention consists in a progressive multicomponent exercise training protocol. There are 2 sessions per week of 1 hour each for a total of 12 weeks. Sessions involve functional, resistance and balance exercises. Intensity is based on rating perceived effort (Borg's scale CR1-10) and volume towards 1 to 3 sets of 6 to 15 repetitions. Progressiveness in intensity and volume was based on effort tolerance, contraction regimen, velocity and load. Training schedule is described elsewhere (Delaire et al, 2023 ; doi.org/10.3390/nu15194100). Participants are allocated to an homogenous group based on functional status and cardiorespiratory comorbidities. Trained kinesiologists supervised the exercise program. Participants used free weights and elastic bands.
224294210|NCT02494817|BEHAVIORAL|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
224294211|NCT02909738|OTHER|Volunteer to pedal a bicycle|
223984766|NCT03463551|DRUG|ABL-101|ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
223984767|NCT03463551|OTHER|0.9% NaCl|Placebo
224294212|NCT03552094|OTHER|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
224294213|NCT03552094|OTHER|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
224294214|NCT01490931|DRUG|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
224294215|NCT04293094|DRUG|AMG 650|AMG 650 administered orally as a tablet.
223984768|NCT03863132|DEVICE|TAVR|Repair of defective aortic valve by microsurgical Intervention.
224294216|NCT06531369|DRUG|Flumazenil Injection（F1 group）|Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
224294217|NCT06531369|DRUG|Flumazenil Injection（F2 group）|Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.
223727952|NCT04470674|DRUG|Pemetrexed|pemetrexed 500 mg/m2
223727953|NCT04649060|DRUG|Melflufen|Powder for solution for i.v. infusion
223727954|NCT04649060|DRUG|Dexamethasone|Oral tablets
223727955|NCT04649060|DRUG|Daratumumab|Solution for s.c. injection
223727956|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
223984769|NCT06123715|DRUG|Vitamin C|Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.
223984770|NCT06123715|DRUG|Placebo|Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
223984771|NCT06381648|DIAGNOSTIC_TEST|LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)|A panel of exosomal miRNAs, whose expression levels are tested in serum or plasma samples collected prior to primary tumor resection, with reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
223984772|NCT05317559|BEHAVIORAL|room light|The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.
223984773|NCT01178307|BEHAVIORAL|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
223727957|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
223727958|NCT01325298|DEVICE|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
223727959|NCT01325298|DRUG|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
224294218|NCT06531369|DRUG|Saline（C group）|Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
223984774|NCT01178307|BEHAVIORAL|Interview|Each interview will take approximately 30 minutes.
223727960|NCT05502601|PROCEDURE|Non-surgical periodontal treatment|"SRP will be performed under local anesthesia during a single, 2-hour, full-mouth ultrasonic and hand instrument debridement using curettes.~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
223727961|NCT02866552|DRUG|Stromal Vascular fraction|
223727962|NCT02866552|DRUG|Ringer lactate|
223727963|NCT01427686|DRUG|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
223984775|NCT01178307|BEHAVIORAL|MDASI-GIST Questionnaire|Every 4 weeks for one year
223727964|NCT01427686|DRUG|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
223984776|NCT00636662|OTHER|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
223984777|NCT01347671|DRUG|GRT6005|25µg/day once daily
223984778|NCT01347671|DRUG|GRT6005|75 µg/day once daily
223984779|NCT01347671|DRUG|GRT6005|200 µg/day once daily
223984780|NCT01347671|DRUG|Matching Placebo|Once daily
223984781|NCT02178930|OTHER|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
223984782|NCT02429908|DEVICE|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
223984783|NCT03051425|DIETARY_SUPPLEMENT|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
223984784|NCT03051425|DIETARY_SUPPLEMENT|Placebo|120 mL of low-fat milk
223984785|NCT00459914|DEVICE|cpap treatment during sleep|CPAP
223984786|NCT00252083|BEHAVIORAL|Popular Opinion Leader|
223984787|NCT02053610|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
223984788|NCT02053610|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
223984789|NCT02053610|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
223984790|NCT00197795|BIOLOGICAL|"Meningococcal outer membrane vesicle vaccine MenBVac"|
223984791|NCT06367634|DEVICE|injection in NLF|TEOSYAL® PureSense ULTRA DEEP is a sterile, transparent, non-pyrogenic, viscoelastic gel made of HA of non-animal origin
224294219|NCT03886246|DRUG|Spesolimab|Solution for infusion
224294220|NCT03886246|DRUG|Spesolimab|Solution for injection
223984792|NCT05286294|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
223984793|NCT01798979|DRUG|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
223984794|NCT01798979|DRUG|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
224119902|NCT03667664|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3+6 months:~Investigators interviewed participants for 30 minutes. During the interview, data collection include:record of undesirable events in the interval T3 / T3+6 (falls, unscheduled hospitalization, illness, institutionalization), medication changes, ADL, IADL, FES-I, and RAPA. Goal-settings at T3 are adjusted if not reach. Finally, investigators stimulate intrinsic motivation for PA.~Follow-up at T3 + 12 months:~Investigators re-assessed physical capacity, physical activity level, quality of life, fall risk and frailty for the last visit. Data collection include:~* SPPB~* Handgrip test and maximal isometric strength of the quadriceps~* Questionnaires : SarQoL©, FES-I, RAPA~* Gait quality analysis using inertial sensors~* Undesirable events in the interval T3+6 / T3+12 (falls, unscheduled hospitalization, illness, institutionalization)~* Medication changes~* Body mass index~* ADL and IADL At last, goals in physical activity are adjusted if they are still not reach"
223727965|NCT04717115|GENETIC|Genetic diagnosis|No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
223727966|NCT02695498|OTHER|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
224119903|NCT05430568|PROCEDURE|robot-assisted surgery|"1. traditional sternotomy for coronary bypass graft or valvular replacement~2. robot-assisted surgery for coronary bypass graft or valvular replacement"
224119904|NCT06224348|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: SC injection
224119905|NCT06224348|DRUG|Placebo|Pharmaceutical form: injection solution Route of administration: SC injection
223727967|NCT02695498|OTHER|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
224119906|NCT06224348|DRUG|Topical corticosteroids|Pharmaceutical form: Topical formulation Route of administration: Topical
224119907|NCT06224348|DRUG|Topical calcineurin inhibitors|Pharmaceutical form: Topical formulation Route of administration: Topical
224119908|NCT06781099|DEVICE|Low-volume continuous veno-venous haemodialysis with MEX-CD1 use|MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in low-volume continuous veno-venous hemodialysis. Intervention includes 3 low-volume continuous veno-venous hemodialysis for a duration of 4 hours each. For non-hospitalized patients, the treatment is performed on an outpatient basis.
224119909|NCT01234402|BIOLOGICAL|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
223727968|NCT05070598|DRUG|Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur|Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
224119910|NCT01234402|BIOLOGICAL|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
224119911|NCT01234402|DRUG|Capecitabine|"1000 mg/m\^2 orally~Twice a day for 14 days"
223727969|NCT02366520|DEVICE|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
223727970|NCT03791840|DIAGNOSTIC_TEST|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
223727971|NCT00160251|DRUG|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
223727972|NCT00160251|BIOLOGICAL|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
223727973|NCT00160251|DRUG|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
223727974|NCT04334629|DRUG|Ibuprofen|Lipid ibuprofen 200 mg
223727975|NCT06123104|DEVICE|Occlusion of blood flow diagnosed by Point of Care UltraSound (POCUS)|Tourniquets will be applied until peripheral blood flow occlusion is achieved. Total intervention time: up to 60 seconds
223727976|NCT06478355|DRUG|Immunotherapy|Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
223727977|NCT06478355|DRUG|Chemotherapy drug|TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W
223727978|NCT06478355|RADIATION|radiotherapy|Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
223727979|NCT03362008|DRUG|Zeropix|administration of Zeropix
223727980|NCT03362008|DRUG|Champix®|administration of Champix®
224119912|NCT06473623|DEVICE|vagus nerve stimulation|Non-invasive Auricular Fiber Vagus Nerve Stimulation (afVNS)
224119913|NCT04283890|DRUG|Ipilimumab and nivolumab|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
224119914|NCT04283890|DRUG|Melphalan chemosaturation via percutaneous hepatic perfusion|The effect of ipilimumab and nivolumab has previously been tested in metastatic uveal melanoma. In this study the combination with percutaneous hepatic perfusion will be performed in order to evaluate the effect.
224119915|NCT02758717|DRUG|Brentuximab Vedotin|Given IV
224119916|NCT02758717|BIOLOGICAL|Nivolumab|Given IV
224119917|NCT02992522|DRUG|Lenalidomide|Given PO
224119918|NCT02992522|BIOLOGICAL|Obinutuzumab|Given IV
224119919|NCT02992522|DRUG|Venetoclax|Given PO
224119920|NCT04459273|PROCEDURE|Computed Tomography|Undergo PET/CT
224119921|NCT04459273|DRUG|Gallium Ga 68 FAPi-46|Given IV
224119922|NCT04459273|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224119923|NCT04459273|RADIATION|18F-FDG|Given IV
224119924|NCT05401877|PROCEDURE|therapies for breast cancer|the type of tumor removal surgery, combined therapy
224119925|NCT06409013|OTHER|Non-Interventional Study|Non-interventional study
224119926|NCT04457089|DRUG|Simvastatin 40mg|Simvastatin 40mg by mouth nightly for approximately 6 months during treatment with carboplatin and liposomal doxorubicin
224119927|NCT06182774|DRUG|Daratumumab|Dose determined at enrollment
223984795|NCT04297592|DRUG|Cephalexin|500 mg oral tablet, 4 times daily for 7 days
223984796|NCT04297592|DRUG|Doxycycline|100 mg oral tablet, 2 times daily for 7 days
223984797|NCT04297592|DRUG|Cefadroxil|500 mg oral tablet, 2 times daily for 7 days
223984798|NCT00698282|DRUG|AZD1981|Oral tablet, 250 mg single dose
224119928|NCT06182774|DRUG|Lenalidomide|Dose determined at enrollment
224119929|NCT06182774|DRUG|Dexamethasone|Dose determined at enrollment
223984799|NCT00698282|DRUG|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
223984800|NCT00698282|DRUG|Placebo|
223984801|NCT00429143|RADIATION|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
223984802|NCT00429143|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
224119930|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224119931|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224294221|NCT06482892|DRUG|TP03HN106|"During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia."
224294222|NCT06609226|DRUG|Etavopivat A|Participants will receive an oral dose of Etavopivat A.
224294223|NCT06609226|DRUG|Etavopivat B|Participants will receive an oral dose of Etavopivat B.
224294224|NCT06609226|DRUG|Etavopivat C|Participants will receive an oral dose of Etavopivat C.
224294225|NCT06330181|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart"
223984803|NCT00429143|DRUG|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
223984804|NCT00429143|DRUG|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
223984805|NCT00429143|DRUG|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
223984806|NCT00429143|BIOLOGICAL|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
223984807|NCT06086041|PROCEDURE|cochlear implant|cochlear implant
223984808|NCT03427060|DRUG|Coversin|Coversin - 22.5mg followed by 45mg for 6 months.
223984809|NCT02617979|OTHER|SAFECARE at Home customized lessons|
223984810|NCT01296763|DRUG|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
223984811|NCT01296763|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
223984812|NCT01296763|DRUG|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
223984813|NCT01296763|DRUG|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
223984814|NCT01296763|DRUG|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
223984815|NCT05508269|GENETIC|quantitative polymerase chain reaction(QPCR) for four genes|quantitative polymerase chain reaction(QPCR) for four genes
224119932|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224119933|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224119934|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224119935|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
224119936|NCT05262400|DRUG|PF-07104091 + PF-07220060 + fulvestrant dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
224119937|NCT05262400|DRUG|PF-07104091 + PF-07220060 + letrozole dose expansion|PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
223984816|NCT05508269|PROCEDURE|Cardiac biopsy, blood sampling|In the studied thirteen peripheral blood subjects, five milliliters blood samples were taken from each patient in potassium EDTA tubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators. All studied thirteen cardiac tissue subjects were underwent cardiac biopsy after PCI in order to take two specimens from the left ventricle using judkin right seven french catheters for femoral access and cardiac bioptome 2.3 mm wide. All cardiac specimens were collected in cryotubes, immediately inserted in liquid nitrogen container and then stored in -80 refrigerators.
223984817|NCT02866396|DRUG|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
223984818|NCT02866396|OTHER|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS \> 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS\>3
223984819|NCT03462043|COMBINATION_PRODUCT|ND0612|s.c. infused
223984820|NCT03462043|COMBINATION_PRODUCT|CLES|Carbidopa-Levodopa Enteral Suspension.
223984821|NCT04921137|OTHER|No endocrine therapy|No endocrine therapy given
223984822|NCT04921137|OTHER|Endocrine therapy|Endocrine therapy given for at least 5 years
223984823|NCT04461769|DEVICE|Transcranial Electrical Stimulation|Oscillating electrical current
223984824|NCT01869114|DRUG|Sirolimus|Given PO
223984825|NCT01869114|DRUG|Azacitidine|Given IV
223984826|NCT05808127|BEHAVIORAL|PainTracker|The PainTracker tool reframes the patient visit around improving functional status and obtaining functional goals, understanding psychological concerns that may exacerbate pain such as traumatic stress, anxiety, and depression. This approach may promote an increase in referrals for physical therapy, mental health counseling, and psychiatric follow-up.
223984827|NCT05673733|OTHER|scapular stabilization exercises with exergaming training|Group A will receive scapular stabilization exercises with exergaming training
223984828|NCT05673733|OTHER|exergaming training|Group B will receive only exergaming training
223984829|NCT00543062|DRUG|Inhaled placebo|Inhaled Staccato placebo (0 mg)
223984830|NCT00543062|DRUG|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
223984831|NCT00543062|DRUG|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
223984832|NCT00543062|DRUG|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
223984833|NCT00543062|DRUG|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
223984834|NCT03703726|DIETARY_SUPPLEMENT|Reference meal|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
223984835|NCT03703726|DIETARY_SUPPLEMENT|Test meal A|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
223984836|NCT03703726|DIETARY_SUPPLEMENT|Test meal B|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice"
223984837|NCT03703726|DIETARY_SUPPLEMENT|Test meal C|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice."
223984838|NCT03703726|DIETARY_SUPPLEMENT|Test meal D|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
223984839|NCT03703726|DIETARY_SUPPLEMENT|Test meal E|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice."
223984840|NCT03703726|DIETARY_SUPPLEMENT|Test meal F|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice."
223984841|NCT02075619|DRUG|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
223727981|NCT06254404|DRUG|Low dose protamine|Administration of 70% of the normal dose of protamine
223984842|NCT02075619|DRUG|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
223984843|NCT02075619|DRUG|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
223984844|NCT05429255|BEHAVIORAL|Aerobic Exercise|Bicycle training
223984845|NCT05429255|BEHAVIORAL|Exergame Training|Nintendo Wii
223984846|NCT06298708|BIOLOGICAL|Mevac-A vaccine|"Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time."
223727982|NCT02687945|PROCEDURE|Outpatient physiotherapy|
223727983|NCT02687945|PROCEDURE|Self-guided physiotherapy|
223727984|NCT05557799|RADIATION|Photobiomodulation|The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
223727985|NCT05557799|RADIATION|Placebo Photobiomodulation|The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
223727986|NCT06039826|DRUG|LY3437943|Administered SC.
223727987|NCT06039826|DRUG|Ethinyl Estradiol|Administered orally
223727988|NCT06039826|DRUG|Drospirenone|Administered orally
223727989|NCT05718128|PROCEDURE|Endocardiomyocardial biopsy|Endocardiomyocardial biopsy
223727990|NCT03747328|DRUG|ABI-009|nanoparticle albumin bound sirolimus
223727991|NCT02389010|BIOLOGICAL|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
223727992|NCT02389010|OTHER|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
223727993|NCT01336920|DRUG|carfilzomib|Given IV
223727994|NCT01806948|DRUG|Ramosetron|
223727995|NCT04334408|DRUG|Fremanezumab|Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
223727996|NCT04334408|DRUG|Placebo|Placebo injections during the run in and washout serves as the control condition. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
223727997|NCT01822340|DRUG|HM10560A|Once weekly HM10560A
223727998|NCT01822340|DRUG|Genotropin|Once daily Genotropin
223727999|NCT03557463|DIETARY_SUPPLEMENT|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
223728000|NCT04426981|BEHAVIORAL|Behavioral Activation|Behavioral activation is a behavioral treatment that focuses on helping participants engage in more rewarding and enjoyable activities. In the first session, participants will begin to identify domains of their life which are important to them. In the second session, participants will be assisted in creating an action plan to engage in more activities in one or more domains of importance. In session 3-8, participants will be assisted in problem solving any challenges they encountered in implementing their previous action plan and will develop a new action plan. The intervention will continue until participants achieved three action plans or reach the eight-session limit, whichever comes first.
223728001|NCT01906203|DEVICE|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
223728002|NCT01645696|DEVICE|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
223728003|NCT01645696|DEVICE|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
223728004|NCT01645696|DEVICE|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
223728005|NCT00594984|DRUG|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
223728006|NCT00594984|DRUG|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
223728007|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
223728008|NCT00594984|DRUG|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
223728009|NCT00594984|DRUG|Brivanib Placebo|Oral, tablet, QD, until progression
223728010|NCT02730455|DRUG|natalizumab|Administered as specified in the treatment arm
223728011|NCT02730455|DRUG|Placebo|Matched placebo
223728012|NCT04334551|DRUG|Doravirine|switches from etravirine to doravirine, in experienced HIV patients
223728013|NCT05457673|DEVICE|AtaCor StealthTrac Lead|Subjects will receive the AtaCor StealthTrac Lead being evaluated in the study.
223728014|NCT04941001|DEVICE|ReferID|The ReferID tool is a digital tool which can be used to facilitate a review of asthma in primary care
223984847|NCT06298708|BIOLOGICAL|Havrix 720 Junior|"Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval."
223984848|NCT05070832|PROCEDURE|Deep Hyperthermia|Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.
223728015|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
223728016|NCT03903445|BEHAVIORAL|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
223728017|NCT03077750|DRUG|VBP-245 Topical Gel|Topical application BID
224294226|NCT06330181|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
224119938|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224294227|NCT05802186|PROCEDURE|Computed Tomography|Undergo CT
224294228|NCT05802186|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223728018|NCT03077750|DRUG|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
223728019|NCT02356744|OTHER|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
223728020|NCT04540029|OTHER|Maternal stress|Prenatal COVID-19-related stress retrospectively self-reported by mothers after delivery.
223728021|NCT00424671|DRUG|Licarbazepine|
223728022|NCT05564429|DRUG|18F-SF12051|Injected intravenously followed by PET scanning
224119939|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224119940|NCT05262400|DRUG|PF-07220060 + PF-07104091 combination dose escalation|PF-07104091 and PF-07220060 will be administered orally
224119941|NCT06283771|OTHER|Heated socks to be developed with wearable technology|The study group will wear heated socks to be developed with wearable technology
224119942|NCT02055521|PROCEDURE|Blood sample, biopsy|
224119943|NCT02652858|PROCEDURE|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
224294229|NCT05802186|PROCEDURE|Positron Emission Tomography|Undergo PET
224294230|NCT05802186|OTHER|Quality-of-Life Assessment|Ancillary studies
224294231|NCT05802186|OTHER|Radiology, Treatment Planning|Undergo radiation planning with AI-directed analysis for dose recommendation
224294232|NCT05802186|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224294233|NCT05802186|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223984849|NCT05080205|PROCEDURE|Bariatric surgery|Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
223984850|NCT04648826|DEVICE|AeroEclipse II Breath Actuated Nebulizer|Patients will receive AZA via commercial device, AeroEclipse II Breath Actuated Nebulizer.
223984851|NCT04648826|DRUG|Bintrafusp alfa|Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
223984852|NCT04648826|DRUG|Azacytidine|Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
223984853|NCT05203861|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
223984854|NCT05203861|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
223984855|NCT03360578|DEVICE|Garmin|A commercial grade health wearable
223984856|NCT00424788|PROCEDURE|Plasma exchange|
223984857|NCT00424788|DRUG|natalizumab treatment|
223984858|NCT01513330|DEVICE|SenSura Mio|Ostomy product - 1 piece closed bag
223984859|NCT01513330|DEVICE|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
223984860|NCT00207753|DRUG|albendazole vs. combined albendazole/ivermectin treatment|
223984861|NCT00703183|DRUG|ACU-4429|administered as a single dose, orally
223984862|NCT00703183|DRUG|matching placebo|administered as a single dose, orally
223984863|NCT01858051|DIETARY_SUPPLEMENT|Cholecalciferol|
223728023|NCT02480439|DRUG|TAK-648 Tablet|Tak-648 tablet
223984864|NCT01858051|DIETARY_SUPPLEMENT|Placebo|
223984865|NCT04136600|DRUG|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
223984866|NCT04136600|DRUG|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA\>1.5, 50 mg for 1.5\>BSA\>1.25 , 40mg for BSA\<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
223984867|NCT04178447|DRUG|Glepaglutide|Single dose of Glepaglutide 10 mg
223728024|NCT02480439|DRUG|TAK-648 Oral Solution|TAK-648 oral solution
223728025|NCT00114946|DRUG|Avastin|
223728026|NCT04572932|DRUG|lactobacillus delbruekii|Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl
223984868|NCT04719715|DIAGNOSTIC_TEST|Indirect immunofluorescence (IIF) , myeloperoxidase antibody(MPO)- and anti-proteinase 3 (PR3-) ANCA immunoassays|Measurement and evaluation of the ANCA testing
223984869|NCT04815343|DEVICE|Naída CI M90 Sound Processor (hearing aid and cochlea implant sound processor)|Speech perception measures, Hearing thresholds, Enjoyment rating, Sound identification, Subjective feedback
224119944|NCT06798714|DRUG|NSAID|standard CABG without performing pericardial fenestration intraoperatively
223728027|NCT04268810|PROCEDURE|Bladder instillations|bladder instillations with either solution (DMSO or Uracyst)
223728028|NCT01965496|DRUG|PEX168|A injection administered subcutaneously
223728029|NCT02495441|OTHER|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
223728030|NCT02431234|OTHER|serum RANKL|
223728031|NCT00954434|DIETARY_SUPPLEMENT|red wine|intake of red wine on a daily basis
223728032|NCT04811989|BEHAVIORAL|Instructive video on diabetic foot care|In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
223728033|NCT04811989|BEHAVIORAL|Informative leaflet with real-time guided reading|The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
223728034|NCT04811989|BEHAVIORAL|Informative leaflet to read at home|Patients receive a leaflet about diabetic foot care to read at home.
223728035|NCT04811989|BEHAVIORAL|Face-to-face teaching|Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
223728036|NCT01733602|DEVICE|transcranial direct current stimulation|
223728037|NCT01018186|DRUG|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
223728038|NCT01018186|DRUG|Fluticasone propionate|Inhaled corticosteroid
223728039|NCT03608592|BIOLOGICAL|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
223728040|NCT03608592|BIOLOGICAL|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
223728041|NCT02356068|OTHER|ROTEM analysis|3 blood samples for ROTEM analysis
223728042|NCT01931852|PROCEDURE|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
223728043|NCT01931852|OTHER|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
223728044|NCT03649464|DRUG|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
223984870|NCT04636645|OTHER|Normal treadmill|Participants will exercise for 25 minutes under low-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. For each session, 20% support will be given to participants.
223984871|NCT04636645|OTHER|Anti-gravity treadmill with lower limb positive pressure|Participants will be exercised for 25 minutes under normal-load walking conditions three times a week for 8 consecutive weeks on the AGT treadmill at a set speed of 3.1 mph at 0-degree incline. Participants will be blinded to the study groups.
223984872|NCT04636645|OTHER|Anti-gravity treadmill with without lower limb positive pressure|Participants will be exercised for 25 minutes three times a week for 8 consecutive weeks on the normal treadmill at a set speed of 3.1 mph at a 0-degree incline. Participants will be blinded to the study groups.
223984873|NCT05029011|DEVICE|BRAEBON VTS|The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours.
223984874|NCT03236610|DRUG|tenofovir monotherapy|switching to tenofovir monotherapy
223984875|NCT03236610|DRUG|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
223984876|NCT02561208|OTHER|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
223984877|NCT01159951|OTHER|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
223984878|NCT03002142|DEVICE|Hearing aids|Phonak Audéo B-R (Target V 5.0)
223984879|NCT03002142|DEVICE|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
224119945|NCT06798714|DRUG|Colchicine 0.5 MG|Colchicine will be prescribed in a dose of 500 micrograms 4 hours before surgery and 500 micrograms 2 times a day for 10 days after surgery with pericardial fenestration
224119946|NCT04609592|DRUG|Lutathera|4 administrations of 7.4 gigabecquerel (GBq) (200 mCi) 177Lu Dotatate +/ 10% at the date and time of infusion, accumulative dose of 29.6 GBq (800 mCi). T
224119947|NCT04609592|DRUG|Gallium 68 Dotatate|Standard of care, 2 Megabecquerel (MBq)/kg (0.054 mCi/kg) up to 200 MBq (5.4 mCi)
224119948|NCT04609592|PROCEDURE|Computed Tomography (CT)|Medical Imaging
224119949|NCT04609592|PROCEDURE|Magnetic Resonance Imaging (MRI)|Medical Imaging
224119950|NCT04609592|PROCEDURE|PET/CT|Medical Imaging
224119951|NCT04655105|DEVICE|root canal rotary files|post operative pain evaluation using different rotary file system
224119952|NCT00385268|DRUG|acamprosate|1998 mg/dau fpr 8 weeks
223728045|NCT05984160|OTHER|Paragastric neural block|A block method used to control patients' symptoms of pain, nausea and vomiting after surgery.
223728046|NCT03049280|DEVICE|Transoral robotic surgery|Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
223728047|NCT04216095|DEVICE|Electroconvulsive Therapy (n=30)|Right unilateral (RUL) ECT (n=15) or bitemporal (BT) ECT (n=15) using a Thymatron IV device (Somatics LLC, USA) twice weekly.
223728048|NCT04216095|DEVICE|Magnetic Seizure Therapy (n=30)|High-dose magnetic seizure therapy (HD-MST) over the vertex using Magstim Theta device (Magstim Company Limited, Whitfield, Wales, UK) at 100% maximal output of the device (constant), with pulse frequency 100Hz and train duration 10 seconds twice weekly.
223728049|NCT01382823|PROCEDURE|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
223728050|NCT04386980|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
223728051|NCT04386980|DRUG|Placebo|Diluent in normal saline
223728052|NCT03235076|DRUG|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
223728053|NCT03590106|BEHAVIORAL|Peer Recovery Support Program|See above
223728054|NCT00633386|DRUG|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
223728055|NCT00633386|OTHER|Placebo|Matched placebo
223728056|NCT04217876|DIAGNOSTIC_TEST|post-processing analysis of cardiac imaging (strain echocardiography)|"A dedicated software package for two-dimensional speckle tracking strain analysis (XStrain™, Esaote, Florence, Italy) was used to quantify both ENDO and EPI strains. Our echocardiographic imaging acquisition protocol for 2DSTE consisted in the acquisition of three consecutive cardiac cycles from non-foreshortened apical views (4, 2, and 3 chambers) obtained during breath hold. Frame-by- frame displacement of ENDO and EPI points was automatically evaluated, generating strain curves for each segment.~The tracking quality was verified for each segment, and subsequent manual adjustments were performed, when required. All data were analyzed with the aid of Fourier techniques, which ensure greater accuracy using the periodicity of the heart motion."
223728057|NCT00929318|PROCEDURE|blood sampling|
223728058|NCT00929318|PROCEDURE|blood sampling|
223728059|NCT03552198|BEHAVIORAL|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
223728060|NCT02916342|PROCEDURE|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
223728061|NCT02916342|PROCEDURE|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
223984880|NCT06064747|DEVICE|LF-rTMS|"LF-rTMS group: using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);"
223984881|NCT06064747|DEVICE|Sham stimulation|Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
224119953|NCT00385268|DRUG|placebo|placebo pills
224119954|NCT04770337|DEVICE|STARSTIM device|Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
224119955|NCT04770337|DEVICE|Sham Device|Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
224119956|NCT02710266|DRUG|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
224119957|NCT02710266|DRUG|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
224119958|NCT02710266|DRUG|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
224119959|NCT02417233|BEHAVIORAL|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
224119960|NCT02417233|BEHAVIORAL|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
224119961|NCT03649321|DRUG|Bemcentinib|200mg orally starting Cycle 1 day 2 every 21 days or 28 days.
223984882|NCT04176289|DIAGNOSTIC_TEST|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI\> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
223984883|NCT01409005|DRUG|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1\~21~Interval: every 4 weeks"
223984884|NCT01041989|BEHAVIORAL|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
223984885|NCT01041989|BEHAVIORAL|Exercise|Guided muscle strength training and aerobic exercise.
223984886|NCT01041989|BEHAVIORAL|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
223984887|NCT01041989|OTHER|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
223984888|NCT04752800|DEVICE|Direct Current Transcranial Stimulation - tDCS|Intervenção Ativa
223984889|NCT04752800|DEVICE|Sham Intervention|Direct Current Transcranial Stimulation - Sham Intervention
223984890|NCT03922152|RADIATION|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
223984891|NCT00981708|DRUG|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
224119962|NCT03649321|DRUG|Nab-paclitaxel|25 mg/m\^2 Day 1 /8 every 21 days or 28 days.
223984892|NCT02768597|DEVICE|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
223984893|NCT02768597|DEVICE|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
224119963|NCT03649321|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 Day 1 /8 every 21 days or 28 days
224119964|NCT03649321|DRUG|Cisplatin|Cisplatin 25 mg/m\^2 Day 1 /8 every 21 days
224119965|NCT01026701|DRUG|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
224119966|NCT05009316|OTHER|Questionnaires|Online-based questionnaires
224119967|NCT02046343|BEHAVIORAL|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
223984894|NCT02768597|DEVICE|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
223984895|NCT02768597|DEVICE|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
223984896|NCT05928468|BIOLOGICAL|LYB002V14|Participants receiving one or two boost doses of LYB002V14 after a three-dose primary series of inactivated COVID-19 vaccine.
223984897|NCT05928468|BIOLOGICAL|LYB002V14A|Participants receiving one or two boost doses of LYB002V14A after a three-dose primary series of inactivated COVID-19 vaccine.
223984898|NCT05928468|BIOLOGICAL|LYB002CA|Participants at 18-59 years old receiving two boost doses of LYB002CA after a three-dose primary series of inactivated COVID-19 vaccine.
223984899|NCT00293345|DRUG|gemcitabine hydrochloride|
223984900|NCT00293345|DRUG|triapine|
223984901|NCT02232399|DRUG|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
223984902|NCT02232399|DRUG|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
223984903|NCT05429047|BIOLOGICAL|Tozinameran|Tozinameran during pregnancy
223984904|NCT05429047|OTHER|COVID-19|SARS-CoV-2 infection during pregnancy
223984905|NCT05429047|OTHER|No SARS-CoV-2 exposure|No SARS-CoV-2 exposure during pregnancy
223984906|NCT06838169|BEHAVIORAL|Virtual reality glasses|virtual reality glasses application
223984907|NCT06838169|BEHAVIORAL|breathing exercise|breathing exercise app
223984908|NCT01146977|OTHER|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
223984909|NCT01146977|OTHER|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
223984910|NCT01124968|OTHER|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
224119968|NCT02046343|BEHAVIORAL|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
224119969|NCT02046343|OTHER|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
224119970|NCT02046343|OTHER|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
223728062|NCT06051929|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|The MIED program integrates the rationales and practices from the Unified Protocol for Treatment of Emotional Disorders (UP) and Mindfulness based Interventions. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth brushing) were adapted from Mindfulness based intervention (MBIs). The offline received the 8-week (2.5-h per week) sessions.The online MIED program was delivered by a Chat Mini Program and lasted for 49 days. Each day, participants received different materials including (a) an audio recording of mindfulness meditation guidance; (b) learning materials in text or audio; and (c) assignments (for example, informal mindfulness practice, emotion journal, and challenging tasks). In total, it took about 30 min per day to finish all the tasks.
223728063|NCT05908695|DRUG|GV-971|Administered PO
223728064|NCT05908695|DRUG|Placebo|Administered PO
223728065|NCT05673512|COMBINATION_PRODUCT|Injection of IAH0968 + CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
223984911|NCT01777334|DRUG|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
223984912|NCT01777334|DRUG|Tiotropium 18 mcg|Inhalation Powder
223984913|NCT05216042|DIETARY_SUPPLEMENT|Study diet|Participants will consume the study diet for 5 days provided by the clinical research unit's metabolic kitchen (at UAB)
223984914|NCT05216042|OTHER|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
223984915|NCT05216042|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
223984916|NCT05216042|OTHER|Glucose Challenge|Participants will come in fasting state on day 6th and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
224119971|NCT00204425|DIETARY_SUPPLEMENT|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
223728066|NCT05673512|COMBINATION_PRODUCT|PLACEBO+CAPEOX|PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
223728067|NCT02402439|DRUG|Islet cells|Transplantation of islets into the gastrointestinal submucosa
223728068|NCT02402439|PROCEDURE|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
223728069|NCT03587012|OTHER|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
223728070|NCT03587012|OTHER|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
223728071|NCT03668912|BEHAVIORAL|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
224119972|NCT01954303|OTHER|Progress of CHD|
224119973|NCT02413125|DEVICE|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
224119974|NCT02413125|DRUG|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
224119975|NCT05139368|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224119976|NCT01702363|DRUG|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
224119977|NCT02531789|OTHER|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
223728072|NCT01329731|DRUG|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
223728073|NCT01329731|DRUG|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
223728074|NCT03235154|DRUG|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasvir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
223728075|NCT05875090|DIAGNOSTIC_TEST|Glaucoma Screening|Non-invasive diagnostic techniques will screen subjects in primary care setting for the existence of Glaucoma and categorised them in a binary system: referrable vs non-referrable to a Hospital-based Glaucoma Clinic
223728076|NCT02834208|OTHER|MRI (Magnetic resonance imaging)|
223728077|NCT02834208|GENETIC|Polymorphism (SNP in DNA)|
223728078|NCT02834208|GENETIC|quantitative measures of mRNA|
223728079|NCT02834208|OTHER|Neuropsychological assessment|
223728080|NCT06189651|DEVICE|wrist splint|The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
223728081|NCT06189651|PROCEDURE|5% dextrose injection using USG-guided nerve hydrodissection method|2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
223728082|NCT03648060|DEVICE|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
223728083|NCT04746261|BEHAVIORAL|ASSIP + treatment as usual|"ASSIP:~First session: Videotaped narrative interview focusing on the background to the suicidal crisis.~Second session: Video playback. The patient and the therapist watch the recorded interview together, stopping the film regularly to add information. The patient is given a psychoeducational text to read and comment on as homework.~Third session: Compilation of a written case formulation of the individual's vulnerability and triggering events that preceded the suicidal crisis. Individual preventive measures are developed by the patient and the therapist together and written down in a document that the patient keeps and which is attached to the patient's medical record.~Fourth session (optional): Mini-exposure.~Standardized letters: The therapist contacts the patient by letter during two years, every three months the first year and every six months the second year.~Treatment as usual: As described bellow"
223728084|NCT04746261|OTHER|Treatment as usual and patient safety|"All patients follow their usual care, regardless of whether they are treated with ASSIP or not. Usual care is multidisciplinary and combines psychotherapy, pharmacotherapy and other treatments, including referral to specialist psychiatric units or primary care. This depends on the assessments made by the patient's usual care provider. Treatment as usual is monitored by the research team through a standardised medical record review.~In order to increase patient safety, some standardisation of usual care takes place. The research nurse communicates with the referring healthcare provider to ensure that the patient receives a follow-up appointment within the usual care setting after the initial visit and the research team informs the usual care provider and acts when acute suicide risk is detected. In most sites, some information from SIS, CSSR-S and MINI assessments is noted in the patient's medical records."
223728085|NCT05329701|OTHER|Individualized treatment duration strategy|As listed under arm description.
224119978|NCT04629989|OTHER|Standard Oxygen Delivery System|The standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
224119979|NCT04629989|OTHER|Double-Trunk Mask|The Double-Trunk Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
224119980|NCT04629989|OTHER|Surgical Mask|The Surgical Mask above the standard oxygen delivery system (low-flow nasal cannula or oxygen mask) is worn by the patient for 1 hour.
224119981|NCT01881594|PROCEDURE|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
224294234|NCT05852457|DEVICE|DAT Clip|All patients scheduled to undergo endoscopic procedures as medically indicated will be considered for the study. Data will be prospectively recorded according to the data collection form. The use of the DAT clip will be performed as medically indicated and consistent with the indications for endoscopic clipping (e.g., management of bleeding, treatment of fistulas, perforations, tissue approximation). The investigators on this project will also oversee the medical care of all patients that will participate in the study. Therefore, follow-up will be carried out as medically indicated and no clinical visits will be needed specifically for the purpose of this study.
224294235|NCT06612918|DEVICE|high-intensity laser acupuncture and the exercise program|The experimental group will receive high-intensity lasers, and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40, and GB30. Exercises program: The patients will perform this exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises; and stretching exercises.
223728086|NCT05846204|BEHAVIORAL|Progressive Muscle Relaxation|"The PMR exercise, which includes the systematic relaxation of the main muscle groups of the body aimed at physical and psychological relaxation, was applied twice a day, every weekday, for eight weeks.~DB exercises training was given to the patients in this group individually by face-to-face interview. During the application, the importance of deep and comfortable breathing was explained and correct breathing technique was taught."
223728087|NCT05846204|BEHAVIORAL|Deep Breathing Exercise Group-DBE|Breathing exercise is an exercise to improve breathing and functional performance. deep breathing exercise; It is a nursing intervention that helps to increase the function of respiratory muscles and improve ventilation and oxygenation.
223728088|NCT02626546|PROCEDURE|Major surgical procedure|observation of postoperative outcomes
223728089|NCT01962805|DRUG|Proellex Formulation A|
223728090|NCT01962805|DRUG|Proellex Formulation B|
223728091|NCT04975685|BEHAVIORAL|SMART|SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
223728092|NCT04975685|BEHAVIORAL|Sham brain training (Sudoku)|Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
223728093|NCT03236740|DRUG|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
223728094|NCT03236740|DRUG|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
223728095|NCT04367220|DIAGNOSTIC_TEST|Diagnostic testing performed as per routine care|
223728096|NCT01454622|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
224119982|NCT01744509|DEVICE|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
224119983|NCT01293032|PROCEDURE|Neoadjuvant Therapy|Undergo neoadjuvant therapy
224119984|NCT01293032|PROCEDURE|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
223728097|NCT01454622|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
224119985|NCT01293032|OTHER|Laboratory Biomarker Analysis|Correlative studies
224119986|NCT01293032|GENETIC|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
224119987|NCT01293032|DRUG|Systemic Chemotherapy|Undergo chemotherapy
224119988|NCT01293032|DRUG|Tamoxifen Citrate|Undergo hormonal therapy
224119989|NCT01293032|DRUG|Aromatase Inhibition Therapy|Undergo hormonal therapy
224119990|NCT05365893|COMBINATION_PRODUCT|Paricalcitol, Hydroxychloroquine, Losartan|Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily
223984917|NCT05948423|OTHER|Tisue Flossing Technique|"Experimental Group (Tissue Flossing + conventional therapy) Tissue Flossing involved active and passive movement with elbow wrapped with a floss band made from latex rubber (7m x 2 inch) Floss band was wrapped around the elbow (distal to proximal) using 25% overlapping pattern with an elongation stretch of 25%. During treatment the compression of floss band was measured with modified sphygmomanometer by placing cuff under floss band (which is applied on muscle) and note the pressure on manometer.~Control Group (Conventional Therapy) Conventional therapy was applied for 23 minutes for both groups which include hot pack for 10 minutes, PNF (hold-relax with agonist contraction): It started with a gentle stretch of bicep muscle for 10 seconds followed by isometric contraction for 6 seconds then the patient tried to flex their elbow and the therapist also assisted."
223984918|NCT04740723|DEVICE|iRF System Renal Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the artery
223984919|NCT00491621|PROCEDURE|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
223984920|NCT06332898|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
223984921|NCT06332898|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
223984922|NCT03322553|DEVICE|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
223984923|NCT04070768|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m\^2, Days 1,4,7
223984924|NCT04070768|DRUG|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
223984925|NCT04058236|OTHER|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
223984926|NCT04058236|OTHER|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
223984927|NCT01855477|PROCEDURE|Histological biopsy procedure|
223984928|NCT04921553|OTHER|Data collection and quality of life questionnaire|"* Data collection from the medical file~* Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months"
223728098|NCT01265290|DEVICE|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
223728099|NCT01265290|DEVICE|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
223984929|NCT02492698|DIETARY_SUPPLEMENT|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
223984930|NCT02492698|DIETARY_SUPPLEMENT|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
223984931|NCT05911178|RADIATION|[11C]-UCB-J|"PET tracer binding to SV2A protein, used to study synaptic vesicle density."
223984932|NCT05911178|RADIATION|[18F]-DPA-714|"PET tracer binding to TSPO protein, used to study microglial activation."
223984933|NCT05911178|RADIATION|[18F]-RO-948|"PET tracer binding to tau protein, used to study the topography of tau deposition."
223984934|NCT05911178|RADIATION|[11C]-PiB|PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
223984935|NCT01973062|BIOLOGICAL|rituximab|Given IV
224119991|NCT05365893|OTHER|Neoadjuvant therapy and surgery only (Control)|Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
224119992|NCT04911101|DEVICE|Excision with 7G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
224119993|NCT04911101|DEVICE|Excision with 10G needle|Vacuum-assisted excision using a biopsy needle with two alternative dimensions
224119994|NCT00260572|BEHAVIORAL|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
223984936|NCT01973062|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223728100|NCT03851068|DEVICE|Foldax Tria Aortic Valve|Aortic Valve Replacement
223984937|NCT04288206|DRUG|Cefazolin|intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
223984938|NCT04288206|DRUG|normal saline|intravenous normal saline placebo
223984939|NCT05109000|DRUG|Sodium Chloride 0.9% Inj|10 mL subcutaneous injection into one randomized anterior thigh of subject
224119995|NCT00260572|BEHAVIORAL|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
224119996|NCT00260572|BEHAVIORAL|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
223984940|NCT05109000|DRUG|Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)|10 mL subcutaneous injection into the contralateral anterior thigh of subject
223984941|NCT05278013|OTHER|Dermabond|High viscosity Dermabond is a sterile, liquid topical skin adhesive containing monomeric (2-OCA) formulation and the colorant D \& C Violet # 2. The product has a syrup-like in viscosity and polymerizes within minutes when applied to the skin. 2-OCA is an effective barrier against microbial penetration by Gram-positive (inc. methicillin-resistant Staphylococcus aureus) and Gram-negative motile and nonmotile species as long the as the film is intact (11-13). The high viscosity of Dermabond is intended to reduce the risk of unintended placement of the adhesive during the application process to other body parts, patient's clothing or in between the skin layers in the wound, which can result in delayed wound healing.
223984942|NCT00020722|BIOLOGICAL|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
223984943|NCT00020722|DRUG|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
223984944|NCT00020722|DRUG|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
223984945|NCT00020722|PROCEDURE|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
223984946|NCT00020722|PROCEDURE|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
223984947|NCT04642547|DRUG|Lenvatinib and Gefitinib|"First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral."
223984948|NCT01586481|DEVICE|SANIDIAB|off-loading shoe
223984949|NCT01586481|DEVICE|BAROUK|old shoe
223984950|NCT01126320|DEVICE|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
223984951|NCT01126320|DEVICE|routine mechanical ventilator|routine mechanical ventilation
223984952|NCT01472614|DRUG|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
223984953|NCT05260593|DEVICE|Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of vitamin B12 gel will be applied over the wrist. The following parameters will be used: intensity of 1.0 W/cm2 at a 1MHz frequency for 5 minutes and pulsed (25%) ultrasound waves to transfer the vitamin B12 gel. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
223984954|NCT05260593|DEVICE|Placebo Vitamin B12 phonophoresis|Therapeutic pulsed ultrasound using Phyaction UbMF ultrasound device in presence of Vitamin B12 will be applied over the wrist. The ultrasound probe will be held over the wrist using topical gel containing Vitamin B12 which was the same as in group A. Ultrasound device will seem to be working for 5 min period with light-off position. This therapy will be applied for 5 min/session, 5 d/wk, for 3 weeks.
223984955|NCT05260593|DEVICE|Wrist splint|Patients were instructed to wear a neutral volar splint at night and while performing strenuous activities during the day for 5 weeks. Patients were given forms in order to check if they won't be compliant to the splint application and will be asked to bring the forms at the post treatment evaluation. Patients who won't check the form more than once a week will be regarded as non-compliant to splinting.
223984956|NCT05260593|OTHER|tendon and nerve gliding exercises|During tendon-gliding exercises, the fingers will be placed in five discrete positions (straight, hook, fist, tabletop, and straight fist). During the median nerve-gliding exercise, six different hand and wrist positions will be used to mobilize the median nerve. During these exercises, the patient must maintain the neck and the shoulder in neutral position with a supinated forearm and elbow flexed 90 degrees. Each position must be maintained for 5 seconds. Each exercise will be repeated 10 times at each session and patients will be encouraged to apply exercise 3-5 times per day for 5 weeks.
223984957|NCT05222100|DIAGNOSTIC_TEST|Mammography screening|Breast screening mammograms use X-rays to look for cancers that are too small to see or feel.
223984958|NCT00763451|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
223984959|NCT00763451|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
223984960|NCT00763451|DEVICE|Pen auto-injector|
223984961|NCT00763451|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
223984962|NCT01473992|DEVICE|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
223984963|NCT01473992|DEVICE|Otto Bock Genium|Study knee.
223984964|NCT02673411|DEVICE|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
223984965|NCT00725543|BIOLOGICAL|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
223984966|NCT06336798|DRUG|Pioglitazone 30mg|Study participants will take Pioglitazone 30 mg PO daily
224119997|NCT00260572|BEHAVIORAL|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
223984967|NCT06336798|DRUG|Placebo|Study participants will take a placebo PO daily
224119998|NCT01666080|DRUG|Busulfan|0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
224119999|NCT01666080|DRUG|Fludarabine|40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.
224120000|NCT01666080|RADIATION|Total body irradiation|200 cGy on Day -1
224120001|NCT01666080|BIOLOGICAL|Stem cell transplant|stem cell infusion on day 0
223984968|NCT06336798|DIAGNOSTIC_TEST|Labs|Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).
223984969|NCT05594589|DRUG|Lemborexant|Lemborexant oral tablet.
223984970|NCT05594589|OTHER|PBO|Lemborexant-matched PBO tablet.
223984971|NCT03200444|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
223984972|NCT03200444|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
223984973|NCT03200444|OTHER|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
223984974|NCT03200444|OTHER|P-4|Newly developed adhesive P-4
223984975|NCT03200444|OTHER|P-15|Newly developed adhesive P-14
223984976|NCT03200444|OTHER|P-16|Newly developed adhesive P-8
223984977|NCT05949567|OTHER|urodynamic exam in sitting and lying position|Urodynamic exam with 1st filling in sitting or lying position. Then , during the same procedure, a second filling in the opposite position of the 1st filling (lying or sitting)
223984978|NCT03688997|OTHER|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
223984979|NCT02168478|DRUG|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
223984980|NCT02168478|OTHER|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
223984981|NCT02168478|OTHER|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
223984982|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
224120002|NCT01666080|DRUG|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
224120003|NCT02243527|OTHER|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
223984983|NCT00087555|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
223984984|NCT00087555|DRUG|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
223984985|NCT03168399|DIETARY_SUPPLEMENT|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
223984986|NCT01233271|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
223984987|NCT04793581|DEVICE|Atherectomy|Directional atherectomy of lesions below the knee.
224120004|NCT02243527|OTHER|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
224294236|NCT06612918|OTHER|sham laser acupuncture and the exercises program|The patients will receive a sham laser acupuncture and the exercise program in the form of: strengthening exercises for abdominal and back muscles; lumbar stabilization exercises and stretching exercises.
223984988|NCT00723918|DRUG|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
223984989|NCT00723918|DRUG|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
223984990|NCT00723918|DRUG|SAB placebo|an inactive substance
223984991|NCT00723918|DRUG|Methadone placebo|Methadone placebo
223984992|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 1 application|
223984993|NCT02251756|DEVICE|Actinica, 0.8 mg/cm2, 2 applications|
223984994|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 1 application|
223984995|NCT02251756|DEVICE|Actinica, 2 mg/cm2, 2 applications|
223984996|NCT01324700|DRUG|High severity group: Escitalopram|Participants within high severity group were stratified to receive escitalopram.
223984997|NCT01324700|DRUG|High severity group: Placebo|Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
223984998|NCT01324700|DRUG|Low severity group: Escitalopram|Participants within low severity group were stratified to receive escitalopram.
223984999|NCT01324700|DRUG|Low severity group: Placebo|Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
223985000|NCT05194228|BEHAVIORAL|Ecologial Momentary Assessment settings|Various settings for ecological momentary assessments
223985001|NCT00000959|DRUG|Isoniazid|
223985002|NCT00000959|DRUG|Pyridoxine hydrochloride|
223985003|NCT05122741|DRUG|P2Y12 Potent Inhibitor + Aspirin for STEMI patients|Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
223985004|NCT05122741|DRUG|Clopidogrel + Aspirin for CCS patients|Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
223985005|NCT05479747|DRUG|post operative analgesics|post-operative pain killer
223985006|NCT06414005|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts (TPX-115)
223985007|NCT06414005|OTHER|Placebo (Saline)|Ultrasound-guided intratendinous placebo injection
223985008|NCT03618810|DRUG|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
223985009|NCT03618810|DRUG|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (\<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
223985010|NCT05432505|OTHER|ligamentum teres tenodesis|Identification of ligamentum teres ligamentum teres tenodesis
223985011|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
223985012|NCT02628483|DIETARY_SUPPLEMENT|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
223985013|NCT01691547|DRUG|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
223985014|NCT01691547|DRUG|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
224294237|NCT04242095|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, and stool samples
223985015|NCT01691547|DRUG|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
223985016|NCT01691547|DRUG|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
223985017|NCT03108638|BEHAVIORAL|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
223985018|NCT03845023|DRUG|AD036 Dose 1|AD036 Dose 1 oral capsule administered before sleep
223985019|NCT03845023|DRUG|AD036 Dose 2|AD036 Dose 2 oral capsule administered before sleep
223985020|NCT03845023|DRUG|AD036 Dose 3|AD036 Dose 3 oral capsule administered before sleep
223985021|NCT03845023|DRUG|Placebo|Placebo oral capsule administered before sleep
223985022|NCT04061070|OTHER|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
223985023|NCT04061070|OTHER|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
223985024|NCT05696223|OTHER|Ultrasound|Doppler mesure
223985025|NCT02220218|DRUG|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
223985026|NCT02220218|DRUG|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
223985027|NCT02220218|DRUG|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
223985028|NCT06183671|DRUG|JX09 or placebo SAD|For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.
223985029|NCT06183671|DRUG|JX09 or placebo MAD|For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.
223985030|NCT06183671|DRUG|JX09|For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
223985031|NCT05193747|OTHER|Anesthesia depth monitoring|BIS monitor will be placed on the forehead according to the manufacturer recommendation and the anaesthesia team will be blinded to BIS monitor during the whole case. The initial BIS tracing will be recorded starting the surgery initiation (defined as the depth of anesthesia by the anaesthesiologist to initiate surgical intervention) and ending with end of surgical intervention.
223985032|NCT04103502|DEVICE|MicroPort Medial Pivot TKA|Subjects will have been implanted with the MicroPort Medial Pivot TKA
223985033|NCT04103502|DEVICE|DePuy Attune PCR TKA|Subjects will have been implanted with the DePuy Attune PCR TKA
223985034|NCT05314374|DIETARY_SUPPLEMENT|Ileocolonic-release conjugated bile acid|500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.
223985035|NCT05314374|DRUG|Placebo|Placebo looks exactly like the study drug, but it contains no active ingredient. 500 mg tablets orally twice daily on an empty stomach, 30 minutes prior to breakfast and evening dinner for 90 +/- 5 days. Subjects will receive 500 mg twice daily during their first week and 1000 mg twice daily for the rest of the study.
223985036|NCT05124821|DEVICE|Central venous catheter intended to be used for children during routine clinical practice|Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
223985037|NCT06003699|BEHAVIORAL|Search Inside Yourself (SIY) program|The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
223985038|NCT02351336|DEVICE|Ultrasound imaging|"1. \- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~2. \- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~3. \- CL measurement using 2D ultrasound ( in cm)"
224120005|NCT02936505|DRUG|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
224120006|NCT02936505|DRUG|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
223985039|NCT00895388|BEHAVIORAL|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
223985040|NCT05111743|DRUG|Brolucizumab|Participants received brolucizumab injection during the index period
223985041|NCT03691142|OTHER|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
223985042|NCT02151071|DEVICE|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
223985043|NCT02151071|DEVICE|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
224120007|NCT02936505|DRUG|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
224120008|NCT02936505|DRUG|Corticosteroids|"Corticosteroids:~* Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~* From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg \> 6 months."
223985044|NCT00847158|PROCEDURE|phacoemulsification alone|phacoemulsification alone
224120009|NCT02936505|DRUG|Tacrolimus|"* Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
224120010|NCT01841658|DIETARY_SUPPLEMENT|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
224120011|NCT00870948|DRUG|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
224120012|NCT05399706|DIAGNOSTIC_TEST|CTA Aorta|Computed Tomography Angiography - Aorta Whole
224120013|NCT02237495|DRUG|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
224120014|NCT02237495|DRUG|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
224120015|NCT04664920|DEVICE|exergame|motor-cognitive training device
223985045|NCT00847158|DEVICE|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
223985046|NCT03096756|DRUG|GC4702 dry powder|5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
223985047|NCT03096756|DRUG|GC4702 lipid suspension|112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
223985048|NCT03096756|OTHER|GC4419 IV|infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
223985049|NCT03096756|OTHER|Placebo Dry Powder|Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
224120016|NCT01540188|BEHAVIORAL|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
224120017|NCT05224622|DIAGNOSTIC_TEST|VOX|Breath exhalation into the mouthpiece of the VOX breath diagnostic device.
224120018|NCT02191202|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
223985050|NCT03096756|OTHER|Placebo lipid suspension|Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
223985051|NCT03096756|OTHER|Fed Condition|with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
223985052|NCT03096756|OTHER|Fasting Condition|For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
223985053|NCT03096756|DRUG|GC4702 lipid suspension - Part 2|Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
223985054|NCT02719756|DRUG|Metformin|Metformin tablets 1000 mg
223985055|NCT02719756|DRUG|Dapagliflozin|Dapagliflozin 10 mg tablets
223985056|NCT02719756|DRUG|Metformin up-titration|
223985057|NCT02302703|OTHER|low FODMAP diet vs Gluten free diet|
224120019|NCT02262039|DEVICE|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
223985058|NCT02554383|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
223985059|NCT02554383|DRUG|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
223985060|NCT04580498|DRUG|SHR-1701+Paclitaxel+carboplatin|Drug: SHR-1701 30mg/kg Drug: Paclitaxel 175mg/m2 Drug: Carboplatin AUC 5
223985061|NCT04580498|DRUG|SHR-1701|Drug: SHR-1701 30mg/kg
223985062|NCT00420225|DEVICE|Low-weight prolypropylene mesh|
223985063|NCT01965106|DRUG|QPI-1007 Injection|1.5 mg QPI-1007 Injection
223985064|NCT01965106|DRUG|(including placebo)|Sham injection procedure
223985065|NCT00827736|PROCEDURE|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
223985066|NCT00827736|DRUG|ISDN ointment|application of ISDN 1% ointment 6 times a day
223985067|NCT00827736|DRUG|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
223985068|NCT06140394|OTHER|diode laser|low level diode therapy
223985069|NCT06140394|OTHER|non surgical scaling|non surgical scaling using ultrasonic
223985070|NCT02915562|OTHER|exercise|
223985071|NCT02918292|DRUG|Antithymocyte Globulin (ATG)|Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
223985072|NCT02918292|DRUG|Fludarabine|Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.
223985073|NCT02918292|DRUG|Cyclophosphamide|Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
224120020|NCT02262039|DEVICE|Conventional pressure|15 mmHg target pressure
223985074|NCT02918292|RADIATION|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1.
223985075|NCT02918292|PROCEDURE|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
223985076|NCT02918292|DRUG|Tacrolimus|Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.
223985077|NCT02918292|DRUG|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.
223985078|NCT02918292|DRUG|G-CSF|G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.
223985079|NCT05399615|DIAGNOSTIC_TEST|VOX|Breath biopsy
223985080|NCT01966978|DRUG|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
223985081|NCT01966978|DRUG|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
223985082|NCT01966978|DRUG|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
223985083|NCT01966978|DRUG|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG \<180
223985084|NCT01801982|OTHER|non-interventional|non-interventional
223985085|NCT01126697|DRUG|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
223985086|NCT00476528|BEHAVIORAL|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
223985087|NCT00476528|BEHAVIORAL|Reality Orientation|A quasiexperimental study
223985088|NCT00002406|DRUG|Indinavir sulfate|
223985089|NCT01185171|DRUG|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance \[CC\] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
223985090|NCT03772093|DEVICE|Trabert current|Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
223985091|NCT03772093|OTHER|Manual massage|Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
223985092|NCT01869140|DEVICE|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
223985093|NCT05936918|OTHER|Transcutaneous electrical acupoint stimulatios|Percutaneous electrical stimulation technology of acupuncture points is a technology that uses a trace current close to human bioelectricity on the surface of acupuncture points to prevent and treat diseases guided by meridian theory, and is a new treatment of percutaneous nerve electrical stimulation combined with acupuncture points. As one of the related techniques of acupuncture, it is a safe, non-invasive, simple and new acupoint stimulation method
223985094|NCT05936918|OTHER|Bilateral transverse abdominal plane block|Transverse abdominis plane block is a technique in which a local anesthetic is injected into the transverse abdominis plane to block sensory nerves passing through this plane to achieve analgesic effect
223985095|NCT01493999|DRUG|Clopidogrel reloading|Up to three times 600 mg clopidogrel
223985096|NCT01493999|DRUG|Prasugrel|60 mg prasugrel in patients with HPR
223985097|NCT04574232|DRUG|knee intra-articular infiltration with Triamcinolone acetonide|knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
223985098|NCT03518242|DRUG|Cyclophosphamide|Given PO
223985099|NCT03518242|DRUG|Methotrexate|Given PO
223985100|NCT03518242|DRUG|Capecitabine|Given PO
223985101|NCT03518242|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
223985102|NCT00282945|DRUG|Rosiglitazone|
223985103|NCT00282945|DRUG|Metformin|
223985104|NCT03482947|DRUG|ultrasonography-guided TAP block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
223985105|NCT03482947|DRUG|Caudal epidural block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
223985106|NCT04629937|OTHER|SPECT acquisitions|All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.
223985107|NCT05716776|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
223985108|NCT00727506|DRUG|BIBW 2992|BIBW 2992 once daily
223985109|NCT00727506|DRUG|TMZ|TMZ 21/28
223985110|NCT00727506|DRUG|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
223985111|NCT00223210|DRUG|Quetiapine|Active Quetiapine
223985112|NCT00223210|DRUG|PLacebo|Placebo
223985113|NCT01977027|OTHER|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
223985114|NCT01555398|DIETARY_SUPPLEMENT|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
223985115|NCT02081937|BIOLOGICAL|anti-CD19-CAR vector-transduced T cells|
223985116|NCT00302926|PROCEDURE|energy restriction and maintenance|
223985117|NCT04459221|DRUG|Gardasil 9, 9-Valent Intramuscular Suspension|access to HPV vaccination near the college in a health bus
223985118|NCT00080522|BEHAVIORAL|Monitoring by HIV-trained primary care nurses|
223985119|NCT00080522|BEHAVIORAL|Community-based directly observed therapy (DOT)|
223985120|NCT00080522|DRUG|stavudine|
223985121|NCT00080522|DRUG|lamivudine|
223985122|NCT00080522|DRUG|efavirenz|
223985123|NCT00080522|DRUG|zidovudine|
223985124|NCT00080522|DRUG|didanosine|
223985125|NCT00080522|DRUG|lopinavir/ritonavir|
223985126|NCT01463228|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
224120021|NCT04174638|OTHER|Motivational Interviewing and Education Based on Watson's Theory of Human Caring|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
224120022|NCT02364193|DEVICE|MRI|"Cardiac MRI for LVEF and segmentation.~* Phase-contrast MRI for CO in aorta and each pulmonary vein.~* DCE-MRI for bolus kinetic parameter analysis."
223985127|NCT01463228|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
223985128|NCT03339947|OTHER|Questionnaire|
223985129|NCT02391077|OTHER|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
223985130|NCT02391077|OTHER|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
223985131|NCT02391077|OTHER|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
223985132|NCT00149617|DRUG|Buspirone|
223985133|NCT03226301|DRUG|Ibrutinib + Venetoclax 15 cycles|"Cycle 1 + 2: 420 mg ibrutinib, day 1-28 \| Cycle 3: 420 mg ibrutinib, day 1-28 \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28"
223985134|NCT03226301|DRUG|Ibrutinib until progression/relapse|420mg ibrutinib daily until progression/relapse
223985135|NCT03226301|DRUG|Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles|"Cycle 1: 420 mg ibrutinib \| 20 mg venetoclax, day 1-7 \| 50 mg venetoclax, day 8-14 \| 100 mg venetoclax, day 15-21 \| 200 mg venetoclax, day 22-28 \| cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28"
223985136|NCT00715117|DRUG|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
223985137|NCT00715117|OTHER|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
223985138|NCT04966559|DRUG|Placebo treatment|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
223985139|NCT04966559|DRUG|Naldemedine 0.2 MG Oral Tablet|Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
223985140|NCT02394522|DEVICE|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
223985141|NCT02394522|DEVICE|Active Ingredient|Transfluthrin (Active ingredient)
223985142|NCT02394522|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
223985143|NCT03954288|DIAGNOSTIC_TEST|serum for sclerostin ELISA test|Blood sample to measure serum sclerostin level
223985144|NCT04373837|BEHAVIORAL|Prismatic googles inducing prismatic adaptation (PA) associated to Virtual Reality (VR)|"The experimental condition consists of PA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward shift of the visual field (experimental condition). After lenses removal, a leftward shift of spatial attention will be produced.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
224120023|NCT02364193|DRUG|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
224294238|NCT04242095|OTHER|Medical Chart Review|Review of medical records
223544271|NCT06159907|DIAGNOSTIC_TEST|the diagnostic and prognostic value of PET/MRI and PET/CT with 18F-FDG in patients presenting with gynecological tumors|"For the evaluation of patients affected by endometrial cancer, the correlations between semi-quantitative PET parameters (SUVmax, SUVmean, MTV and TLG calculated at different SUVmax thresholds) and histological data, such as for example myometrial invasion, will be investigated. lymph node invasion, tumor grade and type, risk level, probability of mutation of the p53 gene, etc.~In addition to traditional imaging parameters we will also investigate the usefulness of radiomic features, i.e. quantitative data extracted from PET images (PET/CT or PET/MRI), in predicting and explaining histological data"
223544272|NCT01938261|DRUG|paracetamol|
223544273|NCT01938261|DRUG|0.45 % saline solution|Placebo
223985145|NCT04373837|OTHER|Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)|"The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action."
223985146|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
223985147|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
223985148|NCT06547307|DIETARY_SUPPLEMENT|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects.
223544274|NCT03761056|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
223544275|NCT03761056|DRUG|Fludarabine|Administered according to package insert
223544276|NCT03761056|DRUG|Cyclophosphamide|Administered according to package insert
223985149|NCT01652859|DRUG|Liposomal Amphotericin B|
223985150|NCT01652859|DRUG|AmBisome|
223985151|NCT06546059|DEVICE|narrow band ultraviolet-B|vitiligo patients will recevie twice sessions per week
224294239|NCT06387173|OTHER|Non-Interventional Study|Non-interventional study
224294240|NCT05004350|DRUG|Encorafenib|oral hard capsule
224294241|NCT05004350|DRUG|Cetuximab|intravenous infusion
223985152|NCT04292080|DRUG|Dimethyl Fumarate (TECFIDERA™)|Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
223985153|NCT04292080|OTHER|No active : no treatment|30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
223985154|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
223985155|NCT00471172|BEHAVIORAL|Face-to-face counseling by a dietitian (monthly)|
223985156|NCT00471172|BEHAVIORAL|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
223985157|NCT00471172|BEHAVIORAL|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
223985158|NCT00471172|BEHAVIORAL|Self help|
223985159|NCT02332200|OTHER|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
223985160|NCT05028036|OTHER|Personalized lifestyle treatment program|"The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components:~* Dietary changes~* Supplements~* Measures to improve sleep / circadian rhythm~* Stress management~* Physical exercise~The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program."
223985161|NCT01338376|BEHAVIORAL|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~* Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~* Physician Activity: frequent insulin titration"
224294242|NCT05004350|DRUG|FOLFIRI|"Combination of:~irinotecan ( also known as: Camptosar, Camptothecin-11 and CPT-11) intravenous infusion, folinic acid (also known as: 5-formyl tetrahydrofolic acid and leucovorin) intravenous infusion, and 5-FU (also known as; fluorouracil) intravenous bolus/intravenous infusion"
223985162|NCT01338376|BEHAVIORAL|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~* Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~* Physician Activity: less frequent insulin titration"
223985163|NCT01338376|DRUG|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
223985164|NCT02450097|OTHER|Caloric restriction|
223985165|NCT01454388|OTHER|breakfast|
223985166|NCT01440413|BIOLOGICAL|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
223985167|NCT04414631|DRUG|Conestat alfa|Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
223985168|NCT00169845|DIETARY_SUPPLEMENT|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
224294243|NCT02371421|DRUG|Allopurinol|
223985169|NCT00169845|DIETARY_SUPPLEMENT|Placebo|Provided by Roche Vitamins Inc
223985170|NCT04322812|DEVICE|Active PBMT|The Active PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA) will be used. The ACTIV PRO emits 30mW of 905nm, 300mW of 850nm, 200mW of 660nm and 0mW of 455nm light via an electric diode energy source. PBMT will be applied using the direct contact method with light pressure on the skin. The PBMT application time will be 120 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according widespread pain index \[WPI\] ), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 60 Joules (J) per region. The total dose might vary between patients and each session.
224120024|NCT02364193|DEVICE|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
224120025|NCT02364193|DEVICE|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
224120026|NCT03636776|OTHER|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
224120027|NCT04775212|DRUG|Desﬂurane|compare effects of inhaled anaesthetic desflurane and sevoflurane on liver functions.
224120028|NCT04775212|DRUG|Sevoflurane|Sevoflurane
224120029|NCT06367868|PROCEDURE|After 5 ml CSF Drainage|Optic Nerve Sheath Diameter and Intracranial Pressure measurements will be after 5 ml CSF drainage
224120030|NCT05208424|DIAGNOSTIC_TEST|Coronary angiography|Invasive coronary angiography
224120031|NCT02627131|BIOLOGICAL|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
224120032|NCT04929262|BEHAVIORAL|Supporting Anxious Youth: Strategies for Caregivers|The outreach presentation will last 75 minutes with an additional 15 minutes for caregiver questions. The presentations will occur in the evening via Zoom. The presentation will include information about identifying anxiety disorders, strategies for caregivers to help their youth with anxiety, evidence-based practices to treat youth anxiety, and strategies for finding a therapist who uses cognitive behavior therapy with exposures. The text on the presentations is written at a 5.3 grade reading level. Presentations will incorporate stigma reduction strategies, such as education to dispel myths, and behavioral decision-making tools to elicit hope, empowerment, and motivation.
224120033|NCT01387295|DRUG|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
224120034|NCT01847664|DRUG|Rifamycin SV-MMX® 400 mg b.i.d.|
223728101|NCT02303288|DEVICE|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
223728102|NCT05377385|BEHAVIORAL|Questionnaire|Questionnaire about usability of the Omnipod DASH insulin administration system
223728103|NCT04341454|DRUG|DWP14012 X mg|DWP14012 X mg, tablet, orally, once daily for 2 weeks
223728104|NCT04341454|DRUG|DWP14012 X mg placebo|DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks
223728105|NCT04341454|DRUG|DWP14012 Y mg|DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
223728106|NCT04341454|DRUG|DWP14012 Y mg placebo|DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
223728107|NCT00276744|BIOLOGICAL|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223728108|NCT00276744|DRUG|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223985171|NCT04322812|DEVICE|Placebo PBMT|The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The 660nm light via an electric diode energy source with outputs to \>1% to appear like the active comparator. PBMT will be applied using the direct contact method with light pressure on the skin. The placebo PBMT application time will be 115 seconds per region and the total time will vary according to the number of regions to be treated. Only the painful regions on that day will be treated (according WPI), which can comprise a minimum of 3 and a maximum of 18 regions in total. The dose used for applications during the treatment will be 0 Joules (J) per region. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo).
224120035|NCT01847664|DRUG|Rifamycin SV-MMX® 600 mg t.i.d.|
224120036|NCT01847664|DRUG|Rifamycin SV-MMX® Placebo|
224120037|NCT02985450|BIOLOGICAL|Engerix-B|Hepatitis B Vaccine
224120038|NCT03392155|BEHAVIORAL|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
224120039|NCT00816907|DRUG|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
224120040|NCT00816907|DRUG|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
223728109|NCT00276744|DRUG|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223728110|NCT00276744|DRUG|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
224120041|NCT00431847|PROCEDURE|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
223985172|NCT01482429|OTHER|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
223985173|NCT00176059|DRUG|intravenous immunoglobulins (IVIG)|
223985174|NCT00176059|PROCEDURE|kidney transplantation|
223985175|NCT03747809|DEVICE|CIEDs Remote Monitoring System|Cardiac device remote monitoring system
223985176|NCT02759796|PROCEDURE|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
223985177|NCT02759796|PROCEDURE|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
223985178|NCT04567810|DRUG|anti-SARS-CoV-2 IgY|anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
223985179|NCT04567810|DRUG|Placebo|Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
223985180|NCT05032846|PROCEDURE|Ultrasound guided laparoscopic ovarian cystectomy|Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
223985181|NCT05032846|OTHER|Laparoscopic Ovarian Cystectomy|Laparoscopic Ovarian Cystectomy will be performed as standard clinical practice.
223985182|NCT04286763|DIAGNOSTIC_TEST|Biliary RMI and CT scan.|"For a good appreciation of the anatomy of the biliary lesion, an MRI was systematically performed on all our patients.~For a good appreciation of the presence of an associated vascular lesion, a CT-scan was systematically performed on all our patients."
223985183|NCT03492710|BIOLOGICAL|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
223985184|NCT02311088|DRUG|Caffeine|
223985185|NCT02311088|DRUG|Placebo|
223985186|NCT05739539|DIAGNOSTIC_TEST|optical coherence tomography angiography|optical coherence tomography angiography will be done postoperatively in both groups to assess the retinal microvascular changes
223985187|NCT05739539|DIAGNOSTIC_TEST|spectral domain optical coherence tomography|optical coherence tomography for ganglion cell complex (GCC) measurement and assessment of macular edema or epiretinal membrane formation will be done postoperatively in both groups
223985188|NCT01089296|OTHER|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.
223985189|NCT00002722|DRUG|cisplatin|
223985190|NCT00002722|DRUG|fluorouracil|
223985191|NCT00002722|DRUG|leucovorin calcium|
223985192|NCT02207036|BEHAVIORAL|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
223985193|NCT02207036|BEHAVIORAL|Smokefree.gov|referral to the NCI Smokefree.gov website
223985194|NCT04805957|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
223985195|NCT05802771|PROCEDURE|surgical resection|surgical resection of the lung cancer
223985196|NCT01214421|DRUG|Tolvaptan|Tablets of 15 or 30 mg
223985197|NCT01692093|DIETARY_SUPPLEMENT|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
223985198|NCT01692093|DIETARY_SUPPLEMENT|Placebo|Placebo
224120042|NCT00431847|PROCEDURE|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
223985199|NCT03561597|BEHAVIORAL|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
223985200|NCT02399397|PROCEDURE|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
223985201|NCT02399397|PROCEDURE|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
223985202|NCT02399397|PROCEDURE|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
223985203|NCT02399397|DRUG|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
223985204|NCT02399397|PROCEDURE|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
223985205|NCT04297072|DRUG|Rivaroxaban (Xarelto, BAY-597939)|Non-vitamin K antagonist oral anticoagulants (NOACs). The prescription of drug is at the discretion of physician following the routine clinical practice.
223985206|NCT04297072|DRUG|VKAs|Oral anticoagulant. The prescription of drug is at the discretion of physician following the routine clinical practice.
223985207|NCT02744339|DRUG|Riociguat|Adempas up-titrated to max. 1.5mg TID
223985208|NCT02744339|DRUG|Placebo|Placebo sham-titrated TID
223985209|NCT06457685|DEVICE|Pulse Intravascular Lithotripsy (Pulse IVL)|The Pulse Intravascular Lithotripsy (Pulse IVL) System is used for the treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
223985210|NCT00542412|DRUG|Riluzole|
223985211|NCT05079594|OTHER|Mother voice|"Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale."
223728111|NCT00276744|DRUG|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223985212|NCT05079594|OTHER|White noise|"Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed."
223985213|NCT00940862|BIOLOGICAL|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
224120043|NCT02524860|DEVICE|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
223985214|NCT00940862|DEVICE|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
224120044|NCT04081935|DEVICE|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
224120045|NCT01469013|DRUG|Placebo|
224120046|NCT01469013|DRUG|Baricitinib|
224120047|NCT01469013|DRUG|Baricitinib|
224120048|NCT01469013|DRUG|Baricitinib|
223985215|NCT00940862|OTHER|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
223728112|NCT00276744|DRUG|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223728113|NCT00276744|DRUG|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223985216|NCT00985270|DRUG|Rifampicin|
223985217|NCT00985270|DRUG|Placebo|
223985218|NCT03391856|DRUG|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
223985219|NCT03391856|OTHER|supportive therapy|prophylactic platelet transfusion was given when platelet count \<20000/ul
223985220|NCT03545412|DEVICE|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
223985221|NCT00509405|DRUG|potassium citrate|6 times 10 mEq per day, oral for 24 months
223985222|NCT03783689|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
223985223|NCT06266598|DRUG|Metformin|Only obese children with insulin resistance were treated with metformin.
223985224|NCT06202768|OTHER|data collection|data collection : age, gestational age, BMI, history of vaginal delivery after cesarean section, indication for cesarean section, preeclampsia for this pregnancy, the cervix dilatation, position in the pelvis, cervix consistency
224120049|NCT01469013|DRUG|Methotrexate|Administered orally as background therapy
223985225|NCT05874310|GENETIC|FT-002|Comparison of different dosages of FT-002
223985226|NCT04191408|PROCEDURE|PEEP increase|PEEP increase +5 to +15 cmH2O. PLR at 30 degrees.
223985227|NCT03465943|DRUG|Ringer|1L of Ringer's solution as a preload in one group.
223985228|NCT03465943|DRUG|Voluven|500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
223985229|NCT01621789|OTHER|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
223985230|NCT00104767|DRUG|celecoxib|
223985231|NCT01493037|DEVICE|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
223985232|NCT01931982|DRUG|Victoza|
223985233|NCT00550212|DRUG|neratinib|HKI-272, Single-dose capsule and solution
223985234|NCT02900898|OTHER|Dynamic exercise and Mediterranean diet|DE, MD
223985235|NCT02900898|OTHER|Dynamic exercise|DE
223985236|NCT02900898|OTHER|Mediterranean diet|MD
223985237|NCT02900898|OTHER|Control|Control
223985238|NCT05768399|DIAGNOSTIC_TEST|The level of biomarkers in Peripheral blood|All participants will be extracted 5ml peripheral blood into the anticoagulant tube by nurses and the peripheral blood will be detected for biomarkers of asthma. Children with asthma will take pulmonary function, blood test and specific IgE test etc. The lung function test will be performed by professional technicians and the results will be interpreted by specialists. The blood test and specific IgE test will be collected by specialist nurses and the results will be issued by professional inspectors. Children with asthma and their guardians will be asked for filling the questionnaire of Childhood Asthma Control Test (C-ACT). And then the doctor will check and calculate the scores after completion.
223985239|NCT02321267|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
223985240|NCT02581059|DRUG|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
223985241|NCT02581059|DIETARY_SUPPLEMENT|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
224120050|NCT01350349|BEHAVIORAL|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
224120051|NCT01350349|BEHAVIORAL|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
224120052|NCT04686006|DRUG|Potassium Iodide|
224120053|NCT00002663|BIOLOGICAL|Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
224120054|NCT02040194|DRUG|AM-101|AM-101 gel for intratympanic injection
223985242|NCT03975842|OTHER|Sinonasal and otologic evaluation|"At onset, each participant had:~* sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~* otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
223985243|NCT05144399|OTHER|Accelerated antibiotic treatment|"E. faecalis uncomplicated: 4 weeks.~E. faecalis complicated: 4 weeks.~S. aureus uncomplicated: 2 weeks.~S. aureus complicated: 4 weeks.~Streptococci spp. NVE: 2 weeks.~Streptococci spp. PVE or abscess: 3 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 1 week after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
223985244|NCT05144399|OTHER|Standard treatment length|"E. faecalis uncomplicated: 6 weeks.~E. faecalis complicated: 6 weeks.~S. aureus uncomplicated: 4 weeks.~S. aureus complicated: 6 weeks.~Streptococci spp. NVE: 4 weeks.~Streptococci spp. PVE or abscess: 6 weeks.~Subsequent to cardiac surgery with a negative valve culture (organism NOT grown in laboratory from valve): Minimum 2 weeks after surgery regardless of previous antibiotic treatment received.~Subsequent to cardiac surgery with a positive valve culture (organism grown in laboratory from valve): treatment will continue with the start date of antibiotics changed to the date of surgery.~Complicated IE defined as patients with abscess, embolic event, surgically treated IE, and/or PVE.~NVE: native valve endocarditis, PVE: prosthetic valve endocarditis."
224120055|NCT02040194|DRUG|Placebo|Placebo gel for intratympanic injection
224120056|NCT01351766|DRUG|Transdermal Nicotine Patch|Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
224120057|NCT00002250|DRUG|CD4-IgG|
224120058|NCT02142894|DEVICE|CST001|
223985245|NCT04115189|DRUG|Sunitinib|Patients to receive Sunitinib as first line therapy for mRCC
223985246|NCT02392104|DRUG|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
223985247|NCT01582698|BIOLOGICAL|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
223985248|NCT03239327|DRUG|Misoprostol|
223985249|NCT04887506|DRUG|TAVT-45|250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
223985250|NCT04887506|DRUG|Zytiga|500 mg tablet, two tablets administered once daily
223985251|NCT04887506|DRUG|Prednisone|mCSPC patients received 5 mg orally once daily. mCRPC patients received 5 mg orally twice daily.
223985252|NCT01999777|DRUG|USL261|
223985253|NCT01999777|DRUG|Placebo|
223985254|NCT04460833|DEVICE|Feedback modalities given through an augmented reality headset|All children wear the augmented reality headset. After a habituation period to the holograms, they start the protocol. It consists of a warm-up session, training session (which three feedback modalities are presented), calibration session (to get the maximal speed and spontaneous speed of the child), and test session. During test session, all the children walk on the 30m corridor. They have 6 feedback modalities + the control, given randomly. On the way out, they have to walk fast as possible ; on the return they have to walk at intermediate speed.
223985255|NCT03666806|BIOLOGICAL|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
223985256|NCT04238013|OTHER|Whole Body Vibration (WBV)|The WBV session will consist of 8 bouts of 45s vibration (50Hz) with a minute of rest in between each bout.
223985257|NCT04238013|OTHER|Electrical Stimulation|The electrical stimulation intervention serves to account for any effects of standing and/or of repeated performance of the sit-to-stand behavior on neurophysiological outcomes. In the electrical stimulation intervention, participants will receive electrical stimulation while standing on the vibration platform for 8 bouts for 45s with a minute of rest in between without vibration.
223985258|NCT02394665|RADIATION|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
223985259|NCT02394665|DRUG|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~* Concurrent during Radiation Therapy: 75 mg/m\^2 orally for 6 weeks;~* Post-radiation, adjuvant therapy: 150 mg/m\^2 - 200 mg/m\^2 orally daily on days 1 - 5 of each cycle."
224294244|NCT03729154|BEHAVIORAL|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
224294245|NCT01089621|DRUG|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
224294246|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
223985260|NCT02394665|BEHAVIORAL|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
223985261|NCT02394665|RADIATION|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
223985262|NCT02394665|RADIATION|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
223985263|NCT02394665|DEVICE|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
223985264|NCT02906722|DRUG|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
223985265|NCT02906722|DRUG|Intravenous placebo|administration once, twice or 3 times per day according to renal function
224120059|NCT03085706|BIOLOGICAL|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
224120060|NCT06387238|DIAGNOSTIC_TEST|PSMA PET/CT|pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy.
223544277|NCT03493139|BEHAVIORAL|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
223985266|NCT02906722|DRUG|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
223985267|NCT02906722|DRUG|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
223985268|NCT06445088|DIAGNOSTIC_TEST|VCA-IgA, EBNA1-IgA, and EBV-DNA|Detect VCA-IgA, EBNA1-IgA, and EBV-DNA for all participants.
223985269|NCT06445088|DIAGNOSTIC_TEST|EBV C Promoter Methylation Detection in nasopharyngeal swab samples|Detection of methylation status of Epstein-Barr virus C promoter in human nasopharyngeal swab samples
223985270|NCT03170843|DEVICE|use of plastic ring wound retractor|the experimental arm will use the plastic ring wound retractor for wound protection.
224120061|NCT05276713|DRUG|Tucidinostat|Tucidinostat in combination with endocrine drugs
224120062|NCT03721185|COMBINATION_PRODUCT|Dr.K. Treatment|Overweight and obesity treatment response
223985271|NCT04399343|DRUG|Dexmedetomidine|Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
224120063|NCT04776291|RADIATION|4D PET-CT Scan|The recruited patients will have a 4d PET-CT scan that is additional to the usual care.
223985272|NCT04399343|DRUG|Normal saline|Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.
223985273|NCT01774136|BEHAVIORAL|Enhanced HIV and MCH training for CHW|
223985274|NCT00922402|PROCEDURE|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
223985275|NCT01805245|BEHAVIORAL|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
223985276|NCT06019364|OTHER|Whole blood transfusion|Transfusion of whole blood in a situation with acute bleeding according to routine practice.
223985277|NCT04669769|OTHER|interview|telephone interview
223985278|NCT05473936|BEHAVIORAL|Community Health Worker led curriculum|The intervention arm will consist of a CHW-based health educational program via Zoom, where participants will be provided with information about COVID-19, COVID-19 resources and services in Los Angeles County, and engagement with Los Angeles County Department of Health Services CHWs who will lead the curriculum and be available to answer questions of the intervention arm patients.
223985279|NCT05161741|DRUG|Insulin|Human rDNA Insulin (Insuget, local brand of Getz Pharma)
223985280|NCT01957540|DRUG|Ticagrelor|
223985281|NCT01957540|DRUG|Prasugrel|
223985282|NCT06050447|PROCEDURE|Right hemicolectomy|Resection of the caecum and ascending colon is appropriate for patients with tumors located anywhere from caecum to the transverse colon
223985283|NCT06050447|PROCEDURE|Left hemicolectomy|Resection of the sigmoid colon is appropriate for patients with tumors located anywhere from the distal transverse colon to the rectosigmoid junction.
223985284|NCT06050447|PROCEDURE|Sigmoid colon resection|Resection of the sigmoid colon is appropriate for patients with tumors located in the sigmoid colon
223985285|NCT06050447|PROCEDURE|Anterior resection of the rectum|AR is appropriate for tumors located in rectosigmoid junction and in the proximal rectum
223985286|NCT06050447|PROCEDURE|Low anterior resection of the rectum|LAR is appropriate for tumors located in the middle and low rectum
223985287|NCT06050447|PROCEDURE|Abdominoperineal resection|APR is appropriate for distal rectal cancers that invade the external sphincter or the levator muscles
223985288|NCT06050447|PROCEDURE|Total Colectomy|Total abdominal colectomy may be indicated for patients with primary multiple cancer tumors
223985289|NCT03860090|DEVICE|Pacemaker implant|Implantation of endovenous cardiac stimulation device.
223985290|NCT03860090|DEVICE|Defibrillator implant|Implantation of endovenous cardiac defibrillation device.
223985291|NCT03860090|PROCEDURE|AXILLARY VEIN ACCESS|Fluoroscopy-guided axillary puncture to get vein access
223985292|NCT03860090|PROCEDURE|CEPHALIC VEIN ACCESS|Optimized cephalic vein cutdown to get vein access
223728114|NCT00276744|DRUG|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223728115|NCT00276744|PROCEDURE|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
223728116|NCT06474052|DRUG|Gelofusine 4%|Gelofusine 4% 10 ml/kg is administered following anaesthesia induction in 30 minutes.
223728117|NCT06451601|DEVICE|Intermittent hypoxia-hyperoxia therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, occupation, environment, body mass index, nutritional status, abdominal circumference, hip circumference, smoking, alcohol. Also, the patients performed a 6-minute walking test.~Other Names:~* Hydrokinetotherapy~* Hydrothermotherapy~* Electrotherapy~* Massage therapy~* Kinetotherapy"
223728118|NCT00189150|DRUG|Mycophenolate mofetil|
223728119|NCT00189150|DRUG|Valganciclovir|
223985293|NCT02227797|DRUG|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
223985294|NCT05421767|PROCEDURE|nerve stimulation guided renal denervation procedure|RNS-in
223985295|NCT04182347|OTHER|Health Research ToolKit Development|"The Toolkit will be an accessible, structured process for people with IDD and people with IDD's paid and unpaid caregivers to be engaged partners. Learning activities are focused on leadership, information about research, health for individuals with IDD. Learning activities will include topics:~What is health research? What is the health research process? How can individuals with IDD be involved in health research? Where is research happening? How to think like a researcher. Creating health stories for research and care advocacy.~The learning activities will teach individuals with IDD information and allow participants to practice the learning."
224294247|NCT00865631|DRUG|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
224294248|NCT00865631|DRUG|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
223985296|NCT05692219|BEHAVIORAL|Lifestyle medicine|6 weeks booklet-delivered multicomponent lifestyle medicine intervention
223985297|NCT05692219|BEHAVIORAL|Cognitive behavioral therapy|6 weeks booklet-delivered self-help cognitive behavioral therapy
223985298|NCT05849623|PROCEDURE|Endoscopic Mucosal Resection (EMR)|EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
223985299|NCT05849623|PROCEDURE|Cold Endoscopic Mucosal Resection (C-EMR)|C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
223985300|NCT05849623|PROCEDURE|Underwater Endoscopic Mucosal Resection (U-EMR)|U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
223985301|NCT01386723|DRUG|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
223985302|NCT03411785|OTHER|CPC+ model|CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
223985303|NCT01280851|PROCEDURE|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
224120064|NCT04131309|DRUG|Daratumumab|As of Protocol Amendment 1, all new subjects are dosed with daratumumab subcutaneous injection (SC) co-formulated with recombinant human hyaluronidase rHuPH20. Subjects who already began treatment with daratumumab intravenous (IV) infusion (i.e., prior to Am 1) switch to SC on the next administration date according to the protocol schedule. Subjects receive daratumumab IV at a dose of 16 mg/kg and daratumumab SC at a fixed dose of 1800 mg for the first 8 weeks (Cycles 1 and 2) of treatment and then every 2 weeks for 4 cycles (Cycles 3 to 6) and then every 4 weeks until progression of disease (according to MOD-PFS), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total. All treatment cycles are 4 weeks (28 days) in length.
223544278|NCT06629688|DRUG|semaglutide|Patient demographic and clinical data was collected and entered into a database made specifically for the study. The patients were examined, and their vital signs and body measures were recorded. Before the introduction of semaglutide therapy all participants completed an oral absorption iron test (OIAT). As described in previous studies, OIAT was conducted in an outpatient setting. Following the initial OIAT therapy with semaglutide was started. Each subject received parenterally administered one-weekly semaglutide. To enhance glycaemic control, the therapy was up-titrated every four weeks. Initially, the dose was set at 0.25 mg once a week, four weeks later, it was raised to 0.5 mg once weekly, and four weeks after that, it was increased to 1 mg once weekly. After reaching the maximum maintenance dosage of 1 mg for two weeks, each T2DM patient completed a follow-up OIAT at week 10 of the study. Data from the first and subsequent OIATs were analysed statistically.
223544279|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive sulfentanil for PCIA.
223544280|NCT06690307|PROCEDURE|patient controlled intravenous analgesia(PCIA)|Patients will receive oxycodone for PCIA.
223985304|NCT01255761|BIOLOGICAL|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
223985305|NCT03506347|DRUG|Vancomycin|Antibiotic
223985306|NCT05167084|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
223985307|NCT05167084|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
223985308|NCT05167084|DRUG|Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8 in a total daily dose of 19.9mg
224120065|NCT04131309|DRUG|Bortezomib Injection|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
223985309|NCT05167084|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 8
223985310|NCT03616483|OTHER|This is a non-interventional trial|This is a non-interventional trial
223985311|NCT01255956|DEVICE|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
223985312|NCT01255956|DEVICE|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
223985313|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
223985314|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
223985315|NCT00445575|DRUG|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
223985316|NCT00445575|DRUG|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
224294249|NCT06577051|DIAGNOSTIC_TEST|Eustachian tube function test with 226 and 1000 Hz probes|In children undergoing tonsillectomy ± adenoidectomy without eustachian dysfunction, tympanometry with 226 Hz and 1000 Hz probes, ipsi and contralateral acoustic reflexes with 226 Hz probe, eustachian function test with 226 Hz probe (automatic Williams test) and play audiometry in young children and pure tone audiometry in older children are aimed to control tubal functions in preoperative period, postoperative day 1 and week 2.
223544281|NCT06691126|OTHER|Terpinolene in olive oil|Single oral dose of 200mg food-grade terpinolene in 5ml of olive oil
223985317|NCT05355129|DRUG|TT-00920|Tablets
223985318|NCT05355129|DRUG|TT-00920 Placebo|Tablets
223985319|NCT01539577|DRUG|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
223985320|NCT05613088|DRUG|MORAb-202|Specified dose on specified days
223985321|NCT05613088|DRUG|Paclitaxel|Specified dose on specified days
223985322|NCT05613088|DRUG|Pegylated Liposomal Doxorubicin (PLD)|Specified dose on specified days
223985323|NCT05613088|DRUG|Topotecan|Specified dose on specified days
223985324|NCT01437488|DRUG|Cabazitaxel|"* Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~* Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~* Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
223985325|NCT01437488|DRUG|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
223985326|NCT01437488|PROCEDURE|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
223544282|NCT02305121|DEVICE|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
223985327|NCT01437488|BIOLOGICAL|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
223985328|NCT05392491|OTHER|No intervention|No intervention. It is an observational study
223985329|NCT05063331|PROCEDURE|Minimally invasive supracervical hysterectomy and sacrocolpopexy (MI-SCH+SCP)|Minimally invasive robotic or laparoscopic supracervical hysterectomy will be done, and the vaginal apex (including cervix) will be suspended utilizing sacrocolpopexy mesh to the anterior spinous ligament.
223985330|NCT05063331|PROCEDURE|Vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)|The uterus will be removed vaginally and the vaginal apex will be suspended utilizing sutures in the uterosacral ligament.
223985331|NCT00669734|BIOLOGICAL|Falimarev|Given intratumorally or SC
223985332|NCT00669734|BIOLOGICAL|Inalimarev|Given SC
223985333|NCT00669734|OTHER|Laboratory Biomarker Analysis|Correlative studies
223985334|NCT00669734|BIOLOGICAL|Sargramostim|Given SC
223985335|NCT06163651|BEHAVIORAL|Parent-Child Assistance Program - One-Year Version|Case managers work closely with parents over the course of one year, meeting them in their own homes when possible, to help them set goals and take advantage of available resources.
223985336|NCT01717586|DRUG|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
223985337|NCT01717586|DRUG|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
223985338|NCT03127839|PROCEDURE|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
223985339|NCT03127839|PROCEDURE|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
223985340|NCT03127839|BEHAVIORAL|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
223985341|NCT03912532|BIOLOGICAL|NGM282|NGM282
223985342|NCT03912532|OTHER|Placebo|Placebo for NGM282
223985343|NCT05424003|DRUG|Semaglutide Pen Injector|Starting dose of 0.24 mg injected weekly and increased every 4 weeks to a potential maximum dose of 2.4 mg weekly at 20 weeks followed by 52 weeks of weekly injections at the maximum tolerable dose
224120066|NCT04131309|DRUG|Dexamethasone oral tablet|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
224120067|NCT02255851|DEVICE|SENTINEL (Cerebral Protection System)|
224120068|NCT00000461|DRUG|pravastatin|
223985344|NCT05424003|DRUG|Placebo|Placebo solution injected weekly for 72 weeks
223985345|NCT06514274|DRUG|Berberine|Berberine 500 mg, twice daily for 14 days
223985346|NCT06514274|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
223985347|NCT06514274|DRUG|Amoxicillin|Amoxicillin 1000mg, twice daily for 14 days.
223985348|NCT06514274|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
223985349|NCT06514274|DRUG|Clarithromycin|Clarithromy 500mg, twice daily for 14 days.
223985350|NCT06514274|DRUG|Esomeprazole|Esomeprazole 10mg, twice daily for 14 days.
223985351|NCT04356807|PROCEDURE|Reflex Locomotion Therapy|The exercises corresponding to the motor complexes of the 1st phase of the rolling reflex and the original creeping reflex were performed, dedicating one minute to each side and performing two repetitions in each session.
224120069|NCT00000461|DRUG|niacin|
224120070|NCT00000461|DRUG|cholestyramine|
224120071|NCT00000461|DRUG|gemfibrozil|
224120072|NCT00000461|DRUG|fatty acids, omega-3|
224120073|NCT03202069|OTHER|Even protein|Intake of even protein 5 day rotating menu
224120074|NCT03202069|OTHER|Skewed protein|Intake of skewed protein 5 day rotating menu
223985352|NCT04356807|PROCEDURE|Passive Joint Mobilizations|Passive Joint Mobilizations with articular pressure described by Moyer-Mileur, et al. 1995 and modified by Vignochi, et al. 2008
224120075|NCT05697939|DIAGNOSTIC_TEST|NSite 3D Scanning|"Three separate users will enter the exam room and use the NSite application to scan the patient in the bending position. These users may include research coordinators, physicians, or other authorized staff.~The NSite application will have a user tutorial on how to scan patients that users are instructed to watch prior to conducting a scan.~All participants are asked to remove clothing above the waist but may keep a bra or tight-fitting shirt on during the scanning procedures. The patient will be asked to assume a forward bending position. One user will capture a scan of the patient's back in this position. The user will calibrate the device and then walk around the patient while scanning per app directions. Once this user captures the scan, it will be processed by the application. New scans will then be obtained by the two other users. Once all users have captured a scan, the scanning process and patient participation will be completed."
224120076|NCT05782101|DIAGNOSTIC_TEST|Integrated proteomic HPLC-ESI-MS analysis of salivary peptides|A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
224120077|NCT01154972|PROCEDURE|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
224120078|NCT04141644|DRUG|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
224294250|NCT00650988|PROCEDURE|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
223728120|NCT01294267|DEVICE|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
223728121|NCT00848471|DEVICE|Quark RMR|Quark RMR calorimeter (Cosmed)
224294251|NCT02603978|BEHAVIORAL|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
224294252|NCT02603978|BEHAVIORAL|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
224294253|NCT02603978|BEHAVIORAL|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
223728122|NCT00848471|DEVICE|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
223728123|NCT04581161|DEVICE|Life2000® Ventilator|"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."
223728124|NCT04856189|BIOLOGICAL|Pembrolizumab|Given IV
223728125|NCT04856189|DRUG|Selinexor|Given PO
223985353|NCT04356807|PROCEDURE|Massage|Soft massage with soft pressures in limbs, tactile stimulation and no motion.
223985354|NCT06391398|BEHAVIORAL|Stoma care education with the Stoma Care Training Belt|Stoma care education
223985355|NCT06339463|BEHAVIORAL|Self-Distancing Intervention|"In the Self Distancing Intervention condition, participants will be instructed to describe the exposure task from a self-distanced perspective (e.g., Emily is going to touch the spider)."
223985356|NCT06339463|BEHAVIORAL|First-person self-talk|"Youth will be randomized to a BAT with a control condition. In this arm, participants will be instructed to describe the exposure task from a self-immersed perspective (e.g., I'm going to touch the spider)"
223985357|NCT04068649|RADIATION|Palliative Radiation Therapy|Undergo palliative RT
223985358|NCT04068649|OTHER|Quality-of-Life Assessment|Ancillary studies
223985359|NCT04068649|OTHER|Questionnaire Administration|Ancillary studies
223985360|NCT04068649|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223985361|NCT05213234|BEHAVIORAL|Chronotherapy|Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
223985362|NCT05357092|DEVICE|Appliance. Orthodontic appliance to carry out dentoalveolar movement|"A digital 3D model obtained with a 3D scanner: (T1,baseline), (T2, aprox 8 weeks), and at the end of othopedic treatment previous to primary lip surgery (T3, aprox 16 weeks).~Once a week, clinical check."
223985363|NCT06014827|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223985364|NCT06014827|PROCEDURE|Computed Tomography|Undergo CT or PET/CT scan
223985365|NCT06014827|DRUG|Osimertinib|Given PO
223985366|NCT06014827|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223985367|NCT06014827|RADIATION|Stereotactic Body Radiation Therapy|Undergo BgRT/SBRT
223985368|NCT06014827|OTHER|Survey Administration|Ancillary study
223985369|NCT03951831|DRUG|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
223544283|NCT06710080|DRUG|Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]|Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.
223985370|NCT03951831|DRUG|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
223985371|NCT03951831|DRUG|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
223985372|NCT03951831|DRUG|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
223985373|NCT04284397|DRUG|Low dose ASA|A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
223985374|NCT04284397|OTHER|Control|All participants will be tested with no treatment.
223985375|NCT05505084|PROCEDURE|Tooth extraction and ridge preservation using different barrier mermbranes|The hopeless and unrestorable teeth are planned for extraction and implant placement.
223985376|NCT04560712|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
223985377|NCT04560712|OTHER|Best Practice|Undergo usual care
224294254|NCT00378950|BEHAVIORAL|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
224294255|NCT00378950|BEHAVIORAL|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
224294256|NCT05677100|DEVICE|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy.
223544284|NCT06710080|DRUG|Placebo|Placebo twice daily
223544285|NCT06715813|PROCEDURE|pelvic floor strengthening|"pelvic floor strengthening exercises includes :~1. breathing exercises,~2. kegels exercises~3. bridging exercises~4. squatting~5. Elevator exercises"
223544286|NCT06715813|PROCEDURE|Transversus abdominal strengthening|core stabilization exercises for 2 weeks like stomach hallowing , dead bugs and pelvic tilt exercises and after 2 weeks dead bug progression, planks
223544287|NCT06712095|DEVICE|Video capsule investigation|Participants will undergo both a video capsule examination and a colonoscopy on the same day.
223985378|NCT04560712|OTHER|Questionnaire Administration|Ancillary studies
223985379|NCT03947918|BEHAVIORAL|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
223985380|NCT03947918|BEHAVIORAL|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
223985381|NCT05289908|DRUG|Pemetrexed (1)|Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
223985382|NCT05289908|DRUG|Pemetrexed (2)|The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
223985383|NCT05289908|DRUG|Folic Acid|Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
223985384|NCT05289908|DRUG|Vitamin B12|A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
223985385|NCT05289908|DRUG|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
223985386|NCT06124131|BEHAVIORAL|Financial incentive for colorectal cancer screening|$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
223985387|NCT06124131|BEHAVIORAL|Financial incentive for flu shot|$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
223985388|NCT06124131|BEHAVIORAL|Financial incentive for COVID-19 shot|$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
223985389|NCT01628640|OTHER|Laboratory Biomarker Analysis|Correlative studies
223985390|NCT01628640|OTHER|Pharmacological Study|Correlative studies
223985391|NCT01628640|BIOLOGICAL|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
223985392|NCT03783871|DEVICE|Microwave ablation|Subjects will be treated with microwave ablation.
223985393|NCT06434961|DRUG|SHR6508 plus oral placebo tablets|SHR6508 plus oral placebo tablets
223985394|NCT06434961|DRUG|Cinacalcet plus intravenous placebo|Cinacalcet plus intravenous placebo
223985395|NCT06636942|DEVICE|Intermittent pneumatic compression|Following a soccer match, athletes will be enrolled in a recovery treatment: placebo intervention or intermittent pneumatic compression. Participants will be randomly assigned to each group. Neuromuscular tests (cmj) and perceptual questionnaires (hooper index) will be conducted.
223985396|NCT05824910|OTHER|Exercise program (virtual/remote)|Intervention (8 weeks): using the participants' initial assessment and personal characteristics, the therapist will provide personalized recommendations (e.g. maximum heart rate, minimum SpO2), explain the educational materials, and instruct patients on safety precautions
223985397|NCT03569891|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
223985398|NCT03569891|BIOLOGICAL|Factor IX (FIX)|During the lead-in phase, which lasted for a minimum of 26 weeks (i.e., ≥6 months), subjects recorded their use of FIX replacement therapy and bleeding episodes in their dedicated e-diary.
223985399|NCT05663528|PROCEDURE|orotracheal intubation|Clinical and laboratory data will be collected from patients who are intubated after 48 hours of admission to the intensive care unit
223985400|NCT01315015|OTHER|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
223985401|NCT05916235|DEVICE|THOR® laser system|We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
223985410|NCT06369363|DRUG|Placebo|Subjects will be assigned to 1 week of transdermal placebo patch.
224120079|NCT04141644|DRUG|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
224294257|NCT04273282|DRUG|Dexycu intracameral dexamethasone|To evaluate the safety and ocular efficacy of Dexycu.
224120080|NCT06150209|DEVICE|Vendaje|Dehydrated Human Amniotic Membrane
224120081|NCT00604448|OTHER|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
224120082|NCT00604448|OTHER|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
224120083|NCT01719081|PROCEDURE|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
224120084|NCT05384743|DRUG|Rituximab Monotherapy|Rituximab 375mg/m2. This regimen was repeated after 1 week. A total of 2-4 courses of treatment.（After two courses of treatment, EBV-DNA turned negative, no need to apply again. If EBV-DNA is still positive after two courses of treatment, 2 courses of treatment are applied again).
224294258|NCT04273282|DRUG|Prednisolone Acetate|To evaluate the safety and ocular efficacy, and patient acceptance of post cataract surgery drug treatment regimen that minimizes topical medications.
224294259|NCT03808740|DRUG|Atomoxetine|atomoxetine 0.5 mg/kg/day.
223985411|NCT06369363|DRUG|Estradiol|Subjects will be assigned to 1 week of transdermal estradiol (0.05 mg/day) patch.
223985412|NCT06131203|DEVICE|DeepView SnapShot Portable (DV-SSP)|DV-SSP assistive imaging to collect observational data
224120085|NCT03415074|BEHAVIORAL|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
224120086|NCT01299597|DRUG|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
224120087|NCT01299597|DRUG|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
224120088|NCT01299597|DRUG|SB649868|20mg daily given for 14 days.
224294260|NCT03808740|DRUG|Placebo|sugar pill
224294261|NCT06812494|BIOLOGICAL|VRC07-523LS 400mg|Intravenous infusion (IV)
224120089|NCT01588574|BIOLOGICAL|MT10109|Botulinum toxin type A
224120090|NCT01588574|BIOLOGICAL|BOTOX(Registered trade mark)|Botulinum toxin type A
224294262|NCT06812494|BIOLOGICAL|PGT121.414.LS 400mg|IV infusion
224294263|NCT06812494|BIOLOGICAL|PGDM1400LS 400mg|IV infusion
224294264|NCT06812494|BIOLOGICAL|VRC07-523LS 3200mg|IV infusion
224294265|NCT06812494|BIOLOGICAL|PGT121.414.LS 1600mg|IV infusion
224294266|NCT06812494|BIOLOGICAL|PGDM1400LS 1600mg|IV infusion
224294267|NCT06234774|PROCEDURE|Robot-assisted laparoscopic surgery|
224294268|NCT06234774|PROCEDURE|Conventional (non-robotic) laparoscopic surgery|
223985413|NCT05443880|BEHAVIORAL|Exercise|The exercise intervention will focus on working the core muscles, starting with low-intensity isometric contraction of the core muscles that stabilize the trunk; increasing intensity by performing functional tasks (phase 1: independent isometric contraction of transversus-abdominis and multifidus, phase 2: co-contraction and functional tasks of the deep trunk muscles; phase 3: functional task with load; phase 4: functional task with unstable surface)
223985414|NCT05443880|BEHAVIORAL|Exercise + mindfulness|The Mindfulness Based Stress Reduction (MBSR) program will strictly follow the protocol developed by Jon Kabat Zinn. Each session will include three activities: the presentation of a topic, moments of dialogue and exploration in group (using appreciative inquiry) and a Mindfulness practice. Participants will be provided with workbooks, audios with guided meditations, and instructions for practice at home. In addition, the Exercise + mindfulness intervention will include the exercise program described in the exercise intervention.
223985415|NCT05443880|OTHER|Control group|The control group will be provided with the usual care received in the Physical Medicine and Rehabilitation Service: stretching, breathing and motor control exercises 2 days / week (45 minutes per session) during a period of 8 weeks.
223985416|NCT06538298|OTHER|Multimodal Exercise Program with Gamification|A comprehensive exercise program for 3 days a week for 6 weeks that utilizes non-contact boxing and gamification at moderate to vigorous intensity.
223985417|NCT04670770|DRUG|Drug - SHR1459|Oral Tablets taken once daily for 52 weeks
223985418|NCT04178811|DEVICE|Holmium Laser Enucleation of Prostate|Use of Holmium Laser Enucleation of Prostate in management of Benign Prostatic Hyperplasia patients
223985419|NCT01898715|DRUG|ATR-101|
223985420|NCT04594733|DRUG|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo|minocycline (200 mg daily) and NAC (1200 mg daily) followed by placebo
223985421|NCT04594733|DRUG|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)|Placebo followed by minocycline (200 mg daily) and NAC (1200 mg daily)
223985422|NCT06802081|DRUG|Tirzepatide|Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.
223985423|NCT06802081|DRUG|Placebo|Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
223985424|NCT06646224|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides circulatory support for patients with cardiogenic shock.
223985425|NCT06646796|OTHER|Yoga|Yoga with certified teacher, 3 times a week during 3 months.
223985426|NCT00277342|PROCEDURE|measurement of lipid-induced hepatic insulin resistance|
223985427|NCT05575063|DEVICE|Investigational Healon Endocoat|Ophthalmic Viscoelastic device
223985428|NCT05575063|DEVICE|Control Healon EndoCoat|Ophthalmic Viscoelastic device
224120091|NCT00814840|DEVICE|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
224120092|NCT00814840|DEVICE|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
224294269|NCT05524428|BEHAVIORAL|Implementation Science Strategy|The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
224294270|NCT04883424|BEHAVIORAL|Diabetes Education Program Based on Health Belief Model|After the application, increase in family support and decrease in blood sugar levels are expected in diabetic patients. Family members' diabetic attitudes are expected to increase.
224294271|NCT06297525|DRUG|STP938|Small molecule
224294272|NCT03662763|DRUG|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
223985429|NCT06266442|OTHER|Whole genome sequencing testing|Whole genome sequencing
223985430|NCT00885326|DRUG|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
223985431|NCT00885326|DRUG|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
223985432|NCT00885326|DRUG|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
223985433|NCT00796627|GENETIC|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
223985434|NCT00796627|OTHER|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
223985435|NCT02055456|DRUG|Nandrolone Decanoate|
223985436|NCT01804998|PROCEDURE|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
223985437|NCT01804998|PROCEDURE|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
223985438|NCT03588598|DRUG|SHC014748M|a selective PI3Kδ inhibitor
223985439|NCT02647645|DEVICE|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
223985440|NCT02647645|PROCEDURE|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
223985441|NCT02647645|DEVICE|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
223985442|NCT00507806|DRUG|perflutren lipid microsphere|
223985443|NCT00801411|DRUG|cyclophosphamide|Given IV
223985444|NCT00801411|DRUG|docetaxel|Given IV
223985445|NCT00801411|DRUG|doxorubicin hydrochloride|Given IV
223985446|NCT03965780|OTHER|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
223985447|NCT01832662|OTHER|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
224294273|NCT03662763|DRUG|Placebo oral capsule|
224294274|NCT03527654|OTHER|Observational|Surveys, blood and urine collected prospectively over 24 months.
223544288|NCT06706167|DEVICE|stainless steel crown|Participants in this arm received a stainless steel crown for primary teeth restoration. The crowns were selected based on the clinical assessment of the patient's dental need.
223544289|NCT06706167|DEVICE|Zirconia crown|Participants in this arm received a zirconia crown for primary teeth restoration. The crowns were selected to provide a more aesthetic and durable option compared to stainless steel.
223985448|NCT01832662|OTHER|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
223985449|NCT01832662|OTHER|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
223985450|NCT00169975|DEVICE|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
223985451|NCT00658840|DRUG|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
223985452|NCT00658840|RADIATION|Localization, simulation and immobilization|"Radiation dose and planning~1. Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~2. Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~3. The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
223985453|NCT04626986|PROCEDURE|microwave ablation|Microwave ablation has the advantages of aesthetics, precise positioning, minimally invasive and painless for patients with early breast cancer.The tumor can be completely killed without injurying adjacent tissue. Some studies have suggested MWA is a safe and effective therapy for the treatment of breast cancer.
223985454|NCT04626986|PROCEDURE|breast conserving surgery|The treatment of early-stage breast cancer tends to be less-invasive including less morbidity, shorter hospitalization, and improved cosmetic results. Many reports have concluded that there was no difference between breast-conserving surgery and the traditional radical mastectomy for early stage breast cancer in time to distant metastases or overall survival, so breast-conserving surgery is becoming an alternative treatment for early-stage breast cancer.
223985455|NCT02230462|OTHER|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
223985456|NCT04584879|BEHAVIORAL|Standard UP Treatment|Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
223985457|NCT04584879|BEHAVIORAL|Capitalization UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
223985458|NCT04584879|BEHAVIORAL|Compensation UP Treatment|Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
223985459|NCT05484232|PROCEDURE|Laparoscopic Cholecystectomy|Early laparoscopic cholecystectomy in patients with acute calcular cholecystitis
223985460|NCT00175591|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
223985461|NCT03134261|DIAGNOSTIC_TEST|WB-MRI|scanning methods
223985462|NCT03134261|DIAGNOSTIC_TEST|SPECT-CT|scanning methods
223985463|NCT03134261|DIAGNOSTIC_TEST|Cholin-PET-CT|scanning methods
223985464|NCT03134261|DIAGNOSTIC_TEST|PSMA-PET-CT|
223985465|NCT04795076|DIETARY_SUPPLEMENT|Infant formula|Regular infant formula will be concentrated to give a calorie density of about 90 kcal/100 mL.
223985466|NCT00758823|DEVICE|Paranix|pediculicide product
223985467|NCT04417400|BEHAVIORAL|medicines use review|The provision of MUR service as defined in the SOP MUR (Slovene Chamber of Pharmacies). It is classified as a type 2a review (PCNE typology) and it is intended for the patients to support them in regular and proper medicines use. MUR is performed based on medication history and information provided by the patient in a purposely scheduled conversation with the pharmacist. Pharmacists must be certified to provide MUR. MUR goal is to identify DRPs and recommend interventions to resolve them. During the MUR interview, the pharmacist completes a working sheet that records information regarding medicines, identified DRPs and recommended interventions. After the MUR interview, patients are provided with a personal medicines card that contains all the information that is needed to support effective and safe medicines use (dosing regimen, taking with/without food, special warnings, recommendations, etc.).
223985468|NCT02360800|PROCEDURE|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
223985469|NCT02360800|PROCEDURE|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
223985470|NCT00356811|DRUG|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
223985471|NCT00356811|DRUG|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
223985472|NCT00503724|DRUG|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
223985473|NCT02386839|DRUG|rhIGF-1/rhIGFBP-3|"Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study."
223985474|NCT01198847|BEHAVIORAL|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
223985475|NCT02101983|DRUG|Cytosine Arabinoside|
223985476|NCT05047978|OTHER|Cow's milk protein infant formula|A routine cow's milk-based infant formula
224120093|NCT05648344|BEHAVIORAL|WW|"WW assigns foods to a point value calculated through a proprietary algorithm that accounts for the food's caloric value, saturated and unsaturated fat, sugar, fiber, and protein. Members are encouraged to track their food and beverage intake, with the goal of staying within their personal points targets assigned based in an individual's sex, age height, weight, goals, and activity. The program also has Zero Point Foods (list of healthy foods with no point value) and can be eaten freely. In addition to the personal points, participants will be asked to attend WW coach-led virtual workshops conducted over Zoom, engage with peer- support, and WW-trained behavior change experts via 24/7 chat."
224120094|NCT05648344|BEHAVIORAL|Control|Usual care with information from myplate.gov
223985477|NCT05047978|OTHER|Partially hydrolyzed protein infant formula|A partially hydrolyzed cow's milk protein (PHP) infant formula
223985478|NCT04251546|DIAGNOSTIC_TEST|p2PSA|p2PSA test(for calculation of PHI)
223985479|NCT04251546|DIAGNOSTIC_TEST|Ultrasonic parameters|Ultrasonic parameters(TPV)
223985480|NCT04251546|DIAGNOSTIC_TEST|Transperineal prostate biopsy|Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
223985481|NCT03406650|DRUG|Neoadjuvant and adjuvant durvalumab|Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles
223985482|NCT03220685|BIOLOGICAL|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
223985483|NCT04038671|DEVICE|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
223985484|NCT04038671|DEVICE|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
223985485|NCT04038671|DEVICE|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
224120095|NCT04501653|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic compound produced by psilocybin mushrooms, and has been shown to have antidepressant and anti-anxiety effects after one dose of 25 mg. Common side effects are slight elevations in blood pressure and heart rate. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
223985486|NCT04840498|BEHAVIORAL|Autism Research|Measuring aspects such as self esteem, social skills, and social anxieties.
223985487|NCT05756179|DRUG|Diosmin and Hesperidin Combination|Diosmin 450 mg and Hesperidin 50 mg Combination
223544290|NCT06706167|DEVICE|Bioflx crown|Participants in this arm received a Bioflx crown, which is a flexible, biocompatible material often used for pediatric crowns.
223985488|NCT04198922|DRUG|Acalabrutinib|Given PO
223985489|NCT04198922|OTHER|Questionnaire Administration|Ancillary studies
223985490|NCT05523414|BEHAVIORAL|SKY|The SKY intervention will be administered in-person over three sessions spread over three consecutive days by qualified instructors. Participants will then be followed up over eight weeks' time, where they will be given the option to attend daily 35 minute breathwork sessions, again, guided by experienced instructors. Participants will be required to log whether or not they practiced for each day in the eight-week period. They will also receive intermittent reminders about their daily practice during the 8-week follow-up period.
223985491|NCT06223841|DRUG|IAP0971|IAP0971 should be subcutaneous injected，q3w
223985492|NCT01716091|PROCEDURE|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
223985493|NCT06862011|BEHAVIORAL|control group|Only surveys will be filled out.
223985494|NCT05304858|PROCEDURE|Biopsy|Standard of care surgical procedures to collect prostate cancer tissue from men with metastatic prostate cancers. Non-experimental.
223985495|NCT05098652|BEHAVIORAL|CuRB-IT|9 1-hour coaching sessions delivered over a videoconferencing platform (Zoom); 6 delivered weekly, 3 delivered biweekly
223728126|NCT06404502|BEHAVIORAL|PRISMA|"PRISMA has been developed adapting PM+, a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The adapted manual was developed to tailor the sessions to the structure of the Swiss prison system and the needs of inmates of jails in Switzerland. PRISMA involves the following elements: stress management, problem-solving, meaningful activities and relapse prevention~PRISMA has four core features:~* Evidence-based problem-solving strategies~* Brief and easy to learn~* Delivered by lay-helpers (trainers)~* Transdiagnostic, addressing depression, anxiety, stress, and practical problems as defined by participants;~PRISMA has four sessions."
223985496|NCT06738316|BEHAVIORAL|Simulation|Simulation of a patient safety incident in practice. The simulation closely replicates the workplace experience.
223985497|NCT06831929|BEHAVIORAL|Intervention Arm|Within the intervention clinics, parents of patients between the ages of 10-12 (who are eligible for the HPV vaccine) will receive a culturally tailored customized HPV vaccine message and testimonial video from a patient/survivor of an HPV associated cancer (e.g., oropharyngeal, or cervical) via the MyChart patient portal. Parents will also receive a personal call from the research coordinator to remind them that their child is due for the HPV vaccine. If the parent is interested in scheduling the HPV vaccine appointment during this call, the research coordinator will transfer the parent to UC Davis appointment call center to schedule the appointment. Also, primary care team members will receive a semi-annual learn at lunch workshop focused on strategies to introduce the HPV vaccine to parents and how to address concerns from vaccine hesitant parents. Workshop content will be tailored/adapted to include patient/parent cultural considerations.
223985498|NCT04314492|PROCEDURE|Tonsillectomy|Intracapsular removal of tonsillar tissue (\>90%) with coblation
223985499|NCT01803347|DRUG|◦Drug: ASCs. + fibrin glue|Experimental group
223985500|NCT01803347|DRUG|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
223985501|NCT05116605|OTHER|Photobiomodulation (PBM)|Photobiomodulation (PBM) is light therapy in both the visible and near-infrared range (non-UV). This light is absorbed through the skin and functions at the cellular level, providing a lowering of inflammation and oxidative stress. Participants will undergo 20 minute sessions three times a week for 4 weeks using the NovoTHOR as the only intervention.
223985502|NCT06933628|PROCEDURE|Patient-Specific Titanium Plates|Custom 3D-printed titanium fixation plates and cutting guides
223985503|NCT06933628|PROCEDURE|3D-Printed Intermediate Splint|CAD/CAM-fabricated occlusal splint for maxillary positioning
223985504|NCT06939413|DEVICE|Continuous glucose monitor (CGM)|The glucose data from the CGM will help participants to understand the effect of lifestyle and medications on their glucose levels. The glucose levels from the CGM will be remotely monitored. Outreach will be made to participants not reaching glycemic goals. Appropriate adjustments in treatment regimen will be made based on the glucose data obtained from CGM and RPM
224120096|NCT04501653|DRUG|Methylphenidate|Methylphenidate is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is used as an active control for this study because it is metabolized similarly to psilocybin and has similar effects on heart rate and blood pressure. Participants will be randomized to receive either psilocybin or control at two separate imaging timepoints in this study.
224120097|NCT00060086|DIETARY_SUPPLEMENT|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
224120098|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
224120099|NCT02844504|BEHAVIORAL|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
224120100|NCT00739297|DRUG|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
224120101|NCT00739297|DRUG|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
223728127|NCT03899571|DRUG|Oseltamivir Oral Capsule for 5 days post-exposure|Patients will receive oseltamivir for 5 days after last influenza exposure.
223985505|NCT06936683|DIAGNOSTIC_TEST|Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy|"Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy~1. Site selection: For patients with limited lesions, the lesion segment was chosen; For patients with diffuse lesions, the right middle lobe or left upper lobe tongue should be severed.~2. Injecting physiological saline: After the top of the bronchoscope is embedded in the target bronchial segment or subsegment opening, 37 ℃ or room temperature physiological saline is rapidly injected through the operating channel, with a total volume of 60-120ml, injected in batches (20-50ml each time).~3. Negative pressure suction: After injecting physiological saline, immediately use appropriate negative pressure (generally recommended below 100mmHg) to suction and obtain BALF, with a total recovery rate of ≥ 30%.~4. BALF collection: Specimens used for pathogen analysis need to be collected in sterile containers; Cytological analysis requires the selection of plastic containers or siliconized glass containers to reduce cell adhesion."
223985506|NCT06936683|DIAGNOSTIC_TEST|throat Swab|"A throat swab is a diagnostic sampling technique used to collect microbial specimens from the oropharynx and tonsillar areas. The standardized procedure involves:~1. Positioning the patient with their head tilted slightly backward;~2. Using a sterile, synthetic-fiber swab with a plastic shaft (avoiding calcium alginate or wooden shafts);~3. Vigorously rubbing the swab over both tonsillar pillars and the posterior pharyngeal wall while avoiding contact with the tongue, teeth, or uvula;~4. Immediately placing the swab into appropriate transport media viral/bacterial);~5. Maintaining cold chain (2-8°C) for specimen transport if required."
223985507|NCT06943001|BEHAVIORAL|Fit24+|This is a digital diabetes prevention program for adolescents that leverages a Fitbit device, rule-based chatbot, and eLearning platform to deliver a comprehensive nutrition and physical activity lifestyle intervention to Hispanic adolescents with obesity.
223985508|NCT06945874|DIAGNOSTIC_TEST|Validation of sleep quality by the Richards-Campbell Sleep Questionnaire (RCSQ) in french version|"The RCSQ questionnaire translated into French (RCSQ-F) will be distributed to intensive care patients who meet the inclusion and non-inclusion criteria and who have given their informed consent to participate in the study.~The questionnaire will be distributed on two occasions: at the first visit and on the day of discharge from intensive care for survivors, or at the latest on the 14th day of hospitalisation.~Patients' use of the questionnaire will enable internal validation (primary objective) by exploratory factor analysis."
224120102|NCT06401655|BEHAVIORAL|Financial Coaching for People living with Acquired Brain Injury (FC-ABI)|This is an individualized, in-person 10-session financial coaching intervention program. Each session is 45-minutes. In total, participants will be asked to participate in up to 7 hours and 30 minutes of intervention time with a trained Occupational Therapist. Each session will happen 1-1.5 weeks apart and the financial coaching program will last over 3-4 months. The financial coaching sessions will only be offered in-person (at MBIA Winnipeg location, in their home, at the University of Manitoba/Banntyne Campus, or other community locations acceptable/consented by the participant).
224120103|NCT01337011|OTHER|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
224120104|NCT00375882|PROCEDURE|hypothermia|
224120105|NCT00375882|PROCEDURE|cochlear implantation with mild hypothermia|
223985509|NCT06945289|BEHAVIORAL|Let's Know!|This intervention is modified from a whole-classroom intervention by LARRC, 2018 and modified by Hogan et al. used in a larger NIH R01 investigation. We are examining the efficacy of the first two units used by Hogan et al.
223985510|NCT06944275|PROCEDURE|Blood draw for thromboelastography - admission|Two blood samples will be collected at admission for thromboelastography using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.
223985511|NCT06944275|PROCEDURE|Blood draw for thromboelastography - follow-up|Two blood samples will be collected 3 - 7 days after initial thromboelastography for follow-up analysis using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.
223985512|NCT06944275|PROCEDURE|Blood draw for transcriptomic analysis|One blood sample will be collected at admission for transcriptomic analysis. Blood sample will be collected into a PAXgene® RNA tube and analysed using nanopore sequencing to characterise the viral and host transcriptome.
223544291|NCT06714721|DEVICE|Repetitive peripheral magnetic stimulation|"Repetitive peripheral magnetic stimulation treatment will be performed with the BTL-6000 Super Inductive System Elite available in our clinic. rPMS treatment will be adjusted to use the stimulus intensity above the motor threshold determined specifically for each patient by selecting the respiratory muscle strengthening protocol set in the device menu. The patient will be given a side-lying position, with the arms in front of the body and the elbows flexed, and the hips and knees in semiflexion. The applicator will be aligned to the diaphragm placement determined by ultrasonography (ninth intercostal space) and placed as close as possible to the skin, and rPMS will be applied for a total of 16 minutes, 8 minutes to the right diaphragm muscle and 8 minutes to the left diaphragm muscle. The treatment period is a total of 16 sessions according to the respiratory muscle strengthening protocol created by the company that developed the device."
223544292|NCT06714721|OTHER|Sham (No Treatment)|rPMS will be applied to the sham group as sham and the device will not be operated, the applicator of the device will be positioned on the right and left diaphragm muscle for a total of 16 minutes in the same way as the patients in the treatment group, and the sounds recorded during the operation of the device will be played to the patients as if the device was operating in the background. The patients will not know which group they are in.
223985513|NCT06944275|OTHER|Data collection - clinical/demographic/epidemiological data|Routine clinical/demographic/epidemiological data will be collected at admission and throughout hospitalisation. This will relate to clinical presentation (day of illness at presentation, presenting symptoms); demographics and epidemiology (age, gender, site of infection); clinical course during hospitalisation (maximum level of care, dialysis use, blood product use, survival outcome).
223985514|NCT06944275|OTHER|Data collection - routine laboratory parameters|Data on routine laboratory parameters will be collected throughout hospitalisation. These will relate to laboratory clotting parameters (platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer); liver function tests (aspartate aminotransferase, alanine aminotransferase); laboratory haematology parameters (haemoglobin, white cell count, blood film); laboratory biochemistry parameters (urea, creatinine); viral load.
223985515|NCT06944275|OTHER|Severity score calculation|A severity score will be assigned to each patient based on clinical and laboratory data at admission according to a pre-defined scoring system.
223985516|NCT06944236|OTHER|No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.|No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.
223985517|NCT06945588|BEHAVIORAL|Music listening|Happy music group listened to happy music (major mode with a tempo of \>120 beats per minute).
223985518|NCT06945588|BEHAVIORAL|Music listening|Sad music group listened to sad music (minor mode with a tempo of \<80 beats per minute).
223985519|NCT06945601|DRUG|ICI monotherapy or combinations of chemo- immunotherapy|ICI monotherapy or combinations of chemo- immunotherapy
223985520|NCT06944873|BIOLOGICAL|Blood test 4 EDTA tubes|Blood test 4 EDTA tubes for biological check-up
223985521|NCT06944782|DIAGNOSTIC_TEST|Electromyography (EMG) of the Oropharynx|The transmembranous electromyography (tmEMG) probe is a disposable single-use bipolar recording device with the sensor configured with two electrodes located at the distal end of the probe in a parallel orientation. Unlike conventional EMG probes that are designed to be inserted into the muscle, the tmEMG probe is placed on the surface of the muscle similar to a surface electrode; the tip of the probe is approximately the size of a ball point pen, which allows us to record from the smaller muscles inside the mouth. Recordings will be taken from the genioglossus and palatoglossus in the mouth bilaterally. Recordings will be taken while the subject performs various maneuvers such as shallow breathing, deep breathing, and pressing their tongue against the side of their mouth.
223985522|NCT06944392|DIETARY_SUPPLEMENT|Pumpkin Seed Extract|This is the only intervention
223985523|NCT06944652|OTHER|Stretching|Stretching of the plantar flexors or the shoulder joint
223985524|NCT06940986|BEHAVIORAL|Empowered Relief|ER is provided in a single, 2-hour session delivered remotely by trained instructors. ER has two main components: didactics and skills acquisition as outlined below. The ER class is administered virtually. The class includes the didactic and skill acquisition content. At the end of the class participants receive tangible items including the self-crafted, personalized catastrophizing cessation plan, a guided relaxation response audio file, and an electronic copy of the didactic class content.
223985525|NCT06940986|BEHAVIORAL|Move to Health|The M2H intervention is delivered virtually by trained health coaches using a 6-step process. The administration of M2H begins with an initial session with follow-up sessions scheduled every 1-2 weeks for up to 8 weeks or until the participant is ready to transition to self-management.
223985526|NCT06940986|OTHER|Usual Care as determined by primary care provider|Patients will receive care as determined by their primary care provider, with no input or control by the research team.
224120106|NCT03885739|OTHER|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
223544293|NCT06714305|DEVICE|Group B will be assigned to rotary instrumentation.|group B, NiTi rotary protaper system will be used for canal preparation by crown down technique.
223544294|NCT06714305|DEVICE|will be assigned to rotary instrumentation.|the canal will be prepared by conventional hedstorm files manually by step back technique.
223728128|NCT03899571|DRUG|Oseltamivir Oral Capsule for 10 days post-exposure|Patients will receive oseltamivir for 10 days after last influenza exposure.
223728129|NCT02742480|DRUG|Dabigatran|
223728130|NCT02742480|DRUG|Acenocoumarol|
223985527|NCT06945146|DRUG|Ponatinib|Ponatinib treatment will be initiated per usual treatment procedure at 45 mg once daily p.o., which will be gradually decreased to 30 mg and 15 mg according to the predefined criteria based on responsiveness to treatment and AEs in the course of the treatment.
223985528|NCT06944301|DIAGNOSTIC_TEST|blood sampling|measuring troponine preoperative and postoperative first and second day
223985529|NCT06944249|DRUG|NaCl (placebo)|During the safety margin excision, the placebo (NaCl) will be injected into the wound before suturing.
223985530|NCT06944249|DRUG|Verteporfin Injection|During the safety margin excision, the study drug (Verteporfin) will be injected into the wound before suturing.
223985531|NCT06945705|DRUG|furmonertinib combined with anlotinib|furmonertinib: 160 mg po qd Anlotinib: 8 mg per day, orally administered.The treatment cycle is every 3 weeks, with each cycle lasting 21 days. Anlotinib are taken on Days 1-14 of each cycle.
223985532|NCT06944834|DEVICE|Implant|Implantation of the device and follow-up
223985533|NCT06945614|DRUG|Xenon gas inhalation|Administration of xenon gas in the mixture with oxygen for the period of time via inhalation
223985534|NCT06945510|DEVICE|PCT detection|Clinicians will prescribe PCT tests every day for enrolled patients, with assigning a dedicated person monitoring the daily PCT results. Once the PCT \<0.5 ng/ml or ΔPCT (drop from the peak value) \>80%, the clinicians will receive a notification and will strictly adhere to guidelines and PCT values to adjust antibiotic prescriptions.
223985535|NCT05824169|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
223985536|NCT02425345|BEHAVIORAL|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
223985537|NCT05532735|BIOLOGICAL|ANXV|ANXV (Human recombinant Annexin A5 protein)
223985538|NCT04761367|OTHER|Physical activity. Physical Activity program is performed in a group in a gym|The intervention groups will be trained in a gyms under the direct supervision of a graduate trainer. All subjects will be requested to choose an additional third day of the week to carry out at least one of the following activities: walking, cycling or swimming
224120107|NCT06536985|BEHAVIORAL|treatment group|Researchers will collaborate with participants to develop personalized intervention plans, which include physical exercise, oral function training, basic dietary guidance, and detailed oral health knowledge directly related to oral health behaviors. To facilitate better communication and management, a WeChat group will be created to encourage participants to share their daily exercise achievements. In the first week, face-to-face oral function training sessions will be organized for the intervention group at the nursing home activity center. Concurrently, once a week, the intervention group will gather at the nursing home activity center to practice together using illustrated videos. On Wednesdays, educational articles and videos about oral health are sent via text message. On Fridays, a group communication activity is organized to enhance their social connections. Additionally, we will guide elderly participants to master essential internet skills, enabling them to use smartphones to
223728131|NCT03312478|DRUG|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
223728132|NCT05881928|DRUG|Sodium Valproate 500 Mg Prolonged-Release Oral Tablet|sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
223985539|NCT02275013|DRUG|Levosimendan|
223985540|NCT00826228|DRUG|teriparatide|teriparatide 20ug daily sc for 6 months
223985541|NCT00826228|OTHER|weight-bearing|device assisted walking
223985542|NCT02893488|DRUG|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
223985543|NCT02893488|DRUG|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
223985544|NCT02893488|DRUG|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
223985545|NCT06397794|OTHER|Quantitative surveys and qualitative interview|All participants will complete online surveys on topics including demographic and socioeconomic information, medical history (parent and child), pregnancy history, and mental health and well-being. They will then participate in a qualitative interview about their pregnancy and parenting experiences as gestational parents with Lyme disease.
224120108|NCT06536985|BEHAVIORAL|Contral group|Participants in the control group will receive general lifestyle advice via text message once or twice a week.They will not participate in the intervention\&#39;s fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group\&#39;s complaints or questions will always be answered with basic health information and suggestions. Researchers won\&#39;t ask for individual advice or comments from other professionals.
224120109|NCT02583789|DRUG|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
223728133|NCT05881928|DRUG|Lamotrigine|lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
223728134|NCT05881928|DEVICE|E.E.G|device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
223728135|NCT00946699|BIOLOGICAL|MEDI-551|0.1 mg/kg
223728136|NCT00946699|BIOLOGICAL|Placebo|0.3 mg/kg
223728137|NCT00946699|BIOLOGICAL|MEDI-551|1.0 mg/kg
223728138|NCT00946699|BIOLOGICAL|MEDI-551|3.0 mg/kg
223728139|NCT00946699|BIOLOGICAL|MEDI-551|10.0 mg/kg
223728140|NCT00946699|OTHER|Placebo|Placebo
223728141|NCT03502980|DEVICE|Bard PowerPICC|PICC Insertion
223985546|NCT04845490|DRUG|Mitomycin|Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
223985547|NCT04845490|DRUG|Lobaplatin|Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
223985548|NCT05999890|DRUG|Tapentadol Hydrochloride|Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
224120110|NCT02583789|DRUG|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
223985549|NCT00698347|DEVICE|M2a-Magnum™ Hip System|
223985550|NCT00297804|DEVICE|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
223985551|NCT00297804|DEVICE|Control stent|control stent
223985552|NCT02764099|BEHAVIORAL|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
223985553|NCT00717548|BEHAVIORAL|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
223985554|NCT00823537|PROCEDURE|therapeutic electrical stimulation|
223985555|NCT02336100|DEVICE|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
223985556|NCT01606423|DRUG|Placebo|Administered orally, single dose
223985557|NCT01606423|DRUG|LY2409021|Administered orally, single dose
223544295|NCT06717061|PROCEDURE|Harvesting of biological material|During the sampling of biological material, the test subjects will be under general anesthesia, which is why the sampling will not mean increased pain or discomfort other than what is standard after a gallbladder operation with the peephole technique. . The sampling is not planned to be repeated, but is performed at the time when the patients perform their biliary surgery. During the sampling, centimeter-sized pieces of skin, fatty tissue, connective tissue and muscle are taken. Furthermore, serum and plasma will be collected. Two tubes of blood samples (10 ml total) are taken, centrifuged and pipetted before being frozen for later analysis. Pieces of tissue are placed in formalin before transport to the laboratory. The study form regarding the patient\&#39;s basic state of health will be filled in by the operator on the day of surgery.
223728142|NCT03502980|DEVICE|Bard PowerMidline catheter|Midline Insertion
223728143|NCT02784275|DRUG|Cyclo-Z|
223985558|NCT01593930|OTHER|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
223985559|NCT01593930|OTHER|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
223985560|NCT01593930|OTHER|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
223985561|NCT01593930|OTHER|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
223985562|NCT02441439|DIETARY_SUPPLEMENT|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
223985563|NCT02441439|DIETARY_SUPPLEMENT|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
223985564|NCT00296738|DEVICE|SPECT/CT|GE INFINIA HAWKEYE
223985565|NCT00903760|DRUG|Decitabine|Decitabine 20 mg/m\^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
223985566|NCT00903760|DRUG|Clofarabine|Clofarabine 10 mg/m\^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
223985567|NCT01718951|DRUG|golimumab|golimumab
223728144|NCT02784275|DRUG|Placebo|
223985568|NCT01718951|DRUG|Pamidronate|pamidronate
223985569|NCT06173011|DRUG|QL2107|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
223985570|NCT06173011|DRUG|Keytruda®(china)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
223985571|NCT06173011|DRUG|Keytruda®(US)|intravenous infusion 35 min (±5min, minimum infusion 30min), D1 (Day 1, single dose)
223985572|NCT02711319|DEVICE|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
223985573|NCT02711319|DEVICE|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
223985574|NCT05366543|DIAGNOSTIC_TEST|Visual acuity measurement|Visual acuity will be measured using autorefractometer after cycloplegic eye drops 3 times and glasses will be prescribed for those who are needed.
223544296|NCT06717490|DRUG|Magnesium sulphate|"In patients allocated to the MS group, a fixed dose of magnesium sulfate diluted in a fixed volume of natural saline will be administered intravenously.~Thromboelastometry will be performed pre and post magnesium administration."
223985575|NCT01115686|DRUG|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
223985576|NCT01115686|DRUG|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
223985577|NCT03774290|DRUG|PBF-680|PBF-680 is an adenosine A1 receptor antagonist
223985578|NCT03774290|DRUG|Placebo oral capsule|Oral gelatine capsule
223985579|NCT02388347|DRUG|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
223985580|NCT02388347|BIOLOGICAL|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
223985581|NCT02388347|BIOLOGICAL|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
223985582|NCT02388347|BIOLOGICAL|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
223985583|NCT02388347|BIOLOGICAL|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
223985584|NCT05440604|OTHER|Fortified milk|Commercially available milk-based fortified beverage that has an updated profile of key micronutrients along with appropriate levels of protein and other macro- and micro- nutrients, in accordance with global and local nutritional recommendations
223985585|NCT03423810|DRUG|Hydralazine|Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
224120111|NCT06224894|OTHER|Music Therapy|Music Therapy
224120112|NCT06224894|OTHER|antiemetic treatment|antiemetic treatment
224120113|NCT02041351|DRUG|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
223544297|NCT06717490|OTHER|Placebo Drug|"In patients allocated to the NS group, a fixed dose of natural saline will be administered intravenously, through a fixed volume of solution.~Thromboelastometry will be performed pre and post magnesium administration."
223544298|NCT06710210|DEVICE|PCI with a bioresorbable scaffold and drug-coated balloon(s)|Hybrid PCI combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland)
223985586|NCT01177956|BIOLOGICAL|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
223728145|NCT00640601|DRUG|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
223985587|NCT01177956|DRUG|Cisplatin|Subjects will receive 75 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
223985588|NCT01177956|DRUG|5-Fluorouracil|Subjects will receive 750 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
223985589|NCT04775147|OTHER|Intensive BP lowering|The aim is to achieve a systolic BP level of \<120mmHg within 1hour after successful recanalization and to maintain this BP level for the next 72 hours (or until hospital discharge or death of this should occur earlier)
223985590|NCT04239599|RADIATION|Hypofractionated IMRT Radiation treatment|
223985591|NCT04935216|PROCEDURE|Laparoscopic|Laparoscopic resection of the pancreas has become widely accepted in the treatment of lesions which are benign or of low-grade malignancy
223985592|NCT00733395|DIETARY_SUPPLEMENT|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
223985593|NCT00733395|DIETARY_SUPPLEMENT|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
223985594|NCT00609856|DRUG|pioglitazone|tablet, 30 mg, once daily, 26 weeks
223985595|NCT00609856|DRUG|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
223985596|NCT02825251|DRUG|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
223985597|NCT02825251|DRUG|insulin aspart|Injected s.c. /subcutaneously (under the skin)
223985598|NCT00260247|DRUG|carbamazepine oxcarbazepine|
223985599|NCT00959777|DRUG|DA-3031|
223985600|NCT00959777|DRUG|Filgrastim|
223985601|NCT03662269|DRUG|indomethacin|indomethacin (75mg, bid, po, 14days)
223985602|NCT03662269|DRUG|Placebo|placebo (75mg, bid, po, 14days)
223985603|NCT03662269|DRUG|Omeprazole|placebo (20mg, qd, po, 14days)
223985604|NCT04923490|BEHAVIORAL|state and trait anxiety scale levels|"While the STAI-I anxiety level is scored as (1) never, (2) somewhat, (3) frequently, and (4) almost always, the scoring options in STAI-II are (1) almost never, (2) sometimes, (3) most of the time, and (4) almost always."
223985605|NCT02371772|OTHER|Training|Patients were trained to monitor INR and dose warfarin
223985606|NCT02475304|DRUG|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
224120114|NCT02401555|DEVICE|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
224120115|NCT00420394|PROCEDURE|Chemotherapy|
224120116|NCT00420394|PROCEDURE|surgery|
223544299|NCT06710210|DEVICE|PCI with drug-eluting stent(s)|PCI with \>1 newer-generation drug-eluting stent (Orsiro Mission, Biotronik AG, Switzerland)
223985607|NCT02475304|DRUG|Placebo|
223985608|NCT05588544|PROCEDURE|Er,Cr:YSGG laser|Use of laser at the degranulation step of the treatment
223985609|NCT03815383|BIOLOGICAL|C-CAR088|Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
223985610|NCT01845805|DRUG|oral azacitidine|
223985611|NCT01845805|OTHER|Observation|
223985612|NCT02549417|DRUG|KHK7580|Oral administration
223985613|NCT00277368|OTHER|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
223985614|NCT02531867|BIOLOGICAL|Asfotase Alfa|
223985615|NCT03852108|OTHER|Comfort Care|Face, Hand and body care for 15 to 45 minutes
223985616|NCT01674322|DRUG|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
223985617|NCT00130845|DRUG|Octreotide Acetate in Microspheres|
223985618|NCT00130845|DRUG|Placebo|
224120117|NCT00420394|PROCEDURE|radiotherapy|
224120118|NCT00860340|DRUG|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
224120119|NCT01882998|BEHAVIORAL|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
224120120|NCT01146067|DRUG|Rivastigmine|Rivastigmine capsules 1.5 mg
224120121|NCT03854955|OTHER|iScribes|Device-based scribing service.
224120122|NCT03356314|OTHER|MRI between 30-35 GA|MRI between 30-35 GA
224120123|NCT03356314|OTHER|Pediatric surgeon meeting|Pediatric surgeon meeting
224120124|NCT03356314|OTHER|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
224120125|NCT03356314|OTHER|+/- prophylactic surgery|+/- prophylactic surgery
224120126|NCT00984230|OTHER|BSF|feeding amount according to individual baby need
223985619|NCT06544850|OTHER|experimental group|Oswestry Low Back Pain Questionnaire will be used to assess functional limitations in daily life activities of patients with low back pain. Recognize mobile application will be used to assess lateralization performance. Evaluation will be made with hand, foot and back modules of this application. Reaction time and accuracy given at the end of the application will be recorded. The most accurate response instruction will be given in the shortest possible time. Visual Analog Scale (VAS) will be used to measure general pain status of patients. Tampa Kinesiophobia Scale will be used to assess fear of movement. Pain catastrophizing level will be assessed with Pain Catastrophizing Scale. Two-point discrimination device will be used to assess two-point discrimination. Central Sensitization Inventory will be used for central sensitization findings.
223985620|NCT06544850|OTHER|control group|Healthy volunteer participants who meet the inclusion criteria will be evaluated with the tests applied to the experimental group
223544300|NCT06716125|BEHAVIORAL|aerobic treadmill walking plus low calorie diet|this group (n =20 for the group) will administer low calorie diet for 12 weeks plus additionally administering supervised walking treadmill aerobic training for 45 minutes 3 times per week for 12 weeks).
223544301|NCT06716125|BEHAVIORAL|low calorie diet|this group (n =20 for the group) will administer low calorie diet for 12 weeks
223985621|NCT06484374|PROCEDURE|Robot-assisted minimally invasive treatment|An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
223985622|NCT02419768|OTHER|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
223985623|NCT02738905|DRUG|Rifaximin|One 550 mg tablet taken orally two times a day.
223544302|NCT06719024|DRUG|Ruxolitinib Cream 1.5%|a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
223544303|NCT06719024|DRUG|Aqueous cream|a thin layer of the assigned topical to the selected lesions twice daily, maintaining at least an 8-hour interval between applications
223544304|NCT06719271|DEVICE|Participants this group will receive gait training in robotic assisted gait training (RAGT) three times per week for eight weeks|Robotic Assited Gait Training is a device used to train children with CP how to walk in effective manner by connecting their body to the harness, robotic devices that attached to the electronic treadmill
223728146|NCT03194607|OTHER|Functional walk tests|
223544305|NCT06719271|DEVICE|Body Weight Supported Treadmill Training|Participants in this group will receive gait training on conventional treadmill three times per week for eight weeks
223544306|NCT05900076|DIAGNOSTIC_TEST|Curettage for the evacuation of the product of conception|The product of conception taken during the intervention will be recovered at Day 1
223985624|NCT06326879|OTHER|No intervention|Questionnaires compilation and sample collection
223985625|NCT05815615|DEVICE|Plasmapheresis|Plasma donation at different frequencies
223985626|NCT04080713|DRUG|Budesonide|Budesonide 9 mg prolonged release tablet
223985627|NCT02820597|DEVICE|ClariFix device|
223985628|NCT00575042|DRUG|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
223985629|NCT00960609|PROCEDURE|Ultrasound guided liver resection|
223985630|NCT05383638|OTHER|Health education|Intervention is achieved through health education. Analyze the factors that may affect patients' satisfaction with primary medical services through existing data, and carry out targeted health education.
223544307|NCT06716788|DRUG|68Ga-HSA|68Ga-HSA PET/CT: after intravenous injection of 2.22 MBq/kg body weight of quality-controlled 68Ga-HSA, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.
223544308|NCT06718205|DRUG|Nimotuzumab|Combined chemotherapy phase Nimotuzumab 400mg，I.V.，D1，QW Maintenance treatment period:Until unbearable or PD Nimotuzumab 400mg，I.V.，D1，Q3W
223544309|NCT06718205|DRUG|Sintilimab|Sintilimab 200mg，I.V.，D1，Q3W，Until unbearable or PD
223985631|NCT00273286|BEHAVIORAL|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
223985632|NCT00726271|DIETARY_SUPPLEMENT|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
223985633|NCT01663558|DRUG|imiquimod|
223985634|NCT01663558|PROCEDURE|ablative|
223985635|NCT04718311|DRUG|Oral lichen clinical Healing evaluation|Treatments were topically applied for 5 days
223985636|NCT04795336|DRUG|Melatonin 5 mg|Melatonin is a widely sold synthetic molecule in various forms including tablets, gummies and liquid. In the present study, the tablet version of the medication will be used at a dose of 5mg
224120127|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
224120128|NCT00984230|OTHER|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
224120129|NCT03940573|DEVICE|Eclipse Insert|Rectal Control System.
224120130|NCT06220344|BIOLOGICAL|Honey Dressing|Honey Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
223985637|NCT04795336|OTHER|Placebo|The placebo ingredients are Microcrystalline Cellulose, Silica, Gelatin, Titanium Dioxide, Red #3, and Blue #1.
223985638|NCT00008281|DRUG|FOLFOX regimen|
223985639|NCT00008281|DRUG|fluorouracil|
223728147|NCT03194607|OTHER|3D analysis of locomotion and posture|
223985640|NCT00008281|DRUG|leucovorin calcium|
223985641|NCT00008281|DRUG|oxaliplatin|
223985642|NCT00619268|DRUG|Temsirolimus|25 mg once per week administered intravenously
223985643|NCT00619268|DRUG|Bevacizumab|10 mg/kg \* 1 time /2 weeks administered intravenously
223985644|NCT00619268|DRUG|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
223985645|NCT00619268|DRUG|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
223985646|NCT02209844|DRUG|BI 44847|
223544310|NCT06718205|DRUG|Paclitaxel-albumin|Paclitaxel-albumin 200 mg/m2，I.V.，D1，Q3W，4-6 Cycle
223728148|NCT03194607|OTHER|questionnaires|
223985647|NCT02209844|DRUG|Placebo|
223985648|NCT03544645|OTHER|"Audiovisual material video"|an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
223985649|NCT03544645|OTHER|"Printed material brochure"|an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
223985650|NCT02857075|OTHER|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
223544311|NCT06718205|DRUG|Cisplatin|Cisplatin:75 mg/m2，I.V.，D1,Q3W，4-6 Cycle
223544312|NCT06718608|DIAGNOSTIC_TEST|imaging|Magnetic resonance imaging (MRI) Shear wave elastography (SWE) Electronic oscillatory device (EOD)
223544313|NCT06717997|OTHER|ultrasound|The placenta thickness will be performed on transabdominal images obtained in a longitudinal plane. Three measurements will be performed at the thickest portion of the placenta. The average of these three measurements was used for statistical analysis. The cohorts will be classified into 1) thick placenta (\>4 cm) and average placenta (2-4 cm).
223544314|NCT06718725|DIAGNOSTIC_TEST|ROSE-AI system|The cytopathological slide images of the patients' ROSE samples will be identified by the ROSE-AI system.
223985651|NCT06304467|BEHAVIORAL|Contingency Management|Study subjects who have received a liver transplant and have been randomized to the treatment arm will receive contingency management, a positive reinforcement behavioral treatment with escalating rewards for consecutive either negative urine and blood tests (or lower value of metabolites than the previous week for PeTH) depending on which results are received first, capped at a maximum of $80 (in the form of a gift card) at the week 10 visit.
223985652|NCT04901832|OTHER|Intradialytic stretching exercises|Exercises performed actively and passively to reduce or prevent muscle cramps during hemodialysis procedure.
224120131|NCT06220344|DRUG|Iodine Dressing|Iodine Dressing will be applied from the 1st Post-Op day till the fully healed wound, which is described as no dehiscence, no exudate, no warmth, and sutures removed.
224120132|NCT01347567|OTHER|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
224120133|NCT02113748|OTHER|Downhill walking training|Walk on a treadmill with a negative inclination.
224120134|NCT02113748|OTHER|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
224294275|NCT06843356|PROCEDURE|Endovascular Treatment|Neurointerventionist determine whether to proceed with interventional therapy after assessing the location and degree of occlusion, the tortuosity of the access vessel, and the presence of stenosis or occlusion in the proximal artery. In cases where there is no proximal stenosis or occlusion, mechanical thrombectomy is performed, and the specific thrombectomy strategy is tailored by the researcher based on the patient's condition. For lesions associated with proximal vascular stenosis or occlusion, it is necessary to navigate the catheter through the proximal stenosis or occlusion to access the intracranial occlusion. Researchers have the discretion to treat the stenotic or occluded vessels, which may include options such as no treatment, stent thrombectomy, thrombus aspiration, balloon angioplasty, stent replacement, intra-arterial thrombolysis or various combinations of these methods.
223728149|NCT04138121|DEVICE|Ultrasound|Ultrasound scan of the cricothyroid membrane
223728150|NCT06255106|OTHER|cast treatment|Surgical intervention vs cast treatment
223728151|NCT01721655|DRUG|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
224294276|NCT05283720|DRUG|Epcoritamab|Subcutaneous Injection (SC)
224294277|NCT05283720|DRUG|Lenalidomide|Oral; Capsule
223728152|NCT01721655|DRUG|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
223728153|NCT02817308|OTHER|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
223728154|NCT03798496|PROCEDURE|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
224294278|NCT05283720|DRUG|Ibrutinib|Oral; Capsule
224294279|NCT05283720|DRUG|Rituximab|Intravenous (IV); Injection
224294280|NCT05283720|DRUG|Cyclophosphamide|IV; Injection
223728155|NCT00525330|DRUG|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
223728156|NCT00525330|DRUG|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
223728157|NCT00525330|DRUG|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
223728158|NCT03092921|DEVICE|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
223728159|NCT03092921|DEVICE|F&P Mask|Investigative Mask to be used for OSA therapy
223728160|NCT06169696|DEVICE|Intervention/Treatment|Non-invasive EEG headband device
223728161|NCT05533684|DRUG|Gabapentin|single preoperative dose of 600 mg gabapentin
223728162|NCT02393170|OTHER|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
223728163|NCT02393170|OTHER|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
223728164|NCT03681405|OTHER|Informational Intervention|Given information about mindful movement and breathing
223728165|NCT03681405|OTHER|Questionnaire Administration|Ancillary studies
223728166|NCT03681405|BEHAVIORAL|Telephone-Based Intervention|Receive caring attention phone call
223728167|NCT04397783|PROCEDURE|construction of an end colostomy|longitudinal incision in the construction of an end colostomy
223728168|NCT03328312|DRUG|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR \>0.9
223728169|NCT03328312|DRUG|neostigmine+atropine|Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation
223728170|NCT03328312|DRUG|neostigmine+atropine+sugammadex|4\. Time of extubation
223728171|NCT04238702|DRUG|Empagliflozin 10 MG|Empagliflozin 10 MG 7 days intervention period
223985653|NCT04800939|OTHER|Acupressure|The experimental group will start with HT7 points and continue with SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
223728172|NCT04238702|DRUG|Losartan 50Mg Tab|Losartan 50 MG 7 days intervention period
223728173|NCT04238702|OTHER|Placebo|Placebo 7 days intervention period
224294281|NCT05283720|DRUG|Doxorubicin Hydrochloride [HCl]|IV; Injection
224294282|NCT05283720|DRUG|Prednisone|Oral; Tablet
224294283|NCT05283720|DRUG|Polatuzumab Vedotin|IV; Injection
224294284|NCT05283720|DRUG|Venetoclax|Oral; Tablet
224294285|NCT05283720|DRUG|CC-99282|Oral; Capsule
224294286|NCT05283720|DRUG|Pirtobrutinib|Oral; Tablet
223985654|NCT04800939|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the HT7 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
223985655|NCT02112890|OTHER|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
223985656|NCT03898700|BEHAVIORAL|strength based coaching|strength based and solution focused coaching
223985657|NCT04692701|DEVICE|Pulvinar deep brain stimulation|Stimulation of the medial pulvinar
223985658|NCT04432545|BIOLOGICAL|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly|Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
223985659|NCT00663975|DRUG|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
223985660|NCT02472002|BIOLOGICAL|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~* Registry Type: autologous~* Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~* Route of administration: endomyocardial injection~* Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
223985661|NCT01629212|DRUG|Tiropramide HCl 100mg|
223985662|NCT01629212|DRUG|Octylonium bromide 20mg|
223544315|NCT04749745|DRUG|L-theanine|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.
223985663|NCT02666664|DRUG|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
224294287|NCT06598423|DEVICE|Specialized soft contact lens 1|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 2 in material, comfort, and lens geometry. They differ only in their spectral profile.
223985664|NCT02666664|DRUG|Placebo|Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
223985665|NCT02061878|DRUG|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
224294288|NCT06598423|DEVICE|Specialized soft contact lens 2|These are daily-wear, daily-replacement lenses. They are identical to specialized soft contact lens 1 in material, comfort, and lens geometry. They differ only in their spectral profile.
223985666|NCT02061878|DRUG|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
223985667|NCT05000632|BEHAVIORAL|Smoke Free SafeCare|SFSC is the systematically braided curriculum which combines both SafeCare and STBO programs, but in a new delivery format. To take full advantage of the home delivery mechanism of SafeCare, the content delivery of STBO has been adapted so that original mailings will be delivered in the SafeCare sessions. STBO has been fully braided into the Health and Safety modules. One of these interventions will be delivered first throughout the course of the study. The Smoke Free SafeCare intervention will involve 25 providers receiving training for the SFSC program. They will each recruit 10 mothers and conduct the SFSC program for each family. Overall, 250 families will receive the SFSC intervention.
223985668|NCT05000632|BEHAVIORAL|Standard SafeCare|SafeCare is a brief parenting intervention that is highly effective in reducing child maltreatment perpetration and improving behavioral outcomes for CPS-involved parents of young children (0 to 5 years) as the result of child physical abuse or neglect (the two most common forms of substantiated maltreatment). The Standard SafeCare intervention will involve 25 SafeCare providers delivering the SafeCare program as usual. They will each recruit 10 mothers and conduct SafeCare for each family. Overall, 250 families will receive the standard SafeCare.
223985669|NCT03616964|DRUG|Baricitinib|Administered orally.
223985670|NCT03616964|DRUG|Placebo|Administered orally
223985671|NCT02836288|DRUG|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
223985672|NCT02836288|OTHER|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
223985673|NCT00971997|DRUG|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
223985674|NCT04520568|COMBINATION_PRODUCT|High flow nasal cannula|using sedation with the HFNC F\&P AIRVOTM 2 to maintain oxygenation
223985675|NCT04520568|COMBINATION_PRODUCT|CONTROL|using general anaesthesia with one lung ventilation (OLV) technique
223985676|NCT00478283|OTHER|survey administration|
223985677|NCT00568841|DRUG|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
223985678|NCT00568841|PROCEDURE|FDG-/FLT-PET|
224294289|NCT04789967|BEHAVIORAL|Guided Imagery|Individualized Guided Imagery (GI) technique, an alternative type of relaxation therapy. The content of GI usually includes scenery, places or any image projected to the mind. By using information generated, participants are guided to create a place in their mind using their senses of touch, sound, smell, sight and taste.
223728174|NCT05221515|BEHAVIORAL|Anger can go!|"The intervention Anger Can Go! was designed to treat anger regulation problems in autistic children aged 8 to 13 years old. The intervention consists of nine sessions of 60 minutes and is divided in four phases. Phase 1: psycho-education, affect-education and measuring anger with an anger-thermometer. This is a self-report scale presented as the drawing of a thermometer, that allows the child to indicate his level of anger, as linked to specific bodily and behavioral representations on a scale from 0 to 3. Phase 2: making a functional behavior assessment (FBA) and taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts. Phase 3: taking a time-out at a low anger-level (between 1 and 2 on the scale 0 to 3) to prevent aggressive outbursts, shifting attention away from aversive stimuli, to cope with the stress of the anger provoking situation. Phase 4: creating solutions to cope with an anger provoking situation."
223985679|NCT01450293|BIOLOGICAL|AdCh63 ME-TRAP, MVA ME-TRAP|1x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
223985680|NCT01450293|BIOLOGICAL|AdCH63 ME-TRAP, MVA ME-TRAP|5x10\^10 vp AdCH63 ME-TRAP followed by 1x10\^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
223985681|NCT03243240|DIAGNOSTIC_TEST|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.~Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
223985682|NCT00954005|DRUG|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
223985683|NCT03596398|GENETIC|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
223985684|NCT02022111|BEHAVIORAL|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
223985685|NCT02022111|BEHAVIORAL|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
223985686|NCT02022111|OTHER|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patients and their usual care providers.
223985687|NCT02022111|OTHER|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
223985688|NCT02022111|OTHER|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
223985689|NCT02515006|OTHER|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
223985690|NCT06330935|DRUG|Tranexamic Acid (TXA)|30 patients will be randomized to A arm and 30 patients to B arm
223985691|NCT06330935|DRUG|Normal saline|30 patients will be randomized this arm C
223728175|NCT05221515|BEHAVIORAL|Parent psycho-education|Three psycho-educational parent group sessions (take place before the children's sessions in intervention group). Parents meet with other parents and a therapist to learn about the nature of their Expressed Emotion (EE) and how it relates to the child's aggressive behavior.
223985692|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
223985693|NCT01699464|DRUG|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
223985694|NCT01699464|DRUG|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
223985695|NCT05543239|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation(TaVNS)|"Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) works by stimulating the auricular branches of the vagus nerve (mainly distributed in the concha cavity and conchae) through electrical impulses.Electrodes were placed on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. Stimulation pulses (frequency 30 Hz, pulse width 300 us) were generated by TaVNS device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then descend within 15 seconds to the maximum tolerable amount without pain. Inform the subject that target stimulus has been reached, then stimulate for 30 minutes."
223985696|NCT05543239|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation(SS)|"Place electrodes on the concha of the left ear after cleaning the skin of the concha with a small disposable alcohol pad. The same stimulation pulses (30 Hz frequency, 300 us pulse width) were generated by the same device, the amplitude was increased within 30 seconds to the subject produced a tingling sensation, and then ramps down to zero stimulus over 15 seconds. The subjects were told that the target stimulus has been reached. Patients receive sham stimulation for 30minutes."
223985697|NCT05875649|COMBINATION_PRODUCT|CLAG|Acute myeloid leukemia patients are re-induced by CLAG Regimen after first-induction failure
223985698|NCT02434757|DRUG|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
223985699|NCT01266018|DRUG|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
223985700|NCT05801445|BEHAVIORAL|Occupation-based activity|Painting large-scale canvas
223985701|NCT05801445|BEHAVIORAL|Body-Weight Exercise|Body-weight exercises designed for older adults
223985702|NCT03167151|DRUG|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial
223544316|NCT04749745|DRUG|Placebo|The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
223985703|NCT06197659|OTHER|Liberal Fluid Grubu|Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
223985704|NCT06197659|OTHER|Restrictive Fluid Group|Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
223985705|NCT00560157|DIETARY_SUPPLEMENT|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
223985706|NCT02165410|PROCEDURE|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
223985707|NCT02165410|PROCEDURE|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
224294290|NCT04789967|BEHAVIORAL|Progressive Muscle Relaxation|Progressive muscle relaxation (PMR) therapy works by progressively relaxing and tensing the muscle groups throughout the entire body. Each muscle group will be tensed for about 5 seconds. If there's any pain or discomfort at any of the targeted areas, participants were told to omit that particular step. Constant purposeful deep breathing was instructed throughout the session especially in between changes of muscle.
224294291|NCT04789967|OTHER|Educational Audiobook|Participants in the control group will receive an audiobook that targets to educate patients regarding gut-brain disorders, functional gastrointestinal disorders, causes of functional abdominal bloating, and treatment modalities available. Relaxing musical background will be added to facilitate the delivery.
223728176|NCT04180228|OTHER|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
223728177|NCT04548570|PROCEDURE|approximation of both rectus muscles|closure of both rectus muscle before closure of rectus sheeth
223728178|NCT04942691|OTHER|physical activity|training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
223728179|NCT06504602|DEVICE|Active Virtual Reality|Active virtual reality group will play a game through a virtual environment.
223985708|NCT02165410|PROCEDURE|Resting state MRI|This sequence is based on the synchronization of fluctuations in the blood-oxygen level dependent (BOLD) signal of different brain regions that work as a network. Therefore this sequence allows for the establishing of maps of funcitonal connectivity.
223985709|NCT02165410|PROCEDURE|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
224294292|NCT04387071|BIOLOGICAL|Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Given IT
224294293|NCT04387071|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC and IT
224294294|NCT05981495|DEVICE|NanoDetect-TB|This study of the NanoDetect-TB investigational device will test plasma and serum samples from TB suspects. There is no intervention for the subjects and there will be a single visit blood draw.
223728180|NCT06504602|DEVICE|Passive Virtual Reality|Passive virtual reality group will watch a movie through a virtual environment.
223985710|NCT02165410|PROCEDURE|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
223985711|NCT02098447|DEVICE|PrimeStim|
223985712|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
223985713|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
223985714|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
223985715|NCT01081847|DRUG|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
223985716|NCT01081847|OTHER|Placebo|PLacebo: Isotonic saline solution
223985717|NCT03145012|DRUG|Ranitidine|Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
223985718|NCT04955977|OTHER|Physical exercise program|"Step 1 • Diaphragmatic reeducation: • Aerobic capacity: Intensity: zone 2, 60% HRMax, 4-6 / 10 Borg Scale; Charge: 20 m.~Step 2 • Aerobic capacity: Intensity: zone 2, 65% HRMax, 4-6 Borg Scale; Charge: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 3-4 / 10 Omni-Res; Load: 20% 1RM; Series: 3; Reps: 1. • Flexibility and elasticity: Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 3 • Aerobic capacity: Intensity: zone 3, 70% HRMax, 5-6 / 10 Borg scale, Load: 25 m. • Muscular strength: Method: Pyramidal; Intensity: 4-5 / 10 Omni-Res; Load: 30% 1RM; Series: 4; Reps: 10. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s.~Step 4 •Aerobic capacity: Intensity: zone 3, 75% HRMax, 6-7 / 10 Borg scale, Load: 30 m. • Muscular strength: Intensity: 5-6 / 10 Omni-Res; Load: 40-50% 1RM; Series: 4 s; Reps: 13. • Flexibility and elasticity: Method: active stretching; Intensity: 31-60 Perflex Scale; Charge: 10 - 20 s."
223985719|NCT04955977|OTHER|Health education in COPD|Week 1-2: Health education: COPD and respiratory care at home. Week 3-4: Importance of daily physical activity in COPD. Week 5-6: Early Signs of COPD Exacerbation and Action Plan Week 7-8: Use and care of respiratory devices at home.
223985720|NCT00709501|BEHAVIORAL|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
223985721|NCT00709501|BEHAVIORAL|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
223985722|NCT02470689|DRUG|Diacerin cream|Diacerin tablet solubule in ultraphil cream
223985723|NCT06957457|BEHAVIORAL|Exercise|The exercise program lasts 32 minutes in total. The first 6 (six) minutes of this program consists of warm-up exercises. Active exercise time is 21 (twenty-one) minutes. Relaxation exercises consist of 5 (five) minutes of relaxation exercises. exercise was accompanied by music. it consists of warm-up exercise and relaxation sections.
223985724|NCT06957457|BEHAVIORAL|Control (Standard treatment)|do nothing
223985725|NCT06957691|DRUG|fezolinetant - reference formulation|Daily oral administration of fezolinetant at a dose of 45 mg
223985726|NCT06957691|DRUG|Placebo|Daily oral administration of placebo
223985727|NCT06957652|DEVICE|DBMM-C plus Resorbable collagen membrane|A trapezoidal flap design will be employed, including a sulcular incision and vertical releasing incisions extending approximately 2-3 mm beyond the mucogingival junction. Flap advancement will be facilitated through a periosteal-releasing incision at the flap base. Granulation tissue will be removed using a titanium curette, and implant surface decontamination will be performed with a titanium brush. The graft material will be placed in both supra- and intrabony defect components, followed by coverage with a resorbable collagen membrane. The flaps will then be coronally advanced and stabilized over the biomaterials.
223728181|NCT03978520|DRUG|Elsubrutinib|Capsule; Oral
223728182|NCT03978520|DRUG|Placebo for elsubrutinib|Capsule; Oral
223728183|NCT03978520|DRUG|Upadacitinib|Film-coated tablet; Oral
223728184|NCT03978520|DRUG|Placebo for upadacitinib|Film-coated tablet; Oral
223985728|NCT06957652|DEVICE|DBMM-C|A trapezoidal flap design will be employed, including a sulcular incision and vertical releasing incisions extending approximately 2-3 mm beyond the mucogingival junction. Flap advancement will be facilitated through a periosteal-releasing incision at the flap base. Granulation tissue will be removed using a titanium curette, and implant surface decontamination will be performed with a titanium brush. The graft material will be placed in both supra- and intrabony defect components, and then the flaps will be coronally advanced and stabilized over the graft material.
223985729|NCT00950196|DRUG|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
223985730|NCT01439386|PROCEDURE|Catheter ablation|PVAI with or without CTI ablation
223985731|NCT01439386|PROCEDURE|Catheter ablation|CTI ablation only
223985732|NCT03984877|DIAGNOSTIC_TEST|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
223985733|NCT02023359|DRUG|Everolimus and exemestane|
223728185|NCT04804969|DEVICE|MyoVista wavECG Test|The MyoVista wavECG is a standard 12-Lead high-performance, multi-channel resting interpretive electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information.
223728186|NCT02771054|DRUG|TAF/FTC|Change of nucleoside backbone
223728187|NCT01927224|DRUG|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
223728188|NCT01927224|DRUG|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
223985734|NCT01021709|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 \& 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
224120135|NCT01212328|OTHER|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
223728189|NCT01927224|DRUG|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
223985735|NCT01458522|DRUG|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
223728190|NCT02860169|BEHAVIORAL|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
223728191|NCT00188669|DRUG|pentoxifylline|
223728192|NCT00188669|DRUG|alpha-Tocopherol|
223728193|NCT06394297|RADIATION|SBRT|SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
223728194|NCT04743297|DRUG|Prostaglandin E2 (Propess)|Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
223728195|NCT04743297|DRUG|Prostaglandin E2 (Prostin)|Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
223985736|NCT01458522|DRUG|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
223985737|NCT05526365|OTHER|Reduced Idea Density|Question idea density reduced (ratio of propositions to total words used).
223985738|NCT06401278|DEVICE|Transcutaneous electrical acupoint stimulation|"It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)"
223985739|NCT06401278|DEVICE|Transcutaneous electrical nerve stimulation (group b):|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
223985740|NCT00656032|OTHER|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
223985741|NCT00656032|OTHER|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
223985742|NCT05775159|DRUG|Volrustomig|CTLA-4/Anti-PD-1 Bispecific Antibody
223985743|NCT05775159|DRUG|Bevacizumab|15 mg/kg, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
223985744|NCT05775159|DRUG|Lenvatinib|Daily use per oral (8 mg capsules/day for participants \< 60 kg or 12 mg/day for participants ≥ 60 kg) of 21 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
223985745|NCT05775159|DRUG|Rilvegostomig|anti- PD-1 and TIGIT bispecific antibody
223985746|NCT05775159|DRUG|Gemcitabine|1000 mg/m2, IV infusion
223985747|NCT05775159|DRUG|Cisplatin|25 mg/m2, IV infusion
223985748|NCT02684123|DRUG|Apremilast|Subjects will get drug or placebo
223985749|NCT02684123|DRUG|Placebo|
223985750|NCT00513201|DRUG|lyspro|
223985751|NCT00513201|DRUG|regular insulin|
223985752|NCT00516139|DRUG|Lamotrigine|Open-label
223985753|NCT00466609|DRUG|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
223985754|NCT00466609|DRUG|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
223985755|NCT00466609|DRUG|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
223985756|NCT02638688|OTHER|ultrasound|
223985757|NCT03553381|OTHER|hypocaloric balanced diet|
223985758|NCT02755701|DRUG|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
223728196|NCT02612974|BIOLOGICAL|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
223728197|NCT03793738|PROCEDURE|Anterior component separation|
223728198|NCT03793738|PROCEDURE|Posterior component separation|
223728199|NCT00138996|DEVICE|automated direct feedback on CPR from defibrillator|
223728200|NCT02481232|BIOLOGICAL|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
223728201|NCT01119417|DRUG|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
223985759|NCT02755701|DRUG|Placebo|Placebo will be administered in the same way
223985760|NCT04770870|DEVICE|Hintermann Series H3 Total Ankle Replacement System|Intervention will include receiving the FDA approved Hintermann Series H3 Total Ankle Replacement System, to include a tibial component, a polyethylene inlay, and a talar component.
223728202|NCT01119417|DRUG|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
223728203|NCT01119417|DRUG|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
223728204|NCT01119417|DRUG|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
223728205|NCT01119417|DRUG|Saline|2-3 IV saline infusions for 15 min each.
223728206|NCT03116971|DRUG|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
223728207|NCT03116971|DRUG|Cisplatin|Cisplatin 75 milligram per square meter (mg/m\^2) was administered over a 60-minute intravenous infusion on Day 1.
223728208|NCT03116971|DRUG|Etoposide|Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
223728209|NCT05544604|DEVICE|Transcranial direct current stimulation|tDCS will be delivered with current strength of 2 mA for 20 min . Current will be applied through two concentric electrodes target electrode; return electrode. First we will fill the electrode cage with an electroconductive gel, and then position the electrodes, with the target electrode over the FDI hotspot, and finally we fasten the electrodes with a tubular net-shaped elastic bandage in mesh tissue, making sure that it will not push the electrode forward or backward. This procedure will aim at reducing contact impedance and at creating a uniform adherence between the whole surface of the electrodes and the scalp, avoiding uneven distribution of the current (Fertonani, 2015). We will position the central electrode (anode) according to the study group over C3 or C4 , the stimulating electrode will be placed on the scalp at T7 or T8 for the insular cortex per the 10-20 (EEG) system.
223728210|NCT01939743|DRUG|Diclofenac suppository plus lidocaine gel|
224120136|NCT01212328|OTHER|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
224120137|NCT02165540|OTHER|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
223985761|NCT03305887|DEVICE|"STRATAFIX™ Symmetric Knotless Tissue"|This devices will be used in deep and intermediate layers of barbed suture group.
224120138|NCT02177669|OTHER|quick Contrast Sensitivity Function test|
224120139|NCT00894530|DRUG|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
224120140|NCT00894530|DRUG|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
224120141|NCT06309810|RADIATION|Radiotherapy|"The treatment will be administered with a TrueBeam™ (Varian Medical Systems, Palo Alto, CA, USA) linac, equipped with a Millenium 120-leaves MLC.~The target will be represented by 5 mm of the specific spinal nerve responsible for the spams. A lateral~1 mm margin will be added to the target to generate the corresponding planning treatment volume (PTV). The prescribed dose will be 45-60 Gy in a single fraction. The treatment dose will be chosen based on patients' general condition, and possibility to respect the dose limits (constraints) for the organs at risk (OARs)."
223985762|NCT03305887|DEVICE|VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
223985763|NCT03305887|DEVICE|"STRATAFIX Spiral sutures"|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
223985764|NCT03305887|DEVICE|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
223985765|NCT03142347|PROCEDURE|Remote endarterectomy|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
223985766|NCT03142347|PROCEDURE|Remote endarterectomy + DCB balloon|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
223985767|NCT00517036|DIETARY_SUPPLEMENT|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
224120142|NCT03553238|DRUG|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
224120143|NCT03553238|DRUG|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
224120144|NCT03553238|DRUG|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
224120145|NCT03553238|DRUG|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
224120146|NCT03553238|DRUG|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
224294295|NCT02067767|DRUG|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~* group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~* group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
224294296|NCT04830917|OTHER|Immobilization type for mallet injury|Method to hold the DIP joint in full extension to allow healing of terminal tendon injury/mallet injury
223728211|NCT01939743|DRUG|Lidocaine gel only|
223728212|NCT02032810|DRUG|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
223728213|NCT02032810|DRUG|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
223985768|NCT00517036|DIETARY_SUPPLEMENT|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
223985769|NCT00517036|DIETARY_SUPPLEMENT|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
223985770|NCT05276271|DIAGNOSTIC_TEST|the blood sample test results|Retrospectively the fasting blood samples results were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration.
223985771|NCT04427176|DEVICE|ARFC mask|Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
223985772|NCT00416598|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
223985773|NCT00416598|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
223985774|NCT00416598|DRUG|Busulfan|Given IV
223985775|NCT00416598|DRUG|Cytarabine|Given IV
223985776|NCT00416598|DRUG|Daunorubicin Hydrochloride|Given IV
223985777|NCT00416598|DRUG|Decitabine|Given IV
223985778|NCT00416598|DRUG|Etoposide|Given IV
223985779|NCT00416598|BIOLOGICAL|Filgrastim|Given SC
223985780|NCT00416598|OTHER|Laboratory Biomarker Analysis|Correlative studies
223985781|NCT00416598|OTHER|Pharmacological Study|Correlative studies
223985782|NCT01266746|PROCEDURE|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
223985783|NCT02594449|DRUG|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
223985784|NCT05015582|DEVICE|Pre op upper body forced air warming (32˚C)|Use of upper body forced air warming at ambient (32˚C) for at least 30 minutes
223985785|NCT05015582|DEVICE|Pre op lower body forced air warming (32˚C)|lower body forced air warming at ambient (32˚C) for at least 30 minutes
223985786|NCT05015582|DEVICE|Pre op fluids (45˚C)|fluids from warmed cabinet set at 45˚C
223985787|NCT05015582|DEVICE|Intra op upper body forced air warming (32˚C)|Use of upper body forced air warming intra-operative at ambient (32˚C)
223985788|NCT05015582|DEVICE|Intra op fluids at room temperature|IV fluids at room temperature
223985789|NCT05015582|DEVICE|Intra op upper body forced air warming at (32˚C)|upper body forced air warming intra-operative at ambient (32˚C)
223985790|NCT05015582|DEVICE|Intra op upper body forced air warming at (42˚C)|upper body forced air warming intra-operative at ambient (42˚C)
223985791|NCT05015582|DEVICE|Intra op lower body forced air warming at (32˚C)|Lower body forced air warming intra-operative at ambient (32˚C)
223985792|NCT05015582|DEVICE|Intra op lower body forced air warming at (42˚C)|Lower body forced air warming intra-operative at ambient (42˚C)
223985793|NCT05015582|DEVICE|Intra op fluid (42˚C)|IV fluids with hotline fluid warmer set at 42˚C
223985794|NCT04367480|DEVICE|Placebo Administration|Wear placebo TENS device
223985795|NCT04367480|OTHER|Questionnaire Administration|Ancillary studies
223985796|NCT04367480|DEVICE|Transcutaneous Electrical Nerve Stimulation|Wear active TENS device
223985797|NCT00529477|OTHER|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
223985798|NCT00529477|OTHER|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
223985799|NCT00529477|OTHER|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
223985800|NCT00286988|DRUG|Topiramate|
223985801|NCT01156740|DRUG|Penicillin G, Benzathine|IM BPG; 600,000 U \> 27kg or 1,200,000 U \<27 kg)
223985802|NCT01156740|DRUG|Amoxicillin|750 mg/QD
223985803|NCT03034850|PROCEDURE|CRS/HIPEC|The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size \> 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
223985804|NCT03503929|DEVICE|LaparoGuard System|Adjunctive safety system for laparoscopic surgery
223985805|NCT00253331|DRUG|topical organogel with nitroglycerin|
223985806|NCT04692545|DIETARY_SUPPLEMENT|Immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
223985807|NCT01335906|OTHER|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
223985808|NCT02608736|DRUG|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
223985809|NCT02608736|DRUG|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
223728214|NCT05914805|DRUG|Clascoterone 5% solution|Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)
223985810|NCT03740243|DRUG|Buprenorphine/naloxone|Buprenorphine/naloxone tablet or film
223985811|NCT03740243|DRUG|Buprenorphine|Buprenorphine tablet
223985812|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed 600mg/m2 body surface area per dose about every 12 hours
223985813|NCT05538208|DRUG|Mycophenolate Mofetil|MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA \>=60-70 mg\*h/L
223544317|NCT02478541|OTHER|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
223544318|NCT00226356|DRUG|Supplements of L-methionine, betaine and folate|
223728215|NCT05914805|DRUG|Vehicle solution|Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)
223728216|NCT00000489|PROCEDURE|coronary artery bypass|
223985814|NCT04290377|DEVICE|BMI-assisted motor imagery OT|As the goal of the intervention is to promote finger extension in participants who are unable to extend his/her finger due to stroke, the pneumatic glove provides extension assist when appropriate brain activity is present. The brain activity is obtained by Functional Near-Infrared Spectroscopy (fNIRS). Hypothetically, this will repeatedly induce brain activation that is related to finger extension.
223985815|NCT04290377|OTHER|Motor imagery OT|In Motor imagery OT, Subjects try to extend their fingers (imagine) without BMI assistance. All other setting is equal to BMI-assisted motor imagery OT.
223985816|NCT05724199|DRUG|Rocatinlimab|Subcutaneous (SC) injection
223544319|NCT00003156|DRUG|topotecan hydrochloride|
223544320|NCT04254406|OTHER|Descriptive study|Evaluation of routine treatment
223728217|NCT04124276|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (300mg/day) for 6 weeks
223728218|NCT04124276|DIETARY_SUPPLEMENT|Placebo|Placebo control group takes placebo (300mg/day) for 6 weeks.
223728219|NCT03566316|DRUG|Telmisartan/Amlodipine|
223728220|NCT03566316|DRUG|Rosuvastatin|
223544321|NCT01679483|DRUG|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
223544322|NCT04541667|OTHER|Air|Air will be used for luminal inflation.
223544323|NCT04541667|OTHER|Carbon Dioxide|Carbon dioxide will be used for luminal inflation.
223544324|NCT01186276|DIETARY_SUPPLEMENT|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
223544325|NCT01186276|DIETARY_SUPPLEMENT|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
223544326|NCT01987076|DRUG|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
223728221|NCT03566316|DRUG|Telmisartan|
223728222|NCT01441206|DRUG|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth \< 32 weeks - PNA \< 14 days: 10 mg/kg QD GA at birth \< 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA \< 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
223728223|NCT01648205|DRUG|Placebo|Matching Placebo will be given for first month.
223728224|NCT01648205|DRUG|Ranolazine|Patients will receive ranolazine 1000mg bid for subsequent 5 months.
223985817|NCT05724199|OTHER|Placebo|SC injection
223985818|NCT06391736|GENETIC|GC301|GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
223985819|NCT06564285|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
223985820|NCT06564285|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
223985821|NCT02731911|DRUG|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
223985822|NCT01458925|DEVICE|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
223985823|NCT04120376|BEHAVIORAL|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an APP in the Emergency Department
224120147|NCT03553238|DRUG|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
224120148|NCT03553238|DRUG|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
223544327|NCT01987076|DRUG|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
223544328|NCT04494685|DEVICE|Intervention group (Robotic rehabilitation)|Robotic rehabilitation with Erigo® equipment (Hocoma, Volketswil, Switzerland). The training protocol has a progression of the board inclination up to 90º associated with flexion/extension movements of the knees and hips, with time evolution of up to 40 minutes. Such equipment is associated with electrostimulation of the quadriceps, hamstrings, sural triceps and anterior tibialis.
223544329|NCT04494685|OTHER|Control group (Conventional physiotherapy)|Knee and hip flexion and extension movements, hip adduction, and abduction, respecting the articular physiology of each joint. Weight transfer will also be performed in the sitting and standing position, mini squat, and gait training. All exercises will have a total of 10 repetitions in three sets. In the end, stretching of the upper and lower limbs will be performed.
223985824|NCT05728190|OTHER|steril/salin water|Five days seven drops of saline/sterile water were dripped onto a 5x5 gauze pad in the morning and evening, and they were put to sniff for 20 minutes, 10 cm away from the nose. Green food coloring was added (one drop of food coloring to 5 ml of sterile/saline water) to make sterile/saline water similar to lavender oil.
223985825|NCT05728190|OTHER|Lavender essential oil|Five days seven drops of lavender essential oil were dripped onto a 5x5 gauze pad in the morning and evening, for 20 minutes, 10 cm away from the nose, and sniffed.
223985826|NCT03270800|BIOLOGICAL|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
223985827|NCT03270800|BIOLOGICAL|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
223544330|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
224120149|NCT03553238|DRUG|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
224120150|NCT03553238|DRUG|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
224120151|NCT03553238|DRUG|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
224120152|NCT03553238|DRUG|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
224120153|NCT03553238|PROCEDURE|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
224120154|NCT03553238|PROCEDURE|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
224120155|NCT03553238|RADIATION|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
224120156|NCT03553238|GENETIC|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
223985828|NCT02379143|OTHER|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
223985829|NCT03790709|DRUG|High dose ANAVEX2-73|Oral capsule
223985830|NCT03790709|DRUG|Mid dose ANAVEX2-73|Oral capsule
223985831|NCT03790709|DRUG|Placebo oral capsule|Oral capsule
223985832|NCT06120647|DIETARY_SUPPLEMENT|Essential amino acids (EAA)|intake of 240 mg EAA per kg lean body mass after a resistance exercise session
223728225|NCT04748120|PROCEDURE|Operative management|Patients will undergo surgical removal of the affected organ. The initial approach will be in a minimally invasive, laparoscopic fashion. If necessary, conversion to an open operation may be performed. These patients will be treated preoperatively and postoperatively with similar antibiotic regimens, however the duration of antibiotic therapies will be dependent on factors such as intraoperative findings, resolution of laboratory abnormalities, and tolerance of oral medications.
223728226|NCT04748120|PROCEDURE|Non-operative management|"Patients will be treated with 3 days of intravenous antibiotics followed by 7 days of oral antibiotics, as described below:~Non-penicillin allergic patients~* piperacillin/tazobactam 3.375g IV every 6 hours for 3 days~* amoxicillin/clavulanate 875/125mg by mouth every 12 hours for 7 days~Penicillin allergic patients~* ertapenem 1g IV every 24 hours for 3 days~* ciprofloxacin 500mg every 12 hours AND metronidazole 500mg every 8 hours for 7 days~Patients may be considered to have failed non-operative management (e.g. treatment failure) if they experience absence of clinical improvement, worsening abdominal pain and/or localized/diffuse peritonitis in the judgment of the treating surgeon at any point within the study window. If this occurs, then surgeons may proceed with rescue appendectomy or percutaneous drainage in the setting of appendicitis, or with placement of a percutaneous cholecystostomy tube in the setting of acute cholecystitis."
223728227|NCT01700777|OTHER|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
223728228|NCT05339737|DEVICE|Nociception Level (NOL) Index|The NOL integrates multiple physiologic parameters that are captured through a finger probe with disposable sensor. These parameters include heart rate, heart rate variability, photoplethysmography pulse wave amplitude, skin conductance and temperature, and their time derivatives. All these parameters are analyzed simultaneously to provide the NOL index which can range from 0 to 100. Values \>25 were found to be indicative of nociception and related-pain in the field of anesthesia. The investigators will use the Pain Monitoring Device-200 (PMD-200)TM, which offers the multi-parametric NOL index (0-100) (Medasense Biometrics Ltd., Ramat Gan, Israel), and was approved by Health Canada for clinical use in September 2017.
223728229|NCT01777100|DRUG|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
223728230|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
223728231|NCT01640223|DEVICE|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
223728232|NCT05925660|DIAGNOSTIC_TEST|Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)|Mucorales PCR screening twice weekly during hospitalisation
223728233|NCT01201382|BEHAVIORAL|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
223728234|NCT01201382|BEHAVIORAL|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
223728235|NCT06386250|PROCEDURE|regional block|In group A, iliohypogastric and ilioinguinal nerves were blocked by using 0.25% bupivacaine 2ml/kg of combined with skin infiltration of adrenaline 1:200 000.
223728236|NCT06386250|PROCEDURE|Caudal block|In group B 0.25% bupivacaine 0.5ml/Kg was infiltrated at the surgical site.
223728237|NCT06386250|PROCEDURE|Epidural|In group C 0.25% Bupivacaine 1ml /kg was given into epidural space at L4-L5 or L5-S1.
223728238|NCT03358121|DIAGNOSTIC_TEST|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
223728239|NCT00954070|DEVICE|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
223985833|NCT02641587|OTHER|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
223985834|NCT02641587|OTHER|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
223985835|NCT01954433|PROCEDURE|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
223985836|NCT01954433|PROCEDURE|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
223985837|NCT01954433|PROCEDURE|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~1. RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~2. RISA with FCR-Ligament modified according to Weilby~3. RISA with APL-Ligament (abductor pollicis longus ligament)~4. RISA with Graftjacket modified according to Weilby~5. Resection arthroplasty"
223985838|NCT01114451|PROCEDURE|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
223985839|NCT05921669|BEHAVIORAL|Provide breastfeeding education|Providing breastfeeding education within the first 24 hours after birth
223985840|NCT01165177|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
223985841|NCT01165177|BIOLOGICAL|Placebo|Intramuscular injection
223985842|NCT04907279|DRUG|Aripiprazole Once-Monthly (AOM)|Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.
223985843|NCT03082937|DRUG|3 mg [14C]-A4250 capsule|Each subject will receive a single administration of 3 mg \[14C\]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.
223985844|NCT05567107|OTHER|massage|Classical foot massage was applied by the researcher with efflorescence, superficial friction and petrissage techniques for 10 minutes on each foot.
223985845|NCT06370923|BEHAVIORAL|Peer Distribution|In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
223985846|NCT06370923|BEHAVIORAL|Community Health Worker Distribution|Distribution of HIV self tests by community health workers
223985847|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
223985848|NCT01648153|OTHER|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
223985849|NCT01648153|BIOLOGICAL|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
223985850|NCT00216047|DRUG|PTK787|PTK787 daily
223985851|NCT00216047|DRUG|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle\*
223985852|NCT02922205|DEVICE|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
223985853|NCT00631345|BEHAVIORAL|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
223985854|NCT00631345|OTHER|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
224120157|NCT03553238|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
223544331|NCT00914576|DRUG|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
223728240|NCT06234657|BEHAVIORAL|Telerehabilitation for stroke patient|The subjects of the study were intervened by telerehabilitation through video instructions and online group training via Online meeting software. The content of the intervention program included upper limb exercises, transfer, and ambulation functions. This training program was designed based on the clinical practice guidelines for post-stroke physiotherapy management from the United States Department of Veterans Affairs and the guidelines for the diagnosis, and treatment of rehabilitation stroke patients of the Vietnam Ministry of Health. The training results of the subjects will be evaluated by the Barthel Index
223728241|NCT03172455|DRUG|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
223728242|NCT05832398|DRUG|FOLFOX , FOLFIRI or FOLFOXIRI regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
223985855|NCT00631345|BEHAVIORAL|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
223985856|NCT00631345|BEHAVIORAL|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
223728243|NCT05832398|DRUG|FOLFOX or CapeOX regimens|FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
223728244|NCT05945043|OTHER|Surface parasternal eletromyogram|The surface parasternal EMG of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
223728245|NCT05945043|OTHER|Surface diaphragm electromyogram|The ipsilateral and contralateral surface diaphragm EMG of participants will be measured pre and immediately post pleural fluid removal
223728246|NCT05945043|OTHER|Parasternal muscle ultrasound|The thickness of the parasternal intercostal muscle of participants will be measured using thoracic ultrasound pre and immediately post pleural fluid removal
223985857|NCT03419676|DEVICE|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
223985858|NCT02579824|DRUG|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
223985859|NCT00634842|DRUG|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
223985860|NCT00634842|DRUG|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
223985861|NCT01403870|OTHER|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
223985862|NCT06016699|OTHER|blood draws|Blood draws to collect PBMCs at baseline (week 0), during (chemo)radiation treatment (end of week 3 and/or before delivery of cycle 4 of cisplatin) and after conclusion of (chemo)radiation (week 9, week 12, week 20, week 34 and week 60, respectively 1 week, 5 weeks, 3 months, 6 months and 12 months after completion of (chemo)radiation) in order to compare immunological function upon treatment with either protons or photons
223985863|NCT05923346|OTHER|GLUTLEARN|"The group will be made up of users of the social network Instagram who have celiac disease or are close to a celiac patient (parent/guardian of celiac children or cohabitants).~The intervention will be carried out through the social network Instagram. Participants will be recruited through the same social network. Participants must agree to take part in the study.~The educational intervention will be carried out for one month, where each day a post will be uploaded with specific, truthful and current information. The content of the intervention has been divided into 5 main blocks: 1) general concepts about CD, 2) balanced GFD, 3) food labelling, 4) cross-contact/cross-contamination, 5) new research on CD and useful resources for disease management."
223985864|NCT03085199|PROCEDURE|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
223985865|NCT03113747|BIOLOGICAL|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
223985866|NCT05967182|DRUG|Pembrolizumab|Given by IV (vein)
223985867|NCT05967182|DRUG|Gemcitabine|Given by IV (vein)
223985868|NCT05967182|DRUG|Cisplatin|Given by IV (vein)
223985869|NCT00240214|DRUG|sirolimus|Tablet, dosage is determined by trough level
223985870|NCT02409095|BIOLOGICAL|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
223985871|NCT02409095|DEVICE|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
223985872|NCT02409095|OTHER|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
223985873|NCT00712647|DRUG|Beta Carotene and Retinol|"Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard \& Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
223985874|NCT00712647|OTHER|Placebo|Two placebos, one each/day
223985875|NCT06566261|BIOLOGICAL|ABA-101|ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy
223985876|NCT04200898|DEVICE|Cheetah System|For each subject, surgeons will create an iLEX refractive correction using the investigational Cheetah femtosecond laser and Cheetah patient interface (regular or small diameter designs) on one eye (phase I) and one/both eyes based on refractive correction needs (phases II and III).
223985877|NCT00839566|PROCEDURE|Ablation|AV-node ablation
223985878|NCT00839566|OTHER|Rate Control|Rate control by drug
223985879|NCT01176318|DRUG|Erdosteine|capsule 300mg twice daily for 10 days
223985880|NCT01176318|DRUG|Placebo|placebo capsule, twice daily for 10 days
223985881|NCT00915083|DRUG|Amrubicin|40mg/m\^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
223985882|NCT04213677|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd. Additionally, participants will receive lifestyle modification and nutrition education.
223985883|NCT04213677|DRUG|Placebo|Participants will receive placebo po qd. Additionally, participants will receive lifestyle modification and nutrition education.
223985884|NCT05146115|OTHER|Realization of the Athletic Shoulder Test and the Modified Athletic Shoulder Test|The participants will have to perform both tests two times, with a 7-10 days rest period between the two sessions
223985885|NCT01642147|DEVICE|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
223985886|NCT01642147|PROCEDURE|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
223985887|NCT01642147|PROCEDURE|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
223985888|NCT01642147|PROCEDURE|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
223985889|NCT01642147|PROCEDURE|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
223985890|NCT03040245|BEHAVIORAL|Whiplash book|
223985891|NCT05921097|DIAGNOSTIC_TEST|Histamin-induced axon-reflex flare response|Histamin-induced axon-reflex flare response
223985892|NCT05921097|DIAGNOSTIC_TEST|Local heating-induced axon-reflex flare response|Local heating-induced axon-reflex flare response
223985893|NCT05921097|DIAGNOSTIC_TEST|2-point discrimination tasks|2-point discrimination tasks
223985894|NCT05921097|DIAGNOSTIC_TEST|NC-Stat DPNCheck|NC-Stat DPNCheck
223985895|NCT05921097|DIAGNOSTIC_TEST|QST|QST
223985896|NCT05921097|DIAGNOSTIC_TEST|Biothesiometry|Biothesiometry
223985897|NCT00810342|BEHAVIORAL|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
223985898|NCT00810342|BEHAVIORAL|physical activity standard|standard print and website information on how to become more active
223985899|NCT01636583|DEVICE|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
223985900|NCT01636583|DEVICE|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
223985901|NCT01636583|OTHER|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
223985902|NCT04144647|OTHER|Single testing session|"All participants that meet the inclusion criteria, will have to attend the research laboratory at Centre for Human and Applied Physiological Sciences, Shepherd's House, Guy's Campus, King's College London, SE1 1UL to be assessed in a single testing session.~The testing session will require them to complete some questionnaires regarding balance confidence, psychological state, sleep and physical function and to undertake some simple tests of cognitive function. They will also undertake a brief dynamic balance assessment and the dual-task gait test. The dual-task component involves two cognitive tasks (a numeracy and a literacy task) or auditory task. The gait test will be performed separately and then together with each of two cognitive tasks or auditory task.~On the day, after the testing, each participant will, also, be provided a physical activity monitor (accelerometer-AX3) to wear on their wrist for 24 hours a day, seven days a week without taking it off."
223985903|NCT01542346|PROCEDURE|subcutaneous adaption|
223985904|NCT01852032|RADIATION|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
223985905|NCT01852032|RADIATION|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
223985906|NCT03932578|DRUG|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
223985907|NCT03932578|DRUG|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
224120158|NCT03553238|DIAGNOSTIC_TEST|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
223544332|NCT00914576|DRUG|Placebo|2 capsules/day for 14 days
223985908|NCT04504630|DEVICE|High Definition Transcranial Direct Current Stimulation|This wireless device delivers a very low electrical current to focused regions on the scalp in order to modulate underlying brain circuits to promote neuroplasticity. The device will be fitted onto a neoprene EEG cap, with 1 anode electrode placed and surrounded by 4 cathode electrodes in a ring pattern. Electrical stimulation will be applied using a constant voltage cortical stimulator (Model D185, Digitimer Ltd, UK, maximal output 1000 V/1.5 A) with single square-wave 50-μs pulses (0.1 A/μs rise time).
223985909|NCT04504630|DEVICE|Sham HD-tDCS|Sham HD-tDCS
223985910|NCT02674269|DRUG|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
223985911|NCT02674269|DRUG|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
223985912|NCT02674269|DEVICE|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
223985913|NCT04962451|DRUG|ticagrelor + ASA|On day 1, ticagrelor loading dose (2 tablets, ticagrelor 90mg) was given, followed by ticagrelor 90mg, twice daily Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
223985914|NCT04962451|DRUG|Placebo+ASA|Placebo loading dose on day 1 (2 tablets, matched with ticagrelor 90mg), followed by placebo twice daily (matched with ticagrelor 90mg) Basic treatment: the first day received ASA loading dose, 300-325mg, and the server received ASA 75-100mg, once a day
223985915|NCT04451447|PROCEDURE|The White test uses fat emulsion (SMOFLIPID), for localization of bile leakage.|The White test uses fat emulsion (SMOFLIPID), which is a lipid emulsion with a lipid content of 0.2 grams/mL in 100 mL, 250 mL, and 500 Ml that is normally used for parenteral nutrition, for localization of bile leakage.
223985916|NCT04451447|PROCEDURE|Saline test (routine test)|The conventional intra-operative saline test, which involves injecting an isotonic sodium chloride solution through the cystic duct, has been used for detection of leaking points from the transected liver surface.
223985917|NCT04540445|OTHER|Pupillary Assessment|Pupillary assessment with handheld pupillometer
223985918|NCT06450236|DRUG|Perampanel 10 MG|1 tablet of Perampanel Tablets 10mg
223985919|NCT06450236|DRUG|Fycompa 10Mg Tablet|1 tablet of Perampanel Tablets 10mg
223985920|NCT02070770|DIETARY_SUPPLEMENT|Very low calorie diet|
223544333|NCT00914576|DRUG|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
223544334|NCT00914576|DRUG|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
223544335|NCT03719014|DEVICE|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
223544336|NCT04676906|DRUG|NNC0113-6861|Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
223544337|NCT04676906|DRUG|NNC0113-6860|Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
223544338|NCT04676906|DRUG|NNC0113-6891|Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
223544339|NCT04050384|DEVICE|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
223544340|NCT01594242|DRUG|Bortezomib|
223544341|NCT00577278|BIOLOGICAL|rituximab|Given IV
223544342|NCT00577278|DRUG|fludarabine phosphate|Given IV
223544343|NCT00577278|DRUG|melphalan|Given IV
223544344|NCT00577278|DRUG|sirolimus|Given PO
223544345|NCT00577278|DRUG|tacrolimus|Given PO or IV
223544346|NCT00577278|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
223544347|NCT00577278|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
223544348|NCT00577278|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223544349|NCT00577278|OTHER|laboratory biomarker analysis|Correlative Studies
223985921|NCT02070770|OTHER|Standard weight loss diet|
223985922|NCT02693704|DEVICE|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
223985923|NCT03624153|BEHAVIORAL|Robotic-assisted intervention|Participants received the 12-session robot-assisted intervention 3 sessions a week for 4 consecutive weeks. Each session consisted of 20-minute continuous passive motion, 20-minute active motion practice, and 30-minute task-oriented practice.
223985924|NCT03624153|BEHAVIORAL|Conventional rehabilitation intervention|Participants received the 12-session conventional rehabilitation intervention 3 sessions a week for 4 consecutive weeks. The intervention consisted of warm up including range of motion exercise, and strengthening exercise followed by task-oriented training for activities of daily living.
223985925|NCT06474065|PROCEDURE|Myomectomy|Patients submitted to operation of fibroids removal
223985926|NCT01472029|DRUG|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
224120159|NCT03553238|DIAGNOSTIC_TEST|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
223544350|NCT03965403|DEVICE|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
223544351|NCT01926743|PROCEDURE|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
223985927|NCT01472029|DRUG|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
223985928|NCT01819142|DEVICE|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
223985929|NCT00040287|BEHAVIORAL|smoking cessation program|
223985930|NCT00040287|BEHAVIORAL|weight control program|
223985931|NCT02700854|OTHER|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE \> -5 mmol/L in arterial blood gas samples
223985932|NCT04283708|PROCEDURE|Submental liposuction|Advancement Genioplasty With Submental Liposuction
223985933|NCT02689570|OTHER|observational|no interventions; observational study
224120160|NCT03553238|DIAGNOSTIC_TEST|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
223985934|NCT04513353|DEVICE|Rehabilitation using Digital Healthcare System (Uincare Homeplus)|"Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to total knee arthroplasty post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 3 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 3 to 12 weeks post surgery."
224120161|NCT03553238|DIAGNOSTIC_TEST|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
224120162|NCT03568006|OTHER|Specific passive mobilization|Specific passive mobilizations for the shoulder
224120163|NCT03568006|OTHER|Standardized treatment (standard protocol)|Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
224294297|NCT05054218|BIOLOGICAL|mRNA-1273|Participants will receive a 0.5 mL injection of the vaccine that contains a 100-μg dose of mRNA1273. The vaccine will be administered into the deltoid muscle.
223985935|NCT04513353|OTHER|Conventional Rehabilitation|Home-based self-rehabilitation using brochure for 12 weeks post surgery.
223985936|NCT03186586|DRUG|Ulipristal acetate|5mg/day/five days
223985937|NCT03186586|DRUG|Placebo|Placebo one pill a day for 5 days at the bleeding episode
224120164|NCT03065673|PROCEDURE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
223985938|NCT02429479|BEHAVIORAL|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
223985939|NCT02429479|BEHAVIORAL|Standard advance care planning|This is a online simple living will form.
223985940|NCT05802927|OTHER|DSF|Diabetes-specific formula
223985941|NCT05802927|OTHER|Breakfast 1|Noodle Soup
223985942|NCT05802927|OTHER|Breakfast 2|Glutinous rice
223985943|NCT04040049|GENETIC|FLT190|Gene Therapy product.
223985944|NCT03310671|PROCEDURE|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~* Mean transvalvular pressure gradient~* Aortic valve~* Aortic valve opening area~* Aortic valve opening area adjusted for body mass index~* Bicuspid or tricuspid aorta~* Thickness of the upper valve\> 3 mm"
223985945|NCT02865551|DEVICE|Foley catheter|Extended bladder catheterization after epidural anesthesia.
223985946|NCT02865551|DEVICE|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
223985947|NCT02865551|DRUG|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
223985948|NCT00297843|PROCEDURE|allergen challenge (grass pollen), nasal lavage|
223985949|NCT05282836|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) during a 7-day stay in the intensive care unit.
223985950|NCT04182113|DEVICE|1 Hz rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
223544352|NCT02622269|DEVICE|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
223544353|NCT02622269|DEVICE|Standard compression device|Compression of the abdomen with the standard compression device
223544354|NCT01474967|DRUG|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
223544355|NCT01474967|DRUG|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
223544356|NCT00712478|DRUG|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223544357|NCT00664313|DRUG|Linezolid|600 mg po daily for 112 doses (16 weeks)
223544358|NCT00664313|DRUG|Placebo|Placebo given daily for 112 doses (16 weeks)
223544359|NCT05121025|DIAGNOSTIC_TEST|Analysis of gut microbiome and immune signatures|The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
223985951|NCT04182113|DEVICE|Sham rTMS Stimulation|rTMS is an electromagnetic device that provides non-invasive stimulation to the cortex or a sham placebo stimulation that mimics properties without stimulation.
223985952|NCT01667406|DRUG|Kisspeptin 1.6nmol/kg|single kisspeptin dose 1.6 nmol/kg subcutaneously
223985953|NCT01667406|DRUG|Kisspeptin 3.2nmol/kg|single kisspeptin dose 3.2 nmol/kg subcutaneously
223985954|NCT01667406|DRUG|Kisspeptin 6.4nmol/kg|single kisspeptin dose 6.4 nmol/kg subcutaneously
223544360|NCT03672630|DRUG|Azithromycin|Azithromycin 500 MG Oral Tablet \[ZITHROMAX\]
223985955|NCT01667406|DRUG|Kisspeptin 9.6nmol/kg|single kisspeptin dose 9.6 nmol/kg subcutaneously
223985956|NCT01667406|DRUG|Kisspeptin 12.8nmol/kg|single kisspeptin dose 12.8 nmol/kg subcutaneously
223985957|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg double|kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
223985958|NCT01667406|DRUG|Kisspeptin 9.6 nmol/kg + saline|kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
224294298|NCT00759278|PROCEDURE|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
223985959|NCT00943787|PROCEDURE|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
223985960|NCT00206297|DRUG|Pramlintide|
223985961|NCT04338412|DEVICE|ProSeal-LMA™|It is a second generation LMA that is commonly used among all other LMAs
223985962|NCT04719299|BEHAVIORAL|Tell-Play-Do|Using smart phone application
223985963|NCT04719299|BEHAVIORAL|Tell-Show-Do|Using traditional behavior management technique
223728247|NCT05945043|OTHER|Breathlessness assessment|The VAS breathlessness score and Dyspnoea-12 questionnaire of participants will be measured pre, immediately post and at days 1 and 7 following pleural fluid removal
223728248|NCT03598556|DIETARY_SUPPLEMENT|Vitamin D3|180,000IU Vitamin D3 oral emulsion
224120165|NCT03065673|PROCEDURE|Placebo gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the placebo gel~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
224120166|NCT01651182|DRUG|No tranexamic acid|Control
224120167|NCT01651182|DRUG|Tranexamic Acid|
223728249|NCT03598556|OTHER|Placebo|Placebo
223728250|NCT00981734|OTHER|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
223728251|NCT04397224|DIAGNOSTIC_TEST|Device interrogation|Ventriculo-ventricular conduction time measurement using device analyzer
223985964|NCT01495351|DRUG|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
224120168|NCT04452812|BIOLOGICAL|Convalescent plasma|"Best available treatment + convalescent plasma~Best available treatment: hemodynamic support, oxygen supplementation, antibiotic therapy (if required), and individualized treatment judged by the attending physician.~Plasma will be split by aliquots of 200 ml for its storage on -60 celsius degrees until it's used. After defrosting, it will be administered on 2 200 ml separated doses on a 12 hours interval."
224120169|NCT02458612|OTHER|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
224294299|NCT06807918|DIETARY_SUPPLEMENT|Kenetik|Drink a single dose of ketone supplement 25g, three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits.
223544361|NCT03672630|DRUG|Ethambutol|Ethambutol 25 mg/kg \[MYAMBUTOL\]
223544362|NCT03672630|DRUG|Rifampin|Rifampin 600 MG \[RIFADIN\]
223544363|NCT06518304|OTHER|GentleWave|GentleWave System employs a degassing process that removes dissolved gases from the solution. This optimization prevents the vapor-lock effect and ensures effective energy transmission through the root canal. As the solution enters the pulp chamber, hydrodynamic cavitation occurs, creating microbubbles that implode and generate sound waves across a broad frequency spectrum
223728252|NCT03341949|BIOLOGICAL|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
223728253|NCT03674996|OTHER|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
223728254|NCT03674996|OTHER|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
223728255|NCT03674996|OTHER|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
223728256|NCT01161147|DRUG|Meloxicam|Meloxicam Tablets 15 mg
223728257|NCT01050426|OTHER|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
223728258|NCT01050426|OTHER|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
223728259|NCT02052674|DEVICE|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
223985965|NCT01300442|OTHER|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
223985966|NCT01300442|OTHER|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
223985967|NCT04627051|DEVICE|Atherectomy and balloon angioplasty|Atherectomy and balloon angioplasty of arterial-venous graft stenosis
223985968|NCT01216072|DRUG|Fingolimod|0.5 mg/day oral capsule
223985969|NCT01216072|DRUG|Standard MS DMTs|
223985970|NCT05289661|DRUG|Topical Ripasudil|To determine the effect of rho-kinase inhibitors on endothelial cell loss
223985971|NCT05289661|DRUG|Topical Placebo|topical Placebo
223985972|NCT04294667|DRUG|DZP|Subjects will receive dapirolizumab pegol at prespecified time-points.
224120170|NCT02458612|OTHER|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
224120171|NCT02270632|DRUG|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
223985973|NCT04294667|OTHER|Placebo|Subjects will receive placebo at prespecified time-points.
223985974|NCT05860569|GENETIC|GC304|Self-complementary adeno-associated virus serotype 5 (AAV5) carrying a codon-optimized LPL coding sequence(coLPL) driven by a liver-specific promoter (LP)
223985975|NCT06801717|DEVICE|KTP Laser Therapy|Participants will receive full face treatments with 532 nm KTP laser for 3 sessions at 8-12 weeks apart. Laser therapy will be conducted in person. Each laser treatment session will last up to 10 minutes.
224120172|NCT02270632|DRUG|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
224120173|NCT02270632|DRUG|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
224120174|NCT00000637|DRUG|Zidovudine|
224120175|NCT00000637|DRUG|Didanosine|
223985976|NCT06801717|DEVICE|Radiofrequency microneedling|Participants will receive unilateral facial treatments with radiofrequency microneedling device for 3 sessions at 8-12 weeks apart. Radiofrequency microneedling will be conducted in person. Each treatment session will last up to 1 hour.
223985977|NCT05398549|OTHER|Conventional Physical therapy|Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise
223985978|NCT05398549|OTHER|Virtual reality group|group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414. Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training.
223985979|NCT00756457|DEVICE|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
223985980|NCT00756457|OTHER|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
223985981|NCT00756457|OTHER|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
223985982|NCT03889873|BEHAVIORAL|Narrative Writing|An writing task in which participants are given a description of a possible future self (that varies 3 factors: topic; drinking vs. smartphone; perspective: 1st vs. 3rd-person; and social network: specifically asked to be included vs. not specifically asked to be included). Participants are asked to imagine that future self vividly and to write about the thoughts and feeling describe themselves and their experiences, the characteristics they hope or wish they will ideally possess, the characteristics that they would need to have and the roles they will take on or things they will be doing. Participants are given 20 minutes to think and write. They will write and think about the same future on each of three lab-sessions (which occur at 1-week intervals).
223985983|NCT02113410|BEHAVIORAL|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
223985984|NCT02113410|BEHAVIORAL|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
223985985|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
223985986|NCT01777490|BEHAVIORAL|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
223985987|NCT01309477|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
223985988|NCT04915131|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate and maternal heart rate on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes."
224120176|NCT00564707|BEHAVIORAL|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
224120177|NCT00564707|PROCEDURE|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
224120178|NCT03435653|OTHER|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
224120179|NCT03435653|OTHER|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
224120180|NCT00207376|DEVICE|Solysafe Septal Occluder|
223985989|NCT00930345|DRUG|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
223985990|NCT02818998|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
223985991|NCT03286309|DEVICE|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
223985992|NCT02193659|DIETARY_SUPPLEMENT|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
223985993|NCT05069298|DIETARY_SUPPLEMENT|Silibinin A|The compound will be administered following a 300 mg / 3 day schedule, before each main meal.
223985994|NCT04787432|BEHAVIORAL|Salutogenic Frailty Prevention Program|"Laughter yoga: The first component of intervention is the laughter yoga that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Each session of laughter yoga will be offered twice a weekly and 40 minutes each time.~Health education: The second component of intervention consisted of six health issues which are health, frailty and generalized sources of resistance for frailty, the most common medical condition and medication use, physical activity, healthy diet, falls prevention and cognitive and psychosocial well-being.~Case management: The third component of intervention is activities that determine each participant's health needs with the Omaha System and support them for the use of appropriate resources."
223985995|NCT02906475|OTHER|standardized skin care regimen|"Application of a standardized daily skin care regimen:~* milk lotion once daily and~* application of addendum for bathing as needed"
223985996|NCT00926380|DRUG|denosumab|denosumab: 60 mg SC every 6 months
223985997|NCT00926380|DRUG|teriparatide|teriparatide: 20 mcg SC QD
223985998|NCT00565838|PROCEDURE|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
224120181|NCT00876980|DEVICE|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
223544364|NCT06518304|OTHER|Conventional Protocol|Delivers irrigants (NaOCl, EDTA) through a needle-syringe system, often fails to reach the entire working length. This inadequacy can result in residual bacteria and necrotic tissue, potentially compromising treatment efficacy and increasing the risk of treatment failure.
223544365|NCT06184178|OTHER|Socio-health care|Socio-health care under TEC-MED model and an integral assessment
223544366|NCT06114719|DRUG|Silymarin|Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
223985999|NCT00244647|DRUG|RESTEN-MP|
223986000|NCT00136110|DRUG|Sodium Valproate|
223986001|NCT01601912|DRUG|Atomoxetine|40 mg, 1 application
223986002|NCT01601912|DRUG|Citalopram|20 mg, 1 application
223986003|NCT03349411|DIAGNOSTIC_TEST|Confusion Assessment Method|This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
224120182|NCT03528044|PROCEDURE|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
223986004|NCT03349411|DIAGNOSTIC_TEST|Behavioral Inattention Test|This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
224120183|NCT02645448|OTHER|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
224120184|NCT02084134|DRUG|hydrocortisone|100mg at the time of surgery
224120185|NCT02084134|DRUG|dexamethasone|0.5mg every 6 hours for a total of four doses
223728260|NCT02052674|DEVICE|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
224120186|NCT02526615|DRUG|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
224120187|NCT02526615|DRUG|Metformin|Patients received either placebo, metformin or rosiglitazone
224120188|NCT02526615|DRUG|Placebo|Patients received either placebo, metformin or rosiglitazone
223728261|NCT03642405|DIAGNOSTIC_TEST|Electrocardiogram examination|12-lead ECG monitored by Holter
223728262|NCT03642405|DIAGNOSTIC_TEST|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
223728263|NCT03642405|PROCEDURE|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
223728264|NCT03642405|BEHAVIORAL|Questionnaire|Questionnaire regarding patients quality of life
223728265|NCT04689633|PROCEDURE|nerve block|bilateral ultrasound-guided posterior quadratus lumborum block was done in the lateral decubitus and linear or curvilinear probe was used according to the depth and placed in the midaxillary line in the transverse plane above the iliac crest
223728266|NCT04023604|OTHER|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
223728267|NCT04023604|OTHER|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
223986005|NCT03349411|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
224120189|NCT01517789|DEVICE|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
224120190|NCT01512394|PROCEDURE|standard bowel prep|standard bowel prep
224120191|NCT01512394|PROCEDURE|no bowel prep|no bowel prep
224120192|NCT05951764|DIAGNOSTIC_TEST|Non-invasive measurement of arterial stiffness by Pulse Wave Velocity (PWV)|For all patients PWV in (cm/s) will be collected from D-30 to D-1 before the procedure and at D3 postoperatively.
224120193|NCT04857398|DRUG|insulin icodec|"Participants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin.~The study will last for 15 to 22 weeks."
224120194|NCT00004747|DRUG|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
224120195|NCT00763204|DRUG|AN2728 Cream, 2%|
224120196|NCT00763204|DRUG|AN2728 Cream, 1%|
224120197|NCT00763204|DRUG|AN2728 Cream, 0.3%|
224120198|NCT00763204|DRUG|AN2728 Cream Vehicle|
224120199|NCT00763204|DRUG|Betnesol®-V Creme, 0.1%|
224294300|NCT06807918|OTHER|magnetic resonance imaging scan|Each subject will undergo 2 research MRI scan evaluations of the brain (up to 90 min.). The MRI is FDA-approved 7.0T Magentom Prisma scanner (Siemens Medical Solutions USA, Inc., Malvern, PA) with an approved radiofrequency head coil.
224120200|NCT01142986|BEHAVIORAL|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
224120201|NCT01142986|BEHAVIORAL|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
223728268|NCT03667924|BEHAVIORAL|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
223728269|NCT01126476|OTHER|Proton Radiotherapy|
223728270|NCT02128178|DRUG|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
223728271|NCT02128178|DRUG|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
224294301|NCT06807918|OTHER|fludeoxyglucose-18 positron emission tomography scan|Each subject will undergo 2 FDG PET/CT scans. FDG is a positron emitting radiopharmaceutical. In addition to the radioactive FDG tracer, a low-dose CT of the chest is typically performed with the FDG PET/CT for the purpose of anatomical registration and attenuation correction of PET images. There are no separate diagnostic CT scans performed as part of this study.
223728272|NCT01593215|DRUG|Yohimbine|Yohimbine capsule
223544367|NCT03130907|DEVICE|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
223544368|NCT01506635|DRUG|Timolol|
223544369|NCT01506635|DRUG|Placebo|artificial tear twice a day
223728273|NCT04160897|DRUG|Entecavir|entecavir naive for chronic hepatitis B patients
223728274|NCT04160897|DRUG|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
223544370|NCT02494973|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
223544371|NCT02494973|DRUG|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
223544372|NCT02494973|DRUG|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
223544373|NCT02494973|DRUG|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
223544374|NCT04799002|DRUG|Topotecan|Topotecan intraocular injection for chemotherapy in retinoblastoma
223544375|NCT04799002|DRUG|Melphalan|Melphalan intraocular injection for chemotherapy in retinoblastoma
223544376|NCT00552071|DRUG|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
223986006|NCT03349411|DIAGNOSTIC_TEST|Florida Mental Status Examination|This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
223986007|NCT03349411|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
223986008|NCT03349411|DIAGNOSTIC_TEST|Geriatric Depression Scale|Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
223986009|NCT03349411|DIAGNOSTIC_TEST|Kessler Foundation Neglect Assessment Process|This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
223986010|NCT03533205|DIAGNOSTIC_TEST|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
223986011|NCT06404983|OTHER|Opioid Free Anaesthesia (OFA)|Patients are allocated to receive non-opioid anaesthesia intraoperatively. Patients will receive a mixture of dexmedetomidine, ketamine and lidocaine for intraoperative analgesia.
223986012|NCT06404983|OTHER|Conventional General Anaesthesia (CGA)|Patients are allocated to receive conventional general anaesthesia intraoperatively with the use of fentanyl and morphine for intraoperative analgesia.
223986013|NCT02045290|DRUG|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
223986014|NCT02045290|DRUG|Placebo|
223986015|NCT00632021|BEHAVIORAL|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
223986016|NCT04624945|DIAGNOSTIC_TEST|APTT CWA (Activated partial thromboplastin time clot waveform analysis), Procalcitonin and Serological/Inflammatory markers (KL-6, SPA, MIG, Presepsin)|"Primary Aim: To validate the use of APTT CWA (Activated partial thromboplastin time clot waveform analysis) and ICIS (Intensive Care Infection Score), as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.~Secondary Aim: To examine the evolution of CWA, immuno-parameters (KL-6, SP-A, MIG, presepsin) and various WBC (white blood cell count) activation markers over the time in relation to diagnosis of sepsis, development of positive blood cultures and mortality or recovery. Blood parameter measurements using a 3-part and 5-part differential analyser will be performed. KL-6, SP-A, MIG, presepsin are serum biomarkers - MIG (Monokine induced by gamma interferon), SP-A (Surfactant protein A), KL-6 (Krebs von den Lungen 6)."
223986017|NCT04394195|OTHER|measurement of circulating sFlt1 concentration|blood circulating sFlt1 concentration will be determined
223986018|NCT00480064|DRUG|Lomustine, intermediate dose cytarabine|
223986019|NCT03563313|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.
223986020|NCT03563313|DEVICE|Sensor-augmented pump (SAP)|Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
223986021|NCT00952848|OTHER|questionnaire administration|Pain Rating Score
223986022|NCT00952848|OTHER|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
223986023|NCT00952848|OTHER|Quality of Life instrument|Uniscale 0-100 scale global quality of life
223986024|NCT00952848|DEVICE|MC5-A Scrambler device|Electrical stimulation for 60 minutes
223986025|NCT00458393|DRUG|daily TDF/FTC|daily oral medication
223986026|NCT00458393|DRUG|Placebo|daily oral medication
224120202|NCT02379923|DEVICE|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
224120203|NCT05148208|DEVICE|Creatine supplementation to dialysate|Creatine supplementation to dialysate
224120204|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
223986027|NCT02486419|OTHER|Outdoor weather|Seasonal changes in temperature
223986028|NCT04582513|OTHER|AnCHor-Checklist implementation|a standardized checklist using the SBAR concept according to the recommendations of the DGAI
223986029|NCT00788164|BIOLOGICAL|TA-HPV|Given intramuscularly
223986030|NCT00788164|BIOLOGICAL|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
223986031|NCT00788164|DRUG|imiquimod|Given topically
223986032|NCT03177681|OTHER|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
224120205|NCT02151409|DRUG|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
224120206|NCT02151409|DRUG|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
223986033|NCT03177681|OTHER|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
223986034|NCT03177681|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
223986035|NCT03177681|DEVICE|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
223986036|NCT03177681|OTHER|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
224120207|NCT04005092|DEVICE|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
224120208|NCT00100373|DRUG|RSV challenge material|
223544377|NCT01503814|OTHER|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
223544378|NCT02505373|BEHAVIORAL|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
223544379|NCT02505373|BEHAVIORAL|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
223544380|NCT03076281|DRUG|Metformin Hydrochloride|Given orally
223544381|NCT03076281|DRUG|Doxycycline|Given orally
223544382|NCT03076281|DRUG|Metformin +Doxycycline|Given orally
223986037|NCT01690923|DEVICE|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
223986038|NCT01690923|DEVICE|Pillows mask|Nasal pillows mask (Swift FX)
223986039|NCT02377011|BEHAVIORAL|Problem solving cognitive behaviour therapy (PS CBT)|
223986040|NCT04315116|DRUG|pyrotinib maleate|a single oral dose of pyrotinib maleate on day 1 \& day10 .
223986041|NCT04315116|DRUG|Loperamide|Loperamide 4 mg bid from day 7 to day 13
224120209|NCT00156546|DRUG|antibiotic to reduce the recurrence of infection|
223986042|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
223986043|NCT04148118|BIOLOGICAL|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
223986044|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
223986045|NCT04148118|BIOLOGICAL|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
224120210|NCT00005022|DRUG|cisplatin|
224120211|NCT00005022|DRUG|etoposide|
223544383|NCT00638300|DEVICE|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
223544384|NCT00638300|OTHER|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
223986046|NCT04148118|BIOLOGICAL|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
223986047|NCT04148118|BIOLOGICAL|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
223986048|NCT04148118|BIOLOGICAL|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
223986049|NCT04035330|COMBINATION_PRODUCT|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
224120212|NCT00005022|RADIATION|radiation therapy|
224120213|NCT04458038|OTHER|driving simulator|For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
224120214|NCT03464708|DIETARY_SUPPLEMENT|HMB|Powder form
224120215|NCT03464708|OTHER|Lactose (placebo)|Powder form
224120216|NCT03679208|DEVICE|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
224120217|NCT03679208|DEVICE|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
224120218|NCT00426751|DRUG|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
223986050|NCT04035330|COMBINATION_PRODUCT|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
223986051|NCT05313906|DRUG|RC48+AK105+cisplatin|RC48 plus AK105 and cisplatin
223986052|NCT05526456|PROCEDURE|Esophagectomy|McKeown, Ivor-Lewis, and Sweet procedure
223986053|NCT04846855|DRUG|local anaesthetic injection|Realization by the anesthesiologist of the local anesthesia by single dose of ropivacaine 0.35% in perinervous under ultrasound with distraction by a tablette.
223986054|NCT00521443|PROCEDURE|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
223986055|NCT06164015|DIAGNOSTIC_TEST|3D Ultrasound scan with power Doppler angiography|The study group and the control group will be offered a 3D ultrasound scan as a part of this trial.
223986056|NCT06102226|DIAGNOSTIC_TEST|coronary artery imaging (coronary CTA or coronary angiography)|In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
224120219|NCT00426751|DRUG|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
224120220|NCT03356158|BIOLOGICAL|CPGJ602|Injection, q.w., 20 mg: 100 ml
224120221|NCT03356158|BIOLOGICAL|Cetuximab|Injection, q.w., 20 mg: 100 ml
224120222|NCT00921856|OTHER|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
223986057|NCT02937896|DRUG|Desmopressin|40 micrograms Nasal Desmopressin.
223986058|NCT02937896|DRUG|Ketorolac|30mg intravenous Ketorolac.
223986059|NCT02937896|DRUG|Normal Saline|1cc intravenous Normal Saline.
223986060|NCT02937896|DRUG|Normal Saline|4 puffs nasal Normal Saline.
223986061|NCT02615678|DEVICE|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
223986062|NCT05585177|DRUG|Growth hormone|3 months of growth hormone treatment (2 units daily)
223986063|NCT06315101|DRUG|Chinese Herbal Medicine|Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
223986064|NCT04419363|DRUG|Burosumab Injection|Children affected with X-linked hypophosphatemia were switched from conventional therapy to burosumab
223986065|NCT00857233|DRUG|Memantine|20 mg oral tablets once daily
223986066|NCT06488885|BEHAVIORAL|Elderly care training|The 60 experimental group students included in the study will have three lesson hours each week. Face-to-face training will be provided. Their consent was obtained before training was given to the experimental group. Participant Information Form and Positive and Negative Ageism Scale (PNYAÖ) will be applied as a pre-test. Trainings are 3 lesson hours, one day a week. It will be given as eight weeks and 24 hours in total. Upbeat and positive after the end of the training A posttest will be administered with the Negative Ageism Scale (PNSAS). Posttest PNSAÖ will be administered again one month after administration, and follow-up data will be obtained. Participant Information Form and Positive and Negative Ageism Scale (PNSAS) will be applied as a pre-test. Eight weeks. At the end, PNCAS will be administered again as the final test.
223986067|NCT05052710|DRUG|AZD4831|Subjects will receive oral doses once daily from Days 2-11.
223986068|NCT05052710|DRUG|Midazolam|Subjects will receive oral single doses on Day 1 and Day 11.
223986069|NCT04517942|BEHAVIORAL|EVERYbody Project|Brief behavioral intervention (4 hours across two meetings)
223986070|NCT04517942|OTHER|Video + Expressive Writing|Brief video-based intervention (4 hours across two meetings)
223986071|NCT05043883|DEVICE|CathVision Cube® system|Intracardiac signals will be passively recorded using the investigational CathVision Cube® System in parallel with the commercial (bearing CE mark) EP recording systems LabSystem Pro, Boston Scientific EP, or EP-Tracer, Schwarzer Cardiotek. The investigational device will not be used for direct clinical care decisions or therapy. The validation of the PVI Analyzer will be performed offline and retrospectively.
223986072|NCT01587118|DRUG|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
224120223|NCT05784909|DEVICE|rezum|"Technique With the patient in a lithotomy position, after cystoscopy, an RF current is applied to. Water vapour is delivered through a retractable vapor needle via emitter holes in the transurethral device. This is done in 9-second bursts to the transition zone of the prostate, where, via convection, it diffuses evenly throughout the target tissue. The depth of the needle penetrating is approximately 10 mm.~Upon contact with body-temperature tissue, the water vapour then condenses. This phase shift to a liquid state dispenses concentrated energy onto the cell membranes of the target tissue, triggering instant cell necrosis. Overlapping injection sites can be established with repeated applications in order to fully target areas of hypertrophy. Saline flush irrigation is used to both cool the urethra and to promote visualization.~At the end of the procedure Urethral catheter is fixed for 1-3 days."
223986073|NCT01447862|DRUG|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
223544385|NCT00638300|OTHER|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
223544386|NCT04169646|OTHER|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
223544387|NCT04169646|OTHER|Control|No intervention takes place during the control phase.
223544388|NCT05359315|DRUG|Interferon-Gamma|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
223544389|NCT05140772|DRUG|Dipeptiven|IV administration daily for 7 days
223544390|NCT05140772|DRUG|normal Saline|IV administration daily for 7 days
223544391|NCT05770635|DEVICE|Embosphere and chemotherapy drug|chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition
223986074|NCT01447862|DRUG|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
223986075|NCT00537329|DRUG|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
223986076|NCT00574600|BIOLOGICAL|SAAVI DNA-C2 vaccine|DNA vaccine
223986077|NCT00574600|BIOLOGICAL|SAAVI MVA-C vaccine|Boost vaccine
223986078|NCT00574600|BIOLOGICAL|Placebo|Placebo vaccine
223986079|NCT01658956|DRUG|GCSF administration on days 8 and 12 after chemotherapy|
223986080|NCT05946122|DRUG|Atorvastatin 40 Mg Oral Tablet|oral atorvastatin for renal protection
223986081|NCT05946122|DRUG|placebo drug|tablet resembles atorvastatin
223986082|NCT00103272|DRUG|tanespimycin|Given IV
223986083|NCT00103272|DRUG|bortezomib|Given IV
223986084|NCT04117815|DEVICE|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~* Minimum 30 minutes pre-infusion cooling~* Cooling for the duration of chemotherapy infusion~* Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
223986085|NCT04117815|OTHER|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~* Baseline~* at the half-way Point of the cyles~* at the last CT cycle~* 3 months after completion of Treatment~* 6-9 months after treatment completion~The assesments include the following~* Photographs of the head, which are evaluated using the CTCAEv4.0~* Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
223986086|NCT03118245|DEVICE|AuraGain|After anesthetic induction, AuraGain is inserted in children
223544392|NCT05770635|DEVICE|Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug|chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
223544393|NCT01979614|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
223986087|NCT03118245|DEVICE|I-gel|After anesthetic induction, I-gel is inserted in children
223544394|NCT01979614|OTHER|Placebo|5% v/v glucose solution
223544395|NCT03598049|DEVICE|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
223986088|NCT01792843|BEHAVIORAL|data|"* comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features"
223986089|NCT01152476|DRUG|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
223544396|NCT03598049|DEVICE|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
223986090|NCT01152476|DRUG|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
223986091|NCT05331976|DIAGNOSTIC_TEST|Proof Lab Test System|Includes the Proof Lab Reader and the Proof Lab COVID-19 Test Kit containing: Proof Lab COVID-19 Test Cartridge, Sample Vial, Sample Swab, Exact Volume Transfer Pipette
223986092|NCT01749163|BIOLOGICAL|Saline|
223986093|NCT01749163|BIOLOGICAL|GIP|
223986094|NCT01749163|BIOLOGICAL|GLP-1|
223986095|NCT02484989|OTHER|Surviellance card|
223986096|NCT05213442|DIAGNOSTIC_TEST|To estimate the prevalence rates of liver disease in psychiatric inpatients and to explore factors associated with the existence of liver disease.|"Patients will receive the usual clinical and paraclinical examinations as part of their hospitalization diagnostic workup. For the biological analyses, a blood sample will be taken following inclusion as well as a Fibroscan examination.~Data will be collected from the patient, or if necessary from the health care team, using the medical record (interview and/or self-questionnaires)."
223986097|NCT05742048|DIAGNOSTIC_TEST|traumatic patient suspect to have long bone fracture between 18 - 65 years old|Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
223986098|NCT02287233|DRUG|Venetoclax|Venetoclax will be taken orally once daily.
223986099|NCT02287233|DRUG|Cytarabine|Low-dose cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
223986100|NCT04113057|OTHER|Remote Coaching|In patients randomized to the remote coaching arm, study staff will provide feedback on home-based supplemental exercise based on heart rate and walking distance measurements from the LIVMOR health monitoring system.
223986101|NCT00085566|DRUG|everolimus|
223986102|NCT00085566|DRUG|gefitinib|
223986103|NCT06454045|DRUG|Clopidogrel|Clopidogrel 75 mg once a day for 14 days.
223986104|NCT04592081|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dextenza 0.4Mg Ophthalmic Insert
223986105|NCT05891145|DRUG|Remimazolam|Remimazolam is dispensed at 2 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
223986106|NCT05891145|DRUG|midazolam|Midazolam is dispensed at 1 mg/ml by the designated researchers who are not involved in enrollment, anesthesia administration, and postoperative follow-up.
223986107|NCT04730674|DRUG|tetracycline mixed with xylocaine|10 cc of saline containing 2 gm of tetracycline mixed with 5 ml of 2% xylocaine (as a pain relieving agent) was injected at the seroma bed.
223986108|NCT03174782|DRUG|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
223986109|NCT03174782|DRUG|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
223986110|NCT02925845|DEVICE|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
224120224|NCT06671275|BIOLOGICAL|Cell therapy|Subjects were placed sequentially into three different dose groups, 5.0×107 cells/time (low-dose group), 1.5×108 cells/time (medium-dose group), and 5.0×108 cells/time (high-dose group) for dose escalation
224120225|NCT06672653|DRUG|"The monoterpenoid zinc tetra-ascorbo-camphorate (C14)"|The trial phase will consist of hospital administration by vaginal syringe of 5ml of 1% C14, twice a day for 7 days, starting the first cure during the follicular phase of the cycle, just after the last menstrual period (S1), the second cure the following month (S5), the third cure 4 weeks later (S9) and the last cure 8 weeks later (S13). Gynaecological follow-up with HPV molecular testing and cervical smear will be performed two days after each course of treatment at S2, S6, S10, S14 and 2 weeks after the last course of treatment (S16). Unprotected sexual intercourse will not be permitted during each course of treatment, and for at least 72 hours before each genital swab.
223728275|NCT02135302|DRUG|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
223986111|NCT03754790|DRUG|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223986112|NCT03178045|OTHER|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
223986113|NCT03178045|OTHER|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
223986114|NCT00450138|DRUG|ZD6474 (vandetanib)|once daily oral dose
223986115|NCT00450138|DRUG|Cisplatin|intravenous infusion
223986116|NCT00450138|RADIATION|Radiation|radiation of head and neck
223986117|NCT04802304|OTHER|Beyond Bias Treatment|The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony.
223986118|NCT01280604|DRUG|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
223986119|NCT04086238|DRUG|Decitabine|Capsules containing a combination of decitabine and THU
223986120|NCT05907642|OTHER|Prune (dried plum)|Subjects who are assigned to the treatment group consume a total of 100 g of prune per day for 18 days and the subjects who are assigned to the control group are allowed to have a normal meal without prune for 18 days.
223986121|NCT02119338|DRUG|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
223986122|NCT04429802|DRUG|Prucalopride|Orally administered
223986123|NCT04429802|DRUG|Placebo|Orally administered
223986124|NCT02888379|DRUG|TOP1288|
223986125|NCT02888379|DRUG|Placebo (for TOP1288)|
223986126|NCT00541905|DRUG|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
223986127|NCT03432390|DEVICE|Continuous Positive Airway Pressure|A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station
223986128|NCT03432390|DEVICE|Open system ventilation|Facemask ventilation adapted to the anesthesia work station
223986129|NCT00358007|DEVICE|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
223986130|NCT04237285|OTHER|Inhalation aromatherapy|Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
223986131|NCT02058836|DRUG|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
223728276|NCT00881582|DRUG|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
223728277|NCT02822768|PROCEDURE|Packing|The patient will receive packing as part of their wound care
223986132|NCT02058836|PROCEDURE|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
223986133|NCT03376750|BEHAVIORAL|CO - OP|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
223986134|NCT02297685|DEVICE|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
223986135|NCT02297685|DEVICE|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
223986136|NCT02297685|DEVICE|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
223986137|NCT00470028|DEVICE|Transcranial Magnetic Stimulation|
223986138|NCT00267098|DEVICE|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
223986139|NCT00267098|DEVICE|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
223986140|NCT03144297|OTHER|Lumbar puncture|diagnostic lumbar puncture
223986141|NCT03144297|OTHER|BOD POD (air-displacement plethysmography)|Assessment of body fat
223986142|NCT00835185|BIOLOGICAL|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
223986143|NCT00835185|DRUG|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
223986144|NCT00835185|DRUG|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
223986145|NCT00835185|DRUG|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
223986146|NCT05702541|DEVICE|Lehfilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses
223986147|NCT05702541|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses
223986148|NCT05702541|DEVICE|Hydrogen peroxide-based cleaning and disinfection system|Commercially available cleaning and disinfection system for silicone hydrogel contact lenses
223986149|NCT02903303|OTHER|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~* 1st session : contact with the therapist, body scan, basic suggestions~* 2nd session : hypnosis induction followed by suggestions tu build a safe place~* 3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~* 4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
223986150|NCT02519946|OTHER|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
223986151|NCT02802397|OTHER|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
223986152|NCT04902469|BEHAVIORAL|Pleasant Odor|Each participant in the pleasant odor condition will sniff an odor that they rated as the most intense out of a sample of odors rated to be pleasant. If this odor is the same as their self-reported preferred e-cigarette flavor, we will choose the next most intense odor out of the odors rated to be pleasant. Odors are generic and commercially available in supermarkets such as vanilla, coconut, and chocolate. Importantly, the investigators are not testing the specific odors, rather the participant's idiosyncratic response to a menu of odors. In other words, the key is that each participant in the experimental condition receives the odor that they like the best, regardless of which one it is.
223986153|NCT04902469|BEHAVIORAL|Odor Blank|Each participant in the odor blank condition will sniff a neutral olfactory cue (odor blank). This involves a container with no added scent. This serves as the control condition.
223986154|NCT05429593|DRUG|Semaglutide|Tablet given orally
224120226|NCT06672653|DRUG|Distilled water group|Instead of C14, distilled water will be administered in this group.
224120227|NCT06672887|OTHER|MiLES|The MiLES intervention is an open access website, accessible via an URL, but not traceable through any online search engine during the study period. Tailored for specific preferences and needs of different employees with cancer, the MiLES intervention consists of interactive videos, conversation checklists, tips and information regarding RTW guidance of employees with cancer, and an overview of involved stakeholders and relevant legislation. The MiLES intervention intends to optimize the RTW support the employer provides to the employee with cancer by enhancing the willingness and ability to implement the employer actions. The MiLES intervention focuses for example on fostering effective communication between the employer and employee, while disregarding assumptions based on previous experiences.
224120228|NCT04833985|PROCEDURE|LAAC combined with radiofrequency ablation|Each patient received the same group of patients with simple radiofrequency ablation and LAAC
224120229|NCT00787696|BEHAVIORAL|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
224120230|NCT01066078|OTHER|Echocardiography and SonR recording|
224120231|NCT00027040|DRUG|Selegiline hydrochloride|
224294302|NCT06807918|OTHER|Alcohol bar lab|Each subject will undergo 2 alcohol bar labs. Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%.
224294303|NCT06807918|OTHER|Placebo beverage|Drink a single dose of placebo beverage, that will look and taste the same as the ketone supplement. Subjects will recieve the beverage three times, randomly given at 1 of 2 MRI scan visits, 1 of 2 FDG PET/CT scan visits, and 1 of 2 alcohol bar lab visits, opisite of the Kenetik beverage.
223986155|NCT05429593|DRUG|Dapagliflozin|Tablet given orally
223986156|NCT05429593|DRUG|Semaglutide/dapagliflozin|Tablet given orally
224120232|NCT04680286|DRUG|Methadone Hydrochloride|Single dose, intravenous bolus, 0,1 mg/kg administered at induction of anesthesia.
224294304|NCT05883033|DEVICE|VAC|Vacuum Assisted Closure device
224294305|NCT06984328|BIOLOGICAL|Acasunlimab|Intravenous (IV) infusion
224294306|NCT06984328|BIOLOGICAL|Pembrolizumab|IV infusion
223986157|NCT04718636|DRUG|Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent)|Daily
223986158|NCT04718636|DRUG|CC-99677|Daily
223986159|NCT01508338|DIETARY_SUPPLEMENT|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
223986160|NCT01508338|DIETARY_SUPPLEMENT|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
223986161|NCT01508338|DIETARY_SUPPLEMENT|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
223986162|NCT01508338|DIETARY_SUPPLEMENT|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
224120233|NCT04680286|OTHER|Placebo|Single dose, intravenous bolus. Administered as the experimental arm.
224294307|NCT03143387|OTHER|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
224294308|NCT03143387|OTHER|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
224294309|NCT06589245|DRUG|Alvesco Inhalant Product|Inhaled Alvesco will be administered daily for 14 days at escalating doses of 80mcg and 160mcg.
224294310|NCT06656351|DRUG|Tafenoquine 100mg|Tafenoquine
224294311|NCT01875471|DEVICE|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
223986163|NCT01115608|OTHER|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
223986164|NCT05302297|DRUG|Cemiplimab|Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
223986165|NCT00136370|DRUG|Chlorhexidine|
223986166|NCT00136370|PROCEDURE|Birth canal wipe|
223986167|NCT00136370|PROCEDURE|sterile water external genital wipe|
223986168|NCT03723226|BEHAVIORAL|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
223986169|NCT03723226|BEHAVIORAL|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
223986170|NCT00843427|BEHAVIORAL|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
223986171|NCT00299923|DRUG|Peginterferon alfa-2a, Ribavirin, Amantadine|
223986172|NCT01408745|DEVICE|Sternumfix|sternotomy closure with Sternumfix
223986173|NCT01408745|PROCEDURE|steel wire|sternotomy closure with steel wire
223986174|NCT04201145|DRUG|Pembrolizumab|IV, predetermined dosage, twice per cycle
223986175|NCT04201145|DRUG|Defactinib|Defactinib oral, twice daily, per predetermined dose and predetermined duration as defined by cohort
223986176|NCT04201899|DIETARY_SUPPLEMENT|No intervention - pure observation|Phosphate administration (yes or no)
223728278|NCT02822768|OTHER|No packing|The patient will not receive packing as part of their wound care
224120234|NCT01833273|DRUG|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
223728279|NCT00709930|DEVICE|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
223728280|NCT00709930|DEVICE|Placebo magnetic field generator|Placebo device with no magnetic fields
223986177|NCT04767724|DEVICE|Extracorporeal shock wave|Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
224294312|NCT01875471|DEVICE|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
223986178|NCT00980590|DEVICE|Airway Scope|Tracheal intubation by Airway Scope
223986179|NCT00980590|DEVICE|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
223986180|NCT01844713|BEHAVIORAL|Workbook|Subjects will read a workbook about sun protection
223986181|NCT03798873|DEVICE|FeelWell™ Compression garment|"Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back."
223986182|NCT03798873|BEHAVIORAL|Increase Mobility|Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
223986183|NCT00547534|DRUG|bortezomib|1.3 mg/m\^2 on days 1, 4, 8, 11
224120235|NCT03344601|BEHAVIORAL|physical activity|The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
224120236|NCT05057585|BEHAVIORAL|Turning in bed, arm and leg exercises|Exercises (arm and leg exercises, turning in bed) were applied only to the experimental group. It was applied for 15 minutes 12-24 hours before the operation.
224294313|NCT01155778|BIOLOGICAL|Recombinant human heparan N-sulfatase (rhHNS)|
223986184|NCT00547534|DRUG|bendamustine|90 mg/m\^2 days 1 and 4
223986185|NCT00547534|DRUG|rituximab|375 mg/m\^2 day 1
223986186|NCT04330651|PROCEDURE|ECLS|Emergency application of Extracorporeal Life Support in post-surgical patients
223986187|NCT03747887|BEHAVIORAL|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
223986188|NCT03747887|OTHER|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
223986189|NCT06360211|DRUG|BAY2927088|Oral administration
223986190|NCT06360211|DRUG|Midazolam|Oral administration
223986191|NCT00136279|BEHAVIORAL|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
223986192|NCT05668299|DEVICE|TrachFlush|See detailed description previously entered.
223986193|NCT00164268|BEHAVIORAL|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
223986194|NCT01348152|DRUG|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
223986195|NCT01348152|DRUG|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
223986196|NCT01303250|DRUG|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
224120237|NCT05998993|RADIATION|Stereotactic Body Radiation Therapy SBRT|This is a non-randomized Phase II study in which all patients receive the experimental treatment with Stereotactic Ablative Radiotherapy (SABR) to residual tumor lesions (up to 5 residual metastatic lesions in a maximum of 2 organs) following 12 weeks of systemic treatment with Osimertinib. The study aims to enroll 35 patients diagnosed and treated at CTIC Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo.
223728281|NCT03305653|DEVICE|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
223728282|NCT01218230|DRUG|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
223728283|NCT03403660|OTHER|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
223728284|NCT02042378|DRUG|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
223728285|NCT01133483|DRUG|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
223728286|NCT00076284|DRUG|GW873140|
223728287|NCT03242057|OTHER|NAVA|Infant will be extubated to NAVA, settings based per protocol
223728288|NCT03242057|OTHER|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
223728289|NCT06248892|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223986197|NCT01303250|DRUG|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
223986198|NCT02717182|OTHER|interviews|interviews
223986199|NCT02286453|DRUG|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
223986200|NCT02286453|DRUG|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
223986201|NCT03062696|BEHAVIORAL|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
223986202|NCT00861822|OTHER|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
223986203|NCT02891642|DEVICE|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
224120238|NCT04039685|OTHER|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
224120239|NCT04039685|OTHER|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
224120240|NCT04039685|OTHER|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
223986204|NCT02111863|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
223986205|NCT02111863|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
223986206|NCT02111863|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
223986207|NCT02111863|BIOLOGICAL|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
223986208|NCT04816864|DIAGNOSTIC_TEST|extracardiac vagal nerve stimulation (ECANS) + EPS|"The study intervention will consist of 3 steps, all of which will be performed under general anesthesia:~1. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing.~2. ECANS of the right and the left vagus nerve (from the right and left internal jugular vein, respectively; patients will be randomized to start from the right or the left side) performed during: 1) the patient's spontaneous heart rhythm (if present); 2) HB/LBB pacing with permanently programmed impulse parameters; 3) HB/LBB pacing at a pacing threshold of +0.1 V; and 4) 5 minutes after intravenous injection of atropine (0.02-0.04 mg/kg).~3. EPS with the measurement of parameters of atrioventricular conduction and programmed atrial and ventricular pacing."
223986209|NCT04921579|PROCEDURE|En masse retraction|Retraction stated on a 0.017''x 0.025'' Stainless steel wire using elastomeric chain ( force applied 200 g per side) extending between the crimpable hooks and the mini-screw.
223986210|NCT04921579|PROCEDURE|Two-Step retraction|Retraction of canine started on a 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 150 g per side) followed by anterior teeth retraction on 0.017''x0.025'' Stainless steel wire using elastomeric chain ( force applied 160 g per side) extending between crimpable hooks and the mini-screw.
223986211|NCT04402697|OTHER|Dietary and physical activity intervention|"OW-OB group: 6-month program of weight loss consisting in a low-calorie food plan (30% reduction in the individual energy requirements) with dietary sessions and exercise counselling.~MONW group: 6-month program to improve eating habits (Mediterranean diet) with dietary sessions and exercise counselling."
223986212|NCT00672451|DIETARY_SUPPLEMENT|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
224120241|NCT02004756|OTHER|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
223986213|NCT00672451|DIETARY_SUPPLEMENT|placebo|placebo titrated up to 6 pills daily as patient tolerates
223986214|NCT03478137|BEHAVIORAL|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
223986215|NCT00484692|DRUG|sustained-release bupropion (Zyban(R))|
223986216|NCT00484692|BEHAVIORAL|Psychodynamic Model Training (R) = PDM(R)|
223986217|NCT00375531|BEHAVIORAL|Mindfulness Meditation (MfM)|
223986218|NCT05422989|DIAGNOSTIC_TEST|X-ray, CT|Just a diagnostic procedure to confirm the diagnosis
223986219|NCT00569543|OTHER|high performance liquid chromatography|urine analysis
223986220|NCT00569543|OTHER|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
223986221|NCT00569543|OTHER|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
223986222|NCT00569543|OTHER|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
223986223|NCT02689453|BIOLOGICAL|IL-15 plus|Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.
224120242|NCT05256277|DRUG|CT101a|cytokine-induced memory-like NK cells
224120243|NCT03659747|DIETARY_SUPPLEMENT|Probiotic|\- 6 g sachet containing probiotic powder (1.8 x 10\^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
224120244|NCT03659747|DIETARY_SUPPLEMENT|Lactrase|\- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
224120245|NCT03659747|OTHER|Placebo|\- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
223986224|NCT02689453|BIOLOGICAL|alemtuzumab|Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
223986225|NCT01425177|PROCEDURE|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
223986226|NCT00661843|OTHER|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
223986227|NCT04211077|OTHER|Date collection|Data collection from national SNIIRAM and PMSI database
223986228|NCT05515783|DRUG|68Ga-FAP-RGD|The dose will be 4-7mCi given intravenously.
224120246|NCT00968253|DRUG|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
224120247|NCT00968253|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
223986229|NCT05515783|DRUG|68Ga-FAP-RGD|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging. 68Ga-FAPI-02, the dose will be 1.8 (MBq /kg) given intravenously at a single time prior to imaging; 18F-FDG, the dose will be 3.7 (MBq / kg) given intravenously at a single time prior to imaging.
223986230|NCT03879174|DRUG|Pembrolizumab + Tamoxifen|"The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.~A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage."
223986231|NCT04121780|BIOLOGICAL|Growth Hormone|"Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase"
223986232|NCT04121780|OTHER|Placebo|"Daily self-injections by subjects:~1-year double-blind phase"
223986233|NCT01044992|RADIATION|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
223986234|NCT01044992|DRUG|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
223986235|NCT01337206|DEVICE|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
223986236|NCT01337206|PROCEDURE|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
223986237|NCT05295394|DRUG|Dolutegravir plus lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
223986238|NCT01807429|DRUG|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
223986239|NCT01807429|DRUG|Morphine|morphine 0.05 mg/kg
223544397|NCT03320187|DRUG|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
223986240|NCT02737423|DRUG|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
223986241|NCT04321122|PROCEDURE|ultrasound cyclo plasty|"The ultrasonic glaucoma treatment instrument produced by French EYE TECH CARE company is referred to as EyeOP1.It uses high-intensity focused ultrasound technique to make target part of the ciliary coagulative necrosis, reduce the production of aqueous humor and thereby lower the intraocular pressure. EyeOP1 is ergonomic and suitable for the human eye, making the treatment process more accurate, simple and fast."
223986242|NCT01919515|DEVICE|ZR Crown|This is an esthetic primary molar crown.
223986243|NCT01919515|DEVICE|Stainless Steel Crown|This is a conventional stainless steel crown.
223986244|NCT02688530|DRUG|IV Saline|
223986245|NCT02688530|DRUG|IV Dexamethasone 4mg|
223986246|NCT02688530|DRUG|IV Dexamethasone 6mg|
223986247|NCT02688530|DRUG|IV Dexamethasone 8mg|
223986248|NCT01658020|DRUG|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
223986249|NCT01658020|DRUG|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
223986250|NCT04206085|DEVICE|Viveve - Active|Radiofrequency and Cryogen-Cooling
223986251|NCT04206085|DEVICE|Viveve - Cryogen-Alone|Cryogen-Cooling
223986252|NCT04206085|DEVICE|Viveve - Sham|Sham
223986253|NCT03165578|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
223986254|NCT03165578|OTHER|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
223986255|NCT00453024|PROCEDURE|Pericardial graft & tissue glue|
223986256|NCT00453024|PROCEDURE|scleral flap & sutures|
223544398|NCT03320187|DRUG|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
223544399|NCT01172444|DRUG|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
223986257|NCT04258657|DRUG|paclitaxel-albumin and S-1|neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
223986258|NCT04741737|PROCEDURE|reSLNB arm|Radioisotope, blue dye, dual mapping methods are all allowed for re-SLNB mapping. Positive finding in re-SLNB is defined according to AJCC 8th edition, as micrometastasis or macrometastasis. Isolated tumor cell is considered negative. When sentinel lymph node is not identified, axillary operation is via physician's choice. When re-SLNB finding is negative, no further axillary lymph node dissection is performed. If there is node metastasis from re-SLNB, axillary lymph node dissection or radiation therapy can be performed as in physician's choice.
223986259|NCT04135508|DRUG|BAT1406|40mg/0.8ml
223986260|NCT04135508|DRUG|Humira|40mg/0.8ml
223986261|NCT06021587|DRUG|Levosimendan|Initiation of levosimendan 48 hours before surgery
223544400|NCT01172444|DRUG|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
223544401|NCT01172444|DRUG|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
223986262|NCT06021587|DRUG|No Levosimendan|Without Levosimendan Infusion
223986263|NCT00364364|DRUG|Radiolabeled humanized PAM4 IgG|
223986264|NCT00003428|DRUG|arzoxifene hydrochloride|
223986265|NCT04741854|DEVICE|Positive Airway Pressure (PAP) Therapy|PAP therapy supplies pressurized air from the flow generator to the upper airway via air tubing and a mask to prevent the repetitive collapse of the upper airway during sleep.
223986266|NCT02897999|BIOLOGICAL|QBKPN|QBKPN Site Specific Immunomodulators
223986267|NCT02897999|OTHER|Placebo|Placebo
224120248|NCT00968253|DRUG|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
223986268|NCT05787249|BEHAVIORAL|Patient nudge|Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
223986269|NCT05787249|BEHAVIORAL|Provider nudge|Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
223986270|NCT06430671|DRUG|CLS12311 low|Peptide-coupled Red Blood Cells (RBCs)
223986271|NCT06430671|DRUG|CLS12311 medium|Peptide-coupled Red Blood Cells (RBCs)
223986272|NCT06430671|DRUG|CLS12311 high|Peptide-coupled Red Blood Cells (RBCs)
223986273|NCT06430671|DRUG|uncoupled RBCs|autologous Red Blood Cells (RBCs)
223986274|NCT04364685|OTHER|Walking on soft-sand|The participants are required to walking on sand for 30 minutes. Walking is self-paced.
223986275|NCT04364685|OTHER|Walking on Levelled Surface|The Participants will be require to walk on the firm surface for 30 minutes. The participants would decide the pace of walking.
223986276|NCT05470361|PROCEDURE|stellate ganglion block (SGB)|The protocol for the SGB plus SCGB will be followed, wherein participants are given right-side procedures followed by left-side procedures on a different day if no initial improvement is seen. This procedure is carried out by injecting a local anesthetic into the neck to target the Stellate Ganglion and Superior Cervical Ganglion nerve bundles.
223986277|NCT04219917|OTHER|Kinesio Tape|Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
223986278|NCT02621554|DIETARY_SUPPLEMENT|resveratrol supplementation|6 months of resveratrol supplementation
223986279|NCT02621554|DIETARY_SUPPLEMENT|Placebo|6 months of placebo intake
223986280|NCT02640170|OTHER|Registry|
223986281|NCT03243500|DRUG|Atracurium|5mg in 1 ml normal saline
223986282|NCT03243500|DRUG|Lidocaine 2%|
223986283|NCT03243500|DRUG|Bupivacaine 0.5%|
223986284|NCT03243500|DRUG|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
223986285|NCT03243500|PROCEDURE|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
223986286|NCT04185922|DEVICE|Hemopatch|As stated in Hemopatch arm description
223986287|NCT04422977|DIAGNOSTIC_TEST|Sars-Cov-2 serology|Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff
223986288|NCT02731456|OTHER|altitude exposure|altitude exposure
223986289|NCT03928392|BEHAVIORAL|SCUBA with Occupational Therapy (OT)|Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
224120249|NCT00968253|DRUG|Doxorubicin|50 mg/m\^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
224120250|NCT00968253|DRUG|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
224120251|NCT00968253|DRUG|Mesna|600 mg/m\^2 IV continuous infusion daily for 24 hours days 1-3.
224120252|NCT00968253|DRUG|Methotrexate|200 mg/m\^2 IV over 2 hours followed by 800 mg/m\^2 IV over 22 hours day 1.
223986290|NCT03928392|BEHAVIORAL|Self-Contained Underwater Breathing Apparatus (SCUBA) without OT|Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
223986291|NCT04749407|GENETIC|biomarker detection|PBMC and ctDNA analysis
223986292|NCT03851835|DRUG|Ondansetron Oral Solution|Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use), as needed.
223986293|NCT03851835|DRUG|Oral Placebo|Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24-hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use), as needed.
223986294|NCT02689947|DEVICE|Restylane Silk|
223986295|NCT04959526|DIAGNOSTIC_TEST|Shear-wave elastography|Ultrasound based imaging of diaphragm muscle activity
223986296|NCT06839196|OTHER|VR and first aid training|"Intervention Stages:~Stage 1: Descriptive Information Form and the Home Accident Awareness Questionnaire for Parents of Children with Special Needs will be administered to the parents as pre-tests.~Stage 2: A total of 100 parents will participate in the virtual reality simulation scenarios, organized into four separate groups of 25 for implementation.~Stage 3: Balance assessments for children will be conducted using the Children's Balance Assessment Form, the Tinetti Balance and Gait Assessment, and the Nintendo Wii Fit Balance Board.~Stage 4: Each group of 25 participants will receive hands-on training at three different stations focusing on basic first aid and home accidents, delivered by nurses, and transfer training provided by physiotherapists.~Stage 5: Post-tests will be administered to the parents using the Home Accident Awareness Questionnaire for Parents of Children with Special Needs."
223986297|NCT00815919|DRUG|bortezomib|Given intravenously at a dose of 1.3 mg/m\^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
223986298|NCT00815919|DRUG|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
223986299|NCT05520723|DRUG|Sacituzumab govitecan|"Upon meeting all selection criteria, patients enrolled in the single-arm study will receive the combination of: sacituzumab govitecan and prophylaxis (loperamide and G-CSF).~Sacituzumab govitecan :10 mg/kg, intravenously (IV) on Days 1 and 8 every 21-day cycle . This treatment will continue until disease progression, unacceptable toxicity, or physician's/patient's decision."
223986300|NCT05520723|DRUG|Loperamide|Loperamide : 2 mg orally (PO), twice a day (BID), or 4 mg once a day (QD) during three consecutive days after administration of sacituzumab govitecan, (D2, D3, D4 and D9, D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
223986301|NCT05520723|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF : 30 MU subcutaneously (SC) QD during two consecutive days, 48 hours after administration of sacituzumab govitecan (D3, D4 and D10, D11) during the first two cycles (consider extending to the next cycle at the discretion of the physician).
223986302|NCT03833804|OTHER|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
223986303|NCT02854397|OTHER|blood sample|
224120253|NCT00968253|DRUG|Ara-C (Cytarabine)|3 gm/m\^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
224120254|NCT00968253|DRUG|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
223544402|NCT06442904|OTHER|Digital education program|The approximately six hours long digital education program will be available for three months and implies further education in intraoral radiographic examinations.
223544403|NCT03134859|BEHAVIORAL|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
224120255|NCT00968253|DRUG|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
224120256|NCT03569111|DEVICE|Bronchoscopic ablation catheter|The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.
224120257|NCT01267097|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
224120258|NCT01267097|BEHAVIORAL|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
223986304|NCT01951521|RADIATION|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
223986305|NCT01700283|BEHAVIORAL|exercise education and walking program|12-week moderate intensity walking program
223986306|NCT00910260|PROCEDURE|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
223986307|NCT01287845|DRUG|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
223986308|NCT01287845|DRUG|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
223986309|NCT04147559|DEVICE|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
224294314|NCT00962988|DRUG|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
223728290|NCT06248892|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223728291|NCT06248892|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223728292|NCT05849389|DRUG|Vosoritide|Vosoritide administered daily via subcutaneous injection for 12 months using the FDA approved weight-based dosing band strategy for achondroplasia.
223728293|NCT04019665|OTHER|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
223728294|NCT04019665|OTHER|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
223728295|NCT04557371|OTHER|Serum|Participants will topically apply the serum to the face as per normal home use application in place of their current facial serum product.
223728296|NCT04557371|OTHER|Lotion|Participants will topically apply lotion to the face as per normal home use application in place of their current facial lotion product.
223986310|NCT00231764|DRUG|daclizumab|
223986311|NCT03542162|BIOLOGICAL|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
223986312|NCT06547047|BEHAVIORAL|Speed, Agility, and Quickness (SAQ) Training|The SAQ training will include exercises designed to improve speed, agility, and quickness, such as ladder drills, cone drills, sprint drills, and reaction drills.
223986313|NCT06547047|BEHAVIORAL|Regular Training|Participants in the control group will follow a standard soccer training regimen, which includes general conditioning exercises, skill drills, and tactical training.
223986314|NCT03635736|OTHER|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
223986315|NCT04585100|DRUG|FM101 tablet|Bio-equivalent test (tablet vs oral solution)
223986316|NCT04585100|DRUG|FM101 oral solution|Bio-equivalent test (tablet vs oral solution)
223986317|NCT04585100|DRUG|Placebo|Placebo BID for 28 days
223986318|NCT04585100|DRUG|FM101 150 mg|FM101 (150 mg) BID for 28 days
223986319|NCT04585100|DRUG|FM101 300 mg|FM101 (300 mg) BID for 28 days
223986320|NCT04431219|BIOLOGICAL|LIS1|LIS1 is an induction treatment on top of maintenance immunosuppressive regimen. All patients from AD and TD cohort will receive the conventional immunosuppressive regimen: tacrolimus (0.2 mg/kg) / mycophenolic acid (MMF, 2x1000 mg) / prednisone (20 mg from day 2). This conventional treatment should be started and monitored for all patients independently of their participation in the clinical trial. Methylprednisolone 500 mg / 100 mL saline / 30 minutes will be administered before reperfusion during the surgery and on post operation day 1 just before LIS1 administration.
223728297|NCT04557371|OTHER|Cream|Participants will topically apply cream to the face as per normal home use application in place of their current facial cream product.
223986321|NCT03780010|DRUG|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
223986322|NCT05196880|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
223986323|NCT05774041|DEVICE|SIS System|FDA-cleared software that enhances standard clinical images for the visualization of structures in the basal ganglia area of the brain which are commonly targeted for DBS lead placement.
223986324|NCT01466790|DRUG|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
223986325|NCT01466790|DRUG|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
224120259|NCT03680794|OTHER|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
224120260|NCT01223976|OTHER|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
223728298|NCT02356224|DRUG|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
223728299|NCT02356224|DRUG|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
224120261|NCT05599126|DRUG|Mianserin|Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.
224120262|NCT05599126|DRUG|Lorazepam|Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
224120263|NCT02731508|DEVICE|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
224120264|NCT05052775|OTHER|Chlorhexidine Mouthwash|Patients were given chlorhexidine mouthwash 2 times per day for 15 days
224120265|NCT05052775|OTHER|Morus Alba 20%|Patients were given morus alba 20% concentration 2 times per day for 15 days
224120266|NCT05052775|OTHER|Morus Alba 30%|Patients were given morus alba 30% concentration 2 times per day for 15 days
224120267|NCT03912922|OTHER|Activity regime|Activity regime of 4 days followed by a test day.
224120268|NCT03141086|DRUG|LML134|LML134
224120269|NCT03141086|DRUG|Placebo|placebo
224120270|NCT05196243|OTHER|Patients diagnosed as gastrointestinal mucosal lesions|Patients diagnosed as gastritis, gastric cancer, intestinal polyps and colorectal cancer
224120271|NCT01415622|DEVICE|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
224120272|NCT01415622|PROCEDURE|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
224120273|NCT01072864|OTHER|Walnuts|Consumption of 5 g of walnuts.
224120274|NCT01072864|OTHER|Walnuts|Consumption of 20 g of walnuts.
224120275|NCT01072864|OTHER|Walnuts|Consumption of 30 g of walnuts.
224120276|NCT01072864|OTHER|Walnuts|Consumption of 40 g of walnuts.
224294315|NCT00962988|OTHER|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
224294316|NCT01838928|DRUG|Bupivacaine|
223986326|NCT01466790|DRUG|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
223986327|NCT00495092|DRUG|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
223986328|NCT00495092|DRUG|Biperiden|Biperiden 2-4 mg/d p.o.
223986329|NCT00495092|DRUG|Placebo|Placebo + Placebo
223986330|NCT04172012|BIOLOGICAL|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
223986331|NCT04172012|OTHER|Placebo|Placebo mixture
223986332|NCT01888809|BEHAVIORAL|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
223986333|NCT01888809|BEHAVIORAL|Screening and referral|
223986334|NCT03638921|DRUG|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
223986335|NCT03753243|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
223986336|NCT03753243|DRUG|Enzalutamide|Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
223728300|NCT01217840|DRUG|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
223728301|NCT01217840|DRUG|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
223986337|NCT03865290|DRUG|Ondansetron 8mg|Oral Ondansetron 8 mg
223986338|NCT03865290|DRUG|Placebo|Oral matched placebo
223986339|NCT00307047|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223986340|NCT00307047|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
223986341|NCT06282211|DRUG|Ondansetron Oral Soluble Pellicles|patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.
223986342|NCT04445298|DIAGNOSTIC_TEST|Transepidermal water loss|We will assess the skin with transepidermal water loss (TEWL) by using a condenser-chamber system placed lightly on the skin. This will be performed at baseline, then after every 4 skin tape strips.
223986343|NCT04445298|DIAGNOSTIC_TEST|Skin tape stripping|Adhesive skin sampling discs will be pressed against the skin in a hairless location followed by lifting it free of the skin. The discs will be evaluated for lipid content, protein, and filaggrin byproducts in the collected skin sample.
223986344|NCT04445298|DIAGNOSTIC_TEST|Blood draw|We will draw blood to look at the vitamin D, total immunoglobulin E (IgE), and the filaggrin gene which is important in maintaining the skin barrier.
223986345|NCT04445298|DIAGNOSTIC_TEST|Bacterial PCR swab|Skin swab from the superficial skin will be collected to be assessed in the laboratory via PCR for the presence of staphylococcus aureus.
223986346|NCT01726569|BEHAVIORAL|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
223986347|NCT01726569|OTHER|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
223728302|NCT00897104|DRUG|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
223728303|NCT00897104|DRUG|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
223728304|NCT00897104|DRUG|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
223986348|NCT02723097|BEHAVIORAL|3 RP|
223986349|NCT06141200|DRUG|NW Roselle|NW Roselle is a powdered extract from the flowers of Hibiscus Sabdariffa (300mg) and the leaves of Olea europaea (200 mg).
223986350|NCT06141200|DRUG|Captopril 25Mg Tab|Active Comparator
223986351|NCT02812992|DRUG|Nab-paclitaxel|
223986352|NCT02812992|DRUG|Gemcitabine|
223986353|NCT02812992|OTHER|Best Supportive Care|
223728305|NCT05776199|DIAGNOSTIC_TEST|Sonoelastography, tensiomyography and mechanosensitivity|To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
223728306|NCT04834076|DIAGNOSTIC_TEST|ELISA|ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
223986354|NCT01792531|BEHAVIORAL|Parent training group|The More \& Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More \& Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
223544404|NCT01056081|OTHER|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
223544405|NCT03375086|DRUG|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
223544406|NCT06513611|DIAGNOSTIC_TEST|Serum cortisol.|Serum cortisol levels obtained on admission.
223544407|NCT03621072|DRUG|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
223544408|NCT03621072|DRUG|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
223544409|NCT03240562|PROCEDURE|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
223544410|NCT03240562|DRUG|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
223544411|NCT05863390|BEHAVIORAL|McKenzie exercise|routine simple McKenzie exercise
223544412|NCT05863390|DIAGNOSTIC_TEST|Trochanteric belt|Trochanteric belt with conventional physical therapy
223544413|NCT02407743|BEHAVIORAL|Surgical patients' clinical progression|Study the dynamic nature of pain
223544414|NCT02407743|GENETIC|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
223544415|NCT05814718|DRUG|modified BEAM|Mitoxantrone liposome 24 mg/m2，ivgtt，d-7；BCNU 300 mg/m2，ivgtt，d-6； Ara-C 200 mg/m2 q12h，ivgtt，d-5- -2； Vp16 200 mg/m2 ，ivgtt，d-5- -2；
223544416|NCT05814718|DRUG|BEAM|BCNU 300 mg/m2，-7d； Vp16 200 mg/m2，-6～-3d； Ara-C 100mg/m2 q12h，-6～-3d； Mel 140mg/m2，-2d
223544417|NCT04206631|DRUG|Doxycycline Capsule|Doxycycline capsule 100 mg/day, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
223544418|NCT04206631|PROCEDURE|Comedone extraction|Comedone extraction, tretinoin cream 0.05% on face every night, benzoyl peroxide gel 2.5% on face in the morning and afternoon.
223544419|NCT00670566|DRUG|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
223986355|NCT01792531|BEHAVIORAL|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
223986356|NCT01792531|BEHAVIORAL|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
223986357|NCT01176461|BIOLOGICAL|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
223986358|NCT01176461|BIOLOGICAL|NY-ESO-1|NY-ESO-1 peptide vaccine
223986359|NCT01176461|BIOLOGICAL|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
223986360|NCT01176461|BIOLOGICAL|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
223986361|NCT01176461|DRUG|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
223986362|NCT01176461|BIOLOGICAL|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)
223986363|NCT01992367|DRUG|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
223986364|NCT00009906|DRUG|Imatinib Mesylate|Given orally
223986365|NCT00512616|DRUG|Ceftriaxone|
223986366|NCT03550079|PROCEDURE|fixation|treated with different fixation method
223986367|NCT00122486|DRUG|Tenofovir Disoproxil Fumarate|
223986368|NCT00487825|DRUG|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
223986369|NCT00487825|DRUG|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
223986370|NCT00487825|DRUG|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
223986371|NCT00671710|DRUG|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
223986372|NCT02192593|BEHAVIORAL|Computer CBT|
223986373|NCT01993771|PROCEDURE|Surgery with general anaesthesia.|
223986374|NCT01993771|PROCEDURE|Raw EEG|
223986375|NCT05113797|DIAGNOSTIC_TEST|Lower Quarter Y-Balance Test|Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.
223986376|NCT05113797|BEHAVIORAL|OPTIMAL motor learning theory|OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
223728307|NCT04834076|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
223986377|NCT02104505|DRUG|Gamma Tocopherol 700 mg capsules,|2 capsules daily
223986378|NCT02104505|DRUG|Placebo|Safflower oil capsules
223986379|NCT04669743|OTHER|Ozone exposure|Exposures will take place at the UCSF Human Exposure Chamber Core Facility. Ozone will be added to the air in the chamber and concentration measured every 30 seconds. Subjects will exercise for two 15-minute intervals of each hour on a cycle ergometer, and will rest for two 15-minute intervals between exercise sessions. The rate of exercise will be individually adjusted to produce a targeted minute ventilation of 15-20 L/min/m2 body surface area. Subjects will be sent home post-exposure and will return to the laboratory on the following day and six days after the exposure for bronchoscopy.
223986380|NCT00170274|DEVICE|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
223986381|NCT00170274|DEVICE|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
223986382|NCT02779348|DRUG|BIA 3-202|Nebicapone tablets 200 mg
223986383|NCT02779348|DRUG|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
223986384|NCT00249782|DRUG|Vehicle control, 2x/day|
223986385|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 2x/day|
223986386|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day|
223986387|NCT00249782|DRUG|MetroGel® (metronidazole gel), 1.0% 1x/day|
223986388|NCT00249782|DRUG|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
223986389|NCT02665585|PROCEDURE|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
223986390|NCT02448498|BEHAVIORAL|Exercise Intervention|
224294317|NCT02121561|BEHAVIORAL|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
223728308|NCT04834076|DIAGNOSTIC_TEST|Sequencing|DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
223986391|NCT05895708|OTHER|Specific strengthening and stretching exercise|The program consisted of two strengthening (deep cervical flexors and shoulder retractors) and two stretching (cervical extensors and pectoral muscles) exercises based on Harman and Mostafa et al's approach. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted for 30 minutes.
223986392|NCT05895708|OTHER|General Exercise|The program will consist of regular general postural exercises such as postural awareness exercises as well as general strengthening exercises such as range of motion exercises for the upper quadrant. The program will also be repeated 4 times per week for 10 weeks, with each session lasting 30 minutes
223986393|NCT01639742|DEVICE|New texture round breast implants|Breast implant surgery
223986394|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 1, for 12 days
223986395|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 2, for 12 days
223986396|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 3, for 12 days
223986397|NCT05203705|DRUG|SHR2285 tablet|SHR2285 tablet; dose 4, for 12 days
223986398|NCT05203705|DRUG|Enoxaparin|Enoxaparin, for 12 days
224120277|NCT03228251|OTHER|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
223728309|NCT00959309|BEHAVIORAL|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
223728310|NCT00959309|BEHAVIORAL|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
223728311|NCT00572585|DRUG|AEB071|
223728312|NCT00572585|DRUG|Placebo|
223728313|NCT00636142|BIOLOGICAL|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
224120278|NCT06094777|DRUG|HY-0102|Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle
223728314|NCT00821977|DRUG|Vildagliptin|
224120279|NCT02488759|DRUG|Nivolumab|
223728315|NCT00821977|DRUG|Vildagliptin|
223728316|NCT00821977|DRUG|Placebo|
223728317|NCT05008497|OTHER|Questionnaire|Questionnaire
223728318|NCT02697812|PROCEDURE|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
223728319|NCT01847794|DEVICE|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
223728320|NCT04671550|DIAGNOSTIC_TEST|questionnaire|"Questionnaire on Driving performances and Visual Field"
223728321|NCT00477971|BIOLOGICAL|filgrastim|No administration information given
223728322|NCT00477971|DRUG|dexamethasone|Given orally
223728323|NCT00477971|DRUG|melphalan|Given IV or orally
223728324|NCT00477971|PROCEDURE|autologous hematopoietic stem cell transplantation|Given on day 0
223728325|NCT04984798|DRUG|Vitamin E|Twice daily oral supplementation with Vitamin E for 6-9 weeks.
223728326|NCT06357754|BIOLOGICAL|Idecabtagene vicleucel|As per product label
224120280|NCT02488759|DRUG|Ipilimumab|
223728327|NCT06357754|BIOLOGICAL|Lisocabtagene maraleucel|As per product label
223728328|NCT00115687|DRUG|placebo|
223728329|NCT00115687|DRUG|2 mg nicotine polacrilex|
223728330|NCT04676282|OTHER|Hypothetical Scenario|Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
224120281|NCT02488759|DRUG|Relatlimab|
224120282|NCT02488759|DRUG|Daratumumab|
224120283|NCT06671990|DRUG|Vericiguat|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
223986399|NCT01295203|BEHAVIORAL|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
223728331|NCT07000760|DRUG|Ultrasonic atomization of lidocaine|After induction of general anesthesia and before the end of the surgery, 100mg of 2% lidocaine was nebulized and inhaled respectively, and the nebulization time was 15-20 minutes each time.
223986400|NCT03082755|DRUG|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
223986401|NCT03082755|DRUG|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
224120284|NCT06671990|DRUG|Placebo|Participants will receive vericiguat and placebo with a cross-over intermediate wash-out period. Patients will randomly be allocated 1:1 to two 6-week treatment sequences: either vericiguat first then placebo, or vice versa. The study drug dose will be doubled every 2 weeks (e.g., 2.5, 5, and 10 mg)
223728332|NCT07000760|DRUG|Ultrasonic atomization of normal saline|After anesthesia induction and before the end of the surgery, the same volume of normal saline (5ml of 0.9% NaCl) was ultrasonically atomized, and the atomization time was 15-20 minutes each time.
223986402|NCT00673608|DRUG|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
223986403|NCT04066517|PROCEDURE|SBRT|Multimodal-imaging guided SBRT for VT ablation.
223986404|NCT04515407|OTHER|PAS at Rest|Paired Associative Stimulation will be delivered while the participant is seated and resting.
223728333|NCT07001176|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
223728334|NCT07001176|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg)
223544420|NCT03653234|DEVICE|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
223986405|NCT04515407|OTHER|PAS - Active|Paired Associative Stimulation will be delivered while the participant is seated and producing submaximal background activity in the plantarflexor muscles.
223986406|NCT04515407|OTHER|PAS - Walking|Paired Associative Stimulation will be delivered while the participant is walking, during the late stance phase of the gait cycle.
223986407|NCT04864366|DRUG|Tenofovir Alafenamide 25 MG [Vemlidy]|TAF is administered as a 25mg/tablet, taken orally with food once daily, for 48 weeks.
223986408|NCT01509443|OTHER|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
223986409|NCT05221138|DRUG|VV116|VV116 oral tablets, 400mg
223986410|NCT01190644|DRUG|Sotatercept|single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
223986411|NCT04533009|PROCEDURE|spine surgery|Tramadol-paracetamol 325mg/37,5mg two tablets twice daily
223986412|NCT01452568|DRUG|Aspirin|150mg/daily for three months, starting day after surgery
223986413|NCT01452568|DRUG|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
223986414|NCT02366143|DRUG|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
223986415|NCT02366143|DRUG|Bevacizumab|Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
223986416|NCT02366143|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
223986417|NCT02366143|DRUG|Paclitaxel|Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
223986418|NCT00373919|DRUG|intravenous (IV) administration of erythromycin|
224120285|NCT06672029|OTHER|combining pattern-specific manual therapy, Schroth Best Practice exercise, and Gensingen brace application|"* The pattern-specific manual therapy: It was developed by our author. This therapy was done immediately before each SBP (Schroth Best Practice) exercise session, targeting both the spine and extra-spinal regions.~* The Schroth Best Practice exercises: It contains following 6 components: The physio-logic® program for sagittal profile correction, education on activities of daily living (ADLs), the 3D made easy program, the new Power Schroth program, the rehabilitation of walk, and neuromobilization.~* The Gensingen brace application: it was made according to the patients' Lehnert Schroth Classifications. the investigators recommended the patients to wear the brace for 21-23 hours per day during the first year. As the bone maturation reached Risser 4 to 4.5, the daily brace wearing time was gradually reduced."
223986419|NCT00807703|PROCEDURE|Select Stim|Select Stim: see summary
223986420|NCT04411186|PROCEDURE|Standard Enhanced Recovery After Surgery (ERAS) Protocol|Subjects receive standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations.
223544421|NCT06164964|DIAGNOSTIC_TEST|study of higher cognitive functions|"General objective: increase knowledge about neural correlates:~of the cognitive processing of stimuli of a social nature; of decision-making processes in the context of individual choice; of the influence of the social context on individual decision-making processes."
224294318|NCT03996551|BEHAVIORAL|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
224294319|NCT03686020|DIAGNOSTIC_TEST|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
224294320|NCT03252327|OTHER|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
223544422|NCT03333928|DRUG|HTD1801|HTD1801 tablets, 250 mg
223544423|NCT03333928|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
223544424|NCT03372720|PROCEDURE|Laser Therapy|Undergo fractional CO2 laser therapy
223544425|NCT03372720|OTHER|Questionnaire Administration|Ancillary studies
223544426|NCT03372720|PROCEDURE|Sham Intervention|Undergo sham laser therapy
223544427|NCT06417827|DIAGNOSTIC_TEST|SP patients-actors|SP Actors employed by MesserMSR, the Israeli Center for Medical Simulation, trained to simulate symptoms of psychiatric illnesses.
223544428|NCT06417827|DIAGNOSTIC_TEST|Patients|Patients (n=150) examined in the psychiatric division and emergency room (ER) of Sheba Medical center. Or people who applied following an advertisement on social networks.
223544429|NCT06417827|DIAGNOSTIC_TEST|Control group- patients|Control group (n=50) Patients who came to the ER at the hospital due to physical complaints, and no psychiatric history.
223544430|NCT04781556|OTHER|No intervention|All patients treated between 01/01/2017 and 12/31/2018 in the Fracture sector will be screened through the computerized medical file. For patients who meet all the eligibility criteria, the information note, study questionnaire and a stamped envelope will be sent to them by post. Without feedback from him within 30 days of this submission, the patient is considered not to have objected to the study. The patient's information as well as his non-objection will be recorded in his medical file.
223544431|NCT01266278|OTHER|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
223986421|NCT04411186|PROCEDURE|ERAS and 5 Lung Protective Interventions|"Subjects will receive the standard MUSC ERAS protocol - fluid intake, hydration, anti-emetics, pain control, and several other considerations. The subject will also receive the following lung protective interventions:~Pressure control ventilation-volume guaranteed (PCV-VG) ventilation at approximately 7cc/kg of predicted body weight (derived from combination of sex and height) Positive end-expiratory pressure (PEEP) 7cm H2O5 Immediately post intubation recruitment breath (30cm water for 30 seconds) Every 1 hour recruitment breath (30cm water for 30 seconds) 40% FIO2 initially - titrate up as necessary to maintain SPO2 \>94%"
223986422|NCT04912310|DEVICE|Argon laser peripheral iridoplasty|Argon laser peripheral iridoplasty was performed in patients with severe acute angle closure glaucoma whose intraocular pressure could not be controlled by medication
223986423|NCT02244138|BEHAVIORAL|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
223986424|NCT04945447|OTHER|Systematic pharmacist intervention|Already described in the arm group intervention group for patient level
223986425|NCT00167154|DRUG|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
223986426|NCT04339712|DRUG|Anakinra|In case of diagnosis of MAS treatment with anakinra
223986427|NCT04339712|DRUG|Tocilizumab|In case of diagnosis of immune dysregulation treatment with tocilizumab
223986428|NCT03985436|BEHAVIORAL|Trek for Surgical Success|Cognitive behavioral therapy for pain
223986429|NCT01053247|DRUG|0416|Topical 0416 test product applied twice daily for 2 weeks
223986430|NCT01053247|DRUG|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
223986431|NCT01053247|DRUG|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
223986432|NCT03038269|BEHAVIORAL|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
223986433|NCT04303507|DRUG|Chloroquine or Hydroxychloroquine|A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months
223986434|NCT04303507|DRUG|Placebo|Placebo
223986435|NCT00701909|DRUG|Morphine plus Ketamine|Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV. Then, Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV
223986436|NCT00701909|DRUG|Morphine plus Saline (placebo)|Morphine 0.1 mg/kg (maximum dose of 8 mg) IV plus Saline IV. Then, Morphine 0.05 mg/kg (maximum dose of 4 mg) IV plus Ketamine 0.25 mg/kg IV.
223986437|NCT03637413|DIETARY_SUPPLEMENT|Hindmilk|Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
223986438|NCT00582725|DRUG|R-CHOP+GM-CSF|addition of GM-CSF
223986439|NCT00720564|DRUG|arsenic trioxide|
223986440|NCT00720564|DRUG|temozolomide|
223986441|NCT00720564|PROCEDURE|adjuvant therapy|
223986442|NCT00720564|RADIATION|intensity-modulated radiation therapy|
223986443|NCT00720564|RADIATION|radiation therapy|
223986444|NCT00068432|DRUG|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
223986445|NCT00068432|DRUG|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
223986446|NCT01053481|DIETARY_SUPPLEMENT|vitamin D|Vitamin D supplement
223986447|NCT01053481|BEHAVIORAL|exercise program (rebounding on a trampoline)|40 days at 30 min/d
223544432|NCT01266278|OTHER|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
223986448|NCT03126071|DRUG|Raltitrexed|Raltitrexed:3mg/m2,iv 15min,d1,q3w.
223986449|NCT03126071|DRUG|Irinotecan|Irinotecan:250mg/m2,iv 90min,d1,q3w.
223986450|NCT03126071|DRUG|Oxaliplatin|Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
223986451|NCT03126071|DRUG|Bevacizumab|Bevacizumab:75mg/kg,iv 30min,d1,q3w.
223986452|NCT02425540|DEVICE|Pelvic MRI|
223986453|NCT01385748|DRUG|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
223986454|NCT01385748|DRUG|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
223544433|NCT01266278|OTHER|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
223544434|NCT02334072|DEVICE|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
223986455|NCT01385748|DRUG|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
223986456|NCT00656201|DRUG|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
223986457|NCT00656201|DRUG|Intramuscular Progesterone|Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
223986458|NCT00850122|DRUG|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
223986459|NCT01193998|OTHER|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
223986460|NCT01193998|OTHER|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
223986461|NCT02551211|PROCEDURE|blood drawn|blood drawn
223986462|NCT02551211|PROCEDURE|surgical resection of cancer|
223986463|NCT06199154|DRUG|Misoprostol|Participants will receive with 25 mcg or 50 mcg vaginal misoprostol every 4 hours.
223986464|NCT04676789|DRUG|Pegaspargase|Pegaspargase 2500IU/m2 administered by intramuscular injection on Day 1
223986465|NCT04676789|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1
223986466|NCT04676789|RADIATION|Definitive intensity-modulated radiotherapy (IMRT)|Definitive intensity-modulated radiotherapy (IMRT) of 50 Gy will be given in 25 days
223986467|NCT04030689|OTHER|data collected from patient file|socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
223986468|NCT02007200|OTHER|Laboratory Biomarker Analysis|Correlative studies
223986469|NCT02007200|DRUG|Soy Isoflavones|Given PO
223986470|NCT02007200|OTHER|Survey Administration|Ancillary studies
223986471|NCT01921647|DRUG|YH4808|
223986472|NCT01921647|DRUG|Nexium|
223986473|NCT01921647|DRUG|Amoxicillin|
223986474|NCT01921647|DRUG|clarithromycin|
223986475|NCT04339660|BIOLOGICAL|UC-MSCs|1\*10E6 UC-MSCs /kg body weight suspended in 100mL saline
223986476|NCT04339660|OTHER|Placebo|100mL saline intravenously
223986477|NCT00648687|BEHAVIORAL|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
223986478|NCT04218474|PROCEDURE|Evaluation Of Cross Mental Nerve Transfer In Restoration Of Chin &Lip Sensation Post Inferior Alveolar Nerve Injury|-sural nerve harvest ,and use it as conduit between injured mental nerve and the normal one
223986479|NCT01543022|DEVICE|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
223986480|NCT01543022|PROCEDURE|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
223986481|NCT00890578|PROCEDURE|adhesive to suture|surgical closure
223986482|NCT02911194|DIETARY_SUPPLEMENT|a2 milk|replace all milk with a2 milk
223986483|NCT02911194|DIETARY_SUPPLEMENT|a1 containing milk|use a1 containing milk
223986484|NCT05352945|DEVICE|HyPNOS self-hypnosis mask from DREAMINZZ|"The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections"
223986485|NCT05221177|BEHAVIORAL|TR-30|Suspension training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
223986486|NCT05221177|BEHAVIORAL|TR-45|Suspension training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
223986487|NCT03043430|DRUG|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
223986488|NCT03043430|DRUG|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
223986489|NCT01803334|OTHER|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
223986490|NCT03792490|DRUG|Fasudil|Fasudil hydrochloride hydrate IV solution
223544435|NCT02334072|DEVICE|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
223544436|NCT02334072|DEVICE|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
223986491|NCT03792490|DRUG|Placebo|Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
223986492|NCT03487198|DRUG|Brexpiprazole|Brexpiprazole 2-3mg/day
223986493|NCT03487198|DRUG|Placebo|Placebo 2-3 mg/day
223986494|NCT03253432|OTHER|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
223986495|NCT06008223|DRUG|vitamin B6|The Patients in experimental group were given vitamin B6 injection 300mg/d (100mg/2ml× 3) intravenous injection.
223986496|NCT06008223|DRUG|0.9% sodium chloride solution|That in control group were injected with 0.9% sodium chloride solution 6 ml intravenously.
223986497|NCT00534053|OTHER|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
223986498|NCT06074692|COMBINATION_PRODUCT|Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)|Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
223986499|NCT00174447|DRUG|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
223986500|NCT03560570|BIOLOGICAL|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
223986501|NCT03560570|OTHER|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
224294321|NCT00792727|DRUG|ketoprofen Patch|2 topical patches applied once daily for 28 days
223986502|NCT01437423|BIOLOGICAL|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
223986503|NCT00907764|DRUG|regadenoson|400 ug, IV
223986504|NCT03851081|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223728335|NCT07000968|OTHER|Virtual Reality Training Group|Virtual Reality Training Procedure; In general, virtual reality training will be developed taking into account neurorehabilitation principles; Type of game and specificity (there will be exercises specific to the disease), Intensity (will be gradually increased), Progress (exercises will be gradually progressed, variability (the environment will be changed) and Feedback (visual and auditory feedback will be provided). The virtual reality training to be applied will also be fun, It will include attention and problem-solving ability. The difficulty and skill level will gradually increase in order to ensure continuity of motivation and motor learning in individuals. It will be aimed to perform the exercises at moderate to severe intensity. The intensity level of the exercises will be at moderate intensity, and the perceived effort according to the Borg Scale will be 12- It will be checked by asking for 15 points.
223986505|NCT03851081|OTHER|Quality-of-Life Assessment|Ancillary studies
223986506|NCT03851081|DRUG|Vincristine Sulfate Liposome|Given IV
223986507|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using blunt dissection technique|Renuvion/j-Plasma procedure using blunt dissection technique
223986508|NCT04902599|PROCEDURE|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique|Renuvion/j-Plasma procedure using ultrasound-guided dissection technique.
224120286|NCT06672757|DEVICE|CV_AID|"Upon arrival at the scene, the paramedic utilizes a mobile app with an integrated camera to aid in conducting the National Institutes of Health Stroke Scale (NIHSS) assessment. The app assists in scoring the patient\&#39;s responses according to NIHSS criteria to determine the severity of stroke symptoms.~If the app assessment indicates a high likelihood of stroke, transport can be initiated without a conference with the neurovascular centre. The app shares the recorded NIHSS assessment and video of the patient with the neurovascular centre for review.~While en route, the paramedic confer with the neurovascular centre to discuss the patient\&#39;s condition and determine appropriate course of action. If the neurovascular centre decides not to treat the patient, transport can be diverted to the nearest hospital.~The paramedic documents all assessment findings, interventions, and communications related to the stroke patient in the patient care record. U"
224294322|NCT00792727|OTHER|Placebo Patch|2 topical placebo patches applied once daily for 28 days
224294323|NCT00773682|OTHER|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
223544437|NCT02334072|DEVICE|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
223544438|NCT02334072|DEVICE|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
223986509|NCT01526837|DRUG|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
223986510|NCT06484868|DRUG|Metreleptin|Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
223986511|NCT05194163|DRUG|MW150|oral-delivered capsule of study drug
223986512|NCT05194163|DRUG|Placebo|oral delivered capsule matched to study drug capsule
223986513|NCT01186731|DRUG|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
223986514|NCT04908345|DRUG|Methadone|Used at induction and during surgery
223986515|NCT04908345|DRUG|Fentanyl|Used at induction and during surgery
223986516|NCT00633945|DRUG|Lenalidomide|
223986517|NCT01928667|OTHER|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
223986518|NCT04528823|OTHER|Strategy 2: Symptom screen, Genexpert and TST|Participants follow an algorithm similar to the standard care, however participants with positive symptom screen and/or positive TST will receive GX (i.e., GX replaces CXR in standard care algorithm). GX positive are considered to have active TB. TST positive and GX negative receive LTBI treatment. If an individual is not able to provide sputum, they will undergo a CXR.
223986519|NCT04528823|OTHER|Strategy 3:Symptom screen, CXR but NO TST|Participants will receive symptom screening and CXR. No TST will be performed. If CXR abnormal or symptom positive, they undergo microbiological investigation. If the CXR is normal, and/or microbiological investigations negative - they receive LTBI treatment as per national guidelines. If microbiological investigation is positive they will be offered treatment for active TB.
223986520|NCT06269159|OTHER|Concept mapping: brainstorm|"Group health care providers:~* Duration: 1.5 hour for HCP via zoom session~* Brainstorm question: what would help your clients to change their sedentary behavior into more physical activity?~Group adults with overweight and obesity~* Duration: online survey (REDCAP) of approx. 10 minutes~* Brainstorm question via an online survey. What would help you to change your sedentary behavior into more physical activity?"
223986521|NCT06269159|OTHER|Concept mapping: clustering and rating|"The same participant of the brainstorm session are asked to join session 2 to complete the clustering and rating). All interested adults will get access to the online cluster and rate tool described below.~* Duration: flexible use of the online tool (available for two weeks)~* The clustering and rating of all needs mentioned in session 1 will be done online and individually via a web application. In this online tool, the final list of 'needs' generated in session 1 will be presented.~* Individually sort the 'needs' into groups and give the group a theme. In addition, each need will be scored on effectiviness, feasibility, modifiability. Thhe participants have unlimited access for two weeks."
223986522|NCT01861977|BEHAVIORAL|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
223986523|NCT01861977|BEHAVIORAL|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
223986524|NCT02634047|DEVICE|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
223986525|NCT02634047|DEVICE|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
223986526|NCT03865953|DRUG|LAT8881|LAT8881 oral capsule
223986527|NCT03865953|DRUG|Placebo|Placebo oral capsule
223986528|NCT01271504|DRUG|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
223986529|NCT01271504|DRUG|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."
223986530|NCT01514851|DRUG|Lanthanum carbonate (BAY77-1931)|
223986531|NCT01514851|DRUG|Calcium carbonate|
223986532|NCT05828836|DRUG|Allopurinol Tablet|allopurinol300mg once daily
223986533|NCT05828836|DRUG|Placebo|placebo once daily
223986534|NCT00912210|DIETARY_SUPPLEMENT|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
223986535|NCT00912210|DIETARY_SUPPLEMENT|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
223986536|NCT00730613|BIOLOGICAL|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
223986537|NCT00730613|GENETIC|gene expression analysis|At the time of excess pathology samples documenting response/relapse
223986538|NCT00730613|OTHER|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
223986539|NCT02229578|DRUG|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
223986540|NCT02229578|DRUG|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
223986541|NCT03792347|DRUG|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
223986542|NCT03306004|OTHER|Questionare|
223986543|NCT03673995|DIETARY_SUPPLEMENT|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
223986544|NCT05213546|OTHER|Aerobic exercise training|bicycle ergometer exercise training
223986545|NCT03091322|DEVICE|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
223986546|NCT02706951|DRUG|Methotrexate|Capsule; Oral
223986547|NCT02706951|DRUG|Upadacitinib|Tablet; Oral
223986548|NCT02706951|DRUG|Placebo Upadacitinib|Tablet; Oral
223986549|NCT02706951|DRUG|Placebo Methotrexate|Capsule; Oral
223986550|NCT00289575|DEVICE|MBCP|
223986551|NCT06956677|DEVICE|Novel UE rehabilitation device training|The novel UE rehabilitation device training includes the single-joint exercise and dual-joint exercise, each performed 20 repetitions per set, for a total of 5 sets with 30-second rest intervals between sets.
223986552|NCT06956677|OTHER|The UE functional training|The UE functional training focuses on the affected arm, incorporating exercises such as push-pull boxes (standing or seated), alternating push-pull boxes, and hand-crank exercises.
223986553|NCT06956677|OTHER|Conventional occupational therapy|Conventional occupational therapy
223986554|NCT01834612|DEVICE|CM1500|blood volume monitor
223986555|NCT00508495|DRUG|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
223986556|NCT00508495|DRUG|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
223986557|NCT00508495|DRUG|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
223986558|NCT03193242|OTHER|Electronic Asthma Management System: eAMS|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
223986559|NCT05656469|OTHER|Personalised medication advice based on pharmacogenetic testing|Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile
223986560|NCT05361811|BEHAVIORAL|Waitlist|8 weeks of maintaining usual routine followed by 8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
223986561|NCT05361811|BEHAVIORAL|ACT Intervention|8-week intervention that emphasizes mindfulness, acceptance, perspective taking, and values-based actions.
223986562|NCT05758805|DEVICE|mini-invasive esophagoscopy|mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter
223986563|NCT05758805|DEVICE|HP-SD AF ablation by a CF sensing catheter|AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
223986564|NCT01076790|DRUG|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
223728336|NCT07000968|OTHER|Task-Oriented Training Group|ask Oriented Training Procedure; Task-oriented training focusing on improving balance and walking will consist of 8 different exercise stations. Individuals will continue the exercise at each station for 4 minutes and rest for 1 minute before moving on to the next station. The training completed in this way will consist of a total of 40 minutes and the exercise stations will be applied following the determined order: The exercises will first be demonstrated by the physiotherapist. The aim is to perform exercises at moderate to vigorous intensity. It will be checked that the intensity level of the exercises is moderate and that the perceived effort is 12-15 points according to the Borg Scale. Perception of perceived exertion; It will be controlled by asking to increase the speed, changing the ground, giving double tasks and using obstacles made of wooden blocks. Individuals will be given visual and auditory positive feedback during the exercises.
223728337|NCT07000968|OTHER|Conventional Training Group|Individuals in this group will continue classical physiotherapy exercises. There will be no intervention by us in the traditional training group.
223986565|NCT01076790|DRUG|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
223986566|NCT03895528|DRUG|Lonafarnib|Farnesyl transferase inhibitor
223986567|NCT01112436|DRUG|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
223544439|NCT04072835|DRUG|Etripamil NS|Participants were provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS was self-applied by the participant, when PSVT symptoms begin. Participants self-administered etripamil NS if vagal maneuver was ineffective. After implementation of protocol amendment 2.1, participants had the option to administer a second dose of etripamil 70 mg 10 minutes after the first dose, if symptoms persisted. After an episode of PSVT where drug was administered, the participant returned to the investigative site for a study visit and was given the option to continue in NODE-303 and manage up to three subsequent episodes of PSVT with etripamil NS for a maximum of four episodes.
223544440|NCT05330936|COMBINATION_PRODUCT|Potent topical steroid|Cyanocobalamin in Avocado Oil Cream
223544441|NCT04723355|DEVICE|An innovative 3-lead wireless water resistant Holter device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
223544442|NCT04723355|DEVICE|A conventional device|The participant will use the innovative 3-lead wireless water resistant Holter device simultaneously with the conventional Holter device for 24 hours.
223544443|NCT02786212|DRUG|Dexmedetomidine|
223544444|NCT02786212|DRUG|Normal Saline|
223544445|NCT04856605|PROCEDURE|surgery|regular surgery
223544446|NCT03166462|OTHER|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
223544447|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
223544448|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
223544449|NCT01568281|DRUG|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
223544450|NCT01568281|DRUG|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
223986568|NCT01112436|DRUG|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
224120287|NCT05196997|OTHER|Mobility and Functional Assessments|"The first evaluation was made on the day the patient was discharged from the intensive care unit. DEMMI, Bartel Index, Katz Activities of Daily Living Rating Scale and MRC Muscle Strength Test were performed to the patient, respectively.~De-Morton Mobility assessment for test-retest reliability was performed again on the 1st day of the patient's service."
224120288|NCT00972998|DRUG|Phenyephrine|Phenyephrine coated suppositories
223986569|NCT04812743|BEHAVIORAL|Colorectal Health Research Champions|"20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs."
223728338|NCT07000838|DEVICE|Medially wedged ortheses|3 month long wear of medially wedged ortheses. Ortheses have to be worn for 6 to 8 hours daily during work shifts.
223728339|NCT06876103|OTHER|Religiously-integrated Cognitive Behavioral Therapy|"This study aims to assess the efficacy and feasibility of a newly developed online intervention for death anxiety based on Religiously Integrated Cognitive Behavioral Therapy (RCBT). Building upon the framework of Furer and Walker's 2008 intervention protocol, this adaptation incorporates beliefs in an afterlife, aligning with Turkish society's cultural and religious values.~The RCBT intervention consists of seven structured group therapy sessions, each lasting 90 minutes. The program is designed to help participants identify and challenge unhelpful thoughts related to death anxiety while integrating religious resources to promote cognitive restructuring. Key components of the intervention include psychoeducation, cognitive restructuring, exposure exercises, the concept of repentance in the context of trust and belief in the afterlife, gratitude, and value-oriented behaviors."
223986570|NCT04175561|OTHER|Green prescription|Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
223986571|NCT02440334|DRUG|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
223986572|NCT05856136|DRUG|Fentanyl Injection|Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
223986573|NCT01435148|PROCEDURE|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
223986574|NCT05306444|DRUG|CLN-418|Intravenous (IV) administration
223986575|NCT02357602|DRUG|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
223986576|NCT04266444|DEVICE|Exergaming in virtual environment|"The 10Cubes game (by I. Cikajlo) will be used. In the game, the motion of the hand, wrist and fingers is tracked by an infra-red camera (by LeapMotion, Inc.) and hand motion is reflected in the virtual environment. The software will run on a powerful computer with a 19 display. Each group will have the game set to a different level of difficulty."
224120289|NCT05050630|DRUG|TR2-ICE|Rituximab 375 mg/m2 d0; Lenalidomide 25mg/d d1-10; Ifosfamide 5g/m2 d2; Carboplatin calculate according to AUC=5 (single dose ≤800 mg); Etoposide 100mg/m2 d1-3; Tirelizumab 200mg d6.
223986577|NCT05411263|DIAGNOSTIC_TEST|Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)|As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
223986578|NCT01785147|DRUG|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
223986579|NCT01785147|DRUG|Placebo|
223986580|NCT04611347|DRUG|CBD|Topical CBD application for thumb basal joint osteoarthritis.
223986581|NCT04611347|DRUG|Shea Butter|Placebo Shae Butter for comparison
223986582|NCT06266364|DEVICE|Active VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive active Vagus nerve stimulation (VNS) in phase 1
223986583|NCT06266364|DEVICE|Sham VNS stimulation|The subjects in this group will be implanted with the ReStore device and receive sham Vagus nerve stimulation (VNS) in phase 1
223986584|NCT01184534|BEHAVIORAL|Video|5 minute multimedia presentation (video)
223986585|NCT01184534|BEHAVIORAL|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
223986586|NCT06043453|OTHER|revitalization|The main idea behind revitalization is to firstly disinfect the root canal and subsequently attract or transplant mesenchymal stem cells from the (remaining) dental pulp and apical papilla (in case of immature permanent teeth) into the root canal. More specifically, this therapy is not based on mechanical and (aggressive) chemical debridement as in conventional root canal treatment but is supported by the pillars of tissue engineering: stem cells, growth factors and a scaffold .
223986587|NCT02599688|OTHER|Observation only|No intervention in this study.
223986588|NCT01841697|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
223986589|NCT01841697|DRUG|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
223986590|NCT01841697|DRUG|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
223986591|NCT01841697|DRUG|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
223986592|NCT01841697|DRUG|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
223986593|NCT01841697|DRUG|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
223986594|NCT03656276|BEHAVIORAL|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
223986595|NCT06026475|PROCEDURE|Goal directed Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining SVV below 11
223986596|NCT06026475|PROCEDURE|Conventional Fluid Therapy|Patients will receive fluid during surgery with goal of maintaining CVP between 8-12 cms H20
223728340|NCT06876103|OTHER|Classical Cognitive Behavioral Therapy|"The standard CBT intervention follows the structured protocol developed by Furer and Walker (2008), which targets cognitive distortions, avoidance behaviors, and excessive safety-seeking behaviors contributing to death anxiety. The researcher has adapted the session content to fit the protocol's core components while maintaining fidelity to the original intervention model. Sessions last 90 minutes and are conducted in an online group format.~Session Structure: Session 1: Treatment Rationale, Session 2: Reducing Excessive Checking, Reassurance Seeking, and Safety Behaviors, Session 3: Exposure, Session 4: Cognitive Reappraisal, Session 5: Enhancing Enjoyment of Life, Session 6: Healthy Lifestyle, and Session 7: Relapse Prevention."
223986597|NCT03019081|DRUG|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
224120290|NCT06671964|OTHER|Anthropometric measurements|Anthropometric measurements of the students, including weight, height, muscle mass, fat quantity, and waist circumference, were measured. The WHO BMI charts were utilized for classification. Stratified Random selection
223544451|NCT03461562|OTHER|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
223544452|NCT02330354|BEHAVIORAL|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
223544453|NCT05711875|OTHER|Virtual Reality (VR) glasses|During the Non Stress Test (NST), the pregnant women in the experimental group watched a video of nature scenery with Virtual Reality (VR) glasses for 10 minutes
223728341|NCT06590987|DEVICE|Strolll AR|Strolll AR is an augmented-reality (AR) neurorehabilitation platform for delivering gait and balance exercises (assisted with cues when deemed beneficial) for Parkinson's disease onto state-of-the-art AR glasses.
223728342|NCT04016753|DRUG|BMS-986256|30 mg(6ml)
223986598|NCT03019081|OTHER|placebo|placebo
224120291|NCT06671964|OTHER|Questionnaire|"The collection of data was performed using the Atlas questionnaire (Al-Hazzaa et al., 2011) and nutrition knowledge and healthy lifestyle behavior questionnaire (Kalender et al., 2011) with additional questions related to self-efficacy and dietary practices adapted from the literature (Becher, 2009; Voss et al., 2017; Kowalski et al., 2004). Stratified Random selection"
224120292|NCT06671964|OTHER|Educational sessions|The topics that covered included a healthy eating lifestyle, energy balance, food portion control, healthy snacking, the importance of physical activity and healthy eating, dietary practices, and nutrition-related self-efficacy.
224120293|NCT06862596|DRUG|Mexiletine hydrochloride|Mexiletine hydrochloride 300 mg is administered orally divided into three times a day after meals for 12 weeks.
224120294|NCT06862596|OTHER|Placebo|Placebo is administered orally divided into three times a day after meals for 12 weeks.
223986599|NCT04682561|BEHAVIORAL|Supportive Trauma Exposure Preparation Program|The Supportive Trauma Exposure Preparation Program is based on the theory that the ability to set compassionate boundaries will enhance acceptance of the reality of trauma in the workplace, and will also increase the cognitive/emotional/physical energy needed to engage in adaptive emotional strategies in response to trauma exposure. Therefore, the goal of therapy is to learn to set compassionate boundaries and engage with oneself and others from a perspective of self-empowerment and acceptance of life events. Concepts and skills will be addressed through the following modules: 1) understanding of trauma and its effects, 2) personal rights and boundaries, 3) emotional literacy, 4) distress tolerance and emotion regulation skills building, 5) communication skills building, 6) self-compassion and acceptance, and 7) enhancing self-care.
223986600|NCT01028872|DEVICE|Intraocular lens|
223986601|NCT01028872|DEVICE|Intraocular lens|
223986602|NCT01028872|DEVICE|Intraocular lens|
223986603|NCT01612273|DRUG|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
223986604|NCT01612273|DRUG|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
223986605|NCT02518815|DEVICE|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
223986606|NCT03919409|DRUG|TS-161|TS-161 capsules
223986607|NCT03919409|DRUG|TS-161 Placebo|TS-161 matching placebo capsules
223986608|NCT00251056|DRUG|mannitol|120mg BD
223986609|NCT00251056|DRUG|mannitol|40 mg BD
223986610|NCT00251056|DRUG|mannitol|240mg BD
223986611|NCT00251056|DRUG|mannitol|400mg BD
223986612|NCT01910883|DRUG|Finafloxacin i.v. solution 200 mg|
223986613|NCT01910883|DRUG|Finafloxacin i.v. solution 400 mg|
223986614|NCT01910883|DRUG|Finafloxacin i.v. solution 600 mg|
223986615|NCT01910883|DRUG|Finafloxacin i.v. solution 800 mg|
223544454|NCT02342860|OTHER|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~* Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~* Software: operations and maintenance (O\&M) training for teachers, hygiene training, and basic hygiene package."
223544455|NCT04415294|DIAGNOSTIC_TEST|Critical flicker frequency|Measure the critical flicker frequency as a screening test for hepatic encephalopathy using a portable self administered device
223544456|NCT06199908|DRUG|AMT-562|Administered AMT-562 for injection intravenously
223986616|NCT01910883|DRUG|Finafloxacin i.v. solution 1000 mg|
223986617|NCT01910883|DRUG|Placebo i.v. solution|
223986618|NCT00822770|DRUG|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
223986619|NCT00822770|DRUG|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
223986620|NCT00822770|DRUG|Fludarabine|Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.
223986621|NCT00822770|DRUG|Busulfan|Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.
223986622|NCT00822770|PROCEDURE|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
223986623|NCT00822770|DRUG|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
223544457|NCT02657694|DRUG|Sofosbuvir+Ledipasvir|DAA medication treatment
223544458|NCT02657694|DRUG|Sofosbuvir+Daclatasvir|DAA medication treatment
223544459|NCT02657694|DRUG|Sofosbuvir+Velpatasvir|DAA medication treatment
223544460|NCT00551434|DIETARY_SUPPLEMENT|Creatine|Creatine 21 g daily
223544461|NCT00551434|DIETARY_SUPPLEMENT|L-arginine and creatine|L-arginine
223544462|NCT00551434|DIETARY_SUPPLEMENT|l-arginine|l-arginine 9 g daily
223544463|NCT00551434|DIETARY_SUPPLEMENT|placebo, double|placebo
223544464|NCT01037335|DRUG|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
223544465|NCT06464731|PROCEDURE|EVT|Interventionist choose the optimal EVT strategy and device based on the patient's condition and local guidelines. This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on. The EVT regimen and relevant time points will be accurately recorded. The patient will receive the best medical treatment according to the local guidelines.
223544466|NCT00841776|DRUG|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
223544467|NCT00841776|DRUG|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
223986624|NCT00051623|DRUG|Infliximab|
223986625|NCT01975298|DRUG|Laquinimod|Oral Administration
223986626|NCT01975298|DRUG|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
223986627|NCT05140083|DRUG|68Ga-NOTA Evans Blue|Each subject receives a single subcutaneous injection of 68Ga-NOTA Evans Blue, and undergo PET/CT imaging within the specific time.
223986628|NCT06499662|OTHER|Vagus Nerve Neurodynamics|This intervention involves passive cervical movements designed to enhance vagus nerve functionality.
223986629|NCT06499662|OTHER|Guided Breathing|This intervention consists of diaphragmatic breathing guided by a recording to maintain a rate of 6 breaths per minute.
223986630|NCT06499662|OTHER|Manual Therapy|This intervention includes suboccipital inhibition techniques applied during the session.
223986631|NCT05040945|PROCEDURE|Traditional corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with traditional corticotomy will be applied.
223986632|NCT05040945|PROCEDURE|Flapless corticotomy|Adult patients will be treated by extraction of maxillary first premolars with applying mini-screws between maxillary second premolar and first molar as temporary skeletal anchorage devices (TSADs). Then en-masse retraction associated with flapless corticotomy will be applied.
223986633|NCT02444468|DEVICE|Flowtron ACS800|Flowtron ACS800 and bandage
223986634|NCT02444468|OTHER|Bandage|Bandage only
223986635|NCT04560478|DEVICE|Pro Seal Sealant|Sealant was reapplied every 3 months
223986636|NCT04560478|DEVICE|MI Varnish|Fluoride varnish was applied every 4-6 weeks
223986637|NCT05264701|OTHER|Physiotherapist supervised exercise training|Exercise training for 12 weeks will be given by video talk accompanied by a physiotherapist.
223544468|NCT01921556|BEHAVIORAL|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
223728343|NCT04016753|DRUG|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
223728344|NCT00311610|DRUG|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
223986638|NCT05264701|OTHER|Exercise training via phone app|Exercise training for 12 weeks will be given over the developed phone application.
223986639|NCT05264701|OTHER|Physical activity recommendations|The program will be consist of 12 weeks of physical activity recommendations.
223986640|NCT00004254|DRUG|raltitrexed|
223986641|NCT01101061|DRUG|Romosozumab|Administered by subcutaneous injection
223986642|NCT01101061|DRUG|Placebo|Administered by subcutaneous injection
223986643|NCT06478901|DEVICE|Echocardiography|Echocardiography assited by Artificial intelligence
223986644|NCT03181906|OTHER|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
223986645|NCT01041768|PROCEDURE|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
223986646|NCT03598881|OTHER|Treatment|
223986647|NCT02033473|DRUG|Apelin|An apelin clamp in which an apelin infusion will be administered
223986648|NCT02033473|DRUG|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
223986649|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
223986650|NCT00738985|DRUG|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
223986651|NCT00299598|DEVICE|alkylated polyethylenimine nanoparticles antibacterial evaluation|
223986652|NCT05744583|OTHER|Packed red cell transfusion|Type O RhD negative packed red cell transfusion during prehospital emergency care
223544469|NCT03836872|DEVICE|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
223544470|NCT00699946|DRUG|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
223544471|NCT00699946|DRUG|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
223986653|NCT05744583|OTHER|Whole blood transfusion|Type O RhD positive, low titer whole blood transfusion during prehospital emergency care
223986654|NCT04532762|DEVICE|nasal spray|Application of a nasal spray
223986655|NCT05514171|PROCEDURE|Neoadyuvant therapy|Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
223986656|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
223986657|NCT03886597|OTHER|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
223986658|NCT03886597|OTHER|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
223986659|NCT01530386|DRUG|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
223986660|NCT02164006|DRUG|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
223986661|NCT02049515|DRUG|IPI-145|PI3K Inhibitor
223986662|NCT02049515|DRUG|Ofatumumab|Monoclonal antibody
223986663|NCT02425241|BIOLOGICAL|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
223986664|NCT02425241|BIOLOGICAL|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10\^10 vp at week 12.
223986665|NCT02425241|BIOLOGICAL|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10\^8 pfu at week 20
223986666|NCT02425241|DRUG|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
223986667|NCT02425241|OTHER|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
223728345|NCT05094622|OTHER|Physical exercise program|A specially designed exercise training program based on a previous study. The intervention of physical exercise will consist of different exercises to enhance muscle strength and endurance and will be individually adjusted and start in a different position with a progression in dose, intensity, and position. It will be performed 3 times /week during a period of 12-20 weeks.
224120295|NCT06672354|PROCEDURE|Otago Exercise Program|"1- Otago Exercise Program: i) This exercise program will consist of strengthening, balance exercises and walking plan. The OEP will be performed according to the following: 5 min warm-up, 10 min resistance training and 15 min balance exercises.~ii) The strength training protocol targets, on hip abductors, knee flexors, knee extensors, plantarflexors, and dorsiflexors.All exercises will be performed for 10 repetitions. This protocol recommends strength training 3 days per week.~iii) The balance retraining protocol incorporates various exercises. The exercises progress in difficulty through four levels, with Level 1 being the easiest and Level 4 the most challenging. Balance exercises will progress from holding onto a stable supporting structure such as heavy furniture to perform the exercises independent of the support. The protocol recommends participants to carry out balance exercises 3 days a week.~iv) Participants will be instructed to walk at their usual pace for 30 minutes, twice"
223544472|NCT01453452|BEHAVIORAL|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be \< 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
223544473|NCT01453452|BEHAVIORAL|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
223544474|NCT01453452|OTHER|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
223544475|NCT01453452|PROCEDURE|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
223544476|NCT05369377|DRUG|Zanubrutinib|Zanubrutinib 80mg po qd 6 weeks
223544477|NCT05369377|DRUG|Eltrombopag|eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
223728346|NCT02201654|OTHER|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
223544478|NCT03346421|BEHAVIORAL|diet and physical activity|
223544479|NCT00129090|DRUG|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
223544480|NCT00003923|DRUG|porfimer sodium|
223544481|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
223986668|NCT02100683|DEVICE|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
223986669|NCT01308268|DRUG|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (\>= 2 years old) single dose, PO
223986670|NCT06248112|DRUG|Sacubitril and Valsartan-Test product|Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Manufactured by: Hetero Labs Ltd., India
223986671|NCT06248112|DRUG|Sacubitril and Valsartan-Reference product|Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland
223986672|NCT02577588|BIOLOGICAL|re-activated T cells|autologous reactivated T cells against p53
224120296|NCT06672354|PROCEDURE|Non-Immersive Virtual Reality Training|In this interventional group, VR training exercises will be performed by using Xbox Kinect, which includes a Kinect sensor.-The monitor or Tv screen will recognize the movements of participants via camera and infra-red motion sensors.-In order to perform simulated exercises in each session, the participant will be positioned at 1.5-2 meter from the monitor or TV screen.-The virtual reality training exercises will include Kinect Adventure games (Rally Ball, 20,000 leaks, Reflex Ridge) and Sports pack 1 games (Super Saver, Target Kick, Body ball).-Exercises will be continued for 30-45 minutes each session, for 3 alternate days per week for a total period of 12 weeks.
224294324|NCT04399876|COMBINATION_PRODUCT|Microdevice|"Surgery Cohort: Placement of 1-6 microdevices: Drugs chosen have all been FDA approved for the treatment of cancer (so therefore safe) and there are phase 2 or 3 data that the drug has efficacy in prostate cancer. Agents of interest included Abiraterone, Enzalutamide, Pembrolizumab, Ipilimumab, Carboplatin, Docetaxel, and Olaparib as well as combinations~Ex vivo Cohort: Placement of multiple microdevices with miniature drug reservoirs but no drug is loaded into the removed prostate"
224294325|NCT02906865|OTHER|Proximal hamstring tendons repair|Proximal hamstring tendons repair
224294326|NCT01900496|BIOLOGICAL|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
223544482|NCT01999842|BIOLOGICAL|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
223544483|NCT01999842|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
223544484|NCT00034021|DRUG|Ginkgo Biloba|
223544485|NCT00034021|BEHAVIORAL|Sex Therapy (genital focus)|
224120297|NCT02887144|DEVICE|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
224120298|NCT02887144|DEVICE|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
224120299|NCT06688084|OTHER|Molecular epidemiology of the collection|Next-generation genomic sequencing (MICRO\&BIO platform, MiSeq, Illumina) and bioinformatics analyses. After validating data quality, genomes will be re-assembled using Spades software (version 3.15.4) and CLC® (Qiagen), then compared with the National Center for Biotechnology Information GenBank database. They will also be analysed on the online Type-Strain Genomes Server platform to accurately identify the bacteria. Genome annotation will be done using the DDBJ Fast Annotation and Submission Tool. Single nucleotide polymorphisms (SNP) analysis based on the alignment of whole genomes and core-genomes will be carried out using version 7 of MAFFT (multiple alignment using fast Fourier transform) software, then quantified using snp-dists (version 0.6.3). This approach will enable the molecular epidemiology of the collection of strains in France and other European countries to be clarified, and the main circulating clades to be assessed, particularly depending on the origin of samples.
224120300|NCT06688084|OTHER|Study of the resistome of the S. pettenkoferi population|The resistome will be assessed by identifying known and described resistance genes in staphylococci using bioinformatics analyses of sequenced complete bacterial genomes. A search for plasmids will also be made using various specific software packages (ResFinder, CARD, PointFinder, Plasmidfinder, in-house pipeline).
224120301|NCT06688084|OTHER|Study of the virulome of the S. pettenkoferi population|The virulome of the strains will be studied based on the genomic sequencing data obtained and with reference to the literature on Staphylococci. Various specific software packages (Pathogenfinder, Virulencefinder, in-house pipeline) will be used for this purpose.
224120302|NCT06688084|OTHER|Study of the resistance profiles of all S. pettenkoferi isolates|Antibiotic resistance will be assessed using a Sensititer® plate (Thermo ScientificTM, Illkirch) to evaluate the minimum inhibitory concentration of isolates against a series of antibiotics commonly used for S. pettenkoferi infections, including new molecules currently on the market or in development, such as Ceftaroline, Ceftobiprole, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Minimum inhibitory concentration values will be interpreted in accordance with the recommendations of the Antibiogram Committee of the Société Française de Microbiologie (https://www.sfm-microbiologie.org/2021/04/23/casfm-avril-2021-v1-0/).
224120303|NCT06688084|OTHER|Selection of strains for in-depth phenotypic study|"Different strains of S. pettenkoferi isolated from foot osteitis in diabetic patients and non-diabetic osteitis will be selected according to the clades identified and phenotypically characterised by further analysis:~* Observation of culture characteristics (culture requirements, growth time, colony size and haemolytic capacity), (n=20)~* Determination of growth curves by measuring absorbance at 600 nm using the Infinite M Mano automatic absorbance reader (TECAN, Lyon), (n=20)~* Study of the ability to form biofilm in the presence (antibiofilmogram) (n=85) or absence (BioFilm Ring® test, Biofilm Control, St Beauzire) (n=85) of various antibiotics commonly used for the treatment of S. pettenkoferi infection during osteitis."
224120304|NCT06688084|OTHER|Selection of strains (n=3) for the virulence study|"Three strains of S. pettenkoferi isolated from foot osteitis in diabetic patients will be selected on the basis of the clades identified and the study of the virulome in order to be analysed on :~* In vitro cell culture models of macrophages (RAW 264.7) and osteoblasts (MC3T3-E1) to assess the invasion potential of these isolates by measuring internalisation rates (TECAN, Lyon) and LDH release (CyQUANT LDH Cytotoxicity kit), a sign of cellular toxicity of the isolate.~* An in vivo wound model on diabetic zebrafish (Dario rerio) with evaluation of their survival at 48h in the presence of the isolates by immersion.~These models were developed at the MICRO\&BIO Platform and the INSERM 1047 VBIC unit."
223986673|NCT05394090|DIAGNOSTIC_TEST|saliva stimulation|In 50 patients with ischemic stroke, saliva was the option of a neurologopedic massage of choice
223986674|NCT01363310|DRUG|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
223986675|NCT01363310|DRUG|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
224120305|NCT04947566|DRUG|Comparison of Efficacy of Naproxen versus Ibuprofen|Comparison of Efficacy of Naproxen Versus Ibuprofen in the Management of Post-Operative Endodontic Pain in Teeth with Irreversible Pulpitis
224120306|NCT06693453|OTHER|Electroacupuncture and Dry cupping|This group will perform electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
224120307|NCT06693453|OTHER|Electroacupuncture and Sham Dry cupping|This group will perform Electroacupuncture for 20 minutes daily (10 sessions over 2 weeks) and Sham Dry cupping for 7 minutes every 4 days (3 sessions over 2 weeks)
224120308|NCT06693206|OTHER|Evaluation of aerobic capacity|A stepwise protocol will be used in which the load increases gradually with the bicycle ergometer. In these protocols, the load increases continuously in small amounts throughout the exercise.
223986676|NCT01640171|PROCEDURE|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
223986677|NCT01640171|DRUG|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
223986678|NCT01640171|DRUG|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
223986679|NCT01640171|DRUG|Acuvail|Anti-inflammatory drop given after treatment
224120309|NCT06246825|DIAGNOSTIC_TEST|Polysomnography|Patients with a high likelihood of having obstructive sleep apnea will undergo a polysomnography, as recommended by the guidelines
224120310|NCT04661618|DEVICE|Gym Tonic programme and Gym equipment|12 week progressive training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol twice a week 12 weeks maintenance training - Strength exercises on 6 pneumatic gym equipment following Gym Tonic's protocol once a week
224120311|NCT07035106|DEVICE|Wearable Health Monitoring|Participants receive a Garmin Vivosmart 5, Garmin Index S2 Smart Scale, and Garmin Index BPM blood pressure monitor for daily health tracking. Devices sync to the Fitrockr mobile application.
224120312|NCT07035106|BEHAVIORAL|Digital Health Summary and Lifestyle Counseling|Participants receive bi-weekly health summaries via email generated from wearable data and may opt in to monthly video-based lifestyle consultations with trained study staff.
223544486|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
223544487|NCT04023292|DRUG|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
223544488|NCT00672594|DRUG|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
223544489|NCT03039387|DEVICE|anodal transcranial direct current stimulation|
223986680|NCT01640171|DRUG|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
223544490|NCT03039387|DEVICE|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
223544491|NCT06187324|DIAGNOSTIC_TEST|biomarkers|by th use of perio paper GCF was collected and Biomarkers level was estimated
223544492|NCT01123343|DEVICE|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
223544493|NCT02791347|OTHER|Nutrition Intervention|
223544494|NCT01798147|PROCEDURE|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
223544495|NCT01798147|PROCEDURE|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
223986681|NCT05575570|DEVICE|EVAR|EVAR stent graft and embolization material CE marked.
223986682|NCT05749861|DRUG|CKD-348(5)|QD, PO
223986683|NCT05749861|DRUG|CKD-828, D097, D337|QD, PO
224120313|NCT06926062|OTHER|Best Practice|Provide vaccinations per usual care
224120314|NCT06926062|OTHER|Educational Intervention|Review messages on safety and side effects
224120315|NCT06926062|OTHER|Educational Intervention|Review messages on vaccine effectiveness
224120316|NCT06926062|OTHER|Educational Intervention|Review messages on sexual activity
224120317|NCT06926062|OTHER|Educational Intervention|Review messages on HPV vaccine for boys
224120318|NCT06926062|OTHER|Educational Intervention|Review message on age to start vaccine
224120319|NCT06926062|OTHER|Educational Intervention|Review messages on school entry requirements
224120320|NCT06926062|OTHER|Interview|Ancillary studies
224120321|NCT06926062|OTHER|Questionnaire Administration|Complete a survey
224120322|NCT06926062|OTHER|Questionnaire Administration|Ancillary studies
224120323|NCT06926062|BEHAVIORAL|Training and Education|Receive interpersonal communication training
223728347|NCT00998660|DEVICE|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
223728348|NCT04738344|DEVICE|Percutaneous Coronary Intervention and Stent Implantation|Percutaneous Coronary Intervention and Stent Implantation will be implanted as recommended by guidelines and according to the standard techniques.
223728349|NCT00973739|DRUG|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
223728350|NCT03683108|DRUG|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
223728351|NCT03683108|OTHER|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
223728352|NCT06293755|DEVICE|Microneedle patch|with 20 units botulinum toxin
223986684|NCT06183411|BEHAVIORAL|Assessment|"* Observations using two valid, observational instruments (MABC-2 and ToM test-R) that each child completes once at random.~* A demographic and developmental questionnaire is completed once by the parent/guardian at recruitment.~* Standardized questionnaires (Coordination Questionnaire For Parents (CVO), Social Responsiveness Scale second edition (SRS-2), Strengths and Difficulties Questionnaire (SDQ) and Theory of Mind Behavior Checklist (ToMBC)) are also questioned once to parent/guardian for data collection."
223986685|NCT05482490|PROCEDURE|Maintenance protocol for the hygiene of implant supported prosthesis|Sequence of phases that include the hygiene and cleaning of the prosthesis and the implants, the motivation of the patients and reinforcement of oral hygiene.
224120324|NCT06926062|BEHAVIORAL|Training and Education|Receive the vaccination workflow training
223544496|NCT00705705|BEHAVIORAL|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
223544497|NCT00705705|BEHAVIORAL|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
223544498|NCT01399112|BEHAVIORAL|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
223544499|NCT02609425|DEVICE|Stratafix PGA Suture|Subject leak Stricture rates post procedure
223544500|NCT03757507|DEVICE|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
223544501|NCT01803971|OTHER|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
223544502|NCT05575700|DRUG|Ibuprofen|400 mg tablet three times daily
223544503|NCT05575700|DRUG|Placebo|tablet three times daily
223544504|NCT00618007|DRUG|PF-00734200 30 mg QD|30 mg QD
223544505|NCT00618007|DRUG|PF-00734200 20 mg QD|20 mg QD
223544506|NCT00618007|DRUG|Placebo|Placebo
223728353|NCT06293755|DEVICE|Intradermal injection|with 20 units botulinum toxin
223728354|NCT02740777|BIOLOGICAL|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
223728355|NCT00531232|DRUG|Clofarabine|"Pharmaceutical form: Tablet,~Route of administration: Oral"
223728356|NCT00840346|DRUG|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
224120325|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using the interpersonal communication strategy
224120326|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using the vaccination workflow training strategy
223986686|NCT04648098|OTHER|Discharge training and telephone counseling|"The discharge training was given by using different teaching methods in the form of verbal expression, demonstration, and question and answer. The care guide prepared by the researchers in line with the literature was used as a training material for stroke patients and their caregivers.The training varied according to the learning level of individuals but took an average of 40-60 minutes.~Consultation service was given to the caregivers one week after discharge and once a month for three months by telephone call."
223986687|NCT00754598|DEVICE|Tomosynthesis digital mammography imaging system|a full-field digital mammography system where multiple images are acquired at various angles near the normal to the detector. Breast compression is performed in a standard geometry. The acquired images are reconstructed using mathematical algorithms, not unlike CT reconstructions, to generate a set of thin slices parallel to the breast platform. The reconstructed slices can be viewed individually or in a movie format.
223986688|NCT00224029|DRUG|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
223986689|NCT03043482|DRUG|Single VS-105/placebo to healthy|In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
223986690|NCT03043482|DRUG|Multiple VS-105/placebo to healthy|In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
223986691|NCT03043482|DRUG|Multiple VS-105/placebo to HD subjects|In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
223986692|NCT03357978|DIAGNOSTIC_TEST|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
223986693|NCT03357978|DIAGNOSTIC_TEST|blood draw|Blood samples are taken from sober patients
223986694|NCT03357978|DIAGNOSTIC_TEST|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
223986695|NCT03357978|DIAGNOSTIC_TEST|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
223986696|NCT03357978|DIAGNOSTIC_TEST|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
223986697|NCT01793077|DRUG|Depo-Eligard®|Subcutaneous
223986698|NCT02051569|DIETARY_SUPPLEMENT|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
223986699|NCT02316262|PROCEDURE|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
223986700|NCT05364034|OTHER|Urban Afforestation Intervention Program|An afforestation intervention program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
224120327|NCT06926062|PROCEDURE|Vaccination|Provide vaccinations using both the interpersonal communication strategy and the vaccination workflow training strategy
224120328|NCT04379804|PROCEDURE|Lateral approach|Following the ligation of upper pole vessels, the thyroid lobe was pulled anteromedially and the RLN was dissected within the carotid triangle at the level of inferior thyroid artery (ITA).
224120329|NCT04379804|PROCEDURE|Cranio-caudal approach|Following the ligation of upper pole vessels, the upper pole was retracted antero-medially to expose crico-pharyngeal muscle. The RLN was identified at the point of entry both visually and with hand held stimulation probe
224120330|NCT03306069|OTHER|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
224120331|NCT03306069|OTHER|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~* 2 sessions per week~* 5x1 min at 80-95% HRmax~* time-effort per week: \~30 min"
224120332|NCT03306069|OTHER|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~* 2 sessions per week~* 5x1 min at 65-79% HRmax~* time-effort per week: \~30 min"
224120333|NCT03306069|OTHER|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~* 2 sessions per week~* session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~* time-effort per week: \~30 min"
224120334|NCT03806595|DRUG|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
224120335|NCT03806595|DRUG|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
224120336|NCT02429427|DRUG|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
224120337|NCT02429427|OTHER|Placebo|Two capsules once daily with food
224120338|NCT01173627|DRUG|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
224120339|NCT01173627|DRUG|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
223728357|NCT03475537|DEVICE|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
223728358|NCT02152696|DRUG|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
223728359|NCT02152696|PROCEDURE|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
223728360|NCT02152696|OTHER|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
223728361|NCT05937191|DRUG|Leflunomide|Leflunomide+Glucocorticoids treatment Group
223728362|NCT05937191|DRUG|Steroid Drug|Steroid Treatment
223728363|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
223728364|NCT02231541|DEVICE|Very Low Frequency Magnetic Fields|The device is turned off.
223728365|NCT03401424|PROCEDURE|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
223728366|NCT03401424|PROCEDURE|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
223728367|NCT03780283|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
223728368|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
223728369|NCT04812964|DIETARY_SUPPLEMENT|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
223728370|NCT02492347|PROCEDURE|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
223728371|NCT00428896|DRUG|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
223728372|NCT03898141|OTHER|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
223728373|NCT03898141|OTHER|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
223728374|NCT03898141|OTHER|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
223728375|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
223728376|NCT02345850|PROCEDURE|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
223728377|NCT02345850|PROCEDURE|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
223986701|NCT04295330|DRUG|Lidocaine Hydrochloride, Injectable|In the lidocaine group, at the end of the induction of general anesthesia, a bolus injection of lidocaine 1.5 mg/kg, calculated using the patient's ideal body weight and given as an infusion over 10 minutes, followed by a continuous infusion of lidocaine at 1.5 mg/kg per hour for the whole surgical procedure and will be discontinued at the end of surgery. Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
223986702|NCT04295330|DRUG|0.9% normal saline|In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
223986703|NCT05480462|BIOLOGICAL|Clodivac|A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.
223986704|NCT05480462|BIOLOGICAL|Td-Impfstoff Merieux|One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
223986705|NCT04539067|DRUG|HHMG|Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
224120340|NCT06786286|DRUG|[14C]-ITI-1284|\[14C\]-ITI-1284 20 mg oral solution (not more than 22 μCi), subcutaneous administration
223728378|NCT02345850|DRUG|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
224120341|NCT00931788|DRUG|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
223544507|NCT05065593|OTHER|resistance and aerobic exercise|Resistive exercises allow loading the muscle under suitable conditions with various weights or resistances. In order to increase the level of physical fitness with the increase of muscle strength and bone mass in individuals, resistance exercises were preferred. Aerobic exercises, on the other hand, are a special type of exercise that develops both the musculoskeletal system and the cardiovascular system, which includes large muscle groups and should be performed for at least 20 minutes when the heart rate accelerates at certain rates. Aerobic exercise was preferred in order to increase cardiovascular endurance, accelerate fat burning and reduce fatigue.
223986706|NCT05088109|DIAGNOSTIC_TEST|early mortality prediction using septic shock indices|The Shock Index (SI) is the ratio of pulse rate to systolic blood pressure calculated by dividing pulse rate (beat/min) by systolic blood pressure (mm Hg). The adjusted shock index (ASI) is SI calculated after adjusting the heart rate according to body temperature that 10 beats will be added to the heart rate for every 1.0 °C rise in the body temperature above 37.0 °C. The modified shock index (MSI) is a ratio of heart rate to mean blood pressure (MAP). The DSI is a ratio of heart rate to diastolic blood pressure (DAP).
223986707|NCT04470869|OTHER|Phone call|The relatives of both groups will be contacted by phone one month after the discharge of the ICU of the death, three month after, six month after and twelve month after. During these interviews the PTSD symptoms, the anxiety and depression symptoms, the complicated grief symptoms (in case of death) and the satisfaction about the ICU stay will be collected.
224120342|NCT00931788|OTHER|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
224120343|NCT02945449|BIOLOGICAL|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
224294327|NCT01900496|BIOLOGICAL|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.
224294328|NCT00208117|DRUG|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
224120344|NCT02468089|DRUG|Carbepenem|
224120345|NCT02468089|DRUG|Albumin|
224120346|NCT02468089|DRUG|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
224120347|NCT00358618|DRUG|Propofol|See Detailed Description.
224120348|NCT06854315|BEHAVIORAL|ChatGPT-Based Digital Counseling|Participants in this group received standard clinician-led chemotherapy education plus access to ChatGPT-based digital counseling. They could submit up to 10 personalized questions regarding their treatment, side effects, and supportive care. Oncology specialists reviewed ChatGPT-generated responses for accuracy. This intervention aimed to assess whether AI-assisted counseling could reduce anxiety and depression levels in newly diagnosed cancer patients.
224120349|NCT06854315|BEHAVIORAL|Standard Clinician-Led Education|Participants in this group received only standard clinician-led chemotherapy education, delivered by oncology physicians and nurses. The education covered key aspects of chemotherapy, including potential side effects, treatment schedules, and supportive care recommendations. Unlike the ChatGPT group, these participants did not receive AI-assisted counseling or additional interactive educational tools.
224120350|NCT06930144|DRUG|active folate|Daily oral intake of active folate 800ug combined with basic diabetic treatment
224294329|NCT00208117|DRUG|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
224294330|NCT02667002|PROCEDURE|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
224294331|NCT02667002|PROCEDURE|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
224294332|NCT02667002|OTHER|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
224294333|NCT03407118|DRUG|LY900014|Administered SC.
224294334|NCT03407118|DRUG|Insulin Lispro|Administered SC.
224294335|NCT04209335|OTHER|isometric core muscle endurance testing|holding previously described isometric positions until fatigue
224294336|NCT00190242|DRUG|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
224294337|NCT00190242|DRUG|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
224120351|NCT06930144|DRUG|Placebo|take oral placebo daily combined with basic diabetic treatment
224120352|NCT06930924|BEHAVIORAL|Parent self-help psychological resource|A self-help psychological resource designed alongside families and clinicians, to be delivered to parents of CYP with coeliac disease. The resource will focus on providing psychoeducation on the gluten-free diet, concerns around dietary management, using family's strengths to support dietary management, managing outside the home, and transition to independent management of the gluten-free diet. Parents will also attend a 60-minute online peer support and information workshop
224120353|NCT06930235|DRUG|Weaning critically ill patients from norepinephrine using midodrine as an adjuvant to norepinephrine|• Patients in group I will receive midodrine (10 mg orally every 8 hours) in addition to administered concurrently with ongoing intravenous norepinephrine after being on norepinephrine for more than 24 hrs.
224294338|NCT05077956|DIAGNOSTIC_TEST|Cerebrospinal and Blood Serum Semaphorin 4A Levels|Cerebrospinal fluid and serum will be collected at baseline to measure the level of semaphorin 4A.
224294339|NCT00729131|DRUG|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
224294340|NCT02254018|DRUG|bivatuzumab mertansine|
224294341|NCT03050918|BEHAVIORAL|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
224294342|NCT01362465|PROCEDURE|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
224294343|NCT02788149|DEVICE|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
223544508|NCT05065593|OTHER|physical activity recommendation|Patients will be informed about the importance of lifestyle change in disease management, walking training will be given to increase their physical activity level, and participants will be asked to follow a 45-minute walking program every day within their own means.
223986708|NCT00394420|BEHAVIORAL|Telephone Quitline|
223986709|NCT02276534|BEHAVIORAL|SENSE Theatre|A peer-mediated, theatre-based intervention.
223986710|NCT02276534|BEHAVIORAL|Delayed Intervention|
223986711|NCT05414383|DEVICE|CADx|A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
223986712|NCT06061380|OTHER|no intervation taken|
223986713|NCT01390441|BIOLOGICAL|MK-8808|MK-8808 500 mg/m\^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
223986714|NCT01390441|BIOLOGICAL|MabThera® (rituximab)|MabThera® 500 mg/m\^2 or 1000 mg administered by IV on Day 1 and Day 15
223986715|NCT01390441|DRUG|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
223986716|NCT01390441|BIOLOGICAL|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
223986717|NCT01390441|DRUG|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
223986718|NCT01390441|DRUG|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
223544509|NCT02479880|DRUG|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
223986719|NCT01390441|DRUG|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
223986720|NCT00272350|DRUG|Steroids|
223986721|NCT00272350|DRUG|ZD6474|
223986722|NCT04486599|DEVICE|Electromagnetic Navigation|The echo-guided sclerotherapy procedure, assisted by electromagnetic navigation, will be carried out in a clean room during the day hospitalisation and followed by a control Echo-Doppler carried out 2 hours after the procedure.
223986723|NCT02573545|DEVICE|Planning@IFE and Standard@IFE Software|
223986724|NCT02573545|DEVICE|MR Syngo (Numaris/4) software|
223986725|NCT05703152|OTHER|Combined Exercise|Therapeutic exercise program will be applied that will include two modalities: aerobic and resistance exercise. The duration will be 8 weeks with a frequency of 3 sessions per week, with a duration per session of 60 minutes.
223986726|NCT00532246|DRUG|raloxifene|
223986727|NCT00532246|DRUG|Placebo|
223986728|NCT04799847|DRUG|Catumaxomab|This study is conducted in 3 phases sequentially: dose escalation phase, dose expansion phase and dose extension phase. In the dose escalation phase, the preliminary safety and pharmacokinetic profile of catumaxomab by instillation, at 2 dose levels(20ug group and 100ug group）, in NMIBC patients are investigated.
223986729|NCT00752245|PROCEDURE|Dialysis during 4 hours|Blood and dialysate sampling
223986730|NCT00752245|PROCEDURE|Dialysis during 6 hours|Blood and dialysate sampling
223986731|NCT00752245|PROCEDURE|Dialysis during 8 hours|Blood and dialysate sampling
223986732|NCT02039544|DRUG|Xuebi formula|
223986733|NCT02039544|DRUG|placebo|
223986734|NCT00004072|DRUG|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
223986735|NCT00004072|DRUG|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
223544510|NCT02479880|RADIATION|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
223544511|NCT01424943|BEHAVIORAL|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
223544512|NCT01424943|OTHER|BabyNet Services As usual|BabyNet services as usual based on IFSP
223986736|NCT04964895|OTHER|Questionnaires|"Patients will fill in multiple questionnaires for this study :~EORTC quality of life questionnaire (QLQ) QLQ-C30, EORTC Shq22, Male Sexual Health Questionnaire (MSHQ) only for Men, FSFI (only for women)"
223986737|NCT04690478|DEVICE|Electronic remote blood pressure monitor|Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders
223986738|NCT04690478|DEVICE|Ordinary household electronic sphygmomanometer|One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up
223986739|NCT04690478|DEVICE|Office electronic sphygmomanometer|One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
223986740|NCT05005299|DRUG|Venetoclax|Venetoclax is administered as an oral tablet once daily.
223986741|NCT05005299|DRUG|Fludarabine|Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.
223986742|NCT05005299|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
223986743|NCT03833362|DRUG|Narlaprevir|yellow film-coated 100 mg. tablets
223986744|NCT03833362|DRUG|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
223986745|NCT03833362|DRUG|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
223986746|NCT03833362|DRUG|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
223986747|NCT03833362|DRUG|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
223986748|NCT03833362|DRUG|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b"
223986749|NCT04192864|PROCEDURE|Lingually based triangular flap|"A lingually based triangular flap was used to remove the impacted third molar. An incision was made adjacent to the distal surface of the mandibular second molar and extended along the sulcus to the distobuccal corner of the mandibular second molar, an oblique vestibular incision was made and extended into the vestibular fornix of the mandible. Aligned with the mesiobuccal cusp of the second molar.~It was continued posterosuperior towards the anterior border of the mandibular ramus An incision will be made from the anterior border of the mandibular ramus to the distal surface of the mandibular second molar."
223986750|NCT04192864|PROCEDURE|Buccally based triangular flap|The impacted teeth was removed using a buccal based triangular flap. It will be extended along the sulcus to the distobuccal corner of the second molar . The incision was continuous, with a relieving vertical incision, oblique into the mandibular vestibular fornix, aligned with the mesiobuccal cusp of the second molar.
223986751|NCT04703400|OTHER|anonymous survey|anonymous survey with 25 mandatory questions
223986752|NCT01498562|DRUG|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
223986753|NCT01498562|DRUG|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
223986754|NCT01210378|DRUG|Nitroglycerin patch|Nitroglycerin patch
223986755|NCT04731350|DEVICE|radial extracorporeal shock wave|Radial shock wave device, Swiss DolorClast (EMS Electro Medical Systems, Nyon, Switzerland)
223986756|NCT04731350|DEVICE|iontophoresis|Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED):
223986757|NCT04731350|OTHER|Exercise|strengthening exercise
223986758|NCT02754193|OTHER|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
223986759|NCT04912713|OTHER|Stress group|This group will perform the MAST stress protocol
223986760|NCT04912713|OTHER|Control group|This group will perform the MAST control protocol
223986761|NCT01727661|BEHAVIORAL|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
224120354|NCT06930235|DRUG|Weaning critically ill patients from norepinephrine without use of midodrine as an adjuvant|Patients in group II with ongoing intravenous norepinephrine only
224120355|NCT06926023|DEVICE|1550nm non-ablative fractional laser|Treatment with the 1550nm non-ablative fractional laser for female pattern hair loss to the frontal and crown of scalp.
224120356|NCT06926023|DEVICE|1927 thulium fractional laser|Treatment with the 1927 thulium fractional laser for female pattern hair loss to the frontal and crown of scalp.
223544513|NCT05910515|OTHER|Debriefing|Structured debriefing in non-technical skills. (This is an educational study)
223544514|NCT01144143|DRUG|Infliximab|the study drug will be injected into the joint through a needle
223728379|NCT02345850|DRUG|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
223728380|NCT02345850|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
223728381|NCT00720837|PROCEDURE|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
223728382|NCT05296759|DRUG|botulinum toxin A|botulinum toxin A injection
223728383|NCT05296759|DRUG|Gabapentin|Gabapentin oral intake
223728384|NCT05296759|DRUG|Duloxetine|Duloxetine oral drug intake
223728385|NCT02590653|DRUG|Atorvastatin|Lipid-lowering therapy
223728386|NCT04801160|PROCEDURE|REMS+TAI|Radiation-Emitting Metallic Stents (REMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
223728387|NCT04801160|PROCEDURE|SEMS+TAI|Uncovered Self-Expandable Metallic Stent (SEMS) Combined With Trans-Arterial Infusion (TAI) for Unresectable Hilar Cholangiocarcinoma
223728388|NCT01110954|DRUG|PD L 506|Two different doses will be compared
223728389|NCT01045889|OTHER|Rituximab and CHOP regimen + PBSCT|
223728390|NCT06084403|DRUG|20 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine (Buvasin %5 flakon) 20ml will be injected here.
223986762|NCT01727661|BEHAVIORAL|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
223986763|NCT01727661|BEHAVIORAL|quality of life|assessing quality of life using short-forum 36 (questionnaire)
223986764|NCT01613963|DRUG|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
223986765|NCT04776902|BEHAVIORAL|Survey|Patients will fill a questionary with 8 questions.
223986766|NCT02698306|DRUG|Dexamethasone|Dexamethasone
223986767|NCT02698306|DRUG|Diclofenac Sodium|Diclofenac Sodium
223986768|NCT02386878|BEHAVIORAL|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
223986769|NCT02386878|BEHAVIORAL|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
223986770|NCT01764308|DIETARY_SUPPLEMENT|Omega-3|1200mg twice a day for 24 weeks
223986771|NCT01764308|DIETARY_SUPPLEMENT|Placebo|4 tablets twice a day for 24 weeks
223986772|NCT02489409|DRUG|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
223986773|NCT02489409|DRUG|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
223986774|NCT02489409|DRUG|Navelbine|40 mg/d, iv, d1, 8
223986775|NCT02489409|DRUG|Platinum|30 mg/m2, iv 3h, d1-3
223986776|NCT02489409|DRUG|Xeloda Tablets:|2 000 mg/m2, po, d1-14
223986777|NCT01407276|DRUG|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
223986778|NCT01544504|DRUG|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
223986779|NCT06420050|BEHAVIORAL|Instagram Intervention|The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
223986780|NCT00827398|BIOLOGICAL|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
223986781|NCT03035110|BEHAVIORAL|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
223986782|NCT02635386|DRUG|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
223986783|NCT02635386|DRUG|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
223986784|NCT02635386|DRUG|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
223986785|NCT02635386|DRUG|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
224294344|NCT02788149|DEVICE|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as \>50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : \< 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
223544515|NCT01144143|DRUG|Placebo|the placebo will be injected into the joint through a needle
223986786|NCT02635386|DRUG|Phentermine /Topiramate (PHEN/ TPM) ER|PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
223986787|NCT01982409|BIOLOGICAL|Live Attenuated Varicella Vaccine|
223986788|NCT04171349|DRUG|Articaine|Vial
223986789|NCT04171349|DRUG|Dexmedetomidine|Vial
223986790|NCT00715689|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
223986791|NCT00715689|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
223986792|NCT00715689|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
223986793|NCT00715689|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
223986794|NCT00715689|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
223986795|NCT00715689|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
223986796|NCT00715689|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
223986797|NCT00715689|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
223986798|NCT02446613|OTHER|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
223986799|NCT04302129|PROCEDURE|Erector spinae plane block|20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.
223986800|NCT04302129|DRUG|Multimodal analgesia|Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
223986801|NCT02063581|DRUG|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
223986802|NCT02063581|DRUG|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
223986803|NCT04695704|DRUG|Montelukast|10 mg oral montelukast once daily for 28 days
223986804|NCT04695704|OTHER|placebo|10 mg oral placebo once daily for 28 days
223986805|NCT06422442|BEHAVIORAL|Threat-related stimulus exposure|Participants will view threat-related stimuli (words or faces) paired with nonthreat matches in three related experimental paradigms.
223986806|NCT01062269|DRUG|Cholestyramine|Cholestyramine 4 grams one time dose
223986807|NCT01062269|DRUG|Cholestyramine|Cholestyramine 12 grams one dose, one day
223986808|NCT01062269|DRUG|Tang|Tang one dose one day
223986809|NCT02612506|DRUG|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
223986810|NCT02612506|DRUG|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
223986811|NCT04805450|PROCEDURE|ES before fully covered SEMS placement|
223986812|NCT04805450|PROCEDURE|no ES before fully covered SEMS placement|
223986813|NCT00296010|DRUG|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
223986814|NCT00296010|DRUG|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
223986815|NCT00296010|DRUG|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
223986816|NCT00296010|PROCEDURE|adjuvant therapy|
223986817|NCT00296010|RADIATION|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
223986818|NCT04553588|OTHER|Disposal pouch|Medication Disposal Pouch
224294345|NCT05575635|DRUG|fruquintinib + concurrent radiotherapy + chemotherapy|"mFOLFOX6: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days, continuous infusion.~fruquintinib: 3mg/d, qd po, for 7 weeks continuously.~Radiation Therapy: radiation 45.0\~50.0 Gy (1.8-2.0 Gy/day or 25 fractions weeks 3-7)"
223544516|NCT01144143|DRUG|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
223986819|NCT04073797|DRUG|Inclisiran|Inclisiran 284 mg, one injection
223986820|NCT04073797|DIAGNOSTIC_TEST|68Ga-DOTATATE PET-MRI|68Ga-DOTATATE PET-MRI at baseline and 12 weeks
223986821|NCT04073797|DRUG|Colchicine|Colchicine 500 mcg tablet once daily
223986822|NCT05701241|DRUG|Somatostatin analog|Somatostatin analog treatment every 4 weeks
224294346|NCT01995721|BIOLOGICAL|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
223986823|NCT04762303|OTHER|MedReviewRx|During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which: a) identifies potentially inappropriate medications (PIMs), b) explains why the medication is potentially inappropriate and c) provides instructions on how to safely stop/taper the medication.
223986824|NCT05500079|DEVICE|Wrist splint|A wrist splint is a It stabilizes your wrist. Wearing a wrist splint minimizes pressure on the median nerve.
224294347|NCT03353402|PROCEDURE|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
223728391|NCT06084403|DRUG|30 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 30ml will be injected here.
223728392|NCT06084403|DRUG|40 ml volume adductor canal block|ACB will be performed at the end of the surgery. After identifying the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be removed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine(Buvasin %5 flakon) 40ml will be injected here.
223728393|NCT01089959|DRUG|Esomeprazole|40 mg daily for 7 days
223728394|NCT01089959|DRUG|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
223728395|NCT02867189|OTHER|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
223728396|NCT03952000|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
223728397|NCT01347450|DIETARY_SUPPLEMENT|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
223728398|NCT01347450|DIETARY_SUPPLEMENT|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
223728399|NCT02715076|OTHER|Ambient Temperature 19°C|Ambient Temperature 19°C
223728400|NCT02715076|OTHER|Ambient Temperature 21°C|Ambient Temperature 21°C
223728401|NCT02715076|OTHER|Ambient Temperature 23°C|Ambient Temperature 23°C
223728402|NCT02715076|DEVICE|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
223728403|NCT02715076|OTHER|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
223728404|NCT04834427|DRUG|Conventional therapy + S (+)-Ketamine|"In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg."
223728405|NCT04834427|DRUG|Conventional therapy|Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
223986825|NCT05500079|OTHER|Pulsed radiofrequency current|Pulsed rf current is delivered to the median nerve trace via transcutaneous pads. Pain expression is suppressed in the dorsal horn of the spinal cord.
224294348|NCT02972502|DRUG|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
223986826|NCT05979428|DRUG|NNC0491-6075|NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
223986827|NCT05979428|DRUG|Placebo|Placebo matched to NNC0491-6075 will be administered as a subcutaneous injection in a skinfold in the abdomen or intravenously into a vein in the wrist, elbow, or the back of the hand.
223986828|NCT02775305|BEHAVIORAL|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
223986829|NCT00424567|PROCEDURE|Fracture surgery|
223986830|NCT00424567|DRUG|Cultured Bone Marrow Tissue|
223986831|NCT04378374|OTHER|Food-1|Baked food made of lentil flour
223986832|NCT04378374|OTHER|Food-2|Baked food made of lentil flour and wheat flour
223986833|NCT04378374|OTHER|Food-3|Baked food made of wheat flour
223986834|NCT04378374|OTHER|Food-4|Potable water (energy and carbohydrate-free control)
223986835|NCT06140342|BEHAVIORAL|Feasibility study of music-based mobile app|To determine the performance and usability of the app, 20 dyads will be recruited to test it for 2 weeks. The investigators will collect physiological measures based on the application's demonstration to auto-play music according to movement or sedentary states.
223986836|NCT00184379|BEHAVIORAL|Psychoeducation|Structured disorder-related educational program for relatives
223986837|NCT00778921|DRUG|Amlodipine 10 mg|Amlodipine 10 mg
224294349|NCT02972502|DRUG|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
223728406|NCT05219656|DRUG|Cyclosporine A|Rescue therapy in acute severe ulcerative colitis
223728407|NCT03395912|DRUG|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
223728408|NCT01991067|BIOLOGICAL|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
223728409|NCT00378274|BEHAVIORAL|Observation|
223986838|NCT00778921|DRUG|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
223986839|NCT00778921|DRUG|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
223986840|NCT04805073|DRUG|Promethazine|1cc 25mg/ml Promethazine (study medication)
223986841|NCT04805073|DRUG|Placebo|1cc 0.9% Sodium Chloride (placebo)
223986842|NCT01163474|OTHER|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
223986843|NCT02991586|BEHAVIORAL|Dialectical Behaviour Therapy|Group of families
223986844|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).
224294350|NCT02972502|OTHER|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
224294351|NCT02972502|DRUG|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
224294352|NCT05895721|OTHER|Virtual Reality|Virtual Reality as adjunct treatment
224294353|NCT00592202|DEVICE|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
223986845|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).
224120357|NCT06930742|DEVICE|Cognitive-Motor Dual-Task Training|"Participants perform physical exercises using the balance training system and isokinetic muscle strength training system while simultaneously completing cognitive tasks to improve motor-cognitive coordination. The training follows a task-segmentation approach:~Balance Task Module: Participants perform dynamic balance training on the balance training system while engaging in cognitive tasks (e.g., digit span, arithmetic, or word fluency tasks).~Strength Task Module: Participants conduct isokinetic strength training while performing corresponding cognitive tasks.~Task difficulty is progressively adjusted based on participant performance."
223986846|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
224120358|NCT06930742|OTHER|Mindfulness Training|Guided by a professional mindfulness instructor, participants engage in mindfulness meditation to enhance attention, emotional regulation, and cognitive readiness. The training includes breath awareness, body scan, and present-moment awareness, delivered through guided meditation.
224120359|NCT06930742|DEVICE|Single-task Training|Participants perform physical exercises using the balance training system and isokinetic muscle strength training system without any concurrent cognitive tasks. The training follows a task-segmentation approach, including dynamic balance training and isokinetic strength training to enhance motor function.
224120360|NCT06930742|OTHER|Quiet Rest|Participants remain seated in a quiet environment without engaging in mindfulness training or cognitive tasks.
223544517|NCT06110559|DEVICE|Active transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received 1.5 mA stimulation for 30 minutes."
223986847|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
224120361|NCT06930196|OTHER|Counterstrain|Subjects were first analyzed for tissue texture changes with the SA201 then given an osteopathic treatment and analyzed post treatment with the SA201 to analyze for tissue texture changes.
224120362|NCT06930196|OTHER|Muscle Energy|Subjects were first analyzed with the Ultralign SA201/Spineliner, then treated with an osteopathic technique, and then reassessed with the SA201 for tissue texture changes.
224294354|NCT05767203|OTHER|Biological samplings|Blood and/or skin samples
224294355|NCT01047579|DRUG|Rivastigmine transdermal|
223986848|NCT00133575|BIOLOGICAL|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).
224294356|NCT03290287|DRUG|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
223986849|NCT00133575|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
223544518|NCT06110559|DEVICE|Sham transcranial direct current stimulation (tDCS)|"Description of the tDCS session:~* Placement of conductive electrodes, attached to the scalp. The electrodes are placed in individual sponge cases moistened with a saline solution. A sponge towel is placed on the patient's shoulders to prevent any clothing from becoming damp. The electrodes are held in place by a dedicated net.~* The anode is placed in the left supraorbital region (site Fp1 EEG 10/20 system). The cathode was placed in the right supraorbital region (site Fp2 EEG 10/20 system).~* Patients received effective stimulation of 1.5 mA for 30 seconds, after which the current was switched off. The entire session lasted 30 minutes, with 29 minutes and 30 seconds without stimulation."
223544519|NCT03824951|BIOLOGICAL|Anti-CD19 iCAR NK Cells|Anti-CD19 iCAR NK Cells injection
223728410|NCT00653146|BEHAVIORAL|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
223728411|NCT00653146|BEHAVIORAL|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
223728412|NCT02299479|DEVICE|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
223728413|NCT02299479|DEVICE|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
223728414|NCT01012518|DEVICE|Standard PCT|The standard technique, performed without video guidance
223728415|NCT01012518|DEVICE|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
223728416|NCT00543348|PROCEDURE|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
223728417|NCT00543348|PROCEDURE|Balloon angioplasty|HIGH PRESSURE BALLOON
223728418|NCT02066740|DEVICE|EverFlex™ stent with Entrust™ delivery system|
223728419|NCT03600974|PROCEDURE|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
223728420|NCT03600974|PROCEDURE|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
223728421|NCT03600974|DRUG|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
223728422|NCT03600974|DRUG|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
223728423|NCT03600974|DRUG|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
223728424|NCT03600974|DRUG|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
223728425|NCT05455788|DRUG|Aminoglycoside|injection of sewing ring of prosthetic valve with aminoglycoside
223728426|NCT06468631|BEHAVIORAL|Complex Nursing Intervention|"Training prepared as an expert opinion on patient handover, starting to use the standard patient handover form for each patient, ensuring standardization in handover and supporting this improvement work by managers were expressed as interventions.~Training offered; It includes the importance of patient handover, how to ensure standardization and why we should use the standard patient handover form."
223728427|NCT03780868|PROCEDURE|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
223728428|NCT03780868|PROCEDURE|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
223728429|NCT02323230|BIOLOGICAL|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
223728430|NCT02323230|DRUG|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
223728431|NCT04812054|PROCEDURE|Hypothermic oxygenated machine perfusion|Hypothermic oxygenated perfusion using a Liver Assist device (Organ Assist, Groningen, the Netherlands). Temperature of the perfusate will be set to 12 degrees Celsius. Dedicated cannulas will be placed in the aorta for arterial perfusion and in the portal vein for portal perfusion. Pressure will be set at 25 mmHg for arterial line (pulsatile flow, 30 mmHg systolic pressure and 20 mmHg diastolic pressure, 60 beats per minute) and 3 mmHg for portal line (continuous flow). 100% oxygen will be supplied to the oxygenators with a flow of 500 ml / min or higher, in order to achieve pO2 of at least 450 mmHg.
223728432|NCT04812054|PROCEDURE|Simple cold storage|Following back-table preparation, the allograft will either be transferred to the operating room for implantation or stored in preservation solution at 4 degrees Celsius in a refrigerator
223728433|NCT05973383|BEHAVIORAL|LongLife Active- Basic|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars."
223728434|NCT05973383|BEHAVIORAL|LongLife Active- Standard|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Standard are also offered a community with social support."
223986850|NCT00133575|OTHER|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
223986851|NCT02757820|DEVICE|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
223986852|NCT02757820|DEVICE|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
223986853|NCT02757820|DEVICE|Air-Q|Patients will be anesthetized using Air-Q\_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
223986854|NCT01078922|DRUG|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
223986855|NCT04021082|DRUG|Cerdulatinib|Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
223986856|NCT04721964|DIETARY_SUPPLEMENT|Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)|Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
223986857|NCT04583644|DEVICE|Fetoscopic Endoluminal Tracheal Occlusion Surgery|"Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.~Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation."
223986858|NCT04434001|DRUG|Fibrinogen Concentrate Human|Treatment of acquired postoperatively fibrinogen deficiency as assessed by ROTEM FIBTEM test.
224120363|NCT06930196|OTHER|High Velocity Low Amplitude|Subjects were first analyzed for tissue texture changes with the SA201 then given an osteopathic treatment and analyzed post treatment with the SA201 to analyze for tissue texture changes.
224120364|NCT06930196|DEVICE|The Ultralign SA201 used for measuring tissue texture changes|The Ultralign SA201 was used for diagnostic purposes to measure the tissue texture changes of the paraspinal cervical muscles pre and post treatment
224120365|NCT06930196|DEVICE|IsoTouch|The IsoTouch is a palpation monitoring system that uses capacitance pressure sensors in the pads of gloves to measure the palpation pressures used for both diagnosis and treatment using OMT. No sensation is felt by either the subject or operator other than a feeling of a glove being used during treatment. No electrical impulses are sent or should be experienced by either party as the sensors are merely pads that sense pressure.
224120366|NCT03740542|PROCEDURE|Esophagectomy|Surgical removal of part of esophagus
224120367|NCT03740542|PROCEDURE|Pyloroplasty|pyloric drainage procedure
223986859|NCT04434001|DRUG|Prothrombin Complex Concentrate|Treatment of acquired postoperatively thrombin generation deficiency as assessed by ROTEM EXTEM test.
223986860|NCT04434001|BIOLOGICAL|Fresh Frozen Plasma|Treatment of acquired postoperative coagulopathy as assessed by ROTEM FIBTEM and INTEM tests.
223986861|NCT03382769|DEVICE|Cochlear implantation|Unilateral implantation with a commercially approved Nucleus cochlear implant
223986862|NCT05260099|DEVICE|LPS Adsorber|LPS Adsorber, binding endotoxin caused by suspected or verified gram-negative bacteria.
223986863|NCT02706847|DRUG|Placebo|Tablet; Oral
224120368|NCT03531645|DRUG|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
223544520|NCT02550444|DRUG|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
224120369|NCT03531645|DRUG|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
223544521|NCT02550444|DRUG|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
223544522|NCT02550444|DRUG|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
223544523|NCT06288633|PROCEDURE|Ganglionated plexi ablation|"Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size."
223544524|NCT06288633|DIAGNOSTIC_TEST|Electrophysiological study|Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
223728435|NCT05973383|BEHAVIORAL|LongLife Active- Premium|"The digital service LongLife Active with three core subjects:~1\) a Healthy diet, 2) Physical activity, and 3) Mental balance. The service includes tracking and self-monitoring of behaviors, goal setting, action planning, feedback and digital rewards, an AI chat, a database with food recipes, a database with exercises, inspiration, and skills training webinars.~Users with the membership Premium are also offered a community with social support plus private on-line health consultations. The number of private health consultations is 3 for a 3 months subscription, 4 for a 6 months subscription, and 6 for a 12 months subscription."
223728436|NCT01199523|DRUG|Placebo|oral
223728437|NCT01199523|DRUG|mirabegron|oral
223728438|NCT01199523|DRUG|moxifloxacin|oral
223728439|NCT06358365|DEVICE|The AquaPass System|The system is a non-invasive, renal-independent, single-patient, multiple-use device intended for use at the hospital, outpatient clinic, or home. The system administers warm, dry air around the patient's body to create an environmental condition that activates the eccrine glands to produce sweat, in return it removes fluids from the interstitial compartment, where fluids accumulate in fluid overload.
223728440|NCT06083272|DEVICE|Vitalthings Guardian M10 fixed and M10 mobile|VitalThings Guardian M10 / M10 mobile (VitalThings, Norway), are the investigational devices. These are the same technical devices made in two versions: one wall-mounted (VitalThings Guardian M10 fixed) and one mounted on a trolley (VitalThings Guardian M10 mobile). The Nox T3s and Nonin will be used as comparator devices.
223728441|NCT05773508|DEVICE|Video regulation and emergency kit|Video regulation and emergency kit
223986864|NCT02706847|DRUG|Upadacitinib|Tablet; Oral
223986865|NCT01174264|OTHER|Pharmacological Study|Correlative studies
223986866|NCT01174264|DRUG|Vismodegib|Given PO
223986867|NCT00675584|DRUG|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
223986868|NCT00675584|DRUG|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
223986869|NCT00645580|DRUG|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
223986870|NCT01298882|DRUG|Diacerein|
223986871|NCT01298882|OTHER|Placebo|
223986872|NCT02872389|DRUG|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
223986873|NCT02872389|DRUG|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
223986874|NCT03045913|DEVICE|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
223986875|NCT00001107|DRUG|Fluconazole|
223986876|NCT00001107|DRUG|AmBisome|
223986877|NCT01867970|DEVICE|Tool|"The It's LiFe! tool consists of three different elements:~1. the 3D accelerometer (Figure 7-8);~2. the application (app) on a Samsung Smartphone (Figure 6);~3. a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
223986878|NCT01867970|BEHAVIORAL|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
223728442|NCT06334783|BIOLOGICAL|Autologous tumor-infiltrating lymphocyte cells|On day 0, all patients will receive autologous tumor-infiltrating lymphocyte cells administered.
223986879|NCT02353871|BIOLOGICAL|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
223986880|NCT02353871|DRUG|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
223986881|NCT00001649|DRUG|Valaciclovir|
224120370|NCT06904794|BEHAVIORAL|GAMBL-OUT program|The GAMBL-OUT program consists of two sessions: the first one involves a digital escape room to be delivered in the classroom and a series of physical props to be used during the experience. In small groups (4-5 students), participants need to work together to solve different puzzles and riddles, all of them related to the story of young adults who are dealing with problem gambling. By the end of the game, which will have a limited time (50 minutes), each group will have gained access to a different password. The second session will start from here: each group will share their password so the final puzzle can be solved, and the game will conclude with in a group discussion about what was learned (40 minutes).
224120371|NCT03245632|OTHER|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
224120372|NCT04389801|DRUG|Desferal 500 MG Injection|iron chelating agent
223728443|NCT02322918|GENETIC|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
223728444|NCT04590365|DEVICE|Carrageenan nasal and throat spray|Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)
223728445|NCT04590365|DEVICE|Saline nasal and throat spray|Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
223728446|NCT04525664|DRUG|Clarithromycin 500mg|500 mg per os twice daily for 14 consecutive days.
223728447|NCT04525664|DRUG|Amoxicillin 1000 MG|1000 mg per os twice daily for 14 consecutive days.
223728448|NCT04525664|DRUG|Omeprazole 40 MG|40 mg per os twice daily for 14 consecutive days.
223728449|NCT04525664|DRUG|Omeprazole 20 MG Oral Tablet|20 mg per os daily for 1 month; only for patients with chronic dyspepsia and who are negative for Helicobacter pylori.
223728450|NCT01780636|DRUG|botulinum toxin|
223728451|NCT01708681|DIETARY_SUPPLEMENT|Lean seafood|
223728452|NCT01708681|DIETARY_SUPPLEMENT|Meat, egg, milk|
223728453|NCT00464087|DRUG|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
223728454|NCT02442362|DRUG|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
223728455|NCT02442362|DRUG|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
224120373|NCT05725148|DEVICE|CART-I plus|CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
223728456|NCT00814190|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
223728457|NCT00609492|BIOLOGICAL|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
223728458|NCT00609492|BIOLOGICAL|Infanrix™-IPV/Hib|Single dose, intramuscular injection
223728459|NCT00418314|DEVICE|Control|Empiric programming or one-time optimization using a non-IEGM method.
223728460|NCT00418314|DEVICE|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
223728461|NCT00139009|DRUG|Cyclosporine A|
223728462|NCT04849455|DRUG|0.2% ropivacaine local anesthetic continuous erector spinae plane block|Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)
223986882|NCT00571896|DRUG|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
224120374|NCT00719732|DEVICE|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
224120375|NCT06233032|DRUG|Ephedrine|Patient Will receive 6mg IV
223544525|NCT04884607|OTHER|subthreshold low-level autonomic nerve stimulation using external auditory canal electrodes|"* Evaluation of electrocardiogram measurement from external auditory canal electrodes: Participants are required to attach specially designed external auditory canal electrodes to their both ears to record electrocardiogram. Both electrocardiogram from the precordium and the ear would be simultaneously recorded and compared.~* Evaluation of low-level autonomic nerve stimulation using external auditory canal: Using the electrodes described above, Arnold's nerve will be stimulated with low-level electric impulses using TENS device. During and after the stimulation, heart rate variability will be measured to investigate the impact of nerve stimulation on autonomic function modulation on the heart."
223544526|NCT01323985|DRUG|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
223544527|NCT01323985|DRUG|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
223544528|NCT04037098|DIETARY_SUPPLEMENT|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
223986883|NCT00571896|DRUG|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
223986884|NCT00115336|DRUG|Intravenous Ketorolac|Intravenous ketorolac
223986885|NCT00115336|DRUG|Ibuprofen|Ibuprofen, taken orally
223986886|NCT02526186|DEVICE|Battlefield Auricular Acupuncture|
223986887|NCT04115267|RADIATION|Radiotherapy|Combined modality
223986888|NCT00841230|DRUG|Deanxit|Deanxit 1x/day
223986889|NCT00841230|DRUG|Lactose placebo|Lactose used as placebo
223544529|NCT04037098|DIETARY_SUPPLEMENT|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
223544530|NCT03091387|DIAGNOSTIC_TEST|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
223544531|NCT00843336|BEHAVIORAL|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
223544532|NCT00843336|BEHAVIORAL|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
223544533|NCT00005844|DRUG|oxaliplatin|
223728463|NCT04849455|DRUG|0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block|Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr
223986890|NCT04093388|DIAGNOSTIC_TEST|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
223986891|NCT04093388|DIAGNOSTIC_TEST|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
223986892|NCT00762645|DRUG|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
223986893|NCT00762645|DRUG|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
223986894|NCT02128698|DIETARY_SUPPLEMENT|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
224120376|NCT06233032|DRUG|Dexmedetomidine|Patient Will receive 30mcg IV
223728464|NCT04849455|DRUG|Spinal Morphine|200-300 mcg of spinal morphine
223986895|NCT02128698|DIETARY_SUPPLEMENT|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
223986896|NCT02128698|BEHAVIORAL|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
223986897|NCT02128698|BEHAVIORAL|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
223986898|NCT02998398|OTHER|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
223986899|NCT00095043|DRUG|MK0928, gaboxadol|
223986900|NCT00095043|DRUG|Comparator: placebo|
223986901|NCT03634722|DEVICE|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
223986902|NCT00002498|DRUG|CMF regimen|
223986903|NCT00002498|DRUG|cyclophosphamide|
223986904|NCT00002498|DRUG|fluorouracil|
223986905|NCT00002498|DRUG|methotrexate|
223986906|NCT00002498|DRUG|mitoxantrone hydrochloride|
223544534|NCT04469205|OTHER|Coaching sessions|There are 3 sessions : the first session will last 1h30 and will be in consultation within the Institut Curie. The second session will last 1h30 and will be done remotely (by phone or by videoconference). The duration of the 3rd and last session will be adapted according to the needs of each patient and will last a maximum of 1 hour. It will also be done remotely (by phone or by videoconference).
223544535|NCT05801848|DIAGNOSTIC_TEST|[18F]NaF PET/CT scan|Patients will have their lower back scanned using \[18F\]NaF PET/CT
223544536|NCT02533310|OTHER|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
223728465|NCT00017498|DRUG|gemcitabine hydrochloride|
223728466|NCT02692716|DRUG|semaglutide|For oral use once daily.
223728467|NCT02692716|DRUG|placebo|For oral use once daily.
223986907|NCT03581669|DEVICE|Cerclage and total hip arthroplasty|acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
223986908|NCT05434585|BIOLOGICAL|ABO1009-DP|Vaccine
223986909|NCT05434585|BIOLOGICAL|ABO-CoV.617.2|Vaccine
223986910|NCT05434585|OTHER|Placebo|Placebo
223986911|NCT04786613|OTHER|Intra-articular 20 mg, 1.0% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 20 mg 1.0% hyaluronic acid injection in 5 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
223986912|NCT04786613|OTHER|Intra-articular 32 mg, 1.6% Hyaluronic Acid Injection|"Intra-articular 2 ml linearly linked 32 mg 1.6% hyaluronic acid injection in 3 sessions will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
223986913|NCT04786613|OTHER|Intra-articular 48 mg, 2.0% Hyaluronic Acid Injection|"Intra-articular 2,4 ml linearly linked 48 mg 2.0% hyaluronic acid injection in single session will be applied.~As a home exercise program, hamstring and quadriceps stretching, quadriceps isometric strengthening, short arc terminal extension exercises will be given at least three days a week with 3 sets of 10 repetitions."
223986914|NCT01545557|DEVICE|Hyaluronic acid dermal filler gel|1 Emervel Volume injection per indication and 1 touch-up injection if necessary
223986915|NCT00487032|DRUG|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
223986916|NCT00487032|DRUG|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
223986917|NCT00487032|DRUG|Prazosin hydrochloride|Prazosin 1mg one dose only
224120377|NCT03103269|BEHAVIORAL|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
223728468|NCT04478474|DRUG|Ganciclovir|Type of allogeneic transplant, HLA match, graft manipulation, use of ATG and/or Campath, CMV status (donor and recipient), maximal acute GVHD stage and grade, CMV viremia/disease through day +100, days received ganciclovir prophylaxis, adverse events related directly or secondary to ganciclovir prophylaxis.
223728469|NCT03709771|DIAGNOSTIC_TEST|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~Follow-up Visit (approx 1 month after starting treatment): Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
223728470|NCT03980106|OTHER|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
223728471|NCT03980106|OTHER|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
223728472|NCT03421821|DRUG|Ropivacaine|Subfascial injection OR extrafascial injection
223728473|NCT05445986|PROCEDURE|flap elevation and guided bone regeneration|to rebuild the alveolar ridge convexity
223728474|NCT05445986|PROCEDURE|gap filling|to use biomaterials to fill the jumping gap
223728475|NCT05445986|PROCEDURE|connective tissue graft|to change the soft tissue phenotype by connective tissue graft
223728476|NCT01024803|DEVICE|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
223986918|NCT00487032|DRUG|Placebo to Prazosin|Placebo 1 tablet one dose only
223986919|NCT06152679|OTHER|None - qualitative interviews|Qualitative interviews with patients asking about their experience of day-case endourology.
223986920|NCT02326259|OTHER|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
223986921|NCT03434028|DRUG|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
223986922|NCT03434028|OTHER|Early Fluids|"Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
223986923|NCT02712970|PROCEDURE|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
224120378|NCT03103269|OTHER|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
223728477|NCT02284594|BEHAVIORAL|text message|series of text messages regarding influenza vaccination
223728478|NCT05983276|DRUG|Decitabine|Decitabine is classified as hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
224120379|NCT04497246|OTHER|Questionnaire|Data collection by means of various questionnaires
224120380|NCT02004652|DRUG|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
224120381|NCT02004652|DRUG|Placebo|Vitamin, 50mg, tablet.
224120382|NCT00436670|BIOLOGICAL|AMG 317 75 mg|75 mg SC weekly injection
224120383|NCT00436670|BIOLOGICAL|AMG 317 150 mg|150 mg SC once weekly injection
224120384|NCT00436670|BIOLOGICAL|AMG 317 300 mg|300 mg weekly SC injection
224120385|NCT00436670|BIOLOGICAL|Placebo|Placebo SC once weekly injection
223986924|NCT02712970|PROCEDURE|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
223986925|NCT02712970|PROCEDURE|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
223986926|NCT02712970|PROCEDURE|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
223986927|NCT05928663|OTHER|double surgical gloves|In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove
223986928|NCT05928663|OTHER|single surgical gloves|MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
223986929|NCT05115708|PROCEDURE|ab externo viscotrabeculotomy|In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group
223986930|NCT05115708|PROCEDURE|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy|The Kahook dual blade® (KDB) assisted ab-interno trabeculotomy
223986931|NCT04753944|DIETARY_SUPPLEMENT|Active Comparator: Probiotic|The evaluation of the influence of a probiotics therapy on mood improvement and the reduction of depressive symptoms in women in the perimenopausal age group.
223986932|NCT04753944|DIETARY_SUPPLEMENT|Placebo group|Patients will be introduced for 5 weeks with placebo consisting of starch, maltodextrins and vegetable protein. The placebo dose is going to be 4 capsules daily. The treatment will be administered two times a day, during breakfast and supper.
223986933|NCT03729713|OTHER|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
223986934|NCT03729713|OTHER|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
223986935|NCT02578498|DIETARY_SUPPLEMENT|High carbohydrate intake|Carbohydrate intake \< 50 gram
223986936|NCT02578498|DIETARY_SUPPLEMENT|Low carbohydrate intake|Carbohydrate intake \> 250 gram
223986937|NCT02037776|DRUG|Rikkunshito|\- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
223986938|NCT02037776|DRUG|Rikkunshito placebo|\- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
223986939|NCT00763594|BEHAVIORAL|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
223986940|NCT00763594|BEHAVIORAL|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
223986941|NCT04131764|DIAGNOSTIC_TEST|Reflex (Brightlamp Inc., Purdue University)|The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
223986942|NCT04032912|DIAGNOSTIC_TEST|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
223986943|NCT00332969|DRUG|Octreotide|
224294357|NCT03290287|DRUG|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
224294358|NCT03832738|DRUG|JTE-451 Tablets|Active drug tablets containing JTE-451
223728479|NCT05983276|DRUG|Carboplatin|Carboplatin is classified as an alkylating agent that is used to treat ovarian cancer.
223986944|NCT01368237|RADIATION|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
223728480|NCT05983276|DRUG|Paclitaxel|"Paclitaxel is classified as a plant alkaloid, a taxane and an antimicrotubule agent."
223728481|NCT05983276|DRUG|Selinexor|Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
223728482|NCT04252456|PROCEDURE|Aflibercept, 5fluorouracil, Folinic Acid andIrinotecan|All patients will receive aflibercept in combination with FOLFIRI according to the Italian label
223728483|NCT02187185|OTHER|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
223728484|NCT02187185|OTHER|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
223728485|NCT00672412|DRUG|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
223728486|NCT00672412|DRUG|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
223986945|NCT03230825|DRUG|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
223728487|NCT00672412|DRUG|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
223728488|NCT00672412|DRUG|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
223728489|NCT02364973|OTHER|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
223728490|NCT04859023|DIAGNOSTIC_TEST|saliva sample combined to an anterior nare self-swabbing (Self-samples)|Tested by antigenic test.
223986946|NCT03230825|OTHER|Expectant management|No intervention and a follow up visit a wewk later
223728491|NCT04859023|DIAGNOSTIC_TEST|saliva sample (Self-sample)|Tested by RT-PCR.
223986947|NCT03575676|DRUG|SOM3355 100mg BID|Oral
223986948|NCT03575676|DRUG|SOM3355 200mg BID|Oral
223986949|NCT03575676|DRUG|Placebo BID|Oral
223986950|NCT01850537|DEVICE|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
223728492|NCT04859023|OTHER|Survey of SARS-COV-19 knowledge|collection of : socio-professional characteristics, questions on health literacy on the transmission of the virus and barrier gestures, adherence to barrier gestures, isolation modalities in case of positivity, motivations for participating in this screening campaign.
223728493|NCT04859023|OTHER|Survey of acceptability of the different self-samples.|collection of : assessment and acceptability of the tolerance of self-samples.
223728494|NCT02964351|BIOLOGICAL|High PSA levels|
223728495|NCT00468416|DEVICE|Compression Anastomosis Ring (CAR)|
223728496|NCT01012960|DRUG|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
223728497|NCT00972569|DRUG|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
223728498|NCT00972569|DRUG|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
223728499|NCT05431452|OTHER|Pain management|Nonpharmacological pain management during blood collection in preterm infants
223728500|NCT02782780|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
223728501|NCT03562481|DRUG|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
223728502|NCT03562481|DRUG|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
223728503|NCT02075229|DEVICE|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
223986951|NCT00552864|DRUG|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
224294359|NCT03832738|DRUG|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
224294360|NCT01933464|DRUG|Cromolyn Sodium|
224294361|NCT01933464|DRUG|Normal Saline|
223728504|NCT05352334|DIAGNOSTIC_TEST|self-report Emotional Intelligence test (SSCEIT)|The participants fulfilling the inclusion criteria will be selected from above mentioned different government and private universities. The total number of participants in data collection procedure will be 44. Informed consent will be taken from all the students and self-administered questionnaire will be distributed to students for data collection procedure. The emotional intelligence and physical activity will be measured and collected through Schutte self-report Emotional Intelligence test (SSCEIT) and international physical activity questionnaire. The questionnaires for physical activity will consist of 12 questions and for SSCEIT consist of 33 questions. Emotional intelligence will be measured by schutte self-report emotional intelligence scale and physical activity will be measured by international physical activity questionnaire.
223728505|NCT03989453|OTHER|Chi Kung|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
223728506|NCT02061267|DIETARY_SUPPLEMENT|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
223728507|NCT02061267|DIETARY_SUPPLEMENT|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
223728508|NCT02061267|DIETARY_SUPPLEMENT|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
223728509|NCT02061267|DIETARY_SUPPLEMENT|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
223728510|NCT04774107|DRUG|P1101 + Ribavirin|P1101 400 µg SC
223986952|NCT00552864|DRUG|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
223986953|NCT01568385|DRUG|TAK-438|
223986954|NCT01963169|BEHAVIORAL|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
223986955|NCT01963169|BEHAVIORAL|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
223986956|NCT02832349|OTHER|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
223986957|NCT03892005|PROCEDURE|Total Hip Arthroplasty using MOTIVATION HIP Total Hip System|To systemically document the clinical safety and performance of the commercially available MOTIVATION HIP Total Hip System in primary THA.
223986958|NCT01279837|BEHAVIORAL|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
223986959|NCT05354882|BEHAVIORAL|Physical activity program|The single group will access to the twelve-week DEFACTO program containing one adapted physical activity session, two discussion group sessions and several motivational interviewing
223986960|NCT01696786|PROCEDURE|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
223986961|NCT00873327|DRUG|piperacillin-tazobactam|"6 doses intravenously at the following doses:~Infants \<32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6~Infants ≥32 weeks gestation at birth \< 14 days PNA 100 mg/kg Q6~≥ 14 days PNA 100 mg/kg Q6"
223986962|NCT04877613|DRUG|single dose of CART-GFRa4 cells|Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide.
223986963|NCT04877613|DRUG|Fludarabine|Lymphodepletion
223986964|NCT04877613|DRUG|Cyclophosphamide|Lymphodepletion
223986965|NCT02780895|DRUG|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
223986966|NCT01554722|PROCEDURE|Needle placement|In plane versus out of plane needle placement techniques
223986967|NCT01486381|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
223728511|NCT05744544|PROCEDURE|External Oblique Block|Patients will be followed after EOIB which are routinely performed in our clinic.
223728512|NCT05744544|PROCEDURE|m-TAPA block|m-TAPA block
223728513|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 1|Mango (pulp/flesh) (500 g)
223728514|NCT03365739|DIETARY_SUPPLEMENT|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
223728515|NCT03365739|DIETARY_SUPPLEMENT|Control Comparator|Vitamin C (100 mg)
223728516|NCT00269282|BEHAVIORAL|Self-Management Training|Asthma education and self-monitoring strategies
223728517|NCT00269282|BEHAVIORAL|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
223986968|NCT03960853|PROCEDURE|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
223728518|NCT01522989|DRUG|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
223986969|NCT03960853|PROCEDURE|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
223986970|NCT01191008|DRUG|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
223986971|NCT03060018|DEVICE|Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor|The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
223986972|NCT03786744|BIOLOGICAL|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
223986973|NCT03786744|OTHER|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
223986974|NCT05906706|DRUG|dupilumab|Subcutaneous (SC) administration
223986975|NCT04741594|DEVICE|Densah|Alveolar bone remodeling after tooth extraction may result in significant ridge resorption and inadequate bone volume for implant placement. Several methods have been designed for ridge augmentation, among which is the new technique of osseodensification, using the Densah® burs by Versah® (Versah®, LLC, Jackson, MI, USA). This method compresses the trabecular bone to periphery of the osteotomy site and has shown up to 80% ridge expansion in animal histological studies , , , , , . Apart from being an animal model with a short follow-up, another limitation of these studies is the lack of three-dimensional evaluation of the change in morphology of the ridge. Human clinical studies , , , , have reported similar results, but they do not evaluate if this bone volume is retained during osseointegration and loading periods. No standardization method or long-term evaluation of peri-implant health was reported.
223986976|NCT04905849|BEHAVIORAL|Adaptive Cognitive Control Trainer (ACCT)|"Module 1: Attention=\> This module demands an active scan of the screen in search for a target, much like traditional visual search tasks. Participants quickly identify the direction that a probe target is facing (up, down, left, right), and are aided by the presence of directional cue indicating where the location of the target will appear.~Module 2: Goal Management=\> Requires participants to rapidly switch their focus based on distinct rules. Participants are presented with exemplar objects along with a target, and are asked to indicate which exemplar presented is most like the target.~Module 3: Working Memory=\> Engages spatial working memory resources similar to the Corsi block task. Participants memorize the location of objects on screen followed by a 5-7 second delay period, with a correct response leading to a greater number of potential targets to be memorized on the next trial (and vice versa)."
223986977|NCT04905849|BEHAVIORAL|Active Control App|The app used here is undergoing expectancy-matching at the present time, will be updated with the final app characteristics when completed out of a list of several possibilities
223986978|NCT05404555|OTHER|two-dimensional speckle tracking echocardiography|Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients
223986979|NCT04430257|OTHER|HIV and PrEP education|Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.
223986980|NCT04430257|BEHAVIORAL|Motivational interviewing|Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.
223986981|NCT04430257|BEHAVIORAL|Problem-solving and planning|Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.
223728519|NCT01522989|DRUG|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
223728520|NCT01522989|DRUG|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
223986982|NCT04430257|BEHAVIORAL|Patient navigation|Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites
223728521|NCT02050074|DRUG|Colesevelam|
223986983|NCT04430257|OTHER|PrEP information|A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.
223728522|NCT02050074|DRUG|Metformin|
223986984|NCT04430257|OTHER|Referrals|Study staff will provide basic information about PrEP and referrals to PrEP clinicians.
223986985|NCT06464315|PROCEDURE|Functional Substrate-Only Mapping without VT Induction|In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
224294362|NCT04076670|OTHER|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
223986986|NCT06464315|PROCEDURE|Standard-of-Care Mapping/Imaging|Conventional invasive scar (voltage) and electrical VT (entrainment, activation, pace) mapping will be used to guide VT ablation. Functional substrate mapping will not be used in this arm. VT will be induced using standard protocols.
223986987|NCT06523764|DRUG|tegoprazan|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
223986988|NCT06523764|DRUG|Minocycline|tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
223986989|NCT06523764|DRUG|bismuth potassium citrate|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
223986990|NCT06523764|DRUG|Esomeprazole 40mg|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
223986991|NCT06523764|DRUG|Amoxicillin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
223986992|NCT06523764|DRUG|clarithromycin|bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
223986993|NCT05010850|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
223986994|NCT05010850|PROCEDURE|Stoma Creation|Protective ileostomy
223986995|NCT06316700|DIETARY_SUPPLEMENT|Nutritional supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
223986996|NCT06316700|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
223986997|NCT02810873|DEVICE|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
223986998|NCT02810873|DEVICE|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
223544537|NCT02533310|OTHER|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
223544538|NCT06524271|DIETARY_SUPPLEMENT|Fermented Soybean|Same as described earlier
223544539|NCT06524271|DIETARY_SUPPLEMENT|Supplement without fermented soybean|Same as described earlier
223544540|NCT01899430|DRUG|liraglutide|
223544541|NCT01899430|DRUG|metformin|
223544542|NCT04458246|OTHER|Exercise training group|Online aerobic home-based exercise training, 3 times per week, during 3 months. The exercise program is composed by 3 levels (starter, intermediate and advanced) which be completed in the first, second and third month of intervention, respectively.
223986999|NCT02810873|RADIATION|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
223987000|NCT02810873|DRUG|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
223987001|NCT06194331|BEHAVIORAL|iCHART/cASAP|When patients disclose suicidal ideation on the PHQ-9, the intervention of iCHART/cASAP will be implemented in the pediatrician's office, and in collaboration with parents, which includes safety planning, teaching skills to improve distress tolerance and emotion regulation all on the teen's smart device. iCHART/cASAP will include: Screening Wizard, a digital screening tool that will guide the provider to gauge patient satisfaction with current treatment and making further personalized treatment recommendations; cASAP, a computerized version of the As Safe As Possible intervention that focuses on psychoeducation in safety planning, distress tolerance, and emotion regulation skills; BRITE, a safety planning app with distress monitoring that a teen can be guided through with automated onboarding manuals; Text2Connect, an automated text messaging sent centrally to patients and parents to enhance treatment adherence.
223987002|NCT06194331|BEHAVIORAL|Treatment as usual|When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
223987003|NCT05362344|PROCEDURE|Stool tests|Non-invasive, stool-based tests for colorectal cancer screening.
223987004|NCT04683510|OTHER|Navigation - Study Specific - Researcher Voice|The intervention is delivered over the telephone
223987005|NCT04683510|OTHER|Navigation - Study Specific - Cancer Survivor Voice|The intervention is delivered over the telephone
223987006|NCT04683510|OTHER|Navigation - Research General - Researcher Voice|The intervention is delivered over the telephone
223987007|NCT04683510|OTHER|Navigation - Research General - Cancer Survivor Voice|The intervention is delivered over the telephone
223987008|NCT04683510|OTHER|Brochure - Study Specific - Researcher Voice|The invention is mailed to the participant in a brochure.
223987009|NCT04683510|OTHER|Brochure - Study Specific - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
223987010|NCT04683510|OTHER|Brochure - Research General - Researcher Voice|The invention is mailed to the participant in a brochure.
223987011|NCT04683510|OTHER|Brochure - Research General - Cancer Survivor Voice|The invention is mailed to the participant in a brochure.
223987012|NCT06018493|DEVICE|focused power ultrasound mediate inferior perirenal adipose tissue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
223987013|NCT06018493|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
223728523|NCT02050074|OTHER|Placebo|
223987014|NCT06267911|OTHER|Cognitive stimulation and psychological support (RGS-ICU)|The RGS-ICU intervention consists of daily 20-minute sessions of early cognitive stimulation and psychological support adjuvant to standard ICU care administered by research staff and supervised by clinical staff each morning in the patient's own room during ICU admission and until ICU discharge or up to a maximum of 28 days after randomization. The sessions consist of orienting the patient to space and time, cognitive training of attention, working memory, learning/memory, executive function and processing speed, viewing of relaxing videos inspired by nature and fantasy scenarios to reduce stress and anxiety, and psychoeducation about the ICU environment and the characteristics of the cognitive, mental and physical state of critically ill patients.
223987015|NCT05365178|DRUG|TQB3616 capsule|TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
223987016|NCT05365178|DRUG|Placebo|It is a placebo
223987017|NCT05365178|DRUG|Fulvestrant injection|Fulvestrant is a competitive estrogen receptor antagonist, and its mechanism is related to the down-regulation of estrogen receptor (ER) protein level
223987018|NCT02023775|DEVICE|Melody valve implantation|
223987019|NCT03059004|BEHAVIORAL|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
223987020|NCT03059004|BEHAVIORAL|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
223987021|NCT03059004|BEHAVIORAL|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
223987022|NCT03059004|BEHAVIORAL|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
223987023|NCT05901987|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
223987024|NCT04942158|PROCEDURE|Non-instrumentation technique with use of CTZ paste|After local anesthesia and rubber dam isolation, the pulp chamber will be accessed. After the location of root canals entrance, an initial irrigation will be conducted using 1% sodium hypochlorite. Then, a paste containing two antibiotics (chloramphenicol and tetracycline) and zinc oxide and eugenol (CTZ paste) will be placed in the pulp chamber floor, into the root canal entrances. Then, a layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
223987025|NCT04942158|PROCEDURE|Instrumentation technique and filling with Zinc Oxide and Eugenol paste|After anesthesia and rubber dam isolation, pulp chamber will be accessed with burs, and the root canals entrance will be prepared using a Gates Glidden bur. The root canal length determination will be done subtracting 1 mm from the radiographic measurements performed on the different roots. The instrumentation will be performed with 21mm stainless steel endodontic hand K-files, with International Organization for Standardization (ISO) tip ranging from #08 to #35. Irrigation will be performed using 1% sodium hypochlorite. After the last file, a final irrigation will be conducted with ethylenediaminetetraacetic acid and tegentol (EDTA-T) and 0.9% sodium chloride solution, and the root canals will be dried with paper points. Then, the root canals will be filled with a Zinc Oxide and Eugenol paste (ZOE paste), inserted into the root canals with a lentulo spiral. A layer of glass ionomer cement will be placed, and the teeth will be restored with bulk-fil resin composite.
223544543|NCT04062188|OTHER|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire developed based on the combination of Barthel Index questionnaire and simplified modified Rankin Scale questionnaire with internal rules.
223987026|NCT05464641|OTHER|Oxford knee score|The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
223987027|NCT04913948|OTHER|No intervention|No intervention
223987028|NCT06279728|DRUG|Datopotamab deruxtecan|6 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)
224120386|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet (PROMED) Intervention|Researchers will provide individually tailored dietary advice and written materials to encourage 'a little and often' meal plan to support adoption of the PROMED intervention. The daily energy and protein requirements of each participant will be calculated based on National Institute of Health \& Care Excellence guidance for Nutrition Support in Adults at Risk of Malnutrition. Several resources have been developed to facilitate behaviour change: a) A PROMED Diet Information Booklet to include an overview of the PROMED Diet, tips for incorporating more PROMED foods into the diet and information on the health benefits of a PROMED diet, b) A PROMED Recipe Book offering ideas for breakfast, lunch and dinner as well as suitable snack ideas and c) key PROMED foods ordered through a local supermarket's online delivery service and delivered to participants' homes on a weekly or fortnightly basis for the 3-month active intervention phase.
223544544|NCT00845247|OTHER|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
223987029|NCT02591719|DEVICE|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
223987030|NCT02591719|DEVICE|MagPro magnetic stimulator (sham)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
223987031|NCT02591719|DEVICE|MagPro magnetic stimulator (LF rTMS)|"Most activated area from fNIRS findings: Contralesional homologs of Broca's area.~Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session"
223987032|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
223987033|NCT00170313|DEVICE|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
223987034|NCT05255380|BEHAVIORAL|Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day|The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
223987035|NCT05255380|BEHAVIORAL|Mindful awareness and reporting of current thoughts and feelings, 2 times/day|Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
223987036|NCT05446584|DEVICE|High Definition Transcranial Direct Current Stimulation|HD-tDCS for this study is not intended to be a treatment, and will be applied continuously for 30 minutes at sham (0 mA) or 2 mA for active conditions across 3 consecutive daily sessions to probe neural circuit integrity. This specific HD-tDCS device is completely computer driven, running on a laptop using specialized software. Circular electrodes (12-mm in diameter) filled with conductive gel will be placed in a 4x1 ring configuration with the central electrode being the anode surrounded by four cathodes.
223987037|NCT04199052|BEHAVIORAL|LinkPositively|LinkPositively is a culturally tailored, trauma-informed smartphone app for Black women living with HIV/AIDS affected by interpersonal violence. Core components of LinkPositively include: a) Virtual Peer Navigation that includes phone and text check-ins and 4 weekly one-on-one video sessions to build skills to cope with barriers and navigate care; b) Social Networking platform to receive peer support; c) Educational and Self-care database with healthy living and self-care tips; d) GPS-enabled Resource Locator for HIV care and ancillary support service agencies; and e) ART self-monitoring and reminder system.
223987038|NCT01476163|DRUG|migalastat HCl 150 mg|150 mg capsule
223987039|NCT01476163|DRUG|migalastat HCl 20 mg|20 mg dispersible tablets; dosing will be based on body weight
223987040|NCT06555302|BEHAVIORAL|Cognitive Rehabilitation|Cognitive rehabilitation will be OT-led, one-on-one sessions focused on teaching cognitive strategies and their application to a broad set of activities/settings. The goal is to facilitate cognitive skill learning and generalization, by applying the new cognitive strategies to the participant's performance of home-based and community-based activities (taught through the subsequent OT portion of the intervention).
223987041|NCT06555302|BEHAVIORAL|Occupational Therapy|OT upper extremity rehabilitation will have 2 components: task-practice and metacognitive strategy training. The task-practice involves a patient repetitively practicing stroke-impaired movement skills within the context of a functional task to promote recovery of the impaired skills. THE task practice sessions will be coached/guided by the therapist through a metacognitive strategy training process which is based on the Cognitive Orientation to Occupational Performance (CO-OP) approach aimed at enhancing self-management during home and community living tasks.
223987042|NCT05842928|BEHAVIORAL|PARTNER intervention|"The PARTNER intervention includes the following components:~1. Education for health care professionals~   A) written manual on deprescribing PSA-PIM, which consists of brief information and more detailed explanations;~   B) access to digital instructional videos/podcasts that address potential problems in deprescribing and provide possible solutions;~   C) checklist for identification of drug-related problems for pharmacists;~   D) tapering support tool to facilitate the selection of tapering schemes;~   E) divisibility list for PSA-PIM to support the implementation of tapering schemes;~   F) empowerment brochures for patients each focussing on one PSA-PIM subgroup~2. Interprofessional workshop and case conference for GPs and pharmacists~3. Pharmacy visit (brown bag/medication review) including patient empowerment~4. GP practice visit including shared decision making (SDM)"
223987043|NCT05842928|BEHAVIORAL|Control intervention|The control intervention only comprises a pharmacy visit with brown bag review.
223987044|NCT06853340|BIOLOGICAL|blood sampling|Patients with septic shock will have three differents times of blood sampling and of clinical and biological statements. Healthy volunteers will have a unique visit to collect clinical data and blood samples.
223987045|NCT05304208|BIOLOGICAL|Mesopher|autologous monocyte-derived DCs loaded with PheraLys (tumor cell lysate)
223987046|NCT05365802|DRUG|68Ga-FAPi-46|Radiopharmaceutical will be administered via IV
223987047|NCT05365802|PROCEDURE|Computed Tomography|As part of PET/CT scan
223987048|NCT05365802|PROCEDURE|Positron Emission Tomography|As part of PET/CT scan
223987049|NCT05365802|PROCEDURE|High Resolution Computed Tomography|Will be conducted immediately after FAPI PET/CT
223987050|NCT06028438|DRUG|Placebo|Placebo will be administered intravenously.
223987051|NCT06028438|DRUG|Nipocalimab|Nipocalimab will be administered intravenously.
223987052|NCT06028438|DRUG|Certolizumab|Certolizumab will be administered subcutaneously.
223987053|NCT00699842|DRUG|Lenalidomide|"Dose Level Lenalidomide Schedule~1. 15mg/day for d1-21 out of 28 days~2. 20mg/day for d1-21 out of 28 days~3. 25mg/day for d1-21 out of 28 days"
223987054|NCT06356610|OTHER|Test Product A|Use of Test Product A in controlled use and ad libitum use sessions
223728524|NCT01654367|DRUG|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
223728525|NCT00001830|DRUG|Th2 cells in allo HSCTT|
223728526|NCT00001830|DRUG|Th2 Cells|
223987055|NCT06356610|OTHER|Test Product B|Use of Test Product B in controlled use and ad libitum use sessions
223987056|NCT06356610|OTHER|Test Product C|Use of Test Product C in controlled use and ad libitum use sessions
223987057|NCT06356610|OTHER|Test Product D|Use of Test Product D in controlled use and ad libitum use sessions
223987058|NCT06356610|OTHER|Reference Product E|Use of Reference Product E in controlled use and ad libitum use sessions
223987059|NCT06356610|OTHER|Reference Product F|Use of Reference Product F in controlled use and ad libitum use sessions
223987060|NCT06531538|BIOLOGICAL|PG4|Multivalent pneumococcal conjugate vaccine.
223987061|NCT06531538|BIOLOGICAL|20-valent pneumococcal conjugate vaccine (20vPnC)|20-valent pneumococcal conjugate vaccine (20vPnC)
223987062|NCT05939570|OTHER|Interview|Prospective, semi-structured, qualitative interview.
223987063|NCT06188559|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
223987064|NCT05709327|OTHER|Integrating Smart Ring Wearable Technology in Pregnancy Health Monitoring (I-SMART)|Single-arm observational study where all participants in the study will be given a smart ring (Oura Ring) to wear throughout the duration of the study.
223987065|NCT06402006|PROCEDURE|PENG block|pericapsular nerve group block
223987066|NCT06402006|PROCEDURE|LFCN block|Lateral femoral cutaneous nerve block
223987067|NCT06402006|PROCEDURE|ESP block|Erector spinae plane block
223987068|NCT01076998|OTHER|Lubricant eye drop FID 115958D|1 drop in each eye, one time
223987069|NCT01076998|OTHER|Refresh PM Ointment|1 drop in each eye, one time
223987070|NCT03522389|PROCEDURE|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
223987071|NCT03522389|PROCEDURE|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
223987072|NCT03522389|OTHER|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
223987073|NCT04750577|DRUG|Placebo matching BI 685509|film-coated tablet
223987074|NCT04750577|DRUG|BI 685509|film-coated tablet
223987075|NCT05368350|DEVICE|high-definition transcranial direct current stimulation (HD-tDCS)|"Other Names:~tDCS~1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with (1) Pre-SMA stimulation arm -- anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns or (2) LIFG stimulation arm -- at electrode F7 (International 10/10 System for electroencephalography electrode placement) and electrodes T7, FP1, AF3, and FC5 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds."
223987076|NCT04934605|PROCEDURE|Cochlear implantation|Cochlear implantation
223987077|NCT00814645|DRUG|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
223987078|NCT00814645|DRUG|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
223987079|NCT05082207|OTHER|Remote Ischemic Preconditioning|Three cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure of systolic blood pressure plus 50 mm Hg.
223987080|NCT05082207|OTHER|sham group|a deflated cuff placed on the upper arm for 30 min
223987081|NCT04980378|DEVICE|Simplify Disc|The Simplify Disc is a cervical artificial disc manufactured from polyether ether ketone (PEEK) endplates and a mobile, zirconia-toughened alumina ceramic core.
223987082|NCT04599907|DEVICE|Roll-In Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for 10 subjects
223728527|NCT04207970|OTHER|Adapted Structured Clinical Management|Adapted form of a previous Evidence Based Treatment- adapted to local context, in light of input from service-users and commissioners.
223987083|NCT04599907|DEVICE|Randomized Cohort: Single Application of N-SWEAT Patch|Single Application of N-SWEAT Patch in both axillae for subjects randomized to the treatment group
223987084|NCT04599907|DEVICE|Randomized Cohort: Single Application of Sham Patch|Single Application of Sham Patch in both axillae for subjects randomized to the control group
223987085|NCT03192969|DRUG|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
223987086|NCT03192969|OTHER|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
223987087|NCT03192969|DRUG|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
223987088|NCT00370643|DRUG|human regular insulin|
223987089|NCT00311246|DRUG|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.
223987090|NCT03557242|DEVICE|TAVR|Transcatheter Aortic Valve Replacement
223987091|NCT03557242|OTHER|Warfarin plus Aspirin|Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
223987092|NCT03557242|OTHER|Aspirin Only|Subjects randomized to this arm will receive aspirin only post TAVR
223987093|NCT05858398|BIOLOGICAL|pharmacokinetics blood sample assessment|pharmacokinetics blood sample assessment during the first exposure to docetaxel
223987094|NCT01251887|DIETARY_SUPPLEMENT|Linoleic Acid|
223987095|NCT01251887|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|
223987096|NCT01251887|DIETARY_SUPPLEMENT|Eicosapentaenoic Acid|
223987097|NCT02324478|PROCEDURE|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
223987098|NCT02275299|DRUG|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
223987099|NCT02275299|DRUG|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
223987100|NCT02275299|DRUG|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
223987101|NCT06577649|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|cTBS (50 Hz, 600 pulses, 80% resting motor threshold) for 40s was applied continuously as active rTMS at the face representation area of primary somatosensory cortex (S1)
223987102|NCT06577649|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|A sham rTMS was applied using the same stimulation parameters as with cTBS, but using a placebo coil, which produced similar sound as the real coil.
223987103|NCT05488119|BEHAVIORAL|Intervention to increase diabetes technology uptake|The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will also evaluate youth diabetes management and technology use. Families will be compensated in a stepwise fashion. Virtual delivery of the pilot intervention will facilitate national recruitment and allow for recruitment during the pandemic or any ensuing limitations to in-person recruitment. I will recruit 20 families or providers to participate in the delivery of the pilot intervention designed in Phase 1 of the study via a stakeholder advisory board.
223987104|NCT04823117|OTHER|music therapy|music includes nature sounds recommended by the Turkish Psychological Association
223987105|NCT00915785|DRUG|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
223987106|NCT06297031|OTHER|heat application|• Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
223987107|NCT03668223|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
223987108|NCT01103232|PROCEDURE|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
223987109|NCT01103232|PROCEDURE|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
223987110|NCT05742568|DRUG|Esomeprazole|High-dose dual therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablet TID plus amoxicillin 500 mg 2 capsules TID
223987111|NCT05742568|DRUG|Amoxicillin|High-dose dual therapy: given for 14 days at a dose of amoxicillin 500 mg 2 capsules TID plus esomeprazole 20mg 2 tablet TID
223987112|NCT05742568|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
223987113|NCT05742568|DRUG|Esomeprazole|BBismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
223987114|NCT05742568|DRUG|Amoxicillin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
223987115|NCT05742568|DRUG|Clarithromycin|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID, amoxicillin 500mg 2 capsules BID and clarithromycin 250mg 2 tablets BID
223987116|NCT03115671|DIETARY_SUPPLEMENT|Vayarin|Vayarin capsule
223987117|NCT04938934|BEHAVIORAL|Lipids infusion|Lipids infusion via intestinal tube
223987118|NCT04938934|BEHAVIORAL|Sham infusion|Sham infusion via intestinal tube
223987119|NCT04156893|BIOLOGICAL|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
223987120|NCT04498754|BEHAVIORAL|Cognitive Behavior Therapy for Insomnia|8 sessions of treatment for insomnia.
223987121|NCT04498754|BEHAVIORAL|Weekly phone contacts|Weekly calls to monitor insomnia symptoms.
223987122|NCT01793662|PROCEDURE|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
223987123|NCT06022055|OTHER|Blood and tissue collection|"Blood will be collected for group 1 during (i) the enrolment visit, (ii) in the 24 hours following a seizure, (iii)before the surgery and (iv) in the 36 months following the surgery. The left-over tissue, not useful for diagnostic purpose, will be kept for research.~Blood will be collected for group 2 right before the surgery and in the 36 months following the surgery. The left-over tissue not useful for diagnostic purpose will be kept for research."
223987124|NCT04919382|BIOLOGICAL|Atezolizumab|Given IV
223987125|NCT04919382|DRUG|Temozolomide|Given PO
223987126|NCT06603064|DEVICE|Active continuous theta burst stimulation|This intervention involves an active form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
223987127|NCT06603064|DEVICE|Sham continuous theta burst stimulation|This intervention involves an sham form of continuous theta burst stimulation (cTBS) that will be targeted to the dorsal anterior cingulate cortex based on neural navigation software. cTBS will be delivered in one session, lasting a few minutes, before participants complete additional testing.
223987128|NCT05660031|PROCEDURE|LHB Tenotomy|Will be performed arthroscopically by cutting the LHB at its origin with arthroscopic scissors
223987129|NCT05660031|PROCEDURE|LHB Tenodesis|"ill be performed arthroscopically with a tenodesis at the top of the articular margin using an onlay technique."
223987130|NCT03906032|DEVICE|TFNA IM Nail|IM nail
223987131|NCT03906032|DEVICE|Sliding hip screw|SHS surgical fixation
223544545|NCT04335630|DIAGNOSTIC_TEST|Electrocardiogram, telemetry, echocardiogram, laboratory values|Serial electrocardiograms, telemetry monitoring, echocardiographic assessment and serial laboratory testing will be used to identify differences among the two study groups.
223728528|NCT00777478|DRUG|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
223987132|NCT06860971|DRUG|AL2846 Capsules|AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET).
223987133|NCT06860971|DRUG|AL2846 Placebo|AL2846 Placebo without drug substance.
223987134|NCT06242925|DEVICE|AbCLO (Abdominal Wall Closure) Device|They will receive the standard of care (Lahey bag covering the bowel, 2 drains in the subcutaneous tissue and Ioban covering everything). The AbClO device has two Rectus Muscle Splints (RMS) to stabilize the rectus abdominis (preventing buckling of these muscles and stabilize the circumferential dynamic retainer (CDR)). The CDR is passed behind the patient's back. The RMSs are positioned on the abdominal wall approximately 2 cm lateral to the wound edges on each side. Additional padding can be applied underneath the RMS. The CDR is passed between the cross bar and the locking strip of each RMS and stretched until taut. The locking strips are locked in position. Four tensioners bridge across the OA from one RMS to the other. Gauze packs should be interposed between the undersurface of the tensioners and the surface of the temporary abdominal coverage to prevent friction. The Tensioners are tightened progressively until complete facial closure.
224294363|NCT03351387|COMBINATION_PRODUCT|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
223987135|NCT06371586|DRUG|Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy|Albumin paclitaxel+SOX+BEV bi weekly neoadjuvant therapy for 6 cycles, with PD-1 monoclonal antibody therapy interspersed for 4 cycles. Review CT and gastroscopy every 3 cycles to evaluate the therapeutic effect. Patients who have been evaluated as effective after 6 cycles of treatment may consider surgery; Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles. Afterwards, the therapeutic effect will be evaluated, and surgery, radiotherapy, or maintenance medication treatment will be determined based on the therapeutic effect. Surgical patients begin adjuvant treatment 1-2 months after surgery based on the curative and pathological results of the surgery. Those who fail to evaluate during neoadjuvant therapy will undergo surgery or radiation therapy, or switch to a second-line systemic treatment plan.
223987136|NCT05347485|DRUG|Cilta-cel|Cilta-cel will be administered as an IV infusion.
223987137|NCT05347485|DRUG|Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)|Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.
223987138|NCT05423041|DIAGNOSTIC_TEST|BOSS Imaging|Biomechanical Imaging of Cornea and Lens
223987139|NCT05414019|OTHER|Mini-screw|7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
223987140|NCT05414019|OTHER|Utility arch|7 patients will receive an intrusive force delivered by intrusive utility arch.
223987141|NCT05414019|OTHER|Nitinol reverse curve wire|7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
223987142|NCT04634227|DRUG|Ascorbate|Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
223987143|NCT06619210|DRUG|HL231 Dose 1/2/3/4|HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
223987144|NCT06626711|DRUG|Propofol|Propofol as a part of total venous anesthesia
223987145|NCT06626711|DRUG|Sevoflurane|Sevoflurane as a part of intravenous anesthesia
223987146|NCT06694155|DIETARY_SUPPLEMENT|Whey Protein Isolate Crossover|This crossover intervention includes 1 week of whey protein isolate supplementation and 1 week of placebo supplementation.
223987147|NCT06694155|DIETARY_SUPPLEMENT|Placebo|1 week of Non-whey protein Placebo supplement
224120387|NCT05166564|BEHAVIORAL|A Protein Enriched Mediterranean Diet & Exercise (PROMED-EX) Intervention|Participants will receive a dietary intervention identical to PROMED participants, plus an exercise intervention. The home-based exercises are based on a modified version of the 'ExWell@home' programme developed by health professionals with significant expertise in community-based exercise rehabilitation for chronic disease. Cardiorespiratory fitness will be determined using a 3-minute step test and pulse rate. Participants will receive access to pre-recorded exercise classes and a written resource designed for older adults (ExWell@home) and adapted for the current study. Participants will be encouraged to complete two sessions per week (30-60 minutes per session). To cater for differing abilities, four levels of classes will be available for participants: Chair based, basic, standard and advanced.
223728529|NCT05657314|DIETARY_SUPPLEMENT|Active Comparator|Consists of 15 grams of pea protein
223544546|NCT03345446|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
223728530|NCT04478955|DIAGNOSTIC_TEST|Schirmer test|Tear tests Meibomian gland grading test
223987148|NCT00610571|DRUG|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
223987149|NCT06888427|OTHER|Questionnaires|With the help of a questionnaires, determination of postoperative sleep quality
223987150|NCT06724510|DEVICE|HIFU treatment with ULTRAFOMER MPT|The high-intensity focused ultrasound (HIFU) treatment, which is the primary intervention being evaluated for efficacy and safety in eyebrow lifting.
223544547|NCT03263325|OTHER|Discarded urine sample|Collection of discarded urine during surgery and following surgery
223544548|NCT00856635|DRUG|Glatiramer Acetate|20 mg injected daily subcutaneously
223544549|NCT00856635|DRUG|placebo|injected daily subcutaneously
223544550|NCT04293276|DRUG|Pyrotinib|Pyrotinib Tablets
223987151|NCT06765902|DRUG|N-803|A subcutaneous injection of an IL-15 superagonist.
223987152|NCT06765902|DRUG|ETBX-071|A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.
223987153|NCT06765902|DRUG|M-CENK|An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.
224294364|NCT04269733|DEVICE|Right ventricular pacing|Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
223544551|NCT04293276|DRUG|SHR6390|SHR6390 Tablets
223544552|NCT04478903|OTHER|Questionnaire|Zarit Burden Inventory French version and SF12
223544553|NCT02479958|PROCEDURE|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
223544554|NCT02479958|PROCEDURE|Tooth drying|The tooth was dried with air jet.
223544555|NCT02479958|PROCEDURE|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
223544556|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
223987154|NCT06326554|BEHAVIORAL|Virtual and in-person Symptom screening with Targeted Early Palliative care (STEP2)|Study nurse will offer a palliative care clinic visit referral alongside usual cancer care to participants who report moderate to high symptom burden.
223987155|NCT06893406|DIAGNOSTIC_TEST|Cervical MRI|Participants whose history and physical exam indicate signs or symptoms of cervical myelopathy will be scheduled for a cervical MRI.
223987156|NCT06893406|OTHER|History & Physical Exam|A history and physical exam to evaluate for specific signs and symptoms of cervical myelopathy will be performed.
223728531|NCT00481000|BEHAVIORAL|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
223728532|NCT01417273|DIETARY_SUPPLEMENT|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
223728533|NCT01417273|DRUG|Drug: placebo|1 cap placebo/day for 12 month
223728534|NCT04390945|DRUG|Camrelizumab|Camrelizumab combined with concurrent radiotherapy and chemotherapy
223987157|NCT06773000|DIETARY_SUPPLEMENT|XR™ Recovery Supplement|Participants will receive a total daily dosage of 59.2 grams of XR™ Recovery Supplement orally, divided into two doses of 29.6 grams each (or two pouches). The dosing regimen will begin upon hospital admission and continue for three weeks post-operatively.
223728535|NCT05841394|DRUG|Esomeprazole 40mg|40 mg i.v. twice daily (q12h)
223987158|NCT06773000|DIETARY_SUPPLEMENT|XR Carbohydrate Loading Supplement|2 packets of XR Carbohydrate Loading will be administered the evening before surgery and one packet on the day of surgery up to 2 hours prior to the scheduled operating time. The powder will be mixed with 14 oz of room temperature water only until dissolved then may be served over ice for desired temperature of consumption by the participant.
223987159|NCT05501665|PROCEDURE|Biospecimen Collection|Correlative studies
223987160|NCT05501665|DRUG|Carboplatin|Given carboplatin
223987161|NCT05501665|PROCEDURE|Computed Tomography|Undergo PET/CT
223987162|NCT05501665|OTHER|Fludeoxyglucose F-18|Given IV
223728536|NCT05841394|DRUG|Ilaprazole Sodium|10 mg i.v. once daily, 20 mg i.v. in the first day.
223728537|NCT05841394|DRUG|Placebo 1|Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
223728538|NCT05841394|DRUG|Placebo 2|Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
223728539|NCT00294268|BEHAVIORAL|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
223728540|NCT03750604|DIAGNOSTIC_TEST|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ \[36.58 + (1.89 × BMI)\] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / \[39.68 + (1.88 x BMI)\] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
223728541|NCT03247530|DRUG|Placebo|Placebo was administered once daily
223728542|NCT03247530|DRUG|100mg SPN-812|100mg SPN-812 was administered once daily and compared to placebo
223728543|NCT03247530|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
223728544|NCT00635960|DRUG|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
223728545|NCT00635960|DRUG|Placebo|Same as for Growth hormone group
223987163|NCT05501665|DRUG|Nab-paclitaxel|Given nab-paclitaxel
223987164|NCT05501665|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
223987165|NCT05501665|DRUG|Pemetrexed|Given pemetrexed
223987166|NCT05501665|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223987167|NCT05501665|RADIATION|Radiation Therapy|Undergo radiation therapy
223987168|NCT05501665|OTHER|[18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan|Undergo PET scan
223987169|NCT05501665|BIOLOGICAL|Ipilimumab|Given Ipilimumab
223987170|NCT05501665|BIOLOGICAL|Nivolumab|Given Nivolumab
223987171|NCT05501665|BIOLOGICAL|Cemiplimab|Given Cemiplimab
223987172|NCT05501665|BIOLOGICAL|Atezolizumab|Given Atezolizumab
223987173|NCT06899711|DEVICE|External Cranial Prosthesis|The external cranial prosthesis is a 3D printed external plate that approximates patients' post-craniectomy skull defect. The prosthesis is made from the same material used in other external Craniofacial prostheses. Patients will be counseled on securing it properly and comfortably on their scalp. Patients will be asked to wear this prosthesis as much as possible until Cranioplasty takes place. After Cranioplasty, the participant will be asked to stop wearing the prosthesis.
223987174|NCT06494904|DRUG|Buprenorphine|All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
223987175|NCT03733899|DIAGNOSTIC_TEST|Local Anesthesia|Minims Proxymetacaine hydrochloride Eye Drops
223987176|NCT03733899|DIAGNOSTIC_TEST|Placebo|Sodium Chloride Solution
223987177|NCT03716765|DIETARY_SUPPLEMENT|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
223987178|NCT05820698|OTHER|The Mediterranean style diet|"Participants in the Mediterranean style diet group will be provided with recommendations to include a minimum of 5 servings of fruits and vegetables (combined) per day, 2 servings of whole grains per meal per day, at least two servings of extra virgin olive oil per day, a maximum two servings of dairy products per day (excluding milk in coffee/tea), a minimum of 3 servings of fish per week (of which two should be oily fish), less than 2 servings of red meat or processed meat per week. Confectionary and sugar sweetened beverages should be limited to less than 2 servings per week.~Participants randomised to the Mediterranean style intervention will be provided with support documents including a dietary guideline booklet, recipes, meal plans, shopping and product swap lists, as well as eating-out and budget-eating advice sheets. Food deliveries containing key food items of the diet intervention will be scheduled for week 1, week 4, and week 8 of the study."
223987179|NCT05820698|OTHER|The UK diet|"Participants in the UK diet with time-restricted eating group will be provided with recommendations of a nutritionally balanced diet, corresponding to the average intakes of the UK population. Participants will be advised to consume no more than 4 portions of fruits and vegetables combined per day, to have at least two servings of dairy per day, to limit the consumption of white fish to less than 1 serving per week, with ≤1 serving of oily fish per month. Nuts and seeds consumption should also be limited to ≤1 serving per week and at least 3 servings of white and red meat should be consumed per week.~Participants randomised to the UK diet will be provided with support documents including a dietary guideline booklet, recipes, and meal plans. A £30 reimbursement will be provided to participants for their grocery shopping on week 1, week 4, and week 8 of the study."
223987180|NCT05820698|OTHER|Time-restricted eating|Participants randomised to the time-restricted eating interventions will be advised to limit food intake to a 10-hour eating window and to abstain from food intake for a 14-hour fasting window. Hydration is to be maintained during the fasting window with water and/or plain teas/coffees
223987181|NCT06525636|DRUG|KK8123|Subcutaneous administration
223987182|NCT02646839|DEVICE|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
223987183|NCT06857474|PROCEDURE|Bristle Brush Polishing|After ultrasonic scaling, teeth will be polished using a bristle brush attached to a low-speed contra-angle handpiece with prophylaxis paste in a circular motion for 10 seconds.
223987184|NCT06857474|PROCEDURE|Rubber Cup Polishing|After ultrasonic scaling, teeth will be polished using a rubber cup attached to a low-speed contra-angle handpiece with prophylaxis paste in a circular motion for 10 seconds.
223987185|NCT06857474|PROCEDURE|Air Polishing|After ultrasonic scaling, teeth will be polished using sodium bicarbonate air polishing with an air polishing device in a circular motion for 10 seconds.
223987186|NCT06857474|PROCEDURE|Ultrasonic Scaling|Teeth in the control group will undergo ultrasonic scaling only, with no additional polishing procedures.
223987187|NCT05961449|BEHAVIORAL|Cycling exercise|Participants will complete an experimental exercise that will consist in 25 minutes of cycling between 60-80 Revolution Per Minute (RPM) on a cycle ergometer (CST BX40; Cardiostrong; Germany) at ≥ 70% of the Heart Rate Reserve (HRR).
224294365|NCT01774279|OTHER|Tissue, blood and clinical data collection|
223987188|NCT05961449|BEHAVIORAL|Cycling control|The control condition will include an exercise design similar to the experimental condition except that the resistance will be kept at 25 W and the RPM below 50. The intensity of the exercise will be kept at minimal levels by ensuring that the heart rate does not increase \>25% from baseline.
223987189|NCT06907628|DRUG|SHR-3792 Injection|SHR-3792 injection.
223987190|NCT06829836|BEHAVIORAL|Hight intensity interval training|Participants assigned to this intervention group will complete 6 supervised HIIT sessions over 2 weeks.
223987191|NCT06829836|BEHAVIORAL|Cyclic Hyperventilation with Retention|Participants of this intervention group will complete a total of 10 remote guided breathing sessions on Zoom over 2 weeks.
223987192|NCT06044649|BEHAVIORAL|Cognitive Behavioral Therapy|CBT endorses a pain management model and teaches people skills to cope with chronic pain.
223987193|NCT06044649|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
224120388|NCT06018350|BEHAVIORAL|Clinician-led adherence intervention|The clinician will review real time pharmacy refill data during clinic and use effective communication techniques to discuss adherence with the patient
224120389|NCT06135753|OTHER|psychosomatic intervention based on cognitive restructuring.|Participants will receive information on psychosomatic phenomena and over-listening of somatic manifestations (Session 1), interpretation and possible catastrophization of somatic manifestations even when they might be well-known health problems or potential physiological or para-physiological manifestations (Session 2), pain-proneness (Session 3) and mental pain and psychological distress in somatizers (Session 4). The second part of each session will be devoted to group cognitive restructuring, thus participants will be stimulated in verifying how the phenomena illustrated are in their lives and how they can be differently conceptualized in order to be less intrusive and less able to reduce their own functioning.
223728546|NCT05263323|OTHER|Patient education|Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
223728547|NCT05263323|OTHER|Data Collecting, No Education|Data were collected at the beginning and end of the study without training the control group.
223728548|NCT05953220|OTHER|Exclusive tobacco smoking|No intervention, participants own tobacco products
224120390|NCT06135753|BEHAVIORAL|Control condition|The control condition will include 4 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health.
224294366|NCT01405287|DEVICE|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
224294367|NCT00442000|PROCEDURE|Prostatectomy|Patients undergoing prostatectomy.
224294368|NCT04794387|BIOLOGICAL|Amended LLS COVID-19 Registry|Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?
223987194|NCT06044649|BEHAVIORAL|Emotional Awareness and Expression Therapy|EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
223987195|NCT06044649|OTHER|Treatment as Usual|Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.
223987196|NCT06933901|PROCEDURE|Oocyte retrieval|Oocyte retrieval is performed at the end of ovarian stimulation (OS) to collect oocytes for use in IVF or ICSI cycles.
223987197|NCT06944990|BEHAVIORAL|Meta self-efficacy internet intervention|The meta self-efficacy intervention is a three-week program comprised of activities designed to enhance meta self-efficacy (the ability to leverage self-efficacy sources). The intervention is contextualized to young employees.
223987198|NCT06944990|BEHAVIORAL|Placebo|The placebo condition contains educational material delivered with the same modality as in the experimental condition.
223987199|NCT06945770|BEHAVIORAL|POLSIS|web based smoking cessation psycho-education
223987200|NCT06945770|DRUG|routine service delivery(Nicotine Replacement Theraphy, Cytisine)|routine smoking cessation service delivery
223987201|NCT01321983|OTHER|Inspiratory muscular training - IMT|
223987202|NCT06944366|OTHER|Imagery intervention|Imagery rescripting or imaginal exposure
223987203|NCT06945445|DRUG|SLN12140|SLN12140 for sc injection or IV infusion
223987204|NCT06945445|OTHER|Placebo|Placebo for sc injection or IV infusion
223987205|NCT00873262|DRUG|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
223987206|NCT00873262|DRUG|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~1. Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~2. Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~3. Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
223987207|NCT02531854|DRUG|ADXS11-001|ADXS11-001 is a live attenuated Listeria monocytogenes (Lm) bacteria bioengineered to secrete an antigen-adjuvant fusion protein (tLLO¬HPV-E7) consisting of a truncated fragment of the listeriolysin O (tLLO) fused to the full length E7 peptide of HPV-16.
223987208|NCT02531854|DRUG|Pemetrexed|Chemotherapy
223987209|NCT03371147|OTHER|CancerLife|CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.
223987210|NCT04650698|DRUG|Tranexamic acid (TXA) injection|IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
223987211|NCT00616824|PROCEDURE|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
223987212|NCT00616824|PROCEDURE|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
223987213|NCT03527641|BEHAVIORAL|CookingMatters|Nutrition education and hands-on cooking lessons for the whole family
223987214|NCT03527641|BEHAVIORAL|Parent Education|Parenting, physical activity and nutrition education, and family health education for parents
223728549|NCT05953220|OTHER|Exclusive e-cigarette use|No intervention, participants own e-cigarette products
223987215|NCT03527641|BEHAVIORAL|Physical Activity|Physical fitness activities for teens
223987216|NCT03527641|BEHAVIORAL|Health Education|Health knowledge curriculum for adolescents
223987217|NCT03527641|BEHAVIORAL|Mindfulness-based Stress Reduction|Adolescent mindfulness curriculum
223987218|NCT03527641|BEHAVIORAL|Brief Mindfulness Intervention|Parent-based education and experiential learning of mindfulness-based tools
223987219|NCT02559401|OTHER|MRI|
223987220|NCT02559401|OTHER|Neurocognitive battery|
223987221|NCT02069197|OTHER|Ketogenic diet|ketogenic diet will consist of 3:1\[fat\]:\[protein+carbohydrate\]weight ratio with 1600 kcal restriction. Diet will last 9 months.
223987222|NCT02069197|DRUG|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
223987223|NCT02069197|OTHER|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
223987224|NCT00855790|OTHER|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
223987225|NCT02149238|DIETARY_SUPPLEMENT|flavanol|
223987226|NCT02149238|DIETARY_SUPPLEMENT|methylxanthine|
223987227|NCT02149238|DIETARY_SUPPLEMENT|flavanol + methylxanthine|
223987228|NCT01144390|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
223987229|NCT01144390|DRUG|methadone maintenance treatment|methadone maintenance treatment
223987230|NCT03778294|PROCEDURE|Computed Tomography|Undergo PET/CT
223987231|NCT03778294|OTHER|Fluorodopa F 18|Given IV
223987232|NCT03778294|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223987233|NCT03778294|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
223987234|NCT03778294|RADIATION|Proton Beam Radiation Therapy|Receive proton beam RT
223987235|NCT03778294|OTHER|Quality-of-Life Assessment|Ancillary studies
223987236|NCT03778294|OTHER|Questionnaire Administration|Ancillary studies
223728550|NCT05953220|OTHER|Dual use of e-cigarettes and tobacco smoking|No intervention, participants own tobacco and e-cigarette products
223987237|NCT03778294|DRUG|Temozolomide|Drug
223987238|NCT04259697|OTHER|Clinical pilates|Clinical pilates exercises will be performed progressively. The duration of each exercise session will be an average of 40 minutes initially and then will be increased to 60 minutes as the program progress.
223987239|NCT04259697|OTHER|Whole body vibration|Whole body vibration exercises will be performed using the Power Plate pro5 AIRdaptive machine.The duration of each exercise session will be an average of 20 minutes initially and then will be increased to 30 minutes as the program progress.
223987240|NCT01641653|OTHER|Normal saline|Normal saline 2cc. one dose prior to OR
223987241|NCT01641653|DRUG|Midazolam|1-2.5 mg
223987242|NCT01511497|BIOLOGICAL|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
223728551|NCT05953220|OTHER|No use of e-cigarettes or tobacco smoking|No intervention
223987243|NCT01511497|OTHER|Normal saline|Intravenous, normal saline
223987244|NCT01197612|DRUG|pulmicort|applied to nasal packing after surgery
223728552|NCT00936585|OTHER|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
223728553|NCT01413529|BEHAVIORAL|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
224294369|NCT01888575|DRUG|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
223728554|NCT01413529|BEHAVIORAL|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
223728555|NCT01442493|OTHER|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
223728556|NCT01442493|OTHER|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
223987245|NCT03484494|DEVICE|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
223987246|NCT04928807|COMBINATION_PRODUCT|Short course radiotherapy sequential camrelizumab and chemotherapy|Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
223987247|NCT01473745|PROCEDURE|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
223987248|NCT01473745|PROCEDURE|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
223987249|NCT02230722|BEHAVIORAL|Motivational Interviewing|
224294370|NCT01352728|DRUG|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
224294371|NCT00468078|PROCEDURE|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
224294372|NCT00468078|DRUG|F-18 FPCIT|5mCi, intravenous injection
224294373|NCT01801683|OTHER|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
224294374|NCT05734131|OTHER|Bio-psychosocial assessment|Kinematic parameters were analyzed by two functional tests, the 10-Meter Walking Test (10MWT) and the Time Up\&Go test (TUG).
223728557|NCT05885204|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted laparoscopic radical cystectomy
223728558|NCT05885204|PROCEDURE|Conventional laparoscopic radical cystectomy|Conventional laparoscopic radical cystectomy
224294375|NCT04912882|DIAGNOSTIC_TEST|Circulating tumor cell|detecting circulating tumor cell pre- and post operatively
224294376|NCT00227331|DRUG|Oral amoxicillin|
224294377|NCT03580291|OTHER|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10\^6/kg body weight
224294378|NCT03580291|DRUG|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
224294379|NCT03580291|OTHER|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
224294380|NCT03580291|DRUG|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
224294381|NCT05877391|BEHAVIORAL|SGM Communication Intervention|Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
224294382|NCT03763760|DRUG|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
223987250|NCT02230722|BEHAVIORAL|Attention Control|
223987251|NCT03225898|OTHER|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
223987252|NCT03225898|OTHER|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
223987253|NCT02155049|DRUG|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
223987254|NCT04470661|DIAGNOSTIC_TEST|Ultrasonography|"Point-of-care ultrasound:~1. Kidney length and echogenity,~2. Bladder scanning~3. VCI measures~4. Lung B lines and effusion~5. Cardiac measurements; EF, TAPSE, TR Vmax, Diameters, LV filling pressures"
223987255|NCT03996265|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224120391|NCT06135753|OTHER|Experimental and control condition: Museum therapy|"Session 5-6-7: preselected painting works from the Uffizi Galleries (Florence) will be presented to the participants in order to trigger reflections and emotional responses on specific pain related topics. Session 8: visit the Galleria di Arte Moderna at Palazzo Pitti, in person. Each session will be aimed at facilitating emotional expressions and partecipants' behavioral activation and identifying thoughts associated with those emotions and, if appropriate, remodulating them in a functional way (cognitive restructuring).~Session 9: share the experience of the previous meetings and to recap strategies and skills which could be implemented in FM participants' daily life to cope with their illness."
224120392|NCT03625986|OTHER|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 58 mg/mL of nicotine."
224120393|NCT03625986|OTHER|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a pod-based device and comprises a replaceable pre-filled liquid reservoir (pod) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
224120394|NCT06787781|DRUG|Alpha Lipoic Acid|ALA was administrated in capsules at a xed oral daily dose of 600 mg for the entire duration of the study in addition to the atypical antipsychotic therapy.
223987256|NCT03996265|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
223987257|NCT03996265|OTHER|Placebo Administration|Given PO
223987258|NCT03996265|OTHER|Quality-of-Life Assessment|Ancillary studies
223987259|NCT03996265|OTHER|Questionnaire Administration|Ancillary studies
223987260|NCT03376035|OTHER|Temperature measurement of breast|Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
223987261|NCT04992754|BEHAVIORAL|psychotherapy, lifestyle counseling|psychotherapy, lifestyle counseling
223987262|NCT03480113|BEHAVIORAL|Mindfulness-based Intervention|mindful breath, body scan, sitting meditation and walking meditation and so on.
223987263|NCT03480113|BEHAVIORAL|Physical fitness intervention|giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
223987264|NCT06146192|DRUG|Colchicine|colchicine 1-2 mg/day
223987265|NCT00171236|DRUG|Fluvastatin|
223987266|NCT05571826|BEHAVIORAL|telerehabilitation|No specific treatments will be applied. The persons who experienced telerehabilitation interventions will be included.
223987267|NCT01026298|OTHER|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
223987268|NCT01240538|BIOLOGICAL|wild-type reovirus|Given IV
223987269|NCT01240538|DRUG|cyclophosphamide|Given PO
223987270|NCT01240538|OTHER|laboratory biomarker analysis|Correlative studies
223987271|NCT01240538|OTHER|pharmacological study|Correlative studies
223987272|NCT03118167|DIETARY_SUPPLEMENT|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
223987273|NCT03118167|DIETARY_SUPPLEMENT|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
223987274|NCT03118167|OTHER|Placebo|Edible starches 0.35g, edible capsule
223987275|NCT03118167|OTHER|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
223987276|NCT03575949|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
223987277|NCT03575949|OTHER|Fludeoxyglucose F-18|Given IV
223987278|NCT03575949|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223987279|NCT00566813|DRUG|Islet Cell Transplant|1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
224120395|NCT01803451|DRUG|exendin-(9-39)|hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
224120396|NCT01803451|DRUG|exendin -(9-39)|2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
224120397|NCT06426121|DIAGNOSTIC_TEST|test Aerobic/F Culture Vials|an additional blood sample will be collected compared to clinical routine of blood culture, inoculated into the test culture vial, and compared with the blood culture results of the control vial collected from the same site and the same puncture point
224120398|NCT06426121|DIAGNOSTIC_TEST|control Aerobic/F Culture Vials|according to the clinical routine of blood culture, this blood sample should be collected and inoculated into the control vial, and its culture result will be collected
224294383|NCT03520868|DIAGNOSTIC_TEST|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
224294384|NCT02046668|DRUG|spironolactone|spironolactone 25mg daily for 12 weeks
224294385|NCT01569776|OTHER|Amino Acid formula|Amino Acid baby formula
223728559|NCT00741637|BIOLOGICAL|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
223728560|NCT00741637|BIOLOGICAL|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
223987280|NCT00566813|DRUG|Islet Cell Transplant plus|1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
223987281|NCT01863628|OTHER|aerobic exercise|
223987282|NCT01863628|OTHER|psychoeducation|
223987283|NCT05633498|OTHER|Book|Self-help book describing advice to cope with shift work
223987284|NCT05633498|OTHER|Sleep hygiene|Basic sleep hygiene advice on a piece of paper
223728561|NCT03124875|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
223728562|NCT00422175|DRUG|BAF 312|
223728563|NCT03220516|PROCEDURE|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
223728564|NCT03220516|PROCEDURE|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
223728565|NCT03220516|PROCEDURE|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
223728566|NCT03741179|DRUG|ASA-withdrawn group|Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
223728567|NCT00456131|BEHAVIORAL|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
223728568|NCT02601131|BIOLOGICAL|Platelet transfusion|
223728569|NCT03992820|DEVICE|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
223728570|NCT03992820|COMBINATION_PRODUCT|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
223728571|NCT06339723|BEHAVIORAL|Pecha Kucha|Pecha Kucha Method training was given
223728572|NCT00837304|DEVICE|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
224120399|NCT04920084|OTHER|Plant based meals|For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
223544557|NCT02479958|PROCEDURE|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
223728573|NCT00837304|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
223728574|NCT02664454|OTHER|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
223728575|NCT01327898|BEHAVIORAL|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
223728576|NCT01327898|BEHAVIORAL|individual resilience counseling|one individual resilience counseling session
223728577|NCT04326907|PROCEDURE|Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy|Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
223987285|NCT03927898|DRUG|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
223987286|NCT03927898|RADIATION|Stereotactic Body Radiotherapy|Participants receive SBRT (BED\>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
223987287|NCT06547463|OTHER|nasal oxygenation device|Use of the nasal oxygenation device on one of the two nights during which polysomnography will be performed.
223544558|NCT01643642|OTHER|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
223987288|NCT05783713|OTHER|Influenza Vaccination|Describe and measure any differences in total influenza vaccination coverage, in different categories of professionals and in different operational units.
223987289|NCT00319800|DRUG|Gefitinib|
223987290|NCT00319800|DRUG|Irinotecan|
224120400|NCT05512130|DRUG|Empagliflozin 25 mg|Participants will take empagliflozin daily for 2 weeks.
224120401|NCT05512130|DRUG|Placebo|Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
223987291|NCT01278147|BEHAVIORAL|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
223987292|NCT01636908|DRUG|Sunitinib|50 mg once daily, oral use, 14 days
223987293|NCT01636908|DRUG|Sorafenib|400 mg, twice daily, oral use, 14 days
223987294|NCT01636908|DRUG|Erlotinib|150 mg once daily, oral use, 14 days
223987295|NCT01636908|DRUG|Everolimus|10 mg once daily, oral use, 14 days
223987296|NCT01636908|DRUG|Lapatinib|1250 mg once daily, oral use, 14 days
223987297|NCT01636908|DRUG|Dasatinib|100 mg once daily, oral use, 14 days
223987298|NCT01636908|DRUG|Pazopanib|800 mg once daily, oral use, 14 days
223987299|NCT01636908|DRUG|Vemurafenib|960 mg twice daily, oral use, 15-21 days
223987300|NCT01636908|PROCEDURE|tumor biopsy|
223987301|NCT01636908|PROCEDURE|skin biopsy (optional)|
223987302|NCT06330493|DEVICE|PCB|Paclitaxel coated PTA balloon catheter
224294386|NCT01569776|OTHER|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
223544559|NCT01643642|OTHER|Treatment As Usual|Other: Treatment As Usual
223544560|NCT02229981|DRUG|ABC294640|
223544561|NCT02796833|DRUG|SMOFlipid20%|
223544562|NCT03234647|DEVICE|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
223544563|NCT04660175|OTHER|non-resistance therapy|The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
223544564|NCT04660175|OTHER|acupuncture|According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
223544565|NCT04660175|OTHER|chuna|Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.
223544566|NCT04660175|OTHER|pharmacoacupuncture|This is an oriental medical practice in which a certain amount of a drug extracted from a specific herbal medicine is injected with an injector to treat the patient's constitution, disease state, etc., and then injected into the treatment acupuncture points and body surface reaction points. Depending on the condition of the inpatient, acupuncture is used in parallel.
223544567|NCT04660175|DRUG|Korean herbal medicine|Formulated with herbal medicinal and pack the extract in a pouch, and have the hospitalized patient take it once in the morning and afternoon for 30 minutes after meals.
223544568|NCT01389674|PROCEDURE|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
223544569|NCT01244035|DRUG|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
223544570|NCT01244035|DRUG|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
223544571|NCT01244035|DRUG|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
223544572|NCT01244035|DRUG|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
223544573|NCT01244035|DRUG|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
223544574|NCT01244035|DRUG|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
223544575|NCT05407805|OTHER|Electronic Diary|Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
223987303|NCT06330493|DEVICE|PTA|Non-coated FDA cleared (US) or CE-marked (EU) standard percutaneous transluminal angioplasty balloon catheter
223987304|NCT01229774|DRUG|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
223987305|NCT01229774|DRUG|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
224294387|NCT02249676|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
223987306|NCT02772328|BEHAVIORAL|Peer Mentor|comparison of communication training to equal attention control
223987307|NCT00158197|BEHAVIORAL|contingency management voucher|participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
223987308|NCT03023722|DRUG|anetumab ravtansine|Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
224120402|NCT01096446|DRUG|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
224120403|NCT05517525|DRUG|Brensocatib|Oral tablet.
224120404|NCT05784948|OTHER|Virtual Reality Mindfulness Treatment|once a week for 30 minutes, over 8 weeks
224120405|NCT05784948|OTHER|Experience relaxing scenery and music|once a week for 30 minutes, over 8 weeks
224120406|NCT00620321|DRUG|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
224120407|NCT00620321|DRUG|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
223728578|NCT01808287|DEVICE|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
223728579|NCT03315208|BEHAVIORAL|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
223728580|NCT03315208|OTHER|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
223728581|NCT03234751|DRUG|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
223728582|NCT03234751|DRUG|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
224120408|NCT00620321|DRUG|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
224120409|NCT03958617|DEVICE|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
224120410|NCT04094350|OTHER|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
224120411|NCT04094350|OTHER|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
224120412|NCT04094350|OTHER|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
224120413|NCT04094350|OTHER|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
224120414|NCT06280261|OTHER|parenting stress index, Zarit burden scale, Rosenberg self esteem scale, stait trait anxiety inventory, struggles and difficulties questionnaire|Scales and questionnaires
224120415|NCT03355599|OTHER|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
224120416|NCT03335852|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
224120417|NCT00547599|DRUG|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
223987309|NCT01118559|DRUG|YM150|oral
223987310|NCT04644211|DRUG|Ruxolitinib|Pill taken by mouth.
223728583|NCT03234751|DRUG|Placebo|48 hours of placebo.
224120418|NCT06082557|DRUG|T60c injection|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and TROP2-CAR (TROP2-chimeric antigen receptor). The obtained T60c is used for one-time intravenous infusion."
224120419|NCT02156960|DRUG|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
224120420|NCT02156960|DRUG|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
224120421|NCT02156960|DRUG|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
224120422|NCT03148431|DRUG|LY3002815|Administered IV
224120423|NCT03148431|DRUG|Placebo|Administered IV
224120424|NCT00136773|DRUG|amlodipine/benazepril|
224120425|NCT00913718|DRUG|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
224120426|NCT00913718|DRUG|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
224120427|NCT04191967|DEVICE|Thermocoagulation|Treatment of positive screening results will be performed using the Liger Thermocoagulator device
224120428|NCT01431144|PROCEDURE|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
224120429|NCT01431144|PROCEDURE|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
224120430|NCT01734187|DIETARY_SUPPLEMENT|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
224120431|NCT01734187|DIETARY_SUPPLEMENT|Placebo|Placebo (30g/day)
224120432|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
224120433|NCT01109004|DRUG|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
224120434|NCT01109004|DRUG|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m\^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
224120435|NCT03444818|DRUG|[14C]-E6007|Oral administration
224120436|NCT04169594|DIAGNOSTIC_TEST|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
224120437|NCT06260644|PROCEDURE|VertiseTM flowable composite (Kerr,USA)|self adhesive flowable resin composite restoration.
224120438|NCT04251208|OTHER|Observational Study|No intervention will be administered.
224120439|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.
224120440|NCT05141435|PROCEDURE|infants receive primary non-invasive respiratory support by mean of NHFOV|neonates assigned to NHFOV will be started with the following boundaries: a) Paw of 6 cmH2O (the range 6-10 cmH2O); b) frequency of 10 Hz (the range 8-12 Hz). c) Inspiratory time 50% (1:1). d) amplitude 15 cmH2O(the range 15-25 cmH2O) NHFOV will only be provided with piston/ membrane oscillators able to provide an active expiratory phase (that is, Acutronic FABIAN-III, SLE 5000, Loweinstein Med LEONI+, Sensormedics 3100A).
224120441|NCT04721236|OTHER|hyperimmune plasma|plasma collected from convalescent Covid-19 donors with titre 1:80 or more
224120442|NCT02410902|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
224120443|NCT02410902|DRUG|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
224120444|NCT00219843|DRUG|PV-10 (rose bengal disodium, 10%)|
224120445|NCT03111134|PROCEDURE|modified component separation technique|a new abdomen closure technique based on component separation technique
224120446|NCT03412474|DRUG|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
224120447|NCT03412474|DRUG|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
224120448|NCT03412474|DRUG|paracetamol|paracetamol
223544576|NCT05135039|DRUG|Canagliflozin|Canagliflozin 100mg/day/patient
223544577|NCT05135039|DRUG|Placebo|Placebo 100mg/day/patient
224120449|NCT06342804|DRUG|4-MUST, 2 tablets, fasted|2 tablets (256 mg), fasted
224120450|NCT06342804|DRUG|4-MUST, 2 tablets, after meals|2 tablets (256 mg), after meals
224120451|NCT03134950|BEHAVIORAL|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
223987311|NCT05250765|DEVICE|Twistflex retainer|twisted 0.0195 dead-soft coaxial wire (Respond; Ormco, Orange, Calif)
223987312|NCT05250765|DEVICE|Orthoflex retainer|Ortho-flextech (Reliance orthodontic products, Itasca III, USA)
223987313|NCT02147847|BEHAVIORAL|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
223544578|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
223728584|NCT02875860|DEVICE|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
223987314|NCT02147847|BEHAVIORAL|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
223987315|NCT04183998|OTHER|Trans-spinal Electrical Stimulation (tsES)|Stimulation will be achieved with two self-adhesive stimulation electrodes attached to the dorsal aspect of the neck overlying the cervical vertebrae and two self-adhesive rectangular return electrodes placed over the shoulders. Spinal motor evoked potentials (sMEP) induced by trans-spinal electrical stimulation (parameters, 1 Hz with a 0.1-1 ms pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10 to 200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-40 Hz and 20-100 milliampere.
224120452|NCT04002154|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
224120453|NCT05890417|OTHER|questionnaire|Female Sexual Function Index (FSFI) and WHO Quality of Life-BREF (WHOQOL-BREF) questionnaires at baseline and 6 months after starting hormone replacement therapy
224120454|NCT01734941|DRUG|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
224120455|NCT01734941|DRUG|Placebo|
224120456|NCT03021798|OTHER|No Drug and no aspecific intervention|No intervention
224120457|NCT00002288|DRUG|Zidovudine|
224120458|NCT02159326|DRUG|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
224120459|NCT02159326|DRUG|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
224120460|NCT00092040|DRUG|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
224120461|NCT00092040|DRUG|Comparator: risedronate / Duration of Intervention: 12 mo|
224120462|NCT05041959|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours
223987316|NCT06957028|OTHER|Diabetes Treatment|"Management will include an unblinded CGM sensor worn 24/7, GDM specific nutrition information, training on using CGM in daily glucose management to achieve euglycemia (maximizing time 63-140 mg/dL \[3.5-7.8 mmol/L\]).~Visits (which could be telehealth) per usual obstetrical care for glycemia management (expected to be about every 4 weeks for most participants) and weekly glycemic management with review of CGM data by site and by central CGM Resource Center for flagged cases.~Participants not receiving glucose lowering medication by 24-28 weeks will undergo OGTT per usual obstetrical management and those with positive OGTT will be treated for GDM per usual clinic routine and continue to wear an unblinded CGM."
223987317|NCT06957028|OTHER|Usual Care Group|"The control group will receive usual obstetrical care at the clinical center. A general pregnancy nutrition information handout will be provided to each participant and a blinded CGM sensor will be placed at routine obstetrical care visits and worn for 10-14 days each time throughout the pregnancy beginning between 18-22 weeks' gestation.~At 18-22 weeks, blinded CGM data will be reviewed to assess if participant has ≥25% time \>140 mg/dL to determine if an early OGTT or glycemic management is required. Site clinicians will be unblinded to the masked CGM data for participants with CGM data ≥25% time \>140 mg/dL and those participants may be treated as those with a positive OGTT.~An OGTT will be performed at \~24-28 weeks per the clinic's usual routine and those with positive OGTT will be treated for GDM per usual clinic routine. If real-time CGM is to be used, then unblinded study CGM sensors can be used instead of blinded sensors for the duration of the study."
223987318|NCT06776172|PROCEDURE|Extended Pelvic Lymph Node Dissection|Extended pelvic lymph node dissection during radical prostatectomy
223987319|NCT01052363|DRUG|Bevacizumab, CA4P|
223728585|NCT02875860|DEVICE|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
223728586|NCT02875860|OTHER|Standardized postnatal care|After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
223728587|NCT03698747|DEVICE|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
223728588|NCT05487638|OTHER|Nursing Education and Counseling Service Provided to Patients by Video Calling on the Phone|Nursing Education and Counseling Services were provided to the patients by video calling on the phone for the problems they may encounter in the postoperative period.
223728589|NCT01835067|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
223987320|NCT00990951|DRUG|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
223987321|NCT00676104|DEVICE|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
223728590|NCT01835067|DRUG|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
223728591|NCT01835067|DRUG|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
223987322|NCT05244369|OTHER|Only TENS|Rehabilitation program consisting of joint range of motion, stretching and strengthening exercises for 30 minutes, 5 days a week for only 4 weeks, and application of transcutaneous electrical nerve stimulation (TENS) to the tip of the stump
223987323|NCT05244369|PROCEDURE|Acupuncture+TENS|acupuncture application twice a week - a total of 8 sessions, rehabilitation program consisting of exercises 5 days a week for 4 weeks and transcutaneous electrical nerve stimulation (TENS) to the stump tip.
223987324|NCT06252012|BEHAVIORAL|Mobile application|The mobile application will be designed as a health assistant for women aged between 30-65 to encourage healthy choices and positively develop their behaviors regarding the prevention of cancer. Within the scope of the mobile application, information modules on cervical cancer screening tests, cervical cancer risk factors, ways to prevent cervical cancer, types of HPV, and HPV vaccine will be provided. A parallel-group pretest-posttest randomized controlled trial design will be used in the second stage of the study
223987325|NCT03752177|DRUG|LY3415244|Administered IV
223987326|NCT00589303|DRUG|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~* metoprolol~* atenolol~* carvedilol~Calcium Channel Blocker:~* verapamil~* diltiazem~Rhythm Control:~* procainamide~* quinidine~* disopyramide~* propafenone~* flecainide~* sotalol~* dofetilide~* amiodarone"
223987327|NCT00589303|DEVICE|AV Node ablation and device implant|"Pacing Systems:~* Enpusle Premarket Approval Number (PMA#) P980035~* EnRhythm PMA# P980035~* Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~\- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~* EnTrust PMA# P980016~* Virtuoso PMA# P980016~ICD CRT Pacing Systems:~* InSync Maximo PMA# P980016~* InSync Sentry PMA# P890003~* Concerto PMA# P980016"
223987328|NCT06292390|OTHER|Pet Therapy|Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy.
223987329|NCT04840342|DRUG|Eplerenone|Dose escalations of eplerenone 50, 100, or 200mg
223987330|NCT04840342|DRUG|Amlodipine|Dose escalations of amlodipine 2.5, 5, or 10mg
223987331|NCT03049670|DEVICE|latent available chlorine (LAC)|local application on the necrotic infected tissue
223987332|NCT03038035|DRUG|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
223987333|NCT03038035|DRUG|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
223987334|NCT00304382|BIOLOGICAL|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
223987335|NCT00304382|BIOLOGICAL|Pneumovax|0.5 ml IM one time
223987336|NCT02931422|BEHAVIORAL|Financial incentive|Conditional cash transfer upon HIV testing
223987337|NCT01421212|BIOLOGICAL|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).~Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
223987338|NCT00068172|DRUG|PI-88|
223544579|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
223544580|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
223544581|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
223544582|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
223544583|NCT04951765|DRUG|XZP-3287|Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
223544584|NCT01810900|DEVICE|Protescal|
223987339|NCT05055947|DRUG|First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 days
223987340|NCT00749697|OTHER|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
223987341|NCT03549091|DIAGNOSTIC_TEST|transthoracic echocardiography|This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.
223987342|NCT03549091|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
223987343|NCT03121820|DRUG|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
223987344|NCT03121820|DRUG|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
223987345|NCT04681053|DRUG|Ivermectin Powder|\- Administration through inhalation (6mg) BID for 3 days
223987346|NCT05863767|OTHER|Baduanjin sequential therapy|Baduanjin sequential therapy consists of eight different movements including the preparatory phase till final movement (gathering the energy). The session will account for 30 minutes twice a day for four weeks.
223987347|NCT05863767|OTHER|Conventional Therapy|Neck stretches Arm circles Triceps stretch Calf stretch Forward step up Strengthening exercises Every exercise 5 repetitions three times a day
223987348|NCT02766127|OTHER|Veritise Flow|Self-adhering composite
223987349|NCT02766127|OTHER|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
223987350|NCT02766127|OTHER|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
223987351|NCT02766127|OTHER|Flor-Opal® Varnish|fluoride-based varnish
223987352|NCT04985578|OTHER|Dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds.
223987353|NCT04985578|OTHER|Sham dry needling|The therapist will located the TrP that refers the most pain and will apply manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrP for 60 seconds with a sham needle without tip.
223987354|NCT02805478|OTHER|There is no intervention|This is a prospective observational cohort study without any intervention
223987355|NCT04526093|OTHER|Medical Cannabis|Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements
223987356|NCT05850663|OTHER|Ecologic Momentary Assessment (EMA)|"EMA enables measurement of phenomena in real-time, natural settings.~EMA data will be used to identify moments of high distress, assess cancer treatment side effects, and assess barriers to care.~The EMA methodology used in this study will ask about current emotional, physical, behavioral, and social states.~The EMAs will consist of time-based sampling (i.e. a daily dairy), which will be prompted and initiated by the phone."
223987357|NCT03088540|DRUG|Pemetrexed|Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
223987358|NCT03088540|DRUG|Paclitaxel|Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
223987359|NCT03088540|DRUG|Gemcitabine|Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
223987360|NCT03088540|DRUG|Cisplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
223544585|NCT03067402|OTHER|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
223544586|NCT03067402|DIAGNOSTIC_TEST|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
223987361|NCT03088540|DRUG|Carboplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
223987362|NCT03088540|DRUG|cemiplimab|Patients will be administered cemiplimab as per protocol.
223544587|NCT00447798|BEHAVIORAL|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
223544588|NCT00511758|PROCEDURE|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
223544589|NCT00002186|DRUG|Crofelemer|
223544590|NCT00002186|DRUG|Acyclovir|
223544591|NCT00412191|DRUG|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
223544592|NCT01590368|DEVICE|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
223544593|NCT01590368|DEVICE|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
223544594|NCT05816746|DRUG|Low-Dose Decitabine plus anti-PD-1|Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
223544595|NCT06301646|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223544596|NCT06301646|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223987363|NCT06492603|DEVICE|Ultrasonography|Ultrasound is an assessment device that uses high-energy sound waves to look at either superficial tissues like linea alba and/or organs inside the body. The sound waves make echoes that form pictures of the tissues and organs on a computer screen (sonogram).
223987364|NCT06492603|DEVICE|The MyotonPRO Device|The MyotonPro is a portable device for measuring biomechanical and viscoelastic properties in superficial soft tissues
223987365|NCT04836559|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
223987366|NCT04836559|DRUG|Placebo|Placebo will be administered orally.
223728592|NCT03730493|BEHAVIORAL|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
223728593|NCT02402543|DRUG|Gabapentin|
223728594|NCT02402543|DRUG|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
223728595|NCT02402543|DRUG|Acetaminophen|
223728596|NCT02402543|DRUG|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
224294388|NCT03983694|OTHER|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
223728597|NCT02402543|DRUG|Placebo|
223728598|NCT03144388|PROCEDURE|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
223987367|NCT00730015|DRUG|Matching Placebo|Oral, once daily
223987368|NCT00730015|DRUG|Linaclotide|Oral, once daily
223987369|NCT01003119|BEHAVIORAL|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
224120463|NCT05041959|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
224294389|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
224294390|NCT01347866|DRUG|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
224294391|NCT01347866|DRUG|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
224294392|NCT01347866|DRUG|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
224294393|NCT01817465|DRUG|Motilitone ®|
224294394|NCT01817465|DRUG|Pantoline®|
224294395|NCT01817465|DRUG|Motilitone® and Pantoline®|
223728599|NCT03144388|PROCEDURE|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
223728600|NCT05715073|DIETARY_SUPPLEMENT|TeaCrine and Caffeine|Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
223728601|NCT05715073|DIETARY_SUPPLEMENT|Caffeine|Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.
223728602|NCT05715073|OTHER|Placebo|Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
223728603|NCT01541774|DEVICE|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
223728604|NCT02320149|DRUG|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
223728605|NCT02320149|DRUG|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
223987370|NCT03807609|OTHER|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
223987371|NCT03807609|OTHER|EX -30. Condition with an acute exercise set 30 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224120464|NCT02194101|PROCEDURE|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
224120465|NCT01073527|DRUG|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
224120466|NCT01073527|DRUG|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
223987372|NCT03807609|OTHER|EX-180. condition with an acute exercise set 180 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
223987373|NCT06373796|DEVICE|Echographic scan|Liver ultrasound exam
223987374|NCT03095170|BEHAVIORAL|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
223987375|NCT03095170|BEHAVIORAL|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
223987376|NCT03095170|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
223987377|NCT03095170|BEHAVIORAL|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
223987378|NCT03095170|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
223987379|NCT02370251|DRUG|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB \<2 mg/dL) occurs.
223987380|NCT04264715|DEVICE|405nm light|In this room, surgeries will be performed under ambient light including the wavelength 405nm
223987381|NCT06425172|DEVICE|Cranial Remolding Orthosis|A custom made FDA-approved cranial remolding orthosis will be retrofit with sensors used in the research.
223987382|NCT05643040|OTHER|femoral nerve block|To evaluate the intraoperative analgesia effectiveness of femoral block in patients who will have knee surgery.
223987383|NCT05643040|OTHER|adductor canal block|To evaluate the intraoperative analgesia effectiveness of adductor canal block in patients who will have knee surgery.
223987384|NCT05643040|OTHER|4in1 block|To evaluate the intraoperative analgesia effectiveness of 4in1 block in patients who will have knee surgery.
223987385|NCT04573660|DEVICE|Coronary and peripheral stents|The participants in the Coronary and peripheral stents arm will receive Coronary and peripheral stents
223728606|NCT00560079|DRUG|Allopurinol|Allopurinol 600mg/day bid for 28 days
223987386|NCT04573660|DEVICE|Pacing catheters|The participants in the Pacing catheters arm will receive Pacing catheters
223987387|NCT04573660|DEVICE|Vascular plugs|The participants in the Vascular plugs arm will receive Vascular plugs
223987388|NCT04573660|DEVICE|Measurement and imaging (FFR and OCT)|The participants in the Measurement and imaging (FFR and OCT) arm will receive Measurement and imaging (FFR and OCT)
223987389|NCT04573660|DEVICE|Peripheral dilatation catheters|The participants in the Peripheral dilatation catheters will receive Peripheral dilatation catheters
223987390|NCT04573660|DEVICE|Coronary dilatation catheters|The participants in the Coronary dilatation catheters will receive Coronary dilatation catheters
223987391|NCT04573660|DEVICE|Coronary and peripheral guidewires|The participants in the Coronary and peripheral guidewires will receive Coronary and peripheral guidewires
223987392|NCT04573660|DEVICE|Vessel closure/compression devices|The participants in the Vessel closure/compression devices will receive Vessel closure/compression devices
223987393|NCT04573660|DEVICE|Vascular access introducers|The participants in the Vascular access introducers arm will receive Vascular access introducers
223987394|NCT06465433|DRUG|Tafasitamab|Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
223987395|NCT06108206|OTHER|Adaptive Radiotherapy|"Each patient will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of chemo-RT,~2. Week #1- on Fractions # 4 or 5~3. Week #2- between Fractions # 6-10 (at least 5 days after the Week 1 MRI)~4. Week #3- between Fractions # 11-15 (at least 5 days after the Week 2 MRI)~5. Week #4- between Fractions # 16-20 gadolinium contrast (at least 5 days after the Week 3 MRI)~6. Week #5- on Fractions # 24 or 25 (after the start of the Conedown)~7. Week #6- +/- 3 days of Fraction #30 (end of RT)~Patients receiving hypofractionated radiotherapy will undergo a brain MRI at the following time points:~1. Baseline- within 2 weeks prior to the start of your standard of care chemotherapy radiation treatment (chemo-RT),~2. Week #1 - on Fractions #4 or 5~3. Week #2 - between Fractions #6-10 (at least 5 days after the Week 1 MRI)~4. Week #3 - between Fractions #11-15 (at least 5 days after the Week 2 MRI)"
223987396|NCT05574296|DRUG|Hydrogen|Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
223987397|NCT05574296|OTHER|Usual care|Usual care post-ECPR event, including targeted temperature management.
224120467|NCT04105205|DRUG|Apramycin injection|30-min infusion
224120468|NCT04105205|DRUG|Placebo injection|30-min infusion
224120469|NCT06055881|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223728607|NCT00560079|DRUG|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
223728608|NCT00560079|DRUG|Placebo|Placebo
223728609|NCT06420843|DIETARY_SUPPLEMENT|FOODMAP|Dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) have been recently investigated in the management of functional gut symptoms in IBS.
223987398|NCT05582772|OTHER|GA+M Intervention|Typically 8 domains (cognition, comorbidities, falls risk, functional status, medication use, mood - depression, nutritional status, social support) are examined by a team consisting of a nurse and geriatrician. A GA has multiple benefits and has been recommended for all older adults considering chemotherapy by the American Society of Clinical Oncology (ASCO). For a GA to be most useful it needs to be followed by co-management of identified issues.
223987399|NCT05582772|OTHER|RSM intervention|Telephone-based, symptom management of patients with cancer
223987400|NCT05582772|OTHER|GA+RSM intervention|Combining a geriatric assessment and remote symptom control
223987401|NCT03012529|DRUG|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
223987402|NCT03012529|DRUG|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
223987403|NCT04697953|DRUG|brolucizumab|Pre-filled Syringes for intravitreal injection
223987404|NCT00420875|DEVICE|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
223987405|NCT06022068|DRUG|Sirolimus|7 mg taken once per week during 26 weeks.
223987406|NCT06479109|BEHAVIORAL|Motivational materials for pregnant women attending antenatal care visits to improve supplement adherence|During the antenatal care visit, pregnant women will receive the information sheet used by the provider and a dangler/poster to hang in a visible location in the participant's house. This will serve as a reminder for her and her family to take the daily pill.
223987407|NCT06479109|OTHER|Providers|"Providers in intervention sites use an information sheet that serves as a job aid to counsel women about the benefits of the supplements. The sheet also includes adherence tips, such as involving family to increase adherence. The information sheet is provided to the woman to take home.~Antenatal care providers will use an information sheet describing the supplement's benefits and adherence tips to help pregnant women take IFAS or MMS."
223987408|NCT00013611|DRUG|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
223987409|NCT02379962|OTHER|no intervention|
223987410|NCT04799769|DEVICE|Percutaneous arterial closure device|Large hole percutaneous arterial closure device
223987411|NCT00298688|DRUG|Gefitinib|
223987412|NCT00234897|DRUG|adalimumab|
223987413|NCT01150045|DRUG|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
223987414|NCT01150045|DRUG|5-fluorouracil|Patients receive 400 mg/m\^2 intravenous bolus then 2400 mg/m\^2 continuous intravenous infusion over 46-48 hours.
224294396|NCT00773695|DRUG|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
224294397|NCT00773695|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
223987415|NCT01150045|OTHER|placebo|Patients receive placebo administered by mouth, once daily.
224294398|NCT00773695|DRUG|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
224294399|NCT00773695|DRUG|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
223987416|NCT01150045|DRUG|oxaliplatin|Patients receive 85 mg/m\^2 intravenous over two hours.
223987417|NCT01150045|DRUG|leucovorin|Patients receive 400 mg/m\^2 intravenous over two hours.
223987418|NCT05425407|DIETARY_SUPPLEMENT|whey protein|Daily 45g of whey protein supplementation during a three week eccentric training period
223987419|NCT05425407|DIETARY_SUPPLEMENT|whey protein + collagen peptide|Daily 15g of whey protein and 20g collagen peptide supplementation during a three week eccentric training period
223987420|NCT03167853|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
223987421|NCT02838784|OTHER|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
223987422|NCT02838784|PROCEDURE|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
223987423|NCT00370110|DRUG|Itopride 100 mg|100 mg three times daily
223987424|NCT00370110|OTHER|Placebo|
223987425|NCT00370110|DRUG|Itopride 200 mg|200 mg three times daily
223987426|NCT03124693|DEVICE|Rainbow DCI pulse oximeter sensor|
223987427|NCT06277180|PROCEDURE|Surgery|Surgery is performed based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, and all 68Ga-TCR-FAPI-avid lesions are resected.
223987428|NCT06277180|PROCEDURE|Surgery|68Ga-TCR-FAPI PET/CT identified distant metastasis or unresectable lesions, but the patient is still recommended to undergo surgery for debulking or reduce symptoms.
223987429|NCT06546085|BEHAVIORAL|Exercise|Supervised treadmill exercise at 85% VO2max, 3x/wk for 16 weeks. Exercise duration will be adjusted based on individual VO2-heart rate (HR) relationship so that \~400 kcals will be expended during each training session.
223728610|NCT01342146|DRUG|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
223728611|NCT01342146|DRUG|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
223728612|NCT01342146|DRUG|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
223728613|NCT00190996|DRUG|Duloxetine Hydrochloride|
223728614|NCT00190996|DRUG|placebo|
223728615|NCT02089633|BIOLOGICAL|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
223728616|NCT01481233|DRUG|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
223987430|NCT02431052|DRUG|Olumacostat Glasaretil|
223987431|NCT02431052|OTHER|Vehicle|
223987432|NCT02094898|DRUG|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
223987433|NCT04312932|DRUG|LCPUFA Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
223987434|NCT04312932|DIETARY_SUPPLEMENT|Canola Oil Placebo|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
223987435|NCT02875145|PROCEDURE|Cataract surgery|
223987436|NCT05455372|DRUG|PPI quadruple therapy|PPI quadruple therapy refers to ilaprazole 5mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid.
223987437|NCT00073398|BIOLOGICAL|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
223987438|NCT05382039|DEVICE|Transcutaneous Electrical Nerve Stimulation|High frequency sensory transcutaneous electrical nerve stimulation
223728617|NCT00473642|DRUG|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
223728618|NCT00473642|DRUG|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
223728619|NCT00473642|DRUG|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
223728620|NCT00539331|DRUG|AZD2171|oral tablet
223728621|NCT00539331|DRUG|Paclitaxel|intravenous infusion
223728622|NCT00539331|DRUG|Carboplatin|intravenous injection
223987439|NCT01432626|DRUG|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
223987440|NCT05864677|DRUG|Cerebrolysin|Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
223987441|NCT00610909|DRUG|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
223987442|NCT00610909|DRUG|Placebo|Placebo
223987443|NCT02411617|DEVICE|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
223987444|NCT01276769|DRUG|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles"
223987445|NCT01276769|DRUG|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles"
223987446|NCT00867737|DRUG|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
223987447|NCT00867737|DRUG|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
223987448|NCT03963427|PROCEDURE|Breast reconstruction|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
223987449|NCT05947656|DEVICE|NaviFUS System|NaviFUS System (Neuronavigation-Guided Focused Ultrasound System) is a new non-invasive device, which uses the neuronavigation principle to guide focused ultrasound (FUS) energy precisely delivering through the skull to selected brain tissues without surgery in real-time. In this clinical study, the NaviFUS System is intended to deliver low intensity FUS to generate neuromodulation effects on a predetermined treatment region (one or both of the hippocampi which are associated with seizure), for the treatment for drug-resistant temporal lobe epilepsy (TLE).
223987450|NCT04626804|OTHER|Remember Stuff: A Dyadic-focused Technology to Support Persons with Alzheimer's Disease in the Community|testing the usability, perceptions, and acceptability of R/S among dyads of older adults with early Alzheimer's disease and other related dementias
223987451|NCT03895697|DRUG|dasiglucagon|Glucagon analogue
223987452|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A' ) in fluid responsive position
223987453|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'A') in non-fluid responsive position
223987454|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in fluid responsive position
223544597|NCT06301646|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223544598|NCT00268281|DEVICE|Left Ventricular Capture Management Software|
223987455|NCT04745845|PROCEDURE|Noradrenalin|Norepinephrine challenge (concentration 'B') in non-fluid responsive position
224120470|NCT06055881|OTHER|Surveys|"Patients complete the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) survey and Was it Worth It questionnaire."
224120471|NCT06055881|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Patients receive stereotactic body radiation therapy (SBRT), metastasis-directed radiation therapy .
223544599|NCT00348946|DRUG|androgen oxandrolone|Oxandrolone ,06 \>mg/kg/day, orally, for 2 years
223728623|NCT00055081|BEHAVIORAL|Critical Time Intervention|
223544600|NCT00348946|OTHER|placebo|an inactive substance
223728624|NCT01156311|DRUG|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
223728625|NCT05505019|OTHER|Music listening|This intervention involves listening to participant-selected music that they have evaluated as rewarding/motivating. YouTube Music will be used to build both personalized music and podcast interventions.
223728626|NCT05505019|OTHER|Podcast listening|This intervention involves listening to participant-selected podcasts of neutral content. YouTube Music will be used to build both personalized music and podcast interventions.
223987456|NCT00579709|BIOLOGICAL|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained \<4000/cumm Csa weaned over 8 weeks. If T cell \>4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, \& mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
223987457|NCT02488083|DEVICE|Ultrashape|circumference reduction
223987458|NCT05492968|DRUG|Epinephrin|Patients in the epinephrine group will receive a continuous infusion containing epinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
223987459|NCT05492968|DRUG|Norepinephrine|Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
223987460|NCT05492968|DRUG|Phenylephrine|Patients in the phenylephrine group will receive a continuous infusion containing phenylephrine with a concentration of 0.2mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
223987461|NCT05036954|DEVICE|EyeBrid Excel hybrid lenses|new lenses
223987462|NCT05679999|DIAGNOSTIC_TEST|CIMT (Carotid artery intima media thickness measurement)|Carotid artery intima media thickness measurement with ultrasound
223987463|NCT00932971|DRUG|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
223987464|NCT00932971|DRUG|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
223987465|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
224294400|NCT00773695|DRUG|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
223544601|NCT04527055|DRUG|Bismuth Subcitrate 120 MG Oral Tablet|Bismuth Subcitrate (120 MG Oral Tablet) 1 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223544602|NCT04527055|DIETARY_SUPPLEMENT|Lactobacillus acidophilus and Bifidobacterium lactis Bb12|"The probiotic powder per oral twice daily for 24 weeks. The probiotic powder is named as President AB powder, which contains an approximately equal mixture of Lactobacillus acidophilus and Bifidobacterium lactis Bb12 at a concentration of \>= 10E9 CFU/mL (President Corp., Tainan, Taiwan)."
223544603|NCT04527055|DRUG|Esomeprazole 40mg|Esomeprazole (40 mg) 1 tab per oral twice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223544604|NCT04527055|DRUG|Metronidazole 250 MG|Metronidazole (250 MG) 2 tab per oral thrice per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223544605|NCT04527055|DRUG|Tetracycline Pill|Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
223544606|NCT03688919|BEHAVIORAL|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
223544607|NCT02234440|DRUG|Metformin|
223544608|NCT02234440|DRUG|Insulin|
223544609|NCT04572646|OTHER|NRT proposition and exhaled CO measurement|"Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy."
223544610|NCT02370368|DEVICE|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
223544611|NCT02370368|OTHER|Agility Ladder Drills|Types of ladder drill exercises including single leg hop right and left leg, bunny hop, slalom jumps, bunny twist, lateral runs right and left, high knees with forward progression, backward run, bunny hop backward, single leg lateral hops, lateral bunny hops and snake carrioca moguls.
223544612|NCT03349255|BIOLOGICAL|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
223544613|NCT01370304|OTHER|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
223987466|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
223987467|NCT01501409|OTHER|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
223987468|NCT00981539|PROCEDURE|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
223987469|NCT01958242|OTHER|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
223987470|NCT00371059|DRUG|Memantine|Memantine 10mg BD
223987471|NCT00371059|DRUG|Placebo|Placebo 10 mgs BD
223987472|NCT01275599|DRUG|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
223987473|NCT01275599|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
223987474|NCT01979263|OTHER|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
223728627|NCT00740142|DRUG|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
223728628|NCT00740142|DRUG|placebo and lactulose|placebo 3 times a day for 7 days
223728629|NCT05013567|DRUG|Ibuprofen gel|Ibuprofen gel 5% topically four times a day
223728630|NCT05013567|OTHER|Placebo|Placebo gel topically four times a day
223728631|NCT03128112|OTHER|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
223728632|NCT03909256|OTHER|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
223728633|NCT00344747|BEHAVIORAL|dietary, behavioral, physical activity|
223987475|NCT01979263|OTHER|Placebo Computer Task|Computer task that does not actively modify attention bias
223987476|NCT01234883|DRUG|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
223987477|NCT01234883|DRUG|saline|IV solutions dosed as clinically indicated for rehydration
223987478|NCT03210519|DIETARY_SUPPLEMENT|Eleutherococcus senticosus|taken orally once/day for 90 days
223987479|NCT03210519|OTHER|Placebo|taken orally once/day for 90 days
223728634|NCT01288248|DEVICE|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
223987480|NCT05452551|OTHER|Myotonometric measurement|MyotonPRO is a non-invasive myotonometer used to evaluate the viscoelastic properties of soft tissues. Data collection will be carried out by three researchers experienced in the use of myotonometer. Before the evaluations, participant and repeated measurement information for both researchers will be recorded on the device. All assessments will be made bilaterally. The first researcher will perform two measurements 30 minutes apart from the measurement point standardized with MyotonPRO to evaluate the plantar mechanical properties. Then, the second researcher will take two measurements with MyotonPRO from the same point with 30 minutes intervals. One day later, the first researcher will measure again from the same reference point once.
223987481|NCT03562390|DRUG|Irinotecan|The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
223987482|NCT04351269|DEVICE|CanGaroo Envelope|CanGaroo Envelope with Cardiac Implantable Electronic Device (CIED) implantation
223987483|NCT04351269|DEVICE|TYRX Envelope|TYRX Envelope with Cardiac Implantable Electronic Device (CIED) implantation
224120472|NCT06055881|PROCEDURE|Computed Tomography|Undergo CT, MRI and/or PET/CT
224120473|NCT06055881|PROCEDURE|Magnetic Resonance Imaging|Undergo CT, MRI and/or PET/CT
224120474|NCT06055881|PROCEDURE|Positron Emission Tomography|Undergo CT, MRI and/or PET/CT
223987484|NCT03042403|OTHER|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
223987485|NCT01179776|DRUG|Ilomedin|Ilomedin
223987486|NCT01179776|DRUG|Placebo|i.v saline
223987487|NCT01179776|DRUG|Ilomedin|
223987488|NCT01179776|DRUG|Ilomedin and standard low dose treatment|
223987489|NCT03540277|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
223987490|NCT03540277|BEHAVIORAL|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
223987491|NCT01481688|OTHER|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
223987492|NCT01481688|OTHER|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
223987493|NCT05577325|BEHAVIORAL|control group will be followed without health education|After the whole universe is evaluated in terms of percentile value, students with a percentile value of ≥95 will be filled with a pre-application form in terms of inclusion criteria in the research. Randomization will be made by drawing lots from the closed envelope in a way that will be homogeneously distributed between the classes and genders of the students who accept to participate in the research. Pre-tests will be given to those who accept to participate in the research. In the first week of the training, pedometers will be distributed and their use will be explained. This group is follow up without planned education. At the end of the sixth month of the study, the post-test data collection forms, excluding the personal information form, will be applied to the intervention group and anthropometric measurements will be made again.
223987494|NCT02342990|OTHER|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
223987495|NCT02342990|OTHER|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
223987496|NCT06085105|BEHAVIORAL|CPIPE Training|A two day training covering the following topics: understanding stress \& burnout and developing positive coping mechanisms, bias awareness \& mitigation, person-centered maternity care mindfulness, dealing with difficult situations, emergency obstetric and neonatal care, teamwork and communication, mentorship and peer support.
223728635|NCT01288248|DEVICE|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
223728636|NCT03012958|OTHER|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
223728637|NCT00226954|DRUG|zoledronic acid|
224294401|NCT00773695|DRUG|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
224294402|NCT00773695|DRUG|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
223728638|NCT03695107|DRUG|Nifedipine controlled released tablets|lower blood pressure
223728639|NCT04876443|DIAGNOSTIC_TEST|Study questionnaire|Study questionnaire related to drinking behaviour
224294403|NCT01762826|DIETARY_SUPPLEMENT|Myo-inositol|Dietary control plus Myo-inositol
224294404|NCT01762826|DIETARY_SUPPLEMENT|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
224294405|NCT01762826|DIETARY_SUPPLEMENT|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
224294406|NCT01762826|DIETARY_SUPPLEMENT|Placebo|Dietary control plus folic acid 400 mcg daily
224294407|NCT01389466|BIOLOGICAL|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
224294408|NCT01389466|BIOLOGICAL|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
224294409|NCT04946565|DIAGNOSTIC_TEST|Semen analysis|Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
223728640|NCT05955950|BEHAVIORAL|Gratitude list|Participants must to write 3-5 words a day for 14 days about aspects of their daily experience that they are grateful for.
223728641|NCT05955950|BEHAVIORAL|List of any event|Participants must to write 3-5 words a day for 14 days about events of your own choosing that impressed the participant during the day, whether positive or negative.
223728642|NCT02812147|DRUG|L-DOPS|Added as described in the Arm/Group Descriptions.
223987497|NCT06085105|BEHAVIORAL|Peer support groups|Groups for healthcare providers to meet with other healthcare providers of their cadre, and discuss issues they are facing, brainstorm solutions, and provide support to one another.
223987498|NCT06085105|BEHAVIORAL|Mentorship|Mentor-mentee relationships that provide the opportunity to coach junior healthcare providers on professional development, work-life balance, clinical skills, career advancement and other topics. Mentors develop their mentorship and leadership skills.
223987499|NCT06085105|BEHAVIORAL|Leadership engagement|Engagement of County leadership at the onset of the project through a community advisory board, regular updates of the study and findings, and discussing systemic gaps that impact provider stress and bias.
223728643|NCT02812147|DRUG|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
223728644|NCT02118844|DRUG|rocuronium|
223728645|NCT01741701|DRUG|Oxaloacetate (OAA)|
223728646|NCT01741701|DRUG|Placebo|
223728647|NCT04931355|OTHER|Acupuncture|The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.
223728648|NCT04931355|OTHER|Western medicine|Western medicine
224294410|NCT06496074|DIAGNOSTIC_TEST|Head-up Tilt Test|Two protocols for the head-up tilt test (HUTT) are used in our center and in the collaborating centers: (1) passive or prolonged inclination protocol \[40 minutes\], (2) mixed protocol: passive phase \[first 20 minutes\] plus nitrate-provoked phase \[last 20 minutes\], with the use of 1.25 mg sublingual isosorbide dinitrate. All patients are submitted to 10 minutes of rest in the supine position at zero degree before the tilt phase of the HUTT. During this period, HR and systolic (SBP) and diastolic (DBP) measurements are obtained every 2 minutes. After this phase, the table is tilted at an angle of 70° with measurement of SBP / DBP and HR every minute. Patients older than 60 years are routinely investigated for carotid sinus hypersensitivity by carotid sinus massage during the passive phase of the HUTT. The exam is considered positive according to the criteria defined in guidelines.
223728649|NCT01669915|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
223728650|NCT01669915|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
223728651|NCT01669915|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D placebo
223728652|NCT01669915|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
223728653|NCT05025189|OTHER|Table Grape Powder|Freeze Dried Whole Table Grape Powder
223728654|NCT05025189|OTHER|Beige Diet|Low Fiber, low polyphenol Diet
223728655|NCT00006488|DRUG|recombinant-methionyl human glial cell line-derived neurotrophic factor|
223728656|NCT04500210|DIETARY_SUPPLEMENT|Placebo|Placebo in gelatin capsules
223728657|NCT04500210|DIETARY_SUPPLEMENT|Turmeric|Turmeric in gelatin capsules
223728658|NCT03134287|PROCEDURE|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
223728659|NCT03762109|DRUG|Dantrolene|muscle relaxant
223728660|NCT03762109|DRUG|Placebo Oral Tablet|inactive pill
223728661|NCT05590754|DEVICE|Hyper-buoyancy Floatation (HBF)|Participants remained on a waterbed encased within a wooden frame partially (≈50%) filled with water super-saturated with magnesium sulphate at a temperature between 34-36°C regulated by an ultra-thin underbed heater. Participants remained supine and motionless when lay on the HBF except for temporary passive re-orientation to/and back from the prone position for vertebral compliance assessment
223987500|NCT06085105|BEHAVIORAL|Embedded champions|To facilitate ongoing engagement and sustainability at the facility level, we identified facility champions who lead in organizing and facilitating peer support groups and refreshers at their facilities and serve as role models.
224294411|NCT01791231|DRUG|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
223987501|NCT04387877|DEVICE|Graston|"Graston technique will be applied on the lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~For the first 2 weeks; dorsolumbar stabilization, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
223987502|NCT04387877|OTHER|Sham|"Sham graston technique will be applied on lateral and posterior fascia (tensor fascia lata, gluteus medius, gluteus minimus, gluteus maximus, hamstring, gastrocnemius and soleus muscles) in 15 minutes.~(Sham graston technique will be applied by partially touching the skin overlying the muscle or fascia region via ultrasound gel with the flat part of the Graston instrument so as not to provide any activity of the fascia) For the first 2 weeks; dorsolumbar stabilization, counting on spot, straight and side leg lifting, gluteal setting, side walking exercises For the second 2 weeks; dorsolumbar stabilization counting on spot, straight and side leg lifting, gluteal setting, side walking exercises with 0.5 kg weight on the ankle, piriformis, tensor fascia lata and hamstring stretching exercises"
223987503|NCT00000490|PROCEDURE|jejunoileal bypass|
223987504|NCT00000490|BEHAVIORAL|diet, fat-restricted|
223987505|NCT00284232|BEHAVIORAL|Use and interpretation of blood glucose results|
223987506|NCT00284232|DRUG|Insulin dosing based on SMBG chart and education|
223987507|NCT02713399|DEVICE|Optical Coherence Tomography|
223987508|NCT00476242|DRUG|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
223987509|NCT00476242|DRUG|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
223987510|NCT02270671|BEHAVIORAL|ABMT|Attention Bias Modification Training
223987511|NCT02270671|OTHER|Placebo|Placebo Training
224294412|NCT00430950|DRUG|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
223728662|NCT05590754|DEVICE|Axial Load after 4h of HBF|Participants from observational sat upright in a chair without back support for 15 min before post testing (1G), whilst experimental group participants performed a 30s seated squat with 50% of their body weight (BW) before returning to the upright seated position.
223728663|NCT03033394|DRUG|Beta-lactam antibiotic|Routine clinical dosing
223728664|NCT03759847|OTHER|Fluid intake app|Use of fluid app to monitor intake of fluids
223728665|NCT03759847|OTHER|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
223728666|NCT05699395|DIAGNOSTIC_TEST|Non interventional|No intervention
223728667|NCT02036294|OTHER|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
223987512|NCT00916708|PROCEDURE|Intensive/Low-Risk follow up (IA G1; IA G2)|"\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~\- Since the third to the fifth year of FU: clinical visit\* every 6 months; Pap test every 12 months~\* clinical visit with gynecological exploration"
223987513|NCT00916708|PROCEDURE|Intensive/High-Risk follow up (≥ IA G3)|"\- First 3 years of FU since the end of primary treatment: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~\- In the fourth and fifth years of FU: clinical visit\*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~\* clinical visit with gynecological exploration"
223987514|NCT00916708|PROCEDURE|Minimalist/Low-Risk follow up (IA G1; IA G2)|"\- First 5 years of FU since the end of primary treatment: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration"
223987515|NCT00916708|PROCEDURE|Minimalist/High-Risk follow up (≥ IA G3)|"\- First 2 years of FU since the end of primary treatment: clinical visit\* every 4 months; chest, abdomen, pelvis CT every 12 months~\- Since the third to the fifth year of surveillance: clinical visit\* every 6 months.~\* clinical visit with gynecological exploration"
223728668|NCT02036294|OTHER|Usual Care|Standard Healthcare Services
223728669|NCT01965275|DRUG|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
223728670|NCT03001531|DEVICE|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
223728671|NCT03001531|DEVICE|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
223987516|NCT01306123|DRUG|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
223987517|NCT01306123|DRUG|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
223728672|NCT05002855|OTHER|Enhanced Recovery After Surgery (ERAS)|Multidisciplinary approach to perioperative care.
223728673|NCT00260403|PROCEDURE|Photodynamic therapy versus Transpupillary thermotherapy|
223728674|NCT03362073|DRUG|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -\> 0.10mg/kg/hr -\> … -\> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
223728675|NCT04737083|GENETIC|CGH array|a CGH array is systematically offer to women when the fetus show bilateral clubfoot during prenatal ultrasound screening
223987518|NCT03144544|PROCEDURE|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
223987519|NCT00399841|DEVICE|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
223987520|NCT05063695|OTHER|Multimodal Erector spinae catheter protocol|Patients either received multimodal epidural or ESP protocol
223987521|NCT01578213|DRUG|Imatinib mesylate|"* Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~* Total dosage per day: 800 mg~* Oral use"
223987522|NCT05141396|OTHER|Telehealth- enabled support for SAT/SBT adherence|Telehealth-enabled support over and above usual audit and feedback includes identifying candidates for spontaneous awakening and breathing trials, prompting bedside providers and guiding execution of the coordinated spontaneous awakening and breathing trials as needed.
223987523|NCT05141396|OTHER|Usual audit and feedback for SAT/SBT adherence|Usual audit and feedback
223987524|NCT02838537|DRUG|Exposure to Triptan|
223987525|NCT02838537|DRUG|Exposure to Ergot|
223987526|NCT00316433|DRUG|Irinotecan (CPT-11)|
223987527|NCT00316433|DRUG|Oxaliplatin (Eloxatin)|
223987528|NCT00535938|OTHER|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
223987529|NCT03598699|DRUG|AXR-159|AXR-159 Ophthalmic Solution
223987530|NCT03598699|DRUG|Vehicle|AXR-159 Ophthalmic Solution Vehicle
223728676|NCT03459547|DEVICE|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
223987531|NCT04154969|OTHER|Physiotherapy including Vestibular rehabilitation|vestibular exercise (VOR TX1)
223987532|NCT04154969|OTHER|conventional Physiotherapy|conventional Physiotherapy
223987533|NCT04412083|BEHAVIORAL|PPA Tele-Savvy Pilot Intervention|We will engage PPA caregivers in the process of adapting the existing Tele-Savvy program to fit their needs and then pilot test the adapted PPA Tele-Savvy program.
223987534|NCT05893589|OTHER|test group|Women in the intervention group participated in face-to-face and virtual meetings based on social cognitive theory structures for 4 weeks
223987535|NCT00393653|PROCEDURE|N-of-1 prescription method|
223987536|NCT02422732|OTHER|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
223987537|NCT02422732|RADIATION|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
223987538|NCT02422732|GENETIC|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
223987539|NCT02356796|OTHER|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
223987540|NCT02356796|OTHER|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
223987541|NCT01383811|OTHER|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
224294413|NCT00430950|DRUG|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
223987542|NCT01383811|OTHER|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
223987543|NCT01601613|DRUG|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
224294414|NCT00266526|BIOLOGICAL|Recombinant birch pollen|
223544614|NCT01370304|OTHER|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
223544615|NCT01370304|OTHER|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
223987544|NCT01601613|DRUG|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
223987545|NCT05469724|OTHER|Role of ct pulmonary angiography in diagnosis of pulmonary embolism|Role of ct pulmonary angiography in diagnosis of acute pulmonary embolism as filling defect in pulmonary artery
223987546|NCT00639327|DRUG|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
224294415|NCT05874440|DRUG|Tenofovir Disoproxil Fumarate and Entcavir|Regular registration of side effects of the drugs, cause of non-compliance to treatment
223987547|NCT00639327|DRUG|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
223987548|NCT06060483|DEVICE|CGM|Wear CGM continuously and manage patients based on CGM. The treatment goals are TIR\>70%, TBR\<4%, TAR\<25%, and HbA1c\<7.0%. After the treatment reaches the standard, CGM is worn every six months.
223987549|NCT01585441|DRUG|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
223987550|NCT01585441|DRUG|Placebo|Capsule with no active ingredients to mimic finasteride
223987551|NCT01448369|DEVICE|Blephasteam|10 minute treatment twice daily
223987552|NCT01448369|DEVICE|EyeGiene|10 minute treatment, twice daily
223987553|NCT01448369|DEVICE|Hot compresses|10 minute treatment, twice daily
223987554|NCT00979693|DRUG|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
223987555|NCT00979693|DRUG|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
223987556|NCT05889949|DRUG|Sorafenib|oral sorafenib
223987557|NCT05889949|DRUG|Lenvatinib|oral lenvatinib
223987558|NCT03486483|OTHER|Exercise|Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
223987559|NCT01535001|OTHER|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
223987560|NCT01535001|BEHAVIORAL|Information|"Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.~Information will be given in a leaflet."
223987561|NCT01535001|DRUG|Paracetamol|1 g x 4/day
223987562|NCT01535001|DRUG|Burana|400 mg x 3/day for three weeks
223987563|NCT01535001|DRUG|Pantoprazole|20mg x 1/day for three weeks
223987564|NCT01535001|BEHAVIORAL|Dietary counseling|For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
223728677|NCT04412824|DRUG|Intravenous blood draw|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
223987565|NCT01535001|BEHAVIORAL|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
223987566|NCT01535001|OTHER|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
223987567|NCT02775838|DRUG|Indocyanine green|perioperative application of Indocyanine green (ICG)
223987568|NCT02140736|DRUG|Epoetin biosimilar|
223987569|NCT02274077|DRUG|EXPAREL|
223987570|NCT02274077|DRUG|Normal Saline|
223987571|NCT00311415|BIOLOGICAL|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
223987572|NCT01054378|PROCEDURE|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
223987573|NCT05525507|COMBINATION_PRODUCT|Conditioning and Stem cell infusion|Patients will undergo a conditioning with TLI and ATG, followed by infusion of hematopoietic stem cells from the same HLA-identical donor that provided the original kidney
223987574|NCT04695652|BIOLOGICAL|MVC-COV1901(S protein with adjuvant)|Approximately 3180 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region
223987575|NCT04695652|BIOLOGICAL|MVC-COV1901(Saline)|Approximately 530 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region
223987576|NCT05878873|BEHAVIORAL|Split-belt Treadmill|Split-belt treadmill training, where the speed of each leg is controlled independently has been shown to create gait adaptation where the coordination of each leg is altered, creating improved gait symmetry for people with walking impairments.
223987577|NCT05878873|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS is a form of nerve stimulation that stimulates at a frequency below motor threshold, targeting activation of sensory receptors, such as muscle spindles. Electrodes that create this stimulation will be placed on the skin superficial to the muscle bellies of the tibialis anterior and rectus femoris.
223987578|NCT02639806|DRUG|Sevoflurane|
223987579|NCT02639806|DRUG|Lidocaine|
223987580|NCT02695147|PROCEDURE|TAVI|
223987581|NCT04563598|BEHAVIORAL|Intensive lifestyle intervention (ILI)|Lifestyle intervention focused on weight loss through diet and physical activity
224120475|NCT03398369|DIAGNOSTIC_TEST|CMR/CTA Guidance for CRT|The intervention is the use of CMR and CTA to determine the optimal pacing site in the left ventricle for cardiac resynchronization therapy (CRT) and guide left ventricular lead placement.
224120476|NCT06200987|DEVICE|Penile vibrator|In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
224120477|NCT00988741|DRUG|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
224120478|NCT00988741|DRUG|Placebo|The placebo is provided in a capsule form.
224120479|NCT01746732|DRUG|Ortho-Cyclen|Oral administration
224120480|NCT01746732|DRUG|Evacetrapib|Oral administration
224120481|NCT01204619|BEHAVIORAL|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
224120482|NCT02222038|OTHER|skin biopsy|
224120483|NCT03509207|DRUG|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
224120484|NCT02817555|DRUG|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
224120485|NCT02817555|DRUG|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
223544616|NCT02797756|PROCEDURE|Esophago-gastro-duodenoscopy (EGD) with biopsy|
223544617|NCT02797756|PROCEDURE|Esophageal Impedance Monitoring (EIM)|
223987582|NCT04563598|BEHAVIORAL|Diabetes support and education (DSE)|Behavioral intervention focused on diabetes support and education
223987583|NCT02114762|PROCEDURE|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
223987584|NCT01383447|DRUG|entinostat|Given PO
223987585|NCT01383447|DRUG|imatinib mesylate|Given PO
223987586|NCT01383447|OTHER|laboratory biomarker analysis|Correlative studies
223987587|NCT01383447|OTHER|pharmacological study|Correlative studies
223987588|NCT01383447|GENETIC|western blotting|Correlative studies
223987589|NCT01383447|OTHER|immunohistochemistry staining method|Correlative studies
223987590|NCT01383447|OTHER|flow cytometry|Correlative studies
223987591|NCT01383447|GENETIC|polymerase chain reaction|Correlative studies
223987592|NCT01383447|OTHER|high performance liquid chromatography|Correlative studies
223987593|NCT01383447|OTHER|mass spectrometry|Correlative studies
223987594|NCT04142099|BEHAVIORAL|skin to skin contact 60 min group|Newborns are exposed to maternal and child skin within five minutes of birth for 60 min.
223987595|NCT04142099|BEHAVIORAL|skin to skin contact 20min group|Newborns are exposed to maternal and child skin within five minutes of birth for 20 min.
223987596|NCT02738645|OTHER|pneumonia|
223987597|NCT01409122|DRUG|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
223987598|NCT01409122|DRUG|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
223544618|NCT04218812|DIAGNOSTIC_TEST|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT
223987599|NCT01409122|DRUG|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
223987600|NCT01409122|DRUG|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
223987601|NCT01409122|DRUG|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
223987602|NCT03839810|OTHER|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
223987603|NCT01579643|PROCEDURE|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"1. The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~2. The host cornea bed will be prepared with an excimer laser.~3. Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
223987604|NCT01579643|PROCEDURE|Penetrating Keratoplasty (KP)|"1. A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~2. The donor cornea is then sutured where the patient's cornea was."
223987605|NCT06545318|DEVICE|Density Gradient Centrifugation|Sperm separation with density gradients
223987606|NCT06545318|DEVICE|CA0 chamber|Sperm separation with a novel device
223987607|NCT01487187|PROCEDURE|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
223987608|NCT01487187|PROCEDURE|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
223987609|NCT00882115|DRUG|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
223987610|NCT03936842|BEHAVIORAL|Breast Pain video|An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
223987611|NCT03936842|BEHAVIORAL|Semi-structure interviews|A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
223987612|NCT02552147|DRUG|Transdermal nicotine|
224120486|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
224120487|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
223544619|NCT04218812|DIAGNOSTIC_TEST|Automated electrical source imaging (ESI)|"The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch."
223544620|NCT03228862|DRUG|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
223987613|NCT02552147|OTHER|Transdermal placebo|
223987614|NCT04412525|DEVICE|vitrectomy (27G gauge or larger needle)|vitrectomy surgery for either floater removal or macular surgery, with or without combined cataract (phaco) surgery.
224120488|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
224120489|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing OneTouch® Verio|
224120490|NCT03033849|DEVICE|Blood glucose monitoring system for self-testing GlucoMen® areo|
224120491|NCT05390450|DEVICE|Ultrasound-Guided Popliteal Plexus Block|Patients in this group will receive Popliteal plexus block. Prior to Popliteal plexus block, the proximal end of the adductor canal will be identified. The transducer will be slid distally along the femoral artery until the artery deviated away from the sartorius muscle in the distal part of the adductor canal towards the adductor hiatus. The nerve block needle will be inserted from the anterolateral end of the transducer and advanced in-plane through the medial vastus muscle. The endpoint of injection will be inside the distal end of the adductor canal close to the adductor hiatus. The injection will be adjacent to the femoral artery, between the medial vastus muscle and the adductor magnus muscle. The Popliteal plexus block will be carried out with 10 mL of local anesthetic mixture, containing 50 mg of bupivacaine and 0.05 mg of epinephrine.
223544621|NCT00237237|DRUG|vildagliptin|
223987615|NCT04737837|DRUG|lacosamide|lacosamide as first add on therapy
223987616|NCT04513743|DIAGNOSTIC_TEST|24/7 EEG™ SubQ|24/7 EEG™ SubQ device will be worn by each subject for 365 nights
223987617|NCT04699045|OTHER|No active intervention|
223544622|NCT00389753|DRUG|Application of Aruba Aloë formula F-BC-096 or control|
223987618|NCT01545947|DRUG|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
223987619|NCT01545947|DRUG|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
223987620|NCT01545947|DRUG|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
223987621|NCT04181112|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT using retention enema
223987622|NCT03502577|BIOLOGICAL|BCMA-specific CAR-expressing T Lymphocytes|Receive CAR T infusion
223987623|NCT03502577|DRUG|Cyclophosphamide|Given IV
223987624|NCT03502577|DRUG|Fludarabine|Given IV
223987625|NCT03502577|DRUG|Gamma-Secretase Inhibitor LY3039478|Given PO
223987626|NCT03502577|OTHER|Laboratory Biomarker Analysis|Correlative studies
223987627|NCT03502577|OTHER|Pharmacokinetic Study|Correlative studies
223987628|NCT04575181|DRUG|NNC0268-0965|For subcutaneous (s.c., under the skin) injection once daily for 26 weeks
223987629|NCT04575181|DRUG|Insulin glargine|For s.c. injection once daily for 26 weeks
223987630|NCT04575181|DRUG|Placebo (NNC0268-0965)|For s.c. injection once daily for 26 weeks
223987631|NCT04575181|DRUG|Placebo (insulin glargine)|For s.c. injection once daily for 26 weeks
223987632|NCT03888599|BEHAVIORAL|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
223987633|NCT01547598|DRUG|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
223728678|NCT03325283|DEVICE|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
223987634|NCT01547598|DRUG|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
223987635|NCT01547598|DRUG|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
223987636|NCT00635401|DRUG|Varenicline|0.5 mg BID for 7 weeks
223987637|NCT02423889|RADIATION|Radiotherapy|
223987638|NCT02229227|DRUG|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
223987639|NCT02229227|DRUG|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
223987640|NCT05775783|PROCEDURE|Transvenous lead extraction|Each TLE procedure was started using the single traction method. If this attempt was not sufficient to extract the lead, then the following methods were used: mechanical extraction sheaths (Byrd, Cook Vascular Inc., Leechburg, PA, USA), locking and nonlocking stylets (Liberator® Beacon® Tip Locking Stylet, Cook® Medical, Leechburg, PA, USA), powered extraction sheaths (Evolution or Evolution II Mechanical Dilator Sheath, Cook® Medical, Leechburg, PA, USA). A side retrieval snare loop (Needle's Eye Snare, Cook® Medical, Leechburg, PA, USA) was used for the femoral approach when the subclavian-only approach was insufficient.
223987641|NCT04071301|DEVICE|TENA SmartCare Change Indicator|"Each participating subject will be provided with a Change Indicator and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration."
223987642|NCT02480699|BIOLOGICAL|Recurring blood sample|
223987643|NCT02480699|OTHER|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
223987644|NCT00548743|BEHAVIORAL|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
223987645|NCT00548743|BEHAVIORAL|Usual care|usual care for identification and management of postpartum depression
223987646|NCT00419289|BEHAVIORAL|follow-up rehabilitation of participants with COPD|
223987647|NCT04072705|DRUG|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
223987648|NCT00883298|DRUG|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 \& 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 \& 5 every 28-day cycle
223987649|NCT01355276|DRUG|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
223987650|NCT01355276|DRUG|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
223987651|NCT05646147|DEVICE|Maximal Systolic Acceleration|Reliability of the maximal systolic acceleration
223728679|NCT05318170|PROCEDURE|Laparoscopic ultra-radical lymph node debulking|Laparoscopic ultra-radical lymph node debulking using Yasargil clamps
223728680|NCT02026739|PROCEDURE|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
223728681|NCT02026739|PROCEDURE|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
223728682|NCT03535610|DEVICE|Uterine Embolization|Uterine Embolization with PVA Microspheres
223728683|NCT04981769|DIAGNOSTIC_TEST|Covid-19 test|PCR Covid-19 test
223987652|NCT02125279|DRUG|Calcitriol|
223987653|NCT01948674|BEHAVIORAL|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
223987654|NCT01126034|OTHER|intervention letter|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~1. The name and medical record # of the patients involved~2. Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~3. A reminder of the adverse effect of long-term metoclopramide therapy~4. A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~5. A request that the physician document the discontinuation trial in the electronic medical record"
223987655|NCT00567840|DRUG|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
223987656|NCT01850589|OTHER|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~* Chantix (varenicline) GlaxoSmithKline,~* Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
223987657|NCT00823953|DRUG|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
223987658|NCT00823953|OTHER|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
223987659|NCT00111995|DRUG|Aranesp®|
223987660|NCT01392703|DRUG|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
223987661|NCT01392703|DRUG|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
223987662|NCT01392703|DRUG|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
224120492|NCT05390450|DEVICE|Ultrasound-Guided Fascia Iliaca block|Patients will be placed in a supine position, and the skin will be cleaned aseptically. The inguinal ligament from the anterior superior iliac spine to the pubic tubercle will be drawn on the skin and divided into 3 parts. The injection point was 1 cm caudally from the point where the lateral and middle part of the inguinal ligament met. The skin and deep tissues were infiltrated with 1% lidocaine. A 18G nerve block needle will be inserted into the skin perpendicularly until the first (fascia lata) and second loss of resistance (fascia iliaca) will be felt. Following aspiration to exclude intravascular injection, 40 mL of 0.25% bupivacaine (1-1.5 mg/kg), which will be prepared under aseptic conditions, and then injected. Sensorial block will be evaluated using the pinprick test 20 minutes after injection for areas of the thigh innervated by the femoral, lateral cutaneous and obturator nerves.
224120493|NCT06496321|PROCEDURE|Conventional Saphenous vein harvest|The conventional one involves harvesting only the vein, without perivascular tissue or the nerve.
224120494|NCT06496321|PROCEDURE|No touch Saphenous vein harvest|"During the extraction of the saphenous vein using the no touch technique, it is sectioned with the perivascular adipose tissue and the saphenous nerve of the leg."
223728684|NCT03090178|OTHER|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
223728685|NCT01830972|DRUG|SA-ER 500 mg|oral tablets
223728686|NCT01830972|DRUG|SA-IR 500 mg|oral capsules
223728687|NCT06093698|BIOLOGICAL|Recombinant Anti-EpCAM-CD3 Antibody Injection|Intravenous Infusion
223987663|NCT06058715|PROCEDURE|Transverse Abdominal Plan block (TAP block)|Bilateral TAP block is administered intraoperatively at laparoscopy, directly after insufflation and insertion of the first trocar and camera. The ultrasound probe is placed longitudinally on the midaxillary line near umbilicus, and the transversus abdominis and internal oblique muscles are scanned and observed. The needle (22-gauge 90 mm disposable spinal needle) is inserted in plane and after placing the needle-tip into the fascia between transversus abdominis and internal oblique muscles, 20 ml of ropivacaine 0.25% is injected bilaterally. It is all done by one Anesthetist which is expert in that area and is not in charge of collecting the data.
224120495|NCT05214781|PROCEDURE|modified radical mastectomy|excision of the whole breast tissue including nipple and skin with axillary clearance
224120496|NCT01838174|DRUG|ACTHAR Gel (ACTH)|15 days of daily injections
224120497|NCT01838174|DRUG|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
224120498|NCT00137436|DRUG|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
224120499|NCT00137436|DRUG|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
224120500|NCT00137436|DRUG|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
224294416|NCT05160467|DIAGNOSTIC_TEST|Segmental multi-frequency bio electrical impedance analysis|"A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5.~Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50Ω in trunk, or over 700Ω in limb; sudden drop of impedance in trunk (more than 10Ω), or in limb (more than 50Ω). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis."
223987664|NCT03714659|DEVICE|Lipogems|Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
223987665|NCT06319157|DEVICE|minimal access breast reconstruction with a latissimus dorsi muscle flap|minimal access breast reconstruction with a latissimus dorsi muscle flap
223987666|NCT06319157|DEVICE|conventional breast reconstruction with a latissimus dorsi muscle flap|conventional breast reconstruction with a latissimus dorsi muscle flap
223987667|NCT04468230|DRUG|Nicotine Transdermal Patch|Nicotine Treatment Condition
223987668|NCT00417053|BIOLOGICAL|filgrastim|
224120501|NCT05745116|DEVICE|Notal Vision Home OCT|Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.
224120502|NCT00443378|BEHAVIORAL|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
224120503|NCT04743245|DEVICE|TherOx DownStream System|SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
223987669|NCT00417053|DRUG|busulfan|
223987670|NCT00417053|DRUG|carboplatin|
223987671|NCT00417053|DRUG|cyclophosphamide|
224120504|NCT04743245|DEVICE|PCI|Standard Care of PCI
223987672|NCT00417053|DRUG|doxorubicin hydrochloride|
223987673|NCT00417053|DRUG|etoposide phosphate|
223987674|NCT00417053|DRUG|melphalan|
223987675|NCT00417053|DRUG|vincristine sulfate|
224120505|NCT05412719|BEHAVIORAL|THE EFFECT OF FINGER PUPPET MANIPULATION ON PAİN AND PHYSİOLOGıCAL PARAMETERS DURING URINARY CULTURE WITH URINARY CATHETERIZATION IN INFANTS|the effect of finger puppet manipulation on pain and physiological parameters during urinary culture with urinary catheterization
223987676|NCT00417053|PROCEDURE|autologous bone marrow transplantation|
223987677|NCT00417053|PROCEDURE|bone marrow ablation with stem cell support|
223987678|NCT00417053|PROCEDURE|conventional surgery|
224120506|NCT04657016|DRUG|Tirzepatide|Administered SC
224120507|NCT04657016|OTHER|Placebo|Administered SC
223987679|NCT00417053|PROCEDURE|peripheral blood stem cell transplantation|
223987680|NCT00417053|RADIATION|radiation therapy|
223987681|NCT00839384|DEVICE|Advisa IPG|Implantable Pulse Generator will be implanted
223987682|NCT02691988|OTHER|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
223987683|NCT02691988|OTHER|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
223987684|NCT03090750|DRUG|Lavender Oil|Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
223987685|NCT03090750|DRUG|Bergamot Oil|Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
223987686|NCT03090750|OTHER|Water|Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
223987687|NCT02503098|BEHAVIORAL|Recovery Record adaptive smartphone application|
223987688|NCT02503098|BEHAVIORAL|Recovery Record standard smartphone application|
223987689|NCT03091816|DEVICE|Computed Tomography Perfusion Imaging|Undergo DPCT
223987690|NCT03091816|OTHER|Laboratory Biomarker Analysis|Correlative studies
223987691|NCT03091816|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223987692|NCT02454504|DRUG|sugammadex|
223987693|NCT02454504|DRUG|Neostigmine|
223987694|NCT00415701|DRUG|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
223987695|NCT00415701|DRUG|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
223987696|NCT00415701|DRUG|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
223987697|NCT00415701|DRUG|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
223987698|NCT00415701|OTHER|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
223987699|NCT05860621|BEHAVIORAL|Brief Physical Activity Counselling|The brief physical activity counselling program will comprise 8 sessions (120 minutes each), every fifteen days, addressing the following themes: reasons to change, an introduction to the PAC-WOMAN program and principles, types of physical activity and their benefits, strategies on how to become more active and less sedentary, how to safely practice exercise at home, the importance of social support for doing more physical activity, barriers and facilitators for becoming more active, development of coping plans and strategies to overcome those barriers, establishing SMART goals, self-monitoring, medical aspects related to symptom management in breast cancer survivors, body image and self-acceptance, sharing experiences with role models, and re-evaluating action plans. It will be delivered in a need-supportive interpersonal climate, according to Self-Determination Theory principles.
223987700|NCT05860621|BEHAVIORAL|Structured Exercise Program|The structured exercise program was informed by the most recent guidelines for exercise prescription and safe practice in cancer populations. A supervised program of 32 sessions (over 4 months), lasting 90 min each, and taking place twice a week, was developed. The program combines aerobic, strength and mobility exercises, and is organized in four mesocycles, with progressive intensity, always adapted according to participants' initial assessments and evolution throughout the weeks. Once every 15 days, a thematic group class will be offered to participants, so that they can experiment and discover new physical activities, and more easily maintain regular practice in the future.
223987701|NCT04381923|DEVICE|Helmet Continuous Positive Airway Pressure (CPAP)|Helmet CPAP will be initiated at a pressure of 5 cmH20 and fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (Sp02) remains \< 92%, pressure will be increased to 10 cmH20. FiO2 will then be tapered to target a SpO2 ≥ 92%. Breaks with intervening HFNO use will be provided as needed for meals and during hours of sleep.
223987702|NCT04381923|DEVICE|High Flow Nasal Oxygen (HFNO)|HFNO will be initiated at a flow rate of 40 LPM and a fraction of inspired oxygen (Fi02) of \< 60%. If oxygen saturation (SpO2) remains \< 92%, the flow rate will be increased to 60 LPM. FiO2 will then be adjusted to target a SpO2 ≥ 92%. Patients with discomfort due to HFNO may have their flow rate decreased until the discomfort resolves.
223987703|NCT05933785|PROCEDURE|transanal endoscopic ISR|perform ISR using laparoscopy through transanal port
223987704|NCT01560845|PROCEDURE|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
223987705|NCT01560845|PROCEDURE|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
223987706|NCT02839005|OTHER|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
223987707|NCT02839005|OTHER|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
224120508|NCT02975440|DRUG|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
224120509|NCT02975440|DRUG|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
224294417|NCT03265067|DEVICE|autoRIC|Application of the autoRIC device
223728688|NCT02319993|DRUG|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
223728689|NCT02319993|DRUG|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
223728690|NCT02319993|DRUG|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
223728691|NCT05623098|DIETARY_SUPPLEMENT|dietary fiber nutrients|Whether to add nutrients containing dietary fiber
223987708|NCT04202445|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
223987709|NCT02735304|OTHER|Impression intervention|The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
223987710|NCT01371422|OTHER|Paravertebral Block (PVB)|"The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level."
223987711|NCT01371422|OTHER|Saline|Ultrasonography and local infiltration of saline will only be performed
223987712|NCT04560374|DEVICE|crochet octopus|Delivering crochet octopus to the hands of the neonates
223987713|NCT02274090|DRUG|Placebo gel|Placebo gel consist of drug without the active component.
223987714|NCT02274090|DRUG|1% Metformin gel|Metformin gel consist of active component.
223987715|NCT03721705|DEVICE|Renew NCP-5|Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.
224120510|NCT02975440|DRUG|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
224120511|NCT02242227|DRUG|Salmeterol xinafoate|
224120512|NCT02242227|DRUG|Serevent® Diskus®|
224120513|NCT02242227|DRUG|Placebo (HandiHaler®)|
223987716|NCT05783609|DRUG|Epcoritamab|T-cell bispecific antibody, via subcutaneous injection
223987717|NCT05783609|DRUG|Rituximab|Chimeric anti-CD20 monoclonal antibody, via IV infusion
223987718|NCT01790295|DRUG|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
223987719|NCT03105063|DIAGNOSTIC_TEST|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
223987720|NCT00389272|DRUG|Ibuprofen, acetaminophen|
223987721|NCT02489734|DRUG|sevoflurane|extubation when end-tidal concentration of sevoflurane \< 0.5%
223987722|NCT02489734|DRUG|Sevoflurane|extubation when end-tidal concentration of sevoflurane \>= 0.5%
223987723|NCT01746147|OTHER|No intervention and study treatment|
223987724|NCT03597373|OTHER|reintubation|Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
223987725|NCT03204162|OTHER|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
223987726|NCT03721172|DRUG|Apremilast|Apremilast, oral, twice daily
223987727|NCT03721172|OTHER|Placebo|Placebo, oral, twice daily
223987728|NCT00179738|DRUG|CC5013|
223987729|NCT04594837|DEVICE|PTR Physical Therapy while wearing Robot group (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
223987730|NCT04594837|OTHER|Physical Therapy Only (Phase II)|Subjects receive 18 one-hour PT training sessions over 9 weeks. Subjects perform over-ground mobility tasks of increasing challenge with therapist assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
224120514|NCT02242227|DRUG|Placebo (Diskus®)|
224120515|NCT03971084|OTHER|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
224120516|NCT03971084|OTHER|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
224120517|NCT02600026|DEVICE|DriveCam|Video event monitoring device
224120518|NCT02600026|BEHAVIORAL|Feedback|Video feedback intervention
224120519|NCT05263128|OTHER|Investigation of the validity of the Hand-20 Questionnaire in individuals with carpal tunnel syndrome|To investigate the validity and reliability of the Hand-20 questionnaire used in individuals with upper extremity disease by comparing it with the Boston carpal tunnel syndrome questionnaire in individuals with carpal tunnel syndrome in Turkey
224120520|NCT04771052|OTHER|COVID Rehabilitation Program for the Elderly (CORE)|In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
224120521|NCT04077307|DRUG|Karonudib|First part of the study - four different dose cohorts Extension part of the study - karonudib BID (twice a week) and Idarubicin days 1-3.
224120522|NCT01104558|DRUG|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
224120523|NCT03810690|BIOLOGICAL|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
224294418|NCT00005586|DRUG|L-leucovorin|
223987731|NCT04594837|DEVICE|Cross over group for Physical Therapy n Sub-Acute group. (Phase II)|Participants enrolled in the physical therapy only group will be given the option to re-enroll as a cross over participant to receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
223987732|NCT04594837|DEVICE|Chronic Stroke Subjects to receive robotic gait training therapy.|Chronic stroke subjects receive 18 one-hour PT training sessions over 9 weeks while wearing the robot initially parameterized to individual deficit severity. Subjects perform over-ground mobility tasks of increasing challenge with robotic assist, as needed. Training is generally divided into 3 phases based on individual ability to address gait deficits, postural transitions, physical demand and environmental terrain.
223987733|NCT00420784|DRUG|Telaprevir|tablet
223987734|NCT00420784|DRUG|Ribavirin|tablet
223987735|NCT00420784|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
223987736|NCT00420784|DRUG|Matching Placebo|Tablet
223987737|NCT00092053|DRUG|Placebo|tablets
223987738|NCT00092053|DRUG|ibandronate|50 mg tablets
223987739|NCT05764161|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
223987740|NCT05764161|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
223987741|NCT06441864|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares|The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. Partners will attend 2 of the 7 treatment sessions. During the sessions, participants will learn techniques for managing and changing nightmares.
223987742|NCT06183541|PROCEDURE|Pericapsular Nerve Group (PENG) Block|Pericapsular nerve group (PENG) block The femoral nerve and obturator nerve terminal branches, which provide sensory innervation of the hip joint, are blocked, thus providing analgesia without creating a motor block.
223987743|NCT00157794|DEVICE|Search AV+ algorithm|
223987744|NCT06179290|OTHER|Ploom HTP Menthol HTS; MX3 (681)|Menthol heated tobacco product
223987745|NCT06179290|OTHER|Ploom HTP Tobacco HTS; R8 (120)|Non-menthol heated tobacco product
223987746|NCT06179290|OTHER|Smoking Abstinence (menthol)|No smoking or other tobacco product use for duration of the study, menthol group comparator
223987747|NCT06179290|OTHER|Smoking Abstinence (non-menthol)|No smoking or other tobacco product use for duration of the study, non-menthol group comparator
223987748|NCT03052660|DRUG|Midazolam|Oral administration preoperatively
224120524|NCT01755195|DRUG|Cabozantinib|Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
223987749|NCT03052660|DRUG|Placebo oral capsule|Oral administration preoperatively
223987750|NCT00148408|DRUG|Montelukast|
223987751|NCT00148408|BEHAVIORAL|Education|
223987752|NCT04884919|DEVICE|Regular Gauze|Regular gauze
223987753|NCT04884919|DEVICE|Chitosan Dressing|Dressing made of chitosan material
223987754|NCT06846775|DIAGNOSTIC_TEST|DNA-methylation testing in patient-collected urine and vaginal samples|DNA-methylation testing of methylation markers CDO1, GHSR and ZIC1 for patient-collected vaginal samples and GHSR, CDH13 and SST for patient-collected urine samples.
223987755|NCT04589299|BIOLOGICAL|Immunoglobulin|Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
223987756|NCT01914081|OTHER|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
223987757|NCT01914081|OTHER|Placebo|Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
223987758|NCT03005990|OTHER|Exercise training group|The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
223987759|NCT03845270|DRUG|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
223987760|NCT05679804|OTHER|validity and realibility of scale|Turkish validity and realibility of Bipolar Recovery Questionnare
224120525|NCT02139995|BEHAVIORAL|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
224120526|NCT01132677|DEVICE|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
223728692|NCT04134468|DRUG|Pegvorhyaluronidase alfa|IV infusion
223728693|NCT04134468|DRUG|Abraxane|IV infusion
223987761|NCT04081077|DRUG|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
224294419|NCT00005586|DRUG|fluorouracil|
223987762|NCT04081077|DRUG|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
223987763|NCT04081077|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
223987764|NCT04081077|DRUG|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
223987765|NCT04081077|DRUG|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
223987766|NCT01951768|DRUG|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
223987767|NCT01951768|DRUG|Systemic Antibiotic|"Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
223987768|NCT05534932|DEVICE|Remote Patient Monitoring|Subjects in this group will receive RPM therapy through the University of Chicago Heart Failure program. This therapy consist of a bluetooth tablet, blood pressure cuff and a health scale for subjects to bring home and take thier measurements on a daily bases up to their 3 month clinic visit. This data will then be transmitted to EPIC where the study team will retrieve the data.
223987769|NCT02509520|DIETARY_SUPPLEMENT|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
223987770|NCT00951470|OTHER|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
223987771|NCT00951470|OTHER|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
223987772|NCT00951470|OTHER|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
223987773|NCT04061135|PROCEDURE|Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
223987774|NCT05567757|BIOLOGICAL|Arteriovenous conduit implant|Study subjects will be implanted with an arteriovenous shunt for hemodialysis access in the upper extremity
223987775|NCT05425264|OTHER|Tele-exercise|Exercise training 2x/week at home. Sessions include circuit exercises of aerobic and resistive training stations which are led remotely.
223987776|NCT00745771|DRUG|Diractin|
223987777|NCT00745771|DRUG|Diractin|
224120527|NCT01132677|DRUG|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
224294420|NCT00005586|PROCEDURE|adjuvant therapy|
223728694|NCT04134468|DRUG|Gemcitabine|IV infusion
223987778|NCT01198483|PROCEDURE|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
223987779|NCT01198483|PROCEDURE|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
223987780|NCT06477861|OTHER|calculation of the elastic power of the lung in case of the ARDS and corolating with the severity index of Berline definition of ARDS in respect to mortality and severity|calculation of variables of the elastic power of the lung from the lung pressures on the ventilator : Elastic power = 0.098 \* tidal volume \* respiratory rate \* 1/2(PEEP+Pplat)
223987781|NCT00037713|BIOLOGICAL|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 \& 10.
223987782|NCT01093443|DRUG|ovarian stimulation|rFSH with GnRH antagonists
223987783|NCT01093443|DRUG|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
223987784|NCT00621205|BEHAVIORAL|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
223987785|NCT00025909|PROCEDURE|Leukapheresis|
223987786|NCT02402322|BEHAVIORAL|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
223987787|NCT02402322|BEHAVIORAL|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
223987788|NCT06035536|DEVICE|Symphony™ plus Off-loading|Application of Symphony™
223987789|NCT06035536|DEVICE|Wound Dressing comprising of calcium alginate Fibracol|Application of Wound Dressing comprising of calcium alginate Fibracol.
223987790|NCT04593823|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
223987791|NCT00530582|DRUG|progesterone|300mg progesterone /placebo each for 21 days
223987792|NCT04442347|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) mRNA formulated in a lipid nanoparticle (LNP) under development.
223987793|NCT04442347|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
223987794|NCT01408810|DRUG|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
223987795|NCT03511690|BEHAVIORAL|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
223987796|NCT01061099|BIOLOGICAL|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
223987797|NCT02472145|DRUG|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/\[m\^2\]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
223987798|NCT02472145|DRUG|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
223987799|NCT05297344|PROCEDURE|direct pulp capping|direct pulp capping
223987800|NCT05297344|PROCEDURE|pulpotomy|pulpotomy
223728695|NCT02202408|DRUG|SKI2670|Oral, Single Dose
223987801|NCT05833659|PROCEDURE|The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy|Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
223987802|NCT01296555|DRUG|Fulvestrant|Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics \[SmPC\]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
223987803|NCT01296555|DRUG|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
223987804|NCT01296555|DRUG|Letrozole|Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
223987805|NCT01296555|DRUG|Midazolam|Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
223987806|NCT05762419|DRUG|Etoposide; Oral, 50 Mg|Subjects will receive focused ultrasound sonication followed by once daily oral etoposide (50mg/m\^2/dose). Oral etoposide will be taken every day for 21 days, followed by one week of rest. For the first cycle, etoposide will be administered immediately following confirming of the blood brain barrier opening through contrast magnetic resonance imaging (MRI) which will occur within 4 hours of the focused ultrasound procedure. For subsequent cycles, etoposide will be administered immediately following the focused ultrasound procedure. Subjects may continue for a maximum of 4 cycles.
223987807|NCT05762419|DEVICE|Focused ultrasound with neuro-navigator-controlled sonication|Focused ultrasound sonication will be performed a maximum of three times a week for two weeks with two weeks of rest.
223987808|NCT03998722|DEVICE|Vagivital|Vagivital once Daily for 12 weeks
223987809|NCT03115398|BEHAVIORAL|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
223728696|NCT02202408|DRUG|Placebo|Same shape as the experimental drug
223728697|NCT00380497|DRUG|PEG-Lyte®|
223728698|NCT00380497|DRUG|Pico-Salax®|
223987810|NCT02602483|DRUG|Ibuprofen|
223987811|NCT02602483|DRUG|Magnesium|
223987812|NCT02602483|DRUG|Ascorbic Acid|
223987813|NCT02602483|DRUG|Placebo|
223987814|NCT06333977|DRUG|LC542019|oral dose, once daily
223987815|NCT06333977|DRUG|Placebo|matching placebo
223987816|NCT01617499|BEHAVIORAL|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
223987817|NCT01183442|DRUG|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
223987818|NCT03817723|RADIATION|c-arm cholangiography|
223987819|NCT05964959|OTHER|Mouth Educational Program|The Mouth Educational Program is a nurse-led patient education program for dry mouth in patients with a life-limiting condition or frailty.
223987820|NCT05964959|OTHER|Care as Usual|Care as usual is defined as the standard dry mouth care as provided by participants' own treating physicians.
223987821|NCT05643898|BEHAVIORAL|Mamá, te entiendo (Mom, I get you)|"Mamá, te entiendo is a guided 8-week cognitive-behavioral app-based intervention that targets postpartum women with minor and major depression. The development of the intervention followed the CeHRes Roadmap. It includes some elements from attachment and mentalization theories.~The intervention consists of six main sequential modules and three optional modules. All modules except the two psychoeducational ones include homework. Participants will receive feedback from an e-coach. They also can contact the e-coach to solve doubts about the app content and exercises. Other sections of the app include infographics about other relevant topics (for example, How to strengthen the couple relationship), a shareable document with reading about how to support a loved one struggling with depression and a resources section with links to websites and documents of interest."
223987822|NCT01052389|DRUG|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
223987823|NCT01052389|DRUG|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
223987824|NCT01052389|DRUG|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
223987825|NCT00677768|OTHER|No intervention|Sample collection
223987826|NCT01200498|DRUG|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
224120528|NCT04452162|DIAGNOSTIC_TEST|MRI|You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
224120529|NCT00419913|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|DHEA 25 mg tid
224120530|NCT05710887|DRUG|Nitrous oxide gas for inhalation|Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
224120531|NCT05710887|DRUG|Placebo|Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
224120532|NCT04980833|DRUG|Alpelisib|Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
223987827|NCT02444728|DRUG|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
223987828|NCT02444728|DRUG|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
223987829|NCT02444728|DRUG|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
223987830|NCT02444728|DRUG|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
223987831|NCT05281289|OTHER|kinesio-tape|KT is comprised of a polymer elastic strand warped by 100% cotton fibers and designed to allow a longitudinal stretch of 55-60% of its resting length.
223987832|NCT05281289|OTHER|stretching exercise|15 seconds of passive stretching exercise for calf muscle followed by 30 seconds of rest
223987833|NCT05281289|OTHER|instructions about dealing with calf cramps|instructions about dealing with calf cramps by self low sustained stretch of calf muscle
223987834|NCT01989949|DRUG|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
223987835|NCT03980990|DRUG|Metformin|Continuation of Metformin
223987836|NCT01586975|DRUG|Clopidogrel|Clopidogrel 75 mg QD
223987837|NCT01586975|DRUG|Aspirin 81 mg|Aspirin 81mg QD
223987838|NCT01586975|DRUG|Aspirin >300 mg|Aspirin \>300 mg QD
223987839|NCT00966030|DRUG|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
223987840|NCT00966030|DRUG|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
223987841|NCT04376112|OTHER|Pharmacist and pillpack intervention|These participants will be randomized into one of the following two cohorts: standard of care (SOC) and pharmacy intervention group (blister packaging + MTM services). For pharmacy intervention (PI) group, the POCT will be used to measure HbA1c and blood pressure (BP) at baseline, 3, and 6 months during medication therapy management (MTM) service. Recommendation from MTM services will be documented in the patients' electronic medical records (EMRs) and shared with their primary care providers. For the SOC group, HbA1c and BP will be measured at the physician's office and researchers will have an access to participants' EMR.
223987842|NCT04376112|OTHER|Standard of care|None. Regular visits to primary care physician. Will measure HbA1c and blood pressure at baseline, 3, and 6 months
223987843|NCT04040998|BEHAVIORAL|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
223987844|NCT04053569|DIETARY_SUPPLEMENT|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
223987845|NCT03380364|DEVICE|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
223987846|NCT04657562|DRUG|Tacrolimus|Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
223987847|NCT04657562|DIAGNOSTIC_TEST|Unbound tacrolimus measurement|Unbound tacrolimus measurement in plasma ultrafiltrate.
223987848|NCT04657562|DIAGNOSTIC_TEST|CYP3A4 and CYP3A5 genotyping|DNA purification and genotyping
223987849|NCT04533828|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
224120533|NCT05429736|BEHAVIORAL|Motor Skill Training (MST)|During MST participants will perform a series of 6 motor skill exercises designed to challenge balance, lower extremity coordination, agility, and speed. Five of these activities will be performed while standing to promote upright control and one activity will be performed while seated (alternating toe-tapping) to provide opportunity for active recovery. Participants will perform each exercise for one minute each, until 4 cycles of the circuit have been completed (approximately 45 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). During MST, participants will wear a chest-worn heart rate monitor to ensure that the optimal HRR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
223987850|NCT05967078|DEVICE|ExerG|"The intervention for primary end users (PEU, (patients)) includes the performance of two training rounds with the device. The first round includes a predefined training sequence, whereas the second round is a training sequence defined by the therapist.~For the secondary end user group (SEU, (therapists)), there are two study visits. At their first visit they get an introduction and training on how to use the system. At their second visit, SEU will have to prepare the device (switch on hard- and software) and guide the patient through the training."
223987851|NCT02163707|DRUG|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
223987852|NCT03970499|PROCEDURE|brain tumor resection|Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
223987853|NCT05156515|DIAGNOSTIC_TEST|68Ga-THP-APN09|APN09, nanobody targeting PD-L1, labeled with PET radio-nuclide (68Ga) will be used as a molecular imaging tracer for PET/CT scan.
223987854|NCT03000348|DRUG|Cysteamine|Oral Cysteamine Capsule
223987855|NCT03000348|DRUG|Placebo Oral Capsule|Placebo Oral Capsule
223987856|NCT06034899|DRUG|BMS-986196|Specified dose on specified days
223987857|NCT00741208|DIETARY_SUPPLEMENT|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
223987858|NCT02429986|DEVICE|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
223987859|NCT06314139|DEVICE|continuous theta-burst stimulation (cTBS)|Continuous theta-burst stimulation (cTBS) was performed with a CCY-I Magnetic Stimulator (YIRUIDE Medical Co., Wuhan, China) with an air-cooled, figure-of-eight 70 mm coil. The site of stimulation during the TMS treatment sessions was bilateral M1 and cerebellum. Real cerebellar cTBS was delivered with the coil positioned over the cerebellar hemisphere, i.e., 3 cm laterally to and 1 cm below the inion. The cTBS protocol uses a complex pattern of stimulation consisting of three-pulse bursts at 50 Hz repeated every 200ms. A total of 600 pulses that lasts for about 40 seconds were applied which could result in a sustained reduction in corticospinal excitability that outlasted the period of stimulation by 45 min. It was delivered at an intensity corresponding to 80 % of the active motor threshold (AMT), this is the minimum stimulation intensity that evokes MEPs of approximately 200 μV in amplitude in tonically contracted muscles.
223987860|NCT02661633|DEVICE|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
223987861|NCT02661633|DEVICE|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
223987862|NCT04042077|DRUG|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
223987863|NCT04042077|DRUG|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
223987864|NCT04042077|DRUG|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
223987865|NCT04042077|DRUG|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
223987866|NCT04042077|DRUG|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
223987867|NCT00696488|DRUG|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
223987868|NCT01159522|DRUG|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
223987869|NCT01758744|DRUG|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
223987870|NCT00745498|DRUG|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
223987871|NCT03672942|BEHAVIORAL|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
223987872|NCT03672942|BEHAVIORAL|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
223987873|NCT03672942|BEHAVIORAL|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
223987874|NCT00079755|DRUG|SGN-30 (anti-CD30 mAb)|
223728699|NCT01050972|BEHAVIORAL|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
224120534|NCT05429736|DEVICE|Transcutaneous Spinal Stimulation (TSS)|TSS will be delivered using a commercially available neuromuscular electrical stimulator. The active electrode will be positioned directly over the spine at the T11/T12 spinous interspace, and the reference electrode will be positioned over the umbilicus. Stimulation intensity will be gradually increased until paresthesia of the lower legs and feet is achieved or to the highest level each participant can tolerate. Stimulation will be delivered for a total duration of 30 min after paresthesia/ maximum tolerability is reached.
224120535|NCT04686318|DIAGNOSTIC_TEST|Biomarkers for acute pyelonephritis|"Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of CRP, PCT and suPAR. Laboratory staff will be blinded to participant diagnosis and outcome. CRP and PCT results will be available to the treating physician, but the suPAR result will not be available.~* Diagnostic test of CRP. CRP will be measured using an immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi Cobas© systems.~* Diagnostic test of PCT: Plasma PCT will be quantified by an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas© within two hours from collection according to standard procedure.~* Diagnostic test of suPAR: Plasma suPAR will be quantified by using the commercial available suPARnostic© Tubilatex assay reagents (ViroGates, Denmark) on Cobas© as previously validated (35). Separated plasma is kept refrigerated and analysed for suPAR within 48 hours after collection."
224120536|NCT00479024|DRUG|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
223728700|NCT01169974|OTHER|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 \& 3 minutes
223728701|NCT00869453|OTHER|test meal|Mixed meal containing bread, butter, beef
223728702|NCT00869453|OTHER|glucose|administration of a glucose meal
223987875|NCT03159351|DEVICE|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
223987876|NCT03159351|DEVICE|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
223987877|NCT00298675|DRUG|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
223987878|NCT00298675|DRUG|irinotecan|Irinotecan administered weekly, IV.
223987879|NCT00299806|DRUG|Aliskiren|
223728703|NCT00869453|OTHER|fat|administration of a lipid meal
223728704|NCT00869453|OTHER|protein|administration of a protein meal
223728705|NCT00869453|OTHER|control|no meal
223987880|NCT04502797|BEHAVIORAL|Electronic Patient Visit Assessment (ePVA)|The ePVA is an mHealth clinical support tool. The ePVA consists of a patient-reported measure that focuses on symptoms common to HNC (i.e. pain, eye, ear, nasal, mouth, voice, fibrosis, edema, skin, gastrointestinal, fatigue, limitation in movement, sleep, breathing, difficulty eating or drinking, swallowing, communication, social activities, anxiety, depression, and daily activities). PROMIS® questionnaires (pain intensity 3a, fatigue 6a, sleep disturbance 6a, anxiety 6a, depression 6a) are embedded within the ePVA.
223987881|NCT05196451|BEHAVIORAL|Rehabilitation based on CBT principles|Cf. arm description
223728706|NCT06505616|DEVICE|Compared the trombogenicity of the Solacea dialyzer with synthetic dialyzers after progressively decreasing heparin until discontinuing it|The duration of the study was four weeks, carried out in two phases. After screening, patients were randomized to be dialyzed with the Solacea™ hemodialyzer versus the usual hemodialyzer, which in all cases had to be a synthetic membrane. In both arms, heparin was progressively decreased until it was discontinued. Afterwards the patients were crossed over to the other arm.
223987882|NCT05597423|OTHER|Massage|The massage will be applied for 16 minutes on the quadriceps, calf, hamstrings and lower back bilaterally with 4 different pressures.
223987883|NCT05597423|OTHER|Placebo|The cream will be applied to the quadriceps, calf, hamstring and lower back bilaterally and the participant will wait 16 minutes lying down in the supine position.
223987884|NCT02442193|OTHER|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
223987885|NCT02188537|DRUG|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
223987886|NCT02188537|DRUG|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
223987887|NCT02188537|DRUG|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
223987888|NCT00005599|DRUG|bryostatin 1|
224120537|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer relaxing acupressure
224120538|NCT06442891|PROCEDURE|Acupressure Therapy|Self-administer sham acupressure
223987889|NCT00005599|DRUG|paclitaxel|
223987890|NCT02409446|DIETARY_SUPPLEMENT|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
223987891|NCT02365103|OTHER|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
223987892|NCT02365103|OTHER|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
223987893|NCT02365103|OTHER|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
223987894|NCT02365103|OTHER|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
223987895|NCT05578430|DRUG|Cadonilimab|10mg/kg by intravenous infusions every 3 weeks
223987896|NCT05578430|PROCEDURE|TACE|TACE will be performed per institutional standard of care.
223987897|NCT05578430|PROCEDURE|Surgery|Surgery will be performed per institutional standard of care.
223987898|NCT00943046|DEVICE|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
223987899|NCT00827554|DRUG|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
224120539|NCT06442891|OTHER|Internet-Based Intervention|Receive access to acupressure mobile app
224120540|NCT06442891|OTHER|Interview|Ancillary studies
224120541|NCT06442891|OTHER|Medical Device Usage and Evaluation|Receive an AcuWand
224120542|NCT06442891|OTHER|Questionnaire Administration|Ancillary studies
224120543|NCT00772512|DRUG|PF-04802540|5 mg capsule, single dose
223728707|NCT01200602|DRUG|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
223728708|NCT01200602|OTHER|clinical observation|No treatment is given.
223987900|NCT00827554|PROCEDURE|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
223987901|NCT01084226|DIETARY_SUPPLEMENT|Rye-2008|
223728709|NCT02648178|DEVICE|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
223987902|NCT06260488|PROCEDURE|Endovascular surgery|routine endovascular surgery and FPAS harvesting from amputated limbs to evaluate the technical feasibility of histological segmentation by the FPAS algorithm from CT
223987903|NCT02271022|OTHER|Non-Interventional Study|Non-Interventional Study
223987904|NCT02595320|DRUG|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
223987905|NCT02191904|OTHER|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
223987906|NCT00085397|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
223987907|NCT00085397|BIOLOGICAL|gp100 antigen|Given IV
223987908|NCT00085397|BIOLOGICAL|therapeutic autologous dendritic cells|Given IV
223987909|NCT00884897|DRUG|Oxytocin|Oxytocin given as 20 IU BID
223987910|NCT00884897|DRUG|Placebo|Placebo given as 20 IU BID
224120544|NCT00772512|DRUG|PF-04802540|15 mg capsule, single dose
224120545|NCT00772512|DRUG|Placebo|Placebo capsule, single dose
224120546|NCT01447173|DRUG|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
224120547|NCT01740622|OTHER|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
223987911|NCT04679155|BEHAVIORAL|Eating Time Restriction|early vs late time of day restriction
223987912|NCT03639727|DIAGNOSTIC_TEST|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
223987913|NCT03639727|DIAGNOSTIC_TEST|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
224120548|NCT00568789|DRUG|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
224120549|NCT03445013|DRUG|SB414 6%|Twice daily
224120550|NCT03445013|DRUG|Vehicle|Vehicle Comparator
224120551|NCT05791318|DRUG|VYD222|Monoclonal antibody
224120552|NCT05791318|OTHER|Placebo|Matching Placebo
224120553|NCT05027646|DRUG|Sancuso - Part 1|Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
224120554|NCT05027646|DRUG|Sancuso - Part 2|Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
224120555|NCT01150877|DRUG|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
224120556|NCT05142657|OTHER|diet survey|Dietary survey applied to all participants
224120557|NCT05482269|OTHER|no intervention|no intervention
224120558|NCT02423824|BIOLOGICAL|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
223987914|NCT01510353|DEVICE|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
224120559|NCT01003028|DRUG|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
224120560|NCT01003028|DRUG|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
223728710|NCT02041611|PROCEDURE|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
223728711|NCT00271583|DRUG|CDB-2914|
223728712|NCT00271583|DRUG|levonorgestrel|
223728713|NCT00933374|DRUG|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
223728714|NCT00933374|DRUG|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
223728715|NCT00438984|DRUG|cyclophosphamide|Given IV
223728716|NCT00438984|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
223728717|NCT00438984|BIOLOGICAL|aldesleukin|Given IV or SC
223987915|NCT02806843|DEVICE|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
224120561|NCT03312777|DRUG|Omnitram|Omnitram tablets overencapsulated
224120562|NCT03312777|DRUG|Tramadol|Tramadol tablet overencapsulated
224120563|NCT03312777|DRUG|Placebo|Microcrystalline powder overencapsulated
224120564|NCT00595699|DRUG|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
224120565|NCT00595699|DRUG|placebo|Placebo
224120566|NCT03640806|OTHER|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
224120567|NCT03451864|PROCEDURE|Vaginal delivery|classic vaginal delivery
224120568|NCT03451864|PROCEDURE|Cesarean Section|routine lower segment cesarean scetion
223987916|NCT05923645|DEVICE|Transcranial magnetic stimulation (Hf rTMS)|"TMS protocol - 5 Hz High frequency rTMS, at 100% RMT, 60 pulses per train, total 10 trains , gap between 2 consecutive trains of 30 sec, at left IPL and left STG localised using 10-20 EEG based system at P3 and P5 respectively , using figure of 8 coil~1st cycle of 10 sessions over 10 consecutive days, 2nd cycle of 5 sessions over 5 consecutive days , 3rd cycle for 5 sessions over 5 consecutive days ; gap of 6 weeks between 2 consecutive cycles Total 3 cycles per patient"
223987917|NCT01980004|DIETARY_SUPPLEMENT|Potassium Citrate Supplementation|20 mEq taken twice daily
224120569|NCT03587675|DIAGNOSTIC_TEST|EVH test|
224120570|NCT03811223|DRUG|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
224120571|NCT03811223|DRUG|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
224120572|NCT00527215|DRUG|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
224120573|NCT04141787|DRUG|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
224120574|NCT04141787|DRUG|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
224120575|NCT02258009|DRUG|Ranibizumab|0.5 mg intravitreal injections
224120576|NCT02258009|DRUG|Aflibercept|2 mg intravitreal injections
224120577|NCT02850887|OTHER|general endotracheal anesthesia|sedation with the use of endotracheal intubation
224120578|NCT02850887|OTHER|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
224120579|NCT02656992|DEVICE|Inspiratory muscle training group|
224120580|NCT01743586|OTHER|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
224120581|NCT01931462|DEVICE|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
224120582|NCT02361762|BEHAVIORAL|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
223728718|NCT00438984|OTHER|immunohistochemistry staining method|Correlative studies
223728719|NCT00438984|PROCEDURE|biopsy|Optional correlative studies
223728720|NCT00438984|OTHER|laboratory biomarker analysis|Correlative studies
223728721|NCT00438984|OTHER|immunologic technique|Correlative studies
223728722|NCT00438984|GENETIC|polymerase chain reaction|Correlative studies
223987918|NCT01980004|OTHER|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
224120583|NCT03940924|OTHER|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
224120584|NCT02053389|BEHAVIORAL|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
224120585|NCT02053389|BEHAVIORAL|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
224120586|NCT01383395|DRUG|simvastatin/cilostazol|
224120587|NCT02819310|DRUG|BLI400 Laxative|oral laxative
224120588|NCT03483324|BIOLOGICAL|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
224120589|NCT03483324|BIOLOGICAL|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
224120590|NCT02046265|BEHAVIORAL|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
224120591|NCT02046265|BEHAVIORAL|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
224120592|NCT02046265|BEHAVIORAL|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
224120593|NCT02046265|BEHAVIORAL|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
224120594|NCT06530602|OTHER|3 D SPA (shoulder complex pain alignment) Moblization|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
224120595|NCT06530602|OTHER|Shoulder Moblization (KaltenBorn)|3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
223987919|NCT03375736|DEVICE|whole body vibration|The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
223987920|NCT04088929|DRUG|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
223728723|NCT00002602|RADIATION|3D-CRT|3 dimensional conformal radiation therapy
223987921|NCT01096576|DRUG|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
223987922|NCT01096576|DRUG|placebo|orally twice daily for 5 days
223987923|NCT01502592|PROCEDURE|Cryoablation|"OncCore Biopsy (+ Cryo) Date\*~* Pre- and post- cryo MRI~* Core biopsy x ≥3~* Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date\* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.\*"
223987924|NCT01502592|BIOLOGICAL|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date\*~* MRI~* Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date\* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
223987925|NCT04452136|DRUG|68GA PSMA-HBED-CC|Given IV
223987926|NCT00358982|DRUG|MGCD0103|MGCD0103 administered orally three times per wek
223987927|NCT02609542|OTHER|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
223987928|NCT02768350|PROCEDURE|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
223987929|NCT02768350|PROCEDURE|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
223987930|NCT05196971|DRUG|HS-10345 84mg|6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
223987931|NCT05196971|DRUG|Placebo|6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
223987932|NCT05834868|DRUG|THDB0206 Injection|Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.
223987933|NCT05834868|DRUG|Insulin Lispro Injection|Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.
223987934|NCT02830282|OTHER|Blood Collection|
223987935|NCT06119152|BEHAVIORAL|DESA|Intervention group is monitored via remote bp monitoring and telehealth device.
223987936|NCT05735665|DIAGNOSTIC_TEST|bowel ultrasound|Bowel US is a non-invasive tool which is able to measure intestinal inflammation by the use of emission of US from a specific probe. It is used externally, just moving the probe on the skin of the patient along the abdominal section. It does not require any contrast. The preparation used is just a fasting period of 6 hours.
223987937|NCT05735665|DIAGNOSTIC_TEST|colonoscopy|Colonoscopy is an endoscopic procedure where a tube is inserted from the anus up to the ileum of the patient. It requires bowel cleansing with polyethilenglicole up to 4 liters (depending on the preparation and the desired grade of cleansing) the day before the examination. Because it may be painful, usually sedation is provided.
223987938|NCT00501683|DRUG|Radiolabelled GSK189075|
223987939|NCT04530578|DRUG|Heparin sodium|Nebulized Heparin every 8 hours plus Subcutaneous Enoxaparin every 24hours
223987940|NCT04530578|DRUG|Enoxaparin|Subcutaneous Enoxaparine every 24 hours
224120596|NCT02266901|PROCEDURE|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
223728724|NCT04821921|OTHER|No intervention|Care as usual
223987941|NCT06234553|PROCEDURE|surgery of pituitary adenomas|evaluate pathological type and treatment effect after treatment
223987942|NCT02853487|DEVICE|Actigraphy|An actigraph from Philips
223987943|NCT02853487|OTHER|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
223987944|NCT02031536|DRUG|everolimus|Given PO
223987945|NCT02031536|OTHER|placebo|Given PO
223987946|NCT06370442|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 100mcg
223987947|NCT06370442|DRUG|Lorazepam|0.5mg IV
223987948|NCT06370442|DRUG|Haloperidol|0.5mg IV
223987949|NCT06028490|BIOLOGICAL|GR1802 injection-1|subcutaneous，dose\*1
224120597|NCT04345991|DRUG|Transfusion of COVID-19 convalescent plasma|Two convalescent plasma units of 200 to 220 ml each will be transfused i.v. as early as possible and no later than 10 days after onset of clinical symptoms. In the absence of acute unforeseen adverse events in the first 3 patients, an additional 2 plasma units of 200/220 ml each will be transfused 24 hours after first 2 units: a total of 4 units / patient
223987950|NCT06028490|BIOLOGICAL|GR1802 injection-2|subcutaneous，dose\*2
223987951|NCT06028490|BIOLOGICAL|Placebo|subcutaneous，dose\*2
223987952|NCT04449237|OTHER|music therapy|music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
223987953|NCT00905047|DRUG|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days"
223987954|NCT00905047|DRUG|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days."
223987955|NCT04678778|BEHAVIORAL|Physical and Cognitive Activity|There are three sessions a week for the course of 12 weeks. Each session consists of 5 trials.
223987956|NCT00799955|PROCEDURE|Placebo block|100 micrograms of spinal morphine
223987957|NCT00799955|PROCEDURE|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
223987958|NCT04530604|DRUG|Defibrotide|"All patients will receive 25 milligram/kilogram/day (mg/kg/day) of defibrotide, given in 4 divided doses (approximately every 6 hours), each dose infused over 2-hours intravenously (IV).~The planned duration of study therapy is 7 days (while in the hospital), with the following qualifications:~* Patients who respond to study therapy prior to day 7 (able to discontinue oxygen) will discontinue study therapy at that earlier time point.~* Patients who have not responded to study therapy by day 7 of therapy, evidenced by \<20% reduction (or a worsening) of the amount of supplemental oxygen they are receiving, will discontinue study therapy at day 7.~* Patients who have evidence of a partial pulmonary response by day 7 (\>20% reduction in supplemental oxygen requirement, but still require supplemental oxygen) may elect to continue to receive study drug through an additional 7 days of study (total 14-day therapy course)."
223987959|NCT03180944|DRUG|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
223987960|NCT03180944|DRUG|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
223987961|NCT03180944|DRUG|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
223987962|NCT03180944|DRUG|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
223987963|NCT03180944|DRUG|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
223987964|NCT05442450|DRUG|oral semaglutide|Participants in Experimental group will receive oral Semaglutide along with diet and exercise. Treatment will be initiated with the 3 mg once-daily dose. The dose will be increased to 7 mg and then maximum of 14mg per day in 2-4weeks interval based on patient tolerance.
223987965|NCT01282515|DRUG|clobetasol propionate 0,05% ointment|continuously daily treatment for 6 weeks
223987966|NCT01282515|DRUG|hexaminolevulinate|one PDT treatment
223987967|NCT00304772|DRUG|Fluconazole|400mg/day
223728725|NCT01840501|DRUG|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
223987968|NCT00304772|DRUG|Micafungin|150mg/day
223987969|NCT02718222|DEVICE|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
223987970|NCT00561106|DRUG|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
223987971|NCT00561106|DRUG|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
223987972|NCT01702870|PROCEDURE|Magnetic Resonance Imaging|
223987973|NCT00838929|DRUG|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
224120598|NCT03239756|BIOLOGICAL|TK006|Subcutaneous injection
224120599|NCT01790893|DRUG|aflibercept|
223987974|NCT00838929|RADIATION|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
223987975|NCT06181474|OTHER|ESAS|Observation of symptoms
223987976|NCT04101565|BEHAVIORAL|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
223987977|NCT04461158|BEHAVIORAL|Patient Navigator Services|The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
223987978|NCT06114277|OTHER|ETCO2 levels|Intraoperative ETCO2 values between 26 and 35 in laparoscopic robotic prostatectomy patients were included in group 1.
223987979|NCT06114277|OTHER|Patients with high ETCO2 levels|Intraoperative ETCO2 values between 36 and 45 in laparoscopic robotic prostatectomy patients were included in group 2.
223987980|NCT03652571|DRUG|Nortriptyline|"Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg"
223987981|NCT03652571|DRUG|Placebo|Placebo
223987982|NCT02353312|DRUG|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
223987983|NCT00170261|DEVICE|Use of an Implantable Loop Recorder|
224120600|NCT01300468|DRUG|PHA-848125AC|
223987984|NCT01068210|BEHAVIORAL|Aerobic Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (\~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (\~70%-100% VO2peak / \~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
223987985|NCT01068210|BEHAVIORAL|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
223987986|NCT01068210|BEHAVIORAL|Resistance Training|The ultimate goal for resistance training alone is 3 resistance training session/week at an intensity above 50% to 85% of 1-RM for 30-60 minutes/session. Resistance trainings will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Participants will be progressively trained to perform two to three sets of 75-85% of maximal strength.
224120601|NCT01333267|DRUG|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
223728726|NCT01840501|DRUG|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
223728727|NCT01840501|DRUG|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
223728728|NCT01840501|DRUG|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
223728729|NCT01426373|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
223728730|NCT03766308|DIETARY_SUPPLEMENT|Highland Barley Diet|Highland Barley Diet
223728731|NCT03766308|DIETARY_SUPPLEMENT|ADA diet|ADA diet
223987987|NCT01068210|BEHAVIORAL|Aerobic and Resistance Training|The ultimate goal will be three combined exercise sessions per week at an intensity above 50% VO2speak and above 50% 1-RM for aerobic and resistance training, respectively for 30-90 minutes/session.
223987988|NCT04925258|BEHAVIORAL|SPACE Parenting Program|The program involves a two-arm randomized trial of differing parenting interventions which include: a service as usual (SAU) cohort, in which parents are provided with local and online parenting and family mental health resources; An intervention group called SPACE that includes weekly parenting materials (i.e., two online \~10-minute videos, ten parent-child activities that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program (NCT04347707 and NCT04639557) intervention group. Additionally, this group will receive weekly drop-in sessions with a facilitator-led (trained MA-level or higher psychology student or psychologist) interactive parenting group to re-enforce concepts and provide social support.
223987989|NCT05549609|BIOLOGICAL|XSTEM-VLU|XSTEM-VLU is an allogeneic, adipose tissue-derived, integrin alpha10beta1-selected and expanded mesenchymal stem cell (MSC) product for the treatment of venous leg ulcers.
223987990|NCT05549609|OTHER|Vehicle|CryoStor CS10 cryomedium
223987991|NCT00170300|DEVICE|Implantable Cardiac Resynchronisation (pacing) device|
224120602|NCT01333267|DRUG|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
224120603|NCT01333267|DRUG|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
223987992|NCT06944886|OTHER|Active Static Stretching Exercise Combined with Breathing Exercise (Experimental Group)|"Participants in the intervention group performed active static stretching exercises using a pictorial exercise booklet. The booklet contained a series of self-directed stretching postures targeting major muscle groups. Each stretch was held in a static position without external assistance, encouraging the participant to engage and maintain the stretch voluntarily.~Each stretch was held for 30 seconds and repeated 3 times per muscle group. The targeted areas included the hamstrings, quadriceps, calves, hip flexors, and shoulders."
223987993|NCT01527162|DEVICE|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
223987994|NCT01527162|OTHER|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
223987995|NCT05900986|DRUG|LS301-IT 0.025 mg/kg|The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
223987996|NCT05900986|DRUG|LS301-IT 0.05 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
223987997|NCT05900986|DRUG|LS301-IT 0.075 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
223987998|NCT05900986|DRUG|LS301-IT 0.1 mg/kg|Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
223987999|NCT00702598|BEHAVIORAL|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
223988000|NCT00702598|BEHAVIORAL|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
224120604|NCT03664622|DRUG|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
224120605|NCT03664622|DRUG|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
224120606|NCT00029848|DRUG|Rimonabant (SR141716)|
224120607|NCT00429039|DRUG|L-leucyl-L-leucine methyl ester (LLME)|
224120608|NCT05308225|BIOLOGICAL|STI-6129|Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
224120609|NCT04534439|DRUG|APX-115|oral administration of APX-115 400mg capsule once daily for 12 weeks
224120610|NCT04534439|DRUG|Placebo|oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
224120611|NCT04985799|DEVICE|Gynecare TVT Exact Continence System|Participants will have placement of Gynecare TVT Exact sling.
224120612|NCT04985799|DEVICE|Neomedic KIM (Knotless Incontinence Mesh)|Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
223728732|NCT04341389|BIOLOGICAL|Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Intramuscular injection
224120613|NCT06128798|DIETARY_SUPPLEMENT|Oral Impact|A serving of 74 gm (containing 309 kcal ) of oral impact mixed with 250 ml of water. Each participant will receive total of 3 servings daily for 7 days pre operatively .
224120614|NCT06128798|DIETARY_SUPPLEMENT|Nutren Optimum|A serving of 66.8 gm ( containing 304 kcal ) of nutren optimum mixed with 300 ml of water.Each participant will receive total of 3 servings daily for 7 days pre operatively .
224120615|NCT04449783|OTHER|pre-operative screening|reported symptoms plus nose and throat swabbing 48 hrs prior to surgery
224120616|NCT04449783|OTHER|telephone consult|telephone consult 14 days (+/- 2 days) to assess for any COVID-19 symptoms
224120617|NCT01585935|DRUG|SMOFLIPID|target dose: 3g/kg/d
224120618|NCT01585935|DRUG|INTRALIPID|target dose: 3g/kg/d
224120619|NCT01666418|DRUG|Pazopanib/Paclitaxel|
224120620|NCT04067765|BEHAVIORAL|Cue Exposure|Participants will undergo a validated in-scanner alcohol cue and neutral cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, or liquor) and neutral beverages (water).
224120621|NCT03425942|BEHAVIORAL|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
224120622|NCT03425942|BEHAVIORAL|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
224120623|NCT01881620|DEVICE|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
224120624|NCT03281772|OTHER|Clinical Decision Software - provider portal|As noted in Arms
223728733|NCT04341389|OTHER|Placebo|Intramuscular injection
223728734|NCT04887714|OTHER|Mask|Mask wearing
224120625|NCT03281772|OTHER|Clinical Decision Software - patient portal|As noted in Arms
224120626|NCT06471634|BEHAVIORAL|CBTi|A 12 week intervention using CBTi to improve sleep measured using objective and subjective measures. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
223988001|NCT05945615|DRUG|Oxymetazoline 0.1% (Pf) Oph Soln Ud|"Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis."
223988002|NCT05945615|OTHER|Preservative free lubricating drops|Over the counter ophthalmic lubricating drop.
223988003|NCT06037499|DIAGNOSTIC_TEST|Glucometer Test|measurement of blood glucose concentration using different BGM and Reference Method
223988004|NCT02774668|OTHER|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
224120627|NCT06471634|OTHER|Control - usual care|Participants will be given a leaflet summarising good sleep practice and the advantages of reducing sedentary behaviour. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
224120628|NCT06471634|BEHAVIORAL|Sedentary behaviour reduction|Participants will be encouraged to increase activity and thus reduce sedentary time. Investigators will use behaviour change techniques to aid in this goal. Participants will complete a number of questionnaires and tests at baseline and at completion to allow comparisons to be made.
224120629|NCT03750201|DEVICE|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
224120630|NCT03750201|DEVICE|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
224120631|NCT04841499|DRUG|BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)|take 2 capsules orally each day for 7 days
224120632|NCT04803708|BIOLOGICAL|TP-102|One mL of IP solution will be applied topically per cm3 of target ulcer. The titer of each bacteriophage in TP 102 is 1x10\^9 plaque forming units per milliliter (PFU/mL).
224120633|NCT06579040|DEVICE|Monoplace Hyperbaric Chamber (Class III medical device)|Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
224120634|NCT03070730|DRUG|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
224120635|NCT03070730|DRUG|Atenolol|Atenolol: 50 mg Q.D.
224120636|NCT03070730|DRUG|Placebos|Placebo: t.i.d
224120637|NCT04511078|DRUG|Panitumumab-IRDye800|single dose infusion of panitumumab-IRDye800CW
224120638|NCT00921505|DRUG|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
223988005|NCT02774668|OTHER|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
223988006|NCT04886518|DRUG|Pitolisant Oral Tablet|"Pitolisant 4.45 mg tablets: white, round, plain, biconvex film-coated tablet, 3.7 mm in diameter. Each tablet contains 5 mg of pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.~Pitolisant 17.8 mg tablets: white, round, plain, biconvex film-coated tablet, 7.5 mm in diameter. Each tablet contains 20 mg of pitolisant hydrochloride equivalent to 17.8 mg of pitolisant."
223988007|NCT04886518|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
223988008|NCT06611696|DRUG|Avacopan, prednisolone and rituximab|Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.
223988009|NCT06611696|DRUG|Prednisolone and rituximab|Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.
224120639|NCT00921505|DRUG|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
224120640|NCT00921505|DRUG|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
224120641|NCT00921505|DRUG|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
224120642|NCT03237260|DRUG|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
224120643|NCT06021652|DEVICE|MindCotine Virtual reality|Virtual reality platform
224120644|NCT04467164|OTHER|exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)|Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
224120645|NCT04467164|OTHER|Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)|Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
223988010|NCT06707883|DRUG|TQC2731 injection|TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP)
223988011|NCT06707883|DRUG|TQC2731 Placebo|TQC2731 Placebo without drug substance.
223988012|NCT01390597|GENETIC|DNA analysis|
223988013|NCT01390597|GENETIC|cytogenetic analysis|
223988014|NCT01390597|GENETIC|gene mapping|
223988015|NCT01390597|GENETIC|mutation analysis|
223988016|NCT01390597|GENETIC|polymerase chain reaction|
223728735|NCT04952402|BIOLOGICAL|Study-provided Moderna mRNA-1273 COVID-19 vaccine|Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
223988017|NCT01390597|OTHER|laboratory biomarker analysis|
223988018|NCT04594616|DEVICE|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
223988019|NCT02035696|BIOLOGICAL|Trivalent influenza vaccine (TIVc)|
224120646|NCT04743037|BEHAVIORAL|iSMART|This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
223988020|NCT02035696|BIOLOGICAL|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
224120647|NCT02369835|DRUG|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
223988021|NCT05202873|DIAGNOSTIC_TEST|Gait analysis|Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.
223988022|NCT04474444|OTHER|attendance by ambulance crew|hear, attendance, convey
224120648|NCT02369835|OTHER|Placebo|Applied topically
224120649|NCT03209544|BEHAVIORAL|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
224120650|NCT00690716|DRUG|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
223728736|NCT04952402|BIOLOGICAL|Community-provided Moderna mRNA-1273 COVID-19 Vaccine|Participants received a two-dose series.
223728737|NCT04952402|BIOLOGICAL|Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine|Participants received a two-dose series.
223728738|NCT01126450|DRUG|lenalidomide|Given orally
223728739|NCT01126450|BIOLOGICAL|cetuximab|Given IV
223728740|NCT01126450|OTHER|mutation analysis|Correlative studies
223728741|NCT01126450|OTHER|polymerase chain reaction|Correlative studies
223728742|NCT01126450|GENETIC|polymorphism analysis|Correlative studies
223728743|NCT01723592|DIETARY_SUPPLEMENT|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
223728744|NCT01723592|DIETARY_SUPPLEMENT|Oral lactose placebo|Placebo
223988023|NCT06486142|DRUG|Afatinib/Dacomitinib|Second-generation EGFR-inhibitors
223988024|NCT06486142|DRUG|Osimertinib|Third-generation EGFR-inhibitor
223988025|NCT00616590|OTHER|medical chart review|
223988026|NCT00616590|OTHER|questionnaire administration|
223988027|NCT00616590|PROCEDURE|fatigue assessment and management|
223988028|NCT00616590|PROCEDURE|quality-of-life assessment|
223988029|NCT01530581|PROCEDURE|G-PB Transplant|G-PB Transplant
223988030|NCT01530581|PROCEDURE|G-BM Transplant|G-BM Transplant
223988031|NCT05987020|OTHER|Aromatherapy|"The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil."
223988032|NCT03243097|DEVICE|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
223988033|NCT03243097|DEVICE|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
223988034|NCT03243097|DEVICE|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
224120651|NCT00690716|DRUG|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
224120652|NCT03940651|DRUG|Spinal Anesthesia|Patients will be randomized to type of anesthesia
223988035|NCT02672449|RADIATION|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
223988036|NCT00585871|DRUG|clonidine|0.1 mg tid
223988037|NCT00585871|DRUG|metoprolol|25 mg tid
223988038|NCT04814602|DRUG|Proglumide|CCK receptor antagonist
223988039|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete active episodic thinking task
223988040|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete active future thinking priming task
223988041|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete control episodic future thinking task
223988042|NCT04297332|BEHAVIORAL|Behavioral Intervention|Complete control future thinking priming task
223988043|NCT04297332|OTHER|Informational Intervention|Provided with Forever Free relapse prevention booklet
223988044|NCT04297332|DRUG|Nicotine Replacement|Receive nicotine patches, gum, or lozenges
223988045|NCT04297332|OTHER|Telephone-Based Intervention|Receive coaching call
223988046|NCT02209753|DRUG|BIRB 796 BS, low dose|
223988047|NCT02209753|DRUG|BIRB 796 BS, medium dose 1|
223988048|NCT02209753|DRUG|BIRB 796 BS, medium dose 2|
223988049|NCT02209753|DRUG|BIRB 796 BS, high dose|
223988050|NCT02209753|DRUG|Placebo|
223988051|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
223988052|NCT01090011|DRUG|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
223988053|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
223988054|NCT01090011|DRUG|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
223988055|NCT01181245|DRUG|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
223988056|NCT03422861|DRUG|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
223988057|NCT03422861|DRUG|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
223988058|NCT00979186|DEVICE|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
223988059|NCT00379769|DRUG|Rosiglitazone|Rosiglitazone maximum 8 mg per day
223988060|NCT00379769|DRUG|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
223988061|NCT00379769|DRUG|Metformin|Metformin maximum permitted daily dose .
223988062|NCT00406614|BEHAVIORAL|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
223988063|NCT05249647|OTHER|Instrument based Fascial abrasion technique|Participants were in a comfortable position during treatment. Emollient (anti-allergic) was applied to prevent skin irritation prior to Fascial Abrasion application. Each session included 1 minute of sweeping (longitudinal strokes performed parallel to the muscle fibers similar to compression with oscillations) directly over the Myofascial trigger points, 2 minutes of fanning (one end of the instrument was held in place \& the other end moved through a semicircular pattern similar to petrissage) and concluded with 1 min of sweeping. Fascial Abrasion tool was washed in alcohol-based sanitizer before and after every treatment session and all norms of COVID-19 precautions were maintained. Myofascial trigger points were marked with a 1×1 cm piece of tape/under wrap to confirm consistency of subsequent treatments.
224120653|NCT03940651|DRUG|General Anesthetics|Patients will be randomized to type of anesthesia
224120654|NCT04420871|DRUG|150 mg of Xeloda®|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period. 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.The subjects randomly received single oral administration of 150 mg of Xeloda®.
224120655|NCT04420871|DRUG|150 mg of capecitabine|Subjects were allocated to one of three groups randomly and equally with a 1-day wash time period.The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.The subjects randomly received single oral administration of 150 mg of capecitabine.
224120656|NCT05149937|OTHER|interprofessional, person-centered care concept|interprofessional, person-centered care concept
224120657|NCT03865017|BIOLOGICAL|Regulatory T cells|The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
224120658|NCT03865017|OTHER|Saline|Saline+cell suspension solution infusion
224120659|NCT01761955|OTHER|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
224120660|NCT03924674|OTHER|Education, clinical decision support tools|"Interventions will include:~1. Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~2. Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~3. Tools to promote discussion about timing and necessity of routine lab draws~4. Education and feedback for physicians regarding costs and harms of routine lab testing"
223988064|NCT05249647|OTHER|Myofascial release technique|All participants will get Conventional therapy i.e heating pad for 10 minutes. For the application of technique, the patient position will be supine lying with head fully supported on therapist hands and therapist places 3 middle fingers just inferior to the nucle line, lifts the finger tips towards the ceiling while resting the head on the table and then therapist applied a gentle upward pull. This procedure done for 2-3 minutes, 5-7 repetitions, 3 sessions per week on alternate days given for 6 weeks.
223988065|NCT04446806|DRUG|Ruxolitinib|Ruxolitinib as second treatment in patients with severe DS failed in responding to hormone.Furthermore
223988066|NCT04420039|DEVICE|Endoscopic biliary transmural drainage|"Endosonography-guided biliodigestive anastomosis using a dedicated biliary lumen-apposing stent in order to proveide a biliary drainage in cases of palliative malignant biliary obstruction.~Two different strategies will be compared: single lumen-apposing stent vs lumen-apposing stent plus dousble-pigtail plastic stent."
223988067|NCT04560751|DRUG|Lenvatinib|Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
223988068|NCT04560751|PROCEDURE|TACE|TACE will be performed as needed.
223988069|NCT03890198|BIOLOGICAL|LCAR-C182A cells|Patients receive fludarabine (3×300 mg/ m\^2) and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
223988070|NCT04476212|OTHER|Topical antibiotic prophylaxis|The surgical wound will be irrigated with an antibiotic solution, and then we will apply the same solution using gauze for two minutes on the wound
223988071|NCT02859077|DRUG|EGFR-TKI|EGFR-TKI (gefitinib)
223988072|NCT02859077|DRUG|Chemotherapy（pemetrexed/gemcitabine）|Chemotherapy (pemetrexed/gemcitabine)
223988073|NCT02859077|DRUG|Chemotherapy（carboplatin）|Chemotherapy（carboplatin）
223988074|NCT00234598|PROCEDURE|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
223988075|NCT00234598|PROCEDURE|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
223988076|NCT00234598|PROCEDURE|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
223988077|NCT06119347|DRUG|AntiVEGF|anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
223988078|NCT06119347|DRUG|ICIs|immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
223988079|NCT02852356|DEVICE|MIRI-TL Incubator|MIRI-TL Timelapse incubator
223988080|NCT01689363|DRUG|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
223988081|NCT01689363|DRUG|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
223988082|NCT01689363|DRUG|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
223988083|NCT02859064|DRUG|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
223988084|NCT02859064|DEVICE|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
224120661|NCT05488561|DIAGNOSTIC_TEST|CBC with differential ,ESR ,CRP, Amyloid level , FMF gene|leucocytosis , high ESR and CRP ,amyloid level indicates inflammation positive FMF gene indicates having the disease .
224120662|NCT04008433|DRUG|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
223988085|NCT00404885|DRUG|Placebo|PO BID
223988086|NCT00404885|DRUG|LX211|0.2 mg/kg, twice a day (BID)
223988087|NCT00404885|DRUG|LX211|0.4 mg/kg, twice a day (BID)
223988088|NCT00404885|DRUG|LX211|0.6 mg/kg, twice a day (BID)
223988089|NCT02414009|DRUG|Capecitabine|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days
223988090|NCT02414009|DRUG|Temozolomide|Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.
223988091|NCT02414009|DRUG|Irinotecan|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
223988092|NCT02414009|DRUG|Fluorouracil|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
223988093|NCT02414009|DRUG|Leucovorin|Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
223988094|NCT00321685|BIOLOGICAL|Bevacizumab|Given IV
223988095|NCT00321685|DRUG|Capecitabine|Given PO
223988096|NCT00321685|DRUG|Fluorouracil|Given IV
224120663|NCT04177056|RADIATION|SBRT|Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
224120664|NCT05863689|DIAGNOSTIC_TEST|Spectralis SD-OCT|Optical Coherence Tomography
224120665|NCT03074513|DRUG|Atezolizumab|Given IV
223988097|NCT00321685|DRUG|Leucovorin Calcium|Given IV
224120666|NCT03074513|BIOLOGICAL|Bevacizumab|Given IV
224120667|NCT03074513|OTHER|Laboratory Biomarker Analysis|Correlative studies
224120668|NCT03074513|OTHER|Pharmacological Study|Correlative studies
223728745|NCT05508191|DEVICE|Fractional CO₂ Laser|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. Half of the face will be irradiated with AMIⓇ fractional CO₂ laser according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
223988098|NCT00321685|DRUG|Oxaliplatin|Given IV
223988099|NCT00321685|RADIATION|Radiation Therapy|Undergo radiotherapy
223988100|NCT00321685|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223988101|NCT05286463|COMBINATION_PRODUCT|bee venom gel phonophoresis|a noncontact low-frequency pulsed ultrasound delivered through Bee Venom previously prepared gel as topical application using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
223988102|NCT05286463|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only using an ultrasonic therapy instrument with frequency, 0.5-MHZ pulsed mode (applicator 1.9 cm2) applied around the incision site, Ren 4 and Ren 6. The movement was over the incision margins, Ren 4 and Ren 6 with a pulsed duty cycle of 40% (4 ms on, 6 ms off), and power density of 0.5 W/cm2, Before and after each patient exposure, the ultrasonic applicator's performance was tested on a regular basis, and each test included all essential acoustic field characteristics (pressure amplitude, frequency), as well as the uniformity of the field distribution.
223988103|NCT05815537|OTHER|Low-Reverberation|The exposure to low-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., small classroom.
223988104|NCT05815537|OTHER|High-Reverberation|The exposure to high-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., large lecture hall/auditorium.
223988105|NCT02573272|DRUG|eslicarbacepine|
223988106|NCT02619526|DRUG|Nebivolol|Nebivolol 10mg, once a day
223988107|NCT02619526|DRUG|Carvedilol|Carvedilol 25mg, twice a day
223988108|NCT00172939|PROCEDURE|foreskin from healthy adults|
223988109|NCT01019239|PROCEDURE|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
223988110|NCT01019239|PROCEDURE|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
223988111|NCT00127842|DRUG|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
223988112|NCT01589926|DEVICE|Bi-level positive airway pressure device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
223988113|NCT01589926|DEVICE|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
223988114|NCT01898780|PROCEDURE|pancreaticojejunostomy with horizontal mattress suture|
223988115|NCT01898780|PROCEDURE|pancreaticojejunostomy with interrupted suture|
223988116|NCT04253938|OTHER|Education|Subjects will be provided education about AAP approved feeding practices for infants 1 to 12 months of age.
223988117|NCT01289132|DRUG|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
223988118|NCT01289132|DRUG|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
223988119|NCT01289132|DRUG|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
223988120|NCT01289132|DRUG|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
223988121|NCT01289132|DRUG|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
223988122|NCT01289132|DRUG|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
223988123|NCT01289132|DRUG|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
223988124|NCT00000469|DRUG|aspirin|
223988125|NCT00000469|DRUG|lovastatin|
223988126|NCT03436303|DRUG|CEE 0.625 mg/MP 100mg|CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
223988127|NCT03436303|DRUG|CEE 0.3 mg/MP 100mg|CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
223988128|NCT03436303|DRUG|CEE 0.625mg/dydrogesterone|CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
223988129|NCT02364596|BIOLOGICAL|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
223988130|NCT02364596|PROCEDURE|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
223988131|NCT01638390|DEVICE|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
223988132|NCT01536587|DRUG|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
223988133|NCT04435964|DRUG|Immunotherapy|Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
223988134|NCT00551850|DRUG|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
223988135|NCT00143104|DRUG|Inhaled insulin|
223988136|NCT04397211|PROCEDURE|Angiography-derived FFR|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the Angiography-derived FFR-guided strategy arm~\*Criteria for revascularization: Angiography-derived FFR ≤ 0.80"
223988137|NCT04397211|PROCEDURE|IVUS|"The percutaneous coronary intervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\*Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or 3\< MLA ≤ 4mm2 \& Plaque burden \> 70%"
223988138|NCT05858255|BEHAVIORAL|Exergaming|Please see Arms description.
223988139|NCT02354651|OTHER|Diaphragm conditioning via phrenic nerve stimulation|Diaphragm pacing will be prescribed by the patient's clinical team.
223988140|NCT01377389|DRUG|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
223988141|NCT01377389|DRUG|Leuprolide|7.5 mg intramuscular once a month for 8 months
223988142|NCT01377389|DRUG|Goserelin|3.6 mg subcutaneous once a month for 8 months
223988143|NCT01377389|DRUG|Degarelix|80 mg subcutaneous once a month for 8 months
223988144|NCT05708547|BIOLOGICAL|Blood samples|at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1
223988145|NCT05708547|PROCEDURE|myocardial tissue samples|use of usually harvested right auricular tissue
223988146|NCT05708547|OTHER|Data collection|pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital
223988147|NCT00645177|DRUG|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
223988148|NCT00645177|DRUG|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
223988149|NCT00645177|DRUG|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
223988150|NCT03430544|DRUG|Cariprazine Oral Capsule [Vraylar]|Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).
223988151|NCT03430544|DRUG|Placebo oral capsule|PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
223988152|NCT00577070|DEVICE|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
224120669|NCT03879148|OTHER|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
224120670|NCT00589888|DRUG|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
224120671|NCT00589888|DRUG|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
224120672|NCT00589888|DRUG|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
223988153|NCT02882997|BEHAVIORAL|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
223988154|NCT02882997|BEHAVIORAL|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
223988155|NCT04682782|DRUG|Esketamine|Esketamine is infused through the whole period of surgery. Participants randomized to the esketamine arm will receive 1 mg/ml solution infused at 0.1 mg/kg/hour (0.1 ml/kg/h) .
223988156|NCT04682782|DRUG|Saline|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.1 ml/kg/hour throughout the surgery.
223988157|NCT05519553|OTHER|Peer support|: 1 hour individual session with a peer support specialist at 1, 3 and 5 months after baseline
223988158|NCT06957379|DRUG|Letrozole|Oral administration at a dose of 2.5 mg once daily for a 4-week cycle
224120673|NCT00589888|DIETARY_SUPPLEMENT|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
224120674|NCT00589888|DIETARY_SUPPLEMENT|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
224120675|NCT00490373|DRUG|pemetrexed|
224120676|NCT04439630|DIETARY_SUPPLEMENT|Nopal fractions|Nopal flour were divided in two fractions and mixed in two different test breads
224120677|NCT04439630|DIETARY_SUPPLEMENT|Test product without the active components|Test product without the active components
224120678|NCT06253286|DEVICE|clear aligner treatment for orthodontics patients|patient are instructed to wear aligners
224120679|NCT02306707|PROCEDURE|Endoscopic Mucosal Resection|
223988159|NCT06957379|DRUG|Anastrozole|Oral administration at a dose of 1 mg once daily for a 4-week cycle
223988160|NCT06957379|DRUG|Exemestane|Oral administration at a dose of 25 mg once daily with a meal every 4 weeks
223988161|NCT06957379|DRUG|Fulvestrant|Fulvestrant: IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle
223988162|NCT06957379|DRUG|Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
223988163|NCT04334616|DEVICE|Video Laryngocope|VDL used for VDL arm
223988164|NCT04334616|DEVICE|Macintosh Conventional Laryngocope|Used for Conventional laryngocope arm
223988165|NCT01615172|PROCEDURE|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
223988166|NCT00628277|BEHAVIORAL|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
223988167|NCT00628277|BEHAVIORAL|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
224120680|NCT04631120|OTHER|Integrated Dementia Practice Unit Design|"* Dementia Central: monthly review of participant progress~* Dementia Mobile: monthly nurse/lay health educator visits for assessments, education and coaching~* Dementia Link: communication between Dementia Central and Dementia Mobile using the eTransX mHealth platform and HealthStream educational interface for care providers and the patient/caregiver dyad."
224120681|NCT04631120|OTHER|Standard of Care|Standard clinical practices of the physician and institution including an initial assessment, Zarit Burden Interview (ZBI) for caregiver, followed by provision of standard patient- and caregiver-centered educational material. Two phone sessions with a study nurse post-enrollment in months 1 and 6 to discuss the educational material and perform a needs assessment.
224120682|NCT00137852|DRUG|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
224120683|NCT00137852|DRUG|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
224120684|NCT00137852|DRUG|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
224120685|NCT00137852|PROCEDURE|Radiation Therapy|5 days a week for 5-6 weeks
224120686|NCT00137852|PROCEDURE|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
224120687|NCT01675011|DEVICE|Embozene® Microspheres|
224120688|NCT01675011|DEVICE|Embosphere®|
223988168|NCT05184270|DEVICE|Acoustic stimulation|"In this project, the intervention is a presentation of low-volume non-arousing auditory stimuli during deep NREM sleep via attached headphones. Stimuli will be applied targeting the up-phase of slow waves to enhance sleep slow-wave activity.~Previous studies showed that this procedure does not lead to reduced sleep quality nor result in changed sleep architecture. Therefore, no negative consequences as a result of our intervention are to be expected. In fact, it is currently applied in several other studies including children, adults, and the elderly. Importantly, stimulation is not arousing, as the sounds presented during deep sleep are brief (50 ms) and at low volume (around 50 dB). In case of arousal during sleep (detected using the surface EEG signal), the volume will be adjusted."
223988169|NCT00709397|OTHER|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
223988170|NCT04885348|BEHAVIORAL|Intervention Group (Dental Home Visits + Dental Home Education Leaflets)|No drugs were given in the Intervention. The intervention group received Dental Home Visits consisted of 6 monthly home visits by oral health therapists/dental home visitors where they deliver dental care advice to the parents for durations of approximately 30 minutes until follow-up at two years. Dental Home Education Leaflets (DHELs) and oral health messages were delivered through a personalized approach that avoids direct persuasion. These messages included information on daily tooth brushing with fluoride toothpaste, controlling dietary sugar intake, and the need for regular dental check-ups. The families were also be provided with information about local dental services available in their vicinity and how to access these services.
223988171|NCT04885348|BEHAVIORAL|Control Group (Dental Home Education Leaflets)|Only Dental Home Education Leaflets were provided every six months for 2 years.
223988172|NCT02375451|OTHER|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
223988173|NCT04003766|DIAGNOSTIC_TEST|biopsy|Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
223988174|NCT04872023|OTHER|Blood and bone marrow sampling|Blood and bone marrow sampling
223988175|NCT00807105|DEVICE|H-coil dTMS|treatment with deep TMS stimulation.
223988176|NCT00421629|BEHAVIORAL|After-sales service and supportive supervision (AfterSS)|
223988177|NCT00421629|BEHAVIORAL|Prospective reimbursement (PR)|
224120689|NCT03445052|BEHAVIORAL|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
223728746|NCT05508191|DEVICE|Microneedle|Prior to the treatment, each participant will be evaluated for their initial skin status, followed by daily priming with 0.05% retinoic acid cream, applied topically at night for two weeks. At second week, the participants will undergo facial skin anesthesia utilizing 2.5% lidocaine+2.5% prilocaine cream for 30 minutes. The other half of the face will be treated with DrPenⓇ dermapen according to the instrument manual for 20 minutes, succeeded by the topical administration of 1.5 mL 4-fold concentrated ADMSCs secretome. The participants are all instructed not to: (1) wash their face for the next 4 hours; (2) apply sunscreen for the next 1 day; and (3) apply retinoic acid cream for the next 3 days. After the restriction, they should use the mentioned products on daily basis until the next appointment when the protocol is repeated (fourth week). At sixth week, the final skin condition is reevaluated with the same tools, along with the additional variables.
223988178|NCT00421629|BEHAVIORAL|Both (AfterSS and PR)|
224120690|NCT05915754|OTHER|Hip abductors stretching and strengthening exercises|Treatment consist of four stretches for the ITB including: ITB stretch with trunk side bend, ITB stretch with trunk side bend and upward lateral reach, trunk side bend with downward lateral reach and side lying leg adduction and Strengthening exercise plan involving the gluteal muscle groups. These exercises include clams, side-lying abduction, reverse clams and supine bridge
224120691|NCT05915754|OTHER|Posterior oblique sling strengthening exercises|Treatment consists of treatment A plus the intervention program of POSS consisted of four different exercises utilizing activation of the POSS. The intervention program focuses on one specific exercise each week that will progress in difficulty over the 4 weeks. The equipment used in the exercise progression included a blue, latex-free, medium-resistance theraband (TB), and the final exercise of the progression will include the use of a step stool. The TB will be used to increase the activation of the latissimus dorsi while simultaneously performing lower-extremity exercise to increase gluteal muscle involvement. The exercises are to be used in the 4-week progression.
224120692|NCT01821170|DRUG|Methylphenidate|Patient will take treatment during two months
224120693|NCT01821170|DEVICE|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
224120694|NCT01821170|BEHAVIORAL|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
224120695|NCT01821170|OTHER|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
224120696|NCT05883592|DEVICE|Fabulous Thoracic Aortic Stent System|Endovascular treament in patients with aortic dissection with Fabulous Thoracic Aortic Stent System
224120697|NCT04477824|DIAGNOSTIC_TEST|Diagnostic imaging|Ultrasonography, computerized tomography, magnetic resonance imaging
224120698|NCT04041076|PROCEDURE|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
224120699|NCT03927937|PROCEDURE|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
224120700|NCT03725995|DRUG|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
223988179|NCT06790082|DRUG|[68Ga]Ga-FAPI-46 PET/CT|"Patients with suspected pleural mesothelioma undergo FAPI PET/CT in addition to conventional imaging at primary staging.~The subgroup of patients undergoing anticancer treatment will undergo an additional FAPI PET/CT and FDG PET/CT after completing 2-3 series of anticancer treatment."
223988180|NCT01419340|DRUG|Torrent's Donepezil Hydrochloride Tablets 10mg|
223988181|NCT03382561|DRUG|Carboplatin|Given IV
223988182|NCT03382561|DRUG|Cisplatin|Given IV
223988183|NCT03382561|DRUG|Etoposide|Given IV
223988184|NCT03382561|BIOLOGICAL|Nivolumab|Given IV
223988185|NCT01131104|DRUG|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
223988186|NCT01282528|BIOLOGICAL|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
223988187|NCT05496153|BEHAVIORAL|Adaptive posture-balance cardiac rehabilitation exercise|The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
223988188|NCT01245140|DRUG|alitretinoin|to receive verum (20 patients)
223988189|NCT01245140|DRUG|Placebo|to receive placebo (10 patients)
223988190|NCT04889469|PROCEDURE|Breast reduction|Procedure to remove excess fat, tissue and skin from the breasts.
223988191|NCT00334542|DRUG|simvastatin|24-28 weeks of simvastatin
223988192|NCT05600140|BEHAVIORAL|Viewing strategy training|Children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol-based. A textbook is used to describe the reactions of the children during training.
223988193|NCT04868838|DRUG|Daratumumab|1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
223988194|NCT00497666|DRUG|Rosiglitasone (retrospective observation)|
223988195|NCT05282251|DRUG|Intrapleural bupivacine nebulization|Intrapleural nebulization of bupivacine (10 ml of bupivacaine 0.5%) + Intravenous normal saline as a placebo
223988196|NCT05282251|DRUG|Intravenous paracetamol and ketorolac|Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
223988197|NCT04739410|DRUG|Ivermectin|Ivermectin Prescribing protocol: Participants were prescribed Ivermectin 12 mg per oral stat and then 12 mg per oral after 12 hours and 12 mg per oral after 24 hours and we looked at the response at day 7 on follow up in terms of improvement of symptoms like (Fever, Cough, sore throat, Headache, Shortness of breath, lethargy, and fatigue.Any side effects of the drugs were noted as well
223988198|NCT01943682|DRUG|CPX-351|Comparison of Different doses of drug
223988199|NCT04471545|PROCEDURE|Pectoral nerve block type II|A pectoral nerve block type II will be given to the patient after induction. This is performed ultrasound guided
224120701|NCT03725995|DRUG|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
224120702|NCT03725995|DRUG|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
224120703|NCT04060173|DRUG|ABP-671|ABP-671 is an investigational drug
223988200|NCT00002838|BIOLOGICAL|Filgrastim (G-CSF)|
224120704|NCT04060173|OTHER|Placebo|Matching placebo
223988201|NCT00002838|DRUG|Cyclophosphamide|
223988202|NCT00002838|DRUG|Fludarabine Phosphate|
223988203|NCT00002838|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
223988204|NCT01080326|DEVICE|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
223988205|NCT02008071|BEHAVIORAL|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
223988206|NCT02008071|BEHAVIORAL|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
223988207|NCT03735953|DIAGNOSTIC_TEST|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
223988208|NCT04457817|DEVICE|CRI|Monitoring via CRI
223988209|NCT03531554|DIETARY_SUPPLEMENT|ketone ester drink|395 mg of ketone ester/kg
223988210|NCT03531554|BEHAVIORAL|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
223988211|NCT03531554|PROCEDURE|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
224120705|NCT06546124|OTHER|Deep Fascia Dry needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating subcutaneously to the deep fascia. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
223988212|NCT03531554|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
224120706|NCT06546124|OTHER|Intramuscular Trigger Point Dry Needling Technique|"Participants will undergo a single session of dry needling on the painful area of the upper trapezius muscle on the right and/or left side of the neck, either unilaterally or bilaterally. All participants will be positioned upright in a chair with their backs supported, heads in a neutral position, and arms at their sides. A myofascial trigger point on the upper trapezius muscle will be marked. A sterile acupuncture needle, 0.25 mm in diameter and 40 mm in length, will be used. Under ultrasound guidance, the needle will be inserted at three points, including 1 cm lateral and medial to the marked point, penetrating through the deep fascia into the upper trapezius muscle. After leaving the needle in place for 5 minutes, it will be rotated clockwise and left in place for an additional 5 minutes. The needles will be removed after a total of 10 minutes. Participants will be advised to perform upper trapezius stretching exercises."
223988213|NCT05760521|OTHER|Provider Educational Intervention|Following the informed consent (10 min) and sociodemographic survey (5 minutes), the providers in Arm A will be offered education of two days, six hours each day, with support and follow-up. They will also be asked to complete brief knowledge and confidence surveys pre-post-intervention (30 minutes total).
223988214|NCT01355640|OTHER|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
223988215|NCT01355640|OTHER|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
223988216|NCT05502822|DEVICE|High definition transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
224120707|NCT01151995|OTHER|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
224294421|NCT05905263|OTHER|Application group with virtual reality|Each student will be introduced to the materials to be used for virtual reality and will be informed about the application. After the introduction and information is given, the lens and pupil distances of the virtual reality glasses will be adjusted according to each student and students will be asked to wear them on their heads. Students will then be required to wear gloves. The application will be made one-on-one with each student. The application will be carried out sitting in the laboratory. If the student experiences symptoms such as dizziness and nausea during the application, the application will be terminated. If the student wants to continue the practice after listening, it will be continued. While the students are inside the application, the interface will be introduced through the images projected to the computer simultaneously.
224294422|NCT02554734|DRUG|levodopa, carbidopa, ODM-104|
224294423|NCT02554734|DRUG|levodopa, carbidopa, entacapone|
224294424|NCT02429934|BIOLOGICAL|abatacept also known as Orencia also known as CTLA4-Ig|125mg injected subcutaneously weekly for 16 weeks
224294425|NCT02429934|DRUG|Placebo|
224294426|NCT00971984|OTHER|Medical records summary|Summary of Medical files and laboratory results.
224294427|NCT00283413|DEVICE|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
224294428|NCT00283413|DEVICE|Bare metal stent|Any commercially available bare metal stent for coronary indication
224294429|NCT01763749|DRUG|Closone|Closone 75mg/100mg, 4weeks, PO
224294430|NCT01763749|DRUG|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
223988217|NCT05502822|DEVICE|sham high definition transcranial alternating current stimulation|. In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
223988218|NCT01651533|BEHAVIORAL|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
223988219|NCT01651533|BEHAVIORAL|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
223988220|NCT03640247|DRUG|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
223988221|NCT03640247|DRUG|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
224120708|NCT01151995|OTHER|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
224120709|NCT00615290|DRUG|tipranavir|
224120710|NCT04066816|OTHER|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
224120711|NCT05205434|OTHER|Synchronous telerehabilitation programme|Exercise program and educational program
224120712|NCT05205434|OTHER|Asynchronous telerehabilitation programme|Exercise program educational program
224120713|NCT02778516|DIETARY_SUPPLEMENT|Sodium Restriction|
224120714|NCT02220348|DRUG|linaclotide|
224120715|NCT06024772|PROCEDURE|ultiparametric Magnetic Resonance Imaging|Undergo mp-MRI
224120716|NCT06024772|DRUG|Perflutren lipid microsphere|Given IV
224294431|NCT03626506|DRUG|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
223988222|NCT05554042|DIAGNOSTIC_TEST|Kintsugi Voice Device|The Kintsugi Voice Device is an API with an underlying machine learning algorithm that drives the Device outputs. Depression and Anxiety are separate algorithms. The Device is designed to be adjunct to clinical assessment and estimate the presence of vocal characteristics consistent with a significant depressive episode and/or a clinically significant anxiety state, which are a necessary condition for the diagnosis of lifetime mood disorders, such as major depressive disorder and/or generalized anxiety disorder. Kintsugi Voice Device is not to be used in-lieu of full patient evaluation or relied upon to make or confirm diagnosis.
223988223|NCT05175300|DEVICE|Prosthesis with CoPXE couple.|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
223988224|NCT05175300|DEVICE|Prosthesis with CoC torque.|Prosthesis with ceramic-on-ceramic (CoC) torque.
223988225|NCT05976230|DRUG|Entresto|There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
223988226|NCT04288414|DIAGNOSTIC_TEST|functional near-infrared spectroscopy|Functional near-infrared spectroscopy (fNIRS) is a non-invasive method that can evaluate the brain function by measuring the change in brain metabolic activity and hemodynamics during a given task with near-infrared spectroscopy.
224120717|NCT06024772|PROCEDURE|Transrectal Ultrasound|Undergo transrectal mp-US
224120718|NCT06024772|PROCEDURE|Biopsy of Prostate|Undergo prostate biopsies
224120719|NCT05781815|PROCEDURE|dynamic hip screw|using dynamic hip screw in treatment of trochanteric fracture and dynamic hip screw with trochanteric stabilizing plate
224120720|NCT02524652|DRUG|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
224120721|NCT04762108|OTHER|Standard of care|Patients will be given standard of care as per their clinical needs
224120722|NCT01252134|DEVICE|Biotrue multipurpose solution|Contact lens care solution
224120723|NCT01252134|DEVICE|Sauflon Synergi multipurpose solution|Contact lens care solution
224120724|NCT01252134|DEVICE|OTE Elements multipurpose solution|Contact lens care solution
224120725|NCT01252134|DEVICE|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
224120726|NCT03073655|OTHER|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
224120727|NCT03073655|OTHER|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
224120728|NCT03073655|OTHER|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
223988227|NCT05759377|DEVICE|V-A ECMO AUTO Mode algorithm|"The clinical effects of utilizing the V-A ECMO AUTO Mode in parallel with VA ECMO treatment shall be assessed in different clinical settings. For this, a set of relevant clinical situations and findings (events) has been defined as trigger points where technical (via AIC) and clinical data shall be collected, linked, and analyzed. This assessment of raw data is important to further develop and adapt the software."
223988228|NCT05856578|DRUG|Mulberry Twig Alkaloid Tablet|Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet 50mg po tid
223988229|NCT05856578|DRUG|Canagliflozin|Canagliflozin 100mg po qd
223988230|NCT01607931|BEHAVIORAL|Exercise|1 hour of cycling at 50% of maximum power output
224120729|NCT04058119|BEHAVIORAL|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
224120730|NCT03650452|DRUG|TAK-935|TAK-935 tablets or mini-tablets.
223988231|NCT04263805|OTHER|Vignette with emphasis on research climate|A vignette describing a dilemma situation for a researcher (e.g. adding an honorary author) with or without a research environment factor (i.e. an environment where other researchers commit detrimental research practice)
223988232|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
223988233|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
224120731|NCT03650452|DRUG|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
224120732|NCT03257930|DRUG|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
224120733|NCT02273050|DRUG|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
224120734|NCT02273050|DRUG|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
224120735|NCT02273050|DRUG|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
224120736|NCT02273050|DRUG|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
224120737|NCT00750555|DRUG|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
224120738|NCT01795898|DRUG|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
224120739|NCT04820452|BIOLOGICAL|Low dose IBI302|Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection
223988234|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
224120740|NCT04820452|BIOLOGICAL|High dose IBI302|High dose IBI302 intravitreal injection given as every other month after three loading monthly injection
223988235|NCT01046422|DRUG|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
223988236|NCT01046422|DRUG|Placebo|Capsule, Oral, 0mg, Daily, 28 days
223988237|NCT01046422|DRUG|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
223988238|NCT04696783|DRUG|Esomeprazole Magnesium Enteric-coated Tablets|Nexium taken once every 2 days plus lifestyle adjustment
224120741|NCT04820452|DRUG|Aflibercept|Intraocular injection
224120742|NCT01968720|DRUG|CAT-2003|
224120743|NCT01968720|DRUG|Placebo|
224120744|NCT05359445|BIOLOGICAL|IMA401 (Phase Ia)|Intravenous infusions in escalating dose levels
224120745|NCT05359445|BIOLOGICAL|Pembrolizumab (Phase Ia)|Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab
224120746|NCT05359445|BIOLOGICAL|IMA 401 (Phase Ib)|Treatment at recommended dose for extension (RDE)
224120747|NCT03539458|DEVICE|Tendyne Mitral Valve System|Mitral valve replacement
224120748|NCT02214836|DEVICE|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
224120749|NCT06374342|DEVICE|Bone defect|Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.
224120750|NCT06374342|DEVICE|Spine fusion|Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together
224120751|NCT06374342|DEVICE|Cage filling|Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.
224120752|NCT06413485|BEHAVIORAL|Level of recreational water contact activities|We will examine a graded classification of this exposure based on individuals' minimum level of water contact: 1) no water contact; 2) minimal contact; 3) body immersion; 4) swallowed water. Minimal contact is defined as water contact that does not result in body immersion (e.g., wading below one's waist, boating, fishing). Body immersion is defined as entering the water above one's waist (e.g., swimming, surfing, snorkelling), and swallowing water as ingestion of any amount of water.
223988239|NCT04696783|BEHAVIORAL|Lifestyle adjustment|Lifestyle adjustment
223988240|NCT03536078|OTHER|home phototherapy|
223988241|NCT04657601|DEVICE|DiLumen C2 Endolumenal Interventional Platform|Dual balloon accessory to an endoscope and related instruments
223988242|NCT05002530|DRUG|Aerosolized 13 cis retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223988243|NCT05002530|DRUG|Aerosolized All trans retinoic acid plus Vitamin D|Patients with Post COVID-19 Anosmia (Loss of Smell) will receive one dose daily of Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 3 weeks. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223988244|NCT05002530|OTHER|Standard therapy|Standard therapy
223988245|NCT04012723|DEVICE|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
223988246|NCT02247843|BIOLOGICAL|βAS3-FB vector transduced peripheral blood CD34+ cells|CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
223988247|NCT01087515|OTHER|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
223988248|NCT04756206|DRUG|Dutasteride 0.5 mg|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
224120753|NCT06296017|OTHER|Experimental: Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.
224120754|NCT06296017|OTHER|Trigger Finger Splint|A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.
223988249|NCT04756206|DRUG|Placebo|patients were randomized into 2 equal groups with 1:1 ratio using a computer-based system. Dutasteride of 0.5 mg once daily was given for 3 months compared to a placebo. Patients, data collector,s and the statistician were blinded to the type of intervention.
223988250|NCT02716363|DEVICE|Rotational Atherectomy by Rotablator|
223988251|NCT01607528|DIETARY_SUPPLEMENT|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
223988252|NCT01607528|DIETARY_SUPPLEMENT|Placebo|A similar looking and tasting powder with no active substances
223988253|NCT05277077|OTHER|Pain neuroscience education|The experimental group will follow a PNE protocol based on previous procedure for a whole period of 6 weeks in addition the conventional treatment.
223988254|NCT05277077|OTHER|Conventional treatment|Patients from both groups will receive a conventional 6-week treatment programme (30 treatment sessions, five a week, for 90min duration).
223988255|NCT03137706|PROCEDURE|Biospecimen Collection|Undergo fresh tumor tissue collection
223988256|NCT03137706|OTHER|Laboratory Biomarker Analysis|Correlative studies
223988257|NCT03137706|OTHER|Laboratory Procedure|Tissue stiffness and cell viability analysis
223988258|NCT04666363|OTHER|Lavender oil|the essence was diluted 1:10 with sweet almond oil. A cotton ball soaked in 3 drops of diluted lavender essence was kept at a 10 cm distance from the patients' nose and they were asked to breathe slowly for 5 min.
223988259|NCT01125462|OTHER|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
223988260|NCT00134771|DRUG|Nutrient enriched infant formula|
223988261|NCT00723125|DRUG|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
223988262|NCT00723125|DRUG|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
223988263|NCT00723125|DRUG|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
223988264|NCT02126462|BIOLOGICAL|Na-APR-1 (M74)/Alhydrogel®|
223988265|NCT02126462|BIOLOGICAL|Na-GST-1/Alhydrogel®|
223988266|NCT02126462|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
224120755|NCT06296017|OTHER|Extracorporeal Shock Wave Therapy+ Trigger Finger Splint|Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart. Also, A trigger finger splint that immobilizes the MCF joint will be recommended.
223988267|NCT02196077|DRUG|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
224120756|NCT04653922|DEVICE|LinkCor Bioengineered Corneal Implant|Intrastromal implantation of a bioengineered corneal equivalent device
224120757|NCT06567470|DRUG|CIT-013 low dose|Subcutaneous injection
224120758|NCT06567470|DRUG|CIT-013 high dose|Subcutaneous injection
224120759|NCT06567470|DRUG|Placebo|Subcutaneous injection
223988268|NCT02196077|DRUG|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
223988269|NCT02196077|DRUG|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
223988270|NCT02196077|DRUG|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
223988271|NCT02196077|DRUG|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
223988272|NCT05592977|DEVICE|Intra-Oral Distalizing Device|The inner bow (1.2mm) is a modified version of the inner part of a conventional face bow. Two hooks were soldered onto the inner bow distal to the lateral incisor teeth regions, and U loop at 1st premolar region, and bends acting as mesial stop will be bent in front of the maxillary first molars. The anterior component of the inner bow is 3 mm free from the labial surface of anterior teeth
223988273|NCT03316807|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
223988274|NCT03316807|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
223988275|NCT05713162|BEHAVIORAL|Adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004).|The social skills intervention program was based on a consented adaptation of the Social Adjustment Enhancement Intervention of the UC Davis MIND Institute (Solomon, 2004). In order to be feasible in a hospital-based service, we adapted the program to 10 sessions. Session structure included initial greeting, free play time, didactic, joke telling, and closing activities. Topics of didactic sessions were related to social competence, such as empathy, talking about feelings, and solving social problems. We also adapted the content of the sessions, including activities proposed by Solomon (2004) but also from other experts in social cognition, such as García-Winner (2000). Each group was comprised by 7-10 participants. Children groups were conducted by a clinical psychologist, a mental health nurse and the support of two master degree students. Adolescent groups were conducted by a psychologist, a psychiatrist and the support of two master degree students.
223988276|NCT00387699|BIOLOGICAL|bevacizumab|
223988277|NCT00387699|DRUG|cisplatin|
223988278|NCT00387699|DRUG|etoposide|
223988279|NCT00387699|RADIATION|radiation therapy|
223988280|NCT06191081|PROCEDURE|lymphaticovenous anastomosis|lymphaticovenous anastomosis
223988281|NCT02046512|DIETARY_SUPPLEMENT|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
224120760|NCT06567470|DRUG|CIT-013 medium dose|CIT-013 medium dose
224120761|NCT05763199|DIETARY_SUPPLEMENT|AHCC|AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.
224120762|NCT05763199|DRUG|Chemotherapy|Chemotherapy will be administered per standard of care.
224120763|NCT05763199|OTHER|Placebo|Dextrin
223988282|NCT02046512|OTHER|Placebo|Sugar pill
223728747|NCT06088706|PROCEDURE|Intra-articular injection of ozone|the patient is lying on the bed with his knee flexed at about 45 degrees. Then The syringe containing ozone is prepared by a sports medicine assistant and covered with a label so that the clinician is not aware of the injected ozone dose. Lateral Approach will be used for intra-articular injection. after preparation and drape of the desired position and aspiration, the ozone composition will be injected into the joint. In order to inject for this group, a 10 cc needle and a predetermined concentration of 20 and 40 micrograms ozone are used under sterile conditions. The duration of the injection will be 15-20 seconds. The number of sessions considered for injection will be three sessions, once a week for three weeks. The second and third injection will be done under the same conditions as the first session. In this study, Ozonette Sedecal device ( Spain) will be used. And the exercise therapy protocol is performed.
223728748|NCT00686660|BEHAVIORAL|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
223728749|NCT00686660|BEHAVIORAL|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
223728750|NCT00686660|BEHAVIORAL|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
223728751|NCT00686660|BEHAVIORAL|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
223728752|NCT00699621|BIOLOGICAL|platelets|Four units of fresh platelets will be infused immediately
223728753|NCT05040321|DRUG|MIB-626|Participants will be randomized to either receive MIB-626 or matching placebo. The proposed intervention - targets multiple contributors to the pathology of AD; MIB-626 improves mitochondrial function, bioenergetics, and insulin sensitivity, inhibits A beta accumulation by reducing its synthesis and increasing its clearance, reduces neuroinflammation, exerts neuronal protective effects, and promotes neuronal regeneration and connectivity in preclinical models.
223728754|NCT05040321|DRUG|Placebo|Subjects will be randomized to receive either the placebo or 1000 mg MIB-626 twice daily orally.
223728755|NCT01634815|PROCEDURE|The Edge|measuring blood lactate
223728756|NCT05935852|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses
223728757|NCT02669732|DRUG|DS-8500a|tablets
223728758|NCT02669732|DRUG|placebo|tablets
223728759|NCT01285310|DRUG|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
223988283|NCT01367444|DRUG|SAR422459|"Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection"
223988284|NCT03995342|DIETARY_SUPPLEMENT|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
223988285|NCT03995342|DIETARY_SUPPLEMENT|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
223988286|NCT01932268|DRUG|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
223988287|NCT00513747|BIOLOGICAL|rituximab|Given IV over 4 hours
223988288|NCT00513747|DRUG|fludarabine phosphate|Given IV over 30 minutes
223988289|NCT01198106|DRUG|scopolamine|0.6 mg
223988290|NCT01198106|DRUG|cinnarizine|50 mg
223988291|NCT00003477|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
223988292|NCT04610411|DEVICE|surgical navigation|surgical navigation for pedicle screw placement and rod beinding using AR-glasses and a specially developed software
223988293|NCT04610411|OTHER|standard surgical method|standard surgical method established at the institution
223988294|NCT01236352|DRUG|BMS-911543|
223988295|NCT05575297|DRUG|Methotrexate Sodium|Methotrexate oral administration alone
223988296|NCT05575297|DRUG|Rifampicin Sodium|Co-administration of methotrexate and rifampicin
223988297|NCT05575297|DRUG|Febuxostat Tablets|Co-administration of methotrexate and febuxostat
223988298|NCT00820261|OTHER|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
223988299|NCT01575873|DRUG|Denosumab|Administered by subcutaneous injection once every 6 months
223988300|NCT01575873|DRUG|Placebo for risendronate|Administered orally once a day
223988301|NCT01575873|DRUG|Risendronate|Administered orally once a day
223728760|NCT01285310|DRUG|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
223728761|NCT01285310|DRUG|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
223728762|NCT00208039|DRUG|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
223728763|NCT03764501|DEVICE|Image fusion system|Image fusion system for the 3D preoperative planning
223728764|NCT01832987|DRUG|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
223988302|NCT01575873|DRUG|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
223988303|NCT04623606|BIOLOGICAL|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
223988304|NCT05253768|BIOLOGICAL|Fecal microbiota transplant (FMT)|"Patients will randomized to a fecal microbiota transplantation by using a nasointestinal tube for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
223988305|NCT05253768|OTHER|normal saline and glycerin/food coloring|"Patients will receive an equivalent volume of normal saline and glycerin/food coloring via a nasointestinal tube (sham transplantation) for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of placebo FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice."
223988306|NCT02266342|DEVICE|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
223988307|NCT00965497|DRUG|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
223988308|NCT02799641|DRUG|Diazepam|5 mg Diazepam
223988309|NCT02799641|DRUG|Lidocaine|2 ml of 2% lidocaine
223988310|NCT02799641|OTHER|Placebo pill|Placebo pill
223988311|NCT02799641|OTHER|Placebo injection|Placebo injection
223988312|NCT00001905|DRUG|Interferon gamma|
223988313|NCT05034068|DRUG|0.15% bezaydamine hydrochloride.|0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
223988314|NCT05034068|DEVICE|low power laser with a wavelength of 870 nm|the irradiations will be done three times a week using low power laser with a wavelength of 870 nm. The irradiation mode will be punctual and in contact, perpendicular to the oral mucosa. The power will be 60 mW, energy density of 6 J/cm2. Irradiation time will be 6 seconds per point based on the laser beam spot size of 0.55cm2
223988315|NCT05146089|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask.
223728765|NCT03789045|DIAGNOSTIC_TEST|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables. Bland-altman will be used to determine levels of agreement.
223728766|NCT06204744|OTHER|Home-based GRASP program|The home-based Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve the upper extremity function for people with stroke, including exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.
223728767|NCT06204744|OTHER|Conventional occupational therapy home program|The conventional OT home program will be prescribed by the occupational therapists, customizing stroke rehabilitation exercises to individual patient goals, with a primary focus on improving upper extremity function.
223728768|NCT01743053|DEVICE|Standard Care plus ReCell|
223988316|NCT05146089|OTHER|modified Oxford test|An intravenous bolus of sodium nitroprusside (100 μg) will be given to decrease blood pressure, followed 1 minute later by a bolus of phenylephrine (150 μg) to increase blood pressure, occurring before and after intermittent hypoxia exposure.
223988317|NCT05146089|DRUG|Oral Bosentan 62.5 mg|Prior to completion of visit 2, male subjects will consume 62.5 mg twice daily for 3 days as well as the morning of the study visit (7 pills) at home and experimental sessions will be performed 3 hours after oral intake of the final dose.
223988318|NCT05146089|OTHER|Hypoxic ventilatory response test|Hypoxia will be achieved using breaths of low oxygen air (5% oxygen) followed by room air through a mask. This will be repeated 4-5 times per test, occurring before and after intermittent hypoxia exposure.
223988319|NCT02965105|DEVICE|Coloplast Test Catheter|This is a newly developed intermittent catheter
223988320|NCT02965105|DEVICE|Speedicath|This is a marketed Catheter which is used as comparator
223988321|NCT03180567|DIAGNOSTIC_TEST|Genetic Mutations|By next generation sequencing
223988322|NCT02952521|PROCEDURE|Blood Draw|CA125 and ctDNA
223988323|NCT02952521|PROCEDURE|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
223988324|NCT04510181|DIETARY_SUPPLEMENT|amino acid-based blend|blended (listed in descending order) L-lysine, L-arginine, oxo-proline, N-acetyl-l-cysteine, L-glutamine, and Schizonepeta tenuifolia
223988325|NCT02181153|OTHER|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
223988326|NCT03701048|PROCEDURE|Cesarean Section|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.
223988327|NCT03981939|OTHER|No intervention|This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.
223988328|NCT00246090|DRUG|E7389|E7389 1.4 mg/m\^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
223988329|NCT03402074|BEHAVIORAL|Group hypnosis|5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
223988330|NCT01896622|DRUG|Ritonavir|Impact on dabigatran PK/PD
223988331|NCT01896622|DRUG|Cobicistat|Impact on dabigatran PK/PD
223988332|NCT05427227|DEVICE|EV-array detection|Collect peripheral blood sample of 500 GI patients at treatment baseline, every time point response till disease progression.Blood samples will be transferred to central lab to detect certain exosome proteins expression by EV-array.Tumor response evaluation will be performed after two cycles of therapy by CT/MRI based on RECIST.Clinical data, including tumor stage,metastatic organ ,regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
223988333|NCT04198389|PROCEDURE|PARTIAL KNEE REPLACEMENT|PARTIAL KNEE REPLACEMENT
223988334|NCT01031498|DRUG|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
223728769|NCT01743053|OTHER|Standard Care|
223728770|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
223728771|NCT00861276|DRUG|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
223988335|NCT01031498|DRUG|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
223988336|NCT01810523|BEHAVIORAL|Narrative|Narrative form as described above.
223988337|NCT01810523|BEHAVIORAL|Control|Blank piece of paper
223988338|NCT00631267|PROCEDURE|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
223988339|NCT00631267|PROCEDURE|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
223988340|NCT02825342|DRUG|Citalopram|
223988341|NCT02471989|DIETARY_SUPPLEMENT|Low-FODMAP diet|
223988342|NCT02471989|DIETARY_SUPPLEMENT|GERD diet|
223988343|NCT01827046|DRUG|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
223988344|NCT03143738|PROCEDURE|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
223988345|NCT03143738|PROCEDURE|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
223988346|NCT03143738|PROCEDURE|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
223988347|NCT04454034|PROCEDURE|arthroscopic synovectomy|arthroscopic synovectomy
223988348|NCT02734004|DRUG|Olaparib|Olaparib
223988349|NCT02734004|DRUG|MEDI4736|MEDI4736
223988350|NCT02734004|DRUG|Bevacizumab|Bevacizumab
223988351|NCT00889967|DRUG|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
223988352|NCT00889967|DRUG|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
223988353|NCT00889967|DRUG|Placebo|Placebo once daily by inhalation for 28 days
223988354|NCT01294436|DRUG|Dapagliflozin|Oral Dose 5 or 10 mg
223988355|NCT04796675|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
223988356|NCT03153813|DRUG|capsaicin 8% patches (Qutenza)|
223988357|NCT03153813|OTHER|Placebo patches|
223988358|NCT05946694|OTHER|intubation in manikin|Evaluation of 3 videolaryngoscopes under simulated out-of-hospital conditions by people without clinical experience on a manikin model
223988359|NCT02595775|OTHER|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
223988360|NCT02595775|OTHER|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
223988361|NCT02595775|OTHER|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
223988362|NCT02595775|OTHER|A/F report alone|
223988363|NCT02343289|DRUG|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
223988364|NCT02343289|DRUG|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
223988365|NCT00822146|DEVICE|CRT|classified
223988366|NCT04737265|OTHER|Biomarker Guided Intervention|NTproBNP above the upper limit of normal will trigger the initiation of heart failure therapy with counseling from a study investigator based on protocol specified algorithm.
223988367|NCT01379456|PROCEDURE|physiotherapy|exercises, 20 sessions over 10 weeks
223988368|NCT00535093|DEVICE|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
224120764|NCT05889702|BEHAVIORAL|KATR Linkage Strategy|"The Kentucky ATR (KATR) strategy is a 25-county program that links county residents at or below the 200% national poverty level who have an illicit SUD and are in treatment or early recovery to evidence-based RSSs such as recovery housing, and to other RSSs.~The KATR linkage approach uses vouchers as a linkage strategy for individuals in SUD treatment who have no other funding options to acquire critical RSSs. As such, KATR's linkage through vouchers is a last resort approach for linking to RSSs."
224120765|NCT06332625|DIAGNOSTIC_TEST|Brain quantitative magnetic resonance imaging|Identification and predictability of early structural and metabolic markers from 3T and 7T quantitative magnetic resonance imaging (qMRI)
224120766|NCT00174746|DRUG|AVE2635A|
223988369|NCT03272711|DRUG|Vortioxetine 10 mg|
223988370|NCT03272711|BEHAVIORAL|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
223988371|NCT06056271|DEVICE|AF Ablation|Percutaneous, catheter-based ablation of atrial fibrillation
223988372|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
223988373|NCT00821938|PROCEDURE|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
223988374|NCT00105105|DRUG|Mifepristone|
223988375|NCT04488042|OTHER|Stapler-less gastrectomy|After the LSG stapler line removal by electrothermal bipolar-activated device (LigaSure Atlas™, Valleylab, Boulder, CO, USA), a stapler-less hand-sewn reconstruction was adopted. A single extra-mucosal running barbed suture (3/0 V-Loc™ suture; Covidien, Mansfield, MA, USA), incorporating sero- and submucosal gastric layers, closed the gastric tube.
223988376|NCT04488042|OTHER|Suture|No reinforcement was performed, the stomach was re-sleeved along a 40F bougie with Echelon Flex Endopath 60-mm linear stapler (Ethicon Endo-Surgery, Cincinnati, OH, USA) to reproduce standard volume of remnant LSG stomach and/or eliminating zig-zag shape of suture-line.
223988377|NCT02149706|BIOLOGICAL|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
223988378|NCT02149706|BIOLOGICAL|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
223988379|NCT06168084|DRUG|Vonoprazan|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
223988380|NCT06168084|DRUG|amoxicillin|Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID
223988381|NCT06168084|DRUG|Bismuth|Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
223988382|NCT06168084|DRUG|Esomeprazole|Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID
223988383|NCT06168084|DRUG|Tetracycline|Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
223988384|NCT06168084|DRUG|Furazolidone|Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID
223988385|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|20 μg
223988386|NCT03547245|BIOLOGICAL|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|100 μg
223988387|NCT03547245|BIOLOGICAL|DPBS Sucrose|Placebo
223988388|NCT04565262|DRUG|NAs+IFN-α|NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
223988389|NCT01018732|BIOLOGICAL|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
223988390|NCT06542406|DEVICE|Endotracheal intubation|The first 40 successful and the first 40 unsuccessful ETE procedures were included in the study.
223988391|NCT01536171|OTHER|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
223988392|NCT00585078|DRUG|Capecitabine|
223988393|NCT00585078|DRUG|Oxaliplatin|
223988394|NCT02745639|RADIATION|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
223988395|NCT02745639|DRUG|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
223988396|NCT04198571|DRUG|Zinforo (ceftaroline fosamil)|IV Solution
223988397|NCT02781311|DRUG|Setipiprant|Setipiprant tablets, orally, BID for 24 weeks.
223988398|NCT02781311|DRUG|Placebo|Placebo tablets, orally, BID for 24 weeks.
223988399|NCT02781311|DRUG|Finasteride|Finasteride tablet, orally, once daily for 24 weeks.
223988400|NCT02874599|PROCEDURE|Dental restoration|Damaged teeth will be restored
223988401|NCT05474547|BEHAVIORAL|Meditation|Students will meditate for 30 min every day for 10 days
223988402|NCT00288951|DRUG|Travoprost 0.004% with and without BAK|
223988403|NCT01335945|PROCEDURE|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
223988404|NCT00160082|DRUG|Xepol|
223988405|NCT02562898|DRUG|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
223988406|NCT02562898|DRUG|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
223988407|NCT02562898|DRUG|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
223988408|NCT02119247|DEVICE|CHF 6001 dry powder for inhalation via NEXThaler®|
223988409|NCT02119247|DEVICE|CHF 6001 DPI capsules for inhalation via Aerolizer|
223988410|NCT01299142|DRUG|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
223988411|NCT02788071|DIETARY_SUPPLEMENT|FMT capsules|25 capsules per day for 12 days
223988412|NCT02788071|DIETARY_SUPPLEMENT|FMT placebo|25 capsules per day for 12 days
223988413|NCT01056263|DRUG|axitinib: observational study|Non-interventional observational study
223988414|NCT01002716|BIOLOGICAL|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
223988415|NCT02626247|DIETARY_SUPPLEMENT|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
223988416|NCT02626247|OTHER|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
223988417|NCT06338085|OTHER|emotional liberation technique|In this intervention, with the technique taught by the researcher, women will self-administer the practice of lightly touching certain points 5 days and 1 time per week for 8 weeks. A whatsup group will be created by the researcher. A reminder message will be sent from this group to do the practice 1 time every day.
223988418|NCT04975503|OTHER|Observing cardiovascular risk factors|Documenting the presence or absence of CVD risk factors in each participant.
223988419|NCT03612076|OTHER|Global cost of management of PJI|estimation of the global cost to manage PJI with 2-step exchange over 3 years
223988420|NCT00891553|PROCEDURE|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
223988421|NCT05026489|GENETIC|G6PD gene deficiency|we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.
223988422|NCT05678686|OTHER|Active Comparator: Routine Exercise Group|Exercises (tongue-palate exercises, tongue base exercises, Masako Maneuver, Mendelson Maneuver, Effortful Swallowing, Supraglottic exercises, thermal tactile stimulation) will be performed 2 days a week for 8 weeks, in total 16 sessions and these exercises applied by the physiotherapist.
223988423|NCT05678686|OTHER|Experimental: PNF Exercise|In addition to the practices in the control group, head-neck PNF(Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to both movement patterns by the physiotherapist using the combined isotonic contraction technique ), 2 days a week for 8 weeks, in total 16 sessions.
223988424|NCT05678686|OTHER|Experimental: CTAR Exercise|In addition to the practices in the control group, CTAR exercises will be applied in the presence of a physiotherapist, 2 days a week for 8 weeks, a total of 16 sessions. In the CTAR exercise, the patient is asked to flexion and extension the neck by pressing a standard size and inflatable rubber ball placed under his chin against his sternum. Patients will be asked to do the exercise protocol, which consists of isometric and isotonic components.
223988425|NCT02400775|DRUG|Azilsartan|Azilsartan tablets
223988426|NCT00328575|RADIATION|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
223988427|NCT05803681|DEVICE|Capacitive Coupled Electric Fields (CCEF)|In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.
223988428|NCT05803681|OTHER|Calssic clinical protocol|(1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
224120767|NCT03819179|OTHER|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
224120768|NCT03819179|OTHER|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
224120769|NCT03819179|OTHER|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
224294432|NCT03626506|DRUG|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
224294433|NCT03626506|DRUG|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
223988429|NCT03789084|BEHAVIORAL|Brief Cognitive-Behavioral Therapy for Health Anxiety|4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
223988430|NCT03789084|BEHAVIORAL|Referral to mental health provider|Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
223988431|NCT03423160|OTHER|None--observational|Observational study of behavior and electrical brain activity
223988432|NCT05834907|BEHAVIORAL|Circle of Security Parenting|"COS-P is an attachment-based, home visiting intervention intended to supporting parents in serving as a secure base from which their children can explore the world, and to which their children can return in times of distress (Bowlby, 1988). Such secure base parenting increases the likelihood of children's secure attachment. COS-P also targets parental responses to children's expression of their needs (e.g., crying), and is designed to help parents understand the ways in which their own (parental) dysregulated emotional, physiological, and behavioral responses to children's emotions and behaviors can limit their responsiveness to their children's attachment needs."
223988433|NCT05834907|BEHAVIORAL|Little Talks|Little Talks is an early literacy home visiting intervention developed for low-income, racial and ethnic minority infants and toddlers, and has been tested in Early Head Start contexts (Manz et al., 2016; Manz et al. 2017). Little Talks uses book sharing to promote early literacy and has been adapted in both English and Spanish. The intervention utilizes modular treatments during home visits, teaching parents how to facilitate language interactions with their children through book sharing. Age appropriate books are given to parents to share with their children during the intervention.
223728772|NCT03551860|PROCEDURE|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
223988434|NCT05990387|DRUG|Mirabegron|Dose-response effect on thermogenesis
224120770|NCT03819179|OTHER|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
224294434|NCT03621319|DEVICE|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
223988435|NCT05990387|DRUG|Placebo|Placebo control condition
223988436|NCT05840510|DRUG|Adagrasib|KRAS G12C inhibitor
223988437|NCT05840510|DRUG|nab-Sirolimus|mTOR inhibitor
223988438|NCT03764033|BEHAVIORAL|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
224120771|NCT03819179|OTHER|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
224120772|NCT03115489|DRUG|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
223988439|NCT03764033|BEHAVIORAL|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
223988440|NCT05118854|DRUG|AMG 510|Given by IV
223988441|NCT05118854|DRUG|Cisplatin|Given by IV
223988442|NCT05118854|DRUG|Carboplatin|Given by IV
223988443|NCT05118854|DRUG|Pemetrexed|Given by IV
223988444|NCT02257918|DRUG|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
223988445|NCT02257918|DRUG|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
223988446|NCT01674452|BEHAVIORAL|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
223988447|NCT01674452|BEHAVIORAL|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
224120773|NCT03115489|DRUG|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
224120774|NCT03177837|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
224120775|NCT03177837|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
223988448|NCT02422225|DEVICE|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention\]~* Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~* Stimulation site \<Experimental group\>~  * Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~ * Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~ * Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit \<Control group\> Sham stimulation"
223988449|NCT02422225|DEVICE|Sham Eldith DC-STIMULATOR|
223988450|NCT06215859|DRUG|MR-107A-02|tablet
223988451|NCT06215859|DRUG|Tramadol|over-encapsulated tablet
223988452|NCT06215859|DRUG|Placebo|over-encapsulated tablet and/or tablet
223988453|NCT04170491|DIAGNOSTIC_TEST|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
224120776|NCT02690480|DRUG|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
224120777|NCT02690480|DRUG|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
224120778|NCT02690480|DRUG|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
223988454|NCT05432921|BEHAVIORAL|Lifestyle modification|50min of endurance combined with 50min of strength training; 1-2 sessions/week for 6 month, follow up after 3-6month
223988455|NCT00056810|DRUG|4-aminopyridine (4-AP)|
223988456|NCT00428025|DRUG|diclofenac|100 mg diclofenac rectal suppository
223988457|NCT00428025|DRUG|placebo|similar shape and size suppository
224120779|NCT02927808|BEHAVIORAL|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
224120780|NCT06511713|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
224120781|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
223988458|NCT02496598|PROCEDURE|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
224120782|NCT01703286|DRUG|Linagliptin|given once daily for 28 days
224120783|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
224120784|NCT01703286|DRUG|Placebo|Placebo matching Linagliptin
224120785|NCT01703286|DRUG|Placebo|Placebo matching Glimepiride
224120786|NCT01703286|DRUG|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
224120787|NCT06112990|DIETARY_SUPPLEMENT|creatine monohydrate|Creatine is part of the phosphagen system and plays a critical role in energy metabolism. Creatine monohydrate supplementation increases availability of creatine and phosphocreatine in the skeletal muscle. Increased phosphocreatine enables greater buffering of adenosine triphosphate, an organic compound providing energy to cells, enhancing training volume (e.g., an individual can work-out harder and longer).This augmentation in exercise capacity amplifies training adaptations. Additionally, creatine monohydrate supplementation reduces levels of inflammatory markers, which are associated with severe muscle loss.
224120788|NCT06112990|OTHER|Placebo|Placebo supplementation consists of a flavorless, colorless, dextrose powder and will be supplied in concealed, unlabeled packaging.
224120789|NCT06112990|BEHAVIORAL|Home-based, telehealth|Home-based, individualized, whole-body RT program, supervised via the telehealth platform within the electronic medical record system. The RT program consists of 12 resistance exercises, focusing on all major muscle groups including upper and lower body, core, and whole-body. Exercises within each participant's individualized RT program progress with a periodization model as recommended by the American College of Sports Medicine. In addition, the cancer exercise trainer will inquire about space availability in the home for completing resistance prior to developing the personalized prescription. This logistical information is key to ensure feasibility of completing the exercises prescribed. Participants will be provided with beginner and advanced sets of elastic resistance bands to enable progression throughout the 52-week study.
224120790|NCT01744847|DEVICE|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
224120791|NCT06121947|PROCEDURE|The DBS electrodes are implanted into MLR.|MLR-DBS#Deep brain stimulation of the mesencephalic locomotor region#The arm will be switched on one month postoperatively for electrical stimulation therapy,exercise training rehabilitation and EMG-triggered neuromuscular stimulation. Specialist doctors will assess the patient's rehabilitation status through the telerehabilitation system every week, and provide guidance on rehabilitation training and electrical stimulation therapy.
224120792|NCT06121947|PROCEDURE|The electrodes are implanted into the patient's vagus nerve|A pre-surgery assessment was performed. Device implantation was done under general anaesthesia. A horizontal neck crease incision was created left of the midline at the level of the cricoid cartilage. After the vagus nerve was identified, the stimulation lead was wrapped around the vagus nerve. The lead was then tunnelled subcutaneously to the pulse generator device which was contained in a subcutaneous pocket in the pectoral region
224120793|NCT01984346|DEVICE|AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax|Convergent Epicardial Endocardial Ablation Procedure
224120794|NCT01984346|DEVICE|Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering|Endocardial Catheter Ablation Procedure
224120795|NCT06245018|BIOLOGICAL|iNK Injection|Subjects will receive about 4 cycles of iNK
223988459|NCT02496598|DRUG|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
223988460|NCT00695825|DIETARY_SUPPLEMENT|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
224294435|NCT03621319|DEVICE|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
223988461|NCT00695825|DIETARY_SUPPLEMENT|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
224120796|NCT02973529|DEVICE|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
224120797|NCT02973529|DEVICE|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
224294436|NCT01564459|DRUG|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
223988462|NCT03445117|OTHER|Educational intervention|a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
223988463|NCT04403906|DIAGNOSTIC_TEST|PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)|The PCL COV05 - COVID 19 Ag Rapid FIA test has FSC and CE approvals for the qualitative detection of SARS-CoV-2 Antigens from human oropharyngeal swabs and deep sputum samples. The manufacturer is PCL Corporation Ltd 17F, 128 B-dong, Courthouse-ro, Songpa-gu, Seoul, South Korea.
223988464|NCT05256810|DRUG|ALN-XDH|ALN-XDH administered by SC injection
223988465|NCT05256810|DRUG|Placebo|Placebo administered by SC injection
223988466|NCT05092698|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of cholecalciferol weekly and 5,000 IU of cholecalciferol (two drops) daily until discharge or death.
223988467|NCT05092698|DIETARY_SUPPLEMENT|Herbal oil|Patients will receive 45 ml of herbal oil orally or via feeding tube after serum Vitamin D concentrations measurement followed by the same dose of pure herbal oil weekly and two drops of herbal oil daily until discharge or death.
223988468|NCT01084993|DRUG|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
223988469|NCT01084993|DRUG|Heparin|70 U/kg
223988470|NCT05612646|PROCEDURE|Acupressure|"The patients assigned to the experimental group received acupoint massage designed to improve constipation for 7 days during hospitalization. The selection of acupoints in this study includes Tianshu (double) (Tianshu, ST25: Stomach Meridian 25, the 25th point of the stomach meridian), Zhongwan (single) (Zhongwan CV12: Conception Vessel 12, the 12th point of the Ren meridian) ), Qihai Point (Single) (Qihai CV6: Meridian Vessel 6 Renmai 6th point) 3 points."
223988471|NCT05612646|PROCEDURE|routine nursing and fake acupressure|control groups: receiving routine nursing and fake acupressure to improve constipation for 7 days during hospitalization.
223988472|NCT01071837|DRUG|APG101|400mg weekly as intravenous infusion
223988473|NCT01071837|PROCEDURE|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
223988474|NCT01688310|PROCEDURE|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
223988475|NCT01688310|PROCEDURE|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
223988476|NCT02121912|DEVICE|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
224120798|NCT05009472|DEVICE|expander with deferential opening and petit face mask|bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
224120799|NCT04150874|DIAGNOSTIC_TEST|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
224294437|NCT01564459|DRUG|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
223988477|NCT02121912|DEVICE|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
224120800|NCT05490628|OTHER|Cognitive Rehabilitation|Language, memory, attention and executive function exercises are performed for the participants' deficient cognitive functions.
224120801|NCT05490628|OTHER|Conventional Therapy|Strengthening, walking, balance and coordination exercises are performed according to the needs of the participants.
224294438|NCT02957266|RADIATION|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
224120802|NCT06086639|OTHER|Online Occupational Therapy Group Training|In this study, a 4-week online occupational therapy group training was conducted by an occupational therapist specialized in the field of nutrition. The content of the training, which takes place one hour a week, is given below; Session-1 Defining the problem Understanding the causes Oral motor structures and anomalies Discussion Session-2 Feedback sharing The relationship between feeding and sensory integration Recognizing the symptoms of sensory integration Disorders Strategies for sensory integration disorders Discussion Session-3 Feedback sharing Parent behaviors and attitudes Behavioral strategies for feeding problems Discussion Session-4 Feedback sharing Self-compassion and self-regulation Cope with stress Discussion Review of outputs
224120803|NCT06428643|OTHER|Chlamydia, gonorrhea, syphilis, and HIV screening|Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
223728773|NCT03551860|PROCEDURE|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
223988478|NCT04865692|OTHER|BFRT|Patients of Interventional group were treated with routine physiotherapy program combined with LI-BFR consist of 10 minutes' session 3 per week for 12 weeks. In order to determine the training load 20% of 1RM, participants had performed knee extension in full range with a challenging weight. After each test, participants rated their perceived exertion level on (RPE) scale to determine the difficulty of the resistance. The derived 1RM was used to determine the 20% 1RM load used for low-load training. Blood flow restriction proximal to the working muscles achieved through using pressure cuffs. The cuff was applied to the proximal thigh. During week 1 the inflation pressure was 100mmHg. Final exercise pressure based the week of the training. Quadriceps size was measured by tape measures thigh
223728774|NCT05553002|OTHER|Deneroll cervical extension traction|"Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~1. In the upper cervical region (C2-C4) region.~2. The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~3. The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region."
223988479|NCT04865692|OTHER|Routine Physical Therapy|knee isometrics, resisted knee extension with chalanging weight 2 sets of 10 Reps with 5 sec hold
223988480|NCT04266847|DEVICE|monofocal IOL,bifocal IOL,or trifocal IOL|phacoemulsification and implantation of IOL.IOL may be monofocal IOL,bifocal IOL,or trifocal IOL
223988481|NCT03668171|PROCEDURE|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
223988482|NCT00284193|DRUG|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
223988483|NCT00284193|DRUG|FEIBA- Activated Prothrombin Complexes|
223988484|NCT02842983|DRUG|Esmolol|conventional management plus esmolol infusion
223988485|NCT05783999|DEVICE|vibra plus|the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
223988486|NCT03667937|COMBINATION_PRODUCT|CUTIMED|Hydrophobic Dressing
223988487|NCT03667937|OTHER|AQUACEL silver|Silver Dressing
223988488|NCT05205564|OTHER|This is a cross-sectional research design.|No intervention will be involved in the study.
223988489|NCT05947266|BEHAVIORAL|an adaptation of the iENGAGE|Haitian immigrant iENGAGE (H-iENGAGE) is an adaptation of the iENGAGE intervention culturally adapted for Haitian immigrants with HIV that will be tested in a quasi-experimental pilot for preliminary efficacy among recently diagnosed or nonvirally suppressed adults across two Federally Qualified Health Centers (FQHCs) in Miami.
223988490|NCT05696925|OTHER|Motor Imagery|Motor imagery (MI) is a cognitive process that involves the ability to perform an action mentally, without the need to perform the movement itself. The perspective that the person uses to imagine can be: internal perspective (first person - imagines himself/herself), which relates to the person's view of the content of the images or to his/her kinesthetic sensation - the person imagines the movement being performed, as if feeling the movement of the action; or external perspective (third person - imagines another person), which relates to the visual imagination of scenes outside the person.
223988491|NCT05696925|OTHER|Action Observation|Action observation consists of watching another person acting, or doing a motor task, on video or in real-time.
223988492|NCT05696925|OTHER|Exoskeletons|The term Brain-Machine Interface (BMI) refers to systems that capture brain activity signals, translating them into computer commands to control external devices, with the robotic exoskeletons. The electrodes are positioned on the skull cap.
224120804|NCT06528938|DEVICE|Theta Burst Stimulation|Cool B70 coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
224120805|NCT00427388|DRUG|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
224120806|NCT00427388|OTHER|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
224120807|NCT02531373|BIOLOGICAL|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
224120808|NCT02531373|BIOLOGICAL|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
224294439|NCT02957266|RADIATION|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
224294440|NCT02957266|DRUG|Cisplatin|Weekly Cisplatin
224294441|NCT02957266|DRUG|Gemcitabine|Weekly Gemcitabine
223988493|NCT05696925|OTHER|Execution of the Action|In the sitting or standing position, depending on the action to be performed, the participant must execute the same action imagined or observed previously.
223988494|NCT03371823|OTHER|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
223988495|NCT03371823|DRUG|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
223988496|NCT02930252|DEVICE|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
223988497|NCT02930252|DEVICE|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
223988498|NCT03330964|OTHER|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
223988499|NCT02635178|BEHAVIORAL|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
224120809|NCT02531373|BIOLOGICAL|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
224294442|NCT02957266|GENETIC|PIK3CA|PIK3CA mutations rate
224294443|NCT02957266|GENETIC|KRAS|KRAS mutations rate
224294444|NCT02957266|GENETIC|BRAF|BRAF mutations rate
223988500|NCT02635178|BEHAVIORAL|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
223988501|NCT02675049|DRUG|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
223988502|NCT02675049|DRUG|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
224120810|NCT02531373|BIOLOGICAL|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
224294445|NCT02957266|GENETIC|RRM1|RRM1 mutations rate
223988503|NCT02675049|DRUG|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
223988504|NCT02675049|DRUG|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
223988505|NCT01876615|DRUG|YH4808|experimental drug
224120811|NCT02531373|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
224120812|NCT05482126|DIAGNOSTIC_TEST|Intraoperative Behavioral Testing|During DBS surgery, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
224120813|NCT05482126|DIAGNOSTIC_TEST|Behavioral Testing|In the lab, tasks will be administered via a tablet PC or mounted monitor, and the subject may hold a response box, joystick, or dynamometer to record responses. During task periods, sensory stimuli will be delivered to the participant, who may be asked to perform a motor behavior in response. Stimuli will consist of audiovisual cues presented on a computer screen, vibration applied to specific parts of the body via a tactor, mild electrical pulses delivered through the skin of specific parts of the body via the attached EMG electrodes, and/or a movement of the arm or joint. Motor responses will consist of simple movements such as finger-tapping or hand-opening, or use of a joystick or dynamometer to move a computer cursor on the screen. Participants may be asked to respond only to a particular sensory stimulus and ignore others, in order to modulate the relevance of each stimulus to the task.
224120814|NCT03838250|BIOLOGICAL|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
224120815|NCT06077968|BIOLOGICAL|Prior standard of care receipt of Pfizer's ABRYSVO vaccine|Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
224120816|NCT04644419|OTHER|none (observational study)|This is an observational study and does not include intervention delivery.
224294446|NCT04135521|DRUG|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
223988506|NCT01876615|DRUG|Diclofenac|Depain tablet 25mg
224120817|NCT02793908|DRUG|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
224120818|NCT02793908|DRUG|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
224120819|NCT00369434|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|
224120820|NCT00491114|DRUG|Gemcitabine|
224120821|NCT00003068|DRUG|amifostine trihydrate|
224120822|NCT00003068|DRUG|cyclophosphamide|
224120823|NCT00003068|DRUG|mitoxantrone hydrochloride|
224120824|NCT00003068|DRUG|thiotepa|
224294447|NCT03951584|OTHER|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
224120825|NCT00003068|PROCEDURE|peripheral blood stem cell transplantation|
224294448|NCT00106938|DEVICE|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
224294449|NCT00106938|PROCEDURE|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
224294450|NCT03096275|DRUG|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
223988507|NCT01876615|DRUG|YH4808+Diclofenac|
223988508|NCT06021938|DEVICE|Immersive virtual reality (IVR) & Music therapy|The patient will be offered a digital therapy session based on immersive virtual reality (IVR) and a music therapy session, 60 minutes apart. The IVR session will be based on medical hypnosis (GAMIDA®) and the music therapy session will be based on the choice of music the patient wishes. Each session will last 15 minutes. Patients will start either with the medical hypnosis session by IVR or with the music session depending on the randomization carried out before the start of the study. The random order will be provided by software (CleanWeb).
223988509|NCT00002740|BIOLOGICAL|filgrastim|
223988510|NCT00002740|DRUG|carboplatin|
223988511|NCT00002740|DRUG|cyclophosphamide|
224120826|NCT02440178|DRUG|Micafungin|
223988512|NCT00002740|DRUG|doxorubicin hydrochloride|
223988513|NCT00002740|DRUG|etoposide|
223988514|NCT00002740|DRUG|mesna|
223988515|NCT00002740|DRUG|vincristine sulfate|
223988516|NCT00002740|PROCEDURE|conventional surgery|
223988517|NCT00002740|PROCEDURE|peripheral blood stem cell transplantation|
223988518|NCT00002740|RADIATION|low-LET cobalt-60 gamma ray therapy|
223988519|NCT00002740|RADIATION|low-LET photon therapy|
223988520|NCT01633476|DRUG|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
223988521|NCT00220623|DRUG|antidepressant medications, flexible drug choice|
223988522|NCT00220623|BEHAVIORAL|CBT, Psychodynamic or Supportive Psychotherapy|
223988523|NCT02145169|DRUG|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
223988524|NCT02923193|DEVICE|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
223988525|NCT02923193|DRUG|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
223988526|NCT01670071|DRUG|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
223988527|NCT01670071|DRUG|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
223988528|NCT01902186|DRUG|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
223988529|NCT01902186|DRUG|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
223988530|NCT01812798|OTHER|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
223988531|NCT06061224|BEHAVIORAL|early mobilization (physical therapy)|"The investigators will consult rehabilitation department for Physical Therapy and patients will be grouped as clinically allocation.~Protocols for consideration of initiation The timing is 72 hours after admission to ICU, early mobilization doses and duration is as the protocol of rehabilitation department"
223988532|NCT03843294|BIOLOGICAL|TAA-T cells|The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.
224120827|NCT00863785|DRUG|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
224294451|NCT03096275|DRUG|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
223988533|NCT03843294|DRUG|Nivolumab|Nivolumab: For patients \<18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks
223988534|NCT03259399|GENETIC|detection of genotype|detection of genotype by next generation sequencing
223988535|NCT02328586|OTHER|Group Acupuncture|
223988536|NCT02180347|DEVICE|Contact lenses|
223988537|NCT06382389|DRUG|EMONO|Exposure of Emono via facial mask
223988538|NCT06382389|DRUG|Medical air|exposure to Medical Air
223988539|NCT04708483|DEVICE|Extra DCE-CT scan|DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria.
224120828|NCT05314166|OTHER|meditation practice|Description: meditation practice
223988540|NCT05087836|DEVICE|Sensor at forehead area|NIRS sensor attached at forehead area.
223988541|NCT05087836|DEVICE|Sensor at temporal area|NIRS sensor attached at temporal area.
223988542|NCT03796000|PROCEDURE|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
223988543|NCT05120154|OTHER|Online educational materials|The CAPACITI program is comprised of three independent modules, taken separately (each constituting an intervention): (1) Identify and Assess; (2) Enhance Communication Skills; (3) Enhance Skills for Ongoing Care (including involvement of family and specialists). Each module addresses a critical component of implementing a palliative care approach into primary care practice. The CAPACITI program emphasizes practice supports in each module, integrating two components: 1) clinical education in the form of expert advice and tips, and 2) evidence-based tools with action steps.
223988544|NCT05120154|BEHAVIORAL|Facilitated online webinars|Intervention participants will be invited to participate in facilitated online discussions. These discussions review the online materials and share strategies for problem-solving.
223988545|NCT03616795|DRUG|LY3154207|Administered orally
223988546|NCT03616795|DRUG|[14C]-LY3154207|Administered orally
223988547|NCT01263054|DEVICE|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
223988548|NCT01263054|OTHER|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
224120829|NCT02549690|DRUG|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
224120830|NCT02549690|DRUG|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
224120831|NCT01532700|DRUG|Ofatumumab with GSK2110183|"* GSK2110183 125mg OD continuously~* Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
223988549|NCT00554645|BEHAVIORAL|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
223988550|NCT00554645|OTHER|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
223988551|NCT02398032|DEVICE|CPAP nasal|During the night
223988552|NCT02398032|DEVICE|sham CPAP nasal|During the night
223988553|NCT05074199|PROCEDURE|W-plasty/Linear closure|"The patient's wound will be labeled A if it is on the left or superior side of the investigator and B if it is on the right or inferior side. A predetermined, concealed randomization number will be obtained from the RedCap randomization module, which will specify how side A is to be treated. Side B will be treated the opposite way as A. Side A will always be closed first. The side assigned to be closed in a traditional straight line (SL) will have the standing cutaneous deformity (dog ear) excised in the standard manner using Burrow's triangles, resulting in an elliptical defect amenable to linear closure. The side assigned to be closed with W-plasty will have the dog ear excised in a zig-zag fashion consistent with the W plasty flap design. Both sides of the wound will receive subcuticular closure with interrupted subdermal sutures as is the standard of care, followed by a standard running cuticular closure with absorbable suture material."
223988554|NCT01310699|DEVICE|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
223988555|NCT03293069|DRUG|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
223988556|NCT03293069|DRUG|Placebo Oral Tablet|the placebo twice daily morning and evening.
223988557|NCT00936598|DRUG|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women \<65; 5 mg for women = or \> 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
223988558|NCT00936598|DRUG|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
223988559|NCT05436015|OTHER|Virtual nature-based intervention|"Virtual nature-based intervention is video with Finnish naturepictures and naturesounds shown from a 75 vertical screen monitor"
223988560|NCT00127361|BEHAVIORAL|doula training|
223988561|NCT01158989|DEVICE|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
223988562|NCT02413814|BEHAVIORAL|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
223988563|NCT02413814|BEHAVIORAL|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
223988564|NCT02405897|DEVICE|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
223988565|NCT02405897|DEVICE|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
223988566|NCT00926575|DRUG|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
223988567|NCT00926575|DRUG|Placebo|Two tablets QID for 50 days
224294452|NCT03096275|DRUG|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
224294453|NCT03096275|DRUG|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
223988568|NCT05761340|PROCEDURE|Helfer skin tap injection technique|"1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle.~2. After determining the injection site, use the tips of the dominant hand fingers to hit the skin (about 15 strokes) for about five seconds to soften the muscles.~3. After cleaning the skin with alcohol, remove the syringe cover from the dominant hand. Make a V with the non-dominant hand and hit the skin three times.~4. During the third stroke, prick the syringe into the muscle at 90 degrees angle at the same time.~5. After aspiration, continue to hit the skin with the tips of the non-dominant hand fingers while injecting the drug with the dominant hand at a rate of 1 ml / 10 seconds.~6. After injecting the drug, make the non-dominant hand V-shaped and hit the skin three times, pulling the syringe needle out at the same time during the third stroke"
223988569|NCT05761340|PROCEDURE|Standard Injection technique|"1. Place the patient in a seated position and open his right arm to inject into the deltoid muscle area.~2. After determining the injection site, prepare the skin with alcohol.~3. Grasp the skin with the thumb and index finger of the non-dominant hand and prick the syringe into the muscle at a 90-degree angle.~4. After aspiration, inject the drug with the dominant hand at a rate of 1 ml /10 seconds.~5. Remove the syringe needle 10 seconds after the drug is consumed"
223988570|NCT06018038|DIAGNOSTIC_TEST|Maximal Exercise Capacity, Maximal Oxygen Consumption (VO2max)|Cardiopulmonary Exercise Testing (CPET)
223988571|NCT03278743|OTHER|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
223988572|NCT01179503|DIETARY_SUPPLEMENT|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
223988573|NCT01179503|DIETARY_SUPPLEMENT|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
223988574|NCT01939301|DRUG|Inhaled Nitric Oxide|Nitric Oxide + oxygen
223988575|NCT01939301|DRUG|Sham|Nitrogen + Oxygen
223988576|NCT06110065|DRUG|CT-guided Pudendal Nerve Cryoneurolysis|CT-guided bilateral pudendal nerve cryoneurolysis involves using advanced imaging technology to precisely target and freeze the pudendal nerves, which are responsible for transmitting pain signals.
223988577|NCT06110065|DRUG|Percutaneous image-guided cryoneurolysis|Percutaneous image-guided cryoneurolysis focuses on using extremely cold temperatures to alleviate pain originating from the pudendal nerves. This method has demonstrated extended pain relief compared to alternatives like injections or catheters. Additionally, it presents a lower risk of certain complications.
223988578|NCT02201901|DRUG|SOF/VEL|400/100 mg tablets administered orally once daily
223988579|NCT02201901|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223988580|NCT00449345|PROCEDURE|Blood test for Quantiferon-GOLD assay|
223988581|NCT02242643|BIOLOGICAL|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
223988582|NCT02242643|BIOLOGICAL|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects \<12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
224120832|NCT03182205|OTHER|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
223728775|NCT05553002|OTHER|Traditional treatment|The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
224120833|NCT03182205|OTHER|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
224120834|NCT05058664|BEHAVIORAL|A-F texting component|Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
224120835|NCT05058664|BEHAVIORAL|P-F texting component|Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
223728776|NCT01574326|DRUG|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
223728777|NCT01574326|DRUG|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
223728778|NCT01330589|DRUG|Placebo|Non-active placebo for 7 days: PO/TID
223728779|NCT01330589|DRUG|St. Johns Wort|For 7 days: 300mg PO/TID
224120836|NCT05635162|DRUG|Zanubrutinib|Zanubrutinib dose is 160 mg twice daily (BD) orally (PO) on days 1-28 of each 28-day cycle.
224120837|NCT05635162|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous (IV)\* on day 1 (+/-3 days) of each 28-day cycle
224120838|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
224120839|NCT03330899|BIOLOGICAL|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
224120840|NCT03330899|BIOLOGICAL|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
224120841|NCT03330899|BIOLOGICAL|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
224120842|NCT01004783|GENETIC|DNA methylation analysis|
224120843|NCT01004783|GENETIC|gene expression analysis|
224120844|NCT01004783|GENETIC|loss of heterozygosity analysis|
223988583|NCT00003495|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223988584|NCT02634814|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
223988585|NCT02634814|OTHER|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
223988586|NCT02634814|DEVICE|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (\~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
223988587|NCT00668785|DRUG|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
223988588|NCT04342988|DRUG|Cequa|The effect of Cequa treatment on the accuracy of pre-operative biometry and on corneal higher-order aberrations (HOAs) in cataract patients who have signs of dry eye disease.
223988589|NCT05587452|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is performed to identify whether the patient has colorectal adenoma or cancer
223988590|NCT05587452|DIAGNOSTIC_TEST|Test of ctDNA methylation|A specified panel is used to detect the site of methylation of ctDNA in plasma
223988591|NCT05587452|DIAGNOSTIC_TEST|Test of characteristics of ctDNA fragment|Low pass whole genome sequencing is used to detect the characteristics of ctDNA fragment
224120845|NCT01004783|GENETIC|microarray analysis|
224120846|NCT01004783|GENETIC|mutation analysis|
223988592|NCT00078143|BEHAVIORAL|Behavior Therapy|
223988593|NCT00101998|DRUG|alvimopan|
223988594|NCT00101998|DRUG|placebo|
223988595|NCT04001738|OTHER|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
223988596|NCT00129142|DRUG|Toremifene Citrate|
223988597|NCT02616484|DRUG|Dichloroacetate (DCA)|"Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12 mg/kg/12hr DCA. EGT non-carriers will receive 6 mg/kg/12 hr DCA."
224120847|NCT01004783|GENETIC|polymerase chain reaction|
224120848|NCT01004783|GENETIC|reverse transcriptase-polymerase chain reaction|
224120849|NCT01004783|OTHER|laboratory biomarker analysis|
224120850|NCT06038097|PROCEDURE|Radiofrequency Pallidotomy|Radiofrequency bilateral simultaneous pallidotomy
223988598|NCT02616484|OTHER|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
223988599|NCT02616484|GENETIC|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
223988600|NCT03766373|COMBINATION_PRODUCT|Drug: OP0201 20mg|OP0201
223988601|NCT03766373|COMBINATION_PRODUCT|Drug: Placebo 0mg|Placebo
224120851|NCT00184249|PROCEDURE|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
224120852|NCT06295055|PROCEDURE|Ridge augmentation with semi-rigid shell barrier system|The semi-rigid shell, fixed to the outside cortex by tacks, acts as a bone wall. Bone particles are placed in the gap and covered with the semi-resorbable covering membrane, serving as a barrier membrane.
224120853|NCT03696069|OTHER|Non-Interventional|Non-Interventional
224120854|NCT06413173|COMBINATION_PRODUCT|Active tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with active tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
224120855|NCT06413173|COMBINATION_PRODUCT|Sham tDCS and Cognitive Training Intervention|Cognitive training will occur concurrently with sham tDCS session. The cognitive training occurs on a computer and consists of 5 exercises specifically selected and scientifically supported to (i) place demands on the executive function system (e.g. working memory, behavioral inhibition, decision making, and set- shifting), (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across visual and auditory modalities During each 45-minute training period, participants will complete the daily assigned adaptive training module. Following the completion of training sessions 1, 5, and 10, participants will be asked to supply a subjective workload assessment.
223988602|NCT02351713|OTHER|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
224120856|NCT02752529|DRUG|Tacrolimus（FK506）|
224120857|NCT00397969|OTHER|counseling intervention|
223988603|NCT06201546|PROCEDURE|TAP block group|TAP block will be administrated after LSG. In TAP block local anesthetic(%0,25 bupivacaine-20ml)will be administrated the between the transversus abdominis muscle and the internal abdominal muscle fascia.
223988604|NCT06201546|PROCEDURE|m-TAPA block group|m-TAPA block will be administrated after LSG. In m-TAPA block local anesthetic (0.25% bupivacaine-20ml) will be administrated between the transversus abdominis muscle and the internal abdominal muscle fascia under the costochondrial region
223988605|NCT03750253|OTHER|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
223988606|NCT00004448|DRUG|omega-3 fatty acids|
223988607|NCT00004448|DRUG|prednisone|
223988608|NCT00004448|DRUG|Placebo|
223988609|NCT03298269|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
223988610|NCT03298269|BEHAVIORAL|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
224294454|NCT03096275|DRUG|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
224294455|NCT00070538|DRUG|cytarabine|
223988611|NCT02183077|DRUG|Meloxicam gel|
223988612|NCT02183077|DRUG|Meloxicam tablet|
223988613|NCT04516005|PROCEDURE|foot reflexology|Acupressure was applied at the plantar side of the right foot at the first metatarsal bone, around 1-1.5 centimeters proximal to the first metatarsophalangeal joint. (Figure 2) Approximately 3-kilogram pressure was applied by using a knuckle of the right index finger (dorsal part of the proximal interphalangeal joint in flexing position) in a perpendicular manner and held for 15 seconds (sec) then released for 5 sec. This hold-release cycle was done 5 times over the course of 2 min. This method was recommended by the Department of Thai Traditional and Alternative Medicine in accordance with the Zone theory and the Meridian theory.
223988614|NCT04243512|BEHAVIORAL|Time-restricted eating|Restrict food and beverage intake (except water) to a 10-hour window
223988615|NCT06392009|DRUG|Radiprodil|Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
224294456|NCT00070538|DRUG|laromustine|
224294457|NCT04109859|DRUG|Saline|When using saline, if found mean arterial pressure \<65mmHg, Cardic Output\>4L/min, Sequential Vascular Response\<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
224294458|NCT04109859|DRUG|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
224294459|NCT02416011|BEHAVIORAL|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
224294460|NCT02416011|BEHAVIORAL|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
224294461|NCT03277209|DRUG|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
223988616|NCT02633397|DRUG|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
223988617|NCT02633397|DRUG|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
223988618|NCT03595878|RADIATION|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
223988619|NCT03595878|RADIATION|Standard WBRT|Standard Whole Brain Radiation Therapy
223988620|NCT04673357|DRUG|Ustekinumab|Ustekinumab will be administered intravenously in induction period and subcutaneously in maintenance period.
223988621|NCT04673357|DRUG|Placebo|Matching placebo will be administered as SC injection.
223988622|NCT06976424|DRUG|Eflornithine Topical|Eflornithine cream will be applied to the face of group B female patients
223988623|NCT06976424|RADIATION|Instense pulsed light|Intense pulse light will be applied to the face of patient of Group A on areas having increase hair. Patient will be called for a followup every month for next session.
223988624|NCT06976424|DRUG|Eflornithine Topical|Eflornithine will be given to group A patient along with intense pulsed light and results will be compared to group B who recieved only Eflornithine cream
223988625|NCT03313895|BEHAVIORAL|Aerobic & Cognitive Training (ACT)|ACT stands for combined aerobic exercise and cognitive training.
223988626|NCT03313895|BEHAVIORAL|Cycling Only|Cycling on a recumbent stationary cycle
223988627|NCT03313895|BEHAVIORAL|Cognitive Training Only|Engage in cognitive training on a computer
224294462|NCT01138111|DRUG|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
224294463|NCT03794791|BEHAVIORAL|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
224294464|NCT03794791|BEHAVIORAL|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
224294465|NCT00256711|DRUG|Gefitinib|
224294466|NCT00256711|DRUG|Vinorelbine|
223728780|NCT02532790|DRUG|Prednisone|1.5mg/kg/d
223988628|NCT03313895|BEHAVIORAL|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
223988629|NCT04025814|DEVICE|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
223988630|NCT04025814|BEHAVIORAL|Behavioral Parent Training (CLS Parent Group)|Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
223988631|NCT05441982|OTHER|Non-Nutritive Sweetener Intake and impact on glucose homeostasis|Provision of either saccharin, acesulfame potassium, or control with no non-nutritive sweeteners to a controlled feeding study to determine impacts on glucose homeostasis.
223988632|NCT05131789|PROCEDURE|dementia case management information system|The investigators will develop an information system based on the data collected in our previous research, the content and method of dementia case management which will be established by the Delphi method, and then the dementia case management information system will be constructed accordingly.
223988633|NCT03494985|DEVICE|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
223988634|NCT03494985|DEVICE|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
223988635|NCT03494985|DEVICE|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
223988636|NCT03494985|OTHER|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
223988637|NCT00581841|OTHER|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
224120858|NCT00397969|PROCEDURE|screening colonoscopy|
224120859|NCT00331825|DRUG|Risperidone and Olanzapine|
224120860|NCT04421196|OTHER|Exclusion of opioid analgesics|The intervention involves removing the option of patients having an opioid analgesic at any time point during the perioperative period.
224120861|NCT00257387|DRUG|Cyclosporine|
223988638|NCT06028594|DRUG|Pozelimab|Subcutaneous (SC) administration
223988639|NCT06028594|DRUG|Cemdisiran|Subcutaneous (SC) administration
223988640|NCT00244686|DRUG|Mepolizumab|open label investigational product
223988641|NCT06194032|DRUG|Baxdrostat|Participants will receive baxdrostat as two separate doses.
223988642|NCT06194032|DRUG|Placebo|Participants will receive baxdrostat matching placebo.
224120862|NCT01597557|DRUG|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
224120863|NCT01597557|OTHER|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
224120864|NCT03086200|BEHAVIORAL|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
224294467|NCT03694366|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
223988643|NCT06194032|DRUG|Moxifloxacin|Participants will receive a single dose moxifloxacin
223988644|NCT05424094|BEHAVIORAL|multi-professional group programme 'kinderleicht'|12-16 children/adolescents who participate in the multi-professional group programme 'kinderleicht' receive coaching in the areas of behaviour, exercise, nutrition and medicine from qualified professionals on fridays during 11 months.
223988645|NCT03036124|DRUG|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
223988646|NCT03036124|DRUG|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
223988647|NCT04359264|OTHER|Cash transfer|Cash transfer of $1000
223988648|NCT04274699|DIAGNOSTIC_TEST|Hemosonics Quantra coagulation monitor|There is no categorisation or allocation of any subject to any intervention vs non-intervention group. Blood sampling and the addition of a Quantra coagulation test is the only 'intervention', and the sampling protocol is identical for all subjects. Post-testing treatment of all subjects is as per established routine and Quantra results will not be used by clinical team.
223988649|NCT02282059|DRUG|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
223988650|NCT06632236|DRUG|Amivantamab|Amivantamab will be supplied in single-use 350 mg injectable solution, provided as a 7 ml per glass vial (50mg/ml), intended for IV infusion.
223988651|NCT02908984|BEHAVIORAL|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and vestibular rehabilitation, included oculomotor function if indicated, and general exercises
223988652|NCT02908984|OTHER|Standard primary health care|The treatment may include pharmacological medication, chiropractic and physiotherapy or no active treatment
223988653|NCT03863860|DRUG|Fluzoparib capsules|Fluzoparib capsules
223988654|NCT03863860|DRUG|Placebo capsules|Placebo capsule
223988655|NCT06209476|DIAGNOSTIC_TEST|Experimental|Eligible subjects with sphere component of the subjective spherocylindrical refraction between +1.50 to -6.00D (inclusive) and 2.00D or less astigmatism in the right eye will be unilaterally measured with the WAM-5500 autorefractor by 3 testers.
223988656|NCT04906954|OTHER|NMES|Standardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.
223988657|NCT05708313|BEHAVIORAL|lifestyle modification|Participants will undergo an exercise program designed by AHH
223988658|NCT04979156|PROCEDURE|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors|SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors
223988659|NCT06334640|DIAGNOSTIC_TEST|Three questionaires|Berlin, Pittsburgh and Epworth tests administered during study visit
223988660|NCT05619822|BEHAVIORAL|TAU + A comprehensive third-generation intervention|This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES\_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future
223988661|NCT05619822|BEHAVIORAL|TAU|Treatment as usual
223988662|NCT05093504|DEVICE|Sham comparator|Sham comparator in similar position to the investigational device, but NOT integrated into the cardiopulmonary bypass (CPB) circuit
223988663|NCT05093504|DEVICE|DrugSorb-ATR system|Sorbent hemoperfusion system integrated into the cardiopulmonary bypass (CPB) circuit
223988664|NCT02574351|BIOLOGICAL|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
224294468|NCT05278572|BEHAVIORAL|Stress Management and Relaxation Training/Expressive Supportive Therapy (SMART/EST)|Cognitive-behavioral stress management/expressive supportive therapy (CBSM+) group targeting depression
223988665|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via prefilled syringe (PFS)
223988666|NCT05274100|DRUG|Risankizumab|Intravenous Infusion
223988667|NCT05274100|DRUG|Risankizumab|Subcutaneous Injection via on-body delivery system (OBDS)
223988668|NCT06276114|DEVICE|Stent Underexpansion|Stent underexpansion was diagnosed as stent expansion of \<80% assessed with intravascular imaging.
223988669|NCT00439361|DRUG|Bortezomib|1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4
223988670|NCT00439361|DRUG|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
223988671|NCT00439361|DRUG|Etoposide|100 mg/m\^2 By Vein Over 2 Hours On Days 1-3
223988672|NCT00439361|DRUG|Ifosfamide|5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1
223988673|NCT00439361|DRUG|Mesna|5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
223988674|NCT04684771|DIETARY_SUPPLEMENT|MYOSTIM®|Food supplement n° NCT 2485/8 (Red fruits flavor bar) and NCT 2485/7 (Black chocolate flavor bar) delivered by the Federal Public Service, Health, Food chain safety and environment.
223988675|NCT04684771|DIETARY_SUPPLEMENT|PLACEBO|Bars with no active ingredient and the same flavor (chocolate and red fruits).
224294469|NCT02494050|BEHAVIORAL|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
223988676|NCT02394925|DEVICE|Multifocal Test Contact lens|Used in a daily wear modality
223988677|NCT02134847|OTHER|SCS intervention schedule|
223988678|NCT04592809|DRUG|Ketamine Hydrochloride|infused over a 40 minute period
223988679|NCT04592809|DRUG|Midazolam Hydrochloride|infused over a 40 minute period
223988680|NCT02272244|BEHAVIORAL|Decision Support & Navigation|
223988681|NCT02272244|BEHAVIORAL|Standard|
223988682|NCT03430661|DRUG|ACT-246475|Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection
223728781|NCT02532790|DRUG|ACEI|0.2-0.3mg/kg/d
223728782|NCT00192842|DRUG|curcumin (+ gemcitabine)|
223988683|NCT03430661|DRUG|Clopidogrel|Tablet for oral administration (300 or 600 mg)
223988684|NCT03430661|DRUG|Prasugrel|Tablet for oral administration (60 mg)
223988685|NCT03430661|DRUG|Placebo|Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
223728783|NCT02278250|DRUG|M4344 10 mg BIW|Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223988686|NCT03430661|DRUG|Ticagrelor|Tablet for oral administration (180 mg)
223988687|NCT05580601|DRUG|CIML-NK Cells|"The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product. At the time of infusion, the product is comprised of:~* Cytokine-Induced Memory-Like NK cells (CIML-NK cells)~* Human Serum Albumin~* Plasmalyte~The concentration and total cell number of CIML-NK cells in the product will vary based on the recipient body weight and the dose requested."
223988688|NCT03223922|RADIATION|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
223988689|NCT00151827|DRUG|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
223988690|NCT00151827|DRUG|Losartan|Medications are taken once daily before breakfast with water.
223988691|NCT00151827|DRUG|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
223988692|NCT03670277|DEVICE|etafilcon A|Test Soft Contact Lens
223988693|NCT03670277|DEVICE|Habitual Orthokeratology Lenses|CONTROL
223988694|NCT02660112|DRUG|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
224294470|NCT02494050|BEHAVIORAL|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
223988695|NCT04339374|DEVICE|Photoacoustic imaging, photoacoustic microscopy|-Emerging technique in which a short-pulsed laser beam penetrates diffusely into a tissue sample, causing the release of acoustic waves due to a transient temperature rise -The transient acoustic waves, or photoacoustic waves, are then measured around the sample by US transducers -The resolution of the devices can be altered by changing the wavelengths of laser light and spectrum analysis of the receiver. In this manner, human colorectal pathology will be examined under multiple types of photoacoustic ranges (broadly termed photoacoustic microscopy and photoacoustic imaging)
223988696|NCT04339374|DEVICE|Endorectal photoacoustic imaging probe|-An endorectal imaging device using coregistered photoacoustic and ultrasound imaging has been constructed. This probe is used to perform in vivo imaging among patients with rectal pathology intraoperatively.
223988697|NCT04339374|OTHER|Reader Performance|After initial training, the study surgeon will grade the lesion as either PAM/US non-cCR or PAM/US cCR at the time of PAM/US imaging. The study radiologist, blinded from the surgeon's read, will also grade the lesion based on MRI. PAM/US-CNNs provide a real-time imaging tool to assist the reader team in diagnosis. The pathological outcomes of the patients will be assessed based on Tumor Regression Score by standard pathologic evaluation. The study will evaluate the effect of the assistance of PAM/US-CNNs for trained readers on their performance i.e. sensitivity and specificity of their diagnosis of rectal cancers from images obtained from the testing cohort of (Group 2) patients.
223988698|NCT06605196|BEHAVIORAL|Resources and guided facilitation|Participants in the intervention arm will participate in a planning period at the beginning of the intervention period to establish the goals for the partnership. The investigators will use the prioritized list of AHD partnership features developed in prior research to guide the initial planning period and then assist the partnership members to plan to implement the corresponding strategies focused on their areas of interest (e.g., developing collaborative projects, hiring faculty, staff, or students to conduct data analysis). The investigators will use telephone, email communication, and video conferencing to communicate with AHD partnerships, regularly assess progress towards goals, and adjust goals and strategies based on the progress. One additional in person visit to each AHD partnership in the intervention arm will be made in year 2 of implementation to review goals and progress and provide additional guidance and tailored support as needed.
223988699|NCT06605196|BEHAVIORAL|Existing resources|Individuals will be referred to existing resources in the Learning Community.
223988700|NCT00212992|PROCEDURE|Fixed lower-energy defibrillation|Every shock administered at 150 J
223988701|NCT00212992|PROCEDURE|Escalating higher-energy defibrillation|First shock administered at 200 J, second shock at 300 J, all subsequent shocks at 360 J
224294471|NCT02494050|BEHAVIORAL|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
224294472|NCT00068081|DRUG|Capsaicin Dermal Patch|
224294473|NCT02504346|DRUG|AZD9291|
224294474|NCT00960830|DRUG|mirtazapine|mirtazapine 15 mg daily tablets
223988702|NCT04762069|DRUG|Berubicin|Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
223988703|NCT04762069|DRUG|Lomustine|"Lomustine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an alkylating agent."
223988704|NCT06816498|DRUG|nL-LMNB1-001|Personalized antisense oligonucleotide
223988705|NCT06659211|BEHAVIORAL|Mentalisation-Based Therapy|MBT is conducted according to the treatment manual developed by Bateman \&amp; Fonagy. Patients are offered weekly individual sessions with an MBT therapist for 12 months.
224294475|NCT00960830|DRUG|mirtazapine|15 mg daily
224294476|NCT06392204|PROCEDURE|CAD/CAM patient specfifc fracture reduction/plate guide and customized 3D grid plate|Mandibular angle fracture reduction and fixation using digitally designed and fabricated patient specific fracture reduction/plate positioning guide and customized 3D grid plate
224294477|NCT06392204|PROCEDURE|Champy's techqniue|Mandibular angle fracture reduction and fixation using a single superior border 2.0 miniplate
224294478|NCT01491035|DRUG|Vortioxetine|5 mg tablets for 14 days; orally; once daily
224294479|NCT01491035|DRUG|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
224294480|NCT01491035|DRUG|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
224294481|NCT01491035|DRUG|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
224294482|NCT02527239|OTHER|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
224294483|NCT05991596|BEHAVIORAL|Psychodramatic psychotherapy|"The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows:~* 1 individual motivational interview;~* 1 weekly group session lasting 2 hours for 1 month (total 4 meetings);~* 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings).~Patients will also receive the pharmacological treatment usually recommended for vitiligo."
224294484|NCT05991596|BEHAVIORAL|Self-help activities|"The self-help activities will include:~* 1 individual motivational interview;~* 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings);~* 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings).~Patients will also receive pharmacological treatment usually recommended for vitiligo."
224294485|NCT05759117|PROCEDURE|thoracentesis|A type of pleural procedure that will yield pleural fluid for subsequent analysis
224120865|NCT02912000|BEHAVIORAL|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
224120866|NCT04156750|DRUG|LY3556050|Administered orally.
223988706|NCT06659211|OTHER|Treatment as Usual (TAU)|The TAU group will receive treatment as usual, which in mental health services might include medication, supportive counseling, short therapy, and other limited psychotherapeutic treatments such as DKT. There is no requirement for a frequency of visits for the usual psychiatric care of the TAU group, as this would not be realistic in the current service system, and the usual treatment would not be the usual treatment currently provided.
223988707|NCT04322955|DRUG|Cabozantinib|2 x 20 mg capsules taken orally daily
223988708|NCT04322955|DRUG|Nivolumab|480mg IV on first day of each 28-day cycle
223988709|NCT04322955|PROCEDURE|Cytoreductive nephrectomy|Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.
223988710|NCT05455203|BEHAVIORAL|ADAPT-ITT|ADAPT-ITT is an implementation framework that guides adaptation of evidence-based interventions (EBI) for specific settings/populations. It will be used to adapt target interventions with a Family and Community Advisory Board. It has 8 phases: (1) Assess the risk profile of Black families in Paterson and East Orange, (2) Adopt or adapt an EBI, (3) Administer novel methods with families and children to facilitate the adaptation process, (4) Plan on what aspects of the EBI need to be adapted/how best to evaluate the adapted EBI, (5) Identify additional experts to assist in the adaptation process, (6) Integrate material from experts to adapt the EBI, (7) Train staff to implement the adapted intervention, and (8) Test the adapted intervention. Given time and financial constraints, five phases will be completed at the end of the pilot study. Qualitative data collected from individual dyad interviews will be used to inform the data.
223988711|NCT00578578|DIETARY_SUPPLEMENT|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
223988712|NCT05954182|BEHAVIORAL|Cognitive Intervention|This is a virtual, group cognitive intervention. 12 live, weekly sessions will occur during the first 3 months of the study. Groups will be made up of 5-10 participants and will be led by a neuropsychologist. These sessions will include education on the brain and cognitive function as it relates to epilepsy, as well as compensatory strategies for use in daily life. After the 12 sessions, participants will be asked to continue to practice what they learned for the next nine months until their participation ends.
223988713|NCT06278831|OTHER|Questionnaire|Patients will be approached three times throughout the study at the beforementioned interview dates to fill out a questionnaire. They will be contacted via e-mail, telephone and/or mobile app.
223988714|NCT04439708|OTHER|Blood and aqueous humor biomarker of treatment response|Blood analyses and aqueous humor analysis
223988715|NCT06590675|DRUG|Chlorhexidine Gluconate (CHG)|A locally-prepared CHG formulation as a 1% or 2% solution
224120867|NCT04156750|DRUG|Placebo|Administered orally.
224120868|NCT04156750|DRUG|Iohexol|Administered IV.
224120869|NCT04156750|DRUG|Metformin|Administered orally.
223988716|NCT06518720|DRUG|Psilocybin 25 mg|The psilocybin used in this study meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin. The psilocybin will be administered once during the trial in combination with supportive therapy.
223988717|NCT06615284|DRUG|Atorvo+™ (Arm1)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
223988718|NCT06615284|DRUG|Atorvo+™ +CBD (Arm 2)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
223988719|NCT06615284|DRUG|Atorvo+™ +CBD (Arm 3)|Atorvo+™ is a combination product containing atorvastatin and cannabidiol (CBD).
223988720|NCT00541151|DEVICE|MiniArc|sling system
223988721|NCT03034096|DRUG|Propofol|Maintenance of general anesthesia with propofol infusion
223988722|NCT03034096|DRUG|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
223988723|NCT01729715|BEHAVIORAL|Internet|
223988724|NCT01729715|BEHAVIORAL|DVD|
224120870|NCT01975779|DRUG|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
224120871|NCT01975779|DRUG|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
224120872|NCT01975779|DRUG|Cohort B1: Lu AE58054|Two single oral doses 60 mg with \>=7 days washout.
224120873|NCT02173496|OTHER|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
224120874|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
224120875|NCT01076634|DRUG|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
224120876|NCT02389816|DRUG|Placebo|Placebo tablets
224120877|NCT02389816|DRUG|Vortioxetine|Vortioxetine tablets
224120878|NCT04713566|OTHER|oral rinces|natural and commercial oral rinses were compared for efficacy
224120879|NCT05169307|DRUG|CPX-351|This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.
223988725|NCT05275972|DRUG|Ripasudil|Topical Ripasudil 0.4%
223988726|NCT05275972|DRUG|Placebo|Topical Placebo
223988727|NCT07043777|PROCEDURE|Modified Catheter Antegrade Cerebral Perfusion (Modified bACP)|Bilateral modified catheter antegrade cerebral perfusion technique applied during acute type A aortic dissection repair; avoids additional right-axillary incision while providing continuous cerebral flow.
223988728|NCT07043777|PROCEDURE|Conventional Brain Perfusion|Conventional cerebral perfusion strategy (e.g., standard bilateral antegrade cerebral perfusion) used during arch repair according to surgeon preference.
223988729|NCT06717815|DRUG|IPG11406|"Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed."
223988730|NCT06721494|DRUG|Methamphetamine|Methamphetamine HCl for intravenous administration
223988731|NCT06721494|DRUG|Sterile Saline|Sterile Saline for intravenous administration
223988732|NCT06721494|DRUG|CS-1103|CS-1103 for intravenous administration
223988733|NCT07050134|DRUG|DR10624 Injection；|"The experimental group(Trial Drug)~* Name: DR10624 Injection (referred to as DR10624)~* Specification: 60mg (1mL)/vial~* Active Ingredient: DR10624~* Route of Administration: Subcutaneous injection~* Packaging: Vial~* Expiry Date: See the drug label~* Storage Conditions: 2\~8℃, protected from light~* Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd.~* Supplier: Zhejiang Daor Biotechnology Co., Ltd."
224294486|NCT05368441|DRUG|Midazolam|Patients of midazolam group will be treated with midazolam premedication (3 cc mixture of 0.1 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given.Before the patients were given muscle relaxants, the patients were evaluated with the Han scale.
223988734|NCT07050134|DRUG|DR10624 Injection Placebo (referred to as placebo)|(The control group)Placebo: Name: DR10624 Injection Placebo (referred to as placebo) Specification: 0mg (1mL)/vial (no active ingredient) Main Component: Normal saline Route of Administration: Subcutaneous injection Packaging: Vial Expiry Date: See the drug label Storage Conditions: 2\~8℃, protected from light Manufacturer: Zhixiang Bio (Suzhou) Co., Ltd. Supplier: Zhejiang Daor Biotechnology Co., Ltd.
223988735|NCT07049302|COMBINATION_PRODUCT|Conventional Risk Factor Assessment|Participants in Group 1 will undergo evaluation for conventional cardiovascular risk factors associated with Acute Coronary Syndrome (ACS
223988736|NCT07049302|COMBINATION_PRODUCT|Non-Conventional Risk Factor|Participants in Group 2 will be assessed for non-conventional cardiovascular risk factors associated with Acute Coronary Syndrome (ACS).
223988737|NCT07050901|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|Kolcaba's Nursing Care Applications Based on Comfort Theory were carried out individually; each application was planned for one and a half hours, one day a week and for 8 weeks, and each session was carried out for each individual through home visits. The topics of Nursing Care Based on Kolcaba's Comfort Theory were; Physical Care Practices (2 weeks), Psychospiritual Care Practices (2 weeks), Environmental Care Practices (2 weeks) and Sociocultural Care Practices (2 weeks).
223988738|NCT07049718|DEVICE|whole body vibration|Whole-body vibration (WBV) is a training method that uses mechanical vibration and external resistance loading to stimulate the body, causing muscle vibration and increasing central nervous system adaptations (Rittweger, 2010).
223988739|NCT06735482|BEHAVIORAL|Therapeutic play program|Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills.
223988740|NCT05896644|OTHER|Eat Well|A program offered by Reinvestment Partners giving clients gift/debit cards that allow the purchase of WIC approved fruits and vegetables.
223988741|NCT06761781|OTHER|Augmented Reality|"Each participant will receive a standard trial consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Each session will consist of 2-10 exercises selected by the trainer from a pool of 46 exercises. The selected exercises will be tailored based on the participant's condition and progress. The exercise pool will be designed as comprehensively as possible to cover the upper limb (22 exercises and lower limb (7 exercises) motor functions, balance ability (11 exercises), or/and coordination (6 exercises).~Each exercise with a duration ranging from 3 to 23 min, and will be determined by a set of parameters that can be adjusted to the individuals dynamically according to the participant's performance."
223988742|NCT06761781|OTHER|Traditional Training|Each participant will receive a Traditional training based on Task oriented training consisting of 20 training sessions (2-5 sessions per week, 120 min per session) in consecutive 4-10 weeks. Exercises will be tailored based on the participant's condition and progress. The exercises will cover the upper limb, lower limb, motor functions, balance ability and coordination.
223988743|NCT06003192|OTHER|Universal Opt-out HIV Screening|Using a tablet device, offering universal opt-out HIV screening to adolescents seeking care in a pediatric emergency department.
223728784|NCT02278250|DRUG|M4344 20 mg BIW|Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728785|NCT02278250|DRUG|M4344 40 mg BIW|Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728786|NCT02278250|DRUG|M4344 80 mg BIW|Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728787|NCT02278250|DRUG|M4344 160 mg BIW|Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728788|NCT02278250|DRUG|M4344 300 mg BIW|Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728789|NCT02278250|DRUG|M4344 450 mg BIW|Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728790|NCT02278250|DRUG|M4344 700 mg BIW|Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728791|NCT02278250|DRUG|M4344 1050 mg BIW|Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
224120880|NCT05987293|DEVICE|Tracheal tube-tongue pressure is measured using a computerized occlusal analysis system based on T-Scan® technique, suitable for multi-point real-time monitoring of intraoral pressure.|A flexible film sensor with a thickness of 0.11mm is placed between the tongue and the tracheal tube to measure the distribution, join force and dynamic changes of pressure at different site of the tongue. Five channels of pressure values will be recorded separately: (Ch1) the tip of the tongue, (Ch2) the middle of the tongue, (Ch3) the base of the tongue, (Ch4) the right side at the base of the tongue, (Ch5) the left side at the base of the tongue. The pressure values at the following points during the operation will be recorded: (t1) after intubation, (t2) highest pressure during patient positioning, (t3) after position fixed, (t4) at the end of surgery, (t5) before extubation.
224120881|NCT01594476|DRUG|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
224120882|NCT02520804|DRUG|sterofundin|sterofundin for shock patients in the first 72 hours
223728792|NCT02278250|DRUG|M4344 1200 mg BIW|Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728793|NCT02278250|DRUG|M4344 100 mg BID|Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728794|NCT02278250|DRUG|M4344 150 mg QD|Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728795|NCT02278250|DRUG|M4344 250 mg QD|Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728796|NCT02278250|DRUG|M4344 350 mg QD|Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728797|NCT02278250|DRUG|M4344 400 mg|Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728798|NCT02278250|DRUG|M4344 500 mg|Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728799|NCT02278250|DRUG|Carboplatin|Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
223728800|NCT02848183|DRUG|Cytarabine|
223728801|NCT02848183|DRUG|Idarubicin|
223728802|NCT02848183|DRUG|Mitoxantrone|
223728803|NCT02848183|DRUG|Etoposide|
223728804|NCT02848183|PROCEDURE|Hematopoietic stem cell transplantation|
223728805|NCT00523003|DIETARY_SUPPLEMENT|high protein|2.2 g protein/kg of LBM per day
223728806|NCT00523003|DIETARY_SUPPLEMENT|standard protein|1.1 g protein/kg LBM/day standard protein diet
223728807|NCT03775057|OTHER|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
223728808|NCT04848545|OTHER|Observational|Prenatal maternal exposure to endocrine disrupting chemicals
223728809|NCT03971890|OTHER|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
223728810|NCT03971890|OTHER|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
223728811|NCT01171339|OTHER|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
223728812|NCT03232021|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
223728813|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
223728814|NCT03232021|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
224120883|NCT02520804|DRUG|normal saline|Normal saline for shock patients in the first 72 hours
224120884|NCT00745485|DRUG|zoledronic acid|
224120885|NCT00543751|DRUG|MK0767|
224120886|NCT00757939|OTHER|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
224120887|NCT00757939|OTHER|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
224120888|NCT04746612|DRUG|HH30134|HH30134 administered orally on a continuous once daily(QD) in patients with advanced solid tumors
223988744|NCT06775730|DRUG|Ensitrelvir|Ensitrelvir will be administered per schedule specified in the arm description.
224120889|NCT04336046|PROCEDURE|erector spinae block|will receive real bilateral ultrasounded guided erector spinae block by bupivacaine at 1 mg /kg in a total volume of 20 ml for each side after induction of anaesthesia in prone position
224120890|NCT04336046|PROCEDURE|sham bilateral ultrasounded guided erector spinae block|will receive sham bilateral ultrasounded guided erector spinae block using 1 mg /kg normal saline in a total volume of 20 ml for each side after induction of anaesthesia in prone position after induction of anaesthesia in prone position.
224120891|NCT04336046|DRUG|normal saline|using 1 mg /kg normal saline
224120892|NCT04336046|DRUG|Bupivacaine|bupivacaine
224120893|NCT02000570|PROCEDURE|Sitting position (neurosurgery)|
223988745|NCT06320717|OTHER|Blood sample|To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients
223988746|NCT04581343|DRUG|Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine|Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
223988747|NCT06934694|DEVICE|Instrument-Assisted Soft Tissue Mobilization|Participants will receive a single session of instrument-assisted soft tissue mobilization (IASTM) applied to the gastrocnemius muscle using a stainless-steel instrument. The treatment consists of longitudinal and transverse strokes targeting both the medial and lateral heads of the muscle. The procedure will be performed by a trained clinician, following a standardized protocol lasting approximately 5 minutes. The goal is to induce mechanical and neuromodulatory effects on muscle tissue. This intervention is designed to assess acute changes in muscle stiffness (via shear-wave elastography) and ankle dorsiflexion range of motion (via the weight-bearing lunge test).
223988748|NCT06944327|PROCEDURE|MANAGEMENT CARE|Administration of the sealing element after canalization and initial treatment of the device, prior to fixation with a suture system and a 7-day vs. 14-day cadence test.
223988749|NCT06944327|OTHER|traditional care|Traditional cure administration with sutureless device fixation every 7 days
223988750|NCT06944613|DEVICE|Augmented reality-based programme/Microsoft Hololens version 2|Participants play two exergames, the aim of this process is to engage cognitive double tasks
223988751|NCT06944184|DEVICE|Intraarticular microdialysis|The intervention decive is placed during the routine surgery to remove the infected knee prosthesis and implantation of the static cement spacer. A microdialysis catheter is implemented to generate continious intra-articular samples of the knee joint. To ensure complete removal and no damage of the membrane it is inserted via a regular drainage tube. The catheter membrane is placed intra-articularly next to the spacer and continious to an outlet tube for sample collection.
223988752|NCT06945679|DRUG|CPLE|It will be a double-blind study,CPLE and Placebo will be marked as either Group A or Group B.Half of the patients will receive Group A and other half will receive Group B drug along with standard treatment according to national guideline,Each participant will receive either CPLE or Placebo,500 mg 2 capsules three times daily for 5 days and will be followed up daily upto study day 5.
223988753|NCT06945679|DRUG|Placebo|"The patients will be assigned to visually matched placebo 2 capsule t.i.d for 5 days The oral capsule of CPLE and placebo will be provided by the Institute of Technology Transfer and Innovation (ITTI), an institute in Bangladesh Council of Scientific and Industrial Research (BCSIR). On receipt, the medications will be stored in a secure area at room temperature. Enrolled patients will receive CPLE or placebo for 5 days.~Clinical data will be captured on structured case report forms."
223988754|NCT06945185|PROCEDURE|Intervention Group A Conventional Physical Therapy|"Active Range of Motion Exercises: (5-10 reps with 2 sets) Finger bends, finger spreads, finger to thumb opposition, thumb to palm stretches, palm up and down, wrist rotation, wrist bends, elbow bends, shoulder shrugging and shoulder rotation.~Strengthening Exercises: (10-15 reps 2 sets weight 500 ml to 1L water bottle). Finger pinch, power grip, finger spread, pushing movement, wrist curls, roll and squeeze, bicep curls, side arm raise, lifting objects to a height, pulling resistance band.~Coordination Exercises: (10-15 reps 2 sets) finger to finger, finger to doctor's finger, finger to nose, holding and lifting coins, buttoning, holding and lifting coins, alternate hand movement, closing and opening hand."
224120894|NCT00148733|DRUG|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
224120895|NCT03106493|OTHER|None (observational)|None (observational)
224120896|NCT01603641|BIOLOGICAL|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
223728815|NCT02727023|OTHER|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
224120897|NCT05889494|OTHER|Autologous Whole Blood Management|Intraoperative high volume autologous whole blood withdrawal with re-transfusion following weaning from CPB.
224120898|NCT05889494|OTHER|Standard Care involving allogenic and/or derivative transfusion.|Therapeutic treatment of CPB-induced coagulopathy using donated allogenic blood products including plasma, platelets, and cryoprecipitate and/or derivative administration using prothrombin complex and fibrinogen concentrates.
224120899|NCT06534346|DRUG|15 mg DA-302168S tablet|"Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration."
224120900|NCT03161678|DRUG|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
224120901|NCT03161678|DRUG|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
224120902|NCT02110134|DEVICE|Revlite Laser System with hydroquinone skin care regimen|Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma
224120903|NCT02110134|OTHER|Hydroquinone skin care regimen|Hydroquinone skin care regimen for the Treatment of Melasma
224120904|NCT03968445|DRUG|[18F]DPA-714-PET/MRI|\[18F\]DPA-714-PET/MRI
224120905|NCT04859127|OTHER|effects of neck pain|Within the scope of the evaluation for the assessment of pain by visual analog scale (VAS), standard evaluation posture Postural Analysis, range of motion for the evaluation of Elektrogonyometer, Nov stabilizer and force evaluation for a hand-held Dynamometer, Nov for brevity, brevity reviews left internal rotator muscles of the pectoral muscles with standard, fear of movement kinezyofobi Tampa scale for the assessment of the neck in apology, questioning of the status of the inquiry Neck Disability Survey, stars in the evaluation of balance dynamic balance test, stand on one leg Test in the evaluation of static balance, dynamic balance and physical performance Term rise and walk test, gait speed for the assessment of the 10-meter walk test and dual-task for the evaluation of the motor-the motor and motor-Cognitive dual-task will be used for the evaluation.
223988755|NCT06945185|PROCEDURE|Intervention Group B Motor Imagery with Conventional Physical Therapy|"1. Subjects will be asked to sit comfortably on a chair with a backrest. A Quiet environment is ensured for proper concentration of subject .Take deep breaths for 2-3 min to relax.~2. Subjects will be asked to close their eyes and imagine the training scene for each task for 5 min while listening to the therapist 's voice describing the motion.~3. The non-paralysis part of the body's movement was imagined first and then the movement of the paralysis part was imagined.~4. Upon completion of the mental practice for the first activity, the subject will be given a comfortable break.~Motor Imagery Training:~Week 1-2: Approaching and holding a cup, turning book pages and grasping pencil to write.~Week 3-4: wiping desk, turning door handle and drinking water from cup. Week 5-6: pressing light switch on and off, turning faucet and putting card in wallet.~Week 7-8: folding towel, brushing teeth and brushing hair. Imagine for 30 sec 2-3 repetitions."
223988756|NCT06944288|PROCEDURE|total knee replacement|The Orthopedic Surgeon will remove the damaged cartilage and bone then implant the new metal and plastic knee to restore the alignment and function of your knee. The surgical procedure takes about 1-2 hours on average. While in case of infection, an antibiotic cement is inserted, which will be removed with the subsequent prosthetic implant surgery. Finally, prosthetic components can be more filling, depending on the amount of bone that is previously removed.
223988757|NCT06945315|PROCEDURE|RALP (Robotic-assisted radical prostatectomy)|Robotic-assisted radical prostatectomy (RALP) is a standard surgical procedure for managing localized prostate cancer that focuses on prostate anatomy and surrounding structures to enable personalized surgeries. The procedure incorporates nerve-sparing techniques through careful dissection of the neurovascular bundle and can use a thermal and traction-free dissection to improve functional outcomes, particularly erectile function.
224120906|NCT05632497|BIOLOGICAL|Stool and blood samples|Stool and blood samples
224120907|NCT01895010|DEVICE|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
224120908|NCT01895010|DRUG|tropisetron|only tropisetron 6mg before TACE
224120909|NCT04408521|OTHER|NEUROFEEDBACK|EEG recording during alpha-related TV viewing
223988758|NCT06945315|DRUG|SAFE (Saline assisted fascial engorgement)|SAFE (Saline assisted fascial engorgement) an innovative technique to achieve enhanced nerve-sparing outcomes among patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP). Essentially a new method of hydro dissection, SAFE involves an injection of 30 cc of normal saline solution between the layers of the periprostatic fascia after early release of the neurovascular bundle. This injection effectively pushes the nerves away from the prostate, enabling a dissection of the prostate that is atraumatic vis a vis the neural hammock.
224120910|NCT04408521|OTHER|CONTROL|EEG recording during passive TV viewing
224120911|NCT03962998|DRUG|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
224120912|NCT03962998|DRUG|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
224120913|NCT01787500|BIOLOGICAL|Cetuximab|Given IV
224294487|NCT05368441|DRUG|Saline|Control group patients are treated with 3 cc normal saline at waiting area 3 minutes before transportation to an operating room. In anesthesia induction, propofol 2 mg/kg will be given. Before the patients were given muscle relaxants, the patients were evaluated with the Han's grading scale.
224294488|NCT01418716|OTHER|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
224120914|NCT01787500|DRUG|Irinotecan Hydrochloride|Given IV
224294489|NCT01418716|OTHER|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
224294490|NCT02900963|OTHER|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
224294491|NCT05978739|DRUG|Orelabrutinib High dose|Orelabrutinib will be administered as 3 tablets once per day
224294492|NCT05978739|DRUG|Orelabrutinib Low dose|Orelabrutinib will be administered as 1 tablet once per day
224294493|NCT03282734|OTHER|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
224294494|NCT03282734|OTHER|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
223728816|NCT04541576|DEVICE|Merit WRAPSODY Endovascular Stent Graft|Target lesion treated with stent graft placement
224120915|NCT01787500|OTHER|Laboratory Biomarker Analysis|Correlative studies
224120916|NCT01787500|OTHER|Pharmacological Study|Correlative studies
224120917|NCT01787500|DRUG|Vemurafenib|Given PO
223728817|NCT00237601|OTHER|obstetric care|
223988759|NCT06945211|PROCEDURE|LOW INTENSITY TASK ORIENTED MIRROR THERAPY|"Group A Low Intensity Task Oriented Mirror Therapy will be administered for 2 and half hour per week for 30 min a day, 10 rep five times a week for 8 weeks.~Task-oriented Activities for Group A:~Using Sponge Balls Reaching and Grasping Objects. Handling Water Cups(pouring water ) Wiping with Rags (cleaning a table ). Using a Spray Bottle Writing and Drawing Folding Towels Turning Pages Brushing Hair keyboard typing Grabbing and releasing a cup. Spoon Feeding Practice Drinking from a Cup Card flip activity Stacking Wooden Blocks Total number of sessions 40 , 5 days a week for 30 min with 10 reps per day for 8 consecutive weeks."
223988760|NCT06945211|PROCEDURE|High Intensity Task Oriented Mirror Therapy|"Group B High Intensity Task Oriented Mirror Therapy will be administered for 5 hours per week for 60 min a day, 20 rep five times a week for 8 weeeks. The mode of mirror therapy will be unilateral as subjects will perform movement only on unaffected arm.~Task-oriented Activities for Group B:~Using Sponge Balls Reaching and Grasping Objects. Handling Water Cups(pouring water ) Wiping with Rags (cleaning a table ). Using a Spray Bottle Writing and Drawing Folding Towels Turning Pages Brushing Hair keyboard typing Grabbing and releasing a cup. Spoon Feeding Practice Drinking from a Cup Card flip activity Stacking Wooden Blocks Total number of sessions 40 , 5 days a week for 60 min with 20 reps per day for 8 consecutive weeks"
223988761|NCT06943911|BEHAVIORAL|AI Chatbot for Breast Cancer Patient Education and Empowerment|The AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital.
223988762|NCT06945393|OTHER|Cosmetic topical products|Cosmetic topical products efficacy evaluation
223988763|NCT06944691|OTHER|Major depressive disorder scale|Pass HDRS to patient taking PrEP to study prevalence of Major Depressive Disorder
223988764|NCT03439475|BIOLOGICAL|AMG 714|
223988765|NCT06944470|DRUG|Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma|"Carboplatin Injection:~One dose of carboplatin AUC 5 IV on Day 1 of each 3-week cycle.~Cisplatin injection:~Cisplatin 75 mg/m2 IV on Day 1 of every 3-week cycle.~Paclitaxel injection:~175 mg/m2 IV on Day 1 of each 3-week cycle.~Pemetrexed Injection:~Pemetrexed 500 mg/m2 IV on Day 1 of each 3-week cycle."
223988766|NCT06944470|PROCEDURE|surgery|Subjects with surgical indications will undergo radical surgery for NSCLC，within 4-6 weeks after the last dose of neoadjuvant therapy.
223988767|NCT06944470|RADIATION|Radiochemotherapy|If radical surgery is not suitable after MDT evaluation, the subjects will receive comprehensive treatment mainly based on radiotherapy.
223988768|NCT06944470|DRUG|JS207|JS207 will be administered every 3 weeks for a treatment cycle of 21 days.
223988769|NCT06940895|DRUG|Sirolimus 0.2%|sirolimus 0.2% gel
224120918|NCT06494059|OTHER|Intermittent theta burst stimulation (iTBS)|iTBS is a magnetic stimulation applied using a magnetic coil that is placed on top of the participants head to activate the brain. It consists of three very rapid bursts of electrical pulses at a frequency of 50 Hz (per burst) delivered at a rate of 5 per second for 2 seconds (10 bursts). The burst of pulses will be repeated every 10 seconds for a total duration of about 3 minutes. The stimulation will be applied to activate the brain regions that control upper limb, lower limb or trunk muscles. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
223728818|NCT04208620|DRUG|Placebo|Placebo administered subcutaneously
223988770|NCT06944756|OTHER|Global Postural Reeducation|"Two stretching postures were maintained for 10 minutes each.~* In order to stretch the posterior muscle chain(the supine posture with hip ﬂexion, which stretches the posterior muscle chain) the patient lay in the supine position with the occipital, lumbar, and sacral spine stabilized, with the lower limbs at 90° hip flexion, and performed gradual knee extensions, and dorsiﬂexion of the ankle.~* In order to stretch the anterior muscle chain (the supine posture with leg extension, which progressively stretches the anterior muscle chain) the patient lay in the supine position with the upper limbs abducted at 30° and the forearms supine.. Hips were flexed, abducted, and laterally rotated, with the soles of the feet touching each other. Gradually, respecting the patient's limits, the lower limbs were extended as much as possible and adduction of the upper limbs."
223988771|NCT06944756|OTHER|Scapular Stabilization Exercises|"1\) Push up plus and 2) press up, were selected in reference to a study for scapular stabilization.~During the 5-week intervention training, sets of repetitions were increased progressively. In the ﬁrst week participants performed 3 sets of each exercise (10 repetitions × 10-second duration each) and worked up to a maximum of 5 sets of 10 repetitions in the last weeks of the intervention."
224294495|NCT00306163|DRUG|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
224294496|NCT00306163|DRUG|Fluticasone|inhaled Fluticasone 100 µg, twice daily
224294497|NCT00775684|DRUG|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
224294498|NCT00775684|DRUG|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
223728819|NCT04208620|DRUG|Cotadutide|Cotadutide administered subcutaneously
223728820|NCT06332651|OTHER|Black beans|Black beans cooked and mashed and amino acid mixture as liquid drink to make methionine the limiting amino acid in the food consumed
223988772|NCT06944574|BEHAVIORAL|Guided online intervention|"The intervention combines a one-hour in-person workshop with a four-week app-based program tailored to elite athletes. The workshop focuses on sleep education and individual motivation setting. Athletes then complete seven self-paced audio modules via the 7-Schläfer app, covering strategies to improve sleep quality. Weekly reminder emails reinforce motivation. Unlike other interventions, this program is fully integrated into the elite sport context, emphasizes behavioral change through personalized goal-setting, and includes no therapist contact, ensuring scalability. No control group is included in this one-arm pre-post design."
223988773|NCT06945367|BEHAVIORAL|Active Learning-Based Research Methods Course|A four-month educational intervention based on active learning strategies, delivered as part of a Research Methods course for fourth-year undergraduate students in physiotherapy. The intervention included weekly group activities focused on literature retrieval, critical appraisal, oral presentations, peer feedback, and structured formative assessments using rubrics. The aim was to improve beliefs, attitudes, perceived skills, and frequency of use of evidence-based practice.
224120919|NCT06494059|OTHER|Functional electrical stimulation (FES)|FES is applied using electrodes that stick to the skin over the muscles or nerves. It will will be applied using an electrical stimulator to produce movements of the hand, leg or the trunk. The stimulation intensity will be determined by gradually increasing strength from 20-100 hertz (hz) until the right amount of movement is obtained. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
224120920|NCT06494059|OTHER|Transcutaneous spinal cord stimulation (TSCS)|TSCS is applied using electrodes that stick to the skin over the spinal cord to activate spinal cord. Mild electrical stimulation will be applied to make sure the nerves on the back are activated (switched on). Different stimulation intensities (strength) will be tested at different frequencies (pulses per second) to determine the best setting for activating the nerves on the back. The stimulus current strength will be adjusted between 0-250 milliamperes (mA) and will remain within the self-reported tolerance limit of each participant. Each subject is expected to participate longitudinally at least 9 times over 2 months. Each visit will take approximately 2-3 hours.
224120921|NCT06494059|OTHER|Sham Intermittent theta burst stimulation (iTBS)|Subjects will be fitted with a magnetic coil that is placed on top of the head that does not deliver any stimulation to the brain. Each subject is expected to participate longitudinally at least 9 times over 2 months.Each visit will take approximately 2-3 hours.
224120922|NCT03656887|DEVICE|Continuous interstitial glucose sensor|Installing and removing the sensor
224120923|NCT03656887|OTHER|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
224120924|NCT03970447|DRUG|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
224120925|NCT03970447|DRUG|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
224120926|NCT03970447|DRUG|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
224120927|NCT03970447|RADIATION|Radiation|60 Gy
224120928|NCT03970447|DRUG|Paxalisib|Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
224294499|NCT00775684|DRUG|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose \< 110mg/dl
224294500|NCT05859321|OTHER|Virtual reality Exercises|Virtual reality exercises along with transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
224294501|NCT05859321|OTHER|Routine Physiotherapy|transcutaneous electrical nerve stimulation, Heat Therapy and Stretching and strengthening exercises
224294502|NCT02925806|OTHER|Non-interventional study - retrospective database review|
224294503|NCT02902718|DEVICE|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
224294504|NCT00195013|DRUG|glutamine|10 grams three times a day (orally) for four days and then stop
224294505|NCT00195013|DRUG|Placebo|10 grams three times a day (orally) for four days and then stop
224294506|NCT00280878|DRUG|gemcitabine|
224120929|NCT03970447|DRUG|VAL-083|Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
224294507|NCT00280878|DRUG|vinorelbine|
224294508|NCT00280878|DRUG|ifosfamide|
224294509|NCT00280878|DRUG|rituximab|
224294510|NCT02397005|DRUG|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
224294511|NCT02397005|DRUG|Placebo matching ZL-2102|
224294512|NCT02459145|BEHAVIORAL|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)\_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
223988774|NCT06945055|BEHAVIORAL|FAMES|225 dyads (family member/support persons and individuals receiving services for psychosis) will be recruited over a period of 30 months. Family member/support persons will be connected to a family peer for a period of 12 weeks who will use the cultural formulated interview to develop rapport and identify unique cultural needs which can inform treatment and resource identification. Participants will receive brief contact, family psychoeducation, and be connected to an online family resource group where they can receive additional support from certified peers and other family member/support persons.
223988775|NCT06945055|BEHAVIORAL|Control|participants will receive 12 weeks of automated communication which contain positive messaging, appointment reminders, links to community resources, and coping skills.
223988776|NCT06945692|PROCEDURE|patient specific reconstruction plates|Use of patient specific reconstruction plates on the 3-D virtually-generated defect using Artificial Intelligence.
223988777|NCT06944054|OTHER|Group 1|Every 2 hours, the heat probes were replaced. Hypoallergenic patches were removed with a silicone-based spray used in the clinic. The application continued for 24 hours. In total, 12 heat probe displacements were made to different points in the abdominal, chest or lower extremity region. Heat probe stabilising tapes were attached to different points in a clockwise direction. At the end of 24 hours, the skin conditions of the newborns were re-evaluated with scales and recorded. This application continued for 3 days.
223988778|NCT06944457|DRUG|MPD-1|It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer.
223988779|NCT06944769|OTHER|Group A myofascial technique|"Group A with MET (latissimus dorsi), myofascial release (thoracolumbar fascia) and posterior oblique sling strengthening it will be a six-week protocol, with sessions conducted five times a week for 30-40 minutes, focusing on posterior oblique sling activation. Week 1: Myofascial release (thoracolumbar fascia, 60-90 sec), MET (latissimus dorsi, 7-10 sec isometric + 30-sec stretch, 5 reps), glute max strengthening (prone hip extensions, 10-sec holds ×5; bilateral bridges, 5-sec holds ×5).~Week 2: Prone hip extension (3-kg resistance), arm extension (1-kg dumbbell, 5-sec holds ×5), bird-dog (5-sec holds ×10, 1 set).~Weeks 3-4: Prone hip extensions (5-sec holds ×10), single-leg bridges (5-sec holds ×10), twice daily.~Weeks 5-6: Increased intensity to 10-sec holds ×10 reps"
223988780|NCT06944769|OTHER|Group B posterior sling exercises|A six-week conservative protocol, was conducted five times weekly for 30-40 minutes, focuses on core stability exercises. Week 1 includes static stretching of the latissimus dorsi (30-second hold, 3 reps) and prone hip extensions with knee flexed at 90° (5-second hold, 10 reps). By Week 2, bird-dog exercises are introduced (5-second hold, 10 reps per side). In Weeks 3-6, these exercises are maintained to provide a stable baseline for comparison with Group A's more intensive protocol. The latissimus dorsi stretch is performed 2-3 times daily for improved flexibility.
223988781|NCT06945757|OTHER|Physical Exercise|"Patients will participate in the routine rehabilitation program for 12 weeks, consisting of two 1h30 one-to-one sessions per week of physical activity administered by experienced physical therapist. Both sessions of the week are tailored to the need of the individual participant and are typically structured as follow:~* 10 minutes of warming up by light exercises~* 20 minutes of coordination exercises~* 20 minutes of strengths exercises~* 20 minutes of mobility exercises~* 10-15 minutes of cool down and stretching~Patients will further benefit during the 12-weeks program of several individual encounters with a psycho-oncologist, a nurse specialized in cognitive support and a nutritionist. Furthermore, a dietician will conduct an introductory evaluation, several intermediate evaluations and a final evaluation on nutritional status and habits of the patients."
223988782|NCT06944132|PROCEDURE|Excision of the pterygium|The surgical procedure involved excision of the pterygium, including the fibrovascular head and associated conjunctival tissue, followed by bare sclera closure using an autologous conjunctival graft harvested from the superior bulbar conjunctiva. The graft was secured in place using either fibrin glue or 8-0 absorbable sutures. In Group B, 0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.
223988783|NCT06944132|DRUG|Post-operative application of CsA|Patients received topical cyclosporin A (0.05%) twice daily for three months postoperatively.
223988784|NCT06944132|DRUG|Intra-operative application of MMC|0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.
223988785|NCT06945835|BEHAVIORAL|Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.|Partticipants will be performing supported and unsupported walking, free weights, rowing, cycling, resistance bands, adaptive bikes and body weight exercises.
223988786|NCT06944210|OTHER|'Rosy Red Valencia' sweet orange|The participants consume 2 'Rosy Red Valencia' sweet oranges daily for 4 weeks
223988787|NCT06944210|OTHER|'Olinda Valencia' sweet oranges|The participants consume 2 'Olinda Valencia' sweet oranges daily for 4 weeks
223988788|NCT06945003|BEHAVIORAL|Exercise Intervention|Those assigned to the intervention group will be invited to attend one of three group activity sessions with their parent/guardian that will occur at one of Ulster University's sport centres. Three group activity sessions will be delivered separately for each cohort (i.e Primary, Post-Primary and those with an Intellectual Disability) and their respective parent/guardian.) Parents/guardians and their child will then meet one-to-one with Professor Frank Casey, a paediatric cardiologist, will discuss with them, their child's results from their cardiopulmonary exercise test and from wearing their activity monitor. Using these results, alongside their age and diagnosis and likes and dislikes, Professor Casey will provide an individualised physical activity recommendation plan for each child that will be safe and beneficial to them, to be implemented at home over 12-weeks.
223988789|NCT06944977|BEHAVIORAL|Anticipatory guidance and postnatal home visits|Anticipatory guidance to pregnant women, followed by scheduled home visits at 6, 12, and 18 months
223988790|NCT06944977|BEHAVIORAL|Anticipatory guidance|Postnatal anticipatory guidance
223988791|NCT06944808|OTHER|Sham-BFR + EMS|Daily passive sham-BFR with a fixed pressure of 20mmHg in combination with electrical stimulation of the m. vastus lateralis and mediales
223728821|NCT06332651|OTHER|Milk|Skimmed milk as liquid drink and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
224120930|NCT03970447|DRUG|VT1021|"Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration."
223988792|NCT06944808|OTHER|BFR + EMS|Daily passive BFR with an individual pressure of 80% of the limb occlusion pressure in combination with electrical stimulation of the m. vastus lateralis and mediales
223988793|NCT06945562|DEVICE|collagen cone (resorbable material used for socket sealing )|The test group include those sites enrolled for placement of immediate dental implant (N=8) with application of collagen cone
224120931|NCT03970447|DRUG|Troriluzole|Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
224120932|NCT03970447|BIOLOGICAL|ADI-PEG 20|Dosage Form: Solution for intramuscular injection Strength: 11.5 ± 1.0 mg/ml Standard Regimen: For newly diagnosed patients, 36mg/m2. For recurrent disease patients, dose as confirmed through the dose finding phase intramuscularly once a week
223728822|NCT06332651|OTHER|Sorghum|Sorghum cooked and mashed and amino acid mixture as liquid drink to make lysine the limiting amino acid in the food consumed
223728823|NCT03930576|OTHER|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
223988794|NCT06945562|PROCEDURE|Placement of Immediate Dental Implant Only|Participants will receive placement of an immediate dental implant without any additional material (N=8).
223988795|NCT06938269|DRUG|MWN109 tablet|Strength: 7.5mg, 15mg, 30mg, and 45 mg; Administration: Oral.
223988796|NCT06938269|DRUG|Placebo|Administration: Oral.
223988797|NCT06950944|DEVICE|Theranova 500|Participants will dialysis by Theranova 500 dialyzer during study period, the dialyzer will reprocessing with standard hospital protocol and dialyzer will check before use in dialysis session.
223988798|NCT06950502|PROCEDURE|transversus abdominis plane block|Transversus abdominis plane block was performed with the patient lying in the supine position via an oblique subcostal approach from the anterior abdominal wall. After skin asepsis of the anterior abdominal wall was provided with 10% polyvinylpyrrolidone-iodine, the linear ultrasound probe was placed parallel to the subcostal border at the level of the xiphoid bone and the subcutaneous fat tissue, rectus abdominis muscle and transversus abdominis muscle were visualized, respectively. A 10 cm 20G needle (BRAUN Stimuplex Ultra 360, GERMANY) was advanced towards the transversus abdominis muscle fascia with the in-plane technique and 0.3 ml/kg 0.25% bupivacaine was injected into this area.This procedure was performed bilaterally.
224120933|NCT03970447|DRUG|AZD1390|Standard Regimen Newly Diagnosed: Given once daily on days of radiation and once daily for 14 consecutive days after completion of radiation.
224120934|NCT00733382|DRUG|dexamethazone|injection form, 8 miligram, injected once
224120935|NCT06808321|DRUG|Benidipine Hydrochloride|The safety and efficacy of a dihydropyridine calcium channel blocker for the treatment of high blood pressure and/or angina pectoris
224120936|NCT06038617|BIOLOGICAL|mRNA COVID-19 Vaccine|ACIP Recommended Vaccine
224120937|NCT06038617|BIOLOGICAL|Routine Childhood Vaccinations|ACIP Recommended Vaccines
224120938|NCT03919253|COMBINATION_PRODUCT|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
224120939|NCT01270646|DEVICE|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
224120940|NCT06339996|DIETARY_SUPPLEMENT|Male supplement|Participants will be administered supplements for a three-month treatment period
224120941|NCT06048003|OTHER|No specific intervention|No specific intervention
224120942|NCT01847144|DRUG|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
224120943|NCT01847144|DRUG|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
224120944|NCT01757704|PROCEDURE|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
223988799|NCT06950502|PROCEDURE|Quadratus Lumborum Block (QLB)|Quadratus lumborum block; after the patient was lying in the lateral decubitus position and skin asepsis of the posterior abdominal wall was provided with 10% polyvinylpyrrolidone-iodine, the ultrasound probe was moved from the level of the iliac crest to the 4th lumbar vertebra and the quadratus lumborum muscle was visualized on the transverse process of the 4th lumbar vertebra at the point where the anterior abdominal wall muscles end. The needle was advanced in-plane between the quadratus lumborum muscle and the erector spinae-latissimus dorsi muscles (QLB2) located on the posterior-superior side of this muscle, and 0.15 ml/kg 0.25% bupivacaine was injected under the thoracolumbar fascia located between these two muscles. Then, the needle was advanced towards the quadratus lumborum and the psoas major (QLB3) muscle located on the anterior-inferior side, and 0.15 ml/kg 0.25% bupivacaine was injected between these two muscles.This procedure was applied to the patient bilaterally.
224120945|NCT01757704|PROCEDURE|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
223988800|NCT06950502|DRUG|quadratus lumborum block using bupivacaine|The needle was advanced in-plane between the quadratus lumborum muscle and the erector spinae-latissimus dorsi muscles (QLB2) located on the posterior-superior side of this muscle, and 0.15 ml/kg 0.25% bupivacaine was injected under the thoracolumbar fascia located between these two muscles. Then, the needle was advanced towards the quadratus lumborum and the psoas major (QLB3) muscle located on the anterior-inferior side, and 0.15 ml/kg 0.25% bupivacaine was injected between these two muscles.This procedure was applied to the patient bilaterally.
223988801|NCT06950502|DRUG|transversus abdominis plane block using bupivacaine|A 10 cm 20G needle (BRAUN Stimuplex Ultra 360, GERMANY) was advanced towards the transversus abdominis muscle fascia with the in-plane technique and 0.3 ml/kg 0.25% bupivacaine was injected into this area.This procedure was performed bilaterally.
223988802|NCT06947512|DEVICE|Seleggo Test|Seleggo Test is a computerized procedure to identify the personalized visual and auditory parameters facilitating reading and writing for each participant. By applying these parameters to the visualization and to the TTS software during reading of school texts, the participants are expected to be facilitated in reading and understanding the text.
223988803|NCT06546137|DIAGNOSTIC_TEST|whole genome sequencing|whole genome sequencing of genomic DNA extracted from buccal swab
223988804|NCT06245213|DRUG|ANAVEX3-71 oral capsules|ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.
223988805|NCT06245213|DRUG|Placebo oral capsules|The placebo comparator for the study.
223988806|NCT03728985|DEVICE|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
223988807|NCT03778502|DRUG|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
223988808|NCT02604563|OTHER|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
223988809|NCT02604563|OTHER|Activities of Daily Living Questionnaire|"* 10 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
223988810|NCT02604563|OTHER|Instrumental Activities of Daily Living, subscale of the OARS|"* 7 items about daily functional status~* Baseline and no more frequently than every 6 months until death"
223988811|NCT02604563|OTHER|Karnofsky Self-reported Performance Rating Scale|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
223988812|NCT02604563|OTHER|Number of Falls|"* 1 item about daily functional status~* Baseline and no more frequently than every 6 months until death"
223988813|NCT02604563|OTHER|Physical Health Section, subscale of the OARS|"* 13 items about comorbidity~* Baseline and no more frequently than every 6 months until death"
223988814|NCT02604563|OTHER|MOS Social Activity Survey|"* 4 items about social activity~* Baseline and no more frequently than every 6 months until death"
223988815|NCT02604563|OTHER|Unintentional Weight Loss|"* 2 items about nutrition~* Baseline and no more frequently than every 6 months until death"
223988816|NCT02604563|GENETIC|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
223988817|NCT02604563|GENETIC|Buccal Swab|"* Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death"
223988818|NCT02604563|OTHER|Heart Health and Smoking History from BRFSS questionnaire|"* 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death"
223988819|NCT02604563|OTHER|Gait Speed|"* Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death"
223988820|NCT02604563|OTHER|Grip Strength|"* Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death"
223988821|NCT02604563|OTHER|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
223728824|NCT04962633|OTHER|Probiotic Pasta|Subjects will consume for 4 weeks 80 g per day of probiotic durum wheat pasta. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
223728825|NCT04962633|OTHER|Control Pasta|Subjects will consume for 4 weeks 80 g per day of conventional durum wheat pasta without probiotics. All subjects will be requested not to change the other daily dietary habits and their physical activity levels during the 4 week intervention period.
223988822|NCT02604563|OTHER|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
223988823|NCT02604563|PROCEDURE|Optional bone marrow biopsy|-1 optional bone marrow biopsy
224120946|NCT01879618|DRUG|Fragmin|variable dosing regimen
223988824|NCT02604563|PROCEDURE|Blood draw for trauma measurements|-For Arm E only
223988825|NCT06432972|OTHER|Pulmonary Rehab|Prehab will include 2, one-hour sequential sessions of PR per day as is standard, however this intervention will increase the frequency from 2 days to 4 days per week, for 2 weeks, thus completing 16 sessions of PR prior to surgery. An exercise prescription will be written by the medical director based on initial 6MWD, age, height, weight, and co-morbidities, as is standard of care. Prior to each session, patients are evaluated for symptoms and vital signs are measured. Exercise will include 30 minutes of warm-up and upper and lower extremity resistance training, either against gravity or with resistance bands as appropriate. Exercise will then move to the open gym, where patients utilize endurance equipment of their choosing, such as a treadmill or recumbent bicycle. As with traditional PR, participants will be given online education videos regarding lung health to complete at home, with a supplementary video on breathing techniques to reduce atelectasis from pain.
223988826|NCT02070679|DRUG|Vitamin E|
223988827|NCT00966264|DRUG|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
223988828|NCT00966264|PROCEDURE|Hysterectomy|operation
223988829|NCT03811990|BEHAVIORAL|Cleveland Clinic Stress Free Now Meditations For Healers|Phone-based meditation application
223988830|NCT01867047|DRUG|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
223988831|NCT01867047|DRUG|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
223988832|NCT04350099|OTHER|quetionnary|Participants will complete self-questionnaires at different times during the epidemic
223988833|NCT02895919|OTHER|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
223988834|NCT01918592|DEVICE|MRI/acetate-PET imaging|
223988835|NCT02517814|DIETARY_SUPPLEMENT|Vitamin D|
223988836|NCT00003622|DRUG|paclitaxel|
224120947|NCT03075397|OTHER|blood sample|A sample of HIV-1 infected patients's blood is collected
224120948|NCT03075397|OTHER|sperm sample|A sample of HIV-1 infected patients's sperm is collected
224120949|NCT06842680|BEHAVIORAL|Control|Products do not carry ultraprocessed warning label. To match the current Chilean legislation, products carry octagonal nutrient labels when applicable.
223988837|NCT00003622|DRUG|vinorelbine tartrate|
223988838|NCT03089996|PROCEDURE|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
224120950|NCT06842680|BEHAVIORAL|Ultraprocessed warning label|Products carry ultraprocessed warning label. To match the current Chilean legislation, products carry octagonal nutrient labels when applicable.
224120951|NCT06841627|OTHER|Osteopathic Manipulative Therapy|Evaluation looking for Somatic Dysfunction (SD) involving the head, neck, upper thoracic spine, rib cage and sacroiliac joint. OMT techniques will include a mix of the following: Osteopathic Cranial Manipulative Medicine, Muscle Energy Technique, Facilitated Positional Release, Indirect Myofascial Release, and Counterstrain.
224120952|NCT05579093|COMBINATION_PRODUCT|Cognitive test + Pupillary measure|"Patients will be put into a quiet room with a computer and a webcam for a five minute assessment with the NeuroTrack™ testing. Study personnel will stay in the room, and be available for answering questions about using the online testing tool.~After Neurotrack, pupillary responses will be recorded with the pupillometer with the PLR -3000TM. In brief, an eye cup attached to a pupillometer will be placed over one eye to allow measurement of the pupillary response to light. Once the eye cup is properly positioned, the reading takes approximately 5 seconds, after which time the eye cup will be removed. The reading will then be taken in the contralateral eye."
224120953|NCT00138099|DRUG|Fragmin (dalteparin sodium)|
224294513|NCT03848169|OTHER|Radiofrequency|See previous page
223988839|NCT03089996|PROCEDURE|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
224120954|NCT02005601|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
224120955|NCT02005601|DRUG|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
224120956|NCT04933279|DIETARY_SUPPLEMENT|iodine-containg spareribs soup|administrated a 150 ml - 200 ml of iodine-containg spareribs soup delivering ≈ 600 µg or 1200 µg iodine
224120957|NCT04933279|DIETARY_SUPPLEMENT|intrinsic iodine in natural kelp|administrated 45 g or 80 g natural kelp delivering ≈ 600 µg or 1200 µg iodine (intrinsic iodine). The natural kelp will be approximately produced in an experimental barn feeding supplementary iodine to reach a final iodine intake of ≈ 600 µg or 1200 µg. The iodine intake of natural kelp will be adjusted to the required dose by determing iodine content in the natural kelp.
224120958|NCT02496728|BEHAVIORAL|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
224120959|NCT02496728|BEHAVIORAL|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
224120960|NCT02496728|BEHAVIORAL|Social Support|Participants may interact with each other through a private Facebook group.
224120961|NCT02496728|BEHAVIORAL|Educational Materials|Educational materials regarding healthy behaviors.
224120962|NCT06589713|DRUG|Enpatoran|Participants will receive a single oral dose of enpataron tablets once daily.
224120963|NCT04040712|OTHER|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
224120964|NCT04040712|OTHER|Sham FMT|Sham fecal microbiota transplantation
224120965|NCT02890329|DRUG|Decitabine|Given IV
224294514|NCT01754506|DIETARY_SUPPLEMENT|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
224120966|NCT02890329|BIOLOGICAL|Ipilimumab|Given IV
224120967|NCT03647371|PROCEDURE|Macintosh laryngoscopy|intubation with MAcintosh laryngoscopy after anesthetic induction
224120968|NCT03647371|PROCEDURE|McGrath MAC video laryngoscopy|intubation with McGrath MAC videolaryngoscopy after anesthetic induction
224120969|NCT00938327|BIOLOGICAL|Rotarix™|Two doses of oral vaccine.
224120970|NCT02890199|DRUG|Bupivacaine liposomal|
224120971|NCT02890199|DRUG|Lidocaine|
224120972|NCT03014219|DRUG|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
224120973|NCT01052987|DRUG|Tranilast|Tranilast tablets, 300 mg, QD
224120974|NCT01052987|DRUG|Allopurinol|Allopurinol tablets 300 mg, QD
224120975|NCT01052987|DRUG|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
224120976|NCT01052987|DRUG|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
224120977|NCT01052987|DRUG|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
224120978|NCT02549911|OTHER|HIPEC,Chemotherapy AND surgery|"1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
224294515|NCT01911663|DIETARY_SUPPLEMENT|KRG|500 mg Korea red ginseng (KRG)
224294516|NCT01911663|DIETARY_SUPPLEMENT|Placebo|500 mg placebo
224294517|NCT06624514|BEHAVIORAL|Training Group|Implicit approach bias is the behavioral action tendency to be faster to approach rather than avoid cues for a stimulus category. The Approach-Avoidance Task (AAT)is a computerized program in which participants make approach or avoidance movements in response to an irrelevant feature of an image presented on a computer screen (e.g., push when in portrait, pull when in landscape). The intervention in this study is a treatment version of the AAT used as an Approach Bias Modification (ABM) intervention, to retrain participants' implicit biases toward or away from stimuli by presenting the target stimuli predominantly in one format (e.g., push or pull).
224294518|NCT06624514|BEHAVIORAL|Sham Training Group|A sham-training control condition
223988840|NCT03089996|DEVICE|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
223988841|NCT03089996|PROCEDURE|Micro-osteoperforations|All micro-osteoperforations will be performed only once time in the experimental group on the same day of the installation of the upper incisors' retraction mechanics. Perforations will be performed with an individualized surgical guide and a 1.6 mm diameter stainless steel surgical drill perpendicular to the alveolar bone, 3 mm deep on the buccal surface, and 5 mm, on the palate. The depth of the perforations will be controlled and standardized by a cursor developed and patented by the research group. Two micro-osteoperforations will be aligned vertically distally from each upper incisor. Due to the proximity of the roots in the cervical third, only the most apical perforation will be performed between the two central incisors. The first perforation will be performed 6 mm away from the gingival margin, and the second, 5 mm from the first, in the vertical direction.
223988842|NCT06137612|DIAGNOSTIC_TEST|MRI|axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
223988843|NCT03153150|DRUG|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
223988844|NCT03153150|DRUG|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
224120979|NCT02902705|OTHER|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
224120980|NCT05517447|OTHER|Observational cohort study|Observational cohort study
223988845|NCT03153150|DRUG|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
223988846|NCT03153150|DRUG|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
223988847|NCT03153150|DRUG|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
223988848|NCT03153150|DRUG|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
223728826|NCT01453114|BEHAVIORAL|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
223988849|NCT03153150|DRUG|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
223988850|NCT01076764|DRUG|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
223988851|NCT01076764|DRUG|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
224120981|NCT05517447|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
224120982|NCT05903833|DRUG|Pembrolizumab|400 mg Q6W
223728827|NCT01373372|DRUG|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
223988852|NCT01076764|DRUG|UFH|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
223728828|NCT03676933|DRUG|DS107E|
223728829|NCT03676933|DRUG|Vehicle|
223728830|NCT03676933|DRUG|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
223728831|NCT02792933|PROCEDURE|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
223988853|NCT01076764|DRUG|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
223988854|NCT01076764|DRUG|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
224120983|NCT05903833|DRUG|Lenvatinib|20 mg QD
224120984|NCT05366816|DRUG|Sunitinib|37.5 mg of Sunitinib orally (PO), once daily on a 28-day treatment cycle.
224120985|NCT05366816|DRUG|Regorafenib|120.0 mg of Regorafenib, once daily by mouth 3 weeks on 1 week off on a 4-week treatment cycle.
224294519|NCT02999477|DRUG|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
224294520|NCT02999477|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
223544623|NCT05544435|BEHAVIORAL|Motivational İnterviewing|Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
223988855|NCT01076764|DRUG|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
223988856|NCT04142411|DRUG|Insulin|Ultrasound guided perineural injection therapy (PIT)
223988857|NCT04142411|DRUG|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
223988858|NCT04142411|DEVICE|Ultrasound|Philips Neuromuscular Ultrasound
223988859|NCT03055169|GENETIC|genetic analysis|
223988860|NCT03055169|BIOLOGICAL|blood and stools samples|
224120986|NCT02242890|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
224120987|NCT02749721|DRUG|vortioxetine|Open-label vortioxetine
224120988|NCT01220648|DRUG|Nilotinib, interferon-alfa|
224294521|NCT02999477|PROCEDURE|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
224294522|NCT04722601|DRUG|Venetoclax|A drug used with other drugs to treat acute myeloid leukemia that is newly diagnosed. It is used in adults who are 75 years and older or in adults who cannot be treated with other anticancer drugs. Venetoclax is also used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma in adults. It is also being studied in the treatment of other types of cancer.
223988861|NCT04930497|PROCEDURE|vestibular socket technique with bone grafting|a vestibular horizontal incision was made then a subperiosteal tunnel was created and a facial bone membrane was placed. The facial gap was filled with a mixture of autogenous bone and deproteinized bovine bone mineral
223988862|NCT04930497|PROCEDURE|vestibular socket technique without bone grafting|the vestibular incision was done horizontally about 3 to 4 mm apical to the mucogingival junction and extending 5 to 10 mm horizontally. A submucoperiosteal tunnel was created labially from the socket orifice till the vestibular access incision
223988863|NCT06096584|PROCEDURE|Triple Injection Perisartorius block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone.~Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata"
223988864|NCT06096584|PROCEDURE|Dual sub sartorial block|"Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone~Patients will receive a combination of femoral triangle block and distal ACB."
223988865|NCT06096584|PROCEDURE|Femoral triangle block|Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.
223988866|NCT06096584|PROCEDURE|Distal adductor canal block|Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.
224120989|NCT03628469|BEHAVIORAL|Proactive Health Support|Active listening, coaching and counselling
223988867|NCT06096584|PROCEDURE|Suprasartorial plane block|Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata
223988868|NCT04707950|DRUG|Tranexamic Acid 100 milligram/Milliliter|"Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements)."
223988869|NCT04707950|DRUG|Oxytocin|both groups will be given oxytocin as a standard management
223988870|NCT05311254|DRUG|Fosfomycin Calcium|Oral fosfomycin, three times daily, starting from the first day of induction chemotherapy or conditioning until absolute neutrophil count \>0,5x109/L.
223988871|NCT01060397|BEHAVIORAL|Extended Brief Intervention|Frames motivational interviewing approach
223988872|NCT01060397|BEHAVIORAL|Control|Usual care
223988873|NCT04596995|DRUG|Rozanolixizumab|Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
224120990|NCT05801926|DEVICE|Heel2Toe[TM] sensor|Heel2Toe is a new generation of wearables that provides real-time auditory feedback when the person takes a good step, one in which the step is initiated with a strong heel strike.
224120991|NCT02691247|BIOLOGICAL|CLBS03 Low Dose|
224120992|NCT02691247|BIOLOGICAL|CLBS03 High Dose|
224120993|NCT02691247|BIOLOGICAL|Placebo|
224120994|NCT05336968|DRUG|Triamcinolone acetonide-Ketorolac-Ropivacaine|Experimental for Osteoarthrosis of the Knee. One randomized injection to intraarticularly into affected knee at time of randomization
224120995|NCT05742464|BEHAVIORAL|RUBI|"RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials."
224120996|NCT02552355|DRUG|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
224120997|NCT02552355|DRUG|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
224120998|NCT02552355|DIETARY_SUPPLEMENT|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
224120999|NCT02552355|DIETARY_SUPPLEMENT|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
224121000|NCT01519245|DRUG|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
224121001|NCT01519245|DRUG|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
224294523|NCT04722601|DRUG|Obinutuzumab|Obinutuzumab is a prescription medicine that can be used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease.
224294524|NCT04722601|DRUG|CC-486|An oral form of azacitidine (a standard chemotherapy drug).
224294525|NCT07015905|DRUG|REGN7508|Administered per the protocol
224294526|NCT07015905|DRUG|Apixaban|Administered per the protocol
224294527|NCT07015905|DRUG|Enoxaparin|Administered per the protocol
224294528|NCT07015905|DRUG|Placebo|Administered per the protocol
224294529|NCT00695435|DRUG|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
224294530|NCT00695435|DRUG|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
224294531|NCT00695435|DRUG|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
224294532|NCT04944134|BIOLOGICAL|COVID-19 Vaccination|Receipt of full COVID-19 vaccination
224294533|NCT00555802|OTHER|exercise|exercise
224294534|NCT07015957|BEHAVIORAL|In-person training|An in-person educational session.
224294535|NCT07015957|BEHAVIORAL|Virtual training|A virtual educational session.
224294536|NCT07015957|BEHAVIORAL|Coaching|Short video vignettes plus reinforcing messages
224294537|NCT07015957|BEHAVIORAL|Prompts|Visual aide to remind providers to discuss cervical cancer prevention methods.
224294538|NCT04464993|BEHAVIORAL|Device-based feedback, self-monitoring, and education: CORE|"Participants will receive a core intervention which will include a basic version of the StandUPTV app on an android tablet and a Fitbit to use throughout the 16-week intervention.t. SST feedback will be provided within the smartphone application. Self-monitoring will provide passive and objective feedback regarding SST behaviors. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation."
223544624|NCT02745496|PROCEDURE|TRUS Biopsy|Standard of Care Treatment
223544625|NCT02745496|PROCEDURE|TRUS/FUSION Biopsy|Interventional Treatment
223544626|NCT03723980|DRUG|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
223544627|NCT03723980|DRUG|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
223544628|NCT02491177|BEHAVIORAL|cMM|Home visits from community mentor mothers
224294539|NCT04464993|BEHAVIORAL|Sedentary Screen Time lockout: LOCKOUT|Sedentary Screen Time lockout: LOCKOUT Sedentary Screen Time lockout: LOCKOUT The investigators will enforce a 50% per week reduction in SST, based upon a baseline week of observation. If SST reaches the prescribed threshold, the investigators will use the limits feature to restrict screen time through the end of the week (Monday-Sunday); at which point, 50% baseline allotment will be reinstated for an additional week. Participants will be prompted to plan for their screen time and provided modest allowances for exceeding their screen time in a given week.
224294540|NCT04464993|BEHAVIORAL|Context-based prompts: TEXT|The TEXT component uses app-based prompts (i.e., prompts generated through StandUPTV, not text message based) that will provide simple adaptive content. Content of the prompts will be educational (i.e., based on risks of sedentary screen time) and motivational (i.e., advice to reduce sedentary screen time).
223728832|NCT02792933|PROCEDURE|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
223728833|NCT00290368|PROCEDURE|Skin Prick Test|
223728834|NCT00290368|PROCEDURE|Nasal allergen challenge|
223544629|NCT02491177|BEHAVIORAL|Text Messaging|Text messages received on mobile phone
223544630|NCT04462029|DRUG|BR4002|"* Administration to the T1 group: 5 mg of BR4002 (patch) will be attached using an applicator for 24 hours~* Administration to the T2 group: 5 mg of BR4002 (patch) will be attached without using an applicator for 24 hours"
223544631|NCT04462029|DRUG|BR4002-1|Administration to the R group: 5 mg of BR4002-1 (oral formulation) will be administered with 150 mL of water
223728835|NCT00290368|PROCEDURE|Nasal filter paper placement|
223728836|NCT00290368|PROCEDURE|Nasal lavage|
223728837|NCT00290368|PROCEDURE|Nasal scrape|
223728838|NCT00290368|PROCEDURE|Nasal symptoms score|
223728839|NCT04360954|DIAGNOSTIC_TEST|Diagnostic test|There is no intervention. This study will test deidentified archived biosamples.
223728840|NCT06384716|OTHER|rehabilitation programme based on motor control of core muscles|The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
223988874|NCT05996367|RADIATION|Single-dose involved-site radiotherapy|Single-dose of 8 Gy at involved-site radiotherapy
223988875|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
223988876|NCT00755729|DIETARY_SUPPLEMENT|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
223988877|NCT02517177|OTHER|Parabolic flight|
223988878|NCT02517177|OTHER|Cardiovascular parameters measurements|
223988879|NCT02701998|BEHAVIORAL|mHealth-Enhance Physical Activity Intervention|
223988880|NCT02701998|OTHER|Physical Activity Intervention|
223988881|NCT01377298|DRUG|Pazopanib|200mg/tablet, 800mg/day PO.
223988882|NCT00590564|DRUG|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
223988883|NCT05369949|DRUG|DEX group|Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.
223544632|NCT02782845|DRUG|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
223544633|NCT02782845|DRUG|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
223544634|NCT02782845|DRUG|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
223544635|NCT04645511|PROCEDURE|Balloon sinuplasty of maxillary sinuses|A shapeable tip of the balloon dilatation device (Entellus XprESS LoProfile; Stryker Corporation, Kalamazoo, Michigan, U.S.A.), with maxillary bending, is inserted into the maxillary sinus ostium. Then guided with the tip, a flexible balloon (6 mm x 20 mm) is gently inserted into the ostium and inflated up to 12 atm for 15 seconds. The dilatation is repeated one more time. The same procedure is performed for both maxillary sinuses.
223544636|NCT04645511|PROCEDURE|Sham surgery|"The middle meatus is gently palpated with a curved suction tip (the tip is not connected to a suction unit). The curved suction tip is placed medial to the uncinate process. In order to create a better placebo effect, the operating doctor says: Now inflate the balloon up to 12 atm for 15 seconds. After 15 seconds the doctor says: Deflate the balloon. This is repeated one more time. Similar procedure is carried out on both sides."
223544637|NCT05772403|DIAGNOSTIC_TEST|CEUS|CEUS for atypical liver nodules
223544638|NCT04648917|DRUG|Caffeic acid|40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight \>50kg, 200mg per time, weight \< or =50kg, 100mg per time)
223544639|NCT01261364|BEHAVIORAL|GeneSightRx|Multi-genetic pharmacogenomic panel
223544640|NCT01261364|BEHAVIORAL|Treatment as usual|Treatment as usual
223728841|NCT06185504|BEHAVIORAL|systemic therapy|"All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training, as follows~1. The mendelson maneuver: performed 5 days per week, twice per day, 5-10 minutes each time.~2. Cold stimulation of the pharynx: performed every day, twice per day, 3-5 minutes each time.~3. Passive head extension: to stretch the submental muscle for 2-3 seconds, with upward resistance applied to the lower cheek for no less than 5 times a day and no less than 5 minutes each time.~4. Direct feeding training: with powdered milk, once a day, 5 days a week."
223728842|NCT06185504|DEVICE|Intermittent Oro-Esophageal Tube Feeding|Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support. Before each feeding, the infant should rest for approximately 1 hour and undergo oral clean. During feeding, the infant should be held by the caregiver in a semi-reclined or upright position. Firstly, the tail of the tube was inserted via mouth into the upper part of the esophagus with a depth of 18-20cm, and the external part of the tube should be placed in water with the absence of bubbles indicating the successful tube placement. Subsequently, 1ml of water was slowly injected, followed by liquid food or water at a rate of approximately 50ml/min through a syringe connected to the feeding tube. After feeding, the tube should be slowly removed, and the feeding position should be maintained for 30-60 minutes to prevent reflux.
223728843|NCT06185504|DEVICE|Persistent Nasogastric Tube Feeding|The control group was given nutrition support with Persistent Nasogastric Tube Feeding, of which the tube passed through the nasal cavity into the stomach. After successful intubation, the tube was secured on the cheek. Liquid food was then syringe-fed into the stomach and the feeding was conducted every 2-3 hours, with each meal not exceeding 200 ml. The daily intake was generally consistent with that of the observation group. Besides, after successful intubation, the tube was secured on the infant's face and changed every one to two weeks.
223728844|NCT06126133|DEVICE|Near Infrared Spectroscopy|Two NIRS probes will be attached to the extremity to be operated on and to the other lower extremity on the opposite side, at a level approximately coinciding with the midline above the quandriceps femoris muscle.
223728845|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
223728846|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
223728847|NCT01657045|BIOLOGICAL|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
223728848|NCT04862845|DRUG|Duloxetine and Pregabalin|will be received pregabalin with duloxetine 90 minutes preoperatively, then pregabalin every 12 hours with duloxetine once daily postoperatively until the fifth postoperative day.
223728849|NCT04862845|DRUG|pregabalin|received pregabalin with a placebo capsule at 90 minutes preoperatively, then every 12 hours postoperatively with a placebo capsule once daily until the fifth postoperative day.
223728850|NCT04862845|DRUG|sham|received two placebo capsules at 90 minutes preoperatively then placebo capsules every 12 hours, with one capsule daily postoperatively until the fifth postoperative day.
223728851|NCT01370174|OTHER|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
223988884|NCT05369949|OTHER|Control group|Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
223988885|NCT01791998|PROCEDURE|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
223988886|NCT01791998|PROCEDURE|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
223988887|NCT02611453|OTHER|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
223988888|NCT04696393|DRUG|Mitapivat tablet|Oral tablets
223988889|NCT03051399|DIETARY_SUPPLEMENT|Placebo|The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.
223544641|NCT00506402|DRUG|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
223988890|NCT03051399|DIETARY_SUPPLEMENT|EpiCor|The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
223988891|NCT00925392|DRUG|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
223988892|NCT00925392|DRUG|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
223988893|NCT01964846|DIETARY_SUPPLEMENT|Resveratrol, curcumin|
223988894|NCT01964846|DIETARY_SUPPLEMENT|Placebo|
223988895|NCT01434680|BIOLOGICAL|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
224121002|NCT00170248|DEVICE|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
223544642|NCT01065025|DRUG|4SC-205|Repeated ascending oral doses of 4SC-205.
223544643|NCT05232214|DEVICE|Biometry|Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
223988896|NCT01434680|BIOLOGICAL|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
223988897|NCT01434680|BIOLOGICAL|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
223988898|NCT04819061|OTHER|tDCS Active|This group will undergo the motor training and active tDCS. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks. We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies.
223988899|NCT04819061|OTHER|tDCS sham|"This group will undergo the motor training and tDCS sham. Will be performed 12 sessions in three sessions per week for 30 minutes. Participants will undergo an electroencephalogram before starting the clinical trial. The duration between this baseline EEG and entry into the clinical trial that will assess the effectiveness of tDCS will be two weeks.~We will determine the clinical improvement labels used for machine learning classification based on data obtained during the clinical trial (baseline and post-treatment assessments), according to procedures conducted in similar studies."
224121003|NCT04841382|OTHER|Supporting information.|CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.
224121004|NCT04611295|PROCEDURE|Teleneurological evaluation and support|The study is aimed at developing a remote neurological consultancy system (teleconsultation) for patients with acute neurological symptoms in charge of hospital facilities without 24-hour availability of neurologist consultant.
224121005|NCT04848116|DRUG|Nivolumab|Nivolumab is an investigational drug in this study.
224121006|NCT04848116|DRUG|HuMax-IL8|HuMax-IL8 is an investigational drug in this study.
224121007|NCT04962321|BEHAVIORAL|Wellness Education|Psychoeducation on relationships between mood, anxiety, eating, and exercise behaviors. One one-hour session each week for 8 weeks.
223544644|NCT03822143|DIAGNOSTIC_TEST|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
223544645|NCT03915158|PROCEDURE|bariatric surgery|sleeve gastrectomy
224121008|NCT00002118|DRUG|Zalcitabine|
223544646|NCT05862974|DRUG|LPM3480392|Intravenous infusion of 30min duration
223544647|NCT05862974|DRUG|Placebo|Intravenous infusion of 30min duration
223544648|NCT03700164|OTHER|Temperature|Water-perfused suit.
223544649|NCT03389308|DRUG|diacerein 1% ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
223544650|NCT03922464|DEVICE|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV-associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
223988900|NCT03947008|OTHER|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
223988901|NCT02939339|DEVICE|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
223988902|NCT02939339|DEVICE|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
223988903|NCT04617249|PROCEDURE|median anesthesia|giving median anesthesia
223988904|NCT04617249|PROCEDURE|paramedian anesthesia|giving paramedian anesthesia
224121009|NCT05930249|BEHAVIORAL|Personalized multidomain intervention|"1. Patients will complete personalized cognitive training based on baseline fNIRS on APP (20-30 mins/day, 3-4 days/week, 6 months).~2. Shared decision-making on risk factor of stroke between doctors and patients~3. Social support by grouping patients online to ensure close interaction with other patients in the same arm"
224121010|NCT02564159|OTHER|Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels|"* Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels"
224121011|NCT01912040|DRUG|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
223988905|NCT01515943|OTHER|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
224121012|NCT03616769|DRUG|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
224121013|NCT01818557|BEHAVIORAL|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
224121014|NCT03488940|DEVICE|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
224294541|NCT04464993|BEHAVIORAL|Earn sedentary screen time through moderate-vigorous physical activity: EARN|Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a \>5 min continuous bout of exercise (as defined by Fitbit minutes \>4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
224294542|NCT04266795|DRUG|Pevonedistat|Pevonedistat IV infusion.
224294543|NCT04266795|DRUG|Venetoclax|Venetoclax tablets.
224294544|NCT04266795|DRUG|Azacitidine|Azacitidine IV or SC injection.
223544651|NCT03100448|DEVICE|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
223544652|NCT05060692|DIAGNOSTIC_TEST|Bloot testing|NFL measruments in serum
223544653|NCT01952743|PROCEDURE|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
223544654|NCT01952743|PROCEDURE|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
224294545|NCT02680418|DRUG|FDL169|
224294546|NCT06688916|BEHAVIORAL|Behavioral assessment|A comprehensive behavioral assessment of embodiment and its effect on daily living, taking into account pain, interoception, emotions and anxiety, sleep quality, life satsfaction and cognition.
223988906|NCT01515943|PROCEDURE|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
223988907|NCT01515943|OTHER|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
223988908|NCT01515943|PROCEDURE|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:~* Weeks 1-4: View the target through prism flippers~* Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers~* Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
223988909|NCT03020069|DEVICE|CGMS Device|
223988910|NCT03020069|OTHER|No Device|
224294547|NCT06688916|BEHAVIORAL|Functional Magnetic Resonance Imaging (fMRI)|"Neural mechanisms of embodiments will be explored with MRI sequences including structural MRI, resting-state and task-based fMRI of the head.~The task will be a modified version of the rubber hand illusion, previously used to asess embodiment. Participants will be required to lay in the MRI with their legs bended upright and a screen placed at the level of their hips, which will show a pair of legs. The participant's leg will be stroked with a paintbrush while the image on the screen will be showing the virtual legs being stroked. Participants will be required to report how strongly they perceive the virtual legs as their own, as a measure of embodiment."
223988911|NCT01535651|BEHAVIORAL|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
223988912|NCT02655289|DEVICE|Modulated TENS|"* Frequency: 100 Hz~* Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~* Mode: intensity modulation (40% decrease every 0.5 seconds)~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
223988913|NCT02655289|DEVICE|Placebo TENS|"* Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~* Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~* Mode: continuous~* TENS device: ARTROSTIM® SELECT~* Channels: 2~* Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
223988914|NCT05572749|DIETARY_SUPPLEMENT|Crocus Kozanis|In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.
223988915|NCT05572749|DIETARY_SUPPLEMENT|Placebo of Crocus Kozanis|Placebo of Crocus Kozanis
223988916|NCT05572749|DRUG|Metformin|Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.
223988917|NCT02204020|DRUG|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
223988918|NCT05163795|PROCEDURE|Lateral locking plate|Plating of the distal femur fracture with lateral locking plate.
223988919|NCT01951404|DRUG|Allopurinol|
223988920|NCT01951404|DRUG|Placebo (for allopurinol)|
223728852|NCT05545254|GENETIC|genetic testing|Two questionnaires were included in the link, one referring to the demographic information, and another one involving the health-promoting lifestyle. In the demographic information, the genetic test results were not requested to be written, but the participants need to answer whether they understand the results. The HPLP-Ⅱ is an scale instrument used to evaluate a person's health-promoting lifestyle behaviors, which contains 52 items and has been translated into Chinese in 1997. It contains 6 subscales: self-actualization, health responsibility, physical activity, nutrition, interpersonal relationships and stress management.
223728853|NCT04997161|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Participants in the active arm will receive SZC dosed as per the local label to control hyperkalaemia and maintain normokalaemia.
223988921|NCT04684667|DRUG|Propranolol Therapy for Infantile Hemangioma|If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
223544655|NCT03198767|DRUG|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
223988922|NCT03236532|DIETARY_SUPPLEMENT|Glutamine and exercise|
223988923|NCT03236532|DIETARY_SUPPLEMENT|Maltodextrin and exercise|
223988924|NCT04435444|OTHER|Masterful supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
223728854|NCT04997161|OTHER|Enhanced dietary advice|Participants will receive enhanced dietary advice in addition to taking SZC. This will include advice from dietitians to consume fruit and vegetables. Participants will be encouraged to consume up to 70 mmol K+ per day.
224294548|NCT05049031|OTHER|Questionnaire|A questionnaire will be given to patients who will ask them about their possible fractures, their bone and oncological follow-ups and their possible cardiovascular events since the end of treatment with hormone therapy.
223988925|NCT04435444|OTHER|Attention control supportive care|"Three study questionnaires:~Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)"
223988926|NCT05224843|BEHAVIORAL|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
223988927|NCT05834192|OTHER|Backward treadmill walking|Backward Treadmill walking will be given to this group. Speed settings of treadmill will be established based on the previous motor function of participants. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.
223988928|NCT05834192|OTHER|Lower extremity cross training|"For cross-training, a strong resistance will be applied by the therapist until a response will be achieved on the contralateral lower extremity at the end range of motion. Resistance will be consistently applied for 10 seconds once a response will be achieved.~All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down."
223988929|NCT03684876|PROCEDURE|diuretic use|use of diuretic
223988930|NCT03422445|DRUG|Apatinib|Apatinib：500mg/d，qd，po，d1-28
223988931|NCT03422445|DRUG|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
223988932|NCT01613690|DRUG|NVA237|NVA237 is administered via a BREEZHALER device
223988933|NCT02422680|PROCEDURE|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
223988934|NCT06830850|DRUG|HRS-5041 Single dose of HRS-5041 orally administered|HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle.
223988935|NCT04663477|DIAGNOSTIC_TEST|patient-completed Caprini Risk Score|The participants will be asked to complete patient-completed Caprini Risk Score
223728855|NCT04997161|OTHER|Standard dietary advice including K+ restriction.|Participants randomised to the SoC arm of the Diet Comparison Phase will receive standard dietary advice including K+ restriction.
223988936|NCT02294747|DEVICE|Sliding Hip Screw with Trochanteric Stabilization Plate|
223988937|NCT02294747|DEVICE|Sliding Hip Screw without Trochanteric Stabilization Plate|
223988938|NCT05058053|OTHER|Cold application|Cold application was applied a total of 12 times on the infused PVC with cold gel packs for 15 minutes at 2-hour intervals.
223988939|NCT01135654|OTHER|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
224294549|NCT00810628|BEHAVIORAL|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
224294550|NCT04847596|OTHER|Ofatumumab|Prospective observational cohort study. There is no treatment allocation. Patients administered Ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
224294551|NCT04847596|OTHER|Covid-19 vaccine|Prospective observational cohort study. There is no treatment allocation. Participants will obtain the COVID-19 FDA approved Emergency Use mRNA vaccine through their HCP (private insurance) or appropriate federal, state or local program.
223728856|NCT01500161|DRUG|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
223728857|NCT01500161|DRUG|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
223728858|NCT01500161|DRUG|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
224294552|NCT02498535|DRUG|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
223988940|NCT03415243|DRUG|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters \[mcL\]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel \[MBq\] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
223988941|NCT03415243|DRUG|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi\[4MBq\]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
223988942|NCT03258320|DRUG|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
223988943|NCT05230537|DRUG|Iptacopan (LNP023)|oral capsules
223988944|NCT05230537|DRUG|Placebo|oral capsules
223988945|NCT05364580|BIOLOGICAL|PROTOXIN|Botulinum toxin Type A
223988946|NCT05364580|BIOLOGICAL|Botox®|Botulinum toxin Type A
223988947|NCT05867017|OTHER|Measure of physiologic parameters|Participants will have hepatic muscle and adipose tissue insulin sensitivity tested
223988948|NCT04796220|DEVICE|Focused Ultrasound|Focused ultrasound will be applied to up to 2 breast lesions on day 8.
223988949|NCT04796220|OTHER|Gemcitabine and Focused Ultrasound|Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
223988950|NCT04762888|PROCEDURE|Computed Tomography|Undergo PET/CT
224121015|NCT03488940|DEVICE|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
224121016|NCT03488940|DEVICE|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV\<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV\>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
224121017|NCT04196036|PROCEDURE|Day of vitrification|Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5
224121018|NCT00933335|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
224121019|NCT03519308|DRUG|Nivolumab|Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
224121020|NCT03519308|DRUG|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
224121021|NCT03519308|DRUG|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
223728859|NCT01500161|DRUG|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
224121022|NCT03519308|DRUG|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
224121023|NCT02480075|OTHER|Observational|Observational Study only
224121024|NCT00739778|OTHER|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
224121025|NCT00739778|OTHER|food vehicle blank|water blank
224121026|NCT00739778|OTHER|food - sweetener, positive control|4.7% sucrose in water
224121027|NCT00739778|OTHER|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
224121028|NCT03688646|DIETARY_SUPPLEMENT|Intensive Nutrition Intervention|
224121029|NCT05754827|DIAGNOSTIC_TEST|RDW to platlet count ratio|RDW to platlet ratio will be measured for all patients and results will be compared between groups
224121030|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
224121031|NCT04098926|RADIATION|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
223988951|NCT04762888|DRUG|Gallium Ga 68 Gozetotide|Given IV
223988952|NCT04762888|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223988953|NCT04762888|PROCEDURE|Positron Emission Tomography|PET/MRI or PET/CT
223988954|NCT06261957|DRUG|Salbutamol HFA-134a|100 microgram (μg) (ex-valve) at 30-second intervals per actuation
223988955|NCT06261957|DRUG|Salbutamol HFA-152a|100 μg (ex-valve) at 30-second intervals per actuation
224121032|NCT06242340|OTHER|Preterm group bathing 24 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
224121033|NCT06242340|OTHER|Preterm group bathing 48 hours after birth.|Preterm (between 32 0/7 and 36 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
224121034|NCT06242340|OTHER|Early term group bathing 24 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 24 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
224121035|NCT06242340|OTHER|Early term group bathing 48 hours after birth.|Early term (between 37 0/7 and 38 6/7 weeks) babies (n=30) were bathed in the form of a shower 48 hours after birth. Before the bath, after the bath, 10 minutes after the bath and 60 minutes after the bath, heart rate, body temperature, respiratory rate, oxygen saturation value, and skin color were evaluated.
224121036|NCT04621123|BIOLOGICAL|Convalescent anti-SARS-CoV-2 MBT plasma|Subjects randomized to combination convalescent anti-SARS-CoV-2 MBT plasma plus SMT will undergo an ABO compatibility test and will receive a single infusion of 200 to 300 ml of ABO-compatible convalescent plasma
224121037|NCT04621123|OTHER|Control Group|Subjects randomized to placebo plus SMT will receive one infusion of 200 to 300ml of sterile saline solution 0.9%.
224121038|NCT03105154|OTHER|Prevena Dressing|Prevena dressing is applied on one groin
224121039|NCT03105154|OTHER|Conventional Dressing|Conventional dressing is applied on the contralateral groin
224121040|NCT04734756|DEVICE|Dragonfly Transcatheter Mitral Valve Repair System|To conduct edge-to-edge repair with Dragonfly System under the guidance of transesophageal echocardiography.
223728860|NCT01500161|DRUG|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
223728861|NCT01500161|DRUG|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
223988956|NCT06151899|OTHER|Kinesio taping with angle and tension|Kinesio taping by applying angle and tension to back muscle
223988957|NCT05634876|BIOLOGICAL|UB-312 Injection|UB-312, provided by Vaxxinity, contains 300 μg of p4573kb Drug Substance (synthetic peptide immunogen) formulated with CpG1 and Adju-Phos as a white, opaque, liquid suspension. The biological will be injected intramuscularly. The injection site will be the deltoid muscle.
223988958|NCT05634876|BIOLOGICAL|Placebo Injection|Placebo will be injected intramuscularly. The injection site will be the deltoid muscle.
223988959|NCT06062212|PROCEDURE|Transpulmonary pressure|Use transpulmonary pressure to guide ventilator setting in ECMO for severe ARDS patients.
223988960|NCT06348134|DRUG|Trastuzumab emtansine|A chemotherapy drug.
223988961|NCT06348134|DRUG|Pertuzumab Injection|A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
223988962|NCT06348134|DRUG|Docetaxel|A chemotherapy drug.
223988963|NCT06348134|DRUG|Tamoxifen|A medication used to treat breast cancer.
223988964|NCT06348134|DRUG|Letrozole|A medication used to treat breast cancer.
223988965|NCT06348134|DRUG|Goserelin|A hormone therapy drug.
223988966|NCT06571669|DEVICE|Neuromodulation|Neuromodulation
223988967|NCT06011200|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
223988968|NCT06011200|BIOLOGICAL|MSPV4|1 dose of MSPV4 on Day 0
223988969|NCT05233891|PROCEDURE|Breast reconstruction|Breast reconstruction after breast cancer.
223988970|NCT05233891|PROCEDURE|Breast reduction|Breast reduction due to breast hypertrophy.
223988971|NCT03593278|DRUG|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
223988972|NCT05844930|DRUG|Corticosteroid|Triamcinolone 20 mg (1cc)
223988973|NCT05844930|OTHER|ActiveMatrix|1cc ActiveMatrix (Skye Biologics, Inc.)
223988974|NCT05844930|DRUG|Lidocaine|Lidocaine 10 mg/mL (5cc)
223988975|NCT06001008|OTHER|PQA|PQA is a questionnaire consisting of 16 questions developed to measure the quality of anesthesia service received by patients based on their experiences. Patients will be asked to answer questions by the researcher 24 hours after surgery.
223988976|NCT02078726|DRUG|Glucagon|glucagon (hormone produced by the body) administered through IV
223988977|NCT04400292|OTHER|Injection of indocyanine green (ICG)dye|Patients will receive a perilesional injection of indocyanine green (ICG) before the laparoscopic phase of the esophagectomy.
224121041|NCT02350894|BEHAVIORAL|Graded and behavevial theraphy|Graded and behavevial theraphy
224121042|NCT03829189|DIETARY_SUPPLEMENT|inulin|prebiotic supplement
224121043|NCT03829189|DIETARY_SUPPLEMENT|maltodextrin|placebo supplement
224121044|NCT06024330|DIAGNOSTIC_TEST|VAN assessment|An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.
223988978|NCT04400292|DEVICE|Near-Infrared Image-Guided|Real-time near-infrared (NIR) fluorescence imaging will be performed by use of the Novadaq PINPOINT minimally invasive system with a laparoscopic camera.
223988979|NCT04400292|PROCEDURE|Sentinel Lymph Node (SLN) mapping|Any identified SLNs will be dissected during the standard completion lymphadenectomy and esophagectomy.
223988980|NCT02130245|PROCEDURE|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
223988981|NCT02130245|PROCEDURE|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
223988982|NCT02383992|DRUG|3% H2O2 solution|
223988983|NCT02383992|DRUG|0.9% normal saline|
223988984|NCT02453061|DRUG|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
223988985|NCT02453061|DRUG|Placebo|Safflower oil orally administered at 1g/kg/day
223988986|NCT06182345|PROCEDURE|spray skin|autologous skin cell suspension combined with skin graft
223988987|NCT06182345|PROCEDURE|skin graft|skin graft
223988988|NCT02484378|DRUG|CER-001|Engineered pre-beta HDL particle
223988989|NCT02484378|DRUG|Placebo|Normal saline
223988990|NCT02605486|DRUG|Palbociclib|
223988991|NCT02605486|DRUG|Bicalutamide|
223988992|NCT03836573|BEHAVIORAL|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
223988993|NCT02761798|DEVICE|Automated Mobile Interactive Audiometer|iPad game
224121045|NCT06024330|DIAGNOSTIC_TEST|VES assessment|An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.
224121046|NCT06024330|DIAGNOSTIC_TEST|LARIO assessment|An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
224121047|NCT00995735|PROCEDURE|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
224121048|NCT00995735|PROCEDURE|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
223544656|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 50%|50% carbohydrate in breakfast meal
223988994|NCT05765435|OTHER|12-week exercise and walking program|The exercise program requires isometric quadriceps contractions in a supine position with a rolled-up towel placed behind the knee. The exercise program will be performed by participants 5 days per week for 12 weeks. The walking program will be performed 3 days per week for 12 weeks. Participants will walk for 10 minutes and then gradually increase walking time to 30 minutes by the end of the study. Participants will wear the device during the exercise and walking program, which may range from 1 minute to 35 minutes per day.
223988995|NCT05765435|DEVICE|NMES|Sleeve applies neuromuscular stimulation during exercises to help contract appropriate muscles at appropriate times.
223988996|NCT05765435|DEVICE|FES|Sleeve applies functional electrical stimulation as patients walk to help contract appropriate muscles at appropriate times.
223988997|NCT01985815|DEVICE|VC/VS stimulation|
223988998|NCT00333905|PROCEDURE|Ischemic exercise training|
223988999|NCT03834389|BEHAVIORAL|Case- based Learning|critical thinking, self efficacy, focus group interview
223989000|NCT01467310|DRUG|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
223989001|NCT05172492|DEVICE|Endocare|Endocare will be administred through a virtual reality headseat used one to twice a day.
223989002|NCT05172492|DEVICE|Digital control|Digital control will be administred through a virtual reality headseat used one to twice a day.
223989003|NCT04377854|OTHER|Observation. No intervention per se.|Observation. No intervention (no collection of blood).
223989004|NCT04377854|OTHER|2) Observation and collection and of blood sample|All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
223989005|NCT01597843|OTHER|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
224121049|NCT02911363|DEVICE|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
224121050|NCT02911363|OTHER|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
224121051|NCT05699616|PROCEDURE|Repair of perforated peptic ulcer|Repair of perforated peptic ulcer either open or laparoscopic.
224121052|NCT05868967|DRUG|[14C]DWP14012|Each subject will receive a single oral dose of \[14C\]DWP14012 suspension (containing approximately 40 mg/80 μCi \[14C\]DWP14012) under fasting conditions.
224121053|NCT03067662|OTHER|Aerobic exercise|
223989006|NCT00166062|PROCEDURE|Screening patients for IPV|
223989007|NCT02701062|DEVICE|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
223989008|NCT02701062|DRUG|Anticoagulation Therapy|Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
224121054|NCT01461863|DIETARY_SUPPLEMENT|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
224121055|NCT01461863|DIETARY_SUPPLEMENT|multivitamin|Standard multivitamin
224121056|NCT02385461|DRUG|Low Molecular Weight Heparins (LMWHs)|
224121057|NCT03059303|DRUG|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
223544657|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 25%|25% carbohydrate in breakfast meal
223544658|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 8%|8% carbohydrate in breakfast meal
223544659|NCT03198767|DIETARY_SUPPLEMENT|Carbohydrate 0%|0% carbohydrate in breakfast meal
223544660|NCT03198767|DIETARY_SUPPLEMENT|Psyllium|Powder 6 grams
223544661|NCT03198767|DIETARY_SUPPLEMENT|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
223544662|NCT00570323|DRUG|Arimidex|Aromatase inhibitors
223989009|NCT00517049|DRUG|PRO95780|Intravenous repeating dose
223989010|NCT00517049|DRUG|rituximab|Intravenous repeating dose
223989011|NCT03363347|DRUG|Redifferentiation with retinoid acid|In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
223989012|NCT02677077|DRUG|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
224121058|NCT03059303|DRUG|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
224121059|NCT03059303|DRUG|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
224121060|NCT03059303|DRUG|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
223989013|NCT00151398|DRUG|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
223989014|NCT00151398|DRUG|Donepezil|10 mg donepezil QD dosed up to 40 weeks
223989015|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from animal sources.|Diet was prescribed to the participant and menus and recipes were also provided.
223989016|NCT05456347|BEHAVIORAL|Low-calorie and high-protein diet with the majority of protein coming from plant sources.|Diet was prescribed to the participant and menus and recipes were also provided.
223989017|NCT00121121|BIOLOGICAL|Lipopeptides LIPO-4|
223989018|NCT03823144|DEVICE|Diagnostic Microscopy|Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
223989019|NCT03823144|DRUG|Fluorescein Sodium Injection|Given IV as part of IVM procedure
223989020|NCT00337753|BEHAVIORAL|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
223989021|NCT00337753|BEHAVIORAL|Wait-list|subjects assigned to wait-list condition for six-weeks
223989022|NCT04952363|DEVICE|A vertical vibration platform PowerVibe Zen Pro 5900|Subjects received the interventions twice a week for 8 weeks. HFCWO+WBVT group received additional 30 minutes WBVT treatment. In every WBVT session, three rounds of 3 minutes of vibration (amplitude: 2 mm; frequency: 20 Hz) were provided, with a 60-second rest between rounds.
223989023|NCT04952363|DEVICE|HFCWO|Subjects received the interventions twice a week for 8 weeks. The HFCWO was delivered by a respiratory therapist using a percussive vest at 10-13 Hz oscillating frequency and at a pressure setting of 2 cm H2O. The treatment duration was 25 minutes, and the participants remained in a sitting position.
223989024|NCT04546802|DRUG|Elbasvir / Grazoprevir Oral Tablet|Elbasvir / Grazoprevir
223989025|NCT05988242|OTHER|Primrose oil|group A will take primrose oil
223989026|NCT05988242|OTHER|Lavender oil|group B will take lavender oil
223989027|NCT05988242|OTHER|placcebo|this is the comparator group who will take the same bottle of oil which dosnt contain the active substances but have the sampe shape, same oder, same color
223989028|NCT00697398|OTHER|Transcranial stimulation|Stimulation to white
223989029|NCT00697398|OTHER|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
223989030|NCT01973140|DRUG|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
223989031|NCT01973140|DRUG|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
223989032|NCT02738528|OTHER|Mental practice and brushing guidance in patients with Parkinson Disease|
223989033|NCT02162498|BEHAVIORAL|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
223989034|NCT02015988|DRUG|Fenofibrate|
223989035|NCT02015988|DRUG|Simvastatin|
223989036|NCT04434248|DRUG|Favipiravir|200 mg coated tablets
223989037|NCT04434248|DRUG|Standard of Care|Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
223989038|NCT05633069|OTHER|Datas analysed by medical records|"Datas analysed by medical records : pupillary parameters: pupillary diameter and pupillary diameter variation. heart rate, the blood pressure, the Behavioral Pain Scale (BPS) pain score before and during painful procedures.~The pupillary parameters were recorded with the AlgiScan® pupillometer (iDMed, Marseille, France), which allows the recording of Pupillary Diameter (PD) variations at the patient's bed at a sampling frequency of 67 hertz."
223989039|NCT05627869|PROCEDURE|Transversus thoracic plane block|TTPB group will receive bilateral ultrasound-guided transversus thoracic muscle plane block using 20 ml of bupivacaine 0.25% for each side.
223989040|NCT05627869|PROCEDURE|Pecto intercostal fascial block|PIFB group will receive bilateral ultrasound-guided Pecto-intercostal fascial plane block using 20 ml of bupivacaine 0.25% for each side.
223989041|NCT03003377|DEVICE|laryngeal mask supreme|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
223989042|NCT03003377|DEVICE|laryngeal mask proseal|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
223989043|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
223989044|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm A (day 1)
223989045|NCT00701324|DRUG|BI 811283|dose escalation BI 811283, Arm A (day 15)
223989046|NCT05252845|BIOLOGICAL|R21/Matrix-M vaccination|R21/Matrix-M is the standard formulation of the vaccine (Once prepared, a standard dose of R21/Matrix-M contains approximately 5 µg of R21 antigen, in 0.5 mL of liquid adjuvant containing 50 µg MatrixM). The reconstituted vaccine will be administered by slow IM injection on Day 0 at Study Months 0, 1 and 2.
223989047|NCT05252845|DRUG|DHA-PIP|Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day dihydroartemisinin and 16-26 mg/kg/dose piperaquine. Participants will receive three rounds of antimalarial drugs - each round starting on the day of vaccination (Day 0) at Study Months 0, 1 and 2. Each round consists of three daily doses of co-formulated dihydroartemisinin/piperaquine on Day 0, 1, and 2.
223989048|NCT05252845|DRUG|PQ|Each participant will receive a single low dose primaquine on the day of vaccination (Day 0) at Month 0, Month 1, and Month 2. One single low dose primaquine of approximately 0.25 mg/kg will be administered.
224121061|NCT03059303|DRUG|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
224121062|NCT03059303|DRUG|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
224294553|NCT06257316|DRUG|EPHEDrine Hydrochloride 5 mg/ml|"In the present study, the expected rate of recovery of the internal carotid artery according to the dose of the inotropic agent was similar to that in a previous study in which the fraction maintaining mean arterial pressure within 80% of baseline by dose of inotropic agent was 0.9% for the ephedrine 0.1, 0.6, 0.8, 1. 0, 1.2, and 1.4 doses (mg/kg) were 9.9%, 21%, 41%, 47%, 65.5%, and 40%, respectively (Br J Anaesth. 2023 May;130(5):603-610), and it was assumed that the rate of internal carotid artery recovery by inotrope dose would be 90% of that result.~The study will randomize to dose in six cohorts and will include dose group and cohort variables in a logistic regression model to assess the trend between inotropic dose and rate of carotid revascularization after correcting for cohort effects on the outcome variable."
224121063|NCT03059303|DRUG|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
224121064|NCT05926986|OTHER|Exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise. Additionally, pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
223544663|NCT00570323|DRUG|Faslodex|Hormone Receptor
224121065|NCT05926986|OTHER|control|No additional treatment will be practiced to the control group.
224121066|NCT05379023|BEHAVIORAL|Face-to-face evaluation (FF)|The intervention is the assessment modality. The control condition is face-to-face evaluation (FF).
224121067|NCT05379023|BEHAVIORAL|TeleNP evaluation|The intervention is the assessment modality. The intervention condition is TeleNP evaluation.
224294554|NCT03351231|DRUG|BMS-986242|Specified dose on specified days
224294555|NCT03351231|BIOLOGICAL|Nivolumab|Specified dose on specified days
224121068|NCT00493116|DRUG|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
223989049|NCT02061059|OTHER|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
223989050|NCT02061059|OTHER|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
224121069|NCT00493116|DRUG|methylprednisolone|dosage and frequency as per Biogen Idec protocol
224294556|NCT00280176|DRUG|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
224294557|NCT00280176|DRUG|fluorouracil|225mg/m2 given weekly, up to 6 weeks
224294558|NCT00280176|RADIATION|radiation therapy|180 cGy, every 5 days, up to six weeks
223728862|NCT01500161|DRUG|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
223989051|NCT02061059|OTHER|standard|patient wears shoes produced with standard method
223989052|NCT02061059|OTHER|with measurements|patient wears shoes produced with plantar pressure measurements
223989053|NCT06474299|DRUG|Varenicline|0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (at least 8 hours apart) for 4 days prior to the TQD. On the 8th day (the TQD), participants will increase to their target maintenance dose of a 1 mg pill twice daily
223989054|NCT06474299|DRUG|Nicotine patch|Following package inserts starting on the TQD, participants who smoke \>10 cigarettes per day at baseline will be given 8 weeks of 21 mg nicotine patches, followed by 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches. Participants who smoke ≤10 cigarettes per day at baseline will be given 10 weeks of 14 mg nicotine patches followed by 2 weeks of 7 mg patches.
223989055|NCT06474299|BEHAVIORAL|Dual Focused Cessation Counseling|Dual Focused Cessation Counseling will focus on quitting both smoking and vaping. Specifically, participants will be instructed to change smoking and vaping patterns (e.g., not smoking or vaping in specific places such as the car or at specific times of day) prior to quitting and to practice cessation coping strategies (e.g., distraction techniques, getting social support).
223989056|NCT06474299|BEHAVIORAL|Smoking Focused Cessation Counseling|Smoking Focused Cessation Counseling will focus on quitting smoking and using ENDS as a harm reduction strategy (i.e., using ENDS as a substitute for cigarettes).
223989057|NCT06474299|OTHER|Counseling Intensity: 1 Session|Participants assigned to one session will complete a single, 15-20 minute, session at Visit 2 (1 week pre-TQD).
223989058|NCT06474299|OTHER|Counseling Intensity: 4 Sessions|Participants assigned to intensive counseling will have four, 15-20-minute sessions.
224294559|NCT01745354|DRUG|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
223989059|NCT00781937|DRUG|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
223989060|NCT00781937|DRUG|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
223989061|NCT01263249|PROCEDURE|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
223989062|NCT01263249|PROCEDURE|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
223989063|NCT04920747|DRUG|Taxane|docetaxel or paclitaxel
223989064|NCT02967276|DRUG|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
223989065|NCT02967276|DRUG|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
223989066|NCT04698915|DRUG|Drug GC4711|15 Minute IV Infusion
223989067|NCT04698915|DRUG|Placebo|15 Minute IV Infusion
223989068|NCT02992847|OTHER|Unenhanced MRI|
223544664|NCT04636567|DRUG|Nerindocianine for injection|Procedure: routine minimally invasive abdominopelvic surgery.
223544665|NCT03067792|DRUG|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
223544666|NCT03067792|DRUG|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
223544667|NCT05734664|DEVICE|Pulsify sensor|A positioning system will move the 1X1 cm Pulsify sensor step-by-step over a marked area of 10x10 cm on the subjects' chest to record a complete 3D data set of the heart. For accurate 3D reconstruction, the ECG and breathing cycle are also recorded during the acquisition using commercially available devices (Bitalino HeartBIT + Respiration Sensor). From the 3D dataset of the heart, the end-systolic and end-diastolic volumes will be extracted automatically to calculate the cardiac output.
223989069|NCT03964051|DRUG|Omalizumab Injection|Omalizumab 300 mg for subcutaneous injection
223989070|NCT00236262|DEVICE|ventilatory strategies with pressure|
223989071|NCT01907906|DEVICE|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
223989072|NCT00791193|DRUG|Paliperidone ER|
223989073|NCT01430637|GENETIC|DNA analysis|
223989074|NCT01430637|GENETIC|RNA analysis|
223989075|NCT01430637|GENETIC|gene expression analysis|
223989076|NCT01430637|GENETIC|mutation analysis|
223989077|NCT01430637|GENETIC|nucleic acid sequencing|
223989078|NCT01430637|GENETIC|polymerase chain reaction|
223989079|NCT01430637|OTHER|laboratory biomarker analysis|
223989080|NCT01430637|OTHER|pharmacogenomic studies|
224121070|NCT01926379|BEHAVIORAL|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators."
223989081|NCT00002430|DRUG|Indinavir sulfate|
223989082|NCT00002430|DRUG|Nelfinavir mesylate|
223989083|NCT00002430|DRUG|Lamivudine|
223989084|NCT00002430|DRUG|Stavudine|
223989085|NCT06109597|OTHER|75 g glucose tolerance test|Pregnant patient who visited obstetric clinic , who did 75 g glucose tolerance test
223989086|NCT02407210|DRUG|azilsartan|
223989087|NCT02407210|DRUG|Olmesartan medoxomil|
223989088|NCT03234946|BEHAVIORAL|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
223989089|NCT04855942|DEVICE|Focused Extracorporeal Shock Wave Therapy (ESWT)|2000 impulses of 5 Hz and 0.32 mJ/mm2 , twice per week for 3 weeks
223989090|NCT04855942|DEVICE|physiotherapy|therapeutic ultrasound, 12 times in 3 weeks
224121071|NCT01926379|DRUG|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
223989091|NCT04025268|BEHAVIORAL|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
223989092|NCT04025268|BEHAVIORAL|Standard of Care|Standard of prenatal care
223989093|NCT03435146|COMBINATION_PRODUCT|3HP plus DTG +2NRTIs|"* HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC (Groups 1 and 2) or with TDF/3TC (Groups 3 and 4).~* LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg (Groups 1,2 and 4) Isoniazid at standard of care dosing (Group 3)"
223989094|NCT04253847|PROCEDURE|Radical antegrade modular pancreatosplenectomy|"Radical antegrade modular pancreatosplenectomy (RAMPS) includes the following aspects. Firstly, the surgical approach is antegrade, which means from the right to the left, the pancreatic neck will be transected at first and the spleen will be seperated at last. Secondly, lymph nodes dissection includes not only the regional lymph nodes(No.10,11,18 lymph nodes), but also N1 station lymph nodes (N1: 6, 8a, 8p, 12a2/b2/p2, 13a/b, 14b/c/d, 14v, 17a/b), No.7, 9 lymph nodes, the lymph nodes anterior and left of superior mesenteric artery, as well as the peripheral nerve of celiac trunk. Thirdly, the transection platform is in the pancreatic neck, which is mandatory. At last, left prerenal fascia will be resected. When the tumor abuts or infiltrates the left adrenal gland, left adrenalectomy will be performed, which is also called posterior approach RAMPS. While in normal cases, left adrenal gland will be preserved."
223544668|NCT05734664|DEVICE|State-of-the-art ultrasound equipment|A complete 2D and 3D ultrasound data set using a GE Vivid E95 ultrasound machine, version 203 (General Electric Healthcare, Chicago, IL, United States) will be recorded. All data will be processed offline with a specialized software packet (EchoPAC, version 203, General Electric Healthcare, Chicago, IL, United States
223544669|NCT00402844|DEVICE|Transvaginal mesh- PROLIFT®-system|
223544670|NCT06368284|PROCEDURE|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident|Patients who experienced an ano-perineal trauma following a PWC/Jet-Ski accident between January 2017 and December 2023, managed and followed up in France
223989095|NCT04253847|PROCEDURE|Standard retrograde pancreatosplenectomy|"Standard retrograde pancreatosplenectomy(SRPS) includes several aspects. Firstly, the surgical approach is retrograde, which means from the left to the right, spleen will be seperated at first and the pancreas will be transected later on. Secondly, only the regional lymph nodes will be dissected, which include No.10, No.11, No.18 lymph nodes, and No.9 lymph nodes should be dissected only when the lesion is in pancreatic neck. Thirdly, the transection platform is in the left side of the lesion, but transection at pancreatic neck is not mandatory. At last, the surgical plane is anterior to the left renal fascia, prerenal fascia will be preserved."
223989096|NCT01714167|GENETIC|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
223989097|NCT04029805|COMBINATION_PRODUCT|Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
223989098|NCT04029805|COMBINATION_PRODUCT|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
223989099|NCT03520075|DRUG|ASTX029|PiB
223989100|NCT03520075|DRUG|ASTX029|Tablet
223989101|NCT01947712|DIETARY_SUPPLEMENT|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
223989102|NCT01947712|DIETARY_SUPPLEMENT|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
223989103|NCT02039648|OTHER|Rumex acetosa L. extract|
223989104|NCT02039648|OTHER|Placebo|
223989105|NCT02786004|DEVICE|Full Field Digital Mammography|
223989106|NCT02786004|DEVICE|Digital Breast Tomosynthesis|
223989107|NCT02557126|DRUG|URC102|
223989108|NCT02557126|DRUG|Placebo|
224294560|NCT01745354|RADIATION|Local Radiation|
224121072|NCT03230175|BIOLOGICAL|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
224121073|NCT03230175|PROCEDURE|Surgical resection and debridement|"Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate."
224121074|NCT03230175|DRUG|Systemic antibiotics|Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
224121075|NCT03230175|DEVICE|Off-loading|Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
224121076|NCT02422043|OTHER|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
224121077|NCT00854763|DRUG|olmesartan|olmesartan
224121078|NCT01129791|BEHAVIORAL|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
224121079|NCT01129791|BEHAVIORAL|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
224121080|NCT01129791|BEHAVIORAL|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
224121081|NCT02553720|OTHER|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
224121082|NCT02553720|OTHER|aquatic activity plus conventional management|walking in water or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
224121083|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.5 mL|Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
224121084|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.5 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
223989109|NCT01833689|DIETARY_SUPPLEMENT|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
223989110|NCT00919945|OTHER|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
223989111|NCT00919945|OTHER|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
223989112|NCT01970254|OTHER|Hepatitis B Screening|Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
223989113|NCT01970254|OTHER|Survey Administration|Ancillary studies
223989114|NCT04451811|DRUG|OPL-002|Spray dried dispersion and tablet formulation
223989115|NCT05878912|OTHER|Diet intervention|The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
223989116|NCT01517997|PROCEDURE|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
223989117|NCT01517997|PROCEDURE|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
223989118|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
223989119|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
223989120|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
223989121|NCT02593383|DRUG|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
223989122|NCT02593383|DRUG|Placebo|
223989123|NCT06375486|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)
223989124|NCT03405077|BEHAVIORAL|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
223989125|NCT04860440|DEVICE|GeneActiv wrist worn accelerometer|Wrist worn device worn for 7 days
223989126|NCT03723577|DEVICE|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
223989127|NCT03182998|OTHER|Internet-Based Intervention|"Receive Knowing your Options decision aid"
223989128|NCT03182998|OTHER|Internet-Based Intervention|"Receive Prostate Choice decision aid"
223989129|NCT03182998|OTHER|Best Practice|Undergo usual care
223989130|NCT03182998|OTHER|Quality-of-Life Assessment|Ancillary studies
223989131|NCT03182998|OTHER|Questionnaire Administration|Ancillary studies
223989132|NCT03182998|OTHER|Survey Administration|Ancillary studies
224121085|NCT05470582|BIOLOGICAL|Flu-M, Inactivated split influenza vaccine 0.25 mL|Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
224294561|NCT03940482|BEHAVIORAL|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
224294562|NCT02130778|DRUG|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
223989133|NCT03182998|OTHER|Laboratory Biomarker Analysis|Correlative studies
223989134|NCT01907932|DEVICE|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
223989135|NCT00126659|PROCEDURE|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
223989136|NCT00126659|DRUG|sorafenib tosylate|Given orally
223989137|NCT00126659|OTHER|laboratory biomarker analysis|Correlative studies
223989138|NCT02272361|OTHER|laparoscopic sacrocolpopexy|
223989139|NCT02272361|OTHER|vaginal mesh surgery|
223989140|NCT05021445|COMBINATION_PRODUCT|plates based exercises|12 elderly participants receive intervention protocol of Plates- based exercises program total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
223989141|NCT05021445|COMBINATION_PRODUCT|conventional exercises|12 elderly participants,intervention protocol of Conventional balance training exercises,total 12-sessions will be given for thrice a week for four weeks for 50-minutes.
223989142|NCT02367352|DRUG|Alisertib|Alisertib tablets
223989143|NCT02367352|DRUG|Paclitaxel|Paclitaxel intravenous solution
223989144|NCT04400968|PROCEDURE|Auricular therapy|The auricular therapy points were selected following the protocol for dysmenorrhoea described by Oleson (Oleson, 2008). These points were (the name of the European cartography is specified by the name of the point): Shenmen \[FT2\], uterus \[FT5\], sympathetic \[HI4\], kidney \[CS6\], heart \[CI4\], endocrine \[IT2\] and thalamus \[PC2\].
224121086|NCT05470582|BIOLOGICAL|Vaxigrip, Inactivated split influenza vaccine 0.25 mL|Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
224294563|NCT02130778|OTHER|500 ml 0.9% saline|infusion of saline
224294564|NCT05296382|DRUG|Tebipenem tablet form|Tebipenem tablets will be administered intact or crushed
224294565|NCT05296382|OTHER|Tube feeds|Tebipenem tablets will be administered with or without tube feeds
223989145|NCT04400968|PROCEDURE|kinesio tape|Before the tape application, the skin surface was removed of hair when needed and cleansed. The tapes were applied at 25% of tension and were placed horizontally covering the area between the antero-superior iliac spines and the postero-superior iliac spines and vertically from the navel to the symphysis pubis. All bandages were adhered to the skin with a technique type I with a space augmentation. The centre of the tape was removed and applied at 25% of tension. Afterwards, the rest of the protector were removed and the laterals anchors of the tape were adhered with no tension. The participant maintained a slight extension of the trunk while the tape was applied on the anterior aspect of the truck and a slight flexion while the tape was applied in the posterior aspect of the trunk.
223989146|NCT04400968|PROCEDURE|Auricular therapy Placebo group|Sham auricular therapy
223989147|NCT04400968|PROCEDURE|kinesio tape Placebo group|Sham kinesio tape
223989148|NCT06547567|BEHAVIORAL|Motivational Interviewing|In addition to receiving the same health education intervention as the control group, the children and adolescents in the intervention group will undergo a group-based motivational interviewing intervention. This will be conducted by a professional team that has been trained and is qualified in motivational interviewing. The intervention will embody the spirit of motivational interviewing and the stages of group motivation development, primarily including: introductory tasks, exploratory tasks, expansion tasks, and action planning tasks.
223989149|NCT03931993|BIOLOGICAL|Placebo comparator|
223989150|NCT03931993|BIOLOGICAL|Grass MATA MPL|
223989151|NCT01013961|BIOLOGICAL|alemtuzumab|Given IV
223989152|NCT01013961|BIOLOGICAL|rituximab|Given IV
223989153|NCT01006525|DRUG|zolpidem|placebo or zolpidem (10mg)daily for one year
224294566|NCT00290394|DRUG|rosiglitazone(drug), blood pressure lowering effect|
223989154|NCT02866669|BEHAVIORAL|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
223989155|NCT02866669|BEHAVIORAL|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
223989156|NCT02866669|BEHAVIORAL|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
224121087|NCT02588274|DEVICE|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
224121088|NCT02588274|DEVICE|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
224121089|NCT04187222|OTHER|Mechanical debridements|Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.
224294567|NCT06368557|BEHAVIORAL|CoolMinds: Internet-based cognitive behavioral therapy (iCBT)|The intervention consists of 14 weeks of iCBT, where the main treatment components are psychoeducation, cognitive restructuring, exposure therapy, and relapse prevention. The program comprises eleven sessions for adolescents and ten sessions for parents to be completed simultaneously. The participants will have the opportunity to get therapist feedback during the treatment period, the therapist may spend a maximum of 15 minutes giving feedback per week per participant.
224121090|NCT04187222|BIOLOGICAL|Bifidobacterium animalis subsp. lactis|Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
224294568|NCT06632977|OTHER|Genetic testing|undergo genetic testing
224294569|NCT06632977|DRUG|Valemetostat Tosylate|Given PO
224294570|NCT06632977|PROCEDURE|Magnetic Resonance Imaging|undergo Magnetic Resonance Imaging
224294571|NCT06632977|PROCEDURE|Computed Tomography|undergo Computed Tomography
224294572|NCT06632977|PROCEDURE|Bone scan|undergo Bone scan
224294573|NCT06632977|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET
224294574|NCT06632977|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
224294575|NCT06632977|PROCEDURE|Biospecimen Collection|undergo blood collection
224294576|NCT06632977|DRUG|Carboplatin|Given IV
224294577|NCT06632977|DRUG|Cabazitaxel|Given IV
224294578|NCT06632977|DRUG|Abiraterone Acetate|Given PO
224294579|NCT06632977|DRUG|Enzalutamide|Given PO
224294580|NCT06632977|DRUG|Lutetium Lu 177 Vipivotide Tetraxetan|Given IV
224294581|NCT06142149|PROCEDURE|ultrasonographic evaluation|Screen the front of neck using ultrasound
224294582|NCT04209010|PROCEDURE|one-stage technique|breast reconstruction in one stage using silicone implant and acellular dermal matrix.
224294583|NCT03487848|DRUG|Daclatasvir|Specified dose on specified days for specified duration
224294584|NCT03487848|DRUG|Sofosbuvir|Specified dose on specified days for specified duration
224294585|NCT00731549|DRUG|Aripiprazole IM Depot|300mg or 400mg
223728863|NCT01908374|DIETARY_SUPPLEMENT|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
223728864|NCT05261256|DIAGNOSTIC_TEST|Exercise stress echocardiography|Study participants perform an exercise stress echocardiography on a semi-supine bicycle ergometer using using a continuous incremental bicycle protocol with a work rate increment every 3 minutes according to gender and weight.
223728865|NCT00425360|BIOLOGICAL|sargramostim|
223728866|NCT00425360|BIOLOGICAL|telomerase peptide vaccine GV1001|
223728867|NCT00425360|DRUG|capecitabine|
223728868|NCT00425360|DRUG|gemcitabine hydrochloride|
223728869|NCT00680381|BEHAVIORAL|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
223728870|NCT00680381|BEHAVIORAL|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
223728871|NCT00680381|BEHAVIORAL|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
223728872|NCT03750799|DEVICE|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
223728873|NCT03750799|DEVICE|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
223728874|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
223728875|NCT03810898|RADIATION|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
223728876|NCT04403971|DRUG|0.12% Chlorhexidine Oral Liquid Product|The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
224294586|NCT05946902|DRUG|tolterodine|tolterodine 4 mg per day
223728877|NCT04403971|DRUG|Listerine Oral Liquid Product|The intervention group 2 received 10ml Listerine solution for oral rinse twice a day.
223728878|NCT04403971|OTHER|Normal Saline Product|The control group received 10ml normal saline for oral rinse twice a day.
223728879|NCT00192205|BIOLOGICAL|CAIV-T or TIV|
223728880|NCT00748683|OTHER|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
223728881|NCT05760833|PROCEDURE|Ablation|Ablation of either the pulmonary veins or the atrioventricular node
223728882|NCT00005937|DRUG|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
223728883|NCT00005937|DRUG|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
223728884|NCT06286904|DEVICE|Skiin Garment system|Individuals will be asked to wear a Skiin Garment system for the duration of their hospitalization (minimum one day).The system will collect accelerometer, ECG, temperature, heart rate, steps and sleep metrics data if enable. Then, they will be asked to answer a questionnaire about their experiences with the device and the study.
223728885|NCT06507319|DEVICE|Direct bone anchored pull distal slider|distalization from the palatal side only.
223728886|NCT06507319|DEVICE|Indirect bone anchored dual force distalizer.|distalization from the palatal and buccal sides.
223728887|NCT04068090|OTHER|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
223728888|NCT04068090|OTHER|Blood Collection|biomarker analysis
223989157|NCT03796078|PROCEDURE|Maxillomandibular advancement|Treatment: Mono or Bimaxillary Orthognathic Surgery. The surgery of Reposition of the jaws is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
223989158|NCT03796078|PROCEDURE|monomaxillary surgery (isolated MaxS)|Monomaxillary surgery (Isolated MaxS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
223989159|NCT03796078|PROCEDURE|monomandibullary surgery (MandS)|Monomandibullary surgery (Isolated MandS): The surgery of Reposition of the maxilla is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
223989160|NCT04658563|OTHER|High Density Exercise Training Program - Yoga|A total of 8 weeks will be applied in our study, each session of the high-density yoga program will be started with 10 minute pranayama (breath) exercises as it is in classical yoga as a preliminary preparation for the participation of individuals; the program will be completed by applying 10-20 minutes warming-stretching movements, 40 minutes surya namaskar (SN) sets, 20-30 minutes dynamic yoga asanas and 10 minutes savasana. Participants will be encouraged to study the perceived difficulty levels between 14 and 17 using the Borg scale during the sessions
223989161|NCT02097186|PROCEDURE|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
223989162|NCT03835962|DEVICE|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
223989163|NCT02164019|PROCEDURE|long-stem cemented hemiarthroplasty (LSCH)|
223989164|NCT02164019|PROCEDURE|intramedullary nailing (IMN)|
223989165|NCT02164019|BEHAVIORAL|questionnaires|
223989166|NCT00448006|DEVICE|Allium Biliary Stent|device
223989167|NCT00448006|DEVICE|allium biliary stent|allium biliary stent
223989168|NCT00737828|OTHER|Perioperative care pathway guided by CPX results|"* AT \> 11ml/min/kg no myocardial ischaemia or Ve/VO2 \<35 - Level 1 Ward Care~* AT \> 11ml/min/kg with myocardial ischaemia or Ve/VO2 \>35 - Level 2/3 (ITU) Critical Care Unit~* AT \<11mls/min/kg - Level 2/3 Critical Care Unit~* AT \<8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
223989169|NCT02296749|DRUG|Sirolimus|Sirolimus tablets 2 mg
223989170|NCT00232219|DRUG|Fish oil|
223989171|NCT02813902|DRUG|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
223989172|NCT02813902|OTHER|Sugar Pill|A pill that appears similar to the supplement
223989173|NCT01375751|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223989174|NCT01375751|BIOLOGICAL|Placebo|d by subcutaneous injection
223989175|NCT02980523|DRUG|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
223989176|NCT02980523|DRUG|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
223989177|NCT02980523|DRUG|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
223989178|NCT02980523|DRUG|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
223989179|NCT00254969|BIOLOGICAL|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
223989180|NCT04515056|DRUG|Papain 10 µg|The area will be exposed to 10 µg of papain.
223989181|NCT04515056|DRUG|Papain 50 µg|The area will be exposed to 50 µg of papain.
223989182|NCT04515056|DRUG|Papain 100 µg|The area will be exposed to 100 µg of papain.
223989183|NCT04515056|OTHER|Vehicle|The area will be exposed to vehicle
223989184|NCT04515056|DRUG|Papain 1 SPT|Papain will be applied by 1 SPT prick thought the skin
223989185|NCT04515056|DRUG|Papain 5 SPT|Papain will be applied by 5 SPT pricks thought the skin
223989186|NCT04515056|DRUG|Papain 25 SPT|Papain will be applied by 25 SPT pricks thought the skin
223989187|NCT04515056|OTHER|Cowhage|The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
223989188|NCT01192789|DRUG|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
223989189|NCT01192789|OTHER|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
223989190|NCT00540943|DRUG|Pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
223989191|NCT00540943|DRUG|Cetuximab|"Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline"
223989192|NCT00540943|DRUG|Irinotecan|Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
223989193|NCT00132197|BEHAVIORAL|Cognitive Behavioral Therapy|1\. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
223989194|NCT00132197|PROCEDURE|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
223989195|NCT02028286|DRUG|CLS001|
223989196|NCT02392754|DEVICE|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
223989197|NCT02375347|OTHER|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
223989198|NCT04467645|OTHER|reflexology|Reflexology is the stimulation of the reflex points in the hands and feet by massage, designed to provide relaxation and relief in the body.
223989199|NCT04789343|OTHER|Root canal treatment|The patient usually takes anaesthesia before treatment and access cavity was prepared on the tooth and root canal removed and instrumented and obturated. However, in the present study, previously done root canal was retreated. Usually no anaesthesia was used because all root canals were done before. So just instrumentation and obturation was done.
223989200|NCT06442696|OTHER|Health Education: Healthy Choices Program|Six session for students and school personel
223989201|NCT00131963|DRUG|cyclophosphamide|Given IV
223989202|NCT00131963|DRUG|doxorubicin|Given IV
223989203|NCT00131963|DRUG|paclitaxel|Given IV
223989204|NCT05625347|DRUG|single dose (100 mg) of ASA|powder for oral inhalation via a Dry Powder Inhaler (DPI)
223989205|NCT05625347|DRUG|single dose (162 mg) of non-enteric-coated chewable aspirin tablets|orally administered
223989206|NCT00114296|DIETARY_SUPPLEMENT|omega-3 fatty acid|
223989207|NCT02034097|DRUG|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
223989208|NCT02034097|DRUG|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
223989209|NCT00559377|OTHER|18F-fluoromisonidazole|Undergo \^18F FMISO PET scan
223989210|NCT00559377|RADIATION|fluorodeoxyglucose F 18|Undergo \^18F FDG PET scan
223989211|NCT00559377|PROCEDURE|positron emission tomography|Undergo \^18F-FMISO and \^18F FDG PET scan
223989212|NCT00559377|OTHER|tissue oxygen measurement|Undergo \^18 F FMISO PET and \^18F FDG PET
223989213|NCT00037206|DRUG|Anidulafungin, VER002|
223989214|NCT02884037|DRUG|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
223989215|NCT00940875|DRUG|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
223544671|NCT05186935|DEVICE|Injectable Hydrogel treatment|The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
223989216|NCT00940875|DRUG|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
223989217|NCT00940875|DRUG|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
223989218|NCT05241132|DRUG|Tislelizumab plus chemotherapy|"1. Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)~2. Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).~3. Tislelizumab: 200mg, given intravenously every 3 weeks until disease progression or unacceptable toxicity or death or subject withdrawal of informed consent."
223989219|NCT03469726|DIAGNOSTIC_TEST|Contrast-enhanced Diffusion-weighted MRI|An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
223989220|NCT02412579|OTHER|None - Standard of Care|
223989221|NCT01202799|DRUG|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
223989222|NCT01202799|DRUG|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
223989223|NCT01202799|DRUG|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
223989224|NCT00490945|DRUG|VEC-162|
223989225|NCT01114490|DRUG|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
223989226|NCT02968706|DEVICE|High Flow Nasal Cannula|Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%
223989227|NCT02968706|DEVICE|Conventional Nasal Cannula|Supplemental oxygen of 2-5 L/min
223989228|NCT02968706|OTHER|Patient satisfaction questionnaire|Questionnaire
223989229|NCT05472103|BEHAVIORAL|ergonomics surgical workshop|ergonomics surgical workshop
223989230|NCT00590226|DRUG|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
223989231|NCT00590226|DRUG|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
223989232|NCT00959010|DIETARY_SUPPLEMENT|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
223989233|NCT00959010|DIETARY_SUPPLEMENT|Placebo|capsules containing middle chain triglycerides
224121091|NCT01037374|OTHER|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
224294587|NCT05946902|DRUG|mirabegron|mirabegron 25 mg per day
223989234|NCT03815253|OTHER|acupuncture|"Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
223989235|NCT02743897|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
223989236|NCT02743897|DRUG|Mavyret|Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
223989237|NCT00371176|BEHAVIORAL|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
223989238|NCT00371176|DRUG|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
223989239|NCT00371176|OTHER|Placebo pill|
223989240|NCT01573949|DRUG|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
223989241|NCT03263247|BEHAVIORAL|Memory Training|
223544672|NCT05334472|OTHER|Kesimpta|There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
223544673|NCT03896477|BIOLOGICAL|Pneumosil|One single dose contains 2 μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4 μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
223989242|NCT03263247|BEHAVIORAL|Psychoeducation|
223989243|NCT03263247|BEHAVIORAL|Alphabet search|
223989244|NCT00777634|OTHER|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
223989245|NCT01349452|DRUG|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
223989246|NCT01349452|DRUG|Artificial tear|Artificial tear 5 times per day
223989247|NCT06428864|DEVICE|Plaster cast|Wearing a Garchois brace produced after a plaster cast
223989248|NCT06428864|DEVICE|3D Scanning|Wearing a Garchois brace produced after assessment of the thoracic volume with the 3D scan
223989249|NCT05383339|OTHER|Blood collection|\- 56mL blood collected additionally to routine care
223989250|NCT06475794|OTHER|Patients with osteoporosis group|Pain, Q angle, muscle strength and foot posture will be evaluated.
223989251|NCT06475794|OTHER|Patients with osteoarthritis group|Osteoarthritis patients will be evaluated in terms of pain, foot posture, Q angle and lower limbs muscle strength.
224121092|NCT00708994|DRUG|THC|"* Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~* Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~* Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
223989252|NCT01114347|DIETARY_SUPPLEMENT|cranberry type A pro anthocyandines|One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water
223989253|NCT01114347|DIETARY_SUPPLEMENT|Placebo|One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
223989254|NCT03917745|BEHAVIORAL|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
223989255|NCT04829123|DRUG|HEC88473 injection|HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen
223989256|NCT04829123|DRUG|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
223989257|NCT05186311|DEVICE|Capillary Blood Collection System|Test Blood Sample Collection
223989258|NCT02879383|PROCEDURE|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
223989259|NCT02879383|PROCEDURE|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
223989260|NCT04901923|DRUG|ACP-196|Participants will receive ACP-196 oral capsule(s) in all parts.
223989261|NCT04901923|DRUG|Itraconazole|Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
223989262|NCT03178344|DEVICE|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
224121093|NCT00708994|DRUG|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
224121094|NCT01095250|DRUG|AIN457|
224121095|NCT01095250|DRUG|AIN457|
224121096|NCT01095250|DRUG|AIN457|
224121097|NCT01095250|DRUG|Placebo|
224121098|NCT01984593|OTHER|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~1. Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~2. Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
224121099|NCT05579561|OTHER|Diet|Participants, in both groups, will be required to eat a diet that is very low in carbohydrates, moderate in protein, with added healthy fats. They will also have to breath in the device to estimate the level of different exhale gaz.
223544674|NCT03896477|BIOLOGICAL|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
223544675|NCT03896477|BIOLOGICAL|Synflorix|One single dose contains 1 μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
223544676|NCT03974074|DRUG|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
223544677|NCT03770858|DRUG|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
223544678|NCT03770858|DEVICE|Scratch sensor|advanced, flexible and wearable skin sensor
223544679|NCT02770027|DRUG|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
223989263|NCT03178344|DEVICE|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
223989264|NCT01537692|DRUG|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
223989265|NCT01537692|DRUG|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
223989266|NCT01537692|DRUG|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
223989267|NCT05052918|BEHAVIORAL|Exercise|1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
223989268|NCT05215691|PROCEDURE|Group I: TAPA block|Postoperative analgesia will be provided with peripheral nerve block (TAPA)
223989269|NCT05215691|PROCEDURE|Group II: IV Morphine|Postoperative analgesia will be provided with opioids
224121100|NCT00585299|OTHER|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
224121101|NCT00585299|OTHER|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
224121102|NCT02269059|DRUG|MK-7680|MK-7680 10 mg and 100 mg capsules
224121103|NCT01221675|DRUG|Antibody TF2|preciblage with an antibody
224121104|NCT01221675|RADIATION|IMP-288-Lutetium|Internal Radiation
224121105|NCT01221675|RADIATION|IMP-288-Indium|Imaging
223544680|NCT02770027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
223544681|NCT01791517|OTHER|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
223989270|NCT05194670|DEVICE|enhanced depth of focus IOL|Acunex Vario AN6V, enhanced depth of focus IOL
223989271|NCT05194670|DEVICE|monofocal IOL|Acunex AN6, monofocal IOL
223989272|NCT06291064|DRUG|Cyclophosphamide|Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
223989273|NCT06291064|DRUG|Epirubicin|Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
223989274|NCT06291064|DRUG|Docetaxel|Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
223544682|NCT01791517|OTHER|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
223544683|NCT01791517|OTHER|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
223544684|NCT01791517|OTHER|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
223544685|NCT02995512|DRUG|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
223544686|NCT04011735|DRUG|Respimat|Soft Mist Inhaler product
223544687|NCT04471376|DRUG|Sugammadex|Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
223544688|NCT02951234|OTHER|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
223544689|NCT02951234|OTHER|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
223544690|NCT03056833|DRUG|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
223544691|NCT03056833|DRUG|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
223544692|NCT03056833|DRUG|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
223544693|NCT03990532|RADIATION|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
223544694|NCT03990532|RADIATION|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
223544695|NCT03368196|DRUG|DS-8201a|An antibody drug conjugate
223544696|NCT03576781|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
223544697|NCT03576781|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
223544698|NCT03576781|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
223544699|NCT03576781|DEVICE|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
223544700|NCT01227226|DRUG|Artificial tears|Instill one drop of artificial tears
223544701|NCT01234181|PROCEDURE|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10\^7 BMSCs Sham Comparator: inject the same volume saline
223544702|NCT00463086|DRUG|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
223544703|NCT00463086|DRUG|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
223544704|NCT06138938|OTHER|Intraoperative abdominal irrigation|All blood clots and other remnants were manually externalized with a sponge holder forceps from the pelvic areas following the uterine incision closure. Then, 1,000 mL of warm saline irrigation was poured into the vesicouterine cavity and aspirated as much as possible in the reverse Trendelenburg position using an aspirator, carefully avoiding any contact with the intestines.
223544705|NCT04656808|BEHAVIORAL|Guilt Focused Intervention|Psychotherapy, group intervention
223544706|NCT04656808|BEHAVIORAL|Cognitive behavioral therapy|Psychotherapy, group intervention
223544707|NCT02255929|RADIATION|Gamma Knife Radiosurgery|
223544708|NCT02994966|DEVICE|Surrosense|
223544709|NCT02994966|OTHER|Standard care|
223544710|NCT03149146|OTHER|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
223544711|NCT03149146|OTHER|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
223989275|NCT06291064|DRUG|Carboplatin|Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
223989276|NCT06291064|PROCEDURE|Breast Surgery|Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
223989277|NCT06291064|DRUG|Capecitabine|Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
223728889|NCT05329272|OTHER|Virtual Reality Cognitive Training Intervention (VRCTI)|The VRCTI was developed to improve cognitive function. The intervention was designed that simulated schema of underwater world fish swimming. Each 1-hour session was typically divided into three parts: easy, medium and difficult, each with 4 different tasks, so there are 12 tasks/session in total. In some tasks, the VRCTI also distinguished between the real lure (e.g. a red triangle fish with a half-moon pattern) as well as unrelated lure items (i.e., blue square fish with polka dot pattern and other irrelevant items). The use of hardware elements for this study included visual (head-mounted display \[HMD\] in delivering the VR intervention), audio, and motor equipment.
223728890|NCT03240250|PROCEDURE|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
224121106|NCT05869851|OTHER|Pavlik Harness|The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
224121107|NCT01800227|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
224121108|NCT04376268|DRUG|Chlorhexidine mouthwash|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
224121109|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
223544712|NCT03116425|DEVICE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
223728891|NCT03240250|PROCEDURE|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
223989278|NCT06046833|DEVICE|FreeStyle Libre 3 continuous glucose monitoring sensor|The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
223989279|NCT06046833|OTHER|Nutritional drink|Balanced nutritional drink (Boost plus 8 ounces/237 mL)
223989280|NCT05139290|BEHAVIORAL|Prototype Intervention|The prototype intervention will be likely family-based and focused on issues of communication, problem-solving, health system literacy, and family systems, all considered in the context of the African-American (AA) adult daughter role and cultural identity.
224121110|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (0.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
224294588|NCT05946902|DRUG|tolterodine , mirabegron|tolterodine 4 mg and mirabegron 25 mg per day
224294589|NCT05098002|BEHAVIORAL|Mindfulness program|6 week class designed to improve psychological well-being
223728892|NCT03676595|OTHER|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
224294590|NCT06232239|DRUG|Empagliflozin-Test product|Empagliflozin 10 mg tablets Test product Manufactured by: Thai Meiji Pharmaceuticals Co., Ltd., Thailand
223728893|NCT03676595|OTHER|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
223728894|NCT00505531|DRUG|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
223728895|NCT00505531|DRUG|Benadryl|Placebo group will take up to 25 mg of Benadryl
223728896|NCT00326989|PROCEDURE|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
223728897|NCT01516814|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
223728898|NCT01516814|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
223728899|NCT01516814|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
223728900|NCT01574612|DRUG|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
223728901|NCT06229197|PROCEDURE|Billroth II reconstruction|Billroth II reconstruction, in which a loop of jejunum is mobilized and anastomosed to the gastric remnant
223728902|NCT06229197|PROCEDURE|Braun Anastomosis|This is an additional surgical connection (anastomosis) created between two parts of the small intestine, specifically between the afferent (incoming) and efferent (outgoing) limbs of the jejunum near the gastrojejunostomy (the new connection between the stomach and small intestine created during a Billroth II procedure).
223728903|NCT03634462|OTHER|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
223728904|NCT02904330|DRUG|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
223728905|NCT03970798|DRUG|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
223728906|NCT03970798|DRUG|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
223728907|NCT03970798|DRUG|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
223728908|NCT03970798|DRUG|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
223728909|NCT03661632|DRUG|BMS-986310|Specified dose on specified days
223728910|NCT03661632|BIOLOGICAL|Nivolumab|Specified dose on specified days
223728911|NCT02245308|DRUG|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
223728912|NCT02245308|BEHAVIORAL|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
223728913|NCT02245308|BEHAVIORAL|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
224294591|NCT06232239|DRUG|Empagliflozin-Reference product|Empagliflozin 10 mg tablets Reference product Manufactured by: Boehringer Ingelheim Pharma Gmbh \& Co. Kg, Germany
224294592|NCT05466175|DRUG|Olverembatinib|Given PO
224294593|NCT05466175|DRUG|Prednisone|Given Intravenous
224294594|NCT05466175|DRUG|Vincristine|Given Intravenous
224121111|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
223989281|NCT05868941|DEVICE|Broncho Muco Cleaner|"The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract.~In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally."
223728914|NCT02245308|DRUG|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
223728915|NCT02245308|DRUG|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
223728916|NCT02407704|DRUG|Venlafaxine XR|
223989282|NCT06516679|DRUG|Consolidation #4(without daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. Low Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, intrathecal methotrexate~3. Low Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. Low Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. Low Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
223989283|NCT06516679|DRUG|Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Maintenance chemotherapy(about 2yrs) : Vincristine, Dexamethasone, 6-mercaptopurine, intrathecal methotrexate"
224121112|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (1.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
224294595|NCT04940702|OTHER|Focal Vibration|"Training with Focal Vibration on rectus anterior, vastus medialis and vastus lateralis muscles with an intensity of 120 Hz and an amplitude of 1.2 mm. Time of training 20-25 min.~The exercise is the same than traditional training group."
224294596|NCT04940702|OTHER|Blood Flow Restriction|Training with Blood Flow Restriction, the restriction is in the proximal part of the lower limb. The exercise is the same than traditional training group.
224294597|NCT04940702|OTHER|Traditional Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
224294598|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
224294599|NCT06020001|DIETARY_SUPPLEMENT|AP203 mixture (RESCOVIN®)|Polyphenol-rich plant extracts Twice a day
223728917|NCT02407704|OTHER|Aerobic Exercise|
223989284|NCT06516679|DRUG|Allogeneic hematopoietic stem cell transplantation after Consolidation #4(with daunorubicin)|"1. Induction chemotherapy(5wks) : Prednisolone, Dexamethasone, Vincristine, Daunorubicin, L-asparaginase, Cytarabine, intrathecal cytarabine, intrathecal methotrexate~2. High Risk Cosolidation 1 chemotherapy(3wks) : Cytarabine, Etoposide, Cyclophosphamide, Daunorubicin intrathecal methotrexate~3. High Risk Cosolidation 2 chemotherapy(3wks) : Methotrexate, 6-mercaptopurine, intrathecal methotrexate~4. High Risk Cosolidation 3 chemotherapy(3wks) : Cytarabine, L-asparaginase, intrathecal methotrexate~5. High Risk Cosolidation 3 chemotherapy(8wks) : Dexamethasone, Vincristine, Daunorubicin, Cytarabine, Cyclophosphamide, 6-mercaptopurine, intrathecal methotrexate~6. Allogeneic hematopoietic stem cell transplantation"
223989285|NCT01908751|PROCEDURE|Sliding Hip Screw|
223989286|NCT01908751|PROCEDURE|Cancellous Screws|
223989287|NCT01908751|DRUG|Vitamin D|
223989288|NCT01908751|DRUG|Vitamin D Placebo|
223989289|NCT03908892|DRUG|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
223989290|NCT03908892|DRUG|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
223989291|NCT05698251|BEHAVIORAL|Uncertainty distress model|Psychological therapy intervention based on elements of traditional Cognitive Behaviour Therapy (CBT) for anxiety, illness uncertainty and intolerance of uncertainty.
224121113|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
224121114|NCT04376268|PROCEDURE|Chlorhexidine mouthwash with boric acid (2.5%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
224294600|NCT06020001|OTHER|Placebo|Twice a day
224294601|NCT02336620|DRUG|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
224294602|NCT02336620|DRUG|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
224294603|NCT01233843|DRUG|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
224294604|NCT01233843|DRUG|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
224294605|NCT01233843|RADIATION|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
223728918|NCT02407704|DRUG|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
223728919|NCT04216017|DRUG|kenalog|Cortisone injection into shoulder
223728920|NCT04216017|DRUG|Lidocaine|Lidocaine injection into shoulder
223989292|NCT01441219|DEVICE|Colon 2|Ingest one colon 2 capsule
223989293|NCT00181506|PROCEDURE|dose escalation (radiotherapy treatment schedule)|
223989294|NCT00092183|DRUG|MK0869, aprepitant / Duration of Treatment: 3 days|
223989295|NCT00092183|DRUG|Comparator: ondansetron / Duration of Treatment: 3 days|
223989296|NCT02719288|OTHER|CLARIX® CORD 1K graft|
223989297|NCT00148668|DRUG|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
223989298|NCT00148668|DRUG|Navelbine|Weekly injections given starting week 3 and ending week 14
223989299|NCT00148668|DRUG|Taxotere|Given every three weeks starting week 3 and ending on week 14
223989300|NCT00148668|DRUG|Carboplatin|Given every three weeks starting week 3 and ending on week 14
223989301|NCT02417441|DEVICE|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
223989302|NCT05508815|DRUG|Modified Zhiwang Decoction Combined with methotrexate|Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.
223989303|NCT05508815|DRUG|Methotrexate|Methotrexate(7.5-15mg, once a week) for 12 weeks.
223989304|NCT01180504|RADIATION|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
223989305|NCT06331455|DRUG|Durvalumab|Two doses of durvalumab (1500 mg IV)
223989306|NCT06331455|RADIATION|Non-ablative oligofractionated radiation (NORT)|12 Gy of Radiation in 3 fractions
223989307|NCT05053880|DRUG|ACT001|Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
223989308|NCT05053880|DRUG|ACT001 + Pembrolizumab|Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
223989309|NCT06544356|OTHER|No intervention, questionnaire filled out|Mother introductory information form, Health Literacy Scale, Knowledge and Attitude Scale about Newborn Screenings were completed.
223989310|NCT03567044|DIAGNOSTIC_TEST|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
223989311|NCT02328079|DRUG|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
223989312|NCT04205357|DRUG|Sulfasalazine|Sulfasalazine combined with stereotactic radiosurgery
223989313|NCT00983853|DRUG|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
224294606|NCT03010618|OTHER|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
223989314|NCT00983853|DRUG|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
223989315|NCT00983853|BIOLOGICAL|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
223989316|NCT00983853|DRUG|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
223989317|NCT00983853|DRUG|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
223989318|NCT03946202|DRUG|Hydrogen Peroxide|Hydrogen Peroxide
223989319|NCT02346929|OTHER|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
223989320|NCT01632189|DRUG|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
223989321|NCT03603639|DRUG|Placebo|Participants will receive E2730-matched placebo capsule, orally.
223989322|NCT03603639|DRUG|E2730|Participants will receive E2730 capsule, orally.
223728921|NCT05318599|DEVICE|Lung auscultation|Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
223728922|NCT05318599|DEVICE|Lung ultrasound|Lung ultrasonography
223728923|NCT05318599|OTHER|Quality of Life's questionnaires|Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
223989323|NCT00502502|BEHAVIORAL|Questionnaire|Weekly questionnaires lasting about 30 minutes.
223989324|NCT00607672|DRUG|Placebo|Placebo
223989325|NCT00607672|DRUG|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
223989326|NCT00607672|DRUG|Candesartan|Candesartan 16mg/d
223989327|NCT02934204|DRUG|methotrexate|
223989328|NCT02934204|DRUG|temozolomide|
223989329|NCT04944667|DIAGNOSTIC_TEST|TAVR planning|TAVR planning without VR vs after VR
223989330|NCT00485953|DRUG|risedronate|risedronate 35 mg per week
223989331|NCT03496077|OTHER|Flavored and unflavored little cigars/cigarillos (LCCs)|Flavored and unflavored LCCs that are currently available for purchase
223989332|NCT02900950|PROCEDURE|Multicolour inking specimens|
223989333|NCT02900950|PROCEDURE|Monocolour inking specimens|
223989334|NCT01673789|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
223989335|NCT04456387|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received on-demand treatment, doses range from 30 IU/kg to 50 IU/kg, or doses divided on the discretion of the Investigator.
223989336|NCT04456387|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/kg every three days.
223989337|NCT01436747|DRUG|Paricalcitol|2 micrograms daily, peroral, 24 weeks
223989338|NCT01436747|DRUG|Placebo|2 micrograms daily, peroral, 24 weeks
223989339|NCT04817423|OTHER|No intervention|No intervention
223989340|NCT03736538|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
223989341|NCT03736538|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
223989342|NCT05034939|DEVICE|FLEX Vessel Prep System|"The FLEX Vessel Prep System™ is an over-the-wire sheathed catheter with a three-strut treatment element near the distal tip. As the device is pulled back in a retrograde fashion through the target lesion, the Treatment Element flexes providing continuous engagement along the lesion to create controlled depth micro-incisions."
223989343|NCT05034939|DEVICE|Angioplasty|The brand and type of PTA balloon(s) used will be at the discretion of the treating physician and used according to its Instructions for Use (IFU). PTA balloons consist of an over-the-wire catheter with a balloon fixed at the distal tip. Within the lesion the balloon is inflated to a pressure that allows full effacement.
223989344|NCT04576793|DRUG|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. 11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
223989345|NCT04576793|DRUG|18F-MK6240|MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
223989346|NCT04576793|DRUG|18F-Florbetaben|Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
224294607|NCT01845402|BIOLOGICAL|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
223989347|NCT04576793|PROCEDURE|Lumbar Puncture|Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
223989348|NCT04714463|PROCEDURE|Implant-based breast reconstruction|All types of implant based breast reconstructions
223989349|NCT04714463|PROCEDURE|Autologous breast reconstruction|All types of autologous breast reconstructions
223989350|NCT04714463|PROCEDURE|Combined methods|All types of breast reconstructions combining autologous and implant based techniques
223989351|NCT06003881|DRUG|Pozelimab|Subcutaneous (SC) administration
223989352|NCT00489801|OTHER|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
223989353|NCT05681273|DRUG|Chiglitazar|Chiglitazar 48mg
223989354|NCT05681273|DRUG|Empagliflozin|Empagliflozin 10mg
223989355|NCT05681273|DRUG|Atorvastatin|Atorvastatin 20mg
223989356|NCT05681273|DRUG|Valsartan|Valsartan 160mg
223989357|NCT01968889|OTHER|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
223989358|NCT00532168|DRUG|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
223989359|NCT00532168|DRUG|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
223989360|NCT00532168|DRUG|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
223989361|NCT00551499|DEVICE|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
223989362|NCT03910777|DIAGNOSTIC_TEST|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
223989363|NCT04267055|DEVICE|Valiant Navion Thoracic Stent Graft System|Placement of the Valiant Navion for endovascular repair of a dissection in the thoracic aorta.
223989364|NCT05465759|OTHER|disease|Frequency of SARS COV-2 infection among malignant patients at south Egypt Cancer institute.
223989365|NCT03515304|DRUG|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
223989366|NCT03515304|DRUG|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
223989367|NCT06144593|OTHER|Dietary macronutrient composition|Intermittent carbohydrate restriction
223989368|NCT04042818|DIAGNOSTIC_TEST|Rehabilitative Ultrasound|Ultrasound imagining
223989369|NCT00483028|DRUG|donezepil (Aricept)|
223989370|NCT00301483|DRUG|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
224121115|NCT04376268|PROCEDURE|Boric acid mouthwash (2%)|After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
224121116|NCT05005208|OTHER|rehabilitation program with the support of the technological platform SI-ROBOTICS|"A 16-treatment session will be conducted, divided into 2 training sessions per week, for 8 weeks. The therapy sessions last 60 minutes; each session will involve 2 patients at time. Cardiac and respiratory activity monitoring is planned during robotic treatments in order to detect the heart rate during physical activity. Individual participants must complete at least 80% of the sessions. Recovery of 2 sessions will be possible.~Each session involves the following activities:~* Breathing, relaxation and postural harmonization exercises;~* Active mobility and stretching exercises;~* Irish dance with the SI-ROBOTICS system;~* Relaxation exercises."
224121117|NCT05901714|DRUG|Afimetoran|Specified dose on specified days
223989371|NCT00301483|OTHER|Standard of Care|Standard Therapy
223989372|NCT02137577|PROCEDURE|DEB catheter|DEB catheter (trade name: Litos/Tulip)
223989373|NCT02137577|PROCEDURE|common PTA balloon catheter|common PTA balloon catheter
223989374|NCT06086678|OTHER|Conventional physical therapy|"1. Deep breathing exercise.~2. Diaphragmatic breathing exercise.~3. Pursed lip breathing exercise."
223989375|NCT06086678|OTHER|Hydrotherapy|"1. Water walking exercise.~2. Forward lunges exercise.~3. Single leg balance exercise.~4. Side stepping exercise.~5. Push ups exercise.~6. Standing knee lifts exercise."
224121118|NCT05901714|DRUG|Phenytoin|Specified dose on specified days
224121119|NCT05901714|DRUG|Midazolam|Specified dose on specified days
224121120|NCT02272322|DEVICE|cystocele repair with biomesh soft prolaps and endofast reliant|
224121121|NCT06472258|DRUG|IV Artesunate|IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.
224121122|NCT06472258|DRUG|IV Quinine Hydrochloride|IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
224121123|NCT04838691|BEHAVIORAL|interpersonal counseling|In the intervention group, it will be administered for 40 minutes for 8 weeks to people with symptoms of premenstrual syndrome.
224121124|NCT01675804|OTHER|Computerized cognitive rehabilitation|\- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
223989376|NCT06086678|OTHER|Aerobic exercise|Aerobic exercise in form of treadmill training when each child was standing on the treadmill, should be ensure that this standing in an upright position, and according to each child, the therapist corrected the height of the handrails. Ask the child to keep looking forwards along the walking on the treadmill aiming to encourage the setting of walking free. The treadmill training would be completed for each child when the child completes three stages in 1-min training cycles. First stage: the child grasped on to the rails with both hands in first 15 s of every 1-min. Second stage: the child grasped on to the railings with one hand in the second 15 s. And final stage: the child didn't grasp on to the railings in last 30 s. Every child performed this procedure twenty times
223989377|NCT00678483|DRUG|rimonabant (SR141716)|once daily
223989378|NCT01980602|PROCEDURE|Supervised Exercise program|
223989379|NCT06566183|PROCEDURE|Guideline-directed medical therapy (GDMT)|Participants receive guideline-directed medical therapy (GDMT).
223989380|NCT06566183|PROCEDURE|Coronary artery bypass grafting (CABG)|Participants receive coronary artery bypass grafting (CABG).
223989381|NCT06566183|PROCEDURE|Percutaneous coronary intervention (PCI).|Participants receive percutaneous coronary intervention (PCI).
223989382|NCT05980416|DRUG|EO-3021|Anti-Claudin 18.2 antibody drug conjugate
223989383|NCT05980416|DRUG|Ramucirumab (CYRAMZA®)|VEGFR2 inhibitor
223989384|NCT05980416|DRUG|Dostarlimab|anti-PD-1 antibody
223989385|NCT04874558|DIAGNOSTIC_TEST|Ultra-low dose chest CT|A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.
223989386|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + dual attention|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with double attention.
223989387|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + fixed point|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with fixed point.
223989388|NCT05600868|BEHAVIORAL|A comprehensive third-generation intervention EMDR + exposition|This is a individual intervention with a total of 10 sessions. In the processing the traumatic event phase will be realized with exposition.
223989389|NCT02952196|DRUG|drug administration|administering drug to patient with amphetamine addiction
223989390|NCT01954225|OTHER|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
223989391|NCT04051918|BEHAVIORAL|Piano Training|Cognitive training via music learning
223989392|NCT05036525|DEVICE|HANBIO BarriGel|an anti-adhesive product
223989393|NCT03913559|DRUG|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
223989394|NCT03913559|DRUG|Methotrexate|Intrathecal (IT) therapy
223989395|NCT03913559|DRUG|Hydrocortisone|Intrathecal (IT) therapy
223989396|NCT03913559|DRUG|Cytarabine|Intrathecal (IT) therapy
223989397|NCT03913559|DRUG|Diphenhydramine|1 mg/kg (max 50 mg) IV
223989398|NCT03913559|DRUG|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
223989399|NCT03913559|DRUG|Methylprednisolone|1 mg/kg IV x 1
223989400|NCT04924049|OTHER|Video-assisted education|Prior the study, the content and comprehensibility of the VE were evaluated by an orthopedic surgeon, two orthopedic nurses, and a physiotherapist who were not involved in the study and relevant amendments were made based on their suggestions. The preview of the final version of the VE was shown to four patients (10% of the sample) and these patients were excluded from the study. The patients were interviewed by phone calls on a weekly basis and watching VE at home, the frequency of watching VE, and doing home-based exercises were questioned.
223989401|NCT06213324|DRUG|Ketamine|0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously
223989402|NCT06213324|DRUG|Placebo|Normal saline delivered intravenously
223989403|NCT03200652|DIETARY_SUPPLEMENT|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
223989404|NCT00996502|DRUG|Docetaxel|"Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
223989405|NCT00996502|DRUG|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
223989406|NCT00996502|DRUG|Erlotinib|200 mg of Erlotinib PO daily days 2-16
223989407|NCT00996502|DRUG|Prednisone|5 mg of Prednisone PO bid
223989408|NCT02520583|DIETARY_SUPPLEMENT|Lactic acid bacteria and bifidobacteria|
223989409|NCT02520583|OTHER|Placebo|
223989410|NCT04162002|DRUG|Restylane® Lyft|Filler Injection
224121125|NCT01675804|DRUG|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
224121126|NCT01675804|OTHER|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
224121127|NCT00705224|BIOLOGICAL|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
224121128|NCT00705224|DRUG|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
224121129|NCT05925816|BEHAVIORAL|Video|Video uses BA techniques for approximately 5 minutes
223728924|NCT05318599|DIAGNOSTIC_TEST|Pulmonary functional tests|Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
223728925|NCT01610544|DRUG|3'-deoxy-3'-18F fluorothymidine (FLT)|
223728926|NCT01610544|OTHER|PET/CT scan|
223728927|NCT01957644|DRUG|Azacitidine|
223728928|NCT01957644|DRUG|Volasertib|
223728929|NCT04044716|DEVICE|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 5 acupoints on each ear (cingulate gyrus, thalamus, omega-2, point zero, and Shen Men). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 5 days. Acupoints were selected based on recommendation of faculty acupuncturist.
223728930|NCT04044716|OTHER|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
223728931|NCT05974033|COMBINATION_PRODUCT|Stenting plus medical therapy|Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
223728932|NCT05974033|DRUG|Medical therapy alone|Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.
223728933|NCT02093845|DEVICE|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
223728934|NCT02093845|DEVICE|SYNERGY stent|Percutaneous coronary intervention involving use of stent
223728935|NCT03117101|DRUG|Lucitanib|
223728936|NCT03357159|DRUG|Cyclophosphamide|In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
223728937|NCT03357159|DRUG|anti-human T-lymphocyte immunoglobulin (ATLG)|15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
223728938|NCT04245696|DEVICE|Dermal Handpiece / SubQ Handpiece|Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
223728939|NCT03209687|DRUG|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
223728940|NCT01516554|DRUG|Testosterone undecanoate|40 mg twice daily
223728941|NCT01516554|DRUG|placebo|twice daily
223728942|NCT03763591|BEHAVIORAL|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
223728943|NCT02193568|PROCEDURE|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
223728944|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
224121130|NCT05925816|BEHAVIORAL|Active game|Game provides positive feedback in response to decisions made by participants
224121131|NCT05925816|BEHAVIORAL|Neutral game|Game without feedback
224121132|NCT05060510|DIAGNOSTIC_TEST|Take home saliva kit|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
223728945|NCT02193568|PROCEDURE|Arm II (intubated general anesthesia)|Undergo craniotomy
223728946|NCT02193568|OTHER|Arm II (intubated general anesthesia)|Ancillary studies
223728947|NCT02193568|PROCEDURE|Arm I (light sedation)|Undergo craniotomy
223728948|NCT02193568|OTHER|Arm I (light sedation)|Ancillary studies
223728949|NCT00816985|PROCEDURE|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
223728950|NCT00816985|OTHER|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
223728951|NCT06384040|PROCEDURE|platelet-rich plasma knee injection|platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
224121133|NCT06671847|DEVICE|THERABand resistance exercise bands|The training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises
224121134|NCT06672562|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|NECT-Y consists of 14 90-minute sessions over the course of 14 weeks. The intervention combines psychoeducation, cognitive therapy, narrative therapy, goal-setting and peer support. Each group meeting includes educational materials, reflections, and active exercises that participants are guided through to personalize the content to their experiences. Participants will be provided with a workbook which allows them to follow the activities easier.
223728952|NCT00620867|DRUG|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
223728953|NCT00620867|DRUG|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
223728954|NCT00620867|OTHER|placebo|matched placebo orally for 6 weeks
223728955|NCT01324999|DRUG|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
223728956|NCT03902288|OTHER|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG \< 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
223728957|NCT02336971|BEHAVIORAL|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
223728958|NCT02336971|BEHAVIORAL|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
223728959|NCT03627247|BEHAVIORAL|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar \& Kofman, 2012).
223728960|NCT03630952|BIOLOGICAL|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
223989411|NCT02167919|DEVICE|Microspheres|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
223989412|NCT01873326|DRUG|Paclitaxel|
223989413|NCT01873326|DRUG|Ifosfamide|
223989414|NCT01873326|DRUG|Cisplatin|
223989415|NCT01873326|DRUG|Mesna|
223989416|NCT01873326|DRUG|Bleomycin|
223989417|NCT01873326|DRUG|Etoposide|
223989418|NCT05986045|OTHER|Quality of Life|ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period
224121135|NCT06672562|OTHER|Usual care|Standard usual care. No study-specific care, but participants will be provided with information on community resources and support, and will also be encouraged to speak to their clinician if they are interested in learning about other services.
224121136|NCT06672965|DIETARY_SUPPLEMENT|anti-stress supplement|The anti-stress supplement was developed to provide relief from anxiety and depression levels.Subjects were given 60 capsules of calming supplement (30-day supply) and instructed to take two capsules each day orally with water.
224121137|NCT06672965|DIETARY_SUPPLEMENT|Placebo|Subjects were given 60 capsules of placebo (30-day supply) and instructed to take two capsules each day orally with water.
224121138|NCT06671470|DRUG|YZJ-1139 tablets|Oral dose 20 mg
224121139|NCT06671470|DRUG|Ticagrelor Tablets|Oral dose 90 mg twice daily
223989419|NCT01013545|BEHAVIORAL|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
223989420|NCT00119652|DRUG|quetiapine fumarate (Seroquel)|
224121140|NCT05847270|PROCEDURE|Anterior and posterior treatment strategy|Before surgery, a large weight traction of 1/6 body weight was used to determine the reversibility of atlantoaxial dislocation. After determining that it is difficult to restore the dislocation, a technique of anterior oral release and posterior fixation fusion was used for reduction, with sequential release of the longus colli and longus capitis, the anterior longitudinal ligament, the blitateral lateral mass joints, the contracted soft-tissue mass between the odotiod and the anterior C1 tubercle, and the peri-odontoid ligaments (i.e., the alar ligaments and the apical ligament), followed by posterior internal fixation and bone grafting was used between C1 and C2 lamina.
223989421|NCT00119652|DRUG|paroxetine|
223989422|NCT00119652|BEHAVIORAL|mood stabilizing activity|
223989423|NCT03662646|OTHER|no intervention performed- observational only|no intervention performed- observational only
223989424|NCT00549978|DRUG|Cilostazol|cilostazol, then cilostazol/probucol
223989425|NCT00549978|DRUG|Probucol|Probucol probucol/ cilostazol
223989426|NCT03943017|OTHER|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
223989427|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Cone Coil|The cone coil Cool-DB80 (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). TMS interventions will involve the following parameters: 1. Hippocampal directed stimulation at ISI 0ms, 2. Hippocampal directed stimulation at ISI 200ms, 3. Motor cortex stimulation at ISI 0ms, and 4. Motor cortex stimulation at ISI 200ms.
223989428|NCT05462782|DEVICE|Transcranial Magnetic Stimulation (TMS) Sham Coil|The sham coil Cool B65 A/P (MagPro, MagVenture, Alpharetta GA, US) will be used with an MRI-based TMS navigation system (Localite, St Augustin, Germany). The different TMS interventions will be involve the following parameters: 1. Sham stimulation at ISI 0ms, and 2. Sham stimulation at ISI 200ms.
223989429|NCT05488288|PROCEDURE|Mesh repair|Abdominal ventral hernia (VH) repair with mesh during bariatric surgery. the repair technique and the type of mesh are left to the choice of the center, as there are no strong data to demonstrate which technique is the best for VH repair in this population.
223989430|NCT05488288|PROCEDURE|Suture repair|The hernia sack is resected through an open approach, and the fascial defect is systematically closed with a slowly absorbable monofilament suture.
223989431|NCT00022815|DEVICE|Tissue ultrafiltration|
223989432|NCT02927015|OTHER|Purple Majesty potato chips|Purple Majesty potato chips
223989433|NCT02927015|OTHER|Mountain Rose potato chips|Mountain Rose potato chips
223989434|NCT02927015|OTHER|White potato chips|White potato chips
223989435|NCT02927015|OTHER|Crackers|Crackers
223989436|NCT05046925|PROCEDURE|postoperatively transferral to PACU|patients undergoing major thoracic and abdominal surgery will be transferred to PACU for postoperative care.
223989437|NCT05046925|PROCEDURE|postoperatively transferral to ICU|patients undergoing major thoracic and abdominal surgery will be transferred to ICU for postoperative care.
223989438|NCT01375998|DRUG|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
223989439|NCT02947100|DRUG|SCD-Omegatex™|"Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose."
223989440|NCT04706689|BEHAVIORAL|SWADOC tool|"The tool explores some oral and pharyngeal components of swallowing as well as a range of prerequisite and related components of swallowing in DOC patients.~It is composed of an average of 50 qualitative items and a subsection named SWADOC-scored comprising 8 quantitative items."
223989441|NCT04706689|BEHAVIORAL|FOTT-SAS|"Facial Oral Tract Therapy Swallowing Assessment of Saliva : the results of the SWADOC-scored in one of the sessions will be compared to the FOTT Swallowing Assessment of Saliva (FOTT-SAS) (27). The test is based on 7 questions under which if items 1-4 are answered Yes and items 5-7 are answered No, oral intake should be initiated. The FOTT-SAS includes items that can be scored based on the administration of the SWADOC tool. In that respect, no additional administration will be required"
223989442|NCT04958720|PROCEDURE|Surgery|Surgery
223989443|NCT04958720|DRUG|Chemotherapy, anti-targeted agents and immunotherapy|Chemotherapy, anti-targeted agents and immunotherapy
223989444|NCT04958720|RADIATION|Radiotherapy|Radiotherapy
223989445|NCT06320002|BEHAVIORAL|Communication Intervention for fecal ostomy surgery|This is a educational video-based supportive intervention to address practical skills and adaptation to life with a fecal ostomy
223989446|NCT00819702|OTHER|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
223989447|NCT05400837|COMBINATION_PRODUCT|Corrie Virtual Atrial Fibrillation Management Program|Intervention aims to implement guideline-recommended Afib care
223989448|NCT00272259|PROCEDURE|Participants will interact with up to two small robots and a visual display|
223989449|NCT00742326|DRUG|Pioglitazone|45 mg/daily
223989450|NCT00742326|DRUG|Placebo|one capsule daily
224294608|NCT04072549|BEHAVIORAL|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
223989451|NCT03567642|DRUG|Osimertinib|Osimertinib 80mg daily
223989452|NCT03567642|DRUG|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
223989453|NCT03567642|DRUG|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
223989454|NCT01828866|BEHAVIORAL|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
224294609|NCT03163849|DRUG|Sofosbuvir , daclatasvir|Tablets
224294610|NCT03163849|DRUG|Placebos|oral tablets
224294611|NCT05160714|RADIATION|Real-time ADC-guided response adaptive Boost in HNC|"40 Gy in 20 fractions over 5 weeks (Monday to Thursday) to the adjuvant neck, simultaneous integrated boost with 56 Gy in 20 fractions in 5 weeks to the low-risk macroscopic tumor.~Once weekly Dose-escalated SBRT adaptive boost to an ADC-based high risk subvolume with graduated dose levels of 5x5 Gy, 5x5.5 Gy, 5x6 Gy, 5x6.5 Gy"
224294612|NCT01876849|DRUG|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
223989455|NCT01828866|BEHAVIORAL|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring"
223989456|NCT05100810|OTHER|Natural History Study|Longitudinal assessment of disease progression of Angelman syndrome in patients
223989457|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
223989458|NCT00922688|DRUG|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
223989459|NCT00922688|DRUG|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
223989460|NCT04097847|DRUG|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
223989461|NCT04189055|DRUG|Cetuximab|Cetuximab 500mg/m² IV, day 1
224294613|NCT02858648|BEHAVIORAL|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
223989462|NCT04189055|DRUG|Irinotecan|Irinotecan 180mg/m² IV, day 1
223989463|NCT06002646|DRUG|Formocresol|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with Formocresol solution
223989464|NCT06002646|DRUG|Sodium Hypochlorite Solution|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 3% Sodium Hypochlorite Solution.
223989465|NCT06002646|DEVICE|Diode laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 940 nm diode laser.
223989466|NCT06002646|DEVICE|Er,Cr:YSGG laser|Hemostasis of pulpal tissue in primary teeth pulpotomy techniques with 2790nm Er,Cr:YSGG laser.
223989467|NCT00074295|BIOLOGICAL|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
223989468|NCT00385307|DRUG|amibegron (SR58611A)|
223989469|NCT00828555|OTHER|Vaccination Program|Design \& implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, \& pertussis
223989470|NCT03218566|DEVICE|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
223989471|NCT04443478|PROCEDURE|Radical gastrectomy with dissection of lower mediastinal lymph node|Radical gastrectomy for gastric cancer should be consistent with Japanese gastric cancer treatment guideline.
223989472|NCT00573547|DRUG|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
223989473|NCT05861765|DRUG|Papaverine Hydrochloride|Slowly inject 10ml of papaverine hydrochloride solution (30mg/10ml) through the successfully implanted radial artery sheath, and continuously drip papaverine hydrochloride solution (60mg/500ml, 4ml/min) through the artery sheath during the operation. The compatible solutions are normal saline(0.9%);
223989474|NCT05861765|DRUG|normal saline|After inserting the radial artery sheath, slowly inject 10ml normal saline(0.9%) through the artery sheath, then continuously drip normal saline(0.9%, 500ml, 4ml/min) through the artery sheath during the operation.
224294614|NCT02858648|BEHAVIORAL|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
223989475|NCT00443209|DRUG|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
223989476|NCT00443209|DRUG|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
223989477|NCT00443209|DRUG|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
223989478|NCT00443209|DRUG|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
223989479|NCT00443209|DRUG|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
224294615|NCT00588640|DRUG|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
224294616|NCT00588640|DRUG|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
223728961|NCT03630952|BIOLOGICAL|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
223728962|NCT03630952|BIOLOGICAL|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
223728963|NCT04258397|DRUG|Pirfenidone|Pirfenidone vs. matching placebo
223728964|NCT04258397|DRUG|matching placebo|matching placebo
223728965|NCT04614064|OTHER|Exposure to London Underground ambient particulate matter|Exposure to particulate matter on the London Underground
223728966|NCT04614064|OTHER|Exposure to London air ambient particulate matter|Exposure to ambient particulate matter on the London Overground (as a proxy as a proxy for a clean air London area while maintaining other aspects of a train journey)
223728967|NCT01714635|DEVICE|Tecnis Multifocal Intraocular Lens|
223728968|NCT01714635|DEVICE|Monofocal Intraocular Lens|
223728969|NCT01979887|PROCEDURE|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
223728970|NCT04355845|DRUG|Sumatriptan|25 milligrams (mg) single dose tablet
223728971|NCT04355845|DRUG|PF-06651600|PF-06651600 400 mg single dose
223728972|NCT03103737|BEHAVIORAL|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
223728973|NCT01288105|DEVICE|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom \>95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with \<95% stent strut coverage will receive perioperative bridging.
223728974|NCT00230607|DRUG|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
223728975|NCT00095901|DRUG|Capecitabine|
223728976|NCT04031937|OTHER|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
223728977|NCT01917474|DIETARY_SUPPLEMENT|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
223728978|NCT01917474|DIETARY_SUPPLEMENT|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
223728979|NCT02258698|PROCEDURE|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
223728980|NCT00738595|DRUG|EVT 302|EVT 302 5 mg once daily
223728981|NCT00738595|DRUG|Placebo|Placebo to match EVT 302, 5 mg
223728982|NCT00738595|DRUG|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
223728983|NCT00738595|DRUG|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
223728984|NCT04690491|OTHER|follicular cyclus|Days of cyclus 6-12
223728985|NCT04690491|OTHER|luteal cyclus|Days of cyclus 20-24
223728986|NCT03790488|DRUG|JTX-4014|Specified dose on specified days
223728987|NCT03355040|OTHER|induction of labour|induction of labour
223728988|NCT02677467|BIOLOGICAL|Blood-pressure variability|Day to Night Blood pressure variability
223728989|NCT01412359|DRUG|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
223728990|NCT01584102|BEHAVIORAL|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
223728991|NCT01584102|BEHAVIORAL|group fitness classes only|15 weeks biweekly group fitness
223728992|NCT00071513|BEHAVIORAL|CAST-T/HSTS|Skills training small group.
223728993|NCT00071513|BEHAVIORAL|Brief Intervention|Assessment of needs and referral to services as needed.
223728994|NCT00790855|DRUG|Bendamustine|Starting dose of 50 mg/m\^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
224294617|NCT00588640|DRUG|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
224294618|NCT03365999|DRUG|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
223728995|NCT05154006|BEHAVIORAL|Information about benefits of the behavior|The women will be informed that the safe carrying behaviors can reduce pelvic strain. She is informed about the benefits reducing pelvic strain may imply \[5.1; 5.3.,5.6 Information about health; environmental; social; and emotional consequences, (Michie et al., 2013)\]
223728996|NCT05154006|BEHAVIORAL|Instruction on how to perform a behavior|"For the target behavior reduce carried weight information on recommended weight limits will be given. The women will be encouraged, that even if these limits may not be feasible for them, any reduction of weight can still reduce the strain on the pelvic floor.~For the target behavior safe lifting techniques, instructions to learn the correct behavior (how to perform safe lifting techniques?) based on leaflets developed and validated by Caagbay et al., (2017, 2020) \[4.1 Instruction on how to perform a behavior (Michie et al., 2013)\]"
224294619|NCT03365999|DRUG|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
224294620|NCT05114759|DRUG|SHR-A2009|"In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy."
223728997|NCT05154006|BEHAVIORAL|Self-efficacy|Self-efficacy will be promoted by the four sources of self-efficacy (Bandura, 1977): 1) Mastery Experiences (experience that one is able to successfully apply the behavior), vicarious experience (observing successful others performing the safe carrying behavior), verbal persuasion (receiving positive feedback when performing the behavior and encouraging messages to do so) and emotional state (e.g. being in a positive emotional state when performing the behavior). \[6.1 Demonstration of the behavior; 8.1 Behavioral practice/rehearsal; 15.1 Verbal persuasion about capability; 15.2 Mental rehearsal of successful performance; 15.3 Focus on past success;15.4 Self-talk; 5.4 Monitoring of emotional consequences (Michie et al., 2013)\]
223728998|NCT05154006|BEHAVIORAL|Social Support|A self-selected social partner from the same or neighboring household (e.g. husband, mother-in-law) will be involved in the learning process (observational learning, feedback). The partner will participate in the intervention activities and will be instructed to provide emotional social support and practical informational support. \[3.2 practical support, 3.3 emotional support; 6.3 Information about others' approval (Michie et al., 2013).\]
223728999|NCT04225611|DRUG|Dexamethasone|The investigators have developed a topically-applied corticosteroid-delivery system that has the potential to treat recurrent cystoid macular edema with fewer risks to patient, and more dose control. The system is comprised of a drug-polymer film that is completely encapsulated within the periphery of a hydrogel that is commonly used to make contact lenses.
223729000|NCT05284214|BIOLOGICAL|Sargramostim|Sargramostim for injection
223729001|NCT05284214|BIOLOGICAL|Ipilimumab-containing therapy|Treatment for cancer containing ipilimumab at either 1 mg/kg or 3 mg/kg, intravenously..
223729002|NCT04347044|OTHER|Pulmonary Rehabilitation|Exercise training+ Optimal medication and clinical follow-up
223989480|NCT00443209|DRUG|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
223989481|NCT03945643|DRUG|Sildenafil|50mg administration of sildenafil, one time, one hour prior to measurements.
223989482|NCT03945643|OTHER|Placebo|50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
223989483|NCT04522661|PROCEDURE|Vitrectomy|Vitrectomy within 48 hours of randomisation
223989484|NCT04522661|PROCEDURE|Intravitreal antibiotics|Intravitreal Antibiotics at 48 hours
223989485|NCT03219762|DRUG|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
223989486|NCT05564481|BEHAVIORAL|diabetes education and parent coaching support|Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
223989487|NCT03452683|BEHAVIORAL|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
223989488|NCT05489562|DEVICE|Intraoral Suction|stabilization of the tongue using intraoral suctioning and its effects on sleep parameters in patients with obstructive sleep apnea (OSA).
223989489|NCT03427983|PROCEDURE|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
223989490|NCT03427983|PROCEDURE|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
223989491|NCT03922607|DRUG|ABBV-157|ABBV-157 will be administered orally as capsule
223989492|NCT03922607|DRUG|Placebo for ABBV-157|Placebo for ABBV-157 will be administered orally as capsule
223989493|NCT06300983|BEHAVIORAL|Psychoeducative|The intervention consiste of 5 sessions (Table 1), with each lasting 100 minutes and delivered on a weekly basis. Individual meetings will be conducted with each participant prior to starting the group work. These were considered pre-intervention sessions, during which patients provided informed consent to participate in the study and the first assessment tests were administered.
223989494|NCT06300983|BEHAVIORAL|Placebo|The control group, which do not receive any psychoeducative intervention
223989495|NCT05426993|OTHER|Complex decongestive physiotherapy|CDT is a treatment approach consisting of manual lymph drainage, skin care, compression bandage and exercises.
223989496|NCT01151514|OTHER|Nephrologist referral|Nephrologist specialty, renal replacement therapy
223989497|NCT01486368|DRUG|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
223989498|NCT01628692|DRUG|Daclatasvir|Tablets, oral, 30 mg, once daily
223989499|NCT01628692|DRUG|Simeprevir|Capsule, oral, 150 mg, once daily
223989500|NCT01628692|DRUG|Ribavirin|Tablets, oral, 500-600 mg, twice daily
223989501|NCT04563299|DRUG|Dextenza 0.4Mg Ophthalmic Insert|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
223989502|NCT04563299|DRUG|Prednisolone Acetate|All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
223989503|NCT03959852|DRUG|Fentanyl|1 mg/kg of Fentanyl IV administered over at least 1 minute
223989504|NCT03959852|COMBINATION_PRODUCT|Fentanyl and Ketamine|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
223989505|NCT03959852|DRUG|Ketamine|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
223989506|NCT03212755|DIAGNOSTIC_TEST|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
223989507|NCT04452591|BIOLOGICAL|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
223989508|NCT04452591|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
223989509|NCT00047541|DRUG|Alcon Investigational Agent|
223989510|NCT00409409|DRUG|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
223989511|NCT00409409|DRUG|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
223989512|NCT04296045|DIETARY_SUPPLEMENT|MCE|Ingestion of 15g MCE in water after min 10 hours of fasting
223989513|NCT04296045|DIETARY_SUPPLEMENT|Glucose|Ingestion of 15g glucose in water after min 10 hours of fasting
223989514|NCT00643318|RADIATION|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as \< 2 cm from carina and \< 2 cm from right and left mainstem bronchus and/or \< 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being \> 2 cms from the carina and \> 2 cms from the right and left mainstem bronchus and/or \> 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
223989515|NCT02472054|DRUG|Alemtuzumab|
223989516|NCT02472054|DRUG|Methyl Prednisolone (MP)|
223989517|NCT02472054|DRUG|Cyclosporin A (CSA)|
223989518|NCT00820664|DRUG|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
223729003|NCT04347044|OTHER|Standart care|Optimal medication and clinical follow-up
223989519|NCT00820664|DRUG|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
223989520|NCT00820664|DRUG|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
223989521|NCT03635086|BIOLOGICAL|MV-CHIK lyophilised formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, lyophilized low dose (powder for suspension in water for intramuscular \[IM\] injection): 5x10\^4 ±0.5 log tissue culture infectious dose 50 (TCID50)/dose.
223989522|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
223989523|NCT03635086|BIOLOGICAL|MV-CHIK SPS® formulation, low dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid SPS® low dose (suspension for IM injection): 1x10\^5 ±0.5 log TCID50/dose.
223989524|NCT03635086|BIOLOGICAL|MV-CHIK liquid frozen formulation, high dose|MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, liquid frozen high dose (suspension for IM injection): 1x10\^6 ±0.5 log TCID50/dose.
223989525|NCT03635086|OTHER|Placebo|Sterile physiological saline solution (0.9% sodium chloride \[NaCl\]), administered by IM injection.
223989526|NCT00080860|GENETIC|microarray analysis|
223989527|NCT00080860|OTHER|immunohistochemistry staining method|
223989528|NCT00080860|PROCEDURE|conventional surgery|
223989529|NCT00080860|PROCEDURE|lymphangiography|
223989530|NCT00080860|PROCEDURE|radionuclide imaging|
223989531|NCT00080860|PROCEDURE|sentinel lymph node biopsy|
223989532|NCT00080860|RADIATION|technetium Tc 99m sulfur colloid|
223989533|NCT05290012|OTHER|Dark Chocolate|A daily consumption of 36 g dark chocolate (400 mg/day flavanol) was made. No Cocoa/chocolate product was consumed other than the intervention product.
223989534|NCT04353206|BIOLOGICAL|Multiple Doses of Anti-SARS-CoV-2 convalescent plasma|Subjects to receive single or double plasma units infused on day 0 and potentially days 3 and 6.
223989535|NCT00458588|OTHER|physiologic testing|
223989536|NCT00458588|OTHER|questionnaire administration|
223989537|NCT00458588|PROCEDURE|breast imaging study|
223544713|NCT03116425|DEVICE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
223989538|NCT00458588|PROCEDURE|dual x-ray absorptometry|
223989539|NCT00458588|PROCEDURE|evaluation of cancer risk factors|
223989540|NCT00458588|PROCEDURE|magnetic resonance imaging|
223989541|NCT06544681|PROCEDURE|Coronary stenting with planned drug eluting stent (DES).|Stenting will be performed with OCT guidance according to the algorithm described in the protocol. A deep learning-based OCT system was used to measure the adherence of coronary stents.
223989542|NCT00478205|DRUG|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
223989543|NCT00478205|DRUG|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
223989544|NCT03214445|PROCEDURE|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
223989545|NCT03214445|PROCEDURE|Sealing margins with seal|Seal the margin of restoration with sealant without filler
223989546|NCT04748536|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
223989547|NCT04748536|DRUG|Placebo|Matching placebo for IRL201104
224294621|NCT05213260|OTHER|Flipped Teaching method|Before the clinical skill laboratory session, the students will receive the learning materials that they have to read and assimilate before the in-class part which will include interactive, discussion-oriented, and practice-oriented activities.
223989548|NCT00947323|DRUG|Simvastatin|simvastatin 20 daily for six months.
223989549|NCT00947323|DRUG|Placebo|
223989550|NCT03993275|DEVICE|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
223989551|NCT04003194|OTHER|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
223989552|NCT04003194|OTHER|Green Beans - control|The control was 1/2 cup of green beans each day.
223989553|NCT01012947|BEHAVIORAL|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
223989554|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
223989555|NCT01012947|BEHAVIORAL|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
223989556|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
223989557|NCT01012947|BEHAVIORAL|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
223989558|NCT01078961|DRUG|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
223989559|NCT01078961|DRUG|sorafenib|400mg taken orally twice a day
223989560|NCT00382447|DEVICE|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
223989561|NCT00382447|DEVICE|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
223989562|NCT05837299|DRUG|IMC008|allowing 10% dose error
223989563|NCT01010087|DRUG|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
223989564|NCT00405938|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
223989565|NCT00405938|DRUG|Anastrozole|anastrozole (1 mg orally daily)
223989566|NCT00405938|DRUG|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
223989567|NCT04016272|DEVICE|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
223989568|NCT04016272|DEVICE|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
223989569|NCT00825305|BIOLOGICAL|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
223989570|NCT00825305|BIOLOGICAL|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
223989571|NCT03617289|DRUG|Magnesium Sulfate|
223989572|NCT03617289|DRUG|D5W|
223989573|NCT00435747|DRUG|PARECOXIB SODIUM|
223544714|NCT03116425|DEVICE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
223729004|NCT05174260|DEVICE|perfusion index, pleth variable index|a clip will be attached to the patient's finger and the perfusion index and pvi will be measured
223989574|NCT01854606|DRUG|AEB071|a Protein Kinase C Inhibitor
223989575|NCT01854606|DRUG|Everolimus|mTOR inhibitor
223989576|NCT03272737|PROCEDURE|1RM Test|The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study \[37\]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
223989577|NCT03272737|PROCEDURE|Speed gait test|To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of \< 0.,9 m/s (Guralnik, 1994).
223989578|NCT03272737|DEVICE|Venous occlusion plethysmography protocol|A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
223729005|NCT02863029|PROCEDURE|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
223729006|NCT01244425|DRUG|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
223729007|NCT01244425|OTHER|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
223729008|NCT01259505|BIOLOGICAL|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
223729009|NCT01240447|BIOLOGICAL|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
223729010|NCT01240447|OTHER|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
223729011|NCT00159471|DRUG|capecitabine, gemcitabine, docetaxel|
223729012|NCT02619955|OTHER|samples with DNA|
223729013|NCT03705676|BEHAVIORAL|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
223729014|NCT03705676|DEVICE|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
223729015|NCT03705676|DEVICE|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
223729016|NCT02749981|PROCEDURE|blood and tissue sampling|
223729017|NCT02516683|OTHER|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
223729018|NCT03861351|DEVICE|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
223729019|NCT01923493|OTHER|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
223729020|NCT01923493|OTHER|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
223729021|NCT03785002|OTHER|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
223729022|NCT03785002|OTHER|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
223729023|NCT06361030|DRUG|surufatinib combined with gemcitabine plus nab-paclitaxel|"Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\&#39;s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery."
223729024|NCT02374801|DEVICE|"SonR automatic optimization feature turned ON (AV+VV)."|
223729025|NCT01202474|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
223989579|NCT03272737|DEVICE|Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity|"Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity \[33\]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ \* distance travelled by the pulse wave (m) / transit time(s)."
223989580|NCT03272737|DEVICE|Isometric handgrip exercise protocol|In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
223989581|NCT03272737|DEVICE|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
223989582|NCT03272737|DEVICE|Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)|Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
223989583|NCT03272737|DIAGNOSTIC_TEST|Quality of Life EuroQol-5 Domain|This questionnaire is used to estimate the quality of life in participants before and after the study.
223989584|NCT03272737|OTHER|Anthropometric Assessment|Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
223989585|NCT01915797|OTHER|blood and tumor samples|all tumor pathology associated with anomaly of development
223989586|NCT01587482|PROCEDURE|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
223989587|NCT03473210|DRUG|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
223729026|NCT01202474|DRUG|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
223989588|NCT03473210|DRUG|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
223989589|NCT03473210|PROCEDURE|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
223989590|NCT03783676|DRUG|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
223989591|NCT03783676|DRUG|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
223989592|NCT02580747|BIOLOGICAL|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
223989593|NCT05671497|DRUG|Cilostazol 100 MG|An antiplatelet agent used for intermittent claudication , it has an anti-inflammatory effect which will help control patients with Rheumatoid arthritis
223989594|NCT05671497|DRUG|conventional synthetic antirheumatic drugs|methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily
223729027|NCT04575922|DRUG|Nivolumab|Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.
223989595|NCT02777645|OTHER|Growth, feeding evaluation|Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
223729028|NCT04575922|DRUG|Ipilimumab|Administered into vein by intravenous infusion day 1 of each 6 week study cycle.
223989596|NCT04625010|OTHER|Swaddling|Swaddling is a wrapping procedure in which a baby's arms and legs are comfortable, sometimes only the arms are wrapped inside, and two ends of fabric are crossed on the chest of the baby, generally with thin cotton and soft fabric or a blanket. In the swaddling group, neonates were placed in the supine position on a blanket. In compliance with the newborn anatomic posture, the legs were wrapped in the flexion and abduction position. The arms of the neonates were placed close to their torso with both hands, without restraining limb movements. Swaddling was carried out 1 minute before the heel stich procedure and continued 3 minutes after the procedure. The neonate remained on the examination table during the swaddling procedure. Swaddling was applied not too loose or too tight during the procedure.
223729029|NCT04575922|RADIATION|Radiation Therapy|3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.
223729030|NCT06242951|DIAGNOSTIC_TEST|VO2 max assessment|Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)
223729031|NCT01299792|OTHER|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
223729032|NCT04073589|BIOLOGICAL|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
223729033|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
223729034|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
223729035|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
223729036|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
223729037|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
223729038|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
223729039|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given 2 doses intravenously
223729040|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
223729041|NCT02743871|BIOLOGICAL|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
223729042|NCT02743871|OTHER|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
223729043|NCT05471622|BEHAVIORAL|Nudge for PHPC Referral|The case manager and covering providers for inpatients who have been identified according to the study's inclusion criteria as appropriate for Penn Home Palliative Care (PHPC) upon hospital discharge will be asked to refer their patient for these home palliative care services.
223729044|NCT05042167|OTHER|Resistance exercise|4 total resistance exercises that target all major muscle groups.
223729045|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
223729046|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
223729047|NCT00260351|BIOLOGICAL|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
223729048|NCT00531999|DRUG|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
223729049|NCT00531999|DRUG|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
223989597|NCT04625010|OTHER|Maternal holding|Neonates in this group were held in their mothers' lap while their mothers were seated reclining on a comfortable chair. Neonates remained clothed in their mothers' lap during the heel stick procedure, and no breastfeeding was administered during the procedure. Holding was continued for a minimum of 3 minutes during and after the procedure.
223989598|NCT03235206|OTHER|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
223989599|NCT04684433|OTHER|Data extraction from medical files|Data extraction from medical files
223989600|NCT01680081|OTHER|Adenosine stress dynamic CT perfusion|
223989601|NCT01850030|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
223989602|NCT01850030|DRUG|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
223989603|NCT01850030|DRUG|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
223989604|NCT01850030|DRUG|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
223989605|NCT00463853|PROCEDURE|Autologous stem cell therapy|
223989606|NCT00463853|PROCEDURE|CABG|
223989607|NCT00463853|RADIATION|CMRI|
223989608|NCT02920840|DEVICE|Intermittent theta-burst stimulation|see associated arm/group description
223989609|NCT02920840|DEVICE|Negative-peak-triggered-TMS|see associated arm/group description
223989610|NCT02920840|DEVICE|Open-loop replay TMS|see associated arm/group description
224121141|NCT05847270|PROCEDURE|Simple posterior approach treatment strategy|Preceding the surgical procedure, an assessment was conducted utilizing 1/6 weight traction to ascertain the reducibility of atlantoaxial dislocation. Upon confirmation of IAAD, the chosen approach involved the utilization of a specially designed spreader, tailored to the patient's atlanto-axial joint morphology. Upon entering the joint space, the spreaders were skillfully maneuvered to gently open the joint through rotational and prying actions. Subsequently, two cages, pre-filled with autogenous bone grafts, and designed with the appropriate angle and height, were meticulously placed between the Atlanto-axial joints via a posterior approach. This procedure facilitated direct distraction and reduction of the dislocated joint. In the final step of the surgical process, stabilization was achieved by securing the atlas and axis with screws and rods. This surgical approach was selected to address the unique challenges posed by IAAD, with the aim of achieving optimal patient outcomes.
223989611|NCT01407055|BEHAVIORAL|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
224121142|NCT00000650|DRUG|Ditiocarb sodium|
223989612|NCT01407055|BEHAVIORAL|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
223989613|NCT02263807|PROCEDURE|MPFL Group|MPFL reconstruction or standard treatment followed by physiotherapy
223989614|NCT02263807|PROCEDURE|Control|Arthroscopy followed by active rehabilitation
223989615|NCT04678739|DRUG|Remdesivir|Remdesivir 100 IV Infusion as a lyophilized powder
223989616|NCT04678739|DRUG|Tocilizumab|Actemra IV Infusion
224121143|NCT06672770|OTHER|Functional Inspiratory Muscle Training|"The functional inspiratory muscle training group will perform basic inspiratory muscle training in the first four weeks of the study and the following exercises with the Powerbreath device in muscle training in the following four weeks:~1. Diaphragmatic breathing exercises~2. Warm-up exercises~3. Trunk strength and lumbopelvic stability exercises~4. Dynamic trunk exercises~5. Postural control exercises~6. Cool-down exercises"
224121144|NCT06672770|OTHER|Basic Inspiratory Muscle Training|The basic inspiratory muscle training group will do muscle training with the POWERbreathe device for eight weeks.
224121145|NCT01635556|BEHAVIORAL|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
224121146|NCT02177851|DIETARY_SUPPLEMENT|Single oral iron dose of 120 mg per day for 3 consecutive days|
224121147|NCT02177851|DIETARY_SUPPLEMENT|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
224121148|NCT03596177|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
224121149|NCT03596177|DRUG|Placebo|Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
224121150|NCT06047301|BEHAVIORAL|Pathways|Delivered by a nurse or other healthcare provider, includes 2 in-person sessions, and phone check-ins, and occurs primarily during infusion visits. Includes a Pathways Toolkit with handouts on values and goal setting, as well as resources on symptom management, lung cancer stigma, communication strategies, and other cancer center resources.
224121151|NCT06047301|BEHAVIORAL|Enhanced Usual Care|Pathways Toolkit handouts on symptom management, lung cancer stigma, communication strategies, and other cancer center resources provided to participants. The Toolkit will be reviewed with patients in person to orient them to its purpose and contents.
224121152|NCT01736202|BIOLOGICAL|fat orally|Oral ingestion of palm oil or canola oil or water at timepoint zero
224121153|NCT00248313|DRUG|Rapamune®|
224121154|NCT05509205|OTHER|Turkish Validity and Reliability of The PSS Scale|This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
224121155|NCT05633576|DRUG|steroid eye drops|Self-administration of steroid eye drops three times a day for four consecutive weeks.
224121156|NCT05633576|DRUG|Placebo|Self-administration of placebo eye drops three times a day for four consecutive weeks.
224121157|NCT03398018|DRUG|repository corticotropin injection|80 units twice per week as a subcutaneous injection
223989617|NCT05006118|DRUG|Radio-labeled rodatristat ethyl 600 mg|Single dose of rodatristat ethyl 600 mg as an oral suspension containing a mixture of \[12C\]-rodatristat ethyl and \[14C\]-rodatristat ethyl to contain approximately 600 microcuries (uCi) of radioactivity
223989618|NCT02708381|OTHER|Screening|Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
223989619|NCT05784610|DEVICE|Monitorage by TOF/PTC|Installation of TOFscan® and monitoring by MAR appreciation on one of the patient's wrists and installation of TOFscan® and monitoring by ATP mode (MAR blind) on the other wrist Installation of TOFscan® and monitoring by ATP mode
223989620|NCT05784610|DEVICE|Monitorage by ATP|Installation of TOFscan® and monitoring by ATP mode on one of the patient's wrists
223989621|NCT06017908|DEVICE|Optokinetic stimulation through Virtual Reality|The experiment will be conducted in two phases. In the first experiment the patients will be passively watch the visual images while seated. An optokinetic stimulus will be delivered through the VR headset by displaying rotating visual patterns. In the second trial they will have to perform the enhanced rod and disc test.
223989622|NCT01258621|PROCEDURE|Laparoscopy|Laparoscopic distal pancreatectomy
224121158|NCT01916122|DRUG|Fluorestradiol (FES)|
224121159|NCT01916122|PROCEDURE|PET/CT Imaging|
224121160|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
224121161|NCT01301742|DRUG|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
223989623|NCT05005702|OTHER|Inspiratory Muscle training|"Patients received IMT for 30-minute per day, 3 days per week for 3 weeks using the Threshold Inspiratory Muscle training device (product Phillips). During training, patients were instructed to maintain diaphragmatic breathing, and try to maintain 10-15 breaths, and rested 5-10 between breaths. As soon as the patients managed; they were encouraged to maintain 25-30 breaths at each workload. All patients wore nose-clip during training.~Inspiratory muscle training diaries were checked weekly. The inspiratory load was set at 40%of maximal inspiratory pressure."
223989624|NCT02214953|DRUG|BI 11634 ER formulation A|
223989625|NCT02214953|DRUG|BI 11634 ER formulation B|
223989626|NCT02214953|DRUG|BI 11634 ER formulation M|
223989627|NCT02214953|DRUG|BI 11634 ER formulation C|
223989628|NCT02214953|DRUG|BI 11634 IR tablet|
223989629|NCT02499523|PROCEDURE|THR with conventional technique|THR with conventional technique.
223989630|NCT02499523|PROCEDURE|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
223544715|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
223729050|NCT04667650|OTHER|Use of nomogram for predictions of Ocular Mysathenia Gravis generalization|The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.
223729051|NCT01366170|GENETIC|microarray analysis|
223729052|NCT01366170|GENETIC|protein expression analysis|
223729053|NCT01366170|GENETIC|western blotting|
223729054|NCT01366170|OTHER|flow cytometry|
223729055|NCT01366170|OTHER|immunohistochemistry staining method|
223729056|NCT01366170|OTHER|laboratory biomarker analysis|
223729057|NCT01366170|OTHER|mass spectrometry|
223729058|NCT04073069|DRUG|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
223729059|NCT04073069|DRUG|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
223989631|NCT00505154|DRUG|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
223989632|NCT00505154|DRUG|placebo|placebo
223989633|NCT01267240|DRUG|Capecitabine|Given PO
223989634|NCT01267240|DRUG|Vorinostat|Given PO
223989635|NCT02638103|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
223989636|NCT02638103|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
223989637|NCT01770795|DRUG|Genexol-PM/Gemcitabine|
223989638|NCT01731964|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
223989639|NCT01731964|DEVICE|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
223989640|NCT00214747|DRUG|Vehicle gel formulations|
224121162|NCT01301742|DRUG|BI 10773|1 tablet single dose BI 10773 in the morning
224121163|NCT01321294|PROCEDURE|laparoscopic anti-reflux surgery|
224121164|NCT02614872|DRUG|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) \[GLASSIA®\] add-on pharmacotherapy and Institution standard of care (SOC)
224121165|NCT00013624|DRUG|IV Levodopa|
223544716|NCT03116425|PROCEDURE|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
223989641|NCT05864404|DRUG|remimazolam-remifentanil|In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
223989642|NCT05864404|DRUG|dexmedetomidine-remifentanil|In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
223989643|NCT04545333|DIAGNOSTIC_TEST|clonoSEQ Assay|minimal residual disease (MRD) assay using blood, bone marrow, or other tissue containing tumor cells
223989644|NCT05520853|RADIATION|SBRT combined with PD-1 inhibitors and thoracic hyperthermia|At least one lesion (primary or metastatic) was selected for SBRT treatment, and the radiotherapy dose of each lesion was 32Gy/4Fx. SBRT was combined with thoracic hyperthermia from the first fraction, and hyperthermia was performed 6 times, twice a week. PD-1 inhibitor was used on the second day after the completion of SBRT. The PD-1 inhibitor was administered at a dose of 200mg every time, every 3 weeks for 2 years (35 times total), or until the investigators deem that the patient need to discontinue the drug because of treatment-related toxicity or disease progression.
223989645|NCT04633850|DRUG|Dexamethasone|Intravenous dexamethasone 8 mg. Given once at the end of surgery.
223544717|NCT03116425|PROCEDURE|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
223544718|NCT03577262|OTHER|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
223544719|NCT00568594|DRUG|APL180|
223544720|NCT00568594|DRUG|Placebo|
223544721|NCT01336244|DRUG|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
223544722|NCT01336244|DRUG|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
223989646|NCT04633850|DRUG|Bupivacain|"Bupivacaine dose according to weight. \<60 kg: Total dose 100mg 60-90kg: Total dose 150mg \>90kg: Total dose 200mg~Given once at the end of surgery."
223989647|NCT01098916|RADIATION|Home X-rays|X-rays examinations performed at home
223989648|NCT01098916|RADIATION|X-rays in hospital|
223989649|NCT02292472|DRUG|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
223989650|NCT02292472|DRUG|Placebos|Inject intramuscularly once in visit 2
223989651|NCT02037620|DEVICE|5-6-5 Specify electrode|
223989652|NCT02037620|DEVICE|Restore Advance Pulse Generator|
223989653|NCT05312346|DIAGNOSTIC_TEST|seum zinic,vit B12, parathyriod function|seum zinic,vit B12, parathyriod function
223989654|NCT02275208|PROCEDURE|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
223989655|NCT00270192|BEHAVIORAL|individual lactation counseling and educational material|
223989656|NCT00270192|BEHAVIORAL|educational material alone|
223989657|NCT00270192|BEHAVIORAL|routine antenatal care without educational intervention|
224121166|NCT04666324|DRUG|Simethicone Solution|Oral daily treatment for four weeks
224121167|NCT04666324|DIETARY_SUPPLEMENT|Multilac Baby|Oral daily treatment for four weeks
224121168|NCT06673693|DRUG|Tislelizumab|SBRT
223989658|NCT04527484|DRUG|SHR-1314|each group subjects will be given different formulations of SHR-1314
223544723|NCT06266559|OTHER|Chang Geng Healthy Drink|Chang Geng Healthy Drink consists of Zingiberis Rhizoma, Codonopsis pilosula, Atractylodis Macrocephalae Rhizoma, Poria cocos, Citri reticulatae Pericarpium
223544724|NCT00451399|DRUG|metformin|
223544725|NCT00451399|BEHAVIORAL|lifestyle intervention|
223544726|NCT04538131|DEVICE|sensor-driven position-adaptive SCS|Medtronic sensor-driven position-adaptive SCS is capable to monitor the position change and change the parameters accordingly, so as to reduce the position change related side effects.
223544727|NCT04538131|DEVICE|conventional SCS|Conventional SCS can not change the parameter when the body position changes.
223989659|NCT03132675|BIOLOGICAL|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks
223989660|NCT03132675|BIOLOGICAL|Pembrolizumab|Intravenous 3 weekly treatments
223989661|NCT03132675|DEVICE|ImmunoPulse|Device that electroporates the tavokinogene telseplasmid
223989662|NCT05639608|PROCEDURE|SCALING|SCALING WILL BE DONE AT BASELINE IN TEST GROUP.
223989663|NCT05350046|DEVICE|Ear-worn prototype devices|Hearing instrument including sensors to track movement and estimations of biological information.
223989664|NCT02933086|OTHER|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
223989665|NCT02933086|OTHER|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
223989666|NCT01005797|DRUG|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
223989667|NCT00171912|DRUG|imatinib mesylate|
223989668|NCT02817061|DEVICE|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
224121169|NCT02419183|OTHER|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
224121170|NCT02419183|OTHER|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
223544728|NCT03926377|PROCEDURE|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
223544729|NCT03926377|BIOLOGICAL|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
223989669|NCT05973123|BEHAVIORAL|Group Nature Outings|A 6 week nature-based intervention for pediatric anxiety. Every other week group outings for families in nature, alternating with every other week nature-based goals for families at home.
223989670|NCT05973123|BEHAVIORAL|Family Outings|6 weeks of weekly outings into nature. These will be supported by the research team through a weekly text message and written materials on skill building and activities to do outdoors.
223989671|NCT05037253|DRUG|Vitamin D|Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week, followed by a switch to a daily intake of 5,000 IU for 3 months or low dose vitamin D (2,000 IU weekly) for 3 months.
223989672|NCT02482610|OTHER|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
224121171|NCT01745627|DEVICE|755nm Alex laser|
224121172|NCT04180410|DEVICE|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
224121173|NCT00390364|DRUG|everolimus|
224121174|NCT00390364|PROCEDURE|antiangiogenesis therapy|
224121175|NCT00390364|PROCEDURE|biopsy|
224121176|NCT00390364|PROCEDURE|diagnostic procedure|
224121177|NCT00390364|PROCEDURE|gene expression analysis|
224121178|NCT00390364|PROCEDURE|immunohistochemistry staining method|
224121179|NCT00390364|PROCEDURE|laboratory biomarker analysis|
224121180|NCT00390364|PROCEDURE|mutation analysis|
224121181|NCT00390364|PROCEDURE|protein tyrosine kinase inhibitor therapy|
224121182|NCT00390364|PROCEDURE|reverse transcriptase-polymerase chain reaction|
223989673|NCT02482610|OTHER|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
223989674|NCT02482610|OTHER|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
223989675|NCT02928211|DEVICE|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
223989676|NCT02928211|DRUG|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
223989677|NCT02928211|RADIATION|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
223989678|NCT02653209|DRUG|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
223989679|NCT02653209|DRUG|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
223989680|NCT02653209|DRUG|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
223989681|NCT04268056|DIAGNOSTIC_TEST|Collection of skin culture samples|Collection of skin culture samples using a sterile swab. the swab will gently rubbed on the skin on the 3 different skin areas. The target areas are i) regions surrounding the RT treatment area (if possible, not from the scar area or from skin folds areas), ii) a control site of the normal (healthy) breast , iii) a control area on the forehead.
223989682|NCT06543563|DRUG|esketamine|After the craniotomy, a continuous infusion of ketamine at a rate of 0.3 mg/kg/h (0.3 ml/kg/h) is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
223989683|NCT06543563|DRUG|normal Saline|After the craniotomy, a continuous infusion of normal saline at a rate of 0.3 ml/kg/h is administered until the completion of electrode implantation, prior to microelectrode recording (MER) and electrode insertion. After the administration of the drug, close monitoring of the patient's blood pressure and heart rate is conducted to maintain circulatory stability.
223989684|NCT02165826|DRUG|Roflumilast|Roflumilast tablets
223989685|NCT02165826|DRUG|Roflumilast Placebo|Roflumilast placebo-matching tablets
223989686|NCT02165826|DRUG|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
223989687|NCT00597142|DEVICE|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~* Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~* Lesion length ≤15mm~* Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~* RVD 4.0-7.0mm"
223989688|NCT00005964|BIOLOGICAL|filgrastim|
223989689|NCT00005964|DRUG|cyclophosphamide|
223989690|NCT00005964|DRUG|doxorubicin hydrochloride|
223989691|NCT00005964|DRUG|etoposide|
223989692|NCT00005964|DRUG|prednisone|
223989693|NCT00005964|DRUG|vincristine sulfate|
223989694|NCT01936467|DEVICE|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
223989695|NCT01936467|DEVICE|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
223989696|NCT05535413|DRUG|UTD1 combined with capecitabine|"UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle.~Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle."
223989697|NCT05903092|DRUG|Durvalumab|1500mg IV on Day 1 of every Cycle
223989698|NCT05903092|DRUG|Monalizumab|1500mg IV on Day 1 of every Cycle
223989699|NCT05903092|DRUG|Carboplatin or Cisplatin|"On Day 1 of Cycles 1-4 by IV:~Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2"
223989700|NCT05903092|DRUG|Etoposide|80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
223989701|NCT06184659|DRUG|Meropenem|For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
223989702|NCT06184659|DRUG|Piperacillin/Tazobactam|Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion
223989703|NCT01246999|BIOLOGICAL|Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
223989704|NCT01246999|BIOLOGICAL|Trivalent Influenza Vaccine|.25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
223989705|NCT01246999|BIOLOGICAL|TIV followed by LAIV|TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
223989706|NCT01246999|BIOLOGICAL|LAIV followed by TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
223989707|NCT00746629|BEHAVIORAL|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
223989708|NCT04309695|DEVICE|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
223989709|NCT04702516|DRUG|Ozempic|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
223989710|NCT04702516|DRUG|Placebo|2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
223989711|NCT03249870|DRUG|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~* First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~* Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
223989712|NCT06378697|DRUG|AK111|Drug: AK111 subcutaneous injection at week 0,1, 4 and 4-weekly thereafter until week 48.
223989713|NCT06378697|DRUG|Placebo+AK111|Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
223989714|NCT00113815|DRUG|topiramate|15 mg/kg/day
223989715|NCT00113815|DRUG|topiramate|5 mg/kg/day
223989716|NCT00113815|DRUG|topiramate|25 mg/kg/day
223989717|NCT00113815|DRUG|placebo|placebo
224121183|NCT02630277|DRUG|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
223544730|NCT03926377|PROCEDURE|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
223544731|NCT03926377|PROCEDURE|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
223989718|NCT04536389|PROCEDURE|Office Hysteroscopy|"The hysteroscope with its light source and flowing fluid was gently introduced into the vagina allowing for gradual distention. Once this was accomplished, the anatomy was followed with delicate movements. The hysteroscope was advanced under vision to the level of the ectocervix, and guided into the endocervical canal. Once the endocervical canal was completely explored, the endoscope was advanced across the internal cervical os to allow evaluation of the panoramic view of the uterine cavity.~hysteroscopic correction of any detected lesion will be scheduled to the endoscopic operative list or the patient will receive the appropriate medical treatment."
223989719|NCT00349466|DRUG|CF101|Orally CF101 1mg
223989720|NCT00349466|DRUG|Placebo|Orally matching Placebo
223989721|NCT04608747|OTHER|Tahini|Fifty grams of tahini were consumed by 20 healthy males
224121184|NCT03201653|PROCEDURE|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
223544732|NCT05629455|DEVICE|CareSuperb COVID-19 Antigen Home Test Kit|At home COVID-19 antigen test kit
223989722|NCT02185547|DRUG|Zoloft|Sertraline treatment 25 mg
223989723|NCT02185547|BEHAVIORAL|ICBT|Internet behavioral cognitive therapy only
223989724|NCT03554720|DEVICE|ATTUNE PS Knee|The ATTUNE PS Knee is the standard implants.
224121185|NCT01052597|DRUG|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
224121186|NCT05582577|COMBINATION_PRODUCT|Intravitreal bevacizumab injection with subthreshold micropulse laser|Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser
224121187|NCT05582577|DRUG|Intravitreal bevacizumab injection alone|Group B: Intravitreal injection of Bevacizumab alone
224121188|NCT02994589|OTHER|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
224121189|NCT02994589|DEVICE|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
223989725|NCT03554720|DEVICE|ATTUNE S+ PS Knee|The ATTUNE S+ PS Knee is the enhanced fixation.
223989726|NCT04661943|DRUG|Tucidinostat|Tucidinostat Specification: 5mg / tablet. Dosage: oral, 20 mg (3 tablets) each time, twice a week, with the interval of no less than 3 days (such as Monday and Thursday, Tuesday, Friday, Wednesday and Saturday, etc.)
223989727|NCT04698746|PROCEDURE|Pericapsular nerve group block|PENG block will be made with 15 ml 0.5% bupivacaine + 2 mg dexamethasone + 14.5 ml NaCl under US-guidance
224121190|NCT02994589|OTHER|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
224121191|NCT06673121|DRUG|Traditional Chinese Medicine|Received treatment with traditional Chinese medicine
223989728|NCT04698746|PROCEDURE|Intra-articular local anesthetic injection|Intra-articular local anesthetic injection will be made with 10 ml 0.5% bupivacaine + 2 mg dexamethasone + 9.5 ml NaCl
223989729|NCT03058380|OTHER|Stated-Preferences Evaluation Instrument|A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
223989730|NCT02555553|BEHAVIORAL|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
223989731|NCT05574283|PROCEDURE|Erector spinae plane block and transmuscular quadratus lumborum block|"All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side"
223989732|NCT04012619|DRUG|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
223989733|NCT05614440|DRUG|Local anesthetic + tramadol hydrochloride|Using tramadol hydrochloride and articain HCL for inferior alveolar nerve block
223989734|NCT05614440|DRUG|Only local anesthetic|Using articain HCL for inferior alveolar nerve block
223989735|NCT03880253|DRUG|CTP-692|Placebo or CTP-692
223544733|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
223544734|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
223989736|NCT06432114|BEHAVIORAL|Sensory Awareness Program (SAP)|SAP is a new rehabilitation program for people with severe mental health problems. SAP aims to help the target group manage anxiety outburst and live an active life through sensory modulation techniques.
223989737|NCT06432114|OTHER|Treatment as usual (TAU)|Treatment as usual is standard psychiatric care for the target group.
223989738|NCT00233662|DRUG|Alefacept|
223989739|NCT04058470|DRUG|Toripalimab, Rituximab|Toripalimab in combination with Rituximab will be administered every 3 weeks up to 4 cycles.
223989740|NCT04058470|DRUG|R-CHOP Protocol|After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
223989741|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin block graft|Atraumatic extraction of non restorable tooth, then the extracted tooth will be prepared and demineralized by HCL acid and inserted as demineralized dentin block graft in the socket
223989742|NCT05347017|PROCEDURE|Alveolar ridge preservation using autogenous bone block graft|Atraumatic extraction of non restorable tooth, then the autogenous bone block graft will be harvested from the maxillary tuberosity and reshaped and inserted into the socket
223989743|NCT02986191|PROCEDURE|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
223544735|NCT01239173|DRUG|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
223544736|NCT01239173|DRUG|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
223544737|NCT01419496|GENETIC|protein expression analysis|
223544738|NCT01419496|OTHER|flow cytometry|
223544739|NCT01419496|OTHER|laboratory biomarker analysis|
223544740|NCT06314854|OTHER|Running water sound|Running water sound for experimental group Standard care for control group
223544741|NCT00739310|DEVICE|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
223544742|NCT01341535|RADIATION|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
223544743|NCT01341535|RADIATION|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
223989744|NCT02986191|PROCEDURE|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
223989745|NCT02344875|DRUG|FYU-981, (Oral single dosing)|
223989746|NCT00194324|DRUG|Miconazole nitrate|
223989747|NCT00194324|PROCEDURE|Magnetic resonance imaging|
223989748|NCT00194324|BEHAVIORAL|Moderate levels of exercise|
223989749|NCT05657756|DEVICE|Randomize clinical trial using hand dynamometer|Our research article involves 100 patients aged over 18 years old with ASAI\&II divided into two groups, 50 patients will receive atracurium (0.5 mg/kg) and 30 patients receive Rocuronium (0.6 mg/kg). All of our patients will be undergoing elective laparoscopic surgery for cholecystectomy; the patients will randomly select to receive standard anesthesia induction with propofol (2 mg/kg), fentanyl (1-2 mcg/kg), and isoflurane 1.2 Mac, except muscle relaxant. Neuromuscular will monitoring by Train-of-Four (TOF) during surgery.
223989750|NCT05161793|DEVICE|Tele-Monitor DM|Remote monitoring of CGM data to identify, contact, and provide diabetes management for patients who are having episodes of hypoglycemia, hyperglycemia and/or difficulty using their CGM device.
223989751|NCT00214253|DRUG|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
223989752|NCT05163223|BIOLOGICAL|AST-301(pNGVL3-hICD)|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
223989753|NCT05163223|DRUG|rhuGM-CSF|Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection
223989754|NCT05163223|DRUG|Placebo|Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
223989755|NCT05163223|DRUG|Pembrolizumab|Q3W; IV infusion
223989756|NCT05163223|DRUG|Capecitabine|On days 1-14 (Q3W), BID ; Oral administration,
223989757|NCT01142167|PROCEDURE|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
223989758|NCT01142167|PROCEDURE|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
223989759|NCT03930329|BEHAVIORAL|MBRP group|same as arm description
223989760|NCT02788266|PROCEDURE|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
223989761|NCT02788266|PROCEDURE|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
223989762|NCT02788266|PROCEDURE|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
223989763|NCT04082351|DIETARY_SUPPLEMENT|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
223989764|NCT04082351|DIETARY_SUPPLEMENT|ordinary water|Ordinary bottled water
223989765|NCT03428308|OTHER|Screening|Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.
223989766|NCT03428308|OTHER|Treatment|Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
223989767|NCT05730114|DRUG|Antiplatelet Drug|anti-P2Y12 oral agent administered during primary percutaneous coronary intervention.
223989768|NCT06956456|OTHER|Supervised Multicomponent Training Protocol|"Supervised Multicomponent Training Protocol~Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
224121192|NCT05585411|PROCEDURE|Left bundle branch area pacing|"LBBAP success is defined if ventricular lead is successfully placed at interventricular septum and RBB configuration observed during unipolar tip pacing.~LBB capture is defined if fulfilling criterion 1 and at least one in criteria 2.~1. RBBB configuration observed during unipolar tip pacing~2. One of the following should be met:~   1. Abrupt shortening of Stim-LVAT (stimulus to peak of the R wave in V6 \[LV activation time\]) of \>10ms during increasing output~  2. Short and constant stim-LVAT and the shortest stim-LVAT \<75ms in non-LBBB and \<85ms in LBBB~  3. Programmed stimulation by pacing lead changes QRS morphology from nonselective LBB to LV septal capture~  4. LBB potential (LBB-V interval of 15 to 35ms)~  5. Transition from nonselective LBB capture to selective LBB capture at near threshold outputs~If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be deep septal pacing (DSP)."
224121193|NCT05585411|PROCEDURE|Right ventricular pacing|Right ventricular pacing is the traditional pacing modality for ventricular pacing. Implantation of a RV pacing lead (apex or septum of right ventricle) will be attempted using the standard-of-care technique first
224121194|NCT01764646|RADIATION|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
224121195|NCT01764646|RADIATION|Volumetric modulated arc therapy|Highly conformational dose distribution
224121196|NCT01764646|RADIATION|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
224121197|NCT03860844|DRUG|Isatuximab|Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous
223729060|NCT05993468|OTHER|TMC Treatment Approach|The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.
223989769|NCT06956456|OTHER|Non-Supervised Home-Based Multicomponent Training Protocol|"Participant will receive a personalized exercise plan tailored to their fitness level.~Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
223989770|NCT02997332|DRUG|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
223989771|NCT02997332|DRUG|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
223989772|NCT02997332|DRUG|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
223989773|NCT02997332|DRUG|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
223989774|NCT00467415|BEHAVIORAL|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
223989775|NCT00467415|BEHAVIORAL|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
223989776|NCT01439867|DRUG|Cinacalcet hydrochloride|Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
223989777|NCT01439867|DRUG|Standard of Care|Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
223989778|NCT04432792|OTHER|Questionnaire|Study survey participants will be administered 3 online surveys.
223989779|NCT02806492|OTHER|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP \<60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
224121198|NCT03860844|DRUG|Dexamethasone or equivalent|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
223989780|NCT02806492|OTHER|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
224121199|NCT03860844|DRUG|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121200|NCT03860844|DRUG|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121201|NCT03860844|DRUG|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121202|NCT03860844|DRUG|Daunorubicin (nonliposomal)|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
224121203|NCT03860844|DRUG|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121204|NCT03860844|DRUG|Filgrastim or equivalent|Pharmaceutical form: Solution for injection Route of administration: Intravenous
223544744|NCT02954887|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
223544745|NCT02622477|DRUG|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
223544746|NCT03924219|OTHER|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
224121205|NCT03860844|DRUG|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
223729061|NCT03532334|DIAGNOSTIC_TEST|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, \< 1 hour
223729062|NCT01259908|PROCEDURE|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
223729063|NCT03534557|DIAGNOSTIC_TEST|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
223729064|NCT00000938|DRUG|ceftriaxone|
223729065|NCT00000938|DRUG|doxycycline|
223729066|NCT03952104|OTHER|Strength training|Strength training
223729067|NCT06012825|BEHAVIORAL|Physical Activity|"The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min)."
223729068|NCT02848651|DRUG|Atezolizumab|Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
223729069|NCT03057431|DRUG|Placebo oral capsule|Once daily for 3 years
223729070|NCT03057431|DRUG|12.5 mg hydrochlorothiazide|Once daily for 3 years
223729071|NCT03057431|DRUG|25.0 mg hydrochlorothiazide|Once daily for 3 years
223729072|NCT03057431|DRUG|50.0 mg hydrochlorothiazide|Once daily for 3 years
223729073|NCT00847860|DRUG|Cilostazol|Cilostazol 100 mg bid for 12 months
223989781|NCT02806492|OTHER|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
223989782|NCT02806492|OTHER|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
223989783|NCT02806492|OTHER|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
223989784|NCT00540462|PROCEDURE|gastric bypass|
223989785|NCT00540462|PROCEDURE|sleeve gastrectomy|
223989786|NCT03597984|RADIATION|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~\- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
223989787|NCT00157781|DEVICE|Medtronic AT500|
223989788|NCT00322244|PROCEDURE|Massage Therapy|
223989789|NCT02622555|DRUG|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
223989790|NCT00863512|DRUG|cisplatin|Given IV
223989791|NCT00863512|DRUG|docetaxel|Given IV
223989792|NCT00863512|DRUG|gemcitabine hydrochloride|Given IV
223989793|NCT00863512|DRUG|pemetrexed disodium|Given IV
223729074|NCT00847860|DRUG|Aspirin|Aspirin 100 mg qd for 12 months
223729075|NCT05245370|BEHAVIORAL|Control video|Control group 1 will see a control video consisting of basic information about the different types of psychotherapy that are covered by insurance in Germany and the process of applying for psychotherapy with the insurance. The control video is matched in duration (10 minutes), set-up and the overall topic (psychotherapy) to the intervention video testimonials.
223729076|NCT05245370|BEHAVIORAL|Rationale video|The active control group 2 will see a short rationale and the control video. The rationale is a 2:45 minute-long animated video (designed via the visual communication platform powtoon, https://powtoon.com/) explaining some of the underlying mechanisms of depression.
223729077|NCT05245370|BEHAVIORAL|Clinician testimonial|This group will see the rationale video first, followed by testimonial of a professional clinician/psychotherapist.
223729078|NCT05245370|BEHAVIORAL|Patient testimonial|This group will see the rationale video first, followed by testimonial of a patient who is being treated for depression with psychotherapy.
223989794|NCT00863512|DRUG|vinorelbine tartrate|Given IV
223989795|NCT00863512|PROCEDURE|standard follow-up care|Standard care
223989796|NCT02259660|DEVICE|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
223989797|NCT02259660|DEVICE|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
223989798|NCT05153928|DRUG|Norethisterone acetate|Norethisterone acetate for 5 months
223989799|NCT03527797|OTHER|Titration of support level|Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
223989800|NCT02015507|DRUG|ivacaftor|
223989801|NCT02015507|DRUG|VX-661|
224121206|NCT03860844|DRUG|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121207|NCT03860844|DRUG|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121208|NCT03860844|DRUG|Pegaspargase (PEG) Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
224121209|NCT03860844|DRUG|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
224121210|NCT03860844|DRUG|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
223989802|NCT02015507|DRUG|ciprofloxacin|
223989803|NCT05360498|BEHAVIORAL|Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C)|This group will get weekly calls for 16 weeks and two follow-up assessments. Participants will be asked to rate their symptoms on a 0-10 scale at each call. This group will receive the SMSH, a printed evidence-based self-care management handbook with specific modules, that will be directed to use for symptoms rated 4 or higher on a 0-10 scale. For symptoms ≥7, participants will be asked to report the symptom to their provider. At each weekly call, participants will be asked: if they tried symptom self-management strategies and, if yes, which strategies were used. These calls will take 10-15 minutes. If during 8 weeks of SMSH, either the survivor or caregiver have distress (symptoms 4 or greater on a 0-10 scale) for any two consecutive weeks during weeks 2-8, TIP-C will be added for the dyad for 8 weeks. The addition of TIP-C can start between weeks 4 and 9. Dyads will continue the SMSH in addition to the TIPC. TIP-C calls will take 35-45 minutes.
223989804|NCT05360498|BEHAVIORAL|NCI Brochure|The attention control arm will receive an NCI brochure: Facing Forward: Life After Cancer Treatment. This group will also get weekly calls for 16 weeks and complete two exit interviews. The NCI brochure will not be address, the purpose of these calls will only be to record participant's symptoms throughout the study. These calls will take about 10 minutes or less.
223989805|NCT02616159|OTHER|Oatmeal|
223989806|NCT00642525|PROCEDURE|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
223989807|NCT02037477|DRUG|Vonoprazan|Vonoprazan tablets
223989808|NCT02037477|DRUG|Esomeprazole|Esomeprazole capsules
223989809|NCT02037477|DRUG|Rabeprazole sodium|Rabeprazole sodium tablets
223989810|NCT00633269|DRUG|AZD2281|100mg Oral Dose
223989811|NCT01211301|BEHAVIORAL|Food-based, Reduced Energy Diet Plan|Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
224121211|NCT03860844|DRUG|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
224121212|NCT03860844|DRUG|L - Asparginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
224121213|NCT03860844|DRUG|Hydroxyurea|Pharmaceutical form: Solution for injection Route of administration: PO
224121214|NCT03860844|DRUG|L - Asparaginase (Erwinase)|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
224121215|NCT03809572|BEHAVIORAL|Mindfulness Based Cognitive Therapy|See Arm description
224121216|NCT05582837|DRUG|nortriptyline + topiramate|nortriptyline (7.5mg) + topiramate (10mg) taken 1x per day and escalate weekly as needed for 8 weeks
223989812|NCT01211301|OTHER|Medifast 5 & 1 Plan|Participants randomized to the Medifast group will enroll online in the Medifast 5 \& 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean \& Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are \>70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 \& 1 Plan. The Medifast 5 \& 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean \& Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 \& 1 Plan.
223989813|NCT02511444|OTHER|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
223989814|NCT06960980|BEHAVIORAL|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. During phase 1 of each training session, on a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. During phase 2 of each training session, teens will complete five 5-minute simulated drives using a fixed-base driving simulator. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
223989815|NCT06960980|BEHAVIORAL|VR-FOCAL+|Weekly for 5 weeks, teens complete a training program designed to train teens to limit the length of glances away from the roadway. The training has two phases, each of which will be administered using immersive virtual reality. The first phase will have teens switch between the upper half of a virtual reality screen which will play a simulated video drive while the bottom half contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. During the second phase of each session, teens will complete five 5-minute simulated drives in a virtual reality environment where teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
223989816|NCT04110925|GENETIC|Genetic Mutations|DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.
223989817|NCT04110925|OTHER|Inflammatory and lipid markers|Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.
223989818|NCT04110925|OTHER|Computed Tomography (CT) of the heart|Sunnybrook Patients with no history of cardiovascular disease \[ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents\], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
223989819|NCT02961257|DRUG|cabazitaxel|"* Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~* Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~* Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~* Standard cabazitaxel premedication will be used"
223989820|NCT02961257|DRUG|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
223989821|NCT02961257|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
223989822|NCT00463905|PROCEDURE|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
223989823|NCT01632826|DRUG|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
223989824|NCT02635360|DRUG|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
223989825|NCT02635360|RADIATION|Brachytherapy|Radiation is done for standard clinical care purposes.
223989826|NCT02635360|DRUG|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
223989827|NCT04602377|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|"Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression."
223989828|NCT05413005|COMBINATION_PRODUCT|ECP regular-intensity arm|"* Weeks 1-8: Once every 2 weeks: weeks 1, 3, 5, 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Once per month: weeks 9, 13 (cryo-ECP bags infused once-a-week)~* Weeks 17-24: One: week 17 (cryo-ECP bags infused every two weeks)"
224294622|NCT06045520|BEHAVIORAL|Information-Motivation-Behavioral Skills Model|1.-2.Meeting:Regarding the information component of the IMB model; Answers given by the adolescents to the epilepsy knowledge test, the topics on which the adolescent wants to get information will be agreed with the adolescent and an education training will be created.3.,4.,5.-6. Meeting:Personal motivation, which is the first step of the motivation component; A meeting will be held regarding the obstacles to the disease, attitudes and behaviors towards the disease. In order to strengthen social support systems, a one-session seizure management training will be planned with a person chosen by the adolescent from his parent or friend group.7-8. Meeting:Seizure self-efficacy and treatment compliance will be evaluated in the behavioral skills component. During training, achievable goals will be set to ask the adolescent to provide personal feedback, ask open-ended questions, engage in reflective listening, and increase personal and social motivation to comply with medical recommendations
224294623|NCT00522444|DRUG|Nebulized Magnesium Sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
224294624|NCT00522444|OTHER|Nebulized normal saline|standard of care
224294625|NCT01001260|DRUG|No ASA|Alternative antiplatelet therapy instead of aspirin
224294626|NCT01001260|DRUG|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
223544747|NCT04476667|BEHAVIORAL|e-Psychotherapy|Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
223729079|NCT02435784|OTHER|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
223729080|NCT02435784|OTHER|Treatment as usual|Patients will attend a psychiatric consultation as usual.
223729081|NCT03806998|DIETARY_SUPPLEMENT|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
223729082|NCT03806998|DIETARY_SUPPLEMENT|Placebo|Provision of placebo capsules similar to active supplement
223729083|NCT01353326|DEVICE|Cormet|Cementless hip resurfacing system
223729084|NCT01353326|DEVICE|Conserve|Cemented hip resurfacing system
223989829|NCT05413005|COMBINATION_PRODUCT|ECP accelerated-intensity arm|"* Weeks 1-8: Once every week: weeks 1- 7 (cryo-ECP bags infused twice-a-week)~* Weeks 9-16: Cryo-ECP bags infused once-a-week~* Weeks 17-24: Cryo-ECP bags infused every two weeks"
223989830|NCT05413005|BIOLOGICAL|T1DM standard of care|"The standard of care is defined as per the DOH Standards for diagnosis, management and data reporting for diabetes in combination with the DOH recommended NICE guidelines Type 1 diabetes in adults: diagnosis and management (NG17)"
223989831|NCT04516369|GENETIC|voretigene neparvovec|Voretigene neparvovec is an adeno-associated viral type 2 (AAV2) gene therapy vector driving expression of normal human retinal pigment epithelium 65 kDa protein (hRPE65) gene.
223989832|NCT04978350|BEHAVIORAL|Educational Workbook|"Let's Talk is an educational workbook on Lynch Syndrome and the benefits of cascade screening containing a series of lessons and activities on the following topics:~What is Lynch Syndrome? Why should a patient tell a patient's family members about Lynch Syndrome? Create a list of the patient's first-degree relatives at risk for inheriting Lynch Syndrome What should a patient tell family members about Lynch Syndrome? Create a script for the patient to use in discussing Lynch Syndrome with family What are common concerns the patient might hear from family members? How should the patient tell family members about Lynch Syndrome? Create a plan and goals for the patient to reach out to family members What the patient should do if conversation with family is difficult What are common terms and questions about Lynch Syndrome? How can the patient manage having Lynch Syndrome? Where can the patient find additional information about living with Lynch Syndrome?"
223989833|NCT02165553|DIETARY_SUPPLEMENT|Hibiscus sabdariffa calyces extract as a cold drink|
223989834|NCT03366532|OTHER|Dietary assessments|We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
223989835|NCT02963675|OTHER||external unexposed reference group
224294627|NCT01001260|DRUG|325 mg ASA|high dose of aspirin prior to PTCA
224294628|NCT06071819|DIAGNOSTIC_TEST|Structured Clinical Interview for DSM-5|A structured interview will be administered to confirm the diagnosis reported in clinical charts
224294629|NCT03544151|DEVICE|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
224294630|NCT04013113|DRUG|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
224294631|NCT04013113|DRUG|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
224294632|NCT04013113|OTHER|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
224294633|NCT00794482|DRUG|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
224294634|NCT02879110|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
224294635|NCT02879110|OTHER|Placebo|Placebo tablet is composed of starch.
224294636|NCT00027508|DRUG|trabectedin|
224121217|NCT06693596|DIAGNOSTIC_TEST|Group 2: Conservative management (follow-up)|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the adnexal mass is seen and if the decision is to manage the adnexal mass conservatively, the patient will be re-scanned at 6 weeks (maximal range 6-8 weeks), 3 months (+/- 2 weeks) and 12 months (maximal range 10-14 months)"
224121218|NCT06693596|PROCEDURE|Group 1: Surgical management|"A standardised transabdominal examination is performed, including color or power Doppler examination. Transvaginal ultrasonography can be performed in sexually active adolescents with consent. Transrectal examination is also acceptable for younger patients who are not sexually active. All the variables required for the Simple Rules, simple descriptors and ADNEX model are assessed.~Before entering ultrasound information about the tumour and getting model results, the ultrasound examiner' s diagnosis (benign, borderline, malignant; specific diagnosis) based on subjective assessment is recorded. Results based on Simple Rules, simple descriptors and ADNEX model are documented as well.~If the patient requires surgery, no further ultrasound scans will be required."
224121219|NCT00968578|DRUG|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
224121220|NCT00968578|DRUG|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
224121221|NCT05814406|DRUG|JW0201|JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
224121222|NCT05814406|DRUG|Placebo|C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2204: 10 mg/day for 24 Weeks(PO, BID)
224121223|NCT06713213|OTHER|Flow-regulated nasal oxygen delivery system (FRNDS)|"FRNDS is a novel cannula device that can both measure tidal volume (VT) in real time while simultaneously delivering air to the test subject.~After collecting data without any flow through the FRNDS cannula for 2 minutes, varying amounts of medical air ( 21% Fio2) starting with 2 Liters for two minutes , 4 liters for 2 minutes, 6 liters for two minutes and 8 liters for two minutes would be delivered while monitoring and recording data previously described with the FRNDS device."
223989836|NCT03743779|BEHAVIORAL|Mastering Diabetes|"The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q\&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered."
224121224|NCT06703190|BIOLOGICAL|Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated|Non-interventional observed exposure of the receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation) ≥14 days before testing for SARS-CoV-2
224121225|NCT06703190|BIOLOGICAL|Not vaccinated with 2024-2025 formulated COVID-19 vaccine|The reference group will be no receipt of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation), or any other 2024-2025 formulated COVID-19 vaccine, ≥14 days before testing for SARS-CoV-2.
224121226|NCT06715982|DRUG|JAK Inhibitor|JAK inhibitors for 28 days
224121227|NCT04384263|BEHAVIORAL|Tai Chi|Participants in the Tai Chi group will practice a Yang style, 8-form Tai Chi routine. Specifically, the routine will incorporate slow, deep breathing and mental relaxation by utilizing Tai Chi movements which: 1) are slow and smooth; 2) without break or pause; and 3) have minimal muscular force and exertion. In addition, investigators will emphasize the breathing techniques of Tai Chi exercise. Investigators will adopt methods of progression to enable the participants learn and safely adapt to the Tai Chi routine and improve skills of practicing, specifically: 1) Tai Chi forms will be taught one at a time; 2) participants will receive instructional videos with step-by-step instructions of how to perform the new Tai Chi form that has been taught in the live online Tai Chi exercise session. Participants will be encouraged to practice Tai Chi offline between live online Tai Chi exercise sessions; however, no time requirement will be proposed.
224121228|NCT01556399|OTHER|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
223989837|NCT04360720|DRUG|Antiplatelet Monotherapy|"All subjects randomized to the Monotherapy Group will have acetylsalicylic acid discontinued immediately after randomization.~Subjects randomized to the Monotherapy Group will be treated with ticagrelor or prasugrel alone until the end of the study, at Month 12."
223989838|NCT01673022|DRUG|IC Green|IC Green
224121229|NCT05901597|DEVICE|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer|Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer
224121230|NCT05482646|BEHAVIORAL|Tai Chi|The Tai Chi intervention will be prescribed as a 3-month program with two 1.5-h sessions weekly instructed by qualified Tai Chi instructors.
224121231|NCT05482646|BEHAVIORAL|Conventional exercise|The conventional exercise intervention will be prescribed as a 3-month program with two 1.5-h sessions of generic fitness training weekly instructed by qualified instructors.
224121232|NCT05482646|BEHAVIORAL|Health Education Control|Participants in the control group will participate in a health education program delivered by research personnel.
224121233|NCT05329155|DRUG|Heparin Sodium Injection|Heparin Sodium Injection (100U/Kg body weight)
224121234|NCT06327321|DRUG|Deucravacitinib|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
224121235|NCT06327321|OTHER|Volunteer without treatment|Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
223989839|NCT04843410|OTHER|Hand-foot exercise|The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.
223989840|NCT04843410|OTHER|The routine care|Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
223989841|NCT02778672|OTHER|Thermal imaging of infant's chest with a mobile phone|
223989842|NCT02833805|DRUG|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
223989843|NCT02833805|DRUG|Fludarabine|Days -6 through -2: 30 mg/m\^2 IV daily
223989844|NCT02833805|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
223989845|NCT02833805|RADIATION|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
223989846|NCT02833805|DRUG|Tacrolimus|Start on Day 5 through Day 365
223989847|NCT02833805|DRUG|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
223989848|NCT00983749|DEVICE|Full-pressure ECP|A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
223989849|NCT00983749|DEVICE|Sham-pressure ECP|A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
223989850|NCT05267795|BEHAVIORAL|Experimentally-induced pain|Specific pain levels were applied on the participants' fingernails in each of 40 experimental trials using pressure algometry.
223989851|NCT02552017|DEVICE|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
224121236|NCT06212232|PROCEDURE|Piezoelectric surgery|Application of a new piezoelectric technique in third molar surgery
223989852|NCT02656550|PROCEDURE|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
223989853|NCT05439330|DEVICE|MRI of teeth and surrounding structures|included above
223989854|NCT02975063|BEHAVIORAL|A&T IYCF intervention|(1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
223989855|NCT03587766|DRUG|Fexinidazole|Drug: fexinidazole (FEXI)
223989856|NCT03587766|DRUG|Placebo Oral Tablet|Drug: fexinidazole
223989857|NCT01296009|DRUG|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
223989858|NCT01177761|PROCEDURE|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
223989859|NCT01952847|OTHER|Placebo|mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
223989860|NCT01952847|DRUG|Glutamine|mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
224121237|NCT04958096|DEVICE|Standard Therapeutic Deep Brain Stimulation|DBS to the standard subcortical targets (anterior limb of the internal capsule- ALIC) will be used to treat OCD
224121238|NCT04958096|DEVICE|Cortical Stimulation for PFC|Patients enrolled in this study will have a second pair of leads placed in the prefrontal cortex (PFC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
223989861|NCT01952847|BEHAVIORAL|Questionnaires|Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
223989862|NCT06242769|DRUG|Stannous Fluoride Toothpaste (SnF)|test
223989863|NCT06242769|DRUG|Colgate Fluoride Toothpaste (CDC)|negative control
223989864|NCT01598103|DRUG|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
223989865|NCT01598103|DRUG|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
223989866|NCT03908567|DRUG|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
223989867|NCT03908567|DRUG|Oral Tablet|Oral dosing with tablets 3 times a day
224121239|NCT04958096|DEVICE|Cortical Stimulation for ACC|Patients enrolled in this study will have a second pair of leads placed in the anterior cingulate cortex (ACC) bilaterally as well the surrounding white matter tracts and stimulation will be delivered through these leads to improve OCD symptoms
224121240|NCT06417762|BEHAVIORAL|Science Communication Curriculum Cohort 1|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
224294637|NCT00906113|DRUG|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
223544748|NCT06311591|DEVICE|Jaspr App|Jaspr was designed to improve delivery of evidence-based, personalized suicide care in the ED. Jaspr (Dimeff, R44MH108222) is rooted in EBPs, including Collaborative Assessment and Management of Suicide (CAMS) and Dialectical Behavior Therapy (DBT). Briefly, Jaspr provides a patient interface, optimized for a tablet computer provided to the patient, which uses an avatar to administer: (1) the CAMS Suicide Status Form (SSF), an evidence-based suicide risk assessment; (2) crisis stabilization planning (CAMS' version of safety planning) or Stanley-Brown Safety Planning Intervention, depending on site choice; (3) lethal means safety counseling. Further, Jaspr teaches behavioral skills from DBT to manage imminent distress and has a library of over 40 racially and culturally diverse, inspirational videos of people with lived experience. Finally, Jaspr@home provides access to these resources after the visit during the high-risk transition to outpatient care.
223544749|NCT04541485|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
223544750|NCT04541485|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
223989868|NCT03908567|OTHER|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
223989869|NCT00326053|DRUG|Budesonide/formoterol|
223989870|NCT05227781|DIETARY_SUPPLEMENT|L-Citrulline|8 weeks of L-Citrulline supplementation (10 grams/day)
223989871|NCT05227781|DIETARY_SUPPLEMENT|Placebo|8 weeks of Placebo (maltodextrin; 10 grams/day)
223989872|NCT04621253|DRUG|Novalgin|Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake
223989873|NCT06259669|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
223989874|NCT06352073|DRUG|Dupilumab|300mg weekly subcutaneous injection
223989875|NCT05146206|OTHER|Observational|In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.
223989876|NCT04484389|OTHER|Telerehabilitation|Exercise protocol according to Ipaq will be prepared for 30 patients with chronic disease . Exercise protocol; warm-up exercises include, stretching exercises, postural exercises, aerobic exercise and cooling exercises. People will practice the exercises 3 days a week for 6 weeks. People will need to reserve 30 minutes a day for this study.
224294638|NCT00906113|DRUG|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
224294639|NCT02021253|DIETARY_SUPPLEMENT|Probiotic|Lactibiane TOLERANCE vs Placebo
224294640|NCT02021253|DIETARY_SUPPLEMENT|Placebo|
224294641|NCT01920542|DRUG|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
223544751|NCT01071954|BIOLOGICAL|Romiplostim|Administered by subcutaneous injection once a week.
223544752|NCT05070130|DEVICE|dPR and FFR|OpSens non-hyperemic dPR and/or OpSens FFR
223544753|NCT01459666|DRUG|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
223989877|NCT04484389|OTHER|Exercise brochure|General exercise protocol will be prepared and given to the control group as a brochure
223989878|NCT02577003|DRUG|Ipragliflozin|50 mg tablet administered orally
223989879|NCT02577003|DRUG|Placebo|Placebo to ipragliflozin tablet administered orally
223989880|NCT02577003|DRUG|Sitagliptin|Background medication; 50 mg tablet administered orally
223989881|NCT02185898|OTHER|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
223989882|NCT02185898|OTHER|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
223989883|NCT02185898|OTHER|Electronic cigarette #1|Electronic cigarette
223989884|NCT02185898|OTHER|Electronic cigarette #2|Electronic cigarette
223989885|NCT02185898|OTHER|Electronic cigarette #3|Electronic cigarette
223989886|NCT02185898|OTHER|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
223989887|NCT01502046|DRUG|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
223989888|NCT01502046|DRUG|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
223989889|NCT02835027|PROCEDURE|Open versus endovascular surgery|Treatment for acute ischemia
224121241|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 2|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
224294642|NCT01920542|DRUG|no dexmedetomidine|no administration of dexmedetomidine on control group
224294643|NCT06331520|DRUG|Netupitant / Palonosetron Oral Capsule [Akynzeo]|Akynzeo is the fixed-combination antiemetic comprising netupitant (neurokinin-1 receptor antagonist \[NK1 RA\]) and palonosetron (5-hydroxytryptamine-3 receptor antagonist \[5-HT3 RA\]).
224294644|NCT06331520|DRUG|Olanzapine|Olanzapine is an effective antipsychotic drug used in psychiatry to treat psychoses, especially schizophrenia and schizoaffective disorders. It belongs to the 2nd generation antipsychotics, its mechanism of action ranks among multireceptor antagonists (MARTA); it affects the dopamine, serotonin, adrenaline, histamine, and muscarinic systems.
224294645|NCT06331520|DRUG|Dexamethasone Oral|synthetic glucocorticoids
223544754|NCT01459666|DRUG|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
223544755|NCT02814188|OTHER|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
223544756|NCT02814188|OTHER|Placebo Beverage|750 ml of an artificially-sweetened beverage
223989890|NCT00708851|OTHER|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
223989891|NCT00708851|DEVICE|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
223989892|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
223989893|NCT00676845|DRUG|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
223989894|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
223989895|NCT00676845|DRUG|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
223989896|NCT05857254|OTHER|Patient with chronic intestinal failure|"The negociation component will be assessed during an office visit with the help of forms, by the difference between  ideal  parenteral nutrition prescription proposed by prescriber and the  final  prescription, that the patient ultimately receives at the end of the office visit.~The compliance component will be assessed by a telephone interview, 8 weeks after the office visit."
223989897|NCT01882153|BEHAVIORAL|Pivotal Response Training (PRT)|The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, \& Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
223989898|NCT01882153|BEHAVIORAL|PACE Therapy|The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
223989899|NCT01882153|BEHAVIORAL|PACE and PRT Hybrid|The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
223989900|NCT03334253|DRUG|Atropine|Daily 0.01% atropine eyedrops
223989901|NCT03334253|OTHER|Placebo Eyedrops|Daily placebo eyedrops
223989902|NCT02324777|DRUG|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
223989903|NCT02324777|DEVICE|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
223989904|NCT01359839|BEHAVIORAL|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
223989905|NCT00203047|DRUG|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
223989906|NCT00203047|DRUG|Placebo|Placebo for prednisone given daily
223989907|NCT00203047|DRUG|Prednisone|Prednisone 1250 mg taken daily
223989908|NCT01580904|BEHAVIORAL|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
223989909|NCT01446146|BEHAVIORAL|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
223989910|NCT01446146|BEHAVIORAL|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
223989911|NCT02768883|BEHAVIORAL|Respira Sano|The intervention is all three components: clinic + home + community.
223989912|NCT00340704|DRUG|tamsulosin hydrochloride|oral
223989913|NCT04197167|PROCEDURE|Hysteroscopy|Diagnostic procedure
223989914|NCT04197167|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of Chronic Endometritis
223989915|NCT02214511|BEHAVIORAL|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
224294646|NCT01198834|DRUG|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
224294647|NCT01198834|DRUG|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
224294648|NCT01198834|DRUG|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
224294649|NCT01198834|DRUG|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
223544757|NCT03156218|DRUG|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
223989916|NCT02214511|BEHAVIORAL|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
223989917|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
223989918|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
223989919|NCT00121667|DRUG|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
223989920|NCT00121667|DRUG|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
223989921|NCT00121667|DRUG|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
223989922|NCT01453023|DRUG|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
223989923|NCT01453023|DRUG|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
223989924|NCT00890292|DRUG|JNJ-31001074|
223989925|NCT00312585|PROCEDURE|Acupuncture|
223989926|NCT00312585|PROCEDURE|Sham comparator|
223989927|NCT00637468|DRUG|Intravenous injection of heparin|
223989928|NCT00637468|DRUG|Intravenous injection of acetazolamide|
223989929|NCT00637468|PROCEDURE|Local intra-arterial fibrinolysis|
223989930|NCT00637468|PROCEDURE|Globe massage|
223989931|NCT00637468|DRUG|Topical use of beta-blocker|
223989932|NCT00637468|DRUG|Isovolaemic haemodilution|
223989933|NCT00637468|DRUG|Acetylsalicylic acid|
223989934|NCT05332678|DRUG|SLS-005 - Once Weekly|Please see Arm description.
223989935|NCT05332678|DRUG|SLS-005 - Twice Weekly|Please see Arm description.
223989936|NCT01721889|RADIATION|Radiostereometric Analysis|The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
224294650|NCT07028853|DRUG|Mevrometostat|Oral continuous
224294651|NCT07028853|DRUG|Placebo|Oral continuous
224294652|NCT07028853|DRUG|Enzalutamide|Oral continuous
223989937|NCT02480647|DRUG|Levonorgestrel|20μg/day.
223989938|NCT02480647|DRUG|Etonogestrel|20μg/day.
223989939|NCT00980642|DEVICE|Draeger double-sensor|The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
223989940|NCT00980642|DEVICE|Esophageal stethoscope temperature sensor|Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
223989941|NCT00980642|DEVICE|Foley catheter temperature sensor|Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
223989942|NCT05104255|PROCEDURE|Spinal anesthesia|Twins delivered under under spinal anesthesia
223989943|NCT05104255|PROCEDURE|General anesthesia|Twins delivered under general anesthesia
223989944|NCT01953445|DRUG|paclitaxel|
223989945|NCT01953445|DRUG|BKM120|
223989946|NCT04577131|BEHAVIORAL|Weekly check-in|Weekly check-in phone calls from a pharmacist to review blood pressures and the number of times tested in that week
223989947|NCT01627262|DRUG|Mesalamine|3x1000mg mesalamine granules per day
223989948|NCT01627262|DRUG|Placebo|3x1000mg placebo granules per day
223989949|NCT02018653|DRUG|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
223989950|NCT02018653|OTHER|Placebo|1 by mouth every 6 hours for up to 6 days.
223989951|NCT02018653|BEHAVIORAL|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
223989952|NCT01338753|OTHER|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.~The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.~The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
223989953|NCT03699189|BEHAVIORAL|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
223989954|NCT00195377|DRUG|Etanercept|
223989955|NCT00349414|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|
223989956|NCT00349414|PROCEDURE|Conventional Transscleral Cyclophotocoagulation|
223989957|NCT06311370|OTHER|Observation|Observed by trained staff and wearing a sensor watch
223989958|NCT02677870|DRUG|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
224294653|NCT04841330|DEVICE|Securis™ Stabilization Device|A trained clinician will apply and remove, and participants will wear the Securis™ Stabilization Device for up to one week (7 days) on their forearm. A shortened catheter will be placed (not inserted) over the Securis™ device in accordance with the product Information for Use (IFU), and an extension set attached to the catheter and secured in place, to simulate clinical use.
224294654|NCT01066949|BEHAVIORAL|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
224294655|NCT01066949|BEHAVIORAL|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
223989959|NCT02677870|OTHER|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
223989960|NCT02710227|OTHER|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
223989961|NCT04889027|DIAGNOSTIC_TEST|Standardized Infant NeuroDevelopmental Assessment|The neurological scale of SINDA is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome (Hadder-Algra et al., 2018).
223989962|NCT00648999|DRUG|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
223989963|NCT05518695|DRUG|BAT2022|Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
223989964|NCT03343093|BEHAVIORAL|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
223989965|NCT03343093|BEHAVIORAL|Control|usual care, surveys every 3 months
223989966|NCT03042832|BEHAVIORAL|LOCI|Leadership development with coaching and organizational change support
223989967|NCT03042832|BEHAVIORAL|Internet Based Webinar Leadership Training|Internet Based Webinar Leadership Training
223989968|NCT04225741|BEHAVIORAL|Training group|The single-session training lasted for approximately 40-45 minutes and was conducted in the training room of Sıtmapınarı family health center, as a suitable environment. The health belief model predicts the determinants of preventive health behaviors and explains inadequate participation in disease prevention and screening programs. Furthermore, this model not only explains behavior regarding screening, but also evaluates the cognitive factors that facilitate health-promoting behaviors.
223989969|NCT01108315|OTHER|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
223989970|NCT04990778|DRUG|Eprenetapopt|Given IV
223989971|NCT04990778|DRUG|Venetoclax|Given PO
224121242|NCT06417762|BEHAVIORAL|Science communication curriculum Cohort 3|"Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy"
223989972|NCT03618004|OTHER|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
223989973|NCT03618004|OTHER|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
224121243|NCT05110742|DRUG|Fludarabine Phosphate|Given by IV
224121244|NCT05110742|DRUG|Cyclophosphamide|Given by IV
224121245|NCT05110742|DRUG|CAR.5/IL15-transduced CB-NK cells|Given by IV
223989974|NCT05252832|PROCEDURE|Superficial Cervical Plexus Block|Location of injection for block.
223989975|NCT05252832|PROCEDURE|Local Infiltrate|Local infiltration location.
223989976|NCT05521711|OTHER|Food|Commercially available powders or liquids
223989977|NCT06405412|OTHER|MUST malnutrition score|MUST malnutrition score
223989978|NCT04918004|BEHAVIORAL|Sleep Hygiene|"1. One-to-one sleep hygiene training, the content of which was created by the researchers,~2. A brochure containing 10 lifestyle changes related to sleep hygiene"
223989979|NCT03055962|DRUG|E2609|tablet
223989980|NCT03055962|DRUG|Placebo|tablet
223989981|NCT01598077|DRUG|LJM716|
223989982|NCT00506805|DRUG|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
223989983|NCT05641779|DEVICE|pigtail|pigtail catheter insertion in chest in the pleural cavity
223544758|NCT01404650|DRUG|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
223989984|NCT05948969|OTHER|Decision support|"This implementation strategy will include the clinician education of the previous arm and apply audit and feedback of prior care to inform recommendations for future care. These suggestions will encompass 5 different domains based on eligibility and potential opportunity for an SGLT2i, GLP-1RA, angiotensin converting enzyme inhibitors (ACEi)/angiotensin-receptor blockers (ARB), antiplatelet or antithrombotic therapy, and statin therapy. The incorporation of clinical decision support technology will be utilized to identify tailored opportunities for each CV risk reduction based on guideline recommendations for individual patients. Clinicians will be presented prompts with patient-specific recommendation(s) for further optimization of cardioprotective agents. These prompts will be conveyed by a Study Coordinator to responsible clinicians. The follow-up clinical prompts will be based on auditing of updated clinical parameters and medication use."
223544759|NCT03586271|PROCEDURE|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
223989985|NCT05948969|OTHER|Facilitated referral to a cardiometabolic team-based center|Each site will have access to clinicians caring for patients in structured, multidisciplinary cardiometabolic centers. Clinicians caring for patients randomized to this intervention strategy will receive a facilitated referral via the EHR together). If the clinician approves the referral, the patient will be referred to this local team-based comprehensive risk factor management clinic. All patients randomized to this group will be considered in this group whether or not a visit to the cardiometabolic center is completed.
223989986|NCT00003704|DRUG|capecitabine|
223989987|NCT00003704|RADIATION|radiation therapy|
223989988|NCT02322086|DRUG|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
223989989|NCT05487235|DRUG|GDC-1971|Capsule or tablet administered orally.
223989990|NCT05487235|DRUG|Atezolizumab|Administered as IV infusion.
223989991|NCT05487235|DRUG|Omeprazole|Administered orally as tablet or capsule in the acid-reducing agent assessment.
224121246|NCT06362057|OTHER|Subperiosteal implant framework|"A 3D image of an edentulous maxilla bone will be derived from a computed tomography scan of an adult patient and saved as stl data. The solid geometry of the maxilla, including the cortical and spongious bone, was rebuilt from the stl data into the Digital Imaging and Communications in Medicine (DICOM) format with 3D-Doctor (Able Software Corp., MA, USA).~With the Boolean method, force loading will be achieved between prosthetic parts, subperiosteal implant screws and bone tissues"
223989992|NCT00448526|BEHAVIORAL|low protein diet|
223989993|NCT02003677|DRUG|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
223989994|NCT02003677|DRUG|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
223989995|NCT04709653|OTHER|Occupation-based nursing program|"First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille."
224121247|NCT03272334|DRUG|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
224121248|NCT03404336|BEHAVIORAL|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
223989996|NCT04709653|OTHER|Control Group|Routine nursing care
223989997|NCT03748862|OTHER|Taper Plan|Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
223989998|NCT00292344|DRUG|Rifaximin and loperamide|
224121249|NCT03404336|OTHER|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
223989999|NCT01821768|PROCEDURE|Sentinel Lymph Node Biopsy|
223990000|NCT03080142|DRUG|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
223990001|NCT03080142|DRUG|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
223990002|NCT04413370|DIAGNOSTIC_TEST|Dry eye diagnostic test|The artificial intelligent dry eye screening platform
223990003|NCT04345380|OTHER|Implantation of an Alcon Acrysof SN60WF intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
223990004|NCT04345380|OTHER|Implantation of an AMO Tecnis ZCB00 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
223990005|NCT04345380|OTHER|Implantation of an Envista MX60 intraocular lens|Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
223990006|NCT03016598|DRUG|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
223990007|NCT03016598|DRUG|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
224121250|NCT04883437|DRUG|Acalabrutinib|Given PO
223990008|NCT06023251|OTHER|Clinical Nutrition|"Nutritional care plan implementation, including~* A step-up and step-down nutritional protocol guided by caloric and protein ratio~* Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~* Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~* Dedicated and specialized dietician and nurse involvement~* Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition."
223990009|NCT03848884|BEHAVIORAL|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
224121251|NCT04883437|BIOLOGICAL|Obinutuzumab|Given IV
224121252|NCT04883437|OTHER|Quality-of-Life Assessment|Ancillary studies
224121253|NCT04883437|OTHER|Questionnaire Administration|Ancillary studies
224121254|NCT05914649|OTHER|IV normal saline (999 mL infusion)|999 mL of IV normal saline will be infused intravenously
224121255|NCT05914649|OTHER|IV normal saline (50 mL infusion)|50 mL of IV normal saline will be infused intravenously as a placebo control.
224121256|NCT06303986|OTHER|NeoMonki|Collection of Data for assessing the reliability of Neomonki and Realtime monitoring
224121257|NCT03022032|DEVICE|Fitbit Zip|Fitbit Zip
223544760|NCT03586271|PROCEDURE|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
223544761|NCT03586271|PROCEDURE|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
223544762|NCT03586271|PROCEDURE|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
223544763|NCT02112305|DRUG|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
223544764|NCT02112305|DRUG|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
223544765|NCT00590967|RADIATION|IMRT extended field external beam radiation therapy|
223544766|NCT00590967|RADIATION|Brachytherapy|
224121258|NCT03022032|OTHER|HOPE App|HOPE App
223990010|NCT04382235|DEVICE|Non-invasive ventilatory support|All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
223990011|NCT03567135|DRUG|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
223990012|NCT03567135|DRUG|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
223990013|NCT00519545|BEHAVIORAL|Prayer|Data collection on physiological biomarkers
223990014|NCT02474043|BEHAVIORAL|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
223990015|NCT02474043|BEHAVIORAL|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
223990016|NCT00034554|BIOLOGICAL|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5\* patient safely completing the 2nd vaccination at the lower dose level.
223990017|NCT03569215|BEHAVIORAL|Questionnaire|All included patients will be exposed to questionnaires and psychiatric diagnostic tests
223990018|NCT03968068|PROCEDURE|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
223990019|NCT03968068|PROCEDURE|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
223990020|NCT03585686|DRUG|Vemurafenib|vemurafenib 20 mg/kg/day
223990021|NCT03585686|DRUG|Cytarabine|100 mg/m2/12 h, days 1-5
223990022|NCT03585686|DRUG|2-chlorodeoxyadenosine|6 mg/m2/d, days 1-5
223990023|NCT02676609|DEVICE|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
223990024|NCT05359692|BIOLOGICAL|INCAGN01876|INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.
223990025|NCT05359692|BIOLOGICAL|retifanlimab|retifanlimab will be administered via IV Q4W
223990026|NCT05972798|OTHER|Omega-3 fatty acids|2.2 g/d omega-3 PUFAs (1.2g EPA and 1g DHA per day) in patients with LLD
223990027|NCT05972798|OTHER|Soybean oil|Soybean oil in patients with LLD
223990028|NCT00433875|DRUG|AMG 714|
223990029|NCT03614806|DIAGNOSTIC_TEST|Simultaneous Transcutaneous and End-tidal CO2 measurements|Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement
223990030|NCT02799355|DRUG|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
223990031|NCT03513068|DEVICE|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
223990032|NCT01808183|DEVICE|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
223544767|NCT00590967|DRUG|Cisplatin|
223990033|NCT06129032|PROCEDURE|Wound infiltration (LWI) + Intraperitoneal local anaesthetic (IPLA) instillation|"a solution containing 20 ml of 0.5% bupivacaine, 20 ml of 2% lidocaine and 1:200,000 epinephrine with a total volume of 40 ml. A volume of 10 millilitres of the solution will be administered through the drip technique into each of the four quadrants of the uterus prior to the subsequent closure of the parietal peritoneum or fascia.~A total volume of 10 ml of the solution will be administered through infiltration at the edges of the rectus aponeurosis, while the remaining 20 ml will be infiltrated subcutaneously into the incision"
224121259|NCT03022032|OTHER|Standard of Care|Standard of Care
224121260|NCT03022032|DEVICE|Fitbit Charge 2|Fitbit Charge 2
224121261|NCT03022032|OTHER|SMART Study Intervention|SMART study app + Beiwe study app + Fitbit
224121262|NCT03894553|DEVICE|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
223990034|NCT06129032|PROCEDURE|Group QUADRATUS LUMBORUM BLOCK (QLB)|quadratus lumborum type 1 block will be applied bilaterally on both sides with a total of 40 ml of solution containing 20 ml of 0.5% bupivacaine + 20 ml of 2% lidocaine + 1:200.000 epinephrine, under ultrasound guidance
223990035|NCT02682940|DEVICE|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
223990036|NCT01566097|DEVICE|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~1. Information on the risk of continued smoking and benefits of cessation~2. Messages that address common misbeliefs regarding smoking cessation services and medications~3. Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~1. Behavioral only~2. Nicotine replacement therapy~3. Bupropion~4. Varenicline"
223990037|NCT00175747|DRUG|Inhaled Budesonide 800 µg twice daily|
223990038|NCT02264782|OTHER|Computer-Assisted Intervention|Complete PreView
223990039|NCT02264782|OTHER|Computer-Assisted Intervention|Watch an educational video
223990040|NCT02264782|OTHER|Questionnaire Administration|Ancillary studies
223990041|NCT03190512|OTHER|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
223990042|NCT06212089|DRUG|TR-012001|A single dose of TR-012001 will be administered.
223990043|NCT06212089|OTHER|Placebo|A single dose of placebo will be administered.
223990044|NCT04034849|RADIATION|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
223990045|NCT04034849|RADIATION|Placebo|Device turned off
223990046|NCT04547023|BEHAVIORAL|Fasting before gestational diabetes screen|Fasting for at least 6 hours before 1-hour gestational diabetes screen.
223990047|NCT04547023|BEHAVIORAL|Per oral intake of food and drink|Per oral intake of food and drink within 2 hours of gestational diabetes screen
223990048|NCT00170326|PROCEDURE|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
223990049|NCT00170326|PROCEDURE|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
223990050|NCT04319146|PROCEDURE|robot-assisted radical prostatectomy|robot-assisted radical prostatectomy as first-line treatment
223990051|NCT04214353|DIAGNOSTIC_TEST|68Ga-PSMA-PET/CT|All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
223990052|NCT04214353|DIAGNOSTIC_TEST|18FDG-PET/CT|All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
223990053|NCT03764995|OTHER|Standard bowel management|Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
223990054|NCT03764995|OTHER|Abdominal massage|Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
224121263|NCT01372696|OTHER|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
224121264|NCT05875038|OTHER|video system|The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.
224121265|NCT05875038|OTHER|Tele-alarm|Tele-alarm
223990055|NCT03764995|OTHER|Placebo Ultrasound|Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
223990056|NCT00830687|DEVICE|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
223990057|NCT02760901|DRUG|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
223990058|NCT02760901|DRUG|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
223990059|NCT02760901|DRUG|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
223990060|NCT02760901|DRUG|saline|saline hydration 2500 ml before cisplatin therapy
223990061|NCT02760901|DRUG|Cisplatin|patients with tumours already prescribed cisplatin
223990062|NCT01663038|DRUG|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
223990063|NCT01663038|DRUG|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
223990064|NCT01663038|DRUG|Aspirin|
223990065|NCT00627354|DRUG|etoposide|
223990066|NCT00627354|DRUG|mitoxantrone hydrochloride|
223990067|NCT00627354|DRUG|prednisone|
224121266|NCT05102864|DEVICE|Intermittent Theta Burst Stimulation to the Left Dorsolateral Prefrontal Cortex|iTBS will be administered to the left DLPFC for 10 consecutive days
224121267|NCT02198729|PROCEDURE|Endoscopic Submucosal Dissection|
224121268|NCT02198729|PROCEDURE|Endoscopic Mucosal Resection|
223990068|NCT00627354|DRUG|vinorelbine tartrate|
223990069|NCT05226676|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
223990070|NCT03981497|PROCEDURE|Microwave ablation (MWA)|Thermal ablation
223990071|NCT05438836|RADIATION|online adaptive radiotherapy|Online adaptive radiotherapy compared to standard non-adaptive Image-Guided Radiotherapy
223990072|NCT01262092|DRUG|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
223990073|NCT04518904|OTHER||
223990074|NCT00855855|BIOLOGICAL|DTaP-IPV/Hib|0.5 mL, Intramuscular
223990075|NCT01655303|DRUG|Propranolol|
223990076|NCT01655303|DRUG|Metoprolol|
223990077|NCT01655303|DRUG|Verapamil|
223990078|NCT01655303|DRUG|Diltiazem|
223990079|NCT02694042|BEHAVIORAL|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
223990080|NCT03784820|BEHAVIORAL|UNITE|UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.
223990081|NCT03784820|BEHAVIORAL|CBT-E|CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
223990082|NCT05638347|DRUG|HRS-7085 tablets|Single oral administration
223990083|NCT05638347|DRUG|Placebo tablet|Single oral administration
223990084|NCT00736411|PROCEDURE|acupuncture|16 treatments over 8 weeks
223990085|NCT00736411|PROCEDURE|IVF|one 4 week IVF cycle
223990086|NCT04413422|DRUG|type of hypnotic used for induction of general anesthesia|
223990087|NCT05321199|DRUG|Tranexamic acid|Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to be effective in reducing blood loss and the need for transfusions after several orthopaedic surgeries.
223990088|NCT04539223|DRUG|Evolocumab|Autoinjector 1-mL deliverable volume of 140 mg/mL
223990089|NCT04147858|DRUG|NYX-2925|NYX-2925 administered orally
223990090|NCT04147858|DRUG|Placebo|Placebo administered orally
223990091|NCT05536206|DEVICE|Wireless and continuously monitoring|Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.
223990092|NCT06067607|OTHER|eye gaze technology|eye gaze technology and software activities
223990093|NCT03573193|OTHER|ridge preservation|"Intra operative procedures (for both groups) ridge preservation~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~* In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~* In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP)."
223990094|NCT00751660|OTHER|laboratory biomarker analysis|
224121269|NCT05406700|DRUG|Niraparib|Oral, daily, dosage per protocol,4 Weeks
223990095|NCT00751660|OTHER|screening questionnaire administration|
223990096|NCT00751660|PROCEDURE|bronchoscopic and lung imaging studies|
223990097|NCT00751660|PROCEDURE|computed tomography|
223990098|NCT00751660|PROCEDURE|endoscopic biopsy|
224121270|NCT05406700|DRUG|Resection/Treatment with Niraparib|"The participants in both arms will resume/start on treatment with niraparib 2 -4 weeks after surgery.~Treatment can be held for an additional 28 days to allow for recovery from surgery, at the investigator's discretion. Participants will continue treatment for up to 12 total cycles of treatment or until tumor progression, unacceptable toxicity or withdrawal of consent."
224121271|NCT05495906|BIOLOGICAL|Nonavalent HPV vaccine|Routine dosing form and dosage
223990099|NCT00751660|PROCEDURE|quality-of-life assessment|
223990100|NCT05652439|OTHER|Observational retrospective data collection|Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
223990101|NCT03439358|DRUG|Magnesium Sulfate|Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
223990102|NCT03439358|OTHER|Normal Saline|Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
223990103|NCT00794170|BEHAVIORAL|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
223990104|NCT00658606|DRUG|alefacept|IM
223990105|NCT00658606|PROCEDURE|Narrow Band UVB Phototherapy|UVB Phototherapy
223990106|NCT00006462|DRUG|gemcitabine hydrochloride|
223990107|NCT04831879|DEVICE|GONDOLA AMPS|The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
223990108|NCT03543553|OTHER|This is not an intervention study|This is not an intervention study
223990109|NCT04312542|PROCEDURE|Measurement of Biomarkers|Participants will have blood drawn at a 9-month and 12-month visit for the measurement of biomarkers.
223990110|NCT04217772|DEVICE|Optical Coherence Tomography Angiography|A device testing the vascular density in the retina
223990111|NCT05884489|BEHAVIORAL|A gamified smartphone app-based eating behaviour intervention|All patients gained access to the healthy nutrition application and were encouraged to make full use of its feature, and they were also required to maintain a logbook through the application at home to follow-up on their diet. The intervention last for six weeks.
223990112|NCT01885169|BIOLOGICAL|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
223990113|NCT05097391|BEHAVIORAL|Warm-up (5 minutes)|Participants will benefit from passive stretches of hamstrings, calf muscles including a range of motion (ROM) exercise to the lower limbs as mat exercises.
223990114|NCT05097391|BEHAVIORAL|Conventional physiotherapy exercise (15 minutes)|The conventional treatments will be active-assisted and free active exercises to the lower limbs on the mat for five (5) minutes. This will be followed by strength training such as sit-to-stand exercises for five (5) minutes and squatting exercises for five (5) minutes prior to the over-ground training.
223990115|NCT05097391|BEHAVIORAL|Over-ground training with lower limb loading (15-25 minutes)|"Participants will perform the over-ground training exercise with an external 1.5kg load on the paretic lower limb placed 2cm above the ankle joint. Before commencing the over-ground training, all the participants will observe a pre-exercise rest period of about two (2) minutes during which their heart rate and blood pressure measurements will be recorded.~The over-ground training will involve the patients walking within a demarcated path. Each participant will be instructed to stand and walk 15meters to and fro for five (5) minutes after which they will be asked to stop and rest for two (2) minutes. The over ground training exercise will be repeated 3 times in the first 2 weeks of the training (15 minutes); 4 times in weeks 3-4 of the training (20 minutes); and 5 times in weeks 5-8 of the training (25 minutes)."
223990116|NCT06601140|DEVICE|EMOCARE software|Use of the EMOCARE software on the digital device of participant (smartphone, computer, etc.). The participant can activate and deactivate the software whenever he wishes.
223990117|NCT04577716|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
223990118|NCT04577716|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
223990119|NCT04577716|DIAGNOSTIC_TEST|12-month CT Aortic Angiogram|CT scan to assess aortic morphology and the stent graft
223990120|NCT04577716|OTHER|24-month review|This will consist of a telephone consultation with the study participant and review of electronic clinical records
223990121|NCT04929184|BEHAVIORAL|Speech and non-speech tasks|Participants will complete speech tasks such as listening to and/or producing speech and non-speech sounds.
223990122|NCT03814200|DRUG|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
223990123|NCT03814200|DRUG|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
223990124|NCT03814200|DRUG|Rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
223990125|NCT03771638|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
223990126|NCT03771638|OTHER|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
223990127|NCT05520528|BEHAVIORAL|Language intervention with group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia|The participants will read through a designated book incrementally across multiple weeks at home and complete reading, writing, and discussion related to weekly readings in a group setting.
223990128|NCT05422144|DEVICE|Antimicrobial Skin & Wound Cleanser (AWC)|BIAKŌS™ Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site. BIAKŌS™ Antimicrobial Skin and Wound Cleanser is a pure, colorless, isotonic cleanser that is safe. The preservative, polyhexamethylene biguanide (PHMB), at a concentration of 0.1% w/w is added to the product to inhibit the growth of microorganisms such as Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA). and fungus Candida albicans within the product.
223990129|NCT05422144|DEVICE|Antimicrobial Wound Gel (AWG)|"BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial polyhexamethylene biguanide (PHMB).~BIAKŌS Antimicrobial Wound Gel:~* Resists microbial colonization within the gel during shelf storage.~* Provides an amorphous gel covering.~* Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
223990130|NCT05673967|OTHER|Non-Interventional|No study treatment will be administered on this study.
223990131|NCT05688852|DRUG|VTX958|Dose A VTX958
223990132|NCT05688852|DRUG|VTX958|Dose B VTX958
223990133|NCT05688852|DRUG|VTX958 Placebo|Placebo
223990134|NCT04112186|BEHAVIORAL|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
223990135|NCT04112186|BEHAVIORAL|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
223990136|NCT03025308|DRUG|Filgotinib|Tablet(s) administered orally once daily
223990137|NCT03025308|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
223990138|NCT04407650|DRUG|Metformin|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
223990139|NCT04407650|DRUG|Ursodeoxycholic Acid|"Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or \>6.2),~* Recruitment centre"
223990140|NCT06267092|OTHER|No treatment given|Participants will not get any medicine during this study.
223990141|NCT06267092|DRUG|Cagrilintide and Semaglutide|Participants will receive subcutaneous (s.c.) injections of Cagrilintide and Semaglutide.
223990142|NCT06267092|DRUG|Placebo|Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
223990143|NCT06132828|DRUG|DR30206|Subjects receive DR30206 intravenously
223990144|NCT04511234|DEVICE|MagicTouch PTA sirolimus drug coated balloon (DCB)|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch PTA sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
223990145|NCT04511234|DEVICE|POBA standard balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
223990146|NCT06314438|BEHAVIORAL|Family Care Project|Caregivers will be administered the Family Care Project workbook.
223990147|NCT06191042|DRUG|si-544|Subcutaneous injection in the abdomen
223990148|NCT06191042|DRUG|Placebo|Subcutaneous injection in the abdomen
223990149|NCT04253262|DRUG|Rucaparib|Rucaparib (PO twice daily continuous)
223990150|NCT04253262|DRUG|Copanlisib|Copanlisib (IV day 1, 8, 15; 28 day cycle)
223990151|NCT04468607|DRUG|BLYG8824A|BLYG8824A will be administered at a flat dose independent of body weight.
223990152|NCT04734015|BEHAVIORAL|Together Overcoming Diabetes (TOD)|Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
223990153|NCT03641456|DRUG|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
223990154|NCT03641456|DRUG|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
223990155|NCT03641456|DRUG|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
223990156|NCT04800783|DIAGNOSTIC_TEST|Swallowing ultrasound|Ultrasound assessment of the tongue movement and thickening, the geniohyoid and suprahyoid muscles echogenicity, thickness and thickening, the hyoid bone elevation, and the number of swallowing trial.
223990157|NCT01972945|PROCEDURE|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
223990158|NCT01972945|PROCEDURE|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
223990159|NCT00365547|BIOLOGICAL|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
223990160|NCT00365547|DRUG|topotecan hydrochloride|Topotecan 4 mg/m\^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
223990161|NCT00198003|BEHAVIORAL|Educational program to address patients' expectations|
223990162|NCT01258647|DIETARY_SUPPLEMENT|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
223990163|NCT00546247|DRUG|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
223990164|NCT00728000|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
223990165|NCT00728000|DRUG|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
223990166|NCT00728000|DRUG|Erlotinib|100mg/day PO on days 1-14 and 15-28
223990167|NCT05435911|DRUG|REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]|Remimazolam Besylate is used as an intervention drug for general anesthesia, followed by flumazenil administration at the end of anesthesia, compared to propofol-based total intravenous anesthesia during breast cancer surgery under general anesthesia
223990168|NCT05435911|DRUG|Flumazenil|Flumazenil is used as an additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
223990169|NCT05435911|DRUG|Propofol|Propofol is used as an active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during breast cancer surgery under general anesthesia.
223990170|NCT01287728|DRUG|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
223990171|NCT02693951|DRUG|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
223990172|NCT04444934|OTHER|histological examination|Patients were classified in two groups based on the surgeon's visual examination of the right diaphragmatic peritoneum. The accuracy of visual examination has been assessed comparing surgeon's opinions to histological examination
223990173|NCT04704089|OTHER|spectrophotometer|"* Calibration of the spectrophotometer (calibration of white and green color on the provided support),~* Placing the patient or witness in the chair,~* Placement of intraoral retractors,~* Photographs of the dental arch in occlusion as well as slightly open mouth to visualize the mandibular incisors,~* If MIH is suspected, occlusal images of the occlusal surfaces of the first molars will be taken with the help of a dental mirror,~* Shooting with the spectrophotometer centered on each of the teeth of interest in the anterior sector with verification of the good quality of the shot according to the axis (validated in green on the camera),~* Backup of images with coded identification number"
223990174|NCT04704089|OTHER|Biological (protein analysis by western blot or mass spectrometry of matrix proteins), structural (electron microscopy) and physico-chemical analyses|"* Chemical analysis of enamel mineral.~* Techniques of spectrometry and spectroscopy (Raman and FTIR)~* Atomic Probe Tomography and Protein Mass Spectrometry (ICP-MS)."
223990175|NCT06545461|OTHER|Fruits and Vegetables (F+V)|Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups daily of F+V provided in weekly allotments. Amount provided will be that calculated for the participant multiplied times number of household members to assure participants eat the prescribed amount and do not share with household members.
223990176|NCT06545461|OTHER|Sodium Bicarbonate (NaHCO3)|Participants will receive 0.3 mEq/kg bw/day NaHCO3 tablets to match the alkali provided by F+V given to F+V participants. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in two divided oral doses.
223990177|NCT06545461|OTHER|Usual Care|Participants will receive standard medical care but no additional alkali (F+V nor NaHCO3).
223990178|NCT02033447|OTHER|Magnetic Nanoparticle Injection|
223990179|NCT00000951|DRUG|Fluconazole|
223990180|NCT06851806|DRUG|Palivizumab 15 mg/kg|Single-dose liquid solution vials, 50 mg/0.5 mL, IM injection
223990181|NCT04827745|DRUG|BLINCYTO (Blinatumomab)|Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®). Blinatumomab directs CD-3 positive effector memory T cells to CD19-positive target cells (Hoffmann et al, 2005; Dreier et al, 2002). The targeted CD19 antigen is constitutively expressed on normal B cells throughout a person's lifetime (Smet et al, 2011) and is highly conserved in B-cell malignancies (Tedder, 2009; Wang et al, 2012).
223990182|NCT04447833|DRUG|Mesenchymal Stromal Stem Cells - KI-MSC-PL-205|Allogeneic bone marrow derived mesenchymal stromal stem cells (MSCs).
223990183|NCT06646653|DEVICE|Alma System|Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
223990184|NCT05924386|PROCEDURE|patients reciveing all on 4 fixed mandibular prosthesis usimg conventionally screw retained multiunit abutments|Multiunit abutments is considered a gold standard screw retained abutments. Multi-unit abutments are used to correct for varying heights among the implants, to establish a level restorative platform for the prosthesis, as well as to situate the implant connection even with or just below the gingival surface. Also they are used to correct the angulation of implants, helping to keep the screw access holes away from the facial surfaces of the restoration, and facilitate the path of insertion of prosthesis.
223990185|NCT05924386|PROCEDURE|all on 4 fixed mandibular prosthesis using OTbridge attachment system|"The OT bridge attachment system introduced by (Rhein 83) is a global, well-established system used in the removable prosthetic protocols, the presence of seeger acetal ring placed between the sub-equatorial area of the OT Equator and the cylindrical Extragrade abutment compensates the space between the extragrade abutment and the OT equator attachment correcting the minor misalignments that produced during the prosthetic procedure and resulting in more passive fit."
223990186|NCT03170518|DRUG|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
223990187|NCT03170518|DRUG|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
223990188|NCT03170518|DRUG|Placebo|Matching placebo tablet will be administered orally once-daily.
223990189|NCT04428476|BIOLOGICAL|Deramiocel (CAP-1002)|Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months
223990190|NCT05955664|DIAGNOSTIC_TEST|MRI indlcuding DTI|A novel technique in MR imaging, which allows tracking of the pelvic floor muscle fibers, Diffusion Tensor Imaging (DTI) will be performed in addition to the standard scanning protocol. We think that MRI with DTI is superior to routine MRI in visualization of LAM.
223990191|NCT05955664|DIAGNOSTIC_TEST|Pelvic floor ultrasound.|"The patient will be scanned in a supine position and the probe is inserted into the vagina in the neutral position to avoid excessive pressure on surrounding structures to avoid distortion of the anatomy. The 3D data automatic acquisition takes approximately 70 seconds.~The analysis of the ultrasound images will be performed on the Trust computers by Radiologists experienced in pelvic floor ultrasound.~Participant will be asked to complete a VAS score for the US."
223990192|NCT00546078|BIOLOGICAL|Cervarix™|Intramuscular injection, one or three doses
223990193|NCT04637516|DEVICE|"Animation program BlinkBlink"|Computer program that presents horizontal bars on the computer screen that move from above and below towards each other, mimicking a blink movement.
223990194|NCT00135785|DRUG|Bupropion|
223990195|NCT00135785|DRUG|Placebo|
223990196|NCT02068378|DEVICE|CMPE Optical Sensor Device|Christie Medical Physics \& Enginieering visual feedback with optical sensing device.
223990197|NCT04455607|BEHAVIORAL|perturbation training|A Randomized control trial we will compare two perturbation motor learning paradigms with different challenge level of the practice condition (i.e. blocked practice vs random practice). According to motor learning theory we hypothesize that a) healthy older adults will benefit more from random practice. The purpose of this stage is to investigate the effects of task practice order (random vs blocked) on motor learning (i.e. responding to perturbations during walking) in older adults. According to motor learning theory we hypothesize that a) healthy older adults will benefit more from the random motor learning approach as compared to using blocked practice.
223990198|NCT02325830|DEVICE|Carillon Mitral Contour System|Percutaneous mitral valve repair
223990199|NCT03023423|DRUG|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
223990200|NCT03023423|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
223990201|NCT02854618|OTHER|additional blood sample|
223990202|NCT03001622|BIOLOGICAL|IFX-1|chimeric, monoclonal antibody
223990203|NCT03454659|PROCEDURE|Craniotomy|Extracting the part of the sculpt
223990204|NCT00280865|DRUG|Tesaglitazar|
223990205|NCT00280865|DRUG|Pioglitazone|
223990206|NCT00280865|BEHAVIORAL|Dietary and Lifestyle Modification Counseling|
223990207|NCT06972212|DRUG|suzetrigine 100mg|Suzetrigine is an inhibitor of the NaV1.8 voltage-gated sodium channel and FDA approved for the treatment of moderate-to-severe acute pain in adults
223990208|NCT06972212|OTHER|Placebo|biologically inactive placebo comparator
223990209|NCT01498783|DRUG|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m\^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
223990210|NCT02335645|OTHER|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
223990211|NCT03512197|DRUG|Midostaurin|Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.
223990212|NCT03512197|DRUG|Placebo|Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
223990213|NCT03512197|DRUG|Chemotherapy|Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
223990214|NCT03842436|DEVICE|Digital pill|Digital pills over encapsulating Truvada
223990215|NCT03842436|DRUG|Truvada|Truvada prescribed with digital pills for PrEP
223990216|NCT03214536|PROCEDURE|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
223990217|NCT03214536|DRUG|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
223990218|NCT03214536|PROCEDURE|Spine surgery|Surgery of lumbar spine
223990219|NCT03214536|PROCEDURE|anesthesia|general anesthesia
223990220|NCT01155076|DIETARY_SUPPLEMENT|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
223990221|NCT01155076|DIETARY_SUPPLEMENT|Placebo|Placebo taken twice a day for 8 weeks
223544768|NCT02045784|DIETARY_SUPPLEMENT|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
223544769|NCT02045784|OTHER|Breast milk|Unlimited breast feeding
223544770|NCT02512380|DRUG|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
223544771|NCT02512380|DRUG|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
223990222|NCT05568368|OTHER|No intervention|no intervention
223990223|NCT05716529|OTHER|rehabilitation protocol|It's a four phases rehabilitation protocol mainly based on the remodeling process of the graft., emphasizing full passive knee extension, immediate weight bearing as tolerated and functional exercises
223990224|NCT06038851|PROCEDURE|Para-Sartorial Compartments (PACS) Block|"This intervention was selected because it has the potential to optimize analgesia by skin coverage of the upper third of the surgical incision. The intervention will be performed as follows:~* The intermediate femoral cutaneous nerve will be visualized at the supralateral level of the sartorius muscle, in a duplicature of the fascia lata.~* The needle will be inserted at the same puncture site as for the femoral triangle block, with a latero-medial orientation in the plane (intracanalar compartment).~* In addition to the injection performed in the femoral triangle, two injections of 5 mL of 0.5% ropivacaine + epi 1:400 000 will be performed in addition, below the sartorius muscle (subsartorial compartment) and above the sartorius muscle (suprasartorial compartment)."
223990225|NCT06038851|PROCEDURE|Femoral Triangle Block (FTB)|"* The high frequency linear ultrasound probe will be positioned midway between the superior edge of the patella and the anterosuperior iliac spine. It will then be moved to visualize the apex of the femoral triangle, confirmed by visualization of the sartorius muscle laterally and the long adductor medially.~* The needle will be inserted with a latero-medial orientation in the plane.~* The initial injection will be a single injection of 15 ml of 0.5% ropivacaine + epi 1:400 000 under the sartorius muscle, lateral to the femoral artery, at the level of the apex of the femoral triangle."
223990226|NCT06038851|PROCEDURE|Infiltration between popliteal artery and capsule of the knee (IPACK) block|It will be performed in order to block the sensory branches of the innervation posterior to the knee with 15 ml of ropivacaine 0.3% + epi 1:400 000.
223990227|NCT03514381|DRUG|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)"
223990228|NCT00556647|PROCEDURE|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
223990229|NCT00556647|PROCEDURE|conventional diagnosis|out-patient diagnosis
223990230|NCT00273208|BEHAVIORAL|10 week behavioral intervention program|
223990231|NCT03893110|PROCEDURE|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
223990232|NCT01267669|DRUG|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
223990233|NCT01267669|DRUG|Placebo|Emergency EVL plus placebo infusion for 5 days
223990234|NCT05026268|PROCEDURE|intracorporeal anastomosis|"intracorporeal stapled side-to-side isoperistaltic anastomosis"
223990235|NCT00333255|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|
223990236|NCT00490698|DRUG|Zoledronate|4 mg IV Once Every 4 Weeks
223990237|NCT00490698|DRUG|Atorvastatin|20 mg PO Daily
223990238|NCT01907269|BEHAVIORAL|Video-based Intervention|Video clips delivered by DVD and Internet
223990239|NCT01654068|RADIATION|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
223990240|NCT01227616|DRUG|Ferumoxytol|IV Ferumoxytol
223990241|NCT01227616|DRUG|Iron Sucrose|IV Iron Sucrose
223990242|NCT00611169|DRUG|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
223990243|NCT04618380|DIAGNOSTIC_TEST|bUD-VA,bUN-RA, bUI-RA, bUI-CPS, bUN-CPS, contrast sensitivity|"The following clinical indexes are evaluated:~1. Binocular uncorrected distant visual acuity (bUD-VA) using the Greek version of the Early Treatment Diabetic Retinopathy Study Chart at four meters distance~2. Binocular uncorrected reading acuity at 60cm (bUI-RA) and at 40cm (bUN-RA), and~3. Binocular uncorrected critical print size at 60cm (bUI-CPS) and at 40cm (bUN-CPS).~All near and intermediate vision parameters are obtained using the Democritus Digital Acuity Reading Test (DDART), which is based on the Greek version of MNREAD.~Contrast sensitivity are evaluated with the Pelli-Robson test."
223990244|NCT03358238|BEHAVIORAL|Weekly review|Each week in the study, an interviewer will review manic and depressive symptoms self-reported by a participant and patterns of activity, sleep, and heart rate collected by the participant's activity tracker.
223990245|NCT03358238|OTHER|No weekly review|An interviewer will not review self-report symptoms and patterns collected from an activity tracker.
223544772|NCT00473109|PROCEDURE|Dialysis without systemic heparinization|Dialysis without systemic heparinization
223990246|NCT05137925|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT is an 8-week group-based treatment modality designed specifically to prevent recurrence of depressive symptoms. MBCT combines principles of cognitive behavioral therapy and mindfulness meditation to help participants change the way in which they relate to automatic negative thinking patterns that trigger symptom recurrence. Through awareness and acceptance of negative thoughts and emotions, participants learn how to dismiss negative thoughts and to tolerate distress and uncertainty.
223990247|NCT05137925|BEHAVIORAL|Treatment as Usual (TAU)|TAU (the control group) provides participants with information about the benefits of mindfulness in pregnancy and offers referrals for psychotherapy in the community. Participants in TAU are contacted monthly via phone or videoconference call to maintain engagement.
223990248|NCT03128528|DRUG|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
223990249|NCT03128528|DRUG|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
223990250|NCT01431950|DRUG|fluticasone furoate|Inhaled corticosteroid
223990251|NCT01431950|DRUG|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
223990252|NCT03210649|DRUG|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1\~D14
223990253|NCT03210649|DRUG|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1\~D14
223990254|NCT04749355|DRUG|BST-236|BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
223990255|NCT03297762|BEHAVIORAL|gamification|incentives/rewards and contact between standard visits
224121272|NCT06785025|BEHAVIORAL|Group-Based Dance Fitness Intervention|This group-based intervention will be conducted with women only. Women enrolled in the study and assigned to the intervention condition will complete 2 30-minute classes per week for 6 weeks. All classes will be held on a university campus and take place during the lunch hour (12:30-1pm). All classes will be led by a certified group fitness leader who is a member of the research team.
223990256|NCT03297762|BEHAVIORAL|Use of Dexcom G5|Dexcom G5 continuous glucose monitor
223990257|NCT05688163|OTHER|programme based on everyday cognition|Will carry out a programme based on everyday cognition, As material for use as for the traditional cognitive stimulation sessions, a training booklet on everyday cognition has been created which includes all the sessions mentioned above. Each day one of these tasks will be worked on.
223990258|NCT05688163|OTHER|traditional cognitive stimulation|Individual cognitive skills such as attention, memory, executive functions, orientation, praxis, calculation, visual perception and reasoning will be trained. The materials and media used will be a cognitive stimulation notebook created for the study which includes cards in printed paper format to be completed by the participants.
223990259|NCT01611961|DRUG|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
224121273|NCT06248593|DRUG|Continuous infusion of Norepinephrine|The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
223990260|NCT01611961|DRUG|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
223990261|NCT06171022|OTHER|Cherry seed pillow|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of heated cherry seed pillow will be applied to the participant's back area.
223990262|NCT06171022|OTHER|Control|4 Weeks, 5 days a week, in addition to the routine physiotherapy application, 20 minutes of hotpack will be applied to the participant's back area.
223990263|NCT06294197|OTHER|Pelvic Floor Exercises|In the intervention types, women are given training on pelvic floor exercises, that they can perform in the form of home exercises for 12 weeks. Before starting pelvic floor exercises therapy, a physiotherapist who specializes in pelvic floor compatibility will provide information about the location of the pelvic floor muscles through anatomical models and their effect on healthy, vaginal and sexual function. The effects of pelvic floor exercises on this system will be explained on an individual basis, and normal palpation is required to demonstrate their correct execution of contraction of the pelvic floor muscles. Participants will be taught how to contract and contract different muscles, such as the abdominal muscles, hip muscles, and gluteal muscles, or how to avoid pelvic tilt during contraction, and how to perform both rapid and sustained contractions.
223990264|NCT02387697|DEVICE|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
223990265|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
223990266|NCT00139581|DRUG|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
223990267|NCT03772769|DIAGNOSTIC_TEST|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
223990268|NCT03772769|DIAGNOSTIC_TEST|Microbial culture|Standard diagnosis by microbial culture.
223990269|NCT00583947|DRUG|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
223990270|NCT00583947|DRUG|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
223990271|NCT02314689|DRUG|Intravenous (IV) citrulline|
223990272|NCT03534583|OTHER|Sudarshan Kriya Yoga|Participants in the SKY group will undergo an oline 12-week training course conducted by certified teachers of the Art of Living Foundation
223990273|NCT03534583|OTHER|Health Enhancement Program|Participants in the online HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
223990274|NCT04588766|OTHER|constipation group|Constipation symptoms of individuals with cerebral palsy who were randomly evaluated were questioned and recorded according to Rome IV criteria. The group with cerebral palsy constipation was included in this group.
223990275|NCT04588766|OTHER|control group|Constipation symptoms of individuals with cerebral palsy who were evaluated randomly were questioned and recorded according to Rome IV criteria. The group with cerebral palsy without constipation was included in this group.
223990276|NCT00895726|DRUG|APD209|Oral tablets twice per day for 56 days
223990277|NCT01740154|PROCEDURE|transcranial magnetic stimulation|Undergo TMS
223990278|NCT01740154|PROCEDURE|electromyography|Undergo EMG
223990279|NCT01740154|OTHER|survey administration|Ancillary studies
223990280|NCT01740154|DRUG|sunitinib malate|Given PO
223990281|NCT03070704|DRUG|insulin degludec/liraglutide|Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
223990282|NCT06049368|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
223990283|NCT00141999|BIOLOGICAL|hepatitis B vaccine|
223990284|NCT02132871|DEVICE|Impedance cardiography Physioflow ®|
223990285|NCT05172752|OTHER|Citizen Scientist Training Program|Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
223990286|NCT05172752|OTHER|Stakeholder Consultation Core Program|Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
223990287|NCT05224661|OTHER|Prospective determination of the clinical utility of measurable residual disease (MRD) testing|Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
223990288|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (active comparator)|Active nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that stimulates the vagus nerve.
223990289|NCT05226130|DEVICE|Cervical transcutaneous vagus nerve stimulation (sham comparator)|Sham nVNS produces low-voltage electrical signal that generates sensations on the skin on upper anterior cervical area (overlying carotid artery) and that does not stimulate the vagus nerve.
224121274|NCT06248593|DRUG|Continuous infusion of Phenylephrine|The rate of phenylephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
224121275|NCT05871268|OTHER|Physician Awareness|The patients' pre-visit Control Preference Scale response are shared with their physician.
223990290|NCT03358472|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
223990291|NCT03358472|DRUG|Epacadostat|Epacadostat administered orally twice daily.
223990292|NCT03358472|DRUG|Cetuximab|Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
223990293|NCT03358472|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
223990294|NCT03358472|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
223990295|NCT03358472|DRUG|5-Fluorouracil|5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
223990296|NCT05789433|BEHAVIORAL|Aerobic exercise|Moderate- to vigorous-intensity aerobic exercise
223990297|NCT05789433|BEHAVIORAL|Progressive stretching|Statistic stretching of eight major muscle groups
223990298|NCT06015256|BIOLOGICAL|blood sample|Blood sample (56mL) taken in a heparin tube
223990299|NCT06411548|DEVICE|InsuLearn|InsuLearn is an artificial intelligence (AI)-algorithm that analyses collected participants data: CGM, insulin, and meal categories to learn the optimal insulin dose. InsuLearn will run offline in a study laptop to generate the optimal insulin dose for each meal category. The algorithm will generate an ambulatory glucose profile (AGP) report with new settings for the InPen™ meal estimation bolus calculator. The study physician will review the report and the algorithm recommendations. The study physician can accept or modify the algorithm recommendations as per his judgment. The new settings will be used during the intervention admission.
223990300|NCT04577209|DEVICE|Disposable oxygen face tent|Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
224121276|NCT05871268|OTHER|Usual Care|The patients' pre-visit Control Preference Scale response are not shared with their physician.
223990301|NCT04811079|OTHER|419 nm Spectacle Filter|TEST
223990302|NCT04811079|OTHER|437 nm Spectacle Filter|TEST
223544773|NCT06181981|DIAGNOSTIC_TEST|MRI fingerprinting|This method allows to get quantitative magnetic resonance imaging for the simultaneous measurement of multiple tissue properties in a single, time-efficient acquisition
223544774|NCT00265915|BIOLOGICAL|rituximab|
223990303|NCT04811079|OTHER|456 nm Spectacle Filter|TEST
223990304|NCT04811079|OTHER|476 nm Spectacle Filter|TEST
223990305|NCT04811079|OTHER|373 nm Spectacle Filter|CONTROL
223990306|NCT05237869|DEVICE|Blood Flow Restriction Device|Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.
223990307|NCT05237869|OTHER|Standard Physical Therapy|Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
223990308|NCT04323046|BIOLOGICAL|Nivolumab|Given IV
223990309|NCT04323046|OTHER|Quality-of-Life Assessment|Ancillary studies, given in person or online
223990310|NCT04323046|OTHER|Questionnaire Administration|Ancillary studies, given in person or online
223544775|NCT00265915|BIOLOGICAL|sargramostim|
223544776|NCT01685814|DRUG|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
223990311|NCT04554212|DEVICE|Blood Flow Restriction Training|Participants will undergo 8 weeks of blood flow restriction training with cuff inflated to 60% occlusion.
223544777|NCT01685814|BIOLOGICAL|autologous stem cell transplant|
223544778|NCT01685814|BIOLOGICAL|allogeneic stem cell transplant|
223544779|NCT05089292|BEHAVIORAL|Narrative breast health education|Health education program utilizing narrative messages to promote breast cancer screening in Chinese immigrant women will be delivered in a group format in the community
223990312|NCT04554212|DEVICE|Sham Blood Flow Restriction Training|Participants will undergo 8 weeks of sham blood flow restriction training with cuff inflated to less than 10% occlusion.
223990313|NCT01965509|DRUG|PEX168 or placebo|injection has to administered subcutaneously weekly
223990314|NCT02520310|DEVICE|AVJ-514|Patients receiving AVJ-514 device
223990315|NCT01340014|DRUG|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
223990316|NCT01340014|DRUG|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
224121277|NCT01847833|OTHER|MRI scan|
223990317|NCT01237847|BEHAVIORAL|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
223990318|NCT01237847|BEHAVIORAL|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
223990319|NCT01237847|BEHAVIORAL|Wait list comparison group|Wait list comparison group to receive intervention at later point.
223990320|NCT06380179|DEVICE|THOR3 training + Photobiomodulation Therapy (PBMT)|"PBMT will be delivered at 32-40W (depending on participant skin pigmentation). PBMT will be applied to the quadriceps area. A study team member will use the quadriceps measurements of the treatment area to calculate the PBMT treatment time (approximately 5-20 minutes) and specified J/cm2. PBMT treatment will be provided 3 times per week, for 3 weeks.~PBMT will be delivered by a trained study team member using the LightForce® XLi 40W device with the Smart Hand Piece technology, which has a built-in accelerometer in the hand piece that controls the speed of light delivery to the treatment area. The trained team members will use the Smart Hand Piece technology, which assesses the operator's speed and provides real-time visual and sensory feedback calibrated to shut-off when moving too slowly and warns the operator when moving too quickly by vibrating. Treatment is delivered through a flexible optical fiber threaded through the hand piece, which contains a rolling glass massage ball."
223990321|NCT06380179|DEVICE|THOR3 training + sham PBMT|Sham PBMT will be provided by a trained study team member. Sham PBMT will be delivered in the same manner as indicated for the PBMT process above, but the device will stay in standby mode (i.e., the treatment mode will not be turned on). As infrared light is invisible to the naked eye, the only visible difference between treatment and standby modes is the presence of a few tiny amber lights (these lights are on during treatment mode).
223990322|NCT06903312|PROCEDURE|Deferred Cytoreductive Nephrectomy + medical treatment|Patients randomized to Deferred Cytoreductive Nephrectomy can be treated with one among radical nephrectomy; partial nephrectomy or lumpectomy. Patients will continue to receive the ongoing medical treatment before the randomization.
223990323|NCT06903312|RADIATION|Radiotherapy + medical treatment|Patients randomized to RT should be treated with single shot of 25 Gy (or with multiple fractions with equivalent biological dose). Patients will continue to receive the ongoing medical treatment before the randomization.
224121278|NCT05892133|BEHAVIORAL|Maximal strength training|3 sessions/ week. leg press at \~85% of one repetition maximum for 8 weeks
224121279|NCT02299765|DRUG|Gefitinib|patients in arm A will be given gefitinib as target therapy
224121280|NCT02299765|DRUG|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
224121281|NCT02299765|DRUG|carboplatin|patients in arm A will be given carboplatin chemotherapy
224121282|NCT05836532|PROCEDURE|Central edge-to-edge|Suture of free margins of the mitral leaflets in central position to restore coaptation
224294656|NCT06142123|OTHER|3-D Ankle Mobility Exercises(A)|"The techniques will be first performed in prone lying against the resistance of the therapist and then in crook lying.~1. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the prone position according to the resistance of therapist.~2. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the prone position according to the resistance of therapist.~3. The participant will perform the D2 extension pattern (Planter-flexion-supination inversion-toe flexion) using the CI technique in the crook-lying position according to the resistance of therapist.~4. The participant will perform the D2 flexion pattern (Dorsi-flexion-pronation eversion-toe extension) using CI technique in the crook-lying position according to the resistance of therapist."
224294657|NCT06142123|OTHER|Eccentric Heel Drop Training(B)|": Group B will be treated with Eccentric Heel Drop Training. It will comprise of following exercises (14).~1. Eccentric loading exercises of calf muscles.~2. Conventional physiotherapy treatment including Ultrasound Plantar fascia stretching Calf muscle stretching Intrinsic muscles strengthening"
224294658|NCT02427295|DRUG|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~* Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -\> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~* Frequency: every 4 weeks.~* Route of administration: IM injection."
223990324|NCT06903312|DRUG|Medical therapy|Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or lenvatinib + pembrolizumab or nivolumab alone after nivolumab + ipilimumab.
223990325|NCT04535544|DRUG|JNJ-73763989|JNJ-73763989 will be administered as a SC injection.
223990326|NCT04535544|DRUG|Placebo|Matching placebo to JNJ-73763989 will be administered as a SC injection.
223990327|NCT04535544|DRUG|Entecavir (ETV) monohydrate|ETV monohydrate film coated tablet will be administered orally.
223990328|NCT04535544|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
223990329|NCT04535544|DRUG|Tenofovir alafenamide (TAF)|TAF film coated tablet will be administered orally.
223990330|NCT01754987|DRUG|Ascorbic Acid + Sorafenib|
223990331|NCT01754987|DRUG|Sorafenib|
223544780|NCT00042237|BEHAVIORAL|Schema Therapy|
223544781|NCT04229888|DEVICE|LipiFlow|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
223990332|NCT06590558|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223990333|NCT06590558|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223990334|NCT06590558|PROCEDURE|Computed Tomography|Undergo CT
223990335|NCT06590558|DRUG|Eribulin Mesylate|Given IV
223990336|NCT06590558|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223990337|NCT06590558|DRUG|Tolinapant|Given PO
223990338|NCT06590558|PROCEDURE|X-Ray Imaging|Undergo chest X-ray
223990339|NCT03746509|DEVICE|Laryngeal Vibration (Treatment)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
224121283|NCT06845514|OTHER|Condition LL-RE|"LL-RE condition will consist of a 5-minute warm-up (slow-paced walking) and the following exercises: leg press, chest press, leg curl, and seated row. Three sets will be performed for each exercise with a 3-minute rest period between sets/exercises. Each exercise will be executed through a full range of motion, with participants encouraged to follow a 2-sec eccentric phase (guided by a mobile app metronome and supervised by an exercise physiologist) and to perform the concentric phase as fast as possible. Participants will be informed to: stop the set when they perceive to have reached the RIR target.~• LL-RE: The low load intensity protocol consists of 3 sets of each exercise at 50% 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2)."
224121284|NCT06845514|OTHER|Control|Control condition: During the control condition, participants will sit quietly in a room maintained at a temperature of 22-24°C to prevent any influence on blood pressure values, for 60 minutes. During this period, they will perform a standardized non-fatiguing cognitive task: watching Earth, a documentary following the migration paths of four animal families.
224294659|NCT06718998|DRUG|NNC0519-0130|Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.
223990340|NCT03746509|DEVICE|Laryngeal Vibration (Comparator)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
223990341|NCT06005675|DEVICE|Intervention|No study treatments will be administered during this study.
223990342|NCT06590168|PROCEDURE|Socket Preservation by vestibular socket therapy|Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
223990343|NCT06590168|PROCEDURE|Socket Preservation by icecream cone technique|Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
223990344|NCT02194829|DRUG|AZD1775|Given PO
223990345|NCT02194829|DRUG|Gemcitabine|Given IV
223990346|NCT02194829|DRUG|Nab-paclitaxel|Given IV
223990347|NCT00755456|DRUG|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
223990348|NCT00755456|DRUG|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
223990349|NCT06819098|OTHER|Multicomponent Training Protocol|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
224294660|NCT06723015|DRUG|18F-AV-1451|"Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.~Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment.."
224294661|NCT07043647|OTHER|Shamba Maisha|"The Shamba Maisha Intervention has three key parts: A. Agricultural Commodities: KickStart Starter Pump (\~$60 USD, 2.5 Kg), hosing, fertilizer, and seeds. B. Training: We developed model farms near each health facility where didactic and hands on training will be conducted. Our weekly didactic and practical skills training will rotate topics to ensure all participants receive full coverage. Women will be encouraged to invite a key farming support person to trainings. C. Model farm harvest: Participants will harvest vegetables at the model farms for their own consumption until their individual farms start producing in 6-8 weeks to ensure access to a nutritious diet from the time of enrollment."
223990350|NCT06819098|OTHER|Isometric Multicomponent Training|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Isometric training: Gradual progression of 8 isometric exercises targeting major muscle groups, such as wall squats, isometric bicep curls, lateral raises, and rows (1-3 sets, 30 seconds per exercise, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
223990351|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Active|Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.
223990352|NCT04700683|DEVICE|Noctrix Health NPNS device v1.0 - Sham|Wearable device programmed to deliver sham stimulation.
223990353|NCT02884492|DRUG|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
223990354|NCT02884492|PROCEDURE|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
223990355|NCT02706249|DRUG|Enoxaparin|
223990356|NCT06658314|OTHER|Experimental interventional group 1(Kinesiotaping)|"Kinesiotape will be applied by using two I-bands application technique:~Short band: to apply this ask the patient to move your arm behind her back as much as possible, then apply kinesiotape at the anterior glenohumeral joint.~Longer band: to apply this ask the patient to horizontal adduct her arm as much as possible, than apply kinesiotape targeting the posterior side of glenohumeral joint.~Apply both these band with paper-off stretch for 3-5 days or as depending upon skin sensitivity and tape adherence.~Kinesiotape will be applied once a week for total time period of 3 weeks."
223990357|NCT06658314|OTHER|Experimental interventional group II (Graded exposure therapy)|"First week: gentle arm raises with 10 repetitions/day, slow and controlled stretch 25 to 50% force with 5 repetitions, passive internal and external rotations (with towel) with 5 repetitions each/day.~Second week: overhead arm raises (wall climbing) with 10 repetitions/day, pendulum exercises 10 repetitions/day, cross arm stretches 5 repetitions/day, active internal and external rotations with 5 repetitions each/day.~Third week: resistance exercises (initially with minimum weight or manual resistance), scapular squeezes 10 repetitions/day, gentle chest stretches 5 repetitions/day and gentle stretch with 75 to 100 % force 5 repetitions each/day."
223990358|NCT05176626|BEHAVIORAL|Online Lifestyle Behavioral Therapy|Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
223990359|NCT05176626|DRUG|Phentermine Hydrochloride 8 MG|At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
223990360|NCT06606691|DEVICE|Xiaomi Mi Smart Band 8|The wearable device, Xiaomi Mi Smart Band 8, will be used solely for observational purposes to assess its accuracy in measuring sleep parameters, oxygen saturation, and heart rate in comparison to nocturnal polygraphy. Participants are receiving routine care as prescribed by their clinicians, and the wearable device is not part of their medical treatment but is being observed alongside standard polygraphy tests.
223990361|NCT01124838|DRUG|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
223990362|NCT01124838|DRUG|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
223990363|NCT01124838|DRUG|Placebo|Administered by subcutaneous injection
224121285|NCT06845514|OTHER|Condition HL-RE|"HL-RE condition will consist of a 5-minute warm-up (slow-paced walking) and the following exercises: leg press, chest press, leg curl, and seated row. Three sets will be performed for each exercise with a 3-minute rest period between sets/exercises. Each exercise will be executed through a full range of motion, with participants encouraged to follow a 2-sec eccentric phase (guided by a mobile app metronome and supervised by an exercise physiologist) and to perform the concentric phase as fast as possible. Participants will be informed to: stop the set when they perceive to have reached the RIR target.~• HL-RE: The high load intensity protocol consists of 3 sets of each exercise at 80% of 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2)."
224121286|NCT03805932|DRUG|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
224121287|NCT03805932|BIOLOGICAL|Rituximab|Rituximab will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
224121288|NCT03805932|BIOLOGICAL|Ruxience|Ruxience will be administered at 375mg/m\^2 intravenous (iv), 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)
223544782|NCT04229888|DEVICE|Light Based (Sham) Treatment|A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.
224121289|NCT03805932|DRUG|Dexamethasone|12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
224121290|NCT03805932|DRUG|Acetaminophen|650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
223544783|NCT03538093|OTHER|Experimental: Local Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load."
223990364|NCT04513977|OTHER|Geriatric Oncology Supportive Clinic|Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
223990365|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
223990366|NCT03693209|BEHAVIORAL|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
223990367|NCT03708796|DIAGNOSTIC_TEST|SIRS, qSOFA, NEWS, RETTS scores evaluation|Simple data collection from regular vital signs recordings during the initial phase of care management in the emergency department. Missing data is then possibly completed by the physician when made available during the regular medical management of the patient.
223990368|NCT02390661|DEVICE|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
223990369|NCT00000505|DRUG|tissue plasminogen activator|
223990370|NCT00000505|PROCEDURE|angioplasty, transluminal, percutaneous coronary|
223990371|NCT04297618|DRUG|Xiidra|Xiidra (lifitegrast 5% ophthalmic solution)
223990372|NCT06682650|BEHAVIORAL|NPT-PLA|"NPT-PLA was developed and initially tested in 5 European countries in the EU-funded RESTORE study. PLA Participatory Learning in Action is a set of participatory research techniques in which participants use democratic processes to identify key actions needed to achieve a specific goal e.g. implementation of a tested decision making tool such as I2; and prioritize which of these need to be acted upon first and subsequently (in which order). Normalization Process Theory (NPT) is combined with PLA to help implementation teams using PLA to assess organization capacity and readiness to enact the selected action steps vis-a-vis NPT constructs, iteratively. These are coherence does everyone understand what needs to be done?; Cognitive participation Does everyone who needs to act 'buy in' to take action; collective action Is everyone who needs to act taking steps to make the change?'; and reflexive monitoring After the step has been taken, has it had the desired impact on the goal?"
223990373|NCT06682650|BEHAVIORAL|Usual Quality Improvement|Usual quality improvement includes principles of continuous quality improvement, such as Plan-Do-Study-Act cycles, to implement a specific goal. In this study, 'usual QI' methods already in use in 'active comparator' arm will be documented during the baseline assessment of clinical workflows in clinics assigned to that arm; and will be provided with a 'preset protocol' to implement the study shared decision-making tool (I2). Processes that implementation teams in these clinics use to achieve implementation will be documented.
223990374|NCT06627335|DRUG|Ruxolitinib Cream|Ruxolitinib Cream
223990375|NCT06627335|DRUG|TCS|Topical corticosteroid
223990376|NCT05890963|DRUG|ART|ART is a combination of three or more drugs from different classes of antiretroviral medication.
224121291|NCT03805932|DRUG|Diphenhydramine|25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
224121292|NCT03805932|DRUG|Famotidine|20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
223544784|NCT03538093|OTHER|Experimental: Global Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load."
223990377|NCT05890963|DRUG|10E8.4/iMab|10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
223990378|NCT05890963|DRUG|VRC07-523LS|VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
223990379|NCT05419388|DRUG|RO7247669|Participants will receive intravenous (IV) RO7247669 Q3W
224121293|NCT03805932|DRUG|Aspirin|81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
224121294|NCT05742087|OTHER|Clinical examination|The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
224121295|NCT05742087|OTHER|electroneuromyography (ENMG)|Data from the ENMGs will be extracted from the cohort and analyzed.
224121296|NCT00953043|DRUG|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
224121297|NCT00953043|DRUG|Placebo|Placebo medication given for three days
224121298|NCT00953043|OTHER|Bowel preparation|Polyethylene glycol-based bowel preparation
224121299|NCT03059810|DEVICE|etafilcon A|Investigational Contact Lens
224121300|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
223990380|NCT06875154|PROCEDURE|Valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy or minitoracothomy Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium or from peripheral access. Left ventricle was vented through the right superior pulmonary vein.~In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion.. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
223990381|NCT07049224|OTHER|Meat diet|Participants will be subjected to a 10-day diet containing meat and animal products. During the interventional period participants will perform unilateral lower limb resistance exercise.
223990382|NCT07049224|OTHER|Plant diet|Participants will be subjected to a 10-day diet containing plant products. During the interventional period participants will perform unilateral lower limb resistance exercise.
223990383|NCT07050524|DIETARY_SUPPLEMENT|Omega-3 Supplementation|Participants assigned to the experimental group will receive Omega-3 fatty acids supplementation as part of their treatment regimen. The Omega-3 supplementation will consist of high-quality fish oil capsules, providing a daily dose of \[specific dosage, e.g., 2000 mg of EPA and DHA combined\], taken orally. This supplementation will commence concurrently with the initiation of neoadjuvant immunotherapy and will continue throughout the treatment period.
223990384|NCT07050524|DRUG|Neoadjuvant Immunotherapy|"Participants in both the experimental and control groups will receive neoadjuvant immunotherapy designed to stimulate the body's immune response against locally advanced gastric and gastroesophageal junction adenocarcinomas. The specific regimen will involve administration of \[specific immunotherapeutic agents, e.g., pembrolizumab, nivolumab, etc.\] in accordance with established clinical protocols.~The neoadjuvant immunotherapy will be administered through intravenous infusion, typically starting \[specify timeline, e.g., 4-6 weeks\] prior to surgical resection of the tumor. Treatment cycles will be scheduled every \[specify interval, e.g., 2 or 3 weeks\], depending on the specific agent used and participant response."
223990385|NCT07051135|DEVICE|"HablaRÉ: Emotional Reasoning bias correction training"|"The HablaRÉ bias correction training for Emotional Reasoning consists of ten online, self-administered sessions that last no more than 30 minutes each. These courses include practice tasks in addition to textual and audio-visual content. The explanation of ER bias, motivation to change, emotional psychoeducation, and the distinction between emotionally biassed and objective information are all addressed."
223990386|NCT07049835|DRUG|Ilioinguinal/iliohypogastric Nerve Block|15cc 0.25% of Bupivacaine + Dexamethasone 8 mg 2cc
223990387|NCT07049835|OTHER|Ilioinguinal/iliohypogastric with Placebo Block|17 cc of Placebo
223990388|NCT07050849|BEHAVIORAL|Slackline Training|This intervention consisted of a six-week supervised slackline training program designed to improve core stability, physical performance, and dynamic balance. Participants in the intervention group performed 18 sessions (3 sessions per week, 45 minutes each) using a Gibbon-brand slackline (12.5 meters in length, 50 mm wide). The training protocol included a structured progression of 11 exercises, ranging from assisted standing to unassisted long walks and dynamic movements on the slackline. All sessions were conducted under the supervision of a licensed physiotherapist to ensure participant safety and training fidelity. Exercises were adapted weekly to increase difficulty, challenge motor control, and stimulate neuromuscular adaptation.
223990389|NCT07048990|BEHAVIORAL|Empowerment Group Therapy|Empowerment is a manualized, culturally sensitive treatment program. The treatment is based on a modular principle that transdiagnostically targets major symptom domains (e.g. stress, depression, anxiety), and can be flexibly adapted to individual mental health conditions of clients who participate in this program. The intervention is designed as a psychological group intervention for resource-limited settings and scalable for different formats (i.e. in-person, online, hybrid) to be feasible under the unstable conditions of war (e.g. missile attacks, power outrages). Key therapeutic elements are psychoeducation, emotion regulation strategies, problem solving and building coping skills. The activation of individual and culture-specific resources as well as building self-help skills are at focus of the treatment.
223990390|NCT07050446|DRUG|Vizol S DIGI EYE eye drops|1 drop 4 times a day
223990391|NCT07050446|DRUG|0,9% saline solution, eye drops|1 drop 4 times a day
223990392|NCT06727799|DIAGNOSTIC_TEST|Docking Assessment / Observation|One eye of each subject will have corneal marks placed and will be docked at the study visit.
223990393|NCT07050394|DRUG|CD-GA-102|CD-GA-102 will be administered intravenously at 50 μg per dose, with dosing scheduled at 2 weeks (±3 days) and 4 weeks (±3 days) after the initial dose, followed by maintenance therapy every 3 weeks (±3 days). Dosing intervals may be adjusted based on participant tolerability and safety. After receiving at least two doses of CD-GA-102 monotherapy and completing safety assessments, participants may be offered combination therapies, as determined by the investigator.
223990394|NCT07050329|DEVICE|Electrocautery|Axillary dissection was done through bipolar electrocautery
223990395|NCT07050329|DEVICE|Ultrasonic dissector|Axillary dissection was done through ultrasonic dissector.
223990396|NCT07050043|DRUG|Nivolumab 40mg|Nivolumab is an immunotherapy medicine used to treat several cancers, including lung cancer.
223990397|NCT07050043|DRUG|Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel|Cisplatin, carboplatin, pemetrexed, paclitaxel, Gemcitabine, and docetaxel are chemotherapy drugs used to treat various types of cancer, including non-small cell lung cancer.
223990398|NCT07050199|PROCEDURE|Emergency laparotomy|Emergency laparotomy
223990399|NCT06861712|RADIATION|SBRT|The experimental group will first receive SBRT (Stereotactic Body Radiotherapy) for the primary tumor and positive lymph nodes (prescribed dose: 6 Gy × 3 fractions, once every other day).
223990400|NCT06861712|DRUG|Docetaxel, Cisplatin, Toripalimab|Toripalimab 240mg (free medicine) + Docetaxel 75mg/m2 + Cisplatin 75mg/m2, q3w for 3 courses
223990401|NCT06861712|PROCEDURE|Radical resection surgery|Radical resection surgery
223990402|NCT06861712|RADIATION|IMRT ± chemotherapy/toripalimab|According to the preoperative staging and postoperative pathological characteristics, all patients will receive postoperative radiotherapy with or without cisplatin-based chemotherapy. Additionally, patients can choose whether to continue maintenance therapy with toripalimab after surgery.
223990403|NCT03835273|OTHER|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
223990404|NCT03835273|OTHER|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
223990405|NCT03835273|OTHER|Questionnaires|Three validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and LASORS questionnaire.
223990406|NCT04447131|OTHER|venipuncture in peripheral vein|single vacuum venipuncture in peripheral vein
223990407|NCT06753331|COMBINATION_PRODUCT|DSP-1083 implantation|DSP-1083 subjects will receive 2.7M viable cells per hemisphere; 5.4M total cell dose as implants.
223990408|NCT06753331|PROCEDURE|Sham surgery treatment|Sham surgery subjects will undergo a partial thickness burr hole surgical procedure on each side of the skull with no DSP-1083 administration.
223990409|NCT06715371|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE) and Transesophageal Echocardiography (TEE)|"Transthoracic echocardiography (TTE) is a non-invasive imaging technique performed by placing an ultrasound transducer on the chest to obtain detailed heart images. TTE is conducted preoperatively on awake patients within two weeks prior to cardiac surgery, following ASE chamber quantification guidelines.~Transesophageal echocardiography (TEE) is an invasive imaging technique where an ultrasound transducer is placed in the esophagus, providing closer and clearer images of the heart. TEE is performed intraoperatively under general anesthesia as part of routine care."
223990410|NCT06751407|PROCEDURE|Single level SPSIPB|The procedure will be performed with the patient in the prone position in the preoperative period. After the scapula is slightly shifted laterally, the US probe is held sagittally at the upper corner of the scapula spine, and the 3rd rib and the serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and entered between the serratus posterior superior and the 3rd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be used.
224121301|NCT00909766|DRUG|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
224121302|NCT00909766|DRUG|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
224121303|NCT00909766|DRUG|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
224121304|NCT00909766|DRUG|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
224121305|NCT00909766|DRUG|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
223990411|NCT06751407|PROCEDURE|Two-level SPSIPB|In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 2nd rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block location is confirmed, 10 ml of 0.25% bupivacaine will be used. Then, the US probe will be held sagittally in the medial part of the scapula spine, and the 4th rib and serratus posterior superior muscle will be visualized. In plane technique will be used. The block needle will be advanced in the caudo-cranial direction and inserted between the serratus posterior superior and the 4th rib. The block location will be confirmed by injecting 2 ml of saline between the rib and the muscle. After the block site is confirmed, 10 ml of 0.25% bupivacaine will be used. A total of 20 ml of 0.25% bupivacaine will be used.
223990412|NCT00157846|DEVICE|CRT-P or CRT-D Device|Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
223990413|NCT06892327|OTHER|standard biometric ultrasound|In this study, biometric measurements were systematically performed for each patient using both manual methods and an artificial intelligence (AI) system (Live View Assist, Samsung). The AI system provided real-time guidance by identifying anatomical landmarks and assisting in the measurement of key biometric parameters, including Femur Length (FL), Abdominal Circumference (AC), Head Circumference (HC), and Biparietal Diameter (BPD). This dual approach ensured that both manual and AI-assisted methods were applied uniformly as part of routine clinical care.
223990414|NCT06830733|GENETIC|ARI0002h|"* Treatment with ARI0002h cells~* Other names: CARTBCMA\_J22.9-h:CD8TM:4-1BB:CD3. Adult differentiated autologous T cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory domain and the CD3z signalling domain that has been humanized."
223990415|NCT06837103|DEVICE|Intermittently Scanned Continuous Glucose Monitor|intervention used by the isCGM and isCGM+Coaching groups
224121306|NCT00909766|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
224121307|NCT01810198|PROCEDURE|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
223729085|NCT06058676|PROCEDURE|carotid artery stenting|The procedures will be performed for patients with general or local anesthesia. Implantation of stents at the site of carotid artery stenosis for the treatment of carotid severe stenosis. A suitable balloon will be selected based on the internal carotid arterial（ICA）diameter, as shown on the digital subtraction angiography（DSA）image. The use of a balloon for predilatation or postdilatation depends on the degree of stenosis. The type of stent will be selected according to several factors, such as the length and configuration of the lesion, vascular morphology, vessel diameter, plaque characteristics, stent characteristics, and surgeon experience.
223729086|NCT03649750|DRUG|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
223990416|NCT06910059|OTHER|Observational|It is a observational study and patients with pacing indications who plan to receive Micra AV implantation will be recruited. No intervention procedure will be performed.
223990417|NCT06911112|DRUG|NBI-1065845|NBI-1065845 tablets
223544785|NCT03538093|OTHER|Experimental: Mixed Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load."
223544786|NCT04240431|DIAGNOSTIC_TEST|Probing /irrigation of lacrimal passages|Probing of the lacrimal passage was done using #00 Bowman's lacrimal probe which can reveal any narrowing (resistance) or obstruction (soft stop) of the canaliculi during its advancement from punctum towards the lacrimal sac.
223990418|NCT06911112|DRUG|Placebo|Matching placebo tablets
223990419|NCT06914050|DRUG|Adebrelimab|Induction therapy：Adebrelimab, 1200mg, d1, q3w, 2 cycles; Maintenance therapy：Adebrelimab, 1200mg, d1, q3w, until disease progression or unbearable toxicity.
223990420|NCT06914050|DRUG|EC/EP|Chemotherapy: standard chemotherapy EC/EP
223990421|NCT06914050|RADIATION|SBRT|8Gy\*3
223990422|NCT06914050|RADIATION|Chest radiotherapy|Chest radiotherapy: conventional fractionation mode 2Gy QD total dose 60Gy or 1.5Gy BID total dose 45Gy, according to the patient's physical condition, concurrent EP or EC chemotherapy can be considered
223990423|NCT06918158|OTHER|Mobilization with Movement|"Mobilization with Movement~* The proximal row of carpals glides passively radially.~* Active thumb and wrist movements superimposed on the glide.~Therapeutic excercises:~* Ball Toss~* Static web gripping~* Gentle ROM activities to maintain mobility~* Isometric exercises in all direction"
223990424|NCT06918158|OTHER|Joint Specific Manipulation|"Joint Specific Manipulation~* High-velocity, low-amplitude thrust to the first carpometacarpal joint~* Radiocarpal wrist mobilization .Grade III-IV applied at end range. 2. Therapeutic excercises:~* Ball Toss~* Static web gripping~* Gentle ROM activities to maintain mobility~* Isometric exercises in all direction Ergonomics modifications"
223990425|NCT03506672|OTHER|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
223990426|NCT03506672|OTHER|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
223990427|NCT06844903|OTHER|Pulsed ultrasound at acupuncture points|The experimental group will receive pulsed ultrasound at bilateral acupuncture points of St29, Sp6 and unilateral acupuncture points on Ren4 and Ren5 in addition to standard care program for 12 weeks.
223990428|NCT06844903|OTHER|Placebo ultrasound at acupuncture points|The placebo group will receive the same but in Placebo manner for 12 weeks.
223990429|NCT06844903|OTHER|Standard care program|All participants in both groups will be given an info brochure, that included advice on a healthy diet as a low-carbohydrate and high-protein diet, high dietary fiber, and less saturated fat in addition to engagement in aerobic exercise, fast walking for at least 30 - 45 min, 3 days a week for 12 weeks.
223990430|NCT04714710|DRUG|IV Potassium Canrenoate|"Administration of 200 mg of IV potassium canrenoate (diluted in sodium chloride 0.9%) in brain-dead donors within 10 hours after the diagnosis of brain death and before the departure to the operating room.~Second administration of potassium canrenoate 6 hours after first administration if the patient is not YET admitted IN the operating room"
223990431|NCT04714710|DRUG|IV Sodium Chloride 0.9 %|"Administration of IV sodium chloride 0.9% (placebo) in brain-dead donors within 10 hours after the diagnosis of brain death is made and before the departure to the operating room.~Second administration of IV sodium chloride 0.9% (placebo) 6 hours after first administration if the patient is not YET admitted IN the operating room."
224121308|NCT01810198|PROCEDURE|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
224121309|NCT06049771|OTHER|Collect blood sample|Collect blood samples at different time points: after tigecycline administration 1 h, 2-4 h, 4-6 h, 6-11.5 h and 30 minutes before next dose
224121310|NCT03706534|DEVICE|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
224121311|NCT03706534|DEVICE|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
224121312|NCT03706534|DEVICE|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
223990432|NCT06931535|DEVICE|remote ischemic conditioning|The cuff of the remote ischemic conditioning device was placed on both upper arms (at the same position as blood pressure measurement) and inflated to 200 mmHg. The treatment protocol consisted of 5 cycles of 5-minute inflation followed by 5-minute deflation, performed twice daily. The treatment duration was 8-12 consecutive days.
223990433|NCT06937957|DRUG|BR111 for Injection|BR111-101 for injection will be administered by intravenous drip, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
223990434|NCT06937957|DRUG|BR111 for Injection|BR111-101 for injection will be administered via intravenous drip at a fixed frequency and cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study occurs. The dose for each administration will be calculated based on the body weight measured prior to administration. The dosing regimen (dosing frequency and interval) for subsequent studies may be adjusted based on prior data. The intravenous drip duration should be ≥ 90 minutes for the first dose and may be adjusted to ≥ 30 minutes for subsequent doses if the first dose is well tolerated.
223990435|NCT06938568|OTHER|Personalized back exercises|"The study intervention is a 12-week personalized physical back training program. It consists of six to eight exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.~An initial one-on-one training session will take place to familiarize participants with the back training program, corresponding to the first week's session of the 12-week intervention period. During the 12-week intervention period, the training comprises one supervised group session per week, lasting 30 minutes, along with three individual unsupervised sessions, each lasting 10-15 minutes. Our procedures ensures that both participants and instructors are blinded to the group allocation, allowing both groups to train together (e.g., mixed training groups)."
223990436|NCT06938568|OTHER|Non-personalized back exercises|"The active control intervention is a 12-week non-personalized physical back training program. It consists of six to eight exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.~An initial one-on-one training session will take place to familiarize participants with the back training program, corresponding to the first week's session of the 12-week intervention period. During the 12-week intervention period, the training comprises one supervised group session per week, lasting 30 minutes, along with three individual unsupervised sessions, each lasting 10-15 minutes. Our procedures ensures that both participants and instructors are blinded to the group allocation, allowing both groups to train together (e.g., mixed training groups)."
223990437|NCT06939907|DEVICE|Nexpowder™|Nexpowder™ hemostatic powder
223990438|NCT06941506|OTHER|VA-SPOZ exercise program|The VA-SPOZ exercise program has three phases and takes 40 minutes to complete. The program will be performed in a seated position, and the participants will wear SPOZ devices on both hands to record and track the accuracy of the movements.
223990439|NCT06941506|OTHER|Control|Participants maintain their routine activities.
223990440|NCT06941714|OTHER|Perturbation|Jack is attached to force plates and it is used to give perturbation when participants are standing on force platform. Balance is assessed after perturbation and readings will be taken through HRV and GSR.
223990441|NCT06941714|OTHER|Working Memory Task|Arithmetic test (Backward counting with serial 3 subtraction and articulation): participants are asked to count out loud backward with serial subtraction of 3 from each number, starting with a random number provided by the researcher. while participants are standing on force plates. During all this process cognitive loading will be measured through Heart Rate Variability (HRV) and Galvanic Skin Response (GSR).
223990442|NCT06941714|OTHER|Visual and Verbal Fluency Task|Modified Stroop test or Stroop color word test: Participants are asked to name the color of ink that each word is printed. The test will appear on screen while participants are standing on force plates. During all this process cognitive loading will be measured through Heart Rate Variability (HRV) and Galvanic Skin Response (GSR).
223990443|NCT06940843|BEHAVIORAL|Hopeful and Healthy Living (HHL)|The HHL intervention is a 16-week long, manualized group intervention. Classes will be held weekly for 90 minutes. The class covers 15 topics centered on building social connections, developing healthy lifestyle routines around eating, exercise, and sleep. Each class will target one social skill (i.e. starting conversations) and one cognitive self-management strategy (i.e. memory tips), which will be taught and practiced in class. Each class also includes a facilitated exercise component and individually tailored take home application activity.
223990444|NCT06945666|DRUG|Combined therapy of Iguratimod and tofacitinib|This study aims to evaluate the efficacy and safety of the combination of iguratimod and tofacitinib in the treatment of RA patients with poor responses to traditional or biological DMARDs, providing evidence-based support for clinical treatment.
223990445|NCT06945068|BIOLOGICAL|GB261|GB261 will be dosed according to the assigned group.
223990446|NCT06944418|OTHER|observation|observation
223990447|NCT06945302|DIETARY_SUPPLEMENT|Intervention Group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
223990448|NCT06945302|DIETARY_SUPPLEMENT|Control group (placebo)|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
223990449|NCT06944015|OTHER|normal saline|After completion of surgery, Study Group patients underwent intraperitoneal irrigation with 30 mL/kg of normal saline at 37C infused under the right hemidiaphragm. Patients were placed in Trendelenburg position and reverse Trendelenburg position, to allow contact between the liquid and all abdominal structures, including the diaphragm and surgical wounds. At the end of the procedure, all the introduced liquid was carefully removed.
223990450|NCT06944028|PROCEDURE|Selective excavation|Partial removal of carious dentine, soft carious tissue is intentionally left over the pulp to avoid exposure. The peripheral enamel and dentine are prepared to hard dentine, and a permanent restoration is placed on the tooth.
223990451|NCT06944028|PROCEDURE|Stepwise excavation|Partial removal of carious dentine is performed, soft dentine is intentionally left over the pulp to avoid exposure. The peripheral enamel and dentine are prepared to hard dentine, application of a provisional restoration. After approximately 3-5 months, the provisional restoration is removed, and any remaining carious dentine is further removed until firm dentine is reached. A permanent restoration is then applied.
223990452|NCT06944561|DIAGNOSTIC_TEST|Culture and identify Mycobacterium tuberculosis from patient faeces|When faecal samples have been identified only by a pseudo-anonymised label they will be transferred to the designated secure collection point (Vaccine Institute). Professor Tim Bull will then be informed of their availability and will collect and transport to the research laboratory, located in the same building, making a log of all samples received. All samples will then be processed by the research laboratory as defined in the sample processing protocol. Culture result data will be obtained and stored on a secure password protected PC Excel file for collation and archiving by the chief analyst.
223990453|NCT06937463|BEHAVIORAL|Rehabilitation|This is a study on the recovery of physical function in bed patients through a digital rehabilitation exercise system
223990454|NCT06945731|DEVICE|TMS|20 sessions 10 Hz rTMS
223990455|NCT06945731|DEVICE|Transcranial Magnetic Stimulation Sham|Sham TMS
223990456|NCT06944431|DEVICE|Continuous Passive Motion (CPM)|Continuous passive motion was applied to the left ankle joint for 60 minutes per day using a motorized CPM device. The therapy was initiated within 48 ho
223990457|NCT06945848|DRUG|Acetazolamide|Acetazolamide will be maintained and weight loss will be recommended
223990458|NCT06945848|DEVICE|Stent (Tentos 4F or Precise ProRX)|Transverse venous sinus will be stented by neuroradiological intervention
223990459|NCT06945133|OTHER|Clinical testing|"Intervention includes :~* Surface EMG to measure inhibition of the VM and the rectus femoris (RF) on the injured and non-injured sides during attempts at voluntary contractions of the knee extensor muscles.~* Myotonometry to measure the stiffness of the semimembranosus and biceps femoris (long head) on the injured and non-injured sides under resting conditions"
223990460|NCT06944743|PROCEDURE|Transurtheral Resection of prostate ( TURP)|"TURP involves an endoscopic approach via the patient's urethra to surgically remove the inner portion of the prostate that encircles the urethra. A bipolar electrified wire loop is used to remove the portion of the prostate between the bladder neck and the verumontanum to a depth of the surgical capsule. Before the resection is begun, the bladder should be inspected for any bladder pathology (e.g., tumor, diverticula or stones).~The bladder neck, trigone, and position of the ureteral orifices, verumontanum, and external sphincter should be noted. Three-way Foley catheter is usually placed to and traction for a short time, release of traction based on clearance of hematuria."
224121313|NCT03706534|PROCEDURE|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
224121314|NCT02709993|BIOLOGICAL|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10\^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
224121315|NCT00003207|DRUG|pegylated liposomal doxorubicin hydrochloride|
224121316|NCT00003207|DRUG|PSC 833|
224121317|NCT00246467|BIOLOGICAL|Alhydrogel|
224121318|NCT00246467|BIOLOGICAL|rF1 and rV protein antigens|
224121319|NCT03542045|DEVICE|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
224121320|NCT01043185|DRUG|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
223990461|NCT02726945|DEVICE|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
223990462|NCT02726945|OTHER|Placebo|Placebo Control
223990463|NCT06944496|BIOLOGICAL|Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine|Disitamab Vedotin: 2.5 mg/kg, IV, D1, Q2W; Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 100 mg/m², IV, D1, Q3W; Capecitabine: 750 mg/m², po, BID, D1-D14, Q3W
224121321|NCT01043185|DRUG|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
224121322|NCT01043185|DRUG|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
224121323|NCT01043185|DRUG|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
224121324|NCT01043185|DRUG|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
224121325|NCT06286436|OTHER|Dual-task training|The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
224121326|NCT06106321|PROCEDURE|Transalveolar crest maxillary sinus floor lift|Transalveolar crest maxillary sinus floor lift + bone grafting + implant implant is used
224121327|NCT06106321|PROCEDURE|transalveolar crest parietal maxillary sinus floor secondary lift|Transalveolar crest parietal maxillary sinus floor secondary lift + bone grafting + implant implantation were used body
223990464|NCT06944496|BIOLOGICAL|Tislelizumab+Oxaliplatin+Capecitabine|Tislelizumab: 200 mg, IV, D1, Q3W Oxaliplatin: 130 mg/m², IV, D1, Q3W; Capecitabine: 1000 mg/m², po, BID, D1-D14, Q3W
223990465|NCT06945029|DEVICE|Ambu Aura Gain|compare between Laryseal Pro and Ambu Aura Gain extraglottic devices as conduits for fiberoptic endotracheal intubation regarding time of endotracheal intubation in pediatric population.
223990466|NCT06945029|DEVICE|Laryseal Pro|compare between Laryseal Pro and Ambu Aura Gain extraglottic devices as conduits for fiberoptic endotracheal intubation regarding time of endotracheal intubation in pediatric
223990467|NCT06950840|DRUG|Acetaminophen|Acetaminophen 1 g IV once
223990468|NCT06950840|DRUG|dipyrone|Dipyrone IV 1 g once
223990469|NCT06948227|OTHER|Daily Living Activities (ADL) Training Program|After the 1st assessment, activities that the investigators frequently use in daily life such as eating and brushing our teeth and activities that are appropriate for the age group of the participants and that affect their participation such as throwing a ball or playing games will be implemented with the therapist for 6 weeks. During the session, the therapist will provide practical training so that the participants can do the activities correctly and will provide a demonstration of the activity, observe whether the child compensates while performing the movements during all these activity steps and will make corrections for the movements that he/she compensates for. At the same time, the therapist will give reinforcing verbal affect for the activity skills that the participants do correctly in order to increase their motivation during the session. The 2nd Assessment will be made at the end of the 6th week in order to analyze the change during the 6-week period.
224121328|NCT04875039|DRUG|Dexamethasone|dexamethasone 2 mg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
224121329|NCT04875039|DRUG|Dexmedetomidine-Dexamethasone|A mixture of dexamethasone 2mg with dexmedetomidine 50mcg will be added to the local anesthetic used to block the cords of the brachial plexus with an infraclavicular approach.
224121330|NCT05275738|DIETARY_SUPPLEMENT|Nicotinamide|Study tablets for nicotinamide are produced by Blackmores Ltd.
224121331|NCT05275738|OTHER|Placebo|Study tablets for placebo are produced by Blackmores Ltd.
223990470|NCT06948227|OTHER|Social Robot Application|The basic daily life activities that the Social Robot can perform, such as eating and brushing teeth, and the ball throwing activity that affects their participation, will be coded into the robot by engineers. 1. The evaluations will be applied as in the other group, and occupational therapy sessions for upper extremity skills will be applied with the Social Robot Nao accompanied by a therapist for 6 weeks. In this group, the robot will show the selected activities to the children according to the activity application steps during the session and then ask the child to apply them. The verbal feedback that the Social Robot Nao will use will be determined and applied by the therapist. At the end of the 6th week, the second evaluations will be made and the 6-week developments of the participants in this group will be analyzed. Each session will be applied once a week for 40 minutes.
223990471|NCT06949982|COMBINATION_PRODUCT|experimental group x-MAP|hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.
223990472|NCT06949982|DRUG|Regorafenib (BAY 73-4506)|Regorafenib 160 mg PO daily on days 1-21, every 28 days OR 1st cycle: Regorafenib 80 mg PO daily on days 1-7, followed by 120 mg PO daily on days 8-14, followed by 160 mg PO daily on days 15-21, every 28 days, 2nd and subsequent cycles: Regorafenib 160 mg PO daily on days 1-21, every 28 days
223990473|NCT00233753|DEVICE|Cordis Neurovascular Self-Expanding Stent|
223990474|NCT06261619|DEVICE|Adult Sotair Device|Adult Sotair® device employs a flow limiting valve mechanism.
223990475|NCT05363189|PROCEDURE|Venous augmentation|Increasing the venous drainage of a deep inferior epigastric artery perforator (DIEP) flap by anastomosing the superficial inferior epigastric vein to the cephalic vein
223990476|NCT05363189|PROCEDURE|Traditional ERAS (enhanced recovery after surgery) protocol|Pre-, peri-, and post-operative care as described in the ERAS protocol
223990477|NCT05363189|PROCEDURE|Sahlgrenska recovery protocol|Pre-, peri-, and post-operative care as described in the Sahlgrenska recovery protocol
223990478|NCT05363189|PROCEDURE|No venous augmentation|Traditional deep inferior epigastric artery perforator flap (DIEP)
223990479|NCT05992922|DRUG|IC265 Ophthalmic Solution 1%|1 drop will be instilled in each eye twice a day
223990480|NCT05992922|DRUG|Placebo Ophthalmic Solution (Vehicle)|1 drop will be instilled in each eye twice a day
223990481|NCT06476938|OTHER|Gene PilotLX|eHealth decision making tool regarding tumor genomic profiling
223990482|NCT01882413|OTHER|No intervention|No intervention
223990483|NCT00551746|DIETARY_SUPPLEMENT|Purple Grape Juice|Grape Juice
223990484|NCT00243906|DRUG|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
223990485|NCT00243906|PROCEDURE|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS \>/= 10) treated within 3 hours of symptoms onset.
223990486|NCT00269906|DRUG|Abciximab|
223990487|NCT00269906|DRUG|Placebo|
223990488|NCT06051110|DEVICE|Combined risk score|Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin
223544787|NCT01305187|DEVICE|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
223990489|NCT06051110|OTHER|Usual care|Prehospital risk stratification by EMS protocols
223990490|NCT06051110|DEVICE|point-of-care troponin|Prehospital risk stratification by the use of a POC-troponin
223990491|NCT01895790|DEVICE|Pancreatic Duct Stent Placement|
223544788|NCT02560727|DEVICE|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
223990492|NCT01442922|OTHER|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
223990493|NCT01442922|OTHER|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
223990494|NCT05389553|OTHER|Ultrasound exam|We included all full-term pregnancies accepted for delivery that received an accurate ultrasound scan before the birth
223990495|NCT03514316|PROCEDURE|Scalpel Gingivectomy|The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
223990496|NCT03514316|PROCEDURE|Laser Gingivectomy|In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
223990497|NCT03514316|PROCEDURE|Nonsurgical periodontal treatment|In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
223990498|NCT04200469|DIAGNOSTIC_TEST|Quantitative Flow Ratio (QFR) measurement|Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
223544789|NCT02560727|DEVICE|colonoscope|FMT via colonoscope is the most common approach.
223990499|NCT04161651|DEVICE|eversense|eversense CGM
223990500|NCT00554996|DEVICE|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
223990501|NCT01606371|DRUG|Placebo|Administered orally
223990502|NCT01606371|DRUG|LY2409021|Administered orally
223990503|NCT06044246|BIOLOGICAL|PRF membrane|Placing implant with PRF membrane treatment
223990504|NCT02796768|OTHER|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
224294662|NCT03512184|BEHAVIORAL|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
223990505|NCT02796768|OTHER|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
223990506|NCT00785837|OTHER|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
223990507|NCT02560753|DRUG|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
223544790|NCT03847831|BEHAVIORAL|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
223990508|NCT00000416|OTHER|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
223990509|NCT01893489|OTHER|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
223990510|NCT03795857|BEHAVIORAL|Semi-structured interviews|The purpose of this study is to describe the experience of pregnancy by parents who have chosen to carry to term despite a lethal fetal diagnosis. Therefore, semi-structured interviews will be conducted to explore the links between context, feeling, involvement, decision and actions during pregnancy, whether within the couple or in its environment.
223990511|NCT05835271|DEVICE|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
223990512|NCT03944642|BEHAVIORAL|Breastfeeding support|Breastfeeding self-efficacy enhancing through professional support
223990513|NCT05442268|PROCEDURE|Acetaminophen group|patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively
223990514|NCT05442268|PROCEDURE|Duloxetine group|Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively
223990515|NCT02881372|OTHER|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
223990516|NCT03267810|DEVICE|TENS|TENS: TENS 7000 - : TENS applies low-level electrical current via four pads, 2 pads affixed paraspinally, at the level of the spinal cord injury, and 2 affixed on the ventral side to areas within the dermatome corresponding to the level of injury. 15 minutes of high frequency followed by 15 minutes of low frequency will be applied at each session
223990517|NCT03267810|OTHER|Sham TENS|Inactive electrodes - for two 15 minute trials, neither high nor low frequency.
223990518|NCT04371237|DEVICE|Compression sleeve|From foot to hip/groin on both legs with only 1 leg connected to pneumatic pump for 1 hour
223990519|NCT04371237|DEVICE|Heat therapy|Custom leg garment with one leg heated by circulating hot water approx 40 degrees C, the other leg approx 32 degrees C (thermoneutral) for 1 hour
223990520|NCT04371237|OTHER|Glycogen-depleting exercise session|Prolonged intermittent high intensity running (LIST protocol)
223990521|NCT04371237|OTHER|Nutrient Intake (beverage)|Post-exercise, all participants will receive a beverage containing 1.0 g/kg carbohydrate and 0.3 g/kg protein from the mixture of Gatorade Recover Protein Shake and Gatorade Thirst Quencher
223990522|NCT04371237|PROCEDURE|Skeletal muscle biopsy|Vastus lateralis muscle in the lower thigh will be obtained by the percutaneous needle technique
224294663|NCT01374984|BIOLOGICAL|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
224294664|NCT05418244|OTHER|Inhaled Isopropyl Alcohol|Isopropyl alcohol pad (Covidien Webcol 2 ply prep pads, saturated with 70% isopropyl alcohol) held 1-2 cm under the subject's nares
224294665|NCT05418244|DRUG|Oral Ondansetron|4 mg oral disintegrating ondansetron tablet once
223544791|NCT02143349|DIETARY_SUPPLEMENT|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
223544792|NCT02143349|OTHER|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
223544793|NCT03960879|DIAGNOSTIC_TEST|DNA methylation|DNA methylation for the cervical cytology
223544794|NCT03960879|DIAGNOSTIC_TEST|High-risk HPV|High-risk HPV testing for the cervical cytology
223544795|NCT03960879|DIAGNOSTIC_TEST|TCT|Thin prep liquid-based cytology test for the cervical cytology
223544796|NCT03533088|OTHER|Hospitalized rehabilitation|Patients will recive a rehabilitation prgram at the clinic twice in a week until the post-operative 12. weeks
223990523|NCT00140374|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
223990524|NCT02820545|OTHER|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
224294666|NCT05418244|OTHER|Inhaled Placebo|Normal saline pad (Hygea sterile saline wipe) held 1-2 cm under the subject's nares
223990525|NCT02820545|OTHER|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
223990526|NCT01775293|DEVICE|Non-absorbable polypropylene mesh|"2 step procedures~* first step is insertion of Non-absorbable polypropylene mesh under the facial skin~* second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
223990527|NCT05654623|DRUG|ARV-471|orally, once daily on a 28-day continuous dosing schedule
223990528|NCT05654623|DRUG|Fulvestrant|intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)
223990529|NCT00624910|DRUG|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
223990530|NCT00624910|DRUG|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
223990531|NCT06171555|DEVICE|CTM|decellularized particulate human placental connective-tissue matrix products, intended solely for homologous use to supplement or replace damaged or inadequate connective-tissue. These are structural tissue allografts processed according to the criteria contained in 21CFR 1271.10(a) for regulation solely under section 361 of the Public Health Service Act.
223990532|NCT06171555|DRUG|Celestone|standard of care
223990533|NCT03501810|DEVICE|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
223990534|NCT01947322|DRUG|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
223990535|NCT05989594|BEHAVIORAL|Home-based mobile guided exercise-based cardiac rehabilitation|Discharge preparation, telerehabilitation, scheduled onsite follow-ups, telephone follow-ups, self-reporting, health education, online communication, family and peer support, mailing letters, institutional referrals, and security management.
223990536|NCT05989594|BEHAVIORAL|Routine Care|Discharge preparation, scheduled onsite follow-ups, telephone follow-ups
223990537|NCT00778245|DRUG|cefprozil 500mg tablets|
223990538|NCT05792098|PROCEDURE|percutaneous dilatational tracheostomy (PDTS)|Tracheostomy made by percutaneous dilatational technique
223990539|NCT05792098|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound verification of guidewire position
224294667|NCT06852053|DEVICE|Closed-loop Vibro-Tactile Stimulator|Vibro-Tactile stimulation when bradycardia is predicted or predicted.
223990540|NCT05792098|DIAGNOSTIC_TEST|Bronchoscopy|Bronchoscopic control of guidewire position
224294668|NCT06852053|DEVICE|Control|Sham closed-loop vibrotactile stimulator
224294669|NCT02475382|DRUG|Nivolumab|Specified dose on specified days
223990541|NCT01149122|DRUG|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
223990542|NCT01149122|DRUG|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
223990543|NCT02172911|BIOLOGICAL|INO-3112|1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.
223990544|NCT02172911|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
223990545|NCT04669379|BEHAVIORAL|EXPECT: Preoperative optimization of patient's expectations|Patients work through an online-tool (around 30 minutes). This preoperative intervention aims to optimize patients' expectations by focusing on positive and realistic expectations regarding the surgery-benefits and recovery process, giving information, and giving advice for coping resources.
223990546|NCT05472064|OTHER|Persona: Primary care doctor|The chatbot persona is a Black woman who is a primary care doctor.
223990547|NCT05472064|OTHER|Persona: Breast cancer survivor|The chatbot persona is a Black woman who is a breast cancer survivor.
223990548|NCT05472064|OTHER|Communication Style: Direct|The chatbot messages are characterized by commands and direct addresses (''you'').
223990549|NCT05472064|OTHER|Communication Style: Indirect|"The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's)."
223990550|NCT05831137|PROCEDURE|shorter cryoanalgesia|duration time of cryoanalgesia
223990551|NCT05641116|OTHER|physical activity program|24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).
224294670|NCT04143243|BEHAVIORAL|ACT on Life|1 day group workshop of ACT plus ERS
223990552|NCT05641116|OTHER|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
223990553|NCT03328377|DIAGNOSTIC_TEST|Metagenomic analysis of gut microbiota|All patients have rectal swaps/fecal samples subjected to metagenomic analysis
223990554|NCT00043069|DIETARY_SUPPLEMENT|calcium carbonate|
223990555|NCT00043069|DIETARY_SUPPLEMENT|cholecalciferol|
223990556|NCT00043069|DRUG|Estrogen Antagonists|
223990557|NCT00043069|DRUG|risedronate sodium|
223990558|NCT00043069|OTHER|placebo|
223990559|NCT01227291|DRUG|SYL040012|SYL040012 ophthalmic drops, daily single dose administration
223990560|NCT01682551|DRUG|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
223990561|NCT01682551|DRUG|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
223990562|NCT05230719|PROCEDURE|Radial Artery Approach|dTRA or conventional TRA for radical artery approach
223990563|NCT03349619|DRUG|Resveratrol plus Carboxymethyl-β-Glucan|Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks
223990564|NCT03349619|DRUG|Placebo|Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
223990565|NCT02737826|DRUG|Buprenorphine Initiation - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an 8 hour induction window.
223990566|NCT02737826|DRUG|Gabapentin + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
224294671|NCT04143243|BEHAVIORAL|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
224294672|NCT06891755|DEVICE|Apreo BREATHE Airway Scaffold|The experimental treatment involves placement of up to 6 Apreo BREATHE Airway Scaffolds (up to 3 per lung), in a single procedure using bronchoscopy and fluoroscopy. Treatment group subjects will also receive optimal medical management (OMM).
223990567|NCT02737826|DRUG|Placebo + Buprenorphine - Phase II|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to oral gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
223990568|NCT02737826|DRUG|Buprenorphine taper - Phase II|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
223990569|NCT03430622|BEHAVIORAL|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.
223990570|NCT03430622|OTHER|TAU|This group will be on their routine care and will not be given any intervention
224121332|NCT03416686|DEVICE|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode\_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
224121333|NCT00121030|DRUG|darbepoetin alfa|
224121334|NCT00121030|DRUG|recombinant human erythropoietin (rHuEPO)|
223990571|NCT05838963|DIAGNOSTIC_TEST|CTQ-SSS scores|"The CTQ-SSS is a self-reported questionnaire that measures the severity of symptoms related to carpal tunnel syndrome, including pain, numbness, tingling, and weakness in the hand and wrist.~Participants in this study will complete the CTQ-SSS and other functional measures that include:~1. demographic information~2. hand dominance~3. Boston Carpal Tunnel Questionnaire (BCTQ)~4. nerve conduction studies (NCS) to measure median nerve conduction velocity (NCV), distal motor latency (DML), and sensory nerve action potential (SNAP) amplitude, Compound muscle action potential (CMAP) amplitude.~5. Hand grip strength~Outcomes will be measured at baseline, 3 months, 6 months, and 12 months.~The primary outcome will be progression to carpal tunnel release surgery, and logistic regression models will be used to assess the predictive value of baseline CTQ-SSS scores for this outcome, adjusted for potential confounding factors such as age, sex, and baseline symptom severity."
223990572|NCT01973153|BEHAVIORAL|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
223990573|NCT01973153|BEHAVIORAL|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
223990574|NCT01973153|BEHAVIORAL|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
223990575|NCT02369471|DRUG|GWP42006|
223990576|NCT02369471|DRUG|Placebo|
223990577|NCT02790697|OTHER|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
223990578|NCT00919451|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
223990579|NCT02539849|DIETARY_SUPPLEMENT|FOS|
223990580|NCT02539849|DRUG|Adalimumab|
223990581|NCT00129935|DRUG|Docetaxel|
223990582|NCT00129935|DRUG|Capecitabine|
223990583|NCT00129935|DRUG|Epirubicin|
223990584|NCT00129935|DRUG|Cyclophosphamide|
223990585|NCT04055428|DRUG|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
223990586|NCT04055428|DRUG|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
223990587|NCT04055428|OTHER|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
223990588|NCT04055428|DIETARY_SUPPLEMENT|Standardized Meals|Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.
223990589|NCT04055428|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
223990590|NCT02783573|DRUG|Lanabecestat|Administered orally
223990591|NCT02783573|DRUG|Placebo|Administered orally
223990592|NCT00233480|DRUG|atorvastatin|atorvastatin 10mg PO QD
223990593|NCT00233480|DRUG|placebo|matched placebo Qd x 3 months
223990594|NCT00581893|DRUG|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
223990595|NCT00581893|DRUG|Placebo oral capsule|Placebo
223990596|NCT01896765|BEHAVIORAL|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
223990597|NCT01896765|OTHER|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
223990598|NCT05157945|DRUG|ALTO-300 PO Tablet|One tablet daily
223990599|NCT02503826|DRUG|Sufentanil|low dose
223990600|NCT02503826|DRUG|Sufentanil|moderate dose
223990601|NCT02503826|DRUG|Sufentanil|high dose
223990602|NCT02503826|DRUG|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
223990603|NCT02503826|DRUG|propofol|
223990604|NCT02503826|DRUG|cisatracurium|
223990605|NCT02760563|DRUG|BAY 987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application (Formulation number V26-160)
223990606|NCT01378806|BEHAVIORAL|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
223990607|NCT04204382|DRUG|Levofloxacin Injection|Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
223990608|NCT04204382|DRUG|Compound Kushen Injection（CKI）|CKI, 20mL each time, once a day, intravenous drip. Treatment course is 7 days.
223990609|NCT00159263|DRUG|Placebos|Dry powder inhaler
223990610|NCT00159263|DRUG|Formoterol Inhalant Powder|12ug
223990611|NCT00159263|DRUG|Budesonide Powder|Inhaler
223990612|NCT00159263|DRUG|Budesonide and Formoterol Product|Combination Inhaler, Symbicort
223990613|NCT04834713|OTHER|clinical classification of HFRS|Based upon clinical classification of HFRS , the patients were classified into four types
223990614|NCT01375413|BEHAVIORAL|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
223990615|NCT04349007|DIETARY_SUPPLEMENT|Standard meal|local porridge with a vitamin and mineral sprinkle powder that will be mixed in after cooking
223990616|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, maize, and vitamin and minerals
223990617|NCT04349007|DIETARY_SUPPLEMENT|School food ready-to-use plus Milk|80 gram per day sachet containing peanut paste with oil, sugar, cowpea, non-fat dried milk and vitamin and minerals
223990618|NCT04519593|PROCEDURE|Laparoscopic myomectomy with prior temporary uterine blood supply occlusion|Visualization and temporary bilateral clipping of uterine/internal iliac arteries and suspensory ligaments of ovaries.
223990619|NCT04519593|PROCEDURE|Conventional laparoscopic myomectomy|Laparoscopic myomectomy without prior temporary uterine blood supply occlusion
223990620|NCT01012245|OTHER|no intervention|
224121335|NCT01093924|BEHAVIORAL|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
223990621|NCT00174694|DRUG|Telithromycin|
223990622|NCT04429282|DRUG|ibuprofen|Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
223990623|NCT04429282|DRUG|Placebo|Placebo
223990624|NCT00158067|DEVICE|external Responsive Neurostimulator (eRNS) System|
223990625|NCT02797522|DRUG|ARC-521 Injection|
223990626|NCT02797522|OTHER|Placebo|0.9% normal saline
223990627|NCT02797522|DRUG|antihistamine|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
223990628|NCT02797522|DRUG|acetaminophen|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
223990629|NCT02797522|DRUG|entecavir|Participants take entecavir OR tenofovir daily throughout the study.
223990630|NCT02797522|DRUG|tenofovir|Participants take entecavir OR tenofovir daily throughout the study.
223990631|NCT00004940|DRUG|cysteine hydrochloride|
223990632|NCT00725712|DRUG|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
223990633|NCT06541769|DEVICE|Limb hypothermia|Limb hypothermia with special gel-gloves
223990634|NCT06541769|DEVICE|Limb compression|compression with sterile one way Latex gloves. Size measured for every Patient individually
223990635|NCT05799469|DRUG|Envafolimab|SC
223990636|NCT05799469|DRUG|Cisplatin|IV infusion
223990637|NCT05799469|RADIATION|External Beam Radiotherapy (EBRT)|45-50.4Gy
223990638|NCT05799469|RADIATION|Brachytherapy (BT)|Performed according to clinically required dose
223990639|NCT04826276|OTHER|smoking abstinence|participants will be asked to not smoke for at least 12 hours
224121336|NCT00827996|DRUG|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
224121337|NCT01158833|OTHER|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
223990640|NCT04826276|OTHER|smoking satiety|participants will be asked to smoke as usual
223990641|NCT04239131|OTHER|Skin prick test|a Skin prick test is planned in all patients
223990642|NCT02509949|DRUG|Dexmedetomidine|
223990643|NCT02509949|DRUG|Saline|
223990644|NCT01561482|DRUG|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
223990645|NCT01561482|DRUG|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
224121338|NCT01996306|BIOLOGICAL|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
224121339|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
224121340|NCT01996306|DRUG|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
224121341|NCT01996306|DRUG|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
224121342|NCT01996306|DRUG|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
224121343|NCT01996306|BIOLOGICAL|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
223990646|NCT01872481|DEVICE|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
223990647|NCT01872481|DEVICE|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
223990648|NCT00757224|BEHAVIORAL|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
223990649|NCT00132678|DRUG|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
223990650|NCT00132678|DRUG|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
224121344|NCT01996306|DRUG|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
224121345|NCT01996306|DRUG|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
224121346|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
223990651|NCT03318029|DIETARY_SUPPLEMENT|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
223990652|NCT03318029|DIETARY_SUPPLEMENT|Placebo|rice flour with no vitamin D
223990653|NCT03815370|DEVICE|Experimental: ABRO™ Binder Arm|ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
223990654|NCT03815370|DEVICE|Placebo Comparator: Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
223990655|NCT01758679|BIOLOGICAL|Licartin and CIK|Licartin and CIK
223990656|NCT05711277|DIETARY_SUPPLEMENT|Standard milkshake ONS (Fortisip Compact Protein)|Two 125ml bottles of standard ONS administered a day for two days
223990657|NCT05711277|DIETARY_SUPPLEMENT|High protein, fortified, ice cream|Two 80g servings of N-ICE CREAM administered a day for two days
223990658|NCT01367847|BEHAVIORAL|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon \& Forehand) for parents of 3 to 8 y.o. children with externalizing problems
223990659|NCT01367847|BEHAVIORAL|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
224121347|NCT01432262|BIOLOGICAL|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
224121348|NCT00165646|DRUG|E3810|E3810 5mg: once daily orally for 4 weeks
224121349|NCT00165646|DRUG|E3810|E3810 10mg: once daily orally for 4 weeks
224121350|NCT00165646|DRUG|Placebo|Placebo: once daily orally for 4 weeks
224121351|NCT05291598|DRUG|IV meloxicam|Participants will be administered meloxicam 30 mg IV push pre-operatively.
224121352|NCT05291598|DRUG|Ketorolac|Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
224121353|NCT02855684|DRUG|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224121354|NCT02855684|DRUG|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223544797|NCT03533088|OTHER|Home-based rehabilitation|Patients will recive a home program once in a two weeks until the 6. weeks of post-operative period. Then will start to recieve a rehabilitation program ar the clinic once in a week auntil the 12. week of the post-operative period.
223990660|NCT03215147|DIAGNOSTIC_TEST|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6\~8 weeks later.
223990661|NCT04511624|DRUG|IBI112 dose1|Drug: IBI112 SC dose1 Drug:placebo
223990662|NCT04511624|DRUG|IBI112 dose2|Drug: IBI112 SC dose2 Drug:placebo
223990663|NCT04511624|DRUG|IBI112 dose3|Drug: IBI112 SC dose3 Drug:placebo
223990664|NCT04511624|DRUG|IBI112 dose4|Drug: IBI112 SC dose4 Drug:placebo
223990665|NCT04511624|DRUG|IBI112 dose5|Drug: IBI112 IV dose5 Drug:placebo
223990666|NCT04511624|DRUG|IBI112 dose6|Drug: IBI112 SC dose6 Drug:placebo
223990667|NCT04511624|DRUG|IBI112 dose7|Drug: IBI112 IV dose7 Drug:placebo
224121355|NCT02855684|DRUG|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
224121356|NCT00082706|DRUG|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
223990668|NCT06957314|OTHER|Hospital-at-Home/HAH|After discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence
223990669|NCT04665609|DRUG|Anlotinib and TQB2450 solution|Anlotinib is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
223990670|NCT04665609|DRUG|TQB2450 solution|TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
223990671|NCT00174837|DRUG|Tirapazamine|in combination with cisplatin and concomitant radiation
224121357|NCT00082706|DRUG|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
224121358|NCT00082706|DRUG|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
224121359|NCT00082706|DRUG|Gemcitabine|Day: 1 \& 5 Dose: 200 mg/m2 (Two doses only)
224121360|NCT02211976|DRUG|Bisacodyl|
224121361|NCT02211976|DRUG|Simeticone|
224121362|NCT00523341|BIOLOGICAL|Denosumab|Administered by subcutaneous injection once every 6 months.
224121363|NCT03766724|DRUG|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
224294673|NCT06891755|OTHER|Optimal Medical Management (OMM)|Subjects will receive optimal medical management tailored to patient needs and per standard of care and as outlined in the 2024 GOLD report. This may include smoking cessation, vaccination, long-acting bronchodilator therapy, corticosteroids (when appropriate), and participation in or maintenance of an exercise program or pulmonary rehabilitation program.
223990672|NCT00174837|DRUG|Cisplatin|with concomitant radiation
223990673|NCT05205070|BIOLOGICAL|Rosnilimab|humanized monoclonal antibody
223990674|NCT05205070|BIOLOGICAL|Placebo|Placebo solution
223990675|NCT01949181|PROCEDURE|Lung surgery|
223990676|NCT03148522|DRUG|Escitalopram|receive escitalopram
223990677|NCT03148522|DRUG|Duloxetine|receive duloxetine
223990678|NCT03148522|DRUG|Mirtazapine|receive mirtazapine
224121364|NCT03766724|DRUG|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
224121365|NCT03766724|DRUG|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
224121366|NCT03766724|DRUG|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
223544798|NCT00314821|DRUG|ropinirole|
223544799|NCT03479489|OTHER|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
223990679|NCT05665569|DEVICE|Flourish HEC, which contains BioNourish|The Flourish HEC vaginal hygiene system comprises Balance intimate wash used daily, BioNourish vaginal moisturizing gel used daily, and BiopHresh homeopathic vaginal suppository containing probiotics, used once every 3 days. In addition, for all therapy requiring insertion in the clinic or at home, or for sex if desired, BioNude personal lubricant will be used. These four products are intended to allow the vaginal microbiome to self-correct by supporting the vaginal environment in terms of providing pH, osmolality, and lactic acid levels that match those in a healthy vagina.
223990680|NCT05665569|OTHER|Routine pelvic physical therapy|Routine pelvic physical therapy may include external and internal manual techniques, exercises, diaphragmatic breathing exercises, and other modalities.
223990681|NCT02856516|OTHER|Boost Glucose Control (A)|Oral nutrition supplement
224121367|NCT05131880|OTHER|Gait Re-education Program Using the Fisior® Mat Sequential Training System in Subjects with Parkinson's Disease|"Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called TAPIZ FISIOR®- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition."
224121368|NCT04864392|DRUG|LNA043 Dosing Regimen A|Injection to the knee
224121369|NCT04864392|DRUG|LNA043 Dosing Regimen B|Injection to the knee
223544800|NCT06486766|BEHAVIORAL|Norwegian SMS|Individuals receive a SMS in Norwegian language at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is applicable to all three populations (general population, immigrants born in Poland, immigrants born in Ukraine)
223544801|NCT06486766|BEHAVIORAL|Polish/Ukrainian SMS|Individuals receive an SMS in the official language of their native country (i.e., Polish or Ukrainian) at the start of the influenza season, to remind them they are recommended to get the influenza vaccine. This intervention arm is only applicable to the two immigrant populations (immigrants born in Poland, immigrants born in Ukraine)
223544802|NCT01847755|DRUG|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
223544803|NCT00920556|DRUG|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
223990682|NCT02856516|OTHER|Boost Glucose Control (B)|Oral nutrition supplement
223990683|NCT02856516|OTHER|Boost Original|Oral nutrition supplement
223990684|NCT00487955|PROCEDURE|Resting Energy Expenditure examination|
223990685|NCT03289559|DRUG|GnRH antagonist|
223990686|NCT03289559|DRUG|Aromatase Inhibitors|
223990687|NCT03289559|DRUG|Testosterone gel|
223990688|NCT05308394|OTHER|No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.|Each participant will provide a blood and fecal sample.
223990689|NCT02056626|DRUG|carvedilol|
224121370|NCT04864392|DRUG|LNA043 Dosing Regimen C|Injection to the knee
224121371|NCT04864392|DRUG|LNA043 Dosing Regimen D|Injection to the knee
224121372|NCT04864392|DRUG|Placebo|Injection to the knee
224121373|NCT06490315|BEHAVIORAL|OkeyMind intervention|The intervention group will receive a one-month mobile psychoeducation program (OkeyMind), which includes both psychoeducation and meditation components, with all content fully automated.
224121374|NCT06490315|BEHAVIORAL|Wait-list control|Participants in the waiting list control group will withhold access to the OkeyMind intervention until after the 3-month follow-up assessment.
224121375|NCT06187103|DEVICE|HyperSight Imaging|Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
223990690|NCT02834767|DEVICE|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
223990691|NCT02834767|DEVICE|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
223990692|NCT04047277|BEHAVIORAL|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
223990693|NCT00640770|DEVICE|balloon angioplasty|balloon angioplasty
223990694|NCT00640770|DEVICE|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
223990695|NCT00756041|DRUG|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
223990696|NCT02292862|PROCEDURE|Lymph node and blood sampling|"By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant."
223990697|NCT05495321|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
223990698|NCT04591379|DRUG|Influenza Vaccines|Intratumoral application of an unattenuated influenza vaccine
223990699|NCT01235000|BIOLOGICAL|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
223990700|NCT02622399|BEHAVIORAL|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
224121376|NCT03395197|DRUG|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
224121377|NCT03395197|DRUG|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
224121378|NCT05137041|DEVICE|ITP FIRTECH|Infrared Therapy Patch
224294674|NCT06743126|BIOLOGICAL|IMA203|one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy
224294675|NCT06743126|BIOLOGICAL|nivolumab plus relatlimab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294676|NCT06743126|BIOLOGICAL|lifileucel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294677|NCT06743126|BIOLOGICAL|nivolumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294678|NCT06743126|BIOLOGICAL|pembrolizumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294679|NCT06743126|BIOLOGICAL|ipilimumab|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294680|NCT06743126|DRUG|Dacarbazine|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
223990701|NCT02693197|DRUG|T-817MA|A single oral dose of 448 mg
223990702|NCT05214547|DEVICE|Focal VibrationTherapy|Myovolt delivers oscillatory mechanical vibration of focussed frequency and low amplitude to stimulate physiological benefits in soft tissues. Myovolt is non-aggressive and gentle to the body so can be safely targeted. Digitally tuned to transmit a discrete vibration frequency range between 30 - 100Hz for effective neuromuscular stimulation.
223990703|NCT01614353|OTHER|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
223990704|NCT01614353|OTHER|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
223990705|NCT06177951|OTHER|NICU Discharge Passport|"The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns."
224121379|NCT03588767|DRUG|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
224121380|NCT03588767|OTHER|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
224121381|NCT05901831|DRUG|Finerenone|Dose A, Dose B, oral
224121382|NCT05901831|OTHER|Placebo|Oral
224121383|NCT02545296|OTHER|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
224294681|NCT06743126|DRUG|temozolomide|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294682|NCT06743126|DRUG|paclitaxel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294683|NCT06743126|DRUG|paclitaxel plus carboplatin|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
223990706|NCT06177951|OTHER|NICU Infant Care Class|The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
223990707|NCT05454345|DRUG|Sitafloxacin|In our Intervention group, sitafloxacin replace the ethambutol, 200mg/d
223990708|NCT05454345|DRUG|SMZ/TMP|In our The three-month Rifapentine\&Isoniazid\&Pyrazinamide\&Sitafloxacin\&SMZ/TMP-containing regimen, Six weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and Sitafloxacin, followed by seven weeks of daily treatment with rifapentine, isoniazid, ,SMZ/TMP and Sitafloxacin, SMZ 80mg/kg/d, TMP16mg/kg/d
223990709|NCT05454345|DRUG|Rifampin|Rifampin is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, Rifampin 600mg (8-12mg/kg/d)
223990710|NCT05454345|DRUG|Pyrazinamide|Pyrazinamide is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 2000mg (20-30mg/kg/d)
223990711|NCT05454345|DRUG|Rifapentine|In our Intervention group, rifapentine replace rifampin, 600mg/d
223990712|NCT05454345|DRUG|Isoniazid|Isoniazid is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 300mg (4-6mg/kg/d)
223990713|NCT05454345|DRUG|Ethambutol|Ethambutol is a first-line antimicrobial agent against drug-susceptible tuberculosis in WHO guideline, 1200mg (15-25mg/kg/d)
223990714|NCT05454345|DRUG|Moxifloxacin|Moxifloxacin is a fourth-generation fluoroquinolone with potent activity against M. tuberculosis in vitro and in vivo, 400mg (7.5-10mg/kg/d)
223990715|NCT06958848|DEVICE|16 F chest tube|Insertion of 16F chest tube
223990716|NCT06958848|DEVICE|24 F chest tube|Insertion of 24F chest tube
223990717|NCT06958848|PROCEDURE|Early removal|Removal 2-6h after end of skin closure
223990718|NCT06958848|PROCEDURE|Standard removal|Removal 1day postoperative
223990719|NCT03991741|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
223990720|NCT03991741|BIOLOGICAL|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
223990721|NCT06314971|OTHER|Tw1CE|A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
223990722|NCT05992896|DRUG|Bupivacaine liposome|Injection into pelvic area and into the edges of wound at the end of the procedure.
223544804|NCT00920556|DRUG|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
223544805|NCT02565992|BIOLOGICAL|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
223990723|NCT05992896|DRUG|Placebo|Looks exactly like the study drug, but contains no active ingredients. Injection into pelvic area and into the edges of wound at the end of the procedure .
223990724|NCT04488250|OTHER|Robot Therapy|Robot Therapy
223990725|NCT00580489|DRUG|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
223990726|NCT02559427|OTHER|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
223990727|NCT02559427|OTHER|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
223990728|NCT00421655|DRUG|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
223990729|NCT01454739|DRUG|rFVIIIFc|Administered as specified in the treatment arm.
223990730|NCT05692869|DRUG|Propranolol|Administered orally.
223990731|NCT05692869|DRUG|Pseudoephedrine|Administered orally.
223990732|NCT05692869|DEVICE|ABPM and Wearable Novel Devices|ABPM and wearable novel devices including chest patch device, wrist device and smartwatch device worn throughout the trial.
223990733|NCT05692869|OTHER|No Intervention|No intervention during this period (Control Period)
223544806|NCT02565992|DRUG|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
223544807|NCT00509327|DRUG|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
223544808|NCT00509327|DRUG|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
223990734|NCT03564197|OTHER|18F-PD-L1|18F-PD-L1 PET/CT scan
223990735|NCT00218608|DRUG|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
223990736|NCT06378723|OTHER|Balance Tests|With the scales and tests the children trunk control, quality of upper extremity skills, single leg stance duration will be measured
223990737|NCT03504345|DRUG|Prometrium|The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
223990738|NCT05330988|DEVICE|anodal transcranial direct current stimulation (a-tDCS)|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
223990739|NCT05330988|DEVICE|sham stimulation|The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
223990740|NCT05371366|DEVICE|ASD closure with the novel occluder (ReAces)|Transcatheter closure atrial septal defect with the novel occluder (ReAces)
223990741|NCT05371366|DEVICE|ASD closure with normal occluder|Transcatheter closure atrial septal defect with normal occluder
223990742|NCT00258752|BEHAVIORAL|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
223990743|NCT00258752|OTHER|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
223990744|NCT00258752|OTHER|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
223990745|NCT01543997|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
223990746|NCT01543997|BEHAVIORAL|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
223990747|NCT00629005|BEHAVIORAL|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
223990748|NCT00629005|BEHAVIORAL|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
223990749|NCT04803747|DRUG|Tranexamic acid (TXA)|TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
223990750|NCT04803747|DRUG|Placebo (0.9 % Saline)|Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).
224121384|NCT03067896|DRUG|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
224121385|NCT03067896|DRUG|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
223544809|NCT02961036|OTHER|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
223544810|NCT02961036|OTHER|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
223990751|NCT05688553|DEVICE|Flexi-bar|two groups, experimental group intervention Flexi-bar with balance and strength training
223990752|NCT05688553|OTHER|balance and strength training|the control group intervention only balance and strength training
223990753|NCT01784523|DRUG|Hydroxychloroquine|
223990754|NCT02926222|DRUG|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
224121386|NCT03067896|DRUG|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
224121387|NCT05293132|DRUG|Montelukast Sodium 10 mg|Film coated tablets containing 10 mg montelukast
224121388|NCT05293132|DRUG|Co-Enzyme Q10|Capsules contain 210 mg Co-Enzyme Q10
224294684|NCT06743126|DRUG|Albumin-Bound Paclitaxel|in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC)
224294685|NCT07052929|GENETIC|ASP2957|Intravenous infusion
224294686|NCT07052929|DRUG|Methylprednisolone|Intravenous infusion
224294687|NCT07052929|DRUG|Prednisolone|Route of administration based on locally sourced product
223990755|NCT02926222|DRUG|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
223990756|NCT06271876|OTHER|Inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances
223990757|NCT01173276|OTHER|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
223990758|NCT01720576|DRUG|REGN1033 (SAR391786)|
223990759|NCT01720576|DRUG|Placebo|
223990760|NCT01609426|GENETIC|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
223990761|NCT00960362|DRUG|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
223990762|NCT00960362|DRUG|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
224121389|NCT05293132|DRUG|Standard Treatment|Standard sepsis treatment includes fluid resuscitation, early administration of intravenous broad spectrum antibiotic (ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours) till obtaining the microbiological culture to narrow the coverage, paracetamol intravenous antipyretic (paracetamol 1gm/8 hours) till no fever and temperature less than 380c, and prophylactic anticoagulant low molecular weight heparin (enoxaparin 40/24 hours), prophylactic stress ulcer (pantoprazole 40mg/24hours)
224121390|NCT02460588|DRUG|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
223544811|NCT02961036|OTHER|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
223544812|NCT02961036|OTHER|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
223990763|NCT05903157|BEHAVIORAL|Control Group: Delivery of a health literacy flyer|"A health literacy flyer was delivered, by e-mail, in the first week of the intervention (the flyer contained its original source - the European Centre for Disease Prevention and Control). Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and follow-up moments (3 and 6 months after the intervention)."
223990764|NCT05903157|BEHAVIORAL|Experimental Group: Weekly group sessions for weight management|"The eHealth intervention was designed based on: i) the Health Action Process Approach determinants, ii) the Health Belief Model constructs, and iii) behaviour change techniques (BCT, Taxonomy v1, by Michie et al., 2013) to implement healthy behaviours.~The intervention consists of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, are led by the psychologist responsible for the study. Whatsapp groups were created, to share experiences, knowledge, doubts, fears...~All primary and secondary outcome measures were assessed at baseline, one month later (in the middle of the intervention), post-intervention, and in follow-up moments (3 and 6 months after the intervention)."
223990765|NCT04340947|OTHER|Very low nicotine cigarette: menthol|Participants will be randomized to smoke either menthol non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory first and then crossed over to receive the opposite intervention. The study consists of two treatment periods of 7 days separated by a 1 week wash-out period
223990766|NCT04340947|OTHER|Very low nicotine cigarette: non-mentol|Participants will be randomized to smoke either menthol non-menthol flavored very low nicotine cigarettes in their home environment for 7 days and in the laboratory first and then crossed over to receive the opposite intervention. The study consists of two treatment periods of 7 days separated by a 1 week wash-out period
223990767|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Ketamine
223990768|NCT02562820|PROCEDURE|Intravenous infusion|Intravenous infusion of Normal Saline
223990769|NCT02092532|DRUG|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
224121391|NCT02460588|DRUG|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
224294688|NCT07052929|DRUG|Sirolimus|Route of administration based on locally sourced product
223990770|NCT02092532|PROCEDURE|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
223990771|NCT03608059|DRUG|ATG/PTCy|low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
223990772|NCT03608059|DRUG|standard ATG|in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
223990773|NCT03608059|DRUG|standard PTCy|post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
223990774|NCT04646369|BEHAVIORAL|"screening as usual"|Participants in this group will receive usual care at their pediatric primary care practice following information, psychoeducation, and referral to a mental health treatment provider
223990775|NCT04646369|BEHAVIORAL|Screening Wizard 2.0|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
223990776|NCT04646369|BEHAVIORAL|Screening Wizard 2.0 + SOVA|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment. SOVA is a peer-support website that social workers and doctors moderate on a 24 hour a day basis.
223990777|NCT01124097|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
223990778|NCT01124097|DRUG|Placebo|Tablets will be used.
223990779|NCT06489275|BEHAVIORAL|Building Financial Wellness|In addition to receiving services as usual, subjects attend financial literacy classes and booster sessions.
223990780|NCT06489275|OTHER|Services as Usual|Subjects continue to receive services as usual.
223990781|NCT01677299|DRUG|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
223990782|NCT01677299|DRUG|EFB0026 (metformin immediate-release)|Active comparator
223990783|NCT06486337|DRUG|CMOP±R|Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
223990784|NCT00193479|DRUG|Cyclophosphamide|Cyclophosphamide
223990785|NCT00193479|DRUG|Mitoxantrone|Mitoxantrone
223990786|NCT00193479|DRUG|Vincristine|Vincristine
223990787|NCT00193479|DRUG|Prednisone|Prednisone
223544813|NCT02961036|OTHER|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
223544814|NCT02961036|OTHER|Group A Reminder|One survey reminder at 14 days
223544815|NCT02961036|OTHER|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
223990788|NCT00193479|DRUG|Rituximab|Rituximab
223990789|NCT01862497|DRUG|Carvedilol vs. Prazosin|
223990790|NCT00787072|DRUG|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
223990791|NCT00787072|DRUG|Placebo|Oral suspension
223990792|NCT04312256|DEVICE|TetraGraph|FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.
223990793|NCT04976647|DRUG|HLX10+chemo|HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
223990794|NCT04976647|DRUG|HLX10+HLX07+chemo|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle
223990795|NCT04976647|DRUG|HLX10+HLX07|HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
223990796|NCT04830189|DEVICE|shoulder sling|Patients were used shoulder slings
223990797|NCT04830189|DEVICE|forearm sling|Patients were used forearm slings
223990798|NCT04541368|DRUG|CS1 Targeted CAR T-cells|Each subject receive CS1 Targeted CAR T-cells by intravenous infusion
223990799|NCT03667118|DIETARY_SUPPLEMENT|Food Supplement|A powder blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3
223990800|NCT00867698|DRUG|AST-120|AST-120
223990801|NCT04329572|DRUG|Hydroxychloroquine Sulfate|All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D5) for 5 days.
224121392|NCT02460588|DRUG|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
224121393|NCT02887534|DRUG|SPARC1401-low dose|SPARC1401- low dose
224121394|NCT02887534|DRUG|SPARC1401-mid dose|SPARC1401- mid dose
224121395|NCT02887534|DRUG|SPARC1401-high dose|SPARC1401-high dose
224121396|NCT02887534|DRUG|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
224121397|NCT02887534|DRUG|Placebo1401|Placebo
224121398|NCT01287234|OTHER|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
223990802|NCT04329572|DRUG|Azithromycin Tablets|All patients included in the study will receive AZT 500 mg per day for 5 days.
223990803|NCT06072976|DIETARY_SUPPLEMENT|Standard of Care|Standard of care arm: Mothers will consent to providing DHM (if qualifies per hospital policy) or formula if MOM is not available. Infants are only eligible to receive donor milk only if 1) MOM is not available 2) if infant initiates feeds before day 3 of age. The donor milk feed would be stopped on day 5 of age.
223990804|NCT06072976|DIETARY_SUPPLEMENT|Exclusive Human Milk|Mothers will consent to providing DHM if MOM is not available. If the infant reaches 100 ml/kg/day of feeds (one feed advancement prior to full feeds) and MOM remains unavailable, they will transition to formula in preparation for discharge. Infants cannot be discharged on donor milk.
224121399|NCT00820703|DRUG|Nexagon®|
223990805|NCT04266353|DIETARY_SUPPLEMENT|Resveratrol (RSV)|Participants will receive Resveratrol at 150 mg daily for 6 weeks.
224121400|NCT00820703|DRUG|Nexagon® vehicle|
224121401|NCT04116632|DRUG|BMS-963272|Single dose with varying frequency among groups
224121402|NCT04116632|DRUG|Placebo|Specified dose on specified days
224121403|NCT06551077|PROCEDURE|POSTERIOR RECTUS SHEATH HIATAL AUGMENTATION (PORSHA)|Use of a novel permanent autologous vascularized biologic fascial flap to reconstruct the diaphragmatic hiatus following standard hiatal hernia repair in selected patients. This technique is called a posterior rectus sheath flap hiatal augmentation or PoRSHA.
224121404|NCT00392171|DRUG|Temozolomide|Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression
223544816|NCT01299389|DRUG|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
224121405|NCT01605071|DRUG|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
224121406|NCT04792853|BEHAVIORAL|Tab-G|Participants receive a tablet preloaded with Tab-G application and an accelerometer.
224121407|NCT03499808|BIOLOGICAL|Isatuximab|Given IV
223990806|NCT01615549|PROCEDURE|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
223990807|NCT00297947|DRUG|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
223990808|NCT00297947|DRUG|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
223990809|NCT00872001|DRUG|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
224121408|NCT03499808|OTHER|Laboratory Biomarker Analysis|Correlative studies
224121409|NCT03470922|BIOLOGICAL|Relatlimab|Specified dose on specified day
224121410|NCT03470922|BIOLOGICAL|Nivolumab|Specified dose on specified days
223990810|NCT00872001|DRUG|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
223990811|NCT02603692|OTHER|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
223990812|NCT03471377|OTHER|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
223990813|NCT03471377|OTHER|assigned a planned case duration value from predictive model|"Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model."
223990814|NCT00047723|DRUG|minocycline|
223990815|NCT06106867|PROCEDURE|External pressure to the palm|During the 5-6 cm, 7-8 cm, and 9-10 cm cervical dilatation stages of the labor process, palm external pressure was applied to the pregnant women in the experimental group.
223990816|NCT00016224|DRUG|thalidomide|
223990817|NCT04211090|DRUG|Camrelizumab|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
223990818|NCT04211090|DRUG|Pemetrexed|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
223990819|NCT04211090|DRUG|Carboplatin|Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
223990820|NCT06186297|DIETARY_SUPPLEMENT|Cranberry extract|polyphenol PAC-1
223990821|NCT02030002|DEVICE|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
223990822|NCT02030002|DEVICE|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
223990823|NCT00512486|BIOLOGICAL|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~* 0.03 mg/kg intravenous injection~* 0.1 mg/kg intravenous injection~* 0.3 mg/kg intravenous injection~* 1.0 mg/kg intravenous injection~* 3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
224121411|NCT03987412|BEHAVIORAL|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
224121412|NCT02340819|DRUG|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
224121413|NCT04423926|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
224121414|NCT04423926|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
224121415|NCT04423926|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 d1
223990824|NCT03504722|BEHAVIORAL|RESCUE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
223990825|NCT03504722|BEHAVIORAL|Prolonged Exposure|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
223990826|NCT05256212|OTHER|exposure to environmental contaminants|to measure levels of contaminants in different matrixes
223990827|NCT00015080|DRUG|Naltrexone|
223990828|NCT05020145|BIOLOGICAL|BNT162b2 (Tozinameran)|Covid-19 Vaccine
223990829|NCT03935256|DRUG|Carboplatin and Paclitaxel|Regimen I: Carboplatin AUC 6 \& Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 \& Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 \& 7 concurrent with radiotherapy
223990830|NCT03935256|RADIATION|Radiation Therapy|"An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist."
223990831|NCT04375267|DRUG|177Lu-DOTA-TATE + olaparib|177Lu-DOTA-TATE in four cycles in combination with escalated doses of olaparib
223990832|NCT00220064|DRUG|Irinotecan, 5-Fluorouracil, Leucovorin|
223990833|NCT01893047|BEHAVIORAL|live music|live harp music
223990834|NCT01893047|BEHAVIORAL|recorded music|recorded harp music
223990835|NCT03188367|DIAGNOSTIC_TEST|Gluten or placebo capsules|Administration of gluten or placebo capsules
223990836|NCT00167232|DRUG|Naltrexone|
223990837|NCT00376415|DRUG|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
223990838|NCT00376415|DRUG|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
223990839|NCT03313141|DIAGNOSTIC_TEST|Ultrasound|Volitional and non volitional respiratory tasks
223990840|NCT00531726|DEVICE|DBS of Cg25|
223990841|NCT05950451|OTHER|No intervention|No intervention is led during this descriptive study
223990842|NCT04970290|DEVICE|Definisse threads free floating and definisse threads double needle|Definisse threads are two class III medical devices, for evaluate the performance of the reshaping effect of the face at day 30
223990843|NCT00494468|DRUG|Zolpidem|
223990844|NCT01139359|DRUG|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
223990845|NCT01139359|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
223544817|NCT01299389|DRUG|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
223990846|NCT00564616|DEVICE|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
223990847|NCT03333161|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
223990848|NCT03653923|BEHAVIORAL|Exposure Therapy|"Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase."
223990849|NCT02239744|BEHAVIORAL|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
223990850|NCT03833791|BEHAVIORAL|education and modifying diet|The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
224121416|NCT04423926|DRUG|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
224121417|NCT04423926|DRUG|Prednisolone|Prednisolone 60mg/m2 d1-5
224121418|NCT00704743|DEVICE|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
223990851|NCT03833791|BEHAVIORAL|education, modifying diet and physical activity prescription|"One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity."
223990852|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
223990853|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
223990854|NCT06835738|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles|MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
223990855|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
223990856|NCT01651169|OTHER|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
223990857|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic RFA assisted TE|
223990858|NCT02924597|PROCEDURE|zero ischemia robot-assisted laparoscopic partial nephrectomy|
223990859|NCT04653428|DEVICE|Interventional treatment of tricuspid regurgitation|Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair
223990860|NCT03922789|DIAGNOSTIC_TEST|6 minute walking test|change of 6MWT pre to post pulmonary rehabilitation
223990861|NCT06509360|DEVICE|Feelee app|Adolescents uses the Feelee app for 4-weeks in addition to treatment as usual in the forensic outpatient setting. The use of Feelee involves: submitting one emoji every day and allow the Feelee app to read the following passive data from the health app on the smartphone: number of steps and number of hours of sleep. The collected Feelee data will be presented in a dashboard in the Feelee app itself which will be discussed by the clinician in the weekly treatment session (in case the adolescents agreed to show the Feelee data to the clinician).
223990862|NCT06007196|DEVICE|non-invasive device (Task Force CORE(R) and Task Force CARDIO(R)|Intraoperative cardiac output will be measured using the non-invasive device (Task Force CORE(R) and Task Force CARDIO(R) and will be compared with the invasive thermodilution method (PiCCO).
223990863|NCT02844452|DEVICE|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
224121419|NCT00704743|DEVICE|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
224121420|NCT00704743|DEVICE|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
224121421|NCT00004285|DEVICE|Standard dose, low flux hemodialysis|
224121422|NCT00004285|DEVICE|Standard dose, high flux hemodialysis|
224121423|NCT00004285|DEVICE|High dose, low flux hemodialysis|
223990864|NCT02844452|DEVICE|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
223990865|NCT02792595|OTHER|Negative Control|Untreated area
223990866|NCT02792595|OTHER|Positive Control|High SPF Standard P3/SPF 15
223990867|NCT02792595|OTHER|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
223990868|NCT02792595|OTHER|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
223990869|NCT02792595|OTHER|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
223990870|NCT02792595|OTHER|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
223990871|NCT02792595|OTHER|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
223990872|NCT02792595|OTHER|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
223990873|NCT02792595|OTHER|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
223990874|NCT02792595|OTHER|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
223990875|NCT02410005|DIETARY_SUPPLEMENT|Calcitriol|
223990876|NCT02410005|DRUG|Losartan|
223990877|NCT02664597|PROCEDURE|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
223990878|NCT02664597|OTHER|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
223990879|NCT04955899|DEVICE|Active Stimulation|The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
223990880|NCT03453047|DIAGNOSTIC_TEST|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
223990881|NCT03424070|OTHER|Shoulder Roll|The POGO score assesses the percent of the glottic opening that can be seen with and without the shoulder roll.
223990882|NCT03424070|OTHER|No shoulder roll (placebo)|Placebo
223990883|NCT05101512|BEHAVIORAL|Questionnaires on quality of life after surgery|Patient has to answer different questionnaire about quality of life, pain, functional scores
223990884|NCT03453723|PROCEDURE|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
223990885|NCT03453723|DRUG|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
223990886|NCT02610075|DRUG|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
223990887|NCT02562157|RADIATION|HYALURONIQUE ACIDE|Intradermal delivery of fractional CO2 laser-assisted hyaluronic acid in facial skin contouring
223990888|NCT04197076|DRUG|anti-PD-1 or anti-PD-L1|immunotherapy anti-PD-1 or anti-PD-L1
223990889|NCT04197076|DRUG|EGFR-TKI, ALK inhibitor, ROS1 inhibitor|targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor
223990890|NCT04197076|DRUG|investigator decided|chemotherapy
223990891|NCT04652388|BEHAVIORAL|Nutritional counseling|Nutritional counseling about mediterranean diet
223990892|NCT04510480|OTHER|Observational study without specific intervention|Observational study with standard cardiac arrest approach
223990893|NCT05428280|OTHER|Physiotherapy|Conventional treatment consisted of Transcutaneous Electrical Nerve Stimulation and Progressive Back Strengthening Exercise
223990894|NCT05428280|OTHER|Muscle Energy technique|Muscle Energy Technique (MET) is a technique that was developed in 1948 by Fred Mitchell, Sr, D.O\[1\]. It is a form of manual therapy, widely used in Osteopathy, that uses a muscle's own energy in the form of gentle isometric contractions to relax the muscles via autogenic or reciprocal inhibition and lengthen the muscle.
223990895|NCT05428280|OTHER|Myofacial mobilization|It is a type of gentle, constant massage that releases tightness and pain throughout your myofascial tissues
223990896|NCT00325598|RADIATION|Partial Breast Irradiation (PBI)|
223990897|NCT04723290|DIAGNOSTIC_TEST|Serological tests for SARS Cov-2|Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood
223990898|NCT05288829|DRUG|ALXN1210 SC|All doses of ALXN1210 SC were administered by four 100-milligram (mg) SC injections of 1 milliliter (mL) each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
223990899|NCT05288829|DRUG|ALXN1210 IV|All doses of ALXN1210 IV were administered by IV infusion, using IV sets with in-line filters, at a maximum rate of 333 mL/hour, excluding interruption for safety or technical reason. There were at least 15 minutes between the end-of-infusion/injection in 1 participant and the start-of infusion/injection in the next participant.
223990900|NCT05288829|DRUG|Placebo|All doses of placebo SC were administered by four 100-mg SC injections of 1 mL each in the abdominal area. All four 1-mL injections were administered over a 15-minute period with at least 15 minutes between the end of injection in 1 participant and the start of injection in the next participant.
223990901|NCT05666817|OTHER|breastfeeding education|"Mothers in the intervention group will be given breastfeeding training after the pre-test application. The content of breastfeeding education is as follows;~* General information about breastfeeding,~* General information about breast milk and the benefits of breast milk,~* Benefits of breastfeeding for mother and baby,~* How the baby should be held during breastfeeding, the baby's position,~* Effective breastfeeding positions for the mother,~* Ensuring that the baby holds the breast correctly,~* Providing the correct breastfeeding technique,~* Breast milking and storage conditions,~* The necessity and benefits of continuing breastfeeding."
223990902|NCT00508989|DRUG|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
223990903|NCT00508989|DRUG|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
224121424|NCT00004285|DEVICE|High dose, high flux hemodialysis|
224121425|NCT00313807|DRUG|Amino Acid|7% amino acid infusion
223990904|NCT00508989|DRUG|L-NMMA|
223990905|NCT00508989|DRUG|Acetylcholine|
223990906|NCT02640105|OTHER|Neurological clinical examination|Diagnostic and description of cluster headache
223990907|NCT02640105|OTHER|Psychological clinical examination|Scale and questionnaires
223990908|NCT02640105|OTHER|Questionnaires|Psychopathological and cognitive questionnaires
223990909|NCT02640105|OTHER|Blood sample|Blood sample for DNA collection
223990910|NCT02640105|OTHER|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
224121426|NCT00313807|DRUG|Placebo|0.9% Saline Infusion
224121427|NCT03779425|OTHER|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
224121428|NCT01452958|BIOLOGICAL|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
224121429|NCT01452958|BIOLOGICAL|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
224121430|NCT01880255|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
223990911|NCT02413593|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223990912|NCT02413593|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223990913|NCT01702883|OTHER|Internet Survey|prompt to complete internet survey
223990914|NCT05828563|DIAGNOSTIC_TEST|Blood sample test|Blood sample will be taken to determine immunological indices
223990915|NCT05542121|DEVICE|Robot-Assisted Therapy with Rehab CARES system|60 min sessions; 3 sessions per week; for 4 weeks; Patients uses 1 or more affordable robots to exercise the UL with adaptive games assessments as OT; standard of care PT and SLP; Subjects' motor and cognitive impairment will be used to set the game and modes. The game parameters will be adjusted according to motor and cognitive impairment of that station's user while the controller will automatically adjust assisting or resisting torques experienced. The 60 minutes will be broken up into 15-minute training intervals.
223990916|NCT05542121|OTHER|Standard of Care|60 min sessions; 3 sessions per week; for 4 weeks of OT, PT, and SLP
223990917|NCT05174598|DRUG|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Topical spray formulation containing Calcipotriol 50 μg/g. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
223990918|NCT05174598|DRUG|Calcipotriol Ointment 50 micrograms/g|Topical Ointment formulation containing Calcipotriol 50 micrograms/g. Twice daily treatment by applying on a psoriasis affected area for 8 weeks.
223990919|NCT05174598|OTHER|Placebo|Topical spray formulation containing Vehicle of test formulation. Twice daily treatment by spraying on a psoriasis affected area for 8 weeks.
223990920|NCT02319863|PROCEDURE|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
224121431|NCT02856581|DRUG|Varenicline|Given PO
223990921|NCT02319863|PROCEDURE|hepatectomy (rapid ligating)|
223990922|NCT03112447|PROCEDURE|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
224121432|NCT02856581|DRUG|Placebo|Given PO
224121433|NCT02856581|OTHER|Tobacco Cessation Counseling|Complete counseling session
224121434|NCT05946135|DRUG|Lansoprazole|taking lansoprazole + placebo for Fexuprazan Hydrochloride for 4 weeks
224121435|NCT05946135|DRUG|Fexuprazan Hydrochloride|taking placebo for lansoprazole + Fexuprazan Hydrochloride for 4 weeks
224294689|NCT06895161|OTHER|Remotely supervised exercise at home or outdoors|Aerobic exercise at home/outdoors 30 minutes each session,five days a week for three weeks using a Polar H9 heart rate monitor.
223990923|NCT03112447|PROCEDURE|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
224121436|NCT01557608|PROCEDURE|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
223990924|NCT06487663|PROCEDURE|TACE with ICI|Transcatheter hepatic artery chemoembolization and immune checkpoint inhibitors
223990925|NCT00776022|DRUG|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
223990926|NCT01807182|BIOLOGICAL|Aldesleukin|Given IV
223990927|NCT01807182|DRUG|Cyclophosphamide|Given IV
223990928|NCT01807182|DRUG|Fludarabine Phosphate|Given IV
223990929|NCT01807182|OTHER|Laboratory Biomarker Analysis|Correlative studies
223990930|NCT01807182|BIOLOGICAL|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
223990931|NCT00924222|DRUG|Sevoflurane|Sedation with sevoflurane
223990932|NCT00924222|DRUG|Propofol|Sedation on intensive care unit with propofol
223990933|NCT01991847|BEHAVIORAL|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
223990934|NCT02637102|OTHER|Not applicable - observational study|
223990935|NCT05191147|DIETARY_SUPPLEMENT|Dietary supplement|We will study dietary supplement consumption among pregnant women
223990936|NCT03174665|OTHER|No intervention|
223990937|NCT03444740|OTHER|ICIQ-FLUTS, ADMN-20|Questionnaire
223990938|NCT03026647|PROCEDURE|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
223990939|NCT00813982|DEVICE|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
223990940|NCT00813982|DEVICE|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
223990941|NCT00150618|DRUG|SPD503 (1 mg)|
223990942|NCT00150618|DRUG|SPD503 (2 mg)|
223990943|NCT00150618|DRUG|SPD503 (3 mg)|
223990944|NCT00150618|DRUG|SPD503 (4 mg)|
224121437|NCT01557608|PROCEDURE|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
224121438|NCT03415919|OTHER|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
224121439|NCT02147704|DIETARY_SUPPLEMENT|High-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
223990945|NCT00150618|DRUG|Placebo|
223990946|NCT03758495|OTHER|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
223990947|NCT04458818|PROCEDURE|Prolene Mesh Vocal Cord Medialization Implant|The surgery will be performed under local anesthesia (lignocaine with adrenaline 2%) and procedural sedation with propofol 25-100mcg/kg/min (only sedative dose) will be administered, so that the patient remains vocally responsive during the procedure. Incision will be made at the lower border of thyroid cartilage under aseptic measures. Skin flaps will be raised in sub-platysmal plane, strap muscles will be separated in the midline to expose the laryngeal cartilaginous framework. A simple laryngeal window approach will be used to place the Ethicon prolene mesh 6 x 6cm Swiss roll, secured with prolene 2/0 suture trimmed to the required size. Post op voice analysis will be done on 7th day and 14th post-operative day. Monthly follow up will be advised after that.
223990948|NCT02999243|BEHAVIORAL|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
223990949|NCT02999243|BEHAVIORAL|Harm reduction education|Both arms will receive harm reduction education
223990950|NCT00663637|DEVICE|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
223990951|NCT03451708|DEVICE|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
223990952|NCT01791413|DRUG|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
223990953|NCT03294824|OTHER|blood sample|peripheral blood samples are collected
223990954|NCT00003664|BIOLOGICAL|aldesleukin|
223990955|NCT00003664|BIOLOGICAL|recombinant interferon alfa|
223990956|NCT00003664|DRUG|fluorouracil|
223990957|NCT00003664|DRUG|gemcitabine hydrochloride|
223990958|NCT03747406|PROCEDURE|Erector spinae plane block|the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.
223990959|NCT03747406|PROCEDURE|TAP block|a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
223990960|NCT04910633|OTHER|COCA is an observational study based on retrospective data issued from patient medial file.|"The following parameters will be collected from the medical files of the patients involved in this study:~* Age~* Gender~* Cancer type~* Cancer Stage~* Cancer Treatment~* COVID-19 severity (based on chest X-Ray damage. Low ≤25%, Middle: between 25-50%, High above 50%)~* Living Status~* Attribution of Mortality to COVID status~* Comorbidities"
223990961|NCT01583504|PROCEDURE|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
223990962|NCT01583504|PROCEDURE|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
223990963|NCT01583504|BEHAVIORAL|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
223990964|NCT05567042|OTHER|No intervention|No intervention
223990965|NCT03452215|BEHAVIORAL|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
223990966|NCT03452215|BEHAVIORAL|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
223990967|NCT00178347|RADIATION|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
223990968|NCT06031831|OTHER|airway anomalies|with or without airway anomalies
223990969|NCT01018108|PROCEDURE|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
223990970|NCT01018108|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
223990971|NCT01018108|OTHER|Questionnaire Administration|Ancillary study
223990972|NCT01018108|OTHER|Laboratory Biomarker Analysis|Correlative Study
223990973|NCT04253119|DRUG|Antiretroviral/Anti HIV|NNRTI plus two NRTIs or PI boosted by ritonavir with 2 NRTIs per the usual standard of care of the investigator in AIDS clinics of Russia
223990974|NCT05810805|OTHER|gas component of digestive tract|Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
224121440|NCT02147704|DIETARY_SUPPLEMENT|low-sodium diet|"1. One of high- or low sodium intake for 7 days during each period~2. Low sodium intake : 50 mmol/day by diet"
224121441|NCT02218658|DRUG|WE941 OD tablets|
224121442|NCT02218658|DRUG|Brotizolam|
223544818|NCT04038294|DIETARY_SUPPLEMENT|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
224121443|NCT05655637|OTHER|Exercise|There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
224121444|NCT00511407|DEVICE|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
223544819|NCT04038294|DIETARY_SUPPLEMENT|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
223544820|NCT03882281|DRUG|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
223544821|NCT02573571|OTHER|Development of biomarkers|Blood sampling
223990975|NCT02876952|OTHER|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
223990976|NCT02876952|OTHER|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
223990977|NCT02876952|OTHER|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
223990978|NCT02876952|OTHER|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
223990979|NCT04129476|BEHAVIORAL|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
223990980|NCT00250432|DRUG|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of \~2 hrs. Duration of Treatment - 14-90 days.
223990981|NCT02039895|RADIATION|HITS|Helical irradiation of the total skin by helical tomotherapy
223990982|NCT03833895|DRUG|Norepinephrine|0.05ug/kg/min Norepinephrine during Cesarean Section Operation
223990983|NCT03833895|DRUG|Phenylephrine|0.25ug/kg/min phenylephrine during Cesarean Section Operation
223990984|NCT03833895|DRUG|Ringer's Solution|3 ml/kg/min of LR was administrated according to standard weight.
223990985|NCT03525470|BIOLOGICAL|Water|150 mil of water was drunk on two occasions
223990986|NCT03525470|OTHER|No drink|Although body weight lost no drink consumed
223990987|NCT00652509|BEHAVIORAL|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
223990988|NCT00652509|BEHAVIORAL|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
223990989|NCT04517240|OTHER|endoscopy|upper and lower endoscopy and fecal calprotectin test
223990990|NCT04501393|OTHER|Clear liquid intake|Clear oral fluid including water, pulp-free juice and tea or coffee without milk
223990991|NCT03554031|DRUG|Recombinant Human Growth Hormone (rhGH) Injection|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
223990992|NCT01836172|DRUG|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
223990993|NCT00175539|BEHAVIORAL|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
223990994|NCT06479928|OTHER|delivery mode|Based on delivery mode, we will divide them into two groups, including Cesarean section and Natural delivery.
223990995|NCT06311305|PROCEDURE|Early Laparoscopic cholecystectomy|laparoscopic cholecystectomy early after ERCP with assessing the risks and complications
223990996|NCT06426602|DEVICE|mindBEAGLE daily device use|If participants are considered responsive, they will continue to use the device daily for the remainder of their stay at inpatient rehab, or until they regain consciousness.
223990997|NCT06123689|DEVICE|AMT-Regenera activa|"Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine."
223544822|NCT04245709|DRUG|Clenbuterol|The intervention is treatment with oral clenbuterol at 40-80 micrograms twice daily for 24 weeks. Dosage will initially be 40 mcg daily for one week, then 40 mcg BID per oral daily for the next 5 weeks. If the 40 mcg BID per oral is well tolerated in the opinion of Dr. Bedlack, the dose will be increased to 80 mcg each morning/40 mcg each evening for one week, followed by 80 mcg BID per oral for the remainder of the study. The selected target dose (80 mcg BID) is based upon the experience with the long-term administration of clenbuterol, specifically the beneficial muscle effects in a Phase I/II clinical trial that enrolled patients with late-onset Pompe disease who were previously treated with enzyme replacement therapy (Koeberl et al. 2018).
223990998|NCT06123689|DEVICE|Hyalubrix|"Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed"
223990999|NCT03491267|DRUG|Retinoic acid|The study team will treat skin with topical retinoic acid
223991000|NCT03491267|DEVICE|Laser|The study team treat skin with a surface laser.
223991001|NCT03491267|DRUG|Sham treatment|No drug will be given
223991002|NCT03491267|DEVICE|Sham treatment|No laser treatment will be given
223991003|NCT04946942|BEHAVIORAL|Collaborative Healthcare Encounters with Caregivers (CHEC)|CHEC is a brief checklist designed to identify family caregivers' unmet needs and concerns.
223991004|NCT04946942|BEHAVIORAL|Usual Care|Attendance at primary care appointments as usual.
223991005|NCT06368583|OTHER|Interview|Patients will be interviewed by the research team to learn about their experience of vaginal delivery with neuraxial analgesia
223991006|NCT04907357|DEVICE|rTMS|Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
223991007|NCT04907357|DEVICE|Sham (Placebo)|Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
223991008|NCT00196352|DRUG|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
223991009|NCT05368155|BEHAVIORAL|Brief ACT for Pelvic Pain|The Brief ACT for Pelvic Pain treatment will include three weekly, 90-minute group sessions that teach Veterans new ways to respond to difficult thoughts and emotions related to pain (Acceptance and Mindfulness Training) and encourage behavioral (re)engagement in meaningful life activities (Behavioral Change Training). The overall goal is to cultivate psychological flexibility by helping Veterans learn to respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. Workshop content is integrated with education on pelvic pain (its diagnostic criteria, etiology, and associated health outcomes) to increase alignment of the treatment with patient needs.
223991010|NCT03189173|DEVICE|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
223991011|NCT03189173|DRUG|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
223991012|NCT03189173|OTHER|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
223991013|NCT03189173|OTHER|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
223991014|NCT05035797|PROCEDURE|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation program which encompasses six evidence-based components according to literature review: 1) positioning; 2) passive range of motion (PROM) training; 3) neuromuscular electronic stimulation (NMES); 4) surface electrical phrenic nerve stimulation (SEPNS); 5) PNF techniques; and 6) airway clearance techniques; Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
224294690|NCT06895161|OTHER|Hospital-based exercise program|The aerobic exercise ,30 minutes each session,five days a week for three weeks at cardiopulmonary rehabilitation unit under supervision.
223544823|NCT01749527|BEHAVIORAL|minimal activity|Pad test with minimal activity
223991015|NCT05035797|PROCEDURE|Usual care|Control group will be treated with usual care and ECMO therapy. Usual care normally comprises pharmacotherapy, mechanical ventilation, continuous renal replacement therapy (CRRT), intra-aortic balloon pump (IABP), and specific nursing for ECMO therapy and their original injuries, as appropriate.
223991016|NCT04896788|BIOLOGICAL|Monitoring of the immune response|Blood sample at 3,6,12,18 and 24 months in order to assess the blood level of anti-S1 / RBD anticoprs
223991017|NCT00521859|DRUG|Cloretazine|800 mg/m\^2 by vein daily
223991018|NCT00521859|DRUG|Fludarabine|25 mg/m\^2 by vein daily x 5 Days
223991019|NCT04264975|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation (FMT) is the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to directly change the recipient's microbial composition and confer a health benefit
223991020|NCT00428337|BIOLOGICAL|EP-1233|DNA-HIV-recombinant vaccine
223991021|NCT00428337|BIOLOGICAL|MVA-mBN32|HIV-recombinant viral vaccine
224294691|NCT06895161|OTHER|Phone calls with reinforcement feedback|Calls twice a week that include symptom inquiries and encouraging feedback on exercise
223544824|NCT00005579|DRUG|dolastatin 10|
223544825|NCT01746290|OTHER|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
223991022|NCT04277507|DEVICE|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
223991023|NCT05680324|PROCEDURE|Monsplasty|liposuction assisted monsplasty
223991024|NCT02975791|OTHER|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
223991025|NCT02975791|PROCEDURE|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
223991026|NCT04673045|DEVICE|Active Electrical stimulation|The intensity of stimulation will be set within the subject's tolerance level. The amplitude was adjusted to produce muscle contraction without affecting the patient's comfort. The cathode electrode will be placed over the common peroneal nerve as it passes over the head of the fibula and the anode will be placed on mid-muscle belly on one third of the line between fibular head and medial malleolus on paretic limb.
223991027|NCT04673045|DEVICE|Sham Electrical Stimulation|For sham group, the current intensity will gradually decreased after few seconds to 0. Therefore, the participant will experience a passage of current on the muscle at the beginning but received no current for the rest of the stimulation period. The participants will be informed that the stimulation below the sensory level.
223991028|NCT04765410|DIAGNOSTIC_TEST|EUS FNA (endoscopic ultrasound fine needle aspiration)|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
223991029|NCT05015725|DIAGNOSTIC_TEST|Quality of life assessment, biochemical measures|"Psychological tests: ThyDQol, ThySRQ and the Somatosensory Amplification Scale (SASS) adding up to \~50 items including demographic variables.~Recording of basic anthropometric data. Blood draw Laboratory tests: TSH, T3, FT3, FT4, aTPO, rT3, serum cholesterol, CK, GOT, GPT, creatinine and sodium levels."
223991030|NCT00569192|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
223991031|NCT00569192|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
223991032|NCT00569192|DRUG|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
223991033|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing every 2 weeks~* Intravenous injection"
223991034|NCT01765790|BIOLOGICAL|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"* Dosing weekly~* Intravenous injection"
223991035|NCT06544564|DEVICE|Membrane Wrap™|Membrane Wrap™
223991036|NCT06544564|OTHER|Standard of Care|SOC treatment will be defined as: 1) debridement of non-viable, necrotic tissue, 2) application of Biologic as the primary, wound covering, 3) application of a dressing over Biologic that maintains moisture balance, 4) application of a Class 3 high compression system, and 5) wrapping with a covering dressing
223991037|NCT05365399|DEVICE|smartphone-based screening tool for neonatal jaundice|In this study we aim to collect data of newborns with wider range of bilirubin levels and high melanin content, and additionally measurements of skin color reflectance with a spectrophotometer, to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors. .
223991038|NCT00691600|DRUG|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
223991039|NCT00691600|DRUG|Placebo|Placebo caps or suspension every 12 hours for 10 days
223991040|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
223991041|NCT02643147|DRUG|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
223991042|NCT02643147|DRUG|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
223991043|NCT02737813|DRUG|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
223991044|NCT02737813|DRUG|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
223991045|NCT03169998|DEVICE|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
223991046|NCT05238753|DEVICE|Non-invasive electromagnetic stimulation|Non-invasive bilateral electromagnetic stimulation of the phrenic nerve
224294692|NCT06784336|DRUG|Iron chelation|Patients will receive Iron chelation with deferasirox (Jadenu 7 mg/kg/day preferred versus Exjade 10 mg/kg/day) beginning on day -14 and continuing through day +100
224294693|NCT06784336|DRUG|Potato Resistant Starch|Patients will receive PRS beginning on day -6 and continuing through day +100. Patients will take 20g packet twice daily
224294694|NCT06802224|DRUG|Norepinephrine|Intravenous Norepinephrine for both infusion and bolus dosing
223991047|NCT03866096|OTHER|Experimental|The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes
223991048|NCT03866096|OTHER|Control|Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
223991049|NCT06024915|DRUG|TQ05105 tablets|TQ05105 is a Janus kinase 2 (JAK2) inhibitor.
223991050|NCT06024915|DRUG|Itraconazole capsule|Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).
223991051|NCT06024915|DRUG|Rifampicin Capsule|Rifampicin is a strong inducer of CYP3A.
223991052|NCT03019419|DRUG|Perampanel|4mg/d or 8mg/d
223991053|NCT03019419|DRUG|placebo|placebo
223991054|NCT00486252|OTHER|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
223991055|NCT00958542|PROCEDURE|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
223991056|NCT00788242|DRUG|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
223991057|NCT00788242|DRUG|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
223991058|NCT00869947|DEVICE|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
223991059|NCT00869947|OTHER|No device|
223991060|NCT01210651|BEHAVIORAL|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
223991061|NCT01210651|BEHAVIORAL|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
224294695|NCT06802224|DRUG|Phenylephrine|Intravenous Phenylephrine for both infusion and bolus dosing
224294696|NCT05334069|OTHER|Questionnaire Administration|Complete questionnaire
224294697|NCT05334069|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
224294698|NCT06567743|DRUG|Cretostimogene Grenadenorepvec|Respective Cohort
223544826|NCT04138095|DEVICE|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
223544827|NCT01382771|DRUG|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
223991062|NCT05405699|BEHAVIORAL|digitalized group psychoeducation|"Problem Solving Approach based problem solving skills psychoeducation's session topics of eight weeks are as follows:~1. Introduction and warm-up,~2. Problem orientation-identifying the problem,~3. Identifying prior problems-Which do I want to start from?~4. Recognizing the losses caused by problems and complaints,~5. Setting reachable and realistic goals,~6. Generating alternatives -What can I do?~7. Regulating emotions,~8. Experimenting and exploring. The main outcomes of each session were determined, and sessions were completed in approximately one hour as a semi-structured interactive group training according to group dynamics.~Three days a week for eight weeks, informative posts were shared, asynchronous testing and self-discovery activities were carried out, and a synchronous tele-psychoeducation session was held once a week. Participants were connected to the live broadcast of the research team and interacted via text messages."
223991063|NCT01855711|DRUG|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
223991064|NCT01261247|DRUG|panobinostat|Given orally
223991065|NCT01261247|OTHER|laboratory biomarker analysis|Correlative studies
223991066|NCT01261247|GENETIC|western blotting|Correlative studies
223991067|NCT01261247|GENETIC|DNA analysis|Correlative studies
223991068|NCT01261247|OTHER|flow cytometry|Correlative studies
223991069|NCT01261247|OTHER|pharmacological study|Correlative studies
223991070|NCT01261247|OTHER|immunohistochemistry staining method|Optional correlative studies
223991071|NCT01498315|OTHER|Ultrasound examination|Ultrasound examination following hysterectomy
223991072|NCT02559310|DRUG|lefamulin|antibacterial agent
223991073|NCT02559310|DRUG|Moxifloxacin|antibacterial agent
223991074|NCT02559310|DRUG|Linezolid|antibacterial agent
223991075|NCT04246398|OTHER|FMT|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
223991076|NCT04246398|OTHER|FMT - placebo|"Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration."
223991077|NCT01815853|RADIATION|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy \[Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle (non-concurrent); Oxaliplatin 100 mg/m² IV on Day 1 + Capecitabine 825 mg/m² orally BID on Days 1-14 of a 21-day cycle (concurrent chemoradiotherapy)\]
223991078|NCT01815853|DRUG|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
223991079|NCT01815853|PROCEDURE|R0 D2 Gastrectomy|
223991080|NCT01815853|DRUG|Adjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Oxaliplatin 130 mg/m² IV on Day 1 + Capecitabine 1000 mg/m² orally BID on Days 1-14 of a 21-day cycle)
223991081|NCT06282640|DRUG|Vitamin D|Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
223991082|NCT03472989|DEVICE|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
223991083|NCT03472989|DEVICE|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
223991084|NCT03472989|BEHAVIORAL|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
223991085|NCT03472989|BEHAVIORAL|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
223991086|NCT04134884|DRUG|Talazoparib|Talazoparib will be taken on days 4-21, 6-21 or 1-21 at a dose level of 0.25, 0.5, 0.75 or 1.0 mg depending on cohort assignment
223991087|NCT04134884|DRUG|ASTX727|ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
223991088|NCT02592707|DRUG|Satoreotide tetraxetan|Satoreotide tetraxetan administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
223991089|NCT02592707|OTHER|Amino acid solution|"Given as an auxiliary product the day of the IMP infusion for safety reasons to protect the renal function.~Centres can use their established amino acid infusion or Ipsen amino acid solution (auxiliary medical product OPS301)"
224121445|NCT01094002|OTHER|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
223991090|NCT02592707|OTHER|Antiemetic|To counteract the known side effects of the amino acid infusion, such as nausea, dexamethasone (antiemetic) and as-required ondansetron will be administered 15 to 30 minutes before the start of the amino acid infusion (unless there are contraindications for these drugs).
223991091|NCT03358368|DEVICE|Vitalscan|Vitalscan is a magnetocardiograph device
223991092|NCT00469859|DRUG|cytarabine|given IV
223991093|NCT00469859|DRUG|idarubicin|Given IV
223991094|NCT00469859|DRUG|lestaurtinib|Given orally
224121446|NCT03422406|OTHER|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
224294699|NCT06841614|BIOLOGICAL|Ervebo|Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
223991095|NCT02214680|DRUG|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
223991096|NCT02214680|DRUG|Timolol|0.5% eye drop
223991097|NCT06195865|PROCEDURE|DIEP-flap|Breast reconstruction with a deep inferior epigastric perforator flap
223991098|NCT06195865|PROCEDURE|Implant|Breast reconstruction with an implant-based technique
223991099|NCT04124471|BEHAVIORAL|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
223991100|NCT01972997|DEVICE|SENSIMED Triggerfish|
224121447|NCT00028002|PROCEDURE|Conventional Surgery|Undergo surgical resection
224121448|NCT00028002|DRUG|Imatinib Mesylate|Given orally
224294700|NCT06841614|BIOLOGICAL|Inmazeb|Inmazeb (REGN-EB3), developed by Regeneron, is a cocktail of 3 neutralising humanised mAbs directed against 3 epitopes of the EBOV GP (atoltivimab, maftivimab and odesivimab). It is indicated for the treatment of EVD in adult patients (including pregnant women) and in children, including neonates born to mothers with confirmed EVD.
224294701|NCT06126276|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224294702|NCT06126276|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223991101|NCT04511247|DEVICE|MagicTouch PTA Sirolimus drug coated balloon|For participants randomised to MagicTouch PTA sirolimus DCB, following successful plain balloon angioplasty of the arterial lesion (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), MagicTouch sirolimus coated balloon will be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty.
223991102|NCT04511247|DEVICE|POBA balloon|For participants randomised to the standard balloon angioplasty group, a placebo standard balloon which is identical to the SCB will also be applied at the lesion after appropriate sizing using the diameter of the plain balloon angioplasty
223991103|NCT01607541|BEHAVIORAL|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
223991104|NCT01607541|BEHAVIORAL|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
223991105|NCT04092660|BEHAVIORAL|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~1. Health Pamphlet at the initial screening~2. Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~3. Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~4. Booster phone calls in between the follow-up visits"
223991106|NCT04092660|DEVICE|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances \[MAA\] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
223991107|NCT04405024|DIAGNOSTIC_TEST|Hepatitis C testing|Hepatitis C Screening
223991108|NCT04855734|BEHAVIORAL|FAmily CEntered (FACE) pACP Intervention|The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach \[Sessions 1 \& 2\] and Respecting Choices \[Session 3\].
223991109|NCT03701581|DRUG|4-Aminopyridine|FDA-approved tablets.
223991110|NCT03701581|OTHER|Placebo|Placebo will be tooled to look similar to the study drug.
223991111|NCT05127824|BIOLOGICAL|Autologous alpha-DC1/TBVA vaccine|"Dendritic cells (DC) are derived from autologous (the subject's own) mononuclear cells in the peripheral blood obtained from the PRBC. In this case, biologic product and biologic substance are the same. The vaccine will be manufactured in the HCC-IMPCL, under cGMP conditions."
223991112|NCT05127824|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
223991113|NCT06823947|DRUG|Placebo|Placebo is administered single dose or multiple dose by SC injection.
223991114|NCT06823947|DRUG|KK3910|KK3910 is administered single dose or multiple dose by SC injection.
223991115|NCT04402840|PROCEDURE|Stellate Ganglion Block|The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
223991116|NCT05129631|BEHAVIORAL|HEARTPrep|HEARTPrep is a virtually-delivered psychosocial intervention for mothers expecting a baby with CHD.
223991117|NCT05767177|OTHER|Glucemia following Mixed Meal Test|On day 12 of each diet, a venous catheter is placed in one arm for blood sampling and the research person must answer questions about any gastrointestinal complaints in connection with the current diet. At approximately 09:00, the research subject may eat a brunch for approximately 15 minutes (sandwich, juice, fried egg and sausage; 550-600kcal). Venous blood samples are taken before and 15, 30, 45, 60, 90 and 120 minutes after the meal.
223991118|NCT05767177|OTHER|Enteroscopy - mucosal ketogenic activity as well as glucose transport|On day 14 of each diet period, an enteroscopy is performed. This step is performed to obtain samples (biopsy) of the mucosa of the small intestine (duodenum and jejunum) and is performed at the Gastro-endoscopic departments SU-Sahlgrenska, or SU-Eastern hospital. Endoscopy is experienced by some individuals as unpleasant, which is why local anesthesia and sometimes sedation (midazolam + pethidine or rapifen) can be offered according to standard routine in the endoscopy department.
223991119|NCT03780647|OTHER|questionnaire|Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
223991120|NCT01991925|OTHER|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionnaires and focus group interviews
223991121|NCT04500600|OTHER|Quality-of-Life Assessment|Ancillary studies
223991122|NCT04500600|OTHER|Questionnaire Administration|Complete questionnaire
223991123|NCT05902897|DEVICE|Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis.|Heart Valve Replacement
223991124|NCT05216198|OTHER|Check of the different exams performed at the emergencies|Check of the different exams performed at the emergencies
223991125|NCT00809679|DRUG|T-62 Dose 1|Capsule dosage form 100 mg bid
223991126|NCT00809679|DRUG|T-62 Dose 2|Capsule dosage form 200 mg bid
223991127|NCT00809679|OTHER|Placebo|Capsule dosage form placebo bid
223991128|NCT02270307|DRUG|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
223991129|NCT02270307|BIOLOGICAL|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
223991130|NCT01864460|BEHAVIORAL|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
223991131|NCT01769430|OTHER|Observational Study of influenza aerosol shedding -- No Intervention|No intervention -- observational study only
223991132|NCT06587958|DIETARY_SUPPLEMENT|Fermented plant-based foods|Participants will daily consume five different types of fermented plant-based foods, in addition to their habitual diet.
223991133|NCT06587958|DIETARY_SUPPLEMENT|Non-fermented plant-based foods|Participants will daily consume five different types of non-fermented plant-based foods, in addition to their habitual diet.
223991134|NCT06587958|OTHER|Habitual diet|Participants will follow their habitual diet.
223991135|NCT00155532|PROCEDURE|3 mm-punch biopsies of the skin|
223991136|NCT04529811|DRUG|Rifaximin Novel Formulation|Rifaximin Novel Formulation
223991137|NCT04529811|DRUG|Placebo|Placebo
223991138|NCT06376461|OTHER|Data collection|Sites will recruit all consecutive adult patients admitted to ICU, to a maximum of 120 patients or a maximum recruitment period of 8 weeks, whichever comes first
223991139|NCT05131477|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223991140|NCT05131477|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223991141|NCT06595368|PROCEDURE|Vimala massage|The massage will be given three times per day, each lasting 15 minutes and planned one hour after the first feeding of each shift.
223991142|NCT06595368|PROCEDURE|Hydrotherapy|Hydrotherapy will be applied two times per day before feeding, each lasting 5-10 min.
223991143|NCT06267807|DIAGNOSTIC_TEST|Dynamic contrast-enhanced lymphangiography|The subject is placed supine on a detachable MR imaging table, outside the scanning room. Both inguinal regions are prepared under sterile conditions. Using Ultrasound guidance, the thoracic duct outlet at the left venous angle is identified. Under US guidance, a small 25 gauge needle is placed at the corticomedullar junction of an inguinal lymph node on each side. The needle position is confirmed and checked that there is no extravasation at saline injection under US visualization. The subject is then transferred to the MR imaging machine. First, pre-contrast imaging is performed, this takes around 20 minutes.
223991144|NCT05009199|DRUG|[18F]MNI-444|Subjects will undergo PET imaging using \[18F\]MNI-444.
223991145|NCT06336512|DIAGNOSTIC_TEST|ELISA|Estimation of Zonulin by ELISA from the Blood samples which were obtained at time of pregnancy .
224294703|NCT06126276|PROCEDURE|Computed Tomography|Undergo CT scan
223991146|NCT00730821|DRUG|BIBW 2992|
223991147|NCT00730821|DRUG|BIBF 1120|
224294704|NCT06126276|PROCEDURE|Echocardiography Test|Undergo ECHO
223991148|NCT03539029|PROCEDURE|Surgery|Surgical fracture fixation
223991149|NCT03539029|PROCEDURE|Conservative treatment|immobilisation with plaster cast
223991150|NCT02536495|DRUG|Docetaxel|Given IV
223991151|NCT02536495|OTHER|Laboratory Biomarker Analysis|Correlative studies
223991152|NCT02536495|OTHER|Pharmacological Study|Correlative studies
223991153|NCT02536495|DRUG|Selinexor|Given PO
223991154|NCT06819904|BEHAVIORAL|Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE)|Participants will receive the ACT treatment. It is comprised of three processes: Open Up, Be Present, and Do What Matters. Each of these is further sub-divided, for a total of six core processes. These processes include, but are not limited to, present moment awareness, de-fusion, and committed action. This group will also receive targeted vestibular therapy and standardized behavioral management strategies (physical activity, sleep, hydration, and nutrition prescription). Participants will also receive usual care at the discretion of each site's treating providers. They will also receive vestibular therapy that may include one or more exercises in the following groups: 1) gaze stability, 2) visual-vestibular habituation, and 3) balance/gait.
223991155|NCT06819904|BEHAVIORAL|Usual Care Vestibular Rehabilitation|Participants will receive usual care at the discretion of each site's treating providers, excluding any components associated with ACT. They will also receive vestibular therapy that may include one or more exercises in the following groups: 1) gaze stability, 2) visual-vestibular habituation, and 3) balance/gait.
223991156|NCT05101993|DEVICE|AtriClip|Received AtriClip for exclusion of left atrial appendage during concomitant cardiac procedure
223991157|NCT03920176|DIAGNOSTIC_TEST|Computed tomography coronary angiography|CTCA \>64 detector row scanner
223991158|NCT03920176|OTHER|ASSIGN Score|ASSIGN Cardiovascular Risk Score
224294705|NCT06126276|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223991159|NCT06661356|BEHAVIORAL|COMPrEP|Participants will be paired with peer lay workers and will meet with peer lay workers at private community location. They will discuss options for oral PrEP with peer lay workers and be provided provide daily oral PrEP or event-driven (2-1-1) PrEP. Participants will take part in rapid HIV testing at each visit. They will also meet with peer lay workers at private community location for follow-up at 1, 5, 9, and 13 months.
224294706|NCT06126276|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224294707|NCT06126276|DRUG|Neratinib Maleate|Given PO
224294708|NCT06126276|DRUG|Palbociclib|Given PO
223991160|NCT06030986|DIAGNOSTIC_TEST|ILCOR Utstein OHCA Core Outcome|ILCOR Utstein OHCA Core Outcome
223991161|NCT04577573|DEVICE|Cognition glove|The investigators have developed and tested a functional prototype of an instrumented glove to alert the user about secure grasp of objects. Onboard force and flex sensors provide inputs to a machine learning algorithm (artificial neural network, ANN) to estimate secure grasp based on previously collected training data. The glove enhances agency by alerting the user to secure grasp through sensory feedback modules (visual - LED, audio - beeper, tactile - vibrator).
223991162|NCT04577573|DEVICE|Sensory brace|"A a size- and position-adjustable arm brace with weight-support capability and housing for vibration motors and EMG sensors. Position adjustment allows for physical therapists to find and recommend arm postures that are clinically relevant to~each person. The participant can then isometrically push/resist against the brace to strengthen target muscles while performing VR reach-to-touch. The person will receive visual feedback from the virtual environment to train movement performance and vibrotactile feedback at tendons to subconsciously adjust their muscle activation patterns"
223991163|NCT05706844|DRUG|Spinal anesthesia|plain or heavy Bupivacaine hydrochloride 10 mg (2 mL) injected in the spinal canal
223991164|NCT05706844|DRUG|General anaesthesia|Propofol (induction: 1.0-2.0 mg/kg. infusion: 3-5 mg/kg/hour) + Remifentanil (induction: 3-5 mcg/kg, infusion: 0.5 mcg/kg/min) given intravenously
223991165|NCT06608966|BEHAVIORAL|Epilepsy Journey web-based modules|Participants assigned to Epilepsy Journey modules will independently review web-based EJ modules focused on executive functioning skills. The modules cover 10 topic areas: Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Participants will complete 10 modules (\~15-30 minutes each session) within a 14-week time frame. The goal is to complete one module per week.
223991166|NCT06608966|BEHAVIORAL|Telehealth with a therapist|Therapist will cover 10 areas of executive functioning during telehealth sessions, including Positive Thoughts, Problem-Solving, Initiation, Working Memory, Monitoring, Inhibition, Emotional Control, Organization and Planning, Sleep/Stress, and a Wrap-Up. Telehealth sessions with a therapist will occur via HIPAA-compliant videoconference (e.g. Microsoft Teams) each week ideally over the course of 14 weeks.
223991167|NCT06820528|BEHAVIORAL|Occupational Therapy|Formal therapy with a certified hand therapist, weekly for 6 weeks
223991168|NCT06820528|BEHAVIORAL|Home Exercise Program|A booklet on hand exercises to complete following surgery, including range of motion and strengthening exercises
223991169|NCT06600373|BEHAVIORAL|Mindful Walking meditation|Conduct approximately 10 minutes of mindful walking after the 110-minute regular physical education group class.
223991170|NCT06600373|BEHAVIORAL|physical education group class|120 minutes physical education group class about volleyball.
223991171|NCT06600607|DRUG|pregabalin 300 mg|pregabalin is an FDA-approved anticonvulsant medication commonly used to treat nerve pain
223991172|NCT06600607|OTHER|Placebo|biologically inactive placebo comparator
223991173|NCT06658873|OTHER|Proximal arterial cannulation|Radial arterial cannulation from the proximal part of the artery 5 cm proximal to the level of the styloid process.
223991174|NCT06658873|OTHER|Distal arterial cannulation|Radial arterial cannulation from the distal part of the artery at the styloid process.
223991175|NCT06857929|BEHAVIORAL|energy reduced Mediterranean diet (25% caloric restriction) plus physical activity program|An intensive multifactorial lifestyle intervention involving monthly individual and group sessions during 6 months. Participants will be asked to follow a Mediterranean diet with a 25% reduction in energy and a physical activity program based on WHO recommendations to achieve a moderate physical activity level.
223991176|NCT06857929|BEHAVIORAL|Usual Care|Participants in the control group will be asked to follow general recommendations to adhere to a healthy lifestyle, as indicated in the clinical guidelines of general practitioners and nurses for adults with metabolic syndrome
223991177|NCT06856863|BEHAVIORAL|Test of personality : questionnary|The questionnary Temperament and Character Inventory (TCI) describes personality through temperament traits governed by the individual's neurobiological systems and predetermined by heredity; and character traits shaped by social and cognitive experience
223991178|NCT06859138|OTHER|Manual Therapy|Manual therapy techniques including massage, trigger point pressure, muscle stretching and joint mobilization.
224121449|NCT05787353|OTHER|Exercise programme|Both protocols consisted of aerobic, breathing and flexibility exercises. Hospital-based CPR: three or four days per week for a total of 20 sessions. Home-based CPR: three or four days/a week over a period of six weeks.
223544828|NCT01382771|DRUG|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
224121450|NCT01793051|DRUG|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
224121451|NCT01793051|OTHER|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
224121452|NCT01793051|BEHAVIORAL|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
224121453|NCT01972880|DRUG|ASP1941|Oral
224294709|NCT06347133|DRUG|Plozasiran Injection|ARO-APOC3 Injection
224294710|NCT06347133|DRUG|Placebo|sterile normal saline (0.9% NaCl)
223544829|NCT00403143|PROCEDURE|cataract surgery|
224294721|NCT04083599|BIOLOGICAL|GEN1042|Intravenous
224294722|NCT04083599|DRUG|Pembrolizumab|Intravenous
224294723|NCT04083599|DRUG|Cisplatin|Intravenous
224121454|NCT03334162|BEHAVIORAL|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
224121455|NCT03209180|DRUG|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
224121456|NCT03209180|DRUG|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
224121457|NCT02477085|OTHER|all women with an induced labor|all women who have an induced labor
224121458|NCT00782015|DIETARY_SUPPLEMENT|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
224121459|NCT00782015|DIETARY_SUPPLEMENT|Placebo Comparator:|NCEP Step 2 diet
223991179|NCT06859138|OTHER|Splint therapy|Dental splint used for temotoromandibular disorders treatment
223991180|NCT06670768|DIAGNOSTIC_TEST|Stress Dynamic MPI SPECT|BMI standardized radiopharmaceutical injection in pharmacological stress (dipyridamole or adenosine) is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
223991181|NCT06670768|DIAGNOSTIC_TEST|Stress Static MPI SPECT|30-60 minutes after stress dynamic SPECT imaging is performed, an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
223991182|NCT06670768|DIAGNOSTIC_TEST|Rest Dynamic MPI SPECT|3 hours after the stress phase, the rest phase is also recorded. A radiopharmaceutical injection with a three-fold dose at rest is performed under the SPECT camera to record the temporal distribution of the activity. A one-day protocol and multi-pinhole collimator are used.
223991183|NCT06670768|DIAGNOSTIC_TEST|Rest Static MPI SPECT|30-60 minutes after rest, dynamic SPECT imaging is performed, and an ECG-gated static SPECT MPI is conducted with a conventional LEHR collimator.
223991184|NCT06670768|DIAGNOSTIC_TEST|Cardiac CT|Within 30 days of MPI SPECT imaging, a cardiac CT is performed for every patient, including a native calcium-scoring scan and a coronary CT angiography as a reference standard. A photon-counting detector CT is used.
223991185|NCT04182997|DRUG|Dexamethasone|Patients included in the treatment group will have their surgical site lavaged with dexamethasone at the end of their surgery.
223991186|NCT04182997|DRUG|saline 0.9%|Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
224121460|NCT03013322|DRUG|Physostigmine|
224121461|NCT03013322|DRUG|Isotonic Saline|
224121462|NCT01041690|DRUG|Bevacizumab|
224121463|NCT02073435|BEHAVIORAL|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is \> 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
224121464|NCT03572439|DIAGNOSTIC_TEST|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
224294724|NCT04083599|DRUG|Carboplatin|Intravenous
224294725|NCT04083599|DRUG|5-FU|Intravenous
223991187|NCT06989541|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|Intravenous immune globulin replacement
224294726|NCT04083599|DRUG|Gemcitabine|Intravenous
224294727|NCT04083599|DRUG|Nab paclitaxel|Intravenous
224294728|NCT04083599|DRUG|Pemetrexed|Intravenous
224294729|NCT04083599|DRUG|Paclitaxel|Intravenous
223991188|NCT06989541|BIOLOGICAL|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous immune globulin replacement
223991189|NCT06998667|BEHAVIORAL|Standard Heat Illness Prevention Measures|Standard CAL-OSHA workplace heat illness prevention interventions, which require availability of cool, potable water; availability of shade when temperatures exceed 80F; and encouragement of rest for cool down breaks
223991190|NCT06998667|OTHER|Cooling bandana|Cooling bandana embedded with a polymer to slow evaporation
223991191|NCT06998667|OTHER|Cooling glove|Cooling glove with ability to circulate cool water interface with palmar skin
223991192|NCT03534011|PROCEDURE|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
223991193|NCT03534011|DEVICE|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
223991194|NCT03832855|BIOLOGICAL|pING-hHER3FL|Plasmid vaccine containing HER3
223991195|NCT06618794|OTHER|Recovery Legal Care|These patients will receive support from our HVIP standard of care (Violence Recovery Program) plus our Medical Legal Partnership (Recovery Legal Care) for additional legal support to address health-harming legal needs and public benefits.
223991196|NCT06618794|OTHER|HVIP Standard of Care|These patients will receive HVIP standard of care (Violence Recovery Program Support)
223991197|NCT07014852|OTHER|Traditional Country Foods|Participants will receive weekly distributions of traditional foods, including caribou and fish. Guided conversations will explore changes in dietary habits, emotional well-being, and cultural connections
224294730|NCT00791141|DRUG|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
223991198|NCT07014852|BEHAVIORAL|Cultural Workshops|Weekly workshops led by Elders will focus on traditional country food, food preparation, and sharing practices, enhancing cultural identity and community bonds. Participants will also engage in cultural camps where they will be led by Elders in land based teachings on country food.
223991199|NCT02775006|DRUG|Docetaxel|75mg/m2
223991200|NCT02775006|DRUG|Erlotinib|150mg/day
223991201|NCT02325583|DRUG|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
223991202|NCT02325583|DRUG|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
223991203|NCT06000891|DRUG|ZP7570|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
223991204|NCT06000891|DRUG|Placebo|13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
223991205|NCT07031180|OTHER|educational video|"The experimental educational intervention will consist of professional video recordings that will cover the following topics:~1. Disease knowledge (VLU)~2. Medication management~3. The importance of compression therapy~4. Diet and physical activity The video recordings' contents will result from a review of the literature and guidelines, which will be later reviewed by a panel of experts in VLU. The video will be recorded by experienced video-maker and by a group of volunteers who will be the actors."
223991206|NCT07031180|OTHER|educational pamphlet (standard educational intervention)|The educational brochure is an educational intervention already in use at the setting involved in the study.
223991207|NCT07030218|PROCEDURE|Office hysteroscopy|In office hysteroscopy will utilize 1.9-2.9 mm hysteroscopes (primarily Bettocchi) by the technique of vaginoscopy, without anesthesia or up to level 3a analgesia, in accordance with International Consensus Statement for Recommended Terminology Describing Hysteroscopic Procedures. The choice of distension medium and hysteroscope is left to the operator's discretion. A nurse positioned at the head of the patient will record signs and symptoms of VVR/VVS.
223991208|NCT07031544|DEVICE|deep brain stimulation|Deep Brain Stimulation (DBS) involves the use of stereotactic techniques to implant microelectrodes into specific target nuclei within the brain through minimally invasive surgery. These electrodes are connected via leads to a subcutaneously implanted pulse generator, typically placed beneath the clavicle. By delivering low-intensity electrical pulses, DBS suppresses abnormal intracranial neural activity, thereby alleviating symptoms. Long-term stimulation can also induce neuroplastic changes in neural networks and neurotransmitter systems, contributing to the restoration of neurological function.
223991209|NCT07033572|PROCEDURE|Endoscopic Hemithyroidectomy with Central-Neck Dissection|Gas-less axillo-breast approach (trans-axillary + peri-areolar), carbon-dioxide-free working space, removing dominant thyroid lobe plus level VI lymph nodes; intra-operative neuromonitoring used throughout.
224121465|NCT03593967|BEHAVIORAL|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~* Week 1: Food and Play as our National Heritage~* Week 2: Our Voices, Our Singapore: Strengthening Bonds~* Week 3: Overcoming Adversities: Stories of Resilience~* Week 4: Beholding the Future: Dreams and Aspirations~* Week 5: Passing It On: The Stories We Share"
224121466|NCT03742401|PROCEDURE|Surgery|Traditional open excisional surgery
224121467|NCT03742401|DEVICE|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
224121468|NCT02297334|DEVICE|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
224121469|NCT01141634|OTHER|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
224121470|NCT04907539|DRUG|RXC004|"RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules."
223544830|NCT05908838|DRUG|Modified Banxia Xiexin Decoction|The treatment group#Modified Banxia Xiexin Decoction group#was given Modified Banxia Xiexin Decoction, 2 bags each time, 2 times a day, and 1 hour after meals. The control group(chemotherapy group)#Chemotherapy regimen was based on the Chinese Clinical Oncology Association Guidelines for the Diagnosis and Treatment of Gastric Cancer (2018), including oxaliplatin +5-FU/CF, SOX regimen, XELOX regimen, and S-1 monotherapy regimen.
224121471|NCT04907539|BIOLOGICAL|Nivolumab|Nivolumab will be administered via IV infusion, 480 mg q4w.
224121472|NCT04907539|BIOLOGICAL|Denosumab|"Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic"
224121473|NCT04037670|PROCEDURE|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
224121474|NCT04200677|OTHER|Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
223991210|NCT07033572|PROCEDURE|Ultrasound-Guided Radiofrequency Ablation of Contralateral Nodule|17-gauge internally-cooled electrode, 0.7 cm active tip, power 40 W; moving-shot technique under real-time ultrasound until hyperechoic halo fully covers ≤ 7 mm papillary microcarcinoma ≥ 2 mm from posterior capsule; same anesthesia session as surgery.
223991211|NCT06710899|DRUG|Methenamine Hippurate 1g BD|Methenamine Hippurate 1g BD for 6 months
223991212|NCT06710899|DRUG|Methenamine Hippurate 1g BD + Vitamin C 1g BD|Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
223991213|NCT06882720|BEHAVIORAL|Exercise|Cardiorespiratory exercises include walking at a normal pace for 30 minutes three times a week, or three 10-minute sessions. The resistance exercises involve five leg muscle strengthening exercises, including knee extensors, knee flexors, hip adductors, ankle plantar flexors, and ankle dorsolflexors, performed 8-10 times, 1-2 sets, 3 times a week, with 1 day intervals in between. Balance training includes 12 exercises such as kneeling, walking backwards, walking and turning, walking sideways, tandem standing (heel-toe standing), tandem walking (heel-toe walking), standing on one leg, walking on the heel, and walking on the tip of the foot. Only 1 set of 1 exercise, 3 times a week, 1 day interval in between. Add 4 upper body strength exercises and 4 lower body strength exercises to the OEP, using water bottles and elastic bands as AIDS. Each movement is completed 8-12 times, 1-3 sets, 3 times a week, 1 day apart.
223991214|NCT06881264|DRUG|HR17031 injection|HR17031 injection
223991215|NCT06881264|DRUG|insulin glargine|insulin glargine
223991216|NCT06719986|DRUG|Nalmefene HCl injection|Nalmefene Hydrochloride injection 1.5 mg for intramuscular (IM) administration
223991217|NCT06719986|DRUG|Naloxone HCl intranasal|Naloxone 4 mg for intranasal (IN) administration
223991218|NCT07039864|DIAGNOSTIC_TEST|protein bar first|Take protein bar(after one week fried eggs intake) to evaluate the size of the gallbladder with ultrasound
223991219|NCT07039864|DIAGNOSTIC_TEST|fried eggs first|Take fried eggs (after one week protein bar intake) to evaluate the size of the gallbladder with ultrasound
224121475|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
223991220|NCT06726408|OTHER|Neuromonitoring with 10 electrodes|"In case of no parental objection, the clinician may begin neuromonitoring according to standard indications. The number of electrodes applied to the child's skull will be 10 electrodes (8 recording electrodes, 1 reference electrode, and 1 ground electrode) instead of the current 5.~The intensivist will analyze the quantitative EEG trace as they currently do but will also have access to additional tools for seizure detection support (CDSA and seizure detection software) and targeted review of part of the recording by a neurophysiologist in case of doubt. Access to the neurophysiologist will be available during current working hours on weekdays. Data will be collected in 12-hour periods."
223991221|NCT05944614|OTHER|Magnetic Resonance imaging (MRI) examination|3D CINE and 4 dimensional (4D) flow MRI sequence
223991222|NCT06915285|DIAGNOSTIC_TEST|Automated software for malarial retinopathy detection|"ASPIRE mobile application (App) software is intended to perform computer-aided detection of malarial retinopathy (MR) in digital retinal images of clinically diagnosed cerebral malaria (CM) patients under 21 years of age, to be used by a healthcare provider (user) with basic training, in primary care settings such as healthcare clinics and hospitals. The mobile Application hosts a software module developed using Deep-Learning algorithms to analyze digital retinal images of diagnosed CM patients for features suggestive of malarial retinopathy. ASPIRE requires at least four adequate quality retinal images (as determined by the image quality analysis software) captured from a patient to process it for MR detection. ASPIRE outputs a screening result of Malarial retinopathy detected or Malarial retinopathy not detected to the user. ASPIRE software is designed and validated to perform at clinically acceptable sensitivity and specificity in the detection of MR."
224121476|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
223991223|NCT06728787|DEVICE|Robot-Assisted Gait Training|15 sessions of robot-assisted gait training(LOKOMAT)+ 15 session of usual treatment for a total of 30 sessions in three weeks. 45 minutes for each session.
223991224|NCT07044466|BEHAVIORAL|CBT4CBT-Buprenorphine|CBT4CBT-Buprenorphine is an evidence-based, Internet-delivered cognitive behavioral therapy program for individuals prescribed buprenorphine by a medical provider. It includes eight 30-minute modules.
223991225|NCT07045428|DRUG|68Ga-GP-01 Injection|A certain mass dose of 68Ga-GP-01 will be used in this study, and the radiation dose will be no more than, enabling all participants will receive a radiation dose of 5±2 mCi in the study.
223991226|NCT06921213|DRUG|Linezolid (LZD)|Ten day course. Oral Linezolid dosed at 10mg/kg twice a day.
223991227|NCT06921213|DRUG|Amoxicillin|Ten day course. Oral Linezolid dosed at 50mg/kg twice a day.
223991228|NCT06921213|DRUG|Benzathine Penicillin G|Single IM dose 50,000iu/kg
223991229|NCT07050316|DRUG|CBT101|"Part 1 (SAD): at the morning~* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg~* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg~* Cohort 3: 3 puffs in each nostril (total 6 puffs), total 12.6 mg~Part 2 (MAD):~* Cohort 4: 1 puff per nostril/day (total 2 puffs/day), total 4.2 mg/day (morning)~* Cohort 5: 2 puffs per nostril/day (total 4 puffs/day), total 8.4 mg/day (morning and evening)~* Cohort 6: 3 puffs per nostril/day (total 6 puffs/day), total 12.6 mg/day (morning, midday and evening)"
223991230|NCT07050316|DRUG|Placebo|"Part 1 (SAD): at the morning~* Cohort 1: 1 puff in each nostril (total 2 puffs), total 4.2 mg~* Cohort 2: 2 puffs in each nostril (total 4 puffs), total 8.4 mg~* Cohort 3: 3 puffs in each nostril (total 6 puffs), total 12.6 mg~Part 2 (MAD):~* Cohort 4: 1 puff per nostril/day (total 2 puffs/day), total 4.2 mg/day (morning)~* Cohort 5: 2 puffs per nostril/day (total 4 puffs/day), total 8.4 mg/day (morning and evening)~* Cohort 6: 3 puffs per nostril/day (total 6 puffs/day), total 12.6 mg/day (morning, midday and evening)"
224121477|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Tibial Nerve|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
224121478|NCT04200677|OTHER|Monophasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Monophasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
224121479|NCT04200677|OTHER|Biphasic current (100 Hz) with pulse width 0.5ms applied to the Triceps Surae muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
223991231|NCT07049666|DEVICE|Bag-valve mask|A BVM equipped with an oxygen reservoir, coupled with a correctly fitted oronasal mask was used.
223991232|NCT07049666|DEVICE|Noninvasive mechanical ventilation|Preoxygenation was conducted over a three-minute period using NIMV employing a properly fitted oronasal mask. This was facilitated by a mechanical ventilator operating in pressure support mode. The preoxygenation protocol entailed the administration of 100% FiO2, applying Positive End-Expiratory Pressure set at 5 cmH2O, delivering breaths at a frequency of 15 per minute, and providing a tidal volume ranging between 6 to 8 ml/kg of body weight.
224121480|NCT04200677|OTHER|Biphasic current (100 Hz) with 1ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
224121481|NCT04200677|OTHER|Biphasic current (100 Hz) with 2ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current , 100 Hz, pulse duration 2 ms, Ton: 6 s, Toff: 18 s)
223991233|NCT07050602|BEHAVIORAL|Health Belief Model Nursing Intervention|Participants received a one-year health belief model nursing intervention. This included: comprehensive assessment and psychological interventions (Perceived Susceptibility); education on OSAHS risks and consequences (Perceived Severity); weekly weight/blood pressure monitoring, dietary/exercise guidance, sleep posture correction aids, and a daily health diary (Perceived Benefits); and regular phone follow-ups (2-3 times/week for 0-8 weeks post-discharge, bi-weekly up to 1 year) for support and addressing difficulties (Perceived Barriers).
223991234|NCT07050602|BEHAVIORAL|Routine Care|Participants received routine postoperative care for OSAHS for one year, including general education, dietary and exercise guidance. Post-discharge monitoring was conducted via monthly phone calls.
223991235|NCT07049471|BEHAVIORAL|Swallowing Exercise and Maneuver Program for Older Adults with Dysphagia|The intervention is a structured swallowing exercise and maneuver program designed specifically for older adults with oropharyngeal dysphagia in nursing homes. It combines four evidence-based techniques: Masako Maneuver, Chin Tuck Against Resistance (CTAR), Supraglottic Swallow, and Super-Supraglottic Swallow. The program was delivered by nurses using video-guided instructions and was conducted three times daily before meals for six weeks. Unlike interventions targeting post-stroke dysphagia, this program focuses on non-stroke-related swallowing difficulties in frail elderly populations residing in long-term care facilities.
223991236|NCT07050069|DEVICE|Transcranial Magnetic Stimulation (TMS) Device / Respiratory Training Device|Participants received group-specific interventions 5 days/week for 4 weeks.
223991237|NCT07049146|PROCEDURE|EUS-guided tissue glue/coil injection|Under linear array endoscopic ultrasound (EUS), puncture GVs with a 19G/22G needle, deploy coils, and inject 1-2ml tissue glue until blood flow in GVs disappears (or inject glue directly if coils are unsuitable). Treat moderate-to-severe esophageal varices (EVs) with band ligation during or after the procedure.
223991238|NCT07049146|PROCEDURE|BRTO|Establish vascular access via the femoral or internal jugular vein, occlude gastrorenal shunts with a balloon catheter, and inject sclerosant foam. Treat moderate-to-severe EVs with band ligation within 5 days post-procedure.
223991239|NCT07049237|BEHAVIORAL|Evidence-Based Nursing Under Quantitative Assessment Strategy (EB-NQAS)|A multifaceted nursing program using the Edmonton Symptom Assessment Scale (ESAS) for quantitative symptom assessment to guide personalized, evidence-based care plans. Interventions included tailored strategies for pain management (graded, music therapy, heat, opioids), fatigue (supervised walking, sleep optimization), nausea/vomiting prevention (prophylactic antiemetics, ginger, dietary advice), and psychological support (cognitive-behavioral therapy). Care plans were dynamically monitored and adjusted.
223991240|NCT07049237|BEHAVIORAL|Routine Nursing Care|Standard hospital oncology nursing care including health education, general psychological support (weekly 15-minute sessions), dietary guidance based on nutritional risk screening, and verbal instructions for managing common adverse effects.
223991241|NCT07046637|DEVICE|Inspiratory muscle fatigue group|The subjects will perform deep inspirations against a threshold device with varying resistances
223991242|NCT07046637|DEVICE|Inspiratory muscle warm-up group|The subjects will perform deep inspirations against a threshold device with varying resistances
223991243|NCT07045792|PROCEDURE|Body Awareness Therapy|Individuals trained for body awareness therapy.
224121482|NCT04200677|OTHER|Biphasic current (25 Hz) with 0.5ms pulse width applied to the Triceps Surae Muscle Belly|The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 25 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
224121483|NCT04616443|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
224121484|NCT04616443|BIOLOGICAL|HX008 injection|Recombinant humanized anti-PD-1 monoclonal antibody of injection
224121485|NCT03046628|DEVICE|TcPO2|
224121486|NCT03046628|DEVICE|Green laser (at 532nm) and a fast camera|
224294731|NCT06927791|OTHER|Machine learning based development of a diagnostic tool for acute cardiovascular disease|MALBEC will be delivered through five integrated work packages (WP) encompassing: (0) platform development and implementation, (1) data pooling, (2) model development, (3) performance comparison, (4) performance validation, and (5) platform plugin
224294732|NCT02218307|DRUG|Mupirocin|
224121487|NCT01673503|DEVICE|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
224294733|NCT02218307|DRUG|Placebo|
224294734|NCT02332980|DRUG|Ibrutinib|Given PO
224294735|NCT02332980|DRUG|Idelalisib|Given PO
224121488|NCT01710111|DEVICE|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
224121489|NCT00510224|DRUG|Sandostatin|Sandostatin 30mg intramuscular every 28 days
224121490|NCT00051558|DRUG|Teriparatide|20 micrograms/day, injection, 36 months
224294736|NCT02332980|OTHER|Laboratory Biomarker Analysis|Correlative studies
224121491|NCT00051558|DRUG|Alendronate Sodium|10 mg/day, oral, 36 months
224294737|NCT02332980|BIOLOGICAL|Pembrolizumab|Given IV
224294738|NCT06857240|DRUG|Ruxolitinib Topical Cream|1.5% cream
224294739|NCT05693142|GENETIC|RGX-202|RGX-202 is a recombinant AAV8 containing a transgene encoding a novel microdystrophin
224294740|NCT00554320|PROCEDURE|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
223991244|NCT07049913|DEVICE|Gore® TAG® Thoracic Aortic Branch Stent Graft System|Patients who attempted implant of TBE in Zone 2 during the enrollment period of this surveillance.
223991245|NCT07050888|DIETARY_SUPPLEMENT|Inulin (prebiotic, fermentable fiber)|inulin (prebiotic, fermentable fiber)
223991246|NCT07050888|DIETARY_SUPPLEMENT|Placebo|placebo (matodextrin)
223991247|NCT06421155|OTHER|MRF with neurocognative studies|Magnetic Resonance Imaging is used to assess the risk of neurocognitive side effects in pediatric and AYA patients with acute leukemia receiving chemotherapy and participants will also be asked to complete a neurocognitive battery designed by Cogstate and administered on iPad in a simple gaming format
223991248|NCT06743321|BEHAVIORAL|Speech-to-speech Voice-Cloning Care (SVCC)|After patients in the intervention group were transferred to the ICU, the SVCC intervention was initiated. It is administered three times daily: in the morning, at noon, and in the evening. The SVCC intervention includes three types of activities: awakening, reassurance, and preparatory exercises for the removal of the endotracheal tube (ETT). Before each intervention is carried out, the clinical status of the participants must be assessed to determine whether they are suitable for SVCC and to decide on the specific content of the intervention. Once the removal of the ETT is implemented, the SVCC intervention will no longer be carried out.
223991249|NCT04165746|OTHER|Foster Care|"Upon entry into the Child Protection System, if the child is assigned to one of the districts participating in the RCT, the court will notify the study team. Children that have been randomly assigned to Foster Care will be placed in a foster home within 48 hours of referral to the Family Court/Child Protection System.~Children and Foster Parents will receive biweekly visits from Social Workers. Children and Foster parents will also participate in the caregiving intervention described below. Children will remain in the placement until such time as the social workers, psychologists and Family Court Judge determine that one of the following outcomes is appropriate: reunification with biological family or adoption."
224121492|NCT00051558|DRUG|Placebo|Oral placebo, daily, 36 months
224121493|NCT00051558|DRUG|Placebo|Injection placebo, daily, 36 months
224121494|NCT04936724|OTHER|Pictorial Warning Labels|Participants will be randomized to one of two conditions and will view 4 pictorial warning labels from the assigned group for an eye-tracking task.
224121495|NCT02647762|DRUG|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
224121496|NCT02647762|DRUG|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
224121497|NCT02647762|DRUG|Placebo|Placebo tablets, 1mg BID for 12 weeks
224121498|NCT02647762|DRUG|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
224121499|NCT04798261|DEVICE|Indigo Aspiration System|Indigo Aspiration System
224121500|NCT01808118|BIOLOGICAL|adalimumab|40 mg every other week
224121501|NCT01808118|BIOLOGICAL|Placebo|every other week
224121502|NCT03539172|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
224121503|NCT03217617|BIOLOGICAL|Direct intravenous injection of ivlv-X1 lentiviral vector|ivlv-X1 LV intravenous injection at a dose of \~1x10e9/kg body weight.
224121504|NCT01768598|OTHER|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
223991250|NCT04165746|BEHAVIORAL|Caregiving Intervention|During AVI an intervenor meets with a caregiver (foster parent or caregiver at the institution) and child in the home environment. During each session, the intervenor videotapes the caregiver and child doing play-based activities. During that meeting, the intervenor reviews the videos with the caregiver and provides positive, constructive feedback to the caregiver. AVI is aimed at increasing sensitivity in parents/caregivers in order to encourage positive interactions. The guiding principles are to create a positive environment and to convey that the caregiver is the expert on their own child. The AVI methodology was selected to be used as a method of caregiving intervention with the study participants due to its demonstrated results in its use with children in contexts of social vulnerability, as well as families included in the child protection system. This will be the first time that AVI is being used in foster and institutional care in Brazil.
224121505|NCT01768598|OTHER|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
224121506|NCT01768598|OTHER|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
224121507|NCT01768598|OTHER|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
224121508|NCT01244334|DRUG|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
224121509|NCT01244334|DRUG|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
224121510|NCT02752425|DEVICE|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
224121511|NCT04376333|BEHAVIORAL|Cognitive-Behavioral Treatment|Cognitive-behavioral coping skills training
224121512|NCT04376333|BEHAVIORAL|Individualized Assessment and Treatment Program|Experience-sampling based cognitive behavioral coping skills assessment and training
224121513|NCT04376333|OTHER|Standard Conservative Care|Standard conservative dental care for orofacial pain
224121514|NCT01224353|DRUG|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
224121515|NCT01224353|OTHER|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
224121516|NCT05170893|DIETARY_SUPPLEMENT|Coenzyme Q10|Oral capsules
224121517|NCT05170893|OTHER|Placebo|Oral capsules
224121518|NCT00377065|DRUG|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
224121519|NCT06960252|DEVICE|OPTRELL™ Mapping Catheter|PVI plus substrate modification of LA chamber coexisting with low unipolar voltage (\< 3.0 mv) or bipolar voltage (\< 0.5 mv) in SR and stable (STD \< 30), fast AF CL detected by CLM module and OPTRELL™ Mapping Catheter.
224121520|NCT03406338|PROCEDURE|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
224121521|NCT03406338|DRUG|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
224121522|NCT06837480|DEVICE|LTU-904 Portable Laser Therapy Unit (active laser device)|The RianCorp LTU-904 laser therapy unit (active laser device) will be used for photobiomodulation therapy (PBMT).
224121523|NCT06837480|DEVICE|LTU-904 Portable Laser Therapy Unit (sham/inactive laser device)|The RianCorp LTU-904 laser therapy (sham/inactive laser device) unit will be used for sham therapy.
224121524|NCT03301766|DRUG|lidocaine 5% patch|transdermal patch
224121525|NCT03301766|DRUG|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
224121526|NCT03301766|DRUG|Non-medicated patch|non-medicated patch
224121527|NCT05008913|DRUG|[14C]Adavosertib|Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.
224121528|NCT03165513|BEHAVIORAL|mhGAP-IG|psychosocial interventions
224121529|NCT05197595|BEHAVIORAL|Attachment-based compassion therapy|Compassion program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
223544831|NCT05908838|DRUG|combination chemotherapy with Placebo granules|combination chemotherapy with Placebo granules
224121530|NCT05197595|BEHAVIORAL|Relaxation program|Relaxation program consists of 6 sessions of 90 minutes/session (15-20 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
224121531|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|
224121532|NCT01864642|PROCEDURE|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
224121533|NCT04738513|PROCEDURE|Vertical preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
224121534|NCT04738513|PROCEDURE|Conventional Preparation technique|Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
224121535|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
223991251|NCT02600897|DRUG|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
223991252|NCT02600897|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
223991253|NCT02600897|DRUG|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
223991254|NCT02600897|DRUG|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m\^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m\^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
223991255|NCT01945814|DRUG|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
223991256|NCT01945814|DRUG|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
223991257|NCT05203471|OTHER|integrated care model|The investigators are piloting an integrated care model for rural patients with diabetic foot ulcers. The model uses two tools to promote collaboration between providers: a care algorithm and a referral checklist. The care algorithm will be used by rural primary care providers to guide integrated care addressing glycemic control, vascular disease, wound care, and infection. The referral checklist will be used by rural schedulers who place referrals to urban specialists. It prompts schedulers to fax appropriate supporting documents (e.g. notes, labs, vascular testing results) with the referral request.
223991258|NCT06804213|BEHAVIORAL|Mobile health app with positive psychological activities|Mobile health app with step tracking, sleep tracking, and positive psychological activities
223991259|NCT03377517|RADIATION|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
223991260|NCT06823765|OTHER|Large Language Model Clinical Decision Support|A Large Language Model (LLM) integrated into the clinic's Electronic Medical Record system provides real-time feedback on patient assessments. Community Health Extension Workers first create a standard SOAP note, submit it to the LLM, and receive detailed feedback and key recommendations. They can then update their assessment based on this feedback. All final treatment decisions are made by Medical Officers who independently evaluate patients.
224121536|NCT05942651|DEVICE|Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals|The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
223991261|NCT06898476|DIETARY_SUPPLEMENT|Silkworm pupa powder|Silkworm pupa powder, 2 times a day, two packets (12\*2 g) each time, take with warm water, before meals, for three months
223991262|NCT06898476|DIETARY_SUPPLEMENT|Placebo|Placebo, 2 sachets (12\*2 g) twice a day, with warm water, before meals, for three months
224121537|NCT06831838|BEHAVIORAL|Cognitive Behavioral Therapy based Pain Management Program|Subjects will participate in a two-day structured class that will focus on Cognitive-Behavioral skills and strategies to improve pain control, fatigue, sleep disturbance, cognitive symptoms, and stress while educating patients on the efficacy of Aromatase Inhibitors in prolonging cancer-free survival with the goal of eliminating non-adherence.
224121538|NCT03997539|DRUG|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
224294741|NCT00554320|PROCEDURE|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
224294742|NCT06916806|DRUG|AZD5492|IMP: subcutaneous.
224294743|NCT07140614|DRUG|EDK060, dose A|EDK060, dose A, Single dose, IV infusion
224294744|NCT07140614|DRUG|EDK060, dose B|EDK060, dose B, Single dose, IV infusion
223991263|NCT04550676|BEHAVIORAL|HIIT (intervention)|Following a 5-minute warm-up, high and moderate-intensity exercise bouts will alternate: a five bouts of 4-minute high-intensity exercise (90% VO2peak) will alternate with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8. This is followed by a 5-minute cool-down. The total exercise time will be 42 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
224294745|NCT07140614|DRUG|EDK060, dose C|EDK060, dose C, Single dose, IV infusion
224294746|NCT07140614|DRUG|EDK060, dose D|EDK060, dose D, Single dose, IV infusion
224294747|NCT07140614|OTHER|Placebo|Placebo
224294748|NCT04818034|DRUG|Dapagliflozin|Dapagliflozin is to lower blood sugar levels in adults with type 2 diabetes.
223991264|NCT04550676|BEHAVIORAL|CME (active control)|Following a 4-minute warm-up, the participant will walk/jog for up to 42 continuous minutes at 60% VO2peak. This is followed by a 4-minute cool-down. The total exercise time is 50 minutes. For resistance exercise, the initial goal will be to complete 3 sets of 8-10 repetitions of 3 exercises at low intensity (50% 1-RM) and then progress to moderate intensity (70-80% 1-RM). Exercise intensity will increase every 4 weeks or when participants can complete more than 8 repetitions with proper form at the prescribed weight.
223991265|NCT06816264|DRUG|HRS-5346|HRS-5346
223991266|NCT06816264|DRUG|Placebo|Placebo
223991267|NCT04802161|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223991268|NCT04802161|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspirate and biopsy
223991269|NCT04802161|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223991270|NCT04802161|DRUG|Pomalidomide|Given PO
223991271|NCT02919280|OTHER|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,500 participants. There is no medication or non-medication treatment or intervention provided by this study.
223991272|NCT06903741|DEVICE|T2769|Preservative-free combination of trehalose, sodium hyaluronate and N-acetyl-aspartyl-glutamate
223991273|NCT06906783|PROCEDURE|Transtibial Pull Out Method|The Transtibial Pull-Out Repair is a surgical technique used to fix posterior root tears of the meniscus, particularly in the medial meniscus. This method restores the hoop stress mechanism of the meniscus, which is essential for knee stability and function.
223991274|NCT06906783|PROCEDURE|Suture Anchor Method|The Suture Anchor Technique is an alternative to the Transtibial Pull-Out Method for repairing posterior meniscal root tears, especially in the medial meniscus. Instead of using a tibial tunnel, this technique fixes the meniscal root directly to the native footprint using suture anchors.
224294749|NCT01795742|DEVICE|Human-Powered Nebulizer|
223991275|NCT06817967|DEVICE|PSNS|The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
223991276|NCT06817967|DEVICE|ISNS|The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
224121539|NCT03997539|DRUG|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
224121540|NCT03997539|DRUG|vinorelbine|vinorelbine
224121541|NCT01230671|OTHER|Yoga|A 12 week yoga session will be offered to women with breast cancer.
224121542|NCT05699746|DRUG|Capecitabine tablets|Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.
224294750|NCT04075552|BEHAVIORAL|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
223991277|NCT06913140|DRUG|Erector Spinae plane Block|Patients received (20ml) plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath at the level of the second thoracic segment (T2)
223991278|NCT06913140|DRUG|Costoclavicular block|Patients received (20ml) plain bupivacaine 0.25% injected in the costoclavicular space lateral to axillary artery.
223991279|NCT06913140|DRUG|Control group|Patients received sham block
224121543|NCT05699746|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
224121544|NCT02455791|PROCEDURE|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
224121545|NCT00290576|DIETARY_SUPPLEMENT|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
224121546|NCT01523808|DRUG|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
224121547|NCT04257162|OTHER|Tumor and Blood sample collection|"This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study"
224121548|NCT02794051|BEHAVIORAL|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
224121549|NCT00390000|DRUG|vatalanib|Given orally
224121550|NCT00390000|DRUG|pemetrexed disodium|Given IV
224121551|NCT00390000|OTHER|pharmacological study|Correlative study
224121552|NCT00390000|PROCEDURE|ultrasound imaging|Correlative study
224121553|NCT03834129|DRUG|Dexmedetomidine|Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
224121554|NCT03834129|DRUG|sodium chloride 0.9%|Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
224121555|NCT06721338|DEVICE|Mechanical thrombectomy via blood flow reversal using BOBBY balloon guide catheter|After 2 min. of mechanical thrombectomy (MT), the side port of a BOBBY balloon guide catheter will be flushed again with heparin and the balloon deflated. A follow up angiogram will be performed to determine whether to proceed with another MT pass using the same procedure or to stop if successful recanalization has been achieved. At the end of the procedure, multiple angiograms will be performed and used to record the final TICI score. Angiograms of neck vessels will be used to rule out complications. Groin angiograms will evaluate the puncture site before closure. The catheters will then be removed, allowing hemostasis to be achieved in the groin. An angioseal closure device will be used on the arterial site if not contraindicated and a venous Vascade for the venous side.
224121556|NCT04753203|DRUG|Alpelisib plus Capecitabine combination|Adding Alpelisib to Capecitabine as a salvage regimen in mCRC with PIK3CA mutation
223544832|NCT01060787|PROCEDURE|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
223544833|NCT01060787|PROCEDURE|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
223544834|NCT03734822|OTHER|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
223544835|NCT03734822|DEVICE|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
223544836|NCT03734822|DIAGNOSTIC_TEST|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
223544837|NCT03734822|DIAGNOSTIC_TEST|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
223544838|NCT02516501|DIETARY_SUPPLEMENT|MyAmino|MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
223544839|NCT02516501|DIETARY_SUPPLEMENT|betaquik|betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
223544840|NCT02516501|RADIATION|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
224121557|NCT00718419|DRUG|Enzastaurin|"Enzastaurin: Cycle 1 Day 1 only: 3, 125-milligrams (mg) tablets three times on Day 1 (Day 1 total dose = 1125 mg)~Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally twice a day (500 mg total per day).~Cycle length (all cycles): 28 days. Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression."
223991280|NCT06871904|DRUG|Metformin Hydrochloride 500Mg Tablet|"Metformin 500 mg is being tested for its potential role in treating oral submucous fibrosis (OSF) due to its antifibrotic and anti-inflammatory effects. This intervention will be administered orally at a dose of 500 mg twice daily (OD) for a specified 6 months treatment period for Group 2 .~Metformin activates AMPK (AMP-activated protein kinase), which inhibits TGF-β signaling and collagen deposition, reducing fibrosis and inflammation.~Distinction from Other Arms: Unlike Pirfenidone, which directly targets profibrotic cytokines, Metformin modulates metabolic pathways to exert antifibrotic effects. The Control Group will receive supportive care for OSF."
223991281|NCT06871904|DRUG|Pirfenidone (PFD)|"Pirfenidone 200 mg (Pirfibet by Mactor Pharma, Pakistan) is an antifibrotic drug being tested for its potential role in treating oral submucous fibrosis (OSF). This intervention will be administered orally at a dose of 200 mg, twice daily for a specified treatment period which will be 6 months for Group 3 .~Pirfenidone modulates fibrotic pathways by inhibiting TGF-β and collagen synthesis, reducing fibrosis progression.~Distinction from Other Arms: Unlike Metformin, which has antifibrotic effects via AMPK activation, Pirfenidone specifically targets profibrotic cytokines. The Control Group will receive either a supportive care for OSF"
223991282|NCT06871904|DRUG|Beclomaethasone and Vitamin E|"The Supportive Care Group will receive Beclomethasone mouthwash (three times daily) and Vitamin E 400 mg (once daily) as part of supportive care for oral submucous fibrosis . This intervention serves as a comparison group to evaluate the efficacy of Metformin and Pirfenidone.~Beclomethasone is a topical corticosteroid that reduces inflammation and provides symptomatic relief in OSF.~Vitamin E is an antioxidant that may help reduce oxidative stress and improve tissue healing.~Distinction from Other Arms:~Unlike Pirfenidone and Metformin, which target fibrosis at the molecular level, Beclomethasone + Vitamin E primarily focus on symptom relief.~This arm will serve as an active comparator to determine whether the antifibrotic effects of Metformin and Pirfenidone provide superior therapeutic benefits."
223991283|NCT06848335|BEHAVIORAL|Remote Physical Activity Intervention|The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6, with maintenance doses in months 8 and 10. Mailings include motivation-matched physical activity manuals, tip sheets (on stretching, boredom, places to be active, etc.) and computer expert system-tailored PA feedback reports which draw from a bank of over 330 messages addressing psychosocial and environmental factors affecting PA. Participants receive one interactive text message on PA (goal setting and tips for increasing PA) daily for the first 6 months and weekly for months 7-12.
224121558|NCT00771407|DEVICE|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
224121559|NCT00771407|OTHER|Standard ostomy creation|Ostomy will be created as routinely performed
224121560|NCT02076555|BEHAVIORAL|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
224121561|NCT01037504|DRUG|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
224121562|NCT01037504|DRUG|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
224121563|NCT03545724|DEVICE|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
224121564|NCT00000567|PROCEDURE|high-frequency ventilation|
223544841|NCT02251496|OTHER|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
224121565|NCT00878163|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
224121566|NCT00878163|DRUG|Erlotinib Hydrochloride|Given PO
224121567|NCT00878163|DRUG|Gemcitabine Hydrochloride|Given IV
224121568|NCT00878163|DRUG|Vismodegib|Given PO
224121569|NCT03417011|DEVICE|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
224121570|NCT06452537|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, with oral prednisone.
224121571|NCT06452537|DRUG|Prednisone|Prednisone tapering protocol : If the starting dose is over 20mg/day, then reduce by one tablet weekly. Until the dose is reduced to 20mg/day then 20mg/day for two weeks→17.5mg/day for two weeks→12.5mg for four weeks→10mg for four weeks→7.5mg as a maintain dosage
224121572|NCT04628728|OTHER|Survey based on questionnaire (self-designed)|Participants are handed a questionnaire to asses comprehension of medical content provided in the referral letters.
224121573|NCT04378023|DRUG|Neoadjuvant Chemo-radiotherapy|Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
224121574|NCT04378023|PROCEDURE|Liver Transplantation|If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
224121575|NCT06187402|DRUG|LM-24C5|Administered intravenously
224121576|NCT06847022|PROCEDURE|US-guided transversalis fascia plane block|US-guided bilateral transversalis fascia plane block, using Sonotap 110 mm and 0.25% bupivacaine 20 ml on each side, will be done after wound closure.
224121577|NCT01072097|DRUG|Atorvastatin|Atorvastatin 20mg/day for 6 months
224121578|NCT01072097|DRUG|Placebo|Placebo for 6 months
224121579|NCT04263285|DEVICE|rTMS|The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.
224121580|NCT05438875|DRUG|all-trans retinoic acid|ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.
224121581|NCT05438875|DRUG|Eltrombopag|The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
224121582|NCT06138431|BEHAVIORAL|CBT|Virtual CBT groups
224121583|NCT06422234|OTHER|Exergame|Video-based game exercises will be performed 3 days a week for 6 weeks. Participants will be taught how to play the games before starting the game called Ring Fit Adventure, one of the Nintendo Switch games. Among the games within Ring Fit, games that aim to increase lower extremity muscle strength, core stabilization and balance have been selected, and game types and number of repetitions are changed every week.
223991284|NCT06848335|BEHAVIORAL|Mindfulness Enhanced Remote Physical Activity Intervention|Women who do not meet the PA guidelines (60% based on our prior work), will be randomized to receive the Attention Matched Enhanced Remote PA intervention or Mindfulness enhanced remote Physical Activity intervention. The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6. In months 7-12, they will receive 4 monthly calls, 11 mailers and daily texts. In months 13-18, they will receive 1 call, weekly texts to self monitor daily PA and meeting goals. For the Mindfulness enhanced remote Physical Activity intervention participants will receive additional messaging and support to manage their stress through incorporating evidence based MBSR and mindful movement into their daily routine.
224121584|NCT06422234|OTHER|Game-free Exercise|All activities in the exergame group were done without games and screens. The progression of the exercises proceeds in the same way as the other group.
224121585|NCT05902741|BEHAVIORAL|RiSE|RiSE provides participants with a platform to share the emotional impact of race-based stress and to offer supportive listening to their peers. Participants explicitly discuss the experiences they have as African American women, taking into account the ways which the interaction between their racial and gender identities shapes their experiences. Facilitators review difficulties associated with addressing racism and unique experiences of Black women at interpersonal and structural levels, and provide evidence of strategies to promote effective communication and internal emotional regulation regarding experiences of racism. Facilitators provide psychoeducation on intersectionality, structural racism, overt racism, microaggressions, and internalized racism. Following this education, facilitators help participants utilize cognitive-behavioral strategies to understand consequent thoughts, feelings, and actions associated with such experiences.
224121586|NCT05902741|BEHAVIORAL|HEP|The HEP group will consist of classes focusing on wellness promotion. Expert speakers provide the HEP classes (e.g dietician, pharmacist).
224121587|NCT01480154|DRUG|Akt Inhibitor MK2206|Given PO
224121588|NCT01480154|DRUG|Hydroxychloroquine|Given PO
224121589|NCT01764178|DRUG|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
224121590|NCT01764178|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
224121591|NCT01660971|DRUG|Dasatinib|Given PO
224121592|NCT01660971|DRUG|Erlotinib Hydrochloride|Given PO
224121593|NCT01660971|DRUG|Gemcitabine Hydrochloride|Given IV
224121594|NCT04869579|DRUG|Selenium (as Selenious Acid)|Interventional arm participants will receive Selenium as Selenious Acid infusion plus the standard of care therapy.
224121595|NCT04869579|OTHER|Placebo|Active comparator arm participants will receive the standard of care therapy plus a Saline-based placebo.
224121596|NCT04793672|OTHER|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.|Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
224121597|NCT01837147|BEHAVIORAL|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
224121598|NCT01837147|BEHAVIORAL|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
224294751|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
223729087|NCT03149198|OTHER|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
223991285|NCT06848335|BEHAVIORAL|Attention Matched Enhanced Remote PA intervention|Women who do not meet the PA guidelines (60% based on our prior work), will be randomized to receive the Mindfulness enhanced remote Physical Activity intervention or the Attention Matched Enhanced Remote PA intervention as described here. The intervention includes a Zoom goal setting session on PA at baseline and phone calls at week 1, and months 1, 2, 3, and 9 for new goal setting and to address questions and monitor progress on PA goals. Participants will receive mailings weekly in month 1, bi- weekly in months 2 and 3, and monthly in months 4 to 6. In months 7-12, they will receive 4 monthly calls, 11 mailers and daily texts. In months 13-18, they will receive 1 call, weekly texts to self monitor daily PA and meeting goals.
223991286|NCT06945471|BEHAVIORAL|1) Face-to-face, and 2) Computer-mediated motivational type interviews|
223991287|NCT06944093|BEHAVIORAL|audio book|Listen to a audio book
224121599|NCT03764215|DRUG|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
224121600|NCT00676273|DEVICE|TVT-Obturator (TVT-O)|sub urethral sling
224121601|NCT00676273|DEVICE|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
224121602|NCT01984541|BIOLOGICAL|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
223991288|NCT06944405|DEVICE|Mechanocardiography|Using mechanocardiography for the detection of signs of heart failure.
223991289|NCT06944730|BEHAVIORAL|Structural Exercise|Multi-joint limb movement with force vector through the spine. The spine is held at neutral position
223991290|NCT06944730|BEHAVIORAL|Isolated Trunk Exercise|Holding the spine in neutral position with no limb movement, with static loading through the spine
223991291|NCT06944730|BEHAVIORAL|Back school|Patient education that has been proven to not be effective and has been used as control in past low back pain intervention studies
224121603|NCT02742870|OTHER|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
224121604|NCT01002534|DRUG|Vardenafil|Nasal instillation of Vardenafil
224121605|NCT01002534|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
223544842|NCT02251496|OTHER|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
223991292|NCT06944665|DEVICE|Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture theory|Based on the theory of wrist and ankle needles, transcutaneous electrical nerve stimulation is a kind of analgesic treatment device that combines wrist and ankle needles with transcutaneous electrical nerve stimulation, and can be worn on the human wrist and ankle. Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture Theory uses low-frequency electronic pulses to stimulate the entry point of the wrist-ankle needle, which has the advantages of easy to wear, concentration of the treatment site, safety of the treatment, and no needles.
223991293|NCT06945822|OTHER|Blood sample|"For febrile patients with confirmed (group 1) or refuted (group 2) diagnosis of leptospirosis:~\- At D0, D1, D3 and D15 a 20-ml blood sample~For healthy patients (group 3):~\- At D0 and D15: a 20-ml blood sample"
223991294|NCT06945822|OTHER|Urine Sample|For all participants, a 5-ml urine sample at D0
224294752|NCT04075552|BEHAVIORAL|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
223991295|NCT06944587|DRUG|Chemotherapy|The choice of chemotherapy regimen follows national guidelines, preferably mFOLFIRINOX or gemcitabine-nab-paclitaxel.
223991296|NCT06944587|DIAGNOSTIC_TEST|Radiology|PET/CT is optional. PET/CT will be offered as a part of the diagnostic work up at baseline and one additional scan after a minimum of two months of chemotherapy.
223991297|NCT06944587|PROCEDURE|Pancreatectomy|Surgery is scheduled within 4 weeks after the last neoadjuvant infusion. Resection will be performed as a standard or pylorus-preserving pancreatoduodenectomy (PD), distal pancreatectomy (DP) with splenectomy, or total pancreatectomy (TP) with splenectomy, and with or without venous or arterial resection and reconstruction.
224121606|NCT06241599|DRUG|GP/PFLL+AK104|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks)."
224121607|NCT06241599|DRUG|GP/PFLL+placebo|"Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks)."
224121608|NCT03957109|PROCEDURE|general anesthesia|
224121609|NCT05662137|BEHAVIORAL|Emotions Recognition and Expression|Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
224294753|NCT06944522|BIOLOGICAL|bemdaneprocel|Investigational cell therapy comprising midbrain dopaminergic neuron progenitors derived from human embryonic stem cells
223544843|NCT02784392|DRUG|Ulimorelin|Active
223991298|NCT06944587|PROCEDURE|Endoscopy|Endoscopic ultrasound fine-needle biopsy to establish the diagnosis with histopathology and to obtain an adequate sample for molecular pathology (KRAS status (mutation or wild type), microsatellite instability (MSI)).
223991299|NCT06945497|BEHAVIORAL|Art Therapy|The art therapy program will include different weekly experientials to explore mindfulness, establish safety, cultivate relaxation, find strength, honor self-identity, and cultivate community. Art media will include markers, colored pencils, fabrics, watercolors, collage, and yarn.
223991300|NCT06945497|BEHAVIORAL|Yoga/Mindfulness|The yoga/mindfulness curriculum will explore consciousness (awareness of self and others), compassion, confidence, courage, and community. Each week, new movement and breathing exercises will be learned.
223991301|NCT06944847|BEHAVIORAL|Acute (24-hour) abstinence|Participants will be asked to abstain from all tobacco/nicotine for 24 hours prior to the visit
223991302|NCT06944847|BEHAVIORAL|Ad libitum smoking/vaping|Participants will be asked to smoke/vape as usual during the 24 hours prior to the visit
224121610|NCT05960188|BEHAVIORAL|AI Opinion|For each case, we give the radiologist a numeric score reflecting the AI's rating of the abnormality of the case.
224294754|NCT06944522|PROCEDURE|Sham surgery|Sham surgery will be performed on Day 0
224294755|NCT07139132|BEHAVIORAL|Health Wellness Coaching|Health wellness coach will provide education and guidance about cultural nutrition
224294756|NCT07139132|DIAGNOSTIC_TEST|Carotid ultrasound|Participants will undergo an ultrasound
224294757|NCT07139132|BEHAVIORAL|School-age nutritional education program|Educational program will teach students about healthy Native American food choices
224294758|NCT07139132|DIAGNOSTIC_TEST|Cognitive Testing|Participants will undergo a cognitive test.
224294759|NCT07139132|DIAGNOSTIC_TEST|Blood work|Participants will undergo blood work.
223544844|NCT02784392|DRUG|Metoclopramide|Comparator
224294760|NCT07142291|DRUG|Cromolyn Sodium (34.2 mg BID)|17.1 mg, BID, oral inhalation
224294761|NCT07142291|DRUG|Cromolyn Sodium (17.1 mg BID)|34.2 mg, BID, oral inhalation via dry powder inhaler
224121611|NCT05566678|OTHER|Cigarette|Subjects who self-selected to continue smoking their own preferred brand of commercially available cigarettes.
224294762|NCT07142291|DRUG|Placebo|Placebo comparator matched to active treatment.
224294763|NCT07142291|DRUG|Riluzole (100 mg)|50 mg, oral tablet, BID, standard of care treatment
224294764|NCT00603291|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
224121612|NCT05566678|OTHER|THS|Subjects who self-selected to quit smoking during the study duration will switch from cigarettes to using THS.
224121613|NCT05566678|OTHER|Smoking Abstinence|Subjects who self-selected to quit smoking may be prescribed Nicotine Replacement Therapy (NRT) to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
224121614|NCT00520195|BEHAVIORAL|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
224121615|NCT04358094|OTHER|Conversational hypnosis script|Conversational hypnosis during peripherical veinous catheter set up
224121616|NCT04358094|OTHER|Standard script|Standard script during peripherical veinous catheter set up
224121617|NCT02528500|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
224121618|NCT02446730|DEVICE|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
224121619|NCT02446730|DRUG|Prasugel|
224121620|NCT02446730|DRUG|Clopidogrel|
224121621|NCT02196194|DRUG|Tiotropium|
223991303|NCT06944938|PROCEDURE|Non-Surgical Periodontal Treatment|Participants in this arm received standard non-surgical periodontal treatment, including scaling and root planing, without any additional supplementation or dietary modification.
223991304|NCT06944938|DIETARY_SUPPLEMENT|Probiotic Supplementation|Participants in this arm received standard periodontal treatment along with a daily probiotic supplement (1 capsule/day, containing 10⁹ CFU of Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis) for six consecutive weeks.
223991305|NCT06944938|OTHER|Probiotic Supplementation + Personalized Diet|Participants in this arm received standard periodontal treatment, the same probiotic protocol as the probiotic group, and a personalized anti-inflammatory diet. The diet was developed by a clinical dietitian and emphasized high-fiber, antioxidant-rich, and prebiotic foods. Consumption of refined carbohydrates, added sugars, and trans fats was restricted.
223991306|NCT06945081|OTHER|Preparation of forearm molds with SILFLO® silicone|Preparation of forearm molds with SILFLO® silicone (MONADERM, Monaco), CE-marked and already used routinely in dermocosmetics. These molds will, then, be analyzed.
223991307|NCT00903071|BEHAVIORAL|Real PPL|See above arm description
224121622|NCT00788515|DRUG|Volinanserin (M100907)|2 mg tablets QD
224121623|NCT00788515|DRUG|Lormetazepam|1 mg tablets (overencapsulated) QD
224121624|NCT06014554|OTHER|Low-risk subgroup|Self-managed exercise programme.
224121625|NCT06014554|OTHER|Medium-risk subgroup|Education, goal-orientated mobility programme, and enhanced discharge planning.
223991308|NCT00903071|BEHAVIORAL|Sim PPL|See above arm description
224121626|NCT06014554|OTHER|High-risk subgroup|Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.
224121627|NCT06014554|OTHER|Control group|Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
224294765|NCT00603291|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
224294766|NCT00603291|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
224294767|NCT00261963|DEVICE|ultraviolet light|
224294768|NCT07166094|DRUG|Rina-S|Intravenous (IV) infusion.
224294769|NCT07166094|DRUG|IC|"* Paclitaxel: IV infusion~* Doxorubicin: IV bolus injection/infusion"
223991309|NCT05350969|DRUG|CDR132L|CDR132L is a synthetic antisense oligonucleotide (ASO) and a selective inhibitor of microRNA-132-3p (miR-132). miR-132 in cardiomyocytes is a central switch affecting the expression of genes that are crucially involved in maladaptive cardiac remodeling, transformation, and pathological cardiac growth (hypertrophy), contributing to adverse cardiac remodeling and heart failure (HF).1-5 Aberrant expression of miR-132 in cardiac cells is causally associated with cardiac remodeling and HF progression.
223991310|NCT05350969|DRUG|Placebo to CDR132L|Placebo to CDR132L
224121628|NCT05374408|BEHAVIORAL|Aim 2: BounceBack Now (BBN) for Trauma Informed Care Deployment|"Brief explanation of BounceBack Now (BBN) will be provided. Participants will be directed to areas of the application that are congruent with treatment focus identified during their standard of care appointment.~Participants will complete a baseline survey by either going online or being contacted by a member of the investigational team. The investigative assistant will contact all participants in 2-3 days to help the participant navigate the BBN and complete the baseline survey, if needed.~The participant will continue to meet with their behavioral health provider (BHP) as determined by the standard of care interactions. BHP will highlight features contained in BBN for participant to use in between appointments.~Follow-up phone calls will be scheduled for 2 weeks and 6 weeks after initial visit. During these phone- calls the participant will be contacted by a member of the investigational team to complete follow-up surveys."
224121629|NCT05374408|BEHAVIORAL|Aim 1 Participant Focus Groups|"At the beginning of the focus group the patients will be asked to download BBN on their smartphone device with the assistance of the research team, if they have not already done so. A basic tutorial of the BBN and the developed educational materials will be conducted/reviewed with the participants.~After the tutorial and education has been provided the participants will be asked to try some of major features of the app. Then, they will be asked to review the patient education materials. They will be asked to discuss strengths and weaknesses of the materials. They will be also asked whether there is any content missing from the education material."
224294770|NCT07160725|DRUG|BMS-986517|Specified dose on specified days
224294771|NCT07172438|OTHER|P2611222|Menthol flavor
224294772|NCT07172438|OTHER|P2615022|Non-tobacco non-menthol flavor
223991311|NCT06388317|BEHAVIORAL|Adaptive Step Goal (Intervention)|Receiving automated personalized daily step goals,
223991312|NCT06388317|BEHAVIORAL|Static Step Goal (Control)|Receiving personalized static daily step goals.
223991313|NCT01340248|DRUG|Dilatrend 64mg capsule|"1. Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~2. Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
223991314|NCT02432664|DRUG|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
223991315|NCT02432664|DRUG|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
223991316|NCT02432664|DRUG|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
224294773|NCT07172438|OTHER|P2615122|Non-tobacco non-menthol flavor
224294774|NCT07172438|OTHER|P2613422|Tobacco flavor
224294775|NCT07186101|DRUG|LY4268989|Administered PO
224294776|NCT07186101|DRUG|Mirikizumab|Administered IV then SC
224294777|NCT07186101|DRUG|LY4268989 Placebo|Administered PO
224294778|NCT07211932|DRUG|Tofacitinib|Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
224294779|NCT07211893|OTHER|Send myopia-related health education message|Guardians of students in the intervention group will receive regular myopia-related health education messages, comprising text and images, from the MyopiaEd information repository via class-based WeChat groups. The intervention will last for 12 months.
224294780|NCT07212829|DEVICE|Active tDCS|tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site). For active tDCS, the current is ramped up for 30 seconds until the center electrode reaches a target intensity of 2 mA, then remains for 29 minutes before dropping for another 30s.
223544845|NCT00889707|DRUG|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
223544846|NCT00889707|DRUG|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
223991317|NCT02432664|DRUG|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
223991318|NCT02432664|DRUG|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
223991319|NCT02432664|DRUG|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
223991320|NCT02047162|DRUG|Bismuth subsalicylate|
223991321|NCT02047162|OTHER|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
223991322|NCT05656755|OTHER|Strengthening|The strengthening exercises were executed with the body weight without any additional weight and were composed of exercises like the squats, the lunges, the plank, and the mountain climbers
223991323|NCT05656755|OTHER|Running|running for two supervised training sessions of one hour, and one free session of 30 minutes per week during 24 weeks
223991324|NCT03514615|PROCEDURE|Incision|A skin incision will be made on the medial aspect of the upper arm.
224121630|NCT05374408|BEHAVIORAL|Aim 1 BHP Focus Groups|"At the beginning of the focus group the BHPs will be asked to download BBN on their smartphone device with the assistance of the research team, if they have not already done so. A basic tutorial of the BBN and the developed educational materials will be conducted/reviewed with the BHPs.~After the tutorial and education has been provided the participants will be asked to try some of major features of the app. Then, they will be asked to review the patient education materials. They will be asked to discuss strengths and weaknesses of the materials. They will be also asked whether there is any content missing from the education material."
224121631|NCT05374408|BEHAVIORAL|Aim 2: BHP, Provider, Staff and Admin Focus Groups|Semi-structured interviews will be conducted with BHPs, Clinical Staff, Providers and Administration They will ask questions to BHPs, Clinical Staff, Providers and Administration about feasibility, acceptability, and usability of BBN and overall clinical protocol.
223544847|NCT02345655|PROCEDURE|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
223991325|NCT03514615|DRUG|Active gel|The incision site on one arm will be dosed with the active gel.
223991326|NCT03514615|DRUG|Placebo gel|The incision site on the other arm will be dosed with placebo gel.
223991327|NCT03112915|PROCEDURE|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
223991328|NCT03112915|PROCEDURE|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
223991329|NCT02858453|DRUG|AQX-1125 100 mg|Synthetic SHIP1 activator
224121632|NCT05374408|BEHAVIORAL|Aim 2 : Participant Focus Group|Semi-structured interviews will be conducted with Participants to assess the feasibility, acceptability, and usability of BBN.
223544848|NCT02345655|OTHER|no test|normal procedure decided by the general practitioner
223544849|NCT03729843|RADIATION|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
223991330|NCT02858453|DRUG|AQX-1125 200 mg|Synthetic SHIP1 activator
223991331|NCT02858453|DRUG|Placebo|Appearance and weight matched placebo tablets
223991332|NCT02989090|OTHER|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
223991333|NCT02989090|OTHER|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
223991334|NCT00372736|DRUG|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
223991335|NCT00372736|DRUG|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
223991336|NCT00372736|GENETIC|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs \> 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs \> 5 x ULN1
223991337|NCT00372736|GENETIC|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
223991338|NCT00372736|OTHER|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
223991339|NCT00372736|OTHER|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
223991340|NCT00372736|OTHER|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
223991341|NCT00372736|OTHER|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
223991342|NCT06814197|BEHAVIORAL|Motivational Interviewing and Cognitive Behavioural Therapy for Procrastination|This intervention incorporates Motivational Interviewing (e.g., open-ended questions, affirmations, reflective listening, summarising) and Cognitive Behavioural Therapy (e.g., cognitive restructuring) techniques in natural conversations instead of having a fully manualised programme. This approach resembles coaching instead of traditional therapy to build therapeutic relationships naturally and keep clients engaged with genuine human connection.
223991343|NCT04398329|DRUG|HTX-034|HTX-034, low dose
223991344|NCT04398329|DRUG|HTX-034|HTX-034, high dose
224121633|NCT06534905|OTHER|E-cigarette|Each participant assigned to the e-cigarette group will given a rechargeable NJOY Ace e-cigarette that is either tobacco or mint-flavored (based on their preference). Participants will also be given disposable pods prefilled with nicotine. When the pod is empty, the participant will throw it away and replace it with a new pod provided by the study staff. Participants will be asked to use as little or as much of the e-cigarette during their study participation, including choosing not to use the product. Participants will also be given information on the relative harms of nicotine and tobacco products as recommended by the American Society of Addiction Medicine.
224121634|NCT06534905|BEHAVIORAL|Control/Standard Advice|Brief advice to quit according recommendations from the American Society of Addiction Medicine
224121635|NCT00878917|DRUG|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
224121636|NCT06960083|OTHER|Transcranial Magnetic Stimulation (TMS)|Transcranial Magnetic Stimulation (TMS) is an FDA-approved non-invasive brain stimulation technology. It is currently used for treating depression. Applications to other disorders such as OCD and anxiety using TMS are currently under investigation. TMS will be administered for 25 minutes.
224121637|NCT00004879|BIOLOGICAL|panitumumab|
224294781|NCT07212829|BEHAVIORAL|Aerobic exercise|Participants will perform a moderate aerobic exercise (AE, known as aerobic power index), using a cycle er-gometer. The exercise intensity is moderate and individually tailored based on each participant's estimated maximum heart rate (HRmax), calculated using the validated formula: HRmax = 211 - (0.64 × age).
223991345|NCT04398329|DEVICE|Luer lock applicator|Applicator for instillation
223991346|NCT04398329|DRUG|Bupivacaine HCl|Bupivacaine HCl, 50 mg
223991347|NCT01605682|DIETARY_SUPPLEMENT|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
224121638|NCT04150497|BIOLOGICAL|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
224121639|NCT04150497|BIOLOGICAL|CLLS52|A monoclonal antibody that recognizes a CD52 antigen
224121640|NCT04752813|DRUG|BPM31510|Subjects will receive a weekly, 96-h infusion of BPM31510 for a duration of 8 weeks.
224121641|NCT04752813|OTHER|Vitamin K1|Subjects will receive prophylactic Vitamin K1 at a recommended dose of 10 mg subcutaneously prior to the beginning of each week of BPM31510 therapy.
224121642|NCT04752813|DRUG|Temozolomide (TMZ)|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent TMZ 75 mg/m2 once daily (qd) × 42 days. Subjects will receive the standard TMZ treatment for up to 12 cycles post BPM31510 treatment.
224121643|NCT04752813|RADIATION|Radiation|After 2 wk of treatment with BPM31510 (ie, on Day 15), subjects will start concurrent standard RT for 42 days.
224121644|NCT03952468|DEVICE|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
224294782|NCT07212829|DEVICE|Sham tDCS|"tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site).~In the sham condition, current is ramped up to 2.0 mA for 30 seconds and then ramped down to 0 mA, with the total session duration matched to the active condition. This procedure was used to mimic the tingling sensa-tions typically experienced at the beginning of stimulation. Participants received identical instructions, session timing, and room setup across conditions."
223729088|NCT03149198|OTHER|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
223991348|NCT01475305|DRUG|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
223991349|NCT01475305|DRUG|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
223991350|NCT06277505|COMBINATION_PRODUCT|Take prebiotics and probiotics|Take 3.5g prebiotic +2g prebiotic twice a day before meals; At the same time, lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
223991351|NCT06277505|BEHAVIORAL|lifestyle guidance|lifestyle guidance is given, including adjusting dietary structure, increasing the intake of foods high in dietary fiber and moderate exercise
223991352|NCT01949636|OTHER|Functional Magnetic Resonance Imaging|
223991353|NCT02781805|DRUG|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
223991354|NCT02276105|OTHER|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
223991355|NCT03659162|DRUG|Azole Antifungal|oral gel \& injections
224121645|NCT03952468|OTHER|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
224121646|NCT03932201|DRUG|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
223991356|NCT04264377|PROCEDURE|Bronchoscopy|Bronchoscopy for retrieval of airway cells
223991357|NCT03602300|DRUG|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
223991358|NCT03602300|DRUG|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
223991359|NCT04765878|DEVICE|RespirAq Humidification|Humidifier
223991360|NCT02979106|OTHER|Test meal|Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
223991361|NCT01037426|OTHER|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~* History of falls and fractures during the 12 months before pacemaker implantation~* Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~* History of falls and fractures during the 12 months after pacemaker implantation~* Medical and Arrhythmia History~* Cardiovascular Events~* Cardiovascular Medication~* Device programming information"
223991362|NCT00943345|DRUG|indometacin|"* capsule for oral consumption~* at 22h00 evening before test day: 75 mg~* at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms)."
223991363|NCT05989828|BIOLOGICAL|Aldesleukin|Given IV
223991364|NCT05989828|BIOLOGICAL|Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|Given IV
224121647|NCT00280189|PROCEDURE|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
224121648|NCT00280189|BEHAVIORAL|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
224121649|NCT00280189|BEHAVIORAL|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
224121650|NCT02948140|PROCEDURE|MRI|
224121651|NCT02948140|PROCEDURE|Abdominal scanner|
224121652|NCT06667999|DRUG|Albumin|Albumin should be used for the following indications: 1. During circulatory failure in addition to crystalloids (resuscitation). 2. For substitution in case of: suspected or overt albumin loss OR P-albumin levels below or equal to 25 g/L. Decisions around timing, volume, and concentration of albumin, and its use for other indications, are at the clinician's discretion. P-albumin should be measured according to local practice.
224121653|NCT06667999|OTHER|No albumin use|Albumin should not be used. In case of the following special circumstances, albumin may be considered: 1. Large ascites drainage (i.e., equal to or more than 1 L tapped) 2. Spontaneous bacterial peritonitis 3. Hepatorenal syndrome.
223991365|NCT05989828|PROCEDURE|Biopsy|Undergo biopsy of breast tumor
223991366|NCT05989828|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223991367|NCT05989828|PROCEDURE|Computed Tomography|Undergo CT scan
223991368|NCT05989828|DRUG|Cyclophosphamide|Given IV
223991369|NCT05989828|PROCEDURE|Echocardiography|Undergo ECHO
223991370|NCT05989828|DRUG|Fludarabine|Given IV
223991371|NCT05989828|PROCEDURE|Leukapheresis|Undergo leukapheresis
223991372|NCT05989828|PROCEDURE|Magnetic Resonance Imaging|Undergo breast MRI
223991373|NCT05989828|PROCEDURE|Mammogram|Undergo mammogram
223991374|NCT05989828|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223991375|NCT05989828|PROCEDURE|Ultrasound Imaging|Undergo ultrasound of breast
223991376|NCT01955187|DRUG|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
224294783|NCT07213284|BEHAVIORAL|MI MOM App|Participants enrolled in the Michigan Healthy Moms (MI MOM) app will receive initial interactive app content followed by regular text messages with information related to pregnancy health, designed to increase patient awareness of warning signs, help them with self-advocacy, and otherwise improve health in pregnancy and postpartum. They will also have online live chat (text) access to a community healthcare worker who can assist them in enrolling in services to improve their health. They will also have the option of enrolling support persons (partners, family members, close friends, etc.) in the MI MOM app to receive similar information designed to help them support the pregnant participant. Providers at intervention sites will also receive information designed to improve their awareness of techniques for preventing maternal morbidity and mortality.
223991377|NCT01955187|DRUG|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
223991378|NCT01955187|DRUG|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
223991379|NCT01955187|DRUG|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
223991380|NCT00592293|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
223991381|NCT05022537|DEVICE|retrograde nephrostomy|this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
223991382|NCT05022537|DEVICE|antegrade nephrostomy|this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
223991383|NCT04632043|OTHER|Endotracheal intubation|Endotracheal intubation
223991384|NCT02820064|PROCEDURE|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
223991385|NCT01710059|BEHAVIORAL|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
223991386|NCT01710059|BEHAVIORAL|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
223991387|NCT01710059|BEHAVIORAL|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
223991388|NCT01710059|BEHAVIORAL|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
223729089|NCT02141243|PROCEDURE|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
223729090|NCT02141243|PROCEDURE|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
223991389|NCT02022722|DRUG|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
224121654|NCT04372953|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|"PEEP is the delivery of any level of positive pressure to the lungs during expiration, by any method of assisted respiratory support. As the intervention in the Delivery Room PEEP will be administered via any of:~1. Continuous Positive Applied Pressure (CPAP; non-invasive respiratory support) During CPAP, no other type of positive pressure is delivered as the infant supports tidal ventilation using her/his own spontaneous breathing effort.~2. Positive Pressure Ventilation (PPV) During PPV, PEEP is delivered between periods of an applied inflating pressure (PIP) delivered at a clinician-determined rate. PPV can be delivered via a mask or other non-invasive interface (also termed non-invasive positive pressure ventilation; NIPPV), or via an endotracheal tube (often termed continuous mechanical ventilation; CMV)."
223729091|NCT02141243|PROCEDURE|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
223991390|NCT02022722|PROCEDURE|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
224121655|NCT06388122|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224121656|NCT00511589|OTHER|chagas disease diagnostic|
224121657|NCT04258111|BIOLOGICAL|IBI310 (anti-CTLA-4 antibody)|Specified dose on specified days
224121658|NCT04258111|BIOLOGICAL|Sintilimab(anti-PD-1 antibody)|Specified dose on specified days
224121659|NCT06226233|OTHER|Juniver program|The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evidence-based curriculum, interactive tools, and moderated peer support groups.
223991391|NCT03922022|BEHAVIORAL|EIM exercise classes and intervention|This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
223991392|NCT01606319|DRUG|Acetaminophen|15 mg/kg every 6 hours as needed
223991393|NCT01606319|DRUG|Ibuprofen|9.4 mg/kg every 6 hours as needed
223991394|NCT06305442|DIETARY_SUPPLEMENT|Microbiota-Directed Food|MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
223991395|NCT06305442|DIETARY_SUPPLEMENT|Ready-to-Use Supplementary Food|RUSF is standard ready-to-use supplementary food for MAM children aged 6 months and above.
223991396|NCT00162617|DRUG|Red blood cell transfusion|
224121660|NCT05224206|DEVICE|Theta burst stimulation|Cool B65 active/placebo coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
224121661|NCT05224206|DEVICE|Theta burst stimulation|Cool B70 coil (left DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
224121662|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
224121663|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
223729092|NCT03336047|BEHAVIORAL|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
223991397|NCT04584892|DRUG|Turoctocog alfa|Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
223991398|NCT04073342|GENETIC|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
223991399|NCT05639452|OTHER|Data collection for developing an algorithm for an Early Warning Score|Data collection of patient parameters (heart rate, respiratory rate, clinical outcomes (death, transfer to intensive care unit, adverse events like sepsis, infection, heart attack))
223991400|NCT01898377|DRUG|Imatinib mesylate, Mycophenolate mofetil|
223991401|NCT00241488|DRUG|Rosuvastatin|
223991402|NCT05661435|DEVICE|RESP Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
223991403|NCT00390520|DRUG|Vildagliptin|
223991404|NCT05478382|DRUG|Pregabalin 25 MG|Patients are given 0 to 3 capsules per administration according to their allocated group.
223991405|NCT05478382|DRUG|Placebo|Patients are given 0 to 3 capsules per administration according to their allocated group.
223991406|NCT04127903|OTHER|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
223991407|NCT03181347|PROCEDURE|RYGB|Roux-en-Y Gastric Bypass
223991408|NCT03181347|PROCEDURE|SG|Sleeve Gastrectomy
223991409|NCT03181347|BEHAVIORAL|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
223991410|NCT03293459|PROCEDURE|Shunt Occlusion|Catheterization of the Porto-systemic shunt (via the left renal vein for gastro-lienorenal shunt) will be accomplished using a catheter and occlusion will be performed with balloon catheter/vascular plug. Occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours deflated under fluoroscopy the next day/plug is deployed and sclerosant is injected to obliterate the shunt and follow up CT is done to look for completion on the next day. Follow up CT abdomen is done periodically to look for effect on shunt and organ.
223991411|NCT03293459|DIETARY_SUPPLEMENT|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
223991412|NCT01517204|DEVICE|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
223991413|NCT01517204|DEVICE|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
223991414|NCT02634424|DEVICE|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
224121664|NCT00365716|BIOLOGICAL|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
224121665|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
224121666|NCT00365716|BIOLOGICAL|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
223991415|NCT03069144|DRUG|HAT1 topical solution|HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
223991416|NCT03069144|DRUG|Calcipotriol|Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
223991417|NCT03709108|OTHER|SI-Informed Bolus Calculator|The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
223991418|NCT01594827|DRUG|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
224121667|NCT05665465|DRUG|Nicotine nasal spray 0.5 mg|Participants will be administered nicotine nasal spray and provide subjective reactions
224121668|NCT05665465|DRUG|Placebo|Participants will be administered placebo nasal spray and provide subjective reactions
223991419|NCT01594827|DRUG|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
223991420|NCT01594827|DRUG|Rifampin|"Oral Rifampin by mouth for 28 days~1. \>45 kg: 600 mg by mouth daily~2. 35-45 kg : 450 mg by mouth daily~3. 25-34.9 kg: 300 mg by mouth daily"
223991421|NCT01594827|DRUG|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)~1. \>45 kg: two DS tablets twice a day by mouth (320/1600)~2. 25-45 kg: one DS tablet twice a day by mouth (160/800)"
223991422|NCT01594827|DRUG|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. \>45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
223991423|NCT01594827|DRUG|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
223991424|NCT01594827|DRUG|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
223991425|NCT04480606|BEHAVIORAL|Home exercise program|47 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in home exercise group. A video exercise protocol was created and each exercise session was planned as daily 30 minutes for 6 weeks. Individuals will ask to do their exercises. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic, balance and strengthening exercises. The exercise program consists of 3 levels and individuals will be provided to start at a level appropriate to their level of physical activity.
223991426|NCT02291822|DRUG|Gadobenate Dimeglumine|gadolinium contrast agent
223991427|NCT02484664|DRUG|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
223991428|NCT02847442|DRUG|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
223991429|NCT02847442|DRUG|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
223991430|NCT01782521|PROCEDURE|No primer|Primer not used when bonding orthodontic brackets
223991431|NCT00620269|DRUG|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
223991432|NCT00620269|DRUG|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
223991433|NCT00620269|DRUG|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 \& 8 every 3 weeks X 2 cycles
224121669|NCT06416657|OTHER|Different anesthesia methods, namely local anesthesia and general anesthesia|"Patients in the local anesthesia group received only local anesthesia at the femoral artery puncture site without anesthesia drugs such as conscious sedation.~Patients in the general anesthesia group received not only local anesthesia at the femoral artery puncture site, but also fast-induction anesthesia with tracheal intubation or laryngeal mask insertion using isoproterenol, remifentanil, and muscle relaxants."
224121670|NCT05761444|DRUG|Atozet 10/40 mg or 10/80 mg|Atozet 10/40 mg or 10/80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
223991434|NCT00620269|RADIATION|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
223991435|NCT04344210|BEHAVIORAL|Tele-interventions related to diabetes management and mental well-being|Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
224121671|NCT05761444|DRUG|Lipitor 40 mg or 80 mg|Lipitor 40 mg or 80 mg Dosage Formulation: Tablet Dosing Instructions: oral. Take 1 tablet daily
224121672|NCT03461653|OTHER|Telemedicine counselling|women on web counselling
224294784|NCT07212478|OTHER|PFMT|O PFMT consistirá em 10 contrações voluntárias máximas que devem ser mantidas por pelo menos 6 segundos. Os participantes serão incentivados a sustentar a contração máxima por um tempo maior a cada semana. O intervalo entre as contrações será de segundos. Os participantes realizarão 4 séries de 10 contrações e, ao final de cada série de 10 contrações, serão realizadas cinco contrações rápidas. Cada série será realizada em uma posição: deitado em decúbito lateral; sentado; de quatro apoios e em pé.
223991436|NCT04964245|DEVICE|accelometer|the respiration parameters are measured using an accelometer.
223991437|NCT04964245|DEVICE|thermographic camera|the respiration parameters are measured using an thermographic camera.
223991438|NCT04964245|DEVICE|Electrical Impedance Tomography|the respiration parameters are measured using an electrical impedance tomograhy.
223991439|NCT04964245|DEVICE|Mattress Sensor|the respiration parameters are measured using an Mattress pressure
223991440|NCT01748305|BEHAVIORAL|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
223991441|NCT06407609|DIETARY_SUPPLEMENT|Curcuma and boswellia extracts plus low fodmap diet|Low Foodmap diet + Curcuma and boswellia extracts both formulated in sunflower lecithin (Phytosome™) and processed with a strong commitment to sustainability
223991442|NCT06407609|OTHER|Low Foodmap diet|such as lactose or gluten free diet in the last 6 months
223991443|NCT04482153|DEVICE|fibroscan|The Controlled Attenuation Parameter (CAP) can using transient elastography (TE) (Fibroscan®) permits to efficiently separate different grades of severity of steatosis. CAP is based on the properties of ultrasonic signals acquired by the Fibroscan®. It allows to simultaneously measure liver stiffness and CAP in the same liver volume.
223991444|NCT03038204|PROCEDURE|The papillary muscle approximation|"Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.~After coronary anastomosis, the mitral valve is exposed by a transseptal incision.~The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.~Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured."
223991445|NCT01821937|DRUG|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
224121673|NCT03802604|BIOLOGICAL|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10\^6 PFU/mL. On week 3 (i.e. 21 days \[± 2\] days), a second talimogene laherparepvec injection will be administered at a dose of 10\^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 \[± 2\] days). The maximum volume for each injection will be 4.0 mL.
224121674|NCT03802604|DRUG|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 \[± 2\] days), for a total of 4 treatment courses.
224294785|NCT07212478|OTHER|Pilates exercises|The Pilates group will perform 10 solo exercises, containing stretching and strengthening for the main muscle groups, with a single series of 10 repetitions.
223729093|NCT03336047|BEHAVIORAL|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
223991446|NCT01821937|DRUG|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
223991447|NCT01754415|DEVICE|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
224121675|NCT04694846|DRUG|Nicotine Replacement|Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges
224121676|NCT04694846|DRUG|Bupropion Hydrochloride Controlled-release|Given PO
224121677|NCT04694846|DRUG|Varenicline|Given PO
224121678|NCT04694846|OTHER|Tobacco Cessation Counseling|Receive counseling
224121679|NCT04694846|OTHER|Questionnaire Administration|Ancillary studies
224121680|NCT04694846|OTHER|Quality of Life Assessment|Ancillary studies
224121681|NCT04694846|OTHER|Best Practice|Receive standard treatment
224294786|NCT07213414|DIETARY_SUPPLEMENT|Probiotics|The intervention is giving probiotic supplementation that contains Bifidobacterium longum BB536, Bifidobacterium breve M-16V, Bifidobacterium longum subs.infantis M-63 from Morinaga.
223991448|NCT05671354|DEVICE|the auto-wrapping commode chair|The auto-wrapping commode chairs will seal off the excretions in a plastic bag when a button is pressed, and then prepare a new bag for next excretions. The sealed excretions will then be disposed of as usual garbage. The same staff, who are responsible for disposing of the excretions from the commodes in the pre-test, will dispose of the excretions from the auto-wrapping commode chairs during the trial.
224294787|NCT07213232|OTHER|Core Stability Training|Core stability training will be designed to prepare participants for subsequent balance and gait exercises by promoting normal proprioceptive input through activation of deep core muscles. This training will be performed in the supine position at the beginning of each session for both groups.
223991449|NCT00787306|BEHAVIORAL|Active risk factor surveillance|Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
223991450|NCT01717079|PROCEDURE|Sham rTMS|120 pulses 0.2Hz
223991451|NCT01717079|PROCEDURE|rTMS|120 pulses 0.2Hz
223991452|NCT04035980|BEHAVIORAL|Telemedicine based healthcare programme|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
224294788|NCT07213232|OTHER|Dual-Task Balance and Gait Training|Dual-task balance and gait training will be provided with task-oriented motor-cognitive and motor-motor exercises with the augmented and virtual reality system C-Mill VR+ (Motek Medical, Amsterdam, The Netherlands). Sessions will be individualized based on each participant's current abilities and the difficulty level of the tasks to address specific patient needs. Each training session will have a duration of 30 minutes for both groups.
223991453|NCT03432468|DRUG|Valsartan 1|the high dose of valsartan
223991454|NCT03432468|DRUG|Valsartan 80 mg|a single dose of valsartan
223991455|NCT01621243|DRUG|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
223991456|NCT01621243|DRUG|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
223991457|NCT01621243|DRUG|placebo|Placebo will be dosed daily
223991458|NCT01621243|DRUG|Necuparanib|Necuparanib will be dosed daily
224121682|NCT05786742|RADIATION|grade and compare reported side effects between groups|"Compare experimental ultra hypo fractionation (25 Gy in 5 daily fractions administered starting mid week and ending mid following week) to our standard fractionation (either 37,5 Gy given in 15 daily fractions, or 36 Gy in 12 daily fractions).~* Toxicity analysis will be quantitatively evaluated using CTCAE (v5) at 1, 2 and 5 years post-therapy, and has needed at FU visits. Kaplan-Meier statistical analysis will be used to report toxicity evolution through time.~* median IPSS scores will be reported at 3, 6, 12 months and yearly (1, 2, 3, 4 et 5) post-therapy. IPSS median time to baseline return will be calculated.~* IPSS urinary scores, sexual function (SHIM) and GI toxicity (CTCAE-v5) and quality of life questionnaires ( EPIC-26) will be given at 3, 6 months and yearly thereafter (1, 2, 3, 4 et 5) post-treatment."
223991459|NCT02723227|BEHAVIORAL|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
223991460|NCT02723227|BEHAVIORAL|Referral to Social Services|
223991461|NCT05063877|DRUG|Placebo|Matched placebo
223991462|NCT05063877|DRUG|EQU-001|EQU-001 in 10 mg and 20 mg capsules
223991463|NCT02964702|DEVICE|Thrombectomy Device T-01|
223991464|NCT04089397|DEVICE|Light Therapy|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
223991465|NCT02849613|OTHER|Adipose Derived Stem Cells|
224121683|NCT06303648|DRUG|Methylone|Oral dose of methylone
223991466|NCT02849613|OTHER|Vehicle media|
223991467|NCT00280215|DRUG|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
223991468|NCT00280215|DRUG|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients \< 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients \< 40 kg) to be taken for 24 months.
223991469|NCT00280215|DRUG|Placebo|Patients will receive placebo for 24 months
224294789|NCT07213232|OTHER|Cognitive Training|"Cognitive training will be provided with RehaCom software, a program that emphasizes learning principles, provides task-specific exercises, delivers positive feedback, and allows individualized progression based on patient-specific difficulty levels. In the present study, the cognitive training will target the Attention, Memory, and Executive Functions domains, which are known to be affected from the early stages of Parkinson's disease. Exercises will be initiated at a level appropriate to each participant's cognitive abilities and will gradually increase in difficulty. Each training session will have a duration of 30 minutes."
224294790|NCT07212946|DRUG|Ayahuasca|Ayahuasca (oral)
223991470|NCT05689892|OTHER|Decision Coach Sessions|"Participants in the intervention group and their families will be referred to the DC to meet independently and discuss recommended treatment pathways.~Multiple sessions may be necessary until a final decision is reached. All SDM consults will be done virtually using a secure videoconferencing platform. The Ottawa Family Decision Guide will be used to facilitate the discussion. A DA will be provided to the study participants in the form of information cards containing information about different treatment options in pediatric IBD. This includes administration schedule, side effects, risk of cancer, among others. The DA has been developed and provided by the Cincinnati Children's Hospital Medical Center and adapted to the Canadian setting with electronic version by this research group with approval from the authors."
223991471|NCT04211259|DRUG|Loratadine|Given PO
223991472|NCT04211259|OTHER|Placebo|Given PO
223991473|NCT04211259|OTHER|Questionnaire Administration|Ancillary studies
223991474|NCT00200070|DEVICE|Spinal Cord Stimulation|
223991475|NCT03724253|DRUG|[68Ga]-NeoBOMB1|\[68Ga\]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
223991476|NCT03396068|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
223991477|NCT03396068|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
223991478|NCT02388152|DRUG|Lu AF20513, low dose|
223991479|NCT02388152|DRUG|Lu AF20513, medium dose|
223991480|NCT02388152|DRUG|Lu AF20513, high dose|
223991481|NCT02388152|DRUG|Lu AF20513, double high dose|
223991482|NCT04785118|DRUG|Hyoscine N Butylbromide|Patients will receive IV hyoscine butyl-bromide 20 mg in 2 ml, just before spinal anaesthesia.
223991483|NCT04785118|DRUG|Ondansetron|Patients received IV ondansetron 4 mg in 2 ml, just before spinal anaesthesia.
223991484|NCT04785118|DRUG|Saline|Patients received 2 ml of IV normal saline as a placebo just before spinal anaesthesia.
224121684|NCT06303648|DRUG|Placebo|Placebo to match methylone
224294791|NCT07212946|DRUG|Esketamine|oral esketamine (2 mg/kg)
223991485|NCT03849703|BEHAVIORAL|Full Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
223991486|NCT03849703|BEHAVIORAL|Full Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
223991487|NCT03849703|BEHAVIORAL|Partial Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
223991488|NCT03849703|BEHAVIORAL|Partial Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
224121685|NCT04502407|RADIATION|Cisplatin-based Radiation Therapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive radiation dose of 50 Gy in 25 fractions over 5 cycles on Days 1, 8, 15, 22, and 29 of radiation treatment.~* All other patients will receive radiation dose of 30 Gy in 15 fractions over 3 cycles on Days 1, 8 and 15 of radiation treatment."
224121686|NCT04502407|DRUG|Cisplatin Chemotherapy|"* High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation."
223991489|NCT01070576|OTHER|no intervention|no intervention
223991490|NCT02579590|DRUG|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
224121687|NCT06164028|OTHER|cognitive interview|Participants will take part in a semi-structured qualitative interview (\~1 hour).
224121688|NCT01552356|OTHER|Laboratory Biomarker Analysis|Correlative studies
224121689|NCT01552356|DRUG|Pazopanib Hydrochloride|Given PO
224121690|NCT01552356|OTHER|Pharmacological Study|Correlative studies
223991491|NCT02579590|DRUG|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
224121691|NCT01334021|PROCEDURE|Biopsy|Undergo tumor biopsy
223991492|NCT02579590|DRUG|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
224121692|NCT01334021|PROCEDURE|Conventional Surgery|Undergo surgery
224121693|NCT01334021|OTHER|Genetic Testing|Undergo genetic testing
224121694|NCT06272968|DIAGNOSTIC_TEST|Neuropsychological Testing|Neuropsychological Testing via Cambridge CANTAB Connect
224121695|NCT05478018|BEHAVIORAL|High Intensity Interval Training (HIIT)|Supervised high-intensity interval training for 12 weeks three times per week
224121696|NCT04807504|DRUG|Ropivacaine|All patients receive erector spinae plane blocks with ropivacaine.
224121697|NCT04686305|DRUG|T-DXd|T-DXd: administered as an IV infusion
224121698|NCT04686305|BIOLOGICAL|Durvalumab|Durvalumab: administered as an IV infusion
224121699|NCT04686305|DRUG|Cisplatin|Cisplatin: administered as an IV infusion
224121700|NCT04686305|DRUG|Carboplatin|Carboplatin: administered as an IV infusion
224121701|NCT04686305|DRUG|Pemetrexed|Pemetrexed: administered as an IV infusion (drug not used)
224121702|NCT04686305|DRUG|Volrustomig|Volrustomig: administered as an IV infusion
224121703|NCT04686305|DRUG|Rilvegostomig|Rilvegostomig: administered as an IV infusion
223991493|NCT04853615|DRUG|Empagliflozin 25 MG|PAtient will receive empagliflozin 25 mg daily
223991494|NCT06146478|DRUG|Thalidomide|Thalidomide given at an average dose of 1.5mg/kg/day
223991495|NCT04043897|DRUG|Rifaximin 550mg|Rifaximin 550mg
223991496|NCT00959686|DRUG|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
223991497|NCT00737503|BIOLOGICAL|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
223991498|NCT00887770|DRUG|AZD5672|12 x 50mg tablet, oral, single dose
223991499|NCT00887770|DRUG|Moxifloxacin|1 x 400mg capsule, oral, single dose
223991500|NCT00887770|DRUG|placebo|12 x matched to AZD5672 50 mg tablet
223991501|NCT00887770|DRUG|AZD5672|3 x 50mg tablet, oral. single dose
223991502|NCT00887770|DRUG|placebo|9 x matched to AZD5672 50mg tablet
223991503|NCT00887770|DRUG|placebo|1 x matched to Moxifloxacin capsule
223991504|NCT02478437|PROCEDURE|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
223991505|NCT02478437|PROCEDURE|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
223991506|NCT03863145|DRUG|CB-03-10|CB-03-10, 100 mg capsule for oral use
223991507|NCT05492305|DRUG|GLP-1 receptor agonist|Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
223991508|NCT03498703|DRUG|Azathioprine Pill|Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
223991509|NCT03498703|DRUG|Placebo Oral Tablet|Placebo tablets
223991510|NCT02406248|DRUG|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
223991511|NCT01351168|DRUG|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
223991512|NCT01351168|DRUG|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
223991513|NCT01351168|DRUG|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
224121704|NCT05524272|OTHER|This study aims to evaluate the effects of colour by number mandala in decreasing the stress of children hospitalized due to their chronic disease.|Colour by number Mandala in different sizes includes pictures and numbers. The child has to find the colour specified in the number and colour it with the specified colour. Colourful pictures emerge as a result of colouring
224121705|NCT02540252|OTHER|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
224121706|NCT05151770|OTHER|Measure of glycemia levels and comparison to algorithm predictions|The study aims to evaluate the efficacy of a new algorithm in predicting the evolution of glycemia levels after a full meal. Glycemia levels measured during and after a full meal will be compared to the values predicted by the algorithm. Composition of the meals will also be collected.
224121707|NCT05593497|DRUG|Capivasertib|400 mg (2 tablets) BID given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week (4 days on, 3 days off). Treatment will be given in combination with abiraterone for 16 weeks duration (+/- 1 week for surgery window).
224121708|NCT05593497|DRUG|abiraterone acetate|"Administered orally as tablets at a dosage of 1000 mg daily. To be administered with prednisone 5mg po daily.~Subjects will be on concurrent GNRH agonist therapy (leuprolide, administered as standard of care). Intensified androgen deprivation (iADT) consisting of abiraterone and leuprolide will be administered for a 4 week run-in prior to addition of capivasertib."
223991514|NCT01351168|DRUG|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
223991515|NCT02257476|DRUG|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
223991516|NCT02257476|DRUG|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
223991517|NCT05451667|DRUG|YJ001 for Spray Use|YJ001 (active ingredient)
223991518|NCT05451667|DRUG|Placebo of YJ001 for Spray Use|Hydroxypropyl Methylcellulose
223991519|NCT02917772|BIOLOGICAL|Nivolumab/Ipilimumab|"* Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
223991520|NCT00790205|DRUG|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
223991521|NCT00790205|DRUG|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
223991522|NCT03102866|OTHER|Best Practice|Receive usual care
223991523|NCT03102866|BEHAVIORAL|Exercise Intervention|Undergo aerobic and strength training exercise
223991524|NCT03102866|OTHER|Quality-of-Life Assessment|Ancillary studies
223991525|NCT03102866|OTHER|Questionnaire Administration|Ancillary studies
223991526|NCT04484584|OTHER|complex decongestive therapy|Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
223991527|NCT02394652|DRUG|Metformin|Metformin is an antidiabetic agent given orally.
223991528|NCT02394652|DRUG|Cisplatin|Cisplatin is an antineoplastic agent given intravenously.
223991529|NCT02394652|DRUG|FAZA|FAZA is an investigational imaging agent for positron emission tomography scans indicated for hypoxia.
223991530|NCT04706858|DIETARY_SUPPLEMENT|Dietary fiber supplementation|Randomization to the order of first fiber: either inulin or arabinoxylan. Third cycle will include a mix of 5 fibers: inulin, arabinoxylan, resistant starch, glucomannan, and acacia gum.
223991531|NCT04770480|BEHAVIORAL|Standard Care (SC)|No attempt will be made to change usual care practice after surgery
223991532|NCT04770480|BEHAVIORAL|Enriched Pain Management Pathway (EPM)|Enriched Pain Management Pathway will be delivered by physical therapists trained to integrate physical therapy and mindfulness techniques grounded in a biopsychosocial context. The intervention will be delivered within the context of the post-operative physical therapy routine (the mindfulness approach will be integrated into the post-operative physical therapy care).
223991533|NCT02669134|OTHER|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
223991534|NCT03344406|OTHER|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
223991535|NCT03344406|OTHER|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
223991536|NCT03344406|OTHER|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
223991537|NCT03344406|OTHER|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
223991538|NCT03344406|OTHER|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
223991539|NCT03344406|OTHER|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
223991540|NCT05530330|DIAGNOSTIC_TEST|Platelet/Endothelial proteomics|Samples taken will undergo a targeted proteomic investigation examining platelet/endothelial markers and associated extracellular vesicles
223991541|NCT05815706|DEVICE|MEDELA Supplemental nursing system|The experimental group participants were fed based on the MEDELA Supplemental Nursing System, which consists of a syringe/container and a feeding catheter. One end of the feeding probe is in the syringe/container, while the other is fixed to the mother's nipple through a plaster. MEDELA SNS is a sterile product with an adjustable breast milk flow system and neck strap. It is bisphenol A (BPA) free. All its parts are in direct contact with breast milk. This system allows the baby to both suck and feed (MEDELA Supplemental Nursing System, 2018).
223991542|NCT00080990|DRUG|alvocidib|Given IV
223991543|NCT00080990|DRUG|fluorouracil|Given IV
223991544|NCT00080990|DRUG|oxaliplatin|Given IV
223991545|NCT00080990|DRUG|leucovorin calcium|Given IV
223991546|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
223991547|NCT01294410|DRUG|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
223991548|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
223991549|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
223991550|NCT01294410|DRUG|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
223991551|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
223991552|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
223991553|NCT01294410|DRUG|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
223991554|NCT02726477|DRUG|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
223991555|NCT02726477|DRUG|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
223991556|NCT00501956|DRUG|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
224121709|NCT01869010|OTHER|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
224121710|NCT01465698|BEHAVIORAL|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
224121711|NCT01465698|BEHAVIORAL|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
223544850|NCT02185534|DRUG|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
224121712|NCT01465698|BEHAVIORAL|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
224121713|NCT01465698|OTHER|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
223544851|NCT04596683|PROCEDURE|Same-day NSM or SSM|Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
224121714|NCT02356406|RADIATION|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
223544852|NCT04236271|DEVICE|connected objects|a combination of connected devices for measuring physiological parameters and for clinical self-assessment by the patient, for early postoperative coronary bypass surgeries.
223544853|NCT05330871|BIOLOGICAL|1 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223991557|NCT01834586|DRUG|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
223544854|NCT05330871|BIOLOGICAL|2 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223544855|NCT05330871|BIOLOGICAL|3 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223544856|NCT05330871|BIOLOGICAL|4 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223544857|NCT05330871|BIOLOGICAL|5 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
223544858|NCT05330871|BIOLOGICAL|6 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
223991558|NCT05783687|DIAGNOSTIC_TEST|NCC-Sp Assay|Orphalan has developed a new NCC speciation assay (NCC-Sp) using liquid chromatography inductively coupled plasma mass spectroscopy (LC-ICP-MS) to measure serum copper and ceruloplasmin bound copper from which non ceruloplasmin bound copper (NCC) is estimated.
223991559|NCT02839785|DRUG|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
223991560|NCT02839785|DRUG|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
223991561|NCT04969809|DIAGNOSTIC_TEST|Ultrasound of the jugular veins|Ultrasound of the jugular veins to assess the thickness of the carotid intima media
224121715|NCT06018922|BEHAVIORAL|Psychological treatment|The treatment is module-based, and the clinician are supposed to choose a small number of modules to work with depending on the patients need. The individual CBT modules are: 1) Behavioral activation, 2) Accepting thought, 3) Emotion regulation, 4) Impulse control, 5) Procrastination, 6) Relationships, 7) Problem-solving skills, 8) Structuring everyday-life, 9) Diet-Exercise-Sleep, and 10) Social anxiety. The family therapy modules are: 1) Psychoeducation about gaming, 2) Encourage other activities, 3) Positive time together, 4) Expectations and the patients abilities, 5) Making agreements in the family, 6) Emotional validation, and 7) Conflict management.
224121716|NCT06312956|DEVICE|Continuous Positive Airway Pressure Ventilotherapy|Breathing support device during sleeping
224121717|NCT03951857|OTHER|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
223991562|NCT04969809|DIETARY_SUPPLEMENT|addition of phenylalanine-free protein substitutes|addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
223991563|NCT00440245|DRUG|salbutamol|200 micrograms salbutamol from MDI
223991564|NCT02880839|DEVICE|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
223991565|NCT02880839|DEVICE|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
224294792|NCT05051644|BEHAVIORAL|Steps 2 Change (S2C)|Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.
224294793|NCT05051644|BEHAVIORAL|Control|The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
223991566|NCT02880839|DEVICE|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
223991567|NCT03497715|DRUG|Ibuprofen lysine|Test 1
224294794|NCT00003138|BIOLOGICAL|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
223991568|NCT03497715|DRUG|Ibuprofen Sodium|Test 2
223991569|NCT03497715|DRUG|Ibuprofen|Test 3
223991570|NCT03497715|DRUG|Ibuprofen (Nurofen)|Reference 1
223991571|NCT03497715|DRUG|Ibuprofen (Wockhardt)|Reference 2
223991572|NCT03446638|DRUG|FDA-approved drug or combination of drugs|Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
223991573|NCT03446638|DRUG|FLAG induction|Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count \> 500/ microliter for 3 days.
224121718|NCT04735978|BIOLOGICAL|RP3|Genetically modified HSV-1
224121719|NCT04735978|BIOLOGICAL|Nivolumab|anti-PD1 monoclonal antibody
224121720|NCT01255748|RADIATION|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
224294795|NCT00003138|BIOLOGICAL|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
224294796|NCT00003138|PROCEDURE|Transfusion|Red cell and platelet transfusions
223991574|NCT03446638|DRUG|7 + 3 induction|Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
223991575|NCT03446638|DRUG|Low-dose cytarabine|Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
223991576|NCT03446638|OTHER|Supportive care alone|Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
224121721|NCT01665326|OTHER|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
224121722|NCT06435442|DRUG|Epaminurad, Naproxen|Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen
224121723|NCT06435442|DRUG|Epaminurad|Epaminurad
224121724|NCT06435442|DRUG|Epaminurad placebo|Epaminurad placebo
224121725|NCT06449677|DEVICE|iLet Bionic Pancreas System (BP)|The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.
224121726|NCT06449677|DEVICE|Usual Care (UC)|Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump.
224121727|NCT06535139|BEHAVIORAL|Brief training|Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.
224121728|NCT06535139|BEHAVIORAL|Parent-targeted motivational aids|Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.
224121729|NCT06535139|BEHAVIORAL|Healthcare access|Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.
224121730|NCT03768570|DRUG|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
223991577|NCT03446638|DEVICE|Computational biology simulations software|Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
223991578|NCT04867109|OTHER|Patients with Post menopausal bleeding|"Any patient presenting post-menopausal bleeding who is to undergo hysteroscopy or hysterectomy will have an additional blood tube taken during her pre-operative blood work-up for the determination of the serum markers HE4 and CA125, after having obtained her non-opposition to participate in the study.~The blood tube collected for the research will be sent to the biochemistry laboratory of the Nantes University Hospital for a centralized analysis.~This analysis will be done sequentially and the results will not be transmitted to the investigator.~At D0, the day of surgery, the operative report will be retrieved as well as the quality of life questionnaires SF12 and PGI-I and the acceptability questionnaire completed before surgery.~At 1 month after surgery, the anatomopathological results will be retrieved as well as the value of the tumour markers CA125 and HE4."
223991579|NCT04867109|DIAGNOSTIC_TEST|CA125 and HE4 assays|Blood was collected in a standard heparinized vial. Samples were sent to a central laboratory unit (biochemistry laboratory at the Nantes university hospital), centrifuged and plasmas were stored at -20°C until analysis. Plasma CA125 and HE4 concentrations were determined by run in single measurements using an electrochemiluminescence Elecsys immunoassay (ECLIA) on a Roche Diagnostics Cobas 8000® e602 analyser (Roche Diagnostics, Mannheim, Germany).
223991580|NCT05247008|OTHER|Thyme honey|"* Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day."
223991581|NCT02722811|DRUG|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
223991582|NCT02722811|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
223991583|NCT04537598|PROCEDURE|Morphine patient controlled analgesia|30 patients will receive PCA only for postoperative analgesia
223991584|NCT04537598|PROCEDURE|Erector Spinae plane block|30 patients will receive continuous ESPB for postoperative analgesia
223991585|NCT03258671|DRUG|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
224121731|NCT04329039|DRUG|Somatostatin analog|Somatostatin analog plus perioperative antibiotics Placebo plus perioperative antibiotics
223544859|NCT05330871|BIOLOGICAL|7 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
224121732|NCT06052072|DEVICE|Gradient Denervation System|Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
224121733|NCT05387720|PROCEDURE|Manual diaphragmatic facilitation (PNF) technique|"Diaphragmatic PNF is a facilitator technique used to improve chest expansion, increase epigastric excursion, promote breathing frequency and depth, by applying external proprioceptive tactile stimuli over diaphragm. The therapist places the thumbs toward the xiphoid process and the fingers along the costal margins of the lower ribs and pushing deep to stimulate the diaphragm During inspiration, the patient will be instructed take a deep breath breathe in and the therapist assists the movement to promote the subject's respiratory pattern in downward movement. At the maximum inspiration, therapist will say hold your breath for 5 seconds. The therapist gives mild resistance to the inferior movement of the contracting diaphragm during inspiration while pushing diaphragm superiorly. During expiration, therapist says breathe out and pushed under lower ribs on both sides upward to assist the discharge of air remaining in the lungs."
224121734|NCT05387720|PROCEDURE|Trigger sensitivity adjustment on mechanical ventilation|The pressure trigger sensitivity will be adjusted to 20% of the first recorded MIP at the start of training by decreasing trigger sensitivity towards negative pressure. In the first session, inspiratory muscle training (IMT) will be limited to 5 min; afterwards the duration will be increased by 5 min at every session until it reaches 30 min. If a patient tolerates 30 min of IMT, The next session will be performed with increasing negative pressure of the trigger sensitivity by 10% of the initial MIP. The maximal acceptable intensity is 40% of MIP, Patients who can't tolerate IMT with 20% of MIP for 5 min will be trained with 10% of MIP
223544860|NCT05330871|BIOLOGICAL|8 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
223544861|NCT05330871|BIOLOGICAL|9 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
223544862|NCT05330871|BIOLOGICAL|10 Intramuscular injection for booster groups|1 dose 0.5ml
223544863|NCT05330871|BIOLOGICAL|11 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223991586|NCT03258671|RADIATION|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；~* first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~* first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~* late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
223991587|NCT06544369|BIOLOGICAL|COVID-19 vaccin|injection
223991588|NCT04041830|BEHAVIORAL|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
223991589|NCT04041830|BEHAVIORAL|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
223991590|NCT02119897|DEVICE|Low Level Light Therapy|
223991591|NCT01512797|DRUG|Sitagliptin phosphate|100 mg/day orally
223991592|NCT01512797|OTHER|Placebo|1 Placebo Pill per day
223991593|NCT04582747|DIAGNOSTIC_TEST|Urinary Biomarkers (NGAL, DKK-3, IGFBP-7/TIMP-2, KIM-1)|"Validation of Urinary biomarker tests for the rapid prediction of AKI.~No intervention is being proposed as part of the study. Concentrations of Urinary biomarkers will be obtained post operatively. These concentrations will be assessed to ascertain their predictive ability for the development of Acute Kidney Injury post-operatively."
223991594|NCT05950100|DEVICE|Virtual reality group|"It is composed of the physiotherapeutic procedures usually used in the hospital applied by the institution's physiotherapist, and the immersive virtual reality therapy that will be conducted by a third researcher (blind to the sampling and evaluations). Physiotherapeutic consultations will have the conventional duration offered by the Institution and therapy with virtual reality will last 10 minutes, using the game Aviãozinho. Both interventions will have a frequency of 2x a day (morning and afternoon shifts), during the period of 4 days."
224121735|NCT05387720|PROCEDURE|concurrent trigger sensitivity adjustment and manual diaphragmatic facilitation (PNF) technique|Diaphragmatic PNF technique will be applied synchronously in the same time, on each breath with trigger sensitivity adjustment on mechanical ventilation in same manner as discussed before
224121736|NCT00963521|BIOLOGICAL|therapeutic autologous dendritic cells|
223991595|NCT01895036|DRUG|Naltrexone|
223991596|NCT01945398|OTHER|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
223991597|NCT01945398|OTHER|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
223991598|NCT02552459|DRUG|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
224121737|NCT01106534|DRUG|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
223991599|NCT02552459|DRUG|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
223991600|NCT02552459|DRUG|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
223991601|NCT02552459|DRUG|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
223991602|NCT00375622|DRUG|Tamoxifen|
223991603|NCT03482752|DRUG|Molgramostim|300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
223991604|NCT05750836|OTHER|Specific nursing support|"* 3 mandatory on-site nursing consultations with the patient's caregiver at inclusion, 6 months and 12 months post-randomisation.The caregivers will complete the questionnaires (Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36, Caregiver's satisfaction).~* interviews once a month with a nurse either by phone, on-site consultation or teleconsultation.~Nurses assess the general health of the caregiver and Identify the socio-professional situation of the caregiver"
223544864|NCT05330871|BIOLOGICAL|12 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223544865|NCT05330871|BIOLOGICAL|13 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223544866|NCT05330871|BIOLOGICAL|14 Nebulized inhalation for booster groups|Ad5-nCoV-IH, 1 dose 0.1ml
223544867|NCT05330871|BIOLOGICAL|15 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
223991605|NCT05750836|OTHER|Non-specific nursing support|Caregivers will only have to complete on site Health indicators, Zarit scale, Hospital Anxiety and Depression scale, Medical Outcome Study Short Form - 36 at inclusion, 6 months and 12 months post-randomisation.
223991606|NCT04155970|OTHER|Manual therapy|Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
223991607|NCT04155970|OTHER|Evidence-informed home management booklet|The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
223991608|NCT04947514|DRUG|Tranexamic acid|Topical tranexamic acid (1000mg) will be administered to the raw surface of the breast prior to closure of the incisions.
223991609|NCT04947514|OTHER|Placebo (topical saline)|The untreated breast will receive topical saline.
223991610|NCT01080300|DRUG|Gabapentin Extended Release|Gabapentin ER 1800mg daily
223991611|NCT01080300|DRUG|Placebo|Sugar pill
223991612|NCT00369096|DRUG|bemiparin 3500 IU/day|
223991613|NCT01883284|OTHER|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
223991614|NCT04636762|PROCEDURE|Radiation Therapy|Thoracic Radiation Dose: 3Gy, QD, total dose: 30-45Gy; Particpants with brain metastases：metastatic lesions≤3:whole brain radiotherapy with local simultaneous PGTV:50Gy/10F；metastatic lesions\>3:whole brain radiotherapy PTV:30Gy/10F.
223991615|NCT04467892|DRUG|methylprednisolone|received high dose (30 mg/kg) methylprednisolone slowly intravenous in 250 ml normal saline every 8 hours for only 4 days
223991616|NCT04467892|DRUG|Methyl Prednisolonate|received 1 mg/kg/day methylprednisolone divided to three doses given every 8 hours for two weeks.
224121738|NCT01106534|DRUG|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
224121739|NCT01106534|DEVICE|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
224121740|NCT06302569|DRUG|Pembrolizumab + Enfortumab Vedotin|"* Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab are eligible for up to 1 year of additional pembrolizumab (second course) upon experiencing disease progression.~* Enfortumab Vedotin will be given for a maximum of 3 cycles on day 1 and day 3 each 3 weeks. EV treatment could be re-started in case of Progressive Disease RECIST v1.1 during pembrolizumab monotherapy treatment."
224121741|NCT06239467|DRUG|OKI-219|Oral twice daily
224121742|NCT06239467|DRUG|Fulvestrant|Intramuscular injection
224121743|NCT06239467|DRUG|Trastuzumab|Intravenous (IV)
224121744|NCT06239467|DRUG|Tucatinib|Oral twice daily
224121745|NCT06239467|DRUG|Atirmociclib|Oral twice daily
224121746|NCT06239467|DRUG|Ribociclib|Oral once daily continuous for 21-days followed by 7 days off
224121747|NCT00137774|DRUG|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
223991617|NCT04467892|DEVICE|ventilators|all patients in both groups will be ventilated with CMV for 2 weeks
223991618|NCT05790525|DRUG|Standard bismuth quadruple|Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
224121748|NCT00137774|DRUG|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
223991619|NCT04210843|DRUG|Ligelizumab|"For the first 12 weeks of treatment: i) participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) previously treated with ligelizumab 72 mg LIVI s.c. Q4W were treated with the same dose regimen in a double-blind manner; ii) all other participants transitioning from CQGE031C2302 (NCT03580369) and CQGE031C2303 (NCT03580356) were treated with ligelizumab 120 mg LIVI s.c. Q4W in a double-blind manner; iii) participants transitioning from CQGE031C1301 (NCT03907878) and CQGE031C2202 (NCT03437278) were treated with ligelizumab 120 mg LIVI s.c. Q4W in an open-label manner.~Thereafter, all participants were switched to ligelizumab 120 mg s.c. PFS Q4W in an open-label manner and they were offered an opportunity to self-administer ligelizumab.~The longest possible treatment was 104 weeks, however this treatment might not be continuous and might span over a period of 156 weeks due to the possibility of entering the intervening observation period."
223991620|NCT00967083|BEHAVIORAL|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
223991621|NCT00791375|BEHAVIORAL|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
223991622|NCT01776008|DRUG|Akt Inhibitor MK2206|Given PO
223991623|NCT01776008|DRUG|Anastrozole|Given PO
223991624|NCT01776008|DRUG|Goserelin Acetate|Given SC
223991625|NCT01776008|OTHER|Laboratory Biomarker Analysis|Correlative studies
223991626|NCT01776008|PROCEDURE|Neoadjuvant Therapy|Given before standard-care surgery
223991627|NCT01776008|OTHER|Pharmacological Study|Correlative studies
224121749|NCT03434964|DIAGNOSTIC_TEST|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
224121750|NCT02047513|DRUG|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
224121751|NCT02047513|DRUG|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
223544868|NCT05330871|BIOLOGICAL|16 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
223544869|NCT05330871|BIOLOGICAL|17 Intramuscular injection for booster groups|Ad5-nCoV-IM, 1 dose 0.3ml
223544870|NCT05330871|BIOLOGICAL|18 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
224121752|NCT00127556|PROCEDURE|Label applied to blood bag|
224121753|NCT00210340|DRUG|intrathecal rituximab|
224121754|NCT05115279|PROCEDURE|breast conservative surgery for post chemotherapy tumour size|"* Skin preparation by povidine iodine.~* Excision of the mass with safety margin.~* Sentinel axillary lymph node or complete axillary clearance depend on axillary lymph node status~* All specimens were oriented with sutures~* A frozen section examination of the specimen was performed intraoperative~* When the margin status was inadequate, a re-excision was performed~* Closure as drawn by different oncoplastic technique"
224121755|NCT02096146|PROCEDURE|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
223544871|NCT05330871|BIOLOGICAL|19 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
223544872|NCT05330871|BIOLOGICAL|20 Intramuscular injection for booster groups|ICV, 1 dose 0.5ml
223544873|NCT05330871|BIOLOGICAL|21 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
223544874|NCT05330871|BIOLOGICAL|22 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
223544875|NCT05330871|BIOLOGICAL|23 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
223991628|NCT01776008|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard-care surgery
223991629|NCT04444843|DRUG|Mycophenolate Mofetil Capsules|Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
223991630|NCT00926081|BEHAVIORAL|Supervised exercise training|A standardized supervised exercise training program
223991631|NCT01132469|PROCEDURE|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
223991632|NCT02432833|DRUG|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
223991633|NCT02432833|DRUG|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
223991634|NCT02432833|DRUG|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
223991635|NCT03463499|DRUG|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
223991636|NCT04810468|OTHER|Anthropometric measurment|Anthropometric measurment used to asses the wheight in kelogram and asses height in cetemeter and also asses BMI
223991637|NCT05336175|DRUG|Angiotensin 1-7|"A substance, Angiotensin-(1-7) \[Ang-(1-7)\], is known to decrease inflammation in the brain. This substance is naturally produced in the body and works by activating areas in the brain involved in memory. Previous studies examining the ability of Ang-(1-7) treatment to prevent memory loss post open-heart surgery found that 21 days of treatment with Ang-(1-7) protected memory post-surgery. Participants treated with Ang-(1-7) were protected from post-surgery increase in NfL levels. This clinical sub-project within the existing study will allow us to obtain preliminary data to evaluate the safety and efficacy of treatment with Ang-(1-7) to improve cognitive function and determine if this treatment is associated with changes in plasma levels of NfL protein.30 participants will take 100 micrograms of Ang-(1-7) per day via subcutaneous injection for 90 days."
223991638|NCT05336175|DRUG|Saline solution|Saline solution will be given as a placebo intervention to 10 participants. These participants will take 100 micrograms of saline solution per day via subcutaneous injection for 90 days.
223991639|NCT04368845|DEVICE|Telerehabilitation|The treatment arm will be given up to 1-hour breathing exercises, aerobic and resistive training exercises administered by a physiotherapist via a telerehabilitation device every 10 days for a six-month period.
223991640|NCT04344951|DRUG|UNIKINON (Chloroquine phosphate) 200mg tablets|Two and a half tablets (500mg) twice daily for seven days.
223991641|NCT05693077|BIOLOGICAL|10E4 NTCD spores|in capsule for oral ingestion.
223991642|NCT05693077|BIOLOGICAL|10E7 NTCD spores|in capsule for oral ingestion.
223991643|NCT05693077|OTHER|placebo|in capsule for oral ingestion.
223991644|NCT05693077|DRUG|Vancomycin Oral Capsule|4 times a day 250mg
223991645|NCT02493842|DEVICE|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
223991646|NCT00855413|DRUG|Darunavir|800 mg orally once daily
224294797|NCT03967951|OTHER|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
223991647|NCT00855413|DRUG|Ritonavir|100 mg orally once daily
223991648|NCT00855413|DRUG|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
224294798|NCT00102518|DRUG|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
224294799|NCT01752647|PROCEDURE|Low dose computed tomography|Low dose computed tomography scan
223991649|NCT00004251|DRUG|letrozole|2.5 mg of letrozole per day
223991650|NCT02736279|DRUG|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
223544876|NCT05330871|BIOLOGICAL|24 Nebulized inhalation for primary groups|Ad5-nCoV-IH, 2 doses 0.1ml
223991651|NCT05143164|DEVICE|hydrocolloid dressing|Duoderm Extra Thin hydrocolloid dressing will be used to cover the catheter exit-site of participants in the intervention group. The dressing will be changed every 7 days or early if the dressing is no longer adhesive.
223991652|NCT05143164|DRUG|Gentamicin Sulfate, Topical|Application of gentamicin to exit site daily
223991653|NCT02296216|DEVICE|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
223991654|NCT02493946|BIOLOGICAL|Botulinum toxin type A|
223991655|NCT02493946|DRUG|Placebo|
223991656|NCT02353468|DRUG|Bortezomib|Given IV
223991657|NCT02353468|DRUG|Lenalidomide|Given PO
223991658|NCT02353468|DRUG|Dexamethasone|Given PO or IV
224294800|NCT04495283|DRUG|Pregabalin|Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.
223544877|NCT00625534|PROCEDURE|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
223991659|NCT00729638|DRUG|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
223991660|NCT00729638|DRUG|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
223991661|NCT02793310|PROCEDURE|DMEK|The intervention group will receive cornea transplantation by DMEK
223991662|NCT02793310|PROCEDURE|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
223991663|NCT05105048|BIOLOGICAL|mRNA-1647|Lyophilized product that is reconstituted with saline
223991664|NCT05105048|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
223991665|NCT04375553|OTHER|Aerobic exercise|Intradialytic aerobic exercise
223991666|NCT00848484|DRUG|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
223991667|NCT00848484|DRUG|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
223991668|NCT04857567|BEHAVIORAL|TSC program (Three Self-Commitment program)|"1. Self-Competence program~   \- A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~2. Self-Care program~   \- A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~3. Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent"
224121756|NCT02096146|PROCEDURE|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
224121757|NCT05565300|OTHER|Cycling exercise|30 minutes of cycling (90 rpm).
223544878|NCT00625534|PROCEDURE|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
223991669|NCT04192110|DRUG|Diuretic initiation or augmentation|The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
223991670|NCT01907698|BEHAVIORAL|Vaginal intercourse|vaginal intercourse at least twice a week
224294801|NCT04495283|DRUG|Acetaminophen|Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
224294802|NCT04495283|OTHER|Placebo 1|Placebo for APAP
224294803|NCT04495283|OTHER|Placebo 2|Placebo for combination
224294804|NCT00107705|BIOLOGICAL|Tree MATA MPL|
224294805|NCT03383237|DRUG|Apatinib|500mg/d,q.d.,p.o.
224294806|NCT06645444|OTHER|immediate implant placement with customized PEEK healing abutment|"* an intraoral examination will be done and a digital impression will be taken by the intraoral scanner (MEDIT i500) for a pre-extraction digital model, and CBCT will be taken for prosthetic-driven planning.~* Once the treatment plan formulated, both STL (Standard Triangle Language) and DICOM (CBCT raw data) files format will be sent to produce the digital surgical guide with metal sleeve.~* Then, a customized PEEK healing abutment will be made mimicking the anatomical cervical contour and pseudo-CEJ will be made by merging the STL and DICOM digitally and the exterior surface of the healing abutment will be designed to resemble a tooth.~* Then, the technicians will mill the customized healing abutment digital design from a pre-milled 14 × 14 mm PEEK block (BioHPP, Bredent®, Bolzano, Italy) with a non-hex connection type, polished it, and sterilized it.~* The digital surgical guide with a metal sleeve will be back for scheduled patient implant surgery."
224294807|NCT01792934|DRUG|XELOX regimen according to standard procedures|
224294808|NCT01792934|DRUG|FOLFOX regimen according to standard procedures|
223544879|NCT00175929|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
223991671|NCT05808296|OTHER|Lavander oil Aromatherapy|Lavander oil Aromatherapy
223991672|NCT05808296|OTHER|Saline Solution|Saline solution application
223991673|NCT03151746|DRUG|Placebo|Placebo pill administered orally 1 hour before planned surgical procedure
223991674|NCT03151746|DRUG|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
223991675|NCT00290901|DRUG|Tramadol Hydrochloride 50mg|
223991676|NCT00290901|DRUG|Celebrex 200mg|
224121758|NCT05565300|OTHER|Cognitive tasks|30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
224121759|NCT02641236|DRUG|Vancomycin-polymyxin B|
224121760|NCT03683433|DRUG|Azacitidine|Given SC or IV
224121761|NCT03683433|DRUG|Enasidenib Mesylate|Given PO
224121762|NCT00069576|BEHAVIORAL|nutritional counseling|
224121763|NCT00069576|BEHAVIORAL|self blood glucose monitoring|
224294809|NCT01792934|PROCEDURE|Surgery|
224294810|NCT01792934|OTHER|radiofrequency ablation (RFA)|
224294811|NCT01792934|OTHER|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
224121764|NCT05544422|OTHER|The Timed Up & Go Test and 30second Chair-Stand Test'|"Evaluation of the participants will be carried out in the following order; 1) traditional assessment, 2) tele-assessment, 3) post-test. In the final test, only tele-assessment of the tests will be made.~During testing sessions, the results of each TUG and 30s-CST trial will be recorded on a standard test paper. TUG and 30s-CST will be tested in two different ways, traditional and tele, as 2 sessions every other day. Participants will rest for five to ten minutes between trials and an hour between sessions. During the one-hour rest between two test sessions, participants will rest in a chair, wheelchair or bed. Assessors will not know the TUG and 30s-CST results scored by each other."
224121765|NCT05955586|DRUG|SPR720|SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
224121766|NCT04431154|BEHAVIORAL|Provision of HIV self-screen kit with incentives and linkage promotion|This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
223991677|NCT01059305|DRUG|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
223991678|NCT01234415|DEVICE|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
223991679|NCT00785954|DRUG|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
223991680|NCT03109236|DRUG|GCSF|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
223991681|NCT03109236|PROCEDURE|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10\^6 and up to 50-100 x 10\^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
223991682|NCT01239784|BEHAVIORAL|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
223991683|NCT00969683|DEVICE|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
223991684|NCT00969683|DEVICE|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
223991685|NCT01244165|DEVICE|Cytrix|
223991686|NCT01244165|OTHER|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
224121767|NCT05279612|RADIATION|Short-term neoadjuvant chemoradiotherapy|Short-term radiotherapy ( 25 Gy, 5f ) + XELOX regimen was performed before operation for two cycles. After the condition was evaluated by enhanced CT, whether the patients belonged to PD, SD, PR and CR was analyzed (reference RECIST 1.1). Surgery was performed four weeks after chemotherapy.
224294812|NCT01792934|RADIATION|stereotactic body radiation therapy (SBRT)|
224294813|NCT01792934|DRUG|Bevacizumab|may be added to both regimens according to standard procedures
224294814|NCT01792934|PROCEDURE|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
224294815|NCT02058082|PROCEDURE|Intracytoplasmic sperm injection|
224294816|NCT03028948|OTHER|Internet-Based Intervention|Access ITW
224294817|NCT03028948|OTHER|Questionnaire Administration|Ancillary studies
224294818|NCT03028948|OTHER|Survey Administration|Ancillary studies
224294819|NCT03093818|OTHER|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 48 genetic variants for the following 13 pharamacogenes: CYP2B6 (cytochrome P450), CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), NUDT15 (Nudix hydrolase), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
224294820|NCT05142566|DEVICE|MANTA Vascular Closure Device|Evaluate the safety of ultrasound guided deployment of MANTA VCD.
223991687|NCT00153985|DRUG|Busulfex|Given once daily for 4 days
223991688|NCT00153985|DRUG|Fludarabine|Given intravenously once daily for 4 days
223991689|NCT00153985|DRUG|Alemtuzumab|One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
223991690|NCT00153985|PROCEDURE|Stem Cell Transfusion|Performed three days after the end of chemotherapy
223991691|NCT02595099|OTHER|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
223991692|NCT02102412|BIOLOGICAL|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
223544880|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
223991693|NCT00535379|DRUG|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
223991694|NCT01225497|PROCEDURE|Standard eccentric exercise|"Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.~The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.~All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain."
223991695|NCT01225497|PROCEDURE|Eccentric exercise-Experimental group|Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
223991696|NCT00431613|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
223991697|NCT00431613|DRUG|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
223991698|NCT00431613|DRUG|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
223991699|NCT00431613|RADIATION|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
223991700|NCT00431613|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
223991701|NCT03135990|BEHAVIORAL|Cognitive Behavioral Therapy with Virtual Reality Technology|Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
223991702|NCT05051969|BEHAVIORAL|Remote Mindfulness-Based Stress Reduction Program|Enrolled participants will participate in a remote-delivered (online with audio and video) Mindfulness-Based Stress Reduction (MBSR) program. MBSR is a well established behavioral health intervention consisting of 10-sessions lasting 2.5 hours, with one session lasting 7.5 hours in an all-day retreat format over a 2-month period.
223991703|NCT03530748|PROCEDURE|Endovascular therapy and Imaging Acquisition|"1. Endovascular repair for renal artery stenosis;~2. Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney"
223991704|NCT01983423|DEVICE|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
223991705|NCT01715883|DRUG|Sodium Nitrite|Same as the details in Arm Description.
223991706|NCT00251342|PROCEDURE|Edinburgh Postnatal Depression Scale|
224121768|NCT01940016|BEHAVIORAL|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
223991707|NCT01806012|DEVICE|Sealing tissue with the Enseal device|
223991708|NCT01806012|PROCEDURE|Conventional supracervical hysterectomy|
223991709|NCT00356005|DRUG|azithromycin plus artesunate|
223991710|NCT00356005|DRUG|Artesunate|
223991711|NCT00005637|DRUG|carmustine|
223991712|NCT00005637|DRUG|temozolomide|
224121769|NCT01940016|BEHAVIORAL|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
223544881|NCT00175929|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
223991713|NCT05000047|DEVICE|3D ear scanner|A commercially-available ear scanning device used according to standard of care. A hand-held device is used and is considered less invasive than conventional earmold impressions.
223991714|NCT05000047|OTHER|Conventional silicon ear impressions|A two part silicon impression material that is used to fill the ear and produce a physical cast of the ear canal. The procedure is standard of care.
224121770|NCT02833610|DRUG|Denosumab Q4W|
224121771|NCT00496522|PROCEDURE|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
223544882|NCT03849664|DRUG|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
223544883|NCT03849664|DRUG|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
223544884|NCT03849664|DRUG|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
223991715|NCT03017742|DEVICE|Pulse Oximeter|
223991716|NCT04038242|OTHER|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
223991717|NCT00537342|BIOLOGICAL|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
223991718|NCT00950482|PROCEDURE|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
223991719|NCT00950482|OTHER|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
223991720|NCT00950482|OTHER|WC|Waiting Group
223991721|NCT03928223|OTHER|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
223991722|NCT00154687|DRUG|Paclitaxel, Cisplatin, 5-Fluorouracil|
223991723|NCT02445651|DIETARY_SUPPLEMENT|Intravenous and Oral n-acetyl cysteine|
223991724|NCT05329168|DRUG|Tonabacase (LSVT-1701)|4.5 or 6.0 mg/kg IV once daily for 4 days
223991725|NCT03330613|DIAGNOSTIC_TEST|PAEDS|pediatric emergency delirium scale
223991726|NCT03330613|PROCEDURE|TIVA|Total intravenous anesthesia with propofol
223991727|NCT03330613|PROCEDURE|Inhalational anesthesia|Inhalational (volatile) anesthesia with sevoflurane
223991728|NCT04069585|DEVICE|RHA® Redensity with new anesthetic agent|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
223991729|NCT04069585|DEVICE|RHA® Redensity with lidocaine|A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
223991730|NCT05620615|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
223991731|NCT01075477|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
223991732|NCT00508209|DRUG|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
223991733|NCT02931305|DRUG|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
223991734|NCT02931305|DRUG|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
223991735|NCT05822492|PROCEDURE|Group QLB3|"Patients who applied the QLB3 block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
224121772|NCT04430738|DRUG|tucatinib|For Cohort 1A, 150 mg will be administered twice daily by mouth (orally) from Cycle 1 Day 8 onwards. For all other cohorts, 300 mg (or intermediate dose) will be given orally twice daily starting on Cycle 1 Day 1.
224121773|NCT04430738|DRUG|trastuzumab|Cohorts 1A and 1B: a 6 mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 Day 1, followed by a dose of 4 mg/kg IV every 2 weeks starting on Cycle 2 Day 1. Cohorts 1C, 1D, 1E, 1F, 1G, 2A, and 2B: an 8 mg/kg loading dose will be administered IV on Cycle 1 Day 1, followed by a dose of 6 mg/kg IV every 3 weeks thereafter.
224121774|NCT04430738|DRUG|oxaliplatin|85 mg/m\^2 given IV every 2 weeks for cohorts using FOLFOX. For cohorts using CAPOX regimen, 130 mg/m\^2 given every 3 weeks.
224121775|NCT04430738|DRUG|leucovorin|200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
224121776|NCT04430738|DRUG|fluorouracil|400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
224121777|NCT04430738|DRUG|capecitabine|1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
224121778|NCT04430738|DRUG|pembrolizumab|400 mg given by IV on day 1 of cycle 1, then every 6 weeks.
224121779|NCT02834312|DRUG|Estetrol|All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
224121780|NCT02834312|DRUG|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
224121781|NCT05590793|DRUG|Triptorelin pamoate (embonate) salt|Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.
224121782|NCT06533293|DEVICE|Neck Brace Device|"The neck brace device will be manufactured in the Mechanical Department at Columbia University. The device measures head motion and EMG by electronic sensors, passively supports the head in certain configurations by springs, and actively assists head movement by motors.~Motor learning principles will be combined with robotics to apply gentle forces on the head-neck during training."
224121783|NCT02978118|DEVICE|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
223991736|NCT05822492|PROCEDURE|Group ESPB|"Patients who applied ESP block before PCNL surgery were included in this group~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
224121784|NCT04653545|DIAGNOSTIC_TEST|HbA1c|"Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method).~All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications."
224121785|NCT06526169|OTHER|Food Frequency, Social, Lifestyle, Demographic Questionnaires and Blood Collection|Questionnaires on food frequency, social, lifestyle, and demographics will be administered to participants and will be correlated with the presence of chemical hazards in the blood. The chemical hazards analyzed will be referenced from Singapore's Total Diet Study, based on the prioritized chemical hazards of interest to investigate the distribution of risk in the population.
224121786|NCT05640999|RADIATION|Vaginal brachytherapy|Vaginal brachytherapy should be delivered using a vaginal cylinder, or alternatively ovoids
224121787|NCT05640999|RADIATION|Adjuvant radiotherapy (EBRT +/- brachytherapy)|Treatment is to be delivered using 4-18 MV photons. MV, kV or CBCT imaging capabilities are required. Planning systems with capability for DICOM data transfer must be used.
224121788|NCT05640999|OTHER|Observation|Observation
224121789|NCT05635084|DRUG|YN001|Dose ranges from 2-90mg
224121790|NCT05635084|DRUG|Placebo for YN001|5% dextrose injection to mimic the YN001
223991737|NCT05822492|OTHER|Group Control|"Patients who did not use block before PCNL surgery were included in this group.~Multimodal analgesia protocol is applied to all patients undergoing PCNL surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg after induction of general anesthesia and iv paracetamol 1 gr intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv PCA of 0,2mg/ml morphine (the bolus dose is 20 mcg/kg, the lock-in time of 6-10 minutes, and the 4-hour limit is adjusted to be 80% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥4), 100 mg tramadol is administered to patients. The prophylaxis for postoperative nausea and vomiting (PONV) involved the routine administration of 8 mg IV dexamethasone to patients before induction and 0.15 mg/kg IV ondansetron 20 minutes before the end of the procedure."
223991738|NCT04107753|BEHAVIORAL|Brief counseling based on the 5As model|"It is a structured brief counselling perfomed by nurse who takes clinical care of the patient and it is performed as follow:~1. ASK: every patient should be asked whether he/she is or is not a smoker;~2. ADVICE: the patient is advised to quit in a strong, clear and personalized way;~3. ASSESS: the patient is asked if he/she would like to quit and the strenght of his/her dependence is assessed.~4. ASSIST: The smoker interested in quitting are assisted in their attempts, for example by helping them to define a quit date, by advising them about strategies against withdrawal symptoms and by providing them information material; patients are asked whether they want to be contacted by the CTT.~5. ARRANGE: this step is only addressed to the patients who have started a treatment in the CTT and is expected to prevent or treat eventual relapses."
223991739|NCT03843099|BEHAVIORAL|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
223991740|NCT03843099|BEHAVIORAL|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
223991741|NCT00279188|PROCEDURE|Guiding therapy by bronchial hyperrsponsiveness|
224121791|NCT03036592|BEHAVIORAL|Early OGTT|Oral glucose tolerance test using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
223729094|NCT00671892|BIOLOGICAL|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
224121792|NCT03036592|BEHAVIORAL|Late OGTT|Oral glucose tolerance test using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
224121793|NCT05471843|DRUG|BGB-11417|Administered orally
224121794|NCT06562543|DRUG|Fruquintinib|Oral capsules
224121795|NCT05407714|DEVICE|SpaceOAR Treatment|"SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
224121796|NCT05915351|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25 mg/kg on D1, D8, D15 every 28 days
223729095|NCT01635946|DRUG|Isavuconazole|oral
223729096|NCT01635946|DRUG|atorvastatin|oral
223729097|NCT04614740|DRUG|VC004|25 mg capsules,50 mg capsules,100 mg capsules.
223729098|NCT03730246|PROCEDURE|cesarean sectio|consecutive parturients due for cesarean sectio
223729099|NCT04981951|DRUG|Dexmedetomidine|Highly selective α2-adrenergic receptor agonist. With sedative, analgesic, peri-operative sympatholytic and hemodynamic stabilizing properties.
223991742|NCT00762476|DRUG|3804-250A|"* topical product~* apply 2 pumps~* apply at least every 4 hours or after hand washing"
223991743|NCT00762476|DRUG|3804-291|"* topical~* apply 2 pumps~* apply at least every 4 hours or after hand washing"
223991744|NCT00992342|DRUG|PF-03893787|oral solution, 5 mg, QD for 14 days
223991745|NCT00992342|DRUG|PF-03893787|oral solution, 15 mg, QD for 14 days
223991746|NCT00992342|DRUG|PF-03893787|oral solution, 50 mg, QD for 14 days
223991747|NCT05444946|DRUG|Prednisone tablet and Itraconazole|Oral prednisolone 0.5 mg/Kg body weight tapered over 4 months and oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. traconazole will be given for 12 months
223991748|NCT05444946|DRUG|Oral itraconazole|Oral itraconazole (400 mg/day). The dose of itraconazole will be adjusted according to therapeutic drug monitoring to achieve a serum trough level of 0.5 microgram/mL. Itraconazole will be given for 12 months
223991749|NCT02116569|DRUG|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
223991750|NCT01636245|BIOLOGICAL|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
223991751|NCT01636245|BIOLOGICAL|placebo|placebo, two doses, 28 days interval
223991752|NCT06517238|OTHER|There is no intervention|Observal Study.There is no intervention
223991753|NCT05072652|OTHER|Neuromuscular Electrical Stimulation|Participants in this group will perform twice daily neuromuscular electrical stimulation training sessions of the quadriceps muscles (specifically, the vastus lateralis and rectus femoris) or the immobilized left leg.
224121797|NCT02499146|DRUG|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
224121798|NCT02499146|DRUG|Letrozole|2.5 mg , orally once daily (continuously)
224121799|NCT06313190|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.
224121800|NCT06313190|DRUG|Sintilimab|Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.
224121801|NCT05776758|DRUG|cisplatin based neoadjuvant chemotherapy|cisplatin based neoadjuvant chemotherapy
223729100|NCT02637453|PROCEDURE|PVI|Pulmonary vein isolation
223991754|NCT05072652|OTHER|Action Observation + Mental Imagery|Participants in this group will perform daily action observation + mental imagery training via video and audio recordings.
223991755|NCT05323019|BEHAVIORAL|Psychotherapy|Participants will receive 8 remote therapy sessions conducted via phone or video, Therapy sessions consists of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participant. Participants will also receive supportive text messages on selected days during the 28 day study.
223991756|NCT05323019|BEHAVIORAL|Treatment as Usual|Participants will continue to receive the therapy that their treating physician felt was appropriate at the time of enrolment in the study, These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical exercise or relaxation.
223991757|NCT05323019|DRUG|Intranasal Ketamine (esketamine)|Intranasal Ketamine (esketamine) - participants will receive a dose of 56 mg for a maximum of 2 weeks, followed by 56 mg or 84 twice a week for a total of 8 doses during the 28 -day study
223991758|NCT04446091|DRUG|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs for colorectal mucinous adenocarcinoma
224121802|NCT05776758|PROCEDURE|Radical cystectomy alone|RC alone
224121803|NCT00049959|DRUG|verteporfin PDT|
224121804|NCT00022711|DRUG|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
223991759|NCT04446091|DRUG|Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan|Observe the efficacy of immune checkpoint inhibitors combined with anti-angiogenic drugs and chemotherapy for colorectal mucinous adenocarcinoma
223991760|NCT01658111|DEVICE|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
223991761|NCT01658111|PROCEDURE|Traditional physiotherapy|Active or passive exercises.
223991762|NCT03931759|DIAGNOSTIC_TEST|laparoscopic surgery|patients with diabetes mellitus in laparoscopic surgery
223991763|NCT02878603|BIOLOGICAL|Caplacizumab|
223991764|NCT02878603|OTHER|Standard of Care|• PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab).
223991765|NCT02892643|PROCEDURE|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
223991766|NCT02892643|PROCEDURE|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
223991767|NCT00866489|PROCEDURE|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
223991768|NCT01551368|DRUG|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
223991769|NCT01551368|DRUG|Placebo|Identical inactive tablets.
223991770|NCT03620097|DIETARY_SUPPLEMENT|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
223991771|NCT03620097|OTHER|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
223991772|NCT03127670|DRUG|Solanum melongena peel extract 0.05%|Administered topically twice daily for 12 weeks
223991773|NCT01543542|RADIATION|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
223991774|NCT05845203|DIAGNOSTIC_TEST|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere|perform a simultaneous bilateral DTC acquisition of 20 seconds per hemisphere
223991775|NCT00246935|DRUG|Roflumilast|
223991776|NCT04154852|DRUG|Adalimumab|
223991777|NCT04154852|DRUG|Methotrexate|
223991778|NCT04154852|DRUG|Placebo|Placebo to replace adalimumab
223991779|NCT04154852|DRUG|Folic Acid|
223991780|NCT00599274|DRUG|Interferon beta-1a|injection once a week
223991781|NCT00599274|DRUG|Interferon beta-1a|injection three times a week
223991782|NCT03889847|DEVICE|Fibreoptic intubation with silicone double lumen tube|Fibreoptic intubation with silicone double lumen tube
223991783|NCT03889847|DEVICE|Fibreoptic intubation with PVC double lumen tube|Fibreoptic intubation with PVC double lumen tube
223991784|NCT02838134|OTHER|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
223991785|NCT02838134|OTHER|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
223991786|NCT04674189|BIOLOGICAL|CVnCoV Vaccine|Intramuscular injection
223991787|NCT04674189|DRUG|Placebo|Intramuscular injection
223991788|NCT01357642|DRUG|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
223991789|NCT01357642|DRUG|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
223991790|NCT01357642|DRUG|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
224121805|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
224121806|NCT02235753|BEHAVIORAL|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
224121807|NCT02275026|PROCEDURE|Functional magnetic resonance imaging|Diffusion tensor imaging
224121808|NCT02974062|OTHER|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
224121809|NCT01585129|DRUG|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
224121810|NCT01585129|DRUG|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
224121811|NCT05883267|DEVICE|Virtual reality glasses|"PICO model neo 2 VR glasses"
223729101|NCT02637453|PROCEDURE|CPVI+6L|After PVI, 6 ablation lines were added with an extension from pulmonary vein ostium at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
223991791|NCT06502392|OTHER|Assessment of creatine phosphokinase|Assessment will be done through collecting a blood sample.
223991792|NCT06502392|OTHER|Assessment of pelvic floor muscle strength|Assessment will be done by a biofeedback.
223991793|NCT00111267|BEHAVIORAL|vitamin B12 supplementation|
223991794|NCT00111267|BEHAVIORAL|vitamin B12 + folic acid combined supplementation|
223991795|NCT05403931|DEVICE|Low level laser therapy|Omega XP is the particular device producing low level laser therapy and has been in use for therapeutic purposes to treat different musculoskeletal conditions.
223991796|NCT04489108|DRUG|Tranexamic acid|Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
224121812|NCT05883267|DEVICE|Vocal-guided affective imagery|Audio via telephone
224121813|NCT01728272|DRUG|blood concentration of metoprolol|measure blood concentration of metoprolol
224121814|NCT05544825|DIETARY_SUPPLEMENT|Ice plant group|Ice plant extract 2,000 mg/day for 12 weeks
224121815|NCT05544825|DIETARY_SUPPLEMENT|Placebo group|Placebo 2,000 mg/day for 12 weeks
224121816|NCT05468086|DEVICE|VR Solace|Participants will use the VR audio and visual head-mounted device. The device is a standalone VR headset. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
224121817|NCT05415202|DRUG|Remimazolam 20 MG [Byfavo]|Remimazolam will be administered for sedation and efficacy and safety will be recorded
224121818|NCT04591314|BEHAVIORAL|Neurofeedback|The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
224121819|NCT04578717|PROCEDURE|Air-abrasion|A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
224121820|NCT04578717|PROCEDURE|Adhesive application - Etch&rinse|Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
224121821|NCT04578717|BIOLOGICAL|Adhesive application - Self-etch|The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
223729102|NCT01144923|OTHER|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
223729103|NCT01144923|PROCEDURE|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
223991797|NCT04489108|OTHER|Standard Medical Treatment|Standard Medical Treatment
223991798|NCT04489108|OTHER|Placebo|isotonic solution (saline)
223991799|NCT04240249|BEHAVIORAL|Constructive self-assertiveness program via the internet|"Participants will get one chapter a week to work with. All chapters are presented on web pages and include information and exercises and end with homework assignments."
223991800|NCT02847481|PROCEDURE|fecal microbiota transplantation|fecal microbiota transplantation
223991801|NCT02847481|DRUG|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
223991802|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
223991803|NCT02847481|PROCEDURE|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
223991804|NCT01889576|DIETARY_SUPPLEMENT|Magnesium Oxide|
223991805|NCT04017338|DRUG|Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet|A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
223991806|NCT04017338|DRUG|Ezetimibe 10Mg Oral Tablet|A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
223991807|NCT04017338|DEVICE|Ex Vivo Lung Perfusion|A technology that allows for the assessment and treatment of lungs prior to transplant.
223991808|NCT01564277|DRUG|rasburicase|Given IV
224121822|NCT04098952|OTHER|Group 1: Manual Therapy|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
223991809|NCT01564277|DRUG|allopurinol|Given PO
223991810|NCT01637077|DRUG|pregabalin|Given PO
223991811|NCT01637077|DRUG|placebo|Given PO
223991812|NCT01637077|OTHER|questionnaire administration|Ancillary studies
223991813|NCT03643549|DRUG|Bortezomib and Temozolomide Phase IB|In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
223991814|NCT03643549|DRUG|Bortezomib and Temozolomide Phase II|The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
223991815|NCT04833413|DRUG|Continuous intensive insulin therapy|After initial intensive insulin therapy in hospital, patients were grouped according to different treatment regimens within 6 months of discharge
223991816|NCT04796311|DIAGNOSTIC_TEST|blood samples|T cells, B cells and cytokines testing
223991817|NCT03867162|BIOLOGICAL|Live Attenuated Tularemia Vaccine|Subjects will be vaccinated with a bifurcated needle; approximately 0.06 mL of the reconstituted vaccine will be placed on the volar surface of the forearm and applied by multiple puncture.
223991818|NCT04091035|OTHER|To describe the incidence of disease and evaluate risk factors|Se above
223991819|NCT03979534|OTHER|low protein diet|Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
223991820|NCT03731923|DIAGNOSTIC_TEST|Biannual ultrasonography|Biannual liver ultrasonography for HCC surveillance, without contrast agent.
223991821|NCT03731923|DIAGNOSTIC_TEST|Annual abbreviated liver MRI|Abbreviated liver MRI using standard dose of extracellular contrast agent (Dotarem, Guerbet, France) on weight-based dosing. Table time targets 10 minutes.
223991822|NCT02320513|OTHER|Wearing activty monitoring device (Fitbit Flex)|
223991823|NCT02320513|DEVICE|Fitbit Flex|
223991824|NCT02842437|DRUG|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
223991825|NCT02842437|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
223991826|NCT00515788|DRUG|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
223991827|NCT00515788|DRUG|Temozolomide|100 mg/m\^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
223991828|NCT02595372|DRUG|Omeprazole|
223991829|NCT00500344|DRUG|Lucentis (ranibizumab)|intravitreal injection
223991830|NCT04937322|PROCEDURE|Interventional Endoscopy procedures|• All patients who have had Interventional Endoscopy procedures done which involved radio frequency ablations and stent insertion(s) for pancreatico-biliary disorders.
224121823|NCT04098952|OTHER|Group 2: Interferential massage plus Manual Therapy|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
224121824|NCT00279903|DRUG|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
223991831|NCT01552759|PROCEDURE|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
223991832|NCT01552759|BEHAVIORAL|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
223991833|NCT01552759|BEHAVIORAL|Test meal|Subjects are presented with an ad libitum buffet meal.
223991834|NCT00794924|DIETARY_SUPPLEMENT|VSL#3|one sachet per day, for 45 consecutive days
223991835|NCT00794924|DIETARY_SUPPLEMENT|placebo|one sachet per day, for 45 consecutive days
223991836|NCT05334043|DRUG|CuminUP30|7 capsules, 500 mg / capsule
223991837|NCT05334043|DRUG|Curcumin capsules|5 capsules, 450 mg / capsule
223991838|NCT00953615|DRUG|Thalidomide|Titrate to 400 mg daily for 6 months
223991839|NCT01594970|DRUG|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
224121825|NCT00279903|DRUG|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
223544885|NCT03849664|DRUG|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
223991840|NCT04794153|DIETARY_SUPPLEMENT|whole food sources|Foods selected are naturally high in protein and consumed by the general population as part of a meal.
223991841|NCT03053453|PROCEDURE|Spinal Surgery|TKA under standard of care spinal surgery.
223991842|NCT03053453|DEVICE|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
223991843|NCT02985359|DIETARY_SUPPLEMENT|Nutributter|Daily 20g Nutributter provided to children 6 to 24 month of age
223991844|NCT02985359|BEHAVIORAL|Social Behavioral Change Communication (SBCC)|Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
223991845|NCT04600388|DEVICE|Nerivio|Nerivio Remote Electrical Neuromodulation (REN) device
223991846|NCT00521157|DRUG|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
223991847|NCT03306420|DRUG|M4112|All participants who received M4112 100,200,400,600 and 800 mg twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
223991848|NCT02337621|OTHER|No intervention|
223991849|NCT01055704|DRUG|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
223991850|NCT01055704|DRUG|Codeine only|30 mg taken orally four times daily for 5 days
223991851|NCT01055704|DRUG|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
223991852|NCT01055704|DRUG|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
223991853|NCT01969851|DRUG|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
223991854|NCT00065624|DRUG|lipoic acid|
223544886|NCT05455125|DIAGNOSTIC_TEST|CMR CGI|High resolution ECGI plus advanced CMR
223991855|NCT04727177|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive biological stimulation technique born in the middle of 1980's.
223991856|NCT04351308|DRUG|MAPI chemotherapy|"AP = Doxorubicin (Adriamycin) 37.5 mg/m2/day \* 2day (total/cycle 75 mg/m²)~\+ Cisplatin 120 mg/m2/course (total/cycle 120 mg/m²) ; M = Methotrexate 12000 mg/m2 (total/cycle 12000 mg/m²) with leucovorin rescue; I = Ifosfamide 2400 mg/m2/day \*5day (total/cycle 12000 mg/m²)"
223991857|NCT04351308|DRUG|Apatinib Mesylate|anti-angiogenesis tyrosine kinase inhibitors 500 mg orally daily
223991858|NCT04351308|DRUG|Camrelizumab|anti-PD-1 antibody 200mg ivgtt. Q2W
223991859|NCT00452140|BIOLOGICAL|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
223991860|NCT04196634|OTHER|Risk assessment|People on sick leave due to musculoskeletal conditions will be screened for potential risk factors for prolonged sickness absence. No intervention will be given.
223991861|NCT04640740|PROCEDURE|hip arthroplasty|two different approaches of total hip arthroplasty
223991862|NCT00763464|PROCEDURE|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
223991863|NCT00763464|PROCEDURE|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
223991864|NCT05615584|DIAGNOSTIC_TEST|Quantitative mass spectrometry assay|ORX-A determination by quantitative mass spectrometry
223991865|NCT01722279|PROCEDURE|Bariatric surgery|
223991866|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
223991867|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
224121826|NCT05251935|OTHER|Foot Muscle Exercise Protocol|Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
224121827|NCT05251935|COMBINATION_PRODUCT|Arch Support Insole and One Leg Balance Activities|Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
224121828|NCT01937208|RADIATION|intensity modulated radiation therapy in both arms|
224121829|NCT01937208|DRUG|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
223991868|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
223991869|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
223544887|NCT01833858|DRUG|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
223991870|NCT01299480|BIOLOGICAL|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
223991871|NCT03122470|DEVICE|MRI guided biopsy|The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
223991872|NCT03122470|PROCEDURE|TRUS biopsy|The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
223991873|NCT03570268|OTHER|Experimental Group: Education|Participants in the experimental intervention group received an educational program and tailored home exercises.
223991874|NCT03570268|OTHER|Control Group: Usual care|Participants allocated to the control group received stretching exercises.
223991875|NCT00566891|DRUG|tirofiban|tirofiban high dose bolus 25µ/Kg
223991876|NCT00566891|DRUG|Clopidogrel|
223991877|NCT00763490|PROCEDURE|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
223991878|NCT00763490|DRUG|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
223991879|NCT00763490|RADIATION|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
224121830|NCT02494349|DRUG|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
223544888|NCT01833858|DRUG|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
223544889|NCT00898170|PROCEDURE|myoma removal|surgical removal of myoma by hysterectomy
223991880|NCT00763490|DRUG|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
224121831|NCT02494349|DRUG|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
224121832|NCT00841295|DRUG|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
224121833|NCT00841295|DRUG|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
224121834|NCT03558932|DIAGNOSTIC_TEST|pleural biopsy|diagnostic sampling
224121835|NCT03280732|DEVICE|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
224121836|NCT02244359|BEHAVIORAL|Training|
224121837|NCT02244359|BEHAVIORAL|Usual care|
223544890|NCT00235183|OTHER|plasma|transfusion of more than 15 mL/Kg of plasma
223729104|NCT01144923|OTHER|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
224121838|NCT04869956|OTHER|Dietary pattern : High-fiber diet rich in PUFA|High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
224121839|NCT04869956|OTHER|Dietary pattern: Standard diet|standard nutritional recommendations
224121840|NCT01108809|DRUG|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
224121841|NCT01892254|DRUG|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
224121842|NCT01892254|DRUG|Placebo|Placebo (to metformin)
224121843|NCT00002677|DRUG|chemotherapy|
224121844|NCT00002677|DRUG|tributyrin|
224121845|NCT04736511|OTHER|Star Excursion Balance Test|"The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average."
223991881|NCT00763490|DRUG|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) \< 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
223991882|NCT03808792|DIAGNOSTIC_TEST|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
223991883|NCT04906681|DEVICE|i-ACT|i-ACT is a Microsoft Kinect-based system that provides individualised exercises based on patients own goalsetting.
223991884|NCT03072524|DIAGNOSTIC_TEST|FAST PLUS test|FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
224121846|NCT04736511|OTHER|Single leg Drop Vertical Jump|The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.
224121847|NCT04736511|OTHER|Unplanned sidestep cutting manoeuvre|"The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed."
224121848|NCT04736511|OTHER|Tendon vibration|The subject will be asked to stand, motionless in bipodal (both feet on the ground) support on a stable and unstable ground (foam). A tendon vibration (80Hz) will be randomly applied to the subject in the Achilles tendons or paravertebral muscles. This vibration will cause an alteration of proprioceptive information in the vibrated area leading to a disruption of postural balance. Thus, according to the amount of displacement of the center of pressure (CoP), the proprioceptive weighting ratio (dRPW) is calculated to deduce therefrom the weight assigned by the CNS to the various proprioceptive inputs during the postural task.
224121849|NCT03262493|DEVICE|Interventional Group|Use of the feeding tube attachment device (FTAD).
224121850|NCT02549677|DRUG|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
224121851|NCT02549677|DRUG|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
224121852|NCT02549677|DRUG|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
224121853|NCT01270893|DRUG|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
224121854|NCT04815629|RADIATION|Radiotherapy|Radiotion therapy squamous cell carcinoma in cancer bladder
224121855|NCT00393289|BEHAVIORAL|Calcium controlled diet|
223991885|NCT04625959|BEHAVIORAL|Behavioral Therapy for Eating Disorders|Change behaviors that maintain binge eating (e.g. rigid dietary restriction outside of binge episodes, irregular or chaotic eating patterns).
223991886|NCT04625959|BEHAVIORAL|MABT: Mindful Awareness|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically mindful awareness, designed to enhance self-regulation. Mindful awareness strategies include developing inner and outer wisdom, formal meditation, and shifting awareness to the present moment. Mindful awareness skills also include increasing awareness of thoughts, feelings, physical sensations, and hunger and fullness cues.
223991887|NCT04625959|BEHAVIORAL|MABT: Values|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically values, designed to enhance self-regulation. Values skills include identifying and clarifying values, living a values life, making values-consistent decisions, addressing competing values, values awareness, and using values to address negative moods.
224121856|NCT05518344|DEVICE|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."|"Viziatek ISL™ (hereinafter referred to as the ISL) implanted in blind eye."
224121857|NCT01283191|BEHAVIORAL|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
224121858|NCT01283191|BEHAVIORAL|Education Control|Education class
224121859|NCT03395340|DRUG|Ruxolitinib 1.5% cream|Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
224121860|NCT03395340|DRUG|vehicle cream|Matching vehicle cream applied as a thin film
224121861|NCT04691596|BEHAVIORAL|Non-cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk at any time of day
224121862|NCT04691596|BEHAVIORAL|Cue-contingent weekly incentives|Eligible to win $5 Amazon gift card conditional on completing a daily ≥10-minute walk within a +/-1 hour window of the pre-specified time of their chosen contextual walking cue
224121863|NCT04691596|BEHAVIORAL|Habit Coaching|Received an instructional video on the benefits of contextual-cue-dependent habits and instructions on how to identify an optimal personalized cue that would consistently trigger their ≥10-minute walking habit
223991888|NCT04625959|BEHAVIORAL|MABT: Emotion Modulation|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically emotion modulation, designed to enhance self-regulation. Emotion modulation skills include long-term habits for emotion regulation, coping strategies, crisis management, and cognitive reappraisal.
223991889|NCT04625959|BEHAVIORAL|MABT: Distress Tolerance|Integrates behavioral treatment for eating disorders with a set of psychological strategies, specifically distress tolerance, designed to enhance self-regulation. Distress tolerance skills include psychological acceptance, uncoupling, willingness, and dealing with dirty distress.
223991890|NCT06533488|OTHER|Perceptual learning module|Perceptual learning module providing feedback on the most relevant image for clinical practice in a spinal ultrasound video.
223991891|NCT06533488|OTHER|Control|Participants in the control group will view the same videos as participants in the intervention group without feedback on the best image.
223991892|NCT00115518|DRUG|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
223991893|NCT00329680|DIETARY_SUPPLEMENT|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
223991894|NCT00329680|DIETARY_SUPPLEMENT|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
223991895|NCT02847039|GENETIC|Blood samples|Blood samples at baseline.
223991896|NCT02583529|DEVICE|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
223991897|NCT02583529|DEVICE|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
223991898|NCT02016378|BEHAVIORAL|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
223991899|NCT02016378|BEHAVIORAL|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
223991900|NCT02389764|DRUG|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
223991901|NCT02389764|BEHAVIORAL|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
223991902|NCT05167890|DIETARY_SUPPLEMENT|Coffee|Coffee 3 times per day
223991903|NCT05167890|DIETARY_SUPPLEMENT|Orange juice|Orange juice 3 times per day
223991904|NCT06121804|DRUG|Immunosuppressive Agents|Prescribing immunosuppressive agents
223991905|NCT05714605|BEHAVIORAL|THRIVE Intervention|The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals following hospitalization.
224121864|NCT04691596|BEHAVIORAL|App use instructions|Received a basic training with the StepUp app
224121865|NCT05399758|DEVICE|NOL monitor|NOL monitor data will be acquired, as well as clinical assessment of pain and fentanyl dosage.
223991906|NCT06069453|DEVICE|Hyaluronic Acid (HA) sodium salt and Hydeal-D|intravesical solution containing Hyaluronic Acid (HA) sodium salt and Hydeal-D
223991907|NCT01405677|BIOLOGICAL|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
223991908|NCT01405677|BIOLOGICAL|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
223991909|NCT01405677|BIOLOGICAL|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
223991910|NCT02802358|PROCEDURE|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
223991911|NCT04686682|DRUG|JAB-8263|Variable dose, orally Q2D with 28 days each cycle
223991912|NCT04686682|DRUG|JAB-8263|RP2D dose, orally Q2D with 28 days each cycle
223991913|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
223991914|NCT01320878|DRUG|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
223991915|NCT01320878|DRUG|distilled water|distilled water 2 ml per session
223991916|NCT02401971|DRUG|Thalidomide|Given orally
223991917|NCT02401971|DRUG|CPT-11|Given Ivgtt
223991918|NCT04792398|DRUG|Incobotulinumtoxin A (BTX A) Xeomin®|Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)
224121866|NCT01010841|DIETARY_SUPPLEMENT|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
224121867|NCT01010841|OTHER|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
224121868|NCT01968044|DRUG|Gemigliptin|
224121869|NCT01968044|DRUG|Placebo to Linagliptin|
224121870|NCT00034112|PROCEDURE|osteopathic manipulative treatment|
223544891|NCT04188990|DIETARY_SUPPLEMENT|Nutritional dietary intervention|The intervention will be carried out by the Endocrinology and Nutrition Service of hospital 1, where the type of therapeutic action to be developed will be established (Dietary advice, Oral Nutritional Supplementation (SNO), Enteral Feeding or Parenteral Nutrition). The Total Calorie Balance, calories from feeding or with Oral Nutritional Supplementation (ONS), enteral, parenteral, and protein intake will be recorded. The steps to be taken are the following: A.-In patients with preserved oral intake capacity apply the most appropriate dietary measures in each case. B.-If the oral route is contraindicated, it will be assessed if it is possible to use the gastrointestinal tract and enteral nutrition will begin until the patient recovers the oral intake capacity. C.-If the use of the gastrointestinal tract is not indicated, parenteral nutrition will be assessed until digestive function is restored.
223991919|NCT02803099|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number-SR15-63-Z13-084).
223991920|NCT04751240|BEHAVIORAL|SIT and resistance training|Participants complete 30 sessions of sprints and resistance training. Outcomes are assessed acutely and at 6 months.
223991921|NCT04355936|DRUG|Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.|Control arm will receive standard care.
223991922|NCT04479072|DRUG|Aspirin 81 mg|Subjects in the interventional arm will receive a daily dose of aspirin 81 mg, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
223991923|NCT04479072|DRUG|Placebo|Subjects in this group will receive a daily dose of a placebo pill, starting at their baseline visit and to be taken up to their 6-month follow-up visit.
223991924|NCT02134509|BEHAVIORAL|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
223991925|NCT02134509|BEHAVIORAL|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
223991926|NCT00107523|DRUG|cytarabine|
223991927|NCT00107523|DRUG|idarubicin|
223991928|NCT00107523|DRUG|pravastatin|
223991929|NCT01035541|DEVICE|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
223991930|NCT02498236|DRUG|Intranasal Oxytocin|
223991931|NCT02296892|DRUG|Remimazolam|For induction and maintenance of sedation
223991932|NCT02296892|DRUG|Placebo|Inactive control arm
223991933|NCT02296892|DRUG|Midazolam|For induction and maintenance of sedation
223991934|NCT00383123|BIOLOGICAL|Fluarix™|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
223991935|NCT00383123|BIOLOGICAL|Fluzone|"Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children \> 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1."
223991936|NCT01814072|BEHAVIORAL|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
223991937|NCT01814072|BEHAVIORAL|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
223991938|NCT01814072|BEHAVIORAL|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
223991939|NCT01814072|BEHAVIORAL|Text Messages|Participants will receive regular text messages
223991940|NCT01814072|BEHAVIORAL|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
223991941|NCT01814072|BEHAVIORAL|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
223991942|NCT02529423|DIETARY_SUPPLEMENT|Multi-nutrient supplement|"* Omega 3 fatty acids~* Folic acid~* Calcium~* Selenium~* Vitamin D3"
223991943|NCT02529423|BEHAVIORAL|Behavioral Activation|21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood-related snacking) and helpful food-related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
223991944|NCT02529423|OTHER|Placebo|Placebo pills identical in look and taste but including no active ingredients
223991945|NCT00061425|DRUG|radiolabeled epratuzumab|
223991946|NCT03566979|DRUG|Test naproxen sodium tablet|Single dose of 2 test naproxen sodium 220 mg tablets
223991947|NCT03566979|DRUG|Commercial naproxen sodium tablet|Single dose of 2 naproxen sodium 220 mg tablets
223991948|NCT03566979|DRUG|Commercial naproxen sodium liquid gels capsule|Single dose of 2 naproxen sodium 220 mg liquid gel capsules
223991949|NCT03566979|DRUG|Placebo tablet|2 placebo tablets
223991950|NCT01774045|DRUG|PDC-1421|
223991951|NCT01774045|DRUG|Placebo|
223991952|NCT00315679|DRUG|Pentoxifylline (also known as oxpentifylline)|
223991953|NCT04041973|DRUG|Artemether-lumefantrine|"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
223991954|NCT04041973|DIETARY_SUPPLEMENT|Multivitamin|"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
223991955|NCT04622098|PROCEDURE|Endoscopic ultrasound|"this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~1. the tumor location,~2. layer of origin,~3. maximal diameter,~4. regularity of extraluminal border,~5. echopattern,~6. presence of cystic spaces or echogenic foci."
224121871|NCT01641315|BIOLOGICAL|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
224121872|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of bupivacaine|270 ml of 0.5 % bupivacaine. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
224121873|NCT05131178|DEVICE|ON-Q Pump® with continuous infusion of saline|270 mL of normal saline. The device being used is a fixed flow pump meaning the rate of 2 mL/hour. The pump is connected to the catheter and left in place for up to 4 post-operative days or until the completion of the infusion.
224121874|NCT00830427|DRUG|PF-00610355|100 mcg, QD, dry powder inhaler
223991956|NCT02568670|OTHER|clinical signs|to remove the peripheral venous catheter according clinical signs
223991957|NCT01011868|DRUG|BI 10773 placebo|BI 10773 placebo
223991958|NCT01011868|DRUG|BI 10773 low dose|BI 10773 low dose
223991959|NCT01011868|DRUG|BI 10773 high dose|BI 10773 high dose
223991960|NCT01011868|DRUG|BI 10773 placebo|BI 10773 placebo
223991961|NCT00533364|DRUG|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
223991962|NCT05987254|PROCEDURE|suprainguinal fascia iliaca block|ultrasound guided suprainguinal fascia iliaca block
223991963|NCT05987254|PROCEDURE|pericapsular nerve group block|ultrasound guided pericapsular nerve group block
223991964|NCT04699760|DIETARY_SUPPLEMENT|Fish Oil|8 weeks, 2.2 G EPA/day
223991965|NCT04699760|DIETARY_SUPPLEMENT|Placebo|Placebo
224121875|NCT00830427|DRUG|PF - 00610355|600 mcg, QD, dry powder inhaler
224121876|NCT00830427|OTHER|Placebo|QD, dry powder inhaler
224121877|NCT00830427|DRUG|PF - 00610355|300 mcg, QD, dry powder inhaler
224121878|NCT01123239|BEHAVIORAL|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
223991966|NCT01727869|DRUG|REGN1400|
223991967|NCT01727869|DRUG|Erlotinib|
223991968|NCT01727869|DRUG|Cetuximab|
223991969|NCT04049981|DEVICE|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
223991970|NCT02336425|DRUG|QGE031|QGE031 120 mg per 1 mL liquid in vial
223991971|NCT02336425|DRUG|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
223991972|NCT00978562|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
223991973|NCT00978562|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
223991974|NCT00978562|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
223991975|NCT00978562|DRUG|Gadolinium|Given IV
223991976|NCT02250053|OTHER|Exercise|
223991977|NCT05393089|DRUG|AGN-190584|Eye drops
223991978|NCT05393089|DRUG|Vehicle|Eye drops
223991979|NCT06430229|PROCEDURE|Volume controlled ventilation (VCV) mode|"Patients to be ventilated with VCV mode were placed on respiratory support (Dräger Primus) with a breathing rate that would provide 8 ml/kg tidal volume, 5 cmH2O PEEP, and 30-35 mmHg end-tidal carbon dioxide concentration (etCO2) level.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded."
223991980|NCT06430229|PROCEDURE|Pressure controlled ventilation (PCV) mode|"Appropriate peak inspiratory pressure was set to create a tidal volume of 8 ml/kg in patients who would be ventilated with PCV mode. The number of breaths (Dräger Primus) was adjusted to provide an end-tidal carbon dioxide concentration (etCO2) level of 30-35 mmHg. PEEP was set to 5 cmH2O.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded."
223991981|NCT01782690|DRUG|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
223991982|NCT01782690|DRUG|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
223991983|NCT04121897|OTHER|Therapist Education and Massage for Parents of Extremely Preterm Infants|"TEMPO includes these components:~* Early Parent Education Session~* Weekly Parent Education Sessions~* Infant Massage Parent Education Sessions~* Discharge Parent Education Session~* Parent Education Post-Discharge~* Bi-weekly emails (or texts)~* 2 Month Follow-up Massage Review Session"
223991984|NCT04614168|PROCEDURE|Stepped hyperinsulinaemic-hypoglycaemic clamp study|Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
223991985|NCT04614168|DEVICE|Insulin pump|Insulin pump with a built-in algorithm that allows it to work with a CGM device to adjust insulin delivery based on CGM readings.
223991986|NCT04614168|DEVICE|Continuous glucose monitor|Continuous glucose monitoring device that sends data to the insulin pump to allow the algorithm to adjust insulin delivery. Participants are able to see the glucose data from the device when it is used in open mode.
223991987|NCT04614168|OTHER|Low carbohydrate diet|30-40g of carbohydrate per main meal portion.
223991988|NCT04614168|DEVICE|Blinded continuous glucose monitor|Allows data on blood glucose to be collected without values altering the behaviour of the participant. Participants have to continue to monitor their own blood glucose while wearing the device in the blinded mode.
223991989|NCT04614168|PROCEDURE|Stable isotope studies- D2 Glucose and D5 Glycerol|These studies will take place at the same time as the hyperinsulinaemic hypoglycaemic clamp studies. Participants will receive a priming dose of each stable isotope followed by a continuous infusion for the remainder of the clamp study.
223991990|NCT06074562|DRUG|LY3556050|Administered orally.
223991991|NCT06074562|DRUG|Placebo|Administered orally.
223991992|NCT05763342|DEVICE|The Phoenix Research System|Focused Multipolar Stimulation (FMS) strategy in adult cochlear implant recipients.
223991993|NCT06166056|DRUG|CHF6333|CHF6333 Part I SAD; CHF6333 Part II MD.
223991994|NCT06166056|DRUG|CHF6333 Placebo|Placebo Part I SAD; Placebo Part II MD.
223991995|NCT03751501|PROCEDURE|Indocyanine green-Guided Targeted Laser photocoagulation|Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.
223991996|NCT03751501|PROCEDURE|Sham laser|Therapeutic procedure used in ophthalmology
223991997|NCT00205647|DRUG|Oral N-acetycystein (NAC)|
223991998|NCT04216888|DRUG|Ketamine Hydrochloride|Intranasal administration of 40mg ketamine hydrochloride using an intranasal mucosal atomization device
223991999|NCT06646913|DEVICE|Transcutaneous Electrical Nerve Stimulation|Patients will utilize the TENS device for 45 minutes, two times per day for the 4 week treatment period.
223992000|NCT06054009|BEHAVIORAL|Brief CBT|In Study 1: x4 CBT sessions addressing cognitive appraisals of dissociation. In Study 2: x4 CBT sessions addressing rumination/worry. In Study 3: x4 CBT sessions addressing affect intolerance.
223992001|NCT00040495|DRUG|Pantoprazole|
223992002|NCT01948076|DEVICE|resident with GE vscan|resident with GE vscan
223992003|NCT01745276|DEVICE|Biphosfonate|External pins coated by biphosfonate.
223992004|NCT01745276|DEVICE|Hydroxylapatit|External pins coated by Hydroxylapatit.
223992005|NCT03995225|BEHAVIORAL|Smartband automatic smoking detection combined with brief mindfulness interventions|Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions and learn to work mindfully with cravings and triggers rather than smoke using RAIN prior to smoking episodes.This is a 3 step intervention.
224121879|NCT01123239|BEHAVIORAL|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
224121880|NCT03677089|BEHAVIORAL|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
224121881|NCT00783705|OTHER|placebo|Given orally
224121882|NCT00783705|DRUG|inositol|Given orally
224121883|NCT06058780|PROCEDURE|Implantable Collamer Lens (ICL)|Phakic intraocular lenses (pIOL) have proven to be a great alternative to corneal refractive surgery in certain situations. They offer several advantages over corneal techniques, such as being suitable for high myopes and causing relatively fewer higher-order aberrations
224294821|NCT02006368|OTHER|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
224294822|NCT01121341|PROCEDURE|Vein harvesting|Endoscopic versus conventional vein harvesting
223992006|NCT03799419|BEHAVIORAL|Cognitive bias modification for interpretation bias|Eight sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
223992007|NCT03799419|BEHAVIORAL|Psychoeducation|Eight sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
223992008|NCT03799419|BEHAVIORAL|Approach avoidance training|Eight sessions of this computerized training program will be used to train approach tendencies, following previously validated procedures (Najmi, Kuckertz, \& Amir, 2010). During the training program, participants will view a series of these images and be prompted to push or pull a joystick according to prompts on the screen, instead of the content of the picture. Avoidance will be stimulated through both pushing away (images on the screen will decrease in size upon the joystick being pushed), and approach will be stimulated through pulling towards pictures (images will increase in size to simulate approach).
223992009|NCT03799419|BEHAVIORAL|Inactive sham approach avoidance training|Eight sessions of the approach avoidance training will be administered, however the percentage of push vs pull trials will be altered in this sham version of the training.
224121884|NCT06058780|PROCEDURE|Implantable Intraocular Lens (IPCL)|The IPCL offers a distinct economic advantage as the cost of the IPCL implant is only 2. times that of the ICL implant. Moreover, the IPCL can correct higher degrees of myopia, up to -30. D, compared to the maximum correction of -18. D provided by the ICL.
224121885|NCT03854591|OTHER|No intervention|No intervention
223992010|NCT05663905|DRUG|Ambroxol Hydrochloride|IV ambroxol hydrochloride 30mg TDS as adjunct therapy to standard therapy for severe pneumonia in ICU for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour.
223992011|NCT05663905|OTHER|Standard Therapy|Standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC). This includes antibiotics stewardship and supportive therapy.
223992012|NCT04443959|BEHAVIORAL|PUMAS|Treatment consists of 6 weekly telemedicine sessions during pregnancy.
223992013|NCT05592184|OTHER|Exercise|The experimental protocol begins with the assessment of self-perceived pain intensity and perceived exertion when using different intensities of elastic resistance, during wrist flexion and extension, at a controlled speed of 1.5sec/ phase. To assess the intensity at which they will work, participants will perform 2 repetitions and will be allowed a rest of 60s between sets until they obtain a score of 3 on the Borg CR10 scale. Exercises should be performed with the subject's available ROM. Participants are asked to move their body and trunk as little as possible and to perform the exercise smoothly, without stopping or accelerating. The exercise will be performed in a seated position, with the back supported by the backrest and the forearm resting on a table, with the shoulders and elbows bent at 90o, leaving the wrist free, with the elastic bands held under the feet (stepping on them).
223992014|NCT01044927|OTHER|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
223992015|NCT01044927|OTHER|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
223992016|NCT01390350|DRUG|Canakinumab|150mg subcutaneous injections on day 0
223992017|NCT01390350|DRUG|Placebo|150mg subcutaneous injections on day 0
223992018|NCT05261841|OTHER|Standard care for T2D patients, Smartwatch|No intervention, observational study
223992019|NCT05996978|OTHER|Intensive Drug Therapy|Observational only and no predesigned interventions in this study
223992020|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
223992021|NCT04058002|OTHER|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
223992022|NCT02565550|DIETARY_SUPPLEMENT|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
224121886|NCT05242276|DEVICE|USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY|The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use based only on their personal choice and surgical experience. . It is inserted vaginally through the cervical canal into the endometrial cavity. The uterine manipulator facilitates the uterus mobilization during the surgery, generating tension on the main supporting elements of the uterus to improve surgical field exposure and provide a landmark for the colpotomy.
224121887|NCT01818167|DRUG|10% Benzoyl Peroxide Topical Body Wash|
224121888|NCT01818167|DRUG|Provodine Topical Cream|
224121889|NCT03699982|OTHER|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
224121890|NCT04162886|OTHER|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
224121891|NCT04532463|DRUG|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week|To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
224121892|NCT01563627|OTHER|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
224121893|NCT01563627|DEVICE|Magnetic Resonance Imaging|
224121894|NCT06385964|DRUG|SHR-4597|SHR-4597 by dry powder inhalation
224121895|NCT06385964|DRUG|Placebo|Placebo by dry powder inhalation
224121896|NCT00194636|PROCEDURE|nerve block|
224121897|NCT04045249|DIETARY_SUPPLEMENT|Home based food|Home based food is compare able to RUTF
223544892|NCT04188990|DIETARY_SUPPLEMENT|By demand|"In the By demand arm, it is by clinical judgement of the doctor responsible of each patient that can be demanded a nutritional intervention to the nutrition unit of the center's endocrinology service that will judge the type of intervention. This is their usual care right now"
223992023|NCT02910843|DRUG|Regorafenib|"* Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
223992024|NCT02910843|DRUG|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
223992025|NCT02910843|RADIATION|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
223992026|NCT02910843|PROCEDURE|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
223992027|NCT00723385|DIETARY_SUPPLEMENT|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
223992028|NCT00723385|OTHER|Placebo|Administration of placebo for 12 weeks with repeated D measurements
223992029|NCT06770972|BEHAVIORAL|Family Foundations|The FF intervention is 9 sessions, 5 in the prenatal period and 4 in the postpartum period.
223992030|NCT04687098|DRUG|Idarubicin|12 mg/m2/day; intravenous, administration at induction phase, days 1 to 3.
223992031|NCT04687098|DRUG|Ara-C|"200mg/m2/day, intravenous at induction phase; days 1-7.~\- High dose during consolidation phase. In patients up to 60 years 3g/m2/12hours days 1,3,5, and patients 60 to 70 years: 1.5g/m2/12hours days 1,3,5."
223992032|NCT04687098|DRUG|G-CSF|"* Administration at induction phase to remission days 1 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatment arises 30x10e9/L.~* Administration at consolidation phase day 7."
223992033|NCT04687098|PROCEDURE|Allogeneic matched or unrelated donor transplant.|To be performed in patients in the intermediate or adverse risk groups.
223992034|NCT04687098|PROCEDURE|Autologous peripheral blood stem cell transplant|To be considered in patients in the intermediate risk group without an available allogeneic donor and negative measurable residual disease, per center decision.
223992035|NCT04687098|PROCEDURE|Measurable residual disease|To be performed either with molecular monitoring or, if not applicable, by flow cytometry. Pre-stablished cut-off values are defined for decision-making.
223992036|NCT06559839|OTHER|Vestibulocortical Stimulation|50cc of cold water (4℃) irrigated to the right external ear canal, at 1-2 cc/second, with the patient laying supine.
223992037|NCT00405119|DRUG|AH23844 (lavoltidine)|
223992038|NCT00405119|DRUG|NEXIUM (esomeprazole)|
223992039|NCT00405119|DRUG|ZANTAC (ranitidine)|
223992040|NCT05511337|OTHER|Caloric restriction and control oxalate and citrate foods|Restriction of 500 kilocalories from the usual diet plus a decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) for 28 days. The treatment will be given through an individualized meal plan.
223992041|NCT05511337|OTHER|Caloric restriction|Restriction of 500 kilocalories from the usual diet for 28 days. The treatment will be given through an individualized meal plan
223992042|NCT05511337|OTHER|Real-life intervention with control oxalate and citrate foods|Decrease in oxalate-rich foods (\< 40 mg per day) and an increase in citrate-rich foods (\> 40 mEq per day) without restriction in kilocalories from the usual diet for 28 days. Treatment will be given only through dietary counseling.
223992043|NCT00161265|PROCEDURE|tissue procurement|tissue procurement
223992044|NCT04833478|BEHAVIORAL|Anxiety|Techniques used to reduce anxiety in paediatric patients.
223992045|NCT02314351|DRUG|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
224294823|NCT00969319|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
223992046|NCT02314351|DRUG|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
224294824|NCT02710513|DIETARY_SUPPLEMENT|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
224294825|NCT02287909|DRUG|Clopidogrel|Swiching from ticagrelor to clopidogrel
224294826|NCT02287909|DRUG|Ticagrelor|Continue treatment with ticagrelor
223992047|NCT02314351|DRUG|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
223992048|NCT01976572|DRUG|colestilan|
223992049|NCT01976572|DRUG|candesartan|
223992050|NCT00382525|DEVICE|Cardiac Rhythm Management device|
223992051|NCT00403910|DRUG|Canrenone|
223992052|NCT05615688|PROCEDURE|Pain Intensity following Placement of Orthodontic Separators|Elastomeric separators will be placed on the mesial and distal of lower first permanent molars for a total of four separators per subject. Subjects will wear receive an activity monitor prior to placement of elastic separators and instructed to wear it 24/7 unless showering or swimming. Subjects will complete a recurrent Pain Scale Questionnaire 2-4 hrs after placement of elastics and every 24 hrs from day 2- 7.
223992053|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
223992054|NCT01633138|BEHAVIORAL|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
223992055|NCT00721929|PROCEDURE|MRI|Magnetic Resonance Imaging
224121898|NCT06228183|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224121899|NCT06228183|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224294827|NCT03732261|OTHER|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
223544893|NCT04188990|DIETARY_SUPPLEMENT|Usual current care|"In th Usual care arm, there is no explicit nutritional intervention performed at this time for those patients and, therefore, their usual regular nutritional care will be provide"
223544894|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
223544895|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
223544896|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
223992056|NCT04404166|BEHAVIORAL|PINGS 2|Home BP monitoring, medication reminders using phone alerts, and patient education on hypertension, cardiovascular risk reduction \& stroke
223729105|NCT01059799|DRUG|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
223992057|NCT04560621|BEHAVIORAL|Managed Problem Solving (MAPS)|MAPS is an individual-level, problem-solving intervention delivered in person and via telephone calls to HIV clinic patients. The intervention focuses on improving medication adherence through an iterative, five-step process which consists of 1) identifying barriers to adherence, 2) brainstorming to generate potential solutions, 3) decision-making and developing a plan of action, 4) implementing the plan, and 5) evaluating and modifying the plan as necessary. In-person sessions include education related to the treatment regimen and to common medication misperceptions; problem-solving to identify daily routines, cues, cognitive aids and social supports; screening to identify barriers related to depression, substance use, toxicity management and competing demands; and review of adherence data to determine where problems have occurred and to develop solutions.
223992058|NCT05261412|OTHER|Standard Consent|Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
223544897|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
223544898|NCT02948582|DRUG|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
223544899|NCT02948582|DRUG|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
223992059|NCT05261412|OTHER|Digital health education tool (dHET)|Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
223992060|NCT06434116|DEVICE|Immersive virtual reality|"The virtual reality headset is a device that simulates a realistic, three-dimensional environment, allowing the patient to be totally immersed, so that they feel as if they are really present in a virtual world. This environment can be combined with hypnotic verbal support.~Virtual reality will be achieved using a virtual reality headset (GAMIDA®, Pico G2 4K, France) and audio headphones with noise reduction (Bose® Quiet Comfort 35 II, France). A tablet (Samsung® Galaxy Tab A 2019, 4G / Lenovo M8, France) equipped with Healthy Mind software will enable patients to enjoy a 360° visual and auditory 3D experience via a Bluetooth connection."
223992061|NCT02574325|DRUG|Placebo|Control
223992062|NCT02574325|DRUG|ARI-3037MO|Treatment
223992063|NCT05260320|OTHER|Standardized Anesthetic Course from Premedication to Induction|See information in intervention group description
223992064|NCT03732677|DRUG|Durvalumab|Anti- PD-L1 Antibody
223992065|NCT03732677|DRUG|Cisplatin|Chemotherapy Agent
223992066|NCT03732677|DRUG|Gemcitabine|Chemotherapy agent
223992067|NCT05954286|DRUG|Upamostat|Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.
223992068|NCT05954286|DRUG|Placebo (PO)|Oral Capsules
223992069|NCT04013971|OTHER|AGRF Biofeedback Game|During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
224121900|NCT06228183|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224121901|NCT04291417|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients.
224121902|NCT03782740|DRUG|Melatonin 10 mg|Melatonin capsule
224121903|NCT03782740|DRUG|Placebo|Sugar pill manufactured to mimic Melatonin capsule
224121904|NCT03782740|DRUG|Melatonin 20 mg|Melatonin capsule
224121905|NCT01570985|DRUG|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
224294828|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
224294829|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
223544900|NCT03762161|DRUG|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
223992070|NCT04013971|OTHER|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes."
223992071|NCT04013971|OTHER|Control Condition|Participants will complete a control walk with out feedback.
223992072|NCT05853900|DEVICE|ReMMi-D Digital Therapeutic|Evaluate the effectiveness and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
223992073|NCT02538198|DRUG|Lenalidomide|
224121906|NCT01570985|DRUG|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
224294830|NCT02472171|DIETARY_SUPPLEMENT|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
223544901|NCT01263457|DEVICE|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
224294831|NCT01032018|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
223544902|NCT02213068|DRUG|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
223544903|NCT02213068|DRUG|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
223992074|NCT05129410|DRUG|Mycophenolate Mofetil|"1. Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. MMF1.5g-2.0g/d"
224121907|NCT03643432|BEHAVIORAL|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
223544904|NCT02213068|DRUG|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
223544905|NCT01151020|DEVICE|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
223992075|NCT05194033|DIETARY_SUPPLEMENT|Probiotics daily|Probiotics 1 time/day for 7 consecutive days
223992076|NCT05194033|DIETARY_SUPPLEMENT|Placebo daily|Placebo 1 time/day for 7 consecutive days
223992077|NCT03040947|OTHER|Cardiovascular Magnetic Resonance|
223992078|NCT04286854|DIAGNOSTIC_TEST|Stress echocardiography with semi-supine bicycle|"The patient is accelerating against a workload that gradually increases at a constant rate, during the exercise the images will be obtained by echocardiography.~The patient begins with 25 Watts with increments of 25 Watts every 3 minutes, continuing the exercise until significant electrocardiographic changes occur or the patient starts with symptoms."
223992079|NCT04557280|COMBINATION_PRODUCT|Selatogrel|A single subcutaneous injection of 16 mg.
223992080|NCT04557280|DRUG|Selatogrel|A single subcutaneous injection of 16 mg.
224121908|NCT03643432|BEHAVIORAL|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
223992081|NCT05928533|OTHER|clean and boost enamel cleanser of vista apex , RE GEN universal adhesive from vista apex , RE GEN Bio active flowable composite form vista apex|the clean and boost use to clean the tooth surface after cavity preparation without causing severe form of hypersensitivity then the RE GEN universal adhesive is applied by using a brush and cured with the RE GEN flowable composite for 20 seconds. Curing both together increase the bioactivity of the material.
223992082|NCT06521268|OTHER|Inspiratory muscle training|Inspiratory muscle training
223992083|NCT06521268|OTHER|Decongestive treatment|Decongestive treatment
223992084|NCT04157036|DRUG|Ibuprofen|Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
223992085|NCT04157036|DRUG|Methylprednisolone|Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
223992086|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D
223992087|NCT02215213|DRUG|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
223992088|NCT00257114|DRUG|bortezomib|
223992089|NCT06547788|OTHER|Mitral valve repair with creation of an 8 mm inter-atrial shunt|Mitral valve repair with creation of an 8 mm inter-atrial shunt
223992090|NCT03429166|BEHAVIORAL|Skills Training in Affective and Interpersonal Regulation|A non-trauma-focused treatment
223992091|NCT03429166|BEHAVIORAL|Present Centered Therapy|A non-trauma-focused treatment
223992092|NCT00344032|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223992093|NCT00344032|BIOLOGICAL|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223544906|NCT02067143|DRUG|Prephase PDN + CY|
223544907|NCT02067143|DRUG|Cycle 1 Induction|
223544908|NCT02067143|DRUG|Cycle 2 Induction / Early consolidation|
223544909|NCT02067143|DRUG|Cycle 3 Early consolidation|
223992094|NCT02000778|DRUG|EC17|
223992095|NCT06056128|DEVICE|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways for the purpose of biopsying lung lesions
223992096|NCT04893850|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to improve parent well-being and promote supportive parenting practices. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target parental mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
223992097|NCT04893850|BEHAVIORAL|Community Services as Usual Clinical Referral list|The community services as usual clinical referral list provides information on accessing psychological and family support services in Winnipeg. This resource is used to locate: crisis, distress, and support phone lines, counselling and peer-support resources, and free apps relating to mindfulness and meditation.
223992098|NCT02065882|DRUG|BT524 (Part I)|Single intravenous infusion of 70 mg BT524 per kg body weight.
223992099|NCT02065882|DRUG|BT524 (Part II)|Single or repetitive intravenous infusion(s) of BT524, depending on the severity of the disorder, location and extent of the bleeding and patient's clinical condition. Dosage based on individual body weight and fibrinogen level.
223992100|NCT05535166|PROCEDURE|Surgical resection|"All participants enrolled will undergo surgical resection prior to treatment. The maximal resection that can be achieved without undue risk to the patient will be attempted, with decisions about feasibility and extent of resection left to the discretion of the neurosurgeon. In instances where an STR is the best extent of resection achieved prior to start of therapy, a second-look surgery may be performed between cycles of chemotherapy after discussion with the principal investigator."
223992101|NCT05535166|PROCEDURE|Ommaya/VPS|All participants enrolled on S-1 will undergo
223992102|NCT05535166|DRUG|Methotrexate|Route of administration: Intravenously (IV)
223992103|NCT05535166|DRUG|Cisplatin|Route of administration: Intravenously (IV)
223992104|NCT05535166|DRUG|Vincristine|Route of administration: Intravenously (IV)
223992105|NCT05535166|DRUG|Cyclophosphamide|Route of administration: Intravenously (IV)
223992106|NCT05535166|DRUG|Carboplatin|Route of administration: Intravenously (IV)
223992107|NCT05535166|DRUG|Topotecan|Route of administration: Intravenously (IV)
223992108|NCT05535166|DRUG|Etoposide|Route of administration: Intravenously (IV)
223992109|NCT05535166|DRUG|Pegfilgrastim|Route of administration: subcutaneous (SQ)
223544910|NCT02067143|DRUG|Cycle 4 Consolidation|
223544911|NCT02067143|DRUG|Cycle 5 Consolidation|
223992110|NCT05535166|DRUG|Filgrastim|Route of administration: subcutaneous (SQ) or Intravenously (IV)
223992111|NCT05535166|RADIATION|Irradiation|All participants in stratum N will undergo craniospinal irradiation (CSI) with boost to the primary tumor site once they reach 36 months of age. The dose given is based on the molecular risk group and disease response to chemotherapy as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
223992112|NCT05535166|OTHER|Educational and Media Intervention|Participants watch a 75-minute caregiver education video program and receive access to interactive games on a smartphone or tablet throughout the optional cognitive study.
223992113|NCT05535166|OTHER|SOC, Educational and Media Intervention|Standard-of-care (SOC) treatment during main cognitive study. After the one-year serial cognitive evaluation, participants will be offered participation in the cognitive study group I intervention.
223992114|NCT06604754|OTHER|Assigned Intervention for VR Training|In VR training patients use VR headsets to engage in virtual environments for 8 weeks where they perform exercises designed to enhance balance, coordination, and strength. Simultaneously, the VR platform incorporate pulmonary exercises that focus on improving breathing techniques, lung capacity, and overall respiratory health. Patients will engage in 3 sessions per week with total time duration of 45 to 60 minutes. VR-based training provides real-time feedback and adapts to the patient's progress, offering a comprehensive approach to rehabilitation that addresses both balance and pulmonary function in a motivating and controlled manner.
224294832|NCT01032018|DRUG|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
224294833|NCT01032018|OTHER|Standard care|Participants will receive standard of care from the current physicians
224294834|NCT02402114|DRUG|Hydrocortisone|120 mg Hydrocortisone given orally one time.
224294835|NCT00015769|DRUG|levetiracetam|
223544912|NCT02067143|DRUG|Cycle 6 Consolidation|
223544913|NCT02067143|DRUG|Cycle 7 Consolidation|
223544914|NCT02067143|DRUG|Cycle 8 Reinduction|
223544915|NCT02067143|DRUG|Maintenance|If MRD negative MRD u/k SR
223544916|NCT02067143|PROCEDURE|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
223992115|NCT06604754|OTHER|Assigned Intervention for Traditional Physical Therapy Training|In Traditional physical therapy balance training for patients with chronic obstructive pulmonary disease (COPD) involves exercises designed to improve stability, strength, and coordination for duration of 8 weeks. These exercises, such as static balance tasks, dynamic movement drills, and strength training, help address the balance deficits often seen in COPD patients due to muscle weakness and reduced physical activity. Additionally, pulmonary effects are managed through breathing exercises such as deep breathing and pursed lip breathing that enhance respiratory functions, improve lung capacity and efficiency.
223992116|NCT07002294|OTHER|Transfer to specialty care|Interfacility transport and treatment at the specialty care hospital
223992117|NCT07002294|OTHER|Usual care|Hospitalization and treatment at the closest appropriate facility
223992118|NCT06669975|DRUG|AP402 (Part 1 Dose esclation)|Dose escalation will consist of 7 cohorts where an Intraveous infusion of AP402 will be administered once every 2 weeks to determine the maximum tolerated dose (MTD) (ie, the highest safe dose administered to patients) and the recommended phase 2 dose (RP2D) of AP402.
223992119|NCT06669975|DRUG|AP402 (Part 2 Dose Expansion)|After the MTD and/or RP2D are determined by the SRC, additional patients will be enrolled in Phase 2 dose expansion and will be treated with AP402 at that dose.
224121909|NCT05657288|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on finger and left wrist|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the whole experiment, non-invasive SpO2 measurements will be performed on the middle finger and on the wrist of left hand.
223544917|NCT02389465|DRUG|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
223544918|NCT02389465|DRUG|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
223992120|NCT04466566|OTHER|Saline|Saline will serve as the control
223992121|NCT04466566|BIOLOGICAL|Exendin-9,39|Exendin-9,39 will block the GLP-1 receptor
223544919|NCT00846846|DEVICE|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
223544920|NCT02563145|BEHAVIORAL|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
223544921|NCT02563145|BEHAVIORAL|Treatment as usual|Psychoeducation, general counselling
224121910|NCT00757562|DRUG|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
224121911|NCT00757562|DRUG|Placebo|placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.
223544922|NCT05211193|DEVICE|eTNM delivered by URIS I nerve stimulation device|eTNM delivered by URIS I nerve stimulation device, self administered in the subject's home for 30 minutes per day, for a minimum of 34 therapy session between day 1-42.
223992122|NCT06546150|BIOLOGICAL|RE002 T cell|All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
224121912|NCT00543829|DRUG|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
224121913|NCT00543829|DRUG|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
224121914|NCT04415489|DEVICE|Office hysteroscopy|Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
224121915|NCT00262262|DRUG|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
224121916|NCT06555367|DEVICE|scleral lenses|Wear scleral lenses
224121917|NCT01617434|DRUG|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
223992123|NCT05388435|DRUG|SKL27969|SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
223992124|NCT01688011|DRUG|Luspatercept|Prescribed by treating physician as per product label.
223992125|NCT07017478|DRUG|LSD|The serotonin 2A receptor agonist LSD
223992126|NCT07017478|DRUG|Placebo|Distilled water
224121918|NCT01617434|DRUG|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
224121919|NCT00659919|DRUG|Placebo|
224121920|NCT00659919|DRUG|Trazodone|
224121921|NCT03283163|BEHAVIORAL|Exercise Testing and Training|The study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
223729106|NCT01059799|DRUG|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
223992127|NCT07024160|DRUG|MT1011|MT1011 is a novel synthetic small molecule anticoagulant reversal agent for reversing anticoagulant effects including factor IIa and Xa inhibitors.
223992128|NCT07024160|DRUG|Placebo|This intervention contains no active ingredients
223992129|NCT06880406|OTHER|MMSE and blood draw|Each patient will be evaluated by Mini-Mental State Examination (MMSE) and will have a blood draw
223992130|NCT06921746|DIAGNOSTIC_TEST|Urine Microbiological and Metabolomic Analysis|Microbiological and metabolomic analysis of a urine sample will be performed in the study subjects, before and after the end of the treatment.
223992131|NCT07049250|BEHAVIORAL|Evidence-Based Nursing Intervention under Quantitative Evaluation Strategy|A multifaceted nursing program incorporating comprehensive risk assessment, dynamic risk stratification, psychological and cognitive interventions (including cognitive-behavioral techniques, peer mentoring, family counseling), systematic complication prevention strategies (including prophylactic antiemetics, dietary guidance, infection control), and sleep optimization protocols.
223992132|NCT07049250|BEHAVIORAL|Routine Nursing Care|Standard disease education on chemotherapy side effects and self-management, personalized exercise guidance, and medication adherence counseling. Delivered in 30-minute sessions twice weekly for two months.
223992133|NCT07050940|DIETARY_SUPPLEMENT|Postbiotic|postbiotic food supplement PostbiotiX-HLA 1 capsule (200mg) /day
223992134|NCT07050940|DRUG|AntiPD1|Antibody to PD1 approved for standard of care
223992135|NCT07049601|OTHER|Insulin Therapy|The effect of this intervention on HbA1c leading to either tight glycemic control HbA1c less than 7% or less tight glycemic control HbA1c less than 7.5%
223992136|NCT07049601|OTHER|Antidiabetic therapy, lifestyle modification|Individualized adjustments in antidiabetic therapy, lifestyle modification, and monthly clinical follow-up.
223992137|NCT07050342|OTHER|Personalized Nutrition-Based Psychosomatic Care|This intervention involves personalized, nutrition-focused care provided in a specialized outpatient clinic for individuals with psychosomatic and mental health conditions. The care model integrates nutritional counseling, education on gut-brain interactions, and patient-centered support to promote psychological well-being and reduce stress. No experimental drugs or diets are administered. Instead, the intervention focuses on individualized recommendations based on clinical assessments and ongoing routine laboratory markers (e.g., inflammatory markers, vitamin levels). Participants also receive guidance aimed at improving dietary habits and resilience within a biopsychosocial framework. The intervention is part of regular clinical care and not blinded or randomized.
223992138|NCT07051096|DEVICE|A novel device developed providing nature-driven responsive imagery that responds to the patient's physiological to distract, engage, and de-escalate behaviours of delirium.|This device will be provided on top of routine post-operative management and standard delirium reduction measures. It has proven effective in a previous clinical trial by reducing agitation and unscheduled medications. It displays nature-driven responsive imagery through an available mobile screen/device for the first 7 days after surgery or discharge, whichever comes first. The imagery adapts in real-time to the participant's movement and sound. The device will be placed at the foot of the bed while the patient is awake and may be interrupted at the discretion of the patient, bedside RN or attending physician.
223992139|NCT07051096|PROCEDURE|Routine post-operative management and standard delirium reduction measures.|Examples of routine post-operative care are sleep optimization, avoidance of delirium-promoting medications, orientation, and mobilization.
223992140|NCT07049406|DIAGNOSTIC_TEST|Structured Pre-tested|This will analyzed forthe differences in cultural perceptions and their Influence on health-seeking behavior.
223992141|NCT07049549|BIOLOGICAL|Injectable PRF|Autologous injectable platelet-rich fibrin (i-PRF) will be prepared from venous blood using low-speed centrifugation and administered subgingivally to the test quadrants following full-mouth scaling and root planing.
223992142|NCT07049549|OTHER|Plasebo (Sterile Saline)|sterile saline solution will be administered subgingivally to the control quadrants following full-mouth scaling and root planing (SRP).
223992143|NCT07051083|DIAGNOSTIC_TEST|Risk Stratification|Risk Stratification for Assessing Muscle Infiltration in Bladder Cancer.
224121922|NCT00237796|BEHAVIORAL|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
224121923|NCT00237796|BEHAVIORAL|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
223992144|NCT06741280|DEVICE|Profilm Mouth Sores|Daily applications of the product as soon as a mouth sore appears, until its complete disappearance or healing, as follows: application every 8 hours, with the possibility of shortening the interval to 6 hours if needed (a maximum of 3-4 applications).
223992145|NCT07050095|OTHER|Virtual Reality Group|Patient will undergo virtual reality (VR) immersion using oculus.
223992146|NCT07050095|DRUG|Midazolam Group|Patient will receive midazolam premedication only.
223992147|NCT07049185|DRUG|QL1706 Plus Celecoxib Group|QL1706 (anti-PD-1/CTLA-4 bispecific antibody) will be administered at 5 mg/kg by intravenous infusion every 3 weeks. Celecoxib 200 mg will be taken orally twice daily starting on Day 1 of each 3-week treatment cycle. Treatment continues until disease progression, intolerable toxicity, or for a maximum of 2 years.
224121924|NCT03881917|DIAGNOSTIC_TEST|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
224121925|NCT05774912|OTHER|Ultrasound evaluation|Fetal ultrasound evaluation will be collected longitudinally during the prenatal period from the weeks 14 every 4-5 weeks, for a total of maximum 6 ultrasound scans
224121926|NCT00231920|BIOLOGICAL|Fluzone|
224121927|NCT05438680|DIETARY_SUPPLEMENT|The bovine colostrum ( trade name : baby steps sachets, 300mg )|"The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally."
224121928|NCT05438680|DIETARY_SUPPLEMENT|Placebo|distilled water with no bovine colostrum
224121929|NCT04484519|OTHER|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging
224121930|NCT06671951|OTHER|Focal Vibration|Focal vibration is a 3x3 electrode placed on the athlete's muscle belly, and emits a high frequency vibration (150Hz) to stimulate the muscle spindle and generate greater muscle activation.
223992148|NCT07050979|OTHER|Goal-Directed Fluid Therapy (GDFT)|This arm administers fluid and vasopressor therapy based on SVV (less than 15%) and CI (\>2.6 L/min/m²) targets using the Pressure Recording Analytical Method (PRAM) system with the help of intra-arterial pressure monitoring method. Basal fluid replacement is provided with 5 mL/kg/hr of Lactated Ringer's solution.
223992149|NCT07050979|OTHER|Conventional Fluid Therapy|This arm administers fluid and vasopressor therapy based on targets of Mean Arterial Pressure (MAP) 65-95 mmHg and hourly urine output minimum of 0.5 mL/kg/hr. Basal fluid replacement is provided with 5 mL/kg/hr of Lactated Ringer's solution.
223992150|NCT07049003|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of the Deep Cerebellar Nuclei
223992151|NCT05775523|DRUG|No intervention|No intervention
223992152|NCT07050953|OTHER|focused cardiac ultrasound|A focused cardiac ultrasound will be performed to measure the dimensions of ascending aorta
223992153|NCT07049055|DRUG|E-EDV-D682|"E-EDV-D682 is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different chemotherapeutic drugs and specifically targeted to cancer cell receptors via single chain bispecific antibodies (BsAb).~E-EDV-D682 packages a chemotherapeutic payload PNU159682 into the EDV which targets the epidermal growth factor (EGFR) on cancer cells via a BsAb."
223992154|NCT07049055|DRUG|EDV-GC|EDV-GC is a product based on the EnGeneIC EDV™ technology. EDVs are bacterially derived nanocells 400 nm in diameter that can be packaged with a range of different drugs. EDV-GC packages the immunomodulatory adjuvant aplha-galactosyl ceramide (GC) into the EDV and is designed to recruit anti-tumor immune cells.
223992155|NCT07049055|DRUG|Gemcitabine|Gemcitabine in combination with nab-paclitaxel is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU based combination in the first line setting. In this trial the safety and efficacy of E-EDV-D682/GC will be tested in combination with a reference therapy - gemcitabine and nab-paclitaxel.
223992156|NCT07049055|DRUG|Nab paclitaxel.|Nab-paclitaxel in combination with gemcitabine is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU based combination in the first line setting. In this trial the safety and efficacy of E-EDV-D682/GC will be tested in combination with a reference therapy - gemcitabine and nab-paclitaxel.
223992157|NCT07050914|DEVICE|McGrath Video Laryngoscope|A video laryngoscope.
223729107|NCT00003596|DRUG|cisplatin|
223729108|NCT00003596|DRUG|fluorouracil|
223992158|NCT07050914|DEVICE|Macintosh Laryngoscope|A classic laryngoscope.
223992159|NCT07050277|DRUG|Intrathecal Morphine|Intrathecal morphine
223729109|NCT00003596|DRUG|mitomycin C|
223992160|NCT07050277|DRUG|No Intrathecal Morphine|No Intrathecal Morphine
223992161|NCT07049458|DRUG|CHO-A04|CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.
223992162|NCT07050147|DEVICE|Nasal high flow|3 sonographic measurements after use of 30 minutes
223992163|NCT07050147|DEVICE|NIV|3 sonographic measurements after 30 minutes use
223992164|NCT07048977|PROCEDURE|Needle-Knife Precut Papillotomy over Pancreatic Stent|If the papilla was treated with three unintended MPD cannulations, a needle-knife precut papillotomy with a small incision over a pancreatic stent (NKP-SIPS)
223992165|NCT07048977|PROCEDURE|Transpancreatic Sphincterotomy|TPS was performed as Goff reported; in short, after cannulation of the pancreatic duct was achieved, a pull-sphincterotome on a guidewire was used to cut the septum between the bile and pancreatic ducts along the direction from 11 o'clock to 12 o'clock. After that, the pancreatic stent is placed first, and the sphincterotomy is extended to expose the biliary lumen, and the biliary duct can be cannulated.
223992166|NCT06840769|DRUG|Fosnetupitant 235 mg solution|Fosnetupitant free base 235 mg (corresponding to 260 mg of the chloride hydrochloride salt) in 20 mL ready to use injectable solution for intravenous administration
224121931|NCT06671951|OTHER|Sham focal vibration|Is a focal vibration intervention but without conctact in the athelte's skin. Doing this we got a sham therapy
223992167|NCT06840769|DRUG|Akynzeo solution|235 mg fosnetupitant (corresponding to 260 mg of the chloride hydrochloride salt) / 0.25 mg palonosetron in 20 mL injectable solution
223992168|NCT05780177|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTI)|Participants in this arm will receive 4 sessions (30-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.
223992169|NCT05780177|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|Participants in this arm will receive 4 sessions (30-60 minutes) of progressive muscle relaxation training called PMRT.
223992170|NCT06753110|DEVICE|OPRA transhumeral|Skeletal anchorage of amputation prostheses.
223992171|NCT02107976|DIETARY_SUPPLEMENT|Vitamin E|400 IU per day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
223992172|NCT02107976|DIETARY_SUPPLEMENT|Vitamin C|500mg twice a day after discharge, for a minimum of 8 weeks between Stage 1 and Stage 2
223992173|NCT06205498|DRUG|acalabrutinib|patients with CLL who initiated treatment with acalabrutinib over the period between 1st May 2021 and 30th April 2022, according to Italian legislation dlg 219/2006 art.125
223992174|NCT06538844|DRUG|Intravenous infusion of human albumin|Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
223992175|NCT06538844|DRUG|Saline|Equivalent volume of isotonic saline control
223992176|NCT01161381|DEVICE|Estimation of nonlinear indices from Polysomnography|All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
223992177|NCT01225380|DRUG|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
223992178|NCT01225380|DRUG|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
223992179|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
223992180|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
223992181|NCT01225380|DRUG|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
223992182|NCT01225380|DRUG|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
223992183|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
223992184|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
223992185|NCT01225380|DRUG|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
223992186|NCT01225380|DRUG|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
223992187|NCT01225380|BIOLOGICAL|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
223992188|NCT01225380|DRUG|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), 48 weeks
223729110|NCT00003596|RADIATION|radiation therapy|
223992189|NCT04103996|DIAGNOSTIC_TEST|Ultrasound|Sonographic measurements (diaphragm, abdominal muscle, and quadriceps thickness) will be acquired when listed for lung transplantation. Sonographic measurements will be recorded on a daily basis for up to 1 week after transplantation (while the patient remains intubated).
224121932|NCT01273688|BEHAVIORAL|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
224121933|NCT01273688|DEVICE|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
224121934|NCT04238663|DRUG|MB02 (Bevacizumab Biosimilar)|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
224121935|NCT04238663|DRUG|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
224121936|NCT04238663|DRUG|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
223992190|NCT04103996|DIAGNOSTIC_TEST|Respiratory function measurements|Maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) will be acquired after listing for lung transplantation. After transplant, MIP will be recorded once patients are eligible for a trial of spontaneous breathing and weekly thereafter. MEP will also be recorded at ICU discharge.
223992191|NCT04330690|DRUG|Artesunate|2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
223992192|NCT04330690|DRUG|Imatinib|400 mg enterally daily for 14 days plus standard of care
223992193|NCT04330690|DRUG|Infliximab|5 mg/kg IV given one time, over 2 hours plus standard of care
223992194|NCT04330690|DRUG|Dexamethasone|6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
223992195|NCT04330690|DRUG|LSALT Peptide|5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
223992196|NCT02758743|DRUG|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
223992197|NCT02758743|DRUG|Placebo|Placebo with no active substance will not have the effect on intervention device.
223992198|NCT04949802|DEVICE|ViaLase Laser|ViaLase Laser System to create an aperture through the trabecular meshwork for the reduction of IOP in subjects with primary open-angle glaucoma
223992199|NCT00380315|DRUG|AG1321001(drug)|
224121937|NCT04388280|DIAGNOSTIC_TEST|Echocardiography|Functional assessment of coronary artery disease
224121938|NCT04388280|DIAGNOSTIC_TEST|CT angiography|Anatomical assessment of coronary artery disease
223992200|NCT04946578|DIETARY_SUPPLEMENT|Prebiotic|6 weeks of prebiotic supplementation twice a day
223992201|NCT04946578|OTHER|Placebo|6 weeks of maltodextrin supplementation twice a day
223992202|NCT02177253|DRUG|Ipratropium bromide / Salbutamol|
223992203|NCT02177253|DRUG|Placebo Inhalation solution|
223992204|NCT02177253|DRUG|Ipratropium bromide|
223992205|NCT02177253|DRUG|COMBIVENT Inhalation Aerosol|
223992206|NCT02177253|DRUG|Placebo Inhalation Aerosol|
223992207|NCT02288169|BEHAVIORAL|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
223992208|NCT02288169|BEHAVIORAL|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
223992209|NCT03427697|DEVICE|Virtual reality and accommodation relax techniques in combination|The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
223992210|NCT02473965|DRUG|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
223992211|NCT02473965|DRUG|Placebo|
223992212|NCT02356627|OTHER|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
223992213|NCT03192462|BIOLOGICAL|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10\^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
223992214|NCT00294411|PROCEDURE|elective cesarean section|
223992215|NCT03816761|DRUG|Fast-acting insulin aspart|In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
223992216|NCT03816761|DEVICE|iLet™|The bionic pancreas including pigtail adapters, used in insulin-only configuration
224121939|NCT02510729|DEVICE|Neurostimulation|
224121940|NCT02510729|DEVICE|Sham stimulation|
224121941|NCT01193348|DRUG|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
223992217|NCT00279253|DRUG|clonidine (drug) intravenously|
223992218|NCT01030393|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
223992219|NCT05925257|OTHER|ePRO application and proactive clinical care with nurses.|The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
223992220|NCT04920266|DEVICE|Smart Cap, running and fitness exercisers only|Bottle cap
223992221|NCT04920266|DEVICE|Sweat Patch, all subjects- running, fitness, cycling|Regional contralateral forearm patch
223992222|NCT04920266|DEVICE|Reference sweat patch, all subjects - running, fitness, cycling|Regional contralateral forearm patch
223992223|NCT04920266|OTHER|Bottle Scale, all subjects - running, fitness, cycling|Bottle weight
223992224|NCT01174069|PROCEDURE|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
223992225|NCT04358432|DRUG|AK102|Administered by subcutaneous injection
223992226|NCT04358432|DRUG|Placebos|Administered by subcutaneous injection
223992227|NCT04358432|DRUG|Statins and/or Ezetimibe|Lipid-lowering therapies
223992228|NCT03587337|OTHER|POEM|Pt. are going to submit a POEM procedure.
223992229|NCT02344589|DRUG|Lidocaine|used for the active blocks
223992230|NCT02344589|DRUG|Saline|used for the placebo-block
223992231|NCT00502268|DRUG|Doxercalciferol administration|Doxercalciferol administration
223992232|NCT00502268|DRUG|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
223992233|NCT02419417|DRUG|BMS-986158|Specified dose on specified days
223992234|NCT02419417|BIOLOGICAL|Nivolumab|Specified dose on specified days
223992235|NCT01240551|DRUG|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
223992236|NCT00398190|BEHAVIORAL|Control|Standard anti-tobacco programming
224121942|NCT04475185|DEVICE|MakAir|MakAir artificial ventilator
223992237|NCT00398190|BEHAVIORAL|Media Literacy|Anti-smoking media literacy curriculum intervention
223992238|NCT04879212|OTHER|PCIA +Acupuncture group:|Acupuncturing bilateral Zusanli (ST36) and Sanyinjiao (SP6)
223992239|NCT04331483|OTHER|Physical activity program|"Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge."
224121943|NCT04070378|DRUG|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
224121944|NCT00501033|DEVICE|Mechanical induction of labor|
223992240|NCT05995509|PROCEDURE|Micro-osteo-perforations|small perforations drilled in Alveolar bone, adjacent to site of tooth movement.
223992241|NCT04266015|DIETARY_SUPPLEMENT|Enteral nutrition formula|Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
223994456|NCT04626349|OTHER|FOCUS+ (face-to-face nurse-led intervention)|"Home-based psycho-educational intervention consisting of two 90-minute home visits and one 30-minute video-conferencing session, conducted by a trained intervention nurse over a period of 12 weeks (4 weeks between each session).~The intervention is comprehensively manualized and there is a protocol to guide delivery of the intervention for each home visit and video call. The content of the sessions is always tailored to the needs of the dyads, so certain topics can be discussed more in-depth and specific information can be shared. The nurses who will deliver the FOCUS+ intervention will receive an extensive online training and additional continuous follow-up training to provide them with the knowledge and skills required to successfully implement the intervention. A FOCUS+ core booklet is provided as a supporting guide for the dyads that they can refer to at their own discretion and reinforces key intervention messages linked to the core components of the intervention."
224121945|NCT00501033|DEVICE|Double Balloon|
224121946|NCT00501033|DEVICE|Foley Catheter|
224121947|NCT01370278|OTHER|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
224121948|NCT01370278|OTHER|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
223992242|NCT05648487|DRUG|HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery|"1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy."
223544923|NCT05434494|DRUG|Remimazolam|"Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19."
223992243|NCT03191513|DIETARY_SUPPLEMENT|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
223992244|NCT03191513|DIETARY_SUPPLEMENT|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
223992245|NCT03191513|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
223992246|NCT03325790|DRUG|200mg SPI-1005 BID|Active: low dose
223992247|NCT03325790|DRUG|400mg SPI-1005 BID|Active: high dose
223992248|NCT03325790|OTHER|Placebo|Placebo Comparator
224121949|NCT06512441|DRUG|Vitamin B6 Tablets|The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.
223544924|NCT05434494|DRUG|remifantanil|25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
223544925|NCT06416228|DIETARY_SUPPLEMENT|Beetroot juice|Participants will take on dose in the morning and one in the afternoon, for 7 days during their final academic examinations
223544926|NCT03667989|DIAGNOSTIC_TEST|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
223544927|NCT06308744|BEHAVIORAL|Body-scan meditation|Participants listen to a 15-minute Body-Scan mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
223544928|NCT06308744|BEHAVIORAL|Mindful Breathing meditation|Participants listen to a 15-minute Mindful Breathing mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
223544929|NCT06308744|BEHAVIORAL|Loving Kindness meditation|Participants listen to a 15-minute Loving Kindness mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
223992249|NCT05864651|OTHER|Tele-exercise program|The tele-exercise program focused on lunge movement with additional strengthening abdominal and lumbopelvic muscle training while maintaining neuromuscular control. The difficulty of training was adjusted every week according to the five-step mastery program
223992250|NCT05864651|OTHER|Conventional Fencing Exercise|The conventional exercise was based on 'displacement', a basic footwork training in fencing. The Displacement is also basic footwork to approach the opponent. The Displacement consisted of seven movements including 'Marche', 'Retraite \& Rompre', 'Passe avant', 'Passe arrière', 'Bond en avant', 'Bond en arrière', and 'Balestra'.
224121950|NCT06512441|DRUG|Placebo|The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
224121951|NCT03008746|OTHER|water used for oral wash|
224121952|NCT03008746|OTHER|sputum|
223992251|NCT02567851|DRUG|Brentuximab Vedotin|Monoclonal antibody drug conjugate
223992252|NCT03313492|BEHAVIORAL|UV4.me2|"UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~1. A mobile version of the site~2. Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~3. Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback"
224121953|NCT03008746|OTHER|oral wash|
224121954|NCT03259334|DRUG|Ontamalimab|Participants will receive 1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
224121955|NCT03259334|OTHER|Placebo|Participants will receive 1 mL of sterile aqueous buffered solution.
224121956|NCT00110656|OTHER|Observations|This is a non-interventional study- only observational.
224121957|NCT02929563|DRUG|Pantoprazole|
224121958|NCT02929563|DRUG|Placebo (for pantoprazole)|
223544930|NCT06308744|BEHAVIORAL|Mindful Walking|Participants listen to a 15-minute Mindful Walking mindfulness meditation recorded by a certified instructor. The audio track is embedded in the Qualtrics survey.
224121959|NCT02756390|BEHAVIORAL|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
224121960|NCT02756390|BEHAVIORAL|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
224121961|NCT02756390|BEHAVIORAL|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
224121962|NCT05264090|OTHER|Ambulatory blood pressure monitoring|The ambulatory monitoring (7-day ABPM) was performed with ambulatory blood pressure monitoring devices TM-2430 (A\&D; Tokyo, Japan) based on both the cuff-oscillometric and Korotkoff sound method. The cuff was placed on the non-dominant arm according to the same rules applying to casual auscultation measurement. The monitoring device with a weight of 250 g was worn by the monitored subjects in a waist-fixed case continuously for 7 days except for times involving personal hygiene. During every automatic measurement, the arm was resting and hung along the body. The device automatically recorded all the regular measurements for seven days, between 6:00 a.m. and 10:00 p.m. every 30 minutes and between 10:00 p.m. and 6:00 a.m. every 60 minutes. Such short intervals are necessary to obtain a sufficient number of representative measurements.
223544931|NCT06308744|BEHAVIORAL|Listening of a story|Participants listen to a 15-minute story. The audio track is embedded in the Qualtrics survey.
223544932|NCT00530634|DRUG|cisplatin|
223544933|NCT00530634|DRUG|gemcitabine hydrochloride|
223544934|NCT00530634|GENETIC|gene expression analysis|
224121963|NCT05264090|OTHER|Combined aerobic-resistance exercise|Combined aerobic-resistance exercise (group 2) was scheduled twice weekly in the form of 60-minute workouts with a load intensity at the level of sub-maximum heart frequency (75-85% SFmax). The minimum time span between the workouts was 24 hours. The workout consisted of a 10-minute warm-up, 25 minutes of aerobic exercise (spinning bicycle or bicycle ergometer), 15 minutes of resistance exercise on gym machines (bench press, leg extension and pull down) with 40-50% 1-RM (one repetition maximum) intensity (3 series of 10 exercises), and a 10-minute cool-down (stretching of the main muscle groups).
223992253|NCT03313492|BEHAVIORAL|UV4.me|Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
223992254|NCT03313492|BEHAVIORAL|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention."
223992255|NCT04822779|DEVICE|Sonopuls 490u, Enraf-Nonius, Rotterdam, Kingdom of the Netherlands|"Ultrasound therapy will be applied in continuous output, 1 MHz frequency, the intensity of 1.5 W / cm2, and duration 10 min per treatment, on the front of the shoulder, on the surface of 2 ultrasound heads (10 cm2).~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
223992256|NCT04822779|OTHER|Placebo|"Sham ultrasound therapy will be applied using a frequency of 0 Hz, intensity 0 W / cm2, 10 min per treatment.~The position of the arm will be in adduction and internal rotation in RCT of the supraspinatus, adduction and external rotation of the arm in RCT of the subscapularis, and the position of the arm over the opposite shoulder in RCT of the infraspinatus."
223992257|NCT04376151|OTHER|Acceptance and Commiment Therapy (ACT) bibliotherapy 'Get Out of Your Mind and Into Your Life'|The intervention has been described in the arm/group descriptions.
223992258|NCT05914870|OTHER|Multi-component training|"The multicomponent training group will perform 60 minutes of training per session:~* 10 minutes of joint mobility exercises and dynamic stretching.~* 20 minutes of strength work with 2 exercises; the first, bench press, at an intensity of 50% of your 1RM. The number of repetitions will be individualised for each subject by testing the loss of speed in the series with respect to the first repetition (15% loss); the second, the squat, at an intensity of 60% of your 1RM. The number of repetitions shall be individualised for each subject by means of the loss of speed test in the series with respect to the first repetition (10% loss). The rest between sets will be 3 minutes.~* 20 minutes of continuous cardiovascular work. The intensity will be increased every 4 weeks, from week 1 to 4 between 55%-65%FCR or VO2peak, from week 5 to 8 between 65%-%75%FCR or VO2peak and from week 9 to 12 between 75%-%85%FCR or VO2peak.~* 10 minutes of cool down and static stretching."
223992259|NCT05914870|OTHER|Continuous Cardiovascular Training|"The Continuous Cardiovascular Training group will perform 60 minutes of training per session distributed as follows:~Preparatory Phase: 10 minutes of standardised warm-up with joint mobility exercises and dynamic stretching.~Main Training Phase:~In this phase we will work 40 minutes of continuous aerobic exercise, maintaining the same intensity range throughout the session. We will increase the intensity every 4 weeks, from 1 to 4 you will work between 55%-65%FCR or VO2peak, from 5 to 8 between 65%-%75%FCR or VO2peak and from 9 to 12 between 75%-%85%FCR or VO2peak.~Post-training phase: 10' cool down and static stretching."
223992260|NCT03640572|DIAGNOSTIC_TEST|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
223992261|NCT02155270|PROCEDURE|Corneal precut 600µm|
223992262|NCT02155270|PROCEDURE|Corneal stabincision|
223544935|NCT00530634|GENETIC|reverse transcriptase-polymerase chain reaction|
223992263|NCT00078377|DRUG|Armodafinil|Armodafinil 250 mg once daily in the morning
224121964|NCT05264090|OTHER|The cardiovascular exercise|The cardiovascular exercise (group 4) took the form of sixty-minute workouts scheduled two to three times weekly. The nature of the workouts was similar, combined aerobic-resistance exercise (a 10-minute warm-up, aerobic endurance on bicycle ergo meter for 25 minutes, resistance exercise on multifunctional gym machines for 15 minutes, and a 10-minute cool-down). The workout intensity was set at the level of the first ventilation threshold (VAT-1), corresponding to the following workout parameters: load (W) and heart rate (HR).19,20 The resistance exercise intensity was specified by the 1-RM (one repetition maximum) method. The maximum load lifted across the full range of motion for every exercise was used as the benchmark for the workload intensity specification, corresponding to 30 - 60% 1-RM.
224121965|NCT06998550|OTHER|Patient Satisfaction Questionnaire|An online survey designed to assess patient experiences and satisfaction levels with pulmonary rehabilitation (PR) programs. The questionnaire covers aspects such as accessibility, communication, program structure, perceived outcomes, and overall satisfaction. It is administered via Google Forms and completed voluntarily by patients who have completed a PR program.
224121966|NCT06998550|OTHER|Institutional Survey on PR Program Structure and Team Composition|A structured online questionnaire completed by the designated PR program coordinator or team member. It includes questions on organizational features of the PR program, such as team composition, session frequency, assessment tools, referral and admission
224121967|NCT00042081|DRUG|CGT003 (E2F Duplex Decoy)|
223544936|NCT00530634|OTHER|immunohistochemistry staining method|
223992264|NCT00078377|DRUG|Armodafinil|Armodafinil 150 mg once daily in the morning
223992265|NCT00078377|DRUG|Placebo|Matching placebo tablets once daily
224121968|NCT03321240|PROCEDURE|visual and quantitative SEEG signal analysis|signal SEEG analysis
223544937|NCT00530634|PROCEDURE|adjuvant therapy|
223544938|NCT00530634|PROCEDURE|conventional surgery|
223544939|NCT00530634|RADIATION|radiation therapy|
224121969|NCT03321240|PROCEDURE|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
224121970|NCT03328130|BIOLOGICAL|AAV2/5-hPDE6B|Subretinal administration in one eye
223992266|NCT02593877|DEVICE|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
223992267|NCT01627535|OTHER|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
223992268|NCT01820520|DRUG|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
223992269|NCT03554408|DRUG|10-1074-LS|Subcutaneous injection of 10-1074-LS
223992270|NCT03554408|DRUG|10-1074-LS|Intravenous infusion of 10-1074-LS
223992271|NCT03554408|DRUG|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
223992272|NCT03554408|DRUG|3BNC117-LS|Intravenous infusion of 3BNC117-LS
223992273|NCT03231124|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
223992274|NCT03231124|DRUG|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
223992275|NCT04697134|BEHAVIORAL|Conscious Discipline-Based Environmental Enrichment Intervention|Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
223992276|NCT00863759|PROCEDURE|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
223992277|NCT03437889|OTHER|Cold Stimulus (Ice)|The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
223992278|NCT02774811|DRUG|Prostaglandin analogue|Topical therapy
223992279|NCT02774811|PROCEDURE|Selective laser trabeculoplasy|Laser therapy into drainage angle
223992280|NCT02774811|DEVICE|laser|
223992281|NCT03715777|DRUG|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
223992282|NCT05169892|PROCEDURE|Aquablation|Aquablation
223992283|NCT01200342|DRUG|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
223992284|NCT01200342|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
223992285|NCT01200342|DRUG|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
223544940|NCT00122616|BIOLOGICAL|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
223544941|NCT00122616|DRUG|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
223544942|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
223992286|NCT03076905|DRUG|F901318|Evaluation of AUC0-t
223992287|NCT03065140|OTHER|Training or detraining|A period of detraining or a supervised exercise program.
223992288|NCT00258739|DRUG|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
223992289|NCT00258739|OTHER|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
223992290|NCT02086318|OTHER|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
223992291|NCT00297921|DRUG|tandutinib|
223992292|NCT06317324|OTHER|Different treatments|NSCLC patients receive the treatment of SBRT
224121971|NCT05152446|OTHER|Infusion management scheme|"* To set up a pediatric intravenous infusion team;~* To form standardized procedures by carrying out a quality improvement program in collecting and sending samples for inspection once suspected CLABSI occurs (1 month for training and 3 months for continuous improvement ); providing infusion training curriculums to nurses in forms of lectures, group discussions, operation demonstrations, and scenario simulations, holding practice review meeting with them; providing elements to caregivers of educational leaflet, nurse-provided education during patients' infusion therapy( 6-month implementation);~* To observe the continued daily infusion practice in 6 months."
224121972|NCT06863649|OTHER|Gamified NON-IMMERSIVE VIRTUAL REALITY EXERCISES|The game phase lasts for 2 minutes. These targets are challenging for the participant.
224121973|NCT06863649|OTHER|video-based exercises|The participant will exercise by replicating the exercises demonstrated in a 2-minute video, recorded with the same movement patterns that they will find in the gamified intervention.
224121974|NCT07003100|OTHER|Non-Interventional Study|Non-interventional study
224294836|NCT04171713|BEHAVIORAL|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
223544943|NCT00122616|DRUG|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
223544944|NCT05973708|OTHER|Clamshell Exercise|Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
223544945|NCT05973708|OTHER|Frog pump exercise|Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
223544946|NCT00872274|DRUG|sumatriptan 100mg|
223544947|NCT03301779|DEVICE|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
223544948|NCT00047905|BEHAVIORAL|examine the process of prenatal genetic counseling|
223544949|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
223992293|NCT00598845|PROCEDURE|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
223992294|NCT04144712|DRUG|Caffeine Citrate|study rate of occurrence of Apnea of Prematurity between the 2 groups
223544950|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
223544951|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
223992295|NCT04358770|DRUG|Clocortolone Pivalate|Cream, 0.1%
223992296|NCT03773575|DEVICE|PREVENA™ PEEL & PLACE™ Dressing Kit|In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
223992297|NCT05083390|DRUG|norUrsodeoxycholic acid|500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
223992298|NCT02960503|DRUG|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
223992299|NCT02960503|OTHER|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
223992300|NCT04292704|RADIATION|the fractional CO2 laser|The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 \~ 1000 μ m
223992301|NCT04292704|DRUG|Clotrimazole|Clotrimazole vaginal tablets
224121975|NCT03760432|PROCEDURE|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
223992302|NCT00570284|DRUG|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
223992303|NCT03235700|OTHER|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
223992304|NCT03235700|OTHER|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
224121976|NCT07007819|BEHAVIORAL|Modified Sleep and Circadian Intervention|The modified sleep and circadian intervention has 5 individual sessions that will be delivered via Zoom to parents over 12 weeks and consists of 4 cross-cutting modules (functional analysis, goal setting, motivational interviewing, sleep education), 5 core sessions, and 7 optional modules that are delivered based on personalized treatment goals. The intervention format is as follows: (1) 60-minute session with consultation on setting goals and developing an action plan to improve sleep timing, quantity, and regularity; (2) 5-minute weekly follow-ups and a 3-night sleep diary; and (3) four 30-45-minute booster sessions every 3 weeks. Child attendance is optional.
224294837|NCT04171713|BEHAVIORAL|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
223992305|NCT02294357|DRUG|Carfilzomib|
223992306|NCT02294357|DRUG|Dexamethasone|If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
223992307|NCT02294357|DRUG|Prednisone|f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
223992308|NCT02294357|DRUG|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
223992309|NCT02294357|DRUG|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
223992310|NCT02294357|DRUG|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
223992311|NCT04411004|DIAGNOSTIC_TEST|Transvaginal ultrasound|Transvaginal ultrasonographic scan to diagnosis the recurrence of rectal endometriosis
223992312|NCT04411004|BEHAVIORAL|5-point Likert scale|Subjective scale to evaluate satisfaction to previous surgical treatment for rectal endometriosis
223992313|NCT03063151|DIAGNOSTIC_TEST|Surface Electromyography (EMG)|
223992314|NCT00953147|DRUG|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
223992315|NCT00953147|DRUG|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
223992316|NCT00953147|DRUG|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
224121977|NCT07007819|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is an active comparison treatment balanced for time and attention. Participants will be asked to maintain their typical sleep schedules. EUC sessions will review the interrelationships between stress, diet, health, exercise, and behavior, with a sleep education portion \< 10 minutes and no encouragement to change behavior. EUC sessions will be used to establish rapport and promote study retention. EUC participants will not complete weekly sleep diaries. At the end of Week 12, EUC participants will receive a 1-hour optional Zoom session with the PI on sleep education.
223992317|NCT03854747|OTHER|cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
224121978|NCT06353945|DEVICE|vaginal moisturizer|vaginal moisturizer
223992318|NCT01484431|DRUG|Tadalafil- Tablet or Oral suspension|Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
223992319|NCT01703728|OTHER|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
223992320|NCT05071638|BIOLOGICAL|autologous cord blood mononuclear cells|preterm neonates less than 28 weeks who suffer BPD and also stored cord blood are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg).
223992321|NCT03683992|DEVICE|Triathlon total knee system|Implantable
223992322|NCT04559321|PROCEDURE|Fragmentation of calculi with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization.|General anesthesia, Valdivia-Galdakao position, cystoscopy and ascending pyelography will be performed. A systematic nephroscopy will be performed and once the calculation will proceed to its fragmentation with 100 W Holmium laser or LithoClast Trilogy EMS and 1.5 mm x 440 mm probe, according to randomization
223992323|NCT03251092|DRUG|PTI-808|Active
223992324|NCT03251092|DRUG|Placebo|Placebo
223992325|NCT03251092|DRUG|PTI-428|Active
223992326|NCT03251092|DRUG|PTI-801|Active
223992327|NCT02120001|DEVICE|ETT cleaning maneuver|"EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.~We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
223992328|NCT04374747|BEHAVIORAL|Dietary Counseling|The counseling approach will employ strategies shown to be successful in previous and ongoing dietary modification studies including supportive and motivational interviewing techniques. Each woman in the diet intervention group will be assigned a trained nutrition coach/counselor. Counselors will focus on helping participants identify and address barriers to achieving the goal of consuming at least 8 to 10 servings of nutrient dense fruits and vegetables each day (e.g., modifying recipes and food preparation). Participants will also receive weekly boxes of fruits and vegetables .
223992329|NCT02751749|BEHAVIORAL|Unified Protocol|
223992330|NCT04897204|PROCEDURE|Catheter ablation and left atrial appendage occlusion|The patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion.
223992331|NCT04897204|PROCEDURE|Additional left atrial appendage electrical isolation combined with catheter ablation and left atrial appendage occlusion|These patients underwent routine pulmonary vein isolation and linear ablation and left atrial appendage occlusion, combined with additional left atrial appendage occlusion.
223992332|NCT01060891|DRUG|colimycin|
223992333|NCT02763215|DRUG|Standard of Care Medications|Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
223992334|NCT00347698|DRUG|intravitreal injection of bevacizumab|
223992335|NCT00347698|PROCEDURE|panretinal photocoagulation|
223992336|NCT00475644|DRUG|Enzastaurin|Administered orally
223992337|NCT02039076|DRUG|avatrombopag|
223992338|NCT06216652|OTHER|downhill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the first group performed downhill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
223992339|NCT06216652|OTHER|uphill walking|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the second group performed uphill walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
223992340|NCT06216652|OTHER|walking with no incline|All participants received a conventional physiotherapy program for 2 days/week, 40 min/day for 8 weeks. In addition to this program, the third group performed walking with no incline walking exercise on the treadmill for 2 days/week, 30 min/day on different days.
223992341|NCT01411241|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
223992342|NCT01411241|BIOLOGICAL|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
223992343|NCT01411241|BIOLOGICAL|Placebo|0.5 mL, subcutaneous
223992344|NCT01411241|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
223992345|NCT01411241|BIOLOGICAL|Pneumococcal vaccine|0.5 mL, intramuscular
223992346|NCT01411241|BIOLOGICAL|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
223992347|NCT01411241|BIOLOGICAL|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
223992348|NCT01411241|BIOLOGICAL|Placebo|0.5 mL, subcutaneously
223992349|NCT01411241|BIOLOGICAL|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
223992350|NCT01411241|BIOLOGICAL|Pneumococcal vaccine|0.5 mL, intramuscular
224121979|NCT07018336|OTHER|Mirror Therapy|Mirror Therapy will be applied to the affected upper extremity of hemiplegic patients by placing a mirror in the midsagittal plane, reflecting movements of the non-paretic limb to create the illusion that both limbs are moving symmetrically. Each session will include task-specific, functional hand and arm movements (e.g., grasping, wrist flexion/extension) performed for 30 minutes. Patients will be instructed to focus on the mirror image while actively engaging in the exercises.
224121980|NCT07018336|OTHER|Virtual Reality (VR) Therapy|Virtual Reality (VR) therapy will consist of a single 30-minute immersive session designed to engage the upper extremity of hemiplegic patients. Participants will wear a VR headset and interact with a virtual environment using motion-tracking controllers. Activities are task-oriented and aim to stimulate functional movement through simulated real-life scenarios (e.g., reaching, grabbing, stacking). This intervention offers multisensory feedback and high user engagement.
224121981|NCT06692218|DEVICE|Leadless pacemaker|Patients who will implant leadless pacemakers or already implanted leadless pacemakers since 1 Jan 2015 will be recruited. After the implantation, patients will be invited back for a noncontrast, ECG-gated CT heart. It will be timed at the end diastole and a 3D reconstruction will be performed.
224121982|NCT07021573|DEVICE|KINEVO 900 S with BLUE 400|The investigational device consists of a CE marked (MDR) surgical microscope KINEVO 900 S by Carl Zeiss Meditec AG, including the BLUE 400 fluorescence option. This microscope is equipped with an additional component (CALLAO), provided by the Carl Zeiss Meditec AG, that allows for extended, multispectral, image acquisition in the operating room. CALLAO consists of an optical setup with additional cameras, that can be mounted on the main system KINEVO 900 S, and a second light source for specific illumination during image acquisition with the CALLAO cameras.
223544952|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
223544953|NCT01299467|DRUG|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
223544954|NCT01299467|DRUG|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
223992351|NCT00600327|DEVICE|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
223992352|NCT00600327|DEVICE|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
223992353|NCT03063684|DEVICE|Fractional / Pixel CO2 Laser|"The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application."
223992354|NCT05147870|PROCEDURE|Peritoneal irrigation|For patients allocated to the irrigation group, peritoneal lavage was performed at the surgeon's discretion based on surgical findings and preference.
223992355|NCT05147870|PROCEDURE|Suction only|In the suction only group, one surgical gauze each was placed in the splenophrenic space and Morison's pouch to soak up any remaining purulent fluid followed by turning the patient into the Trendelenburg position for inspection of the lower abdominal cavity. Any interloop adhesions were carefully divided and the gauze-wiping maneuver was used to soak up the residual peritoneal fluid, and all bowel loops were investigated to the root of the mesentery.
224121983|NCT04805567|DEVICE|endocuff|The Endocuff is a device that can be mounted on the tip of an endoscope and may assist to inspect a greater surface of the colonic mucosa by pulling backwards, flattening, and stretching the colonic folds as the endoscope is gradually withdrawn.
223544955|NCT02945163|DRUG|Tenofovir|Tenofovir Disoproxil Fumarate
223544956|NCT02945163|DRUG|Lamivudine|Lamivudine
223544957|NCT02945163|DRUG|Efavirenz|Efavirenz
223544958|NCT00358059|BEHAVIORAL|Behavioral Family Systems Therapy for Diabetes|
223544959|NCT01220401|BEHAVIORAL|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
223992356|NCT01913145|DEVICE|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
224121984|NCT01678807|BIOLOGICAL|MK-8237 6 DU|
224121985|NCT01678807|BIOLOGICAL|MK-8237 12 DU|
224121986|NCT01678807|BIOLOGICAL|Placebo|
224121987|NCT04527172|DIAGNOSTIC_TEST|neuromuscular ultrasound|ultrasound to visualize the peripheral nerves of lupus patients and to compare it with results of the raditional electrophysiological studies
224121988|NCT02645305|BIOLOGICAL|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
224121989|NCT02718833|DRUG|Elotuzumab|
223992357|NCT04009031|DEVICE|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
223992358|NCT01853501|PROCEDURE|Autologous fat grafting|ADSC ovary injection
223992359|NCT01976273|DEVICE|1064nm Q-switch Laser|
223992360|NCT01976273|OTHER|Glycolic Acid Peels|
223992361|NCT05407831|GENETIC|Genetic|Calculate MODY probability
223992362|NCT05407831|BEHAVIORAL|Social habits|Alcohol vs Smoking vs Drug use
223992363|NCT05407831|OTHER|Perinatal stress|Survey
223992364|NCT00498472|PROCEDURE|Pre-discharge NT-ProBNP based treatment|"Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is \>3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy."
223992365|NCT02980042|DRUG|Ocrelizumab|A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
223992366|NCT02980042|DRUG|Rituximab|A chimeric monoclonal antibody against CD20.
223992367|NCT00725270|DRUG|Mifepristone|600 mg of mifepristone
223992368|NCT00725270|DRUG|Placebo Oral Tablet|Placebo comparator
223992369|NCT02958605|DEVICE|Smartphone apps|If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
223992370|NCT02958605|DEVICE|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
223992371|NCT02301377|DEVICE|Spiro PD personal spirometer|
223992372|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 2 servings (18.78g) of powdered Pleurotus oyster mushroom.|Ingredients: celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
223992373|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 1 serving (9.39g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
223992374|NCT05594329|OTHER|Instant noodle soup containing containing the equivalent of 0.5 serving (4.70g) of powdered Pleurotus oyster mushroom.|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
223992375|NCT05594329|OTHER|Control instant noodle soup|Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
223992376|NCT03981848|OTHER|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
224121990|NCT02718833|DRUG|Pomalidomide|
224121991|NCT02718833|DRUG|Bortezomib|
224121992|NCT02718833|DRUG|Dexamethasone|
224121993|NCT06929325|DRUG|Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
224121994|NCT06929325|DRUG|Fulvestrant Injection|IM injection, 500 mg, on day 1 and day 15 of Cycle 1, and then on day 1 of each cycle thereafter, 4 weeks per treatment cycle
224121995|NCT06929325|DRUG|Placebo for Sirolimus for Injection (Albumin-bound)|IV infusion, every 2 weeks, 4 weeks per treatment cycle
224121996|NCT06929689|PROCEDURE|three dental implants|fixed detachable prosthesis
224121997|NCT06929234|OTHER|Peer-Supported Health Education|Peer-supported health education will be provided to paticipants in 1 session for an average of 60 minutes in a suitable classroom. In this session, health education will be provided by the researchers and the peer will support the health education. The peer will share her experiences about each part of the training content with the target group in line with the guidance of the researchers, answer questions and make a motivational speech for screening.
224121998|NCT06929234|OTHER|Basic Health Education|What is cervical cancer, what is the importance of cervical cancer, what are the risk factors for cervical cancer, what are the symptoms of cervical cancer, how to screen for cervical cancer, where to get cervical cancer screenings. Participants will be given health education with a power point presentation in a suitable classroom for an average of 45-50 minutes in 1 session.
224121999|NCT06929455|OTHER|Flavor additives|Various flavors will be added to API samples. The particular APIs and flavor additives to be studied will be determined in part by on-going in work using in vitro taste models (cell systems expressing taste receptor proteins), so there is no full prespecified list.
223992377|NCT06062004|PROCEDURE|Small Incision Lenticule Extraction (SMILE)|"All surgeries will be performed under topical anesthesia using the VisuMax femtosecond laser with the following parameters:~* Cap thickness of 120 μm~* Cap diameter of 1 mm larger than the lenticule diameter~* Cap side cut angle 70°~* 3 mm incision positioned at 100° and angled at 45°~* Transition zone of 0.1 mm and clearance of 0.5 mm~* Lenticule side cut angle of 90° and edge lenticule thickness of 15 μm"
223992378|NCT03798275|DIETARY_SUPPLEMENT|coffee|2 g Nescafe Clasico contains approximately 65 mg caffeine
223992379|NCT03205670|PROCEDURE|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
223992380|NCT00269412|DRUG|Rifaximin|
223992381|NCT01020877|DRUG|Metronidazole|Vaginal Gel, 0.75%
223992382|NCT01020877|DRUG|Metronidazole|Vaginal Gel, 0.75%
223992383|NCT04465266|DRUG|Tolperisone|tablets
224122000|NCT06930339|DEVICE|Portable Neuromodulation Stimulator (PoNS)|No intervention
224294838|NCT04171713|BEHAVIORAL|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
223992384|NCT04237389|PROCEDURE|Ablation Index Guided endocardial catheter radiofrequency ablation|Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).
223992385|NCT04237389|PROCEDURE|minimally invasive thoracoscopic surgical epicardial ablation.|"Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA."
223992386|NCT03814577|DIAGNOSTIC_TEST|Total Antioxidant Status|Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
223992387|NCT03814577|DIAGNOSTIC_TEST|Total Oxidant Status|Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
223992388|NCT03814577|DEVICE|Bispectral Index|Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
223992389|NCT03814577|OTHER|Invasive arterial monitorization|Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
223992390|NCT02749097|DRUG|SHR0534|
223992391|NCT02749097|DRUG|Placebo|
224122001|NCT06929728|DEVICE|blood pressure measurments devices|measure arterial blood pressure by arm cuff devises
224122002|NCT05887167|BIOLOGICAL|autologous hematopoietic stem cells added to planned CAR T|Autologous hematopoietic stem cells (aHSCs) infused on Day 10 after CAR T (any FDA-approved CAR T product) infusion on Day 0.
224122003|NCT00155285|PROCEDURE|computed tomography|
224122004|NCT07091448|DEVICE|Amnion chorion membrane|Alveolar ridge preservation of a single extraction socket site with a barrier membrane Biotivity™ A/C Plus.
224122005|NCT07091448|DEVICE|Collagen membrane|Alveolar ridge preservation of a single extraction socket site with a barrier membrane CopiOs..
224122006|NCT05590637|DRUG|Pimavanserin|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
224122007|NCT05590637|DRUG|Quetiapine|Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
224122008|NCT07092228|DEVICE|virtual reality and plyometric workout|to evaluate exercise capacity in teenage females with abdominal obesity using virtual reality and plyometric workouts
224122009|NCT07098403|DRUG|SHR-1905 Injection|SHR-1905 injection.
224122010|NCT07098403|DRUG|SHR-1905 Placebo Injection|SHR-1905 placebo Injection.
223992392|NCT01978951|BEHAVIORAL|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
223992393|NCT01978951|BEHAVIORAL|Conventional CKD care|group counselling about optimal diets for CKD patients
224122011|NCT06679231|BEHAVIORAL|Stress Ball|After the initial measurements of the participants assigned to the experimental group, the students involved in the project will accompany the patient and prepare the patient for the gynecological examination. To make the patient feel more comfortable during the gynecological examination, she will be given two stress balls. The patient will be asked to count each time she squeezes the stress ball during the examination. During the gynecological procedure, the participant will be administered the first EC-3. The stress ball intervention will help to reduce the participant's anxiety level and make the examination process more tolerable. In addition, the student's support to the patient will make the examination more comfortable and contribute to the participant's psychological well-being.
224122012|NCT06929104|OTHER|No intervention|No intervention
224122013|NCT06929169|DRUG|iSGLT2|"Participants randomized to the experimental arm will receive a once-daily dose of a sodium-glucose cotransporter 2 inhibitor (SGLT2i), administered orally, in addition to their standard hemodialysis care. The specific agent (e.g., dapagliflozin or empagliflozin) and dose will be selected based on safety data and clinical guidelines applicable to patients with end-stage renal disease (ESRD) on dialysis. The intervention will be maintained for 12 months. Dosing will be monitored by the research team to ensure tolerability and adherence. All patients in the experimental group will undergo comprehensive cardiovascular assessment, including serial cardiac MRI, echocardiography, and measurement of fibrosis-related biomarkers.~This intervention differs from standard care by introducing a pharmacologic agent not routinely administered in the dialysis population, targeting cardiac remodeling, fibrosis, and intradialytic complications."
224122014|NCT01704872|DRUG|ch14.18/CHO|
224122015|NCT00370149|DEVICE|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
224122016|NCT00370149|DEVICE|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
223544960|NCT05723744|DEVICE|ECG Holter and investigational device recordings for the purpose of developing Continuous Measurement of Heart Arrythmias|"For Candidates for pacemaker implantation: ECG Holter and investigational device recordings (of PPG, ECG, and motion sensors tracings non-invasively) will be recorded before procedure, during patient's hospitalization at cardiology division. Blood pressure values that are collected by an automated cuff will be collected including any notes attached to the values.~All collected data will be analyzed offline"
223544961|NCT00562822|PROCEDURE|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
223992394|NCT01400360|OTHER|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
223992395|NCT04912830|PROCEDURE|Tension-free vaginal tape|female incontinence surgery with polypropylene tape applied
223992396|NCT00004139|DRUG|docetaxel|
223992397|NCT00004139|DRUG|gemcitabine hydrochloride|
223992398|NCT00004139|DRUG|irinotecan hydrochloride|
223992399|NCT02387151|DRUG|mesenchymal stromal cells|2 doses of 1-2x10\^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
223992400|NCT00664963|DEVICE|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
223992401|NCT00664963|DEVICE|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
224122017|NCT04094961|DRUG|Ixazomib|Oral, administered four times per cycle
224122018|NCT04094961|DRUG|Pomalidomide|Oral, administered 14 times per cycle
224122019|NCT04094961|DRUG|Dexamethasone|Oral, fixed dose administered 8 times per cycle
223992402|NCT00790400|DRUG|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
223992403|NCT00790400|DRUG|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
224122020|NCT06910137|DRUG|retifanlimab|Administered intravenous as defined in the protocol.
224122021|NCT05602597|DRUG|Itraconazole 200 mg|Study participants will be administered 200 mg itraconazole by mouth twice daily after the pharmacokinetic blood draw on Day 3 and once daily on Days 4 to 10, inclusive.
224122022|NCT05602597|DRUG|Fluconazole 400 mg|Study participants will be administered 400 mg fluconazole by mouth daily on Day 3 after the pharmacokinetic blood draw, and 200 mg fluconazole by mouth daily on Days 4 to 10, inclusive.
224122023|NCT05602597|DRUG|Rifampin 600 mg|Study participants will be administered 600 mg rifampin by mouth daily starting on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 11, inclusive.
223992404|NCT03745677|BEHAVIORAL|Advanced and Integrated MicroSystems (AIMS) interventions|Each of 4 sites is receiving mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
223992405|NCT01376453|DRUG|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
223992406|NCT01376453|DRUG|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m\^2 daily through a catheter in a large vein continuously until the last day of radiation.
223992407|NCT01376453|RADIATION|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
223992408|NCT02277054|DEVICE|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
223992409|NCT00777075|DRUG|L-arginine|
223992410|NCT00777075|DRUG|Placebo|
223992411|NCT02436291|DEVICE|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
223992412|NCT04315753|OTHER|LDCT (Low Dose CT)|validate the role of non-invasive molecular and cellular biomarkers and combined radiomic signature, as complementary tools to assist early detection of lung cancer by LDCT using bioinformatic techniques for the integration of the results
223992413|NCT01125033|DRUG|Vitamin C & Vitamin E|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
223992414|NCT01125033|DRUG|Vitamin C|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
223992415|NCT01125033|DRUG|Vitamin E|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
223992416|NCT01125033|DRUG|Vitamin C Placebo & Vitamin E Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
223544962|NCT00562822|OTHER|Physical and medical therapy|Treatment with physical and medical therapy alone
223992417|NCT00725335|PROCEDURE|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
223992418|NCT00725335|PROCEDURE|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
223992419|NCT03513926|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
223992420|NCT03592043|DEVICE|MitraClip|Transcatheter Mitral Valve Repair with MitraClip
223992421|NCT00000877|DRUG|Indinavir sulfate|
223992422|NCT00000877|DRUG|Rifabutin|
223992423|NCT00078338|DRUG|Rebif®|Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
223992424|NCT00078338|DRUG|Copaxone®|Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
223992425|NCT05305170|DIAGNOSTIC_TEST|Levels of EETs, DHETs and HETEs|The plasmatic concentration of EETs, DHETs, and HETEs.
223992426|NCT02614378|PROCEDURE|air insufflation|modulated air insufflation of the ear canal
223992427|NCT02614378|PROCEDURE|placebo|no air will be introduced in the ear canal
223992428|NCT05756712|DIETARY_SUPPLEMENT|Phase 1 Wonderlab Product|Chew two tablets of Wonderlab Product for phase 1 (day 1)
223992429|NCT05756712|DIETARY_SUPPLEMENT|Phase 1 Placebo|Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).
223992430|NCT05756712|DIETARY_SUPPLEMENT|Phase 2 Placebo|Chew two tablets of placebo for phase 1 (day 1)
223992431|NCT05756712|DIETARY_SUPPLEMENT|Phase 2 Wonderlab Product|Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).
223992432|NCT00218231|DRUG|300 mg/day bupropion-sr|300 mg/day for 1 week
223992433|NCT00218231|DRUG|0 mg/day bupropion-sr|0 mg/day bupropion-sr
223992434|NCT02530710|DRUG|Q203|
223992435|NCT02530710|DRUG|Placebo|
223992436|NCT04292470|DRUG|Amitriptyline|Amitriptyline tablet
223992437|NCT00867100|DRUG|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
223992438|NCT00867100|DRUG|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
223992439|NCT00867100|DRUG|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
223992440|NCT00867100|DRUG|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
223992441|NCT02906020|DRUG|venglustat GZ/SAR402671|Pharmaceutical form: capsule Route of administration: oral
223992442|NCT02906020|DRUG|Placebo|Pharmaceutical form: capsule Route of administration: oral
223992443|NCT02765789|DEVICE|Immunoadsorption (Immunosorba)|Immunoadsorption as an alternative to plasma exchange
223992444|NCT04232904|PROCEDURE|Transversus abdominous plane block (TAP Block)|TAP block which is a peripheral nerve block preferred to postoperative pain management.
223992445|NCT06092320|OTHER|Simulation on Pediatric Status Epilepticus|The participants will complete a simulation session and debrief lead by a pediatric emergency medicine physician on status epilepticus.
223992446|NCT06092320|OTHER|Didactic Lecture on Pediatric Status Epilepticus|The participants will complete a lecture on pediatric status epilepticus
223992447|NCT05065606|DIAGNOSTIC_TEST|Dual-energy computed tomography|Dual-energy scanner examinations stored in the PACS (medical imagery) at Lariboisière Hospital are to be analyzed retrospectively and prospectively
223992448|NCT00463671|DRUG|N-acetylcysteine|
223992449|NCT00966563|DRUG|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
223992450|NCT00966563|DRUG|Placebo|
223992451|NCT03508947|DRUG|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
223992452|NCT03508947|DRUG|Placebo|Sodium Chloride
223992453|NCT01449786|DRUG|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
223992454|NCT01449786|DRUG|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
223992455|NCT01449786|OTHER|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
223992456|NCT02484586|DEVICE|Etafilcon A|Prototype lens material
223992457|NCT02484586|DEVICE|Etafilcon A|Control lens for presbyope group
223992458|NCT02484586|DEVICE|Nelfilcon A|Control lens for presbyope group
223992459|NCT02484586|DEVICE|Nesofilcon A|Control lens for presbyope group
223992460|NCT02484586|DEVICE|Nelfilcon A|Control lens for non-presbyope group
223992461|NCT02484586|DEVICE|Etafilcon A|Control lens for non-presbyope group
223992462|NCT02484586|DEVICE|Somofilcon A|Control lens for presbyope group
223992463|NCT02484586|DEVICE|58% Poly-HEMA|Control lens for presbyope group
223992464|NCT02484586|DEVICE|Omafilcon A|Control lens for non-presbyope group
223992465|NCT01375673|OTHER|Exercise|Walking Strength Training Bicycling
223992466|NCT01384812|DRUG|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
223992467|NCT01384812|DRUG|isoton sodium chloride|intravenous injection for 25 min
223992468|NCT00374751|DRUG|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
223992469|NCT01863147|DRUG|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
223992470|NCT00513162|DRUG|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
223992471|NCT00513162|DRUG|Etoposide|25 - 50 mg/m\^2 By Mouth Daily
223992472|NCT05820399|DIETARY_SUPPLEMENT|Organic Guayusa Extract|Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (\~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition.
223992473|NCT05820399|DIETARY_SUPPLEMENT|Placebo|Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition.
223992474|NCT05724238|DIETARY_SUPPLEMENT|Traditional Herbal Supplements (Kuan Sin Yin)|Astragalus-based Kuan Sin Yin
223992475|NCT05724238|DIETARY_SUPPLEMENT|Placebo|Placebo starch powder with 10% Kuan Sin Yin
223992476|NCT03059277|DRUG|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
223992477|NCT02700542|OTHER|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
223992478|NCT06198270|OTHER|Closed Kinetic Chain Exercise|Closed chain exercise plan of 5 exercises, 10reps x 3sets of each, 3 days in a week for 4-weeks, all values measured before and after 4-weeks.
223992479|NCT06198270|OTHER|Neuromuscular Training with K Tape|Neuromuscular training plan of 5 exercises, 10reps x 3sets of each, 3 days in a week, for 4-weeks, all values measured before and after 4-weeks. Just After the session k-tape applied.
223992480|NCT02179177|DRUG|Apixaban|Drug is taken by mouth twice a day for 6 months
223992481|NCT02179177|DRUG|Placebo|
223992482|NCT04770727|BEHAVIORAL|CBT workshop|The CBT based intervention for adolescents will include psychoeducation on food allergy and anxiety and also focus on providing skills, knowledge and support.
223992483|NCT02878694|BIOLOGICAL|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
223992484|NCT01660386|DRUG|Sitagliptin|100mg po once
223992485|NCT01660386|DRUG|Saxagliptin|5mg po once
223992486|NCT01660386|DRUG|Glimepiride|2mg po once
223992487|NCT01660386|DRUG|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
223992488|NCT03843853|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
223992489|NCT03843853|DRUG|S-1|S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14
223992490|NCT03843853|DRUG|Bevacizumab|Bevacizumab 7.5 mg/kg d1
223992491|NCT05127759|DRUG|HLX208|HLX208 450mg bid po
223992492|NCT00008476|DRUG|Capsaicin|
223992493|NCT06273449|DEVICE|Group 3 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Intraoral scan RPD Design Method: Based on intraoral scan, using design software RPD Fabrication Method: Additive manufacturing
223992494|NCT06273449|DEVICE|Group 2 - 3D Printed Removable Partial Denture|Teeth Profile Capture Method: Physical impression RPD Design Method: Based on stone model, using design software RPD Fabrication Method: Additive manufacturing
223992495|NCT02036437|DRUG|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
223729111|NCT02694510|OTHER|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
223992496|NCT02036437|DRUG|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
223992497|NCT05044923|DEVICE|Targeted Epidural Spinal Stimulation|Two lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) will be implanted epidurally over the dorsal aspect of the spinal cord through two laminotomies. Two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) will be connected to the lead electrodes and implanted in the upper buttocks of the participant.
223992498|NCT04873427|GENETIC|clonal heterogeneity evaluation|Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis
223992499|NCT03907267|DRUG|Taurine Solution|Taurine Solution
223992500|NCT03907267|DIETARY_SUPPLEMENT|Normal Saline|Normal Saline
223992501|NCT00880022|DEVICE|Flexitouch System|( 10 to 30 treatments depending on group assignment)
223992502|NCT04476940|BEHAVIORAL|COVID-19 Breastfeeding Support|Intervention will be implemented by trained prenatal care providers to provide comprehensive exclusive breastfeeding and COVID-19 breastfeeding guideline education and support to study participants.
223992503|NCT01634269|DEVICE|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
223992504|NCT06433895|OTHER|Manual Therapy|Manual Therapy
223992505|NCT06433895|OTHER|Exercise|Isometric and strengthening exercises for the cervical region, which are provided to patients with cervical pain and limitation
223992506|NCT00865852|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
223992507|NCT00865852|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
223992508|NCT02987647|OTHER|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
223992509|NCT02987647|OTHER|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
223992510|NCT02987647|OTHER|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
223992511|NCT02987647|OTHER|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
223992512|NCT03258736|PROCEDURE|inguinal hernia surgery|repair of inguinal hernia
224122024|NCT05602597|DRUG|Rabeprazole 40 mg|Study participants will be administered 40 mg rabeprazole by mouth daily on Day 3, after the pharmacokinetic blood draw, and on Days 4 to 9, inclusive.
224294839|NCT06273826|DIAGNOSTIC_TEST|"Colorectal Leakage App"|"The Colorectal Leakage App is a mobile application designed to aid in the early detection of anastomotic insufficiency after colorectal surgeries. The app is based on the Dutch Leakage Score (DLS) algorithm, which is a standardized protocol for postoperative monitoring."
224294840|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
224122025|NCT03434132|PROCEDURE|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
224122026|NCT00195559|DRUG|Levonorgestrel/Ethinyl Estradiol|
224122027|NCT03344497|OTHER|VC Group|VC (Conventional Consultation/Video) Group
224122028|NCT04977505|DEVICE|pushlock|The surgery procedure was performed with pushlock for fixation
224122029|NCT04977505|DEVICE|gryphon|The surgery procedure was performed with Gryphon for fixation
224122030|NCT02719483|DEVICE|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
224122031|NCT02719483|PROCEDURE|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
223992513|NCT04787237|OTHER|VST and immediate implants|One-cm long vestibular access incision was made using a 15c blade 3-4 mm apical to the mucogingival junction at the related socket . A subperiosteal tunnel was created connecting the socket orifice and the vestibular access incision using periotomes and micro periosteal elevators (. Implant fixture were then inserted after drilling to its pre-planned location 3-4 mm apical to socket base with adequate primary stability achieved using a torque wrench reaching 30 Ncm torque . A flexible cortical membrane shield that is made of cortical bone of heterologous origin of 0.6 mm thickness was hydrated and then trimmed and introduced from the vestibular access incision reaching 1 mm below the socket orifice through the tunnel . The socket gap between the implant and the shield was then packed thoroughly with particulate bone graft
223992514|NCT04787237|OTHER|Buser technique and early implants placement|In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks (depending on the size of the extracted tooth) was followed. Then an open flap implant surgery using a triangular flap design was cut. After preparing the implant bed, the site was irrigated using normal saline. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone. A non-cross liked membrane was then placed, after being soaked with BCM. Finally, the healing abutment was removed and the flap was released to allow for its suturing.
223992515|NCT03193463|DRUG|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
224294841|NCT00548951|OTHER|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
223992516|NCT03193463|DRUG|Topotecan (>8cc)|In predominantly enhancing mass with a volume of \> 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
223992517|NCT03193463|DEVICE|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
223992518|NCT03193463|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
223992519|NCT03193463|DRUG|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
223992520|NCT01139788|DRUG|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
223992521|NCT05772143|PROCEDURE|Percutaneous discectomies under CT|Percutaneous discectomies under CT guidance to treat lumbar disc herniations resistant to conservative treatment and nerve root infiltrations.
223992522|NCT01795599|DRUG|Mifegyne ®|
223992523|NCT01795599|DRUG|Gymiso®|
223992524|NCT04510298|DRUG|SP-624|Oral Capsule
223992525|NCT04510298|DRUG|Placebo|Oral Capsule
223992526|NCT00824330|BEHAVIORAL|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
223992527|NCT02153905|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
223992528|NCT02153905|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
223992529|NCT02153905|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
223992530|NCT02153905|BIOLOGICAL|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
223992531|NCT00577135|DRUG|Furosemide-Q12 hour bolus|Q12 hours bolus
223992532|NCT00577135|DRUG|Furosemide-Continuous Infusion|Continuous infusion
223992533|NCT00577135|DRUG|Furosemide-Low Intensification|1x oral dose
223992534|NCT00577135|DRUG|Furosemide-High Intensification|2.5x oral dose
223992535|NCT03904940|DEVICE|Total Contact Insole|Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
223992536|NCT03904940|DEVICE|Ethyl vinyl acetate flat insole|Flat insole made of the same material ethyl vinyl acetate
223992537|NCT06463236|OTHER|Guiding treatment|Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process
223992538|NCT06463236|OTHER|empirical therapy|Experiential treatment by grassroots doctors
223992539|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
223992540|NCT04849299|DRUG|AT-527 550 mg + cyclosporine|550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
223992541|NCT02909465|DRUG|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
223992542|NCT02909465|DRUG|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
223992543|NCT02909465|DRUG|placebo|distilled water
223992544|NCT02909465|DRUG|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
223992545|NCT02238249|DRUG|Alesion®|Dry Syrup
223992546|NCT04250779|DEVICE|CapMedic smart inhaler device|The CapMedic device provides active coaching to promote correct and regular use of MDI.
223992547|NCT04250779|BEHAVIORAL|Video-based guidance|Patients are shown a video of how to use inhalers correctly and any questions are answered by the clinician. They are also encouraged to use inhalers regularly and correctly at home.
224122032|NCT06232772|DIAGNOSTIC_TEST|α- Synuclein Ultrafine Fluorescence Detection Method|This technology belongs to the detection of a-syn aggregates in extracranial tissues, which can replace brain biopsy operations that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.
224122033|NCT05636618|DRUG|[203Pb]VMT-α-NET|\[203Pb\]VMT-α-NET is administered by intravenous bolus injection for single-photon emission computed tomography imaging.
224122034|NCT05636618|DRUG|[212Pb]VMT-α-NET|\[212Pb\]VMT-α-NET is administered by intravenous infusion for treatment of SSTR2 expressing neuroendocrine tumors.
224122035|NCT06915467|PROCEDURE|Umbilical vein catheterization through Wharton's jelly procedure|All patients included will receive the Umbilical vein catheterization through Wharton's jelly procedure as first-line treatment: placement of the umbilical line through Wharton's jelly, with simultaneous and systematic preparation of umbilical venous catheter (UVC)
224122036|NCT05295615|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
224122037|NCT04973345|DRUG|Terbutaline|management of asthma symptoms
224122038|NCT06920901|DRUG|APG777|APG777 subcutaneous injection
224294842|NCT00548951|OTHER|Control|Receive no sessions in a Snoezelen Room.
224294843|NCT02044406|DRUG|BI 1181181|single dose (low to high dose)
224294844|NCT02044406|DRUG|BI 1181181, R|powder for oral solution
224294845|NCT02044406|DRUG|BI 1181181, T2|tablet, fasted
224294846|NCT02044406|DRUG|Placebo to BI 1181181|Placebo to BI 1181181
224294847|NCT02044406|DRUG|BI 1181181, T1|tablet, fed
224294848|NCT02970435|BEHAVIORAL|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
223544963|NCT00757952|OTHER|Fourier transform ion cyclotron resonance mass spectrometry|
223544964|NCT00757952|OTHER|chromatography|
223544965|NCT00757952|OTHER|diagnostic laboratory biomarker analysis|
224294849|NCT02970435|BEHAVIORAL|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
223544966|NCT00757952|OTHER|questionnaire administration|
223544967|NCT00093262|DRUG|clevidipine|
223544968|NCT00093262|DRUG|placebo|
223992548|NCT04455022|OTHER|Bedside blood culture bottles weighing combined with educational interventions.|Educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
223992549|NCT00046306|DRUG|Antioxidants|
223992550|NCT06470477|DRUG|Guideline-based treatment|Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
223992551|NCT02784743|DRUG|''albendazole'' and ''ivermectin''|annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
223992552|NCT04118413|OTHER|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
224122039|NCT06920901|DRUG|Placebo|Matching placebo subcutaneous injection
224122040|NCT06922110|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.
224122041|NCT02158221|DRUG|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
224122042|NCT06931860|DIAGNOSTIC_TEST|Cologuard|Multi-target stool DNA test for colorectal cancer screening implemented by Exact Sciences. Cologuard has 94% sensitivity and 87% specificity to detect colorectal cancer.
224122043|NCT06931860|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Stool blood test for colorectal cancer screening. FIT has 75% sensitivity and 90% specificity to detect colorectal cancer.
224122044|NCT04405271|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Emtricitabine/Tenofovir alafenamide (FTC/TAF) in 200 mg/25 mg tablets. A dose of 1 tablet per day will be administered for a total of 12 weeks
224122045|NCT04405271|DRUG|Placebo|A dose of 1 tablet per day will be administered for a total of 12 weeks.
224122046|NCT00413569|PROCEDURE|cervical spine surgery|
224294850|NCT02970435|BEHAVIORAL|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
224294851|NCT03596619|DEVICE|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation \[SD\] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
224294852|NCT00353652|DRUG|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
224294853|NCT00353652|DRUG|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
224294854|NCT00353652|DRUG|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
224294855|NCT00353652|DRUG|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
224294856|NCT00353652|DRUG|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
224294857|NCT04693338|OTHER|Quality-of-Life Assessment|Ancillary studies
224294858|NCT04693338|OTHER|Questionnaire Administration|Ancillary studies
224294859|NCT04693338|OTHER|Supportive Care|Receive ICP tasks
224294860|NCT02041936|DEVICE|NanoKnife IRE System|
223992553|NCT03685682|BIOLOGICAL|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
223992554|NCT02420249|BEHAVIORAL|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong \[in Chinese\]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
223992555|NCT01322191|DRUG|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
223992556|NCT00351377|DRUG|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
223992557|NCT01516749|DRUG|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
223992558|NCT05090189|OTHER|Exercise Training|"The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period."
223992559|NCT03768622|PROCEDURE|surgery for pertrochanteric femoral fracture|surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
223992560|NCT03768622|PROCEDURE|surgery for femoral neck fracture|surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
223992561|NCT01661608|DEVICE|Using the EOS for gastric restriction|
223992562|NCT05847049|OTHER|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy|Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy
223992563|NCT01607879|DRUG|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
223992564|NCT01607879|OTHER|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
224122047|NCT07146997|DIETARY_SUPPLEMENT|Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB|"Group I - Placebo Group (Control) Intervention: Patients in this group will receive an oral placebo (e.g., sugar tablet or inert capsule) 1 hour before the IANB.~Purpose: This group serves as the control to establish a baseline anesthetic success rate without active premedication.~Expected Outcome: Lower IANB success rate due to lack of anti-inflammatory intervention."
224122048|NCT07146997|DRUG|Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB|"Group II - Ibuprofen Group Intervention: Patients will receive ibuprofen (400-600 mg, standard therapeutic dose) orally, 1 hour prior to IANB.~Purpose: Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and inflammation, which can enhance anesthetic efficacy.~Expected Outcome: Improved IANB success rate compared to placebo, but possibly lower than combination therapy."
223992565|NCT02607787|BEHAVIORAL|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
224122049|NCT07146997|DRUG|Group III - Serratiopeptidase Group|"Group III - Serratiopeptidase Group Intervention: Patients will receive serratiopeptidase (10 mg or standard dose) orally, 1 hour before the IANB.~Purpose: Serratiopeptidase is a proteolytic enzyme with anti-inflammatory, mucolytic, and fibrinolytic properties. It helps reduce tissue inflammation by breaking down inflammatory mediators and possibly inhibiting prostaglandin production.~Expected Outcome: Improved IANB success rate compared to placebo; effectiveness may vary compared to ibuprofen alone"
224294861|NCT03181321|BEHAVIORAL|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
224294862|NCT03141879|OTHER|HUR equipment resistance training intervention|Resistance training intervention
224294863|NCT04910659|OTHER|acupuncture|P6, LI4 and LI 11 stimulation
224294864|NCT06341387|OTHER|Breath, urine and blood analysis|"breath sampling: all subjects exhale into two sterile Tedlar bags, connected to a mouthpiece, in a condition similar to traditional spirometry.~Urine will be collected usual urine container.~The blood sample (\~ 5 ml) will be taken with a serum separator tube."
223992566|NCT02607787|OTHER|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
223992567|NCT04324905|DRUG|HIP1802|Test drug
224122050|NCT07146997|COMBINATION_PRODUCT|Group IV - Combination Group (Ibuprofen and Serratiopeptidase)|"Group IV - Combination Group (Ibuprofen and Serratiopeptidase) Intervention: Patients will receive a combination of ibuprofen and serratiopeptidase orally, 1 hour before IANB. The doses will be the same as those used in Groups II and III, respectively.~Purpose: This group is designed to test the synergistic effect of combining an NSAID (ibuprofen) and a proteolytic enzyme (serratiopeptidase) to maximize inflammation control and increase the success of IANB in inflamed pulp tissue.~Expected Outcome: Highest success rate of IANB due to dual action on prostaglandin inhibition and tissue inflammation reduction"
224122051|NCT07147062|PROCEDURE|Rectus Sheath Block|A total volume of 0.5 mL/kg of 0.25% bupivacaine-distributed equally between both sides-will be injected bilaterally under direct ultrasound guidance.
223992568|NCT04324905|DRUG|HGP1705|Reference drug
224122052|NCT07147062|PROCEDURE|Caudal Epidural Block|"A 22G caudal epidural needle will be inserted at approximately a 45° angle toward the sacral hiatus, and the characteristic click sensation will be felt upon passing the sacrococcygeal ligament. The needle will then be advanced carefully in the cephalad direction, parallel to the longitudinal axis of the spinal canal. After confirming correct placement by negative aspiration, 1 mL/kg of 0.25% bupivacaine will be administered."
224122053|NCT01461577|DRUG|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
224122054|NCT07150520|DEVICE|Virtual Reality-Based Optokinetic Stimulation (OKS)|A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.
224122055|NCT07150156|BEHAVIORAL|brief intervention|Provision of personal feedback on drinking risk level and guidance that encourages the patient to develop a realistic plan to reduce his or her alcohol consumption to a less risky level
224122056|NCT07152470|BEHAVIORAL|Diet and Exercise Tracking|To determine if diet and/or exercise had any impact on weight loss while taking motus.
224122057|NCT07162402|OTHER|Super Skills for Life (SSL) Program|Its Cognitive Behaviour Therapy (CBT) Based 8 sessions Super Skills for Life (SSL) Program for childhood Anxiety Management.
224122058|NCT07162402|OTHER|No Active Intervention|Routine Activities in Class
224122059|NCT07162233|PROCEDURE|derotation osteotomy utilizing Kirschner wires for the correction of congenital proximal radioulnar synostosis|"The level of distal radial and proximal ulnar osteotomies is determined under C- arm. A k-wire is inserted in the outer border of the metaphysis of the radius distal to the level of the osteotomy, engaging and transfixing the radioulnar joint, small skin incision is made over the dorsal aspect of the forearm at the level of distal radial osteotomy, dissection of subcutaneous tissue with good exposure of the extensor tendons, transverse osteotomy is done using 2.5 mm drill bit and small sharp osteotme, allowing derotation movement of the distal part of the radius using the k-wire.~Another small skin incision is made over the level of proximal ulnar osteotomy, dissection of subcutaneous tissue, another ulnar transverse osteotomy is done distal to the level of the proximal radioulnar synostosis. Derotaion of the forearm is adjusted in the functional position of the forearm in around (10˚:20˚supination), wound closure using absorbable Vicryl sutures. Above elbow cast is used f"
224122060|NCT07161908|DEVICE|Pulse oximeter|"To ensure proper treatment, the infant will be continuously monitored with a pulse oximeter. Based on oxygen saturation levels, the treatment may be adjusted according to pre-established protocols. It is required that the saturation stays above a certain value for more than 95 % of the 12-hour measurement period. If the defined saturation values are reached, the parents will reduce the oxygen flow by one degree for 20 minutes in the hospital/home setting (20 minute test) and if the saturation values remain at 93 % or more during this period, overnight 12 hour monitoring will also be performed to confirm stable saturation values of 93 % or more for 95 % or more of the monitoring time.~Thanks to modern specialized pulse oximeters, it is possible to ensure accurate, long-term, remotely managed monitoring of the infant and to interactively optimize oxygen therapy based on current oxygen saturation levels."
224122061|NCT07162090|DRUG|Roxadustat|Patients were administered roxadustat orally to observe its impacts on renal anemia and sarcopenia.
224122062|NCT07162090|DRUG|Recombinant human erythropoietin (EPO)|Recombinant human erythropoietin was administered to patients as a control group to investigate its impacts on renal anemia and sarcopenia.
224122063|NCT07162545|OTHER|stroboskopic visual training|Players in the study group will wear stroboscopic glasses for 10 minutes a day, two days a week, for eight weeks during their routine training. Evaluations will be repeated at the end of the eight weeks.
224122064|NCT07164014|OTHER|Mediterranean diet|Mediterranean Diet Total Calories: \~1,980 kcal Protein: \~110 g Carbohydrates: \~132 g Fat: \~117 g Diet Type: Mediterranean: Moderate-calorie, high in unsaturated fats, includes fermented dairy Omega-3 Sources: Present: Fish, Olive Oil, Nuts Oil/Fat Types: Olive oil, tahini, nuts (mostly monounsaturated \& polyunsaturated)
223992569|NCT04550819|PROCEDURE|intraintestinal extended biliary stents|The test group will be placed intraintestinal extended biliary stents in intrahepatic bile duct in ERCP
223992570|NCT04550819|PROCEDURE|ordinary plastic biliary stents|The test group will be placed ordinary plastic biliary stents in intrahepatic bile duct in ERCP
223992571|NCT04079205|DEVICE|Wearable Device(exoRehab)|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
223992572|NCT04079205|BEHAVIORAL|Home rehabilitation program|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
223992573|NCT04315805|OTHER|Integrative Yoga Therapy|Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
223992574|NCT06427733|BIOLOGICAL|Placebo comparator|SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
223992575|NCT06427733|BIOLOGICAL|Active Comparator|SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract
223992576|NCT00470197|DRUG|alvocidib|Given IV
223992577|NCT00470197|DRUG|cytarabine|Given IV
223992578|NCT00470197|DRUG|mitoxantrone hydrochloride|Given IV
223992579|NCT00470197|OTHER|pharmacological study|Correlative study
223992580|NCT05201053|DIAGNOSTIC_TEST|Exploratory for different markers|Test biomarkers for development of mild, moderate or severe disease
223992581|NCT04788745|DRUG|Trimetazidine Dihydrochloride|Oral tablet, twice-daily
223992582|NCT05807906|OTHER|virtual reality application|The patient will continue to monitor the virtual reality application during the fistula puncture procedure.
223992583|NCT02395419|DEVICE|Orotracheal intubation with Totaltrack|
223992584|NCT02395419|DEVICE|Orotracheal intubation with Airtraq|
223992585|NCT03994731|BIOLOGICAL|Pegloticase|IV pegloticase 8 mg Q2W
223992586|NCT03994731|DRUG|methotrexate|Oral MTX 15 mg weekly
223992587|NCT03994731|DRUG|placebo|Oral placebo for MTX
223992588|NCT03994731|DIETARY_SUPPLEMENT|folic acid|Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.
223992589|NCT03994731|DRUG|gout flare prophylaxis regimen|Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al. 2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.
223992590|NCT03994731|DRUG|fexofenadine|For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.
223992591|NCT03994731|DRUG|acetaminophen|For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.
223992592|NCT03994731|DRUG|methylprednisolone|For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
223992593|NCT04966026|OTHER|No inervention|No inervention
223992594|NCT00500968|PROCEDURE|stent|ERCP guided stent insertion before transection of the gland
223992595|NCT00500968|PROCEDURE|Distal pancreatectomy|conventional distal pancreatectomy
223992596|NCT01100606|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
223992597|NCT01100606|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
223992598|NCT06042972|OTHER|Questionnaire including Edinburgh postnatal depression scale, Patient Health Questionnaire 2 and background variables|"Patients meeting the inclusion criteria will be recruited by health professionals who have agreed to participate in the study.~Patients must fill out an anonymous self-questionnaire which will consist of 2 tests aimed to help diagnose postpartum depression, recommended in France by the Haute Autorité de Santé (HAS), and background variables.~The self-questionnaire will be given back by the patient in a sealed envelope. Each questionnaire will only be filled out once per patient."
223992599|NCT04249570|OTHER|Povidone iodine|
223992600|NCT00027391|DRUG|Albuterol|
223992601|NCT00027391|DRUG|Oxandrolone|
223992602|NCT02838979|DIETARY_SUPPLEMENT|First Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
223992603|NCT02838979|OTHER|Washout (3 weeks)|No study product is taken prior to beginning crossover
223992604|NCT02838979|DIETARY_SUPPLEMENT|Second Intervention (14 days)|Oral Glutamine or Maltodextrin for 2 weeks
223992605|NCT00830323|DRUG|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
223992606|NCT00830323|DRUG|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
223992607|NCT00830323|DRUG|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
223992608|NCT03142269|PROCEDURE|360°anterior capsule polishing|360°anterior capsule polishing was performed with double-ended capsule polisher
223992609|NCT04709458|BIOLOGICAL|TBX-2400|Hematopoietic stem cells transplantation
223992610|NCT00675532|BEHAVIORAL|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
224122065|NCT07164014|OTHER|Hospital diet|Hospital diet Total Calories: \~3,100 kcal Protein: \~160 g Carbohydrates: \~280 g Fat: \~150 g Diet Type: High Protein, High Calorie: High in saturated fats, refined carbs, and animal proteins Omega-3 Sources: Minimal: Mostly absent Oil/Fat Types: Animal fats (saturated), dairy fat, minimal unsaturated fat
224122066|NCT04389749|DEVICE|CPM|CPM-continuous passive motion device.
223992611|NCT00675532|BEHAVIORAL|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
223992612|NCT01749852|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
223992613|NCT01749852|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
224122067|NCT04821973|DEVICE|Radius PPG Tetherless Pulse Oximetry (Masimo)|continuous monitoring by a portable, wireless and stand-alone device
224122068|NCT04821973|DEVICE|usual monitoring|usual nurse respiratory monitoring
224122069|NCT00701727|DRUG|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
224122070|NCT00701727|DRUG|Placebo|1 tablet, once a day, for 7 weeks
224122071|NCT02757066|DRUG|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
224122072|NCT02757066|DRUG|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
223992614|NCT02868840|BEHAVIORAL|Tai Chi exercise|exercise twice a week each for one hour
223992615|NCT02868840|BEHAVIORAL|symptom management|sending text message weekly to manage symptoms related to stroke
223992616|NCT02361086|DRUG|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
224122073|NCT02757066|DRUG|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
224122074|NCT05113953|DRUG|Centanafadine|Sustained-release oral tablets
223992617|NCT00609947|DEVICE|Endeavor Zotarolimus-Eluting Coronary Stent|
223992618|NCT03088774|OTHER|Information material|Online web-application developed together with patients with low back pain
223992619|NCT01721733|DRUG|Placebo|
224122075|NCT05113953|DRUG|Placebo|Oral tablets
224122076|NCT04921722|DRUG|Percutaneous sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.
224122077|NCT04921722|DRUG|Oral sirolimus|We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
224122078|NCT00649649|DRUG|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
224122079|NCT00649649|DRUG|Accupril® Tablets 40 mg|40mg, single dose fed
223992620|NCT01721733|DRUG|EPI-743 15 mg/kg|
223992621|NCT01721733|DRUG|EPI-743 5 mg/kg|
223992622|NCT04977570|DRUG|SYHA1805 tablets|Oral tablets of SYHA1805 with three pre-designed doses
223992623|NCT04977570|DRUG|Placebo|Oral tablets of placebo with matching doses
223992624|NCT03516305|DRUG|Staccato Alprazolam 1 mg|alprazolam I mg administered via the Staccato hand-held inhaler device system.
223992625|NCT05230953|BIOLOGICAL|mRNA1273 vaccine|fourth dose of the mRNA1273 vaccine (50 microgram) adminstered IM
223992626|NCT02675257|BEHAVIORAL|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
224122080|NCT02491437|DRUG|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
224122081|NCT02491437|DRUG|intravaginal progesterone gel 90 mg|
224122082|NCT00502307|DRUG|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
224122083|NCT00502307|DRUG|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
224122084|NCT05039580|DRUG|PD-1 monoclonal antibody|PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
224122085|NCT06009224|OTHER|ERAS perioperative management|"* Epidural analgesia~* Fluid balance~* Other items are the same as conventional"
224122086|NCT05372341|OTHER|descriptive|posotcovid patients will be elective surgery postoperative outcomes
224122087|NCT03078036|GENETIC|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
223992627|NCT02675257|BEHAVIORAL|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
223992628|NCT02675257|BEHAVIORAL|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
224122088|NCT03078036|GENETIC|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~* Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~* Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
223992629|NCT02675257|BEHAVIORAL|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
223992630|NCT02675257|BEHAVIORAL|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
223992631|NCT02675257|BEHAVIORAL|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
223992632|NCT02675257|BEHAVIORAL|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
223992633|NCT02675257|BEHAVIORAL|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
223992634|NCT02675257|BEHAVIORAL|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
223992635|NCT02675257|BEHAVIORAL|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
223992636|NCT02675257|BEHAVIORAL|Sports, activities and exercise|Education on sports, activities and exercise
223992637|NCT02675257|BEHAVIORAL|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
223992638|NCT02675257|BEHAVIORAL|Diabetes complications|Education on diabetes complications
223992639|NCT02675257|BEHAVIORAL|Social aspects of living with diabetes|Education on social aspects of living with diabetes
223992640|NCT04701723|OTHER|cardiac coherence|standard care associated to cardiac coherence training during 3 months
223992641|NCT04046458|BEHAVIORAL|Nighttime Vital Sign EHR Alert|A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
223992642|NCT04046458|OTHER|No EHR alert|No change to EHR function; no alert visible to providers
223992643|NCT00569114|DRUG|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
223992644|NCT00657735|DEVICE|H-Coil deep TMS|20 daily deep rTMS treatments
223992645|NCT00657735|DEVICE|sham|inactive treatment
223992646|NCT06544603|DEVICE|Multiwave Locked System (MLS) laser|Laser probe directly contacts with skin of the all the acupoints. The probe was fixed on each point for 1 min. In this study, the laser acupuncture used have wavelength of 808 nm and 905nm, 1.2 W power (808nm is 1 W, 905 nm is 200 mW), continuous mode emission (808 nm) and pulsed mode emission (905 nm)
223992647|NCT01304498|BIOLOGICAL|V503|9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
223992648|NCT01304498|BIOLOGICAL|GARDASIL|Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
223992649|NCT02643628|PROCEDURE|Microneedling|
223992650|NCT02643628|DEVICE|Microneedling followed by Bellafill treatment|
223992651|NCT02016209|DRUG|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
223992652|NCT05054569|BEHAVIORAL|Cognitive-Behavioral Stress Management and Health Education|Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
223992653|NCT03321279|BEHAVIORAL|Social Incentive|Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
223992654|NCT04937920|BIOLOGICAL|DBI-002 probiotic gel|Topical application on skin affected with tinea versicolor
223992655|NCT04937920|BIOLOGICAL|Aqueous gel|Topical application on skin affected with tinea versicolor
223992656|NCT00226122|DRUG|Indomethacin|Indomethacin capsules 50 mg
224122089|NCT03078036|OTHER|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~\- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
224122090|NCT06188832|DIETARY_SUPPLEMENT|glucomannan, inulin, and psyllium|the subjects recieved fiber supplement containing glucomannan, inulin, and psyllium
224122091|NCT06188832|OTHER|placebo|the subjects recieved placebo
224122092|NCT01801046|DRUG|mitoxantrone hydrochloride|Given IV
223992657|NCT00894504|DRUG|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
223992658|NCT00894504|DRUG|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
223992659|NCT00894504|DRUG|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
223992660|NCT05580497|DEVICE|Soft Wearable Robotic Knee System|Power assistance will be provided from the motor to the knee joint
224122093|NCT01801046|DRUG|cytarabine|Given IV
224122094|NCT01801046|PROCEDURE|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
224122095|NCT01801046|OTHER|laboratory biomarker analysis|Correlative studies
224122096|NCT06071793|OTHER|Family involvement|Family delivery of mobility activities
223992661|NCT00259571|DRUG|retarded release phosphatidylcholine|2g daily, given orally QTD
223992662|NCT04012086|OTHER|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
223992663|NCT03569592|BEHAVIORAL|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
223992664|NCT00219245|DRUG|Rivastigmine|
223992665|NCT00168493|DRUG|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
223992666|NCT00265720|OTHER|Control|Written materials only
223992667|NCT00265720|OTHER|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
223992668|NCT00265720|BEHAVIORAL|one on one education|one on one education with a health educator
223992669|NCT00265720|BEHAVIORAL|Group education|Education in a small group
223992670|NCT01667549|OTHER|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
223992671|NCT01617122|BIOLOGICAL|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
223992672|NCT01749098|DRUG|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
224122097|NCT06166914|DRUG|Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml)|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group A received intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml).
224122098|NCT06166914|DRUG|Placebo|After informed consent, children under 14 years of age with high-risk PRRD underwent pars plana vitrectomy and silicone oil injection with scleral buckle divided into 2 groups in prospective randomized trial. Group B received infusion of normal saline.
224122099|NCT00751530|DRUG|raltegravir|New combination ART incorporating raltegravir with other ARVs.
224122100|NCT03017248|DRUG|Ketamine|ketamine
224122101|NCT03017248|DRUG|Placebos|0.9% normal saline
224122102|NCT03017248|DRUG|Morphine|Morphine
224294865|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated with inorganic bovine bone associated.|Dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) associated with inorganic bovine bone associated with collagen matrix (Bio-Oss® Collagen).
223992673|NCT01749098|DRUG|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
223992674|NCT01749098|DRUG|Placebo|Placebo capsule orally administered on Days 1 - 5
223992675|NCT01749098|DRUG|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
223992676|NCT02844777|DRUG|Placebo|200 mg applied once-daily for 28 days
223992677|NCT02844777|DRUG|5% VDA-1102|200 mg applied once-daily for 28 days
223992678|NCT02844777|DRUG|10% VDA-1102|200 mg applied once-daily for 28 days
223992679|NCT02686099|DEVICE|SternaLock 360|Sternal closure with SternaLock 360
223992680|NCT02686099|DEVICE|Wire Cerclage|Sternal closure with standard wire cerclage
223992681|NCT00609401|DRUG|Nexavar (Sorafenib)|400 mg bid
223992682|NCT00609401|DRUG|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
223992683|NCT04092452|DRUG|PF-06650833|400 mg QD
223992684|NCT04092452|DRUG|PF-06700841|45 mg QD
223992685|NCT04092452|DRUG|PF-06826647|400 mg QD
223992686|NCT04092452|DRUG|Placebo|placebo
223992687|NCT02127125|DRUG|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
223992688|NCT02127125|DRUG|Synbiotic|Synbiotic \[5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
223992689|NCT02127125|DRUG|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
223992690|NCT03645148|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
223992691|NCT03645148|OTHER|GM-CSF|immune adjuvant
223992692|NCT04711083|DIAGNOSTIC_TEST|overnight pulse oximetry|"Wrist worn Overnight oximetry was performed using portable Nonin 2500 (Nonin Medical Inc., USA) pulse oximeters. The test was explained to the subjects and their caregiver by experienced health-care staff from the sleep unit. The recording was done at home and started just before going to bed and ended on awakening; the recommended duration was a minimum of 5 h and a maximum of 7 h. The awake SpO2, mean SpO2. The data were analysed to calculate the overnight minimum SpO2, mean SpO2, dip frequency (defined as a fall in SpO2 of \> 4%), the percentage of oximetry sleep time spent with a SpO2 of \< 90%, and the total oximetry time. Recordings were classified as normal (\< 4.9 desaturation events an hour), equivocal (5 to 14.9 desaturation events an hour), or abnormal (\> 15 desaturation events an hour) according to the severity and pattern of nocturnal desaturation observed ."
223992693|NCT00003626|DRUG|dolastatin 10|
223992694|NCT01356563|BEHAVIORAL|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
223992695|NCT00002145|DRUG|Foscarnet sodium|
223992696|NCT02097303|DRUG|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
223992697|NCT00854204|DRUG|TMC114; TMC41629|
223992698|NCT02975102|DEVICE|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
223992699|NCT02975102|DEVICE|Vismed® Multi Eye Drops|Vismed® Multi 3 to 6 times per day for 3 months.
223992700|NCT05776290|BIOLOGICAL|Hyaluronic Acid|This material will be injected into the prepared impact socket prior to inserting the implant. This injection will be done inside the socket as well as on the periphery of the socket.
223992701|NCT03952442|OTHER|standardized nutrition education|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
223992702|NCT03952442|OTHER|routine nutrition education|Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
223992703|NCT04855045|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
223992704|NCT05741190|DEVICE|Pentacam Imaging|Imaging of the corneal surface
223992705|NCT02883036|OTHER|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
223992706|NCT02883036|OTHER|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
223992707|NCT06061237|OTHER|Aerobic Thai dance exercise|Aerobic Thai dance exercise 60 minute per times, 3 times per weeks of 12 weeks. Aerobic exercise of modulate intensity (12-13 Borg's RPE)
223992708|NCT05941117|COMBINATION_PRODUCT|stretching exercises|stretching exercises for Hamstring, quadriceps and calf muscle for both lower limbs of the same patients. each exercise was repeated 5 times and each repetition hold for 30 seconds in the same session.
223992709|NCT05941117|COMBINATION_PRODUCT|Transcutaneous electrical nerve stimulation|it is one of the electrical stimulation modalities which is used to relief pain, each patient receive it on both knees every session.
223544969|NCT06293716|DRUG|CVL237 tablets|CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
224122103|NCT03515434|PROCEDURE|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
224122104|NCT03515434|PROCEDURE|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
224122105|NCT03515434|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
223992710|NCT05941117|COMBINATION_PRODUCT|weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of weight bearing from standing position each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
223992711|NCT05941117|COMBINATION_PRODUCT|Non-weight bearing strengthening exercises|strengthening exercises for quadriceps, gluteus maximus, gluteus Medius and calf muscle in the form of non-weight bearing from lying and setting positions each exercise was repeated for 10 times with 5 seconds hold in the same set and patient perform three sets in the same session for both lower limbs.
224122106|NCT00039273|BIOLOGICAL|panitumumab|
224122107|NCT02424955|DRUG|perflutren lipid microspheres|
224122108|NCT02424955|DIAGNOSTIC_TEST|3D ultrasound|
223992712|NCT04492813|DRUG|Pharmacokinetic of propofol and remifentanil|Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
223992713|NCT00208247|BEHAVIORAL|Cognitive behavioral psychotherapy|
223992714|NCT04160806|DEVICE|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
223992715|NCT02649205|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
223992716|NCT03544294|DEVICE|Xience alpine, ultimaster, resolute onyx, synergy|PCI will be performed
223992717|NCT04560647|OTHER|No intervention - Psoriasis Subject|Not currently treated plaque psoriasis patients
223992718|NCT04560647|OTHER|No intervention - Control Subject|Control subjects without plaque psoriasis and no family history of psoriasis
224122109|NCT00109187|DRUG|Xolair (omalizumab)|
224122110|NCT01492647|DRUG|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
224122111|NCT01492647|DRUG|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
224122112|NCT01492647|DRUG|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
224122113|NCT03385473|GENETIC|Pharmacogenomic index|All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
223992719|NCT00160277|DRUG|Moxonidine|
223992720|NCT02272829|BEHAVIORAL|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
223992721|NCT02272829|OTHER|Health Education|
224122114|NCT03385473|DIAGNOSTIC_TEST|Therapeutic drug monitoring|The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
224122115|NCT06582056|PROCEDURE|Investigational Procedure|It consists of prospective blood and/or tissue collection from healthy subjects and/or patients with the appropriate clinical annotation. Study without any IMP administration.
223729112|NCT05343351|OTHER|Technique of injection method|"In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel."
223729113|NCT03954756|DRUG|Apatinib and PD1|"1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
223729114|NCT01554384|PROCEDURE|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
223729115|NCT01554384|PROCEDURE|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
223992722|NCT02089555|PROCEDURE|Lumbar puncture|Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
223992723|NCT02089555|PROCEDURE|Blood draw|One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
223729116|NCT01073553|DRUG|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
223729117|NCT01073553|DRUG|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
223729118|NCT06092710|DIAGNOSTIC_TEST|neuro-sensorial subjective evaluation of the airways collapsibility|verbal and manual guidance of subjects from a therapist to experiment the subjective perception of the air flow through their airways and airways collapsibility
223992724|NCT02089555|PROCEDURE|Magnetic Resonance Imaging (MRI)|Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
223992725|NCT02614690|PROCEDURE|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
223729119|NCT00237094|BEHAVIORAL|Nurse Practitioner led multidisciplinary team approach|
223992726|NCT02614690|PROCEDURE|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
223992727|NCT02614690|PROCEDURE|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
223992728|NCT01727505|DEVICE|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
223729120|NCT01160978|DRUG|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
223729121|NCT01160978|DRUG|Control Rx|The transplant recipients who have received an organ from non-treated donors.
223729122|NCT06434259|DEVICE|Digi-physical support system|A support system named Evira will be used to provide behavioral treatment.
223729123|NCT05230290|BIOLOGICAL|KD6001 Injection|Solution for intravenous injection
223729124|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
223992729|NCT01727505|DEVICE|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
223992730|NCT01441635|DRUG|Elagolix|Elagolix tablets
223992731|NCT01441635|DRUG|Placebo|Matching placebo tablets
223992732|NCT01441635|DRUG|Estradiol/Norethindrone acetate (E2/NETA)|A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.
223992733|NCT01441635|DRUG|Estradiol|1.0 mg micronized estradiol tablets administered once a day
223992734|NCT01441635|DRUG|Progesterone|Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
223992735|NCT02847390|OTHER|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
223992736|NCT03827447|DRUG|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
223992737|NCT03827447|DRUG|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
223992738|NCT00004077|DRUG|cisplatin|
223544970|NCT06293716|DRUG|CVL237 placebo tablets|CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
223544971|NCT01791491|DRUG|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
223544972|NCT01296750|OTHER|Early Physiotherapy start|Physiotherapy starting at one day post op
223544973|NCT06292377|DIAGNOSTIC_TEST|ECG|An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.
223544974|NCT06292377|DIAGNOSTIC_TEST|Transthoracic echography (TTE)|A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.
223544975|NCT06292377|DIAGNOSTIC_TEST|Blood sampling|Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
223544976|NCT02824523|DRUG|aspirin|
223544977|NCT01279876|DRUG|Melatonin|3mg oral, daily, one hour before sleep
223544978|NCT01715363|DRUG|Oxaliplatin|
223544979|NCT01715363|DRUG|Folinic Acid|
223544980|NCT01715363|DRUG|Fluorouracile|
223544981|NCT03413033|OTHER|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
223544982|NCT03413033|OTHER|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
223544983|NCT04718740|DRUG|fluzoparib|Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
223544984|NCT06172816|OTHER|SARS-CoV-2|a virus infection
223544985|NCT04379453|PROCEDURE|Robot Assisted Percutaneous Cardiovascular Intervention|Robot Assisted Percutaneous Cardiovascular Intervention
223544986|NCT05585073|OTHER|Whether lymph node dissection is qualified or not|Klass-02-QC LND scale and general error score tool were used to quantitatively evaluate the intraoperative performance of D2 LND
223544987|NCT05679960|DIAGNOSTIC_TEST|Urine PolypDx machine Versus Colonoscopy|"1. Urine samples of the participants in each group will be analyzed to check for preidentified metabolites that signified colorectal cancer~2. Colonoscopy, which is the gold standard for colorectal cancer diagnosis/screening will be performed on all the participants positive for metabolites signifying CRC on Urine PolypDx machine in all the groups"
223992739|NCT00004077|DRUG|ifosfamide|
223992740|NCT00004077|DRUG|paclitaxel|
224122116|NCT06111235|DRUG|Cretostimogene Grenadenorepvec|Engineered Oncolytic Adenovirus
224122117|NCT06111235|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent
224122118|NCT05132569|DRUG|Tolebrutininb|Pharmaceutical form: Film-coated tablet Route of administration: Oral
224122119|NCT05132569|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral
224122120|NCT04102098|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
224122121|NCT04102098|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
224122122|NCT06158958|DRUG|ABBV-303|Intravenous (IV) Infusion
224122123|NCT06158958|DRUG|Budigalimab|IV Infusion
224122124|NCT04042961|OTHER|Reactive balance training|A variety of tasks will be included to induce external or internal perturbations. External perturbations will be caused by forces outside participants' control (e.g. a push or pull from the physiotherapist). Internal perturbations are when the participant fails to control the centre of mass-base of support relationship during voluntary movement; e.g., 'agility' tasks such as kicking a soccer ball. Each session will include a five-minute warm-up, at least 60 perturbations, and a five-minute cool-down. The difficulty of the task will be set such that participants will 'fail' to recover balance \~50% of the time; 'failure' is defined as use of an upper extremity response, use of external assistance (i.e. from the overhead harness or physiotherapist), or taking more than 2 steps to regain stability. Training tasks will progressed by increasing the perturbation magnitude, including cognitive or movement tasks, or imposing sensory or environmental challenges (e.g. eyes closed, obstacles).
224122125|NCT04042961|OTHER|Aerobic and strength training (AST)|"AST sessions will consist of 30 minutes of aerobic and 30 minutes of strength training.~Aerobic training: Aerobic training will be done using treadmill walking or combination of modalities (e.g. cycling or recumbent stepping) for those unable to maintain the target heart rate with walking. The heart rate that occurred at the ventilatory threshold (V̇O2VT) during the cardiopulmonary exercise test will be used to prescribe intensity. In the absence of a discernible V̇O2VT a combination of the following will be used: 60-80% of heart rate reserve, peak oxygen uptake, and rating of perceived exertion of 11-16 (Borg 6-20 scale). Prescriptions will be initially progressed by increasing duration to ≥20 minutes and then increasing intensity to target heart rate.~Resistance training: Participants will be prescribed 1-2 sets of 8 exercises per session (squat, heel raise, ankle dorsiflexion, knee extension and flexion, abdominal curl-up, wall push up, bicep curl), at 70% of 1 repetition maximum."
224122126|NCT00138710|DRUG|Letrozole (Femara)|
224122127|NCT04969016|PROCEDURE|LSA (liquid skin adhesive)|surgical wound closure with liquid skin adhesive (LiquiBand®)
223992741|NCT02975076|DRUG|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
224122128|NCT04969016|PROCEDURE|stapler|surgical wound closure with stapler
224122129|NCT04070313|DRUG|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
224122130|NCT04627415|BEHAVIORAL|Promoting Engagement with ADHD Pre-Kindergarteners|Optimism Training includes the following strategies: 1) Identifying situations and associations 2) Determining consequences of beliefs 3) Use distractions to interrupt negative thinking 4) dispute current thinking 5) substitute positive, productive thoughts 6) practice skills to recognize/modify self-talk 7) Maintain positive changes in self-talk
224122131|NCT06551857|OTHER|Chemotherapy, chemoradiation, radiation therapy|Cancer treatment
224122132|NCT05610748|PROCEDURE|Sub-Periosteal Peri-implant Augmented Layer technique|In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.
224122133|NCT05610748|PROCEDURE|Soft tissue augmentation|In patients assigned to the STA group, flap management will be performed as described by Stefanini et al. (2016). Implant site preparation will be performed according to the same procedures described for the SPAL group. SVG will be placed underneath the buccal flap and the latter will be then released from tension by means of periosteal and muscular incisions, and will be coronally advanced and adapted to the healing abutment with a 6/0 resorbable sling suture. Interrupted sutures will be used to accomplish primary intention closure in the interproximal areas.
224294866|NCT04450849|PROCEDURE|guided tissue regeneration with using an absorbable collagen membrane associated or not with inorganic bovine bone associated with collagen matrix.|dental surgical procedures that use barrier membranes to direct the growth of new bone and gingival tissue at sites with insufficient volumes or dimensions of bone or gingiva for proper function, esthetics or prosthetic restoration. Using an absorbable collagen membrane (Bio-Gide® Perio) alone.
223992742|NCT02975076|DRUG|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
223992743|NCT02975076|DRUG|Aspirin|
223992744|NCT02975076|DRUG|Clopidogrel|
223992745|NCT02975076|DRUG|placebo of clopidogrel|
223992746|NCT04557358|OTHER|COVID-19 survey|A questionnaire locally developed to explore access to medical care and to medications, access to communication with their primary rheumatologist, and patients risk perception about COVID-19 disease
223992747|NCT04557358|OTHER|RAPID-3|The instrument measures function, pain, and patient global estimate of status, with correspond to activity disease
223729125|NCT01507597|DRUG|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
223992748|NCT04557358|OTHER|WHOQOL-BREF|The instrument measures the patient´s quality of life (4 dimensions: physics, phycological, social, and environment)
223992749|NCT04557358|OTHER|DASS-21 instrument (depression and anxiety)|The instrument measures the presence of depression and anxiety
223992750|NCT04557358|OTHER|IER-R (posttraumatic stress)|The instrument measures the presence of posttraumatic stress
223992751|NCT04515498|DEVICE|CloudCath Monitoring System|The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
223992752|NCT01358331|DRUG|MK-8353|Administered orally twice daily for 28 days for each cycle
223992753|NCT00639522|DRUG|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
223992754|NCT06146764|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|Integrated scoring method and up-and-down scoring method
223992755|NCT03477357|DEVICE|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
223992756|NCT03876470|OTHER|Hepatitis C treatment as chosen by provider|Participants' providers will determine the type of HCV treatment as appropriate.
223992757|NCT02895932|RADIATION|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
223992758|NCT01081275|BEHAVIORAL|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
223992759|NCT01081275|BEHAVIORAL|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
223992760|NCT00292097|PROCEDURE|Early tracheostomy|early conversion - less than or equal to 72 hours
223992761|NCT00292097|PROCEDURE|Late tracheostomy|Late conversion (10-14 days)
223992762|NCT01851551|DRUG|Vincristine Sulfate Liposome Injection plus rituximab|
223992763|NCT05788692|DEVICE|electric tootbrush|Participants will brush twice per day with an electric toothbrush
223992764|NCT05788692|DEVICE|manual toothbrush|Participants will brush twice per day with a manual toothbrush
223729126|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
223992765|NCT05788692|DEVICE|toothbrushing assisting application|Participants will brush twice per day with toothbrushing assisting application
223992766|NCT05105776|DEVICE|Galvanic stimulation|Galvanic stimulation during physiotherapy sessions
223992767|NCT02464605|BIOLOGICAL|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
223992768|NCT02700360|DIETARY_SUPPLEMENT|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
223992769|NCT02700360|DRUG|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900\~1,000 kcal, contains 50\~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
223992770|NCT04277884|DRUG|Firibastat|Oral administration 2×250 mg capsules bid
223992771|NCT04277884|DRUG|Placebo|Oral administration 2 capsules bid
223992772|NCT03274895|DRUG|PHMB 0.08%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
223992773|NCT03274895|DRUG|Propamidine 0.1%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
223992774|NCT03274895|DRUG|placebo|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
223992775|NCT03274895|DRUG|PHMB 0.02%|16 drops in a day in the affected eye for 5 days followed by 8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
223992776|NCT01093469|DRUG|Atopiclair Nonsteroidal Cream|
223992777|NCT01093469|OTHER|Aquaphor Healing Ointment|
223992778|NCT01093469|DRUG|EpiCeram|
223992779|NCT04922177|PROCEDURE|Indirect ceramic restoration|Indirect ceramic restoration using an optical impression.
223992780|NCT04922177|PROCEDURE|Direct restoration|Restoration using a Glass Ionomer Cement
223992781|NCT06180213|DIAGNOSTIC_TEST|FDG PET|Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.
223992782|NCT00250744|DRUG|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
223992783|NCT00250744|DRUG|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
223992784|NCT00600470|BEHAVIORAL|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
223992785|NCT00600470|BEHAVIORAL|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
223992786|NCT01893476|OTHER|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
223992787|NCT05320510|DIETARY_SUPPLEMENT|Se-yeast|The participants will be asked to take Se-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223992788|NCT05320510|DIETARY_SUPPLEMENT|Placebo|The participants will be asked to take placebo-yeast tablet. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
223992789|NCT06018662|OTHER|A medication management mobile application|A mobile application to select the most appropriate drugs for anesthetics, antimicrobials and analgesics, in addition to dose calculations
223992790|NCT03346005|DEVICE|Aeonose|An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
224122134|NCT05680870|DRUG|Omeprazole|Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
224122135|NCT04742907|DRUG|TU-100|Treatment with investigational product
224122136|NCT04742907|DRUG|Placebo|Treatment with placebo product
223992791|NCT01971151|BEHAVIORAL|Exposure therapy|"Treatment protocol:~1\) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments."
223992792|NCT05029453|DRUG|Apatinib|In experimental group, the drug used with apatinib and chemotherapy.
223992793|NCT02731079|DEVICE|Covidien iDrive|Surgery performed with Covidien powered stapler
223992794|NCT02731079|DEVICE|Ethicon Echilon|Surgery performed with Ethicon powered stapler
223992795|NCT00536653|DRUG|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
223992796|NCT00536653|DRUG|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
223992797|NCT00536653|DRUG|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
223992798|NCT02694445|OTHER|observation|The study is non-interventional.
223992799|NCT04792177|BEHAVIORAL|Emotion regulation skills training|The intervention will involve an online emotion-regulation skills training for individuals with sexual problems. It will last for 8 weeks, encompassing psycho-educational and emotion-regulation skills components. Every week participants will gain access to a different intervention module of the training, containing videos, presentation slides, written support material and a recommendation of activities to be completed until the following week of training. Participants are expected to dedicate 30 minutes to one hour per week to complete each module.
223992800|NCT01540942|DIETARY_SUPPLEMENT|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;\[W=weight（Kg）；H=height（cm）；A=age（year）\]
223992801|NCT01540942|OTHER|surgery|bowel resection
223992802|NCT04248478|OTHER|Eating Behaviours|Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
223992803|NCT04248478|OTHER|Health Status|The effect of fibromyalgia on the daily life of the patients will be questioned with Fibromyalgia Impact Questionnaire (FIQ). The FIQ was developed from information gathered from patient reports, functional status instruments, and clinical observations. This instrument measures physical functioning, work status (missed days of work and job difficulty), depression, anxiety, morning tiredness, pain, stiffness, fatigue, and well-being over the past week.
223992804|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 14
224294867|NCT00726154|BEHAVIORAL|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
224294868|NCT00726154|BEHAVIORAL|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
224294869|NCT03443193|OTHER|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
224294870|NCT00466908|DEVICE|Pentacam and IOL Master|Pentacam and IOL Master
223992805|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 23
223992806|NCT05594602|DRUG|EDP-235|Subjects will receive EDP-235 on Days 1 and 8
223992807|NCT05594602|DRUG|Itraconazole|Subjects will receive itraconazole QD Days 5-18
224294871|NCT00350649|BEHAVIORAL|Standard CBT|Manualized delivery of CBT by trained clinicians
223729127|NCT01507597|DRUG|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
223992808|NCT05594602|DRUG|Carbamazepine|Subjects will receive carbamazepine BID Days 5-23 and Days 24-27
223992809|NCT05594602|DRUG|Quinidine|Subjects will receive quinidine BID Days 5-12
223992810|NCT01661764|DRUG|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
223992811|NCT01661764|DRUG|Oleic Acid|Placebo
223992812|NCT02700659|OTHER|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
223992813|NCT04592159|DRUG|Nabiximols|oromucosal spray
224294872|NCT00350649|BEHAVIORAL|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
224294873|NCT00350649|BEHAVIORAL|CM/abstinence|Contingency Management
224294874|NCT00350649|BEHAVIORAL|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
224294875|NCT01991665|OTHER|Digital examination|
224294876|NCT01991665|OTHER|Sonography evaluation|
223992814|NCT04592159|DRUG|Placebo|oromucosal spray
224122137|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact|The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
224122138|NCT04341194|BEHAVIORAL|Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing|Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
224122139|NCT01168713|DRUG|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
224122140|NCT01168713|DRUG|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
223729128|NCT04768595|DIETARY_SUPPLEMENT|Placebo|Two, 1g capsules taken daily with food
223729129|NCT04768595|DIETARY_SUPPLEMENT|Ceto 10|Two, 1g capsules daily with food
223992815|NCT05674162|BEHAVIORAL|Unobserved|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher.
223992816|NCT05674162|BEHAVIORAL|Observed|Participants walk a distance of 40 meters wearing the sensors, observed by the researcher.
223992817|NCT05674162|RADIATION|Unobserved & Measured|Participants walk a distance of 40 meters wearing the sensors, unobserved by the researcher and aware of the gait measurement by the sensors.
223992818|NCT04662229|DEVICE|Eco-guided Percutaneous Electrical Stimulation|Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.
223992819|NCT04662229|DEVICE|Sham stimulation|Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
223992820|NCT00012753|PROCEDURE|Automated telephone health status assessments with nurse follow-up.|
223992821|NCT03394131|DRUG|Hylase|hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline
223992822|NCT03394131|DRUG|Insulin|hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline
224122141|NCT02273440|DRUG|BIIL 284 BS|
224122142|NCT02273440|DRUG|Theophylline|
224122143|NCT02273440|DRUG|Placebo|
224294877|NCT03263039|DRUG|Pembrolizumab|Pembrolizumab 200 mg Q3W
224294878|NCT02899832|DEVICE|NIRS|Near Infra Red Spectroscopy
223992823|NCT03394131|OTHER|saline|hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
223992824|NCT03470259|DRUG|IV adminstration of EMI-137|Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
223992825|NCT03470259|DEVICE|Multispectral Fluorescence Reflectance Imaging|A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
223992826|NCT03470259|DEVICE|Spectroscopy|A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
223992827|NCT05011344|OTHER|Blood sample|Seroneutralization and Elisa tests
224122144|NCT04209296|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.
224122145|NCT05218850|DRUG|Butyrate|Butyrate enemas will be administered once a day for 12 weeks
224294879|NCT03533374|DIAGNOSTIC_TEST|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
224294880|NCT03336320|DEVICE|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
224294881|NCT02072148|PROCEDURE|PET/CT|PET scan or CT scan q 4 months for 5 years
224294882|NCT02072148|RADIATION|Radiotherapy|Postoperative XRT 5000 cGy
224294883|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
224294884|NCT02072148|RADIATION|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
224294885|NCT02466230|DEVICE|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
224294886|NCT06223217|OTHER|Surveys and Questionnaires|The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
224294887|NCT04132895|OTHER|observational only, no interventions are prescribed in protocol.|"* Treatment will be given as per usual standard of care.~* No treatments are specified by this protocol."
223729130|NCT04768595|DIETARY_SUPPLEMENT|Fish oil|Two, 1g capsules daily with food
223992828|NCT04176731|DEVICE|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
223992829|NCT04518046|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
224294888|NCT03456895|OTHER|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
224294889|NCT03456895|OTHER|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
224294890|NCT03456895|OTHER|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
223729131|NCT00002581|DRUG|cyclophosphamide|
223729132|NCT00002581|DRUG|fluorouracil|
223992830|NCT04518046|DRUG|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
223992831|NCT04518046|DRUG|Ipilimumab|Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
223992832|NCT03157245|DIAGNOSTIC_TEST|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
223992833|NCT00276198|DIETARY_SUPPLEMENT|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
223992834|NCT00276198|DIETARY_SUPPLEMENT|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
223992835|NCT03037203|DRUG|JZP-110|75 mg, 150 mg, 300 mg
223992836|NCT03037203|OTHER|Placebo|
224122146|NCT02280291|DRUG|Ankle SSB|general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
224122147|NCT02280291|DRUG|Ankle OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
223729133|NCT00002581|DRUG|methotrexate|
223729134|NCT00002581|DRUG|tamoxifen citrate|
223729135|NCT00002581|PROCEDURE|conventional surgery|
223729136|NCT00002581|RADIATION|radiation therapy|
223729137|NCT02952781|DEVICE|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
223729138|NCT01343498|DRUG|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
223729139|NCT02215187|BEHAVIORAL|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
223729140|NCT02215187|BEHAVIORAL|Attention Control|Social contact control (health education/no skill training)
223992837|NCT05616676|BEHAVIORAL|Brief digital imagery-competing task|"First session guided by a researcher: A memory cue followed by playing a computer game with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session."
223992838|NCT05616676|BEHAVIORAL|Brief digital music-listening task|"First session guided by a researcher: Information about the composer's music followed by listening to classical music.~Option to engage in self-administered/guided sessions after the first session."
223992839|NCT05616676|OTHER|Treatment As Usual|Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events.
223992840|NCT03518567|DRUG|Smoked marijuana cigarettes: High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose \[6% THC\])
223992841|NCT04380883|DEVICE|InnoSEAL+TRB|InnoSEAL is a catecholamine chitosan-based pad (InnoSEAL hemostatic pad, InnoTherapy, Inc.). Chitosan-Catechol in InnoSEAL instantly forms an adhesive barrier upon blood contact. It is intended for use under the care of a healthcare professional. The dressing is indicated for the skin surface puncture sites for vascular procedures, percutaneous catheters/tubes. TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. We will apply InnoSEAL and TRB together.
223992842|NCT04380883|DEVICE|TRB alone|TRB is a pneumatic device which is applied routinely at the puncture site and inflated with air to stop bleeding from the access site. It will be the comparing arm.
224122148|NCT02280291|DRUG|DR SSB|general anesthesia/sedationwith a single shot; general anesthesia/sedation with a single shot; Primary predictor variable: single shot block, a 22 gauge, 3.5 inch needle will be used and 20cc of 2% lidocaine with 1:200,000 epinephrine + 20cc of 0.5% bupivacaine with 1:300,000 epinephrine will be injected around the nerve after confirming negative aspiration every 5 cc.
223729141|NCT01306591|DRUG|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
223729142|NCT01306591|DRUG|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
223729143|NCT02744014|BEHAVIORAL|Add-on Therapy for Axial Spondyloarthritis|
223729144|NCT04219943|PROCEDURE|Surgical Treatment for Impacted Femoral Neck Fracture|Surgical Treatment for Impacted Femoral Neck Fracture
223729145|NCT01302093|DRUG|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
223729146|NCT01302093|DRUG|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
223729147|NCT02299297|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
223992843|NCT00020761|DRUG|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
224122149|NCT02280291|DRUG|DR OnQ|versus regional block with continuous infusion using an OnQ pump. 17 gauge Tuohy needle will be used and 20cc of 2% lidocaine with epinephrine +20cc of 0.5% bupivacaine with1:300,000epinephrine will be injected around the nerve after confirming negative aspiration every 5cc.
223992844|NCT00020761|DRUG|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
223992845|NCT05887739|DIAGNOSTIC_TEST|Inertial gait analysis|All groups will be evaluated with inertial gait analysis
223992846|NCT01584518|DRUG|Furosemide|Based on clinical standard per clinician
223992847|NCT01884220|OTHER|There are no interventions in this study.|
223992848|NCT03124147|DEVICE|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
223992849|NCT01383330|DRUG|megace|800mg
223992850|NCT01383330|DRUG|DW-ES(A)|625mg
224122150|NCT02537301|OTHER|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
224122151|NCT05364905|DRUG|Chemotherapy|Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
223992851|NCT01383330|DRUG|DW-ES(B)|625mg
224122152|NCT06357715|OTHER|"slumpposition"|"neurodynamic sliding mobilisation in the slump position"
224122153|NCT06357715|OTHER|"no slump position"|placebo
224294891|NCT03456895|OTHER|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
223992852|NCT00603811|BIOLOGICAL|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
223992853|NCT00603811|BIOLOGICAL|Placebo|Placebo
223992854|NCT00617929|BIOLOGICAL|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
223992855|NCT00617929|BIOLOGICAL|rituximab|administered 375 mg/m\^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
223992856|NCT00617929|DRUG|clofarabine|administered 30 mg/m\^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
223992857|NCT00617929|PROCEDURE|stem cell transplantation|administered on Day 0 per institutional guidelines.
224122154|NCT04763109|OTHER|Whole-body Magnetic Resonance Imaging|Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months
224122155|NCT06455462|DRUG|Tezepelumab|tezepelumab treatment initiated between 1st January 2023 and 31st March 2024
224122156|NCT03585621|RADIATION|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
224122157|NCT03727555|GENETIC|Intrathecal and intravenous LV gene therapy|Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 multiplicity of infection/ml which carry normal ABCD1 gene
224122158|NCT06503900|BIOLOGICAL|mRNA COVID-19 vaccine|ACIP-CDC recommended vaccine
224122159|NCT06503900|BIOLOGICAL|IIV4 (quadrivalent inactivated influenza vaccine)|ACIP recommended vaccine
224122160|NCT06154369|BEHAVIORAL|JoyPop|Participants will be asked to use the app at least twice daily for the first 4 weeks with no further instructions on feature usage or time spent using the app.
224122161|NCT05175261|DIAGNOSTIC_TEST|Prolocor pFCG test|Perform pFCG test on patients admitted with myocardial infarction to assess prognosis
224122162|NCT02889081|OTHER|maternal biological folate level|supplementation status and serum level
224122163|NCT02889081|OTHER|maternal biological Vitamin D level|supplementation status and serum level
224122164|NCT00210158|PROCEDURE|Air|Patients undergo long-term morphine treatment and vertebral cementoplasty. During the procedure, patients are ventilated with a mixture of air and oxygen.
224122165|NCT00210158|PROCEDURE|Protox|Patients undergo long-term morphine treatment and vertebral cementoplasty. During the procedure, patients are ventilated with a mixture of oxygen and nitrous oxide.
223729148|NCT03951844|DEVICE|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
223992858|NCT04502992|BEHAVIORAL|Acceptance and Committment Therapy|Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles \& McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
223992859|NCT01309698|DRUG|Vildagliptin (LAF237)|
223992860|NCT01309698|DRUG|Voglibose|
223992861|NCT01309698|DRUG|Vildagliptin and Voglibose|
223992862|NCT00724386|DRUG|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
223992863|NCT00724386|DRUG|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
223992864|NCT00724386|DRUG|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
223992865|NCT00724386|RADIATION|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
223992866|NCT00953732|DRUG|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
223992867|NCT01638845|PROCEDURE|continuous perineural catheter|continuous perineural catheter
223992868|NCT01500993|DRUG|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
223992869|NCT01500993|DRUG|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cycle of 5-FU based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
223544988|NCT04179305|BEHAVIORAL|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
223544989|NCT04179305|BEHAVIORAL|Usual Care Arm|Oncologists will provide care in non-specific manner.
223729149|NCT03789318|DRUG|CA-008 5 mg|5 mg CA-008 reconstituted in saline.
223729150|NCT03789318|DRUG|Placebo|Each cohort will use placebo reconstituted in saline.
223729151|NCT03789318|DRUG|Bupivacaine Hydrochloride|0.25% administered pre-surgery
224122166|NCT06533865|DRUG|Romosozumab|Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
223544990|NCT00361972|DRUG|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
223729152|NCT03789318|DRUG|Hydromorphone|0.02 mg/kg IV administered intraoperatively
223729153|NCT03789318|DRUG|Fentanyl|100 mcg IV administered intraoperatively
223729154|NCT03789318|DRUG|Acetaminophen|1000 mg IV administered intraoperatively
223729155|NCT03789318|DRUG|Oxycodone|5-10 mg PO administered post-surgery
223729156|NCT03789318|DRUG|CA-008 10 mg|10 mg CA-008 reconstituted in saline.
223729157|NCT03789318|DRUG|CA-008 15 mg|15 mg CA-008 reconstituted in saline.
223729158|NCT00213798|PROCEDURE|Biopsy samples|
223992870|NCT06023810|BEHAVIORAL|Watson's human care theory-based motivational interviewing method|The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
223992871|NCT01512550|PROCEDURE|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
223992872|NCT01512550|PROCEDURE|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
223992873|NCT01512550|DEVICE|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
223992874|NCT00806637|PROCEDURE|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
223992875|NCT00806637|PROCEDURE|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
223992876|NCT03374293|RADIATION|Radiation|RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
223992877|NCT03374293|DRUG|Anti-PD-1 Antibody|Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
224122167|NCT06533865|DRUG|Placebo|Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
224122168|NCT06533865|DRUG|Zoledronic acid|One intravenous infusion
223544991|NCT00361972|DRUG|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
224122169|NCT03214562|DRUG|Cytarabine|Given IV
224122170|NCT03214562|BIOLOGICAL|Filgrastim|Given SC
224122171|NCT03214562|DRUG|Fludarabine|Given IV
224122172|NCT03214562|DRUG|Idarubicin|Given IV
224122173|NCT03214562|BIOLOGICAL|Pegfilgrastim|Given SC
224122174|NCT03214562|DRUG|Venetoclax|Given PO
224122175|NCT05029570|DEVICE|Conduction System Pacing (pacemaker implantation)|Conduction System Pacing (pacemaker implantation) and Atrioventricular node ablation
224122176|NCT06128551|DRUG|Assigned interventions|Drug: RMC-6291 and RMC-6236 Oral tablets
224122177|NCT04716933|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
224122178|NCT04716933|DRUG|Carboplatin|IV infusion Q3W
223992878|NCT06406699|BEHAVIORAL|Pain Reprocessing Therapy (PRT)|PRT is a psychological intervention for chronic pain patients with a primary nociplastic component. PRT aims to help patients reconceptualize their pain as a non-dangerous signal that is not indicative of tissue pathology or structural abnormality. Through decreasing the threat level of their chronic pain, the pain itself can also resolve.
223992879|NCT02083289|DRUG|ONO-9054|
223992880|NCT02083289|DRUG|Latanoprost|
223992881|NCT01021371|BEHAVIORAL|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
223992882|NCT02784964|BIOLOGICAL|Elixcyte 8 ml|ADSC 6.4\*10\^7 cells, allogeneic injection
223992883|NCT02784964|DEVICE|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
223992884|NCT02784964|BIOLOGICAL|Elixcyte 4 ml|ADSC 3.2\*10\^7 cells, allogeneic injection
223992885|NCT02784964|BIOLOGICAL|Elixcyte 2 ml|ADSC 1.6\*10\^7 cells, allogeneic injection
223992886|NCT01856517|DRUG|Clonidine|
223992887|NCT01856517|DRUG|Placebo|
223992888|NCT05961540|OTHER|Conventional care|"1. Instruct parents to follow up with the baby at the doctor's appointment.~2. Provide telephone follow-up visits at 1 month, 3 months, and 6 months of age to assess the baby's feeding and physical development (height and weight)."
223544992|NCT02501681|OTHER|priming solution during cardiovascular surgery|
223544993|NCT01606904|BEHAVIORAL|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
223992889|NCT05961540|BEHAVIORAL|Breastfeeding behavioural intervention for mothers of infants with CHD|"Based on the Behavioural Change Wheel theory,the intervention program is developed and implemented to promote the change in breastfeeding behavior of mothers with CHD infants,so as to improve the exclusive breastfeeding rate of this population.Specific programs include:~1. Evaluate signs of hunger and satiety in infants.~2. Family visits, face-to-face guidance on breastfeeding skills, breast milk storage and management.~3. Training methods for promoting breast milk secretion.~4. To explain common feeding difficulties manifestations and treatment methods in infants with CHD.~5. Establish a breastfeeding promotion alliance.~6. Teach mothers to weigh their babies before and after breastfeeding to determine breast milk intake.~7. Assess and guide the growth and development of infants with CHD."
223992890|NCT00480051|DEVICE|Cardiac Resynchronization Pacing|
224122179|NCT04716933|DRUG|Cisplatin|IV infusion Q3W
223992891|NCT03203837|OTHER|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
224122180|NCT04716933|DRUG|Pemetrexed|IV infusion Q3W
224294892|NCT03456895|OTHER|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
224294893|NCT01376817|DRUG|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
224294894|NCT01376817|DRUG|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
224294895|NCT05555368|OTHER|Quality of Recovery Score|Descriptive
223729159|NCT00664391|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
223729160|NCT02480114|OTHER|Educational Intervention|Undergo oral care and pain management education session
223992892|NCT00135681|DRUG|nedocromil budesonide|
223992893|NCT00002489|BIOLOGICAL|dactinomycin|
223729161|NCT02480114|DRUG|Gabapentin|Given PO
223729162|NCT02480114|OTHER|Pain Therapy|Receive usual oral health care
223992894|NCT00002489|BIOLOGICAL|filgrastim|
223992895|NCT00002489|DRUG|carboplatin|
224294896|NCT02145026|DRUG|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
224294897|NCT03207841|OTHER|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake.
224294898|NCT02935166|OTHER|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
224294899|NCT02501434|DRUG|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
223729163|NCT02480114|OTHER|Quality-of-Life Assessment|Ancillary studies
223729164|NCT02480114|OTHER|Questionnaire Administration|Ancillary studies
223729165|NCT02480114|DRUG|Oxycodone/Acetaminophen|Analgesia
223729166|NCT02480114|DRUG|Hydrocodone/Acetaminophen|Analgesia
223729167|NCT02480114|DRUG|Fentanyl|Transdermal Analgesia
223729168|NCT02480114|DRUG|Ibuprofen|NSAID Analgesia
223729169|NCT02480114|DRUG|Magic Mouthwash|Oral Solution to treat mucositis
223992896|NCT00002489|DRUG|cyclophosphamide|
223992897|NCT00002489|DRUG|doxorubicin hydrochloride|
223992898|NCT00002489|DRUG|etoposide|
224294900|NCT01799317|DRUG|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
224294901|NCT04126421|DEVICE|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
224294902|NCT04126421|DEVICE|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
223992899|NCT00002489|DRUG|leucovorin calcium|
223992900|NCT00002489|DRUG|methotrexate|
223992901|NCT00002489|DRUG|vincristine sulfate|
223992902|NCT00002489|PROCEDURE|conventional surgery|
223992903|NCT00989547|OTHER|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
223992904|NCT01635023|DRUG|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
223992905|NCT01635023|DRUG|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
223992906|NCT01635023|DRUG|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
223992907|NCT01635023|DRUG|AZD6244 Dosing Period 4|Treatment B
223992908|NCT03028597|BEHAVIORAL|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
224122181|NCT04716933|DRUG|Lenvatinib|Oral capsule once daily
224122182|NCT04716933|DRUG|Placebo matching lenvatinib|Oral capsule once daily
224122183|NCT05832931|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
224122184|NCT05832931|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
224122185|NCT05832931|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
224122186|NCT03036228|DRUG|Karonudib|Dose escalation of administration with Karonudib.
224122187|NCT04233749|DRUG|Tranexamic acid tablets|325mg of tranexamic acid twice daily for six months
223992909|NCT03028597|BEHAVIORAL|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
223992910|NCT04499612|PROCEDURE|Cardiac implantable electronic device implantation.|Patients who have indications will receive cardiac implantable electronic device implantation.
223992911|NCT04499612|PROCEDURE|Cardiac implantable electronic device replace.|Patients who have indications will receive cardiac implantable electronic device replace.
223992912|NCT04499612|DIAGNOSTIC_TEST|Duplex ultrasound.|Patients will undergo ultrasound examination of the vessels of the upper and lower extremities.
223992913|NCT04499612|DIAGNOSTIC_TEST|Echocardiography.|Patients will undergo an ultrasound examination of the heart.
224122188|NCT05172271|DEVICE|MagPro TMS Stimulator and coil|TMS measurements of cortical excitability pre and post study intervention
223992914|NCT04499612|DIAGNOSTIC_TEST|Blood sampling.|Patients will be taken venous blood to determine the studied markers of hemostasis system.
223992915|NCT03230604|DEVICE|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
224122189|NCT05172271|DEVICE|Thymatron(R) System IV|The Thymatron(R) System IV (Somatics LLC, Venice, FL, USA) is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.
223992916|NCT03230604|DEVICE|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
223992917|NCT03329677|OTHER|Transference-focused Psychotherapy (TFP)|Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
223992918|NCT04982575|DRUG|Semaglutide 2.4 mg|Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
224122190|NCT05172271|DEVICE|Magnetic Resonance Imaging Scanner|Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.
224122191|NCT05172271|OTHER|ECT device without stimulation|Anesthesia alone
224294903|NCT02138942|DEVICE|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
224294904|NCT02613325|DEVICE|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
224294905|NCT02613325|PROCEDURE|Standard of care surgical excision|
223544994|NCT00503425|DRUG|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
223544995|NCT03512574|DRUG|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
223544996|NCT03512574|DRUG|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
223544997|NCT03512574|OTHER|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
224294906|NCT02613325|DEVICE|Single cell photoacoustic microscopy|
224294907|NCT00852566|DRUG|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
224294908|NCT00852566|DRUG|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
224294909|NCT02091323|PROCEDURE|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
223992919|NCT04982575|DRUG|Cagrilintide 2.4 mg|Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
223992920|NCT04982575|DRUG|Placebo (semaglutide)|"Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
223992921|NCT04982575|DRUG|Placebo (cagrilintide)|"Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks"
223992922|NCT04471909|DEVICE|NEXUS Aortic Stent Graft System|"Arch Stent Graft, whose cranial narrow end is intended to be deployed into the Brachiocephalic artery and whose distal end is intended to be deployed into the Descending Thoracic Aorta.~Ascending Stent Graft intended to be deployed in the Ascending Aorta.~OPTIONAL: Descending Extension can be used in case the aortic lesion elongates further distally and out of the covered length offered by the Arch Stent Graft. Multiple Descending Extensions can be used if needed to cover the entire length of the lesion."
224294910|NCT05355714|DEVICE|Sofwave|High-Frequency Non-Focused Ultrasound Device
224294911|NCT05355714|DEVICE|Ultherapy|Microfocused Ultrasound with Visualization
224294912|NCT03532113|BEHAVIORAL|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
223992923|NCT05521997|DRUG|Telaglenastat|-800 mg twice per day by mouth
223992924|NCT05521997|RADIATION|Radiation treatment|"* Standard of care~* External beam radiation therapy delivered daily 4 days a week and 1 day per week of brachytherapy."
223992925|NCT05521997|DRUG|Cisplatin|"* Standard of care~* Weekly administration of cisplain"
223992926|NCT05853978|DRUG|BSS Plus|BSS PLUS® Sterile Intraocular Irrigating Solution (balanced salt solution enriched with bicarbonate, dextrose, and glutathione)
223992927|NCT05853978|DRUG|BSS|BSS® Sterile Irrigating Solution (balanced salt solution)
223992928|NCT06481163|DRUG|Telacebec|The test product will be supplied as Telacebec 100mg tablets.
223992929|NCT03921944|DIAGNOSTIC_TEST|CT scan of the shoulders|studies of both operative and nonoperative shoulders
223992930|NCT04505436|DRUG|HM15211|A sterile solution of HM15211 (efocipegtrutide) contained in pre-filled syringes
223992931|NCT04505436|DRUG|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
223992932|NCT06457191|DRUG|Roflumilast|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
223992933|NCT06457191|DRUG|Placebo|Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.
224294913|NCT03532113|BEHAVIORAL|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
224294914|NCT03532113|BEHAVIORAL|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
224294915|NCT04132336|DRUG|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
224294916|NCT04132336|DRUG|Naproxen sodium (Aleve)|Tablet, oral, single dose
224294917|NCT04132336|DRUG|Caffeine|Tablet, oral, single dose
224294918|NCT04132336|DRUG|Placebo|Tablet, oral, single dose
224294919|NCT03256084|PROCEDURE|Blood and tumor samples|Blood and tumor samples
224294920|NCT00177502|BEHAVIORAL|behavioral exercise intervention|
224294921|NCT00061243|BIOLOGICAL|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
224294922|NCT02129296|DEVICE|Air filled balloon|Balloon filled with air according to the manufacturing company orders
224294923|NCT02129296|DEVICE|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
224294924|NCT04561687|DRUG|Montelukast|Montelukast and nasal budesonide
224294925|NCT04561687|DRUG|Azelastine|Azelastine and nasal budesonide
224294926|NCT04561687|DRUG|Budesonide|To all groups
224294927|NCT04561687|DRUG|Placebo|Placebo and nasal budesonide
223992934|NCT06457191|DEVICE|Intermittent theta-burst stimulation transcranial magnetic stimulation|Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.
223992935|NCT06457191|DEVICE|Continuous theta-burst stimulation transcranial magnetic stimulation|Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 40 seconds.
223992936|NCT01609777|PROCEDURE|SBAR|situation, background, assessment, recommendation
223992937|NCT02304081|DRUG|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
223992938|NCT02304081|DRUG|Placebo for Saxagliptin|
223992939|NCT04966065|DEVICE|Parietex Parastomal mesh|Laparoscopic Modified Sugarbaker technique for repair of parastomal hernias in end-colostomies
223992940|NCT01151423|BIOLOGICAL|Caplacizumab|"* Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received caplacizumab up to 30 days after the last PE session."
224122192|NCT06235684|OTHER|Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion|During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
224122193|NCT05754944|DIAGNOSTIC_TEST|ABI/TBI|ABI/TBI to be performed after surgery while patient is still admitted at the hospital.
224294928|NCT05218382|DEVICE|Virtual reality|immersive virtual reality technology
224294929|NCT05218382|DEVICE|No virtual reality|Virtual reality with blank screen
223992941|NCT01151423|BIOLOGICAL|Placebo|"* Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~* The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~* All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~* Subjects received placebo up to 30 days after the last PE session."
223992942|NCT01249508|OTHER|nutrition label|
223992943|NCT04141722|BEHAVIORAL|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
223992944|NCT04141722|BEHAVIORAL|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
223992945|NCT02772237|BIOLOGICAL|Riboflavin|Riboflavin 400mg daily
224294930|NCT00584844|BIOLOGICAL|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (\< 1:20).
224294931|NCT04729192|OTHER|ObsQoR-10T Questionnaire|The ObsQoR-10T questionnaire consists of 10 items assessing physical comfort and pain, physical independence, and emotional status. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
224294932|NCT01566357|OTHER|Toothpaste|
224294933|NCT01566357|DIETARY_SUPPLEMENT|Milk|
224294934|NCT01566357|DIETARY_SUPPLEMENT|Fluoridated Milk|
224294935|NCT01566357|DRUG|Tooth Mousse|
224294936|NCT01566357|DRUG|MI Paste Plus|
223992946|NCT02772237|BIOLOGICAL|Placebo|
223992947|NCT01515852|PROCEDURE|general anesthesia in stereotactic biopsy|stereotactic biopsy
223992948|NCT01515852|PROCEDURE|local anesthesia in stereotactic biopsy|stereotactic biopsy
224294937|NCT01566357|DRUG|Elmex Erosion Protection|
224294938|NCT02915965|DRUG|DCX|docetaxel, cisplatin and capecitabine
224294939|NCT02915965|PROCEDURE|surgery|Ivor Lewis Esophagectomy
223992949|NCT00338988|DRUG|Capecitabine|1500 mg/m\^2 PO twice daily x 14 days.
223992950|NCT00338988|DRUG|Oxaliplatin|130 mg/m\^2 IV over 2 hours on day 1 of cycle.
223992951|NCT02984254|DEVICE|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
223992952|NCT02984254|DEVICE|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
223992953|NCT02984254|DEVICE|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
223992954|NCT02984254|DEVICE|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
223992955|NCT02984254|DEVICE|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
224294940|NCT01350843|DIETARY_SUPPLEMENT|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
223992956|NCT02984254|DEVICE|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
223729170|NCT02127879|DEVICE|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
223729171|NCT02127879|DEVICE|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
223992957|NCT02984254|DEVICE|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
223992958|NCT01675349|BIOLOGICAL|Prick test Chenopodium album allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
223992959|NCT05225987|BEHAVIORAL|Postpartum Nurse Navigation Program based care|In addition to routine hospital care, the intervention group will receive navigation program-based nursing care that includes three home visits, three phone calls, and sending text messages at five different times.
223729172|NCT01535053|BIOLOGICAL|Dactinomycin|Given IV
223729173|NCT01535053|DRUG|Leucovorin Calcium|Given PO
223729174|NCT01535053|DRUG|Methotrexate|Given IV and IM
224122194|NCT05754944|OTHER|Questionnaires|PAD symptoms questionnaire to be administered at baseline before surgery. mLEFS (included in PAD symptoms questionnaire) and WIQ to be administered at baseline before surgery. mLEFS and WIQ will be administered 1 month, 3 months, 6 months after surgery and every 6 months after that for a goal of at least 1 year.
224122195|NCT05781321|RADIATION|Accelerated Hypofractionated Radiation Therapy|Undergo short course RT
224122196|NCT05781321|PROCEDURE|Computed Tomography|Undergo CT simulation
224122197|NCT05781321|DRUG|Fluorodopa F 18|Given IV
224122198|NCT05781321|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223729175|NCT01535053|OTHER|Quality-of-Life Assessment|Ancillary studies
223729176|NCT01627522|PROCEDURE|TURP|Transurthral resection of prostate
224122199|NCT05781321|PROCEDURE|Positron Emission Tomography|Undergo PET
223729177|NCT00512707|DRUG|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
223729178|NCT00512707|DRUG|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
223992960|NCT02671110|BEHAVIORAL|Transforming Your Life|See Transforming Your Life Arm
223992961|NCT02671110|BEHAVIORAL|Diabetes Prevention Program|See Diabetes Prevention Program Arm
223992962|NCT03542110|DRUG|Alirocumab 150 MG/ML subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
223992963|NCT03542110|DRUG|Matching Placebo subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
223992964|NCT04328103|BEHAVIORAL|Cognitive Behavior Therapy (CBT)|Following established procedures at the DES at NYSPI, 12 sessions of individual manual-driven CBT (Emery, 2000) will be conducted by highly trained master degree clinicians.
224122200|NCT05781321|OTHER|Quality-of-Life Assessment|Ancillary studies
224122201|NCT05781321|OTHER|Questionnaire Administration|Complete questionnaires
224122202|NCT05781321|RADIATION|Radiation Therapy|Undergo standard course RT
224122203|NCT05781321|DRUG|Temozolomide|Given PO
224122204|NCT05781321|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224122205|NCT06585033|DEVICE|Spinal cord stimulation|Stimulation off
224122206|NCT06585033|DEVICE|Spinal cord stimulation|Stimulation on
224122207|NCT02003742|DRUG|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
224122208|NCT02003742|DRUG|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
224122209|NCT06448260|OTHER|Questionnary|Data from theses patients will be collected in our personnal data base with ask of consent according to the law Then each patient alive will have questionnary to answer by phone or during a visit.
224122210|NCT00124267|DRUG|Intrarectal quinine|
223992965|NCT04328103|BEHAVIORAL|Nonspecific Supportive Therapy (PBO)|As a non-CBT intervention that includes warmth, genuineness and empathy (Linde et al., 2011), nonspecific supportive therapy (PBO) will be administered in a parallel format to CBT, also consisting of 12 individual sessions.
223992966|NCT06239415|OTHER|observation|Observation for 1 year of patients suffering from symptomatic peripheral atherosclerotic disease of the lower limb, with or without chronic ischemic heart disease, and indication for treatment with rivaroxaban 2.5 mg bid and acetylsalicylic acid 100 mg.
223992967|NCT00962806|BEHAVIORAL|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
223992968|NCT00962806|BEHAVIORAL|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
223992969|NCT04306146|DRUG|CAD-9303|Capsules filled with CAD-9303 from 3 mg up to 1000 mg.
223992970|NCT04306146|DRUG|Placebos|Capsules
223992971|NCT01137669|BIOLOGICAL|Live attenuated herpes zoster vaccine|ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.
223992972|NCT01137669|OTHER|Placebo|Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
223992973|NCT04652661|DRUG|Dexmedetomidine|30 children will be sedated with 2 μg/kg intranasal DEX.
223992974|NCT04652661|DRUG|Midazolam|30 children will be sedated with 0.3 mg/kg intranasal midazolam.
223992975|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Raw|Low Dose- 70g bar
223992976|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Raw|High Dose- 100g bar
223992977|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
223992978|NCT00691249|DIETARY_SUPPLEMENT|Resistant Starch Type 4-Cooked|High dose: 100g bar
223992979|NCT00691249|DIETARY_SUPPLEMENT|Shredded Wheat|70g bar
223992980|NCT06482515|BEHAVIORAL|Time-restricted eating|Participants will be asked to eat all their food in a self-selected 10-hour eating window every day.
223992981|NCT06482515|BEHAVIORAL|Nutrition counseling|Participants will meet with a nutritionist to discuss their dietary habits and how they compare to the American Cancer Society nutrition guidelines.
223992982|NCT00693433|DRUG|dexamethasone|Given orally
224122211|NCT03181165|BEHAVIORAL|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
224122212|NCT01244542|OTHER|unpleasant stimuli|
224122213|NCT04653909|OTHER|Rehabilitation|The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
224122214|NCT04717843|OTHER|4D Flow MRI|Acquisitions of MR imagining with special contrast phase CMR sequences. There is no need for agent contrast injection. The CMR is performed at the time of inclusion.
224122215|NCT04717843|OTHER|Medical consultation with 12 leads ECG|Collection of medical history, treatment, physical examination and realization of a 12 leads ECG.
224122216|NCT04717843|OTHER|Holter ECG|48 hours ECG recording
224122217|NCT04717843|OTHER|Trans thoracic echocardiography|Trans thoracic echocardiography with standard measures performes in the core lab.
224122218|NCT04717843|BIOLOGICAL|Blood sample|Blood sample in a peripheral vein, send to medical laboratory to dosage of NT pro BNP and troponin serum level.
223992983|NCT00693433|DRUG|temsirolimus|Given IV
223992984|NCT00693433|OTHER|laboratory biomarker analysis|Correlative studies
223992985|NCT03498352|PROCEDURE|Thoracic surgery|Lung resection surgery
223992986|NCT02600078|DEVICE|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
223992987|NCT02600078|OTHER|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
223992988|NCT02600078|OTHER|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
223992989|NCT02600078|OTHER|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
223992990|NCT05794477|BIOLOGICAL|Adebrelimab|Specified dose on specified days
223992991|NCT05794477|BIOLOGICAL|SHR-1802|Specified dose on specified days
223992992|NCT05794477|DRUG|Carboplatin/Cisplatin|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
223992993|NCT05794477|DRUG|Paclitaxel/Nab-Paclitaxel/Pemetrexed|Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
223992994|NCT02132715|BEHAVIORAL|Resistance Exercise|
223992995|NCT02132715|BEHAVIORAL|KAATSU exercise|
224122219|NCT04717843|OTHER|Standard MRI|Acquisitions of MR imagining
224122220|NCT02660424|DRUG|VX-150|
224122221|NCT02660424|DRUG|Placebo|
224122222|NCT05701969|DIETARY_SUPPLEMENT|Melatonin|Melatonin
224122223|NCT05701969|OTHER|Placebo|Placebo control
224122224|NCT00138931|PROCEDURE|Blood draw (genetic testing)|Blood draw (genetic testing)
224122225|NCT00041223|DIETARY_SUPPLEMENT|IH636 grape seed proanthocyanidin extract|
223729179|NCT00512707|OTHER|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
223992996|NCT05263960|BIOLOGICAL|CM350 group1|CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
223992997|NCT05263960|BIOLOGICAL|CM350 group2|CM350 will be administered intravenously (IV) once a week (QW) through step-up dosing until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
223992998|NCT05263960|BIOLOGICAL|CM350 group3|CM350 will be administered intravenously (IV) once a week (QW). Individual subjects may continue study treatment until the participant discontinues study treatment, develops disease progression, initiates a new anti-tumor therapy, develops unacceptable toxicity, death, lost to follow-up, the investigator discontinue study treatment, or a female participant becomes pregnant (whichever occurs first).
223992999|NCT05647109|OTHER|No intervention|No intervention
223993000|NCT04067271|OTHER|Analyze changes in intestinal microbiome|Descriptive Analysis
223993001|NCT04166396|DRUG|Resveratrol|500 mg resveratrol, BID
223993002|NCT04166396|DRUG|NR|500 mg NR BID
223993003|NCT04166396|DIETARY_SUPPLEMENT|Placebo|Placebo
223993004|NCT06872684|DEVICE|Surpass Elite with Guardian Flow Diverter System|The Surpass Elite with Guardian Flow Diverter System is indicated for use in the endovascular treatment of adults (age 18 or above) with unruptured wide-neck saccular or fusiform intracranial aneurysms arising from a parent vessel with a diameter ≥ 3.0 millimeter (mm) and ≤ 6.0 mm and located on the Internal Carotid Artery (ICA) or its branches.
223993005|NCT06537271|COMBINATION_PRODUCT|experimental group|Autism awareness, breastfeeding cessation and toilet training knowledge and attitude training guide and weekly training content animation videos will be prepared for the experimental group and uploaded via WhatsApp and training will be provided. All participants will be interviewed face to face before the training and the necessary information about our study will be provided. Feedback will be received from the researcher regarding the videos, and participants in the study will be able to ask their questions via WhatsApp and share digital content in a digital environment. Evaluation will be made by conducting group work with individuals. Reminders such as mobile phone messages will be used. Training will be carried out within an 8-week program. Each week, training videos on the topics prepared in line with the training guide will be prepared and shared via WhatsApp. Feedback will be received by creating interactive communication environments.
223993006|NCT06537271|COMBINATION_PRODUCT|Control Group|After the purpose of the study is explained to the control group by the researcher and written and verbal permission is obtained from those who voluntarily agree to participate in the study, the pre-test data will be collected by the researcher.At the end of the training, survey forms will be filled out by the researcher for the control group and post-test data will be collected.
224294941|NCT03393871|DIAGNOSTIC_TEST|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
224294942|NCT02793570|OTHER|observational|
224294943|NCT04614493|DEVICE|SonoCloud-9 (SC9) device|"daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months) with 6 concomitant Blood Brain Barrier opening sessions by ultrasound~\+ 9 Blood Brain Barrier opening sessions by ultrasound without any associated drug"
224294944|NCT04614493|DRUG|Temozolomide according Stupp protocol|daily temozolomide (TMZ) during Radiation, followed by 6 months of adjuvant TMZ (5 days/months)
223729180|NCT02642328|OTHER|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
223729181|NCT02642328|OTHER|Control|Continuous aerobic exercise at 65% of VO2Max
223729182|NCT01369797|OTHER|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
223993007|NCT06858540|BEHAVIORAL|Unified protocol for transdiagnostic treatment of emotional disorders in adolescents|The blended UP-A includes 8 weekly modules, 6 of which (Module 2 - 7)are online self-guided sessions. The online self-guided sessions will last approximately 45 minutes each. Over the course of these 6 weeks, participants will also have 6 therapist-guided online sessions via videoconference, each lasting 30 minutes. Two face-to-face individual sessions are scheduled, one at the beginning of each (Module 1) and one at the end (module 8), each with an expected duration of 90 minutes.
223993008|NCT07009548|DRUG|Cytogam|CytoGam 150 mg/kg intravenously (IV) administered as a single dose
224294945|NCT05578365|OTHER|Pilates method|Individuals in the Pilates group will perform specific exercises online. There will be 16 sessions, lasting 60 minutes, with 10 minutes of warm-up, 30 to 40 minutes of exercises focusing on the trunk stabilizers muscles, and 10 minutes of cool-down with relaxation, stretching, or meditation. In addition, the individuals will have access to the same information of the control group.
224294946|NCT05578365|OTHER|Pain education|Individuals in the control group will receive information on self-management of low back pain, pain education, and changes in lifestyle habits once a week during 8 weeks.
224294947|NCT02932514|DEVICE|Eversense (Senseonics) Continuous Glucose Monitoring System|"* Evaluate accuracy of Eversense CGM System to SMBG Meter.~* Compare performance between abdomen and arm insertion sites.~* Determine the usability of the Eversense System in a home-use setting for 180 days."
223993009|NCT06869824|DIETARY_SUPPLEMENT|Minayo Iron-rich Nutritional Gummies|Participants need to eat one piece of the assigned product after meal three times a day, for 4 consecutive weeks.
223993010|NCT06869824|DIETARY_SUPPLEMENT|Common Gummies|Participants need to eat one piece of the assigned product after meal three times a day, for 4 consecutive weeks.
223993011|NCT03687593|DEVICE|Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts|Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert
223729183|NCT02454998|OTHER|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
223729184|NCT01414907|BEHAVIORAL|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
223993012|NCT07037589|PROCEDURE|investigation setting (cystoscopy + CTU + cytology)|Observational study. All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for acute macroscopic hematuria.
223993013|NCT07037589|PROCEDURE|Cystoscopy - CTU - cytology (if needed)|All patients in this group undergo standard diagnostic evaluation including cystoscopy, CT urography, and urine cytology (if clinically indicated), performed during initial assessment for atypical or chronic presentations of macroscopic hematuria.
223993014|NCT07041619|DEVICE|Intersection short-pulse (ISP) stimulation|The intervention aims to terminate pathological brain oscillations (i.e. epileptiform activity) in patients.
223993015|NCT07039669|DRUG|611|611 subcutaneous (SC) injection
223993016|NCT07039669|DRUG|Placebo|placebo Q2W, subcutaneous (SC) injection
223993017|NCT07044583|BEHAVIORAL|Opioid Educational Video|The video includes information on (1) how to consume appropriate over-the-counter pain medication alongside opioids for optimal pain control, (2) how prescribed opioids should be used only to treat pain related to the surgery, and (3) the proper disposal of unused opioids. The video was created through the University of Utah Office of Patient Experience. Feedback regarding the educational content was provided by surgeons, pain management physicians, and pharmacists throughout the process.
223993018|NCT07049588|OTHER|Quantitative neuromuscular MRI|Quantification of biomarkers as fat fraction, magnetization Transfer Ratio, muscular volume, relaxation time T2
223993019|NCT07049588|OTHER|Skin biopsy|Performed on the arm or index finger, depending on patient age
223993020|NCT07049588|OTHER|Clinical scores|ONLS, CMTES-R, CMT-Peds, CMT-FOM
223993021|NCT07049588|OTHER|Blood test|10 ml sample
223993022|NCT07049588|OTHER|Patient Report Outcomes Measures|pCMT-QoL, EVA, WALK-12, PGI-c, SF-12
223993023|NCT07049393|DIAGNOSTIC_TEST|Road traffic accident (RTA) victims(SAQ)|"Road traffic accident (RTA) victims present with respiratory and/or cardiac complications. a self-administered questionnaire.~Patients transported to healthcare facilities in District Karak using emergency transport systems.Road traffic accident (RTA) victims presenting with respiratory and/or cardiac complications."
223993024|NCT07050615|PROCEDURE|Continuous suturing|In this group, episiotomy repair was done using the continuous suturing.
224122226|NCT03521167|DRUG|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
224122227|NCT03521167|DRUG|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
224122228|NCT03521167|DRUG|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
224122229|NCT03521167|DRUG|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for \>65y or if patient having significant sedation/dizziness
224294948|NCT04567914|DIAGNOSTIC_TEST|Bilaterally abdominal muscle thickness with ultrasonography|AIS group was evaluated for localization of curvature and degree of curvature. Ultrasonographic measurements were performed of bilaterally abdominal muscle thickness in the supine and standing positions in both groups. Spirometry evaluation was performed in both groups
223729185|NCT03700671|OTHER|High intensity interval training|Participants performed HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
223993025|NCT07050615|PROCEDURE|Interrupted suturing|In this group, episiotomy repair was done using the interrupted suturing.
223993026|NCT07050485|DIETARY_SUPPLEMENT|PoZibio|1 gummy once daily
224122230|NCT03521167|DRUG|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if \<70kg
224122231|NCT03521167|DRUG|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients \>65y or with GFR \< 50 Consider dose reduction in patients with sleep apnea
224122232|NCT03521167|DRUG|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if \<70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
224294949|NCT04744350|PROCEDURE|Treatment of FFP type IIb and IIc|Patients will either be randomized in the surgical or conservative group.
224294950|NCT05847439|DRUG|[14C]BMS-986419|Specified dose on specified days
224294951|NCT03820934|DIAGNOSTIC_TEST|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
224294952|NCT06000917|DRUG|pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel|"Pyrotinib tablets: 320mg qd, oral administration after breakfast, 21 days for 1 cycle, continuous administration of 6 cycles.~Trastuzumab: The first cycle was 8mg/kg, the second to sixth cycle was 6mg/kg, 21 days was 1 cycle, continuous administration of 6 cycles.~Albuminpaclitaxel: On the first day of cycle 1, 260mg/m2 was given intravenously, 21 days for 1 cycle, and 6 consecutive cycles were given.~Carboplatin: Endogenous creatinine clearance was calculated using the Cockcroft formula, with AUC 5 for the 1st to 6th cycle and 1 cycle for the 21st day and 6 consecutive cycles of administration"
223993027|NCT07050485|DIETARY_SUPPLEMENT|Inert placebo|1 gummy once daily
223993028|NCT07050004|BEHAVIORAL|SMOKING|Patients who agree to take part in the study will complete a questionnaire covering the pre- and post-transplant aspects of smoking on their lifestyle
223993029|NCT07048886|DRUG|Rocklatan (netarsudil 0.02% and latanoprost 0.005%)|Additional intraocular eye pressure lowering post-Hydrus
223993030|NCT07048886|DRUG|Systane|Placebo Comparator (artificial tears)
223993031|NCT07049770|DIETARY_SUPPLEMENT|Eczeva supplementation|Intervention contains 0.2g of eczefolia extracts, and 0.01g of rice ceramides as main active ingredients.
223993032|NCT07048899|DRUG|Chlorhexidine|Intraperitoneal irrigation with Irrisept solution
223993033|NCT07048899|DRUG|Normal Saline|Intraperitoneal irrigation with normal saline
224122233|NCT05356624|OTHER|Mulligan Mobilization|It is technique in which passive mobilization is applied by therapist to improve the normal position and by holding the passive glide active movement in restricted direction of motion to reduce pain or improve range of motion or function. A total of 3 sets of 10 repetition three times a week on alternate days for 6 week
223993034|NCT07050992|PROCEDURE|Laser posterior nasal nerve neurolysis|Posterior nasal nerve ablation using laser is performed through an angled nasal probe at 20 degrees and a 90-degree endoscope to deliver laser energy to the posterior nasal nerve area. The thermal energy is conducted to the middle meatus and the posterior superior part of the inferior turbinate, targeting the area supplied by the posterior nasal nerve. The ablation continues until there is widespread mucosal blanching and the formation of at least one continuous brown eschar
224122234|NCT05356624|OTHER|Soft Tissue Mobilization|in this technique for joint the passive glides are applied, for CMC joint mobilization patient hand is rest on table. The therapist grasp trapezium with one hand and 1st metacarpal between index and thumb of other hand to apply glide. A total of 3 sets of 10 repetition three times a week on alternate days for 6 weeks.
224122235|NCT00145548|DEVICE|Intra Bronchial Valve|
224122236|NCT03196505|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
224122237|NCT03196505|DRUG|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
224122238|NCT01911624|DRUG|direct thrombin inhibition|
224122239|NCT01911624|DRUG|enoxaparin|
224122240|NCT02032537|DRUG|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
224122241|NCT02032537|DRUG|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
223729186|NCT03700671|OTHER|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated
224122242|NCT01005719|DRUG|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
224122243|NCT01005719|DRUG|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
224122244|NCT05548127|DRUG|ARV-471|Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
224122245|NCT05548127|DRUG|Abemaciclib|Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
224122246|NCT03879317|DEVICE|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
224122247|NCT03179592|DRUG|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
223729187|NCT01317160|DEVICE|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
223729188|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Metallic)|Calcaneus Displacement Osteotomy using two metallic screws
224122248|NCT02778750|PROCEDURE|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
224122249|NCT02080689|OTHER|Decipher|
224294953|NCT04361903|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours
224294954|NCT01939496|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
223993035|NCT07050992|PROCEDURE|Sham surgery|The same laser surgical instrument is used to enter the nasal cavity for a sham procedure with minimal dosage. The energy setting uses the lowest limit of 0.5W with intermittent emission (0.01 second emission with 1 second rest), and the emission mode is Super Pulse to reduce heat dispersion. It is applied to the mucosal surface without blood supply at the lower edge of the middle turbinate for 2 minutes on each side, totaling only 1.2 seconds of cumulative laser emission. Compared to the experimental group using 2W energy with continuous irradiation for 2 minutes, the total energy release difference in the sham surgery group is only 1/400 of the experimental group (2W120sec/0.5W1.2sec). This is to produce the sound, light, and tactile effects of the laser, but without sufficient energy transfer to cause high-temperature mucosal changes and tissue alterations, serving as a high-quality sham surgery control group.
223993036|NCT01507077|DRUG|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
223993037|NCT01507077|DRUG|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
224294955|NCT01939496|DRUG|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
224294956|NCT05223296|DEVICE|Compare between two procedure for II-IV degree pile excision|LigaSure or diathermy excision of III-IV degree pile?
224294957|NCT02756936|DRUG|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
224294958|NCT02756936|DRUG|Clatazev|1 tablet contains 60 mg Daclatasvir
223544998|NCT03512574|DRUG|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
223544999|NCT02122497|PROCEDURE|abdominal aortic surgery|
223545000|NCT05424965|OTHER|no intervention|no intervention
223545001|NCT05246878|DRUG|EDP-235|Oral administration
223545002|NCT05246878|DRUG|Placebo|Placebo to match EDP-235, oral administration
223545003|NCT00326599|DRUG|carboplatin|Given IV
223545004|NCT00326599|DRUG|cediranib maleate|Given orally
223993038|NCT07050498|DEVICE|Virtual reality|"Virtual reality hypnosis software applications are Class I medical devices according to Rule 12 of Directive 93/42/EC. They allow, through a virtual reality headset and headphones, to immerse the patient in a hypnotic sound and visual environment. Several visual scenarios can be proposed, allowing the patient to virtually travel to a beach, the seabed, on an alpine walk, etc.).~The HypnoVR Biofeedback virtual reality device is provided by the HypnoVR company."
223993039|NCT07050498|PROCEDURE|Usual Care Group|Routine preoperative procedure (local anesthesia)
223993040|NCT06581536|BEHAVIORAL|Yes and Know curriculum|Yes and Know is fully virtual intervention that integrates group-based education with digital tools to support young people ages 14 to 19 by increasing their relationship and healthy life skills. The curriculum focuses on sexual and reproductive health; healthy relationships; life skills; and educational and career success. It is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
223993041|NCT06581536|BEHAVIORAL|Nutrition Education for Adolescents|Youth will receive a fully virtual intervention that integrates group-based education with digital tools focused on adolescent nutrition and wellness. The curriculum is delivered over nine synchronous sessions of 60-minutes each for a duration of nine hours, plus asynchronous online resources and activities.
223545005|NCT00326599|DRUG|gemcitabine hydrochloride|Given IV
223545006|NCT02370472|OTHER|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
223545007|NCT03686878|DRUG|Lifitegrast|Lifitegrast used twice a day
223729189|NCT05018130|PROCEDURE|Calcaneus Osteotomy (Bio-integrative)|Calcaneus Displacement Osteotomy using two bio-integrative screws
223729190|NCT03601689|PROCEDURE|rectal resection|total mesorectal excision
223729191|NCT03898050|PROCEDURE|transcutaneous cardiac pacing|transcutaneous cardiac pacing
223993042|NCT07050537|PROCEDURE|Constant oxygen concentration protocols in embryo culture|Participants were randomly assigned to constant (5%) oxygen concentration group and received different blastocyst culture protocols.
223993043|NCT07050537|PROCEDURE|Sequential oxygen concentration protocols in embryo culture|Participants were randomly assigned to sequential (5%-2%) oxygen concentration group and received different blastocyst culture protocols.
223993044|NCT05304117|BEHAVIORAL|Advance Care Planning|Community Information Session and Private Sharing Session with trained social worker
223993045|NCT06735456|OTHER|Mandala|The patient will undergo mandala painting during 1 session of chemotherapy.
223993046|NCT06880627|BEHAVIORAL|Brain Boost group|There will be 8 group educational sessions over an 8-week program period to learn strategies for improving cognitive function. Participants will also be asked to engage in 20 minutes, at least 5 times per week online game-like cognitively stimulating activities to improve cognitive health. In addition, surveys will be completed as certain timepoints.
223993047|NCT06880627|OTHER|Waitlist group|This group will continue to receive usual health and care routines. Participants will be asked to complete surveys at certain timepoints that are the same as the boost group. After the 6-month follow-up, participants will receive the intervention materials, which include 8 weekly educational session recordings with slides, 8 weeks' subscription to online brain games, and biweekly online office hours. The office hours, hosted by the principal investigator and a trained patient co-facilitator, will give participants a chance to discuss participant's progress and ask questions.
223993048|NCT05899816|DRUG|Rocatinlimab|Subcutaneous (SC) injection
223993049|NCT05899816|DRUG|Placebo|SC injection
223993050|NCT04212143|OTHER|there is no intervention|There is no intervention in this study. It is observational only.
223993051|NCT05814341|DRUG|Citrate|Comparison of two dosage adjustment protocols for medication according to different post-filter iCa targets
223993052|NCT01457690|DRUG|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
223993053|NCT01457690|DRUG|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
223993054|NCT01457690|DRUG|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
223993055|NCT04748042|DRUG|Abiraterone|Abiraterone 1000 mg by mouth per day for approximately 6 months.
223993056|NCT04748042|DRUG|Prednisone|Prednisone 5 mg by mouth per day for approximately 6 months.
223993057|NCT04748042|RADIATION|External Beam Radiotherapy|External beam radiotherapy, dose will depend on lesion location. Completed within 40 days of study start.
223993058|NCT04748042|BIOLOGICAL|Androgen Deprivation Therapy (ADT)|ADT by luteinizing hormone-releasing hormone (LHRH) agonist or antagonist for 6 months.
223993059|NCT04748042|DRUG|Olaparib|Olaparib tablets 300 mg by mouth twice a day for approximately 5 months.
223993060|NCT04383847|BEHAVIORAL|Sumadhur Aarambha|Group intervention for newly married women, their husbands, and mothers-in-law with information mainly about nutrition, but also pre-pregnancy health, reproductive/pregnancy health and gender equality.
223993061|NCT04678531|DRUG|Swabs containing tea tree oil and chamomile oil|Swabs will be used in 26 patients for 8 weeks and will be discontinued in the following 4 weeks.
223993062|NCT04678531|DRUG|Baby shampoo|Baby shampoo will be used in 23 patients for 8 weeks and will be discontinued in the following 4 weeks.
223993063|NCT03848039|BIOLOGICAL|Gardasil-9|administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
223993064|NCT03848039|DRUG|Placebo|administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
223993065|NCT04400110|DRUG|Amoxicillin and Clavulanic Acid in Oral Dose Form|50 mg/kg three times daily administered orally
223993066|NCT02568397|DRUG|Lanabecestat|Administered orally
223993067|NCT02568397|DRUG|Dabigatran etexilate|Administered orally
223993068|NCT01757951|PROCEDURE|Unimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
223993069|NCT01757951|PROCEDURE|Bimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
223993070|NCT01317875|DRUG|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
223993071|NCT06155188|PROCEDURE|applying of FLU+CY post-HSCT|The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
223993072|NCT02223910|PROCEDURE|Neurofeedback training of functional connectivity|
223993073|NCT05141851|DEVICE|Implants with 0,7 mm threads|Implants were placed, with threads of 0.7 mm in the location of premolars and molars.
223993074|NCT05141851|DEVICE|Implants with 0.3 mm threads|Implants were placed, with threads of 0.3 mm in the location of premolars and molars.
223993075|NCT02514239|DRUG|BI 836909|Intravenous Infusion of BI 836909.
223993076|NCT00107887|DRUG|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
223993077|NCT00107887|DRUG|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
223729192|NCT07000929|DIAGNOSTIC_TEST|Videonystagmography|In the regular examination of patients with vertigo, videonystagmography with thermal testing (caloric) is already an established and necessary examination procedure that is used to diagnose many different vertigo disorders.
223729193|NCT04449575|OTHER|eSwabs|from skin
223729194|NCT01083368|DRUG|temsirolimus|Given IV
223993078|NCT00903825|PROCEDURE|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (\< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
223993079|NCT00903825|PROCEDURE|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
223993080|NCT01511263|DRUG|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
223993081|NCT01511263|DRUG|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year."
223993082|NCT03969680|BIOLOGICAL|Auotologous BMSCs plus autologous PRP|30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
223993083|NCT03969680|BIOLOGICAL|Auotologous PRP|30 mL of blood will be collected from each patient to produce 3ml PRP by cenrifugation.
223993084|NCT01155414|OTHER|Hydrolysate based infant formula|Infant formula ad lib
223993085|NCT01155414|OTHER|Investigational Infant Formula A|Investigational infant formula ad lib
223993086|NCT01155414|OTHER|Investigational Infant Formula B|Investigational infant formula ad lib
223993087|NCT06381167|PROCEDURE|Endoscopic Decompressive Laminectomy|the patients will undergo block randomization for either endoscopic or microscopic decompression
223729195|NCT01083368|BIOLOGICAL|bevacizumab|Given IV
223729196|NCT01083368|GENETIC|polymorphism analysis|Correlative studies
223729197|NCT01083368|OTHER|laboratory biomarker analysis|Correlative studies
223993088|NCT05410080|DIAGNOSTIC_TEST|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study|Fasting blood sugar, 2 hours postprandial, HBA1C ,Ultrasound and Doppler study
223993089|NCT05135676|DEVICE|Blinded CGM|A masked CGM sensor will be worn
223993090|NCT05135676|DEVICE|real-time CGM|An unmasked CGM sensor will worn
223993091|NCT00005977|BIOLOGICAL|filgrastim|Given IV
223993092|NCT00005977|DRUG|cyclophosphamide|Given IV
223993093|NCT00005977|DRUG|cytarabine|Given IV
223993094|NCT00005977|DRUG|dexamethasone|Given IV
223993095|NCT00005977|DRUG|doxorubicin hydrochloride|Given IV
223993096|NCT00005977|DRUG|etoposide|Given IV
223993097|NCT00005977|DRUG|ifosfamide|Given IV
224122250|NCT01570712|OTHER|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~* Support in the development and the maintenance of the housing;~* Support in the diverse steps (administrative, judicial, financiers, etc.);~* Support around addictions / alcohol;~* Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~* to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
224122251|NCT01570712|OTHER|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\\or the restoring, but this by means of the existing devices"
224122252|NCT05747690|DEVICE|KIO015|Innovative carboxymethyl chitosan-based biomaterial intended for intradermal injection
224122253|NCT00969111|RADIATION|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
224122254|NCT00969111|RADIATION|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
224122255|NCT00969111|RADIATION|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
224122256|NCT00969111|RADIATION|Proton to 66.6 CGE|Post-Op Non High Risk
224122257|NCT05653739|BEHAVIORAL|Mindfulness Based Stress Reduction Intervention|MBSR is Mindfulness based intervention designed by Kabat-Zinn (1990) in order to deal with the stress and other psychological issues among individuals. This has been very effective intervention across different cultures . In this 8 week intervention participants will be given some home tasks to practice for at least 40 minutes a day.
224122258|NCT01107522|DRUG|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
223729198|NCT07035457|DRUG|Vicadrostat|Vicadrostat
223729199|NCT07035457|DRUG|Jardiance®|Jardiance®
223993098|NCT00005977|DRUG|leucovorin calcium|Given IV
223993099|NCT00005977|DRUG|methotrexate|Given IV
223993100|NCT00005977|DRUG|vincristine sulfate|Given IV
223993101|NCT05026021|BIOLOGICAL|Blood sample|For each patient blood (17 ml of whole blood) will be collected during a peripheral venous blood sample carried out in the the standard care at inclusion visit, M3 visit (3 months after inclusion), M6 visit (6 months after inclusion) and M12 visit (12 months after inclusion).
223993102|NCT03405090|DRUG|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
223993103|NCT03405090|DRUG|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
223993104|NCT06055504|OTHER|Control Strategy|ICDs will be implanted in all patients according to current recommendations
224122259|NCT01107522|DRUG|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
223993105|NCT06055504|OTHER|Personalized precision ICD implantation Strategy based in genetic findings and CMR results|Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.
223993106|NCT03176264|DRUG|PDR001|400 mg every 4 weeks
223993107|NCT03176264|DRUG|bevacizumab|5 mg/kg every 2 weeks
223993108|NCT03176264|DRUG|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
223993109|NCT01508949|DRUG|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
223993110|NCT01508949|DRUG|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
223993111|NCT01483144|DRUG|Eflornithine|Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]
224122260|NCT01107522|DRUG|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
223993112|NCT01483144|DRUG|Eflornithine Placebo|Eflornithine placebo \[three tablets orally once a day\]
223993113|NCT01483144|DRUG|Sulindac 150 MG|Sulindac \[one tablet orally once a day\]
223993114|NCT01483144|DRUG|Sulindac placebo|Sulindac placebo \[one tablet orally once a day\]
223993115|NCT00010153|DRUG|fulvestrant|
223993116|NCT00010153|PROCEDURE|conventional surgery|
223993117|NCT00230750|BIOLOGICAL|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
223993118|NCT00230750|DRUG|Placebo|Saline placebo.
223993119|NCT01891175|PROCEDURE|Elective caesarean section under spinal anaesthesia.|Patients with scheduled caesarean.
223993120|NCT01891175|PROCEDURE|Elective caesarean section under spinal anaesthesia.|
223993121|NCT01049451|DRUG|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
223993122|NCT01049451|DRUG|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
223993123|NCT04184453|DRUG|Deferiprone treated|Deferiprone (25 mg/kg/day) was given to the enrolled patients.
223993124|NCT00949377|DRUG|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
223993125|NCT00949377|DRUG|Placebo|Normal saline
223993126|NCT00295815|DRUG|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
223993127|NCT00295815|DRUG|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
223993128|NCT02784457|DRUG|Cetrorelix|
224122261|NCT06439875|DIETARY_SUPPLEMENT|effect of L-arginine and liposomial vitamin C on pulmonary rehabilitation|Patients with a certified diagnosis of COPD and chronic respiratory failure will be randomized in a 1:1 ratio into the interventional arm or the placebo controller arm. All patients will undergo multidisciplinary intensive pulmonary rehabilitation for 28 days. The patients in the interventional group will receive a twice-daily oral supplementation with either a combination of 1.66 g l-arginine plus 500 mg liposomal vitamin C
223545008|NCT05508646|BEHAVIORAL|Music therapy intervention|The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.
223545009|NCT05508646|BEHAVIORAL|Personalized music CD|Participants will receive a personalized music CD that they keep and can listen to as they wish.
223993129|NCT04219995|DRUG|methylprednisolone sodium succinate|Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
223993130|NCT04219995|OTHER|Placebo|The placebo used in this study will be simple syrup.
223993131|NCT00218114|DRUG|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
223993132|NCT00218114|DRUG|Placebo|Participants will be on matching placebo.
224122262|NCT06439875|OTHER|placebo|Patients in this arm will undergo multidisciplinary intensive pulmonary rehabilitation without any dietary supplementation.
223993133|NCT01784120|DRUG|Doxorubicin/Genexol-PM|
223993134|NCT04415320|DRUG|X-396(Ensartinib)|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
223993135|NCT03355339|DEVICE|Binasal occlusion|Binasal occlusion glasses
223993136|NCT03355339|DEVICE|No binasal occlusion|Non-occluded glasses
224122263|NCT06565416|BEHAVIORAL|Implementation Strategies|Culturally centering screening and brief intervention for chronic pain and opioid misuse/opioid use disorder among American Indian/Alaska Native clients
223545010|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
223545011|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
223545012|NCT04048889|DRUG|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
223729200|NCT06912919|OTHER|BFR-Aerobic Training|Low-intensity cycling exercise with BFR (pressure of 160-180 mmHg) for 20 minutes, 3 days a week for 6 weeks.
223993137|NCT03941600|BEHAVIORAL|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
223993138|NCT03941600|BEHAVIORAL|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
223993139|NCT04149938|DRUG|Lidocaine topical system 1.8%|
223993140|NCT04149938|DRUG|Lidocaine patch 5%|
223993141|NCT05378334|DRUG|ICI|PD-1 inhibitors selected by clinicians based on patients' condition
223993142|NCT05378334|DRUG|Chemotherapy|AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
223993143|NCT05378334|DRUG|Placebo|The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
223993144|NCT05378334|DRUG|Bone-protecting and Mass-dispersesing Decoction|Chinese Herbal Formula,also named as HGXJT
223993145|NCT03258723|BEHAVIORAL|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
223993146|NCT03258723|DRUG|Metformin|At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
223993147|NCT05123599|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
224122264|NCT06519929|PROCEDURE|ESP block with catheter using ropivacaine (bolus followed by continuous infusion)|A total of ropivacaine 75mg will be injected into the plane via the needle, followed by placement of a catheter 3-5 cm into the plane. A continuous infusion of ropivacaine 0.2% will be started at 8 mL/h and may be titrated up to a maximum of 10mL/h. Bolus doses of 5 mL using ropivacaine 0.2% will be permitted for breakthrough pain (pain score ≥ 7/10) and may be administered no more frequently than every 6 hours. Patients will be assessed for LAST twice daily by asking about tinnitus, perioral numbness, or metallic taste. Any patient who responds positively to these symptoms will have infusion stopped for 2 h and then restarted at a rate 2 mL/h lower. If the symptoms occur again, the catheter infusion will be stopped and the catheter removed. After the 72-hour study period the ESP catheter may remain in place if the patient has ongoing analgesia needs or if analgesia is controlled with oral medication the catheter may be removed at request of the treating team.
224122265|NCT06519929|DRUG|Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h|A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
223545013|NCT03400410|BEHAVIORAL|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
223545014|NCT00135616|DEVICE|surgical placement of a suburethral sling tvt or tvt-o|
223993148|NCT05123599|BIOLOGICAL|JNJ-64300535|JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.
223993149|NCT05123599|DRUG|ETV monohydrate|ETV monohydrate film-coated tablets will be administered orally.
223993150|NCT05123599|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablets will be administered orally.
224122266|NCT06969001|DRUG|SCAI-005 0.04% or placebo|axitinib 0.014mg or placebo
224122267|NCT06969001|DRUG|SCAI-005 0.08% or placebo|axitinib 0.028mg or placebo
224122268|NCT06969001|DRUG|SCAI-005 0.08% or placebo 2drops|axitinib 0.056mg or placebo
224122269|NCT04083430|DRUG|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
224122270|NCT04380987|BIOLOGICAL|Biological sampling|For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.
224122271|NCT00756587|DEVICE|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
224122272|NCT00756587|DEVICE|Bottle Feeding|receiving all feeding by bottle
224122273|NCT00633438|OTHER|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
224294959|NCT03560349|DRUG|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
224294960|NCT03560349|DRUG|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
224294961|NCT04390321|OTHER|LLMcare|Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
224294962|NCT00405613|DRUG|Aspirin|
223993151|NCT05123599|DRUG|TAF|TAF film-coated tablets will be administered orally.
223993152|NCT04489290|DEVICE|D005 Vaginal Mousse|D005 Vaginal Mousse is class IIa medical device for treatment of Bacterial Vaginosis.
223729201|NCT06912919|OTHER|Aerobic Training Without BFR|Low-intensity cycling exercise (without BFR) for 20 minutes, 3 days a week for 6 weeks.
223993153|NCT04489290|OTHER|Placebo|Placebo
223993154|NCT04211311|OTHER|hybrid high-intensity training|FES-legcycling combined with either arm skiergometer or arm-cycling in 4 x 4 min. intervals at 90% peak power output, 3 times a week for 8 weeks
223993155|NCT02356705|DRUG|Midazolam|midazolam 0.2 mg/kg given intranasally
223993156|NCT02356705|DRUG|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
223993157|NCT02356705|DRUG|saline placebo|intranasal saline given as placebo
223993158|NCT06146777|DRUG|Pembrolizumab|Intravenous infusion
223993159|NCT06146777|DRUG|Placebo|Intravenous infusion
223993160|NCT01107899|DRUG|clopidogrel|taken orally, day one, single dose
223993161|NCT01107899|DRUG|prasugrel|taken orally, day one, single dose
224122274|NCT00633438|DRUG|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
224122275|NCT01956409|DRUG|18F-FCH|
224122276|NCT01956409|DRUG|Magnevist|
224122277|NCT04460378|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy with Focus on guided exposure
224122278|NCT03606252|OTHER|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
224122279|NCT03606252|OTHER|urine sampling|2 urine sample (1 at J0 and 1 at J7)
224122280|NCT03825276|DIETARY_SUPPLEMENT|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
224122281|NCT00946946|DRUG|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
224122282|NCT00946946|DRUG|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
224122283|NCT00946946|DRUG|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
223993162|NCT00605488|PROCEDURE|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
223993163|NCT03689751|OTHER|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
223993164|NCT03689751|OTHER|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
223993165|NCT00157768|DEVICE|Implantable cardioverter defibrillator|
223993166|NCT04425590|DRUG|DLBS1033|DLBS 1033 490 mg tablet 3 times daily
223993167|NCT04425590|DRUG|Aspirin|Aspirin 100 mg tablet once daily
223993168|NCT04425590|DRUG|Statin|Atorvastatin 20 mg tablet once daily
224122284|NCT00946946|DRUG|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
223729202|NCT05084638|DRUG|Ofatumumab|20mg subcutaneous injection
223993169|NCT04425590|DRUG|Vit B12|Vit B12 100 mg tablet three times daily
223993170|NCT00974259|DEVICE|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (\> 20 mm Hg) or pBrO2 (\< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
223993171|NCT00974259|DEVICE|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
223993172|NCT04893681|OTHER|Fluoridated bottled drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
224122285|NCT04336241|BIOLOGICAL|RP2|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
224122286|NCT04336241|BIOLOGICAL|nivolumab|Programmed death receptor (PD-1) blocking antibody
224122287|NCT06442761|DRUG|Motixafortide|Given Subcutaneously (under the skin).
224122288|NCT05478343|BIOLOGICAL|IM21 CAR-T cells|IM21 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
224122289|NCT05187013|BEHAVIORAL|mHealth for Hypertension in Homeless Persons|SMS text messages sent to participants' mobile phones
224122290|NCT06391294|PROCEDURE|Focal cortical cooling|Focal cortical cooling will be applied
223729203|NCT06152133|OTHER|Therapeutic core stability exercises|exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (ball). The exercise involves changes in the position of the body with or without resistance, aiming to improve strength, endurance, proprioception and coordination. Training is determined by the patient's ability to undertake easy exercises and progress to more challenging exercises.
223729204|NCT06791356|BEHAVIORAL|Cognitive-behavioral therapy for insomnia|8 sessions of therapy that focus on psychoeducation about sleep hygiene, cognitive restructuring of dysfunctional beliefs that reinforce insomnia, stimulus control to eliminate the association between the bed and wakefulness, sleep restriction in order to establish a consistent sleep schedule, and relaxation training to reduce anxiety that interferes with sleep
223729205|NCT06791356|BEHAVIORAL|Sleep hygiene education|One session of education about behavioral strategies to optimize sleep quality
223729206|NCT06470373|DRUG|RBS-001 Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
223993173|NCT04893681|OTHER|Non-fluoridated drinking water|Study participants are asked to consume study water, as frequently and in amounts as necessary or desired, whenever they drink water (e.g., as plain water or mixed with other ingredients) or use water in food preparation.
223993174|NCT06145750|DIAGNOSTIC_TEST|Ability to order FirstLook™|FirstLook™ is a commercially available, validated next generation sequencing assay of plasma cell-free DNA (cfDNA) that analyzes the distribution of cfDNA fragment sizes to indicate the presence of possible lung cancer. FirstLook™ is intended to be used by a qualified healthcare provider and is not a replacement for computed tomography (CT) or low-dose computed tomography (LDCT). FirstLook™ is validated for use in individuals aged 50 or older who either currently or previously smoked cigarettes and accumulated 20 pack-years or more of exposure.
223993175|NCT06145750|OTHER|Continuing Medical Education for Lung Cancer|Physician practice will receive standard education on lung cancer screening for CME credit.
223993176|NCT06024278|BEHAVIORAL|Caregiver educational videos for African American caregivers|The intervention will be culturally tailored education videos for African American caregivers receiving hospice services.
223993177|NCT06024278|BEHAVIORAL|Caregiver educational videos for Puerto Rican caregivers|The intervention will be culturally tailored education videos for Puerto Rican caregivers receiving hospice services.
223993178|NCT04911764|DIAGNOSTIC_TEST|Three-min Step Test and Exercise desaturation detection in COPD|For this research, 2 visits will be scheduled (V1 and V2) for each patient. During V1, after collecting the filled and signed consent form from the patient, anthropometric measurements and pulmonary function assessment will be performed before the realization of a maximal graded test. This inclusion visit will be carried out as part of an inclusion within a respiratory rehabilitation program. During V2, each patient will randomly perform a 6-minute walking test and a 3-minute step test, in similar standard conditions. A 30-minute resting period will be allowed between the two field tests. During the realization of the tests, cardio-respiratory adaptations will be monitored throughout both tests with portable gas analyzer and pulsed oxymetry system.
223993179|NCT05323630|DEVICE|Renuvion APR System|The Apyx Medical Corporation Renuvion/J-Plasma helium plasma family of products has received FDA clearance under 510(k) numbers K191542, K192867 for the cutting, coagulation, and ablation of soft tissue.
223993180|NCT00776477|DRUG|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
223993181|NCT00776477|DRUG|aspirin|aspirin 100mg daily
223993182|NCT03177720|DRUG|Ciprofloxacin|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
223993183|NCT03177720|DRUG|Imipenem|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
223993184|NCT00044746|DRUG|Piperacillin/Tazobactam|
223993185|NCT03112109|OTHER|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
223993186|NCT00448877|DEVICE|fNIR light emitting and sensing device|
223993187|NCT00223301|DRUG|Mycophenolate Mofetil (cellcept)|
223993188|NCT03251729|PROCEDURE|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
223993189|NCT03251729|DRUG|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
223729207|NCT06470373|DRUG|Eylea® Solution for intravitreal injection|Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
223729208|NCT04203238|OTHER|Reduced Meat High Potato Diet|The main entrée in the PLM arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with potatoes.
223729209|NCT04203238|OTHER|Reduced Meat High Pulses Diet|The main entrée in the LMP arm will consist of a menu item in which 40% of the meat in the original recipe will be replaced with pulses.
223729210|NCT01955733|DRUG|BI 695500|
223729211|NCT03232047|DEVICE|Combined executive function and memory training|Computerized combined executive function and memory training
223729212|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 50mg|
223993190|NCT00066651|BIOLOGICAL|SS1(dsFv)-PE38 immunotoxin|
223993191|NCT00561717|DRUG|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
223993192|NCT00561717|DRUG|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
224122291|NCT05127616|BEHAVIORAL|Minimal Contact-Cognitive Behavior Therapy|This 4 session largely home-based version of CBT with minimal therapist contact treatment is aimed at improving UCPPS symptoms by teaching symptom self-management skills that modify illness beliefs, information processing strategies, and reactions that aggravate pelvic pain and urinary symptoms.
224122292|NCT05127616|BEHAVIORAL|Patient Education/Support|This 4 session largely home-based treatment is aimed at improving UCPPS symptoms through the provision of support and science-based information about UCPPS symptoms, how it is diagnosed, its causes, impacts, and triggers, treatment options and a collaborative relationship between the patient and clinician.
223729213|NCT04782024|DIETARY_SUPPLEMENT|7-Keto 25mg|
223729214|NCT04782024|DIETARY_SUPPLEMENT|Placebo|
223729215|NCT00733408|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223729216|NCT00733408|BIOLOGICAL|bevacizumab|Given IV
223729217|NCT00733408|DRUG|erlotinib hydrochloride|Given PO
223729218|NCT02965547|DEVICE|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
223729219|NCT02965547|PROCEDURE|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
223993193|NCT00561717|DRUG|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
223993194|NCT00561717|DRUG|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
223993195|NCT00944229|DRUG|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
223993196|NCT00944229|DRUG|Placebo|4 capsules of placebo every 24 hours
223993197|NCT03708237|DRUG|Ropinirole|ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
223993198|NCT03708237|DRUG|Gabapentin|GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
223993199|NCT03708237|DRUG|Placebos|Opaque gel capsules filled with methylcellulose 1500 filler
224122293|NCT04488822|DRUG|Pexidartinib|400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
224122294|NCT06822530|OTHER|Best Practice|Receive usual care CRC screening program navigation
224122295|NCT06822530|OTHER|Educational Intervention|Receive QR code and link to video addressing fears of colonoscopy
224122296|NCT06822530|OTHER|Electronic Health Record Review|Ancillary studies
224122297|NCT06822530|OTHER|Interview|Ancillary studies
224122298|NCT06822530|OTHER|Supportive Care|Receive rideshare transportation home after colonoscopy
224122299|NCT06822530|OTHER|Survey Administration|Ancillary studies
224122300|NCT03838367|DRUG|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
224122301|NCT03838367|DRUG|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
224122302|NCT03838367|DRUG|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
224122303|NCT03838367|DRUG|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
223993200|NCT01901822|PROCEDURE|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
223993201|NCT01901822|PROCEDURE|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
223545015|NCT04522050|DRUG|Gemcitabine combined with cisplatin induction chemotherapy|Patients receive gemcitabine (1000mg/m² d1,8) and cisplatin (80mg/m², d1) every 3 weeks for 2 cycles before radiotherapy. And then intensity modulated radiotherapy (IMRT) is given a total dose of GTVnx 70Gy, GTVnd 66Gy, CTV1 60Gy and CTV2 54Gy for 33 times in total, concurrently with gemcitabine. The initial dose of gemcitabine is 25mg/m² once a week for 6 times. The patients are divided into 9 groups (25mg/m², 50mg/m², 100mg/m², 200mg/m², 300mg/m², 350mg/m², 400mg/m², 450mg/m², 500mg/m²) with 6 patients in each group.
223545016|NCT04522050|DRUG|concurrent chemoradiotherapy with gemcitabine|followed by concurrent gemcitabine chemoradiotherapy
223993202|NCT03663907|PROCEDURE|Telemonitoring|"The system (the home tele-healthcare platform) designed jointly by engineers and clinical personal to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring. The system allow weekly follow up through videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses daily."
223993203|NCT01278706|PROCEDURE|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
224122304|NCT03838367|DRUG|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
223993204|NCT06512844|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Intervention|The MBSR training program consist of 8-week group session with the duration of 45-60 minutes each. Participants of the experimental group were given Mindfulness based stress reduction intervention in which they practice different mindfulness techniques. Each week focused on motor, cognitive and emotional issues of students with physically disabled. All the techniques also included psycho education
223993205|NCT05519566|DIAGNOSTIC_TEST|Retrograde Urethrogram|Fluoroscopy Retrograde Urethrogram Vs the Traditional Retrograde Urethrogram
223993206|NCT03209869|BIOLOGICAL|Ex vivo Expanded and Activated Haploidentical Donor NK Cells|Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
223993207|NCT03209869|BIOLOGICAL|Hu14.18-IL2|The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
223993208|NCT05603364|COMBINATION_PRODUCT|100ml carbohydrate containing 12.5g maltodextrin, fructose and glucose|Drank 10.5% of 5 ml/kg body weight (100ml containing 12.5g maltodextrin, fructose and glucose) after extubation in the resuscitation room.
224122305|NCT06968390|DEVICE|Transcranial Magnetic Stimulation|Non-invasive form of brain stimulation.
224122306|NCT03406104|GENETIC|GS010|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
224122307|NCT03406104|OTHER|Sham Intravitreal Injection|Lenadogene nolparvovec Intravitreal ocular unilateral Injection
224122308|NCT03277729|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
224122309|NCT03277729|DRUG|Cyclophosphamide|Given IV
224122310|NCT03277729|OTHER|Laboratory Biomarker Analysis|Correlative studies
224122311|NCT03277729|PROCEDURE|Leukapheresis|Undergo leukapheresis
224122312|NCT03277729|DRUG|Fludarabine Phosphate|Given IV
223545017|NCT02252640|BIOLOGICAL|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
223545018|NCT02252640|BIOLOGICAL|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
223545019|NCT02252640|BIOLOGICAL|ChAd63 ME-TRAP (5 x 10^10 vp)|
224122313|NCT04734990|DRUG|Azacitidine|Given IV or SC
224122314|NCT04734990|DRUG|Seclidemstat|Given PO
223993209|NCT05603364|OTHER|Routine feeding|Patients in group C were observed with 60min of abnormal vital signs after extubation, and returned to the ward for fasting and fasting for at least 6 h, and began to eat gradually through the mouth after anal exhaust
223993210|NCT02957955|BEHAVIORAL|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
223993211|NCT00283283|BIOLOGICAL|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
223993212|NCT04654910|BEHAVIORAL|PROMIS Score Explanation|The surgeon completing the clinical visit with the participant will explain what the PROMIS tool is, the purpose of the tool and what the participant's scores mean using a script.
223993213|NCT04654910|BEHAVIORAL|Placebo|Subjects will complete the PROMIS assessment but will not receive an explanation of the tool.
223993214|NCT04556812|PROCEDURE|Four-in-one procedure|"four-in-one surgical technique centered on tibial tuberosity osteotomy and proximal displacement"
223993215|NCT04556812|PROCEDURE|soft-tissue surgery|traditional soft-tissue surgery
223993216|NCT01810939|DRUG|Patiromer|
223993217|NCT01810939|DRUG|Placebo|
223993218|NCT04061369|OTHER|Low fat meal|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
224122315|NCT05278962|DRUG|SGLT2i|empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
224122316|NCT05278962|OTHER|No SGLT2i|No SGLT2i
224122317|NCT05358964|BEHAVIORAL|African American Family Health History Education Program|The AAFHHEP arm is an intervention to increase utilization of FHH and increase preventative screening. This tool will be culturally tailored by African Americans for African Americans.
224122318|NCT05139498|PROCEDURE|Conservative management for placenta accreta spectrum (PAS)|Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
223545020|NCT02252640|BIOLOGICAL|MVA ME-TRAP (2 x 10^8 pfu)|
223993219|NCT04061369|OTHER|Moderate fat meal|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
223993220|NCT04061369|OTHER|High fat meal|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
223993221|NCT04061369|OTHER|High fat liquid meal|Liquid meal that is high (60% of energy) in fat calories.
223993222|NCT02944929|OTHER|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
223993223|NCT03953131|PROCEDURE|Computed Tomography|Undergo PET/CT
223993224|NCT03953131|RADIATION|Gallium Ga 68-DOTATATE|Given IV
223993225|NCT03953131|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223993226|NCT06417034|DEVICE|Game Software|The software is interfaced with a modified version of Frets on Fire (FOF)-an open source computer game similar to Guitar Hero.
223993227|NCT06370845|COMBINATION_PRODUCT|Inhalation - Natural Odour|Inhalation of 50 uL of a natural odour via nasal septum mini-inhaler.
223993228|NCT06370845|COMBINATION_PRODUCT|Inhalation - Placebo|Inhalation of 50 uL of Placebo via nasal septum mini-inhaler.
223993229|NCT01007110|DIETARY_SUPPLEMENT|DHA|Docosahexaenoic Acid (DHA) from algal oil
223993230|NCT01007110|OTHER|Placebo|Placebo capsule
223993231|NCT02580929|RADIATION|radiotherapy|radiotherapy before surgery
223993232|NCT03995927|OTHER|Data collection and analysis|Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
224122319|NCT05139498|PROCEDURE|Cesarean hysterectomy for placenta accreta spectrum (PAS)|Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
224122320|NCT05090150|OTHER|Home delivery of ART|Home ART refill and monitoring, adherence support
224122321|NCT05090150|OTHER|Smart Lockers (Pele boxes)|Decentralized ART refills and monitoring, adherence support
224122322|NCT05090150|OTHER|Best clinic practices + conditional lottery incentives|Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART
224122323|NCT05090150|OTHER|Best clinic practices|Continue with best clinic practices
224122324|NCT04397068|PROCEDURE|phaco-vitrectomy|phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
224122325|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
224122326|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
223993233|NCT03995927|OTHER|Quality of Life Questionnaire|Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
223993234|NCT02438553|DEVICE|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
223993235|NCT02438553|DEVICE|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
223993236|NCT02582294|OTHER|Questionnaire|
223993237|NCT01845506|DEVICE|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
223993238|NCT01845506|DEVICE|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
223993239|NCT04340661|DIETARY_SUPPLEMENT|BIOintestil|Ginger ryzoma powder and Palmrose essential oil (Cymbopogon Martinii)
223993240|NCT04340661|DIETARY_SUPPLEMENT|PLACEBO|Cornstarch
223993241|NCT04974333|DEVICE|Mobile health application on phone|Patients will use a mobile app on their smart phones
223993242|NCT01037556|DRUG|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
223993243|NCT00137410|DRUG|Celebrex|
223993244|NCT05678283|DRUG|[14C]CC-90010|Specified dose on specified days
223993245|NCT05678283|DRUG|CC-90010|Specified dose on specified days
223993246|NCT02349152|DRUG|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
223993247|NCT02349152|DRUG|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
223993248|NCT05655923|BIOLOGICAL|ozonized olive oil|ozonized oil will be mixed with xenograft in group II and Group III
223993249|NCT05655923|BIOLOGICAL|xenograft bone substitute|Xenograft bone substitutes in all Groups
223993250|NCT06074705|DRUG|DS-1471a|Intravenous administration on Day 1 of each 28-day cycle
223993251|NCT00398281|DRUG|dutasteride|Given orally
223993252|NCT00398281|OTHER|placebo|Given orally
223993253|NCT05932147|OTHER|Pilates exercise|"1. Shoulder Abduction with External Rotation exercise~2. Shoulder bridge exercise~3. Mermaid sitting exercise.~4. Standing Pilates mermaid exercise with towel~5. Rocking exercise~6. Saw Pilates exercise.~7. Bird-dog Pilates exercise.~8. Roll up exercise.~9. Cobra pose exercise.~10. Child pose exercise."
223993254|NCT05932147|OTHER|Manual lymphatic massage|"procedures of Manual lymphatic drainage program Things to know about MLD Massage~* Use only gentle pressure, just enough to see your skin move.~* Massage should not be painful.~* Do not rub your skin red.~* Do massage each day.~* Repeat each step 5 to 10 times.~* The massage should take about 15 to 30 minutes."
223993255|NCT06009042|DRUG|IVIG 20g/d|The dose of IVIG(intravenous immunoglobulin) is 20g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
223993256|NCT06009042|DRUG|IVIG 10g/d|The dose of IVIG(intravenous immunoglobulin) is 10g/d. Participants also receive conventional liquid therapy and symptomatic and supportive treatment.
223993257|NCT04603742|DRUG|Anakinra|100 mg of Anakinra will be mixed with 100 mL of 0.9% saline solution for IV administration.
223993258|NCT04603742|DRUG|0.9% Saline|The placebo preparation will consist of a 100 mL of 0.9% saline solution without the addition of anakinra.
224122327|NCT01048190|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
224122328|NCT05703802|DIAGNOSTIC_TEST|Procalcitonin-variants ELISA-Assay|Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
223545021|NCT04767672|DIETARY_SUPPLEMENT|Non digestible carbohydrates|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
223545022|NCT04767672|DIETARY_SUPPLEMENT|Placebo|the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
223993259|NCT03903718|DRUG|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
223993260|NCT03903718|BIOLOGICAL|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
223993261|NCT03903718|DRUG|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
223993262|NCT06359496|OTHER|No intervention factor|No intervention factor
223993263|NCT04619602|DRUG|GSNO|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
223993264|NCT02330094|DRUG|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
223993265|NCT02330094|DRUG|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
223993266|NCT02790879|OTHER|Transition pediatric - adult|
223993267|NCT00079339|RADIATION|radiation therapy|Undergo radiotherapy
223993268|NCT00079339|DRUG|tipifarnib|Given orally
223993269|NCT02946671|BIOLOGICAL|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
223993270|NCT02946671|BIOLOGICAL|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
223993271|NCT00520845|DRUG|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
223993272|NCT00520845|DRUG|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
223993273|NCT00520845|DRUG|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
223993274|NCT00520845|OTHER|laboratory biomarker analysis|Blood collection
224122329|NCT01665417|DRUG|Experimental|Icotinib: 125mg, oral administration, three times per day.
223993275|NCT03274453|DRUG|Ketamine|0.12 mg/kg/hr of ketamine post surgery
224122330|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
224122331|NCT01665417|DRUG|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
224122332|NCT04697472|DEVICE|LIFT System|The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
224122333|NCT00075348|GENETIC|mutation analysis|
224122334|NCT03308084|DRUG|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
224122335|NCT03308084|DRUG|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
224122336|NCT03015610|DRUG|commercially available lansoprazole|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
224122337|NCT03015610|DRUG|matched placebo|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
224122338|NCT02944071|DEVICE|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
224294963|NCT00948727|BEHAVIORAL|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
224294964|NCT00948727|DRUG|Cyclosporine (CsA)|Cyclosporine (CsA)
224294965|NCT05396131|DEVICE|Lung Sealant|The Aeriseal System uses a polymer foam to block or seal fissures, peripheral airways, alveoli, and collateral channels to achieve lung volume reduction.
224294966|NCT05396131|DEVICE|Endobronchial Valve (EBV)|The Zephyr EBV System are one way valves inserted into the airways to reduce lung hyperinflation.
224294967|NCT05225974|DRUG|Liraglutide injection|At a single dose of 0.6 mg of Liraglutide injection by subcutaneous injection
224294968|NCT05225974|DRUG|Liraglutide injection(Victoza®)|At a single dose of 0.6 mg of Liraglutide injection(Victoza®) by subcutaneous injection
224294969|NCT05075720|DIETARY_SUPPLEMENT|Meat with added nitrate|"The intervention comprises 50 g salami and 35 g ham on white bread sandwich at breakfast and lunch.~This intervention will allow us to determine both endogenous formation of N-nitrosamines as well as N-nitrosamines present in the commercially prepared meat."
224294970|NCT05075720|DIETARY_SUPPLEMENT|Meat without added nitrate|"The intervention comprises 65 g Pork mince on white bread sandwich at breakfast and lunch. Nitrate is not an allowed additive in pork mince.~This intervention will allow us to determine if there is endogenous formation of N-nitrosamines as well as N-nitrosamines present in the prepared meat due to the natural content of nitrate in meat."
224294971|NCT05075720|DIETARY_SUPPLEMENT|Control|The control comprises low nitrate vegetable protein burger on white bread. Protein content matched to interventions 1 and 2.
224294972|NCT03703648|RADIATION|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
223993276|NCT03274453|DRUG|Saline|Saline will be administered at the same rate as the ketamine infusion.
223993277|NCT00583466|DRUG|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
223993278|NCT00583466|DRUG|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
223993279|NCT00583466|DRUG|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
223993280|NCT01476683|DRUG|Racecadotril|Film-coated tablet
223993281|NCT01476683|DRUG|Racecadotril|Racecadotril Powder Blend
223993282|NCT01476683|DRUG|Racecadotril|Marketed Capsule
223993283|NCT01476683|DRUG|Racecadotril|Marketed Film-coated Tablet
223993284|NCT04076462|DRUG|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
223993285|NCT04076462|DRUG|Matching placebo|Matching placebo for CAM2029
223993286|NCT02932930|PROCEDURE|QLB bloc|
223993287|NCT02932930|DRUG|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
223993288|NCT02932930|DRUG|0.9% normal saline|0,2ml/kg of 0.9% normal saline
223993289|NCT00703339|DRUG|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~* Cohort 1: dosed at 3 breaths (18 mcg)~* Cohort 2: dosed at 6 breaths (36 mcg)~* Cohort 3: dosed at 9 breaths (54 mcg)~* Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
223993290|NCT00945672|BIOLOGICAL|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
223993291|NCT00945672|BIOLOGICAL|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
223993292|NCT00945672|DRUG|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
223729220|NCT02965547|PROCEDURE|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
223729221|NCT01035515|DRUG|Placebo|Single dose oral capsule placebo comparator
224122339|NCT04687774|DEVICE|ExaltTM Model D Single-Use Duodenoscope|The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
224122340|NCT06973434|DEVICE|intubation|intubation
223729222|NCT01035515|DRUG|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
223729223|NCT01035515|DRUG|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
223729224|NCT00950547|DEVICE|CARDIOPAT|Cell Saver System at bedside for ICU stay
223729225|NCT00950547|DEVICE|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
223729226|NCT02762266|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223729227|NCT02762266|PROCEDURE|Transarterial Chemoembolization|Undergo TACE
223729228|NCT02762266|DRUG|embolic agent|". Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads"
224122341|NCT06969261|BEHAVIORAL|Penny COPILOT|The Penny COPILOT chatbot is an interactive short messaging system (SMS) program that provides educational and supportive content for postpartum individuals. The chatbot has been adapted to include information relevant to opioid use disorder recovery in order to decrease the risk of returning to use among people who use drugs. Messages are sent at specified intervals relevant to the postpartum course and the chatbot allows for two way messaging with an interactive lens.
224122342|NCT01684397|BIOLOGICAL|Bevacizumab|Given IV
223993293|NCT04324216|OTHER|3D virtual reality and hands-on aromatherapy|Participants will receive 8-session 3DVR aroma therapy activities. Each session was delivered over 2 hours once a week, and at each session, the participant received hands-on guidance for preparing an aromatherapy product that they could use for the next seven days.
223993294|NCT02209090|PROCEDURE|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
223993295|NCT02209090|PROCEDURE|maternal free positions|At least 40 minutes each hour during labour
223993296|NCT02935803|PROCEDURE|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
224122343|NCT01684397|OTHER|Laboratory Biomarker Analysis|Correlative studies
223993297|NCT04392492|DEVICE|MANTA vascular closure device|Femoral access site closure using the MANTA closure device
223993298|NCT00001039|DRUG|Ethambutol hydrochloride|
223993299|NCT00001039|DRUG|Clarithromycin|
223993300|NCT03735043|DEVICE|cardiac output by ccNexfin ©|Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
223993301|NCT02897505|BEHAVIORAL|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
223993302|NCT00016588|DRUG|Tenofovir disoproxil fumarate|
224122344|NCT01684397|DRUG|Pazopanib Hydrochloride|Given PO
224122345|NCT01684397|OTHER|Pharmacological Study|Correlative studies
224122346|NCT04801849|DRUG|Vitamin E|Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks
224122347|NCT04801849|DRUG|Placebo|Participants will take a placebo vitamin E capsule daily for 24 weeks
223729229|NCT02762266|DRUG|lipiodol|
224122348|NCT05836220|DRUG|PLS240|Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.
224122349|NCT05836220|DRUG|Placebo|Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.
223993303|NCT04487678|DIETARY_SUPPLEMENT|Ketone ester supplement|Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.
223993304|NCT02492230|DEVICE|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
223993305|NCT02492230|DRUG|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
223993306|NCT02106962|DRUG|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
223993307|NCT02106962|OTHER|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
223993308|NCT03845140|DRUG|L-PZQ ODT 50 mg/kg|Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
223993309|NCT03845140|DRUG|Biltricide®|Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.
224122350|NCT05836220|DRUG|Open-Label Extension PLS240|Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.
224122351|NCT06665425|DRUG|Epaminurad 9 mg|Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
223993310|NCT03845140|DRUG|L-PZQ ODT 60 mg/kg|Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.
223993311|NCT04566562|DIAGNOSTIC_TEST|Brain Imaging|Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .
223993312|NCT04566562|DIAGNOSTIC_TEST|Cognitive Testing|Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)
223993313|NCT04566562|DIAGNOSTIC_TEST|Blood Biomarkers|Inflammatory Markers
224122352|NCT06665425|DRUG|C2406|Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
224122353|NCT02941783|DRUG|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
223993314|NCT01418404|OTHER|Noxious TS|hot, cold alternately, noxious TS in study A
223993315|NCT01418404|OTHER|Innocuous TS|warm, cool alternately, Innocuious TS in study A
223993316|NCT01418404|OTHER|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
223993317|NCT01418404|OTHER|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
223993318|NCT01418404|OTHER|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
223993319|NCT01418404|OTHER|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
223993320|NCT05292053|DRUG|TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation|TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
223993321|NCT01592045|BIOLOGICAL|ch14.18 -NCI|25 mg/m\^2/day IV for four consecutive days
223993322|NCT01592045|BIOLOGICAL|ch14.18-UTC|17.5 mg/m\^2/day IV for four consecutive days
223993323|NCT01592045|BIOLOGICAL|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m\^2/day for 14 days during Courses 1, 3, and 5.
223993324|NCT01592045|BIOLOGICAL|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.
224122354|NCT05100199|DRUG|OnabotulinumtoxinA X|Injection
224122355|NCT05100199|DRUG|Placebo|Injection
224122356|NCT05638711|DEVICE|Built-in calculator to calculate Filtration fraction|A calculator built in electronic CVVH prescription system to calculate Filtration fraction
224122357|NCT02598349|RADIATION|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
224122358|NCT02598349|DRUG|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
223993325|NCT01592045|DRUG|Isotretinoin|"Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight \> 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily)."
223993326|NCT01150461|DRUG|losartan|Losartan 50 mg b.i.d
223993327|NCT01150461|DRUG|placebo|Placebo b.i.d.
223993328|NCT01681992|BIOLOGICAL|Priorix|Subjects receive one dose of either minimum (Inv\_MMR\_Min) or medium (Inv\_MMR\_Med) potency lot at Day 0 and a dose of separate potency lot (Inv\_MMR\_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
223993329|NCT01681992|BIOLOGICAL|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
223993330|NCT01681992|BIOLOGICAL|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
223993331|NCT01681992|BIOLOGICAL|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
224122359|NCT02598349|PROCEDURE|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
223993332|NCT01681992|BIOLOGICAL|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
223993333|NCT03728751|PROCEDURE|Dry needling|Paravertebral dry needling C7-T4. Total of 8 needles.
223993334|NCT00915824|OTHER|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
224122360|NCT06227754|PROCEDURE|Angiography-guided PCI group|The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
223993335|NCT00793247|DRUG|PRU-PLA-PRU-PLA|
223993336|NCT00793247|DRUG|PLA-PRU-PLA-PRU|
223993337|NCT00793247|DRUG|PLA-PRU-PRU-PLA|
223993338|NCT00793247|DRUG|PRU-PLA-PLA-PRU|
223993339|NCT02968238|BEHAVIORAL|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
223993340|NCT02968238|BEHAVIORAL|Yoga|10 weeks of biweekly yoga sessions (N = 20)
223993341|NCT02516865|DEVICE|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
223993342|NCT02516865|DEVICE|Ankle weights|Worn during typical daily activities.
223993343|NCT01415934|OTHER|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
223993344|NCT03585088|DEVICE|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score \<=60.
224294973|NCT01007565|PROCEDURE|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
224294974|NCT04547530|DIETARY_SUPPLEMENT|Vitamin D|as above
224294975|NCT04547530|DIETARY_SUPPLEMENT|Placebo|as above
223729230|NCT00195182|BEHAVIORAL|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
223993345|NCT02403518|DEVICE|Freedom Spinal Cord Stimulator System|
223993346|NCT03488680|BEHAVIORAL|Behavior change communication|Behavior change communication about optimal complementary feeding
224294976|NCT01612026|PROCEDURE|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
223993347|NCT03609268|DEVICE|microwave ablation (MWA)|microwave ablation (MWA) for recurrent small liver cancer
223993348|NCT03609268|RADIATION|stereotactic body radiotherapy (SBRT)|stereotactic body radiotherapy (SBRT) for recurrent small liver cancer
223993349|NCT01028677|DRUG|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
224122361|NCT06227754|PROCEDURE|Optical coherence tomography-guided PCI group|"\[Stent Optimization\]~1. Stent Expansion:~   Visually assess residual angiographic diameter stenosis \<10% AND~   ① In non-LM lesions: In-stent minimal lumen area (MSA) \>80% of the average reference lumen area OR \>4.5 mm2~   ② In LM lesion: MSA\>7 mm2 for distal LM and \>8 mm2 for proximal LM~2. Stent Apposition:~   No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and \< 1mm length) of the stent over its entire length against the vessel wall~3. Edge Dissection:~No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as \>60° of the circumference of the vessel at site of dissection and/or \>2 mm in length of dissection flap)"
224122362|NCT06400472|DRUG|LY4170156|Intravenous
224122363|NCT06400472|DRUG|Bevacizumab|IV
223729231|NCT05542927|DIAGNOSTIC_TEST|urine chloride|Serum chloride, urinary chloride \& serum creatinine will be requested on the first day of admission in Intensive Care Unit (ICU). 2. Serum chloride \& urinary chloride will be requested every 48 hours in ICU with correlation between urinary chloride concentrations, AKI \& mortality. 3. Serum creatinine will be requested every 24 hours in ICU. 4. Monitoring of Urinary Output (U.O.P.) every 24 hours
223993350|NCT01028677|OTHER|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
223993351|NCT03414021|DIAGNOSTIC_TEST|SPECT-CT Scan|Injection of a Tracer and SPECT-CT Scan
223993352|NCT01267773|BEHAVIORAL|Integrated Treatment|
223993353|NCT02594787|DIETARY_SUPPLEMENT|Phosphorus|
223993354|NCT02594787|DIETARY_SUPPLEMENT|Placebo|
223993355|NCT06179147|OTHER|cervical traction|Traction of the uterine cervix applied in the study; It is the process of pulling the anterior and posterior lips of the cervix towards the intraoitus, downwards and backwards for approximately 90 seconds using overpens. Traction is applied until the cervix reaches the level of vaginal introitus. It is a cost-effective, new, simple intervention with no reported adverse effects.
223993356|NCT00354757|DRUG|rabeprazole|
223993357|NCT02806362|DRUG|Ombitasvir/paritaprevir/ritonavir|Tablet
223993358|NCT01661205|DEVICE|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
224122364|NCT06400472|DRUG|carboplatin|IV
224122365|NCT06233435|BEHAVIORAL|PADSS|Observe PADSS after total knee arthroplasty at 6 and 24 hours
223993359|NCT04627610|OTHER|Rectal prolapse, rectocele and elytrocele|Recurrence of dyschesia on rectal prolapse, rectocele and elytrocele
223993360|NCT00224744|DEVICE|ultracision|Surgery by Ultracision
223545023|NCT01183429|DRUG|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
223729232|NCT01438424|DRUG|Entecavir|Tablets, Oral, 1.0 mg, once daily
223729233|NCT01438424|DRUG|Lamivudine|Oral, 100 mg, daily
223729234|NCT03038191|DEVICE|Neuroelectrics Enobio 8(R)|Monitoring
223993361|NCT00224744|DEVICE|classical lymphadenectomy|classical lymphadenectomy
223993362|NCT04191421|BIOLOGICAL|Siltuximab|Given IV
224122366|NCT05061550|DRUG|Durvalumab|Participants will receive Durvalumab via intravenous route.
223993363|NCT04191421|BIOLOGICAL|Spartalizumab|Given IV
223993364|NCT05424835|DRUG|SHR-A1811|SHR-A1811 4.8mg/kg
223993365|NCT05424835|DRUG|Pyrotinib in combination with Capecitabine.|Pyrotinib in combination with Capecitabine.
223993366|NCT05424835|DRUG|SHR-A1811|SHR-A1811 6.4mg/kg
223993367|NCT03111095|OTHER|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
223993368|NCT05631041|DRUG|Silymarin|participants in silymarin group will receive silymarin 140 mg once daily.
223993369|NCT04709588|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml every night for 14, 28 days
224294977|NCT02922101|BEHAVIORAL|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
224122367|NCT05061550|DRUG|Oleclumab|Participants will receive Oleclumab via intravenous route.
224122368|NCT05061550|DRUG|Monalizumab|Participants will receive Monalizumab via intravenous route.
224122369|NCT05061550|DRUG|Dato-DXd|Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route.
223729235|NCT05508581|PROCEDURE|microwaves ablation of varicose veins|"Microwave ablation is an endovenous treatment. This is a similar treatment approach as laser ablation and radiofrequency ablation. Endovenous means that the treatment device is inside the vein during treatment."
223729236|NCT00118963|DRUG|Metformin|Tablets of 500 mg; 1000 mg two times daily.
223729237|NCT00118963|DRUG|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
223729238|NCT00118963|DRUG|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
224122370|NCT05061550|DRUG|AZD0171|Participants will receive AZD0171 via intravenous route.
224122371|NCT05061550|DRUG|Carboplatin|Carboplatin as chemotherapy
224122372|NCT05061550|DRUG|Cisplatin|Cisplatin as chemotherapy
224122373|NCT05061550|DRUG|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin as chemotherapy
224122374|NCT05061550|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin as chemotherapy
224122375|NCT05061550|DRUG|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as chemotherapy
224122376|NCT05061550|DRUG|Volrustomig|Participants will receive Volrustomig via intravenous route.
224122377|NCT05061550|DRUG|Rilvegostomig|Participants will receive Rilvegostomig via intravenous route.
224122378|NCT05456035|BEHAVIORAL|Cognitive behavioral therapy plus social cognitive training (CBTSCT)|The study has two intervention arms to which depressed adolescents will be randomized: (1) CBTSCT is cognitive behavioral therapy enhanced with training in social cognitive abilities (e.g., social perspective taking), and (2) CBT only is cognitive behavioral therapy without the additional social cognitive training component.
224122379|NCT05557279|DRUG|500 mg NDS-446|All participants will receive 500 mg NDS-446 daily for 12 weeks following a baseline assessment
224122380|NCT04992013|DRUG|Niraparib|Capsule taken by mouth
224122381|NCT03229915|BEHAVIORAL|cognitive processing therapy|Group therapy for PTSD patients
224122382|NCT05909514|BEHAVIORAL|PelvicSense(R)|PelvicSense® is a home-based physiotherapy program integrating multiple techniques, including relaxation, breathing, stretching, strengthening and at-home manual therapy. This program also educates participants about the anatomy and physiology of the pelvis and teaches strategies to strengthen the mind-muscle connection to the pelvis.
224122383|NCT04434053|DEVICE|MIETHKE M.blue®|The programmable shunt will be adjusted through the MIETHKE M.blue® valve.
223993370|NCT04709588|DIETARY_SUPPLEMENT|collagen drinkss|subjects drank 50 ml every night for 14, 28 days
223729239|NCT00118963|DRUG|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
223729240|NCT00118963|DRUG|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
223993371|NCT01546246|OTHER|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
223993372|NCT06311903|DRUG|Low dose of Norepinephrine (NE)|Patients were received resuscitative fluid \[administered at beginning with the arrival of the patient in the emergency department (mean blood pressure \>70 mmHg)\] followed by low dose of NE (0.05-0.2 μg/kg/min).
224294978|NCT02922101|BEHAVIORAL|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
224294979|NCT00045669|DRUG|imatinib mesylate|
223729241|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
223729242|NCT02790398|BEHAVIORAL|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
223729243|NCT02346630|DRUG|Placebo|Placebo capsules daily for 3 weeks.
223729244|NCT02346630|DRUG|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
223729245|NCT02346630|DEVICE|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
223729246|NCT03192254|BEHAVIORAL|self-monitoring|recording fruit and vegetable consumption
223729247|NCT03192254|BEHAVIORAL|daily monetary incentives|daily payments for consuming fruits and vegetables
223729248|NCT03192254|BEHAVIORAL|delayed lump sum monetary incentives|lump sum payments for consuming fruits and vegetables
223729249|NCT00022308|DRUG|cisplatin|
223729250|NCT00022308|DRUG|irinotecan hydrochloride|
223729251|NCT00022308|RADIATION|radiation therapy|
223729252|NCT01709591|BEHAVIORAL|Prenatal education|
224294980|NCT05927272|PROCEDURE|SKIN SAMPLES|"At baseline: one 4 mm Ø skin biopsies: on forearms (excluding skin folds): fresh At month 3 and month 6: Two 4 mm Ø skin biopsies will be performed on the same lesion selected at baseline (one on a repigmented area, one on a non-responded area): fresh~Fresh Skin biopsies will be analyzed the same day using Single-cell RNA sequencing (scRNAseq)."
223729253|NCT06106516|DEVICE|novel vital sign monitor|Devices that are to be introduced into the clinic but where data from clinical relevant conditions such as complications are lacking to assess the validity under clinical conditions
223729254|NCT03284827|DRUG|NOAC|edoxaban (60 mg once daily \[OD\]) for at least 6 months
223729255|NCT03284827|DRUG|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
223729256|NCT04508244|DRUG|Placebo|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
223729257|NCT04508244|DRUG|Propranolol|12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.
223729258|NCT06501066|BIOLOGICAL|umbilical cord mesenchymal stem cells|Patients assigned to UC-MSC administration groups will receive one administrations
223729259|NCT06240975|OTHER|Theragun Technique|Use the Theragun for a designated duration per session, such as 5-10 minutes for one session per week for 6 weeks
223729260|NCT06240975|OTHER|Dry Needling Technique|Dry needle deep (20 mm) TrP acupuncture of myofascial duration per session, such as 5-10 minutes for one session per week for 6 weeks
223729261|NCT00763477|BIOLOGICAL|ghrelin|subcutaneous injection
223729262|NCT00360789|BEHAVIORAL|Conventional UK physical therapy|
223729263|NCT00360789|BEHAVIORAL|Increased intensity of UK conventional physical therapy (PT)|
223729264|NCT00360789|BEHAVIORAL|UK conventional PT plus functional strength training|
223729265|NCT05967806|PROCEDURE|assessment|2 ml volume of blood withdrawal
223729266|NCT05565651|OTHER|Fecal microbiota analysis|Data analysis
223729267|NCT02315781|DEVICE|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
223729268|NCT02315781|DEVICE|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
223993373|NCT06311903|DRUG|High dose of Norepinephrine (NE)|Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min).
223993374|NCT00504075|BIOLOGICAL|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
223993375|NCT02963948|BEHAVIORAL|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
223993376|NCT02963948|BEHAVIORAL|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
223993377|NCT02963948|BEHAVIORAL|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
223993378|NCT05260879|BEHAVIORAL|Diabetes prevention program|Adaptation of the Centers for Disease Control and Prevention (CDC) Diabetes Prevention Program Power to Prevent for use in low income neighborhoods in Bamako, Mali
223729269|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
223993379|NCT03120429|BEHAVIORAL|Fish group|Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
223993380|NCT03120429|BEHAVIORAL|Control group|Control group will have hypo-energetic diet in which subjects have no seafood.
223729270|NCT01991028|DRUG|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
223729271|NCT06539559|DRUG|Eribulin|Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
223993381|NCT03444402|DRUG|CKD-381(formulation I)|1 tablet administered before the breakfast during 7 days
223993382|NCT03444402|DRUG|CKD-381(formulation II)|1 tablet administered before the breakfast during 7 days
223993383|NCT03444402|DRUG|D026(Nexium 40mg)|1 tablet administered before the breakfast during 7 days
223993384|NCT01891019|DRUG|Thalidomide oral|Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.
224122384|NCT04434053|DEVICE|MIETHKE proGAV 2.0® (with SA 2.0®)|The programmable shunt will be adjusted through the MIETHKE proGAV 2.0® valve that will be implanted together with a shunt-assistant SA 2.0®.
223993385|NCT04699942|DEVICE|Conventional (low flow) oxygen delivery via nasal cannula|Conventional (low flow) oxygen delivery via nasal cannula or face mask for 20 minutes
223993386|NCT04699942|DEVICE|Revoxa Oxygen Rebrearther|Oxygen delivery via Revoxa Oxygen Rebreather device for 20 minutes
223993387|NCT01186705|DRUG|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
223993388|NCT01035853|DRUG|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
223993389|NCT02639455|BEHAVIORAL|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
223993390|NCT01528319|DEVICE|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
223993391|NCT04052815|BEHAVIORAL|Diabetes prevention program culturally tailored|Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
223545024|NCT05807152|DEVICE|RenalGuard device|Patients will be given an intravenous loading dose of 40 mg of furosemide and continuous infusion of furosemide based on baseline eGFR. An additional bolus of 40 mg of furosemide will be administered and the infusion rate increased according to the same protocol of the control group (Figure 1). The venous peripheral cannula will be connected with the extracorporeal circuit of the RenalGuard System (PLC Medical Systems Inc., MA) for fluid infusion. The RenalGuard System is capable of delivering sterile replacement solution to a patient in an amount matched, or higher or lower, to the volume of urine produced by the patient. Thus, in the RenalGuard group, estimated daily targeted negative fluid balance will be utilized to define, for each patient, hourly negative fluid balance to be set in the RenalGuard system display.
223993392|NCT01258257|PROCEDURE|Insertion of a lumbar drain|In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
224122385|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
224122386|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
223545025|NCT04832529|PROCEDURE|No packing of perianal abscess cavity|introducing new method to no packing of abscess cavity.
223729272|NCT06539559|DRUG|Bevacizumab|Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
223729273|NCT04602832|OTHER|Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19|ENHANCE is a 12-session program designed to help improve subjective well-being, especially through the challenges of a pandemic. The ENHANCE program introduces and teaches people about the evidence-based principles and skills that have been shown across decades of research to improve overall health and well-being.
223729274|NCT02415881|DRUG|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
223993393|NCT06179745|COMBINATION_PRODUCT|EEG-based brain-computer interface|EEG-based brain-computer interface detecting the patient's EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient.
224122387|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS C|High casein-protein, high-caloric control product.
223545026|NCT06184230|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine
223993394|NCT06179745|COMBINATION_PRODUCT|Sham EEG-based brain-computer interface|Fake (Sham) EEG-based brain-computer interface which outputs a decision at random about whether EEG sensorimotor rhythms associated to attempted reach-gasp-release upper limb movements by the patient are currently detected.
223993395|NCT06179745|DEVICE|Functional Electrical Stimulation|Neuromuscular stimulation of several upper limb muscles (elbow extensors, hand extensors/flexors) to effectuate reach, grasp and release movements of the affected upper limb.
223993396|NCT06179745|DEVICE|Active hand orthosis|Active hand orthosis effectuating reach, grasp and release movements of the affected uppe r limb.
223993397|NCT04849767|OTHER|Questionnaire|Questionnaire about socio-behavioral items and conditions of vulnerability. interview with female to male transgender person will be about life conditions, trajectory of the medical transition from female to male and actual medical following of the transition, migration trajectory and condition of HIV acquisition.
223729275|NCT02415881|DEVICE|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
223729276|NCT02415881|DEVICE|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
223729277|NCT01430091|DRUG|Prasugrel (clinical formulation)|Administered orally
223729278|NCT01430091|DRUG|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
223729279|NCT04099927|DRUG|SHR0410|SHR0410 monotherapy,given intravenously
223729280|NCT00131833|BIOLOGICAL|Typhoid Vi vaccine|
223729281|NCT00131833|BIOLOGICAL|Meningococcal A (control)|
223729282|NCT04040478|DEVICE|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
223993398|NCT01914770|DRUG|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
224122388|NCT02013466|DIETARY_SUPPLEMENT|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
224294981|NCT05927272|PROCEDURE|BLOOD SAMPLES|Blood samples will be taken (30 mL) at week 0, week 12, week 24 for the measurement of pro-inflammatory cytokines and chemokines ligands in blood sera.
224294982|NCT05927272|DEVICE|narrowband UVB|narrowband UVB (Nb-UVB) 2 times a week
224294983|NCT05927272|DRUG|Systemic Steroids|Oral minipuls of systemic steroids (Medrol 16mg twice a week) for 24 weeks
224294984|NCT03052322|DRUG|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
224294985|NCT03052322|DRUG|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
224294986|NCT05783648|DRUG|Use of tranexamic acid|Percentage of correct use according to POISE-3 criteria of tranexamic acid
224294987|NCT03712839|OTHER|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
223729283|NCT03218033|BEHAVIORAL|Social Media|
223729284|NCT00888251|OTHER|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
224294988|NCT06168565|DEVICE|Intermittent pneumatic compression (AirRelax)|Moderate pressure (around 80mmHg); high pressure (around 200mmHg), both applied on the lower-limbs
223729285|NCT01382056|OTHER|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
223729286|NCT01382056|OTHER|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
223729287|NCT01382056|OTHER|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
224122389|NCT00752609|DRUG|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
224122390|NCT04246528|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
224122391|NCT03115333|DIAGNOSTIC_TEST|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
224122392|NCT05216393|OTHER|RecTech Match Website|Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.
224122393|NCT05374447|PROCEDURE|Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy|Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.
224122394|NCT05186714|BEHAVIORAL|Tai Chi versus wellness education|12 weeks of Tai Chi (2x/week) or a wellness education (2x/week)
223729288|NCT03240796|PROCEDURE|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
223729289|NCT03240796|PROCEDURE|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
223729290|NCT03011398|PROCEDURE|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
223729291|NCT00969176|DRUG|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
223993399|NCT01914770|DRUG|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
223993400|NCT01914770|DRUG|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
223993401|NCT04700553|DEVICE|Localized muscle vibration|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
223993402|NCT04700553|OTHER|Conventional physiotherapy intervention|All patients in both experimental and control groups received CPT protocol consisted of 30 minutes of manual resistance exercise (3 sets/10 repetitions each for knee extensors and flexors) and 30 minutes of treadmill training, short breaks (1-5 minutes) were allowed, depending on the patient tolerance. The training was conducted for 3 days per week for 8 weeks. The patients in CPT+LMV experimental group received localized muscle vibration at the end of each CPT session. The LMV was applied for 5 minutes perpendicularly along quadriceps muscle fibers. The frequency set at 30 Hz, amplitude of 2 mm.
223993403|NCT04223544|DIAGNOSTIC_TEST|Influenza POC and laboratory testing|Participation in the study is voluntary and carried out after the consent of the examined person. The examination consists of: 1) completing the questionnaire and 2) taking the throat swab twice by the researcher. Two throat swab samples will be taken at the same time. Both samples will be used for virological examination to determine the presence of influenza virus material using non-invasive tests: one sample will be analyzed by a quick 'on-site' test - Flu SensDx kit, while the other sample will be transported to the laboratory, where the reverse transcriptase polymerase chain reaction (RT-PCR) - reference method - will be performed to confirm the presence of influenza genetic material. Swabs are planned to be collected during the 2019/2020 influenza epidemic season (January-March).
224294989|NCT05727917|DRUG|Hetrombopag|After hematopoietic stem cell reinfusion, the patients begin to take hetrombopag orally 7.5mg/d, until the patients reach complete platelet response.The treatment will stop when patients accept 21 consecutive days of treatment or reach the discontinuation criteria.
224294990|NCT05727917|OTHER|placebo|After hematopoietic stem cell transfusion, the patients will be only observed, and the observation during the treatment period will be ended after 30 days
224294991|NCT03660358|DEVICE|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
224294992|NCT04920916|BIOLOGICAL|Dupilumab|Participants will receive a loading dose of dupilumab (600 mg, given as two 300 mg subcutaneous injections) on day 0/1. If participants are still hospitalized a second and third dose (300 mg) will be given on days 14 and 28.
224294993|NCT04920916|DRUG|Placebo|Normal Saline.
224294994|NCT05818618|DRUG|Clobetasol Topical Gel|Topic Clobetasol gel applied locally on OLP lesions.
224294995|NCT05818618|DRUG|Placebo|Placebo oral gel applied locally on OLP lesions.
224294996|NCT05992818|DIAGNOSTIC_TEST|comparing DRS-R-98 (The Delirium Rating Scale--Revised-98) and 3D-CAM (3-minute diagnostic assessment for CAM-Confusion Assessment Method-defined delirium) tests to assess postoperative delirium|determine the test that is more effective and practical in the assessment of POD
224294997|NCT03832309|BEHAVIORAL|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
223993404|NCT02614612|DRUG|Itacitinib (200 mg)|
224122395|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
224122396|NCT06469736|PROCEDURE|Standard of Care Ureterorenoscopy with MediNiK|The patient provides written informed consent and is positioned in the supine position. After disinfection, sterile draping, and single-shot antibiotic administration a rigid cystoscopy is performed. Intubation of the ostium with a hydrophilic guidewire and placed into the renal pelvis under fluoroscopic control. After a semirigid URS, a working sheath is placed up to the Kidney. A flexible URS with lithotripsy with a Thulium lase is then performed to dust the stones. The fragments are retrieved for analysis. Application of MediNiK to embbed the residual stones in the hydrogel and extract it with a basket. Finally, a double-J or mono-J stent and a transurethral catheter are placed.
224122397|NCT06287489|OTHER|Mediterranean diet|Mediterranean diet for three month
224122398|NCT06287489|OTHER|Regular diet|regular diet
224122399|NCT04948736|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|"Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink."
224122400|NCT04948736|OTHER|Conventional medial care|"Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits."
224122401|NCT02781467|BIOLOGICAL|PNK-007|
224122402|NCT02781467|DRUG|Cyclophosphamide|
224122403|NCT02781467|DRUG|Fludarabine|
224294998|NCT03832309|BEHAVIORAL|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
224294999|NCT05754307|PROCEDURE|Access Flap|Intrasulcular incisions at the teeth adjacent to the defect, using the simplified papilla preservation technique (SPPT) or modified papilla preservation technique (MPPT). Granulation tissue is excised and debridement via hand and power-driven instruments follows. Flaps are repositioned and papilla are sutured with horizontal internal mattress doubled by a single interrupted interdental suture.
224295000|NCT05754307|PROCEDURE|Closed Surgical Technique|"Strictly intrasulcular incisions are performed at the teeth adjacent to the defect (mid-buccal to mid-lingual) without incising the interdental papilla. Full thickness gingival flaps, at the base of the papilla, which is retained intact, are elevated in a closed-tunneling manner, granting access to the interdental osseous defect. Debridement is performed via power-driven tips and mini curettes, without intentionally excising the granulation tissue that lines the osseous defect. Flaps are repositioned by gentle pressure and suturing is not required."
224295001|NCT02583893|DRUG|Sirolimus|Given PO
224295002|NCT02583893|DRUG|Mitoxantrone|Given IV
224295003|NCT02583893|DRUG|Etoposide|Given IV
224295004|NCT02583893|DRUG|Cytarabine|Given IV
224295005|NCT04327856|PROCEDURE|Cataract Surgery|The cataract will be removed from patient's eye and artificial intraocular lens will be implanted
223993405|NCT02614612|DRUG|Itacitinib (300 mg)|
223993406|NCT02614612|DRUG|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
223993407|NCT00767429|DEVICE|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
223993408|NCT04148989|OTHER|Code Sepsis protocol (full implementation)|Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
223993409|NCT03812029|DRUG|Vonafexor|Oral tablets
223729292|NCT05745558|BEHAVIORAL|Prehabilitation|"The prehabilitation program consists of 4 components:~1. Fitness training led by a physiotherapist. The patients will receive personalized training schedules to perform at home. The training sessions focus on improving aerobic fitness (biking or walking) and muscle strength (specific exercises for the different patient groups) and respiratory exercises aimed to relax.~2. Nutritional counseling led by a dietician. All patients will be offered an intake with a dietician (60 min) to discuss current eating habits and give personalized advices. Based on indication, patients will receive follow-up consults.~3. Smoking cessation counseling led by a trained social worker. For patients that are currently smoking, a social worker will offer counseling sessions to coach the patient in the process of smoking cessation.~4. Psychosocial counseling led by a psychologist. All patients will be offered counselling by a psychologist."
223729293|NCT01132404|DRUG|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
223993410|NCT03812029|OTHER|Placebo|Oral tablets
223993411|NCT00590655|BEHAVIORAL|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
223993412|NCT00590655|BEHAVIORAL|weight loss programme|
223993413|NCT05627453|OTHER|Arm-in-arm gait training|An older adult walk side-by-side, arm-in-arm with a younger adult while synchronizing steps.
223993414|NCT05627453|OTHER|Normal gait training|An older adult walk side-by-side, without contact, with a younger adult without step synchronization.
223993415|NCT02194504|OTHER|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
223993416|NCT02194504|OTHER|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
223993417|NCT04991376|DIAGNOSTIC_TEST|Blood-specific miRNA levels|Blood-specific miRNA levels associated with renal tubular damage change in patients treated with vancomycin or gentamicin compared to septic patients treated with other antimicrobials.
223993418|NCT03149042|DIAGNOSTIC_TEST|CCTA|Diagnostic Test
223993419|NCT01178008|PROCEDURE|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
224122404|NCT02781467|DRUG|Human recombinant Interleukin-2 (rhIL-2)|
224122405|NCT05692154|DRUG|Fexofenadine|Fexofenadine oral tablet
224122406|NCT05692154|DRUG|Placebo|Fexofenadine matching placebo oral tablet
223993420|NCT01178008|PROCEDURE|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
223993421|NCT02600390|BIOLOGICAL|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
223993422|NCT03840005|DRUG|Ursonorm|Ursodeoxycholic acid
223993423|NCT03471858|DEVICE|Cervical balloon|To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
223993424|NCT03471858|DRUG|Prostaglandins|Prostin will be used in the control arm.
223993425|NCT04867447|DIAGNOSTIC_TEST|Psychological trauma evaluation|"Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE)."
223993426|NCT04351945|PROCEDURE|Blood test|Hormone levels will be measured just before transplantation, and three day after the transplantation. In case of the donors hormone levels will be defined during the explantation.
223993427|NCT03423329|DRUG|Brufen|Brufen Syrup
223993428|NCT03423329|DRUG|Cital|Cital Cyrup
223993429|NCT03423329|DRUG|Placebo for Brufen|Sansovit Syrup
223993430|NCT05724927|BEHAVIORAL|Animal assisted activity|The interviews consist of a total of six interviews, including an introduction, four studies, and a termination. Interviews will be held individually in each person's own room in the nursing home. Materials such as plastic aquarium, fish, fish food, fish food scales that will be given to the individuals during the interviews will be taken to the institution by the researchers before and will be given to the elderly individuals in the second interview.
223993431|NCT04267068|BEHAVIORAL|Growth Mindset and Modifiable Risk Factor Information|15 minute interactive article describing neuroplasticity followed by 15 minute interactive article describing modifiable risk factors for depression and anxiety
223993432|NCT04267068|BEHAVIORAL|Control|30 minute interactive article describing symptoms of depression and anxiety, common concerns of college student
223993433|NCT02833298|BEHAVIORAL|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
223993434|NCT02833298|BEHAVIORAL|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
223993435|NCT01434745|DRUG|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
223993436|NCT01434745|DIETARY_SUPPLEMENT|Lactose|Lactose will be administered in a capsule formula.
223993437|NCT02522988|BEHAVIORAL|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
223993438|NCT00537121|DRUG|fluorouracil|Given IV
223993439|NCT00537121|DRUG|irinotecan hydrochloride|Given IV
223993440|NCT00537121|DRUG|leucovorin calcium|Given IV
223993441|NCT00537121|DRUG|vorinostat|Taken Orally
223993442|NCT00537121|OTHER|pharmacological study|Correlative Study
223993443|NCT05906797|PROCEDURE|Non-surgical periodontal treatment|Subgingival biofilm ultrasonic debridement
223993444|NCT01206699|DRUG|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
223993445|NCT01206699|DRUG|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
223993446|NCT01046045|DRUG|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
224122407|NCT05711407|GENETIC|Gene Polymorphisms of MMP-8|Saliva Samples
223545027|NCT00149799|DRUG|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
223993447|NCT03209947|DIAGNOSTIC_TEST|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
224122408|NCT02059421|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"\- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~* Sleep restriction therapy~* Stimulus control instructions~* Sleep hygiene education"
224122409|NCT02059421|OTHER|Johrei therapy|"* Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~* Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~* Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~* Therapy will be administered without physical contact.~* During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
224122410|NCT04023591|PROCEDURE|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
224122411|NCT00498875|BEHAVIORAL|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
224122412|NCT00498875|BEHAVIORAL|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
224122413|NCT05298033|DRUG|Crisaborole 2 % Topical Ointment|Twice daily crisaborole 2% topical ointment
224295006|NCT02274844|BEHAVIORAL|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
223545028|NCT00149799|DRUG|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
223545029|NCT05453071|OTHER|Cognitive Exercise Therapy Approach (BETY)|BETY, based on function-oriented core stabilization exercises, will be applied in patients with systemic sclerosis. This exercise model includes pain management strategies, dance therapy-authentic movement. Function-oriented core stabilization exercises have the feature of being made difficult against gravity according to the person's ability to do. Initial exercises start from the stage where the distal segment of the extremity is on the ground, called closed-kinetic. This level, which is quite easy, becomes more difficult following the success of the individual. It can be started from the mat level and progressed by modifying it with theraband and exercise ball. It is used at the beginning and end of dance therapy and authentic movement sessions. In the session, cognitive restructuring technique is used to break the vicious cycle of pain-emotional-spasm during exercise. This exercise model is the main rehabilitation approach of the Rheumatological Rehabilitation Unit.
223545030|NCT00452075|DRUG|erlotinib|150mg daily
223545031|NCT01191515|DEVICE|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
224122414|NCT05298033|DRUG|PF-07038124 0.01% topical ointment|Twice daily PF-07038124 0.01% topical ointment
224122415|NCT05298033|DEVICE|NBUVB phototherapy|Home narrow band UVB phototherapy exposure sessions 3 times per week
224122416|NCT05298033|DEVICE|Sham phototherapy|Non-NBUVB visible light radiation exposure sessions 3 times per week
224122417|NCT05298033|DRUG|Vehicle|Twice daily vehicle ointment
224295007|NCT01892657|DRUG|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
224122418|NCT05384158|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy
224122419|NCT05384158|BEHAVIORAL|valuation with instruction|repeat laboratory sessions of computerized learning game
224122420|NCT05384158|BEHAVIORAL|valuation without instruction|repeat laboratory sessions of computerized learning game
224295008|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
224295009|NCT01206114|OTHER|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
224295010|NCT04779541|OTHER|observation|observation of the mechanisms of acceptance or rejection of the vaccine
223993448|NCT01356771|OTHER|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~* Current and past skin cancer screening practices~* Current and past sun protection practices~* Attitudes about skin cancer and sun protection~* Knowledge of melanoma"
223993449|NCT06186947|OTHER|No intervention|Participants are not subjected to any specific intervention.
223993450|NCT03644524|BEHAVIORAL|Heat therapy|Regular hot tub use
223993451|NCT06429982|DRUG|Dexamethasone|Steroid five day treatment
223993452|NCT06429982|DRUG|Placebo|Placebo control group
223545032|NCT02821156|DRUG||Inhaled Nitric Oxide with monitoring by EZ-KINOX device
223545033|NCT03288844|PROCEDURE|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
223993453|NCT03085056|DRUG|Trametinib|trametinib orally 2mg daily during each 4 week cycle
223993454|NCT03085056|DRUG|Paclitaxel|paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
223993455|NCT06555393|DIETARY_SUPPLEMENT|Egg White Powder|"Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption."
223545034|NCT03288844|OTHER|Digital pictures|Digital pictures 2D to be taken at each visit
223545035|NCT03288844|OTHER|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
223545036|NCT00374517|DRUG|Pimonidazole hydrochloride|
223545037|NCT03654144|DRUG|Dienogest|oral tablets
223545038|NCT03654144|DRUG|Combined Oral Contraceptive|oral tablets
223545039|NCT03680534|PROCEDURE|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
223545040|NCT05634330|OTHER|exercise treatment|core stabilization exercise
223545041|NCT01952938|PROCEDURE|LINK SL versus EnduRo|
223545042|NCT00437268|DRUG|enzastaurin|1125 milligrams (mg) loading dose, then 500 mg orally, daily, of each 21-day cycle until progressive disease
223993456|NCT04229810|PROCEDURE|STD-02|Conventional standardized ventilatory approach.
224122421|NCT06978231|PROCEDURE|EUS+ERCP|EUS were performed during the same session with ERCP under continuous sedation/anesthesia
224122422|NCT06978231|PROCEDURE|ERCP|Only ERCP was performed in the control group
223993457|NCT04229810|PROCEDURE|iOLA-iHFNC|Indivudualized perioperative open lung ventilatory approach.
223993458|NCT00525278|DRUG|Levocetirizine dihydrochloride|
223993459|NCT05505370|DEVICE|Colonoscopy|Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
223993460|NCT06771830|DEVICE|Pediatric eCART|Integration of the pediatric version of electronic Cardiac Arrest Risk Triage as a clinical decision support tool within Epic for use by clinicians
223993461|NCT03632083|DEVICE|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
223545043|NCT00437268|DRUG|irinotecan|300 milligrams per square meter (mg/m\^2) intravenously on Day 1 of each 21-day cycle until progressive disease
223545044|NCT00437268|DRUG|cetuximab|400 mg/m\^2, intravenously on Day 1, 250 mg/m\^2 on Day 8, Day 15 Cycle 1 then 250 mg/m\^2, on Day 1, 8 and 15 of each cycle, intravenously 21-day cycles until progressive disease
223545045|NCT06068374|OTHER|Break of sedentary behavior with dual task|Patients will interrupt sedentary behavior performing walking and cognitive activities simultaneously
223993462|NCT03632083|DEVICE|Lite Contact Lens Solution|Lite Contact Lens Solution
223993463|NCT03632083|DEVICE|fanfilcon A soft contact lens|fanfilcon A soft contact lens
223993464|NCT03632083|DEVICE|comfilcon A soft contact lens|comfilcon A soft contact lens
223993465|NCT00543153|BEHAVIORAL|Interview|Interview lasting approximately 30-45 minutes.
223993466|NCT04245345|DEVICE|Accelerometer Sensing for Micra AV Study|Characterize AV synchrony in subjects implanted with Micra AV device. The study will be conducted upon market approval of the Micra AV Transcatheter Pacing System.
223993467|NCT03450499|DRUG|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
223993468|NCT03450499|DRUG|Placebo|the analgesic requirement will be calculated in placebo group.
224122423|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every other day.|6mg/kg of oral iron as ferrous sulfate administered every other day instead of 6 mg/kg of oral iron daily supplementation.
224122424|NCT06555315|DIETARY_SUPPLEMENT|6 mg/kg of oral iron as ferrous sulfate administered every day.|6 mg/kg of oral iron as daily ferrous sulfate instead of 6mg/kg of oral iron supplementation administered every other day.
224122425|NCT00045682|DRUG|Paclitaxel Poliglumex|Given IV
224122426|NCT01379534|DRUG|TKI258|
224122427|NCT05730712|PROCEDURE|Biopsy|Undergo biopsy
223993469|NCT01729468|DRUG|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
223993470|NCT01729468|DRUG|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
224122428|NCT05730712|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223545046|NCT06068374|OTHER|Break of sedentary behavior with walking|Patients will interrupt sedentary behavior performing walking
223993471|NCT02281123|OTHER|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
223993472|NCT01531101|BEHAVIORAL|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
223993473|NCT06485739|DRUG|Irinotecan liposomes combined with cisplatin/carboplatin|Irinotecan liposomes 70mg/m2，use on the first day of each cycle The dosage of cisplatin and carboplatin is determined by the researchers
223993474|NCT01518907|BIOLOGICAL|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
223993475|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
223993476|NCT00732992|DRUG|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
224122429|NCT05730712|PROCEDURE|Computed Tomography|Undergo CT
224122430|NCT05730712|PROCEDURE|Echocardiography|Undergo ECHO
224122431|NCT05730712|DRUG|Enzalutamide|Given PO
224122432|NCT05730712|DRUG|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given SC
224122433|NCT05730712|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224122434|NCT05730712|OTHER|Questionnaire Administration|Ancillary studies
224122435|NCT04759248|DRUG|Atezolizumab + Trastuzumab + Vinorelbine|"* Atezolizumab IV 1200 mg in combination with~* Trastuzumab sc 600mg or IV 6mg/kg every 3 weeks and~* Vinorelbine 25 mg/m² IV or 60 mg/m2 PO on days 1 and 8, every 3 weeks during the first cycle and if there are no toxicity signs dose will be increased to 80 mg/m2 PO o 30 mg/m2 IV."
224295011|NCT00299936|DRUG|Ribavirin, PEG-Intron|
224295012|NCT05284396|RADIATION|IFRT vs NFRT|involved field irradiation versus nodal field irradiation
223993477|NCT01079247|OTHER|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
223993478|NCT01079247|OTHER|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
223993479|NCT00000598|BEHAVIORAL|diet, fat-restricted|
223993480|NCT00000598|BEHAVIORAL|exercise|
223993481|NCT04569019|OTHER|Vacciantion status in health care workers|Education among HCW about benefits of influenza vaccination. Using posters, email, conversations, informations about vaccination used during vaccination Vaccinating during working hours Vaccinating for free Vaccinating inside departments ( not in special clinic)
223993482|NCT03338647|DRUG|DEB|Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
223993483|NCT03338647|RADIATION|SBRT|High precision radiation therapy to the liver tumor(s)
223993484|NCT04777110|DRUG|Esketamine|The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s;
223993485|NCT04777110|OTHER|Saline|The main anesthesiologist standing on the right side of the patient injects saline (0.05ml/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30 s
223993486|NCT05006326|DRUG|68Ga-PSMA|Intravenous access is established in advance, intravenous bolus injection, 68Ga-PSMA dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg). Patients were encouraged to drink water after injection and asked to empty their bladder before PET scan.
223993487|NCT05006326|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
223993488|NCT05006326|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
223993489|NCT06243237|PROCEDURE|Acupuncture|Applied acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
223993490|NCT06243237|PROCEDURE|Sham Acupuncture(Superficial Acupuncture)|Applied superficial acupuncture on specific acupoints in patient with acute intracranial hemorrhage.
224122436|NCT06853483|BEHAVIORAL|Family-School based smoking cessation intervention package|The Family-School based smoking cessation intervention programme will be developed using the multiple strategies provided by the BCW framework, with face-to-face + online as the primary mode of implementation. Specifically, educational training based on the school curriculum will be conducted to create a supportive environment for smokers to quit, guide smokers to discover motivation to quit, encourage smokers to cope with key barriers to quitting, as well as incorporate relapse prevention strategies, using formats such as online videos and supplemental materials, with interventions designed to help students and parents of smokers to understand the health hazards of smoking, to enhance cessation action and supportive skills, and inspire healthy action.
223993491|NCT03869177|OTHER|Implementation support program|"The IFIP intervention consists of the following elements:~I. Clinical interventions 1.1 A basic level of family involvement and support 1.2 Family psychoeducation in single-family groups~II. Implementation interventions 2.1 Training and guidance of health care personnel 2.2 A family coordinator 2.3 Other implementation measures"
223993492|NCT02184299|DRUG|Nevirapine|
223993493|NCT02184299|DRUG|Prednisone|
223993494|NCT03509246|DRUG|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
223993495|NCT02344342|DEVICE|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
223993496|NCT02344342|OTHER|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
224122437|NCT06659627|BEHAVIORAL|Aerobic exercise therapy|Participants will follow an aerobic exercise therapy program for 16 weeks.
223993497|NCT00825539|DRUG|AQW051|
223993498|NCT00825539|DRUG|Placebo|
223993499|NCT02526498|RADIATION|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
223993500|NCT02526498|RADIATION|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
224122438|NCT06659627|BEHAVIORAL|Cognitive behavioural therapy|Participants will follow an cognitive behavioural therapy program for 12-16 weeks.
224122439|NCT06659627|OTHER|Usual care|Participants do not follow a program, but continue with care as usual
223993501|NCT02526498|OTHER|Questionnaire Administration|Ancillary studies
223993502|NCT03355209|DRUG|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
223993503|NCT03355209|DRUG|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
223993504|NCT06383650|DRUG|Acetylsalicylic Acid|Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
223993505|NCT01139853|DEVICE|Nasogastric Tube|Insertion of a 10 French Nasogastric tube prior to surgery
223993506|NCT02712749|DEVICE|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
223993507|NCT02712749|DEVICE|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
223993508|NCT03034590|OTHER|questionnaire|
223993509|NCT02117986|DRUG|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
223993510|NCT03400683|DRUG|Misoprostol|200 microgram misoprostol in sublingual every four hours for a maximum of five doses
223993511|NCT03400683|DRUG|Letrozole|15mg( letrozole 2.5mg) on three successive day
223993512|NCT03400683|PROCEDURE|Foley's catheter|transcervical 16F Foley's catheter with 30 ml balloon capacity inserted under aseptic conditions
223993513|NCT03937141|DRUG|ADU-S100|intratumoral
223993514|NCT00335101|DRUG|Iodixanol, Ioversol, Iopromide|
223993515|NCT04779437|BEHAVIORAL|Imagery Cognitive Bias Modification|"The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell \& Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. The training aims to train a bias to automatically imagine positive resolutions for ambiguous situations encountered in daily life.~Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website."
223993516|NCT04779437|BEHAVIORAL|Cognitive Control Training|The cognitive control training is an adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015; Blackwell et al., 2018). Participants will complete one introductory session of the training with the researcher present (in the outpatient center, or via videoconferencing software), then 8 sessions over two weeks completed from home via the study website.
224295013|NCT05949671|OTHER|mediterranean, gluten-free and mediterranean gluten-free diet intervention|This study is a prospective, single-blind study including case and control groups. Before the study started, participants were informed about the benefits and risks of the study. Participants were randomly divided into four different groups (MD, GFD, MGFD and control group). The intervention groups (MD group (n=10), GFD (n=10), MGFD (n=10)) were administered weekly diets by a dietitian for 12 weeks according to individual-specific and daily energy needs and weight loss was not targeted. Patients in the control group (n=10) did not receive any special dietary intervention. Patients were interviewed weekly to assess adherence to the study protocol and food consumption was recorded at each interview; those who complied with the weekly planned menus by less than eighty percent were excluded from the study.
223545047|NCT03837990|DRUG|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
224295014|NCT03163004|BEHAVIORAL|Implementation of standing desks|Three standing desks will be introduced to the classroom
223993517|NCT00780455|DRUG|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
223993518|NCT00780455|DRUG|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
223993519|NCT05780086|DRUG|30% icodextrin and 10% dextrose|Dwell time of 24 hours using a 500 ml sodium-free peritoneal dialysis solution based on 30% icodextrin and 10% dextrose
223545048|NCT04538157|OTHER|Comprehensive Geriatric Assessment|A CGA is a diagnostic and therapeutic intervention which initially identifies an older person's medical, functional, psychosocial problems and then tailors coordinated management plans to address them.
223993520|NCT00673907|OTHER|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
223993521|NCT02510833|BEHAVIORAL|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
223545049|NCT00057057|BEHAVIORAL|Telephone Care|
223993522|NCT02510833|BEHAVIORAL|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
223993523|NCT03690427|OTHER|Traditional hookah smoking|Charcoal-heated hookah smoking
223993524|NCT03690427|OTHER|Electronic hookah vaping|Electronic hookah bowl inhalation
223993525|NCT02251236|DRUG|Stribild|To be administered orally, once daily with food.
223993526|NCT02251236|DRUG|Genvoya|To be administered orally, once daily with food.
223993527|NCT03002298|BEHAVIORAL|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
223993528|NCT03002298|BEHAVIORAL|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
223993529|NCT03002298|BEHAVIORAL|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
223545050|NCT05905237|PROCEDURE|Cataract surgery, Femtosecond-LASIK, SMILE|Cataract surgery includes both conventional and femtosecond laser assisted. Femtosecond-LASIK and SMILE are options for patients to correct myopia.
223545051|NCT06350422|OTHER|Head-Down tilt Bed Rest test|All of the volunteers underwent 60 days of the Head-Down tilt Bed Rest test.
223993530|NCT03002298|BEHAVIORAL|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
224295015|NCT04057469|DRUG|Tulobuterol Hydrochloride|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
223993531|NCT00136643|DRUG|Invisible Condom®|
223993532|NCT04591171|PROCEDURE|n-of-1 trial guided clinical decision making|The n-of-1 trial will, on the level of the individual patient, test which treatment strategy produces superior blood pressure reduction without unacceptable side effects. After discussion with the patient/caregiver dyad to identify whether they have specific concerns about particular medications, the nephrologist (clinician) will decide which two drugs and dosages will be tested in the n-of-1 trial (the protocol does not determine drug or dose). The two drugs chosen by the clinician will be assessed at clinician-selected dosing in a randomized treatment order (e.g., ABAB) for two weeks per treatment period and two treatment periods per drug.
224295016|NCT04057469|DRUG|Placebo transdermal patch|The appropriate time interval between the patch attachment and the end of surgery was within 8 to 10 hours.
224295017|NCT05444686|DIAGNOSTIC_TEST|99mTc-FAPI|inject the tracer to subjects and perform SPECT/CT scans
224295018|NCT00792870|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
224295019|NCT00653952|DRUG|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
223545052|NCT00444925|DRUG|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
223545053|NCT00444925|DRUG|placebo|once daily (OD)for 12 weeks
223545054|NCT00444925|DRUG|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
223993533|NCT02609672|OTHER|Exercise|A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
223993534|NCT02609672|OTHER|No Exercise|A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
223993535|NCT05725772|OTHER|Location of Visit|Participants will perform visits 1) at-home via telemedicine, 2) in-person and 3) at a local regional clinic via telemedicine
223993536|NCT00509132|DRUG|trodusquemine|
223993537|NCT00867971|OTHER|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
223993538|NCT03353597|BIOLOGICAL|Plasma Transfusion|All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
224295020|NCT00653952|DRUG|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
224295021|NCT03055663|OTHER|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
224295022|NCT03055663|PROCEDURE|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
224295023|NCT03055663|DRUG|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
224295024|NCT05738759|DRUG|Epidural Anesthetic Cocktail|The anesthetic cocktail, consists of triamcinolone 40 mg, marcaine 5 mg, and morphine 3 mg, is soaked in the gelfoam size 1x2 cm and applied on the epidura before removal of the endoscope.
224295025|NCT05738759|DRUG|Placebo|The placebo is soaked with NSS in the gelfoam size 1x2 cm as well and applied on the epidura before removal of the endoscope.
224295026|NCT03373734|DEVICE|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
223545055|NCT00227084|DRUG|Arista AH hemostasis powder|
223545056|NCT04573790|PROCEDURE|eFONA|Surgical Tracheotomy
223993539|NCT04122547|DRUG|Roflumilast|Active drug
223993540|NCT04122547|DRUG|Placebo|Placebo one tablet oral od
223993541|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
223993542|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
223729294|NCT01132404|DRUG|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
223729295|NCT03715218|OTHER|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
223993543|NCT02956837|BIOLOGICAL|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
223993544|NCT02956837|DRUG|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
223993545|NCT06297044|OTHER|Neuropsychological assessment|"* APACS assessing various aspects of pragmatic communication abilities;~* SET assessing cognitive and emotional theory of mind;~* COAST assessing functional communication impairments in daily activities and their impact on the quality of life after the illness onset;~* PWB assessing the individual's perceived quality of life and psychological well-being;~* other neuropsychological assessment tools depending on the participant's pathology and routinely used in the clinical practice within the Institution."
223993546|NCT02597712|DRUG|YF476|gastrin receptor antagonist
223993547|NCT02597712|DRUG|YF476 placebo|placebo
223993548|NCT01783132|DEVICE|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
223993549|NCT03688776|OTHER|1805AA|A moist snuff product
223993550|NCT03688776|OTHER|1805AB|A moist snuff product
223993551|NCT03470636|DEVICE|HeartLight X3|Pulmonary vein isolation
223993552|NCT05037643|PROCEDURE|TIPS|Transjugular Intrahepatic Portosystemic Shunt is performed to prevent / treat symptomatic portal hypertension
223993553|NCT00263653|BIOLOGICAL|Haemophilus influenzae type b- and meningococcal (vaccine)|
223993554|NCT05276089|BEHAVIORAL|Video message|"The five-minute video will be sent to the patient's mobile phone, outlining reasons to reduce opioid use and highlighting the support available. It invites patients to consider 3 responses:~1. I would like to reduce my opioid medication with support.~2. I understand this video but I want to continue my current dose.~3. I would like to speak to someone to understand more. Option 1) will enable the GP practice to initiate existing opioid reduction support, Option 2) will continue care and support as usual, and Option 3) will enable the team to offer more information."
223729296|NCT03715218|OTHER|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
223993555|NCT00001072|BIOLOGICAL|ALVAC-HIV MN120TMGNP (vCP300)|
223993556|NCT00001072|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
223993557|NCT00001072|BIOLOGICAL|rgp120/HIV-1 SF-2|
223993558|NCT02637323|DRUG|FX006 32 mg|Single 5 mL IA injection
223993559|NCT02637323|DRUG|TCA IR 40|Single 1 mL IA injection
223993560|NCT02437942|OTHER|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
223993561|NCT05010876|DRUG|C1 Inhibitor Human|standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units
223993562|NCT05010876|DRUG|Icatibant Injection|a single injection of 30 mg subcutaneously
223993563|NCT05010876|OTHER|Placebo|The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.
223993564|NCT01825577|DRUG|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
223993565|NCT06126679|PROCEDURE|1-year dietary and physical activity intervention of childhood obesity|"The 1-year lifestyle intervention includes intensive, family-based diet and physical activity counselling. Children with their parents meet the pediatrician two times, the specialist nurse five times and the clinical nutritionist three times during the 1-year intervention. One of the meetings with the clinical nutritionist is only for parents and the child is with the nurse at the same time.~The participants in the intervention group are advised and motivated to increase their regular daily physical activity and to reduce sedentary habits. They have one group session for the training in the gymnasium with physical education instructor. The physical education instructor gives a voluntary lecture for parents about increasing physical activity and reducing sedentary time."
223993566|NCT03202680|OTHER|USDA Style Diet|USDA style healthy diet, low in saturated fats.
223993567|NCT03202680|OTHER|Lean Beef Diet|A lean beef containing healthy diet, low in saturated fats.
223993568|NCT04969705|DRUG|Dexmedetomidine|"60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) ."
223993569|NCT05390177|BEHAVIORAL|Video type|One of two videos presenting health research findings (each 2.5 minutes in length) will be shown to a participant.
223993570|NCT00358644|DRUG|Decitabine|20 mg/m\^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
223993571|NCT01121705|DRUG|Peg Interferon alpha2b + Ribavirin|"B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"
223993572|NCT00064142|DRUG|halofuginone hydrobromide|Applied topically
223993573|NCT00064142|OTHER|placebo|Applied topically
223993574|NCT00064142|OTHER|laboratory biomarker analysis|Correlative studies
223993575|NCT00064142|OTHER|pharmacological study|Correlative studies
223993576|NCT00911651|DRUG|Salbutamol|400 µg inhalation once
223993577|NCT00911651|DRUG|ipratropium bromide|80 µg inhalation once
223993578|NCT00513708|BEHAVIORAL|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
223993579|NCT00513708|BEHAVIORAL|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
223993580|NCT05719753|DEVICE|Camstent Coated Catheter|The Camstent Coated Foley Catheter is an all-silicone two-way Foley-type urinary catheter, to which a proprietary polymeric coating has been applied.
223993581|NCT05719753|DEVICE|Standard Care|Bard Catheter
223993582|NCT03377296|OTHER|Plasmodium vivax infection|Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.
223993583|NCT03377296|PROCEDURE|Collection of 250mL blood from each volunteer (N=2)|Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
223993584|NCT02866032|DRUG|MOB015B|
223993585|NCT02866032|DRUG|Ciclopirox 80 mg/g|
223993586|NCT06089005|DEVICE|Instrument Assisted Soft Tissue Mobilization device|Application of IASTM tool on specific muscle areas twice daily for intervention protocol of 7 days
223993587|NCT03327831|DRUG|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
223993588|NCT02164903|OTHER|QoL Survey Booklet|
224295027|NCT02712333|BEHAVIORAL|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
223993589|NCT01059162|DEVICE|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
223993590|NCT01162486|DRUG|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
224295028|NCT02712333|BEHAVIORAL|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
224295029|NCT02199678|DRUG|Placebo|placebo
224295030|NCT02199678|DRUG|ketamine 25 mg|ketamine
223993591|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
223993592|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
223993593|NCT01162486|DRUG|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
223993594|NCT01162486|DRUG|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
223993595|NCT01162486|DRUG|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
224295031|NCT02199678|DRUG|ketamine 35 mg|ketamine
224295032|NCT02199678|DRUG|ketamine 50 mg|ketamine
224295033|NCT04975074|DRUG|Iron|One of each type of iron was taken orally according to the instructions and followed every two weeks
224295034|NCT00932230|OTHER|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
224295035|NCT06285630|OTHER|Observational, no intervation will be made|No intervention will be made, only longitudinal sample collection.
223545057|NCT01991379|DRUG|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
223545058|NCT01991379|DRUG|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
223545059|NCT01991379|OTHER|Blood draws|
224295036|NCT00683267|DRUG|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
224295037|NCT00683267|DRUG|Placebo|One dose administered by direct instillation into the surgical site
224295038|NCT00149188|DRUG|Lanreotide (Autogel formulation)|
224295039|NCT02709954|DRUG|Active inhaled delta-9-THC|"Low dose THC (\~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
224295040|NCT02709954|DRUG|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
224295041|NCT02709954|DRUG|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
224295042|NCT02709954|DRUG|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
224295043|NCT05308264|DRUG|R906289 Monosodium (R289 Na)|Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)
223545060|NCT01991379|PROCEDURE|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
223545061|NCT05670912|DRUG|Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
223729297|NCT02189746|OTHER|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
223993596|NCT01790919|BEHAVIORAL|Cognitive therapy for depression|"Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory."
223993597|NCT03308175|DEVICE|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
223993598|NCT03308175|DEVICE|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
223993599|NCT00607581|DRUG|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
223993600|NCT00607581|DRUG|lenalidomide|lenalidomide: 15 mg orally on days 1-21
223993601|NCT00607581|DRUG|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
223993602|NCT02588872|BIOLOGICAL|Platelet-rich Plasma (PRP)|
223993603|NCT02588872|BIOLOGICAL|Hyaluronic Acid|
223993604|NCT06453070|OTHER|No intervention was made|No intervention was made
223993605|NCT06273280|PROCEDURE|SOC|Physician-guided GDMT up-titration
223993606|NCT06273280|PROCEDURE|Protocolized up-titration|Renal-based protocolized GDMT up-titration
223993607|NCT04600986|OTHER|Repeated dose of GnRH agonist|0.2 mg triptorelin plus a repeat dose of 0.1 mg 12 hours following the first dose.
223993608|NCT01998789|DRUG|Everolimus|Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
224295044|NCT03654664|BIOLOGICAL|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
223545062|NCT05670912|DRUG|Placebo Comparator of Wei Li Bai capsules|The distribution ratio between the groups was 1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the active group or placebo group will be determined by the randomized system.
223545063|NCT05828186|DEVICE|Shockwave Coronary Intravascular Lithotripsy (IVL) catheter|Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of Shockwave IVL catheter treatment by their physicians.
223545064|NCT05973201|DEVICE|Virtual reality headset|"A HEALTHY MIND® brand VR headset is dedicated to the study. The kit includes a noise-reducing audio headset, a face mask diffusing the visual part, a touchscreen tablet connected to the two VR headset systems, and a microphone connected to the tablet.~The available software allows patients to choose between 5 natural environments in which a hypnotic speech is broadcast, available in several languages (French, English, Spanish, Russian, Arabic)."
223993609|NCT01998789|DRUG|Standard Tacrolimus|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
223993610|NCT02770729|DRUG|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
223993611|NCT02770729|DRUG|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
223993612|NCT05114343|BEHAVIORAL|Exercise|Participants will perform weight-bearing exercises for 12 weeks. The intervention will be delivered remotely through video calling with an exercise specialist.
223993613|NCT04781270|DRUG|mFOLFOXIRI regimen|oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
223993614|NCT04781270|DRUG|mFOLFOX regimen|oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
223993615|NCT04781270|DRUG|Bevacizumab|5 mg/kg on day 1
223993616|NCT03332784|DRUG|TAK-925|TAK-925 Intravenous Infusion
223993617|NCT03332784|DRUG|Placebo|TAK-925 Placebo Intravenous Infusion
223993618|NCT02727153|OTHER|"Ultra E.R.A.S."|
223993619|NCT02727153|OTHER|Classic E.R.A.S.|
224122440|NCT04293874|BEHAVIORAL|Personalized Meal Plan|Personalized dietary plans will be developed incorporating the NPAGCS, while personalizing the plan based upon anthropometric characteristics, gender, age and self-reported activity level upon entry into the investigation, goals, typical dietary consumption patterns, and food preferences. A trained research assistant will use the USDA MyPlate88 site (www.choosemyplate.gov) to enter participant characteristics and determine the appropriate calorie level. A daily checklist will be then generated outlining the number of daily servings that should be consumed for each food group. Information will also be provided regarding serving sizes for different foods in the respective food groups and education will be provided regarding tailoring personal dietary preferences to meet the guidelines. Participants will be provided with a printed copy of their meal plan and instructed to initiate it for a 8-week period.
224122441|NCT04293874|BEHAVIORAL|Dietary Omega-3LC intervention|Following randomization, participants will be provided with fish to be consumed for 6 weeks. As a component of the dietary intervention, participants in high and low omega-3LC group will be provided with frozen, wild caught salmon (or if they dislike salmon, prepackaged, individual use foil packs of chunk light tuna). Salmon and chunk light tuna were chosen due to high omega-3LC content, low methylmercury content, low cost and ease of use. Vacuum packed, frozen salmon will be delivered to participants in large freezer bags and instructed to arrange visit times to ensure they can go directly home following the visit. Instructions for safe storage, fish handling and recipes to avoid fatigue of fish will be also be provided to participants when they receive the fish.
224122442|NCT02228278|BEHAVIORAL|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
224295045|NCT03654664|BIOLOGICAL|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
223993620|NCT00401258|DRUG|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
223993621|NCT06086288|DRUG|Pembrolizumab, Etoposide, Cisplatin or Carboplatin|Induction Phase (4 cycles, 1Cycle=3W): Pembrolizumab 200 mg + Etoposide + Cisplatin or Carboplatin; Maintenance Phase (16 Cycles, 1Cycle=6W): Pembrolizumab 400 mg
223545065|NCT03129464|DEVICE|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
223545066|NCT05008705|DIETARY_SUPPLEMENT|Protein supplementation|Patients will receive diary 2 doses of the protein supplement
223545067|NCT05008705|DEVICE|Neuromuscular electrostimulation.|Patients will receive diary sessions of neuromuscular electrostimulation.
223993622|NCT06047574|OTHER|This study does not involve any interventions|This study does not involve any interventions
223545068|NCT05008705|DIETARY_SUPPLEMENT|Placebo (isocaloric supplement)|Patients will receive diary 2 doses of the isocaloric supplement
223545069|NCT05008705|DEVICE|Sham for neuromuscular electrostimulation.|Patients will not receive neuromuscular electrostimulation.
223993623|NCT02469142|PROCEDURE|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
223545070|NCT05858177|DRUG|Temozolomide capsule|Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
223545071|NCT04023942|BEHAVIORAL|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
223993624|NCT00788970|BEHAVIORAL|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
223545072|NCT05525741|OTHER|Non segmental vitiligo|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
223993625|NCT02497989|OTHER|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
223993626|NCT02497989|OTHER|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
223993627|NCT01133080|DRUG|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
223993628|NCT01133080|DRUG|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
223993629|NCT01328353|OTHER|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
223993630|NCT03913572|PROCEDURE|Injection of adipose-derived stem cells into perianal fistula|The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
223729298|NCT02189746|OTHER|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
223993631|NCT00292968|BEHAVIORAL|Computer based care|
223993632|NCT00292968|BEHAVIORAL|Telephone counseling|
223993633|NCT00292968|BEHAVIORAL|Group visits|
223993634|NCT00292968|BEHAVIORAL|Usual care|
223993635|NCT04118881|OTHER|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
223993636|NCT02259023|OTHER|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
223993637|NCT02259023|OTHER|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
223993638|NCT01357122|DEVICE|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
223993639|NCT01357122|PROCEDURE|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
223993640|NCT01430468|PROCEDURE|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
223993641|NCT00391703|BEHAVIORAL|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
223993642|NCT00391703|BEHAVIORAL|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
223993643|NCT04874753|OTHER|change in kidney function and proteinuria|change in eGFR nad proteinuria in patients with chronic kidney disease
223993644|NCT03570723|PROCEDURE|A glove-loaded Foley's catheter tamponade|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
223993645|NCT03570723|PROCEDURE|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
223993646|NCT02984007|BEHAVIORAL|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
223993647|NCT02984007|OTHER|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
223993648|NCT04766723|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223993649|NCT04766723|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223993650|NCT03556800|DRUG|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel"
224122443|NCT02228278|OTHER|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
223993651|NCT00343070|DRUG|Oral administration of escitalopram during 8 weeks|
223993652|NCT00360295|DRUG|Azithromycin SR|
223993653|NCT04309591|DEVICE|CytoSorb haemoadsorption (HA) device|CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
223993654|NCT00122213|BEHAVIORAL|Behavior change on physical activity and diet|
223993655|NCT01549834|DRUG|ABT-126|Low Dose
223993656|NCT01549834|DRUG|ABT-126|High Dose
223993657|NCT01549834|DRUG|placebo|Placebo
224122444|NCT05366855|BIOLOGICAL|Imsidolimab|Solution for infusion; Solution for injection
223993658|NCT03949400|OTHER|Exercise therapy and education.|Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
223993659|NCT02546297|DRUG|Symbicort|drug are used for 12 months
223993660|NCT02546297|DRUG|Spiriva|drug are used for 12 months
223993661|NCT04239677|PROCEDURE|Conventional crystalloid solution-based priming|CPB circuit is also prepared with crystalloid solution-based priming in all participants (same as the RAP group). In this group (control group), CPB is initiated with antegrade priming (conventional priming).
223993662|NCT04239677|PROCEDURE|Retrograde autologous priming|CPB circuit is prepared with crystalloid solution-based priming in all participants. In RAP group, retrograde autologous priming is performed by displacing the crystalloid priming volume of arterial and venous lines via passive exsanguination of native blood prior to CPB initiation.
224122445|NCT05366855|OTHER|Placebo|Solution for injection
224122446|NCT06858813|DRUG|Lenvatinib|Oral Capsule
223993663|NCT04356534|OTHER|plasma therapy using convalescent plasma with antibody against SARS-CoV-2|convalescent patient plasma plus routine local standard of care
223993664|NCT04356534|OTHER|Routine care for COVID-19 patients|local standard of care which include antivirals and supportive care
224122447|NCT06858813|DRUG|ABBV-324|Intravenous (IV) Infusion
223993665|NCT01004523|GENETIC|fluorescence in situ hybridization|
224122448|NCT06992804|OTHER|NirsCure with Lecanemab|Near-infrared light therapy (one session per day, 30 minutes per session, 6 sessions per week) combined with lecanemab (10mg/kg).
224122449|NCT06992804|OTHER|sham NirsCure with Lecanemab|Sham near-infrared light therapy (where only the equipment appearance is consistent with the true near infrared light device, one session per day, 30 minutes per session, 6 sessions per week) in combined with lecanemab (10mg/kg).
224295046|NCT02686203|DEVICE|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
224295047|NCT00136318|DRUG|Escitalopram|
224295048|NCT00136318|DRUG|Placebo|
224295049|NCT00136318|DRUG|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
224295050|NCT00136318|DRUG|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
224295051|NCT01835379|DEVICE|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
223993666|NCT01004523|GENETIC|loss of heterozygosity analysis|
223993667|NCT01004523|GENETIC|polymerase chain reaction|
223993668|NCT01004523|OTHER|flow cytometry|
223993669|NCT01004523|OTHER|immunohistochemistry staining method|
223993670|NCT04743531|BEHAVIORAL|HEROs|Intervention Description: The intervention will consist of a 6-week family workshop series, held one evening per week for six consecutive weeks. The intervention modules will be delivered by trained researchers at two preschool sites in rural Colorado in Fall 2019 and Spring 2020. The primary caregiver and preschool child will be the targets of the study. Each of the workshops will be structured to include joint caregiver-child activities and programming that is tailored for caregivers and children individually. Caregivers will learn about and engage in activities related to healthy eating and picky eating; physical activity and motor development; and parenting strategies. Children will participate in activities focused on healthful eating and physical activity that supports content their parents are learning.
223993671|NCT05299255|DRUG|Utidelone|Utidelone Versus placebo in Third-line and above treatment of Extensive Small-cell Lung Cancer
224122450|NCT06992804|OTHER|NirsCure with Lecanemab|Near-infrared light therapy (one session per day, 30 minutes per session, 6 sessions per week) combined with lecanemab (10mg/kg).
224122451|NCT00552539|OTHER|'educational video'|'educational video'
224122452|NCT06600659|OTHER|Non-Interventional Study|Non-interventional study
224122453|NCT06991153|DEVICE|Lung Boost Device Training|Patients in the experimental group will train with the Lung Boost Respiratory Trainer (MD800) for 8 weeks, three times weekly, totaling 24 sessions. The procedure will be explained, and equipment sanitized before use. Training begins in strength mode at level 1, where patients inhale deeply through a mouthpiece, with feedback provided via on-screen balls. If level 5 is easily reached, resistance increases using a cone, restarting at level 1. Sessions include 15 repetitions of 2-3 second inhalations and exhalations, performed in three sets with 15-second rests to prevent fatigue. In endurance mode, patients inhale or exhale as long as possible, progressing gradually from level 1. Each session lasts 15 minutes, divided into three sets of five breaths with 15-second rests. This structured program enhances respiratory muscle strength and endurance.
223993672|NCT05299255|DRUG|Placebo|the placebo as control group.
224122454|NCT06991153|OTHER|Traditional physical therapy program|Patients in both groups will receive a traditional physical therapy program for the chest in form of diaphragmatic breathing exercise and pursed-lip breathing exercise for 8 weeks.
224122455|NCT06991153|DRUG|Medical Treatment|Patients in both groups will receive medical treatment for 8 weeks.
224295052|NCT01835379|OTHER|Standard|
224295053|NCT04845906|DEVICE|StatLock™ Catheter Stabilization Device and the StatLock™ stabilization device accessory (Foam Strip)|Each participant will have 2 separate devices applied, one to each arm, with or without a Foam Strip.The participant will also wear a dressing over top of a StatLock™ compatible catheter, which will be connected to an extension set. For this study, the catheter will not be inserted into the study participant but instead will be shortened or modified and placed on the skin and secured with the StatLock™ Stabilization Device. The use of the catheters, extension set, and the dressing represents how the device would be used in a clinical setting.
224295054|NCT06254144|BEHAVIORAL|functional magnetic resonance imaging (fMRI)|The investigators will utilize standard BOLD fMRI in blocked-design tasks and resting state (participant is given no overt task) in the study. Anatomical scans with T1-weighted contrast, quantitative measurement of spin relaxation times, and diffusion tensor imaging (DTI) are also used as an anatomical reference for functional activation as well as to investigate a brain structural relationship with the participants' task performance, including successful emotion regulation.
223993673|NCT01788293|OTHER|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports \[Cannesson et al., 2008; Zimmermann et al., 2010\].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
223993674|NCT05165927|DEVICE|BFR|BFR cuffs will be used at home during specified exercises in addition to SOC for post hip scope PT.
224295055|NCT05272982|DIAGNOSTIC_TEST|Thoracic fluid content by electrical cardiometry group|Thoracic fluid content will be measured using electrical cardiometry device (ICON ® Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). The ICON device will be connected to four electrocardiogram electrodes which will be placed over patients' skin after cleaning with alcohol at the neck below the left ear, just above the left clavicular midpoint, and two electrodes at left mid-axillary line one at the level of the xiphoid process, and the other electrode 5 cm below this point. The thoracic fluid content will be observed for 30 s and the average of the highest and lowest values will be recorded.
223993675|NCT05170815|PROCEDURE|Spine surgery|Implantation of spine Interbody Fusion Devices and/or Posterior fixation System.
223993676|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
223993677|NCT00348387|BIOLOGICAL|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
223993678|NCT02907437|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
223993679|NCT02907437|DRUG|Placebo|(200 mg/day)
223993680|NCT02907437|OTHER|Probiotics|(450 mg/day)
223993681|NCT03013140|DRUG|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%"
223993682|NCT03013140|PROCEDURE|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
223993683|NCT03722511|DIETARY_SUPPLEMENT|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
223545073|NCT05525741|OTHER|Health Volunteers|"The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit.~The Investigator:~* Inform the subject of the goals, constraints and risks of the study and obtain written consent.~* Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including.~If the subject consents and they meet all the criteria a 20 ml blood sample will be taken."
223993684|NCT01495910|DRUG|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
223993685|NCT05284955|DEVICE|CardioMEMS HF System|The CardioMEMS HF System is a wireless pulmonary artery pressure monitor. We will use measurements from the device to guide medical heart failure therapy.
223993686|NCT05284955|DRUG|Standard heart failure medical therapy|Standard heart failure medical therapy as recommended by guidelines.
223993687|NCT05672771|BEHAVIORAL|Different Mixed Condition (DM)|Participants engage in home-based training on two working memory tasks, both different from those in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
223993688|NCT05672771|BEHAVIORAL|Different Single Condition (DS)|Participants engage in home-based training on a working memory task that is different from that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
223993689|NCT05672771|BEHAVIORAL|Same Task (ST) Practice Control|Participants engage in home-based training on the exact same working memory tasks as that in the target task training. Goal is 10 days of training, with 4 8-min blocks of training each day.
223993690|NCT05672771|BEHAVIORAL|Non-WM Placebo Control (PC)|Participants engage in home-based training on speeded verbal decision, which unlike the target task training, has no memory component. Goal is 10 days of training, with 4 8-min blocks of training each day.
223993691|NCT01838954|DEVICE|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
223993692|NCT00760747|DRUG|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
223993693|NCT01443923|DRUG|Boceprevir|
223993694|NCT01443923|DRUG|Peg-Interferon-alfa 2B|
223993695|NCT01443923|DRUG|Ribavirin|
223993696|NCT00902811|DRUG|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
223993697|NCT00902811|DRUG|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
223993698|NCT00902811|DRUG|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
223993699|NCT00902811|DRUG|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group \<6yrs of age, a subdivision according to weight is made
223993700|NCT00902811|DRUG|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
223993701|NCT00000104|PROCEDURE|ERP measures of attention and memory|
223993702|NCT02498262|OTHER|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
223993703|NCT01642433|DRUG|Placebo|Placebo capsules, 3x daily
223993704|NCT01642433|DRUG|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
223993705|NCT00323206|BIOLOGICAL|IL-12p DNA|Plasmid IL-12 will be administered as an intratympanic (IT) injection.
223993706|NCT00323206|PROCEDURE|Intratumoral Electroporation|The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
223993707|NCT02761447|OTHER|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
223993708|NCT02761447|OTHER|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
223993709|NCT05440747|OTHER|TFR(Treatment-Free Remission)|Withdrawal TKIs(Tyrosine kinase inhibitors: Imatinib or Flumatinib or Nilotinb or Dasatinib)
223993710|NCT01082237|DRUG|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
223993711|NCT06319183|DRUG|Salbutamol|We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
223993712|NCT01303315|DEVICE|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
223993713|NCT02808247|DRUG|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
223993714|NCT02808247|DRUG|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
223993715|NCT00108745|OTHER|Clinical Observation|Undergo observation
223993716|NCT00108745|OTHER|Laboratory Biomarker Analysis|Correlative studies
223993717|NCT00108745|DRUG|Paclitaxel|Given IV
223993718|NCT00108745|DRUG|Paclitaxel Poliglumex|Given IV
223993719|NCT00108745|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223993720|NCT00307476|DEVICE|Rusch Nasopharyngeal Airway|For placement of rectal trumpet (Rusch nasopharyngeal airway-32FR): Patient's skin is cleansed with Smith and Nephew Personal cleanser and rinsed thoroughly with water to remove any soap residue and dried. Apply 3M no sting barrier film to provide skin protectant. Attach the shaft end of the trumpet to a urinary drainage bag. Using hemostats, clamp the tubing beneath the sample port of the drainage bag. Instill 5cc of mineral oil through the flange end of the trumpet, being careful not to over fill or spill mineral oil onto flange. Release the clamp and allow the mineral oil to drain into urinary drainage bag. If possible, place patient into side-lying position with knees drawn toward the chest. Fold flange into quarters, insert into the rectum. Pull back gently until there is slight resistance. Secure the drainage bag to the bed frame. Drainage tubing should be positioned to prevent tension or pull on trumpet.
224295056|NCT05272982|DIAGNOSTIC_TEST|Ultrasound examination group|The 12-region technique for lung assessment will be performed using Philips ® (CX50 - Extreme edition) equipped with phased array transducer. B-line will be defined as laser like vertical hyperechoic artefact which extends between the pleural line and the bottom of the screen and moves with respiratory movements. Two types of B-lines will be evaluated.
224295057|NCT06046248|DRUG|Belumosudil|200mg PO QD x 24 cycles (28-day cycle)
224295058|NCT06046248|DRUG|Rituximab|375mg/m2 IV Q1 week x 4 weeks, then Q3 months x4 doses
224295059|NCT06849648|DEVICE|The Buzzy Device|In essence, the Buzzy device offers a multi-sensory approach (vibration + cold) in conjunction with a hygienic protocol, which is a key differentiator from other non-pharmacological interventions such as distraction through toys, videos, or verbal techniques. Currently, there is no studies evaluating the use of the Buzzy device and finger puppets, which are nonpharmacologic methods, in relation to the levels of pain, fear, and anxiety in children aged 4-7 years undergoing venipuncture procedures in emergency department settings.
223545074|NCT06313203|DRUG|Floxuridine|A laparotomy will be performed and a catheter placed in the hepatic artery Connected to a subcutaneous pump. This pump will be percutaneously filled with Floxuridine 6 times in 2 weeks cycles, alternating with heparin-solution. The patients in this arm will also be given GemOX as systemic chemotherapy
223545075|NCT06313203|PROCEDURE|Selective Internal Radiation Therapy (SIRT)|Radioactive Yttrium 90 (Y-90) labeled particles are injected selectively into the feeding arteries of the tumour(s). This allows a high radiation dose in the lesions while limiting systemic side effects.
223993721|NCT01889069|DRUG|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
223993722|NCT01889069|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
223993723|NCT01889069|DRUG|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
223993724|NCT01889069|DRUG|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
223993725|NCT01889069|DRUG|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
223545076|NCT03333356|RADIATION|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
223545077|NCT01293812|DRUG|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
223545078|NCT01293812|DRUG|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
223545079|NCT03495934|DRUG|pracinostat|\[14C\]-pracinostat
223545080|NCT04700150|OTHER|Tai Chi 2 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
223545081|NCT04700150|OTHER|Tai Chi 4 month|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
223545082|NCT05829837|OTHER|Ultrasonographic evaluation|Ultrasonographic evaluation for the thickness of piriformis muscle
223545083|NCT02136784|DRUG|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
223545084|NCT02136784|DRUG|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
223545085|NCT02136784|DRUG|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
223545086|NCT02136784|DRUG|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
223545087|NCT02136784|DRUG|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
223545088|NCT02136784|DRUG|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
223545089|NCT02136784|DRUG|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
224295060|NCT06849648|DEVICE|Finger Puppet|Finger puppets were used to distract the participants during venepuncture procedure. Children are allowed to pick their favourite animals. These soft in various shaped finger puppets can be placed on adult's fingers. One minute before the venipuncture procedure, the researcher (K.O.) engaged the participants in finger puppet play and initiated conversation by asking; 'Hello, how are you? What is this figure? Do you know where this animal/figure live in? Have you previously seen this animal/figure alive? Have you been in a zoo? Additionally, techniques such as having the animals 'sing' or 'interact' with each other were employed to capture the child's attention on the finger puppets. Children in this group were not given any distraction techniques prior to the procedure. All groups' parents accompanied over their children during the process, but they were not permitted to comfort them.
223993726|NCT01889069|DRUG|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
223545090|NCT02025790|PROCEDURE|Per Oral Endoscopic Myotomy (POEM)|"* Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~* Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~* Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~* Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~* Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
223545091|NCT02025790|PROCEDURE|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
223545092|NCT03198156|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
224295061|NCT01884064|DEVICE|rTMS|rTMS
223545093|NCT03198156|DEVICE|Sham stimulation|Sham stimulation
223993727|NCT00665093|DRUG|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
224295062|NCT01884064|DEVICE|Sham rTMS|Sham rTMS
224295063|NCT01164215|DRUG|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
224295064|NCT01164215|DRUG|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
223993728|NCT00665093|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
223993729|NCT03302390|PROCEDURE|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than \<3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
223993730|NCT06339749|DIAGNOSTIC_TEST|blood pressure|Based on first-trimester BP measurements, pregnant women were reclassified as normotensive (systolic BP \< 120mmHg and diastolic BP \<80mmHg on at least two occasions) and stage 1 hypertensive (systolic BP 130-139 mmHg and/or diastolic BP 80-89 mmHg on at least two occasions, without a diagnosis of chronic hypertension and/or elevated BP).
223993731|NCT06339749|OTHER|Clinical protocols for preeclampsia risk screening|"In this study, the risk factors of preeclampsia in pregnant women with combined maternal factors, MAP and PLGF were comprehensively analyzed by the Bayesian rule developed by the British Fetal Medicine Foundation (FMF). The online calculation website is: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester."
223993732|NCT00723749|DRUG|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine \& 0.5 mg naloxone and 8 mg buprenorphine \& 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
223993733|NCT06156917|DIAGNOSTIC_TEST|diagnostic accuracy|Aims of the present project are: to investigate the relationship between incident PD dementia and multimodal parameters as cardiovascular autonomic dysfunction, altered cerebral glucose metabolism, and genetic biomarkers; development of an algorithm predictive for PD-related dementia, combining the rele- vant multidimensional parameters under study; longitudinal follow-up of clinical and cognitive status in PD patients with and without dementia along four years.
224295065|NCT01164215|DRUG|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
223993734|NCT01426347|DRUG|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
223993735|NCT01426347|DRUG|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
223993736|NCT00455741|DRUG|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
223993737|NCT00455741|DRUG|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
223993738|NCT05102058|DRUG|Magnesium-Dexmedetomidine|Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively
223993739|NCT01292304|DRUG|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
224122456|NCT01494961|BEHAVIORAL|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
224122457|NCT05372575|BIOLOGICAL|PCV13 PAC study|To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
224122458|NCT00009594|PROCEDURE|Naturopathic Medicine|
224122459|NCT00009594|PROCEDURE|Traditional Chinese Medicine|
224122460|NCT00632034|OTHER|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
224122461|NCT00004640|DRUG|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
224122462|NCT00170157|DRUG|Bicalutamide|Given orally
224122463|NCT00170157|DRUG|Flutamide|Given orally
224122464|NCT00170157|DRUG|Goserelin Acetate|Given SC
223545094|NCT05424601|BEHAVIORAL|Rethink game|REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention to reduce emotional symptoms of children and adolescents.
223545095|NCT05424601|BEHAVIORAL|PsyPills|PsyPills is a mobile app designed to provide personalized psychological pills
223993740|NCT02903017|DRUG|Tranexamic acid 5%|Via nasogastric tube, 100 mL
223993741|NCT02903017|DRUG|Placebo|Via nasogastric tube, 100 mL
223993742|NCT01606410|OTHER|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
224122465|NCT00170157|DRUG|Ipilimumab|Given IV
224122466|NCT00170157|DRUG|Leuprolide Acetate|Given IM
224122467|NCT00170157|OTHER|Pharmacological Study|Correlative study
224122468|NCT02495649|OTHER|[18F]-DOPA|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
223993743|NCT04682132|DIAGNOSTIC_TEST|COVID-19 antigen and antibody tests, and influenza rapid test|Study volunteers will be offered free COVID-19 and influenza testing and the opportunity to complete an electronic survey about any symptoms.
223993744|NCT02332902|DRUG|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
223993745|NCT02043743|BIOLOGICAL|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
223993746|NCT03998449|BIOLOGICAL|Vaccination against cholera|Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
223993747|NCT04865042|DRUG|Gabapentin 300mg|"The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
223993748|NCT04865042|DRUG|PLACEBO|"The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed."
223993749|NCT01160627|OTHER|Hydration|Saline hydration
223993750|NCT01160627|DRUG|Acetylcysteine|Acetylcystein tablets for 2 days
223993751|NCT01160627|DRUG|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
224122469|NCT02495649|DEVICE|PET-CT|To evaluate the feasibility of PET-CT with \[18F\]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
224122470|NCT05592470|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).|Reverse transcription-quantitative polymerase chain reaction on bone marrow aspirates to detect The expression pattern of COMMD7 gene in acute lymphoblastic leukemia
224122471|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
224122472|NCT00687154|PROCEDURE|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
223545096|NCT04743713|OTHER|UWRI-Tr|Questionnaire
223545097|NCT02520778|DRUG|Navitoclax|Given PO
223545098|NCT02520778|DRUG|Osimertinib|Given PO
223993752|NCT01160627|DRUG|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
223993753|NCT05345730|DIAGNOSTIC_TEST|3 DImensional Late Enhanced Gadolinium cardiac MRI scan|A cardiac MRI scan is made using late gadolinium enhancement to detect atrial fibrosis in the left atrium.
223993754|NCT00002341|DRUG|Itraconazole|
223993755|NCT05614518|DRUG|Sodium Fluoride F-18 Injection|Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.
223545099|NCT03841942|OTHER|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
223993756|NCT05614518|DRUG|Technetium[99mTc] Methylenediphosphonate Injection|Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
223993757|NCT00574418|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
223993758|NCT02848768|DRUG|Sunitinib|
224122473|NCT02729454|OTHER|Mental practice and physical therapy|
224122474|NCT02729454|OTHER|physical therapy|
224122475|NCT02114632|DIETARY_SUPPLEMENT|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
224122476|NCT02703805|OTHER|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
224122477|NCT02703805|OTHER|Standard YMCA membership|A 12 week standard YMCA membership.
224122478|NCT02436486|DRUG|Placebo|Capsules, orally, single dose
223993759|NCT01245374|DEVICE|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
223993760|NCT01476605|PROCEDURE|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
223993761|NCT01476605|PROCEDURE|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
223993762|NCT01476605|PROCEDURE|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
223993763|NCT02762188|DEVICE|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
223993764|NCT01568125|DRUG|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
223993765|NCT00935532|DRUG|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
223993766|NCT00935532|DRUG|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
223993767|NCT06211777|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223729299|NCT02189746|OTHER|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
223729300|NCT02189746|OTHER|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
223993768|NCT06211777|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223994457|NCT04626349|OTHER|iFOCUS (web-based intervention)|"Self-managed psycho-educational intervention that is completed autonomously by the patient-caregiver dyads together. It encompasses four sessions (with three weeks between each session) over a period of 12 weeks.~The sessions are completed simultaneously by the patient and the family caregiver, sitting side by side at a computer. Patient-caregiver dyads have flexibility as to when they want to complete the intervention session. Based on the information patients and caregivers provided at enrollment and during the web-based sessions, they receive tailored individual and dyadic messages. An online personal workbook is provided containing the results of the interactive exercises that are provided to the dyads during the web-sessions. Any information brochures, leaflets and information sheets that the dyad indicated as 'of interest to them' during the web-sessions will be included as a hyperlink in their personal workbook."
223729301|NCT03120546|DEVICE|rigid video stylet intubation|intubation using rigid video stylet
223729302|NCT03120546|DEVICE|video laryngoscope intubation|intubation using video laryngoscope
223729303|NCT03486132|PROCEDURE|repair of episiotomy|Different techniques for repair of episiotomy incsicion
223729304|NCT00937443|OTHER|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
223729305|NCT00937443|BIOLOGICAL|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
223993769|NCT06211777|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223993770|NCT01935752|OTHER|blood samples|blood samples
223993771|NCT01935752|OTHER|vascular echotracking|endothelial function study and virtual histology study
223993772|NCT06236633|PROCEDURE|Ischemic preconditioning|Embolization performed via a common right femoral or radial approach, depending on the patient's conformation. Minor complications such as hematoma at the puncture site are rare in less than 1% of cases, and serious complications are exceptional. Proximal occlusion of the inferior mesenteric artery, before its dividing branches, using material adapted to arterial occlusion according to anatomical findings. Proximal occlusion during embolization is evaluated by intravascular injection into the inferior mesenteric artery, and resumption of vascularization of the distal inferior mesenteric artery is controlled by the border arcade injecting into the superior mesenteric artery. In the event of a high-risk anatomical variant, or absence of a border arcade, no embolization will be performed and the patient will be excluded from the study; this will represent no more than 1-2% of patients (surgical series describing 0.83% of ischemia in connection with absence of a border arcade).
223994458|NCT02623998|DRUG|insulin glargine|Dose is titrated to achieve fasting normoglycemia
223994459|NCT02623998|DRUG|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
223994460|NCT02623998|BEHAVIORAL|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
224122479|NCT02436486|DRUG|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
223729306|NCT01951742|BIOLOGICAL|ANT-1401|Active
223729307|NCT01951742|BIOLOGICAL|Vehicle|Vehicle
223994461|NCT01535027|DRUG|teriparatide|teriparatide 20 ug/day, sc.
223994462|NCT01535027|DRUG|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
223994463|NCT01535027|DRUG|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
223994464|NCT03041792|DRUG|Liraglutide|Liraglutide
223994465|NCT03041792|OTHER|Placebo|Placebo
224122480|NCT02436486|DRUG|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
224122481|NCT02436486|DRUG|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
224122482|NCT00001262|DRUG|Copper Histidine|
224122483|NCT02200458|DEVICE|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
224122484|NCT06245577|DEVICE|interdisciplinary mesh sacro colpopexy with resection rectopexy|surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
223729308|NCT02201706|PROCEDURE|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
223729309|NCT01907880|DRUG|Pamidronate|90mg IV once every 4 weeks for 3 cycles
223729310|NCT01907880|DRUG|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
223729311|NCT01907880|DRUG|placebo|
223729312|NCT04565431|DRUG|Tysabri|Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.
223729313|NCT03900767|OTHER|Electronic Health Record intervention|AAC
223729314|NCT03900767|BEHAVIORAL|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
223729315|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive text messages
223994466|NCT05078177|DRUG|Rituximab|All patients receive AHSCT with RIC (Cyclophosphamide, Antithymocyte globulin/Rituximab). After resolution of cytopenia (approximately from about D+12 to D+14 AHSCT), patients will receive intrathecal Rituximab.
223993773|NCT06236633|PROCEDURE|Arteriogram|The interventional radiologist performs an arteriogram of the inferior and superior mesenteric arteries (IMA and SMA respectively) to check that the SMA is free of anomalies and that the IMA has a proximal trunk long enough for embolization. The radiologist also checks for the presence of a colonic border arcade. If this is absent, embolization will not be performed: the patient will be excluded from the study.This arteriogram is carried out under local anaesthetic specifically for research purposes, as follows: Common right femoral or radial approach and placement of a small introducer. Selective arteriogram of the inferior and superior mesenteric arteries to check perfusion of the border arcade.Arterial closure system or manual compression. Return to surgery or interventional radiology department. Patient discharged the same day after medical assessment (surgeon or interventional radiologist).Telephone check-up on Day1 (standard management) and Day 7 (added as part of the protocol).
223993774|NCT02592915|DRUG|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
223993775|NCT02592915|OTHER|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
223729316|NCT03900767|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls
223729317|NCT01014520|DRUG|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
223993776|NCT05445947|BEHAVIORAL|The EASEL (Enhancing And Supporting Early Development to Better Children's Lives) Approach|"The EASEL Approach consists of a set of educator-led practices that can be incorporated into the daily classroom environment for children three to six years of age. The overall purpose of this approach is to enhance early childhood educators' teaching practices that would promote children's SEB+EF development.~Nine EASEL practices were selected for inclusion in the EASEL Approach. These are a) core fundamental practices that are evidence-based, b) practices that expert stakeholders identified as ones for which local early childhood educators may need additional training, c) practices that are not already covered in pre-service training to avoid replication for educators, d) a combination of practices that educators may already be implementing and can enhance, and new practices, and e) a balance of antecedent and consequential practices (i.e., practices that can be implemented before and after a target behavior)."
223993777|NCT00658294|OTHER|Stop treatment|
223993778|NCT02809560|PROCEDURE|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
223993779|NCT00614562|DEVICE|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
223729318|NCT00469989|PROCEDURE|Infection with hookworm larvae|
223729319|NCT03625791|BIOLOGICAL|blood sample|1 tube with 4 ml of blood per patient
223729320|NCT03564847|BEHAVIORAL|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
223729321|NCT01554423|OTHER|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
223993780|NCT02280876|DRUG|1 - Andrographis paniculata p/st extract|"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile."
223993781|NCT02280876|DRUG|2 - Excipients|"Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile"
224122485|NCT05110898|DRUG|fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg|Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.
224122486|NCT05110898|DRUG|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)|Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
224122487|NCT04516486|OTHER|retrospective metagenomics on clinical samples collected during hospitalization|Massive sequencing of respiratory samples (restrospective)
224122488|NCT04227249|PROCEDURE|no lymph node dissection|do not undergo lymph node dissection
224122489|NCT00758927|DRUG|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
224122490|NCT00758927|DRUG|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
224122491|NCT04363086|BEHAVIORAL|iFightDepression online self-help tool|Computerized cognitive behavior therapy
223729322|NCT01554423|BEHAVIORAL|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
223993782|NCT02380053|DRUG|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
223993783|NCT02380053|DRUG|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
223993784|NCT00178854|DRUG|Risperidone|
223993785|NCT00000685|DRUG|Zidovudine|
223993786|NCT01422473|DEVICE|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
223993787|NCT05516043|PROCEDURE|Implantation with POLYTHESE®|thoracic vascular surgery, abdominal vascular surgery and peripheral vascular surgery
223993788|NCT04174209|BEHAVIORAL|Cylinder|Patients who receive the Jackson Cross Cylinder Method
224122492|NCT04363086|BEHAVIORAL|Treatment as Usual|TAU
224122493|NCT04363086|BEHAVIORAL|phone call|phone call
224122494|NCT00878072|DRUG|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
224122495|NCT00713401|DRUG|Tecadenoson|Tecadenoson administered intravenously (i.v.)
224122496|NCT00713401|DRUG|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
224122497|NCT04240067|DIAGNOSTIC_TEST|READ-MA Multimarker Approach|The presence or absence of ALSHF (gold standard used in the READ study) : diagnosis by 2 experts (cardiologist and emergency physician) based on data collected in the ED and during hospitalization (clinical examination, history, usual treatment, haemodynamic parameters, ECG, chest X-ray, emergency treatment, clinical and paraclinical results during hospitalization), biological assays (except NT-proBNP) and echocardiography (Left Ventricular Ejection Fraction, segmental kinetic, potential valvulopathy, transmitral flow, tissue doppler E' velocity) performed by a cardiologist within 24 hours of admission.
223993789|NCT04174209|BEHAVIORAL|Dial|Patients who receive the Astigmatic Dial Technique Method.
223993790|NCT04174209|BEHAVIORAL|Slit|Patients who receive the Stenopeic slit Method.
224122498|NCT04470310|DRUG|Glimepiride|
224122499|NCT04470310|DRUG|Alogliptin 25Mg Tab|
224122500|NCT04470310|DRUG|Alogliptin-Pioglitazone 25 Mg-15 Mg Oral Tablet|
224122501|NCT01280123|DRUG|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
224122502|NCT01280123|DRUG|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
223993791|NCT00656747|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
223993792|NCT00656747|DRUG|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
223993793|NCT00001046|BIOLOGICAL|MF59|
223993794|NCT00001046|BIOLOGICAL|rgp120/HIV-1 SF-2|
224122503|NCT01043523|DRUG|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
223545100|NCT03841942|OTHER|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI \< 150 for CD, Partial Mayo score \< 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
223993795|NCT00223275|DRUG|Naltrexone|
223993796|NCT04954326|DRUG|Lyophilized S95014|"Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
223993797|NCT04954326|DRUG|Liquid S95014|"Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol."
223993798|NCT00029224|DRUG|zoledronic acid|
223993799|NCT00475228|DRUG|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D\&E procedure and for arm 2 at 3-6 weeks post-procedurem
223993800|NCT05331469|DRUG|NPH basal insulin titration|Comparing both arms NPH basal insulin titration in reducing hba1c after 3 months
223993801|NCT03188653|OTHER|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
224122504|NCT02558881|PROCEDURE|Virtual colonoscopy|
224122505|NCT02558881|PROCEDURE|Colon capsule|
224122506|NCT01954121|DRUG|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~* Down-titration Period (Week 30 up to Week 33)"
223545101|NCT05827705|OTHER|need for Ephedrine hydrochloride|ephedrine dose in hypotension
223993802|NCT03188653|OTHER|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
223993803|NCT03188653|OTHER|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
223993804|NCT03188653|OTHER|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
223993805|NCT03188653|OTHER|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
223993806|NCT03188653|OTHER|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
223993807|NCT03188653|OTHER|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free \& Clear Liquid Cleanser
223993808|NCT03033758|OTHER|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
223993809|NCT04554537|BEHAVIORAL|SMART|A treatment program developed to address specific brain functions found to be crucial for the recovery following brain injury.
223993810|NCT04554537|BEHAVIORAL|Brain Health Workshop|A psychoeducation program designed to provide in depth information to participants about the neuroscience behind their TBI and PTSD and the symptoms and challenges they may experience.
223993811|NCT03763045|DRUG|Sildenafil|Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
223993812|NCT03763045|DRUG|Sildenafil|Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
223993813|NCT03763045|OTHER|Placebo|Placebo tablet.
223993814|NCT04721015|DRUG|ABBV-637|Intravenous (IV) Infusion
223993815|NCT04721015|DRUG|Docetaxel|Intravenous (IV) Infusion
223993816|NCT04721015|DRUG|Osimertinib|Oral Tablets
223993817|NCT05453162|BEHAVIORAL|Prolonged Exposure Therapy for Posttraumatic Stress Disorder|Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
223993818|NCT06630221|DRUG|Eltrombopag (EPAG)|50 mg, 28-day cycles, 3 initial cycles + 12 cycles on extension arm (maximum of 15 cycles)
223993819|NCT05425537|OTHER|Drowning incident|"Drowning is defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid"
223993820|NCT07047586|DRUG|Tislelizumab|Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223993821|NCT07047586|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223993822|NCT07047456|PROCEDURE|Time of umbilical cord blood infusion|Randomization of patients according to the time of umbilical cord blood infusion
223993823|NCT07050420|OTHER|Training|Education on Child Abuse and Neglect
223993824|NCT07049016|OTHER|restoring the MIH affected young permanent molars using Direct nanohybrid flowable composite|(Shofu)is a bioactive flowable nano-hybrid restorative with a newly developed patented nanofiller. It is indicated for all classes including occlusal and cusp. It has all of the Giomer Technology attributes, anti-bacterial, acid neutralization, and fluoride release and recharge, with improved handling and effortless polishing, and maintains a long-lasting shine. Beautifil Flow Plus X has the strength, durability, and aesthetics of a hybrid composite.
223993825|NCT07049016|OTHER|restoring the MIH affected young permanent molars using IPS e.max CAD|glass-ceramic-based restorations still offer the best translucency and esthetic qualities. The novel generation of lithium disilicate-based materials as IPS e.max CAD provides standard thickness and quick fabrication. Moreover, the adhesive technique used with this restoration type significantly raises its mechanical properties.
223993826|NCT07049120|DEVICE|ZENFLEX Pro™ Peripheral Drug-eluting Stent System|The ZENFLEX Pro™ Peripheral Drug-eluting Stent System will be implanted in patients with femoropopliteal artery lesions to evaluate safety and efficacy outcomes. The device is designed to provide mechanical support and deliver antiproliferative drug locally to reduce restenosis. The procedure will be performed via standard endovascular techniques.
223993827|NCT07049965|PROCEDURE|Suture ligation|Participants will undergo laparoscopic appendectomy in which the base of the appendix is ligated using intracorporeal suturing with absorbable material. This is the conventional technique used to prevent stump leakage.
223993828|NCT07049965|DEVICE|Harmonic Scalpel|Participants will undergo laparoscopic appendectomy where the base of the appendix is sealed and divided using the harmonic scalpel. This ultrasonic energy-based device cuts and coagulates tissue simultaneously, potentially reducing operative time and blood loss.
223993829|NCT07049211|DEVICE|Individualized online stimulation|The individualized online stimulation group will calculate precise targets based on the collected multimodal MRI (structural images, resting-state/task-state functional images, and diffusion tensor imaging), plan the coil position and placement angle of TMS through electric field simulation, and achieve individualized intervention. At the same time, when patients receive TMS treatment, they are matched with specific upper limb motor tasks. When the task starts autonomously, TMS stimulation is triggered by acceleration-EMG feedback. When the task stops or is completed, TMS stimulation also stops immediately according to the acceleration-EMG feedback to achieve real-time effects.
223993830|NCT07049211|DEVICE|Non-individualized online stimulation|In the non-individualized online stimulation group, patients receive TMS treatment synchronized with task training. However, the targeting uses traditional positioning methods, i.e., determining the target with a positioning cap instead of precise target localization.
223993831|NCT07049211|DEVICE|Sham stimulation|In the individualized online sham stimulation group, patients receive TMS treatment combined with specific tasks. The stimulation targets are the same as those in the online stimulation group, all determined by precise target localization, except that a sham stimulation coil is used for TMS stimulation.
223993832|NCT07049094|DRUG|scalp nerve block with 0.25% hydrochloride bupivacaine and 0.67% bupivacaine liposome solution|Using 0.25% hydrochloride bupivacaine and 0.67% bupivacaine liposome solution for scalp nerve block
223993833|NCT07049094|DRUG|scalp nerve block with 0.50% hydrochloride bupivacaine|Using 0.50% hydrochloride bupivacaine for scalp nerve block
223993834|NCT07050667|DEVICE|Cold atmospheric plasma|Treatment of chronic wounds with cold plasma
223993835|NCT07050667|DEVICE|Placebo treatment|Treatment of chronic wounds with the placebo device
223993836|NCT07050875|DEVICE|ABLE Exoskeleton|Participants will undergo a 10-session gait training program with the exoskeleton, twice a week for up to 6 weeks. Each session will last 60 minutes.
223993837|NCT07050459|DRUG|SIM0686|Administered intravenously
223993838|NCT07050459|DRUG|SIM0686|Administered intravenously
223993839|NCT06735820|DRUG|APG-115|Combination therapy of APG-115 and Selumetinib
223993840|NCT06735820|DRUG|Selumetinib|Combination therapy of APG-115 and Selumetinib
223993841|NCT07049614|DIAGNOSTIC_TEST|Diabetic Patients|"This group consists of 66 adult diabetic patients (Type 1 or Type 2) undergoing elective general surgical procedures. These patients will be managed as per standard clinical protocols, including preoperative evaluation, glycemic control assessment (via recent HbA1c and blood glucose levels), and administration of prophylactic broad-spectrum antibiotics-typically second-generation cephalosporins and metronidazole.~Postoperative follow-up will be conducted on Day 1, Day 7, and Day 14 to monitor for the development of surgical site infections (SSIs), which will be classified by the unit chief as superficial, deep, or organ/space infections."
224295066|NCT00466895|DRUG|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
223994467|NCT04996433|BEHAVIORAL|inpatient CBASP individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual CBASP therapy sessions (duration: 50 min per session).
224295067|NCT04000243|DIAGNOSTIC_TEST|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
223545102|NCT06176248|DRUG|Triamcinolone Acetonide|1 injection of local anaesthetic (5 ml levobupivacaine 2.5 mg/mL) opposite the subscapular nerve, under ultrasound control, in a lateral decubitus or sitting position. Subsequently, they underwent Xray-controlled arthrodistension by injection of 1 ml of Triamcinolone Acetonide, combined with 10 ml of visipaque 270 contrast medium and 5 ml of Xylocaine.
223545103|NCT06176248|DRUG|saline solution|intramuscular injection of 1 ml saline under ultrasound control under the same conditions as the experimental group. Subsequently, they will undergo Xray-controlled arthrodistension under the same conditions as the experimental group
223545104|NCT00708357|DRUG|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
224295068|NCT03910764|OTHER|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
223993842|NCT07049614|DIAGNOSTIC_TEST|Non-Diabetic Patients|This group includes 66 adult non-diabetic patients undergoing elective general surgical procedures at DHQ Hospital, Dera Ismail Khan. These participants will serve as the comparison group for evaluating the incidence and characteristics of postoperative surgical site infections (SSIs). All patients will receive standard preoperative assessments and prophylactic antibiotics (second-generation cephalosporins with metronidazole) as per institutional protocols. Postoperative follow-up will be carried out on Day 1, Day 7, and Day 14, and SSIs, if any, will be classified based on CDC criteria into superficial, deep, or organ/space infections
224295069|NCT05342649|PROCEDURE|P-CTG|soft tissue closure of extraction sockets was done by pediculated connective tissue grafts (P-CTG)
224295070|NCT05342649|PROCEDURE|CTG|soft tissue closure of extraction sockets was done by connective tissue grafts (CTG)
224295071|NCT01546649|DRUG|TAP-144-SR(6M)|
224295072|NCT01546649|DRUG|TAP-144-SR(3M)|
224295073|NCT00380549|DIAGNOSTIC_TEST|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
224295074|NCT05442242|PROCEDURE|Unicompartmental knee arthroplasty|Medial Unicompartmental knee arthroplasty
224295075|NCT05442242|PROCEDURE|High tibial osteotomy|Medial open wedge high tibial osteotomy
223993843|NCT06742333|DRUG|Bimekizumab|Bimekizumab 320mg given at weeks wk0, wk4, wk8 and wk12
223993844|NCT06742333|DRUG|Clobetasol|Once daily evening application of 0.05% of clobetasol ointment for up to 4 weeks
223993845|NCT06854393|DRUG|0.00025% Lacripep ophthalmic solution and Placebo|Participant will receive Lacripep in one eye and placebo in the other eye at the same time.
223993846|NCT06538194|PROCEDURE|Mesotherapy|For 1. group, a solution containing 1 cc each of lidocaine, pentoxifylline, vitamin B complex diluted 1/10 with saline, thiocolchicoside, and meloxicam diluted 1/5 with saline will be made. A 30 gauge, 4 mm mesotherapy injector will be used for the application. The lateral epicondyle will be the site of an intradermal injection. Of that amount, 2.5 cc will be applied point-by-point at intervals of 1-2 cm, and the remaining 2.5 cc will be applied using the napage method, 0.1 cc of solution were given with each injection. This injection will be applied once a week for a total of 4 sessions. Group 2 received dextrose prolotherapy: A 22 gauge syringe was used to apply a total of 5 cc of 15% dextrose solution (a combination of 3.75 ml 20% dextrose and 1.25 mg 2% lidocaine) to at least 5 most sensitive points of the lateral epicondyle. It was injected 3 times with 3 weeks intervals.
223993847|NCT06181370|DRUG|AGMB-447|AGMB-447 inhaled drug
223993848|NCT06181370|OTHER|placebo|placebo inhaled drug
223993849|NCT03931746|DEVICE|Porcine xenograft|The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
223993850|NCT05454813|DEVICE|Wetness Sensing System Validation|Participants will use the Wetness Sensing System in a simulated setting in the sitting, supine and side position (participants are randomized to either the left or right side position).
223993851|NCT00910286|OTHER|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
223993852|NCT01183390|DRUG|Anastrozole|1 mg Tablets
223993853|NCT01183390|DRUG|Anastrozole|1 mg Tablets
223993854|NCT04873882|DEVICE|Acoustic ventilation|"1. Placement and removal of the esophageal stethoscope~2. Connection of a microphone to the esophageal stethoscope outside of and removed from the patient's body at the location on the figure above Connection fo monaural earpiece.~3. Digital breath sound real-time monitoring will be collected as .wav files from the device with no identifiable elements and the data from the device will be downloaded onto a desktop and we will keep and store the data on a secure departmental server.~4. Additional monitoring schedule includes evaluation of breath sounds with a conventional stethoscope every 30 minutes intraoperatively, at the start of one-lung ventilation, at the return to two-lung ventilation and prior to extubation and during any changes on the digital breath sounds recording monitor."
223993855|NCT00500032|PROCEDURE|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
223993856|NCT03384303|OTHER|Standardized meal test|Preoperatively and postoperatively standardized meal test
223993857|NCT02358668|DRUG|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
223993858|NCT02358668|DRUG|BTI320 matching placebo|Placebo
223993859|NCT04057573|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
223993860|NCT04057573|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
223993861|NCT00128297|DRUG|Pamidronate|
223545105|NCT06506110|OTHER|Retrieving of retrospective data from Epic|Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
223993862|NCT02952859|OTHER|Irreversible electroporation|
223993863|NCT01507649|BEHAVIORAL|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
223993864|NCT01255254|PROCEDURE|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
223993865|NCT03455998|OTHER|questionnaires|
223993866|NCT03064945|DEVICE|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
223993867|NCT02592213|PROCEDURE|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
223993868|NCT03348410|BEHAVIORAL|Motivational interviewing|Motivational interviewing with insurance officer
223993869|NCT04403542|DEVICE|Lehfilcon A contact lens|Investigational silicone hydrogel contact lens
223993870|NCT04403542|DEVICE|Comfilcon A contact lens|Commercially available silicone hydrogel contact lens
224122507|NCT01954121|DRUG|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~* Down-titration Period (Week 30 up to Week 33)"
223993871|NCT00693979|DEVICE|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
223993872|NCT02981927|OTHER|Physical inactivity|
223993873|NCT05609604|DEVICE|tDCS|Electric current will be delivered to the pre-frontal cortex for 30 minutes.
223993874|NCT05609604|DEVICE|Shame- No current|
223993875|NCT03987971|OTHER|acupuncture|Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
223993876|NCT05654233|DRUG|Sulodexide|The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
224122508|NCT05791799|DRUG|Etonogestrel|Etongestrel implant will be implanted subcutaneously in the participant's non-dominant arm for one year
224122509|NCT02797106|OTHER|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
224122510|NCT05528042|OTHER|Heart rate and respiratory rate measurement|"Validation of the performance of the heart rate (HR) measurement using COBOX medical device compared to a measurement carried out by applying the reference processes for taking measurements via a CE marked device.~Evaluation of the performance of the respiratory rate (RR) measurement using COBOX medical device compared to a measurement carried out by a reference method of manual counting"
224122511|NCT00982306|BEHAVIORAL|Brief intervention|20 minute one to one counseling session
223993877|NCT04198155|RADIATION|stereotactic body radiotherapy (SBRT)|Image-guided stereotactic body radiation therapy
224122512|NCT02345642|DEVICE|ActiveCare+SFT Supine|
224122513|NCT02345642|DEVICE|VenaFlow Elite Supine|
223545106|NCT02793661|DEVICE|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
223993878|NCT01730950|BIOLOGICAL|bevacizumab|Staring within 14 days of randomization, IV 10mg/kg every two weeks until disease progression.
223993879|NCT01730950|RADIATION|radiation therapy|Starting with second dose of bevacizumab, 35 Gy in 10 fractions of 3.5 Gy each delivered on consecutive treatment days (typically 5 fractions per week).
223993880|NCT00336518|DRUG|peginterferon alfa-2a|
223993881|NCT00336518|DRUG|ribavirin|
223993882|NCT06249997|DRUG|Leniolisib|The doses selected range from 40 to 70 mg BID (based on body weight, resulting in total daily doses ranging from 80 to 140 mg a day for 12 weeks in Part I and 1 year in Part II, or until marketing approval in Japan, whichever is longer.
223993883|NCT02646787|BEHAVIORAL|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
223993884|NCT02646787|BEHAVIORAL|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
223993885|NCT00006501|PROCEDURE|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
224122514|NCT02345642|DEVICE|ActiveCare+SFT Standing|
224122515|NCT02345642|DEVICE|VenaFlow Elite Standing|
224122516|NCT05379361|BEHAVIORAL|Emotional Intelligence Development Program|It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
224122517|NCT05379361|BEHAVIORAL|Plasebo Training Group|It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
223993886|NCT04091698|DRUG|Co-Enzyme Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
223993887|NCT05591053|DEVICE|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted esophagectomy.
223993888|NCT05168462|DRUG|Reduced noradrenaline use|Reduced noradrenaline by using a lower MAP target
223993889|NCT02080962|RADIATION|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
223993890|NCT02080962|RADIATION|40 Gy in 10 fractions|tumors \> 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
223993891|NCT04317378|DEVICE|Braun thermoscan /, IRT 6520|The temperature will be measured in both ears with an ear thermometer. Practically, we will measure the temperature twice when generel anaesthsia is established, and immidiately before and after the MRI scan.
223993892|NCT03689634|DEVICE|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
223993893|NCT00243594|BIOLOGICAL|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
224295076|NCT04428099|BEHAVIORAL|Lifestyle change promotion program|The intervention consists of 8 group sessions centered on healthy physical activity, healthy diet, social life, Good Sleep Hygiene, healthy sun exposure, nature contact, how to stop ruminating, review and maintenance tips.
224295077|NCT04428099|BEHAVIORAL|Mindfullness based cognitive program|The intervention consists of 8 group sessions with a mindfulness-based cognitive program
224295078|NCT04428099|BEHAVIORAL|Written Information|Written information about lifestyle change suggestions
224295079|NCT00371306|DRUG|Insulin versus glucovance (glyburide/metformin)|
223993894|NCT00396695|PROCEDURE|Blood test|
223993895|NCT03963869|OTHER|Malaria Camps|The Govt. of India Malaria Control Programme (MCP) of Odisha provides ITNs and IRS, and trains community health workers (ASHAs) on the diagnosis and treatment of malaria, providing them with antimalarial drugs so that malaria treatment is available even in remote villages. Faced with a persistent burden of malaria in forest villages, the MCP recently introduced malaria camps (MCs) combining focused screening and treatment in villages with intensified vector control. The program includes one round of testing and treatment for the whole village population before the monsoon season, followed by one round of screening and treating of fever cases only during the monsoon season.
223993896|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
224295080|NCT03304028|DEVICE|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
224295081|NCT03304028|BEHAVIORAL|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
223993897|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
223993898|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
223993899|NCT01615289|DIETARY_SUPPLEMENT|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
223993900|NCT00667459|DEVICE|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
223993901|NCT00667459|DEVICE|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
223993902|NCT05436405|PROCEDURE|Trans-pedal access for endovascular revascularization in complex infra-popliteal lesions in critically ischemic limb|"Briefly, conventional femoral access will be conducted in the traditional manner and involve the sheath while the catheter was introduced close to the proximal degree of lesion.~Access to a pedal vessel: Using a 21-guage needle or by utilizing a micro puncture access set. Such vessel is recognized using the US probe. such approach performed in 54 patients.a fluoroscopy might enable a good possibility for efficient access. In addition, it was suggested to utilize micro-puncture needle supposed to have echogenic pattern as the tip of regular needle is very hard to visualize utilizing the duplex US probe. Also, use of straight fluoroscopy or road mapping may offer a better chance for successful access, this method is done in 31 cases . Another method is open method (cut down) on tibial vessels, this method is done in 11 cases."
224295082|NCT03304028|DEVICE|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
224295083|NCT03304028|OTHER|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team…etc.
224295084|NCT03304028|BEHAVIORAL|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
223994468|NCT04996433|BEHAVIORAL|inpatient CBASP group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 CBASP group therapy sessions (duration: 100 min per session).
224295085|NCT00767338|BEHAVIORAL|Timed intercourse|Timed intercourse
224295086|NCT00767338|PROCEDURE|Microsurgical varicocelectomy|Microsurgical varicocelectomy
224295087|NCT00767338|PROCEDURE|Intrauterine insemination|Intrauterine insemination
224295088|NCT03185403|OTHER|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
223545107|NCT02793661|OTHER|Control|Hydration protocol following ESC Guidelines 2014
223545108|NCT04581811|OTHER|Prolonged Proned Positioning|Patients will be placed in the prone position for 24 hours followed by 8 hours supine for consecutive periods for the duration of the study period
223545109|NCT04581811|OTHER|Traditional Proning Arm|Patients will be placed in the prone position for 16 hours followed by 8 hours supine for consecutive periods for the duration of the study period
223993903|NCT04851158|DEVICE|Effectiveness of ShotBlocker on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: ShotBlocker will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
223993904|NCT04851158|DEVICE|Effectiveness of local vibrator device on the perceived pain and satisfaction during intramuscular antibiotic injection|"Intervention: Verbal information was given to the participants prior to the intramuscular injection, and their written consents were obtained. The Structured Information Form consisting of five questions was applied by face-to-face interview method. Height and weight were measured, and BMI (kg/m2) was calculated and recorded in the Structured Information Form.~Application: Local vibrator device will be used on 35 patients during intramuscular injection.~Final assessment: VAS will be applied immediately after the intramuscular injection to determine the pain and satisfaction levels of the participants."
223993905|NCT01109511|DRUG|naloxone|
223993906|NCT01109511|DRUG|oxycodone|
223993907|NCT01764893|OTHER|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
223993908|NCT01764893|OTHER|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
223993909|NCT05174533|OTHER|Data collection|electrocardiogram
223993910|NCT03708497|DRUG|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
223993911|NCT03708497|DRUG|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
223993912|NCT03708497|DRUG|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
223993913|NCT03863977|DRUG|Dexamethasone|After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
223993914|NCT03863977|DRUG|Bupivacaine|After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
223993915|NCT03647904|BEHAVIORAL|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
223993916|NCT04601324|DRUG|Fluticasone Propionate|Participants will be required to use fluticasone propionate nasal spray twice daily.
223993917|NCT04601324|DRUG|Azelastine hydrochloride and fluticasone propionate|Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.
223993918|NCT04601324|DRUG|Rupatadine|Rupatadine once daily for a total of 2 weeks.
223993919|NCT02702778|DRUG|Delayed-Release (DR) Prednisone|delayed release prednisone
224122518|NCT04509492|DIAGNOSTIC_TEST|Endoscopic ultrasound ( EUS )|"\- EUS will be done to all patients. During EUS examination the liver will be examined thoroughly to detect hepatic focal lesions with possible EUS-FNA of any detected lesions.~All EUS examination will being done by EUS linear array Echoendoscope, Pentax EG-3870UTK attached to Hitachi Avius US machine under Propofol deep sedation"
223993920|NCT02702778|DRUG|Immediate Release (IR) Prednisone|standard prednisone
223993921|NCT01381575|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
224295089|NCT03185403|OTHER|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
224295090|NCT03185403|DRUG|ropivacaine|
223993922|NCT05078541|PROCEDURE|Ultrasound-guided Radiofrequency Ablation of Parotid Warthin's Tumor|"The Procedure~1. Injection of local subcutaneous and pericapsular anaesthesia~2. Needle radiofrequency ablation under ultrasound guidance~3. Patients should communicate with operating surgeon upon excessive heat or pain~4. The procedure usually lasts 30-45 minutes"
224122519|NCT05964725|DEVICE|Receive traditional medical therapy and transcranial direct current stimulation|Equipment used: Bricon tDCS stimulator, high-precision electrode stimulation method Stimulant dose: 1.5mA Stimulation time: 20 minutes/time, continuous treatment for 5 days Stimulation course: 5 days/course Stimulation target: left auditory cortex area, i.e., under system 10-20, left T3 position.
223993923|NCT01145989|DRUG|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
223993924|NCT01002677|BEHAVIORAL|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
223993925|NCT01002677|BEHAVIORAL|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
223993926|NCT00278447|BEHAVIORAL|Chronic Disease Management for substance abuse|Referral to primary medical care \& longitudinal, multidisciplinary care for persons with substance dependence.
223993927|NCT00278447|BEHAVIORAL|Standard care|Referral to primary medical care for persons with substance dependence.
223993928|NCT00721201|DRUG|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
223993929|NCT01443403|DRUG|Placebo|Matching placebo tablets administered orally once a day.
223993930|NCT01443403|DRUG|Naldemedine|Naldemedine tablets administered orally once a day.
223993931|NCT00557557|DRUG|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
223993932|NCT00557557|DRUG|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
223993933|NCT03563326|BIOLOGICAL|CAR-T cells targeting EpCAM|Biological: CAR-T cells targeting EpCAM
223993934|NCT03563326|BIOLOGICAL|Chemotherapy|Chemotherapy: determined by medical Oncologist
223993935|NCT00821262|DRUG|sevoflurane|
223993936|NCT00821262|DRUG|propofol|
223993937|NCT02916550|BEHAVIORAL|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
223993938|NCT06509399|OTHER|care package|"Before the patients in the application group started to be observed, the nurses working in the clinic were trained about the risk assessment, skin assessment, incontinence management, nutrition assessment, positioning, support surfaces and injuries caused by the devices in the BP content to be used in the prevention of IU. After the trainings given to the nurses were completed, care was given to the patients in the practice group in accordance with BP. In addition, patient information was collected from patient information files, nurse observation forms and hospital automation system. In the evaluation step, full compliance with the 7 compliance steps specified in the BP was sought. If any one of these parameters was incomplete, the others were considered as incomplete.~The patients in the control group were followed up for 30 days until the determined number of patients was reached and their data were collected."
223993939|NCT00249938|DRUG|Minute Maid Heart Wise orange juice|
223993940|NCT00249938|DRUG|Welchol|
223993941|NCT00803192|DRUG|Famotidine Tablets, 40 mg|
223993942|NCT04592094|DEVICE|Blueback® Physio|Blueback® Physio is monitoring the activation level of the transversus abdominis muscle in real time during the exercises
223993943|NCT01913457|RADIATION|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
224122520|NCT05964725|DEVICE|Receive traditional medical therapy and sham stimulation|By controlling the tDCS stimulator to mimic only the first 30 seconds of tDCS stimulation, after 30 seconds of pathway resistance control, so that the stimulation intensity is below the threshold, without giving real stimulation, in this process, the position of the stimulation target is not changed, and the rest of the operation is the same.
224122521|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
224295091|NCT03185403|DRUG|Sufentanil|
223993944|NCT00474526|BIOLOGICAL|Meningococcal ACWY Conjugate Vaccine|
223993945|NCT00474526|BIOLOGICAL|DTaP-IPV-HBV|
223993946|NCT00474526|BIOLOGICAL|Hib|
223993947|NCT00474526|BIOLOGICAL|Rotavirus|
223993948|NCT00474526|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine|
223993949|NCT00474526|BIOLOGICAL|HAV|
223993950|NCT00474526|BIOLOGICAL|MMR-V|
223993951|NCT00474526|BIOLOGICAL|DTaP|
223993952|NCT05459155|OTHER|Synapse medicine platform|Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics
223993953|NCT04093089|DEVICE|Bionode IOP Lowering System|Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
223993954|NCT04093089|DEVICE|Bionode IOP Lowering System|Control: No stimulation
223993955|NCT02748889|DRUG|Carboplatin|Standard chemotherapy
223993956|NCT02748889|DRUG|Etoposide|Standard chemotherapy
223993957|NCT02748889|BIOLOGICAL|MPDL3280A|Experimental biologic
223993958|NCT04747223|OTHER|Run Gait Retraining|Running step rate will be retrained by real-time biofeedback via a watch accelerometer. Recent literature showed that performing gait retraining by altering step rate reduces loading rates and joint stress that are associated with lower extremity injuries (Wilson et al 2014, Lenhart et al 2014, Heidersheit et al 2011).
223993959|NCT05614492|BEHAVIORAL|Individual PrEP Decision Aid|Participant engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV independently. They also enter data independently.
223993960|NCT05614492|BEHAVIORAL|CDC PrEP Video|A video from the Centers for Disease Control and Prevention that provides basic, general information on PrEP
223993961|NCT05614492|BEHAVIORAL|Shared PrEP Decision Aid|Domestic violence service advocate (DVA) engages with the decision support tool designed to optimize PrEP uptake among Black cisgender women who have experienced IPV with the participant and enters data
223993962|NCT04546217|COMBINATION_PRODUCT|Treadmill training + transfer package (TT+TP)|Participants will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. In combination with the gait training, participants will also receive a group of behavioral strategies (Transfer Package). Participants will sign the behavioral contract to achieve safety while engaging in activities, increase use of the paretic leg in daily activities, and increase coordination of both legs. A list of activities to be performed outside the clinical setting, the Home Skill Assignment, will be developed for each day of the week during the treatment period and given to the participants at the end of the session. The Home Practice after treatment aims to assure continued progress with LE use after the intervention program is completed. The LE-MAL Log will be administered in all sessions to assess quality of movement of the affected leg, level of assistance needed to perform daily activities, and level of confidence.
223993963|NCT04546217|DEVICE|Treadmill training (TT)|Participants in this group will walk in different speeds, step over obstacles, and keep their balance during perturbations in the robotic treadmill. The treadmill training will be identical to the experimental group, but no element of the TP will be delivered.
223993964|NCT03684564|DRUG|Rivaroxaban|Oral tablet 15 mg twice daily for 24 months
224122522|NCT02811484|DRUG|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
223545110|NCT00714948|DRUG|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) \> 2.1), after consultation with the Principal Investigator.
223993965|NCT03684564|DRUG|Warfarin|Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
223993966|NCT02793739|PROCEDURE|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
223993967|NCT05314270|DIAGNOSTIC_TEST|Diagnostic tests|Diaagnostic tests for all pt diagnosed as Non-B Non-C Liver Cirrhosis
223993968|NCT00453167|DRUG|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
223993969|NCT00453167|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
223993970|NCT05429242|OTHER|Ultrasonographic examination|Measurement of placental volume at the first trimester of pregnancy by using ultrasound.
223993971|NCT03222505|DEVICE|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
223993972|NCT03222505|OTHER|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
224122523|NCT02811484|DRUG|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c\>8%
224122524|NCT02811484|BEHAVIORAL|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
224122525|NCT01830153|DRUG|RAD001|
223994469|NCT04996433|BEHAVIORAL|inpatient CBASP nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP nurse contact (duration: 30 min per session).
224295092|NCT00454519|PROCEDURE|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
224295093|NCT00454519|PROCEDURE|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
223993973|NCT02550938|DEVICE|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
223993974|NCT05102877|DEVICE|Neuromuscular electrical stimulation|Motor stimulation was administered at an intensity sufficient to produce muscle contractions. Sensory stimulation was defined as the threshold when the patient feels a tingling sensation on their skin.
223545111|NCT03537638|BEHAVIORAL|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
223993975|NCT06044506|DRUG|Autologous Natural Killer Cell Therapy|The therapy will be administered intravenously
223993976|NCT06044506|DEVICE|Clinimacs Plus|The CliniMACS Plus device is an automated cell separation tool that uses MACS Technology. It incorporates a flexible system designed for isolating clinically labeled cells using MicroBeads.
223993977|NCT04131816|BEHAVIORAL|HeartHome|The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
223993978|NCT03285607|BIOLOGICAL|MCS110|-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
223993979|NCT03285607|DRUG|Doxorubicin|-Standard of care
223993980|NCT03285607|DRUG|Cyclophosphamide|-Standard of care
223993981|NCT03285607|DRUG|Paclitaxel|-Standard of care
223993982|NCT03285607|PROCEDURE|Bone marrow aspirate|-Time of enrollment and at time of surgery
223993983|NCT03285607|PROCEDURE|Peripheral blood samples|-Time of enrollment and at time of surgery
224122526|NCT05915819|OTHER|Plyometric Training|Exercise prescription according to weeks, sets and repetition. Weeks 1 and 2 1-2 sets / 10 repetitions Double leg jump Medicine ball(MB) stuffer flutter MB overhead throw MB single leg dip, Arrow cone drill Figure 8 drill Weeks 3 and 4 1-2 sets / 8 repetitions Ankle jumps Lateral cone hops Zigzag jump drill MB chest pass Jump \& turn 90° High-5 drill MB split squat Power skipping Clock drill T-drill Weeks 5 and 6 1-2 sets / 6 repetitions Dot drill Single leg cone hops Long jump and sprint Single leg zigzag drill MB lunge chest pass Jump and turn 180° Split squat jump Alternate bounding X-drill Shuttle drill
224122527|NCT05915819|OTHER|Eccentric Training|The eccentric training will be Pull-ups 3-5 sets X 6-8 reps Glute-ham raise 3-5 sets x 10rep Manual glute-ham raise 3-5 sets x 10rep single-leg Romanian dead lift or good morning(barbell or dumbbell) 3-5 sets x 10rep Glute-bridge and hip thrust (can also perform single leg movement) 3-5 sets x 10rep Half-kneel-bottom-up press-eccentric only. 3-5 sets x 8rep The eccentric exercise technique will be 2/1 technique, Two-movement technique, Slow/super slow, Negative (supramax)
223993984|NCT03285607|PROCEDURE|Tumor tissue|-Time of enrollment and at time of surgery
223993985|NCT01860599|BEHAVIORAL|Exercise|150 minutes of moderate exercise per week
223993986|NCT01860599|BEHAVIORAL|Without exercise|Pre-study activity level (i.e. no exercise)
224122528|NCT01618955|DEVICE|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
224295094|NCT04414436|BEHAVIORAL|GYNEA- digital coping program for women after gynaecological cancer|6 modules with relevant information and tools for coping after cancer
224295095|NCT00004997|DRUG|Leucovorin|
224295096|NCT00732433|PROCEDURE|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
223993987|NCT01251770|DRUG|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.
223993988|NCT01251770|DRUG|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
224295097|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
224295098|NCT01064141|BIOLOGICAL|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
223993989|NCT03085836|DRUG|TAK-438|TAK-438 tablets.
223993990|NCT02895204|DIETARY_SUPPLEMENT|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
223993991|NCT02895204|DIETARY_SUPPLEMENT|Placebo|6g of maltodextrin
223993992|NCT02613377|OTHER|Blood transfusion|
223993993|NCT01004887|OTHER|diagnostic laboratory biomarker analysis|
223993994|NCT00894400|PROCEDURE|catheter ablation|catheter ablation using radiofrequency energy
223993995|NCT05691946|PROCEDURE|Kinesiology Taping|The experimental group was applied 'Y shaped' kinesiology taping on gastro-soleus muscle group, based on facilitation technique with 25-50% stretching.
223993996|NCT05691946|PROCEDURE|Placebo Taping|The placebo group was applied kinesiology taping on gastro-soleus muscle group without any stretching.
223993997|NCT05464407|DIETARY_SUPPLEMENT|Cubitan|2 bottles of Cubitan daily, for 12 weeks.
223993998|NCT01065467|DRUG|LBH589|Taken orally three times per week.
223993999|NCT01888874|DRUG|GLPG0634|GLPG0634 capsules.
224295099|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
224295100|NCT01064141|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
223994000|NCT01888874|DRUG|Placebo|Placebo capsules.
223994001|NCT03550469|DEVICE|Computer-assisted Oxygen Weaning|Oxygen therapy weaning will be guided by a model-based computer algorithm. The computer will detect patients' oxygen saturation and made recommendations for oxygen weaning. A clinical at the bedside will make the adjustments in oxygen therapy if appropriate.
223994002|NCT05037747|BEHAVIORAL|Time-restricted feeding(TRF)|The TRF group was asked to restrict the eating window to 8 hours a day, during waking hours and also continue a low-protein diet.
223994003|NCT04420247|DRUG|Chloroquine|5 days of treatment with Chloroquine + Standard Care
223994004|NCT04420247|DRUG|Hydroxychloroquine|5 days of treatment with Hydroxychloroquine + Standard Care
224295101|NCT01134627|DRUG|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
223994005|NCT04420247|OTHER|standard care|Standard Care according to Brazilian Guidelines for treating COVID-19
223994006|NCT05302440|DEVICE|remote real-time health monitoring system with ring-like sensor|The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
223994007|NCT02858570|BIOLOGICAL|MenCC-BIO Vaccine|The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
223994008|NCT02858570|BIOLOGICAL|Combined - CRM197|The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
223994009|NCT00306813|DRUG|Revlimid|
223994010|NCT00790387|DRUG|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
223994011|NCT00790387|DRUG|Tirofiban|
223994012|NCT00790387|DRUG|unfractionated heparin|
223994013|NCT00429013|DEVICE|Tongue Display Unit|lingual electric stimulation
223994014|NCT04395170|BIOLOGICAL|COVID-19 convalescent plasma|Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.
223994015|NCT04395170|BIOLOGICAL|Anti-COVID-19 human immunoglobulin|"Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:~Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment.~Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment.~The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met."
223994016|NCT04395170|DRUG|Standard (specific) therapy for COVID-19|"Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin."
223994017|NCT02571088|OTHER|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
223994470|NCT04996433|BEHAVIORAL|inpatient CBASP exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 CBASP exercise therapy (duration: 75 min per session).
223994471|NCT04996433|BEHAVIORAL|outpatient CBASP group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 CBASP group therapy session (duration: 100 min per session).
224122529|NCT05431413|DRUG|Control group: Fluoxetine and Placebo|Cap Fluoxetin 20mg OD for four weeks and injection 100ml normal saline(NS) BD for two weeks.
224122530|NCT05431413|DRUG|Experimental group: Fluoxetine and ATP|Cap Fluoxetin 20mg OD for four weeks and injection ATP 100mg in NS BD for two weeks.
224122531|NCT05431413|DRUG|Control group: Fluoxetine and Phosphocreatine|Cap Fluoxetin 20mg OD for four weeks and injection Phosphocreatine 1g in NS BD for two weeks.
224122532|NCT00122746|RADIATION|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
224122533|NCT00122746|RADIATION|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
224122534|NCT02702908|OTHER||Historical Reference group.
224122535|NCT00661752|DEVICE|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
224122536|NCT00661752|DEVICE|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
223994472|NCT04996433|BEHAVIORAL|inpatient BA individual therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 individual BA therapy sessions (duration: 50 min per session).
224122537|NCT03901287|OTHER|dual energy CT scans|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
224122538|NCT02372903|DRUG|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
224295102|NCT01134627|DRUG|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
223994018|NCT06156553|BEHAVIORAL|PULSE school-based intervention|"PULSE - School-based intervention is a feasibility study designed to support active travel among adolescents. The curricular intervention is designed to increase the students' health literacy as well as their autonomous motivation for active travel. The intervention will last for 6 weeks during fall 2023. The first session will be delivered by a science and education center, and the consecutive sessions will be delivered by teachers. PULSE sessions will contribute to the attainment of specific competence aims related to two interdisciplinary topics, Health and life skills and Sustainability, as defined in PE, social science, and science. The research question is the following: Can increased attention to the barriers and benefits of active travel increase physical activity for youths?"
223994019|NCT04962529|PROCEDURE|Blood Draw|Blood will be drawn from each patient to check the concordance between liquid and tissue biopsy
223994020|NCT05640492|BEHAVIORAL|Metacognitive Training for Depression in Later Life (MCT-Silver)|"MCT-Silver consists of eight modules, each of which begins with psychoeducational and normalizing elements. A mastery is presented through examples and exercises, and the fallibility of human cognition is discussed and illustrated. In a second phase, the pathological extremes of each cognitive bias are highlighted and the participant is shown how the exacerbation of (normal) thinking biases can lead to problems in daily life. It is intended with this exercise that participants learn how to identify and mitigate cognitive traps. Dysfunctional coping strategies (social isolation and negative thoughts) are highlighted, and suggestions for replacing them with adaptive strategies are given. Homework assignments are distributed at the end of each session (Schneider et al., 2018)."
223994021|NCT05549492|DRUG|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present."
223994022|NCT00769600|DRUG|Itraconazole|Itraconazole 200 mg once daily
223994023|NCT00769600|DRUG|Pemetrexed|Pemetrexed every 21 days.
223994024|NCT04958577|DEVICE|Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)|This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.
223994025|NCT02673632|DRUG|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 \< 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
223994026|NCT01473277|DRUG|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
224122539|NCT03742960|BEHAVIORAL|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
224122540|NCT00424580|DRUG|Montelukast (10mg) and Desloratadine (5mg)|
224122541|NCT02588248|DRUG|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
223994473|NCT04996433|BEHAVIORAL|inpatient BA group therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 2 BA group therapy sessions (duration: 100 min per session).
224122542|NCT02588248|OTHER|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 80 ml of Solution B, also has 0 mg of L-Menthol).
223994027|NCT04342143|DEVICE|Blood pressure and ultrasound assessment|No intervention. Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will be asked to visit the lab on four separate occasions; the first two sessions will involve triplicated measures of carotid-femoral PWV (cfPWV), brachial-femoral PWV (bfPWV), brachial-ankle PWV (baPWV), femoral-ankle PWV (faPWV) and TT by the Vicorder in both seated and supine position. The SphygmoCor will also be used to assess cfPWV in both seated and supine. During the third and fourth sessions individuals will be randomised into either a supine or seated position. A 3 lead ECG will be attached and ultrasound video clips will be taken at the carotid, brachial, femoral and posterior tibial artery on both the symptomatic and asymptomatic sides to look at stiffness and blood velocity. Following this, the Vicorder will be used to look at cfPWV, bfPWV, baPWV, faPWV and TT on both sides.
223994028|NCT05917353|DIETARY_SUPPLEMENT|Hinex Jelly|"1. Name: Hinex Jelly~2. Dosage form: Semi-solid jelly/ A-114001297-00000-2~3. Dose(s): 300g/pack (per serving)~4. Dosing schedule: one pack (serving) per day~5. Mechanism of action: Nutritional supplement semi-solid food (content 61-91g/100g, protein 4.0-6.0/100g, saturated fatty acid 0.72-1.08g/100g, carbohydrate 12.56-18.84g/100g, dietary fiber 1.0-1.4g/100g), It is used as a nutritional supplement food."
223994029|NCT05091177|DIAGNOSTIC_TEST|Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation|Use relevant instruments for inspection
223994030|NCT02936726|BEHAVIORAL|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
223545112|NCT04461496|PROCEDURE|Hybrid revascularization|The first stage is performed femoral-popliteal bypass surgery above the fissure of the knee joint according to conventional technology. Conduit is at the discretion of the operating surgeon. Intraoperatively bolus is administered sol. heparin 5000 IU. The second step is the puncture of the selected CFA with a retrograde installation of the introducer sheath. The iliac segment is recanalized with angioplasty and stent implantation in the affected area
223994031|NCT02936726|BEHAVIORAL|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
223994032|NCT03867695|DRUG|Ropivacaine|At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
223994033|NCT03867695|DRUG|sterile saline|Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
223994034|NCT05306249|DRUG|CBD LGP 50|Patients will receive CBD LGP 50 at a dose of 1 mg/kg twice a day in the form of oil dispensed through a graduated pipette until the end of week 12.
223994035|NCT05306249|DRUG|Placebo|Patients will receive the MCT oil placebo without CBD until the end of week 12.
223994036|NCT00547612|OTHER|high performance liquid chromatography|
223994037|NCT00547612|OTHER|pharmacological study|
224122543|NCT02526927|DEVICE|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
223545113|NCT04461496|PROCEDURE|Full metall Jacket|The first step is the puncture contralateral CFA with a retrograde installation of the introducer. Intraoperatively bolus is administered sol. heparin 5000 IU. A conductor is placed in the contralateral iliac artery along the conductor. A stent is implanted in the iliac artery lesion. The second stage is the recanalization of the femoral-popliteal segment with angioplasty and stent implantation in the affected area.
224122544|NCT02526927|DEVICE|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (\< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
224122545|NCT02526927|OTHER|Blood samples|
223994038|NCT00547612|RADIATION|[18F]-labeled substance P antagonist receptor quantifier|
223994039|NCT03997487|OTHER|TOFTEE|Smartphone app for taking quality images of conjunctivae
223994040|NCT02883595|DRUG|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
223994041|NCT02883595|OTHER|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
223994042|NCT02799459|PROCEDURE|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
223994043|NCT02799459|PROCEDURE|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
224122546|NCT04120792|BEHAVIORAL|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
223994044|NCT01644864|DRUG|0.375% ROPIVACAINE|
223994045|NCT01644864|DRUG|placebo|
223994046|NCT04233112|DRUG|Melatonin 5 mg|Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
224122547|NCT04120792|BEHAVIORAL|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
224122548|NCT04120792|BEHAVIORAL|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
223994047|NCT04233112|DEVICE|Osteogenic loading|Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
223994048|NCT04233112|DEVICE|Mock for Osteogenic Loading|Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.
223994049|NCT04233112|DRUG|Placebo (plant fiber) for melatonin|Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
223994474|NCT04996433|BEHAVIORAL|inpatient BA nurse contact|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA nurse contact (duration: 30 min per session)
223994050|NCT06737861|OTHER|Group A|Participants will perform Buerger exercises three times daily, with each session including three cycles. Additionally, they will receive Whole Body Vibration therapy at a frequency of 25 Hz, three times per week. Each WBV session will last 12 minutes, divided into four 3-minute bouts, aiming to improve pain, balance, and lower limb circulation in diabetic peripheral neuropathy patients.
223994051|NCT06737861|OTHER|Group B|Participants will perform Buerger exercises three times daily, with each session consisting of three cycles. This exercise regimen is aimed at assessing its effectiveness on pain, balance, and circulation in diabetic peripheral neuropathy patients, serving as a comparison to the combined intervention with WBV therapy.
223994052|NCT03489252|DEVICE|Monitoring Device|Wear Fitbit Charge 3
223994053|NCT06156059|DRUG|Oral Bedtime Melatonin|100 mg oral suspension or capsule given at bedtime
223994054|NCT06156059|DRUG|Placebo suspension or capsule|Indistinguishable suspension or capsule
223994055|NCT00953771|DRUG|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
223729323|NCT01554423|BEHAVIORAL|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
223729324|NCT03247075|BEHAVIORAL|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
223729325|NCT03247075|BEHAVIORAL|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
223729326|NCT00128947|DRUG|Mycophenolic Acid|
223729327|NCT00128947|DRUG|Mycophenolate 7-O-Phenolic Glucuronide|
223994056|NCT03132532|DRUG|Carboplatin|Chemotherapy
223994057|NCT03132532|DRUG|Cisplatin|Chemotherapy
223994058|NCT03132532|DRUG|Etoposide|Chemotherapy
223994059|NCT03132532|DRUG|Paclitaxel|Chemotherapy
223994060|NCT03132532|DRUG|Pemetrexed|Chemotherapy
223994061|NCT03132532|RADIATION|Proton Beam Radiation Therapy|Undergo PBT
223994062|NCT03132532|OTHER|Quality-of-Life Assessment|Ancillary studies
223994063|NCT03132532|OTHER|Questionnaire Administration|Ancillary studies
223729328|NCT06486090|BEHAVIORAL|#Utviklingsklar|The intervention consists of 1) an e-learning course, 2) a workshop to create plans and practices for injury-prevention, 3) a mid-season meeting
223729329|NCT02123355|DRUG|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
223994064|NCT04596982|OTHER|Placement of IMPELLA®|ultrasound and hemodynamic parameters of patients in order to establish a predictive score for right-sided dysfunction after placement of IMPELLA®
223994065|NCT03356392|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
223994066|NCT02499939|BEHAVIORAL|Standard Care|Education and home exercises
223994067|NCT02499939|OTHER|Ultrasound Therapy|"Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)"
223994068|NCT06427889|DRUG|Canoderm|humectant
223729330|NCT02123355|PROCEDURE|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35\~40 mmHg，pulse oxygen saturation is more than 95%.
223729331|NCT02123355|DRUG|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
223994069|NCT06427889|DRUG|Oviderm|humectant + antimicrobial
223994070|NCT06427889|DRUG|Decubal|Non-humectant
223994071|NCT04747600|PROCEDURE|surgical resection|surgical resection
223994072|NCT04038918|OTHER|progressive muscle relaxation exercise|In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
223994073|NCT04038918|OTHER|standard postoperative physiotherapy program|After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
223994074|NCT06485583|OTHER|Constraint-induced movement therapy|is a rehabilitation technique used to improve motor function in people who have had a stroke or other neurological conditions. CIMT restricts the use of the unaffected limb, typically with a mitt or sling, to encourage the use of the affected limb.
223994075|NCT06485583|OTHER|Neurodevelopmental Treatment|Therapy, is a rehabilitation approach used to address movement and motor control deficits in people with neurological illnesses such as stroke, cerebral palsy, or traumatic brain injury.
223994076|NCT02385383|DRUG|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
223994077|NCT02385383|OTHER|Standard Care|Standard Care in a historical control cohort
223994078|NCT00884650|DRUG|oral analgesic|per clinical standard of care
223994079|NCT00884650|DRUG|intravenous analgesic per pump|per clinical standard of care
223994080|NCT00919204|DRUG|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
223994081|NCT02054676|RADIATION|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~* Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~* Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
223994082|NCT02054676|PROCEDURE|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~* implant drill slippage deeper than planned;~* implant threads coverage;~* etc."
223994083|NCT02054676|DEVICE|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
224122549|NCT04120792|BEHAVIORAL|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
223994475|NCT04996433|BEHAVIORAL|inpatient BA exercise therapy|During the 5-week inpatient phase I and the 5-week inpatient phase II / dayclinic treatment all patients in this arm will receive 1 BA exercise therapy (duration: 75 min per session).
224122550|NCT03403491|OTHER|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
224122551|NCT03403491|OTHER|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
224122552|NCT01355068|DRUG|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
224122553|NCT01355068|DRUG|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
223994084|NCT02054676|RADIATION|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
223994476|NCT04996433|BEHAVIORAL|outpatient BA group therapy|During the 6-week outpatient treatment all patients in this arm will receive 1 BA group therapy session (duration: 100 min per session).
224122554|NCT03516292|DIAGNOSTIC_TEST|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume \<30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
224122555|NCT05380414|BIOLOGICAL|Tumor samples (archival FFPE) and blood samples|Molecular screening
224122556|NCT01724736|DRUG|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
224122557|NCT01724736|DRUG|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
223729332|NCT02123355|DRUG|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
223729333|NCT02123355|DRUG|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
223729334|NCT02355353|OTHER|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
223729335|NCT02136186|DEVICE|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
223729336|NCT03114228|DRUG|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
223994085|NCT02054676|DRUG|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
223994086|NCT02054676|PROCEDURE|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
223994087|NCT02605746|DRUG|ceritinib 750mg|
223994088|NCT00003058|DRUG|troglitazone|
223994089|NCT00531622|DRUG|saredutant (SR48968)|oral administration, capsules
223994090|NCT00531622|DRUG|escitalopram|oral administration, capsules
223994091|NCT00531622|DRUG|placebo|oral administration, capsules
223994092|NCT05688618|DIETARY_SUPPLEMENT|Enteroccocus Facieum and Agave Inulin|A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks
223994093|NCT05688618|OTHER|Placebo|A pack of unsweetened almond powder milk will be administered daily for 8 weeks
223994094|NCT06155097|DRUG|transversus thoracis muscle plane block (TTP)|patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard monitors. After determining the anterior T4-T5 interspace using US, the US probe places in the longitudinal plane 1 cm lateral to the sternal border. A parasternal sagittal view of the internal intercostal muscle and the transversus thoracis muscle between the fourth and fifth rib will be visualized above the pleura. A 22-gage needle will be inserted in plane to the transducer with the tip of the needle located in the TTP between the internal intercostal and transversus thoracis muscles. After excluding intravascular and intrapleural placement, LA will administer with intermittent aspiration (administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side. After block administration, the patients will be monitored for LA toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes.
223994095|NCT06155097|DRUG|parasternal intercostal nerve block (PSI block)|patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard. Ultrasound scan will be performed from lateral to medial in the intercostal space. The intercostal muscles and pleura will be identified along the lower border of the rib. At the lateral border of the sternum, internal thoracic vessels lying anterior to transverse thoracic muscle are identified. The needle will be inserted in-plane to follow its tip using 4-mL injections per intercostal space across levels two through six bilaterally, for a total of 40 mL (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone)
223994096|NCT03670251|PROCEDURE|Blood sampling|Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
223994097|NCT03272503|DRUG|Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Pimozide 2mg tablets will be taken once daily.
223994098|NCT03272503|DRUG|Placebo Oral Tablet|Identical matching placebo lactose tablets
223994099|NCT00979953|DRUG|ADL5859|
223994100|NCT00979953|DRUG|ADL5747|
223994101|NCT00979953|DRUG|Oxycodone CR|
223994102|NCT00979953|DRUG|Placebo|
223994103|NCT02154906|DEVICE|DFDBA|
223994104|NCT02154906|DEVICE|autologous platelet rich fibrin|
223994105|NCT03681743|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
223994106|NCT05625932|DRUG|Tinzaparin|Patients \< 80 kg will receive a fixed dose of 4500 IU daily. Patients between 80-100 kg will receive a fixed dose of 6000 IU daily. Patients \> 100 kg will receive a fixed dose of 8000 IU daily.
223994107|NCT03755011|DEVICE|white noise|Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.
223994108|NCT03755011|BEHAVIORAL|usual care|normal ICU activity noise
223994109|NCT01173978|BEHAVIORAL|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
223994110|NCT01173978|OTHER|No intervention|
223994111|NCT04052425|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
223994112|NCT04052425|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
223994113|NCT04334278|BEHAVIORAL|GetHealthy-OA|The GetHealthy-OA is an 6-week group mind body program with efficacy in improving depression, physical function and aiding in weight loss, that has been adapted for the unique needs of patients with knee osteoarthritis, depression and obesity. The GetHealthy-OA will be delivered by secure telehealth.
223994114|NCT04334278|BEHAVIORAL|Health Enhancement Program|The Health Enhancement Program is a chronic pain-specific program adapted for the specific needs of patients with knee osteoarthritis. It is an 6-week group mind body program that will be delivered via secure telehealth.
223994115|NCT03023553|BIOLOGICAL|Fluzone®|Influenza Virus Vaccine Suspension for Intramuscular Injection
223994116|NCT03023553|BIOLOGICAL|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
223994117|NCT05187429|DRUG|Nivolumab 10 MG/ML [Opdivo]|Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
223994118|NCT05187429|DRUG|Nivolumab 10 MG/ML [Opdivo]|Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
223994119|NCT05187429|DRUG|Saline|Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
223994120|NCT05344677|OTHER|Trendelenburg Position|Group 1 (trendlenburg position group) in which the women will be positioned in a Trendelenburg position (20 °) once fully awake and cooperative in the recovery room and will remain in this posture for the first 24 hrs postoperatively. The maximum time allowed in a straight-up position will be three 15-min intervals over a 24-h period.
223994121|NCT05344677|OTHER|Warm Pad Application|• Group 2 (warm pad application group) in this group warm pad (38◦C -40◦C) will be applied on the shoulder after four hours postoperatively for a period of 5-10 minutes. Each woman will be asked to place heat pads when needed during the first 24 hours.
224122558|NCT01492114|DIETARY_SUPPLEMENT|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
224122559|NCT01492114|DIETARY_SUPPLEMENT|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
224122560|NCT03544671|DIETARY_SUPPLEMENT|Vitamin D|
224122561|NCT02493309|OTHER|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
224122562|NCT02493309|OTHER|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
224122563|NCT00307593|DRUG|Infliximab|Infliximab
224122564|NCT00307593|DRUG|Rituximab|Rituximab
224122565|NCT02015598|DRUG|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
223729337|NCT06409572|DIAGNOSTIC_TEST|GeneXpert MTB/RIF|Rapid and accurate method for detection of tuberculosis.
223729338|NCT00002904|DRUG|trabectedin|
223994122|NCT05344677|BEHAVIORAL|Deep Breathing Exercise|• Group 3: (deep breathing group) the researcher will instruct women after the end of surgery and upon consciousness to take slowly deep breathing while observing her chest and hold her breath for about 5 seconds and then exhale slowly, repeating this deep breathing technique five times after full vigilance within the first 3 hours after surgery. Then, the process will be repeated 6, 12, and 24 h later. The patient will be instructed about this type of breathing before surgery by researchers.
224122566|NCT02015598|DEVICE|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
224122567|NCT02504892|DRUG|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
223729339|NCT02064868|DRUG|Serelaxin|30 µg/kg/day IV infusion
224122568|NCT04034979|BEHAVIORAL|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
224122569|NCT00524745|BIOLOGICAL|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
224122570|NCT03633071|OTHER|Web-knee brace|Web -Knee Brace
223729340|NCT02064868|DRUG|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
223994123|NCT04829747|DRUG|Atogepant|Oral Tablet
223994124|NCT02667106|DRUG|RX0041-2|Pharmacokinetic study
223994125|NCT04199286|PROCEDURE|symmetrical and asymmetrical horizontal strabismus surgery|surgery was done on the medial rectus muscle on both eyes, lateral rectus muscle in both eyes or medial and lateral rectus muscle in one eye
223994126|NCT01168947|OTHER|5% dextrose solution|The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
223994127|NCT02615509|RADIATION|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
223994128|NCT03622255|PROCEDURE|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
223994129|NCT03622255|PROCEDURE|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
223729341|NCT00711711|OTHER|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
223994130|NCT05410093|DRUG|Resveratrol|Take Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months
223994131|NCT05410093|DRUG|Vitamin E|Take vitamin E at a dose of 100 mg per day for three months
223994132|NCT00425607|DRUG|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
223994133|NCT02211547|DEVICE|Epic 10 Diode Laser by Biolase Inc.|
223994134|NCT02211547|OTHER|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
223994135|NCT02563548|DRUG|PEGPH20|PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
223994136|NCT02563548|DRUG|Pembrolizumab|Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
223994137|NCT05332470|DRUG|Lamivudine and Dotiravir Sodium Tablets|3TC (300 mg p.o. q 24 h) plus DTG (50 mg p.o. q 24 h)
223994138|NCT03267446|DEVICE|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
223994139|NCT01233661|OTHER|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
223729342|NCT00711711|OTHER|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
223994140|NCT05096039|DRUG|Sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan (from the PDE file) during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
223994141|NCT05096039|DRUG|ACEI or ARB and no sacubitril/valsartan|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window. Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
223994142|NCT03453697|DEVICE|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%\~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
223994143|NCT02497846|DEVICE|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity \[I\]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
223994144|NCT02294851|DRUG|BMS-986168|
224122571|NCT03130101|OTHER|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
224122572|NCT02329795|RADIATION|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
224122573|NCT02329795|DRUG|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
224122574|NCT03553017|DEVICE|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
223994145|NCT02294851|DRUG|BMS-986168 Placebo|
223994146|NCT01686867|DEVICE|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
223994147|NCT01189110|DEVICE|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
223994148|NCT04710199|DRUG|Maraviroc experimental group|300-milligram dose of the drug two times daily , oral way. During 14 days.
223994149|NCT04710199|OTHER|Standard treatment|It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient.
223729343|NCT03858114|OTHER|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~1. warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~2. Active phase (45 minutes), from \>40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~3. cool down (10 minutes), \< 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
223994150|NCT02503319|DRUG|Tranexamic Acid|"2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)~2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)"
223994151|NCT02503319|DRUG|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
223994152|NCT02503319|DRUG|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
223994153|NCT01732549|DRUG|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
223994154|NCT01732549|DRUG|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
223994155|NCT00333749|BIOLOGICAL|Drinking or rinsing the mouth 2-3 times for 1 day|
223994156|NCT00333749|BIOLOGICAL|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
223994157|NCT04231045|DEVICE|PiCCO device cardiac monitoring|"PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated"
223994158|NCT05580835|DIAGNOSTIC_TEST|PET MRI with PSMA|A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent
223994159|NCT00662597|DRUG|ASA404|
223994160|NCT00662597|DRUG|Placebo|
223994161|NCT00662597|DRUG|carboplatin|
223994162|NCT00662597|DRUG|Paclitaxel|
223994163|NCT02036138|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
223994164|NCT02036138|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
223994165|NCT02036138|DRUG|Advanced Medical Therapy|
223729344|NCT03858114|OTHER|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
223994166|NCT06179121|OTHER|DNA test for screening HLA-DQ2 and DQ8 from dried blood spots to early detect Celiac Disease|Phase 1 and 2: After blood collection (in combination with regular care) and informed consent, a blood droplet obtained by an additional fingerprick (Phase 1 and just an extra droplet from an existing finger prick for Phase 2) will be deposited on filter paper S\&S 903™ (Schleicher and Schuell). DNA will be isolated using the QIAamp method designated for this purpose from dried blood spots (Qiagen). The results of the HLA-DQ2 and DQ8-typing using the dried blood spots will be compared with the results of the traditional HLA-typing. Factors that may influence the quality of the material will be taken into account in the validation process.
224122575|NCT02984826|OTHER|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
224122576|NCT02984826|OTHER|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
223994167|NCT02805712|OTHER|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
223994168|NCT02805712|OTHER|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
223994169|NCT04355377|OTHER|Non intervention|Non intervention
223994170|NCT00872209|DRUG|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
223994171|NCT00872209|DRUG|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
223994172|NCT04201873|BIOLOGICAL|Dendritic Cell Tumor Cell Lysate Vaccine|Given ID
224122577|NCT01676376|DEVICE|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
224122578|NCT01676376|OTHER|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
223994173|NCT04201873|BIOLOGICAL|Pembrolizumab|Given IV
223994174|NCT04201873|OTHER|Placebo Administration|Given IV
223994175|NCT04201873|DRUG|Poly ICLC|Given IM
223994176|NCT00566540|DRUG|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
223994177|NCT00566540|DRUG|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
223994178|NCT00566540|RADIATION|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
223994179|NCT00566540|PROCEDURE|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
223994180|NCT02986945|BEHAVIORAL|Resiliency App|
223994181|NCT02885662|DRUG|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
223994182|NCT00013585|DRUG|Selegiline hydrochloride|
223994183|NCT01395004|DRUG|GSK2110183|GSK2110183 was orally administered at 125 mg once daily.
223994184|NCT03186001|DRUG|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
224122579|NCT05329467|OTHER|Validation of Faces Thermomether Scale|Participants are introduced to all three painscales and are asked to rate their pain with each and one of them according to instructions for each scale
223994185|NCT01276808|PROCEDURE|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
223994186|NCT01276808|PROCEDURE|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
223994187|NCT03750864|BEHAVIORAL|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance \& Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
223994188|NCT00692731|DIETARY_SUPPLEMENT|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
223994189|NCT00692731|OTHER|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
223994190|NCT00447590|DEVICE|LAP-BAND System|Restriction of food intake
223994191|NCT01967069|DRUG|DFD01 Spray|
223994192|NCT01967069|DRUG|Vehicle Spray|
223994193|NCT00452907|DRUG|Artesunate|oad, per os, 3 days of treatment
223994194|NCT00452907|DRUG|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
223994195|NCT00452907|DRUG|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
223994196|NCT04688177|DEVICE|Body Composition|The subjects should lie in the supine position on a non-conducting surface for 5 min. 4 surface electrodes with cables will be attached to the right hand and ankle of subjects.
223994197|NCT04688177|DEVICE|Heart rate variability|After supine quietly for 20 min, a lead I electrocardiogram will be taken for 5 min.
223994198|NCT04688177|DEVICE|Grip Strength|The participants will squeeze the hand dynamometer as hard as possible with the dominant hand. 3 successive measurements will be taken.
223994199|NCT04688177|DEVICE|Exhale Carbon Monoxide Concentration|Subjects in sitting position, performing 1 inspiration, then exhale to carbon monoxide meter.
223994200|NCT04688177|DEVICE|Pulmonary Function Test|Subjects should be in a sitting position with a nose clip, then perform pulmonary function test. Participants should perform at least 3 acceptable attempts, but no more than 8 attempts in total.
223994201|NCT04688177|DEVICE|Respiratory Muscle Function|Subject will perform both maximal inspiratory pressure and maximal expiratory pressure for 3 times in sitting position with the nose clip.
223994202|NCT04688177|BEHAVIORAL|Fagerström Test for Nicotine Dependence|Fagerström Test for Nicotine Dependence Traditional Chinese version will be adopted. It is a 6-item questionnaire that could help quantify the smoking frequency, amounts, and level of dependence.
223994203|NCT04688177|BEHAVIORAL|Seven-Day Physical Activity Recall Questionnaire|Physical activity will be measured by the Chinese Version of the Seven-Day Physical Activity Recall Questionnaire. Participants will need to recall the time (hours) they spent in various leisure activities in the past 7 days.
223994204|NCT04688177|DEVICE|Cardiopulmonary exercise testing|Bruce protocol as the treadmill evaluation protocol will be adopted for cardiopulmonary exercise testing.
223994205|NCT00256022|DRUG|Lactobacillus Probiotic|
223994206|NCT00256022|OTHER|Lactose Powder|
223994207|NCT02301338|OTHER|Usual care|
223994208|NCT02301338|OTHER|Phone Calls|
223994209|NCT03638076|DRUG|GLS4|Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.
223994210|NCT03638076|DRUG|RTV|Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
223994211|NCT00025077|BIOLOGICAL|filgrastim|
223994212|NCT00025077|DRUG|carboplatin|
223994213|NCT00025077|DRUG|cyclophosphamide|
223994214|NCT00025077|DRUG|thiotepa|
223994215|NCT00025077|PROCEDURE|conventional surgery|
223994216|NCT00025077|PROCEDURE|peripheral blood stem cell transplantation|
223994217|NCT00025077|RADIATION|radiation therapy|
223994218|NCT00529880|DRUG|Fludarabine , cytarabine|
223994219|NCT01739257|BEHAVIORAL|Medical Lecture|
223994220|NCT01739257|BEHAVIORAL|Dramatic Reading|
223994221|NCT04496323|OTHER|EE Golf|Exercise in Golf and Playing 9 holes
223994222|NCT03820297|BEHAVIORAL|10 sessions of ASGI|10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
223994223|NCT00287443|PROCEDURE|Oral Glucose tolerance test|
223994224|NCT00287443|PROCEDURE|Whole body protein turnover|
223994225|NCT00287443|PROCEDURE|IV glucose tolerance test|
223994226|NCT00287443|PROCEDURE|Indirect Calorimetry|
223994227|NCT00287443|PROCEDURE|Dual Energy X-ray Absorptiometry (DEXA)|
223994228|NCT00287443|PROCEDURE|Growth Hormone Stimulation Test|
223994229|NCT00202189|DRUG|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
223994230|NCT00775411|DRUG|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
223994231|NCT00775411|BIOLOGICAL|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
223994232|NCT01445119|DRUG|Enzastaurin (LY317615)|
223994233|NCT01445119|DRUG|Carboplatin|
223994234|NCT04358718|PROCEDURE|general anesthesia|Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
223994235|NCT04358718|PROCEDURE|general anesthesia combined with epidural analgesia|Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
223994236|NCT01111253|DRUG|Amoxicillin-clavulanate|"Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days."
223994237|NCT05387967|DRUG|Sacubitril/valsartan|All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.
223994238|NCT05563389|DRUG|Atorvastatin 20mg|active arm
223994239|NCT05563389|DRUG|Placebo|placebo arm
223994240|NCT00346905|DRUG|Enteryx|
223994241|NCT01167790|PROCEDURE|buccal cavity examination|autofluorescence examination
223994242|NCT02393742|DRUG|Sodium nitrite|
223994243|NCT02393742|DRUG|Placebo|
223994244|NCT04079634|DEVICE|Esophageal warming|Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure
223994245|NCT04079634|DEVICE|Control|Standard temperature probe monitoring
223994246|NCT00004178|BIOLOGICAL|therapeutic autologous lymphocytes|
223994247|NCT00504283|DRUG|Toradol|
223994248|NCT00504283|DRUG|Morphine|
223994249|NCT02660515|PROCEDURE|Additional wrist arthroscopy|
223994250|NCT02660515|PROCEDURE|ORIF|
223994251|NCT01708434|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
223994252|NCT02103114|DRUG|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level\*%) X body weight)/1.4~* expressed as a % normal level based on functional ATIII assay"
223994253|NCT02103114|OTHER|Placebo|Normal saline placebo
223994254|NCT06497803|OTHER|Nurse-Led Body Protection Education|"Based on BST and Safe Touches education programs and in line with the studies conducted in the literature on children who are not visually impaired, NLBPE was created by the researchers (Akgul et al., 2021; Citak-Tunc et al., 2018; Pulido, 2019; Wurtele, 2007). The program aims to teach visually impaired children how to protect the private parts of their bodies, to distinguish between good and bad touch, to distinguish between good and bad secrets, to say no, scream, and ask for help when necessary. As education tools, dolls and distress whistles were used. In order for children to learn the private parts of their bodies, a doll was used. The practice of Say No, Scream, Run, and Blow Your Whistle While Running in order for the students to protect their body from bad touch was applied by the students one by one firstly, and in groups later."
223994255|NCT06497803|OTHER|Reminder Education Brochure|The brochure was prepared in line with the NLBPE and included what is a good touch and a bad touch, how to distinguish a good touch from a bad touch, examples of good touch and bad touch, and what to do when encountered with a bad touch (Say No, Scream, Run, and Blow Your Whistle While Running). The brochure, the content of which was prepared by the researcher, was translated into Braille Alphabet by a visually impaired teacher working at the school where the research was conducted, before it was distributed to the intervention group members.
223994256|NCT05553093|DRUG|Tirzepatide|Tirzepatide ih qw
223994257|NCT05553093|DRUG|Insulin Glargine|6 IU ih qd
223994258|NCT03933462|DEVICE|InnoSpire Go|Participants will use for 30 days.
223994259|NCT03933462|DEVICE|Jet Nebulizer|Participants will use for 30 days.
223994260|NCT01937975|DRUG|Grazoprevir|100 mg oral tablet administered once a day for 10 days
223994261|NCT01937975|DRUG|Elbasvir|50 mg oral tablet administered once a day for 10 days
223994262|NCT06342336|DRUG|HS-IT101 Injection|Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
223994263|NCT05585918|BEHAVIORAL|SEL + Equity|For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.
223994264|NCT05585918|BEHAVIORAL|SEL Only|For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
223994265|NCT02028325|DRUG|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
223994266|NCT05262452|DEVICE|ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system|Device to deliver mechanical stress and force to enhance drug delivery, using focused ultrasound
223994267|NCT05262452|DRUG|FOLFIRINOX regimen|"a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis"
223994268|NCT05196282|OTHER|Smoking cessation|Patients are forced to stop smoking
223994269|NCT00706654|DRUG|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
223729345|NCT01938378|BIOLOGICAL|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
223729346|NCT00507962|DRUG|Cisplatin|100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks
223994270|NCT00706654|DRUG|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
223994271|NCT00706654|DRUG|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
223994272|NCT00706654|DRUG|Placebo depot|Placebo depot was supplied in lyophilized vials.
223994273|NCT00706654|DRUG|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
223994274|NCT03438682|DEVICE|Essure|Essure hysteroscopic sterilization
223994275|NCT03438682|PROCEDURE|Laparoscopic sterilization|Laparoscopic sterilization via electrocautery, ring, or clip.
223994276|NCT03438682|DEVICE|Intrauterine Device (IUD)|Intrauterine Device (IUD)
223994277|NCT00657462|OTHER|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
223994278|NCT01445327|OTHER|Specimen collection|
223994279|NCT00002439|DRUG|Alitretinoin|
224122580|NCT03921229|BEHAVIORAL|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
224122581|NCT00571363|PROCEDURE|standard surgery|excision with 4 mm margins
224122582|NCT00571363|PROCEDURE|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
224122583|NCT01413178|DRUG|Busulfan|Test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
224122584|NCT01413178|DRUG|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
223994280|NCT05219838|DRUG|Lu AG06466|Lu AG06466 will be administered per dose and schedule specified in the arm description.
223994281|NCT00625300|DEVICE|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
223994282|NCT00625300|DEVICE|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
223994283|NCT01335347|BIOLOGICAL|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
223994284|NCT01335347|BIOLOGICAL|Placebo control|Capsules of the same size and shape as experimental groups
223994285|NCT06031636|DRUG|Oncolytic Adenovirus H101|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
223994286|NCT06031636|DRUG|Programmed death receptor-1 inhibitor|The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
224122585|NCT01413178|OTHER|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
224122586|NCT01413178|DRUG|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
224122587|NCT01413178|DRUG|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
224122588|NCT01413178|PROCEDURE|Stem cell transplant|Stem cell infusion on Day 0.
223994287|NCT00594022|DEVICE|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
224122589|NCT00073593|DRUG|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) \>300 seconds (s).
223994288|NCT00594022|DEVICE|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
223994289|NCT03194997|OTHER|Dance|The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
223994290|NCT03194997|OTHER|Pilates|The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
223994291|NCT06117423|DRUG|Adalimumab-680LT|First, adalimumab-680LT was administered intravenously. 2-3 days later, a Fluorescence Molecular Imaging procedure was performed to enable the visualisation and detection of fluorescence signals.
223994292|NCT06117423|OTHER|Control|Fluorescence Molecular Imaging was performed to enable the visualisation and detection of fluorescence signals.
223994293|NCT05284630|OTHER|Exercise follow up with mobile application|Exercises will be followed by mobile application. Electrotherapy will be performed.
223994294|NCT05284630|OTHER|Home-Based Exercise Program followed by paper booklet|Exercise will be followed by paper booklet. Electrotherapy will be performed.
223994295|NCT05284630|PROCEDURE|Electrotherapy|Electrotherapy will be performed.
223994296|NCT01120873|DRUG|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
223994297|NCT02225262|RADIATION|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
223994298|NCT00118612|BIOLOGICAL|Tree MATA MPL - Therapeutic Regimen|600, 1600, 4000, 4000 SU/0.5 mL
223994299|NCT00118612|BIOLOGICAL|Tree MATA MPL - Intermediate dose|300, 600, 1600, 1600 SU/0.5 mL
223994300|NCT00118612|BIOLOGICAL|Tree MATA MPL - Low dose|300, 300, 300, 300 SU/0.5 mL
223994301|NCT00118612|BIOLOGICAL|Placebo|L-tyrosine 2% w/v , 4 injections
223994302|NCT02968615|BEHAVIORAL|Dietary Intervention|Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
223994303|NCT00351572|PROCEDURE|Cell Search Assay|
223994304|NCT02840864|DEVICE|Sonography assisted breast surgery|
223994305|NCT00098527|DRUG|romidepsin|Given IV
224122590|NCT00073593|DRUG|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of \>300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
224122591|NCT00073593|DRUG|Protamine|Per institutional practice. Batches from hospital stock.
223729347|NCT00507962|DRUG|Liposomal Doxorubicin|Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
223729348|NCT00931762|DRUG|Panobinostat|Panobinostat oral capsules
223729349|NCT03061838|DRUG|MabThera®|1000 mg intravenously
223729350|NCT03061838|DRUG|Ritumax®|1000 mg intravenously
223729351|NCT03902197|BIOLOGICAL|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
223994306|NCT00098527|OTHER|laboratory biomarker analysis|Correlative studies
223994307|NCT01465945|PROCEDURE|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
223994308|NCT01465945|PROCEDURE|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
223994309|NCT05317442|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks"
223994310|NCT00196391|DRUG|DR-2021a|1 capsule daily for 10 days
223994311|NCT00196391|DRUG|DR-2021b|1 capsule daily for 10 days
223994312|NCT00196391|DRUG|DR-2021c|1 capsule daily for 10 days
223994313|NCT00196391|DRUG|DR-2021d|1 capsule daily for 10 days
223994314|NCT00196391|DRUG|DR-2021e|1 capsule daily for 10 days
223994315|NCT00196391|OTHER|Placebo|1 matching placebo capsule for 10 days
223994316|NCT03600025|BIOLOGICAL|Typbar-TCV vaccine|vaccine will receive intramuscularly
223994317|NCT03327272|DRUG|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
223994318|NCT03327272|DRUG|Saline|Administration of saline at surgical site prior to incision closure
223994319|NCT02224547|RADIATION|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
223994320|NCT00555243|PROCEDURE|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
223994321|NCT00555243|PROCEDURE|Traditional Surgical Education|Traditional surgical teaching (no simulator)
223994322|NCT06254170|DIETARY_SUPPLEMENT|Euterpe Edulis juice|The preparation will be obtained with the same methods already well established in previous studies (SCHULZ et al., 2016.; MENDES et al., 2021). Participants will receive commercial samples of juçara (E.edulis) refrigerated to 4°C to 10°C, per day, for 10 days, and on the 11th will be the exercise and on this day will be administered the juice of the juçara 2 h before on the day of the monitored exercise. The chemical characterization of Euterpe edulis will be with at least 350.0 + or - 17.5 mg of total phenolics (gallic acid equivalent), 186.0 + or - 7.5 mg of total monomeric anthocyanins (cyanidin 3-glycoside), 0.73 + or less 0.01 g of proteins, and 2.75 + or - 0.03 g of lipids (ether extract). During the 10 days of previous treatment, maintain the routine of physical exercises.
223994323|NCT06254170|DIETARY_SUPPLEMENT|Placebo|Participants will receive 250 ml of water + purple dye + pectin (control) refrigerated to 4°C to 10°C, per day, for 10 days, and on the 11th will be the exercise and on this day will be administered the juice of the juçara 2 h before on the day of the monitored exercise. The chemical characterization of Euterpe edulis will be with at least 350.0 + or - 17.5 mg of total phenolics (gallic acid equivalent), 186.0 + or - 7.5 mg of total monomeric anthocyanins (cyanidin 3-glycoside), 0.73 + or less 0.01 g of proteins, and 2.75 + or - 0.03 g of lipids (ether extract). During the 10 days of previous treatment, maintain the routine of physical exercises.
223994324|NCT01397279|BIOLOGICAL|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
223994325|NCT01397279|BIOLOGICAL|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
223994326|NCT00684905|DRUG|bicalutamide|
223994327|NCT00684905|DRUG|leuprolide acetate|
223994328|NCT00684905|PROCEDURE|adjuvant therapy|
224122592|NCT00576693|DEVICE|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl).
224122593|NCT00576693|OTHER|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure \< 140 / 90 mm Hg (\< 130 / 80 if diabetic) and LDL \< 70 mg / dl)
224122594|NCT00812071|BIOLOGICAL|RiVax|vaccine
224122595|NCT03527615|OTHER|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
224122596|NCT06175507|DRUG|Naltrexon|Naltrexone 50mg orally once daily will give for 12 weeks
224122597|NCT06175507|DRUG|Baclofen|Baclofen 10mg orally thrice daily will give for 12 weeks
224122598|NCT00003667|DRUG|cyclophosphamide|
224122599|NCT00003667|DRUG|dexrazoxane hydrochloride|
224122600|NCT00003667|DRUG|disaccharide tripeptide glycerol dipalmitoyl|
224122601|NCT00003667|DRUG|doxorubicin hydrochloride|
224122602|NCT00003667|DRUG|vincristine sulfate|
223994329|NCT00684905|PROCEDURE|neoadjuvant therapy|
224122603|NCT00003667|PROCEDURE|surgical procedure|
224122604|NCT00003667|RADIATION|radiation therapy|
224122605|NCT02596347|PROCEDURE|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
223994330|NCT00684905|PROCEDURE|quality-of-life assessment|
223994331|NCT00684905|RADIATION|brachytherapy|
223994332|NCT00368875|DRUG|vorinostat|Given orally
223994333|NCT00368875|DRUG|paclitaxel|Given IV
223994334|NCT00368875|BIOLOGICAL|bevacizumab|Given IV
224122606|NCT02596347|PROCEDURE|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
224122607|NCT02689336|BIOLOGICAL|Erlotinib|
224122608|NCT02689336|DRUG|Temozolomide|
224295103|NCT05665517|DEVICE|Chatbot Little K Nurse|"The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed."
223994335|NCT02754362|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
223994336|NCT02754362|BIOLOGICAL|Peptide Vaccine|"Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg"
223994337|NCT02754362|DRUG|Poly-ICLC as immune adjuvant|Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
223994338|NCT02754362|DRUG|Keyhole limpet hemocyanin (KLH)|Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
223994339|NCT05212753|DEVICE|Conventional physical therapy|Hot packs or hot water bags are superficial warming agents that will be used to heat muscle tissue, reduce muscle spasms and pain sensation. TENS is a pain reliever application.
223994340|NCT05212753|OTHER|Lumbar stabilization exercises|Training about the concepts of stabilization and abdominal bracing is given before starting the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface. The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
223994341|NCT05212753|OTHER|Breathing exercises|Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During diaphragmatic breathing, attention is focused on the correct abdominal breathing. The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over-breathing. This intervention also includes Sleep Hygiene education to the subjects,
223994342|NCT04012177|DIETARY_SUPPLEMENT|Balanced-energy protein (BEP)|Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
223994343|NCT04012177|DRUG|Azithromycin Tablets|Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
224122609|NCT01596075|DRUG|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
224122610|NCT00416767|DRUG|fluorouracil|
224122611|NCT00416767|DRUG|irinotecan hydrochloride|
224122612|NCT00416767|DRUG|leucovorin calcium|
224122613|NCT04053179|DEVICE|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
224122614|NCT00657761|DRUG|Enfuvirtide|90 mg/12h sc for 7 days
224122615|NCT00657761|DRUG|Placebo|0.9% saline solution/12h sc for 7 days
224295104|NCT02382367|OTHER|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
224295105|NCT02592772|OTHER|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
223994344|NCT04012177|DRUG|Choline Bitartrate|Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
223994345|NCT04012177|DRUG|Nicotinamide|Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
224122616|NCT05305638|OTHER|Exercise|Home-based physical activity programs are very important to strengthen the immune system, which is extremely important in the fight against COVID-19 infection, and to protect physical and mental health. In addition, since the pulmonary rehabilitation sessions carry a high risk of transmission, it is recommended that the program be carried out with applications such as single-session training, tele-rehabilitation or home program. Although the home pulmonary rehabilitation program is adapted to the individual, it generally includes positioning, mobilization, relaxation exercises, respiratory training, respiratory muscle exercises, upper and lower extremity exercises, walking, climbing stairs and cycling exercises. The general opinion is that telerehabilitation practices have many benefits such as increasing the quality of life and physical activity. In addition to these benefits, telerehabilitation applications come to the fore in the Covid-19 period with its complementary feature.
223994346|NCT03586908|DRUG|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2\~D6: PHP-201 0.5% topical eye drop OU TID
223994347|NCT05844059|OTHER|Validated questionnaires|BPIC-SS, ICIQ-OABqol, IIEF-EF oder FSFI, ICIQ-MLUTS oder ICIQ-FLUTS
223994348|NCT01305239|DRUG|Aromasin|Aromasin 25 mg daily.
223994349|NCT01512316|DRUG|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
223994350|NCT01512316|DRUG|Lactose pill|one dose, 2hrs prior to fmri
223994351|NCT01512316|GENETIC|Saliva sample|Buccal cell material will be sampled from all participants on day3
223994352|NCT01512316|OTHER|Functional neuroimaging (fMRI)|
223994353|NCT02865512|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization for the management of postoperative pain
223994354|NCT05756296|PROCEDURE|Therapeutic hypothermia|whole-body cooling to an esophageal temperature of 33.5°C initiated within the first 6 hours of life, continued for 72 hours, and then they were slowly rewarmed for moderate or severe NE
223994355|NCT05974683|DRUG|placebo|Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
223994618|NCT06707402|BEHAVIORAL|WALK|The intervention covers a personalized 24-week progressive brisk walking program. The program consists of moderate to high-intensity walking (i.e., 55-85% maximal heart rate) performed as both continuous and interval training sessions 2-3 times/week lasting 30-60 min/session. Four individually supervised sessions will be conducted in the first 2 weeks, while 1 supervised group session will be received bi-weekly. Furthermore, the group will receive an activity tracker and monthly telephone calls will be offered to adjust the intensity of the program (if necessary), clarify any questions regarding the intervention, and give verbal motivation. At the baseline assessment and at week 12, during a group training session, the figure of 8 walk test will be conducted to gain insigh tinto the current status of the training program. Lastly, after completion of the baseline test, the participants are given a brief educational session (walking advice) on recommended guidelines for physical activity
223994619|NCT06707402|BEHAVIORAL|ACTIVE|Will receive an activity tracker is provided alongside monthly telephone calls and walking advice after the baseline test. Similar to WALK, 3 telephone calls are provided during the follow-up period.
223994620|NCT06707402|BEHAVIORAL|CON|Receives a brief educational session (walking advice) is provided at baseline, after which no further contacts are made.
223994621|NCT06926673|DRUG|Dostarlimab|Dostarlimab will be administered
223994622|NCT06926673|DRUG|Belrestotug.|Belrestotug will be administered
223994623|NCT06926673|DRUG|Nelistotug|Nelistotug will be administered.
223994624|NCT07050303|OTHER|Mobile Application Developed Based on Social Cognitive Theory|Measuring the Benefits of a 3-Month Mobile Application Use in Hypertension Patients
223994625|NCT07049367|DIAGNOSTIC_TEST|Hand Function Improvement|Finger Extension and Tripod Grip as Indicators of Hand Function Improvement in Subacute Stroke Patients
223994626|NCT07049419|DEVICE|Provision of an environmental control system|Part of standard clinical care for patients referred to the NHS Lothian environmental control service.
223994627|NCT07044778|OTHER|Questionnaire|An online Questionnaire designed by Google Forms will be shared on social media for medical students in Egypt to fill
223994628|NCT07049510|BEHAVIORAL|Experimental: Experimental: Combating violence against women|"After the Personal Information Form, Domestic Violence Awareness Scale and Gender Role Attitude Scale are applied to all women as a pre-test, the women in the experimental group will be included in the Combating Violence Against Women program. The program will be given in 4 sessions in 1 day. Demonstration, powerpoint, feedback and brainstorming methods will be used in the training.~8 weeks after the completion of the training, all women will be reunited and the Domestic Violence Awareness Scale and Gender Role Attitude Scale will be applied as a post-test."
223994629|NCT04856735|OTHER|Intraperİtoneal local anaesthesİc İn cesarean sectİon|After the birth of the newborn and placenta, the uterus is closed and the blood accumulated in the pelvis is carefully wiped with surgical towels, after hemostasis is fully achieved, a total of 20 ml solution containing 10 cc of 0.5% bupivacaine +10 cc 2% lidocaine and 2 injectors containing 20ml saline and the 20ml solution were given to the surgeon area.
223994630|NCT04856735|OTHER|Local wound infiltrasyon|A solution containing 20 ml of saline was added to all four quadrants of the uterus in 5 ml volume and 20 ml solution containing lidocaine and bupivacaine were subcutaneously in the form of LWI before the skin was closed
223994631|NCT04856735|OTHER|Control group|One of the two sterile injectors containing 20 ml of saline was applied to the uterine peritoneal region and the other was applied to the incision area as a local subcutaneous wound infiltration.
223994632|NCT02328118|DRUG|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
223994633|NCT02328118|DRUG|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
223994634|NCT04086277|PROCEDURE|Continuous Intrapartum Support|Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
223994635|NCT01529489|OTHER|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
223994636|NCT01529489|OTHER|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
223994637|NCT01529489|OTHER|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
223994638|NCT01529489|OTHER|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
223994639|NCT00371384|PROCEDURE|massage|UP to 10 massages over 10 weeks
223994640|NCT06108518|DRUG|Carvedilol|Treatment group will take carvedilol 12.5mg once a day for 2 days; this is increased to 25 mg once a day or 12.5 mg twice a day for 3 months.
223994641|NCT02224404|DEVICE|Fast Gelling Dressing (Exufiber)|
223994642|NCT03744013|DEVICE|Fortiva® 1mm|Post mastectomy immediate reconstruction
223994643|NCT06299735|PROCEDURE|Minimally Invasive Cardiac Surgery (airway management with double-lumen tube)|Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, a double-lumen tube will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
223994644|NCT06299735|PROCEDURE|Minimally Invasive Cardiac Surgery (airway management with endobronchial blocker)|Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, endotracheal tube-bronchial blocker will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
223994645|NCT00601263|DRUG|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
223994646|NCT03466047|DIETARY_SUPPLEMENT|Protein stomach|encapsulated protein stomach
223994647|NCT03466047|DIETARY_SUPPLEMENT|Protein distal small intestine|encapsulated protein distal small intestine
223994648|NCT03466047|DIETARY_SUPPLEMENT|CHO stomach|encapsulated CHO stomach
223994649|NCT03466047|DIETARY_SUPPLEMENT|CHO distal small intestine|encapsulated CHO distal small intestine
223994650|NCT03466047|DIETARY_SUPPLEMENT|Fat stomach|encapsulated Fat stomach
223994651|NCT03466047|DIETARY_SUPPLEMENT|Fat distal small intestine|encapsulated Fat distal small intestine
223994652|NCT02747823|BIOLOGICAL|CBT124|1 mg/kg IV infusion
223994653|NCT02747823|BIOLOGICAL|EU Sourced Avastin®|1 mg/kg IV infusion
223994654|NCT02747823|BIOLOGICAL|US Sourced Avastin®|1 mg/kg IV infusion
223994655|NCT01653938|BEHAVIORAL|video decision aid|
223994656|NCT04160442|BEHAVIORAL|Carevive CarePlanning System|Subject will complete brief survey prior to seeing provider in clinic. Utilizing the CarePlanning System, the provider will review the subject's responses directing the conversation and treatment decision will be made. A treatment careplan will be developed and given to the subject.
223994657|NCT00641680|DRUG|Budesonide|
223994658|NCT00641680|DRUG|Fluticasone propionate|
223994659|NCT00641680|DRUG|Placebo|
223994660|NCT06297720|BEHAVIORAL|Oral hydration|"* Researchers moisten the patient's throat with a wet cotton swab. If no nausea or vomiting occurs after five minutes, proceed to the next stage.~* Provide an ice cube of potable water for the patient to hold in their mouth. If no nausea or vomiting occurs after ten minutes, proceed to the next stage.~* Offer 10-20ml of potable water for the patient to drink under medical supervision. If no nausea or vomiting occurs and the patient requests more water, administer 10-20ml every ten minutes, assessing for any adverse effects each time. The total water intake should not exceed 500ml."
223994661|NCT05916703|DIAGNOSTIC_TEST|SOLUS examination|"The examination of each subject will include: i) B-mode US, ii), color Doppler US, iii) shear wave elastography, and iv) SOLUS multimodal imaging.~For each subject various ultrasound images (modalities i-iii) will be taken and these images will determine the location for the SOLUS measurements (iv).~All measurements (i-iv) will be taken at the lesion location, in the normal breast tissue around the lesion, and in the mirror location of the contralateral breast.~Optically derived data (blood volume, blood oxygen saturation, water, lipid and collagen concentrations, tissue scattering parameters) will be obtained. Every subject included in the study will be evaluated separately by 3 radiologists, with different level of experience in breast imaging."
223994662|NCT04465799|BEHAVIORAL|ENTREN|ENTREN intervention for children (cognitive-behavioral perspective + motivational interview)
223994663|NCT04465799|BEHAVIORAL|ENTREN-F|ENTREN intervention for children + family intervention.
223994664|NCT04465799|BEHAVIORAL|Control group|Behavioral modification of habits
223994665|NCT05461287|DRUG|QLS31904|QLS31904 ONLY
223994666|NCT00961467|DRUG|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
223994667|NCT00961467|DRUG|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
223994668|NCT00266123|DRUG|Sirolimus|
223994669|NCT03061422|OTHER|Xylitol|caries prevention chewing gum
223994670|NCT03061422|OTHER|xylitol with bicarbonate|caries prevention chewing gum
223994671|NCT03061422|OTHER|paraffin|chewing gum
223994672|NCT05104489|BIOLOGICAL|AdimrSC-2f|IM injection
223994673|NCT03473353|OTHER|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
223994674|NCT04267965|PROCEDURE|parathyroidectomy plus bilateral thymectomy and autotransplantation|Patients should receive total parathyroidectomy plus bilateral thymectomy and autotransplantation
223994675|NCT02679326|DEVICE|Therapeutic ultrasound|
223994676|NCT05959798|PROCEDURE|High power short duration ablation|Pulmonary vein isolation by high power short duration radiofrequency catheter ablation
223994677|NCT06056843|OTHER|Triage of clinical breast examination positive women using handheld ultrasound by non-radiologists.|Women screened for breast cancer by clinical breast examination (CBE). Those with positive CBE will be triaged by portable ultrasound device by non-radiologists. All recruited women will receive a diagnostic mammography and, if necessary, an ultrasound performed by a radiologist. The radiologist will be blinded to the portable ultrasound device findings. Those with suspected lesions either on mammography or ultrasound will have fine needle aspiration cytology (FNAC) or core biopsy. The women with confirmed diagnosis of breast cancer will be staged and appropriately treated as per the policy of the hospital.
223994678|NCT02460575|BIOLOGICAL|Lactobacillus reuteri 17938|probiotic
223994679|NCT02460575|BIOLOGICAL|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
223994680|NCT02162004|PROCEDURE|Continuous Correction|
223994681|NCT03821103|BEHAVIORAL|Training|The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department (ED) administration within 3 month study period
223994682|NCT03821103|BEHAVIORAL|Behavioral economic enhanced arm|Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
223994683|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
223994684|NCT01345864|DRUG|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
223994685|NCT01345864|DRUG|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
223994686|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
223994687|NCT01345864|DRUG|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
223994688|NCT05969301|OTHER|Specific spinal exercises for idiopathic scoliosis|The spinal esercises mainly include: active self-correction, strengthening spinal deep muscles while maintaining self-correction, segmentary stretching involving the limbs and back muscles, and postural task-oriented exercises (e.g. walking, standing, sitting).
223994689|NCT04307940|DRUG|Naproxen Sodium (Aleve, BAY117031)|220 mg per tablet, two tablets (440 mg), intake a single dose orally.
223994690|NCT04307940|DRUG|Hydrocodone/Acetaminophen|5/325 mg per tablet, two tablets (10/650 mg), intake a single dose orally.
223994691|NCT04307940|DRUG|Placebo|two tablets, intake a single dose orally.
223994692|NCT04517097|BIOLOGICAL|blood sample|one blood sample and one questionnaire to each patient and salaried staff included
223994693|NCT00734136|PROCEDURE|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
223994694|NCT00734136|PROCEDURE|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
223994695|NCT05543174|DRUG|TAK-625|TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
223994696|NCT06523140|DEVICE|Boracare remote monitoring solution|Bora Band wristband measuring vital signs at home, Bora Connect platform for caregiver visualization and BVS3 early detection of COPD exacerbations
223994697|NCT04074720|PROCEDURE|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
223994698|NCT04074720|OTHER|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
223994699|NCT04074720|OTHER|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
223994700|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation alone|Ablation of the pulmonary veins for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
223994701|NCT06364215|DEVICE|Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation|Ablation of the pulmonary veins and the left atrium posterior wall for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
223994702|NCT05518474|OTHER|Self-proning|Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
223994703|NCT00910897|DRUG|Velcade-Dexamethasone|
223994704|NCT00910897|DRUG|Velcade-Thalidomide-Dexamethasone|
223994705|NCT00005593|DRUG|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
223994706|NCT00005593|DRUG|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
223994707|NCT00005593|DRUG|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
223994708|NCT03192345|BIOLOGICAL|SAR439459|"Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion"
223740075|NCT06790784|PROCEDURE|Vitrectomy|The vitrectomy must occur within 4 weeks of randomization. A single injection of faricimab is allowed at any point before the vitrectomy. It is recommended that this injection is within 1 week of the vitrectomy. Requirement of triamcinolone staining to assist in complete elevation and removal of the posterior hyaloid and in removal of as much peripheral vitreous as is safely possible, 20 gauge not permitted. Allows subconjunctival steroid at investigator discretion; however, sub-tenon's triamcinolone or other long-acting steroid will not be permitted.
223994709|NCT03192345|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
223994710|NCT06794008|DRUG|BCMA-CD19 CAR-T therapy|Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.
223994711|NCT06079294|OTHER|FDG PET|Brain FDG PET performed 3 months after treatment initiation
223994712|NCT06291766|DEVICE|FreeStyle Libre 2, continous glucose monitoring|The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
223740076|NCT06790784|DEVICE|Endolaser|Complete panretinal photocoagulation (PRP) during vitrectomy
223994713|NCT03932773|DEVICE|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
223994714|NCT03932773|DEVICE|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
223994715|NCT03932773|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
223994716|NCT04896008|DRUG|Sotatercept|SC injection
223994717|NCT04896008|OTHER|Placebo|Placebo-matched SC injection
223994718|NCT05154981|BEHAVIORAL|Education communication skills (ECS) training|Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
223994719|NCT05154981|BEHAVIORAL|Partners in School|Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
224037808|NCT02673619|DRUG|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2
223994720|NCT03309540|OTHER|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
223740077|NCT06790784|DRUG|Faricimab|Treatment must be initiated on the day of randomization with one faricumab injection. The remainder of the randomized treatment includes 2 additional injections every 4-weeks. Injections must be completed within 90 days of randomization.
223994721|NCT04495153|BIOLOGICAL|Aglatimagene besadenovec|Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) of CAN-2409 injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
223994722|NCT03223779|DRUG|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
223994723|NCT03223779|RADIATION|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
223994724|NCT06476132|DRUG|Belumosudil|Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
224299086|NCT03917017|DEVICE|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
223994725|NCT06476132|DRUG|Placebo for Belumosudil|Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
223994726|NCT02339623|DEVICE|Ultrasound imaging|"1. \- Fetal adrenal gland volume calculation using 3D ultrasound~2. \- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~3. \- CL measurement using 2D ultrasound"
224037809|NCT06277908|PROCEDURE|Elective Surgery for gastric cancer|Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach
223425458|NCT01882881|OTHER|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide \~33% of calories from fat. The SFA (\~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (\~9g).
223740078|NCT06790784|DEVICE|Panretinal Photocoagulation (PRP)|Complete PRP. PRP may be completed in 1-3 sessions, with the timing at the investigator's discretion. All PRP sessions must be completed within 90 days of randomization.
223740079|NCT05647122|DRUG|AZD9592|Varying doses of AZD9592
223564097|NCT06409871|OTHER|Physiotherapy treatment and modification of the biorhythm.|"* Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.~* Modification of the biorhythm will consist of eliminating methylxanthine-rich foods and/or beverages from their diet, as well as no exposure to electronic devices two hours before bedtime."
223564098|NCT03200834|PROCEDURE|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
223740080|NCT05647122|DRUG|Osimertinib|tablets administered orally
223740081|NCT05647122|DRUG|5-Fluorouracil (5-FU)|IV infusion
223994727|NCT06564077|OTHER|Eldoa technique with conventional therapy|"is myofascial stretching technique of the cervical spine. Patients were asked to adopt desired position to target intervertebral segments. Breathing is also important factor in ELDOA stretch. Patients were instructed to not to hold or strain breathing through promoting diaphragmatic breathing.~* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
223994728|NCT06564077|OTHER|conventional therapy|"* Hot pack for 20 minutes~* Strengthening exercises for deep neck flexors, rhomboids, serratus anterior, and lower trapezius (2 sets of 10 reps per day).~* Stretching exercise for pectoralis muscle (20 sec hold,5 reps)"
223994729|NCT01270828|DRUG|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
223994730|NCT01270828|DRUG|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
223994731|NCT04101955|PROCEDURE|Incisionless Threaded Carpal Tunnel|ultra-minimally invasive thread carpal tunnel release
223994732|NCT04101955|PROCEDURE|Standard Mini-Open Carpal Tunnel|open surgical carpal tunnel release
223994733|NCT04940364|DRUG|Pozelimab|Administered intravenous (IV) or subcutaneous (SC) per protocol
223994734|NCT04940364|DRUG|Cemdisiran|Administered SC per protocol
223994735|NCT06456385|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The intervention applied is called transcutaneous auricular vagus nerve stimulation (taVNS) which administers electrical stimulation at the ear which targets the auricular branch of the vagus nerve.
223994736|NCT06456385|DEVICE|Sham Auricular Stimulation|The sham auricular stimulation administers electrical stimulation at the ear lobe which has less auricular branch of the vagus nerve.
223994737|NCT02643264|OTHER|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
223994738|NCT02643264|OTHER|Sham rTMS|Sham stimulation with the same regimen as active treatment
223994739|NCT03611725|PROCEDURE|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
223994740|NCT03611725|PROCEDURE|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
223994741|NCT02963090|DRUG|Topotecan|"Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities."
223994742|NCT02963090|DRUG|Pembrolizumab|200 mg IV every 21-days until progression of disease or unacceptable toxicities.
223994743|NCT06490302|DEVICE|Lens A (ocufilcon D)|15 minutes of daily wear
223994744|NCT06490302|DEVICE|Lens B (fanfilcon A)|15 minutes of daily wear
223994745|NCT00015847|BIOLOGICAL|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
223994746|NCT00015847|DRUG|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
223994747|NCT00636415|DRUG|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
223994748|NCT05044507|DEVICE|BQ 2.0|frequency and intensity parameters will be set to zero so that no stimulation is delivered
223994749|NCT05044507|DEVICE|BQ 2.0|The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
223994750|NCT00709228|DRUG|PegIntron|1.5 ug/kg/week
223740082|NCT05647122|DRUG|Leucovorin|IV infusion
223740083|NCT05647122|DRUG|Bevacizumab|IV infusion
223994751|NCT00709228|DRUG|Rebetol|800-1200 mg/day
223994752|NCT05984927|GENETIC|NG101 AAV gene therapy|Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
223994753|NCT05970705|DRUG|Regorafenib|this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
223994754|NCT05970705|DRUG|Trifluridine/Tipiracil|this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
223994755|NCT03422575|DRUG|Etoricoxib 120Mg Film-coated Tablet|One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
224299087|NCT01126411|PROCEDURE|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
223994756|NCT03422575|DRUG|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)|One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
223994757|NCT04776642|OTHER|Biobank for Left atrial appendage tissue|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
223994758|NCT04776642|OTHER|Biobank for Blood|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
223994759|NCT04776642|OTHER|Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.|Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.
223994760|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
223994761|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
223994762|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
223994763|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
223994764|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
223994765|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
223994766|NCT00750295|DRUG|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
224299088|NCT02796118|DRUG|ASP2151|Oral
224299089|NCT02796118|DRUG|Placebo|Oral
223994767|NCT04497389|BIOLOGICAL|Human Amniotic Fluid|Patients will receive 10ml intravenous hAF each day for 5 consecutive days.
223994768|NCT02724852|BIOLOGICAL|0.5 ml of MMR vaccine|Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
223994769|NCT00325689|DRUG|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
223994770|NCT00325689|DRUG|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
223994771|NCT04687462|DEVICE|1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)|TKRA operation undergoing 1-mm thickness variance polyethylene insert total knee arthroplasty system (Exult, Corentec)
223994772|NCT00789360|DRUG|Inhaled Placebo|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
223994773|NCT00789360|DRUG|Inhaled Loxapine|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
223994774|NCT01929824|OTHER|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
223994775|NCT00022659|BIOLOGICAL|bevacizumab|Given IV
223994776|NCT00022659|OTHER|laboratory biomarker analysis|Correlative studies
223994777|NCT02154880|PROCEDURE|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
223994778|NCT02154880|PROCEDURE|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
223994779|NCT02154880|PROCEDURE|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
223994780|NCT02154880|OTHER|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
223994781|NCT03025750|BIOLOGICAL|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
223994782|NCT03025750|BIOLOGICAL|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
223994783|NCT02079324|BIOLOGICAL|GX-051|intratumoral injection
223994784|NCT05890027|DRUG|Phenylephrine Ophthalmic|One drop of Phenylephrine 2.5% ophthalmic solution to be administered to the eye with ptosis to evaluate for surgical repair.
223994785|NCT05890027|OTHER|Eyelid Tape|Participants will have the affected eye with ptosis manually lifted using tape.
224299090|NCT00316147|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine|
223740084|NCT06768489|DRUG|JNJ-79635322|JNJ-79635322 will be administered subcutaneously.
224122757|NCT07003763|DEVICE|Electroacupuncture treatment|"Participants in this group will receive electroacupuncture (EA) based on a semi-standardized protocol. Each treatment session will involve needling at six main acupoints and two supplementary points, selected based on individual symptoms.~* Main acupoints: Baihui (GV20), Yintang (EX-HN3), Guanyuan (CV4), Qihai (CV6), bilateral Zusanli (ST36), bilateral Sanyinjiao (SP6).~* Supplementary acupoints: Selected from Shenting (GV24), Sishencong (EX-HN1), Fengchi (GB20), Neiguan (PC6), Hegu (LI4), Shenmen (HT7), Yanglingquan (GB34), Taixi (KI3), and Taichong (LR3).~All patients will be placed in the supine position. After routine disinfection of all acupoints using 75% alcohol, needles will be inserted using a gentle tapping technique. Once Deqi sensation is achieved, three pairs of electrodes from an EA device will be connected to the handles of the needles at Baihui and Yintang, and bilaterally at Zusanli and Sanyinjiao. Each treatment session will last for 30 minutes."
223740085|NCT06768489|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
223740086|NCT06768489|DRUG|Pomalidomide|Pomalidomide will be administered orally.
223740087|NCT06768489|DRUG|Lenalidomide|Lenalidomide will be administered orally.
223740090|NCT06927947|OTHER|Communication Intervention|Use relative invitation tool
223740091|NCT06927947|OTHER|Health Promotion and Education|Receive access to the VGN
223994786|NCT03804216|OTHER|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
223994787|NCT03322540|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
223994788|NCT03322540|DRUG|Epacadostat|Epacadostat administered orally twice daily.
223994789|NCT03322540|DRUG|Placebo|Matching placebo administered orally twice daily.
223994790|NCT00170183|DRUG|Nesiritide|
223994791|NCT01981005|DRUG|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
223994792|NCT03526653|OTHER|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
223994793|NCT03526653|OTHER|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
223994794|NCT03526653|OTHER|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
223994795|NCT03020459|PROCEDURE|peeling-reposition|"After dying with Brilliant Blue G (BBG, Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to maintain facedown position for two weeks postoperatively."
223994796|NCT03020459|PROCEDURE|peeling|After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for two weeks postoperatively.
223994797|NCT03020459|DRUG|Brilliant Blue G|We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.
223994798|NCT03020459|OTHER|postoperative posture|Patients of both two groups need to keep prone position for two weeks after the operation.
223425459|NCT01882881|OTHER|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide \~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing \~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
223994799|NCT03020459|DEVICE|Constellation 23-gauge vitrectomy system|All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
223994800|NCT05090527|DIAGNOSTIC_TEST|Risk stratification|advanced penicillin challenge after risk stratification
223994801|NCT00540033|DIETARY_SUPPLEMENT|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
223994802|NCT00540033|DIETARY_SUPPLEMENT|infloran|Study group was fed with infloran \[Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)\] and Bifidobacteria bifidum \[(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)\]; Laboratorio Farmaceutico S.I.T S.r.I ITALY\] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
223994803|NCT02922283|DEVICE|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
223994804|NCT02922283|PROCEDURE|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
223994805|NCT02922283|DEVICE|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
223740092|NCT06927947|OTHER|Informational Intervention|Receive access to a Genetic Testing Family Letter
223740093|NCT06927947|OTHER|Survey Administration|Ancillary studies
223994806|NCT02922283|PROCEDURE|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
223994807|NCT04361812|DRUG|HS632|Subcutaneous injection of HS632
223994808|NCT04361812|DRUG|Omalizumab (Xolair®)|Subcutaneous injection of Omalizumab Xolair®)
223994809|NCT02339597|PROCEDURE|Automatic Positive Airway Pressure (APAP) initiation|
223994810|NCT02617953|DEVICE|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
223994811|NCT02617953|DEVICE|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
223994812|NCT02617953|DEVICE|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
223994813|NCT04548986|DEVICE|Aktiia.product|The participants wear Aktiia.bracelet for the duration of the cardiac rehabilitation program. The device is initialized once per week.
223994814|NCT03158909|DEVICE|Eyemask and earplugs|Eyemask and earplugs for use during the night, to improve sleep.
223994815|NCT03158909|OTHER|Orientation about space and time|Information and orientation about space and time, given every night.
223994816|NCT06109610|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment will be offered to participants free of charge. Cognitive Behavioral Therapy (CBT) sessions will be delivered in a group therapy format and the sessions will be offered in successive weeks. The protocol will be then administered to the intervention group (in 8 groups over a period of six months, eight sessions, each of 30 minutes' length).
223994817|NCT03321110|OTHER|Placebo|Placebo (dextrin)
223994818|NCT03321110|DIETARY_SUPPLEMENT|Coenzyme Q10|150 mg or 300 mg
223994819|NCT05573581|DRUG|Botox|Botulinum toxin type A will be first injected into anterior belly of digastric muscles 2-3 days prior to any surgical intervention (for the BTX to be clinically effective)(Sadick and Matarasso 2004). A total of 20 U of Botox will be injected bilaterally by using 25g needle, 1 cc insulin syringe through extraoral approach in 4 point
223994820|NCT01210326|PROCEDURE|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
223994821|NCT01210326|PROCEDURE|testicular sperm extraction|testicular sperm extraction
223994822|NCT01210326|PROCEDURE|testicular sperm aspiration|testicular sperm aspiration
223994823|NCT00390260|DRUG|MK0966 / Duration of Treatment: 1 Days|
223994824|NCT00390260|DRUG|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
223994825|NCT00390260|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
223994826|NCT05494970|OTHER|Accompaniment by the dental assistant.|"Inclusion visit (before radiotherapy treatment):~* oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~* a written information guide on oral hygiene will be given to the patient.~* the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient."
223994827|NCT05317676|DRUG|Palmitoylethanolamide|2-month supply of PEA will be given upon discharge. 300mg will be taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
223994828|NCT05317676|DRUG|Placebo|2-month supply of placebo will be given upon discharge. Placebo will taken twice a day in conjunction with discharge medications (opioid and NSAIDs).
223994829|NCT04492059|DEVICE|Blood flow restriction augmented physical therapy|Using a blood flow restriction cuff during physical therapy. It is a pressurized cuff that is used to decrease the amount of oxygen that is available to the muscle during exercise. This stimulates the muscle to believe it is in an anoxic state and can produce greater strength and hypertrophy with fewer reps and less weight which would mean less stress on a surgically repaired tendon.
223994830|NCT04492059|OTHER|Physical therapy|Completing traditional physical therapy.
223994831|NCT00968526|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
223994832|NCT05214664|PROCEDURE|Anesthesia|"Once the anesthesia is performed by the Anesthesia practitioner either with the EZ-Block® device or by the conventional freehand technique, the surgical procedure will be performed in the same way in both arms, and for each tooth, by the Surgery practitioner:~* The Surgery practitioner takes charge of the patient after a post-anesthesia time of 10 minutes and performs a new antisepsis then completes the anesthesia by anesthetizing the buccal and lingual nerve with a carpule of 1.8ml of articaine + adrenaline at 1/200000.~* The Surgery practitioner starts the surgical procedure.~* In the absence of pain, the practitioner Surgery carries out the surgical act in its totality (situation of success for the principal criterion of the study) then records the EVA at the end of the intervention."
223994833|NCT00168389|DRUG|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
223994834|NCT00168389|OTHER|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
223994835|NCT04828941|DEVICE|Electronic Headache Diary|The electronic headache diary is an app-based diary that permits the registration of headaches, their acute treatment and their associated work incapacity. It also permits real-time monitoring of these data.
223994836|NCT04828941|DEVICE|Paper Diary|The paper diary permits the registration of the same variables as the electronic diary in paper format.
223994837|NCT05997628|OTHER|Detection of NAD+/NADH concentration of Peripheral Blood Samples|Peripheral blood samples are taken before breakfast and before lunch to detect NAD+/NADH levels, hematology, blood biochemical indicators, immune cells and SIRT1 level in peripheral blood in different age groups. This experiment monitors indicators mentioned above without any drug intervention.
223994838|NCT03045705|BEHAVIORAL|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman's wishes to receive analgesia by the medical team.
223994839|NCT03045705|BEHAVIORAL|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
223994840|NCT02727244|PROCEDURE|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
223994841|NCT04053998|PROCEDURE|Pancreaticoduodenectomy with portal vein resection|Pancreatic surgery with vein resection to achieve disease clearance.
223994842|NCT03926195|DRUG|Filgotinib|200-mg tablet administered orally once daily
223994843|NCT03926195|DRUG|Placebo|Placebo to match filgotinib tablet administered orally once daily
223994844|NCT03926195|DRUG|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
223545115|NCT05110326|OTHER|Proprioceptive Neuromuscular Facilitation (PNF) stretching|"* The patient will be laid down prone and moist heat will be given for 15 minutes prior to stretching the hamstrings.~* Then patient will be lying supine with hip in 90⁰ of flexion. Patient's knee will be extended until a very mild stretching sensation is felt in hamstring muscles.~* Then patient will be asked to flex the knee against the resistance applied by hand of therapist.~* The patient will be asked to use a force of around 50% of maximal strength and an isometric form of contraction will be gained in the hamstring muscles. The patient will hold the contraction for 8 seconds and then the therapist command to relax the hamstring muscle.~* Immediately after the muscle relaxation the therapist further stretches the hamstring muscles up to a point where the subject reported a mild to moderate stretching sensation without any pain and will be held for 30 seconds.~* The procedure will be repeated 3 times in every session.~Strengthening Exercises:~* Same as ERGON Group"
223994845|NCT02373540|DEVICE|Algovita Spinal Cord Stimulation system|
223994846|NCT03054337|DRUG|Vadadustat|
223545116|NCT00002593|DRUG|fluorouracil|Given IV as described in Arm Description
223545117|NCT00002593|DRUG|leucovorin calcium|Given IV as described in Arm description.
223545118|NCT00002593|DRUG|levamisole hydrochloride|Given as described in arm description
223545119|NCT03310944|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
223545120|NCT01384851|DRUG|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
223545121|NCT01384851|DRUG|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
223545122|NCT01384851|DRUG|Refresh Contacts|One drop both eyes four times daily for two weeks
223545123|NCT03382912|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Nivolumab
223994847|NCT03054337|DRUG|Placebo|
223994848|NCT03882151|DIAGNOSTIC_TEST|electrical source imaging|automated analysis of surface EEG with electrocal source imaging
223994849|NCT01290276|DRUG|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
223994850|NCT01290276|DRUG|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
223994851|NCT01290276|DRUG|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
223994852|NCT01290276|DRUG|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
223994853|NCT04014244|DRUG|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
223994854|NCT04014244|PROCEDURE|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
223545124|NCT03382912|DRUG|Nivolumab|Nivolumab Alone
223545125|NCT01086696|DRUG|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
223545126|NCT05588440|BIOLOGICAL|ONCT-808|"A single infusion of ONCT-808 autologous CAR-T cell infusion will be administered intravenously~Phase 1: Dose Escalation with bridging therapy as needed~Phase 2: Patients with LBCL or MCL will be enrolled into two separate dose expansion cohorts."
223994855|NCT01762904|OTHER|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
223545127|NCT05588440|DRUG|Bridging Therapy|Bridging therapy can be oral chemotherapy or IV radiotherapy/chemotherapy per institution's guidelines
223545128|NCT04839653|DRUG|Oral Paste(0,5 g) containing 10 mg of polymyxin B, 10 mg of gentamycin and 150 mg of amphotericine B or 500 000 U of nistatin q6h|The oral paste will be applied topically on the oropharyngeal mucosa q6h.
223994856|NCT01762904|OTHER|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
223994857|NCT02345590|DRUG|Eplerenone|25mg of eplerenone
223994858|NCT02906826|DEVICE|Video game|Video game operated by performing therapy correctly
223994859|NCT05770960|DRUG|Naloxegol|Oral administration of Naloxegol after waking up from the Midazolam administration during the colonoscopy.
223994860|NCT05770960|DRUG|codeine phosphate|Oral administration of Codeine after waking up from the Midazolam administration during the colonoscopy.
224122758|NCT07003763|OTHER|Superficial acupuncture at Non-Acupoints|"Participants in this group will receive superficial acupuncture at six pseudo-acupoints that do not correspond to any recognized meridian or traditional acupoint. These points are anatomically matched in location (head, upper limbs, lower limbs, and trunk) to the main acupoints used in the electroacupuncture group but are located at non-meridian, non-acupoint sites in a horizontal position. Acupuncture needles will be connected to an electroacupuncture device with broken wires and thus no electrical stimulation is actually delivered.~All patients will be placed in a supine position. After routine disinfection of the selected sites using 75% alcohol, adhesive pads will be gently affixed to the designated locations. A blunt-tipped, retractable needle will then be used to lightly tap the pad, without penetrating the skin, until the patient perceives a tactile sensation, at which point the stimulation will be stopped. The needle will be retained for 30 minutes."
224299091|NCT04280705|OTHER|Placebo|The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.
224299092|NCT04280705|DRUG|Remdesivir|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
223994861|NCT05770960|OTHER|Placebo|Oral administration of siripus simplex syrup after waking up from the Midazolam administration during the colonoscopy.
223994862|NCT00527761|DRUG|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
223994863|NCT00527761|DRUG|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
223994864|NCT00527761|DRUG|Temodar|150 mg by mouth (PO) on Days 1 - 5.
223994865|NCT03965442|DRUG|Control|Patients who underwent mastectomy under standard general anesthesia
223994866|NCT03965442|DRUG|Esmolol|Patients who underwent mastectomy under general anesthesia with esmolol infusion
223994867|NCT02171299|PROCEDURE|Wound infiltration with local anaesthetic|
223740094|NCT05650645|DRUG|incobotulinum toxin A|The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
223994868|NCT02171299|DRUG|Ropivacaine|
223994869|NCT02330770|DRUG|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
223994870|NCT02330770|DRUG|GnRHa then HCG (single low-dose)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
223994871|NCT02330770|DRUG|GnRHa then HCG (multiple low-doses)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
223994872|NCT04631731|DIAGNOSTIC_TEST|Blood screening|Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
223994873|NCT04631731|DIAGNOSTIC_TEST|Tissue screening|Archival tumor tissue (FFPE) will be spatially analysed in order to define tissue heterogeneity in tumor samples regarding cancer immune cell transcriptional profiles and correlate it with the occurrence/development of immune-related adverse events.
223994874|NCT04113070|DEVICE|Anthropometric measuring|To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.
223994875|NCT04113070|OTHER|Growth environment evaluation|The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
223994876|NCT03730506|DEVICE|Intra oral scanner|computer guided implant
223994877|NCT01991327|DRUG|Androxal|
223994878|NCT01991327|DRUG|Placebo|
223994879|NCT03738475|DRUG|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
223994880|NCT03738475|DRUG|Placebo|Administered intravenously on days 1 and 8.
223994881|NCT04966975|OTHER|neoadjuvant chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
223994882|NCT00737477|DRUG|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
224299093|NCT03222583|DRUG|Placebo|Matching placebo tablet for oral administration
224299094|NCT03222583|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
224299095|NCT03573505|DRUG|BG00011|Administered as specified in the treatment arm.
224299096|NCT03573505|DRUG|Placebo|Administered as specified in the treatment arm.
223994883|NCT04139382|OTHER|Telephone Consultation|A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
223994884|NCT04139382|OTHER|Face-to-Face Consultation|A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
223994885|NCT00002475|BIOLOGICAL|allogeneic tumor cell vaccine|
223994886|NCT00002475|BIOLOGICAL|autologous tumor cell vaccine|
223994887|NCT00002475|BIOLOGICAL|recombinant interferon alfa|
223994888|NCT00002475|BIOLOGICAL|recombinant interferon gamma|
223994889|NCT00002475|BIOLOGICAL|sargramostim|
223994890|NCT00002475|DRUG|cyclophosphamide|
223994891|NCT03477487|BIOLOGICAL|XT-150|Human IL-10 variant transgene in a plasmid DNA vector
223545129|NCT04839653|DRUG|Suspension (10 ml) containing 100 mg of polymyxin B, 80 mg of gentamycin, 350 mg of amphotericine B or 8000000 U of nistation and 500 mg of vancomycin q6h|The suspension will be administered through the nasogastric tube q6h.
223994892|NCT00581477|DRUG|Droxidopa Oral Product|Droxidopa administered in increasing dosages up to 300 mg
223994893|NCT04659564|DEVICE|User of Dayspring device|The Dayspring™ device is a novel FDA-cleared wearable solution that is portable and easy-to-use sequential compression system.
223994894|NCT05695560|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
223994895|NCT00562458|DRUG|anastrozole|
223994896|NCT03106753|DRUG|Bupivacaine|intrathecal bupivacaine 7.5 mg
223994897|NCT03106753|DRUG|Terbutaline|0.25 mg Terbutaline subcutaneously
223994898|NCT02323958|OTHER|acupoint stimulation|stimulation is given at acupoints
223994899|NCT02323958|OTHER|non-acupoint stimulation|stimulation is given at acupoints
223994900|NCT02323958|OTHER|electrode attached|electrodes are attached to skin
223994901|NCT02323958|DEVICE|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
223994902|NCT03261544|PROCEDURE|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
223994903|NCT06181071|OTHER|Distal Muscle Fatigue Protocol|Initially, sociodemographic data, muscle viscoelastic properties, foot plantar pressure, and static and dynamic balance are assessed. Additionally, the strengths of the plantar flexor and dorsiflexor muscles are evaluated. After these assessments, the heel raise exercise will be implemented in this protocol. Firstly, dominant leg, the heel raise exercise will be performed for 3 sets with the knees in full extension until the individual reaches fatigue. Subsequently, the heel raise exercise will be conducted for another 3 sets with the knee in flexion until the individual reaches fatigue. Following these exercises, Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
223994904|NCT06181071|OTHER|Proximal Muscle Fatigue Protocol|One week after the application of the distal muscle fatigue protocol, the same individuals will undergo the proximal fatigue protocol. In this protocol, individuals will perform, dominant leg, a single-leg squat exercise targeting the fatigue of the hip flexor and extensor muscles. Prior to this exercise, the viscoelastic properties of the muscles, foot plantar pressure, static and dynamic balances, as well as the strengths of the hip flexor and extensor muscles will be assessed. Then, individuals will perform the single-leg squat exercise, 3 sets. When the individual indicates fatigue, the set will conclude, allowing a 30-second rest between sets. Then, the strengths of the hip flexor and extensor muscles will be re-evaluated. If the individual reports a value of 7 or higher on the modified Borg scale, the viscoelastic properties of the muscles, foot plantar pressure, and static and dynamic balance will be reassessed when a 50% decrease in the initial strength is detected.
223994905|NCT02874014|RADIATION|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
223545130|NCT04839653|DRUG|Intravenous Antibacterial Agent - a 3-day course of systemic cefotaxime 1 g q6h or ceftriaxone 1 g qd|Patients who do not receive systemic antibiotics for other reasons will get a short course of systemic antibiotic
223545131|NCT05000372|DRUG|68Ga-grazytracer|68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
224299097|NCT05145179|DRUG|SSGJ-705|0.1, 1, 3, 6, 10, 15 or 20mg/kg, IV, Day 1, 8, 15 of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first. Every 4 weeks a treatment cycle.
223740095|NCT05650645|DRUG|Placebo-Saline|Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
224299098|NCT03145636|DEVICE|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
224299099|NCT03145636|OTHER|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
224299100|NCT03145636|OTHER|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
223545132|NCT01405430|BIOLOGICAL|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
223994906|NCT02838992|DRUG|Rabbit ATG, (Genzyme)|ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
223994907|NCT02838992|DRUG|Cy|Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
223994908|NCT02838992|DRUG|CsA|CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
223994909|NCT02838992|BIOLOGICAL|Cord blood|Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
223994910|NCT00485277|BIOLOGICAL|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
223994911|NCT03586791|PROCEDURE|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
223994912|NCT03586791|PROCEDURE|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
223994913|NCT03586791|PROCEDURE|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
223994914|NCT06381986|DRUG|SHJ002|Topical ophthalmic
223994915|NCT06381986|OTHER|Vehicle|Topical ophthalmic
223994916|NCT05169840|OTHER|Genetic Risk Score for Coronary Artery Disease|Blood samples will be genotyped for million of genetic risk variants for Coronary Artery Disease (CAD)
223740096|NCT04488198|OTHER|Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with acupuncture needles.
223740097|NCT04488198|OTHER|Placebo-Acupuncture|Patients receive 8 acupuncture sessions (1 session per week, 20 minutes per session) with placebo-needles.
223740098|NCT07069738|DEVICE|CRT-D with a Quadripolar LV lead|Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), Quadripolar LV Lead.
223994917|NCT06533319|DRUG|sofosbuvir/velpatasvir|Patients who qualify for the study will be provided with sofosbuvir/velpatasvir for chronic hepatitis C treatment.
223994918|NCT02451176|DEVICE|Davol Bard Soft Mesh synthetic|soft mesh synthetic
223994919|NCT02451176|DEVICE|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
223994920|NCT02472340|PROCEDURE|Muscle Biopsy|Muscle Biopsy
223994921|NCT04061876|DRUG|Ruxolitinib|Participants began oral administration of ruxolitinib at 5 mg QD;Methylprednisolone: 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
223994922|NCT04061876|DRUG|Corticosteroid|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 3 days, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
223545133|NCT01643460|PROCEDURE|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
223545134|NCT05195203|DRUG|HS-10353|Single or multiple dose(s) of HS-10353
223994923|NCT03884322|OTHER|Prepod|the prepod is either a 4 way stretch polyester blend fleece with 8 to 10% lycra, or a 95%cotton5% lycra blend knit. It comes in 4 different sizes to assure a pod that has a conforming but not restricting fit so that the infant is free to stretch in any direction at any time but is loosely held in a position of physiological flexion (the fetal position) when not stretching.
223994924|NCT03884322|PROCEDURE|Joint compression exercises|Each premature infant enrolled as a control subject received approximately 10 minutes of joint compression exercises provided by a NICU trained physical or occupational therapist 5x a week. The exercises consisted of waking the infant slowly, gently if necessary just before feeding with a simple range of motion stretching program then stabilizing an extremity and applying force distally to proximally for 6 repetitions with a brief pause between each compression.
223994925|NCT06359418|DEVICE|Acupuncture|The acupuncture needle (size 0.30x40mm) will be inserted into DU20, EX-HN3 and GB8 acupoints at the depth of 15-30mm; The acupuncture needle (size 0.30x50mm or size 0.30x75mm) will be inserted into other acupoints at the depth of 40-70mm; Manipulation will be done after insertion (6 times of small amplitude and uniform twist).
223994926|NCT06359418|DEVICE|Sham acupuncture|The acupuncture needle (size 0.20x25mm) will be inserted into all acupoints at the depth of 2mm without any manipulation.
223994927|NCT06169072|DRUG|Superparamagnetic Iron Oxide|Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
223994928|NCT06169072|DEVICE|Technetium99|Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
223545135|NCT05195203|DRUG|Placebo|Single or multiple dose(s) of placebo
223994929|NCT04278027|BEHAVIORAL|Cognitive Remediation Therapy|"CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)"
223994930|NCT01835405|DEVICE|LiquiBand Flex|
223994931|NCT01835405|DEVICE|Dermabond Advanced|
223994932|NCT01835405|DEVICE|Sutures (Prolene)|
223994933|NCT05161598|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
223994934|NCT05108753|OTHER|Procedure/Surgery|Transanal Total Mesorectal Excision
223994935|NCT03897231|OTHER|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH, AH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (TM) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
223994936|NCT05138289|OTHER|Total Plaque Volume|Compare total plaque volume with IVUS obtained during ICA (invasive coronary angiography)
223994937|NCT03924102|DRUG|Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT|A rest and stress imaging study will be conducted on the PET/CT scanner with \[11C\] Acetate.
223994938|NCT00021424|BIOLOGICAL|recombinant fowlpox-TRICOM vaccine|
223994939|NCT03423927|BEHAVIORAL|Self-hypnosis + Self-care|Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
223994940|NCT02694367|OTHER|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
223994941|NCT02885584|DEVICE|High frequency percussive ventilation|
223994942|NCT03415633|OTHER|Home Respiratory Polygraphy (APNIA)|Randomizing to start with home respiratory polygraphy (APNIA)
223994943|NCT03415633|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
223994944|NCT03415633|OTHER|Home Respiratory Polygraphy (APNIA)|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA)
223545136|NCT02366325|DRUG|EPO-018B|
223994945|NCT03415633|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
223740099|NCT07069738|DEVICE|CRT-D with INGEVITY+ pace/sense lead|Participants randomized to this cohort will receive a BSC system: CRT-D, Right Atrial Lead (RA), Defibrillation Lead (RV), INGEVITY+ pace/sense Lead (implanted in the LBBA)
223994946|NCT04060693|DEVICE|P0.5|Investigational Medical Device collecting spectral raman data from tissue.
223994947|NCT01336049|DRUG|Nimotuzumab|Nimotuzumab 200mg/week
223994948|NCT05431218|DRUG|Cholecalciferol Liquid|daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
223994949|NCT05762952|DRUG|Dapagliflozin 10mg Tab|Once daily oral dapagliflozin 10mg
223994950|NCT05762952|DRUG|Placebo|Placebo capsules formulated by pharmacy to be indistinguishable from active drug
223994951|NCT06228716|DEVICE|Training with hybrid simulation method|Subcutaneous biological drug self-administration training was given by the researcher in two stages, theoretical and practical, face to face. Power point presentation and training brochure were used in theoretical training. The practical training given after the theoretical training was given using the Hybrid simulation method. The Wearable Subcutaneous Injection Hybrid Simulator developed by the researcher was worn by the individuals after being informed about its purpose and function. Afterwards, they were expected to apply the subcutaneous application step by step as explained to them. Each application step they made incorrectly was corrected and repeated with the support of the researcher. The application was considered successful if they completed all application steps correctly from start to finish. The training took approximately 40 minutes. After the practical training, the individuals' questions, if any, were answered and the training was terminated.
223994952|NCT06228716|OTHER|Broshure|Subcutaneous biological drug self-administration training was given theoretically face to face by the researcher using a power point presentation and training brochure. The training lasted approximately 25 minutes and was given in the same room where the experimental group received training. After the training, any questions the individuals had were answered and the training was ended.
223994953|NCT02345109|DEVICE|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT."
224299101|NCT04268316|DEVICE|Virtual Reality Behavioral Activation|"Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities."
223994954|NCT02345109|DEVICE|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
223994955|NCT03992391|BEHAVIORAL|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
223994956|NCT01853475|DRUG|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
224299102|NCT04268316|BEHAVIORAL|Behavioral Activation in real-life|Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
223994957|NCT01853475|DRUG|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
223994958|NCT01853475|DRUG|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
223994959|NCT01853475|DRUG|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
223994960|NCT03836859|DRUG|rhNGF 20μg/mL|"Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days."
223994961|NCT03836859|OTHER|Placebo|Vehicle: formulation containing L-methionine as excipient.
223994962|NCT01667809|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
224299103|NCT00845819|DRUG|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) \& nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
223994963|NCT01667809|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
223994964|NCT02470780|DRUG|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
223994965|NCT02470780|DRUG|Placebo|Placebo matching Rifaximin treatment.
223994966|NCT05575817|BEHAVIORAL|Web Based Patient Tutorial on Prolonged Grief Disorder Therapy|"The patient tutorial will contain 9 modules, each designed to be used flexibly in conjunction with Prolonged Grief Disorder Therapy (PGDT) telehealth sessions with the therapist. Each module takes about 15-30 minutes to complete. The patient tutorial consists of information about grief and adaptation to loss, including a description of seven healing milestones that are the focus of PGDT and an explanation of prolonged grief and how to understand it. In addition, the tutorial has descriptions of the procedure, goals and rationale for a series of in-session therapeutic exercises to be undertaken with the therapist, as well as descriptions and encouragement to participate in interim therapeutic activities (i.e., homework) assigned by the therapist after each treatment session. The tutorial also contains a self-assessment component for each module that can be completed by the patient and shared with the therapist."
223994967|NCT01023958|DRUG|BI 6727, IV infusion|phase II
223545137|NCT04663074|DIAGNOSTIC_TEST|IVUS control|Intravascular Control of the bridging stentgrafts during branched EVAR
223545138|NCT00204529|DRUG|pegylated interferon-alpha-2a|
223545139|NCT00204529|DRUG|interferon-alpha-2a|
223994968|NCT05824000|DEVICE|Eye drops for itchy and water eyes|Ocular drops for itchy and watery eyes
223729531|NCT03762421|BEHAVIORAL|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
223729532|NCT03762421|BEHAVIORAL|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
223729533|NCT01261689|DRUG|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
223729534|NCT01261689|OTHER|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
223729535|NCT05331274|OTHER|exercise group|"1 stage~* In a sitting position, pull the leg up and extend the knee forward~* Standing, bending forward and bending the knee~* Supine, tucked legs~* Maintaining spinal smoothness in crawling~* Prone heel pull to buttock~Stage 2~* Prone on forearms-hands~* Extending the supine hands to the knees~* Rounding and hollowing the waist in crawling~* Progressive sit-stand~* Standing up from sitting and putting on and taking off socks~* Reaching up while standing and maintaining the straightness of the spine~* Squatting~* Climbing and descending stairs~Stage 3~* Maintaining standing, arms forward~* Slipping hands on the bed while standing~* Initiating the standing throw and maintaining the position until the final interval~* Putting on and taking off socks while standing~* Taking weight towards the ground from a certain height~* Picking up different weights from the ground~* Push-pull items~* Crossing obstacles of certain height~* Walking a certain distance"
223729536|NCT05331274|OTHER|pain training group|"The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group."
223729537|NCT05657834|DRUG|[14C]-TVB-2640|50 mg of TVB-2640 oral administration
223729538|NCT04671407|DRUG|Hypertonic Saline|Hypertonic Saline 3% and 0.9%
223994969|NCT02859090|PROCEDURE|tonsillectomy|
223994970|NCT02859090|BIOLOGICAL|blood sample|
223994971|NCT00905905|DRUG|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
223994972|NCT00905905|DRUG|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
223994973|NCT02159040|DRUG|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
223994974|NCT02159040|DRUG|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
223994975|NCT01484600|DRUG|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
223994976|NCT01484600|DRUG|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
223994977|NCT01301040|DRUG|epirubicin, cyclophosphamide, docetaxel|"* Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~* Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles."
223994978|NCT05005962|DEVICE|Neurothrombectomy|Neurothrombectomy device will be used to treat patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well to collect real-world data and to access clinical outcomes associated with the use of these devices.
223994979|NCT00605332|DEVICE|inferior vena cava filter|Crux Biomedical IVC Filter
223994980|NCT03106454|DRUG|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
223994981|NCT03106454|DRUG|Norethindrone|Norethindrone 1.05mg
223994982|NCT06378684|DRUG|Group 1: JW0104(Period 1), C2207(Period 2), JW0104 + C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
223994983|NCT06378684|DRUG|Group 2: JW0104 + C2207(Period 1), JW0104(Period 2), C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
223994984|NCT06378684|DRUG|Group 3: C2207(Period 1), JW0104 + C2207(Period 2), JW0104(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
223994985|NCT06378684|DRUG|Group 4: JW0104(Period 1), JW0104 + C2207(Period 2), C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
223994986|NCT06378684|DRUG|Group 5: JW0104 + C2207(Period 1), C2207(Period 2), JW0104(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
223994987|NCT06378684|DRUG|Group 6: C2207(Period 1), JW0104(Period 2), JW0104 + C2207(Period 3)|Tablet, Oral, QD for 10 Days, Washout period is more than 14 days after administration
223994988|NCT02207855|DRUG|Chloroprocaine|
223994989|NCT05701878|BEHAVIORAL|SMARTest mobile app for COVID-19 self-testing|The mobile app has self-testing features and information with regard to self-testing and COVID-19.
223994990|NCT01285700|DRUG|Lamazym|ERT, infusion weekly
223994991|NCT01359787|DRUG|Mapracorat|Daily topical application
223994992|NCT01359787|DRUG|Vehicle without active|Daily topical application
223994993|NCT04851639|OTHER|Wolverhampton Assessment Tool|a proxy means for assessing whether clinician intervention is required and to assess patient's lived quality of life
223994994|NCT06189885|DRUG|Cefazolin with Daptomycin|For patients randomized to receive daptomycin (8 mg/kg), the drug will be administered in a 50 cc bag, accompanied by a 500 cc bag of normal saline within 60 minutes before surgical incision and discontinued after 24 hours postoperatively.
223994995|NCT06189885|DRUG|Cefazolin with vancomycin|Then vancomycin (15 mg/kg) will concurrently be given and completed within 60 minutes before surgical incision and discontinued after 24 hours postoperatively9. Patients in the vancomycin arm will receive this drug in a 50 cc bag accompanied by a 500 cc bag of normal saline.
223994996|NCT05861245|RADIATION|5-fraction hipofractionated protontheray|"The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~* For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~* For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction."
223994997|NCT05905159|BEHAVIORAL|ABM|Direct attention away from pain-related information (i.e., facial expressions) through implicit training procedures
223994998|NCT05905159|BEHAVIORAL|Control|Direct attention equally towards pain-related and neutral information (i.e., facial expressions) through implicit training procedures
223994999|NCT00054678|DRUG|MyoCell™|
223995000|NCT00054678|DEVICE|MyoCath™|
223995001|NCT01932476|DIETARY_SUPPLEMENT|Gluten Challenge|Three-day gluten containing dietary challenge.
223995002|NCT01932476|DIETARY_SUPPLEMENT|Sham Challenge|Three-day sham (gluten free) dietary challenge
223995003|NCT03982212|DRUG|Copaxone|"* Agent: Glatiramer acetate (Copaxone®)~* Dose: 40 mg~* Route: Intratumoral injection~* Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
223995004|NCT03145922|OTHER|Observational Study|Observational study utilizing bronchoscopy, and imaging
223995005|NCT05853705|BEHAVIORAL|Strong Hearts Exercise Program|The participant will either begin at the easiest variation of each strength exercise (level A), or will be placed at a specific level for each strength exercise based on their assessment with physical therapy. Participants can progress to the next level of difficulty of a specific strength exercise based on their rating of perceived exertion (RPE) with the opportunity to move to the next level if they have RPE score of 6 or less and if their heart rates are at goal. Each participant will be provided with heart rate ranges based on the heart rate reserve (HRR) method using their baseline resting and peak heart rates obtained during their cardiopulmonary exercise testing (CPET) or percent predicted heart rate based on age if CPET is not available. HRR goals will be set individually for patients and adjusted per protocol to guide effort.
223995006|NCT05969860|PROCEDURE|Clinical Encounter|Receive treatment in clinic
223995007|NCT05969860|OTHER|Home Health Encounter|Receive at-home treatment
223995008|NCT05969860|OTHER|Quality-of-Life Assessment|Ancillary studies
223995009|NCT05969860|OTHER|Questionnaire Administration|Ancillary studies
223995010|NCT02656589|DRUG|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
223995011|NCT02656589|DRUG|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
223995012|NCT01424462|DRUG|A|Single dose treatment IR formulation
223995013|NCT01424462|DRUG|B|Low Extended release single dose
223995014|NCT01424462|DRUG|C|Medium extended release formulation
223995015|NCT01424462|DRUG|D|High extended release rate single dose
223995016|NCT01972932|DIETARY_SUPPLEMENT|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
223995017|NCT01972932|DIETARY_SUPPLEMENT|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
223995018|NCT03080493|DRUG|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
223995019|NCT03080493|DRUG|Placebo oral capsule|Packaged identical to gabapentin dosing
223995020|NCT03080493|DRUG|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
223995021|NCT00801463|DRUG|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
223995022|NCT05347862|OTHER|Control group|At baseline, this group will receive only the usual standard advice to practice physical activity as an important measure to promote health benefits. During the intervention period, they will receive only telephone calls monthly to assess the physical activity practice, changes in medication, and adverse events. When appropriate, evaluations of 12 and 24 weeks will be scheduled.
223995023|NCT05347862|OTHER|Physical activity promotion|"The intervention will be based on a remote approach, for 24 weeks. The intervention will consist of telephone calls and sent messages to promote the practice of 150 minutes/week of physical activity in the daily life of participants, plus short text messages promoting health behaviors related to self-care, nutrition, physical activity, and sedentary behavior.~Initially, this group will be followed weekly during the first 4 weeks. After this period this group can up to two weekly calls, according to their preference. The text messages will be weekly. During the telephone calls, the research team will verify the volume of PA achieved and help the participants to identify and overcome barriers to PA practice, and motivate and register any adverse events related or not to the study."
223995024|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
223729539|NCT02133287|DEVICE|AVI® Arsenic trioxide drug eluting stent delivery system|
223995025|NCT00755417|DRUG|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
223995026|NCT00755417|DRUG|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
223995027|NCT00759642|DRUG|lapatinib|lapatinib 1500 mg PO daily
223995028|NCT00813722|BEHAVIORAL|phone call|patients received or not phone calls to give orientation abou treatment
223995029|NCT00813722|DRUG|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
223995030|NCT00813722|DRUG|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
223995031|NCT03867539|OTHER|Differing pain management strategy|"The investigators aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated."
223995032|NCT04773925|BEHAVIORAL|Mindfulness counseling|Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
223995033|NCT05333822|DIETARY_SUPPLEMENT|Bashan|a vegetable plant based compound drink add after three meals for 14 days
223995034|NCT05333822|OTHER|water|water as placebo
223995035|NCT02362503|DRUG|BMS-663068|BMS-663068
223995036|NCT02362503|OTHER|Placebo|Placebo
223995037|NCT04545528|BEHAVIORAL|Dietary recommendations|The test group will be seen by a nutritionist and will receive specific dietary recommendations according to their specific comorbidities and drugs
223995038|NCT01340001|PROCEDURE|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
224295348|NCT05342207|PROCEDURE|Endoscopic plantar fascia release in cases of chronic resistant plantar fasciopathy|A medial portal will be developed 1cm away from the plantar skin along a vertical line passing through the posterior border of the medial malleolus with the foot in neutral position. A 5 mm cannula will be then introduced through the lateral portal over the trocar. Irrigation fluid will be then connected. A 30-degree 4.0 mm endoscope will be inserted inside the cannula. A 4.5 motorized incisor blade will be then used to debride the subcutaneous tissue until full visualization of the shiny fibers of the plantar fascia will be possible. A needle was inserted vertically through the heel skin to act as a land mark for the middle of the plantar fascia. A scalpel blade will then introduced through the medial portal to divide the full thickness of the medial half of the plantar fascia into two leaflets under direct visualization . The posterior leaflet will be then totally debrided using a motorized incisor blade . The tunnel will then be irrigated and stitches will be done.
223729540|NCT02133287|DEVICE|Firebird2® sirolimus eluting stent system|
223995039|NCT02306590|DIETARY_SUPPLEMENT|Calogen|
223995040|NCT02306590|DIETARY_SUPPLEMENT|Placebo|
223995041|NCT06456489|DRUG|Solumedrol|125 mg methylprednisolone intravenous pulse on 2 consecutive days
223995042|NCT05335200|DIAGNOSTIC_TEST|(S)-[18F]FBFP PET/CT|Patients will be intravenously injected with 185-370MBq (S)-\[18F\]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
223995043|NCT06377085|DRUG|Placebo for the AZA 10mg/m^2|Placebo control group for the 10mg/m\^2, one-time subcutaneous injection without the active treatment.
223995044|NCT06377085|DRUG|Placebo for the AZA 20mg/m^2|Placebo control group for the 20mg/m\^2, one-time subcutaneous injection without the active treatment.
223995045|NCT06377085|DRUG|Placebo for the AZA 35mg/m^2|Placebo control group for the 35mg/m\^2, one-time subcutaneous injection without the active treatment.
223995046|NCT06377085|DRUG|Placebo for the AZA 75mg/m^2|Placebo control group for the 75mg/m\^2, one-time subcutaneous injection without the active treatment.
223995047|NCT06377085|DRUG|5-Azacytidine 10mg/m^2|5-Azacytidine 10mg/m\^2, one-time subcutaneous injection
223995048|NCT06377085|DRUG|5-Azacytidine 20mg/m^2|5-Azacytidine 20mg/m\^2, one-time subcutaneous injection
223995049|NCT06377085|DRUG|5-Azacytidine 35mg/m^2|5-Azacytidine 35mg/m\^2, one-time subcutaneous injection
223995050|NCT06377085|DRUG|5-Azacytidine 75mg/m^2|5-Azacytidine 75mg/m\^2, one-time subcutaneous injection
223995051|NCT06423950|OTHER|Peds Evolutionary Tumor Board (pedsETB)|The pedsETB consists of evolutionary biologists, mathematicians, research scientists, statisticians, data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators. The pedsETB membership is inclusive of members from the participating institutions. The pedsETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The pedsETB will collect data through a chart review regarding adherence and results of ETB recommendation.
223995052|NCT05636228|DRUG|INV-102|INV-102 Ophthalmic Solution
223995053|NCT05636228|DRUG|Vehicle|Vehicle Ophthalmic Solution
223995054|NCT04197479|DRUG|Placebo|Matching tablets
223995055|NCT04197479|DRUG|Resmetirom|Tablet
224122759|NCT07003763|OTHER|Standard care|"All participants, regardless of group assignment, will receive standard care as part of routine oncological and psychological management. Standard care includes:~* Basic psychological support: General psychological counseling or emotional support provided by nursing staff or clinical psychologists as needed, without structured psychotherapy or pharmacological antidepressant interventions unless clinically indicated.~* Health education: Guidance on sleep hygiene, nutrition, and stress management, along with education about cancer-related emotional symptoms and coping strategies.~* Medication management: Participants will continue their current medications for chronic comorbidities (e.g., antihypertensives, antidiabetics) as previously prescribed. However, cancer-related medications associated with active treatment-such as chemotherapy, targeted therapies, immunotherapy, or hormonal therapy-will be excluded during the trial period to avoid confounding effects."
224122760|NCT07007676|DEVICE|real-time CGM|real-time CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.
223995056|NCT00884416|DRUG|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
223729541|NCT00650624|DRUG|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
223995057|NCT02803593|BEHAVIORAL|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
223995058|NCT02803593|BEHAVIORAL|American Cancer Society information on breast cancer|The American Cancer Society (ACS) webpage has a wide range of information on breast cancer including prevention, treatment, and ways to connect with breast cancer survivors.
223995059|NCT00005871|DRUG|fluorouracil|
223995060|NCT00005871|DRUG|rubitecan|
223995061|NCT06355323|OTHER|Blood test|Blood test
223995062|NCT06355323|OTHER|chest CT scan|chest CT scan
223995063|NCT00302523|DRUG|Tacrolimus|FK506,0.1mg/kg/d
223995064|NCT05143138|DEVICE|GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
223995065|NCT01993849|DRUG|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
223995066|NCT01993849|OTHER|Placebo|Placebo, designed to match in appearance to NAC
223545140|NCT05158920|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)|MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
223545141|NCT00001937|DRUG|FK463|
223995067|NCT00164710|DRUG|sulfadoxine-pyrimethamine|
223995068|NCT00164710|DRUG|amodiaquine plus sulfadoxine-pyrimethamine|
223995069|NCT00164710|DRUG|amodiaquine plus artesunate|
223545142|NCT00001937|DRUG|Fluconazole|
223995070|NCT00164710|DRUG|chlorproguanil-dapsone plus artesunate|
223995071|NCT00164710|DRUG|lumefantrine-artemether|
223995072|NCT00480675|PROCEDURE|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
223995073|NCT00480675|PROCEDURE|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
223995074|NCT02195479|DRUG|Velcade|Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
223995075|NCT02195479|DRUG|Melphalan|Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
223995076|NCT02195479|DRUG|Prednisone|Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
223995077|NCT02195479|DRUG|Daratumumab IV|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
223995078|NCT02195479|DRUG|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
223995079|NCT02195479|DRUG|Daratumumab SC|Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
223995080|NCT02023749|DIETARY_SUPPLEMENT|Nut group|
223995081|NCT06411509|OTHER|TC plus active rTMS|The rTMS intervention is performed using a MagPro X100 by MagVenture with a water-cooled figure-of-eight coil. Before the treatment session, the resting motor threshold of the left abductor pollicis brevis is determined. The rMT is defined as the minimum intensity which produces five motor evoked potential responses of at least 50 μV in 10 trials at rest. A protocol of 1 Hz rTMS at 80% of RMT is applied over the frontal area of the right DLPFC. The coil position is localized using a frameless stereotactic neuronavigation system (TMS-Navigator, Localite GmbH, Bonn, Germany). Participants receive only three sessions of TC per week without rTMS during in the week 1 and 2, and the TC potocol is same as the TC-alone group. Participants receive daily rTMS (30 minutes) for 5 days a week combined with three sessions of TC in the last 2 weeks. Active rTMS deliveres at 1 Hz for 30 min (1800 pulses per session) with the intensity of 80% rMT.
223995082|NCT06411509|OTHER|Tai Chi plus sham rTMS|Sham rTMS is administrated the same procedures as the active rTMS but with low intensity of 20% rMT to elicit similar skin sensations and sounds. The TC protocol in this group is the same as the TC-alone group.
223995083|NCT06411509|BEHAVIORAL|TC-alone|Participants in the TC-alone group attend a simplified Yang style 8-Form Easy TC training program in a group format. Each session lasts for 60 minutes and are conducted three times per week over a period of four weeks. In the first session, the certified TC instructor explains the exercise theory and procedures. The remaining sessions includes 5 to 10 minutes warm-up and a review of TC principles, 45 minutes meditative movements, and 5 to 10 minutes cool-down
223995084|NCT06411509|BEHAVIORAL|Low intensity physical exercise|To achieve the same exercise volume with TC-alone group, participants in the low-intensity physical exercise control group attend a four-week exercise training in group format. Exercise sessions are 60 minutes with three times per week. Each exercise session consists of 5 to 10 minutes warm-up, 45 minutes of aerobic training, and a 5 to 10 minutes cool-down.
223995085|NCT05450536|OTHER|Video Model and Role Play|Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
224122761|NCT06866613|DRUG|Esflurbiprofen Topical System (EFTS)|One EFTS is applied to the injured area over consecutive 7 days
224122762|NCT06866613|DRUG|Placebo Patch|One placebo patch is applied to the injured area over consecutive 7 days
224122763|NCT06682793|BIOLOGICAL|A2B395|Allogeneic logic-gated Tmod CAR T cells
224122764|NCT06682793|DIAGNOSTIC_TEST|xT CDx with HLA-LOH assay|An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
224122765|NCT04080154|DRUG|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
224122766|NCT05412212|OTHER|LTBI video intervention|3-minute educational video about latent tuberculosis and importance of taking and completing treatment
224122767|NCT07018869|OTHER|Intervention website access|Receive access to CTAC intervention website with educational content and interactive modules
224122768|NCT07018869|OTHER|Control website access|Receive access to CTAC control website with general health education
224122769|NCT07018869|OTHER|Interview|Ancillary studies
224122770|NCT07018869|OTHER|Questionnaire Administration|Ancillary studies
224122771|NCT02415296|OTHER|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
223545143|NCT02137070|PROCEDURE|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
224122772|NCT02415296|OTHER|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
224122773|NCT02415296|OTHER|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
224122774|NCT03988829|BEHAVIORAL|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
224122775|NCT03988829|BEHAVIORAL|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
224122776|NCT03988829|BEHAVIORAL|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
224122777|NCT06873802|OTHER|Non-Interventional Study|Non-interventional study
224122778|NCT06693505|COMBINATION_PRODUCT|caffeinated chewing gum|two pieces of caffeinated chewing gum at an absolute dose of 200 mg (Military Energy Gum®, Ford Gum and Machine Go, Akron, NY, USA)
224122779|NCT06693505|COMBINATION_PRODUCT|placebo|two pieces of similar looking and tasting placebo gum that did not contain caffeine (xylitol, lime mint, green; Lotte, Saitama, Japan) (PLA trial)
224295349|NCT05307887|DEVICE|Sync VR Medical PICO G2 4K Virtual Reality Technology|Virtual reality headset and software
223995086|NCT00927498|DRUG|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
223995087|NCT00927498|DRUG|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
223995088|NCT00728299|DRUG|PomWonderful Juice|8 oz per day each day for 78 weeks
224122780|NCT06693271|DIETARY_SUPPLEMENT|intervention of protein, blueberries|intervention of 30g/day (1 scoop) of a colorless, tasteless whey protein isolate powder supplement and 1 cup (150 grams) of blueberries per day.
224122781|NCT06693271|BEHAVIORAL|Exercise training|Three 60-minute multimodal exercise sessions per week. Exercise interventions will be individualized to each participant based on their fitness level as per recommended guidelines for older adults. Each session will include a warm-up and cool-down (\~5 minutes each), 30 minutes of moderate intensity aerobic exercise and 20 minutes of moderate intensity resistance training.
223729542|NCT00650624|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
223995089|NCT00728299|DRUG|Placebo juice|8 oz per day for 78 weeks
224122782|NCT06502977|DRUG|Tarlatamab|IV infusion
224295350|NCT01758146|DRUG|Tamoxifen|20 mg once daily for 5 years
223995090|NCT05289219|BEHAVIORAL|EXPOBAR|Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
223995091|NCT04430803|DIETARY_SUPPLEMENT|Hydrogen-rich water|A tablet that produces hydrogen dissolved in a glass of water
223995092|NCT04430803|OTHER|Control Water|A glass of tap water
223995093|NCT03659383|COMBINATION_PRODUCT|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
223995094|NCT00002668|BEHAVIORAL|Observation|
223995095|NCT00002668|BEHAVIORAL|Educational Intervention and Behavioral Skills Training|
223995096|NCT02735434|BEHAVIORAL|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
223995097|NCT02735434|OTHER|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
223995098|NCT00499278|BEHAVIORAL|Rehabilitation after joint replacement surgery|
223995099|NCT05773911|DEVICE|4% chitosan gel (pH 3.48).|Reciprocal Chitosan brush with 4% chitosan gel (pH 3.48).
223995100|NCT05773911|DEVICE|Reciprocal Chitosan brush|Reciprocal Chitosan brush
223995101|NCT05584605|BEHAVIORAL|Aerobic treadmill training|The intervention will be delivered based on the initial exercise testing and graded based by increasing the duration, speed and/or altitude of the treadmill training.
223995102|NCT05584605|BEHAVIORAL|Stretching exercise|Interventions, such as stretching, relaxation, passive soft-tissue technics (excl. manipulation) that do not elevate the heart rate above 20HRR
223995103|NCT03924115|DEVICE|Transmedial Psychoeducational Program to improve adherence full or partial (PS)|Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
223995104|NCT02627378|OTHER|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
223995105|NCT02627378|OTHER|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
223995106|NCT04088045|DEVICE|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
223995107|NCT01497106|BEHAVIORAL|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
223995108|NCT01497106|BEHAVIORAL|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
223995109|NCT02704013|DRUG|Oxybutynin|Anticholinergic
223995110|NCT03443414|DRUG|RPL554 suspension|A dual PDE3/PDE 4 inhibitor
223995111|NCT03443414|DRUG|Placebo|Placebo solution
223995112|NCT02353416|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
223995113|NCT02353416|OTHER|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
223995114|NCT00760344|DRUG|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
223995115|NCT00760344|DRUG|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
223995116|NCT00760344|DRUG|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
223995117|NCT00760344|DRUG|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
224295351|NCT01758146|DRUG|Letrozole|Letroz, Femara, Letronat
223995118|NCT00760344|DRUG|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
223995119|NCT00760344|DRUG|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
223995120|NCT04380077|PROCEDURE|vitrectomy with sulfur hexafluoride gas|vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy
223995121|NCT04380077|PROCEDURE|vitrectomy with balanced salt solution|vitreous substitution with balances salt solution during vitrectomy
223995122|NCT00377988|DRUG|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
223995123|NCT00377988|DRUG|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
223995124|NCT00940745|DEVICE|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
223995125|NCT00940745|DRUG|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
223995126|NCT01389089|BEHAVIORAL|ice gel pack|ice gel pack combined with elevation
223995127|NCT01389089|OTHER|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
223995128|NCT01389089|DEVICE|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
223995129|NCT03329300|BEHAVIORAL|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
223995130|NCT03325777|BEHAVIORAL|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
224122783|NCT06695325|DIAGNOSTIC_TEST|HbA1c test|Patients will be asked to have a HbA1c test in the clinic with a venous draw and then either fingerprick or upper arm draw. They will do the latter again at home.
224122784|NCT06688136|DRUG|ropivacaine|Ropivacaine 200 mg diluted to 50 mL
223995131|NCT03325777|BEHAVIORAL|SHAM Training|SHAM Training
223995132|NCT03516097|BEHAVIORAL|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
223995133|NCT03516097|DEVICE|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
223995134|NCT01181791|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
223995135|NCT01181791|OTHER|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
223995136|NCT05692583|DIAGNOSTIC_TEST|ultrasound examination of wrist|musculoskeletal ultrasound examination of affected wrist
224122785|NCT06292494|DEVICE|Exablate 4000 Transcranial MRgfUS System|Focused ultrasound interrupt structure of epilepsy network to improve seizure.
224122786|NCT06692101|OTHER|oral care|We prepared the necessary tools and suction devices, then helped patients sit upright before starting oral care. Using a flashlight and toothbrush, we assessed the mouth and removed any food debris, aspirating saliva if needed. We cleaned the teeth using a toothbrush, dental floss, and an interdental brush with a small amount of fluoridated toothpaste. The Bass method was used for brushing. Finally, we cleaned the front two-thirds of the tongue with a damp toothbrush.
224122787|NCT06692101|DEVICE|Neuromuscular Electrical Stimulation (NMES)|We used the VitalStim® device to deliver neuromuscular electrical stimulation (NMES). Before placing the electrodes, participants were asked to shave any facial hair and clean their neck skin with alcohol wipes. We positioned four electrode pads horizontally, above and below the hyoid bone. The device provided stimulation at a pulse rate of 80 Hz with a biphasic pulse duration of 300 microseconds. Each session lasted 30 minutes, with the intensity gradually increased in 0.5 mA intervals, based on the patient's comfort level, and adjusted to their maximum tolerance.
224122788|NCT06693180|OTHER|HBOT|Hyperbaric Oxygen Therapy
224122789|NCT06693388|OTHER|Exercise|2 minutes each exercise with 30 sec break - 4 exercises prior to serial casting
224122790|NCT06693388|OTHER|Whole-Body Vibration|WBV prior to serial casting
224122791|NCT06693388|OTHER|Serial Casting|Serial Casting as provided by standard of care
224295352|NCT01443559|GENETIC|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
224295353|NCT01443559|GENETIC|homogenic cornea|homogenic corneas were sterilised by radiation
224295354|NCT03357887|OTHER|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
223545144|NCT02137070|OTHER|Non surgical/Community volunteers|Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
223545145|NCT06022926|PROCEDURE|warmed with electric blankets|warmed with electric blankets
223545146|NCT06022926|OTHER|patients without warming|patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
223995137|NCT05490212|OTHER|Single Molecule Array (SiMoA)|The Single Molecule Array (SiMoA), capable of quantifying multiple salivary cytokines from a single sample source at a femtoscale level. The SiMoA platform has been adapted to detect up to nine inflammatory biomarkers, including CRP, PCT, tumor necrosis factor α (TNF α) and ILs 1ß, 6, and 8 in neonatal saliva.
223995138|NCT00786643|DRUG|5-Fluorouracil|5-FU bolus was administered at 400mg/m\^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m\^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
223995139|NCT00786643|DRUG|Leucovorin (LV)|Leucovorin 200mg/m\^2 was administered over 2 hours on day 1 and day 2 of each cycle.
223995140|NCT00786643|DRUG|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m\^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
223995141|NCT00786643|DRUG|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
223995142|NCT02165995|PROCEDURE|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
223995143|NCT02165995|PROCEDURE|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
223995144|NCT06154928|OTHER|Drinking Warm Water Intervention|Patients in the Warm Water Group (WG) received a warm water drinking intervention post-laparoscopic cholecystectomy. Before intake, the bed head was elevated to 45°C, and gagging and swallowing reflexes were assessed using an Abeslang to touch the oropharynx. Nausea indicated a positive reflex. Two patients with negative reflexes were excluded from WG. To maintain water temperature, individual insulated cups with thermal features were used, preventing infection transmission. Water was boiled in a clinic kettle, cooled to 37-38°C, and given to patients to drink within 15 minutes. Swallowing ability was monitored after the first sip; successful swallowing allowed the patient to continue. Patients were observed for 15 minutes with an aspirator on standby for aspiration risks. No complications occurred during the water drinking process in WG.
223995145|NCT03004404|DRUG|Placebo|Placebo
223995146|NCT03004404|DRUG|BI 730357|powder for reconstitution of an oral solution (PfoS)
223995147|NCT03004404|DRUG|BI 730357|BI 730357 film-coated tablet
223995148|NCT04883112|DEVICE|Magnetic Tape®|Magnetic tape® is applied without creating any tension over low back
223995149|NCT04883112|DEVICE|Kinesiology Tape|Kinesiology tape is applied without creating any tension over low back
223995150|NCT06798753|DEVICE|Occlusion Balloon Catheter|The occlusion balloon catheter (OBC) is a type of ureteral catheter equipped with a small inflatable balloon at its tip. When inflated, the balloon can help prevent the migration of stone fragments.
223995151|NCT06798753|DEVICE|5FR Ureteral Catheter|The 5FR ureteral catheter (5FR-UC) is an open-ended small-caliber tube inserted at the beginning of PCNL to facilitate visualization of the collecting system using fluoroscopy and assist with renal access.
223995152|NCT03773913|OTHER|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~1. Community engagement meetings and feedback;~2. Elimination of public sector facility user fees for children under five and pregnant women;~3. Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing \& referrals;~4. Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~5. Basic infrastructure improvements and supply chain management training of pharmacy managers"
223995153|NCT03883464|OTHER|Diet|Restriction in postoperative fat diet
223995154|NCT01336998|DIETARY_SUPPLEMENT|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
223995155|NCT01530737|DRUG|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
223995156|NCT01530737|OTHER|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
223995157|NCT04011007|PROCEDURE|vitrectomy with or without inverted ILM flap technique|vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
223995158|NCT06327776|OTHER|Serum and saliva biomarkers|2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.
223995159|NCT02145845|DEVICE|Injectable SIS|Injectable SIS
223995160|NCT02522728|DEVICE|Triathlon CR|Implantation of Knee Prosthesis
223995161|NCT02522728|DEVICE|Triathlon PS|Implantation of Knee Prosthesis
223995162|NCT00276835|BIOLOGICAL|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
224122792|NCT04349254|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The change of modulus produces a change of corneal stiffness and shape that modifies the distribution of light onto the retina. Light rays are redirected from dysfunctional areas of the retina that have been damaged by age-related macular degeneration (AMD) to functional areas of the retina, thereby improving patient vision.
224122793|NCT06218238|OTHER|Powered prosthetic knee joint|Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
224122794|NCT06218238|OTHER|Conventional prosthetic knee joint|Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
224122795|NCT07030283|DRUG|Paclitaxel|Paclitaxel is a chemotherapy medication that is FDA-approved to treat a number of cancer types. In this study, paclitaxel will be administered via the intraperitoneal port. Intraperitoneal paclitaxel is not FDA approved for pancreatic cancer.
224122796|NCT07030283|DRUG|NALIRIFOX|NALIRIFOX is a systemic chemotherapy treatment for metastatic pancreatic cancer that was approved by the FDA in February 2024. It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.
224122797|NCT06704724|DRUG|PF-07985045|KRAS inhibitor
224122798|NCT06704724|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
223729543|NCT00650624|DRUG|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
223995163|NCT00276835|DIETARY_SUPPLEMENT|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
223995164|NCT06102447|DRUG|Netopitam Palonosetron capsules and dexamethasone|On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
223995165|NCT03131947|OTHER|HIV positive patients|As above
223995166|NCT02465736|DRUG|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
223995167|NCT02465736|DRUG|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
223995168|NCT02465736|RADIATION|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
223995169|NCT02465736|PROCEDURE|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
223995170|NCT02465736|DRUG|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
223995171|NCT02465736|DRUG|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
223995172|NCT05210075|BEHAVIORAL|Mindful with your Baby program|The training Mindful with your baby consists of eight weekly 2-h sessions, plus a follow-up session 8 weeks later. The first and the fifth sessions are with the mothers only. The rest of the sessions are with both mothers and babies present. The sessions are finished by explaining the new home practices. Home practice consists of reading handouts about mindfulness and mindful parenting for mothers with a baby, formal and informal meditation practice.
224122799|NCT06704724|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
223995173|NCT01099917|DRUG|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
223995174|NCT04852913|OTHER|Bowen's Technique|The thumb of the therapist was placed on the top of the targeted muscle (upper trapezius, levator scapulae, tight pectoralis and sternocleidomastoid, longissimus capitis, splenius capitis cervical multifidus). The skin was carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb was flattened in the medial direction, when this happened the muscle would plop or 15 respond in some way. Heating pad + TENS will be given The session lasted for 20 minutes 3sessions/week for 6th week
224122800|NCT06704724|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
224122801|NCT06704724|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
224122802|NCT06704724|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
224122803|NCT06704724|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
224122804|NCT06704724|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
224122805|NCT06704724|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor
224122806|NCT06704724|COMBINATION_PRODUCT|Sasanlimab|immune checkpoint inhibitor (PD-1 inhibitor)
224122807|NCT06704724|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
224122808|NCT06704724|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
223995175|NCT04852913|OTHER|Convention Physical Therapy|"Myofascial Release + Active Range of Motion Deep transverse friction was given for 10 minutes followed by myofascial stretching of muscle for 3 times, each holding for 90 seconds. Then myofascial release was given using ulnar border of both palms of the therapist.~Active range of motion exercises will be given 10 reps with 5 seconds hold. Heating pad + Transcutaneous Electrical Nerve Stimulator (TENS) will be given The session lasted for 20 minutes 3sessions/week for 6th week"
223995176|NCT00711308|DRUG|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
223995177|NCT00711308|DRUG|acenocoumarol|acenocoumarol for 6 months
223995178|NCT00914745|DRUG|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
223995179|NCT02850042|BEHAVIORAL|Occupation-based practice (OBP)|
223995180|NCT02850042|BEHAVIORAL|Modified-constraint induced therapy (m-CIT)|
223995181|NCT00980746|DRUG|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
223995182|NCT00980746|DRUG|Placebo|oral route
223995183|NCT01782768|DEVICE|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
223995184|NCT06091059|DIAGNOSTIC_TEST|Ultrasound MRI fusion|Fused MRI images with direct ultrasound guidance
223995185|NCT00003564|DRUG|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
223995186|NCT00003564|DRUG|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
223995187|NCT02136368|BEHAVIORAL|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
223995188|NCT02136368|BEHAVIORAL|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
223995189|NCT02136368|BEHAVIORAL|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
223995190|NCT03828890|OTHER|Screening eye exam using Optos technology|Retinal imaging using Optos technology to identify Diabetic Retinopathy
223995191|NCT04296747|DRUG|induction chemotherapy|Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles
223995192|NCT04296747|PROCEDURE|surgery|After induction chemotherapy, patients with resectable hypopharyngeal cancer would accept surgery within 2-4 weeks and investigator-selected postoperative treatment
223995193|NCT04296747|RADIATION|chemoradiotherapy|After induction chemotherapy, patients with unresectable hypopharyngeal cancer who achieved CR/PR/SD in the tumor evaluation according to RECIST1.1 would accept another cycle of chemotherapy, and then radical chemoradiotherapy with cisplatin 100mg/m2, q21d
223995194|NCT02767752|DIETARY_SUPPLEMENT|T-ChOS|
223995195|NCT02767752|DRUG|Gemcitabine|
223995196|NCT02767752|DIETARY_SUPPLEMENT|Placebo|
223995197|NCT02767752|DRUG|Capecitabine|
223995198|NCT04692467|DRUG|Amlodipine 5mg|Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
223995199|NCT02813044|DRUG|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
223995200|NCT02813044|DRUG|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
223995201|NCT01160237|BIOLOGICAL|PandemrixTM|One dose intramuscular injection
223995202|NCT01160237|BIOLOGICAL|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
224122809|NCT06704724|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
224122810|NCT06704724|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
224122811|NCT06704724|COMBINATION_PRODUCT|PF-07284892|SHP2 Inhibitor
224122812|NCT06686030|DRUG|AK112 low dose|10mg/kg, Q3W, ivgtt
224122813|NCT06686030|DRUG|Chemotherapy|ivgtt
224122814|NCT06686030|DRUG|Olaparib|bid, oral
224122815|NCT06686030|DRUG|AK112 high dose|20mg/kg, Q3W, ivgtt
224295355|NCT01988168|PROCEDURE|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
223729544|NCT00650624|DRUG|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
223995203|NCT02019862|DEVICE|TRJ® Total Hip Arthroplasty|
223995204|NCT02926287|OTHER|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
224122816|NCT03227848|DEVICE|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
224122817|NCT06722846|BEHAVIORAL|Randomized Case Vignette Study|Particpants will complete about 16 questionnaires that will have questions about particpants quality of life, anxiety, health, andcase scenarios that are not real or based on particpants actual health situation.
224122818|NCT06731933|DRUG|BVEC|The study drug will be administered by home nurse at Subjects home for the participants residing in US. No drug will be applied when at study site. The subjects enrolled in Bari, Italy will not be administered BVEC.
223995205|NCT01485120|DEVICE|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
223995206|NCT00422734|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
223995207|NCT00422734|DRUG|Placebo|placebo tablet taken by mouth once a day for 12 weeks
223995208|NCT03058393|OTHER|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
223995209|NCT00169247|DRUG|cetuximab|
223995210|NCT00169247|DRUG|Cisplatin|
223995211|NCT00169247|PROCEDURE|Radiotherapy 70 Gy, 35 fractions|
224122819|NCT06733519|DRUG|Nalmefene|Th-104 Nalmefene Mucoadhesive Buccal strip
223995212|NCT01831037|OTHER|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (\>50% of cases).
223995213|NCT01831037|OTHER|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
223995214|NCT02400008|PROCEDURE|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
223995215|NCT04559178|OTHER|Fluid challenge|fluid challenge administration when patient is in the gray zone
223995216|NCT04771377|DIETARY_SUPPLEMENT|Protein Supplementation|protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
223995217|NCT03071237|PROCEDURE|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
224122820|NCT06733519|DRUG|Placebo|Matching placebo to TH-104
224122821|NCT06739226|BIOLOGICAL|Antigen-specific CAR T, CTL and DCvac to treat melanoma.|Antigen-specific CAR T, CTL and DCvac to treat melanoma.
224122822|NCT06896513|OTHER|Isthmus|The neck skin thickness from the thyroid isthmus to the skin will be measured in millimeters using a linear ultrasound probe (3-13 Hz) in the supine position with neck hyperextension. Measurements will be taken in a transverse view at the level of the 2nd-3rd tracheal rings, and the average of three measurements will be recorded.
223729545|NCT03038334|DIETARY_SUPPLEMENT|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
223995218|NCT02441998|OTHER|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
223995219|NCT01817920|BEHAVIORAL|integrated multidisciplinary fall prevention program|
224122823|NCT07058077|DRUG|Enlicitide Decanoate|Enlicitide decanoate taken by mouth
224122824|NCT07058077|DRUG|Placebo|Placebo tablet matched to enlicitide decanoate taken by mouth
224122825|NCT04322448|DEVICE|Mechanomyography (MMG)|MMG, as described in the cohort descriptions, to be used during surgery to see if they are predictive of patient outcomes.
224122826|NCT06780423|PROCEDURE|Minimal invasive fine needle muscle biopsies|Fine needle muscle biopsies will be taken from the m. erector spinae and the m. vastus lateralis. Participants are placed in a standardized prone position on the examination table for measurements of the m. erector spinae and in a supine position for measurements of the m. vastus lateralis.
223995220|NCT00289250|DRUG|Sulfadoxine-pyrimethamine|
223995221|NCT00289250|DRUG|Sulfadoxine-pyrimethamine plus artesunate|
223995222|NCT01081886|DEVICE|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
223995223|NCT01081886|DEVICE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
223995224|NCT02567708|DRUG|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
224122827|NCT01653366|BEHAVIORAL|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
224122828|NCT04212793|DRUG|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
224122829|NCT04212793|DEVICE|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
224122830|NCT06158841|DRUG|Etentamig|Intravenous (IV) Infusion
224122831|NCT06158841|DRUG|Carfilzomib|IV Infusion
224122832|NCT06158841|DRUG|Pomalidomide|Oral Capsule
224122833|NCT06158841|DRUG|Elotuzumab|IV Infusion
224122834|NCT06158841|DRUG|Selinexor|Oral Tablet
224122835|NCT06158841|DRUG|Bortezomib|Subcutaneous or IV Injection
224122836|NCT06158841|DRUG|Dexamethasone|Oral Tablet or IV Infusion
224122837|NCT06927375|DRUG|Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)|Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8. Flupentixol/Melitracen is given orally at a dose of 0.5 mg/10 mg twice daily for 8 consecutive weeks starting from Week 0.
224122838|NCT06927375|DRUG|Tocilizumab(400mg)|Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8.
223729546|NCT01631578|PROCEDURE|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
223995225|NCT02567708|DRUG|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
223995226|NCT03119545|BEHAVIORAL|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
223995227|NCT00335751|PROCEDURE|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
223995228|NCT06062524|DEVICE|Aorta Vascular Plug System|The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
223995229|NCT06160661|DEVICE|mandibular saggital split osteotomy|orthognathic surgery
223995230|NCT01035268|PROCEDURE|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
223995231|NCT04148651|DEVICE|The CO2RE® System|The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN) for the treatment of leukoplakia (vulvar dystrophies).
223995232|NCT04729205|DRUG|Promitil|The first 6 patients recruited to the study will receive 1.6 mg/kg Promitil. Dose escalation to cohort 2 (PROMITIL dose of 2mg/kg) will be authorized after 5 or 6 patients of cohort 1 have completed the second cycle with DLT detected in fewer than two patients. If ≥2 patients of Cohort 1 develop DLT, dose escalation will be halted and Cohort -1 (PROMITIL dose of 1.2 mg/kg) will be opened. Should ≥2 patients in Cohort -1 or Cohort 2 experience DLT events, the study will be discontinued. In parallel, on days 1 and 15 of each cycle, patients will be treated with the mFOLFOX6 regime, which involves concurrent treatment with oxaliplatin 85 mg/m2 IV and leucovorin 200 mg/m2 IV, immediately followed by 5-FU 400 mg/m2 IV bolus, and then continuous infusion of 5-FU 1200 mg/m2/day, for 2 days (46-48 h).
223995233|NCT03431753|DIAGNOSTIC_TEST|PSA, STHLM3 and mpMRI for PC detection|"Men who request a prostate specific antigen test from their general practitioner will be offered study participation.~Men with increased PC risk as judged from the STHLM3 test and/or an elevated PSA test will be offered an mpMRI examination."
223995234|NCT04943471|OTHER|Big Five Questionnaire, Patient health questionnaire-9 and generalised anxiety disorder -7 questionnaire|Questionnaire
223995235|NCT00961506|PROCEDURE|LESS cholecystectomy|LESS cholecystectomy
223995236|NCT00961506|PROCEDURE|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
223995237|NCT05262751|DRUG|Ofev®|Ofev®
224122839|NCT07075276|PROCEDURE|Liquid Phase Concentrated Growth Factor|16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with injection of liquid phase concentrated growth factor
224295356|NCT01988168|PROCEDURE|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
223995238|NCT05262751|DRUG|Nintedanib formulation 1|Nintedanib formulation 1: Monolithic Nintedanib Modified Release Tablet (MR1) as two Prototypes (MR1-1 and MR1-2).
223995239|NCT05262751|DRUG|Nintedanib formulation 2|Nintedanib formulation 2: Polyox Nintedanib Modified Release Tablet (MR2) as two Prototypes (MR2-1 and MR2-2).
223995240|NCT04944498|PROCEDURE|Modified Tarsorrhaphy|A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip
223995241|NCT04944498|PROCEDURE|Gold Weight Implant|Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess
223995242|NCT02463045|DRUG|TOP1288|
224122840|NCT07075276|PROCEDURE|Conventional arthrocentesis|16 patients with anterior disc displacement with or without reduction randomly allocated to be treated with conventional arthrocentesis
224122841|NCT07076407|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
224122842|NCT07076407|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
224122843|NCT06813651|DRUG|TBO-309: 60 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
224122844|NCT06813651|DRUG|TBO-309: 120 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
224122845|NCT06813651|DRUG|TBO-309: 30 mg|TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation. By targeting PI3Kβ, TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal haemostasis.
223564099|NCT03200834|PROCEDURE|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
224122846|NCT06894563|BEHAVIORAL|12-week exercise regimen|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week, and strength/balance exercise performed 2 days a week.
224122847|NCT06894563|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
224295357|NCT00998972|DRUG|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
223995243|NCT05926869|DRUG|Clindamycin and Dapsone gel for 03 months|Clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. Topical Dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . It is a new topical drug used in the treatment of Moderate Acne Vulgaris. It has antibacterial as well as anti inflammatory effects
223995244|NCT01001390|DEVICE|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
223995245|NCT02626442|OTHER|Exercise|6 month group exercise class
224295358|NCT06374966|DRUG|Zonisamide|This is a real-world study，so we prospectively enrolled patients with focal epilepsy suitable for taking zonisamide as an add-on medication
224295359|NCT00821366|BEHAVIORAL|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
224295360|NCT00821366|DIETARY_SUPPLEMENT|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
224295361|NCT00821366|DRUG|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
224295362|NCT00278187|BIOLOGICAL|volociximab|
223995246|NCT05396508|PROCEDURE|interfacial injection|10 ml of bupivacaine and steroid injection was applied between the leaves of the thoracolumbar fascia under the guidance of ultrasonography.
223995247|NCT05396508|PROCEDURE|physical therapy|protocol including hot pack for 20 min/session, therapeutic continuous Ultrasound (frequency, 1 MHz; intensity 1.5 W/cm2) for 6 min/session, therapeutic exercises for low back muscles. Therapeutic exercises included stretching ,posterior pelvic tilt ,hyperextension ,bridge and cat-camel exercises
223995248|NCT01246089|DRUG|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
223995249|NCT01906697|PROCEDURE|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
223995250|NCT01906697|PROCEDURE|middle turbinate resection|middle turbinate resection
223995251|NCT01906697|PROCEDURE|middle turbinate medialization|middle turbinate medialization
223995252|NCT01151215|DRUG|AZD8931|Tablet, oral, bd
223995253|NCT01151215|DRUG|anastrozole|Tablet, oral, od
224122848|NCT06816147|OTHER|Investigators will evaluate the acceptance and adherence to a healthy lifestyle recommender solution (HLRS), a digital app, among participants|The intervention will include collecting blood, stool, urinary samples as well as measuring anthropometrics and collecting data (socio-demographics, general health, well-being, PA, and eating patterns, among others) via questionnaires completed in part from a mobile application.
223995254|NCT01151215|DRUG|Placebo|Tablet, oral
223995255|NCT02432651|DRUG|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
223995256|NCT02432651|DRUG|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
223995257|NCT02432651|DRUG|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
223995258|NCT02432651|DRUG|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
223995259|NCT00831077|DRUG|ORM-14540|i.v.
223995260|NCT00831077|DRUG|ORM-12741|i.v.
224122849|NCT07124013|DRUG|Olomorasib|Administered orally
224122850|NCT06081621|BIOLOGICAL|REGEND001|REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.
224122851|NCT06081621|BIOLOGICAL|Placebo|Placebo: Sodium chloride injection administrated by bronchoscopy.
224122852|NCT06929494|OTHER|Identification of risk factors for candidemia|Identification of risk factors for candidemia
224122853|NCT06930027|OTHER|Resistance Training (High-Intensity)|Leg press exercise performed at 70-80% of 1RM, structured as 4 sets × 10 repetitions, with controlled tempo and standardized rest intervals (2 minutes).
224122854|NCT06930027|OTHER|Resistance Training (Low-Intensity)|Leg press exercise performed at 20-30% of 1RM, structured as 4 sets (30/15/15/15 repetitions), with controlled tempo and shorter rest intervals (1 minute).
224122855|NCT06930027|OTHER|Normobaric Hypoxia|Environmental intervention simulating an altitude of approximately 3500 meters (\~13.5% FiO₂) using a normobaric hypoxic chamber.
224122856|NCT06930027|OTHER|Normoxia|Training under normal atmospheric oxygen conditions (\~20.9% FiO₂).
223995261|NCT04193423|OTHER|Neck extensors training versus deep cervical flexors training, compared to a control group.|"During the first month, the participants of the experimental groups will come at Rehabilitation Service to do the exercises individually and supervised by the physiotherapist and to received the conventional treatment (10 minutes of infrared heat, 10 minutes of massage and 15 minutes of TENS). The last six months, they will perform daily home exercises.~* A-group: the degrees respect to the floor in wich each participant can hold the craniocervical extension and the cervicothoracic extension during 5 seconds will bo measured with the BDI.~* B-group: Using an air-filled pressure sensor placed behind the neck, the physiotherapist will identify the target level that the patient can hold steadily a craniocervical flexion (CCF) for 5 seconds in a controlled manner. They will train following the protocol described by Jull et al.~Of each of this exercises, they will perform 10 isometric contractions, at the corresponding degrees or target level, of 10 seconds with a rest of 3-5 seconds."
224295363|NCT00278187|DRUG|erlotinib hydrochloride|
224122857|NCT06930573|DRUG|AK112|After enrollment, patients receive AK112 at 20 mg/kg, administered via intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W). After four cycles, surgery is performed four weeks after the last dose. AK112 at 20 mg/kg is administered again four to eight weeks after surgery, via intravenous infusion on day 1 of each cycle, every 3 weeks (Q3W), until disease progression, death, intolerable toxicity, withdrawal of consent, initiation of new anti-tumor therapy, or other reasons specified in the protocol for discontinuation of treatment. The maximum postoperative treatment duration with AK112 is 12 months.
224122858|NCT06929091|OTHER|Prenatal Intervention|Antenatal Breast Milk Expression (ABME). Collection of colostrum before delivery.
224122859|NCT06929091|OTHER|Postnatal Intervention|Follow a personalized Mediterranean-style meal plan for 6 months.
224122860|NCT06929819|RADIATION|Intraoperative Radiation Therapy in Malignant Cerebral Tumor|This technique can fully expose the tumor bed during the operation, and pull the brain tissue around the tumor under the microscope to de-radiation, so as to exceed the total dose level of standard conformal conventional external radiation therapy (EBRT), maximize the radiobiological effect of a single high-dose irradiation, and deliver precise radiation to the tumor bed, while minimizing the radiation dose of peripheral nerve tissue. This technique is also a good choice for patients with orthotopic recurrent tumors who can no longer tolerate one more EBRT. Intraoperative radiotherapy technology can reduce the chance of postoperative tumor recurrence and improve the survival and prognosis of patients by providing a higher effective total dose to the tumor bed, while promoting dose escalation without significantly increasing the occurrence of complications in normal tissues, and improving the local control rate.
224122861|NCT06930599|PROCEDURE|Pulmonary vein isolation plus transition zone modification|For those who are randomized to PVI+TZM arm, additional TZM should be performed after finishing PVI ablation. PVI could be performed using open-irrigated contact-force catheter.
224295364|NCT03532633|PROCEDURE|cord blood|collection of cord blood
224295365|NCT03532633|PROCEDURE|blood sample infant|collection of remnant of clinically indicated blood sample
223729547|NCT00528385|DRUG|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
223729548|NCT05004753|DIETARY_SUPPLEMENT|Artemisinin|a herbal supplement
224295366|NCT03532633|PROCEDURE|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
224295367|NCT03532633|PROCEDURE|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
224295368|NCT05590156|PROCEDURE|Conventional Rehabilitation|Conventional treatment for the upper extremity will be applied according to the patient's individual needs. A physiotherapist will apply this method in the clinic for 60 minutes. The duration of treatment is 60x3x8 minutes/day/week. Other methods will be applied in addition to the conventional treatment program.
223995262|NCT01721954|DRUG|FOLFOX6m|
223995263|NCT01721954|DEVICE|SIR-Spheres microspheres|
223995264|NCT00727740|DRUG|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
223995265|NCT00727740|DRUG|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
223995266|NCT03392168|DRUG|ARQ-151 cream 0.5%|0.5% active concentration
223995267|NCT03392168|DRUG|ARQ-151 cream 0.15%|0.15% active concentration
223995268|NCT03392168|DRUG|ARQ-151 vehicle cream|Vehicle cream
223995269|NCT03266718|BEHAVIORAL|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
223995270|NCT02144103|OTHER|Subtenon administration of autologous ADRC|
223995271|NCT02144103|PROCEDURE|Liposuction|
223995272|NCT02144103|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
223995273|NCT00653731|BEHAVIORAL|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
223995274|NCT00653731|BEHAVIORAL|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
223995275|NCT00653731|BEHAVIORAL|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
223995276|NCT00653731|BEHAVIORAL|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
223995277|NCT04341129|DRUG|Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)|To test the diagnostic effectiveness of an abbreviated MRI to a full MRI in the evaluation of breast lesions using Dotarem
223995278|NCT05089045|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper arm of 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223995279|NCT04549818|DEVICE|sacral neuromodulation|Sacral neuromodulation group, N=22 will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
223995280|NCT06003205|DEVICE|Wearable bioimpedance sensor|The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
223995281|NCT01803581|OTHER|X92001327|
223995282|NCT01803581|OTHER|RID shampoo|
223995283|NCT01824589|DEVICE|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
224122862|NCT06930599|PROCEDURE|Pulmonary vein isolation alone|In periprocedural period, all antiarrhythmic drugs were discontinued for at least 5 half-lives and amiodarone for 2 months before the procedure. An electrophysiological study was performed after overnight fasting and mild sedated state with administration of intravenous midazolam and fentanyl. PVI should be performed under the CARTO or Ensite electroanatomic mapping system using an open-irrigated contact-force ablation catheter.
223995284|NCT01824589|DEVICE|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
223995285|NCT00002068|DRUG|Fluconazole|
223995286|NCT00002068|DRUG|Amphotericin B|
223995287|NCT03335436|DRUG|Gabapentin|Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
223729549|NCT05004753|DRUG|Dexamethasone|corticosteroids
223995288|NCT03335436|DRUG|Placebo|Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
223995289|NCT06128096|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|"Patients (180 diabetic patients with CAD that are using SGLT-2 inhibitors and 180 diabetic patients with CAD that are not using SGLT-2 inhibitors) who fulfil the inclusion and exclusion criteria will be recruited from the following sources:~UMMC Cardiology and Diabetes out-patient clinics UMMC Cardiology and Endocrinology in-patients (wards)~During the recruitment, patients will do baseline echocardiography in which includes epicardial adipose tissue and cardiac function. The same procedure will be repeated 6 months post intervention."
224122863|NCT06930365|OTHER|Anti-itching and repairing treatment. Emollient.|Anti-itching and repairing treatment. Emollient.
224122864|NCT06930365|OTHER|Emollient cream|Emollient cream
224295369|NCT05590156|DEVICE|Robotic Rehabilitation (ExoRehab X)|Robotic Rehabilitation
224295370|NCT05590156|PROCEDURE|Action Observation Therapy (AOT)|Action Observation Therapy (AOT)
223995290|NCT04301895|BEHAVIORAL|Continuous conversational interaction|Maintaining continuous conversation, requiring that the subject answer questions and engage in discussion without interruption.
223995291|NCT04301895|DRUG|Remifentanil infusion|10 minute remifentanil infusion
223995292|NCT03388476|DIAGNOSTIC_TEST|Capnography|Measuring of the exhaled air, especially endtidal co2, through capnography.
223995293|NCT05988723|OTHER|ELISA kits|Making biochemical measurements with the ELISA kit
223995294|NCT02627118|DEVICE|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
223995295|NCT02627118|DEVICE|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
223995296|NCT04513093|OTHER|Aromatherapy Massage|The elderly individuals in the intervention group underwent aromatherapy massage with ginger and lavender oils for a period of five days and 15 minutes on weekdays for four weeks according to the abdominal massage application protocol.
223995297|NCT04760262|DRUG|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
223995298|NCT04760262|DRUG|Propofol|BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
223995299|NCT03104010|DRUG|Somatropin Injection|Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.
223995300|NCT03176004|OTHER|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
223995301|NCT06457243|DEVICE|Closed-loop cTBS stimulation based on addiction induced states|We conducted a longitudinal controlled study of closed-loop cTBS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed loop cTBS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
223995302|NCT00268372|DRUG|cisplatin|
223995303|NCT00268372|DRUG|docetaxel|
223995304|NCT00268372|DRUG|5-fluorouracil|
223995305|NCT00268372|PROCEDURE|surgery|
223995306|NCT00268372|RADIATION|radiation therapy|
223995307|NCT00129753|DRUG|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
223995308|NCT02521714|DRUG|Lenalidomide|
223995309|NCT01154140|DRUG|treatment|crizotinib 250mg orally continuous twice daily dosing
223995310|NCT01154140|DRUG|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
223995311|NCT06415110|DEVICE|Allosync Expand|Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)
223995312|NCT02718261|DRUG|Pantoprazole|
223995313|NCT02718261|DRUG|Saline 0.9% (matching placebo)|
223995314|NCT04039373|DRUG|BMS-986256|specified dose on specified days
223995315|NCT04039373|DRUG|Mycophenolate Mofetil|specified dose on specified days
223995316|NCT00689182|PROCEDURE|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
223995317|NCT05315570|OTHER|BD4QoL platform|The BD4QoL platform consists of a set of services to allow patient monitoring and empowerment, through two main tools: Point of Care application to manage all patients data and follow-up by clinical investigators, and a mobile application (App) installed on participating subject's smartphone. Also, a web-form tool is delivered to allow the QoL questionnaire completion.
223995318|NCT03969134|BIOLOGICAL|ChAd63-KH|The vaccine will be injected intramuscularly into the arm.
223995319|NCT03969134|OTHER|Placebo|The placebo will be injected intramuscularly into the arm.
223995320|NCT04571190|BEHAVIORAL|Prenatal MBSR|Prenatal MBSR is an adaptation to the original MBSR program. The essential program elements characterizing MBSR is maintained and integrated with the particular context and specific needs of this group of pregnant women. Adaptations to the MBSR program draw upon both empirical data as well as existing research and theory.
223995321|NCT03952091|DRUG|TJ202, Lenalidomide and Dexamethasone|One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
223995322|NCT03952091|DRUG|Lenalidomide and Dexamethasone|Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
223995323|NCT06117228|OTHER|Data collection|Data collection
223995324|NCT03664102|DEVICE|Cor Knot|Heart valve replacement with or without the use of automated fastener device Cor Knot
223995325|NCT05967325|PROCEDURE|Stromal Vascular Fraction (SVF) combined with Functional self-assembling peptide nanofiber hydrogels|Transplantation of SVF and biomimetic nanohydrogel
224295371|NCT02713815|RADIATION|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
223545147|NCT06663501|DEVICE|Assisted Motion with Enhanced Sensation training|During the AMES intervention, the AMES device will flex or extend the wrist/hand joint, and the participant's task will be to assist this motion. As the wrist/hand joint moves, the machine will be delivering a vibratory mechanical stimulus on the opposite side to the direction of movement. The activity of the muscles during the movement of the wrist/hand joint will be recorded by the device and it will be shown on a screen to be used as feedback during the training
223545148|NCT05961371|OTHER|Resistance Training|Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
223995326|NCT01243788|DRUG|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
224295372|NCT02713815|RADIATION|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
224295373|NCT00378651|PROCEDURE|Neck Auscultation|
224295374|NCT00366041|DRUG|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
223995327|NCT02391142|DRUG|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
223995328|NCT05788627|DRUG|Tap water|Oral lactulose in a dose of 30ml BD and tap water enema 1000ml BD
223995329|NCT05788627|DRUG|Lactulose|Oral lactulose in a dose of 30ml BD and lactulose enema (300ml lactulose and 700ml water) in a dose of 1000ml BD.
223995330|NCT04489277|DEVICE|Endovascular Arch Procedures|Endovascular Arch Procedures (TEVAR, Branch endografts, Fenestrated endografts)
223995331|NCT00358020|DRUG|THALIDOMIDE|
223995332|NCT00358020|DRUG|BORTEZOMIB|
223995333|NCT02812056|DRUG|Alisertib|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
223995334|NCT02812056|DRUG|TAK-228|"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
223995335|NCT00286806|DRUG|AT-101|
224295375|NCT00366041|DEVICE|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
223995336|NCT00749229|DEVICE|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
223995337|NCT05261308|OTHER|new prosthesis|Operation to fix the new prosthesis
223995338|NCT00061594|DRUG|rhuFab V2 (ranibizumab)|
223995339|NCT01653054|PROCEDURE|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
223995340|NCT03697122|DEVICE|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
224295376|NCT02030483|DRUG|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
223545149|NCT04543851|DEVICE|CARA - carbon fibre adjustable re-usable accessory for breast positioning|Breast positioning to alleviate infra-mammary fold and lateral breast sag
223995341|NCT02651025|OTHER|Resistance Exercise Program|"During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6."
223995342|NCT00476164|DRUG|Rituximab|2 doses of 1g 14 days apart
223995343|NCT00476164|OTHER|Control arm|Continue of optimised oral immunosuppression
223995344|NCT00807339|RADIATION|Stereotactic radiation|Dose escalation three consecutive treatments
223995345|NCT00807339|DEVICE|CyberKnife Robotic Radiosurgery System|
223995346|NCT02992691|DRUG|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
223995347|NCT02992691|DRUG|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
223995348|NCT02992691|DRUG|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
223995349|NCT02992691|DRUG|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
223545150|NCT02664519|BEHAVIORAL|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
223545151|NCT06622044|OTHER|Vision therapy group|accommodation and vergence exercise
223545152|NCT06622044|OTHER|Prism|wearing prism glasses
223995350|NCT02992691|DRUG|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
223995351|NCT05419622|BIOLOGICAL|bronchial biopsies|This fibroscopy will make it possible to perform 4 bronchial biopsies at the level of the 4th bronchial generation (subsegmental bronchi), using suitable pediatric forceps.
223995352|NCT04276051|DEVICE|Cryoablation of the Vagus Nerve|The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.
223995353|NCT04276051|BEHAVIORAL|Lifestyle Intervention|The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.
223995354|NCT00392925|DRUG|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
223545153|NCT06625528|BIOLOGICAL|open flap debridement|does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
223995355|NCT00392925|DRUG|metreleptin|subcutaneous injection, twice a day, 5mg
223545154|NCT06685198|PROCEDURE|Titrated administration of propofol to an OAA/S score of 1 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 1, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
223545155|NCT06685198|PROCEDURE|Titrated administration of propofol to an OAA/S score of 2 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve an OAA/S score of 2, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
223545156|NCT06685198|PROCEDURE|Titrated administration of propofol to a BIS value ≤ 60 as the endpoint|Propofol is titrated at a rate of 0.5 mg/kg/min to achieve a BIS value ≤ 60, followed by a maintenance dose of 2-4 mg/kg/h, concurrently with remifentanil 2 ug/kg and rocuronium 0.6 mg/kg for anesthesia induction.
223545157|NCT06037564|DRUG|DOR/DTG/3TC|Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
223545158|NCT06717022|BIOLOGICAL|CHT102 allogeneic CAR T cells|CHT102 allogeneic CAR T cells
223545159|NCT06717035|DEVICE|EYE001|Defocus incorporated multiple segments (DIMS) clear vs DIMS photochromic
223545160|NCT06715345|DEVICE|Bone graft materials and rhBMP-2|NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2 and β-tricalcium phosphate/hydrogel complex.
223545161|NCT06714981|DRUG|Opioid Free Anaesthesia|patients received opioid free anesthesia
223995356|NCT00392925|DRUG|placebo-pramlintide 600 uL|twice a day
223995357|NCT00392925|DRUG|placebo-metreleptin 1 mL|twice a day
223995358|NCT00392925|DRUG|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
223995359|NCT00213200|DRUG|morphine, amethocaine|
223995360|NCT00211224|DRUG|Riluzole|
223995361|NCT03362385|OTHER|Patients with OSA based on sleep study|Polysomnography or Polygraphy
223995362|NCT03362385|OTHER|Patients without OSA based on sleep study|Polysomnography or Polygraphy
223995363|NCT04237532|DRUG|Intranasal Dexmedetomidine|The mucosal atomizing device will be used intranasally where the sedative drug will be equally divided and sprayed into each nostril while the child semi reclined position.
223995364|NCT04237532|DRUG|Sublingual Dexmedetomidine|The mucosal atomizing device will be used sublingually by asking the child to touch their maxillary incisor teeth with the tip of their tongue and instruct the child not to swallow the drug for 30 seconds.
223995365|NCT06380452|DRUG|5% Permethrin Creme|At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
223995366|NCT06380452|DRUG|10% Permethrin Creme|At visit V0, the investigational cream is applied once topically to the whole body. For patients who are not cured at visit V1, i.e. 14 days later, the application is repeated analogously once at this time.
223995367|NCT05932953|OTHER|questionary|questionary about cutaneous tolerance
223995368|NCT01690377|BIOLOGICAL|PDC or myDC|PDC or myDC; first patient 0.3 \* 10E6 PDC; second and third 1 \* 10E6 PDC; fourth and fifth 3 \* 10E6 PDC.
223995369|NCT01173068|DRUG|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
223995370|NCT00334334|BIOLOGICAL|Pneumococcal (vaccine)|
223995371|NCT02800551|RADIATION|dose-intensified image-guided SBRT using simultaneous integrated boost|
223995372|NCT02800551|RADIATION|External 3-dimensional conformal radiotherapy (3D-CRT)|
223995373|NCT01522690|OTHER|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
223545162|NCT06714981|DRUG|Opioid based Anesthesia|patients received opioid based anesthesia
223995374|NCT04317261|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)|Urine sample is evaluated for RNA and urinary metabolites
223995375|NCT03289702|DRUG|CORETOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
223995376|NCT03289702|DRUG|BOTOX®|Upper limb will be injected and evaluated in the study. Maximum injection dose is 360U.
223729550|NCT06155409|DEVICE|Anterior cervical interbody fusion|Anterior cervical interbody fusion indicates a surgical approach in the cervical spine to fuse the discal space between two vertebrae. These are joined by removing the disc and placing a cage in its place to restore the vertebral height.
223729551|NCT00053040|BIOLOGICAL|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
223729552|NCT00053040|PROCEDURE|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
223729553|NCT02520843|DRUG|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
223729554|NCT02959944|DRUG|ibrutinib|Ibrutinib capsules administered orally daily
223729555|NCT02959944|DRUG|Placebo|Placebo capsules administered orally daily
223729556|NCT02959944|DRUG|Prednisone|Prednisone administered daily
223729557|NCT01521208|DEVICE|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
223729558|NCT01521208|OTHER|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
223729559|NCT06182189|OTHER|Observation of patients with a benign prostatic hyperplasia condition|Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
223995377|NCT03908593|DRUG|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
223995378|NCT04662983|DEVICE|VR-training|A musical game called Beat Saber was used to conduct training sessions. The participant's task was to cut through the blocks of various colors in his direction to the rhythm of music, using two virtual swords. The swords were controlled by the player with controllers of different colors. Blocks had to be cut with a sword whose color matches the block and in the right direction which is indicated by an arrow on the block. The training session consisted of 4 music tracks with different pace and intensity of objects. In addition, during the song, the participant had to avoid objects-objects that randomly appeared in the game scenario - forcing the whole body to move.
223995379|NCT02761863|OTHER|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
223995380|NCT04268537|DRUG|PD-1 blocking antibody+standard treatment|After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
223995381|NCT04268537|DRUG|Thymosin+standard treatment|Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
223995382|NCT04268537|OTHER|standard treatment|Standard treatment is according to the protocol of treatment of 2019-nCoV infection
223995383|NCT03557606|PROCEDURE|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
223995384|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
223995385|NCT05269862|DEVICE|Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)|Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
224122865|NCT06930456|DRUG|hydrocortisone|A deidentified syringe (10 mL) containing 100 mg hydrocortisone will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
224295377|NCT02030483|DRUG|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
224295378|NCT02030483|DRUG|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
223995386|NCT00120809|DRUG|Sulfadoxine-pyrimethamine|
223995387|NCT06237777|GENETIC|SKG0106 intravitreal injection dose level 1, 2 or 3|SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
223995388|NCT05588583|DEVICE|Mepilex Up|"Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~* a soft silicone wound contact layer (Safetac)~* a flexible absorbent pad of compressed polyurethane foam~* an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane"
223425460|NCT01882881|OTHER|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at \~34-35% and the SFA will match that of the Almond Diet at \~8-9%. The fiber content of this diet will be highest (\~35g); cholesterol will remain ≤200 mg/day.
223995389|NCT01228877|OTHER|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
223729560|NCT00740844|DEVICE|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
223729561|NCT03507894|BEHAVIORAL|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
223729562|NCT00203177|DRUG|rasagiline mesylate|0.5 rasagiline mesylate
223729563|NCT00203177|DRUG|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
224122866|NCT06930456|DRUG|ondansetron|A deidentified syringe (10 mL) containing 8 mg ondansetron will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
224295379|NCT01431443|OTHER|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
223729564|NCT00003081|BIOLOGICAL|filgrastim|
223729565|NCT00003081|DRUG|busulfan|
223729566|NCT00003081|DRUG|melphalan|
223729567|NCT00003081|DRUG|thiotepa|
223729568|NCT00003081|PROCEDURE|peripheral blood stem cell transplantation|
223729569|NCT00003081|RADIATION|radiation therapy|
223729570|NCT02775162|DEVICE|Normothermic Machine Perfusion (NMP)|
223729571|NCT02775162|OTHER|Standard of Care (Ice)|
223729572|NCT06049784|DEVICE|Visual Biofeedback using self operated home ultrasound device|participants will receive a handheld home ultrasound device, learning to perform self-biofeedback at home. Session records will be sent electronically to the sonographer for assessment and feedback.
223729573|NCT06049784|DEVICE|Visual Biofeedback using ultrasound at hospital|A single ultrasound biofeedback session using Transperineal Ultrasound will guide maternal pushing.
223729574|NCT03325361|OTHER|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
223729575|NCT01810354|DRUG|Cefazolin|
223729576|NCT03886350|OTHER|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
223729577|NCT04934384|DIAGNOSTIC_TEST|prehospital extended focused assessment sonography for trauma|Sonographic procedure performed in the prehospital environment aiming at evaluating peritoneal free fluid in trauma patients
223729578|NCT03428789|PROCEDURE|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
223729579|NCT03454893|DRUG|AVR-RD-01|Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.
223729580|NCT05841251|DRUG|Topical Phenylephrine Solution|phenylephrine-soaked pack using the whole 5 ml of the solution provided with.5% phenylephrine will be applied after induction of surgery and intubation, 15 minutes before surgery. 100 ml of normal saline will be given.
223729581|NCT05841251|DRUG|intravenous tranexamic acid|patients will receive intravenous Single dose of tranexamic acid 15 mg/kg in 100 mL normal saline over 10 minutes. Saline-soaked pack will be applied.
223729582|NCT04876274|BEHAVIORAL|TMU-LOVE|Patients in intervention group could attend diabetes-related health educational video through the TMU-LOVE platform. Researcher would also send 2-3 videos per week with care massage every 2 weeks to the patients.
223729583|NCT02051608|DRUG|Placebo|Participants received Placebo SC injection Q4W.
223729584|NCT02051608|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
224295380|NCT01431443|OTHER|Placebo Chocolate|Placebo intervention
223995390|NCT02858128|OTHER|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
223995391|NCT02078492|DRUG|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
223995392|NCT02078492|DRUG|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
223995393|NCT02078492|DRUG|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
223995394|NCT00359047|BEHAVIORAL|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
223995395|NCT00359047|BEHAVIORAL|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
223995396|NCT05578508|DRUG|Mesenchymal Stem Cells (MSCs)|Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.
223995397|NCT01485107|DEVICE|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
223995398|NCT00002264|DRUG|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
224122867|NCT06930456|DRUG|Placebo|A deidentified syringe (10 mL) containing sterile distilled water for intravenous injection will be given 15 minutes prior subarachnoid blockade. Spinal anesthesia will be performed with a 25-gauge Quincke spinal needle to administer 3.5 ml of a 0.5% hyperbaric bupivacaine plus 25 micrograms of fentanyl at the L3-L4 or L4-L5 level. Then, Patient will lie supine with slight head elevation. Intravenous Infusion of 500 ml normal saline over the initial post spinal 30 minutes. Sensory level and motor block will be verified. Heart rate (HR), systolic (SBP), diastolic (DBP) and mean blood pressure (MBP) will be measured every 5 min for 6 readings during which the patient remains in the supine position with no application of torniquet.
224122868|NCT07077746|DRUG|HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells|Allogeneic HB-adMSCs (Hope Biosciences adipose derived mesenchymal stem cells). Dose: 200 million cells (+/- 20%) suspended in 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: HB-adMSCs syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).
223995399|NCT01461005|DEVICE|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
223995400|NCT00832468|OTHER|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
223995401|NCT00832468|OTHER|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
224122869|NCT07077746|DRUG|0.9% sodium chloride|0.9% sodium chloride Dose: N/A - 20mL 0.9% sodium chloride. Route: Intravenous. Regimen: Weeks 0, 2, 4, 8, 12, and 16. Preparation: Placebo syringe should be diluted in 250 mL 0.9% sodium chloride (for a total volume of 270 mL).
224295381|NCT05667350|OTHER|Blood drawing|Blood drawing before anti-cancer therapy
224295382|NCT05667350|OTHER|Blood drawing|Blood drawing before radical treatment
224295383|NCT02168725|DRUG|briciclib|
224295384|NCT03823235|OTHER|Human embryo culture|humidifed or dry incubator
223995402|NCT06051071|DEVICE|Transcranial Direct Current Stimulation (tDCS)|In tDCS, surface electrodes (anode and cathode) inject low-intensity direct current through the skull to modulate brain activity and cortical excitability
223995403|NCT01544634|DRUG|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
223995404|NCT01544634|DRUG|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
224122870|NCT06930248|BIOLOGICAL|Platelet rich plasma injection|Our first step is the local anesthesia using a solution of decongestion nasal drops with 5% Emla and 10% Xylocaine spray in cotton, which is placed in the nose for 30 minutes. The 2nd step of the administration is the PRP injection in the olfactory area of the noseVia1 ml syringe with 30 G needle, PRP is injected in the olfactory area(located at superior turbinate and superior portion of lateral an medial portion of nasal cavity) approximately every 1 cm2 with the help of a nasal endoscope. The procedure is repeated 3 times with a 4 week interval with follow up patients for 6 months. A 4th time is injected after 3 months.
224122871|NCT07087002|BIOLOGICAL|GPC2-CAR T cells|Autologous T cells transduced with retroviral vector encoding a second-generation GPC2-targeted chimeric antigen receptor (GPC2-CAR), administered intracerebroventricularly. Up to 8 doses are given every 28 days, following an intrapatient dose escalation schema.
223995405|NCT01544634|DRUG|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
223995406|NCT01544634|DRUG|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
223995407|NCT05765201|OTHER|High IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
223995408|NCT05765201|OTHER|Low IOP|Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
224122872|NCT07087002|DRUG|Fludarabine|Administered as part of a lymphodepleting chemotherapy regimen prior to GPC2-CAR T cell infusion. Dose: 30 mg/m²/day for 3 days.
224122873|NCT07087002|DRUG|Cyclophosphamide|Administered with fludarabine for lymphodepletion. Dose: 500 mg/m²/day for 3 days.
224122874|NCT01941368|DIETARY_SUPPLEMENT|Placebo|
224122875|NCT01941368|DIETARY_SUPPLEMENT|HMB-FA|
224122876|NCT01941368|PROCEDURE|High Intensity Interval Training|
224122877|NCT06783569|DRUG|JR8603|IV infusion on Days 1, 8, and 15 of continuous 28-day cycles
223545163|NCT06719479|BIOLOGICAL|IAE0972+ Methotrexate|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Methotrexate is used according to the instructions.
223995409|NCT04423419|PROCEDURE|PENG block|The US probe placed in a transverse plane over the AIIS . the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic drug was injected while observing for adequate fluid spread for a total volume of 20 mL of Bupivacain 0.25%
223995410|NCT04423419|PROCEDURE|fascia iliaca block|ultrasound guidance landmarks are the anterior superior iliac spine and the pubic tubercle (inguinal ligament). The injection site along the lateral one-third of aline joining the anterior superior iliac spine (ASIS) and pubic tubercle (PT) targeting the compartment between fascia iliaca and fascia lata ,the total volume of injection is 20ml of Bupivacain 0.25%
223995411|NCT04423419|OTHER|IV analgesia|IV analgesia
223995412|NCT02579772|DRUG|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
223995413|NCT02579772|DRUG|Placebo|Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
223995414|NCT05586412|DEVICE|vagus nerve stimulation|Vagus stimulation, TENS device with specially designed and shaped surfaces that can be shaped according to the magnifying ear will be performed. The electrodes will be placed in such a way that the tragus is facing the inner and outer world. The wave formula is biphasic asymmetrical, pulses less than 500 microseconds and 10 hertz for 30 minutes. will be custom-made and the amplitude will be set as the sensory threshold.
224122878|NCT05891249|BIOLOGICAL|Luspatercept|Specified dose on specified days
223995415|NCT01550055|DRUG|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
223995416|NCT01550055|DRUG|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
223995417|NCT02416245|DIETARY_SUPPLEMENT|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
223995418|NCT02416245|OTHER|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
223995419|NCT05115045|DIAGNOSTIC_TEST|plasmatic SARS-CoV-2 RNA quantification|plasmatic SARS-CoV-2 RNA was quantified by droplet digital PCR
223995420|NCT04147195|DRUG|LYS006|5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks
223995421|NCT04147195|DRUG|Tropifexor|100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks
224122879|NCT06417177|DRUG|Placebo|Participants will receive a placebo in pill form.
224122880|NCT06417177|DRUG|Propranolol|Participants will receive oral propranolol (1 mg/kg).
224122881|NCT06417177|DRUG|Gemtesa|Participants will receive oral gemtesa (75 mg).
223995422|NCT00402805|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|
223995423|NCT07050810|DEVICE|TheraClean|Begins after Week 0 visit and continues through Week 8. Participants will take at least 3 baths/week (20-30 minutes each bath) but may bathe daily, if desired.
223729585|NCT03441776|OTHER|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
223729586|NCT03441776|OTHER|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
223995424|NCT07050862|DEVICE|Transcranial Magnetic Stimulation|The first group will receive 10 Hz DTMS (standard TMS) with a protocol of 3 seconds on, 15 seconds off, and a total of 1800 pulses/session, lasting 18 minutes, targeting the bilateral insula and lateral prefrontal cortex.
223995425|NCT07050862|DEVICE|personalized-image-guided and E-field-modeling dose rTMS (precision TMS)|with a protocol of 5 seconds on, 10 seconds off, and a total of 3000 pulses/session, lasting 15 minutes, targeting the left DLPFC.
223995426|NCT05823012|DRUG|levothyroxine sodium|Levothyroxine sodium 10 mg/mL
224122882|NCT03398408|BEHAVIORAL|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
224122883|NCT06746259|DIAGNOSTIC_TEST|Rapid point of care test to detect host immune response in ARI|FebriDx is a rapid lateral flow immunoassay for the visual, qualitative, in vitro detection of elevated levels of host response proteins, Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), directly from fingerstick blood to aid in the differentiation of bacterial from non-bacterial acute respiratory infections.
223995427|NCT07049107|DRUG|HRS-8427|HRS-8427
223995428|NCT07051109|DEVICE|multimodal analgesia via dual-chamber PCA|combination of fentanyl and ketorolac through dual-chamber PCA
223995429|NCT07051109|DEVICE|single regimen (only fentanyl)|fentanyl only through dual-chamber PCA
223995430|NCT07050251|BEHAVIORAL|Mentoring Intervention Delivery|The intervention will utilize a culturally specific, socio-emotional learning (SEL) curriculum, adapted based on feedback from the focus groups. The intervention will consist of 10 weekly mentoring sessions lasting 1 hour each. Licensed clinicians will lead sessions and will also serve as mentors.
223995431|NCT03319940|DRUG|Tarlatamab|Tarlatamab is a Half-Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
223995432|NCT03319940|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized IgG4 monoclonal antibody (mAb) with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2
223995433|NCT03319940|DRUG|CRS Mitigation Strategies|Participants will be treated with one of the CRS mitigation strategies.
223995434|NCT06947499|BIOLOGICAL|LBVD|Intramuscular injection into the anterolateral area of the thigh
223995435|NCT06947499|BIOLOGICAL|Pentavalent vaccine and Inactivated Polio vaccine|Intramuscular injection into the anterolateral area of the thigh
223995436|NCT06952452|DRUG|Bevacizumab|The dosage for each intravitreal injection is 1.25mg of BVZ in 0.05ml
223729587|NCT02829450|OTHER|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
223995437|NCT06952452|DRUG|Ranibizumab Ophthalmic|The dosage for each intravitreal injection contains 0.5mg of RBZ in 0.05ml
223995438|NCT01686139|BIOLOGICAL|ABMD-MSC|10-20 x 10\^6 cells/20mL
223995439|NCT03763136|BIOLOGICAL|hPSC-CM Therapy|Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
223995440|NCT05120037|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) uses a mild electrical current to make small (or subtle) changes to how the brain works (or functions).
224295385|NCT01566864|BEHAVIORAL|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
224299104|NCT00845819|DRUG|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC\>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
223995441|NCT03710122|DRUG|Vancomycin|Firvanq by Azurity Pharmaceuticals, Inc.
223995442|NCT03710122|OTHER|Placebo|Placebo for Vancomycin
223995443|NCT03557645|DEVICE|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
223995444|NCT03557645|DEVICE|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
223995445|NCT03557645|DEVICE|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
223995446|NCT03078569|DRUG|Testosterone gel|treatment with testosterone gel
223995447|NCT05855525|BEHAVIORAL|Experience sampling|Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
223995448|NCT05248477|OTHER|Premex Protocol|"This protocol presupposes stages during which staff are informed and trained. It is based on the following principles:~* Administration of corticosteroid therapy to all eligible women, independent of the decision about active or palliative care~* A prognostic evaluation in a non-emergency meeting of the obstetricians and neonatologists/pediatricians involved, no longer based only on gestational age, and enabling the team to provide consistent, consensual, and individualized information to parents;~* A joint decision about the obstetric and neonatal (active or palliative) care to be proposed to parents at the end of this evaluation;~* An interview with parents, also on non-emergency basis, to give them information about the child's prognosis and the management proposed, to answer their questions, and to obtain their opinion;~* Management at birth consistent with that decided in consultation with the parents."
224122884|NCT07091591|BEHAVIORAL|Changing (version: pandemic)|The application explains that, faced with a complex situation such as a pandemic, decision-makers have to navigate through uncertainty, often without knowing exactly how the situation will evolve. Scientific research guides their choices, but early studies can sometimes prove inaccurate and require adjustments. For example, during the COVID-19 pandemic, some initial studies showed that certain drugs could help, but more rigorous research showed that they were not effective. Over time, accumulated knowledge enables us to better understand the situation and make informed decisions. Lessons learned from past crises help to better prepare for future complex situations.
224122885|NCT07091591|BEHAVIORAL|Changing (version: nutrition)|The intervention discusses the evolving nature of scientific research on diet and health. It explains how initial studies can suggest one thing, only for later studies to offer new insights or clarify previous findings. For example, while early research linked high fat intake with heart disease, more recent studies have shown that some fats, like those in nuts, avocados, and oily fish, are actually beneficial. It emphasizes that science often advances gradually, and rigorous, long-term studies help understanding. It also points out that health recommendations are influenced by multiple factors, and over time, accumulated knowledge enables us to better understand the situation and make informed decisions.
223995449|NCT06223360|DRUG|Low Dose Benfotiamine|300mg benfotiamine capsules (BID, twice a day)
223995450|NCT06223360|DRUG|High Dose Benfotiamine|600mg benfotiamine capsules (BID, twice a day)
223995451|NCT06223360|DRUG|Placebo|Placebo capsules to mimic benfotiamine capsules (BID, twice a day)
223995452|NCT01385046|BEHAVIORAL|Project Fit|physical activity and nutrition education
223995453|NCT01817322|DRUG|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
223995454|NCT01817322|DRUG|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
223995455|NCT01817322|DRUG|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
223995456|NCT01920477|BIOLOGICAL|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
223995457|NCT01920477|BIOLOGICAL|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
223995458|NCT03388268|DRUG|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
223995459|NCT03388268|DRUG|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
223995460|NCT03388268|DEVICE|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
223995461|NCT03388268|DEVICE|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
223995462|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
223729588|NCT05061810|BEHAVIORAL|Smartphone application self-management programme|The intervention in this trial is a self-management programme via a smartphone app. This self-management programme measures lung function (FEV1), oxygen saturation (SP02), dyspnoea score (m MRC) and step count. It also provides educational videos such as recognising symptoms of an exacerbation and physical activity. The smartphone app self-management programme will provide real time data monitoring resulting in baseline trends in patient's disease pattern. Additionally, it also provides subjective data that will allow the clinician to develop an understanding of the patient's quality of life.
223995463|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
223995464|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
223995465|NCT01681277|DRUG|Placebo to BI 113608 PIB qd|powder for oral solution
223995466|NCT01681277|DRUG|Placebo to BI 113608 PIB bid|powder for oral solution
223995467|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
223995468|NCT01681277|DRUG|BI 113608 PIB bid|powder for oral solution
223995469|NCT01681277|DRUG|BI 113608 PIB qd|powder for oral solution
223995470|NCT05420233|DIAGNOSTIC_TEST|MRE|Magnetic Resonance Enterography at year 1 (in some patients)
223995471|NCT05067595|PROCEDURE|Colonoscopy|Undergo lower FMT via colonoscopy
223995472|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Given upper FMT PO or via post-pyloric or NG feeding tube
223995473|NCT05067595|BIOLOGICAL|Fecal Microbiota Transplantation|Undergo lower FMT via colonoscopy
223995474|NCT05067595|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given dietary fiber supplementation PO or via post-pyloric or NG feeding tube
223995475|NCT05067595|OTHER|Survey Administration|Ancillary studies
223995476|NCT05067595|PROCEDURE|Biospecimen Collection|Undergo tissue, stool, stool swabs, and blood sample collection
223995477|NCT05867823|BEHAVIORAL|OcuApp|The participants will have instaled a mobile aplication (OcuApp) by a member of the researchs team who will teach them how to use it. The person must register the activities they carry out throughout a week and mark each one of them with a punctuation (from 1 to 5) related to the meaning of the following dimensions: identity, pleasure, competence, importance and value of the activity by other people.The application also allows to collect other information such as where the activity takes place, its duration, and the people with whom it is carried out. Also, at the end of the week, the application will ask users about their perceived occupational balance. All the information registered in the mobile application will be returned to the person in a dynamic and understandable way. Based on this, the person can establish two goals to accomplish. In this sense, OcupApp will offer personalized recommendations based on the objectives to be achieved related to the dimensions of meaning.
224122890|NCT05128162|DRUG|Psilocybin|Two oral doses of psilocybin in a capsule formulation taken approximately 2 weeks apart.
224122891|NCT05128162|BEHAVIORAL|Psychotherapy|1\. Pre-dose preparatory sessions; 2. Dosing day monitoring; and, 3. Post-dose integration sessions.
224122892|NCT03663530|BEHAVIORAL|Meal times|Meal times vary based on the arm: aligned or misaligned
224122893|NCT06241222|DRUG|Probiotic Blend Oral Tablet|In our study, fourteen pregnant women were randomly assigned to the probiotic group, and the rest were assigned to the control group. After enrollment, pregnant women in the probiotic group received a combination of living Bifidobacterium longum (5 ∗ 106 CFU), Lactobacillus delbrueckii bulgaricus (5 ∗ 105 CFU) and Streptococcus thermophilus (5 ∗ 105 CFU) tablets produced by Neimengu Shuangqi Pharmaceutical Co., Ltd. Pregnant individuals in the probiotic group were administered two tablets twice a day (2 g/d) until natural delivery
223545164|NCT06719479|BIOLOGICAL|IAE0972+Docetaxel|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Docetaxel is used according to the instructions.
223729589|NCT00047814|DRUG|FK788|
223995478|NCT05867823|BEHAVIORAL|Three-part work|The intervention on the control group will focus on offering to the participants an informative three-part work on the positive effects of performing activities to control anxiety and depression. After providing this information, any doubts in this regard will be answered.
223995479|NCT00176982|DRUG|Hydroxychloroquine|
223995480|NCT06523296|PROCEDURE|Adults with Alzheimer's disease|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
223995481|NCT06523296|PROCEDURE|Adults with Myasthenia|"Each patient will undergo a blood draw for the analysis of RACH antibodies in serum.~Also an aliquot of frozen spinal fluid of patient kept in biobank ( spinal fluid taken during a puncture as part of routine care) will be used for the analysis of RACH antibodies."
224122894|NCT04902443|DRUG|Pomalidomide|Pomalidomide will be administered as an oral planned starting dose of 3 mg daily (dose escalation) or at an MTD of 4 mg (dose expansion). Pomalidomide will be given from day 1 to day 21 of each cycle.
224122895|NCT04902443|DRUG|Nivolumab|Nivolumab will be administered IV at a dose of 480 mg at day one of each cycle, except for cycle one when it will be administered on day 8. One cycle equals 28 days
224122896|NCT06910943|DRUG|Choline Chloride for Injection|Intravenous use
224122897|NCT06910943|DRUG|Placebo|Water for injection
224122898|NCT07091734|DRUG|Tirzepatide|"Participants will receive study drug (Tirzepatide) according to the dose titration plan described in the FDA-approved Prescribing Information (starting with 2.5 mg/wk and increasing the dose every 4 weeks by increments of 2.5 mg.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."
224122899|NCT07091734|DRUG|Usual care medications|"Participant's will continue on participant's regular diabetic and hypertriglyceridemia medications that were used during the run-in period for 24 weeks. This will be either Phase 1 or Phase 2 based on randomization.~Additionally, participants will have visits (virtual or remote visits every four weeks) as well as various tests and evaluations during the trial."
224122900|NCT06911905|DIETARY_SUPPLEMENT|Nutritional supplements|The nutritional supplements, including Vitamin B1, Vitamin B2, folic acid, Mecobalamin, Vitamin D3, Choline, and Coenzyme Q10, will be administered for a period of three months.
224122901|NCT06911905|BEHAVIORAL|Treatment as usual (TAU)|Participants will undergo treatment as usual, such as behavioral interventions
224122902|NCT04359446|PROCEDURE|NC ( Non- Compliant) Balloon dilatation|NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
224295386|NCT01566864|BEHAVIORAL|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
224295387|NCT01566864|BEHAVIORAL|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
224295388|NCT01993602|PROCEDURE|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
224299105|NCT04141124|OTHER|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
224122903|NCT04359446|PROCEDURE|Laser Excimer + NC Balloon|Laser Excimer + NC Balloon dilatation at pressure \> NC-RBP (18-20 atm) with \> 1 long inflation (\> 20 minutes each)
223995482|NCT06523296|OTHER|Healhty controls|Frozen spinal fluid of 10 healthy controlled stored in a biobank in Munster, Germanywill be compared to the ones of Adults with Myasthenia and Adults with Alzheimer's disease
223995483|NCT04076709|PROCEDURE|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
223995484|NCT06190106|OTHER|Cognitive Behavioral Therapy (Psychotherapeutic Intervention)|A psychotherapeutic intervention CBT is given to assess the improvement and betterment in mental health and to assess the reduction of Psychiatric symptoms like depression, anxiety and stress
223995485|NCT04392024|DEVICE|Triumf|Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.
223995486|NCT00547014|DRUG|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
223995487|NCT00547014|DRUG|52364 3 mg|3 mg capsule single dose administered orally as a single dose
223995488|NCT00547014|DRUG|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
223995489|NCT00547014|DRUG|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
224122904|NCT06076928|DEVICE|Brain Computer Interface integrated HandyRehab platform (BCI-HR)|To test the usability, safety and efficacy of an experimental prototype of a wearable hand robotic glove integrated with brain computer interface system being developed and researched.
224122905|NCT06076928|DEVICE|HandyRehab (HR)|A wearable hand robotic glove approved by Health Sciences Authority, class I commercial device
224122906|NCT06076928|OTHER|Standard Treatment of Care|Standard Conventional Occupational Therapy
224122907|NCT07100847|PROCEDURE|Periprostatic neurolysis with dehydrated alcohol (ethanol)|Pre-operative ultrasound guided periprostatic neurolysis by injection of dehydrated alcohol
224295389|NCT05582252|OTHER|Non-Invasive saliva sampling|"There are two types of intervention in this ambidirectional study.~1. Non-Invasive Saliva Sampling will be done for DNA extraction for the purpose of genetic analysis. This would be the prospective sampling and it's not part of the related medical centre's clinical routine.~2. ICD that is already implanted in the patients and had been indicated by related medical centre's clinical routine approach. This is not a prospective approach to this study since the study would be retrospectively gathered phenotypic parameters from the hospital data records."
223729590|NCT02071251|PROCEDURE|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
223995490|NCT00547014|DRUG|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
223995491|NCT00547014|DRUG|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
223995492|NCT00547014|DRUG|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
223995493|NCT05050825|OTHER|Patient clinical management based on the CDSA strategy|The CDSA strategy is a combination of point of care tests (rapid diagnostic tests targeting malaria, dengue fever and streptococcus group a sore through) and a mHealth tool that provides patient management recommendations, including treatment, based on an algorithm integrating patient clinical signs and symptoms, history and diagnostic test results.
223729591|NCT06224101|BEHAVIORAL|Simulation-based training|simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
223729592|NCT01830699|DRUG|Rilonacept|160 mg intra-bursal once
223729593|NCT01830699|DRUG|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
223729594|NCT02338531|DRUG|PF-03084014|
223729595|NCT02338531|PROCEDURE|Breast cancer surgery|
223729596|NCT03683446|PROCEDURE|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
223729597|NCT03683446|PROCEDURE|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
223729598|NCT05211791|PROCEDURE|erector spinae block|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
223729599|NCT05211791|PROCEDURE|paravertebral block anesthesia|Ultrasound-guided insertion of different analgesic procedures as paravertebral block anesthesia and paravertebral block anesthesia
223729600|NCT05211791|PROCEDURE|Thoracic epidural anesthesia|insertion of Thoracic epidural catheter for anesthesia analgesia at level of T6
223729601|NCT03992157|DEVICE|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
223729602|NCT02478801|DIETARY_SUPPLEMENT|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
223729603|NCT01018368|DRUG|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
223729604|NCT01018368|DRUG|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
223729605|NCT01845350|OTHER|M2 macrophage introduction|"* Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages"
223729606|NCT01948050|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|
223729607|NCT00558025|DRUG|Pramipexole Extended Release|
223729608|NCT00558025|DRUG|Pramipexole Immediate Release|
223729609|NCT01057550|PROCEDURE|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
223729610|NCT01057550|PROCEDURE|TVT|Standard TVT as described by Ulmsten 1996
223729611|NCT01057550|PROCEDURE|Pelvicol|retropubic mid urethral sling made from Pelvicol
223729612|NCT02651298|DEVICE|Fractional Co2-laser|laser treatment
223729613|NCT06215599|OTHER|Survey|The survey consisted of 14 questions that thoroughly examined the participants' knowledge levels of these conditions, as well as their indication preferences related to BAHIs.
223729614|NCT02187250|DRUG|metformin|
223729615|NCT02187250|DRUG|liraglutide|
223729616|NCT02187250|DRUG|roflumilast|
223729617|NCT01314443|OTHER|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
223995494|NCT01249495|PROCEDURE|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
223729618|NCT01314443|DIETARY_SUPPLEMENT|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
223729619|NCT01314443|OTHER|Placebo|Participants will take placebo for 7 days
223729620|NCT01314443|BEHAVIORAL|Smoking cessation|Participants will quit smoking without any pharmacological aids
223995495|NCT03680547|OTHER|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
223995496|NCT04056988|DRUG|Perflutren Lipid Microsphere|Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
224122908|NCT07101705|DRUG|OriV508 Injection|OriV508 injection is one kind of non-replicative self-inactivating lentivirus vector which carries an effective BCMA/CD19 dual-target CAR. OriV508 can be administered intravenously and produce BCMA/CD19 CAR-T in vivo.
224122909|NCT06063967|DRUG|Risankizumab SC|subcutaneous (SC) injection
224122910|NCT06063967|DRUG|Placebo for risankizumab|subcutaneous (SC) injection
224122911|NCT07109856|DIAGNOSTIC_TEST|POP-Score Assessment|A non-invasive score calculated within the first 6 hours after birth using peripheral muscle oxygenation (pTOI, measured via near-infrared spectroscopy), heart rate, arterial oxygen saturation (SpO2), systolic blood pressure (SABP), and subcutaneous fat layer thickness. The score is evaluated for its ability to predict C-reactive protein (CRP) levels ≥ 20 mg/L within 48 hours.
224122912|NCT07109856|DEVICE|Near-Infrared Spectroscopy (NIRS)|NIRS measurements are performed within 6 hours after birth using the NIRO 200NX device at four anatomical sites (forearm, forehead, infraumbilical region, and left flank). Measurements assess peripheral muscle, cerebral, intestinal, and flank oxygenation to identify possible differences in tissue perfusion associated with early inflammation or infection.
224122913|NCT06916728|DEVICE|Marketed Product - MP01|Marketed Product - MP01 was implanted via a mini-arthrotomy or arthrotomy approach, using the designated surgical tools and surgical technique.
224299106|NCT04141124|OTHER|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
223729621|NCT00109889|PROCEDURE|magnetic resonance imaging|magnetic resonance imaging (MRI)
223729622|NCT00109889|PROCEDURE|positron emission tomography|positron emission tomography (PET)
223729623|NCT01980914|DEVICE|iPro2 glucose sensor attachment|At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
223729624|NCT00449540|DEVICE|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
223729625|NCT00449540|DEVICE|Sham TMS Device|Simulated Sham treatment without TMS delivery
223995497|NCT01504776|DRUG|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
223995498|NCT01504776|DRUG|Bortezomib|
223995499|NCT04921618|OTHER|2 online self-administered questionnaires on|"1. Participant profile~2. Spontaneous partner notification practices collected one month after STIs diagnosis"
223729626|NCT05560984|COMBINATION_PRODUCT|cervical internal os plasty|A long Allis forceps will be passed through the uterine incision and used to grasp the anterior lip of the cervix, pulling the cervix upwards into the uterine cavity. An assistant sometimes needs to elevate the cervix upwards from the vaginal aspect. The anterior lip of the cervix will be sutured to the anterior wall of the lower uterine segment using two or three simple interrupted absorbable stitches (Vicryl or Vicryl rapid no. 0). This aids to compress the bleeding sites of the placental bed and support the very thin lower uterine segment. If the placenta was implanted posteriorly and the bleeding areas will be mainly from the posterior wall of the uterus, the same procedure could be repeated using the posterior lip of the cervix. A Hegar dilator (size 12) will be inserted in a retrograde manner from the abdominal aspect toensure patency of the cervical canal .
223995500|NCT04921618|OTHER|2 online self-administered questionnaires on|"1. Participant profile~2. Experiences with partner notification and use of STI testing following notification"
223995501|NCT05629299|BIOLOGICAL|Samples|Men will give semen, saliva, skin, urine and blood specimens
223995502|NCT00088933|DRUG|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
223995503|NCT00088933|DRUG|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
224122914|NCT06916728|PROCEDURE|Surgical Standard of Care|"As no single, current therapy could be used as a single comparator for the treatment of the knee lesions treated in the pivotal study which included focal cartilage lesions on the one hand and moderate knee osteoarthritis on the other, current general practice (e.g., SSOC: Deb and MFx) was used.~Deb (SSOC) is a common orthopedic surgical procedure that removes damaged cartilage and tissue from the knee. MFx (SSOC) is another common orthopedic surgical procedure that treats knee cartilage defects by creating small holes in the bone beneath the damaged cartilage."
224122915|NCT07110090|BIOLOGICAL|Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002)|dosage form: Injection dosage: 10 mL/bag, 1×10⁷ cells/mL frequency: Each subject will be administered a single infusion of XJ-MK-001 at their respective enrolled dose level.
223729627|NCT06152757|BIOLOGICAL|First dose|1.0×10\^8cells,Intravenous infusion，1 subject is planned to be enrolled
223729628|NCT06152757|BIOLOGICAL|Second dose|3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
223729629|NCT06152757|BIOLOGICAL|The third dose|1.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
223729630|NCT06152757|BIOLOGICAL|The fourth dose|3.0×10\^9cells,Intravenous infusion，3 subject is planned to be enrolled
223995504|NCT00088933|DRUG|docetaxel|Given IV
223995505|NCT00088933|DRUG|sargramostim|Given subcutaneously
223995506|NCT06331637|PROCEDURE|Transanal Transection and Single-Stapled anastomosis (TTSS)|Restorative proctectomy with Transanal Transection and Single-Stapled (TTSS) Ileal Pouch-Anal Anastomosis (IPAA)
223995507|NCT06331637|PROCEDURE|Double-stapled anastomosis|Restorative proctectomy with Tdouble-stapled Ileal Pouch-Anal Anastomosis (IPAA)
223995508|NCT05364567|DRUG|cholecalciferol (vitamin D3)|The study group with vitamin D deficiency was treated with intramuscular injection of 200,000 IU cholecalciferol (Kwangdong Pharmaceutical Co., Seoul, Korea) once at baseline.
224122916|NCT07112222|DRUG|LM-350 for injection|Q3W,Intravenous Drip
224122917|NCT06920056|DRUG|Paracetamol|oral, postprandial
223729631|NCT00022009|DRUG|gemcitabine hydrochloride|
224122918|NCT06920056|DRUG|Metformin Hydrochloride|Oral , Fasting
224122919|NCT06920056|DRUG|Warfarin|Oral , Fasting
224122920|NCT06920056|DRUG|BGM0504|Administered SC
224295390|NCT06868420|BEHAVIORAL|Play therapy with transport cart|he intervention consisted of allowing pediatric patients to engage in five minutes of play with a toy transport cart, after which they were transported to the operating room in the same cart.
224299107|NCT04141124|OTHER|Control|5 minutes of reading fictitious biological medical results
224299108|NCT01405716|BEHAVIORAL|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
224299109|NCT01405716|BEHAVIORAL|Health Education|8-week health education program
224299110|NCT00228514|DRUG|Rosuvastatin|
224299111|NCT00228514|PROCEDURE|Positron emission tomography|
224299112|NCT00005634|DRUG|vorinostat|
224299113|NCT02637661|OTHER|earlobe crease positive|
224299114|NCT02637661|OTHER|earlobe crease negative|
224299115|NCT03188718|DEVICE|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
224138364|NCT03016546|BEHAVIORAL|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
223729632|NCT05000125|DIAGNOSTIC_TEST|Hologic's Genius Digital Diagnostics System|Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
223729633|NCT01910610|BIOLOGICAL|FOLFIRI-cetuximab|
223729634|NCT01910610|BIOLOGICAL|mFOLFOX6-bevacizumab|
223729635|NCT01910610|BIOLOGICAL|OPTIMOX-bevacizumab|
223729636|NCT01910610|BIOLOGICAL|irinotecan-based chemo + bevacizumab|
223729637|NCT01910610|BIOLOGICAL|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
223729638|NCT01910610|BIOLOGICAL|XELOX + bevacizumab|
223729639|NCT03415841|DEVICE|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
223729640|NCT03272074|OTHER|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
223729641|NCT02135146|DRUG|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
223729642|NCT02135146|DRUG|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
223729643|NCT00000507|DRUG|streptokinase|
223995509|NCT05364567|PROCEDURE|Phototherapy|The phototherapy for treating depigmented areas was by using 308-nm xenon chloride excimer laser (E1, Jetema, Seoul, Korea) or NB-UVB (N-UVB 6000C, Choyang medical, Seongnam, Korea). The initial dose for excimer laser was decided based on the location of depigmented lesion with consideration of the previous results of the phototherapy;40-42 eye = 100mJ/cm2; head, face, ear, neck, axilla = 150mJ/cm2; arm, leg, trunk = 200mJ/cm2; wrist = 250mJ/cm2; elbow, knee = 300mJ/cm2; hand, foot = 400mJ/cm2; finger, toe = 600mJ/cm2; Meanwhile, initial dose for NB-UVB was 400mJ/cm2. If the erythema after laser disappears within 24 hours, the energy dose was increased by 50 mJ/cm2 for each treatment. But if the erythema sustained for 24-48 hours, the energy dose was maintained. If the erythema last longer than 48 hours, the energy dose was decreased by 50-100 mJ/cm2 at each session. If blistering or pain occured, the treatment was omitted until resolution of symptoms.
223995510|NCT00557908|DRUG|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
223995511|NCT02819167|OTHER|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
223995512|NCT01346631|OTHER|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
224299116|NCT01034787|DRUG|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
223995513|NCT01124383|PROCEDURE|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
223995514|NCT01124383|PROCEDURE|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score \< 4.
223995515|NCT02597335|RADIATION|Spectro-MRI|Spectro-MRI for D-2HG detection
223995516|NCT02597335|OTHER|Dosage of free circulating plasmatic DNA|
223995517|NCT02597335|OTHER|Dosage of D-2HG in the urine|
223995518|NCT05692700|OTHER|aromatherapy|essential oil application by inhalation
223995519|NCT05692700|OTHER|Placebo|Placebo essential oil
223995520|NCT02381093|OTHER|Modified BLS course|BLS using CI
223995521|NCT02381093|OTHER|Standard BLS Course|Usual BLS teaching
223995522|NCT05266443|DIETARY_SUPPLEMENT|Lactobacillus containing cultured milk drink|Each bottle of 125ml cultured milk drink contains a billion colony forming unit (CFU) Lactobacillus acidophillus (LA-5) and Lactobacillus paracasei (L. CASEI-01). Each patient will be given 2 bottles to consume daily for a period of 12 weeks.
223995523|NCT05266443|DIETARY_SUPPLEMENT|Placebo cultured milk drink|The placebo prepared was identical to the probiotic-containing product in terms of color, taste and packaging. However, there is no trace of live microorganism in this product.
223995524|NCT03310034|DIETARY_SUPPLEMENT|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
223995525|NCT03310034|DIETARY_SUPPLEMENT|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
223995526|NCT01637805|BIOLOGICAL|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
223995527|NCT05737862|DIETARY_SUPPLEMENT|Moringa oleifera capsules|In this arm, pregnant mothers receive capsules containing 500 mg of powdered Moringa oleifera leaves which contain 13.09 mg of iron per100 gram. Dose: 2 × 2 capsules per day for 30 days
223995528|NCT05737862|DIETARY_SUPPLEMENT|iron and folic acid supplements|In this arm, pregnant mothers receive IFA tablets 2 × 1 tablet a day for 30 days. Each IFA tablet contains 400 mcg folic acid and 180 mg Ferrous Fumarate.
223995529|NCT03165487|OTHER|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
223995530|NCT03165487|OTHER|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
223995531|NCT05869318|OTHER|ECIG own|Participants will vape using their own ecig device
223995532|NCT05869318|OTHER|ECIG Vuse|Participants will vape a VUSE e-cigarette (GOLD 5%)
223995533|NCT03668639|DRUG|Akynzeo|Weekly administration of akynzeo for five weeks.
223995534|NCT03668639|DRUG|Dexamethasone|Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
223995535|NCT02260713|BIOLOGICAL|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
223995536|NCT03621462|DEVICE|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
223995537|NCT06061822|DIAGNOSTIC_TEST|AI-assisted cardiac magnetic resonance imaging|An AI algorithm will be used to automatically position (plan) the scan planes used in a cardiac MRI scan. The resultant images will be compared with standard radiographer-positioned images.
223995538|NCT02051062|BIOLOGICAL|Blood sample collection|One to three 5 mL blood samples will be collected from pediatric participants treated with BAT product ideally 6-24 hours after administration but within a maximum of 32 hours after administration.
223995539|NCT05525247|DRUG|SLC-3010|Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle
224122922|NCT06930001|OTHER|Etamine Application Group /Intervention|Before the intervention, students in the intervention group will complete the Informed Consent Form, Personal Information Form, Perceived Stress Scale, and Attitudes Towards Learning Scale (pre-test). In the first week, a 45-minute etamine training (history, tools, basic techniques) will be given individually by the scholarship holder (Şeyma Demir). Techniques such as threading, knotting, and cross-stitching will be taught, and students will apply a simple pattern, correcting mistakes. Room conditions (21℃) and student comfort will be ensured, with restricted access. One week later, students will practice weekly for 3 weeks (45 minutes each) using the Etamine starter set. In week five, the project manager will provide 2 hours of theory and 4 hours of practical episiotomy training. Students will then be assessed with the Episiotomy Repair Skill Form (post-test). Final evaluations will include the Perceived Stress Scale and Attitudes Towards Learning Scale (post-test).
223995540|NCT05525247|COMBINATION_PRODUCT|Gemcitabine|1000 ㎎/㎡ IV infusion over 30 minutes on day 1 and 8 of each 21-day cycle
223995541|NCT04699968|DRUG|SHR-1701，Famitinib|SHR -1701, Intravenous ；Famitinib, oral
223995542|NCT04699968|DRUG|SHR-1701|SHR -1701, Intravenous
223995543|NCT03142854|DRUG|Polyethylene Glycol (PEG)|participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
223995544|NCT03142854|DRUG|Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
223995545|NCT02320526|BEHAVIORAL|Control|
223995546|NCT02320526|BEHAVIORAL|Continuous walking|
223995547|NCT02320526|BEHAVIORAL|Interval walking|
223995548|NCT06099886|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate 30-45mg/day
223995549|NCT06444490|BEHAVIORAL|General Approach Instruction|Oral health instruction focused more broadly on the different topics of oral diseases and oral hygiene care.
223995550|NCT06444490|BEHAVIORAL|Personalised Technique Instruction|Oral health instruction based on the specific needs of each participant.
223995551|NCT00064649|DEVICE|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
223995552|NCT00064649|DEVICE|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
223995553|NCT00064649|DRUG|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
224122923|NCT06929520|BEHAVIORAL|ENDS Prevention Intervention (TBD)|The ENDS Prevention Intervention will consist of (1) a modular classroom curriculum with ENDS-focused lessons and lessons covering alcohol, tobacco, and other drug use; (2) social media content that is related to the classroom curriculum and video content, and (3) a print media campaign across school campuses on Hawaii Island.
223995554|NCT01906983|OTHER|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
223995555|NCT01750970|OTHER|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
223995556|NCT04486625|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
223995557|NCT04486625|DRUG|Aztreonam-Avibactam|675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
223995558|NCT00263237|DRUG|STA-5326|
223995559|NCT02422576|OTHER|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
223995560|NCT02422576|OTHER|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
223995561|NCT02422576|OTHER|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
223995562|NCT02422576|OTHER|Thicken Up clear: TUC|
223995563|NCT05396651|OTHER|low fodmap diet|elimination of high fodmap diet - High FODMAP diet: ice cream, soft cheese , yoghurt, cabbage , cauliflower, green bean, garlic, okra, onions, snow peas, broccoli, avocado , apple, mango , dates, watermelon, legumes , pulses, wheat , pasta , artificial sweeteners
223995564|NCT05396651|OTHER|NICE guidelines for IBS|"follow NICE guidelines for IBS :have regular meals and take time to eat. avoid missing meals or leaving long gaps between eating. drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.~restrict tea and coffee to 3 cups per day. reduce intake of alcohol and fizzy drinks."
223995565|NCT03429777|DEVICE|HearMe Smartphone Application|The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
223995566|NCT04226989|BIOLOGICAL|CT-RD06|CT-RD06 cell injection by intravenous infusion
223995567|NCT01205022|DRUG|irinotecan hydrochloride|Given IV
223995568|NCT01205022|DRUG|leucovorin calcium|Given IV
223995569|NCT01205022|DRUG|fluorouracil|Given IV
223995570|NCT01205022|BIOLOGICAL|bevacizumab|Given IV
223995571|NCT01205022|RADIATION|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
224122924|NCT07122661|BIOLOGICAL|ABRYSVO|This is a non-interventional retrospective study; therefore, ABRYSVO vaccine has already been administered according to the standard of care. ABRYSVO is a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both RSV-A and RSV-B.
223995572|NCT01205022|OTHER|laboratory biomarker analysis|Correlative studies
223995573|NCT00002385|DRUG|Fozivudine tidoxil|
223995574|NCT01431820|DRUG|Luliconazole Solution, 10%|Topical
223995575|NCT01431820|DRUG|Vehicle Solution|Topical
223995576|NCT03283475|PROCEDURE|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
224122925|NCT06933381|DEVICE|Vapocoolant spray|Pain Ease will be used per manufacturer instruction, applying the spray for 5 seconds or until the skin turns white, whichever occurs first.
224122926|NCT06933381|OTHER|Placebo|Nature's Tears will be applied to the arm as a placebo spray
224295391|NCT01576094|DRUG|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
224295392|NCT01576094|DRUG|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
223995577|NCT00777738|DRUG|BORTEZOMIB|"* Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~* For responding patients : up to 6 cycles~* For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
223995578|NCT00551330|DRUG|Vicriviroc|One tablet of vicriviroc 30 mg once daily
223995579|NCT00551330|DRUG|Placebo|One tablet of placebo once daily
223995580|NCT03613389|DIETARY_SUPPLEMENT|oral topical vitamin E|Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
223995581|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
223995582|NCT01762332|DRUG|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
223995583|NCT01762332|OTHER|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
224122927|NCT02609685|OTHER|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
224122928|NCT06439719|PROCEDURE|Blood sample collection|Collection of blood sample
224122929|NCT06951828|BIOLOGICAL|CT-P43|CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via auto-injector (AI)
224122930|NCT06951828|BIOLOGICAL|CT-P43|CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
223995584|NCT05003492|COMBINATION_PRODUCT|Combination therapy plus Standard therapy|"Methylene Blue 1 mg/kg water solution. Participants will orally receive Methylene Blue solution of 1 mg/kg concentration one time if any. After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.~Patients will be administered study medication (Inhaled 100-150 mg phenformin per day; or, if broken into 3 doses/day, 30-50 mg/dose. this dose well be once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.~Patients will receive an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)~Patients received will receive Zinc gluconate capsule 15 mg x 2 per day during 14 days"
223995585|NCT05003492|RADIATION|Photodynamic therapy|After 3 hours of Methylene Blue administration irradiation of chest using 650 nm laser source with 18 J/cm\^2 energy dose will be performed.
223995586|NCT05003492|DRUG|Standard therapy|Infected patients will receive the standard therapy for COVID-19 for 14 days
223995587|NCT05942820|DRUG|BWC0977|SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
223995588|NCT05942820|DRUG|Placebo|"SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977"
223995589|NCT06066411|OTHER|Massage Ball|The massage ball application will be applied to the patients by the researcher for 20 minutes every day for 3 days.
223995590|NCT00402012|DRUG|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
224122931|NCT07142707|DRUG|MBX 4291|MBX 4291 will be administered subcutaneously (SC)
224122932|NCT07142707|DRUG|Placebo|Placebo: Placebo will be administered subcutaneously (SC)
224122933|NCT01922427|DRUG|RNS60|
224122934|NCT07149584|PROCEDURE|ESPB|10 mL of 0.375% bupivacaine is injected on each side between the deep fascia of the erector spinae muscle and the transverse process. Additionally, tramadol is administered via intravenous patient-controlled analgesia.
224122935|NCT07149584|PROCEDURE|TPVB|10 mL of 0.375% bupivacaine is injected on each side between the superior costotransverse ligament and the pleura.
224122936|NCT07149584|PROCEDURE|IV|Tramadol is administered via intravenous patient-controlled analgesia.
223995591|NCT03211234|DRUG|2.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
223995592|NCT03211234|DRUG|4.0 mg DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
223995593|NCT03211234|DRUG|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
223995594|NCT01619189|BIOLOGICAL|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
224122937|NCT07152860|OTHER|5 Hz electroacupuncture combined tipronone capsules|Intervention Description: The intervention in this study involves the use of electroacupuncture (EA), a combination of traditional acupuncture and electrical stimulation. Acupoints Selection: Electroacupuncture will be performed at specific acupoints associated with the stomach and digestive system. The local acupoints chosen are Liangmen (ST21) and Tianshu (ST25), while the distal acupoints are Zusanli (ST36) and Xiajuxu (ST39). This selection is based on Traditional Chinese Medicine (TCM) principles for treating functional dyspepsia. Frequency: 5 Hz Patients will also be administered SviShu (tipronone capsules) (Wei Cai Pharmaceutical Co., Ltd., National Drug Approval Number H20093656, dosage: 50 mg) orally, one capsule at a time, three times daily, after meals.
224122938|NCT07152860|DRUG|Simple tipronone capsules group(The basic treatment group)|Patients in the Simple tipronone capsules group(basic treatment group) will receive only conventional basic drug therapy. They will be given Svi-Shu (tipronone capsules) (Eisai Pharmaceutical Co., Ltd., national drug approval number H20093656, specification: 50 mg) orally, one capsule at a time, three times a day, after meals.
224122939|NCT05860881|DRUG|Sirolimus Topical Cream|The intervention topical cream consists of sirolimus 1% in a vehicle. Patients randomised to the intervention will be required to apply the sirolimus topical cream to their face for 6 months
223995595|NCT01619189|PROCEDURE|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
223995596|NCT04802889|OTHER|scanning electron microscopy|scanning electron microscopy of the сentral retina and preretinal structures
223995597|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
224122940|NCT05860881|OTHER|Placebo|Cream containing only the base, or vehicle.
223995598|NCT02271984|DRUG|Cysticide|Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
223995599|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
223995600|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
223995601|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
223995602|NCT02271984|DRUG|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
223995603|NCT01457638|PROCEDURE|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
223995604|NCT01457638|PROCEDURE|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
223995605|NCT00115908|DRUG|Albuferon|
223995606|NCT00115908|DRUG|Ribavirin|
223995607|NCT00115908|DRUG|PEG-IFNalfa2a|
223995608|NCT03620539|OTHER|Lifestyle intervention|Sauna bathing
223995609|NCT01201577|DIETARY_SUPPLEMENT|Bifidobacterium longum BB536|2 capsules od
223995610|NCT01201577|DIETARY_SUPPLEMENT|Active hexose correlated compound (AHCC)|One capsule tds
223995611|NCT01201577|DIETARY_SUPPLEMENT|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
223995612|NCT01201577|DIETARY_SUPPLEMENT|Corn starch placebo capsule|One capsule tds and two capsules od
223995613|NCT01201577|DRUG|Azithromycin|250mg od
223995614|NCT02244970|OTHER|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
223995615|NCT02244970|OTHER|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
223995616|NCT06530004|DRUG|Rituximab|B lymphocyte reconstitution was performed regularly after the administration of rituximab, and 1-4 doses of rituximab were given according to the exhaustion of B cells in children.
223995617|NCT04821557|DIETARY_SUPPLEMENT|Protease + Protein|Participant will consume a microbial protease supplement (31,875 Hemoglobin Unit Tyrosine base (HUT); protease activity) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
224122941|NCT07154121|DRUG|5-fluorouracil group|Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; After suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in 12.5 mg/mL 5-fluorouracil for 3 minutes, after which the gelatin sponge was removed and the area thoroughly rinsed with saline.
223995618|NCT04821557|DIETARY_SUPPLEMENT|Placebo + Protein|Participant will consume a placebo supplement (250 mg maltodextrin) combined with a pea protein beverage (25 g pea protein; Roquette Nutralys® S85F)
223995619|NCT04730141|OTHER|Patient mobilization with pre-operative mobilization training and mobilization protocol|Postoperative mobilization for the first 24 hours
223995620|NCT04246164|DEVICE|HD-tDCS combined with CT|HD-tDCS treatments will be administered during a cognitive training session.
223995621|NCT04246164|DEVICE|sham HD-tDCS combined with CT|sham-HD-tDCS treatments will be administered during a cognitive training session.
223995622|NCT02349997|OTHER|no interventions|This is an observational study and no intervention applied.
223995623|NCT01423591|DRUG|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
223995624|NCT01423591|DRUG|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
223995625|NCT03546153|BEHAVIORAL|Aerobic exercise program|Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
223995626|NCT02772939|DEVICE|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
223995627|NCT03245905|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
223995628|NCT04553562|DEVICE|Acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) will be inserted through the pads by the needles (0.30mm in diameter, 40 mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 25-30mm. Yintang (GV4) will be inserted through the pads by the needle (0.30mm in diameter, 25mm in length, Hwato Brand, Suzhou Medical Appliance Factory, China) to a depth of 10-15mm. The needles at all points will be lightly lifting, thrusting, and twirling every 10 minutes during each session with the sensation of sourness, achiness, heaviness and numbness (deqi). The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
224122942|NCT07154121|OTHER|saline group|Patients in the intervention group underwent standard En-DCR surgery, with all procedures performed by the same senior oculoplastic surgeon; Similarly, after suturing to create a new nasolacrimal duct during surgery, Schirmer strips were placed at the ostium to measure its size and photographed for record-keeping. The ostium was then covered with a gelatin sponge soaked in saline solution for 3 minutes, after which the gelatin sponge was removed and the ostium was thoroughly rinsed with saline solution.
224122943|NCT07156708|OTHER|Aquatic aerobic exercise program|The aquatic exercise sessions include the following exercises: butt kick, frontal kick, cross-country skiing, and stationary running. These exercises are commonly used in water aerobics classes and provide controlled osteoarticular impact, being safe for older women (Alberton et al., 2019). Training intensity is prescribed using Borg's 6-20 rating of perceived exertion (RPE) scale. The adopted strategy is based on interval training, which alternates between high-intensity effort and low-intensity active recovery phases. Each block consists of 4 minutes of effort (RPE 13 - 15), with one minute for each exercise (butt kick, frontal kick, cross-country skiing, and stationary running) followed by 1 minute of active recovery (RPE 11), performed with stationary running. To facilitate monitoring, an RPE scale (measuring 0.90 × 1.20 m) is fixed to the outside of the pool, in front of the participants.
224122944|NCT07156708|OTHER|Cognitive tasks|This group performs the same aerobic training protocol used by the conventional aquatic program group. Additionally, cognitive tasks are performed during the active recovery phases. Cognitive training encompasses different domains of cognition in all sessions, including semantic fluency, processing speed, cognitive flexibility, inhibitory control, memory, attention, and reasoning. The exercises vary in each class, with progression in complexity in each mesocycle.
224295393|NCT04918160|OTHER|Exposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)|The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
223995629|NCT04553562|DEVICE|Sham acupuncture|Sterile adhesive pads will be placed after skin disinfection on the acupoints. Needles (0.30 mm in diameter, 25 mm in length) with a blunt tip will be inserted at the Guanyuan (CV4)，Qihai (CV6)，bilateral Sanyinjiao (SP6), Yinbao (LR9), Qixue (KI13) and Fujie (SP14) without penetrating the skin. The participants will be treated three times a week, on alternate days (ideally), for 6 successive weeks; 18 sessions for each patient in total.
223995630|NCT00167804|BEHAVIORAL|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
223995631|NCT00003391|BIOLOGICAL|monoclonal antibody muJ591|
223995632|NCT05034406|DRUG|2% Lidocaine|6 mL of 2% lidocaine injected at the trocar insertion site.
223995633|NCT05034406|DRUG|0.5% levobupivacaine|6 mL of 0.5% levobupivacaine injected at the trocar insertion site.
223995634|NCT05529680|OTHER|Scapular mobilization and Scapular strengthening exercises|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
223995635|NCT05529680|OTHER|Conventional physical therapy program|The intervention was applied for four weeks, 3 sessions/week. and the Shoulder Pain and Disability Index (SPADI): for measurement of shoulder disability and the Inclinometer: for measurement of shoulder flexion, abduction, external rotation, and scapular upward rotation were used for shoulder assessment before and after the intervention for both groups.
223995636|NCT05509049|OTHER|Precision nudging|Precision nudging (i.e., the application of behavioral science and reinforcement learning to create individualized, tailored health messaging at scale that matches the right message to the right person at the right time)
223995637|NCT05509049|OTHER|Standard of care|Standard of care communication (e.g., personalized letters and patient portal notices)
223995638|NCT00317018|BEHAVIORAL|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
223995639|NCT06341777|BEHAVIORAL|Audio-visual training (AVT) telerehabilitation|Participants are trained at home, with remote supervision, for 3 weeks (5 days/week, 2 hours/day) using an audio-visual device suitable for telerehabilitation (AVDESK, Linari Medical). Specifically, visual stimuli (LEDs) appear on a semicircular panel, either alone or paired with an acoustic cues, at different eccentricities. Stimuli to the blind visual field (70%) and intact visual field (30%) are presented in random sequence. Patients are trained to scan the visual field by shifting their gaze (from the central fixation point) towards the visual target (with or without sounds), without head movements, and to report its presence by pressing the response key.
224122945|NCT07152613|DRUG|Saline (0.9%, sterile, for infusion)|Saline for control
224122946|NCT07152613|DRUG|Low Dose Corticosteroids|Methylprednisolone 0.5mg/kg ivgtt qd
223995640|NCT03633292|DRUG|Antiseptic clorhexidine gel (Lacer, Barcelona, Spain)|"Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use."
223995641|NCT03633292|DRUG|Master formula of aloe vera gel 80%|Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented
223995642|NCT06451640|DRUG|210mg of TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
223995643|NCT06451640|DRUG|420mg of TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
224122947|NCT07152613|DRUG|Moderate dose corticosteroids|Methylprednisolone 1.0mg/kg ivgtt qd
224122948|NCT07163884|OTHER|electrotherapy treatment|Patients in the electrotherapy group will receive 15 sessions of TENS, hotpack, and ultrasound, 45 minutes each, 5 days a week, for 3 weeks. The treatment program is planned for 20 minutes of TENS, 15 minutes of hotpack, and 10 minutes of ultrasound.
223995644|NCT06334315|DRUG|Desogestrel / Ethinyl Estradiol Pill|Standard pill packs containing 21 active pills and 7 placebo pills
223995645|NCT04743609|DIAGNOSTIC_TEST|nasopharyngeal samples|rapid antigen test for Sars Cov-2, influenza and RSV. multiplex RT-PCR for a subgroup of 500 patients
223995646|NCT02912390|PROCEDURE|Cerclage|Macdonald cerclage placed in standard fashion
223995647|NCT02912390|OTHER|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
223995648|NCT05753436|DIETARY_SUPPLEMENT|Puritans Pride Turmeric curcumin® 500 mg|Turmeric curcumin 500 mg per oral capsule of Puritans Pride company supplement composed of Turmeric (curcuma longa) root 450mg and Turmeric extract (curcuma longa root 50mg ) standardized to contain 95%curcuminoids.It is added because of its possibility to reduce the risk of ASCVD by lowering blood pressure, lipid profile, blood glucose, inflammation, and oxidative stress.
223995649|NCT05528523|OTHER|Writing a clinical narrative|The participants had to write a clinical narrative regarding a significant encounter with a patient.
223995650|NCT04548284|DRUG|Glucocorticoids|Periorbital injection of glucocorticoid. Once every 3 weeks, the number of injections was determined according to the condition of the eyes during the follow-up.
223995651|NCT00362245|DRUG|Systemic and Intra-Thecal Amikacin Therapy|
223995652|NCT03459872|PROCEDURE|Acupuncture|Alternative medicine therapeutic intervention
223995653|NCT03459872|DEVICE|RU-Fit|FDA approved medical device for the measurement of fine motor control
223995654|NCT06446687|PROCEDURE|Dental implant with sinus lifting.|Surgery will be performed under local infiltration anaesthesia. Flap will be done. For maxillary sinus lifting by using Crestal approach with Membrane Control Technique by Wang (Wang, 2017) will be employed. After reflecting on the flap, Magic Split will be used to confirm bone quality clinically. This will be followed by site preparation using Magic Marking Drill. Bone drilling will then be performed by Magic Drill shorter by 2 mm from the sinus floor. This will be followed by sinus lifting by using Magic Sinus Lifter (MSL). The 3mm space of the apex of the Sinus Lifter instrument enables direct control of the bone-block and consequently the membrane, which is connected to the bone-block. the fixture will be installed in the conventional method. Then cover the fixture with the cover screw. The flap will be sutured. An immediate CBCT will be requested to ensure the implant is in its proper position.
223995655|NCT00370864|BIOLOGICAL|H5N1 pandemic influenza vaccine|
223995656|NCT03714698|OTHER|Pilates exercise group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
224122949|NCT07163884|OTHER|Facsial therapy|In addition to electrotherapy, the patients in the study group will receive a total of five sessions (one day per week for five weeks) of fascial therapy. The protocol will be developed by us. Fascial mobilization will be performed by a trained physiotherapist on the pectoral fascia, deltoid fascia, axillary fascia, and supscapularis fascia, once a week, for 180 seconds each repetition. These sessions will be performed at the pain threshold, and care will be taken to ensure that the pain does not exceed a VAS score of 2.
224122950|NCT07162194|PROCEDURE|Digital Rectal Examination|Undergo DRE
223995657|NCT03714698|OTHER|Control Group|The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
223995658|NCT03480477|OTHER|ACE questionnaire|No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire
224122951|NCT07162194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI/TRUS
223995659|NCT05757076|PROCEDURE|Blood test for ARR|Blood test for calculating aldosterone and renin ratio (ARR)
224122952|NCT07162194|PROCEDURE|Pathologic Examination|Undergo prostate tissue mapping and evaluation using a special mold
224122953|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy based on PIRADS
224122954|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy using GL AI predictions
224122955|NCT07162194|PROCEDURE|Targeted Prostate Biopsy|Undergo targeted prostate biopsy using DL AI predictions
224122956|NCT07162194|PROCEDURE|Transrectal Ultrasound|Undergo MRI/TRUS
224122957|NCT07162272|DRUG|Melatonin Patches|Group 1 (n=26): Participants in the intervention group will receive two melatonin patches on their forearm (each containing 1mg of melatonin, AVEELA, USA) attached to the skin of their forearm 30 minutes prior to their invasive dental treatment. Pulse Rate, Blood Pressure, and Modified Child Dental Anxiety Scale will be measured before melatonin patches application, after 30minutes of patches application, then after local anesthesia injection, and finally after completing the invasive dental treatment.
223995660|NCT02521363|DEVICE|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.
223995661|NCT02521363|DRUG|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
223995662|NCT04169321|DRUG|Single Arm|\[68Ga\]-NOTA-hGZP is a PET imaging agent.
224122958|NCT07162272|OTHER|Placebo Group|Group 2 (n=26): Participants in the intervention group will receive two placebo patches on their forearm attached to the skin of their forearm 30 minutes prior to their invasive dental treatment. Pulse Rate, Blood Pressure, and Modified Child Dental Anxiety Scale will be measured before placebo patches application, after 30minutes of patches application, then after local anesthesia injection, and finally after completing the invasive dental treatment.
224122959|NCT07162779|DRUG|Radioactive drugs are administered through intravenous injection.|\[68Ga\]DOTA-IR-780-C-4 is administered through a superficial vein on the back of the hand. A PET/CT scan was performed approximately 1 h,2 h and 3 h after injection
223995663|NCT06791239|OTHER|Thoracic squeeze technique|The Thoracic Squeeze Technique is a manual therapy method used primarily in respiratory physiotherapy to improve lung expansion, enhance respiratory function, and facilitate secretion clearance in patients with respiratory conditions.
223995664|NCT06791239|OTHER|Manual diaphragmatic release technique|The Manual Diaphragmatic Release Technique is a soft tissue manipulation technique used to improve the mobility, function, and efficiency of the diaphragm. It is commonly applied in physiotherapy, particularly in respiratory, musculoskeletal, and manual therapy practices, to address breathing dysfunctions, postural imbalances, and associated pain or discomfort.
224122960|NCT07163975|PROCEDURE|complete pulpotomy|the exposed pulp tissue will be amputated using fresh sterile large round diamond bur in a high-speed hand-piece under water coolant to the level of canal orifices. The pulp wound will be irrigated with 3% NaOCl. For hemostasis, sterile cotton soaked in 3% NaOCl will be placed over the pulpal wound for 2 minutes, repeated for up to 5 min if required. Root canal therapy will be initiated in cases in which haemostasis is not achieved within 5 minutes. After hemostasis, MTA will be placed in thickness of 2 to 3 mm over the pulp exposure site using a carrier. This will be followed by application of a layer of light-cure RMGIC and light-curing for 20 sec. The tooth then will be restored using composite resin following etch and rinse technique.
224122961|NCT07163975|PROCEDURE|Root canal treatment|"RCT will be performed in single visit. Root canal orifices will be explored using a DG 16 probe. A size 10 or 15 K-file will be passively inserted into the coronal two- thirds of the canal to verify a smooth glide path.~Coronal enlargement will be done using Gates-Glidden drills. Working length will be determined with the help of electronic apex locator and will be confirmed radiographically. Canals will be prepared using the crown down technique with NiTi rotary instruments. The master apical file (MAF) size for each canal will be selected to be three sizes larger than the initial apical binding file at the WL. 5ml of 5.25% sodium hypochlorite using a 30-gauge side-vented needle will be used for optimal irrigation after each instrument.~After completion of canal instrumentation, the canals will be irrigated with 5.0 ml of 17% ethylene-diamine-tetra acetic acid for 1 minute followed by a final irrigation with 5.0 ml of 5.25% sodium hypochlorite. Canals will be dried with"
224295394|NCT04788160|OTHER|Cervical SNAGs along with conventional therapy|"cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position."
223995665|NCT05281874|BEHAVIORAL|Positive Change (+Change)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. It targets alcohol, sexual assault victimization risk, sexual assault perpetration, and bystander intervention. It is tailored by gender and sexual orientation.
223995666|NCT05281874|BEHAVIORAL|A healthy lifestyles attention control|A healthy lifestyles attention control will be used as the control condition. We will match the control and intervention conditions on content (text, pictures, number of pages); type (interactive vs. psychoeducation); and average completion time.
223995667|NCT05281874|BEHAVIORAL|Positive Change (+Change) Plus Booster|Positive Change (+Change) Plus Booster
223995668|NCT04975841|DEVICE|Adipose Derived Regenerative Cells|"The Cytori Celution technology is an automated version of the process and techniques used in the research laboratory to isolate regenerative cells from adipose tissue. The Cytori Celution System uses a proteolytic enzyme blend (Celase) to disrupt the adipose tissue matrix and release the entrapped adipose derived regenerative cells (ADRCs), also referred to in the literature as stromal vascular fraction cells. Once digested, the digestate is separated into fractions (buoyant adipocytes (fat cells) and pelleted ADRCs) by centrifugation. The non-buoyant cell pellet (ADRCs) is then washed and centrifuged through several cycles to remove residual enzyme reagent and cellular debris. Although the Cytori Celution technology replicates known laboratory techniques, it offers significant improvements to the manual laboratory technique by controlling the processing in a closed system that has been validated for safety, performance, and reproducibility."
223995669|NCT05608668|DEVICE|Pro2 - 60% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Participants will be instructed to inspire forcefully through PrO2™ until the device signals that the user has achieved the target resistance (via audible alarm and visible light signal). The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 60% of their MIP.
223995670|NCT05608668|DEVICE|Pro2 - 15% of participant's MIP|Participants in the control intervention will also use the same PrO2™ device but at a reduced peak resistance of 15% MIP. The research team will implement biofeedback signals at a specific inspiratory resistance to provide precise and individualized training target. Successful IMR repetitions will require that subjects achieve a pressure target that is 15% of their MIP for each repetition
223995671|NCT00248352|BEHAVIORAL|Consultation with Endocrinologist|
223995672|NCT00248352|BEHAVIORAL|Counseling from Dietician|
223995673|NCT00248352|BEHAVIORAL|Counseling from Diabetes Educator|
223995674|NCT04951999|OTHER|Blood sampling|For 10 visits (out of the 12 of the protocol), \~40 ml of blood is sampled for research purposes in addition to care sampling.
223995675|NCT06797674|DRUG|MK-7602|Capsule
223995676|NCT06797674|DRUG|Efavirenz|Tablet
223995677|NCT06840106|PROCEDURE|Nasal steam therapy|Nasal steam therapy is performed once a every other day for a total of 3three times. The steam inhalation stimulates the acupoints of bilateral LI20, EX-HN8, and EX-HN9
223995678|NCT06840106|PROCEDURE|Routine management strategy|Depending on the patient's symptoms and degree of improvement, the clinician may utilize all drugs currently used in clinical practice to improve upper respiratory symptoms, if necessary. All drugs that fall under the Anatomical Therapeutic Chemical Classification System (ATC) codes of non-disease treatment (R01), throat disease treatment (R02), lung disease or expectorant (R03, R05), and other respiratory organ drugs (R06, R07) and other drugs. The usage and dosage should be within the range of the current clinical guidelines.
223995679|NCT03374488|DRUG|Pembrolizumab|Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
223995680|NCT03374488|DRUG|Epacadostat|Epacadostat administered orally twice daily.
223995681|NCT03374488|DRUG|Placebo|Matching placebo administered orally twice daily.
223995682|NCT06479382|DEVICE|ETX-4143 2.0|Treatment of the eye with the ETX-4143 2.0 device
223995683|NCT03475186|DRUG|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
223995684|NCT03104075|BIOLOGICAL|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
223995685|NCT03104075|BIOLOGICAL|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
223995686|NCT04024462|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
223995687|NCT04024462|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
223995688|NCT04024462|DRUG|Pertuzumab and Trastuzumab FDC SC|The pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
223995689|NCT04024462|DRUG|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m\^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
223995690|NCT04024462|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m\^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
223995691|NCT04024462|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m\^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
223995692|NCT04024462|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
223995693|NCT04024462|RADIATION|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
223995694|NCT04024462|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
223995695|NCT06842628|OTHER|Savoring|"Participants will follow an e-savoring training for 3 weeks. The first week will be focused on savoring past positive experiences (positive reminiscence and life lessons); the second week will be focused on savoring the present (absorption during an activity and writing a letter of gratitude to a significant person); and the third week will be focused on savoring the future (anticipating positive future events and making kind gestures to a significant person). After each activity, they will be guided to reflect and savor the positive emotions that emerge from the activity.~The participants will complete some questionnaires at baseline, post-intervention, and in the one-month follow-up."
224122962|NCT07162298|OTHER|Dragon Boat Training|"The total training duration is 12 weeks, divided into cycles of 4 weeks each, with distinct training contents and goals for every cycle. Training sessions are held 3 times a week, and all participants train together on the same day. Each training session lasts approximately 60 minutes.~In the first 4 weeks, participants spend half an hour training on land and the subsequent half an hour training on dragon boats.~Then, from week 4 to week 8, they train for 20 minutes on land and 40 minutes on dragon boats.~Finally, from week 8 to week 12, they only conduct 10-15 minutes of land training (as warm-up) followed by nearly an hour of on-boat training.~This progressive training plan is designed to ensure that each participant can tolerate the training intensity as much as possible, preventing injuries caused by training."
223995696|NCT06842628|OTHER|Positive Emotional Induction|"Participants will follow a positive emotional induction training for 3 weeks, with 2 exercises per week.~The first week, they will listen to a piece of music and watch a video that elicits positive emotions; the second week, they will do an activity that they particularly enjoy in solitude and listen to a narrative about gratitude; the third week, they will listen to a narrative about hope and carry out an activity they like with a loved one. The participants will complete some questionnaires at baseline, post-intervention, and in the one-month follow-up."
223995697|NCT05950334|DRUG|FT522|FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.
223995698|NCT05950334|DRUG|Rituximab|Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.
223995699|NCT05950334|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
223995700|NCT05950334|DRUG|Fludarabine|Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.
223995701|NCT05950334|DRUG|Bendamustine|Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.
223995702|NCT06374849|OTHER|phone interview|Patient's phone interview 3 months after operating room discharge. The interview consisting of 3 questionnaires to detect the presence of CPSP, its intensity, its characteristics and its related analgesic consumption.
223995703|NCT04595682|DRUG|Placebo|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
224122963|NCT07162298|OTHER|Home-based Unsupervised Training|"The total training duration is 12 weeks. After a 15-minute warm-up (including walking, exercises, etc.), participants will perform the following 10 movements in sequence: squats, rowing simulation with rubber bands, lateral raises, sit-ups, shoulder presses, alternating bilateral lunges, dumbbell curls (for biceps), sit-ups, and planks.~Each movement lasts 60 seconds, with a 10-second rest allowed midway through the same movement (i.e., 15 seconds of exercise followed by a 10-second rest, then another 15 seconds to complete the movement). A 20-second rest is permitted before moving on to the next movement.~Once participants can complete 30 seconds of the same movement without needing rest or adjustment, the training intensity will be increased-progressing from one round of training (10 minutes) to two rounds (20 minutes) or even three rounds (30 minutes)."
223995704|NCT04595682|DRUG|Alcohol|Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol effects on disinhibition and impulsive choice. The alcohol dose consists of 0.60 g/kg absolute alcohol that produces a peak blood-alcohol concentration of 80 mg/dl. Doses will be mixed with a carbonated, non-caffeinated, lemon-flavored soda and consumed within 10 minutes.
223995705|NCT01933243|DRUG|Fish oil|Participants will take 4 capsules daily
223995706|NCT01933243|DRUG|Placebo pill|Participants will take 4 capsules daily
223995707|NCT05163405|DRUG|Bortezomib|Self-administration of subcutaneously Velcade.
223995708|NCT04557995|PROCEDURE|Erythropheresis|Draw blood from patient's vein and remove red blood cells as other components would be transfused back.
223995709|NCT06215378|DRUG|Antagonization of heparin with protamine sulfate|A systematic use at the end of procedure of Protamine Sulfate for antagonization of heparine.1 mg of protamine sulfate neutralizes approximately 100 heparin unit. To be administered in slow infusion (10 min) not exceeding 50mg of protamine sulfate to reverse 100% of the anti-IIa activity of heparin sodium. If the ACT is not back to the baseline value after the end of this infusion, additional doses of protamine should be performed depending on the ACT value to obtain complete antagonization of anti-IIa activity of heparin sodium
223995710|NCT06316986|DIAGNOSTIC_TEST|pH indication with NGPOD|"The NGPOD sensor is inserted into the naso- or oro-gastric tube, then reconnected to the NGPOD handheld device, and the pH measurement is taken within 15 seconds.~When the 15 seconds have elapsed, the pH button is pressed. If the green LED lights up and the pH indicates a value \< 5.5, the sensor tip is in a pH environment associated with the stomach.~If the red LED lights up, the sensor tip is in a pH environment NOT associated with the stomach."
223995711|NCT04027413|DIETARY_SUPPLEMENT|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
223995712|NCT04027413|DIETARY_SUPPLEMENT|preOp|(100% carbohydrate).
224122964|NCT07162649|DRUG|Dexmedetomidine|30μl
224122965|NCT07162649|DRUG|Placebo|30μl
224122966|NCT07163403|BIOLOGICAL|Autologous Tolerogenic Dendritic cells|Autologous peripheral blood differentiated and matured adult dendritic cells loaded with Frameshift-derived neopeptides (FSDN) (DC-DELAY). Eligible participants will receive six intradermal immunizations of DC-DELAY at week 0, 2, 4, 6, 8 and 10.
224122967|NCT07162480|DRUG|P-Sam|Given by IV
224295395|NCT04788160|OTHER|Conventional Therapy|"* Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position."
224295396|NCT00356980|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
224295397|NCT00356980|OTHER|pharmacological study|
224295398|NCT00653991|BEHAVIORAL|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
223995713|NCT05949320|OTHER|e-Motivational Interviewing|"This study evaluates a 90-day mobile phone-based intervention using the e-Motivational Interviewing app for individuals with chronic conditions like hypertension and diabetes. The app provides short conversations with health messages and reflective questions on lifestyle choices, such as physical activity and diet. The intervention incorporates change talk from Motivational Interviewing and principles from Basic Psychological Needs Theory (BPNT) to encourage positive behavior change. Users interact via multiple-choice questions, promoting self-assessment and reflection. The goal is to facilitate sustained lifestyle changes and improved health outcomes."
223995714|NCT03195361|DEVICE|SRS - Self Retaining Support system|
223995715|NCT00713986|PROCEDURE|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
223995716|NCT00713986|PROCEDURE|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
223995717|NCT00713986|PROCEDURE|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
223995718|NCT00713986|PROCEDURE|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
223995719|NCT04845399|DRUG|Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection|Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
223995720|NCT01877148|DEVICE|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
223995721|NCT01877148|BEHAVIORAL|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
223995722|NCT00041652|DRUG|hMN14 (labetuzumab)|
223995723|NCT00975468|OTHER|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
223995724|NCT06157567|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
223995725|NCT05234840|DRUG|platelet rich plasma|1\. 26 ml of blood was obtained from each patient (6ml each in 4 CPDA and 2ml in EDTA for CBC) 2. First-spin of 900g for 5 minutes (Kokusan, H-19alpha, 25°C) 3. Three layers formed: transfer top layer (platelet poor plasma) and middle layer (platelets and WBC) to another sterile tube (about 3.3 ml), discard bottom layer (RBC) 4. Second-spin of 1000g for 10 minutes 5. The upper one third was discarded (platelet poor plasma) by pipet, the remaining was mixed by turning 10 times 6. Total 4 ml of PRP
223995726|NCT05234840|DRUG|Triamcinolone|40 mg triamcinolone with 1% lidocaine, total of 2 ml
223995727|NCT05614726|DIETARY_SUPPLEMENT|575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase|A multi-strain probiotic blend
223995728|NCT02870972|DRUG|BCX7353|Plasma kallikrein inhibitor
223995729|NCT02870972|DRUG|Placebo|
223995730|NCT03901001|DRUG|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
223995731|NCT03901001|DRUG|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
223995732|NCT03065075|DRUG|Phenazopyridine|Phenazopyridine 200 mg on morning of postoperative day 1
223995733|NCT01022541|DRUG|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
223995734|NCT01022541|DRUG|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
223995735|NCT01022541|DRUG|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
223995736|NCT01022541|PROCEDURE|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
223995737|NCT01796626|DEVICE|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
223995738|NCT02988323|OTHER|Cervicovestibular Physio (CV PT)|See description in CVPT arm
223995739|NCT02988323|OTHER|Low-Level Aerobic Exercise (LLAE)|See description in LLAE arm
223995740|NCT02988323|OTHER|Combination (LLAE and CV PT)|See description in LLAE and CVPT arm
223995741|NCT03806283|PROCEDURE|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. After delivery, during the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
223995742|NCT04400487|DRUG|Voxelotor|500 mg Tablet, Oral, With or Without Food
223995743|NCT01802905|GENETIC|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
223995744|NCT05330598|DEVICE|Connected Catheter|The Connected Catheter System is a replaceable wireless urinary prosthesis that is indicated for bladder emptying in male patients who have impaired bladder emptying due to chronic Urinary Retention. The Connected Catheter resides fully internally in the male lower urinary tract (urethra and bladder neck) and remains in place for up to 7 days before removal.
223995745|NCT02908295|DRUG|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
223995746|NCT02908295|DRUG|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
223995747|NCT02735928|DEVICE|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (\< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
223995748|NCT05408195|DEVICE|CHATBOT use|Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.
223995749|NCT00412412|DRUG|CNF2024|Oral doses of CNF2024 as specified in the protocol.
223995750|NCT00412412|DRUG|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
223995751|NCT02963012|OTHER|ultrasound examination|
223995752|NCT06328218|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
223995753|NCT06373198|OTHER|standard of care|An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.
223995754|NCT03559062|DRUG|TEZ/IVA|Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
223995755|NCT03559062|DRUG|IVA|Participants weighing \<40 kg IVA 75 mg tablet and those weighing ≥40 kg received IVA 150 mg tablet.
223995756|NCT03559062|DRUG|Placebo|Placebo matched to TEZ/IVA FDC
223995757|NCT03559062|DRUG|Placebo|Placebo matched to IVA
223995758|NCT04490759|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
223995759|NCT05444608|BEHAVIORAL|Breast milk olfactory stimulation|Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.
223995760|NCT05444608|BEHAVIORAL|White noise auditory stimulation|Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
223995761|NCT03073252|OTHER|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
223995762|NCT03073252|OTHER|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
223995763|NCT02453984|OTHER|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
223995764|NCT05927857|DRUG|nal-IRI /Experimental|infusional 50/60/70 mg/m2 over 90 minutes day 1, every 14 days.
223995765|NCT05927857|DRUG|Ramucirumab /Experimental|infusional 8mg/kg over 60 minutes day 1, every 14 days.
223995766|NCT05927857|DRUG|Trifluridine/Tipiracil /Experimental|oral 30 mg/m2/b.i.d. day 1-5, every 14 days.
223995767|NCT04697927|OTHER|Questionnaires|The epidemiologic questionnaires used in this study are a composite of validated questions from multiple sources. Many of the questions are an expansion of the MSK General Medical Health clinical questionnaire. Validated questions capturing demographics, employment, risk behaviors, family history, as well as, specific research domains including psychosocial, food security, and financial toxicity have already been utilized in other MSK minimal risk studies. The COVID-19 symptom and history tracker questions were largely drawn from the COronavirus Pandemic Epidemiology (COPE) consortium study.
223995768|NCT02418936|DEVICE|gene diagnostic kit|
223995769|NCT05428995|DEVICE|C-MAC videolaryngoscope|Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy
223995770|NCT05428995|DEVICE|Airtraq videolaryngoscope.|Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
223995771|NCT00903500|BEHAVIORAL|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
223995772|NCT06159179|PROCEDURE|Medical thoracoscopy|Medical thoracoscopy is a minimally invasive procedure to have access to pleura with combination of visual and medical instrument. The procedure is done with local and light anesthesia. Medical thoracoscopy plays role in basic diagnosis and therapeutic. A Flex-rigid thoracoscope will be inserted through the trocar cannula in the rigt or left mid axillary line of the hemithorax
223995773|NCT03445533|DRUG|Ipilimumab|Arm A: 4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.
223995774|NCT03445533|DRUG|Tilsotolimod with Ipilimumab|IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24. WITH (Arm B): Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11. in combination with tilsotolimod
223995775|NCT02714712|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
223995776|NCT03920098|OTHER|Nutrition and mental health during pregnancy|Altered metabolic milieu is defined as a fasting glucose level \>100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels \> 92 mg/dL and/or plasma glucose levels \> 153 mg/dL two hours after load in the oral glucose tolerance test according to ADA guidelines or a fasting glucose \>100 mg/dL and/or \> 140 mg/dL two hours after load in the oral glucose tolerance test according to national guidelines. The COVID-19 pandemic is considered as a natural nutritional and mental health exposure.
224138365|NCT03016546|BEHAVIORAL|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
223995777|NCT05182307|DEVICE|DurAVR™ THV System|Transcatheter Aortic Valve Implantation (TAVI) Procedure
223995778|NCT05272709|DRUG|TT-702|TT-702 will be administered orally, once daily, for up to 12 months.
223995779|NCT05272709|DRUG|Darolutamide|Darolutamide will be administered orally, twice daily, for up to 12 months.
223995780|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
223995781|NCT00226915|DRUG|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
223995782|NCT00778232|DRUG|Gabapentin tablets 800 mg|
223995783|NCT04310332|DRUG|1L-PEG|"The drug is 1L-PEG plus ascorbic acid (Plenvu®). It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
223995784|NCT04310332|DRUG|4L-PEG|"The drug is 4L-PEG. It will be administered either the day before colonoscopy, or half the day before and half the day of colonoscopy, or the day of colonoscopy.~Patients are prescribed bowel prep according to local clinical practice and then all undergo colonoscopy. No standardized intervention on bowel prep is applied, as the design of the study is observational."
223995785|NCT01783340|DRUG|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
223995786|NCT01783340|DRUG|Placebo|Placebo capsules will be administered at each immunization
223995787|NCT01783340|BIOLOGICAL|Immunization with falciparum|three inoculations with 5 infected mosquito bites
223995788|NCT02453243|BEHAVIORAL|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
223995789|NCT02453243|BEHAVIORAL|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
223995790|NCT00012064|BIOLOGICAL|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
223995791|NCT04505839|DRUG|STP1002|Oral capsule, QD
223995792|NCT01183039|OTHER|Training|20 sessions of training
223995793|NCT02134938|DIETARY_SUPPLEMENT|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
223995794|NCT02493062|DEVICE|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
224138366|NCT03709524|DEVICE|Airtraq + fiberoptic|video laryngoscope with a monitor
224138367|NCT03709524|DEVICE|Airtraq|video laryngoscope with a monitor
224138368|NCT03709524|DEVICE|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
224138369|NCT04091230|DEVICE|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
224138370|NCT01107405|DRUG|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
224138371|NCT01107405|DRUG|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
223425461|NCT03364517|OTHER|Predictor score of the imminence of a childbirth (SPIA)|The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
223995795|NCT04801732|OTHER|mulligan thoracic Sustained Natural Apophyseal Glides|"Extension Thoracic Sustained Natural Apophyseal Glides :~Patient position: The patient sits astride the end of the table with hands placed behind the neck to protract the scapulae allowing access to the mid thoracic spine for the therapist's hand.~Therapist position: Therapist stands on their most efficient side for a centrally applied Sustained Natural Apophyseal Glides.~Therapist grasp: The therapist's mobilizing hand (ulnar border) will apply a cephalad glide in line with the facet joint plane of the involved spinal level and the other arm holds the thoracic wall above the level to be mobilized.~Traction is applied prior to glide, which is achieved by therapist knee extension~Repetitions: Three sets of ten repetitions will be done after a trial for the patient to be familial with the technique.~and traditional treatment."
223995796|NCT04801732|OTHER|traditional treatments|"includes: Ice pack and Pendulum exercise and shoulder range of motion (elevation, depression, flexion, abduction, rotations).Stretching exercise for internal rotators and posterior capsule.~Strengthening exercise will be isometric in nature include external shoulder rotators, internal rotators, biceps, deltoid, and scapular stabilizers (rhomboids, trapezius, serratus anterior, Latissimus Dorsi , and pectoralis major muscles)."
223995797|NCT05043922|DRUG|CYH33|a Selective PI3Kα Inhibitor
223995798|NCT01236378|DRUG|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
223425462|NCT02806544|DRUG|Tamoxifen|Tamoxifen 20mg by mouth daily
224122968|NCT07163663|OTHER|Hight intensity functional trainning|"Warm-up phase: Low-intensity walking 30-50% MHR combined with dynamic mobility exercises~High Intensity Functional Training (HIFT)~The raised HIFT intervention proposal is divided into three exercises:~1. Strength exercise of the lower limbs such as Sit to Stand / Stand to sit and elevation of the upper limbs up in a standing position or lateral gait with knee flexion of one limb among many others.~2. Upper limb strength exercises: In a standing position with a medicine ball and in front of the wall, throw the ball against it and catch it o Walk while taking the medicine ball from right to left with smooth rotation of the trunk among many others.~3. Coordination and balance exercises: Go up and down stairs or steps in four steps with arms stretched out in front of you and exercises such as standing, knee flexion and raising the contralateral hand with weights.~Cooling phase: Stretching of upper and lower limb muscle groups and head and neck muscles."
224122969|NCT07163078|DIETARY_SUPPLEMENT|Common form supplementation|The intervention product would represent part of a typical supplement given to people including those with CF
223995799|NCT01327612|DRUG|Modified FOLFOX6|The mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m² administered as a 2-hour intravenous (IV) infusion on day 1 and leucovorin 400 mg/m² racemate or 200 mg/m² levo-leucovorin administered as a 2-hour infusion on day 1, followed by a loading dose of 5-fluorouracil (5-FU) 400 mg/m² IV bolus administered on day 1, then 5-FU 2400 mg/m² via ambulatory pump administered for a period of 46 to 48 hours every 14 days.
223995800|NCT01327612|BIOLOGICAL|Conatumumab|Administered by intravenous infusion Q2W or Q3W.
223995801|NCT01327612|BIOLOGICAL|Ganitumab|Administered by intravenous infusion Q3W or Q4W.
223995802|NCT01327612|BIOLOGICAL|Bevacizumab|Administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle.
223995803|NCT02777437|DRUG|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
223545165|NCT06719479|BIOLOGICAL|IAE0972+Gemcitabine|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Gemcitabine is used according to the instructions.
223545166|NCT06719479|BIOLOGICAL|IAE0972+Taxanes|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Taxanes is used according to the instructions.
223729644|NCT04417920|PROCEDURE|Express implant device|"Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock."
223729645|NCT03231033|DRUG|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
223995804|NCT00872053|DEVICE|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
223995805|NCT00872053|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
223995806|NCT02470676|DEVICE|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
223995807|NCT02470676|DRUG|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
223995808|NCT00426127|DRUG|Docetaxel|
223995809|NCT00426127|DRUG|Liposomal Doxorubicin|
223729646|NCT01095016|DRUG|Meptin swinghaler|"* Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days"
223995810|NCT00426127|DRUG|Enoxaparin|
223995811|NCT05569421|DRUG|Treatment A: BGF MDI HFO|Participants will receive 4 oral inhalations as a single dose - test formulation; administered during 1 treatment period.
223995812|NCT05569421|DRUG|Treatment B: BGF MDI HFA|Participants will receive 4 oral inhalations as a single dose - reference formulation; administered during 2 treatment periods.
223995813|NCT06690372|OTHER|virtual reality exercise|"Over the 12-weeks, participants will be instructed to exercise with the VR-Move 3x/week for 30 minutes for 12-weeks total, with modules presented in a prescribed weekly sequence to provide novel and re-enforcement of modules, while ensuring all modules are performed. Further, participants will be provided the opportunity of a 30 minute free-play of module of choice once a module has been introduced."
223995814|NCT02370264|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223995815|NCT02370264|OTHER|Questionnaire Administration|Ancillary studies
224122970|NCT07163078|DIETARY_SUPPLEMENT|Uncommon nutrient supplementation|The intervention product would represent part of a possible new supplement given to people including those with CF
224122971|NCT07163260|OTHER|No treatment given|No treatment given
224122972|NCT07162246|RADIATION|Radiation Therapy|Adaptive radiation therapy with GK boost
223995816|NCT02370264|OTHER|Medical Chart Review|Ancillary studies
223995817|NCT03242512|BIOLOGICAL|TK006|Subcutaneous injection
223995818|NCT05035147|DRUG|albumin-bound paclitaxel|Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
223995819|NCT01689857|DEVICE|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
223995820|NCT01689857|DEVICE|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
223995821|NCT01702857|BIOLOGICAL|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
223995822|NCT01702857|BIOLOGICAL|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
223995823|NCT01702857|OTHER|Phosphate buffered saline|
223995824|NCT01702857|BIOLOGICAL|1 µg TDENV-PIV with Alum adjuvant|
223995825|NCT01702857|BIOLOGICAL|1 µg TDENV-PIV with AS01E adjuvant|
223995826|NCT03555253|BEHAVIORAL|Resilience-Based Program for Support Partners of PwMS|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
223995827|NCT00692549|DEVICE|ultrasound|
223995828|NCT01627015|OTHER|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
223995829|NCT01627015|OTHER|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
224122973|NCT07162415|PROCEDURE|Open resection|A transverse or longitudinal incision is done depending on surgeon's preference. The ganglion and its pedicle are traced up to its origin. The pedicle is resected tangentially, usually, from the SL ligament for dorsal ganglions and depending on the site for volar ganglion. Wrist capsule is not closed.
223425463|NCT04973059|DEVICE|SmartDrive Summer|The SmartDrive is a power assist accessory for a manual wheelchair
223425464|NCT04973059|DEVICE|SmartDrive Winter|The SmartDrive is a power assist accessory for a manual wheelchair
223425465|NCT03879057|DRUG|Surufatinib/humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
223995830|NCT01730378|BIOLOGICAL|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
223995831|NCT01730378|BIOLOGICAL|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
223995832|NCT00387244|DEVICE|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
223995833|NCT02725021|BEHAVIORAL|Education Against Tobacco school-based intervention by medical students|
223995834|NCT01746589|DEVICE|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
223995835|NCT05238831|DRUG|Alectinib|Given orally (PO)
223995836|NCT05238831|DRUG|Alpelisib|Given PO
223995837|NCT05238831|DRUG|Anastrozole|Given PO
223995838|NCT05238831|BIOLOGICAL|Atezolizumab|Given IV
223995839|NCT05238831|BIOLOGICAL|Bevacizumab|Given IV
223995840|NCT05238831|PROCEDURE|Biopsy|Undergo tissue biopsy
223995841|NCT05238831|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223995842|NCT05238831|DRUG|Capecitabine|Given PO
223995843|NCT05238831|DRUG|Carboplatin|Given IV
223995844|NCT05238831|DRUG|Cobimetinib|Given PO
223995845|NCT05238831|DRUG|Entrectinib|Given PO
223995846|NCT05238831|DRUG|Eribulin|Given IV
223995847|NCT05238831|DRUG|Fulvestrant|Given by injection
223995848|NCT05238831|BIOLOGICAL|Hyaluronidase-zzxf/Pertuzumab/Trastuzumab|Given phesgo SC
223995849|NCT05238831|DRUG|Irinotecan|Given IV
223995850|NCT05238831|DRUG|Letrozole|Given PO
224122974|NCT07162415|PROCEDURE|Arthroscopic resection|Portals are selected by surgeon's preference. The pedicle of the ganglion is located and resected with a shaver. It is not necessary to remove all the ganglion walls. The portal incisions do not need to be sutured.
224138372|NCT01107405|DRUG|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
223995851|NCT05238831|DRUG|Nab-paclitaxel|Given IV
223995852|NCT05238831|DRUG|Niraparib|Given PO
224138373|NCT01107405|DRUG|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
223995853|NCT05238831|DRUG|Olaparib|Given PO
223995854|NCT05238831|DRUG|Paclitaxel|Given IV
223995855|NCT05238831|DRUG|Palbociclib|Given IV
223995856|NCT05238831|BIOLOGICAL|Pertuzumab|Given subcutaneously (SC)
223995857|NCT05238831|OTHER|Quality-of-Life Assessment|Ancillary studies
223995858|NCT05238831|BIOLOGICAL|Trastuzumab|Given SC
223995859|NCT05238831|BIOLOGICAL|Trastuzumab Emtansine|Given intravenously (IV)
223995860|NCT05238831|DRUG|Vemurafenib|Given PO
223995861|NCT05238831|DRUG|Vinorelbine|Given IV
223995862|NCT05238831|DRUG|Vismodegib|Given PO
223995863|NCT03137043|OTHER|Questionnaire|Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
223995864|NCT03137043|OTHER|Software of Big Data|Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
223995865|NCT03160846|DRUG|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
223995866|NCT00874731|DRUG|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
223995867|NCT00874731|DRUG|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
223995868|NCT00874731|DRUG|Placebo|Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
223995869|NCT02565433|OTHER|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
223995870|NCT02450812|DRUG|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
224138374|NCT01107405|DRUG|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
223995871|NCT03944655|DRUG|Strepsils Anaesthetic Formula|Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
223995872|NCT03944655|DIETARY_SUPPLEMENT|Clear Mint Drops|Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
223995873|NCT00538772|OTHER|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
223995874|NCT00955708|DEVICE|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
224138375|NCT01404442|DRUG|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
224138376|NCT01404442|DRUG|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
223995875|NCT02443753|DEVICE|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
223995876|NCT05105087|DRUG|Perflubutane Microbubble|Given subdermally
223995877|NCT05105087|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo ultrasound
223995878|NCT06518811|OTHER|Video-Based Exercise Programme|The asynchronous video-based telerehabilitation programme had a duration of eight weeks. The participants were instructed to perform the exercises on a regular basis, three days a week, with a time interval of 24 hours between each session. The exercises were to be performed using the instructional videos and recorded in the exercise diaries provided. The participants were used exercise balls and resistance bands distributed by the researchers according to exercise programme.
223995879|NCT02132832|DRUG|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
223995880|NCT02132832|DRUG|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
223995881|NCT01016262|DRUG|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
223995882|NCT01016262|DRUG|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
223995883|NCT01016262|DRUG|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
223995884|NCT04490577|OTHER|Pilates exercises|Pilates exercises are a combined exercise procedure including strengthening and stretching. Pilates exercises are performed with different equipment for example; therabands, mats, reformer, etc.
223995885|NCT04490577|OTHER|Whole body vibration|Whole-body vibration gives vibration to the body with a platform at different frequencies (Power-plate). The participant performed exercises on the platform.
223995886|NCT02791568|PROCEDURE|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
223995887|NCT02791568|PROCEDURE|MRI Scan|MR imaging will take approximately 30 minutes.
223995888|NCT02791568|DRUG|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
223995889|NCT06290245|DEVICE|PEP Buddy|It is a hands-free, oral PEP device (PEP buddy) which held by the patient's lips like a whistle and is attached to a necklace/lanyard. Different grades of PEP-buddy generate expiratory pressures of 5-17cm H2O
223995890|NCT06290245|OTHER|aerobic exercise|Exercise training will start and finish with a 5-minute warm-up and cool-down on the cycle ergometers at (40% of PHR). The cycling active phase will last for 30 min. at 70% of HRmax (moderate-intensity continuous exercise).
223995891|NCT05338125|PROCEDURE|Micro-electrode measurement|Electrophysiological measurement with single-unit micro-electrode
223995892|NCT00458081|DRUG|Rimonabant|20 mg once per day + slightly reduced calorie diet
224138377|NCT01404442|DRUG|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
223995893|NCT00458081|DRUG|Placebo|placebo once per day + slightly reduced calorie diet
223995894|NCT00514579|PROCEDURE|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
224138378|NCT01608399|BEHAVIORAL|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
224138379|NCT01827930|DRUG|Imatinib Mesylate 600 MG Oral Tablet|Imatinib Mesylate for CP CML
223995895|NCT01405651|DRUG|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
223995896|NCT01405651|DRUG|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
223995897|NCT03776305|DRUG|Imipenem|1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
223995898|NCT03364777|OTHER|emotional state|anxiety or depression state evaluated by emotional scale
223995899|NCT01736540|DEVICE|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2\*, respectively).
223995900|NCT05614622|DRUG|Cyclopentolate Hydrochloride 1.0% eye drops|A short-acting mydriatic agent
223995901|NCT04544150|OTHER||
223995902|NCT06122922|DRUG|Hyperpolarized Xe129|Hyperpolarized Xenon Gas
223995903|NCT01458054|DRUG|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
223995904|NCT01458054|DRUG|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
223995905|NCT05616299|DEVICE|BrightPoint|Data from the BrightPoint device during epidural placement will be collected in real time on a tablet with pre-programmed software including tissue color and light reflectance with time stamps of when epidural space is entered as voiced by clinician per LOR.
223995906|NCT01076777|BEHAVIORAL|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
223995907|NCT01076777|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
223995908|NCT01269151|DRUG|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
223995909|NCT00479882|DRUG|Comparator: simvastatin|
223995910|NCT00479882|DRUG|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
223995911|NCT00479882|DRUG|Placebo|
223995912|NCT00479882|DRUG|MK-0524B|
223995913|NCT05411172|BEHAVIORAL|Mastery Learning Model for Chemical, Biological, Radiological, and Nuclear threats and hazards (MLM-CBRN Education Program) on student nurses|"The MLM-CBRN Education Program was carried out with the students in the experimental group face-to-face as theoretical and practical education once a week for four weeks. . The data were collected before and right after the intervention and in the 1st and 3rd months after the intervention using the Personal Information Form, Nursing Student CBRN Knowledge Test, Nursing Student CBRN Attitude Scale, and Nursing Student CBRN Self-Efficacy Scale. Moreover, only the knowledge scores of the students in the experimental group were collected using the unit follow-up tests, which enabled us to check whether the Learning Objective related to the unit taught was achieved. During the skill training, the START Triage and JumpSTART Triage Skill Check List, Gas Mask Wearing-Removing Skill Check List, and Level C Clothes Wearing-Removing Skill Check List were scored for each student in the experimental group after observing the students twice."
223995914|NCT05084339|DIAGNOSTIC_TEST|CGM|blinded CGM used at 4 different time points in pregnancy
223995915|NCT03728270|DEVICE|Patient Specific Titanium Eminoplasty|"* The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~* Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~* After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~* The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~* Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~* A multilayer closure of the incisions will be accomplished using Vicryl"
224122975|NCT07162415|OTHER|Conservative treatment|Participant will be informed about the natural course of wrist ganglions. The conservative treatment may include needle aspiration of the ganglion, but it is not performed routinely. Participants are informed that wrist loading in extension may exacerbate the pain, and that the pain is not a sign of further injury to wrist joint. They can avoid heavy use it if they have too much pain, but they are advised to use hand as tolerated. Participants may use NSAIDs and acetaminophen for pain management as needed; however, the protocol does not specify a required course or dosage. A simple self-implemented exercise therapy instructions are given to every participant.
223425466|NCT06618131|OTHER|Exercise|Exercise program with virtual reality applications for lower extremities
223729647|NCT01095016|DRUG|Berotec|"* Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days"
223995916|NCT03728270|PROCEDURE|Inlay Autogenous Bone Graft|"\* Steps to harvest the bone graft:~* Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~* To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis."
224138380|NCT01827930|DRUG|Imatinib Mesylate 400 MG Oral Tablet|Imatinib Mesylate for CP CML
224138381|NCT01827930|DRUG|Imatinib Mesylate|Imatinib Mesylate for CP CML
224138382|NCT03991884|DRUG|Etoposide|Given IV
224138383|NCT03991884|DRUG|Doxorubicin|Given IV
224138384|NCT03991884|DRUG|Vincristine|Given IV
224138385|NCT03991884|DRUG|Prednisone|Given PO or IV
223995917|NCT02129868|DEVICE|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
223995918|NCT04968431|OTHER|2D Echocardiography|Mitral valve area will be determined by 2 D echo-Doppler methods
223995919|NCT04968431|OTHER|3D Echocardiography|Patients included in the study will undergo 3D Echo after being evaluated with 2D Echo. Mitral valve area will be determined by real time 3D.
223995920|NCT01083953|DRUG|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
223995921|NCT01083953|DRUG|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
224122976|NCT07162519|DRUG|romiplostim N01|Eligible subjects who pass the screening will undergo a baseline visit and will receive romiplostim N01 administration once weekly for a maximum of 4 weeks. Dosing will be discontinued when the platelet count rises to ≥100×10⁹/L. When a subject resumes anti-tumor therapy, those with a baseline platelet count of \<50×10⁹/L will receive prophylactic administration of romiplostim N01 (administered 2 hours prior to anti-tumor therapy) before the anti-tumor drugs are given.
223995922|NCT02646020|DRUG|Aprepitant|aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
223995923|NCT02646020|DRUG|Desloratadine|Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
223995924|NCT02646020|DRUG|Placebo of aprepitant|Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
223995925|NCT02646020|DRUG|Placebo of desloratadine|Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
223995926|NCT05977205|OTHER|No interventions, observational study|Not applicable, no interventions, observational study
223995927|NCT05688631|OTHER|Dietary antioxidant intake|Decreased intake of dietary antioxidant is associated with decreased thiol disulfide homeostasis parameters in diabetic and healthy participants.
223995928|NCT03157297|DEVICE|MARVEL algorithm|Software download into implanted Micra device
223995929|NCT01024153|BEHAVIORAL|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
224122977|NCT07162623|OTHER|Oziva Bioactive Gluta Fizzy Effervescent Tablets 4.1 g containing Glutathione|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
224299117|NCT02479542|OTHER|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
223995930|NCT01132820|DRUG|Cediranib Maleate|Given PO
223995931|NCT01132820|OTHER|Laboratory Biomarker Analysis|Correlative studies
223995932|NCT05872191|OTHER|No intervention|There is no intervention to be administered, only collection of data through various tests and questionnaires.
223995933|NCT06166550|BEHAVIORAL|Parent's Emotional Intelligence Network|A two-day in-person training session will be arranged for the participating parents at least one week apart. The psychologists will conduct the training session on emotional intelligence. A training of the trainer manual will be developed to train the psychologists. The training session will include a power point presentation and certain group and individual activities to practice emotional intelligence. The participants will also be given a diary and a mobile app in order to practice emotional intelligence at home.
224122978|NCT07162623|OTHER|Placebo Effervescent Tablets 4.1 g|"Mode of Usage: Dissolve one effervescent tablet in a full glass of water in 200 mL. Allow it to fully dissolve before consuming. For best results, consume the solution immediately after preparation before the fizz ends.~Frequency: Once Daily Route of administration: Oral Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
224122979|NCT07163598|OTHER|No Intervention: Observational Cohort|This study is a observational cohort study, and we have no intervention.
223995934|NCT06166550|DEVICE|Mobile App|A mobile app (MonKotha) has been developed along with user manual. It contains different videos, audios, and texts related to emotional intelligence. It also provides a communication platform where users can communicate through texts and upload documents.
223995935|NCT06166550|DEVICE|Diary|A diary (Onuvutir Diary) is also developed that contain different practice materials regarding emotional intelligence. It is a personal diary given to the participants to take to home.
223995936|NCT04962737|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.
223995937|NCT03470740|BEHAVIORAL|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
223995938|NCT04538846|OTHER|Culinary art therapy|Culinary art therapy is a novel approach which broadly perceives food and cooking as enabling participants to explore needs, patterns and relationships and facilitate therapeutic processes.
223995939|NCT02136953|BEHAVIORAL|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
223995940|NCT02136953|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
223995941|NCT01370655|DRUG|MK-7145|
223995942|NCT01370655|DRUG|Hydrochlorothiazide (HCTZ)|
223995943|NCT01370655|DRUG|Placebo to MK-7145|
223995944|NCT01370655|DRUG|Placebo to HCTZ|
224122980|NCT07162441|DRUG|treatment A|UIC202502 1 Tab/day for 7 days
224122981|NCT07162441|DRUG|treatment B|UIC202505 1 Tab/day for 7 days
224122982|NCT07162441|DRUG|treatment C|UIC202502+UIC202505 2 Tab/day for 7 days
224122983|NCT03281889|RADIATION|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
224122984|NCT02816697|OTHER|CEASE|"* Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~* CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
224122985|NCT02816697|OTHER|Usual Care Tobacco Treatment Services|
224122986|NCT05096481|BIOLOGICAL|PEP-CMV|The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
224122987|NCT05096481|DRUG|Temozolomide|Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
224122988|NCT05096481|BIOLOGICAL|Tetanus Diphtheria Vaccine|Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
224122989|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily~Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening~Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
224122990|NCT05306873|DRUG|Placebo for Mycophenolate Mofetil|"Stage 2 Dosing:~Week 1: Participants will receive 500mg MMF/Placebo twice daily Week 2: Participants will receive 500mg/Placebo in the morning and 1,000mg MMF/Placebo in the evening Weeks 3-48: Participants will receive 1000mg MMF/Placebo twice daily"
224122991|NCT05306873|DRUG|Voclosporin|Weeks 1-24: 23.7 mg Voclosporin (3 x 7.9 capsules) twice daily
224122992|NCT05306873|DRUG|Placebo for Voclosporin|Weeks 1-24: 23.7 mg Placebo for Voclosporin (3 x 7.9 capsules) twice daily
224122993|NCT05306873|DRUG|Mycophenolate Mofetil|"Stage 3 Dosing:~Participants who received placebo MMF in Stage 2:~* Week 1: Participants will receive 500mg MMF plus matching placebo for MMF (to appear like a 1000mg dose) twice daily~* Week 2: Participants will receive 500mg plus matching placebo for MMF (to appear like a 1000mg dose) and 1000mg in divided doses~* Weeks 3-24: 1000mg MMF twice daily~Participants who received MMF in Stage 2~• Week 1-24: 1000mg MMF twice daily"
224122994|NCT04590144|DEVICE|INVICTA lead|The implant or the attempt to implant an INVICTA lead
224122995|NCT06771739|OTHER|Electronic Health Record Review|Ancillary studies
224122996|NCT06771739|OTHER|Interview|Ancillary studies
223995945|NCT00296257|DRUG|SMP-114|
223995946|NCT05108441|OTHER|Ultrasound and magnetic resonance imaging measurements of quadriceps femoris|In sedated critically ill children, quadriceps femoris thickness and cross sectional area will be measured with thigh bedside ultrasound, performed by two trained operators consecutively. These two measurements will also be made at the exact same location on a magnetic resonance imaging transverse view of the thigh, to allow comparing them to ultrasound measurements.
223995947|NCT03733353|DRUG|EDP1815|EDP1815 is an orally administered monoclonal microbial
223995948|NCT03733353|DRUG|Placebo oral capsule|Placebo
223995949|NCT03733353|DRUG|Placebo oral tablet|Placebo
223995950|NCT02872558|OTHER|Acute Otitis Media Choice Decision Aid|Decision Aid
223995951|NCT02872558|OTHER|Usual Care|Usual Care
224122997|NCT06771739|OTHER|Support|Receive $1000 preloaded cash card
224122998|NCT06771739|OTHER|Support|Receive $100 preloaded cash card
223995952|NCT05017051|BEHAVIORAL|Chocolate cake|The participants will have to make a chocolate cake following an imposed recipe at 4 visits (initially (M0), after 12 months (M12), after 24 months (M24) and after 36 months (M36)).
223995953|NCT05017051|BEHAVIORAL|Lego model|The participants will have to build a Lego model at 4 visits (M0, M12, M24 and M36).
223995954|NCT05017051|DEVICE|Measurement of sensorimotor abilities|The measurement of sensorimotor abilities is based on a multi-sensor device called Smart Flat specifically designed for this study at 4 visits (M0, M12, M24 and M36).
223995955|NCT05017051|OTHER|Measurement of facial expression of emotions|Participants will have to evoke an emotionally charged autobiographical story by modulating facial expressions through a mirror at 4 visits (M0, M12, M24 and M36).
223995956|NCT02026492|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
223995957|NCT02026492|OTHER|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
223995958|NCT02026492|OTHER|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
224122999|NCT06771739|OTHER|Survey Administration|Ancillary studies
224123000|NCT01608074|PROCEDURE|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
224123001|NCT01608074|OTHER|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
224123002|NCT06126380|DRUG|AT-1501|AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
224123003|NCT06126380|DRUG|Tacrolimus|Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
224123004|NCT06259708|DEVICE|Low intensity focused ultrasound|Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
223995959|NCT01048697|DRUG|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) \> 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
223995960|NCT03033940|RADIATION|Observational use of fluoroscopy|
223995961|NCT03214653|DRUG|Propofol|Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
223995962|NCT03214653|DRUG|Sevoflurane|Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
223995963|NCT03248544|DRUG|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
223995964|NCT03248544|OTHER|control|No intervention
223995965|NCT03837951|OTHER|Figure-of-eight tape measure measurements on both hands|Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.
223995966|NCT03837951|OTHER|Volumeter measurements|Volumeter measurements to uninjured participants had 3 measurements taken of each hand.
223995967|NCT02660645|DRUG|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
223995968|NCT02660645|DEVICE|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
223995969|NCT05835609|DRUG|PM534|PM534 drug product is provided as a powder for concentrate for solution for infusion, is a sterile, preservative-free, lyophilized white cake in a single-dose vial for reconstitution prior to intravenous infusion.
223995970|NCT05000216|BIOLOGICAL|Moderna mRNA-1273|Administration: One dose administered intramuscularly.
223995971|NCT05000216|BIOLOGICAL|BNT162b2|Administration: One dose administered intramuscularly.
223995972|NCT05000216|BIOLOGICAL|Ad26.COV2.S|Administration: One dose administered intramuscularly.
223995973|NCT05000216|DRUG|Continue IS (MMF or MPA)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
223995974|NCT05000216|DRUG|Continue IS (MTX)|Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
223995975|NCT05000216|BIOLOGICAL|Continue IS (B cell depletion therapy)|Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.
223425467|NCT04977362|OTHER|Enhanced Recovery After Surgery|Enhanced recovery after surgery is a multimodal, transdisciplinary care approach for patients undergoing surgical procedures. It is implemented in various surgical specialties, among others in cardiac surgery. The care approach aims at promotion of recovery of the patients throughout their perioperative process, reduction of complications, and early return to normal activities.
223425468|NCT04977362|OTHER|Treatment as Usual|treatment as usual according to standard care in heart valve surgery
223995976|NCT05000216|BIOLOGICAL|Monovalent [B.1.351] CoV2 preS dTM-AS03|One dose administered intramuscularly
223995977|NCT05000216|DRUG|Withhold IS (MMF or MPA)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
223995978|NCT05000216|DRUG|Withhold IS (MTX)|Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.
223995979|NCT05000216|DRUG|Withhold IS (B cell depletion therapy)|Participants who are taking MMF, MPA, or MTX in addition to BCDTs will withhold these medications (MMF, MPA, or MTX ) before and after the additional vaccine dose per protocol instructions. Participants will continue to take their prescribed BCDTs without alterations in schedule and dosing.
223995980|NCT05000216|BIOLOGICAL|Moderna mRNA-1273, Bivalent|Administration: One dose administered intramuscularly.
223995981|NCT05000216|BIOLOGICAL|BNT162b2, Bivalent|Administration: One dose administered intramuscularly.
224138386|NCT03991884|DRUG|Cyclophosphamide|Given IV
224138387|NCT03991884|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
224138388|NCT03466021|DRUG|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
224138389|NCT03466021|DRUG|Placebo|Matching injection
224138390|NCT01895452|DRUG|ALKS 9072, Low Dose|Intramuscular injection, given monthly
224138391|NCT01895452|DRUG|ALKS 9072, High Dose|Intramuscular injection, given monthly
223995982|NCT06173544|BEHAVIORAL|Standard of Care (SOC)|Participants randomized to this arm will received enhanced standard of care.
223995983|NCT06173544|BEHAVIORAL|Adapted Friendship Bench (AFB)|Participants randomized to this arm will receive the Adapted Friendship Bench protocol delivered by a trained counselor.
224123005|NCT06789107|DRUG|Blinatumomab 9ug|Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
224123006|NCT01379495|BEHAVIORAL|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
224123007|NCT02420158|DEVICE|Trans-cutaneous vagal nerve electrical stimulation|
223729648|NCT05328882|OTHER|Monitoring of paroxysmal atrial fibrillation recurrence after pulsed field catheter ablation|The implanted loop recorder will be interrogated to see how many patients had an early recurrence of AF (up to 3 months after the procedure). Then the late recurrence rate will be compared (3-12 months post-procedure) between groups with and without early recurrences.
223729649|NCT05611203|PROCEDURE|An Oropharyngeal swab|An Oropharyngeal swab performed for diagnostic purposes
224123008|NCT04370093|DRUG|Pioglitazone 45 mg|45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study
224123009|NCT04370093|BEHAVIORAL|Weight Loss|Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
224123010|NCT04370093|OTHER|Pioglitazone + Weight Loss|Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
224123011|NCT01419704|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
224123012|NCT06043050|DRUG|Platelets|Observational data: all platelet transfusions recorded in routine care medical file data.
224123013|NCT00726817|DRUG|Butyrate|
224123014|NCT04710862|BEHAVIORAL|Breathing training without a device|Breathing training without a mouth device
223729650|NCT05304156|OTHER|Biobanking blood and bone marrow specimens|"Interventions, procedures added for research purposes :~Blood Samples :~* Peripheral blood (20mL EDTA) (at Screening, pre-ICT Day 1, Day1 H8, Day 2, Day 3, Day 4 and Day of EOI evaluation~Bone Marrow samples :~* Biopsy at Screening and at EOI Evaluation~* Additional volume (2mL EDTA) on the Screening,2 and EOI Evaluation aspirations for single-cell analyses.~* Aspiration at D8 for Smears and 2 mL EDTA for single-cell analyses (instead of D15 standard care)."
223995984|NCT06173544|BEHAVIORAL|Enhanced Friendship Bench (EFB)|Participants randomized to this arm will receive the Enhanced Friendship Bench protocol delivered by a trained counselor and a peer supporter.
223995985|NCT06771765|OTHER|Chia Seeds|Chia seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.
223995986|NCT06771765|OTHER|Hemp Seeds|Hemp seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.
223995987|NCT06771765|OTHER|Control (placebo) group|This intervention is a lunch meal made from standard recipes. This intervention is the placebo control intervention.
224123015|NCT04710862|BEHAVIORAL|Breathing training with a device|Breathing training with a mouth device
224123016|NCT06410612|DRUG|regional anesthesia and PAI|this is the block portion of the study
224123017|NCT06410612|DRUG|PAI|this is the no block portion of the study
224123018|NCT05574400|DRUG|Dextrose Water|Dextrose 5% in water
224123019|NCT05574400|DRUG|Caffeine citrate|Low-dose caffeine citrate (1.5 mg/kg)
224123020|NCT05574400|DRUG|Caffeine citrate|High-dose Caffeine citrate (3 mg/kg)
224123021|NCT02626819|BEHAVIORAL|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
223729651|NCT00010374|DEVICE|NeuRx DPS|Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
223995988|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 1|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil and nuts
223995989|NCT06374199|BEHAVIORAL|Med-South Lifestyle Intervention for Pregnancy--Arm 2|Intervention includes lifestyle counseling and food provisions including extra virgin olive oil, nuts, and medically tailored meals
223995990|NCT06253884|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
224123022|NCT02626819|BEHAVIORAL|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
223729652|NCT03305198|BIOLOGICAL|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
223729653|NCT01961323|DRUG|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
223729654|NCT00170053|DRUG|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
223729655|NCT03791476|DRUG|rhC1INH|C1 esterase inhibitor
223729656|NCT03791476|OTHER|Saline Solution|saline solution
223729657|NCT06013540|COMBINATION_PRODUCT|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)|TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
223995991|NCT04605640|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
223995992|NCT05758168|PROCEDURE|Addition of Tie-Over Bolster Dressing|Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
223995993|NCT04763226|DRUG|BMS-986308|Specified dose on specified days
223995994|NCT04763226|OTHER|Placebo (for BMS-986308)|Specified dose on specified days
223995995|NCT04763226|DRUG|Furosemide|Specified dose on specified days
224123023|NCT06405022|OTHER|Brain Endurance Training|Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
224123024|NCT06405022|OTHER|Control|No intervention
223995996|NCT06250790|DIAGNOSTIC_TEST|Coronary CT angiography and FFRct analysis|A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
223995997|NCT06300151|DEVICE|Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia|Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
223995998|NCT06300151|DEVICE|Dural Puncture Epidural Labor Analgesia|Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
223995999|NCT06287151|DEVICE|BlockSynop surface electromyography device|The EMG monitor uses non-invasive surface electrodes that measures electrical activity in response to muscle stimulation. After all electrodes have been placed on the patient, the electrodes will be connected to a prototype non-significant risk device (NSR) BlockSynop surface electromyography device and monitoring of sEMG signal will begin. The device is a non-invasive and non-significant risk device.
224123025|NCT02786732|BIOLOGICAL|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
224123026|NCT02786732|BIOLOGICAL|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
224123027|NCT02786732|BIOLOGICAL|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
223996000|NCT06287151|DRUG|Clonidine|Clonidine is an alpha-2-agonist which is commonly used as an adjunct in spinal anesthesia and caudal anesthesia to improve both the quality and duration of blockade.
223996001|NCT06287151|DRUG|Sevoflurane|5.3. Sevoflurane is FDA approved for the induction and maintenance of general anesthesia in adults and pediatric patients.
223996002|NCT05418127|DIETARY_SUPPLEMENT|Active|Traditionally-fermented coconut milk kefir
223996003|NCT05418127|OTHER|Placebo|Solution of Calcium Carbonate and coconut extract
224123028|NCT02786732|BIOLOGICAL|Placebo|Placebo administered subcutaneously
224123029|NCT04716166|OTHER|Volume-oriented incentive spirometry|3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
224123030|NCT04716166|OTHER|Flow-oriented incentive spirometry|3 sets of 5 repeated deep breaths using flow oriented incentive spirometry 3 times a day for 2 days
223996004|NCT04161729|DRUG|Magnesium Sulfate|Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
223996005|NCT04161729|DRUG|Isotonic saline 0.9%|Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
223545167|NCT06719479|BIOLOGICAL|IAE0972+Capecitabine|IAE0972: every 21 days is defined as a treatment cycle, and IAE0972 is infused intravenously on the 1d, 8d and 15d of each cycle. The first infusion time is about 120 min (which can be adjusted according to the actual situation); If the subjects are well tolerated when they receive the study drug for the first time (according to CTCAE 5.0, the infusion-related reaction is ≤ grade 1), the follow-up infusion time can be 60\~90 min (which can be adjusted according to the actual situation).Capecitabine is used according to the instructions.
223996006|NCT02735746|RADIATION|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
223729658|NCT06013540|COMBINATION_PRODUCT|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)|Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
223996007|NCT02735746|RADIATION|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
223996008|NCT02735746|RADIATION|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
223996009|NCT02735746|DEVICE|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy"
223996010|NCT00245180|BEHAVIORAL|Diet|
223996011|NCT00245180|BEHAVIORAL|Exercise|
223996012|NCT05850195|OTHER|non invasive ventilation|compare indices and diaphragmatic ultrasonography for prediction of NIV failure in acute RF patients
223996013|NCT02035618|OTHER|Exercises|Strengthening and stretching
223996014|NCT02035618|OTHER|Exercises + Manual Therapy|Mobilization; massage; post-isometric relaxation; strengthening; stretching
223729659|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
224123031|NCT01839292|DEVICE|uncovered D-type stent insertion|
224123032|NCT01839292|DEVICE|double-layered ComVi stent insertion|
223996015|NCT03119233|DEVICE|DETOUR System|The DETOUR System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
223996016|NCT00835653|PROCEDURE|median nerve block|median nerve block performed under echographic guidance
223996017|NCT00835653|PROCEDURE|median nerve block|median nerve block performed under echographic guidance
223425469|NCT06621056|OTHER|not applicable for observational research|This is an observational research and has no intervention
223425470|NCT00642109|PROCEDURE|midurethral sling procedure|quality of life, voiding dysfunction
223425471|NCT01883947|PROCEDURE|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
223425472|NCT01883947|OTHER|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
223729660|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223729661|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223729662|NCT03958799|BIOLOGICAL|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223729663|NCT03958799|BIOLOGICAL|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223729664|NCT02186912|DEVICE|Nobel Active, Nobel Procera IBO|
223729665|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
223996018|NCT04701346|OTHER|Low SAA diet|Diet with low content of methionine and cysteine
223996019|NCT04701346|OTHER|High SAA diet|Diet with high content of methionine and cysteine
224123033|NCT03114306|PROCEDURE|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
224123034|NCT03114306|PROCEDURE|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
223729666|NCT01509430|OTHER|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
223996020|NCT04151836|OTHER|Exercise education|"weekly telephone or mobile application LINE consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects."
223996021|NCT02228902|DRUG|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
223996022|NCT02228902|DRUG|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
223996023|NCT06240819|OTHER|Sleeper Stretch|They will receive three sessions a week for four weeks. In a session three sets with three repetitions of sleeper stretch in a side lying position
223996024|NCT06240819|OTHER|Cross Body Stretch|They will receive three sessions a week for four weeks. In a session, three sets with three repetitions of cross-body stretch will be done in sitting position.
223996025|NCT05039073|DRUG|Brentuximab Vedotin|Given IV
223996026|NCT05039073|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
223996027|NCT05039073|BIOLOGICAL|Nivolumab|Given IV
223996028|NCT05039073|OTHER|Quality-of-Life Assessment|Ancillary studies
223996029|NCT05039073|OTHER|Questionnaire Administration|Ancillary studies
223996030|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
223996031|NCT02057575|DRUG|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
223996032|NCT02057575|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
223729667|NCT04262505|BEHAVIORAL|Mediterranean Diet Group|Participants will be advised to follow a traditional Mediterranean diet
223729668|NCT04262505|BEHAVIORAL|Healthy Eating Group|Participants will be advised to follow the Healthy Eating Guidelines in Ireland
223996033|NCT02057575|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
223729669|NCT00449046|DRUG|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
223729670|NCT00192829|PROCEDURE|Blood sample withdrawal|
223729671|NCT03472469|DRUG|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
223729672|NCT03472469|DRUG|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
223729673|NCT03472469|DRUG|Ketorolac|Ketorolac 30mg IV once
223996034|NCT00332462|DRUG|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
223996035|NCT00332462|DRUG|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
223996036|NCT04389034|DRUG|Pollinex Quattro with tree- and grass pollen extracts and their mixtures|retrospective analysis of patient records of allergen-specific immunotherapy
223996037|NCT01643044|BEHAVIORAL|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
223996038|NCT01643044|BEHAVIORAL|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
223996039|NCT03129126|DRUG|LP-10|Intravesical tacrolimus
223996040|NCT01527747|DRUG|Saxagliptin|5 mg daily
223996041|NCT02377167|PROCEDURE|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
223996042|NCT03080168|DEVICE|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
223996043|NCT03032718|BEHAVIORAL|Whole-body vibration training|Whole-body vibration exercise
223996044|NCT00578162|BEHAVIORAL|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
223996045|NCT04222777|DIAGNOSTIC_TEST|Cinematographic Recording|A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
223729674|NCT03472469|DRUG|Celebrex|Celebrex 200mg PO every 12 hours
223996046|NCT01735175|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
223996047|NCT01735175|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
223425473|NCT05192408|BEHAVIORAL|Multi-component intervention|"Individual intervention will comprise:~1. Cognitive- behavioral therapy (CBT) which includes: - Behavioural activation, cognitive restructuring, promotion of safety, relaxation techniques~2. Exercise recommendation utilizing current Exercise in older adults Patient Education Materials (PEMs) and videos, tailored based on frailty level and readiness to progress - Components include balance and strength~3. Use of motivational interviewing (MI) techniques for goal setting~There will be 4 sessions in total. Initial sessions will be carried out face to face or via videoconferencing platform if participant prefers due to ongoing COVID-19 pandemic. Subsequent sessions will be carried out via telephone."
223996048|NCT03943472|BIOLOGICAL|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
223996049|NCT03943472|DRUG|Fludarabine|30mg/m2/d
223996050|NCT03943472|DRUG|Cyclophosphamide|300mg/m2/d
223996051|NCT03943472|DRUG|Immune inhibitors|Immune inhibitors
223996052|NCT05833646|DEVICE|Group 1|In each group, patients will be applied both standard subcutaneous heparin injection and with ShotBlocker.
223996053|NCT05833646|DEVICE|Group 2|In each group, patients will be applied both standard subcutaneous heparin injection and with virtual reality glasses.
223425474|NCT05192408|OTHER|Usual Care|Patient Education Materials
223425475|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
223729675|NCT03472469|DRUG|Naproxen|Naproxen 500mg PO every 12 hours
223996054|NCT05833646|DEVICE|Group 3|In each group, patients will be applied both standard subcutaneous heparin injection and with cold application.
223996055|NCT01956604|DRUG|Clonidine|
223996056|NCT01956604|DRUG|Placebo|
223996057|NCT00462878|DRUG|Meropenem|antibiotic
223996058|NCT00462878|DRUG|Vancomycin|Antibiotic
223996059|NCT00462878|DRUG|Teicoplanin|Antibiotic
223996060|NCT01720160|DEVICE|BAROSTIM NEO® System|Implant procedure
224123035|NCT01914887|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
223996061|NCT01720160|OTHER|Standard of care medical managment therapy for heart failure|Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
223996062|NCT02287298|PROCEDURE|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
223996063|NCT00659880|OTHER|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
223996064|NCT05531071|DEVICE|Biofeedback electrical stimulation|treated with biofeedback electrical stimulation, 3 times a week for 30 minutes for 15 times.
223996065|NCT05531071|PROCEDURE|Acupuncture|acupuncture treatment, including Guanyuan, Qihai, Zhongji, Zusanli, Sanyinjiao and Yinlingquan, once a day, Monday to Friday, 30 minutes each, a total of 10 times.
223996066|NCT05531071|COMBINATION_PRODUCT|Acupuncture combined with biofeedback electrical stimulation|treated with acupuncture combined with biofeedback electrical stimulation.
223996067|NCT04570696|OTHER|NON INTERVENTIONAL|NON INTERVENTIONAL
223996068|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
224123036|NCT05797454|PROCEDURE|Wire-guided localization and marker clip localization|Positioning guide wire and marker clip in the center of the lesion
223425476|NCT03153267|DRUG|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
223425477|NCT03153267|DRUG|Controls without a history of lyme disease.|No intervention.
223425478|NCT00923663|DRUG|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
223425479|NCT01825083|DRUG|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
223729676|NCT03472469|DRUG|Tramadol|Tramadol 100mg PO every 6 hours
223729677|NCT03472469|DRUG|Pregabalin|Pregabalin 100mg PO every 8 hours
223729678|NCT03472469|DRUG|Gabapentin|Gabapentin 300mg PO every 8 hours
223729679|NCT03472469|DRUG|Lidocaine|Lidocaine patch every 12 hours
223729680|NCT03472469|DRUG|Opioids|Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)
223996069|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
223996070|NCT00978367|DRUG|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
223996071|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
223996072|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
223996073|NCT00978367|DRUG|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
223996074|NCT02963155|OTHER|Blood samples|
224123037|NCT05797454|PROCEDURE|Wire-guided localization|Positioning guide wire in the center of the lesion
224123038|NCT02375958|DRUG|PCA062|
224123039|NCT05343806|DRUG|Nifedipine 20 Mg|The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.
223729681|NCT03472469|DRUG|Regional anesthesia|Regional anesthesia
223996075|NCT06372704|DEVICE|HIFEM|All patients had a total of 6 sessions lasting 28 minutes, twice a week, sitting on an electromagnetic chair (BTL EMSELLA®, BTL Industries Inc, Boston, MA, USA).
223996076|NCT04766359|DRUG|Albumin-Bound Paclitaxel|Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal carcinoma.
223996077|NCT04004104|DIAGNOSTIC_TEST|Upright Exercise|Exercise is generally performed in the upright position.
223996078|NCT04004104|DIAGNOSTIC_TEST|Supine Exercise|Since HPS patients with orthodeoxia experience an improvement in their symptoms and oxygen levels when supine, the intervention will involve them performing exercise in the supine position.
223996079|NCT01518959|DRUG|Cholecalciferol|180.000 IU monthly
223996080|NCT01518959|DRUG|oleum neutralicum|Placebo comparator, 9 ml monthly
223996081|NCT01886287|DRUG|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
223996082|NCT02833324|BEHAVIORAL|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
223996083|NCT02833324|BEHAVIORAL|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
223996084|NCT02833324|OTHER|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
223996085|NCT03699891|DEVICE|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
223996086|NCT02954978|DRUG|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
223996087|NCT02954978|DRUG|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
223996088|NCT02954978|DRUG|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
224123040|NCT05343806|DRUG|Magnesium Sulfate|Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.
224123041|NCT01604057|DRUG|ZT-034 Low Dose Nasal Spray|Nasal Spray
223996089|NCT01279928|PROCEDURE|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
223996090|NCT01279928|DEVICE|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
223996091|NCT01279928|PROCEDURE|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
223996092|NCT01279928|PROCEDURE|Laser Doppler Flowmetry|Examination of vascular flow
223996093|NCT06314100|DEVICE|Tobacco heating systems|The study aims to explore the effect of tobacco heating system consumption on microbiome of the supragingival dental biofilm and the risk of developing caries lesions
223996094|NCT06314100|BEHAVIORAL|cigarette smoking|The study aims to explore the effect of cigarette smoking on microbiome of the supragingival dental biofilm and the risk of developing caries lesions
223996095|NCT06314100|BEHAVIORAL|non smoking|The non smoking group of subjects serve as control for the other two groups
223996096|NCT04483180|OTHER|Comparison of sweetener blends in liquid form (cross-over study)|The aim is to compare the effects of different sweetener blends on glycemia, subjective appetite parameters and safety parameters when consumed in a beverage as part of a breakfast
223996097|NCT03099252|OTHER|Parent-targeted BSweet2Babies video|The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
223996098|NCT01031628|DRUG|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
223996099|NCT01031628|DRUG|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
223996100|NCT01031628|DRUG|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
224123042|NCT01604057|DRUG|ZT-034 Mid Dose Nasal Spray|Nasal Spray
224123043|NCT01604057|DRUG|ZT-034 High Dose Nasal Spray|Nasal Spray
224123044|NCT01604057|DRUG|Teriparatide|20 mcg subcutaneous daily
224123045|NCT01604057|DRUG|Placebo|Nasal Spray
224123046|NCT05978362|PROCEDURE|Latarjet technique|Realization of a stop according to Latarjet
223425480|NCT01825083|DRUG|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
223425481|NCT01871402|DRUG|000-0551 Lotion|
223425482|NCT01871402|DRUG|Vehicle Lotion|
223425483|NCT00509379|DRUG|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
223425484|NCT00509379|DRUG|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
223729682|NCT00162656|DRUG|half cyclophosphamide|
223996101|NCT06076317|BEHAVIORAL|Telemedicine session|The content of telemedicine session is semi-standardized and includes: (1) evaluation of the tolerance and efficacy of drug treatment; (2) evaluation of depressive symptoms (PHQ9 scale); (3) identification of the daily difficulties; (4 ) personalized advice and orientation towards appropriate care pathways. Among the personalized advice, investigators will use the digital tools available to maintain remission, psychoeducation and monitoring tools (for example, application to learn mindfulness meditation, conversational chatbot coupled with artificial intelligence, etc.). Support on the use of these tools can be provided during telemedicine sessions.
223996102|NCT02676843|DRUG|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
223996103|NCT06055946|DEVICE|robotic assisted radical prostatectomy|Adult male patients undergoing elective robotic assisted radical prostatectomy.will be included in the study
223996104|NCT06273813|DRUG|Ketorolac Tromethamine 15 MG/ML|Single intravenous administration of Ketorolac Tromethamine injection in Cohort 1 on day 1
223996105|NCT06273813|DRUG|Ketorolac Tromethamine|Three doses of topical ketorolac tromethamine over the course of 1 day, 6 hours apart for each of 3 subsequent treatment periods in cohort 1 Three doses of Ketorolac Tromethamine, 6 hours apart, over the course of 5 days in cohorts 2 and 3
223996106|NCT02562144|DRUG|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
223996107|NCT02562144|DRUG|Placebo|Cutaneous placebo before intravenous cannulation.
224123047|NCT04647227|DRUG|coagulation factor VIIa [recombinant]-jncw|a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
224123048|NCT02397993|PROCEDURE|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
224123049|NCT02397993|PROCEDURE|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
223379595|NCT01496976|DRUG|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m\^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
223379596|NCT01496976|DRUG|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
223379597|NCT01496976|DRUG|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
223996108|NCT02977286|DRUG|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
223996109|NCT02977286|DRUG|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
224123050|NCT02397993|PROCEDURE|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
224123051|NCT03902366|DIAGNOSTIC_TEST|Neuropsychological assessment|Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
224123052|NCT03902366|BEHAVIORAL|Neuroimaging|Subjects, well characterized with respect to their substance use, will be evaluated with functional magnetic resonance imaging (fMRI) tasks, resting state MRI (rsMRI), high resolution anatomical MRI, standard diffusion weighted imaging (DWI) and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
224123053|NCT06527274|DEVICE|Experimental: Myopic defocus soft lens design (MDSL)|An optical device designed to provide a myopic defocus to control myopia progression
224123054|NCT06527274|DEVICE|Active Comparator: Single vision soft lens design (SVSL|An optical device designed to correct refractive error like myopia
224123055|NCT03393845|DRUG|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
224123056|NCT03393845|DRUG|Fulvestrant|Fulvestrant, 500mg IM, Loading dose: C1 D1 \& 15. Thereafter, Q4 wks
224123057|NCT01294735|DRUG|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
223425485|NCT03117894|DRUG|Ropivacaine 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
223425486|NCT03117894|DRUG|Remifentanil 50 microg/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
223996110|NCT02977286|DRUG|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
223996111|NCT02977286|DRUG|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement \>/=6 days after scheduled opioid initiation.
223996112|NCT02977286|DRUG|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement \>/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
223379600|NCT03225794|DIAGNOSTIC_TEST|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
223996113|NCT02977286|DRUG|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement \>/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation.
224123058|NCT01294735|DRUG|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
224123059|NCT01102153|DEVICE|Coolgard|invasive cooling via femoral ICY-catheter
224123060|NCT01102153|DEVICE|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
224123061|NCT03299517|DRUG|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
224123062|NCT03299517|DRUG|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
223996114|NCT02977286|DRUG|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement \>/= 5 days after scheduled opioid initiation.
223996115|NCT02977286|DRUG|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement \>/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
224123063|NCT01325831|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
223379641|NCT06781489|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb
223379642|NCT06781489|DRUG|Gabapentin 300mg|Oral gabapentin capsule
223379643|NCT06781489|DRUG|Ibuprofen Arginine|Oral ibuprofen arginine tablets
223379644|NCT01821690|DRUG|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
223379645|NCT01821690|DRUG|Placebo|The placebo tablets taste and look identical to buspirone.
223379648|NCT06778759|COMBINATION_PRODUCT|median nerve neural mobilization combined with oral ibuprofen arginine|Manual therapy maneuver performed in the upper limb combined with ibuprofen arginine oral tablets
223379649|NCT06778759|DRUG|Ibuprofen Arginine|Ibuprofen arginine oral tablets
223996116|NCT04533048|COMBINATION_PRODUCT|MW33 injection|a recombinant fully human antibody to coronavirus
223996117|NCT04533048|COMBINATION_PRODUCT|MW33 injection placebo|Placebo
223996118|NCT00038480|DRUG|Lopinavir/Ritonavir|
223379650|NCT02555254|PROCEDURE|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
223379651|NCT02555254|PROCEDURE|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
223379652|NCT02830724|DRUG|Cyclophosphamide|"For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV"
223379653|NCT02830724|DRUG|Fludarabine|"For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB"
223379654|NCT02830724|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
223379655|NCT02830724|BIOLOGICAL|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
223379656|NCT06247670|DRUG|CMP-CPS-001|CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
223379657|NCT06247670|OTHER|Placebo|Placebo is 0.9% normal saline solution and will be administered subcutaneously.
223379662|NCT03597399|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
223379665|NCT00000971|DRUG|Clarithromycin|
223379666|NCT00000971|DRUG|Zidovudine|
223996119|NCT04218747|BEHAVIORAL|VA 365 Demonstration Benefits|Reducing hunger 365 days a year in households with school children by transforming schools into food hubs ( free breakfast, lunch, supper, and food backpacks for the weekend) and providing nutrition education to parents.
223379667|NCT00000971|DRUG|Didanosine|
223425487|NCT03117894|DRUG|Betamethason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
223729683|NCT00162656|DRUG|without COPADM3|
223729684|NCT00162656|DRUG|mini CYVE, without 3 maintenance courses|
223729685|NCT00162656|DRUG|LMB B|
223729686|NCT00162656|DRUG|LMB C|
223996120|NCT02264262|OTHER|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
224123064|NCT01325831|DEVICE|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
223996121|NCT05021471|OTHER|biofeedback|Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
223996122|NCT05021471|OTHER|hamstrings stretching|Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
223996123|NCT04346810|OTHER|Patient management suffering of coronavirus infection|Welle-being and stress of the caregivers
223996124|NCT02430753|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
223996125|NCT02430753|DEVICE|NanoKnife|
223996126|NCT01013142|DRUG|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
223996127|NCT01013142|DRUG|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
223996128|NCT01013142|DRUG|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
223996129|NCT01055236|DRUG|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
223996130|NCT02949245|PROCEDURE|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
223996131|NCT01025505|DRUG|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
223996132|NCT01025505|DRUG|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
223996133|NCT01266161|DRUG|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
223996134|NCT01266161|DRUG|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
223996135|NCT02990468|DRUG|BMX-001|Subcutaneous injection.
223425488|NCT03117894|DRUG|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
223425489|NCT03117894|DRUG|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
223425490|NCT03117894|DRUG|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
223425491|NCT03117894|DRUG|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
223996136|NCT02990468|RADIATION|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
223996137|NCT02990468|DRUG|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
223996138|NCT06439732|DEVICE|Acumen IQ cuff|Use of Acumen IQ cuff for haemodynamic monitoring
223996139|NCT01224522|PROCEDURE|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
223996140|NCT01224522|PROCEDURE|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
223996141|NCT04467047|BIOLOGICAL|Mesenchymal Stromal Cells infusion|Intravenous 1\*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion
223996142|NCT02335905|DRUG|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if \> 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
223996143|NCT01436305|DRUG|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
223996144|NCT01436305|DRUG|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.~Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
223996145|NCT01436305|BIOLOGICAL|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication\[s\])
223996146|NCT01436305|DRUG|Short-term Tac|Short-term (3 months)
223996147|NCT01436305|DRUG|tacrolimus|maintenance
223996148|NCT01436305|BIOLOGICAL|Belatacept|maintenance
223996149|NCT01436305|DRUG|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
223996150|NCT01613144|DEVICE|OsseoScrew Spinal Fixation System|Surgical intervention
223379673|NCT03575000|DRUG|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
223379674|NCT04140032|BEHAVIORAL|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
223729687|NCT02550548|DRUG|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
223996151|NCT00580060|BIOLOGICAL|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
223996152|NCT02931370|DIETARY_SUPPLEMENT|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
223996153|NCT01582230|DRUG|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
223996154|NCT01582230|DRUG|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
223996155|NCT05610124|OTHER|Ad libitum full-fat French fries with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
223996156|NCT05610124|OTHER|Ad libitum instant mashed potatoes with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
224123065|NCT06629675|DEVICE|Music walking application BeatClearWalker (BCW)|The music walking application (BCW) is a smartphone application that can monitor the walking pace and allow individuals to listen to music and give immediate feedback so they can correct their walking pace to match their target walking speed, as prescribed by the healthcare professional. The application provides real-time audio feedback in the form of music; the music sound quality will reduce whenever the walking speed drops below or exceeds the participant\&#39;s target walking speed. Simply, the application will work to supervise service users while exercising walking. The investigators are trying to assess the feasibility of this application with service users during their Pulmonary Rehabilitation programme (at the hospital/ home) to find out how participants interact with listening to music while exercise walking and how well they're able to keep to their target speed.
224123066|NCT02739022|BEHAVIORAL|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
224123067|NCT02979886|DRUG|GnRH-a|the hormone reaction to the down regulation of the patients
224123068|NCT02979886|DRUG|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
224123069|NCT01938963|BEHAVIORAL|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
223729688|NCT02550548|DRUG|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
223729689|NCT02550548|DRUG|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
224123070|NCT02227017|DRUG|TPV capsule|
224123071|NCT02227017|DRUG|TPV solution|
224123072|NCT02227017|DRUG|RTV capsule|
224123073|NCT02227017|DRUG|RTV solution|
224123074|NCT02227017|OTHER|standard meal|
224123075|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
224123076|NCT00366548|BIOLOGICAL|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
223425492|NCT03117894|DRUG|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
223996157|NCT05610124|OTHER|Ad libitum macaroni pasta with beef meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
223996158|NCT05610124|OTHER|Ad libitum full-fat French fries with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the French fries ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g French fries and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked French fries (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
223996159|NCT05610124|OTHER|Ad libitum instant mashed potatoes with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the meatballs but to eat the mashed potatoes ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g mashed potatoes and about 120 g vegetarian meatballs (25 g protein), additional plates of freshly cooked mashed potatoes (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
223996160|NCT05610124|OTHER|Ad libitum macaroni pasta with vegetarian substitute meatballs|"Participants will consume 1 of the 6 treatment meals at each of the 6 study sessions in random orders such that by the end of the study, they will have consumed all 6 treatments.~Participants will be given 30 minutes to consume the treatment meal and will be instructed to eat all the vegetarian meatballs but to eat the macaroni pasta ad libitum (250 g), until comfortably full, simulating at home meal consumption. After providing the participants with the first plate of 250 g macaroni pasta and about 120 g meatballs (25 g protein), additional plates of freshly cooked macaroni pasta (250 g) alone will be provided 10 and 20 min later and they will be given 30 min to complete the treatment meal. Each treatment will be served with water."
223996161|NCT03482089|PROCEDURE|Cystoprostatectomy|Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
223996162|NCT03482089|RADIATION|external beam radiotherapy|Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
223996163|NCT00218049|DRUG|GBR 12909|50mg GBR 12909 over 12 days
223996164|NCT00218049|DRUG|GBR 12909|GBR 12909 75 mg over 12 day period
223996165|NCT00218049|DRUG|GBR 12909|GBR 12909 100 mg over 12 day period
223996166|NCT04659122|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
223425493|NCT05500482|BIOLOGICAL|Typhoid conjugate Vaccine|TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
223996167|NCT01387191|DRUG|Epoprostenol|
223996168|NCT00003094|OTHER|preventative dietary intervention|
223996169|NCT03663062|DIAGNOSTIC_TEST|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
223996170|NCT02334280|BEHAVIORAL|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
223996171|NCT01016847|DRUG|Montelukast|10 mg Q day
223996172|NCT01016847|OTHER|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
223996173|NCT02261753|DIETARY_SUPPLEMENT|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
223996174|NCT00000683|BIOLOGICAL|HIVAC-1e|
223996175|NCT00000683|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223996176|NCT04988789|DRUG|Paclitaxel Drug Coated Balloon|Failing AVF/AVGs treated with Paclitaxel Drug Coated balloons are captured in this database
223996177|NCT04441944|OTHER|Telemedicine|Use of provider-to-provider telemedicine
223996178|NCT03212768|PROCEDURE|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
223996179|NCT02280512|DEVICE|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
223996180|NCT03538782|PROCEDURE|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
223996181|NCT03697694|DIETARY_SUPPLEMENT|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
223996182|NCT03697694|OTHER|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
223996183|NCT03128671|BEHAVIORAL|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
223996184|NCT02869256|OTHER|Practices evaluation|Practices evaluation
223996185|NCT03850132|BEHAVIORAL|FAM-SOTC-PL|"The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~1. Drawing forward narratives about the pre- and post-loss experience.~2. Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~3. Validating/acknowledging emotional responses.~4. Assessing the need for specific information and recommendations regarding bereavement.~5. The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver."
223996186|NCT04001335|DIAGNOSTIC_TEST|Dental Broach|Dental broach, RDT and PCR
223996187|NCT04568863|DRUG|Melatonin intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.
223996188|NCT04568863|DRUG|Placebo intravenous|7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
224123077|NCT02987764|OTHER|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
224123078|NCT02849990|DRUG|Abiraterone Acetate|Given PO
223996189|NCT05132894|OTHER|Osteopathic Assessment|As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.
224123079|NCT02849990|DRUG|Apalutamide|Given PO
224123080|NCT02849990|DRUG|Degarelix|Given SC
224123081|NCT02849990|DRUG|Indomethacin|Given PO
224123082|NCT02849990|OTHER|Laboratory Biomarker Analysis|Correlative study
224123083|NCT02849990|DRUG|Prednisone|Given PO
224123084|NCT02150187|DIETARY_SUPPLEMENT|HCap Formula|Pill should be taken every other day during the treatment phase.
224123085|NCT02150187|DIETARY_SUPPLEMENT|Placebo|Similar pills without active ingredients
223379693|NCT06075277|DRUG|zongertinib|Participants received a single oral dose of 240 mg Zongertinib (4 x 60 mg tablets) in two periods: in Period 1 after an overnight fast of at least 10 hours, and in Period 2 following a high fat/high calorie meal.
223996190|NCT02413281|DRUG|ALKS 5461|Sublingual tablets, single administration
223425494|NCT04594941|DRUG|Flurpiridaz (18F) Injection|All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein at rest.
223425495|NCT04012281|DEVICE|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
223996191|NCT02413281|DRUG|Buprenorphine|Sublingual tablets, single administration
223996192|NCT02413281|DRUG|Placebo|Sublingual tablets, single administration
223996193|NCT00203034|DRUG|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
223425496|NCT04399603|OTHER|no intervention-mechanistic study|no intervention-mechanistic study
223425497|NCT00600990|DRUG|GW597599|
223996194|NCT00203034|DRUG|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
223996195|NCT00203034|OTHER|Placebo|oral placebo once daily
223996196|NCT01376154|DRUG|Lamivudine|
223996197|NCT04463680|DRUG|Rifampin 600 MG|Administered daily for 2 weeks
223996198|NCT01690468|DRUG|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m\^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
223996199|NCT01690468|DRUG|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
223996200|NCT00205595|DEVICE|Positron Emission Tomography|
223996201|NCT02171247|DRUG|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
223996202|NCT02171247|DRUG|Visipaque 320|Visipaque 320 is standard protocol.
223996203|NCT00938405|DRUG|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
223996204|NCT00938405|DRUG|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
223996205|NCT05389605|OTHER|No intervention was undertaken|This was an observational study, no intervention was done.
223996206|NCT05239598|DRUG|Mouth rinse|Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
223996207|NCT05038540|PROCEDURE|Scaling and root planing|Phase 1 periodontal therapy
223996208|NCT02222870|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
223996209|NCT02222870|BIOLOGICAL|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
223996210|NCT04391543|OTHER|Experimental session|"* comprehensive interview~* cognitive tests~* anthropometric measures~* postural balance test~* critical force test~* Astrand-Ryhming test~* self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~* actimetry~* clinical and biological characteristics~* determination of inflammatory markers~* skeletal muscle index"
223996211|NCT05223218|OTHER|Schirmer strip, a Class I Medical Device typically used to test for dry eye.|Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
223996212|NCT00777764|DRUG|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI."
223996213|NCT00777764|DRUG|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline."
223996214|NCT00160550|DRUG|Levetiracetam|
223379697|NCT05075824|DRUG|Crovalimab|Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.
223379698|NCT05075824|DRUG|Placebo|Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.
223379699|NCT03755804|DRUG|bendamustine|Given intravenously (IV)
223379700|NCT03755804|DRUG|Etoposide|Given intravenously (IV)
223379701|NCT03755804|DRUG|Doxorubicin|Given intravenously (IV)
223379702|NCT03755804|DRUG|Bleomycin|Given intravenously (IV)
223379703|NCT03755804|DRUG|Vincristine|Given intravenously (IV)
223379704|NCT03755804|DRUG|Vinblastine|Given intravenously (IV)
223379705|NCT03755804|DRUG|Prednisone|Given orally (PO)
223379706|NCT03755804|DRUG|Filgrastim|Given subcutaneously (SQ) or IV
223379707|NCT03755804|DRUG|Brentuximab Vedotin|Given intravenously (IV)
223379708|NCT03755804|DRUG|Cyclophosphamide|Given intravenously (IV)
223379709|NCT03755804|DRUG|DTIC|Given intravenously (IV)
223379710|NCT03755804|OTHER|Quality of Life Measurements|Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
223379711|NCT03755804|RADIATION|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
223996215|NCT04295850|DRUG|Aspirin 81 mg|Aspirin 81mg daily PO
223996216|NCT06488443|BEHAVIORAL|Yoga|Participants in yoga arm will receive intervention from an instructor who would be trained in the intervention by the yoga adviser.All the yoga exercises selected for this study are low-impact and involve highly controlled movements. All yoga exercises will be taught and supervised by a skilled yoga-instructor. The yoga-instructor will take great care to emphasize to participants that they should not go beyond their usual range of motion/comfort for any of the yoga exercises.
223996217|NCT06488443|BEHAVIORAL|WHO 5As model intervention|"WHO 5As model to help patients ready to quit. The five major steps to intervention are the 5 A's: Ask, Advise, Assess, Assist, and Arrange."
223996218|NCT01181453|DEVICE|Dermagraft|Weekly application of Dermagraft(R) with standard care
223996219|NCT01181453|OTHER|Comparator|Weekly application of standard care
223996220|NCT04224168|DIETARY_SUPPLEMENT|Green Beans|Please see arm group Green beans for description
223996221|NCT04224168|DIETARY_SUPPLEMENT|Liquid Pectin|Please see arm group liquid pectin for description
223996222|NCT06064656|OTHER|Non-Interventional|No study treatment will be administered in this study.
223996223|NCT06994286|DRUG|MT-7117|Oral
223996224|NCT06994286|DRUG|Placebo|Oral
223996225|NCT06421831|GENETIC|GC101|Self-complementary AAV9 carrying a codon-optimized SMN coding sequence(coSMN1) driven by CMV enhancer and chicken β-actin promoter
223996226|NCT06855719|OTHER|Training in high-fidelity simulation and knowledge of care protocols in patients with multimorbidity and heart failure|Participants will perform an individual simulation as nurses related to the patient profile in their home (pretest and postest). After each simulation, each participant will receive a recording of their simulation, and both individual and group debriefings will be conducted. In addition, they will be trained in scientific evidence and international and national protocols regarding the care of these patients in the context of home health nursing.
223996227|NCT02474849|OTHER|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
223996228|NCT07049757|OTHER|Smoking cessation education|Quit Smoking for a Healthy Family (QS) and Smokefree Family Living (SFL) education sessions to promote smoking cessation and reduce tobacco smoke exposure.
223996229|NCT07049757|BEHAVIORAL|Survey Administration|Administered for ancillary studies
223996230|NCT07049757|BEHAVIORAL|Telephone-Based Intervention|Participants will receive follow-up calls
223996231|NCT07049757|PROCEDURE|Urine Specimen Collection|Undergo urine sample collection at baseline
223996232|NCT07049757|OTHER|Silicone Wrist Band|Non-smoking family/household members will wear a silicone wristband for 2 days at each assessment for ancillary studies
223996233|NCT07049757|OTHER|Interview|Selected participants will take part in an interview for ancillary studies
223996234|NCT07049757|OTHER|Focus Group|Participants will review and comment on materials under development to be used in randomized clinical trial.
223996235|NCT07050108|OTHER|neurodynamic mobilization|the patients will receive neurodynamic mobilization in the form of opening technique which include; static opening and dynamic opening. also, sliding and tensioning technique+ selected physical therapy program
223996236|NCT07050108|OTHER|mulligan therapy|sustained natural apophyseal glide SNAGs are mobilisation techniques and are used as part of the Mulligan Concept+ selected physical therapy program The patient position is stitting on the edage of the plenth non weight bearing position. The therapist will stand behind the patient, the therapist will apply SNAG for 3 repetitions during the initial screening session,the patient will be asked to lean forwared while applying the technique .the therapist apply onle from fove to seven repetitions.patients who experienced no worsening or showed improvement of pain and ROM were considered good indication for the effectivness of treatment .
223996237|NCT07050108|OTHER|selected physical therapy program|"The program of therapeutic exercises consisted of upper and lower back exercises. Each exercise will repeat from ten to thirty times, three repetitions in three sets with rest one to two minutes between the sets. The repetition of each exercise vary according to the physical ability of each patient.~Lower back strengthening exercises: From prone lying position, the patient will asked to raise one lower limb then the other then both lower limbs+ TENS and US"
223996238|NCT07051031|DRUG|Nuvaxovid (NVX-CoV2705)|COVID-19 vaccination
223996239|NCT07051031|DRUG|Pfizer-BioNTech COVID-19 vaccine|COVID-19 vaccination
223996240|NCT07048873|DRUG|Dexmedetomidine|IV dexmedetomidine
223996241|NCT07048873|DRUG|Ketamine|IV ketamine
223996242|NCT07048873|DRUG|Saline (control group)|no drugs
224123086|NCT03157154|OTHER|Non interventional study|A query form to all concerned patients by each investigating centre will be send
223996243|NCT07050966|PROCEDURE|Group A (Active Comparator) 1. Mulligan's Spinal Mobilization with Leg Movement (SMWLM) 2.Lower Limb Neurodynamic Mobilization|This group will receive Mulligan's Spinal Mobilization at the Lumbar Spine Region (L4-L5 level) along with Lower extremity movement (3 repetitions, 3 sets) followed by Neurodynamic Mobilization which will include slump technique (3 repetitions, 1 set). This protocol is given to the patient for a total of 6 sessions (1 session per day).
223996244|NCT07050966|PROCEDURE|Group B (Experimental) 1. Maitland's Lumbar Rotation Mobilization 2.Lower Limb Neurodynamic Mobilization|This group will receive Maitland's Lumbar Rotation Mobilization at the Lumbar Spine Region (L4-L5 level) along with Lower extremity movement (3 repetitions, 3 sets) followed by Neurodynamic Mobilization which will include slump technique (3 repetitions, 1 set).This protocol is given to the patient for a total of 6 sessions (1 session per day).
223545168|NCT06718231|BEHAVIORAL|Transcutaneous electrical acupoint stimulation|After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints, and sham acupoints. The target treatment acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery.
223996245|NCT07050797|BEHAVIORAL|Individualised whole-school intervention, developed using data sharing and co-design.|Individualised whole-school intervention, developed using data sharing and co-design.
223729690|NCT05421234|OTHER|diagnostic test and sperm analysis|"Diagnostic Test: 2x14 ml of peripheral blood collected in the tube with anticoagulant, for platelet isolation, respirometry mitochondrial analysis, antioxidants (coenzyme Q10, vitamin E, gamma-tocopherol, beta-carotene) and TBARS estimation.~Sperm analysis: standard spermiogram examination (volume, pH, number, motility and pathology) in the broker chamber, as well as extended examinations: mioxsys for redox potential, Vitalsperm (eosin-nigrosine staining) for sperm vitality and anti-sperm antibody (IgG) test."
223996246|NCT05165940|BEHAVIORAL|Treatment As Usual|Care Coordination Treatment as usual with a VA mental health treatment coordinator
224123087|NCT03135587|PROCEDURE|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
224123088|NCT03463941|BEHAVIORAL|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
224123089|NCT02584933|DRUG|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
224123090|NCT03951688|OTHER|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
224123091|NCT01184404|DRUG|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
224123092|NCT05271019|DEVICE|Threshold load device|"Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale."
223996247|NCT05165940|BEHAVIORAL|New Health Services Intervention|The experimental care coordination intervention begins with a 60-minute in-person session and continues with regular, brief contacts between the Veteran and clinician. During the first session, the clinician and Veteran will (1) discuss the Veteran's beliefs about their presenting problem; (2) collaboratively identify SMART goals; (3) discuss treatment options; (4) use shared decision-making to match treatment to SMART goals; (5) develop criteria to evaluate treatment progress; and (6) manage treatment expectations. During follow-up sessions, the clinician and Veteran will reflect on treatment progress, make appropriate updates to SMART goals, and re-evaluate barriers to CPT or PE.
223996248|NCT06641180|BIOLOGICAL|High-Dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
223996249|NCT06641180|BIOLOGICAL|Standard-dose trivalent influenza vaccine (Split virion, Inactivated)|Liquid suspension for intramuscular injection
223729691|NCT03140020|PROCEDURE|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
223729692|NCT03140020|PROCEDURE|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
223996250|NCT05847868|DEVICE|Moment Tumour Hip Prothesis|"In the case of irreversible bone loss due to bone tumors, large and multi-part fractures, and pseudarthrosis in the proximal region of the femur bone, the defective bone area is removed and implants made of artificial materials are placed in order to replace the integrity of the bone. In addition, implant applications are made to the proximal femur region for the purpose of revision arthroplasty, which is typically replaced by total hip prosthesis depending on the wear condition.~In this way, the bone integrity will be preserved, long-term stabilization will be provided to the patient and existing pain will be eliminated.~Moment Tumor Hip Replacement Systems consist of proximal main body, extension pieces and intramedullary stems. Components are available in a variety of sizes to meet anatomical requirements and surgeon needs."
223996251|NCT06774313|DRUG|ABBV-142|Intravenous (IV) Infusion
223996252|NCT06774313|DRUG|ABBV-142|Subcutaneous (SC) Injection
223996253|NCT06774313|DRUG|Placebo|IV Infusion
223996254|NCT06774313|DRUG|Placebo|SC Injection
224295399|NCT03757273|PROCEDURE|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
224299118|NCT02479542|DEVICE|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
223996255|NCT00002198|DRUG|Abacavir sulfate|
223996256|NCT02614183|DRUG|Galcanezumab|Administered SC
223996257|NCT02614183|DRUG|Placebo|Administered SC
223996258|NCT07097285|BEHAVIORAL|sensory awareness training|Presentations to inform during training will be done, then Graded Sensory Discrimination, Graded Motor Imagery (DMI) and a home exercise program, as well as a body awareness training program. protocol will be applied. Graded Sensory Discrimination protocol, localization training It includes level 1, localization training level 2 and graphesthesia training. Graded Engine Visualization (DMI) protocol includes right/left discrimination training and visual imagery training.
223996259|NCT07137169|PROCEDURE|LIMA protocol|Cleft palate repair using Hybrid / One-flap technique
223996260|NCT07137169|PROCEDURE|RSCM Protocol|Cleft palate repair using Two-flap technique
223996261|NCT05540730|DIAGNOSTIC_TEST|Gait Analysis|Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.
224123093|NCT04573452|DIAGNOSTIC_TEST|Galectin-3|Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R\&D Systems, Minneapolis, MN, USA).
223545169|NCT06718231|BEHAVIORAL|Sham-TAES|After entering the operating room, an experienced traditional Chinese medicine doctor will locate the bilateral sham acupoints. The Sham acupoints is 4 cm interior to the bilateral Shenmen, Neiguan, Hegu, Chize, and Anmian acupoints. The sham acupoints will be wiped with 75% ethanol, and after the ethanol had evaporated, electrode pads (50 × 50 mm) will be placed and fixed according to the different groups. Thirty minutes before anesthesia, a TAES stimulator (Hwato Electronic Acupuncture Treatment Instrument, model no: SDZ-III; Suzhou Medical Appliances Co. Ltd, Suzhou, China) will be connected with a frequency setting of 2/10 Hz (2 Hz for 10 s and 10 Hz for 5 s), in dense-disperse mode. The current intensity will be set according to the patient's maximum tolerance and muscle twitching and continued until the end of the surgery
223996262|NCT01469520|DRUG|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
224123094|NCT04573452|DIAGNOSTIC_TEST|Placental Galactin-3|Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
223996263|NCT01469520|DRUG|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
224123095|NCT00133237|DEVICE|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
224123096|NCT00133237|DEVICE|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
224123097|NCT01051986|PROCEDURE|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
224123098|NCT01051986|PROCEDURE|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
223996264|NCT01469520|DRUG|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
223545170|NCT06716684|BEHAVIORAL|Cognitive-Behavioral Approach Based Psychoeducation Program|A 6 session cognitive-behavioral approach based psychoeducation program developed in line with the literature review is applied in the research. Group training sessions have been held once a week with each session 90 minutes on average. The techniques such as automatic thought recording, finding cognitive errors, thought-stopping, forming alternative thoughts, daydreaming, countdown, problem solving, role playing, modeling, deep breathing, relaxation exercises, summarizing, explaining, informing, homework were used in the sessions.
223996265|NCT06920914|OTHER|Low-potassium, ultra-processed diet|A diet restricted in potassium, primarily composed of industrially processed foods such as packaged snacks and processed meals.
224123099|NCT00556218|BEHAVIORAL|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
224123100|NCT00556218|BEHAVIORAL|No Meditation|No meditation; usual care.
224123101|NCT02728258|DRUG|Copanlisib|Given IV
224299119|NCT04375852|DIAGNOSTIC_TEST|Detection of autoantibodies|Blood was obtained from each patient for testing the endocrine functions and determination of a panel of autoantibodies to the following: Side-chain cleavage enzyme (SSC), Aromatic L-amino acid decarboxylase (AADC), Tryptophan hydroxylase (TPH),Tyrosine hydroxylase ( TH), 17α-hydroxylase (17α-OH), Cytochrome P450 1A2 (CYP1A2), 21-hydroxylase (21-OH), Potassium channel regulatory protein (KCNRG), Tyrosine phosphatase-like protein IA-2 (IA-2), Glutamic acid decarboxylase 65 (GAD65), NACT Leucine-Rich-Repeat-Protein 5 (NALP5), and Interleukin (IL) 22.
223996266|NCT06920914|OTHER|Low-potassium, minimally processed diet|A diet restricted in naturally occurring potassium, primarily composed of fresh fruits, vegetables, whole grains, and other minimally processed foods.
223996267|NCT06920914|OTHER|Normal potassium-rich, minimally processed diet|A diet with normal potassium content, primarily composed of fresh fruits, vegetables, whole grains, and other minimally processed foods, rich in naturally occurring potassium, following a Mediterranean-style pattern.
223996268|NCT06920914|OTHER|Normal potassium-rich, ultra-processed diet|A diet with normal potassium content, primarily composed of industrially processed foods such as packaged snacks and processed meals
223996269|NCT04340934|DEVICE|REZUM system|Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
224123102|NCT02728258|OTHER|Laboratory Biomarker Analysis|Correlative studies
224123103|NCT02928549|BEHAVIORAL|semi-structured interviews|
224123104|NCT02145923|PROCEDURE|Peripheral blood stem cell mobilisation and collection|
224123105|NCT02145923|DRUG|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
224123106|NCT02145923|DRUG|Bone marrow derived allogeneic MMSCs infusion|
224123107|NCT02145923|PROCEDURE|Autologous peripheral blood stem cells infusion|
224123108|NCT05728086|OTHER|Group art therapy|The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
224123109|NCT02273752|DRUG|Everolimus|Given PO
224123110|NCT01503060|BEHAVIORAL|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
224123111|NCT01503060|BEHAVIORAL|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
224123112|NCT01503060|DRUG|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
224123113|NCT01503060|DRUG|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
224123114|NCT01503060|DRUG|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
223996270|NCT06927284|OTHER|Neurocognitive Therapy with Soft Robotic Hand|There will be 23 participants received Neurocognitive Therapy with soft robotic hand . Total 45 minutes session will be provided to patient including 15 minutes of routine physical therapy training for upper limb. The following hand exercises will be performed . Passive localization, passive identification, and active object exploration .For localization placed a part of the patient's limb, typically the fingertip, on one external object (e.g. sand paper, toothpick, sponge, paint brush, cotton ball, pencil, eraser ) and for identification water bottle, sponge, toothpaste tube, electrical plug, plastic ball, paper cup, tape roll, metal bolt with nut, tape roll . During active exploration the The training object repositioned, and another object of a different shape or size offered (water bottle, water bottle with ice in it, sponge. The blindfolded patient then used his effected hand to explore different objects and asked to identify each object with soft robotic hand.
224123115|NCT01503060|DRUG|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
223996271|NCT06927284|OTHER|Neurocognitive Therapy without Soft Robotic Hand|There will be 23 participants received Neurocognitive Therapy without soft robotic hand . Total 45 minutes session will be provided to patient including 15 minutes of routine physical therapy training for upper limb. The following hand exercises will be performed . Passive localization, passive identification, and active object exploration .For localization placed a part of the patient's limb, typically the fingertip, on one external object (e.g. sand paper, toothpick, sponge, paint brush, cotton ball, pencil, eraser ) and for identification water bottle, sponge, toothpaste tube, electrical plug, plastic ball, paper cup, tape roll, metal bolt with nut, tape roll . During active exploration the The training object will be repositioned, and another object of a different shape or size will be offered (water bottle, water bottle with ice in it, sponge. The blindfolded patient then used his effected hand to explore different objects and asked to identify each object .
223996272|NCT00170287|PROCEDURE|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
223996273|NCT00170287|DEVICE|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
223996274|NCT04198493|DEVICE|CPAP|CPAP treatment every night plus conservative treatment for OSA: sleep hygiene and dietary counseling
223996275|NCT04198493|OTHER|CONSERVATIVE TREATMENT for OSA|Conservative treatment for OSA: sleep hygiene and dietary counseling
223996276|NCT06938776|BEHAVIORAL|Musical Toy (Xylophone)|Children in this group will play with a colorful xylophone toy for 5 minutes before and during peripheral intravenous cannulation. A nurse (researcher) will assist the child in playing with the toy to distract them from the procedure. The toy will be cleaned between uses. This non-pharmacological method aims to reduce pain and fear.
224123116|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Conventional free gingival graft was applied to the area of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
224123117|NCT04970524|PROCEDURE|Comparison of conventional free gingival graft versus partial free gingival graft|"Partially de-epithelialized free gingival graft was applied to the other region of the patient with attached gingival insufficiency determined by randomization.~Clinical and aesthetic comparisons were made in the postoperative 1st, 3rd and 6th months."
223379881|NCT06184399|DRUG|Ivermectin 1.5 mg ODT|Oro-dispersible tablets of 1.5 mg ivermectin
223379882|NCT06184399|DRUG|Ivermectin 3 mg Oral Tablet|Tablets of 3 mg ivermectin
224138392|NCT06192953|OTHER|Functional Proprioceptive Stimulation|Orthoses with a system of 12 stimulators producing mechanical oscillations are attached to the joints of the upper limbs (wrist, elbow and shoulder) or lower limb joints (ankle, knee, hip). These stimulators, which are all synchronized, deliver mechanical oscillations (FPS) that give the illusion of complex movements, while the patient is bedridden, neither moving nor producing effort.
224138393|NCT01784952|DIETARY_SUPPLEMENT|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
223996277|NCT06938776|OTHER|Standard Care (in control arm)|Children in this group will receive routine peripheral intravenous cannulation according to standard hospital protocols. No distraction or behavioral intervention will be applied.
223996278|NCT06939686|DEVICE|Miro3D Wound Matrix|Miro3D is a sterile, acellular, three-dimensional biologic wound matrix derived from porcine liver via perfusion decellularization and drying. It is trimmed to fit the wound and rehydrated with sterile saline or Lactated Ringer's solution before application. It provides a porous scaffold to support granulation and healing in chronic or post-surgical wounds.
223996279|NCT06939686|OTHER|Standard of Care (SOC)|SOC includes standard wound care practices such as wound cleansing, debridement, infection management (if applicable), use of protective dressings (e.g., Aquacel or foam covered with Adaptic), and offloading devices (e.g., Foot Defender boot) to relieve pressure on the wound.
223379883|NCT06184399|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
223379884|NCT06184399|DRUG|Placebo Ivermectin ODT|Placebo for ivermectin ODT
223996280|NCT06941701|OTHER|Mild-intensity physical fatigue|Participants will undergo mild-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 50-60% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce mild physiological stress while maintaining safety and feasibility for all participants.
223996281|NCT06941701|OTHER|Moderate-intensity physical fatigue|Participants will undergo Moderate-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 60-70% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce mild physiological stress while maintaining safety and feasibility for all participants.
223996282|NCT06941701|OTHER|High-intensity physical fatigue|Participants will undergo High-intensity physical fatigue through a structured treadmill training protocol. The training will be conducted within a target heart rate range of 70-80% of their maximum heart rate (HRmax), ensuring controlled and consistent exercise intensity. This approach aims to induce sufficient physiological stress while maintaining safety and feasibility for all participants.
223996283|NCT06944080|OTHER|base material(Tetric® N-Flow,Beautifil-Flow PLUS,GC fuji II LC capsule)|subgingival restoration, deep marginal elevation procedure with different base materials will be applied then plaque index, gingival index, probing depth, clinical attachment level and biochemical marker will be measured at base line and after 3 months.
224123118|NCT04695106|DRUG|Ticagrelor|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months.
224123119|NCT04695106|DRUG|Dabigatran Etexilate|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
224123120|NCT04695106|DRUG|Aspirin|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
223379886|NCT06365736|BEHAVIORAL|Contemplating in nature|"Participants will spend 30 minutes in nature per day for 10 times over 14 days.~Each time, participants will walk for 10 minutes and then choose a nice spot to sit for 10 minutes. During these minutes they will be asked to be silently present and observe trees, plants, flowers or other aspects of nature and contemplate their connectedness to nature and their own awareness. Then walk back 10 minutes."
223379887|NCT02570594|OTHER|questionary|
223996284|NCT06945484|OTHER|Precision Exercise Regimen for Cancer Care (PERCC)|PERCC has exercise modes including basic transfer and calisthenics mobility, aerobic, and resistance exercises, and will be performed in various postures (supine, sitting, standing, and walking) with variable challenges (level walking, bending, inclines, steps, and squatting). Each participant will complete one supervised, home-based exercise training session per week, delivered through telehealth, that will focus on the resistance exercise prescription. Other unsupervised exercise training sessions will focus on the aerobic exercise prescription and will be completed individually
223996285|NCT06945744|OTHER|Standard Treatment|The control group followed a standard diabetic habitual diet
224123121|NCT04695106|DRUG|Clopidogrel|Within 72 hours post PCI, patients will be randomized in a 1:1 ratio to receive one of the two treatments: dual therapy with ticagrelor (90 mg twice daily for one month, followed by 60 mg twice daily up to 12 months) plus dabigatran (150 mg twice daily or 110 mg twice daily; standard of care) or triple therapy with clopidogrel (75 mg once daily) plus aspirin (75 mg once daily) plus dabigatran (150 mg twice daily or 110 mg twice daily), according to current guidelines. Study treatment will be continued for 12 months
224138394|NCT01365377|OTHER|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
223379894|NCT01625988|DRUG|LY2951742|
224123122|NCT03628417|PROCEDURE|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
223996286|NCT06945744|DEVICE|Carbohydrate|"Eligible participants provided informed consent and underwent baseline assessments, including demographics, medical history, insulin doses, and fasting blood samples for HbA1c and lipid profile. Participants used the FreeStyle Libre 2 sensor, with AGP data collected bimonthly. The primary outcome was Time in Range (TIR, 70-180 mg/dL), while secondary outcomes included TAR, TBR, GV%, GMI, HbA1c, and BMI.~A registered dietitian provided structured CHOC-BC education. The intervention group used the CHOC-BC app, validated against expert-calculated carbohydrate counts, while the control group followed standard diabetes education. Virtual follow-ups occurred bimonthly for three months. At study completion, HbA1c, lipid profile, insulin doses, weight, and AGP data were collected for comparison."
223996287|NCT02401659|DEVICE|CareLinK|
223996288|NCT00769457|DEVICE|Access Arm|Active OptiVol-System with CareAlert via CareLink
223996289|NCT01165606|PROCEDURE|Chest physiotherapy|
223996290|NCT05274204|DRUG|CA102N|
223996291|NCT01551797|DRUG|Paracetamol 500 mg|Standard Paracetamol formulation
223996292|NCT01551797|DRUG|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
223996293|NCT01551797|DRUG|Paracetamol 750 mg|Paracetamol Sustained Release formulation
224123123|NCT03628417|PROCEDURE|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
224299120|NCT02893137|DEVICE|Optune|For further information see www.optune.com
223379895|NCT01625988|DRUG|Placebo|
223996294|NCT00730548|BEHAVIORAL|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
223996295|NCT06371976|OTHER|Blood sampling|Blood samples of 5 mL are taken at 4 stages of the study. Samples are taken from an arterial catheter inserted as part of the treatment, for a total volume of 20 mL maximum for the study.
223996296|NCT06371976|OTHER|Vital status|Patients will be followed until their discharge from intensive care, or at most until D28, and their vital status will be collected at the end of their participation in the study.
223996297|NCT04715984|OTHER|Neurophysiology recordings|Neurophysiology recordings will be performed during deep brain stimulation surgery and their relationship to performance on a gambling task evaluated
223996298|NCT04715984|OTHER|Neural stimulation|Neural stimulation will be delivered during a gambling task and its impact on task performance quantified
223996299|NCT05636774|DRUG|Heart failure medication|Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
223996300|NCT05636774|DRUG|Placebo|Placebo tables / infusion
223996301|NCT06325917|BEHAVIORAL|what's app ongoing support|"daily educational messages and reminders sent through WhatsApp. The educational material related to diabetes self-management behaviors (AADE7 Self-Care Behaviors, diabetes and genetics, and endocrinology center, also the Ministry of Health in Jordan diabetes.~individual bidirectional communication between the participants and the investigator, which will allow participants to seek advice and get free-of-charge feedback and consultation."
223996302|NCT06325917|BEHAVIORAL|usual care|monthly visit and follow-up at the diabetes education clinic by a diabetes nurse specialist providing DSMES
224295400|NCT03757273|PROCEDURE|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
223379907|NCT01644617|DRUG|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
223379908|NCT01644617|DRUG|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
223379909|NCT01644617|DRUG|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
223996303|NCT02319473|OTHER|JAC Registry|patients who received acute reperfusion therapy
223996304|NCT03402698|DIETARY_SUPPLEMENT|cholecalciferol|supplementation at a dose 1000 IU/d
223379918|NCT04237272|OTHER|Pod System E-cig|Participants assigned to this intervention will try to pod system e-cigarette in the lab and receive a pod system e-cigarette to use for a three week sampling period.
223379919|NCT04237272|OTHER|Customizable Tank E-cig|Participants assigned to this intervention will try to customizable tank system e-cigarette in the lab and receive a customizable tank system e-cigarette to use for a three week
223379920|NCT04237272|OTHER|Control|Participants will not receive any e-cigarette
223379921|NCT05726786|DRUG|Immunonutrition|"Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag"
223996305|NCT04991753|OTHER|Placebo|Placebo infusion will be administered intravenously.
223996306|NCT04991753|DRUG|Nipocalimab|Nipocalimab infusions will be administered intravenously.
223996307|NCT03080948|BEHAVIORAL|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
223996308|NCT03080948|OTHER|Saliva samples|Germline DNA analysis
223996309|NCT00993005|OTHER|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
223996310|NCT00993005|OTHER|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
223996311|NCT01848613|DRUG|Vinorelbine|
223996312|NCT05357976|PROCEDURE|Thoracic Paravertebral Block|Thoracic paravertebral block will be applied to the patients under real-time ultrasound guidance.
223996313|NCT00783276|DRUG|SYN115|100 mg single dose
223996314|NCT00783276|DRUG|PLACEBO|PLACEBO
223996315|NCT02696876|DEVICE|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
224295401|NCT01947231|OTHER|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
223379935|NCT00325871|PROCEDURE|concurrent chemoradiation|
223379936|NCT05223920|DRUG|Bomedemstat|Capsule (oral)
223379940|NCT03443531|DRUG|Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
223729693|NCT01881776|PROCEDURE|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
223729694|NCT01037647|OTHER|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
223729695|NCT02190084|DEVICE|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
223996316|NCT02696876|PROCEDURE|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
223996317|NCT04673266|DRUG|Romiplostim|All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
224295402|NCT01947231|OTHER|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
223379941|NCT03443531|DRUG|Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
223379942|NCT03443531|DRUG|Placebo Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
223379943|NCT03443531|DRUG|Placebo Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
223379944|NCT04766112|OTHER|Group I|Group I will receive yang style Tai chi exercises combined with mental imagery training
223379945|NCT04766112|OTHER|Group II|Group II will receive yang style Tai chi exercise which consist of 10 positions.
223996318|NCT03518190|DEVICE|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
223996319|NCT02812095|PROCEDURE|Refeeding|when amount of feeding reach to 120mL/kg a day,
223996320|NCT06556433|BEHAVIORAL|Financial Incentive Rewards|Participants in the Rewards Group will have abstinence reinforced through escalating financial incentives.
223996321|NCT03956251|PROCEDURE|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
223996322|NCT03956251|PROCEDURE|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
223996323|NCT02575716|DEVICE|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
223996324|NCT04220398|DRUG|Neoadjuvant chemotherapy combined with hormone therapy|Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
223996325|NCT04220398|DRUG|Neoadjuvant hormone therapy|HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
223996326|NCT04220398|PROCEDURE|Radical Prostatectomy (RP)+ extended lymph node dissection|"Radical Prostatectomy (RP)+ extended lymph node dissection: Within three months after neoadjuvant treatment.~Treatment after prostatectomy: There will not have any drug treatment after surgery until disease progression.~Pelvic lymph node dissection is required to reach the level of bilateral iliac artery. If the postoperative pathology indicated positive incisional margin or pelvic lymph node metastasis, pelvic adjuvant radiotherapy should be performed within 3 months after surgery."
223996327|NCT03923517|DEVICE|RHAPSODY online program and MEET online sessions|"internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).~MEET is a software for online meetings."
223996328|NCT01079351|DRUG|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
223996329|NCT01516255|DRUG|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
223996330|NCT01516255|DRUG|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
223996331|NCT01516255|DRUG|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
223996332|NCT01516255|DRUG|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
224123124|NCT03263936|DRUG|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over \_\_ hour on days 1 through 5
224123125|NCT03263936|DRUG|Vorinostat|Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
223729696|NCT03484481|DIETARY_SUPPLEMENT|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. \]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
224123126|NCT03263936|DRUG|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
223379961|NCT01095302|DRUG|OMBRABULIN (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
223379962|NCT01095302|DRUG|cisplatin|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
223379963|NCT01095302|DRUG|docetaxel|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
223996333|NCT01516255|PROCEDURE|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
223996334|NCT01516255|PROCEDURE|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
223996335|NCT03455257|BEHAVIORAL|Cash Transfer|The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
223996336|NCT03299049|DRUG|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
223379968|NCT03723356|DIAGNOSTIC_TEST|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
223379969|NCT03723356|DIAGNOSTIC_TEST|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
223379970|NCT03723356|DIAGNOSTIC_TEST|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
223996337|NCT03299049|DRUG|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
224123127|NCT03263936|DRUG|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
224123128|NCT03263936|DRUG|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
224123129|NCT06163794|OTHER|Nutritional postprandial test|Metabolic responses to several test meals
224123130|NCT06540859|DEVICE|Transcutaneous Spinal Cord Stimulation|Non-invasive electrical stimulation of the spinal cord over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver 1ms pulses with 10kHz carrier frequency at 30 Hz, which has demonstrated autonomic recovery in our previous studies. The location of tSCS is predetermined (at T10 and T11 vertebral levels). The stimulation intensity will range from 10 to 200 mA and specific criteria will be followed to determine the optimal therapeutic stimulation.
224123131|NCT06540859|DEVICE|Sham Stimulation|Non-invasive electrical stimulation of a lower extremity muscle group over the skin. A portable tSCS device, SCONE or TESCoN (SpineX Inc., USA), whichever available, will be used to deliver sham stimulation. The intensity of electrical stimulation will be briefly ramped up to a level at which the participants report perceiving the stimulation (i.e., sensory threshold), then ramped down and turned off for the remainder of the intervention.
223379976|NCT03439956|PROCEDURE|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
224123132|NCT05948722|BEHAVIORAL|Motivational Interview Group (MIG)|Brief MI intervention with the conventional treatment
223379980|NCT03586089|DRUG|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
223379981|NCT03586089|DRUG|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
223996338|NCT03299049|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
223996339|NCT03299049|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
223996340|NCT05559970|DRUG|Inhalational sedation|Inhalational sedation with isoflurane for 12 hours
223996341|NCT05559970|DRUG|Convention sedation|Conventional sedation receiving analgosedation with fentanyl
223996342|NCT01901419|DRUG|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
223996343|NCT03683303|BEHAVIORAL|mobile applications (APP)|"the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses."
223996344|NCT03683303|BEHAVIORAL|oral education|"the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
224123133|NCT05948722|PROCEDURE|Conventional treatment group (CTG)|Conventional treatment
223996345|NCT02296502|OTHER|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
224123134|NCT04085445|DEVICE|AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter|To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
223996346|NCT02639039|DRUG|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
223996347|NCT02639039|PROCEDURE|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
223996348|NCT03712878|RADIATION|Total-Body Irradiation|Undergo TBI
223996349|NCT03712878|PROCEDURE|Donor Lymphocyte Infusion|Given IV
224123135|NCT02297438|DRUG|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
224123136|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
224295403|NCT04715360|COMBINATION_PRODUCT|autologous activated platelet-rich plasma|Patient received standard medication for COVID-19 management and autologous activated platelet-rich plasma on day 1, 3 and 5 while patient in ICU. On day 0, 4 and 6, hematology analysis, multicytokines measurement and thorax X-ray were done to each patient
224295404|NCT04715360|DRUG|Avigan|Patient received avigan 2x1,600 mg for a day, followed by 2x600 mg for five consecutive days.
223996350|NCT03712878|DRUG|Cyclophosphamide|Given IV
223996351|NCT03712878|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223996352|NCT03712878|DRUG|Tacrolimus|Given IV
224123137|NCT02297438|DRUG|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
224123138|NCT02297438|DRUG|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
224123139|NCT01816646|DRUG|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
224295405|NCT00165230|DRUG|Thalidomide|
223379988|NCT04522726|DRUG|Weiyang Yuping Fang|Weiyang Yuping fang is a combination of the classic ancient Yuping dispersion used to prevent qi deficiency and susceptibility and Bushen Naqi granules optimized formated by Professor Shao Changrong's experience in treating chronic cough and asthma.
223996353|NCT03712878|DRUG|Mycophenolate Mofetil|Given IV
223996354|NCT05677386|DIAGNOSTIC_TEST|Primary preventive treatment guided by CTCA|Computed tomography coronary angiography (CTCA)
223996355|NCT05677386|OTHER|Cardiovascular risk Score|Systematic COronary Risk Evaluation 2 model for cardiovascular risk prediction
224123140|NCT01816646|DRUG|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
224123141|NCT03009656|OTHER|No study specific interventions|
223379992|NCT01656057|DRUG|Acetaminophen|Acetaminophen dissolved in 50 ml of water
224295406|NCT00165230|DRUG|Temodar|
224295407|NCT03431974|DRUG|LD-Aminopterin oral capsule|anti-folate treatment
223996356|NCT06503484|DEVICE|Brain-computer interface|Patients will perform kinesthetic motor imagery of the affected upper extremity in response to auditory cues from the BCI system. The averaged oxygenated hemoglobin (HbO) level, extracted from optimal channels identified during the localizer session, will serve as signal intensity. This intensity, quantified as percent signal change relative to baseline, will trigger neurofeedback when reaching a predefined threshold. Visual feedback, delivered via the digital mirror therapy system, will guide patients to perform observational imitation tasks using bilateral upper extremities. Each session will include 5-6 movements tailored to the patient's functional performance. After observational imitation training, patients will practice functional adaptation tasks in a virtual environment, where they apply learned movements to functional activities. Sessions will last approximately 75 minutes.
223996357|NCT06503484|DEVICE|Sham brain-computer interface|In the sham group, patients will wear a similar headset equipment as those in the BCI group. However, the visual feedback provided through the digital mirror therapy system will not be based on their own brain activity. Instead, it will be derived from the brain activity of a participant in the BCI group using the simulation mode of Turbo-Satori. Patients in the sham group will receive constant visual feedback, with a fixed duration of 60 seconds for motor imagery, regardless of their actual brain signals. Like the BCI group, patients will be instructed to use kinesthetic motor imagery and imitate the movement when receiving visual feedback, and practice functional adaptation tasks after observational imitation training. The sham training will also last for around 75 minutes per session.
223996358|NCT05271344|DIETARY_SUPPLEMENT|Nutritional Products|Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
223379993|NCT01656057|DRUG|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
223379994|NCT01656057|DRUG|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
223996359|NCT05121389|DRUG|normal saline|Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
223996360|NCT03274115|DEVICE|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
223996361|NCT06832540|DRUG|[14C]TJ0113|Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.
223996362|NCT04112706|DRUG|CPP-ACP|CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
223996363|NCT05257447|DRUG|Baclofen 20 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
223996364|NCT05257447|DRUG|Chlorzoxazone 500 mg Tablet|Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
223996365|NCT05257447|DRUG|Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet|Concurrent single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
223996366|NCT04706936|BIOLOGICAL|anti-BCMA CAR-T|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
224123142|NCT04972071|OTHER|Knowledge translation (KT) of the CSRS based practice recommendations|The components of the practice recommendations include: 1) evidence-informed systematic clinical evaluation with appropriate history, physical examination and in-ED investigations (e.g., troponin testing, work-up for pulmonary embolism and CT head) for detecting serious underlying conditions and predicting 30-day serious outcomes; 2) application of the CSRS for risk-stratification at the end of ED visit after no serious underlying conditions for the syncope were identified; 3) use of patient information materials to aid in disposition; and 4) the use of 15-day outpatient cardiac monitoring for CSRS medium and high-risk patients upon ED discharge. All the components of the practice recommendations will be applied by the ED physician treating the patient.
223379995|NCT01656057|OTHER|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
223379996|NCT01656057|OTHER|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
223996367|NCT04706936|DRUG|Cyclophosphamid|300mg/m2/d
223996368|NCT04706936|DRUG|Fludarabine|30mg/m2/d
223996369|NCT01667926|DRUG|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
223996370|NCT01667926|DRUG|Placebo|
223996371|NCT00558922|DRUG|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
223996372|NCT03572647|DRUG|Eritromax|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
223996373|NCT03572647|DRUG|Eprex|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
223996374|NCT05311722|DRUG|Dexmedetomidine|Inj dexmedetomidine, will be given in infusion over 10 mins and their effect on post spinal shivering will be assessed.
223996375|NCT05311722|DRUG|Ketamine|Ketamine
223996376|NCT05311722|DRUG|Tramadol|Tramadol
223996377|NCT03360734|DRUG|First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab)|Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
223996378|NCT01798875|DRUG|oral metformin|
223996379|NCT01798875|DRUG|oral contraceptive|
224295408|NCT03431974|DRUG|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
223996380|NCT02084758|DIETARY_SUPPLEMENT|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
223996381|NCT02084758|DIETARY_SUPPLEMENT|Placebo supplementation|7 days of supplementation with sodium chloride solution
223996382|NCT03774615|DRUG|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
223379997|NCT02281422|DRUG|BIA 2-093|
223996383|NCT01833377|DIETARY_SUPPLEMENT|caraway sample|
223996384|NCT01833377|DIETARY_SUPPLEMENT|placebo|
223996385|NCT04651140|BEHAVIORAL|aerobic exercise|Participants ride an Acon-8650 model exercise bicycle 3 times a week for 1 hour each time for four consecutive weeks
223996386|NCT04127981|DIAGNOSTIC_TEST|18F-FDG PET + Dexa Scan|18F-FDG PET will be compared with Dexa Scan result within and between arms.
223996387|NCT04467918|DRUG|Cannabidiol|Already described
223996388|NCT04467918|OTHER|PLACEBO|Already described
223996389|NCT01908504|OTHER|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
223996390|NCT01202149|DEVICE|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
223996391|NCT00623259|BIOLOGICAL|MVA-mBN120B|
223996392|NCT04523675|DIETARY_SUPPLEMENT|N-acetylcysteine|Orally in three daily dosages (morning-midday-evening), at 20 mg/kg/day, for seven consecutive days.
223996393|NCT04523675|DIETARY_SUPPLEMENT|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder. Orally in three daily dosages (morning-midday-evening), for seven consecutive days.
223996394|NCT03591484|RADIATION|Photodynamic therapy|Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
223996395|NCT03591484|DEVICE|Treatment with tongue scraper|Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
223996396|NCT03591484|PROCEDURE|Periodontal treatment|Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
223996397|NCT03591484|PROCEDURE|hygiene procedures for the mucosa and dentures|edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
223996398|NCT01225653|DRUG|Latanoprost|Topical application
223996399|NCT00506246|DRUG|Propofol|"* intravenous (total intravenous anaesthesia)~* induction and maintenance"
223996400|NCT03485664|PROCEDURE|tooth extraction|tooth extraction
223380003|NCT03362814|DRUG|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
223996401|NCT02412735|DRUG|Rexlemestrocel-L|Rexlemestrocel-L injection
223996402|NCT02412735|DRUG|Rexlemestrocel-L + HA Mixture|Rexlemestrocel-L was combined in 1:1 by-volume ratio with HA solution and the resulting mixture was injected
223996403|NCT02412735|DRUG|Placebo|Saline control solution
223996404|NCT02468362|PROCEDURE|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
223996405|NCT02468362|PROCEDURE|open intersphincteric resection|
223996406|NCT00234702|DRUG|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
223996407|NCT00234702|DRUG|Placebo|Placebo
224123143|NCT02713230|DRUG|bupivacaine liposome injectable suspension|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline
224123144|NCT02713230|DRUG|bupivacaine liposome injectable suspension|20 mL EXPAREL (bupivacaine liposome injectable suspension)
223996408|NCT02566057|BIOLOGICAL|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
223996409|NCT00876824|DRUG|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
223996410|NCT00876824|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
223996411|NCT04717453|OTHER|No Intervention|No Intervention
223996412|NCT03171662|OTHER|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
223996413|NCT04508855|DRUG|Low molecular weight heparin|Switch from direct oral anticoagulants to low molecular weight heparin
223996414|NCT04075877|BEHAVIORAL|FOCUS|See prior section.
223996415|NCT00136877|PROCEDURE|(adeno)tonsillectomy|
223996416|NCT04361955|OTHER|EMG|recordings of muscle electrical activity during nerve stimulation using EMG
223996417|NCT04361955|OTHER|EEG|recordings of brain activity using EEG
223996418|NCT04462783|OTHER|Symptoms entered into the CovidX application|Participants are asked to enter symptoms into the CovidX application at least daily for 30 days. Additionally, they will enter demographic information and some survey information will be collected.
224123145|NCT02713230|DRUG|Placebo|20 mL normal saline as single-injection
224138395|NCT04799951|OTHER|a survey questionnaire to find knowledge, attitude and practices in treatment of breast cancer.|an electronic webbased survey to assess knowledge, attitudes and practices amongst surgeons with regards to breast conservation surgery and mastectomy
223996419|NCT00449267|DEVICE|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
223380004|NCT03362814|DRUG|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
223380005|NCT03362814|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
223380006|NCT03362814|DRUG|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)
223380007|NCT03362814|DRUG|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
223380008|NCT03362814|DRUG|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
223380009|NCT03362814|DRUG|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
223380010|NCT03362814|DRUG|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)
223380012|NCT05585203|BEHAVIORAL|Contingency management|"The investigators will implement a prize-based contingency management protocol in which residents will complete three pre-planned recovery-oriented activities each week for a period of up to 12 weeks. Upon verified completion of the activities each week, participants may earn prize incentives through drawing from a prize fishbowl or spinning a virtual prize wheel.~Prizes will be money added to a debit card. On the first week and individual has completed pre-planned activities, s/he can receive up to 1 draw per activity completed (3 total), and each week the number of prize draws per activity will escalate by 1. If a participant fails to complete any activities, he/she will not receive the draws for the uncompleted activities, and the prize draws would be reset to 1 in the next week. Participants can earn up to $75 in incentives in total."
223380013|NCT05585203|BEHAVIORAL|Usual Care|Participants in this arm will receive usual care that they would normally receive at the recovery houses. Recovery residences vary considerably, this form of housing benefits individuals in recovery by reinforcing a substance-free lifestyle and providing direct connections to other peers in recovery, mutual support groups and recovery support services.
223996420|NCT00348270|DEVICE|Tecnis Z9000 intraocular lens|
224295409|NCT03196674|OTHER|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
224295410|NCT00869986|DRUG|dirucotide|500mg, intravenous, every 6 months for 15 months
224295411|NCT00869986|DRUG|placebo|intravenous, once every six months for 15 months
224295412|NCT03440541|COMBINATION_PRODUCT|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
223380014|NCT03154125|DRUG|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
224295413|NCT02939014|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
224295414|NCT03436914|DRUG|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
223380017|NCT06333418|DEVICE|Virtual Reality Glasses Group|Before the colonoscopy procedure, 360-degree VR video scenes will be watched to patients 30 minutes using VR head device.
223996421|NCT00348270|DEVICE|MA60 intraocular lens|
223996422|NCT04043143|OTHER|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
223996423|NCT04043143|OTHER|Arm 2 Prescription Tool Intervention|The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
223996424|NCT03480932|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
224295415|NCT05183295|OTHER|NEAAR Medical Food|Standardized non-essential amino acid restricted medical food
224295416|NCT03515902|DEVICE|mouthguard|mouthguard
224295417|NCT03515902|DEVICE|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
224295418|NCT01806038|OTHER|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
223380018|NCT06333418|DEVICE|Glass waterfall|Before the colonoscopy procedure, patients will watch and listen 30 minutes a portative glass waterfall
223996425|NCT03480932|DRUG|Daclatasvir|Direct acting antiviral agent used for the treatment of hepatitis C
223996426|NCT03480932|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
223996427|NCT00254826|BIOLOGICAL|YF-VAX® plus saline|YF-VAX® plus saine
223380023|NCT06128408|DRUG|risperidone, olanzapine, aripiprazole|Participants from the retrospective cohort were randomly assigned to one of the three drug groups of risperidone, olanzapine and aripiprazole for a period of 1 years of treatment.
223380035|NCT00810511|DEVICE|Lotrafilcon A contact lens|Silicone hydrogel contact lens
223380036|NCT00810511|DEVICE|Comfilcon A contact lens|Silicone hydrogel contact lens
223545171|NCT06718504|DEVICE|Virtual Reality Glasses|Virtual reality is a method that can be used to distract and prepare patients for medical procedures. Virtual reality is a computer-generated environment where three-dimensional interaction is possible. It is an advanced technology that allows an individual to move into a virtual environment and focus their attention on other thoughts, allowing them to pay less attention to pain and anxiety. In this study, the virtual reality glasses were put on for the intervention group five minutes before the procedure began and were kept on until the procedure was completed. The virtual reality glasses showed the patient-selected images of a relaxing nature setting or images without any violent content.
223545172|NCT06717984|DIAGNOSTIC_TEST|Biopsy, Mastectomy, Histopathology|"Biopsy:~This intervention involves the collection of breast tissue samples through a biopsy procedure. These samples are obtained from women undergoing investigation for unusual cell growth and are analyzed to detect potential abnormalities, including benign, in situ, or invasive cancerous changes.~Mastectomy:~This intervention refers to the surgical removal of breast tissue, typically performed to treat or prevent the spread of breast cancer. It may involve the removal of part or all of the breast and is considered in cases of invasive breast cancer or high-risk noninvasive breast cancer.~Histopathology:~This intervention focuses on the microscopic examination of breast tissue samples collected through biopsy or mastectomy. Histopathological analysis is conducted to assess cellular abnormalities, determine the presence of cancer, and classify the tissue as benign, in situ, or invasive, providing the basis for diagnosis and treatment decisions."
223996428|NCT00254826|BIOLOGICAL|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
223996429|NCT06134999|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA."
223996430|NCT06134999|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
223996431|NCT00703417|DEVICE|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
223996432|NCT00703417|DEVICE|Computed Tomography|CT scan of the lower back and hip
223996433|NCT00703417|DEVICE|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
223996434|NCT01409551|PROCEDURE|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
223996435|NCT01409551|PROCEDURE|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
223996436|NCT02535039|DRUG|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg \* d for application to the third day after surgery
223996437|NCT02535039|OTHER|Physiological saline|The same volume of physiological saline will be given in Placebo group
223996438|NCT04624243|DRUG|MK-8189|MK-8189 administered QD at a dose of 8 mg, 16 mg, or 24 mg via oral tablet.
223996439|NCT04624243|DRUG|Risperidone|Risperidone administered QD at a dose of 6 mg via oral capsule.
223996440|NCT04624243|DRUG|Placebo to MK-8189|MK-8189-matching placebo administered QD via oral tablet.
223996441|NCT04624243|DRUG|Placebo to risperidone|Risperidone-matching placebo administered QD via oral capsule.
223996442|NCT02552628|DEVICE|"Medtronic, Activa® PC on"|
223996443|NCT02552628|DEVICE|"Medtronic, Activa® PC off"|
223996444|NCT03561298|DRUG|BGB-3111 and Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
223996445|NCT05658003|DRUG|[177Lu]Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
223996446|NCT05658003|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
223996447|NCT05658003|DRUG|[68Ga]Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
223996448|NCT05658003|OTHER|Best supportive care|Best supportive/best standard of care as defined by the local investigator
223996449|NCT01546506|DRUG|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
223996450|NCT05293405|DIAGNOSTIC_TEST|18F-DPA-714 PET|TSPO expression are quantitatively analyzed in all brain regions or spinal cord using 18F-DPA-714 PET
223996451|NCT03494153|OTHER|Non applicable - Non interventional study|Non interventional study
223996452|NCT06508489|BIOLOGICAL|SAR443579|Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion
223996453|NCT06508489|DRUG|venetoclax|Pharmaceutical form :Film coated tablet Route of administration: oral
223996454|NCT06508489|DRUG|azacitidine|Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous
223996455|NCT03381872|PROCEDURE|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~1. Intravascular imaging arm~2. Angiography arm~   * Definition of Complex Lesions~     1. True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~    2. Chronic total occlusion (≥3 months) as target lesion~    3. PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~    4. Implanted stent length ≥38mm~    5. Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~    6. Multiple stent needed (≥3 more stent per patient)~    7. In-stent restenosis lesion as target lesion~    8. Severely calcified lesion (encircling calcium in angiography)~    9. Ostial coronary lesion (LAD, LCX, RCA)"
224123146|NCT02474940|BEHAVIORAL|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
223380044|NCT02325492|DRUG|Aramchol|
223380045|NCT02325492|DRUG|Placebo|
223380046|NCT02325492|DEVICE|Ultrasound|
223380047|NCT04177082|COMBINATION_PRODUCT|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
223729697|NCT03484481|DIETARY_SUPPLEMENT|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
223996456|NCT03381872|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
223996457|NCT03381872|DEVICE|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden \<50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: \[1\] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.~\[2\] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm."
223996458|NCT03381872|DEVICE|Drug-coated balloon|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.
223996459|NCT05878236|DIAGNOSTIC_TEST|CyTOF Analysis|CyTOF laboratory testing for cytokine levels to correlate with severity of acute pancreatitis
223996460|NCT02135562|DIETARY_SUPPLEMENT|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
223996461|NCT02135562|OTHER|Informational Material|Receive carbohydrate reintroduction handout
223380049|NCT01494116|OTHER|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
223996462|NCT02135562|OTHER|Dietary Education|Receive education on nutrition label reading for carbohydrates
223996463|NCT02135562|DIETARY_SUPPLEMENT|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
223996464|NCT02135562|OTHER|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
223996465|NCT06090721|DRUG|DMT310|Topical Powder
223996466|NCT06090721|DRUG|Placebo|Placebo Topical Powder
223996467|NCT00142090|DRUG|3% Hypertonic saline|
223996468|NCT00142090|DRUG|Placebo|Normal saline
223996469|NCT05176938|PROCEDURE|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients of the group will be placed supine and elevate arm to the head, Serratus intercostal plane block will be with the probe in the midaxillary line, The subcutaneous tissue and serratus muscle will be identified in the superficial plane, whereas the external intercostal muscles will be identified in the intermediate plane and finally in the deep plane the ribs, pleura and lung will be identified. The needle will be advanced from caudal to cranial direction after giving 3 ml lidocaine locally. In-plane technique was used until the tip of the needle placed between the serratus anterior muscle and the external intercostals muscle a volume of 20 ml plain bupivacaine will be injected.
223996470|NCT05176938|PROCEDURE|Ultrasound guided Erector Spinae plane Block (ESPB)|The patient will be placed in setting position and a superficial (5-12 MHz) ultrasound transducer will be placed in a longitudinal orientation, 3 cm lateral to the T4 spinous process. An 8-cm 22-gauge spinal needle will be inserted in cephalic direction after giving 3 ml lidocaine locally until the needle tip hit the transverse process of T4 under ultrasound image visualization, then the needle will be withdrawn slowly to be within the interfacial plane below the erector spinae muscle, then the anesthetic mixture will be injected here. Successful injection will be evidenced by visible linear free spread (cranially and caudally) of injectate below the muscle.
223996471|NCT04654949|OTHER|Horticultural Therapy|The horticultural therapy sessions are conducted by the occupational therapists or therapy assistants using the mobile horticultural kits. The horticultural activities are designed to stimulate the senses through interaction with specific tasks and the environment, promote social interaction, mobility and also promote a sense of self-worth through various horticultural activities such as planting seeds, transplanting plants, trimming and watering plants.
223996472|NCT03405675|OTHER|SLAS 1|NA. Observational study, no interventions administered.
224123147|NCT02474940|BEHAVIORAL|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
224295419|NCT01806038|OTHER|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
223996473|NCT03405675|OTHER|SLAS 2|NA. Observational study, no interventions administered.
224295420|NCT02599259|DEVICE|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
223380053|NCT03106675|DEVICE|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
223380054|NCT03106675|DEVICE|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
223729698|NCT01668550|DRUG|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
223729699|NCT00005610|BIOLOGICAL|sargramostim|
223996474|NCT01735903|PROCEDURE|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.~Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
223996478|NCT03181659|PROCEDURE|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
223996479|NCT03181659|PROCEDURE|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
223996480|NCT05005377|PROCEDURE|Socket Preservation with Platelet-Rich Fibrin|10cc of blood was drawn from each patient and centrifuged at 2700 revolutions per minute (rpm) for 12 minutes to obtain PRF. The extraction socket was filled with PRF and covered using a membrane made of PRF.
223996481|NCT05005377|PROCEDURE|Socket Preservation with Freeze-Dried Bone Allograft|The extraction socket was filled with FDBA (CenoBone®; Tissue Regeneration Corp., Kish Island, Iran) without flap elevation. The socket was covered using a free palatal mucosal graft obtained by the pouch technique.
223996482|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 25 mg.
223996483|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 50 mg.
223996484|NCT06539182|DRUG|DZD8586|Daily oral dose of DZD8586 at 75 mg.
223996485|NCT00285701|DRUG|hexaminolevulinate|
223996486|NCT03476759|PROCEDURE|Tubal adhesiolysis|125 patients will undergo tubal adhesiolysis or tuboplasty
223996487|NCT03476759|DRUG|IVF/ICSI|125 patients will undergo IVF-ICSI procedures.
223996488|NCT06650644|OTHER|Placebo of Lactococcus lactis KD10|"* Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
223996489|NCT06650644|DIETARY_SUPPLEMENT|Lactococcus lactis KD10 (health food)|"* Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals"
223996490|NCT02308397|OTHER|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
223996491|NCT02308397|OTHER|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
223996492|NCT02308397|OTHER|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
224123148|NCT02474940|BEHAVIORAL|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
224123149|NCT04257110|DRUG|BB-1701|BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.
224123150|NCT06236698|DIAGNOSTIC_TEST|24-hour urinary aldosterone measurement|Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
223729700|NCT03297996|DIAGNOSTIC_TEST|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
223729701|NCT01390311|DRUG|Azacitidine|
223996493|NCT02308397|OTHER|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
223996494|NCT01979406|BIOLOGICAL|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
223996495|NCT01979406|BIOLOGICAL|Ad4-PA-1|Ad4-PA will be given at 10\^9, 10\^10 and 10\^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
223996496|NCT01979406|BIOLOGICAL|Ad4-PA-GPI-1|"Given at 10\^9, 10\^10 and 10\^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
223996497|NCT04440020|OTHER|Beverage of Olive Oil Leaves|Beverage of Olive Oil Leaves,Oleuropein
223996498|NCT04440020|OTHER|Mediterranean Diet|Mediterranean Diet ,for a personal nutrition with the same dietary habits
223996499|NCT04420429|PROCEDURE|Descemet membrane endothelial keratoplasty (DMEK)|All participants underwent DMEK surgery
223996500|NCT00095277|DRUG|Darbepoetin Alfa|
223996501|NCT03078335|OTHER|Glove based care|Described in Experimental Arm: Glove based care
223996502|NCT03078335|OTHER|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
223996503|NCT03251053|DEVICE|Electronic cigarette use|Replacement of tobacco smoking with electronic cigarette vaping
223996504|NCT03251053|OTHER|Control regular cigarette smokers|
223996505|NCT04862442|OTHER|Qigong exercises|Specific Qigong exercises 1- Painting the rainbow 2-Raising the arms 3-Looking at the moon 4- Pushing the waves
223996506|NCT04370015|DRUG|Hydroxychloroquine|Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.
223996507|NCT04370015|DRUG|Placebo oral tablet|• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.
223996508|NCT06050616|OTHER|MRI scans|"Neuroimaging data will be collected with magnetic resonance imaging (MRI).~Structural neuroimaging will include T1 and T2-weighted scans, and diffusion tensor imaging (DTI).~Functional neuroimaging will include scans under the stop-signal task, monetary incentive delay task, and emotional faces task, and resting state."
223996509|NCT06050616|OTHER|Psychological measures|"Cognitive performance assessed by Wechsler Adult Intelligence Scale 4th Edition.~Personalities assessed by NEO Five-Factor Inventory (NEO-FFI), Substance Use Risk Profile Scale (SURPS), and Temperament and Character Inventory (TCI).~Other psychological assessments include Interpersonal Reactivity Index, Perceived Stress Scale, Kirby Monetary Choice Questionnaire, Passive Avoidance Learning Paradigm, and Stimulus-response compatibility."
223996510|NCT06050616|OTHER|Life experiences|Self-report questionnaires on experiences of bullying and trauma.
223996511|NCT06050616|BIOLOGICAL|Blood and urine samples|Blood and urine samples will be collected but will not undergo analysis in this study. Instead, these samples will be stored in a biobank for potential analysis in future research.
224295421|NCT01252875|PROCEDURE|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
223996512|NCT06050616|OTHER|Mental health symptoms|"Symptoms of depression measured by the Patient Health Questionnaire -8.~Symptoms of generalised anxiety, obsessives compulsive disorder, attention deficit hyperactivity disorder, social phobia, specific phobia, agoraphobia, post-traumatic stress disorder, measured by the Development and Well-Being Assessment (DAWBA).~Harmful drinking measured by the Alcohol use disorders identification test.~Drug use measured by the European School Survey Project on Alcohol and Other Drugs (ESPAD).~Suicide risk measured by the the Mini International Neuropsychiatric Interview."
223996513|NCT06147297|BEHAVIORAL|Tuned In|The Tuned In programme is based on Russell's (1980) circumplex model of emotion, which categories emotions along the two dimensions of valence and arousal. Through psychoeducation and group discussions, participants in the programme first learn how to categorise their emotions in terms of intensity (i.e., arousal level) and positivity (i.e., valence). They then reflect on and develop a list of songs that they relate to personally and use them to increase or decrease the intensity and positivity of their emotions. In other words, the participants practise monitoring their emotional state and use music to help them modify how they feel. The programme will be conducted by a facilitator with a psychology background, and a registered music therapist.
223996514|NCT04030871|DEVICE|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
223996515|NCT04030871|DEVICE|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
223996516|NCT01923662|DEVICE|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
223996517|NCT01294397|DRUG|Etanercept|Administered by subcutaneous injection once a week
223996518|NCT01294397|DRUG|Denosumab|Administered by subcutaneous injection
223996519|NCT04567381|OTHER|Enhanced Services|In enhanced services, the provision of services go beyond just referring a patient and leaving them to follow-through on their own accord. ES varies based on resources, model of service delivery, philosophy, and role and responsibilities of team members. Enhanced services usually includes longer-term case management which can then facilitate the connection to clinical counseling, victim assistance, familial assistance, legal assistance, emergency financial funding, transportation for subsequent appointments related to a patient's medical condition, employment assistance, and assistance in educational program enrollment.
224295422|NCT01252875|PROCEDURE|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
223996520|NCT04567381|OTHER|Treatment as Usual|Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
223996521|NCT05249608|DEVICE|A prospective, open-label, multicenter, single-arm clinical study to evaluate the safety and performance of the Gastric Bypass Stent System as a weight loss treatment for obesity|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 9 months.
223996522|NCT03245047|DIETARY_SUPPLEMENT|Oral Nutritional Supplement with AN 777|Oral Nutritional Supplement with AN 777, 2 servings a day
223996523|NCT03245047|OTHER|Oral Nutritional Supplement|Oral Nutritional Supplement, 2 servings a day
223996524|NCT05022433|PROCEDURE|UVC insertion|To compare two formulae namely UN-1 and Shukla method to estimate the UVC insertion length in achieving optimum UVC tip position.
223996525|NCT06344468|OTHER|Early Mobilization|Essentially, early mobilization practices consist of two parts: in-bed and out-of-bed. In-bed mobilization; Active-passive joint range of motion (ROM) Exercises include raising the head in bed, turning in bed, in-bed exercises and sitting at the end of the bed. Out-of-bed mobilization includes the process of transferring from bed to chair, standing up, and returning to bed after standing up. In studies conducted on cardiac surgery, the early mobilization period is the first 12 hours.
223996526|NCT06329323|DIAGNOSTIC_TEST|Blood test|Serum and plasma microRNA quantification
223996527|NCT06329323|DIAGNOSTIC_TEST|Pathology specimen miRNA expression|Pathology specimen mirNA expression - ALL MOGCT; OPTIONAL for BOGCT
223996528|NCT04890405|PROCEDURE|Standardized FMT|The group includes 35 patients. They will receive standardized FMT. Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally. It was given only once.
224295423|NCT03864042|DRUG|losartan|taken orally
224295424|NCT03864042|DRUG|dextromethorphan|taken orally
223996529|NCT04890405|COMBINATION_PRODUCT|Precision Flora Transplantation|The group includes 35 patients. They will receive Precision Flora Transplantation. They were used self-developed precision transplant capsules for precision flora transplantation. 4 capsules are used each time. Each capsule contains 400mg of various probiotics effective against diarrhea. It is used orally, once a day,for 28 days.
223996530|NCT06415136|DEVICE|SeaSpine Shoreline|The SeaSpine Shoreline device is a minimally invasive cervical plate/cage system.
223996531|NCT00780728|DRUG|Sildenafil|
223996532|NCT03990740|PROCEDURE|Corneal sampling|Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
224123151|NCT01770418|RADIATION|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
224123152|NCT04998669|DRUG|Loncastuximab tesirine|"Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle."
224123153|NCT04998669|DRUG|Rituximab|"Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician."
224123154|NCT01132573|DRUG|entinostat|Given PO
224123155|NCT01132573|DRUG|clofarabine|Given IV
224123156|NCT01132573|OTHER|pharmacological study|Correlative studies
223996533|NCT00663585|BEHAVIORAL|Vipassana Meditation|12 day retreat where participants learn to meditate
223996534|NCT06116747|BEHAVIORAL|Intervention|Support for fathers of preterm infants
223996535|NCT03610672|BEHAVIORAL|OD prevention/response training|Participants will view a 13-minute OD prevention and response training video (available online free-of-charge). This video covers NY State's recommended curriculum for Overdose Prevention: how to prevent, identify, and respond to an OD, including information on the factors that could heighten risk for overdose (mixing drugs, changes in tolerance and drug purity, and using alone), how to respond to an overdose (rescue breathing, calling 911), and specific instructions on how and when to administer naloxone to someone who is overdosing. After the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to assemble it. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
224123157|NCT01132573|OTHER|laboratory biomarker analysis|Correlative studies
224295425|NCT03864042|DRUG|caffeine|taken orally
224295426|NCT03864042|DRUG|omeprazole|taken orally
224295427|NCT03864042|DRUG|midazolam|taken orally
224295428|NCT03864042|DRUG|rosuvastatin|taken orally
224295429|NCT03864042|DRUG|bupropion immediate release (IR)|taken orally
223729702|NCT01390311|DRUG|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
223729703|NCT01390311|BIOLOGICAL|Donor Leukocyte Infusion (DLI)|
224295430|NCT03864042|DRUG|encorafenib|taken orally
223996536|NCT03610672|BEHAVIORAL|OD prevention/response training + PI mobile application|Participants will receive the same OD intervention as those in the first arm, as well as receiving mobile phones pre-loaded with the PI App. This intervention includes daily prompts plus key components of evidence-based cognitive behavioral interventions, including Functional Analysis of Drug Use, Self-Management, and Social/Recreational Counseling and additional content on Distress Tolerance, the relationship between Peer Networks and Drug Use, and pertinent resources.
223996537|NCT05399901|OTHER|Electromyographic biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback
223996538|NCT05399901|OTHER|M-mode US biofeedback|Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
223996539|NCT02465918|DEVICE|motor cortex stimulation (Change of Stimulation Timing)|
223996540|NCT05778942|DEVICE|Eyestil SYNFO|Instillation of study drug in both eyes: preservative-free ophthalmic solution based on sodium hyaluronate and xanthan gum
223996541|NCT02264119|DRUG|Lefradafiban tablet|
223996542|NCT02264119|DRUG|Pantoprazole tablet|
223996543|NCT02264119|DEVICE|Lefradafiban double chamber sachet|
223996544|NCT01249846|DRUG|PerioChip ®|
223996545|NCT02318615|PROCEDURE|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
223996546|NCT01277692|DRUG|GSK2336805 10mg|single dose once daily
223729704|NCT04071496|OTHER|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
223996547|NCT01277692|DRUG|GSK2336805 30mg|single dose once daily
223996548|NCT01277692|DRUG|GSK2236805 100mg|single dose once daily
223996549|NCT01277692|DRUG|GSK2236805 200mg|single dose once daily
223996550|NCT01277692|DRUG|GSK2236805 10mg|repeat dose once daily for 7 days
223996551|NCT01277692|DRUG|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
223996552|NCT01277692|DRUG|GSK2236805 5mg|single dose in HCV infected patients
223996553|NCT01277692|DRUG|GSK2236805 30mg|single dose in HCV infected patients
223996554|NCT01277692|DRUG|GSK2236805 100mg|single dose in HCV infected patients
223996555|NCT01342198|DRUG|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
223996556|NCT01342198|DRUG|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
223996557|NCT01342198|DRUG|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
223996558|NCT01939353|DRUG|CTN SR|CTN SR tablets
223996559|NCT01939353|DRUG|Placebo|CTN SR-matching placebo tablets
223996560|NCT00458952|DRUG|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
223996561|NCT03099902|DIAGNOSTIC_TEST|Lung function|Spirometry test
223996562|NCT03099902|DIAGNOSTIC_TEST|White blood cell DNA extraction|GSTP1 and TNFa polymorphisms with PCR
223996563|NCT03099902|DIAGNOSTIC_TEST|Urinary testing|Urinary nicotine and cotinine detection
223996564|NCT01653600|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
223996565|NCT01653600|DEVICE|LifeStent|same to SMART STENT
223996566|NCT04980222|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
223996567|NCT04980222|DRUG|Tocilizumab|Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
223996568|NCT04980222|DRUG|Doxorubicin|Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
223996569|NCT04980222|DRUG|Vincristine|Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
223996570|NCT04980222|DRUG|Prednisone|Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
223996571|NCT04980222|DRUG|Rituximab|Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
223996572|NCT04980222|DRUG|Cyclophosphamide|Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
223996573|NCT06210854|DRUG|pBI-11|HPV16/18 vaccine
223996574|NCT03937102|PROCEDURE|cardiac output measure with TTE|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
224295431|NCT03864042|DRUG|binimetinib|taken orally
224295432|NCT03864042|DRUG|modafinil|taken orally
223380196|NCT06456034|BEHAVIORAL|Perinatal palliative care|Intervention group will receive specialized perinatal palliative care support from moment of severe perinatal diagnosis. This intervention is aimed at 5 major care components, namely 1. Support offered by a fixed perinatal palliative care team, 2. that team has received specialized perinatal palliative care training, 3. care is structured within a new perinatal palliative care approach or pathway, including fixed means of communication with team members, 4. psychological support is structurally being offered to parents and healthcare providers, and 5. debriefings after every perinatal death are being organized in the involved team.
223380197|NCT06463002|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring and Montreal Cognitive Assessment|Noninvasive tests to assess blood pressure control and cognition
223380203|NCT04382287|PROCEDURE|Remin Pro® and MI Paste Plus®|Te toothastes were applied at home twice a day over the six anterior upper primary teeth
223380204|NCT04225910|DRUG|225Ac-PSMA|all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
223380205|NCT04167592|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
223380206|NCT04167592|DRUG|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
223380207|NCT04414774|DEVICE|GG-Suicide-Ideation|GG-Suicide-Ideation (GGSI) is a mobile application, consisting of 55 stages. The content of each stage is a list of statements representing core themes, that were found in research and clinical practice to be related to suicide ideation. These are, for example, hopelessness, helplessness, thwarted belongingness, perceived burdensomeness, low self-esteem, tolerance of mental pain, and more. On each stage, several statements are presented on screen, one at a time. The statements express adaptive or maladaptive thinking in the specific core theme of that stage. In case the statement is positive and adaptive, the user needs to drag the statement downwards, towards him. In case the statement is negative and maladaptive, the user needs to drag the statement upwards, away from him. The user advances in stages - three stages per day.
223380208|NCT05298826|DRUG|recombinant factor VIIa|using recombinant factor VIIa
223729705|NCT00639054|PROCEDURE|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
223729706|NCT00639054|PROCEDURE|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
223996575|NCT03937102|PROCEDURE|cardiac output measure with Physioflow® thoracic electrical bioimpedance|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
223996576|NCT03831542|BEHAVIORAL|direct follicular aspiration|direct follicular aspiration
223996577|NCT03831542|BEHAVIORAL|follicular flushing|follicular flushing
223996578|NCT02413645|BIOLOGICAL|TriMix_100|100 μg of TriMix in
224123158|NCT05936385|BEHAVIORAL|Healthy Lifestyle|Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.
223996579|NCT02413645|BIOLOGICAL|TriMix_300|300 μg of TriMix in
223996580|NCT02413645|BIOLOGICAL|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
223996581|NCT02413645|BIOLOGICAL|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
224123159|NCT05936385|BEHAVIORAL|Standard of Care|Weight checks and lifestyle counseling with primary care provider every other month.
224123160|NCT04486443|BEHAVIORAL|music therapy|patients in the intervention group received music therapy in 10-minutes sessions with the support of a specialist from the Conservatory Department in the Ege University, using the Turkish classical music (Hejaz and Rast modes) accompanied by a tambour.
224123161|NCT00909142|DRUG|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
224295433|NCT05128370|OTHER|Visual observation of arm swing during walking|The gait pattern of the stroke patients will be scored based on a visual observation scale. Additional components concerning the arm swing have been added to an existing scale.
224295434|NCT00377507|DIETARY_SUPPLEMENT|catechin extracts|catechin extracts solution
224295435|NCT04407078|DRUG|Sugammadex Injectable Product|Sugammadex of 2 mg/kg is injected.
224295436|NCT04407078|DRUG|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
224295437|NCT00038337|PROCEDURE|Health Literacy|
224295438|NCT02139371|OTHER|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
224295439|NCT05344651|DEVICE|Surgery/implantation|The glaucoma drainage device consists of a plate and a tube. During surgery the plate is positioned underneath the conjunctiva and two extraocular muscles in the upper temporal quadrant of the eye. The tube is positioned in the anterior chamber.
224295440|NCT00336115|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
224295441|NCT01627925|DEVICE|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
224295442|NCT00810173|BEHAVIORAL|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
224295443|NCT05099523|PROCEDURE|taking arterial blood sample through the injector|taking blood samples from patients applied with different oxygen concentrations
224295444|NCT02220725|BIOLOGICAL|Andexanet|
224295445|NCT02220725|OTHER|Placebo|
223996582|NCT02413645|BIOLOGICAL|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
223996583|NCT06404853|DIETARY_SUPPLEMENT|Manna|"Administration is by the oral route according to weight at a dosage of 1 g/kg/day, dissolved in a glass of water, up to a maximum of 30 g. Administration should be repeated every 24 h for 8 weeks, accompanied by plenty of hydration.~In case an effective dosage is achieved (evacuation within 72 h) it will be maintained until the end of the study. If evacuation has not occurred after 72 h, evacuative enema and increased dosage to 1.5 g/kg/day will be indicated. If further evacuative enema is needed, product administration will be discontinued and classical polyethylene glycol therapy will be started as per guidelines."
223996584|NCT05048238|DRUG|Tofacitinib|10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
223996585|NCT04648137|DIAGNOSTIC_TEST|study intervention: 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)|single administration of MDMA (100mg): 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) will be prepared as gelatin capsules with mannitol as the filler. MDMA will be administered in a single absolute dose of 100 mg corresponding to a medium high dose of (mean ± SD) 1.3 ± 0.3 mg/kg body weight.
223996586|NCT04648137|DIAGNOSTIC_TEST|Control intervention: Placebo|Identical placebo (only mannitol) capsules
223996587|NCT02657499|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
223996588|NCT01053767|BIOLOGICAL|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study."
223996589|NCT02261077|DRUG|Hyoscine butylbromide|
223996590|NCT02261077|DRUG|Placebo|
223996591|NCT00158704|DRUG|Hepsera|
223996592|NCT06034691|BIOLOGICAL|pcsk9 inhibitor|The treatment group received postoperative use of 140 mg of Ribavirin, administered every two weeks, with 140 mg administered subcutaneously for a total of 48 weeks. There was no additional intervention with lipid-lowering drugs in the control group.
223996593|NCT03563066|DRUG|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 \& 56.
223996594|NCT03563066|DRUG|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.
224295446|NCT04596397|OTHER|Inpatient setting|These women stay at the hospital.
224295447|NCT04596397|OTHER|Outpatient setting|These women can leave the hospital.
224295448|NCT00697840|BIOLOGICAL|Engerix™-B|Intramuscular injection, 2 doses
224295449|NCT00697840|BIOLOGICAL|HBV-MPL 208129|Intramuscular injection, 2 doses
223996595|NCT01049438|DRUG|nasal mupirocin|twice daily for 10 days
223996596|NCT01049438|DRUG|topical 3% hexachlorophene body wash|daily for 10 days
224295450|NCT00697840|BIOLOGICAL|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
224295451|NCT00026052|DRUG|riluzole|
224295452|NCT04878237|OTHER|Nasal Secretion Sampling|Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
224295453|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .23s|Aortic CTA performed with short (0.23 sec) gantry rotation time.
224295454|NCT05709652|DIAGNOSTIC_TEST|Aortic CTA, .28s|Aortic CTA performed with standard (.28 sec) gantry rotation time.
223996597|NCT01049438|DRUG|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
223380221|NCT05324332|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
223380222|NCT05324332|DRUG|68Ga-PSMA-11|Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
223996598|NCT05390814|DRUG|PET-MRI|\[18F\]-Fludarabine imaging in the diagnostic workup of primary central nervous system lymphomas: a PET-MRI pilot study
223996599|NCT02281162|OTHER|Blood Draw|Blood Draw
223380238|NCT01920529|OTHER|aerobic exercise|Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
223545173|NCT06715137|BEHAVIORAL|Exercise training|Each participant received a personalized rehabilitation schedule combining aerobic interval cycle training and a dynamic strength exercise program, developed to ensure that the participants met the physical activity guidelines. For the aerobic training, the patients cycled for 30-45 minutes on an exercise bike at home 3 times a week. During each training session, the heart rate (HR) was continuously recorded using a chest strap and displayed in a smartphone application. The target HR zones were predefined with alternating intervals of intensive and extensive aerobic training. The program followed a progressive structure with the objective of completing 40 minutes of intensive aerobic training after 16 weeks. In the strength training program, 4 dynamic exercises targeting major muscle groups were performed 3 times a week. Every 2 weeks, these exercises were intensified by altering the starting position or adding extra weight.
223996600|NCT00751543|RADIATION|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
223996601|NCT04641169|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
223996602|NCT03435731|COMBINATION_PRODUCT|Dual Therapy|Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
223996603|NCT01322737|PROCEDURE|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
223996604|NCT02876445|OTHER|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
223996605|NCT02740738|DEVICE|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
224295455|NCT04812639|OTHER|Buccal infiltration technique|a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth
224295456|NCT04812639|OTHER|Inferior alveolar nerve block technique|a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
223380248|NCT01221389|DRUG|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
223380249|NCT01906515|DEVICE|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
223996606|NCT02740738|DEVICE|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
223996607|NCT02019186|DIETARY_SUPPLEMENT|Vitamin C|\<30 kg 250 mg 30-60 kg 500 mg \>60 kg 750 mg
223996608|NCT02019186|DIETARY_SUPPLEMENT|Vitamin E|\<30 kg 100 IU, 30-60 kg 200 IU, \>60 kg 300 IU
224295457|NCT04690569|DIAGNOSTIC_TEST|MeMed BV|The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
223380263|NCT06684847|BIOLOGICAL|Efgartigimod PH20 SC|subcutaneous efgartigimod PH20 SC given by prefilled syringe
223380264|NCT06684847|OTHER|Placebo PH20 SC|subcutaneous placebo PH20 SC given by prefilled syringe
223380265|NCT05957744|PROCEDURE|Colorectal surgery|Right hemicolectomy, left colectomy, total colectomy, anterior resection
223380280|NCT06872840|BEHAVIORAL|Parent Fear of Recurrence Therapy (Parent-FORT)|7 weekly sessions of 120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
223996609|NCT01871337|BEHAVIORAL|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
223996610|NCT01937169|BEHAVIORAL|Motor Task|A motor task executed for 30 minutes after drug adminidtration
223996611|NCT01937169|DRUG|Levodopa tablet|
223996612|NCT01937169|BEHAVIORAL|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
223996613|NCT01937169|DRUG|Placebo pill|
223996614|NCT05392647|DRUG|Hetrombopag|All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (\>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
223996615|NCT05761613|DEVICE|CeraShield Endotracheal Tube|An endotracheal tube coated with with an antimicrobial hydrophilic coating containing ceragenins (CSAs)
223996616|NCT05761613|DEVICE|Endotracheal tube with subglottic secretion drainage|An endotracheal tube with subglottic secretion drainage
223996617|NCT00108251|DRUG|Eplerenone|aldosterone receptor blocker
223996618|NCT00108251|DRUG|Placebo|matching placebo
223996619|NCT00654797|PROCEDURE|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
223996620|NCT05083845|PROCEDURE|Same blocks with different local anesthetic volume|Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.
223996621|NCT02405598|DRUG|Salbutamol|"1. Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~2. VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)"
223996622|NCT03573869|PROCEDURE|Cryoballoon ablation|Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
223996623|NCT02495766|DRUG|XCEL-MC-ALPHA|Single infusion
223996624|NCT02495766|DRUG|Placebo|Single infusion
223996625|NCT01193010|PROCEDURE|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
223996626|NCT01193010|PROCEDURE|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
223996627|NCT06026930|DEVICE|low-level laser therapy|LLLT and LIPUS has been found to speed up OTM by stimulating the RANK/RANKL/OPG system to initiate osteoclast formation.
223996628|NCT00022945|DRUG|Iodine-131 Anti-B1 Antibody|
223996629|NCT00022945|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
223996630|NCT06511492|OTHER|No intervention in this study|No intervention in this study
223996631|NCT04670445|OTHER|Educational Video and QPL List|The intervention includes a 15-minute educational video and a 2- page list of suggested questions to review with oncology team about immunotherapy.
223996632|NCT04670445|OTHER|Usual Care|Surveys
224123162|NCT05635734|DRUG|Azeliragon 5 mg|"Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
224123163|NCT05635734|DRUG|Azeliragon 10 mg|"Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
223996633|NCT04325633|DRUG|1: Naproxen|Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
223996634|NCT04325633|DRUG|2: Standard of care|Standard of care
223996635|NCT00798252|DRUG|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
223996636|NCT00798252|DRUG|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
223996637|NCT00798252|DRUG|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
223996638|NCT00798252|DRUG|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
223996639|NCT00798252|DRUG|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
224299121|NCT02893137|PROCEDURE|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
223996640|NCT00798252|DRUG|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
223996641|NCT04970719|DRUG|Baricitinib|4 mg of baricitinib administered as 2 tablets taken orally daily while hospitalized for up to a 14-day total course
223996642|NCT04970719|DRUG|Dexamethasone|and 6 mg\* of dexamethasone administered as an intravenous injection daily while hospitalized for up to a 10-day total course
223996643|NCT04970719|DRUG|Remdesivir|200 mg of remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of remdesivir while hospitalized for up to a 5-day total course
223996644|NCT00003877|BIOLOGICAL|filgrastim|
223996645|NCT00003877|DRUG|carboplatin|
223996646|NCT00003877|DRUG|cyclophosphamide|
223996647|NCT00003877|DRUG|paclitaxel|
223996648|NCT00003877|DRUG|thiotepa|
223996649|NCT00003877|PROCEDURE|in vitro-treated bone marrow transplantation|
223996650|NCT00003877|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223996651|NCT01602510|DRUG|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
223996652|NCT01602510|DRUG|Placebo|Placebo
223996653|NCT00927173|DEVICE|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
223996654|NCT00927173|DEVICE|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
223996655|NCT01798342|DIETARY_SUPPLEMENT|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
223996656|NCT01798342|DIETARY_SUPPLEMENT|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
223996657|NCT02655926|PROCEDURE|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
223996658|NCT00643292|DRUG|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
223996659|NCT00643292|DRUG|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
223996660|NCT04127097|OTHER|cartoon group|The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
223996661|NCT03185884|OTHER|Control|control carbohydrate blend
223996662|NCT03185884|OTHER|Experimental|experimental carbohydrate blend
223996663|NCT01391637|BIOLOGICAL|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
223996664|NCT03519204|DEVICE|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.
223996665|NCT03519204|OTHER|No-treatment Control|No-treatment was administered.
223996666|NCT03832842|DIAGNOSTIC_TEST|Blood sample|Blood sample
223996667|NCT03377686|DIAGNOSTIC_TEST|inflammation markers in exhaled breath|non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)
223996668|NCT05446753|DIETARY_SUPPLEMENT|Animal-based meats|Animal-based meats from beef, pork and chicken
223996669|NCT05446753|DIETARY_SUPPLEMENT|Plant-based meat alternatives|Plant-based meat alternatives of beef, pork and chicken
223996670|NCT04419233|DRUG|Nusinersen Sodium Injection|Administered as specified in the treatment arm.
223996671|NCT00806481|DRUG|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
223996672|NCT00806481|DRUG|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
223996673|NCT04553055|OTHER|online questionnaires|questionnaire (with detailed questions including how/when/which/for how long antibiotics are prescribed)
223996674|NCT05946720|OTHER|Training including aggression and the use of BVC.|After obtaining verbal consent from the nurses who met the inclusion criteria of the study before the pre-test was applied to the nurses, the nurses who volunteered to participate in the study were randomized within their own clinic using the simple randomization method. For this, after the data collection form was distributed before the pre-test, the nurses were asked to write the letter that came to them on the data collection form and not forget it. In order for nurses to be included in the training or comparison group, the letter A, written on the closed papers in the box prepared for simple randomization, represents the Education group, and the letter B represents the comparison group.
223996675|NCT03965715|DEVICE|3D printing AFO, anterior AFO, off-the-shelf AFO|Subjects wear different AFOs and performed gait analysis.
223996676|NCT00478192|DRUG|Conivaptan|premix bag
223996677|NCT00478192|DRUG|Placebo|premix bag
223996678|NCT05733182|DEVICE|3000K Reading lamp|Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
223996679|NCT05733182|DEVICE|4500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
223996680|NCT05733182|DEVICE|6500K Reading lamp|Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
223996681|NCT02378038|DRUG|PNT2258|
223996682|NCT00802347|DRUG|I5NP|"Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
223996683|NCT00802347|DRUG|Saline|"Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
223996684|NCT05538026|DRUG|Mesalazine|daily dose of 3 g (2 g orally + 1 g rectally)
223996685|NCT05538026|BIOLOGICAL|Fecal transplantation|Preparation of fresh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of UC patient by colonoscopy after standard bowel preparation.
223996686|NCT01343758|OTHER|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
223996687|NCT02795364|PROCEDURE|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
223996688|NCT02795364|PROCEDURE|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
223996689|NCT05433649|BEHAVIORAL|Therapeutic exercise|The therapeutic exercise intervention with the help of elastic bands was carried out for 8 weeks with a frequency of two sessions per week, for a total of 16 sessions of 45 minutes duration.
223996690|NCT02977767|PROCEDURE|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
223996691|NCT02348944|OTHER|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
223996692|NCT00600613|RADIATION|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
223996693|NCT05994638|DIETARY_SUPPLEMENT|Aerosol (Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3)|Polyphenol-rich plant extracts, Hyaluronic Acid, Cetraria Islandica, Vitamin B3
223996694|NCT05510050|DIETARY_SUPPLEMENT|Aloe Vera Extract 1|2 capsules taken daily for 30 days
223996695|NCT05510050|DIETARY_SUPPLEMENT|Control|2 capsules taken daily for 30 days
223996696|NCT05510050|DIETARY_SUPPLEMENT|Aloe Vera Extract 2|2 capsules taken daily for 30 days
223996697|NCT00130065|DRUG|Sulfadoxine-pyrimethamine/folic acid|
223996698|NCT00130065|DRUG|Sulfadoxine-pyrimethamine/placebo|
223996699|NCT02704650|PROCEDURE|fluid sample|taking a vaginal fluid sample
223996700|NCT01715207|DRUG|Aliskiren|
223996701|NCT01715207|DRUG|Atenolol|
223996702|NCT03530137|BEHAVIORAL|Healthy Home|An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
224299122|NCT00787397|BEHAVIORAL|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
224299123|NCT03192865|PROCEDURE|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
223996703|NCT03530137|BEHAVIORAL|Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).|ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
223996704|NCT03530137|BEHAVIORAL|HealthySteps|Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
223996705|NCT05442684|BIOLOGICAL|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O
223996706|NCT05442684|BIOLOGICAL|Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH
223996707|NCT05442684|BIOLOGICAL|mRNA-based COVID-19 vaccine|Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine
223996708|NCT05590429|OTHER|Blood transfusion|No intervention
223996709|NCT03487965|DIETARY_SUPPLEMENT|Low dose Polyphenol|botanical supplement with 25 mg polyphenol
223996710|NCT03487965|DIETARY_SUPPLEMENT|High dose Polyphenol|botanical supplement with 13 mg polyphenol
224299124|NCT03754374|OTHER|access to healthcare|use or non-use of dedicated health facilities
223996711|NCT03487965|DIETARY_SUPPLEMENT|Placebo Control|inert tablet made to mimic the experimental tablets
223996712|NCT02307045|DRUG|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
223996713|NCT02307045|DRUG|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
223996714|NCT01509547|DRUG|Varenicline|participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
223996715|NCT01509547|DRUG|placebo|participants \>55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
223996716|NCT00561145|OTHER|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
223996717|NCT03181490|DIAGNOSTIC_TEST|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
223729707|NCT03470818|OTHER|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
223996718|NCT01909297|DEVICE|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
223996719|NCT01909297|DEVICE|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
223996720|NCT01909297|DEVICE|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
224123164|NCT05635734|DRUG|Azeliragon 20 mg|"Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles."
224123165|NCT02574780|OTHER|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
224123166|NCT02574780|OTHER|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
224123167|NCT02042404|DEVICE|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
224123168|NCT01134692|DRUG|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
224123169|NCT05826275|DRUG|TGN-S11|Small Molecule
224123170|NCT05826275|DRUG|Pembrolizumab|PD-1 checkpoint blockade
224123171|NCT01619384|BEHAVIORAL|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
223729708|NCT03470818|OTHER|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
223996721|NCT00102024|DRUG|Unconjugated IDEC-159|
223996722|NCT00102024|DRUG|111In-IDEC-159|
223996723|NCT00102024|DRUG|90Y-IDEC-159|
223996724|NCT02544165|DIETARY_SUPPLEMENT|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
223996725|NCT02544165|OTHER|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
223996726|NCT02544165|OTHER|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
223380388|NCT06888466|BEHAVIORAL|The result of the Polygenic Risk Score will be communicated to the patient with the aim of encouraging a change in behavior|Blood samples collected for the calculation of the genetic predisposition profile for Cardiovascular risk will be used for DNA extraction and genotyping, and the PRS will subsequently be calculated. Based on the results, individuals will be classified into three main CVD risk categories (high risk, intermediate risk, low risk)
223729709|NCT03259854|DEVICE|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
223996727|NCT03910322|DIETARY_SUPPLEMENT|Bif195|Two different doses of the bacterial strain Bif195 is compared to placebo
223996728|NCT03910322|DIETARY_SUPPLEMENT|Placebo|Placebo
223996729|NCT03242343|DEVICE|VasQ|An external support device for AV fistula
223996730|NCT04618367|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks
223996731|NCT04618367|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224123172|NCT03884660|DEVICE|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
224123173|NCT01405846|DRUG|Gefitinib|250mg od for 6 months
223996732|NCT04618367|DRUG|Sintilimab|200mg intravenously every 3weeks
223996733|NCT05396937|RADIATION|Multifocal Stereotactic Radiotherapy|Radiotherapy will be given in combination with atezolizumab and bevacizumab. The patient will be initially treated with atezolizumab and bevacizumab after enrollment. Radiotherapy will be administered to the metastases 1-2 weeks after the completion of the first intravenous injection of atezolizumab and bevacizumab, in the mode of multifocal stereotactic radiotherapy, with a planned total dose to the planned target volume of 25-50 Gy in five divided doses of 5-10 Gy/fraction. Systemic therapy could be continued 48 hours after completion of radiotherapy.
223729710|NCT03259854|DEVICE|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
223729711|NCT03449082|BIOLOGICAL|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
224123174|NCT04520763|OTHER|5min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-80% MVV 15-30min after ingestion of 75g of glucose
224123175|NCT04520763|OTHER|15min respiratory muscle exercises|5 min of hyperpnea at a target intensity of 60-70% MVV 15-30min after ingestion of 75g of glucose
223380414|NCT02908087|DRUG|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
223380415|NCT02908087|DRUG|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
223996734|NCT05396937|DRUG|Atezolizumab Injection [Tecentriq]|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
223380427|NCT05410964|DEVICE|VIO System|To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
223996735|NCT05396937|DRUG|Bevacizumab|Bevacizumab will be administered by IV, 10 mg/kg on day 1 of each 21 day cycle
223996736|NCT00402051|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
223996737|NCT00402051|DRUG|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
223996738|NCT00402051|DRUG|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
223996739|NCT02514551|DRUG|Ramucirumab|Administered IV
223996740|NCT02514551|DRUG|Paclitaxel|Administered IV
223996741|NCT02204553|DRUG|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
223996742|NCT03507907|OTHER|Mulligan Mobilization for Study Group|Mulligan Mobilization techniques were applied to the older adults who included in study group.
223996743|NCT03507907|OTHER|Conventional therapy for Control Group|Conventional therapy was applied to the older adults who included in control group.
223996744|NCT02142153|DRUG|F901318|"Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile"
223996745|NCT02142153|DRUG|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
223996746|NCT00618579|DRUG|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
223996747|NCT03749135|DRUG|Dupilumab|anti-IL4-Receptor alpha
223996748|NCT03749135|DRUG|Placebo|Placebo
223996749|NCT02928731|OTHER|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
223996750|NCT02928731|OTHER|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
223729712|NCT03449082|BIOLOGICAL|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
223996751|NCT02604823|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
223996752|NCT02338063|BEHAVIORAL|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
223996753|NCT02338063|BEHAVIORAL|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
223996754|NCT03257527|BEHAVIORAL|ENHANCE group|The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
224299125|NCT03899311|OTHER|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
223380431|NCT02304029|DEVICE|MRI|
223996755|NCT03257527|BEHAVIORAL|MBSR group|"The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase."
223380443|NCT05801588|OTHER|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.
223380444|NCT05801588|OTHER|Usual care|The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
223729713|NCT03449082|DRUG|Fibrin glue|Fibrin glue 0.5cc
223729714|NCT03449082|DRUG|Normal saline|Normal saline 0.5cc
223996756|NCT05863468|DEVICE|ArchSinus implantation|Unilateral or bilateral in-office middle turbinate medialization and subsequent ArchSinus implantation
223996757|NCT04529005|DRUG|Angiotensin II|If intraoperative or postoperative hypotension occurs (e.g. SBP \< 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.
223996758|NCT00833378|DRUG|Eltrombopag|Eltrombopag 100 mg single oral dose
223380445|NCT01954745|DRUG|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
223380447|NCT06264063|BEHAVIORAL|control group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
223380448|NCT06264063|BEHAVIORAL|experimental group|the investigators have to assess the neuropsychological and psychological profile with specific questionnaire that evaluated the moral index, presence of obsessive and compulsive disorders and Montreal Cognitive Assessment to evaluate cognitive functions
223380449|NCT06264063|DIAGNOSTIC_TEST|EEG power in alpha band|partecipants were submitted to registration of electrical activity with EEG to study the EEG power in alpha band
223380450|NCT01729403|DRUG|aleglitazar|150 mcg orally daily, 16 weeks
223996759|NCT00833378|DRUG|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
223380451|NCT01729403|DRUG|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
223380452|NCT01729403|DRUG|placebo|orally daily, 16 weeks
223996760|NCT00833378|DRUG|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
223996761|NCT03520218|DEVICE|Performance of R-PEM|R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
223996762|NCT01686737|BEHAVIORAL|Iyengar Yoga|"* 12 weeks of Iyengar yoga~* 2 weekly sessions of 60 minutes"
223996763|NCT01686737|BEHAVIORAL|Walking|"* 12 weeks of walking~* 2 weekly sessions of 60 minutes"
223996764|NCT02170545|OTHER|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
223996765|NCT01791972|DRUG|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
223996766|NCT01791972|DRUG|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
223996767|NCT00167206|PROCEDURE|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
223996768|NCT00167206|PROCEDURE|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
223996769|NCT00167206|PROCEDURE|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
223996770|NCT00167206|DRUG|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
223996771|NCT02539316|DRUG|Smoflipid|
223996772|NCT02539316|DRUG|Médialipides|
223996773|NCT00545649|BEHAVIORAL|Exercise and education|
223996774|NCT00545649|BEHAVIORAL|Education|
223996775|NCT03605888|BEHAVIORAL|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
223996776|NCT04047173|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
223996777|NCT04047173|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual, no more than 2 times.
223996778|NCT00797888|BEHAVIORAL|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
223996779|NCT02803281|OTHER|Frailty Assessment|Various physiologic and frailty assessment tests
223996780|NCT00570908|DRUG|sunitinib|Sutent
223996781|NCT00570908|DRUG|capecitabine|concurrently
223996782|NCT00570908|RADIATION|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
223996783|NCT03497403|PROCEDURE|Socket preservation control|After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
223996784|NCT03497403|PROCEDURE|Socket preservation experimental|After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
223996785|NCT00987662|DRUG|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.
223996786|NCT00987662|DRUG|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg
223996787|NCT03694977|DRUG|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
223996788|NCT00346853|DRUG|4-Methylpyrazole|15 mg/kg dose
223996789|NCT00346853|OTHER|saline|
223996790|NCT01474629|DIETARY_SUPPLEMENT|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
223996791|NCT01474629|DIETARY_SUPPLEMENT|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
223996792|NCT00132275|DRUG|Amoxicillin potassium clavulanate|
223996793|NCT02398253|BEHAVIORAL|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
223996794|NCT02398253|BEHAVIORAL|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
223996795|NCT00002377|DRUG|Valganciclovir|
223996796|NCT00002377|DRUG|Ganciclovir|
223996797|NCT02880943|DRUG|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
223996798|NCT01250795|BIOLOGICAL|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
223996799|NCT01250795|OTHER|Saline|
223996800|NCT03455270|DRUG|G1T48|oral SERD
224123176|NCT02259036|OTHER|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
223996801|NCT03455270|DRUG|Palbociclib|CDK 4/6 Inhibitor
223996802|NCT05191602|DIAGNOSTIC_TEST|drainge fluid|including bilirubin
223996803|NCT03287895|BEHAVIORAL|Decision Support|A two-part intervention to help patients make better decisions about CPR
223996804|NCT00602849|DRUG|Sertraline|
223996805|NCT05521243|DIETARY_SUPPLEMENT|Beam Organics Dream Powder|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
223996806|NCT05521243|DIETARY_SUPPLEMENT|Beam Organics Dream Powder Extra Strength|The Dream Powder and Dream Powder Extra Strength both use nano hemp, reishi, magnesium. L-theanine, and melatonin to promote a healthy sleep pattern
223996807|NCT05521243|DIETARY_SUPPLEMENT|Placebo|"The main ingredients in the placebo are:~Coconut milk powder, cocoa, cinnamon, monk fruit, natural vanilla flavor"
223996808|NCT06106139|DIETARY_SUPPLEMENT|Strict ketogenic diet group|the patients ate ketogenic biscuits or ketogenic foods provided by the researchers every day. During the study, the patients were not allowed to drink any drinks or eat other foods except drinking water, so as to ensure that the daily intake of calories was roughly the same as that of the normal diet group.
223996809|NCT06106139|DIETARY_SUPPLEMENT|Cyclic ketogenic diet group|"the patients took 7 days as a cycle, and 7 days of strict ketogenic diet+7 days of normal diet as a cycle. During the strict ketogenic diet, the patient should eat the ketogenic biscuit or ketogenic food provided by the researcher every day, and should not drink any beverage or eat other food except drinking water; During the normal diet period, patients followed the Dietary Guidelines for Chinese Residents (2022) to ensure nutritional balance. During the study period, patients were guaranteed to eat approximately the same amount of calories per day as the normal diet group."
223996810|NCT06106139|DIETARY_SUPPLEMENT|Autonomous ketogenesis group|Patients choose ingredients for cooking and consumption under the guidance of researchers, ensuring that the nutritional composition is about 90% fat, 10% protein, and can contain a small amount of carbohydrates (10%). The daily calorie intake is around 1600\~2400 kcal.
223996811|NCT03016351|OTHER|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
223996812|NCT03016351|OTHER|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
223996813|NCT01930097|OTHER|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
223996814|NCT01213524|BEHAVIORAL|sensorimotor replacement|denicotinized cigarettes
223996815|NCT01213524|DRUG|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
223996816|NCT01213524|DRUG|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
223996817|NCT01213524|OTHER|usual brand smoking|participant smokes usual brand of cigarette
223996818|NCT00630734|DRUG|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
223996819|NCT00630734|DRUG|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
223996820|NCT00630734|DRUG|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
223996821|NCT00630734|DRUG|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
223996822|NCT00630734|OTHER|Washout|Washout (no medication) on days 5-11.
223996823|NCT01956097|DIETARY_SUPPLEMENT|HX106 590mg|
223996824|NCT01956097|DIETARY_SUPPLEMENT|HX106 1180mg|
223996825|NCT01956097|DIETARY_SUPPLEMENT|Placebo|
223996826|NCT06331624|DRUG|Tazarotene (GRI-0621)|Oral 4.5mg soft gel capsule
223996827|NCT06331624|DRUG|Placebo|Oral 4.5mg soft gel capsule
223729715|NCT02296268|BEHAVIORAL|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
223996828|NCT05217940|DIAGNOSTIC_TEST|Diagnostic tests for anal cancer screening|The initial screening interventions will include the collection of (1) anal cytology; (2) self-collected HPV testing specimens (by subjects); (3) a clinician collected HPV specimen. A digital rectal exam will also be done on all patients.
223996829|NCT05380362|OTHER|Venous Angioplasty|venous angiogram to look for lesions or flaps and then plastying vessels open.
223996830|NCT05380362|OTHER|Sham Angioplasty|Patients will be brought to the angio suite and will not know if they are having the venous angioplasty or not.
223996831|NCT06053333|OTHER|Non-Interventional Study|Non-interventional study
223996832|NCT05415748|DRUG|Tamsulosin|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
223996833|NCT05415748|DRUG|Placebo|Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
223996834|NCT05975099|BIOLOGICAL|mRNA-1975|Dispersion delivered IM
223996835|NCT05975099|BIOLOGICAL|mRNA-1982|Dispersion delivered IM
223996836|NCT05975099|BIOLOGICAL|Placebo|Solution delivered IM
223729716|NCT00946959|PROCEDURE|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
223996837|NCT05985538|BEHAVIORAL|Vaping prevention text messages|Participants will receive text messages (2 daily, on average) about the harms of e-cigarette use and vaping for 28 days, with introductory messages sent on day 1 and concluding messages sent on day 28. Each vaping prevention text message will focus on one of six topics: nicotine addiction, monetary costs of vaping, chemical exposures from e-cigarette vapor, cosmetic effects of vaping, mental and physical use symptoms of vaping, and health impact on organs from vaping. Some text messages will ask participants for a reply (i.e., two-way messages).
223996838|NCT05985538|BEHAVIORAL|Wellness behaviors text messages|Participants will receive text messages (2 daily, on average) about general wellness topics, with introductory messages sent on day 1 and concluding messages sent on day 28. Each wellness text message will focus on one of six topics: sleep hygiene, safe driving, sun safety, study habits, nutrition, and exercise. This attention control condition is matched with the intervention condition in that participants will receive the same number of text messages over the same number of days, the same intervention structure (e.g., 6 topics), and the same number and types of two-way messages.
223996839|NCT05306886|OTHER|ICB Medical Insoles|After the foot analysis of the participants in the intervention group, special insoles will be designed in a computer program. In these insoles, 3-6 mm medial wedge support, 1-3 mm heel wedge support, 2-4 mm medial longitudinal arch support will be provided. These values will be determined according to the needs of each participant. A single physiotherapist will design all insoles. All drawings will be made by a single physiotherapist. After the design of the insoles is completed, insoles will be produced by transferring them to a Computer Numerical Control (CNC) machine. Ethyl vinyl acetate (EVA), the use of which has been found useful before, will be used as the material in the insoles molds. After processing, 1mm thick fabric will be used for the top coating. All insoles will be produced by the same physiotherapist.
223996840|NCT05306886|OTHER|ICM Insoles|As in the intervention group, insoles will be designed for the participants in the control group, processed by CNC machine and the production will be completed. Only 2mm medial longitudinal arch support will be given to the insoles of the people in this group.
223996841|NCT06246929|BEHAVIORAL|MBCT+w|MBCT+w uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The MBCT+w sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with 90-minute weekly meetings that will focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. MBCT+w uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
223996842|NCT06246929|BEHAVIORAL|ALED|ALED is a behavior change program. ALED offers different options to traditional exercise program to help participants overcome barriers to physical activity and increase their physical activity. The format is a 12-week program with 60-minute sessions that include a short lecture and group discussions to help participants set goals, decrease barriers to exercise, and find an activity they enjoy. The ALED program is conducted in the same format as MBCT+w, but participants are not taught the mind-body, walking or cognitive-behavioral skills. ALED will also use a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
223996843|NCT05362045|DRUG|Mavacamten|Specified dose on specified days
223996844|NCT05777109|DRUG|HS-20090|A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
223996845|NCT05777109|DRUG|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once
223996846|NCT04608838|BIOLOGICAL|JTR-161|JTR-161 (1 or 3 × 10\^8 cells/subject) will be suspended and administered in an intravenously infusion.
223996847|NCT04608838|BIOLOGICAL|Placebo|Placebo will be suspended and administered in an intravenously infusion.
223996848|NCT05291377|OTHER||
223996849|NCT00281320|DRUG|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
223996850|NCT00921947|BIOLOGICAL|VAX102|Universal M2e influenza vaccine
223996851|NCT01647945|DRUG|Placebo|placebo pill
223996852|NCT01647945|DRUG|FK506 level < 2 ng/ml|FK506 goal trough blood level \< 2 ng/ml
223996853|NCT01647945|DRUG|FK506 level 2-3 ng/ml|FK506 goal trough blood level 2-3 ng/ml
223996854|NCT01647945|DRUG|FK506 level 3-5 ng/ml|FK506 goal trough blood level 3-5 ng/ml
223996855|NCT02902770|DRUG|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
223996856|NCT02902770|DRUG|Ketorolac Tromethamine|IV ketorolac 30mg push
223996857|NCT02902770|DRUG|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
223996858|NCT02902770|DRUG|Normal Saline Push|Normal Saline Push Placebo
223996859|NCT06184035|DRUG|[177Lu]Lu-SN201|Intravenous infusion
223996860|NCT03432741|DRUG|Belinostat|Given intralesionally
223996861|NCT03432741|DRUG|Carfilzomib|Given intralesionally
223996862|NCT03432741|DRUG|Copanlisib Hydrochloride|Given intralesionally
223996863|NCT03432741|BIOLOGICAL|Daratumumab|Given intralesionally
223996864|NCT03432741|DRUG|Fludeoxyglucose F-18|Undergo FDG-PET
223996865|NCT03432741|DRUG|Gemcitabine Hydrochloride|Given intralesionally
223996866|NCT03432741|OTHER|Laboratory Biomarker Analysis|Correlative studies
223996867|NCT03432741|BIOLOGICAL|Nivolumab|Given intralesionally
223996868|NCT03432741|BIOLOGICAL|Obinutuzumab|Given intralesionally
223996869|NCT03432741|BIOLOGICAL|Pembrolizumab|Given intralesionally
223996870|NCT03432741|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET
223996871|NCT03432741|BIOLOGICAL|Rituximab|Given intralesionally
223996872|NCT03432741|DRUG|Romidepsin|Given intralesionally
223996873|NCT03432741|OTHER|Saline|Given intralesionally
223996874|NCT03432741|BIOLOGICAL|Trastuzumab|Given intralesionally
223996875|NCT06176690|BIOLOGICAL|C7R.CD30.CAR-EBVST cells|The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
223996876|NCT03958006|DEVICE|Cochlear implant|Tumor resection with cochlear implant
223996877|NCT03097406|PROCEDURE|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
223996878|NCT03097406|PROCEDURE|Global Advantage|A total shoulder prosthesis used for osteoarthritis
223996879|NCT03097406|PROCEDURE|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
223996880|NCT03097406|PROCEDURE|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
223996881|NCT05239715|DIAGNOSTIC_TEST|Ocular biometry|Biometry using swept-source OCT Argos, swept-source OCT IOLMaster 700, swept-source OCT Anterion, PCI Pentacam AXL, OcuScan RxP and Itrace measurement
223996882|NCT02755129|OTHER|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
223996883|NCT02755129|OTHER|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
223996884|NCT02755129|OTHER|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
223996885|NCT02755129|OTHER|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
223996886|NCT02755129|OTHER|Reveal LINQ accelerometer|Walking exercises test
223996887|NCT02755129|OTHER|3D accelerometer|Walking exercises test
223996888|NCT04601636|DEVICE|Active Prewarming|Active prewarming with Flex Warming Gown (Bair Paws, 3M) for at least 30 minutes before induction of anesthesia, with active warming intraoperatively with Bair Hugger (3M)
223996889|NCT04601636|OTHER|Standard Care|Standard care with a passive prewarming (warm cotton blankets) before induction of anesthesia, with active warming intraoperatively with (Bair Hugger, 3M)
223996890|NCT01447576|DRUG|ADT|Once daily dosing during the duration of the study.
223996891|NCT01447576|DRUG|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
223996892|NCT04382846|DRUG|Nitazoxanide|Nitazoxanide
223996893|NCT00557661|DRUG|CD-NP|24 hr intravenous infusion
223996894|NCT04925869|OTHER|Observational study|Observational study
223996895|NCT01530893|DIETARY_SUPPLEMENT|Flavanone - supplement|acute single optimal dose
223996896|NCT01530893|OTHER|Flavanone - food|acute single dose
223996897|NCT01530893|OTHER|Flavanone - placebo|acute single dose (flavanone free)
223996898|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - supplement|acute single optimal dose
223996899|NCT01530893|OTHER|Isoflavone - food|acute single optimal dose
223996900|NCT01530893|OTHER|Isoflavone - placebo|acute single dose (isoflavone free)
223996901|NCT01530893|DIETARY_SUPPLEMENT|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
223996902|NCT01530893|DIETARY_SUPPLEMENT|Flavan-3-ol - supplement|acute single optimal dose
223996903|NCT01530893|OTHER|Flavan-3-ol - food|acute single optimal dose
223996904|NCT01530893|OTHER|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
223996905|NCT01530893|DIETARY_SUPPLEMENT|Anthocyanin - supplement|acute single optimal dose
223996906|NCT01530893|OTHER|Anthocyanin - food|acute single optimal dose
223996907|NCT01530893|OTHER|Anthocyanin - placebo|acute single dose (anthocyanin free)
223996908|NCT06423651|BEHAVIORAL|Cognitive Remediation (REHACOP)|REHACOP is a structured neuropsychological rehabilitation program that covers most of the cognitive deficits present in psychotic disorder: attention, learning and memory, executive functions, language, social cognition, daily life activities, social skills and psychoeducation. The modules of language, social cognition and psychoeducation will not be used in the present clinical trial. Each module includes a hierarchy of exercises based on the cognitive subarea to be worked on and the grade of difficulty demanded for the performance of each task.The format of the sessions will be the same as MCT, that is, groups of 6-10 patients who will receive weekly sessions of 45-60 minutes in length. In this case, the duration of the intervention will be 12 sessions.
223996909|NCT06423651|BEHAVIORAL|Metacognitive Training (MCT)|The MCT consists in 8 weekly sessions of 45-60 minutes in length. Each group of patients should be made up of 6-10 patients. The material of the training program is available online at: http://www.uke.de/mkt. The material contains 16 powerpoint presentations (2 per each module), one manual and 6 pamphlets of tasks to do at home. The modules are as follows: Module 1: Attribution; Module 2: Jumping to conclusions (1st part); Module 3: Changing beliefs; Module 4: To emphatise (1st part); Module 5: Memory; Module 6: To emphatise (2nd part); Module 7: Jumping to conclusions (2nd part); and Module 8: Self-esteem and mood.
223996910|NCT00146445|BEHAVIORAL|Peer Mentoring Intervention|
223996911|NCT06169137|BEHAVIORAL|Early Time-Restricted Eating|Participants will be provided all meals to consume within a 6-hour timeframe (9:30-3:30p)
223729717|NCT01710956|RADIATION|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
223996912|NCT06169137|BEHAVIORAL|Conventional dietary regimen (12-hr, 9:30a-9:30p)|Participants will be provided all meals to consume within a 12-hour timeframe (9:30a-9:30p)
223996913|NCT00460902|DEVICE|Transcranial Magnetic Stimulation (TMS)|
223996914|NCT02538315|DRUG|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by \[18F\]FDOPA PET/CT imaging
223996915|NCT00975676|OTHER|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
223996916|NCT02546947|OTHER|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
223996917|NCT04036851|BEHAVIORAL|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
223996918|NCT02548078|BIOLOGICAL|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
223996919|NCT02548078|BIOLOGICAL|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
223996920|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
223996921|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
223996922|NCT00372853|DRUG|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
223996923|NCT00372853|DRUG|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
223996924|NCT03745547|OTHER|Adherence to wearing a Spire wearable health monitor|Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.
223996925|NCT04788342|DEVICE|pulse wave recording, echocardiography.|pulse wave recording using a single-channel electrocardiogram cardiomonitor with photoplethysmography, conducting echocardiography according to a standard protocol with the determination of systolic function of the left ventricle
223996926|NCT03356964|DRUG|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
223996927|NCT02281500|BIOLOGICAL|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20 mg/ml of active substance fibrinogen when reconstituted.
223996928|NCT04906265|OTHER|Intervention|The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking)
223996929|NCT04906265|OTHER|Control|Standard rehabiliation
223996930|NCT02712489|OTHER|No intervention|
223996931|NCT01164111|OTHER|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
223996932|NCT02570997|DRUG|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
223996933|NCT02570997|DRUG|Placebo|Matching placebo administered.
223996934|NCT00388804|PROCEDURE|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
223996935|NCT00388804|DRUG|Bicalutamide|50 mg By Mouth (PO) Daily
223996936|NCT00388804|DRUG|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
223996937|NCT00388804|DRUG|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
223996938|NCT00388804|DRUG|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
223996939|NCT00388804|BEHAVIORAL|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
223996940|NCT00023998|DRUG|doxorubicin hydrochloride|Given IV
223996941|NCT00023998|DRUG|cisplatin|Given IV
223996942|NCT00023998|DRUG|methotrexate|Given IV
223996943|NCT00023998|DRUG|leucovorin calcium|Given IV or orally
223996944|NCT00023998|BIOLOGICAL|filgrastim|Given IV
223996945|NCT00023998|PROCEDURE|therapeutic conventional surgery|Undergo resection
223996946|NCT00023998|RADIATION|radiation therapy|Undergo radiotherapy
223996947|NCT00023998|DRUG|etoposide|Given IV
223996948|NCT00023998|DRUG|ifosfamide|Given IV
223996949|NCT00023998|BIOLOGICAL|trastuzumab|Given IV
223996950|NCT00023998|OTHER|laboratory biomarker analysis|Correlative studies
223996951|NCT02600312|DEVICE|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
223996952|NCT02502747|DRUG|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
223996953|NCT02502747|DRUG|optimal standard of care|Optimal standard of care
223996954|NCT02502747|PROCEDURE|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
223996955|NCT03006640|DRUG|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
223996956|NCT03006640|DRUG|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
223996957|NCT06237166|BEHAVIORAL|mylovia|Participants will receive access to the digital health intervention mylovia in addition to TAU.
223996958|NCT02437357|OTHER|Metacognitive Training|8 group sessions á 60 min
223996959|NCT02437357|OTHER|Positivity Training|8 group sessions á 60 min
223996960|NCT02605369|BEHAVIORAL|Intervention arm: An integrated package|See description in previous column
223996961|NCT04566913|PROCEDURE|Pontic Shield Technique|• Together the apical and the palatal portions of the root in the esthetic region will be delivered and the buccal part is left for assessment of stability of bucco-palatal dimension of alveolar ridge
223996962|NCT02373631|OTHER|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
223996963|NCT02373631|OTHER|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
223996964|NCT01317329|OTHER|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
223996965|NCT04694807|BEHAVIORAL|Group-based Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 2.25 hours for the group format.~Group-based CBTgrief will follow the same content and exercises for each session as individually delivered CBTgrief."
223996966|NCT04694807|BEHAVIORAL|Individually delivered Cognitive Behavioural Therapy for Complicated Grief Reactions|"CBTgrief is a transdiagnostic psychotherapeutic treatment for complicated grief reactions, i.e., symptoms of prolonged grief disorder as well as post-loss depression, anxiety, and posttraumatic stress. The treatment manual is developed by Professor Paul A. Boelen. CBTgrief includes methods such as psycho-education, homework, exposure, alteration of grief-related negative automatic thoughts, behavioural activation, and goal-oriented work. CBTgrief consists of 12 sessions with a session duration of 1 hour for the individually delivered format.~Individually delivered CBTgrief will follow the same content and exercises for each session as group-based CBTgrief."
223996967|NCT06553391|DRUG|The tetralogy of medication regimen|"During the rewarming process, the study group received an injection of 0.15g amiodarone via the extracorporeal circulation oxygenator. After heart re-beating：~1. If the heart rate is ≥70 beats per minute without specific therapy and in sinus rhythm or atrioventricular junctional rhythm, no special treatment is required. If the heart rate \<70 beats/min, intravenous injection of isoproterenol 2 ug may be administered.~2. In cases where there is sinus rhythm or atrioventricular junctional rhythm with a heart rate \<70 beats/min and perfusion pressure \<60mmHg, intravenous injection of ephedrine 10 mg + aminophylline 0.15 g should be given.~3. For patients with atrioventricular junctional rhythm or sinus rhythm and a heart rate \<70 beats/min but perfusion pressure ≥60mmHg, intravenous injections of aminophylline (0.15g) and ephedrine (10 mg) .~4. In cases where there is atrial fibrillation (AF), and the heart rate is ≥70 beats/min without special treatment."
223996968|NCT00134355|DRUG|PTK787|
223996969|NCT00092092|DRUG|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
223996970|NCT00092092|DRUG|Budesonide inhaler|Budesonide 200 mcg inhalation powder
223996971|NCT00092092|DRUG|Placebo to montelukast chewable tablets|Placebo chewable tablets
223996972|NCT00092092|DRUG|Placebo to budesonide inhaler|Placebo inhalation powder
223996973|NCT05691608|BIOLOGICAL|Solid tumor and CT DNA|Biopsy and blood sample
223996974|NCT00999999|PROCEDURE|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
223996975|NCT00925678|DRUG|DSP-3025|
223996976|NCT00925678|DRUG|Placebo|
223996977|NCT06398912|OTHER|Music Based Intervention|Measuring how the fundamental frequency of differential music facilitators (mother, father, male and female music therapist) impacts the premature infant brain
223996978|NCT05676463|PROCEDURE|MRI-guided Intensity-Modulated Radiation Therapy|Undergo MRI-guided IMRT
223996979|NCT05676463|DRUG|Antiandrogen Therapy|Receive SOC ADT
223996980|NCT05676463|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
223996981|NCT05676463|PROCEDURE|Computed Tomography|Undergo CT
223996982|NCT05676463|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223996983|NCT05676463|PROCEDURE|Bone Scan|Undergo bone scan
223996984|NCT05676463|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223996985|NCT05676463|OTHER|Quality-of-Life Assessment|Ancillary studies
224123177|NCT03297099|PROCEDURE|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
224123178|NCT03297099|PROCEDURE|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
224295458|NCT04544137|BEHAVIORAL|BOKS|BOKS is an evidence-based physical activity program developed by Reebok to get kids active and establish a lifelong commitment to health and fitness. It was originally developed and tested as a 12-week program offered before or after school. In the present study, BOKS will be offered four days per week for eight weeks over the summer at a public park in one low-income community. The program will run one-hour prior to lunch service by the USDA's Summer Food Service Program. The BOKS curriculum includes lesson plans for 40-45 minute classes that follow the same daily format and focus on a functional fitness skill of the week (squat, plank, push up, etc) and engage participants in team-oriented games.
223996986|NCT00433758|DEVICE|GlucoTrack|GT
223996987|NCT00178451|DRUG|Abciximab|
223996988|NCT06480331|PROCEDURE|Ultrasound-guided fistuloplasty|Radiation free fistuloplasty
223996989|NCT06480331|PROCEDURE|Fluoroscopy-guided fistuloplasty|Conventional fistuloplasty
223996990|NCT03556787|DEVICE|BPI 1000013 (Dr Scholls Insole)|Full length foam insole
224123179|NCT06235463|OTHER|Osteopathic Pedal Pump|Participants randomized to this condition will receive 5 minutes of myofascial release to the thoracic inlet and 5 minutes of the pedal pump technique.
224123180|NCT06235463|OTHER|Light Touch Treatment|Participants randomized to receive the sham treatment will receive light touch from the operator on the base of the neck and the balls of the feet. This light touch is meant to mimic the pedal pump through touching the same areas of the body but without palpating so that no lymphatic fluid is removed from the lower limbs.
224123181|NCT02745223|DRUG|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
224123182|NCT02745223|DRUG|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
224295459|NCT01010815|PROCEDURE|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
223996991|NCT05730491|BEHAVIORAL|Social Learning and Cognitive Behavioral Therapy (SLCBT)|Participants assigned to this group will complete an online program with 3 core skills, which will include strategies to promote wellness behaviors, use adaptive cognitive coping strategies, model wellness behaviors for their children, and determine when it is appropriate to take further action re: potential illness in their child. The website is interactive and self-guided. All participants will have access to the same resources and content, although based on responses to quizzes and skills practice questions, the automated feedback may differ slightly. The website includes treatment modules that share content via text, images, videos and recordings, a skills library that includes audio recordings of relaxation exercises, infographics to support skills practice, and behavioral assignments to record skills practice and receive automated feedback. Participants will review their knowledge at the end of each treatment module with brief quizzes.
223996992|NCT05730491|BEHAVIORAL|Attention Education Control|Participants assigned to the control group will receive access to a web program and complete 3 modules focused on child health and safety behaviors, such as sports and water safety. These participants will review written/visual content on the above topics, take quizzes to test knowledge gained, and will be provided with brief assignments to increase child safety behaviors. All participants assigned to the control group will have access to the same educational content.
223996993|NCT01755377|DRUG|Benznidazole|
223996994|NCT00852605|OTHER|Intermittent Non-Invasive Ventilation|
223996995|NCT00004068|DRUG|irinotecan hydrochloride|
223996996|NCT00004068|DRUG|temozolomide|
223996997|NCT00004068|PROCEDURE|conventional surgery|
223996998|NCT00004068|RADIATION|radiation therapy|
223996999|NCT05472740|DEVICE|TENS 7000|TENS device to be used in both the active and placebo groups
223997000|NCT02998476|DRUG|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
223997001|NCT03039413|DRUG|Copper Cu 64 TP3805|Given IV
223997002|NCT03039413|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
223997003|NCT03039413|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
223997004|NCT03567629|DRUG|Irinotecan|Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
223997005|NCT03567629|DRUG|Oxaliplatin|Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
223997006|NCT06027034|BEHAVIORAL|Online program for psoriasis (GAIA-PSO-01)|The program to-be-tested (GAIA-PSO-01) is an interactive online program for independent use by users with psoriasis. It focuses on recognized treatment elements of cognitive behavioral therapy (CBT) and behavior change techniques.
223997007|NCT03080337|OTHER|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
223997008|NCT06051331|BEHAVIORAL|simulation-based breast health education|The intervention group will receive simulation-based breast health education once a week for eight weeks. The simulation- based breast health education program will compose two part. The first part, it will theoretical education and second part will continue as practical education. On the plan date, a 60-min lecture will give about breast cancer, its risk factors, interventions to reduce the risk of breast cancer, the value of early diagnosis and cancer screening. After a 10-min break, course attendees watched a 20-min video, after which the course attendees' questions will answer.
223997009|NCT05426863|BEHAVIORAL|DeVI|A multi-component intervention is devised from the components of PM+ developed by WHO incorporating the components of violence prevention. The intervention is anticipated to provide behavioral skills to the participants in the intervention arm which will enhance their coping skills with past experiences of violence, stress management skills, problem-solving skills and safety planning skills. Further, they will be shared the best practices and lessons learned which will aid in danger assessments and prevention of future violence. The intervention will be given to intervention arm in 5 different sessions, one in each week. The 1st session of the intervention is about understanding the multi-component intervention. The 2nd session is identifying and managing problem, 3rd session is about stress management, followed by development of safety plan in 4th session and last session is about promotion of social support.
223997010|NCT06417450|DEVICE|Non-invasive Neuromodulation|Patients receive non-invasive neurostimulation through the Nesa device
223997011|NCT06417450|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
223997012|NCT03729557|PROCEDURE|Nephrectomy|Unilateral nephrectomy
223997013|NCT01398696|PROCEDURE|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
223997014|NCT01398696|PROCEDURE|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
223997015|NCT04157933|DRUG|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
223997016|NCT04157933|DRUG|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
223997017|NCT04157933|DRUG|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
223997018|NCT04157933|DRUG|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
223997019|NCT04157933|DRUG|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
223997020|NCT04157933|DRUG|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
223997021|NCT03277352|DRUG|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
223997022|NCT03277352|DRUG|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
223997023|NCT03277352|DRUG|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
223997024|NCT00707499|DRUG|BMS747158|Single dose administration.
223997025|NCT06853938|DEVICE|Myoelectric prosthesis|The interventions in this study are (1) an enhanced muscle training protocol and (2) fitting with a myoelectric (muscle signal-controlled) prosthetic device after receiving an osseointegrated implant and targeted muscle reinnervation.
223997026|NCT04732845|BIOLOGICAL|Fully human anti CD19 CAR-T Cell Dose|"Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes."
223997027|NCT04732845|DRUG|Fludarabine|25 mg/m2 daily from day -5 to -3
223997028|NCT04732845|DRUG|Cyclophosphamide|60mg/Kg on day -6
223997029|NCT06546228|OTHER|No intervention. Only observational.|Only collection of data or parameters already required by the medical examination programmed.
223997030|NCT02923505|PROCEDURE|polygraphy or polysomnography|
223997031|NCT02760147|DEVICE|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
223997032|NCT02760147|DEVICE|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
223997033|NCT02760147|DEVICE|PEEP Over Level|PEEP Level upward by 50%, 2 hours
223997034|NCT02760147|DEVICE|PEEP Under Level|PEEP Level downward by 50%, 2 hours
223997035|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
223997036|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
223997037|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
223997038|NCT01390155|PROCEDURE|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
223997039|NCT06368856|DRUG|Mupirocin (50 mg)|50 mg de mupirocin
223997040|NCT06368856|DRUG|Mupirocin (500 mg)|500 mg de mupirocin
223997041|NCT06368856|BIOLOGICAL|blood samples after Single dose part|3 blood samples will be performed sampling time ater application of mupirocin (single dose part): 00h30, 1h00, 02h00
223997042|NCT06368856|DIAGNOSTIC_TEST|nasal swab after Single dose part|7 nasal swab for the detection of S. aureus (type Swab) will be performed after application of mupirocin (single dose part): 00h00, 1h00, 02h00, 04h00, 06h00, 08h00, 12h00
223997043|NCT06368856|OTHER|Collection of urine after Single dose part|Collection of urine during 12 hours after the application of mupirocin (Single dose part)
223997044|NCT06368856|DIAGNOSTIC_TEST|nasal swab during Repeated dose part|5 nasal swab for the detection of S. aureus (type Swab) will be performed during administration of mupirocin (Repeated dose part): 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
223997045|NCT06368856|OTHER|Collection of urine during Repeated dose part|5 collections of urine during Repeated dose part: 2, 3, 4, 5 et 6 days after the first application of mupirocin (Repeated dose part)
223997046|NCT06368856|OTHER|nasal swab after Repeated dose part|2 nasal swab for the detection of S. aureus (type Swab) will be performed: 1, 3 months after the first application of mupirocin (Repeated dose part)
223997047|NCT03003585|OTHER|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
223997048|NCT03003585|OTHER|Fiberoptic bronchoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
223997049|NCT00505310|BEHAVIORAL|Writing|20 minutes of writing on different topics at four different times.
223997050|NCT00505310|BEHAVIORAL|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
223997051|NCT05652803|BEHAVIORAL|bibliotherapy-based psychoeducation program|In this study, the researcher aimed to gain awareness, skills and attitudes in order to help the participants reduce the negative consequences of depression and hopelessness. Based on the general purpose, a separate target has been established for each session of both intervention types. For bibliotherapy-based psychoeducation, story texts compatible with the goals were added to each session, and the psychoeducation part was supported by bibliotherapy. Considering the ability of the elderly to attend the training regularly, their attention and coordination, it was decided that the study would consist of 6 sessions and each session would be 60 minutes on average.
223997052|NCT05652803|BEHAVIORAL|psychoeducation program|The General Purpose of the Psychoeducation Program for Reducing Depression and Hopelessness: To help the participants gain awareness, skills and attitudes in order to help them reduce their depression and hopelessness levels.
223997053|NCT05954572|DIAGNOSTIC_TEST|standardized skin surface biopsy (SSSB)|This technique is applied in four facial localizations, including the forehead, cheeks, and nose. The surface biopsy procedure is performed as follows: one cm² area was marked on a glass slide using a fine ruler. The designated skin area for sampling is gently swabbed with a dry gauze pad to create mild irritation. Subsequently, one drop of cyanoacrylate adhesive is applied to the marked area on the glass slide. The glass slide is carefully pressed onto the skin, allowing the adhesive to adhere. After approximately one minute, the glass slide is gently lifted. The sampled area on the glass slide is examined under x10 and x40 magnification. Immersion oil is applied to enhance visualization and determine the number of Demodex parasites within the marked area. An increased demodicosis is defined as the presence of five or more Demodex parasites per square centimeter of skin.
223997054|NCT00160797|DEVICE|MIS™ Minimally Invasive Solutions™ TKA System|
223997055|NCT07135401|DIAGNOSTIC_TEST|Breath-hold conditions|Functional Residual Capacity/End-Expiration (breath-hold technique) with/without oxygen to optimize MRI image quality.
223997056|NCT07136662|OTHER|educational|see arm description
224123183|NCT05020652|DRUG|TQ05105 tablets|TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.
224123184|NCT05020652|DRUG|Hydroxycarbamide tablets|Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.
224123185|NCT02568033|DRUG|Pemetrexed|
224123186|NCT02568033|DRUG|Carboplatin|
224123187|NCT02568033|DRUG|Cisplatin|
223997057|NCT07136480|DEVICE|Microwave Diathermy|Continuous mode microwave diathermy (2,450 MHz) will be applied to the lumbar region using a standard physiotherapy unit. Each session will last 20 minutes, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
223997058|NCT07136480|DEVICE|Shortwave Diathermy|Continuous mode shortwave diathermy (27.12 MHz) will be delivered to the lumbar region using capacitive or inductive electrodes according to manufacturer guidelines. Each session will last 20 minutes, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
223997059|NCT07136480|DEVICE|Therapeutic Ultrasound|Continuous mode therapeutic ultrasound at 1 MHz frequency and 1.5 W/cm² intensity will be applied to the lumbar paraspinal muscles with slow circular movements using a coupling gel. Treatment will last 10 minutes per session, 5 sessions per week for 3 consecutive weeks, in addition to a standardized lumbar stabilization exercise program.
223997060|NCT07136480|BEHAVIORAL|Lumbar Stabilization and Flexibility Exercise|Participants will perform a home-based lumbar stabilization exercise program, including stretching, core strengthening, and posture correction exercises, supervised weekly by a physiotherapist. The program will be performed 3 sessions per week for 4 consecutive weeks.
224123188|NCT02568033|DRUG|Docetaxel|
224295460|NCT01010815|OTHER|stool collection|Stool will be collected from participants at study entry
223729718|NCT04247581|DEVICE|1-lead ECG|"1 lead ECG - All participants will record three single-lead ECGs at rest and three single-lead ECGs after exercise.~Intervention Other: Exercise - All participants will undergo three trials of exercise.~Other interventions: 12-lead ECG - All participants will simultaneously record 12-lead ECGs during rest and exercise sessions."
224123189|NCT02568033|DRUG|Paclitaxel|
224123190|NCT02568033|RADIATION|stereotactic radiosurgery|
224295461|NCT01010815|PROCEDURE|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
223729719|NCT05634460|DRUG|potassium hydroxide|Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
224123191|NCT01623531|DRUG|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
224123192|NCT03095924|OTHER|News items with spin|Interpretation of news items with spin
224123193|NCT03095924|OTHER|News items without spin|Interpretation of news items without spin
224123194|NCT02947516|PROCEDURE|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
224123195|NCT02947516|PROCEDURE|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
224123196|NCT00861367|DRUG|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
223729720|NCT04828447|DIETARY_SUPPLEMENT|Olive Oil|Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.
223729721|NCT04826705|DEVICE|Drug-coated Balloon|To observe the effectiveness and safety of the drug-coated balloon in the treatment of lower extremity arteriosclerosis obliterans of the femoral popliteal artery segment.
223729722|NCT00256191|DRUG|TPI 287 Injection|
224123197|NCT03620266|DIETARY_SUPPLEMENT|Bilberry|The dietary intervention will continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture as both oat and bilberry), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
224123198|NCT03620266|DIETARY_SUPPLEMENT|Placebo|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
224123199|NCT03620266|DIETARY_SUPPLEMENT|Bioprocessed oat bran|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
224295462|NCT01010815|OTHER|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
223997061|NCT07137689|DRUG|LY3537982|Administered orally
223997062|NCT07137780|DEVICE|Lokomat® V6 (GF < 90%)|Robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force of less than 90%. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
223997063|NCT07137780|DEVICE|Lokomat® V6 (GF ≥ 90%)|Robotic-assisted gait training using the Lokomat® V6 system (Hocoma AG, Switzerland) with an average guidance force of 90% or higher. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
223997064|NCT07137780|DEVICE|RoboGait®|Robotic-assisted gait training using the RoboGait® system (BAMA Teknoloji, Türkiye) with an average guidance force of 90% or higher. Training was delivered three times per week for 4 weeks, totaling 10 sessions. In addition to robotic gait training, participants received conventional physiotherapy, including stretching, strengthening, balance, walking, and mobility exercises.
223997065|NCT07138092|OTHER|i jel LMA|Patients will be inserted i jel laryngeal mask under general anesthesia.
223997066|NCT07138092|OTHER|proseal LMA|Patients will be inserted proseal laryngeal mask under general anesthesia.
223997067|NCT07135544|DRUG|Adebrelimab combined with the GC regimen and Apatinib|Adebrelimab 1200mg, intravenous infusion, on day 1, repeated every 3 weeks; Gemcitabine 1000mg/m2, on days 1 and 8, every 3 weeks Cisplatin 50mg/m2, on day 1, every 3 weeks Apatinib 250mg, once daily, orally
223997068|NCT01435772|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
223997069|NCT03238963|DRUG|BI 1467335|Once daily
223997070|NCT03238963|DRUG|Placebo|Once daily
223997071|NCT07048938|COMBINATION_PRODUCT|Five-Element Music 1 combined with antidepressant medication|The self-composed musical piece Five Elements Music 1 was selected to intervene with the patients, with the songs primarily based on the Gong tone and Zhi tone in traditional Chinese music. On this basis, the intervention was combined with fluoxetine hydrochloride treatment
223997072|NCT07048938|COMBINATION_PRODUCT|Five-Element Music 2 combined with antidepressant medication|The self-composed musical piece Five Elements Music 2 was selected to intervene with the patients, with the songs primarily based on the Shang mode (A) and Yu (E) mode in traditional Chinese music. On this basis, the intervention was combined with fluoxetine hydrochloride treatment
223997073|NCT07048938|OTHER|No Intervention: Observational Cohort|No intervention will be applied to healthy people
223997074|NCT07050680|OTHER|Dietary intervention|Single dose of commercially available Oat food test meal
223997075|NCT07049874|DIETARY_SUPPLEMENT|Huel|Ready to eat huel foods. Containing 2 ready to drink shakes, one savoury meal pack and meal replacement powder. Consumption amounts were based on energy needs of each person
223997076|NCT07048951|DIAGNOSTIC_TEST|The Near-Death Experience Content (NDE-C) scale|Questionnaire to detect occurence of NDE. A NDE is identified if score \> or = 27/80
223997077|NCT07048951|OTHER|Threat perception measure|7 items scale investigating the participant's psychological vulnerability during their stay at the ICU
223997078|NCT07048951|OTHER|Interview about the participant's memories of the ICU|"Participants will be asked to describe any dream, hallucination, or any other unusual experience they can recall from their stay at the ICU.~Additionally, the participants will be asked to describe any memory they have of the environment of the ICU, such as the appearance of the room, medical staff, family visiting, noises, etc."
223997079|NCT05626452|BEHAVIORAL|PrEP Education|Education for participants regarding PrEP
223997080|NCT05626452|BEHAVIORAL|Provider training|Training for medical providers at CHCs about how to identify participants eligible for PrEP, how to perform behavioral risk assessment and discussion of PrEP, and how to prescribe PrEP and monitor PrEP
223997081|NCT05626452|OTHER|EMR Optimization|EMR modifications to enhance PrEP care continuum outcomes including HIV risk assessment, identification of participants eligible for PrEP, provision of PrEP education, clinical decision support tools for prescription of PrEP, and tracking of PrEP care continuum outcomes using an electronic population health management tool
223997082|NCT05626452|OTHER|PrEP Navigation|Use of CHC staff members to assist participants with obtaining PrEP and attending PrEP care appointments
223997083|NCT05626452|OTHER|Provider Audit and Feedback|Audit of provider rates of PrEP prescription and persistence among participants and regular provision of feedback to providers with their performance on these PrEP measures
223729723|NCT04404296|DEVICE|25-gauge, bevel-tip, 20000 cut per minute pars plana vitrectomy|Pars plana vitrectomy using 25-gauge, bevel-tip, 20000 cut per minute vitrectomy probe
223729724|NCT02393547|DRUG|Varenicline|All subjects receive Varenicline
223729725|NCT02393547|DRUG|Lorcaserin|All subjects receive Lorcaserin
223997084|NCT07051005|BEHAVIORAL|Feasibility RCT of a tailored online self-compassion intervention|"This is a four-week online self-compassion course supplied by Balanced Minds. The researches of this study and an Expert by Experience have consulted with the owner of Balanced Minds to tailor this programme to people with diabetes.~The self-help, self-compassion course is based on Compassionate Mind Training. This provides participants with opportunities to develop skills and attributes of compassion through a weekly 30-minute video on a specified topic, a 10-minute compassionate exercise that participants are encouraged to engage in daily for the week and a brief summary of the compassionate topic. The topics of the course are:~The Foundations of Self-Compassion Developing your Compassionate Self Deepening the Compassionate Relationship with Yourself Self-compassion in Everyday Life."
223997085|NCT07048847|OTHER|Exercise|The exercise program will be started with 25 Watt (W) for 5 minutes of warm-up. Then it is steadily increased automatically by 5W in 5 minutes apart for 25 minutes for the loading period. The last 5 minutes which will be started by lowering the load to 25 W for cooling will be implemented for cooling down. To prevent acommodation, the warm-up period will be modified by increasing nearly 10% of its previous rate three weeks apart.A submaximal exercise prescription will be followed according to the American College of Sports Medicine guideline by taking into attention 50-70% of Heart Rate Reserve.A submaximal exercise prescription will be followed according to the American College of Sports Medicine guideline by taking into attention 50-70% of Heart Rate Reserve.
223997086|NCT07049445|BEHAVIORAL|Music Activity Program|Participants in the experimental group will receive the standard day care center activities plus a music activity intervention. The music activity consists of pre-recorded video sessions conducted twice a week, each lasting one hour, for a total duration of 8 weeks.
223997087|NCT07049380|DIAGNOSTIC_TEST|Comparative cross sectional|evaluating the efficacy of two analgesics, tramadol and nalbuphine. The primary objectives are to estimate pain severity in smokers versus nonsmokers and identify the effect of tramadol and nalbuphine between these groups
223997088|NCT07050576|DIAGNOSTIC_TEST|The prediction model of lymph node metastasis in early esophageal squamous cell carcinoma|The predictive performance of the model was validated in the test set. The optimal prediction model was determined based on the AUC and ACC. To assess the robustness of the chosen model, ROC analysis was conducted on the external validation set.
223997089|NCT01986088|DRUG|Placebo|matching placebo
223997090|NCT01986088|DRUG|Eletriptan 40 mg|40mg oral
223997091|NCT01986088|DRUG|Eletriptan 80 mg|80mg oral
223997092|NCT01986088|DRUG|Sumatriptan 50 mg|50mg oral
223997093|NCT01986088|DRUG|Sumatriptan 100 mg|100mg oral
223997094|NCT07049198|DEVICE|Real-time 2D motion capture and visual feedback system gait training|The difference between the VF group and the PT group lies in the use of real-time visual feedback during gait training; the VF group receives real-time visual feedback, while the PT group undergoes gait training without visual feedback.
223997095|NCT07049198|OTHER|Conventional physical therapy group|Ten minutes of strength training followed by thirty minutes of gait training, during which the 2DMV system is not used to provide visual feedback. During the gait training, the therapist provides gait correction feedback typically used in conventional physical therapy.
223997096|NCT02506933|OTHER|Laboratory Biomarker Analysis|Correlative studies
223997097|NCT02506933|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223997098|NCT02506933|OTHER|Placebo|Given IM
223997099|NCT06832085|DRUG|Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)|Participants in this group will apply 1 NRT patch each morning for up to 26 weeks. Patches will be titrated based on cigarettes consumed. Short-acting NRT products (gum and lozenge) will be used as needed by the participants in this group.
223997100|NCT06832085|DRUG|Cytisine|Participants in this group will take 3mg of cytisine 3 times per day for 12 weeks.
223997101|NCT06832085|DRUG|Varenicline (Champix)|Participants in this group will take 1mg of varenicline 2 times per day for 12 weeks.
223997102|NCT06805786|DEVICE|real-time continuous glucose monitor|Individuals who switched from using isCGM to rtCGM
223997103|NCT01424813|DRUG|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
223997104|NCT01424813|DRUG|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
223997105|NCT07057063|DEVICE|810 nm Light Therapy|Light therapy at 810 nm, 39 J/cm², delivered via wearable device.
223997106|NCT07057063|DEVICE|Sham Light Therapy|Identical device, no light output, delivered via wearable device.
223997107|NCT01395069|DRUG|Nepafenac 0.1%|1 drop QID for 1 month
223997108|NCT01395069|DRUG|Ketorolac 0.5%|1 drop QID for 1 month
223545174|NCT06718556|BEHAVIORAL|Virtual reality|"The virtual reality intervention program was carried out in a 30-meter2 area covered with soft ground to prevent injuries. The Microsoft Kinect for Xbox 360 was used for the virtual reality intervention. For the current study, a team of experts was formed to select the games to be used within the virtual reality intervention program. This team determined which skills were required for the games to be run successfully, which skills could be developed, which games were purposeful, and independently observed each game. As a result, 9 different games were chosen. Since all games involve similarly intense visual, cognitive and motor skill requirements, game selection was left to the participants' preference during the intervention process to encourage motivation and participation. The virtual reality intervention procedure was created by utilizing the literature"
224123200|NCT03620266|DIETARY_SUPPLEMENT|Combination bilberry/oats|The dietary intervention will be continued for three months. After randomization, participants will be given bilberry shakes (active), liquid oat shakes (active), a combination shake with bilberry and oats, or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake two times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
224123201|NCT01902082|DRUG|Mesenchymal stem cells|
224123202|NCT01902082|DRUG|Placebo|
224123203|NCT04893564|BIOLOGICAL|bone marrow sample|8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.
224123204|NCT04893564|BIOLOGICAL|blood sample|20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.
224123205|NCT06846697|OTHER|Home-based Exercise|The subjects in this group will be given the exercises included in the Physical Activity guideline of the Ministry of Health as a home programme.
224123206|NCT06846697|OTHER|Hatha Yoga Group|The sessions will begin with the classic sun salutation series (Suryanamaskar) consisting of 12 basic poses of yoga. The sun salutation series will be used as a warm-up for 10 minutes. After warming up, postures aimed at stretching the front group muscles of the body and strengthening the back group muscles will be preferred. In the cooling phase, the session will be ended by relaxing with Savasana pose for 10 minutes.
223997109|NCT01395069|OTHER|Placebo (sterile saline drops)|1 drop QID for 1 month
223997110|NCT06771414|OTHER|data collection|data collection
223997111|NCT05153330|DRUG|BMF-219|BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.
223997112|NCT06853613|OTHER|Multicomponent Training Protocol|"Each session consists of:~Warm-up (10 minutes): Low-intensity walking (Borg scale 10-11) to increase heart rate, improve blood flow, and prepare joints.~Main phase (40 minutes):~Aerobic exercises: Controlled jumping jacks, step-ups, alternating knee lifts, lateral steps, and leg lifts.~Mobility exercises: Thoracic extensions, cat-to-cows, overhead stretching with a stick, and hip internal rotations (1-3 sets, 30-60 seconds per exercise).~Resistance training: Gradual progression of 8 exercises targeting major muscle groups, such as squats, bicep curls, shoulder presses, and rows (1-3 sets, 10-15 reps, RPE 13-15).~Cool-down (10 minutes): Breathing exercises and stretching (1-3 sets, 10-30 seconds per stretch)."
223997113|NCT06853613|OTHER|Aerobic Training Protocol|"Each training session will include an initial 10-minute muscle activation phase (low-intensity walking, Borg = 10-11) to increase heart rate, improve muscle blood flow, and prepare the major joints for the next work phase.~main exercise period (40-minute):~25 minutes of progressive aerobic exercises (controlled and rhythmic jumping jacks, step-ups on a sturdy platform (such as a low step or stable surface), standing knee raises (alternating legs), fast side steps or side leg raises).~15 minutes of walking, exercises will be performed at an intensity to ensure that perceived exertion (RPE) will remain between 13 and 15 points on the Borg Scale (6-20). Progression over the weeks will be by maintaining intensity in this range.~Cool down period: breathing and stretching exercises on all major muscle groups."
223997114|NCT06800651|DRUG|JMKX003142 will be administered orally|JMKX003142 will be administered orally
223997115|NCT06800651|DRUG|Plcacebo|matched to JMKX003142
223997116|NCT06744595|PROCEDURE|Biospecimen Collection|Undergo collection of blood or salvia samples
223997117|NCT06744595|OTHER|Educational Intervention|Receive personalized EPIC message
223997118|NCT06744595|OTHER|Electronic Health Record Review|Ancillary studies
223997119|NCT06744595|OTHER|Genetic Counseling|Receive pre-genetic test counseling
223997120|NCT06744595|OTHER|Genetic Counseling|Receive post-genetic test counseling
223997121|NCT06744595|GENETIC|Genetic Testing for Cancer Risk|Undergo SOC genetic testing
223997122|NCT06744595|OTHER|Survey Administration|Ancillary studies
223997123|NCT07136974|DRUG|TQB2102|TQB2102 is administered intravenously at 6 mg/kg every 3 weeks for 6 cycles.
223997124|NCT07136974|DRUG|Docetaxel + Carboplatin + Trastuzumab +Pertuzumab|Docetaxel 75 mg/m2(day 1) , Carboplatin (AUC=6) (day 1), Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Pertuzumab (840mg first dose, 420mg/kg sequential) are administered intravenously every 3 weeks for 6 cycles.
223997125|NCT06841133|BEHAVIORAL|Chinese Art Activities|"This activity based on Recreation therapy, aims to heal the psychological symptom cluster and enhance the PWB of the old Chinese transit to the elderly center. The activity follows the usual care during the process with the addition of Chinese art activities. It employed the following two main activities:~(1) Traditional Chinese landscape painting; (2) Calligraphy. The activity will be conducted 50min by researchers. It can be conducted at hall, conference room, etc. in the elderly center (EC), and it is a group intervention"
223997126|NCT06841133|BEHAVIORAL|Chinese Art Activities combined with Peer Group Participation (PGP)|The activity follows the usual care during the process with the addition of Chinese art activities combined with Peer Group Participation. The activity will be conducted 80min by researchers. In groups of 5 people, after the painting and calligraphy activity, under the organization of peers, each group member will show their works and talk about their feelings and views on their works. They will also share the reasons why they chose these words or sentences. Everyone must say words of comfort and encouragement to others' work.
223997127|NCT06874283|PROCEDURE|Eye exam|Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. A standard of care exam will be performed to the reason for the visit. In addition to the standard of care exam, those in the Cancer Therapy arm will have certain biological samples (tear collection, impression cytology, and/or blood) collected, stored, and analyzed so we may obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.
223997128|NCT06765499|OTHER|Chinese medicine - Silkworm pupa powder|Silkworm pupa contains high-quality animal protein and has a wide range of activities in antioxidant, antitumor, antibacterial, and immune enhancement, making it highly nutritious and medicinally valuable.
223997129|NCT06765499|OTHER|Ultra-low dose silkworm pupa powder|0.5% of the effective components in the experimental group
223997130|NCT02875197|OTHER|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
223997131|NCT04716751|DRUG|Toripalimab|"Neoadjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: Patients with tracheal malignant tumor received radical surgery after neoadjuvant therapy, and patients who could not or refused surgical treatment due to various reasons were treated with multidisciplinary discussion.~Adjuvant treatment stage: Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ²,iv, up to 4 cycles (including neoadjuvant stage)."
223997132|NCT05962034|DRUG|Aspirin|650 mg aspirin (Acetylsalicylic acid)
223997133|NCT05962034|OTHER|Placebo|placebo capsule
223380587|NCT05938621|BEHAVIORAL|behavioral therapy and education|Sessions that focus on developing self-awareness and strategies to improve well-being will be the focus of the interventions.
223380588|NCT06308549|BEHAVIORAL|MyDiaMate|MyDiaMate programme
223380589|NCT03598790|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223380590|NCT05646979|BEHAVIORAL|EFT group|EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
223380591|NCT06830577|DRUG|Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy|Intraureteric aminophylline installation prior to ureteric dilatation
223380592|NCT06830577|DEVICE|Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy|traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr
223380593|NCT06830577|OTHER|Aminophylline instillation and Ureteral dilators together|Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B) prior to placing the ureteric access sheath
223380594|NCT03686488|DRUG|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
223380595|NCT03686488|DRUG|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
223380596|NCT02917720|OTHER|TKI discontinuation|2nd or 3rd TKI stop after pre-treatment with nilotinib.
223380597|NCT02917720|DRUG|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
223380598|NCT06526988|BEHAVIORAL|EPIC-HF Patient-facing Tool|A brief, animated video designed to engage and activate patients around their HFrEF medication prescribing sent prior to routine cardiology clinic visit, accompanied by a one-page HeartMeds Guide checklist.
223380599|NCT06526988|BEHAVIORAL|PROMPT-HF Clinician-facing Alert|A best practice alert will appear for each eligible patient upon opening of the order entry screen in the patient's medical record. This alerts the provider of the presence of HFrEF, notes the patient's current LVEF and current evidence-based medications, and gives access to an order set with recommended evidence-based, guideline-recommended, and FDA- approved therapies for patients with HFrEF. Providers will also have access to a link to best available guideline recommended information regarding treatment of heart failure to allow further education if desired by the provider. The alerts will also clearly state the expected monitoring and follow-up required for prescriptions of these medications.
223380600|NCT05410561|BEHAVIORAL|Enhanced Usual Care (EUC)|EUC will comprise one session of brief psychoeducation and referral information to alcohol use disorder (AUD) treatment.
223380601|NCT05410561|BEHAVIORAL|TeleTx intervention|TeleTx will consist of an initial session and then 8 \~counseling sessions.
223380602|NCT06756932|DRUG|BGB-21447|Administered orally.
223380603|NCT06756932|DRUG|Fulvestrant|Administered via intramuscular injection.
223380604|NCT06756932|DRUG|BGB-43395|Administered orally.
223380605|NCT04371445|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
223380606|NCT04371445|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care including topical antibiotics.
223997134|NCT05812092|DEVICE|CONDUIT Interbody Cervical System with DePuy Synthes Cervical Plating System|CONDUIT Interbody Cervical System will be inserted between C2 through T1 and fixated using a DePuy Synthes Cervical Plating System at 1 or 2 levels.
223997135|NCT07138404|OTHER|self administration questioner|A self questionnaire will be distributed to evaluate the levels of stress experienced by dental students currently undertaking clinical training in 4th and 5th academic years at Cairo University during the performance of specific clinical procedures in conservative and endodontics treatment.The data obtained from the questionnaire will be statistically analyzed to identify and interpret the variations in the results.
223380607|NCT01839435|PROCEDURE|outpatient surgery|
223380608|NCT06957483|BEHAVIORAL|REACH-SCI (Reducing sedEntary Activities to improve Cardiovascular Health in individuals with a Spinal Cord Injury)|The REACH-SCI intervention was co-designed with key stakeholders and aims to reduce and break up sedentary behaviour in individuals with paraplegia. The intervention will last eight weeks and involve (1) a wearable activity tracker to give reminders to break up sedentary behaviour, (2) education around what sedentary behaviour is, how to reduce and break up sedentary behaviour, and the benefits of doing so, (3) a goal setting worksheet related to sedentary behaviour, (4) one-to-one motivational support sessions to help set goals, review progress and give motivation, (5) peer support using a smartphone app, and (6) activity tools to support breaking up sedentary behaviour throughout the day.
223380609|NCT06782490|DRUG|BMS-986368|Specified dose on specified days
223380610|NCT06782490|DRUG|Placebo|Specified dose on specified days
223380611|NCT06543693|OTHER|ultrasound training|PoCUS training
223380612|NCT02919215|BEHAVIORAL|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as a support for teachers if needed. All participants can access and/or provide usual services. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
223545175|NCT06718556|BEHAVIORAL|Client-centered|"The client-centered (CC) intervention procedure for individuals with schizophrenia was created using literature and the intervention procedure is presented below:~1. Active Communication and Evaluation~2. Daily Routine, Roles, and Occupational Performance~3. Strengths and Barriers~4. Intervention Program Development~5. Implementation of the intervention program~6. Feedback and Revision:"
223380613|NCT06964412|OTHER|Artificial-intelligence (AI)|Utilizing the addition of artificial intelligence during prostate contouring.
223380614|NCT03501368|DRUG|Ceritinib|Participants will take ceritinib by mouth (PO) once daily at a dose of up to 450 mg (3 capsules of 150 mg)
223380615|NCT03501368|DRUG|Trametinib|Participants will take trametinib by mouth at a dose of 2 mg daily
223380616|NCT04610229|RADIATION|Hypofractionation guioded by dose painting|1
223380617|NCT00111527|OTHER|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
223380618|NCT00111527|OTHER|normal RV pacing|PM or ICD implant according to patient indication
223380619|NCT06632496|DEVICE|BD Prevue(TM) II|Ultrasound-guided peripheral intravenous catheter placement procedure using the BD Prevue(TM) II
223380620|NCT05928390|DRUG|Pasireotide Diaspartate|Injectable ampoules
223380621|NCT06634589|DRUG|BGB-16673|Administered orally
223997136|NCT07138469|OTHER|Questionnaire|The questionnaire was offered on a voluntary basis and completed online by the participants. At the end of the inclusion period, the responses were analyzed. Participant indicated in the questionnaire whether or not they had already undergone oocyte cryopreservation. The responses were analyzed to assess demographic characteristics, the level of knowledge regarding the bioethics law on non-medical fertility preservation, and future perspectives in the event of use (desired parental model, likelihood of use) or non-use.
223380622|NCT06634589|DRUG|Sonrotoclax|Administered orally
223380623|NCT06634589|DRUG|Zanubrutinib|Administered orally
223380624|NCT06634589|DRUG|Mosunetuzumab|Administered subcutaneously
223380625|NCT06634589|DRUG|Glofitamab|Administered intravenously
223380626|NCT06634589|DRUG|Obinutuzumab|Administered intravenously
223380627|NCT06021704|BEHAVIORAL|Enhanced home health aide training in dementia and dementia-related behaviors|8 hours (2 instructional days) of enhanced curriculum dementia-specific instruction for home health aides
223380628|NCT05199688|DRUG|Satralizumab|Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.
223380629|NCT03975491|BEHAVIORAL|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50-70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
223380630|NCT03975491|BEHAVIORAL|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
223380631|NCT06666699|DEVICE|EUS access device|The intervention involves the use of an EUS access device to gain access to the bile duct via hepaticogastrostomy.
223380632|NCT05180773|DRUG|Bromocriptine|Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
223380633|NCT05180773|DRUG|Placebo|Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
223380634|NCT05180773|DRUG|Guideline Directed Medical Therapy for Heart Failure (GDMT)|GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
223380635|NCT05180773|DRUG|Rivaroxaban|Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
223380636|NCT05180773|DRUG|Second Placebo|Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
223380637|NCT03536312|PROCEDURE|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
223380638|NCT06080477|BEHAVIORAL|Enhanced Usual Care|Participants randomized to usual care will continue to receive their standard clinical care at Queen Elizabeth Central Hospital (QECH) as previously. The clinical team will be provided a summary of the results of the eligibility assessment, specifically an interpretation of the scores on the symptomatology and disability scales with any relevant clinical recommendations. These individuals will receive no home-based services.
223380639|NCT06080477|BEHAVIORAL|Adapted ENHANCE Intervention|Participants randomized to the intervention arm will receive community-based rehabilitation (CBR) delivered by the Queen Elizabeth Central Hospital (QECH) clinical team of psychiatric nurses. The ENHANCE CBR intervention will consist of nurse-delivered home visits over approximately a 12-month period with decreasing intensity, with approximately weekly visits for an initial phase of 2-4 months; biweekly visits for an intermediate phase of 4-6 months; and monthly for a final transition phase of 3-4 months. The exact schedule and duration of each phase will be individualized by the nurse to the participant based on the participant's initial presentation and their response during the intervention. The intervention team will deliver intervention content with the participant and/or family members and caregivers as appropriate to the module.
223380640|NCT05503264|DRUG|Satralizumab|In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight. Study drug will be administered by subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments.
223545176|NCT06710925|BIOLOGICAL|TNM001|single dose intramuscular injection
223545177|NCT06710925|BIOLOGICAL|placebo|single dose intramuscular injection
223997137|NCT04303117|DRUG|NHS-IL12|An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.
223997138|NCT04303117|DRUG|M7824|1200 mg administered IV every two weeks while on NHS-IL12.
223997139|NCT02928705|PROCEDURE|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
223997140|NCT02928705|PROCEDURE|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
223380641|NCT05503264|OTHER|Placebo|Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.
223380642|NCT04429295|BIOLOGICAL|DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223380643|NCT04429295|BIOLOGICAL|DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223380644|NCT04429295|BIOLOGICAL|Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223380645|NCT04429295|BIOLOGICAL|Poliomyelitis Vaccine bivalent types 1 and 3|Pharmaceutical form:Oral suspension Route of administration: Oral
223380646|NCT04429295|BIOLOGICAL|Human Rotavirus, live attenuated|Pharmaceutical form:Oral suspension Route of administration: Oral
223380647|NCT04429295|BIOLOGICAL|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223380648|NCT05327387|OTHER|model-based electrical brain stimulation|Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
223380649|NCT04509934|OTHER|Connective Tissue Manipulation|The position of the patients during treatment sessions was sitting with the hips and knees at 90° flexion and feet supported, arms relaxed on the thighs, back naked and straight, allowing optimal tension of the connective tissue. The CTM procedure consisted of treating 3 sections in the back. These sections were basic (sacral and lumbar regions), lower thoracic (L1 through T7) and anterior pelvic. All sessions were ended with bilateral long strokes to the iliac crest and subcostal regions. The physiotherapist applied strokes bilaterally by her middle finger of the right or left hand to the defined zones of the mentioned sections in the back. The treatment started from the basic section, and progress to other regions was decided according to the vascular reaction of the connective tissue. Each session lasted for 5 to 20 minutes, depending on the extent of the treated area.
223380650|NCT06337513|OTHER|Rehabilitation intervention|"The intervention consists of a physiotherapist-coordinated (PT) interdisciplinary outpatient rehabilitation offer for 6-months.~The intervention encompasses 3 individual sessions with the PT, if needed individual sessions with the interdisciplinary team (PT, occupational therapist, OT, nurse, and social worker) (a maximum of 6 hours), and patient education in two group seminars."
223997141|NCT06155812|OTHER|Simultaneous administration of vasopressors|Early, simultaneous administration of norepinephrine, angiotensin II, and vasopressin.
223997142|NCT06155812|OTHER|Successive administration of vasopressors|Administration and titration of norepinephrine and vasopressin. Administration of additional vasoactive drugs (epinephrine, methylene blue, angiotensin II or dopamine) as per clinical team. Initiation of inotropes (dobutamin, levosimendan, milrinone) as per clinical team decision.
223380651|NCT06337513|OTHER|Usual care|Both the intervention and the control group will receive usual care.
223380652|NCT05829317|DRUG|Magnesium sulfate|Intravenous Magnesium sulfate
223380653|NCT05829317|DRUG|Placebo|0.9% NaCl
223380654|NCT05998772|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Application of 82,5 g of glucose monohydrate solved in 300ml water
223380655|NCT05998772|OTHER|Placebo Oral Glucose Tolerance Test|Application of 125mg sucralose solved in 300ml water
223545178|NCT06715059|OTHER|Tele-rehabilitation exercise program|A progressive core stability exercise program will be performed based on motor control principles via an online platform.
223545179|NCT06715059|OTHER|Home-based exercise program|A core stability exercise program will be performed at home.
223545180|NCT03584906|PROCEDURE|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
223545181|NCT03584906|PROCEDURE|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
223545182|NCT03584906|PROCEDURE|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
223545183|NCT03584906|PROCEDURE|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
223545184|NCT03584906|PROCEDURE|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
223545185|NCT06712680|DRUG|Test Product HYP-6589|HYP-6589 should be administered orally at the recommended dosage
223997143|NCT06916845|DEVICE|Colon Capsule|All participants will swallow the CapsoCam® Colon (CV-3E) for this study.
223997144|NCT06922994|DRUG|Atorvastatin 80 mg/day|Atorvastatin 80mg/day will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
223997145|NCT06922994|DRUG|Placebo atorvastatin|One tablet of placebo will be administered for 18 months to patients affected by Arrhythmogenic Cardiomyopathy
223997146|NCT06932536|DRUG|SR750 tablet|Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally
223997147|NCT06932536|DRUG|Placebo|Ascending single and multiple doses of placebo orally
223997148|NCT06293638|DRUG|Alcohol|Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol \[10 mL. or 8 g of pure ethanol\]) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
223997149|NCT06293638|DRUG|Alprazolam|Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
223997150|NCT06293638|DEVICE|Cold Therapy|One or both of the participant's upper limbs will be wrapped with pre-chilled ice packs or a cold water circulating device such as a cryomanchet (e.g., the Breg PolarCare Glacier), and the skin temperature monitored until it lowers to 15-25°C. Participants will then repeat motor task and data collection while the limb is cool.
223997151|NCT06293638|PROCEDURE|Peripheral Nerve Stimulation|Electrical stimulation will be applied using techniques similar to those applied during standard somatosensory evoked potential testing. Specifically, adhesive surface electrodes will be placed above the median and radial nerves at the wrist. Stimulation paradigms will be tailored to each participant based on the frequency characteristics of their tremor. Participants will receive between 20-60 minutes of stimulation, then will repeat motor task and data collection. Transcutaneous peripheral nerve stimulation may help mitigate tremor, with effects lasting beyond cessation of stimulation1-3.
223997152|NCT06938282|DRUG|HRS-4642|HRS-4642 in Combination with Immunotherapy and Chemotherapy
223997153|NCT01531777|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
223997154|NCT01531777|DRUG|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
223997155|NCT00329212|DRUG|San Huang Xie Jin Tang|
224123207|NCT06846697|OTHER|Reformer Pilates Group|Exercise sessions will start with the foot series and the starting position on the back will be preferred. This series, which is progressed by maintaining the body composition, is considered as a warm-up exercise of the body. Then, the body is continued with exercise series targeting the thoracic region and core region.
223380656|NCT05425511|BEHAVIORAL|sophrology / neurolinguistic programming intervention|"2 sessions will be offered per week at 2 different time and will last 1 hour. They can take place in a seated or standing position, without physical contact. The sessions will consist of breathing exercises, visualization, dynamic relaxation and concentration exercises. The program is standardized:~1. Dialogue between the sophrologist and the participants. It is possible to specify the objective(s) of the session. The sophrologist can ask more specific questions to adapt the session.~2. Presentation of the conduct of the session (possible variations) and instructions promoting autonomy~3. Guided by the sophrologist, the goal is to help free yourself from tensions, to play down a situation that worries and finally to realize that we can deal with. Exercises are adapted to the difficulties encountered by the participants.~4. Time for free expression after the practice to promote the integration of the technique while giving elements to the sophrologist to guide the future sessions."
224123208|NCT00726323|DRUG|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
224123209|NCT02288728|PROCEDURE|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
224123210|NCT02288728|PROCEDURE|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
224123211|NCT06115421|DRUG|Roxadustat|hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs)
224123212|NCT03022305|BEHAVIORAL|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
224123213|NCT03022305|BEHAVIORAL|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
224123214|NCT03344731|BEHAVIORAL|Cognitive evaluation|Cognitive task
224123215|NCT03344731|DEVICE|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
224123216|NCT00389896|DRUG|MK0733 / Duration of Treatment: 18 Weeks|
224123217|NCT00389896|DRUG|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
224123218|NCT02122861|BIOLOGICAL|ID-LV305|pembrolizumab
223380657|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention Training|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI Group Training is comprised of three components: TBRI Youth Group Training (youth only), Caregiver Training (caregivers only), and Nurture Groups (youth-caregiver joint roleplay activities), which is conducted prior to youth's release."
223997156|NCT07138235|PROCEDURE|laparoscopic hiatal hernia repair|"Intraoperative endoscopic control and the use of calibration bougies allow for increasing the accuracy of cardiac sphincter reconstruction and reducing the risk of hyper- or hypocorrection. Endoscopic equipment. The Olympus EVIS EXERA III endoscopic video system (Olympus Medical Systems Corp., Tokyo, Japan), series 190, was used for diagnostic and therapeutic endoscopic examinations.~The complex included:~* CV-190 video processor with digital image magnification,~* CLV-190 light source (xenon/LED), providing high brightness and uniformity of illumination, a high definition (HD) video monitor,~* GIF-HQ190, GIF-H190 high-resolution series gastroscopes,~* CF-HQ190L/I series colonoscopes (if necessary). These functions made it possible to more accurately assess the condition of the mucous membrane of the esophagus and stomach, as well as to identify pathological changes.~Medications: omeprazole/esomeprazole, ondansetron, cephalosporins intravenously, metoclopramide."
223997157|NCT07135739|DEVICE|funcional Electrical stimulation combined with mirror therapy|"* Subjects were treated with a combination therapy of task specific mirror therapy and functional electrical stimulation, consisting of two tasks, for a total duration of thirty minutes.~* The subject was positioned on a height adjustable table with the mirror placed in front of the mid line.~* The positive electrode and negative electrode of the muscle simulator were placed over the muscle belly of the wrist extensors on forearm over the motor (between one-third and half-way from the proximal end of the dorsal forearm) of the affected upper limb.~* The subject was then instructed to observe the mirror reflection for one to two minutes, trying to visualize the mirror image as the affected limb, asked to perform slow, easy to achieve simultaneous bilateral movements (perceived bilateral movements) while continuing to look at ,with the affected limb performing synchronously with the duty cycle of electrical stimulation."
223997158|NCT07135739|OTHER|Physical therapy program|"The program will be applied to all children in both groups (A and B). The exercise session for one hour for each child in both groups, conducted 3times/ week for 3 successive months.~1. Flexibility exercises for shorted muscles and spastic muscles.~2. Strengthening training focusing on the trunk lower limb and upper limb muscles for weak muscles.~3. Postural control exercise in different positions and different surfaces~4. General endurance training (Sherief et al., 2020).~5. Exercises to facilitate hand function including basic reaching grasping, carrying, release and the more complex skills of in-hand manipulation and bilateral hand use were conducted."
223997159|NCT06100913|BIOLOGICAL|Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)|The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
223997160|NCT06100913|OTHER|Deuterium Labeled Water|An Emory Investigational Drug Service pharmacist will prepare sterile 50 ml aliquots of D2O with a tamper seal and stored at room temperature. Participants will be asked to drink a pre-measured volume of water three times a day and on days according to their assigned group schedule.
223997161|NCT01446120|DRUG|NPH-Insulin Injection|
223997162|NCT01446120|DRUG|Insulin loaded Orally Dissolved Films (insulin-ODF|
223997163|NCT03572881|DEVICE|Endocardial mapping|An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
223997164|NCT05261373|OTHER|The Moderate-Intensity Continuous Training (MICT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. MICT program will consist of sessions of approximately ˜45 min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
223997165|NCT05261373|OTHER|The High-Intensity Interval Training (HIIT)|3 sessions per week in a cycle ergometer, with 1-2 days off between sessions, during a total of 12 weeks under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes). Depending on the number of training session, the load and the series will increase up to 40% more than the maximum load.
223997166|NCT05261373|OTHER|Behavioral: Nutritional education program|The education intervention will consist of individual nutritional counselling. The nutritional education program will be conducted every 2 weeks for 12 consecutive weeks, with 20-min counselling sessions by an experienced nutritionist. Participants will be provided with an introduction (in an easy-to-understand manner) regarding the association between T2DM, gut microbiome and dietary habits. Firstly, the diet of the patient should be analysed, to determine which aspects can be improved, such as, total calories intake, amount and types of carbohydrates (highlighting the relevance of fibre), etc. Moreover, some suggestions about the combination of foods and culinary technical in order to manage the glycaemic index of foods will be provided. Finally, those pattern of the Mediterranean diet and some qualitative aspects and aids (as the size of the plat or avoid having the food platter on the table) will be taught the patients.
223997167|NCT05319015|DRUG|Neoadjuvant Lenvatinib|20 mg PO daily for 12 weeks prior to surgery
223997168|NCT05319015|DRUG|Neoadjuvant Pembrolizumab|200 mg IV every 3 weeks for 4 doses prior to surgery
223997169|NCT05319015|PROCEDURE|Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection|Resection of locally advanced RCC with IVC tumor thrombus
223380658|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Structured Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Structured Training includes four structured in-home coaching sessions."
223380659|NCT04678960|BEHAVIORAL|Trust-based Relational Intervention In-Home Responsive Coaching|"The intervention (Trust-based Relational Intervention® TBRI®) uses a youth-centered, attachment-based, and trauma-informed approach to strengthen youth/safe adult relationships and improve youth self-regulation (thinking, emotions, and behavior). TBRI includes TBRI Group Training and TBRI In-Home Coaching.~TBRI In-Home Responsive Training includes at least 2 structured in-home coaching sessions plus additional sessions indefinitely as needed."
223997170|NCT05319015|DRUG|Adjuvant Pembrolizumab|200 mg IV every 3 weeks for up to 13 doses after surgery
223997171|NCT04944290|DRUG|Brinzolamide/brimonidine ophthalmic suspension|Test product
223545186|NCT06716827|PROCEDURE|In-office bleaching system|As the whitening agent, an in-office bleaching system containing 35% hydrogen peroxide (Whiteness HP, FGM) was chosen. The gingiva was isolated using an isolation material (Opaldam, Ultradent Products Inc.), which was light-cured with a standard curing light. The whitening gel was applied to the labial surfaces of the maxillary incisors and canines with a 1mm thickness and left for 20 minutes. After cleaning the teeth with an aspiration tip, the whitening procedure was repeated.
223997172|NCT04944290|DRUG|Simbrinza 0.2%/1% Ophthalmic Suspension|Reference product
223997173|NCT04115657|OTHER|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
223997174|NCT04115657|OTHER|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
224123219|NCT00549237|DIETARY_SUPPLEMENT|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
224123220|NCT00549237|OTHER|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
224123221|NCT01617681|DRUG|VAL489|Valsartan 3mg/kg oral solution
224123222|NCT01617681|DRUG|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
224123223|NCT02599766|OTHER|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
224123224|NCT02599766|OTHER|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
224295463|NCT05208879|BIOLOGICAL|Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only)|"Carotenoid status will be determined by measuring plasma and erythrocyte concentrations of lutein and zeaxanthin obtained during an annual blood draw. These molecules will be analyzed by high performance liquid chromatography.~The oxidative stress markers will be measured, in the blood sample already collected, thanks to specific assay kits: Erythrocyte reduced glutathione, Superoxide dismutase (SOD), Glutathione peroxidase (GPx), Plasma and erythrocyte malondialdehyde, Plasma vitamin C, Plasma oxidized cholesterol, F2-isoprostanes.~This study does not result in any change in patient management, but requires the collection of an additional volume of blood (14 ml of study-specific blood) during the annual blood draw performed as part of routine patient follow-up."
223380660|NCT04669041|DRUG|Rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
223380661|NCT04669041|DRUG|SPC ezetimibe/rosuvastatin|Pharmaceutical form:Tablet Route of administration: Oral
223380662|NCT04669041|DRUG|Rosuvastatin active capsule|Pharmaceutical form:Capsule Route of administration: Oral
223380663|NCT04669041|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
223380664|NCT04669041|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
223729726|NCT01967212|DEVICE|Game-based swallow biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
223997175|NCT04115657|OTHER|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
223997176|NCT04115657|OTHER|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
223997177|NCT04115657|OTHER|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
223997178|NCT04115657|OTHER|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
223997179|NCT00132899|DRUG|Methotrexate|Methotrexate and infliximab combination
223997180|NCT00132899|DRUG|Placebo|Placebo and infliximab combination therapy.
223997181|NCT04018274|DRUG|PF-06651600|50 mg by mouth (PO) once daily (QD)
223997182|NCT04018274|DRUG|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
223997183|NCT02385058|DRUG|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
223997184|NCT02385058|DRUG|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
223997185|NCT02385058|DRUG|Placebo|Placebo tablet orally once starting on Day 21.
223997186|NCT05743881|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223997187|NCT05743881|BIOLOGICAL|mRNA-1365|Sterile liquid for injection
223997188|NCT05743881|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) solution for injection
223997189|NCT05743881|DRUG|Nimenrix|Solution for injection
223997190|NCT02097953|DRUG|Daptomycin|
223997191|NCT02097953|DRUG|Rifampin|
223997192|NCT01027052|OTHER|Hamburger meat patty with salt|hamburger meat cooked with salt
223997193|NCT01027052|OTHER|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
223997194|NCT03838731|DRUG|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
224123225|NCT01620385|DEVICE|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
224123226|NCT01883440|DRUG|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
224123227|NCT01883440|DRUG|Saline+glucose|Placebo arm
224123228|NCT02241395|BIOLOGICAL|Intrathecal autologous bone marrow mononuclear cell transplantation|
224123229|NCT03696758|PROCEDURE|Pulmonary Function Testing|Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
224123230|NCT03696758|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
223997195|NCT03838731|DRUG|Placebo|Single subcutaneous (SC) dose of matching placebo
223380665|NCT06294574|DEVICE|HydroMARK Plus Clip|Each patient will undergo a breast localization procedure, and a HydroMARK plus clip will be placed.
223380666|NCT06247111|OTHER|Remote Blood Pressure Monitoring + Telehealth|Remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
223997196|NCT04245553|DIAGNOSTIC_TEST|Abdominal Point of Care Ultrasound|Participants will be have their needle insertion site for a paracentesis land-marked using both the traditional anatomical method, and with a point of care ultrasound. Note that the current standard of care does not require the use of point of care ultrasound.
223997197|NCT04557267|DRUG|low-dose|Dosage 1
223997198|NCT04557267|DRUG|Middle-dose|Dosage 2
223997199|NCT04557267|DRUG|Higher-dose|Dosage 3
223997200|NCT04557267|DRUG|Placebo|Placebo
223997201|NCT02701881|DEVICE|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
223997202|NCT02701881|DEVICE|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
223997203|NCT05106777|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 21-day cycle.
223997204|NCT04227145|BEHAVIORAL|SexHealth Mobile|"It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with."
223997205|NCT05034172|OTHER|Clinical follow-up|"Clinical Follow-up:~demographic data and history,~* Retrospective interview (collection of data useful for genetic studies): -disease history (for patients only);~* Family history - Neurological examination:~* Diagnosis Clinical examination;~* Rating scales specific to the pathology under investigation;~* Cerebral MRI (optional)~* Biological samples (optional)"
223997206|NCT03404895|DEVICE|Conventional Therapy|Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
223997207|NCT03404895|DEVICE|Venous Stent(s)|After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
224123231|NCT03696758|PROCEDURE|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
224123232|NCT03696758|DRUG|Metoprolol|Subjects will receive intravenous metoprolol. Dose titrated 1-5 mg every 2 minutes to achieve goal heart rate of 55-65 beats per minute, or for subjects with a resting heart rate already at goal, titrated to achieve a 10-15% reduction in heart rate.
224123233|NCT03696758|DRUG|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
224123234|NCT03526003|DIAGNOSTIC_TEST|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
223380667|NCT06247111|OTHER|Usual care|Participants receive usual care, no intervention.
223380668|NCT06215846|BIOLOGICAL|BioTTT001 injection|BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
223380669|NCT06500962|BEHAVIORAL|Usual Care|Participants will receive a message sent to their electronic health record portal with instructions about how to sign up for a food is medicine program.
223380670|NCT06500962|BEHAVIORAL|Navigation|Participants will receive a weekly phone call from a navigator to promote enrollment in the food is medicine program and address any barriers to participation.
223380671|NCT06500962|BEHAVIORAL|Text Messaging|Participants will receive two text messages per week to promote healthy eating, enrolling in a food is medicine program, and continuing to participate in a food is medicine program.
224123235|NCT02422953|DIETARY_SUPPLEMENT|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
224123236|NCT02422953|DIETARY_SUPPLEMENT|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
223380672|NCT06217874|OTHER|Non-Interventional Study|Non-interventional study
223380673|NCT03716180|DRUG|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
223380674|NCT03716180|DRUG|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
223380675|NCT03716180|DRUG|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
223380676|NCT05194111|DRUG|Sacubitril-valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
223380677|NCT05194111|DRUG|Valsartan|Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
223997208|NCT02976077|BEHAVIORAL|RC2S+|new cognitive remediation program
223997209|NCT02976077|BEHAVIORAL|active comparator|cognitive remediation program
223997210|NCT00666900|DRUG|Low Strength IDP-107|Once a day for 12 weeks
223997211|NCT00666900|DRUG|High Strength IDP-107|Once a day for 12 weeks
223997212|NCT00666900|DRUG|Placebo Comparator|Once a day for 12 weeks
224123237|NCT02422953|DIETARY_SUPPLEMENT|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
224123238|NCT02422953|BEHAVIORAL|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
223380678|NCT05929651|BIOLOGICAL|MenACYW conjugate vaccine|Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection
223380679|NCT03517475|BEHAVIORAL|SHS Low-Income|An intervention to train caregivers to supervise their children appropriately.
223380680|NCT05929521|OTHER|C-PrEP+|Rather than a one-on-one PrEP care visit, a cohort of 8-12 patients meet with the same providers at each visit for individual health assessments, linkages to services, and 75-90 minutes of group interactive learning and skill-building that centers patients' experiences. This approach to healthcare has great potential meet sex workers' HIV prevention needs, including optimal use of PrEP
223380681|NCT02186470|RADIATION|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
223380682|NCT02186470|RADIATION|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
223997213|NCT04161053|DRUG|Rifaximin|Rifaximin 550 mg twice daily for 6 months
223380683|NCT02186470|RADIATION|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
223380684|NCT02186470|PROCEDURE|therapeutic conventional surgery|Lumpectomy
223380685|NCT02260570|DRUG|Tolcapone|COMT Inhibitor
223380686|NCT02260570|DRUG|Placebo|A pill that contains no active ingredient
223380687|NCT04795973|BEHAVIORAL|5:2 intermittent fasting|All subjects received 5:2 IF. They followed a normal diet for 5 days each week and practiced IF for 2 days discontinuously. On normal eating days, women consumed 1200 to 1500 kcal/day and men consumed 1500 to 1800 kcal/day, with macro-nutrient distribution of 45% to 50% carbohydrate, 20% protein, and 30% to 35% fat. They consumed 500 kcal and at least 50 g of protein on a light fasting day. Noncaloric beverages like water and unsweetened tea were allowed without restriction. A nutritionist provided diet guidance and documented any discomfort symptoms throughout the study.
223997214|NCT04161053|DRUG|Nitazoxanide|Nitazoxanide 500 mg twice daily for 6 months
224123239|NCT01477697|DIETARY_SUPPLEMENT|Omega-3|50 mg/kg per day of omega-3 fatty acids
224123240|NCT01477697|DIETARY_SUPPLEMENT|Placebo|50 mg/kg per day of placebo equivalent
224123241|NCT04808154|DRUG|SNP-630|Subjects will receive one single dose of SNP-630 at Day 1. Blood and urine samples will be obtained to determine the PK of orally administered SNP-630.
224123242|NCT05878808|DIAGNOSTIC_TEST|Psychometric assessment|Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
224123243|NCT03657680|OTHER|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
224123244|NCT04386564|DIAGNOSTIC_TEST|mRNA in urine test|Assessment of renal function, expression of viral RNA in urine and assessment of radiological changes will be performed
224123245|NCT04547738|DRUG|TB treatment according to national guidelines|National clinics in Cameroon will initiate TB treatment according to national guidelines upon positive TB diagnosis
224123246|NCT05894278|OTHER|Prescription data collection|Prescription data collection
223380688|NCT05026177|DRUG|Simufilam|Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.
223380689|NCT05026177|DRUG|Placebo|Matching placebo given b.i.d. for 76 weeks
223380690|NCT04856917|DRUG|Imsidolimab|Humanized Monoclonal Antibody
223380691|NCT04856917|BIOLOGICAL|Placebo|Placebo
223380692|NCT06562075|DEVICE|Decoria Intense Strong|"Decoria® Intense Strong is a HA-based, BDDE-crosslinked dermal filler. Decoria® Intense Strong dermal fillers are injected into dermal tissue to improve and define contouring of jawline profile, supporting overlying tissue to shape facial contours to desired level of correction.~Appropriate injection volume for the jawline will be determined by the Treating investigator according to IFU"
223380693|NCT03793179|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223380694|NCT03793179|DRUG|Carboplatin|Given IV
223380695|NCT03793179|PROCEDURE|Computed Tomography|Undergo CT scan
223380696|NCT03793179|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223380697|NCT03793179|BIOLOGICAL|Pembrolizumab|Given IV
223380698|NCT03793179|DRUG|Pemetrexed|Given IV
223380699|NCT03793179|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223380700|NCT03737981|DRUG|Ibrutinib|Given PO
223380701|NCT03737981|BIOLOGICAL|Obinutuzumab|Given IV
223380702|NCT03737981|OTHER|Observation Activity|Undergo observation
223380703|NCT03737981|DRUG|Venetoclax|Given PO
223380704|NCT06540222|PROCEDURE|Sustained cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
223380705|NCT06540222|PROCEDURE|Routine (< 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
223997215|NCT01478451|BEHAVIORAL|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
223997216|NCT01478451|OTHER|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
223997217|NCT00703495|DEVICE|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
223997218|NCT02872805|OTHER|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
224123247|NCT01785433|DRUG|Tiotropium HFA BAI 4.5 mcg|
224123248|NCT01785433|DRUG|Tiotropium HFA BAI 9.0 mcg|
224123249|NCT01785433|DRUG|SPIRIVA® HandiHaler® 18 mcg/day|
224123250|NCT01785433|DRUG|Spiriva® Respimat® 5 mcg/day|
224123251|NCT01613287|DEVICE|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
224123252|NCT01836575|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment \[dexamethasone + vitamin B12 + folic acid, as per pemetrexed label\] + Antiemetic therapy at investigator's discretion.
223997219|NCT02872805|BEHAVIORAL|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
223380706|NCT01169337|OTHER|Clinical Observation|Undergo observation
223997220|NCT05444634|BEHAVIORAL|Distraction Card|"Suitable for children over 3 years old. 1 set of 32 pieces of thick cardboard cards It has been prepared by child development experts in line with pedagogical principles.~Size: 13cm x 8cm, Each card illustrates the skills and actions the children do."
223380707|NCT01169337|DRUG|Lenalidomide|Given PO
223380708|NCT01169337|OTHER|Quality-of-Life Assessment|Ancillary studies
223997221|NCT05444634|BEHAVIORAL|Stress Ball|Brain Shaped Stress Ball, White rope in the form of mesh around the inner silicone Size: Approx 2.4 inches (6 cm), Color: Colorful, When squeezed, the silicone structure comes out in the mesh spaces and turns into a bunch of grapes.
223380709|NCT03560037|DEVICE|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
223380710|NCT06556563|DEVICE|Optune® device|Optune® device delivering TTFields therapy at 200 kHz.
223380711|NCT06556563|DRUG|Temozolomide|Temozolomide per approved labeling.
223380712|NCT06556563|DRUG|Pembrolizumab|Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
223380713|NCT06556563|DRUG|Placebo|Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
223380714|NCT03463317|DEVICE|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
223997222|NCT04905953|DRUG|Neostigmine|Intrathecal injection of two doses of neostigmine (10 \& 20 mic) during spinal anesthesia for cesarean section.
223997223|NCT01088984|DRUG|Bendamustine|
223997224|NCT03745742|OTHER|HRV measurement|"Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~* Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App."
223997225|NCT05008523|BEHAVIORAL|Opioids and Police Safety Occupational Risk Reduction Training (OPS)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
224123253|NCT01836575|DRUG|Carboplatin|Carboplatin \[Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle\].
224123254|NCT02216253|DRUG|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
224123255|NCT02216253|OTHER|Placebo|Placebo tablet twice a day 7 days before and after surgery
223380715|NCT03463317|DRUG|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
223380716|NCT03463317|DRUG|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulation is not prescribed in this group
223380717|NCT03463317|DRUG|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
223380718|NCT03463317|DRUG|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
223380719|NCT03463317|DRUG|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
223380720|NCT03463317|DRUG|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
223380721|NCT03463317|DRUG|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
223380722|NCT03463317|DRUG|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
223380723|NCT05184582|BEHAVIORAL|Physical training|Participants randomized to the exercise group will complete two structured 60-min exercise sessions per week from initiation of NACT to surgery (approx. five months).
223380724|NCT05118672|DRUG|Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg)|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
223380725|NCT05118672|DRUG|Placebo|Subjects randomized to this group will receive one (01) experimental drug film-coated tablet every eight (08) hours for three (03) days (nine \[09\] dosage administration). Subjects will be instructed to, thereafter, maintain treatment at the same dosage (one \[01\] film-coated tablet every eight \[08\] hours) in case of persistence of symptoms, discontinuing treatment when they present with no symptoms.
223380726|NCT06837987|OTHER|Modified transplantation system|Modified transplantation conditioning include: Fludarabine 30mg/m2\*6 day, Melphalan 100mg/m2\*1 day, cyclophosphamide 50mg/kg\*2 day.
223380727|NCT06831760|DEVICE|SOC and Type-I Collagen-based Skin Substitute|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
223380728|NCT06831760|DEVICE|SOC and Human Amnion/Chorion Membrane|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous, second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap
223997226|NCT05008523|BEHAVIORAL|Opioids and Police Safety Occupational Risk Reduction Training (COVID)|Potential participants are provided with a flyer with directions to enroll online. Groups are randomized by zip code (all participants with the same zip code receive the same training to avoid contamination by precinct) Both the experimental and control groups first take the online GetNaloxoneNow.org First Responder training; then the experimental group takes the online OPS training and the control group takes the online COVID training. Both groups take a pre-survey prior to both trainings and a post-survey after they complete both trainings. Both groups also receive (via email) a resource list with information that was provided in their respective trainings plus additional resources re: occupational risk reduction appropriate to each training. Every quarter for one year, participants are emailed a reminder to get back online to take the survey again.
223997227|NCT00004551|DRUG|nicotine replacement patch|
223997228|NCT00004551|BEHAVIORAL|mood management|
223997229|NCT04855006|BIOLOGICAL|Vaginal Microbiome Transplant|Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe
223997230|NCT04855006|BIOLOGICAL|Vaginal Microbiome Transplant Placebo|Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe
223997231|NCT04855006|OTHER|No intervention|Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
223997232|NCT01982305|PROCEDURE|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
223997233|NCT01982305|PROCEDURE|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
224123256|NCT02939144|DIETARY_SUPPLEMENT|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
224123257|NCT01487668|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
224123258|NCT04632095|PROCEDURE|Aortic valve replacement due to sternotomy|conventional surgery of aortic stenosis
224123259|NCT04632095|PROCEDURE|Aortic valve replacement due to parasternal right anterior mini-thoracotomy|surgery of aortic stenosis in minimally invasive technique
224123260|NCT01856595|DRUG|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
224123261|NCT01856595|DRUG|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
224123262|NCT01986569|DRUG|[18F]fluoroestradiol (FES)|\[18F\]FES PET/CT will be performed 90 min (± 10 min) after administration of \[18F\]FES. Patients will undergo core needle biopsy or surgery within 15 days after \[18F\]FES PET; or patients will undergo core needle biopsy within 30 days before \[18F\]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
224123263|NCT01835496|DRUG|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
223545187|NCT06716827|PROCEDURE|Laser-assisted bleaching|Whitening was performed 10 days prior to treatment, with laser treatment applied without removing brackets in the fixed appliance group and without cleaning attachments in the aligner group. The laser was applied to the buccal surface of the teeth with a 1mm distance for 30 seconds in three applications. After a 10-minute rest, the laser procedure was repeated.
223997234|NCT04707664|DRUG|Sargramostim|All patients randomized to the sargramostim treatment arm will be treated with 250 mcg inhaled sargramostim administered via a vibrating mesh nebulizer once daily for 5 days.
223997235|NCT04707664|DRUG|Placebo|All patients in the control arm will receive an equivalent volume of inhaled placebo diluent administered via a vibrating mesh nebulizer once daily for 5 days.
223997236|NCT03134677|DRUG|Bupivacaine|2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
223997237|NCT03134677|DRUG|Sevoflurane|General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
223997238|NCT01549704|DRUG|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
223997239|NCT01549704|DRUG|Saline|please see intervention description for ropivacaine
223997240|NCT00427505|DRUG|Deferasirox|
223997241|NCT00090155|DRUG|MK0869, aprepitant|
223997242|NCT00090155|DRUG|Comparator: ondansetron IV|
224123264|NCT03221322|BEHAVIORAL|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
224123265|NCT03000309|DRUG|Apremilast|
223380729|NCT06188689|DIAGNOSTIC_TEST|Pacing|"1. Ventricular 10 beat burst at 500ms (120bpm)~2. Ventricular 10 beat burst at 400ms (150bpm)~3. Atrial 10 beat burst at 500ms (120bpm)~4. Atrial 10 beat burst at 400ms (150bpm)."
223380730|NCT06154122|DEVICE|Virtual Reality Upper Limb Rehabilitation Games|"A VR upper limb rehabilitation programme prescribed by the therapist with games chosen depending on the exercise task required and the level of difficulty adapted to the ability of the individual. The participant will use the VR system's user interface to navigate through menus to set their gameplay preferences and select which games to play.~The games of the intervention will involve facilitating and replicating upper limb movements including gross movements of the shoulder, such as rotation, abduction and addiction, movements of the upper and lower arms, such as flexion and extension of the elbow, and hand, wrist and finger movements, including wrist pronation supination, and finger flexion and extension, as well as tenodesis movements, grasping, and pinching."
223380731|NCT06154122|OTHER|Upper Limb Rehabilitation|Usual upper limb rehabilitation is delivered by occupational therapists and physiotherapists and aims to build strength of the upper limbs and optimise function. Patients receive hand therapy once per day and physiotherapy twice per day. Rehabilitation is highly individualised.
223545188|NCT06716827|PROCEDURE|Home-bleaching|The whitening trays were custom-made for the fixed appliance patients, and they used them for 2-4 hours each evening after brushing their teeth. In the transparent aligner group, whitening was done using the aligners worn for treatment.
223997243|NCT03691077|DRUG|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
223729727|NCT01967212|BEHAVIORAL|Swallow training without biofeedback|"The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
224123266|NCT06523452|OTHER|Laser Speckle Imaging|At least three scans (four for skin sparing mastectomy) will be performed on participants randomised to the LSI Assisted Group. Further scans may be taken at the discretion of the surgeon.
224123267|NCT00395252|DRUG|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
224123268|NCT02002442|OTHER|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
224123269|NCT00458406|DEVICE|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
224123270|NCT00458406|DEVICE|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
224123271|NCT03926559|DRUG|Morphine.|Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
224123272|NCT01000194|DIETARY_SUPPLEMENT|High fat meal|A high fat milkshake containing 55g of fat
224123273|NCT04527562|DRUG|Colchicine|Participants in this group will be given a starting dose of 1.2 mg of Colchicine (2 tablets of 0.6 mg )single or 12 hourly divided dose. After that, they will take colchicine 0.6mg daily for 13 days. If they develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
224123274|NCT04527562|DRUG|Placebo|Participants in this group will be given a starting dose of 2 tablets of Placebo, single or 12 hourly divided dose. After that, they will take one placebo tablet daily for 13 days.Placebo tablet will be identical with the Colchicine tablet. If patients develop gastro intestinal side effects e.g abdominal pain, burning, vomiting, diarrhea, omeprazole and antiemetic will be prescribed. Supportive care and treatment will also be given.
224123275|NCT02280928|OTHER|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
224123276|NCT02280928|OTHER|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
224295464|NCT05208879|OTHER|Characterization, evaluation and comparison of macular pigment density|The macular pigment optical density (OD) will be determined by an additional photograph during the fundus usually performed for annual follow-up through two-wavelength autofluorescence imaging. Indeed, the measurement of the optical density consists of an additional post-examination analysis of additional retinal images obtained during the fundus performed for the patients' ophthalmologic follow-up.
224295465|NCT05294835|DRUG|Ketamine|ketamine infusion
224295466|NCT03052972|DRUG|Flortaucipir F18|370 megabecquerel (MBq)(10 millicurie \[mCi\]) single dose
223380732|NCT04554927|OTHER|WEB-Application|The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
223380733|NCT04554927|OTHER|Standard accompaniment|Personalized schedule of medical follow-up given to the patient
223380734|NCT05066061|OTHER|control arm|usual process
223380735|NCT05066061|OTHER|anxiolytic and analgesic gas|add relaxing gas
223380736|NCT05066061|DEVICE|Virtual reality mask|use Virtual reality mask Oculus Quest with age-appropriate software
223380737|NCT06210776|DRUG|Trastuzumab deruxtecan|Intravenous infusion
223545189|NCT06716827|OTHER|Control|This group of patients did not undergo any whitening procedures.
223545190|NCT06717542|DIAGNOSTIC_TEST|histochemical and immunohistochemical analysis|2 µm sections will be cut from the paraffin blocks for histochemical and immunohistochemical (IHC) investigations. IHC will be performed with an automated stainer (Ventana/Roche®, Ventana Medical Systems, USA) for the endothelial markers CD34, ERG, Nestin and Caveolin-1
223380738|NCT05738239|DEVICE|Laser therapy|Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).
223380739|NCT04770766|OTHER|Non-medical practitioners|All observational research activity in each cohort is related to the exposure of non-medical practitioners in the Emergency Department or Urgent Treatment Centre
223380740|NCT03816878|BIOLOGICAL|H5N1 pISV|Administered as an intramuscular (IM) injection
223380741|NCT03038802|BIOLOGICAL|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
223380742|NCT03038802|BIOLOGICAL|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
223380743|NCT05929820|BEHAVIORAL|Protect Your Colon™|Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
223380744|NCT06264180|BIOLOGICAL|Vusolimogene Oderparepvec|Genetically modified Herpes Simplex Type 1 Virus.
223380745|NCT06264180|BIOLOGICAL|Nivolumab|Anti-PD-1 Monoclonal Antibody
223380746|NCT06264180|BIOLOGICAL|Nivolumab + Relatlimab|Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
223380747|NCT06264180|BIOLOGICAL|Pembrolizumab|A programmed death receptor-1 (PD-1)-blocking antibody indicated.
223997244|NCT04660136|BIOLOGICAL|contrast enhanced ultrasound|We injected the second generation, ultrasonic contrast agent (SonoVue, Bracco, Milan, Italy) as a bolus of 0.03 ml/kg through a three-way 20-gauge catheter in an antecubital vein, followed by a bolus of 5 ml saline solution (0.9% NaCl).CEUS was performed with a 7.5MHz linear probe and contrast-tuned technology, based on allow mechanical index and a real-time scan to ensure the preservation of the contrast agent. A low acoustic power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz linear probe.
223997245|NCT05476315|OTHER|Emergency surgery during covid-19 pandemic|Patients undergoing emergency surgery during the covid period and compared with emergency interventions before the pandemic
223997246|NCT00699153|DRUG|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
223997247|NCT00699153|DRUG|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
223997248|NCT02344264|DRUG|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
223997249|NCT02344264|DRUG|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
224123277|NCT02280928|OTHER|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
223380748|NCT06264180|DRUG|Single-agent chemotherapy|Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
223380749|NCT03355469|DRUG|Metformin|Oral metformin 2000 mg/d for 16 weeks. Metformin dosage will follow 500 mg/d ramp up progression: Week 1 = 500 mg/d; Week 2 = 1,000 mg/d; Week 3 = 1500 mg/d; Week 4-16 = 2000 mg/d.
223380750|NCT03355469|DRUG|Placebo|Oral placebo for 16 weeks. Placebo tablets will follow a four-stage progression: Week 1 = 1 tablet; Week 2 = 2 tablets; Week 3 = 3 tablets; Week 4-16 = 4 tablets.
223380751|NCT03355469|BEHAVIORAL|Low Intensity Exercise|Low intensity exercise will consist of 16 weeks of walking at \~55% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk and the duration will be determined based on individual fitness levels to expand 400 kcals. Supervised exercise training will follow a three-phase progression: Weeks 1-2 = 3 supervised sessions at 75% duration; Week 3-4 = 3 supervised sessions at 87% duration; Weeks 5-16 = 3 supervised sessions at 100% duration. Unsupervised exercised will be 2d/wk and the duration will half the time of the supervised training sessions.
223380752|NCT03355469|BEHAVIORAL|High Intensity Exercise|High intensity exercise will consist of 16 weeks of walking at \~85% of each participant's predetermined VO2max and monitored via heart rate. Supervised exercised will occur on a treadmill 3d/wk and the duration will be determined based on individual fitness levels to expand 400 kcals. Supervised exercise training will follow a three-phase progression: Weeks 1-2 = 3 supervised sessions at 75% duration; Week 3-4 = 3 supervised sessions at 87% duration; Weeks 5-16 = 3 supervised sessions at 100% duration. Unsupervised exercised will be 2d/wk and the duration will half the time of the supervised training sessions.
224123278|NCT05504148|DRUG|crocin|Take saffron total glucosides tablets for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day.
224123279|NCT05504148|DRUG|Placebo|Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
224123280|NCT02712372|DRUG|AZD4831|AZD4831 1-50 mg/g oral suspension
224123281|NCT02712372|DRUG|AZD4831 placebo|AZD4831 placebo oral suspension
223380753|NCT05780684|OTHER|FOX dose-escalation algorithm|Chemotherapy dose-escalation algorithm based on the FOLFOX and FOLFOXIRI regimens
223380754|NCT06476808|DRUG|BMS-986463|Specified dose on specified days
223380755|NCT06365723|BEHAVIORAL|Nature-based Walking|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated nature-based, or 'green', urban environment.
224123282|NCT02076256|BEHAVIORAL|The helping relationships intervention program|
223380756|NCT06365723|BEHAVIORAL|Built-environment/Commercial Walking|All participants will be asked to walk three to five times per week for 30-50 minutes per walk, totaling 150 min/week, at moderate intensity over a 6-week period in a designated built-environment/commercial, or 'Gray', urban environment.
223380757|NCT04754906|OTHER|Sequence 1|perform arm movements towards a target
223380758|NCT04754906|OTHER|Sequence 2|judge the verticality of an object
223380759|NCT04754906|OTHER|Sequence 3|In standing position, point as quickly as possible with the right arm at the diode that will light up in front of the participant.
223380760|NCT05976984|OTHER|Aim 1 (case-cohort study)|"* Cases: All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020~* Subcohort: A random sample of all Medicaid enrollees age 15 years or older irrespective of their stimulant overdose history during 2016-2020"
223380761|NCT05976984|OTHER|Aim 2 (case-crossover study)|"* Case period: 60 days before the date of stimulant overdose through the day before the date of stimulant overdose~* Control period: 179 days before the date of stimulant overdose through 120 days before the date of stimulant overdose~* Washout period: 119 days before the date of stimulant overdose through 61 days before the date of stimulant overdose"
223380762|NCT05976984|OTHER|Aim 3 (cohort study)|All Medicaid enrollees age 15 years or older with at least one inpatient hospitalization or emergency department visit indicating a stimulant overdose during 2016-2020
223380763|NCT05780073|DRUG|Dasatinib 70 mg|Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind
223380764|NCT05780073|OTHER|Placebo|Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.
223380765|NCT01708941|BIOLOGICAL|Ipilimumab|Given IV
223380766|NCT01708941|OTHER|Laboratory Biomarker Analysis|Correlative studies
223380767|NCT01708941|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV or SC
223380768|NCT01575548|PROCEDURE|Computed Tomography|Undergo CT
223380769|NCT01575548|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223380770|NCT01575548|DRUG|Pazopanib Hydrochloride|Given PO
223380771|NCT01575548|OTHER|Placebo Administration|Given PO
223380772|NCT01575548|OTHER|Questionnaire Administration|Ancillary studies
223997250|NCT04663412|OTHER|Sentinel lymph node mapping with indocyanine green fluorescence imaging in vulvar cancer (FIGO Stage IB)|Patients diagnosed with vulvar squamous cell carcinoma (FIGO IB stage) underwent bilateral radical vulvectomy, SLN search and removal, and bilateral inguinal lymphadenectomy at the Cannizzaro Hospital Operative Unit of Obstetrics and Gynecology Department (Catania, Italy). 3 ml of indocyanine green (ICG) 0.5 mg/mL was administered in 3 peritumoral injections under general anesthesia to screen the SLN. The images were acquired using an intraoperative infrared camera system, which allowed intraoperative visualization of the SLN. An SLN was identified for each patient. The lymph nodes examined by the pathologist were negative for metastatic localization of the disease. However, patients underwent bilateral inguinofemoral lymphadenectomy, as this procedure is not currently codified as a gold standard for the detection of SLN in vulvar cancer.
224295467|NCT03052972|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
223380773|NCT05309421|DRUG|EVX-01|Investigational drug given in combination with standard of care
223380774|NCT05309421|DRUG|Pembrolizumab 25 MG/ML|Standard of care
223729728|NCT00629681|DRUG|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
224295468|NCT01370486|DRUG|melatonin|melatonin cp 2 mg 1x/d for 1 month
223380775|NCT04772456|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
223380776|NCT05697406|DRUG|Hyperpolarized 13C-Pyruvate|Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.
223380777|NCT05321342|BEHAVIORAL|Bullying Classroom Check-Up (BCCU)|BCCU professional development (PD) modules will be provided to all staff in intervention schools as part of their standard, school-approved professional development practices to provide knowledge and awareness for bullying identification, prevention, and intervention. In addition, consented 3rd-5th grade teachers will participate in the BCCU intervention. The coaching follows the original Classroom Check-Up model (Reinke, Herman, \& Sprick, 2011), embedding 5 steps (i.e., assessment of the classroom, feedback to teacher, goal setting and plan, ongoing coaching and guided practice in the TeachLivE© mixed-reality simulator \[developed at the University of Central Florida (UCF); Dieker, Hynes, Hughes, \& Smith, 2008\], and self-monitoring) and utilizing motivational interviewing (Miller \& Rollnick, 2012) to empower teacher practice change.
223380778|NCT04684368|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood samples
223380779|NCT04684368|DRUG|Carboplatin|Given IV
223380780|NCT04684368|DRUG|Etoposide|Given IV
223380781|NCT04684368|BIOLOGICAL|Filgrastim|Given subcutaneously (SC) or IV
223380782|NCT04684368|DRUG|Ifosfamide|Given IV
223380783|NCT04684368|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223380784|NCT04684368|DRUG|Mesna|Given IV or orally
223380785|NCT04684368|BIOLOGICAL|Pegfilgrastim|Given SC
223380786|NCT04684368|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
223380787|NCT04684368|OTHER|Questionnaire Administration|Ancillary studies
223729729|NCT01850771|PROCEDURE|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
223729730|NCT01850771|PROCEDURE|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
223997251|NCT03054051|BEHAVIORAL|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
223997252|NCT00089960|DRUG|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
223997253|NCT03523026|DEVICE|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
223997254|NCT03523026|OTHER|Inspirator Muscle Training|Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
223997255|NCT03523026|OTHER|Peripheral Muscle Training|Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
223997256|NCT03236623|OTHER|Menthol Popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
223997257|NCT02456519|OTHER|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
223997258|NCT00140010|DRUG|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
223997259|NCT03004001|DRUG|Alirocumab|150 mg biweekly
223997260|NCT03004001|DRUG|Alirocumab placebo|placebo
223997261|NCT03004001|DRUG|Atorvastatin|20 mg/day
223997262|NCT02775370|DRUG|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
223997263|NCT01997905|DEVICE|AtriClip LAA Exclusion Device|
223997264|NCT02188680|OTHER|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
223997265|NCT01857375|DEVICE|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
224123283|NCT06552598|DRUG|KD01(the recombinant oncolytic adenovirus)|"Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged."
224123284|NCT00492947|BIOLOGICAL|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
224123285|NCT04551573|DRUG|Rifapentine daily|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed daily for four weeks (10mg/kg; 600 mg dose)
223380788|NCT04684368|RADIATION|Radiation Therapy|Undergo WVSCI radiation therapy
223380789|NCT04684368|RADIATION|Radiation Therapy|Undergo radiation therapy
223380790|NCT04684368|PROCEDURE|Second-Look Surgery|Undergo second-look surgery if needed
223380791|NCT04684368|DRUG|Thiotepa|Given IV
224123286|NCT04551573|DRUG|Rifapentine weekly|In addition to taking Biktarvy for four weeks, participants will also take Rifapentine dosed weekly for another four more weeks (15 mg/kg; 900mg dose)
224123287|NCT02225444|OTHER|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
223997266|NCT03610711|DRUG|Nivolumab|240mg administered IV over 30 minutes every 2 weeks for one year
224123288|NCT02890082|DRUG|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
223380792|NCT04175912|DRUG|Carboplatin|Given IV
223380793|NCT04175912|DRUG|Paclitaxel|Given IV
223380794|NCT04175912|DRUG|Pevonedistat|Given IV
223380795|NCT05004311|DRUG|Cenerimod|A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
223380796|NCT05273307|DIETARY_SUPPLEMENT|Miraculin|Given orally
223380797|NCT05273307|DIETARY_SUPPLEMENT|Miracle Fruit Placebo Cube|Given orally
223380798|NCT02048813|DRUG|Cyclophosphamide|Given IV
223380799|NCT02048813|DRUG|Fludarabine Phosphate|Given IV
223380800|NCT02048813|DRUG|Ibrutinib|Given PO
223380801|NCT02048813|OTHER|Laboratory Biomarker Analysis|Correlative studies
223380802|NCT02048813|OTHER|Pharmacogenomic Study|Correlative studies
223380803|NCT02048813|OTHER|Quality-of-Life Assessment|Ancillary studies
223380804|NCT02048813|BIOLOGICAL|Rituximab|Given IV
223380805|NCT05425550|DEVICE|medidux™ app|Use of the regular medidux™ application for 12 (maximum 16) weeks
223380806|NCT04310007|PROCEDURE|Biospecimen Collection|Undergo blood collection
223380807|NCT04310007|DRUG|Cabozantinib S-malate|Given PO
223380808|NCT04310007|PROCEDURE|Computed Tomography|Undergo CT
223380809|NCT04310007|DRUG|Docetaxel|Given IV
223380810|NCT04310007|PROCEDURE|Echocardiography Test|Undergo ECHO
223997267|NCT03610711|DRUG|Relatlimab|every 2 weeks for one year
223997268|NCT01824927|PROCEDURE|First eye (FE)|Phacoemulsification cataract extraction surgery
223997269|NCT01824927|PROCEDURE|Second eye (SE)|Phacoemulsification cataract extraction surgery
223997270|NCT01824927|DRUG|Steroids eye drops|Use steroids eye drops to decrease the pain.
223997271|NCT01006980|DRUG|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
223997272|NCT01006980|DRUG|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
223997273|NCT05689242|DRUG|Dexmedetomidine Injection [Precedex]|intravenous dexmedetomidine for group I and nalubphine for group II in colposcopy
223997274|NCT03937518|DRUG|Strontium Ranelate|"Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min ("
223997275|NCT03937518|OTHER|physiotherapy|"Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis"
223997276|NCT05981742|DRUG|Metformin Hydrochloride 500 MG|Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
223997277|NCT05981742|DRUG|Cabergoline 0.5 MG|Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
223997278|NCT05981742|DRUG|Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG|"Metformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration~Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration"
223997279|NCT05817383|OTHER|Freeze-dried Blueberry Powder|Participants will be asked to consume 48 grams of freeze-dried blueberry powder (\~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
223997280|NCT05817383|OTHER|Placebo Powder|Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks. Participants will be asked to save any powder packet wrappers as a means to measure compliance. They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
223997281|NCT05483413|BEHAVIORAL|progressive relaxation exercises|Progressive relaxation exercises are a cognitive behavioral technique that provides relaxation in the muscles that individuals can do alone.
223997282|NCT03438357|OTHER|Analysis of cerebral MRI with automatic segmentation software|Pixyl.Neuro software versus manual analysis of lesions
223997283|NCT00527358|BEHAVIORAL|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"1. community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~2. youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~3. school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~4. Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
223997284|NCT05445453|OTHER|Museum visit|"The intervention is a visit of the MMFA. This visit can be done alone or accompanied.~The visit of the MMFA is free for the patient."
223997285|NCT00835744|DRUG|clomiphene citrate|ovulation induction
223380811|NCT04310007|DRUG|Gemcitabine Hydrochloride|Given PO
223997286|NCT00835744|DRUG|gonadotropins|ovulation induction
224123289|NCT02890082|DRUG|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
224123290|NCT02890082|DRUG|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
224295469|NCT01370486|DRUG|placebo|placebo cp 1x/d for 1 month
223380812|NCT04310007|DRUG|Nab-paclitaxel|Given IV
223380813|NCT04310007|BIOLOGICAL|Nivolumab|Given IV
223380814|NCT04310007|DRUG|Paclitaxel|Given IV
223380815|NCT04310007|BIOLOGICAL|Ramucirumab|Given IV
223380816|NCT06557057|OTHER|Non-Interventional Study|Non-Interventional Study
223380817|NCT01708954|DRUG|Cabozantinib S-malate|Given PO
223380818|NCT01708954|DRUG|Erlotinib Hydrochloride|Given PO
223380819|NCT01708954|OTHER|Laboratory Biomarker Analysis|Correlative studies
223380820|NCT05909748|DEVICE|GEMINUS Transcatheter Aortic Valve Implantation system|Implantation of the GEMINUS Transcatheter Aortic Valve Implantation system
223380821|NCT05488366|DRUG|Pembrolizumab|Given IV
223380822|NCT05488366|RADIATION|Radiation therapy|Single target will be selected by the treating radiation oncologist. A lesion causing symptoms or expected to become symptomatic will be favored for target selection.
223380823|NCT01896999|PROCEDURE|Biopsy Procedure|Undergo biopsy
223380824|NCT01896999|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223380825|NCT01896999|DRUG|Brentuximab Vedotin|Given IV
223380826|NCT01896999|PROCEDURE|Computed Tomography|Undergo CT
223380827|NCT01896999|BIOLOGICAL|Ipilimumab|Given IV
223380828|NCT01896999|BIOLOGICAL|Nivolumab|Given IV
223997287|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
223997288|NCT02239874|DIETARY_SUPPLEMENT|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
223997289|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D placebo and fish oil placebo|placebo
223997290|NCT02239874|DIETARY_SUPPLEMENT|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
223997291|NCT05193903|BEHAVIORAL|Simulation|The participants in the intervention group receive two interactive simulations in addition to a general text module that provides sequential, animated information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.
223380829|NCT01896999|PROCEDURE|Positron Emission Tomography|Undergo PET
223380830|NCT04710758|PROCEDURE|Laparoscopic total gastrectomy|LTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
223380831|NCT04710758|PROCEDURE|Open total gastrectomy|OTG with D2 lymphadenectomy for patients with locally advanced gastric cancer (clinical stage T2-4aN0-3M0)
223380832|NCT03326492|DRUG|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
223380833|NCT06400251|PROCEDURE|Biopsy Procedure|Undergo biopsy
223380834|NCT06400251|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223380835|NCT06400251|PROCEDURE|Computed Tomography|Undergo CT scan
223380836|NCT06400251|DRUG|Ipatasertib|Given PO
223380837|NCT06400251|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223997292|NCT05193903|BEHAVIORAL|Text|"The participants in the control group receive two text-based information in addition to a general text module that provides information on the spread of the virus without prevention, the effectiveness of vaccination and potential side effects of vaccination on a herd protection level and the individual level.~Both conditions ensure the provision of a level of knowledge that at least corresponds to standard care."
223997293|NCT00107094|DRUG|Abraxane|
223997294|NCT02143011|OTHER|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
223997295|NCT02143011|OTHER|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
224123291|NCT05547763|PROCEDURE|surgically mandible will be exposed to reduced the fracture anatomically and then fixated with either resorbable or the titanium plates|under general anesthesia , fracture site of the mandible will be exposed and fracture will be reduced anatomically and held together by either resorbable or titanium plates and then the incsion site will be closed with vicryl sutures and patient will be observed on the follow ups clinically and radiographically for the fracture reduction and stability of the fractures with resorbable plates as compared to the titanium plates.
224295470|NCT00682552|PROCEDURE|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
224295471|NCT05029934|PROCEDURE|use of EndoClot|deployment of EndoClot adhesive spray
223380838|NCT01794403|RADIATION|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
223380839|NCT01794403|RADIATION|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
223380840|NCT06517875|DRUG|Momelotinib|Momelotinib will be administered orally.
223380841|NCT06517875|DRUG|Luspatercept|Luspatercept will be administered subcutaneously.
223997296|NCT05717894|DRUG|Vitex Agnus Castus Extract|The patient group received two pills containing 200mg of VAC daily for six months
223997297|NCT02666144|DEVICE|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
223997298|NCT03416322|OTHER|Water exchange|Infusion and remove water during inertion and withdrawal of colonoscope
223997299|NCT01287325|DRUG|DNK333 100 mg twice daily|
223997300|NCT01287325|DRUG|Placebo|
223997301|NCT05909826|DRUG|Carfilzomib|70 mg/m2 IV days 1, 8 and 15, every 4 weeks
223997302|NCT05909826|DRUG|Cyclophosphamide|50 mg PO days 1 to 21, every 4 weeks
223997303|NCT05909826|DRUG|Dexamethasone|40mg PO or IV days 1, 8, 15, and 22, every 4 weeks
223997304|NCT03076073|OTHER|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
223997305|NCT04020315|PROCEDURE|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
223997306|NCT05723757|DIAGNOSTIC_TEST|blood sampling|Draw a 8.5mL blood sample for detection of SNPs of genomic origin
224295472|NCT03466359|BEHAVIORAL|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
224295473|NCT03466359|BEHAVIORAL|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
224295474|NCT01711749|DRUG|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
223997307|NCT03412851|OTHER|A Direct Aspiration First Pass Technique|Distal aspiration technique
224295475|NCT01711749|DRUG|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
223997308|NCT03412851|OTHER|Stentriever Thrombectomy|Thrombectomy with stent retriever
223380842|NCT06410313|DEVICE|ChampioNIR Ridaforolimus Eluting Peripheral Stent System|ChampioNIR implantation in Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery disease
223380843|NCT06535477|DEVICE|Fall risk assessment|"Assessing frailty in elderly patients using Fried Frailty and Short Emergency Geriatric Assessment scales combined with measurement - via the AbilyCare device - of the two markers of balance and gait"
223380844|NCT02595944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223997309|NCT02354820|OTHER|Evidence Based Constipation Reminders|
224295476|NCT02198924|DRUG|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
224295477|NCT02198924|DRUG|placebo|control patients are supplied with the corresponding placebo with the same instructions.
224295478|NCT00000202|DRUG|Buprenorphine|
224295479|NCT04834739|OTHER|6 minute walk test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. 30 m long corridor is used for this test .
224295480|NCT04834739|OTHER|1 minute Sit to Stand Test|The 1-minute STS test is performed with a chair of standard height of 46 cm without arm rests. The patient should be ensured to be seated upright on the chair positioned against a wall. The patient sat with the knees and hips flexed to 90°, feet placed flat on the floor hip-width apart, and the hands placed on the hips.The number of repetitions is measured.
223380845|NCT02595944|PROCEDURE|Computed Tomography|Undergo CT
223997310|NCT02961439|BEHAVIORAL|Epworth Richmond's Echocardiography Focused Year|a year long echo teaching program
224295481|NCT04834739|OTHER|Fatigue Severity Scale|The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders
223997311|NCT03312023|DRUG|Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|1 pill once daily for 12 weeks for Group A
223997312|NCT03312023|DRUG|Sofosbuvir 400 MG [Sovaldi]|1 pill once daily for 12 weeks for Group C
223380846|NCT02595944|PROCEDURE|Echocardiography Test|Undergo ECHO
223997313|NCT03312023|DRUG|Ledipasvir 90 MG|1 pill once daily for 12 weeks for Group D
223997314|NCT04263168|DIAGNOSTIC_TEST|Continuous Glucose monitoring in the perioperative period|All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
223997315|NCT02706405|BIOLOGICAL|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Given IV
223997316|NCT02706405|DRUG|Cyclophosphamide|Given IV
223380847|NCT02595944|BIOLOGICAL|Nivolumab|Given IV
223380848|NCT02595944|OTHER|Observation Activity|Undergo observation
223380849|NCT02595944|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223380850|NCT02969421|OTHER|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
223380851|NCT02969421|OTHER|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
223380852|NCT02705261|BEHAVIORAL|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
223380853|NCT05463640|BIOLOGICAL|ADGRE2 CAR-T|ADGRE2 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
223380854|NCT02868957|OTHER|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
223997317|NCT02706405|BIOLOGICAL|Durvalumab|Given IV
223997318|NCT02706405|DRUG|Fludarabine|Given IV
223997319|NCT04442100|PROCEDURE|valve prosthetics|"prosthetics of heart valves with dentures MedEng-Bio"
223997320|NCT04447105|DRUG|total intravenous anesthesia with propofol|In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
223997321|NCT04447105|DRUG|inhalation anesthesia with desflurane|In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
223380855|NCT02868957|DEVICE|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
223380856|NCT02868957|DEVICE|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
223380857|NCT00805324|DRUG|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
223380858|NCT00984724|BEHAVIORAL|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
223380859|NCT00984724|BEHAVIORAL|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
223380860|NCT00984724|BEHAVIORAL|Quitline|Letter referring participants to a Quitline providing quit smoking services.
223997322|NCT01228318|DRUG|Zoledronic acid|"1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
223997323|NCT03637218|OTHER|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
223997324|NCT03637218|OTHER|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
223380861|NCT00984724|BEHAVIORAL|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
223380862|NCT04203134|DEVICE|Mouthguard|The mouthguard is a thin clear acrylic protector fabricated from an impression of a patient's upper teeth and palate. The acrylic protector will be trimmed and will fit onto the patient's upper teeth and palate for use during the day, except when eating to minimize trauma to the tongue that exacerbates burning tongue pain.
223380863|NCT00877591|DRUG|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
223380864|NCT00877591|DRUG|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
223380865|NCT00877591|DRUG|Rifampin|600 mg once daily for 15 days total
223380866|NCT00877591|DRUG|Rifabutin|300 mg once daily for 15 days total
223380867|NCT00877591|DRUG|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
223729731|NCT02927431|DRUG|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
223729732|NCT02927431|DRUG|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
223380868|NCT01264510|OTHER|audiological test battery|routine audiological measurements.
223380869|NCT04575610|DRUG|PF-06650833|Subjects randomized to the PF-06650833 arm of the study will receive 200 mg IR suspension formulation every 6 hours (via nasogastric \[NG\] tube, orogastric \[OG\] tube, or equivalent) if unable to take tablets by mouth (PO). Subjects for whom concomitant administration of a strong inhibitor of cytochrome P450 (CYP) 3A4 will have the dose of the IR formulation to 200 mg once daily (QD). Subjects who can take tablets PO will receive 400 mg PF-06650833 (2-200 mg tablets) of the MR formulation QD under fasted conditions (preferably at least 4 hours after and 1.5 hours before a meal). No dose adjustment is needed for subjects taking the MR tablet preparation, except if co-administered with ritonavir in which case the dose should be reduced to 200 mg MR QD. All dosing of PF-06650833 will be in addition to current hospital SOC therapy.
223997325|NCT02886039|OTHER|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
223997326|NCT00225238|DRUG|esomeprazole (PPI)|
223997327|NCT03085823|DEVICE|Sirolimus Coated Balloon|
223997328|NCT01134224|DRUG|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
223997329|NCT01134224|DRUG|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
223997330|NCT01134224|DRUG|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
223997331|NCT01134224|DRUG|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
223997332|NCT01134224|DRUG|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
223997333|NCT01134224|DRUG|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
223997334|NCT03011567|DRUG|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
223997335|NCT03011567|DRUG|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
223997336|NCT01182441|DEVICE|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
223997337|NCT01182441|DRUG|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
223380870|NCT04575610|DRUG|Placebo|Matching placebo tablets will be administered.
223380871|NCT05969535|BEHAVIORAL|Birth preparation education according to travelbee human-human relations theory|human-to-human communication and psychoeducation-assisted birth preparation training
223380872|NCT04835974|DIAGNOSTIC_TEST|"1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S"|"Blood samples were obtained before PCI, and the following parameters will be measured:~1. LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio.~2. Glycemia will be assessed : RBS ( random blood sugar ) .~3. Serum Uric acid : S .UA"
223380873|NCT06430593|PROCEDURE|low-flow anesthesia|0,5 l/min \>1 l/min
223380874|NCT04529135|DRUG|Dexmedetomidine|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
223380875|NCT04529135|DRUG|Remifentanil|The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
223380876|NCT00474500|DRUG|Coca, Cola, Diet Coke|
223380877|NCT02042118|DEVICE|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
223380878|NCT02042118|DEVICE|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
223380879|NCT02018419|BIOLOGICAL|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
223380880|NCT02018419|PROCEDURE|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
223380881|NCT03409588|DRUG|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
224138396|NCT04659434|DRUG|Sintilimab|"Patients receive sintiliman+R-GemOx three weeks for a cycle, detailed as follows:~Combination therapy~* Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 4 cycles~* R-GemOx: Rituximab 375mg/m2, d1; Gemcitabine 1000mg, d2; Oxaliplatin 100mg/m2, d2; every 3 weeks for a cycle, 4 cycle as protocol specified.~Monotherapy:~-Anti-PD-1 antibody (sintilimab): Fixed dose of 200 mg every 3 weeks, d0, intravenous drip (without pretreatment), infusion time: 30 mintutes (no less than 20 mins, no more than 60 mins), for 8 cycles"
224295482|NCT04834739|OTHER|Medical Research Council (MRC) dyspnea scale|"The MRC dyspnea scale is a questionnaire that consists of five statements about perceived breathlessness: grade 1, I only get breathless with strenuous exercise; grade 2, I get short of breath when hurrying on the level or up a slight hill; grade 3, I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level; grade 4, I stop for breath after walking 100 yards or after a few minutes on the level; grade 5,  I am too breathless to leave the house."
224295483|NCT04834739|OTHER|SF-12|The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.
223380882|NCT02881502|OTHER|severe asthma group|No intervention
223380883|NCT01854476|DEVICE|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
223380884|NCT03347682|OTHER|Satisfaction with Prosthesis -SATPRO|questionnaire 1
223380885|NCT03347682|OTHER|Nottingham Health Profile-NHP|questionnaire 2
223729733|NCT02927431|DRUG|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
223729734|NCT02927431|DRUG|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
223997338|NCT00603525|DRUG|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
223997339|NCT00603525|DRUG|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
223997340|NCT04394377|DRUG|Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Routine full anticoagulation strategy
223997341|NCT04394377|DRUG|Group 2: control group with enoxaparin 40mg/d|Usual standard of care and currently have no indication of full anticoagulation.
223997342|NCT03473600|PROCEDURE|Cryotherapy|Liquid Nitrogen spray
223997343|NCT03473600|DRUG|Triamcinolone acetonide injection|Intralesional Triamcinolone Acetonide injection
223380886|NCT03347682|OTHER|Prosthesis donning and doffing questionnaire|questionnaire 3
223997344|NCT00378664|PROCEDURE|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
223997345|NCT04317391|BEHAVIORAL|Pain management program|Mindfulness based stress reduction
223997346|NCT04329637|OTHER|Integrative healt care|Meditation and use of a care cordinator
224295484|NCT04834739|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
223380887|NCT05030792|OTHER|Attention-restorative therapy (ART)-based virtual reality (VR)|The ART-based VR intervention will be provided using an Oculus Go™ which is a commercially available, all-in-one VR headset with a handheld controller.
223997347|NCT05931029|DRUG|Idebenone|The control group took Idebenone orally for 12 weeks.
223997348|NCT05931029|DRUG|Naohuan Dan and Idebenone|The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.
223997349|NCT00146731|DRUG|SP|
223997350|NCT00146731|DRUG|SP + amodiaquine|
223997351|NCT00146731|DRUG|AQ + artesunate|
223380888|NCT04759196|DRUG|Topamax|TPM : 50 mg BID, with increased of 50 mg by week until efficacy, to a maximum of 100 mg BID.
223380889|NCT04759196|DRUG|Levetiracetam|LEV : 500 mg BID, with increase of 1000 mg die divided in two doses each week until efficacy, to a maximum of 1500 mg BID.
223380890|NCT00398424|DRUG|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
223380891|NCT01565356|DRUG|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
223997352|NCT00146731|DRUG|chlorproguanil-dapsone|
223997353|NCT06427421|BIOLOGICAL|Frequency of Treg and Teffs|additionnal blood sampling at inclusion
223997354|NCT06427421|BIOLOGICAL|Phenotype of Treg and Teffs|additionnal blood sampling at inclusion
223997355|NCT06427421|BIOLOGICAL|RNA seq analysis|additionnal blood sampling at inclusion
223997356|NCT06427421|BIOLOGICAL|HLA typing|additionnal blood sampling at inclusion
223997357|NCT06427421|BIOLOGICAL|beta-cell autoantibody dosage|additionnal blood sampling at inclusion
223997358|NCT06427421|BIOLOGICAL|Glycated haemoglobin (HbA1C) dosage|additionnal blood sampling at inclusion
223997359|NCT06427421|BIOLOGICAL|blood glucose dosage|additionnal blood sampling at inclusion
223997360|NCT06427421|BIOLOGICAL|C-peptide dosage|additionnal blood sampling at inclusion
223997361|NCT05673031|DIAGNOSTIC_TEST|68Ga-HA-DOTATATE PET/CT imaging|"Each patient will receive an IV injection 68Ga-HA-DOTATATE. Imaging will be conducted beginning 45-90 minutes after an injection of between 100-250 MBq 68Ga-HA-DOTATATE in patients.~* After the 68Ga-HA-DOTATATE acquisition is complete, a CT scan will be performed for attenuation correction and localization in the same in line gantry without patient movement between the two scans.~* The results of the 68Ga-HA-DOTATATE PET/CT will be compared to any prior imaging and pathologic results."
223997362|NCT03357419|DRUG|Cephalexin|"The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
223997363|NCT03357419|DRUG|Placebo oral capsule|"The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
223997364|NCT02672943|BEHAVIORAL|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
224123292|NCT04628013|DEVICE|Noxious Electrical Stimulation (NxES)|The NxES intervention will be applied with a pair of 2x3 inch electrodes placed orthogonally to the knee joint line with one electrode on the medial and lateral sides of the knee. The device is a commercially available unit(Chattanooga Continuum, DJO Global, Vista CA) and the parameters of the NxES include: 400 μs biphasic square wave pulses delivered at 50-100 pulses/second, using a cycle time of 10-seconds on, with a 2-second ramp-up in intensity, followed by a 10-second off period. The current intensity will be dosed over the first 2-minutes of stimulation to find the sensory perception threshold and the threshold for the first perception of a sharp, prickly buzzing sensation that they would identify as painful. Next, the current intensity will gradually be increased until the participant reports a sharp or prickly buzzing sensation that achieves a pain rating of not more than a 5/10 using a numeric pain rating scale.
224123293|NCT02482363|RADIATION|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
224123294|NCT02482363|RADIATION|Sham Control|20 minutes of sham control exposure
224123295|NCT06517615|BEHAVIORAL|Home Visit Supported Nursing Training Program|Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
224295485|NCT04834739|OTHER|Beck Anxiety Inventory|Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
223997365|NCT02672943|OTHER|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
223997366|NCT02950597|DEVICE|Observational Study to Evaluate Utility of Non-invasive Hemodynamic Monitoring|
223997367|NCT03950752|COMBINATION_PRODUCT|Optimized Bagel|Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
223997368|NCT03950752|COMBINATION_PRODUCT|Conventional Bagel|Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
223997369|NCT03568773|OTHER|High-intensity interval training|HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (\> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).
223997370|NCT03568773|OTHER|Aerobic exercise moderate intensity|The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, \<threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).
223997371|NCT03568773|OTHER|Control Group|The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
223997372|NCT02734498|DEVICE|Electroconvulsive Treatment (ECT) Right Unilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
223997373|NCT02734498|DEVICE|Electroconvulsive Treatment (ECT) - Bilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
223997374|NCT06509100|DEVICE|Device: Altitudes USA|Experimental participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes educational and therapeutic content that is tailored to each individual and their current needs and experiences, including psychoeducation, supporting their loved one, self- care, social support, and so on. Further, the platform includes a moderated social media function, where users and family peer workers can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.
223997375|NCT03043703|DEVICE|AirSense 10 AutoSet for Her|Positive airway pressure
223997376|NCT01896427|DRUG|21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione|single dose of dexamethasone (8mg) will injected
223997377|NCT05973656|DRUG|Alcohol|Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
223997378|NCT05973656|PROCEDURE|Biospecimen Collection|Undergo saliva, mouthwash, and cheek brush collection
223997379|NCT05973656|PROCEDURE|Breath Test|Undergo breathalyzer testing
223380892|NCT04247373|DRUG|Ropivacaine|According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
223380893|NCT02254980|DEVICE|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
223997380|NCT01480063|DRUG|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
223997381|NCT06329258|DRUG|Enstilar|Add on Enstilar
223997382|NCT06329258|DRUG|Deucravacitinib|6mg QD
223997383|NCT06121063|COMBINATION_PRODUCT|CCT-102 A and CCT-102 B|2 day oral regimen
223997384|NCT05889767|OTHER|Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)|"All participants will complete two exercise sessions:~1. VO2 max test on a cycle ergometer~2. Moderate exercise session (45 minutes at 65% measured VO2 max)"
223997385|NCT04703192|DRUG|Valemetostat Tosylate|Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
223997386|NCT06245408|DRUG|Dazodalibep|IV infusion
223997387|NCT06245408|DRUG|Placebo|IV infusion
223997388|NCT01523067|DRUG|Vasomera (PB1046)|Single dose of Vasomera
223997389|NCT01523067|DRUG|0.9% Sodium Chloride|Placebo injection
223997390|NCT06319742|DIAGNOSTIC_TEST|Extracellular vescicles (EV) analysis|"The patients undergo a blood sample for EV analyses: EVs will be characterized by nanoparticle tracking analysis, western blot, bead-based flow cytometry (direct and inverse approach), and ELISA.~We will evaluate diameter and concentration of serum nanoparticles (NPs) by nanoparticle tracking analysis (NTA) using NanoSight LM10. Western Blot analysis will be performed on protein lysate after EV immuno-capture (using beads covered with antibodies against EV specific tetraspanins, CD9, CD63 and CD81). EV profiling will be performed using a standardized multiplex bead-based flow cytometric assay, using MACSPlex Human Exosome Kit (Miltenyi Biotec; Bergisch Gladbach, Germany), as previously described. 22 The detection of 37 different surface antigens commonly expressed on EV membrane (including markers from activated platelets, endothelium, and inflammatory cells) will be simultaneously performed."
223997391|NCT02570659|BEHAVIORAL|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
223997392|NCT00322569|DEVICE|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
223997393|NCT00322569|DEVICE|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
223997394|NCT00322569|DEVICE|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
223997395|NCT00678301|BIOLOGICAL|GSK Biologicals' Synflorix™|3 IM doses.
223380894|NCT02254980|DEVICE|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
223997396|NCT00678301|BIOLOGICAL|GSK Biologicals' Polio Sabin™|3 oral doses
223997397|NCT00678301|BIOLOGICAL|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
223997398|NCT03337438|OTHER|Personalized Feedback Intervention with Values|The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
223997399|NCT03337438|OTHER|Personalized Feedback Intervention Traditional|This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
223380898|NCT05534061|BEHAVIORAL|Connect2Test|Brief motivational enhancement intervention to improve the likelihood of testing and vaccination among syringe exchange clients
223380899|NCT03210792|DEVICE|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
223380900|NCT01027598|DRUG|Pazopanib|Pazopanib: 600 mg orally daily
223380901|NCT01027598|DRUG|Erlotinib|Erlotinib: 150 mg orally daily
223997400|NCT01506440|PROCEDURE|cognitive assessment|Given cognitive assessments
223380902|NCT06821568|OTHER|Personalized Transcranial Direct Current Stimulation (tDCS)|Home-based transcranial direct current stimulation (tDCS) tailored to target the left dlPFC.
223997401|NCT01506440|PROCEDURE|quality-of-life assessment|Ancillary studies
223997402|NCT00186017|DRUG|Olanzapine/Zyprexa|Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
223997403|NCT03901716|DRUG|Sufentanil|Patients in Group S received sufentanil 0.1 mcg/kg.
223380903|NCT06821568|OTHER|Active-Sham|Stimulation administered in very low-level currents (0.5 mA total) designed to not significantly influence cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
223380904|NCT05114096|DRUG|Celestone + placebo|"After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
223380905|NCT05114096|DRUG|Celestone + Celestone|"After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone."
223997404|NCT03901716|DRUG|Fentanyl|Patients in Group F received fentanyl 1 mcg/kg.
223997405|NCT03901716|DRUG|Remifentanil|Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
223997406|NCT03901716|DRUG|Midazolam|Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
223997407|NCT05082753|DRUG|Ivermectin tablets (3 mg Ivermectin)|Two Ivermectin tablets were administered orally.
223997408|NCT05082753|DRUG|Stromectol ® tablets|Two Ivermectin tablets were administered orally.
223997409|NCT03969368|DEVICE|rPMS device|Pelvic floor muscle contractions will be induced by the rPMS device.
223997410|NCT03969368|PROCEDURE|Pelvic floor muscle training|Control group will undergo a pelvic floor muscle training
223997411|NCT02931253|DRUG|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
223380906|NCT04759703|DRUG|Pramipexole|0.25 mg pramipexole tablets
223380907|NCT04759703|DRUG|Placebo|Matching placebo tablets
223380908|NCT04954313|DRUG|Subgingival chlorhexidine irrigation|The dose information for the Chlorhexidine gluconate will be 0.12% with 1 mL in each dental pocket at a frequency of every 3 months for the duration of the study (18 months).
223380909|NCT04954313|OTHER|Dental Supplies|Subjects in the Treatment Group will receive a commercial electric toothbrush (Colgate hum), toothpaste (Colgate Renewal), mouthwash (Colgate Zero), proxabrush (Colgate), and floss (Colgate Palmolive brand) to be used at home along with instructions on their use. Brush heads for the electric toothbrush will be replaced every 3 months and products (toothpaste, mouthwash, proxabrush, and floss) will be replenished at every site visit.
223380910|NCT04954313|OTHER|Periodonal Treatment|Initial periodontal treatment consisting of a pre-procedural rinse and scaling \& root planing (SRP).
223380911|NCT01999634|DEVICE|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
223380912|NCT05961839|DRUG|SGR-2921|SGR-2921 will be administered orally.
223380913|NCT06559215|DRUG|Exparel|Patients will be randomized to receive Exparel intraoperatively via local infiltration.
223380914|NCT01673412|OTHER|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
223380915|NCT05093270|DRUG|BGB-23339|Administered orally as a tablet
223380916|NCT05093270|DRUG|Placebo|Administered orally as a tablet
223380917|NCT06475053|DEVICE|NaturalVue Enhanced Multifocal 1 Day contact lens|Daily disposable multifocal contact lens
223380918|NCT06475053|DEVICE|MiSight 1 Day contact lens|Daily disposable dual-focus contact lens
223997412|NCT00333086|DRUG|Letrozole|
223997413|NCT03416660|DEVICE|Fractional Carbon Dioxide laser|
223997414|NCT00409526|DRUG|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
223997415|NCT01233362|BIOLOGICAL|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
223997416|NCT01233362|BIOLOGICAL|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
223997417|NCT05369559|COMBINATION_PRODUCT|Mini bolus 50|"receiving a mini-bolus A:50 ml of crystalloid solution, regularly infused over 30 seconds"
223997418|NCT05369559|DIAGNOSTIC_TEST|passive leg rising test|Passive leg raising technique: Initially, the patient is placed semi-recumbent with the head of the bed at 45°. After recording baseline measurement, the head of the bed is lowered and the legs are elevated to 45° for 2 minutes
224123296|NCT00174616|DRUG|Oxaliplatin, capecitabine, radiotherapy|"* Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~* Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~* Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
223380919|NCT06642519|OTHER|Brain Stimulation|Studies will be conducted using ECoG, with a bidirectional interface, both recording (aim/phase 1) and stimulating (aim/phase 2), during real-world gait and FOG in PD patients over the course of 7-days of gait experiments.
223997419|NCT04680195|DRUG|Thalidomide|"The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months."
223997420|NCT00233974|PROCEDURE|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
223997421|NCT06405100|DRUG|Supportive care+Prednisone|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Induction period: 1mg/kg/day. The maximum dose is not more than 60mg. The duration of adequate prednisone is a minimum of 4 weeks and a maximum of 16 weeks.~Maintenance period: A reduction of 5-10mg/wk was initiated after 2 weeks of complete remission and finally discontinued after 6 months of maintenance at 5mg/day."
223997422|NCT06405100|DRUG|Supportive care+Tacrolimus+Ripertamab|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Tacrolimus：Induction period: 0.05mg/kg/d. It will be given in two doses 12 hours apart. The blood concentration should be up to 5-10ng/ml. Maintenance therapy was initiated two weeks after complete remission; Maintenance period: Reduced to a blood concentration of 3-8ng/ml, and stopped after 6 months of maintenance treatment.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months."
223997423|NCT06405100|DRUG|Supportive care+Ripertamab|"Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months."
223997424|NCT02042027|DRUG|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
223997425|NCT03578588|DRUG|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
223997426|NCT02974400|BEHAVIORAL|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
223997427|NCT01224977|DRUG|azithromycin|azithromycin 500 mg 3/week for 3 months
223997428|NCT01759524|DRUG|Bupivacaine|
223997429|NCT01759524|DRUG|Lidocaine|
223380920|NCT05081193|DRUG|Testosterone Undecanoate|198mg taken twice daily
223997430|NCT01312259|OTHER|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
223997431|NCT05759962|DRUG|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
223997432|NCT05759962|OTHER|Placebo|Matching Placebo
223997433|NCT00799032|DEVICE|PCI|coronary stent implantation
223997434|NCT04756102|OTHER|Observation of their fetomaternal outcome|observe the fetal outcome and maternal outcome
223997435|NCT03600415|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
223997436|NCT03600415|OTHER|Säntis; 2500m above sea level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
223997437|NCT06436768|DRUG|Sugammadex|"After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered.~Dose will be according to participant actual body weight."
223997438|NCT06436768|DRUG|Neostigmine|"After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine (up to 5 mg maximum dose) plus atropine 0.02 mg/kg (up to 2 mg maximum dose) was administered.~Dose will be according to participant actual body weight."
223997439|NCT04076787|DRUG|Sunitinib|patients who received sunitinib as first line therapy for mRCC
223997440|NCT04646291|DEVICE|Insemination with the Mosie Baby Kit|The participant will have performed at least one cycle of insemination using the Mosie Baby Kit.
223380921|NCT05081193|DRUG|Enzalutamide|160mg taken once daily
223380922|NCT04945018|BIOLOGICAL|HS-001 CS|Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
223380923|NCT04945018|DEVICE|HS-001-D needle, HS-001-D Adaptor|Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
223380924|NCT05835362|BEHAVIORAL|Question prompt list|A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.
223380925|NCT05835362|BEHAVIORAL|Pre-visit video|The 11-minute video has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD.
223997441|NCT00045526|DRUG|erlotinib hydrochloride|Given PO
223997442|NCT00045526|OTHER|laboratory biomarker analysis|Correlative studies
223997443|NCT03596762|DRUG|Elinzanetant (BAY3427080)|BAY3427080 capsules
223997444|NCT03596762|DRUG|Placebo|Placebo capsules
223997445|NCT02231073|BEHAVIORAL|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
223997446|NCT01263509|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
223997447|NCT01263509|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
223997448|NCT04771364|OTHER|ASAP care's protocol|Early geriatrician's advice, prefer locoregional anesthesia techniques where possible, early surgical therapy and medical adaptation on chronic patient's therapy (in particular with regard to sedative, anticholinergic and psychotropic drugs).
223997449|NCT06215209|OTHER|position|patients will be in supine position and prone position
223997450|NCT05930808|DRUG|First Test Concor (Fasted)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
223380926|NCT05835362|BEHAVIORAL|Combined question prompt list/video|"A question prompt list is a list of questions about ADHD (one page) given to study participants to select questions they may want to ask the provider. The youth question prompt list contains 22 questions, and the parent question prompt list contains 20 questions. Both are below a fourth-grade reading level.~And the video is an 11-minute video that has six themes: (a) talking to your doctor about ADHD, (b) controlling ADHD without medicine, (c) ADHD medications, (d) ADHD and school, (e) ADHD and your relationships, and (f) helping your parents understand your ADHD."
223380927|NCT04366934|OTHER|Nasal swab|Nasal swab
223380928|NCT04366934|OTHER|Taste and olfactory function evaluation|Taste and olfactory function evaluation
223380929|NCT04186845|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
223380930|NCT04186845|DIAGNOSTIC_TEST|Positron emission tomography scan|Imaging scan with radioligand
223380931|NCT00938249|DIETARY_SUPPLEMENT|Monascus Garlic Fermented Extract|
223380932|NCT00938249|DIETARY_SUPPLEMENT|Placebo|
223380933|NCT03431493|BEHAVIORAL|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
223997451|NCT05930808|DRUG|First Reference Concor (Fasted)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition
223997452|NCT05930808|DRUG|First Test Concor (Fed)|Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.
223997453|NCT05930808|DRUG|First Reference Concor (Fed)|Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
223997454|NCT05884814|BEHAVIORAL|Morning exercise|Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
223997455|NCT05884814|BEHAVIORAL|Afternoon exercise|Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)
223997456|NCT05884814|BEHAVIORAL|Habitual physical activity levels|Participants will be asked to maintain their normal activity levels
223997457|NCT03345745|DIAGNOSTIC_TEST|salivary samples|Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
223997458|NCT05497115|BEHAVIORAL|Trauma Resilience and Recovery Program|The Trauma Resilience and Recovery Program is a stepped model of care that is designed to deliver education at the bedside about mental health recovery after traumatic injury as well as risk assessment and brief intervention for high-risk patients (Step 1), foster symptom self-monitoring and continued education (Step 2), screen for PTSD and depression 30 days post-injury (Step 3), and provide a referral and warm handoff to mental health services if needed (Step 4).
223380934|NCT05862727|BEHAVIORAL|Telehealth Intervention|Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.
223380935|NCT01814553|DRUG|afatinib|Daily treatment starting 40 mg per day
223380936|NCT01814553|DRUG|loperamide|Follow cohort assignment and diarrhea management guidelines
223997459|NCT04374786|DEVICE|Calm Meditation App|"Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time."
223997460|NCT04574817|DRUG|HX008|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
223997461|NCT02309671|DRUG|FE 999049|
223997462|NCT02309671|DRUG|follitropin beta|
223997463|NCT01649154|PROCEDURE|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
223997464|NCT04210999|OTHER|Homebased resistance training|Resistance training at home instructed via a smart phone training app
223997465|NCT04210999|OTHER|Supervised heavy slow resistance training|Heavy slow resistance training in the gym instructed by a physiotherapist
223997466|NCT05070364|DRUG|Peginterferon Lambda-1a|Immunomodulator
223997467|NCT00795223|DRUG|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
223997468|NCT00795223|DRUG|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
223997469|NCT00795223|DRUG|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
223997470|NCT00795223|DRUG|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
223997471|NCT03124654|BEHAVIORAL|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
223380937|NCT04138823|DRUG|BI 891065|film-coated tablets
223997472|NCT02593123|DRUG|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
223997473|NCT02593123|BIOLOGICAL|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
223997474|NCT02593123|BIOLOGICAL|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
223997475|NCT05071053|DRUG|Ramucirumab (CYRAMZA®)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
223997476|NCT05071053|DRUG|Tusamitamab ravtansine (SAR408701)|"Pharmaceutical Form: Concentrate for solution for infusion~Route of Administration: Intravenous Infusion"
223380938|NCT06206629|DIAGNOSTIC_TEST|blink reflex evaluation|A blink reflex evaluation will be performed in all subjects
223380939|NCT05942625|DRUG|HS-10390 tablet|Oral administration of specified dose of HS-10390
223380940|NCT05942625|DRUG|Placebo tablet|Oral administration of matching dose ofplacebo
223997477|NCT05858684|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
223380941|NCT02018380|OTHER|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
223380942|NCT05264181|DEVICE|Percutaneous pulmonary valve implantation|Percutaneous pulmonary valve implantation using SAPIEN 3 valve in the context of routine care of patients with congenital heart diseases
223380943|NCT03502434|DRUG|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
223380944|NCT03502434|OTHER|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
223380945|NCT03502434|OTHER|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
223380946|NCT03502434|OTHER|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
223997478|NCT00459797|DEVICE|Conventional (reusable) Glidescope|
223997479|NCT00459797|DEVICE|Single-use Glidescope videolaryngoscope|
223997480|NCT02834338|DEVICE|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
223997481|NCT03993210|DEVICE|Magnetic Resonance Fingerprinting (MRF)|In MRF, multiple tissue properties are acquired simultaneously.
223997482|NCT03993210|DEVICE|Q-space Trajectory Imaging (QTI)|By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.
223997483|NCT03993210|DEVICE|Magnetic Resonance Imaging Machine (MRI)|MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.
223997484|NCT01777165|DRUG|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
223997485|NCT01777165|DRUG|Placebo|Placebo infusion
223997486|NCT02650713|DRUG|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
223997487|NCT02650713|DRUG|RO6958688|"RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower."
223997488|NCT04053062|BIOLOGICAL|LIGHT-PSMA-CART cells|LIGHT-PSMA-CART cells will be given IV at split doses
223997489|NCT01261000|DRUG|Pegvisomant|Pegvisomant used as indicated
223997490|NCT02656719|DEVICE|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
223997491|NCT02656719|DEVICE|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
223997492|NCT02090010|PROCEDURE|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel."
223997493|NCT02090010|PROCEDURE|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
223997494|NCT03678090|DRUG|tPA standard dosage|Tissue plasminogen activator 25mg dosage
223380947|NCT06632717|DRUG|Cisplatin|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
223997495|NCT03678090|DRUG|tPA low dosage|Tissue plasminogen activator 2.5mg
223997496|NCT00504777|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
223997497|NCT00504777|DRUG|Methotrexate|10-25mg/week po or parenteral
223997498|NCT03133832|DRUG|Companion Tablet|Chinese-made drug for schistosomiasis treatment
223997499|NCT03274973|DRUG|Zomacton|Injection
223997500|NCT06306469|OTHER|Meditation practice|physical and breathing exercises
223997501|NCT06068764|DRUG|Etomidate|The type of general anesthesia induction agent for CABG surgery
223997502|NCT06068764|DRUG|Propofol|The type of general anesthesia induction agent for CABG surgery
223997503|NCT06117553|PROCEDURE|thorough flushing|The thorough flushing strategy refers to the thorough flushing of all liquid and foam accumulation areas during the inspection. Make all liquid accumulation parts in the intestinal cavity free of aspiratable liquid retention
223997504|NCT03447301|DIETARY_SUPPLEMENT|Extra virgin olive oil (30mL daily)|Intervention arm will take 30 mL of Extra virgin olive oil daily.
223997505|NCT02721992|OTHER|No intervention|No intervention
223997506|NCT02126852|DEVICE|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
223997507|NCT02126852|DEVICE|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
223997508|NCT02126852|DEVICE|Electromyography (EMG)|Neuromuscular monitoring
223380948|NCT06632717|DRUG|5-fluorouracil|"Chemotherapy regimen~• Cisplatin 60mg/m2 on day 2; 5-fluorouracil (5-FU) 500mg/m2 on day 1 - day 3 via the HAIC port, every 3 weeks until progression or intolerable toxicity"
223380949|NCT06632717|PROCEDURE|Lipiodol embolization|"Lipiodol embolization protocol~* Lipiodol embolization will be performed on day 3 after completion of 5-FU infusion, up to 4 cycles. Fixed dose lipiodol of 10mL will be given on day 3 followed by 30mL normal saline flush.~* The administration of lipiodol is mandatory on cycle 1. The administration of lipiodol on cycle 2 to cycle 4 will depend on the discretion of the treating physician and the presence of adverse effects from lipiodol embolization."
223380950|NCT02859142|DRUG|Chantix|Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
223380951|NCT02859142|BEHAVIORAL|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
223997509|NCT04480775|DRUG|Triamcinolone|transversus abdominis plane block with bupivacain and triamicinolone
223997510|NCT04480775|DRUG|Methylprednisolone|transversus abdominis plane block with bupivacaine and methylprednisolone
223997511|NCT04480775|DRUG|bupivacaine|transversus abdominis plane block with bupivacaine alone
223997512|NCT03900910|OTHER|Gastric cancer prevention|Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
223997513|NCT03900910|OTHER|Execution of the program|Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .
223997514|NCT04212351|GENETIC|Frameshift Array blood sample test|Patient blood test samples will be collected and evaluated for frameshift peptide mutations.
223997515|NCT01572740|DRUG|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
223997516|NCT01572740|DRUG|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
223997517|NCT01572740|DRUG|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
223997518|NCT00211380|DRUG|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
223997519|NCT01289210|DRUG|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
223997520|NCT03452852|DEVICE|PICO|NPWT with PICO (Smith and Nephew)
223997521|NCT03452852|OTHER|Coban 2 lite|Compression bandaging with Coban 2 lite
223997522|NCT05526469|PROCEDURE|Serratus anterior plane block|patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
223997523|NCT05526469|PROCEDURE|erector spinae plane blocks|patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
223997524|NCT05526469|DRUG|Bupivacaine 0.25% Injectable Solution|Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
223997525|NCT01204411|DRUG|Artesunate-amodiaquine fixed-dose combination|"* artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~* artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~* artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;"
223997526|NCT00571181|DEVICE|Closed-loop system|Automatic delivery of propofol and remifentanil
223997527|NCT00571181|DEVICE|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
223380952|NCT02859142|DRUG|NicodermCQ|Nicotine patches provided over 12 week participation
223380953|NCT02859142|DRUG|Placebo|Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
223380954|NCT06030336|BEHAVIORAL|Home Health Report|The Home Health Report has been described in the intervention arm description.
223997528|NCT03240653|OTHER|Stratified response to Enzyme Therapy|Observational study involves review of retrospective and prospective data of participants' medical history, pathology, imaging and health questionnaires.
223997529|NCT03423576|BEHAVIORAL|comprehensive patient-centered outpatient health service with multiple components|Individualized multi-component education and counselling program coordinated by a case Manager.
223997530|NCT01224834|DRUG|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
223997531|NCT05837377|OTHER|Control- standard medication education|"Common Procedure:~\- Student Information and Consent Form will be obtained from the students.~For the control group~* Theoretical training in drug administration skills is provided.~* Skill training: Skill training on intramuscular and subcutaneous injection and intravenous medication administration using task trainers in the simulation laboratory.~* After the skill evaluation phase, a safe drug administration scenario will be applied."
224295486|NCT04834739|OTHER|5 times sit to stand test|The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
223380955|NCT03290079|DRUG|Pembrolizumab|200 mg Pembrolizumab by IV on Day 1 of each 3 week cycle.
223380956|NCT03290079|DRUG|Lenvatinib|20 mg Lenvatinib by mouth every day of each 3 week cycle
223380957|NCT02366273|OTHER|PASI and HOMA index|
223380958|NCT02676765|DRUG|allergen extract tablet|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
223380959|NCT02676765|DRUG|Placebo tablet|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
223380960|NCT03874728|OTHER|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
223380961|NCT03874728|OTHER|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
223380962|NCT03874728|OTHER|Barefoot|Participants will conduct the assessments barefoot.
223380963|NCT03874728|OTHER|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
223380964|NCT04114487|OTHER|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
223380965|NCT02391987|DEVICE|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
223997532|NCT05837377|OTHER|Experiment- cognitive load theory based on medication education|"For the experiment group~* Theoretical training will be provided based on the results of both the knowledge test and the self-efficacy test, and will be designed according to the principles of cognitive load theory.~* Skills training: includes the necessary skill applications for students with task trainers and a virtual simulation designed according to the cognitive load theory for these skills.~* After the skill evaluation phase, a safe drug administration scenario will be applied."
223997533|NCT05926778|OTHER|Liver allograft fibrosis|Observational studies without intervention
223997534|NCT00573742|DRUG|Candesartan Cilexeotil 16mg|
223997535|NCT03513705|OTHER|Best practices in pancreatic cancer care|All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
223997536|NCT01818531|DRUG|Adductor canal block|
223380966|NCT00842205|DRUG|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
223380967|NCT00842205|DRUG|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
223380968|NCT01941498|DEVICE|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
223997537|NCT01818531|DRUG|Lumbar plexus block|
223997538|NCT05910905|PROCEDURE|Prefabricated pediatric zirconia crown group|Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).
223997539|NCT05910905|PROCEDURE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
223997540|NCT00137969|DRUG|Rituximab|Rituximab will be supplied as a sterile liquid for IV administration.
223997541|NCT00137969|DRUG|Placebo|Placebo will be supplied as a sterile liquid for IV administration.
223997542|NCT00137969|DRUG|Prednisone|
223997543|NCT00137969|DRUG|Acetaminophen|
223997544|NCT00137969|DRUG|Diphenhydramine|
223997545|NCT00477490|DRUG|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
223997546|NCT00477490|DRUG|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
223997547|NCT04278170|OTHER|no attempt was made to patients|no attempt was made to patients
223380969|NCT01941498|PROCEDURE|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
223380970|NCT05667025|OTHER|Conservative rehabilitation|Joint range of motion, strengthening, balance-coordination and stretching exercises included in the conservative physiotherapy program 5 days a week for a total of 6 weeks
223997548|NCT05226936|DIAGNOSTIC_TEST|Cell free DNA analysis|samples will be analysed using molecular techniques including sequencing for measuring dd-cfDNA or analysis of the presence of HLA-antibodies using commercial bead-technologies (Luminex or Immucor)
223997549|NCT04038164|BEHAVIORAL|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
223380971|NCT05667025|OTHER|Cycling Functional Electrical Stimulation in addition to Conservative Rehabilitation|In addition to conservative treatment, cycling FES to the affected lower extremity for 20 minutes, 3 days a week for 4 weeks. During the treatment, the patient will be seated on a chair and her feet will be fixed to the pedal with velcro tape, and the comfort during the treatment will be provided with calf supports.
223380972|NCT02015845|DEVICE|Accuvein|
223380973|NCT02015845|DEVICE|Routine technique|Placement of peripheral intravenous catheters using the routine technique
223380974|NCT05088785|DRUG|FES|\[18F\]FES PET imaging.
223380975|NCT04391504|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
223380976|NCT01799837|DRUG|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
223997550|NCT02092623|DEVICE|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
223997551|NCT02757677|DEVICE|Optical Coherence Tomography based Angiography|A contrast-free, noninvasive technology to identify blood vessels in the eye
223997552|NCT01110408|DRUG|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
223997553|NCT01110408|DRUG|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
224295487|NCT04834739|OTHER|6 point Likert Scale|"Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent)."
223380977|NCT02965937|OTHER|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
223380978|NCT02965937|OTHER|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
223380979|NCT05783232|DIETARY_SUPPLEMENT|Placebo Control Form 1 Capsules|Participants will use their Placebo Control Form 1 Capsules as directed for a period of 4 weeks.
223380980|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.1 Capsules|Participants will use their Radicle Health Active Study Product 1.1 Capsules as directed for a period of 4 weeks.
223380981|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.2 Capsules|Participants will use their Radicle Health Active Study Product 1.2 Capsules as directed for a period of 4 weeks.
223380982|NCT05783232|DIETARY_SUPPLEMENT|Health Active Study Product 1.3 Capsules|Participants will use their Radicle Health Active Study Product 1.3 Capsules as directed for a period of 4 weeks.
223380983|NCT06164366|DEVICE|0 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 0 degrees
223997554|NCT01110408|DRUG|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
223997555|NCT01110408|DRUG|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
223997556|NCT01110408|DRUG|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
223380984|NCT06164366|DEVICE|45 degrees 3D printed upper complete dentures|3d printed dentures at a build angle of 45 degrees
223997557|NCT05316792|OTHER|walking|30 min walking on the treadmill and tartan floor
223997558|NCT00669877|DRUG|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
223997559|NCT00669877|DRUG|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
223545191|NCT06717542|DIAGNOSTIC_TEST|RT-PCR|Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).
223545192|NCT06714838|DRUG|Rituximab (Mabthera)|Rituximab will be administered in a hospital setting in the course of one day. It will be given intravenously, at time points baseline, week 2 and week 26.
223997560|NCT00669877|DRUG|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
223380985|NCT03044626|DRUG|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
223997561|NCT00669877|DRUG|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
223997562|NCT00669877|DRUG|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
223997563|NCT00669877|DRUG|G-CSF|10 mcg/kg
224123297|NCT03521154|DRUG|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
224123298|NCT03521154|DRUG|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
223380986|NCT03044626|DRUG|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
223997564|NCT00669877|DRUG|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
224123299|NCT02305290|PROCEDURE|Endoscopic Mucosal Resection|
223380987|NCT04521738|DRUG|SAR441255|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
223380988|NCT04521738|DRUG|placebo|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
223380989|NCT02405130|OTHER|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
223380990|NCT02405130|OTHER|no intracoronary epinephrine|patients will receive standard therapy only
223380991|NCT01563497|DRUG|PF-05089771|Oral dispersion TS formulation- fasted
223380992|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fasted
223997565|NCT00669877|DRUG|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
223997566|NCT03113318|PROCEDURE|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
223997567|NCT03113318|PROCEDURE|Only pulmonary metastasectomy|
223997568|NCT03242902|DEVICE|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
223997569|NCT03242902|DEVICE|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
223997570|NCT05116826|DRUG|Nitazoxanide|500 mg Twice Daily for 7 days
223997571|NCT06376877|PROCEDURE|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a focal, non-invasive form of brain stimulation that has FDA clearance for depression. In this study, a form of TMS called accelerated intermittent theta burst stimulation will be administered under the supervision of a physician with TMS expertise.
223997572|NCT06376877|PROCEDURE|Sham transcranial magnetic stimulation|The sham TMS coil mimics the scalp sensation of real TMS by delivering a small amount of electrical current with a pair of surface electrodes.
223997573|NCT02534571|DEVICE|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 \<=150g once
224123300|NCT00377143|DRUG|Warfarin Dosing|
224123301|NCT02143362|DRUG|Anesthesia induction,propofol, remifentanil ,cisatracurium|"1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
224123302|NCT02143362|DRUG|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg)."
224123303|NCT02143362|PROCEDURE|Awaken test|"1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test."
224123304|NCT03747224|DRUG|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
224123305|NCT03747224|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
224123306|NCT00376597|OTHER|quality of life assessment|Ancillary studies
224123307|NCT00376597|OTHER|educational intervention|Receive lymphedema educational materials
223380993|NCT01563497|DRUG|PF-05089771|Tablets TS formulation- fed
223380994|NCT00159224|DRUG|Lopinavir/ritonavir simplification strategy|Simplification
223380995|NCT00314210|DRUG|Quetiapine SR|
223380996|NCT04877457|DRUG|Ocrelizumab|The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
223380997|NCT04877457|OTHER|Placebo|Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
223380998|NCT01888939|OTHER|Walking on a Treadmill|
223380999|NCT01888939|OTHER|Sedendary Activities Only|
223381000|NCT03173157|OTHER|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
223381001|NCT05126329|DRUG|amcenestrant|tablet for oral use
223381002|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
223997574|NCT02534571|DEVICE|Hemo-clipping|Hemo-clipping \<=20 clips
223997575|NCT02534571|DRUG|Epinephrine|epinephrine injection endoscopically \<20 mls
223997576|NCT02534571|DEVICE|thermo-coagulation|contact thermo-coagulation \< = 4 pulses
223381003|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
223381004|NCT04142086|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
223381005|NCT04142086|BIOLOGICAL|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
223997577|NCT01465763|DRUG|tofacitinib|10 mg oral BID
223997578|NCT01465763|DRUG|Placebo|Plabebo oral BID
223997579|NCT01646177|DRUG|Placebo|Administered SC
223997580|NCT01646177|DRUG|50 mg etanercept|Administered SC
223997581|NCT01646177|DRUG|80 mg ixekizumab|Administered SC
223997582|NCT02993185|BEHAVIORAL|Your Move|"Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
223997583|NCT02993185|BEHAVIORAL|Eat Smart|"Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
223997584|NCT01791504|DEVICE|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
223997585|NCT02920970|DEVICE|narafilcon A|contact lens
223997586|NCT02920970|DEVICE|stenfilcon A|contact lens
223997587|NCT00077389|DRUG|carboplatin|
223997588|NCT00077389|DRUG|cisplatin|
223997589|NCT00077389|DRUG|doxorubicin hydrochloride|
223997590|NCT00077389|PROCEDURE|adjuvant therapy|
223997591|NCT00077389|PROCEDURE|conventional surgery|
223997592|NCT00077389|PROCEDURE|neoadjuvant therapy|
224123308|NCT00376597|PROCEDURE|Physical therapy|Complete physical therapy-focused intervention
223381006|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
223997593|NCT01699113|DRUG|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg."
223997594|NCT01699113|DRUG|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg."
223997595|NCT05584358|DIETARY_SUPPLEMENT|Dry protein blend ingestion|Ingestion of protein blend powders mixed in water
223997596|NCT05584358|DIETARY_SUPPLEMENT|Extruded protein blend ingestion|Ingestion of protein blend powders mixed in water
223997597|NCT03944590|OTHER|patient survey|patient survey on clinical outcome after screw osteosynthesis of radial head fractures
223997598|NCT03944590|OTHER|analysis of radiographs|analysis of radiographs on radiological outcome after screw osteosynthesis of radial head fractures
223997599|NCT00770744|DRUG|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
223997600|NCT00770744|DRUG|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
223997601|NCT02690116|OTHER|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
223381007|NCT06028295|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
223381008|NCT06028295|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
223381009|NCT03305133|OTHER|Immunohistochemistry|The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
223545193|NCT06717009|DIAGNOSTIC_TEST|Preoperative three-dimensional reconstruction|On the basis of conventional CT/MRI, the patient will undergo 3D reconstruction within 48 hours before surgery. The surgeon/researcher will conduct surgical planning according to the results of the 3D reconstruction and perform robot-assisted laparoscopic nephron sparing surgery.
223545194|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Control|2 x algal oil gel capsules delivering 400mg DHA in total
223997602|NCT02690116|OTHER|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
223997603|NCT02690116|OTHER|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
223997604|NCT03615053|OTHER|Implementation of WAPPS-Hemo personalized dosing regimen|Twelve months after enrollment in the study, WAPPS-Hemo will be used to calculate each patients individual pharmacokinetic estimate. Once completed, the WAPPS-Hemo clinical calculator will be used to calculate the optimal regimen based on individual needs.
223997605|NCT02204657|DEVICE|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
223997606|NCT05449405|COMBINATION_PRODUCT|Chlorpheniramine Maleate 1% Nasal Spray|Chlorpheniramine Maleate 1% Nasal Spray
223997607|NCT05449405|COMBINATION_PRODUCT|Placebo|Placebo nasal spray
224123309|NCT02194400|BIOLOGICAL|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
223381010|NCT01793493|OTHER|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~* body awakening (10 minutes)~* cognitive stimulation (1 hour and a half) scheduled as follow:~  * temporospatial orientation~ * attentional abilities~ * one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
223381011|NCT01793493|OTHER|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
223381012|NCT04960293|PROCEDURE|uterine artery embolization using spherical gelfoam|Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
223381013|NCT04960293|PROCEDURE|uterine artery embolization using tri-acryl gelatin microsphere|Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
223997608|NCT05306743|OTHER|CONQUEST Quality Improvement Program|"CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations."
223997609|NCT04982770|OTHER|Survey|Reading of ethical guidelines.
223997610|NCT01229605|DRUG|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
223997611|NCT05689775|PROCEDURE|Reconstruction with robot-assisted rectus abdominis muscle flap|Reconstruction of perineum and/or vagina with robot-assisted rectus abdominis muscle flap.
223997612|NCT01711853|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
224123310|NCT02857855|PROCEDURE|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
224123311|NCT02857855|PROCEDURE|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
224138397|NCT03585192|OTHER|Skin Group|"1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
224138398|NCT03585192|OTHER|Warmer Group|"1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
223381014|NCT04470063|DRUG|DDO-3055 tablets|Multi-dose for DDO-3055 tablets
223381015|NCT04470063|DRUG|Placebo|Multi-dose for Placebo
223381016|NCT05680584|DRUG|Melatonin 3 MG|0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia
223997613|NCT04745975|DRUG|Personalized treatment guided by mini-PDX and RNA sequencing|Personalized treatment guided by mini-PDX and RNA sequencing
223381017|NCT05680584|DRUG|Hydroxyzine Pill|1 mg/ kg hydroxyzine in 10 ml apple juice 1 hour before induction of anesthesia
223381018|NCT05680584|OTHER|Placebo|10 ml apple juice 1 hour before induction of anesthesia
223997614|NCT04745975|DRUG|Nab paclitaxel|Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8, 15, q4w
223997615|NCT04745975|DRUG|Eribulin|Eribulin 1.4 mg/m2, d1,8 q3w
223997616|NCT04745975|DRUG|Vinorelbine|Vinorelbine 25mg/m2 d1,8, q3w
224138399|NCT02469792|PROCEDURE|Liposuction|
224138400|NCT02469792|DEVICE|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
223381019|NCT01199146|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
223997617|NCT04745975|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, d1,8, q3w
224138401|NCT02469792|PROCEDURE|Arthroscopic surgery|
224138402|NCT02469792|OTHER|Intraarticular administration of autologous ADRC|
224138403|NCT01653158|DRUG|CP-751,871|"CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
224138404|NCT01653158|DRUG|Docetaxel|Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
224138405|NCT06322524|DEVICE|Gamma sensory flicker|participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.
223381020|NCT05930561|BIOLOGICAL|4D-150 IVT|4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.
223381021|NCT05930561|BIOLOGICAL|Aflibercept IVT|Commercially available Active Comparator
223381022|NCT06245915|BIOLOGICAL|AB-2100|autologous T cell therapy
223545195|NCT04610983|DIETARY_SUPPLEMENT|Experimental: Treatment 1 - Semi-Solid food matrix|"Test Food 1: 200g serve soup + ingredient"
224138406|NCT01933750|DEVICE|PresVIEW Device Implantation|
224138407|NCT02435550|GENETIC|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
223997618|NCT04745975|DRUG|Capecitabine|Capecitabine 1250 mg/m2 bid po
223997619|NCT02885558|DRUG|Efonidipine|8 weeks treatment with either efonidipine
223997620|NCT02885558|DRUG|Nifedipine|8 weeks treatment with either nifedipine
223997621|NCT03434444|DRUG|Oxytocin|Oxytocin in solution, ranging from 10 -12M to 10 -5M
223997622|NCT03434444|DRUG|Propranolol|Propranolol in solution, 10-6M
223997623|NCT03364075|DRUG|Duloxetine|30 mg for seven days, then increased to 60 mg for seven days
223997624|NCT03364075|DRUG|Propranolol|40 mg for seven days, then increase to 60 mg for seven days
224123312|NCT02594475|PROCEDURE|Endoscopic retrograde cholangiopancreatography|"1. Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~2. Selective bile duct cannulation is performed using wire-guided cannulation.~3. In case of difficult cannulation, precut is performed using a needle-knife.~4. After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
224123313|NCT02172521|DRUG|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
224123314|NCT02146079|DRUG|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
224123315|NCT02146079|DRUG|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
224123316|NCT05100316|OTHER|Screening Platform|Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
224295488|NCT06698445|OTHER|Short film video|The short film training video will be prepared by researchers based on literature and appropriate for the level of children aged 7-12. The content will include topics such as preparation for KİAB, KİAB environment and the process after KİAB. Since the short film will be shot in a realistic manner, the scenario will include a doctor, a nurse, a child patient and a parent. The short film will be shot in the clinic where the data will be collected, at the appropriate time for the clinic. After the short film is shot, the editing process will be done and the final version will be given.
223997625|NCT03364075|GENETIC|Genotype for SNPs associated to Serotonin and COMT|DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways
223997626|NCT03364075|DRUG|Placebo Treatment|1 capsule BID for two weeks
223997627|NCT04438720|DRUG|Extended Release Nifedipine Tablets 30 mg|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
223997628|NCT04438720|DRUG|Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)|The subjects randomly received single oral administration of extended release nifedipine tablets 30 mg.
223997629|NCT03722225|OTHER|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
223997630|NCT02334475|BIOLOGICAL|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
223997631|NCT02334475|BIOLOGICAL|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
223997632|NCT04848818|PROCEDURE|Distal radial metaphyseal fracture fixation with percutaneous K-wires|Pediatric distal metaphyseal fractures which are severly displaced will be operated with percutaneous K-wires..
223997633|NCT04848818|PROCEDURE|Distal radial and/or ulnar metaphyseal fracture fixation with bidegradable PLGA-based (Activa Im-Nail) implants|Pediatric distal metaphyseal radial and /or ulnar fractures which are severly displaced will be operated with percutaneous bidegradable PLGA-based (Activa Im-Nail) implants.
223997634|NCT03261687|OTHER|water based exercise|
223997635|NCT03261687|OTHER|land based exercise|
223997636|NCT03261687|BEHAVIORAL|advice|general advice given to all subjects
223997637|NCT02740725|OTHER|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
223997638|NCT02740725|DEVICE|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
223997639|NCT05260177|DEVICE|Light Therapy System (LTS): Active Setting|Exposure for 1 hour á day for consecutive days
223997640|NCT05260177|DEVICE|Light Therapy System (LTS): Sham Setting|Exposure for 1 hour á day for consecutive days
223997641|NCT03265353|OTHER|Moderate Potassium/Low Sodium Diet|7 days of the prescribed diet
223997642|NCT03265353|OTHER|Moderate Potassium/High Sodium Diet|7 days of the prescribed diet
223997643|NCT03265353|OTHER|High Potassium/High Sodium Diet|7 days of the prescribed diet
223997644|NCT02879786|OTHER|Posturographic tests|
223997645|NCT02879786|OTHER|Questionnaire of motion sickness susceptibility|
223545196|NCT04610983|DIETARY_SUPPLEMENT|Treatment 2 - Solid food matrix|"Test Food 2: 50g serve extruded snack (savoury snack) + ingredient"
223545197|NCT02551185|DRUG|ACY-241|
223545198|NCT04167254|BEHAVIORAL|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
223997646|NCT02079025|DEVICE|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
223381023|NCT06371911|OTHER|Cureety telemonitoring|The digital telemonitoring platform, Cureety, has been designed to facilitate the monitoring of signs and symptoms of treatment-specific AEs and disease progression. The platform integrates Cureety TechCare, a CE marked algorithm that is a class I medical device
223381024|NCT06371911|OTHER|OPTIMA or equivalent programs|"The programs consist of three stages:~1. The medical team make structured telephone calls with patients 2 to 3 days before the planned administration of injectable treatment. Adverse events and other relevant data are collected.~2. Patients undergo biological tests within 48 hours of the appointment and the results are sent by the laboratory to the centre.~3. Then, the physician assesses the data and decides whether to anticipate and validate the prescription of injectable treatments."
223381025|NCT02490501|PROCEDURE|SC0806 and rehabilitation|
223381026|NCT02490501|OTHER|Rehabilitation only|
223997647|NCT02079025|DEVICE|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
223381027|NCT06465303|DRUG|RTP-026|Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;
223381028|NCT06465303|DRUG|Placebo|Intervention is for each subject administered as three 30-minutes infusions of placebo
223381029|NCT02155621|GENETIC|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
223381030|NCT05634707|DRUG|Fluoxetine|"Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~* Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~* Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6"
223381031|NCT05634707|DRUG|Temozolomide|Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
223381032|NCT06633380|BEHAVIORAL|Standard Physical Activity - Fasted|30 minutes of walking at a self-selected pace that they must have completed 15 minutes prior to consumption of first meal in the morning.
223381033|NCT06633380|BEHAVIORAL|Standard Physical Activity - Post-Meal|30 minutes of walking at a self-selected pace to start 30 minutes after the start of the first meal in the morning.
223381034|NCT06633380|BEHAVIORAL|Dispersed Physical Activity|10 minutes of walking at a self-selected pace to start 30 minutes after the start of each main meal throughout the day (i.e., three bouts total).
223381035|NCT06633380|BEHAVIORAL|Physical Activity Snacks|2 minutes of walking or marching on the spot at a self-selected pace every 30 minutes throughout the day for 7.5 waking hours.
223381036|NCT06633380|BEHAVIORAL|Muscle Strengthening|30 minutes of muscle strengthening exercises targeting the major muscle groups of the whole body, to start 30 minutes after the start of the first meal in the morning.
223381037|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with capsules containing rosemary and alkylglycerol|
223997648|NCT03566745|DIAGNOSTIC_TEST|Blood for protein activity|Blood for protein activity
223997649|NCT01427725|DRUG|Lipacreon|This study was an observational study and no intervention was specified
223997650|NCT02358434|RADIATION|Observational use of fluoroscopy|
223997651|NCT02906436|DEVICE|Xvivo Chamber|
223997652|NCT04916951|DRUG|Amoxicillin|oral one-time dose of amoxicillin
223997653|NCT04916951|DRUG|Cephalexin|oral one-time dose of cephalexin
223997654|NCT05772182|DEVICE|ACORYS MAPPING SYSTEM|"Diagnostic Test: ECG-Imaging~Diagnostic Test: Standard 12-lead ECG~Diagnostic Test: Endocardial mapping and/or pacing"
223997655|NCT04871399|PROCEDURE|Conventional Right hemicolectomy (Non-CME)|Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
223997656|NCT04871399|PROCEDURE|Right hemicolectomy with CME+CVL|"Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly:~* The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery~* The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery.~The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance."
223381038|NCT03492086|DIETARY_SUPPLEMENT|Dietary supplementation with control capsules|
223381039|NCT02869802|PROCEDURE|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
223381040|NCT02869802|OTHER|Serial Collection of Plasma and Serum Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every cycle of chemotherapy or every 4 weeks, whichever is longer, until end of study.
223381041|NCT05953259|DEVICE|Combination of STERN FIX and wires|Closure of the median sternotomy using a combination of at least one STERN FIX device and wires for a total of 5 fixation points.
223381042|NCT05953259|DEVICE|Wires|Closure of the median sternotomy using the standard of care with steel wires.
223381043|NCT06171126|DIETARY_SUPPLEMENT|Placebo|By gastroscopy
223381044|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor A|By gastroscopy
223381045|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor B|By gastroscopy
223997657|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.05 mg/kg|will be administered 1 hour before arrival to operating room
223997658|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg|will be administered 1 hour before arrival to operating room
223997659|NCT05223010|DRUG|Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg|will be administered 1 hour before arrival to operating room
223997660|NCT05223010|DRUG|Sevoflurane|for anaesthesia induction 3-8 MAC
223381046|NCT06171126|DIETARY_SUPPLEMENT|Faeces from donor C|By gastroscopy
223381047|NCT03545464|DRUG|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
223381048|NCT03545464|DRUG|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
223381049|NCT03545464|DRUG|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
223381050|NCT04395066|DIAGNOSTIC_TEST|CD55|CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.
223381051|NCT02895152|BEHAVIORAL|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
223381052|NCT04697069|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
223381053|NCT04697069|BIOLOGICAL|Placebo|Placebo
223381054|NCT05385705|DRUG|Cyclophosphamide|Cyclophosphamide at a single dose of 600mg/m2 IV between days -5 and -3 before NK cell infusion for preconditioning the tumoral microenvironment by reducing the levels of lymphocyte T regulators (Tregs FOXP3+, CD3+, CD4+, CD25+).
223381055|NCT05385705|DRUG|Trastuzumab|Trastuzumab at a dose of 8mg/kg IV for the loading dose on Day 1, and 6mg/kg IV for the maintenance dose every 3 weeks (Q3W).
223381056|NCT05385705|DRUG|Pertuzumab|Pertuzumab at a dose of 840mg IV for the loading dose on Day 1, and 420 mg IV for the maintenance dose every 3 weeks (Q3W).
223381057|NCT05385705|BIOLOGICAL|NK cells|NK product is a cellular investigational product comprising a live cell suspension of allogenic NK cells derived from a compatible donor that will be infused on Day 2.
223381058|NCT05385705|DRUG|Interleukin-2|IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.
223997661|NCT01374568|DRUG|sitagliptin|sitagliptin 100mg daily
223997662|NCT01374568|OTHER|Placebo|1 pill daily
223997663|NCT03872245|BIOLOGICAL|Probiotics|The patients will receive Adomelle 1caps/12h during 10 weeks
223381059|NCT04586530|BEHAVIORAL|Memory and Attention Adaptation Training (MAAT)|A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
223381060|NCT04586530|BEHAVIORAL|Supportive Therapy (ST)|Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
223381061|NCT03992404|DRUG|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223381062|NCT03992404|DRUG|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
223997664|NCT03872245|PROCEDURE|PENS T6|The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
223997665|NCT01299051|BEHAVIORAL|Steps to Health|"Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~* Face-to-face visit with counselor during Month 1 to set specific health goals.~* Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~* Monthly generic health education materials sent via e-mail.~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments."
223997666|NCT01299051|BEHAVIORAL|Steps to Health Plus!|"The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~* Face-to-face visit with counselor at Month 1~* Meeting with exercise physiologist in Month 2~* Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~* Meeting with exercise physiologist during Month 5~* Quarterly biometric feedback (Months 3, 6, 9, and 12)~* Incentives (up to 1,000 STH dollars \[$100\]) to take part in the program assessments."
223997667|NCT03622970|DEVICE|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
223997668|NCT03622970|BEHAVIORAL|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
223381063|NCT01218854|DEVICE|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
223381064|NCT07123129|DRUG|SHR-7782 Injection|SHR-7782 injection.
223381065|NCT07132567|DRUG|Poteligeo 20mg|Poteligeo 20mg
223381066|NCT02963883|OTHER|SVO2 group / control group|
223381067|NCT04678362|DRUG|Talazoparib + Avelumab|Patients will receive the combined treatment until the investigator considers that the patient no longer obtains benefit from it. The treatment will be continued until disease progression, unacceptable toxicity or discontinuation for any cause.
223381068|NCT06854562|BEHAVIORAL|Therapeutic Robot Intervention|This intervention involves the use of a therapeutic robot seal, PARO, to interact with pediatric patients in the Pediatric Intensive Care Unit (PICU). The intervention is designed to alleviate stress and anxiety in children during their hospital stay. The robot provides emotional support by engaging in 30-minute sessions, where children can interact with the robot, give it a name, and express their emotions. The therapeutic interaction is repeated twice on consecutive days.
223381069|NCT06854562|BEHAVIORAL|Toy Seal Intervention|In this group, children interact with a plush toy seal. The plush seal is used to provide emotional comfort and reduce anxiety during their stay in the PICU. The interaction happens over two consecutive days for 30 minutes per session.
223997669|NCT05497544|BEHAVIORAL|Exercise recommendation group|A verbal exercise recommendation will be provided. This recommendation will be reported also in the hospital resignation letter.
223997670|NCT05497544|BEHAVIORAL|Exercise recommendation plus guidebook group|This group will receive the exercise (verbal and written) recommendation. Additionally, the oncologist hand the patient a guidebook about exercise, specifically designed for cancer patients.
223997671|NCT05071586|DEVICE|Soterix 1x1 tDCS LTE Stimulator Device Model 1401|Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
223381070|NCT06854562|BEHAVIORAL|Standard Care|Children in this group will receive standard care and routine interventions provided by healthcare professionals in the PICU, without the use of therapeutic robots or plush toys.
223381071|NCT06587204|OTHER|Control Group|Participants will receive standard of care.
223381072|NCT06587204|BEHAVIORAL|Decentralized Group|Participants will receive a one time digital lifestyle management program that will be used for the rest of the intervention. The Digital lifestyle management program is a virtual application that manages nutrition, exercise, and sleep. Participants will be using the application at least 1 hour each day.
223381073|NCT06587204|BEHAVIORAL|Digital Literacy Navigation Group|Participants will receive a one time digital literacy training virtual learning digital health education for the rest of the intervention . The digital literacy training is a digital health education program that will be given 1 hour a day for 3 weeks.
223381074|NCT06587204|BEHAVIORAL|Social Care Navigation Group|Participants will receive a one time social care navigation application that will be used for the rest of the intervention. The Social Care Navigation application is a digital application that provides social care resources in the community to participants. The application is used 1 hour a day, each day.
223381077|NCT06592911|DEVICE|Poppins Clinical|Poppins Clinical is a software as a medical device that combines a musical and cognitive training program and written language training program.
223997672|NCT05661318|OTHER|Risk assessment|Collect clinical, laboratoary and genetics data from the participants after informed consent
223997673|NCT00517023|DEVICE|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
223381078|NCT05968326|DRUG|Autogene cevumeran|Autogene cevumeran will be administered intravenously (IV) at a recommended dose at specified timepoints.
223381079|NCT05968326|DRUG|Atezolizumab|Atezolizumab will be administered IV at a dose of 1680 milligrams (mg) at specified timepoints.
223381080|NCT05968326|DRUG|mFOLFIRINOX|mFOLFIRINOX (oxaliplatin, leucovorin, irinotecan, 5-FU) will be administered IV at specified timepoints.
223997674|NCT00517023|OTHER|Other|Routine care and tests usually offered for syncope patients.
223997675|NCT01005082|BEHAVIORAL|Low salt diet|
223997676|NCT01005082|BEHAVIORAL|Water therapy alone|
223997677|NCT04225481|OTHER|isolation of waste material and culturing with different supplement culture media|isolation of waste material and culturing with different supplement culture media
223997678|NCT01445041|BIOLOGICAL|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
223997679|NCT01445041|BIOLOGICAL|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
223997680|NCT03843697|DEVICE|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
223997681|NCT01912404|DRUG|IDN-6556|25 mg BID for 28 days
223997682|NCT01912404|DRUG|Placebo|Placebo controlled
223997683|NCT03462862|OTHER|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
223381081|NCT05889013|DEVICE|Nasal Nitric Oxide testing|Collection of already performed clinical data and nNO testing
223381082|NCT06658522|DRUG|Sotatercept|Participants will receive open label subcutaneous sotatercept (starting dose, 0.3 mg per kilogram of body weight; target dose, 0.7 mg per kilogram) for 24 weeks
223381083|NCT06658782|DIAGNOSTIC_TEST|non contrast enhanced MRI|6 monthly non contrast enhance MRI
224123317|NCT05401240|BEHAVIORAL|information reveal|the experimental group will be informed that there will be an important examination about his/her cardiopulmonary fitness condition at the outpatient department (OPD)
224123318|NCT04491942|DRUG|Cisplatin|Given IV
224123319|NCT04491942|DRUG|Elimusertib|Given PO
223381084|NCT06634264|DEVICE|Soft Oral Appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
223381085|NCT00321191|DRUG|No nitrous oxide|
223381086|NCT00321191|DRUG|Administration of N2O|
223381087|NCT00240279|DRUG|Rosuvastatin|
223381088|NCT00240279|PROCEDURE|aortic pulse wave velocity measurements|
223381089|NCT01224730|DRUG|perifosine|100 mg daily
223381090|NCT01254383|DRUG|Sildenafil Tablet|Tablet, 50 mg, Single Dose
223381091|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
223381092|NCT01254383|DRUG|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
224123320|NCT04491942|DRUG|Gemcitabine Hydrochloride|Given IV
224123321|NCT06432582|DIAGNOSTIC_TEST|hepatomiR|hepatomiR is a CE-certified test intended for gauging liver-related outcomes. It quantifies the levels of hsa-miR-122-5p, hsa-miR-192-5p, and hsa-miR-151a-5p in human plasma samples. A proprietary algorithm is then used to compute a liver function score (hepatomiR p-score).
223997684|NCT03462862|OTHER|Bre-Flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
223997685|NCT03176147|OTHER|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
223997686|NCT03647761|DEVICE|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
223381093|NCT00253721|DRUG|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
223381094|NCT00791895|DRUG|biphasic insulin aspart 30|Treat-to-target dose titration scheme
223381095|NCT05139888|DEVICE|Single wavelength light (red) only|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.
223381096|NCT05139888|DEVICE|Dual wavelength light (red/blue)|Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
223381097|NCT05142397|PROCEDURE|Focused Ultrasound|Focused ultrasound generates heat effects, mechanical effects and cavitation effects that denature the diseased tissues, facilitate necrosis and allow them to be replaced by surrounding normal healthy tissues.
223381098|NCT01192867|DRUG|Placebo|Placebo will be administered orally QD for 56 weeks
223381099|NCT01192867|DRUG|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
223997687|NCT04081064|BEHAVIORAL|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
223997688|NCT01138618|DEVICE|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
223997689|NCT01138618|DEVICE|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
223997690|NCT04186104|OTHER|Routine diagnostic process|Patients follow the procedures of registration, waiting, attendance, waiting, examination, waiting, attendance.
223997691|NCT04186104|OTHER|Artificial intelligence assisted diagnosis process|Patients follow the procedures of registration, AI recommended examination items, Self-service medical history collection ,examination, waiting, AI-assisted attendance.
223997692|NCT05693298|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
223997693|NCT05693298|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
223997694|NCT05259423|OTHER|Enriched Education Program|Enriched play activity education including 9 different activities each with 3 levels depending on the infant's current head and trunk control. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
223997695|NCT05259423|OTHER|Typical Education Program|Typical play activity education including 9 activities commonly described by popular parenting websites, mobile applications, and books. Parents will be instructed to complete 3 activities each day for at least 5 minutes each for a total of 15 minutes per day.
223997696|NCT03764176|PROCEDURE|Conventional impressions|"In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery."
224123322|NCT05954676|OTHER|CareOrbit|CareOrbit is a third-party organization that provides a HIPAA-compliant, patient-centered digital engagement platform that helps create, organize, and update content to educate and serve the patient and caregivers through their entire treatment journey.
224123323|NCT06077071|RADIATION|ViewRay MRIdian Stereotactic Radiosurgery|Participants will undergo stereotactic radiosurgery of the spinal cord on the ViewRay MRIdian, a hybrid MRI-linac platform, with 40 Gy in 5 fractions prescribed to the planning target volume (PTV).
224295489|NCT04126954|OTHER|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
223997697|NCT03764176|PROCEDURE|Digital impressions|"Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery."
223381100|NCT01192867|DRUG|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
223381101|NCT02875691|DIETARY_SUPPLEMENT|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
223381102|NCT02875691|DIETARY_SUPPLEMENT|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
223381103|NCT01119365|OTHER|Bright light|Light is administered through a custom designed mask with LED lights.
223381104|NCT02985671|DRUG|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
223381105|NCT02985671|DRUG|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
223381106|NCT02985671|DRUG|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
223381107|NCT02985671|DRUG|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
223381108|NCT04548765|BEHAVIORAL|Letter|Recipients receive a letter promoting CRC screening.
223381109|NCT04548765|BEHAVIORAL|Loss Frame and Fear Appeals|The letter is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by showing the risks of colorectal cancer, while also showing that screening is an achievable means to address those risks.
223381110|NCT04548765|BEHAVIORAL|Transparency|The letter explains why the kit was sent, which makes the purposes of the mailing clear to the recipient.
223381111|NCT04548765|BEHAVIORAL|Default Effect and Presentation of Alternatives|The pros and cons for screening with FIT kits and colonoscopy are presented. By showing an additional option, the table frames the FIT kit as the default option (since they are included in the mailer). In this situation, inaction is no longer the default option. Changing the default option increases the chance that the FIT kit is used. In addition, another viable alternative is provided (colonoscopy), which still contributes to the goal of the project (getting screened).
223381112|NCT04548765|BEHAVIORAL|Enhanced Fear Appeals and Decoy Effect|Comparisons of the mortality rates between screening with FIT kits, colonoscopy, and inaction (waiting for symptoms to appear) are displayed. Inaction is presented as a decoy, which has worse outcomes than either of the screening options. Due to this contrast, the inclusion of the decoy increases the appeal of the other screening options.
223997698|NCT05431764|DRUG|Camrelizumab, gemcitabin, cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8), cisplatin (80mg/m² d1), and camrelizumab (200mg, iv drip for over 60min) every 3 weeks for 6 cycles before locoregional radiotherapy.
223997699|NCT05431764|RADIATION|Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy|"IMRT: 5 fractions per week for 6 weeks to a total dose of 70 Gy and 33 fractions to the primary tumor.~SBRT: 3 months after locoregional IMRT, patients receive SBRT for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.~Camrelizumab (200mg, iv drip for over 60min) every 2 weeks began on the first day of IMRT until an intolerable toxicity, or disease progression, or withdrawal of consent, or the investigator determines that he or she has to withdraw from treatment, or has been treated for up to 2 years."
223997700|NCT04863482|PROCEDURE|IOC|intra-operative cholangiography near-infrared fluorescence cholangiography
223997701|NCT00522821|DRUG|intravenous immunoglobulins|"* Adults: 600 mg/kg bodyweight every 3 weeks~* Children: 800 mg/kg bodyweight every 3 week"
223997702|NCT00522821|DRUG|antibiotics|"* Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~* Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
223997703|NCT00455806|DRUG|esomeprazole|
223997704|NCT00455806|DRUG|moxifloxacin|
223997705|NCT00455806|DRUG|amoxicillin|
223997706|NCT04472884|BEHAVIORAL|mWACh-PrEP|Participants randomized to mWACh-PrEP will be registered into the system, in addition to receipt of SOC services. Women registered into the mWACh-PrEP platform will indicate their preferences for message delivery including a preferred name for messaging, language (English or Kiswahili or Dholuo), and day of the week and time for SMS delivery. Once registered, women will receive weekly automated push messages on the day/time of their choice from enrollment through 6-months postpartum. All automated push messages will include participant nickname, clinic and nurse name, an educational message or actionable advice targeting PrEP adherence and continuation and/or maternal and child health (MCH) topics, and a question related to the content. SMS topics will include adherence encouragement, PrEP efficacy and safety, self-efficacy for prevention of HIV, support for potential PrEP side effects, behavioral skills (tips for remembering PrEP medications) and visit reminders.
223381113|NCT04966689|BEHAVIORAL|combined speech and music therapy|he telerehabilitation intervention that include both speech therapy and music therapy at the same time
223381114|NCT04966689|BEHAVIORAL|speech therapy|A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
223381115|NCT04966689|BEHAVIORAL|music therapy|music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
223997707|NCT04472884|OTHER|Standard of Care|All participants will receive SOC services for MCH and PrEP that will include health education, clinical assessments, laboratory safety monitoring, STI (syphilis, gonorrhea, and chlamydia) screening and treatment (including expedited partner treatment for
223381116|NCT04557033|OTHER|Mindfulness intervention|My Moments® application (app) is a tool used to facilitate expressive art creation in a digital photography media
223381117|NCT05708716|BEHAVIORAL|Modified ketogenic diet using an exogenous ketogenic formula|Participants will follow a modified ketogenic diet consuming a daily exogenous ketogenic meal replacement formula while limiting their carbohydrate intake for 12 weeks.
223381118|NCT05708716|BEHAVIORAL|Online cognitive training|Participants will complete a daily session of 5 online cognitive training tasks for 12 weeks.
223381119|NCT00507533|PROCEDURE|Continuous positive airway pressure|
223381120|NCT05981703|DRUG|BGB-26808|Planned doses administered orally as a tablet daily.
223381121|NCT05981703|DRUG|Tislelizumab|Planned doses administered by intravenous infusion.
223381122|NCT05981703|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
223381123|NCT06983990|OTHER|No intervention (observational monitoring only)|No intervention is applied. This is an observational study evaluating the correlation between non-invasive monitoring parameters and arterial blood gas values during apnea testing.
223381124|NCT03340506|DRUG|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) taken twice a day
223381125|NCT03340506|DRUG|trametinib|trametinib is available in tablets (0.5mg, 2mg dose)
223381126|NCT06235281|DRUG|Mogamulizumab-Kpkc|Participants will receive 8 total cycles of Mogamulizumab-Kpkc over approximately 224 days.
223997708|NCT00798291|OTHER|Ad lib diet and Control placebo|one packet with water two times a day
223997709|NCT00798291|OTHER|Ad lib diet and An 777|one packet with water two times a day
224295490|NCT05181826|DIAGNOSTIC_TEST|Multi-analyte Blood Test|Intend for the qualitative detection of DNA methylation markers for the detection of various types of cancer
223997710|NCT00798291|OTHER|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
223997711|NCT00798291|OTHER|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
223997712|NCT00318721|DEVICE|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
223997713|NCT05645601|BIOLOGICAL|CD19-CAR-NK|The relapsed/refractory B-cell hematologic malignancies patients will receive FC (F, Fludarabine, C, Cyclophosphamide) chemotherapy followed by 3 infusions of JD010 cells up to 2 dose levels (5x10\^6/kg, 2x10\^7/kg) after FC chemotherapy.
223997714|NCT03804177|PROCEDURE|immediate implant placement with melatonin hyaluronic acid vit C|immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C
223997715|NCT03804177|PROCEDURE|immediate implant placement without melatonin hyaluronic acid vit C|immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
223381127|NCT06235281|DEVICE|Phototherapy|Participants will begin receiving Phototherapy on day 56 and will continue until day 224. Participants with Complete response (CR) or Partial response (PR) to therapy at day 224 will remain on phototherapy maintenance.
223381128|NCT06859268|DRUG|Retatrutide|Administered SC
223997716|NCT05761470|DRUG|Camrelizumab|"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."
223997717|NCT05761470|DRUG|Fluzoparib|Fluzoparib
224295491|NCT02340221|DRUG|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
224295492|NCT02340221|DRUG|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
224295493|NCT02340221|DRUG|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
224295494|NCT00919178|BIOLOGICAL|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
224295495|NCT00919178|BIOLOGICAL|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
223381129|NCT06859268|DRUG|Placebo|Administered SC
223381130|NCT06670001|BEHAVIORAL|Gamification plus social incentive|Participants in the Gamification plus social incentive intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
223381131|NCT06670001|BEHAVIORAL|Gamification plus competition|Participants in the Gamification plus competition intervention arm will receive gamification and a competition as part of the intervention. See arm descriptions for more detail.
223381132|NCT04146103|DRUG|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
223997718|NCT05761470|DRUG|Nab-paclitaxel|Nab-paclitaxel
223997719|NCT04910139|DEVICE|Soniflow System|Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.
224295496|NCT00236249|DRUG|Lidocaine|
224295497|NCT05563818|OTHER|WinterLight Mobile Phone Speech Analysis|N/A- observational study
223997720|NCT04513067|BIOLOGICAL|YQ23|YQ23 as a single agent will be given in Stage 1.
223997721|NCT04513067|COMBINATION_PRODUCT|Pembrolizumab|Pembrolizumab will be given in combination with YQ23 in Stage 2
223997722|NCT05251142|OTHER|Plyometric training|"Jumps in place. Some examples include multiple vertical jumps while reaching an overhead object, squat jump, pike jump, or tuck jump.~* Standing jumps. Examples include the single leg jump, maximal vertical jump ,standing long jump or lateral long jump.~* Multiple hops and jumps. Examples would include multiple long jumps or cone hops performed in succession, such as 5 hops in a row~* Box drills. Examples of these drills include box jumps ,repeated box jumps, and single leg box jumps.~* Depth jumps. Examples include stepping off the box and landing, stepping off the box and jumping vertically immediately after landing, or stepping off the box, landing, and sprinting."
223997723|NCT05251142|OTHER|General exercises|Dumbbell Squat: 3 sets of 15 reps, Dumbbell Alternating Bench Press: 3 sets of 15 reps, Straight Arm Pulldowns: 3 sets of 15 reps, Dumbbell Front Raises: 3 sets of 15 reps, Reverse Flyes: 3 sets of 15 reps, Overhead Tricep Extensions: 3 sets of 15 reps, Dumbbell Bicep Curls: 3 sets of 15 reps, Jackknife Crunches: 3 sets of 20 reps, Oblique Crunches: 3 sets of 20 reps, External Rotation: 3 sets of 15 reps
223381133|NCT06598332|DRUG|5-Azacytidine|"Patients will be treated with 5 azacytidine at a dose of 32 mg/m2 SQ or IV. The investigators aim to start AZA on Day 1 of steroids but it can be started up to 72 hours after steroids are started . Patients will be premedicated with antiemetics.~Patients must receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Steroid Taper for responding patients (Prednisone/Methylprednisolone) Days 1-5 2 mg/kg/day (taper cannot start until 3 days after enrollment) Days 6-10 1.5 mg/kg/day Day 11-15 1.0 mg/kg/day Days 16-20 0.5 mg/kg/day Days 21-28\* 0.25 mg/kg/day Days 29-56 Gradual further taper with a goal of reaching \< 0.2 mg/kg/day of prednisone (or \< 0.16 mg/kg/day of methylprednisolone) by Day 56."
223381134|NCT04780178|BEHAVIORAL|Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias|A telephone-based acceptance and commitment therapy for caregivers
223381135|NCT06861075|DRUG|Carvedilol|"Carvedilol per os, day 1:3.125 mg once, day 2 to day 8: 6.25 mg/day (3.125 mg twice a day), day 9 to day 90 (end of study visit): 12.5 mg/day (6.25 mg twice a day).~After the end of the study, treatment with Carvedilol will be prescribed by a cardiologist and continued at the dose of 12.5 mg/day.~The follow-up of the patient will be then done according to the standard practice."
223381136|NCT06993688|BEHAVIORAL|Prognostic Communication-Patient/parent|"* Patient/parent identifies and selects a communication preferences companion (CPC)~* CPC and patient/parent meet for a Communication Preferences Visit (CPV)~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together."
223381137|NCT06993688|BEHAVIORAL|Prognostic Communication-CPC|"* CPC reviews intervention materials and conversation guide with the research team~* CPC and patient/parent meet for a CPV, and CPC documents patient/parent preferences in a templated form~* CPC and oncologist discuss the CPV form~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together."
223381138|NCT06993688|BEHAVIORAL|Prognostic Communication-Oncologist|"* CPC and oncologist discuss the CPV form~* Oncologist, patient/parent, and CPC attend next disease re-evaluation visit together"
223381139|NCT06539429|BIOLOGICAL|ANT-301|Administration on Day 1
223997724|NCT03693976|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
223997725|NCT03693976|DEVICE|Ectoin Rhinosinusitis Nasal Spray|Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
223997726|NCT01621776|DRUG|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
223997727|NCT01621776|DRUG|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
223997728|NCT01621776|DRUG|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
223997729|NCT06240338|DIAGNOSTIC_TEST|laboratory investigation and Imaging|laboratory parameters (white blood cell count,neutrophil count, lymphocyte count, hemoglobin level, platelet level, red cell distribution width (RDW) level, hematocrit (HCT), renal function, hepatic function, electrolytes, arterial blood gas, HOMA-IR) will be assessed and imaging: Abdominal ultrasonography, Abdominal CT or MRI if needed
223997730|NCT04789031|DIETARY_SUPPLEMENT|Oral nutritional supplementation (ONS)|Patients received a renal specific ONS (Novasource Renal, Nestle) providing 475 kcal and 21.7g of protein per serving on a daily basis for 6 months. This was a ready-to- drink formula available in a tetrabrik pack. Patients consumed the product 30 minutes after commencing their dialysis session or at home after completion of dialysis.
223997731|NCT00195065|BEHAVIORAL|Semi-structured, open-ended interviews|
223997732|NCT00666692|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
223997733|NCT02269423|BIOLOGICAL|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
223997734|NCT02269423|OTHER|Placebo|Normal saline placebo.
223997735|NCT01593605|DIETARY_SUPPLEMENT|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
224295498|NCT02744599|DEVICE|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
224295499|NCT00103402|DRUG|Alfuzosin|
223381140|NCT06578143|OTHER|Placebo|Placebo is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
223997736|NCT01593605|DIETARY_SUPPLEMENT|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
223997737|NCT01593605|OTHER|Placebo treatment|Placebo - one tablet taken twice a day by mouth
223997738|NCT02924090|DRUG|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
224295500|NCT00103402|DRUG|Placebo|
224295501|NCT01393730|DRUG|Abiraterone acetate|
224295502|NCT01393730|DRUG|Dutasteride|
224295503|NCT01393730|DRUG|Prednisone|
223381141|NCT06578143|OTHER|Synbiotics|Synbiotics is administered in capsules (500 mg each). Participants are instructed to take the capsules twice daily, with two capsules per dose, after meals. The duration of the intervention is 6 weeks.
223381142|NCT06422520|DRUG|BGB-C354|Administered by intravenous infusion
223381143|NCT06422520|DRUG|Tislelizumab|Administered by intravenous infusion
223381144|NCT03910933|OTHER|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
223997739|NCT02924090|DRUG|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
223997740|NCT02924090|PROCEDURE|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
223997741|NCT02924090|PROCEDURE|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
223997742|NCT06378736|OTHER|Electroencephalography (EEG) signals, which will be detected noninvasively from dry scalp surface electrodes while the subjects are in a state of wakeful rest.|The proposed study is to determine whether EEG signals, namely theta-gamma coupling (TGC); The investigators are testing whether TGC can be used as a non-invasive novel biomarker in diagnosis and monitoring of insidious and difficult to detect cognitive dysfunction in SLE patients.
223997743|NCT03799913|BIOLOGICAL|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
223997744|NCT03799913|DRUG|Fludarabine|30mg/m2/d
223997745|NCT03799913|DRUG|Cyclophosphamide|300mg/m2/d
223997746|NCT04623749|PROCEDURE|US|Percutaneous Ultrasound guided FNAC
223997747|NCT04623749|PROCEDURE|EUS|Endoscopic Ultrasound guided FNAC
223997748|NCT05576376|PROCEDURE|calcaneal osteotomy for intractable plantar fasciitis|plantar displacement calcaneal osteotomy
223381145|NCT06855212|DRUG|Cemiplimab|Given by IV infusion.
223381146|NCT06855212|DRUG|Cetuximab|Given by IV infusion.
223997749|NCT05576376|PROCEDURE|plantar fascia open release|open partial release with or without baxter's nerve decompression
223997750|NCT05576376|PROCEDURE|plantar fascia endoscopic release|endoscopic partial plantar fascia release
223997751|NCT03285555|DEVICE|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
223997752|NCT03285555|DEVICE|VICRYL|Vicryl #1
223997753|NCT05331690|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
223997754|NCT05331690|DRUG|Nepafenac Ophthalmic|Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
223997755|NCT05331690|DRUG|Dexamethasone Ophthalmic|Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery
223997756|NCT00208559|DRUG|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
223997757|NCT05762562|OTHER|Telerehabilitation with open source platforms|"Telerehabilitation with opensource platforms. Patients enrolled were dived into three groups based on their score in SPPB. Each group corresponded to a Program (Pr): • Pr. A is for patients with capable motor skills, Pr. B is for patients with reduced motor skills, • Pr. C is for patients who didn't show having sufficient motor skills to support a TR program. Patients who were included in TrP.A and TrP.B underwent a TR program using OS platforms for 8 consecutive weeks. A specific exercise program for the parkinsonian patients was structured in relation to the individual residual motor skills based on the FITT - frequency/intensity/type/time - protocol.~Twice a week, the activity was performed with the support of a physiotherapist through OS TR platform.~Subjects included in TmP.C participated in an 8-weeks program. A video-call was scheduled once a week to monitor the patient's clinical condition without any exercise program."
223997758|NCT01161238|OTHER|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
223997759|NCT00267514|DRUG|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
223997760|NCT00267514|DRUG|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
223997761|NCT04588129|DRUG|LB-102|(N-Methyl amisulpride)
223997762|NCT05057338|BEHAVIORAL|CoreDISTparticipation|CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
223997763|NCT05057338|BEHAVIORAL|Standard care|The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist. Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity. These will be registered.
223545199|NCT03670160|DRUG|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
223545200|NCT03670160|DRUG|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
223997764|NCT06336187|OTHER|active surveillance|Follow-up visits will be scheduled 3 (optional) and 6 months after diagnosis, every 6 months up to 3 years and yearly thereafter.
223997765|NCT06336187|GENETIC|molecular investigation|Transcriptomic analysis of tissues
223997766|NCT02221557|DEVICE|easy-graft (beta-Tricalcium Phosphate)|
223381147|NCT05664178|BEHAVIORAL|Tele-Resistance Training|Tele-Resistance training sessions will be supervised and guided by a certified exercise trainer via smartphone, tablet or laptop. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously. Participants will engage in brief warm up exercises lasting 2-3 minutes prior to each RT session and will rest at least 1 minute between sets of the same exercise to aid muscle recovery. Participants will perform at least 2 sets of 12 repetitions for each of 6 exercises. Including warm up, training sets, and rest, sessions will last approximately 30 minutes. RT will include six target exercises focusing on major muscle groups of the upper body, lower body, and core.
223381148|NCT07000448|PROCEDURE|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|For optimal individual PEEP titration, dynamic compliance values observed on the ventilator monitor were recorded when PEEP reached 20 cmH₂O.
223381149|NCT07000448|PROCEDURE|standardized 5 PEEP|Patients in the PEEP 5 group were applied a fixed 5 cmH2O PEEP and no recruitment maneuver was performed.
223381150|NCT04083495|BIOLOGICAL|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen at dose of 2 × 10\^8 CAR-T/m\^2 with a maximum dose of 5 × 10\^8 CAR-T cells
223381151|NCT04083495|DRUG|Bendamustine|70 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first cell infusion
223381152|NCT04083495|DRUG|Fludarabine|30 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to first and second cell infusion
223381153|NCT04083495|DRUG|Cyclophosphamide|300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
223381154|NCT07002060|BIOLOGICAL|Yellow fever vaccine (live)|Powder and solvent for solution for injection Subcutaneous
223381155|NCT07002060|BIOLOGICAL|YF vaccine (live)|Powder and diluent for suspension for injection Subcutaneous
223381156|NCT04025203|OTHER|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
223997767|NCT03846440|OTHER|No intervention|Cross-sectional
224295504|NCT01404117|DRUG|Laquinimod 0.6|Laquinimod 0.6 capsule
224295505|NCT01404117|DRUG|Laquinimod 1.2|Placebo
223997768|NCT02830477|BIOLOGICAL|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
223997769|NCT01792791|PROCEDURE|Tissue sample collection at the time of surgery|"Spanning surgery~* A blood sample (32.5 ml)~* joint aspirate (removal of synovial fluid) from both knees~* urine sample~ORIF surgery~* Joint aspirate (removal of synovial fluid) from both knees~* A blood sample (32.5 ml)~* Urine Sample~If patients only require one surgery, sample will be collected only once."
224295506|NCT01404117|OTHER|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
224295507|NCT03606720|OTHER|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
224295508|NCT03606720|OTHER|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
224295509|NCT02987803|OTHER|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
224295510|NCT03898895|COMBINATION_PRODUCT|Radiotherapy+anti-PD-1 antibody|The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
223381157|NCT04025203|DRUG|Ibuprofen Arginine|Oral tablets
223381158|NCT04025203|DRUG|Gabapentin|oral capsules
223381159|NCT04387656|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223381160|NCT04387656|OTHER|Data Collection|Undergo collection of medical information and imaging
223381161|NCT04387656|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
223997770|NCT02102438|DRUG|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
223997771|NCT02102438|DRUG|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
223381162|NCT04387656|OTHER|Questionnaire Administration|Complete quality of life questionnaires
223381163|NCT06417216|BEHAVIORAL|Head-cancelled virtual reality|Scene in virtual reality moves with the head while performing visual tasks.
223381164|NCT07133373|OTHER|Turkish Coffee (unfiltered, boiled)|Standardized Turkish coffee (unfiltered and boiled) was administered once daily for 4 weeks. Each serving was approximately 75 mL, prepared using a consistent protocol without added sugar or milk. The coffee was sourced from the same batch and brewed in a traditional cezve. Compliance and adverse effects were monitored throughout the intervention.
223997772|NCT02102438|DRUG|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
223997773|NCT00896727|GENETIC|gene expression analysis|
223997774|NCT00896727|GENETIC|protein expression analysis|
223997775|NCT00896727|OTHER|fluorescent antibody technique|
223997776|NCT00896727|OTHER|laboratory biomarker analysis|
223381165|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 1|55/ 59,4 Gy (intermediate / high risk group)
223381166|NCT03396718|RADIATION|De-escalation radio(chemo)therapy - Level 2|48,4/ 55 Gy (intermediate / high risk group)
223381167|NCT03396718|RADIATION|Standard radio(chemotherapy)|60/ 66 Gy (intermediate / high risk group)
223381168|NCT07133386|DEVICE|transcatheter edge to edge repair|Implantation of a tricuspid transcatheter edge to edge device
223381169|NCT07133386|DEVICE|Placebo|placebo
223381170|NCT06680921|DRUG|SIM0270|Experimental
223381171|NCT06680921|DRUG|Everolimus (Afinitor®)|Experimental and Active comparator
223381172|NCT06680921|DRUG|Exemestane tablets|Active Comparator
223381173|NCT06680921|DRUG|Fulvestrant injection|Active Comparator
223381174|NCT06681051|DEVICE|OSTENIL® TENDON|OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.
223381175|NCT07005713|DRUG|BGB-16673|Administered orally
223381176|NCT07005713|DRUG|Placebo|Administered orally
223381177|NCT07006311|DEVICE|Robotic-assisted bronchoscopy under propofol|In this study, patients will undergo a robotic-assisted bronchoscopy under moderate sedation with propofol. While the use of propofol as a sedative is common for manual bronchoscopies, robotic-assisted bronchoscopy is only permitted under general anesthesia. In the study intervention, the investigators want to test the feasibility of the combination of robotic-assisted bronchoscopy under propofol.
223997777|NCT00499967|DRUG|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
223381179|NCT04005014|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
223381180|NCT05160740|DRUG|Indocyanine green for injection|ICG will be injected to participants preoperatively for molecular fluorescence image
223381181|NCT07029178|DRUG|Taurine granule|24 grams of taurine granule + 2 Gray radiation dose each time.
223381182|NCT07029178|DRUG|Placebo granule|24 grams of placebo granule + 2 Gray radiation dose each time.
223381183|NCT06877663|DEVICE|Virtual Reality Device|Patients who will receive entertainment videos via VR headset in the preoperative room before surgery.
223381184|NCT01458873|DRUG|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
223381185|NCT01458873|DRUG|diluted sodium bicarbonate 2.1%|50ml
223381186|NCT01458873|DRUG|normal saline|50ml
223381187|NCT03307265|DEVICE|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
223381188|NCT03307265|DEVICE|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
223381189|NCT04479553|DRUG|Qizhi Tongluo Capsules|Qizhi Tongluo Capsule, a Chinese patent medicine composed of 26 Chinese herbs, has been approved by China Food and Drug Administration for treating recovery period of ischemic stroke (drug approval numbers: B20171001).
223381190|NCT00146497|DRUG|Budesonide-Surfactant|
223381191|NCT00990860|DRUG|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
223381192|NCT00990860|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
223381193|NCT00021827|DRUG|Parathyroid hormone-related protein or ''PTHrP''|
223381194|NCT03654820|DEVICE|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
223381195|NCT03654820|DEVICE|SDF solution|Annual application of 38% SDF solution
223381196|NCT04597632|DRUG|brolucizumab|brolucizumab 6 mg/0.05 mL solution for intravitreal injection
223381197|NCT01672216|DEVICE|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
223381198|NCT01672216|DEVICE|EMG-biofeedback alone|
223381199|NCT00524732|BIOLOGICAL|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
223381201|NCT03127683|OTHER|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
223381202|NCT03127683|OTHER|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
223381203|NCT03127683|OTHER|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
223381204|NCT03127683|OTHER|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
223381205|NCT03127683|DEVICE|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
223381206|NCT00911027|DRUG|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
223381207|NCT00911027|PROCEDURE|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
223381208|NCT01085721|DRUG|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
223381209|NCT01085721|DRUG|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
223381210|NCT00080873|DRUG|Traumeel S|
223381211|NCT00080873|OTHER|Placebo|
223381212|NCT05506150|BEHAVIORAL|Interviews|"Focused conversations to understand features of a GI bleed that are important to patients and families.~Patients and family members are invited to participate in focused conversations. For interviews and focus groups, criterion sampling will be used. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data includes self-reported demographic characteristics of the patient and family members. Qualitative data about participants will be obtained through individual interviews and focused groups and project team field notes."
223381213|NCT05667675|BEHAVIORAL|Community Support Worker|Participants in the intervention group will have a structured review of their financially related needs and resources with a trained CSW, who will have a thorough understanding of potential income supports and community support agencies. The CSW will use a structured approach to identify financial needs and benefits for which the family is eligible The CSW will work intensively with families in the intervention arm to identify and meet their goals. They will conduct weekly meetings to complete forms, and provide advocacy (in person and by telephone) as needed up to six meetings as needed for system navigation.
223997778|NCT00499967|DRUG|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
223381214|NCT05667675|BEHAVIORAL|Control|There is no clear standard of care and potential for practice variation in clinician responses to identified social need. For this proposal, participants in the comparator group will receive Usual care, defined as: Participants in both groups will receive a written summary of available resources.
223381215|NCT05786209|OTHER|Whole-body Balm|Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
223381216|NCT05786209|OTHER|Wash and Shampoo|"Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method."
223381217|NCT02863783|DEVICE|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
223381218|NCT04693897|DRUG|Mirabegron 50 MG|Mirabegron 50mg once daily given to treatment in patients with overactive bladder syndrome
223381219|NCT04693897|DRUG|Solifenacin Succinate 5 MG|Solifenacin 5mg once daily given to treatment in patients with overactive bladder syndrome
223381220|NCT01910246|DRUG|Metformin|
223381221|NCT04743492|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy delivered by clinical psychologists in order to help patients gain coping skills.
223381222|NCT04666389|DRUG|Atorvastatin|To compare the preventive role of low- and high-dose statin regimens in the prevention on contrast-induced acute kidney injury in statin-naive patients with cardiovascular diseases undergoing computer tomography with intravenous contrast media administration
223381223|NCT01893346|DRUG|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
223381224|NCT01449812|BIOLOGICAL|Infanrix+Hib™|Intramuscular, one dose
223381225|NCT01449812|BIOLOGICAL|Poliorix™|Intramuscular, one dose
223381226|NCT02213289|DRUG|Trastuzumab|Trastuzumab
223381227|NCT02213289|DRUG|ABT-806|ABT-806
223381228|NCT02213289|DRUG|Bemarituzumab|Bemarituzumab
223381229|NCT02213289|DRUG|Ramucirumab|Ramucirumab
223381230|NCT02213289|DRUG|Nivolumab|Nivolumab
223381231|NCT02213289|DRUG|Standard cytotherapy|FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
223381232|NCT04207489|PROCEDURE|endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer|Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
223381233|NCT03638726|DRUG|Atropine sulfate and epinephrine|Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
223381234|NCT03638726|DRUG|Topical cyclopentolate and phenylephrine|Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
223381235|NCT05917600|OTHER|APN intervention|"Advanced Practice Nurses (APN) intervention between the ambulatory hospitalization (AH) and the MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
223381236|NCT00148005|PROCEDURE|Questionnaire and micturition and drinking diaries|
223381237|NCT00148005|PROCEDURE|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
223381238|NCT00148005|BEHAVIORAL|Adaptation of the drinking scheme|
223381239|NCT00148005|DRUG|Anticholinergic therapy|
223381240|NCT00148005|BEHAVIORAL|Micturition clock|
223381241|NCT04239027|DRUG|RTH258/Brolucizumab|"Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye."
223381242|NCT04139759|OTHER|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
223381243|NCT04139759|OTHER|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
223381244|NCT04234048|DRUG|Fenretinide|"Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort"
223381245|NCT06738862|OTHER|PET|\[18F\] - FD17 PET imaging
223381246|NCT01579747|PROCEDURE|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
223997779|NCT00499967|DRUG|Placebo|Placebo matching GS-9191 ointment
223381247|NCT01579747|PROCEDURE|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
223997780|NCT03219957|DRUG|AT-527|Ascending doses of AT-527 administered orally.
223381248|NCT05461989|OTHER|Anthropometric measurement|It will be measured with the Xiaomi Body Composition Scale II, and a total of 9 measurements will be made as a result of the measurements.
224295511|NCT05730504|OTHER|Mobile app-based self-guided interventions|self-guided, app-based mobile psychological interventions based on CBT, meditation, mindfulness, journaling, and audio-guided sessions on gratitude, thoughts management, auto-empathy, and relaxation
224295512|NCT00003598|DRUG|tretinoin|
224295513|NCT02333487|DRUG|Lu AF35700|5 mg tablets for oral administration
223997781|NCT03219957|OTHER|Placebo Comparator|Matching placebo
223997782|NCT04181372|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
223997783|NCT04181372|DRUG|platinum-based chemotherapy medicine|(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m\^2 i.v. on day 1; docetaxel was given 75 mg/m\^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
223997784|NCT00043433|DRUG|intravenous T900607-sodium|
223381249|NCT05461989|OTHER|Level of Physical Activity|The scale to be used for this purpose is the Child Physical Activity Questionnaire (CPAQ) developed by Kowalski et al. It is a seven-day self-reported recall scale designed to assess moderate-intensity physical activity in children aged 8-14 years. CFAQ is designed to be implemented throughout the school year.
223381250|NCT05461989|OTHER|Physical Activity Barriers Scale|"It consists of three surveys in total, which are:~A) Scale of Expectations Regarding Physical Activity for Children~B) Children's perception of family support regarding physical activity scale~C) Physical Activity Barriers Scale for Parents"
223381251|NCT05461989|OTHER|Hand Grip Strength|Hand grip strength will be measured using a hand dynamometer (Jamar, Sammons Preston, Rolyon, Bolingbrook, IL).
223381252|NCT05461989|OTHER|Arterial stiffness|Arterial stiffness will be evaluated using the pulse wave velocity (PWV) technique with the blood pressure holter-ABPM (Mobil-O-Graph, I.E.M., Stolberg, Germany) device. The measurement is made from the non-dominant arm based on the principle of blood pressure measurement with the appropriate cuff determined according to the arm diameter. After two consecutive measurements taken 30 seconds apart, the average of the measurement values will be recorded.
223381253|NCT03477604|DEVICE|MicroStent and Standard PTA|Self-expanding stent and standard PTA balloon
223381254|NCT03477604|DEVICE|Standard PTA|Standard PTA balloon
223381255|NCT05769777|DRUG|Amlitelimab|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
223381256|NCT06714253|BIOLOGICAL|RXRG001|Circular ribonucleic acid encoding human aquaporin 1 encapsulated in a lipid nanoparticle
223381257|NCT06714253|BIOLOGICAL|Placebo|Placebo (saline)
223381258|NCT06851754|DRUG|Progesterone|Oral micronized progesterone will be added (100 mg/day for 12 days/month) in the event of spontaneous vaginal bleeding and/or at 12 months over the 2-year protocol.
223381259|NCT06851754|DRUG|Estrogen Patch|participants with POI (n=85) will receive transdermal 17 beta-estradiol (beginning at a dose of 25 microgram/patch applied weekly), with the dose increased at 3 months to 50 microgram, and thereafter every 6 months to 75 and 100 microgram/patch for pubertal induction or estrogen replacement (with 100 microgram/patch representing a full adolescent or young adult estradiol dose). The continued escalation of the estradiol dose and patch strength will be guided by the clinical presentation and physical examination (by the PI or designated AI).
223997785|NCT02228759|PROCEDURE|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
223997786|NCT01281839|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
223997787|NCT01281839|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
223997788|NCT01281839|DRUG|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
223997789|NCT01281839|DRUG|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
224295514|NCT04212533|DIETARY_SUPPLEMENT|Vitamin D|comparison between pre- and postoperative calcium and vitamin d level after vit d and calcium supplementation
224295515|NCT04212533|DIETARY_SUPPLEMENT|rice starch tablets|rice starch tablets as placebo
223997790|NCT01709175|BEHAVIORAL|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
223997791|NCT02892227|PROCEDURE|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
224295516|NCT03405558|OTHER|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
224295517|NCT02677259|DRUG|17-beta estradiol|
224295518|NCT02677259|DRUG|Micronized progesterone|
224295519|NCT05064774|OTHER|myofascial release technique|myofascial release group took myofascial release (MFR) therapy sessions twice a week for 4 weeks between 4 and 7 weeks. MFR was applied to upper trapezius, SCM, pectoralis major-minor and sternocostal fascia. muscle was replaced elongated position and pressure was applied for 60-120 second.
223997792|NCT00001005|DRUG|Zidovudine|
223997793|NCT00001005|DRUG|Aldesleukin|
223997794|NCT01277887|BEHAVIORAL|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
223997795|NCT01277887|BEHAVIORAL|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
223997796|NCT04409171|DIAGNOSTIC_TEST|oral glucose tolerance test|
223997797|NCT00415051|BIOLOGICAL|RVF MP-12|Administer 1 ml SQ
223997798|NCT01424605|PROCEDURE|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
223381260|NCT06750939|OTHER|propofol|"The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,"
223381261|NCT06750939|OTHER|ketamine|"The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,"
223381262|NCT06764186|DRUG|Fulvestrant|2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
223381263|NCT06764186|DRUG|Capivasertib|400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
223381264|NCT06749145|DIAGNOSTIC_TEST|Portable 1-lead electrocardiogram|Portable 1-lead electrocardiogram (ECG) performed with the FDA-approved AliveCor KardiaMobile device.
223381265|NCT06749145|DIAGNOSTIC_TEST|Point-of-care ultrasound|Point-of-care ultrasound performed with the FDA-approved VScan Air device.
223381266|NCT06749145|OTHER|AI-ECG risk algorithm|Artificial intelligence (AI) risk algorithm for aortic stenosis using a 1-lead electrocardiogram
223381267|NCT06749145|OTHER|AI-POCUS|Artificial intelligence (AI) risk algorithm for aortic stenosis using cardiac ultrasound plax videos.
223381268|NCT06752603|DRUG|ONO-1110|ONO-1110 tablets once a day
223997799|NCT00304759|PROCEDURE|7800 cGy/39 fractions in 8 weeks|see above
223997800|NCT00304759|PROCEDURE|6000 cGy/20 fractions in 4 weeks|see above
223997801|NCT03399253|PROCEDURE|surgery|D2 gastrectomy + metastasectomy
223997802|NCT03399253|DRUG|chemotherapy|capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
223997803|NCT02985840|DRUG|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
223381269|NCT06752603|DRUG|Placebo|Placebo tablets once daily
223381270|NCT04540835|DEVICE|Teethmate Desensitizer (Kuraray)|Calcium phosphate desensitizer applied after caries removal. After restored using an oblique incremental technique with a composite resin (Filtek Z250, 3M Espe, USA)
223997804|NCT02985840|DRUG|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
223997805|NCT00209404|DRUG|Iodixanol 320 mg I/Ml|
223997806|NCT03735797|DIAGNOSTIC_TEST|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
223997807|NCT04109781|PROCEDURE|Microscope assisted discectomy|Microdiscectomy
223997808|NCT01495572|DRUG|Fludarabine|25 mg/m\^2 IV (in the vein) for 5 days (day -5 to -1)
223997809|NCT01495572|DRUG|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
223381271|NCT02839707|DRUG|Atezolizumab|Given IV
223381272|NCT02839707|BIOLOGICAL|Bevacizumab|Given IV
223381273|NCT02839707|PROCEDURE|Computed Tomography|Undergo CT
223381274|NCT02839707|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223381275|NCT02839707|OTHER|Quality-of-Life Assessment|Ancillary studies
223997810|NCT01495572|DRUG|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
223997811|NCT01495572|DRUG|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
223997812|NCT02756533|OTHER|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours."
223997813|NCT02756533|OTHER|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
223997814|NCT05857592|DIAGNOSTIC_TEST|Adaptive functioning self-report questionnaire|A self-report questionnaire for assessing level of adaptive functioning
223997815|NCT05857592|DIAGNOSTIC_TEST|Adaptive functioning self-report questionnaire - adapted|A self-report questionnaire for assessing level of adaptive functioning, adapted to the communication level of the participant
223997816|NCT00571467|DRUG|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~* Cohort 1: 0.075 mcg/kg~* Cohort 2: 0.15 mcg/kg~* Cohort 3: 0.30 mcg/kg"
223997817|NCT02104778|DRUG|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
223997818|NCT02104778|DRUG|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
223381276|NCT06780033|DRUG|ART-101 - SAD|Forty participants will be enrolled across 5 SAD cohorts. The planned doses across 5 cohorts are as follows- include 20mg (SAD Cohort 1), 60mg (SAD Cohort 2). 150mg (SAD Cohort 3). 300mg (SAD Cohort 4) and 500 mg (SAD Cohort 5).
223381277|NCT06780033|OTHER|Placebo|Participants will receive matching placebo subcutaneously on Day 1 after 8 hour fast.
223381278|NCT05579470|BEHAVIORAL|NIATx|For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (\<4 weeks).
223381279|NCT07123883|PROCEDURE|Dry Needling|Dry Needling
223381280|NCT07123883|OTHER|sham needling|In the SG, a validated sham needling procedure was simulated.
223381281|NCT06257264|DRUG|BG-68501|Planned doses administered orally.
223381282|NCT06257264|DRUG|Fulvestrant|Standard dose administered via intramuscular injection.
223381283|NCT06257264|DRUG|BGB-43395|Planned doses administered orally.
223381284|NCT06833138|PROCEDURE|pacemaker implantation|The Medtronic 3830 lead should be used as the Conduction System Pacing lead. However, in case of unsuccessful implantation with the 3830 lead, a stylet-driven lead can be used as an alternative.
223381285|NCT06833138|PROCEDURE|atrioventricular node ablation|Right-sided atrioventricular junction ablation will be attempted first with a radiofrequency catheter. The choice of the catheter will be at the discretion of the physician. The catheter will be advanced to the His Bundle and then slightly withdrawn proximally and caudally in order to target the compact atrioventricular node. Repeated ablation procedures will be recommended during follow-up if regression of atrioventricular block occurs.
223381286|NCT06833138|DEVICE|Pacemaker programming|The pacemaker device will be programmed in VVIR mode at a lower rate of 75 beats per minute in bipolar mode for sensing and pacing
223381287|NCT07089875|DRUG|Allopurinol|Over-encapsulated tablets containing active drug substance administered orally (PO).
223381288|NCT07089875|DRUG|Dotinurad|Over-encapsulated tablets containing active drug substance administered PO.
223381289|NCT07089888|DRUG|Allopurinol|Over-encapsulated tablets containing active drug substance administered orally (PO).
223381290|NCT07089888|DRUG|Dotinurad|Over-encapsulated tablets containing active drug substance administered PO.
223381291|NCT06765057|DIETARY_SUPPLEMENT|Winclove's Ecologic® Barrier Probiotics|The investigational product is a multispecies probiotic formulation consisting of 9 selected probiotic strains: the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58.
223381292|NCT06765057|DIETARY_SUPPLEMENT|Winclove's Ecologic® Barrier Probiotics Placebo|The placebo is composed of the carrier of the probiotic product that are identical in physical appearance, it includes maize starch and maltodextrins but contains no bacteria.
223381293|NCT07101640|DRUG|montelukast 4 mg granule|Montelukast sodium (4 mg oral granules) dissolved into 5mL of breast milk/formula yielding a solution concentration of 0.8mg/mL. Dosed once daily by weight, montelukast (0.75 mg/kg/day) or placebo .
223381294|NCT07101640|DRUG|Placebo|Plain breast milk or formula
223381295|NCT06589596|DRUG|BGB-58067|Planned doses administered on specified days per protocol.
223381296|NCT06589596|DRUG|BG-89894|Planned doses administered on specified days per protocol.
223381297|NCT06589596|DRUG|Standard of Care Therapy|Administered in accordance with relevant local guidelines and/or prescribing information.
223381298|NCT07104162|DRUG|Cefiderocol/Xeruborbactam|A fixed dose combination of intravenous cefiderocol and intravenous xeruborbactam
223381299|NCT06256705|OTHER|Simultaneous 68Ga-DOTATOC PET-MRI|on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
223381300|NCT03040973|DRUG|Capmatinib|Tablet for oral use; 150 mg, 200 mg; twice a day
223381301|NCT03040973|DRUG|Nazartinib|Capsule for oral use; 25 mg, 50 mg; once a day
223381302|NCT03040973|DRUG|Gefitinib|tablets for oral use; 250mg; once a day
223381303|NCT03040973|DRUG|Osimertinib|Tablets for oral use; 40 mg, 80 mg; once a day.
223381304|NCT07106125|DRUG|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Kidney transplant recipients will continue to take TMP-SMX daily from months 6-12 after transplant
223381305|NCT07106125|OTHER|Usual Care|Participants will take a placebo from months 6-12 after transplant and continue to receive all standard usual care related to their kidney transplant status
223381306|NCT05100862|DRUG|Zanubrutinib|Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
223381307|NCT05100862|DRUG|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
223381308|NCT05100862|DRUG|Lenalidomide|Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
223381309|NCT05100862|DRUG|Obinutuzumab|Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
223381310|NCT06360081|DRUG|Zongertinib manufacturer 1|Zongertinib
223381311|NCT06360081|DRUG|Zongertinib manufacturer 2|Zongertinib
223381312|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
223381313|NCT04771130|DRUG|Azacitidine|Intravenous or subcutaneous administration for 7 days.
223381314|NCT04771130|DRUG|Posaconazole|Oral administration for 8 days on second cycle only.
223381315|NCT04771130|DRUG|BGB-11417|Oral administration for 28 days on a 28-day cycle.
223381316|NCT04771130|DRUG|BGB-11417|Oral administration for 10, 14 or 21 days on a 28-day
223381317|NCT06596473|DRUG|BG-C477|Administered intravenously.
223381318|NCT06596473|DRUG|Chemotherapy|Administered in accordance with relevant local guidelines and/or prescribing information.
223381319|NCT05345002|DRUG|Retifanlimab|Administered 500mg IV on day 1 of every 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
223997819|NCT02506049|DEVICE|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
223997820|NCT04577053|DEVICE|Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device|Manufactured by QX World Ltd. in Budapest, Hungary
223997821|NCT01518153|DRUG|Fludarabine|40 mg/m\^2 by vein on Day -6 to -3.
223997822|NCT01518153|DRUG|Melphalan|140 mg/m\^2 by vein on Day -2.
223997823|NCT01518153|DRUG|Alemtuzumab|50 mg by vein on Day -1.
223997824|NCT01518153|PROCEDURE|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
224295520|NCT05064774|OTHER|physiotherapy|patients used sling up to 4 weeks. They did first 4 weeks passive/ assistive range of motion exercise. In 6-8 weeks they did active exercises. 8-12 weeks they did progressive resistive exercises.
224295521|NCT03997071|OTHER|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
223381320|NCT05345002|DRUG|All-trans retinoic acid|All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle, continued until disease progression, unacceptable toxicity, or 2 years from the first dose of study medication, whichever occurs first.
223381321|NCT07109219|COMBINATION_PRODUCT|AZD4512 monotherapy|Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22
223381322|NCT07101172|PROCEDURE|stress ball|Patients will be provided with an explanation, and verbal and written consent will be obtained. A patient identification form will be completed 10 minutes before the procedure. Pain levels will be determined with a pre-test VAS, anxiety levels will be determined with a STAI-S, and vital signs will be measured and recorded. The patient will be undressed and helped into a surgical gown to protect their privacy. The patient will be placed in a left lateral position on a stretcher with both legs drawn up toward their abdomen. The environment will be quiet and free from external stimuli. During the biopsy procedure, the patient will be asked to squeeze and release the Stre ball once every five counts for 10 minutes. Because blood pressure may drop or dizziness may occur after the procedure, the patient will be taken to the recovery room and monitored for bleeding. Fifteen minutes after the procedure, the severity of pain and anxiety levels during the procedure will be determined, and vital
223381323|NCT07108920|OTHER|Functional clinical tests|"Functional clinical tests:~* Time Up and Go test~* Berg Balance Scale (BBS)~* Stair climb and descent time test (SCT)~* Number of falls via a questionnaire"
223381324|NCT07110571|DRUG|Adebrelimab Injection|Adebrelimab injection.
223381325|NCT07110571|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
223381326|NCT07110571|DRUG|SHR-A1904 for Injection|SHR-A1904 for injection.
223381327|NCT07110571|DRUG|SHR-8068 Injection|SHR-8068 injection.
223381328|NCT06903819|DRUG|Ketamine|Participants in this group will receive a single intravenous (IV) dose of ketamine at 0.5 mg/kg, administered within 30 minutes of anesthesia induction during surgical fixation for musculoskeletal trauma. The purpose of the intervention is to evaluate ketamine's effect on postoperative pain, opioid consumption, and psychological recovery, including symptoms of depression and post-traumatic stress disorder (PTSD).
223381329|NCT06903819|DRUG|standard general anesthesia|Participants in this group will receive standard general anesthesia during surgical fixation for musculoskeletal trauma. No ketamine will be administered. This group serves as a comparison to evaluate the effects of ketamine on pain, opioid use, and psychological recovery.
224295522|NCT02758249|DRUG|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
224295523|NCT02758249|DRUG|propofol|patients are anesthetized by using propofol infusion
223997825|NCT01518153|DRUG|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
223997826|NCT01518153|DRUG|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
223997827|NCT01518153|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 \* 10/L for 3 consecutive days.
223997828|NCT01518153|PROCEDURE|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 \* 106 CD3+ cells/kg between Day +56 and +64.
223997829|NCT01518153|PROCEDURE|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 \* 107 CD3+ cells/kg between Day +56 and +64.
223997830|NCT03112460|DEVICE|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
223997831|NCT02421575|DRUG|Hydroxychloroquine|Given PO
223997832|NCT02421575|OTHER|Laboratory Biomarker Analysis|Correlative studies
223997833|NCT05780021|BEHAVIORAL|Motivational Support Program Emotiv|A motivational support program including a motivational and self-assessment remote application in the form of a Smartphone application for chronic low back pain patients after multidisciplinary functional rehabilitation.
223997834|NCT01754753|OTHER|Telephone Friendship groups|
223997835|NCT04312269|OTHER|Targeted Memory Reactivation (TMR)|Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
223997836|NCT04526730|DRUG|Tavo|Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume \<0.4 cm3
224295524|NCT01297322|OTHER|Manual compression|Standard of Care
224295525|NCT01297322|DEVICE|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
223997837|NCT04526730|DRUG|Nivolumab|Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions
223381330|NCT07113067|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)|Active treatment will consist of high-dose iTBS-rTMS to left dmPFC delivered in runs of 600 pulses at an intensity of 120% resting motor threshold (rMT). iTBS triplets at 50 Hz will be delivered for 2 seconds, repeated every 10 seconds for a total of 190 seconds. Each session will be separated by at least 10-15 minutes and a total of 12 sessions will be given on each treatment day (3-4 hours per study day). A total of 43,200 pulses will be delivered over the entire six days of treatment.
223381331|NCT07113067|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)|"For the sham stimulation group, a focal electric sham will be used which is indistinguishable from active TMS including a pretreatment individualized sham titration, sham outputs noises synchronized to pulse delivery, and an individualized level of sham stimulation throughout the treatment.~Technicians administering active vs sham TMS will be masked by using a random code generated by the statistician that will indicate whether to use the active or sham side of the coil. Treatments will appear identical to the technician regardless of whether active or sham TMS is administered."
223729735|NCT03975608|BEHAVIORAL|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~1. Symptom management and communication with healthcare providers~2. Changes in self and relations with each others~3. Spirituality, sense of meaning, and purpose~4. Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
223729736|NCT04119882|DIAGNOSTIC_TEST|Blood collection|New biomarker test
223997838|NCT04526730|DEVICE|OncoSec Medical Electroporation Therapy System|"The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence."
223997839|NCT00899977|DRUG|Placebo|Matching placebo
223997840|NCT00899977|DRUG|TC-5214|
223997841|NCT05936424|OTHER|Unilateral Resistance Exercise Leg|One will perform unilateral resistance exercise
223997842|NCT05936424|OTHER|Non-Exercise Control Leg|One leg will serve as a non-exercise control
223997843|NCT02888236|DRUG|LEO 32731|
223997844|NCT02888236|DRUG|LEO 32731 Placebo|
224295526|NCT03898921|RADIATION|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
223381332|NCT07113067|OTHER|Brainsight Neuronavigation System|A brainsight neuronavigation system will be used during TMS treatments to target treatment location using individual MRI data
223729737|NCT05717374|DRUG|caudal block using dexamethasone|patient will receive 0.5 ml/kg volume (bupivacaine 0.25 % + dexamethasone 0.1mg/kg) through the sacral hiatus
223997845|NCT00705601|PROCEDURE|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
223997846|NCT03452865|DRUG|Esomeprazole|"160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml."
223997847|NCT03452865|DRUG|Placebo|0.9% sodium chloride (same ml of the study drug)
223997848|NCT00856245|DRUG|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
223997849|NCT05167136|BEHAVIORAL|Awareness Level|"Demands and expectations about the green hospital were measured with a questionnaire applied to 287 people, consisting of health professionals and employees in a small private hospital that does not have a green hospital certificate in the province of Istanbul."
223997850|NCT03838523|OTHER|Open Label Placebo|See group description
223997851|NCT00624247|OTHER|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
223997852|NCT06265519|PROCEDURE|Holmium laser enucleation of the prostate|Holmium laser enucleation of the prostate is a minimally invasive procedure that uses pulses of laser beam to remove tissue from the inside of the prostate, which surrounds the urethra (the tube leading from the bladder to the urinary opening) in patients with BPH
223997853|NCT01250509|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
223997854|NCT02954705|OTHER|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
223997855|NCT00452231|DRUG|D-cycloserine|
223997856|NCT00452231|BEHAVIORAL|Cognitive-Behavioral Therapy|
224295527|NCT03898921|PROCEDURE|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
223729738|NCT05717374|DRUG|caudal block using methylprednisolone|patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
223381333|NCT07112404|OTHER|Dry Needling|Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.
223381334|NCT07112404|OTHER|Dry needling with high-rate PENS|"Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.~When combined with high-rate percutaneous electrical nerve stimulation (PENS), the needles serve as electrodes for delivering a controlled, high-frequency electrical current directly to the targeted tissues. This electrical stimulation further modulates pain signals, promotes muscle relaxation, and can enhance the effectiveness of dry needling, especially for persistent pain and neuromuscular dysfunction."
223381335|NCT07112404|OTHER|Dry needling with low-rate PENS|"Dry needling is a therapeutic technique where thin, solid filiform needles are inserted into trigger points, tight muscle bands, or areas of muscle tension without injecting any medication. The procedure aims to release muscle knots, reduce pain, and improve muscle function by stimulating the body's natural healing response.~When combined with low-rate percutaneous electrical nerve stimulation (PENS), the needles serve as electrodes for delivering a controlled, low-frequency electrical current directly to the targeted tissues. This electrical stimulation further modulates pain signals, promotes muscle relaxation, and can enhance the effectiveness of dry needling, especially for persistent pain and neuromuscular dysfunction."
223381336|NCT07112885|PROCEDURE|Arthroscopic Microfracture Combined with Autologous SVF Injection|This procedure involved arthroscopic debridement and microfracture of the knee joint. After microfracture, autologous SVF, isolated from adipose tissue through mechanical digestion and centrifugation, was administered intra-articularly under sterile conditions
223545201|NCT03554655|DEVICE|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
223997857|NCT05417295|PROCEDURE|Inflating air into the bronchial cuff before changing position|Inflating air into the bronchial cuff before or after changing position
223997858|NCT05417295|PROCEDURE|Inflating air into the bronchial cuff after changing position|Inflating air into the bronchial cuff after changing position
223997859|NCT04814498|DRUG|Geneva Cocktail|Fixed sequence use of drug cocktail
223997860|NCT04814498|DRUG|BLD-0409|Fixed sequence use of active product
224295528|NCT02726919|DRUG|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
224295529|NCT04219735|DRUG|Minocycline|Minocycline 100mg BID
224295530|NCT04219735|DRUG|Placebos|Placebo
223381337|NCT07112885|PROCEDURE|Arthroscopic Debridement Followed by Autologous SVF Injection|This procedure included only arthroscopic debridement of the knee joint. After debridement, autologous SVF, isolated in the same manner from adipose tissue, was injected into the joint space intra-articularly without microfracture.
223381338|NCT06876714|BIOLOGICAL|Trastuzumab (Herceptin)|Given IV or SC
223381339|NCT06876714|BIOLOGICAL|Pertuzumab|Given IV or SC
223381340|NCT06876714|PROCEDURE|Echocardiography|Undergo ECHO
223381341|NCT06876714|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223381342|NCT06876714|PROCEDURE|Mammography|Undergo mammography
223381343|NCT06876714|PROCEDURE|Ultrasound|Undergo ultrasound
223381344|NCT06876714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223381345|NCT06876714|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223381346|NCT06876714|OTHER|Questionnaire Administration|Ancillary studies
223545202|NCT05281913|OTHER|Psychoeducational Game|Psychoeducational Game
223545203|NCT03653182|DIAGNOSTIC_TEST|Pulse, tongue image, and voice sound|They are four diagnosis methods of TCM
223997861|NCT01843725|DRUG|capecitabine|escalation dose of capecitabine continuously
223997862|NCT01843725|DRUG|aflibercept|Intravenous 6mg/kg every 3 weeks
223997863|NCT01843725|DRUG|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
223997864|NCT03854357|PROCEDURE|Subscapularis Rehabilitation|Specific subscapularis rehabilitation exercises which are not included in the current, standard rehabilitation protocol assigned to total shoulder arthroplasty patients post-operatively.
223997865|NCT03854357|PROCEDURE|Standard Rehabilitation|Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively
224295531|NCT04736563|DEVICE|Joint and muscle gel Puressentiel|To evaluate the antalgic effect in patients with chronic pain related to osteoarthritis of the knee when applied to the skin of Puressentiel Joints and Muscles - Gel with 14 essential oils.
224295532|NCT05333484|OTHER|Programed Pilates|The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of \> 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
224295533|NCT03516084|DRUG|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
224295534|NCT03516084|DRUG|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
224295535|NCT04487002|PROCEDURE|surgical resection|
223997866|NCT03168542|DEVICE|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
223997867|NCT01183247|DRUG|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
223997868|NCT01183247|DRUG|Everolimus|Add everolimus de novo to tacrolimus and MMF
223997869|NCT01183247|DRUG|Prednisone|Add prednisone de novo to tacrolimus and MMF
223381347|NCT07125053|BEHAVIORAL|Education (self-guided)|"The self-guided eduction program consists of a mailed booklet entitled, Learning to live with COPD, along with two additional mailings with information on the ALA's Patient and Caregiver Network and the Respiratory Health Association's COPD Caregiver's Toolkit."
223381348|NCT07125053|BEHAVIORAL|Education (counselor-led)|The counselor-led education program combines mailings with phone counseling delivered by ALA Lung Helpline counselors. Three phone sessions (20-30 minutes each) are completed over the course of 6 weeks in the main treatment phase, with two additional optional booster sessions offered between 6 and 12-weeks post-randomization. The counselor-led program follows a structured outline of curriculum for each session, focusing on the topic areas of developing a COPD exacerbation action plan, recognizing COPD exacerbations, and coping with breathlessness.
223381349|NCT07125053|BEHAVIORAL|Physical Activity|The physical activity program will consist of a personalized prescription for home-based exercise following published guidelines, consisting of aerobic, strengthening, and flexibility exercises, tailored to participants' current fitness level and dyspnea symptoms. Aerobic exercise will incorporate ground-based walking training, a well-established, safe, and feasible physical activity program for individuals with COPD. Participants will complete three videoconference sessions (30-45 minutes each) over the course of 6 weeks in the main treatment phase, with two additional optional booster sessions between week 6 and 12.
223381350|NCT07125053|BEHAVIORAL|Inhaler Training|Participants will receive inhaler technique education using a virtual teach-to-goal method. In each session, individuals are observed using their inhaler, provided feedback, and then observed again. Inhaler technique is scored using a checklist specific to each inhaler device. Participants will complete two inhaler training sessions via videoconference at week 1 and week 4, with an optional booster session offered at week 8.
223381351|NCT07126951|PROCEDURE|Ultrasound-guided Deep Pharmacopuncture Treatment|"Participants in this group will receive ultrasound-guided deep pharmacopuncture in addition to integrative Korean medicine treatment (acupuncture, herbal medicine, and Chuna therapy). The pharmacopuncture involves injecting 4 cc of herbal extract into deep lumbar tissues, targeting the posterior facet joint of the most symptomatic segment.~Using a real-time ultrasound-guided in-plane technique, the needle path and tip are visualized to ensure accurate and safe delivery. Treatment is administered once daily for up to 3 days (hospital Days 2-4).~This intervention differs from conventional methods by using ultrasound to guide precise, deep-tissue injection, enhancing both safety and treatment accuracy."
223381352|NCT07126951|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
223997870|NCT02919553|PROCEDURE|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
223997871|NCT02919553|PROCEDURE|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
223997872|NCT00203268|DRUG|dihydroergotamine mesylate|1.0 mg. intramuscularly
223997873|NCT02448329|DRUG|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1\~3
223997874|NCT02448329|DRUG|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
223997875|NCT01739023|BIOLOGICAL|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
223997876|NCT02071277|OTHER|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
223997877|NCT05231525|DEVICE|WiTOF|Data collection on the WiTOF monitor
224138408|NCT03415763|DRUG|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
223381353|NCT00289120|DRUG|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
223545204|NCT03827239|OTHER|Activity/Moderate Exercise|3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
223545205|NCT02096978|PROCEDURE|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
223997878|NCT05231525|DEVICE|TOFscan|Data collection on the TOFscan monitor
223997879|NCT05131802|DEVICE|upper GIT endescopy|Gastric mucosa alterations as erythema, bile existence in the stomach, gastric folds thickening, erosions, and petechiae were also recorded (Olympus single-channel CLK-4). Multiple biopsies were taken from gastric mucosa for histopathological study. Via Triple Lumen ERCP Cannula, 5 mL of gastric fluid was aspirated through the suction channel of the endoscope and collected in a sterile trap placed in the suction line, to be sent for analysis. Quantitative determination of gastric aspirate total bilirubin level was performed (Gen.3® kit and Cobas 8000 analyzer). The pH monitoring of gastric aspirate was performed during the gastroscopy just after collection with a glass electrode pH meter (Adwa®).
223997880|NCT00438841|DRUG|bortezomib|
223997881|NCT00438841|DRUG|cyclophosphamide|
224295536|NCT03964636|DIAGNOSTIC_TEST|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
223997882|NCT00438841|DRUG|dexamethasone|
223381354|NCT00289120|DRUG|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
223997883|NCT00438841|DRUG|thalidomide|
223381355|NCT06941376|DRUG|Methotrexate (MTX)|Weekly methotrexate dose of 20 mg (oral or subcutaneous).
223381356|NCT06941376|DRUG|Azathioprine (AZA)|Azathioprine dose will be 2-3 mg/kg body weight per day.
223381357|NCT06941376|BIOLOGICAL|Adalimumab|Adalimumab dose will be 40 mg subcutaneously every 1-2 weeks
223381358|NCT06941376|BIOLOGICAL|Infliximab|Infliximab dose will be 5mg/kg at week 0 and week 2, and then every 4-8 weeks.
223381359|NCT06941376|BIOLOGICAL|Tocilizumab|Tocilizumab dose will be 162 mg subcutaneous injection every week or 4-8 mg/kg every 4 weeks
223381360|NCT06940622|DIETARY_SUPPLEMENT|D-Mannose|D-mannose (2g, i.e., 4 x 500mg capsules) daily for 12 months.
223381361|NCT06940622|DIETARY_SUPPLEMENT|Placebo|Placebo daily for 12 months.
223997884|NCT00388440|BIOLOGICAL|MMR vaccine (Priorix)|
223997885|NCT03745898|DRUG|Oxygen|Active nocturnal oxygen concentrator
223997886|NCT03745898|OTHER|Room Air|Sham nocturnal oxygen concentrator (room air)
223997887|NCT03656250|DIAGNOSTIC_TEST|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
223997888|NCT01371708|DRUG|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
223997889|NCT02623660|DEVICE|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
223997890|NCT02623660|OTHER|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
224123324|NCT04451590|OTHER|VR-based simulation|Participants will experience a novel interactive and immersive VR full size trauma bay with an adult patient and healthcare professionals. Immersed in the environment, learners undertake the decision-making steps in managing the medical care for a patient with an airway injury. Learners are first given the case scenario from which they form their own learning goals/plans. They then navigate through the scenario that will provide feedback depending on their actions in the form of either the patient's hemodynamic changes or prompts from healthcare avatars in the scenario. These feedback processes are built-in and designed to promote reflection and reorganization of the learner's decision-making strategies. As learning progresses, fewer prompts will be given. At the end of the scenario, evaluation algorithms pre-programmed into the VR-based simulation will be displayed.
224123325|NCT04451590|OTHER|Mannequin-based simulation|Participants will experience a mannequin-based scenario practice which is the current gold standard in medical education. The trauma airway management scenario will match the VR environment and sequence of events.
224123326|NCT04461639|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Different prophylaxis regimens with damoctocog alfa pegol following approved local labels or any other regimen prescribed by the physician as part of normal clinical practice
224123327|NCT06638151|DRUG|aspirin + clopidogrel|Enrolled patients with acute ischemic stroke will be randomly assigned to the clopidogrel plus aspirin group (300 mg loading dose of clopidogrel plus 160 mg aspirin on day 1; followed by clopidogrel 75 mg plus aspirin 81 mg daily from day 2-day 21, followed by aspirin 81 mg to be continued if no alternate treatment is indicated).
223381362|NCT07144618|DEVICE|National Cheng Kung University Abdominal Muscle Group Medical Imaging Analysis Software|Phase 2: The second phase will involve a prospective multicenter clinical trial, enrolling 294 patients with endometrial or ovarian cancer.Patients will be randomized into two groups (at least 147 per group): AI-assisted group (treatment group): Preoperative CT imaging will be used to assess body composition and classify patients into high-risk or low-risk categories.Chemotherapy dosing will be adjusted accordingly to evaluate treatment-related adverse effects and dose modifications. Non-AI-assisted group (control group): Patients will receive chemotherapy chemotherapy dosing adjustments based on standard clinical care.
223381363|NCT07146191|DRUG|2-[14C]-RE104 for Injection|Single, subcutaneous dose of 2-\[14C\]-RE104 for Injection
223997891|NCT02623660|DEVICE|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
223997892|NCT03652441|DRUG|Brentuximab Vedotin|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
223997893|NCT00022737|BIOLOGICAL|filgrastim|Given SC
223997894|NCT00022737|DRUG|asparaginase|Given IM
223997895|NCT00022737|DRUG|cyclophosphamide|Given IV
223381364|NCT06948175|DEVICE|Abdominal transcutaneous electrical stimulation (TES)|Low-intensity sensory abdominal transcutaneous electrical stimulation (TES)
223381365|NCT07146984|BEHAVIORAL|Behavioral (Educational Training Program)|A structured training program for emergency medicine residents based on the Plan-Do-Check-Act (PDCA) cycle. The intervention includes didactic teaching, simulation-based airway management practice, supervised clinical intubation, iterative performance assessment, and feedback-driven improvement.
223381366|NCT06990867|DRUG|JX10|JX10 is a thrombolytic agent.
223381367|NCT06990867|DRUG|Placebo|Placebo is being used as the comparator.
223381368|NCT07142642|DRUG|Teprotumumab|Administered via IV infusion.
223381369|NCT07142642|DRUG|Placebo|Administered via IV infusion.
223997896|NCT00022737|DRUG|cyclosporine|Given IV
224123328|NCT06638151|DRUG|Aspirin|Aspirin 81 mg once daily alone
224123329|NCT06642402|DIAGNOSTIC_TEST|Kidney biopsy|Patient refered to kidney biopsy independent of the presented study
223997897|NCT00022737|DRUG|cytarabine|Given IT and IV
223381370|NCT07152730|DRUG|Lutrepulse|Lutrepulse administered via the OmniPod delivery pump
223381371|NCT07153783|DIAGNOSTIC_TEST|AI-human collaboration for CE-CTs diagnosis|The system automatically processes all eligible same-day scans and generates results for review the following day. To maintain efficient AI-human collaboration while preserving the standard clinical workflow, the conventional radiological interpretation process remains unchanged (first-line radiologists provide initial reports followed by senior radiologists' review). A dedicated senior radiologist then evaluates any discordances between AI findings and primary radiological report. For complex cases, the review process escalates to a consensus review panel (i.e., pre-designated senior radiologists, Multidisciplinary Team (MDT)). The MDT can recommend clinical interventions including follow-up (e.g., additional imaging examinations, active surveillance), surgical procedures, or adjustments to adjuvant therapy (initiation or modification of treatment regimens). All discordant cases and their outcomes are systematically documented for longitudinal tracking and follow-up analysis.
223381372|NCT07156461|DEVICE|Cochlear™ Osia® System (Osia® 2)|Consists of Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, and Osia Fitting Software 2.
223381373|NCT07156461|DEVICE|Cochlear™ Osia® System (Osia® 3)|Consists of Osia 3 Sound Processor, Osia 3 Sound Processor Magnets, Osia 3 Charger, and Osia Fitting Software 3.
223381374|NCT07154706|DRUG|Taletrectinib|Intervention Label: Taletrectinib Intervention Name: Taletrectinib Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level (s): 400 mg QD Route of Administration: Oral Use: Experimental IMP and NIMP/AxMP : IMP Former Name(s) or Alias(es): AB-106.
223381375|NCT07154706|DRUG|Placebo|Intervention Label: Placebo Intervention Name: Placebo Type: Drug Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level(s): 400 mg QD Route of Administration: Oral Use: Placebo Comparator IMP and NIMP/AxMP: IMP Former Name(s) or Alias(es): Placebo
223997898|NCT00022737|DRUG|daunorubicin hydrochloride|Given IV
223997899|NCT00022737|DRUG|dexamethasone|Given orally
223997900|NCT00022737|DRUG|etoposide|Given IV
223997901|NCT00022737|DRUG|ifosfamide|Given IV
223997902|NCT00022737|DRUG|imatinib mesylate|Given orally
223997903|NCT00022737|DRUG|leucovorin calcium|Given IV or orally
223997904|NCT00022737|DRUG|mercaptopurine tablet|Given orally
223997905|NCT00022737|DRUG|methotrexate|Given IT, IV, and orally
223997906|NCT00022737|DRUG|pegaspargase|Given IM
223997907|NCT00022737|DRUG|vincristine sulfate|Given IV
223997908|NCT00022737|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
223997909|NCT00022737|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
223997910|NCT00022737|PROCEDURE|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
223381376|NCT03839758|PROCEDURE|TSA standard|Glenoid preparation will be done with 2D CT-Scan
223381377|NCT03839758|PROCEDURE|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
223381378|NCT03839758|PROCEDURE|TSA Blueprint|Glenoid preparation will be done with Blueprint software
223381379|NCT03839758|PROCEDURE|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
223381380|NCT07169591|DIAGNOSTIC_TEST|Oral Glucose Tolerance test (75g 2-hour)|Standard oral glucose tolerance test with blood draws every 15-30 minutes for a 2-hour span
223381381|NCT07166289|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
223997911|NCT00022737|RADIATION|radiation therapy|Undergo radiation therapy
223997912|NCT03312400|DRUG|Danazol|Adult: 200 mg daily versus 400 mg daily Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months.
223997913|NCT02729142|PROCEDURE|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
223997914|NCT04970992|DRUG|DZ-002|DZ-002 Injection
223997915|NCT04306536|DIETARY_SUPPLEMENT|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
223997916|NCT05619575|DEVICE|CP1170 Sound Processor|The CP1170 Sound Processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
223997917|NCT05619575|DEVICE|CP1150 Sound Processor|Active comparator off-the-ear sound processor.
223997918|NCT03588091|DRUG|Pyrotinib|pyrotinib: 400mg orally daily;
223997919|NCT03588091|DRUG|Placebo Oral Tablet|placebo: 400mg orally daily;
223997920|NCT03588091|DRUG|Trastuzumab|trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
223997921|NCT03588091|DRUG|Docetaxel|docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
223997922|NCT05499858|OTHER|Spiced|Vegetables provided to volunteers will be spiced.
223997923|NCT05499858|OTHER|Plain|Vegetables provided to volunteers will be plain.
223997924|NCT03562221|OTHER|Gluten free diet|Controlled gluten free diet
223997925|NCT03562221|DIETARY_SUPPLEMENT|Probiotics|Capsules
223997926|NCT03562221|DIETARY_SUPPLEMENT|Placebo|Capsules
223997927|NCT02819024|DRUG|Dexamethasone|Given PO BID
223997928|NCT02819024|DEVICE|Device for PET|Undergo 18F-FLT PET scan
223997929|NCT02819024|OTHER|Laboratory Biomarker Analysis|Correlative studies
223997930|NCT02819024|PROCEDURE|Positron Emission Tomography|Undergo 18F-FLT PET scan
223997931|NCT06780878|OTHER|Progressive muscle relaxation technique|"PMR focuses on the relationship between muscle tension and relaxation. By deliberately tensing a muscle group for a few seconds and then releasing the tension, individuals become more aware of the sensation of relaxation.~Group A Participants will receive PMR for 10 minutes each session, 3 sessions per week for 2 weeks and outcome measures will be recorded pre and post for each session."
223381382|NCT07167641|OTHER|Cognitive Behavioral Therapy for Caregivers|"The intervention includes four Foundational Sessions delivered to all participants: Orientation and Engagement, Narrative Exploration, and Goal Setting Sessions at the beginning of treatment, followed by a structured Closing Session at the end of treatment. Beyond the four foundational sessions, caregiver clients complete an additional module based on their top area of need. These modules are called Core Sessions and are selected through a collaborative process that draws on caregiver preferences, clinical judgment, and assessment results to ensure treatment is tailored to each caregiver's unique experiences, interests, and goals."
223381383|NCT07175454|OTHER|Questionnaire|"Patients/research nurses will complete questionnaires detailing their medical history including mental health and describing their IBD.~Patients will complete baseline scoring questionnaires for depression and anxiety (HADS) and perceived stress (PSS-10).~Patients will also complete a patient reported outcome tool to assess their current disease activity level (PRO-2)"
223381384|NCT07177742|OTHER|Observation|Observation.
223381385|NCT07175584|RADIATION|anal canal-sparing techniques|To contour anal canal and rectum separately and deliver different doses as two single OARs in pelvic radiation therapy planning.
223381386|NCT07177365|BEHAVIORAL|Internet-Based Cognitive Behavioral Therapy (ICBT)|An 8-week Internet-based Cognitive Behavioral Therapy (ICBT) program delivered via the National Health Research Institutes (NHRI) secure online platform. The program consists of 12 sequential modules released every 5 days, covering core CBT techniques such as cognitive restructuring, emotion regulation, behavioral activation, mindfulness, and self-compassion. Participants receive automated email notifications for new modules and supplementary review materials. Progress is monitored through the platform, and participants complete standardized self-report assessments at baseline, mid-intervention (week 5), post-intervention (week 9), and 3-month follow-up.
223381387|NCT07177365|OTHER|Treatment as Usual (TAU) Only|Routine clinical care provided by a psychiatrist, which may include pharmacological treatment, psychoeducation, and regular follow-up visits according to clinical judgment. No ICBT intervention is provided during the study period. Participants follow the same assessment schedule as the experimental group. After the 3-month follow-up, participants in this group may request access to the ICBT program.
223381388|NCT07186478|DRUG|Investigational Drug|IFALMIN® is a standardized herbal preparation derived from Channa micropeltes (ikan toman), containing natural albumin. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
223381389|NCT07186478|DRUG|Placebo|Placebo capsule containing inert ingredients (such as starch/lactose), identical in appearance, size, and color to IFALMIN® capsule. Administered orally in capsule form at a dose of 500 mg, 2-3 times daily, for 1 day.
223381390|NCT07185204|OTHER|Early detection and management of postpartum preeclampsia bundle|Remote blood pressure monitoring, education, and dispensing antihypertensive medication (nifedipine ER) for outpatient management of asymptomatic, mild range BP.
223997932|NCT06780878|OTHER|Stretching exercises|"Stretching exercises are physical activities designed to improve the flexibility of muscles and joints. These exercises involve elongating specific muscle groups to enhance their elasticity and improve the range of motion around a joint.~Participants will be given 15 second stretches for each large muscle group, 3 sessions per week, for 2 weeks. Outcome measures will be assessed pre and post intervention."
223997933|NCT06780878|OTHER|Control Group|This group will consist of 12 participants who will not be given any physical therapy interventions. Same measurements will be taken at same intervals as the experimental groups.
223997934|NCT05589597|DRUG|EO4010|Sequential assignment
223997935|NCT00792948|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
223997936|NCT00792948|DRUG|Cyclophosphamide|Given IV
223997937|NCT00792948|DRUG|Cytarabine|Given IT
223997938|NCT00792948|DRUG|Dasatinib|Given PO
223997939|NCT00792948|DRUG|Dexamethasone|Given IV or PO
223997940|NCT00792948|DRUG|Doxorubicin Hydrochloride|Given IV
223997941|NCT00792948|DRUG|Etoposide|Given IV
224123330|NCT06642402|DIAGNOSTIC_TEST|Urinary extracellular vesicle testing|Urinary extracellular vesicles will be isolated and tested for complement activation and other markers of kidney disease
224123331|NCT06642402|DIAGNOSTIC_TEST|Autoimmunity in plasma|Expected autoimmunity in plasma isolated from blood samples
224123332|NCT01661361|PROCEDURE|blood levels|
224123333|NCT04318743|DRUG|Glepaglutide|GLP-2
224123334|NCT00633581|DIETARY_SUPPLEMENT|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
223997942|NCT00792948|BIOLOGICAL|Filgrastim|Given SC
223997943|NCT00792948|OTHER|Laboratory Biomarker Analysis|Correlative studies
223997944|NCT00792948|DRUG|Leucovorin Calcium|Given IV
223997945|NCT00792948|DRUG|Methotrexate|Given IV or IT
223997946|NCT00792948|DRUG|Methylprednisolone|Given IV
223997947|NCT00792948|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
223997948|NCT00792948|DRUG|Prednisone|Given PO
223997949|NCT00792948|DRUG|Sirolimus|Given PO
223997950|NCT00792948|DRUG|Tacrolimus|Given IV
223997951|NCT00792948|RADIATION|Total-Body Irradiation|Undergo TBI
223997952|NCT00792948|DRUG|Vincristine Sulfate|Given IV
223997953|NCT05988866|BEHAVIORAL|lipodia|Participants will receive access to the digital health intervention lipodia in addition to TAU.
223997954|NCT06094478|BEHAVIORAL|HI-SPEED Protocol|The HI-SPEED Protocol or Bundle consists of 7 components including 1) stroke screening scales, 2) imaging pathways, 3) telestroke operations, 4) a best practice alert, 5) stroke team communication tool, 6) door-to-needle (thrombolysis) treatment pathway, and 7) a standardized hand-off tool. This protocol will be implemented at each participating health system in clusters of 2 health systems.
223997955|NCT03564353|DEVICE|tDCS|tDCS
223997956|NCT01760798|DRUG|Teriparatide|
223997957|NCT02645123|DEVICE|TENS|Enraf-Nonius Sonopuls 692
223997958|NCT02645123|PROCEDURE|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
224123335|NCT00633581|DIETARY_SUPPLEMENT|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
223997959|NCT02645123|PROCEDURE|swedish type massage|petrissage, effleurage, tapotement
224123336|NCT06643130|DRUG|JW0104+C2402|For 8 weeks(PO (Per Oral), QD)
223997960|NCT02645123|PROCEDURE|static hamstring stretch|static hamstring stretching
223997961|NCT02645123|PROCEDURE|sham treatment|touching of the skin overlying the lumbar area
223997962|NCT05500170|DIETARY_SUPPLEMENT|Nicotinamide riboside|Nicotinamide riboside (NR) is a form of vitamin B3, which is found in fruits, vegetables, meat, and milk. NR is converted into nicotinamide adenosine dinucleotide NAD+. Low NAD+ levels have been linked to Alzheimer's disease and sleep disturbances.
223997963|NCT05500170|DIETARY_SUPPLEMENT|Placebo|The placebo pill will contain micro cellulose powder.
223997964|NCT05987332|DRUG|IDE196|Dosed orally, twice daily
223997965|NCT05987332|DRUG|Crizotinib|Dosed orally, twice daily
223997966|NCT05987332|DRUG|Pembrolizumab|IV administration every 3 weeks
223997967|NCT05987332|DRUG|Ipilimumab|IV administration every 3 weeks for 4 Cycles
224123337|NCT06643130|DRUG|JW0104+C2403|For 8 weeks(PO, QD)
224123338|NCT06643130|DRUG|C2402|For 8 weeks(PO, QD)
224123339|NCT06644534|DRUG|TTI-0102|(cysteamine-pantetheine disulfide)
224123340|NCT06644534|DRUG|Placebo|Pearlitol® 100 SD (mannitol)
224123341|NCT06013605|BEHAVIORAL|Walking Exercise and Leg Straightening|Participants performed the exercise on the day agreed upon with the researcher. Respondents did walking exercises 3 times per week for 4 weeks with a duration of 10 minutes of warm-up, 30 minutes of walking exercises, and 10 minutes of cooling down. Respondents also did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
223381391|NCT07185763|BEHAVIORAL|Nano-Learning interventional program|AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.
223381392|NCT07185659|DEVICE|Elastic band|"Thera-Band® elastic band exercise protocol:~First stage (weeks 1-4): Participants performed leg resistance stretching exercises with a red elastic band. In weeks 1-2, exercises were performed 3 times per week, with 2 sets per session; in weeks 3-4, 3 times per week, with 3 sets per session.~Second stage (weeks 5-8): Participants performed leg resistance stretching exercises with a green elastic band. In weeks 5-6, exercises were performed 3 times per week, with 2 sets per session; in weeks 7-8, 3 times per week, with 3 sets per session.~Third stage (weeks 9-12): Participants performed leg resistance stretching exercises with a blue elastic band. In weeks 9-10, exercises were performed 3 times per week, with 2 sets per session; in weeks 11-12, 3 times per week, with 3 sets per session."
223381393|NCT07185659|DEVICE|Xiaomi Mi Band 4 wearable device|The Xiaomi Mi Band 4 wearable device has been certified by the National Communications Commission (Certification No. CCAG19LP0080T6). From weeks 1 to 12, participants' daily walking steps were monitored using the Xiaomi Mi Band 4 wearable device.
223381394|NCT07185659|BEHAVIORAL|Walking|Walking exercise plan
223545206|NCT02428829|PROCEDURE|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
223997968|NCT05987332|DRUG|Nivolumab|IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
224123342|NCT06013605|BEHAVIORAL|Leg Straightening|Respondents did leg straightening every day for 4 weeks with a frequency of 1 time a day for 10 minutes.
223545207|NCT02428829|PROCEDURE|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
223545208|NCT05193006|OTHER|No intervention|No intervention
223545209|NCT02292537|DRUG|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
223545210|NCT02292537|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
224123343|NCT06358859|OTHER|Food is Medicine|Regularly distributed fruit and vegetable produce boxes and nutrition education materials.
224123344|NCT00972478|DRUG|Cyclophosphamide|Given IV
224123345|NCT00972478|DRUG|Doxorubicin Hydrochloride|Given IV
224123346|NCT00972478|OTHER|Laboratory Biomarker Analysis|Correlative studies
224123347|NCT00972478|DRUG|Prednisone|Given IV
223545211|NCT03402932|OTHER|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
224123348|NCT00972478|BIOLOGICAL|Rituximab|Given IV
223545212|NCT03402932|OTHER|Visual|The cognitive test will be administered visually by using timed computer slides.
223545213|NCT03402932|OTHER|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
223545214|NCT02526303|DRUG|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
223545215|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
223997969|NCT05987332|DRUG|Dacarbazine|IV administration every 3 Weeks
224123349|NCT00972478|DRUG|Vincristine Sulfate|Given IV
224123350|NCT00972478|DRUG|Vorinostat|Given PO
224123351|NCT05662280|DEVICE|Active Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
224123352|NCT05662280|DEVICE|Sham Intermittent Theta Burst Stimulation|Standard iTBS protocol with active coil
224123353|NCT06701071|DRUG|Clomiphene Citrate|Clomiphene citrate is an estrogen receptor antagonist that leads to pituitary FSH release and prevention of the LH surge.
224138409|NCT03415763|DRUG|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
224138410|NCT03497234|DIAGNOSTIC_TEST|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
224138411|NCT00980343|DRUG|vismodegib|Given orally
224138412|NCT00980343|PROCEDURE|therapeutic conventional surgery|undergo surgery
224138413|NCT00980343|OTHER|laboratory biomarker analysis|correlative studies
224138414|NCT00980343|OTHER|pharmacological study|correlative studies
224138415|NCT03212664|OTHER|exercise|physical therapy exercises
223997970|NCT03832595|OTHER|EHR-based PHM|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~1. Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every \~6 months,~2. Medication therapy management: PharmD led telephonic medication therapy management with the patient every \~6 months,~3. and Nurse led CKD patient education, every \~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
223997971|NCT03832595|OTHER|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
223997972|NCT05759832|DEVICE|Modified HFNC oxygen therapy|In the modified HFNC group, high-flow devices (AIRVOTM 2; Fisher \& Paykel Healthcare, Auckland, New Zealand) were utilized for respiratory support. The nasal cannula used was a modified single nasal cannula.
223997973|NCT05759832|DEVICE|Non-rebreathing reservoir mask|In the non-rebreathing reservoir mask group, oxygen was delivered via a non-rebreathing reservoir mask during bronchoscopy. The oxygen flow was set to achieve a saturation of pulse oxygen \> 90%.
223997974|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
223381395|NCT07187193|DRUG|Cytarabine (Ara-C)|The treatment regimen consists of Ara-C administered at a dose of 100 mg/m² from days 1 to 5, combined with thalidomide at a dose of 100 mg from days 1 to 35, repeated every 35 days for a total of 12 cycles. Following this, thalidomide will be given as monotherapy at a dose of 100 mg from days 1 to 28, administered every 28 days for an additional 12 cycles of maintenance treatment. In total, participants will undergo 24 cycles of treatment.
223381396|NCT07187193|DRUG|Thalidomide (100mg)|The treatment regimen consists of AraC administered at a dose of 100 mg/m² from days 1 to 5, combined with thalidomide at a dose of 100 mg from days 1 to 35, repeated every 35 days for a total of 12 cycles. Following this, thalidomide will be given as monotherapy at a dose of 100 mg from days 1 to 28, administered every 28 days for an additional 12 cycles of maintenance treatment. In total, participants will undergo 24 cycles of treatment.
223381397|NCT07186920|PROCEDURE|PEEP titration for Minimum Driving Pressure|"This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined.~VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour"
223381398|NCT07186920|PROCEDURE|Lung Protective Ventilation|This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour
223381399|NCT07185282|DRUG|MH004 Ointment|MH004 1% ointment applied topically to the affected area as a thin film twice daily.
223381400|NCT07185282|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film twice daily.
223545216|NCT00678288|DRUG|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
223997975|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
223997976|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
223997977|NCT03893747|BIOLOGICAL|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
223997978|NCT03893747|BIOLOGICAL|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
223997979|NCT03893747|BIOLOGICAL|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
223997980|NCT02397447|DRUG|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
223997981|NCT02397447|DRUG|Placebo|Placebo: 2000 mg per day for three months
223997982|NCT07135791|DIAGNOSTIC_TEST|Real-time monitoring|Complete a brief 20-item survey 10 times a day for seven consecutive days, while wearing an accelerometer and completing daily sleep diaries.
223997983|NCT06923384|BEHAVIORAL|F2F|After T1 assessment, students meet with a trained provider and receive prevention or brief intervention. Students then complete assessments at two additional times.
223997984|NCT06923384|BEHAVIORAL|eSBI|After T1 assessment, students watch and respond to a prevention or brief intervention video series. Students then complete assessments at two additional times.
223997985|NCT06923384|BEHAVIORAL|Control|Students complete the assessments at each time point, but do not receive any intervention or informational material.
223997986|NCT07125027|BEHAVIORAL|Move-MORE|Move-MORE is a multicomponent intervention which combines mindfulness training, physical activity, and motivational interviewing informed by the principles of self-determination theory. The version of Move-MORE being used in this study is specifically designed for use in patients with lumbosacral radiculopathy.
223997987|NCT06931418|OTHER|Early Strengthening Protocol|Patients in the ESP intervention arm will undergo active and passive exercises as well as strengthening exercises after their initial assessment by rehabilitation therapists within 2 weeks of their discharge. Early use of strength and passive stretching will be encouraged immediately after allocation.
224138416|NCT00421603|DRUG|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
224138417|NCT00421603|DRUG|Placebo|Placebo
223997988|NCT06931418|OTHER|Early Motion Protocol|Patients are instructed for active flexion, extension, supination, pronation and finger flexion of the operated wrist along with motion of the shoulder and elbow after operation. Active mobilization is continued for the initial post-operative 6 weeks with allied health therapists. Passive mobilization and strengthening is started at the post-operative 8-10-week period.
223997989|NCT07124130|DRUG|5% Dextrose (D5) in Normal Saline (NS)|A solution of 5% dextrose and lactate ringer will be given to one group of participants.
223997990|NCT07124130|DRUG|Lactate Ringer|A Lactate Ringer solution will be given to one group of participants.
223381401|NCT07186868|BIOLOGICAL|Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab|All participants will receive the study intervention: Iparomlimab and Tuvonralimab (QL1706) at 5.0 mg/kg IV Q3W + Nab-Paclitaxel at 260 mg/m² IV Q3W, with or without Bevacizumab (7.5-15 mg/kg IV Q3W) per investigator's choice, for 6 cycles. This is followed by maintenance therapy with QL1706 ± Bevacizumab until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
223381402|NCT07185932|DRUG|Rifaximin (Xifaxan)|Participants will receive oral rifaximin at a dosage of 1200 mg/day (400 mg, three times daily) for 24 weeks.
223381403|NCT07185074|DRUG|Cisatracurium 0.05 mg/kg IV|Single bolus at induction; used in the experimental arm. Approximate potency reference: 0.05 mg/kg is about 1 x ED95.
223381404|NCT07185074|DRUG|Cisatracurium 0.15 mg/kg IV|Single bolus at induction; used in the active comparator arm. Approximate potency reference: 0.15 mg/kg is about 3 x ED95.
223381405|NCT07185074|DRUG|Lidocaine aerosol 2.4% topical|Three sprays to the glottic area immediately before intubation; used only in the experimental arm.
223381406|NCT07185191|DEVICE|RDM36|Patients treated with RDM36; two perpendicular infiltrations (buccal, palatal) of a quantity of 0.2 ml of PN HPT
223381407|NCT07185191|DRUG|Saline Solution (NaCl 0,9%)|patients treated with saline solution; two perpendicular infiltrations (buccal, palatal) of a quantity of 0.2 ml of saline solution
223381408|NCT07185126|BEHAVIORAL|Reconsolidation of traumatic memories|"The intervention begins with a parent session to review history, provide orientation, and obtain consent. Each child then attends six individual therapy sessions with a trained RTM specialist. Sessions use imagination exercises, film-like replay of traumatic memories in modified formats (e.g., black-and-white, fast-forward, backwards), and structured state-interruption techniques to reduce fear and distress. Animated instructions and cardboard cinema and skreen models may be used to support comprehension if needed."
223381409|NCT07185620|PROCEDURE|Third molar surgery with piezoelectric system|For the surgical removal of the third molar with a mucoperiosteal flap, osteotomy was performed using a piezoelectric system under continuous irrigation. The mucoperiosteal flap was then repositioned and closed primarily with sutures.
223381410|NCT07185620|PROCEDURE|Third molar surgery with Conventional Rotary System|For the surgical removal of the third molar with a mucoperiosteal flap, osteotomy was performed using a conventional rotary system under continuous irrigation. The mucoperiosteal flap was then repositioned and closed primarily with sutures.
223381411|NCT07185607|PROCEDURE|Erector spinae plane block (ESPB)|Erector spinae plane block is not a drug or a device. It is a regional method for anesthesia/analgesia. Before block application, patients were placed in a sitting position. A preliminary examination with a high-frequency linear probe was performed to identify the application site. Sterile conditions were then established. An ultrasound probe was longitudinally placed approximately 2 cm lateral to the T11 spinous process. The transverse process was visualized. 1 ml of 2% lidocaine was applied to the estimated needle entry site. The needle was then guided toward the transverse process using an out-of-plane method using a blocking needle (Stimuplex® Ultra 360® 22G 80 mm, Melsungen, Germany). After bone contact was achieved, facial hydrodissection was observed with 1-2 ml of saline solution to verify the correct injection site. 20 ml of 0.25% bupivacaine was injected into the plane. The distribution of the drug was visualised by USG.
223381412|NCT07185230|DRUG|Atosiban|Participants in the atosiban group will receive an intravenous bolus injection of atosiban (37.5 mg/5 mL, , Tractocile®，Ferring Pharma,Geneva, Switzerland) at a rate of 6.75 mg/0.9 mL 30 minutes prior to embryo transfer, followed by a 1-hour intravenous infusion at a rate of 18 mg/h. After 1 hour, the atosiban infusion rate will be reduced to 6 mg/h, with a total dose of 37.5 mg.
223381413|NCT07185230|DRUG|Placebo Control|Participants in the placebo group will receive an identical saline infusion over the same timeframe. Specifically, saline will be administered intravenously 30 minutes prior to embryo transfer (ET), followed by a continuous intravenous infusion for one hour. This will be succeeded by a further continuous intravenous infusion of saline for 2.125 hours.
223729739|NCT01276353|DRUG|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
223997991|NCT05077098|DRUG|ADXS-504|ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
224138418|NCT05582161|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
224138419|NCT00765128|DRUG|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
224138420|NCT00765128|DRUG|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
223381414|NCT07185295|PROCEDURE|To maintain anticoagulant therapy during the polypectomy of colorectal lesions|Group A
223381415|NCT07184671|BIOLOGICAL|blood sampling|22mL peripheral blood will be collected
223381416|NCT07184671|BIOLOGICAL|broncho-alveolar lavage sampling|Collected on resected tissue
224138421|NCT02217228|DEVICE|Sebacia microparticles and laser|
224138422|NCT02217228|DEVICE|Vehicle suspension and laser|
223381417|NCT07184671|BIOLOGICAL|lung parenchyma sampling|Collected on resected tissue
223381418|NCT07184788|DRUG|Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy|Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Gemcitabine (1000 mg/m2 iv qd d2), Oxaliplatin (100 mg/m2 iv qd d2) as induction therapy.
223381419|NCT07185217|OTHER|class mate teaching subjects only|the participants receive educational classmate subjects.
223997992|NCT07124052|DEVICE|SleeperOne 5|A computerized local anesthetic delivery system (manufactured by Dental Hi-Tec, France) designed to minimize pain perception in children during dental procedures by controlling the pressure and flow rate of anesthetic injection. It will be used to deliver 3% mepivacaine (Mepecaine-L®, Alexandria Co. for Pharmaceuticals, Egypt) during maxillary primary molar extraction in pediatric patients.
223997993|NCT07124052|PROCEDURE|(Conventional Infiltration Anesthesia)|Local anesthetic solution (3% mepivacaine with no vasoconstrictor), manufactured by Alexandria Co. for Pharmaceuticals, Egypt. It will be administered using a 30-gauge short dental needle and standard dental syringe for conventional infiltration anesthesia during primary maxillary molar extraction in pediatric patients.
223997994|NCT07124078|DRUG|INCA034176|Axatilimab at the protocol-defined dose.
223381420|NCT07184697|DEVICE|HD ctACS|Participants received High-Definition closed-loop transcranial Alternating Current Stimulation (HD-ctACS) for 30 minutes daily, 5 days per week. A 4x1 ring electrode montage was used, with the center electrode placed over the bilateral temporal cortices. Stimulation was delivered as a sinusoidal alternating current at a 2 mA peak amplitude, with the frequency individualized for each participant based on their baseline EEG. The stimulation was administered in a closed-loop, task-specific manner: a 500 ms burst of stimulation was triggered only when a subliminal negative facial stimulus was presented and the participant's real-time Nucleus Accumbens gamma power exceeded their baseline by two standard deviations.
223545217|NCT03447405|DEVICE|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
223997995|NCT07124078|DRUG|Best available Treatment (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
223997996|NCT07126288|DRUG|GB08|"In Phase II trial, eligible PGHD patients will receive GB08 0.4mg/kg, 0.8mg/kg, or 1.2mg/kg subcutaneous injection, once a week for 24 weeks.~In Phase III trial, the individuals will receive GB08 subcutaneous injection, once a week for 52 weeks. The dose of GB08 at this stage will be determined by the outcomes of Phase II."
223997997|NCT07126288|DRUG|Norditropin NordiFlex|Norditropin NordiFlex 0.035 mg/kg subcutaneous injection, daily, for 24 weeks (Phase II) or 52 weeks (Phase III)
223997998|NCT07126418|OTHER|observation (cervical proprioception, neck pain and neck disability)|"1\) Assessment of cervical proprioception using CROM device: Head reposition accuracy tests: neutral head position (NHP) and target head position (THP) tests are common tests used to assess cervical proprioception. Repositioning to the NHP and repositioning into THP. The test procedures were the same as those described by Lee et al., 2006. The NHP test measures the subject's ability to actively reposition their head to their self-selected neutral position. The THP test measures the individual's ability to actively reposition the head to a previously demonstrated target position. A) Neutral head position: After explaining the testing procedure, the CROM device will securely fixed on the head of the subject. The participants will instructed to sit upright with their feet flat on the floor, their back against the chair backrest and facing straight ahead, this position will established as their self-selected NHP.~The magnetic part of the unit was then placed so that it was put"
223997999|NCT05903261|RADIATION|SBRT|stereotactic body radiation therapy (SBRT)
223998000|NCT06934668|DEVICE|Extracorporeal Shock Wave Therapy|A single session of focused extracorporeal shock wave therapy (ESWT) applied to the upper trapezius muscle (2300 shocks). The treatment is applied to the muscle belly region with coupling gel, without local anesthesia. The protocol is designed to assess the acute effects of ESWT on muscle stiffness measured using shear-wave elastography.
223998001|NCT06933199|RADIATION|Neoadjuvant Stereotactic Radiotherapy (NaSRT)|Neoadjuvant Stereotactic Radiotherapy (NaSRT) gives radiotherapy before surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
223998002|NCT06933199|RADIATION|Postoperative Stereotactic Radiotherapy (SRT)|Postoperative Stereotactic Radiotherapy (SRT) gives radiotherapy after surgery from many different angles around the body. The beams meet at the tumor. This means the tumor receives a high dose of radiation and the tissues around it receive a much lower dose. This lowers the risk of side effects.
224123354|NCT05641519|BEHAVIORAL|SERVE OC Intervention|"SERVE OC intervention for the family which includes 1) Conducting a family intake of risk factors through the LE8 assessment and discussing prevention/risk reduction 2) Facilitate the creation of a family network-tailored action plan 3) Provide guidance to activate/reinforce action plans using the interactive part of the app/web portal. They will meet with their CHW monthly to learn about CVH, work on their goals, and action plans. Meetings with CHWs will take place in their homes, the UCI FQHC in Santa Ana, over zoom, or other locations such as local churches, parks, community centers, or grocery stores (for field trips) They will also receive messages from them throughout the duration of the study using their preferred method of contact (text, email, webportal/app, phone call) for reinforcement and scheduling meetings"
224138423|NCT02217228|DEVICE|Sebacia microparticles without laser|
224138424|NCT00965783|OTHER|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
223545218|NCT04305626|DEVICE|Endovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms with flow diversion.
223545219|NCT02549989|DRUG|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
223545220|NCT02478112|DEVICE|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
223998003|NCT06934447|BIOLOGICAL|anti-BCMA/CD70-CAR-T cells|Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
223381421|NCT07184697|DEVICE|HD ctACS sham|Participants received High-Definition transcranial Alternating Current Stimulation (HD-tACS) in 30-minute sessions once daily, 5 days per week. A 4x1 ring electrode layout was used to target the bilateral temporal cortices. The stimulation consisted of a sinusoidal alternating current with a 2 mA peak intensity, delivered at an individualized gamma frequency determined from a baseline EEG. The intervention was administered using a closed-loop, task-specific paradigm: upon presentation of a subliminal negative facial stimulus while the real-time Nucleus Accumbens gamma power exceeded a baseline threshold of +2 SD, a 500 ms stimulation was delivered following a random delay of 1000-2000 ms.
223381422|NCT07186972|PROCEDURE|Mild therapeutic hypothermia|Before percutaneous coronary intervention, cooling was maintained with venous-arterial extracorporeal membrane oxygenation in patients receiving mild therapeutic hypothermia. By protocol, cooling down to the target temperature of 33°C-34°C was set at the maximum possible cooling rate. After the target temperature was reached, it was maintained for 24 hours with the temperature regulation function of the extracorporeal membrane oxygenation system by central temperature measurement in the urinary bladder. After 24 hours, rewarming was initiated with a speed of 0.25°C/h to a target temperature of 36.5℃ (± 0.3℃). To avoid shivering in the mild therapeutic hypothermia group, the patients were treated with a protocol including deep sedation and optional muscle relaxation.
223381423|NCT07186036|DEVICE|soft lumbosacral orthosis|The effect of trunk corsets on postural control and walking, GYA independence
223381424|NCT07184879|DEVICE|Conventional Dental Syringe|Palatal infiltration anesthesia using a conventional dental syringe with a 27G needle. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered manually over 15-20 seconds following aspiration.
223381425|NCT07184879|DEVICE|Spring-Activated Syringe (PCJ, PAROJECT™)|Palatal infiltration using a spring-activated push-button syringe (PAROJECT™). Two calibrated 0.2 mL doses of articaine 4% with epinephrine 1:100,000 were administered following aspiration.
223381426|NCT07184879|DEVICE|Needle-Free Jet Injector (NFI, Comfort-in™)|Palatal infiltration using a needle-free jet injector (Comfort-in™). A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was delivered in less than one second at 4-5 bar pressure. Aspiration not applicable.
223381427|NCT07184879|DEVICE|Computer-Controlled Local Anesthetic Delivery (CCLAD, CALAJECT™)|Palatal infiltration using a computer-controlled local anesthetic delivery system (CALAJECT™, Program I) with a 30G, 16 mm needle. AutoFlow rate 0.006-0.009 mL/s, with automatic aspiration after 5 seconds and constant microprocessor-controlled pressure. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered.
223381428|NCT07184879|DEVICE|Manual Pressure Syringe (MCJ, ASPIJECT™)|Palatal infiltration using a manual pressure-controlled syringe (ASPIJECT™) with a 30G, 16 mm needle. A total of 0.4 mL of articaine 4% with epinephrine 1:100,000 was administered manually over 15-20 seconds with aspiration.
223381429|NCT07186504|BEHAVIORAL|Adapted Physical Activity|Group-based, weekly supervised 60-minute sessions including mobility, stability, strengthening, and aerobic exercises adapted for pregnancy and pelvic girdle pain.
223381430|NCT07186504|BEHAVIORAL|Pelvic Floor Rehabilitation|Individual physiotherapy sessions using the PERFECT scheme to assess and retrain pelvic floor muscle function, including education, manual therapy, relaxation, and strengthening
223381431|NCT07186504|OTHER|Standard Care (in control arm)|Usual prenatal care provided by obstetricians or midwives according to local practice.
223381432|NCT07186504|OTHER|Educational Flyer|Written information with evidence-based international guidelines on physical activity during pregnancy.
223545221|NCT06295380|BEHAVIORAL|Virtual environment practiced on the Caren|The virtual environment practised on the Caren will make the scenario totally immersive and allow the subject to perform the motor task by recruiting muscles according to a motor coordination scheme different from the traditional one.
223545222|NCT06295380|BEHAVIORAL|Conventional physiotherapy|Conventional physiotherapy
223545223|NCT00288548|DRUG|Metoprolol|
223545224|NCT02904369|DRUG|Emtricitabine|
223545225|NCT02904369|DRUG|Tenofovir alafenamide|
223545226|NCT02904369|DRUG|Tenofovir disoproxil|
223545227|NCT00972023|DRUG|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
223729740|NCT01276353|DRUG|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
223998004|NCT06936774|OTHER|Intensified follow-up program|The study intervention will be an intensified follow-up program which consists of different measures. Patients will attend follow-up visits 1, 4, 7 and 13 months after ileostomy repositioning, at which LARS symptoms, quality of life as well as sexual and urinary function will be recorded using various questionnaires. In case of LARS symptoms patients will receive medical treatment with loperamide and metamucil as well as pelvic floor muscle training (including biofeedback and home exercises). Regarding pelvic floor muscle training we are planning nine sessions instructed by physiotherapy staff. In case of therapy-resistant LARS symptoms after 6 months sacral neurostimulation is offered to the patients with a focus on incontinence symptoms and desire for surgery or transanal irrigation in patients with a focus on voiding disorders. In case of urinary and sexual complaints patients are referred to our urology or gynaecology department for further diagnostic and treatment.
224123355|NCT05641519|BEHAVIORAL|Enhanced Standard Intervention|Enhanced Standard Intervention will be given informational materials from the American Heart Association on cardiovascular health. ESI includes self-management which is standard care
223545228|NCT00972023|PROCEDURE|Surgical resection|Surgical procedure of the invasive breast cancer
224123356|NCT00525720|DRUG|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
223545229|NCT05225077|DRUG|Dapagliflozin 10 MG [Farxiga]|Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.
224123357|NCT00525720|BEHAVIORAL|Questionnaire|Questionnaires taking 30 total minutes.
224123358|NCT02561000|DRUG|PZ-128|
224123359|NCT02561000|DRUG|Placebo|
224123360|NCT05391061|DRUG|Abrocitinib|Tablets
224138425|NCT00965783|OTHER|Extension|Bedtime is extended by 2 hours per night for 4 nights
223381433|NCT07186881|OTHER|Recommendation from the infectious diseases team|"No commercial product was evaluated in this study. We are assessing the benefits and consequences of a change in clinical practice implemented at the hospital level. At our institution, it is now recommended that TBE serology be performed in all cases of undocumented meningitis or meningoencephalitis.~The infectious diseases team at our hospital simply advises the clinicians responsible for patient care to perform this test."
223381434|NCT07184801|DRUG|Dexmedetomidine|The patient will receive dexmedetomidine bolus dose of 1 µg /Kg over 10 minutes followed by 0.5 µg /kg/hr infusion titrated to desired sedation level (RSS 3). For patients who do not achieve an RSS of 3, we will give 1 mg bolus of midazolam. All additional boluses will be recorded. The patient will initially receive a bolus of 2 mL 0.9% normal saline intravenously for blinding purpose
223381435|NCT07184801|DRUG|Midazolam|The patient will receive midazolam bolus dose of 2 mg IV. They will receive an infusion of normal saline over 10 minutes for blinding purpose. Further need of sedation (as assessed by RSS) will be met by additional IV boluses of 1 mg midazolam. During the procedure they will receive continuous infusion of normal saline at a rate of 0.5 µg /Kg/Hr as placebo.
223381436|NCT07185334|PROCEDURE|Subcutaneous mastectomy using a fluoropolymer-coated polyester mesh endoprosthesis with simultaneous prepectoral placement of textured implants.|For this group of patients, the planned volume of surgical intervention is: subcutaneous mastectomy using a polyester mesh endoprosthesis with a fluoropolymer coating and one-stage prepectoral installation of textured implants.
223381437|NCT07185334|PROCEDURE|Subcutaneous mastectomy with simultaneous prepectoral placement of textured implants.|This group of patients will undergo surgical intervention in deep subcutaneous mastectomy with simultaneous prepectoral placement of textured implants.
223381438|NCT07185165|PROCEDURE|Computed Tomography|Undergo PET/CT
223381439|NCT07185165|DRUG|Fluorine F 18 Flotufolastat|Given IV
223381440|NCT07185165|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223381441|NCT07185165|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo PET/CT/ultrasound fusion biopsy
223381442|NCT07186673|DEVICE|Stainless steel crown placement using Hall Technique|Preformed stainless steel crowns are placed on permanent first molars without local anesthesia, caries removal, or tooth preparation. Orthodontic separators are used as needed, and crowns are cemented with glass ionomer cement
223381443|NCT07186673|DEVICE|Stainless steel crown placement using conventional method|Preformed stainless steel crowns are placed after administering local anesthesia and performing standard tooth preparation, including occlusal and proximal reduction. Crowns are cemented with glass ionomer cement.
223381444|NCT07185594|DRUG|HRS-2129 Tablets|HRS-2129 tablets.
223381445|NCT07185594|DRUG|Blank Preparation.|Blank preparation.
223381446|NCT07185594|DRUG|Tramadol Hydrochloride SR Tablets|Tramadol Hydrochloride SR tablets.
223381447|NCT07186426|DRUG|HSK21542|Patients administrated with HSK21542
223381448|NCT07186426|DRUG|Placebo|Patients administrated with placebo
223381449|NCT07186426|DRUG|morphine|Patients administrated with morphine
223381450|NCT07185724|DRUG|Ketorolac 30 mg IV|We will be evaluating the effect of post-oocyte retrieval ketorolac administration on clinical outcomes in fresh embryo transfer cycles.
223381451|NCT07186686|OTHER|Participants will receive the AMENUCED program including medical care, nutritional counseling, and structured sessions focused on behavioral change and diabetes education.|"Medical Attention: Medical management will be provided by a physician who will assess the participant at the beginning and end of the intervention. The physician will be responsible for pharmacological treatment and follow-up throughout the process.~Nutritional Attention: Nutritional consultations will be provided by a registered nutritionist over a three-month period, with sessions held weekly. During each consultation, the participant will receive an individualized nutrition plan based on scientific evidence and dietary recommendations. The plan will be tailored to the participant's specific needs, including metabolic control and a hypocaloric intake (ranging from 1200 to 1800 kcal), with the goal of achieving a 5-10% reduction in body weight.~Behavioral Lifestyle Change Program: The behavior modification program used in the Action for Health in Diabetes Program (Look AHEAD) study will be adapted to include diabetes self-management activities through a structured manual."
223381452|NCT07184853|DRUG|Ruxolitinib (JAKAVI®)|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (approximately every 12 hours), with or without food. Dose modifications are allowed according to protocol-defined safety and efficacy criteria. Ruxolitinib may be continued for up to 24 weeks, with tapering guided by patient response and GVHD status.
223381453|NCT07184853|DRUG|Etanercept (Enbrel)|Etanercept will be administered as a subcutaneous injection at a dose of 25 mg twice weekly for 4 weeks (total 8 doses). For patients with partial response at day 28, treatment may be extended once weekly for an additional 2-4 weeks at the investigator's discretion.
223381454|NCT07185373|DRUG|Teniposide|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
223425498|NCT03790449|BEHAVIORAL|PreLiFe-programme|The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
224123361|NCT04510597|PROCEDURE|Cytoreductive Nephrectomy|Radical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization
223381455|NCT07185373|DRUG|Orelabrutinib|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
223381456|NCT07185373|DRUG|MTX|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
223381457|NCT07185373|DRUG|Rituximab (R)|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
223381458|NCT07185373|DRUG|Dexamethasone|"This trial enrolls eligible participants (meeting inclusion and exclusion criteria), who will be randomized to one of three induction regimens via stratified block randomization at a 2:2:1 ratio. Stratification factors include age (≤60 vs. \>60 years) and ECOG performance status (0-1 vs. 2-3). Within each stratum, blocks of size 15 will be used to ensure balanced allocation.~Induction regimens:~Arm A: Teniposide, orelabrutinib, rituximab, methotrexate (MTX) and dexamethasone, administered in 21-day cycles.~Arm B: Orelabrutinib, rituximab, MTX and dexamethasone, administered in 21-day cycles.~Arm C: Rituximab, MTX and dexamethasone, administered in 21-day cycles. Following induction therapy, participants achieving complete response (CR) or unconfirmed complete response (CRu) will proceed to consolidation therapy."
223381459|NCT07187050|OTHER|Template-Based LLM Assistant|This study uses CocktailAI, a template-based LLM assistant co-developed by the Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, and Fitting Cloud Inc. (Kyoto, Japan). It is designed to extract relevant information from EHRs using LLMs and embed the extracted content into predefined templates. In this trial, the inputs are six simulated patient records (no real patient data). Text generation uses Gemini-2.0-flash-lite. Templates for discharge summaries and discharge referrals are pre-defined by a team member.
223381460|NCT07187050|OTHER|Manual Writing|The same document templates are provided; however, all LLM instruction prompts are removed in advance. Clinicians manually write the documents, following the template structure, for each of the six simulated cases.
223381461|NCT07187180|DEVICE|holmium laser|Prostate enucleation will holmium laser (control)
223381462|NCT07187180|DEVICE|pulsed thulium laser|experimental group - pulsed thulium laser prostate enucleation
223381463|NCT07187128|DEVICE|drug coating balloon angioplasty|The subjects underwent drug coating balloon angioplasty to treat femoropopliteal artery stenosis or occlusive lesions
223381464|NCT07186062|DRUG|Levosimendan|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~•Levosimendan: loading dose 6-12 microgram/ kg then continuous infusion of 0.05-0.2 µg/kg/min."
223381465|NCT07186062|DRUG|Dobutamine|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Dobutamine: continuous infusion starting at 2.5 µg/kg/min, titrated up to 20 µg/kg/min as needed."
223381466|NCT07186062|DRUG|Milrinone|"Inotropic agents titrated to response to keep mean arterial blood pressure above 55 mmHg :~• Milrinone: 50 mcg/kg loading dose, then 0.375-0.75 mcg/kg/min IV according to patient response."
223381467|NCT07184892|BEHAVIORAL|Daily life actual swallowing movement observation therapy|This group adds the therapy of observing actual swallowing movements in daily life, that is, in real daily life, observing the real eating and swallowing movements of relatives. They select meals that the patient likes or those that are complete in color, aroma and taste and look appetizing. The swallowing movements should be as slow and exaggerated as possible, and a look of savoring and enjoying the food should be shown, so that the patient can better observe the movements of the mouth and larynx during swallowing. Then, the patient imitates the swallowing movements.
223381468|NCT07184892|BEHAVIORAL|Video swallowing action observation therapy|Video swallowing action observation therapy
223381469|NCT07184892|BEHAVIORAL|Traditional swallowing training|Traditional swallowing training
223381470|NCT07186335|OTHER|self-questionnaire|Quantitative survey with self-administered questionnaire offered to all patients
223729741|NCT05167214|DEVICE|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain|The Acute Effect Of Different Kinesiological Tape Application On Pain, Functional Performance And Trunk Endurance In Young Adults With Chronic Back Pain
223998005|NCT06937983|PROCEDURE|Optimised DeEP-guided ablation|Optimised decrement evoked potential (DeEP) mapping in VT ablation.
224123362|NCT04510597|DRUG|Active Comparator|"Nivolumab 240 mg IV 1 q 2 weeks~OR~Nivolumab 480 mg IV 1 q 4 weeks~OR~Pembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID~OR~Avelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID"
224123363|NCT06008626|DEVICE|Cryosa Procedure|Cryotherapy
224123364|NCT01522976|DRUG|Azacitidine|Given SC or IV
224123365|NCT01522976|OTHER|Laboratory Biomarker Analysis|Correlative studies
224123366|NCT01522976|DRUG|Lenalidomide|Given PO
224123367|NCT01522976|DRUG|Vorinostat|Given PO
223381471|NCT07185789|BEHAVIORAL|Healthy and Sustainable Eating|Animated projections, snacks that incorporate fruits and/or vegetables, measuring their hydration status through images where they can observe the color of their urine and relate it to the amount of plain water they have consumed, as well as activities through the mobile messaging platform, WhatsApp.
223381472|NCT07185789|BEHAVIORAL|Movement behaviors|Animated projections, snacks that incorporate fruits and/or vegetables, measuring their hydration status through images where they can observe the color of their urine and relate it to the amount of plain water they have consumed, as well as activities through the mobile messaging platform, WhatsApp.
223998006|NCT06937255|DIAGNOSTIC_TEST|computerized Dynamic Assessment|The DA tests (with a duration of about 30 minutes) can be administered by accessing the digital platform MuLiMi, individually with the experimenter or examiner. The tests are in game form and require children to learn the names of characters presented in the context of stories (preschool version) or to learn new codes for reading and writing (primary school version). In both cases, the new materials (names or codes) are repeatedly presented to the child until (s)he reaches an accuracy threshold. The number of repetitions needed to reach the threshold constitutes the main measure of the child's learning capacity, together with the number of errors committed during the various cycles.
223381473|NCT07185789|BEHAVIORAL|Psychosocial determinants|Workshops on key topics of psychosocial determinants in children, virtual workshops on topics of psychosocial determinants such as obesity and healthy eating.
223729742|NCT00937612|RADIATION|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
223729743|NCT05320120|DRUG|56mg esketamine (2x Spravato® 28 mg nasal spray)|56mg esketamine (2x Spravato® 28 mg nasal spray)
223998007|NCT05899413|DEVICE|Transcutaneous vagal nerve stimulation|The intervention consists of neurostimulation device that is programmed to a stimulus intensity at 0.5mA with a stimulation frequency of 25 Hz at the outer auditory canal.
223998008|NCT06942832|OTHER|VA-SPOZ exercise program|The VA-SPOZ exercise program has 3 phases and takes 40 minutes to complete. The program will be performed in a seated position, and the participants will wear SPOZ devices on both hands to record and track the accuracy of the movements.
223998009|NCT06942832|OTHER|Control|Participants maintain their routine activities.
224123368|NCT04889144|OTHER|Communication Intervention|Participate in PLAN intervention
224123369|NCT04889144|OTHER|Best Practice|Receive usual care
224123370|NCT04889144|OTHER|Questionnaire Administration|Ancillary studies
223998010|NCT01555489|DRUG|Ascorbic Acid|3x per week
224123371|NCT00815412|BEHAVIORAL|Counseling in use of health care|
224123372|NCT00815412|BEHAVIORAL|Counseling in diet, exercise|
224123373|NCT00815412|OTHER|Control|
223381474|NCT07186413|DRUG|Trifarotene|Trifarotene cream applied QD topically.
223381475|NCT07186413|DRUG|Vehicle Cream|Vehicle cream applied QD topically.
223381476|NCT07186322|PROCEDURE|Fat Graft|Non-regenerative standard treatment for post-burn sequelae, involving either corticosteroid injection to reduce scar inflammation and fibrosis, or surgical release for contractures. The procedure type will be chosen based on the clinical indication and severity.
223998011|NCT06939777|BIOLOGICAL|SNA02-48|intramuscular injection
224123374|NCT03368742|GENETIC|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
224123375|NCT06336005|DRUG|NNC6022-0001|Participants will recieve single ascending dose (SAD) of NNC6022-0001. Dose is given in escalating manner for up to seven cohorts.
224123376|NCT06336005|DRUG|Placebo (NNC6022-0001)|Participants will recieve single ascending dose (SAD) of placebo. Placebo is given in escalating manner for up to seven cohorts
224123377|NCT05756764|DRUG|Semaglutide|Medication for weight loss
224123378|NCT05756764|DRUG|Phentermine-Topiramate combination|Medication for weight loss
224123379|NCT05756764|DRUG|Phentermine|Medication for weight loss
224123380|NCT05756764|DRUG|Tirzepatide|Medication for weight loss
224123381|NCT05756764|DRUG|Topiramate|Medication for weight loss
224123382|NCT05756764|DRUG|Diethylpropion|Medication for weight loss
224123383|NCT05756764|DRUG|Naltrexone/Bupropion|Medication for weight loss
224123384|NCT05756764|DRUG|Liraglutide|Medication for weight loss
224123385|NCT05107674|DRUG|NX-1607|Oral NX-1607
224123386|NCT05107674|DRUG|Paclitaxel|Paclitaxel IV
224123387|NCT05313633|OTHER|Occupational therapy|Both groups received a designed occupational therapy program for 30 minutes
224123388|NCT05313633|OTHER|Plyometric training|The designed plyometric training program basically focuses on upper extremity strength training and is developed according to the guidelines of the National Strength and Conditioning Association.
223545230|NCT01621984|OTHER|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
223545231|NCT03412110|OTHER|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
223545232|NCT05605730|OTHER|Maitland mobilization for thoracic spine|The thoracic spine mobilization will be consisting of oscillations to the thoracic vertebrae from the prone positions for repeated 30 times with 1 min interval between each 4 sets for 15 minutes. For central posterio-anterior mobilization, a grade III large amplitude rhythmic oscillation in the postero-anterior direction will be applied to the joint sign segment which is defined as the patient's most painful or hardest to move segment. It will be detected through a passive accessory intervertebral motion (PAIVM) test. T6,7 will be used as a site for application if the joint sign can't be detected. The frequency of treatment sessions will be 3 sessions per week for 4 weeks.
223545233|NCT05605730|OTHER|Mulligan thoracic sustained natural apophyseal glide (SNAGS)|Verbal instructions will be provided for the patient to move into thoracic extension and do over-pressure at the end of ROM while a transverse glide is maintained by the therapist for a set of 10 repetitions. The significance of performing a pain-free movement will be emphasized to the patient all the time. There will be 3 sets of 10 repetitions with one minute rest between each set.
223998012|NCT06939777|BIOLOGICAL|Placebo|intramuscular injection
223381477|NCT07185178|OTHER|Video game-based breathing exercises|"Twenty individuals will be enrolled in the video game-based breathing exercise program. Participants in the study group will undergo the Breathing Games exercise program twice a week for 8 weeks, with each session lasting approximately 50 minutes. This video game-based breathing exercise program includes warm-up, cool-down, and five breathing games designed for the target patients.From the second week onward, posture exercises combined with the breathing games will be added.Thus, the exercise program will consist of a warm-up phase lasting approximately 10 minutes, including breathing control, stretching exercises, and rest; 25-30 minutes of five breathing games combined with posture exercises; followed by a cool-down phase of about 10 minutes with breathing control, stretching exercises, and rest.Additionally, participants will be provided with a home exercise program to be performed twice daily for 30 minutes, three days a week, over 8 weeks."
223381478|NCT07185178|OTHER|Control group|"Participants in the control group will receive a 30-45 minute patient education session after the assessment. The content of the education will include:~Providing general information about Asthma-COPD Overlap Syndrome (ACOS) Teaching dyspnea-relieving positions Instruction in diaphragmatic breathing techniques Teaching secretion clearance methods (Active Cycle of Breathing Techniques - ACBT) Educating on energy conservation strategies Providing information on correct posture Counseling on lifestyle modifications (e.g., smoking cessation, physical activity recommendations) To maintain and improve physical activity levels, patients will be advised to engage in walking activities for 30 minutes, twice a week After covering these topics, participants will be given brochures containing this information. Additionally, follow-up will be conducted by phone every two weeks. All assessments will be repeated at the end of the 8-week period."
223381479|NCT07185412|DEVICE|Pulsed Field ablation: Ablation to treat atrial fibrillation|Pulsed Field Ablation
223381480|NCT07186738|DEVICE|EPOCA telemonitoring|EPOCA is a telemonitoring and tele-coordination platform for medical, paramedical, and social care, enabling the follow-up of acute or chronic patients at home-whether after hospital discharge, as an alternative to hospitalization, or for long-term monitoring. The EPOCA solution relies on connected devices, a digital platform for analyzing incoming data, and a team of medical and paramedical professionals for monitoring and coordination. Remote medical monitoring includes teleconsultations, at-home paramedical care, guidance and support for families, nursing homes, or long-term care facilities, and 24/7 management of home emergencies
223381481|NCT07186855|OTHER|Blood Sample Collection for CTC Detection|Blood Sample Collection for CTC Detection
223381482|NCT07185035|BIOLOGICAL|KN5001|"Subjects will receive KN5001 on day0, 3, and 6. Multiple Doses of KN5001 will infused using the 3 + 3 dose-escalation strategy."
223381483|NCT07186348|PROCEDURE|Ice packing|10 minutes ice packing application after surgery
223381484|NCT07186348|PROCEDURE|Standard Care (in control arm)|Standard Care (in control arm)
223381485|NCT07185958|DIAGNOSTIC_TEST|Dual-energy CT (DECT)|Additional DECT scan performed for tumor and OAR delineation.
223381486|NCT07185958|DRUG|Iodine-based contrast agent|Administered intravenously with DECT for enhanced imaging.
223998013|NCT06939777|BIOLOGICAL|HTIG|intramuscular injection
223998014|NCT06939777|BIOLOGICAL|Tetanus Toxoid|intramuscular injection
223998015|NCT06952907|OTHER|Femoral artery catheterization for continuous invasive arterial blood pressure monitoring|Femoral artery catheterization allow for continuous invasive arterial blood pressure monitoring.
223998016|NCT06952907|OTHER|Radial artery catheterization for continuous invasive arterial blood pressure monitoring|Radial artery catheterization allows for continuous invasive arterial blood pressure monitoring
223998017|NCT04959864|DIETARY_SUPPLEMENT|Isitol®|"1 sachet of Isitol® (2,1g) contains :~* 1000 mg of myo-inositol ;~* 300 mg of N-acetyl-cystein ;~* 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~* 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~* 16 mg of vitamin B3 ;~* 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~* 1.4 mg of vitamin B2 ;~* 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30."
223998018|NCT04959864|OTHER|Placebo|"1 sachet of placebo (2,1g) contains :~* 1765.1 of maltodextrin ;~* 300 mg of magnesium carbonate ;~* 40 mg of citric acid ;~* 5.3 mg of beta-carotene ;~* 2.16 mg of silicon dioxide ;~* 1.44 mg of sucralose.~Sachets are packaged in box of 30."
223998019|NCT07136181|DRUG|NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.|NBM-BMX is a small molecule inhibitor of HDAC8. The majority of metastasizing uveal melanoma (UM) cases are characterized by the presence of BAP1 mutations. However, as BAP1 mutations lead to a loss of function, therapeutic strategies have primarily focused on exploiting vulnerabilities resulting from BAP1 loss or targeting downstream effectors affected by the BAP1-deficient phenotype. In uveal melanocytes, the absence of BAP1 disrupts their differentiated cell identity, potentially contributing to the metastatic behavior observed in BAP1-mutant UM cells. This differentiation block in the melanocytic lineage is thought to be influenced, at least in part, by the activation of HDAC8 downstream, which leads to the repression of differentiation genes through acetylation of the histone H3K27 at the promoter and enhancers associated with these genes. Consequently, inhibiting HDAC8 could potentially reverse the differentiation block caused by the loss of BAP1.
223998020|NCT07136558|DRUG|ICP-B794|Intravenous administration once every 3 weeks
223381487|NCT07185958|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Additional MRI scan performed for tumor and OAR delineation.
223381488|NCT07185958|DRUG|Gadolinium-based contrast agent|Administered intravenously with MRI for enhanced imaging.
223381489|NCT07186556|BEHAVIORAL|RISE-YA Intervention|Participants will receive energy conservation (EC) counseling, behavior coaching, and exercise training.
223998021|NCT07137156|DIAGNOSTIC_TEST|cytobrush|buccal smear
223998022|NCT07137156|DEVICE|next-generation sequencing|next-generation sequencing
224123389|NCT05313633|OTHER|Wii training|The dose of Wii training was 40 minutes, three times a week for 12 weeks which is an interactive motion-based device.
223381490|NCT07186556|BEHAVIORAL|Survivorship Education|During weeks 1-6 and 1 time a week during Weeks 7-12, participants will receive a video call which will last about 60 minutes.
223381491|NCT07187063|DIAGNOSTIC_TEST|UroAmp Test (Convergent Genomics, Inc.)|Non-invasive genomic urine test that can reliably detect, monitor, and predict the risk of urothelial cancer or its recurrence, potentially before signs and symptoms develop or become detectable by historical standards of care.
223381492|NCT07186114|DRUG|MEBO Wound Ointment (MEBO)|MEBO® 0.25% Ointment (Gulf Pharmaceutical Industries) to be applied four times a day for two weeks
223381493|NCT07186114|DRUG|Tantum Verde® mouthwash|Tantum verde (EIPICO®) mouthwash. Patients were asked to swish it for at least five minutes, four times daily for two weeks.
223998023|NCT07137039|DRUG|Adebrelimab+Albumin paclitaxel +Cisplatin|"1. Adebrelimab：1200mg, ivgtt, D1, Q3W;~2. Albumin paclitaxel :260mg/m2, ivgtt, D1, Q3W;~3. Cisplatin :60mg/m2, ivgtt, D1, Q3W."
223998024|NCT07137364|DRUG|spironolactone|The patients receive spironolactone treatment based on their conditions
223998025|NCT03527719|OTHER|Village-doctor-led multifaceted intervention|"* Establishing a network including hypertension specialists at city/county hospitals, primary care physicians at township hospitals, and village doctors to collaboratively manage hypertension~* Using hypertension control rate as one of the metrics for incentive supplements to village doctors~* Providing discounted or free antihypertensive medications to patients with hypertension~* Training village doctors to measure blood pressure according to a standard protocol~* Training village doctors to use a simple stepwise protocol for hypertension treatment~* Training village doctors to conduct health coaching on lifestyle change (e.g., lowering sodium and alcohol intake) and medication adherence~* Providing free blood-pressure monitor and training to patients for home blood pressure measurement~* Encouraging lifestyle change and medication adherence~* Connecting patients through WeChat or telephone for group social support"
223998026|NCT02994771|DRUG|Lymfactin® [1 x 10E10 vp]|Lymfactin® \[1 x 10E10 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
223998027|NCT02994771|DRUG|Lymfactin® [1 x 10E11 vp]|Lymfactin® \[1 x 10E11 vp\] will be administered as a single dose via perinodal injection in a volume of 2 mL.
223381494|NCT07184840|DRUG|Intravenous Methylprednisolone (IVMP)|IVMP arm: 1000mg methylprednisolone x5d, oral prednisone 60mg, 5mg weekly decline + antibiotics
223381495|NCT07184840|DRUG|Complement protein C5 inhibitor|"IVMP+Eculizumab arm: eculizumab (900 mg) will be administered intravenously once per week for a total of four doses (days 1, 8, 15, and 22) in conjunction with IVMP and oral prednisone (60mg, 5mg weekly decline).~All enrolled patients will receive antibiotic prophylaxis against N meningitidis."
223381496|NCT07187089|DRUG|dupilumab|Administered per the protocol
223381497|NCT07185516|OTHER|Airway ultrasound indices|Tongue thickness, hyomental distance in neutral position (HMDRn), hyomental distance in extended position (HMDRe), ratio of hyomental distance in both positions (HMDR), thyromental distance (TMD), ratio of tongue thickness to thyromental distance (TT/TMD), epiglottis thickness \&pre-epiglottic space thickness
223381498|NCT07185516|OTHER|Clinical airway assessment|Mallampati grading and thyromental distance (TMD). The glottic structures displayed during laryngoscopy will be classified according to the Cormack-Lehane
223381499|NCT07187232|BEHAVIORAL|massage acupoints|The massage acupoints involved Zusanli (ST36), Fenglong (ST40), Zhongfu (LU1), Tanzhong (CV17), and Feishu (BL13). Each acupoint was massaged for 2 minutes, totaling 10 minutes per session. The routine care included chest physiotherapy and sputum suction as needed every 3 hours (PRN, Q3H).
223998028|NCT03313947|PROCEDURE|Ultrasound|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
223998029|NCT03313947|OTHER|Questionnaire|"The following 6 questions will be asked during the preoperative visit:~1. While sleeping, does your child snore more than half the time?~2. While sleeping, does your child always snore?~3. Have you ever seen your child stop breathing during the night?~4. Does your child occasionally wet the bed?~5. Did your child stop growing at a normal rate at any time since birth?~6. Is your child overweight"
223998030|NCT04471831|OTHER|Rehabilitation exercise protocol|"The exercise package will then be sent to them after securing video contact with the prospective participant. Only participants with smart phone that can receive the video package will be selected for this study.~Physiotherapy-Patients' Engagements At every morning after their prescribed drugs might have been served in the ward, the physiotherapist will call the participant for the exercises. The patient will be connected to the physiotherapist who is in his clinic (not in the isolation ward with the patients) through a WhatsApp or zoom video call. The physiotherapist will control the rhythm and pace of the exercises through the video interactions."
223998031|NCT04829097|COMBINATION_PRODUCT|Temozolomide|The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
223998032|NCT02304705|DRUG|Sildenafil|20 mg three times daily by mouth for 90 days
223998033|NCT02304705|DRUG|Placebo|One capsule three times daily by mouth for 90 days
223998034|NCT00032175|DRUG|capecitabine|
223998035|NCT00032175|DRUG|gemcitabine hydrochloride|
223998036|NCT01195948|DRUG|B27PD|
223998037|NCT01195948|DRUG|Placebo|Capsule with no active ingredients to mimic B27PD
223381500|NCT07187232|BEHAVIORAL|Routine care|The routine care included chest physiotherapy and sputum suction as needed every 3 hours (PRN, Q3H).
223381501|NCT07185997|DRUG|Firmonertinib|240 mg oral, daily firmonertinib tablet
223381502|NCT07185997|DRUG|EGFR-TKI inhibitor based on investigator's choice|osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet
223381503|NCT07184866|DRUG|Vitamin C|Intravenous Vitamin C, 25 mg/kg (maximum 1.5 g) every 6 hours for 5 days, administered in addition to standard medical treatment
223381504|NCT07184866|OTHER|Standard of Care (SOC)|Supportive and guideline-based management of ACLF with septic shock and AKI, including antibiotics, fluids, vasopressors, renal replacement therapy as required, and other standard therapies
223381505|NCT07185633|DRUG|Gecacitinib-Corticosteroid|Gecacitinib po. 50mg bid at least 28 days
223381506|NCT07185633|DRUG|Methylprednisolone sodium succinate|Methylprednisolone sodium succinate IV 2mg/kg/d.
223381507|NCT07185152|OTHER|mechanical vibration|Mechanical vibration was applied to babies randomized to the mechanical vibration group before and during the vaccination procedure.
223381508|NCT07185152|OTHER|Flick tapping|Before the vaccination procedure, the vaccination site was placed on the nail of the middle finger in the babies randomized to the flick tapping group, and then the vaccination was stimulated with a quick tap using the upper nail part of the middle finger.
223729744|NCT05320120|DRUG|0.9% saline solution nasal spray|0.9% saline solution nasal spray
223998038|NCT04263272|OTHER|Upper Body Circuit Training Program|16 week seated upper body exercise for persons with Spinal Cord Injuries. Participants will attend 2-3 exercise sessions a week, sessions have a mix of SCI community members and inpatients.
223998039|NCT04498637|OTHER|'Attitudes towards people with disability Scale'|The scale 'Attitudes towards people with disability' was completed by the participants. This scale allows the analysis of the attitudes towards disability trough a score whose lower values indicate a more negative attitude and higher values indicate more positive attitudes.
223998040|NCT04782440|OTHER|Telerehabilitaton|Patients will receive telerehabilitation sessions that include strengthening, stretching and range of motion exercises
223998041|NCT04782440|OTHER|Home exercise|Patients will be given a home-based exercise program without telerehabilitation supervision
223381509|NCT07187245|DEVICE|Reality PAWS Program via Meta Quest 3 VR|Reality PAWS is a mixed reality (MR) game that allows patients to interact with a virtual dog. It was developed at Children's Hospital Colorado to serve patients under isolation precautions who are unable to be visited by a facility dog in person. Patients can interact with the game through features such as walking the dog, providing commands, outfitting the dog, giving treats, playing fetch, petting the dog, and playing with others.
223998042|NCT01395459|BEHAVIORAL|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
223998043|NCT01395459|BEHAVIORAL|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
223998044|NCT00770029|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
223998045|NCT00770029|DRUG|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
223998046|NCT02124811|DRUG|Minocycline|
223998047|NCT00736268|BEHAVIORAL|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
223998048|NCT00736268|OTHER|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
223998049|NCT01941173|BIOLOGICAL|ziv-aflibercept|Given IV
223998050|NCT01941173|DRUG|leucovorin calcium|Given IV
223998051|NCT01941173|DRUG|irinotecan hydrochloride|Given IV
223998052|NCT01941173|DRUG|fluorouracil|Given IV
223998053|NCT02535975|DRUG|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
223998054|NCT02535975|DRUG|Placebo|Tablets placebo PO three times a day for 24 weeks
223998055|NCT02092597|DRUG|Exenatide|
224123390|NCT04886622|DRUG|DT2216|DT2216 will be administered by intravenous infusion
224123391|NCT04075266|DRUG|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
224295537|NCT01111019|DRUG|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
223998056|NCT02092597|DRUG|Linagliptin|
223998057|NCT02092597|DRUG|Gliclazide|
223998058|NCT03435445|BEHAVIORAL|Online platform group|The online platform has social network, gamification and short-text sessions.
223998059|NCT03435445|BEHAVIORAL|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
223998060|NCT03435445|BEHAVIORAL|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
223998061|NCT02771821|OTHER|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
223998062|NCT04941599|DRUG|2-Hydroxybenzylamine|2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
223998063|NCT04941599|OTHER|Placebo|Placebo 250 mg three tabs TID (po) for 6 weeks.
224123392|NCT00629694|PROCEDURE|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
224123393|NCT00629694|PROCEDURE|A-M|adenoidectomy and myringotomy alone
224295538|NCT02429141|PROCEDURE|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
224295539|NCT02429141|PROCEDURE|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
224295540|NCT01524302|DRUG|Ceftaroline|600 mg Q12h
223381510|NCT07187206|DEVICE|FETO, Fetal Endoluminal Tracheal Occlusion|Fetal Endoluminal Tracheal Occlusion with Balloon placement for fetuses with congenital diaphragmatic hernia
223381511|NCT07185802|BIOLOGICAL|PRP injection|Ultrasound guided intraarticular PRP is given to the patient with partial ACL tear
223381512|NCT07185802|OTHER|conventional conservative method (physical therapy, functional bracing, lifestyle modification)|conventional conservative method (physical therapy, functional bracing, lifestyle modification)
223381513|NCT07186283|DRUG|CBD soft-gel capsules 600 mg|600 mg
223998066|NCT03688165|DEVICE|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
223998067|NCT03688165|OTHER|Traditional Over-ground Gait Training|Traditional treatment for gait training consists in any conventional technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids.
223998068|NCT06484829|DRUG|Purinostat Mesylate 4 mg/m2|4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
223998069|NCT06484829|DRUG|Purinostat Mesylate 6 mg/m2|6 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
223998070|NCT06484829|DRUG|Purinostat Mesylate 8.4 mg/m2|8.4 mg/m2 Purinostat Mesylate + 4mg Pomalidomide + 20mg Dexamethasone.
223998071|NCT05751278|DEVICE|ERBECRYO® 2 Cryosurgical Unit and Accessories - K190651|ERBE 1.1mm flexible single-use cryoprobe with oversheath
223998072|NCT05751278|DEVICE|Radial Jaw 4 Pulmonary Biopsy Forceps|Radial Jaw 4 Pulmonary Biopsy Forceps Standard Capacity for 2mm endoscope
223381514|NCT07186283|DRUG|CBD soft-gel capsules 900 mg|900 mg
223381515|NCT07186283|DRUG|Epidyolex|25 mg/kg
223381516|NCT07185269|DRUG|626|626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.
223381517|NCT07185269|DRUG|626|626 subcutaneous (SC) injection.
223381518|NCT07185269|DRUG|Placebo|Placebo subcutaneous (SC) injection.
223381519|NCT07187076|BEHAVIORAL|body awareness|"Body Awareness Therapy (BAT) is a somatic-based, movement-centered therapeutic approach that aims to improve individuals' physical, emotional, and psychological well-being by enhancing conscious awareness of bodily sensations, posture, breathing, movement, and internal states.~Originating from Scandinavian physiotherapy models - particularly the work of Berit Heir Bunkan, Roxendal, and Dropsy - BAT integrates principles from:~Proprioceptive neuromuscular retraining~Mindfulness-based movement~Sensorimotor integration~Psychomotor physiotherapy~BAT is not simply a set of physical exercises, but a neuropsychophysical method designed to promote:~Postural control and alignment~Somatic grounding and bodily coherence~Emotional regulation through movement~Enhanced interoception (awareness of internal bodily states)"
223381520|NCT07185893|DRUG|Human Interleukin-11|Human Interleukin-11 for Injection (rhlL-11) 25 - 50 μg/kg, subcutaneous injection, once a day, for at least 7 - 10 days.
223381521|NCT07185893|DRUG|Romiplostim N01|Administer Romiplostim N01 subcutaneously in the abdominal area. The initial dose is 3 μg/kg, once a week. The subsequent dose will be adjusted according to the patient's platelet count
223381522|NCT04569409|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to Diabetic Wagner grade 2 Foot Ulcer
223381523|NCT04569409|PROCEDURE|Vehicle Sheet|Application of Vehicle sheet to Diabetic Wagner grade 2 Foot Ulcer
223381524|NCT03712605|OTHER|Best Practice|Receive standard of care observation
223998073|NCT05846646|DRUG|IMSA101|Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
223998074|NCT05846646|DRUG|Immune checkpoint inhibitor|1st infusion on Cycle 1 Day 2, and then thereafter as per product label
223998075|NCT05846646|RADIATION|PULSAR|1st day of Cycles 1, 2 and 3.
223381525|NCT03712605|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223381526|NCT03712605|PROCEDURE|Computed Tomography|Undergo PET-CT or CT
223381527|NCT03712605|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223381528|NCT03712605|BIOLOGICAL|Pembrolizumab|Given IV
223381529|NCT03712605|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223381530|NCT03712605|RADIATION|Radiation Therapy|Undergo radiation therapy
223998076|NCT06522204|DRUG|%5 Dextrose|All the patients will receive oral 3mL/kg 5%Dextrose
223998077|NCT04611009|BEHAVIORAL|motor training|In the sensorimotor training program task-specific and non-task specific aspects will be combined. It will start with assignments to improve general finger and wrist movements. After four weeks more specific writing exercises will be added.
223998078|NCT04611009|BEHAVIORAL|mindfulness exercises|The awareness training will contain mindfulness exercises. The goal is to consciously experience the here and now in sensual perception of oneself and the environment.
223381531|NCT01290302|DRUG|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m\^2 per day on days 1 and 2 of a treatment cycle
223381532|NCT01290302|DRUG|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m\^2 per day on days 1 and 2 of a treatment cycle
224138426|NCT01523561|BEHAVIORAL|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
224138427|NCT02709928|DRUG|TD-0714|
223381533|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA ≥1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 milligrams per square meter (mg/m\^2) (BSA=0.43-0.50 m\^2).
223381534|NCT04589845|DRUG|Entrectinib|Adults and pediatric participants with a BSA ≥ 1.51 m\^2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m\^2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m\^2) or 300 mg/day (BSA=0.81-1.10 m\^2) or 200 mg/day (BSA=0.51-0.80 m\^2) or 300 mg/m\^2 (BSA=≤0.50 m\^2).
223381535|NCT04589845|DRUG|Alectinib|Alectinib will be administered orally BID with food at a dosage of 600 mg (four 150-mg capsules).
223381536|NCT04589845|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged ≥18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
223381537|NCT04589845|DRUG|Ipatasertib|For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants ≥35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
223998079|NCT05504954|BEHAVIORAL|IMARA-SA (intervention group)|The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
223381538|NCT04589845|DRUG|Trastuzumab emtansine|Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
223381539|NCT04589845|DRUG|Inavolisib|GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
223381540|NCT04589845|DRUG|Belvarafenib|Belvarafenib will be administered at a dose 400 mg, PO, BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
223381541|NCT04589845|DRUG|Pralsetinib|Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
224295541|NCT01524302|DRUG|Levofloxacin|750 mg QD
223381542|NCT04589845|DRUG|Divarasib|Divarasib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric participants. A treatment cycle consists of 3 weeks (21 days).
223381543|NCT04589845|DRUG|Camonsertib|Camonsertib will be self-administered by participants orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
223381544|NCT06037018|BIOLOGICAL|CC312|Doses from 0.3 to 45 µg/dose by intravenous infusion
223381545|NCT06497842|BEHAVIORAL|High-effort resistance exercise training|Six sets per exercise, 8 repetitions per set.
223381546|NCT06497842|BEHAVIORAL|Low-effort resistance exercise training|Three sets per exercise, 4 repetitions per set.
223998080|NCT05504954|BEHAVIORAL|Health promotion control group|The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
224138428|NCT02709928|DRUG|Placebo|
224138429|NCT01866761|PROCEDURE|Periodontal treatment|
224295542|NCT00986453|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
223381547|NCT06952868|DRUG|Drug: B10 L-BPA Injection|"The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.~This single arm of the study is designed to evaluate the therapeutic efficacy of BNCT, wherein patients receive B10 L-BPA administration followed by neutron irradiation."
223381548|NCT03701282|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223381549|NCT03701282|PROCEDURE|Bone Marrow Biopsy|Undergo biopsy
223381550|NCT03701282|PROCEDURE|Computed Tomography|Undergo CT
223381551|NCT03701282|DRUG|Ibrutinib|Given PO
224295543|NCT00986453|PROCEDURE|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
223381552|NCT03701282|BIOLOGICAL|Obinutuzumab|Given IV
223381553|NCT03701282|OTHER|Quality-of-Life Assessment|Ancillary studies
223381554|NCT03701282|DRUG|Venetoclax|Given PO
223381555|NCT06031441|DRUG|RO7566802|RO7566802 solution for infusion will be administered as specified in each treatment arm.
223381556|NCT06031441|DRUG|Atezolizumab|Atezolizumab solution for infusion will be administered as specified in each treatment arm.
223381557|NCT05160129|DEVICE|Selective focal stimulation of ALIC-pathways|DBS will be applied selectively to different electrode contacts/ segments to evaluate clinical, behavioral, and electrocortical responses of specific pathways within the ALIC.
223381558|NCT06517316|DEVICE|Nelfilcon A plano cosmetic contact lenses|Commercially approved colored contact lenses worn to alter or enhance the apparent color of the eye. Plano contact lenses do not contain visual correction and are worn for cosmetic purposes only.
223998081|NCT02601118|OTHER|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
223998082|NCT01634386|DRUG|Torrent's Quetiapine Fumarate Tablets|
223998083|NCT00513188|BIOLOGICAL|denileukin diftitox|
223998084|NCT00513188|DRUG|cyclophosphamide|
223998085|NCT00513188|DRUG|cytarabine|
223998086|NCT00513188|DRUG|doxorubicin hydrochloride|
223998087|NCT00513188|DRUG|leucovorin calcium|
223998088|NCT00513188|DRUG|methotrexate|
223998089|NCT00513188|DRUG|prednisone|
223998090|NCT00513188|DRUG|vincristine sulfate|
223998091|NCT00513188|GENETIC|protein expression analysis|
223998092|NCT00513188|OTHER|flow cytometry|
223998093|NCT00513188|OTHER|laboratory biomarker analysis|
223998094|NCT03260478|PROCEDURE|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
223998095|NCT01969682|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
223998096|NCT01969682|DRUG|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
223998097|NCT04684823|DEVICE|Patch Cap|A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.
223998098|NCT04684823|DEVICE|Patch App|A mobile app that is used with Patch Cap to track adherence to medication regimen
223998099|NCT00876564|OTHER|Trauma patients|
223998100|NCT05310422|DRUG|Tivanisiran sodium ophthalmic solution|1 drop in the affected eye(s) once daily
223998101|NCT05310422|DRUG|Vehicle ophthalmic solution|1 drop in the affected eye(s) once daily
223998102|NCT05352841|DIAGNOSTIC_TEST|Salivary sample analysis|The status of caries will be recorded based on the WHO recommendation, 1997. The children will then be divided into two groups depending on whether they are diagnosed caries (group I) or without carious lesions (group II).After the examination, unstimulated saliva will be collected for analysis (subject to all conditions in proper sampling and without contamination) in a sterile disposable laboratory container with a wide opening and lid. Patients will be asked to tilt their head slightly and not swallow or move their tongue or lips during the collection period. Instructions will be given to accumulate saliva in the mouth for a maximum of 2 minutes and he or she will be asked to spit the accumulated saliva into the receiving court. About 1 ml of unstimulated saliva will be collected.
224295544|NCT01583218|DRUG|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
223381559|NCT06242678|DEVICE|SCS trial lead|placement of spinal cord stimulator trial leads to see if effective in the management of symptoms associated with stiff person syndrome
223998103|NCT05272943|OTHER|Oxgen saturation measurement with validated pulse oximetry|Oxgen saturation will be measured with validated pulse oximetry
224295545|NCT01583218|DRUG|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
223381560|NCT05843500|OTHER|Survey|Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.
223998104|NCT05272943|OTHER|Oxgen saturation measurement with smart electronics|Oxgen saturation will be measured with smart electronics
223998105|NCT01757197|DRUG|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
223998106|NCT04302688|OTHER||
223998107|NCT00001534|DRUG|Losartan|
223998108|NCT02894996|DRUG|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
223998109|NCT05162274|DRUG|Lazertinib(G001)|Current formulation
223998110|NCT05162274|DRUG|Lazertinib(G002)|New formulation
223998111|NCT04984005|BEHAVIORAL|Low intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.
223998112|NCT04984005|BEHAVIORAL|Moderate intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.
223998113|NCT04984005|BEHAVIORAL|Intermittent high intensity exercise training|The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
223998114|NCT04200222|DIAGNOSTIC_TEST|cadmium, lead and vanadium measurements and compare|"The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1\. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363."
223998115|NCT00150878|OTHER|Conditioning therapy|Preparation before allogeneic transplantation
223998116|NCT04200001|OTHER|Quality of life|"The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ-BR23~* EORTC SHQ-C22~* CUPIDON 2 specific questionnaire"
223998117|NCT03674775|OTHER|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
223998118|NCT02523547|DRUG|Cavir|0.5mg/day
223998119|NCT02523547|DRUG|Baraclude|0.5mg/day
223998120|NCT00776906|DEVICE|Advance® 18PTX® Balloon Catheter|
223998121|NCT00776906|DEVICE|Advance® 18LP Balloon Catheter|
224295546|NCT05514236|OTHER|Virtual Reality Therapy|"Participants will be given the virtual reality device (a headset) with immersive video content for use during the hysteroscopy. Designated moving objects with sound will be broadcasted on the screen to the participant in this group.~Participant can adjust the volume of the sound according to her comfort."
223729745|NCT05241496|DIAGNOSTIC_TEST|The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration|Lidocaine in spray form is a simple and convenient local anaesthetic with minimal adverse effects and is often used in dentistry for oral mucosal anaesthesia during minor surgical interventions. The spray form may provide easy application and better patient acceptance than other forms of lidocaine administration. Lidocaine acts by stabilization of the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action (Hüseyin Aksoy et al. ,2016 ) .
223998122|NCT03030313|DEVICE|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
223381561|NCT05426525|DRUG|Empagliflozin|Participants will take 10mg empagliflozin per day for 2 weeks. Absent contraindications, dosing will be increased to 25 mg empagliflozin per day for the next 11 weeks.
223381562|NCT05426525|DRUG|Multivitamin-Placebo|Participants will take 1 multivitamin per day for 13 weeks.
223381563|NCT04546009|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
223998123|NCT05435950|DEVICE|Sono-Intruments|"Spirecut's single use, pre-CE Sono-Instruments (SI) allow the percutaneous treatment of Carpal Tunnel (CT) syndrome and Trigger Finger/thumb (TF) under sonography (instead of open or endoscopic approach).~Two models will be assessed:~* The Carpal Tunnel Sono-Instrument® (CT-SI), for CT syndrome release, by progressively cutting the transverse carpal ligament.~* The Trigger Finger Sono-Instrument® (TF-SI), for TF release by progressively cutting the A1 annual pulley."
223998124|NCT05530577|DRUG|Semaglutide|Semaglutide (subcutaneous)
223998125|NCT05530577|DRUG|Sham/placebo|Sham subcutaneous injection
223998126|NCT06799936|OTHER|"CKD Jumpstart- Tips priming intervention"|"The intervention includes 2 components:~1. Patient Priming: Patients will receive the Jumpstart CKD- Tips communication priming tool within 1 week before and on the day of a target clinic visit, which includes surveys on (i) Understanding of illness and possible treatment options, (ii) Readiness for treatment discussion and information preferences, (iii) Health priorities, goals, and preferences (iv) Preferred roles in decision-making. The Jumpstart CKD- Tips patient priming sheet includes (a) A summary of their survey responses that can be shared with their healthcare team, and (b) Tips on communication with clinician during upcoming visit.~2. Clinician Priming: Within 1 week before and on the day of the target clinic visit, clinicians will receive a Jumpstart CKD- Tips clinician priming sheet which contains (a) An abstracted version of the patients' survey responses and (b) Communication tips tailored to the patient's responses based on Vitaltalk curricula materials."
223998127|NCT06405763|PROCEDURE|Snodgrass repair|"A relaxing incision is made in the midline by using scalpel or scissors~A 6 F stent is passed into the bladder. The neourethra is closed"
224123394|NCT04548089|BEHAVIORAL|Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC)|Each Mindful-Compassion Art Therapy for Dementia Care (MCAT-DC) will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific intervention structure include: Week 1 - Empowering Self-Care: Introduction to the science of stress, self-care, burnout, as well as the arts and mindfulness to cultivate resilience; Week 2 - Reflective Caregiving: Reflection of caregiving experiences that demonstrates strengths and challenges; Week 3 - Understanding Loss: Introduction to the science of loss, how grief can impair hope and wellbeing, and how self-compassion can help transform suffering into blessings.; Week 4 - Meaning Reconstruction: Reflection on caregiver identities, to elicit the lessons and wisdoms learnt, and to create renewed meaning to sustain their caregiving journeys. Guided mindfulness mediation will also be professionally recorded to form a daily take-home mindfulness mediation exercise for participants, each exercise will last 10-20 minutes.
224123395|NCT06150573|DRUG|Test Dentifrice|Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.
224123396|NCT06150573|DRUG|Reference Dentifrice (Aquafresh Cavity Protection)|Dentifrice containing 1150 ppm fluoride as sodium fluoride.
224123397|NCT05264298|OTHER|VIRTUAL|At the time of discharge, stroke survivors in the VIRTUAL arm will receive a package containing an iPad and a remote BP monitoring device that allows transmission of BP to the study team.The first telehealth visit will occur 7-14 days after discharge. Patient will be counseled on the importance of BP monitoring, salt reduction, and the importance of diet and exercise for stroke prevention. Medications, side effects and interactions will be reviewed. The social worker will refer the patient to specific resources according to social needs abd patient will be referred to a primary care provider if they do not have one. Subsequent video visits will be 1-month (30 days +/- 7) , 3 months (90 days +/- 14), and 5 months (150 days +/- 14) days after enrollment.
223381564|NCT04546009|DRUG|Giredestrant-matched Placebo|Giredestrant-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
223381565|NCT04546009|DRUG|Letrozole|Letrozole 2.5 milligrams (mg) is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
223381566|NCT04546009|DRUG|Letrozole-matched Placebo|Letrozole-matched placebo is taken orally once per day on Days 1-28 of each 28-day treatment cycle.
223381567|NCT04546009|DRUG|Palbociclib|Palbociclib 125 mg is taken orally once per day on Days 1-21 of each 28-day treatment cycle.
223381568|NCT04546009|DRUG|LHRH Agonist|Only premenopausal/perimenopausal and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
223381569|NCT01968772|OTHER|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
223729746|NCT02205814|DRUG|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
223729747|NCT02205814|DRUG|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
223729748|NCT02205814|DRUG|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
223729749|NCT02205814|DRUG|Placebo comparator|Single intra-articular injection of placebo
223998128|NCT06405763|PROCEDURE|Snodgrass repair with graft|A relaxing incision is made in the midline by using scalpel or scissors In grafted Snodgrass repairA free graft was measured and harvested from the inner prepuce and was defatted and sutured onto the incised urethral plate The graft was sutured overlying the incision line A 6 F stent is passed into the bladder. The neourethra is closed
223998129|NCT06088498|BEHAVIORAL|Updating Existing Smartphone App|Participants will be asked to use a recently developed study smartphone application to reduce cravings to smoke for a 5-week period. Through the app, participants will be exposed to smoking extinction trials daily. Participants will be encouraged and reminded to complete 2-5 extinction sessions per day. Each session will present 3-8 cues, and each cue will be presented for 20-40 seconds (average amount of extinction per day will be about 10 minutes). Participants will be encouraged to conduct the extinction sessions when high cravings are expected.
223998130|NCT06088498|BEHAVIORAL|Quitline Services|Quitline coaches use cognitive behavioral therapy, reinforcement, and principles of self-efficacy to promote effective behavior change. The quitline approach includes 5 key elements: setting a quit date, coping with triggers, effectively using medications, tobacco proofing, and social support. Individuals who enroll in the quitline's multi-call program receive phone calls and NRT.
223998131|NCT06088498|BEHAVIORAL|Quitline Services and Smartphone App|In addition to quitline services, participants will download a study app that will allow them to track smoking urges and abstinence. After 48 hours of self-reported abstinence, those in the intervention group will be exposed to smoking extinction trials through the study smartphone app.
223998132|NCT01947569|BIOLOGICAL|Biological|
223998133|NCT00460395|PROCEDURE|Surgery|
223998134|NCT00460395|PROCEDURE|Stereotactic radiosurgery|
223381570|NCT00784004|OTHER|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~1. Breathing in through the nose only and out through the mouth only~2. Breathing in through the mouth only and out through the nose only~3. Breathing in and out through the nose only~4. Breathing in and out through the mouth only"
223381571|NCT02018991|PROCEDURE|Everolimus-Eluting Stent (EES)|Patients treated with EES
223381572|NCT02018991|PROCEDURE|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
223381573|NCT02018991|PROCEDURE|Biolimus-Eluting-Stent (BES)|Patients treated with BES
223998135|NCT04210427|DRUG|Polyethylene Glycol 3350|All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.
223998136|NCT04210427|DEVICE|SmartPill Motility System & PillCam Patency Capsule|Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.
223998137|NCT01503762|OTHER|Mirror therapy|mirror therapy
223998138|NCT01503762|OTHER|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
223998139|NCT01482936|DRUG|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
223998140|NCT05422183|DRUG|Envafolimab|400mg，sc，d1，Q3W
223998141|NCT05422183|DRUG|Lenvatinib|8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
223381574|NCT04037280|OTHER|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
223381575|NCT02881398|DEVICE|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
223998142|NCT05422183|DRUG|VP-16|50 mg/d, po,d1-14，Q3W
223998143|NCT01174446|BIOLOGICAL|BAX 326|"* Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~* Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~* Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
223998144|NCT01174446|BIOLOGICAL|BeneFIX|"* Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~* BeneFIX only used in Part 1 of this study.~* Study Part 2 and 3 only utilized BAX326"
223998145|NCT02845232|OTHER|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
223998146|NCT00743977|DRUG|Phenazopyridine HCl|100mg tablet in fasting state
224295547|NCT05514236|OTHER|Music Therapy|"Participants will be given a headphone playing either classical light music or 'POP' songs according to their option during the hysteroscopy.~Participant can adjust the volume of the music according to her comfort."
223381576|NCT02881398|OTHER|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
223381577|NCT02905240|DEVICE|nSTRIDE APS|single intra-articular injection
223381578|NCT02905240|DEVICE|Saline|single intra-articular injection
223381579|NCT03758664|DRUG|ICP-192|"Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified 3+3 dose escalation scheme,"
223381580|NCT05797181|OTHER|medical nutrition therapy in kidney diseases|Planning and implementation of diets containing high protein, low potassium, low phosphorus, personalized adjusted carbohydrates
223381581|NCT04802486|OTHER|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
223381582|NCT04346797|DRUG|Eculizumab|"Intravenous administration as follows:~Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22"
223381583|NCT00048373|DRUG|Etanercept|
223381584|NCT03912363|OTHER|Rotating fluids protocol|"IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 100 mg/dL or less: IV fluids with 5% dextrose~* For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~* For blood glucose \> 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)"
223381585|NCT03912363|OTHER|Insulin infusion protocol|"Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~* For blood glucose \< 80 mg/dL: No insulin AND IV fluids with 5% dextrose~* For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~* For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~* For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~* For blood glucose \> 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose"
223381586|NCT04009148|OTHER|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
223381587|NCT06419907|BEHAVIORAL|Type 2 Live Well (structured diabetes self management education programme)|Structured diabetes self management education programme designed to support those with type 2 diabetes self care and prevent long term associated complications.
223381588|NCT04273061|DRUG|Atezolizumab|1200 mg by intravenous infusion every 3 weeks as tolerated
223381589|NCT04253379|DIAGNOSTIC_TEST|Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills|Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
223381590|NCT06553209|BIOLOGICAL|CM512|CM512 injection
223381591|NCT06553209|DRUG|Placebo|Placebo
223381592|NCT02311933|DRUG|Endoxifen Hydrochloride|Given PO
223998147|NCT04706897|DRUG|Dexmedetomidine, ketamine and lidocaine|A loading infusion of syringe (B) containing the a mixture \[dexmedetomidine (2 µg/ml), ketamine (0.5 mg /ml) and lidocaine (4 mg /ml)\] was started at rate of 0.2 ml/kg/h ten minutes before induction. Then anesthesia was induced with 2 mg/kg IBW of propofol, patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (D) containing normal saline (as masking for fentanyl in the control group).
223998148|NCT04706897|DRUG|Normal saline|A loading infusion of the 50 ml syringe (A) containing normal saline was started at rate of 0.2 ml/ kg/hr ten minutes before induction (as masking for mixture in group S). Then anesthesia was induced with 2 mg/kg ideal body weight (IBW) of propofol , patients were intubated with the aid of 0.5 mg/kg IBW atracurium and received 0.1ml/kg from syringe (C) containing fentanyl (1mic/kg of IBW).
223998149|NCT06287645|DIAGNOSTIC_TEST|Color Fundus Photography/Non-Mydriatic Opthalmic Cameras|Participants will undergo retinal imaging by fundus camera. Three specialists will independently grade images for common retinal disorders like Diabetic Retinopathy. Final grading decisions will be unanimous among the specialists.
223998150|NCT05102318|PROCEDURE|Direct Pulp Capping|Direct Pulp Capping
223998151|NCT05102318|PROCEDURE|Partial Pulpotomy|Partial Pulpotomy
223998152|NCT05102318|PROCEDURE|Pulpotomy|Pulpotomy
223998153|NCT03374943|DRUG|KB004|KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
223381593|NCT02311933|OTHER|Laboratory Biomarker Analysis|Correlative studies
223381594|NCT02311933|OTHER|Pharmacological Study|Correlative studies
223381595|NCT02311933|DRUG|Tamoxifen Citrate|Given PO
223381596|NCT03431688|DRUG|PAM|treatment with PPI, metonidazole, amoxicillin
223381597|NCT03431688|DRUG|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
223381598|NCT06085222|BEHAVIORAL|Emotional Engagement Distress Tolerance Intervention|2.5 hour computerized intervention with smart phone support focused on building tolerance of emotional distress
223381599|NCT06085222|BEHAVIORAL|Health Education Intervention|2.5 hour computerized intervention with smart phone support focused on building healthy habits that support stress management
223381600|NCT05398809|DRUG|Ruxolitinib|Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).
223381602|NCT05420766|BEHAVIORAL|Shortened Sleep|In this experimental condition, children go to bed 90 minutes later than their typical bedtime during Week 2 of the 4-week protocol.
223381603|NCT05420766|BEHAVIORAL|Stabilized sleep|In this control condition, children go to bed at their usual time throughout the 4-week protocol.
223381604|NCT05516537|BEHAVIORAL|Guidelines for Exercise in Multiple Sclerosis (GEMS)|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training.
223381605|NCT05516537|BEHAVIORAL|FLEX Stretching and Toning Program|Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training.
223998154|NCT02815020|OTHER|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
223381606|NCT06001814|BEHAVIORAL|One-Mind One-Heart|One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
223381607|NCT06001814|OTHER|Education|Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
223381608|NCT06520488|DRUG|HRS-4642|Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG
223381609|NCT06120764|OTHER|guided imagery|The children in the experimental group will listen to the first part of the 'Guided Imagery CD' prepared by the Turkish Psychological Association for relaxation 30 minutes before the chemotherapy infusion starts. The suggestions given in the first part of the CD will help the patients relax and focus their attention on their breathing. Patients will be positioned in a supine or semi-fowler position and will listen to the CD with headphones from a laptop. Once the chemotherapy infusion starts, relaxing light background music with the sound of a river or sea will be played based on the patients' preference, and imagery will be applied to the patients. Patients will be encouraged to think of various images, such as imagining that the treatment is over, visualizing themselves as much healthier and recovering quickly, returning to their old life, and doing whatever they want to do first after recovery. If there is an object, person, event, situation, or food that will make them feel good,
223381610|NCT06069700|OTHER|Non-pharmacological Individualized rehabilitative therapy|Treatments will be standardized but components of the treatments will be individualized to the participants based on what subgroup they're classified into at baseline based on their initial clinical examination and self-reported dominant impairment. \*Physiological group - Participants will receive supervised sub-symptom aerobic exercise 20-minutes twice per week and mindfulness-based training 20-minutes twice per week. \*Cervical group - Participants will receive physical therapy to the cervical spine. Physical therapy will include soft tissue therapy directed to the cervical myofascial tissues, and graded cervical spine facet mobilizations. \*Vestibulo-Ocular group - Patients classified to vestibulo-ocular subgroup will receive bi-weekly 30-minute individualized oculomotor, vestibular and balance exercises including adaptation exercises, gaze stability exercises, visual-vestibular integration exercises, habituation exercises, static and dynamic balance exercises.
223729750|NCT00143403|DRUG|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
223998155|NCT03676478|OTHER|delayed start enteral support @ POD5|"instead of caloric suppletion, participants will receive mls of water over the jejunostomy feeding tube daily equivalent to the rate of increase of infusion of the control group as to preserve the same amount of fluid administration through the GI route as the control group.~This is continued until POD5 12.00h when enteral feeding is started according to the incremental regimen as defined for the SOC group. During the intervention, water is used as to maximize stimulation of the enteral route, however without giving nutritional support and need to prolong iv-infusion for maintaining the fluid balance in the participants. Also subjects in this interventional arm will end up with a caloric suppletion of 1.000kCal/24h by the end of postoperative day 7."
223729751|NCT00143403|DRUG|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
223729752|NCT00514540|DRUG|Docetaxel|75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.
223998156|NCT03354936|BIOLOGICAL|Blood sample|Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research
223998157|NCT04949256|BIOLOGICAL|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
223998158|NCT04949256|DRUG|Lenvatinib|8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
223998159|NCT04949256|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
223998160|NCT04949256|DRUG|5-FU|4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
223998161|NCT04949256|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
223998162|NCT04949256|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
223998163|NCT04949256|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
223998164|NCT04949256|DRUG|Paclitaxel|175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
223998165|NCT05736172|BEHAVIORAL|Pain neuroscience grupal education|The face to face education group will be carried out with a physiotherapist addressing various topics in the neurosciences of pain. In the active control group, information will only be provided in written form for the individual patient to read.
223998166|NCT04634474|BEHAVIORAL|Suction|Is DAS an accurate pain descriptor for every application in intensive care unit?;. This question guides the study. This study was planned with the thought that the result may be misleading in applications such as eye care and aspiration that will trigger reflex movements in intensive care. In addition, creating new evidence on whether endotracheal suction is a painful application is the basis of the application.
223998167|NCT06169462|PROCEDURE|PENG block|Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
223998168|NCT06169462|PROCEDURE|PENG block+ SIFCB|Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
223998169|NCT04964856|BEHAVIORAL|ERAS exercise|Take ERAS exercise twice a day from hospitalization to 30 days after surgery
223998170|NCT04964856|BEHAVIORAL|No ERAS exercise|Don't take ERAS exercise in perioperative period
223998171|NCT02039245|DRUG|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
223998172|NCT00480142|DRUG|Oxycodone 10 mg|
223381611|NCT06069700|OTHER|Non-pharmacological Usual care therapy|"All participants in the active control group will receive 'usual care', (twice a week for 6 weeks), which will consist of reassurance and psychoeducation via the bio-psycho-social model on understanding persistent symptoms, including advice on adaptive illness behaviours, such as gradually resuming premorbid activities and avoiding excessive rest and all-or-nothing behaviour. Additionally, participants will be afforded weekly 20-minute supervised progressive sub-symptom aerobic exercise sessions at the KITE clinic under the supervision of study coordinator NM. They will be instructed to also perform daily 20-minutes of subsymptom aerobic exercise outside the supervised exercise sessions."
223381612|NCT06436313|OTHER|Educational Sessions|"Two online educational sessions will be organized before DBS surgery. These will be scheduled between consultation with the neurologist and the consultation with the neurosurgeon. Each virtual session will last about 1 hour. Patients can login from home, together with their caregivers. The virtual sessions will be held on MS Teams virtual platform.~One of the sessions will include a DBS patient where patients will have the opportunity to ask peer-to-peer questions. The session includes testimonials from patient before and after their surgery.~The second session (about two weeks later) is a summary presentation, a quiz and time for Q\&A. During one of the sessions (first or second), a DBS patient (who has been implanted) can be invited to participate togive the attendees the opportunity to ask peer-to-peer questions. The quiz contains questions to assess the patients' knowledge of DBS."
223381613|NCT06565988|DEVICE|Decoria Voluma|"Decoria® Voluma medical device is a sterile, single use Hyaloronic acid based dermal filler intended for aesthetic use, provided in the form of a nonpyrogenic, viscoelastic gel. It is composed of highly purified sodium hyaluronate of high molecular weight, dissolved in a physiological buffer at pH 6.0-7.5. The sodium hyaluronate is derived from microbial fermentation and is stabilized by crosslinking with the chemical agent BDDE (1,4 Butanediol Diglycidyl Ether).~Decoria® Voluma dermal fillers are injected into dermal tissue for the correction of midface volume deficit by tissue augmentation in cheek region, supporting overlying tissue to shape facial contours to desired level of correction. This is possible due to the capacity of HA to attract and bind large amounts of water, forming a viscous gel.~Appropriate injection volume for the cheek region(s) will be determined by the Treating investigator according to IFU."
223381614|NCT04980027|DRUG|Insulin glargine (U300)|Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
223381615|NCT03757793|DEVICE|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
223381616|NCT04199624|DRUG|Omeprazole 20mg|Omeprazole twice daily x 5 days
223381617|NCT04199624|DIETARY_SUPPLEMENT|Vitamin C|Ascorbic acid x 1 on day 5
223381618|NCT02586688|DEVICE|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
223998173|NCT02417649|BIOLOGICAL|Placebo|"1. The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
223998174|NCT02417649|BIOLOGICAL|Ismigen|"1. The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~2. Three months of rest, according to the indications, will be allowed.~3. A second cycle (the same as point 1.) will be performed~4. A second three month rest (according to point 2.) will be provided."
223998175|NCT05690997|OTHER|Intensive treatment|If the mean home SBP preceding clinic follow-up is \>130mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<120mmHg, BP lowering treatment will be stepped down, until the target SBP of 120-129mmHg is achieved, or symptoms of hypotension prevent treatment to be further intensified.
223998176|NCT05690997|OTHER|Standard treatment|If the mean home SBP preceding clinic follow-up is \>140mmHg, BP lowering treatment will be stepped up, and if the mean SBP preceding clinic follow-up is \<130mmHg, BP lowering will be stepped down, until the target SBP 130-140mmg is achieved or symptoms of hypotension prevent treatment being intensified.
223998177|NCT06147492|PROCEDURE|transanal total mesorectal excision|a transanal bottom-up approach was employed for the TME procedure
223998178|NCT06147492|PROCEDURE|Laparoscopic Total Mesorectal Excision|Laparoscopic Total Mesorectal Excision
223998179|NCT05171790|DRUG|QL1706 injection|5 mg/kg, IV, Q3w
224295548|NCT04690036|DRUG|toripalimab injection|when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.
223381619|NCT02586688|DEVICE|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
223381620|NCT05728034|BEHAVIORAL|Injectable PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about injectable PrEP), visit those pages, and return to the main results page.
223381621|NCT05728034|BEHAVIORAL|Oral PrEP information|Participants will be able to click on the links on the search results page (which reflect the five messaging strategies about oral PrEP), visit those pages, and return to the main results page.
223381622|NCT05253053|DRUG|TT-00420|TT-00420 tablet will be administered orally once daily per protocol defined schedule.
223998180|NCT00804505|DEVICE|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
224295549|NCT01436565|DRUG|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
223998181|NCT00804505|DEVICE|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
224295550|NCT01436565|DRUG|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
223729753|NCT00514540|DRUG|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.
223729754|NCT00514540|DRUG|Etoposide|120 mg/m\^2 daily for 3 days of 21 day cycle.
223729755|NCT00514540|DRUG|Cisplatin|25 mg/m\^2 for 3 days of 21 day cycle.
223729756|NCT05505214|DRUG|Bacterial decolonization|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT.
223729757|NCT05505214|DRUG|Mometasone furoate 0.1% cream|Mometasone furoate 0.1% cream to be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
223998182|NCT02901769|OTHER|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
223998183|NCT02547272|PROCEDURE|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
224123398|NCT05264298|OTHER|Standard care|Participants randomized to standard care will receive an educational packet and a blood pressure monitor prior to hospital discharge. They will be contacted by a social worker to determine if they received their medications and appointments. The stroke practitioner will evaluate the patients at 7-14 days and then follow up according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities. The pharmacist will contact patients at 1-month (30 +/- 7 days) days over the telephone to review BP logs and will make recommendations to their primary care provider to adjust BP medications. Subsequent pharmacist calls will occur monthly until 6 months and recommendations for medication adjustments will be communicated to their primary care provider.
224123399|NCT04771806|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224295551|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for D-Dimer|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for D-dimer levels.
224295552|NCT04508036|DIAGNOSTIC_TEST|Withdrawal of blood samples for Fibrinogen|Blood samples are withdrawn at birth via cord blood and at postnatal 3rd and 7th days via umbilical catheter in order to test for Fibrinogen levels.
223729758|NCT05505214|DRUG|Bacterial decolonization and Mometasone furoate 0.1% cream|Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body. This regimen is conducted by the patient for 5 consecutive days prior to the start of RT and is repeated for an additional five days every other week continuing until either the development of moist desquamation or 2 weeks after the completion of RT. Also, mometasone furoate 0.1% cream will be applied twice a day to the irradiated area, starting on the first day of RT and continuing until either the development of moist desquamation or 2 weeks after the completion of RT
223729759|NCT02608710|DRUG|RDEA3170 4.5 mg|
223729760|NCT02608710|DRUG|RDEA3170 6 mg|
223729761|NCT02608710|DRUG|RDEA3170 12 mg|
223729762|NCT00433095|DRUG|Navelbine|
223998184|NCT00929253|DRUG|Suboxone|Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
223998185|NCT00929253|BEHAVIORAL|CRA|Computer-delivered Community Reinforcement Approach
223998186|NCT00929253|BEHAVIORAL|Therapy|Therapist-delivered therapy
223998187|NCT00929253|BEHAVIORAL|CM|Contingency management (vouchers) for providing a drug negative urine sample.
224123400|NCT04771806|OTHER|Neurocognitive Assessment|Undergo neurocognitive testing
224123401|NCT04771806|OTHER|Quality-of-Life Assessment|Ancillary studies
224123402|NCT04771806|OTHER|Questionnaire Administration|Ancillary studies
224295553|NCT04508036|DIAGNOSTIC_TEST|Echocardiographic Examination|At postnatal 3rd, 7th and 14th days, Ductus Arteriosus will be echocardiographically examined to obtain calculations and confirm status of ductal patency or closure.
224295554|NCT03521648|PROCEDURE|PAE|Prostatic artery embolization
224295555|NCT03521648|PROCEDURE|TURP|Transurethral resection of the prostate
223998188|NCT05518071|DRUG|CRGD-ZW800-1|Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
224295556|NCT03521648|PROCEDURE|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
224295557|NCT03168321|DRUG|IDP-123 Lotion|Tazarotene 0.045% Lotion
224295558|NCT03168321|DRUG|IDP-123 Vehicle Lotion|Vehicle Lotion
224295559|NCT05045352|DEVICE|echogenic needles for intravenous access|echogenic needles for intravenous access (subclavian vein) ultrasound guided procedure
224295560|NCT03983252|DRUG|[F-18]PBR06|PET radiopharmaceutical
224295561|NCT00375570|DRUG|ME-609|Topical treatment 5 times daily for 5 days
223729763|NCT00433095|DRUG|Herceptin|
223729764|NCT00433095|DRUG|Navelbine (oraly)|
223729765|NCT03530904|OTHER|mobilization|Early mobilization after CIED implantation
223729766|NCT05693441|OTHER|Active berry product|Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.
223729767|NCT05693441|OTHER|Reference berry-like product|Subjects should consume a reference product (isocaloric to active product, containing berry aromas and colouring but no actual berry compounds) daily during the 12 week intervention period.
223729768|NCT02523898|DRUG|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
223729769|NCT02523898|DRUG|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
223998189|NCT05518071|DEVICE|Intraoperative near-infrared fluorescence imaging|Intraoperative imaging will be performed with at least one of the following CE-marked near-infrared (NIR) fluorescence imaging systems: Quest Spectrum imaging platform (v2/3.0) for open-procedures, the Olympus or Karl-Storz system for the diagnostic laparoscopy or the Intuitive Surgical Da Vinci Xi (Firefly-mode) for minimally invasive robot-assisted procedures. With a NIR-imaging system a potential fluorescent signal of the tumor can be evaluated. Furthermore, the Quest Spectrum platform will also be used for evaluation of ex-vivo fluorescence of resected tissue on the back table (Back table imaging) and pathology department (ex-vivo imaging), which shall be performed during and after every procedure.
223381623|NCT05253053|DRUG|Combination Product: Atezolizumab|Atezolizumab would be administered via infusion on Day 1 of 21-day cycle
223998190|NCT03826524|DRUG|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
223998191|NCT03498469|BEHAVIORAL|Standardized reintegration package|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
223998192|NCT03498469|BEHAVIORAL|Enhanced reintegration package|Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
223998193|NCT03653767|DEVICE|Adjustable Furniture|The intervention will include adjustable school furniture.
223998194|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
223998195|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
223998196|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
223998197|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
223998198|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
223998199|NCT00847626|DRUG|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
223998200|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
223998201|NCT00847626|DRUG|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
223381624|NCT05253053|DRUG|Combination Product: Nab-Paclitaxel|Nab-Paclitaxel would be administered via infusion on Day 1 and 8 of 21-day cycle
223381625|NCT02454608|DRUG|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
223998202|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
223729770|NCT02523898|DRUG|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
223729771|NCT03987529|OTHER|sevoflurane|volatile anesthetic
223729772|NCT03987529|OTHER|propofol|intravenous anesthetic
223998203|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
223729773|NCT00376662|DRUG|Hormone Replacement Therapy and Etidronate|
223729774|NCT00230568|DRUG|Aricept|
223998204|NCT00847626|DRUG|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
223998205|NCT03959761|DRUG|Intraperitoneal (IP) nivolumab infusion|"Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~* Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~* Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~* Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions"
223998206|NCT03471546|BEHAVIORAL|Palliative Care|Initial consultation and follow-up with a palliative care provider
223998207|NCT06052527|OTHER|Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning|A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning
223998208|NCT05976776|BEHAVIORAL|The Childbirth and Parenthood Preparation Education|"The Childbirth and Parenthood Preparation Education program will be applied to the experimental group for a period of 1 month (each week, once a week in total four sessions)."
223998209|NCT05515354|OTHER|Timing of nicotine replacement therapy start date|Nicotine replacement therapy and abstinence from smoking are initiated at a specific period with regard to the menstrual cycle.
223998210|NCT05515354|DRUG|Nicotine Replacement Therapy Agent|Nicotine patch and a choice of nicotine gum or lozenge (2 mg) for 6 weeks. Participants who smoke 10 or more cigarettes per day receive a package of 21 mg, 14 mg, and 7 mg nicotine patches. For participants who smoke 5-9 (inclusive) cigarettes per day, the package contains 14 mg and 7 mg nicotine patches.
223998211|NCT01461889|OTHER|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
223381626|NCT02454608|OTHER|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
223729775|NCT04376710|OTHER|Completion of pre-pandemic survey|Surgeons will take a pre-pandemic survey to determine surgeon perceptions to telemedicine and barriers to implementation.
223998212|NCT01461889|OTHER|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
223381627|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
223381628|NCT04130958|DEVICE|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
223381629|NCT02333084|DIETARY_SUPPLEMENT|PRN Joint Health Formula|
223381630|NCT02333084|DIETARY_SUPPLEMENT|placebo|
223998213|NCT03909490|OTHER|Preference elicitation tool|Ranking tool to assess patient preferences for trigger finger treatment
223381631|NCT02333084|DIETARY_SUPPLEMENT|PRN Flex Omega Benefits® combination|
223381632|NCT01944111|DEVICE|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
223381633|NCT06013098|DRUG|30%Oxygen|60%FiO2 in one lung ventilation and 30% FIO2 in both lungs ventilation
223381634|NCT06013098|DRUG|60%Oxygen|100%FiO2 in one lung ventilation and 60% FIO2 in both lungs ventilation
223729776|NCT04376710|OTHER|Completion of survey after peak of pandemic|Surgeons will take another survey after the peak of pandemic to determine surgeon perceptions to telemedicine and barriers to implementation.
223729777|NCT04376710|OTHER|Completion of post telemedicine encounter survey|Patients will take a post telemedicine encounter survey to determine patient perceptions to telemedicine and barriers to implementation.
223729778|NCT00197964|BEHAVIORAL|Enhance asthma knowledge, self-efficacy, social support|
223998214|NCT03909490|OTHER|handout|handout with information about trigger fingers
223998215|NCT02497495|OTHER|immersion cold water|immersion cold water at different temperatures and exposure times
223998216|NCT03895047|OTHER|tomographic EEG Neurofeedback Training|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
223998217|NCT03057847|DRUG|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
223998218|NCT03056651|OTHER|treatment in day-care heart failure unit|
223998219|NCT06221501|DRUG|Efgartigimod Alfa|Efgartigimod will be administered intravenously on Day (D)1, D8, D15, and D22 at a dose of 10 mg/kg according to the patient's weight (maximum infusion dose of 1200 mg) over approximately 1 hour for a total of 4 doses. Thymectomy will be performed on Day 9.
224123403|NCT04331353|BEHAVIORAL|Comparator 1 (tailored approach)|Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
224123404|NCT04331353|BEHAVIORAL|Comparator 2 (insecticidal bait)|Cockroach bait
224123405|NCT05876377|BIOLOGICAL|Pfizer-BioNTech COVID-19 mRNA vaccine|Pfizer-BioNTech COVID-19 Vaccine, is FDA licensed or authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.
224123406|NCT00069095|DRUG|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
223381635|NCT02663843|DEVICE|i-gel airway|Fibreoptic intubation via i-gel airway device
223381636|NCT02663843|DEVICE|air-Q airway|Fibreoptic intubation via air-Q airway device
223381637|NCT06032078|DEVICE|Cutera laser machine|1064nm Nd: YAG laser
223381638|NCT05076461|DRUG|Ondansetron|Ondansetron group received oral suspension of ondansetron as 0.15mg per body weight
223729779|NCT06335914|DIAGNOSTIC_TEST|Ga 68 PSMA-11 PET|Positron emission tomography (PET) imaging using Ga68 PSMA 11 radiotracer
223729780|NCT06335914|DIAGNOSTIC_TEST|18F-DCFPyL PET|Positron emission tomography (PET) imaging using 18F-DCFPyL radiotracer.
223998220|NCT04765917|OTHER|Selected physical Therapy program|"-Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Strengthening exercises for weakened muscles in upper and lower limbs muscle.~* Strengthening exercises for back and abdominal muscles.~* Stretching exercises for tight muscles in upper and lower limbs.~* Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Jumping in place and jumping a board."
223998221|NCT04765917|OTHER|Motor imagery training program|"As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes."
223998222|NCT00448201|BIOLOGICAL|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
223998223|NCT00448201|BIOLOGICAL|sargramostim|GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) \< 1000/microliter (uL) past day 20
223381639|NCT01531517|DRUG|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
223381640|NCT01531517|DRUG|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~1. Assessment of the patient for inclusion/exclusion criteria~2. Informed consent process~3. Medical history of the patient~4. Blood withdrawn for investigation~5. Drainage of the ulcer if there is a collection~6. Revascularization as needed and indicated by APSV done at visit 0.~7. Swab from the ulcer for culture and micro-organism count: on detailed visits only.~8. Debridement as needed.~9. Dressing:~   * Inspection and assessment of the ulcer~  * Irrigation using 500 ml of saline or as required.~  * Drying of the ulcer (leave to dry)~  * Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~  * Fix the dressing to the ulcer"
223381641|NCT03573830|BEHAVIORAL|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
223998224|NCT00448201|BIOLOGICAL|therapeutic allogeneic lymphocytes|A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10\^6 cells/kg and a maximum 8 x 10\^6 cells/kg will be infused on day 0
223729781|NCT06335914|DIAGNOSTIC_TEST|FDG PET|Positron emission tomography (PET) imaging using (18) F-fluorodeoxyglucose radiotracer.
223998225|NCT00448201|DRUG|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
223729782|NCT05122273|DEVICE|Stella BIO|Individually planned therapeutic procedures, using, among others, the concept of EMG biofeedback
223998226|NCT00448201|DRUG|fludarabine phosphate|fludarabine 30 mg/m\^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
223998227|NCT00448201|DRUG|methotrexate|Methotrexate 5 mg/m\^2 per day on days +1, +3 and +6
223998228|NCT00448201|DRUG|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
223998229|NCT00448201|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
223998230|NCT00448201|PROCEDURE|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10\^6 cells/kg and a maximum of 8 x 10\^6 cells/kg will be infused on Day 0
223998231|NCT06507423|DEVICE|Septicyte Lab Test pre operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
223998232|NCT06507423|DEVICE|Septicyte Lab Test post operative|"SeptiCyte® technology uses proprietary biomarker signatures to assess the response of a patient's immune system to infections. It provides a score which can be used to differentiate sepsis from systemic inflammatory response.~Each included patient will received the Septicyte LAB test before and after surgery for acute mesenteric ischemia suspicion. The results will be compared to standard of care, retrospectively."
223998233|NCT02876289|DRUG|Perampanel|
223998234|NCT04283539|DRUG|systemic corticosteroid or biologic|Treatment with systemic corticosteroids or biologic therapies (for corticosteroid refractory patients or these in which corticosteroids are not the treatment of choice)
223998235|NCT03577847|DIAGNOSTIC_TEST|Rural CT scanning|Rural computer tomography for acute stroke
223998236|NCT00381927|BEHAVIORAL|Physician Counseling|
223998237|NCT00003337|PROCEDURE|immunoscintigraphy|
223998238|NCT00003337|RADIATION|technetium Tc 99m epratuzumab|
223998239|NCT04190576|DEVICE|Low Level Laser Therapy|Hydroxyapatite bone graft with collagen
223998240|NCT06316518|OTHER|mindfulness group|In the study, primigravidas will receive 8-module (8-week-long) trainings, each lasting approximately 45 minutes, 3 days a week.
223998241|NCT01706705|DEVICE|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
223998242|NCT01706705|OTHER|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
223998243|NCT01706705|OTHER|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
223998244|NCT06179225|BEHAVIORAL|HMD AR|Older adults will wear head mounted display to engage in collaborative augmented reality activities: sharing a meal, playing board games, and decorating home.
223998245|NCT06179225|BEHAVIORAL|2-D AV|Older adults will use 2-D AV to engage with family members at a distance.
223998246|NCT05152303|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg IV of Remimazolam Tosilate, Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1mg/kg/h
223998247|NCT05152303|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg, Drug: Propofol Injection Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.2mg/kg/h IV of Propofol Injection
223998248|NCT03386825|DRUG|Regorafenib (Stivarga, BAY73-4506)|Antineoplastic agents, protein kinase inhibitor (L01XE21)
223998249|NCT06317532|OTHER|Lifestyle modification advice|All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.
223998250|NCT06317532|OTHER|Functional exercises|Each female in group (B) will perform the exercise program three times a week for eight weeks at the University Women's Health Unit Exercise protocols mainly consist of relaxation, strengthening, stretching, aerobic exercises, pelvic floor muscle strengthening exercises, yoga, and Pilates
223381642|NCT03573830|BEHAVIORAL|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
223998251|NCT02911233|BIOLOGICAL|Thromboelastograpgy|
223998252|NCT05627258|BIOLOGICAL|VRC-HIVMAB0115-00-AB|VRC01.23LS, a broadly neutralizing monoclonal antibody targeting the HIV-1 envelope CD4 binding site.
223381643|NCT01204567|OTHER|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
223381644|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine-Aclarubicin Association|Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin
223381645|NCT05264883|DRUG|Venetoclax-Decitabine/Azacitidine Association|Treatment with Venetoclax+Decitabine/Azacitidine
223381646|NCT00005598|DRUG|amifostine trihydrate|
223729783|NCT03872167|DEVICE|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
223998253|NCT04773067|BIOLOGICAL|UB-612|Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
223998254|NCT04773067|BIOLOGICAL|Placebo|Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
223998255|NCT02138786|DRUG|selinexor|"* 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0).~* 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0)."
223998256|NCT06460792|PROCEDURE|Ultrasound-guided peripheral nerve block|Ultrasound-guided peripheral nerve blocks. Registration of quality, complications and learning as detailed in the description
223998257|NCT03540745|DEVICE|TES Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
224123407|NCT00069095|DRUG|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
224123408|NCT00069095|DRUG|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
224123409|NCT00069095|DRUG|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
224123410|NCT00069095|DRUG|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m\^2 was administered simultaneously with leucovorin in a 2 h infusion.
224123411|NCT00069095|DRUG|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m\^2 in a 2 h infusion.
224123412|NCT00069095|DRUG|Fluorouracil 400 mg/m^2|
223381647|NCT00005598|DRUG|azacitidine|
223381648|NCT02983747|OTHER|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
223381649|NCT02983747|DRUG|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
223381650|NCT03159247|BEHAVIORAL|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
223381651|NCT01096797|DRUG|Sevoflurane|"* Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~* Anaesthesia maintenance: sevoflurane 2-3 %~* Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~* Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
223381652|NCT04113577|OTHER|usability survey|usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
223729784|NCT03872167|DEVICE|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
223729785|NCT00627003|DRUG|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
224123413|NCT00069095|DRUG|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
224123414|NCT00069095|DRUG|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
224123415|NCT04145297|DRUG|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
224123416|NCT04145297|DRUG|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
224123417|NCT06238817|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
224123418|NCT06238817|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
223998258|NCT03540745|DEVICE|TES-SHAM Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
223381653|NCT01769456|BEHAVIORAL|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
223998259|NCT02029963|DEVICE|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
223381654|NCT01769456|DRUG|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
223381655|NCT03688048|DEVICE|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
223381656|NCT03688048|DEVICE|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
223381657|NCT01068548|OTHER|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
223998260|NCT02029963|BEHAVIORAL|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
223998261|NCT02088957|DRUG|Brivaracetam intravenous solution|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use"
223998262|NCT02088957|DRUG|Brivaracetam oral tablets|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use"
223998263|NCT02088957|DRUG|Phenytoin intravenous solution|"* Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use"
223998264|NCT02088957|DRUG|Phenytoin oral tablets|"* Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use"
223998265|NCT02480192|OTHER|CBT for Menopausal Symptoms (CBT-Meno)|This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
223998266|NCT02671188|DRUG|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
223998267|NCT02671188|DRUG|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
223998268|NCT01199068|DRUG|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice daily
223998269|NCT01199068|DRUG|Erlotinib|Erlotinib 150 mg once daily
223729786|NCT00627003|OTHER|Placebo|Placebo oral tablets administered daily for 5 weeks
223998270|NCT04735848|DIETARY_SUPPLEMENT|Iron-supplement application|The participants will take the corresponding amount of iron-supplement supervised at 8am.
223998271|NCT01815086|BIOLOGICAL|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
223998272|NCT03338296|DRUG|lorcaserin hydrochloride XR|oral tablet
223998273|NCT03338296|DRUG|Placebo|oral tablet
223998274|NCT04727138|DRUG|EXS21546 Powder for Oral Suspension|EXS21546 Powder for Oral Suspension
223998275|NCT04727138|DRUG|EXS21546 Granule in Capsule|EXS21546 Granule in Capsule
223998276|NCT04727138|OTHER|Midazolam|Interaction
223998277|NCT04727138|OTHER|Food Effect|Fed/Fasted
223998278|NCT04727138|OTHER|Placebo Powder for Oral Suspension|Placebo Powder for Oral Suspension
224123419|NCT05369962|DEVICE|Ultrasound|Ultrasound measurements of the Qcsa
224123420|NCT03508622|BEHAVIORAL|Telehealth group sessions|Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
223998279|NCT00531336|DRUG|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
223998280|NCT00531336|DRUG|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
223998281|NCT06064968|OTHER|Intermittent bladder catheterization|Intermittent bladder catheterization will be taught and performed by intervention group twice daily.
224123421|NCT03508622|BEHAVIORAL|Empower clinic|Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
223998282|NCT04773743|OTHER|Yoga|Remotely delivered yoga intervention
224123422|NCT04404660|BIOLOGICAL|AUTO1|Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with a total target dose of 410E+6 of CD19-positive CAR T cells as a split dose on Day 1 and on Day 10 (±2 days).
224123423|NCT06398743|DEVICE|MRD|ctDNA MRD test
224123424|NCT05774392|OTHER|Observational|Observational
224123425|NCT01750567|DRUG|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
224123426|NCT02823665|DRUG|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
223998283|NCT03461770|OTHER|CPAP|Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
223998284|NCT01128270|DRUG|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
223998285|NCT01128270|DRUG|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
223998286|NCT01128270|DRUG|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
223998287|NCT01128270|DRUG|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
223998288|NCT03296800|DRUG|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
223998289|NCT03296800|DRUG|Probenecid|Probenecid tablets, 500 mg; bid
223998290|NCT03296800|DRUG|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
223998291|NCT03296800|DRUG|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
223998292|NCT02212353|OTHER|Observational study, not interventional|
223998293|NCT03266926|DRUG|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
223998294|NCT03266926|DRUG|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
224123427|NCT02823665|DRUG|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
223381658|NCT02134652|OTHER|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
223381659|NCT03478722|OTHER|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
223381660|NCT03478722|OTHER|Stable Isotope Amino Acid Infusion|Continuous infusion of L-\[1-13C\]leucine (0.13 μmol⋅kg⋅min) and L-\[ring- 2H5\]phenylalanine (0.05 μmol⋅kg⋅min)
223381661|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
223381662|NCT02185339|DRUG|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
223381663|NCT01602068|DRUG|Dexamethasone Phosphate Ophthalmic|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
223381664|NCT01602068|DRUG|100 mM Sodium Citrate Buffer|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
223381665|NCT04082897|DRUG|Obinutuzumab 25 MG/ML [Gazyva]|Obinutuzumab will be administered from C1 to C8
223381666|NCT04082897|DRUG|Atezolizumab 60 MG/ML [Tecentriq]|Atezolizumab will be administered iv from C1 to C18
223729787|NCT02845453|DRUG|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
223998295|NCT05638412|BEHAVIORAL|JASPER|JASPER is a therapist and caregiver-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes caregivers as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
223998296|NCT05638412|BEHAVIORAL|Psychoeducational Curriculum|The psychoeducational modules will include written information about child development, communication and social interaction skills, behavioral principles for managing challenging behavior and strategies for teaching new skills. No direct caregiver-child mediated coaching will be provided. The material provided will be similar to what a pediatrician or developmental specialist may review as a part of routine care.
223998297|NCT04419298|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to acute CO poisoned patients with elevated TnI \[during acute (within 7 days after CO exposure) and chronic phase (at 4-5 months after CO exposure)\]~2. TTE be taken to acute CO poisoned patients with elevated TnI \[At the ED and during admission (within 7 days after CO exposure)\]"
224123428|NCT06402994|OTHER|Electrophysiological experiment|Neural envelope tracking to conversational speech at different intensities
224123429|NCT06402994|BEHAVIORAL|Speech audiometry|Speech perception assessment at different intensities
224123430|NCT03969706|DRUG|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
224123431|NCT05079841|DEVICE|Electric breast pump|Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor for at least 2 hours
224123432|NCT05079841|DRUG|Exogenous oxytocin intravenous infusion without nipple stimulation.|Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor as current standard of care
224123433|NCT00992901|DRUG|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
223998298|NCT01539369|OTHER|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
223998299|NCT03254043|BEHAVIORAL|Take-home Dosing Procedures|Within-subject evaluation across 2 phases with a final choice condition
223381667|NCT04082897|DRUG|Venetoclax Oral Tablet|Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35
223381668|NCT03397225|BEHAVIORAL|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
223381669|NCT06583005|DEVICE|Vibrotactile Coordinated Reset|The Stanford CR glove is designed to administer vibrotactile coordinated reset stimulation, which consists of vibratory stimulation of the fingertips delivered in a specific pattern which is design to disrupt and normalize abnormal brain synchrony.
223381670|NCT02465398|PROCEDURE|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
223381671|NCT05105997|DRUG|Dexamethasone/ Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
223381672|NCT05105997|DRUG|Erector Spinae Plane Block|Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
223381673|NCT06388005|OTHER|emotional freedom technique (EFT)|The emotional freedom technique (EFT), founded by American scholar Gary Craig, is based on the methods of meridian science in traditional Chinese medicine (TCM) and Western psychology. Guided by the TCM theory of meridians, it quickly releases negative emotions by combining acupoint stimulation with neuro-linguistic programming, and its effectiveness has been confirmed by multiple studies.
223381674|NCT04005001|OTHER|HindSight|HindSight will examine the dynamic trends of clinical measurements taken from a patient's EHR and analyzes correlations between vital signs to alert for the onset of sepsis.This machine learning based tool is optimized by encoder and utilizes periodic retraining to improve its performance over time.
223381675|NCT04005001|OTHER|InSight|Compared to the ability of the InSight software's recognition of sepsis onset to HindSight's performance. The study determines if the HindSight software has equivalent or better performance than the InSight software.
223381676|NCT05895201|DRUG|Sitagliptin|600 or 400 (or MTD) mg PO every 12 hours on days -1 to +14 depending on dose level assignment.
223381677|NCT05895201|DRUG|Bortezomib|1.3 or 1.0 mg/m2 (or MTD) IV push 6 hours after graft infusion completion (day 0), and 72 hours thereafter depending on dose level assignment.
223729788|NCT02845453|OTHER|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
223729789|NCT02101476|DRUG|Percocet|10mg/650mg
223729790|NCT02101476|DRUG|Xartemis|15mg/650mg
223998300|NCT02687035|DEVICE|SAPIEN S3 valve|Transcatheter aortic valve replacement
223998301|NCT02032082|OTHER|Carbone monoxide|
223998302|NCT04615195|OTHER|cries 13 questionnaire|"Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria."
223998303|NCT02668276|OTHER|Standard NCCN counseling|
223998304|NCT02668276|OTHER|Standard NCCN counseling and Oncotype DX results|
223998305|NCT03400111|RADIATION|low-level laser therapy|low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
223998306|NCT03400111|DRUG|Panadol-extra|Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
223998307|NCT05716724|DRUG|Semaglutide|Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
223998308|NCT02797652|PROCEDURE|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
223998309|NCT02797652|PROCEDURE|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
224123434|NCT00992901|DRUG|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
224123435|NCT00992901|DRUG|GLP-1 and GIP|A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
224123436|NCT04908449|DRUG|Rectus sheath block with bupivacaine|Rectus sheath block with local anesthetic versus sham block with saline
224295562|NCT05377593|DEVICE|eminoplasty with patient specific Zirconium dioxide onlay implant|Eminoplasties will be done for patient with chronic condylar dislocation using patient specific zirconium dioxide implants
223381678|NCT05895201|DRUG|Cyclophosphamide|50 mg/kg IV over 1 hour on days +3 and +4
223381679|NCT04348201|OTHER|foot reflexology|foot reflexology session which takes about 20 minutes. The position of the patient during reflexology session was a relaxed comfortable supine lying position. The therapist was sitting position at the level of the feet. The Session of reflexology was done on three points at both feet.
223381680|NCT04348201|DIETARY_SUPPLEMENT|dietary modification|diet must be rich in vitamins as fish and beans, calcium as milk and chess, low fat food through decrease oil in meals, high fiber food through all types of vegetables and fruits and restrict caffeine
223381681|NCT00801567|DEVICE|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
223381682|NCT05191004|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
223381683|NCT05191004|DRUG|Fulvestrant|Fulvestrant
223998310|NCT00667394|BIOLOGICAL|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
223998311|NCT00667394|DRUG|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
223998312|NCT00667394|PROCEDURE|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
223998313|NCT02160730|DRUG|R-roscovitine|See Arm Description
223998314|NCT01133223|DEVICE|Penumbra™ System|Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
223998315|NCT01133223|DRUG|Recombinant tissue plasminogen activator|Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
223998316|NCT00223223|DRUG|Levetiracetam, Keppra|
223381684|NCT04641104|DRUG|Thiamine 500 MG|A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
223381685|NCT04641104|DRUG|Placebo|100 ml of NaCl 0.9% will be administered in the placebo group.
223381686|NCT04768192|PROCEDURE|Physical Rehabilitation without lokomat|"Conventional physiotherapy is performed in 10 weekly sessions (45 minutes each) over 4 weeks(total 40 sessions).~Specific exercises are administered to improve gait, balance and functional abilities focusing on:~strengthening the gluteus and quadriceps muscles stretching the hip flexor and hamstrings muscles increasing static balance increasing dynamic balance increasing functional abilities improving ground gait going up and down the stairs.~Physiotherapists can choose from a list of 25 standard exercises, according to some constraints:~1. strengthening exercises had to involve all the lower limb joints (no segmental intervention)~2. during each session, at least 4 out of the 7 categories above had to be delivered~3. the impossibility to perform any of the categories above during any session had to be recorded in the patient's treatment diary.~Physiotherapists of the treatments group discuss patients' diaries during weekly meetings."
223381687|NCT04768192|PROCEDURE|Physical Rehabilitation with Lokomat|"The rehabilitation protocol consists of 20 sessions of robotic training alternated with 20 sessions of conventional physiotherapy (CP). Each treatment is performed in 5 weekly sessions (45 minutes each) over 4 weeks.~Robotic training aimed to recovery/improve walking capacity from the initial Gross Motor Function Classification System (GMFCS) level. It is performed using the Lokomat® (Hocoma AG, Volketswil, Switzerland) gait orthosis. Initial set ups includes 50% body weight unload, gait velocity adjusted on the patient individual capability (1.5 km/h on average) and 100% guidance force. Both weight unload and guidance force are gradually reduced across sessions according to patient recovery of muscle strength and allowing patients to work harden and move more freely.~Children engagement, active participation and motivation were reinforced through frequent encouragement by therapists and performance feedback implemented in the exercise video-games."
223381688|NCT04682392|DEVICE|Delfi's PTS Personalized Tourniquet System for Blood Flow Restriction Group|A Delphi Personal Tourniquet system for blood flow restriction (BFR) therapy will be applied to each treatment session for this group. They will do 3-5 exercises with the BFR system on the surgical or both lower extremities for bilateral or unilateral movements.
223381689|NCT04682392|OTHER|Standard ACL rehab|Standard accelerated ACL protocol
223998317|NCT00250549|BEHAVIORAL|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
223998318|NCT06557707|OTHER|Childhood stress|Based on stress-related information, participants will be divided into those who were exposed to adversity during childhood and those who were not exposed.
223998319|NCT04076943|DRUG|Roxadustat|Roxadustat will be administered per schedule specified in the arm description.
223998320|NCT06268197|BEHAVIORAL|Yoga Intervention|The yoga intervention will consist of twice weekly, in-person, gentle Hatha yoga classes delivered by a certified yoga instructor. Each class will last 60-75 minutes and will include an introduction to the day's topic, an opening breathing/meditation practice, yoga postures, a closing breathing/meditation practice, and end with a savasana pose and intention setting for a home practice.
223998321|NCT06157281|BEHAVIORAL|Connect|A multicomponent, clinic-level intervention consisting of strategies aimed at improving retention and viral load suppression by enhancing the patient and staff experience.
223998322|NCT03882177|DRUG|Pravastatin|Tablets, administered orally
223381690|NCT04809922|DEVICE|cardiac wearable devices|"five cardiac wearable devices~* Apple Watch, Apple Inc., Model Number: A1977 / A1978~* Kardia Mobile, AliveCor Inc., AC-009/Kardia Mobile 6L, AliveCor Inc., AC-019~* Fitbit Sense, Fitbit, Inc, Model Number: FB512~* Samsung Galaxy Watch 3 Samsung Inc., Model Number: SM-R855F~* Withings Scanwatch, Withings SA, Model Number: HWA09 Used for recording of one single-lead ECG. The results will be 274 compared to a simultaneous 12-lead ECG, which is considered the gold standard for detecting AF. There is no comparator in this trial."
223381691|NCT02038257|PROCEDURE|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
223381692|NCT02038257|DEVICE|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
223381693|NCT02038257|DEVICE|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
223381694|NCT02038257|DEVICE|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
223381695|NCT02038257|DEVICE|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
223381696|NCT00599248|BIOLOGICAL|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
223381697|NCT00599248|BIOLOGICAL|Placebo|Placebo control (DMEM)
223381698|NCT05244122|BEHAVIORAL|Feedback|presence or absence of trial by trial feedback
223381699|NCT05244122|BEHAVIORAL|Prevalence|"In some blocks, skin cancer target images were present on 50% of trials (high prevalence). In other blocks, disease prevalence was 20%."
223381700|NCT05807204|DIETARY_SUPPLEMENT|Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
223998323|NCT03882177|DRUG|Rifafour|Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
223998324|NCT03882177|DIETARY_SUPPLEMENT|Vitamin B6|Administered orally.
223998325|NCT05551325|OTHER|Chronobundle - light|"Bright daytime light from 09:00 to 13:00 starting on day 1. The light will be 10,000 lux at 12 and provide a minimal intensity of 1,250 lux at the angle of the eye (30 to 36 distance). The light has a temperature of 5,000 Kelvin indicating a high blue wavelength content which should maximize circadian effects (validated device Sunbox Lighting, Maryland). Following the 09:00 to 13:00 bright light, the room lights will remain on and the curtains will remain open to maximize daytime light exposure while not decreasing bright light tolerance."
223381701|NCT05807204|DIETARY_SUPPLEMENT|Placebo|The product will be presented in powder format in a single container and with a measuring spoon of the daily dose.
223998326|NCT05551325|OTHER|chronobundle - feeding|For patients receiving enteral feeds, time-restricted (daytime) intermittent feeding will include 4 meals delivered at 08:00, 12:00, 16:00 and 20:00. Each meal will include one-fourth of the recommended daily tube feed volume.
223998327|NCT05551325|OTHER|chronobundle - mobility|While in the MICU, exercise/mobility sessions led by physical therapy or occupational therapy providers will occur twice daily between 09:00 and 16:00 (i.e., one additional session beyond usual care); intensity will be determined by clinical status and documented in the chart by our physical therapy service. Patients in other hospital locations (e.g., general medical ward post-MICU discharge) will receive one additional session beyond usual care via a study staff-led exercise/mobility session; intensity will be determined by clinical status.
223381702|NCT00296972|DRUG|peg interferon plus ribavirin|
223381703|NCT00290004|DRUG|motexafin gadolinium|
223381704|NCT04077554|GENETIC|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
223729791|NCT05914714|DRUG|Ruxolitinib 5 MG BID Oral Tablet|ruxolitinib 5mgBID will be administrated at the beginning of the conditioning regimen until 3 months post-transplantation.
223381705|NCT01261897|PROCEDURE|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
223381706|NCT01261897|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
223381707|NCT05624645|DEVICE|Pelex Upp|Patients were given the Pelex Upp is a non-invasive device that is designed to guide a user through personalized pelvic floor strengthening exercises. Patients used device for four weeks to treat stress urinary incontinence
223381708|NCT02750137|DRUG|Tetracaine|Application of Ametop prior to intravenous cannulation
223381709|NCT06550557|BEHAVIORAL|counselling sessions|the counselling sessions were adopted from the health belief model with the cues of action depending on mobile phones as muting notifications, removing social media and using computers instead if possible.
223381710|NCT02983786|DRUG|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
223381711|NCT00910676|DRUG|Diprosone|"* Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks"
223381712|NCT01491360|PROCEDURE|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
223381713|NCT06274294|DRUG|CT-P13|Induction treatment.
223381714|NCT03525886|DRUG|NBI-74788|Capsule, administered daily.
223729792|NCT01107041|BEHAVIORAL|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
223998328|NCT05551325|OTHER|chronobundle - sleep|Overnight sleep promotion will occur between 22:00 and 06:00 with a more restricted sleep period between 00:00 and 04:00. This will be achieved by rescheduling non-urgent care. There will be no changes to urgent care. Additionally, room lights will be dimmed, curtains drawn, and room doors closed. Television screens will be fitted with blue light-blocking filters.
223381715|NCT02812563|OTHER|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
223381716|NCT00089804|DRUG|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
223381717|NCT00089804|DRUG|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
223381718|NCT00089804|DRUG|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
223998329|NCT02777892|OTHER|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
223998330|NCT00509249|BIOLOGICAL|ziv-aflibercept|Given IV
223998331|NCT00509249|OTHER|laboratory biomarker analysis|Correlative studies
223998332|NCT00509249|OTHER|pharmacological study|Correlative studies
223998333|NCT00245908|DRUG|azithromycin|
223998334|NCT03873753|OTHER|Cleaning|Gauze and mineral water
223998335|NCT03873753|OTHER|No oral cleaning|Absence of cleaning
223998336|NCT02224703|DRUG|GWP42003-P|
223998337|NCT02224703|DRUG|Placebo Control|
223998338|NCT04048902|DEVICE|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
223998339|NCT04048902|DEVICE|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
223998340|NCT00927134|GENETIC|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
223998341|NCT04956874|BEHAVIORAL|FL-REACH|The FL REACH intervention is a 6-session intervention designed to facilitate transition to care following delivery of a memory disorders diagnosis by a MDC team. The intervention focused on an approach that used a toolbox of strategies to tailor skills-based learning, knowledge transmission, and self-care strategies to dementia caregivers. This pilot study focuses on adapting the established REACH II intervention for translation to the clinical setting, with a focus not only on implementation of the key components of the program, but also on feasibility and sustainability. This is part of a stepped-care model that is being developed at the AdventHealth-Orlando MDC. Caregivers of patients will be referred to the FL REACH intervention for foundational training and skills-development.
223998342|NCT04447508|BEHAVIORAL|Participants receive one on one motivational interviewing and participate in a group exercise class virtually.|Participants have one group exercise class over zoom per week and an online one on one motivational interviewing session every second week.
223998343|NCT00196157|PROCEDURE|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
223998344|NCT00196157|PROCEDURE|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
223381719|NCT01231893|PROCEDURE|olfactory mucosa ensheathing cell grafting, rehabilitation|In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
223998345|NCT03177239|DRUG|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
223998346|NCT03177239|DRUG|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
223998347|NCT05909553|DRUG|Venetoclax|Oral; Tablet
223998348|NCT02932540|OTHER|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
223998349|NCT02922023|DEVICE|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
223998350|NCT02922023|OTHER|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
223998351|NCT04182295|DEVICE|acupuncture|A sterilised stainless steel needle (diameter 0.25mm X length 40mm, Dongbang Acupuncture Inc., Boryeong, Chungchenongnam-do, Korea) will be given at PC3, LI4, LI11, and LU5 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
223998352|NCT04182295|DEVICE|Park Sham Needle|A Park Sham Needle (Meridius Medical Ltd. \& DongBang Acuprime Ltd., Exeter, UK), non-penetrating sham acupuncture, will be given at two points on the belly of biceps brachii, 1 cun proximedially from LI11, and 1 cun laterally from PC3 of non-dominant arm for 15 minutes once a day for 3 days (immediately after inducing delayed onset muscle soreness (DOMS), and 2 consecutive days after inducing DOMS).
223998353|NCT03538938|BEHAVIORAL|1-Call Quitline Counseling|The 1-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 1 proactive call using a standard, evidence-based protocol lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
223998354|NCT03538938|BEHAVIORAL|4-Call Quitline Counseling|The 4-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 4 proactive calls that use a standard, evidence-based protocol with each call lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
223998355|NCT03538938|DRUG|Nicotine patch|Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD).
223998356|NCT03538938|DRUG|Nicotine Patch and Nicotine Lozenge|The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); the Nicotine Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking).
223998357|NCT03538938|BEHAVIORAL|SmokefreeTXT|SmokefreeTXT support is a national program offered at no cost to users (apart from data/minute costs charged by cellular providers about which enrollees are advised at enrollment) and is sponsored by the National Cancer Institute. This program sends up to 5 messages per day for up to 2 weeks prior to the target quit day and 6 weeks following the target quit day (total duration may be longer if participants elect to change the target quit day). The text messages offer tips to help enrollees achieve their goal of quitting smoking and offer real-time interactive tips when participants text in responses indicating cravings, negative moods, or slips. Participants have the option to reset quit dates and have the option to unsubscribe at any time by texting STOP to the program.
223998358|NCT03538938|BEHAVIORAL|No SmokefreeTXT|Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
224123437|NCT05301283|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.
224123438|NCT05301283|DIAGNOSTIC_TEST|MRI|Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
224123439|NCT03334617|DRUG|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
223381720|NCT01231893|OTHER|rehabilitation|In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
223381721|NCT01041144|BEHAVIORAL|lifestyle counseling|supporting diabetes patients using Internet communication
223381722|NCT05850325|OTHER|Group 1 Elbow Flexed at 90 Degrees|subjects will be instructed to exercise the forearm with the elbow positioned by their side, in 90° of flexion.
223381723|NCT05850325|OTHER|Group 2 Elbow Fully Flexed|subjects will be instructed to exercise the forearm with their elbow fully flexed to achieve supination and the elbow extended to achieve pronation.
223381724|NCT06016647|OTHER|Musculoskeletal-specific WSIB programs of care|Clinicians within this network provide care under a standardized framework that limits confounding from different interventions and the researchers will not manipulate treatment decisions.
223381725|NCT05067413|PROCEDURE|Transanterior obturator nerve gateway approach|Distal rectal transection of cases in the experimental group will be performed using transanterior obturator nerve gateway approach
223381726|NCT05067413|PROCEDURE|Total mesorectal excision approach|Distal rectal transection of cases in the control group will be performed using total mesorectal excision approach
223381727|NCT00416390|DIETARY_SUPPLEMENT|lycopene|
223381728|NCT00416390|OTHER|laboratory biomarker analysis|
223381729|NCT00416390|PROCEDURE|biopsy|
223381730|NCT00064987|PROCEDURE|Testicular biopsy|Outpatient surgical procedure.
223998359|NCT03538938|BEHAVIORAL|Financial Incentives for Treatment Engagement|Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
223998360|NCT03538938|BEHAVIORAL|No Financial Incentives for Treatment Engagement|No Financial Incentives for Treatment Engagement are offered.
224123440|NCT03334617|DRUG|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
224123441|NCT03334617|DRUG|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
224123442|NCT03334617|DRUG|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
224123443|NCT03334617|DRUG|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
224123444|NCT03334617|DRUG|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
224123445|NCT03334617|DRUG|trastuzumab deruxtecan|Durvalumab given IV at 1120mg Q3W ±2 days for Module 6 only \& trastuzumab deruxtecan given at 5.4 mg/kg via IV infusion Q3W ±2 days
224123446|NCT03334617|DRUG|cediranib|cediranib given orally at 20 mg tablets on an intermittent schedule (5 days on, 2 days off), starting on C1D1
223998361|NCT05153876|OTHER|Questionnaires|Headache attack descriptions, Headache related disability descriptions, Questionnaires, MIDAS, MSQv2.1, SF36
223998362|NCT03995316|BEHAVIORAL|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
223998363|NCT03995316|BEHAVIORAL|Treatment As Usual Only|NorthShore HealthSystem's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
224295563|NCT06177106|OTHER|Solar Simulated Light|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
224295564|NCT03056079|DRUG|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
224295565|NCT03811626|PROCEDURE|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
224295566|NCT01872052|DEVICE|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
224295567|NCT01025219|GENETIC|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
224295568|NCT00093951|DRUG|SGS742|
223381731|NCT00064987|DRUG|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
223381732|NCT00064987|DRUG|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
223381733|NCT06582082|OTHER|pulmonary rehabilitation|The study group will receive pulmonary rehabilitation
223381734|NCT06582082|OTHER|pursed lip breathing|the control group will stick to pursed lip breathing only
224123447|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given at 240 mg twice daily for 14 days on treatment in each 28-day cycle, between Days 1 and 14.
224123448|NCT03334617|DRUG|AZD6738 (ceralasertib)|AZD6738 given orally at 240mg twice daily for 14 days in each 28 day cycle (starting from Cycle 1) between Days 15-28
224123449|NCT03334617|DRUG|AZD6738 (ceralasertib) (240 mg or 160 mg)|AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
224123450|NCT03334617|DRUG|AZD6738 (ceralasertib) 7 days monotherapy|AZD6738 given orally at 240 mg twice daily for 7 days on Day 1-7 in each 28 day cycle
224123451|NCT05114590|DRUG|Insulin glargine/Lixisenatide|Solution for injection in a pre-filled pen by subcutaneous injection. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
224123452|NCT05673018|DEVICE|Multi-Cancer Early Detection Test (Galleri®)|Blood collection and multi-cancer early detection testing with return of results.
224123453|NCT03504800|DEVICE|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B \& C.
224295569|NCT02428686|DRUG|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
224295570|NCT03257904|PROCEDURE|intracranial pressure monitoring|measurement of intracranial pressure
224295571|NCT02882672|OTHER|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
224295572|NCT02882672|OTHER|Control|They did not do ant exercise training during 8 weeks.
224295573|NCT04177563|OTHER|whole body cryostimulation|Whole-body cryotherapy
223381735|NCT05366452|DEVICE|IMPELLA CP|Implantation of the IMPELLA CP will be performed using the femoral route in most patients. Echo guided puncture to gain access for IMPELLA CP will be encouraged and a local angiography will be promoted to check the feasibility of device implantation. The implantation will follow gold standard after obtaining an ACT \>250 s. As soon as the device is in place it will be started.
223381736|NCT05366452|OTHER|Conventional therapy|The patients will receive up to date management according to the consensus of care regarding inotropes and vasopressors in CS (2,4). A dedicated protocol will ensure that management is similar between centers and in both groups. The shock team will be in charge of all therapeutic decisions.
223381737|NCT02969382|DRUG|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
223381738|NCT02969382|DRUG|Placebo - Cap|One Placebo capsule daily for 4 weeks
223381739|NCT04545840|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
223381740|NCT00209040|BEHAVIORAL|Acoustic Startle Testing|See protocol description for methodological details
223998364|NCT02758275|BEHAVIORAL|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~1. Behavior Modification (4360) Promotion of a behavior change.~2. Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~3. Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~4. Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~5. Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~6. Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
223998365|NCT02765334|DEVICE|nBETTER|60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
223381741|NCT04405882|PROCEDURE|topographic guided trans epithelial excimer laser|In this retrospective study 8 eyes affected by cornea ectasia of 8 patients (mean age 31.50±14.73 years) underwent simultaneous CCR and CXL. Preoperative and 6 month postoperative uncorrected distance visual acuity (UDVC) and distance corrected visual acuity (DCVA) were measured using the Efficacy and Safety index. Objective and subjective quality of vision were respectively evaluated through preoperative and 6 month postoperative corneal morphological irregularity index (CMI), National Eye Institute Visual Function NEI-VFQ25 and NEI-VFQ39 questionnaires.
224295574|NCT05983913|BEHAVIORAL|cognitive-motor training|The cognitive-motor training program consists of five cognitive tasks related to concentration, reaction time, and executive function, combined with physical exercises using an interactive system. The five tasks include: (1) number sequence, (2) number-word sequence, (3) card matching games, (4) memorizing numbers, and (5) route-finding games.
223381742|NCT04664322|DEVICE|non invasive ventilation and high flow nasal canulae oxygen therapy|patients with hypoxemic acute respiratory failure received alternatively non invasive ventilation and high flow nasal canulae oxygen therapy
223381743|NCT04390776|DRUG|PF-06651600|PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
223381744|NCT04045769|DRUG|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
223998366|NCT00072501|PROCEDURE|breast imaging study|
223381745|NCT04045769|DRUG|Placebos|5 tablets of placebo to be administered orally
223381746|NCT04045769|DRUG|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
223998367|NCT00072501|PROCEDURE|comparison of screening methods|
223998368|NCT00072501|PROCEDURE|magnetic resonance imaging|
223998369|NCT00072501|PROCEDURE|radiomammography|
223998370|NCT00072501|PROCEDURE|ultrasound imaging|
223998371|NCT03202017|PROCEDURE|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
223381747|NCT04045769|DRUG|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
223998372|NCT03202017|PROCEDURE|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
223998373|NCT00469690|DRUG|Acular, Xibrom|"1. Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~2. Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)"
223381748|NCT00347646|DRUG|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
223381749|NCT00764881|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
223381750|NCT00764881|DRUG|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
223998374|NCT01361594|OTHER|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
223998375|NCT01361594|OTHER|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
223998376|NCT03219047|OTHER|Best Practice|Receive standard of care
224295575|NCT05983913|BEHAVIORAL|cognition training|The intervention consists of five cognitive tasks (memory, attention, spatial and temporal perception) with difficulty levels adapted to the individual's cognitive abilities.
224295576|NCT02405949|GENETIC|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
223998377|NCT03219047|DRUG|Ibrutinib|Given at standard dose and schedule
223381751|NCT00764881|DRUG|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
223998378|NCT03219047|OTHER|Patient Derived Xenograft|Xenograft developed
223998379|NCT03219047|OTHER|Personalized Medicine|Receive treatment based on the results of the PDX models
223998380|NCT02570919|RADIATION|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
223998381|NCT02570919|RADIATION|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
223998382|NCT04372862|PROCEDURE|Plane block|Two different plane blocks to control post-mastectomy pain
223998383|NCT03340831|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
223998384|NCT01670253|BEHAVIORAL|Group 1|"* 6 hour fast from all solid foods and milk beverages~* 2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~* Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
223998385|NCT01425619|BIOLOGICAL|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
223998386|NCT01425619|DRUG|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
223998387|NCT01425619|BEHAVIORAL|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
223998388|NCT01425619|BEHAVIORAL|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
223998389|NCT01516619|DRUG|Romiplostim|"Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8."
223998390|NCT03697551|DRUG|Satoreotide trizoxetan|Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
223998391|NCT06165757|BEHAVIORAL|noise stimulation|Apply non harmonic and white noise sound stimuli to the subjects, and then measure the threshold and tolerance values of pressure pain, cold pain, and electrical pain.
223998392|NCT01987362|DRUG|RO6870810|Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
223998393|NCT02200653|DRUG|High dose of MICARDIS®, once daily|
223998394|NCT02200653|DRUG|Low dose of MICARDIS®, once daily|
223998395|NCT02200653|DRUG|Low dose of COZAAR® / LORZAAR®, once daily|
223998396|NCT02200653|DRUG|High dose of COZAAR® / LORZAAR®, once daily|
223998397|NCT02200653|DRUG|Placebo|
223381752|NCT02274883|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
223998398|NCT02169570|DIETARY_SUPPLEMENT|Vitamin D|
223381753|NCT02274883|DIETARY_SUPPLEMENT|Protein Fractions|Protein fractions
223381754|NCT02031861|DRUG|nifedipine CR tablets (Xin Ran)|
223381755|NCT02031861|DRUG|nifedipine CR tablets (Adalat)|
223998399|NCT02169570|DIETARY_SUPPLEMENT|Calcium|
223998400|NCT02169570|DIETARY_SUPPLEMENT|Placebo Vit D|
223998401|NCT02169570|DIETARY_SUPPLEMENT|Placebo Calcium|
223998402|NCT03532659|OTHER|Active video game|Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
223998403|NCT04654572|DIAGNOSTIC_TEST|Myotonometric measurement|Myotonometric assessment can predict the muscle stiffness, tone and elasticity
223998404|NCT03985696|OTHER|blood sample|1 blood volume (5-7 ml EDTA)
223998405|NCT00780559|BEHAVIORAL|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
223998406|NCT00780559|BEHAVIORAL|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
223998407|NCT02871505|DRUG|Benzathine Penicillin G|
223998408|NCT01546532|DRUG|RLX030|RLX030 as intravenous infusion for 24 hours.
223998409|NCT01546532|DRUG|Placebo|Intravenous infusion of Placebo over 24 hours
223998410|NCT00541177|DRUG|atropine|0.25% atropine
223998411|NCT00541177|DRUG|tropicamide|0.5% tropicamide
223998412|NCT00002277|DRUG|Fluconazole|
223998413|NCT00002277|DRUG|Amphotericin B|
223998414|NCT03793036|DIETARY_SUPPLEMENT|preoperative nutrition|The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
223998415|NCT01343862|DRUG|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
223998416|NCT01343862|DRUG|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
223998417|NCT03824652|OTHER|walnuts|2 ounces of walnuts daily for 4-10 weeks
223998418|NCT03824652|OTHER|usual diet|Subject continues usual diet
223998419|NCT03824652|OTHER|phone counseling with dietitian|Weekly calls with dietitian
223729793|NCT04809207|OTHER|CF Wellness Program Sessions|The intervention will last approximately 12 weeks. During this time, up to 9 coaching sessions will be delivered. Each will last approximately 45 - 60 minutes. Sessions will be delivered either by web-based video chat (e.g., Zoom) or by telephone. Sessions will cover content such as understanding the physiological, cognitive, affective, behavioral contributors to CF fatigue; understanding the role of physical activity/exercise and fatigue including the importance of balancing activity and rest periods; cognitive restructuring; addressing attention and interpretation processes contributing to fatigue; teaching techniques such as mindfulness meditation relaxation strategies, good sleep hygiene, and activity scheduling and behavioral activation; and engaging social support. Physical activity goals will be set each session. Participants will be encouraged to use the provided fitness tracker and to sync weekly prior the coaching session so that the results can inform session content.
223729794|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy using the OMNI Surgical System
223545234|NCT05605730|OTHER|Traditional exercise management|"Prone back extension. Shoulder external rotation starting in 45° of internal rotation, with the arm by the side and the elbow flexed to 90 °.~Shoulder internal rotation starting in 45 ° of external rotation, with the arm by the side and the elbow flexed to 90 °..~Shoulder abduction (scapular plane) through a 0- to 60-° with the elbow flexed 90 ° and the shoulder in neutral rotation.~Shoulder flexion (sagittal plane) through a 0- to 60-°starting with the elbow flexed 90 ° and the shoulder in neutral rotation and punching forward, simultaneously extending the elbow and flexing the shoulder.~Internal rotation towel stretch: Subjects will be instructed to sit or stand while holding a towel with the affected arm behind the back and to use the other arm to pull the affected arm up the back."
223998420|NCT05873829|OTHER|Hand-foot exercises|Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
224295577|NCT00679536|DRUG|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
223998421|NCT03329729|OTHER|Rosuvastatin|Hyperlipidemic patients treated with rosuvastatin
223998422|NCT05649969|BEHAVIORAL|Consultations with Moffitt Dietician|Participants will have an initial consultation with a dietician and then biweekly follow-up visits (in person or virtually) for 12 weeks.
223998423|NCT05649969|BEHAVIORAL|Daily Food Intake Diary with Fitbit smartphone application|Participants will keep a daily diary of food intake with a Fitbit smartphone application and wear a Fitbit for 12 weeks
224123454|NCT06514352|OTHER|Skin contact immediately after birth|In the immediate skin-to-skin contact group after birth, if the newborn does not need any intervention, he will be placed on the mother's chest immediately (without cord clamping) and skin-to-skin contact will begin. An average of 60 minutes of skin contact will be made until the first breastfeeding occurs. All routine practices for the newborn in the delivery room (except weight measurement) will be performed on the mother's chest. (n=48)
224123455|NCT06514352|OTHER|Very Early Skin contact|In the very early skin-to-skin contact group, skin-to-skin contact will begin within the first 30-40 minutes after birth, after the first and emergency intervention is given to the newborn in need of intervention, and skin-to-skin contact will be carried out for an average of 60 minutes until the first breastfeeding occurs.(n=48)
224123456|NCT06514352|OTHER|Early Skin contact|For newborns who need intervention after birth and whose skin-to-skin contact cannot be started in the delivery room, skin-to-skin contact will begin within the first 24 hours after birth, after the newborn becomes stable.(n=48)
224123457|NCT06474377|BIOLOGICAL|Sinovac PCV24 formulation 1|One dose of Sinovac PCV24 formulation 1（0.5mL）
224295578|NCT00679536|DRUG|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.
223998424|NCT05649969|BEHAVIORAL|Questionnaires|Participants will complete a questionnaire electronically at baseline and again at week 4, 8, 12 and 16.
223545235|NCT03856736|OTHER|MIAT|Moderated aerobic exercise
223545236|NCT03856736|OTHER|Control|Weekly body relaxation and sham group
223998425|NCT06125158|PROCEDURE|Conventional ankle training|The program included ankle elastic band resistance training and balance training, in which the elastic band resistance training required subjects to complete resistance training in ankle plantarflexion, dorsiflexion, inversion and eversion directions with the help of elastic bands; and the balance training required subjects to complete the movements of standing with eyes open, standing with eyes closed, and throwing and catching the ball on flat ground and BOSU ball.
223998426|NCT06125158|PROCEDURE|Hip strength training|Hip strength training required subjects to complete resistance training in hip abduction and posterior extension, anterior step-up and lateral step-up exercises with the help of elastic bands.
224123458|NCT06474377|BIOLOGICAL|Sinovac PCV24 formulation 2|One dose of Sinovac PCV24 formulation 2（0.5mL）
224123459|NCT06474377|BIOLOGICAL|Pneumovax®|One dose of Pneumovax® (0.5 mL) contains 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F saccharides.
224123460|NCT06474377|BIOLOGICAL|Placebo|0.5 mL of 0.9%NaCl solution (normal saline)
224295579|NCT00679536|DRUG|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
224295580|NCT00679536|RADIATION|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
224295581|NCT05262036|DIETARY_SUPPLEMENT|Anti-aging Supplement|Mixture of different vitamins and nutrients
224295582|NCT05262036|DIETARY_SUPPLEMENT|Placebo|Excipient powder
224295583|NCT01649466|DRUG|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
224295584|NCT01649466|DRUG|Protaphane|Protaphane will be used as commercially available injection pens
223545237|NCT05460897|BEHAVIORAL|Health behaviour change|weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
223545238|NCT02628444|BIOLOGICAL|CYD Dengue Vaccine|0.5 mL, Subcutaneous
223545239|NCT02628444|BIOLOGICAL|Placebo (Sodium chloride 0.9%)|0.5 mL, Subcutaneous
223729795|NCT04658095|DEVICE|iStent inject|Ab-interno implantation of iStent inject (2 microstents)
223998427|NCT06125158|PROCEDURE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation of the gluteus mediums and gluteus maximus muscles of the affected side was carried out using the TB6807 low-frequency therapeutic instrument (with prescription for neuromuscular electrical stimulation) manufactured by China Tangbang Science and Technology Company.
223381756|NCT00300924|DRUG|Rizatriptan co-administered with Acetaminophen|
223381757|NCT01116063|DRUG|Inhaled iloprost|Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
223381758|NCT02267018|DEVICE|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
223381759|NCT01418417|DRUG|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
223381760|NCT06144138|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
223381761|NCT05230381|DRUG|Continous infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by 5mg/kg/h tranexamic acid infusion.
223381762|NCT05230381|DRUG|Single infusion|The 20mg/kg tranexamic acid will be diluted into a 50ml syringe and infused followed by same volume of 0.9% saline.
223381763|NCT05230381|DRUG|Placebo|The 0.9% saline is administered with the same volume at the same speed as the other group.
223381764|NCT02330497|PROCEDURE|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
223998428|NCT06319274|DRUG|Iloprost|Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
223998429|NCT06319274|DRUG|Isotonic saline|Continuously infusion for 72 hours at 3 ml/hours
223998430|NCT04311645|DRUG|Activated charcoal|Activated charcoal
223998431|NCT04311645|DIETARY_SUPPLEMENT|Dry seeds|Dry seeds
223998432|NCT00613743|DRUG|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
223998433|NCT00613743|DRUG|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
223998434|NCT02744170|DEVICE|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
223998435|NCT02744170|DEVICE|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
223998436|NCT02744170|DEVICE|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
223998437|NCT05208177|DRUG|SHR-1802＋camrelizumab + famitinib|SHR-1802 for injection，q3w； Camrelizumab for injection, q3w; Famitinib malate capsules, qd.
223998438|NCT06240221|DEVICE|Elevation Spine Saber-C System|Device: Elevation Spine Saber-C System Elevation Spine Saber-C System will be fixated between C2 through T1 according to surgeon standard of care at clinical practices through the United States.
223381765|NCT01628432|PROCEDURE|conservative hysterectomy I|conservative hysterectomy for benign disease
223545240|NCT05687981|DRUG|Bupivacaine|the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
223381766|NCT01628432|PROCEDURE|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
223545241|NCT05687981|DRUG|Dexamethasone|2 mg dexamethasone
223545242|NCT03183765|DRUG|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
223998439|NCT04539483|DRUG|HDIT101 (blinded therapy)|Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
223998440|NCT04539483|DRUG|Placebo (blinded therapy)|Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
223998441|NCT04539483|BEHAVIORAL|Photo documentation of orolabial herpes lesions|Patients will be asked to document their orolabial lesions with photos by using their smart phone
223998442|NCT04539483|BEHAVIORAL|Completion of questionnaires (patient-reported outcomes)|Patients will be asked to document their health status in questionnaires by using their smart phone
223998443|NCT04539483|PROCEDURE|28-day swabbing of orolabial region|Patients will be asked to complete 3 episodes of 28-day swabbing of orolabial lesions
223998444|NCT04539483|PROCEDURE|Blood drawings|Blood will be drawn for e.g. safety lab, HSV-analysis, pharmacokinetic etc.
224123461|NCT05854641|BIOLOGICAL|Stempeucel®|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
224123462|NCT03161067|DEVICE|BiCNS|Surgical implantation
224123463|NCT06804850|DRUG|Tislelizumab|200mg IV Q3W
224123464|NCT06804850|DRUG|Afatinib|30mg PO QD
224123465|NCT06804850|RADIATION|Low dose radiotherapy|4Gy / 2f. Intensity-modulated radiotherapy was used for radiotherapy.
223381767|NCT00304252|DRUG|Interferon beta-1a|
223381768|NCT06079411|DEVICE|virtual reality non-embodied|the non-embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with passive navigation of 8 sessions of 30/40 minutes 3 times a week.
223381769|NCT06079411|DEVICE|virtual reality embodied|the embodied virtual reality spatial training will consist of egocentric and allocentric spatial memory training with active navigation of 8 sessions of 30/40 minutes 3 times a week.
223381770|NCT06079411|OTHER|treatment as usual|"the treatment as usual (TAU; i.e., visuospatial paper and pencil stimulation) will consist of paper and pencil exercises"
223381771|NCT05395260|DRUG|FL-101|FL-101 200mg IV
223998445|NCT00047255|BIOLOGICAL|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
223998446|NCT00047255|DRUG|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
224123466|NCT06550180|DRUG|Spinal anaesthesia group (S)|Spinal anaesthesia is given to all patients in S group. They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl
224123467|NCT06550180|DRUG|Subcostal TAP block and spinal anesthesia group (STAP)|patient receive Subcostal TAP block before spinal anesthesia. Patients in STAP group will receive 20 ml of 0.25% isobaric bupivacaine for each side before spinal anesthesia
224123468|NCT06381466|DRUG|AZD0233|Randomized participants will receive AZD0233 orally as a single ascending dose (dose 1, dose 2, dose 3, dose 4 or dose 5) or multiple ascending dose (dose 6, dose 7 or dose 8)
224123469|NCT06381466|DRUG|AZD0233 Placebo|Randomized participants will receive matching placebo orally as a SAD or MAD.
224123470|NCT05896384|DRUG|BI 456906|BI 456906
224123471|NCT05896384|DRUG|Microgynon®|Ethinylestradiol (EE) and Levonorgestrel (LNG)
223381772|NCT01567462|DEVICE|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
223381773|NCT01567462|DEVICE|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
223381774|NCT03870880|DRUG|Risperidone ISM 75 mg|Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
223381775|NCT03870880|DRUG|Risperidone ISM 100 mg|Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.
223381776|NCT04160650|BEHAVIORAL|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~1. In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~2. In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~3. In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~4. In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
223381777|NCT03820128|OTHER|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
224123472|NCT04833933|OTHER|Phone survey about smoking cessation process since intervention in DISCO trial|We will conduct a phone survey at 2 years follow-up with a random sample of smoking patients at inclusion in DISCO trial, to know the evolution of their smoking habits, the quit attempts since the intervention and the modalities of these attempts.
224123473|NCT02439281|DRUG|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
223381778|NCT01307332|DRUG|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
223381779|NCT02923232|DEVICE|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
223381780|NCT01977417|DRUG|Salsalate|
223381781|NCT01977417|DRUG|Placebo|
223381782|NCT02174640|DIETARY_SUPPLEMENT|Coffee|Coffee Beverage
223381783|NCT02174640|DIETARY_SUPPLEMENT|Water|Water
223381784|NCT05928065|OTHER|Collection of datas|Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
223381785|NCT01692626|DRUG|Pimecrolimus|Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
223381786|NCT01692626|DRUG|Placebo|Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
223381787|NCT00022594|DRUG|liposomal lurtotecan|
223381788|NCT03182933|DRUG|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
223381789|NCT03182933|BEHAVIORAL|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
223729796|NCT04658095|DEVICE|OMNI® Surgical System|Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System
223729797|NCT02601378|DRUG|LXS196|LXS196 as a single agent
223381790|NCT03182933|OTHER|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
223381791|NCT03182933|DEVICE|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
223381792|NCT03260660|DEVICE|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
223381793|NCT00855894|DRUG|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
223381794|NCT00855894|DRUG|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
223381795|NCT04169269|DRUG|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
223381796|NCT04169269|DRUG|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
223381797|NCT05644561|DRUG|Ravulizumab|Ravulizumab will be administered by intravenous (IV) infusion.
223545243|NCT03183765|PROCEDURE|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.Response to treatment will be evaluated 1 month after the last session by decrease in the size of warts, decrease in the number of warts and photographic comparison.~The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size and\\or a decrease in the total number of warts), and no response (no change in size and number of warts)."
223545244|NCT00002798|DRUG|asparaginase|
223998447|NCT00047255|DRUG|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
223998448|NCT00047255|BIOLOGICAL|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
224123474|NCT02439281|DRUG|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
224123475|NCT03016442|DEVICE|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
224123476|NCT03016442|DRUG|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
223381798|NCT06514534|DRUG|ABL001/Asciminib|"The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition.~The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID).~The drug will be administered orally, allowing for convenient and non-invasive administration."
223545245|NCT00002798|DRUG|daunorubicin hydrochloride|
223381799|NCT06355674|BEHAVIORAL|Breastfeeding education provided with Lactation Simulation Model|The Lactation Simulation Model (LSM) is a high-fidelity simulator designed for interactive education, which educators can utilize for practical and wearable breastfeeding training. It is wearable like a shirt and is secured onto the chest by passing it over the shoulders and fastening it with a safety belt from the back. This allows the safety belt to be adjusted according to different body types and weights.
223545246|NCT00002798|DRUG|fludarabine phosphate|
223545247|NCT00002798|DRUG|therapeutic hydrocortisone|
223545248|NCT00002798|PROCEDURE|allogeneic bone marrow transplantation|
223545249|NCT00002798|RADIATION|3-dimensional conformal radiation therapy|
223545250|NCT00002798|BIOLOGICAL|filgrastim|Given SC
223545251|NCT00002798|DRUG|cytarabine|Given IV or IT
223545252|NCT00002798|DRUG|idarubicin|Given IV
223381800|NCT05803421|DRUG|Orforglipron|Administered orally once daily
223381801|NCT05803421|DRUG|Insulin Glargine|Administered SC once daily
223381802|NCT00143923|BEHAVIORAL|Nutrition, Exercise, Stress Management Counseling|Individualized advice
223381803|NCT00143923|OTHER|usual care|usual care
223545253|NCT00002798|DRUG|dexamethasone|Given PO
223545254|NCT00002798|DRUG|thioguanine|Given PO
223545255|NCT00002798|DRUG|etoposide|Given IV
223545256|NCT00002798|DRUG|methotrexate|Given IT
223545257|NCT00002798|DRUG|cyclophosphamide|Given IV
223545258|NCT00002798|BIOLOGICAL|aldesleukin|
223545259|NCT00002798|DRUG|busulfan|
223545260|NCT01084577|DEVICE|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
223381804|NCT06512753|DRUG|Hydroxychloroquine|HCQ (15) is administered orally at a dosage of 400 mg daily.
223998449|NCT00047255|DRUG|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
223381805|NCT06512753|DRUG|Methotrexate|MTX (16) is given at a dose of 15 mg per week, orally or subcutaneously. Additionally, folate supplementation is administered concurrently as part of standard care, with folate 10 mg/week administered 24 hours after MTX intake.
223381806|NCT05348083|PROCEDURE|ESPB|Echo-guided bilateral ESPB performed at T9 level at the end of surgery with a mixture of ropivacaine 0.375% and epinephrine 5 mcg/mL 20 mL each side.
223998450|NCT03751670|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation programmes will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training, education and psychosocial support.
223998451|NCT03751670|DRUG|Daily medical treatment|Patients will be treated with daily medication prescribed by the physician.
223381807|NCT04821089|BIOLOGICAL|IPN10200|"Stage 1: Several different doses will be administrated in a dose-escalation manner.~One single injection will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
223381808|NCT04821089|BIOLOGICAL|IPN10200 Placebo|"Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.~Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.~Stage 3: One single injection will be injected locally into several sites across the upper facial area."
223381809|NCT04821089|BIOLOGICAL|Dysport|Single administration of study intervention in stage 1 / step 2 and 3 only
223381810|NCT02898818|OTHER|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
223381811|NCT02898818|OTHER|papa smear|Papnicolaou Papa Smear test
223381812|NCT00925639|DRUG|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
223381813|NCT00925639|DRUG|Placebo|Starch pill
223381814|NCT06579534|OTHER|Health education strategy|Based on the concept of precise health care, investigators design risk awareness, self-health management and fall prevention care measures, and provide inpatients with high-risk groups with frailty and falls with health education guidance on muscle endurance training and fall prevention. This study adopts purposive sampling, randomization, assignment, and parallel experiments to divide into a control group and an experimental group. The control group uses conventional health education guidance to provide fall prevention education, and the experimental group uses multimedia health education videos to provide education to patients or primary caregivers. Provide health education on the risk, management and prevention of falls.
223381815|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg|single-dose:1mg/kg
223381816|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg|single-dose: 3mg/kg
223381817|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg|single-dose:10mg/kg
223381818|NCT03374007|BIOLOGICAL|Geptanolimab Injection 1mg/kg, q2w*6|multiple dosing: 1mg/kg, q2w\*6
223381819|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w*6|multiple dosing: 3mg/kg, q2w\*6
223381820|NCT03374007|BIOLOGICAL|Geptanolimab Injection 10mg/kg, , q2w*6|multiple dosing: 10mg/kg, , q2w\*6
223381821|NCT03374007|BIOLOGICAL|Geptanolimab Injection 280mg, q3w|multiple dosing: 280mg, q3w
223381822|NCT03374007|BIOLOGICAL|Geptanolimab Injection 3mg/kg, q2w|multiple dosing: 3mg/kg, q2w
223381823|NCT04795947|BEHAVIORAL|Behavioral|There is no intervention in this study
223381824|NCT02031419|DRUG|CC-122|2mg or 3 mg administered orally once daily
223381825|NCT02031419|DRUG|CC-223|20mg or 30mg administered orally once daily.
223545261|NCT01084577|DEVICE|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
223545262|NCT00174850|DRUG|Gaitril|
223381826|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
223381827|NCT02031419|DRUG|CC-122|2mg or 3mg administered orally once daily.
223381828|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
223381829|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
223381830|NCT02031419|DRUG|CC-223|20mg or 30mg per day administered orally daily.
223381831|NCT02031419|DRUG|CC-292|500 mg twice a day administered orally.
223381832|NCT02031419|DRUG|Rituximab|375 mg/m2 administered intravenously once every 28 days
223381833|NCT06438835|DIAGNOSTIC_TEST|PneuFlex AFO Assist|It features a pneumatic artificial muscle designed to enhance ankle foot orthosis functionally for patients with mobility issues.
223381834|NCT03231488|OTHER|Mindfulness intervention|A 10 minute mindfulness of breath exercise
223381835|NCT03231488|OTHER|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
223381836|NCT02422797|DRUG|DTG 50 mg|Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
223545263|NCT00532129|DRUG|Rituximab|375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.
223545264|NCT00532129|DRUG|Chlorambucil|10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
223729798|NCT02601378|DRUG|LXS196 and HDM201|LXS196 in combination with HDM201
223381837|NCT02422797|DRUG|RPV 25 mg|"Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV."
223381838|NCT02422797|DRUG|CAR|CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
223381839|NCT04327011|BIOLOGICAL|Toca 511 vector|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
223381840|NCT04327011|DRUG|Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine|Toca FC is an extended-release formulation of flucytosine.
223545265|NCT02386462|DRUG|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
223545266|NCT02386462|DRUG|Propofol|
223381841|NCT04071405|OTHER|Non-intervention|Non-intervention observational study
223545267|NCT05115370|OTHER|Semi-structured qualitative interview|A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
223381842|NCT05294666|DRUG|Cyclosporine|The chronic ocular GVHD patients in cyclosporine group received local 0.05% cyclosporine 4 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
223381843|NCT05294666|DRUG|tacrolimus|The chronic ocular GVHD patients in tacrolimus group received local 0.05% tacrolimus 2 times/day for 3 months, and then changed to 0.05% cyclosporine for 2 times/day for 3 months
223381844|NCT05096650|PROCEDURE|mesotherapy of platelet rich plasma and platelet poor plasma|Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
223381845|NCT01783795|OTHER|Genetic Analysis|
223381846|NCT00369941|DRUG|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
223381847|NCT00369941|DRUG|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
223545268|NCT03259243|DRUG|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
223381848|NCT00369941|DRUG|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
223381849|NCT00369941|DRUG|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
223545269|NCT04276194|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo intensity modulated proton therapy
223545270|NCT04276194|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223545271|NCT05071612|DRUG|AD109|Oral administration at bedtime
223381850|NCT00369941|DRUG|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
223381851|NCT01707017|OTHER|Strength training|
223381852|NCT00403585|DRUG|adefovir dipivoxil 10mg|
223381853|NCT02893085|BIOLOGICAL|bile sample analysis|tumor mutation profile tumor genotype
223381854|NCT02893085|BIOLOGICAL|biochemical markers, VEGF and MMPs, in bile samples|
223545272|NCT05071612|DRUG|AD504|Oral administration at bedtime
223545273|NCT05071612|DRUG|Atomoxetine Hydrochloride|Oral administration at bedtime
223545274|NCT05071612|DRUG|Placebo|Oral administration at bedtime
223545275|NCT00003846|BIOLOGICAL|filgrastim|
223545276|NCT00003846|DRUG|carboplatin|
223729799|NCT03671460|BIOLOGICAL|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
224123477|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
223381855|NCT03345693|DEVICE|MoTrack Therapy|A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
223381856|NCT04101409|OTHER|Decision aids|Shared decision making with decision aids
223545277|NCT00003846|DRUG|cyclophosphamide|
223545278|NCT00003846|DRUG|thiotepa|
223545279|NCT00003846|DRUG|vincristine sulfate|
223545280|NCT00003846|PROCEDURE|bone marrow ablation with stem cell support|
223545281|NCT00003846|PROCEDURE|peripheral blood stem cell transplantation|
223545282|NCT00003846|RADIATION|radiation therapy|
223545283|NCT00784368|DRUG|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
223545284|NCT00784368|DRUG|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
223545285|NCT04709679|PROCEDURE|MicroPulse TransScleral CycloPhotoCoagulation|A laser power of 2000- 2500 mW, a laser duration time of 50 to 80 sec per hemifield and varying da number of sweeps per hemifield 3, 4 or 5 will be randomized between patients
223545286|NCT05625295|OTHER|data collection protocol in clinical history|collection of data from the clinical history according to the established protocol
224123478|NCT00358917|DRUG|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
224123479|NCT04986449|BEHAVIORAL|nutritional and culinary intervention|"Each family will attend a total of 4 culinary-nutritional workshops between April and June 2021. Workshops 1 and 2 will be held in the kitchen located at the Science Building of the University of Navarra and will be given individually to each family.~Workshops 3 and 4 will be online (Zoom) and will be held in groups of 5 families. These workshops will be held from 5.30 pm to 7.30 pm on Fridays or from 11.30 am to 1.30 pm on Saturdays.~Finally, a meeting will be organized with all the families (parents and children) where the recipes prepared by the children for the n-CHEF challenge will be shared and prizes will be awarded."
223381857|NCT00249431|DRUG|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
223998452|NCT05992857|PROCEDURE|Pancreaticoduodenectomy without retromesenteric omental flap|Resection of the pancreatic head, duodenum, distal common bile duct and gallbladder followed by reconstruction using pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy performed on the first jejunal loop.
223998453|NCT05992857|PROCEDURE|Pancreaticoduodenectomy with retromesenteric omental flap|All exposed peripancratic arteries should be covered with a retromesentric omental flap
223998454|NCT02265666|DRUG|BIIL 284 BS Tablet FF|
223998455|NCT02265666|DRUG|BIIL 284 BS tablet C|
223998456|NCT02265666|OTHER|standard breakfast|
223998457|NCT01701336|BIOLOGICAL|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
223998458|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + OTf|OTf (apo ovotransferrin) + FeSO4
223998459|NCT05233709|DIETARY_SUPPLEMENT|FeSO4 + Lf|Lf (lactoferrin) + FeSO4
223998460|NCT05233709|DIETARY_SUPPLEMENT|FeSO4|Ferrous sulfate
223381858|NCT00249431|BEHAVIORAL|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
223381859|NCT00980031|DRUG|Eplerenone|25mg PO daily (QD)for 6 months
223381860|NCT00980031|DRUG|Lactose Tablet|Lactose tablet
223381861|NCT02461251|DEVICE|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
223381862|NCT05536999|OTHER|Blood sample taking , like to measure hormonal level like LH, FSH, Perlakan ,in a follicular fluid after the oocyte retrival|Blood test measure basal FSH, follicular fluid testing
223381863|NCT04975295|DRUG|LY3361237|Administered SC
223381864|NCT04975295|DRUG|Placebo|Administered SC
223381865|NCT01493869|DRUG|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
223381866|NCT00533286|DRUG|benzodiacepine|diazepam (2 x 5 mg/ die)
223381867|NCT04365803|PROCEDURE|vacuum-assisted breast biopsy|patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery
223381868|NCT02567279|DRUG|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
223381869|NCT02567279|DRUG|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
223381870|NCT06250218|OTHER|Video Interactive Guidance (VIG)|"Video interaction guidance (VIG) is a video feedback intervention through which a guider helps a client to enhance communication within relationships. The client is guided to analyse and reflect on video clips of their own interactions."
223381871|NCT05361915|DRUG|Abivertinib|Abivertinib is a small molecule inhibitor
223381872|NCT05361915|DRUG|Abiraterone|Hormone-based chemotherapy
223381873|NCT01407237|DRUG|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
223381874|NCT02276807|BEHAVIORAL|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
223998461|NCT01816347|PROCEDURE|Routine PCI|
223998462|NCT01046006|DRUG|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
223998463|NCT02383251|DRUG|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
223998464|NCT02383251|DRUG|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
223998465|NCT01766713|DRUG|Ezetimibe|10mg daily oral dose of ezetimibe
223998466|NCT03044977|DRUG|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
223998467|NCT03044977|DRUG|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
223998468|NCT02205034|DRUG|oxytocin|Intranasal administration
223998469|NCT05031949|COMBINATION_PRODUCT|hyperbaric oxygen therapy plus Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
223998470|NCT04540237|DIAGNOSTIC_TEST|Flow-cytometric analysis|Flow-cytometric analysis of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33
223998471|NCT05424146|DIETARY_SUPPLEMENT|Prebiotic Bar +CPT|Participants will be instructed to consume 1 prebiotic bar once daily for 1 week CPT. Starting week 2 they will be asked to consume 1 prebiotic bar twice daily.
223998472|NCT05424146|BEHAVIORAL|Non-Prebiotic Bar +CPT|Participants will be instructed to consume 1 non-prebiotic bar once daily for 1 week while receiving CPT. Starting week 2 they will be asked to consume 1 non-prebiotic bar twice daily.
223998473|NCT01377246|DRUG|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
223998474|NCT01377246|OTHER|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
223998475|NCT04535245|DIAGNOSTIC_TEST|LCI testing|all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
223998476|NCT01064700|DEVICE|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
223998477|NCT01064700|DEVICE|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
223998479|NCT01722370|DRUG|Oxygen|
223998480|NCT01722370|DRUG|Medical air equivalent|
223998481|NCT00900263|GENETIC|cytogenetic analysis|
223381875|NCT02276807|OTHER|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
223381876|NCT06498882|OTHER|Press Needle Acupoint Stimulation Combined with Breast Massage|Press needle acupoint stimulation and breast massage were administered. Key press needle acupoints were identified for selection: Dan zhong (RN17), bilateral Ru gen (ST18), bilateral Shao ze (SI1), bilateral Zu san li (ST36) and bilateral San yin jiao (SP6). The areas were sterilized with 75% alcohol before installing 0.22\*1.55mm press needles. Within 4-6 hours post-surgery, mothers received acupoint stimulation through needle pressing. This procedure was administered by nurses who had undergone six-month standardized training in traditional Chinese medicine techniques. Instructions were then given to mothers and their family members to stimulate the acupoints pulsatively every 3-4 hours for 20-30 minutes per session, removing the press needles after 24 hours. Additionally, a specialized nurse massaged the back, both breast areas, and armpits for 10-15 minutes, three times daily over three days, using a circular and oscillating breast massage device.
223381877|NCT06498882|OTHER|routine care|Very early skin-to-skin contact was initiated by researchers within 30 to 40 minutes after birth, with newborns, optionally wearing caps, being placed on the mothers' chests. Mothers were encouraged to breastfeed 8 to 10 times per day to ensure steady milk production. It was ensured by researchers that mothers completely emptied one breast before switching to the other to maintain cleanliness. Additionally, mothers were guided by researchers on maintaining a well-balanced diet, achieving emotional stability, and securing adequate sleep to facilitate effective breastfeeding.
223998482|NCT00900263|GENETIC|microarray analysis|
223998483|NCT00900263|OTHER|biologic sample preservation procedure|
223998484|NCT00900263|OTHER|laboratory biomarker analysis|
223998485|NCT05136053|DRUG|Lu AG22515|sterile solution for infusion
223381878|NCT03162874|DRUG|Placebo oral capsule|BID
223381879|NCT03162874|DRUG|PXT002331 - dose 1|Oral
223381880|NCT03162874|DRUG|PXT002331 - dose 2|Oral
223381881|NCT03971474|DRUG|Docetaxel|Given IV
223381882|NCT03971474|DRUG|Gemcitabine|Given IV
223381883|NCT03971474|DRUG|Gemcitabine Hydrochloride|Given IV
224123480|NCT05937269|COMBINATION_PRODUCT|Near-infrared fluorescence lymphatic imaging|All subjects will undergo lymphatic imaging at enrollment, 3, 6, and 12 months to assess the extent of dermal lymphatic backflow. Small amounts (0.1 mL) of a solution of indocyanine green (ICG) will be intradermally injected near the ear and along the jaw. Images of the lymphatics will be acquired by shining a dim light on the face and neck and acquiring the resulting fluorescent signal emanating from ICG-laden lymph. Images will be processed to calculate the area of the head and neck that show abnormal dermal lymphatic backflow.
223381884|NCT03971474|BIOLOGICAL|Pembrolizumab|Given IV
223381885|NCT03971474|DRUG|Pemetrexed|Given IV
223381886|NCT03971474|DRUG|Pemetrexed Disodium|Given IV
223381887|NCT03971474|BIOLOGICAL|Ramucirumab|Given IV
223381888|NCT02371382|DEVICE|Arthroplasty hip|Hip replacement
223381889|NCT04623892|DRUG|TQB2618 injection|TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
223381890|NCT00181701|DRUG|Paclitaxel|
223729800|NCT02781493|DRUG|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
223998486|NCT05136053|DRUG|Placebo|sterile solution for infusion
223998487|NCT05136053|DRUG|Immune System Activator|sterile powder for injection
223998488|NCT04175314|OTHER|Clinical examination of gingival tissues|Measure of the periodontal recession
223998489|NCT06098053|OTHER|muscle energy technique|Muscle energy technique is used at a rate of three sessions per week for four and half weeks
223998490|NCT06098053|OTHER|Muscel energy technique along with interferential therapy|Muscle energy technique along with interferential therapy is used at a rate of three sessions per week for four and half weeks
223998491|NCT04797234|OTHER|Control|There will be no intervention to the control group.
223998492|NCT04797234|OTHER|Experiment|The experimental group will be trained for 6 weeks.
223998493|NCT00847522|DRUG|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
223998494|NCT00450229|DRUG|diindolylmethane|Given PO
223998495|NCT00450229|DRUG|placebo|Given PO
223998496|NCT00450229|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223998497|NCT00450229|OTHER|laboratory biomarker analysis|Correlative studies
223998498|NCT00450229|OTHER|pharmacological study|Correlative studies
223998499|NCT00839956|DRUG|Bortezomib|Given IV
223998500|NCT00839956|DRUG|Vorinostat|Given PO
224123481|NCT05937269|DEVICE|advanced pneumatic compression therapy|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy.
224123482|NCT05856773|RADIATION|Proton Therapy|Pencil Beam Scanning (PBS)
224123483|NCT00759473|DRUG|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
224123484|NCT00759473|DRUG|Placebo|
224123485|NCT01225406|DRUG|Tenofovir|
224123486|NCT02154750|DEVICE|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
223998501|NCT02807883|DRUG|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
223381891|NCT00181701|DRUG|Carboplatin|
223381892|NCT03251001|PROCEDURE|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
223381893|NCT03251001|DEVICE|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
223381894|NCT02045901|DRUG|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
223381895|NCT02045901|DRUG|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
223381896|NCT00261950|DRUG|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
223381897|NCT01375946|DRUG|AG200-15|There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
223381898|NCT02237586|BIOLOGICAL|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
223381899|NCT02299323|DEVICE|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
223381900|NCT02875990|BIOLOGICAL|Blood sample|
223381901|NCT00525980|BEHAVIORAL|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
223381902|NCT00525980|BEHAVIORAL|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
223381903|NCT00525980|OTHER|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
223381904|NCT00525980|BEHAVIORAL|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
223381905|NCT05661370|OTHER|Dermloop Learn|Educational Mobile Application with a library of digital patient-cases and written learning modules the user can access on 36 common skin lesions, both benign and malignant.
223381906|NCT04612907|RADIATION|Moderate hypo-fractionation|Patients will receive four weeks of radiotherapy
223381907|NCT04612907|RADIATION|Ultra-hypo-fractionation|Patients will receive two and a half weeks of radiotherapy
223998502|NCT02807883|PROCEDURE|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
223998503|NCT02091115|DIETARY_SUPPLEMENT|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
223998504|NCT02091115|DIETARY_SUPPLEMENT|Dairy drink|
223381908|NCT01937871|DRUG|5 mg Tadalafil|Administered orally
223381909|NCT01937871|DRUG|Placebo|Administered orally
223381910|NCT01937871|DRUG|0.2 mg Tamsulosin|Administered orally
223381911|NCT00037583|DRUG|Gemtuzumab Ozogamicin|
223381912|NCT05273411|DIETARY_SUPPLEMENT|(R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester|Single-dose pharmacokinetic study over 4 hours.
223998505|NCT03404544|DRUG|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
223381913|NCT05273411|DIETARY_SUPPLEMENT|Beta-hydroxybutyric acid|Beta-hydroxybutyric acid
223381914|NCT05273411|DIETARY_SUPPLEMENT|1,3-Butanediol|1,3-Butanediol
223381915|NCT00003126|DRUG|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
223381916|NCT04754841|OTHER|platelet cryopreservation|The cryopreservation of platelets will be carried out using as alternatives of cryopreservative solution: 5% dimethylsulfoxide alone (solution 1) or combined with 5% dextrose 160 mg (solution 2) or with 2% albumin (solution 3) and then be frozen at -80 ° C
223381917|NCT00577863|DRUG|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
223381918|NCT04795895|DIAGNOSTIC_TEST|ultrasonography (US)|US evaluation was performed after insertion of the tube via subxiphoid approach for tube passing esophagogastric (EG) junction. The tube insertion procedure will be repeated no more than three attempts if no visualization by US.
223381919|NCT04795895|DIAGNOSTIC_TEST|Standard routine (SR)|Standard routine (SR)
223381920|NCT00002817|BIOLOGICAL|sargramostim|
223381921|NCT00002817|BIOLOGICAL|vaccinia-GM-CSF vaccine|
223381922|NCT06031558|DRUG|SY-5007|a RET selective Inhibitor
223381923|NCT02665221|OTHER|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
223998506|NCT03404544|DRUG|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
223998507|NCT00219011|DRUG|aliskiren|
223998508|NCT06144619|GENETIC|Genomic and Histological Evaluation|Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
223998509|NCT01521247|OTHER|Asthma Transition Program|Asthma Education.
223381924|NCT02665221|DRUG|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
223381925|NCT03408171|DEVICE|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
224295585|NCT00569790|DRUG|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
223998510|NCT00003485|DRUG|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223998511|NCT04494204|COMBINATION_PRODUCT|Immunofree tablets and Reginmune capsule|2 Immunofree tablets thrice a day at an interval of 4-5 hours for 10 days and 1 Reginmune capsule twice a day for 10 days
223998512|NCT04835792|OTHER|Stool and blood collection|One-time stool and blood collection
223381926|NCT03408171|DEVICE|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
223381927|NCT00754078|RADIATION|Tomotherapy|30 fractions of tomotherapy treatment
223381928|NCT02597829|DRUG|Certolizumab Pegol|Subcutaneous Injection
223381929|NCT05573958|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban 2.5 mg oral tablet will be administered twice daily
224295586|NCT03334721|DRUG|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
223998513|NCT02523690|DRUG|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
223998514|NCT02523690|DRUG|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
224295587|NCT03334721|DRUG|Placebo Oral Capsule|5 day trial of matched placebo
223998515|NCT00011934|BIOLOGICAL|recombinant interferon alfa|
223998516|NCT00011934|BIOLOGICAL|sargramostim|
223998517|NCT00011934|PROCEDURE|autologous bone marrow transplantation|
223998518|NCT04236687|DEVICE|Holmium laser enucleation of the prostate|Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra
224123487|NCT02154750|DEVICE|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
224295588|NCT03771937|OTHER|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
224295589|NCT05709977|OTHER|Acupuncture|Fixed set of acupuncture points
224295590|NCT05709977|DRUG|Antihistamine nasal spray|Carelastin® (1 mg/ml) azelastine nasal spray
224295591|NCT06015477|DRUG|Ticagrelor monotherapy|starting dose of ticagrelor was a single loading dose of 180mg (90mg x 2 tablets) and thereafter 1 tablet (90mg) each time, twice daily.
224295592|NCT06015477|DRUG|Dual Antiplatelet Therapy|Clopidogrel 75mg + Aspirin 100mg 1 month, after 1 month, change to aspirin 100mg 1 year.
223381930|NCT05573958|DRUG|Clopidogrel tablet|Clopidogrel 75 mg once daily orally
223381931|NCT05573958|DRUG|Aspirin tablet|Aspirin 81 mg tablet once daily
223381932|NCT00486850|OTHER|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
223381933|NCT01937221|OTHER|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
223381934|NCT00494702|PROCEDURE|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
223381935|NCT00494702|PROCEDURE|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
223381936|NCT00668317|DRUG|Omeprazole|20 mg BD tablet 8 weeks duration
223381937|NCT00668317|DRUG|Ranitidine|300 mg od nocte tablet 8weeks duration
223998519|NCT04236687|PROCEDURE|Artery embolization of the prostate|A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate
223998520|NCT04041037|DEVICE|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
223998521|NCT00534170|DIETARY_SUPPLEMENT|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
223998522|NCT04148781|DRUG|Fampridine SR|Fampridine-SR 10 mg twice daily for 8 weeks
223998523|NCT02130323|DRUG|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
223998524|NCT02130323|PROCEDURE|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
223998525|NCT01462006|DRUG|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
223998526|NCT01462006|OTHER|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
224123488|NCT03347617|DRUG|Ferumoxytol|Given IV
224123489|NCT03347617|OTHER|Laboratory Biomarker Analysis|Correlative studies
224123490|NCT03347617|PROCEDURE|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
224123491|NCT03347617|BIOLOGICAL|Pembrolizumab|Given IV
224123492|NCT05473520|DRUG|Doxycycline|A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.
224295593|NCT03716245|PROCEDURE|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
224295594|NCT03716245|RADIATION|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
223998527|NCT01871688|BEHAVIORAL|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
223998528|NCT01399918|DRUG|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
223998529|NCT04693039|DRUG|Phenlarmide|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
223998530|NCT04693039|DRUG|Placebo|Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
223998531|NCT06237088|OTHER|online mindfulness program|The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
223998532|NCT06237088|OTHER|eight-week mindfulness programs|The intervention consists of 2.5-hour classes per week over a period of eight weeks.
223998533|NCT06022341|OTHER|Multiomic characterization|Multiomics analysis include targeted-NGS with a 400-genes panel, RNA-seq and methylome. All the genomic libraries will be constructed at the genomic facility of Angers University Hospital and the sequencing will be performed on a NovaSeq6000 in the GenoBIRD Platform in Nantes. Bioinformatic analysis will be performed and will derive for each sample: SNV/Indel and CNV from DNA sequencing, expression of mRNA and lncRNA, genes fusion and splicing events from RNA-seq, and methylation beta-values from methylome.
223998534|NCT06022341|OTHER|In vitro drug screening|The drug screening will be performed on the 'NEXT-AML' platform at St-Louis Hospital, Paris. This platform uses a multiparametric screening strategy based on flow cytometry measurements of cell viability, cell differentiation and stem cell compartment. Primary patient cells will be cultured in a specific niche-like medium with amino-acids, cytokines and stromal cells (Dal Bello et al. 2022). Twenty-five drugs at 6 concentrations covering a 1000-fold concentration range will be studied for each sample.
223998535|NCT05141552|DRUG|Dapagliflozin 10Mg Tab|In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.
223998536|NCT05650762|DEVICE|Cinesteam|Cinnamon-based Secondary dressing
224123493|NCT05473520|DRUG|Placebo|Placebo + standard anti-tuberculous treatment
224123494|NCT05994846|DEVICE|RISES-T System|The RISES-T system is a hardware and software platform that has been designed and developed to help people living with movement impairment due to Spinal Cord Injury (SCI) to improve and/or restore mobility. The hardware consists of a functional electrical stimulation device that delivers stimulation to the skin through surface electrodes; a series of wearable sensors that collect kinematic (IMU) data and muscle activity (EMG) data, and RISES Software, which incorporates algorithms that utilizes the streaming IMU and EMG sensor data to inform the electrical stimulation parameters and enables real-time visualization of the sensor data and stimulation parameters via Graphical User Interface (GUI).
223381938|NCT00064896|PROCEDURE|MRI|
223381939|NCT06052293|DRUG|ANG003|To evaluate four possible combinations of lipase, protease and amylase.
224295595|NCT02706782|DRUG|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
224123495|NCT00584220|DEVICE|senofilcon A toric|contact lens
224295596|NCT00304720|DRUG|Tacrolimus and MMF|
224295597|NCT01624441|DRUG|Dinaciclib|Given IV
224295598|NCT01624441|DRUG|Epirubicin Hydrochloride|Given IV
223381940|NCT00248261|DRUG|ziprasidone, sertraline|
223381941|NCT01057511|DRUG|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
224123496|NCT00584220|DEVICE|alphafilcon A toric|contact lens
224295599|NCT01624441|OTHER|Laboratory Biomarker Analysis|Correlative studies
224295600|NCT00878514|DRUG|Alprazolam|Alprazolam 1 mg tablet
224295601|NCT00878514|DRUG|Xanax|Xanax 1 mg tablet
223381942|NCT01057511|DRUG|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
223381943|NCT02924831|OTHER|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
223381944|NCT02924831|OTHER|moxibustion|Stimulating acupoints by using burned moxa
223381945|NCT02924831|OTHER|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
223381946|NCT04451148|OTHER|Obese with or without metabolic syndromesubjects|Children with obesity and with or without metabolic syndrome
223381947|NCT03037593|DRUG|4000 IU vitamin D3|vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
223381948|NCT03233893|OTHER|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
223381949|NCT05214625|OTHER|Questionnaire|Questionnaire concerning artificial intelligence and its implementation in healthcare. GI patients and GI physicians will be provided with slightly different questionnaires.
223381950|NCT03203317|DRUG|Insulin|2 h insulin clamp
223381951|NCT03203317|OTHER|Exercise|Cycling exercise
224123497|NCT00042354|DRUG|clofarabine (IV formulation)|
224123498|NCT04972032|DEVICE|Estrogen Intrauterine Stent System|A Estrogen Intrauterine Stent System（E-IUS）will be introduced post-operatively. The E-IUS will be removed 60 days after surgery with continuous dydrogesterone administration for 5 days at 20 mg/d, and routine management.
224295602|NCT03145831|DRUG|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
223381952|NCT04540653|BIOLOGICAL|Standard vaccination schedule|Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.
223381953|NCT04540653|BIOLOGICAL|Reinforced vaccination schedule|Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
223381954|NCT01894087|BEHAVIORAL|TBI - Cohort 1|
223381955|NCT01894087|BEHAVIORAL|TBI - Cohort 2|
223381956|NCT01366820|DRUG|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
223381957|NCT01366820|DRUG|Placebo|Sodium Chloride 0.9% Injection
223381958|NCT00972374|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
223381959|NCT00972374|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
223381960|NCT00972374|OTHER|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
223381961|NCT05085379|DEVICE|Ossiview|Imaging of the ear using Optical Coherence Tomography
223381962|NCT02463266|BEHAVIORAL|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
223729801|NCT02781493|DRUG|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
223998537|NCT03617835|DRUG|R - Low dose of BI 655130|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
223998538|NCT03617835|DRUG|T1 - Low dose of BI 655130|Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
223998539|NCT03617835|DRUG|T2 - Low dose of BI 655130|Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
223998540|NCT03617835|DRUG|T3 - High dose of BI 655130|Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
223998541|NCT03197766|DRUG|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
223381963|NCT06510699|OTHER|genotype-directed dosing with dosing software based on therapeutic drug monitoring|Genotype-directed dosing with dosing software based on therapeutic drug monitoring
223381964|NCT01963546|OTHER|different types of anesthesia|
223381965|NCT01963546|DRUG|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
223381966|NCT02685228|DRUG|Decitabine|decitabine 5mg/m2,d1-d5;
223381967|NCT02685228|DRUG|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
223381968|NCT02646605|OTHER|depression screening|Patient Health Questionnaire
223545287|NCT03696550|DRUG|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~* Cohort 1: from 12 to \<18 years of age (N=8)~* Cohort 2: from 8 to \<12 years of age (N=12 or at least 60% of subjects)"
223729802|NCT03012802|PROCEDURE|Colorectal Surgery|Postoperative Audit
223729803|NCT02326025|DRUG|Olaratumab|Administered IV
223998542|NCT03197766|DRUG|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
223998543|NCT06045715|OTHER|follow-up with different time intervals|After radical surgery, patients are followed up with different time intervals
223998544|NCT05700968|OTHER|validity and reability study|Validity and reliability assessment of the Turkish version of the Multidimensional Outcome Expectations For Exercise Scale (MOEES).
223998545|NCT00753064|DRUG|Antiscorpion venom serum(AScVS).|"AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(\>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 \> 10-15 3 6 \>15- 21 4 8"
223998546|NCT00753064|DRUG|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
223998547|NCT00753064|DRUG|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
223381969|NCT00717288|DRUG|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
223381970|NCT00717288|DRUG|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
223381971|NCT00717288|DRUG|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
223381972|NCT00002382|DRUG|Saquinavir|
223545288|NCT04194892|BIOLOGICAL|Pegilodecakin|Administered SQ
223545289|NCT00200707|PROCEDURE|Intracoronary injection of autologous bone marrow mononuclear cells|
223545290|NCT01596855|DRUG|FG-4592|TIW dosing, capsule
223381973|NCT02859766|DRUG|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
223381974|NCT05302531|DRUG|Amoxicillin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
223381975|NCT05302531|DRUG|Levofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
223381976|NCT05302531|DRUG|Ofloxacin|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
223381977|NCT05302531|DRUG|Sulfamethoxazole trimethoprim|Each patient will receive the proper antibiotic to treat the infection, first intravenously, then orally
223381978|NCT05024552|DRUG|Gilteritinib|Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
223381979|NCT05024552|DRUG|Vyxeos|Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.
223381980|NCT05567367|COMBINATION_PRODUCT|Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)|RT234 is a drug/device combination product composed of vardenafil hydrochloride as the drug constituent and will utilize RS01 DPI device.
223381981|NCT05567367|DRUG|Vardenafil Oral Tablet|20 mg oral vardenafil tablet.
223998548|NCT02831023|DRUG|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
223998549|NCT02831023|DRUG|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
223998550|NCT02831023|DRUG|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
223998551|NCT02831023|DRUG|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
223998552|NCT02831023|DRUG|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
223998553|NCT00021138|BEHAVIORAL|smoking cessation intervention|
223998554|NCT00021138|DRUG|nicotine|
223998555|NCT03911934|OTHER|Polypharmacy intervention|A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
223998556|NCT03911934|OTHER|Usual care|Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
223998557|NCT01173432|DEVICE|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
223998558|NCT00672737|DRUG|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
223998559|NCT00672737|PROCEDURE|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
223381982|NCT05888805|OTHER|DIMS spectacle lens|DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.
223381983|NCT05211726|OTHER|Low Added Sugar Diet|Consumption of 10 days of a diet low in added sugars (5% of total caloric intake)
223381984|NCT05211726|OTHER|High Added Sugar Diet|Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
223381985|NCT03509467|BEHAVIORAL|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
223381986|NCT03509467|BEHAVIORAL|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
223381987|NCT03509467|OTHER|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
223381988|NCT03886740|PROCEDURE|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
223381989|NCT05271630|OTHER|Autologous Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled ASCT recipients receiving Single agent vs doublet maintenance chemotherapy post ASCT
223381990|NCT05271630|DRUG|Immunomodulatory Agent|ASCT recipients receiving maintenance therapy consisting of an Immunomodulatory agent (IMID) after ASCT transplant
223381991|NCT05271630|DRUG|Proteasome Inhibitor|ASCT recipients receiving maintenance therapy with a proteasome inhibitor in combination with an immunomodulatory drug after ASCT transplant
223381992|NCT03892603|OTHER|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
223545291|NCT01596855|DRUG|Epoetin Alfa|TIW
223545292|NCT03254628|OTHER|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
223729804|NCT02326025|DRUG|Doxorubicin|Administered IV
223381993|NCT03892603|OTHER|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
223381994|NCT03892603|OTHER|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
223381995|NCT00277693|DRUG|Spironolactone (drug)|
223381996|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
223381997|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd|live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
223381998|NCT05015686|BIOLOGICAL|Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd|live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
223381999|NCT05015686|BIOLOGICAL|Placebo|Sodium chloride and distilled water
223382000|NCT03883503|OTHER|Beer 5%o|Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants
223382001|NCT03883503|OTHER|Beer 8.5%o and water|Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants
223382002|NCT03883503|OTHER|Beer 8.5%o and stock|Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
223382003|NCT03883503|OTHER|Water|Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
223382004|NCT00697151|DRUG|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
223382005|NCT00697151|DRUG|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
223382006|NCT01412086|DRUG|No Intervention|No Intervention.
223382007|NCT05311904|OTHER|Survey|1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months
223382008|NCT02253004|DRUG|Cilostazol|Single oral administration of active or placebo one week apart
224295603|NCT06927401|DEVICE|Flower|"Flower is a single-use capsule endoscope designed for timely visualization of the human stomach. The patient drinks water to fill the stomach before swallowing the Flower capsule, which transmits wireless video, through an external dongle placed near the patient's abdomen, to a physician's computer or smartphone. Flower is weighted to orientationally bias the capsule upward, meaning that with a few simple position adjustments a complete viewing of the stomach can be achieved approximately 10 minutes.~The procedure requires no sedation or equipment other than the Flower System (capsule and dongle). As a simple means of screening, Flower functions equivalent to comparable technologies, but offers advantages of being less invasive and burdensome. Flower has fewer potentially adverse consequences than traditional endoscopy (EGD), and it does not require capital equipment as magnetic endoscopy does. Flower offers the identification and location of bleeding sources in the stomach."
223382009|NCT02253004|DRUG|Placebo|
223382010|NCT00309855|DRUG|Placebo|im and orally
223382011|NCT00309855|DRUG|Testosterone|injections
223382012|NCT00309855|DRUG|Anastrazole|orally x 21 days
223382013|NCT00309855|DRUG|Dutasteride|orally x 21 days
223382014|NCT02829918|DRUG|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 every 4 weeks (Q4W) from 17 weeks to end of study.
223382015|NCT06970106|DRUG|PYC-001|PYC-001 is a peptide-phosphorodiamidate morpholino oligonucleotide administered intravitreally
223382016|NCT03484091|DRUG|Hyruan-One|single dose intra-articular injection
223382017|NCT03484091|DRUG|Hylan G-F 20|single dose intra-articular injection
223382018|NCT03484091|DRUG|Normal saline|single dose intra-articular injection
223382019|NCT05381909|DRUG|BGB-24714|administered orally
223382020|NCT05381909|DRUG|Paclitaxel|administered intravenously
223382021|NCT05381909|DRUG|Carboplatin|administered intravenously
223382022|NCT05381909|DRUG|Docetaxel|administered intravenously
223382023|NCT06421935|DRUG|M9466|Participants will be administered M9466 orally.
223382024|NCT06421935|DRUG|Tuvusertib|Participants will be administered Tuvusertib orally.
223382025|NCT06421935|DRUG|Abiraterone acetate|Participants will be administered with Abiraterone acetate orally.
223382026|NCT06421935|DRUG|Prednisone/Prednisolone|Participants will be administered with prednisone/prednisolone orally.
223425499|NCT03790449|BEHAVIORAL|Attention Control Programme|The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
223998560|NCT00672737|DEVICE|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
223998561|NCT00672737|PROCEDURE|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
223998562|NCT00280722|BEHAVIORAL|patient information leaflet|
223998563|NCT03363139|DRUG|Tirosin Kinase Inhibitors|Patients that received Tyrosin Kinase inhibitors and progressed
223998564|NCT02274155|DRUG|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
223998565|NCT02274155|PROCEDURE|Surgical Resection|Surgical Resection of Tumor
223998566|NCT04531020|DIAGNOSTIC_TEST|PAED measurement|The incidence of emergence delirium, defined as PAED score above 10 points minimally in one of the PAED score measurements. PAED score will be measured in 0., 5., 10., 15., and 20. minute after PACU admission.
223998567|NCT00972322|DRUG|MK-8245|MK-8245 50 mg twice daily for 28 days
223998568|NCT00972322|DRUG|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
223382027|NCT06132763|BEHAVIORAL|Hydration Intervention|"Teacher \& student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, \& update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning."
223998569|NCT04197375|BEHAVIORAL|Thermal stress and performance using a pre-cooling protocol|One hour before a tennis match, participants were wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes. During the tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
223382028|NCT06132763|OTHER|Control - Assessments Only|Assessments only
223382029|NCT05867368|BEHAVIORAL|HABIT-VR|HABIT-VR is a suite of video games designed on the principals of HABIT treatments. The games are delivered in virtual reality, because these systems provide a way to track the movements of both hands and build software that requires both hands to succeed.
223382030|NCT05867368|BEHAVIORAL|Standard HABIT|HABIT is a camp where children play self-select activities that require both hands to succeed.
223382031|NCT03071406|DRUG|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
223382032|NCT03071406|DRUG|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
223998570|NCT04197375|BIOLOGICAL|Thermal stress and performance without a pre-cooling protocol|During a tennis match the following variables were monitored: heart rate, core temperature, skin temperature, thermal sensation and comfort, rating of perceived exertion and hydration status.
224123499|NCT04972032|DEVICE|Foley balloon combined with self-cross-link sodium hyaluronate gel|Foley balloon combined with self-crosslinking sodium hyaluronate gel will be introduced post-operatively，2 cycles of estrogen-progestin sequential therapy comprised of continuous estrogen and progestin added in the second half of the cycle or continuous estradiol valerate for 60 days, followed by dydrogesterone for 10 days
223382033|NCT03071406|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
224123500|NCT03359005|DRUG|Vincristine|vincristine 1.5mg/m2 iv D1,D8
223382034|NCT06719869|DEVICE|Midline intravenous catheter|Patients in the intervention group receive a 10 cm PowerGlide Pro™ Midline Catheter (Becton Dickinson). Catheters are inserted with ultrasound-guidance by an anesthesiologist using sterile gloves, mask, and large drape. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. All catheters are secured with using a StatLock™ Stabilization device (Becton Dickinson), and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. Choice of insertion site on arm below or above the elbow avoiding catheter across joints and at the clinician's discretion.
223425500|NCT00571571|BEHAVIORAL|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
223425501|NCT00571571|BEHAVIORAL|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
223998571|NCT02334579|RADIATION|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
223998572|NCT02625064|OTHER|Blood samples collection before treatment|
223998573|NCT02625064|OTHER|Blood samples collection after treatment|
223998574|NCT02625064|OTHER|laboratory biomarker proteomic analysis|
223998575|NCT02002377|DRUG|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
223998576|NCT02908763|DRUG|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
223998577|NCT03991208|DRUG|Malarone|Malarone
223998578|NCT03439813|BEHAVIORAL|TASK-CBT|.Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
224123501|NCT03359005|DRUG|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
224123502|NCT05186883|BIOLOGICAL|Allogenic parathyroid cells|Allogenic parathyroid cells
224123503|NCT05186883|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of postoperative hypoparathyroidism according to the Clinical protocols
224123504|NCT00782665|PROCEDURE|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
223998579|NCT03439813|BEHAVIORAL|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
223998580|NCT02826382|DRUG|[68Ga]P15-041|Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
223998581|NCT06503081|PROCEDURE|Colonoscopy|Colonoscopy with video recording and biopsy collection
223998582|NCT05795803|OTHER|Forced isolation context|Exposure to the forced isolation context provided by the ongoing Covid-19 pandemic restrictive measures
223382035|NCT06719869|DEVICE|Central Venous Catheter (CVC):|Patients in the control group receive a Celsite 320 or 315 (B. Braun) or Pressure Injectable Arrowg+ard Blue Plus+ (Arrow). Catheters are inserted with ultrasound-guidance by an anesthesiologist with maximal sterile precautions (cap, mask, gown, gloves, and large drape) using the Seldinger technique. The insertion site is treated with a solution of 0.5% chlorhexidine (wt/vol) in 70% alcohol (SCHA) and allowed to dry for 1 to 2 minutes prior to insertion. No prophylactic antibiotics are given as per default. Catheters are secured with monofilament sutures, and the site is dressed with a semipermeable dressing (Tegaderm HP; 3M Healthcare, St. Paul, MN). A red paper tag is attached to the catheter, indicating study participation. The choice of insertion site is at the clinician's discretion
223382036|NCT05358795|BEHAVIORAL|Family Connections|Family Connections is based on the WHO endorsed Positive Connections manual.
223382037|NCT05681026|BEHAVIORAL|Yoga Sessions|Participants will have up to 12 sessions, 3 sessions per week starting two weeks before the transplant and throughout the first 30 days of your hospitalization.
223998583|NCT04033302|BIOLOGICAL|CD7-specific CAR gene-engineered T cells|Infusion of CD7-specific CAR-T cells
223998584|NCT02614053|DEVICE|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI \& spHB
223998585|NCT00671177|PROCEDURE|water immersion colonoscopy|instillation of 300cc of water in the rectum
223382038|NCT05681026|BEHAVIORAL|Questionnaries|Participants will complete 4 questionnaires about any symptoms you may be having, any anxiety and/or depression you may be having, your quality of life, and your expectations about your treatment.
223382039|NCT05681026|BEHAVIORAL|Interviews|Participants will have an exit interview last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom, FaceTime, or other approved video call methods.). The interview will be audio and video recorded and transcribed (typed).
223998586|NCT00671177|PROCEDURE|standard air colonoscopy|air instillation in colon for visualization
223998587|NCT06384105|RADIATION|frames per second|Other settings for frames per second
223998588|NCT01878396|DRUG|Anti-B-RAF|
223998589|NCT04224402|DRUG|mFOLFORINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
223998590|NCT02661191|DRUG|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
223382040|NCT06080256|DRUG|Alirocumab|alirocumab (75 mg every 2 weeks)
223545293|NCT03254628|OTHER|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag \& mask device.
223998591|NCT04004689|OTHER|2 times : 6-minute stepper test with a rest of 20min between each test.|"Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry."
223382041|NCT06080256|DRUG|Atorvastatin|Atorvastatin 20-40mg
223382042|NCT04052360|DRUG|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
223382043|NCT04052360|DRUG|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
223998592|NCT04837339|OTHER|Collection of biological samples|Blood sample, biopsies sample, hair sample.
223998593|NCT03066882|DIETARY_SUPPLEMENT|NCD|negative calorie diet
223998594|NCT03066882|DIETARY_SUPPLEMENT|LCD|low calorie diet
223998595|NCT05125926|BIOLOGICAL|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide. The investigational are administered through Intramuscular injection (IM) at upper arm deltoid on day 0, 28, 56.
223998596|NCT05125926|BIOLOGICAL|Placebo|Aluminum hydroxide
223998597|NCT02214875|OTHER|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
223998598|NCT02214875|OTHER|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
223998599|NCT05602753|BEHAVIORAL|Lifestyle Counseling|Referring to Stop smoking hotline, given pamphlets to encourage quitting smoking, pharmacy guidance, and possible referral to smoking cessation clinic.
223998600|NCT00277095|DEVICE|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
223382044|NCT05157594|BIOLOGICAL|Blood sample|Evaluation of plasma hPG80 concentrations by fasting blood samples. A total of seven 5 mL blood samples will be taken: Before radiation therapy; at the end of radiation therapy; at cycle 3 of chemotherapy; at cycle 6 of chemotherapy; 3 months after the end of treatment; 6 months after the end of treatment; and 9 months after the end of treatment.
223382045|NCT03874273|DRUG|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
223382046|NCT02803658|BEHAVIORAL|smoking behavior|
223382047|NCT02803658|BIOLOGICAL|Sperm collection|
223382048|NCT04202055|OTHER|Biomarker analysis|Detection of biomarker in cerebrospinal fluid
223382049|NCT05326555|DIAGNOSTIC_TEST|Dynamic Vision Testing (Bertec Vision Advantage System) and Balance Error Scoring System|Assessment tool and computerized tests designed to evaluate postural stability and vestibulo-ocular reflex (VOR) function while assisting with return to play decision after a sports-related concussion.
223382050|NCT05200364|DRUG|STRO-002|intravenous antibody drug conjugate
223382051|NCT05200364|DRUG|Bevacizumab|anti-VEGF agent
223729805|NCT06141395|DIAGNOSTIC_TEST|NGS-based assay for bacterial identification|A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
223729806|NCT05713747|OTHER|Life Skills Boot Camp|"The boot camp is designed to be taken by undergraduate students across all disciplines with no pre-requisite coursework and students who participated in the Life skills 101 course and have selected to participate in a boot camp training as part of their Individual Self Development Plan. The boot camp will consist of 3 training programs with 4 sessions (1.5 hour per session) each, including an introductory and a closing part.~Content The boot camp was designed by a team of academics having several years of experience in clinical psychology, educational psychology, and health psychology. The focus of the bootcamp is to teach students practical skills in three different domains of soft skills: a) Interpersonal Skills, b) Resilience and Flexibility and c) Emotion Regulation."
223729807|NCT04159844|DEVICE|URGOBD001|Application with 50% overlapping
223729808|NCT04159844|DEVICE|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
223729809|NCT00237198|DRUG|Letrozole|
223729810|NCT03283592|OTHER|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
223729811|NCT03283592|OTHER|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
223998601|NCT05327556|DRUG|Epinephrine 0.5 mcg/kg|Syringe with 5 mcg/mL epinephrine
223998602|NCT05327556|DRUG|Epinephrine 1 mcg/kg|Syringe with 10 mcg/mL epinephrine
223998603|NCT03899831|BEHAVIORAL|Function-Based Elopement Treatment (FBET)|"The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~* to create a safer environment~* teach adaptive skills to replace elopement~* arrange the environment and rewards to reduce elopement~* and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding."
223382052|NCT01368315|DRUG|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
223382053|NCT01368315|DRUG|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
223382054|NCT01368315|DRUG|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
223382055|NCT01368315|DRUG|No intervention|No intervention to one out of four test fields marked on the patient's back.
223382056|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
223382057|NCT03490656|DIAGNOSTIC_TEST|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
223382058|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
223382059|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
223998604|NCT03899831|BEHAVIORAL|Parent Education Program (PEP)|The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.
223382060|NCT03436056|RADIATION|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
223382061|NCT03436056|DRUG|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
223382062|NCT06442215|OTHER|Data collection|Collection of preoperative demographic, clinical, and radiological variables from patients who meet the inclusion criteria in order to identify possible risk factors for suboptimal surgical treatment
223382063|NCT03340974|DRUG|GC4419|90 mg Avasopasem (GC4419) per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
223382064|NCT03340974|DRUG|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
223382065|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 50 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
223382066|NCT03340974|RADIATION|Stereotactic Radiation Therapy (SBRT) 55 Gy|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
223382067|NCT02885766|DRUG|PF-114|
223382068|NCT02466685|DRUG|JNJ-18038683|JNJ-18038683 10-20 mg/day tablet for 8 weeks
223382069|NCT02466685|DRUG|Placebo|placebo tablet daily
223382070|NCT05741177|DIAGNOSTIC_TEST|lung ultrasound|lung ultrasound score
223382071|NCT02479529|DRUG|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
223382072|NCT02479529|DRUG|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
223998605|NCT05141942|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
223382073|NCT04641598|PROCEDURE|Endometrial Scratch|"An endometrial biopsy pipelle will be used to create endometrial injury in the form of a scratch."
223382074|NCT04641598|PROCEDURE|Sham procedure|Motions of performing an endometrial scratch will be performed including speculum placement and cervix cleansing, however, placement of the tenaculum and the endometrial scratch will not be performed.
223545294|NCT03254628|BEHAVIORAL|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
223382075|NCT03854630|DRUG|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
223545295|NCT03254628|BEHAVIORAL|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
223382076|NCT03490578|DEVICE|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
223382077|NCT03490578|DEVICE|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
223382078|NCT03010683|DRUG|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
223545296|NCT03254628|DRUG|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
223545297|NCT03254628|DEVICE|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
223998606|NCT01460225|DRUG|lubiprostone|24 micrograms twice daily for 1 week
223545298|NCT03170570|DEVICE|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
223998607|NCT03501953|BEHAVIORAL|Physical Activity|Six weeks of instructor-led physical activity sessions.
223998608|NCT02893839|OTHER|Prick to prick test|
223998609|NCT00430833|DRUG|candesartan|
223998610|NCT01981226|DEVICE|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
223998611|NCT00426959|DEVICE|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
223998612|NCT06064071|DEVICE|Nordlys SWT IPL|Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
223998613|NCT06064071|PROCEDURE|Meibomian Gland Expression (MGX)|Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
223998614|NCT06064071|DEVICE|Sham Nordlys SWT IPL|Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
223998615|NCT04536129|DRUG|Hydrocortisone (CORTIVIS ®)|Once enrolled all the patients had to instill topical low dose (1,005 mg) preservative-free hydrocortisone (CORTIVIS ®- Medivis, Catania, Italy) 2 times daily in each eye for two weeks.
223998616|NCT00003768|DRUG|fosbretabulin disodium|
223998617|NCT05335746|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCT-A)|Optical coherence tomography angiography scanning will be done for all subjects in the study.
223998618|NCT03979508|DRUG|Abemaciclib|Given PO
223382079|NCT03010683|DRUG|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
223998619|NCT03979508|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgical resection
223998620|NCT06374875|PROCEDURE|Metabolic surgery|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure
223998621|NCT06374875|DRUG|Incretin-Based Therapy|Three incretin-based medications that have been approved for treatment of obesity including liraglutide, semaglutide, or tirzepatide will be used in the nonsurgical group. Any of these 3 medications (in the injection or oral from) based on availability in each country, access, and clinical indications can be used. If possible, patients will be placed on high-dose tirzepatide (Mounjaro or Zepbound 15 mg once weekly injection) or high-dose semaglutide (Wegovy 2.4 mg once weekly injection or Ozempic 2 mg once weekly injection). Other acceptable, less preferrable, options: liraglutide (Saxenda or Victoza), semaglutide tablet (Rybelsus), or lower dose of tirzepatide and semaglutide injections.
223545299|NCT00727545|OTHER|iron bisglycine chelate|
223545300|NCT00727545|OTHER|placebo|
223545301|NCT03798639|BIOLOGICAL|Ipilimumab|Given IV
223545302|NCT03798639|BIOLOGICAL|Nivolumab|Given IV
223545303|NCT03798639|RADIATION|Radiation Therapy|Receive radiation therapy
224295604|NCT05865977|DEVICE|diaphragmatic tissue Doppler imaging，dTDI|dTDI was performed at the end of the SBT to assess excursion, velocity, and acceleration.
223382080|NCT03456505|BEHAVIORAL|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
223382081|NCT03456505|BEHAVIORAL|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
223382082|NCT00052598|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
223382083|NCT00052598|BIOLOGICAL|aldesleukin|Given SC
223382084|NCT00052598|OTHER|laboratory biomarker analysis|Correlative studies
223382085|NCT00052598|OTHER|flow cytometry|Correlative studies
223382086|NCT05299528|BEHAVIORAL|Direct Feedback|Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
223382087|NCT00600587|DRUG|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
223382088|NCT00600587|DRUG|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
223382089|NCT03209895|DIETARY_SUPPLEMENT|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
223382090|NCT03209895|DIETARY_SUPPLEMENT|Placebo|Palm oil Softgel capsule
223382091|NCT03209895|DIETARY_SUPPLEMENT|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
223382092|NCT01596790|OTHER|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
223545304|NCT02237001|DEVICE|Suture-based meniscal repair|Suture-based meniscal repair
223998622|NCT05898100|DEVICE|Virtual Reality Distraction|The experimental group will receive the VR video game Dream designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. Dream aims at reducing anxiety in children aged 6 to 17 years old by mean of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.
224295605|NCT06928649|DIAGNOSTIC_TEST|Blood sampling|Blood sampling: 3 first days of admision, 2 ml of plasma daily Urine, BALF, CSF sampling: 1 day during 3 first days of admission
224295606|NCT06924528|OTHER|using toy during inhaler treatment|The mask application on the toy will be performed only during the first inhaler treatment that the children receive in the emergency department.
224295607|NCT05783661|OTHER|Conventional antibiotic strategies|Treatment according to the local guidelines of the Hospital Clinic de Barcelona.
224295608|NCT05783661|OTHER|Regimens guided by epidemiological surveillance|Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
223382093|NCT03307226|BEHAVIORAL|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
223382094|NCT03307226|BEHAVIORAL|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
223382095|NCT01549717|DEVICE|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
223382096|NCT04222426|OTHER|89Zr-atezolizumab PET scans|Patients receive a total amount of 10 mg unlabeled atezolizumab, this will be added to the tracer to prevent rapid clearance during imaging. A labeled dose of 37 Megabequerell (MBq) 89Zr-atezolizumab (±10%; 1 Millicurie) will then be administered. The tracer will be administered intravenously (i.v.). All patients will undergo two 89Zr-atezolizumab PET scans, one at baseline and one after two doses carboplatin induction treatment. After each tracer injection, 89Zr-atezolizumab PET scans will be performed on day 4 (96 ± 6h after tracer administration).
223382097|NCT02914223|DRUG|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
223382098|NCT03726853|DRUG|CKD-497 200mg|CKD-497 200mg
223382099|NCT03726853|DRUG|CKD-497 300mg|CKD-497 300mg
223382100|NCT03726853|DRUG|CKD-497 placebo|Placebo of CKD-497
223382101|NCT03726853|DRUG|Comparator|Comparator
223382102|NCT03726853|DRUG|Comparator placebo|Comparator placebo
223382103|NCT05349045|DRUG|an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor|This is an observational study
223382104|NCT00054405|BIOLOGICAL|recombinant interleukin-12|Given IV
223382105|NCT00054405|BIOLOGICAL|aldesleukin|Given IV
223382106|NCT05180227|DEVICE|DS8R|transcutaneous stimulation of the spinal cord.
223382107|NCT04614480|GENETIC|Exome analysis|Exome analysis of tumor DNA and constitutional DNA in patients included in 1st line treatment
223545305|NCT03045614|OTHER|No intervention|No intervention
223545306|NCT01244230|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
223545307|NCT01713582|DRUG|OTX015/Birabresib|OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
223545308|NCT05221996|BEHAVIORAL|Resistance training|Resistance circuit training
223998623|NCT05898100|BEHAVIORAL|Dental Clinic's Standard Treatment|The control group will only receive a care-as-usual approach. This includes a television mounted on the wall showing cartoons and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia. In the event of non-cooperation during the appointment, any re-take or re-scheduling appointments will be compiled by the resident dentist. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose so.
223998624|NCT03561571|OTHER|butter based breakfast|ingestion of proteins : 5 g, lipids 20 g, glucides 57 g
223382108|NCT06656780|BEHAVIORAL|SIT|"Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt."
223382109|NCT06656780|BEHAVIORAL|DCA-FF|Participants will undergo 8-week Standard Firefighting Training
223382110|NCT00235677|PROCEDURE|Endoscopic gastroplication|
223382111|NCT05475860|DEVICE|implantable cardiac electronic device recipients|implantable cardiac electronic device recipients for any clinical indication
223382112|NCT03548337|BIOLOGICAL|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
223382113|NCT03834454|DRUG|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
223382114|NCT03834454|DRUG|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
223382115|NCT04204538|OTHER|Dietary habits|Data collected using food frequency questionnaire
223998625|NCT03561571|OTHER|Chocolate spread based breakfast|ingestion of proteins 7 g, lipids 20 g, glucides 56 g
223998626|NCT04799171|OTHER|Isometric Contraction Exercise - Young Adults (Age group 18-39)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
224123505|NCT06983405|OTHER|Physical Therapy Program for MDD|PT program for hospitalized adults with MDD: twice-weekly, 45-min sessions integrating: 1) Active joint mobility (gentle movements for ROM). 2) Progressive strength (bodyweight/bands, low-mod intensity, major muscles). 3) Balance (stability exercises, adapted difficulty). 4) Progressive muscle relaxation (end of session). Includes health education: exercise \& mental health link (biological/psychological mechanisms), benefits of each exercise type (mood, function, QoL), post-discharge activity strategies, self-assessment, community resources in Zaragoza. Delivered by trained PTs, adaptable to individual needs.
224123506|NCT04994821|DEVICE|transcranial direct current stimulator (tDCS)|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
224123507|NCT04994821|BEHAVIORAL|Cognitive Reappraisal|Emotion regulation therapy
224123508|NCT04086563|OTHER|Action observation|look at a clip of a hand doing neurodynamic exercises.
223382116|NCT04204538|OTHER|Risk factors associated with metabolic syndrome|Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome
223382117|NCT02171780|DRUG|BI 1744 CL|
223382118|NCT02171780|DRUG|Placebo|
224123509|NCT04086563|OTHER|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
224123510|NCT04086563|OTHER|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
224123511|NCT04086563|OTHER|Strength|Execute a short strength training for the dominant hand
224295609|NCT04918641|OTHER|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
223382119|NCT01675648|DRUG|Lofexidine|
223382120|NCT01675648|DRUG|Diazepam|
223382121|NCT01675648|DRUG|Placebo for Lofexidine|
223382122|NCT01675648|DRUG|Placebo for Diazepam|
223382123|NCT04305353|OTHER|Diary (blank journal) plus PTSD psycho-education|A blank journal where a prospective account of a patient's ICU course (everyday events) can be documented by family members and healthcare providers
223382124|NCT04305353|OTHER|PTSD psycho-education alone|"We administered a pamphlet to patients with information regarding PTSD symptoms, potential psychiatric complications after discharge, and available mental health resources.~References for our education include the following which are included in our references section: Jensen 2015, Jones 2010, Knowles 2009, Parker 2015, Wintermann 2015."
223382125|NCT01061476|DEVICE|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
223382126|NCT01061476|OTHER|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
223382127|NCT01061476|OTHER|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
224123512|NCT01925001|DRUG|MP4CO|43 mg/mL pegylated carboxyhemoglobin \[≥ 90% CO hemoglobin saturation\] in physiological acetate electrolyte solution
224123513|NCT01925001|DRUG|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
223382128|NCT03899909|DRUG|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
223382129|NCT03899909|DRUG|Placebo SAD|Placebo oral suspension
223382130|NCT03899909|DRUG|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
223382131|NCT03899909|DRUG|Placebo MAD|Placebo oral suspension, daily for 13 days
223382132|NCT06984562|RADIATION|Adaptive Radiation Therapy|"Adaptive Radiation Therapy (ART) creates a personalized radiation plan for each treatment session. This means the plan can change from day to day to more precisely target the tumor while protecting the surrounding healthy tissue.~By closely shaping the radiation to match the tumor's location, ART may reduce the amount of radiation reaching nearby normal tissues. This can allow for higher, more focused doses of radiation to the tumor itself, which may help improve treatment effectiveness while reducing side effects."
223382133|NCT06856499|DRUG|Cirtuvivint|Cirtuvivint (SM08502) is a first in class pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with suspected multiple anti-tumor mechanisms of action, including Wnt inhibition.
223382134|NCT06856499|DRUG|Olaparib|NCI Definition - A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
223382135|NCT00137176|DRUG|Rebif|Rebif 44mcg TIW
223382136|NCT06763341|DRUG|Azacitidine|Given IV
223382137|NCT06763341|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223382138|NCT06763341|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223382139|NCT06763341|DRUG|PCNA Inhibitor AOH1996|Given PO
223382140|NCT06763341|DRUG|Venetoclax|Given PO
223382141|NCT06860386|DRUG|Pembrolizumab|200 mg every 3 weeks IV infusion (Q3W + or -3 days)
223998627|NCT04799171|OTHER|Isometric Contraction Exercise - Middle Age Adults (Age group 40-59)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
223382142|NCT06860386|DRUG|Axitinib|5 mg twice daily (BID) by mouth
223382143|NCT06397911|DRUG|FB825|The study treatment will be administered as 5 SC doses in total 12 weeks
223382144|NCT06397911|DRUG|Placebo|The study treatment will be administered as 5 SC doses in total 12 weeks
223382145|NCT06994676|DRUG|CBX-250|subcutaneous CBX-250
223382146|NCT01562938|DRUG|Placebo|Placebo
223382147|NCT01562938|DRUG|MEDI-557|MEDI-557 low-dose
223998628|NCT04799171|OTHER|Isometric Contraction Exercise - Old Adults (Age group >60)|Subjects will be asked to lie supine on MRI table with the 31P surface coil placed over the right vastus lateralis, and straps to immobilize the leg. At the start of the scan session, the investigators will instruct the participant on the isometric contraction exercise and coach the participant through a demonstration. The average flexion repetition time is on the order of 1.5 s for a 30 s duration at maximum kick intensity.
223545309|NCT02193009|BEHAVIORAL|SipSmarter|6-month behavioral trial
223998629|NCT03598530|PROCEDURE|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
223998630|NCT06120842|DRUG|Bimatoprost Implant System (High Dose)|Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
223998631|NCT06120842|DRUG|Bimatoprost Implant System (Low Dose)|Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
223998632|NCT06120842|DRUG|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol Maleate Ophthalmic Solution 0.5% BID
223998633|NCT06120842|DEVICE|Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL|Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens
223998634|NCT06120842|DEVICE|SpyGlass IOL|SpyGlass Intraocular Lens
223998635|NCT05410340|OTHER|Vojta Therapy|Minimal digital pressure at costal level to assess the activation and oxygenation occurring at the cerebral level
223998636|NCT05410340|OTHER|Massotherapy|Baby body massage with gliding
223382148|NCT01562938|DRUG|MEDI-557|MEDI-557 high-dose
223382149|NCT06992141|BIOLOGICAL|Streptococcus pyogenes M1UK strain MCRI0102|Human challenge with S. pyogenes M1UK strain MCRI0102
223382150|NCT01546454|DRUG|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
223382151|NCT01546454|DRUG|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
223382152|NCT01546454|DRUG|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
223382153|NCT01546454|DRUG|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
223382154|NCT03479801|PROCEDURE|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
223382155|NCT04074187|DRUG|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
223382156|NCT04074187|DRUG|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
223382157|NCT04074187|DRUG|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
223382158|NCT04074187|DRUG|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
223382159|NCT06674538|DRUG|Moonshot antibodies|Chimeric antibodies
223425502|NCT00179205|DRUG|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
223545310|NCT02193009|BEHAVIORAL|MoveMore|6 month behavioral trial
223998637|NCT04486352|DRUG|Atezolizumab - 28 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1680 mg on day 1 of each 28-day cycle.
223382160|NCT02669797|BEHAVIORAL|In-home Visits and Food Preparation Activities|"Families will participate in eight in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally, a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
223382161|NCT02669797|BEHAVIORAL|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
223382162|NCT02669797|BEHAVIORAL|Feedback on Video-recorded Family Meals|Parents will video-record and upload via their cellphone one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
223382163|NCT02669797|BEHAVIORAL|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
223382164|NCT06661343|BEHAVIORAL|C4 Program|The C4 intervention is a behavioral program designed to provide care coordination to address structural barriers to PrEP adherence among Black men who have sex with men (MSM). It includes personalized support services, focusing on healthcare access, mental health, and stigma reduction to promote consistent PrEP use. Participants will receive counseling sessions and follow-ups based on their individual needs.
223545311|NCT03085459|BEHAVIORAL|work Time|nurse got qualification certificate and the working time
223545312|NCT04930835|PROCEDURE|Implant supported dentures|Placement of dental implants with different loading protocols for supporting full arch dentures.
223998638|NCT04486352|DRUG|Bevacizumab|Bevacizumab will be given to participants intravenously at a dosage of 10mg per participant kilogram every 2 weeks of the 28-day cycle.
223998639|NCT04486352|DRUG|Ipatasertib|Ipatasertib will be given as an orally at a dosage of 400 mg once daily for 21 days of each 28-day cycle.
223998640|NCT04486352|DRUG|Talazoparib|Talazoparib will be given in an orally at a dosage of 1 mg once daily for each day of the 28-day cycle.
223998641|NCT04486352|DRUG|Trastuzumab emtansine|Trastuzumab emtansine be given to participants intravenously at a dosage of 3.6 mg per participant kilogram, on day 1 of each 21-day cycle.
223998642|NCT04486352|DRUG|Tiragolumab|Tiragolumab will be given to participants intravenously at a dosage of 840 mg on day 1 of each 28-day cycle.
224123514|NCT06019780|OTHER|blood flow restriction trainin|"Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated."
223998643|NCT04486352|DRUG|Atezolizumab - 21 Day Cycle|Atezolizumab will be given to participants intravenously at a dosage of 1200 mg on day 1 of each 21-day cycle.
223998644|NCT04486352|DRUG|Inavolisib|Inavolisib will be given in an orally at a dosage of 9 mg once daily for each day of the 28-day cycle.
223998645|NCT04486352|DRUG|Letrozole|Letrozole will be given orally at a dosage of 2.5 mg once daily for each day of the 28-day cycle.
223998646|NCT04486352|DRUG|Giredestrant|Giredestrant will be given orally at a dosage of 30 mg once daily for each day of the 28-day cycle.
223998647|NCT04486352|DRUG|Abemaciclib|Giredestrant will be given orally at a dosage of 150 mg twice daily for each day of the 28-day cycle.
223998648|NCT04225117|DRUG|enfortumab vedotin|intravenous (IV) infusion
223382165|NCT06661343|BEHAVIORAL|C4 + 3MV Program|This intervention combines the C4 care coordination with the 3MV behavioral program. The 3MV program focuses on behavior change, addressing self-efficacy, stigma, and promoting healthy practices. Through this combination, participants receive both structural and behavioral support to maximize their adherence to PrEP.
223382166|NCT06858501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223382167|NCT06858501|PROCEDURE|Computed Tomography|Undergo PET/CT
223382168|NCT06858501|RADIATION|Florbenguane F18|Given IV
223382169|NCT06858501|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223382170|NCT06858501|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
223382171|NCT06858501|OTHER|Questionnaire Administration|Ancillary studies
223382172|NCT03248310|BEHAVIORAL|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
223382173|NCT00307021|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
223382174|NCT01911273|DRUG|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
223382175|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
223382176|NCT01911273|OTHER|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
223382177|NCT01911273|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
223998649|NCT04225117|DRUG|pembrolizumab|IV infusion
223998650|NCT05140915|BEHAVIORAL|Peer Messaging|Peer messages, written by current and former adolescent e-cigarette users and tailored by age and readiness-to-quit.
223998651|NCT05140915|BEHAVIORAL|Peer Coaching via Text|Peer coaching, facilitated by texting
223998652|NCT05140915|BEHAVIORAL|Gamification|Gamification, designed to motivate participation
223998653|NCT05140915|OTHER|E-Cigarette Cessation Materials|E-cigarette cessation materials by the Research Coordinator at the time of study enrollment.
223998654|NCT05867407|DEVICE|Anumana Low EF AI-ECG Algorithm|Clinician will have access to the Anumana Low EF AI-ECG algorithm via a link in the patient's electronic health record which will display results applied to patients' ECGs, as well as supporting information. Using the results of the algorithm, combined with the clinician's knowledge of patient-specific risk factors, the clinician will determine whether further evaluation is warranted.
223998655|NCT05867407|OTHER|Care-as-Usual|Clinicians will not have access to the Anumana Low EF AI-ECG algorithm and will provide care-as-usual.
223998656|NCT04520659|BIOLOGICAL|RSV LID/ΔM2-2/1030s|10\^5 plaque-forming units (PFU); administered as nose drops
223998657|NCT04520659|BIOLOGICAL|Placebo|Administered as nose drops
223998658|NCT04430439|BEHAVIORAL|Psychosocial stress|The TSST is a 15 minute standardized lab-based challenge task that involves speech preparation, speech delivery while being evaluated by strangers and video taped, and complex mental arithmetic with critiques if errors are made.
223998659|NCT04430439|BEHAVIORAL|Control non-stress|Participants will have a relaxed 15 minute conversation with a familiar research team member.
223998660|NCT05194137|OTHER|a proprioception protocol associated with vaginal palpation and feedback|A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.
223382178|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
223382179|NCT01843387|BIOLOGICAL|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
223382180|NCT05933525|BIOLOGICAL|Travelan|6 Travelan tablets (1200mg) administered orally for 7 days
223382181|NCT05933525|OTHER|Placebo|6 tablets of placebo (1200mg) administered orally for 7 days
223382182|NCT02950649|DEVICE|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
223382183|NCT02950649|DEVICE|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
223382184|NCT02035358|BIOLOGICAL|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
223382185|NCT02386293|DRUG|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
223545313|NCT04725045|DEVICE|Boston Scientific: Study tool computer|compare clinical outcome measurements of complex pulse shapes to standard clinical pulse shape
223998661|NCT05194137|OTHER|a proprioception protocol associated with biofeedback|The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
223998662|NCT05459922|DEVICE|Wearable bright light therapy device|Light treatment glasses (Re-timer®) will be used to deliver bright light therapy. This device is available commercially and allows participants to freely move around while receiving light from LEDs positioned below the eyes. Re-timer® can be worn over glasses and does not interfere with vision, reading, or computer work.
223382186|NCT02386293|OTHER|Placebo|Sugar pill made to look identical to irbesartan intervention.
223382187|NCT02953119|OTHER|Prehabilitation|
223382188|NCT01289379|PROCEDURE|High Frequency Jet Ventilation|
223382189|NCT01289379|PROCEDURE|HFJV|
223382190|NCT02478879|DRUG|ZP-PTH|Patch applied daily for 30 minutes, 14 days
223998663|NCT05459922|DEVICE|Wearable placebo light therapy device|The placebo Re-timer® emits light intensity to a level that will not impact sleep and circadian timing and appears identical to the original Re-timer®.
223998664|NCT06303570|DRUG|CBL-514 injection|"The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL ; total of 5 mg CBL-514.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL ; total of 15 mg CBL-514.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 5 mL ; total of 25 mg CBL-514.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 8 mL ; total of 40 mg CBL-514.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 12 mL ; total of 60 mg CBL-514."
223382191|NCT02478879|DRUG|FORTEO|Subcutaneous injection administration daily for 14 days
223382192|NCT00869336|DRUG|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
223382193|NCT00869336|DRUG|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
223382194|NCT00869336|DRUG|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
223382195|NCT00869336|DRUG|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
223382196|NCT02042456|DEVICE|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
223382197|NCT02042456|DEVICE|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
223382198|NCT02042456|DEVICE|Full Field Digital Mammography|
223382199|NCT05375253|BIOLOGICAL|Donor Enriched Activated Natural Killer Cell Infusion|αβ TCR/CD19 depleted (DEA-NK) cells on day +7 post T-cell replete Haplo-Tx with PTCY
223382200|NCT05645133|DEVICE|Diagnostic Test|Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
223382201|NCT07027527|DRUG|APG777|Subcutaneous (SC) injection
223382202|NCT07027527|DRUG|APG990|SC injection
223998665|NCT06303570|DRUG|0.9% Sodium chloride|"The total injection volume per lipoma will based on the lipoma size,as determined by ultrasound. Dosing scheme is presented as below:~Lipoma diameter of \>0mm and \<10mm - total injection volume per lipoma: 1 mL.~Lipoma diameter of ≥10mm and ≤20mm - total injection volume per lipoma: 3 mL.~Lipoma diameter of \>20mm and ≤30mm - total injection volume per lipoma: 5 mL.~Lipoma diameter of \>30mm and ≤40mm - total injection volume per lipoma: 8 mL.~Lipoma diameter of \>40mm and ≤50mm - total injection volume per lipoma: 12 mL."
223998666|NCT04078997|OTHER|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
223998667|NCT04879849|DRUG|Pembrolizumab|IV infusion.
223998668|NCT04879849|DRUG|TAK-676|IV infusion.
223998669|NCT04879849|RADIATION|Image-guided radiation therapy|Radiation therapy.
223998670|NCT05194293|BIOLOGICAL|Durvalumab|Given IV
223382203|NCT07027527|DRUG|Dupilumab|SC injection
223382204|NCT04422041|OTHER|Time to discharge less than 24 hours|Allow the joint medical discharge of the newborn together with its mother in less than 24 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
223382205|NCT04422041|OTHER|Discharge time between 24 and 48 hours|Allow the joint medical discharge of the newborn together with its mother between 24-48 hours after birth in a healthy patient, without obstetric complications and who does not present comorbidities and complications.
223382206|NCT00493896|DRUG|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
223382207|NCT00493896|DRUG|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
223382208|NCT06387134|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
223382209|NCT06387134|DRUG|Conventional treatment with Western medicine|"Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021."
223382210|NCT01434914|DRUG|octenisept®|Cutaneous solution
223382211|NCT01434914|DRUG|Placebo|Cutaneous use
223382212|NCT06253806|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 1% mepivacaine will be injected near the stellate ganglion.
223382213|NCT06253806|DRUG|Placebo Sham Injection|The stellate ganglion will be identified using ultrasound guidance, and after negative aspiration, 6-8 mL of 0.9% saline will be injected near the stellate ganglion.
223382214|NCT06037941|DIAGNOSTIC_TEST|E-Nose testing|At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.
223382215|NCT06037941|DIAGNOSTIC_TEST|Research blood|Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.
223998671|NCT05194293|DRUG|Regorafenib|Given PO
223998672|NCT05883878|GENETIC|PRS|genetic test for the evaluation of PRS cardiovascular risk
223998673|NCT05883878|DEVICE|Digital app and wearable device|a wearable device connected with its app
224123515|NCT06019780|OTHER|exercise|"Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)"
224123516|NCT02026622|BEHAVIORAL|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
224123517|NCT02026622|DEVICE|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
223382216|NCT07022418|DRUG|Formoterol furmarate (20 μg)|Investigators chose to use the long-acting β2-AR agonist, formoterol, because of its efficacy and safety profile in patients with COPD and because formoterol showed the most association with protection from progression of CKD in our retrospective study.
223382217|NCT03610152|BEHAVIORAL|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
223382218|NCT06879665|BEHAVIORAL|Well-Beans for Caregivers Program|This is a brief behavioral intervention consisting of 3 weekly 2-hour sessions. The sessions are based on Acceptance and Commitment Therapy (ACT) and are designed to improve psychological flexibility in caregivers. This in turn is designed to help them connect with their difficult emotions and experiences in a flexible way, and improve emotional well-being.
223382219|NCT01024257|RADIATION|beta-irradiation|
223382220|NCT01024257|PROCEDURE|conjunctival autograft|
223998674|NCT05360719|BEHAVIORAL|Group tele-exercise|This tele-exercise class will be tailored to the physical and emotional needs of individuals with SCI based on results of our feasibility study, the initial emergent themes from qualitative data collection in this study, and input from our co-leader with lived experience (examples: seated exercise to accommodate wheelchair users, active co-leader with SCI).The research clinician will lead the instruction of each class while our co-leader will model movements alongside her and offer tailored modifications as needed. Each 45-minute class provides a comprehensive fitness experience to maximize functional independence and improve global physical activity engagement. Elements incorporated into each class session include a collective check-in and breathing meditation, postural control, trunk and shoulder strength, cardiovascular fitness, and body awareness.
223998675|NCT03361865|DRUG|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
223382221|NCT02445963|BIOLOGICAL|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
223382222|NCT02128321|DRUG|Isavuconazole|oral
223382223|NCT02128321|DRUG|Repaglinide|oral
223382224|NCT02128321|DRUG|Caffeine|oral
223382225|NCT00987779|DRUG|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
223382226|NCT00987779|DRUG|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
223382227|NCT01378247|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
223382228|NCT00125515|DRUG|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
223382229|NCT00125515|DRUG|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
223382230|NCT01957176|DRUG|Eltrombopag (ELT)|Subjects were dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets were white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS was a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet contained ELT olamine equivalent to 20 mg of ELT per gram of powder.
223382231|NCT03964064|RADIATION|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
223382232|NCT03964064|RADIATION|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
223998676|NCT03361865|DRUG|Epacadostat|Epacadostat administered orally twice daily.
223998677|NCT03361865|DRUG|Placebo|Matching placebo administered orally twice daily.
223382233|NCT02571192|DRUG|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
223382234|NCT02571192|RADIATION|5.95 μCi RAD|
223998678|NCT03156790|DRUG|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
223998679|NCT00469339|BEHAVIORAL|Family Health History|
223998680|NCT06963957|OTHER|ChatGPT-4o Recommendations with Hallucinations|ChatGPT-4o's differential diagnoses of six clinical vignettes, three of which will contain deliberately introduced inaccurate information.
223998681|NCT03629171|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223998682|NCT03629171|DRUG|Venetoclax|Given PO
223998683|NCT06444763|DRUG|Maolactin|Once daily dose of 2 capsules containing a total of 500mg/day Maolactin
223998684|NCT06444763|DRUG|Maltodextrin|Once daily dose of 2 capsules of Maltodextrin containing a total of 0mg/day Maolactin
224123518|NCT02026622|DEVICE|transcranial doppler and TPI|transcranial doppler TPI
223382235|NCT06044012|PROCEDURE|Double layer of buccal myomucosal Flap and buccal pad of fat|The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
223382236|NCT01490983|BEHAVIORAL|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
223382237|NCT01490983|BEHAVIORAL|eMedonline access|patients will be given access to eMedonline use for 3 months
223998685|NCT05935384|DIAGNOSTIC_TEST|Guardant360|Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
223998686|NCT03852719|DRUG|Bulevirtide|Administered via SC injections
223998687|NCT02112617|RADIATION|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
224123519|NCT02026622|BEHAVIORAL|explicitative interview|
223382238|NCT01941082|DRUG|RO6867461|Single or multiple ascending dose by intravitreal injection
223382239|NCT03546920|BEHAVIORAL|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
223382240|NCT02359994|DEVICE|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot. The prescribed hemostatic agent will be applied according to its Instructions for Use.
223998688|NCT03746392|BEHAVIORAL|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
224123520|NCT04611685|DRUG|NSAID|Immediately after the operation, the patient is given (parecoxib 40 mg + sodium chloride 100 ml) intravenously once, and then given (loxoprofen 60 mg) orally twice a day during the first three postoperative days.
224123521|NCT04611685|DRUG|Tramadol|Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
223382241|NCT02359994|DEVICE|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
223382242|NCT04859829|OTHER|Current Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dysmotility that are receiving Intravenous Immunoglobulin (IVIG) treatment.
223382243|NCT04859829|OTHER|No Intravenous Immunoglobulin (IVIG) treatment|Questionnaires every two months for patients with a diagnosis of autoimmune dismotility that are not receiving Intravenous Immunoglobulin (IVIG) treatment.
223998689|NCT05543187|DRUG|TAK-625|TAK-625 orally, twice daily (BID)
223998690|NCT03810235|DRUG|Transdermal Lidocaine Patch|Transdermal Lidocaine Patch
224123522|NCT05309369|BEHAVIORAL|Preferred Music|Participants will listen to selected music using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
223382244|NCT01810757|RADIATION|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
224123523|NCT05309369|BEHAVIORAL|Nature Sounds|Participants will listen to nature sounds using over-ear headphones delivered as 10-minute segments at the top of each hour over the course of 3 hours
224123524|NCT02564848|PROCEDURE|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
224123525|NCT06605144|DRUG|1- Vasopressor - Mean arterial pressure 56-60|Vasopressor(s) will be titrated according to 56-60 range.
223382245|NCT01810757|RADIATION|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
223382246|NCT03399071|DRUG|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
223382247|NCT00492440|BIOLOGICAL|recombinant interleukin-7|
223382248|NCT00492440|GENETIC|gene expression analysis|
223382249|NCT00492440|GENETIC|polymerase chain reaction|
224123526|NCT06605144|DRUG|2- Vasopressor - Mean arterial pressure 61-65|Vasopressor(s) will be titrated according to 61-65 range.
224123527|NCT06605144|DRUG|3- Vasopressor - Mean arterial pressure 66-70|Vasopressor(s) will be titrated according to 66-70 range.
224123528|NCT06605144|DRUG|4- Vasopressor - Mean arterial pressure 71-75|Vasopressor(s) will be titrated according to 71-75 range.
223382250|NCT00492440|GENETIC|protein expression analysis|
223382251|NCT00492440|OTHER|flow cytometry|
223382252|NCT00492440|OTHER|immunoenzyme technique|
223382253|NCT00492440|OTHER|immunologic technique|
224295610|NCT04180553|DIAGNOSTIC_TEST|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP \<90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
224295611|NCT04180553|OTHER|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
223382254|NCT00492440|OTHER|laboratory biomarker analysis|
223998691|NCT03810235|DRUG|Transdermal Hydrocolloid Placebo Patch|hydrocolloid placebo patches
223382255|NCT00492440|OTHER|pharmacological study|
223382256|NCT02304393|DRUG|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
223382257|NCT02304393|DRUG|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
223382258|NCT03278691|DRUG|Saline|1 ml saline IV Q6H
223382259|NCT03278691|DRUG|Ketorolac|15 mg (15 mg/ml) IV Q6H
223382260|NCT00038532|DRUG|Amprenavir/ritonavir|
223382261|NCT00038532|DRUG|Saquinavir/ritonavir|
223998692|NCT05593094|DRUG|ZN-A-1041|ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD
223998693|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b|ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
223998694|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b|ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
223998695|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b|ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
224295612|NCT00297726|BEHAVIORAL|Self-Management Program|
223382262|NCT00038532|DRUG|Efavirenz|
223382263|NCT00080314|DRUG|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
223382264|NCT00080314|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
223382265|NCT04719455|BEHAVIORAL|Adherence Improving self-Management Strategy|An in-person delivered intervention imbedded in regular follow-up care during 9-months. Patients will receive an electronic monitoring System to track medication intake and a pedometer to count daily amount of steps. During the baseline visit, the health care professional (HCP) will use pre-tested materials for informing and motivating patients; and collaboratively set goals and plans for medication adherence and physical activity. During regular follow-up consultations with the HCP, personalized visual reports of medication intake and amount of steps will be evaluated to enhance patients awareness of their (non-)adherence and (in)activity and identify any problems and solutions to reduce undesired behaviour. The control group will receive usual treatment only.
223382266|NCT04719455|OTHER|Regular care|Treatment as usual (appointments with nurse/nurse practioner with regular content)
223382267|NCT04702308|OTHER|Clinical Decision Rule Alerts|The
223382268|NCT01823835|DRUG|GDC-0810|GDC-0810 administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
223382269|NCT01823835|DRUG|LHRH Agonist|LHRH agonist administered once monthly until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
223382270|NCT01823835|DRUG|Palbociclib|Palbociclib administered orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, GDC-0810 drug supply exhausted, or study termination (up to 3 years).
223998696|NCT05593094|DRUG|ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c|ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
223998697|NCT05593094|DRUG|ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c|ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
223998698|NCT05593094|DRUG|ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c|ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
223998699|NCT05930379|OTHER|LSVT-Loud delivered by telerehabilitation|LSVT-Loud treatment delivered by telerehabilitation
223998700|NCT05930379|OTHER|LSVT-Loud in the clinic|LSVT-Loud delivered face-to-face in the clinic
223998701|NCT04777864|BEHAVIORAL|Decision Aid|In addition to usual care, participants (parents and adolescents) receive the newly developed decision aid prior to their clinic visit(s). Clinicians receive a summary to review and use to help facilitate the decision making process.
223998702|NCT05538806|DEVICE|TTFields|all patients will receive routine clinical care and TTFields
223998703|NCT01647542|DRUG|TAK-875|TAK-875 tablets
223382271|NCT05822258|OTHER|Walk under 3 conditions (normal, physical tasks, verbal tasks)|"Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions."
223998704|NCT01647542|DRUG|TAK-875 Placebo|TAK-875 placebo-matching tablets
223998705|NCT06457048|OTHER|Stroke Unit|The stroke unit at the University Teaching Hospital is a 12-bed unit on the general medical wards staffed by neurologists and nurses specifically trained in stroke care. This intervention includes new protocols and clinical practice guidelines that were developed by multiple stakeholders in Zambia to standardize stroke care, with a focus on early and consistent mobilization of patients with stroke, minimizing use of urinary catheters, provision of deep vein thrombosis prophylaxis, formal assessment of swallowing and assignment of modified diets as needed, and appropriate initiation of secondary prevention medications for stroke. Nurses and doctors working in this unit were trained on the new stroke unit protocols and are asked to follow these protocols in caring for patients with stroke admitted to the Stroke Unit.
223382272|NCT01021059|BIOLOGICAL|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
223998706|NCT03086655|BEHAVIORAL|Tel-me-box with reminder features|Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
223998707|NCT03086655|BEHAVIORAL|Tel-me-box|Participants receive tel-me-box device with no reminder features added.
223998708|NCT03977896|PROCEDURE|11C-MET PET/MRI|"Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL)."
223998709|NCT03976414|OTHER|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
223998710|NCT05269823|OTHER|Ice-therapy|Ice therapy will be provided prior to intravitreal injection provision
223998711|NCT05269823|OTHER|No Ice-therapy|No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision
223998712|NCT04153331|OTHER|Nasal swab|Patient included in emergency with a nasal swab
224123529|NCT06605144|OTHER|1- Platelet less than 10 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 10 x 109/L at the time of the planned procedure.
224123530|NCT06605144|OTHER|2- Platelet less than 20 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 20 x 109/L at the time of the planned procedure.
224123531|NCT06605144|OTHER|3- Platelet less than 30 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 30 x 109/L at the time of the planned procedure.
224123532|NCT06605144|OTHER|4- Platelet less than 40 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 40 x 109/L at the time of the planned procedure.
223382273|NCT03639454|PROCEDURE|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
223425503|NCT00179205|DRUG|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
223545314|NCT05230446|DEVICE|PCI with OCT guidance|Procedure will be optimize using pre-and post-stent OCT imaging, to improve the accuracy of stent placement and reduce geographic miss, but also to prevent malapposition of the stent and to discover dissections.
223545315|NCT00062855|PROCEDURE|Skin Biopsy|
223998713|NCT05536973|GENETIC|ADVM-022|A single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
223998714|NCT05536973|GENETIC|ADVM-022|A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
223998715|NCT04987203|DRUG|Tivozanib|Tivozanib will be administered orally.
223998716|NCT04987203|DRUG|Nivolumab|Nivolumab will be administered via intravenous infusion.
223998717|NCT04358575|DEVICE|Triathlon CS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
223998718|NCT04358575|DEVICE|Triathlon CS Knee System with metal-backed modular components|Primary Total Knee Replacement
223998719|NCT06967272|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally
224123533|NCT06605144|OTHER|5- Platelet less than 50 x 109/L|Once randomized, the participant will receive a platelet transfusion if their most recent platelet count is less than 50 x 109/L at the time of the planned procedure.
223382274|NCT03639454|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
223382275|NCT04780282|OTHER|Scapular Stabilization Group|Participants will apply the 5 exercises given.
223382276|NCT03115268|BEHAVIORAL|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
223382277|NCT05612373|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
223382278|NCT03017612|DEVICE|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
223998720|NCT06967272|BIOLOGICAL|Oral hexavalent reassortant rotavirus attenuated live vaccine|Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally
223998721|NCT06967272|BIOLOGICAL|Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)|The controlled vaccine three doses administered orally
223998722|NCT05576662|DRUG|Nirmatrelvir|Two 150 mg tablets taken by mouth every 12 hours
224123534|NCT06819657|DEVICE|Remote Ischemic Conditioning Treatment Instrument|Remote ischemic conditioning (RIC) was administered twice daily to the unilateral lower limb using a blood pressure cuff inflated to 200 mmHg for 7 consecutive days post-clipping
224123535|NCT06819657|OTHER|Guideline-based therapy|Guideline-based therapy
224123536|NCT03202316|DRUG|Atezolizumab|Given IV
224123537|NCT03202316|DRUG|Cobimetinib|Given PO
224123538|NCT03202316|DRUG|Eribulin|Given IV
224123539|NCT03202316|OTHER|Laboratory Biomarker Analysis|Correlative studies
223382279|NCT04216667|PROCEDURE|Catheter ablation|Catheter ablation
223382280|NCT01682486|DEVICE|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
223382281|NCT01682486|PROCEDURE|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
223382282|NCT01595763|OTHER|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
223382283|NCT00135863|DRUG|tinzaparin|
223382284|NCT07048093|OTHER|Exercise|Average of 10 minutes relaxation exercises guided with a standard audio record based on reciprocal and autogenic muscle inhibition, proprioceptive training and postural training.
223382285|NCT07048093|OTHER|Sham (No Treatment)|This group take no treatment between actual before and after measurements.
223998723|NCT05576662|DRUG|Placebo|Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
223998724|NCT05576662|DRUG|Ritonavir|One 100 mg capsule taken by mouth every 12 hours
223998725|NCT05323253|DEVICE|DaRT seeds|DaRT source will be inserted using preplanned radiotherapy parameters and reassessed by volumetric imaging 2-3 weeks after placement and then removed.
223998726|NCT04900974|DRUG|Doravirine|100mg
223998727|NCT05524519|DRUG|Basic treatment|"1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist."
223998728|NCT05524519|PROCEDURE|PSA|Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
224123540|NCT03202316|OTHER|Pharmacological Study|Correlative studies
224123541|NCT06609668|BIOLOGICAL|Additional blood samples|"* 1 dry tube (5 mL)~* 1 EDTA tube (6 mL)~Performed at inclusion (before any glucocorticoid and/or immunosuppressive treatment) and at follow-up visit (3 months after inclusion)"
224123542|NCT00515372|OTHER|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
224123543|NCT00515372|OTHER|Usual Care|Lists of professional resources and referral recommendations will be provided.
224123544|NCT06989086|BEHAVIORAL|Fearless in Neuro-Oncology|FearLess is a newly developed, empirically-rooted, manualized psychological intervention consisting of an intake + 8 sessions delivered over a 12-week time period. It consists of weekly individual 60- to 90-minute virtual therapy sessions.
224123545|NCT02738827|PROCEDURE|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
224123546|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
224123547|NCT01254396|DRUG|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
224123548|NCT00923910|DRUG|WT1 Peptide-Pulsed Dendritic Cells|
224123549|NCT00923910|DRUG|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
224123550|NCT00923910|DRUG|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
223382286|NCT04895982|BIOLOGICAL|BNT162b2|Intramuscular Injection
223382287|NCT01649960|DRUG|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
223382288|NCT03460080|DIAGNOSTIC_TEST|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
223729812|NCT03519646|DRUG|Eliglustat|"1. This is a 3-year study and the enrollment time of this study is 24 months.~2. The participants have to receive the investigational agent, Cerdelga~3. The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~4. IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~5. No need for fasting before use, but can't take with grapefruit juice.~6. Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
223729813|NCT03131765|BIOLOGICAL|YS-0N-001|Cancer vaccine
223998729|NCT05524519|PROCEDURE|TSA|Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
223998730|NCT05524519|PROCEDURE|CCA|Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
223998731|NCT02556099|DRUG|Hydroxyurea|drug to be administered
223998732|NCT03008005|DRUG|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
223998733|NCT03008005|DRUG|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
223998734|NCT03008005|DRUG|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
223998735|NCT05534191|OTHER|Experimental, comparator and control|To quantify the effect of a strength intervention for footballers on improved range of motion, balance, speed, jump height, and technical football skills compared to a training group performing basic power exercises and machine-based strength training and a control group.
223998736|NCT05929898|BEHAVIORAL|Ventral tegmental area of dopaminergic midbrain (VTA) fMRI neurofeedback|fMRI neurofeedback training of sustained midbrain/VTA activation via motivational imagery.
223998737|NCT06967818|DRUG|Potassium Nitrate Gel|Topical application of a 5% potassium nitrate gel (Emofrom Actisens) used to treat dentin hypersensitivity.
223998738|NCT06967818|DEVICE|Diode Laser (Active)|Application of a 980 nm diode laser at 1.5 W/cm² for 1 minute without contact and 1 minute with contact, using a sweeping motion perpendicular to the long axis of the tooth.
223998739|NCT06967818|DEVICE|Diode Laser (Sham)|Inactive diode laser device used for 1 minute without contact and 1 minute with contact, mimicking the active laser procedure but without energy output.
224123551|NCT00923910|DRUG|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
224123552|NCT00923910|DRUG|WT1 Peptides|dendritic cell vaccine
224123553|NCT00923910|DRUG|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
224123554|NCT00923910|DRUG|Diphenhydramine|Pre-medication
224123555|NCT00923910|DRUG|Acetaminophen|Pre-medication
224123556|NCT03746574|BEHAVIORAL|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
223382289|NCT03883802|DRUG|Foxy-5|Lyophilized powder for solution for intravenous infusion
223382290|NCT03883802|DRUG|FOLFOX regimen|6 months treatment regimen
223382291|NCT03883802|PROCEDURE|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
223382292|NCT07052292|DEVICE|DuraTouch®|Participants will subcutaneously inject the insulin using DuraTouch®.
223382293|NCT06724601|DEVICE|Electrical Impedance Tomography|Electrical Impedance Tomography data and the physiological and clinical parameters will be recorded continuously in three different positions (supine 1, car seat, supine 2) to assess alterations in lung volume and cardiorespiratory events.
223382294|NCT06858397|DRUG|HM15421/GC1134A|SC
223382295|NCT06759649|DRUG|COM503|Intravenous Infusion
223729814|NCT00433121|DRUG|Risperidone|
223382296|NCT06759649|DRUG|Zimberelimab|Intravenous infusion
223382297|NCT04182334|OTHER|Slow Tempo Music|For up to seven days, enrolled subjects will receive one-hour slow tempo music listening sessions twice daily through noise-cancelling headphones.
223382298|NCT04182334|OTHER|Attention Control|Subjects will receive a noise cancellation headphone-applied condition identical to the music intervention experimental treatment in twice daily one hour-sessions for up to seven days.
223382299|NCT06771336|OTHER|Questionnaires|Quality of life questionnaires, questionnaires for assessing functional results, micro-costing questionnaire, informal support assessment questionnaires
223382300|NCT06604494|BEHAVIORAL|early feeding resumption|Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.
223382301|NCT06604494|BEHAVIORAL|late feeding resumption|Resumption of food on the 7th day post-operatively with a mixed diet.
223382302|NCT07134686|OTHER|Joint consultation|Joint consultation with pneumologist and ENT at baseline.
223998740|NCT04569773|BEHAVIORAL|Impact of Event Scale-Revised|The IES-R is a validated 22-item self-report scale measuring psychological stress reactions after a major life or traumatic event.1-3Items are rated with reference to the past 7 days on a 5-point scale, ranging from 0 to 4. Three subscale scores are calculated by taking the mean of the item responses: Intrustion (8 items), Avoidance (8 items), and Hyperarousal (6 items). The total score is similarly computed by taking the mean of all 22 items. All scores range from 0 to 4, with higher scores indicating higher event-related distress. Internal consistency estimates(Cronbach's alpha) for all scores range between 0.79 to 0.92.
223998741|NCT04569773|BEHAVIORAL|Reproductive Concerns Scale|The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.
223998742|NCT04569773|BEHAVIORAL|Decision Regret Scale|"The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92."
223998743|NCT05499832|DRUG|Tenecteplase|Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
223998744|NCT02465151|OTHER|Protein-based beverage|protein-based beverage
223382303|NCT07134686|PROCEDURE|Mucus sampling|Mucus sampling at baseline and one year follow-up
223382304|NCT07134686|PROCEDURE|Nasal brushing|Nasal brushing at baseline and one year follow-up
223382305|NCT06925100|DRUG|Bempedoic acid 180 mg tablet|180 mg tablet, once daily administered for 12 weeks
223382306|NCT05351827|OTHER|Mild Intermittent Hypoxia|Participants will breathe 8% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. 100% oxygen and carbon dioxide are titrated into the system to ensure the appropriate hypoxic and hypercapnic stimulus is delivered. The investigators will lower oxygen to 55-60 mmHg and maintain end-tidal carbon dioxide 1-3 mmHg above individual baseline values. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
223382307|NCT05351827|OTHER|Sham|Participants will breathe 21% oxygen through a non-diffusable bag that is connected to a 5-way stopcock. The inspiration side of the system is then connected to a 2-way non-rebreathing valve which is connected to a pneumotachometer that is connected to a tight fitting facemask. No supplemental oxygen or carbon dioxide will be used during the sham protocol. The protocol starts with 10 minutes of baseline breathing (room air) then followed by 10 more minutes of breathing room air with the additional carbon dioxide. Thereafter, individuals undergo 12 2-minute bouts of hypoxia with 2 minutes of normoxia (room air) interspersed between episodes. The intervention protocol concludes with 20 minutes of monitoring all breathing and cardiovascular measurements.
223382308|NCT07088731|DRUG|Sintilimab|neoadjuvent chemotherapy plus sintilimab for 2 cycles followed by radical surgery
223382309|NCT07088731|RADIATION|Concurrent chemo-radiotherapy|EBRT+BT+cisplatin
223382310|NCT05430477|DEVICE|Electrical impedance imaging using Non-Significant Risk device (EII probe)|novel small field-of-view Non-Significant Risk device (EII probe)
223382311|NCT03739814|BIOLOGICAL|Blinatumomab|Given IV
223382312|NCT03739814|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223382313|NCT02193282|OTHER|Clinical Observation|Undergo observation
223382314|NCT02193282|DRUG|Erlotinib Hydrochloride|Given PO
223382315|NCT02193282|OTHER|Laboratory Biomarker Analysis|Correlative studies
223382316|NCT02193282|OTHER|Placebo Administration|Given PO
223382317|NCT06325202|DEVICE|Omnipod 5 or Medtronic 780G|Omnipod 5 and Medtronic 780G are hybrid closed loop devices that provide automated insulin delivery.
223382318|NCT06325202|BEHAVIORAL|My HypoCOMPaSS Education|My HypoCOMPaSS is a brief, standardized psycho-educational program delivered in small groups. Facilitated discussions focus on advocating rigorous avoidance of hypoglycemia while maintaining time in target glycemic range.
223382319|NCT06325202|BEHAVIORAL|HARPdoc Education|The HARPdoc program targets cognitions around hypoglycemia that act as barriers to hypoglycemia avoidance and recovery of awareness using motivational and cognitive approaches, delivered by diabetes educators, trained and supported by a clinical psychologist, in small group format.
223382320|NCT07089173|DRUG|Intravenous normal saline (NS 0.9)|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using placebo (normal saline) combined with etomidate (0.3 mg/kg).
223382321|NCT07089173|DRUG|intravenous sufentanil|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using sufentanil (0.2μg/kg) combined with etomidate (0.3 mg/kg).
223382322|NCT07089173|DRUG|Intravenous lidocaine|Under target-controlled infusion (TCI) of remifentanil, anesthesia induction is performed using lidocaine (1.5 mg/kg) combined with etomidate (0.3 mg/kg).
223729815|NCT00433121|DRUG|Olanzapine|
223729816|NCT00433121|DRUG|Haloperidole|
223729817|NCT00433121|DRUG|Quetiapin|
223998745|NCT06413953|DRUG|TQB3107 Tablets|TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.
223998746|NCT04296968|DEVICE|Painful stimulation using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In the experimental paradigm, 160 painful stimuli of two intensities (3 J, 3.5 J) will be applied to the dorsum of the left hand using the laser device listed above.
223998747|NCT04296968|DEVICE|Visual cueing|Preceding to each painful stimulus, visual cues (e.g., blue dot and yellow square) will be presented on a screen indicating the intensity of the subsequent stimulus (low and high intensity) with an accuracy of 75%. The contingencies of the visual cues will be explicitly stated to the participants.
223998748|NCT05826145|BEHAVIORAL|Vocal Expression|There will be a total of 8 sessions. At baseline (week 0), only questionnaires will be completed. There will be 7 treatment sessions beginning at week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration where the vocal expression sessions will be provided.
223998749|NCT05826145|BEHAVIORAL|Cognitive Behavioral|There will be 8 treatment sessions where part of the baseline session of session 1 (week 0) will include some instruction, session 2 will occur in week 2, and the other sessions conducted at approximately every 3 weeks over the 6-month study duration. Sessions will include various cognitive-behavioral techniques including completing a grief monitoring diary, imaginal revisiting, cognitive restructuring, describing positive memories of the deceased, and identifying future goals.
223998750|NCT01744704|DRUG|rhNGF 0.5 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
223998751|NCT01744704|DRUG|rhNGF 5 µg/mL Sentinel|Part 0 represented a sentinel group.
223998752|NCT01744704|DRUG|rhNGF 20 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
223998753|NCT01744704|DRUG|rhNGF 20 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
223998754|NCT01744704|DRUG|rhNGF 60 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
223998755|NCT01744704|DRUG|rhNGF 180 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
223998756|NCT01744704|DRUG|rhNGF 20 µg/mL Part B|In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.
223998757|NCT01744704|DRUG|rhNGF 60 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
224123557|NCT05797350|DEVICE|Glaucoma Drainage Device|Both the Paul glaucoma implant (PGI) and Ahmed glaucoma valve (AGV) are types of glaucoma drainage devices (GDDs) used to lower intraocular pressure in patients with refractory glaucoma. Devices will be implanted during a surgical procedure and work by diverting excess fluid from the eye to an external drainage tube, allowing the fluid to drain away from the eye and be absorbed into the surrounding tissue. This will help to lower the pressure inside the eye, which is important for preventing vision loss and other complications associated with glaucoma.
223382323|NCT07091370|DRUG|Inaticabtagene Autoleucel Injection|"The dose was incremented according to the 3+3 principle, and the three dose levels A, B and C were given in sequence at one time, which were respectively:~A-1 dose group: 0.25×10\^6 CAR-T live cells /kg body weight~Group A (initial dose) : 0.5×10\^6 CAR-T live cells /kg body weight~Group B: 1.0×10\^6 CAR-T live cells /kg body weight~Group C: 1.5×10\^6 CAR-T live cells /kg body weight"
223382324|NCT06904365|DEVICE|HyperSight cone beam computed tomography (CBCT) scan|HyperSight is a novel onboard imaging platform with a rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for simulation and treatment.
223382325|NCT06904365|DEVICE|ETHOS 2.0|ETHOS 2.0, an artificial intelligence treatment planning system, will be utilized in an emulator to create SCRT plans to determine the feasibility of clinically significant ovarian dose reductions in-silico.
223382326|NCT07097792|BEHAVIORAL|CRISP (Concussion Recovery and Support Program)|Mental health intervention targeting suppressed emotion with a goal of facilitating recovery.
223382327|NCT06507137|OTHER|Fractal|Walking in a treadmill while synchronizing their steps with fractal external visual cues
223382328|NCT06507137|OTHER|Isochronous|Walking in a treadmill while synchronizing their steps with isochronous external visual cues
223382329|NCT06507137|OTHER|Control|Walking in a treadmill
223425504|NCT02716493|BEHAVIORAL|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
223425505|NCT05646966|OTHER|one time testing|
223998758|NCT01744704|DRUG|rhNGF 180 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
224123558|NCT01096550|BEHAVIORAL|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
224123559|NCT01096550|BEHAVIORAL|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
223998759|NCT01744704|DRUG|Placebo Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
223998760|NCT01744704|DRUG|Placebo Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
223382330|NCT07098910|PROCEDURE|Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA)|While the infant is spontaneously breathing on nasal CPAP, the NICU physician will place the supraglottic airway device (SAD) and assess airway adequacy via CO₂ detection, chest movement, bilateral breath sounds, gastric insufflation, oxygen saturation, and heart rate. Each placement attempt should last no more than 30 seconds, with up to two attempts allowed. Surfactant (Curosurf 200 mg/kg) will be given slowly in 1-2 ml aliquots via a CE-marked preterm-sized SAD, Neo i-gel® (sizes 0.85, 0.75, 0.65; Intersurgical Ltd). The infant should primarily breathe spontaneously with PEEP from a T-piece resuscitator and receive gentle PPV if needed. PPV is continued for 30 seconds after surfactant administration before SAD removal. A reservoir bag may be used secondarily to provide PPV. If surfactant delivery via SALSA fails, the INSURE method (Intubation-Surfactant-Extubation) will be attempted.
223382331|NCT07098910|PROCEDURE|Intubation - Surfactant administration - Extubation (INSURE)|Study participants will receive surfactant therapy administered via brief endotracheal intubation - surfactant administration - and extubation (INSURE). Infants will be ventilated using a T-piece resuscitator with PEEP of 6 cm H20 and positive pressure ventilation (20 cm H20) for a couple of minutes (no more than 15 minutes) with adjustable FiO2. No mechanical ventilation will be used. Secondarily a reservoir-bag will be used for ventilation.
223382332|NCT03384563|DRUG|Dexmedetomidine|Dexmedetomidine 9 arms
223382333|NCT07093749|DEVICE|Garmin Smartwatch|Garmin Venu 3 - Worn for the duration of antibiotic course
223382334|NCT07082868|DRUG|ibrutinib|Ibrutinib should be self-administered daily by the participant and should be taken at approximately the same time each day
223998761|NCT04522921|DIETARY_SUPPLEMENT|Diet with a higher amount of protein (25E% per day)|In a caloric restricted and increased physical activity setting, the participants will be served a higher protein (25E%/day) diet.
223998762|NCT04522921|BEHAVIORAL|Increased follow-up contact after the 10-week intervention|Both the control-group and the intervention-group were offered an increased follow-up contact after camp.
223998763|NCT04522921|DIETARY_SUPPLEMENT|Diet with a lower amount of protein (15E% per day)|In a caloric restricted and increased physical activity setting, the participants will be served a low-moderate protein (15E%/day) diet.
223382335|NCT07082868|DRUG|Epcoritamab|Epcoritamab will be administered at the study site clinic, as a SC injection
223382336|NCT06210815|DRUG|HLX42|HLX42 is an anti-EGFR monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
223382337|NCT03951324|OTHER|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
223382338|NCT06920628|DRUG|11C-PS13|Injected IV followed by PET scanning.
223382339|NCT07146932|DEVICE|Pediatric Lower Limb Exoskeleton (Bambini Teens)|The Bambini Teens Exoskeleton is a wearable robotic device developed to assist lower limb movement and facilitate gait training for pediatric patients with mobility impairments such as cerebral palsy. The device provides powered assistance at the hip, knee, and ankle joints, supports adjustable gait parameters, and is designed for use in clinical rehabilitation settings under professional supervision.
223998764|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
223998765|NCT00955890|DRUG|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
223998766|NCT00281268|PROCEDURE|pulmonary artery catheter|
223998767|NCT00281268|PROCEDURE|central venous catheter|
223998768|NCT00281268|PROCEDURE|fluid management|
223382340|NCT07166393|DRUG|Valproic Acid (VPA)|VPA (in 250 ml 0.9% sodium chloride solution)
223382341|NCT07166393|OTHER|Standard of care treatment + normal saline|Standard of care treatment + normal saline (0.9% sodium chloride solution) vehicle (250 ml)
223382342|NCT07186166|COMBINATION_PRODUCT|30% HA+70% β-TCP (Osteon II, Dentium, Korea)|A prospective analysis was performed on a single-arm clinical trial involving 60 posterior maxillary edentulous sites in 42 patients with a residual bone height of \<4 mm. All sites were treated with lateral window sinus floor augmentation (LWSFA), followed by grafting using a 1:1 ratio of 30% HA with 70% β-TCP (Osteon II, Dentium, Korea). At 6 months postoperatively, core biopsies were harvested during implant placement to assess the histological outcomes of the grafted sites.
223998769|NCT04201587|OTHER|Henna application|Henna application was performed to the patients in the intervention group. The patient was instructed to apply henna before going to bed at night, and after waking up in the morning (for an average of 8-10 hours) was instructed to wash with only water. The patient was asked to do this application at home after the second and third chemotherapy cycles. Thus, the patient applied henna twice in total (fifteen days apart).
223425506|NCT00997217|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
223425507|NCT00154804|DRUG|Paclitaxel, Cisplatin,Surgery, CCRT|
223729818|NCT00433121|DRUG|Escitalopram|
223729819|NCT00433121|DRUG|Citalopram|
223729820|NCT00433121|DRUG|Sertralin|
223998770|NCT01040169|DEVICE|Arginine/Calcium Carbonate|One application
223998771|NCT01040169|DEVICE|Mint Prophy paste - Fluoride free|one application
223998772|NCT00350727|DRUG|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
223998773|NCT00350727|DRUG|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
223998774|NCT00966147|OTHER|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
224123560|NCT00275405|DRUG|Garlic Oil Macerate|
224138430|NCT01157052|OTHER|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr \& Mg++sulfate 1g given IV pre \& post cycle 1 (Arm A) or cycle 2 (Arm B)"
223382343|NCT07186803|DEVICE|Artificial Intelligence Guidance Models|The intervention will involve the use of two artificial intelligence (AI) models to provide surgical guidance during laparoscopic cholecystectomy procedures. The AI models will provide real-time feedback based on the live surgical feed (internal patient anatomy captured by laparoscopic camera) displayed on an operating room monitor. The GoNoGoNet model identifies safe and unsafe zones of dissection. This is done by showcasing a green overlay over safe zones of dissection, and a red overlay over unsafe zones of dissection. The DeepCVS model provides text-based feedback based on its assessment of the following three criteria defining the Critical View of Safety: 1) complete clearance of the hepatocystic triangle from fat and fibrous tissue, 2) only two structures visible entering the gallbladder (cystic artery and duct) and 3) the lower third of the gallbladder must be dissected off the liver bed, exposing the cystic plate.
223382344|NCT07186751|DRUG|Pregabalin|In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.
223998775|NCT05202054|OTHER|mindfulness stress reduction program|Before the program is implemented, in case women forget, they will be called and reminded of the training time, and they will be invited to the program. The women in the experimental group will be administered 150 minutes of BFSAP once a week, lasting 8 weeks, and consisting of 8 times in total. Afterwards, the women will be given an intermediate test. After the midterm test, women will be asked to individually repeat their BFSAP administration in their own home for 8 weeks (weeks 8-16).
223998776|NCT00558792|DRUG|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
223998777|NCT00558792|DRUG|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
223998778|NCT00558792|DRUG|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of \>=4 mL/second
223998779|NCT03243435|PROCEDURE|Native 1,5 Tesla breast MRI|
223998780|NCT05371665|BEHAVIORAL|Culturally Adapted Cognitive-Behavioral Prevention and Early Intervention (PEI) Program|The prevention and early intervention is originally an indicated cognitive-behavioral program for 8-13-year-old youth with higher anxiety. Our CAB adapted it as a universal prevention and early intervention for all American Indian youth in the tribal community. It was delivered across six weeks with 20-30 min weekly sessions. Youth engaged in games and role-play reducing anxiety and stress in mildly challenging situations to provide in-vivo exposure. Session 1 involved introductions, relaxation training, and discussing emotions. Session 2 taught youth about worries and how to handle them. Session 3 focused on having conversations with others. Session 4 taught youth how to be assertive (CAB identified this as an area of adaption in initial meetings). Session 5 taught youth how to face their fears. Session 6 was a review session. Parents and teachers were sent notes of what youth learned in each session and asked to encourage youth to practice their learned skills.
223998781|NCT06374095|DRUG|RATG|Thymoglobulin, Genzyme corporation, Italy.
223382345|NCT07186751|DRUG|Pregabalin with venlafaxine|In the pregabalin with venlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Venlafaxine will be administered at 75 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 75 mg per day after 4 days, up to a maximum of 225 mg per day. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.
223382346|NCT07184827|DRUG|U101|One capsule (100 mg) of U101 will be administered orally three times per day (TID) for 8 weeks followed by one capsule of U101 twice per day (BID) for 16 weeks.
223382347|NCT07184827|OTHER|Placebo|One capsule of Placebo will be administered orally three times per day (TID) for 8 weeks followed by one capsule of placebo twice per day (BID) for 16 weeks.
223382348|NCT07185399|BIOLOGICAL|Moderna RSV vaccine|Participants will receive the MRESVIA vaccine (Moderna RSV vaccine) as part of the study. The vaccine will be administered by trained clinical personnel at the Hope Clinic. MRESVIA is FDA-approved and will be used in accordance with its licensed indication for adults aged 60 years and older. MRESVIA is an mRNA-based RSV vaccine containing 50 micrograms (mcg) of nucleoside-modified mRNA encoding the RSV prefusion F glycoprotein. It is supplied as a frozen injectable suspension in single-dose, pre-filled syringes. The vaccine is administered as a single 0.5 milliliter (mL) intramuscular injection.
223382349|NCT07185464|DEVICE|tACS|This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity. Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients.
223729821|NCT02423876|DRUG|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~* 0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~* 3 mL/hr RN bolus, to be used as needed based on pain ratings~* 3 mL/30 minutes patient bolus, which is available on patient demand."
223998782|NCT06374095|DRUG|Basiliximab|Simulect, Novartis, Italy.
224138431|NCT03335956|DRUG|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
223998783|NCT03633799|DRUG|VeraCept|VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
223998784|NCT02082470|OTHER|follow-up care|Undergo survivorship care planning
223998785|NCT02082470|OTHER|active surveillance|Undergo cancer surveillance
223998786|NCT02082470|OTHER|questionnaire administration|Ancillary studies
223998787|NCT00631553|DRUG|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
223998788|NCT04993469|DIAGNOSTIC_TEST|Semmes-Weinstein monofilament testing and questionnaires|Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction
223998789|NCT06389292|DRUG|APG-2575(Lisaftoclax )|QD, oral administration, every 28 days for a dosing cycle.
223998790|NCT06389292|OTHER|Placebo|QD, oral administration, every 28 days for a dosing cycle.
223998791|NCT06389292|DRUG|Azacitidine Injection|QD, subcutaneous or intravenous injection, D1-7 in 28-day cycle.
223998792|NCT04554641|OTHER|Fasted breath samples|Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
223998793|NCT04554641|OTHER|Daily Diary|Monitoring stool form, consistency and frequency on a daily basis.
223998794|NCT04554641|OTHER|Stool sample|Participants will provide stool sample pre and post Bio-kult Advanced.
223998795|NCT02370901|DEVICE|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
223998796|NCT02370901|BEHAVIORAL|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
223998797|NCT04200534|OTHER|Best Practice|Receive usual care counseling
223998798|NCT04200534|DRUG|Nicotine Patch|Given nicotine patches
223998799|NCT04200534|OTHER|Quality-of-Life Assessment|Ancillary studies
223998800|NCT04200534|OTHER|Questionnaire Administration|Ancillary studies
223998801|NCT04200534|OTHER|Tobacco Cessation Counseling|Receive counseling over the phone
223998802|NCT01348334|PROCEDURE|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
223998803|NCT03551691|DRUG|Omeprazole 20mg Capsule|Omeprazole 20mg daily for 28 days
223998804|NCT03551691|DRUG|Placebo oral capsule|Identically-appearing capsule to omeprazole for 28 days
224138432|NCT03335956|DRUG|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
224138433|NCT03335956|DRUG|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
223382350|NCT07185464|DEVICE|tACS|In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
223382351|NCT07185815|DRUG|Cariprazine Depot|One single dose of 22 mg
223382352|NCT07185815|DRUG|Cariprazine Depot|One single dose of 44 mg
223382353|NCT07185815|DRUG|Cariprazine Depot MTD|Three monthly doses of MTD (maximum tolerated dose)
223382354|NCT07185815|DRUG|Oral Cariprazine 3 mg/day|Oral Cariprazine 3 mg/day for three months
223382355|NCT07186296|DIAGNOSTIC_TEST|EXoPred|Performing invitro Diagnostics with devices developed by EXoPERT.
223729822|NCT02423876|OTHER|Intraoperative Complication Management and Prevention|Undergo ERP
223729823|NCT02423876|PROCEDURE|Pain Therapy|Undergo ERP
223998805|NCT04187859|BEHAVIORAL|Education Session|Participants will receive an education session from their District Nurse, advising on how to improve their hydration.
223998806|NCT04187859|DEVICE|Prompting Cup|The Droplet Cup is an electronic prompting cup that emits a sound and/or light to encourage the participant to take a drink
223998807|NCT00022581|DRUG|thalidomide|Given orally
223998808|NCT00022581|OTHER|laboratory biomarker analysis|Correlative studies
223998809|NCT03732768|DRUG|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
223998810|NCT06202274|DEVICE|Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE|Subjects will receive up to twelve (12) treatments at minimum treatment interval of 2 weeks and maximum treatment interval of 12 weeks.
223998811|NCT06109467|DRUG|Neratinib|All participants will take 240mg neratinib by mouth every day beginning cycle 1 day 1.
223998812|NCT06109467|DRUG|Trastuzumab|All participants will receive standard dosing (6mg/kg loading dose, 4 mg/kg subsequent doses) of Trastuzumab by IV infusion day 1 of each 2 week cycle.
223998813|NCT06109467|DRUG|Oxaliplatin|All participants will receive 85mg Oxaliplatin by IV infusion day 1 of each 2 week cycle.
223998814|NCT06109467|DRUG|5-Fluorouracil + leucovorin|All participants will receive 400 mg/m\^2 5-Fluorouracil (5FU)+ 400 mg/m\^2 leucovorin day 1 of each 2 week cycle; 5FU continuous infusions on days 1 and 2 of each 2 week cycle. (5FU + leucovorin may be eliminated from regimen per PI discretion)
223998815|NCT06109467|DRUG|Pembrolizumab|All participants will receive 400mg Pembrolizumab by IV infusion day 1 of every 3rd 2 week cycle.
223998816|NCT03520712|BIOLOGICAL|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
223382356|NCT07187154|DEVICE|Smart Symptom Management Program|"During the first six months after surgery, patients in the experimental group will use a WeChat mini-program to proactively self-report their symptoms regularly using the Chinese version of the MD Anderson Symptom Inventory for Esophageal Cancer (MDASI-EC). Based on the reported scores and the pre-defined algorithms in the Post-Esophagectomy Symptom Grading Management Manual, the system will automatically provide personalized self-management guidance for low-grade symptoms. For more severe symptoms, the system will generate alerts to prompt dedicated study nurses to initiate proactive telephone follow-up and provide tailored health coaching."
223382357|NCT07184684|PROCEDURE|Sinonasal microbiome transplant procedure.|A sinonasal microbiome transplant obtained from a healthy donor and administered as a nasal lavage once daily for five consecutive days.
223382358|NCT07184684|OTHER|Placebo saline transplant|Placebo transplant containing saline administered as a nasala lavage once daily for five consecutive days.
223382359|NCT07186582|DIAGNOSTIC_TEST|Coronary physiology assessment using Fractional Flow Reserve (FFR) as per standard of care and angiography-derived FFR|Functional assessment of coronary lesions performed using invasive FFR or angiography-derived FFR during coronary angiography as part of routine clinical care. No active intervention or treatment is assigned by the study.
223382360|NCT07185737|BEHAVIORAL|Adapted RUBI-Telehealth|The Adapted RUBI Parent Training is a culturally tailored version of the Research Units in Behavioral Intervention (RUBI) program, designed for Spanish-speaking caregivers of young autistic children. The intervention consists of 8 weekly sessions delivered virtually in Spanish by trained behavioral therapists. Each session incorporates behavioral skills training methods (instruction, modeling, role-play, and feedback). Caregivers use a Spanish-language RUBI handbook to complete weekly home practice activities and receive feedback during sessions. The program focuses on helping caregivers understand the functions of challenging behavior and apply evidence-based strategies to reduce these behaviors and promote positive child outcomes.
223729824|NCT01310101|DRUG|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
223729825|NCT01927172|DEVICE|AirSonea|
223729826|NCT02139631|OTHER|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
223998817|NCT06493409|DRUG|Repotrectinib|Specified dose on specified days
223998818|NCT06493409|DRUG|Voriconazole|Specified dose on specified days
223998819|NCT06493409|DRUG|Quinidine|Specified dose on specified days
223998820|NCT03694483|DIAGNOSTIC_TEST|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
223998821|NCT05494918|DRUG|JSKN003|JSKN003 is to be administered via intravenous (IV) dose
223998822|NCT05846698|DRUG|Luo-Bu-Fu-Ke-Bi-RI Pill|10 pills twice daily
223998823|NCT05846698|DRUG|tibolone|2.5 mg once daily
223998824|NCT00119561|BEHAVIORAL|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
223998825|NCT03788811|DEVICE|ERG assessment (RSPA)|Processing and analysis of retinal signals
223998826|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a more intense therapeutic blue light.
223998827|NCT05631236|DEVICE|Bright Light Therapy (AYO Glasses)|Bright light glasses that emit a non-therapeutic blue light.
223998828|NCT05436717|BEHAVIORAL|MINDxYOU|The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
224123561|NCT05669378|BEHAVIORAL|Appetite to Play +|In 2017 the province of BC enacted a provincial standard for physical activity, formally titled the Director of Licensing Standard of Practice - Active Play (Active Play Standards) that licensed childcare centers are required to adhere to. Along with this, a provincial capacity-building intervention (Appetite to Play) was released to provide training and education to early years providers working in the province and support the implementation of the Active Play Standards. The intervention, Appetite to Play +, will provide advanced training to early year educators on the Appetite to Play activities and resources. The intervention will include workshops and training on physical literacy, fundamental movement skills, and creating a supportive environment to sustain Active Play practices. As part of the intervention, managers will also be provided with resources to aid them with the integration of Active Play into their curriculums and schedules.
224123562|NCT01659944|DRUG|Eliglustat|Capsules for oral administration
223729827|NCT00952575|DRUG|polyclonal anti-D immunoglobulin|single injection of 300 µg
224123563|NCT01659944|DRUG|Metoprolol|Tablets for oral administration
223729828|NCT00952575|DRUG|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
223998829|NCT06539390|OTHER|Transforaminal Epidural Injections?|Pain, lumbar disc herniation,Transforaminal Epidural Injections?
223998830|NCT05855967|DRUG|Ixekizumab|Administered SC
223998831|NCT07120919|OTHER|Peer Educatıon|The peer educators provided training on reproductive health and safe sexuality for young people and completed the intervention part by giving training brochures to the participants.
223998832|NCT07122180|DEVICE|CT3 Series Continuous Glucose Monitoring System:|The CT3 Series CGM System is a real-time, continuous glucose monitoring device indicated for the management of diabetes in adults (age≥18 years). Interpretation of the CT3 Series CGM System results should be based on the glucose trends and several sequential readings over time. The CT3 Series CGM System also aids in the detection of episodes of hyperglycaemia and hypoglycaemia. It is intended for single-patient use. It is intended to replace fingerstick blood glucose testing for diabetes treatment decisions unless otherwise indicated
223382361|NCT07185867|BEHAVIORAL|Pandora-1 app with high levels of personalization, interaction, monitoring and feedback|Pandora-1 is a behavioral, self-guided and transdiagnostic intervention delivered via an app. It includes predictive risk algorithms, decision support systems (DSS), monitoring and feedback to implement personalized prevention plans (PPP) for anxiety and depression. The intervention has a biopsychosocial approach and offers 4 interactive modules: move more, sleep better, improve relationships and emotional well-being. Participants will receive personalized feedback at baseline, 1, 6 and 12 months, including their levels of depressive and anxiety symptoms over the past two weeks, their predicted risk of developing these disorders in the next year, and related modifiable risk factors (e.g. sedentary lifestyle, insomnia, low social support, poor mental quality of life). Based on this, the app offers suggestions (via DSS) and guides users to relevant content (PPP). Participants follow recommendations of choice, the app tracks these actions and provides feedback at baseline, 1 and 6 months.
223998833|NCT02446821|DRUG|VeraCept|IUD placement of VeraCept
224123564|NCT00088010|DRUG|Arzoxifene|20mg, oral, tablet, once a day for 36 months
224123565|NCT00088010|DRUG|Placebo|oral, tablet, once a day for 36 months
223382362|NCT07185867|OTHER|Pandora-2 app with low levels of personalization, interaction, monitoring and feedback|Pandora-2 is a psychoeducational self-guided and transdiagnostic intervention delivered via an app. This intervention also has a biopsychosocial orientation and includes a set of psychoeducational brochures for the prevention of anxiety and depression that can be used at any time. These read-only brochures will have contents on the same 4 intervention modules (move more, sleep better, improve relationships and emotional well-being). At baseline, 1 and 6, 12 months participants will also receive basic information about their level of depressive and anxiety symptoms over the past two weeks, their risk probability of depressive and anxiety episodes next year and some of their modifiable risk factors associated with such risk (e.g. sedentary lifestyle, insomnia, low social support and poor mental quality of life). However, in Pandora-2 intervention participants will have lower levels of interactive intervention components as suggestions from the DSS about PPP, monitoring and feedback.
223382363|NCT07185711|DIAGNOSTIC_TEST|Resonance Frequency Analysis (RFA)|Resonance frequency analysis performed with the Osstell™ device. SmartPeg was attached with composite resin to the occlusal surface of the tooth, and ISQ values were recorded in mesio-distal and bucco-lingual directions.
223382364|NCT07185711|DIAGNOSTIC_TEST|Bite Force Sensor|Assessment of maximum bite force using a bite force sensor. Measurements were performed on COD-associated teeth and contralateral healthy controls for comparison.
223382365|NCT07186569|BEHAVIORAL|Digital Interactive Peer Support|Individually randomized participants receive digital interactive peer support.
223382366|NCT07186569|BEHAVIORAL|Face-to-Face Peer Support|Individually randomized participants receive face-to-face peer support.
223382367|NCT07186569|BEHAVIORAL|Standard Training (Control)|Standard Training (Usual Curriculum)-Participants receive usual curriculum-based training without structured peer support.
223382368|NCT07186764|OTHER|Questionnaires|questionnaires: WHOQOL-BREF (Quality of Life Study Questionnaire), FSFI (Female Sexual Function Index), FSDS-R (The Femala sexual distress scale-revised), Rosenberg scale (self-esteem assessment)
223382369|NCT07186764|OTHER|Semi-directed interview|Semi-directed interview on the treatment pathway and the impact of utero-vaginal aplasia on intimate and personal life
223382370|NCT06834698|DRUG|Betamethasone Cream|Betamethasone 0.1% cream was administered to the external meatus twice per day for a duration of 21 days.
223382371|NCT06834698|PROCEDURE|meatotomy|"In the event of steroid therapy failure, a meatotomy was performed under general anesthesia. The procedure involved squashing the ventral aspect of the pinpoint meatus for approximately 3-5 millimeters for 10 seconds and then incising it. The mucosal margins were sutured with absorbable sutures to avoid renarrowing.~Urethral catheterization was not employed, and the procedure was performed on an outpatient basis. Patients were discharged following urination."
223382372|NCT05680740|DRUG|VTAMA® (tapinarof) Cream 1%|VTAMA® (tapinarof) Cream 1% applied topically once daily
223382373|NCT05490641|BEHAVIORAL|Glucose-based biofeedback|Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
223382374|NCT05490641|BEHAVIORAL|Standard feedback|Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.
223382375|NCT01059786|DRUG|Pentostatin|28 participants to pentostatin 4 mg/m\^2 days 1 and 15 of each cycle.
223382376|NCT01059786|DRUG|Rituximab|Rituximab 375 mg/m\^2 on day 1, 15 for 6 x 28-day cycles
223382377|NCT01059786|DRUG|Bendamustine|1-4 participants to bendamustine 90 mg/m\^2/day, days 1 and 2 each cycle
223382378|NCT01059786|DRUG|Acetaminophen|Treatment of infusion-related symptoms with acetaminophen is recommended.
223382379|NCT01059786|DRUG|Diphenhydramine|Treatment of infusion-related symptoms with diphenhydramine is recommended.
223729829|NCT00970060|BEHAVIORAL|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
223998834|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive NCPD for 12 weeks and then switch to CAPD for another 12 weeks.Group B: Participants receive CAPD for 12 weeks and then switch to NCPD for another 12 weeks.
223998835|NCT05449067|PROCEDURE|Group A and Group B|Group A: Participants receive NCPD for 12 weeks and then switch to CAPD for another 12 weeks.Group B: Participants receive CAPD for 12 weeks and then switch to NCPD for another 12 weeks.
223998836|NCT01894997|DEVICE|Neuromuscular electrical stimulator|
223998837|NCT01894997|DEVICE|AV Impulse System Model 6000|
223998838|NCT02478645|DRUG|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
224138434|NCT03335956|DRUG|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
224138435|NCT03335956|DRUG|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
223998839|NCT02478645|DRUG|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
223998840|NCT02478645|DRUG|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
224138436|NCT03335956|DRUG|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
223382380|NCT01059786|DRUG|Epinephrine|Epinephrine should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
223382381|NCT01059786|DRUG|Antihistamines|Antihistamines should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
223382382|NCT01059786|DRUG|Corticosteroids|Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
223382383|NCT01059786|DRUG|Bronchodilators|Additional treatment with bronchodilators may be indicated.
223382384|NCT01059786|OTHER|Intravenous (IV) Saline|Additional treatment with intravenous (IV) saline may be indicated.
223998841|NCT06600854|DEVICE|BoneTape|"BoneTape is a craniofacial fracture repair device intended for use in the fixation of non-load-bearing bones of the craniofacial and midfacial skeleton. It can be used in skeletally mature individuals but is not intended for use in the mandible and/or full load bearing procedures. It is composed of: 1) BoneTape implant (device), and 2) BoneTape applicator (applicator)."
223998842|NCT05181787|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
223998843|NCT05181787|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
223998844|NCT04254133|BEHAVIORAL|Questionnaire|Complete questionnaire
223998845|NCT04254133|PROCEDURE|Biospecimen Collection|Provide saliva samples
223998846|NCT04254133|DIAGNOSTIC_TEST|Genetic Testing|Undergo genetic testing
223998847|NCT04254133|OTHER|Genetic Counseling|Undergo counseling
223998848|NCT04254133|OTHER|Laboratory Biomarker Analysis|Correlative Studies
224123566|NCT04965012|BEHAVIORAL|Online CBT with MET treatment|The CBT with MET treatment condition will begin with an MET-therapist guided introduction to the program and first module. After this guided introduction, they will have access to the remaining 7 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
224123567|NCT04965012|BEHAVIORAL|CBT without MET treatment|The CBT without MET treatment condition will begin with a brief non-MET trained research assistant welcome to the program, and will not include working through the first module together. After this welcome, they will have access to the 8 treatment modules and have 6 weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to cannabis use, learn strategies to cope with cravings, triggers, and social pressures, and learn to how prevent relapse. Participants will work through modules sequentially.
223382385|NCT04460885|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 78 weeks.
223382386|NCT04460885|DRUG|Insulin glargine|Participants will receive subcutaneous (s.c.) injections of insulin glargine once daily for 78 weeks
223382387|NCT04559347|DRUG|Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single shot for erector spinae block
223382388|NCT04559347|DRUG|Ropivacaine (0.5% bolus followed by 0.2% infusion)|Continuous catheter infusion for erector spinae plane block
223382389|NCT05291845|BIOLOGICAL|Candida antigen vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
223729830|NCT02056314|OTHER|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
223998849|NCT02638883|DEVICE|Hybrid SRW cochlear implant|Subjects will be implanted with the Hybrid SRW
223998850|NCT06509620|OTHER|Fatigue severity scale|fatigue severity scale is a unidimensional, nine-item questionnaire capturing information on the impact and severity of fatigue. Participants rated the 9-items on a 7-point, Likert-type scale with anchors of strongly disagree (1) and strongly agree (7) based on the previous week. The overall score is an average of the individual item scores and can range between 1 and 7.
223998851|NCT04647747|OTHER|Self measurement with pulse oximeter|Participant will measure peripheral saturation at home, conduct physiotherapy if desaturation occurs, and contact hospital if desatuation persists
224123568|NCT02226614|DEVICE|University of Edinburgh head cooling device|head cooling
223382390|NCT05291845|BIOLOGICAL|Bivalent HPV vaccine|we will study the efficacy and safety of agent in the treatment of multiple warts, we will follow up the recurrence rate of each group
223382391|NCT04771728|DRUG|Metronidazole vaginal suppositories|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )
223382392|NCT04771728|DRUG|Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)|Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）
223998852|NCT03140852|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
223998853|NCT04439045|BIOLOGICAL|VPM1002|VPM1002 is a recombinant BCG (rBCG)
223998854|NCT04439045|OTHER|Placebo|0.9% sodium chloride
223998855|NCT07135492|DIAGNOSTIC_TEST|continuous noninvasive hemoglobin monitoring|noninvasive hemoglobin monitoring, Rainbow® Adult ReSposable™ sensors (Rev E) were placed on either the ring or middle fingertip of each participant and connected to a Radical-7 Pulse CO-Oximeter (SET version 7601; Masimo Corp., Irvine, CA).
223998856|NCT07050628|DEVICE|wireless thermal anisotropy measurement device|Wireless wearable thermal anisotropy measurement device designed for use at home
223998857|NCT07135817|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Hypofractionated SBRT delivered in 1-3 fractions within 10 days before surgery, using MRI-based planning and institutional immobilization standards according to ESTRO guidelines.
224123569|NCT02538666|BIOLOGICAL|Nivolumab|
224123570|NCT02538666|BIOLOGICAL|Ipilimumab|
224123571|NCT02538666|OTHER|Placebo|
224123572|NCT00001693|DRUG|Celecoxib (SC-58635)|
224123573|NCT04367337|OTHER|No intervention|Observational data collection only, accounting for COVID-19 morbidity and mortality levels within each country
224123574|NCT04729452|OTHER|blood test|blood test to test immune response to SARS-CoV-2
223382393|NCT05765877|DRUG|WX-0593 Tablets|60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
223382394|NCT05756634|BEHAVIORAL|Care Coordination after Preterm Birth (CCAPB)|For participants randomized to CCAPB, the care coordinator will follow a manualized intervention to support care planning, health care access, and wellbeing. Contact with participants will be initiated as soon as possible after enrollment, and will continue until six months after enrollment.
223998858|NCT07135817|PROCEDURE|Spinal Surgery for Decompression and/or Stabilization|Surgical intervention is performed following SBRT, based on clinical indication. It includes decompression of the spinal canal in cases of spinal cord or nerve compression (via laminectomy and/or foraminotomy), and/or dorsal instrumentation for unstable spines using pedicle screws guided by a neuronavigation system (Brainlab, Munich, Germany)
223998859|NCT06747910|OTHER|Exercise Intervention - Ewing Battery Assessment|Undergo in-person Ewing battery assessment
223998860|NCT06747910|OTHER|Questionnaire Administration|Receive COMPASS31 questionnaire
223998861|NCT06747910|DEVICE|Medical Device Usage and Evaluation|Wear biosensensor heart monitor that remotely collects heart rate variability.
223998862|NCT06927141|DEVICE|Bilateral Peripheral Intravenous Catheterisation|Participants will have peripheral intravenous catheters inserted. Each participant will receive two different catheters (less flexible = 20 gauge ICUMedical SuperCath5 SP120-20-31T; more flexible = 20 gauge Becton Dickinson Insyte Autoguard Blood Control 381034), with the treatment arm (more flexible) being randomly assigned.
223998863|NCT05478759|BEHAVIORAL|Multimodal affect recognition training|8 session, trains participants to recognize expression of emotion from a variety of stimuli, including dynamic stimuli (e.g., video instead of still pictures) and it employs both facial and vocal examples of emotion expression.
223382395|NCT00449904|DRUG|Liprotamase|Administered orally
223382396|NCT00263354|DRUG|Oxaliplatin|
223382397|NCT04622605|DEVICE|Trabecular bypass and Schlemm's canal stent|ab interno Microstent placement after cataract surgery
223382398|NCT04021238|DRUG|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
223382399|NCT04021238|DRUG|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
223382400|NCT03340012|DEVICE|GTR + radiation-sterilize allogenic bone graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw
223382401|NCT03340012|DEVICE|GTR + xenogenic graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
223998864|NCT05478759|BEHAVIORAL|Attention Training|computerized attention drill training
223998865|NCT05478759|BEHAVIORAL|Brain Health Workshop|an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered.
223998866|NCT05478759|BEHAVIORAL|National Geographic Movies|participant will watch movies and answer questions after
224123575|NCT02316093|OTHER|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
223382402|NCT03721523|DIAGNOSTIC_TEST|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
223382403|NCT03721523|DIAGNOSTIC_TEST|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
223998867|NCT06615635|DEVICE|DaRT seeds|Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients
223998868|NCT06409390|DRUG|Taxotere|75 mg/m2 once every 21 days for 4 cycles
223998869|NCT06409390|DRUG|Cytoxan|600 mg/m2 once every 21 days for 4 cycles
223998870|NCT06409390|DRUG|Trastuzumab deruxtecan|5.4 mg/kg once every 21 days for 5 cycles
223998871|NCT06409390|DRUG|Sacituzumab govitecan|10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
223998872|NCT06409390|DRUG|Xeloda|1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
223998873|NCT06409390|DRUG|Fulvestrant|500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
223998874|NCT06409390|DRUG|Ribociclib|600 mg orally daily 21 days on, 7 days off
223998875|NCT06409390|DRUG|Abemaciclib|150 mg by mouth twice daily
224123576|NCT04590937|DRUG|BI 730357|Film-coated tablet
224123577|NCT04590937|DRUG|CRESTOR®|Film-coated tablet
224123578|NCT04590937|DRUG|Lenoxin®|Tablet
224123579|NCT04590937|DRUG|MetfoLiquid GeriaSan®|Oral solution
224123580|NCT04590937|DRUG|Lasix®|Oral solution
224123581|NCT04742153|DRUG|MRG002|Administrated intravenously
224123582|NCT00518453|BIOLOGICAL|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
224123583|NCT01901133|DRUG|MDV3100|Oral
223382404|NCT05603325|OTHER|Person Centered Practice|"Staff will be asked to:~* Complete two surveys on two occasions, once before the intervention sessions and once following the last session. The first survey is views on patient feedback and the other is about the workplace culture and how person-centred it is.~* Attend 6 x 2 hour facilitated workshops which will involve getting ready to work with patient feedback, establishing values and visions for the intervention group, critically reviewing the ways patients are offered the opportunity to give feedback~* Engage in changes in practice (e.g. how staff offer patients the opportunity to provide feedback and the way staff make changes in response to this feedback);~* Attend a final focus group to evaluate the workshop programme."
223382405|NCT05603325|OTHER|Interview|Interviews will be used to gather views about how easy or difficult it is to give feedback and how it feels to consider and/or give feedback
223382406|NCT02074280|DRUG|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
223382407|NCT01226030|DRUG|M2ES 7.5mg|M2ES 7.5mg
223729831|NCT02056314|OTHER|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
223729832|NCT03178903|OTHER|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
223998876|NCT01483456|OTHER|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~1. Identification of patient's fall risk,~2. Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~3. Get up workshop and morbidity and mortality conferences related to fall cases"
223382408|NCT01226030|DRUG|M2ES 15mg|M2ES 15mg
223382409|NCT01226030|DRUG|M2ES 30mg|M2ES 30mg
223382410|NCT01226030|DRUG|M2ES 60mg|M2ES 60mg
223382411|NCT01838850|DRUG|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
223998877|NCT04427280|DIAGNOSTIC_TEST|Throat/nose swabs|Throat/nose swabs will initially be collected at baseline (D0) as part of the diagnostic workup for SARS-CoV-2 infection. Subsequent throat/nose swabs will be taken at D7 (if an inpatient), D14, D28, D42 and D56. Two samples will be taken, one for standard of care testing and one for lateral flow assay and storage for further analysis later such as quantitative PCR.
223998878|NCT04427280|DIAGNOSTIC_TEST|Saliva collection|Saliva will be collected at each study visit, by asking the participant to provide a small amount of saliva (approximately 0.5 millilitres (mL)) will be collected. Saliva will be tested by the lateral flow assay when available and excess material stored.
224123584|NCT05262595|DRUG|NNC0471-0119 A|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
223382412|NCT01838850|DRUG|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
223382413|NCT02371655|PROCEDURE|Diet|A low-fibre diet for three days before the examination
223382414|NCT02371655|DRUG|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
223382415|NCT02371655|DRUG|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
223382416|NCT02371655|PROCEDURE|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
223382417|NCT02717455|DRUG|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG or H3K27M+ Thalamic DMG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
223382418|NCT01433055|DRUG|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
223729833|NCT03178903|OTHER|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
223729834|NCT03178903|BEHAVIORAL|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
223729835|NCT03566147|BIOLOGICAL|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
223729836|NCT00335868|DRUG|danusertib|
223729837|NCT00335868|OTHER|laboratory biomarker analysis|
223729838|NCT00335868|OTHER|pharmacological study|
224138437|NCT03335956|DRUG|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
224123585|NCT05262595|DRUG|NNC0471-0119 B|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
224123586|NCT05262595|DRUG|NNC0471-0119 D|"NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
223382419|NCT01433055|DRUG|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
223382420|NCT02872428|DRUG|Valproic Acid|By infusion over 1 hour
223382421|NCT02872428|DRUG|Isotonic saline solution|By infusion over 1 hour
223382422|NCT00486525|PROCEDURE|Yoga Therapy|Patients will undergo yoga therapy
223382423|NCT03400592|DRUG|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
223998879|NCT04427280|DIAGNOSTIC_TEST|Blood collection|Approximately 30mL of blood will be taken at each study visit.
223998880|NCT06063850|GENETIC|AAV9-hSyn1-miGRIK2|AMT-260 is an AAV9 gene therapy product that locally delivers miRNA silencing technology to target the GRIK2 gene and suppress aberrantly expressed GluK2 containing kainate receptors. Intervention will be a one-time intracerebral administration of AMT-260.
223998881|NCT04092530|BEHAVIORAL|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
223998882|NCT04494451|DRUG|Vit C|vitamin C (25 mg/kg or max. 1.5 gram every 6 hourly) for maximum 5 day
223998883|NCT04494451|DRUG|Standard medical Treatment|iv antibiotics alone
223998884|NCT05082168|DEVICE|Capnodynamic monitoring|"In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:~ELV x \[(FACO2(n)-FACO2(n-1)\] = delta(n) x EPBF \[CvCO2(n)\] - VTCO2."
223998885|NCT02400944|BEHAVIORAL|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
223998886|NCT02400944|OTHER|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
223998887|NCT04942366|OTHER|High intensity interval training|HIIT using treadmill four sets of 4 minute interval session (at 90%-95% of the individual HR max calculated by using the karvonen method) and each set will be followed by three minute of moderate intensity exercise (at 70% of individual HR max).
223998888|NCT04942366|OTHER|Strength training|Strength training will be performed thrice a week, each session will consist of eight dynamic drills.
223382424|NCT03400592|DRUG|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
223382425|NCT01366131|DRUG|MEGF0444A|Intravenous repeating dose
223998889|NCT03395977|DRUG|Placebos|Lactose placebo for pills and saline for perfusion.
223998890|NCT03395977|DRUG|Febuxostat|Febuxostat tablet.
223998891|NCT03395977|DRUG|Rasburicase|Rasburicase injectable solution.
223998892|NCT06791486|OTHER|AI-assisted predictive model|This study utilizes an AI-assisted predictive model that analyzes multimodal data from electronic health records, including medical history, laboratory results, imaging data, and lifestyle factors, to estimate biological age. The model employs deep learning algorithms to predict biological age, compare it to chronological age, and identify early signs of age-related health risks. The intervention is not a direct treatment or procedure but aims to develop a tool for predicting biological age to help personalize care and improve long-term health outcomes.
224123587|NCT05262595|DRUG|Faster aspart|"Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months"
224123588|NCT02384499|BIOLOGICAL|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
224123589|NCT02384499|DRUG|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
224123590|NCT04340830|PROCEDURE|Free gingival graft|Following recipient site preparation, free gingival graft obtained from palatal mucosa was applied to buccal sites of dental implants having inadequate keratinized attached mucosa.
224138438|NCT03335956|DRUG|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
224138439|NCT03335956|DRUG|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
224138440|NCT03335956|DRUG|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
224138441|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
223382426|NCT01366131|DRUG|bevacizumab|Intravenous repeating dose
223382427|NCT01366131|DRUG|carboplatin|Intravenous repeating dose
223382428|NCT01366131|DRUG|paclitaxel|Intravenous repeating dose
223382429|NCT01366131|DRUG|placebo|Intravenous repeating dose
223729839|NCT02490228|PROCEDURE|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
223382430|NCT06512792|BEHAVIORAL|Telemedicine management through Mobile APP|According to the patient's electronic health records, each participating center researcher conducts personalized medication reminders and follow-up reminders for enrolled patients on a one-on-one basis. Simultaneously, patients are advised to monitor their health at home, regularly record and upload changes in clinical symptoms, medication, diet, exercise, etc., on the Mobile APP platform. Periodically, self-assessment scales are distributed through the Questionnaire Star platform to assess and record the patient's disease activity, quality of life, sleep, psychological status, etc., and update the information in the electronic health records.Based on the patient's clinical symptoms, self-assessment scales, and feedback from medical institution tests and examinations, each participating center researcher will promptly assess potential health risks, send warning alerts, and provide targeted informational support and interventions.
223382431|NCT00003131|DRUG|chemotherapy|
224123591|NCT01544595|DRUG|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
223382432|NCT00003131|DRUG|gemtuzumab ozogamicin|
223382433|NCT00842166|OTHER|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
223382434|NCT00233948|DRUG|nelfinavir mesylate|Given orally
223382435|NCT00233948|PROCEDURE|biopsy|Correlative studies
223382436|NCT00233948|OTHER|laboratory biomarker analysis|Correlative studies
223382437|NCT00233948|OTHER|pharmacological study|Correlative studies
223382438|NCT00233948|GENETIC|gene expression analysis|Correlative studies
223382439|NCT00233948|GENETIC|western blotting|Correlative studies
223382440|NCT00233948|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223382441|NCT00233948|OTHER|immunoenzyme technique|Correlative studies
223382442|NCT01728844|DEVICE|beta-tricalcium phosphate alone|
223382443|NCT01728844|DEVICE|GFeBGS 0.1%|
223382444|NCT01728844|DEVICE|GFeBGS 0.3%|
223382445|NCT01728844|DEVICE|GFeBGS 0.4%|
223382446|NCT03229226|OTHER|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
223382447|NCT00073346|BEHAVIORAL|Cognitive Behavioral Treatment|
223382448|NCT03807726|BEHAVIORAL|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
223382449|NCT03929068|DRUG|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
224123592|NCT01544595|DRUG|Placebo|Placebo
223382450|NCT03929068|DRUG|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
223382451|NCT06306261|OTHER|questionnaire|UC patients will be subjected to a questionnaire each month about their habits.
223382452|NCT04018378|DRUG|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
223382453|NCT04018378|DRUG|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
223382454|NCT01214577|DRUG|PEP005 (ingenol mebutate) Gel|0.015%
223382455|NCT02617797|DEVICE|Radiofrequency|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
223382456|NCT02617797|DEVICE|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
223382457|NCT01744301|DRUG|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
223382458|NCT01109446|BIOLOGICAL|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
223382459|NCT01109446|PROCEDURE|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
223382460|NCT01109446|DRUG|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
223382461|NCT03727789|DRUG|FACT Complex-targeting Curaxin CBL0137|Given IA
223382462|NCT06581302|DEVICE|Magnetic seizure therapy by Magnetic stimulator|The seizure is induced by Magnetic stimulator of MagPro MST(XP)，MagVenture A/S, Farum, Denmark. It is administered in combinations with antipsychotic medications
223382463|NCT06581302|DRUG|Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc)|It mainly includes second-generation antipsychotic medications, such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc, but except clozapine.
223382464|NCT02219412|DRUG|ticagrelor|90 mg bid for 2 weeks
223382465|NCT02219412|DRUG|Aspirin|100mg Qd for 2 weeks.
223729840|NCT05541172|DRUG|Testosterone Undecanoate|Testosterone undecanoate (1000 mg/4 ml) will be administered at a dose of 1 ml every 12 weeks for 6 months, 2 ml every 12 weeks for 6 months, 3 ml every 12 weeks for 6 months and 4 ml every 12 weeks for 6 months.
223729841|NCT00060008|RADIATION|fludeoxyglucose F 18|
223729842|NCT00060008|RADIATION|gadopentetate dimeglumine|
223998893|NCT05441709|BEHAVIORAL|Ci-BPC with Standard of Care (SOC)|"Clinically-integrated breastfeeding peer counseling (ci-BPC) is a practice that, supports the patient and the clinical care team by delivering culturally-appropriate breastfeeding help to motivate breastfeeding initiation, intensity, and duration, inspiring confidence for patients to set breastfeeding goals and meet them. ci-BPC is delivered by community health workers who have breastfed an infant, and have received basic training in breastfeeding support through a qualified BPC training organization. For this project, the Peer Counselor will make initial contact to patients randomized into the treatment arm via phone to schedule the Intake Encounter between 20 and 30 weeks gestation. Subsequently, each patient will receive a minimum of 3 additional encounters which can occur virtually or in-person. Patients randomized to the ci-BPC arm are additionally offered access to a warmline where messages will be returned by the next business day."
223382466|NCT03668678|OTHER|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
223382467|NCT02194361|DRUG|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
223382468|NCT02194361|DRUG|Placebo|
223382469|NCT00618488|DIETARY_SUPPLEMENT|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
223382470|NCT00618488|DIETARY_SUPPLEMENT|Placebo|Placebo administered once a day for 6 weeks
223382471|NCT01170988|PROCEDURE|T-Graft|T-Graft
223382472|NCT03348878|OTHER|assessment of drug compliance|assessment of drug compliance using electronic monitoring devices (2 months duration)
223382473|NCT03435887|BEHAVIORAL|Alere q HIV-1/2 Detect for point of care infant testing|The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.
223382474|NCT03435887|BEHAVIORAL|GeneXpert HIV-1 Qual for point of care infant testing|The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to \<24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.
223382475|NCT03435887|BEHAVIORAL|HIV DNA PCR testing (Standard of Care)|This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
223382476|NCT00419497|BEHAVIORAL|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
223382477|NCT01731639|OTHER|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form \> 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
223382478|NCT04844112|PROCEDURE|automatic CT/MRI-US fusion system guided radiofrequency ablation|automatic CT/MRI-US fusion system guided radiofrequency ablation
223382479|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
223382480|NCT00684281|OTHER|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
223382481|NCT03194919|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
223382482|NCT03911830|OTHER|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
223382483|NCT03897283|DRUG|TQB2450|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle
224123593|NCT00573326|DRUG|Imatinib|200 mg p.o. once a day for 6 months
223998894|NCT01478997|DIETARY_SUPPLEMENT|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
224123594|NCT04525222|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via text notifications
224123595|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Actify app)|Use Actify app
224123596|NCT04525222|BEHAVIORAL|Smoking Cessation Intervention (Current Standard Care app)|Use (USCPG) Current Standard Care app
224123597|NCT04525222|OTHER|Survey Administration|Ancillary studies
224123598|NCT06427681|DRUG|BH006 for injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
224123599|NCT06427681|DRUG|Fosaprepitant for injection+Palonosetron hydrochloride injection|According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
223998895|NCT01478997|DIETARY_SUPPLEMENT|Placebo Capsules|Carboxy Methyl Cellulose
223382484|NCT03897283|DRUG|Anlotinib|Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
223998896|NCT05190783|DRUG|Formocresol|mixture of formalin, cresol and glycerine used for fixation of pulp tissues
223382485|NCT04716647|OTHER|Ayurveda|Dosage was used in common range (Ashwagandha: Doses range from 250 mg to 5 g; Giloy: range from 500mg to 1g; Tulsi: 500mg-1g) Dosage were altered based on age, weight and severity of symptoms.
223382486|NCT03304925|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
223998897|NCT05190783|DRUG|MTA|material used for pulp regeneration, direct and indirect pulp capping
223998898|NCT05190783|DRUG|TheraCal|light cured resin modified calcium silicate filled liner designed for use in direct and indirect pulp capping
223382487|NCT02720666|DRUG|K-001|In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
223382488|NCT01802021|DRUG|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
223382489|NCT04999059|OTHER|Safety and Efficacy Assessments|Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
223382490|NCT00964067|OTHER|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
223382491|NCT00020631|DRUG|pirfenidone|
223382492|NCT01197352|BEHAVIORAL|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
223382493|NCT01197352|BEHAVIORAL|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
223382494|NCT05800886|OTHER|Early mobilization and tea consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of tea (black tea 2 g, caffeine amount: 45-55 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
223382495|NCT05800886|OTHER|Early mobilization and coffee consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of coffee (ınstant coffee 2 g, caffeine amount: 60/80 mg/150 ml) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
223729843|NCT01877434|PROCEDURE|Reversed shoulder arthroplasty|
223998899|NCT05190783|PROCEDURE|pulpotomy|removal of the carious tooth structure and unroofing of the pulp chamber with a round carbide bur with high speed and water spray. The coronal pulp tissue will be then removed using a #4 carbide bur with slow speed and sharp spoon excavator.
223998900|NCT05190783|PROCEDURE|partial pulpotomy|complete removal of caries till exposure occurs. The exposed surface of the pulp will be gently removed using a sterile round diamond bur and a high-speed, water-cooled handpiece with light hand pressure. The removal of the pulp did not exceed approximately two mm.
223998901|NCT02243111|RADIATION|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
223998902|NCT01605578|PROCEDURE|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
223998903|NCT01342289|DRUG|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
223998904|NCT01342289|DRUG|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m\^2/day IV.
223998905|NCT01342289|RADIATION|Total body irradiation|Day -1: 200 centigray in one fraction.
223998906|NCT01342289|DRUG|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
223998907|NCT01342289|DRUG|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
223998908|NCT01342289|DRUG|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
223998909|NCT01342289|DRUG|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
223998910|NCT01342289|BIOLOGICAL|Bone marrow transplant|Donor stem cells infused IV on Day 0.
223998911|NCT04996004|DRUG|Ontorpacept (TTI-621)|Ontorpacept (TTI-621) will be administered by intravenous infusion.
223998912|NCT04996004|DRUG|Doxorubicin|75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
224138442|NCT03335956|DRUG|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
223998913|NCT04749251|PROCEDURE|Individualized blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids
223998914|NCT04749251|PROCEDURE|Standard blood pressure management|During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg
223998915|NCT04439227|DRUG|Adavosertib|Given PO
223998916|NCT06540235|DEVICE|Otolith Device Active|The device will be providing different levels of stimulation hypothesized to affect the vestibular system
223998917|NCT06540235|DEVICE|Otolith Device Inactive|The device will be providing no stimulation to measure test-retest
224138443|NCT03335956|DRUG|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
223998918|NCT02942277|BIOLOGICAL|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
223998919|NCT02942277|BIOLOGICAL|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
223998920|NCT02942277|OTHER|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
223998921|NCT02942277|BIOLOGICAL|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
223998922|NCT02942277|BIOLOGICAL|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
223998923|NCT02942277|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
223998924|NCT02942277|DRUG|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
223998925|NCT05180864|PROCEDURE|Gastrectomy|Open or minimally invasive (sub)total gastrectomy
223998926|NCT06155435|BEHAVIORAL|solution focused approach training|To the woman; A list of education subjects will be sent in order to determine educational changes for birth, birth and postpartum periods. This list will be; It consists of reproductive organs, pregnancy formations, changes, psychological changes, daily life, nutrition, reproductive monitoring, immunization, frequent problems and solution suggestions, danger signs and what to do. Also included in the list are labor, birth cycle, and postpartum periods.
223998927|NCT05363267|DIETARY_SUPPLEMENT|curcumin, high phenolic extra virgin olive oil (HP-EVOO)|"identical for all participants with the exception of the curcumin dose level~Dose 1: 1000 mg Curcumin daily dose with 1 capsule of 25 ml HP-EVOO volume at morning and night Dose 1: 2000 mg Curcumin daily dose with 2 capsules of 25 ml HP-EVOO volume at morning and night Dose 3: 4000 mg Curcumin daily dose with 4 capsules of 25 ml HP-EVOO volume at morning and night"
224123600|NCT01401829|BEHAVIORAL|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
224123601|NCT01401829|BEHAVIORAL|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
223382496|NCT05800886|OTHER|Early mobilization and warm water consumption|At the 4th hour postoperatively, the patients in the tea group were first mobilized after drinking 200 ml of warm water (37 centigrade) within 15 minutes. A thermos cup is used to prevent the heat loss of the beverage. Patients were supported by the investigator for early mobilization from the 4th hour after surgery. After the surgery, the first mobilization of the patients is in the form of walking in the patient room of 10 meters (5 meters going and 5 meters returning). According to Enhanced Recovery After Surgery protocols, it is aimed for the patient to walk for at least 2 hours after surgery.
223998928|NCT05577715|DRUG|MORAb-202|Specified dose on specified days
224123602|NCT01401829|BEHAVIORAL|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
224123603|NCT01892527|DRUG|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
223382497|NCT05800886|OTHER|Ongoing treatment|The first mobilization and oral intake of the patients in the control group started at the 8th hour.
223382498|NCT05637372|RADIATION|CBCT|CBCT scan
223382499|NCT01696123|DRUG|MLC601|It was described
223382500|NCT01250210|DRUG|levonorgestrel and ethinyl estradiol|pregnancy prevention
223382501|NCT01214655|DRUG|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
223382502|NCT02737241|PROCEDURE|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
223998929|NCT04176198|DRUG|Nusivertib|Oral PIM Inhibitor
223998930|NCT04176198|DRUG|Ruxolitinib|Oral JAK inhibitor
223998931|NCT04176198|DRUG|Momelotinib|Oral JAK inhibitor
223998932|NCT05241834|DRUG|LOXO-260|Oral
223998933|NCT05608044|DRUG|Botensilimab|An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
224123604|NCT03873129|BEHAVIORAL|mobile health app (mHealth)|A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
223998934|NCT05608044|DRUG|Balstilimab|An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
223382503|NCT02737241|PROCEDURE|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
223382504|NCT01859338|RADIATION|cone-beam computed tomography|Undergo CBCT
223382505|NCT01859338|RADIATION|magnetic resonance imaging|Undergo MRI
223382506|NCT01859338|RADIATION|computed tomography|Undergo fan beam computed tomography
223382507|NCT03916718|BEHAVIORAL|Care EcoSystem|This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
223998935|NCT05608044|DRUG|Standard of Care|Regorafenib or trifluridine and tipiracil.
223998936|NCT05641168|OTHER|Adhesive material|Newly developed adhesive material
223998937|NCT05641168|OTHER|Standard adhesive material|Standard adhesive material
223998938|NCT06444750|OTHER|Blood sample collection|Blood samples of 30 mL will be collected at admission. For the groups that receive a blood transfusion an extra 30 mL blood sample will be collected.
223998939|NCT04872595|OTHER|Personalized rATG (P-rATG)|P-rATG days (always starting on Day -12 to -10)
223382508|NCT05881824|BEHAVIORAL|MDG intervention|6-month behavioral intervention aiming at weight loss and increasing adherence to the Mediterranean diet
223382509|NCT06352021|DEVICE|kaleidoscope|The children in the kaleidoscope group were shown the kaleidoscope by the researcher five minutes before the blood sampling, and they were encouraged to look at the kaleidoscope during the procedure and describe the patterns they saw. All children in the Kaleidoscope group agreed to participate in the study. All children in the kaleidoscope group were asked to look at the kaleidoscope just before the tourniquet was placed on their arms before the blood sampling procedure and to describe the patterns, they saw in it by turning it slowly during the procedure.
223382510|NCT05989464|DIAGNOSTIC_TEST|Self-swab for genital HPV|Participants will insert a swab in the vagina to collect a sample for HPV testing.
223382511|NCT00005985|BIOLOGICAL|filgrastim|
223998940|NCT04872595|RADIATION|Hyper fractionated total body irradiation|"(1375 - 1500cGy\*) Day -9 to -6~\*TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
223998941|NCT04872595|DRUG|Thiotepa|(5mg/kg/day x 2 day) Day -5 to -4
223382512|NCT00005985|DRUG|carmustine|
223382513|NCT00005985|DRUG|cyclophosphamide|
223998942|NCT04872595|DRUG|Cyclophosphamide|(60mg/kg/day x 2 days) Day -3 to -2
223998943|NCT04872595|DRUG|GCSF|Day +7
223998944|NCT04872595|DRUG|Busulfan|Day -9 to -7 doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg\*h/L
223382514|NCT00005985|DRUG|cytarabine|
223382515|NCT00005985|DRUG|dexamethasone|
223382516|NCT00005985|DRUG|etoposide|
223382517|NCT00005985|DRUG|mitoxantrone hydrochloride|
223382518|NCT00005985|PROCEDURE|peripheral blood stem cell transplantation|
223382519|NCT00005985|RADIATION|radiation therapy|
223382520|NCT05256134|DRUG|Gantenerumab|Gantenerumab will be administered as per the dosing schedule described in the Arm description.
223382521|NCT05256134|DRUG|Placebo|Placebo will be administered as per the dosing schedule described in the Arm description.
223382522|NCT01818882|OTHER|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
223382523|NCT01818882|DEVICE|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
223382524|NCT04369274|DEVICE|Mechanical ventilation with the automated BVM compressor|Mechanical ventilation is accomplished with a device that mechanically squeezes a manual bag valve instead of by hand. The rate and volume of compression are adjustable, and the device has appropriate alarms and safety features.
223998945|NCT04872595|DRUG|Melphalan|(70mg/m2/day x 2 days) Day -6 to -5
223382525|NCT05425212|OTHER|Functional activation with kinesio tapping|These exercises will be carried out thrice a week for 4 weeks. The exercises will be performed for approximately 35-45 minutes, 1 to 2 times a day, in sitting or standing position
223998946|NCT04872595|DRUG|Fludarabine|(25mg/m2/day x 5 days) Day -6 to -2
223998947|NCT06571786|DRUG|Perflutren lipid microsphere|Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
223998948|NCT06340321|DIAGNOSTIC_TEST|Metabolic flexibility in the fasted state|Measured at baseline during the InSight study (2008-2009). Calculated as the respiratory exchange ratio in the fasting state adjusted for the circulating concentrations of free fatty acids
223998949|NCT06340321|OTHER|Metabolic flexibility in euglycemic-hyperinsulinemic clamp|Measured at baseline during the InSight study (2008-2009). Calculated as the change in respiratory exchange ratio adjusted for glucose disposal rate
223998950|NCT06340321|OTHER|Metabolic flexibility in the metabolic chamber|Measured at baseline during the InSight study (2008-2009). Calculated as the difference between awake respiratory exchange ratio (from 8 a.m. to 11 p.m.) and sleeping respiratory exchange ratio during a 23-hour stay in the metabolic chamber
224123605|NCT02508727|OTHER|MRI|
224123606|NCT02508727|OTHER|3D cardiac ultrasound|
224123607|NCT00282165|DRUG|naratriptan|four weeks double blind experimental treatment using oral naratriptan
224123608|NCT00282165|DRUG|placebo|four weeks double blind placebo treatment
224123609|NCT00355004|OTHER|counseling intervention|
224123610|NCT00355004|PROCEDURE|fecal occult blood test|
224123611|NCT00355004|PROCEDURE|screening colonoscopy|
223382526|NCT05425212|OTHER|Conventional physical therapy|strengthening and stretching, combined with Ankle ranges and Hip strengthening. (6) The exercises performed will be Calf stretches, Heel and Toe raises, Hip marching in sitting/standing; 4 days a week for 4 weeks
223998951|NCT05796505|BEHAVIORAL|ADVANCE Steering Committee interventions|Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
223382527|NCT03412695|DEVICE|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
223382528|NCT00281281|DRUG|vancomycin|
223382529|NCT00421161|DRUG|olive oil and omega 3 in a combined cream|
223382530|NCT02871011|DRUG|Nitric Oxide|Delivered as a footbath
223382531|NCT02871011|DRUG|Water|Delivered as a footbath
223382532|NCT05819970|DRUG|Allium Sativum Oil|Allium sativum oil will be used as non-vital pulpotomy medicament
223382533|NCT05819970|DRUG|Turmeric Gel|Turmeric gel will be used as non-vital pulpotomy medicament
223382534|NCT03613181|DRUG|ANG1005|Investigational drug
223382535|NCT03613181|DRUG|Physician's Best Choice|Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
223382536|NCT00886015|DEVICE|TT Clamp|trichiasis surgery performed with TT clamp
223382537|NCT00886015|PROCEDURE|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
223382538|NCT00021385|DRUG|carboplatin|
223382539|NCT00021385|DRUG|squalamine lactate|
223998952|NCT06062888|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Standard of Care + 2 units (400-500 ml) of fresh frozen plasma
223998953|NCT04933149|DRUG|Ketamine Infustion|Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
223998954|NCT01514253|DRUG|Glucose 25%|1 ml glucose 25%, once
223998955|NCT01514253|DIETARY_SUPPLEMENT|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
223998956|NCT01514253|OTHER|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
223382540|NCT03260556|DRUG|Pirfenidone|Increasing doses
223998957|NCT02552979|OTHER|atopic patch test|
224138444|NCT03335956|DRUG|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
223382541|NCT03260556|DRUG|Placebos|Increasing doses
223382542|NCT05082818|COMBINATION_PRODUCT|Chemotherapy, Radiotherapy and surgery|Trans urethral resection of the tumour or radical cystectomy
223382543|NCT03500068|DIAGNOSTIC_TEST|biopsies & blood analyses|They will take blood and a biopsy from the metastase in the patient
223382544|NCT03397589|BEHAVIORAL|Community Health Worker (CHW) services|CHWs are non-clinical people who provide education, care coordination, and support to families.
223382545|NCT02681861|DRUG|ASP6294 Intravenous|Intravenous (IV)
223382546|NCT02681861|DRUG|ASP6294 Subcutaneous|Subcutaneous (SC)
224138445|NCT03335956|DRUG|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
223382547|NCT02681861|DRUG|Placebo Intravenous|Intravenous (IV)
223382548|NCT02681861|DRUG|Placebo Subcutaneous|Subcutaneous (SC)
223382549|NCT02748304|OTHER|control|just follow up
223382550|NCT02748304|DRUG|sorafenib|sorafenib 400mg bid po
223382551|NCT02748304|DRUG|aspirin|aspirin 100mg qd po
223382552|NCT03669510|OTHER|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
223382553|NCT03719768|DRUG|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
223382554|NCT03719768|RADIATION|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
223382555|NCT03395288|DRUG|D-Mannose|A total of 2 g D-mannose daily
223382556|NCT05606783|BEHAVIORAL|Telehealth Follow-up Visits|"• Follow-up with patients once per week for six (6) weeks via scheduled 20-minute telehealth appointment with each patient via the HIPAA secure and compliant platform, VSee~o During this telehealth appointment, the study pharmacists will counsel the patients on their blood pressure readings for that week and provide lifestyle education focusing on patient-specific diet and exercise recommendations"
223382557|NCT05606783|BEHAVIORAL|Surveys|"A pre- and post-survey will be given at the initial and final in-person appointments, respectively~• These surveys will collect basic patient demographics, knowledge of blood pressure, comfort with checking blood pressure at home, and previous experience working with a pharmacist"
223382558|NCT05606783|DEVICE|Devices|"Smart Phones with Apple Health Software will be used to monitor blood pressure once a day, and results will be sent automatically to the patients EHR (Epic)~• The Omron 10 Series Wireless Upper Arm Blood Pressure Device will be given to the patient to monitor blood pressure at home daily"
223382559|NCT04757597|DEVICE|Remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
223382560|NCT00581750|OTHER|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
223382561|NCT05490771|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223382562|NCT05490771|PROCEDURE|Computed Tomography|Undergo CT
223382563|NCT05490771|DRUG|Copanlisib Hydrochloride|Given IV
223382564|NCT05490771|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223382565|NCT03994822|DEVICE|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
223998958|NCT03317990|PROCEDURE|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a significant positive margin (on more than one section from one side or in a single section but greater than or equal to 3mm) is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
223998959|NCT03317990|PROCEDURE|Standard RARP|Patients will undergo the standard intervention - RARP without NeuroSAFE Frozen section analysis
223998960|NCT05674396|RADIATION|Stereotactic body radiotherapy|Participants will receive radiation as per the schedule discussed with the study doctor.
223998961|NCT05674396|RADIATION|Traditional Palliation|Participants will receive radiation as per the schedule discussed with the study doctor.
223998962|NCT01656252|DRUG|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
223998963|NCT01656252|DRUG|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
223998964|NCT01656252|DRUG|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients \>60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
223998965|NCT04903392|OTHER|Backward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. The training, which will take 30 minutes, will be as follows: 5 minutes forward walking (warm-up phase), 20 minutes backward walking (intervention phase) and 5 minutes forward (cooling phase).~-three times a week for six weeks"
223998966|NCT04903392|OTHER|Forward Walking Training|"The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. It will be in the form of walking forward for 30 minutes.~-three times a week for six weeks"
223998967|NCT05278819|OTHER|upper extremity elevation|5 repetitions of active upper extremity elevation in a sitting position
224123612|NCT04122768|BEHAVIORAL|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
224123613|NCT04122768|BEHAVIORAL|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
224123614|NCT00409630|DRUG|fluticasone|
223998968|NCT05278819|OTHER|upper extremity elevation with deep breathing|5 repetitions of active upper extremity elevation with deep breathing in a sitting position
224123615|NCT00716404|DEVICE|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
224123616|NCT02985125|DRUG|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
224123617|NCT02985125|DRUG|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
224123618|NCT03699839|BIOLOGICAL|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
223382566|NCT03994822|DEVICE|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
224138446|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
223382567|NCT06372184|DRUG|Washed Microbiota Transplantation|Patients take four capsules containing washed microbiota once a day for five consecutive days
223382568|NCT06372184|DRUG|Placebo|Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
223382569|NCT01905436|DRUG|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
223998969|NCT05471284|BEHAVIORAL|Proximal|The first factor tested framing of the near, proximal threat of continued smoking.
223998970|NCT05471284|BEHAVIORAL|Distal|The first factor tested framing of the long-term, distal threat of continued smoking.
223998971|NCT05471284|BEHAVIORAL|Cost|Cost framework measures the response efficacy to quitting smoking by displaying costs of continued smoking.
223998972|NCT05471284|BEHAVIORAL|Benefit|Benefit framework measures the response efficacy to quitting smoking by displaying benefits of quitting.
223998973|NCT05471284|BEHAVIORAL|Loss|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing loss of not participating in a smoking cessation.
223998974|NCT05471284|BEHAVIORAL|Gain|The third factor tested framing of the response efficacy of participating in a cessation study by utilizing gain of participating in a smoking cessation.
223998975|NCT05471284|BEHAVIORAL|Control|Does not include any of the three message factors.
223998976|NCT03297177|PROCEDURE|Microcannula Harvest Adipose|Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
223998977|NCT03297177|DEVICE|Centricyte 1000|Closed System, Digestive Isolation \& Concentration of AD-cSVF
223998978|NCT03297177|PROCEDURE|Sterile Normal Saline Infusion|Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
223998979|NCT06395818|PROCEDURE|prefabricated CAD-CAM allogeneic bone block hydrated using hyaluronic acid|exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws ,The block was coated with a nonporous d-PTFE membrane
223998980|NCT06395818|PROCEDURE|prefabricated CAD-CAM allogeneic bone block sterilized hydrated using saline solution|exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws. The block was coated with a nonporous d-PTFE membrane
223998981|NCT02022904|DEVICE|Near infrared (NIR) emissive nanotechnology|
223998982|NCT02021552|OTHER|blood sampling|5 ml blood sampling
223998983|NCT01450384|DRUG|sorafenib tosylate|Given PO
223998984|NCT01450384|DRUG|pemetrexed disodium|Given IV
223998985|NCT01450384|OTHER|laboratory biomarker analysis|Correlative studies
223998986|NCT01450384|PROCEDURE|biopsy|Optional correlative studies
223998987|NCT01194375|DRUG|Low Strength IDP-107|Once a day for 16 weeks
223998988|NCT01194375|DRUG|High Strength IDP-107|Once a day for 16 weeks
223998989|NCT01194375|DRUG|Placebo|Once a day for 16 weeks
223998990|NCT05120869|BEHAVIORAL|Tailored HPV Education and Professional Skills Intervention Group|The provider education and professional skills intervention will involve audio and visual content and will be delivered in the English language.
223998991|NCT05120869|BEHAVIORAL|General HPV Education and Communication Skills Control Group|The general provider education intervention will involve audio and visual content and will be delivered in the English language.
223998993|NCT00942864|DRUG|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
223998994|NCT01762969|OTHER|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
223998995|NCT05282121|DRUG|Avenciguat|one film-coated tablet orally twice a day, at least 10 hours apart. The starting dose (1 mg) was up-titrated up to 3 mg
223998996|NCT05282121|DRUG|Empagliflozin|one 10 mg film-coated tablet of orally once a day
223998997|NCT00429780|BIOLOGICAL|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
223998998|NCT05198245|DRUG|Rimegepant|Rimegepant 75mg
223382570|NCT03377257|DRUG|zolmitriptan by sublingual administration|Experimental group
223382571|NCT03377257|DRUG|zolmitriptan by oral|Active group
223382572|NCT01720225|DRUG|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
223382573|NCT01720225|DRUG|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
223382574|NCT02720497|BEHAVIORAL|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
223382575|NCT02720497|BEHAVIORAL|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
223998999|NCT05198245|DRUG|Various|Various
223999000|NCT05198245|OTHER|No intervention|No intervention
223999001|NCT06220305|DIAGNOSTIC_TEST|DNA methylation joint AI imaging|DNA were extracted from patients'plasma ,then the DNA was bisulfite converted and tested by DNA methylation assay.The results were combined with AI images to differentiate between benign and malignant lung nodules.
223999002|NCT06151639|PROCEDURE|general anesthesia|General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.
223999003|NCT06151639|PROCEDURE|peripheral nerve blocks|With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
223382576|NCT03842644|DEVICE|Tension reduction device|Continue using this device for 3 months post surgery.
223382577|NCT04391296|PROCEDURE|Arm I (Prepectoral), Arm II (Subpectoral)|"Arm I (Prepectoral)De-epithelialized skin flaps are made from the inferior pole of breast skin and soft tissue. The implant pocket is shaped by fixing a sufficiently large amount of ADM to the medial surface of the mastectomy pocket, the upper edge of the pectoralis major muscle and the de-epithelial skin flap. The implant is located in the prepectoral mastectomy pocket and the ADM anchored to the chest wall, serratus fascia, and de-epithelial skin flaps. The pectoralis major muscle is located in the anatomical location behind the ADM.~Arm II (Subpectoral)The pectoralis major muscle is dissected from the thorax to create sufficient space for the implant to be placed behind the pectoralis major muscle. Implant pockets are made by suturing the lower part of the elevated pectoralis major muscle to the top of the de-epithelial skin flap and the ADM patch to the skin flap, the pectoralis major muscle, and the lateral thoracic fascia."
223382578|NCT00372814|BEHAVIORAL|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
223382579|NCT00372814|BEHAVIORAL|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
223999004|NCT01736189|DRUG|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
223999005|NCT04136717|OTHER|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
223999006|NCT04136717|DEVICE|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
223382580|NCT02186002|DRUG|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
223382581|NCT02186002|DRUG|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
223382582|NCT02186002|DRUG|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
223382583|NCT02186002|DRUG|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
223382584|NCT02186002|DRUG|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
223382585|NCT02186002|DRUG|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
223382586|NCT02186002|DRUG|Placebo|
223382587|NCT05477043|DIAGNOSTIC_TEST|Transabdominal ultrasound and cistoscopy|Ultrasound detection of the bilateral ureteral jets vs absence of the ureteral jet on one side compared with the presence of bilateral ureteral jet on cystoscopy vs absence on one side.
223382588|NCT01221207|DEVICE|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
223999007|NCT04136717|DEVICE|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
223999008|NCT04136717|OTHER|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
223999009|NCT04136717|OTHER|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
223999010|NCT06345469|OTHER|Patient blood management (PBM)|PBM means the medical enhancement of the participants own hematopoietic reserve to treat anemia and to reduce the ill effects of disease and bleeding on hematopoiesis and homeostasis.
223999011|NCT06345469|BIOLOGICAL|Allogeneic transfusion|transfusion of donor red cells
223999012|NCT01603888|OTHER|no intervention|
223999013|NCT03022955|DIETARY_SUPPLEMENT|Dark chocolate bar|Dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
223999014|NCT03022955|DIETARY_SUPPLEMENT|Dark chocolate mousse|Dark chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
223999015|NCT03022955|DIETARY_SUPPLEMENT|White chocolate bar|White chocolate bar (0% cocoa solids (\~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
223382589|NCT01221207|DEVICE|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
223382590|NCT01221207|DEVICE|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
223999016|NCT03022955|DIETARY_SUPPLEMENT|White chocolate mousse|White chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
223999017|NCT05222594|OTHER|Behavioral tasks during intracranial monitoring|Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
223999018|NCT02769442|DEVICE|Terumo SurFlash Plus catheter|
223999019|NCT02769442|DEVICE|BD Insyte Autoguard catheter|
224138447|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
223382591|NCT04759807|DRUG|Placebo Comparator|The placebo designed for administration in the proposed clinical study consists of a dry powder composed of the same excipients as the active (sodium sulfate, mannitol and polysorbate 80), pre-metered into HPMC capsules at the same 5 mg powder fill weight as the active formulations. Subjects will receive 14 doses administered once daily in the morning.
223382592|NCT04759807|DRUG|PUR1800 250 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 250 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
223382593|NCT04759807|DRUG|PUR1800 500 ug|The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral delivery via a passive DPI. The capsules contain 5 milligrams (mg) of the powder formulation, corresponding to a 500 μg nominal dose strength of RV1162. Subjects will receive 14 doses administered once daily in the morning.
223382594|NCT05792111|DRUG|Trigger point injection (lidocaine)|trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
223999020|NCT06337487|OTHER|QoL questionnaires|"The EORTC QLQ-C30 questionnaire is a specific cancer questionnaire. A score is calculated per dimension reflecting the patient's level for the corresponding QoL scale (dimension). These scores are calculated according to the EORTC recommendations.~Research work was recently developed by Giesinger et al. within the EORTC QoL group, with the aim of providing thresholds of clinical importance for the different dimensions of the QLQ-C30.~An item was added to complete the QLQ-C30. It comes from the EORTC bank library item based on the INCa organizational framework. This item was chosen because it addressed a theme not addressed in the QLQ-C30, sexual health. After consultation with a multidisciplinary team, the threshold was determined for this additional item. Has your illness or treatment had a negative effect on your sex life? , the threshold is reached when the answer is enough or a lot."
223999021|NCT06337487|OTHER|Qualitative Interview (for one part of nurses only)|At the end of the study, semi-directed qualitative interviews will be conducted with the nurses carrying out the TAS with the aim of understanding the obstacles and facilitators of the routine implementation of the QoL assessment to early identify the SOS needs of patients treated in medical oncology. The semi-structured interviews will be accompanied by an interview grid composed of main questions and follow-up questions. The main questions help introduce the theme. The follow-up questions make it possible to clarify the participants' comments without interrupting the fluidity of the exchanges. The themes discussed between the researcher and the participant during the interview will be as follows: Personal information and overall professional experiences, Knowledge of the study and experience of training with tools (questionnaire and software), Perception of tools (questionnaire and software) and their implementation, Definition and perception of key concepts.
223999022|NCT06337487|OTHER|ORIC questionnaire|Organisational readiness is a factor known to influence the predisposition of individuals to change within an organisation. Based on Weiner's organisational theory, Organizational Readiness for Implementing Change (ORIC) is a questionnaire that has been developed and validated, particularly in French, to measure the organisation's state of in the field of healthcare. It comprises ten items which measure two concepts: commitment to change and effectiveness of change.
223999023|NCT06337487|OTHER|Professionals satisfaction survey|"A satisfaction questionnaire will be offered to all professionals involved once the last patient has been included. This questionnaire has previously been developed by the UMQVC team to assess investigator satisfaction for other studies and adapted to the context of SOS-Deteqt.~This questionnaire evaluates in particular :~* the quality of training~* ease of use of the CHES~* the relevance of using the CHES and the PROs~* the relevance of maintaining the PRO evaluation approach in current clinical practice."
223999024|NCT06337487|OTHER|Patients satisfaction survey|"A patient satisfaction questionnaire was drawn up for the study. It includes items taken from :~* the EORTC's PATSAT33 satisfaction questionnaire, and in particular items relating to the quality of information provided by nurses and the time spent~* the EORTC COMU26 communication evaluation questionnaire, and in particular the items on being comfortable asking questions, professional responses to difficult difficult subjects, explanation of treatment objectives, etc.~* the questionnaire developed jointly by the UMQVC team and the psychology laboratory of the psychology laboratory at the University of Franche Comté as part of the REMOQOL-Poumon study and assessing in particular~* understanding of the purpose of using the QoL questionnaire~* ease of completion and use of the tablet~* satisfaction with the questionnaire and the tablet~* intention to use in the future"
223999025|NCT00398372|DRUG|Rituximab|
223999026|NCT00398372|DRUG|Epratuzumab|
223999027|NCT03809039|DRUG|MT-6345|MT-6345
223999028|NCT03809039|DRUG|MT-6345 Placebo|MT-6345 Placebo
223999029|NCT00967967|DRUG|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
223999030|NCT04875442|DEVICE|Memowave emitting sounds|Memowave is worn during one night and emits sounds to increase slow brain waves
223999031|NCT04875442|DEVICE|Memowave not emitting sounds|Memowave is worn during one night and doesn't emit sounds
223382595|NCT05792111|DRUG|Caudal epidural Group (bupivacaine + triamcinolone + NaCl)|It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space
223999032|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log: Pain display can be seen|Pain scores are displayed on the screen when the participant presses the corresponding button
223999033|NCT03881982|OTHER|PIMPERNEL Novel Electronic Log: Pain display is hidden|Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
223382596|NCT00661193|DRUG|carboplatin|given IV
223382597|NCT00661193|DRUG|erlotinib hydrochloride|given orally
223382598|NCT00661193|DRUG|paclitaxel|given IV
223999034|NCT01869504|DEVICE|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
223999035|NCT04329377|DIAGNOSTIC_TEST|blood test|complete blood count and platelet function
223382599|NCT05397678|BIOLOGICAL|BCG-Denmark|AJ vaccines, Copenhagen 1331 strain
223999036|NCT03272906|DEVICE|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
223999037|NCT03272906|DEVICE|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
223999038|NCT03272906|BEHAVIORAL|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
223999039|NCT01738659|DIETARY_SUPPLEMENT|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
223999040|NCT05209516|BEHAVIORAL|Behavioral data|Participants will be seated comfortably in front of a cathode ray tube screen, at a distance of 50-70 cm. The refresh rate of the monitor will be kept above 75 Hz to avoid visual fatigue. Participants will be asked to perform an instructed-delay choice reaction-time task in which they will have to choose between a left and right finger response. In this task, we measure the reaction-times and movement times.
224123619|NCT03699839|BIOLOGICAL|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
223382600|NCT05397678|BIOLOGICAL|BCG-Bulgaria|BB-NCIPD Ltd., BCG-SL 222 Sofia strain
223382601|NCT02191293|DRUG|Viramune® tablets|
223382602|NCT05506293|PROCEDURE|percutaneous paravalvular leak closure|"the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~* Amplatzer vascular plug 3~* occlutech paravalvular leak device~* amplatzer vascular plug 2~* amplatzer muscular ventricular septal defect~* amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design."
223382603|NCT04511585|BEHAVIORAL|Great Live and Move Challenge|Physical activity program for children
223382604|NCT01108783|DRUG|Bilastine|20 mg (encapsulated) tablets QD/14 days
223382605|NCT01108783|DRUG|Desloratadine|5 mg (encapsulated) tablets QD/14 days
223382606|NCT01108783|DRUG|Placebo|(encapsulated) Tablets QD/14 days
223382607|NCT00843661|DRUG|ezetimibe|10 mg ezetimibe/day
223382608|NCT00843661|DRUG|fenofibrate|200 mg fenofibrate/day
223382609|NCT00843661|DRUG|pravastatin|40 mg pravastatin/day
223382610|NCT03578393|DEVICE|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
223382611|NCT04875351|DIAGNOSTIC_TEST|Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test|The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (\>5 year) endocrine therapy.
223382612|NCT00005811|DRUG|topotecan hydrochloride|Given IT
223382613|NCT00005811|OTHER|laboratory biomarker analysis|Correlative studies
223382614|NCT05063474|DIAGNOSTIC_TEST|No Intervention-Clinical Assessments only|No Intervention. Clinical Assessments include: vital signs, near infrared spectrometry, general leg strength, and 6-minute walking test.
223999041|NCT05209516|DIAGNOSTIC_TEST|Single-pulse transcranial magnetic stimulation (TMS)|While being comfortably seated in a chair and performing the pre-mentioned task, the participants will undergo single-pulse TMS over both primary motor cortices (M1). In order to guarantee the position of the stimulation coils throughout the testing, participants are asked to wear an EEG cap which will be used to mark various scalp locations. Bipolar surface electrodes, linked to an electromyography (EMG) system, will be placed over one or more muscles of each hand in order to measure the amplitude of motor evoked potentials at various stages of the task. Prior to the placement of each adhesive surface electrode, the skin will be gently swabbed with an alcohol solution.
223999042|NCT05209516|OTHER|Questionnaires|Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI) II, Scale on impulsive behaviour (UPPS).
223999043|NCT05209516|OTHER|MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)|Specific Parkinson Questionnaire on Clinical motor status
223999044|NCT00696943|DRUG|([18F]-ML-10)|\[18F\]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of \[18F\]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
224123620|NCT03699839|BIOLOGICAL|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
224123621|NCT05407298|OTHER|Non applicable|Non Applicable
224123622|NCT04461847|PROCEDURE|subcutaneous mastectomy|Operating subcutaneous mastectomy
224123623|NCT04461847|PROCEDURE|endoscopic subcutaneous mastectomy|Operating endoscopic subcutaneous mastectomy
223999045|NCT00843505|BEHAVIORAL|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
223999046|NCT00843505|BEHAVIORAL|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
223999047|NCT05198102|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 12 months after the basic immunization (window period ± 3 months), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
223999048|NCT01510080|BEHAVIORAL|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
223999049|NCT01510080|BEHAVIORAL|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
223999050|NCT05017090|PROCEDURE|M-TAPA block|After tracheal intubation, a high-frequency linear probe will placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
223999051|NCT05017090|OTHER|Standard perioperative and postoperative multimodal analgesia|The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
223999052|NCT06408701|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
223999053|NCT05853952|DEVICE|Non-invasive Neuromodulation|The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
223999054|NCT05853952|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
223999055|NCT03236584|DRUG|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
223999056|NCT03236584|DRUG|Tenofovir Disoproxil Fumarate|switching to tenofovir
223999057|NCT04291053|DRUG|Huaier Granule|standard treatment + Huaier Granule 20g po tid for 2weeks
223999058|NCT00809367|OTHER|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
223999059|NCT04905576|BEHAVIORAL|Relaxation training|Muscle relaxation training
223999060|NCT04905576|BEHAVIORAL|Therapeutic touch|Healing Touch (HT) therapy
223999061|NCT04905576|OTHER|Questionnaire administration|
223999062|NCT04905576|OTHER|Ancillary studies|Subjects in all groups will give 4 blood samples during the study
223999063|NCT02360722|OTHER|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
223999064|NCT02360722|OTHER|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
223999065|NCT03329469|DEVICE|Toshiba CT-FFR|Patients receiving CCTA to diagnose acute chest pain or unstable angina will receive CT-FFR to estimate rate of blood flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
223999066|NCT01126645|PROCEDURE|RFA|"A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).~The study procedure guide will contain further instructions for RFA."
223999067|NCT01126645|PROCEDURE|Radioembolization (SIRT)|"One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.~Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm."
223999068|NCT02658877|DRUG|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
223999069|NCT02658877|DRUG|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
223999070|NCT01928238|DEVICE|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
223999071|NCT01928238|DEVICE|Noninvasive pressure support ventilation (NPSV)|
223382615|NCT06101160|DRUG|onaBoNT-A|injection under ultrasonography
223999072|NCT00608868|DRUG|Gefitinib|Gefitinib tablet 250mg once daily orally
223999073|NCT00988299|OTHER|exercise|exercise sessions at 45% and 60% of maximum effort
224123624|NCT01924897|BEHAVIORAL|Exercise training|
223382616|NCT02964312|DEVICE|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
223382617|NCT04019626|OTHER|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
223999074|NCT05766527|BIOLOGICAL|KM602|Multiple dose levels of KM602 will be administered, including 0.01 mg/kg QW, 0.1 mg/kg QW, 0.6 mg/kg QW, 3 mg/kg QW, and 10 mg/kg QW. KM602 is administered intravenously once a week, and each cycle is 21 days.
223999075|NCT04866381|DRUG|SHR-6390|SHR-6390
223999076|NCT04866381|DRUG|SHR-6390 + Camrelizumab (SHR-1210)|SHR-6390 combined with Camrelizumab (SHR-1210)
223999077|NCT04866381|DRUG|Camrelizumab (SHR-1210) + SHR-1020|Camrelizumab (SHR-1210) combined with SHR-1020
223999078|NCT01541852|DRUG|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
223999079|NCT01541852|DRUG|Placebo|One tablet twice daily
223999080|NCT00999739|BIOLOGICAL|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
223999081|NCT01250925|DRUG|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
223999082|NCT01250925|DRUG|OPTI-FREE® RepleniSH®|Contact Lens care regimen
223999083|NCT01250925|DRUG|Clear Care®|Contact lens care regimen
223999084|NCT04000984|BEHAVIORAL|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
223999085|NCT04000984|BEHAVIORAL|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
223999086|NCT05465590|DRUG|MB1707|"MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism."
223999087|NCT03215862|DRUG|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
223999088|NCT03215862|DRUG|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
223999089|NCT05059444|DIAGNOSTIC_TEST|Guardant Reveal|Guardant Reveal is a minimal residual disease (MRD) panel for use in recurrence detection of early-stage solid tumors.
223999090|NCT02630875|DRUG|A4250|A4250
223382618|NCT04019626|OTHER|myblu Tobacco 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
223382619|NCT04019626|OTHER|myblu Tobacco 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
223382620|NCT04019626|OTHER|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
223999091|NCT03507946|DEVICE|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
223999092|NCT06196775|BIOLOGICAL|AK104+AK112|Cadonilimab (AK104): 10mg/kg or 15mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) AK112: 20mg/kg Q3W iv D1 Eligible patients will receive AK104 plus AK112 until disease progression or withdrawn ICF or death, whichever comes first.
223999093|NCT05721781|BEHAVIORAL|Oral Hygiene instruction|Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).
223999094|NCT05721781|PROCEDURE|Dental Cleaning|Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
223382621|NCT04019626|OTHER|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
223382622|NCT04019626|OTHER|JUUL 5%|Ad-libitum use of JUUL 5% e-cigarette
223382623|NCT06465836|PROCEDURE|O, lreay suture|bilateral uterine artery ligations as described by O- lreay technique in addition to standard conservative methods. Briefly two large vicryl stitches were passed using a large sized needle below and lateral to the lower edge of the uterine incision angle in anteroposterior direction and then redirected from back to the front through avascular window in the posterior leaf of the broad ligament just lateral to the uterine border taking care to avoid injury to bowel posteriorly or bladder/ureter anteriorly. The stitches were tied securely anteriorly
223382624|NCT06465836|PROCEDURE|modified O, lreay suture|"1. Pack Douglas- pouch with a towel.~2. Straight the used vicryl needle mostly no 1.~3. Try to compress and approximate anterior and posterior uterine walls.~4. Start from anterior to posterior 3- 4 cm medial to lateral uterine margin and then pass from posterior to anterior through avascular area in the broad ligament. And we repeat the procedure on the other side. We can repeat this method of uterine ligation at another different plane if needed."
223382625|NCT06113835|PROCEDURE|CTO PCI|percutaneous coronary intervention
223999095|NCT04421950|DIETARY_SUPPLEMENT|Wild blueberry containing foods|Foods that contain wild blueberry supplement to deliver up to 30 grams of blueberry powder
223999096|NCT04421950|DIETARY_SUPPLEMENT|Placebo containing foods|Foods that do not contain the blueberry powder but a placebo
223999097|NCT05686798|BIOLOGICAL|Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)|Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
223999098|NCT04427943|PROCEDURE|revision surgery|The intervention is the planned revision surgery according to local guidelines.
223999099|NCT00966121|PROCEDURE|endoscopic band ligation|"* Perform EBL within 7 days after randomization~* Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).~* Acid suppression using proton pump inhibitor until eradicated.~* After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
223999100|NCT00966121|PROCEDURE|EBL+Propranolol|"* Start with 20 mg b.i.d~* Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min~* After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
223999101|NCT02057211|BIOLOGICAL|autologous mesenchymal stem cell transplantation|
223999102|NCT02057211|PROCEDURE|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
223999103|NCT04517708|OTHER|Nutritional counseling|Each patient was assigned a specific menu which were prepared by research members during the time of staying at the hospital. Before discharge, patients were instructed on preparing their diets at home with the recommended amount of energy and protein and given formula milk within two months
223999104|NCT03993808|BEHAVIORAL|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
223999105|NCT03993808|BEHAVIORAL|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
223999106|NCT03993808|BEHAVIORAL|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
223999107|NCT03993808|BEHAVIORAL|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
223999108|NCT03993808|BEHAVIORAL|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
223999109|NCT01252355|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
223382626|NCT04078321|OTHER|Mollii ®|The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
223999110|NCT01252355|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
223999111|NCT01252355|DRUG|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
223999112|NCT02566564|DRUG|Lopain|intra-articular injection
223999113|NCT03289351|DRUG|Piperacillin, Tazobactam Drug Combination|Single drug therapy
223999114|NCT00338143|DRUG|efalizumab|
223999115|NCT00335140|BIOLOGICAL|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
223999116|NCT00335140|DRUG|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
223999117|NCT00335140|DRUG|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
223999118|NCT00335140|DRUG|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
223999119|NCT00335140|DRUG|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
223999120|NCT00335140|DRUG|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
223999121|NCT00335140|DRUG|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
223999122|NCT05900414|BEHAVIORAL|Electronic patient decision aid|Link to website with information about atrial fibrillation treatments, plus access to the web-based patient decision aid to enable shared decision making between patients and their physicians for atrial fibrillation stroke prevention treatments
223999123|NCT05900414|OTHER|Information|Link to website with information about atrial fibrillation treatments
223999124|NCT05090943|OTHER|QOL to be completed by the participant|The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
223999125|NCT04390932|OTHER|Enhanced TA|The enhanced TA is characterized by the personalization of the conversation, the verbalization of a joint participation in the process, the full presence of the therapist in the development of the exercise protocol, and the inclusion of behaviors such as active listening, empathy, and encouragement. In addition, therapist's body language transmits confidence, security, and attention.
223999126|NCT04390932|OTHER|Limited TA|The limited TA does not consider the personalization of the conversation, uses a unidirectional verbalization and is imperative about the instructions provided to the participant, the therapist is intermittently absent during the therapeutic exercise sessions and uses a neutral or negative nonverbal language cues.
223999127|NCT04390932|OTHER|Therapeutic exercise protocol.|Three 45-60 minute sessions of supervised therapeutic exercise (combination of aerobic, isometric, and isotonic exercise) delivered within a one-week period.
223999128|NCT00431353|DRUG|Ganciclovir|5mg/kg iv bid for 21 days
223999129|NCT00431353|DRUG|valganciclovir [Valcyte]|900mg po bid for 21 days
223999130|NCT03934151|PROCEDURE|intracorporeal ileocolic anastomosis|laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag
223999131|NCT03934151|PROCEDURE|extracorporeal ileocolic anastomosis|ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
223999132|NCT06441253|DIAGNOSTIC_TEST|Deep Friction massage|The calf muscles received a firm, deep-circulation massage with fingertip pressure
223999133|NCT06441253|COMBINATION_PRODUCT|Therapeutic exercises|Four stretching exercises were performed for twenty minutes, five minutes for each technique, and eight to ten repetitions of each exercise (calf wall stretch, back knee straight, bilateral calf stretches, knees straight, ankle plantarflexion/dorsiflexion)
223999134|NCT00002622|DRUG|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
224123625|NCT03208192|PROCEDURE|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
224123626|NCT00843622|DRUG|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
224123627|NCT00843622|OTHER|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke \>15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
224123628|NCT04922125|COMBINATION_PRODUCT|Pulse flour|Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.
224123629|NCT04922125|COMBINATION_PRODUCT|Pre-processed pulse flour|Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
224138448|NCT03335956|DRUG|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
224138449|NCT02284685|BEHAVIORAL|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
223999135|NCT00002622|DRUG|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
223999136|NCT02237677|OTHER|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
223999137|NCT03582527|OTHER|all study participants|patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
223999138|NCT04546425|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
223999139|NCT04546425|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
223999140|NCT05866042|DEVICE|tDCS|TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. In healthy subjects, the administration of excitatory tDCS on the left DLPFC improves the regulation of attention on information characterized by negative emotions, as does the administration of inhibitory tDCS on the DLPFC Right tDCS produces small changes in the neuronal membrane potential, thus increasing or decreasing the excitability of the stimulated tissue. Simultaneous administration to behavioral tasks designed to activate the stimulated cortical region should achieve a synergistic, amplifying the plasticity stimulated by the task.
223999141|NCT05524090|OTHER|Implementation - International best-practice care|The PREOPANC-4 project aims to safely implement the international standard of excellence for LAPC management and surgery using a multidisciplinary best-practice training program, based on the experiences of four leading international expert centers (i.e. NYU Langone Health, University of Colorado, Heidelberg University, and MD Anderson Cancer Center). We hypothesize that the PREOPANC-4 implementation project will result in the improvement in multidisciplinary patient management and selection in line with current international best-practice.
224138450|NCT02209311|PROCEDURE|Oral mucosa biopsy|
224138451|NCT02209311|PROCEDURE|Sinus lift with implantation of tissue engineered construction|
223999142|NCT01753726|OTHER|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
223999143|NCT01753726|OTHER|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
223999144|NCT01725126|DRUG|GSK2890457|Provided as powder and capsule.
224138452|NCT02209311|DEVICE|Dental implant|
224138453|NCT05783193|DRUG|TGIR (Traditional Gastrointestinal Remedy)|TGIR botanical formulation
224138454|NCT05783193|DRUG|Placebo|Placebo capsules
224138455|NCT02090985|PROCEDURE|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
224138456|NCT03591094|DRUG|PTI-428|Active
224138457|NCT03591094|DRUG|Placebo|Placebo
224138458|NCT00046176|DRUG|abacavir/lamivudine|
224138459|NCT00046176|DRUG|abacavir|
224138460|NCT00046176|DRUG|lamivudine|
223382627|NCT04510532|DIAGNOSTIC_TEST|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment
223382628|NCT03240783|DRUG|Betamethasone OR Dexamethasone Injectable|Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).
223382629|NCT03240783|DRUG|Normal Saline Flush, 0.9% Injectable Solution|Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
223382630|NCT03240783|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.
223382631|NCT03240783|OTHER|Sham Injection and/or oral placebo|The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
223382632|NCT00139893|DRUG|Reglan ODT|
223382633|NCT03608397|BIOLOGICAL|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
223382634|NCT03608397|BIOLOGICAL|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
223382635|NCT00512577|OTHER|Red blood cell transfusion|Pre-operative red blood cell transfusion
223382636|NCT03001453|DRUG|Liposomal Bupivacaine|266mg liposomal bupivacaine
223999145|NCT01725126|DRUG|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
223999146|NCT01725126|DRUG|Placebo|Provided as powder and Capsule.
223999147|NCT01725126|DRUG|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
223999148|NCT01849640|DRUG|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
223999149|NCT01022905|BIOLOGICAL|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
223999150|NCT03435913|OTHER|Standard PEEP ventilation|During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation
223999151|NCT03435913|OTHER|Matched PEEP ventilation|During mechanical ventilation PEEP is matched to IAP level
223999152|NCT06349447|DEVICE|LED|308 nm LED light was utilized to induce an vivo PIE/PIH model on the thigh of subjects. The irradiation dose was 1.5 MED. Five circular experimental lesions measuring 1.5 × 1.5 cm were selected on the thighs, categorizing into five groups: control group, 830 nm LED treatment group, 590 nm LED treatment group, 830 nm LED prevention group and 590 nm LED prevention group. 830 nm LED and 590 nm LED were irradiated, respectively. For therapeutic irradiation, the PIH model was induced on D1, and 830 nm (60 J/cm2, 50 mW/cm2) and 590 nm LED (20 J/cm2, 20 mW/cm2) were irradiated on D0, D1, D3, D6 and D8, respectively. For preventive irradiation, 830 nm and 590 nm LED were irradiated on D0, D1, D3, D6 and D8, respectively, and the PIE/PIH model was induced on D9.
223999153|NCT06349447|OTHER|without any LED exposition|without any LED exposition
223999154|NCT05185505|DRUG|Atezolizumab|1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
223999155|NCT05185505|DRUG|Bevacizumab|15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
223999156|NCT05714280|BEHAVIORAL|PA4Health Open Pilot|"The goal of this aim is to collect data that guide the refinement of intervention components and structure to increase appeal to AA women. Fifteen physically inactive AA women will participate in a 12-week study examining the feasibility, acceptability, and usage of the PA4Health app.~They will receive a Fitbit tracker to be worn during the trial. Following the trial, participants will complete self-report measures as well as a semi-structured interview to learn about their experience in using the app, any experienced difficulties, and recommendations for improving the acceptance and usage of the app."
223999157|NCT06000540|DEVICE|RespirAct|RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
223999158|NCT00677534|DRUG|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
223999159|NCT03982251|PROCEDURE|High frequency whole body vibration|1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
223999160|NCT03982251|PROCEDURE|Low frequency whole body vibration|1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
223999161|NCT00690053|PROCEDURE|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
223382637|NCT03001453|DRUG|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
223382638|NCT03001453|DRUG|Saline|Normal saline
223382639|NCT00115453|RADIATION|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
223382640|NCT03270969|DRUG|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
223382641|NCT03849157|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
223999162|NCT06539468|OTHER|Best Practice|Receive SOC treatment
223999163|NCT06539468|OTHER|Educational Activity|Watch an educational video on AS for LR-BCC
223999164|NCT06539468|OTHER|Patient Observation|Undergo active surveillance
223382642|NCT03710980|DEVICE|Oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
223382643|NCT06551194|OTHER|prevalence of difficult-to-treat IBD|To assess the prevalence and risk factors of difficult-to-treat IBD patients
223382644|NCT00317694|DRUG|Fermagate|Film coated tablet 500mg
223382645|NCT00317694|DRUG|Placebo|Oral administration, film coated tablet, 0mg
223382646|NCT05041920|DRUG|famitinib、omeprazole|famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
223999165|NCT06539468|OTHER|Survey Administration|Ancillary studies
223999166|NCT05484414|DRUG|SRP-3D (diethylamide)|SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
223999167|NCT05484414|DRUG|Placebo|Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
223999168|NCT02695875|PROCEDURE|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
223999169|NCT02695875|PROCEDURE|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
223999170|NCT04258332|DIETARY_SUPPLEMENT|High Salt Diet|Patients will be randomized to be on a high salt diet for 7 days.
223382647|NCT02862730|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
223382648|NCT02862730|DEVICE|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
223382649|NCT02862730|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
223382650|NCT02862730|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
223729844|NCT02853110|RADIATION|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (\~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
223999171|NCT04258332|DIETARY_SUPPLEMENT|Low Salt Diet|Patients will be randomized to be on a low salt for 7 days.
223382651|NCT03484546|PROCEDURE|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
223382652|NCT04290455|DEVICE|Microblepharoexfoliative procedure with BlephEx™|The device will be used to clean both upper and lower eyelid in the office visit.
223729845|NCT05184218|DRUG|IGM-6268|Active Comparator
223729846|NCT05184218|DRUG|Placebo|Placebo Comparator
223729847|NCT00299910|DRUG|Montelukast|
223729848|NCT01307397|DRUG|Vemurafenib|Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
223729849|NCT03935204|BIOLOGICAL|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
223999172|NCT05788874|DIAGNOSTIC_TEST|18F-FAPI and 18F-FDG PET/CT|18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
223999173|NCT00773331|DRUG|epoetin beta|As prescribed
223999174|NCT00773331|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
223999175|NCT04468594|OTHER|rigid tapping|Taping techniques We will use rigid tape and apply it bilaterally. In the rigid tape application, a combination pack of zinc oxide tape and the protective tape will be used. The protective tape will be applied first with no tension. To apply the rigid tape, subjects will be instructed to place their thoracic spine in a neutral position, the rigid tape will be applied bilaterally from the first to the twelfth thoracic vertebra. Subjects will be asked to retract and depress the scapula. The rigid tape will be applied diagonally from the middle of the scapular spine to the twelfth thoracic vertebra; this technique will be applied bilaterally. The rigid tape will be applied 3 times per week and will be applied for 6 weeks.
223999176|NCT04468594|OTHER|scapular stabilizing excercise|"consisted of:~1. wall slides with squat,~2. wall push-ups plus ipsilateral leg extension,~3. lawnmower with diagonal squat,~4. resisted scapular retraction with contralateral leg squat and robbery with squat.~5. Robbery with squat~6. Resisted shoulder internal rotation with step~7. Resisted shoulder external rotation with step~8. Resisted full can with step All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands The patient will perform 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly."
223999177|NCT04468594|OTHER|therapeutic exercises|"1. Pectoralis minor stretching~2. Posterior shoulder stretching~3. Levator scapula stretching~4. Latissimus dorsi stretching ( stretching exercises will be 5 repetitions each session - 3 times per week)~5. Resisted shoulder internal rotation~6. Resisted shoulder external rotation~7. Resisted full can (strengthening exercises will be 510 repetitions each session - 3 times per week) All resisted exercises were performed with elastic bands with red color-coded resistance levels and progressed through green and blue bands NOTE. All resisted exercises were progressed from starting 10 repetitions 3 sets to 15 repetitions 3 sets and 20 repetitions 3 sets weekly, supervising movement quality, presence of pain, and fatigue. If the subject achieves 20 repetitions 3 successfully, heavier resistance with resistance band color-coded loading prescribed from 10 repetitions 3 sets."
223999178|NCT05106205|DRUG|DA-5213 10mg|single dose administration (one tablet once a day)
223382653|NCT04290455|PROCEDURE|Eyelid cleansing with eyelid wipes (Optase)|Eyelid cleansing will be done with eyelid wipes (Optase) by one clinician
223382654|NCT04290455|PROCEDURE|Daily eyelid cleansing with eyelid wipes (Optase)|Patients in both arms will be instructed to do self-eyelid cleansing with eyelid wipes (Optase) daily at home for 21 days
223382655|NCT01228617|DRUG|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
223382656|NCT01228617|DRUG|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
223382657|NCT00368758|DRUG|Probiotic bacteria (Trevis R)|
223382658|NCT05470608|DRUG|SL-1002|SL-1002 injectable solution
223382659|NCT05470608|DRUG|Placebo|Matching placebo injectable solution
223382660|NCT03685344|DRUG|Loncastuximab Tesirine and Durvalumab|intravenous infusion
224123630|NCT06993597|DRUG|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Subjects with glaucoma may be prescribed prostaglandin analogs as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
224123631|NCT06993597|DRUG|Beta Blocker|Subjects with glaucoma may be prescribed topical beta blockers as part of their clinical care. This group will be observed longitudinally to assess changes in corneal biomechanics.
224123632|NCT06993597|DEVICE|Brillouin Microscopy|Brillouin microscopy is a non-contact optical imaging method used to assess the biomechanical properties of the cornea in vivo with three-dimensional resolution. It will be used to evaluate corneal stiffness in all study subjects.
224123633|NCT02615717|BEHAVIORAL|Attention Bias Modification|comparison of treatment versus control
224123634|NCT04333433|DEVICE|PRESERFLO® MicroShunt|Device surgically implanted
223382661|NCT03839966|BEHAVIORAL|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard \& Amir, 2008 and Beard, Weisberg, \& Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
223382662|NCT03839966|BEHAVIORAL|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
224123635|NCT04333433|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
223382663|NCT03151174|DRUG|Vitamin D 10000 UNT|10000 IU Vitamin D per day
223382664|NCT03151174|DRUG|Vitamin D 5000 UNT|5000 IU Vitamin D per day
223382665|NCT03474874|DEVICE|NeoMatriX Collagen Dressing|Collagen wound dressing
223382666|NCT01936350|DRUG|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
223382667|NCT01936350|DRUG|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
223382668|NCT02499796|DEVICE|Hygrovent Gold|
223382669|NCT02499796|DEVICE|Heated and moisture exchanger (HME)|
223382670|NCT02499796|DEVICE|Heated humidifier (HH)|
223382671|NCT03126435|DRUG|EndoTAG-1|twice weekly
223382672|NCT03126435|DRUG|Gemcitabine|once weekly
223729850|NCT03935204|BIOLOGICAL|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
223729851|NCT02322398|DRUG|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
223729852|NCT02322398|DRUG|hMG|150-300 IU/d hMG
223729853|NCT00302835|DRUG|non-phenacetin containing analgesics|
223729854|NCT00708968|BEHAVIORAL|FOCUS Program|Supportive, educative sessions with patients and spouses.
223382673|NCT02044913|BEHAVIORAL|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
223729855|NCT05795075|PROCEDURE|Computerized Modified Paramedian Approach Technique|Computerized Modified Paramedian Approach Technique ( CMPAT )
223999179|NCT05106205|DRUG|DA-5213-R 10mg|single dose administration (one tablet once a day)
223999180|NCT01102764|BEHAVIORAL|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
223999181|NCT01102764|BEHAVIORAL|In Person|PE therapy delivered in person at the VAMC
223999182|NCT04256863|BEHAVIORAL|Breakfast / Lunch|Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (\>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
223999183|NCT04256863|BEHAVIORAL|Dinner (DIN)|Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume \>50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
223999184|NCT00200291|BEHAVIORAL|hypocaloric, low-fat diet|hypocaloric, low-fat diet
223999185|NCT05110170|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
223999186|NCT05110170|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
223999187|NCT02506751|DRUG|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
224123636|NCT02434315|DEVICE|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
223382674|NCT03835702|OTHER|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
223382675|NCT03576664|DRUG|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
223999188|NCT03408587|BIOLOGICAL|CVA21|Oncolytic virus
223729856|NCT05795075|PROCEDURE|Conventional Midline Approach Technique|Conventional Midline Approach Technique
223729857|NCT04422470|OTHER|Non-interventional study|Non-interventional study
223999189|NCT03408587|BIOLOGICAL|Ipilimumab|Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.
223999190|NCT04915274|OTHER|uses of an application|Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.
223999191|NCT00446888|BEHAVIORAL|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
223999192|NCT00446888|DIETARY_SUPPLEMENT|Forticare|400 ml of commercially-available nutritional supplement.
223999193|NCT00446888|DIETARY_SUPPLEMENT|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
224123637|NCT02434315|DEVICE|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
224123638|NCT02434315|DEVICE|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
223729858|NCT01932112|DRUG|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
223729859|NCT05475795|OTHER|Metapex|obturation of root canals of primary molars with Metapex
223999194|NCT05355740|DRUG|Corsodyl|Corsodyl (a chlorhexidine mouthwash) will be used to rinse the mouth for one minute with 10 ml twice daily during ten days after oral surgery
223999195|NCT04434326|DRUG|[14]CM082 suspension|Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
223999196|NCT03273842|BIOLOGICAL|PF-06881894|pre-filled syringe 6 mg
224123639|NCT00320385|DRUG|Lapatinib|oral lapatinib once daily
223999197|NCT03273842|BIOLOGICAL|US-approved Neulasta|pre-filled syringe 6 mg
223382676|NCT03576664|DRUG|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
224123640|NCT00320385|BIOLOGICAL|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
223382677|NCT05373199|DRUG|Euglycemic clamp with BC Combo THDB0207|Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
223999198|NCT00960453|DRUG|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
224123641|NCT02492750|BIOLOGICAL|Anakinra|Given SC
224123642|NCT02492750|DRUG|Dexamethasone|Given PO
224123643|NCT02492750|OTHER|Laboratory Biomarker Analysis|Correlative studies
223999199|NCT01384162|DRUG|sNN0029|ICV infusion
224295613|NCT04749836|PROCEDURE|His bundle pacing implantation, Left bundle branch area pacing implantation, Bachmann bundle pacing|"Different active fixation leads and the dedicated delivery sheaths are introduced via standard transvenous approach under fluoroscopic guidance. His bundle potential mapping is performed in a unipolar setting with the use of the electrophysiological system for His bundle pacing. After localizing the His bundle potential, the pacing is attempted before the lead fixation to confirm HB capture. The lead is then screwed into position. Acute HBP threshold ≤ 2.5V at 1ms is considered acceptable. On the other hand, the initial site for LBBP is approximately 1-1.5 cm distal to the HBP lead position in the RV septum along the line between the HBP site and RV apex in the right anterior oblique (30°) fluoroscopic view. Bachmann bundle pacing (upper atrial septum) will be performed with the J-stylet modification technique or with specialized catheter method using the SelectSecure active fixation lead.~Stepwise approach for conduction pacing will also be tested."
223999200|NCT02081053|DEVICE|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
223999201|NCT03870009|OTHER|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
223382678|NCT05373199|DRUG|Euglycemic clamp with Lantus®|Administration of a single dose of Lantus® during an euglycemic clamp procedure.
224295614|NCT05124561|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Nebulized inhalation through the mouth
223382679|NCT05373199|DRUG|Euglycemic clamp with Humalog®|Administration of a single dose of Humalog® during an euglycemic clamp procedure.
223382680|NCT00948532|BIOLOGICAL|biologic, Osteocel Plus|Osteocel® Plus
223382681|NCT03335137|DIAGNOSTIC_TEST|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
223382682|NCT03907371|DRUG|Donepezil Hydrochloride|Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).
223999202|NCT05214378|DEVICE|Finetech-Brindley Sacral Anterior Roots Stimulation System|Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
223999203|NCT02999074|OTHER|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
224123644|NCT02492750|DRUG|Lenalidomide|Given PO
224123645|NCT02492750|OTHER|Placebo|Given SC
224123646|NCT04495361|OTHER|E-learning portal|An online learning portal for the identification and management of pneumonia in under five children
224123647|NCT02807909|DRUG|BMS-986177|
224123648|NCT02807909|DRUG|Itraconazole|
224295615|NCT05124561|BIOLOGICAL|Placebo|Nebulized inhalation through the mouth
224295616|NCT00400621|DRUG|acetaminophen|
224295617|NCT04064619|DRUG|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
224295618|NCT02091141|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
224295619|NCT02091141|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
224295620|NCT02091141|DRUG|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
223382683|NCT03907371|OTHER|Placebo|Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).
223382684|NCT02497911|PROCEDURE|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
223382685|NCT02497911|PROCEDURE|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
223382686|NCT02497911|DRUG|Ropivicaine|
223382687|NCT02497911|DRUG|Bupivicaine|
223382688|NCT01458353|PROCEDURE|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
223382689|NCT01458353|PROCEDURE|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
223382690|NCT01479231|DRUG|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
223382691|NCT04338360|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
224123649|NCT02807909|DRUG|Diltiazem ER|
224123650|NCT04014153|PROCEDURE|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
224123651|NCT00933205|DRUG|Tipranavir|
224123652|NCT06236074|OTHER|Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours|Observation Modified Post-Anesthetic Discharge Scoring System (PADSS) between 4 and 24 hours
224123653|NCT06236074|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
224123654|NCT01598727|DEVICE|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
224123655|NCT06514469|DRUG|Sufentanil intravenous administration followed consultation of remote physician|Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
223382692|NCT02574065|DRUG|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
223999204|NCT02999074|OTHER|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
224123656|NCT06514469|DRUG|Sufentanil intravenous administration based on paramedic competency|Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
223382693|NCT02574065|OTHER|The placebo consists of an identical formulation without L. reuteri DSM 17938|
223382694|NCT04292444|DRUG|Oxytocin nasal spray|Intranasal administration of 24 International Units oxytocin 30 minutes before the start of the tasks.
223382695|NCT04292444|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself (30 minutes before the start of the tasks).
223382696|NCT04235244|OTHER|Thermo mechanical device|The thermomechanical-analgesia device will be placed and operated 30 seconds before the injection into the abdominal area,and injection will be applied by sliding the device to the side of the selected region during the injection,
223382697|NCT04235244|OTHER|local coolant spray|Coolant spray will be applied to the abdominal area for 5 seconds at a distance of 15 cm.
223382698|NCT04235244|OTHER|ıce battery|abdominal bölgeye uygulamadan önce ve sonra 5 dk. lokal soğuk uygulama
223999205|NCT02999074|OTHER|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
223999206|NCT05224089|DRUG|Liposomal Bupivicaine/Bupivacaine Admixture|60mL of 0.25% Bupivacaine (150mg)+ 20 mL of 1.3% Exparel (266 mg)+20mL NS=100mL
223382699|NCT01103492|DEVICE|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
223382700|NCT04099004|OTHER|Neural Imaging|During the acquisition of magnetic resonance (MR) images, the study participants will lie on the scanner table. For most portions of MR acquisition, the study participants will be instructed to lie still. For other parts of the acquisition, study participants will be asked to complete a combined knee and hip flexion/extension movement and a quadriceps contraction task in which they will be asked to 'squeeze' their quadriceps while keeping the rest of their body still. For the last 15 minutes of MR acquisition, the researcher will place one hand above the participants' knee and apply intermittent pressure to their quadriceps and medial aspect of the patella. Pain scales will be administered after every fMRI task to assess subjective perceptions of pain. Peripheral pulse oximetry and respiration waveforms will be collected for data analysis in order to minimize the potential confounding effect from the physiological changes.
223382701|NCT01848925|BIOLOGICAL|SANGUINATE™|40 mg/mL intravenous infusion.
223382702|NCT01848925|DRUG|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
223999207|NCT05224089|DRUG|Bupivacaine HCL|80mL 0.25% bupivacaine (200mg) + 300mcg (0.3mL) epinephrine + 5mg (0.5mL) preservative free dexamethasone + 20mL NS= 100mL
223999208|NCT03247023|DEVICE|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
224123657|NCT02429596|DRUG|Experimental|Switch from brand to generic
223382703|NCT00015886|DRUG|docetaxel|75 milligrams per meter squared intraveneously
223382704|NCT00015886|DRUG|fluorouracil|350 milligrams intraveneously
223999209|NCT04028921|OTHER|No intervention|This is a cross-sectional study; no intervention
224123658|NCT00376402|BIOLOGICAL|H5N1 Pandemic Influenza Vaccine|
224123659|NCT01704781|DRUG|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
224123660|NCT01704781|DRUG|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
223382705|NCT00052455|DRUG|lomustine|
223382706|NCT00052455|DRUG|procarbazine hydrochloride|
223382707|NCT00052455|DRUG|temozolomide|
223382708|NCT00052455|DRUG|vincristine sulfate|
223382709|NCT01023035|DRUG|Boceprevir|800 mg given three times a day (TID), orally (PO)
223382710|NCT01023035|DRUG|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
224123661|NCT01704781|DRUG|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
224123662|NCT01704781|DRUG|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
224123663|NCT00113802|DRUG|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
224123664|NCT03844633|DRUG|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
224123665|NCT03844633|DRUG|Placebos|Placebos -- Shot administered within 48 hours of childbirth
224123666|NCT03288779|DEVICE|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
224123667|NCT01222338|BIOLOGICAL|V-5 immunitor|once per day dosing for 2 months
224123668|NCT02110810|DRUG|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
224123669|NCT02110810|DRUG|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
224123670|NCT05590195|DRUG|Preforpro|Preforpro will be investigated to improve vaginal health in women with BV.
224123671|NCT05590195|OTHER|Placebo|Placebo capsules manufactured to look like Preforpro capsules
224123672|NCT03702582|DRUG|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
224123673|NCT03702582|DRUG|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
223999210|NCT05349227|BEHAVIORAL|Digital Health Coaching Program|Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
223999211|NCT05349227|DEVICE|Fitbit|Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
223999212|NCT06641362|DEVICE|Ultra High Frequency Electrocardiogram (UHF-ECG)|Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.
223999213|NCT03085043|PROCEDURE|Bone Scan|Undergo bone scan
223999214|NCT03085043|PROCEDURE|Computed Tomography|Undergo CT of the abdomen and pelvis
223999215|NCT03085043|PROCEDURE|Magnetic Resonance Imaging|Undergo pelvic MRI
223382711|NCT01023035|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
223999216|NCT03085043|PROCEDURE|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
223999217|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (3 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
223999218|NCT05047718|BIOLOGICAL|COVID-19 vaccine Pfizer (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
223999219|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (3 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
223999220|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (2 doses)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
223999221|NCT05047718|BIOLOGICAL|COVID-19 mRNA Vaccine Moderna (1 dose)|A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
223999222|NCT00572364|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
223999223|NCT03451019|DRUG|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
223999224|NCT03451019|DRUG|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
223999225|NCT02420613|RADIATION|Radiation Therapy|Undergo radiation therapy
223999226|NCT02420613|DRUG|Temsirolimus|Given IV
223999227|NCT02420613|DRUG|Vorinostat|Given PO
223999228|NCT05575375|BEHAVIORAL|Values Affirmation + Usual Care|Participants will engage in a brief values-affirmation exercise to target personal motivation and openness to medication adherence. The interventionist will then review tailored medication education and individual skills training recommendations. The participant's study medication monitoring devices will be labeled with the participants' most important core value(s). Participants will also continue with their usual care.
223999229|NCT05575375|OTHER|Usual Care|Participants will be asked to continue with their usual care (e.g., cardiac rehabilitation, ongoing medical management)
223999230|NCT05345990|DRUG|Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)|"Hepatect® is a solution to be administered Intravenously. Zutectra® is a solution to be administered subcutaneously.~Treatment for 12 weeks with hepatitis B immunoglobulins with following administration scheme:~D0: 10.000 IU Hepatect® i.v. D1-6: 500 IU Zutectra® s.c. D7: 10.000 IU Hepatect® i.v. D9- D84: 500 IU Zutectra® s.c. every 2nd day"
223999231|NCT06801223|DRUG|Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)|25mg/kg SUL and 25mg/kg DUR
223999232|NCT06801223|DRUG|Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)|20mg/kg SUL and 20mg/kg DUR
223999233|NCT06801223|DRUG|Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)|25mg/kg SUL and 25mg/kg DUR
223999234|NCT06801223|DRUG|Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)|20mg/kg SUL and 20mg/kg DUR
223999235|NCT01734239|BIOLOGICAL|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
223999236|NCT04018677|BEHAVIORAL|Use of TOGETHERCare app|TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.
223999237|NCT03390959|OTHER|Proprioceptive Training|"Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints."
223999238|NCT03390959|OTHER|Control Group|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
223999239|NCT03889353|DEVICE|BCI sessions|up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
224123674|NCT02883465|PROCEDURE|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~* a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~* a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
224123675|NCT02028364|DRUG|Everolimus|10mg orally daily
223382712|NCT01023035|DRUG|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
223382713|NCT05044702|OTHER|Retro walking|Retro walking will be performed on treadmill for 15 min per day for 3 days per week for 4 weeks at self-paced speed.
223729860|NCT05475795|OTHER|Endoflas|obturation of root canals of primary molars with Endoflas
223999240|NCT05441462|PROCEDURE|Silastic Joint Replacement|Participants who have had silastic joint replacement surgery for degenerative or inflammatory arthritis within the last three years
223999241|NCT06331390|OTHER|niacinamide cosmetic product|immortella skincare product
223999242|NCT06331390|OTHER|placebo|nothing
223999243|NCT05765305|DRUG|Letrozole with chromium|Letrozole versus letrozole with chromium
223999244|NCT06003842|OTHER|exercise|Stretching exercises for flexion, extension, lateral flexion and rotation, upper trapezius, levator scapula and pectoralis major muscles will be applied in the maximum range of motion of the cervical region in three planes. To increase the mobility of the thoracic region, exercises for thoracic mobility will be given. Strengthening exercises will focus on the back muscles. The resistance of the exercises will be determined according to the individual capacities and strain levels of the participants, and it will be requested to increase the amount of resistance applied depending on the functional developments. You will be asked to perform the exercises twice a day, with 10 repetitions, for 6 weeks. Participants will be asked to hold the position for 3-5 seconds and return to the starting position while doing the strengthening exercises.
223999245|NCT06003842|OTHER|taping|After the Kinesio® Tex application, it will remain in the body for 4 days, and then it will be applied 6 times in total, with a 3-day break. It will be stated that the area to be banded should not contain substances such as cream, hair or oil. Upper Trapeze taping will be performed by applying one end of the Y tape to the upper trapeze and the other end to the lower part of the spina scapula, by affixing the tape to the head of the shoulder while standing upright, and keeping the participant's ear tilted towards the other ear as much as possible. Before attaching the rest of the tape, the participant will be asked to bring the shoulder blades closer together and stand upright. In this position, using a mechanical correction technique along the medial line of the scapula along the spine, the rest of the tape will be adhered as an I tape with 35-50% tension.
223999246|NCT06795022|DRUG|AZD9793 Intravenous (IV) monotherapy|T cell-engaging antibody that targets GPC3 on tumour cells
223999247|NCT06795022|DRUG|AZD9793 Subcutaneous (SC) monotherapy)|T cell-engaging antibody that targets GPC3 on tumour cells
223999248|NCT05248126|OTHER|Standard patient education|The comparator intervention is the usual therapeutic training for patients (ETP) cursus currently used in the General Pulmonology unit at the Arnaud De Villeneuve Hospital, Montpellier, France and approved by the French Regional Health Authority for the Occitanie Region \[Agence Régional de Santé Occitanie\].
223999249|NCT05248126|OTHER|Chatbot patient education|"The experimental intervention consists in providing the patient with access to a specific version of the Vik-Asthme chat bot for the duration of the study. Should the patient be unable to use or refuse to use the chatbot, the reasons for refusal will be documented and the patient will proceed with the comparator intervention."
223999250|NCT06415123|DEVICE|MagnetOs Flex Matrix|MagnetOsTM Flex Matrix is a resorbable and osteoconductive bone graft for the repair of bony defects.
224123676|NCT02028364|DRUG|Exemestane|25mg orally daily
224123677|NCT00872170|DRUG|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
224123678|NCT03590262|DRUG|Metformin|take the metformin 500mg twice or three times a day
224123679|NCT02329873|BEHAVIORAL|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
223382714|NCT05044702|OTHER|conventional physical therapy|"hot pack for 10 mints and conventional exercise program Conventional physiotherapeutic exercise program which consist of exercises such as~* prone leg extension~* prone lying chest elevation~* prone extension with alternate arm and leg lift~* supine bridging, bridging with one leg lift Each exercise will be performed as 2 sets of 12 repetitions of each exercise, each exercise position maintained for 10 s, and a rest of 1 min between the sets will be perform. No external load/resistance will be provided for the exercises, and the participants will be perform the exercise within their available range of motion"
223382715|NCT02398864|PROCEDURE|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
223382716|NCT02134990|DRUG|Oshadi D and Oshadi R|Anti cancer agents
223382717|NCT02134990|DRUG|Docetaxel|Chemotheraphy
223729861|NCT00560859|PROCEDURE|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
223999251|NCT01408420|PROCEDURE|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP \> 60 mmHg during extracorporeal circulation is used.
223999252|NCT01482689|DIETARY_SUPPLEMENT|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
224123680|NCT00601523|DRUG|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
224123681|NCT00601523|DRUG|Pramipexole|ER 0.375-4,5 mg
224123682|NCT06198621|DEVICE|cardiometry|cardiometry is noninvasive method, while swan ganz is invasive method in hemodynamic parameters assessment
224123683|NCT00252902|BEHAVIORAL|Behavior change counseling|
224123684|NCT00059436|BEHAVIORAL|Mental effort in muscle strengthening|
224123685|NCT04352634|OTHER|Exposure to the SARS-CoV-2 and its consequences|This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences
224123686|NCT03136549|OTHER|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
224123687|NCT03136549|OTHER|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
223999253|NCT01482689|DIETARY_SUPPLEMENT|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
223382718|NCT03450473|DEVICE|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
223999254|NCT00307762|BEHAVIORAL|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
223999255|NCT03572426|OTHER|genotyping all subjects|genotyping using SNaPshot genotyping method.
223999256|NCT02859129|DRUG|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
223999257|NCT02859129|DRUG|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
223999258|NCT02859129|DRUG|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
223999259|NCT02859129|DRUG|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
223999260|NCT04614701|PROCEDURE|Carotid Artery Ultrasound Measure|"Cardiac output will be assessed by measuring the LVOT diameter in parasternal long-axis window and the LVOT VTI in apical-four window. Carotid artery flow will be measured on the right neck 1-2cm from the bifurcation of the common carotid artery. All measurements will be taken with participants supine and the head of the bed elevated to 45°. measures all at 3 minute intervals.~1. One-leg compression test: Thigh-sized blood pressure cuff inflated to 60mmHg on middle part of one thigh for 60 seconds. LVOT and CCA measurements taken separately.~2. Two-leg compression test: Thigh-sized blood pressure cuff inflated on middle part of both thighs for 60 seconds. LVOT and CCA measurements taken separately.~3. Passive leg raise test: Bed adjusted to place participant at 0° and legs elevated at 45° by use of pillows. After 1 minute, measurements repeated. LVOT and CCA measurements taken separately."
223999261|NCT01627951|OTHER|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
223999262|NCT01627951|OTHER|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
223999263|NCT01627951|OTHER|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
224123688|NCT01571037|DRUG|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
224123689|NCT01571037|DRUG|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
223382719|NCT05584189|DEVICE|Rapid SARS-CoV-2 Antigen Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person.
224123690|NCT03767205|DEVICE|Ankle Assist Robot|"1. overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~2. treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
224123691|NCT02659111|OTHER|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
224123692|NCT02659111|OTHER|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
224123693|NCT03362346|DEVICE|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
224123694|NCT04290962|BEHAVIORAL|Lifestyle Therapy|Complete web-based lifestyle intervention
224123695|NCT04290962|OTHER|Quality-of-Life Assessment|Ancillary studies
224123696|NCT04290962|OTHER|Questionnaire Administration|Ancillary studies
224123697|NCT00108927|BEHAVIORAL|TRANSLATE|
224123698|NCT04217577|DIETARY_SUPPLEMENT|Dried plums|10-16 dried plums/day, approximately 100-120 g/day
223382720|NCT03493412|DRUG|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
223382721|NCT03493412|DRUG|Placebo|Placebo
223382722|NCT00956072|DRUG|imatinib mesylate|Patients receive imatinib mesylate
223382723|NCT00956072|PROCEDURE|therapeutic conventional surgery|Patients undergo surgery
223382724|NCT00814268|DRUG|Clopidogrel|75mg tablet, oral administration once daily
223999264|NCT04331457|RADIATION|Brain magnetic resonance imaging (MRI) , computed tomography (CT)|imaging
223999265|NCT04403568|DRUG|Ursolic Acid|Ursolic Acid 150mg
223382725|NCT00814268|DRUG|Clopidogrel placebo|Matching tablet, oral administration once daily
223999266|NCT04403568|DRUG|Curcumin|Curcumin 600mg
223999267|NCT03342274|BEHAVIORAL|Lifestyle Program|Participants will receive group weight loss sessions addressing healthy eating, exercise, and weight loss principles adapted from the Diabetes Prevention Program delivered by Community Health Workers.
223999268|NCT03342274|OTHER|Usual Care|Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.
223999269|NCT01430234|DRUG|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
223999270|NCT04737876|BIOLOGICAL|BX002-A|bacteriophage cocktail
223999271|NCT04737876|OTHER|Placebo|Placebo
223999272|NCT00271310|DRUG|hypertonic saline|
223999273|NCT00863681|DRUG|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
223999274|NCT04850664|DRUG|CBOT + TAU|The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.
223999275|NCT04850664|DRUG|Sham + TAU|Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
223382726|NCT00814268|DRUG|Aspirin|100mg tablet, oral administration once daily
223382727|NCT00198055|DRUG|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
223999276|NCT03031496|DRUG|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
223382728|NCT06489210|PROCEDURE|popliteal block|using ultrasound to detect sciatic nerve and popliteal fossa through different approaches using 20ml of the selected local anesthetic mixture (10ml of 0.5% bupivacaine mixed with 10ml of 2% lidocaine, each with 1:200,000 epinephrine) was injected incrementally
223382729|NCT00512122|OTHER|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
223382730|NCT00512122|DRUG|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
223382731|NCT03595007|BEHAVIORAL|Kids Kicking Cancer program|Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
223382732|NCT05172115|PROCEDURE|Conventional catheter-directed thrombolysis (CDT) with recombinant tissue plasminogen activator (rtPA)|Conventional catheter-directed thrombolysis with fixed-dose of 24 mg tissue plasminogen activator infusion over 24 hours
223382733|NCT05172115|DRUG|Enoxaparin|Subcutaneous enoxaparin twice-daily (1mg/kg)
223382734|NCT05084157|DIAGNOSTIC_TEST|Echocardiography|Patients will undergo Doppler echocardiography
223729862|NCT00560859|OTHER|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
223729863|NCT02387060|DRUG|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
223729864|NCT02387060|DRUG|Fentanyl|Intrathecal administration of fentanyl 25 mcg
223729865|NCT01716767|OTHER|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
223999277|NCT03031496|DRUG|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
223999278|NCT00895557|DRUG|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
223999279|NCT01254552|DRUG|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
223999280|NCT01254552|DRUG|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
223999281|NCT03664440|DRUG|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
223999282|NCT03664440|DRUG|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
223999283|NCT03809598|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
223999284|NCT05564000|OTHER|Dating Violence Prevention Program|We designed and constructed the e-learning platform as an education program on dating violence based on the theory of planned behavior to evaluate the effectiveness of the programs in improving dating violence myths, bystander help-giving attitude, subjective norms, self-efficacy, intention, and behavior.
223999285|NCT02764268|DRUG|Apatinib|
223999286|NCT05057871|DEVICE|Pulse electromagnetic field therapy|"It was applied with an electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italia) at 50 Hz frequency, 85 Gauss (8.5 milliTesla) intensity and for 30 minutes. The treatment period was 5 days a week for 4 weeks, in total. It was applied as 20 sessions.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
224123699|NCT03421990|PROCEDURE|General anesthesia|general anesthesia and regional anesthesia techniques are used
224295621|NCT02091141|DRUG|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
223382735|NCT01089465|OTHER|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
223382736|NCT00524420|DEVICE|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
223382737|NCT00524420|DEVICE|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
223382738|NCT02163265|PROCEDURE|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
223382739|NCT00274339|DRUG|Prevacid 30mg BID|
223999287|NCT05057871|DEVICE|Sham pulse electromagnetic field therapy|"Sham pulse electromagnetic field therapy was applied five sessions a week for four weeks, for a total of 20 sessions a day, using electromagnetic field device (ASA Pmt Quatro Pro, ASA Srl Via A.Volta 9-36057 Italy) without current flowing through the device.~Therapeutic Exercise As a therapeutic exercise program; active shoulder ROM, isometric and progressive strengthening exercises for shoulder girdle muscles, codman pendulum exercises will be performed. It was planned to implement a total of 20 sessions 5 days a week for 4 weeks, for approximately 30 minutes. Exercises will be performed by a trained (at least 5 years experienced) physiotherapist, three times a day, in 3 sets, 10 repetitions."
223999288|NCT03478449|PROCEDURE|lymph node sorting for pathological examination|In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
223999289|NCT06256081|DEVICE|Hear Glue ear application|Hear Glue ear is an application used on phones, ipads, tablets or computers which provides free information, songs, audiobooks, games and a home hearing screening game.
223999290|NCT00821340|GENETIC|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
223999291|NCT03908151|DEVICE|CMK21 Hip system|Total hip arthroplasty
223999292|NCT02716636|PROCEDURE|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
223999293|NCT00130325|DRUG|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
223999294|NCT00130325|DRUG|Isoniazid|INH 900mg twice weekly for 6 months
223999295|NCT00130325|DRUG|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
223999296|NCT04914598|DRUG|ENDOSTAR，cisplatin|After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment
223999297|NCT04914598|DRUG|Placebo , cisplatin|Placebo , cisplatin
223999298|NCT04848324|OTHER|Corticosteroid Hydrodissection|The median nerve was examined by US at the scaphoid-pisiform level of the inlet of carpal tunnel. The hydrodissection was achieved by a total volume of 3 mL (1 mL of triamcinolone and 2 mL of saline) in the intervention group based on a study identifying median nerve hydrodissection with this volume. Half of the total volume (1.5 mL ) was delivered via the in-plane ulnar approach and the other half (1.5 mL) via the in-plane median approach to create a fluid plane along the nerve.
223382740|NCT00274339|BEHAVIORAL|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
223382741|NCT01090414|DRUG|Idelalisib|Idelalisib tablets or capsules administered orally
223382742|NCT03481010|PROCEDURE|PAO with hip arthroscopy|Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
223382743|NCT03481010|PROCEDURE|PAO without hip arthroscopy|"Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia."
223382744|NCT05036512|DRUG|GBT021601|Administered orally with water as a single dose in the morning.
223382745|NCT04620408|DRUG|SHR4640|Subjects were randomly divided into the group A, B. On D1, D8, two groups of subjects were respectively given SHR4640 tablet.
223382746|NCT00897910|OTHER|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
223382747|NCT00897910|OTHER|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
223382748|NCT00897910|OTHER|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
223999299|NCT04848324|OTHER|Corticosteroid Injection|1 mL of triamcinolone was delivered via the in-plane ulnar approach
224123700|NCT01380405|BEHAVIORAL|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
224123701|NCT06693128|DRUG|Camrelizumab|Camrelizumab 200mg
224123702|NCT06693128|DRUG|Apatinib|Apatinib 250mg
223382749|NCT03127514|DRUG|AMX0035|AMX0035
223729866|NCT01716767|OTHER|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
224123703|NCT06693128|DRUG|S-1, Oxaliplatin|S-1, Oxaliplatin, q3w
224138461|NCT04248790|BEHAVIORAL|mobile app to improve adherence to PrEP self-management|Access to the mobile app which includes the sex and PrEP diary, information on HIV/STI testing, PrEP reminders and geo-location features.
223382750|NCT03127514|OTHER|Placebo|Matching Placebo Comparator
223382751|NCT02848209|PROCEDURE|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
223382752|NCT02848209|PROCEDURE|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
223382753|NCT02848209|PROCEDURE|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
223999300|NCT01236638|DRUG|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
223382754|NCT04080739|DRUG|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
223382755|NCT03014843|DRUG|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
223382756|NCT03014843|DRUG|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
223382757|NCT03014843|OTHER|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
223382758|NCT02439021|DEVICE|COBRA|
223382759|NCT02439021|DEVICE|LMA|
223382760|NCT04742829|DIETARY_SUPPLEMENT|INTRAVIT ®|2 tablets per day morning and evening before meals
223382761|NCT02413229|DRUG|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
223382762|NCT02413229|DRUG|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
223382763|NCT01145469|GENETIC|DNA analysis|
223382764|NCT01145469|GENETIC|gene expression analysis|
223999301|NCT02979249|DRUG|Oral Iron|for one year
223382765|NCT01145469|GENETIC|polymorphism analysis|
223382766|NCT01145469|OTHER|laboratory biomarker analysis|
223382767|NCT01145469|OTHER|medical chart review|
223999302|NCT01125046|BIOLOGICAL|bevacizumab|Given IV
224138462|NCT03090464|OTHER|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
223382768|NCT04072081|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
223382769|NCT04072081|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
223382770|NCT02037412|DRUG|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
223382771|NCT02037412|DRUG|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
223382772|NCT03064724|BEHAVIORAL|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
223382773|NCT05531864|PROCEDURE|Ultrasound-guided continuous low serratus anterior plane block|Low anterior serratus plane block, move the mid-axillary line 4 and 5 intercostal puncture points are moved down and the puncture is changed to 7 and 8 intercostal.
223382774|NCT05531864|PROCEDURE|Ultrasound-guided single serratus anterior plane block|Ultrasound-guided single anterior saw plane block was performed, and a needle was injected between the 4th and 5th costals in the midaxillary line.
223382775|NCT05635487|DRUG|SHR-A1811|SHR-A1811
223382776|NCT05635487|DRUG|Pyrotinib|Pyrotinib
223382777|NCT04040556|OTHER|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
223382778|NCT03561077|OTHER|Mindfulness-based interventions (MBI's)|Mindfulness Based Intervention with eight sessions (one session per week) of two hours dedicated to adolescents will be provided. The intervention will focus on skill building and will incorporate mindfulness meditation, exercises and activities specially adapted to teenagers with chronic pain. Topics will include mind body connection, the effect of stress on pain, living in the present moment, focused awareness, responding versus reacting to pain and/ or difficult situations, non judgement, gratitude, kindness and compassion towards self and others.
223382779|NCT05212077|OTHER|Advanced Care at Home (ACH)|Inpatient hospitalization offered in the home setting.
223382780|NCT05212077|OTHER|Traditional Brick-and-Mortar Hospitalization|Inpatient hospitalization offered in the hospital setting.
223382781|NCT03594071|DEVICE|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
223382782|NCT04436601|DRUG|Polyethylene Glycols|Polyethylene glycol will be administered to half of the study patients, and their response recorded and compared with that of the Lactulose arm.
223382783|NCT04436601|DRUG|Lactulose|Lactulose (standard of care) will be administered to half of the study patients and their response recorded.
223382784|NCT00988416|PROCEDURE|PET-CT|Pancreas Protocol PET-CT
223382785|NCT05436795|DEVICE|Abbott Panbio rapid antigen self-tests|COVID-19 self-testing will be performed using investigational Abbott Panbio rapid antigen self-test kits that require self-sampled nasal swabs.
223382786|NCT05436795|OTHER|COVIDSmart CARE! app|Guided by the application that connects, educates, and communicates a digital, contactless open access strategy, participants will have the opportunity to self-test and assess their risk level of COVID-19 infection, as well as the option to refer their close contacts to testing for those who are COVID-19 positive, through the study platform.
223999303|NCT00909129|DRUG|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
223999304|NCT00909129|DRUG|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
223999305|NCT02339545|DEVICE|Coronary Orbital Atherectomy plus Stenting|
223999306|NCT06365151|OTHER|Osteopathic manual therapy|osteopathic manual treatment aimed at improving the function and pain of the temporomandibular joint.
223999307|NCT06365151|OTHER|Sham osteopathic manual therapy|a sham osteopathic manual treatment without therapeutic effect
223999308|NCT02620605|DRUG|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
223382787|NCT03895814|BEHAVIORAL|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
223382788|NCT05824624|OTHER|ANIMAL-ASSISTED INTERVENTION|It will be ensured that the child is introduced to the goldfish when he is lying in the observation room, that the child will name the fish, and that he will communicate and feed the fish during his stay. Thus, it is aimed to turn the attention of the child to the goldfish while in the emergency room, to distract the child with the fish while all nursing interventions are presented, and to reduce the fear.
223382789|NCT05824624|OTHER|Routine Care|Routine nursing care will be provided.
223382790|NCT01791309|DRUG|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
223382791|NCT03022370|BEHAVIORAL|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
223382792|NCT00101426|DRUG|ranirestat, (AS-3201)|
223382793|NCT01002924|DRUG|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
223382794|NCT02897024|OTHER|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
223382795|NCT01019434|DRUG|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
223382796|NCT01019434|DRUG|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
223382797|NCT00699816|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
223382798|NCT01416519|PROCEDURE|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
223382799|NCT01416519|PROCEDURE|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
223382800|NCT00371436|PROCEDURE|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
223382801|NCT00371436|PROCEDURE|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
223382802|NCT02962518|DEVICE|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
223382803|NCT02962518|PROCEDURE|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
223382804|NCT02962518|DRUG|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
223382805|NCT02251600|DRUG|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
223382806|NCT01311687|DRUG|pomalidomide|4 mg pomalidomide capsules administered orally
223382807|NCT01311687|DRUG|Dexamethasone|40 mg dexamethasone (or 20 mg for participants \> 75 years of age) tablets administered orally
223382808|NCT02454933|DRUG|AZD9291|Once daily tablet 80 mg
223382809|NCT02454933|DRUG|MEDI4736|10mg/kg q2w (IV) infusion
223382810|NCT03980652|PROCEDURE|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
223382811|NCT04727385|DEVICE|Double Crosslink Microgel|"DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)~The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min."
223382812|NCT00721071|DRUG|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
224138463|NCT02912598|DEVICE|Mallinckrodt™ Endobronchial Tube|
224138464|NCT02912598|DEVICE|Fuji Uniblocker™|
224138465|NCT02912598|DEVICE|ETView VivaSight™-SL+EB|
223999309|NCT02620605|DRUG|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
224123704|NCT06631833|BEHAVIORAL|Intervention measures based on the YPAP model.|The intervention group received an 8-week intervention program aimed at gradually increasing their physical activity levels. The intervention program included the following components: 1) 1-2 sessions of moderate-intensity physical activity per week, each lasting 45 minutes, with activities provided by physical activity experts; 2) one health education lecture every two weeks, each lasting 60 minutes; and 3) one family physical activity session per week, each lasting 30 minutes at a lower intensity. At the end of the intervention period, relevant questionnaires were used for measurement.
223382813|NCT02260661|DRUG|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
223382814|NCT02260661|DRUG|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
223382815|NCT02260661|DRUG|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
223999310|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
223999311|NCT00443924|DRUG|Placebo|One drop of placebo in each eye every 12 hours for three days
223999312|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
223382816|NCT02260661|DRUG|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
223999313|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
224123705|NCT06701851|BEHAVIORAL|Voluntary and involuntary conditions|"An task fMRI/EEG acquisition during the prodromal phase preceding the episode of abnormal movements.~A task fMRI/EEG acquisition the episode of abnormal movements A task fMRI/EEG acquisition when the subject voluntary mimics the sequence of events (prdrosomal phase + episode of dyskinesia)"
223382817|NCT06084793|OTHER|Music|In the pre-transfer room, the personalized playlist will be played through earphones or speakers, according to the patient´s preference. In the transfer room, the personalized playlist will be played through speakers at a volume that is loud enough for the participant to hear but soft enough to ensure clear communication between the patient and doctor, without causing any disturbance to the doctor.
223382818|NCT05915260|DIAGNOSTIC_TEST|All subjects will undergo cardiac magnetic resonance imaging with gadolinium contrast and with adenosine myocardial perfusion|This is a observational follow up study accordingly all subjects will undergo the same examinations
223382819|NCT01644682|OTHER|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
223382820|NCT01644682|OTHER|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
223382821|NCT01644682|OTHER|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
223382822|NCT02224989|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
223382823|NCT02087657|DEVICE|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
223382824|NCT03017768|DIETARY_SUPPLEMENT|Acute tryptophan depletion|an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity
223999314|NCT00443924|DRUG|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
223999315|NCT04074668|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
223999316|NCT04074668|DRUG|Iohexol Inj 300 milligrams/milliliter (mg/ml)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
223999317|NCT04074668|RADIATION|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
223999318|NCT04074668|PROCEDURE|Renal Biopsy|Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.
223999319|NCT00425464|DEVICE|Standard Monofocal Intraocular Lens|"The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
223999320|NCT00425464|DEVICE|Synchrony® Dual Optic Intraocular Lens|"The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
224123706|NCT03654248|BEHAVIORAL|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
223999321|NCT05936723|BEHAVIORAL|Respiratory Muscle Training - VIH|The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
223382825|NCT03017768|DIETARY_SUPPLEMENT|Placebo|an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation
223382826|NCT03017768|DEVICE|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
223382827|NCT03856723|OTHER|Renal Replacement Therapy|"Indications for RRT were defined as previously reported.~1. Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 ;~2. severe sepsis, persistence of hypotension (for more than 6 h) despite preload optimization and use of vasopressors or catecholamines (norepinephrine or epinephrine \>0.1 μg/kg/min),~3. refractory fluid overload (worsening pulmonary edema, PaO2/FiO2 \<300 mm Hg or fluid balance \>10% of body weight),~4. low probability of rapid renal recovery according to the judgment of the intensivists and nephrologists."
223999322|NCT05936723|BEHAVIORAL|Respiratory Muscle Training - ITPL|The IPTL group will train 5 days a week, twice a day, with at least 6 hours break between sessions. The session will consist of 30 dynamic inspiratory maneuvers with progressive overload based on gradually increased resistance. The VIH group will train every second day with gradual progression based on session length and breathing frequency. Participants will begin with 3 minutes of exercise with a frequency of 20 breaths·min-1 during the first session and add no more than 1 minute or 2 breaths·min-1 with each consecutive session.
223999323|NCT05078788|PROCEDURE|Laser uretherotomy|Holmium YAG Laser with pulse energy from 1-2 Joule, frequency from 10-15 Hertz and total power from 3.0 to 30.0 Watt were set up, respectively, based on the extent of the lesions. Scar tissue was incised at the position of 12-o'clock under the guidance of guidewire or ureteric catheter till fresh mucosa appeared.
223999324|NCT05078788|PROCEDURE|Laser uretherotomy with triamcinolone|After laser urethrotomy, 80 mg of triamcinolone (diluted with normal saline to 10 ml) will be injected by using an injection needle (5 F size and 23 G needle size) at 10 sites, 1 ml each, along the site of urethrotomy and circumferentially.
223999325|NCT02306551|OTHER|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
223382828|NCT00580450|DRUG|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
223999326|NCT01685229|DEVICE|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
223999327|NCT01685229|DRUG|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
223382829|NCT06550817|OTHER|Growth mindset intervention|Online intervention is implemented and it lasts about 20 minutes each time, while face-to-face intervention lasts about 30 minutes each time, and they are carried out for a total of six weeks, face-to-face or telephone intervention is implemented once every two weeks for about 15 minutes each time
223382830|NCT06550817|OTHER|E-health Program|face-to-face e-health teaching in the first 6 weeks, and telephone follow-up were conducted once a week, for about 10 minutes each time in the last 6 weeks
223382831|NCT03668808|DRUG|Insulin Degludec|Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
223999328|NCT03705598|BEHAVIORAL|Light physical exercise|One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/walking, upper and lower body strength exercise/walking, and stretching exercise/balance exercise/walking, respectively), each ending with a short break to record the Borg Rating of Perceived Exertion (RPE), followed by a 5-minute break time or cool-down/wrap-up session. The session will be taught by a certified exercise physiologist and a research assistant.
223382832|NCT03668808|DRUG|Insulin Glargine|Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
223382833|NCT03668808|DEVICE|TRESIBA® FLEXTOUCH®|Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
223382834|NCT03668808|DEVICE|LANTUS® SOLOSTAR® INSULIN PEN|Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
223382835|NCT02392585|PROCEDURE|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
223729867|NCT05628532|DEVICE|Use of the DBLG1 system|During the treatment period, the patient will use the DBLG1 system (consisting of a DBLG1 handset with an embedded software named loop mode, a TERUMO MEDISAFE WITH patch pump and a Dexcom continuous glucose monitoring (CGM) G6). The main function of DBLG1 System is to adjust the insulin delivery at the correct time in order to maintain the patient's blood glucose in the target range and thus minimize both hypoglycaemic events and long-term complications associated with elevated average glycemia.
223999329|NCT03705598|BEHAVIORAL|Tai Chi|One hour each session, two sessions each week, for 24 weeks. Each session will be structured into three 15-minute segments (including warm-up activities/balance exercise/breathing exercise, Tai Chi walking drills, and Tai Chi 8-form, respectively), each ending with a short break to record the RPE, and followed by a 5-minute break or cool-down/wrap-up session. The session will be taught by an experienced Tai Chi instructor and a research assistant.
224123707|NCT03654248|DEVICE|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
224123708|NCT06693544|DIETARY_SUPPLEMENT|Peanut protein|Commercially available plant-based protein powders
224123709|NCT06713642|DEVICE|SPOTFIRE ST System|Polymerase chain reaction (PCR) test that identifies up to 13 different viral and bacterial pathogens in about 20 Minutes
223729868|NCT05419869|DRUG|ALTO-100 PO Tablet|Two tablets daily
224138466|NCT02912598|DEVICE|COOK© Arndt Endobronchial Blocker|
223382836|NCT02392585|PROCEDURE|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
223382837|NCT03370640|DRUG|SEP-363856|An oral 25 or 50mg dose of SEP 363856
223382838|NCT01526655|PROCEDURE|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
223545316|NCT00062855|GENETIC|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
223999330|NCT06267144|DRUG|Sintilimab plus chemotherapy|"Sintilimab: 200 mg via intravenous infusion on Day 1 of each 21-day cycle for 2-3 cycles in the neoadjuvant therapy and the maintenance therapy.~Chemotherapy drugs: carboplatin/cisplatin+Pemetrexed/gemcitabine/albuminpaclitaxel.~Carboplatin: AUC 5 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Pemetrexed: 500mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly.~Gemcitabine:1.0g/m2 via intravenous infusion in day1 and day8, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly. Albuminpaclitaxel: 260 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for 2-3 cycles before and after surgery respectly."
223999331|NCT05048498|DRUG|NEX-18a injection|"In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection."
223999332|NCT05048498|DRUG|Azacitidine Injection|In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
223999333|NCT05937867|DRUG|HS-10353 Capsules 30 mg, Oral, QN for 14 days|HS-10353 Capsules 30 mg
223999334|NCT05937867|DRUG|HS-10353 Capsules 50 mg, Oral, QN for 14 days|HS-10353 Capsules 50 mg
223999335|NCT05937867|DRUG|HS-10353 Capsules matching placebo, 30mg, Oral, QN for 14 days.|Placebo
223999336|NCT05937867|DRUG|HS-10353 Capsules matching placebo, 50mg, Oral, QN for 14 days|Placebo
223999337|NCT06022445|OTHER|CARPET prognostic model|For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.
223999338|NCT01857726|DRUG|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
223999339|NCT01857726|DRUG|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
223999340|NCT02780518|DEVICE|Airvo|Applying high flow nasal oxygen
223999341|NCT05129332|OTHER|Vaginal Moisturizer|Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
223382839|NCT01526655|PROCEDURE|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
223382840|NCT03067025|DEVICE|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
223382841|NCT01634841|DIETARY_SUPPLEMENT|Walnuts|30 to 60g (1 to 2 oz) per day of walnuts
223382842|NCT01634841|OTHER|habitual diet|Dietary information will be provided
223382843|NCT02277535|OTHER|Feedback/Reminder email.|
223999342|NCT05129332|DEVICE|Vaginal Dilator|Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
223999343|NCT06515938|BIOLOGICAL|20μg Engerix-B hepatitis B vaccine|
223999344|NCT06515938|BIOLOGICAL|20μg Kangtai hepatitis B vaccine|
223382844|NCT00918424|DRUG|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
223382845|NCT00310921|DRUG|Misoprostol|
223382846|NCT02365987|DIETARY_SUPPLEMENT|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
223382847|NCT02365987|DIETARY_SUPPLEMENT|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
223545317|NCT00025571|DRUG|HPPH|
223999345|NCT06515938|BIOLOGICAL|60μg Kangtai hepatitis B vaccine|
223999346|NCT06515938|BIOLOGICAL|20μg CHO|
223999347|NCT03428906|DRUG|Oxytocin|intranasally administrated
223999348|NCT03428906|DRUG|Placebo|intranasally administrated
223999349|NCT04967898|OTHER|bowen technique|Bowen technique is a soft tissue mobilization technique. This medical care involves short mild rolling moves over the muscles, nerves, ligaments, and tendons of flesh utilizing the hands, fingers and thumb. Sequence of receiving bilateral rolling moves over segments of the erector spinae from the lumber toward cervical spine, latissimus dorsi, the gluteal, the hamstring muscles proximally and distally, tensor facia Lata and a medial hip striated muscle move.
223999350|NCT04967898|OTHER|sustained stretching|static stretching is one of the most common and safest technique used for hamstring tightness. A static stretch is performed by inserting muscles at their greatest attainable length and holding that position for an amount of your time.
223999351|NCT00532207|DRUG|teriparatide|subcutaneous 20 micrograms
223999352|NCT02467439|OTHER|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
223999353|NCT00895895|DRUG|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
223999354|NCT00895895|DRUG|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
223999355|NCT00895895|DRUG|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
223999356|NCT00895895|DRUG|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
223999357|NCT00895895|DRUG|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
223999358|NCT00536276|DIETARY_SUPPLEMENT|Vitamin D2|Daily enteral dose of 100IU/kg
223999359|NCT00536276|DIETARY_SUPPLEMENT|Vitamin D3|Daily enteral dose of 100IU/kg
223999360|NCT00560144|DRUG|RG1507|3mg/kg iv weekly
223999361|NCT00560144|DRUG|RG1507|9mg/kg iv weekly
223999362|NCT00560144|DRUG|RG1507|Pharmacokinetic-derived dose, \<=16mg/kg iv weekly
223999363|NCT03338439|DEVICE|CSII|This retrospective, observational trial will evaluate 104 diabetic patients with prior treatment with MDI initiating CSII therapy compared to 109 diabetic patients continuing MDI.
223999364|NCT03193983|PROCEDURE|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
223999365|NCT03193983|PROCEDURE|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
223999366|NCT00855647|PROCEDURE|Hypo-fractionated Radiotherapy|
223999367|NCT00445835|OTHER|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
223999368|NCT00445835|OTHER|Conservative arm|Conservative medical approach
223999369|NCT03101202|DEVICE|SSD tube|The SSD tube allows the suction of subglottic secretions that collect above the cuff of the endotracheal tube
223999370|NCT06153992|DEVICE|Intelligent portable isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using intelligent portable isokinetic muscle strength test training system
223999371|NCT06153992|DEVICE|isokinetic muscle strength test training|The isokinetic training of knee flexors and extensors was carried out by using isokinetic muscle strength test training system
223999372|NCT06153992|OTHER|without test training|Treatment was performed without using any isokinetic muscle strength test training system
223999373|NCT06520150|PROCEDURE|Regional anaesthetic combined fascial plane block|Prior to the procedure, the anaesthetists will receive an envelope from a person not related to the project (a hospital administrative staff member). This envelope will contain a randomly indicated method of anaesthesia based on simple randomisation. This will determine the type of regional block used during the procedure. It is important to note that the patient will not know which study group they have been classified in. Furthermore, the operator performing the procedure will not be informed of the type of anaesthesia performed. This is to ensure double-blinding. In order to ensure the highest standards of objectivity, the operator performing the procedure will not be informed about the type of block performed. This will allow us to assess the extent and quality of anaesthesia after the procedure, We will use a proprietary scale of subjective operator comfort scale.
223999374|NCT06520150|DRUG|Ropivacaine 0.125% Injectable Solution +Lignocaine 0,25% Injectable Solution|administration under ultrasound guidance of a mixture of 2 local anaesthetics in a fixed total volume
223999375|NCT02944162|BIOLOGICAL|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
223999376|NCT05631704|DRUG|VH4524184|VH4524184 will be administered.
223999377|NCT05631704|DRUG|Midazolam|Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
223999378|NCT05631704|DRUG|Placebo|Placebo will be administered.
223999379|NCT00708318|DRUG|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
223999380|NCT04417205|OTHER|Carbohydrate Rich Breakfast|Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.
223999381|NCT04417205|DIETARY_SUPPLEMENT|Whey protein enriched breakfast|Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
223999382|NCT02744248|DRUG|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
223999383|NCT02744248|DRUG|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
223999384|NCT00990444|DRUG|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
224123710|NCT06713083|OTHER|Exercise|Specifically designed and structured exercise program (based on resistance/strength, designed to be executed in bed or minimal mobility). It is an adaptation from the exercise program described by Brun CR et al (Brun CR, Shoemaker JK, Bocking A, Hammond JA, Poole M, Mottola MF. Bed-rest exercise, activity restriction, and high-risk pregnancies: a feasibility study. Applied Physiology, Nutrition, and Metabolism. 2011;36(4):577-582).
224138467|NCT01560221|BEHAVIORAL|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
224295622|NCT02091141|DRUG|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
223999385|NCT04413305|OTHER|screen of CRKP and infection control measure|For intervention group, we screen admitted patients for carbapenem-resistant Klebsiella pneumoniae and carry out 'Bundle' infection and control measures. When outbreak or tranmission of CRKP was observed, we take whole-genome sequencing to track origin and transmission route to decease CRKP rate.
223382848|NCT04975711|DRUG|HIP2105|Test drug
223382849|NCT04975711|DRUG|RLD2104|Reference drug
223382850|NCT00301197|BEHAVIORAL|Behavioral Skills Maintenance|
223382851|NCT00301197|BEHAVIORAL|Social Facilitation Maintenance|
223382852|NCT00955929|DRUG|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
223382853|NCT00955929|DRUG|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
223999386|NCT04366505|BEHAVIORAL|Treatment as usual (TAU) and neurofeedback (NFB)|This group will receive Treatment as usual (TAU) and neurofeedback (NFB). During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as target region.
223999387|NCT04366505|BEHAVIORAL|mindfulness-based relapse prevention (MBRP) and NFB|This group will receive MBRP and neurofeedback (NFB). MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. During NFB, participants will be asked to regulate the signal from a target brain region during the presentation of alcohol cues. The ventral striatum was chosen as a target region.
223999388|NCT04366505|BEHAVIORAL|TAU and sham NFB|This group will receive TAU and sham NFB. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
223999389|NCT04366505|BEHAVIORAL|MBT and sham NFB|This group will receive MBRP and sham NFB. MBRP consists of 5 extensive sessions of a specific manualized mindfulness-based intervention for alcohol dependent patients which will be carried out by trained psychologists and psychotherapists. Sham NFB means that the signal displayed to the participant is based on activity in a control region, the auditory cortex, which is not involved in cue reactivity.
223999390|NCT05517226|COMBINATION_PRODUCT|Cotadutide|Participants will receive cotadutide subcutaneously.
223999391|NCT05492851|DRUG|Zilretta|Intra-articular injection to treat knee osteoarthritis
223999392|NCT05492851|DRUG|Synvisc-One 48 MG in 6 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
223999393|NCT05492851|DRUG|Monovisc 88 MG Per 4 ML Prefilled Syringe|Intra-articular injection to treat knee osteoarthritis
223382854|NCT00955929|DRUG|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
223382855|NCT05586555|OTHER|Pupillometry (Eve-tracking measurements)|Pupillometry measurements are carried out by a dedicated device (eye tracker), which includes cameras allowing the measurement of pupillary dilation. The subject stands in front of a screen and fixes a point in the center of the screen, the cameras placed on the screen allowing a measurement of the pupillary dilation in a non-invasive way. These eye-tracking measurements are performed simultaneously with an auditory task and allow to study the pupil's response to different stimuli.
223382856|NCT06582303|DEVICE|Virtual reality Game intervention plus conventional physical therapy|The experimental group initially got VR intervention by playing all four easy-level games named hitting a rolling ball, grasping a balloon, swapping hands, and gripping twice for three minutes each during the first and second weeks. This group again underwent VR intervention by playing all four same games with a difficulty level twice 5 min duration for the third, fourth, fifth, and sixth weeks. The experimental group had an intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. During the first two weeks, patients received 24 minutes of VR hand games and 24 minutes of therapy sessions per day and for the next four weeks, this group received 40 minutes of VR hand games and 40 minutes of conventional therapy session per day. This group received conventional physical therapy that consists of range of motion, stretching, resistance, and strengthening exercises. At follow-up of two weeks this group only received conventional physical therapy.
223545318|NCT00342628|BIOLOGICAL|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
223729869|NCT02967835|BEHAVIORAL|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
223999394|NCT04385706|BEHAVIORAL|Applied Coaching Model|The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
223999395|NCT00239408|DEVICE|Pulmonary function Testing|
223999396|NCT00239408|DRUG|tiotropium bromide|
223999397|NCT01169012|DRUG|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
224295623|NCT02091141|DRUG|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
223999398|NCT05842642|OTHER|Cervical|6 weeks of treatment
223999399|NCT05842642|OTHER|Oculomotor|6 weeks of treatment
224295624|NCT02091141|DRUG|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
223382857|NCT06582303|DEVICE|Conventional Physical Therapy|The control group received conventional physical therapy, which consists of range of motion, stretching, resistance, and strengthening exercises by using powerweb, thera putty, and occupational therapy equipment. The CPT group had a conventional intervention of 24 sessions, lasting 4 days/week for a total of 6 weeks. The CPT group was given 48 minutes of conventional physical therapy sessions per day for weeks 1 and 2 followed by 80 minutes of conventional physical therapy sessions per day for the next 4 weeks. At follow-up of two weeks, this group also received conventional physical therapy.
223999400|NCT00668265|DRUG|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
223382858|NCT05716308|BEHAVIORAL|A continuous nursing intervention group was established.|Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
223382859|NCT04209452|BEHAVIORAL|Rehearsal strategy|Teaching children to cumulatively rehearse numbers as they are being said.
223382860|NCT04209452|BEHAVIORAL|Reinforcement|Providing reinforcement for correct recall after a delay.
223999401|NCT02199158|PROCEDURE|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
223999402|NCT00636935|DRUG|Antibiotics only|Antibiotic only for treatment for mild (pO2 \> 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
223999403|NCT00636935|DRUG|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
223999404|NCT00636935|DRUG|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 \< 70mmHg.
223999405|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography
223999406|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter
223999407|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a gray reference card
223999408|NCT05620277|DIAGNOSTIC_TEST|Mobile Dental Photography with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using Mobile Dental Photography with a cross-polarization filter and gray reference card
223382861|NCT04209452|BEHAVIORAL|Rehearsal strategy and reinforcement|Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
223545319|NCT00342628|BIOLOGICAL|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
223999409|NCT05620277|DIAGNOSTIC_TEST|Digital Camera|Tooth color changes of 30 patients will be evaluated using a Digital Camera
223999410|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with cross-polarization filter|Tooth color changes of 30 patients will be evaluated using a Digital Camera with cross-polarization filter
223999411|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with cross-polarization filter and gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a cross-polarization filter and gray reference card
223999412|NCT05620277|DIAGNOSTIC_TEST|Digital Camera with gray reference card|Tooth color changes of 30 patients will be evaluated using a Digital Camera with a gray reference card
223545320|NCT00342628|BIOLOGICAL|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
223999413|NCT05620277|DIAGNOSTIC_TEST|Rayplicker|Tooth color changes of 30 patients will be evaluated using Rayplicker
223999414|NCT05620277|DIAGNOSTIC_TEST|Rayplicker with gray reference card|Tooth color changes of 30 patients will be evaluated using Rayplicker with gray reference card
223999415|NCT05620277|DIAGNOSTIC_TEST|Vita Easyshade|Tooth color changes of 30 patients will be evaluated using Vita Easyshade
223999416|NCT05620277|DIAGNOSTIC_TEST|Vita Easyshade with gray reference card|Tooth color changes of 30 patients will be evaluated using Vita Easyshade with a gray reference card
223999417|NCT03332043|DEVICE|HIRREM|HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.
223999418|NCT03332043|OTHER|Ambient Nature Sounds|Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
223999419|NCT00006375|DRUG|LY293111|
223999420|NCT02663531|DEVICE|DVA|
223999421|NCT02663531|DEVICE|FDOCT|
224295625|NCT02091141|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
223999422|NCT02663531|DEVICE|Pattern ERG|
223382862|NCT04570332|DRUG|BO-112 plus pembrolizumab|Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
223999423|NCT02663531|DEVICE|Optical Coherence Tomography|
223382863|NCT04570332|PROCEDURE|Tissue Biopsies|Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.
223382864|NCT05023915|DRUG|dexamethasone|40 mg qd for 4 days
223382865|NCT05023915|DRUG|diammonium glycyrrhizinate enteric-coated capsule|150mg tid for 3 months
223382866|NCT02929771|DEVICE|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
223999424|NCT00820170|DRUG|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
223999425|NCT04815980|OTHER|Exercise|Home-based mat-based Pilates intervention 3 times a week for 12 weeks prepared by a certified Pilates instructor.
223999426|NCT06479369|BEHAVIORAL|Teaching training program|The investigators will try to carry out a training based on motivational strategies for physical education teachers of the experimental group, with the aim of improving their motivational teaching style during physical education classes, and finally, to obtain benefits in their students, such as a greater adherence to physical activity.
224123711|NCT06713694|OTHER|cognitive-behavioral therapy|The treatment will consist of eight weekly sessions, each lasting one hour. The first session will focus on the rationale of cognitive behavioral therapy, i.e. the influence of (irrational or dysfunctional) cognitions and attitudes on (restrictive) feelings and behaviors. Additionally, goal setting will be initiated. Since patients may have a wide diversity of psychiatric problems (i.e. PTSD, anxiety disorders and depression), the treatment manual will encompass five optional modules for the therapist that focus on each of these disorders (i.e. exposure based for anxiety and PTSD, behavioral activation for depression). The subsequent sessions (2-6) will target teaching the patient to identify and challenge dysfunctional cognitions and attitudes related to IBD. Each session will address specific illness-related cognitions. If possible, dysfunctional cognitions and attitudes will be replaced by helpful cognitions and attitudes.
223382867|NCT02929771|DEVICE|iPad|iPad with headphones. Control
223382868|NCT02288325|DRUG|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
223545321|NCT04551898|DRUG|BGB-DXP593|Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
223999427|NCT00691795|DRUG|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
223999428|NCT02531555|DEVICE|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
223999429|NCT02531555|DEVICE|Gracey curettes|
223999430|NCT03553108|DRUG|Olaparib Treatment A|Olaparib Tablet 25 mg
223999431|NCT03553108|DRUG|Olaparib Treatment B|Olaparib Tablet 100 mg
223382869|NCT02288325|DRUG|Placebo|Dose-matched placebo taken orally once daily.
223382870|NCT02411916|BIOLOGICAL|misoprostol|rectal insertion
223382871|NCT04348877|OTHER|Antibody-Rich Plasma from COVID-19 recovered patients|400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19
223382872|NCT04629378|DRUG|Meropenem Injection|Meropenem IV 6 grams
223382873|NCT04629378|DRUG|Amoxicillin Clavulanate|Amx/CA oral 1000/62.5mg 2 tablets
223545322|NCT04551898|DRUG|Placebo|Placebo to match BGB-DXP593 administered as specified in the treatment arm
223545323|NCT01393483|OTHER|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
223999432|NCT03553108|DRUG|Olaparib Treatment C|Olaparib Tablet 150 mg
223999433|NCT03553108|DRUG|Olaparib Treatment D|Olaparib Tablet 250 mg
223999434|NCT05841589|PROCEDURE|Green tea extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
223999435|NCT05841589|PROCEDURE|Garlic with lime extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
223999436|NCT05841589|PROCEDURE|Pomegranate extract mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
223999437|NCT05841589|PROCEDURE|Chlorhexidine mouth rinse|herbal extracts mouth rinse that was prepared in the microbiology laboratory
223382874|NCT04629378|DRUG|Pyrazinamide|Pyrazinamide 20-30mg/kg
223382875|NCT04629378|DRUG|Bedaquiline|Bedaquiline 400mg
223382876|NCT04629378|DRUG|Rifafour|Rifafour (HRZE) Standard dose
223382877|NCT04020887|DEVICE|Alertwatch - Interaction|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
223382878|NCT00419991|DRUG|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
223999438|NCT01043003|OTHER|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
223382879|NCT01335334|DRUG|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
223382880|NCT02465138|DRUG|Ketorolac|Intravenous ketorolac
223382881|NCT02465138|DRUG|Placebo|Intravenous saline
223382882|NCT03857815|RADIATION|anti-PD-1 antibody|"In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks."
223382883|NCT02683421|DRUG|Tilmanocept|
223382884|NCT04003493|OTHER|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
223382885|NCT06427850|DRUG|Tranexamic acid|receive an injection of Tranexamic acid into the surgical site
223999439|NCT01043003|PROCEDURE|quality-of-life assessment|Ancillary studies
223999440|NCT01043003|OTHER|Questionnaire Administration|Ancillary studies
223999441|NCT01043003|OTHER|psychosocial support for caregiver|Support for caregiver
223999442|NCT01043003|PROCEDURE|assessment of therapy complications|Ancillary study
223999443|NCT01043003|OTHER|informational intervention|Undergo evaluation sessions
223999444|NCT00441922|DRUG|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
223382886|NCT06427850|DRUG|Normal saline|receive an injection of Normal saline into the surgical site
223382887|NCT04298268|DEVICE|CUSA Clarity Ultrasonic Surgical Aspirator System use|Assessment of the CUSA® Clarity Ultrasonic Surgical Aspirator System use during urological or general surgery for soft tissue removal
223382888|NCT00511732|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder
223999445|NCT00441922|DRUG|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
223382889|NCT00511732|DRUG|Technosphere Placebo|Technosphere Inhalation Powder
223999446|NCT00871286|PROCEDURE|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
223999447|NCT00871286|PROCEDURE|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
223999448|NCT03682185|BEHAVIORAL|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
223999449|NCT03682185|BEHAVIORAL|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
223999450|NCT02630407|BIOLOGICAL|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
223382890|NCT01845688|DRUG|Losartan Tablets & QingReMoShen Granule|
223382891|NCT01845688|DRUG|Losartan Tablets & Placebo Granule|
223382892|NCT02403258|OTHER|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
223382893|NCT02403258|BEHAVIORAL|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
223999451|NCT02630407|OTHER|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
223999452|NCT04908631|DEVICE|Transcranial Direct Stimulation|Brain stimulation using low-intensity current via electrodes on scalp to modify neuronal excitability in the underlying cortex. The tDCS system has customizable head gear with disposable, snap-in electrodes wihich can be applied at home without assistance.
223999453|NCT04908631|OTHER|Auditory Training Program|Web-based program uses consonant and vowel recognition and understanding sentences/conversations in quiet and in noise using different talkers, and other types of listening exercises.
223999454|NCT00343551|DRUG|Aliskiren|
223999455|NCT00518895|DRUG|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
223999456|NCT00518895|DRUG|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
223382894|NCT02213159|DRUG|Dexmedetomidine|
223382895|NCT02213159|DRUG|Morphine|
223382896|NCT06585501|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
224138468|NCT01560221|DRUG|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
223999457|NCT05665543|BEHAVIORAL|GLAm app|Game-based Learning Avatar-navigated mobile (app) provides information on HPV infection susceptibility, risk of HPV-associated cancers, screening methods, and ways to overcome screening barriers. Users navigate the app using an avatar, and earn points for game components completed. The app prompts screening using text message reminders based on patient-entered information, and links to schedule cervical cancer screening. Completing cervical cancer screening earns an electronic badge visible to other users via an anonymous screen name and avatar.
223999458|NCT05485987|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
223999459|NCT04947254|DRUG|Abiraterone Acetate|Given PO
223382897|NCT06180356|DRUG|Niraparib oral tablets|Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
223382898|NCT05422469|DEVICE|Medtronic Percept RC neurostimulator|Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted
223382899|NCT06976320|OTHER|Intravenous morphine patient control analgesia|24-hour morphine consumption will be recorded
223382900|NCT06976320|OTHER|Intravenous patient control analgesia|24-hour morphine consumption will be recorded
223382901|NCT06976320|OTHER|Deep rectus sheath block|Deep rectus sheath block will be administered at the end of the surgery.
223382902|NCT03617458|DRUG|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
223382903|NCT03617458|DRUG|Placebo|A treatment with no active ingredients or therapeutic effect.
223382904|NCT03617458|DEVICE|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
223382905|NCT03617458|DEVICE|Usual Care|Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
223999460|NCT04947254|DRUG|Antiandrogen Therapy|Given ADT
223999461|NCT04947254|DRUG|Apalutamide|Given PO
223382906|NCT05526885|DIAGNOSTIC_TEST|CAD4TB|A posterior anterior digital chest X-ray incoporated in a mobile diagnostic unit is analysed by CAD4TB version 7 (Delft Imaging, NL). A trained and qualified person in compliance with national regulations will operate the digital chest X-ray.
223382907|NCT05526885|DIAGNOSTIC_TEST|POC-CRP|A quantitative POC-CRP LumiraDx (LumiraDx Limited, UK) triage test will be performed by finger-prick if CAD4TB scores is within the defined threshold window of study approach 2 triage testing
223999462|NCT04947254|PROCEDURE|Biopsy|Undergo biopsy
223999463|NCT04947254|DRUG|Niraparib|Given PO
223999464|NCT04947254|DRUG|Prednisone|Given PO
223382908|NCT05526885|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra|Depending on CAD4TB (approach 1 \& 2) or POC-CRP score (approach 2) a confirmatory Xpert MTB/RIF Ultra(Cepheid, USA) rapid sputum molecular testing follows for both Mycobacterium tuberculosis complex and rifampicin resistance;
223382909|NCT05673226|OTHER|Surface disinfection with Organosilane|Organosilane will be sprayed on the surfaces, using an atomizer. When the environment has been completely covered (i.e., when all surfaces and equipment have a slightly damp film), we will proceed with the second phase of the disinfection of all heavily touched surfaces. surfaces of the bed, with a microfiber cloth with organosilane.
223382910|NCT05061420|DRUG|Pembrolizumab|Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
223382911|NCT05061420|DRUG|SAR444245 (Thor-707)|Pharmaceutical Form: Concentrate for solution for infusion Route of Administration: Intravenous Infusion
223382912|NCT05061420|DRUG|Cetuximab|Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
223382913|NCT06440993|DRUG|Gemcitabine|Gemcitabine, 1,000 mg/m2 IV
223382914|NCT06440993|DRUG|Cisplatin|Cisplatin, 25 mg/m2 IV
223382915|NCT06440993|DRUG|Durvalumab|Durvalumab, 1,500 mg IV
223382916|NCT06440993|PROCEDURE|ID-RFA|endoscopic intraductal RFA
223382917|NCT00576446|BIOLOGICAL|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
223382918|NCT00022282|DRUG|shark cartilage extract AE-941|
223382919|NCT01657812|DRUG|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
223382920|NCT00590512|DIETARY_SUPPLEMENT|High sodium|
223999465|NCT04947254|RADIATION|Radiation Therapy|Undergo radiation therapy
223999466|NCT03641755|DRUG|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
223999467|NCT03641755|DRUG|Olaparib|Olaparib is an inhibitor of PARP (poly \[adenosine diphosphate-ribose\] polymerase), which means that it stops PARP from working
223999468|NCT04150042|DRUG|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
223999469|NCT04150042|DRUG|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
223999470|NCT04150042|DRUG|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
223999471|NCT04150042|DRUG|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
223999472|NCT04150042|DRUG|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
223999473|NCT04150042|DEVICE|Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive an autologous hematopoietic stem cell infusion.
223382921|NCT00590512|DIETARY_SUPPLEMENT|Low sodium|
223382922|NCT00422500|BEHAVIORAL|Questionnaire|Surveys about symptoms, mood, and quality of life.
223382923|NCT00422500|BEHAVIORAL|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
223999474|NCT03681210|DEVICE|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
223999475|NCT06555263|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
223999476|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
223999477|NCT01026129|DRUG|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
223999478|NCT01026129|DRUG|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
223999479|NCT05743699|BEHAVIORAL|Bright Horizons|Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.
223999480|NCT05743699|BEHAVIORAL|Case Management|Placebo condition
223999481|NCT06983327|BEHAVIORAL|Trauma Focused Emotional Awareness and Expression Therapy (EAET)|The intervention is three-session program which includes pain neuroscience education, education on the relationship between trauma and chronic pain, and skills training to reduce pain- and stress-related symptoms.
223999482|NCT06522269|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
223999483|NCT06522269|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (arriving at the emergency department within 4.5 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
223999484|NCT06663163|OTHER|Observation|This study was an observational study without intervention
223999485|NCT02284009|BIOLOGICAL|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
223999486|NCT02284009|BIOLOGICAL|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
223999487|NCT02284009|BIOLOGICAL|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
223999488|NCT03468478|DRUG|Sirolimus|sirolimus combined to reduced dose of tacrolimus
223999489|NCT03468478|DRUG|Everolimus|everolimus combined to reduced dose of tacrolimus
223999490|NCT03468478|DRUG|Mycophenolic acid|Control arm: mycophenolate combined to regular tacrolimus
223382924|NCT00422500|OTHER|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
223382925|NCT06115772|OTHER|Non-Interventional Study|Non-interventional study
223382926|NCT01509014|BEHAVIORAL|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
223382927|NCT00606164|DRUG|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
223999491|NCT06824194|BIOLOGICAL|PCV21 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223999492|NCT06824194|BIOLOGICAL|Prevnar 20 vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223999493|NCT06824194|BIOLOGICAL|M-M-R II vaccine|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
223999494|NCT06824194|BIOLOGICAL|Rotarix|Pharmaceutical form:Solution-Route of administration:Oral
223382928|NCT00606164|DRUG|Placebo|A single one-hour intravenous infusion of placebo on Day 1
223382929|NCT05024357|DRUG|Dasatinib|Take Dasatinib orally for 1 year or 6 months post-HSCT.
223382930|NCT01724086|DRUG|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
223382931|NCT01724086|DRUG|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
223382932|NCT01724086|DRUG|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
223999495|NCT06824194|BIOLOGICAL|RotaTeq|Pharmaceutical form:Solution-Route of administration:Oral
223999496|NCT06824194|BIOLOGICAL|Vaxelis vaccine|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223999497|NCT06824194|BIOLOGICAL|Varivax|Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
223999498|NCT06824194|BIOLOGICAL|Priorix|Pharmaceutical form:Lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous
223382933|NCT01724086|DRUG|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
223545324|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
223999499|NCT06824194|BIOLOGICAL|VAQTA|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
223999500|NCT06824194|BIOLOGICAL|Havrix|Pharmaceutical form:Suspension for Injection-Route of administration:Intramuscular
223999501|NCT06666036|BEHAVIORAL|Connect|Community level enhancements
223999502|NCT06604832|DRUG|PrabotulinumtoxinA-Xvfs|Each vial of prabotulinumtoxinA-xvfs contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the left side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
223999503|NCT06604832|DRUG|IncobotulinumtoxinA|Each vial of incobotulinumtoxinA contains 100 units of product, and it will be reconstituted with 5 mL of bacteriostatic saline solution. 20 units of this intervention will only be injected to the right side of subject faces - intramuscularly to the corrugator supercilii and intradermally to the forehead region.
223999504|NCT06604832|DRUG|saline solution (placebo)|As a placebo treatment, saline solution will be injected on the right side of the glabellar lines and forehead region instead of an active neuromodulator. The saline solution has no therapeutic effect and is used as a control to compare the results against the active treatment.
223999505|NCT02902159|OTHER|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
223999506|NCT02902159|OTHER|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
223999507|NCT06026553|DRUG|Ketorolac (Toradol)|IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
223999508|NCT06026553|OTHER|Placebo (saline)|IV Placebo (saline) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
223999509|NCT02967640|DRUG|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
223999510|NCT02967640|DRUG|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
223999511|NCT02469883|DRUG|Sinotecean|
223999512|NCT03652350|PROCEDURE|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
223999513|NCT00075777|DRUG|valproic acid|250 mg by mouth twice a day
223999514|NCT03749304|DEVICE|ANI monitor|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index
223999515|NCT03468790|DRUG|CMAB007|the study drug
223545325|NCT01393483|OTHER|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
223999516|NCT03468790|DRUG|Symbicort|asthma-controlled drug
223999517|NCT03468790|DRUG|Seretide|asthma-controlled drug
223999518|NCT03468790|DRUG|Ventolin|asthma rescue drug
223999519|NCT03468790|DRUG|placebo|No active components
223999520|NCT03882086|OTHER|foot reflexology|Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
223999521|NCT01349153|BEHAVIORAL|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
223999522|NCT01349153|BEHAVIORAL|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
223999523|NCT06859957|DRUG|Melatonin 10 mg|10 mg melatonin daily for a period of 6 weeks
223999524|NCT06859957|DRUG|Placebo|Daily placebo for a period of 6 weeks
223999525|NCT03119883|OTHER|5-Carbon C 13-labeled Glutamine|Given IV
223999526|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223999527|NCT03119883|PROCEDURE|Biospecimen Collection|Undergo collection of bone marrow aspirate samples
223545326|NCT06416150|BEHAVIORAL|Stage 1 SOC|Participants will receive high Standard Care, consisting of a telephone call approximately one month before the appointment to confirm the appointment date for the baseline colposcopy appointment, followed by a notification letter including scheduled appointment date and clinic contact information should the clinic be unable to reach the patient by telephone.
223545327|NCT06416150|BEHAVIORAL|Stage 1 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
223545328|NCT06416150|BEHAVIORAL|Stage 2 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
223999528|NCT03119883|OTHER|Uniformly-labeled [13C]glucose|Given IV
223999529|NCT05427084|DRUG|Canagliflozin|Canagliflozin tablet 300mg PO daily
223999530|NCT05427084|DRUG|Placebo|Placebo tablet
223999531|NCT06611930|DRUG|CK-0045|Interleukin-22 agonist
223999532|NCT06611930|DRUG|Placebo|Placebo (liquid for injection, which includes no active ingredient).
223999533|NCT06586190|OTHER|Floor Pedal Bike with Guided Instructions for Home|Patients with lower extremity traumatic injuries that are medically clear for physically ready for therapy and will receive a floor pedal bike with guided exercises at home.
223382934|NCT01724086|DRUG|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
223382935|NCT01724086|DRUG|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
223382936|NCT02889523|DRUG|Tazemetostat|Tablets 200 mg, to be administrated per os
223382937|NCT02889523|DRUG|Rituximab|375 mg/m²/dose, D1
223382938|NCT02889523|DRUG|Cyclophosphamide|750 mg/m²/dose, D1
223382939|NCT02889523|DRUG|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
223999534|NCT06995196|BEHAVIORAL|ReLiver-N App|"Intervention for intervention group: Patients will access all content of ReLiver-N App. The ReLiver-N App has comprehensive health education, patient activation practices, care algorithm, and clinical decision system, to provide and maintain the hepatic rehabilitation of patients with liver cirrhosis and to evaluate the effect of the use of ReLiver-N App on hepatic rehabilitation. Care algorithm and clinical decision system will be evaluated results of patient activation as normal, controllable, urgent. Feedbacks will be sent to patients based on the evaluations."
223999535|NCT06669728|DIAGNOSTIC_TEST|AI diagnostic algorithm|The ICL procedures collected would be assessed by the algorithm. The performance of the algorithm would be assessed, including accuracy, AUC, sensitivity and specificity.
223999536|NCT06996249|BEHAVIORAL|Health-related quality of life and treatment outcome questionnaires|Patients who consented to the completion of questionnaires will be invited to complete questionnaires on multiple time points but not more often than once every 3 months. The length of time required for the completion of questionnaires will not exceed 150 minutes a year.
223999537|NCT06996249|GENETIC|(Tumor) tissue and other biomaterials|Tissue and other biomaterial, such as pleural effusion, is collected from material obtained during a diagnostic procedure or surgical resection. No additional interventional procedures are performed to obtain the material.
223999538|NCT06996249|PROCEDURE|Blood samples|Blood samples can be withdrawn on multiple time points with a maximum of 10 tubes of 10 ml per year during routine blood withdrawals (or in exceptional cases with an additional blood withdrawal).
223999539|NCT06997029|DRUG|BMS-986500|Specified dose of specified days
223999540|NCT06997029|DRUG|Palbociclib|Specified dose on specified days
223999541|NCT06997029|DRUG|Fulvestrant|Specified dose on specified days
223999542|NCT06996769|OTHER|constraint induced therapy|Constraint induced movement therapy (CIMT) is a treatment approach that can be used with patients who have had a CVA. In order to be eligible for the therapy, the clients must have at least 10 degrees of active wrist and finger extension. During this treatment the unaffected limb is restrained (usually with a sling or a mitt) for 90% of their waking hours. This treatment forces the client to use the affected limb throughout their daily tasks in order to combat learned non-use of the affected limb.
223999543|NCT06996769|OTHER|Conventional therapy for stroke patient|general exercises
223999544|NCT05687188|OTHER|Blood Sample Collection|Participants will have 40 mL of blood drawn at baseline/pre-treatment. The study team will aim to have this blood collected at the time of standard of care blood draw if possible.
223999545|NCT05687188|OTHER|Tissue Sample Collection|At the time of tissue biopsy or surgical resection (if applicable) pancreatic tumor tissue, fat, tissue from site of metastasis, and cyst fluid (if applicable) will be collected.
224123712|NCT06713694|OTHER|Wait first, then cognitive-behavioral therapy|participants assigned to the waiting-list control condition will wait 3.5 months before they are treated with CBT. This period corresponds to the duration of the CBT intervention and follow-up assessment of the experimental group. After this 3.5 month waiting period the participants in the waiting-list control condition will be asked to complete a follow-up after waiting/baseline before CBT assessment before starting treatment.
223999546|NCT05687188|OTHER|Data Collection|Participants will complete a study questionnaire at baseline that includes medical history, lifestyle, and family history information.
223999547|NCT05687188|OTHER|Medical Image Collection|Medical images that are obtained during routine care such as computed tomography (CT) scans, magnetic resonance imaging (MRIs) and ultrasounds will be reviewed by the study team throughout the participant's medical care.
223999548|NCT06673134|DRUG|enteral nutrition|exclusive enteral nutrition therapy or Partial enteral nutrition
223999549|NCT06673134|DRUG|Immunotherapy|Immunosuppressants therapy, Including thalidomide, azathioprine, methotrexate, etc
224123713|NCT07031297|DIAGNOSTIC_TEST|Meal Study|"Participants will consume a mixed meal drink (Ensure) equivalent to 40% of basil metabolic rate as calculated via Harris Benedict equation.~Following consumption of the drink they will undergo a series of blood draws over the following 4 hours:~* Plasma glucose will be measured according to a mixed meal test protocol every 10 minutes for the first hour and then every 15, then 30 minutes for the last 3 hours.~* 1 ml plasma aliquots for exosome analysis and insulin concentrations will be drawn every 30 minutes following consumption of ensure for 4 hours.~* Blood gasses will be drawn every 30 minutes for the 4 hours following the meal.~Participants will undergo a second abdominal adipose tissue biopsy 3 hours following mixed meal drink."
224123714|NCT04832841|DIAGNOSTIC_TEST|anti-spike SARS-CoV-2 IgG|Immunochemiluminescent assay by DiaSorin S.p.A. Italy
223382940|NCT02889523|DRUG|Doxorubicin|50 mg/m²/dose, D1
223382941|NCT02889523|DRUG|Prednisolone|40 mg/m2 in the morning D1 to D5
223382942|NCT00791544|DRUG|AVE1642|intravenous infusion
223382943|NCT00791544|DRUG|sorafenib|oral intake
223382944|NCT00791544|DRUG|erlotinib|oral intake
223382945|NCT03814655|PROCEDURE|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
223382946|NCT03814655|PROCEDURE|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
223382947|NCT03864016|DRUG|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
223382948|NCT03864016|DRUG|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
223382949|NCT03864016|DRUG|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
223382950|NCT02925039|OTHER|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
223999550|NCT06673134|DRUG|biological agents|Inflixima , domestic infliximab (Taizhou Mabtech Pharmaceutical Co.,Ltd) and Adalimumab , etc
223999551|NCT06673134|DRUG|Glucocorticoids|Glucocorticoids treatments are given
223999552|NCT06673134|OTHER|fecal microbiota transplantation|Fecal bacteria transplantation treatment, transplantation routes include enema, TET route, capsule fecal bacteria route, etc
223999553|NCT06673056|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
223999554|NCT06673056|OTHER|Placebo|Matching Placebo Sachet
223999555|NCT06324747|PROCEDURE|Vestibular socket therapy|Vestibular socket therapy will be used for the intervention.
223999556|NCT06324747|PROCEDURE|conventional full thickness flap|reflecting the mucoperiosteum to access the extraction socket
223999557|NCT05295433|DRUG|mRNA-3705|A sterile liquid for injection
223999558|NCT04897841|DRUG|Liposomal bupivacaine|20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
223999559|NCT04897841|DRUG|Bupivacaine Hydrochloride|30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
223999560|NCT04897841|OTHER|saline|post-surgical saline
223999561|NCT07000240|OTHER|Midwife-led ultrasound-guided pushing training group|"The pushing training program consists of a two-hour in-person session, structured as follows:~* 30 minutes of theoretical instruction, covering the physiological mechanisms of labor, the role of the levator ani muscle (LAM) during pushing, and optimal pushing techniques.~* 30 minutes of practical exercises, during which women will be guided through breathing techniques, pushing strategies, and perineal relaxation.~Women randomized to the ultrasound-guided pushing training group will receive additional transperineal ultrasound (TPU) evaluations during practical exercises, performed by a midwife trained in ultrasound imaging. These assessments will ensure effective LAM relaxation during pushing practices and provide real-time visual feedback to optimize muscle coordination."
223999562|NCT07000240|OTHER|Midwife-led pushing training only group|"The pushing training program consists of a two-hour in-person session, structured as follows:~* 30 minutes of theoretical instruction, covering the physiological mechanisms of labor, the role of the levator ani muscle (LAM) during pushing, and optimal pushing techniques.~* 30 minutes of practical exercises, during which women will be guided through breathing techniques, pushing strategies, and perineal relaxation."
223999563|NCT06999863|OTHER|Patients of a surgical intensive care unit|Patients of a surgical intensive care unit having an arterial catheter undergoing noninvasive measurements of BP in 3 situations (thick sleeve, thin sleeve, bare arm) and with 2 algorithms (for bare arm measurement only).
223999564|NCT02769845|DRUG|Hydroxyurea|drug to be administered
223999565|NCT02769845|PROCEDURE|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
223999566|NCT05398445|DRUG|Rocatinlimab|Participants will receive Rocatinlimab subcutaneously.
223999567|NCT05398445|DRUG|Placebo|Participants will receive a placebo subcutaneously.
223999568|NCT06502119|OTHER|Designed Questionnaire|Participants in this study, comprised solely of obstetricians and gynecologists practicing in Egypt, will complete a self-administered questionnaire designed to assess their knowledge, attitudes, and practices related to operative vaginal birth. The questionnaire includes four sections: the first gathers demographic data such as name, gender, and years of experience in childbirth care; the second focuses on participants' practices regarding the frequency and types of operative vaginal birth used (forceps, ventouse) and reasons for their use; the third evaluates knowledge of outcomes associated with operative vaginal birth through multiple-choice questions; and the fourth explores attitudes towards operative vaginal birth, including opinions on hospital rates and policy appropriateness. Completion and return of the questionnaire, which takes approximately 5 to 10 minutes, will be considered as consent to participate in the study.
223999569|NCT02603328|DRUG|Atorvastatin|40-80 mg OD
223999570|NCT02603328|OTHER|Placebo|inactive
223999571|NCT06672419|OTHER|AI-Guided Exercise and Pain Neuroscience Education|This intervention consists of a 12-week tele-rehabilitation program using AI and computer vision technology to guide personalized exercise sessions (three per week). Exercises are adjusted in real time by the AI system, and participants also attend weekly sessions of pain neuroscience education to develop improved pain management strategies. The program is delivered remotely via a digital platform that is visually identical for all participants. Supervising physiotherapists oversee progress and provide standardized support but remain blinded to group allocation.
223999572|NCT06672419|OTHER|Usual Care for Fibromyalgia|"Standard care includes pharmacological management (pain relievers, antidepressants, anticonvulsants) and general recommendations on physical activity and disease management.~Drug: Pain Relievers - e.g., paracetamol, tramadol~Drug: Antidepressants - e.g., amitriptyline, duloxetine~Drug: Anticonvulsants - e.g., pregabalin, gabapentin~Other: General Physical Activity and Disease Education - recommendations consistent with current clinical guidelines"
223382951|NCT02925039|OTHER|Treatment as usual|Treatment as usual
223382952|NCT04868500|DEVICE|AMAZE™ Application|Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
223382953|NCT04868500|DEVICE|AMAZE™ Dashboard|Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
223382954|NCT04169152|PROCEDURE|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
223382955|NCT04144361|PROCEDURE|sleeve with plication|sleeve with plication
223382956|NCT04144361|PROCEDURE|sleeve without plication|sleeve without plication
223382957|NCT06157190|OTHER|Unsupervised monitoring|"This study introduces technology-assisted rehabilitation for patients post-total hip or knee arthroplasty, utilizing wearable sensors and mobile health tech. The intervention includes:~Technology-Assisted Rehabilitation: Utilizing wearable sensors and mobile health technologies, the intervention promotes unsupervised, real-world assessments after total hip or knee replacement. It shifts from traditional supervised clinical assessments. The moveUP digital therapies platform, featuring a dedicated mobile app, acts as the primary interface for patients in rehabilitation.~Digital Biomarkers: The intervention involves gathering digital biomarkers from wearable sensors and mobile health tech. These biomarkers offer continuous, objective measurements of patients' biological and physiological data. Examples include mobility and activity level data."
223999573|NCT06920225|BEHAVIORAL|Maintain home-based schedule|The team will maintain their home-based time zone schedule despite being in a location that is three time zones away
223382958|NCT00548470|DRUG|Varenicline|Varenicline 1-2 mg/day
223545329|NCT06416150|BEHAVIORAL|Stage 2 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as health coaching (HC) after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
223999574|NCT07126873|BIOLOGICAL|Allogeneic Human E-islet (E-islet 01)|Allogeneic Human E-islet (E-islet 01), Infused into the hepatic portal vein
223999575|NCT07005427|OTHER|dysphagia therapy|"This group will receive usual dysphagia care as provided in ICU settings~* Standard bedside swallowing evaluation~* Conventional compensatory strategies (postural changes, diet modifications)~* Traditional exercises focusing on oral motor control~* Therapy sessions 3 times per week for 30 minutes"
223382959|NCT00097032|DRUG|risperidone; quetiapine|
223382960|NCT04325932|DRUG|Urinary Kallikrein|
223999576|NCT07005427|BEHAVIORAL|Designed protocol for dysphagia|"* Innovative strengthening exercises adapted for ICU setting~* Early mobilization component~* ICU-specific compensatory strategies~* Therapy sessions 5 times per week for 30 minutes with additional brief daily reinforcement"
223999577|NCT05915234|DEVICE|Crushed ice|Each participant will receive two active devices and one sham comparator in a crossover design.The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of crushed ice. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
223999578|NCT05915234|DEVICE|Frozen peas|Each participant will receive two active devices and one sham comparator in a crossover design. The cryotherapy device used consists of an opaque bag with a plastic outer cover and an aluminum interior filled with 80 grams of frozen peas. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed to reduce skin temperature in ranges that decrease nerve conduction velocity and increase pain threshold.
223999579|NCT05915234|DEVICE|Room temperature gel|Each participant will receive two active devices and one sham comparator in a crossover design. The sham comparator device used consists of an opaque bag with an external plastic cover and an aluminum interior filled with 80 grams of ultrasound gel at room temperature. This device is applied on the skin where the optimal palpation point of the radial artery is located, where arterial puncture for blood gas analysis is usually performed.
223999580|NCT06870201|DIETARY_SUPPLEMENT|Lipid-Based Nutrient Supplement|LNS labeled with a stable iron isotope
223999581|NCT06886139|DRUG|TRS005|Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.
223999582|NCT03898778|DEVICE|Minnesota Medical Technologies Anal Insert Device|Non-sterile soft, flexible, liquid-filled anal insert either 10 mm size or 13 mm size, meant for single use only
223999583|NCT06389786|PROCEDURE|Bilateral Pelvic Lymph Node Dissection|Undergo bilateral pelvic lymph node dissection
224123715|NCT02991053|DRUG|ketamine|
224123716|NCT00540176|DRUG|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
224123717|NCT07036458|DRUG|14C Epaminurad Oral Solution|Subjects will receive a single administration of 14C Epaminurad Oral Solution
223382961|NCT05015452|DEVICE|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
223382962|NCT00004315|DRUG|ursodiol|
223382963|NCT00150787|DRUG|LEVETIRACETAM|
223382964|NCT00686361|DRUG|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
223382965|NCT04187547|DRUG|Tricaprilin|"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"
223382966|NCT04187547|DRUG|Placebo|Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
223545330|NCT06416150|BEHAVIORAL|Stage 3 SOC|Participants will receive a telephone call before their 12-month follow-up appointments to remind participants about their upcoming appointment and schedule/reschedule if needed.
223545331|NCT06416150|BEHAVIORAL|Stage 3 HERS|Participants will receive text message appointment reminders and barriers messages. Text messages will be sent on a prescheduled basis over the course of 2 weeks preceding the scheduled target appointment.
223999584|NCT06389786|PROCEDURE|Biospecimen Collection|Undergo tissue sample collection
223999585|NCT06389786|PROCEDURE|Bone Scan|Undergo bone scan
224123718|NCT02684240|DRUG|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
223382967|NCT03122977|PROCEDURE|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
223999586|NCT06389786|PROCEDURE|Computed Tomography|Undergo CT
223999587|NCT06389786|OTHER|Electronic Health Record Review|Ancillary studies
223999588|NCT06389786|OTHER|Flotufolastat F-18 Gallium|Given IV
223545332|NCT06416150|BEHAVIORAL|Stage 3 HERS+HC|Participants will receive text message barriers counseling as well as HC after their missed appointment. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
223999589|NCT06389786|PROCEDURE|Laparoscopic Radical Prostatectomy with Robotics|Undergo robotic radical prostatectomy
223999590|NCT06389786|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
223999591|NCT06389786|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
223999592|NCT00545415|DIETARY_SUPPLEMENT|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
223999593|NCT00545415|DIETARY_SUPPLEMENT|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
223999594|NCT00545415|DIETARY_SUPPLEMENT|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
223999595|NCT00545415|DIETARY_SUPPLEMENT|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
223999596|NCT00545415|DIETARY_SUPPLEMENT|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
223999597|NCT00545415|DIETARY_SUPPLEMENT|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
223999598|NCT06682039|OTHER|Internet-Based Intervention|Engage in ABM + text messaging prompts
223999599|NCT06682039|OTHER|Internet-Based Intervention|Engage in inert attention task sessions
223999600|NCT06682039|OTHER|Interview|Ancillary studies
223999601|NCT06682039|OTHER|Questionnaire Administration|Ancillary studies
223999602|NCT06682039|OTHER|Text Message-Based Navigation Intervention|Participants will respond to daily messaging prompts.
224123719|NCT02684240|OTHER|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
224123720|NCT07043335|DEVICE|Extracorporeal Shock Wave Therapy|For patients in Group 2, Extracorporeal Shock Wave Therapy will be applied to the lateral epicondyle area at 10-15 Hz frequency, 1.5-2.5 bar energy density, and 2000 pulses. Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days.
224123721|NCT07043335|PROCEDURE|Mesotherapy|Intradermal mesotherapy involving lidocaine, pentoxifylline, meloxicam, and thiocolchicoside will be applied to painful elbow points using a 4 mm, 30G needle in a point-by-point technique at a 90° angle (0.1 cc per point). A nappage technique at a 45° angle will then be applied around the common extensor tendon. A total of five sessions will be administered, one every 7 days.
224123722|NCT07039045|DRUG|LY4065967|Oral dose
224123723|NCT07039045|RADIATION|[14C]-LY4065967 Oral|Oral dose
224123724|NCT07039045|RADIATION|[14C]-LY4065967 IV|IV dose
224123725|NCT01064648|DRUG|Cediranib Maleate|Given orally
224123726|NCT01064648|DRUG|Cisplatin|Given IV
224123727|NCT01064648|OTHER|Laboratory Biomarker Analysis|Correlative studies
224123728|NCT01064648|DRUG|Pemetrexed Disodium|Given IV
224123729|NCT01064648|OTHER|Placebo Administration|Given orally
223382968|NCT03122977|PROCEDURE|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
223382969|NCT01307345|BEHAVIORAL|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
223545333|NCT06416150|BEHAVIORAL|Stage 4 HERS|Participants will receive another barriers assessment and another round of text message appointment reminders and barriers messages.
224123730|NCT06445504|DEVICE|Robotic-Assisted Surgery (RAS) Hernia Repair Surgery|Patients indicated for Robotic-Assisted Surgery (RAS) for ventral and inguinal hernia repair will have the RAS surgery using the Medtronic Hugo RAS system
224123731|NCT00977574|BIOLOGICAL|Bevacizumab|Given IV
224123732|NCT00977574|DRUG|Carboplatin|Given IV
224123733|NCT00977574|DRUG|Ixabepilone|Given IV
224123734|NCT00977574|OTHER|Laboratory Biomarker Analysis|Correlative studies
224123735|NCT00977574|DRUG|Paclitaxel|Given IV
224123736|NCT00977574|DRUG|Temsirolimus|Given IV
224123737|NCT05673811|DRUG|Nab-paclitaxel|Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
223999603|NCT06508775|BIOLOGICAL|MB-CART19.1|Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
223999604|NCT06508775|BIOLOGICAL|MB-CART20.1|Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
223382970|NCT00638053|GENETIC|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
223545334|NCT06416150|BEHAVIORAL|Stage 4 HERS+HC|Participants will receive another barriers assessment and another round of text message barriers counseling as well as HC. Participants that miss their scheduled appointment will receive a HC call within 2 business days. HC calls will be flexibly scheduled based on the preference of the patients and limited to 15 minutes or less.
223545335|NCT03427814|DRUG|Pamiparib|60 mg orally twice daily
223999605|NCT06508775|BIOLOGICAL|MB-CART2019.1|Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
223545336|NCT03427814|DRUG|Placebo|60 mg orally twice daily
223545337|NCT03846427|DRUG|Zanubrutinib|Zanubrutinib at a dose of 160 mg orally twice a day (BID)
223999606|NCT00759122|DRUG|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
223999607|NCT00759122|DRUG|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
223999608|NCT00002154|DRUG|Thioctic acid|
223999609|NCT00002154|DRUG|Selegiline hydrochloride|
223999610|NCT05739331|DEVICE|machine learning algorithm|Machine learning algorithm run on EBUS images for real-time labelling of mediastinal lymph nodes and lymph node level
223999611|NCT05430815|BEHAVIORAL|Enhanced Postpartum Care System|The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
223999612|NCT06632015|DRUG|Calcium Hydroxide (CH)|1 mL distilled water mixed with 1 g calcium hydroxide powder, placed into the root canals using a lentulo spiral.
223999613|NCT06632015|DRUG|Diclofenac Sodium (DCS)|1 mL distilled water mixed with 1 g diclofenac sodium powder, placed into the root canals using a lentulo spiral.
223999614|NCT06632015|DRUG|Calcium Hydroxide + Diclofenac Sodium (CH + DCS)|1 mL distilled water mixed with 950 mg calcium hydroxide powder and 50 mg diclofenac sodium powder, placed into the root canals using a lentulo spiral.
223999615|NCT06810765|OTHER|Hormone Replacement Therapy (HRT)|Hormone Replacement Therapy (HRT) is a medical treatment that involves restoring healthy endocrine functioning through supplementing or balancing hormones, such as testosterone or estrogen, to address deficiencies caused by injury, aging, or stress.
223999616|NCT06810765|OTHER|Magnetic Resonance Therapy (MeRT)|MeRT, an EEG (electroencephalography)-guided Repetitive Transcranial Magnetic Stimulation therapy, is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain, guided by an individual's brain patterns. MeRT is a neuromodulatory tool that has shown therapeutic efficacy in relation to a number of psychopathological targets including PTSD, depression, and TBI-related cognitive impairment through promoting cortical excitability, modulating neurotransmission, and restoring neuroplasticity.
223999617|NCT06810765|DRUG|ibogaine with magnesium treatment|Ibogaine, an indole alkaloid that interacts with mu opioid, kappa opioid, N-methyl-D-aspartate receptor (NMDA), and nicotinic acetylcholine receptors, shows early signs of effectiveness as a rapid-acting treatment for a number of mental health disorders including addiction. It is believed to work by promoting neuroplasticity and modulating brain chemistry, which may help reset dysfunctional neural circuits. The treatment is unique in its psychoactive properties, offering a deeply introspective experience that may help individuals process emotional material from the individual's lives.
223545338|NCT02113774|OTHER|antimicrobial treatment according to in-vitro susceptibility|
223999618|NCT06810765|DRUG|5-MeO-DMT|5-MeO-DMT, as described in the study, is a 5-HT 2A agonist compound used in previous clinical research to address depression. Unlike other treatments, 5-MeO-DMT acts rapidly and has a short duration of action, offering an intense but time-limited psychoactive state. Its potential to enhance neuroplasticity and recalibrate dysfunctional brain networks makes it a unique approach for addressing the complex interplay of psychological and neurological symptoms.
223999619|NCT06697301|DRUG|EIK1001|EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.
223999620|NCT06697301|DRUG|Pembrolizumab (KEYTRUDA® )|Pembrolizumab is a PD-1 inhibitor.
224123738|NCT05673811|DRUG|Gemcitabine|Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.
223382971|NCT02770898|BEHAVIORAL|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
223382972|NCT04770675|DIAGNOSTIC_TEST|Bronchoscopy|All subjects who are scheduled for a bronchoscopy may be eligible.
223382973|NCT04807400|DRUG|Inclisiran|Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection
223382974|NCT04807400|BEHAVIORAL|Behavioural Support|Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.
223382975|NCT04807400|DRUG|Background lipid lowering therapy|lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
223999621|NCT07026084|OTHER|Bio feedback training|"Hot Pack: Applied for 10 minutes, mild warmth sensation to relax muscles and prepare for exercise.~1\. BPU (Biofeedback Pressure Unit): performed at 5 pressure levels (22, 24, 26, 28, 30 mmHg).~Each level involves a 10-second hold, with 30 seconds rest between levels.~Targeted muscles:~* Deep Cervical Flexors (Capitus Longus, Capitus Colli).~* Rhomboids~* Trapezius Total duration (BPU): 20 minutes/session, performed 3 times/week."
223999622|NCT07026084|OTHER|conventional exercise program|"Hot Pack: Applied for 10 minutes, mild warmth sensation to relax muscles and prepare for exercise.~EXERCISE PROGRAM:~* 1\. Supine: Neck curl with Chin Tucks (Deep Cervical Flexors Capitus Longus, Capitus Colli): 10 reps/session, holding each for 5 seconds.~* 2\. Sitting: Chin tuck with Head pushing against palm.~* 3\. Chin Up (Middle and Lower Trapezius): 10 reps/session, holding each for 5 seconds.~* 4\. Scapular Squeezes (Rhomboids): 2-3 sets of 10 reps/session, holding each for 5 seconds• 5. Doorway Pectoral Stretch (pect major) 2-3 reps, 30 sec hold (36)Total duration: 20 minutes/session, performed 3 times/week."
223999623|NCT06700811|DRUG|Ketogenic diet|The ketogenic diet formula will be KetoVie®, supplied by Ajinomoto Cambrooke. Ketogenic diet ratio will aim to achieve ketosis, with a minimum level of beta-hydroxybutyrate of 1.0mmol/L. Ratios of ketogenic diet generally range from 1:1 to 4:1. Ratio will increase per standard clinical care for ketogenic diet initiation. For the trial we will aim to reach a maximum of 4:1 by the 6 week follow-up visit, but stopping at a lower ratio if BHB is ≥ 5mmol/L, CO2 ≤ 18 mmol/L, for tolerance, or to meet protein needs. A minimum 1:1 ratio is required to continue in the trial. Ratios higher than 1:1 are often required to obtain ketosis of ideally 2-5mmol/L in infants.
223382976|NCT03482115|RADIATION|PET examination with radiopharmaceutical drug [18F] DPA-714|Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
223382977|NCT03482115|DIAGNOSTIC_TEST|MRI examination|MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
223382978|NCT03482115|BIOLOGICAL|Blood samples|Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
223382979|NCT02750956|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
223382980|NCT02568605|DIETARY_SUPPLEMENT|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
223382981|NCT02568605|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223999624|NCT06701032|OTHER|Cardiovascular rehabilitation program|The cardiovascular rehabilitation program consists of a 12 weeks supervised exercises therapy (either in person or in tele-care)
223545339|NCT04764240|PROCEDURE|R0 resection with lymphadenectomy|Patients received a surgical R0 resection; patients who received an R1 or R2 resection were excluded.
223999625|NCT06626503|DRUG|Methadone based ERAS|Methadone intervention includes intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.05 mg/kg up to a maximum of 2.5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
223999626|NCT06626503|DRUG|Non-methadone based group|Non-methadone intervention includes standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards. Postoperative pain medication is recommended when reported pain level is considered moderate or higher (≥4 on NRS and FLACC).
223999627|NCT07025148|DRUG|Prasugrel|Prasugrel 5 mg od for 30 ± 5 days
223999628|NCT07025148|DRUG|Clopidogrel|Clopidogrel 75 mg od for 30 ± 5 days
224123739|NCT05673811|GENETIC|VCN-01|VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.
223382982|NCT02568605|BEHAVIORAL|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
223382983|NCT03838497|BIOLOGICAL|Prevenar13|Prevenar13 for both arms
223382984|NCT05712798|OTHER|No intervention|No intervention
223382985|NCT02186444|OTHER|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
223545340|NCT06243614|DRUG|Buagafuran capsules, 15mg/ capsule|Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
223545341|NCT06243614|DRUG|Buspirone tablets, 5mg/ tablet|Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
223545342|NCT06243614|DRUG|Buagafuran capsules mimic, 0mg/ capsule|Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
223545343|NCT06243614|DRUG|Buspirone tablets mimic, 0mg/ tablet|Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
223999629|NCT06699706|OTHER|Continuous theta-burst stimulation|"cTBS targets two regions: the dorsolateral prefrontal cortex (dlPFC) and the M1 area. Before the first treatment, each participant's resting motor threshold (RMT) will be determined using a five-step procedure for the primary motor cortex. RMT is defined as the minimum intensity required to elicit a motor response greater than 50 µV in at least 5 out of 10 consecutive trials in the right first dorsal interosseous muscle.~Participants will then undergo daily cTBS treatment three times a day for 7 consecutive days. Each stimulation session lasts 40 seconds, consisting of triplets of 50 Hz theta-burst stimulation repeated at 5 Hz, delivering a total of 600 pulses. Stimulation of the dlPFC target will be immediately followed by stimulation of the M1 target. To achieve cumulative aftereffects, the protocol will be repeated three times per day (a total of 3600 pulses/day) with two 15-minute breaks between sessions, timed with a stopwatch."
223999630|NCT06699706|OTHER|sham continuous theta-burst stimulation|The treatment pattern for the sham continuous theta-burst stimulation was similar to that for real stimulation. The sham coil is identical in appearance to the active coil, but it only produces sounds and sensations similar to those of the active coil on the scalp without generating a current, preventing participants from identifying their group assignment.
223999631|NCT01331876|BEHAVIORAL|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
224123740|NCT06741189|OTHER|Home monitoring|"The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child.~An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home.~The response will be standardized on the basis of a protocol shared by the 4 investigating centers."
224123741|NCT06741189|OTHER|usual medical monitoring|"During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures."
224123742|NCT06773949|DEVICE|Theta burst stimulation|Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
224123743|NCT05281523|BIOLOGICAL|Depemokimab (GSK3511294)|Depemokimab (GSK3511294) was administered using a pre-filled syringe.
224123744|NCT05281523|DRUG|Placebo|Placebo was administered as normal saline using a pre-filled syringe.
224123745|NCT02798497|OTHER|Serum and Blood samples|
224123746|NCT07054710|DEVICE|LED Light Treatment|The device will guide participants through a treatment that cycles through Red (4 minutes), Red + Infrared (4 minutes), and Blue (4 minutes) LED therapy in combination with vibration therapy, for a 12-minute treatment. Participants will be asked to use the device Monday through Saturday, on a clean face, as part of their evening routine.
224123747|NCT07054710|DEVICE|Vibration Only|On each Sunday of the 12-week program, participants will be asked to complete a 15-minute vibration-only treatment session as part of their evening routine.
224123748|NCT06754943|DRUG|Treatment A_Period 1|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
224123749|NCT06754943|DRUG|Treatment B_Period 2|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
223729870|NCT01115725|DRUG|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
224123750|NCT06754943|DRUG|Treatment A_Period 3|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
224123751|NCT06754943|DRUG|Treatment B_Period 4|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
224123752|NCT06754943|DRUG|Treatment B_Period 1|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
224123753|NCT06754943|DRUG|Treatment A_Period 2|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
224123754|NCT06754943|DRUG|Treatment B_Period 3|"* Administration alone of 1 tablet of JW0105~* Wash-out period: 21 days~* Administration: Treatment B is administered orally with 150 mL of water under fasting conditions"
224123755|NCT06754943|DRUG|Treatment A_Period 4|"* Co-administration of 1 tablet of JW0104 and 1 tablet of C2402~* Wash-out period: 21 days~* Administration: Treatment A is administered orally with 150 mL of water under fasting conditions"
224123756|NCT06898047|DRUG|Rimegepant for acute migraine treatment|Rimegepant for acute migraine treatment
224123757|NCT06815354|DEVICE|TRAQinform Theranostics|This prospective, multi-center, non-interventional clinical study will evaluate actionable outputs from TRAQinform Theranostics, a software only medical device that identifies, quantifies, tracks, and compares lesions between different imaging modalities and multiple imaging timepoints.
223729871|NCT06141109|DRUG|Sintilimab 200mg+MB07133 600mg|"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1."
223382986|NCT02186444|OTHER|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
223382987|NCT04583189|DIAGNOSTIC_TEST|Performance of the test antigenic and test RT-PCR|Each patient will have 1 test rapid antigenic Biosynex Covid-19 Ag-BSS with the results in 15-20 minutes and 1 reference test RT-PCR analyzed in microbiology laboratory of the hospital.
223999632|NCT07137325|BEHAVIORAL|play therapy|"The intervention consisted of a structured play therapy program specifically designed for children residing in institutional care settings. What distinguishes this intervention from others is its targeted focus on reducing learned helplessness and improving social comparison tendencies, two psychological constructs particularly relevant to children in residential care.~The program was conducted over six weekly sessions, each lasting approximately 60 minutes, and implemented in a one-on-one format within a safe, quiet room in the child care facility. The content was developmentally appropriate and included modules on emotional expression, communication, realistic goal setting, resource awareness, problem-solving, and positive self-perception. The therapeutic techniques were based on principles of non-directive and humanistic play therapy, allowing children to express themselves freely while being guided through structured themes.~Unlike general play therapy programs, this intervention"
223999633|NCT07138157|OTHER|External Focus Exercises|The commands given during the exercises will encourage the participants to focus their attention on the effect of the movement/ external focus of attention
223999634|NCT07138157|OTHER|Internal Focus Exercises|The commands given in the second group will encourage the participants to focus their attention on the body part performing the movement/ Internal focus of attention
223382988|NCT02096432|BEHAVIORAL|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
223382989|NCT02096432|BEHAVIORAL|Usual Community Care|Community standard care as usual
223382990|NCT01255137|DRUG|Axitinib|5 mg tab orally twice a day with food every 28 days
224123758|NCT06842693|BEHAVIORAL|Control|"Products carry neutral control label when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
223999635|NCT07136948|BEHAVIORAL|Mindfulness Meditation|Participants will be randomly assigned to one of two different 14-unit smartphone meditation program groups that involve completing a 2-10 minute daily guided practice on their phones. Participants in both groups will follow the same 14 units of mindfulness meditation curriculum that consists of learning and practicing techniques to improve concentration, sensory clarity, and equanimity (Equa meditation app) and have access to additional curriculum. Physiological measures will be tracked throughout the duration of lessons. The control group will not see the graph tracking their physiological responses or the predictive mindfulness skill scores based on the algorithm development.
223999636|NCT07136948|BEHAVIORAL|Mindfulness Meditation with Respiration Feedback Chart and Predictive Mindfulness Skill Scores|Participants will then be randomly assigned to one of two different 14-unit smartphone meditation program groups that involve completing a 2-10 minute daily guided practice on their phones. Participants in both groups will follow the same 14 units of mindfulness meditation curriculum that consists of learning and practicing techniques to improve concentration, sensory clarity, and equanimity (Equa meditation app) and have access to additional curriculum. Physiological measures will be tracked throughout the duration of lessons. Following the guided meditation lessons, a subset of participants (the experimental group) will see a graph tracking their physiological responses from the guided meditation lesson and predictive mindfulness skill scores based on our algorithm development. The feedback chart is produced by the physiological measures tracked throughout the duration of the lesson, and is displayed within the Equa app, moments after the meditation lessons concludes.
223999637|NCT07135882|COMBINATION_PRODUCT|Radiotherapy followed by chemotherapy|"Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.~Radiotherapy Techniques:~* Highly conformal techniques (IMRT/VMAT)~* High-precision techniques are allowed for non-centrally located primaries~Radiotherapy Dose:~\- Several fractionation schedules allowed; minimum biological effective dose approximating 50Gy (α/β ratio = 10); 50Gy in 20 fractions, 40Gy in 15 fractions, and 35Gy in 5 fractions"
224123759|NCT06842693|BEHAVIORAL|Chilean non-nutritive sweetener label|"Products carry rectangular label that states contains non-nutritive sweeteners, not recommended for children when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
223382991|NCT03473015|DEVICE|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
223382992|NCT00231543|PROCEDURE|Laparoscopic fundoplication|
223382993|NCT00231543|PROCEDURE|open Nissen fundoplication|
223382994|NCT00430066|DRUG|Imatinib Mesylate|400 mg/die for 6 months
223382995|NCT01332292|DRUG|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
223382996|NCT01332292|DRUG|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
223382997|NCT01319526|GENETIC|DNA analysis|
223382998|NCT01319526|GENETIC|RNA analysis|
223382999|NCT01319526|OTHER|laboratory biomarker analysis|
223383000|NCT03561324|DEVICE|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
223383001|NCT02054286|BIOLOGICAL|THV01-1|Intramuscular injection of THV01-1 (week 0)
223383002|NCT02054286|BIOLOGICAL|THV01-2|Intramuscular injection of THV01-2 (week 8)
224123760|NCT06842693|BEHAVIORAL|Colombian non-nutritive sweetener label|"Products carry octagonal label that states contains non-nutritive sweeteners  when containing non-nutritive sweeteners. Additionally, to match the current Chilean legislation, products carry an octagonal label that states high in sugar when high in added sugars, and/or an octagonal label that states high in calories when high in calorie density."
224123761|NCT06850870|OTHER|Door-through-door companion rideshare|Door-through-Door Companion Drivers, unlike traditional rideshare services, are certified in CPR and first aid, and undergo onboard training to support older adults, individuals with mobility impairments, and those with AD/ADRD. They are trained to observe behaviors of AD/ADRD patients, monitor and detect risk of falls, elopement, and other events that may require extra assistance or emergency care during transport. Drivers accompany riders continuously until they can hand off riders to clinicians or other caregivers, or return them to their home. Technology features in the rideshare platform enable continuity of care, for consistent rider-driver matching and matching of riders to drivers based on support needs.
224123762|NCT06850870|OTHER|Curb-to-curb rideshare services|Curb to curb rideshare services provided by a transportation network company (TNC) with drivers who don't have specialized training in supporting healthcare riders and who don't undergo fingerprint background checks or drug and alcohol testing.
223383003|NCT02054286|BIOLOGICAL|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
223383004|NCT03979755|OTHER|Application of questionnaires|Application of questionnaires described by telephone.
223383005|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention face-to-face|
223383006|NCT01652989|BEHAVIORAL|Weight loss maintenance intervention delivered via DVD|
223383007|NCT00102622|BIOLOGICAL|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m\^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
223999638|NCT07135882|DRUG|Standard of Care (SOC)|Standard of care (SoC) regimens available on the Australian PBS or relevant practice framework (Ireland and Canada) as per usual standard clinical practice are allowable in this protocol as SoC regimens.
223383008|NCT00102622|DRUG|Paclitaxel|80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
223383009|NCT03912935|OTHER|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
223383010|NCT03068728|DEVICE|Arista|
223999639|NCT07136831|DEVICE|Primary Percutaneous Coronary Intervention (PPCI)|A catheter-based invasive procedure used to open blocked coronary arteries in patients presenting with ST-elevation myocardial infarction (STEMI).
223383011|NCT03068728|DEVICE|Nexfoam|
223383012|NCT03068728|DEVICE|Nasopore|
223545344|NCT00941525|DRUG|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
223545345|NCT02871817|OTHER|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
223545346|NCT02955888|DRUG|PBI4050|Investigational Medicinal Product
223545347|NCT02955888|DRUG|Placebo|Comparator
223545348|NCT04532125|BIOLOGICAL|ARGX-117|Subjects treated with ARGX-117
223545349|NCT04532125|OTHER|Placebo|Subjects treated with placebo
223999640|NCT07135518|BEHAVIORAL|Compassion Focused Staff Support|The Compassion Focused Staff Support (CFSS) intervention is designed to promote emotional resilience, compassion, and affect regulation. The intervention begins with a half-day introductory workshop covering the evolution-informed model of emotion regulation, the three-affect system framework, social mentalities, and the nature of compassion. This workshop provides psychoeducation and experiential exercises to introduce key concepts. Following the workshop, staff participate in six monthly 60-minute team sessions over a six-month period. These sessions involve reflective dialogue, experiential exercises, compassion-focused practices, and group-based exploration of emotionally challenging work situations.
223999641|NCT07135518|BEHAVIORAL|CFT Workshop|Participants attend a single half-day workshop providing psychoeducation and experiential exercises on compassion, affect regulation, and social mentalities based on Compassion Focused Therapy.
223999642|NCT07136519|DRUG|Toripalimab|240mg Q3W
223999643|NCT07136519|DIETARY_SUPPLEMENT|Omega-3|During radiotherapy, take 6 capsules once a day
223999644|NCT07136519|RADIATION|radiotherapy|radiotherapy
223999645|NCT07136519|DRUG|Paclitaxel (albumin bound)|260mg/m2 d1,Q3W
223999646|NCT07136519|DRUG|Cisplatin|80mg/m2 d2, Q3W
223999647|NCT07137819|DRUG|Topical treatment|Self-treatment of patients with ointment of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
223999648|NCT07137299|OTHER|Questionnaire and Physical Exam|"All study participants will be evaluated to assess:~* Healing of the vaginal stump in the case of a total hysterectomy (normal/abnormal),~* Symptoms of stress urinary incontinence (Ingelmann-Sundber scale, where 0 - no symptoms, Grade I - symptoms with coughing, pressure on the suprapubic area, laughing, or strenuous exertion, Grade II - loss of urine when levering, running, or climbing stairs, Grade III - loss of urine when lying down or standing without physical exertion)~* Symptoms of an overactive bladder - present, absent~* Symptoms of prolapse in the anterior and posterior compartments (assessed based on the POPQ scale) with an assessment of the defect site based on the de Lancey classification The examination will be performed by or with the assistance of a specialist in obstetrics and gynecology"
223999649|NCT07135752|OTHER|Precision assessment|Digital tools, imaging markers and biological markers
223999650|NCT07136142|DRUG|FH-006 for Injection|FH-006 for injection.
223999651|NCT07137832|COMBINATION_PRODUCT|Intra-arterial thrombolysis as adjunct to endovascular treatment|Intra-arterial thrombolysis as adjunct to endovascular treatment, in addition to standard medical treatment
223999652|NCT07137832|OTHER|Standard medical treatment|Standard medical treatment
223383013|NCT05123378|BEHAVIORAL|Liberia National Community Health Assistant Program|Through the National Community Health Assistant Program (NCHAP), members of remote communities select Community Health Assistants (CHAs). Once selected, CHAs are trained to deliver direct services which include; treatment of diarrhea, ARI, and malaria following Integrated Community Case Management (iCCM) protocols, referrals for patients with clinical danger signs, family planning for women of childbearing age and birth preparedness and education for pregnant women. CHAs are also trained to deliver indirect services which include; health education, active surveillance, referral for mental health and other special conditions for all age groups. Since 2020 COVID-education has also been included in the CHAs work.
223383014|NCT02443597|OTHER|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
223383015|NCT03593889|BEHAVIORAL|Collaborative stepped care and peer support programme|"For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year."
223383016|NCT03593889|OTHER|Treatment as usual|The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
223383017|NCT06099392|DEVICE|digital stimulators (SNM-FDC01, Ningbo MaidaMedical Device, Inc, Ningbo, China)|TEA at Zusanli(ST 36) 45 min when drinking Polyethylene Glycol Electrolytes Powder
223383018|NCT01433367|DEVICE|CerPass® Total Disc Replacement|Single level cervical disc disease
223383019|NCT06577922|OTHER|Establishment of a simulation lab and provision of simulation based trainings|In each hospital, the investigators will perform an initial need assessment to identify the existing skills labs' space, equipment and trained human resources. Then, maternal and neonatal health simulation labs will be established in each hospital. One simulation lab will have 5 rooms- one auditorium hall, one debrief room, two simulation rooms, and one high fidelity simulation room. Equipment and manikins required for practicing maternal and neonatal health related skills will be installed in the simulation lab, along with guidance/ checklists for skills practice. After completion of lab set-up, trainings will be provided to trainers/ MNH staff of each hospital on simulation based methodology, especially focusing on Essential Care for Labor and Birth (ECLB), Bleeding after Birth (BAB), and Helping Babies Breathe (HBB) modules. Similarly, the investigators will also provide training for simulation lab operation and maintenance.
223999653|NCT07137975|OTHER|autogenous bone plug|"Preoperative assessment of the alveolar defect began with intraoral examination to check a proper transverse relationship between the maxillary segments and the presence of a normal upper arch form.~After the decision on alveolar bone grafting, Radiologic data from the cleft area will be required. Standard protocol is to take a high resolution CT scan of the patient's skull or at least the whole maxilla. Using the DICOM data acquired from the cleft area the bony defect will be segmented with specific software, in our daily routine blender for dental is used. The same program could be used to design the rough shape of the nasoalveolar graft, and this image could be exported in STL (standard tessellation language) format. and once the desired form is aquired, the final step is to construct a mold. For this purpose, the open-source software Blender (Blender Foundation, Amsterdam, and The Netherlands) will be used. After preoperative planning, the designed mold will be printed using polyam"
223999654|NCT07137975|OTHER|regular autogenous bone grafting|Gold standard grafting of alveolar cleft
223999655|NCT07135570|DIAGNOSTIC_TEST|Multimodal Screening for Eye Disease|The eye disease screening process involved twelve distinct steps were that organized through a corresponding software platform (electronic health record). These steps included: (1) community awareness campaign, (2) participant registration, (3) blood pressure and finger-stick blood glucose measurement, (4) basic vision test, (5) on-site optometrist evaluation, (6) obtaining informed consent for imaging, (7) fundus imaging, (8) automated AI-based disease detection, (9) on-site ophthalmologist examination, (10) remote eye specialist review, (11) on-site counselor discussion, (12) referral for local surgery. This standardized protocol promoted the alignment of eye screening with data gathering and ongoing follow-up eye care interventions. All participants were offered steps 1 to 5. Those participants eligible for fundus imaging (Steps 6-8) included those with diabetes, hypertension, age 50+, or optometrist recommendation based on presenting symptoms.
223999656|NCT07135570|PROCEDURE|cataract surgery|Individuals diagnosed with high grade cataracts associated with moderate to sever visual impairment were offered cataract surgery, either through local surgery services or regional specialized vision services.
223383020|NCT04304092|OTHER|Exercise|Participants will exercise under supervision. Exercise dose will vary by amount and intensity
223999657|NCT07136649|DEVICE|Custom CAD/CAM Insoles|Custom insoles will be designed using 3D plantar scanning and pedobarographic analysis, produced with CAD/CAM technology. The insoles will be fitted into participants' regular footwear and worn daily for eight consecutive weeks. The design aims to optimize plantar pressure distribution and improve foot biomechanics in individuals with foot deformities.
224123763|NCT07073976|DIAGNOSTIC_TEST|Transthoracic Echocardiography (TTE)|Non-invasive ultrasound imaging of the heart to evaluate right ventricular and right atrial function using parameters such as TAPSE, tricuspid S', RV-FAC, right atrial area, and pulmonary valve acceleration time. TTE will be performed once within 2 hours prior to extubation decision as part of routine care.
223383021|NCT03557112|DRUG|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
223383022|NCT03557112|DRUG|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
223383023|NCT02326636|BIOLOGICAL|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
223383024|NCT05983354|DRUG|Oral metoclopramide and ibuprofen|10 mg oral metoclopramide, 400 mg oral ibuprofen with 2 x 50 ml normal saline IV administered over 15 minutes.
223545350|NCT04532125|BIOLOGICAL|ARGX-117 + rHuPH20|Subjects treated with ARGX-117 + rHuPH20
223729872|NCT05086991|OTHER|Follow up|like group descriptions
224123764|NCT07075926|DIAGNOSTIC_TEST|Echocardiographic Assessment|"All participants will receive a standardized transthoracic echocardiographic (TTE) examination within 2 hours after meeting weaning criteria. The following cardiac function parameters will be recorded:~LVOT Velocity Time Integral (VTI)~Mitral Annular Plane Systolic Excursion (MAPSE)~E/e' ratio~E/A ratio~Mitral Deceleration Time (MDT)~Myocardial Performance Index (Tei index)~The echocardiographic data will be used to investigate the association between left ventricular function and weaning success."
223383025|NCT05983354|DRUG|Intravenous metoclopramide and ketorolac|10 mg of metoclopramide IV in 50 ml normal saline, 10 mg ketorolac IV in 50 ml normal saline administered over 15 minutes, with 2 placebo tablets.
223383026|NCT01497769|BIOLOGICAL|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10\^7 pfu and intradermal saline placebo
223383027|NCT01497769|BIOLOGICAL|Intradermal MVA85A|Intradermal MVA85A 1 x 10\^7 pfu and inhaled aerosol saline placebo
223383028|NCT00959478|BEHAVIORAL|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
224123765|NCT03471676|OTHER|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
223383029|NCT00302289|DRUG|tyrosine, green tea, caffeine|
223383030|NCT05298865|BEHAVIORAL|Positive imagination stimulation|The intervention messages aim to generate participants' positive mental image toward their life and also to relieve parental stress by shifting their attention to positive life events. The positive affect cues will be developed based on qualitative interviews with 30 parents from our previous study during pandemic and also extended literatures on positive psychology. Our previous qualitative interview aimed to understand parental concerns on flu and COVID-19 vaccination, parental life stressors throughout the pandemic were also explored. The positive cues will be discussed and evaluated by the research team with an aim to cover major positive life events that are personal relevant to parents, including positive social support (friendship), positive family support (family gathering), qualified time spent with children (here we will also embed a gratitude practice to elicit strong positive feelings), and cultivate positive self by imagining achieving personal goals in the future.
224123766|NCT06821555|BEHAVIORAL|Nutrition and Physical Activity Education with Mindful Eating Intervention|Mindful Eating Intervention applied to Obesity treatment for Adolescent alongside with Nutrition and Physical Activity Education from Nutritionist and Psychologist
224123767|NCT06821555|BEHAVIORAL|Nutrition and Physical Activity Education|Nutrition and physical activity education from Nutritionist applied as Obesity treatment for Adolescent
223383031|NCT05298865|BEHAVIORAL|Neutral recall message|The control message aims to equate time and attention as in the intervention group. Therefore, a recall task will be assigned to participants. Brief texts will be provided to guide participants to memorize their life senarios but not to induce emotions. Messages include the following: recall the breakfast and lunch you had yesterday; recall the clothes and shoes you wore yesterday; recall the kitchen in your home; recall one of the chairs in your home; recall the routes to the nearest supermarket and subway of your house.
223383032|NCT01772290|DRUG|fluconazole|Multiple oral doses
223383033|NCT01772290|DRUG|itraconazole|Multiple oral doses
223999658|NCT07136506|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
223999659|NCT07136506|OTHER|Post-recording questionnaire|The post-recording questionnaire aims at describing as much as possible the subject activity and quality of life during the recording period while being as low a burden as possible for the subject. The question formats are, on one hand, inspired by Quality of life and Physical Activity questionnaires usually used in Clinical Research and, on the other hand, based on device-specific needs for an optimal analysis. It covers fatigue status, physical status, physical activity with the Syde®, event(s) or condition(s) that may have impacted the ability to wear the Syde® during the recording.
223999660|NCT07137559|DRUG|CELZ-201-DDT|"CELZ-201-DDT is administered via intramuscular injection.~Dosing, administration, and follow-up will be determined by the treating physician in accordance with the EA authorization and medical judgment. Safety monitoring will be performed during and after treatment, and all serious adverse events will be reported to the FDA and IRB per applicable regulations."
224123768|NCT05094362|BEHAVIORAL|Spinal Reflex Operant Down Conditioning|This is a training intervention in which people with a spinal cord injury are trained to reduce the activity of a certain spinal reflex. By decreasing this reflex, individuals decrease hyperactivity in the reflex and can reduce spasticity.
224123769|NCT07162051|DRUG|Fuzaparib|"Folfoxapril:~Take 2 times a day (once in the morning and once in the evening, 150mg in the morning and 100mg in the evening; vice versa is also acceptable). Each 3-week period constitutes one cycle. For the first to fourth cycles, a total of 4 cycles are required."
223383034|NCT01772290|DRUG|rabeprazole|Multiple oral doses
223383035|NCT01772290|DRUG|vismodegib|Multiple oral doses
223383036|NCT00728234|DEVICE|aEEG recording|weekly recordings with aEEG
223545351|NCT04532125|OTHER|placebo + rHuPH20|Subjects treated with placebo + rHuPH20
223545352|NCT04532125|BIOLOGICAL|ARGX-117 PH20 SC|Subjects treated with ARGX-117 PH20 SC
224123770|NCT07162051|OTHER|standard chemotherapy|standard chemotherapy
223383037|NCT04650204|DRUG|Anticonvulsant Agent|Given ASD
223545353|NCT04532125|OTHER|Placebo PH20 SC|Subjects treated with placebo PH20 SC
223545354|NCT03394781|DRUG|DUR-928|oral suspension daily for 28 days
223729873|NCT04546945|DIAGNOSTIC_TEST|CD56|detection of CD56 by flow cytometry
223383038|NCT04650204|DRUG|Perampanel|Given PO
223999661|NCT07137949|BEHAVIORAL|Music therapy|Live music therapy (MT) sessions will occur 3 times/week, up to 5 sessions. Sessions will be responsive to patient preferences, culture, and identity using information gained from medical record review, intake assessment, and in the moment therapeutic assessments.
223383039|NCT04650204|OTHER|Quality-of-Life Assessment|Ancillary studies
223383040|NCT04650204|OTHER|Questionnaire Administration|Ancillary studies
223729874|NCT05322876|BEHAVIORAL|Healthy Hearts Family Program|Participants will participate in a baseline health and knowledge screening, followed by a 6-week once-weekly class series, and 3- and 6-month follow-up health and knowledge screenings.
223999662|NCT07135635|DIAGNOSTIC_TEST|Middle Cerebral Artery doppler|All cases of pregnant women diagnosed with anemia at 3rd trimester will have baseline assessment of history, clinical examination, HB level, obstetric ultrasonography done then they will have Middle Cerebral Artery Doppler done to assess correlation between MCA Doppler indices \& neonatal outcomes. Then appropriate treatment of anemia will be taken.
223999663|NCT07136363|DEVICE|DynamiCare|DynamiCare is a mobile contingency management (CM) platform. Participants randomized to this intervention receive access to the DynamiCare app, an FDA-approved mobile application that delivers CM through features such as at-home saliva drug testing, appointment check-ins, and incentives for healthy behaviors. The app is designed to promote substance use reduction and engagement in care by providing financial rewards for meeting health-related goals. The intervention aims to improve initiation and retention in HIV prevention or treatment (PrEP or ART), reduce stimulant use, and enhance overall health outcomes among justice-involved individuals.
223999664|NCT07136363|BEHAVIORAL|Patient Navigation (PN)|Participants work with a trained patient navigator (PN) who provides individualized support, assists with linkage to medical and social services, and helps address barriers to care. The PN meets with participants weekly during the first month and biweekly thereafter to conduct a comprehensive needs assessment and provide tailored support. This includes assistance with obtaining housing, identification, insurance, transportation, and linkage to health and social services such as HIV prevention or treatment (PrEP/ART), substance use disorder treatment, and other community-based care. The navigation protocol follows established procedures from prior studies (e.g., ACTION). All participants receive a smartphone to support communication and appointment coordination.
223999665|NCT07135622|DIAGNOSTIC_TEST|Xpert® MTB/RIF Ultra|Xpert® MTB/RIF Ultra test introduced for tuberculosis diagnosis at clinical trial sites randomized to interventional arm
223999666|NCT07135622|OTHER|Referral to the specialized TB clinics|No intervention introduced at clinical trial sites randomized to control arm, patients follow standard care: referral to specialized TB clinics
224123771|NCT07162831|BEHAVIORAL|Mio-Training|The Mio-Training aims to increase metacognitive knowledge, teaches mnemonic skills, trains the working memory capacity and coordinative skills to strenghten cognitive development in children and adolescents with ADHD.
224123772|NCT07163130|DEVICE|Transcutaneous auricular vagus nerve stimulation|"Transcutaneous auricular vagus nerve stimulation (tVNS) is an emerging therapeutic modality in cardiovascular diseases. tVNS has been shown to exert antiadrenergic and anti-inflammatory effects in humans. Recently, tVNS has been tested in experimental and human POTS, leading to improved autonomic function, reduction of anti-autonomic autoantibodies and inflammatory cytokines.~Parasym device; Parasym Health, London, United Kingdom Frequency: 20Hz, pulse width: 200μs, amplitude will be individually titrated to 1 mA below the level that caused mild discomfort."
224123773|NCT07162155|BEHAVIORAL|School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse|Psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription drug misuse among upper elementary school students.
223383041|NCT01330303|DRUG|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
223383042|NCT01330303|DRUG|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
223383043|NCT01107197|DIETARY_SUPPLEMENT|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
223383044|NCT01107197|DIETARY_SUPPLEMENT|Control formula|Isonitrogenous isocaloric oral formula
223383045|NCT01708551|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223729875|NCT00272467|DRUG|Rebamipide|"1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals"
223999667|NCT07136922|COMBINATION_PRODUCT|400mg progesterone Callavid - 2hr wear|400mg progesterone Callavid, 2 hour wear, twice daily for 7 days
223999668|NCT07136922|DRUG|Cyclogest 400 mg|Cyclogest 400 mg pessary, twice daily for 7 days
223999669|NCT07136922|COMBINATION_PRODUCT|400mg progesterone Callavid - 3hr wear|400mg progesterone Callavid, 3 hour wear, twice daily for 7 days
223999670|NCT07138170|PROCEDURE|Proximal Radial Artery Access|Using Proximal Radial Artery Access for Cardiac Catheterization
223999671|NCT07138170|PROCEDURE|Distal Radial Artery Access|Using Distal Radial Artery access for Cardiac Catheterization
223383046|NCT00997867|PROCEDURE|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
223383047|NCT06613568|DEVICE|Moda-flx Hemodialysis System™|The Moda-flx Hemodialysis System™ is a portable hemodialysis system
223383048|NCT04304040|DRUG|Orelabrutinib|BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
223383049|NCT04304040|DRUG|Recombinant humanized monoclonal antibody MIL62 injection|Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.
223383050|NCT04928716|OTHER|voiding phase evaluation|Assessment of voiding phase in multiple sclerosis patients
223383051|NCT03448887|DEVICE|Theranova|Extended HD with theranova
223383052|NCT03448887|DEVICE|Online hemodiafiltration|Online hemodiafiltration
223383053|NCT04691154|COMBINATION_PRODUCT|L606 inhalation suspension|L606 inhalation suspension, twice daily dosing
223383054|NCT03403647|DIETARY_SUPPLEMENT|Vitamin D|Oral daily vitamin D
223383055|NCT00386347|DRUG|GSK364735 oral solution and oral tablets|
223383056|NCT03511092|DIETARY_SUPPLEMENT|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
223999672|NCT07136935|DRUG|Traditional Chinese Medicine treatment|"1. Oral Chinese herbal medicine or decoction: prescribe Chinese medicine based on syndrome differentiation and treatment of the patient's condition.~2. Acupuncture or laser acupuncture treatment: Traditional Chinese medicine practitioners select acupuncture points to treat based on the patient's condition, and treat them once a week.~3. Acupoint massage: Select treatment acupoints and techniques according to the patient's condition, 20 minutes at a time.~4. Traditional Chinese Medicine Cake Acupoint Application: Warm Navel Cream to the CV-4 (Guanyuan) acupoint, the application time is 2 to 4 hours.~5. Nursing and health education and guidance.~6. Dietary hygiene education: personalized western nutrition and TCM dietary guidance suggestions based on TCM constitution syndromes.~7. Lifestyle health education and sports rehabilitation: Playing Baduanjin, ten skilled hand exercise, and health preservation videos, and providing personalized TCM exercise recommendations."
223999673|NCT07136428|COMBINATION_PRODUCT|Asciminib and Trastuzumab|Each study treatment cycle will last 21 days. Asciminib will be taken orally every day during the treatment period at the dose determined as the MTD during the safety lead-in in combination with trastuzumab at a standard dose of 6mg/kg IV. Asciminib dose will begin at 80 mg daily (dose level 1), with a potential range from 40 mg daily (dose level -1A, with trastuzumab) to 200 mg bid (dose level 3, with trastuzumab) depending on the results of the safety lead-in. Trastuzumab will be given intravenously (IV) or subcutaneously (SQ) on Day 1 of each 21 day cycle.
223999674|NCT07135661|RADIATION|moderate hypofractionated proton radiotherapy|moderate hypofractionated proton radiotherapy: Whole Breast Irradiation, at 40 Gy(RBE) in 15 fractions, tumor bed SIB to 48Gy(RBE)
223999675|NCT07135661|RADIATION|ultra-hypofractionated proton radiotherapy|Ultra-hypofractionated proton radiotherapy:Whole breast radiotherapy, 26 Gy(RBE) in 5 fractions，tumor bed boost with 10Gy(RBE) in 2 fractions.
223999676|NCT07137897|OTHER|Telerehabilitation|"Telerehabilitation involves a physiotherapy program delivered remotely using digital tools. Participants perform exercises independently with remote support from a physiotherapist, including:~Weekly scheduled phone consultations~Live virtual consultations via MS Teams, Zoom, or Skype~Text messages and emails for personalized guidance, motivation, and ongoing problem-solving~The intervention includes targeted exercises for:~Core muscle strength~Strengthening of lower extremity muscles~Mobility exercises for the hip, knee, and ankle joints~Balance and stabilization exercises~Each session lasts approximately 20-25 minutes, performed three times per week. Patients can choose the days for their sessions, with the requirement of a minimum of 24 hours and a maximum of 72 hours of rest between sessions.~The intervention will last for at least three months."
223999677|NCT07137897|OTHER|Control group|"Patients in the control group will receive written instructions for a home exercise program. They will independently perform the rehabilitation program at home without remote supervision.~The intervention includes targeted exercises for:~Core muscle strength~Strengthening of lower extremity muscles~Mobility exercises for the hip, knee, and ankle joints~Balance and stabilization exercises~Each session lasts approximately 20-25 minutes, performed three times per week. Patients can choose the days for their sessions, with the requirement of a minimum of 24 hours and a maximum of 72 hours of rest between sessions.~The intervention will last for at least three months."
223999678|NCT07138183|BEHAVIORAL|NP-led MDT|a nurse practitioner-led multidisciplinary team (MDT).
223999679|NCT07138183|BEHAVIORAL|Usual Care|Participants will receive usual inpatient care provided by the primary care team.
223999680|NCT07137715|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
224123774|NCT07161726|COMBINATION_PRODUCT|(-)-Epicatechin-rich cocoa supplementation combined with exercise training|12 weeks of daily cocoa (2 capsules/d containing 450 mg cocoa flavanols/d, including 80 mg of (-)-epicatechin) combined with aerobic (30min of moderate-intensity walking) and resistance (30 min of whole-body workout) exercise training 3 times a week
224123775|NCT07161726|COMBINATION_PRODUCT|Placebo combined with exercise training|12 weeks of placebo (alike-looking cellulose-based capsules) combined with aerobic (30min of moderate-intensity walking) and resistance (30 min of whole-body workout) exercise training 3 times a week
224123776|NCT07161674|BEHAVIORAL|Digital health literacy program|A 6-week digital health literacy program delivered through weekly face-to-face training sessions and WhatsApp activities. Additional support may be provided if needed.
223383057|NCT03511092|DIETARY_SUPPLEMENT|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
223383058|NCT03511092|DIETARY_SUPPLEMENT|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
223383059|NCT03511092|OTHER|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
223383060|NCT04983186|DEVICE|Wearable sensor and smartphone application|Empatica E4 wearable sensor and custom-made headache smartphone application
223383061|NCT04796298|PROCEDURE|Ballistic Hamstring Stretching|Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.
223999681|NCT07137715|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
223999682|NCT07137715|OTHER|Usual Care|Participants will be asked to continue to do whatever they are currently doing to manage their pain.
223999683|NCT07138300|DEVICE|Low Level Laser Therapy by (Eme Physio, Lasermed 2200), GaAs laser, 1 cm2 beam area,7,000 Hz, 17 mW, 1 J/cm2, Pesaro, Italy)|"(Eme Physio, Lasermed 2200), GaAs laser, 1 cm2 beam area,7,000 Hz, 17 mW, 1 J/cm2, Pesaro, Italy) .~Patient lies in side lying on the non-affected side which is opposite to the side of radicular pain, hip and knee in flexion 90. Twenty points were established for treatment, 12 over the lumbar spine, at the same Side of the radicular pain, from l2 to s1 vertebra, distance between these points is 2 cm. In the thigh, eight points were marked at equal distances from each other, four in the path of l5 root and four in the path of s1 root from hip to knee. The leaser probe is held in 90 degree over the skin with complete skin contact"
223383062|NCT04796298|PROCEDURE|Hamstring Extender Exercise|Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.
223999684|NCT07138300|PROCEDURE|neural mobilization|"Mobilization will be through using slump sitting maneuver (Both techniques slider and tensioner.~•The slider neurodynamic mobilization technique: The patient moves actively and conversely from a position of neck and trunk flexion, knee flexion, and ankle plantar flexion, to a position of neck and trunk extension, knee extension and ankle dorsiflexion~The tension neurodynamic mobilization technique:~The patient moves actively and conversely from a position of neck and trunk extension, knee flexion, and ankle plantar flexion, to a position of neck and trunk flexion, knee extension, and ankle dorsiflexion"
223999685|NCT07138300|OTHER|placebo laser therapy|patients receive the same treatment on the same area as experimental group for the same period without turning on the device.
223999686|NCT07136415|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-i)|This is a program called SHUT-i and is composed of six self-guided sessions on a website over 6-9 weeks. Each session will be about 45-60 minutes long. CBT-I involves changing behaviors that cause sleep problems to persist. However, it also includes teaching skills to teach the participant to identify thoughts and feelings that may contribute to sleep problems.
223383063|NCT04796298|PROCEDURE|Kinesiotape|Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
223383064|NCT05745597|OTHER|Follow up|Four samples of cervical exfoliated cells and fornix secretions were collected from all subjects at enrollment, 6 months, 12 months and 24 months for HPV integration status and vaginal microbiota diversity sequencing, and two additional samples of peripheral blood (whole blood + serum) were collected at enrollment.
223999687|NCT07136415|DRUG|Trazodone|"Trazodone is a heterocyclic medication that is FDA-approved for depression (starting dose 150mg). An estimated 4 in 5 trazodone prescriptions are for insomnia. Low-dose trazodone's frequent off-label use stems from a long-standing perception that trazodone is an effective and safer sleep aid compared to other drugs despite potential risks documented in small studies.~A starting dosage of 25 mg will be used. After 1 week, patients will be instructed to increase the dose as needed to 50mg if tolerated. A second dose adjustment will be made at 4 weeks. At four weeks, study staff will contact participants and review medication adherence, and a standardized checklist will be used to assess ongoing symptoms and side effects and to consider an increase in dose to 100mg."
223999688|NCT07136415|DRUG|Daridorexant|"Daridorexant is a DORA drug. Dual orexin receptor antagonists (DORAs) are the newest class of FDA-approved medications for insomnia based on efficacy data from pivotal clinical trials demonstrating their efficacy for sleep onset and maintenance.~A single dose of 50 mg (1 pill each night within 30 minutes of bedtime) was selected based on better efficacy without evidence of higher risks than the 25mg dose."
223999689|NCT07136337|DIAGNOSTIC_TEST|4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by|4 ml. of fresh venous blood will be collected from each patient on EDTA tube and will be used for detection of the following : T cell immunoglobulin G ( TIgG) and T cell immunoglobulin M (TIgM) by flow cytometry
223999690|NCT07135232|DIETARY_SUPPLEMENT|Sarmentosin - L- theanine|A capsule containing 275.184 mg of Sarmentosin and 400mg of L-theanine
224123777|NCT07164066|DEVICE|Digital Occlusal Analysis Device|Computerized occlusal analysis performed using T-Scan and ModJaw devices to record occlusal contacts, timing, and force distribution during prosthesis fitting and function.
223383065|NCT00727597|DRUG|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
223545355|NCT04971967|COMBINATION_PRODUCT|Crowdsourced partner services intervention|The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
223545356|NCT02353858|OTHER|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
223999691|NCT07135232|OTHER|Resistance Training|Home-based Resistance training. Exercises will target the lower and upper body and utilise body weight, resistance bands, dumbbells and push-up handles.
224123778|NCT07162142|PROCEDURE|elastic nailing with pollar K.wire|retrograde elastic nailing of metaphyseal diaphyseal fracture of distal radius in pediatrics
224123779|NCT07162636|OTHER|NMES+|To treat and rehabilitate sarcopenia, participants will undergo physical therapy sessions, using resistance exercises combined with the use of NMES
224123780|NCT07162636|OTHER|NMES -|To treat and rehabilitate sarcopenia, participants will undergo physical therapy sessions using only resistance exercises.
224123781|NCT07161973|DIETARY_SUPPLEMENT|Beetroot Juice - Active|Nitrate-rich beetroot juice
224123782|NCT07161973|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Without Nitrate|Nitrate-free beetroot juice
223383066|NCT00727597|DRUG|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~* To resolve a Grade 3 or 4 Adverse Event~* The subject experienced a virologic failure (as defined in section 3.6.2)~* The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~* The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
223383067|NCT04449211|DEVICE|Implantation|Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
223383068|NCT03305627|OTHER|Short PAP|Perioperative antibiotic prophylaxis for 24h
223383069|NCT03305627|OTHER|Extended PAP|Perioperative antibiotic prophylaxis for \>48h
223999692|NCT07135232|DIETARY_SUPPLEMENT|Placebo Supplement|Capsule matched for taste and appearance, without any active ingredients.
223999693|NCT07137078|OTHER|pilates|"Pilates exercises, particularly those focusing on core stability, balance, and flexibility, are highly beneficial for individuals at risk of falls. These exercises enhance proprioception, which is the body's ability to sense movement, action, and location, thereby improving coordination and balance. For example, exercises like the Single Leg Stretch and Roll-Up target the abdominal muscles, which are crucial for maintaining stability. Additionally, Leg Circles and Side Planks help strengthen hip abductors and stabilizers, contributing to better postural alignment and reducing the likelihood of falls. By regularly incorporating Pilates into a fitness routine, individuals can build strength and confidence, ultimately helping to prevent falls and maintain independence."
223999694|NCT07137078|OTHER|gyrotonic expansion exercise|Exercise phase Training Time Warm-Up Gentle, dynamic stretches focusing on the spine, hips, and legs. Gently roll the head from side to side to release tension, Move shoulders in a circular motion to loosen muscles, While standing, rotate the torso gently from side to side, Rotate each ankle in both directions to improve mobility. 5 minutes Core Activation Using pulley rope system the Arch and Curl, to engage the abdominal muscles, Focus on maintaining proper alignment and breathing deeply. 13 minutes Balance and Coordination Using pulley rope system Standing Series, shifting weight, such as the Spiral Sequence, to improve coordination. 12 minutes Flexibility and Range of Motion Leg stretches using the Leg Extension Unit to improve hip and knee range of motion. 5 minutes
223999695|NCT07137104|DRUG|HeXell-2020|"Phase I Cohort 1: HeXell-2020 with a total of 3 doses, 9x10\^7 cells/dose.~Phase I Cohort 2: HeXell-2020 with a total of 6 doses, 9x10\^7 cells/dose.~Phase IIa: RP2D from phase I."
224123783|NCT07163013|OTHER|Digital cognitive behavioral therapy(DCBT)|Moca is a mobile application designed to deliver structural CBT for adolescents with mood problems. Moca provides six-twelve guided sessions with an estimated proceeding duration of 25-45min each, developed to be processed weekly. The content of each session includes the introduction of the core concepts and principles of CBT, psychological counseling dialogue, skill exercises, and homework. Content presentation forms include text, animation, audio, comics, etc. At the end of each module, the participants will be asked to submit homework that will ask them to apply their learned skills to nursing or daily life situations that they personally perceive as stressful. Participants can review the completed sessions and record their mood status during the intervention period.
224123784|NCT07163013|OTHER|Regular mental health curriculum|The content of regular mental health curriculum includes mental health education lecture. Few lectures address the knowledge and skills involved in CBT in such education lecture.
224123785|NCT07162662|DIETARY_SUPPLEMENT|Oral Sialic acid|This study employs a before-after self-control trial design, recruiting 42 volunteers to take oral sialic acid and collecting fecal samples before and after the intervention.
224123786|NCT07162532|DIAGNOSTIC_TEST|1 Complete blood picture (CBC) with blood film, lymphocytic count 2 and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests ,deletion 17p,IGVH mutation,ESR|Complete blood picture (CBC) with blood film, lymphocytic count 2 Routine liver and kidney function and viral hepatitis 3 Immunophenotyping 4 LDH 5 Coomb's tests 6 Erythrocyte sedimentation rate (ESR). 7 C reactive protein (CRP). 8 Cytogenetic profiles: del(17p) 9 molecular study :IGHV mutation status.
224123787|NCT07163377|OTHER|Experimental Group|Participants in the intervention group will undergo art therapy sessions
223383070|NCT03640416|DEVICE|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
223383071|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
223383072|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
223383073|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
223383074|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359.
223383075|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.
223383076|NCT05546268|DRUG|Oral MRT-2359|Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.
223545357|NCT02353858|RADIATION|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
223545358|NCT02353858|DRUG|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
224123788|NCT07162116|DRUG|XY0206|12.5 mg/table,On the morning of the day of dosing , subjects received XY0206 tablets orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg)；Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg)；Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
224123789|NCT07162116|DRUG|Moxifloxacin (400 mg)|400mg，On the morning of the day of dosing , subjects received moxifloxacin orally on an empty stomach
223545359|NCT01078792|OTHER|CT pulmonary angio, blood tests|
223999696|NCT07138378|DRUG|XS003 (nilotinib)|To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
223999697|NCT07138378|DRUG|Tasigna (nilotinib)|To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
223999698|NCT07137871|DRUG|Avasopasem|Avasopasem has also been shown to exhibit both antitumor effects as well as minimal toxicity. Participants are currently taking a CDK 4/6 inhibitor and hormonal therapy
223999699|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
223999700|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
223999701|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
223999702|NCT07136389|DRUG|Divozilimab|Ant-CD0 human monoclonal antibody, Concentrate for solution for infusion intravenously
223999703|NCT07136389|DRUG|BCD-256|Anti-BDCA2 human monoclonal antibody, concentrate for solution for infusion intravenously
223999704|NCT07027982|DRUG|Diluted Intravenous DA-5217|once a day
223999705|NCT07027982|DRUG|Undiluted Intravenous DA-5217|once a day
223999706|NCT02169310|DEVICE|tDCS|There is no study intervention for Experiment 1. The study intervention for Experiment 2 is tDCS. tDCS is a non-invasive brain stimulation technique that uses electrodes attached to the scalp to deliver very low intensity direct current to the brain. This intervention has been demonstrated to result in neuromodulatory effects.
223999707|NCT02169310|DRUG|[11C] Raclopride|\[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
223999708|NCT07049562|DRUG|HRS-8427|\[14C\] HRS-8427 for injection
223999709|NCT07050290|PROCEDURE|Restoring segmental lordosis at the lumbar spine|All patients will undergo restoring segmental lordosis via one previous posterior approach after failed fusion at the same level.
223999710|NCT07045441|OTHER|Conservative Management for TMD|This intervention includes a standardized conservative treatment protocol for TMDs, comprising splint therapy and a structured counseling program. The counseling covers education on diagnosis, medication adherence, dietary modifications, posture and behavior correction, sleep hygiene, parafunctional habit avoidance, physiotherapy exercises, pain and stress management, and importance of follow-up visits. Patients receive individualized instructions and monitoring as part of their routine clinical care. Adherence to these components is measured after 6 months of treatment using a validated adherence questionnaire.
223999711|NCT07048912|DIETARY_SUPPLEMENT|Beetroot Juice (BJ)|This intervention involves a single 140 mL dose of a commercially available concentrated beetroot juice supplement (Beet-It Pro Elite Shot, James White Drinks Ltd., UK), containing approximately 12.8 mmol (800 mg) of dietary nitrate. Participants consume the juice 2.5 hours prior to performing a 30-second Wingate anaerobic test. The purpose of this intervention is to examine its acute effects on anaerobic performance, muscle oxygenation, and metabolic responses.
223999712|NCT07048912|DIETARY_SUPPLEMENT|Blackcurrant Juice (Placebo)|This intervention involves a single 140 mL dose of a low-calorie blackcurrant juice (Pfanner, Austria) with negligible nitrate content (\<0.1 mmol). The placebo is matched to beetroot juice in appearance, taste, and packaging to ensure double-blind conditions. It is consumed 2.5 hours before the Wingate test and serves as the control condition.
223999713|NCT07046611|DRUG|Ketamine|Intravenous ketamine (5 mg/ml concentration) 2 mg/kg (max 90 mg) over 2 minutes
223999714|NCT07046611|DRUG|Levetiracetam|Intravenous levetiracetam (50 mg/ml concentration) 60 mg/kg (max 4500 mg) over 5 minutes
223999715|NCT07046611|DRUG|Placebo|Intravenous isotonic saline 0.4 mL/kg (maximum 18 mL) over 2 minutes
223545360|NCT00720694|DEVICE|Duolith SD1|
223999716|NCT07049289|OTHER|Telemonitoring|Patients randomized to intervention group will receive biweeky telephone calls and adaption of antiyhpertensive medication if needed
223545361|NCT00720694|DEVICE|Sham Duolith SD1|
223545362|NCT03584048|OTHER|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
223545363|NCT05136222|OTHER|Intervention polysomnography|Please refer to 'Arms: Intervention' section.
223545364|NCT05136222|OTHER|Sham polysomnography|Please refer to 'Arms: Control' section.
223545365|NCT04645992|DEVICE|active TENS|study group will receive only one session of yoga eye exercise for 20 minutes followed by TENS by placing electrodes on skin over urinary bladder (BL) acupoints 61 and 62 for 20 minutes
223545366|NCT04645992|DEVICE|sham TENS|control group will be treated with the same protocol as the study group but with the TENS unit is off .
223545367|NCT00876863|DRUG|CERE-110: Adeno-Associated Virus injection Surgery|Injecting CERE-110 2.0 X 10\^11 vg into brain during surgical procedure.
223545368|NCT00876863|PROCEDURE|Placebo Surgery|Placebo Surgery
223545369|NCT03134391|DRUG|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
223545370|NCT00725686|DRUG|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
223545371|NCT01456793|BEHAVIORAL|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
223545372|NCT05026151|OTHER|Nutrition therapy according to ICU protocol|The study aims a verifying adherence to the ICU nutrition protocol
223545373|NCT00535769|DEVICE|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
223383077|NCT07140419|DIAGNOSTIC_TEST|Coronary computed tomographic angiography with CT - derived fractional flow reserve|A non-invasive coronary computed tomography angiography (CCTA) protocol that visualizes coronary anatomy to evaluate the presence, location, and severity of atherosclerotic stenosis, coupled with CT-derived fractional flow reserve (CT-FFR) analysis-a computational fluid dynamics method applied to CCTA datasets-to assess the hemodynamic significance of identified stenoses and identify lesions likely to induce myocardial ischemia.
223383078|NCT02167334|DEVICE|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
223999717|NCT07051044|DIAGNOSTIC_TEST|AIR-DS|AIR-DS is a supportive, non-diagnostic, risk-indicating software that assists healthcare providers in the early detection and risk assessment of lung cancer in high-risk populations, aiming to improve the cost-effectiveness and accessibility of lung cancer screening. It is imperative to note that the efficacy of the AIR-DS may be affected by the completeness and accuracy of the input data. Hence, any missing data fields should be identified, as they could impact the risk assessment's accuracy.
223999718|NCT04047862|DRUG|Ociperlimab|Administered as an intravenous (IV) injection
223999719|NCT04047862|DRUG|Tislelizumab|Administered as an IV injection
223999720|NCT04047862|DRUG|Pemetrexed|Administered in accordance with local guidelines, prescribing information/summary of product
223999721|NCT04047862|DRUG|Paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
223999722|NCT04047862|DRUG|Nab paclitaxel|Administered in accordance with local guidelines , prescribing information/summary of product
223999723|NCT04047862|DRUG|Carboplatin|Administered in accordance with local guidelines , prescribing information/summary of product
223999724|NCT04047862|DRUG|Cisplatin|Administered in accordance with local guidelines , prescribing information/summary of product
223999725|NCT04047862|DRUG|Etoposide|Administered in accordance with local guidelines , prescribing information/summary of product
223999726|NCT04047862|DRUG|5fluorouracil|Administered in accordance with local guidelines , prescribing information/summary of product
223999727|NCT04047862|DRUG|Oxaliplatin|Administered in accordance with local guidelines , prescribing information/summary of product
223999728|NCT04047862|DRUG|Capecitabine|Administered in accordance with local guidelines , prescribing information/summary of product
223999729|NCT07050927|BEHAVIORAL|Online occupational therapy group training|The intervention is a 4-week online parent training program based on occupational therapy principles, delivered via secure Zoom sessions once per week. Each session lasts approximately 60-75 minutes and focuses on topics such as feeding skill development, sensory-based feeding difficulties, responsive parenting strategies, and stress management techniques. The training includes interactive discussions and practical suggestions for daily feeding routines. Supporting materials, such as PDF slides and short demonstration videos, are shared with participants after each session. Attendance in at least three sessions is required to remain in the study.
223999730|NCT06737705|DRUG|Baritinib|Participants will receive additional baritinib administration with 4-mg dosage once daily (QD) for consecutive 14 days after randomization (adjusted dosage of 2-mg QD for participants with eGFR between 30-60 mL/min/1.73m\^2).
223999731|NCT06889038|OTHER|Hyperbaric oxygen therapy combined with polarized light therapy|Optimum regime of therapy increase healing rate of neuropathic foot ulcer is a challenge for researchers to save patient normal life
223999732|NCT06889038|OTHER|traditional treatment|topical medication
223999733|NCT07050511|DRUG|GB-0669|Single IV infusion of GB-0669.
223999734|NCT07050511|DRUG|Placebo|Single IV infusion of placebo. Sterile 0.9% (w/v) sodium chloride solution.
223999735|NCT07049991|PROCEDURE|surgical or percutaneous heart valve replacement.|para-prosthetic heart valve leakage after after surgical or percutaneous heart valve replacement
224123790|NCT07162116|OTHER|XY0206 Placebo|12.5mg/table,On the morning of the day of dosing, subjects received XY0206 placebo orally on an empty stomach.Each group of 15 subjects was randomly assigned in a 3:1:1 ratio, with 9 receiving XY0206, 3 receiving a placebo of XY0206, and 3 receiving moxifloxacin.Group A (XY0206 tablets: 37.5 mg; moxifloxacin : 400 mg; placebo: 37.5 mg)；Group B(XY0206 tablets: 75 mg; moxifloxacin : 400 mg; placebo: 150mg)；Group C(XY0206 tablets:150 mg; moxifloxacin : 400 mg; placebo: 150mg)
224123791|NCT07163676|BEHAVIORAL|Baduanjin exercise|group I will receive baduanjin exercise for 60 minutes every day ((except fridays) for eight weeks.
224123792|NCT07162259|DRUG|First-line T-DXd followed by SG upon disease progression|Patients will be assigned to Cohort 1 (HER2 IHC 2+) based on different HER2 immunohistochemical expression levels, where they will first receive T-DXd treatment, followed by SG treatment upon disease progression.
223383079|NCT02167334|PROCEDURE|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
223383080|NCT07154446|DRUG|Parestat(generic parecoxib)|This arm will receive IV Parestat 40mg during surgery
223999736|NCT07052695|DRUG|Mosunetuzumab|Subcutaneous injection of a CD20xCD3 bispecific antibody
223999737|NCT07052695|DRUG|Ibrutinib|For participants who have been ibrutinib PO prior to enrollment
223999738|NCT07052695|DRUG|Acalabrutinib|For participants who have been acalabrutinib PO prior to enrollment
223999739|NCT07052695|DRUG|Zanubrutinib|For participants who have been zanubrutinib PO prior to enrollment
223999740|NCT07052695|DRUG|Pirtobrutinib|For participants who have been pirtobrutinib PO prior to enrollment
223999741|NCT07051070|DRUG|RTX treatment|This study used a drug dosage based on previous domestic and international literature as well as clinical experience from our center, set at 375mg/m2 per dose. During the course of the disease, TB lymphocyte subsets are monitored, and if the proportion of B lymphocytes is greater than or equal to 1%, a second dose will be administered.
223999742|NCT06794775|DRUG|Nivolumab|Adjuvant monotherapy with Nivolumab
223999743|NCT06794775|DRUG|Nivolumab + Ipilimumab|Adjuvant combination therapy with Nivolumab and Ipilimumab
224123793|NCT07162259|DRUG|First-line SG followed by T-DXd upon progression|Patients will be assigned to Cohort 2 (HER2 IHC ≤1+) based on different HER2 immunohistochemical expression levels, where they will first receive SG treatment, followed by T-DXd treatment upon disease progression.
223999744|NCT05840770|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223999745|NCT05840770|BIOLOGICAL|Cemiplimab|Given IV
223999746|NCT05840770|PROCEDURE|Computed Tomography|Undergo CT scan
223383081|NCT07154446|DRUG|Dynastat (original Parecoxib)|This arm will receive IV Dynastat 40mg during surgery
223383082|NCT07153822|DEVICE|Collagen-based adhesion barrier|Porcine Atelocollagen (Type I)
223383083|NCT07153822|DEVICE|Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier|Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)
223999747|NCT05840770|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
223383084|NCT07167719|BEHAVIORAL|Cognitive Behavioral Therapy|Brief Cognitive-Behavioral Therapy (CBT) focused on building resiliency in response to the effects of institutionalization
223383085|NCT07161258|DRUG|Fenebrutinib|Fenebrutinib will be administered orally.
223999748|NCT05840770|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223999749|NCT07056556|DRUG|BL-M09D1|Administration by intravenous infusion for a cycle of 3 weeks.
223999750|NCT07053683|DEVICE|Combined RME and Facemask Therapy|This intervention involves two components. First, a tooth-borne Hyrax-type rapid maxillary expander is banded to the maxillary first permanent and deciduous molars. The screw is activated twice daily until posterior crossbite is overcorrected. Second, immediately following expansion, a Petit-type facemask is used to apply orthopedic protraction forces to the maxilla.
223999751|NCT07053683|DEVICE|Facemask Therapy Alone|This intervention involves the use of a Petit-type facemask to apply orthopedic protraction forces (400-500g per side, 12-14 hours/day) to the maxilla. A removable mandibular occlusal splint (flat bite plane) is used concurrently to facilitate anterior crossbite correction.
223999752|NCT06805890|PROCEDURE|Colonoscopy - IBD inflamed tissue|Collection of 10 colonic biopsies in IBD inflamed tissue
223999753|NCT06805890|PROCEDURE|Surgical resection - IBD inflamed mucous membrane|Collection of a portion of IBD inflamed mucous membrane
223383086|NCT07170085|OTHER|positioning|The children will be positioned in the supine and prone position
223383087|NCT07169188|DRUG|Test Fluoride Toothpaste|Toothpaste containing 0.454% SnF2, 0.3% zinc chloride (ZnCl2) and 1% alumina.
223383088|NCT07169188|DRUG|Colgate Cavity Protection Toothpaste|Regular fluoride toothpaste containing 0.76% sodium monofluorophosphate.
223383089|NCT07174258|OTHER|Manual myofascial release group|Manual myofascial release techniques were applied to Group I on the feet, legs, and thighs, twice a week for 4 weeks.
223999754|NCT06805890|PROCEDURE|Colonoscopy - biopsies in healthy tissue|Collection of 10 colonic biopsies in healthy tissue
223999755|NCT06805890|PROCEDURE|Surgical resection - healthy mucous membrane|Collection of a portion of healthy mucous membrane
223999756|NCT07059377|DRUG|Semaglutide|Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks
223999757|NCT07059377|DRUG|Nicotine replacement|Nicotine patch plus short-acting NRT gum or lozenge
224123794|NCT07162571|BIOLOGICAL|CD19/22 CAR-T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 150 x 10⁶ CD19/CD22 CAR-T cells
223383090|NCT07174258|OTHER|Graston group|Graston was applied to the gastrocnemius and hamstring muscles, and before the application, solid petroleum jelly was applied to the area to lubricate the surface. A stainless steel Graston instrument was used for the application, using a superficial sweep technique at a 30-degree angle for 2 minutes, followed by a deep sweep for 30 seconds.
223383091|NCT07174258|OTHER|Home based exercise group|Group III received a home exercise program that included stretching exercises. They were asked to perform the exercises twice a week for four weeks, with 15-20 repetitions, without any intervention from a physiotherapist.
223999758|NCT07054619|BEHAVIORAL|Experiential First Aid Training|A first aid training program based on Kolb's Experiential Learning Model conducted in four sessions using real-life scenarios and group exercises.
223999759|NCT07058194|PROCEDURE|Preoperative Erector Spinae Plane Block|This procedure involves bilateral ultrasound-guided erector spinae plane block at the T7 level using 20 mL of 0.25% bupivacaine per side (total 40 mL) before the induction of general anesthesia. The intervention aims to evaluate the effects of preoperative ESP block on changes in frontal QRS-T angle and other ECG-derived cardiac electrophysiological parameters.
223999760|NCT07058194|PROCEDURE|Postoperative Erector Spinae Plane Block|Patients in this group will undergo standard general anesthesia. At the end of the surgery, bilateral ESP block will be performed under ultrasound guidance at the T7 level using 0.25% bupivacaine (20 mL per side, total 40 mL). The aim is to evaluate the effect of postoperative ESP block on changes in frontal QRS-T angle and other cardiac electrophysiological parameters.
223999761|NCT07058194|PROCEDURE|Standard General Anesthesia|This group will receive standard general anesthesia without any additional regional block. ECG data will be collected preoperatively and 1 hour postoperatively to serve as a comparison for electrophysiological changes observed in the intervention groups.
223999762|NCT07058194|DRUG|Bupivacaine|0.25% bupivacaine, 20 mL per side (total 40 mL), administered bilaterally at T7 level under ultrasound guidance as part of ESP block.
223999763|NCT04731506|BEHAVIORAL|Family Connections|Parent participants will receive an activity workbook that promotes increased physical activity and consumption of fruits and vegetables and decreased screen time and intake of sugary drink consumption, two in-person support sessions to help parents to develop an action plan spaced one week apart \& Interactive Voice Response (IVR) automated telephone system calls of 5 to 10 minutes that provide health education messages over 6 months (4 weekly, 4 biweekly (4), and 2 monthly). During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
223383092|NCT07172763|DEVICE|Siliconepad|Plantar pressure measurement
223383093|NCT07172763|DEVICE|Felted foam|Plantar pressure measurement
223383094|NCT07175441|DRUG|RBS2418|RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
223383095|NCT07175441|DRUG|STRIDE (durvalumab + tremelimumab)|STRIDE: Tremelimumab 300 mg IV (Cycle 1 Day 1 only) Plus Durvalumab 1500 mg IV every 4 weeks
223383096|NCT07177937|DRUG|DXC014|Dose Escalation DXC014, Cohort Expansion DXC014
223999764|NCT06693011|DEVICE|Contour Neurovascular System Treatment Attempt|The subject is brought into the procedure room, an angiogram on the day of the procedure indicates that the subject is anatomically eligible for the trial and any part of the investigational device comes in contact with the patient
223999765|NCT05468619|DRUG|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir.
223999766|NCT07096011|OTHER|Meal Test - Human Milk|Infants will be fed a mixed meal test (meal challenge test) of human milk from his/her human milk donor (e.g., mother). Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents their standard meal, at a larger size. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of human milk that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for human milk is be estimated at 20 kcals/ounce.
223383097|NCT07179185|DIAGNOSTIC_TEST|AI-Assisted ECG Interpretation (AI-ECG)|Neural network-based AI software that analyzes ECG tracings and provides a classification as normal suggestion to the interpreting specialist.
223383098|NCT07179185|DIAGNOSTIC_TEST|Specialist ECG Interpretation Without AI|Manual interpretation of ECGs by specialists without AI support, following standard diagnostic procedures
223999767|NCT07096011|OTHER|Meal Test - Infant Formula|Infants will be fed a mixed meal test (meal challenge test) of ready-to-feed infant formula. Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents a meal different from their habitual food intake and is a standard meal that all participants receive. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of infant formula that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for the ready-to-feed infant formula is 20 kcals/ounce.
223999768|NCT07135973|DRUG|Belumosudil|Pharmaceutical form:Tablet-Route of administration:Oral
223999769|NCT07136311|DIAGNOSTIC_TEST|DPOAE with Contralateral Suppression|Participants will undergo distortion evoked otoacoustic emissions (DPOAE) testing with contralateral broadband noise stimulation. The test is performed to evaluate auditory efferent system function, specifically the presence and degree of contralateral suppression. No medication or treatment is administered as part of the study. The procedure is non-invasive and commonly used in auditory diagnostics.
223999770|NCT07137234|PROCEDURE|Modified Millard rotation advancement flap technique|the cleft is repaired by surgical intervention
223999771|NCT07137234|DRUG|botulinum toxin injection (BTX A) before surgical intervention|the patient will receive Botulinum toxin type A followed by surgical closure of cleft lip
223999772|NCT07135557|DEVICE|R-One vascular interventional navigation control system|"The interventional cardiologist sits at the cockpit and remotely performs the PCI using the console joysticks. The cassette, which is loaded with the interventional devices and connected to the guiding catheters, imposes axial and rotational forces on the intracoronary devices. Fluoroscopic, electrocardiographic, and hemodynamic images are slaved to the duplicate monitors inside the cockpit, enabling visualization from a closer distance. After completion of diagnostic angiography, the guiding catheter was positioned at the ostium of the coronary artery and connected to the disposable cassette on the robotic drive. The guidewire was loaded into the cassette. Treatment was administrated according to local site protocols. Pre and post dilation was done per operator discretion. All intracoronary devices were to be manipulated exclusively by the robotic system, with bailout to manual conversion when needed."
224123795|NCT07162818|DRUG|Nepafenac 0.1% eyedrops|The study eye drops were nepavenac 0.1% eye drops (NEVANAC 0.1%®, Alcon Laboratories, Inc., Fort Worth, Texas). Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.
224123796|NCT07162818|DRUG|Control (placebo) group|Cenfresh® eye drops (Cendo pharmaceutical, Indonesia) for the control group. Subjects were instructed to use eye drops on the side of the eye with the ARR, three times daily for five days before and on the day of surgery. Written instructions and a daily checklist to record the eye drop schedule were provided to each subject.
224138469|NCT01560221|DRUG|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
224138470|NCT05263817|BIOLOGICAL|CD19/BCMA CAR T-cells|Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
224138471|NCT06061042|BEHAVIORAL|Early time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM
224138472|NCT06061042|BEHAVIORAL|Late time restricted eating|Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM
223383099|NCT07179302|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|evaluate the role of the left atrial coupling index (LACI) and left ventricular speckle tracking echocardiography (LVSTE) in enhancing outcome prediction in patients undergoing TAVI.
223383100|NCT07185451|DEVICE|tACS|"This intervention uses the NEXALIN ADI alternating current stimulation device from Beijing Naisilin Technology Co., Ltd., to deliver targeted stimulation to the prefrontal cortex and bilateral mastoid regions. The prefrontal cortex electrode directly stimulates the cerebral cortex, while the mastoid electrodes ensure the synchronized activation of bilateral neural pathways. Stimulation is applied at a frequency of 77.5 Hz and a current intensity of 15 mA, aiming to optimize brainwave synchronization and modulate brain activity.~Participants will undergo daily sessions lasting approximately 40 minutes each, for a total of 20 sessions over 4 weeks. The non-invasive nature of the intervention, combined with its precise targeting of specific brain regions, distinguishes it from other neuromodulation therapies. The treatment aims to enhance neural synchronization, promote neuroplasticity, and provide a non-pharmacological therapeutic alternative for patients."
223383101|NCT07185451|DEVICE|tACS|In the sham stimulation group, participants will receive intervention using a sham device that is identical in appearance, operation, and stimulation protocol to the real tACS device, but does not deliver any current. Both participants and operators will be unable to distinguish between real and sham stimulation based on the device's appearance, sound, or tactile feedback. Device allocation will follow a randomized code generated in advance to ensure blinding and proper group assignment.
223383102|NCT07185529|OTHER|Data of the patients were obtained from patient observation files and hospital information system database.|Data of the patients were obtained from patient observation files and hospital information system database.
223383103|NCT07185698|DIAGNOSTIC_TEST|3D Ultrasound|Virtual Organ Computer-aided AnaLysis (VOCAL) to assess flow and velocity characteristics of the urethral blood supply
223999773|NCT07137793|DRUG|Pentoxifylline 400mg plus chemotherapy|patient will receive standard chemotherapy for breast cancer plus pentoxifylline 400 mg orally 3 times per day with meals.
223999774|NCT07135505|BEHAVIORAL|Early time-restricted eating|The participants will be asked to fast for a target of 16 hours per day (eat ad libitum within the 8-hour eating window, starting between 6:30-8:30 am), 6 days/week for 12 weeks. Participants will be allowed to consume calorie-free beverages, sugar-free gum, and will be encouraged to drink plenty of water throughout the entire intervention period.
223999775|NCT07135271|OTHER|Bespoke Decision Support tool|A newly-developed online patient decision aid offering comparative information of prostate cancer treatments (active surveillance, focal therapy, radical prostatectomy and external beam radiotherapy), personalised estimates of oncological and functional outcomes for each treatment and a value-clarification exercise.
223999776|NCT07135271|OTHER|Standard of Care (SOC) decision support material|"Standard of care information to inform the prostate cancer treatment decision. This includes the nationally approved Prostate Cancer UK information booklet Prostate Cancer - A guide if you have just been diagnosed in all sites. Further educational material may be provided as part of standard of care depending on local practice at each site."
223999777|NCT07136792|DRUG|Pegmolesatide 2mg SC|All patients will receive pegmolesatide 2mg subcutaneously once every 4 weeks.
223999778|NCT07136792|DRUG|Pegmolesatide 4mg SC|All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
223999779|NCT07136792|DRUG|Pegmolesatide 4mg SC|All patients will receive pegmolesatide 4mg subcutaneously once every 4 weeks.
223999780|NCT07136792|DRUG|Pegmolesatide 6mg SC|All patients will receive pegmolesatide 6mg subcutaneously once every 4 weeks.
223999781|NCT06265324|DEVICE|Angioplasty|Drug-coated balloons angioplasty for treatment of de novo and in-stent restenosis lesions
223999782|NCT06551064|BIOLOGICAL|FYB206|FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
223999783|NCT06551064|BIOLOGICAL|Keytruda|Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle
223729876|NCT00272467|DRUG|Omeprazole|"1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea."
223383104|NCT07186985|COMBINATION_PRODUCT|Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy|"Group 1:~* Patients were instructed to identify and sense their pelvic floor muscles and to perform contraction-hold-relaxation exercises.~* Exercises were performed at a frequency of 8 sets per session, 3 sessions per week, progressing from the supine position (month 1), to sitting (month 2), and to standing (month 3). Training was monitored by an electronic diary app. (Appendix)~* Six individual 45-minute intervention sessions at the center using biofeedback, under the supervision of a physical therapy technician. (Appendix)~* The training program consisted of two parts: resistance training and pre-contraction training (the Knack technique). (Appendix)~* Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:~* First 4 weeks: insert one 0.5 mg tablet nightly at bedtime.~* Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses"
223383105|NCT07186985|DRUG|Vaginal estrogen|"Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:~First 4 weeks: insert one 0.5 mg tablet nightly at bedtime. Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses."
223729877|NCT02601508|DRUG|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
223999784|NCT05071846|BIOLOGICAL|MVX-ONCO-2|"One administration of MVX-ONCO-2 (or vaccination) consists of the implantation of 2 capsules containing MVX-2 cells and 1 injection of 4 × 10\^6 lethally irradiated autologous tumor cells. Tumor cells will have prealably been harvested from the participant through a surgical procedure.~A full treatment course with MVX-ONCO-2 consists of a total of 6 vaccinations: 4 vaccinations 1 week apart, followed by 2 boosters 2 weeks apart. Capsules are removed 1 week after implantation."
223999785|NCT01920698|DEVICE|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
223999786|NCT01920698|OTHER|control|
223999787|NCT01876082|DRUG|PAZOPANIB treatment|"Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum"
223999788|NCT01876082|DRUG|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
223999789|NCT02999685|BEHAVIORAL|Home-base Pulmonary Rehab with Health Coaching|
223729878|NCT02601508|DRUG|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine \& Glycopyrrolate
223729879|NCT00755092|BEHAVIORAL|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
223999790|NCT05241314|BEHAVIORAL|Learning to BREATHE|A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
223999791|NCT05241314|BEHAVIORAL|After Deployment Adaptive Parenting Tools (ADAPT)|A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
223383106|NCT07185386|DIETARY_SUPPLEMENT|combination of diosmin, hesperidin, bromelain, and Ruscus aculeatus (Vesvein Gambe)|Although there is extensive clinical and pharmacological evidence regarding the activity of the individual components of the product, the specific effect of the fixed combination of diosmin, hesperidin, bromelain, and Ruscus aculeatus as a single entity on quality of life in subjects with symptoms compatible with the early stages of Chronic Venous Disease (CVD) has not yet been explored.
223383107|NCT07186621|DRUG|Sintilimab|concurrent sintilimab 200mg q3w for 2 cycles followed by maintenance sintilimab 200mg q3w for 15 cycles (approximately 1 year total treatment duration) until disease progression or unacceptable toxicity
223999792|NCT04087811|DEVICE|Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) (Superion® implant)
223383108|NCT07186621|RADIATION|radiotherapy|The experimental group will initiate radiotherapy within 4 months postoperatively with prescribed doses of 44-50Gy in 22-25 fractions to the tumor bed and 56-60Gy in 22-25 fractions to narrow-margin areas adjacent to major blood vessels
223999793|NCT04407689|DRUG|Interleukin-7|Intramuscular (IM) administration of CYT107 at 3 μg/ kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or
223999794|NCT04407689|DRUG|Placebo|Intramuscular (IM) placebo (normal saline) at the same frequency
223999795|NCT01831947|BIOLOGICAL|Ranibizumab|
223999796|NCT00377442|DRUG|GK Activator (2)|100mg po
224123797|NCT07162727|DEVICE|titanium foil in ridge augmentation|Full thickness mucoperiosteal flap was elevated, to expose the alveolar ridge defect. HA graft was placed onto the external defect upon which preformed titanium foil depending on the size and extent of defect was placed. Foil was stabilized with the help of stainless steel screws of diameter 1.5 cm and length varied depending on the depth of the defect. The flaps were approximated and sutured without tension. Periodontal dressing was given.
224123798|NCT07162727|DEVICE|collagen membrane|Full thickness mucoperiosteal flap was elevated, to expose the alveolar ridge defect. HA graft was placed onto the external defect upon which preformed collagen membrane depending on the size and extent of defect was placed. The flaps were approximated and sutured without tension. Periodontal dressing was given.
224123799|NCT07163533|OTHER|wearble vibrotactile feedback sensor and kendel exercises|Wearable vibrotactile feedback sensor will be applied to the neck for assessment and management and secondly kendel exercises consisting of Strengthening of Deep Cervical Flexors, Stretching the Cervical Extensors, Strengthening Shoulder Retraction, Stretching the Pectoralis Muscle. each exercise will be given 3 days per week for 30 min each.
224123800|NCT07163533|OTHER|kendel exercises|kendel exercises consisting of Strengthening of Deep Cervical Flexors, Stretching the Cervical Extensors, Strengthening Shoulder Retraction, Stretching the Pectoralis Muscle. each exercise will be given 3 days per week for 30 min each.
223999797|NCT00377442|DRUG|Simvastatin|80mg po
223999798|NCT04101253|PROCEDURE|new screening procedure with small variations in electrode positioning|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
223999799|NCT00974818|DRUG|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
223999800|NCT00974818|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
224123801|NCT07163780|BEHAVIORAL|HEP Intervention|"This intervention is administered to the HEP Intervention arm.~The HEP approach, which includes intervention, is a child-centered, family-based early intervention approach based on the principles of enriched environment and plasticity, emphasizing the importance of homeostasis. It is based on theories that argue that development occurs as a result of the dynamic interaction between the environment, time, task, and individual (Ecological Theory, Dynamic Systems Theory, Perception-Action Theory, Neuronal Group Selection Theory, and the Person-Environment-Occupation Model). Hypotheses for intervention are generated based on a comprehensive assessment of these four fundamental factors (environment, time, task, and individual), and 10 core principles derived from environmental enrichment studies are applied with the guidance of ecological models."
224123802|NCT07163780|BEHAVIORAL|Traditional Therapy|Participants in this arm will receive conventional pediatric therapy, consisting of 12 weekly sessions of 45 minutes each. Sessions will focus on standard motor and sensory development exercises, delivered by a physical therapist experienced in pediatric rehabilitation.
224123803|NCT07163585|DRUG|Brivaracetam|Brivaracetam was initiated at a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.
224123804|NCT07163585|DRUG|Levetiracetam|Levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.
224138473|NCT03581929|DIETARY_SUPPLEMENT|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
224138474|NCT03581929|OTHER|Placebo|Placebo comparator
223383109|NCT07186621|PROCEDURE|TACE|The control group will receive the first TACE procedure within 4 months postoperatively, with the decision on administering a second TACE to be determined by the investigator based on the patient's condition and first TACE response assessment.
223383110|NCT07185139|DRUG|MSCohi-O Lenses|Each subject will wear MSCohi-O Lenses for 12 hours a day, totally 14 wearings.
223383111|NCT07187102|OTHER|SNAG ( sustained natural apopheseal glide )|SNAG : type of mobilization of vertebral coulmn
223999801|NCT05794490|BEHAVIORAL|Learning from excellence|Health care professionals´ experiences of learning from excellence in a hospital unit
223999802|NCT02570204|BEHAVIORAL|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
223999803|NCT00626197|DRUG|Corticosteroids|Intravenous and oral repeating dose
223999804|NCT00626197|DRUG|Cyclophosphamide|Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.
223999805|NCT00626197|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.
223999806|NCT00626197|DRUG|Ocrelizumab|Ocrelizumab was administed at a dose and as per schedule in arm description
223999807|NCT00626197|DRUG|Placebo|Placebo was administered as per schedule in arm description
223999808|NCT00626197|DRUG|Azathioprine|Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.
223999809|NCT04200638|DIAGNOSTIC_TEST|ProTaper Next|The canal fluid sample before and after will evaluate after root canal instrumentation
223999810|NCT00497731|DRUG|AZD1152|2-hour continuous intravenous infusion
223999811|NCT04833127|BEHAVIORAL|Gender-Enhanced -- Masibambane|"The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators."
223999812|NCT04833127|BEHAVIORAL|Individually accessed|The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
223999813|NCT04440839|OTHER|Telemedicine specialty consultation|Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
223999814|NCT04468945|OTHER|mirror box therapy|"* Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~* The patient is seated close to a table a mirror (33\*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~* The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~* During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously."
223999815|NCT04468945|OTHER|Repetitive Facilitation Exercise|"* The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~* Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~* Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~* Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~* Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)"
223999816|NCT03605576|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
223999817|NCT03605576|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
223999818|NCT01071655|DRUG|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
223999819|NCT01071655|DRUG|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
223999820|NCT02296918|DRUG|acalabrutinib|Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.
224123805|NCT07163195|DEVICE|Smart Bandage with Telemonitoring|A smart wound bandage with integrated sensors (pH, temperature, moisture) connected to a mobile telemonitoring platform. Wound data are transmitted securely to a mobile application monitored by wound care nurses. The device is applied in addition to standard wound care (compression therapy, conventional dressing, debridement when indicated, and patient education).
223383112|NCT07186088|DEVICE|Eyerising RS-200-2A|Eyerising RS-200-2A,1 time,2 times, 3 times a day
223383113|NCT07186088|DEVICE|Airdoc Sky-n1201|Eyerising RS-200-2A,2 times a day
223383114|NCT07185048|BEHAVIORAL|Conventional Foot Care Control Group|Standard Foot Care with Regular Follow-up
223383115|NCT07185048|BEHAVIORAL|Digital Foot Care (Low-Intensity)|On the basis of routine management, the digital intervention modules will be added
223383116|NCT07185048|BEHAVIORAL|Digital Foot Care (Moderate-Intensity)|Further integration of AI image analysis for auxiliary judgment and remote physician response.
223383117|NCT07186595|DEVICE|JUVÉDERM VOLUX XC|Injections
223999821|NCT02296918|DRUG|Obinutuzumab|Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.
223999822|NCT02296918|DRUG|Venetoclax|Participants will receive oral venetoclax in Cohorts 3 and 4. The details are mentioned in the cohort description.
223999823|NCT02296918|DRUG|Rituximab|Participants will receive intravenous rituximab in Cohort 3. The details are mentioned in the cohort description.
223999824|NCT04098146|PROCEDURE|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
223999825|NCT02855736|BEHAVIORAL|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about."
223999826|NCT02855736|BEHAVIORAL|Placebo (food journal)|"Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day."
223383118|NCT07186595|DEVICE|JUVÉDERM VOLUMA XC|Injections
223383119|NCT07186595|DEVICE|JUVÉDERM VOLBELLA XC|Injections
223383120|NCT07186595|DEVICE|JUVÉDERM VOLLURE XC|Injections
223383121|NCT07186595|DEVICE|SKINVIVE by JUVÉDERM|Injections
223383122|NCT07186595|DEVICE|JUVÉDERM ULTRA XC|Injections
223383123|NCT07186595|DEVICE|JUVÉDERM ULTRA PLUS XC|Injections
223383124|NCT07184736|PROCEDURE|Active Manual Syringe Aspiration|For the Active Manual Syringe Aspiration, the operator manually withdraws pleural fluid using a syringe attached to a 3-way stopcock and transfusion set. The fluid is then expelled into a collection bag.
223383125|NCT07184736|PROCEDURE|Passive Gravity Drainage|In Passive Gravity Drainage, after confirming proper needle placement with initial aspiration, the syringe is detached, and pleural fluid is allowed to drain passively by gravity through the transfusion set into a collection bag.
223999827|NCT04835454|DIAGNOSTIC_TEST|piRNAs, miRNA-194, regucalcin and plasma aminoacids levels|PIWI-interacting RNAs (piRNAs), a class of small nuclear RNA molecules, are associated with the PIWI proteins. MicroRNAs (miRNAs) are conserved small non-coding RNAs (19-22 nucleotide-long) that mediate post-transcriptional regulation of gene expression, affecting mRNA stability and translation by binding complementary sites on target mRNAs. Regucalcin (RGN) is an inhibitory protein of calcium signaling with calcium-binding properties. It plays a multifunctional role in the regulation of cell functions, including maintenance of intracellular calcium homeostasis, inhibitions of protein kinases and protein phosphatases linked to cell signaling process, suppressions of protein production and nuclear DNA and RNA synthesis.Free amino acids, in biological fluids can be a reduced invasive method associated to a high diagnostic potential. It was found that free amino acid profiles vary depending on type of cancer and its stage.
223999828|NCT01218347|DRUG|Rosuvastatin|20 mg once daily for 21 days
223999829|NCT04672811|DEVICE|Study App and Apple Watch|Study App and Apple Watch
223999830|NCT06797609|OTHER|Sample analyses|Immunoturbidimetric assay for determination of serum Cys-C levels and the Chronic Kidney Disease Epidemiology (CKD-EPI) equation for GFR estimation
223999831|NCT03459222|BIOLOGICAL|Relatlimab|Specified dose on specified days
223999832|NCT03459222|BIOLOGICAL|Nivolumab|Specified dose on specified days
223999833|NCT03459222|DRUG|BMS-986205|Specified dose on specified days
223999834|NCT03459222|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223999835|NCT06552637|DEVICE|Synchronized Diaphragmatic Stimulation|Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.
223383126|NCT07186933|PROCEDURE|PEEP titration for Minimum Driving Pressure|"This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP Initially 8 cm H2O. Afterwards, the lungs are recruited with the aforementioned maneuver. During subsequent derecruitment, PEEP is decreased by 2 cm H20 and compliance is noted in each stage. The goal is to find PEEP with maximum compliance (Cmax). A new recruitment maneuver follows and during derecruitment PEEP is set at the optimum value that was previously defined.~VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuver (as described) every hour"
223383127|NCT07186933|PROCEDURE|Lung Protective Ventilation|This group is mechanically ventilated with Invasive Mechanical Ventilation with Volume Control Ventilation mode with PEEP 8 cm H2O. VT 8 ml/kg IBW RR --\> PaCO2 = 35-45 mmHg FiO2 0.4 - 0.5 --\> SpO2 \> 93% Recruitment Maneuvers (as described) every hour
223383128|NCT07186816|DEVICE|Behavioral: Supported dCBT|In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
223383129|NCT07186816|DEVICE|Behavioral: Unsupported dCBT|Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
223383130|NCT07185347|DRUG|Fampridine 10 mg prolonged-release tablet (per os)|Patients randomized in the experimental arm will take 1 tablet twice a day, 12 hours apart, on an empty stomach, for 12 weeks.
223999836|NCT05162573|DRUG|177Lu-PSMA-617|Dose-escalation of 177Lu-PSMA-617 (3, 6, 9 or 2x7.4 GBq) combined with external beam radiotherapy (EBRT)
223999837|NCT05162573|RADIATION|EBRT|External Beam Radiotherapy
223999838|NCT05675462|DRUG|Oncorine|a modified human recombinant type 5 adenovirus with genetic modifications
223999839|NCT05675462|DRUG|Tislelizumab|PD-1inhibitor
223999840|NCT05675462|DRUG|Lenvatinib|TKI
223383131|NCT07185347|DRUG|Placebo (tablets per os)|Patients randomized in the control arm will take 1 tablet twice a day, 12 hours apart, on an empty stomach, for 12 weeks.
223383132|NCT07186829|DEVICE|Percutanous pinning|Similar to arm - closed reduction, two percutaneous pins
223383133|NCT07186829|DEVICE|Locked plate|Similar to arm - open reduction, dorsal approach, 3 screws proximal and distal
223383134|NCT07186829|DEVICE|Intramedullary screw|Similar to arm - 1 cm dorsal incision, closed reduction, internal compression screw
223383135|NCT07186153|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|evaluate and follow-up left atrial volume, diastolic function by 2D echocardiography and left atrial strain parameters using speckle-tracking echocardiography in patients with type 2 diabetes mellitus (T2DM) after treatment with SGLT2 inhibitors
223383136|NCT07185542|PROCEDURE|Superficial parotidectomy|Superficial parotidectomy (SP), the traditional approach, involves facial nerve dissection and removal of the superficial lobe. Though effective, it carries risks like nerve dysfunction, Frey's syndrome, and cosmetic concerns
223383137|NCT07185542|PROCEDURE|Intracapsular parotidectomy (ICP)|"ICP excises the tumor along its capsule without dissecting the facial nerve, thereby minimizing trauma and preserving glandular tissue.~ICP is recommended for small, mobile, and superficially located benign tumors with low suspicion of malignancy. However, concerns remain regarding capsular rupture and recurrence, particularly in pleomorphic adenomas with microscopic extensions"
223383138|NCT07186907|DEVICE|Hydrocolloid dressing|Hydrocolloid dressing was used for diaper dermatitis
223383139|NCT07186907|DRUG|Zinc oxide cream %40|Zinc oxide cream was used in diaper dermatitis.
223383140|NCT07186452|DRUG|HS-20093|All participants will receive intravenous infusion of HS-20093 at a dose of 8 mg/kg every 3 weeks (Q3W), with each treatment cycle lasting 21 days.
223383141|NCT07186452|DRUG|Itraconazole|Participants will then take itraconazole capsules orally at 200 mg per dose during C2D17-C3D21
223999841|NCT00561431|DEVICE|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
223999842|NCT00561431|DEVICE|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
223999843|NCT06357988|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223999844|NCT06357988|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223999845|NCT06357988|PROCEDURE|Echocardiography Test|Undergo echocardiography
223999846|NCT06357988|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
223383142|NCT07187284|COMBINATION_PRODUCT|EDN combined with TACE/HAIC and Immuno-Targeted Therapy|"Experimental Intervention (Treatment Group):~This arm evaluates a novel combination strategy. Participants will undergo a single session of Endovascular Denervation (EDN) in conjunction with standard care. The complete intervention includes:~Endovascular Denervation (EDN): A one-time, catheter-based percutaneous procedure for the ablation of peri-arterial sympathetic nerves surrounding the common hepatic artery and/or proper hepatic artery. The procedure utilizes a multi-electrode radiofrequency ablation system (e.g., Netrod®). Ablation parameters are set to 60°C for 120 seconds per site, with a minimum of 20 ablations performed to ensure adequate denervation.~On-demand Transarterial Intervention: Following EDN, participants will receive either Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC), as determined by the treating investigator based on individual patient anatomy and tumor characteristics."
223383143|NCT07187284|COMBINATION_PRODUCT|TACE/HAIC plus Immuno-Targeted Therapy|This is the active comparator intervention representing the current standard-of-care regimen for the study population. Participants randomized to the control group will receive a combination of locoregional and systemic therapy, specifically excluding the experimental Endovascular Denervation (EDN) procedure.
223999847|NCT06357988|DRUG|Vismodegib|Given PO
223999848|NCT02900547|OTHER|Patients with systolic heart failure|
223999849|NCT05658653|OTHER|Educational Materials for Chronic Disease Management Test (CDMT)|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
223999850|NCT03512964|DRUG|Dolutegravir 50 MG|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
223999851|NCT03512964|DRUG|Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
223999852|NCT00785811|DRUG|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
223383144|NCT07185477|BIOLOGICAL|QLS32015|QLS32015 is a GPRC5D × CD3 bispecific antibody.
223999853|NCT00785811|DRUG|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
223999854|NCT03780361|DRUG|Aflibercept Injection|Total 5 times of monthly intravitreal aflibercept injections will be done.
224123806|NCT07163195|DEVICE|Conventional Bandage|A conventional wound bandage without digital monitoring features. It is applied in addition to standard wound care (compression therapy, conventional dressing, debridement when indicated, and patient education). This represents usual care according to international guidelines.
224123807|NCT07162220|OTHER|The clinic's routine education program|As part of the clinic's routine education program, information about kidney function, CKD, nutrition, exercise, medications, and stress management is provided verbally by a nephrology clinic nurse in approximately 20 minutes.
224123808|NCT07162220|DEVICE|Mobile game app|The mobile game software developed for patients with chronic renal failure contains information for children on daily life activities such as nutrition, exercise, personal hygiene, etc.
224123809|NCT07162974|DRUG|anhydrous citric acid - 1197.0 mg, potassium bicarbonate - 967.5 mg, sodium citrate anhydrous - 835.5 mg|The dosage was selected individually for each patient, the target pH was considered to be 7.2
223383145|NCT07186608|DIETARY_SUPPLEMENT|Dietary fiber intervention|Ten patients with short bowel syndrome in clinical practice were subjected to dietary fiber intervention. Blood and fecal samples were collected before and after the dietary fiber intervention, and nutritional and intestinal barrier-related indicators were also collected to observe the improvement effect of dietary fiber on these patients.
223383146|NCT07187024|BEHAVIORAL|mCare PTOA Intervention|The mCare PTOA intervention includes five evidence-based modules that focus on 1) basic joint health following injury, 2) self-management strategies, 3) weight management, 4) physical activity, and 5) occupational management. These educational modules will serve as the primary intervention in this study.
223383147|NCT07185880|DRUG|MT-125|This is an investigational new drug under IND 170975.
223383148|NCT07185854|DRUG|Artificial tears|Topical artificial tears were administered as standard therapy for moderate dry eye disease.
223383149|NCT07185854|OTHER|Traditional Chinese Medicine Acupuncture|Acupuncture therapy performed by a certified specialist using sterile disposable needles at predefined local and systemic acupoints (BL2, ST1, GB1, SJ23, Ex-HN5, LI4, ST36, SP6, LIV3, GB37, GB40, Ex-HN3, Du23, BL64). Sessions were delivered twice weekly for a total of 10 sessions, each lasting 20 minutes. Deqi sensation was obtained by manual stimulation. No additional systemic or topical treatments were provided to participants in this arm.
223729880|NCT00755092|BEHAVIORAL|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
223729881|NCT02420392|DRUG|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
223999855|NCT04255953|BEHAVIORAL|behavioral telehealth|Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
223999856|NCT04255953|OTHER|Treatment as Usual|Treatment as Usual
223999857|NCT04703205|DRUG|Ivermectin 3 MG|Ivermectin approximately 200 μg/kg administered as a single oral dose on Day 1 (fasting state)
223999858|NCT04703205|DRUG|Placebo|Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
223999859|NCT02597244|DEVICE|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
223999860|NCT02849444|OTHER|Anti-myeloma treatment at physician discretion|non Interventional Study
223999861|NCT01576380|DRUG|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
223999862|NCT02523703|BIOLOGICAL|glutamate and aspartate|
223999863|NCT02509832|DEVICE|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
223999864|NCT02509832|DEVICE|PCI only|Standard of Care for PCI
224123810|NCT07163065|PROCEDURE|Inferior Alveolar Nerve Block Anesthesia|Standard inferior alveolar nerve block anesthesia performed with lidocaine and epinephrine for mandibular dental treatment. Success rate and postoperative pain outcomes will be recorded
223729882|NCT04698460|PROCEDURE|Hybrid coronary revascularization|A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
223999865|NCT00461981|BIOLOGICAL|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
223999866|NCT00461981|BIOLOGICAL|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
223999867|NCT02388126|DEVICE|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
223383152|NCT07185490|BIOLOGICAL|CT103d|CT103d is a personalized, BCMA-targeted, genetically modified autologous T-cell immunotherapy product.
223545374|NCT00535769|DEVICE|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
223545375|NCT00682929|DRUG|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
224123811|NCT07164079|DIETARY_SUPPLEMENT|blackberry root|Patients in the intervention group will receive a Rubus Sanctus root extract, which they will consume with breakfast for 8 weeks. The tea will be packaged as 5 grams of Rubus Sanctus root and steeped in 200 ml of water at 80°C for 5 minutes. Participants in the intervention group will receive the Rubus Sanctus root tea along with the necessary equipment (a 200 ml beaker and thermometer). Measurements of TSH, T4, T3, anti-TPO, anti-TG, TSH receptor antibodies, liver function tests, thyroid parenchymal echogenicity, and thyroid volume will be taken at the Endocrinology and Metabolic Diseases Clinic of Muğla Training and Research Hospital before and after the study.
223729883|NCT04698460|PROCEDURE|Coronary artery bypass grafting|A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
223729884|NCT04134013|DIETARY_SUPPLEMENT|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
223729885|NCT04134013|OTHER|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
223729886|NCT02921854|OTHER|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
223999868|NCT02388126|DEVICE|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
223999869|NCT05354414|DEVICE|Virtual reality|Administered as specified in the treatment arm.
223999870|NCT05354414|PROCEDURE|Standard of Care|Administered as specified in the treatment arm.
223999871|NCT03657602|DRUG|Kyleena Intrauterine System|Participant will be randomly allocated to this intervention
223383153|NCT07185061|DEVICE|Acoustic Stimulation|Using hearing loss detection and tinnitus matching data as input parameters, the system automatically generates personalized sound stimulation audio signals through composite signal amplitude, frequency, phase control processing, and notch filtering. The audio tone is fine-tuned based on the patient's initial treatment response to identify their most comfortable range.
223383154|NCT07187037|DRUG|Methylprednisolone (MP)|Methylprednisolone 1 mg/kg IV (diluted to 5 mL with saline) will be administered at induction of anesthesia. Neuromuscular blockade will be achieved with rocuronium. Reversal will be performed with sugammadex 2 mg/kg IV at the reappearance of the second twitch in train of four monitoring.
223383155|NCT07187037|DRUG|Dexamethasone|Dexamethasone 0.2 mg/kg IV (diluted to 5 mL with saline) will be administered at induction of anesthesia. Neuromuscular blockade will be achieved with rocuronium. Reversal will be performed with sugammadex 2 mg/kg IV at the reappearance of second twitch in train of four monitoring.
223383156|NCT07184658|PROCEDURE|Ultrasound-guided peritendinous saline injection|Under ultrasound guidance, 1 mL of sterile normal saline will be injected peritendinously at the tendon repair site at 7, 14, and 21 days after surgery to reduce adhesion formation and preserve tendon healing.
223383157|NCT07184606|DRUG|¼ of the full (target) dose (solution, 5 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive ¼ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive ¼ of the full (target) dose of the study drug (parenteral administration)."
223383158|NCT07184606|DRUG|½ of the full (target) dose (solution, 10 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive ½ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive ½ of the full (target) dose of the study drug (parenteral administration)."
223383159|NCT07184606|DRUG|full dose (solution, 20 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive full (target) dose of the study drug (parenteral administration)."
223383160|NCT07184606|DRUG|1 ½ of the full (target) dose (solution, 30 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive 1 ½ of the full (target) dose of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive 1 ½ of the full (target) dose of the study drug (parenteral administration)."
223383161|NCT07184606|DRUG|2 full doses (solution, 40 ml)|"1. st cohort of volunteers: 3 healthy volunteers will receive 2 full (target) doses of the study drug, and 1 healthy volunteer will receive placebo (parenteral administration).~2. nd cohort of volunteers: in case of AE in 1st cohort, 3 healthy volunteers will receive 2 full (target) dose of the study drug (parenteral administration)."
223383162|NCT07184606|DRUG|course administration of the selected dose|10 healthy volunteers will receive course administration of the selected dose, and 1 healthy volunteer will receive placebo.
223383163|NCT07184606|OTHER|Placebo|1 healthy volunteer from the 1st cohort of each group will receive placebo (parenteral administration)
223729887|NCT02502643|DRUG|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
223999872|NCT03657602|DRUG|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
223999873|NCT00450021|DRUG|[(11)C] MePPEP|
223999874|NCT05467293|DRUG|0.3% YP-P10 Ophthalmic Solution|Drug: YP-P10 Ophthalmic Solution
223999875|NCT05467293|DRUG|1% YP-P10 Ophthalmic Solution|Drug: YP-P10 Ophthalmic Solution
223999876|NCT05467293|DRUG|YP-P10 Placebo Ophthalmic Solution (vehicle)|Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)
223999877|NCT03978039|DRUG|Chemotherapy|treatment as per standard of care
223999878|NCT03978039|DRUG|Immunotherapeutic Agent|treatment as per standard of care
224123812|NCT07164079|DIETARY_SUPPLEMENT|black tea|Patients with Graves' disease assigned to the control group will be asked to consume black tea (Camellia sinensis) with their breakfast for 8 weeks. Black tea is a product consumed almost daily in Turkish society. Black tea will be prepared in 5-g doses and steeped in 200 ml of water at 80°C for 5 minutes. Participants in the control group will be provided with black tea bags along with the necessary equipment (a 200 ml beaker and thermometer). TSH, T4, T3, anti-TPO, anti-TG, TSH receptor antibody, liver function tests, thyroid parenchymal echogenicity, and thyroid volume will be obtained before and after the study at the Endocrinology and Metabolic Diseases Clinic of Muğla Training and Research Hospital.
224123813|NCT07163091|OTHER|ankel stirrup|Ankel stirrups are a patient preferred ankel brace that allow active ankle dorsal and plantar flexion during weightbearing while maintaining lateral stability.
224295626|NCT05417503|OTHER|Non-invasive ventilation bi-level|For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
223999879|NCT03978039|DRUG|target treatment|treatment as per standard of care
223999880|NCT03978039|PROCEDURE|Surgery|treatment as per standard of care
223999881|NCT03978039|RADIATION|Radiotherapy|treatment as per standard of care
223383164|NCT07186179|DRUG|Mobilization Regimen|"This study will utilize a standard mobilization regimen that is used for peripheral blood stem cell mobilization in patients with a variety of underlying conditions.~Upon study initiation, participants will undergo a peripheral blood draw and bone marrow aspiration and biopsy. They will then begin the following mobilization regimen:~1. Granulocyte-colony stimulating factor (G-CSF; filgrastim) dosed at 10mcg/kg/day administered subcutaneously in the morning for 5-7 days~2. Plerixafor dosed at 0.24mg/kg/day administered subcutaneously in the evening for 1-4 days~Participants will undergo daily blood draws until criteria for study completion is achieved."
223999882|NCT03832218|DIAGNOSTIC_TEST|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~* Test : Wechsler Intelligence Scale for Children (WISC-V)~* Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~* Global Assessment of Functioning Scale~* Scale : Brief Psychiatric Rating Scale (BPRS)~* Test : Children Depression Inventory (CDI)~* Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~* Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~* Scale : Conners' scale (parents and teachers)"
223999883|NCT05287997|DIAGNOSTIC_TEST|Neurolytixs Index|Capillary blood sample will be collected on a dried plasma sample (DPS) filter paper. The sample will be sent to a central laboratory where they will undergo metabolite extraction and analysis via mass spectrometry.
223999884|NCT06385509|DRUG|Jatenzo|237 mg JATENZO twice daily
223999885|NCT00597051|DRUG|ARD-0403|
223999886|NCT00196469|DRUG|heparin|
223999887|NCT01416857|OTHER|RDDT|
223999888|NCT05281497|BEHAVIORAL|Health platform|Each participant was provided with a wearable device (a Heart Rate Smart Wristband, GSH405-B6, Golden Smart Home Technology Corporation). Each participant downloaded an app (WowGoHealth app) to connect with the health management platform (GSH AI health platform). Participants' exercise-related data, including number of steps walked, distance, consumed calories, and heart rate, were collected by the wearable devices. All participants were taught to record a dietary diary (taking photos of meals) using a smartphone application. All collected information was uploaded to the health management platform. For the intervention group, we encouraged exercise including an 18-minutes calisthenics made by the Health Promotion Administration, Ministry of Health and Welfare (https://www.youtube.com/watch?v=r3xJW-b2tZY).
224123814|NCT07163091|OTHER|Foot-ankel brace (walker)|Walkers immobilise and stabilise the ankle during weightbearing.
224123815|NCT07163611|DRUG|Obinutuzumab administration|All participants will receive obinutuzumab 1000 mg on day 1 and 15, with two additional infusions after 6 months if the anti-PLA2R antibody IFT assay is still positive with proteinuria \> 2 gram/24 hours and stable kidney function.
223383165|NCT07185321|DRUG|Mosliciguat|Dose level for inhalation
223383166|NCT07185321|DRUG|14C mosliciguat|Dose level
223383167|NCT07185321|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat
223383168|NCT07185568|PROCEDURE|IOUS HydroMark™|"IOUS HydroMarkTM allows marking the tissue during percutaneous breast biopsy. This is a sterile, single-use marker made of resorbable hydrogel, which expands upon contact with bodily fluids and is then gradually absorbed. The hydrogel is visible on ultrasound. Inside the hydrogel, there is a metallic spiral (titanium/steel) that remains permanently visible in radiographic and MRI examinations even after the hydrogel has been fully absorbed.~The HydroMARK Breast Biopsy Site Marker is made of a resorbable hydrogel that expands with fluid and is then resorbed. The hydrogel material is visible under ultrasound. Embedded in the hydrogel is a coiled metallic wire that will be permanently visible under x-ray and MRI when the hydrogel is resorbed. The HydroMARK Biopsy Site Marker is a permanent implant and is not intended to be removed unless the marked tissue is determined to require surgical removal. The marker is supplied pre-loaded in applicator devices designed."
223383169|NCT07185568|PROCEDURE|Magnetic Sirius Pintuition Seed®|"The Pintuition Localization System is intended as a magnetic soft tissue localization system.~The magnetic Pintuition Seed is indicated for preoperative percutaneous implantation into soft tissue (glandular, fibrous or fatty tissue of breast; lymph nodes in the axillary and inguinal region; subcutaneous tissue and skeletal muscle tissue) for temporary marking (\<180 days) of a tissue of interest (e.g. tumor or a suspected lesion) indicated for surgical removal. Using the Pintuition Detector as magnetic guidance or, alternatively, image guidance (ultrasound or x-ray), the Pintuition Seed can be intra-operatively localized and removed together with the tissue of interest."
223383170|NCT07185568|PROCEDURE|Wire localization (WL)|Single-use, repositionable needle for preoperative localization of breast nodules with a single hook, equipped with a depth limiter. Designed for the localization of non-palpable breast lesions in the preoperative phase. It includes a fixation clamp to stabilize the positioning of the wire.
223383171|NCT07186842|DRUG|BNT329|Intravenous (IV) infusion
223383172|NCT07186842|DRUG|CA19-9-targeting monoclonal antibody|Monoclonal antibody
223999889|NCT05281497|BEHAVIORAL|Social media|We built a LINE group to inspire the intervention group.
223999890|NCT05281497|OTHER|Exercise training|exercise including walk and an 18-minutes calisthenics
224123816|NCT07162844|PROCEDURE|Liquid sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure|Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure
224123817|NCT07162844|PROCEDURE|Liquid sclerotherapy in telangectasia and reticular veins wit application of herbal gel post procedure|Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure
224123818|NCT07162844|PROCEDURE|foam sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure|foam sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure
224123819|NCT07162844|PROCEDURE|foam sclerotherapy in telangectasia and reticular veins with application of herbal gel post procedure|foam sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure
224123820|NCT07161778|DRUG|Triamcinolone acetonide IM injection|"An initial loading dosage will be given and then every 4 weeks the patient will be given triamcinolone. Triamcinolone acetonide IM injection should be administered as per individual sites local procedures.~The number of Triamcinolone injections, the volume and the site of administration will be documented in the CRF. The initial dose can be split according to local administration procedures.~Cycle 1~Day 1 Week 1 (loading dose given once only)~o 360 mg IM injection~Subsequent cycles (given 4 weekly thereafter until progression +/-3 days)~Day 1~o 120 mg IM injection"
223999891|NCT04542967|BIOLOGICAL|Biological|"An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.~If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out."
223999892|NCT04393311|DRUG|Ulinastatin|Ulinastatin administered via IV infusion (200,000/infusion)
223999893|NCT04393311|DRUG|Placebo|Placebo to match ulinastatin administered via IV infusion
223999894|NCT04648592|DIETARY_SUPPLEMENT|Low salt diet plus sodium chloride supplements|Patients will receive a low salt diet plus salt supplements.
223999895|NCT04648592|DIETARY_SUPPLEMENT|Low salt diet plus placebo|Patients will receive a low salt diet plus placebo.
223999896|NCT03301155|DRUG|Anaferon for children|Tablet for oral use.
223999897|NCT03301155|DRUG|Placebo|Tablet for oral use.
223999898|NCT00731133|DRUG|Disulfiram|250 mg/day
223999899|NCT05643755|OTHER|Preoperative image-based education|Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
223999900|NCT01052610|DRUG|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
223999901|NCT01052610|DRUG|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
223999902|NCT00004442|DRUG|chenodeoxycholic acid|
223999903|NCT00004442|DRUG|cholic acid|
223999904|NCT00004442|DRUG|ursodiol|
223999905|NCT05408247|DRUG|N-acetyl cysteine|2400mg/day
223999906|NCT05408247|DRUG|Placebo|Matched placebo
223999907|NCT03510455|DRUG|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (4 weeks on drug continuously). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
223999908|NCT01534065|DEVICE|Barricaid|Implanted intra-operatively during discectomy
223999909|NCT01046929|DIETARY_SUPPLEMENT|limonene|oral dosing at 2 gram QD
223999910|NCT06131151|OTHER|Nerve block|Nerve block in percutaneous nephrolithotomy
223999911|NCT05179070|DRUG|Carvedilol|the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
223999912|NCT03414177|OTHER|Asthma Subspecialty Follow-up Visits|Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
223999913|NCT06430957|OTHER|The STOP-BANG questionnaire for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
223999914|NCT06430957|OTHER|ASA recommended criteria for determining OSA risk level.|An assessment questionnaire including OSA-related physical characteristics and symptoms and signs to be questioned individually in each patient will be examined by the physician.
223999915|NCT06430957|OTHER|Record of postoperative complications|Respiratory complications as laryngospasm/bronchospasm, apnea, hypoxia, duration and amount of need for additional oxygen support and recovery time (duration of modified aldrete score of 9 and above) will be recorded.
223999916|NCT03336359|DIAGNOSTIC_TEST|Tandem colonoscopy|Different image enhanced endoscopy systems
223999917|NCT06084767|DIAGNOSTIC_TEST|68Ga-TCR-FAPI PET/CT|A dose of 3.7 MBq/kg 68Ga-TCR-FAPI will be intravenously injected and PET examination will be carried out within the specified time.
223999918|NCT02526966|BIOLOGICAL|blood sample|dosage of anti-hinge region antibodies
223999919|NCT04498364|BEHAVIORAL|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics.
223999920|NCT02218723|DRUG|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
223999921|NCT02218723|DRUG|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
223999922|NCT00827476|PROCEDURE|ovarian transplantation|ovarian xenotransplantation or in vitro culture
223999923|NCT00455221|BIOLOGICAL|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
223999924|NCT00455221|GENETIC|Cytokine gene adjuvant|Cytokine gene adjuvant
223999925|NCT05539443|BEHAVIORAL|Intensive Clinic Management (ICM)|An in-person clinic management based on the intervention tested among stroke patients in the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial
223999926|NCT05539443|BEHAVIORAL|Intensive tailored telehealth management (ITTM)|A remote-monitoring blood pressure (BP) management strategy incorporating individualized lifestyle coaching and care planning based on the HyperLink telehealth management trial
224123821|NCT07163624|DRUG|UBT251 Injection 2.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
224123822|NCT07163624|DRUG|UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
223999927|NCT03270202|BEHAVIORAL|PAI group|"* physical activity defined as 100 weekly PAI during 1 year~* smartphone application and a user-friendly activity wristband (Mio PAI Slice)"
223999928|NCT03270202|BEHAVIORAL|Usual care|Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
223999929|NCT01790841|DEVICE|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
223383173|NCT07186023|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
223383174|NCT07186023|BEHAVIORAL|MBWC|Mindfulness-Based Well-Being Curriculum
223383175|NCT07186023|BEHAVIORAL|MBCI|Mindfulness-Based Curriculum for Insomnia
223545376|NCT00682929|DRUG|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
223545377|NCT00682929|DRUG|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
223545378|NCT00682929|DRUG|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
223383176|NCT07186023|DEVICE|BSI|Brain Stimulation Intervention
223999930|NCT04059627|DEVICE|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
223999931|NCT04150159|DIETARY_SUPPLEMENT|FMD Arm|ProLon Fasting Mimicking Diet Plan
223999932|NCT03950700|DRUG|Bupivacaine-epinephrine|BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
223999933|NCT03950700|DRUG|Saline Solution|Saline solution 0.9% (Baxter laboratories).
223999934|NCT00384189|DRUG|Ciclesonide|inhaled Ciclesonide
224123823|NCT07163624|DRUG|UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
223545379|NCT03040518|BEHAVIORAL|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
223545380|NCT03040518|BEHAVIORAL|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
223545381|NCT04311112|DRUG|Placebos|Placebo
223545382|NCT04311112|DRUG|ZA Low dose|ZA low dose
223999935|NCT00384189|DRUG|Placebo|Ciclesonide placebo-matching inhaler
223545383|NCT04311112|DRUG|ZA high dose|ZA high dose
223999936|NCT00384189|DRUG|Salbutamol|Salbutamol inhalation powder
224123824|NCT07163624|DRUG|UBT251 Injection 6.0 mg and UBT251 Injection Placebo|UBT251 Injection and UBT251 Injection Placebo once weekly
223545384|NCT06149923|GENETIC|quantitative Real-time PCR|: quantitative real time PCR using 7500 fast real time PCR (Applied Biosystems
223545385|NCT06164522|OTHER|Abdominal ultrasound|Abdominal ultrasound to detect sliding sign
223999937|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
223999938|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
223999939|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
224123825|NCT07163624|DRUG|Semaglutide Injection (Ozempic®)|Semaglutide Injection (Ozempic®) once weekly
224123826|NCT07162870|DRUG|Traditional Chinese medicine (TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure is defined as taking the medication continuously for more than 3 months per year, or intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group is divided into an exposed group (TCM cohort) and an unexposed group (non-TCM cohort).
224123827|NCT07162870|DRUG|Non-traditional Chinese medicine (non-TCM)|All intervention measures that do not meet the criteria for TCM exposure are regarded as non-TCM exposure.
223383177|NCT07185906|BEHAVIORAL|education|WhatsApp-based training was provided
223383178|NCT07186218|BEHAVIORAL|Electronic patient-reported outcome measure (ePROM) for symptom monitoring|Patients randomized to the ePROM intervention arm will be asked to complete monthly reporting of their CKD-associated symptoms using an electronic version of the Integrated Patient Outcome Scale (IPOS)-Renal survey. Their responses will be provided in summary form to their nephrology clinicians at regular intervals and prior to any nephrology clinic visits. Clinicians will be provided with guidance on symptom management and will have the option to participate in an informational session on how to interpret patient symptom responses.
223383179|NCT07186309|DEVICE|Diagnostic Test: Enlighten|"The primary analysis will examine the performance of the Enlighten Device by evaluating biomarker status results (elevated risk or low risk) at the third trimester against depression symptoms outcome data collected by the 3 months postpartum time point."
223545386|NCT06425653|OTHER|Exercise Program|"In the intervention group in addition to the standard protocol, an exercise program intervention was applied and after the initial interview the Exercise Program DVD was provided through mobile phone. All patients were evaluated 4 times: at baseline, at the 4th week (first visit), at the 8th week (second visit) and at the 12th week (final visit) after randomization"
223999940|NCT01509144|BIOLOGICAL|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
223999941|NCT01509144|BIOLOGICAL|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
223999942|NCT03912662|DEVICE|Mesh augmented reinforcement|Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh
223999943|NCT04682743|DRUG|paracetamol|received intravenous one gram of paracetamol over a 15-minute period,
223999944|NCT04682743|DRUG|ondansetron|received intravenous 8 mg of ondansetron over a 15-minute period.
223545387|NCT00094926|DRUG|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
223999945|NCT04682743|DRUG|normal saline|received intravenous 0.9% normal saline over a 15-minute period.
223999946|NCT04797052|DEVICE|Prefrontal EEG (VEEGix by NeuroServo)|Prefrontal EEG reading
223999947|NCT02086890|DEVICE|Electro-acupuncture|
223999948|NCT02086890|DEVICE|Laser Acupuncture|
223999949|NCT02086890|DEVICE|Transcorneal Electrical Stimulation|
223999950|NCT02086890|DEVICE|Sham Electro-acupuncture|
223999951|NCT02086890|DEVICE|Sham laser acupuncture|
223999952|NCT02086890|DEVICE|Sham transcorneal electrical stimulation|
223999953|NCT04958642|DRUG|Adrabetadex|Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
223999954|NCT02316327|DRUG|gemcitabine, cisplatin and bevacizumab|Therapeutic
223999955|NCT06037473|DRUG|Polyethylene glycol recombinant human growth hormone injection|0.1-0.3mg/kg.w
223999956|NCT01796015|OTHER|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).~For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.~At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.~As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
223999957|NCT01541384|DEVICE|Vitality GlowCaps|"The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT\&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval."
223999958|NCT03916406|DRUG|PF 06835919|300 mg
223999959|NCT03916406|DRUG|Midazolam|7.5 mg
223999960|NCT06595459|DRUG|Nicotine Pouches|3mg or 6mg nicotine pouches
223999961|NCT06595459|DRUG|Mini Nicotine lozenges|2mg to 4mg mini lozenges
223999962|NCT01246505|DEVICE|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
223999963|NCT04808986|DIAGNOSTIC_TEST|Serological test for the detection of IgG anti-SARS-CoV-2|Self-sampling dried-blood spot (DBS) kits will be send to each participant including material (a DBS card, lancets, pad), detailed printed instructionson how to perform thetest, and a self-addressed stamped padded envelope to be returned with the card to the centralized biobank (CEPH Biobank, Paris, France). Tubes will be sent sent to the virology laboratory (Unité des virus Émergents, Marseille, France) for serological analysis.
223999964|NCT04924712|OTHER|Measurement of blood immune populations and microbiota distribution.|Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
223999965|NCT06161207|PROCEDURE|Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection|Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
223999966|NCT02476175|DRUG|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
223999967|NCT02397551|PROCEDURE|IVF/ICSI|
223999968|NCT02397551|DRUG|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
223999969|NCT03398304|OTHER|Graded Exercise|Study arm 1 (Graded Exercise) participants will complete either 20 minutes of mild or moderate intensity at 2 different study visits. The third study visit will consist of 20 minutes of sitting.
223999970|NCT03398304|OTHER|Marathon participation|Study arm 2 (Marathon participation) participants will take part in a marathon. On the day of the marathon prior to start, the participant will be seated for 10 minutes prior to measuring their baseline heart rate. A 4.5 mL blood sample will be collected prior to initiation of exercise. Immediately after completion of the marathon, a 4.5 mL blood draw will be completed. Additional 4.5 mL blood draws will be taken at 1 and 2 days post-marathon to measure to length of time required to return to baseline coagulation, fibrinolysis, and inflammation following the prolonged, intense exercise.
223999971|NCT06847204|DRUG|Colchicine 0.5 MG Oral Tablet|Colchicine is anti inflammatory drug which will be given to Covid pneumonia patients and their benefit will be observed in them
223999972|NCT05286125|PROCEDURE|erector spinae plane (ESP) block|Using the in plane technique, the needle will be advanced between the transverse process and erector spinae muscle. The correct location will be confirmed using 1ml of Local Anesthetic (LA) to view hydrodissection(12). 19ml of LA will be injected between the muscle and transverse process.
224138475|NCT05654766|DIAGNOSTIC_TEST|Flow cytometry|Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.
224138476|NCT05654766|DIAGNOSTIC_TEST|Platelet aggregation and plasma coagulation|Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
224138477|NCT02466165|BEHAVIORAL|Physical exercise|
223545388|NCT00094926|DRUG|placebo|matching placebo IM injections every 2wks for 52wks
223545389|NCT06315972|DRUG|clemastine (8 mg/day)|add-on clemastine (8 mg/day) + aerobic exercise training
223545390|NCT06315972|DRUG|Placebo|add-on placebo + aerobic exercise training
223545391|NCT02988544|PROCEDURE|Artificial shrinkage|Artificial shrinkage of blastocyst
223545392|NCT00737724|DRUG|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
223545393|NCT00737724|DRUG|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
223383180|NCT07185438|DEVICE|Experimental target rTMS treatment|Participants will undergo MRI-guided identification of the voxel in the left dorsolateral prefrontal cortex (DLPFC) that is most negatively correlated with the functional connectivity of the subgenual anterior cingulate cortex (sgACC) as the stimulation site.
223383181|NCT07185438|DEVICE|Conventional target rTMS treatment|Participants will undergo MRI-guided identification of the standard F3 target in the dorsolateral prefrontal cortex (DLPFC) as the stimulation site.
223383182|NCT07185438|DEVICE|Sham stimulation treatment|Participants will receive a sham stimulation treatment designed to simulate the rTMS procedure without generating an effective magnetic field output.
223383183|NCT07186959|PROCEDURE|endoscopic gastric purse-string suturing|A dual-tail endoloop will be introduced into the stomach with endoscopic forceps, and will be secured to the gastric wall using endoscopic clips. An endoscope hook was used to tighten both tails of the endoloop until all the clips converged.
223999973|NCT05286125|PROCEDURE|oblique subcostal transverse abdominis plane (TAP) block|An echogenic needle will be inserted in-plane until the needle tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles. Once the needle enters the TAP plane, a dynamic injection can be performed by advancing the needle under ultrasound guidance laterally in the pocket created by the initial injection of 5 - 10 mL of local anesthetic; as the needle is advanced, the remaining local anesthetic will be injected. This allows for a more lateral spread of the local anesthetic
223999974|NCT00002320|DRUG|Lamivudine|
223999975|NCT00002320|DRUG|Zidovudine|
223999976|NCT05233475|BEHAVIORAL|Enhanced usual care (EUC)|"Enhanced usual care (EUC):~All participants will by a health professional be shortly informed about the typical recovery process, the given reassurance about the prognosis.as well as advice on adaptive illness behaviours post-concussion."
224123828|NCT07161856|PROCEDURE|a novel balloon-assisted EUS-GE|The patients will receive EUS-NBAGE under general anesthesia with endotracheal intubation. Under direct visualization with a gastroscope, contrast medium is injected to determine the location and length of the stricture. A guidewire is then placed through the stricture into the jejunum, approximately 15 cm distal to the anal side of the stricture. A double-balloon device is inserted over the guidewire. The anal-side balloon is inflated with about 40 mL of air, and under fluoroscopy, the balloon is confirmed to be well inflated. A mixture of contrast medium and methylene blue in a 1:1 dilution is injected into the proximal small intestine through the water injection channel at the proximal end of the catheter. A linear echoendoscope is inserted into the mid-body of the stomach on the greater curvature side to scan the distended small intestine loop. After identifying the distended small intestine loop, a HOT-AXIOS 1.5×1.0cm LAMS is placed under direct visualization.
224138478|NCT06461312|PROCEDURE|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block|Combined pulsed radiofrequency of the pudendal nerve with ganglion impar block
224295627|NCT05417503|OTHER|Non-invasive ventilation placebo|The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
223383184|NCT07185243|BIOLOGICAL|recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
223383185|NCT06173869|DRUG|FE 999049|FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
223383186|NCT06173869|DRUG|GONAL-F|"GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days.~Coasting was not allowed."
223383187|NCT04514679|BEHAVIORAL|Dietician / Health Coach|The order of visit for the two types of providers is first Dietician then Health Coach.
223383188|NCT04514679|BEHAVIORAL|Health Coach / Dietician|The order of visit for the two types of providers is first Health Coach then Dietician.
223383189|NCT03956355|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
223383190|NCT03956355|DRUG|Vehicle Cream|Vehicle cream applied once daily
223383191|NCT06960057|BEHAVIORAL|Virtual Reality Exposure|Participants will be exposed to a standardized 5-minute virtual reality (VR) session using a commercially available VR headset. The session features a calming, immersive environment intended to reduce anxiety and lower office blood pressure (OBP) during a clinical visit. The VR experience is delivered after the return of an ambulatory blood pressure monitoring (ABPM) device and before the final BP measurements are obtained. Blood pressure and anxiety scores are assessed immediately before and after VR exposure.
223383192|NCT06409702|DRUG|Carfilzomib|"Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued"
223999977|NCT05233475|BEHAVIORAL|Get Going after concussIoN Lite|"GAIN Lite:~GAIN Lite in an add-on to EUC, and contains two major components: 1) self-administrated e-learning videos and 2) up to four hours video- or phone sessions with an allocated therapist (either an occupational- or a physiotherapist) during a period of 8 weeks. Health professionals provide feedback and guidance, addressing the specific aims and context of the individual."
223999978|NCT06082570|DRUG|c610 injection|Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
223999979|NCT04057027|PROCEDURE|Delayed umbilical cord clamping|During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
223999980|NCT04057027|PROCEDURE|Cord Milking|Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
223999981|NCT05038124|RADIATION|Preoperative Stereotactic Body Radiotherapy (SBRT)|Target lesions will be treated with preoperative SBRT consisting of biologically effective dose (BED10) of 50.4 - 81.6 Gy delivered in either three fractions or a single fraction.
223999982|NCT01495897|DEVICE|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
224123829|NCT07161856|PROCEDURE|direct EUS-GE|"The patients will receive EUS-DGE under general anesthesia with endotracheal intubation. Under direct visualization with a gastroscope, a guidewire and/or nasobiliary catheter is passed through the stricture into the jejunum. A mixture of contrast medium and methylene blue is injected to distend the target intestinal loop. An echoendoscope is introduced into the stomach to select the optimal puncture site.~A 19G or 22G puncture needle is used to puncture the gastric and jejunal walls. Aspiration of fluid confirms the needle tip is in the jejunum, after which the channel is dilated over the guidewire. Using the delivery system of an electrocautery-enhanced fully covered lumen-apposing metal stent (LAMS), the stent is deployed to complete the gastrojejunostomy."
224123830|NCT07163039|OTHER|Dual-Task Motor-Cognitive Training|Participants assigned to this group will undergo dual-task motor-cognitive training, which combines physical exercises with simultaneous cognitive tasks. Sessions will last 45-60 minutes, three times per week, for 8 weeks. Exercises will include gait and balance activities performed while engaging in cognitive tasks such as arithmetic, memory recall, or word association.
223383193|NCT06409702|DRUG|Daratumumab|"28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued"
223383194|NCT06409702|DRUG|Lenalidomide|"28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression"
223999983|NCT01495897|DEVICE|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
224123831|NCT07163039|OTHER|Conventional Exercise Training|Participants in this group will receive a conventional exercise program focusing on strength, flexibility, and balance without a cognitive component. Sessions will last 45-60 minutes, three times per week, for 8 weeks, and will be supervised by a physiotherapist.
224295628|NCT01681602|OTHER|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
224295629|NCT03602443|BEHAVIORAL|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
224295630|NCT03602443|BEHAVIORAL|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
223383195|NCT06409702|DRUG|Dexamethasone|"28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8"
223383196|NCT06409702|DRUG|VRD for first-cycle induction therapy|"Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。"
223383197|NCT05898776|DEVICE|Lung transplantation after 10°C donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.
223545394|NCT01232439|DRUG|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg"
223545395|NCT04242628|OTHER|Facebook course|The intervention consists of the attendance to a course on Facebook and Social Networking Sites use
223999984|NCT04798170|OTHER|Utrasound|Ultrasound examination
223999985|NCT01779570|DRUG|Macrolide treatment|
224295631|NCT02246439|DRUG|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
223545396|NCT04242628|OTHER|Lifestyle Course|The intervention consists of the attendance to a course on lifestyle education and brain functioning in older people
223545397|NCT04716686|DRUG|Niraparib|Patients received oral niraparib 200/300 mg QD and every cycle (28 days) thereafter until disease progression.
223545398|NCT02942888|DIETARY_SUPPLEMENT|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
223545399|NCT02942888|DIETARY_SUPPLEMENT|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
223999986|NCT00089882|PROCEDURE|APOE Genetic susceptibility testing|
223999987|NCT06224777|BIOLOGICAL|5% Albumin (human) Solution|Albumin is a biological product derived from human blood donors.
223999988|NCT06224777|DRUG|Paeds solution|Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
223545400|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula A|
223545401|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets|
223545402|NCT02980757|DRUG|Gliclazide 120 mg MR Tablets Formula B|
223545403|NCT03580538|OTHER|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
223999989|NCT04830553|BEHAVIORAL|Music-based couple therapy.|"Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks."
223383198|NCT05898776|DEVICE|Lung transplantation after standard ice cooler donor lung preservation|When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
223383199|NCT06491264|DEVICE|Transcranial electrical stimulation|We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
223383200|NCT01437046|DRUG|Doxazosin|Doxazosin were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
223383201|NCT01437046|DRUG|Placebo|Matched placebo were prepared as opaque capsules by a compounding pharmacy and inserted into blister packs. Consistent with the recommended titration, doxazosin or matched placebo was titrated up to 16 mg daily (or maximum tolerable dose) during the first 4 weeks. A 1-week downward titration for safety reasons was also planned. Study medication adherence was assessed by self-report and pill count. Additionally, capsules contained 25mg riboflavin as a marker of adherence through urine sample.
223383202|NCT04952480|RADIATION|Dose-escalated adaptive radiotherapy|Adaptive planning of Radiation Therapy with two re-plans of the treatment field through course of therapy with the shrinking treatment fields according to tumor response to escalate dose, as allowed by dose to organs-at-risk.
223383203|NCT04952480|DRUG|Chemotherapy|Concurrent standard of care platinum doublet based therapy
223383204|NCT03999996|BIOLOGICAL|Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)|TDV subcutaneous injection
223999990|NCT03165747|DRUG|VSL#3|8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
223999991|NCT03165747|OTHER|Placebo|Two placebo sachets taken orally daily in a single administration.
223999992|NCT04320342|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
223999993|NCT04320342|DRUG|Glycopyrronium Bromide|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg
223999994|NCT04320342|DRUG|Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg
223999995|NCT05938270|DRUG|Saruparib (AZD5305)|Saruparib (AZD5305) given orally once daily
223999996|NCT05938270|DRUG|Darolutamide|Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg
223999997|NCT05938270|OTHER|No Treatment|No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice
223999998|NCT06557265|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
223999999|NCT06557265|DRUG|Fludarabine, Cyclophosphamide|Lymphodepletion
224000000|NCT00045201|DRUG|Erlotinib Hydrochloride|Given orally
224000001|NCT00045201|DRUG|Irinotecan Hydrochloride|Given IV
224000003|NCT04047251|DRUG|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
224000004|NCT04439292|DRUG|Dabrafenib Mesylate|Given PO
224000005|NCT04439292|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
224000006|NCT01476449|DRUG|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
224000007|NCT01476449|DRUG|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
224000008|NCT03805776|OTHER|Fasting (diet restruction for specific period)|12-14 hours fasting
224000009|NCT03868787|DEVICE|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
223383205|NCT03999996|BIOLOGICAL|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
223383206|NCT06804018|OTHER|Mandala coloring|Pregnant women who will paint mandalas
223383207|NCT05659173|DIAGNOSTIC_TEST|Blood taking|Blood test for vitamin D level and DNA extraction for VDR gene polymorphism
223383208|NCT01557985|DRUG|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
223383209|NCT05192382|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
224000010|NCT03868787|DEVICE|Sham TENS|Non-active TENS unit
224000011|NCT01635738|BIOLOGICAL|LP GMNL-133 capsule|One capsule with 2x10\^9 (cfu) LP GMNL-133, once daily, PO
224000012|NCT01635738|BIOLOGICAL|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10\^9 (cfu) LF GM-090, once daily, PO
224000013|NCT01635738|BIOLOGICAL|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10\^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
224000014|NCT01635738|BIOLOGICAL|Placebo|Placebo
224000015|NCT04684719|BIOLOGICAL|low titer whole blood|low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site
224295632|NCT02246439|DRUG|Placebo Oral Tablet|Placebo
224123832|NCT07163936|DEVICE|Citrate dialysate with magensium supplementation|Citrate-based bicarbonate dialysate containing: sodium 138 mmol/L, chloride 110 mmol/L, potassium 2 mmol/L, calcium 1.5 mmol/L, magnesium 0.75 mmol/L, citrate 1 mmol/L, glucose 1 g/L, bicarbonate 32 mmol/L.
223383210|NCT05192382|DRUG|Placebo|Placebo, tablets, once daily by mouth
223383211|NCT06137144|DRUG|AZD3470|AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
223383212|NCT04297761|OTHER|Filtered Air|Ambient air will be filtered and used for control exposure.
223545404|NCT05914077|DRUG|Secretin|Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure.
224000016|NCT04684719|BIOLOGICAL|Standard Care|crystalloid infusion or blood component transfusion resuscitation
224000017|NCT02103517|DIETARY_SUPPLEMENT|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
224000018|NCT02103517|DIETARY_SUPPLEMENT|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
224000019|NCT05648630|DIETARY_SUPPLEMENT|PB125|PB125 is a naturally-derived plant-based supplement that activates the Nuclear Factor Erythroid-2-like 2 (Nrf2) system to stimulate induction of endogenous antioxidants and anti-inflammatory pathways.
224000020|NCT05648630|DIETARY_SUPPLEMENT|Placebo|A placebo will be used in combination with exercise rehabilitation allowing for a double blinded placebo controlled design.
224000021|NCT05648630|BEHAVIORAL|Exercise Rehabilitation|A 12-week treadmill based supervised rehabilitation
224000022|NCT04378673|OTHER|not interventional|This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
224000023|NCT05113108|DEVICE|CUS|All neonates undergoing CUS at nursery unit at assiut university hospital. Cranial ultrasound is performed with basic grayscale imaging. For optimal resolution and good overview, a multifrequency (5-10 MHz) linear or convex sector transducer is used. Imaging is obtained through the anterior fontanel in the coronal and sagittal planes.{12,13} Typically, six to eight coronal images are obtained beginning at the frontal lobes just anterior to the frontal horns and extending to the occipital lobes posterior to the lateral ventricle trigones.{14} The transducer is then rotated 90°, and approximately five images are obtained, including a midline sagittal view of the corpus callosum and cerebellar vermis in addition to bilateral parasagittal images beginning in the midline and progressing laterally through the peripheral cortex.Doppler ultrasound may be added to assess ischemic areas.{13-15}
224000024|NCT00241046|DRUG|Letrozole|
224000025|NCT01012362|DRUG|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
224000026|NCT01012362|DRUG|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
224000027|NCT00558844|DRUG|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
224000028|NCT00558844|DRUG|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
224000029|NCT00558844|DRUG|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
224000030|NCT00558844|DRUG|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
224000031|NCT00558844|DRUG|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
224000032|NCT01310608|OTHER|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
224123833|NCT07163936|DEVICE|Acetate dialysate|Acetate-based bicarbonate dialysate containing: sodium 138 mmol/L, chloride 109 mmol/L, potassium 2 mmol/L, calcium 1.5 mmol/L, magnesium 0.5 mmol/L, acetate 3 mmol/L, glucose 1 g/L, bicarbonate 32 mmol/L.
224123834|NCT05521074|DEVICE|Active tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid.
224123835|NCT05521074|DEVICE|Sham tDCS|The investigators will use commercially available tDCS equipment (Neuroelectrics©, Barcelona, Spain). The cathode will be placed over the pre-SMA using the 10-20 EEG system and the anode will be on the right deltoid. tDCS will not be active in this condition.
223383213|NCT04297761|OTHER|Wood Smoke|Wood smoke is generated by smoldering dry white oak logs and the exposure level will be maintained at an average of 500 µg/m\^3 for 2 hours.
223383214|NCT02795338|PROCEDURE|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
223383215|NCT00005603|DRUG|asparaginase|
223383216|NCT00005603|DRUG|cyclophosphamide|
223383217|NCT00005603|DRUG|cytarabine|
223383218|NCT00005603|DRUG|daunorubicin hydrochloride|
223383219|NCT00005603|DRUG|dexamethasone|
223383220|NCT00005603|DRUG|doxorubicin hydrochloride|
223383221|NCT00005603|DRUG|mercaptopurine|
223383222|NCT00005603|DRUG|methotrexate|
223383223|NCT00005603|DRUG|prednisone|
223383224|NCT00005603|DRUG|thioguanine|
224000033|NCT01533818|DRUG|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
223383225|NCT00005603|DRUG|vincristine sulfate|
223383226|NCT01391715|DRUG|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
223383227|NCT01391715|DRUG|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
223383228|NCT04940988|OTHER|Real-time benefits check|Prescribers practicing in outpatient departments assigned to the intervention arm will be shown popup alerts with their patient's insurance benefit design-specific out-of-pocket cost for the drug being ordered as well as out-of-pocket costs for up to 3 lower-cost alternatives if available. Alternatives will only be shown when available and when the patient and his or her benefit design information can be matched by the electronic health record system to accurately query out-of-pocket cost information.
223383229|NCT00573261|DRUG|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
223383230|NCT00573261|DRUG|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
224000034|NCT01533818|DRUG|Sugar Syrup|It will be given 2 times/day for 7 days
224000035|NCT06136104|DIETARY_SUPPLEMENT|Mixhers HERTIME|A daily self-administered powder supplement packet mixed into water.
224000036|NCT06136104|DIETARY_SUPPLEMENT|Placebo|A daily self-administered powder placebo supplement packet mixed into water.
224000037|NCT01720277|BIOLOGICAL|HD Fluzone Vaccine|Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).
224000038|NCT01720277|BIOLOGICAL|SD Fluzone Vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
224000039|NCT00175643|DRUG|imiquimod|
224000040|NCT03333213|OTHER|Gua Sha|
224000041|NCT06044038|BEHAVIORAL|Physical activity|Bi-weekly supervised physical activity intervention
224000042|NCT06044038|BEHAVIORAL|Cognitive rehabilitation program|weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
223383231|NCT00002376|DRUG|Indinavir sulfate|
223383232|NCT00002376|DRUG|Lamivudine|
223383233|NCT00002376|DRUG|Stavudine|
223383234|NCT00002376|DRUG|Zidovudine|
223383235|NCT00002376|DRUG|Didanosine|
223383236|NCT06170697|DRUG|Camrelizumab|200mg, iv, d1, q3w
223383237|NCT06170697|DRUG|Cisplatin|80-100mg/m2, iv, q3w, 2-3 cycles in total
223383238|NCT06170697|DRUG|Carboplatin|AUC 2, iv, q1w, 5-7 cycles in total
223383239|NCT06170697|DRUG|Lobaplatin|30mg/m2, iv, q3w, 2-3 cycles in total
223383240|NCT06170697|DRUG|Nedaplatin|25-30 mg/m2, iv, q1w, 5-7 cycles in total
223383241|NCT06170697|RADIATION|Radiotherapy|PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F；PTV1 60Gy/1.8-2.0Gy/30-33F；PTV2 50Gy/1.8-20Gy/25-28F；Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy
223383242|NCT00929461|DRUG|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
224000043|NCT01907867|DRUG|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
224000044|NCT02277184|DRUG|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
224123836|NCT06395441|DIETARY_SUPPLEMENT|American Ginseng|Given PO
224123837|NCT06395441|DRUG|Placebo Administration|Given PO
224123838|NCT06395441|OTHER|Questionnaire Administration|Ancillary studies
223383243|NCT00956111|BIOLOGICAL|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
223545405|NCT05914077|PROCEDURE|Endoscopic aspiration|Endoscopic aspiration of duodenopancreatic juice after secretin stimulation
223545406|NCT05914077|PROCEDURE|Endoscopic ultrasound-guided fine needle aspiration|Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN).
223545407|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
223545408|NCT02373046|DRUG|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
223545409|NCT00066612|DRUG|irinotecan hydrochloride|Irinotecan will be given 250 mg/m\^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
224123839|NCT05345691|BIOLOGICAL|Bmab 1000|60 mg administered as a single SC (subcutaneous) injection once every 6 months.
224123840|NCT05345691|BIOLOGICAL|Prolia®|60 mg administered as a single SC injection once every 6 months
224123841|NCT06367582|DEVICE|Vertebroplasty (VP)|Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
224123842|NCT06367582|DEVICE|Kyphoplasty (KP)|Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain
223383244|NCT00956111|BIOLOGICAL|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
223383245|NCT00956111|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
223383246|NCT00956111|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
223729888|NCT02502643|DRUG|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
223729889|NCT01661439|DRUG|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
223729890|NCT05229237|DRUG|Conbercept|Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)
224000045|NCT02277184|DRUG|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
224000046|NCT02277184|RADIATION|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
224000047|NCT05785403|OTHER|No intervention|No intervention
224000048|NCT01399697|DRUG|methotrexate|orally, Week 1 - 16
224000049|NCT01399697|DRUG|methotrexate|orally, Week 17-28
224000050|NCT01399697|DRUG|placebo|methotrexate placebo orally, Week 17-28
224000051|NCT01399697|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 28 weeks
224000052|NCT02579135|BEHAVIORAL|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
224123843|NCT06367582|DEVICE|Pedicular Screw Augmentation (PSA)|Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
224295633|NCT04102813|BEHAVIORAL|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
223383247|NCT00956111|BIOLOGICAL|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
224000053|NCT02579135|BEHAVIORAL|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
224295634|NCT03439852|BEHAVIORAL|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
223383248|NCT00956111|BIOLOGICAL|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
223383249|NCT00956111|BIOLOGICAL|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
224295635|NCT05892484|DEVICE|Thermal Imaging|Thermal Imaging device used to evaluate fracture in those presenting with proposed wrist fracture in the emergency department.
223383250|NCT00733005|DRUG|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
223383251|NCT00733005|DRUG|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
223383252|NCT03684577|BEHAVIORAL|Hypnotherapy for Agoraphobia|see description of the experimental arm
223729891|NCT00488176|DRUG|montelukast|montelukast sodium
224000054|NCT04647838|DRUG|Tepotinib|Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
224000055|NCT01146600|DRUG|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
224000056|NCT01146600|DRUG|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
224000057|NCT06107868|DRUG|RP-6306|RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.
224123844|NCT05600400|RADIATION|Stereotactic Ablative Body Radiation|2 Fraction
224123845|NCT06318897|DRUG|Carboplatin|Given by IV
224123846|NCT06318897|DRUG|Paclitaxel|Given by IV
224123847|NCT06318897|DRUG|Pembrolizumab|Given by IV
224123848|NCT06318897|DRUG|Doxorubicin|Given by IV
224123849|NCT06318897|DRUG|Cyclophosphamide|Given by IV
223383253|NCT00136253|BEHAVIORAL|Help dietitians and patients address specific nutritional barriers|
223383254|NCT04827498|DIAGNOSTIC_TEST|Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment|Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
223383255|NCT04552353|DRUG|Vaway|Drug: Voriconazole. Pharmacokinetic study under fasting conditions
223383256|NCT00387777|DRUG|Patch with centrally acting analgesic|
223383257|NCT00387777|DRUG|Transtec(R) PRO (buprenorphine)|
223383258|NCT00324077|DRUG|Dasatinib in combination with imatinib|
224000058|NCT06107868|DRUG|Carboplatin|Carboplatin is an antineoplastic agent.
224000059|NCT06107868|DRUG|Paclitaxel|Paclitaxel is an antineoplastic agent.
224000060|NCT03507426|PROCEDURE|Retrobulbar block|Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% \& Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.
223383259|NCT02377297|PROCEDURE|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
224000061|NCT03507426|PROCEDURE|Ketamine|Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.
223383260|NCT02377297|PROCEDURE|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
224000062|NCT05085171|OTHER|Enhanced care package|The intervention is an improved package of care for patients with advanced HIV disease with point of care CD4 testing, more sensitive screening tests for opportunistic infections and more intensive pre-emptive treatment for opportunistic infections
224000063|NCT02812940|DRUG|Everolimus|GvHD prophylaxis
224000064|NCT05143398|DIETARY_SUPPLEMENT|Diet + protein|Comparison of the efficacy
224000065|NCT05143398|DIETARY_SUPPLEMENT|Diet + EAA|Comparison of the efficacy
224000066|NCT05143398|DIETARY_SUPPLEMENT|Diet + EAA and TCA|Comparison of the efficacy
224000067|NCT05143398|OTHER|Diet|Comparison of the efficacy
224000068|NCT04324450|DEVICE|MRI|"The MRI protocol is composed of:~* T1-weighted anatomical sequences~* DTI sequences~* resting functional MRI~* 3D MR spectroscopic imaging"
224295636|NCT05892484|DIAGNOSTIC_TEST|X-RAY|Routine X-RAY
224295637|NCT04774887|BIOLOGICAL|HPV vaccine, Merck|Vaccination against HPV will be offered to 900 children/grandchildren aged 9 through 18 of women attending the Community Meetings.
223383261|NCT02377297|PROCEDURE|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
223383262|NCT06011447|OTHER|Device to view the skin|Application of device to help view the wound area better
223383263|NCT01205087|DRUG|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
223383264|NCT05622487|OTHER|Neural Therapy|Neural therapy is a form of treatment that aims to act on the autonomic nervous system, by injecting local anesthetics into certain parts of the body.
223383265|NCT05622487|OTHER|Kinesio taping|Kinesiotape is used for injury prevention, rehabilitation and performance enhancement. It has been shown to be clinically effective in increasing joint movements, increasing muscle activity, inducing muscle maximum torque earlier, and improving functional performance
223383266|NCT03771287|DEVICE|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
223383267|NCT03771287|DEVICE|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
224000069|NCT04324450|BEHAVIORAL|Cognitive assessment|Battery of neuropsychological tests
224000070|NCT04870268|PROCEDURE|percutaneous drainage|
224000071|NCT04870268|PROCEDURE|endoscopic approach|
224295638|NCT05732974|OTHER|Resected non small cell lung cancer|plasma sample, tissue sample and computed tomography scan images
224000072|NCT04870268|PROCEDURE|surgical internal derivation of WON|
224000073|NCT04870268|PROCEDURE|surgical necrosectomy|
224000074|NCT01796054|BEHAVIORAL|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
224000075|NCT01796054|BEHAVIORAL|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
224000076|NCT00477503|DRUG|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
224000077|NCT00477503|DRUG|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
223383268|NCT00993356|DRUG|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH \> 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
223383269|NCT00993356|PROCEDURE|Transsphenoidal surgery|
223383270|NCT01624025|OTHER|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
223383271|NCT00484068|DRUG|enalapril|
223383272|NCT00484068|PROCEDURE|chicken diet|
223383273|NCT04418102|DIETARY_SUPPLEMENT|Palmitic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period
223383274|NCT04418102|DIETARY_SUPPLEMENT|Stearic acid rich interesterified fat|Muffins and spread containing the palmitic acid rich IE fat will be consumed daily for a 6-week dietary intervention period.
223383275|NCT00042601|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
223545410|NCT05310123|DIETARY_SUPPLEMENT|AC-11|6-months of treatment with AC-11
224000078|NCT01921153|OTHER|Healthy meal plates and trays|The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
223383276|NCT00042601|DRUG|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
223383277|NCT00876330|OTHER|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
223383278|NCT00876330|OTHER|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
223383279|NCT00876330|OTHER|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
223383280|NCT00876330|OTHER|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
223383281|NCT02480101|BIOLOGICAL|H7N9 live influenza vaccine|H7N9 live influenza vaccine
223545411|NCT01462929|DRUG|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
224000079|NCT01448629|DEVICE|Standard Care|"Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names."
224000080|NCT01448629|DEVICE|River|River is a new developed product with Coloplast as manufacturer
224000081|NCT01428375|DRUG|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
224000082|NCT01428375|OTHER|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
224000083|NCT04387500|DRUG|Sintilimab injection plus Inlyta treatment|Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
224000084|NCT05378477|DEVICE|X92001752|The test product is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
224000085|NCT05378477|DEVICE|RID Super Max Solution|RID Super Max Solution is a lotion to be applied on dry hair for 10 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
224000086|NCT05378477|DRUG|Nix Crème|Nix crème must be applied on dry hair for 10 minutes and then washed out with water. The product is to be applied on Day 0 and repeated again on Day 7.
224000087|NCT05378477|DEVICE|Pouxit Végétal|Pouxit Végétal must be applied on dry hair for 30 minutes and then washed out using shampoo. According to the instructions for use, only 1 treatment must be performed.
224000088|NCT00990795|DRUG|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
223729892|NCT00488176|DRUG|cetirizine|cetirizine
224000089|NCT00990795|DRUG|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
224000090|NCT04594044|BEHAVIORAL|tics training including habit reversal training and exposure response prevention|In an open randomized controlled study, youth were randomized to either individualized, or group treatment. Both therapies included nine sessions, and the parents were offered one group-session.
224000091|NCT04218032|DEVICE|sphygmomanometer, SpyghmoCor, CNAP500|blood pressure is measured with developed new non-invasive technology, oscillometry from the fingertip, and compared to non-invasive standard blood pressure measurement using a standard sphygmomanometer/SpyghmoCor device/CNAP500 device.
224000092|NCT02627417|DRUG|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
224000093|NCT02627417|DRUG|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
224123850|NCT03721068|BIOLOGICAL|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10\^6, 1.0 x 10\^6, 1.5 x 10\^6
224123851|NCT03721068|DRUG|Cyclophosphamide|500 mg/m\^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
224123852|NCT03721068|DRUG|Fludarabine|30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
223383282|NCT02480101|BIOLOGICAL|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
223383283|NCT06139146|OTHER|Muscle energy technique (MET)|"MET treatment protocol of pectoral major:~The patient's position was supine lying. Starting with the position which took the affected fibres to just short of their restriction barrier, the patient introduced a light contraction involving adduction of the arm against resistance from the therapist for 7-10 seconds. As the patient exhaled the therapist stretched across the new barrier.~MET treatment protocol of upper trapezius:~The patient moved the stabilized shoulder in a shrug motion toward the ear, and the ear toward the shoulder, with a light resistance (20% of possible strength). The contraction was sustained for 7-1 0 seconds MET treatment protocol of levator scapula The patient was in a supine position, with the hand supinated and the arm of the side to be tested extended alongside the trunk.~Strengthening of deep neck flexors: Patient was instructed to his nod head to flatten the neck's curve. 10 reps for 10 sec."
223383284|NCT06139146|OTHER|Core stability exercises:|"Warm up: The cat and camel stretches~Exercises:~* It included Crook lying, abdominal bracing, and 10 second - 20 repetitions (reps).~* Crook lying, abdominal Bracing with leg lifts holding the position for 3 second for 10 reps.~* Crook lying, abdominal Bracing with bridging with 10 reps with a 10 second hold.~* It included a Quadruped position with abdominal bracing for 10 s - 10 reps~* Quadruped position arm lifts with abdominal bracing 10 reps on each side.~* Quadruped position leg lifts with abdominal bracing 10 reps on each side.~* Quadruped position alternate arm and leg lifts with abdominal bracing holding position for 3 s - 10 reps on each side.~* The curl-up in hook lying, Fold arms across the torso. Lift shoulder blades off the ground. 1 to 2 seconds holds - 10 reps.~* Side plank on knees; holding position for 10 s - 5 reps ."
224000094|NCT02627417|DRUG|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
223729893|NCT00488176|DRUG|montelukast and cetirizine|montelukast and cetirizine
224000095|NCT04715373|PROCEDURE|LISA|LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP
224000096|NCT02619903|PROCEDURE|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
224000097|NCT05380557|DIAGNOSTIC_TEST|Germline genetic testing|Germline genetic testing will be provided to each patient
224000098|NCT02649738|PROCEDURE|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
224000099|NCT01624077|BIOLOGICAL|Regulatory T cells|Tregs will inject after liver transplantation
224000100|NCT06305052|OTHER|Milk|"Premature newborns allocated to the intervention group will receive olfactory and taste stimuli immediately before feeding through an oral/nasal gastric tube.~In the intervention group, the taste stimulus will be carried out through a drop of milk administered directly to the tongue of the premature baby if he is awake, if the newborn is sleeping the milk will be placed on his lips.~The olfactory stimulus will be offered through a drop of milk using a cotton swab, positioned close to the premature baby's nostrils as close as possible without touching them, immediately before the tube diet."
224000101|NCT06305052|OTHER|Water|In the control group, the taste stimulus will be done through a drop of double-distilled water on a cotton swab, then administered directly to the tongue of the premature baby if he is awake, however, when he is sleeping, the drop of water will be deposited on his lips. The olfactory stimulus in the control group will be carried out with a drop of double-distilled water using a cotton swab, positioned close to the nostrils as close as possible without touching them, immediately before carrying out the tube diet.
224123853|NCT06548386|DEVICE|Pleural gas analysis|"Patients enrolled in this study will undergo both VI and pleural gas analysis to assess for air leak following surgical chest tube placement.~For pleural gas analysis, an outlet gas analyzer will be kept on the outlet port of the chest drain for the entire duration of time that a chest tube is in place. We plan to collect both continuous data, looking for intermittent spikes and gas changes, along with episodic data collected during specific air leak assessments. The gas analyzer may better be able to measure an air leak during these specific procedures conducted twice per day, but it will also be used at the outlet port of the chest drain the rest of the time to continuously check for an air leak throughout the hospital stay."
224123854|NCT06386315|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224123855|NCT06386315|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
224123856|NCT06386315|RADIATION|Involved-site Radiation Therapy (3 Fractions)|Undergo ISRT in 3 fractions
223729894|NCT00488176|DRUG|placebo|placebo
223729895|NCT02973217|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|
224123857|NCT06386315|RADIATION|Involved-site Radiation Therapy (12 Fractions)|Undergo ISRT in 12 fractions
224123858|NCT06386315|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224123859|NCT06386315|OTHER|Questionnaire Administration|Ancillary studies
224123860|NCT06644755|DRUG|DS-2243a|"Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE"
223729896|NCT00547092|DRUG|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
224000102|NCT01857089|DEVICE|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement"
224000103|NCT02766777|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration.
224000104|NCT02179567|DRUG|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
224000105|NCT02179567|DRUG|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
224000106|NCT01457898|DEVICE|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
224000107|NCT03461159|OTHER|Operant conditioning of H-reflexes|Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
224123861|NCT06315218|BEHAVIORAL|iTHRIVE 365 HIV care intervention|iTHRIVE 365 is a multicomponent intervention that combines mHealth features and institutional to support community priorities identified in formative CBPR. In line with best-practices for trials of intervention principles (TIPs) with mHealth interventions, iTHRIVE 365 deploys intervention elements that serve to accomplish intervention strategies. iTHRIVE 365 intervention strategies are to promote: 1)Health knowledge and motivation; 2)Social support coping; 3)Access to culturally-affirming healthcare; and 4)Housing and other economic resources. iTHRIVE 365 pursues these strategies via these intervention elements: 1)Weekly HIV and psychological health information and motivation content and daily health notifications; 2)Online moderated forums, interpersonal chats, and community calendars; 3)Linkage to biopsychosocial healthcare via THRIVE SS's network of Black SGLM-affirming providers; and 4)Housing and economic resources through THRIVE SS's direct support and referral network.
224123862|NCT06195280|RADIATION|Magnetic resonance imaging, 3DT1 sequence|The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
224123863|NCT06195280|PROCEDURE|Laparoscopy|After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
224123864|NCT04188405|DRUG|Decitabine|Given IV
224123865|NCT04188405|DRUG|Ponatinib|Given PO
224123866|NCT04188405|DRUG|Venetoclax|Given PO
223383285|NCT05954520|DEVICE|Tympan|Participants will wear a prototype hearing aid (called the Tympan)
223383286|NCT00266630|DRUG|olanzapine|oral, daily
223729897|NCT00547092|DRUG|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
224000108|NCT03461159|OTHER|Operant conditioning of motor evoked potentials|Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
224000109|NCT06027606|DRUG|Salbutamol 400mcg|Salbutamol is a short-acting beta-agonist used primarily as a rescue inhaler for respiratory disease such as asthma
224000110|NCT06027606|DRUG|Budesonide/formoterol|Budesonide/formoterol is a inhaled corticosteroid with long-acting beta-agonist component primarily used as a maintenance inhaler for respiratory conditions such as asthma
224000111|NCT06027606|DRUG|Placebo|Practice inhaler primarily used in training scenarios so looks identical to medical inhalers
224000112|NCT02238418|DRUG|Cholecalciferol vial (100 000 UI)|"VISIT 1:~Patient \> 60 kg and initial 25OHD serum concentration \< 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration \< 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient \< 20 kg and initial 25OHD serum concentration \< 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~* at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~* at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1"
224000113|NCT01162577|BEHAVIORAL|Weight Concerns|Standard Quitline plus weight coaching
223383287|NCT00266630|DRUG|lithium|Dose adjusted according to local package insert
224000114|NCT04313608|DRUG|Glofitamab|Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.
224000115|NCT04313608|DRUG|Gemcitabine|Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
224000116|NCT04313608|DRUG|Oxaliplatin|Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.
223383288|NCT00266630|DRUG|valproate|Dose adjusted according to local package insert
224000117|NCT04313608|DRUG|Mosunetuzumab|Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.
223383289|NCT00266630|DRUG|carbamazepine|Dose adjusted according to local package insert
223383290|NCT03410056|DRUG|Efavaleukin alfa|Efavaleukin alfa administered as a subcutaneous injection.
223729898|NCT04480437|DEVICE|mp-BUS data collection|Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.
223729899|NCT01168531|DRUG|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
224000118|NCT04313608|DRUG|Obinutuzumab|Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.
224000119|NCT04313608|DRUG|Tocilizumab|Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
224000120|NCT06160817|PROCEDURE|Conservative sharp debridement|The debridement method for all patients, regardless of the assigned sequence, will involve the removal of non-viable tissue from the ulcer bed, edges, and perilesional skin using a scalpel (No. 3) with a No. 10 and/or No. 15 blade, along with Adson forceps and straight dissecting forceps.
224000121|NCT00504673|DRUG|insulin detemir|
224000122|NCT00504673|DRUG|insulin NPH|
224000123|NCT00504673|DRUG|insulin aspart|
224000124|NCT05104203|PROCEDURE|Thoracolumbar Interfascial Plane block|Interfascial block done by injection between m. multifidus and m. longissimus
224000125|NCT05104203|PROCEDURE|Modified Thorcolumbar Interfascial Plane block|Injection of local anesthetics between m. longissimus and m. illiocostalis
224000126|NCT05854407|OTHER|skim milk|pasteurized or high-pasteurized skim milk
224138479|NCT01848639|DRUG|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
223383291|NCT03410056|DRUG|Placebo|Placebo administered as a subcutaneous injection.
223383292|NCT00327366|PROCEDURE|Light therapy|
223383293|NCT05840458|PROCEDURE|PENG Block|Patient will be placed in the supine position and the ultrasound probe will be placed in the transverse plane over the anterior inferior iliac spine (AIIS) and aligned with the pubic ramus by rotating the probe counterclockwise by approximately 45 degrees. A 22-gauge, 100 mm needle will be inserted using the plane approach from lateral to medial, between the psoas tendon anteriorly and the pubic ramus posteriorly. Following a negative aspiration, 20 mL of 0.375% ropivacaine will be injected. The needle position will be confirmed by visualizing the separation of layers with the dispersion of the injected volume.
223383294|NCT06341816|OTHER|VEXUS score|The VExUS score is obtained as follows: VEXUS 0: IVC \< 20mm; VEXUS 1: IVC ≥ 20mm with normal patterns or mild abnormalities; VEXUS 2: IVC ≥ 20mm with severe abnormality in at least one pattern and VEXUS 3: IVC ≥ 20mm and severe abnormalities in multiple patterns.
223729900|NCT01168531|DRUG|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
223729901|NCT01168531|DRUG|placebo|vitamin B complex formula
223729902|NCT00864045|DRUG|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
223729903|NCT00864045|DRUG|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
223729904|NCT01922128|DRUG|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
224000127|NCT03799744|GENETIC|VCN-01|Dose level 1: 3.3x10\^12 viral particles/patient and Dose level 2: 1x10\^13 viral particles/patient
224000128|NCT03799744|BIOLOGICAL|Durvalumab|Dose: 1500 mg Q4W
224000129|NCT05134987|DRUG|NNC0363-0845|Participants will receive 0.5 nmol/kg NNC0363-0845 s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 3 nmol/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
224000130|NCT05134987|DRUG|Insulin detemir|Participants will receive 0.083 U/kg insulin detemir s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 0.5 U/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
224000131|NCT00447746|PROCEDURE|D1 or D2 lymphadenectomy for gastric cancer patients|
224000132|NCT04243551|DRUG|Latiglutenase|Administered orally (daily)
224000133|NCT04243551|OTHER|Placebo|Administered orally (daily)
224000134|NCT04996732|PROCEDURE|hospitalization|Including various treatments such as surgery, radiotherapy, chemotherapy and immunotherapy during hospitalization
224000135|NCT03290053|DRUG|SonoVue|SonoVue-infusion over 1 hour
224000136|NCT03290053|DRUG|Sodium chloride|Placebo
224000137|NCT03290053|PROCEDURE|Transcranial Ultrasound|Transcranial ultrasound aimed at the blockage
224000138|NCT03290053|PROCEDURE|Sham Transcranial Ultrasound|Placebo - machine is attached, but not active
224000139|NCT02964325|DEVICE|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
224000140|NCT02964325|DEVICE|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
224000141|NCT02182050|DRUG|BIBF 1120 ES low dose|
224000142|NCT02182050|DRUG|BIBF 1120 ES high dose|
224000143|NCT02182050|DRUG|Placebo to BIBF 1120 ES|
224123867|NCT06672458|DEVICE|MyndMove Short Term Therapy|FES therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. FES therapy uses surface electrical stimulation to produce muscle contractions in different combinations to achieve a wide range of reaching and grasping functions. To achieve these movements the single use electrodes will be placed in various combinations on the surface of the different upper arm muscles. Participants will perform hand and finger dexterity tests as well as arm functional mobility tasks while receiving FES.
224000144|NCT04659330|BEHAVIORAL|Online education (BdandMe) for injection technique|patients were referred to the relevant modules on BD and Me™ (for online education)
224000145|NCT04659330|DEVICE|4mm needles|Providing a supply of needles for single use of 4mm insulin injection needle.
224000146|NCT00800553|DRUG|donepezil|5mg o.m. p.o. for approx. 2 weeks
224000147|NCT00800553|DRUG|Placebo|5mg of placebo for approx. 2 weeks
224000148|NCT05552300|PROCEDURE|SAAE|SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines
224000149|NCT05552300|DRUG|traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
224000150|NCT02338453|BEHAVIORAL|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
224000151|NCT02338453|BEHAVIORAL|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
224000152|NCT04995770|BEHAVIORAL|Praise Text Messages|Texting messages with praise content, to positive reinforce medication adherence
224000153|NCT01860326|DRUG|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
223383295|NCT06341816|DIAGNOSTIC_TEST|NGAL|Neutrophil gelatinase-associated lipocalin
223383296|NCT04983134|BEHAVIORAL|Enhanced CHW Intervention|community-based intervention
224000154|NCT01368471|DEVICE|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
224000155|NCT01368471|DEVICE|Control BMS or DES|Control BMS or DES
224000156|NCT01133782|PROCEDURE|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
224000157|NCT02510040|DEVICE|Prism|Ground-in or Fresnel prism
224000158|NCT02510040|OTHER|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
224000159|NCT02510040|PROCEDURE|Eye Muscle Surgery|"* Bilateral medial rectus muscle resection surgery~* Single medial rectus muscle resection surgery~* Recess lateral rectus muscle resection medial rectus muscle surgery~* Bilateral lateral rectus muscle recession surgery~* Single lateral rectus muscle recession surgery~* Bilateral lateral rectus muscle resection surgery~* Single lateral rectus muscle resection surgery~* Recess medial rectus muscle resection lateral rectus muscle surgery~* Bilateral medial rectus muscle recession surgery~* Single medial rectus muscle recession surgery~* Vertical rectus muscle recession surgery~* Vertical rectus muscle mini-tenotomy (snip) surgery"
224000160|NCT02510040|PROCEDURE|Botox Injection|Botulinum toxin injection
224000161|NCT04695184|DIAGNOSTIC_TEST|ICG-NIRF Imaging|intraoperative NIRF Imaging using the fluorescence agent ICG (indocyanine-green) at regions of interest before (T1) + after pouch construction (T2) + after ileoanal anastomosis (T3)
224000162|NCT03225326|DRUG|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
223383297|NCT06486714|PROCEDURE|Total knee arthroplasty|All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
223383298|NCT04949412|DIAGNOSTIC_TEST|Vitamin D|serum vitamin D level
224000163|NCT03225326|DRUG|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
224000164|NCT05684549|OTHER|No intervention|Observational study, no intervention
224000165|NCT02157051|BIOLOGICAL|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
224000166|NCT02157051|OTHER|Laboratory Biomarker Analysis|Correlative studies
224000167|NCT06064019|DEVICE|Nevisense|The Nevisense system is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Since skin tissues have different electrical properties depending on cell structure and medical conditions, the resulting electrical impedance spectra will reflect the properties of the skin tissue.
224000168|NCT00198276|COMBINATION_PRODUCT|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
224123868|NCT06672458|OTHER|Conventional Short Term Therapy|Therapy will be provided in one visit (one hour duration) delivered within a 2 week period, in person. Conventional therapy will consist of performance hand and finger dexterity tests as well as arm functional mobility tasks
224123869|NCT06672458|DEVICE|MyndMove Long Term Therapy|FES upper arm therapy will be provided in one-hour in-person sessions for a maximum of 40 sessions delivered no less than 3 times per week and up to 5 times per week during a period of up to 12 weeks. Over the course of 40 sessions, participants will progress through various movement sequences aimed at regaining natural, unassisted voluntary movements in the affected arms while receiving FES.
224000169|NCT06382662|DRUG|metaxalone m640|A single dose of micronize metaxalone 640 mg
224123870|NCT06401642|DRUG|Zavegepant|10 mg intranasal
223383299|NCT00422110|DRUG|Seletracetam|
223383300|NCT01216735|DRUG|Fluticasone|220 ug twice a day for 3 weeks
223383301|NCT01216735|DRUG|Placebo|Placebo for 3 weeks
223729905|NCT05487781|COMBINATION_PRODUCT|Tirfostina/L-Carnitina|Estudio clínico fase 1 para describir la seguridad biológica y la farmacocinética de la tirfostina AG-17
223383302|NCT04133857|OTHER|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
224000170|NCT06382662|DRUG|tizanidine|A single dose of tizanidine 8 mg
224000171|NCT00594698|DRUG|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
224000172|NCT00612118|DRUG|GSK256066|200mcg bd
223383303|NCT02986529|DRUG|GV-971|
223729906|NCT05156853|DIETARY_SUPPLEMENT|Insect menus|The insect menus will consist of 6 different products: flatbread, spice-mix, paste, minced meat, sausage and falafels. The products are based on either crickets, mealworms or buffaloworm larvae.
224000173|NCT00612118|DRUG|azelastine hydrochloride|140mcg
224000174|NCT02145832|DRUG|Fluconazole|
223383304|NCT02986529|DRUG|Placebos|
223383305|NCT06191289|DRUG|Transdermal Estradiol|"1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test~Other Names:~Climara"
223383306|NCT06191289|OTHER|Placebo|Weekly application of a placebo patch for 14 days starting day 7 after positive urine luteinizing hormone test
223383307|NCT05309811|DEVICE|RLRL therapy|Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
223383308|NCT05309811|DRUG|Routine IOP-lowering medications|Medications prescribed for IOP control by glaucoma specialists in the outpatient.
223383309|NCT00050128|DEVICE|rTMS, Magstim|
223383310|NCT05177185|RADIATION|Hippocampal-sparing|Dose constraint placed on hippocampi to minimize dose to hippocampi, while maintaining target coverage (at least 98% of brain metastasis volume must receive 100% of prescription dose).
223383311|NCT05177185|RADIATION|Stereotactic radiosurgery|Stereotactic radiosurgery (SRS) with prescription dose determined based on size of brain metastasis; 21 or 24 Gy in a single fraction if less than or equal to 20 mm, 18Gy in a single fraction in 21 - 30 mm, 15 Gy in a single fraction or 30 Gy in 5 fractions if 31 - 40 mm (physician discretion).
223383312|NCT02342301|BEHAVIORAL|Standing Desk|Participants will be provided with a standing desk for 3 months
224000175|NCT02145832|DRUG|Micafungin|
224000176|NCT03705897|OTHER|Computerized Risk Stratification Tool|Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen
224000177|NCT03705897|OTHER|Algorithmic Risk Stratification Tool|Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy
224000178|NCT03705897|OTHER|Step completion assessment|Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
224000179|NCT06471075|BEHAVIORAL|Mindful Pain Management|The mindfulness intervention will involve a 2-minute introduction to mindfulness as a technique for pain management followed by a 5-minute, audio-guided, mindful breathing practice.
224000180|NCT06471075|BEHAVIORAL|Pain Psychoeducation|In the pain psychoeducation intervention, participants will be provided timematched information about different pain management strategies (e.g., ice, rest) and accessible resources to promote overall well-being.
224000181|NCT02358447|PROCEDURE|TKR|non-navigated versus computer-navigated total knee replacement
223383313|NCT02342301|BEHAVIORAL|Traditional Desk|Participants will use a traditional seated desk for 3 months
223383314|NCT00141050|DRUG|Focalin XR|
223383315|NCT05239611|DIAGNOSTIC_TEST|Xenon MRI|Study participants will be randomized to a 12 week exercise intervention versus usual care. Participants will have Xenon MRI at study start and completion to evaluate impact of exercise on lung function. The exercise intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
223383316|NCT04015271|BEHAVIORAL|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
224000182|NCT06372106|DEVICE|SaO2 Sampling|CO-Oximetry analysis of arterial blood samples
224000183|NCT02885415|PROCEDURE|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
224000184|NCT04099797|GENETIC|C7R-GD2.CART cells (IV and ICV infusion)|"Dose levels administered are by IV infusion followed by ICV infusion.~Cycle 1: 10 million cells/m2 delivered IV with lymphodepletion.~Cycle 2 (and subsequent cycles):~Dose level 1: 2 million cells ICV with lymphodepletion. Dose level 2: 5 million cells ICV with lymphodepletion."
224000185|NCT04099797|GENETIC|C7R-GD2.CAR T cells (IV infusion)|Dose levels administered are by IV infusion. For all cycles, the dose level is 10 million cells/m2 IV with lymphodepletion.
224000186|NCT03079284|OTHER|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
224000187|NCT03966014|DRUG|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
224000188|NCT03966014|DRUG|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
224000189|NCT03966014|DRUG|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
224000190|NCT03966014|OTHER|Controls|No intervention.
224000191|NCT03250988|DIAGNOSTIC_TEST|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
224000192|NCT03085225|DRUG|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
223383317|NCT04015271|BEHAVIORAL|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
224000193|NCT06407024|PROCEDURE|laparoscopic transabdominal adrenalectomy|Adrenalectomy performed by laparoscopic approach
223383318|NCT01873352|PROCEDURE|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
223383319|NCT01873352|PROCEDURE|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
223383320|NCT03519412|DRUG|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
223383321|NCT03519412|BIOLOGICAL|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB\>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
224000194|NCT06407024|PROCEDURE|robotic transabdominal adrenalectomy|Adrenalectomy performed by robotic approach
224000195|NCT05859880|BEHAVIORAL|Expressive writing intervention|4 videoconference-delivered group-based expressive writing sessions
224000196|NCT06545812|DRUG|Transforaminal epidural steroid injection|Transforaminal epidural steroid injection (ESI TF) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.
224000197|NCT06545812|DEVICE|Physical therapy for disc herniation|BTL Laser therapy, BTL ultrasound therapy and BTL Transcutaneous electrical nerve stimulation - TENS
224000198|NCT01238536|PROCEDURE|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
224000199|NCT01238536|PROCEDURE|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
224000200|NCT01238536|DRUG|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
223383322|NCT05408130|DEVICE|Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|All patients randomized to intervention arm will receive 5 cycles of ischemia/reperfusion in non-paralysed upper limb or if no upper limb paralysis non-dominant arm. They will receive it once daily for a period of 7 days or during hospital stay whichever is shorter.
223383323|NCT05408130|DEVICE|Sham Remote Ischemic Conditioning with Novel Optical Sensor Feedback Device|In the sham group subjects will receive pressure sensation by keeping the pressure at 30 mmHg for 3 min in both arms All patients in sham and intervention group will receive standard of care management for ischemic stroke
223383324|NCT01981460|PROCEDURE|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
223383325|NCT06254716|PROCEDURE|disc resection|disc resection refers to the full-thickness resection of the lesion and the intestinal wall, usually anterior rectal wall. During the operation, the anterior intestinal wall is opened and then sutured or anastomosed with a stapler. Segmental bowel resection for the treatment of intestinal endometriosis was first reported by Redwine and Sharpe in 1991, which requires the maximum removal of endometriosis lesions.
223383326|NCT06254716|PROCEDURE|segmental resection|Segmental bowel resection for the treatment of intestinal endometriosis was first reported by Redwine and Sharpe in 1991, which requires the maximum removal of endometriosis lesions.
223383327|NCT03242408|DRUG|LPCN 1021|Oral testosterone undecanoate
223383328|NCT03660319|OTHER|Environmental Music Therapy|Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
223383329|NCT04427540|DRUG|Oxytocin|Oxytocin 10 micrograms IM
223383330|NCT03386552|DRUG|Isifera+|Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
223383331|NCT03386552|DRUG|Buffer|Pertubation solution of Ringer-Acetate buffer
223383332|NCT05514561|DIAGNOSTIC_TEST|Fecal calprotectin|To calculate the diagnostic accuracy of fecal calprotectin in the diagnosis of significant ileocolonic lesions
223729907|NCT05156853|DIETARY_SUPPLEMENT|Plant menus|The plant menus will be based on products which can be purchased in normal supermarkets and chosen to be as equal to the insect-based products as possible.
223729908|NCT00003170|DIETARY_SUPPLEMENT|glutamine|
223383333|NCT05514561|DIAGNOSTIC_TEST|Fecal immunochemical test|To calculate the diagnostic accuracy of the fecal immunochemical test in the diagnosis of significant ileocolonic lesions
223383334|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
223383335|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
223383336|NCT00703651|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
223383337|NCT06069063|DRUG|Zafirlukast|Oral zafirlukast is approved to treat asthma and been shown in previous trials to be effective in blocking or mitigating the symptoms of people allergic to cat dander
223383338|NCT04122040|DRUG|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
223383339|NCT04122040|DRUG|Placebo|Placebo one table oral once dialy
223383340|NCT05308511|DEVICE|PC-I and COLON2|First swallow the trial device(PC-I) for examination, and then swallow the comparator device(COLON2) for examination at an interval of 2h.
223383341|NCT05308511|DEVICE|COLON2 and PC-I|First swallow the comparator device(COLON2) for examination, and then swallow the trial device(PC-I) for examination at an interval of 2h.
223383342|NCT03241641|DRUG|Tenofovir Alafenamide|25mg, Daily Oral
223383343|NCT03241641|DRUG|Tenofovir Disoproxil Fumarate|300mg, Daily Oral
223729909|NCT00003170|OTHER|placebo|
223729910|NCT01846611|DRUG|Trabectedin|1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
223729911|NCT01846611|DRUG|DOXIL|30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
224000201|NCT01238536|DRUG|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
224000202|NCT05827003|OTHER|Exercise|Supervised exercise program with a physiotherapist for 6 weeks, two days a week
224000203|NCT05827003|OTHER|Exercise&Topical Agent|Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.
224000204|NCT05827003|OTHER|Topical Agent|Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
224000205|NCT05933681|DEVICE|Neural recordings and stimulation|Neural activities from the dorsolateral prefrontal cortex and implanted DBS generator will be recorded, during resting and working memory tasks, and with the DBS target turned on and off.
224000206|NCT02400216|DRUG|dual cholate|test for defining disease severity
224000207|NCT00967005|DRUG|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
224000208|NCT00967005|OTHER|Sugar Pill|placebo control
224000209|NCT04554745|RADIATION|Ultrasound|ultrasound assessment of pregnant women
223383344|NCT02834325|PROCEDURE|mechanical ventilation|
224000210|NCT04430166|DRUG|PD-1 monoclonal antibody|200mg / intravenous drip, once every three weeks
223383345|NCT01345201|BIOLOGICAL|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
223383346|NCT02548156|OTHER|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
223383347|NCT02548156|OTHER|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
223383348|NCT02548156|OTHER|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
223383349|NCT02548156|OTHER|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
223383350|NCT02548156|OTHER|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
223383351|NCT01983566|DRUG|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
223383352|NCT01983566|DRUG|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
223383353|NCT01983566|DRUG|BI 207127|BI 207127 as a single dose in fasted state
224000211|NCT05263674|DRUG|Rapid sedation|High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
224000212|NCT02323568|OTHER|Gynecological consultation|
224000213|NCT03866369|DRUG|Moxifloxacin|Single oral dose at D-8
224000214|NCT03866369|DRUG|Placebo|Single oral dose at D-1
224000215|NCT03866369|DRUG|Lanifibranor|Single daily oral dose during 14 days
224000216|NCT03866369|DRUG|Placebo|Single daily oral dose during 14 days
223383354|NCT01983566|DRUG|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
224000217|NCT06336135|OTHER|autologous hair follicle derived secretome|aHFS is a cosmetic topical intended to be applied to the human body after skin resurfacing cosmetic procedures. aHFS is produced from the plucked hair follicles of each individual, making it autologous.
224000218|NCT00001197|DRUG|Hydroxyurea|
223383355|NCT03766295|DRUG|Masitinib|
223383356|NCT03766295|DRUG|Gemcitabine|
223383357|NCT03766295|DRUG|Placebo|
223383358|NCT02937311|OTHER|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
223383359|NCT02937311|OTHER|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
223383360|NCT02937311|OTHER|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
224000219|NCT00656045|BEHAVIORAL|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
224000220|NCT00656045|BEHAVIORAL|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
224000221|NCT00656045|BEHAVIORAL|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
224000222|NCT04792476|OTHER|High Intensity Interval Training|Experimental group will receive, in addition to the conventional treatment, a physical exercise intervention along 12 weeks, which will consist of complying with the general recommendations for physical activity: 75 minutes weekly of high intensity physical exercise. The therapeutic exercise intervention will be supervised by a physiotherapist and designed in a progressive, structured and personalized way.
223383361|NCT04456777|DRUG|Vortioxetine|vortioxetine will be administreted for 3 months
223383362|NCT02323425|DEVICE|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
223383363|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Full|Participants in this active treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 2.0 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
223383364|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Sham|Participants in the sham condition arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT) 21% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session receiving less than a fully pressurized 100% oxygen dose.
224000223|NCT05890053|DRUG|HSK16149 40mg BID|HSK16149 40mg ， orally twice a day, treatment period; 52-weeks fixed dose.
224000224|NCT00758342|DRUG|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
224000225|NCT00758342|DRUG|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
224295639|NCT05055895|DRUG|Anticholinergic burden|"The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1."
223729912|NCT01846611|DRUG|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
223383365|NCT05924022|COMBINATION_PRODUCT|Hyperbaric Oxygen Treatment Partial Pressure|Participants in this partial treatment arm of the protocol will receive Hyperbaric Oxygen Treatment (HBOT)100% oxygen and 1.3 ATA prior to and the day of medically supervised 5% methadone dose reductions while sitting in a wheelchair-accessible, multi-place sealed pressurized chamber for 90 minutes each session.
223383366|NCT03909919|PROCEDURE|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
223383367|NCT03896529|BEHAVIORAL|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
223383368|NCT01068262|DRUG|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
223383369|NCT01068262|DRUG|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
223383370|NCT05277662|DIAGNOSTIC_TEST|cell and molecular diagnostics in accordance with functional test results|"Procedure: Anorectal manometry (ARM) Studies are performed in the left lateral position with the hips and knees of the subject flexed. Manometric sensor records circumferential pressure. The base of the rectal balloon attached to the ARM catheter is sited 3-5 cm above the upper border of the anal canal, to prevent the balloon impinging upon the anal canal during inflation. The most distal recording sensor is external to anal verge. If any pain or discomfort is experienced, the probe is immediately withdrawn.~Procedure: Rectal sensory test (RST) The test is also performed in the left lateral position with hips and knees flexed. Studies are conducted with either an integrated balloon on the manometric probe or with a separate system. Balloon capacity is no less than 400 mls and all components are latex-free. Insufflation is always performed with air. For ramp distension, the rate should be between 1 and 5 mL/s, and for phasic distension, inflation rate should be set at 10 mL/s (C1)."
223729913|NCT01846611|DRUG|DOXIL|50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
224000226|NCT05256615|BEHAVIORAL|30-minute walking intervention|Participants are asked to go for a 30 minute walk once per day at any time except the 1 hour after a meal. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
224000227|NCT05256615|BEHAVIORAL|10-minute|Participants are asked to go for a 10-minute walk after each meal occurring 3 times daily. During these walks they are asked to record heart rate using a heart rate monitor and a phone application.
224000228|NCT00900692|DEVICE|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
224000229|NCT04653233|DEVICE|3D Systems Touch Haptic Simulator|This simulator is computer-aided and allows us to see this application on the computer screen while practicing with a haptic arm. It gives real-like feedback in hand manipulations. The simulator has a choice of 45 minutes of full instruction, 5 minutes of haptic arm only, or the option.
224000230|NCT05715749|OTHER|In-home body weight support harness system|A portable, adjustable body weight support harness system that occupies roughly 9 feet x 9 feet space in the home. The system allows 360 degrees of mobility anywhere within the footprint of the frame. The amount of body weight support is adjustable.
224123871|NCT04369053|DIAGNOSTIC_TEST|Freenome test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled. Participants will undergo blood collection and will then complete a standard-of-care screening colonoscopy.
223383371|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
223383372|NCT01916174|DRUG|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
223383373|NCT06496880|DIETARY_SUPPLEMENT|Oxyjun TM|One capsule daily to be taken after breakfast for 56 days
223383374|NCT06496880|DIETARY_SUPPLEMENT|Placebo|One capsule daily to be taken after breakfast for 56 days
223729914|NCT04021589|DRUG|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
223729915|NCT04021589|DRUG|Chemotherapy|chemotherapy
223729916|NCT01432353|DRUG|DFRF4539A|multiple ascending doses
223729917|NCT03829150|DRUG|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
223729918|NCT03829150|DRUG|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
224000231|NCT05338385|BEHAVIORAL|Mental Skills Coaching|Participants will partake in a 1-hour pre-op initial intake, followed by five 30-min follow-up sessions at 2 weeks, 6 weeks, 3 months, 6 months and 9-months post-op. All sessions will be one-on-one with the same master's-level mental skills coach. At each session, the provider will allow time for participants to share their current injury experience to date (i.e. how they are doing, challenges they have encountered). Following this, participants will be introduced to a series of mental skills tools, including but not limited to mindset awareness, motivation, cognitive restructuring, goal setting, and objective performance assessment. Participants will be provided with handouts outlining the strategies addressed to help maintain consistency of mental skills engagement between sessions.
224000232|NCT00423566|BIOLOGICAL|MVA85A (Tuberculosis vaccine)|
224000233|NCT05529888|DRUG|Isotretinoin|Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration
224000234|NCT05843292|DRUG|Taxane and Carboplatin|"Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles."
224123872|NCT06123013|BEHAVIORAL|Music Assisted Relation Intervention (MARI)|A standardized 30-minute MARI intervention, personalized to the participant's music and imagery preferences. During the MARI intervention, the board certified music therapist (MT-BC) will provide live guitar accompaniment personalized to the participant's music preferences and read from a standardized script directing the participant to relax muscles of the body, practice deep breaths, and explore a relaxing place.
224123873|NCT05299983|OTHER|MyMenoPlan|Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.
223383375|NCT04405297|DEVICE|Adipose-derived regenerative cells|Adipose-derived regenerative cells will be obtained from a small-volume lipoaspirate procedure. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the targeted joint.
223383376|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|Traditional motivational face-to-face workshops with lifestyle (nutritional, physical activity, sleep) advice every 3 months
223383377|NCT05379842|OTHER|Education on a healthy lifestyle and health literacy|E-learning and digital (with videos -YouTube channel or WhatsApp/text message) educational workshops with lifestyle (nutritional, physical activity, sleep) advice every 15 days
223383378|NCT06210022|DIAGNOSTIC_TEST|Neuropsychological Assessment|Cognitive evaluation and clinical monitoring of seizure frequency
224000235|NCT05843292|DRUG|Short-term Sintilimab|Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.
224000236|NCT05843292|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
224000237|NCT01371825|DRUG|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
224000238|NCT01264432|OTHER|Laboratory Biomarker Analysis|Correlative studies
224000239|NCT01264432|OTHER|Quality-of-Life Assessment|Ancillary studies
224000240|NCT01264432|RADIATION|Radiation Therapy|Undergo LDFWAR
224000241|NCT01264432|DRUG|Veliparib|Given PO
224000242|NCT00826332|PROCEDURE|transabdominal ultrasound|transabdominal ultrasound
223383379|NCT02129322|DRUG|Sorafenib|
223383380|NCT02129322|DRUG|S-1|
223383381|NCT02129322|DRUG|Oxaliplatin|
223383382|NCT00743717|DEVICE|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
223383383|NCT00743717|DEVICE|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
223383384|NCT01662219|OTHER|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
223383385|NCT00959218|DRUG|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
223383386|NCT00959218|DRUG|Placebo|oral solution
223729919|NCT03829150|DRUG|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
223383387|NCT00781807|OTHER|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~1. Nutrition management~2. Home-based ergometer training program~3. Psychosocial support"
223383388|NCT01873378|DRUG|Triptorelin 3.75 mg|
223383389|NCT00444587|DRUG|Second line chemotherapy|As prescribed
223383390|NCT00444587|DRUG|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
223383391|NCT01105793|DRUG|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
223383392|NCT03938909|GENETIC|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
223383393|NCT00452556|DRUG|Docetaxel|Weekly
223383394|NCT00452556|DRUG|Leuprolide Acetate (Eligard®)|2.5 years
223383395|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
223729920|NCT03829150|DRUG|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
224000243|NCT00826332|PROCEDURE|transvaginal ultrasound|transvaginal ultrasound
224000244|NCT00891033|DRUG|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
224000245|NCT00891033|DRUG|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
224000246|NCT05729308|PROCEDURE|caudal epidural block|"The patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound guidance using SonoSite M Turbo(USA).The scanning probe is the linear multi-frequency 6-13 MHz transducer (L25 x 6-13 megahertz linear array)that is covered in sterile plastic bag.Short axis (transverse view) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal view) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.25% bupivacaine will expand the epidural space"
224000247|NCT05729308|PROCEDURE|bilateral erector spinae plane block|The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of T12. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T12 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 15 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side
224000248|NCT05729308|PROCEDURE|general anesthesia with intravenous analgesia.|"* Multimodal therapy with acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs) will be used.~* Vital data will be monitored as mentioned Intraoperatively, if the pulse rate and/or mean blood pressure increased above 20% of the baseline, IV fentanyl will be administered as an incremental dose of 50 µg.~* The patients will be monitored for heart rate and blood pressure at regular 10-minute intervals. If blood pressure decreased more than 20% from baseline, then the patient will receive 500 mL saline infusion; if no response is seen, then 5 mg ephedrine will be administered. If heart rate decreased to 45 beats per minute, an IV injection of 0.1 mg /kg atropine will be administered."
223383396|NCT00452556|RADIATION|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
223383397|NCT00032383|BEHAVIORAL|Tai Chi|
223383398|NCT04407273|DRUG|observational|observational study
224000249|NCT03362983|OTHER|CareHND|Multidisciplinary, integrated, person-centered care at the integrated HND-clinic
224000250|NCT05435053|DRUG|Nivolumab|"Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor)."
224000251|NCT05435053|DEVICE|Irreversible electroporation (IRE)|"Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use."
224000252|NCT04977453|DRUG|GI-101|Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
224000253|NCT04977453|DRUG|Pembrolizumab (KEYTRUDA®)|Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
224000254|NCT04977453|DRUG|Lenvatinib|Lenvatinib will be administered at an approved dose orally.
223383399|NCT03512873|DRUG|Tranilast|Subjects will be treated with tranilast
224000255|NCT04977453|RADIATION|Local Radiotherapy|Patients will receive SBRT prior to the first dose of GI-101
224000256|NCT04977453|DRUG|GI-101A|Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
224000257|NCT01376492|OTHER|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
224000258|NCT01376492|OTHER|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
224000259|NCT02633436|OTHER|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
224000260|NCT02893189|GENETIC|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
224000261|NCT03019640|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
223383400|NCT05952531|DRUG|68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image IIM lesions in skeletal muscle, heart, lung, skin and potential tumor by PET/CT.
223383401|NCT04170465|DRUG|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
223383402|NCT04170465|DRUG|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
223383403|NCT00261560|DRUG|acetaminophen|
223383404|NCT00582660|DRUG|Celecoxib|400 mg twice a day for 7 days prior to surgery
223383405|NCT00582660|DRUG|Placebo|one tablet of placebo will be given for 7 days prior to surgery
223383406|NCT02666729|PROCEDURE|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
223383407|NCT02666729|PROCEDURE|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
223383408|NCT00847964|DEVICE|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
223383409|NCT05356507|OTHER|Patient population|Questionnaires, standard of care
223383410|NCT01208805|BEHAVIORAL|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
224000262|NCT03019640|DRUG|Carmustine|Given IV
224000263|NCT03019640|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
224000264|NCT03019640|DRUG|Cytarabine|Given IV
224000265|NCT03019640|DRUG|Etoposide|Given IV
224000266|NCT03019640|BIOLOGICAL|Filgrastim|Given SC
224000267|NCT03019640|DRUG|Lenalidomide|Given PO
224000268|NCT03019640|DRUG|Melphalan|Given IV
224000269|NCT03019640|BIOLOGICAL|Rituximab|Given IV
224000270|NCT00065923|DRUG|Topiramate|
224000271|NCT04606901|DRUG|neostigmine/glycopyrrolate|neuromuscular blockade reversal agents
223383411|NCT02229461|DRUG|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
223383412|NCT02229461|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
223383413|NCT00667680|DEVICE|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
223383414|NCT01842529|BIOLOGICAL|botulinum toxin injection|
223383415|NCT01842529|BIOLOGICAL|0.9% normal saline injection|
223383416|NCT01842529|DEVICE|Implantable loop recorder|
223383417|NCT02909244|BIOLOGICAL|Biological sampling|Biological sampling
224000272|NCT04606901|DRUG|sugammadex|neuromuscular blockade reversal agent
224000273|NCT02175953|BEHAVIORAL|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
224000274|NCT03169400|DEVICE|Theranova dialyzer|Hemoadialysis
224000275|NCT01724034|OTHER|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
224000276|NCT01724034|OTHER|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
224000277|NCT01724034|OTHER|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
224000278|NCT01724034|OTHER|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
224000279|NCT01724034|OTHER|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
224000280|NCT01724034|OTHER|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
224000281|NCT05443113|DIAGNOSTIC_TEST|Genetic analysis|Genetic analysis by geneticists
224000282|NCT00269321|PROCEDURE|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
224123874|NCT05299983|OTHER|Control|"Participants are asked to spend at least 20 minutes on at least one of the following websites:~1. North American Menopause Society: https://www.menopause.org/for-women~2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause~3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause"
224123875|NCT05082597|DEVICE|Low energy ESWT|Therapeutic sessions: 4(once a week, for 4 weeks) Total dosage: 2500 shoots over axillary cord lesion (1000 over most fibrotic area, 500 over upper arm, 500 over forearm, 500 over other area) Energy: 0.056-0.065mJ/mm2
223383418|NCT02633592|OTHER|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
223383419|NCT02633592|OTHER|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
223383420|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
223383421|NCT01045668|PROCEDURE|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
223383422|NCT05258201|OTHER|Strain-counterstrain|Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground
223383423|NCT05258201|OTHER|Muscle Energy Technique|Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
223383424|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.
223383425|NCT04695769|DRUG|Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]|Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.
223383426|NCT05013125|DIAGNOSTIC_TEST|ENDO-AID CADe assisted Colonoscopy|ENDO-AID is a dedicated endoscopy Computer-Aided Diagnosis (CADe) system where suspicious lesions are automatically detected and highlighted on the main monitor in real-time, alerting the endoscopist during the procedure.
223383427|NCT04174625|DIETARY_SUPPLEMENT|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
223383428|NCT03759938|DRUG|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
223383429|NCT02104570|OTHER|Kinesio taping with tension|
223383430|NCT02104570|OTHER|Kinesio taping without tension|
223383431|NCT02104570|OTHER|Fatigue protocol|
223383432|NCT02368418|PROCEDURE|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
223383433|NCT02368418|PROCEDURE|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
223383434|NCT03024788|DEVICE|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
223383435|NCT01473407|BIOLOGICAL|Epoetin Hospira|Variable dose
223383436|NCT01473407|BIOLOGICAL|Epogen (Amgen)|Variable dose
223383437|NCT02825771|BEHAVIORAL|Caring Contacts Messages|Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
223383438|NCT02825771|BEHAVIORAL|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
223383439|NCT06068556|BIOLOGICAL|GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition|Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.
224138480|NCT01848639|DRUG|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
224000283|NCT00269321|PROCEDURE|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
224000284|NCT00269321|BEHAVIORAL|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
223383440|NCT03314909|PROCEDURE|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
224000285|NCT04953962|DRUG|CBP501 (16)|16 mg/m2
224000286|NCT04953962|DRUG|CBP501 (25)|25 mg/m2
224000287|NCT04953962|DRUG|Cisplatin|60mg/m2
224000288|NCT04953962|DRUG|Nivolumab|240 mg
223383441|NCT03314909|PROCEDURE|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
224000289|NCT03566004|DIAGNOSTIC_TEST|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
224000290|NCT05420545|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
224000291|NCT05420545|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
224000292|NCT03822429|DRUG|Controlled ovarian stimulation|Hormonal therapy to induce ovulation by multiple ovarian follicles
224000293|NCT05355675|OTHER|blood sample|collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
224000294|NCT05355675|OTHER|stool sample|collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
224000295|NCT05723445|BEHAVIORAL|Low Glycemic Load Diet|Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
224000296|NCT02977390|OTHER|Passive leg raise|By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
224000297|NCT04630704|DEVICE|Pedra|Diffuse speckle contrast analysis perfusion system
224000298|NCT03514277|DRUG|Exparel|1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
224000299|NCT03514277|DRUG|Bupivacaine|30 mL bupivacaine 0.5% w/v solution
224000300|NCT05017077|DEVICE|DynaVision System|Telemonitoring for pediatric heart failure
224123876|NCT05521568|DIAGNOSTIC_TEST|Index test: Abbott ID NOW STREP A 2|The test under evaluation ('index test') is the rapid molecular test for Group A streptococcus Abbott ID NOW STREP A 2 (performed on saliva samples instead of throat swabs). This test was chosen because of its ease of use and several previous evaluations showing high diagnostic accuracy on throat swabs. The test gives a result after 2 to 6 minutes and will be performed by primary care practitioners participating in the study, in their office, using salivary swabs instead of throat swabs. Investigators will receive one session of specific training prior to the study. Saliva samples will be collected using the cotton swab that comes within the test packages. Index test results will not be used for patient management. Clinicians performing the rapid saliva test will not be blinded to clinical information.
223383442|NCT03314909|PROCEDURE|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
223383443|NCT00003056|DRUG|cyclosporine|
223383444|NCT00003056|DRUG|cyclosporine and methotrexate|
223383445|NCT00002397|DRUG|Nelfinavir mesylate|
223383446|NCT00002397|DRUG|Saquinavir|
223383447|NCT00002397|DRUG|Lamivudine|
223383448|NCT00002397|DRUG|Stavudine|
223383449|NCT03742193|DRUG|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
223383450|NCT03742193|DRUG|GD regimen|"One cycle: gemcitabine 900 mg/m\^2 over 90 min on Day 1, and gemcitabine 900 mg/m\^2 and docetaxel 75 mg/m\^2 on Day 8. Every 21 days were eligible.~1\~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
223383451|NCT01439581|DEVICE|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
223383452|NCT01439581|DEVICE|Non-Mapping System|Standard ICU bed with no mapping system
223383453|NCT05583825|OTHER|Rebozo App|It is a non-invasive, non-drug practical application made with Rebozo, a long and colorful fabric, two meters long and 70 cm wide, worn by Mexican women on their head and shoulders.
223383454|NCT00829725|DEVICE|screws-internal fixation|3-4-screws-internal fixation
224000301|NCT03671577|BEHAVIORAL|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
224000302|NCT06579326|DIAGNOSTIC_TEST|Photoacoustic imaging|It could provide three-dimensional ultrasound images of vessels in the target area. It could also provides super-resolution and large-depth photoacoustic images. By effectively extracting photoacoustic spectral features and using spectral feature unmixing algorithm, blood oxygen saturation can be calculated.
224000303|NCT03435042|BEHAVIORAL|Self care + Hypnosis group|Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
224000304|NCT00534495|BIOLOGICAL|Rilonacept|2.2 mg/kg subcutaneously
224000305|NCT02223104|DEVICE|Flexima Active|
224000306|NCT02223104|DEVICE|Sensura|
224000307|NCT03766776|DRUG|Anlotinib|Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
224123877|NCT05521568|DIAGNOSTIC_TEST|Reference standard test: Composite of culture and PCR-based tests based on a throat swab|"Throat samples will be obtained by use of a double-swab collection-transportation system :~* Swab #1 will be used to perform the rapid antigen detection test (see below)~* Swab #2 will be held at ambient temperature and sent within 72 hours to Robert Debre Hospital microbiology laboratory. Throat swabs will be used to perform throat cultures using standard techniques (PMID: 22768060). Throat swabs will also be used to perform a PCR specific for Group A streptococcus (PMID: 23465407). Samples with a positive culture and/or a positive PCR test result will be classified as reference-standard-positives. Samples with a negative culture and a negative PCR will be classified as reference-standard-negatives. Investigators will be blinded to clinical data, including the result of the rapid antigen detection test and the rapid saliva test."
224123878|NCT05521568|DIAGNOSTIC_TEST|Comparator test: Rapid antigen detection test (usual care)|As per usual care, all children will undergo a rapid antigen detection test (StreptAtest, Biosynex), using Swab#1 (see above). This rapid antigen detection test is the one used in France and is the only commercial kit that is officially recommended by the National Health Insurance system. It detects Lancefield's Group A antigen, which is specific to Group A Streptococcus. The test will be performed by investigators, during consultation time. Clinicians performing the rapid antigen detection test will not be blinded to clinical information.
224123879|NCT06957431|DRUG|Zanzalintinib|Supplied by Exelixis, Inc.
223383455|NCT00829725|DEVICE|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
223383456|NCT03581019|PROCEDURE|uterus transplantation|uterus transplantation from deceased donor
223383457|NCT01699958|BEHAVIORAL|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
224000308|NCT04300465|BEHAVIORAL|10 week MySlainte Program|"The intervention consists of a 10 week community based lifestyle intervention program. It consists of a weekly 1 hour exercise class, a weekly 1 hour health promotion workshop as well as individualised goal setting, exercise prescription and optimisation of cardioprotective medications.~This program is delivered by a multi-disciplinary team; including a physiotherapist, occupational therapist, dietitian, clinical nurse specialist and physician. It will be delivered through a registered Irish charity, Croí."
224000309|NCT03333759|DEVICE|Alma - Harmony XL Laser|The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.
224000310|NCT01809860|DRUG|isavuconazole|Oral
224000311|NCT01809860|DRUG|sirolimus|Oral
223383458|NCT06370741|DEVICE|Stretching with/without device|Participants will be divided into two groups: Achilles tendon stretching and plantar fascia specific stretching. Within these two groups, participants will stretch their dominant side with the help of the designed tool. On the non-dominant side, the Achilles tendon group will complete the Achilles tendon stretching without a tool and the plantar fascia-specific stretching group will complete the self plantar fascia stretching exercise. Each stretching exercise will be performed for 10 seconds and 10 repetitions 3 days a week for 2 weeks.
223383459|NCT01027702|BIOLOGICAL|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10\^4, 4 x 10\^4, 5 x 10\^4, 6 X 10\^4, 8 x 10\^4, and 10 X10\^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
223383460|NCT02301390|DRUG|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
223383461|NCT02301390|DEVICE|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
223383462|NCT00001021|BIOLOGICAL|rgp120/HIV-1IIIB|
223545412|NCT01462929|DRUG|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
223729921|NCT03221400|DRUG|PEN-866 Sodium|PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
224000312|NCT05372107|DRUG|AG-80308|AG-80308 Eye Drop Solution
224000313|NCT06390384|OTHER|blinded-care counselling|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 2) weekly counselling over 6 weeks via videoconference for adolescents and their parents.~The counselling will be provided by experienced psychologists as employers of the Clinic of Child and Adolescent Psychiatry, RWTH Aachen University, the counselling will be supervised by the leading psychologist of the clinic. The counselling will include psychoeducative elements about psychological and psychosocial problems, behavioral interventions from cognitive-behavioral therapy, psychological techniques for better coping with stress, different therapeutic tasks such as fear exposure, activation exercises e.c. The students will be instructed to use the mobile treatment system STEPS in order to continue therapy at home."
224123880|NCT06957431|DRUG|Eribulin|1.1 mg/m\^2 dose.
224123881|NCT06506253|OTHER|Swedish Massage Therapy|Touch therapy
224123882|NCT06506253|OTHER|Light Touch Therapy|Touch therapy
224123883|NCT06481904|DRUG|TZIELD (teplizumab-mzwv)|This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
224123884|NCT04491877|BIOLOGICAL|RSV vaccine formulation 1|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
224123885|NCT04491877|BIOLOGICAL|RSV vaccine formulation 2|Pharmaceutical form: Suspension of virus Route of administration: Intranasal
224123886|NCT04491877|BIOLOGICAL|Placebo|Pharmaceutical form: Suspension Route of administration: Intranasal
224123887|NCT05622864|DRUG|HRS-9821|HRS-9821
224123888|NCT05622864|DRUG|HRS-9821|HRS-9821
224123889|NCT06370715|DRUG|Insulin Lispro-aabc|Administered SC
224123890|NCT06370715|DRUG|Insulin Glargine|Administered SC
224123891|NCT03538652|OTHER|Formative Interviews (not an intervention)|One hour formative-interview session
223383463|NCT00001021|BIOLOGICAL|rgp120/HIV-1MN|
223383464|NCT05443815|DEVICE|HaemoCer-PLUS|HaemoCer-PLUS
223383465|NCT05292807|BEHAVIORAL|Imaginal exposure for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
223383466|NCT05292807|BEHAVIORAL|Imaginal exposure for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.
223383467|NCT05292807|BEHAVIORAL|Imagery rescripting for memories|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
223383468|NCT05292807|BEHAVIORAL|Imagery rescripting for future events|Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
223383469|NCT00129571|DRUG|XL820|
223383470|NCT03678571|OTHER|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
223383471|NCT04018651|BEHAVIORAL|PrEP Master Adherence Intervention|"The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~1. Importance of daily adherence;~2. Three week delay for full effectiveness describing PrEP like taking the birth control pill;~3. Condom use for other sexually transmitted infection (STI) prevention;~4. Pregnancy prevention plans;~5. Plans for follow up calls~6. Referral to other treatment services if necessary"
223383472|NCT06581276|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is an evidence-based behavioral pain treatment intervention for Chronic Pain, anxiety and depression, and substance use disorders, being studied as a group-based therapy delivered by substance use counselors in an opioid treatment program.
223383473|NCT03514966|BEHAVIORAL|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
223383474|NCT06582836|BEHAVIORAL|The objective of the study was to investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pain among orthodontic patients|In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
224000314|NCT06390384|OTHER|App STEPS|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®. The intervention will include: 3) blinded-care use of the mobile treatment system STEPS®.~This is transdiagnostic digital treatment system which consists of a students front-end as an App and a therapist front-end as an online platform. The App and the platform are connected to each other. In such a way, an effective data transter (for example, symptom evaluation by the student and tasks and requests by the therapist), direct communication between a student and a therapist, as well as registration of emergency situation, are possible."
224000315|NCT06390384|OTHER|digital and mental literacy training|"The intervention is a implementation of a weekly psychological counseling for psychiatric problems via videoconference combined with an additionally digital support using a well-established mobile treatment system STEPS®.~The intervention will include: 1) digital and mental literacy training for children, parents and teachers in the school.~This training program (4 weeks, 8 session a 2 lesson units, 2 sessions a week) includes information about rules and functions by using mobile applications, safety aspects of personal data, risks associated with data sharing, sexing and cybergrooming, managing social media, handling with fake news, influence of social media on mental health, forms of digital violence and strategies to cope with them."
224000316|NCT05910970|DRUG|Adjuvant tislelizumab plus lenvatinib|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
224000317|NCT05910970|DRUG|Adjuvant tislelizumab|Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
224000318|NCT01162863|DRUG|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
224000319|NCT01162863|DRUG|Placebo|taken orally for 28 days
223383475|NCT01968564|DRUG|Placebo pill|sugar and other inert substances
223383476|NCT01968564|DRUG|High-dose curcumin pill|2000mg curcumin pill/day
224000320|NCT01162863|OTHER|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
224000321|NCT00588692|DEVICE|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
224000322|NCT02867917|DRUG|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
224000323|NCT02867917|DRUG|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
224000324|NCT02867917|DRUG|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
224000325|NCT01274325|DRUG|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
224000326|NCT01274325|DRUG|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
224000327|NCT02498782|DRUG|Fexinidazole|
224000328|NCT02498782|DRUG|Placebo|
224000329|NCT05142007|BEHAVIORAL|Hypnosis|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
224000330|NCT05142007|BEHAVIORAL|Mindfulness-based stress reduction|A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
224000331|NCT00000920|DRUG|Ritonavir|
224000332|NCT00000920|DRUG|Saquinavir|
224000333|NCT00000920|DRUG|Lamivudine|
224000334|NCT00000920|DRUG|Zidovudine|
224000335|NCT01228253|DEVICE|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
224000336|NCT01228253|DEVICE|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
224000337|NCT00642408|DIETARY_SUPPLEMENT|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
224000338|NCT00642408|DIETARY_SUPPLEMENT|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
224000339|NCT04449419|OTHER|There is not intervention.|There is not intervention
223383477|NCT01968564|DRUG|Low-dose curcumin pill|500mg curcumin pill/day
223383478|NCT01875328|OTHER|Telemedicine|Post stroke follow up in home using telemedicine.
223383479|NCT01875328|OTHER|Clinic|Post stroke clinic group follow up
223425508|NCT04568954|DIAGNOSTIC_TEST|Truenat TB platform/TB assays|"Truenat TB platform/TB assays, a molecular diagnostic test developed by Molbio diagnostics, for the diagnosis of Mycobacterium tuberculosis complex (MTBC) and Truenat MTB-RIF Dx for detection of RIF resistance was endorsed in 2020 by the WHO for TB diagnosis.~The system has been designed to be operated as a point-of-care- diagnostic solution in peripheral laboratories with minimal infrastructure.~It takes about 25 minutes to do the DNA extraction and another 35 minutes to diagnose TB.~It is portable and battery operated, have no need for a computer or laptop, and operate from 2-40 C ambient temperature. The system uses room temperature stable reagents with long shelf life."
224000340|NCT03552523|DEVICE|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
224000341|NCT03552523|OTHER|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
224000342|NCT01872559|OTHER|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
224000343|NCT04462289|BEHAVIORAL|Proactive Outreach|Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
224000344|NCT01755572|DRUG|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
224000345|NCT01755572|DRUG|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
224000346|NCT00095953|DRUG|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
224000347|NCT01167491|BIOLOGICAL|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
224000348|NCT04744753|DRUG|Calcium Ionophore A23187|"Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn).~In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF."
224000349|NCT04652505|OTHER|Questionnaire Administration|Complete questionnaires
224000350|NCT02578446|DEVICE|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
224000351|NCT02578446|DEVICE|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
224000352|NCT04912427|DRUG|Isatuximab|Isatuximab is supplied by Sanofi.
224000353|NCT04912427|DRUG|Bortezomib|Bortezomib is commercially available.
224000354|NCT04912427|DRUG|Dexamethasone|Dexamethasone is commercially available.
224000355|NCT03818126|DRUG|del Nido cardioplegia|"The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit."
224000356|NCT03818126|DRUG|cold blood cardioplegia|"The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius."
224000357|NCT04332055|OTHER|ERVIN|ERVIN is state of the art for IT systems, which uses artificial intelligence (AI) and real-time patient-specific PRO data to support patients and doctors in clinical decision-making. The system is designed for surgical OA treatment of knee and hip replacement, and can be used to predict outcome scores for the actual choice OA patients face in the patient trajectory; to choose surgery or not.
224000358|NCT00577057|PROCEDURE|Conventional Radiotherapy|
224000359|NCT00577057|PROCEDURE|Accelerated Radiotherapy|
224000360|NCT00577057|DRUG|Cisplatin|
224000361|NCT00577057|DRUG|5-fluorouracil|
224000362|NCT00577057|DRUG|Capecitabine|
224000363|NCT06246695|DRUG|Jaktinib Hydrochloride Tablets|Oral Jaktinib 100 mg for 1 day
224000364|NCT06246695|DRUG|Itraconazole capsule|Oral Itraconazole 200 mg for 9 day
224000365|NCT06246695|DRUG|Rifampicin Capsules|Oral Rifampicin 600 mg for 11 day
224000366|NCT03686423|PROCEDURE|Exercise Program|The exercise program will combine moderate intensity aerobic exercise with lower-extremity specific resistance training. A moderate level of intensity will be calculated based on results from a maximal graded exercise test (VO2R) conducted prior to the intervention.
223425509|NCT06086210|OTHER|Low-level laser therapy|Low-level laser therapy was applied to each area for 1 minute, with a wavelength of 808 nm and a dose of 2j/cm2 for a total of 5 minutes,10j/cm2 in continuous mode. A total of 15 sessions were applied 5 days a week for 3 weeks.
224000367|NCT01361542|DRUG|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
224000368|NCT01361542|DRUG|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
224000369|NCT01943942|DRUG|Montelukast 10 mg|Reference product
223425510|NCT06086210|OTHER|Sham|Sham therapy was applied to each area for 1 minute, with a wavelength of 0 nm and a dose of 0j/cm2 for a total of 5 minutes, 0j/cm2. A total of 15 sessions were applied 5 days a week for 3 weeks.
223425511|NCT01654718|DRUG|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
223425512|NCT01654718|DRUG|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
223729922|NCT03221400|DRUG|fluorouracil|Fluorouracil 2400 mg/m2 IV
224000370|NCT01943942|DRUG|Montelukast 10 mg|Test product
224000371|NCT06035302|PROCEDURE|Madany Closure|Madany Closure is a new technique for the porte site closure
224000372|NCT06035302|PROCEDURE|Standard closure|Standard closure technique of the port site from ecternal
224000373|NCT05444270|OTHER|Standard salvage therapy|Subjects will continue to receive current salvage treatment suitable for subjects at the discretion of their doctor, considering the location and size of recurrence, and the patient's comorbidities.
224000374|NCT05444270|RADIATION|Standard salvage therapy + SABR|Subjects receive SABR for lesions found in imaging studies. Before or After SABR, standard salvage treatment continues as planned at the discretion of the doctor.
224000375|NCT01077518|DRUG|Ofatumumab|Ofatumumab was a liquid concentrate solution for infusion presented in glass vials containing 50 mL of solution at a concentration of 20 mg/mL to provide 1000 mg per vial. The ofatumumab infusions were prepared in 1000 mL sterile, pyrogen-free 0.9% NaCl to yield a 1 mg/mL ofatumumab concentration infusion.
224000376|NCT01077518|DRUG|Bendamustine infusion|Bendamustine 100 mg/vial, injection
224000377|NCT01077518|DRUG|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
224000378|NCT01077518|DRUG|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
224000379|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
224000380|NCT03312413|DRUG|Normal Saline|Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
224000381|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
224000382|NCT03312413|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
224000383|NCT02271360|DRUG|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
224000384|NCT02271360|DRUG|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
223383480|NCT05786014|BEHAVIORAL|High Intensity Interval Exercise|Patients in the Cycling Intervention arm will undergo two training sessions at the exercise physiology core lab to ensure participants understand the intervention exercise protocol and can safely perform it at home. The Participants will perform high intensity interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Subjects will then perform this exercise training at their own homes using recumbent exercise bikes provided by the investigators for that purpose. Study investigators will check in up to weekly with participants and remotely track exercise data and compliance via activity tracker.
223383481|NCT05786014|BEHAVIORAL|Moderate Intensity Walking|Patients will undergo two familiarization training sessions in the exercise physiology core lab to ensure participants understands the walking intervention and can properly gauge intensity. Participants will be asked to walk briskly or jog so they achieve a moderate intensity (70-75% of the maximal heart rate achieved during the VO2peak test). The goal for participants in this condition will be to accumulate at least 150-minutes per week at this heart rate by brisk walking or jogging. Participants will also receive a gift card to be used to purchase a pair of walking shoes to facilitate their engagement.
223383482|NCT05991791|OTHER|Early Start Denver Model (ESDM)|"Phase A~* 4 individual sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase B :~* 11 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM with the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~Phase C :~* 4 sessions (1 per week)~* Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM without the help of the robot Pepper~* Satisfaction Evaluation - Parent~* Satisfaction Evaluation - Therapist~* All sessions will also be filmed and recorded"
223383483|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
223425513|NCT04947228|DEVICE|trackPAD|TrackPAD is a smartphone app to provide PAD-specific support for SET
224000385|NCT02387970|PROCEDURE|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
224000386|NCT02387970|PROCEDURE|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
224000387|NCT02387970|DEVICE|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
224000388|NCT02387970|DEVICE|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
224000389|NCT00781105|DRUG|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
224000390|NCT01310231|DRUG|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."
224000391|NCT01310231|DRUG|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."
224000392|NCT04662060|DRUG|Acebilustat|100 mg capsule administered orally once daily
224000393|NCT04662060|DRUG|Placebo|Placebo to match acebilustat administered orally once daily
224000394|NCT05876390|PROCEDURE|Breast surgery|Breast surgery
224000395|NCT05876390|DRUG|analgesia|Multimodal analgesia
224000396|NCT03534895|DRUG|Midazolam Injectable Solution|intravenous
224000397|NCT03534895|OTHER|Normal saline|intravenous
224000398|NCT03534895|PROCEDURE|Spinal anesthesia|8mg of heavy bupivacaine 0.5% injected in the subarachnoid space, during lateral decubitus
224000399|NCT03534895|PROCEDURE|Surgery|Open inguinal hernia repair, varicose vein stripping, knee arthroscopy or hallux valgus surgery
224000400|NCT03534895|DRUG|Postoperative analgesia|IV acetaminophen 1g + IV ketorolac 30mg
224000401|NCT03534895|DRUG|Rescue analgesia|Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS\>3.
224000402|NCT03534895|DRUG|Wound infiltration|Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
224000403|NCT03534895|DRUG|Analgesia at home|Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
224000404|NCT02084199|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 10 days
224000405|NCT05266703|OTHER|Isotopically labelled iron sulfate 15mg|test drink: water containing isotopic iron solution with vitamin C
224000406|NCT02172001|DRUG|Iron isomaltoside 1000|
224000407|NCT02172001|DRUG|Natrium Chloride 0,9%|100 ml or 5 ml
224000408|NCT00494520|PROCEDURE|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
224000409|NCT00494520|PROCEDURE|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
224000410|NCT05223075|DRUG|articaine local anethesia with vasoconstrictor|buccal infiltration only of articaine local anethesia during extraction of lower anterior teeth
224000411|NCT05223075|DRUG|lidocaine local anethesia with vasoconstrictor|buccal infiltration only of lidocaine local anethesia during extraction of lower anterior teeth
224000412|NCT03807895|BEHAVIORAL|REBT Career Intervention|Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.
224000413|NCT03807895|BEHAVIORAL|Regular Career Intervention|Eight sessions of regular career intervention.
224000414|NCT02847286|DRUG|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
224000415|NCT02847286|DRUG|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
223383484|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
223383485|NCT02477410|DIETARY_SUPPLEMENT|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
223383486|NCT04465981|DIAGNOSTIC_TEST|Sampling|Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.
223383487|NCT03027024|DEVICE|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
224000416|NCT02847286|DRUG|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
224000417|NCT01436253|BEHAVIORAL|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
224000418|NCT01436253|DRUG|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
224000419|NCT06307717|DRUG|volatile anaesthetic (sevoflurane, isoflurane, desflurane)|Patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic.
224000420|NCT00271206|DRUG|Progesterone|compared to placebo
224000421|NCT00271206|DRUG|sugar pill|Compared to progesterone
224000422|NCT03659773|BIOLOGICAL|immune biomarkers to evaluate vaccine response in HSCT recipients|a 38mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination and at 4 weeks after influenza vaccination for the ancillary study
224295640|NCT02115217|DEVICE|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
224295641|NCT02115217|DEVICE|Sham kinesiotape|KT put with no effects
223383488|NCT00205387|PROCEDURE|cardiac elastography and echocardiography|standard echocardiogram
223383489|NCT03833778|OTHER|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
224000423|NCT01390870|DRUG|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
224000424|NCT01495598|DRUG|Pomalidomide|5 mg by mouth (p.o.) for 21 of 28 days
224000425|NCT02445053|DRUG|ivacaftor|
224000426|NCT03599687|OTHER|Training in SALAD technique|The training session will be delivered, and will take around 45 minutes to complete, including time for participant practice. The training intervention will adopt the Advanced Life Support Group/Resuscitation Council 4-stage approach of skills teaching, and is comprised of: A real-time demonstration of the SALAD technique by the researcher; A repeated demonstration with an explanation of the rationale of the steps taken when performing SALAD (not real-time); Another demonstration of the SALAD technique conducted by the researcher, but guided by one of the participants; An attempt by the same participant who guided the researcher in the previous step, followed by a practice attempt by the other participants.
224000427|NCT00121927|BEHAVIORAL|Atkins diet (15 grams/day carbohydrates)|
223729923|NCT03221400|DRUG|Folinic acid|Folinic acid 400 mg/m2 IV
224000428|NCT00762775|DIETARY_SUPPLEMENT|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
224295642|NCT00793494|OTHER|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
224295643|NCT00793494|OTHER|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
224295644|NCT03785392|PROCEDURE|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
223383490|NCT01930201|PROCEDURE|Caudal epidural block|
223383491|NCT01930201|OTHER|General anesthesia|
223383492|NCT02121652|BEHAVIORAL|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
223383493|NCT02121652|BEHAVIORAL|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
223383494|NCT02532309|DRUG|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C\>1.1mmol/L and \<1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
223383495|NCT02532309|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
223383496|NCT06550583|DIAGNOSTIC_TEST|Pap smear /Test|"Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina.~• A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination"
223425514|NCT00030667|DRUG|imatinib mesylate|Given orally
223425515|NCT00030667|OTHER|laboratory biomarker analysis|Correlative studies
223729924|NCT03221400|DRUG|Niraparib|Niraparib
224000429|NCT03635372|DRUG|Alginate|10 cc of Alginate peroral
224000430|NCT03635372|DRUG|Sucralfate|10 cc of Sucralfate peroral
224000431|NCT03635372|DRUG|Hydrotalcite|10 cc of Hydrotalcite peroral
224000432|NCT02671500|DRUG|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
223383497|NCT04814173|OTHER|One-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the one-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the maxillary arch between the roots of 2nd premolar and 1st molar and closer to the molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals).
224000433|NCT05499273|PROCEDURE|scalpel-bougie tracheostomy|"1. The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~2. The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~3. Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~4. Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~5. An 8 FR Frova catheter is inserted through the orifice into trachea.~6. A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently."
224000434|NCT05499273|PROCEDURE|rapid sequence tracheotomy|"1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. A tracheal tube (inner diameter 3.0 mm, cuffed) is inserted to secure the airway permanently."
224000435|NCT01836939|DRUG|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
224000436|NCT01836939|DRUG|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
224000437|NCT02479724|DEVICE|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
224000438|NCT01807000|DRUG|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
224000439|NCT03410498|OTHER|Incremental shuttle walk test|"In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself."
224000440|NCT05998408|DRUG|Ruxolitinib|Subjects will be instructed to take ruxolitinib at up to 20mg (total) BID for up to 6 months (with or without food)
224000441|NCT05032976|BIOLOGICAL|Tozinameran 12 Years of age and older|BNT162b2 (purple cap) is administered with dilution, while BNT162b2 (grey cap) is administered without dilution. Both formulations are administered by intramuscular injection (IM) of 0.3 mL. According to the approved and authorized label, the recommended dose of BNT162b2 is a series of two doses (1 day 1 dose, 0.3mL each) 21 days apart and administered IM.
224000442|NCT05032976|BIOLOGICAL|Tozinameran 5 to 11 Years of age|"BNT162b2 (orange cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, the recommended dose of BNT126b2 is a series of two dose (1day 1dose, 0.2mL) 21days apart and administered IM.~But, a third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised aged 5 to 11 years of age."
224000443|NCT05032976|BIOLOGICAL|Tozinameran 6 months to 4 years of age|"BNT162b2 (maroon cap) is administered with dilution by intramuscular injection (IM) of 0.2mL. According to the approved and authorized label, it is recommended that the recommended dose of BNT162b2 is administered by intramuscular injection (IM) twice (once a day, each 0.2mL) at least of 21 days apart, and Dose 3 at least 8 weeks later.~Children who will turn from 4 years to 5 years of age between their doses in the vaccination course should receive their age-appropriate dose at the time of the vaccination and the interval between doses is determined by the child's age at the start of the vaccination course.~The interchangeability of BNT162b2 with COVID-19 vaccines from other manufacturers to complete the vaccination course has not been established.~BNT162b2 (6 months to 4 years of age) should be used only for infants and children 6 months to 4 years of age."
224000444|NCT05032976|BIOLOGICAL|Riltozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 1) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 1) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 1) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
224000445|NCT05032976|BIOLOGICAL|Famtozinameran 12 Years of age and older|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) (grey cap) is administered by intramuscular injection (IM) of 0.3mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
224123892|NCT03538652|BEHAVIORAL|Cognitive-behavioral therapy (CBT)|In CBT, negative emotional states are viewed as problems to be solved, and the client learns skills to solve them.
223383498|NCT04814173|OTHER|Two-jaw mechanic total maxillary arch distalization|A group of patients in which participants will be undergo to the tow-jaw mechanic for mini-implants anchored total-maxillary-arch-distalization (the mini-implants will be inserted in the mandibular arch between the 2nd premolar and 1st molar, then, a class II elastics 3/16 and 6.5oz will be use from the TAD to the hook of canines brackets).
223383499|NCT04814173|OTHER|en-mass retraction|A group of patients in which participants will be undergo to the en-mass retraction with first premolars extraction with mini-implants in the maxillary arch inserted between the 2nd premolar and 1st molar, then a force of 250 g will be applied from the TAD to a hook lateral to the laterals .
224138481|NCT04498572|OTHER|dry needling|dry needling for Gluteus Medius muscle in combination with exercises
223383500|NCT04798092|PROCEDURE|parathyroidectomy|surgical removal of parathyroid adenoma(s) with postoperative biological cure
223425516|NCT00030667|OTHER|pharmacological study|Correlative studies
223383501|NCT03996902|BEHAVIORAL|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
223383502|NCT03996902|BEHAVIORAL|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
223383503|NCT03340090|DEVICE|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
223383504|NCT03409354|BEHAVIORAL|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
224000446|NCT05032976|BIOLOGICAL|Famtozinameran 5 to 11 Years of age|"The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age (orange cap) is administered after dilution by intramuscular injection (IM) of 0.2mL. There should be an interval of at least 3 months between administration of the bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age and the last prior dose of a COVID-19 vaccine.~The bivalent COVID-19 Vaccine for omicron (BA. 4-5) for 5 to 11 years of age is only indicated for individuals who have previously received at least a primary vaccination course against COVID-19."
223383505|NCT03409354|BEHAVIORAL|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
224000447|NCT05032976|BIOLOGICAL|Raxtozinameran 12 years of age and older|"BNT162b2 OMI XBB.1.5 (grey cap) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.~For individuals who have previously been vaccinated with a COVID-19 vaccine, BNT162b2 OMI XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine."
224000448|NCT05032976|BIOLOGICAL|Raxtozinameran 6 months to 4 years of age|BNT162b2 OMI XBB.1.5 (maroon cap) is administered intramuscularly after dilution. For infants and children 6 months to 4 years of age without history of completion of a COVID-19, each 0.2 mL of dose is administered for a total of three vaccinations. The second dose is administered 3 weeks after the first dose followed by a third dose administered at least 8 weeks after the second dose. For infants and children 6 months to 4 years of age with history of completion of a COVID-19 primary course or prior SARS CoV-2 infection, a single dose of 0.2 mL is administered.
224000449|NCT06365788|DRUG|Abemaciclib|150 mg tablet orally twice daily
224000450|NCT06365788|DRUG|Bicalutamide|150 mg tablet orally once daily
224000451|NCT05511038|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Injection, 2mg (equivalent to 50 µL solution for injection)
224000452|NCT05543447|DEVICE|Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device|Flow diversion therapy fpr intracranial aneurysm treatment.
224000453|NCT01366144|DRUG|Carboplatin|Given IV
224000454|NCT01366144|OTHER|Laboratory Biomarker Analysis|Correlative studies
224000455|NCT01366144|DRUG|Paclitaxel|Given IV
224000456|NCT01366144|OTHER|Pharmacological Study|Correlative studies
224000457|NCT01366144|DRUG|Veliparib|Given PO
224000458|NCT04485611|BEHAVIORAL|Supervised aerobic + resistance training and nutritional support|The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
223383506|NCT02936908|OTHER|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
223383507|NCT01153425|OTHER|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
223383508|NCT01153425|DRUG|Teriparatide|Participants are clinically indicated for treatment.
223383509|NCT01153425|DRUG|Zoledronic Acid|Participants are clinically indicated for treatment.
223383510|NCT04081909|DRUG|Fentanyl，Remifentanil|Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
224000459|NCT05698173|BIOLOGICAL|blood sample|48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
224000460|NCT05698173|BIOLOGICAL|blood sample|blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
223383511|NCT04081909|DRUG|Ketamine,Dexmedetomidine|Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
223545413|NCT01462929|DRUG|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
224000461|NCT05985122|DIAGNOSTIC_TEST|C3NEF assay|This assay will consist of a dual test, detecting C3 convertase binding C3NEF autoantibodies and measuring the functional consequence by complement alternative pathway (AP) activity using two distinct ELISA designs: C3NEF detection assay and AP activity assay.
224000462|NCT02468765|OTHER|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
224000463|NCT03789240|BIOLOGICAL|Rituximab|Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
224000464|NCT03789240|DRUG|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
223383512|NCT00778388|BIOLOGICAL|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
223383513|NCT00778388|DRUG|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
224000465|NCT06581159|BIOLOGICAL|HS135|Subcutaneous Injection
224000466|NCT06581159|OTHER|Placebo|Subcutaneous Injection
224000467|NCT01517100|OTHER|Nabilone|CB agonist
224000468|NCT01517100|DRUG|CP-945,598|Cannabinoid Receptor 1 antagonist
224000469|NCT01517100|OTHER|hyperglycemic clamp|assesses beta cell response
224000470|NCT01517100|OTHER|euglycemic-hyperinsulinemic clamp|measures insulin sensitivity
224000471|NCT01517100|OTHER|Nabilone|cannabinoid receptor agonist
224000472|NCT01198067|DRUG|Pomalidomide|Given PO
224000473|NCT05370651|DEVICE|BTL Emsella Chair|Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
223383514|NCT04975204|DRUG|TQB3909 Tablets|TQB3909 is an inhibitor targeting BCL-2 protein
224000474|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
224000475|NCT02101398|DEVICE|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
224000476|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
224000477|NCT02101398|DEVICE|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
224000478|NCT02101398|DEVICE|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
223383515|NCT04515134|DIAGNOSTIC_TEST|assessment of follicular level of coenzyme Q10 in the ovaries in females undergoing ICSI|human coenzyme Q10 (CoQ10) ELISA kit
224000479|NCT04045093|DRUG|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
224000480|NCT04045093|DRUG|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
224000481|NCT06966024|DRUG|DCC-2812|Administered orally
224000482|NCT04557709|OTHER|Medical Chart Review|Review of medical charts
224295645|NCT03785392|PROCEDURE|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
224000483|NCT05656807|BEHAVIORAL|Go NAPSACC Enhanced|Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
224000484|NCT05656807|BEHAVIORAL|Go NAPSACC|Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
224000485|NCT02236832|DEVICE|transcranial magnetic stimulation|
224295646|NCT04732481|PROCEDURE|passive leg lift test|passive leg lift test
223383516|NCT02932462|DRUG|DSXS|topical product
224000486|NCT02236832|OTHER|MRI imaging|
224000487|NCT02236832|OTHER|EEG recording|
224000488|NCT02236832|BEHAVIORAL|Neuropsychological examination|
224000489|NCT04929392|DRUG|Carboplatin|Given IV
224000490|NCT04929392|PROCEDURE|Endoscopic Biopsy|Undergo endoscopic biopsy
224000491|NCT04929392|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224000492|NCT04929392|DRUG|Lenvatinib Mesylate|Given PO
224000493|NCT04929392|DRUG|Paclitaxel|Given IV
224000494|NCT04929392|BIOLOGICAL|Pembrolizumab|Given IV
224000495|NCT04929392|PROCEDURE|Resection|Undergo surgical resection
224000496|NCT03490682|OTHER|Ultrasound assessment of gastric emptying of a flavoured yoghourt.|Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
224000497|NCT05292586|DRUG|Beclomethasone Dipropionate/Formoterol Fumarate|Available in pressurized inhalation solution BDP/FF 200/6 µg
224000498|NCT05292586|DRUG|Beclomethasone Dipropionate|Available in pressurized inhalation solution BDP 100 µg
224000499|NCT03502668|DRUG|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
224000500|NCT03502668|DRUG|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
224000501|NCT06488378|DRUG|Axatilimab|Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.
224000502|NCT06488378|DRUG|Olaparib|Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.
224123893|NCT03538652|BEHAVIORAL|Acceptance and commitment therapy (ACT)|In ACT, negative emotional states are viewed as a necessary and potentially valuable component of a full life. When they occur, the goal is not to solve them, but to experience them in an observant, curious, nonjudgmental way-a practice referred to as mindfulness.
224123894|NCT03538652|OTHER|No intervention|Control group with no intervention administered
224123895|NCT01988480|PROCEDURE|Image-guided surgery|Placement on residual bone around the implant
224000503|NCT00036348|DRUG|Aripiprazole|
224000504|NCT05774288|DEVICE|Cera™ patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Cera™ patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
224000505|NCT05774288|DEVICE|Another patent foramen ovale occluders|Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with the Another patent foramen ovale occluders according to the INSTRUCTIONS for Use (IFU).
224000506|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)|625 mg/m2 IV over 30 minutes, q2weeks
223383517|NCT02932462|DRUG|Placebo|topical product
223383518|NCT02652949|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
224000507|NCT04421820|DRUG|BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)|320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks
224000508|NCT04531982|DRUG|Pimavanserin|Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
224000509|NCT04531982|DRUG|Placebo|Placebo, taken as two blinded tablets once daily by mouth
224000510|NCT05922930|DRUG|TROP2-CAR-NK|Given by IP (intraperitoneal)
224000511|NCT05922930|DRUG|Cyclophosphamide|Given by IV (vein)
224000512|NCT05922930|DRUG|Fludarabine|Given by IV (vein)
224000513|NCT07124585|DIETARY_SUPPLEMENT|Sucralose|Participants will consume one capsule containing sucralose 5mg/kg body weight, with the dosage individualized according to body weight. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
224000514|NCT07124585|DIETARY_SUPPLEMENT|Saccharin|Participants will consume one capsule containing saccharin 2mg/kg body weight, with the dosage individualized according to body weight. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
224123896|NCT01988480|PROCEDURE|Sinus lift surgery|Allograft bone
224123897|NCT05470491|DRUG|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Prednisone tapering doses given orally daily: -days -14 through -12: 1mg/kg/day -days -11 and -10: 0.75 mg/kg/day -days -9 and -9: 050 mg/kg/day -day -7: 0.25 mg/kg/day Pentostatin 4 mg/m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally or IV daily on days -11 through -4. Busulfan IV AUC targeted dose of 14.8-23.0 mg\*h/L, on days -3 and -2.
224123898|NCT05470491|DRUG|GVHD prophylaxis|Cyclophosphamide 50 mg/kg IV daily Bortezomib 1.3 mg/m2 IV +6 hours and +72 hours after graft infusion Mesna 50 mg/kg IV concomitant with cyclophosphamide
224123899|NCT05470491|PROCEDURE|allo HCT|bone marrow transplant
224123900|NCT05470491|DRUG|Plerixafor|In phase 1 dose level 3 and phase 2 only: Plerixafor 240 (Micro)g/kg subcutaneously every other day, starting day +1 through day +21
224123901|NCT05470491|DRUG|Maraviroc|Phase 1 dose level 2: 300 mg orally twice daily starting day-3 through day day+30
223383519|NCT01546428|DRUG|INC280|
223383520|NCT06133361|BIOLOGICAL|PRP injection|The PRP will be prepared according to a well-established technique and then injected into the palatal mucosa of the upper anterior teeth before retraction.
223383521|NCT06133361|PROCEDURE|En-masse retraction of upper anterior teeth|The anterior teeth will be moved backward in an en-masse retraction way using a frictionless method. The anterior teeth will be manipulated as one block. Coil springs will be stretched between the power arms (in the anterior area) to the miniscrews placed in the posterior area bilaterally.
224123902|NCT05280379|OTHER|no intervention will take place|no intervention will take place
223383522|NCT06575543|RADIATION|CT|3D CT scan have been used to evaluate the tunnels location after ACL reconstruction, as they can provide excellent perspective of the tunnel aperture, good visualization of bony structure and shape of the intercondylar notch, that preclude the use of a conventional 2-dimensional CT scan for measurement of the ACL tunnels location
223383523|NCT00894712|OTHER|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
223383524|NCT00894712|DEVICE|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
224123903|NCT06799845|DRUG|ATX101|ATX101 bupivacaine implants, total of 1,500 mg into the surgical site
224123904|NCT06799845|DRUG|bupivacaine hydrochloride|bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration
224123905|NCT06799845|DRUG|saline placebo|normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
224138482|NCT04498572|OTHER|sham dry needling|sham dry needling for Gluteus Medius muscle in combination with exercises
224138483|NCT06299579|DRUG|GD-11 for injection test group|The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
224138484|NCT06299579|DRUG|Placebo control group|The first dose of placebo was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.
224000515|NCT07124585|OTHER|Placebo (Calcium Carbonate)|Participants will consume one capsule per day, containing a fixed dose of 500 mg. The capsule will be taken once daily in the morning, after breakfast, with plain water. This intervention will last for seven consecutive days.
224000516|NCT06324461|DRUG|Dulaglutide 0.75mg subcutaneous injection|Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 1 to 14 days prior to surgery
224000517|NCT04839185|DRUG|Ferumoxytol infusion|"Ferumoxytol will be administered intravenously, by infusion, over 30 minutes. It will be used a contrast agent for MRI imaging to detect placental lesions in fetal growth restriction.~Dose will be 255 mg in 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Ferumoxytol/Feraheme will be administered only once, in one infusion of 255 mg to each subject."
224000518|NCT04839185|PROCEDURE|MRI scan|The MRI scanning procedure will last for approximately 60 minutes.
223383525|NCT03198338|DRUG|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
223383526|NCT03198338|DRUG|Normal Saline|0.9% Normal Saline
223383527|NCT03198338|DEVICE|Ultrasound|Ultrasound guided TAP block
224000519|NCT06982963|BIOLOGICAL|FB102|FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio.
224000520|NCT06982963|OTHER|Placebo|Placebo
224000521|NCT06984120|DIAGNOSTIC_TEST|Lung ultrasound|Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Bilateral or unilateral presence of two or more positive regions define positive interstitial syndrome.
224000522|NCT06984120|DIAGNOSTIC_TEST|Peripheral oxygen saturation|Peripheral oxygen saturation measured by non-invasive pulse oxymetry
224000523|NCT06984120|DIAGNOSTIC_TEST|Lung auscultation|Clinical auscultation of lungs
224000524|NCT06984120|DIAGNOSTIC_TEST|Body temperature|Body temperature measured by ear thermometer.
224000525|NCT03198026|DRUG|Ibrutinib|Given PO
224000526|NCT03198026|BIOLOGICAL|Obinutuzumab|Given IV
224000527|NCT03198026|OTHER|Laboratory Biomarker Analysis|Correlative studies
224000528|NCT00531089|DRUG|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
224000529|NCT04584476|PROCEDURE|superior capsular reconstuction|these patients underwent arthroscopic superior capsular reconstuction
223383528|NCT01751256|DEVICE|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
223383529|NCT05274178|DEVICE|"Audeo P hearing aid labeled as Prescriptive"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as prescriptive in view of the participant."
224000530|NCT04584476|PROCEDURE|partial rotator cuff repair|these patients underwent arthroscopic partial rotator cuff repair
224000531|NCT03841526|DRUG|Glucagon RTU Injection With Insulin Pump Reduction|0.15 mg injection with 50% pump reduction
224000532|NCT03841526|OTHER|Vehicle for Glucagon RTU Injection With Insulin Pump Reduction|vehicle injection with 50% pump reduction
224000533|NCT03841526|DRUG|Glugaon RTU Injection Without Insulin Pump Reduction|0.15 mg injection without pump reduction
224138485|NCT05096013|OTHER|individual nutritional therapy|Intervention arm: Usual care + individualized nutritional therapy. Patients at risk for malnutrition and sarcopenia will receive a counselling by the nutritional therapist twice a week. The therapists will assess the patient's energy and protein demand in order to develope appropriate individual measures (e.g additional meals or supplements) to increase patients' energy and protein intake. Individual nutritional therapy is already usual care in patients with high risk for malnutrition, but not for patients with only light to moderate risk of malnutrition and risk of sarcopenia.
224138486|NCT00004207|DRUG|liposomal daunorubicin citrate|
224138487|NCT05341570|DRUG|BPI-21668|Subjects will receive BPI-21668 until disease progression
223383530|NCT05274178|DEVICE|"Audeo P hearing aid labeled as OTC"|"The Audeo P is a commercially available hearing aid that is fit by a hearing care professional. The devices will be labeled as OTC in view of the participant."
223383531|NCT04362670|DRUG|OTX-CSI|OTX-CSI intracanalicular insert
223383532|NCT04362670|OTHER|Placebo Vehicle|Hydrogel Vehicle intracanalicular insert
224000534|NCT00886353|BIOLOGICAL|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
224000535|NCT00886353|OTHER|Placebo|Physiological saline administrated i.v.
224000536|NCT04281251|PROCEDURE|Endoscopic retrograde appendicitis therapy|"Colonoscopy would be introduced until visualization of the appendiceal orifice. Catheter would be placed in the appendix and decompression performed. After removal of appendicolith, plastic stent would be placed for drainage of appendix.~For patients successfully treated with initial endoscopic drainage, they would be re-admitted at 1 weeks after index procedure for repeat colonoscopy. After reaching the appendiceal orifice, the previous plastic stent would be removed. A contrast appendicogram would be repeated by introducing a wire-guided catheter in the appendix, and any residual fecalith would be removed. Finally, a repeat contrast appendicogram would be performed to confirm complete clearance of fecalith."
224000537|NCT06860022|BEHAVIORAL|Shape Coding|Intervention will include introducing and reviewing the relevant shapes from Shape Coding and the order in which the shapes go in a sentence. The researcher will then model how to put the word tiles in order according to the shapes. Next the researcher and student work together to construct sentences. The student is then given the opportunity to independently construct sentences using the word tiles and Shape Coding. At the end of instruction, the researcher and student review the shapes and the student has the opportunity to independently construct sentences without shape coding.
224000538|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 1|Medium dose, approximately 10\^4.5 TCID50/mL
224000539|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 2|High dose, approximately 10\^5.5 TCID50/mL
224000540|NCT06613737|OTHER|Influenza A H3N2 virus dose arm 3|TBD, depending on outcome of Part A
223383533|NCT01851083|BIOLOGICAL|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10\^6 cells/kg or 10x10\^6 cells/kg weight.
224000541|NCT07006220|BEHAVIORAL|COPE Program|"The COPE Program (Coping Options for Parent Empowerment) is a brief, structured, transdiagnostic intervention designed to enhance parents' emotional regulation skills, improve parenting strategies, and foster a positive family environment. The program consists of four in-person group sessions, each lasting 90 minutes, conducted over four consecutive weeks.~Each session focuses on specific emotional regulation and parenting skills:~Session 1: Understanding emotional responses and parenting strategies based on positive reinforcement, selective attention, and empathy.~Session 2: Identifying family values, promoting healthy routines, and planning alternative parenting behaviors.~Session 3: Practicing mindfulness techniques and modeling emotional regulation in the presence of children.~Session 4: Addressing intolerance to uncertainty, cognitive distortions, and promoting healthy independence in adolescents."
224123906|NCT05790668|BEHAVIORAL|Traditional Schedule Thinning|During traditional schedule thinning during functional communication training with discriminative stimuli (e.g., multiple schedules, chained schedules), practitioners correlate a unique stimulus with reinforcement (e.g., a green card) and another for extinction (e.g., a red card). When the reinforcement and extinction stimuli are presented, the child's communication responses are honored or not honored, respectively. Behavior analysts begin with a brief period of extinction (e.g., 2 s) and gradually increase that duration as the child displays low levels of destructive behavior and high levels of discriminated communication responses (i.e., communication requests during reinforcement components only) until the child reaches a terminal schedule informed by caregiver/child preference (e.g., 2.5-min reinforcement, 10-min extinction). Typically, the starting extinction period is brief and arbitrarily selected and there are no competing stimuli programmed.
224123907|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning|This intervention involves the same general components as Traditional Schedule Thinning. However, rather than starting with an arbitrary duration of the extinction component (e.g., 2 s), the behavior analyst empirically derives the starting point based on a progressive-interval assessment (PIA). The PIA involves rapidly increasing the duration of the extinction component within a single session to determine the leanest schedule of reinforcement that does not produce untoward effects. Behavior analysts will progress through the following extinction durations within a single session: 3 s, 11 s , 21 s, 34 s, 50 s, 70 s, 95 s, 126 s, 164 s, 213 s, and 270 s. For example, if the participant displays destructive behavior at 164 s consistently, but not at 126 s, the experimenters will start schedule thinning with a 126-s extinction component. There will be no competing stimuli programmed in this intervention.
224123908|NCT05790668|BEHAVIORAL|PIA-Informed Schedule Thinning with Competing Stimuli|This intervention is identical to PIA-Informed Schedule Thinning except that behavior analysts will program competing activities (e.g., alternative activities like toys or therapist attention) during extinction components. The competing stimuli will be derived from a competing stimulus assessment in which destructive behavior is analyzed across various conditions in which only the activity is manipulated during the extinction period (e.g., a session with action figures during extinction, a session with tablet during extinction). The items that produce the highest levels of child engagement and lowest levels of destructive behavior are known as highly competing items.
224123909|NCT05233631|PROCEDURE|Therapeutic Endoscopic ultrasound|A minimally invasive procedure to assess digestive (gastrointestinal) and lung diseases. Procedure allows detailed imaging of the regional anatomy by approximating the frequency transducer to the region of interest.
224123910|NCT06039085|DEVICE|custom device to demonstrate a significant difference in electrical impedance signatures|Custom device will be used to measure electrical impedance signatures.
224123911|NCT04736173|DRUG|Domvanalimab|Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
224123912|NCT04736173|DRUG|Zimberelimab|Zimberelimab is a fully human anti-PD-1 monoclonal antibody
223383534|NCT01851083|OTHER|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
223383535|NCT00485511|DRUG|Hydroxyurea|
224123913|NCT04736173|DRUG|Carboplatin|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
224123914|NCT04736173|DRUG|Paclitaxel|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
224123915|NCT04736173|DRUG|Pemetrexed|Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.
224123916|NCT04736173|DRUG|Pembrolizumab|Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
224123917|NCT04802850|OTHER|Mulligan mobilization with movement|
224123918|NCT00532961|DRUG|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
223383536|NCT06252883|OTHER|Serial bedside video call communication|Bedside video call with audio features, given to NICU parent/guardian 2-3 days a week for an 8-week period or till infant is discharged, whichever comes first.
223383537|NCT06081478|DRUG|CD19/CD22-bispecific CAR-T cells|CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
223383538|NCT03203967|PROCEDURE|Epidural morphine|2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
223383539|NCT03203967|PROCEDURE|Epidural placebo|5 ml normal saline is administered through the epidural catheter at the end of surgery.
223383540|NCT03203967|PROCEDURE|Single femoral nerve block|Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
223383541|NCT03203967|DRUG|Intravenous morphine analgesia|Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
223383542|NCT01133730|DRUG|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
223383543|NCT01133730|DRUG|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
224123919|NCT00532961|DRUG|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
223383544|NCT01618448|DRUG|Tolvaptan|Tolvaptan 15mg once daily
223383545|NCT01618448|DRUG|Placebo|Placebo
223383546|NCT03023072|OTHER|Incontinence Detection System|
223383547|NCT01404546|OTHER|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
224000542|NCT07012525|PROCEDURE|Photobiomodulation Therapy + Hyaluronic Acid Gel Injection|This arm includes the test sites (e.g., left maxillary quadrant) in each participant. The same dose of hyaluronic acid (0.2 mL of 0.8% gel) will be injected in the same manner as in the control group. However, photobiomodulation therapy (PBMT) using a diode laser (wavelength 630-670 nm, 25 mW, 1.875 J/cm² for 20 seconds) will be applied before and after the injection. Laser application will be repeated at every follow-up appointment to promote tissue healing, angiogenesis, and papillary regeneration.
224000543|NCT07012525|DRUG|Hyaluronic Acid Gel Injection|This arm includes the control sites (e.g., right maxillary quadrant) in each participant. The interdental papilla with Class I deficiency will be treated using 0.2 mL of 0.8% commercial hyaluronic acid gel, injected 2-3 mm apical to the papilla tip. This is a commonly used non-surgical soft tissue filler in periodontal and esthetic procedures. No photobiomodulation therapy will be applied in this arm.
224000544|NCT06867809|DEVICE|Epidural spinal cord stimulation and paired spine and brain stimulation|The spinal cord and brain stimulator allows for stimulation of the spinal cord and brain. Spinal cord stimulation (SCS) is provided by temporarily implanted SCS catheter electrode leads (Medtronic) that are connected to an external stimulator (Digitimer); brain stimulation is provided by transcranial magnetic stimulation (TMS).
224000545|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 1|Low dose, approximately 10\^4 TCID50/mL
224000546|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 2|Medium dose, approximately 10\^5 TCID50/mL
224000547|NCT06492564|BIOLOGICAL|SARS-CoV-2 omicron virus dose arm 3|High dose, approximately 10\^6 TCID50/mL
224123920|NCT04237402|OTHER|Hair follicles sampling|The hair follicles will be collected by strand of 5 to 6 hairs approximately in the scalp (centro-parietal part), in order to obtain 20 follicles with epithelial sheath.
223383548|NCT01404546|OTHER|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
223383549|NCT06326346|DRUG|Liporaxel|Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
223383550|NCT04855968|OTHER|In addition to standard post-op medication patient will have access to the head space meditation application.|Patients will receive access to head space meditation application in addition to standard pain medication post surgery.
223383551|NCT04855968|OTHER|Patients will take standard post-op pain medication|Standard post-op pain medication
223383552|NCT02839772|OTHER|Current skin care regimen plus 2% glycerine added to soaking water|
223383553|NCT02839772|OTHER|Current skin care regimen|
223383554|NCT00004981|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
223383555|NCT00004981|DRUG|Lamivudine/Zidovudine|
223383556|NCT00004981|DRUG|Abacavir sulfate|
223383557|NCT00897650|GENETIC|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
223383558|NCT00897650|GENETIC|Protein expression analysis|Lung tumor tissue will be collected.
223383559|NCT00897650|PROCEDURE|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
223383560|NCT00897650|PROCEDURE|Blood sample|Patients will be asked for a venous blood sample
223383561|NCT03359655|DRUG|Misoprostol|Rectal administration 2 jours before the procedure
223383562|NCT03359655|DRUG|Hyoscine butyl bromide|Rectal administration 2 jours before the procedure
223383563|NCT02721342|DRUG|Ramipril, Irbesartan and Atorvastin|
223383564|NCT00149461|BEHAVIORAL|Written Asthma Action Plan|
223383565|NCT00302861|BIOLOGICAL|MyVax|
224000548|NCT07135830|OTHER|Handball training|Athletes will perfrom their regular handball training
224000549|NCT07137130|DRUG|Concentrated secretome Injection 3 mL|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
224123921|NCT01640990|DRUG|Saline|30mins run-in period
224123922|NCT01640990|DRUG|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
224123923|NCT01640990|DRUG|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
224123924|NCT06346457|DRUG|Tamoxifen|Tamoxifen is 20 mg once daily for two to three weeks.
223383566|NCT00408512|DRUG|thiazides|Up to 25 mg per day
223383567|NCT00408512|PROCEDURE|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
223383568|NCT00133965|BEHAVIORAL|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
223425517|NCT02424630|DEVICE|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
223383569|NCT00133965|BEHAVIORAL|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
223383570|NCT00133965|BEHAVIORAL|Standard Palliative Care|"If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes."
223383571|NCT03544723|DRUG|Ad-p53|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors. Immunotherapy. Gene Therapy.
223383572|NCT02532686|DRUG|DAAOI-2|500-2000mg/d, oral, for 6 weeks
223383573|NCT02532686|DRUG|placebo|oral, for 6 weeks
223383574|NCT04186312|BEHAVIORAL|ACCESS - Accessing Campus Connections & Empowering Student Success|Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
223383575|NCT00280735|DRUG|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
223383576|NCT00280735|DRUG|docetaxel|75 mg/m² intravenously, once, every 3 weeks
223383577|NCT00554034|DRUG|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
223383578|NCT04753216|BIOLOGICAL|Bevacizumab|Given IV
223383579|NCT04753216|DRUG|Irinotecan Sucrosofate|Given IV
223383580|NCT02142608|DRUG|BR55|Ultrasound contrast agent
224000550|NCT07137130|DRUG|Concentrated secretome Injection 3 mL with addition of TGF Beta 3|The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by Dr. Cipto Mangunkusumo Hospital Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method after the secretome is ready, TGF beta 3 will be added to secretome
223383581|NCT06329570|DEVICE|NaviFUS System|Open the BBB using focused ultrasound and microbubble
223383582|NCT06329570|DRUG|Lumason|Open the BBB using focused ultrasound and microbubble
223383583|NCT06329570|DRUG|Bevacizumab|An anti-angiogenic agent to block tumor growth
223383584|NCT03648099|BEHAVIORAL|Labor dance|The dance group which involved pregnant women who performed the labor dance
223383585|NCT03648099|BEHAVIORAL|Music|The music group involving pregnant women who were exposed to music.
223383586|NCT02001987|DRUG|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
224000551|NCT07135466|OTHER|CD22 CAR-T cells|CD22 CAR-T cells
224000552|NCT07138248|BIOLOGICAL|2D Transvaginal Ultrasound|Three-dimensional transvaginal ultrasound used to assess the same outcomes as 2D, providing volumetric imaging and coronal reconstruction to detect displacement or malposition of the IUD
224000553|NCT07135336|PROCEDURE|surgery|Patients with preexisting cognitive impairment undergoing elective non-cardiac surgery under general anesthesia.
223383587|NCT02001987|DRUG|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
223383588|NCT02001987|DRUG|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
223383589|NCT03524170|DRUG|Bintrafusp Alfa|Given IV
223383590|NCT03524170|RADIATION|Radiation Therapy|Undergo radiation therapy
223383591|NCT06074393|BEHAVIORAL|Tailored Support Group|Participants engage in a secure, confidential environment, sharing caregiving insights and knowledge. Expert-led sessions, lasting 90 minutes, occur biweekly for 16 weeks, held via Zoom and at the University of Calgary's Cumming School of Medicine. These sessions take place twice annually, emphasizing the structured nature of the support group. Weekly themes include self-care, adaptation, coping skills, emotions, anticipatory grief, forgiveness, mindfulness, boundaries, and closure. Care partners actively participate by sharing experiences and asking questions in each session.
223383592|NCT04763629|OTHER|Physical exercise|Patients of both arms will undergo two different modalities of exercise during the 12 weeks study period.
223383593|NCT01895777|DRUG|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
223383594|NCT01895777|DRUG|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
223383595|NCT02613247|DEVICE|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
223383596|NCT01965860|OTHER|additional curriculum (E-learning + simulation)|
223383597|NCT01965860|OTHER|additional E-learning|
223545414|NCT02453698|DRUG|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, \& Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
223545415|NCT02453698|OTHER|Placebo|Lactose Placebo
223545416|NCT00159679|DRUG|Pregabalin|
224000554|NCT07135336|OTHER|norma|Cognitively normal individuals who do not undergo surgery but complete the same cognitive assessments at baseline, 3 months, and 12 months for normative reference.
223383598|NCT04010851|BEHAVIORAL|Peer co-led educational group|The intervention is delivered in a group format, which takes the form of a full day's training, focusing on ADHD diagnosis, its treatment, how to cope with the challenges related to living with ADHD, as well as coping with challenges of parenting a child with chronic health conditions. After this one day-intervention, the participants can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence. Participants are encouraged to adopt an active role in order to achieve a positive parent/provider partnership.
223383599|NCT04010851|BEHAVIORAL|Comparator treatment as usual|Control group will receive treatment as usual, including different treatment options that can help alleviate the symptoms of ADHD and arm families with the tools needed to better handle problem behaviors when they arise. These interventions include: medication, psychotherapy, or a combination of these two approaches.
223383600|NCT04571853|BEHAVIORAL|PNE-explained group|There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
223383601|NCT04571853|BEHAVIORAL|PNE-read group|The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
224000555|NCT07137507|PROCEDURE|Uniportal VATS|Decortication of pleural empyema is done using single-port VATS
224000556|NCT07137507|PROCEDURE|Multi-portal VATS|Decortication of pleural empyema is done using two or more ports with VATS
224000557|NCT07136987|DRUG|Metformin|Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment
224000558|NCT07136987|DIETARY_SUPPLEMENT|N-Acetylcysteine (NAC) Treatment|N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment
224000559|NCT07136987|COMBINATION_PRODUCT|Standard TB treatment|Standard TB treatment
224000560|NCT07052097|DRUG|TQC2938 injection|TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
224000561|NCT07052097|DRUG|TQC2938 Placebo|TQC2938 placebo, 4 weeks as a treatment cycle.
224000562|NCT06839248|OTHER|24-hour clear liquid diet|Participants randomly assigned to this arm will be instructed to follow a 24-hour clear liquid diet, defined as NPO for solids and last intake of clear liquids no less than 2 hours prior to the trial visit.
223383602|NCT04571853|BEHAVIORAL|TAU group|Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
223383603|NCT00876889|DRUG|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
223383604|NCT03936010|DRUG|Canagliflozin|Canagliflozin dispensing claim is exposure
223383605|NCT03936010|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
223383606|NCT05056116|DRUG|Surufatinib Toripalimab|Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
223383607|NCT05204212|OTHER|Left Atrial Appendage closure|Percutaneous closure of the LAA
223383608|NCT05487950|DRUG|Rivaroxaban group|Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
223383609|NCT03412721|PROCEDURE|Laser analgesic procedure|"Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s."
223383610|NCT03412721|PROCEDURE|Placebo analgesic procedure|Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.
223383611|NCT06100523|BEHAVIORAL|Visioconsulation|Meeting by videoconsultation with professionals adapted to the exposures highlighted by the questionnaires for patients who responded on the dedicated application (Arm A)
223383612|NCT06100523|BEHAVIORAL|self-assessment questionnaire|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
223383613|NCT06100523|BIOLOGICAL|hair sampling|hair sampling from the 2 members of the couple
224000563|NCT06839248|OTHER|Standard fasting guidelines|Participants randomly assigned to this arm will be instructed to follow the ASA and ANZCA standards for preoperative fasting prior to presenting for their trial visit. This requires participants to only consume clear liquids up to 2 hours, a light or low calorific meal up to 6 hours, and fasting from fried foods, fatty foods, or meat for at least 8 hours prior to the trial visit.
224123925|NCT06346457|DRUG|Letrozole|Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.
224123926|NCT06346457|DRUG|Letrozole + GnRH|When they take Letrozole + GnRh, the GnRh is an injection once a month.
224123927|NCT01113398|DRUG|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
224123928|NCT01113398|DRUG|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
224000564|NCT06722365|DEVICE|Backscatter Quantitative Ultrasound|The intervention consists of a regular abdominal ultrasound scan for fetal evaluation. The difference with a regular scan is that the scanner used to image the fetus provides access to raw/unprocessed ultrasound echo data that can be extracted from the scanner and processed offline (after acquisition) to extract compute backscatter quantitative ultrasound (bQUS) features. Thus, data acquisition does not represent a significant departure from conventional fetal imaging protocols. Other than the time needed to acquire the images, the participant will not perceive any difference from a regular fetal ultrasound scan.
224000565|NCT07064083|DRUG|intracanal nano-ketrolac|For the subjects of GI nano-ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
224000566|NCT07064083|DRUG|ketrolac gel|For the subjects of GII, ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
224000567|NCT07064083|DRUG|A placebo gel|a placebo gel is placed and retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.
224000568|NCT07069166|DRUG|Para-probiotic oral care|This intervention includes the home use of a para-probiotic-based toothpaste (Biorepair Plus Parodontogel) and mouthwash (Biorepair Plus with para-probiotics), applied twice daily for 15 days after each recall visit, over a 6-month period. The products contain microRepair® (zinc hydroxyapatite), lactoferrin, zinc PCA, and para-probiotic extracts aimed at modulating the oral microbiota and improving periodontal health.
224000569|NCT07069166|DRUG|Chlorhexidine oral care|This intervention includes the home use of toothpaste and mouthwash containing 0.20% chlorhexidine digluconate, applied twice daily for 15 days after each recall visit, over a 6-month period. Chlorhexidine is used for its antimicrobial properties to control dental plaque and gingival inflammation.
224000570|NCT07069153|DEVICE|Laser Therapy|High-power diode laser therapy is applied to the oral mucosa using the Garda Laser LEO PLUS device with a flat-top handpiece at 660 nm wavelength. Treatment is delivered once daily over five consecutive days according to a standardized photobiomodulation protocol (energy density: 2-4 J/cm²).
224000571|NCT07069153|DEVICE|Ozone therapy|Medical ozone gas is delivered intraorally using the Sweden \& Martina DTA device. The treatment is administered once daily over five consecutive days. A flat-tipped probe is used to apply ozone directly to the mucosal lesions at a concentration of 30-40 µg/mL, following a standardized safety protocol.
224000572|NCT07066332|BEHAVIORAL|Cornell Note Taking education group|Students will be trained in the Cornell note-taking technique.
224000573|NCT07069140|DRUG|Lactoferrin-based Toothpaste and Mouthwash (Emoform Glic)|Participants in the experimental arm will receive professional supragingival and subgingival dental hygiene sessions every three months over a six-month period. In addition, they will follow a home oral care protocol consisting of twice-daily use of a lactoferrin-based toothpaste and a lactoferrin-based mouthwash, both commercially available as Emoform Glic (Polifarma Benessere S.r.l.). The toothpaste will be applied with a soft-bristle toothbrush for two minutes, and the mouthwash will be used at a dosage of 10 mL, rinsed for 60 seconds after toothbrushing, twice a day. The intervention aims to assess whether the combined use of lactoferrin-based toothpaste and mouthwash can enhance clinical outcomes related to plaque accumulation and periodontal inflammation in pregnant women between the fourth and eighth month of gestation.
224000574|NCT07069140|DRUG|Lactoferrin-Based Toothpaste Only (Emoform Glic)|Participants in the control arm will also undergo professional dental hygiene sessions every three months for a total duration of six months. At home, they will follow an oral hygiene protocol limited to the twice-daily use of a lactoferrin-based toothpaste (Emoform Glic, Polifarma Benessere S.r.l.), applied with a soft-bristle toothbrush for two minutes. No mouthwash will be used in this arm. The purpose of this intervention is to evaluate the effectiveness of lactoferrin toothpaste alone and to serve as an active comparator for assessing the additional benefit of the mouthwash in improving periodontal parameters.
224000575|NCT07069127|DEVICE|Biorepair Toothpaste and Mousse|Participants assigned to the experimental arm will use Biorepair® Total Protection toothpaste twice daily (morning and evening) and apply Biorepair® Plus Intensive Enamel Repair mousse once daily before bedtime, for a total of 6 months. The toothpaste contains microRepair® particles (zinc-substituted hydroxyapatite), designed to occlude dentinal tubules and promote enamel remineralization. The mousse, applied at night, enhances remineralization through higher concentrations of active hydroxyapatite. This combined regimen targets the reduction of dentin hypersensitivity and enamel demineralization in adult patients with celiac disease.
224000576|NCT07069127|DEVICE|Biorepair® Toothpaste|Participants assigned to the control arm will use Biorepair® Total Protection toothpaste twice daily (morning and evening) for 6 months. The toothpaste formulation contains microRepair® (zinc hydroxyapatite) to support daily enamel protection and tubule occlusion, without the adjunctive effect of the mousse. This arm is used to assess the baseline efficacy of the toothpaste alone compared to the combined regimen.
224000577|NCT03041688|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224000578|NCT03041688|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224000579|NCT03041688|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224000580|NCT03041688|DRUG|Decitabine|Given IV
224000581|NCT03041688|DRUG|Navtemadlin|Given PO
224000582|NCT03041688|DRUG|Venetoclax|Given PO
224123929|NCT06266390|DEVICE|Transcranial Magnetic Stimulation (TMS)|The TMS intervention will involve two sets of Intermittent Theta-Burst Stimulation (iTBS) delivered every weekday for 4-6 weeks. Each iTBS set consists of 40 trains and a total of 1200 pulses, delivered approximately 15 minutes apart, resulting in 2400 pulses per session.
224123930|NCT03280433|OTHER|Aortic valve replacement|
224123931|NCT03087825|PROCEDURE|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
224123932|NCT03087825|PROCEDURE|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
223383614|NCT06100523|BEHAVIORAL|self-assessment questionnaire on dedicated application|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
223383615|NCT06100523|BEHAVIORAL|Specialized follow-up|proactive healthcare pathway : active support of corrective measures implemented with couples by the platform, with the help of the application
223383616|NCT06100523|BEHAVIORAL|self-assessment questionnaire for follow-up|self-administered questionnaire of assessment of reprotoxic exposures, assessment of stress, physical activity, quality of life in infertility course
224000583|NCT07135934|DIETARY_SUPPLEMENT|Sodium Bicarbonate (NaHCO3)|Gelatin capsules each containing 1g sodium bicarbonate (NaHCO₃)
223383617|NCT01018004|OTHER|follow-up care|
223383618|NCT01018004|OTHER|questionnaire administration|
223383619|NCT01018004|PROCEDURE|quality-of-life assessment|
224000584|NCT07135934|DIETARY_SUPPLEMENT|Placebo|Gelatin capsules each containing 1g food-grade starch
224000585|NCT07129135|PROCEDURE|The bladder was filled with 300 ml diluted methylene blue (in normal saline) via Foley's catheter|The bladder was filled with 300 ml diluted methylene blue (in normal saline) via Foley's catheter before uterine incision or bladder dissection to help determine the borders better and enable dissection of the lower uterine segment without excessive bleeding or unintended Bladder kept distended during dissection.
224000586|NCT07138105|OTHER|National AI in Surgical Practice Survey - Sudan|An online, cross-sectional national survey targeting Sudanese doctors who provide surgical care in any capacity. The survey collects data on awareness, prior experience, perceived benefits, barriers, and training needs for adopting artificial intelligence in surgical practice. Participants include house officers, medical officers, registrars/residents, specialists, consultants, and general practitioners performing surgical procedures in public, private, NGO, or military hospitals. The study does not involve the implementation or testing of AI tools but aims to inform the design of future AI solutions tailored for low-resource and conflict-affected health systems.
223383620|NCT04513301|DRUG|Sintilimab|Sintilimab (200 mg q3w ×2 cycle)
224000587|NCT07135804|DRUG|Iparomlimab and Tuvonralimab Injection|Patients will receive Iparomlimab and Tuvonralimab Injection on the basis of 3 cycles of induction chemotherapy, followed by standard concurrent chemoradiotherapy, and then 9 cycles of Iparomlimab and Tuvonralimab Injection as adjuvant therapy
224000588|NCT07084610|DRUG|Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)|Patients will receive neoadjuvant treatment with nivolumab (3 mg/kg, IV) combined with platinum-based chemotherapy (cisplatin 75 mg/m² or carboplatin AUC 5, plus pemetrexed 500 mg/m² for non-squamous or paclitaxel 175 mg/m² for squamous tumors) every 21 days for two cycles. All patients will undergo invasive mediastinal staging before treatment and will be treated with robotic-assisted anatomical lung resection and mediastinal lymphadenectomy after neoadjuvant therapy.
224000589|NCT07085026|BEHAVIORAL|Yoga Intervention|There are studies that have evaluated the effects of prenatal yoga on sleep. None of these studies have reported any negative effects of yoga on pregnancy. In all studies, yoga practice was applied with varying frequencies, durations, and techniques. However, no research has been found that evaluates the effects of a yoga program conducted in accordance with the World Health Organization (WHO) guideline recommendations on both sleep and stress. Therefore, the aim of this study is to evaluate the effects of yoga, practiced during the third trimester of pregnancy in line with WHO guideline recommendations, on sleep and stress.
224000590|NCT07084792|DEVICE|Direct cortical stimulation|Stimulation
224000591|NCT07085728|DRUG|Cyclophosphamide|Arm A
224000592|NCT07085728|DRUG|Bortezomib (VELCADE)|Arm A, Arm B
224000593|NCT07085728|DRUG|Dexamethasone|Arm A, Arm B
224000594|NCT07085728|DRUG|Daratumumab-hyaluronidase|Arm B
224000595|NCT06088004|DRUG|ABO2011 Injection|Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
223383621|NCT04513301|RADIATION|Radiotherapy|RT 50-60Gy/25-30f
223383622|NCT02526667|DRUG|Chlorhexidine gluconate|2% CHG solution on cloth
223383623|NCT02526667|DRUG|DynaHex-2|2% CHG solution
223383624|NCT02526667|OTHER|Vehicle|Excipients of CHG product only
223383625|NCT06251440|DRUG|Fetal Reduction|Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route
223383626|NCT00522730|OTHER|Parenteral nutrition|Duration : 5 days
223383627|NCT00522730|OTHER|Enteral nutrition|Duration : 5 days
223383628|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 1|2-week ad libitum use of the RELX ENDS tobacco flavor 1
223383629|NCT05134415|OTHER|RELX ENDS Tobacco Flavor 2|2-week ad libitum use of the RELX ENDS tobacco flavor 2
224000596|NCT06088004|DRUG|Toripalimab|Anti-PD-1 antibody
224123933|NCT00139334|BIOLOGICAL|Rotavirus|
224123934|NCT00028561|DRUG|ixabepilone|Given IV
224123935|NCT00028561|DRUG|carboplatin|Given IV
223383630|NCT05134415|OTHER|RELX ENDS Menthol Flavor 1|2-week ad libitum use of the RELX ENDS menthol flavor 1
223383631|NCT05134415|OTHER|RELX ENDS Menthol Flavor 2|2-week ad libitum use of the RELX ENDS menthol flavor 2
223383632|NCT01483443|PROCEDURE|Oophrectomy|Both oophrectomy
223383633|NCT02665793|OTHER|DBPCFC to peanut cookie|
223383634|NCT02665793|OTHER|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
223383635|NCT02665793|OTHER|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
223383636|NCT00440661|DRUG|Diacerhein|
223383637|NCT05890651|DIAGNOSTIC_TEST|ECG|Describe the electrocardiography (ECG) changes 24 hours,1,6,12 months after VSD transcatheter device closure in a pediatric population.
223383638|NCT03867240|DRUG|Gabapentin|Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients \<50 kg and 200 mg for patients \> 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.
223545417|NCT00399568|DRUG|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
223545418|NCT00399568|DRUG|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
223383639|NCT03867240|OTHER|Placebo|Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
224000597|NCT06789302|DRUG|DT2-SCT intravenous infusion|"DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects."
223383640|NCT05322772|DEVICE|ECG|ii. 12 leads ECG: 12 leads ECG will be done to all infants \& children using (FUKUDA DENSHI, CARDIMAX, model FCP 7101). The electrocardiograms will be reviewed through the creation of descriptive reports and determination of the following variables: heart rate, QRS duration, The QT interval was measured from the onset of the QRS complex to the end of the T wave, defined by the return of the terminal T wave to the isoelectric T-P baseline. When U waves were present, the end of the T wave will be taken as the nadir between the T and U waves. Then QT interval will be corrected for heart rate using Bazett's formula Interpretation of every ECG paper
223383641|NCT03934346|OTHER|Zinc amino acid complex|Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
223383642|NCT00962819|BIOLOGICAL|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
223383643|NCT01576354|DRUG|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
223383644|NCT01576354|DRUG|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
223383645|NCT03520257|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
223383646|NCT03520257|DEVICE|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
223383647|NCT00631215|PROCEDURE|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
224000598|NCT06789302|OTHER|Placebo|Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
223383648|NCT05602220|BEHAVIORAL|Brain training|Participants will play a few brain training games using an online interface each day. These games train attention, memory and other cognitive functions.
223545419|NCT04910386|DRUG|Envafolimab plus Gemcitabine&Cisplatin|Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
223545420|NCT04910386|DRUG|Gemcitabine&Cisplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
224123936|NCT00028561|OTHER|laboratory biomarker analysis|Correlative studies
224123937|NCT00028561|OTHER|pharmacological study|Correlative studies
224123938|NCT01029431|DEVICE|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
224123939|NCT02165800|PROCEDURE|L-PANP-TME|
224123940|NCT02165800|PROCEDURE|O-PANP-TME|
224123941|NCT02486887|DEVICE|telemonitoring of weight, pulse and blood pressure|
224123942|NCT04310215|BIOLOGICAL|CARTISTEM®|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"
224123943|NCT04310215|PROCEDURE|Microfracture|"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1\. Procedure: Microfracture"
224123944|NCT00074412|DRUG|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
224123945|NCT00074412|DRUG|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
224123946|NCT02891798|DRUG|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
224123947|NCT02891798|DRUG|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
224123948|NCT02917551|OTHER|7 days of adequate antibiotic treatment|
223383649|NCT05602220|BEHAVIORAL|Paced breathing|After completing brain training, they will then immediately do one 15-minute session of paced breathing, followed by a second 15-min session of paced breathing later in the day. During the paced breathing sessions, participants will clip a pulse monitor to their ear lobe and try to inhale and exhale in synchrony with a ball that moves up and down on the screen. They will receive heart rate biofeedback regarding whether they are achieving their relaxation/alertness goal.
223383650|NCT00282646|PROCEDURE|intraarterial stem cell therapy|catheter delivery of stem cells
224000599|NCT01832623|OTHER|Exploration of Vitamin D roles|"* Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~* Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
224000600|NCT05254834|DIAGNOSTIC_TEST|Freenome Test|Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
224000601|NCT04836390|DRUG|Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions|Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
224000602|NCT05899231|BEHAVIORAL|Prehabilitation Programming|"12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence."
224000603|NCT07135362|DIETARY_SUPPLEMENT|TCI604 probiotics|TCI604 probiotics sachet
224000604|NCT07135362|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
224000605|NCT07138196|DRUG|Adrixetinib|Administered orally
224000606|NCT07136961|PROCEDURE|Robot-Assisted Bronchoscopy (RAB)|"1. Preoxygenation \& Navigation Registration~2. Robotic-Guided Navigation~3. Puncture Tunnel Establishment~4. Position Verification \& Adjustment~   Perform confirmatory CT scan to assess tool-nodule relationship:~   Tool-in-lesion (TIL) : Biopsy tool penetrates nodule Center Strike : Tool tip reaches central 1/3 of nodule (coronal/sagittal/horizontal planes) Tool-touch-lesion : Tool contacts but does not enter nodule~  * 4mm deviation : Proceed to biopsy \>4mm deviation : Adjust based on operator judgment~5. Biopsy \& Rapid Evaluation Obtain tissue samples Conduct ROSE (Rapid On-Site Evaluation) to guide next steps~6. Post-Procedure Safety Check Perform postoperative CT to exclude pneumothorax/hemorrhage Maintain identical ventilation settings during imaging and biopsy phases to prevent target shift"
224000607|NCT07136688|DEVICE|Stamobil electric stimulator|The electric stimulation protocol will use stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode for 30 minutes daily. The goal is daily use of tTNS for 4 weeks , 5 days per week.
224000608|NCT07136688|DEVICE|sham tTNS device|The electric sham stimulation protocol will use sham stimulation (low intensity) for 30 minutes daily, for 4 weeks , 5 days per week
223383651|NCT00282646|OTHER|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
223383652|NCT00139451|DRUG|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
224000609|NCT07136571|DEVICE|bland particles|embolization with bland particles of appropriate size
224000610|NCT07136285|DRUG|Olvi-Vec|Olvi-Vec will be administered to patient for 3 days during C1
224000611|NCT07136285|DRUG|platinum (cisplatin or carboplatin)|After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum （Carboplatin or Cisplatin）will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
224000612|NCT07136285|DRUG|Etoposide|After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred.
224123949|NCT02917551|OTHER|14 days of adequate antibiotic treatment|
223383653|NCT00139451|DRUG|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
223383654|NCT06012188|OTHER|sleep toy|The parents of the children in the experimental group will be given a sleeping companion toy to present to their children. At the end of 15 days, the Children's Sleep Habits scale will be applied as a post-test to evaluate the effect of the sleep companion toy.
223383655|NCT03305965|BEHAVIORAL|Patient navigation|Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
224000613|NCT07137533|OTHER|Mandibular Four-Implant-Retained Overdenture (PEEK Framework); Mandibular All-on-4 Fixed Prosthesis (PEEK Framework)|"Group I: Four-implant-retained mandibular overdenture with a CAD/CAM-milled PEEK framework and acrylic denture teeth, retained via attachment mechanisms; implants placed in lateral incisor and first premolar sites; delayed loading protocol.~Group II: Mandibular All-on-4 fixed prosthesis with a CAD/CAM-milled PEEK framework and acrylic denture teeth; two anterior straight and two posterior tilted implants placed in lateral incisor and first premolar sites; delayed loading protocol."
224123950|NCT00924352|DRUG|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
224123951|NCT00924352|DRUG|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
223383656|NCT01740245|DEVICE|Chlorhexidine vaginal suppositories|
223383657|NCT01740245|DEVICE|Polyhexamethylene biguanide vaginal suppositories|
223383658|NCT01880892|PROCEDURE|Cricopharyngeal myotomy|Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
223383659|NCT01880892|DIAGNOSTIC_TEST|PH probe Testing|24 hour PH probe testing, which will measure acid reflux following cricopharyngeal myotomy.
223383660|NCT06225219|BEHAVIORAL|Counseling|To introduce a model of holistic care to the patient populations served by the GCAC through chaplain interventions that focus on spiritual and emotional health.
223383661|NCT04526015|PROCEDURE|Iliohypogastric and ilioinguinal nerve block|Each patient will receive spinal anesthesia plus bilateral ultrasound-guided IL/IH nerve block. The abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualized between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side
223383662|NCT04526015|PROCEDURE|Controlled Group|Each patient will receive spinal anesthesia alone with no block.
223383663|NCT05479825|PROCEDURE|inflation- deflation line combined with ICG fluorography|Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
223383664|NCT03735121|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
223383665|NCT03735121|DRUG|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
223383666|NCT05721014|OTHER|OsteoStrong|"This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are chest press, leg press, pull-down and deadlift. The participants press and/or pull isometrically for around 10-15 seconds 1-3 times on every machine.~The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor."
224000614|NCT07138144|DRUG|Standard Medical Therapy|Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: Bictegravir 50 mg / tenofovir alafenamide 25 mg / emtricitabine 200 mg or dolutegravir 50 mg / lamivudine 300 mg / abacavir 600 mg, both combinations in a single tablet.
224000615|NCT07138144|DRUG|dual therapy|Intervention arm will be dual therapy oh DTG 50 mg/ 3TC 300 mg, this will be compared to standar therapy of 3 drugs
224000616|NCT07088679|DRUG|Sterify Gel (mucoadhesive bioactive gel)|Sterify Gel® is a sterile, ready-to-use mucoadhesive hydrogel formulated with polyvinyl polymers, hydroxytyrosol (a natural antioxidant), magnesium ascorbyl phosphate (a stable vitamin C derivative), and nisin (a naturally occurring antimicrobial peptide). In this study, it is applied into the peri-implant pocket using a 0.6 mm - 23GA sterile needle (Gerhò®) immediately after non-surgical debridement. Application is performed at baseline and at follow-up visits (1, 3, 6, and 9 months). Patients are instructed to avoid rinsing, eating, or using oral hygiene aids at the treated sites for at least 2 hours post-application, and to follow specific hygiene instructions for 48 hours.
224000617|NCT07088679|PROCEDURE|Standard Non-Surgical Peri-Implantitis Therapy|Standard therapy consists of supra- and subgingival professional mechanical debridement of peri-implant sites using ultrasonic inserts and manual curettes covered with biocompatible materials (PEEK, teflon, or titanium) to avoid damage to the implant surface. This is followed by air-polishing using erythritol powder (Air-Flow Plus®, EMS; 14 µm) for supragingival biofilm removal and glycine powder (Air-Flow Perio®, EMS; 25 µm) for subgingival polishing. This procedure is repeated at baseline and at 1, 3, 6, and 9 months without the adjunctive use of any topical gel.
224000618|NCT06889584|COMBINATION_PRODUCT|All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin))|Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin.
223383667|NCT05721014|OTHER|Individually Adapted and Combined Physical Training|"This training method is based on the current recommendations on physical activity for people with osteoporosis.~The training is divided into two training sessions:~Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down.~Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down.~The training session takes around 60 minutes and is performed in a group with the help of a training instructor. The participants also have the option to do a home based exercise programme that they could do in a few cases when they were unable to attend the physical group training."
223383668|NCT04024046|DIETARY_SUPPLEMENT|Uqora|Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily
223383669|NCT04024046|DIETARY_SUPPLEMENT|Group1|Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily
223383670|NCT04024046|DIETARY_SUPPLEMENT|Group 2|Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily
223383671|NCT06480292|OTHER|telerehabilitation exercise|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.
223383672|NCT06480292|OTHER|routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
223383673|NCT04384835|BIOLOGICAL|Blood sample collection (one tube)|Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
223383674|NCT04384835|BIOLOGICAL|Blood sample collection (five tubes)|Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
223383675|NCT05440890|OTHER|Best current rehabilitation protocol|Inflamation control and edema with physical agents, recover full pasive and active range of motion, normalize gait pattern, lower limb strengthening (specially quadriceps and hamstrings), neuromuscular control training, cycling, landings and running.
223383676|NCT05440890|OTHER|Cross-training protocol|Beginning on 2º week after ACLR, 3 times per week during 8 weeks, based on isotonic exercise at least to 80% of 1RM in leg extension. 5 sets o 6 repetions with 1,5 - 2 minutes between series.
224000619|NCT06889584|COMBINATION_PRODUCT|AM Active Supplement Combination (Ashwagandha and Rhodiola rosea)|Ashwagandha and Rhodiola rosea
224000620|NCT06889584|COMBINATION_PRODUCT|PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin)|Magnesium threonate, L-theanine, and apigenin.
224000621|NCT06889584|OTHER|AM and PM Placebo|Placebo AM and PM
224000622|NCT04384627|RADIATION|Delineating the GTV according to the pretreatment or post-IC tumor extension|Delineating the GTV according to the pretreatment or post-IC tumor extension
224000623|NCT04854850|DEVICE|Apollo|The Apollo System offers a convenient novel non-invasive, non-habit-forming solution to improve performance and recovery under stress in children and adults by delivering gentle wave-like vibrations to the body that improve autonomic nervous system balance in real time (Siegle \& Rabin et al., under review). The gentle vibrations delivered by the Apollo System are extremely low intensity in that they are typically just barely noticeable or perceptible by the user. Additionally, the range of frequencies and intensities of the Apollo System have been safely used in numerous commercial products without adverse events reported, including sexual vibrators and massagers. Apollo vibrations activate touch receptors in the skin and are perceived as safety signals by the brain resulting in decreased stress, improved recovery, focus, and energy.
223383677|NCT05581381|BEHAVIORAL|empathy training program|Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
224000624|NCT04299243|DEVICE|Contact Lenses|Contact lenses for vision correction
224000625|NCT04793412|DEVICE|Cochlear Implant|Cochlear implantation of a device from one of the three manufacturers available in the US.
224000626|NCT06045975|DRUG|Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting|"* Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by PA procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions."
224000627|NCT01230866|RADIATION|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
224000628|NCT01230866|RADIATION|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
224000629|NCT05043766|DRUG|PF614|PF614 is an oxycodone prodrug
224000630|NCT05043766|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
224000631|NCT05043766|DRUG|OxyContin|Bioequivalence single-dose comparison to OxyContin
224000632|NCT06199180|DEVICE|pulmonary vein isolation with RFA|Patients randomised to RFA will undergo PVI with point-by-point RFA.
224000633|NCT06199180|DEVICE|pulmonary vein isolation with PFA|Patients randomised to PFA will undergo PVI with PFA.
224000634|NCT04683627|DRUG|Diclofenac sodium active topical patch|A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
224000635|NCT04683627|DRUG|Placebo patch|A placebo patch without diclofenac sodium was used for the placebo arm.
223383678|NCT03044821|PROCEDURE|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
224000636|NCT03829501|DRUG|Alomfilimab|A human anti-ICOS monoclonal antibody
224000637|NCT03829501|DRUG|Atezolizumab|An anti-PD-L1 monoclonal antibody
224000638|NCT03625544|PROCEDURE|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
224000639|NCT03625544|DEVICE|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
224000640|NCT03625544|PROCEDURE|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
224000641|NCT03024463|PROCEDURE|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
224000642|NCT06276400|OTHER|Emotion valence|Positive vs. Negative (temporally extended sequence)
224000643|NCT06276400|OTHER|Time|∆ Temporal evidence (i.e. relative time difference of stimulus-type exposure across a sequence: 1200 vs. 1800)
223383679|NCT00344448|DRUG|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
224000644|NCT06276400|DEVICE|TMS Stimulation|FPl vs. mid-LPFC vs. non-PFC Control (S1); Specific LPFC region (vs. non-PFC active Control) function is manipulated with an inhibitory TMS protocol (cTBS).
223383680|NCT05323669|DIAGNOSTIC_TEST|Molecular testing|Molecular testing of thyroid nodules
223383681|NCT00067041|DRUG|Remodulin (treprostinil sodium) Injection|
223383682|NCT02535286|DRUG|Umbralisib|A once daily oral agent
223383683|NCT02535286|BIOLOGICAL|ublituximab|IV anti-CD20 monoclonal antibody
223383684|NCT02535286|BIOLOGICAL|TG-1501|IV immunotherapy for cancer
223383685|NCT05317338|BEHAVIORAL|Group-based exercise training during hospitalization|Multicomponent exercises for 5-7 days with acutely hospitalized older.
224000645|NCT02446665|DEVICE|MR Elastography (MRE) and FibroScan|
224000646|NCT06280742|RADIATION|PET-MRI with [18F]-DPA-714|PET-MRI with \[18F\]-DPA-714
224000647|NCT05642611|PROCEDURE|Biospecimen Collection|Undergo collection of blood, plasma, and serum
224000648|NCT05642611|PROCEDURE|Cryocompression Therapy|Undergo cryocompression
224000649|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo continuous compression
224000650|NCT05642611|PROCEDURE|Pneumatic Compression Therapy|Undergo low cyclic compression
224000651|NCT05642611|OTHER|Quality-of-Life Assessment|Ancillary studies
224000652|NCT05642611|OTHER|Questionnaire Administration|Ancillary studies
224000653|NCT03642847|BIOLOGICAL|Prevnar 13|13 valent Pneumococcal Conjugate
224000654|NCT03642847|BIOLOGICAL|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
224000655|NCT03642847|BIOLOGICAL|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
223383686|NCT01528007|DRUG|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
223383687|NCT01528007|DRUG|Placebo|Placebo pill with no active ingredients.
223383688|NCT03411135|OTHER|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
224000656|NCT01758445|RADIATION|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol \& physician.
224000657|NCT01123070|BIOLOGICAL|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
224000658|NCT01123070|BIOLOGICAL|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
224000659|NCT03270410|OTHER|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
224000660|NCT04115072|DRUG|Praziquantel 600Mg Oral Tablet x 5|Five doses of Praziquantel 40 mg/kg
224000661|NCT04115072|DRUG|Praziquantel 600Mg Oral Tablet x 1|Single dose of Praziquantel 40 mg/kg
224000662|NCT02891538|DRUG|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).\*
224000663|NCT00084344|DRUG|4-hydroxytamoxifen|
224000664|NCT00084344|PROCEDURE|breast imaging study|
224123952|NCT05656716|BEHAVIORAL|Nutritional intervention|The nutritional intervention will be based on a nutritional education program adapted for patients with breast cancer in active treatment. The nutritional intervention program will be based on the practical guidelines for nutrition in the oncology patient. The main objectives of the nutritional intervention will focus on preventing malnutrition, maintaining an adequate nutritional status and dietary adaptation to secondary symptomatology. To this end, an adequate energy and protein intake will be ensured and the consumption of plant-based foods will be promoted to ensure an adequate intake of vitamins, minerals and antioxidants
223383689|NCT03138655|DRUG|Vedolizumab|Vedolizumab IV infusion.
223383690|NCT01008189|BEHAVIORAL|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
223383691|NCT01008189|BEHAVIORAL|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
223383692|NCT03804814|BEHAVIORAL|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
223383693|NCT00030706|DRUG|ixabepilone|
223383694|NCT02565511|BIOLOGICAL|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
223383695|NCT02565511|OTHER|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
223383696|NCT02565511|DRUG|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
223383697|NCT02565511|OTHER|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
223383698|NCT02565511|OTHER|Alum|Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
223383699|NCT00383305|DEVICE|Cool-Cap|
223383700|NCT05435690|DEVICE|Computer-assisted arthroplasty|Computer-assisted arthroplasty
223383701|NCT04087915|DRUG|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
223383702|NCT04881487|RADIATION|Additional stereotactic body radiation therapy|5 fractions of 8 Gray stereotactic body radiation therapy in addition to standard of care.
224000665|NCT00084344|PROCEDURE|radiomammography|
224000666|NCT03663673|DRUG|EpiCeram|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
224000667|NCT03663673|DRUG|Aveeno Daily Moisturising Sheer Hydration Lotion®|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
224000668|NCT00660322|BEHAVIORAL|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~1. Using asthma controller medications as prescribed~2. Having and Asthma Action Plan available to all who may need it.~3. Using asthma rescue medications with the child's first symptoms.~4. Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
224123953|NCT05656716|BEHAVIORAL|Physical exercise intervention|Weekly physical exercise guidelines will be given following the published Canadian clinical guideline recommendations combining moderate and vigorous aerobic activity. Walking will be performed 3 days a week for 30 minutes at a modified Borg scale intensity of 4-5/10, and 2 days a week for 15 minutes at a modified Borg scale intensity of 7-8/10. There will also be 5 minutes of warm-up and 5 minutes of recovery, in moderate activity at 3/10, and in vigorous activity at 4/10. In addition, 3 days per week (not coinciding with vigorous aerobic activity) of strength training at a modified Borg scale intensity of 7/10 will be included. Two sets of 8-10 repetitions will be performed, adaptable to that intensity according to the progression of the subjec
223383703|NCT00706589|DRUG|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
223383704|NCT00706589|DRUG|placebo|Initial dose: 2mg, Maximum dose:20mg
223383705|NCT03656744|DRUG|HTD1801|HTD1801 tablets, 250mg
223383706|NCT03656744|DRUG|Placebo|tablets manufactured to mimic HTD1801 tablets
223383707|NCT00549432|DEVICE|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
223383708|NCT00399633|DRUG|sumatriptan|
223383709|NCT04441151|BEHAVIORAL|Pulmonary rehabilitation therapy|Comprehensive interventions based on comprehensive evaluation and customization of patients, including, but not limited to, exercise training, education and behavioral changes, aimed at improving the physiological and psychological status of patients with chronic respiratory diseases, and urge patients to adhere to health promotion activities for a long time.
224000669|NCT05873478|OTHER|High Intensity Interval Training|The HIIT sessions ranging from 4-12 minutes in duration for 8 weeks in which three sessions will be conducted each week (weeks 1-3: 4 minutes; weeks 4-6: 8 minutes; weeks 7-8: 12 minutes respectively), with a work to rest ratio of 30sec: 10sec, as mention in table 1. Experimental group/HIT group engaged in their HIIT sessions (inclusive of a short warm-up activity including dynamic exercises i.e., walking/running, 8-10 minutes of HIIT and cool down which include static exercises i.e., shoulder and hip muscle stretches). Session duration and intensity are increased with weekly progression in intervention groups. The high resistance training sessions was be delivered by the researcher to HIT group
224000670|NCT00263172|BEHAVIORAL|behavior modification for weight loss|
224000671|NCT01887704|DEVICE|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
223383710|NCT06458647|OTHER|Video Streaming with Virtual Reality|In the study, patients in the intervention group will be watched videos of natural landscapes such as mountains, beaches and waterfalls with virtual reality goggles before the angiography procedure.
223383711|NCT01696760|DRUG|acetylsalicylic acid|325 mg twice a day
223383712|NCT01696760|DRUG|enoxaparin|40 mg once daily
223383713|NCT01696760|DEVICE|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
223383714|NCT00978614|DRUG|Neramexane|"Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
223383715|NCT04794036|OTHER|Asynchronous telerehabilitation programme|Home-based physical rehabilitation programme using a telerehabilitation platform
223383716|NCT04794036|OTHER|Rehabilitation programme|Home-based physical rehabilitation programme by means of an explanatory booklet
223545421|NCT04169503|DRUG|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
224000672|NCT01887704|PROCEDURE|conventional angioplasty|Conventional angioplasty was used in both arms.
224000673|NCT01887704|PROCEDURE|stenting|Stenting was implanted in both arms.
224000674|NCT01887704|DEVICE|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
224000675|NCT01887704|DRUG|Aspirin|Aspirin will be administrated in participants in both arms.
224000676|NCT01887704|DRUG|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
223383717|NCT03295630|DEVICE|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
223383718|NCT01080183|OTHER|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
223383719|NCT06632652|BEHAVIORAL|Health Education|"Provide 'Health Education' for acquisition of self-management skills, acquiring knowledge of both the disease and self-care. By making self-supported decisions, the patients are able to manage their diet, exercise and medication.~Patients will start implementing diabetes management right after the group education. Each patient will develop monthly goal settings (behavior change plan) related to their diabetes management, daily practice them, and record the results every day on the self-monitoring notebook. The nurses call each patient on the scheduled day, ask/evaluate his/her behavior changes and monitored data, then make step-up goals for the next month. In addition, based on his/her knowledge and practice level, the nurses provide education using the education booklet. Patients and the nurses repeat these activities during 6 months."
223383720|NCT00098774|BIOLOGICAL|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC \> or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
223383721|NCT00098774|BIOLOGICAL|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, \& 24 of Cycle 1 nad Days 3 \& 10 of Cycle 2
223383722|NCT00098774|DRUG|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
223545422|NCT06403553|DIAGNOSTIC_TEST|Fecal Calprotectin|Fecal Calprotectin measurement on days 1and 3
224000677|NCT01887704|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
224000678|NCT01887704|DEVICE|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
224000679|NCT01887704|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
224000680|NCT01887704|DEVICE|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
224000681|NCT03520738|OTHER|Blood samples|Blood samples on an empty stomach
224000682|NCT03520738|OTHER|Urinary samples|first urinary in the morning
224000683|NCT02207504|DRUG|Crizotinib|Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.
223383723|NCT00098774|DRUG|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
223383724|NCT00098774|DRUG|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
223383725|NCT00098774|DRUG|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
223383726|NCT00098774|DRUG|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
223383727|NCT05752825|RADIATION|HR-pQCT|HR-pQCT is a 3-dimensional imaging modality that can be applied to bone and joints in vivo, in order to non-invasively assess the quantity and quality of trabecular and cortical bone compartments separately. HR-pQCT will be applied to peripheral skeletal sites, namely the distal radius and tibia, where image slices equivalent to 9 mm of bone will be acquired. From this, parameters such as volumetric bone mineral density (vBMD), cortical density, cortical porosity, trabecular density, trabecular thickness, trabecular spacing and others will be calculated using specialized software. In the same scanning session, images of the wrist and ankle joints will be produced and analyzed for features of arthrosis, such as erosions, osteophytosis and others.
224000684|NCT02207504|DRUG|Enzalutamide|Enzalutamide is an androgen receptor signaling inhibitor.
224000685|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
224000686|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
224000687|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
224000688|NCT01056705|BIOLOGICAL|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
224000689|NCT01056705|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
224000690|NCT03264937|BEHAVIORAL|Social-software management|Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
224000691|NCT03284229|DEVICE|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
224000692|NCT01702324|DRUG|DD-25|A topical DD-25 cream at 0.025% concentration.
224000693|NCT05411133|DRUG|Cabotamig (ARB202)|Cabotamig (ARB202), Atezolizumab
223383728|NCT05752825|RADIATION|DXA scan|Through DXA scans, we will obtain information regarding body composition, hip and spine bone mineral density, as well as examine any previous vertebral fractures using vertebral fracture assessment (VFA). VFA is a function of DXA scanners which allows for visualization of thoracic and lumbar vertebrae (usually T4-L4) in order to detect vertebral fractures34. Vertebral fractures can then be classified as either mild, moderate or severe using the method described by Genant et al35.
223383729|NCT05752825|DIAGNOSTIC_TEST|Bone microindentation|Using the OsteoProbe®, we will by microindentation measure the bone material strength index (BMSi), an in vivo surrogate measure of the fracture resistance of the cortical bone in the tibia. The participant is placed in a supine position with the examined leg rotated slightly outward. After identifying the site of interest, located midway between the medial tibial plateau and the medial malleolus, disinfectant is applied to the skin of the tibia being examined. Finally, under local anesthesia and fully sterile conditions, a test probe is inserted through the skin and onto the midshaft of the tibia, and the fracture resistance of the bone tissue is measured.
224000694|NCT02665767|DEVICE|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
224123954|NCT06166095|OTHER|high-dose|Participants will be asked to perform a high-dose (HD) (i.e., 300 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
223383730|NCT05752825|DIAGNOSTIC_TEST|Hand grip and leg extension strength|Hand grip strength will be assessed using a digital hand dynamometer as a measure of peripheral muscle strength. Leg extensor strength will be examined using the peak torque measured by an isometric dynamometer mounted on a fixed chair. 3 attempts will be given for each method, and the maximum value recorded.
223383731|NCT05752825|DIAGNOSTIC_TEST|Timed up-and-go test|The TUG test is a functional test frequently used to assess balance in older individuals and is performed by measuring the time it takes for an individual to go from sitting to standing position, walk 3 meters, turn around and return to sitting position. A TUG score of \>13,5 seconds is associated with an increased risk of falls.
223383732|NCT05752825|DIAGNOSTIC_TEST|Stabilometry|Postural control will be assessed by means of a force platform that registers Center of Pressure (CoP) as a measure of postural stability. Measurements are performed under a variety of conditions, including eyes open/closed and on different surfaces. From the CoP measurements, parameters such as CoP range and CoP velocity in both antero-posterior and medial-lateral directions will be calculated using specialized software.
223383733|NCT05752825|DIAGNOSTIC_TEST|Nerve conduction test|To fully examine all components of balance, nerve conduction will be tested using a handheld device called NC-stat DPN-Check in order to assess any peripheral neuropathy.
223383734|NCT05752825|DIAGNOSTIC_TEST|Visual acuity test|Visual acuity will be tested using an automated refractometer (KR-800S Auto-kerato-refractometer, Topcon Healthcare, The Netherlands).
223383735|NCT04010474|PROCEDURE|Modified Surgical APGAR Score|"Four intraoperative factors~1. Lowest heart rate (HR),~2. Lowest mean arterial pressure (MAP)~3. Estimated blood loss~4. Operation time"
223383736|NCT05835674|DIAGNOSTIC_TEST|Early intervention program|"At enrollment visit: History and examination, MRI, evaluation of comorbidities, medication and genomic testing. HINE, GMA (if below 5 mo), AIMS, SHAI, PSS and DASS-21 questionnaire.~At 6 mo visit: Examination and evaluation of comorbidities, medication and HINE and AIMS~At 12 mo visit: Examination and evaluation of comorbidities, medication and HINE, AIMS, HAI, PSS and DASS-21 questionnaire.~At 18 mo visit: Examination and evaluation of comorbidities, medication and HINE~At 24 mo visit: Examination and evaluation of comorbidities, medication and HINE, PDMS-2, GMFM-66, BSID-IV-cog, MPOC-20 ,PSS, and DASS-21 questionnaire. GMFCS and Mini MACS if CP."
224000695|NCT02908932|DIETARY_SUPPLEMENT|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
224000696|NCT02908932|DIETARY_SUPPLEMENT|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
224000697|NCT02833870|BEHAVIORAL|Musical intervention|
224000698|NCT02833870|BEHAVIORAL|Non-musical (cooking) intervention|
224000699|NCT02833870|BEHAVIORAL|Control with no intervention|
224000700|NCT03122132|DRUG|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
223383737|NCT01426074|DRUG|Bevacizumab 5 mg/kg|Intravenously every two weeks
223383738|NCT03910673|DRUG|Fosfomycin disodium|Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
223383739|NCT06581562|DRUG|AB-101|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
223383740|NCT06581562|DRUG|Rituximab|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
223383741|NCT06581562|DRUG|Cyclophosphamide|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
223383742|NCT06581562|DRUG|Fludarabine|"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."
224000701|NCT03122132|DRUG|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
224000702|NCT06446999|OTHER|Yoga-Based Breathing Exercise|"Breathing Exercise Protocol Purpose: This protocol is a guide prepared for patients who agree to participate in the study within the scope of scientific research to do breathing exercises.~Materials Required: A comfortable chair/a comfortable bed to lie on and comfortable clothing.~Exercise Duration: Approximately 20 minutes Exercise Time and Frequency: It should be done twice a day, at the same time, in the morning and in the evening.~You can do the exercise before going for a walk in the corridor in the morning and before going to sleep in the evening.~Normal Breathing and Focusing on Breathing (3 minutes) Alternate Nose Breathing-Nadi Shodhana (15-20 times/6 minutes) Normal Breathing and Focusing on Breathing (3 minutes) Bhramari Pranayama-Bee Buzzing Sound(8-10 times/5 minutes) Normal Breathing and Focusing on Breathing (3 minutes)"
224000703|NCT04318288|OTHER|Observational|Observational
224000704|NCT02165813|DRUG|Nitazoxanide|Nitazoxanide is a synthetic drug of the nitrothiazolide class. The main metabolite of NTZ is tizoxanide. The active ingredient is Nitazoxanide (2-acetyloxy-N(5-nitro-2-thiazolyl)benzamide), a synthetic agent for oral administration, at a concentration of 100 mg/5 ml.
224000705|NCT02165813|DRUG|placebo|An oral suspension is supplied as a pink coloured powder formulation (sugar) that is reconstituted with 48 mL water prior to use to a final volume of 60 mls.
224123955|NCT06166095|OTHER|Walking attention control|The attention control group will be asked to wear the Fitbit activity tracker to monitor their sleep each night for 10 weeks.
224123956|NCT06166095|OTHER|moderate-dose|Participants will be asked to perform a moderate-dose (MD) (i.e., 150 minutes of MVPA per week) of structured exercise for 10 weeks. Exercise modality and schedule will be participant- selected and may consist of any combination of aerobic and strength training that elevates the heart rate between 64 - 95 percent of estimated heart rate max
223383743|NCT03240029|OTHER|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
223383744|NCT02158715|DEVICE|Site of smartphone on chest compressor' arm|
223383745|NCT04201730|PROCEDURE|Enhanced Recovery After Surgery （ERAS）|Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
223383746|NCT00796757|DRUG|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
223383747|NCT00796757|DRUG|interferon alfa-2a|3 MIU sc t.i.w.
224000706|NCT03281161|BEHAVIORAL|Sun Safe Workplaces Program|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
224000707|NCT03281161|BEHAVIORAL|Attention Control|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
224000708|NCT03766477|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (IQSP) and Johansson|All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
224000709|NCT03766477|DIAGNOSTIC_TEST|Smartphone APP|All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
223383748|NCT03792022|BEHAVIORAL|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
224000710|NCT03766477|DIAGNOSTIC_TEST|Polysomnography|All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
223383749|NCT00006286|DRUG|Fluoxetine|
223383750|NCT00006286|BEHAVIORAL|Psychotherapy|
223383751|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.5 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a placebo group
223383752|NCT05134363|DRUG|Dexmedetomidine Hydrochloride 0.75 mic/kg bolus|comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.
223383753|NCT05134363|DRUG|Placebo|equal volume of normal saline
223383754|NCT01312558|BEHAVIORAL|Prudent diet group|
223383755|NCT01312558|BEHAVIORAL|Mediterranean diet group|
223383756|NCT00380835|DRUG|Amrubicin|
223383757|NCT00062530|BIOLOGICAL|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
223383758|NCT00365703|PROCEDURE|Feeding tube insertion|"1. Orogastric feeding tube~2. Nasogastric feeding tube"
223383759|NCT03272178|DEVICE|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
223383760|NCT03272178|DEVICE|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
223383761|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
223383762|NCT00803439|DRUG|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
223383763|NCT00698711|BIOLOGICAL|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
223383764|NCT01277211|DRUG|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
223383765|NCT01277211|DRUG|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
223383766|NCT02939794|DRUG|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
223383767|NCT02939794|DRUG|Placebo|Saline (normal saline, sodium chloride)
223383768|NCT02022878|PROCEDURE|PCI of CTO|
223383769|NCT02898376|OTHER|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
223383770|NCT02898376|DRUG|Pentoxifylline|400 mg bid during at least 6 months
223383771|NCT02898376|DRUG|Tocopherol acetate|500 mg bid during at least 6 months
223383772|NCT00594373|DRUG|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
223383773|NCT00594373|DRUG|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
223383774|NCT04109144|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin during the 2nd of 3 total paracentesis being monitored
223383775|NCT04109144|BIOLOGICAL|Albumin|Albumin will be used during the 1st and 3rd paracentesis
223383776|NCT04109144|PROCEDURE|Large Volume Paracentesis (LVP)|All participants who have this procedure, meet eligibility criteria and who consent
223545423|NCT04777006|BEHAVIORAL|Problem Management Plus|"PM+ is a cognitive-behavioral intervention that trains recipients to improve their management of practical problems, and uses the term problem management rather than problem solving to emphasize that many problems encountered by individuals living in adverse circumstances may not be solvable. The plus in PM+ underscores additional evidence-based behavioral strategies incorporated into the model, including: stress management strategies, behavioral activation, and social support strengthening. In total, PM+ comprises five sessions held once per week for 1.5. to 2.5 hours per session. The model has shown success in reducing depression symptoms in low-resource settings such as Nepal and Pakistan.4"
224000711|NCT03081910|GENETIC|Autologous CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
224000712|NCT03081910|GENETIC|Allogeneic CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"
224000713|NCT04165031|DRUG|LY3499446|Administered orally
224000714|NCT04165031|DRUG|Abemaciclib|Administered orally
224000715|NCT04165031|DRUG|Cetuximab|Administered IV
224000716|NCT04165031|DRUG|Erlotinib|Administered orally
224000717|NCT04165031|DRUG|Docetaxel|Administered IV
224000718|NCT01367288|DRUG|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
224000719|NCT01367288|DRUG|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
224000720|NCT03691675|DEVICE|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
224000721|NCT00113945|DRUG|Cinacalcet|
224000722|NCT04519905|DRUG|Paclitaxel plus carboplatin|Paclitaxel （45mg/m2) plus carboplatin (AUC=2); five cycles; qw
224000723|NCT04519905|RADIATION|radiotherapy|Different radiotherapy dose in different groups.
224000724|NCT01956253|DRUG|Neratinib|240 mg orally once daily
224000725|NCT05877911|DRUG|Sodium Sulfate|Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study.
224000726|NCT05877911|OTHER|Hydration|On the day of surgery, the day of HIPEC, and 24 hours after HIPEC, daily intravenous rehydration should be performed using natrium chloride, glucose chloride or potassium chloride. The amount of fluid to be replenished should not be less than 3000 milliliters.
224000727|NCT05877911|DRUG|Cisplatin|Infuse cisplatin (75mg/m\^2) at 43℃ through the two drainage tubes placed in the upper abdomen, using the two drainage tubes placed in the lower abdomen as the effluent tubes, with an infusion time of 60-90 minutes and an infusion rate of 500-600 mL/min. The first HIPEC should be performed within 24-48 hours after cytoreductive surgery. The second HIPEC should be performed 24 hours after the completion of the first HIPEC. Intravenous sedatives such as dexmedetomidine or propofol at 2-6 ml/h should be administered during HIPEC treatment with continuous intravenous infusion by a pump，or intramuscular injection of 50 mg of pethidine.
224000728|NCT01332630|DRUG|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
224000729|NCT01332630|DRUG|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
224000730|NCT01332630|DRUG|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
224000731|NCT01332630|DRUG|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
224000732|NCT03140280|DRUG|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
224000733|NCT04853446|DRUG|Dexamethasone 12 mg|Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
224000734|NCT04853446|DRUG|Placebo|Two identically appearing, opaque capsules will be administered: two capsules containing placebo.
224000735|NCT04853446|DRUG|Dexamethasone 24 mg|Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
224000736|NCT01125631|BIOLOGICAL|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
224000737|NCT01125631|DRUG|Placebo|Placebo every 8 weeks (4 doses total)
224000738|NCT02981108|DRUG|HS-10296|HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
224000739|NCT06028243|OTHER|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Information stage|The researchers provided the intervention group participants with online training in healthy living awareness to prevent osteoporosis (400 minutes and two days). They held the training at all participants' convenience outside the class hours. The training consisted of four sections: (1) osteoporosis and diagnosis-treatment methods, (2) current approaches to the prevention of osteoporosis, (3) osteoporosis and nutrition, and (4) osteoporosis and physical exercise. The researchers employed interactive teaching methods and consulted three experts to prepare PowerPoint presentations. At the end of the training, the researchers taught the intervention group participants how to fill out the healthy life diary, such as calculating daily calcium intake. The researchers texted the intervention group participants all training videos on WhatsApp to allow them to watch them again.
224000740|NCT06028243|OTHER|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Motivation stage|The researchers regularly texted (WhatsApp) spot and reminder notifications concerning the prevention of osteoporosis. They asked them to assess the health behaviors they recorded in their diaries every week (daily calcium intake, weekly exercise duration, etc.) and the problems they experienced during the process. The researchers provided individual counseling to the participants by telephone (combating smoking, exercise barriers, food exchange for calcium sources, etc.)
223383777|NCT06449976|BEHAVIORAL|blue light defocus and blue light filtering|Subjects are asked to watch a terminal display device for 50 minutes, featuring texts and videos with different defocusing treatments. Specifically, they will start by watching text for 5 minutes, followed by 40 minutes of video, and then another 5 minutes of text, totaling a visual task duration of 50 minutes. The participants will complete a total of 4 sets of tests in a random order.
223383778|NCT01382888|DRUG|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
223383779|NCT01382888|DRUG|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
223383780|NCT00283478|DRUG|Iscar Quercus|
224000741|NCT06028243|BEHAVIORAL|The Healthy Living Awareness Program for the Prevention of Osteoporosis (HLAPPO-IMB)- Behavior skills stage|The target behavior skills were improved self-efficacy in doing weight-bearing exercises, taking calcium, and engaging in physical activity.
224000742|NCT00949000|DEVICE|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
224000743|NCT00073268|BEHAVIORAL|Exercise|
224295647|NCT06423638|BEHAVIORAL|Virtual Tai Chi Easy|"The TCE intervention will be delivered asynchronously online. Participants can complete the classes at a time and in a location that is convenient for them. The classes will be offered for one hour twice weekly and were developed and recorded by a certified Tai Chi Easy practice leader.~TCE is a simple form of mind-body self-care that focuses on four components:~* Mindful movements that help to stretch, and relax the body while improving balance and coordination~* Breathing practices that reduce stress by inducing a relaxation response while improving energy and circulation and enhancing innate healing responses~* Self-applied massage to stimulate blood flow, relax the body, and improve circulation and energy~* Meditation practices to relax the body, center the mind, and calm the emotions"
223383781|NCT00283478|DRUG|Gemcitabine|
223383782|NCT01777178|OTHER|Low bicarbonate dialysis|
223383783|NCT00879086|DRUG|Eribulin Mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m\^2 as a 2 to 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
223729925|NCT01759667|OTHER|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
224000744|NCT04896424|PROCEDURE|cryoballoon-based pulmonary veins isolation|A cryoballoon is introduced to the LA via a steerable sheath following a single transseptal puncture. The balloon is advanced toward the PV ostium and inflated. PV occlusion is documented by the injection of contrast. Optimal vessel occlusion is assumed when the PV showes complete contrast retention without any backflow to the atrium. The freezing time is chosen between 180 and 240s and left at the operator's discretion, along with a decision if to follow with a bonus-freeze cycle. The application is aborted and the cryoballoon is repositioned in the case of ineffective cooling or when the nadir temperature decreases \< -60°C, to avoid excessive cooling. In cases where a real-time recording of PV potentials is available a short time-to-isolation\<60s resultes in a single 180s freeze cycle. CBA always startes from the left upper PV (LUPV) followed by the left lower PV (LLPV).
224000745|NCT00193232|DRUG|Docetaxel|
224000746|NCT00193232|DRUG|Bortezomib|
223383784|NCT00879086|DRUG|Ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m\^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
223383785|NCT01487525|DEVICE|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
223383786|NCT01487525|OTHER|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
223383787|NCT06359301|DEVICE|DELTA Revision acetabular cup|Total hip arthroplasty
223383788|NCT03390335|OTHER|Pressure|Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water
223383789|NCT03390335|OTHER|Breathing Gas|Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
223383790|NCT02990429|PROCEDURE|Forced Air warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using forced air warmer (bair hugger)~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop bair hugger~* record core temperature before recovery room"
223383791|NCT02990429|PROCEDURE|Intravenous Fluid Warmer|"* record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using ranger warmer~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop ranger warmer~* record core temperature before recovery room"
224000747|NCT05444582|DRUG|Levonorgestrel 52 MG Intrauterine System|"Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - \>7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days."
224000748|NCT00469105|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
224000749|NCT00469105|BEHAVIORAL|Control Group|Receives standard diabetes disease management
224000750|NCT05474339|OTHER|Cardiac rehabilitation|Using Cardiac rehabilitation for patients after coronary artery bypass graft
223383792|NCT01872923|DRUG|Amphinex|Photosensitiser
224000751|NCT02754349|DEVICE|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
224000752|NCT05415670|DIAGNOSTIC_TEST|Whole-genome Methylation Sequencing(GM-seq)|A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
224000753|NCT03189940|BEHAVIORAL|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
224000754|NCT03189940|BEHAVIORAL|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
224000755|NCT04953598|DIAGNOSTIC_TEST|Ultrasonography|Patient undergoes diagnostic ultrasound examination
224000756|NCT04898959|OTHER|Filling out Questionaire|Filling out the Arabic Activity Specific Balance Confidence (A-ABC) and the Arabic Prosthetic Mobility Questionnaire twice at 2-3 week intervals
224000757|NCT04078295|DRUG|E7389-LF|E7389-LF Intravenous infusion.
224000758|NCT04078295|DRUG|Nivolumab|Nivolumab Intravenous infusion.
224000759|NCT01282502|DRUG|Midostaurin|50 mg BID for 8 cycles
224000760|NCT00663702|DRUG|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
224000761|NCT04546503|PROCEDURE|Continuous Regional analgesia|"Aseptic placement of one or two tunnelized CPNB at the level of the nerves or plexus of the traumatized limb (s), Nervestimulation and ultrasound guidance by trained operator.~Continuous infusion of ropivacaine 0.2% at 1mL/10 Kg /H~\+ General anaesthesia"
224000762|NCT04546503|PROCEDURE|Control Group|General anaesthesia without regional analgesia
224000763|NCT04654637|BEHAVIORAL|Nutrition and Exercise Strategies|Multiple Interactive with Nutrition and Exercise Strategies
224000764|NCT06804551|DEVICE|iovera system|Reusable, portable Handpiece, along with single patient use sterile Smart Tips (i.e., cryoprobes) and disposable nitrous oxide (N2O) cartridges. The iovera° system produces the desired effect through initiation of a cooling cycle. Each cooling cycle is initiated by fully inserting the Smart Tip into the selected procedure site and activating the cryogen flow. The Smart Tip needles are made of stainless steel and have a closed tip, fully enclosing the cryogen. The STT21180STIM Smart Tip will be used in this study.
224123957|NCT05487716|BEHAVIORAL|High-intensity interval training (HIIT)|Included subjects who underwent an additional 36 sessions (2-3 sessions per week) of supervised bicycle ergometer (Ergoselect 150P, ergoline GmbH, Germany) training as in the previous protocol5 were classified as the HIIT participant. They exercised alternatively at 3-min interval of 80% VO2peak and 3-min interval of 40% VO2peak for 30 min each session.
223383793|NCT01872923|DRUG|Bleomycin|Anticancer agent
223383794|NCT01872923|DEVICE|Laser|Laser that emits red light at 652 nm.
224000765|NCT06804551|DEVICE|Radiofrequency ablation alone|An electrode at the tip of the needle sends radio waves that lesion the nerve bundles.
224000766|NCT02629653|DEVICE|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
224000767|NCT04940975|BEHAVIORAL|Occupation-based sleep intervention program|A program composed of four occupation-based interactive workshops on sleep, insomnia, lifestyle, and change strategies, plus two individual coaching sessions on lifestyle and sleep hygiene.
224000768|NCT04940975|BEHAVIORAL|Insomnia Education Program at Integrated Mental Health Clinic (IMHC)|A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
224123958|NCT03824925|DRUG|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
224123959|NCT03824925|DRUG|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
224123960|NCT03617367|BIOLOGICAL|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
224123961|NCT01904734|DRUG|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
223383795|NCT02333903|OTHER|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
223383796|NCT06331169|DRUG|Anlotinib|Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
224000769|NCT00905385|BIOLOGICAL|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
224000770|NCT03354585|BEHAVIORAL|mindfulness training|A well-validated brief mindfulness-based mental training regimen \[20 min/session(s)\] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
224138488|NCT03280069|DEVICE|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
223383797|NCT06331169|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
223383798|NCT01385774|PROCEDURE|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
223383799|NCT01385774|OTHER|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
223383800|NCT00492505|DRUG|cisplatin|
224000771|NCT03354585|BEHAVIORAL|non-mindfulness training|A well-validated brief meditation-based mental training regimen \[20 min/session(s)\] will be used to teach patients to independently practice deep breathing. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
224000772|NCT03354585|BEHAVIORAL|book-listening|Study volunteers will listen to The Natural History and Antiquities of Selborne throughout the intervention.
224000773|NCT05784623|OTHER|User experience|User experience is assessed by validated scales
224000774|NCT00472810|DEVICE|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
224000775|NCT00472810|DRUG|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
224000776|NCT05344664|BIOLOGICAL|GPC3-CAR-T cells|The patients will receive one dose of GPC3-CAR-T.The dosage ranges from3×10\^6 to 1×10\^8 CAR-T+/kg.
224000777|NCT06175377|PROCEDURE|Percutaneous coronary intervention|A percutaneous coronary intervention for chronic total occlusion lesion with at least one implanted coronary stent will be performed as part of routine care.
224000778|NCT06175377|DRUG|Short dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
224000779|NCT06175377|OTHER|Long dual Aspirin/Clopidogrel therapy|Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 6 to 12 months.
224000780|NCT06175377|OTHER|Follow-up visit at 1 month|At 1 month following the inclusion a visit or a phone call with the referring cardiologist will be organized.
224000781|NCT06175377|OTHER|Follow-up visit at 6 months|At 6 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
224000782|NCT06175377|OTHER|Follow-up visit at 12 months|At 12 months following the inclusion a visit or a phone call with the referring cardiologist will be organized.
224000783|NCT00992043|DIETARY_SUPPLEMENT|creatine|
224000784|NCT00992043|OTHER|Exercise training|
224000785|NCT01498887|DRUG|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
224000786|NCT01215487|PROCEDURE|Stem Cell and Mutational Assay|Laboratory blood testing
224000787|NCT00064233|DRUG|dasatinib|
224000788|NCT01520805|DRUG|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
224295648|NCT00522171|DEVICE|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
223383801|NCT00492505|DRUG|sorafenib tosylate|
223383802|NCT00492505|DRUG|tamoxifen citrate|
223383803|NCT00492505|PROCEDURE|adjuvant therapy|
223729926|NCT00901446|DEVICE|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
224000789|NCT03079297|DRUG|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
224000790|NCT03079297|OTHER|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
224000791|NCT03252717|BIOLOGICAL|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~* Three 6 ml EDTA samples for proteomic and genomic work package~* One 6 ml dry sample for auto-antibodies analysis in the immunology work package~* Two 4 ml EDTA samples for DNA extraction in the immunology work package~* Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
224295649|NCT03744663|DRUG|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
223383804|NCT05933954|RADIATION|5GFR2 non ionizing EMW exposure|"A 5G source, only exposing a small skin-area, will be placed on each arm of the participants. Only one of the two sources will emit waves (controlled by a computer). One arm will be exposed to 20W/m2 (a dose rate inferior to the recommended maximum for EMW exposure in Switzerland), the other not. The exposure time is 20 minutes.~After the exposure, the participants will wait one hour and a 7.5-mm biopsy by punch (two pieces: one 5-mm punch + half a 5-mm punch) will be performed under local anesthesia on each arm. The wound will be closed by a simple suture. A second set of samples will be taken 24h after the exposure, using the same procedure.~For each participant, 1 full biopsy per arm and per time-point will be used for single-cell-RNA-sequencing analysis. The selected method uses generic probed sequencing and does not generate patient-specific genomic information."
223383805|NCT02930967|BIOLOGICAL|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
223383806|NCT05629897|OTHER|Sessions of cognitive stimulation|40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
223383807|NCT02662660|DRUG|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
223383808|NCT02662660|DRUG|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
223383809|NCT02662660|DRUG|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
223383810|NCT03638544|DIETARY_SUPPLEMENT|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
224000792|NCT00667225|DRUG|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
224000793|NCT00667225|DRUG|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
224000794|NCT05737615|DIAGNOSTIC_TEST|PET Scan|Participants will be imaged up to 4 time points post-injection to allow for biodistribution and dosimetry determination
224000795|NCT05737615|DRUG|hu5B1-TCO|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
224138489|NCT05557669|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.
223383811|NCT06633952|DEVICE|MediTrain|MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
224000796|NCT05737615|DRUG|64Cu-Tz-SarAr|On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
224000797|NCT05737615|DIAGNOSTIC_TEST|Pharmacokinetics|All participants receiving 64Cu-Tz-SarAr will have serial blood samples drawn.
224000798|NCT01502774|DRUG|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
224000799|NCT01502774|DRUG|Placebo|One single intravenous bolus injection of Placebo
224000800|NCT01502774|PROCEDURE|Echocardiography|1 year after AMI
224000801|NCT03551964|DRUG|Cangrelor|"Cangrelor: IV bolus 30 µg/kg (application \< 1 minute) followed immediately by continuous infusion at 4 µg/kg. Tables to calculate bolus dose in ml and infusion (in ml per hour) rate for each body weight group will be prepared in advance and will be included in the study medication kit to accelerate treatment start.~* Cangrelor treatment will be discontinued after circulatory stabilization (but no earlier than 2 hours after infusion initiation) i.e. after systolic Blood Pressure (sBP) is maintained at the level \> 100 mmHg for one hour after the end of IABK and/or vasoactive treatment is discontinued, but no later than 4 hours after PCI,~* 30 minutes before the end of Cangrelor infusion, administration of Ticagrelor 180 mg (crushed tablets) and then dose 90 mg every 12 hours."
224000802|NCT03551964|DRUG|Ticagrelor|Ticagrelor: 180 mg loading dose - crushed tablets, 2 x 90 mg maintenance dose
224000803|NCT04402931|PROCEDURE|Transcatheter Valve-in-Valve Intervention|Transcatheter mitral valve-in-valve implantation with SAPIEN 3
224000804|NCT04402931|PROCEDURE|Redo Mitral valve surgery|Transcatheter Valve-in-Valve Intervention
224000805|NCT06776289|BIOLOGICAL|Platelet rich fibrin|Platelet rich fibrin will be used to fill an osteotomy after endodontic microsurgery is completed.
224138490|NCT05133544|DEVICE|Endocuff with AI|Use of endocuff with computer assisted polyp detection
224138491|NCT05133544|DEVICE|AI alone|Use of computer assisted polyp detection
224138492|NCT01583985|OTHER|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
224138493|NCT01583985|OTHER|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
224138494|NCT05261880|OTHER|Neural mobilization|Neural mobilization and bone are two common physical therapy interventions used for Carpal Tunnel Syndrome. Neural mobilization reinstates the plasticity of the nervous system and restoring the capacity of stretching.
224123962|NCT05848037|DEVICE|cymactive™ catheter device (CCD)|"The cymactive™ catheter (manufactured by Ingenion Medical Ltd) received CE marking on the 28th March 2024, as a Class IIb device (n. ECM24MDR002 rev.0, Single Registration Number (SRN) of the Manufacturer UK-MF-000041065) and will be available in the UK market, subject to local arrangements.~The cymactive™ catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body except for 2 removal strings, and has an integral, magnetically controlled valve that allows the user to control their own urination. The study participant will each be supplied with a magnetic Actuator (a separate Class I device supplied by Ingenion Medical) so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items, i.e. mobile phones, laptops and credit cards. Study participants should also avoid contact with MRI machines."
224000806|NCT05462392|DEVICE|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the Micro Hand S robot group.
224123963|NCT05848037|DEVICE|Foley-type catheter device|Routine standard of care. Usually replaced \~ 3 monthly
223383812|NCT06633952|DEVICE|Worder|Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
224000807|NCT05462392|DEVICE|robot-assisted surgery|urological surgeries, such as partial nephrectomy, radical cystectomy, and radical prostatectomy was performed for patients using the da Vinci robot group
224123964|NCT00418834|DRUG|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
224000808|NCT06547164|DRUG|Midazolam|Midazolam will be administered orally.
224000809|NCT06547164|DRUG|Camizestrant|Camizestrant will be administered orally.
224123965|NCT00418834|DRUG|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
224123966|NCT00418834|DRUG|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
223383813|NCT06633952|DEVICE|noninvasive neurostimulation device|A noninvasive neurostimulation device will be used to deliver theta frequency stimulation or sham stimulation to the frontal part of the brain.
223383814|NCT06633952|DEVICE|wrist worn multi-sensor watches|Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
223383815|NCT01855828|DRUG|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
224123967|NCT03813745|OTHER|early denudation|COCs will be denudated in 30 min after oocyte retrieval
224123968|NCT03813745|OTHER|late denudation|COCs will be denudated 2 hr after oocyte retrieval
224123969|NCT01953328|DRUG|Atorvastatin|Administered orally once a day
224123970|NCT01953328|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224123971|NCT01953328|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
223383816|NCT01855828|DRUG|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
223383817|NCT01855828|DRUG|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
223383818|NCT01855828|DRUG|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
223383819|NCT01855828|DRUG|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
223383820|NCT01855828|DRUG|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
223383821|NCT01866098|DRUG|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
223383822|NCT01866098|DRUG|Placebo|
224000810|NCT06547164|DRUG|Carbamazepine|Carbamazepine will be administered orally.
224000811|NCT01325753|PROCEDURE|cryotherapy|Undergo CT-guided CA
224000812|NCT01325753|PROCEDURE|quality-of-life assessment|Ancillary studies
224000813|NCT00894205|BEHAVIORAL|strengthening exercise program|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks."
224000814|NCT05949814|DIAGNOSTIC_TEST|acceptability of a PrEP program among HIV-negative MSM and TG|STI screening by rapid tests and self-sampling after contact on a geolocated community application or a community physical place of sociability
224000815|NCT04288518|DRUG|SPECT or SPECT-CT with 99mTc-1-thio-D-glucose|One single intravenous injection of 99mTc-1-thio-D-glucose, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
224000816|NCT03750929|OTHER|Combined acute physical exercises (strength and aerobic)|Patients will be submmitted to combined acute physical exercises (strength and aerobic)
224123972|NCT01488942|OTHER|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
224123973|NCT04704895|DIETARY_SUPPLEMENT|Total parenteral nutrition|Total parenteral nutrition, TPN also starts from POD 1 and is delivered through a central venous catheter, with a target energy of 1.5 amino acids/kg/day reaching 30 kcal/kg/day
224123974|NCT04704895|DIETARY_SUPPLEMENT|Enteral nutrition|NJEEN was defined as providing at least 50% of the nutritional requirements through the nasojejunal tube prior to the 5th day after surgery (POD) and having no parenteral nutrition for 72 hours or more.
224123975|NCT04671485|OTHER|Standard care|Patient undergoing radiotherapy for head and neck tumor with a compression mask, and assessed as anxious about wearing this mask will have standard care
224123976|NCT04671485|OTHER|Autohypnosis|"The patient will be called to learn autohypnosis during a specific consultation, with a radiotherapy manipulator trained to learn this technic.~The patient will use this technic during the centering scanner and the first 5 radiotherapy sessions"
224123977|NCT04671485|OTHER|Musicotherapy|"the patient will choose the music he want to listen from a music database (3 specific moods).~The chosen music will be broadcast to the patient via a hi-fi system present in the treatment room during the centering scanner and for the first 5 radiotherapy sessions"
224123978|NCT05732532|DRUG|Bupivacaine|2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
223383823|NCT03649347|BEHAVIORAL|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
223383824|NCT04215276|OTHER|Valsalva maneuver|pressure during Valsalva maneuver was measure using sphygmomanometer
223383825|NCT04215276|OTHER|Control|patient was not given any intervention
223383826|NCT04392427|DRUG|Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :|"Target population: any subject with COVID-19 PCR positive pharyngeal swab and referred to the above-mentioned quarantine without any comorbidities and no sensitivity or contraindication to the three drugs.~* Sample size: will depends on sequential analysis until a significant effect will be detected with a maximum of 100 subjects in each arm.~* Randomization: subjects will be allocated to either arm by block randomization method with sealed opaque envelops. Each block will include 10 subjects (to be allocated randomly as 5 in each group)~* Intervention:~A) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days"
223383827|NCT03629080|BIOLOGICAL|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
224000817|NCT04209569|BEHAVIORAL|Nutrition Impact and Positive Practice Circle (NIPP)|GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
224000818|NCT05846841|BEHAVIORAL|Precision Treatment|Precision treatment will be informed by practice guidelines (standard of care, brief advice, and guideline awareness), plus patient-specific risk feedback and personalized tobacco treatment recommendations using patients' clinical, genetic, and biomarker information.
224000819|NCT05846841|BEHAVIORAL|Usual Care|Usual care will be informed by practice guidelines (standard of care, brief advice, and guideline awareness).
224123979|NCT05732532|DRUG|Lidocaine|0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
224000820|NCT00328289|DEVICE|transcutaneous muscle stimulation, treadmill|
224000821|NCT06037304|OTHER|no intervention|no intervention
224000822|NCT02741453|PROCEDURE|Standard Practice|
224000823|NCT02741453|PROCEDURE|Bilateral IJ Ultrasound Scanning|
224000824|NCT02440425|DRUG|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
224000825|NCT02440425|DRUG|Paclitaxel|Paclitaxel: 80 mg/m\^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
224000826|NCT06046417|DRUG|Pramlintide|Pramlintide delivered in a basal-bolus manner.
224123980|NCT05732532|DRUG|Dexamethasone|0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves
223383828|NCT03629080|BIOLOGICAL|placebo|Saline will be used for placebo.
223383829|NCT01948531|DRUG|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
223383830|NCT01505582|OTHER|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
223383831|NCT01505582|OTHER|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
224000827|NCT06046417|DRUG|Lyumjev|Lyumjev delivered in a basal-bolus manner.
224000828|NCT06046417|DEVICE|Automated Insulin Delivery (AID) system|The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.
224123981|NCT05732532|DRUG|Normal saline|0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves
224123982|NCT05732532|PROCEDURE|Greater/lesser occipital nerve blocks|Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
224123983|NCT05171569|DEVICE|Virtual care with remote automated monitoring (RAM)|Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.
224123984|NCT01526018|BEHAVIORAL|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
224123985|NCT02773069|BEHAVIORAL|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
223383832|NCT05389631|OTHER|no intervention|no intervention
223383833|NCT04639492|DIETARY_SUPPLEMENT|MBS oral solution|Oral BIDAC, twice a day before breakfast and dinner times
223383834|NCT02483546|DEVICE|Laerdal®|simulation- based educational intervention
224123986|NCT02519049|OTHER|No intervention|This is an observational study
224123987|NCT05569304|PROCEDURE|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty
223383835|NCT02483546|BEHAVIORAL|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
223383836|NCT02483546|BEHAVIORAL|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
223383837|NCT00764686|OTHER|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
223383838|NCT00764686|OTHER|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
223383839|NCT04752059|DRUG|Trastuzumab deruxtecan|Trastuzumab-deruxtecan 5.4 mg/kg body weight i.v. on day 1 once every three weeks until progression or death
223383840|NCT06329427|OTHER|Dragon Ambient eXperience (DAX) Copilot|The tool (DAX) listens to the conversation between a clinician and patient/caregiver during their visit, provides transcriptions between different speakers for the clinician to review, edit, and included in the final EHR notes.
223383841|NCT02713555|PROCEDURE|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
223383842|NCT02713555|PROCEDURE|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
223383843|NCT02735785|BEHAVIORAL|Harnessing Online Peer Education (HOPE) Social Media Intervention|
223383844|NCT05959252|DRUG|Unfractionated heparin|Unfractionated Heparin protocol with target anti-Xa of 0.3-0.5 IU/mL
224000829|NCT05494957|DRUG|New regimen(BdqCfzLzd+XY)|The basic regimen consists of bedaquiline, clofazimine, linezolid, and 2-3 drugs such as amikacin and tigecycline are selected according to the drug use history and in vitro culture drug sensitivity results to form the regimen, and the treatment period is usually more than 12 months, and the doses of various drugs are used for the regular drug use.
223383845|NCT05959252|DRUG|Bivalirudin|Bivalirudin protocol with target aPTT 50-70 seconds
223383846|NCT03449446|DRUG|SEL|18 mg tablet administered orally once daily without regard to food
224000830|NCT00953277|OTHER|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
223383847|NCT03449446|DRUG|FIR|20 mg tablet administered orally once daily without regard to food
223383848|NCT03449446|DRUG|CILO|30 mg tablet administered orally once daily without regard to food
223383849|NCT03449446|DRUG|Placebo to match FIR|Tablet administered orally once daily without regard to food
223383850|NCT03449446|DRUG|Placebo to match CILO|Tablet administered orally once daily without regard to food
223383851|NCT03449446|DRUG|Placebo to match SEL|Tablet administered orally once daily without regard to food
224000831|NCT00214019|DRUG|salmeterol|salmeterol diskus 50 mcg twice per day
224000832|NCT00214019|DRUG|Fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
224000833|NCT00214019|DRUG|Placebo|placebo diskus
223383852|NCT02318212|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
224000834|NCT03952052|OTHER|Determination of mutation|Recurrent mutation determination by digital PCR and next generation sequencing
224000835|NCT04990362|DIETARY_SUPPLEMENT|Pomegranate oil, Mediterranean Diet|Dietary Supplement: Pomegranate oil in a glass bottle of 0.15ml per day +Mediterranean dietary protocol Dietary Supplement: Mediterranean dietary protocol
224000836|NCT04990362|DIETARY_SUPPLEMENT|Mediterranean Diet|Dietary Supplement: Mediterranean dietary protocol
224000837|NCT06292949|DIETARY_SUPPLEMENT|Resistant starch|Constipated patients take 1 pack of resistant starch (20g/pack) daily for 14 days
224000838|NCT05809505|DIAGNOSTIC_TEST|360-degree Turn Test|The 360-degree turn test is a measure of dynamic balance. The person tested turns in a complete circle (360 degrees) while the time to complete and/or the number of steps to complete the turn is recorded.
224000839|NCT05809505|OTHER|Expanded Disability Status Scale|The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with multiple sclerosis. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.
224000840|NCT05809505|OTHER|Perceived Exertion|The Borg Rating of Perceived Exertion (RPE) is a way of measuring physical activity intensity level. Perceived exertion is how hard you feel like your body is working. It is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. Although this is a subjective measure, your exertion rating based on a 6 to 20 rating scale, may provide a fairly good estimate of your actual heart rate during physical activity.
224000841|NCT05471531|BIOLOGICAL|Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
223383853|NCT04419012|OTHER|observation|observation
223383854|NCT04493567|DRUG|BMS-986036|Specified dose on specified days
223383855|NCT00001946|PROCEDURE|Magnetic resonance angiography|
223383856|NCT01453179|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
223383857|NCT01453179|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
223383858|NCT06176651|DRUG|Miebo|Subjects will be instructed to use the Miebo eye drop four times per day in both eyes during their participation in clinical trial. The subjects will be required to remove their contact lenses prior to instillation of the Miebo eye drop and must wait 30 minutes before reinserting their contact lenses.
223383859|NCT02448368|DRUG|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
223383860|NCT02448368|DRUG|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
223383861|NCT02448368|DRUG|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
223383862|NCT02448368|DRUG|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
223383863|NCT02448368|DRUG|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
223383864|NCT01958073|DRUG|Conjugated Estrogen Vaginal Cream|
224000842|NCT05471531|BIOLOGICAL|Separate vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine|Quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine were manufactured by Sinovac Biotech Co., Ltd.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28 in subgroup 1,and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28 in subgroup 2.
224000843|NCT01346072|DRUG|tolvaptan|oral, 30 mg, single dose, one time administration
224000844|NCT02562170|DEVICE|TiLoop Bra|
224000845|NCT02562170|DEVICE|Protexa|
224000846|NCT01371292|BEHAVIORAL|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
224000847|NCT01371292|BEHAVIORAL|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
224000848|NCT05985226|DEVICE|intraoral scan|All the experimental groups will be developed with an intraoral scanner, a device that emits light and collects the image projected by that light, to build a 3-dimensional digital model. It is more comfortable than conventional impressions and it is a harmless, non-intrusive, and painless procedure.
224000849|NCT03574662|OTHER|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
224000850|NCT03574662|OTHER|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
224000851|NCT02927353|DRUG|DMB-3113|subcutaneously injected in a single dose of 40 mg.
224000852|NCT02927353|DRUG|Adalimumab|subcutaneously injected in a single dose of 40 mg.
223383865|NCT01958073|DRUG|Estradiol Ring|
224000853|NCT03635099|DRUG|Placebo (fasted)|Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
224000854|NCT03635099|DRUG|BI 25 mg (fasted)|25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
224000855|NCT03635099|DRUG|BI 50 mg (fasted)|50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
224123988|NCT00551720|BEHAVIORAL|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
223383866|NCT01958073|DRUG|Placebo|
223383867|NCT06634329|OTHER|Oro or Nasogastric tube feeding|Parental involvement in their premature baby's feeding
223383868|NCT05332873|DEVICE|Rivet Shunt|The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
223383869|NCT03146429|DIAGNOSTIC_TEST|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
223383870|NCT04201626|PROCEDURE|Adapted ERAS|"Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan."
223383871|NCT04525573|DEVICE|LLLT Combination Red/Gold/IR Therapy|Three LLLT combination treatments per week over the course of two consecutive weeks, and a final follow up on day-15 (total of 7 treatments).
223383872|NCT04190017|OTHER|Cranial MRI|Cranial MRI
223383873|NCT06019884|DEVICE|Caries detection method: Intraoral camera|A specialized intraoral camera (C50) with fluorescence signal and selective chromatic amplification will be used to record intraoral structures in the form of videos and/or photos. The camera has four modes (Daylight, Daylight+, Perio and Caries modes) which can differentiate the color of tissues to provide a reliable diagnosis. The camera will be used in a systemic sequence to video record and capture photos of intraoral conditions in both arches. The intraoral camera will be connected to a laptop screen, and the captured videos and/ or photos will be transferred to an electronic platform.
223383874|NCT06019884|DEVICE|Caries detection method: Smartphone camera|This is a low-cost electronic system consisting of a smartphone positioned in front of the oral cavity to scan the upper and lower jaws from the cheek then the tongue sides. The smartphone camera resolution should be sensitive enough to capture the intraoral structures (at least 1000 pixels). The focus will be adjusted, and the inbuilt flash will be used to obtain clear and sharp images. The photos will be transferred to the electronic platform.
223383875|NCT06019884|OTHER|Referral pathway: User fee removal|The child's parent/ legal guardian will receive financial incentives. These a are designed to cover the costs of treatment and transportation and are tied to attending the preventive dental visit. The child will receive complete dental care.
223383876|NCT06019884|OTHER|Referral pathway: Conventional referral|Children will be referred without providing financial incentives following the current standard of care in dental clinics in the public sector in Egypt. Care is planned by the receiving/ treating dentist, based on available resources, and hospital/ clinic policies. The screening/ sending dentist will inform the family about the oral health condition/s and planned treatment costs for which the child needs care and of available public and private facilities that offer the required care.
223383877|NCT01734161|DRUG|Dexamethasone|8mg IV dexamethesone given
223383878|NCT01734161|DRUG|Placebo|Subjects randomized to placebo receive 50cc normal saline
223383879|NCT01965054|DIETARY_SUPPLEMENT|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
223729927|NCT04945551|BEHAVIORAL|Aerobic exercise training|12 weeks intervention period consisting of aerobic exercise training 3 sessions/week, 45 min/session. All training sessions are supervised. Aerobic training is conducted as ergometer bicycle training at an intensity of 70% of maximal oxygen uptake (x2/wk.) and rowing ergometer exercise at 70% of maximal heart rate (x1/wk.). In week 3, 6 and 9 VO2 max is measured to ensure sufficient adjustment of the workload during the training sessions.
223729928|NCT06175260|DIAGNOSTIC_TEST|oral carnitine challenge test|Urine samples will be collected to quantify trimethylamine N-oxide (TMAO) levels at four time points: before, and 24, 48, and 72 hours after the oral administration of 1500 mg of L-carnitine.
223729929|NCT05976750|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
223729930|NCT05976750|DEVICE|Balafilcon A contact lenses|CE-marked silicone hydrogel contact lenses for daily wear use
224000856|NCT03635099|DRUG|BI 100 mg (fasted)|100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
224000857|NCT03635099|DRUG|BI 200 mg (fasted)|200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
224000858|NCT03635099|DRUG|Placebo (fed)|4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
224000859|NCT03635099|DRUG|BI 400 mg once daily (fed)|4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
224000860|NCT03635099|DRUG|BI 200 mg twice daily, 400 mg total (fed)|2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
224000861|NCT02866513|OTHER|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
224000862|NCT03259477|PROCEDURE|precise segmental renal arterial clamping|Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
224000863|NCT03259477|PROCEDURE|laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
224000864|NCT03197753|DEVICE|Laryngeal mask airway|Laryngeal mask airway
224000865|NCT03197753|DEVICE|Nasotracheal intubation|Nasotracheal intubation
224000866|NCT01068665|DRUG|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
224000867|NCT01068665|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
224000868|NCT05588050|DEVICE|smart phone application and AutoCAD software|to assess the validity and reliability of smart phone application and AutoCAD software in assessing knee joint position sense in patients with patellofemoral pain syndrome
224000869|NCT04261764|DEVICE|"Fastening-mimicking diet combined with a dispelling dampness meal replacement"|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
224000870|NCT04261764|OTHER|Normal diet|Carrying out normal diet under the guidance of a dietitian.
224000871|NCT03432442|DRUG|Ivermectin|Ivermectin once every 24 hours for three administrations
224123989|NCT00551720|BEHAVIORAL|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
224123990|NCT01119274|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
224123991|NCT01119274|OTHER|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
223383880|NCT01450683|DRUG|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-\[4-(4-{\[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl\]methoxy}phenyl)piperazin-1-yl\]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
223383881|NCT05222698|PROCEDURE|Facial reanimation surgery by free muscle trasfer.|Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
223383882|NCT03739047|BEHAVIORAL|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
224000872|NCT01987492|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
223383883|NCT03739047|BEHAVIORAL|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
224000873|NCT01987492|DRUG|Placebo|Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
224000874|NCT01567631|PROCEDURE|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
224000875|NCT01567631|PROCEDURE|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
223383884|NCT00324727|DRUG|melphalan|Given throug isolated hepatic artery infusion
223383885|NCT00324727|DRUG|regional chemotherapy|Patients receive the best alternative therapy
223383886|NCT00324727|DRUG|systemic chemotherapy|Patients receive the best alternative therapy
224000876|NCT01373580|DEVICE|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
224000877|NCT02807272|DRUG|Tipifarnib|Oral tablet
224000878|NCT02884284|OTHER|clinical biological database collection|
224000879|NCT00218153|DRUG|Naltrexone|
223383887|NCT00324727|PROCEDURE|hepatic artery embolization|Patients receive the best alternative therapy
223383888|NCT05475327|OTHER|Conventional Physical Therapy|"Heating pad~A total of 3 sessions per week were given for 15 to 20 mins"
224000880|NCT05963945|DEVICE|Carebot AI CXR|The proposed DLAD (Carebot AI CXR) is a deep learning-based medical device designed to assist radiologists in interpreting chest X-ray images acquired in anteroposterior (AP) or posteroanterior (PA) projection. By employing advanced deep learning algorithms, this solution enables automatic detection of abnormal findings by analyzing visual patterns associated with specific conditions. The targeted abnormalities include atelectasis (ATE), consolidation (CON), pleural effusion (EFF), pulmonary lesion (LES), subcutaneous emphysema (SCE), cardiomegaly (CMG), and pneumothorax (PNO). The DLAD functions as a prediction algorithm complemented by various application peripherals, such as web-based communication tools, DICOM file conversion capabilities, and storage and reporting libraries supporting both DICOM Structured Report and DICOM Presentation State formats.
224000881|NCT00344864|DEVICE|LADARWave|
224000882|NCT05717491|OTHER|Biological analysis, Physical examination and Questionnaires|Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
224000883|NCT05717491|OTHER|Physical examination and Questionnaires|In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.
224000884|NCT05840068|DRUG|MetFORMIN 500 Mg Oral Tablet|MetFORMIN 500 Mg Oral Tablet
224000885|NCT05840068|DRUG|Chemotherapy|The standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI).
224000886|NCT00858689|DRUG|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
224000887|NCT01384799|DRUG|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
224000888|NCT01384799|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
223383889|NCT05475327|OTHER|Relaxation exercises|"The experimental group was given Progressive relaxation exercises along with Deep breathing exercises.~A total of 3 sessions per week were given for 15 to 20 mins."
224000889|NCT01384799|RADIATION|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
224000890|NCT03117491|PROCEDURE|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
224000891|NCT03117491|PROCEDURE|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
224000892|NCT03117491|PROCEDURE|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
223383890|NCT02614274|DIETARY_SUPPLEMENT|Nutraceutical joint health formulation|A Proprietary Blend
223383891|NCT00002231|BIOLOGICAL|APL 400-003|
224000893|NCT04191616|DRUG|Carfilzomib|Carfilzomib will be administered intravenously over 30 ± 5 minutes, on days 1, 8, and 15 (± 2 days) of each 28-day cycle for up to 12 cycles or progression. A dose of 20 mg/m\^2 will be administered on day 1 of cycle 1. All subsequent doses will be 56 mg/m\^2. The frequency of carfilzomib administration will be reduced to day 1 and 15 per cycle starting with cycle 13 and continued until progression or end of study.
224000894|NCT04191616|DRUG|Dexamethasone|Dexamethasone will be administered at least 30 minutes, but no more than 4 hours prior to carfilzomib on days of carfilzomib administration. Dexamethasone will be administered at a dose of 40 mg on days 1, 8, 15, and 22 of each 28-day cycle up to progression during cycles 1 to 12. Dexamethasone will be administered at a dose of 20 mg on days 1 and 15 of each 28-day cycle up to progression during cycles 13 onward. For subjects more than or equal to 75 years of age, the dose will be 20 mg during cycles 1 through 12 and 10 mg from cycles 13 onward.
224000895|NCT04191616|DRUG|Pomalidomide|Pomalidomide dose will be 4 mg per day orally on days 1 to 21 of each cycle until progression.
224000896|NCT00002653|DRUG|carmustine|
224000897|NCT00002653|DRUG|cyclophosphamide|
224000898|NCT00002653|DRUG|doxorubicin hydrochloride|
224000899|NCT00002653|DRUG|melphalan|
224000900|NCT00002653|DRUG|prednisone|
224000901|NCT00002653|RADIATION|radiation therapy|
224000902|NCT01038427|DRUG|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals)|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
224000903|NCT01038427|DRUG|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray|Mometasone nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
224000904|NCT01038427|DRUG|Placebo|Placebo nasal spray administered once daily (4 actuations) for 14 days.
224000905|NCT04878315|DRUG|Capoten|Capoten will be administered per the treatment sequence
224000906|NCT04878315|DRUG|Captopril|Captopril will be administered per the treatment sequence
224000907|NCT00101946|DRUG|683699|
223383892|NCT06174467|BEHAVIORAL|SEELearning Training|"This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions."
223383893|NCT06174467|BEHAVIORAL|Waiting list group of the intervention|The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
223383894|NCT05176444|BEHAVIORAL|Music therapy|Individual music therapy sessions across 12-weeks with people with cognitive impairment/dementia. Music therapy training for care home staff at four time points across 12-weeks.
223383895|NCT02945969|BEHAVIORAL|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
223383896|NCT03883035|OTHER|automatic quality-control system|Automatic quality-control system could real-time measuring endoscopic inspection completeness, detecting gastric neoplasms and evaluating gastric mucosal visibility.
223383897|NCT02108912|OTHER|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
224000908|NCT05802823|OTHER|Standardized Simülation Patient|There are preliminary information, information, application and analysis sessions in the research. A rehearsal will be made 10 days before the application and arrangements will be made if necessary. The students will be given the resources 1 week before the application and the scenario 5 minutes before the application and informed consent will be obtained. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
224000909|NCT04243746|BEHAVIORAL|Time Restricted Feeding|Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
224000910|NCT04243746|BEHAVIORAL|Standard Care|Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
224000911|NCT01063998|OTHER|Urine Marker|Urinary KIM-1 measurements
224000912|NCT01364337|OTHER|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
224000913|NCT01364337|OTHER|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
224000914|NCT04230122|DRUG|LY3478006 - IV|Administered IV
223383898|NCT02108912|OTHER|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
223383899|NCT00451646|DRUG|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
223383900|NCT06425965|OTHER|Advanced life support training with high reality simulator|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with a high reality simulator in line with the information (15 min), scenario implementation (15 min) and debriefing sessions (30 min), respectively.
223383901|NCT06425965|OTHER|Advanced life support training with web-based simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out by web-based simulation method. Students participate in the web-based simulation application developed by the researcher.
223383902|NCT06425965|OTHER|Advanced life support training with hybrid simulation|The training consists of theoretical and practical training and lasts 3 hours a day, 5 days, for a total of 15 hours. The first 3 days of the training are theoretical, 1 day is laboratory practice and 1 day is evaluation. Theoretical courses start with introductions and sharing the content of the training and aim to provide the basic professional knowledge and skills required for advanced life support practice (diagnosis of cardiac arrest, ensuring airway patency, monitoring, cardiac rhythm diagnosis, drugs used during advanced life support and advanced life support algorithm). The laboratory application of the training is carried out with the hybrid simulation method in which high reality simulator and web-based simulation method are applied together. Students first apply the web-based simulation developed by the researcher. Then they perform the practice on the high reality simulator.
224000915|NCT04230122|DRUG|LY3478006 - SC|Administered SC
224000916|NCT04230122|DRUG|Placebo - IV|Administered IV
224000917|NCT04230122|DRUG|Placebo - SC|Administered SC
224000918|NCT05822739|DRUG|BBM-P002|Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
224000919|NCT00924742|DRUG|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
224000920|NCT01952067|PROCEDURE|line-to-line reaming and cementing technique|
224000921|NCT01952067|PROCEDURE|standard over-reaming with 2 broach sizes|
224000922|NCT04223986|DIAGNOSTIC_TEST|Ultrasound|decide between the need for intervention or not (Percutaneous coronary intervention)
224000923|NCT04223986|DIAGNOSTIC_TEST|Troponin- T quick test|Quick test for Troponin T blood assessment
224000924|NCT04654559|OTHER|Unobtrusive data collection using wearable non-invasive sensors|Two wearable non-invasive sensors will be mounted to the patients skin (lateral rib cage and foot). These wearable non-invasive sensors are measuring unobtrusively skin based parameters (no diagnosis will be made), which will be used for fever detection algorithm development..
224000925|NCT04235517|OTHER|Temporary hemi-epiphysiodesis or epiphysiodesis|Tension band plate (eight-plate, pedi plate), staple or locking plate
224000926|NCT00604708|BIOLOGICAL|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
224000927|NCT00604708|BIOLOGICAL|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
224000928|NCT00237536|DRUG|Lonidamine|
223729931|NCT02632474|DRUG|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
224000929|NCT00655525|DIETARY_SUPPLEMENT|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
224000930|NCT00655525|DIETARY_SUPPLEMENT|placebo|placebo administered orally every day for 3 months
224000931|NCT02690753|PROCEDURE|A protocol tailored to individual risk factors|
224000932|NCT02690753|DEVICE|The Prevalon® Turn and Position System 2.0|
224000933|NCT02690753|DEVICE|Comfort Shield® barrier cream cloths|
224000934|NCT05029713|DIAGNOSTIC_TEST|Evaluation of appendicular skeletal muscle mass (ASMM) by bioelectrical impedance analysis (BIA)|The use of handgrip dynamometer and BIA will be used to screen all liver transplanted patients for sarcopenic obesity, using a muscle strength cut-off \<27 Kg in men and \<16 Kg in women and a standardized muscle mass cut-off \<0.789 ASMM/BMI for men and 0.512 ASMM/BMI for women.
224000935|NCT03731897|OTHER|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
224123992|NCT04649203|DRUG|Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)|The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
224000936|NCT03731897|OTHER|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
224000937|NCT02180243|BEHAVIORAL|Mindfulness meditation/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
224000938|NCT02180243|OTHER|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
224000939|NCT02202785|DRUG|MLN0264|MLN0264 IV infusion
224123993|NCT04649203|DRUG|Placebo|The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.
224000940|NCT06086899|PROCEDURE|Cervical motion style acupuncture treatment(Trapezius, Rhomboid, Scalene)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
223383903|NCT01794559|DEVICE|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
223383904|NCT02523300|PROCEDURE|TEVAR|The patients will be undertaken TEVAR
224000941|NCT06086899|PROCEDURE|Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
224000942|NCT01137578|PROCEDURE|Ultrasound|Ultrasounds to be performed on children with central venous catheters
224000943|NCT01137578|DRUG|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
223383905|NCT02523300|DRUG|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
224000944|NCT01137578|PROCEDURE|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
224000945|NCT01409629|BEHAVIORAL|Computer game|Participants will play a computer game
224295650|NCT03744663|DRUG|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
224295651|NCT05325073|DRUG|Erythropoietin|Erythropoietin
224295652|NCT01793818|BIOLOGICAL|Tat Oyi|Three injections in the arm
224295653|NCT00854802|DRUG|Debio 025|Debio 025 supplied in soft gel capsules
224295654|NCT00854802|DRUG|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
224295655|NCT00854802|DRUG|Ribavirin|Ribavirin supplied in tablets
224295656|NCT00854802|DRUG|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
224295657|NCT02237742|DRUG|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
223383906|NCT02523300|DRUG|saline|The other 120 patients will be given saline as control group
223383907|NCT01739127|DRUG|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
223383908|NCT01739127|DRUG|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
223383909|NCT01182376|DRUG|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
223383910|NCT01182376|DRUG|Placebo|Placebo will be administered by the patient's team according to established guidelines.
223383911|NCT03458182|OTHER|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
223383912|NCT02128672|PROCEDURE|Spinal Cord Stimulator Lead Placement|
223383913|NCT04619212|DEVICE|breast pumping as per SoC but on new software for the pump|breast pumping as per SoC but on new software for the pump
223383914|NCT06632366|OTHER|Sexual Dysfunction in the Postpartum Period|The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
223383915|NCT00442455|DRUG|Erlotinib chlorhydrate|150 mg/day for 7 weeks
223383916|NCT00442455|DRUG|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
224000946|NCT00002687|BIOLOGICAL|aldesleukin|
224000947|NCT02395731|BEHAVIORAL|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
224000948|NCT00691587|BIOLOGICAL|KB001|Single low-dose, administered intravenously
224123994|NCT05297422|PROCEDURE|Forearm surgey|Microsurgery Clinic , KAT Hospital Athens
223383917|NCT00442455|PROCEDURE|Radiation therapy|63 Gy, five days a week, for 7 weeks
223383918|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)|mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.
224123995|NCT05297422|DRUG|Ropivacaine|Ropivacaine
224123996|NCT05297422|DRUG|Ketamine|Ketamine
224123997|NCT05431517|PROCEDURE|Analysis of ERCP records|Data will be extracted from ERCP records of stenting, mainly including: 1) Age at the time of ERCP; 2) Gender; 3) Indication; 4) Papilla selection (major or minor); 5) Whether endoscopic sphincterotomy (EST) was performed; 6) Presence of nipple diverticulum; 7) Morphology of the pancreatic duct; 8) Status of pancreatic duct stones; 9) Number, shape, material, diameter and length of the stent; and 10) Operation of the bile duct. Additional data were extracted from the pertinent ERCP records of stent migration: 1) Shape, material, diameter and length of the displaced stent; 2) Type of migration; and 3) Removal tools.
224295658|NCT06004778|BEHAVIORAL|Motivational Support Program|In studies conducted on adolescents with poor sleep quality, no study using motivational interviewing technique was found.
224295659|NCT06004778|BEHAVIORAL|Educational support|educational support
224295660|NCT06616909|BEHAVIORAL|ACP GAME|,Using board games as an activity intervention, a tool for discussion between elderly people with lung cancer and potential agents
223383919|NCT04977479|OTHER|Placebo|Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.
223383920|NCT04977479|BIOLOGICAL|Pfizer-BioNTech COVID-19 Vaccine, Bivalent|mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
223383921|NCT00001797|DRUG|Recombinant human interleukin-10|
223383922|NCT03633097|OTHER|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
223383923|NCT03633097|DRUG|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
223383924|NCT02699073|DRUG|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
223383925|NCT02018965|DRUG|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
224000949|NCT00691587|BIOLOGICAL|KB001|Single high-dose, administered intravenously
224000950|NCT00691587|BIOLOGICAL|Placebo|Placebo single-dose, administered intravenously
224000951|NCT00158314|BEHAVIORAL|Referral to Gamblers Anonymous|
224295661|NCT06616909|BEHAVIORAL|acp manual|acp manual
224295662|NCT05631834|PROCEDURE|Thoracic epidurale|Epidurale Perioperative infusion of Ropivacaine
224295663|NCT05631834|PROCEDURE|Erector spinae block|erector spinae interfascia Perioperative infusion of Ropivacaine
224295664|NCT04333238|OTHER|New progress note template|Residents assigned to document with new progress note template
224295665|NCT04333238|OTHER|Standard progress note template|Residents assigned to document with standard progress note template
224295666|NCT00003521|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223383926|NCT02018965|DRUG|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
223383927|NCT03007992|DRUG|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
223383928|NCT06623474|DIAGNOSTIC_TEST|diagnosed by traditional diagnostic markers（such as AFP or CT etc.）|A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
223383929|NCT03308812|BEHAVIORAL|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
224000952|NCT00158314|BEHAVIORAL|Cognitive behavioral therapy|
224000953|NCT00158314|BEHAVIORAL|Cognitive behavioral self-help manual|
224000954|NCT00880204|BEHAVIORAL|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
224000955|NCT04145700|DRUG|Ramucirumab|Ramucirumab given IV
224000956|NCT04145700|DRUG|Gemcitabine|Gemcitabine given IV
224000957|NCT04145700|DRUG|Docetaxel|Docetaxel given IV
224000958|NCT02798042|OTHER|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
224000959|NCT00658905|DRUG|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
224000960|NCT00658905|DRUG|Placebo|One week treatment
224000961|NCT02293577|DEVICE|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
224000962|NCT02152943|DRUG|Everolimus|Given PO
224000963|NCT02152943|OTHER|Laboratory Biomarker Analysis|Correlative studies
224000964|NCT02152943|DRUG|Letrozole|Given PO
224000965|NCT02152943|BIOLOGICAL|Trastuzumab|Given IV
224000966|NCT02473731|BIOLOGICAL|KTN3379|
224000967|NCT03398902|BEHAVIORAL|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
224000968|NCT03398902|OTHER|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
224000969|NCT00818779|DRUG|Aliskiren|150 - 300 mg once daily for 6 weeks
224000970|NCT00818779|DRUG|Amlodipine|5-10 mg once daily for 6 weeks
224000971|NCT03162198|OTHER|Cirrhosis with HCC|Cirrhosis with Hepatocellular Carcinoma
224000972|NCT03162198|OTHER|Cirrhosis without HCC|Cirrhosis without Hepatocellular Carcinoma
224000973|NCT03112824|DIETARY_SUPPLEMENT|Ashwagandha Root Extract Capsule|Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
224000974|NCT03112824|OTHER|Placebo Capsule|Participants will take one placebo capsule orally twice a day for 12 weeks.
224000975|NCT00107939|DRUG|Licarbazepine|
224000976|NCT03746587|DRUG|Arimoclomol|Arimoclomol in 3 different dosages
224000977|NCT03746587|DRUG|Placebo oral capsule|Matching placebo capsule
223383930|NCT03308812|BEHAVIORAL|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
224000978|NCT03552952|OTHER|No intervention|No intervention
224000979|NCT05009160|DEVICE|dreaMS App R2.1|The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
223383931|NCT04843696|DEVICE|cuirass ventilator (cuirass diameter 21 cm or 34 cm, Dima Italia Srl.,Bologna, Italy)|the hospital-based NPV once per week in the maintenance program at least three times per month. The ventilator is set to the control model with a frequency of 12\~15 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot), and delivery of negative pressures ranging from -20 to -35 cm H2O.
223383932|NCT04843696|BEHAVIORAL|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise)|breathing training, and an educational program (relaxation techniques and a home pacing walking exercise) Breathing training consisted of breathing techniques (pursued-lipped, controlled, and diaphragmatic breathing)
223383933|NCT03062384|DIETARY_SUPPLEMENT|AT-001|
223383934|NCT03062384|DIETARY_SUPPLEMENT|Placebo|
223383935|NCT04975854|BEHAVIORAL|Exposure Therapy (Virtual Reality)|Virtual reality scenarios consists of increasingly intense exposures to phobic stimuli (e.g., looking over railings from various floor levels) with the support of the therapist. The goal of VRET is sufficient reduction in anxiety to allow the patients to expose themselves to heights in everyday situations.
223383936|NCT04975854|OTHER|Information Session|This includes 20-minute information session about general principles of exposure therapy before the start of the study.
223383937|NCT06281197|PROCEDURE|Conventional|Le Fort I osteotomy performed with conventional Le Fort
223383938|NCT06281197|PROCEDURE|Subspinal|Osteotomy was performed in the subspinal Le Fort I group that is described by Mommaerts
223383939|NCT02344082|OTHER|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
223383940|NCT02537691|DRUG|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
223383941|NCT02537691|DRUG|LABA|LABA will be administered as per investigator discretion.
223383942|NCT02537691|DRUG|LTRA|LTRA will be administered as per investigator discretion.
224000980|NCT04904198|BEHAVIORAL|Care Management Intervention for non-cardiac chest pain|Multicomponent eight-week care management intervention involving a consultation visit with a cardiologist and nurse. Recommendations from the consultation visit are conveyed to the primary care physician. Following the visit, the participant has eight weekly phone calls with a nurse to provide support, introduce therapeutic principals, and assess symptoms. The study nurse is supervised by a psychiatrist.
223383943|NCT02537691|DRUG|LAMA|LAMA will be administered as per investigator discretion.
223383944|NCT02537691|DRUG|Theophylline|Theophylline will be administered as per investigator discretion.
224000981|NCT04775706|DRUG|HM15912 Active|Randomized, double-blind, placebo-controlled
224000982|NCT04775706|DRUG|Placebo|Randomized, double-blind, placebo-controlled
224000983|NCT06306131|DRUG|Levonorgestrel 0.15 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
224000984|NCT06306131|DRUG|Meloxicam 15 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
223383945|NCT02537691|DRUG|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
223383946|NCT06551662|DEVICE|Paclitaxel drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
223383947|NCT06551662|DEVICE|Sirolimus drug-coated balloons|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
223383948|NCT06551662|DEVICE|New generation drug-eluting stent|Patients will be randomized to Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons or standard therapy with new generation drug-eluting stent
223383949|NCT00316927|DRUG|acetylsalicylic acid|
223383950|NCT00316927|DRUG|dexamethasone|
223383951|NCT00316927|DRUG|diethylstilbestrol|
223383952|NCT00453050|DRUG|imiquimod|
223383953|NCT00453050|DRUG|indocyanine green solution|
223383954|NCT00453050|OTHER|flow cytometry|
223383955|NCT00453050|OTHER|immunologic technique|
223383956|NCT00453050|OTHER|laboratory biomarker analysis|
223383957|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
224000985|NCT06306131|OTHER|calcium carbonate 750 milligram|The study design is an open label randomized single blind clinical trial in which each participant will receive placebo two tablets 48 hours apart in their first menstrual cycle and then levonorgestrel plus meloxicam 48 hours apart in their subsequent menstrual cycle. We will compare the interval from taking the first dose of medication to the development of a functioning corpus luteum based on the shift in the ratio of urinary estrone-3-glucuronide(EC) / pregnanediol-3-glucuronide (PDG).
223383958|NCT01561846|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
223383959|NCT05293821|DIAGNOSTIC_TEST|TriQuik IVD|TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
223383960|NCT00836784|OTHER|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
224000986|NCT06234514|DRUG|Jueling Mingmu decoction|Jueling Mingmu decoction comprises stone cassia, grass cassia, Leonurus, chrysanthemum, red peony, Schizonepeta, poria, plantago, salvia miltiorrhiza, rice bud, licorice. It is designed to clear liver heat, promote diuresis, activate blood circulation, strengthen the stomach, and harmonize spleen functions.
224000987|NCT06234514|DRUG|intravitreal injections of 0.5mg ranibizumab|Patients received monthly intravitreal injections of 0.5mg ranibizumab for the initial three months, followed by additional injections in the subsequent nine months for those who met eligibility criteria.
223383961|NCT00836784|OTHER|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
223383962|NCT04671121|PROCEDURE|Standart pressure pneumoperitoneum|CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
223383963|NCT04671121|PROCEDURE|Low pressure pneumoperitoneum|CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
223383964|NCT04639011|DRUG|Duloxetine|Three doses of 60 mg of oral duloxetine will be given to participants (right before operation, postop day 1, postop day 2)
223383965|NCT04639011|OTHER|Placebo|Three doses of placebo will be given to participants (right before operation, postop day 1, postop day 2).
223383966|NCT04639011|OTHER|Standard of care (SOC) for tibial plateau surgery|Postoperative IV administration of opioids via a patient controlled analgesia (PCA) system which utilizes a hydromorphone pump.
223383967|NCT00931645|PROCEDURE|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
223383968|NCT00931645|PROCEDURE|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
223383969|NCT00931645|PROCEDURE|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) \& cyclophosphamide (300 mg/sqm)
223383970|NCT04884373|DIAGNOSTIC_TEST|Gastric ultrasound|An ultrasound exam will be performed before induction of anaesthesia. GUS results from selected patients will be systematically acquired and assessed following an algorithm (Appendix Ia). The ultrasound results will be collected on a standardized form (Appendix IIa). The technique is performed in the supine and right lateral decubitus position (Appendix Ib) and only by anesthesiologists with sufficient experience with ultrasound and the technique. The patient will be asked to indicate his/her satiety on a predetermined ten-point scale.
223383971|NCT05796076|DEVICE|Virtual reality|Participants in the intervention group will be received VR during the suturing procedure. Virtual reality is a three dimensions of width, height and depth that is generated digitally in a computer-generated environment that allows a user to interact with it 16.
223383972|NCT04650594|PROCEDURE|MUTARS® modular reconstruction prostheses|Patients with MUTARS® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year
224000988|NCT04978493|DRUG|BI 706321|One dose of 8 mg as tablets orally once per day in the morning
224000989|NCT04978493|DRUG|Ustekinumab|A single intravenous infusion of 260 mg (body weight ≤55 kg), 390 mg (body weight 55-85 kg), or 520 mg (body weight \>85 kg) was administered on Day 0, followed by subcutaneous injection of 90 mg every 8 weeks.
224000990|NCT04978493|DRUG|Placebo|One dose of placebo matching BI 706321 as tablets orally once per day in the morning
224000991|NCT03741920|DEVICE|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~* A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~* An application to configure the data logger and transfer the acquired data at the end of a recording.~* A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
224000992|NCT01229878|DIETARY_SUPPLEMENT|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
224000993|NCT03575195|DRUG|Rifaximin|Rifaximin 550mg orally
224000994|NCT03575195|OTHER|Placebo|Placebo control
224000995|NCT01808677|OTHER|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
224000996|NCT06492772|OTHER|experimental group|The experimental group will be asked to use a mobile smoking cessation application based on the transtheoretical model. Individuals will be required to use the mobile application for 6 months. Measurements will be made at 1, 3, and 6 months.
224000997|NCT01342432|OTHER|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
224000998|NCT01342432|OTHER|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
224000999|NCT01853189|OTHER|OMT + Usual Care|patients from this group received 6 sessions of OMT
224123998|NCT06553508|PROCEDURE|Trochanteric bursa repaired|As a routine procedure in our centre, the trochanteric bursa is left unrepaired after a hip arthroplasty.
224295667|NCT02709252|DEVICE|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
224295668|NCT00131378|DRUG|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
224295669|NCT00131378|DRUG|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
224295670|NCT04896411|OTHER|Alternative phrasing for no code|This intervention will use the alternative phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
224295671|NCT04896411|OTHER|Standard of care for no code|This intervention will use the standard of care phrase noted in the literature when discussing code status. This will be the only intervention, and all other aspects of trial participation will be collection of data
224295672|NCT03250949|PROCEDURE|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
223383973|NCT02285374|DRUG|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
223383974|NCT06899126|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
223383975|NCT06899126|DRUG|pembrolizumab|pembrolizumab will be administered at a dose of 200 mg IV Q3W
223383976|NCT06899126|DRUG|Pemetrexed|Pemetrexed will be administered at a dose of 500 mg/m2 IV Q3W
223383977|NCT06899126|DRUG|Chemotherapy|"One of the following two will be administered in Arm B:~Cisplatin at a dose of 75 mg/m2 IV or carboplatin AUC at a dose of 5 mg/mL/min IV"
223383978|NCT06033833|DRUG|Amlitelimab|Injection Solution: by subcutaneous injection (SCI)
223383979|NCT06033833|DRUG|Placebo|Injection Solution: by subcutaneous injection (SCI)
224001000|NCT01853189|OTHER|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
224001001|NCT03326362|OTHER|Resistance training|Comparison between high and low intensities trainings described in arms
224001002|NCT04728139|DIAGNOSTIC_TEST|glypican 3|Assessment of glypican 3 presence in colorectal cancer patients using ELISA
224001003|NCT06120868|OTHER|Surefil one®|For Surefil one® restorations, the capsule will be activated by pressing it against a stable surface, then mixed in a capsule mixer for 10 s. The capsule tip will be inserted into the proximal box, and the material is extruded as the tip is gradually moved in a coronal direction, ensuring that the material adapts to the cavity bottom and walls.
224001004|NCT06120868|OTHER|Filtek One|Scotchbond™ Universal (SBU) will be used as an adhesive system in self-etch mode for FiltekTM One restoration. SBU will be applied actively for 20 seconds with a disposable brush tip, air-dried gently for 5 seconds to create a consistent bond thickness, then light-cured for 10 seconds. The FiltekTM One will be packed in increments up to 4 mm thick. A second layer of FiltekTM One will be applied on top of the first 4-mm layer if 4 mm is not adequate to properly restore the tooth. Each increment will be light cured for 20 seconds.
224001005|NCT01327846|DRUG|Canakinumab|
224001006|NCT01327846|DRUG|Placebo|
224001007|NCT01327846|DRUG|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
224001008|NCT04629456|OTHER|neuromuscular electric stimulation|A total of eight electrodes were placed on the quadriceps femoris muscles (four on each leg): two on the vastus medialis, one on the rectus femoris muscle, and one on the vastus lateralis muscle. The stimulation protocol of the NMES consisted of a symmetrical biphasic square pulse at 75 Hz, a duty cycle of 6 seconds (sec.) on and 29 sec. off, a pulse time of 410 sec. during a session lasting 20 min. The intensity was increased to maximum individual toleration. The muscle contractions were visible and palpable.
224001009|NCT04629456|OTHER|Exercises|The chair-seated exercises were used in the early stages of the program because the participants were frail adults. Repetitions of toe raises, heel raises, knee lifts, knee extensions, and others were performed while seated on a chair. Hip flexions, lateral leg raises, and repetitions of other exercises were performed standing upright behind the chair and holding the back of the chair for stability. To strengthen lower extremities, a fixed weight was placed on the ankle while participants performed strengthening exercises. Weights of 0.50, 0.75, 1.00, and 1.50 kg were used in accordance with each participant's strength level as the resistance progressively increased. The exercises performed using these ankle weights included seated knee flexion and extension and standing knee flexion and extensions. Exercises using a resistance band: Resistance bands were used to strengthen lower body. Lower body exercises included leg extension and hip flexion
224001010|NCT04135612|OTHER|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
223383980|NCT07076277|DEVICE|Clareon PanOptix Pro and Clareon Vivity Intraocular Lens|Bilateral cataract surgery with contralateral implantation: Alcon Clareon PanOptix Pro (or PanOptix Pro Toric) intraocular lens in one eye and Alcon Clareon Vivity (or Vivity Toric) intraocular lens i
223383981|NCT07076277|DEVICE|Clareon PanOptix Pro Intraocular Lenses|Bilateral cataract surgery with implantation of Alcon Clareon PanOptix Pro (or PanOptix Pro Toric) intraocular lenses in both eyes. All surgeries target emmetropia with residual astigmatism ≤0.50 diopters using toric IOLs or arcuate incisions as needed.
223383982|NCT07082439|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complete study intervention after 2 years of pembrolizumab and odetiglucan without disease progression and subsequently experience disease progression while off of treatment are eligible for up to 1 year of additional pembrolizumab and odetiglucan (second course).
223383983|NCT07082439|DRUG|Odetiglucan|Odetiglucan 4 mg/kg intravenous administration on day 1 of each 3-week cycle until disease progression, unacceptable toxicity or participant withdrawal. Participants who complete study intervention after 2 years of pembrolizumab and odetiglucan without disease progression and subsequently experience disease progression while off of treatment are eligible for up to 1 year of additional pembrolizumab and odetiglucan (second course).
223383984|NCT07110922|DIAGNOSTIC_TEST|Angiography only|Superior vena cava (SVC) angiogram will be used to anatomically identify the BB region
223383985|NCT07110922|DIAGNOSTIC_TEST|Angiography and ECG|Superior vena cava (SVC) angiogram will be used to anatomically identify the BB region and correlate with electrogram guidance for BBP
223383986|NCT01061801|BEHAVIORAL|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
223383987|NCT04904133|OTHER|Low/No Calorie Sweeteners|LNCS powdered and then dissolved in water.
223383988|NCT04904133|OTHER|Placebo Group|Water
223383989|NCT07095283|DIAGNOSTIC_TEST|Short International Consultation on Incontinence Questionnaire (ICIQ-SF)|This is a self-administered questionnaire with four questions and a total score ranging from 0 \[best\] to 21 \[worst\] that identifies people with urinary incontinence and its impact on quality of life.
223383990|NCT07095283|DIAGNOSTIC_TEST|King's Health Questionnaire (KHQ)|The KHQ is a self-administered instrument specifically designed to assess quality of life in women with UI. It consists of 21 items distributed across 9 dimensions: perception of overall health (1 item), impact of UI (1 item), limitations in daily activities (2 items), physical limitations (2 items), social limitations (2 items), personal relationships (3 items), emotions (3 items), sleep/energy (2 items), and severity of UI (5 items). The score range for each dimension is from 0 (lowest impact of UI and therefore best quality of life) to 100 (highest impact, worst quality of life). This questionnaire provides an overall value for the quality of life of the patient with UI (Overall Score-OS) and another specific value for each dimension on a scale with the following range: 0: Best possible quality of life - 100: Worst possible quality of life.
223383991|NCT07095283|DIAGNOSTIC_TEST|Ultrasound evaluation|A two-dimensional (2D) ultrasound system with B-mode capability and cine-loop function, a 3.5 to 6 MHz curved convex probe transducer, was used for the perineal image. The examination will be performed in the dorsal lithotomy position, with the hips flexed and slightly abducted and the heels placed close to the buttocks, or in a standing position if necessary.
224001011|NCT05173337|DRUG|Nefopam|"Nefopam 20 mg is mixed to 100 mL of normal saline, and is infused intravenously over 15 minutes.~20 mg of nefopam is administered intravenously for two times, after induction and at the end of surgery."
224001012|NCT01523600|BEHAVIORAL|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
223383992|NCT02506127|DEVICE|Neuronetics XPLOR system|Transcranial magnetic stimulation system
224001013|NCT01523600|BEHAVIORAL|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
224001014|NCT06432673|DRUG|ATR-258 Oral solution|Oral solution
224001015|NCT06432673|DRUG|ATR-258 Oral capsule|Oral capsule
224123999|NCT06553508|PROCEDURE|Trochanteric bursa unrepaired|For the experimental arm, the trochanteric bursa is repaired after a hip arthroplasty. The conventional joint closure is performed after reduction and then the bursa is retrieved and repaired.
224124000|NCT02141646|BEHAVIORAL|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
224124001|NCT02141646|BEHAVIORAL|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
224295673|NCT02291770|BIOLOGICAL|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
224295674|NCT04340349|DRUG|Hydroxychloroquine Sulfate|A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.
224295675|NCT04340349|DRUG|Bromhexine 8 MG|TMPRSS2 blocker
224295676|NCT03122067|DRUG|oxytocin treatment|intranasal administration of oxytocin
224295677|NCT03122067|DRUG|placebo treatment|intranasal administration of placebo
224295678|NCT03247517|DRUG|Placebo|Placebo was administered once daily
224295679|NCT03247517|DRUG|200mg SPN-812|200mg SPN-812 was administered once daily and compared to placebo
224295680|NCT03247517|DRUG|400mg SPN-812|400mg SPN-812 was administered once daily and compared to placebo
223383993|NCT01950390|BIOLOGICAL|Bevacizumab|Given IV
223383994|NCT01950390|BIOLOGICAL|Ipilimumab|Given IV
223383995|NCT06509503|DRUG|Combined oral contraceptive|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
223729932|NCT01656785|DRUG|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
223729933|NCT00271050|OTHER|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
223729934|NCT01057654|DRUG|Pravastatin|Pravastatin 40 mg
224001016|NCT05167422|BEHAVIORAL|Trusted Messenger|A nested waitlist design in which patients and staff are nested within two inpatient psychiatric units. New Hampshire Hospital staff will be trained to deliver the trusted messenger intervention up to 24 patients on the first unit while the second unit receives care as usual, during which time in-house vaccinations among patients on both units will be tracked in a registry. After a 3-week study period, up to 24 patients on the second unit will receive the trusted messenger intervention and followed for a period of 3 weeks. The trusted messenger intervention will consist of staff who are trained to engage patients informally and assist building social norms for vaccine uptake supported by weekly and as-needed check-ins with a content expert who can answer specific vaccine related questions over a 3 week period.
224001017|NCT01509001|DRUG|Metformin|750 to 2500 mg/day, two times a day during 4 months
224001018|NCT01509001|DRUG|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
224001019|NCT06554340|BEHAVIORAL|Home-based aerobic training|The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
223383996|NCT06509503|DRUG|Vaginal Ring|The arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
223383997|NCT01682811|DRUG|Part 1 Levulan injection|Control or treatment lesions will be injected with Levulan vehicle only or active drug and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
223383998|NCT01682811|DRUG|Part 1 Levulan surface application|Control or treatment lesions will be painted with Levulan vehicle only or active drug, allowed to dry, and incubated under occlusion for 3 or 24 hrs. A minimum of three lesions per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
223729935|NCT01057654|DRUG|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
224001020|NCT01840410|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
223729936|NCT01138033|DRUG|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
224001021|NCT01840410|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
224001022|NCT04515433|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
224001023|NCT04343976|DRUG|Pegylated interferon lambda|180 mcg subcutaneous injection of pegylated interferon lambda
224001024|NCT00594880|DRUG|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
224001025|NCT00594880|DRUG|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL \< 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
224124002|NCT05726019|DRUG|Colchicine|Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
224124003|NCT03773341|OTHER|research questionnaire|Patient personal data History taking clinical knee examination
224124004|NCT06464367|DRUG|Psilocybin|synthetic psilocybin 10 mg (oral)
224124005|NCT06464367|DRUG|Placebo|synthetic THC 2.5 mg (oral)
223383999|NCT01682811|DRUG|Part 1 Levulan surface application twice|Control or treatment lesions will be painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 3 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
223729937|NCT03724955|DRUG|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
223729938|NCT03724955|OTHER|Placebo|The placebo group will receive placebo oral daily for 6 months
224124006|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Once Daily|
224124007|NCT02293018|DRUG|0.75% (w/w) MTC896 Gel Twice Daily|
224124008|NCT02293018|DRUG|1.5% (w/w) MTC896 Gel Once Daily|
224124009|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
224124010|NCT03050671|DEVICE|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
224124011|NCT01626911|PROCEDURE|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
224124012|NCT01626911|OTHER|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
224124013|NCT01724983|DRUG|ketamine|
223729939|NCT02159014|BEHAVIORAL|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
223729940|NCT02159014|BEHAVIORAL|Online, video prompted, individual aerobic dance|Supported online activity intervention
224001026|NCT02217215|DEVICE|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
224001027|NCT00661297|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
223384000|NCT01682811|DRUG|Part 1 Levulan surface application twice with microneedling|Control or treatment lesions will be prepared with microneedling, painted twice with Levulan vehicle only or active drug, allowed to dry between and after applications, and incubated under occlusion for 24 hrs. A minimum of three tumors per group on the same subject will be treated. Lesions will then be excised in the normal manner, sectioned vertically, and checked for Protoporphyrin IX using fluorescence microscopy.
224001028|NCT00661297|DRUG|Placebo|Matching placebo
224001029|NCT00694109|DRUG|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
224001030|NCT03557671|DIETARY_SUPPLEMENT|rice formula|new rice based thickened formula
224001031|NCT03557671|DIETARY_SUPPLEMENT|placebo|formula previously tolerated by the subject - only for the 1st part of the study
224001032|NCT00208455|DEVICE|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
224001033|NCT00040417|DRUG|FLUDARABINE|
224001034|NCT00040417|DRUG|CAMPATH-IH|
224001035|NCT00040417|PROCEDURE|Total Body Irradiation|
224001036|NCT00040417|DRUG|FK506|
224001037|NCT00040417|DRUG|G-SCF (Granulocyte-colony stimulating factor)|
224001038|NCT02390453|BEHAVIORAL|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
224001039|NCT02390453|BEHAVIORAL|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
223384001|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 8 minutes to achieve a dose of 50 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
223384002|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 16 minutes to achieve a dose of 100 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
223729941|NCT02159014|BEHAVIORAL|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
224001040|NCT02390453|BEHAVIORAL|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
224001041|NCT02390453|BEHAVIORAL|Active Control|Control modules provide social contact for group discussion of health and successful aging.
224001042|NCT02012023|DEVICE|Low anterior resection|
224124014|NCT01724983|DRUG|fentanyl|
224001043|NCT02012023|DEVICE|tube ileostomy|
224001044|NCT02012023|DEVICE|loop ileostomy|
224001045|NCT02012023|DEVICE|accept reversal operation|
224001046|NCT02012023|DEVICE|remove the tube ileostomy|
224001047|NCT04134624|OTHER|Sepsis care bundle|Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
224001048|NCT05613777|DRUG|Microgynon®|ethinylestradiol (EE) and levonorgestrel (LNG)
224001049|NCT05613777|DRUG|BI 425809|BI 425809
224001050|NCT02487043|BEHAVIORAL|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
224001051|NCT03349151|BEHAVIORAL|Early feeding|Feeding on postoperative 2nd hour on return to the ward
224001052|NCT03349151|BEHAVIORAL|On- Demand feeding|Feeding whenever the patient asks for on return to the ward
224124015|NCT02586753|OTHER|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
224138495|NCT05261880|OTHER|Scaphoid , hamate mobilization|Bone mobilization in Carpal Tunnel Syndrome involves gliding at scaphoid and hamate.
224138496|NCT06554002|OTHER|Control|Participants will be asked to consume glucose on a daily basis (twice per day) for the entire 8 weeks. The supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
223384003|NCT01682811|DRUG|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3|2-6 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 633 nm red light illumination. 633 nm light will be applied for 32 minutes to achieve a dose of 200 J/cm\^2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
224001053|NCT03921853|OTHER|Behavioral|The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
224001054|NCT01254747|DEVICE|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
224001055|NCT01254747|DEVICE|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
224001056|NCT01254747|DEVICE|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
224001057|NCT01254747|DEVICE|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
224001058|NCT04954092|BIOLOGICAL|Gam-COVID-vac M|The vaccine consists of two components: component I and component II. Component I includes a recombinant adenoviral vector based on human adenovirus serotype 26 carrying the gene for the S-protein of the SARS-CoV-2 virus, component II includes a vector based on human adenovirus serotype 5 carrying the protein S gene of the SARS-CoV-2 virus
224001059|NCT04954092|BIOLOGICAL|Placebo|Composition without active ingredients
224001060|NCT00178555|DEVICE|DCI Video Intubation System-Macintosh Laryngoscope|
224001061|NCT00178555|DEVICE|Macintosh Laryngoscope|
224001062|NCT02532127|OTHER|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
224001063|NCT03759782|DRUG|Ribavirin|Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
223384004|NCT04611633|COMBINATION_PRODUCT|Trimbow|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
223384005|NCT01128179|DRUG|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
223384006|NCT01128179|DRUG|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
223384007|NCT04684043|DEVICE|Percutaneous coronary intervention|PCI was performed using drug-eluting stents
223384008|NCT05123703|DRUG|Ocrelizumab|Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.
223729942|NCT02159014|BEHAVIORAL|Self-paced online aerobic dance activity|Self paced physical activity
224001064|NCT03759782|DRUG|Tenofovir|Tenofovir as per standard of care
224001065|NCT00613899|OTHER|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
224001066|NCT00930670|DRUG|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
224001067|NCT00930670|DRUG|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
223729943|NCT02159014|BEHAVIORAL|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
224001068|NCT00930670|DRUG|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
224001069|NCT00930670|DRUG|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
224001070|NCT00930670|DRUG|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
224001071|NCT00930670|DRUG|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
224001072|NCT00930670|DRUG|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
224001073|NCT00930670|DRUG|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
224001074|NCT00245960|DRUG|etanercept|
224001075|NCT00245960|DRUG|etanercept|
224001076|NCT00245960|DRUG|Placebo|
224001077|NCT00147589|DRUG|Eplerenone|
224001078|NCT05395195|DRUG|Erythropoietin|Erythropoietin injections (500u/kg) x 9 doses
224001079|NCT05395195|OTHER|Supportive neonatal intensive care|Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
224001080|NCT03924700|PROCEDURE|Biportal endoscopy|Biportal endoscopic spine surgery (BESS)
224001081|NCT03924700|PROCEDURE|Microdiscectomy|Using microscope for discectomy
223384009|NCT05123703|OTHER|Ocrelizumab Placebo|Ocrelizumab matching placebo will be administered by IV infusion on Day 1 and Day 15 and Q24W thereafter.
223384010|NCT05123703|DRUG|Fingolimod|Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).
223384011|NCT05123703|OTHER|Fingolimod Placebo|Fingolimod matching placebo will be administered daily as a capsule.
223384012|NCT07109388|DRUG|Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound|Participants in the PENG group will first receive a sham sciatic injection; the needle will be inserted into the subcutaneous tissue and 3 ml of 0.9% NaCl will be injected. They will then receive a PENG nerve block in the supine position. A low-frequency (2-5 MHz) curvilinear ultrasound probe (BK Ultrasound) will be used to identify the anterior inferior iliac spine, the pubic eminence, and the psoas tendon with its fascial plane. A 22-gauge, 50 mm needle (SonoPlex® Pajunk) will be inserted into the fascial plane to inject 20 ml of 0.75% ropivacaine (Fresenius Kabi).
223384013|NCT07109388|DRUG|Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine|Participants in the combined group will first receive a sciatic nerve block performed with the patient in a semi-prone position, the lower limb flexed at 90° (hip and knee), elevated with a cushion placed between the legs. A straight line will be drawn between the greater trochanter and the ischial tuberosity. The sciatic nerve is located approximately at the midpoint of this line. Under ultrasound guidance, the ischial tuberosity will be identified medially, the greater trochanter laterally, the gluteus maximus muscle superficially beneath the adipose tissue, and the quadratus femoris muscle in depth. A 22-gauge, 50 mm needle will then be inserted into the fascial plane to inject 20 ml of 0.375% ropivacaine. The patient is then placed supine for femoral and lateral femoral cutaneous nerve blocks. 15 ml of local anaesthetics will be injected around the femoral nerve and 5 around the lateral femoral cutaneous nerve.
224001082|NCT02097589|DRUG|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
224001083|NCT02097589|DRUG|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
224001084|NCT02097589|OTHER|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
224001085|NCT06358248|DEVICE|Physician-modification of Valiant Captivia Endograft (Medtronic, Minneapolis, MN-USA).|"On a sterile back-table a Valiant Captivia thoracic graft is deployed. A dotted line is drawn to mark the graft anterior 0° degree, and fabric holes are performed with cautery in the desired position. The fenestrations need to be 6x6 mm for the renals and 8x8 mm for superior mesenteric artery (SMA) and celiac trunk (CT), and are reinforced with the tip of a 0.018 guidewire through a continuous 5-0 locking suture.~A posterior constraining wire is created to reduce the diameter of the graft by 20-30%, in order to allow rotation during the deployment phase. The four 8 markers on the top of the graft are carefully removed with a scalpel; one of these is modified as an S and re-sutured on the anterior aspect at 0 degree position, with a 5-0 prolene continuous suture. This S marker will allow anteroposterior graft orientation. Finally, the graft is re-sheathed and deployed."
224001086|NCT00737698|OTHER|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
224001087|NCT00737698|OTHER|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
224001088|NCT00912392|DRUG|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
224001089|NCT00912392|DRUG|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
223384014|NCT07122076|BIOLOGICAL|GT719 Injection|GT719 Injection
223384015|NCT06931132|OTHER|Real-life forest bathing|Participants will experience the elements (olfactory, acoustic and haptic) of forest bathing for 30 minutes (sitting) in a forested area. The forests have been previously selected near Stuttgart and Würzburg and are comparable to each other.
223384016|NCT06931132|OTHER|Simulated FOREST bathing (Virtual Reality)|Using virtual reality goggles, a FOREST bathing experience will be simulated. The simulation will have elements of the classic FOREST bathing (olfatory, acoustic and haptic) and will last 30 minutes.
223384017|NCT06931132|OTHER|Imaging FOREST bathing|A therapist will lead an imaginative exercise in which participants will imagine a FOREST bathing. The imaginative exercise will include elements of the classic FOREST bathing (olfactory, acoustic and haptic) and will last 30 minutes.
223545424|NCT04777006|DRUG|Antidepressant Therapy|"Fluoxetine, a serotonin selective reuptake inhibitor (SSRI), and amitriptyline, a tricyclic antidepressant (TCA), are part of Malawi's national formulary. Neno District supply chain is supported by PIH, which reduces stock-outs relative to those observed in other Malawian settings. Fluoxetine is typically the first drug of choice because it is safer and better tolerated.~Daily dose will commence at 20 mg of fluoxetine, or 25 mg of amitriptyline. At monthly follow-up visits, a dose increment or medication change may be considered based on measures of treatment response and side effects, using an Antidepressant Side Effect Checklist. This algorithm-based process will be repeated every other week until the patient is fully responding to treatment (PHQ-9 \< 5) for a period of three months. Dose escalations of more than one increment and medication changes will be reviewed with the doctor-in-charge. If on ADT at end of study, it will be sustained as part of usual care."
223545425|NCT02695017|DEVICE|Iso inertial|
223545426|NCT02695017|DEVICE|Conventional machine|
223545427|NCT04257968|DIAGNOSTIC_TEST|Ultrasonography|carotid ultrasonography (IMT and elastography)
223545428|NCT04257968|DIAGNOSTIC_TEST|MRI|MRI of carotid artery and brain
224001090|NCT00004877|DRUG|BMS-214662|
224124016|NCT02586753|OTHER|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
224124017|NCT01258972|DEVICE|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
224124018|NCT01258972|DEVICE|POBA|Balloon angioplasty
223384018|NCT07132138|OTHER|Scooter Board Activities|"Scooter board bear walk. Scooter board crab walk. Sitting on scooter board, use it to move forward and backward, move the pool rings from one end to another.~Cross sitting on scooter board, pulls along the rope using his/her hands Sit with knees pulled into the chest (like a bug pose) and move around with arms only.~Prone over scooter board, pulling rope to move forward. Pull self along an anchored rope to retrieve items Scooter rolls outs. Place knees on floor and hands holding the edge of the front scooter board. Push board out a few inches then pull back, the further you roll, the harder it gets.~8- Kneeling, Push self forward and backward with the use of a therapy ball (lots of Motor Planning).~Supine flexion on scooter board, Clip clothespins to a rope hanging above."
223384019|NCT07132138|OTHER|Core Stability Exercises|Bridges Bird-dog Sit-ups on therapy ball Static and dynamic trunk holds
223384020|NCT07132762|DEVICE|Radial Extracorporeal Shock Wave Therapy|"A total of 6 sessions of ESWT, applied twice a week. Each ESWT session will last approximately 15 minutes. ESWT will be administered with the patient in the prone position, using an energy density of 0.15 mJ/mm², at 4 Hz frequency, and 1,500 shock waves per session.~The ESWT application will be performed on the right and left paravertebral muscles between the L3 and S1 segments."
224001091|NCT03444896|DEVICE|Acupuncture group|Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.
224001092|NCT03444896|DEVICE|Sham acupuncture group|Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
224001093|NCT02360735|OTHER|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
224001094|NCT02360735|OTHER|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
224001095|NCT00126698|DRUG|trimethoprim-sulfamethoxazole|
224001096|NCT00126698|DRUG|ciprofloxacin|
224001097|NCT00034788|DRUG|Becaplermin|
224001098|NCT00831662|DRUG|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
224001099|NCT00831662|DRUG|Placebo|One to two drops in each eye QID for 6 weeks
223384021|NCT07132762|OTHER|Conventional rehabilitation|A total of 15 sessions of conventional physical therapy will be administered, five times per week. Each session will include 20 minutes of hot pack application, 20 minutes of conventional transcutaneous electrical nerve stimulation (TENS), 5 minutes of ultrasound therapy at 1.5 W/cm², and core stabilization exercises performed under the supervision of a physiotherapist. The treatment will be applied over a total period of 3 weeks.
223384022|NCT06943872|DRUG|Sonrotoclax|Administered orally
223384023|NCT06943872|DRUG|Obinutuzumab|Administered intravenously
223384024|NCT06943872|DRUG|Rituximab|Administered intravenously
223384025|NCT06943872|DRUG|Venetoclax|Administered Orally
223384026|NCT05192889|DRUG|Venetoclax|Given oral (PO).
223384027|NCT05192889|DRUG|Navitoclax|Given oral (PO).
223384028|NCT05192889|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
223384029|NCT05192889|DRUG|Vincristine|Given intravenously (IV).
224001100|NCT01839942|PROCEDURE|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
223384030|NCT05192889|DRUG|Calaspargase Pegol|Given intravenously (IV).
223384031|NCT05192889|DRUG|Dasatinib|Given oral (PO).
224001101|NCT01839942|PROCEDURE|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
223384032|NCT05192889|DRUG|Cytarabine|Given intravenously (IV) or Intrathecal (IT).
224124019|NCT02094872|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
224124020|NCT02094872|DRUG|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
224124021|NCT02094872|PROCEDURE|therapeutic procedure|
224124022|NCT02094872|OTHER|laboratory biomarker analysis|Correlative studies
224124023|NCT02094872|OTHER|quality-of-life assessment|Ancillary studies
224124024|NCT03635398|DEVICE|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
224124025|NCT03635398|DEVICE|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
224124026|NCT03635398|DRUG|midazolam|oral administration of midazolam
224124027|NCT02364947|DRUG|Nalmefene hydrochloride|As-needed; tablets, orally
224124028|NCT02364947|DRUG|Placebo|As-needed; tablets, orally
223384033|NCT05192889|BIOLOGICAL|Blinatumomab|Given intravenously (IV).
223384034|NCT05192889|DRUG|Methotrexate|Given intravenously (IV), oral (PO), or Intrathecal (IT).
223384035|NCT05192889|DRUG|Mercaptopurine|Given oral (PO).
223384036|NCT05192889|DRUG|Cyclophosphamide|Given intravenously (IV).
223384037|NCT05192889|DRUG|Etoposide|Given intravenously (IV).
224124029|NCT03904641|RADIATION|aPDT|For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
223729944|NCT02482623|BEHAVIORAL|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
224001102|NCT01067846|DRUG|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
224001103|NCT01067846|DRUG|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
224001104|NCT01067846|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
224001105|NCT05821920|DEVICE|MUST MINI system|cervical posterior fixation system
224001106|NCT06366412|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.
224001107|NCT06366412|OTHER|normal saline|normal saline will be administrated in placebo group
224001108|NCT03299751|BIOLOGICAL|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory. The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patients), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results.~The adjudication committee composed with 3 neonatalogists will classify patients in 3 groups (infected, not infected or unclassified patientsconfirmed infection, refuted infection), based on their clinical and biological data obtained, through the standard of care practice, during the 48 hours following inclusion. The adjudication committee will be blinded to the biomarkers results."
224124030|NCT03904641|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
224124031|NCT06017583|DRUG|Tislelizumab|Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.
224124032|NCT06017583|DRUG|Capecitabine|Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
224124033|NCT06017583|DRUG|Oxaliplatin|Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
224124034|NCT06017583|RADIATION|SIB-IMRT|The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.
224124035|NCT06017583|RADIATION|IMRT|The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
223384038|NCT05192889|DRUG|Leucovorin|Given oral (PO) or intravenously (IV).
223384039|NCT05192889|DRUG|Intrathecal Triples|Given Intrathecal (IT).
223384040|NCT05192889|DRUG|Pegaspargase|May be used in place of Calaspargase Pegol where available. Given intravenously (IV) or intramuscularly (IM).
223384041|NCT05192889|DRUG|Erwinia asparaginase|To be used in case of hypersensitivity or intolerance to Calaspargase Pegol or Pegaspargase. Given intravenously (IV) or intramuscularly (IM).
223384042|NCT05192889|RADIATION|Radiation|See detailed description section.
223384043|NCT04135846|DRUG|Doxazosin|16 mg or maximum tolerated dose (MTD)
223384044|NCT04135846|DRUG|Placebo|Matching placebo
223729945|NCT00296894|DRUG|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
223729946|NCT00296894|DRUG|Placebo|Placebo
224001109|NCT01396772|BEHAVIORAL|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
224001110|NCT01396772|OTHER|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
224001111|NCT00000300|DRUG|LAAM|
224001112|NCT05367700|DRUG|HS-10382(Part 1: Dose escalation)|Single or multiple dose(s) of HS-10382 once daily.
224001113|NCT05367700|DRUG|HS-10382(Part 2: Dose expansion)|HS-10382 is administered orally once daily.
224001114|NCT05524662|DEVICE|BTL-785-7|Treatment with BTL-785F device (BTL-785-7 applicator) for non-invasive facial rejuvenation.
224124036|NCT02365493|DRUG|Beta-Lactam|
224124037|NCT02163993|DRUG|Galcanezumab|Administered SQ
224124038|NCT02163993|DRUG|Placebo|Administered SQ
224124039|NCT00853489|DEVICE|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
224124040|NCT00853489|PROCEDURE|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
224124041|NCT03508765|DIAGNOSTIC_TEST|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
224124042|NCT03508765|DIAGNOSTIC_TEST|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
224124043|NCT03508765|BEHAVIORAL|Digit Span subtest|Evaluates auditory attention and working memory
224124044|NCT03508765|BEHAVIORAL|Brief Test of Attention|Assesses selective auditory attention
224124045|NCT03508765|BEHAVIORAL|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
224124046|NCT03508765|BEHAVIORAL|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
224124047|NCT03508765|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency.
224001115|NCT02817906|DRUG|ITI-007|
224001116|NCT02817906|DRUG|Placebo|
224001117|NCT02305602|BIOLOGICAL|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
224001118|NCT02458222|OTHER|language game therapy|participants will take part in game therapy
224001119|NCT02458222|OTHER|standard therapy|usual clinical care
224001120|NCT00260377|PROCEDURE|Coronary artery bypass surgery|
223384045|NCT06951347|DIETARY_SUPPLEMENT|Oral Rehydration Solution|one sachet every day for 3 days
224001121|NCT00201877|DRUG|Velcade|"Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 \& 14.~Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23."
224001122|NCT00201877|DRUG|Rituximab|"Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.~Maintenance: 375 mg/m2 day 1 weekly x 4 weeks."
223384046|NCT06767358|DRUG|ketamine hydrochloride|Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour
224001123|NCT03658759|PROCEDURE|Extracorporeal Cardiopulmonary Resuscitation|local ECPR clinical pathway, including transport with mechanical chest compression device and rapid response VA-ECMO
224001124|NCT03508401|OTHER|Passive leg raising (PLR)|"PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs"
224001125|NCT03508401|DEVICE|Echo-Doppler measurements|"Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin))."
224001126|NCT01275742|BEHAVIORAL|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
224001127|NCT04608773|OTHER|Remineralizing Extreme Dry Mouth Spray with Xylitol|oral hydrating spray
224001128|NCT04608773|DEVICE|Alcohol-Free Moisturizing Dry Mouth Spray|oral hydrating spray
224001129|NCT04796077|OTHER|Pop-Up Book|Patients spent 5-10 minutes reading an illustrated pop-up book that promoted active learning about the process of general anesthesia induction.
224001130|NCT02541370|BIOLOGICAL|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
223384047|NCT06767358|OTHER|Normal saline placebo|Normal saline placebo infusion
223384048|NCT04776694|DRUG|Dupilumab|
223384049|NCT07158047|OTHER|Heat therapy|30 sessions of far infrared sauna bathing (45-60C) for up to 45 min
223384050|NCT07163637|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri DSM 17648|One capsule containing L. reuteri DSM 17648 should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
223384051|NCT07163637|DIETARY_SUPPLEMENT|Placebo|One capsule of placebo should be taken once per day with liquid during or immediately after the main meal, for 8 weeks.
224001131|NCT02833077|DEVICE|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator. The maximum total volume administered was up to 4 mL.
224001132|NCT04843267|DRUG|Tislelizumab|Tislelizumab in first-line treatment of Hodgkin's lymphoma
224001133|NCT02710175|OTHER|serum TSH level|
223384052|NCT07185971|DEVICE|PAVE (Parallactic Visual-Field Enhancement) treatment using a virtual reality head mounted display|PAVE (Parallactic Visual-Field Enhancement) treatment is visual stimulation using a virtual reality head mounted display. The treatment is weekly and entails two 7 minute session separated by a minimum 1 minute intermission. The actual therapy is preceded by a visual field assessment and is followed by a second visual field assessment.
223384053|NCT07185971|DEVICE|PAVE Placebo|The placebo uses the same PAVE software but the functional aspect of the software that is intended to produce the effect in the test group is absent.
223545429|NCT04257968|DIAGNOSTIC_TEST|Neuro Psychological Assessment Battery|Hopkins Verbal Learning Test Digit Span WAIS-IV Stroop Color Word test Trail Making Test Brixton Spatial Anticipation Test Fluency letter (B-D-H) Fluency animal naming Symbol Digit Substitution WAIS-IV
223545430|NCT04257968|DIAGNOSTIC_TEST|Questionaires|Cognitive Failures, Depression, Anxiety, Fatigue, Speech handicap, fear for recurrence, Quality of Life.
224001134|NCT01938053|OTHER|Call when test results are ready|Patients are called when the test results are ready
224001135|NCT01938053|OTHER|Text message when test results are ready|Patients receive a text message when results are ready
224001136|NCT01938053|OTHER|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
224001137|NCT04195802|OTHER|Salt and potassium Diet|Self-administration questionnary to evaluate the salt and potassium consumption
224001138|NCT04160377|DRUG|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
224124048|NCT03508765|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
224124049|NCT03508765|BEHAVIORAL|The Center for Epidemiological Study-Depression|assesses perceived depression
223384054|NCT05004883|BEHAVIORAL|Regulation of Cues Enhanced|ROC is based on the Behavioral Susceptibility Theory and designed to incorporate psychoeducation, cue-exposure treatment, appetite awareness training, coping skills, and self-monitoring of satiety and cravings to treat high Food Responsiveness and low Satiety Responsiveness. BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure exercises.
224001139|NCT03704168|DEVICE|CRYOABLATION|The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
223384055|NCT05004883|BEHAVIORAL|Behavioral Weight Loss|The BWL program includes dietary, physical activity, and behavioral change recommendations. All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories, and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
223384056|NCT05004883|BEHAVIORAL|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
223384057|NCT04993313|OTHER|Counseling|Undergo verbal counseling
223384058|NCT04993313|OTHER|Educational Intervention|View photo guide
223384059|NCT04993313|BEHAVIORAL|Questionnaire|Complete questionnaires
223384060|NCT05939713|DEVICE|Cera™ VSD occluder implantation|To collect data from patients who have implanted with the device before 2022.
223384061|NCT06341192|PROCEDURE|Single-bundle ACL combined anterolateral ligament reconstruction|"Single-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo reconstruction of the anterior cruciate ligament (ACL) using a single-bundle graft technique.~In addition, they will have the anterolateral ligament (ALL) reconstructed using a portion of the same graft material.~The single ACL bundle is typically positioned to replicate the anatomic footprint of the native ACL.~For the ALL reconstruction, a commonly used technique is the Sonnery-Cottet ALL reconstruction using a gracilis tendon graft.~This combines an intra-articular ACL reconstruction with an extra-articular lateral tenodesis to improve rotational instability."
223384062|NCT06341192|PROCEDURE|Double-bundle ACL combined anterolateral ligament reconstruction|"Double-Bundle ACL + ALL Reconstruction Group:~Patients in this group will undergo anatomic double-bundle ACL reconstruction using two graft bundles to more anatomically replicate the native ACL\&#39;s anteromedial and posterolateral bundles.~Like the single-bundle group, they will also have supplemental ALL reconstruction performed using a portion of the graft material.~The double-bundle ACL reconstruction aims to better restore the ACL\&#39;s complex anatomic footprint and bundles\&#39; tension patterns."
223384063|NCT05126238|DRUG|Lithium Carbonate|In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.
223384064|NCT05126238|DRUG|Placebo|In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.
223384065|NCT04100148|DEVICE|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
223384066|NCT04100148|DEVICE|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
223384067|NCT01758081|DIETARY_SUPPLEMENT|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
224001140|NCT01947699|DRUG|Glyburide|
223384068|NCT01758081|DRUG|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
224001141|NCT01947699|DEVICE|Continuous glucose monitor|
223384069|NCT01758081|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
223384070|NCT01758081|DIETARY_SUPPLEMENT|fish oil placebo|
223384071|NCT06846450|RADIATION|Intensity-modulated proton radiation therapy|Intensity-modulated proton therapy, will be delivered to the high risk area with a dose of 56 GyRBE in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 GyRBE in 28 fractions.
223384072|NCT06846450|RADIATION|Intensity-modulated photon radiation therapy|Intensity-modulated photon therapy, will be delivered to the high risk area with a dose of 56 Gy in 28 fractions, and if applicable, to the low risk area with a dose of 50.4 Gy in 28 fractions.
223384073|NCT06846450|RADIATION|Intensity-modulated carbon ion radiation therapy|Intensity-modulated carbon ion radiation therapy will be delivered as a boost with a dose of 17.5 GyRBE in 5 fractions to gross tumor.
224001142|NCT03339232|DIETARY_SUPPLEMENT|BCAA Supplement|Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
224001143|NCT03339232|OTHER|Physical Activity|Supervised low impact aerobic physical activity for one hour each week.
223384074|NCT06846450|DRUG|Concurrent chemotherapy|Concurrent chemotherapy will be administered on a weekly basis.
223384075|NCT06846450|DRUG|Induction chemotherapy|Cisplatin-based induction chemotherapy will be administered every three weekly.
223384076|NCT06548776|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS) Scan|Participants will receive MRS Scan
223384077|NCT00548639|OTHER|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
223384078|NCT00548639|OTHER|Control Pamphlet|ADA Diabetes Sheet
223384079|NCT01436097|BEHAVIORAL|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
223384080|NCT01436097|BEHAVIORAL|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
223384081|NCT01436097|BEHAVIORAL|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
223384082|NCT01436097|BEHAVIORAL|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
224001144|NCT06418009|PROCEDURE|Cold needle application|Before use, the needle will be removed from the refrigerator and kept on the nurse's table. When the temperature of the needle reaches 0-2 °C, the patient will be cannulated.
224001145|NCT00316017|DRUG|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
224001146|NCT00316017|DRUG|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
223384083|NCT05789576|DRUG|VTAMA (tapinarof) cream, 1%|VTAMA (tapinarof) cream, 1% applied topically once daily
223384084|NCT06503731|COMBINATION_PRODUCT|Efgartigimod PH20 SC - prefilled syringe|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
223384085|NCT06503731|OTHER|Placebo PH20 SC - prefilled syringe|Subcutaneous placebo PH20 SC given by prefilled syringe
223384086|NCT05821777|DRUG|LB101|Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101
223729947|NCT05647954|DRUG|HX008 + TACE|HX008 Subjects receive HX008 200 mg intravenous (IV) ,day1,every 3 weeks (Q3W) Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions).
223384087|NCT05509439|OTHER|Home Transfusion Program Components|The Home Transfusion Program will include trained transfusion nurse(s) who will administer transfusions in the home setting. The transfusion nurse, who is part of the study team, will work closely with the DFCI/BWH Blood Bank and the hospice agency (Care Dimensions Inc.) that all study patients are enrolled in. The transfusion nurse will administer home transfusions using safe home transfusion practices endorsed by the AABB. The home transfusion program has 4 key aspects Initial home visit, (2) subsequent contact, (3) home transfusion assessment \& administration, (4) usual elements of hospice
223384088|NCT06504264|BEHAVIORAL|phonemic segmentation|during phonemic segmentation activities, articulatory gestures will be used while teaching letters and their sounds.
223384089|NCT02495090|GENETIC|Exome sequencing|Plain DNA sequencing
223384090|NCT06268080|BEHAVIORAL|Depth of anesthesia titration using pEEG|Titration of maintenance anesthetic agent (propofol infusion)
223384091|NCT06286046|DRUG|Mitapivat|Tablets
223384092|NCT02731638|DRUG|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
223384093|NCT02731638|DRUG|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
223384094|NCT04560322|DRUG|Venetoclax|Tablet, taken by mouth
223384095|NCT04560322|DRUG|Obinutuzumab|Intravenous infusion
223729948|NCT05647954|DRUG|Temozolomide + TACE|"Temozolomide Subjects receive Temozolomide 200 mg/sqm intravenous (IV),day1-5, every 3 weeks (Q3W)~Procedure: TACE :~cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm, day2, every 6 weeks; lipiodol is usually 5-10 ml (According to the location and number of lesions)."
224001147|NCT00316017|DRUG|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
223384096|NCT04560322|DRUG|Acalabrutinib|Capsule, taken by mouth
223384097|NCT05211466|OTHER|Digital healthcare platform|In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
223384098|NCT05135702|DIETARY_SUPPLEMENT|Sodium Propionate|a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
223384099|NCT05135702|DIETARY_SUPPLEMENT|Placebo|a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
223384100|NCT06796686|BIOLOGICAL|426c.Mod.Core-C4b|426c.Mod.Core-C4b is supplied at a concentration of 2 mg/mL, 0.55 mL per vial.
223384101|NCT06796686|BIOLOGICAL|HxB2.WT.Core-C4b|HxB2.WT.Core-C4b is supplied at a concentration of 1 mg/mL, 0.5 mL per vial
223384102|NCT06796686|BIOLOGICAL|3M-052-AF adjuvant|immune response modifier (IRM)
223729949|NCT05647954|DRUG|Pembrolizumab|Subjects receive Pembrolizumab 2 mg/kg intravenous (IV),day1, every 3 weeks (Q3W)
223384103|NCT06796686|OTHER|Aluminum hydroxide suspension (Alum) adjuvant|Alhydrogel.
223384104|NCT06796686|OTHER|Diluent|Tris-NaCl buffer
223384105|NCT06335953|BEHAVIORAL|Pharmacist-led deprescribing intervention|The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.
223384106|NCT05679050|DRUG|AG Followed by FOLFIRINOX|"AG（every 28 days) Nab-paclitaxel 125 mg/m2 i.v. over 30 min, gemcitabine hydrochloride 1g/m2 i.v. over 30 min, D1, 8 and 15 ; FOLFIRINOX(every 42 days) Oxaliplatin: 65 mg/m2 i.v. over 2h on D1, 15, 29; Tetrahydrofolate: 400 mg/m2 i.v.2h on D1, 15, 29; Irinotecan: 150 mg/m2 i.v. over 90 min every 42 days on D1, 15, 29; 5-FU: 2400 mg/m2 i.v. over 46h /14 days on D1-3, 15-17, and 29-31; After one round of above therapy, patients achieving stable disease and above without disease progression or unacceptable toxicity underwent pancreatectomy within 4-8 weeks; Patients who did not achieve stable disease and above were treated another round , and patients who achieved stable disease and above underwent pancreatectomy at 4-8 weeks.~Following pancreatectomy, patients underwent AG regimen (2 rounds, 56 days) followed by FOLFIRINOX regimen (42 days) in the absence of disease progression or unacceptable toxicity, and AG and FOLFIRINOX dosing as the preoperative therapy."
223384107|NCT03284723|DRUG|PF-06804103|Dose Escalation Part - 1A Dose Expansion Part - 2A
223384108|NCT03284723|DRUG|PF-06804103 + Palbociclib +Letrozole|Dose Escalation - Part 1B Dose Expansion - Part 2B
223384109|NCT00101634|DRUG|Paliperidone palmitate|
223384110|NCT03517410|OTHER|Smart phone use|Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
223384111|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
224001148|NCT05988944|OTHER|TT+CIMT+VR|TT: Traditional Techniques CIMT: constraint-induced movement therapy VR: virtual reality
224001149|NCT05988944|OTHER|TT+CIMT|TT: Traditional Techniques CIMT: constraint-induced movement therapy
224001150|NCT05988944|OTHER|TT|TT: Traditional Techniques
224001151|NCT00059189|DEVICE|Magstim Rapid Magnetic Stimulator|
224001152|NCT02215525|DEVICE|UVA|device uses UVA
223384112|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
223384113|NCT00615199|DRUG|CP-690,550|administration via oral route twice daily
223384114|NCT00615199|DRUG|Placebo|administration via oral route twice daily
223384115|NCT05975411|OTHER|Anesthesia Consultation with telemedicine|Anesthesia Consultation with telemedicine
223384116|NCT01659957|BEHAVIORAL|Group Couples Counseling|
223384117|NCT01659957|BEHAVIORAL|One-on-One Couples Counseling|
223384118|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
223384119|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
223384120|NCT05869201|BIOLOGICAL|Influenza vaccine [inactivated]|Solution for intramuscular injection, 0.5 ml (1 dose) Vaccination with a single dose vaccine
223384121|NCT06583226|DEVICE|Gelatin sponge stabilization with suture and cyanoacrylate|The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, Ethicon, USA)+ supporting sutures (control group)
223384122|NCT06583226|PROCEDURE|Gelatin sponge stabilization with suture and cyanoacrylate and coconut oil application|Seconder The donor site will be closed both with gelatin sponge +Cyanoacrylate (Spongostan®, USA) and coconut oil (test group)
223384123|NCT04783402|OTHER|e-OTCAT program|"The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions."
223384124|NCT04783402|OTHER|Educational handbook and standard care|At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
223384125|NCT06499402|OTHER|massage|sacral massage
223384126|NCT02042352|OTHER|pH glove|
223384127|NCT01795404|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR)|
223384128|NCT01499095|DRUG|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
224001153|NCT02215525|DIETARY_SUPPLEMENT|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
224001154|NCT04749680|DEVICE|PD cycler Silencia|Treatment for 2 weeks either with PD-Night or Homechoice PD cycler (Comparators) depending on the previous Treatment ((clinical phase I). At the end of these 2 treatment weeks and a subsequent training phase which up to 3 weeks, treatment with the Silencia PD cycler for 2 further weeks (clinical phase II).
224001155|NCT03835741|DEVICE|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
224001156|NCT03835741|OTHER|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
224001157|NCT06354829|DIAGNOSTIC_TEST|Medical imaging procedures|The following medical imaging procedure will b applied: Magnetic resonance images (MRI), computerized tomography images (CT), and ultrasound images (US).
224001158|NCT06302621|DRUG|Afatinib|Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
224001159|NCT06302621|DRUG|Pemigatinib|Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
223384129|NCT01499095|DRUG|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
223545431|NCT04583436|DEVICE|Endovascular recanalization|Recanalization with angioplasty and stenting: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Perform transluminal or subintimal recanalization of the occluded segment of the arteries with a hydrophilic guide wire. Next, balloon angoplasty of the recanalized segment is performed. After control angiography, a biomimetic braided nitinol stent is placed throughout the lesion.
223729950|NCT03423095|BEHAVIORAL|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
223729951|NCT03423095|BEHAVIORAL|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
224001160|NCT06121180|DRUG|ZIV-Aflibercept|Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.
224001161|NCT06121180|DRUG|Cemiplimab|"Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells."
224001162|NCT02858310|BIOLOGICAL|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
224001163|NCT02858310|DRUG|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
224001164|NCT02858310|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224001165|NCT02858310|DRUG|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224001166|NCT03110861|DEVICE|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
224001167|NCT02470897|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
224001168|NCT02470897|RADIATION|SBRT|Undergo moderate dose SBRT with SIB
224001169|NCT02470897|RADIATION|SBRT|Undergo uniform dose SBRT
224001170|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Philips oximeter
224001171|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 90%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 90%) with Nonin oximeter
224001172|NCT05590130|DEVICE|Manual Oxygen titration with Philips oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
223729952|NCT03423095|BEHAVIORAL|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
224001173|NCT05590130|DEVICE|Manual oxygen titration with Nonin oximeter (SpO2 target 94%)|Oxygen titration with FreeO2 device (fixed flow mode) to reach the SpO2 target (set at 94%) with Philips oximeter
224001174|NCT06853132|BEHAVIORAL|Baduanjin with Resistance Training Program|Baduanjin with Resistance Training Program
224001175|NCT02203526|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
224001176|NCT02203526|DRUG|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
224001177|NCT02203526|BIOLOGICAL|Rituximab|Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
224001178|NCT02203526|DRUG|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
224001179|NCT02203526|DRUG|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
224001180|NCT02203526|DRUG|Ibrutinib (Arms 2, 3 and 4)|Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)
224001181|NCT02203526|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
224001182|NCT02203526|DRUG|Ibrutinib (Arm 1 - Closed with Amendment G)|Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
224001183|NCT02203526|DRUG|Ibrutinib (Arm 4)|Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)
224001184|NCT03350399|DIAGNOSTIC_TEST|placenta growth factor|estimation level of derum placenta growth factor
224001185|NCT01217437|BIOLOGICAL|Bevacizumab|Given IV
224001186|NCT01217437|DRUG|Irinotecan Hydrochloride|Given IV
224001187|NCT01217437|DRUG|Temozolomide|Given PO
224001188|NCT04478253|DEVICE|HypnoVR|Insertion of the drain according to the usual management protocol supplemented by the use of a hypnosis software application (HYPNO-VR).
224001189|NCT05826093|PROCEDURE|Ultrasound-guided subcostal transversus abdominis plane block (US-TAP)|US-TAP is a peripheral nerve block applied for postoperative pain relief. Subcostal refers to the approach which can also be lateral or posterior. In this trial the subcostal approach was used.
224001190|NCT07137494|BIOLOGICAL|MB-CART19.1 Cellular Therapy|MB-CART19.1 will be infused as a single infusion during an inpatient admission.
224001191|NCT07033130|DEVICE|OMRP R2 + Percepolis Accessory Software|The Oticon Medical Research Platform Release 2 (OMRP R2) + Percepolis Accessory Software is an investigational or research tool that includes hardware, firmware and software elements, which can connect to an Oticon Medical Cochlear Implant (CI). It is intended to be used exclusively for research with Oticon Medical CI users participating in research experiments or clinical studies. The hardware components are referred to as 'OMRP R2' and the software components are called 'Percepolis Accessory Software'.
223384130|NCT02037425|DRUG|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
223384131|NCT00221338|DRUG|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
224001192|NCT07033130|DEVICE|Nuc8 Sound Path|Nuc8 is the sound path used in Cochlear Nucleus Sound Processors.
224001193|NCT07033130|DEVICE|Neu2 Sound Path|Neu2 is the sound path that is currently used in the Neuro 2 Sound Processor.
224001194|NCT07138313|OTHER|Low-fat dietary intervention|Low-fat diet for approximately 1 week, preceding in-lab study period (approximately 2 days) under standardized conditions (total dietary exposure up to 9-10 days).
224001195|NCT07138313|OTHER|High-fat dietary intervention|High-fat diet for approximately 1 week, preceding in-lab study period (approximately 2 days) under standardized conditions (total dietary exposure up to 9-10 days).
224001196|NCT07137663|OTHER|Educational and practical intervention on menstrual cup use|The intervention implemented in this study is a unique approach tailored to menstrual hygiene management among women who use wheelchairs. What distinguishes this intervention from others is the combination of both education and practical support for menstrual cup use. While menstrual hygiene management in the literature generally targets the general population, this study specifically addresses the unique needs and challenges faced by women with disabilities by providing individualized menstrual cup selection and usage guidance. Additionally, the intervention includes repeated follow-ups over six menstrual cycles, allowing continuous support and monitoring of the participants' experiences. This approach aims not only to improve hygiene practices but also to enhance user satisfaction and long-term adherence. The comprehensive and personalized nature of this intervention differentiates it from most existing studies and seeks to offer practical, sustainable solutions for menstrual hygiene
224001197|NCT07136779|DRUG|VBC101|VBC101
224001198|NCT07138079|OTHER|edentulous geriatric patients|Edentulous geriatric patients will be inserted Air-Q Intubating Airway under general anesthesia.
224001199|NCT07138079|OTHER|dentate geriatric patients|Dentate geriatric patients will be inserted Air-Q Intubating Airway under general anesthesia.
224001200|NCT07135908|BEHAVIORAL|solution-oriented approach|"In this study, the solution-focused intervention was a structured psychosocial support program based on the principles of Solution-Focused Brief Therapy (SFBT). It consisted of six weekly sessions, each lasting 60 minutes, and was designed to help institutionalized children improve their hope levels and social participation skills.~The sessions included:~Enhancing communication and interpersonal skills~Identifying personal strengths and sources of hope~Developing social engagement strategies~Teaching simple problem-solving techniques~The approach focused on children's existing resources and future goals rather than their past problems. It encouraged positive thinking, goal setting, and active participation, promoting emotional resilience and social functioning."
224001201|NCT07136064|BEHAVIORAL|Emotion Regulation Skills Training|This arm will receive training in emotion regulation skills, including mindfulness skills to help redeploy their attention, cognitive reappraisal skills to analyze stimuli or emotion-eliciting events from a more comprehensive perspective, situation change skills to regulate emotions by exposing oneself to nature, and experiential acceptance skills through self-talk. This arm will also receive training in theories of the family emotion system.
224001202|NCT07136064|BEHAVIORAL|Moderation in Consumer Electronics Use Training|This arm will be trained to moderate their and their family members' use of commercial electronics. They will do so by learning mechanisms behind addictions, family communication skills, and various substitute activities for commercial electronics usage.
224001203|NCT07137637|DRUG|HPB-092 tablet|HPB-092 is formulated as a tablet for oral administration, taken twice daily (BID) over consecutive 28-day cycles. This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays a crucial role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in acute myeloid leukemia (AML) and other malignancies.
224124050|NCT03508765|BEHAVIORAL|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
224124051|NCT03508765|OTHER|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
224124052|NCT05525975|OTHER|Educational materials|Educational materials will be developed by our interdisciplinary research team. Will consist of a brochure and a video. Both materials highlight important information about opioid medications, explain proper disposal of excess of opioid medications and provide drug-free pain management tools for postoperative pain.
223384132|NCT05021900|DRUG|Tenalisib 800mg|Tenalisib will be administered 800mg BID, orally
223384133|NCT05021900|DRUG|Tenalisib 1200mg|Tenalisib will be administered 1200mg BID, orally
223545432|NCT04583436|OTHER|Open surgery|Femoropopliteal distal bypass with a synthetic ePTFE graft: Under general anesthesia, 2 standard open surgical approaches are performed: one to the common femoral artery, superficial femoral artery and deep femoral artery; the second - to the third portion of the popliteal artery, the tibioperoneal trunk and the anterior tibial artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the graft. Next, the graft is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Clamps are removed from arteries, blood flow is started, surgical hemostasis, wound drainage, layer-by-layer wound closure is performed.
223545433|NCT03788642|PROCEDURE|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
223545434|NCT03788642|PROCEDURE|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
224124053|NCT06200740|DEVICE|Sonara|web application facilitating asynchronous observation of methadone dosing
223545435|NCT01533441|DIETARY_SUPPLEMENT|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
223384134|NCT05733767|OTHER|Enhanced Usual Care (EUC)|Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.
223384135|NCT05733767|OTHER|Nurse Practitioner Tobacco Treatment Team (NPT3)|Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
223384136|NCT03065855|PROCEDURE|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
224001204|NCT07136532|DIAGNOSTIC_TEST|echocardiography|"Echocardiography will be performed using the ultrasound system echocardiographic equipment (Siemens Advanced Clinical Ultrasound Systems Optimized Navigation (ACUSON) P500), carotid doppler ultrasonography (Carotid blood flow and Corrected flow time) by using the ultrasound system echocardiographic equipment (Siemens ACUSON P500) .~Those measurements will be done at time zero and upon completion of fluid resuscitation .~• Statistical Analysis: All data will be collected, tabulated, and statistically analysed using International Business Machines\_Statistical Package for the Social Sciences (IBM SPSS) version 27."
224001205|NCT07136025|PROCEDURE|Individualized cluster management|Individualized cluster management for treatable traits
224001206|NCT07136025|PROCEDURE|Routine asthma treatment|Routine asthma treatment according to current guidelines
224001207|NCT07136844|DEVICE|Syde|Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
224001208|NCT07136844|DIAGNOSTIC_TEST|Dynamometric measurements of muscle strength|Dynamometric measurements of the maximum force of the following functions will be taken with the MyoTools: palmar grip (MyoGrip) and thumb-index pinch (MyoPinch). Test will be realized on the dominant side. Patients will be encouraged during the test. They will be given three trials and the best score will be entered.
224001209|NCT07136844|DIAGNOSTIC_TEST|The 6-minute walk test (6MWT)|This test consists of covering the greatest possible distance within 6 minutes, walking back and forth along a 25-meter hallway. The subject may stop if they need to. The evaluator will record the elapsed time after each half-lap, and the final distance that was covered at the end of the test. No help will be allowed during the test.
224124054|NCT00539253|DRUG|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
224124055|NCT05936034|OTHER|Patients suffering from chemotherapy-induced ototoxicity|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Control group: standard support; Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
224124056|NCT05936034|OTHER|Patients suffring from chemotherapy-induced ototoxicity wearing hearing aids|"At baseline,~* medical staff carries out a clinical and audiometric and/or tintometric examination~* patient completes the SF36 survey (36 Item Short-Form Health Survey)~* Patients will then be randomized to either:~  * Experimental group: standard treatment with hearing aids (wearing a hearing aid).~Once the patient has been fit, he continues his carcinological treatment with platinum-based chemotherapy according to the recommendations specific to his pathology.~At one, three and six months after fitting,~* medical staff carries out a clinical examination~* This visit will be scheduled when the patient arrives as part of their standard care. all patients included in the study will have a clinical examination and an audiometric and/or tinnitus examination and should complete an SF36 quality of life questionnaire.~Only at the last visit (6 months) all patients included should complete a satisfaction questionnaire."
224124057|NCT05078606|DEVICE|IJV Ultrasonography|"Patient will be in supine position, The linear probe with frequency of 7- 12 M hz; depth of 3 cm. maximum IJV diameter (IJV-D) and area (IJV-A) will be recorded. M-mode will be used to obtain the distance between the 2 walls of the vein during inspiration and expiration.~Then, the patient will be positioned 10° Trendelenburg and similar ultrasonographic measurements will be again performed"
224124058|NCT05078606|DEVICE|Carotid Intima Media Thickness|"US Probe is slided superiorly (toward the head) or inferiorly (toward the feet) until the bifurcation of the common carotid artery (CCA) appears on the left side of the screen. This is the ideal location for imaging and CIMT measurements.~IMT is assessed in longitudinal view from the arterial far wall, along a 10mm length. CIMT will appear as two parallel lines (leading edges of two anatomical boundaries) from it: lumen- intima and media- adventitia interfaces perpendicular to ultrasound beams."
223545436|NCT02943317|DRUG|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
224001210|NCT07136844|DIAGNOSTIC_TEST|The 10-meter test (10MWT)|During this test, the subject must cover a distance of 10 meters as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test. No help will be allowed during the test.
224001211|NCT07136844|DIAGNOSTIC_TEST|The 4 stair-climbing test (4SC)|This is a standardized test during which the subject must climb the 4 stair steps as rapidly as possible. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test, or more if needed.
224001212|NCT07136844|DIAGNOSTIC_TEST|Test of rising from the floor (TRF)|This is a standardized test during which the subject must rise from the floor as rapidly as possible. The test starts with the participant lying on their back. This test will be performed 3 times. The participant will be allowed to rest for one minute after the first and second instances of the test.
224001213|NCT07136844|DIAGNOSTIC_TEST|The Timed up and go test (TUG)|During this standardized test, the subject is observed and timed while he/she rises from a chair, walks 3 meters, performs a 180° turn, walk back toward the chair and sits down.
224001214|NCT07136844|DIAGNOSTIC_TEST|The Progressive Supranuclear Palsy Rating Scale (PSP-RS)|This 28-item clinician-rated scale assesses motor and non-motor symptom severity in patients with PSP, with a score ranging from 0 (normal) to 100.
224001215|NCT07136844|DIAGNOSTIC_TEST|The Montreal Cognitive Assessment (MOCA)|The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0 to 30, with higher score being better outcome.
224001216|NCT07136844|DIAGNOSTIC_TEST|The Charcot-Marie-Tooth examination score (CMTES)|The CMTES is a 28-point composite score that rates the patient's symptoms and signs. It is part of the Charcot-Marie-Tooth (CMT) neuropathy score and has been validated as a reproducible measure of disability in CMT. Higher scores indicate more severe neuropathy.
224001217|NCT07136844|DIAGNOSTIC_TEST|9-Hole Peg Test (9-HPT)|The 9-HPT is a quantitative test of upper limb function. It is the second component of the Multiple Sclerosis Functional Composite (MSFC). The patient sits at a table with a shallow container containing nine sticks and a wooden or plastic block containing nine empty holes. When a timer is started, the patient places the nine sticks one after the other as quickly as possible into the nine holes and, once they are all in the holes, removes them as quickly as possible. The total time taken to complete the task is recorded. Two consecutive attempts with the dominant hand are immediately followed by two consecutive attempts with the non-dominant hand.
223384137|NCT03065855|PROCEDURE|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
224001218|NCT07136844|DIAGNOSTIC_TEST|The Unified Huntington's Disease Rating Scale (UHDRS)|This 74-item clinical rating scale assesses patient performance and capacity in 4 domains: motor function, cognitive function, behavioral abnormalities, and functional capacity.
224001219|NCT07136844|DIAGNOSTIC_TEST|Quantitative Myasthenia Gravis (QMG)|The QMG is a clinician-rated 13-item scale used to quantify disease severity in patients with MG. The scale grades each domain (ocular, bulbar, respiratory, and limb function), with a total score ranging from 0 to 39 (lower score indicating a better clinical outcome).
224001220|NCT07136844|DIAGNOSTIC_TEST|The Myasthenia Gravis Activities of Daily Living Scale (MG-ADL)|This is an 8-item patient-reported scale assessing MG symptoms and their effects on daily activities. The score ranges from 0 to 24, with higher score indicating a worse clinical outcome.
224001221|NCT07136844|DIAGNOSTIC_TEST|The Scale for the Assessment and Rating of Ataxia (SARA)|This 8-item scale was developed to assess ataxia severity and disease progression. It evaluates gait and balance, speech, and upper and lower limb coordination. The score ranges from 0 to 40, with higher score indicating a worse clinical outcome.
224001222|NCT07136844|OTHER|Patient's Global Impression of Change (PGIC)|PGIC is a patient-reported scale used to assess how a patient feels their condition has changed over time. It typically uses a 7-point scale to capture the patient's overall perception of improvement in symptoms, function, and quality of life.
224001223|NCT07138274|DRUG|Metyrapone 250 mg Oral Tablets|Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg
224001224|NCT07138274|DRUG|Placebo|Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding
224001225|NCT07136246|DEVICE|InBody S10|Bioelectrical Impedance Phase Angle Technology Measured via InBody S10 at six frequencies (1kHz-1000kHz) during each follow-up
224001226|NCT07135726|DEVICE|Patient Portal-Based Access to Clinical Notes|An intra-individual comparison of patient-reported outcomes is planned for the intervention group. For this purpose, the pre-intervention survey of the intervention group is conducted upon inclusion in the study, the post-intervention survey at the earliest after the intervention has been used once (accessing their open note). Due to potential selection bias of the intervention group, which occurs due to voluntary participation in the intervention, a control group is surveyed at t0, which does not participate in the intervention, so that an adjustment for the systematic differences, if any, between the intervention and control group is possible at t0. The survey of a post-intervention control group (t1) serves to adjust for any time-varying effects so that a general time effect can be ruled out.
224001227|NCT07135674|DRUG|placebo gel|local drug delivery of placebo gel
224001228|NCT07135674|DRUG|herbal drug|local drug delivery of herbal gel
224001229|NCT07137468|OTHER|Surveys|Electronic surveys will completed via REDCap.
224001230|NCT07137468|OTHER|Video|Focus group sessions and community forums will be conducted via videoconference (Zoom)
223384138|NCT04321629|COMBINATION_PRODUCT|autologous adipose tissue transfer|experimental group: liposuction, adipose tissue preparation and intra-articular injection
224001231|NCT07035379|DRUG|TRS005|TRS005 will be administered at a starting dose of 0.8mg/kg IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles (up to 8).
224001232|NCT07035379|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
223384139|NCT04321629|COMBINATION_PRODUCT|PRP injections|control group: blood collection, blood preparation and intra-articular PRP injection
223384140|NCT06582017|BIOLOGICAL|QXL138AM Injection every 2 weeks by IV Infusion|masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a
223384141|NCT00402077|DRUG|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
223384142|NCT00402077|DRUG|sibutramine|oral tablet, once a day, 10mg
223545437|NCT02943317|DRUG|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
224001233|NCT07035379|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
224001234|NCT07035379|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
224001235|NCT04571541|DEVICE|Stenting|Effect of endoscopic stenting on healing of esophageal wall defects
224001236|NCT07029360|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri Prodentis®|Daily administration of Limosilactobacillus reuteri Prodentis® (1 oral tablet per day, taken after brushing in the evening), as an adjunct to non-surgical periodontal therapy and standard home care. Administered for 6 months only in the experimental arm.
224001237|NCT07029360|OTHER|Coenzyme Q10 Toothpaste|Twice-daily use of a commercially available toothpaste containing coenzyme Q10, used as part of a home oral hygiene regimen for 6 months. All participants in both study arms will use the same toothpaste, with or without adjunctive probiotic supplementation.
224001238|NCT07039253|BEHAVIORAL|Engaging Together for Health Relationships|Dating violence intervention for caregivers and adolescents to be delivered within pediatric primary care
224001239|NCT07041216|OTHER|Squishy Toy Squeezing|In the intervention group, vein suitability was checked using the DIVA score. A tourniquet was applied, the area was cleaned with antiseptic, and the child squeezed a squishy toy 10 times. Afterward,
224001240|NCT07041216|OTHER|Palpation|In this group, once the vein was identified, the area was gently tapped 8 to 10 times using the inner surfaces of four fingers to stimulate blood flow and enhance vein visibility. This light palpation helped increase local circulation, making the vein easier to access. After the tapping procedure, the area was thoroughly cleaned with an antiseptic solution. Once the skin was completely dry, the catheter was inserted under sterile conditions.
224001241|NCT07041216|OTHER|Routine medical care|This group received standard IV insertion with no extra techniques applied.
224001242|NCT04643483|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive certolizumab pegol in a pre-specified sequence during the Treatment Periods."
224001243|NCT04643483|DRUG|Adalimumab|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive adalimumab in a pre-specified sequence during the Treatment Periods."
224001244|NCT04643483|DRUG|Placebo|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods."
224001245|NCT06717971|OTHER|Exergame-based multicomponent training program.|"The training program for the intervention group utilized the Nintendo Switch game WarioWare: Move It,. Participants engaged with the game through Joy-Con controllers, completing rapid micro-games designed to meet specific movement-oriented objectives. Each game session lasted approximately five seconds, requiring participants to quickly adapt to various physical actions and postures, such as waving, jumping, swinging arms, rotating, and mimicking object movements. The game's dynamic structure provides an engaging experience that promotes physical coordination, reaction speed, upper and lower limb strength, and hand-eye coordination through diverse movement patterns. Switching between tasks compels players to adjust to varying motion demands swiftly, enhancing physical agility while strengthening attention-shifting and quick decision-making skills."
224001246|NCT06717971|OTHER|Standard care|The standard care program for the control group is grounded in routine practices of long-term care facilities, aiming to sustain and enhance the physical and mental well-being of elderly residents through structured group activities. These activities encompass tailored fitness exercises, horticultural therapy, and sedentary group engagements for older adults. The fitness exercises are adapted to meet the varying physical conditions of participants, ensuring a safe and comfortable environment that promotes moderate physical activity. Horticultural therapy involves hands-on planting and tending to plants, stimulating the senses, and fostering emotional regulation, contributing to improved psychological health. Sedentary activities, such as tabletop games, emphasize social interaction and cognitive maintenance by promoting a relaxed social environment that helps participants remain cognitively engaged.
224124059|NCT05078606|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be performed in the sitting position at level of L3-4 or L4- 5 interspaces with a 25-gauge spinal needle. Local infiltration of skin and subcutaneous tissue with 2% lignocaine will be applied. After confirming cerebrospinal fluid flow, 10 mg of 0.5% hyperbaric bupivacaine plus 25 mcg fentanyl will be injected. The degree of sensory block (cold test by alcohol gauze) will be assessed in the study with a goal of T8 dermatomal level block.
224124060|NCT00295698|DRUG|Diethylcarbamazine|
224124061|NCT05858138|OTHER|Jing-Si Herbal Tea|patient will receive twice in a day for 24 weeks
224124062|NCT05858138|OTHER|Placebo Jing-Si Herbal Tea|Placebo Jing-Si Herbal Tea
224124063|NCT06629142|BEHAVIORAL|Default Order|A specialist PC consult is automatically ordered for patients meeting a certain threshold of 1-year mortality risk (dependent on arm). An EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
224124064|NCT06629142|BEHAVIORAL|Accountable Justification|An EHR-based Our Practice Advisory alert asks generalist clinicians to self-report whether they have provided primary PC by clicking which of 4 key PC domains they have addressed or to provide a brief justification as to why not.
224124065|NCT06629142|BEHAVIORAL|Standardized Usual Care|Moderately high-risk patients (e.g., with a 1-year mortality risk between 60% and 94%) will receive usual care. For very high-risk patients (e.g., with a 1-year mortality risk of ≥ 95%), an EHR-based Our Practice Advisory (OPA) alert on Open Chart informs clinicians when the default order will become active, and how to cancel an order within 24 hours if they elect to do so.
224124066|NCT06203912|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224124067|NCT06203912|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224124068|NCT06203912|DRUG|Cyclophosphamide|Given IV
224124069|NCT06203912|DRUG|Dexamethasone|Given PO
224124070|NCT06203912|PROCEDURE|Echocardiography|Undergo echocardiography
224124071|NCT06203912|BIOLOGICAL|Isatuximab|Given IV
224124072|NCT06203912|OTHER|Questionnaire Administration|Ancillary study
224124073|NCT06203912|BIOLOGICAL|Universal Donor Expanded TGF-beta-imprinted NK Cells|Given IV
224001247|NCT06707103|DRUG|TR987 0.1% gel + Standard of Care|6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)
224001248|NCT06707103|OTHER|Standard of care|Standard of Care (wound cleansing/dressings and compression bandaging)
224001249|NCT07043595|PROCEDURE|Whole-Body Vibration (WBV)|Participants will stand quietly in an upright position while whole-body vibration (WBV) is applied through a vibration platform. The vibration stimulus is delivered while the participant's left foot remains on the vibration surface and the right foot is elevated or isolated. H-reflex recordings are taken from the soleus muscle during the procedure to assess spinal reflex modulation due to mechanical loading.
224001250|NCT02755870|OTHER|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
224001251|NCT02755870|OTHER|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
224001252|NCT06888557|BEHAVIORAL|Smartphone-based self-management support program ( 3S-C)|The 3S-C include: (1) two 30-minute individual sessions ; (2) a set of instant messages, 10-minute telephone-delivered health coaching ; (3) continuous personalized chat-based messaging, phone call support, and hotline service ; (4) an e-platform for goal setting and self-monitoring ; (5) A mutual support group session.
224001253|NCT07047976|DIETARY_SUPPLEMENT|Sulforaphane|This intervention involves the administration of Sulforaphane, a compound derived from glucoraphanin found in cruciferous vegetables. Participants will receive Avmacol® tablets, each containing 30 mg of glucoraphanin (approximately 68 μmol per tablet). They will take 3 tablets daily, resulting in a total daily dosage of approximately 90 μmol of Sulforaphane. The intervention will last for 8 weeks, during which participants will be monitored for clinical and biological outcomes.
224001254|NCT06729229|DIETARY_SUPPLEMENT|Placebo|Experimental - 2 portions of fish (280g) per week and placebo supplement (corn oil)
224001255|NCT06729229|DIETARY_SUPPLEMENT|Dietary Supplement/Vitamins|Experimental - Control lunch (no fish) and omega 3 supplement
224001256|NCT06729229|DIETARY_SUPPLEMENT|Placebo|Placebo comparator - Control lunch (no fish) and placebo supplement
224001257|NCT06729229|DIETARY_SUPPLEMENT|Dietary Supplement/Vitamins|Experimental - 2 portions of fish (280g) per week and omega 3 supplement
224001258|NCT06717178|DRUG|Chemotherapy|Admission to the hospital for a new chemotherapy regimen (initial or change)
224001259|NCT06732648|DRUG|HRS8179 injection|HRS8179 injection; high dose
224001260|NCT06732648|DRUG|HRS8179 blank preparation.|HRS8179 blank preparation.
224001261|NCT07044401|DRUG|KAI-9531|SC Injection.
224001262|NCT05040347|OTHER|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3) and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
224001263|NCT06745765|DEVICE|Virtual reality headset|Patients will use virtual reality before the procedure in addition to usual preoperative care.
224001264|NCT06015750|DRUG|methotrexate|Methotrexate will be administered SC or orally weekly for 104 weeks.
224001265|NCT06015750|DRUG|rituximab|Rituximab will be administered intravenously (IV) continuously weekly, for up to 74 weeks.
224001266|NCT06015750|DRUG|bortezomib|Bortezomib will be administered via IV bolus or SC, as needed.
224124074|NCT05505643|DEVICE|Endocare SlimLine Cryoprobe|"The Endocare(TM) SlimLine (TM) Cryoprobe is a single use, disposable device designed for use with Endocare Cryocare Surgical Systems. Endocare cryoprobes are designed to deliver cold temperatures for cryoablation using high-pressure argon gas circulated through the cryoprobe, followed by active thawing using helium gas.~The Cryocare CS Surgical System is intended for use in open, minimally invasive, or endoscopic surgical procedures in the areas of general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery. The system is designed to freeze/ablate tissue by the application of extreme cold temperatures."
224124075|NCT05505643|PROCEDURE|Lumpectomy|Patients randomized to cryoablation who experience disease recurrence may undergo crossover to lumpectomy.
223384143|NCT00402077|DRUG|phentermine|oral tablet, once a day, 37.5mg
223384144|NCT00402077|DRUG|placebo|subcutaneous injection, three times a day
223384145|NCT04768660|OTHER|gum|Other: Chewing gum ChiczaTM organic chewing gum 6 pieces a day Other: Glucose 12ml glucose solution (13,6g) per day
224001267|NCT06015750|DRUG|IVIg|IVIg will be administered via IV monthly through initial 74 weeks.
224001268|NCT06015750|DRUG|Folic Acid|Folic acid will be given orally as long as methotrexate is being dosed.
224124076|NCT02991950|DRUG|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
224124077|NCT01701583|DRUG|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
223384146|NCT04828174|DRUG|anti-TRBC1 CAR-T cell therapy|TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
223384147|NCT03825718|BIOLOGICAL|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.
223384148|NCT04385537|DIETARY_SUPPLEMENT|PECAN|Raw pecan halves without other changes to their habitual diet.
223384149|NCT05743010|DRUG|APL-1401|APL-1401 capsules orally once daily
223384150|NCT05743010|DRUG|Placebo|Placebo capsules orally once daily
223384151|NCT01833663|DRUG|Solifenacin Succinate Tablets|
223384152|NCT01833663|DRUG|Estrogen|
224001269|NCT06792500|DRUG|Glycerol Tributyrate|Participants will be administered orally three times a day enteric hard capsules containing 500 mg of glycerol tributyrate with an 8-ounce glass of water on an empty stomach: morning, noon, and evening during the dose-escalation phase. Each MELAS participant will undergo a six-month dose escalation phase of glycerol tributyrate, starting at a dose of 1,000 mg (tid) per day during the first month followed by a monthly increase of 500 mg (tid) per dose of glycerol tributyrate with the maximal oral dose of glycerol tributyrate 3,500 mg (tid) per dose at the end of six-month-long dose escalation phase. Once the participant-specific fixed maximum tolerated dose (MTD) is determined, MELAS participants will take an oral administration of this MTD three times a day during the 12-month-long clinical phase.
223384153|NCT03845192|DEVICE|ORI measurement by Radical 97|"ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®."
223384154|NCT02595801|OTHER|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
223384155|NCT05808322|DRUG|Ropeginterferon alfa-2b|A maximum of 3 doses of ropeginterferon alfa-2b will be given biweekly during the whole study period. A single dose of 250 μg ropeginterferon alfa-2b will be subcutaneous administrated at Day 1 visit. SARS-CoV-2 antigen test will be conducted at D15 and D29 visits. For patients who still have positive result in SARS-CoV-2 antigen test at Day 15 visit, the second dose of ropeginterferon alfa-2b at 350 μg will be subsequently administered at Day 15 visit. For patients who still have positive result in SARS-CoV-2 antigen test at Day 29 visit, the third dose of ropeginterferon alfa-2b at 500 μg will be administered at Day 29 visit.
223384156|NCT05808322|PROCEDURE|SOC|SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
223384157|NCT01379846|BIOLOGICAL|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
223384158|NCT01379846|BIOLOGICAL|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
223384159|NCT01811472|DRUG|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
223384160|NCT01811472|DRUG|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
223384161|NCT05664269|DIETARY_SUPPLEMENT|drink ingestion|drink ingestion of a vanilla-flavoured beverage from a non-transparent shaker
223384162|NCT05664269|BEHAVIORAL|resistance-type exercise|Lower body resistance-type exercise on the supine leg press and seated knee extension machine. Both machines 4 sets at 80% 1RM for 8-10 reps.
223384163|NCT05697614|DRUG|Valproic acid|valproic acid is used for general epilepsy type, used in experimental group
223384164|NCT05697614|DRUG|Carbamazepin|carbamazepine is used for focal type epilepsy, used in experimental group
223384165|NCT05697614|DRUG|Phenytoin|phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
224001270|NCT07069218|DRUG|Biorepair® Total Protection Plus Toothpaste|Participants will use Biorepair® Total Protection Plus toothpaste twice daily for 6 months. The toothpaste contains biomimetic microRepair® particles based on zinc-substituted hydroxyapatite, intended to promote enamel remineralization, reduce sensitivity, and protect against erosion and plaque accumulation. Professional dental cleanings will also be performed every 3 months.
223384166|NCT05697614|DRUG|Lamotrigine|lamotrigine is used for general epilepsy type, used in control group
223384167|NCT05697614|DRUG|Clobazam|clobazam is used for both general or focal epilepsy in case if lamotrigine or oxcarbazepine is not possible to be administered and is used particularly in myoclonic jerk , used in control group
223384168|NCT05697614|DRUG|Oxcarbazepine|oxcarbazepine is used for focal type epilepsy, used in control group
223384169|NCT01525914|DRUG|Dutasteride|dutasteride 0.5mg daily
223384170|NCT02941835|RADIATION|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
223384171|NCT03280264|DRUG|KHK7580|oral administration
223384172|NCT02071030|PROCEDURE|Third molar removal|Surgically removing the third molar in the lower jaw
223384173|NCT01901926|PROCEDURE|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
223384174|NCT00003610|DIETARY_SUPPLEMENT|capsaicin|
223384175|NCT00003610|OTHER|placebo|
223384176|NCT00003610|RADIATION|radiation therapy|
223384177|NCT05153525|DRUG|Intermittent boluses of Cisatracurium|Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
223384178|NCT05153525|DRUG|Intravenous infusion of Cisatracurium for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
224001271|NCT07069218|DRUG|Bioniq® Toothpaste|Participants will use Bioniq® Repair toothpaste twice daily for 6 months. The toothpaste contains 20% conventional hydroxyapatite and is designed to restore enamel, reduce dentin hypersensitivity, and protect against erosion. Professional dental cleanings will also be performed every 3 months.
224001272|NCT07064564|DRUG|Naltrexone implant, 14.4 grams|Subcutaneous bioresorbable implant containing 14.4 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
224001273|NCT07064564|DRUG|Naltrexone implant, 9.6 grams|Subcutaneous bioresorbable implant containing 9.6 grams of naltrexone, inserted into the thigh on Day 1 and designed to release drug steadily over 12 months.
223384179|NCT01043887|DRUG|ridaforolimus|single oral dose administration 10 mg ridaforolimus
223384180|NCT01377220|DRUG|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
223384181|NCT02275169|DRUG|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
223384182|NCT02275169|OTHER|Placebo|Placebo ampoules administered three times a week for three months
223545438|NCT04588636|BEHAVIORAL|behavioral and self-care therapy|It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
223545439|NCT04588636|DEVICE|rigid occlusal splint (ROS)|Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
224001274|NCT07064564|DRUG|Extended-release naltrexone injection, 380 mg|Intramuscular injection of 380 mg extended-release naltrexone (Vivitrol), administered every 4 weeks for 12 months as the active comparator.
223545440|NCT04588636|DEVICE|soft occlusal splint (SOS)|Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
223384183|NCT04254848|OTHER|oral stereognostic test|Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
223384184|NCT03719625|DRUG|Ephedrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
224001275|NCT07137260|DEVICE|Accelerometer (measurement of walking activity)|Wearing an accelerometer (size 23x32,5x8,9 mm, weight 11g) on the lower back consistently for one week at a time to measure walking activity. The sensor is fixed with waterproof plasters. No feedback is given to the participant while wearing the sensor and no data can be read directly from the sensor.
223384185|NCT03719625|DRUG|Norepinephrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
223384186|NCT02738138|DRUG|ABT-493 coformulated with ABT-530|Tablet
224001276|NCT07137520|OTHER|Observation without intervention|Observation without intervention
224001277|NCT07138131|DRUG|Omega 3|Patients received omega-3 supplementation for 3 months.
224001278|NCT07138131|OTHER|Standard follow-up|Patients received standard follow-up without treatment.
224001279|NCT07138352|DRUG|XS003 under fed and fasted condition|XS003 under fed and fasted condition
224001280|NCT07138365|PROCEDURE|oral Cryotherapy|custom made plastic pack measuring 2.5 X5 cm containing ice gel will be placed intraorally in the mouth on the vestibular surface of the treated tooth.
224001281|NCT07138365|PROCEDURE|Intra radicular Cryotherapy|Final flush was done with cold (2-4 oC) Saline for 10 mins.
224001282|NCT06623097|BEHAVIORAL|Supervised Exercise and Diet Program|A home-based, virtually supervised, moderate-to-vigorous aerobic and resistance exercise intervention with a certified cancer exercise trainer. The exercise sessions will include aerobic exercise on a stationary bicycle and total-body resistance training using resistance bands. Stationary bicycle, resistance bands, activity tracking watch, and Wi-Fi enabled tablet (if needed) will be provided to participants. Dyads will receive remotely delivered nutrition coaching sessions (via telephone or video conferencing) with a health coach each week. Mediterranean eating pattern goals will be tracked using the journal feature of the My Wellness Research platform website.
224001283|NCT06623097|BEHAVIORAL|Unsupervised Exercise and Diet Program|A home-based, unsupervised moderate-to-vigorous aerobic and resistance exercise intervention. The exercise sessions will include aerobic exercise on a stationary bicycle and total-body resistance training using resistance bands. Stationary bicycle, resistance bands, activity tracking watch will be provided to participants. Dyads will receive Mediterranean eating pattern goals, with an introductory session conducted by research staff. Diet intake will be tracked using the journal feature My Wellness Research platform website.
224001284|NCT03838991|OTHER|Blood sample|A study specific blood sample will be collected.
224001285|NCT03838991|OTHER|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
224001286|NCT07089862|DRUG|Indobufen treatment|Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.
224001287|NCT07089862|DRUG|Aspirin treatment|Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively.
224001288|NCT07089147|OTHER|questionnaire|Paris questionnaire, EuroQool (EQ-5D-3L) Questionnaire, Low Back Outcome Score
224001289|NCT06906510|DIAGNOSTIC_TEST|Salivary and Serum TMAO Mesurement|Salivary and serum TMAO levels were measured by liquid chromatography-mass spectrometry (LC-MS/MS)
224001290|NCT06906510|DIAGNOSTIC_TEST|Salivary and Serum TNF-α Mesurement|Salivary and serum TNF-α levels were measured by ELISA
223545441|NCT04588636|DEVICE|non-occlusive splint (NOS)|non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
223729953|NCT03423095|BEHAVIORAL|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
223729954|NCT00662363|DRUG|Lubiprostone|24 µg po BID given with meals for 6 days
223729955|NCT00662363|DRUG|Senna|2 tabs daily for 6 days
223729956|NCT01379547|BEHAVIORAL|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
223729957|NCT01379547|BEHAVIORAL|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
224001291|NCT06907602|DRUG|Chemotherapy|carboplatin plus nab-paclitaxel
224001292|NCT06907602|DRUG|Immunotherapy (Pembrolizumab)|Pembrolizumab
224001293|NCT06907602|RADIATION|radiotherapy|40-45Gy/20fx，5 times a week
224001294|NCT06902883|DEVICE|Serum holder connected to the wheelchair|Serum holder connected to the wheelchair
223729958|NCT05495256|DEVICE|Respimetrix|The Respimetrix device has a low resistance airflow sensor with an inhaler to measure patients inspiratory airflow and volume. This device will thereby provide quantifiable measures of lung function and bronchodilator delivery.
224001295|NCT06902883|DEVICE|wheelchair seat|wheelchair seat
224001296|NCT06435273|DRUG|AZD4604|Janus kinase 1 (JAK1) inhibitor
224001297|NCT06435273|DRUG|Placebo to AZD4604|Placebo to AZD4604
224001298|NCT07089745|BEHAVIORAL|Mindfulness-Based Intervention|MBI is a treatment offered as standard clinical care, billable treatments at the Duke ADHD Program. There are eight 90 minute long sessions.
223384187|NCT05477836|DEVICE|MiWEndo-assisted colonoscopy|"All colonoscopies will be performed with high-definition technology. The MiWEndo System (MiWEndo Solutions, Barcelona) will be fitted to the tip of the endoscope before colonoscopy is started and connected to the microwave processor unit. Endoscopies will be performed by experienced endoscopists who will be previously trained on the use of the MiWEndo System.~At the beginning of the extubation, the MiWEndo System will be turned on. During extubation, each segment will be carefully examined with both white light and MiWEndo. In case one of them identifies a polyp, the exploration will be stopped and check if it has been detected by the alternative method as well. All the polyps will be resected and sent to the Pathological Department for histological analysis following the usual clinical practice. A stopwatch will be used to measure both total procedure time and withdrawal time."
223384188|NCT00295893|DRUG|cyclophosphamide|Given IV
223384189|NCT00295893|DRUG|docetaxel|Given IV
223384190|NCT00295893|DRUG|doxorubicin hydrochloride|Given IV
224001299|NCT07089745|BEHAVIORAL|Organizational Skills Training|OST is a treatment offered as standard clinical care, billable treatments at the Duke ADHD Program. There are eight 90 minute long sessions.
224001300|NCT05877027|OTHER|Exercise|The first 3 weeks of the exercise program will include range of motion exercises, isometric and isotonic strengthening exercises for the muscles around the knee and hip, and stretching exercises. In the following 3 weeks, resistance strengthening exercises and closed kinetic chain exercises will be added to the program.
224001301|NCT05877027|OTHER|Topical Diclofenac|They will apply it around the knee joint 4 days a week, 2 times a day (every 12 hours), morning and evening for 6 weeks.
224001302|NCT05877027|OTHER|Platelet-Rich-Plasma (PRP)|8 ml of blood will be taken from each patient in tubes containing 0.9 ml of 3.2% sodium citrate. Swing-out rotor (open-swing type) will be placed in the centrifuge with the tubes facing each other. After centrifugation, 2.5 cc of PRP product will be collected from each tube and the resulting PRP will be administered to patients by injection under sterile conditions.
224001303|NCT06912529|PROCEDURE|Leukapheresis|Axicabtagene ciloleucel is prepared from the patient's peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure.
224001304|NCT06912529|DRUG|Bridging Therapy|Bridging therapy refers to treatment used to control a patient's disease or disease related inflammation prior to lymphodepletion.
224001305|NCT06912529|DRUG|Lymphodepletion|Patients will receive a non-myeloablative lymphodepleting regimen consisting of fludarabine and cyclophosphamide (FC) to induce lymphocyte depletion and create an optimal environment for expansion of axicabtagene ciloleucel in vivo.
223729959|NCT03273374|DEVICE|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
224001306|NCT06912529|GENETIC|Axicabtagene Ciloleucel|Patient will receive the axicabtagene ciloleucel infusion in the hospital followed by daily monitoring in the hospital.
224001307|NCT07137806|PROCEDURE|sacroiliac joint injection|Ultrasound-guided injection of the SI joints The patient is placed in a prone position to receive this injection treatment. The Curvilinear transducer is placed in a transverse orientation to identify the sacral hiatus first. After identifying the sacral cornu, the transducer is moved in a lateral direction until the lateral edge of the sacrum is observed. With the transducer maintained in the transverse orientation, it is then moved in a cephalad or upward direction until the bony contour of the ileum is identified. The cleft between the bony contours of the sacrum and ileum represents the posterior aspect of the SI joint. By tilting the transducer in a caudal direction, the lower one third of the SI joint is identified. Because of its synovial component, the lower one third of the SI joint is the portion of the entire SI joint in which the injection should be performed. The medial to lateral approach and intraarticular deposition is preferred for the ultrasound-guided SI joint
224124078|NCT04282226|DEVICE|active transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.
224124079|NCT04282226|DEVICE|sham transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
224124080|NCT01441440|DRUG|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
224124081|NCT01441440|DRUG|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
224124082|NCT01441440|DRUG|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
224124083|NCT01248234|DRUG|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
224124084|NCT01248234|DRUG|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
223384191|NCT00295893|BIOLOGICAL|Trastuzumab|Given IV
223384192|NCT00295893|DRUG|Carboplatin|Given IV
223384193|NCT00295893|DRUG|Paclitaxel|Given IV
223384194|NCT03894644|OTHER|Simulation technology|The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
223384195|NCT00012922|BEHAVIORAL|Low Literacy Intervention for Colorectal Cancer Screening|
223384196|NCT00381979|OTHER|Supportive Expressive Therapy|
223384197|NCT01184651|BEHAVIORAL|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
223384198|NCT01184651|BEHAVIORAL|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
224124085|NCT01248234|DRUG|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
223384199|NCT05209529|DRUG|olaparib|olaparib 300 mg per os BID
224001308|NCT07137806|PROCEDURE|combined sacroiliac joint injection and sub maltifidous plane block|patients will be positioned prone. A 6-13 MHz linear array ultrasound transducer was placed in the parasagittal orientation with the second sacral foramen (SF-2) in the field. A 21G short bevel needle is inserted in-plane approach from the cephalad to the caudad direction. After hitting the underlying bone, twenty millilitres of local anaesthetic solution (1:1 mixture of lidocaine 2% and bupivacaine 0.25%) will be injected. An anechoic LA spread in the plane between the multifidus muscle (MFM) and the hyperechoic bony area (between the median and intermediate sacral crests) will be confirmed. The Curvilinear transducer is placed in a transverse orientation to identify the sacral hiatus first. After identifying the sacral cornu, the transducer is moved in a lateral direction until the lateral edge of the sacrum is observed. With the transducer maintained in the transverse orientation, it is then moved in a cephalad or upward direction until the bony contour of the ileum is identified.
224001309|NCT07138391|DRUG|chamomile gummy|The chamomile gummy used in this study was Zarbee's Gentle Bedtime Gummies for Kids (Zarbee's Inc., USA).
223384200|NCT05209529|DRUG|Durvalumab|durvalumab 1500 mg IV Q4 weeks
223384201|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
223384202|NCT03213444|DRUG|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
223384203|NCT03517501|DRUG|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
223384204|NCT03517501|DRUG|Placebo Comparator - Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
224001310|NCT07138391|DIETARY_SUPPLEMENT|a multivitamin gummy|multivitamins gummies for kids
224001311|NCT07136727|OTHER|AI-assisted comprehensive management system|Precision Risk Stratification and personalized treatment recommendation through AI models may improve the suitability of treatment regimens and thus reduce the incidence of antineoplastic therapy-related adverse effects (e.g. , reduction of chemotherapy toxicity through nutritional intervention) , and improve the efficacy of chemotherapy, and prolonged progression-free survival (PFS) and overall survival (OS)
224001312|NCT06927362|OTHER|Lee Silverman treatment big|"Half of the treatment sessions consist of standardized multidirectional whole-body movements performed with maximal amplitude of reaching and stepping. The second half is designed to address individual deficits in movement that occur in activities of daily living.~Dosage: 4 consecutive days a week for 12 weeks (16 sessions in one month) for 60 minutes Repetitions: minimum 8-16 repetitions/task"
223384205|NCT00555165|DEVICE|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
224001313|NCT06927362|OTHER|Dual task training|Group B will receive cognitive motor dual task training for 60 minutes, 4 times a week for 12 weeks. The intervention include both motor and cognitive components.
224001314|NCT06137287|DRUG|BOTOX|Intramuscular Injection
224001315|NCT06137287|DRUG|Placebo for BOTOX|Intramuscular Injection
224001316|NCT07105319|DRUG|Ropeginterferon|"1. Investigational arm with Ropeginterferon (50 patients): Patients will be treated with 250 μg at week 0, 350 μg at week 2, and then 500 μg at week 4, and thereafter bi-weekly subcutaneous injection until week 24~2. Comparator arm (50 patients): Patients will be followed with no further CML treatment"
224001317|NCT06102356|OTHER|Questionnaire|DLQI TSQM v.II PHQ-9 DS14
224001318|NCT07113626|BEHAVIORAL|Mobile app|The intervention will be a mobile app adapted from HealthMindr - an app based on Social Cognitive Theory - for young men who have sex with men in Vietnam. The app, which was developed and tested in the US, offers a range of testing and prevention services, including self-screening for HIV and sexually transmitted infection (STI) risk, a scheduling and reminder system for HIV/ STI testing, PrEP eligibility screener, an ordering platform for delivery of at-home test kits and condoms, and locators for HIV services. Additional features and contents might be revised and added depending on the needs of young men who have sex with men in Vietnam.
223384206|NCT01044550|PROCEDURE|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
223384207|NCT01044550|OTHER|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
223384208|NCT01542814|DEVICE|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
223384209|NCT01542814|DEVICE|2D FFDM|Standard of care screening mammogram.
223384210|NCT03295955|DRUG|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
223384211|NCT00436410|BIOLOGICAL|colloidal gold-bound tumor necrosis factor|
223384212|NCT00436410|OTHER|electron microscopy|
223384213|NCT00436410|OTHER|pharmacological study|
223384214|NCT00436410|PROCEDURE|conventional surgery|
223384215|NCT00635310|PROCEDURE|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
223384216|NCT00635310|PROCEDURE|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
223384217|NCT00165555|DRUG|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
223384218|NCT00165555|DRUG|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
223545442|NCT00143559|DRUG|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
223545443|NCT00143559|PROCEDURE|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
223384219|NCT06371625|PROCEDURE|Transeversus Thoracic Plane Block (TTPB) and Pectoral Nerves (PECS) Block|The TTP block will be performed in a supine position before general anesthesia. First, a high linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified. A total of 15 mL of 0.25% bupivacaine will be injected into the interfascial plane, between the transversus thoracic muscle and the internal intercostal muscle between the fourth and fifth costal cartilages connecting at the sternum. Pleural downward displacement will be used as an ultrasound endpoint.
223384220|NCT06371625|PROCEDURE|Pectoral Nerves (PECS) Block|Patients positioned supine with the ipsilateral arm abducted and externally rotated. The infra-clavicular and axillary regions will be cleaned with chlorhexidine. The skin point of and once the structures are identified with ultrasound, the probe will be positioned under the lateral third of the clavicle. After locating the subclavian artery, the axillary artery and the axillary vein we will move the probe distally towards the axilla, until the pectorals major muscle is identified. We will start counting the ribs, from 1st rib under the axillary artery and maintaining the pectorals major. Serratus anterior muscle cover 2nd, 3rd, 4th rib, this point being the entrance into the anterior axillary line we will use atraumatic needle with extension line and electrode for nerve stimulator (Stimuplex D). We will inject 10ml of 0.25% bupivacaine between the pectorals muscles first, then inject 20ml of 0.25% bupivacaine.
223384221|NCT05452018|OTHER|Intervention group|In healthy volunteers, activity measurement of muscles of interest by intramuscular electromyography during predefined swallowing tasks
224001319|NCT07116096|DEVICE|Jamar Hand Dynamometer, Hand Dynamometer|Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests
224001320|NCT05590949|OTHER|Physical Evaluation|Participants will be assessed at Timepoint 0 (last dose of denosumab injection) and then at 9,12,18 and 24 months following discontinuation of denosumab. The evaluation will include history and pain assessment for development of new fractures, weight and height measurement with BMI (body mass index) calculation, and blood work for bone turnover markers (including serum carboxy-terminal collagen crosslinks (CTX) in serum and bone specific alkaline phosphatase). Bone turn-over markers should be drawn in the morning, after at least 8 hours of fasting (water, black coffee and plain tea allowed).
223384222|NCT01995513|DRUG|Enzalutamide|160 mg by mouth once daily
223384223|NCT01995513|DRUG|Abiraterone|1000 mg by mouth once daily
223384224|NCT01995513|DRUG|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
223384225|NCT01995513|DRUG|Prednisone|5 mg by mouth twice daily
223384226|NCT02120196|DRUG|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
223384227|NCT02120196|DRUG|Norfloxacin|FDA approved:400mg once daily
224001321|NCT05590949|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry scans|Dual-energy X-ray absorptiometry (DEXA) scans will be performed at the 12 months timepoint , and then at the 24 month timepoint.
224001322|NCT05590949|DIAGNOSTIC_TEST|Trabecular Bone Score|TBS is an innovative gray-level texture measurement that utilizes lumbar spine DEXA images to discriminate changes in bone microarchitecture. Specifically, TBS measures bone quality through tridimensional bone areas with different trabecular and microstructural characteristics. The combination of TBS microstructure evaluation with bone density measured by DEXA has been shown to be superior to either measurement alone in the assessment of fracture risk.
224001323|NCT07118527|DRUG|SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection|SHR-A1811: intravenous infusion; Adebrelimab Injection: intravenous infusion; Capecitabine Tablets: oral administration Fluorouracil Injection: intravenous infusion
224001324|NCT07118527|DRUG|Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)|Trastuzumab : intravenous infusion; Pembrolizumab: intravenous infusion; Capecitabine Tablets: oral administration; Oxaliplatin: intravenous infusion; Fluorouracil Injection: intravenous infusion; Cisplatin: intravenous infusion;
224001325|NCT00371098|BIOLOGICAL|Influenza vaccination: Influvac (SolvayPharma)|
224001326|NCT00371098|BIOLOGICAL|placebo influenza vaccine|
224001327|NCT07126795|DRUG|magnesium sulfate|IV Magnesium Sulfate 50 mg/kg (max 2 grams) over 20 minutes given immediately prior to initiation of daily sedated dressing change
224001328|NCT07126795|DRUG|Normal Saline (0.9% NaCl)|Normal Saline given in equivalent volume as study drug over 20 minutes, immediately prior to initiation of sedated dressing change
224001329|NCT07127536|BEHAVIORAL|CO-OP (Cognitive Orientation to daily Occupational Performance)|"The CO-OP approach is a client-centered, performance-based intervention that uses cognitive strategies to help individuals improve performance in meaningful daily activities. In this study, CO-OP sessions will be delivered in addition to standard occupational therapy, 5 days per week for 4 weeks, with each session lasting 45 minutes. The intervention group will receive standard occupational therapy intervention in addition to CO-OP.~Standard Occupational Therapy Therapy sessions will follow the usual care protocols for stroke rehabilitation at the study site."
224001330|NCT07127536|BEHAVIORAL|Standard Occupational Therapy|Participants in this group will receive standard occupational therapy only, without the additional CO-OP intervention. Therapy sessions will follow the usual care protocols for stroke rehabilitation at the study site.
224001331|NCT07129772|DRUG|Gemcitabine (GEM)|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
224124086|NCT05636579|BIOLOGICAL|EO2002|Intracameral injection of magnetic human corneal endothelial cells (EO2002)
224124087|NCT05636579|DRUG|Ripasudil|Daily use of Ripasudil drops
224124088|NCT02929095|DRUG|dexmedetomidine|
224124089|NCT02929095|DRUG|midazolam|
223384228|NCT06045013|DRUG|5% dextrose injection|Single ultrasound-guided injection of 4 ml 5% dextrose in carpal tunnel via ulnar approach.
224124090|NCT02929095|DRUG|remifentanil|\- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
223545444|NCT00143559|DEVICE|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
223384229|NCT06045013|DRUG|5% dextrose injections with methylprednisolone acetate 40 mg/ml|Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
223384230|NCT06272721|DIAGNOSTIC_TEST|Griffiths Scale|The Griffiths Mental Development Scales II are key tools for assessing children's psychomotor development from ages 0 to 6, praised for their strong psychometric properties. They evaluate various functional areas through six subscales, combining parental reports and direct observations of the child's behavior. The areas include locomotion, personal-social interaction, learning and language, eye-hand coordination, and performance, excluding the optional practical reasoning section for older children in this study. The Development Quotient (DQ), calculated by comparing mental and chronological ages, indicates developmental progress or delay, with an average score around 100 ± 15.
223384231|NCT05177679|DIETARY_SUPPLEMENT|Active supplement|Carotenoid supplement comprised of 10mg lutein and 2mg zeaxanthin.
223384232|NCT05177679|DIETARY_SUPPLEMENT|Placebo control|Placebo control supplement
223384233|NCT04534452|DRUG|Phenylephrine HCl (Sinus Comfort, BAY112476)|30 mg Extended Release Tablets, single oral dose
223384234|NCT01232452|DRUG|Pemetrexed|Administered intravenously (IV)
224001332|NCT07129772|DRUG|Cisplatin|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
223384235|NCT01232452|DRUG|Cisplatin|Administered IV
223384236|NCT01232452|DRUG|Cixutumumab|Administered IV
224124091|NCT01253681|DRUG|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
223384237|NCT03105518|DRUG|Fentanyl|0.5, 1 mcg/kg
223384238|NCT03105518|DRUG|Acetaminophen|Single + Oxycodone
224001333|NCT07129772|DRUG|PEMBROLIZUMAB (alone or when added to a regimen above)|Gemcitabine, cisplatin and pembrolizumab for up to 6 cycles followed by minimally invasive surgery (either endoscopic nasopharyngectomy or transoral robotic-assisted nasopharyngectomy) and maintenance pembrolizumab for a total of 1 year for locally recurrent nasopharyngeal carcinoma
224001334|NCT07129460|DRUG|Berberine hydrochloride|Subjects will be instructed to take three tablets (300mg) of Berberine hydrochloride two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
224001335|NCT07129460|DRUG|Placebo|Subjects will be instructed to take three tablets (300mg) of placebo two times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.
224001336|NCT07129122|OTHER|Transventricular access|Transventricular access will perform with LBBAP lead from left subclavian way.
224001337|NCT04746846|DEVICE|UG motion sensor with PDVibe3|UG motion sensor (which detects FoG) on worn each ankle. PDVibe3 (which provides vibration) on worn each ankle
224001338|NCT07135414|PROCEDURE|iTBS|Intermittent theta burst stimulation (iTBS) targeting the left Dorsolateral Prefrontal Cortex (LDLPFC) will be delivered using a figure-of-eight coil at 50 Hz (3 pulses per burst, 5 Hz burst frequency), with 10 bursts over 2 seconds, followed by an 8-second pause, resulting in a 10-second cycle duration, repeated 60 times for a total of 1800 pulses.
224001339|NCT07135414|PROCEDURE|dTMS|Deep TMS (dTMS) targeting the medial prefrontal cortex (MPFC) will be delivered using an H7 coil at 20 Hz for 2 seconds per cycle, followed by a 20-second pause, resulting in a 22-second cycle duration, repeated 50 times for a total of 2000 pulses.
224001340|NCT07135414|BEHAVIORAL|ERP|Patients are admitted to a residential program that includes nonverbal therapies, cognitive behavioural therapy, and from week 3 onward, weekly Exposure Relapse Prevention (ERP) sessions (3 hours/week for 8 weeks; total admission = 10 weeks). ERP includes an inventory of OCD symptoms, psychoeducation on the difference between obsessions and compulsions using an OCD model, and the creation of a stepwise fear hierarchy with exposure and response prevention exercises. Patients practice both during and outside sessions, including at home on weekends. Family involvement is integrated: relatives are invited every three weeks to receive psychoeducation on OCD and ERP, are informed about accommodation behaviors, and may attend a session.
224001341|NCT07137390|DRUG|Regorafenib|Given Orally
224001342|NCT07137390|DRUG|Lorigerlimab|Given Orally
223384239|NCT03105518|DRUG|Oxycodone|With Acetaminophen
224124092|NCT02854137|DRUG|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
224124093|NCT02854137|DRUG|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
224124094|NCT05645029|OTHER|glass ionomer-chlorhexidine|chlorhexidine will be added to glass ionomer
224124095|NCT05645029|OTHER|glass ionomer-titanium dioxide powder|titanium dioxide will be added to glass ionomer
224124096|NCT05645029|OTHER|glass ionomer|glass ionomer will be used without any additives
223384240|NCT00013442|PROCEDURE|Auditory Evoked Response|
223384241|NCT00575237|PROCEDURE|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (\> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
223384242|NCT04108299|BEHAVIORAL|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
223545445|NCT03975153|BIOLOGICAL|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
223545446|NCT02776605|DRUG|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
223545447|NCT02776605|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
223545448|NCT02776605|DRUG|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
224124097|NCT02750813|DEVICE|Delefilcon A contact lenses|
224124098|NCT02750813|DEVICE|Senofilcon A contact lenses|
224001343|NCT07137221|OTHER|Post menopausal breast cancer patients|"All selected patients will undergo peripheral blood samplingfor the evaluation of inflammatory biomarkers and must have agreed to store and use part of their sample for research purposes.~A panel of inflammatory cytokines (IFNγ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, TNFα) will be detected by ELISA assay. Other biomarkers such as RANKL, OPG, Vitamin D levels, CTX, PTH will be evaluated by immunoenzymatic assays. In addition, mirNAs as mir-16 and mir-378 will be evaluated by RT-PCR. Glucose metabolic markers such as fasting glucose and insulin, HbA1c and other parameters such as calcemia, PTH, c-telopeptide etc. will be collected.~In particular, the evaluation of the biomarkers will be done on plasma samples at different time points (previously the administration of 10 course of weekly acupuncture; at the end and 6 months after the end of acupuncture and at the time of symptoms recurrence."
224001344|NCT07138287|PROCEDURE|Concerned Growth factor in management of Mature permanent Molar with irreversible pulpitis|Concerned Growth factor in management of Mature permanent Molar of children with irreversible pulpitis
224001345|NCT07137884|DRUG|Anlotinib+Cyclophosphamide+Vinorelbine|"Anlotinib hydrochloride capsules combined with Cyclophosphamide+Vinorelbine), Anlotinib hydrochloride capsules 8mg (weight ≤35kg) or 12mg (weight \> 35kg), po, qd, D1-D14;on an empty stomach ,Two weeks off for one week，with a cycle of 3 weeks.~Cyclophosphamide 25mg/m2, po, qd, D1-D28, with a cycle of 4 weeks. vinorelbine 60g/m2, po, qw, D1, 8,15, with a cycle of 4 weeks."
224001346|NCT07137884|DRUG|Cyclophosphamide+Vinorelbine|Cyclophosphamide 25mg/m2, po, qd, D1-D28, with a cycle of 4 weeks. vinorelbine 60mg/m2, po, qw, D1, 8,15, with a cycle of 4 weeks.
224001347|NCT07136584|OTHER|Screening, Outcomes and Referral Pathways|"All participants complete baseline screening with follow up at 3 and 6 months. A key feature of the study is that a standardised information resource sheet (to community-based services) is provided to all caregivers, regardless of their screening scores. Primary outcomes focus on implementation feasibility and acceptability, while secondary outcomes examine service uptake and longitudinal measurement of caregiver wellbeing.~This differs from existing research by providing resources universally rather than only to those scoring above clinical thresholds. Our longitudinal follow-up addresses an evidence gap identified in our systematic review - limited published data on downstream effects on actual service uptake and mental health outcomes over time. The services in the resource sheet also link to routine clinical care that doesn't require specialist support programs with dedicated funding."
223729960|NCT02496650|DRUG|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
223384243|NCT04108299|BEHAVIORAL|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
223729961|NCT01737151|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223729962|NCT01737151|RADIATION|four fraction split-course SBRT|four fraction split-course SBRT
223729963|NCT00298545|DRUG|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
224001348|NCT07137195|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
224124099|NCT01998581|DEVICE|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
224124100|NCT01998581|DEVICE|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
224124101|NCT00074100|DRUG|amonafide dihydrochloride|
224124102|NCT01251276|BIOLOGICAL|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
224124103|NCT03665376|DIETARY_SUPPLEMENT|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
224124104|NCT03665376|COMBINATION_PRODUCT|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
224124105|NCT01345123|BEHAVIORAL|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
223384244|NCT03076632|DEVICE|Cervical plus transcranial stimulation|Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
223384245|NCT03076632|DEVICE|Cervical stimulation plus hand/wrist exercise|Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
223384246|NCT03076632|DEVICE|Electromyographic (EMG)-triggered (closed-loop) stimulation|Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
223729964|NCT00298545|DRUG|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
223729965|NCT02744391|DRUG|Levodopa|
223729966|NCT02178202|BEHAVIORAL|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
223729967|NCT02178202|DEVICE|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
223729968|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
223729969|NCT01536847|OTHER|Dietary Intervention|300 mL of liquid food product
223729970|NCT01536847|OTHER|Dietary Intervention|300 ml of liquid food product
223729971|NCT01428453|DRUG|250mg rilapladib|Experimental Drug
223729972|NCT01428453|DRUG|placebo|Placebo comparator
224001349|NCT07139925|OTHER|Self-care of COPD Inventory (SC-COPDI)|Self-care of COPD Inventory (SC-COPDI) - Assess the self-care of patients with IPF by adapting a tool designed for patients with COPD to those affected by IPF
224001350|NCT07139197|BEHAVIORAL|Cognitive Behavioral Approach-Based Psychoeducation Program|"Intervention Group: Cognitive Behavioral Approach-Based Psychoeducation Program Participants will receive a cognitive-behavioral psychoeducation program designed to improve cognitive flexibility and reduce rumination. The sessions include structured activities, discussions, and exercises based on cognitive-behavioral principles. Pre-test assessments will be conducted before group allocation.~Control Group: No intervention will be provided during the study period. Participants will complete pre-test assessments administered by an independent evaluator. After the study concludes, control group participants will be offered the opportunity to participate in the psychoeducation program if they wish."
224001351|NCT06927492|OTHER|Cognitive Sensorimotor training along with whole body vibration|This group will receive sensorimotor training with cognitive dual-task training in addition to whole body vibration. The participants will perform 36 sessions (3 times per week on alternate days over 12 weeks). The duration of one session for each group will be 60 minutes, The whole-body vibration will be administered using a vibration machine. This includes asking the patient to stand barefoot on the vibrator platform evenly distributing their body weight on both feet with knees bent at 20 degrees as flexing of knees is a common postural adaptation used to minimize transmission of vibration to the head. The patients will receive the whole body vibration at 30Hz consisting of three sessions per week with at least one day between sessions for 12 weeks. The time for each session will be 15 minutes (five bouts of 2 min) . There will be a rest of 1 minute between each bout of vibration therapy.
224001352|NCT06927492|OTHER|Cognitive Sensorimotor training|This group will receive sensorimotor training with cognitive dual task training simultaneously. The participants will perform 36 sessions (3 times per week on alternate days over 12 weeks). The duration of one session for each group will be 60 minutes,
224001353|NCT06927310|DRUG|Inpegsomatropin Injection|Inpegsomatropin injection, 280 μg/kg/week, s.c., once weekly, for 52 consecutive weeks.
224001354|NCT06927310|DRUG|Recombinant Human Growth Hormone Injection|Recombinant Human Growth Hormone Injection, 350 μg/kg/week, s.c., divided into 7 doses, i.e., 50 μg/kg/day (0.15 IU/kg/day), once daily for 52 consecutive weeks.
224001355|NCT06929598|BEHAVIORAL|Shiatsu Therapy|Participants will receive one 30-minute session of Shiatsu therapy per week for 6 weeks. Therapy will be provided by trained Shiatsu practitioners under a standardized protocol developed for this study.
224001356|NCT07136597|BEHAVIORAL|Narrative Medicine Workshop|participants will be asked to attend 3/6 monthly narrative medicine workshops through the study's duration following an initial workshop that will be used to introduce the concepts of narrative medicine and flash writing.
224001357|NCT07136233|BEHAVIORAL|Informational Flyer Insert on Enhanced Silver Plan Benefits|Alongside the standard eligibility notice informing participants about their upcoming coverage renewal, an informational flyer is also included. The flyer explains that everyone is eligible in 2025 for the Silver plan regardless of income and highlights its benefits, such as $0 deductibles, lower monthly premiums, free preventive visits, and reduced costs for primary care, emergency care, and medications.
224001358|NCT07137962|PROCEDURE|PENG Block|"The curvilinear low-frequency (2-5 MHz) ultrasound probe was placed over the line parallel to the inguinal ligament. It was subsequently rotated 45° to identify the anterior inferior iliac spine, the ilio-pubic eminence, and the psoas tendon.~A 22-gauge echogenic needle was inserted in plain to place the tip in musculo-fascial plain between pubic ramus posteriorly and psoas tendon anteriorly, using hydro-dissection technique. Following negative aspiration, a total volume of 0.5 ml/kg of 0.25% bupivacaine was injected."
224001359|NCT07137962|PROCEDURE|FICB Block|"The linear ultrasound probe was placed over the inguinal ligament in the sagittal plane, inferomedial to the anterior superior iliac spine. Upon identifying the bow-tie sign formed by the sartorius muscle and the internal oblique muscle by sliding medially and rotating the probe. 22-gauge echogenic needle was introduced 1 cm cephalad to the inguinal ligament to place the needle tip in the space between the internal oblique and iliacus muscles, using the hydro-dissection technique. A total volume of 0.5 mL/kg of bupivacaine 0.25% was injected following negative aspiration."
224001360|NCT07137962|PROCEDURE|Caudal Block|"After induction of general anesthesia, the patient was placed in the left lateral position with the upper hip flexed at 90° and the lower hip flexed at 45°. The region was then swabbed in a craniocaudal direction with a 70% alcohol solution.~After palpating the landmarks (the upper posterior iliac spine and sacral hiatus from the edges of an equilateral triangle), an epidural puncture was performed in the most proximal region of the sacral hiatus with the needle inclined 45-60° to the skin. While palpating with the index finger of the left hand, a needle was inserted immediately below the spinous process S4. After perforating the membrane, which occludes the sacral hiatus, the needle was advanced no more than 1-3 mm to avoid a bloody puncture or an intrathecal injection. Bupivacaine 0.25% at a dose of 1 ml/kg was injected."
224001361|NCT07136324|DEVICE|EUS-guided RFA treatment|A 19-gauge EUS-RFA catheter will be inserted into pancreatic lesions under EUS guidance. RFA energy is then applied in 2-10 cycles with each cycle lasting about 10-30 seconds and the power setting ranging from 10-30 Watts.
224124106|NCT01345123|BEHAVIORAL|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
224124107|NCT04348136|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
224124108|NCT03073681|DEVICE|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
224124109|NCT04869904|PROCEDURE|dental and plaque sampling|sampling of dental plaque and saliva during the treatment
224124110|NCT04430049|PROCEDURE|Covid ICU containment measures|The french containment measures during Covid-19 pandemic result in a restrictive visitation for relatives in ICU
223384247|NCT01662687|DRUG|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
223384248|NCT01662687|DRUG|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~* Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~* Kytril tab. 1mg: administered twice a day by orally at Day 2\~4."
223384249|NCT04841837|BEHAVIORAL|Time-restricted feeding|limit daily food intake to a period of 10 hours
223384250|NCT02807337|DRUG|Caphosol|
223384251|NCT02807337|DRUG|0,9% NaCl|
224001362|NCT07137026|BEHAVIORAL|Personnel intervention and patients|The personnel intervention has three components. They are listed above. The patient intervention will include a brief assessment and intervention.
223384252|NCT05751707|DEVICE|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System|High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System is a clinical device which consists in a pump which generates high frequency oscillations and connected to a jacket worn by the patient, intended to facilitate airway secretions clearance by detaching them from the bronchial wall and moving them upwards in the bronchial system.
223384253|NCT05886205|DRUG|iPSC-Exos|iPSC-Exos were administrated for nasal drip, bid for 12 weeks.
223384254|NCT04492228|OTHER|Ketogenic diet|Eucaloric Ketogenic diet % composition : protein (27%), lipids (67%), carbohydrates (6%: \<30g/day). In pts in artificial nutrition : Eucaloric Ketogenic parenteral nutrition % composition : aminoacids (27%), lipids (67%), carbohydrates (6%: \<30g/day)
224001363|NCT07136896|OTHER|Nutritional Assessment Protocol|Participants will undergo a comprehensive nutritional assessment, including anthropometric measurements (weight, height, BMI, skinfold thickness), dietary intake evaluation through 24-hour recall, and bioelectrical impedance analysis to assess body composition. Relevant biochemical parameters will also be measured to evaluate nutritional status
224001364|NCT07137702|PROCEDURE|Erector Spinae Plane Block|A standardized perioperative care management protocol is applied for all breast-conserving surgery procedures in our department. All patients are informed about ESPB and offered its application preoperatively. Patients who accept the procedure receive ESPB (preoperatively, in the sitting position, at the level of ipsilateral T4 vertebra, USG guided, out-of-plane approach) while those who refuse are subjected to routine intravenous analgesia protocols. All blocks were performed by an anesthesiologist experienced in the application of truncal blocks and 20 cc 0.5% bupivacaine (within the safe dose range for all patients to be used according to their weight) are injected and its spread is visualized under USG.
224001365|NCT07138014|DRUG|FHND1002 100mg|Investigational oral granules containing 100mg FHND1002 (chemical entity: 3-n-butylphthalide derivative). Administered once daily for 48 weeks. Granules are packaged in unit-dose sachets with identical appearance across all study arms. Participants dissolve contents in water prior to ingestion. Stability testing confirms compatibility with fasting or fed conditions.
223384255|NCT02258711|DEVICE|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
224001366|NCT07138014|DRUG|FHND1002 200mg|Investigational oral granules containing 200mg FHND1002 (3-n-butylphthalide derivative). Delivered as two 100mg sachets or one 200mg sachet to maintain blinding. Daily dosing regimen for 48 weeks. Granule composition matches 100mg formulation in excipients and organoleptic properties.
224001367|NCT07138014|DRUG|Placebo|Placebo granules identical to active intervention in appearance, taste, packaging, and administration method. Contains inert excipients (microcrystalline cellulose, lactose monohydrate) without active
223384256|NCT00247676|DRUG|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
223384257|NCT05024747|DRUG|NicoDerm CQ patch (GSK Dungarvan)|A single patch of a NicoDerm CQ (GSK Dungarvan) 21 mg per system of 22 centimeter square (cm\^2) surface area will be placed topically.
224001368|NCT07139327|DEVICE|Cochlear Implant|TICI G2 Clinical Investigation System
224001369|NCT07137858|DRUG|Preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adalimumab 1200mg are administered intravenously. According to the allocation to the short-course group or long-course group, two or three cycles are carried out respectively, and surgery is performed 21 days after the end of the last cycle of medication. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive maintenance therapy with PD-L1 inhibitor (adalimumab) alone. Patients who require radiotherapy and chemotherapy receive maintenance therapy with the drug alone at the same time. The duration of medication for all patients is one year (calculated from the time of the first medication at the initial diagnosis to the last medication after the surgery).
224124111|NCT04529551|OTHER|1601A|A filtered, king size cigarette with a menthol capsule in the filter.
224124112|NCT04529551|OTHER|1601B|A filtered, king size cigarette with a menthol capsule in the filter.
224124113|NCT00981383|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
223384258|NCT05024747|DRUG|NicoDerm CQ (Alza)|A single patch of a NicoDerm CQ (Alza) 21 mg/system of 22 cm\^2 surface area will be placed topically.
223384259|NCT03073824|DEVICE|vSculpt|Pelvic Floor Toning and Vaginal Rejuvenation Device
223384260|NCT05924724|DEVICE|Flash Glucose Monitoring|The FGM is a non-invasive device typically worn on the upper arm, designed to continuously measure blood glucose levels without the need for fingerstick capillary measurements.
223384261|NCT04667624|DRUG|Twynsta|Manufactured by Boehringer Ingelheim
223384262|NCT04667624|DRUG|LodineT|•Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
223384263|NCT03786887|DRUG|Nalbuphine|dosage of nalbuphine
223384264|NCT06278896|DRUG|Cessation of antibiotics|Stop antibiotic therapy after episode of fever if afebrile for 48 hours, no clinically documented source of bacterial infection, and no hemodynamic or respiratory decompensation.
223384265|NCT02728700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223384266|NCT02728700|OTHER|Laboratory Biomarker Analysis|Correlative studies
223384267|NCT02728700|DRUG|Mycophenolate Mofetil|Given IV
223384268|NCT02728700|DRUG|Sirolimus|Given PO
223384269|NCT00257400|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
223384270|NCT00257400|BEHAVIORAL|Individual Psychotherapy|Individual Psychotherapy
224001370|NCT07137858|DRUG|Two courses of preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously. Two treatment courses were carried out in total, and surgery was performed 21 days after the end of the second course of medication. Postoperative radiotherapy and chemotherapy were administered based on the pathological stage. Patients who did not require radiotherapy received adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who required radiotherapy and chemotherapy received monotherapy maintenance during the same period. The duration of medication for all patients was one year (from the first medication time at the initial diagnosis to the last medication time after surgery).
224001371|NCT07137858|DRUG|Three courses of preoperative neoadjuvant immunotherapy chemotherapy|Each treatment course lasts for three weeks. On the first day of each three-week period, albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg are administered intravenously. This treatment is carried out for a total of three cycles, and surgery is performed 21 days after the end of the third cycle. Post-surgery, radiotherapy and chemotherapy are administered based on the pathological stage. Patients who do not require radiotherapy receive adebrelimab (PD-L1 inhibitor) monotherapy maintenance. Patients who require radiotherapy and chemotherapy receive monotherapy maintenance simultaneously. The duration of medication for all patients is one year (from the first administration after diagnosis to the last administration after surgery).
223384271|NCT05927870|PROCEDURE|pigtail|placing a small amount of local anaesthetic subcutaneously at the site of the gallbladder, a skin incision was made through which the catheter was introduced. A 7-Fr pigtail catheter was used in all cases . If possible, the catheter was introduced into the gallbladder after passing through the liver. The catheter was thereafter fixed, either by an internal locking device or by means of a suture to the skin. The catheter was rinsed with saline solution daily in order to prevent clogging.
223384272|NCT00440349|DRUG|Tamoxifen|
223729973|NCT04041804|PROCEDURE|semirapid maxillary expansion (SRME)|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
224001372|NCT07138326|DIAGNOSTIC_TEST|Monitoring|Monitoring
224001373|NCT07136376|OTHER|Physical and social environmental interventions.|To be determined in the co-creation groups at the five sites (Denmark, Germany, Poland, Spain, the Netherlands)
224001374|NCT07135219|DRUG|Biological: cizutamig|Cizutamig will be dosed according to the protocol.
224001375|NCT07137416|PROCEDURE|Biopsy Procedure|Undergo biopsy
224001376|NCT07137416|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224001377|NCT07137416|PROCEDURE|Echocardiography Test|Undergo ECHO
224001378|NCT07137416|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224001379|NCT07137416|DRUG|Pidnarulex|Given IV
224001380|NCT07137416|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic imaging
224001381|NCT07137416|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
224001382|NCT07135648|OTHER|VM16|VM16 contains a liquid with a nicotine concentration of 1.6%
224001383|NCT07135648|OTHER|VM32|VM32 contains a liquid with a nicotine concentration of 3.2%
224001384|NCT07135648|OTHER|Cigarette (CC)|Subjects will provide their own usual brand of commercially available cigarettes
224001385|NCT07136298|OTHER|Clinical Opinion|Staff participants will be asked to review video clips of events captured during EEGs performed on the ICU and asked to state whether they think the event was an epileptic seizure or not, and what aspects of each event led them to that decision
224001386|NCT07137676|BEHAVIORAL|AX-CPT|administration of the AX-CPT
224001387|NCT07137676|OTHER|No Interventions|Control group with no intervention treatment
224001388|NCT07135245|DRUG|Semaglutide (Rybelsus®) combined with other interventions|The full intervention includes treatment with semaglutide (Rybelsus®) 3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, and subsequently 14 mg daily. The intervention will also include candesartan up to 32 mg daily, a multivitamin-mineral tablet containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®)
224001389|NCT07135245|OTHER|Placebo|A control group treated with placebo and no further intervention
224001390|NCT07135245|DRUG|Semaglutide (Rybelsus®)|An intervention group treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily and placebo
224001391|NCT04255810|PROCEDURE|Surgical collection of biospecimens|Systemic blood and implant capsule tissue will be collected from two cohorts with breast implants, systemic blood only will be collected from Mastopexy cohort
224001392|NCT06935344|GENETIC|Polygenic Risk Score|For the PRS analysis, SNPs for genotyping will be selected based on the latest findings from GWAS on EOC, particularly leveraging the results, as reported by Dareng et al. (doi:10.1038/s41431-021-00987-7). The PRS will be calculated as a weighted sum of risk alleles based on the selected SNPs.
224001393|NCT01835353|DRUG|Prasugrel 100mg loading dose|
224001394|NCT01835353|DRUG|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
223384273|NCT00440349|DRUG|Prednisone|
223384274|NCT05345106|PROCEDURE|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
223384275|NCT01494259|DRUG|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
223384276|NCT01494259|DRUG|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
223729974|NCT01996709|DEVICE|Hydrogen peroxide-based contact lens solution|
223729975|NCT01996709|DEVICE|Habitual contact lens solution|Biguanide-preserved
223729976|NCT01996709|DEVICE|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
223729977|NCT02412423|DRUG|post-transplantation cyclophosphamide|
224001395|NCT06939023|PROCEDURE|Laparoscopic minimally invasive left-sided pancreatecomy|Laparoscopic minimally invasive left-sided pancreatecomy
224001396|NCT06939023|PROCEDURE|Robot-assisted minimally invasive left-sided pancreatecomy|Robot-assisted minimally invasive left-sided pancreatecomy
224001397|NCT06938438|PROCEDURE|single locking miniplate|Ten patients in whom anterior mandibular fractures will be fixed with titanium single locking miniplate
224001398|NCT06938438|PROCEDURE|double conventional miniplates.|Ten patients in whom, anterior mandibular fractures will be fixed with double conventional titanium miniplates.
224001399|NCT06939933|OTHER|aquatic exercise in addition to physical exercise|"Aquatic exercise refers to the use of water that facilitates the application of established therapeutic interventions, including stretching, strengthening, joint mobilization, balance and gait training and endurance training. Water has been throughout history for a variety of purposes including ; physical therapy, rehabilitation and sport. There activities are made possible by water's special qualities and the influence of these attributes on humans.~Hydrotherapy is one of the most popular forms of complementary therapies that help in the treatment of children with disabilities. It is known to provide an opportunity to the children to do easier exercise. It also improves .~Physical therapy and tailored exercise programs can help improve muscle strength, endurance, and overall physical function in children with SCA. Such programs need to be carefully designed to avoid triggering pain crises while promoting physical health and improving quality of life."
224001400|NCT06939933|GENETIC|designed physical exercises only|"Physical therapy and tailored exercise programs can help improve muscle strength, endurance, and overall physical function in children with SCA. Such programs need to be carefully designed to avoid triggering pain crises while promoting physical health and improving quality of life (Ballas et al., 2010).~benefit from anaerobic activity patterns (Dougherty et al., 2018). A study to examine maximal muscle strength and peak power in children with sickle cell anemia found that maximal muscle strength and peak power are significantly less in children with sickle cell anemia compared to the control group"
224001401|NCT07143006|DEVICE|BestShape Go Intelligent Generation Transformable Electric Vehicle|The specific applications of artificial intelligence in intelligent electric vehicles mainly include gait monitoring and analysis, real-time feedback and guidance, autonomous adaptive assistance, safety prevention and warnings, data collection and long-term tracking, as well as adding interactive and entertainment elements.
224001402|NCT07144696|BEHAVIORAL|structured education and regular follow-up|Regularly carry out structured diabetes courses for patients with type 1 diabetes and offline teaching at Peking University First Hospital. On the basis of structured courses, regular outpatient follow-up visits will be conducted for patients, with on-site visits conducted at the Endocrinology Clinic of Peking University First Hospital. The usual visit period is once every 1-3 months, and the specific follow-up time nodes will be determined by medical staff based on the patient\&amp;#39;s condition. Each visit will last 1-3 hours, and each subject is expected to be followed up for 1 year. During each visit, collect the medical history and some personal information of the subjects, complete the routine physical examination, draw blood to test diabetes related indicators (including the determination of fasting
224001403|NCT06939153|OTHER|LBNP|Participants will be exposed to a lower body negative pressure chamber protocol consisting of 5-min stages in the order of 20, -30, -40 and -50 mmHg.
224001404|NCT06939153|OTHER|LBNP + Isometric handgrip exercise|Participants will undergo 5-minute stages of LBNP at -20, -30, -40, and -50 mmHg in sequence. During the -30, -40, and -50 mmHg stages, they will perform a 2-minute isometric handgrip exercise, starting at the third minute and sustaining it for the remaining duration.
224001405|NCT07136714|DRUG|Semaglutide Injectable Product|Semaglutide (Wegovy) once-weekly injection s.c
224001406|NCT07136714|DRUG|Placebo|Placebo (BD Posiflush) once-weekly injection s.c
224001407|NCT07137481|DRUG|C9/CD5CAR/IL-15 NK cells|Given PO or IV
224001408|NCT07137481|DRUG|Rituximab|Given by IV
224001409|NCT07137481|DRUG|Fludarabine|Given by IV
224001410|NCT07137481|DRUG|Cyclophosphamide|Given by IV
224001411|NCT07135284|DEVICE|Airway clearance system|The device is prescribed as part of each participant's regular medical care, independently of the study. The study does not assign the device or alter standard treatment. Participants are observed while using the device as part of their usual care.
224001412|NCT07136818|BEHAVIORAL|Dynamic 9-Square Grid Health Management with Weekly Feedback|A dual-axis management system categorizing participants into a 3x3 grid based on aerobic capacity (12-min run test) and total exercise volume (smart-device tracked). Includes weekly personalized feedback, tiered exercise prescriptions, and goal recalibration. Arm 1 receives updates every 7 days.
223545449|NCT02776605|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
223545450|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
223545451|NCT02776605|DRUG|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
223545452|NCT02776605|DRUG|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
224001413|NCT07136818|BEHAVIORAL|Dynamic 9-Square Grid Health Management with Monthly Feedback|"Identical grid framework as Arm 1 (aerobic capacity + exercise volume assessment), but with monthly (30-day) feedback cycles. Participants receive delayed optimization strategies and tier adjustments once per calendar month, simulating conventional health programs."
224001414|NCT07138443|DIETARY_SUPPLEMENT|Melatonin 3 MG Oral Tablet|Participants will ingest an acute 3mg oral melatonin tablet
223545453|NCT02776605|DRUG|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
223545454|NCT02776605|DRUG|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
223545455|NCT02776605|DRUG|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
223545456|NCT02776605|DRUG|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
223545457|NCT02776605|PROCEDURE|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
224001415|NCT07138443|DIETARY_SUPPLEMENT|Placebo Oral Tablet|Participants will ingest a placebo tablet (sugar pill) of the same size, shape, and color of the active melatonin supplement
224001416|NCT07135947|DEVICE|Point Powered partial hand prosthetic system|The Point Powered system includes 1-4 3-joint mechatronic digits, low-profile EMG electrodes, a low-profile controller, and flexible batteries. These components will be integrated into a waterproof and dustproof packaging
224001417|NCT07135297|DEVICE|Ultrathin bronchoscope (UTB)|A UTB will be used to perform white light bronchoscopy, then the rEBUS probe was inserted into the working channel and advanced to the PPL to obtain a rEBUS view per the navigation path created by VBN workstation. The probe will be withdrawn from the working channel when an optimal rEBUS view obtained. A 1.5-mm biopsy forceps and 1.4-mm cytology brush will be used to collect samples through the working channel.
224001418|NCT07135297|DEVICE|Thin bronchoscope (TB1)|A thin bronchoscope will be used to perform white light bronchoscopy. A biopsy kit, including a 1.95-mm outer diameter guide sheath, 1.5-mm biopsy forceps, and 1.4-mm cytology brush, will be used to obtain samples with the guidance of VBN.
224001419|NCT07135297|DEVICE|Thin bronchoscope (TB2)|A thin bronchoscope will be used to perform white light bronchoscopy. A biopsy kit, including a 2.55-mm outer diameter guide sheath, 1.9-mm biopsy forceps, and 1.8-mm cytology brush, will be used to obtain samples with the guidance of VBN.
224001420|NCT02533024|OTHER|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
224001421|NCT07135609|DEVICE|Low-level laser therapy (LLLT)|Patients managed by Low-level laser therapy (LLLT).
224001422|NCT07135609|DRUG|Apitoxin|Patients managed with 0.3% Apitoxin Gel.
224001423|NCT07135323|GENETIC|Opioid Used Disorder Risk Assessment|Determine the likelihood of Opioid Used Disorder prior to prescribing opioids
224001424|NCT07137338|GENETIC|RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)|One-time treatment with a single ascending dose
224001425|NCT07146620|OTHER|Forearm massage|A general massage of the forearm will be performed. The physical therapist perform deep, longitudinal strokes. Pressure will be maintained at a level the patient finds comfortable for 3 minutes.
224001426|NCT07146620|OTHER|Pressure release for forearm trigger points|Pressure will be applied to trigger points in the forearm. This will be done in three sets of 30-second applications, with 30 seconds of rest between each.
224001427|NCT07146620|OTHER|Mulligan mobilization with movement technique|A lateromedial glide will be performed. The technique will be applied for three sets of 10 repetitions, with 30 seconds of rest between each set.
224001428|NCT07146620|OTHER|Radial Nerve Neurodynamic Mobilization|Three sets of 30 nerve glides will be performed at a rhythm of one second of tension followed by one second of rest. There will be 30 seconds of rest between sets.
224001429|NCT07146620|OTHER|Diacutaneous fibrolysis (Real)|A real technique of Diacutaneous fibrolysis will be applied to the forearm region for 5 minutes.
224001430|NCT07146620|OTHER|Diacutaneous Fibrolysis (Sham)|A sham Diacutaneous Fibrolysis technique (skin pinch) will be applied to the forearm region for 5 minutes.
224001431|NCT07145164|DRUG|N-803|This is the active drug.
224001432|NCT07145164|DRUG|Saline placebo|This is the placebo.
224001433|NCT07146490|BEHAVIORAL|Low Exercise|Low-Intensity Continuous Training (LICT): Participants ran continuously for 24 minutes at 50-60% of their MAS without breaks.
224001434|NCT07146490|BEHAVIORAL|Long Interval Exercise|Long-interval high-Intensity Interval Training (LI-HIIT): Participants ran at a speed corresponding to 80-90% of their MAS. The protocol consisted of four 4-minute bouts, separated by 2-minute active recovery periods, during which participants ran at 50% of their MAS. This pattern totaled 24 minutes of exercise.
224001435|NCT07146490|BEHAVIORAL|Short Intevral Exercise|Short-interval high-Intensity Interval Training (SI-HIIT): Participants ran at 110-120% of their MAS for 15-second intervals, covering a pre-calculated distance during each bout. After each 15-second sprint, they rested passively for 15 seconds and returned to their starting point. This was repeated continuously for 3 minutes, constituting one set. A total of four 3-minute sets were completed, interspersed with 3-minute passive rest periods, yielding a total exercise time of 24 minutes.
224001436|NCT07144072|DRUG|HeXell-2020|Cohort 1: 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 3 doses Cohort 2 : 5 × 10⁷ cells per dose, administered via IV infusion every 2 weeks for a total of 6 doses
224001437|NCT05258539|OTHER|Questionnaire|"Telephone calls at 2, 3 and 5 years with :~* Lifestyle follow-up questionnaire.~* Satisfaction questionnaire."
224001438|NCT06947447|DEVICE|No intervention|Device
224001439|NCT07137377|BEHAVIORAL|On line teaching CESARCOM teaching programe (immersive podcasts, digital flashcards)|"A short e-learning program (immersive podcasts, digital flashcards) will be carried out for the medical and paramedical staff of the cesarean section operating room, by a specialized team. It will will consist of :~* the presentation of the basic principles of therapeutic communication (listening, empathy, verbal, non-verbal, paraverbal language)~* the distribution of the HUG communication lexicon/wordbook .~* educational scenes illustrating the impact of therapeutic communication in the operating room (good versus bad words)."
224001440|NCT06954441|BIOLOGICAL|Intravenous immunoglobulin (IVIG)|"The investigational product is V-IMMUNE®, a 5% human normal immunoglobulin I.P. (5 g/100 mL) manufactured from qualified human plasma for intravenous use. Each vial contains human immunoglobulin at 50 g/L, maltose at 100 g/L, and water for injection. The 5% Human Immunoglobulin Solution for Intravenous Administration (I.P.) is a sterile and pyrogen-free preparation of human normal immunoglobulin in a single-dose form for intravenous administration. Each 10 mL, 50 mL, or 100 mL vial contains 0.5 g, 2.5 g, or 5 g of human normal immunoglobulin, respectively, and is produced from qualified human plasma using membrane filtration and a combination of chromatographic steps and viral inactivation procedures. The IgA content does not exceed 2 mg/mL.~This manufacturing process uses plasma collected from donors who undergo screening according to guidelines set by regulatory authorities. Blood is tested for all mandatory infectious diseases."
224001441|NCT05592600|BEHAVIORAL|Neurofeedback|Participants will visualize real-time feedback of signals recorded from their brains as measured with functional MRI.
224124114|NCT00981383|OTHER|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
223545458|NCT02776605|PROCEDURE|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
223384277|NCT03532152|DEVICE|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
224001442|NCT07136909|OTHER|Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.|Completion of the OSA-18 questionnaire by parents, during hospitalization planned as part of routine care.
224001443|NCT07137910|DRUG|AHB-137|AHB-137 will be injected
224001444|NCT07138053|OTHER|OFA group|OFA group Premedication with Midazolame and Paracetamol 30 minutes before surgery on ward, Dexamethasona and infusion of Dexmedetomidin and 2% Lidocaine 10 min before intubation( 50mcg Dexmedetomidin and 500mg 2% Lidocaine add up to 50ml normal saline) 1ml/10kg in 10 min after intubation 1ml/10kg/h discontinued after last surgical sutures. TAP bloc ultrasound guided performed after intubation. Ketamine given 60 sec before incision in doses 0.5 mg/kg, and after if it is necessary according to ER and qNOX. Provided value range between 40-60 during surgery.
224001445|NCT06748729|DEVICE|Navii Knee|Microprocessor controlled prosthetic knee (MPK)
224001446|NCT07155629|DRUG|mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine|The benefits of neoadjuvant chemotherapy before surgery in a prospective multicenter randomized setting for resectable left-sided pancreatic cancer patients.
224001447|NCT04961177|OTHER|EITC & ACEs Training|We will deliver up to 56 trainings to 65 frontline health workers and 25 staff of our partner organizations. The training will include: 1.) Information about what ACEs are, and the risk and protective factors associated with ACEs and 2.) Information regarding EITC benefits, eligibility, application procedure and logistics, referrals for free tax preparation assistance, and use of EITC tools., and 3.) frontline health workers will receive additional training in protocols for reporting to support Objective #2.
224001448|NCT04961177|OTHER|EITC Outreach & Screening|"Our partners will screen and refer a minimum of 5200 clients (65 CHWs x 10 clients per quarter x 2 years) for EITC. Our evaluation team will track the number of individuals screened, the number found to be eligible/not eligible, the number referred out and to which free tax prep service, and if available, the number who use the free tax prep service, the number who file a tax claim for EITC, the number who receive EITC benefits, and the amount of the benefit.~We will conduct community-level EIT outreach by integrating EITC outreach and education into planned community events in the neighborhoods and service areas of our partners. The events will provide information about the EITC to the public. We will have a minimum of 48 events to reach a minimum of 480 potential filers (48 events x 10 participants each)."
223729979|NCT02607033|OTHER|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
223729980|NCT02607033|OTHER|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
223729981|NCT02421315|BEHAVIORAL|CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment|CBT treatment consisted of 12-16 hour-long sessions. For exceptional cases not showing clinical improvement after six CBT treatment sessions, complementary pharmacological treatment (SSRI) was offered as part of our treatment protocol. CBT for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
223729982|NCT04500002|DRUG|Isonicotinic Acid Hydrazide|total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
224001449|NCT04961177|OTHER|Assistance with EITC|"We will conduct a statistical analysis of the impact of EITC funds on ACEs risk and protective factors in the lives of EITC benefit recipients. Project CHW team members will invite 200 clients who qualify to receive EITC benefits to participate in the study using an approved recruitment script. With those who agree to participate, the CHW team member will obtain consent and administer a baseline survey. A post-survey will be administered at 4 months.~In addition, we will gather qualitative data to help us understand impacts of this project. The post-survey will contain an open/qualitative response question asking participants to describe how the EITC benefit impacted them, how they felt when they received it, how important it was, and what they did with the funds. In Y2, the Research Team will conduct interviews with a subset of 20 clients who participated in the pre/post survey."
224001450|NCT02795403|OTHER|blood draw of 150ml, twice|
224001451|NCT02940600|DEVICE|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
224001452|NCT02940600|PROCEDURE|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
224001453|NCT04683068|BEHAVIORAL|Message comparison|Message comparison
224001454|NCT00615875|DRUG|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
224001455|NCT00615875|DRUG|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
224001456|NCT00621075|OTHER|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
224001457|NCT03237572|DRUG|Pembrolizumab|Pembrolizumab (200 mg)
224001458|NCT03237572|DEVICE|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
224001459|NCT00225017|DRUG|Atazanavir|atazanavir 400 mg once daily
224001460|NCT00225017|DRUG|current antiretroviral regimen|Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus \> 2 NRTIs
224001461|NCT00140335|BEHAVIORAL|handwashing|
223384278|NCT03532152|DEVICE|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
224001462|NCT04569201|PROCEDURE|Endoscope|The use of the neuro endoscope in excision of intraventricular lesions either alone or in assistance of the surgical microscope
223384279|NCT00662649|DRUG|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
223384280|NCT00662649|DRUG|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
223384281|NCT04019171|BEHAVIORAL|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
223384282|NCT00657189|DRUG|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
223384283|NCT00657189|DRUG|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
223384284|NCT00657189|DRUG|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
223384285|NCT00657189|DRUG|MEDI-545|100 mg every week × 13 doses
223384286|NCT00657189|DRUG|Placebo|SC Placebo every week × 13 doses
223384287|NCT03252067|DRUG|azithromycin eyedrop|Tear samples will be collected using the strips.
223729983|NCT04500002|DRUG|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
224001463|NCT00954187|DRUG|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
224001464|NCT00954187|DRUG|pregabalin|50 mg PO TID
224001465|NCT01132443|DRUG|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily
224001466|NCT04571840|DIAGNOSTIC_TEST|Multiparametric MRI +/- prostate biopsy|MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
224001467|NCT04571840|DIAGNOSTIC_TEST|Biparametric MRI +/- prostate biopsy|MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
224001468|NCT00250445|DRUG|MK0663, etoricoxib|
224001469|NCT00250445|DRUG|Comparator: Diclofenac sodium|
224001470|NCT02914418|DEVICE|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for \~200sec and can promote changes in neural activity.
224001471|NCT00003236|BIOLOGICAL|ISIS 3521|
223384288|NCT04893473|DEVICE|IscAlert|3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and carbon dioxide is measured continuously.
223384289|NCT02688946|OTHER|Not provided|
223384290|NCT00269646|BEHAVIORAL|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
223384291|NCT02411825|DRUG|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223384292|NCT02411825|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223384293|NCT02411825|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223384294|NCT04376658|OTHER|COVID-19 Severity|Disease severity characterized by the highest six-level ordinal scale during the hospital stay, which consists of the following categories: a score of 1 indicated not hospitalized; 2, hospitalized and not receiving supplemental oxygen; 3, hospitalized and receiving supplemental oxygen; 4, hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 5, hospitalized and receiving mechanical ventilation; and 6, death
223384295|NCT03170934|BEHAVIORAL|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
223384296|NCT03399513|DRUG|Ibrutinib Oral Capsule [Imbruvica]|Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
223384297|NCT03399513|DRUG|R-CHOEP chemotherapy|Immunochemotherapy
223384298|NCT04584684|OTHER|0.9% w/v NaCL Saline|saline placebo rinse
223384299|NCT04584684|DRUG|1.5% w/v Hydrogen Peroxide|Over-the-counter antiseptic mouth rinse
223384300|NCT04584684|DRUG|0.12% Chlorohexidine Gluconate|Dentist prescribed antimicrobial mouth rinse
223384301|NCT04584684|DRUG|27% Ethanol plus essential oils|Over-the-counter antiseptic mouth rinse
223384302|NCT04584684|DRUG|0.5% w/v Povidone-iodide|Over-the-counter antiseptic mouth rinse
223384303|NCT04584684|DRUG|0.075% Cetylpyridinium Chloride|Over-the-counter antiseptic mouth rinse
223384304|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 10mcg|BNT162b2 Low/Mid-Dose (10mcg) level
223384305|NCT04816643|BIOLOGICAL|BNT162b2 20mcg|BNT162b2 Mid-Dose (20mcg) level
223384306|NCT04816643|BIOLOGICAL|BNT162b2 30mcg|BNT162b2 High-Dose (30mcg) level
223729984|NCT05090007|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
223729985|NCT05090007|OTHER|gut microbiota|gut microbiota
224001472|NCT00003236|DRUG|ISIS 5132|
224001473|NCT00019552|DRUG|irofulven|
224001474|NCT05104359|OTHER|Observational|HIV-positive versus HIV-negative patients, individuals with at least 2 measurements of antibody levels, and boosted individuals are the subgroups of interest.
224001475|NCT06299800|OTHER|phenotyping of patients followed at a third-level diabetes centre with cancer|"Collection of the following data for each patient enrolled, where possible:~* Gender and age;~* Smoking habits and alcohol consumption (units per day);~* Weight and body mass index (BMI) at first (T0) and last visit (T1);~* Given by the diagnosis of type 2 diabetes mellitus;~* Treatment of type 2 diabetes at T0 and T1;~* Levels of glycated hemoglobin (hba1c) at T0 and T1, mean hba1c and mean fasting blood sugar;~* Creatinine clearance at T0 and T1;~* Liver enzymes at T0 and T1: alanine aminotransferase (ALT) and aspartate aminotransferase (AST);~* T0 and T1 lipid profile: low density lipoproteins (LDL-c) and triglycerides (TG);~* Complications of type 2 diabetes;~* Treatment of cancer;~* Family history of cancer."
224001476|NCT03988244|DEVICE|HeartLight X3|Pulmonary vein isolation
224001477|NCT04315350|DRUG|Curcumin Liposome|Curcumin is given together with prednisolone
223729986|NCT04811625|DRUG|PL-ASA|Pharmacologic profile of different aspirin formulations
224001478|NCT04315350|DRUG|Prednisolone|Prednisolone is given together with curcumin-placebo
224001479|NCT04315350|DRUG|Placebos|Prednisolone-placebo is given together with curcumin-placebo
224001480|NCT04192695|DEVICE|Cytosponge cell collection device|The Cytosponge™ is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus. Cytosponge™ has excellent safety profile and is approved by the Food and Drug Administration (FDA) and the Healthcare Products Regulatory Agency (HPRA) in the UK.
224001481|NCT00192868|PROCEDURE|Distal protection and drug eluting stent|
224001482|NCT00489944|DRUG|cisplatin|
223384307|NCT04816643|OTHER|Placebo|Intramuscular injection
223384308|NCT04816643|BIOLOGICAL|Biological/Vaccine: BNT162b2 3mcg|BNT162b2 Low-Dose (3mcg) level
223384309|NCT04051203|BIOLOGICAL|Autologous Platelet Rich Plasma Injection|60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP.
223384310|NCT04051203|DRUG|Depo-Medrol and lidocaine|Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.
223384311|NCT04051203|OTHER|Normal Saline|2mL normal saline.
223384312|NCT04349202|DIAGNOSTIC_TEST|EUROIMMUN assay|Serology testing to detect SARS-CoV-2 antibodies
223384313|NCT02726659|DRUG|Celecoxib|Adjunct celecoxib
223384314|NCT02726659|DRUG|Placebo|Adjunct placebo
223384315|NCT03249532|DEVICE|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
223384316|NCT03249532|DEVICE|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
223384317|NCT03249532|DEVICE|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
223384318|NCT03249532|DEVICE|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
223384319|NCT00457132|DEVICE|APOS biomechanical gait system|
223384320|NCT04970615|DEVICE|Three-dimensional printed model|Three-dimensional printers are able to print physical objects in real size and colours. As a respresentative of the real tumor, a personalized three-dimensional model enables visualization of the patient-specific tumor and eloquent areas.
223729987|NCT01569711|PROCEDURE|Deep brain stimulation of nucleus accumbens|"* Day0 : surgical placement of electrodes~* M1 : stimulation of nucleus accumbens~* M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
223729988|NCT05573607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin tablet
223729989|NCT05573607|DIETARY_SUPPLEMENT|Chromium|A tablet consisting of a blend of Crominex® 3+, Capros® Amla Extract (Fruit), PrimaVie® Shilajit), and MetaviveTM complex (Salacia Chinensis Extract (Fruit) and a Citrus Bioflavonoids)
223729990|NCT02538250|DIETARY_SUPPLEMENT|Nutricomp Drink Plus|Oral nutritional supplementation
224001483|NCT00489944|DRUG|sunitinib malate|
224001484|NCT00489944|DRUG|tamoxifen citrate|
224001485|NCT00489944|PROCEDURE|adjuvant therapy|
224001486|NCT03329755|OTHER|Dedicated and coordinated e-follow-up during the treatment period|"* Completion of questionnaires using an electronic tool~* Telephone follow-up between the nurse and the patient~* Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)"
224001487|NCT03329755|OTHER|Standard follow-up during the treatment period|\- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)
224001488|NCT02937467|DEVICE|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
224001489|NCT05305729|OTHER|No intervention|No intervention
223384321|NCT02009722|DRUG|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
223729991|NCT01754623|DRUG|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
224001490|NCT04021979|DIETARY_SUPPLEMENT|Enteral Nutrition Powder Ensure|Enteral Nutrition Powder Ensure for each meal.The duration of study is one day before colonoscopy.
224001491|NCT04021979|DRUG|1.5L PEG|Low volume PEG
224001492|NCT04021979|OTHER|Self-controlled diet|Self-controlled low residue diet.
224001493|NCT04021979|DRUG|2L PEG|Normal volume of PEG
224001494|NCT04490590|DRUG|Chidamide+ Etoposide|Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
224001495|NCT02627703|OTHER|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
223384322|NCT02009722|DRUG|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
223384323|NCT06568510|PROCEDURE|Continuous peripheral nerve block|A perineurial catheter is placed to a nerve structure through a Touchy needle
223384324|NCT02955212|DRUG|Upadacitinib|Tablets for oral administration
223384325|NCT02955212|DRUG|Placebo|Tablets for oral administration
223384326|NCT00379314|PROCEDURE|TVT and TVT-O minimally invasive surgical procedures|
224001496|NCT04279132|BEHAVIORAL|POSTOPERATIVE COGNITIVE DYSFUNCTION|NEURON SPECIFIC ENOLASE LEVELS IN LUMBAR DISC HERNIECTOMY WITH GENERAL ANESTHESIA MODALITIES
223384327|NCT00379314|PROCEDURE|Surgery for female stress urinary incontinence|
223384328|NCT05712239|OTHER|Advices|The advices will include patient's reassurance and description of possible causes of neck pain such as poor working ergonomics, common bad postures especially while using electronic devices for long periods and not adjustable sleeping pillows. Also, patient will be educated how to modify these different causes and asked to apply gentle neck range of motion exercises
223384329|NCT05712239|OTHER|Cervical and Scapular Stabilization Exercises|"Deep neck flexor training will be performed in neurodevelopment stages (supine at first week using pressure biofeedback unit , prone at second week, quadrupedal at third week, bipedal at fourth week).~Scapular stabilization exercises will include modified prone cobra, trapezius muscle exercise progression (3 stages), wall press and extension of the thoracic spine using foam roller. The modified prone cobra and the first stage of trapezius muscle exercise progression will be applied during the first two weeks. The second and third stages of trapezius muscle exercise will be applied during the last two weeks of our rehabilitation program. All exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets with 20 sec rest between each set. While wall press and thoracic extension exercises will be applied throughout the 4 weeks for 3 sets of 10 repetitions with 20 sec rest between each set."
223384330|NCT05712239|OTHER|Lumber Core Stability Program|"The program will be performed in three stages: activation, dynamic stabilization, and advanced core strengthening stages. Each stage will be applied for 4 sessions.~The activation stage will be based on the learning to activate transversus abdominis muscle from crock lying position using pressure biofeedback unit. In the dynamic stabilization stage, the patient will be instructed to slowly raise both arms in the scapular plan then return to the sides while maintaining the transversus abdominis muscle activation. Also, the patient will apply bridging exercise in this stage. The advanced core strengthening stage will include prone plank and side plank (right and left sides). All the exercises will be applied for 10 repetitions with 6-10 sec hold for 3 sets. The rest of 20 sec will be taken between each set."
223384331|NCT02570802|PROCEDURE|Ultrasonographic examination|
223384332|NCT03342885|BEHAVIORAL|Specific sleep ergonomics guidance|Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
223384333|NCT03342885|BEHAVIORAL|General sleep ergonomics guidance|Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
223384334|NCT01591083|DRUG|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
223384335|NCT02477956|DIETARY_SUPPLEMENT|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
223384336|NCT02477956|DIETARY_SUPPLEMENT|vitamin D|
223384337|NCT03692507|DIETARY_SUPPLEMENT|HMB|Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 5 days prior to surgery.
224001497|NCT00579800|PROCEDURE|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
224001498|NCT01733173|PROCEDURE|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
224001499|NCT03828643|DRUG|Secukinumab|Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.
224001500|NCT03828643|DRUG|Secukinumab|Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
224001501|NCT00689585|DRUG|Placebo|250mg matching placebo capsules
224001502|NCT00689585|DRUG|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
224001503|NCT04774653|OTHER|No intervention|Associations and prevalence will be calculated
224001504|NCT02767284|DEVICE|UCST-V1|A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
224001505|NCT02767284|DEVICE|UCST-V2|A refined version of the UCST-V1 that randomizes frequency order.
224001506|NCT02767284|DEVICE|UCST-V3|A version that utilises eye-tracking technology to make the measurements more accurate.
224001507|NCT02767284|DEVICE|Quick-CSF (QCSF)|A fast contrast sensitivity measurement method using a Bayesian algorithm.
224001508|NCT02767284|DEVICE|Pelli-Robson|A standard method developed using a Sloan-letter chart with decreasing contrast.
224001509|NCT02767284|DEVICE|Optec 6500|A standard test using sinusoidal gratings to measure the contrast sensitivity function.
224124115|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
223384338|NCT03692507|DIETARY_SUPPLEMENT|Protein and HMB|Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 5 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.
223384339|NCT03692507|DIETARY_SUPPLEMENT|ERAS|Patients in the third group (High protein) will drink 2- 8oz bottles of Ensure surgery daily (morning and night) for 5 days prior to surgery. Each bottle contains 18g of protein. and a clear 50g Pre-surgery drink on the day of surgery
223384340|NCT00835393|DRUG|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
224001510|NCT01097122|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
224001511|NCT04596943|DIAGNOSTIC_TEST|[68Ga]Ga-DOTA-(RGD)2 PET/CT|We have developed a dimeric cyclic RGD peptide conjugated with DOTA as a chelator. If labeled with the positron emitting radionuclide Gallium-68 (68Ga), \[68Ga\]Ga-DOTA-(RGD)2 can be used to visualize αvβ3 integrin expression with PET
224001512|NCT02988050|DRUG|Remifentanil|Remifentanil used for conscious sedation.
224001513|NCT02988050|DRUG|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
224001514|NCT02988050|DRUG|Propofol|Used for conscious sedation.
224124116|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
224138497|NCT06554002|OTHER|Treatment|Participants will be asked to consume a resistant dextrin on a daily basis (twice per day) for the entire 8 weeks. The test supplement will be packed in sachets, and it can be dissolved in water to be consumed as a beverage. Two sachets will be consumed daily.
224138498|NCT04379934|DIETARY_SUPPLEMENT|3-hydroxybuturate|3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
224138499|NCT06110299|DIAGNOSTIC_TEST|air injection|delination of the ureter and pelvis by injecting air under C-ARM
224138500|NCT03598738|DRUG|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
223384341|NCT00835393|DRUG|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
223384342|NCT03995277|DIETARY_SUPPLEMENT|Biotin|Daily intake of 10 mg or 50 µg per day
223384343|NCT03556124|DEVICE|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
223384344|NCT03556124|DEVICE|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
223384345|NCT03556124|DEVICE|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
223384346|NCT03556124|DEVICE|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
223384347|NCT02603016|DRUG|GLSE compound|
223384348|NCT02603016|DRUG|Maitake mushroom extract compound|
224001515|NCT02988050|DRUG|Bupivacaine|Local anaesthetics
223384349|NCT02603016|DRUG|Ginseng compound|
223384350|NCT01705795|DRUG|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
223384351|NCT01705795|DRUG|Placebo|Nacl four times over four months
224001516|NCT02988050|DRUG|Lidocaine|Local anaesthetic
224001517|NCT02988050|DRUG|Epinephrine|With local anaesthetic for skin infiltration.
224001518|NCT01977677|RADIATION|radiation therapy|Undergo radiation therapy
224001519|NCT01977677|DRUG|temozolomide|Given PO
224001520|NCT01977677|DRUG|plerixafor|Given IV
224001521|NCT01977677|OTHER|laboratory biomarker analysis|Correlative studies
224001522|NCT01977677|OTHER|pharmacological study|Correlative studies
224001523|NCT00538148|DRUG|Telithromycin|
224001524|NCT02384187|DRUG|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
224001525|NCT02384187|DRUG|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
224001526|NCT02295943|OTHER|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
224001527|NCT03891771|DEVICE|Telemonitoring sensors|This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
224001528|NCT04274205|OTHER|Intervention group|Brief supportive psychotherapy
223384352|NCT01471743|DIETARY_SUPPLEMENT|Impact Advance Recovery (R)|
223384353|NCT01471743|DIETARY_SUPPLEMENT|Ensure Plus (R)|
223384354|NCT00545714|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
223384355|NCT00545714|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
223384356|NCT00545714|DRUG|Rituximab|Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
223384357|NCT01988181|DEVICE|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
224001529|NCT00124787|DRUG|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
224001530|NCT00124787|DRUG|Placebo|Placebo PO q 6 hours x 4 doses
224001531|NCT02993406|DRUG|Bempedoic acid 180 mg tablet|Patients take bempedoic acid 180 mg tablet orally once daily
224001532|NCT02993406|DRUG|Matching placebo tablet|Patients take matching placebo tablet orally once daily
224001533|NCT02248818|DRUG|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
224001534|NCT02248818|DRUG|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
224001535|NCT04959539|PROCEDURE|endoscopic transcanal tympanoplasty with attico-antrostomy|Transcanal approach followed by atticotomy to remove the attic cholesteatoma sac
224001536|NCT04959539|PROCEDURE|endoscopic assisted canal wall up mastoidectomy|traditional canal wall up mastoidectomy followed by endoscopic evaluation of the attic to exclude any remnant cholesteatoma
224001537|NCT05776043|DRUG|Empagliflozin 10 MG|once daily for 6 or 9 months
224001538|NCT05776043|DRUG|Dapagliflozin 10 MG|once daily for 6 or 9 months
224001539|NCT05776043|DRUG|Placebo|once daily for 3 months
224001540|NCT00400998|DRUG|Fluticasone Propionate|"Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~\- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate."
224001541|NCT00400998|OTHER|Matched FPANS placebo|"Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~* Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL."
224001542|NCT02953405|DRUG|Clopidogrel|
224295681|NCT02399930|OTHER|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
224295682|NCT03149939|DRUG|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
223384358|NCT01988181|DEVICE|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
223384359|NCT02664181|DRUG|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
223384360|NCT02664181|DRUG|oral decitabine|oral decitabine \~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
223384361|NCT02664181|DRUG|Tetrahydrouridine|Oral THU \~10 mg/kg twice weekly on consecutive days
224001543|NCT06788314|DRUG|Enalapril|"Each participant will receive a dose of enalapril 5 mg once daily. If the participant doesn't have effect of the intervention after 3 months, the dose of enalapril will be increased to 10 mg daily, if the tolerance of enalapril is good. Lack of effect will be defined as unchanged or increased NRS score.~Treatment duration will be 12 months."
224001544|NCT04537013|PROCEDURE|Microfracture|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells.
224001545|NCT04537013|DEVICE|Microfracture plus placement of Chondro-Gide® ACC|Debridement of cartilage followed by placement of small holes in the effected area to fill the debrided area with marrow and cells, followed by affixing Chondro-Gide® with fibrin glue.
224001546|NCT06787586|DRUG|ATTO-1310|ATTO-1310 Attobody
224001547|NCT06787586|DRUG|ATTO-1310 Placebo|Placebo preparation to match ATTO-1310 Dose
224001548|NCT01825928|DRUG|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
224001549|NCT01825928|DRUG|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
224001550|NCT04656873|PROCEDURE|Biospecimen Collection|Undergo collection of cheek swab, blood, urine, stool, and tissue samples for research
224001551|NCT04656873|OTHER|Medical Chart Review|Periodic review of medical records for clinical parameters (labs, ICI dosing and frequency, occurrence, timing and type of irAE, irAE management, etc.) along with relevant demographic information (age, sex/gender, race/ethnicity, insurance type, etc.).
224001552|NCT04656873|OTHER|Questionnaires/Surveys|Periodic self-report questionnaires/surveys for symptom tracking, quality of life, perinatal outcomes, etc.
224001553|NCT04993105|OTHER|Exercise + Graston.|"In graston + exercises treatment will be same but after exercises added with proper application of graston which included application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin.The Graston tools will be then used to mobilize the tissues of the triceps surae and plantar foot. In areas of increased tissue restriction, more aggressive pressure with graston was applied using increased force and shorter strokes over the areas of restrictionIce was offered as needed for pain management after each session. This will be continued for three sessions. NPRS score, score on FADI and dorsiflexors range will be assessed after treatment of two weeks. Along with conventional treatment.~."
224001554|NCT04993105|OTHER|exercise only|gastrocnemius and plantarstretching
224001555|NCT05262517|DRUG|Rimegepant|75 mg ODT
224001556|NCT05262517|DRUG|Placebo|matching placebo
224001557|NCT02912546|PROCEDURE|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
224001558|NCT05163769|DEVICE|NeeuroCycle Physical and Cognitive Training System|The NeeuroCycle Physical and Cognitive Training System is a novel multimodal electroencephalogram (EEG)-based physical and cognitive training device. The system mainly comprises of a recumbent bicycle device and a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
223384362|NCT05736055|DIAGNOSTIC_TEST|Cambodia Version Five Minutes Hearing Test|The FMHT was developed by American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). The FMHT is composed of 15 questions. Each answer is scored as 0, 1, 2 or 3 according to the frequency of experience. If they answered 'never', the score was 0. The answer 'occasionally' scored 1, the answer 'half the time' scored 2, and the answer 'almost always' scored 3. Furthermore, it has shown more aspects, more reliability, and more assessments of the hearing impairment of the patients. is a standard hearing questionnaire. So, we plan to translate the FMHT into Cambodian language and validate by comparing its result with those of audiometry.
223384363|NCT01113723|DEVICE|Fiberoptic bronchoscope|Fiberoptic bronchoscope device
224001559|NCT05163769|DEVICE|NeeuroCycle Cognitive Training System|The NeeuroCycle Cognitive Training System is a novel electroencephalogram (EEG)-based cognitive training device. The system mainly comprises of a customized four frontal electrode EEG-headband paired with the gamified NeeuroCycle cognitive training program delivered via an electronic application (app) on a tablet. The cognitive training program is built upon patented EEG-based attention, learning, and memory algorithms.
224001560|NCT06003946|BEHAVIORAL|BreLax: Antenatal education class|An antenatal education class over 9 hours with information regarding pregnancy, labour and birth, pain management as well as the postpartum period with an integrated breathing and relaxation technique (prolonged exhalation in the individual rhythm) and 4 accompanying positions (standing upright, sitting supported, four-footed, supported lying on the side). In addition, participants receive a manual for independent practice at home.
224001561|NCT06003946|BEHAVIORAL|Standard care (control)|An antenatal education class over 9 hours, with information regarding pregnancy, labour and birth, pain management and the postpartum period as well as some relaxation exercises.
223384364|NCT01113723|DEVICE|CMAC|CMAC Device
223384365|NCT02244281|DRUG|tamsulosin hydrochloride|
223384366|NCT02244281|DRUG|Placebo|
223384367|NCT00995124|DRUG|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
223384368|NCT00995124|DRUG|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
223384369|NCT00995124|DRUG|Moov Head Lice Solution|Single application for head lice with 10 min application time.
223384370|NCT04428034|BEHAVIORAL|Learning Skills Together|Information provided in arm/group description.
223384371|NCT02319317|BEHAVIORAL|Risky driving prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
223384372|NCT02319317|BEHAVIORAL|Control group general health promotion|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
223384373|NCT02593617|OTHER|Addiction Profile Index|
223384374|NCT02593617|OTHER|Alcohol Use Disorders Identification Test|
224295683|NCT02968836|DIETARY_SUPPLEMENT|Blend of amino acids|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
224295684|NCT02968836|DIETARY_SUPPLEMENT|Maltodextrin only|The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
223384375|NCT02593617|OTHER|Barratt Impulsiveness Scale|
223384376|NCT02593617|OTHER|Zuckerman Sensation Seeking Scale|
223384377|NCT02593617|OTHER|Energy Drink Consumption Questionnaire|
223384378|NCT04873596|DRUG|Nebulized dexmedetomidine|parturient will receive nebulized 3ug/kg dexmedetomidine.
223384379|NCT04873596|DRUG|Nebulized midazolam|parturient will receive nebulized 0.2 mg/kg midazolam.
223384380|NCT02484937|OTHER|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
223384381|NCT02484937|OTHER|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
223384382|NCT03528616|DRUG|adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.|drugs used for treatment of supraventricular tachycardia
223384383|NCT02017470|OTHER|Gender-tailored women's heart health outpatient programme|
223384384|NCT00261287|DRUG|Ciclesonide|
223384385|NCT00634699|PROCEDURE|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
224295685|NCT04600778|OTHER|placebo|placebo
224295686|NCT04600778|DRUG|Cavosonstat 5 mg|Cavosonstat (low dose)
223384386|NCT03409237|DRUG|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
223384387|NCT03409237|DRUG|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
223729992|NCT01754623|DRUG|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
223729993|NCT01754623|DRUG|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
224001562|NCT05446727|DRUG|Ropivacaine injection|30ml of 0.35% ropivacaine bilaterally
223384388|NCT05714878|BEHAVIORAL|aerobic exercise; resistance exercise; nutritional support; psychological support|Patient with gastric cancer received two weeks of prehabilitation intervention. An individualized exercise program was established according to the FITT (Frequency, Intensity, Time and Type) principle. Aerobic exercise: 3-5 times/week, 30-60 min jogging or brisk walking per time, intensity based on heart rate and modified Borg-scale. Resistance exercise: 2-3 times/week, 10-12 RM per sets, 2-3 sets with 2 min interval rest, seated knee up, knee extension, etc. Nutritional support: 30kcal/kg/d, 1.5mg/kg/d protein, oral nutritional supplement with suggested recipes. Psychological support: provided with guidance on gastric cancer, regular online chat through Wechat, alcohol quitting, smoking cessation and light music.
223384389|NCT02329028|DEVICE|Prehospital mini-EEG|Observational
223384390|NCT03345771|COMBINATION_PRODUCT|Antimicrobial Barrier Dressing|Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
223384391|NCT03345771|DEVICE|Negative Pressure Wound Therapy (NPWT)|PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
224001563|NCT01708343|PROCEDURE|DIMMST|
224001564|NCT02222298|PROCEDURE|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
223384392|NCT04478929|DIAGNOSTIC_TEST|Gastroscopy|Routine gastroscopy
223384393|NCT03098160|DRUG|Evofosfamide|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
223384394|NCT03098160|DRUG|Ipilimumab|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
223384395|NCT04944173|DRUG|Durvalumab|Subjects will receive durvalumab 1500mg IV every four weeks for four cycles, undergo assessment for residual disease, then a subset of subjects will receive an additional eight cycles of durvalumab.
224001565|NCT02222298|PROCEDURE|Bascom Cleft lift procedure|
224001566|NCT03430947|DRUG|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
224001567|NCT03430947|DRUG|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
224001568|NCT04211597|OTHER|Control|No scar prevention or treatment.
224001569|NCT04211597|OTHER|Silicone gel|Dermatix® (Dermatix® Ultra, Menarini Asia-Pacific, Taiwan FDA approved)
224001570|NCT04211597|OTHER|microencapsulated polysaccharide and oligopeptide-1(Me-EGF) 40 mcg & 5 mcg|4ml (40 mcg) of Me-EGF spray will be given by the operating physician prior to wound closure, followed by daily application of 5 mcg until day +5 after delivery. Starting from day +14, participants will receive FDA approved Silicone gel to be applied to the Cesarean wound twice a day for two months. Participants also receive routine post-partum care as usual.
224295687|NCT04600778|DRUG|Cavosonstat 10 mg|Cavosonstat (medium dose)
223384396|NCT04944173|RADIATION|Stereotactic Body Radiotherapy|Subjects will receive stereotactic radiation therapy concurrent with cycle 2 of durvalumab to a dose of 48Gy in four fractions. Fractionation may be modified for central tumors.
223384397|NCT04944173|DIAGNOSTIC_TEST|Circulating Tumor DNA assay|After four cycles of durvalumab, subjects will be evaluated at the MRD Landmark for residual ctDNA to determine subsequent treatment assignment.
223384398|NCT03715920|DEVICE|Electrical currents|The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
224001571|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
224001572|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
224001573|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
224001574|NCT02473705|DIETARY_SUPPLEMENT|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
224001575|NCT00003253|DRUG|paclitaxel|
224001576|NCT00003253|OTHER|antitumor drug screening assay|
224001577|NCT06190964|OTHER|Integrative medicine|Acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) and/or mind-body medicine (for example, relaxation and breathing exercises)
224001578|NCT03203187|OTHER|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
224001579|NCT03203187|OTHER|No intervention|No mango intake for two weeks.
224001580|NCT02185222|DRUG|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
224001581|NCT02185222|DRUG|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
224001582|NCT01666587|DIETARY_SUPPLEMENT|Antioxidant|
224001583|NCT01666587|DRUG|Prostaglandin inhibitor (Ibuprophen)|
224295688|NCT04600778|DRUG|Cavosonstat 25 mg|Cavosonstat (high dose)
223384399|NCT00560391|DRUG|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
223384400|NCT00560391|DRUG|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
223384401|NCT00560391|DRUG|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
223384402|NCT00560391|DRUG|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
224001584|NCT05996432|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants will undergo Magnetic Resonance Imaging
224001585|NCT05996432|PROCEDURE|Positron Emission Tomography (PET)|Participants will undergo Positron Emission Tomography
224001586|NCT05996432|DRUG|18F-fluoromisonidazole|Given by IV
224001587|NCT03972085|OTHER|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
224001588|NCT03972085|OTHER|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
224295689|NCT02188511|OTHER|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to \< 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
224295690|NCT02188511|OTHER|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
224295691|NCT02188511|OTHER|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
223384403|NCT00560391|DRUG|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
223384404|NCT02556801|BIOLOGICAL|SUBLIVAC FIX Phleum Prat.|sublingual daily administration
223384405|NCT03369769|OTHER|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
223384406|NCT02952469|DRUG|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
223384407|NCT05778201|BIOLOGICAL|Baby Drink group|1 packge (20 ml)/ day for 1 month
223384408|NCT05187104|BIOLOGICAL|Cultured retinal stem and progenitor cells|Cultured retinal stem and progenitor cells injected subretinally
223384409|NCT05187104|OTHER|Standard treatment according to the clinical protocols|Standard treatment of age-related macular degeneration according to the clinical protocols
223384410|NCT04826367|OTHER|Telerehabilitation-based relaxation exercise group (EG)|the participants in this group will perform the relaxation exercises thrice a week, for 6 weeks.
223384411|NCT01101412|DRUG|Edetate Calcium Disodium|Given through CVC or PVC.
223384412|NCT01101412|DRUG|Ethanol|Given through CVC or PVC
223384413|NCT01101412|DRUG|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
223384414|NCT01101412|OTHER|Hypertonic Saline|Given through CVC or PVC
223384415|NCT03997812|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
223384416|NCT03997812|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
224001589|NCT01272154|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
224001590|NCT05990114|OTHER|The structured caregiver support program|It consists of 8 sessions in total. It is planned as once a week and 45 minutes.
223384417|NCT02744872|DRUG|Felodipine|Felodipine 10 mg once daily or identical placebo
223384418|NCT02744872|DRUG|Placebo|Placebo
223384419|NCT02287714|PROCEDURE|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
224001591|NCT06334692|DIAGNOSTIC_TEST|"In-house ELISA, and ELISA kits from DBA Italy (Abbexa)."|"Nunc MaxiSorp ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm."
224001592|NCT06316895|PROCEDURE|thyroid surgery|thyroid lobectomy
224001593|NCT06316895|PROCEDURE|ultrasound-guided thermal ablation|radiofrequency ablation; microwave ablation or laser ablation
224295692|NCT02188511|OTHER|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
224001594|NCT06609603|DIETARY_SUPPLEMENT|HTGT compound|oral administration of HTGT compound once daily
223384420|NCT02287714|PROCEDURE|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
223384421|NCT05217212|RADIATION|Radiochemotherapy|Primary radiotherapy of the primary tumor and nodal basin with curative intent with or without concomitant chemotherapy with cisplatin, carboplatin, or cetuximab weekly.
224001595|NCT06609603|DIETARY_SUPPLEMENT|Placebo|Oral administration of placebo once daily
224001596|NCT03896126|OTHER|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
224001597|NCT05777655|OTHER|Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)|Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
224124117|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
223384422|NCT06217913|DEVICE|wearable device to monitor the blood pressure|Pregnant women began to establish antenatal examination records (usually before 12 weeks of pregnancy), and were enrolled through randomized grouping. Pregnant women in the intervention group were provided with wearable blood pressure monitoring equipment, and ambulate blood pressure monitoring was conducted for at least 2 24 hours per week from 12 weeks of pregnancy until 28 weeks of pregnancy, after which blood pressure monitoring was carried out according to routine antenatal examination.
223384423|NCT06582004|DIETARY_SUPPLEMENT|CH2 vaginal gel|The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
224295693|NCT02188511|OTHER|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
224295694|NCT04590066|BEHAVIORAL|Flu shot text messages|Participants will receive text messages per descriptions listed in the arms.
224295695|NCT01996332|DRUG|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
224295696|NCT03049605|DEVICE|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
223384424|NCT06582004|DIETARY_SUPPLEMENT|Placebo hyaluronic acid gel|The usage frequency is 2 units per week, with a 3-day interval between each unit, for a total duration of 24 weeks
223384425|NCT00002425|DRUG|Saquinavir|
223384426|NCT02071225|DRUG|bendamustine|70 milligrams per square meter (mg/m\^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
223384427|NCT02071225|DRUG|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
223384428|NCT02130908|OTHER|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
223384429|NCT02130908|OTHER|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
223384430|NCT02130908|OTHER|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
223384431|NCT01417637|RADIATION|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
223729994|NCT01754623|RADIATION|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
224001598|NCT03892980|DEVICE|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Surgical Systems.
224001599|NCT05314686|OTHER|Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.|"1. Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~2. Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system."
224001600|NCT05314686|OTHER|Telerehabilitation|"An eight-week program including:~* Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~* Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~* Daily walking with automated coaching.~* Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~* A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms."
224001601|NCT04912453|PROCEDURE|Primary anastomosis|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive primary anastomosis
224001602|NCT04912453|PROCEDURE|Enterostomy|At laparotomy, the diseased segment of intestine will be resected and the patients will then receive enterostomy
224001603|NCT00569101|DRUG|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg \~0.02 mg/kg + prednisolone tapering
224001604|NCT04287595|OTHER|Inhalation aromatherapy with orange essential oil|
224001605|NCT06000345|OTHER|AOT + MI|During the AOT session, the patients were shown a video containing motor contents. In particular, the video demonstrated quadriceps concentric and isometric contractions, presented in the third person perspective. At the conclusion of each video, the patients were asked to spend 1 minute imagining what they had just seen.
224001606|NCT06000345|OTHER|Control AOT + MI|The control group was shown a video of landscapes (4 minutes in length). Halfway through and at the end of the video they were asked to imagine what they had just seen for 1 minute.
224001607|NCT04325282|DEVICE|Active rTMS|1Hz rTMS delivered for 15-20 minutes
224001608|NCT04325282|DEVICE|Sham rTMS|sham rTMS delivered for 15-20 minutes
224001609|NCT00703066|BIOLOGICAL|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
224001610|NCT00703066|BIOLOGICAL|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
224001611|NCT00703066|BIOLOGICAL|Rabies vaccine|3 doses of Rabies vaccine
224001612|NCT06411353|DIAGNOSTIC_TEST|MRI acquisition|Non-contrast enhanced acquisitions will be performed using a whole-body MRI scanner operating at 1.5 Tesla or greater.
224001613|NCT06411353|DIAGNOSTIC_TEST|US examination|A complete assessment of the AVF vessels is performed using advanced 3D US procedures.
224001614|NCT05683080|OTHER|Routine Clinical Care|Participants completing the research study will receive routine clinical care
224001615|NCT02662452|DRUG|GLPG2222 single dose|single ascending doses, oral suspension
224295697|NCT03049605|DEVICE|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
223384432|NCT01417637|RADIATION|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
223384433|NCT05902286|BEHAVIORAL|OSC+|The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.
223425518|NCT02424630|DEVICE|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
224001616|NCT02662452|DRUG|Placebo single dose|single doses, oral suspension, matching placebo
224001617|NCT02662452|DRUG|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
224001618|NCT02662452|DRUG|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
224001619|NCT00369252|DRUG|Nimotuzumab (TheraCIM h-R3)|
224001620|NCT03806881|DEVICE|reversed glenoid prothesis|All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
224001621|NCT02211755|DRUG|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
224001622|NCT05483010|DRUG|Atorvastatin|Atorvastatin is commercially available.
224001623|NCT05483010|DRUG|Rosuvastatin|Rosuvastatin is commercially available.
224001624|NCT00545194|DRUG|Prostaglandin E2|
224001625|NCT01628562|DRUG|Esmolol|Esmolol 50 mcg/kg/min
224001626|NCT01628562|DRUG|Remifentanil|Remifentanil 0.5 mcg/kg/min
224001627|NCT06518148|DIAGNOSTIC_TEST|1- uncorrected and best corrected visual acuity (UCVA and BCVA) by Snellen's-chart.2-slit lamp bio microscopy (Haag-Streit, USA).3-IOP measurements (Goldmann Applanation tonometer)|diagnostic test;UCVA, IOP, Electrophysiological study
224001628|NCT05520775|DRUG|Semaglutide|Semaglutide (subcutaneous)
224001629|NCT05520775|DRUG|Sham/placebo|Sham subcutaneous injection
224001630|NCT03213717|OTHER|Heavy Casall HIT weight vest|A weight west with a weight of 10 % compared to the study subject
224001631|NCT03213717|BEHAVIORAL|Standing|Study subjects will be standing for at least 50 minutes every hour
224001632|NCT03213717|DIETARY_SUPPLEMENT|Water load|Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
224001633|NCT03213717|BEHAVIORAL|Sitting|Study subjects will be sitting for at least 50 minutes of every hour
224001634|NCT03213717|OTHER|Light Casall HIT weight vest|A weight west with a weight of 1 % compared to the study subject
224295698|NCT03049605|DRUG|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
223384434|NCT05902286|BEHAVIORAL|OSC-|During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
223384435|NCT02902224|DIETARY_SUPPLEMENT|Tap water|300ml tap water via nasogastric tube
224001635|NCT06500468|DEVICE|PillSense System|"The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected."
224001636|NCT05906251|GENETIC|SRP-6004|Single IV infusion of SRP-6004
223384436|NCT02902224|DIETARY_SUPPLEMENT|Glucose|300ml tap water with 75g glucose via nasogastric tube
224001637|NCT06509373|BEHAVIORAL|Advance Care Planning Tool - ACPVoice|Eligible patients will be sent a secure MyChart message with a motivational message asking them to complete the advance care planning tool (ACPVoice) with their care partner/surrogate decision-maker or loved one before their upcoming primary care visit. The ACPVoice tool will be attached electronically to the mychart message. A reminder message will be sent to an non-responders with a different motivational message.
224001638|NCT06509373|BEHAVIORAL|Standard of Care for Advance Care Planning|Patients will have access to the standardized advance care planning questionnaires readily available already within their mychart account which is part of standard of care.
224001639|NCT06573801|DEVICE|Aktiia Bracelet|Wrist worn bracelet with an optical sensor that measures pulse wave characteristics at the wrist.
224124118|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
224124119|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
224124120|NCT01482741|BEHAVIORAL|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
224124121|NCT06312267|DEVICE|Bioelectric dressing|Participants randomized into the experimental arm will have a bioelectric dressing applied 3 days before surgery, and 3 days post-surgery.
224124122|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
224124123|NCT00682916|DIETARY_SUPPLEMENT|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
224001640|NCT06573801|DEVICE|Healthstats BPro Evo|Wrist worn watch that uses applanation tonometry to measure pulse wave characteristics at the wrist.
224001641|NCT06573801|DEVICE|Spacelabs OnTrak Ambulatory Blood Pressure monitor|Cuffed ambulatory BP monitor that will measure upper arm BP using oscillometry.
224001642|NCT00144352|DRUG|sulfadoxine-pyrimethamine|
224001643|NCT02013921|OTHER|Physical activity|
224001644|NCT01283152|DRUG|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
223384437|NCT02902224|DIETARY_SUPPLEMENT|Fructose|300ml tap water with 25g fructose via nasogastric tube
223384438|NCT04525534|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment
223425519|NCT02424630|DRUG|Placebo|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
223425520|NCT02424630|DRUG|Ropivacaine|All the regional blocks in this study were performed using 10mL ropivacaine.
224001645|NCT01283152|DRUG|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
224001646|NCT00822653|DEVICE|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
224001647|NCT02961803|DRUG|MD1003 100 mg capsule|
224001648|NCT02961803|DRUG|Placebo|
224001649|NCT05355389|BEHAVIORAL|Cognitive training|For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
224001650|NCT05355389|BEHAVIORAL|Motor training|For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
224001651|NCT02441985|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
224001652|NCT02441985|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
224001653|NCT02441985|OTHER|Fullerton Advanced Balance (FAB) Scale|All participants will receive a clinical assessment of balance ability and fall risk.
224001654|NCT02441985|OTHER|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
224001655|NCT02441985|OTHER|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
224001656|NCT02441985|OTHER|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
224001657|NCT02441985|OTHER|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition (CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
224001658|NCT05722353|OTHER|Biocollection|Collection of blood samples and feces specimen at inclusion visit; clinical and biological assessment at each visit.
224001659|NCT06241547|DEVICE|electrical stimualtion via EmeTerm bracelet|We planned to exert electrical stimulation via the bracelet.
224001660|NCT06241547|DRUG|antimetic drugs（ dexamethasone，ondansetron）|Antimetic drugs (dexamethasone ondansetron) are used to prevent postoperative nausea and vomiting.
224124124|NCT05813171|DIETARY_SUPPLEMENT|Allicor|Participants will take Allicor capsules in addition to standard treatment for a year.
224124125|NCT05813171|DRUG|Placebo|Participants will take the placebo capsules in addition to standard treatment for a year.
223425521|NCT02703272|DRUG|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.
223729995|NCT01754623|OTHER|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
224001661|NCT05889741|DRUG|Ropivacaine injection|6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
224001662|NCT05889741|DRUG|Normal saline|6.5cc of Normal Saline one time into the stellate ganglion.
224001663|NCT02247453|OTHER|screening|"All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT."
224124126|NCT03514758|PROCEDURE|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
224124127|NCT05105438|DIETARY_SUPPLEMENT|Consecutive Day Dosing|100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.
223729996|NCT01754623|PROCEDURE|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
223729997|NCT01754623|DRUG|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
224001664|NCT06380296|OTHER|Primary molars pulpotomies with NeoMTA|Primary molar pulpotomies will be performed by trained dentists using NeoMTA, a bioactive material containing calcium silicate known for its bio-active and bone forming potential. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
224001665|NCT06380296|OTHER|Primary molar pulpotomies with NeoPUTTY|Primary molar pulpotomies will be performed by trained dentists using NeoPUTTY, a ready to use bioactive material containing calcium silicate. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
224124128|NCT05105438|DIETARY_SUPPLEMENT|Alternate Day Dosing|100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.
224124129|NCT05120622|DRUG|Tremelimumab|"Tremelimumab 25 mg / 50 mg / 75 mg local cystoscopic injection into bladder wall at or adjacent to site of prior tumour resection (dose divided into 4 injection sites), administered 6 and 3 weeks before radical cystectomy.~Durvalumab 1500mg via IV infusion administered 6 and 3 weeks before radical cystectomy."
223384439|NCT03925675|DRUG|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
223384440|NCT04795037|DRUG|CU06-1004, Single dose|"Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5"
223384441|NCT04795037|DRUG|CU06-1004, Multiple doses|"Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD"
223384442|NCT04795037|DRUG|Placebo|Placebo matched to CU06-1004, oral capsule
223384443|NCT04960371|DIAGNOSTIC_TEST|coronary flow reserve (CFR)|Coronary flow velocity profiles in the left anterior descending artery were obtained using colour-guided pulse wave Doppler. We measured peak diastolic coronary flow velocity of the diastolic coronary waveform at rest and after ATP infusion (140 µg/kg. min) for 2 min. The CFR was calculated as the ratio of hyperaemic peak diastolic velocity to resting baseline diastolic velocity. All patients abstained from caffeine-containing drinks for at least 24h before testing.
223384444|NCT05156671|BIOLOGICAL|Adrecizumab (HAM 8101)|Drip infusion over 60 minutes.
223384445|NCT05156671|DRUG|Placebo|Drip infusion over 60 minutes
223384446|NCT05740111|OTHER|Annual surveillance|Annual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.
224001666|NCT03901599|OTHER|Alveolar ventilation monitoring estimated by the capnographic ventilation|Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
224001667|NCT00717431|PROCEDURE|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
223384447|NCT02064296|DEVICE|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).
224001668|NCT03914001|DEVICE|mpMRI|all eligible patients will undergo mpMRI 4 weks after initial TURBT
224001669|NCT03914001|PROCEDURE|Second look TURBT|after mpMRI all patients will subjected to second look TURBT
223384448|NCT02064296|DEVICE|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
223384449|NCT02119013|DRUG|Octeotride|
223384450|NCT02119013|DRUG|Placebo|
224001670|NCT02811406|PROCEDURE|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
224124130|NCT02876770|DIETARY_SUPPLEMENT|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
224124131|NCT02876770|DIETARY_SUPPLEMENT|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
224124132|NCT02684019|DRUG|Dexmedetomidine|added to propofol sedation
224124133|NCT02684019|DRUG|Magnesium Sulphate|added to propofol sedation
224124134|NCT02245568|DRUG|LMTM|The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
224124135|NCT05909254|OTHER|Palatally impacted canine exposure using a surgical guide|Under local anaesthesia the tissues covering the palatally impacted canine are removed with the help of a surgical guide to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction.
224124136|NCT05909254|OTHER|Palatally impacted canine exposure using the conventional free.hand method|Under local anaesthesia the tissues covering the palatally impacted canine are removed to expose the tooth, to allow the bonding of an attachment on its surface for orthodontic traction. The surgeon relies on the surgical plan and their experience to localize the impacted canine.
224124137|NCT02665234|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
224124138|NCT02665234|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
223384451|NCT02271932|OTHER|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
223384452|NCT03606343|BEHAVIORAL|Teaching Academic Skills to Kids|Group treatment
223425522|NCT02703272|DRUG|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
224124139|NCT01691872|DRUG|Retigabine|Retigabine
224124140|NCT01107275|BIOLOGICAL|rabies vaccine|intradermal vaccination
223384453|NCT03552510|PROCEDURE|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
224001671|NCT02811406|BIOLOGICAL|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of \> 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains \> 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP \< 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
223384454|NCT03099109|DRUG|LY3321367|Administered IV
223384455|NCT03099109|DRUG|LY3300054|Administered IV
224001672|NCT02960737|DEVICE|Oral neuromuscular training using an oral device|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
224001673|NCT04065399|DRUG|revumenib|revumenib orally
224001674|NCT04065399|DRUG|cobicistat|Phase 1 Arm C participants will receive 150 mg cobicistat daily.
224001675|NCT06147349|PROCEDURE|Radical or partial nephrectomy|Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
224001676|NCT02847429|DRUG|Crenolanib|
224001677|NCT02847429|DRUG|Placebo|
224001678|NCT05189210|DRUG|GV1001 Placebo|0.9% normal saline
223384456|NCT01240759|DRUG|S-707106 Dose A|One S-707106 A tablet
223384457|NCT01240759|DRUG|S-707106 Dose B|One S-707106 B tablet
223384458|NCT01240759|DRUG|S-707106 Dose C|Four S-707106 4 X B tablets
223384459|NCT01240759|DRUG|Placebo A tablet|Up to 4 Placebo A tablets
223384460|NCT01240759|DRUG|Metformin|The standard of care dose of metformin for each patient
223384461|NCT00576589|DRUG|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
223384462|NCT00576589|DRUG|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
223384463|NCT06008184|OTHER|24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva)|"24 hours sampling of 4 biological fluids:~* blood: sampling every 20 minutes (through a venous catheter)~* ISF: automated sampling every 20 minutes (microdialysis technique connected to U-Rhythm device)~* Sweat : collection of 1 to 3 samples at 4 differents timepoints~* Saliva : sampling every hour (except during the night)"
223384464|NCT06008184|OTHER|24 hours sampling of ISF or sweat (after validating the correlation with blood)|24 hours sampling in an ambulatory setting
223384465|NCT06373263|OTHER|Plain-language summary|Participants will receive information about a research study via a plain-language summary. The comparator will be a plain-language summary, since plain-language summaries are commonly used and more easily developed than other tools. The summary will be designed based on Canadian government and other key recommendations, including from the Cochrane Collaboration. It will include Background and Objectives, Methods, Results, Limitations, and Key Message for Patients sections and include information on how evidence informs knowledge or health care options. Abstract will be \< 500 words long and use short, positive, active-voice sentence structures and everyday words. Reading level will be between 8th and 9th grade based on Flesch-Kincaid Grade Level and readability score between 60 and 70 based on Flesch Reading Ease.
223384466|NCT06373263|OTHER|Dissemination Tool (Infographic)|The infographic will be developed based on key principles including clearly defining the audience and purpose; sharing a story, rather than just facts, with brief, clear messaging; highlighting main ideas; using an attractive title and images; and following principles of good graphic design.
224001679|NCT05189210|DRUG|GV1001 0.56mg|Lyophilized peptide from hTERT
224001680|NCT05189210|DRUG|GV1001 1.12mg|Lyophilized peptide from hTERT
224001681|NCT00003933|OTHER|laboratory biomarker analysis|
224124141|NCT01712087|DEVICE|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
223384467|NCT06027294|PROCEDURE|Ischemic Conditioning|A cuff will be inflated to a pressure of 225 mmHg.
223384468|NCT05968924|DEVICE|Podimetrics SmartMat|Participants receive training for stepping on SmartMat each day for 6 months. Monthly phone calls will be conducted to assess foot health and mat.
223384469|NCT06088199|DRUG|Apremilast|Oral tablet
224001682|NCT02986308|OTHER|No intervention|
224001683|NCT03845231|BIOLOGICAL|Flucelvax(R)|Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
224001684|NCT03845231|OTHER|Human Challenge virus|A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
224001685|NCT00399464|DRUG|alfuzosin|
224001686|NCT01953705|DRUG|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
224001687|NCT01953705|DRUG|Placebo|
224001688|NCT06209853|DEVICE|PSMA PET/CT|Patients need no specific preparation. F-18 PSMA dose will be 3-4 MBq/kg and injected via IV route scan will be performed 90-120 min after injection
224001689|NCT05645341|DIAGNOSTIC_TEST|screening system for ocular surface malignant tumors|Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.
224001690|NCT04609202|BEHAVIORAL|Nurse led person centred care|Person centred care include patiens narratives, partnership and documentation of a health plan.
224001691|NCT04609202|OTHER|Usual care|Usual care provided by doctors
224001692|NCT02754063|DEVICE|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
224001693|NCT02754063|OTHER|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
224001694|NCT04137744|PROCEDURE|AXILLARY REVERSE MAPPING|subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
224124142|NCT00294502|DRUG|Gentamycin/citrate, Minocycline/EDTA|
224001695|NCT05026762|OTHER|Treatment|Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
223384470|NCT06495060|OTHER|No intervention (Only observation)|No intervention
224001696|NCT00531219|PROCEDURE|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
224001697|NCT00531219|PROCEDURE|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
224001698|NCT01228331|DRUG|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
224001699|NCT01228331|DRUG|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
224001700|NCT01228331|DRUG|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
224001701|NCT01228331|DRUG|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
224001702|NCT01228331|DRUG|Daunorubicin hydrochloride|part of induction and reinduction therapy
223384471|NCT05042258|DRUG|Dupilumab|12 week dupilumab administration
223545459|NCT03417583|OTHER|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
224001703|NCT01228331|DRUG|Dexamethasone|part of reinduction therapy
224001704|NCT01228331|DRUG|Doxorubicin hydrochloride|part of reinduction therapy
224124143|NCT05966909|DIAGNOSTIC_TEST|Doppler Ultrasound|Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
224124144|NCT05281783|DEVICE|percutaneous radiofrequency ablation (RFA)|We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).
223384472|NCT04168879|DRUG|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used to block the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
223384473|NCT04168879|DRUG|normal saline|1.5 ml of normal saline is delivered to the sphenopalatine ganglion by ultrasound guided suprazygomatic approach
223384474|NCT02040077|BEHAVIORAL|Computer + Fluency|
223545460|NCT06004297|PROCEDURE|ACL reconstruction|performed arthroscopically
223384475|NCT02040077|BEHAVIORAL|Computer Only|
223545461|NCT03771040|DRUG|Masitinib|
223545462|NCT03771040|DRUG|Placebo|
223545463|NCT00506779|DRUG|Imatinib Mesylate|Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily
224001705|NCT01228331|DRUG|Etoposide phosphate|part of different chemotherapy blocks
224001706|NCT01228331|DRUG|Mercaptopurine|part of different chemotherapy blocks
224001707|NCT01228331|DRUG|Methotrexate|part of different chemotherapy blocks
224001708|NCT01228331|DRUG|Methylprednisolone|part of different chemotherapy blocks
224001709|NCT01228331|DRUG|Pegaspargase|part of different chemotherapy blocks
224001710|NCT01228331|DRUG|Thioguanine|part of different chemotherapy blocks
224001711|NCT01228331|DRUG|Vincristine sulfate|part of intravenous chemotherapy
224001712|NCT01228331|RADIATION|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
224001713|NCT02643303|DRUG|Durvalumab|
224001714|NCT02643303|DRUG|Tremelimumab|
224124145|NCT02056535|BEHAVIORAL|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
224124146|NCT01013909|DRUG|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
224124147|NCT01013909|DRUG|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
223384476|NCT02040077|BEHAVIORAL|Treatment as Usual|
223384477|NCT03041428|DEVICE|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
224001715|NCT02643303|DRUG|Poly-ICLC|
224001716|NCT06458270|BEHAVIORAL|Salt warning label|A salt warning label will feature on the restaurant menu next to menu items that are high in salt (\>3g, more than 50% of guideline daily amount \[GDA\] in the UK).
224001717|NCT06321601|DRUG|Avacopan|Oral administration
224001718|NCT00283751|DRUG|insulin detemir|
224001719|NCT00283751|DRUG|insulin glargine|
224001720|NCT00767390|DEVICE|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
224001721|NCT02783027|BEHAVIORAL|SleepTrackTXT2|Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
224124148|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
224124149|NCT01013909|DRUG|Placebo|Application of one dose daily by means of an metered dose
224124150|NCT01013909|DRUG|Lamisil Once|One application of Lamisil Once
223384478|NCT04328701|BEHAVIORAL|Mindfulness-based Cognitive Behavioral Therapy|Mindfulness-based CBT methods are based on pain self-management paradigms, and involve the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing), the enhancement of self-efficacy for managing pain, and training in the use of adaptive pain-coping strategies such as relaxation, distraction, and self-talk.
224001722|NCT01460459|BEHAVIORAL|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
224001723|NCT03069703|BIOLOGICAL|PCV13|one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
224001724|NCT03069703|BIOLOGICAL|PPV23|one dose of PPV23 at M5
223384479|NCT00390637|BEHAVIORAL|High or low Glycemic Index and high or low Protein Diet|
223384480|NCT00271232|DEVICE|Cardiac resynchronization therapy|
223384481|NCT00601887|DRUG|Meloxicam|
223384482|NCT02816983|RADIATION|SBRT|
223384483|NCT06387420|DRUG|AK117|Subjects receive AK117 intravenously.
223384484|NCT06387420|DRUG|Azacitidine|Subjects receive azacitidine subcutaneously.
223384485|NCT06387420|DRUG|Venetoclax|Subjects receive venetoclax orally.
223384486|NCT06387420|OTHER|Placebo|Subjects receive placebo intravenously.
223545464|NCT00506779|DRUG|Paclitaxel|175 mg/m\^2 by vein over 3 Hours every 21 Days
224001725|NCT03069703|DRUG|Rituximab|375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
224001726|NCT05860582|DRUG|[14C]GB491|A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
224001727|NCT04744272|DEVICE|myAsthma|myAsthma is an online digital self-management application to support asthma patients by offering education, inhaler technique, pulmonary rehabilitation, symptoms and medication usage tracking remotely.
224001728|NCT04339959|OTHER|Remote Assessment of Physical Function with Direct Observation|An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
223384487|NCT01060241|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
223384488|NCT04409314|DRUG|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
223384489|NCT04409314|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223384490|NCT05517538|DEVICE|Electromyography-Needle Intramuscular Drug guidance|EMG-guided needle neurotoxin injection
223384491|NCT05517538|DRUG|Botulinum toxin type A|Botulinum toxin type A injection into the Corrugator Supercilii muscle
223384492|NCT04495881|DRUG|Sitagliptin 100mg|Sitagliptin 100mg Qd
223384493|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Low Dose|
223384494|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) Medium dose|
223384495|NCT01123915|BIOLOGICAL|Opal-HIV-Gag(c) High dose|
223384496|NCT01123915|OTHER|Dimethyl Sulfoxide|
223384497|NCT06319027|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
223384498|NCT06319027|OTHER|Fluciclovine F18|Given IV
223384499|NCT06319027|DRUG|Gadolinium-Chelate|Receive gadolinium-based contrast agent
223384500|NCT06319027|PROCEDURE|Magnetic Resonance Spectroscopy|Undergo MR spectroscopy
223384501|NCT06319027|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223384502|NCT01721304|OTHER|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
223384503|NCT03796052|OTHER|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
223384504|NCT03519087|OTHER|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
223384505|NCT03519087|OTHER|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
223425523|NCT02703272|DRUG|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
223425524|NCT02703272|DRUG|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
223425525|NCT02703272|DRUG|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.
223425526|NCT02703272|DRUG|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
223425527|NCT02703272|DRUG|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
223425528|NCT02703272|DRUG|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
223425529|NCT01689246|DRUG|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
223425530|NCT01689246|DRUG|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
223384506|NCT03519087|OTHER|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
224001729|NCT04339959|OTHER|Remote Assessment of Physical Function|An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
224001730|NCT03241108|DRUG|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
224001731|NCT03241108|OTHER|Placebo|Placebo
223384507|NCT01137071|BIOLOGICAL|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
223384508|NCT02057887|DRUG|HM10660A|
223384509|NCT02057887|DRUG|Pegasys|180 mcg Pegasys SC once weekly
223384510|NCT02850185|DEVICE|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
223384511|NCT02850185|DEVICE|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
223384512|NCT02850185|DRUG|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
223384513|NCT04708015|OTHER|No Intervention|A retrospective chart review of medical records
223384514|NCT03815526|OTHER|Dynamic tape|Dynamic tape apply 1 time
223384515|NCT03815526|OTHER|Kinesio tape|Dynamic tape apply 1 time
223384516|NCT03815526|OTHER|Sport tape|Dynamic tape apply 1 time
224001732|NCT04552899|DRUG|PRM-151 (Zinpentraxin Alfa)|A 10 mg/kg IV infusion of PRM-151 based on the participants weight will be administered on Days 1, 3 and 5 followed by infusions Q4W to Week 48.
224001733|NCT04552899|DRUG|Placebo|Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
224001734|NCT00288184|DRUG|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
224001735|NCT00288184|DRUG|Placebo|
223384517|NCT02324582|DRUG|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
223384518|NCT03730207|DEVICE|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
223545465|NCT05575544|PROCEDURE|Acupuncture plus morphine|The acupuncture was combined with intravenous use of morphine to achieve anesthesia during the ablation procedure
223545466|NCT01786681|PROCEDURE|Positive pressure|
224001736|NCT03189342|BEHAVIORAL|Single task training|The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
224124151|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg|Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
224124152|NCT05271084|DRUG|Citalopram (tablet) 20 mg + Placebo (tablet)|Selective serotonin reuptake inhibitor (SSRI) + placebo
223384519|NCT03730207|DEVICE|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
223384520|NCT05031585|DEVICE|Roncoliv|The medical device with nasal spray solution should be used 1 time a day, before bedtime, for 30 days.
223384521|NCT05031585|DEVICE|Placebo|The medical device with placebo should be used 1 time a day, before bedtime, for 30 days.
224124153|NCT01725152|DRUG|Ganaxolone|oral suspension, given in 3 divided doses
224124154|NCT01725152|DRUG|Placebo|oral suspension, given in 3 divided doses
224124155|NCT05201274|BEHAVIORAL|Baduanjin sequential therapy|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
223384522|NCT04594681|DRUG|Placebo|Placebo is administered once daily or three times daily.
223384523|NCT04594681|DRUG|KHK4951|KHK4951 is administered once daily or three times daily.
223384524|NCT02556957|BEHAVIORAL|HealthScouts|
223384525|NCT02556957|OTHER|Standard of Care|
223384526|NCT06336265|DIAGNOSTIC_TEST|Diaphragm ultrasound|Respiratory parameters, diaphragmatic activity, and variation rate of diaphragmatic thickness were recorded at the beginning of high-flow nasal cannula oxygen therapy, 1 hour after treatment, 3 hours after treatment, 6 hours after treatment, 9 hours after treatment, and 12 hours after treatment.
223384527|NCT05514223|OTHER|Biomaterial collection for observational purpose|The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
223545467|NCT05529251|RADIATION|Radiotherapy boost|"Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :~* 20 Gy if no more disease is visible (node \< 1 cm in large diameter)~* 24 Gy for nodes \<= 2 cm~* 30 Gy for nodes \> 2 cm"
223545468|NCT05529251|DRUG|Carboplatin AUC7|Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
224001737|NCT03189342|BEHAVIORAL|dual task training|The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
224001738|NCT03189342|BEHAVIORAL|exercise-cognitive activity combined training|The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
224001739|NCT03304678|DRUG|Sirolimus 2mg|Patients with LAM, whose treating physicians have decided that they need to start treatment with sirolimus will be referred to the NIH Clinical Center for these studies.
224001740|NCT06799247|BIOLOGICAL|Decartes-08|Autologous mRNA CAR T-cell therapy
224001741|NCT06799247|OTHER|Placebo Drug|infusion without Decartes-08
224001742|NCT02750449|DRUG|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm\*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm\*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
224001743|NCT02750449|OTHER|Untreated skin|This site is patched without treatment as control
224001744|NCT06563128|OTHER|Clearfil Majesty Posterior|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
223384528|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
224001745|NCT06563128|OTHER|Omnichroma Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
224001746|NCT06563128|OTHER|Zen Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
224001747|NCT06563128|OTHER|Vittra Aps Unique Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
224001748|NCT06563128|OTHER|Charisma Diamond Universal Group|After filling the teeth of the patients with 4 different universal resins and 1 conventional composite resin, the filling will be evaluated and recorded according to the clinical success criteria at the beginning. Then, the patients will be called back to the clinic after 6 months and 12 months, respectively, and the fillings made according to the same criteria will be re-evaluated and recorded.
224001749|NCT03786991|OTHER|No intervention|No intervention
223384529|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
223384530|NCT00320203|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
223384531|NCT00320203|OTHER|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
223384532|NCT00199017|DRUG|Dexamethasone/Prednisolone|
223384533|NCT00199017|DRUG|Cyclophosphamide|
223384534|NCT00199017|DRUG|Vincristine|
223384535|NCT00199017|DRUG|Daunorubicin|
223384536|NCT00199017|DRUG|Asparaginase|
223384537|NCT00199017|DRUG|G-CSF|
223384538|NCT00199017|DRUG|Mercaptopurine|
223384539|NCT00199017|DRUG|Cytarabine|
223384540|NCT00199017|DRUG|Methotrexate|
223384541|NCT00199017|DRUG|VP16|
223384542|NCT00199017|DRUG|Vindesine|
223384543|NCT00199017|DRUG|Adriamycin|
223384544|NCT00199017|DRUG|Thioguanine|
223384545|NCT00199017|DRUG|HDARAC|
223384546|NCT00199017|PROCEDURE|CNS irradiation|
223384547|NCT00199017|PROCEDURE|Mediastinal irradiation|
223384548|NCT00199017|DRUG|Cladribine|
223425531|NCT01689246|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
223384549|NCT04521894|DEVICE|Positron emission tomography/computerized tomography (PET/CT)|"1. Genetic factors and age:~   Epidemiological studies have shown that if an immediate family member (brother or father) suffers from prostate cancer, the risk of prostate cancer will be more than doubled. Age is a relatively strong risk factor for PCa.~2. Prostatitis: Prostatitis is related to PCa. Cancer is usually found in the tissues where inflammation is found.~3. Obesity: Research has found that obese patients have a low grade of PCa, but their risk of developing aggressive cancer is higher.~4. Infection:~5. Exercise: Most studies have found that exercise does not reduce the risk of prostate cancer, but some studies have shown that.~6. Daily diet: The corrective mechanism of diet in PCa is not very clear.~7. Drinking history:"
223384550|NCT03415646|OTHER|Erector Spinae Plane Block|erector spinae plane block with double level injection will be administered before the surgery
223384551|NCT03415646|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
223384552|NCT05378958|OTHER|Individual interview|"Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion."
223384553|NCT04905693|DRUG|Inhaled Treprostinil|Inhaled Treprostinil (6 mcg/breath) administered QID
223384554|NCT04905693|DEVICE|Treprostinil Ultrasonic Nebulizer|Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
223384555|NCT05501821|DRUG|KBA1412|Part A, B, C
224295699|NCT03690661|BEHAVIORAL|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
223384556|NCT05501821|DRUG|Pembrolizumab|Part C only
223384557|NCT06166524|PROCEDURE|Catheter ablation for atrial fibrillation using pulsed-field energy|Patients will undergo pulmonary vein isolation using pulsed-field energy
223384558|NCT06166524|PROCEDURE|Conservative arm|Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
223384559|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g|Agave tequilana Weber blue variety 5 g once a day for 8 weeks
223384560|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 10 g|Agave tequilana Weber blue variety 10 g once a day for 8 weeks
223384561|NCT04716868|DIETARY_SUPPLEMENT|Agave Fructans 5 g + Maltodextrin 10 g|Maltodextrin 10 g + Agave tequilana Weber blue variety 5 g once a day for 8 weeks
223384562|NCT04716868|DIETARY_SUPPLEMENT|Psyllium plantago|Psyllium plantago 15 g once a day for 8 weeks
223384563|NCT03405922|DRUG|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
223729998|NCT03220360|PROCEDURE|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
223729999|NCT03220360|PROCEDURE|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
224001750|NCT04051502|DRUG|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
224001751|NCT04051502|DRUG|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament"
224001752|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
224001753|NCT04051502|DRUG|Method 3: Indocyanine green dye|Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
224001754|NCT04999618|DRUG|Haemoblock|Delivering with transdermal patches
224001755|NCT04999618|OTHER|Placebo|Delivering with transdermal patches
224001756|NCT05755906|DRUG|BFF MDI 160/9.6 μg BID (320/19.2μg/day)|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
223384564|NCT03405922|DRUG|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
223384565|NCT06064305|OTHER|No study-specific interventions|Septic AKI patients, post-cardiothoracic AKI patients and non-AKI patients undergoing routine nephrectomy. Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians and the respective specialists.
223384566|NCT03694756|DEVICE|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
223384567|NCT03694756|PROCEDURE|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
223730000|NCT03220360|PROCEDURE|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
223730001|NCT04675645|OTHER|HU-Go app|A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
223730002|NCT01086722|DRUG|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
224295700|NCT03690661|BEHAVIORAL|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
223384568|NCT03840564|OTHER|Point of care (POC)|All the analyzes will be done in delocalized
223384569|NCT05547997|OTHER|Stretching exercises|Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times
223384570|NCT05547997|OTHER|Two way traction|During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
223384571|NCT03987997|DEVICE|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
223384572|NCT06808477|DRUG|BBT001|BBT001 will be administered
223384573|NCT06808477|DRUG|Placebo|Placebo will be administered
223384574|NCT00778882|DRUG|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
224001757|NCT05755906|DRUG|BD MDI 160 μg BID (320 μg/day)|Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
224001758|NCT05922982|DRUG|norepinephrine weaning protocol|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol
223384575|NCT06978972|OTHER|Cognitive Stimulation Therapy|"CST is an evidence-based, cognitively stimulating therapeutic group intervention for individuals with mild-to-moderate dementia. Individuals participate in CST 2 times per week for 7 weeks. The CST sessions are administered by a variety of professionals who become certified through the St. Louis School of Medicine. The general structure of each session will follow the CST Manual called Making a Difference 1. Each session will be based on a theme and will include an introduction, theme song, current affairs activity, the main activity (physical games, sounds, food, being creative, word and number games, team quizzes, orientation, current affairs, ect.), suggested activities for home, and closure. These sessions are highly structured and will follow the introduction, theme song, current affairs activity, the main activity, suggested activities for home, and closure organization strictly. The participants will spend 45 minutes in each session."
224001759|NCT05922982|DRUG|norepinephrine weaning protocol and guided by the HPI|MAP-based (MAP \> 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
224001760|NCT01499303|DRUG|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
224001761|NCT01588964|PROCEDURE|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
224001762|NCT00900224|GENETIC|DNA analysis|
224124156|NCT05201274|BEHAVIORAL|Aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located at home or cardiac rehabilitation centre lasting 3 months. The program is consistent with the current recommended guidelines of moderate-intensity exercises for MI.
224124157|NCT03614169|PROCEDURE|Implantation of a HIS-pacing lead|This intervention is attempted first
223384576|NCT06982625|PROCEDURE|Ultrasound guided supra inguinal fascia iliaca block|The ultrasound probe is placed in a cephalo-caudal orientation, over the inguinal ligament, lateral to the femoral nerve. The iliacus muscle, which is covered caudally by the sartorius muscle and cephalically by the internal oblique muscle, is visualized in depth. Between these two muscles, an area is identified where the iliacus muscle is covered only by subcutaneous tissue. The needle is introduced in a cranio-caudal direction, and the injection is initiated in this area, beneath the fascia iliaca. The needle then advances through the space created by the injection, as far as possible in a cephalic direction, beneath the internal oblique muscle. An injection of 40 ml of 0.1% ropivacaine is administered.
223384577|NCT06982625|PROCEDURE|Placebo Injection|Five milliliters of saline are injected subcutaneously under ultrasound guidance
223545469|NCT05529251|DRUG|3 cycles of EP|3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
223545470|NCT02869542|OTHER|Data collection|
223545471|NCT02215057|DRUG|topical anesthesia|topical anesthetic drops and Group 2
224001763|NCT00900224|GENETIC|DNA methylation analysis|
224001764|NCT00900224|GENETIC|gene expression analysis|
224001765|NCT00900224|GENETIC|mutation analysis|
224001766|NCT00900224|GENETIC|polymerase chain reaction|
224124158|NCT03614169|PROCEDURE|Implantation of a LV-pacing lead|This intervention is attempted first
224124159|NCT01591226|DIETARY_SUPPLEMENT|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
224124160|NCT01591226|DIETARY_SUPPLEMENT|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
224124161|NCT01591226|DIETARY_SUPPLEMENT|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
224124162|NCT01591226|DIETARY_SUPPLEMENT|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
224124163|NCT02044159|DRUG|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
224124164|NCT02044159|OTHER|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
224001767|NCT00900224|GENETIC|reverse transcriptase-polymerase chain reaction|
224001768|NCT00900224|OTHER|high performance liquid chromatography|
224001769|NCT00900224|OTHER|laboratory biomarker analysis|
224001770|NCT00006405|BEHAVIORAL|Exercise|
224124165|NCT00266721|DRUG|Pancrelipase (Creon) 2 tablets with each meal|
224001771|NCT00508313|PROCEDURE|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
224001772|NCT02762643|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
224001773|NCT02762643|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
224001774|NCT02762643|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
223384578|NCT06982625|PROCEDURE|Surgical and anesthetic protocol|"All patients receive standard general anesthesia:~* Induction of anesthesia by sufentanil, ketamine, propofol and tracrium if needed,~* Maintenance of anesthesia by sevoflurane and sufentanil if needed,~* Prevention of PONV by dexamethasone and droperidol,~* Post-operative analgesia by paracetamol, ketoprofene, nefopam, as indicated. Total hip arthroplasty is performed by anterior or postero-lateral approach, depending on surgeon preference.~In the post-anesthesia care unit, if numerical pain rating scale at rest is \>=4, patients are randomized to receive experimental or placebo intervention."
223384579|NCT05274633|DRUG|Ravulizumab|Participants will be observed for 52 weeks after the start of ravulizumab.
223384580|NCT00549744|DRUG|GSK256066|
223384581|NCT02928445|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
223384582|NCT02928445|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
223384583|NCT05603533|OTHER|Music and video-based group exercise therapy|Each exercise session will last up to 45min. The participants will follow this group exercise therapy twice a week for four months.
223384584|NCT04031755|DRUG|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
223384585|NCT04031755|DRUG|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
223384586|NCT02836210|DEVICE|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
223384587|NCT02965417|DRUG|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
223384588|NCT06469632|OTHER|Active Comparator: Experimental Group 1|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique."
223384589|NCT06469632|OTHER|Experimental: Experimental Group 2|"Multimodal physiotherapy treatment composed of:~Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain.~Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity.~Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.~Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes."
223384590|NCT04358952|DIAGNOSTIC_TEST|Global Longitudinal Strain|Electrocardiogram with measure of the Global Longitudinal Strain to evaluate myocardiac dysfunction
224001775|NCT03389373|DEVICE|GC Strep Mutans Saliva Sampling|Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
224001776|NCT02542800|BEHAVIORAL|Episodic memory task|
224124166|NCT05798689|COMBINATION_PRODUCT|Probiotic administration and gluten|Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
223384591|NCT04663191|PROCEDURE|anatomical resection|Anatomical resection with systematic lymph-node dissection
223384592|NCT04388553|PROCEDURE|single shot lumbar Erector Spinae Plane block|unilateral (operative side), performed at L1 level, under ultrasound guidance
223384593|NCT02123446|DRUG|Cephalexin|Administered orally.
223384594|NCT04604795|DRUG|GSK3915393 Capsules|GSK3915393 capsules will be given orally.
223384595|NCT04604795|DRUG|GSK3915393 Solution for Infusion|GSK3915393 solution for infusion will be administered intravenously.
223384596|NCT04604795|DRUG|Placebo capsules|Placebo matching GSK3915393 capsules will be given orally.
224001777|NCT02542800|DEVICE|fMRI|
224001778|NCT03040934|DEVICE|Firehawk sirolimus target eluting coronary stent system|98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
224001779|NCT03040934|DEVICE|XIENCE Everolimus-Eluting Coronary Stent System|98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
224001780|NCT03916796|OTHER|Exercise|-The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic \& dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.
224001781|NCT03916796|OTHER|Enhanced Recovery after surgery|-The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.
224001782|NCT03916796|OTHER|Psychological screening with counselling services as needed|-The psychological screening will be completed by the Radiation Oncology nurse at the consult visit
224124167|NCT05798689|COMBINATION_PRODUCT|Placebo administration and gluten|The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
223384597|NCT04604795|DRUG|Itraconazole|Participants will be administered with GSK3915393 along with ITZ orally
223384598|NCT04604795|OTHER|Water|Participants will be administered with GSK3915393 along with water orally
223384599|NCT04604795|OTHER|Grape fruit juice|Participants will be administered with GSK3915393 along with GFJ orally
223384600|NCT01000948|DRUG|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
223384601|NCT02998086|BEHAVIORAL|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
223384602|NCT05671458|OTHER|intraoperative navigation and creation of tumor resection maps|TRM are based on intraoperative navigation data and yield anatomically accurate marks of the tumor resection margin and potential residual tumor areas on clinical imaging. These marks will be annotated with histopathological information. Subsequently, the resulting 3-dimensional TRM will be imported into the radiotherapy planning system as part of a multidisciplinary workflow.
223384603|NCT00611624|RADIATION|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
224001783|NCT03916796|OTHER|Dietary Counseling Services|-Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
224001784|NCT04685746|BEHAVIORAL|Balanced Growth Protocol|Assessment of the Balanced Growth Protocol, consisting of audiovestibular testing, motor and cognitive tasks
224001785|NCT01682772|DRUG|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
224295701|NCT02113189|OTHER|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
223384604|NCT05629819|DEVICE|Non-invasive phrenic nerve stimulation|Some studies have shown that PNS can relieve diaphragmatic atrophy and reverse diaphragmatic dysfunction.
223384605|NCT03906110|BEHAVIORAL|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
223384606|NCT03906110|BEHAVIORAL|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
223384607|NCT03906110|BEHAVIORAL|Personalized One on One Education|"* Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~* Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~* For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~* Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
224001786|NCT03673124|DRUG|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
224001787|NCT03673124|DRUG|Letrozole|2.5 mg by mouth daily
224001788|NCT06264128|DEVICE|TPAP|"TPAP is a form of CPAP therapy where the therapy pressure is reduced from the beginning of inhalation through mid or later exhalation. The CPAP therapy pressure is only present at the end of the expiratory phase."
224001789|NCT06264128|DEVICE|CPAP|CPAP is a standard formal at home therapy for obstructive sleep apnea where a device attached via a facemask applies a constant pressure to a patient's lungs during sleep. It is the reference standard in this study.
224001790|NCT05336786|DRUG|Perflutren Lipid Microspheres|Given IV
224001791|NCT05336786|PROCEDURE|Ultrasound|Undergo ultrasound
224001792|NCT05302180|OTHER|Pain neuroscience education|"The online pain neuroscience education program will be based on the model proposed by the Pain Research Group, available in http://pesquisaemdor.com.br, which presents the Path of Recovery. In our program we will hold 10 meetings: (1) conversation with the group, (2) acceptance and pain education, (3) continuation about pain education, (4) sleep hygiene, (5) pharmacological assistance, (6) recognizing stress and negative emotions, (7) increasing positive coping in lifestyle, (8) exercises, (9) communication, and (10) prevention of recurrence. The program will be offered by synchronous meetings; asynchronous (videos) and e-book."
224001793|NCT05302180|OTHER|Usual care|All participants will receive usual care in one of the five physiotherapy clinics accredited to SUS, according to availability of scheduling in the services. The usual care consists of 10 sessions of physical therapy, that is mainly composed by kinesiotherapy and electrothermophototherapy.
224001794|NCT01485497|DEVICE|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
224001795|NCT02038712|DIETARY_SUPPLEMENT|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
224001796|NCT02038712|DIETARY_SUPPLEMENT|Fasted condition|Subjects will consume 600mL plain water.
224001797|NCT02038712|PROCEDURE|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
224001798|NCT02038712|BEHAVIORAL|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
224001799|NCT02038712|PROCEDURE|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
224001800|NCT04396249|DEVICE|Active tVNS|One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.
224001801|NCT04396249|DEVICE|Sham tVNS|Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
224001802|NCT04411329|DRUG|Bupivacaine|local anesthetics, steriod, alpha 2 blockers
224001803|NCT04411329|DRUG|Dexamethasone|dexamethazone
224001804|NCT04411329|DRUG|Dexmedetomidine|dexmedetomidine
224001805|NCT04411329|DRUG|Hyalouridinase|hyalouridinase
224295702|NCT02113189|OTHER|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
224295703|NCT02113189|OTHER|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
224001806|NCT02190903|OTHER|General endotracheal anesthesia|"General Anesthesia~Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol."
224001807|NCT02190903|OTHER|Regional (spinal) Anesthesia|Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed.
224001808|NCT00078351|PROCEDURE|High molecular weight hylan (Synvisc) injection|
224001809|NCT03098563|DRUG|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
224001810|NCT00201708|DRUG|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
224001811|NCT00201708|DRUG|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
224001812|NCT00201708|DRUG|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
224001813|NCT05925231|DIAGNOSTIC_TEST|Box and Block Test|3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
224001814|NCT01209377|BEHAVIORAL|standard|EMDR treatment with bilateral stimulation via eye movement
224001815|NCT01209377|BEHAVIORAL|fixed|EMDR treatment with fixed eyes
224001816|NCT01209377|BEHAVIORAL|no focus|trauma exposure without external focus
224001817|NCT01209377|PROCEDURE|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
224124168|NCT03065712|DRUG|F-18 Fluoroestradiol|F-18 Fluoroestradiol will be administered for PET/CT scan.
223384608|NCT03906110|DIAGNOSTIC_TEST|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
223384609|NCT00719186|DRUG|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
223384610|NCT00719186|DRUG|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
223384611|NCT02864355|DEVICE|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
224001818|NCT02383940|DRUG|Sotagliflozin|Sotagliflozin 400 mg, once daily before the first meal of the day
224001819|NCT02383940|DRUG|Placebo|Placebo, once daily before the first meal of the day
224001820|NCT05510427|DRUG|Infigratinib|Given by PO
224001821|NCT05510427|DRUG|Atezolizumab|Given by (IV) vein
224001822|NCT05510427|DRUG|Bevacizumab|Given by (IV) vein
224001823|NCT01158287|DRUG|sorafenib tosylate|
224001824|NCT01158287|OTHER|laboratory biomarker analysis|
224001825|NCT03523611|PROCEDURE|Lung Resection|Lung resection surgery
224001826|NCT04183036|PROCEDURE|Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The operator positioned the clip and assessed the clip position and made sure the incision was clipped. Four to five endoclips were positioned in the incision in a zipper way from distal to proximal papillary sphincterotomy
223384612|NCT02818101|BEHAVIORAL|Hypnosis session|
223384613|NCT01558960|DRUG|IVit Melphalan|IVit injections of Melphalan
223545472|NCT02215057|DRUG|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
223545473|NCT02153437|DRUG|BMS-919373|
223545474|NCT02153437|DRUG|Sotalol|
224001827|NCT00445627|DRUG|Metformin|
224001828|NCT00445627|DRUG|Insulin|
224001829|NCT00445627|BEHAVIORAL|Nutrition counseling|
224001830|NCT00445627|BEHAVIORAL|Exercise counseling|
224001831|NCT04308590|DRUG|Relacorilant|Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.
224001832|NCT04308590|OTHER|Placebo|Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.
224001833|NCT06013631|OTHER|Prosthesis Training|Training for prostheses at the appropriate amputation level will be provided. Conventional gait training protocols include Tandem walk, within parallel bar, controlled environment, full length Mirror on one side, weight shifting, shifting onto the Prosthetic Side, Pelvic 22 rotation, Stepping on multiple heights and positions, Tandem walk, within parallel bar, and weight shifting. Gait training will last six weeks in total.
224001834|NCT06013631|OTHER|Phantom Exercises|The phantom exercises involved visualizing and then trying to perform the movements of the phantom limb.
224124169|NCT03065712|PROCEDURE|Computed Tomography|Undergo PET/CT
224124170|NCT03065712|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224124171|NCT03065712|OTHER|Laboratory Biomarker Analysis|Correlative studies
224295704|NCT06160505|DEVICE|S53P4 Bioactive glass|Following mastoidectomy, the mastoid cavity, and if the ossicular chain has been removed the epitympanum as well, are obliterated using S53P4 bioactive glass. The bioactive glass is mixed with saline and administered to the cavity, ensuring a tight fit.
224001835|NCT04903418|DEVICE|CBCT software|"* Retrospective Data Analysis will be performed after the CBCT images are pooled from the computer database.~* All the CBCT examinations will be obtained for patients who were scanned using CBCT Software (Planmeca Romexis® Viewer software).~* CBCT images will be analysed in different planes."
224001836|NCT02878447|RADIATION|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
224001837|NCT02474719|OTHER|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
224001838|NCT06489860|DRUG|HIV|"Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.~Humidification: \<5% Dosage Form:~Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date"
224001839|NCT06489860|DRUG|Malignant Neoplasms Safety Study for the Treatment of Neoplasms|Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.
224001840|NCT03853551|DRUG|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
224001841|NCT06230172|RADIATION|Weaning incubator (heat) at an lower postnatal weight|"Infants in the intervention group are weaned in the same manner as the infants in the control arm; however, the wean begins at a lower postnatal weight.~Our institutional guidelines for weaning infants from incubator to crib was unchanged for both groups."
224001842|NCT02511262|DEVICE|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
224001843|NCT04549571|OTHER|Decision Aid iCanDecide - ESE website|Utilize the iCanDecide - ESE website
224001844|NCT04549571|OTHER|Decision Aid iCanDecide - S website|Utilize the iCanDecide - S website
224001845|NCT04549571|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224001846|NCT04549571|OTHER|Interview|Participate in interview
224001847|NCT04549571|OTHER|Training|Receive training
224001848|NCT04549571|OTHER|Media Intervention|Utilize the CDB
224001849|NCT04549571|OTHER|Best Practice|Utilize usual care
224001850|NCT04549571|OTHER|Survey Administration|Ancillary studies
224001851|NCT04549571|OTHER|Quality-of-Life Assessment|Ancillary studies
224001852|NCT05324670|OTHER|Didactic model for suicidal behavior in the framework of impulsivity and ideations|It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
224001853|NCT00560846|DIETARY_SUPPLEMENT|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
224001854|NCT00560846|DIETARY_SUPPLEMENT|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
224001855|NCT03414385|OTHER|Exercise|Acute bout of aerobic exercise at moderate intensity for 2 hours
223384614|NCT03182777|PROCEDURE|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
223384615|NCT02109653|DRUG|LGX818|Oral LGX818 300mg daily
223730003|NCT03482440|DRUG|Salsalate Oral Tablet|1500mg twice daily for 4 days prior to experimental testing
223384617|NCT03264807|PROCEDURE|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
224001856|NCT00056875|DRUG|recombinant human keratinocyte growth factor|
224001857|NCT00897793|PROCEDURE|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
224001858|NCT00897793|RADIATION|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
224001859|NCT06223022|BEHAVIORAL|Proactive nurse-led telephone follow-up|An intervention nurse call the patients regularly with predetermined intervals and give support
223384618|NCT03264807|PROCEDURE|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
223425532|NCT02197832|PROCEDURE|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
224001860|NCT04396288|DEVICE|ultrasound imaging at the forearm and at the tibia|ultrasound imaging will be performed at the radius bone (forearm) and at the tibia, before, during, and after a change of intraosseous blood flow
224001861|NCT04721613|OTHER|Assessment of Melatonin level|Measuring the plasma or serum melatonin in pg/ml during the first 24 hours after delirium diagnosis in two-hour intervals.
224001862|NCT03151070|OTHER|QVLM Intervention package|"QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants"
224295705|NCT04053361|PROCEDURE|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
224295706|NCT00207675|DRUG|infliximab|
224295707|NCT05070000|DIAGNOSTIC_TEST|Radiologic examination|Patients underwent US, CT or CT after US
224295708|NCT00166907|BEHAVIORAL|Balance and Exercise|
224001863|NCT02410616|BEHAVIORAL|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
224001864|NCT02410616|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
224001865|NCT04137328|DRUG|Liraglutide|0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
224001866|NCT04137328|DRUG|insulin|Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
224001867|NCT06223919|BIOLOGICAL|LC16m8|"LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur.~The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution.~Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed.~This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of.~Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses"
224001868|NCT00002107|DRUG|Aldesleukin|
224001869|NCT00310557|DRUG|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
224001870|NCT03250793|DEVICE|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
224001871|NCT06268457|PROCEDURE|Chemoembolization with Doxorubicin|"* Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature)."
224001872|NCT00458276|DRUG|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
224001873|NCT00458276|DRUG|placebo|Placebo (i.e., normal saline) for i.v. use.
224001874|NCT06472726|BEHAVIORAL|IONA Mind app|The IONA Mind app is a smartphone app that delivers mental health support.
224295709|NCT02564146|DRUG|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
223384619|NCT06489236|BEHAVIORAL|Vaccine Confidence: Skills to Promote Vaccination in the Pediatric Consultations|Intervention mapping principles guided a multidisciplinary team through the development of the intervention. The intervention is a 12-hour training program focused on improving vaccination promotion and vaccine hesitancy management during pediatric consultations. The program comprises 10 hours of online education and 2 hours of in-person activities. Online training materials (short video lectures, video case studies, and readings) were structured in three learning modules covering vaccine and vaccine hesitancy technical information, vaccination promotion communication strategies, and practice organizational resources. In-person activities involved role-playings and group discussions. Intervention content is evidence-based. As a participation incentive, pediatric nurses and pediatricians who complete all program activities, including a multiple-choice final test, will receive 2,5 accredited continuing medical education credits.
223384620|NCT04502212|DEVICE|Hepatic Ultrasound Insonification|Hepatic ultrasound insonification will be performed after an overnight fast (no food or drinks except for water for at least 10 hours) at approximately the same time on each day for three days.
223384621|NCT03022916|DRUG|Nail Polish + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish
223384622|NCT03022916|OTHER|Nail polish|Application of nail polish only to both big toe nails
223384623|NCT03022916|DRUG|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat
224124172|NCT01095575|DRUG|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
224124173|NCT01111539|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
224124174|NCT01111539|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
223384624|NCT03022916|DRUG|Nail Polish + Top Coat + Efinaconazole Solution|Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
223384625|NCT01850251|DIETARY_SUPPLEMENT|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
224001875|NCT05716048|BEHAVIORAL|KF-mSMT Plus Aerobic Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
224001876|NCT05716048|BEHAVIORAL|KF-mSMT Plus Stretching Exercise Training|Participants will undergo this combinatory intervention 3 days per week for 12 weeks. The combined session duration will begin with 15 minutes and last up to 2 hours by the end of the 12th week
224001877|NCT03877211|OTHER|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
224001878|NCT03877211|OTHER|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
224001879|NCT03877211|OTHER|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
224001880|NCT03877211|OTHER|Tonal audiometry|Tonal audiometry will be performed with headphones
223384626|NCT01850251|DIETARY_SUPPLEMENT|Standard nutritional supplement|High protein, high calorie nutritional supplement.
223384627|NCT05443178|DRUG|Nivaquine ® (Chloroquine)|dose escalation and extension trial
223425533|NCT02197832|PROCEDURE|control procedure|Using pipelle catheter without entering the uterine cavity.
224124175|NCT01111539|DRUG|Blinded capsule|Blinded capsule administered orally, once daily.
224124176|NCT01274741|BEHAVIORAL|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
224124177|NCT01274741|BEHAVIORAL|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
223425534|NCT02197832|DEVICE|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
223425535|NCT00503958|GENETIC|DNA methylation analysis|
224001881|NCT03877211|OTHER|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
224001882|NCT01423110|BIOLOGICAL|BYM338|
224001883|NCT01423110|BIOLOGICAL|Placebo|
224001884|NCT06176976|DIETARY_SUPPLEMENT|Lugol's iodine solution 5%|4 drops of LS every 8 hours for 10 days preoperatively will be given
224001885|NCT02860897|DRUG|Premarin|Vaginal estrogen cream
224001886|NCT02860897|DRUG|Vagifem|Vaginal estrogen tablet
224001887|NCT00223847|BEHAVIORAL|Constraint Induced Language Therapy|
224001888|NCT05846958|DEVICE|laser acupuncture|"Each patient in experimental group will receive laser acupuncture for 10 s with at least 4J/point for each point.10 minutes, three times per week for 4 weeks (total of 12 sessions)~nieght splint for 4 weeks ."
224124178|NCT05078463|DEVICE|Microneedle|Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
224124179|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)|1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
224124180|NCT05078463|DRUG|1 Finger Tip Unit (FTU) EMLA (15-minute application time)|1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
224124181|NCT05078463|DRUG|0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)|0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
224124182|NCT05078463|DEVICE|Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
224124183|NCT03443843|DRUG|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
224124184|NCT03443843|DRUG|Placebo tablet|Placebo tablet orally
224124185|NCT03443843|DRUG|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
224124186|NCT03443843|DRUG|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
224124187|NCT02808312|DRUG|Cilofexor|Tablet(s) administered orally in a fed state on Day 1
223384628|NCT06550765|DEVICE|Biodegradable Magnesium Metal Clips|The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
223384629|NCT00694200|DRUG|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
223384630|NCT00694200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
223384631|NCT01632397|BEHAVIORAL|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
223384632|NCT01632397|BEHAVIORAL|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
223730004|NCT03482440|DRUG|Placebo Oral Tablet|Placebo oral table twice daily for 4 days prior to experimental testing
224001889|NCT05846958|DEVICE|night splint|wearing night splint for 4 weeks
224001890|NCT05634148|DRUG|Dexmedetomidine|Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
224001891|NCT01820884|PROCEDURE|TH|Total hysterectomy
224001892|NCT01820884|PROCEDURE|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
224001893|NCT01820884|PROCEDURE|BPLND|bilateral pelvic and para-aortic lymph node dissection
224001894|NCT04921891|PROCEDURE|Infraclavicular nerve block|The investigators performed an infraclavicular nerve block to the operated arm group to provide anesthesia.
224001895|NCT04921891|PROCEDURE|Without nerve block|The upper extremity without block was assigned as the control group, and a comparison was made between the two upper extremities.
224001896|NCT01049867|PROCEDURE|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
224001897|NCT02168348|OTHER|biological examination at consultations at 3 and 6 months|
224001898|NCT04324723|BEHAVIORAL|WhatsApp message|"The experimentally evaluated part of the intervention is a WhatsApp message.~The message translated from Arabic to English appears below. Dear \[First name\], Your BP reading during Beirut Marathon was \[reading\]. This indicates that you have elevated blood pressure. You should seek medical attention at your earliest convenience. Your wellbeing matters to us. Nudge Lebanon team"
223384633|NCT00111241|DRUG|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
224001899|NCT02748551|PROCEDURE|Laparoscopic procedures|Laparoscopic surgery
223384634|NCT04725851|PROCEDURE|High concentration Oxygen therapy|FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
224001900|NCT02748551|PROCEDURE|Open Surgery|Open surgery
223384635|NCT04725851|PROCEDURE|Control: Room Air or Low concentration Oxygen|FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
223384636|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Oppanol
223384637|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
223384638|NCT02096744|DRUG|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
223384639|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
223384640|NCT02096744|DRUG|Catapres-TTS-1|Catapres-TTS-1 Vistanex
223384641|NCT02096744|DRUG|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
223384642|NCT06551337|DRUG|Vitamin D3|The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
223384643|NCT00893269|DRUG|eszopiclone|Oral capsule at dose recommended for adults
224001901|NCT02459457|DRUG|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
224001902|NCT02459457|DRUG|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
224001903|NCT02459457|DRUG|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
224001904|NCT02459457|RADIATION|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
224001905|NCT03153553|OTHER|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
224001906|NCT03153553|OTHER|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
224001907|NCT02108002|DRUG|Vorinostat|
224001908|NCT03862677|OTHER|No intervention|Observational study, no intervention
224001909|NCT05862428|DRUG|Rectal misoprostol|This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
224001910|NCT01401153|OTHER|Skipping lunch|Just water.
224001911|NCT02964533|OTHER|thunder-fire moxibustion therapy|burn moxa stick and heat shenque acupoint
223384644|NCT00893269|DRUG|Placebo|Participants receive placebo prior to sleep
223384645|NCT00893269|DRUG|ramelteon|ramelteon
223384646|NCT00893269|DRUG|zolpidem|zolpidem
223384647|NCT03927456|DRUG|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223425536|NCT00503958|GENETIC|DNA stability analysis|
224001912|NCT02964533|OTHER|common moxa-stick moxibustion|burn moxa stick and heat shenque acupoint
224001913|NCT02517762|BEHAVIORAL|Physical activity|
224001914|NCT02212652|DIETARY_SUPPLEMENT|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
224001915|NCT02212652|OTHER|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
224001916|NCT02212652|OTHER|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
224001917|NCT03556904|RADIATION|Ablative Radiation Therapy|Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.
224001918|NCT03556904|DRUG|Hormone therapy or chemotherapy|Current standard of care dosing with standard agents; hormone therapy or chemotherapy.
223384648|NCT03927456|DRUG|Placebo|Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
223384649|NCT03927456|DRUG|Fulvestrant|Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
223384650|NCT04912232|DEVICE|Detection of Occult Hemorrhage in Trauma Patients|Non-invasive monitoring of trauma patients
223384651|NCT01994785|DIAGNOSTIC_TEST|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
223384652|NCT02462863|DIETARY_SUPPLEMENT|Arginine and fish oil|Dietary supplements
223384653|NCT06677359|DIETARY_SUPPLEMENT|Creatine Group|Micronized creatine monohydrate supplementation.
224001919|NCT00162916|DRUG|citalopram|20mg or 40mg, once daily, for 40 weeks
224001920|NCT00162916|DRUG|Placebo|Cornstarch
224001921|NCT01682265|OTHER|Stretta procedure|
224001922|NCT01682265|OTHER|Sham procedure|No radiofrequency delivered
224001923|NCT01653977|OTHER|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
224001924|NCT01653977|OTHER|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
224001925|NCT05752526|DRUG|Diclofenac 1%|vaginal hydrogel containing 1% Diclofenac
224001926|NCT05752526|DRUG|Diclofenac 3%|vaginal hydrogel containing 3% Diclofenac
224001927|NCT05752526|DRUG|Placebo|vaginal hydrogel, no active ingredient
224001928|NCT01546077|PROCEDURE|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
224001929|NCT05768165|BEHAVIORAL|High intensity exercise|"Twelve weeks of supervised high intensity aerobic and resistance exercise including two sessions/week, one additional session of the patient´s own choice, non-supervised. The target of the high intensity intervals (HIIT) is 90%-95% of maximum heart rate alternated with recovery phases at 70% of maximal heart rate. The resistance exercise session of large muscle groups: 8-10 repetitions, 2-3 sets.~Exercise guidance follows principles of self-efficacy and person-centeredness."
224001930|NCT05715177|OTHER|Cura Kinesio-taping|Cura tapes, a cotton strip with an acrylic adhesive. allows for unidirectional elasticity up to 60% beyond its resting length will be applied on origin to insertion on the superficial muscles of Quadriceps femoris (QF) (Vastus Medialis (VM), Vastus Lateralis (VL), Rectus Femoris (RF)
224001931|NCT05715177|OTHER|Placebo kinesio-taping|Placebo kinesiotaping
224001932|NCT03983967|BIOLOGICAL|Immuncell-LC|Activated T lymphocyte
224001933|NCT04210921|DEVICE|Acupuncture|"The acupuncture will be penetrated in an appropriate angle into a depth of 10-15 mm. Acupuncture manually manipulated by lifting, thrusting, and twirling methods to produce a characteristic sensation known as De Qi ."
223384654|NCT06677359|DIETARY_SUPPLEMENT|Placebo Group|Participants will recieved placebo supplementation
223384655|NCT06677359|OTHER|Multicomponent Training|Multicomponent physical exercise intervention
223384656|NCT00215423|DRUG|Formoterol Fumarate|
223384657|NCT03109561|OTHER|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
223384658|NCT03109561|GENETIC|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
224001934|NCT04210921|DEVICE|The park sham needle|When the blunt needle goes through the adhesive and contact with skin, it will move back into the hollow centre of the handle rather than penetrate into skin.
224001935|NCT01667094|DRUG|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
224001936|NCT01667094|DRUG|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
224001937|NCT01667094|DRUG|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
224124188|NCT05327023|PROCEDURE|donor lymphocyte infusion|The DLI will be given on Day +7 (Day +21 for dose level -1). If a recipient participant is deemed too critically ill/unstable to receive DLI on the protocol specified day, the DLI will be delayed up to 4 days at the discretion of the PI and given within this time frame once the recipient participant s clinical status has stabilized or improved. If the DLI cannot be given during this time frame, the recipient participant will be taken off study and not considered evaluable for DLT, outcomes, or adverse events since the experimental intervention will not have been given.
224124189|NCT05327023|DRUG|Cyclophosphamide|HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
223384659|NCT03109561|DIAGNOSTIC_TEST|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
223384660|NCT03109561|OTHER|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
223425537|NCT00503958|GENETIC|gene expression analysis|
224001938|NCT01667094|DRUG|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
224001939|NCT01667094|DRUG|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
223384661|NCT03108885|OTHER|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
223384662|NCT05276362|DEVICE|Study Watch|The Study Watch is an investigational wrist worn wearable device made with biocompatible contact materials containing various sensors capable of continuous recording of physiological, activity, and environmental data.
223384663|NCT05276362|DEVICE|Actiwatch|The Actiwatch is a wrist worn activity device designed to collect general activity and sleep information. This device received 510(k) clearance from the FDA as a wearable medical data collection device for research and clinical use.
224001940|NCT01667094|DRUG|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
224001941|NCT01667094|DRUG|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
224001942|NCT01667094|DRUG|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
224295710|NCT02564146|DRUG|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m\^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m\^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
224001943|NCT01667094|DRUG|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
224001944|NCT01667094|DRUG|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
224001945|NCT02915419|BIOLOGICAL|PRP|platelet rich plasma
224295711|NCT01947478|DEVICE|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
224295712|NCT01947478|DEVICE|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
223384664|NCT06583057|PROCEDURE|Thermal ablation|Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.
224001946|NCT02915419|BIOLOGICAL|PRF|PLATELET RICH FIBRIN
224001947|NCT01344772|PROCEDURE|Internal fixation|Two cannulated screws are placed under x-ray guidance
224001948|NCT01344772|PROCEDURE|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
224001949|NCT03276650|OTHER|data collection|biological, administrative, clinical, outcome date
224001950|NCT06225505|DIAGNOSTIC_TEST|ctDNA monitoring|For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
224001951|NCT06225505|DIAGNOSTIC_TEST|68Ga-FAPI-46-PET-CT|). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
224001952|NCT06330012|DIAGNOSTIC_TEST|GeoMx data analysis with clinical outcome|"1. List of HER2 positive breast cancer~   * Stage IV disease~  * Treated with T-Dxd~  * Available FFPE samples~2. Prepare tissue for digital spatial proteomics~   * FFPE/H\&E slide~  * Region of Interest(ROI) check~  * Make a Tissue microarray~  * Prepare special slide for GeoMx~3. GeoMx data analysis with clinical outcome"
224001953|NCT05568953|BIOLOGICAL|Stamaril|Stamaril is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
224001954|NCT05568953|BIOLOGICAL|Imojev|Imojev is licensed by the Health Sciences Authority (HSA), Singapore. The vaccine are manufactured by Sanofi Pasteur and sourced from Sanofi Pasteur's local distributor.
224001955|NCT05568953|BIOLOGICAL|Ixiaro|Ixiaro is licensed by the Health Sciences Authority (HSA), Singapore. The Ixiaro vaccines are manufactured by Valneva and sourced from local distributor, Aenon Pharmaceuticals SEA Pte Ltd.
224001956|NCT06094946|DRUG|Ropivacaine Hydrocloride|1 mg/ml
224001957|NCT06094946|DRUG|Fentanyl Citrate|2.5 micrograms/ml
224001958|NCT00091559|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
224001959|NCT02736240|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|
224001960|NCT02736240|BIOLOGICAL|13-valent pneumococcal polysaccharide conjugate vaccine|
224001961|NCT03598153|DRUG|Shujinjianyao Pill|According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
224001962|NCT05028114|DRUG|AC-1202|Tricaprilin formulated as AC-1202
224001963|NCT05028114|DRUG|AC-OLE-01|Tricaprilin Formulation
224001964|NCT05028114|DRUG|AC-OLE-02|Tricaprilin Formulation
224001965|NCT05028114|DRUG|AC-OLE-03|Tricaprilin Formulation
224001966|NCT05028114|DRUG|AC-OLE-04|Tricaprilin Formulation
224001967|NCT05028114|DRUG|AC-OLE-05|Tricaprilin Formulation
224001968|NCT05028114|DRUG|AC-OLE-06|Tricaprilin Formulation
224001969|NCT05028114|DRUG|AC-OLE-07|Tricaprilin Formulation
224001970|NCT05028114|DRUG|AC-OLE-08|Tricaprilin Formulation
224001971|NCT05028114|DRUG|AC-OLE-09|Tricaprilin Formulation
223384665|NCT06583057|PROCEDURE|Thyroid lobectomy|Patients who underwent thyroid lobectomy were performed in the operating theater under general anesthesia. Lobectomy (or lobectomy plus isthmusectomy) with prophylactic central neck dissection were performed.
223384666|NCT02193217|DRUG|MT-1303-Low|
223384667|NCT02193217|DRUG|MT-1303-High|
223384668|NCT02193217|DRUG|Fingolimod|
223384669|NCT02193217|DRUG|Placebo|
223384670|NCT01461447|BIOLOGICAL|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
223384671|NCT04511598|DEVICE|"Bellus 3D Face Camera"|The depth sensor uses infrared structured light scanning technology to capture depth and the camera on the phone or tablet to capture color texture of the face.
223384672|NCT04511598|DEVICE|"Planmeca ProMax 3D Proface"|The lasers scan the facial geometry and the digital cameras capture the color texture of the face.
223384673|NCT07017959|DIETARY_SUPPLEMENT|LpD3.5 supplementation.|Dietary Supplement: LpD3.5 are in the form of capsule where LpD3.5 contains 167 mg of LpD3.5, with the remaining portion consisting of inactive ingredients like maltodextrin
223384674|NCT07017959|DIETARY_SUPPLEMENT|Placebo|Placebo capsules contain only inactive ingredient maltodextrin
223384675|NCT03516656|DRUG|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
224001972|NCT05028114|DRUG|AC-OLE-010|Tricaprilin Formulation
224001973|NCT05028114|DRUG|AC-OLE-P|Placebo to tricaprilin formulation
224001974|NCT05646576|BEHAVIORAL|Palliative Care|"* Palliative care (PC) intervention tailored to ACT recipients and addressing multiple PC domains with the input of ACT clinical experts, PC clinicians, and patients and caregivers.~* Domains discussed include therapeutic relationship, symptom management, prognostic awareness and illness understanding, coping with illness, treatment decision-making, EOL care.~* The palliative care intervention will be refined for the randomized control trial based on the feedback from the open pilot."
224001975|NCT05646576|BEHAVIORAL|Usual Care|Standard care for ACT per the treating team.
224001976|NCT04820998|OTHER|Families|Families's interviews about their precarious situation of living and the consequences on their autistic child care
224001977|NCT04820998|OTHER|professionals|Interviews so as to know how the specifics of precarious situations are identified and taken into account by the professionals
224001978|NCT04187326|BEHAVIORAL|Facial Microexpression Training|The METT is a well-validated task designed to improve perception of subtle changes in facial expressions, termed microexpressions. Participants with high trait anxiety will return to the lab approximately six months post scan visit to complete this computer-based task. They will receive feedback during the task on their accuracy.
223384676|NCT03516656|DRUG|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
224001979|NCT03360448|DRUG|Ad5.hAC6|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
223384677|NCT06405594|BEHAVIORAL|Language Condition|The intervention involves asking participants to speak and understand words and sentences with different linguistic manipulations such as morphological, semantic, phonological priming, predictability of the subject and object nouns associated with verbs, naming of verbs and nouns, production of sentences with past, future or present tense. Accuracy, response times and brain activity are the outcome measures.
224001980|NCT03360448|DRUG|Placebo|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
224001981|NCT05559151|PROCEDURE|Remimazolam Benzenesulfonate|"In the experimental group, remazolam 6-12mg/kg/h, atracurium cisphenylate 0.1-0.3 mg/kg and sufentanil 0.3-0.5 μg/kg were infused by micropump for anesthesia induction, and the BIS value was controlled at 50±5 before tracheal intubation.~Anesthesia maintenance: intravenous infusion of remifentanil 0.1-0.3 μg/kg/min, target controlled infusion of remifentanil in experimental group (group R), BIS value was controlled at 50±5, intermittent addition of atracurium cisphenylate to maintain muscle relaxation."
224001982|NCT02843451|DRUG|Milk Thistle|
224001983|NCT02843451|DRUG|Placebo|
224124190|NCT05327023|DRUG|Busulfan|AUC targeted dose based on busulfan test dose, with a default dose of 130 mg/m2/day, given as IV infusion over 3 hours each day for 4 days Transplant days -6 through day -3
224124191|NCT05327023|DRUG|Mycophenolate mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
223384678|NCT05632926|DRUG|40 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
223384679|NCT05632926|DRUG|60 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
223384680|NCT05632926|DRUG|80 mg CBL-514|CBL-514 will be administered at the raised area of cellulite.
223384681|NCT00952731|DRUG|oral placebo|Oral placebo taken daily for 4-10 weeks.
223384682|NCT00952731|DRUG|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
223384683|NCT00952731|DRUG|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
224001984|NCT03394677|DRUG|RVT-501 0.5% ointment|Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
224124192|NCT05327023|DRUG|Fludarabine|40 mg/m2 IV infusion over 30-60 minutes once daily for 4 days Transplant days -6 through -3
223384684|NCT00952731|DRUG|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
223425538|NCT00503958|OTHER|epidemiologic study|
224001985|NCT03394677|DRUG|Vehicle ointment|Placebo comparator - ointment twice daily (BID) for 4 weeks.
224001986|NCT04127500|DRUG|dexmedetomidine|dexmedetomidine
224001987|NCT05105334|DEVICE|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.
224124193|NCT05327023|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, maximum initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +70 with no taper. Doses should be modified as appropriate for drug interactions.
224124194|NCT05384626|DRUG|Neladalkib (NVL-655)|Oral Tablet of Neladalkib (NVL-655)
224124195|NCT01762540|DRUG|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
223384685|NCT03909880|OTHER|Kinesio tape|"Kinesio tape (kinesio taping; kinesio holding corporation,USA) was placed on the skin above muscle belly of finger flexor. There were three types of taping:~Taping20 condition - tape was pulled from the wrist to the proximal forearm. The two ends of the tape (\~5 cm) were held by the therapist and the middle area was pulled 20% additional tension.~TapingN condition - tape was pulled with neutral tension. Control condition - no taping."
223384686|NCT00999427|DRUG|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
223384687|NCT03697863|PROCEDURE|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
223384688|NCT05102812|BEHAVIORAL|Breakfast Group Intervention|An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
223384689|NCT05323279|DEVICE|artificial intelligence assistance system|The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
223384690|NCT04407208|BIOLOGICAL|Convalescent plasma|The minimum titer of specific antibody is 1/80
224001988|NCT05105334|DEVICE|Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA)|Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. This will be alternated with radiofrequency microneedling treatment will include 3 passes each at a depth of 2 mm, 1.5 mm, and 0.8 mm, treatment level 5 (32 w, 50 ms)-7 (40 w, 60 ms), monopolar setting with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions (2 of each modality) at 4-week intervals.
223384691|NCT04635527|DRUG|IBI318|before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W
223384692|NCT04635527|PROCEDURE|cTACE|conventional transarterial chemoembolization
223384693|NCT04635527|DRUG|placebo|before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W
224001989|NCT04014595|PROCEDURE|Rotational atherectomy in combination with cutting balloon|Treatment of severely calcified coronary lesion using rotational atherectomy followed by balloon angioplasty using a cutting balloon and Implantation of the hybrid sirolimus-eluting stent.
223384694|NCT02712580|DEVICE|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
223384695|NCT02712580|DEVICE|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
224001990|NCT01743391|PROCEDURE|Office-hysteroscopy with biopsy|
223384696|NCT02712580|DEVICE|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
223384697|NCT02712580|DEVICE|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
223384698|NCT03651830|DEVICE|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
224001991|NCT04078698|DEVICE|Immunoadsorber GLOBAFFIN®|Documentation of the treatment with one of the immunoadsorber GLOBAFFIN® depending on the patient's underlying disease
224001992|NCT06802276|OTHER|High Cysteine Diet|A healthy diet pattern which contains high levels of cysteine or cysteine-related compounds. The high and low cysteine diets will be designed by a research dietician to differ primarily in their concentration of cysteine while providing similar levels of calories, protein, fats, carbohydrates, fiber, and several micronutrients. No additional supplementation of cysteine will be used. Examples of high cysteine foods: chicken, eggs, lentils, yogurt, garlic, cheese, soybeans
224001993|NCT06802276|OTHER|Low Cysteine Diet|A healthy diet pattern which contains low levels of cysteine or cysteine-related compounds. The high and low cysteine diets will be designed by a research dietician to differ primarily in their concentration of cysteine while providing similar levels of calories, protein, fats, carbohydrates, fiber, and several micronutrients. The low cysteine diet includes lower-protein food sources. Examples of low cysteine foods: rice, bread, oranges, bananas, lettuce, snow peas, peppers
224001994|NCT06803446|OTHER|physical test|continuous and intermittent exercise on cycloergometer
224001995|NCT05686122|BEHAVIORAL|PainPac|Patient-focused behavioral pain intervention delivered via mobile application.
224124196|NCT01762540|DRUG|Calcium Supplement|Placebo
224124197|NCT02165657|DEVICE|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
224124198|NCT01797198|DRUG|ASP3652|Oral
224124199|NCT01797198|DRUG|Gemfibrozil|Oral
224124200|NCT01797198|DRUG|Repaglinide|Oral
224124201|NCT03100942|DRUG|Lanraplenib|1 x 30 mg tablet administered orally once daily
223384699|NCT03651830|DEVICE|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
223384700|NCT06049979|OTHER|Acute gastrointestinal injury|AGIUS score\>2
224124202|NCT03100942|DRUG|Filgotinib|1 x 200 mg tablet administered orally once daily
224124203|NCT03100942|DRUG|Tirabrutinib|1 x 40 mg tablet administered orally once daily
224124204|NCT03100942|DRUG|Lanraplenib placebo|1 x tablet administered orally once daily
223425539|NCT00503958|OTHER|study of socioeconomic and demographic variables|
224001996|NCT05235269|DRUG|124I-AT-01|All participants received 1 mCi 124I-AT-01 on Day 1 and at Week 6 via IV infusion over 2-5 minutes or slow IV bolus at 1 mL/5 seconds.
224001997|NCT00720785|DRUG|Bortezomib|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
224124205|NCT03100942|DRUG|Filgotinib placebo|1 x tablet administered orally once daily
223384701|NCT04421300|BEHAVIORAL|smile exercise|"Launch the smile face recognition APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day"
223384702|NCT04421300|DRUG|0.1% sodium hyaluronate eye drop|0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
223384703|NCT06398275|DRUG|Remimazolam 20 MG Injection [Byfavo]|Remimazolam 0.1 mg/kg intravenous injection
223384704|NCT06398275|DRUG|NaCl 0.9%|NaCl 0.9% 0.04 mL/kg
223384705|NCT04807647|OTHER|"Orhan OSMAN's track Don't Let Your Baby Cry in the Kolik album will be played on the music player."|white noise will be played while breastfeeding
224124206|NCT03100942|DRUG|Tirabrutinib placebo|1 x tablet administered orally once daily
223384706|NCT00001028|DRUG|Pentamidine isethionate|
224001998|NCT00720785|BIOLOGICAL|NK cells|NK Cell Infusion
223384707|NCT00001028|DRUG|Dapsone|
223384708|NCT02167854|DRUG|BYL719|
223384709|NCT02167854|DRUG|LJM716|
223384710|NCT02167854|DRUG|TRASTUZUMAB|
224001999|NCT05660122|DRUG|Fexuprazan Hydrochloride|Fexuclue Tablet 40mg
223384711|NCT02943928|DEVICE|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
223384712|NCT02943928|DEVICE|traditional method by experience|Operator inserted the double lumen tube by experience
223384713|NCT05567276|BEHAVIORAL|Non-Violent Resistance parental training|Non-Violent Resistance parental training
223384714|NCT02045589|GENETIC|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
224002000|NCT01492972|RADIATION|Radiation|"Consists of:~1. Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~2. High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~3. Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
224002001|NCT01492972|DRUG|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
224002002|NCT02585544|PROCEDURE|day-care surgery|day-care surgery
224124207|NCT06334822|DEVICE|Heartfelt Device installed|Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
224002003|NCT03050736|DRUG|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
224002004|NCT06442475|PROCEDURE|Biospecimen Collection|Undergo blood, oral, and/or rectal sample collection
224002005|NCT06442475|PROCEDURE|Computed Tomography|Undergo PET/CT or CT
224002006|NCT06442475|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224002007|NCT06442475|BIOLOGICAL|Mosunetuzumab|Given IV
224002008|NCT06442475|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224124208|NCT06334822|OTHER|Standard care|Patients with heart failure are advised to weigh daily and to report weight increase to their clinician. They should also report changes in breathlessness, tiredness and other symptoms associated with heart failure decompensation.
224124209|NCT06334822|OTHER|Questionnaires|Patients are presented with one or more optional questionnaires (some validated, some bespoke)
224002009|NCT06442475|OTHER|Questionnaire Administration|Ancillary studies
224002010|NCT06383351|OTHER|Questionnaire|"Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire."
223384715|NCT02045589|DRUG|Gemcitabine|1000 mg/m2 intravenous administration
223384716|NCT02045589|DRUG|Abraxane®|125 mg/m2 intravenous administration
223384717|NCT02851745|DRUG|Linagliptin|
223384718|NCT02851745|DRUG|Placebo|
223384719|NCT00224289|DRUG|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
223384720|NCT03361774|DRUG|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
223425540|NCT00503958|PROCEDURE|biopsy|
224002011|NCT05070858|DRUG|Pozelimab + Cemdisiran|Subcutaneous administration as described in the protocol
224124210|NCT06334822|DEVICE|Heartfelt Device in pharmacy|Device used monthly in the pharmacy, with the assistance of the pharmacist, and capturing foot volume data which are processed in the cloud.
224002012|NCT05070858|DRUG|Cemdisiran|SC administration as described in the protocol
224124211|NCT06334822|DEVICE|Heartfelt device alerting system|The Heartfelt device sends alerts to the patients directly (audio-visual alert on the device, and app alerts), carers and/or medical professionals.
224124212|NCT00372190|DEVICE|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
224124213|NCT00372190|PROCEDURE|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
224124214|NCT01188915|PROCEDURE|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
223384721|NCT03361774|DRUG|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
223384722|NCT05410886|OTHER|Questionnaire|A questionnaire including up to 20 questions will be distributed to study participants. This questionnaire will be used to identify women with FHA.
223384723|NCT02002286|DRUG|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
223384724|NCT02002286|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
223384725|NCT02517463|DRUG|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
223384726|NCT04920500|DRUG|Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. d1,3,5 Induction 2: \[100 U/m²\] i.v. d1,3
223384727|NCT04920500|DRUG|Vyxeos、Daunorubicin Cytarabine liposome for injection|Induction 1: \[100 U/m²\] i.v. Vyxeos（d1）,Daunorubicin Cytarabine liposome for injection（d3、d5） Induction 2: \[100 U/m²\] i.v. Daunorubicin Cytarabine liposome for injection（d1、d3 ）
223384728|NCT05758233|PROCEDURE|Patients undergoing transversalis fascia plane block|The investigators applied a transversalis fascia plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
223384729|NCT05758233|PROCEDURE|Patients undergoing transversus abdominis plane block|The investigators applied a transversus abdominis plane block to the group of patients who had a cesarean section under spinal anesthesia to prevent postoperative pain.
223384730|NCT00060983|PROCEDURE|Body weight supported locomotor training|
223384731|NCT00060983|PROCEDURE|Functional electrical stimulation|
223384732|NCT00006183|PROCEDURE|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
223384733|NCT00006183|PROCEDURE|Thoracic Surgery|
223384734|NCT01241747|BEHAVIORAL|Walking Exercise|3 times per week for 3 months
224002013|NCT05070858|OTHER|Placebo|SC administration as described in the protocol
224002014|NCT05070858|DRUG|Pozelimab|SC administration as described in the protocol
224002015|NCT03904862|DRUG|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
223384735|NCT01241747|BEHAVIORAL|Control|Resistance training 3 times per week for 3 months
223384736|NCT01363882|OTHER|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
223384737|NCT01363882|OTHER|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
224002016|NCT06271707|DRUG|0.5% bupivacaine|an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine
224002017|NCT06271707|OTHER|Saline|an ultrasound guided left stellate ganglion block with 5 mL of saline
224002018|NCT05811299|OTHER|Kinesio taping|Total of 8 sessions for 4 weeks 2 sessions in a week.
224002019|NCT05811299|OTHER|Abominal exercises|Total of 8 sessions for 4 weeks 2 sessions in a week.
224002020|NCT00798434|DRUG|Placebo|placebo administered orally in the morning or evening.
223384738|NCT02535793|OTHER|blood test (four dry tubes 7ml) and prick tests|
223384739|NCT04820660|OTHER|Task orientated strengthening training|"1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy."
223425541|NCT00503958|PROCEDURE|evaluation of cancer risk factors|
223425542|NCT00503958|PROCEDURE|study of high risk factors|
224002021|NCT00798434|DRUG|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
224002022|NCT06415266|OTHER|Quality of life questionnaire (QLQ)|Quality of life questionnaire : EORTC QLQ-C30, EORTC QLQ-Breast cancer module (BR) 23, EORTC SHQ-C22 et HADS at inclusion, visit 1 (6 months +/-1 month before the inclusion), visit 2 (12 months +/-1 month before the inclusion), visit 3 (18 months +/-1 month before the inclusion) and visit 4 (24 months +/-1 month before the inclusion).
224002023|NCT06415266|OTHER|Satisfaction survey|The satisfaction score will be collected using a visual analog scale from 0 to 10 and the satisfaction questionnaire will also be completed at visit 4 (24 months +/- 1 month before the inclusion).
224002024|NCT06415266|OTHER|Assessment of patient needs in the field of oncosexology|Assessment of patient needs in the field of oncosexology during a face-to-face or virtual interview at inclusion and every 6 months for 2 years. If a need is identified, an oncosexology consultation will be organised. Following this, a personalised care plan may be proposed.
224002025|NCT03898167|BEHAVIORAL|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
224002026|NCT03898167|BEHAVIORAL|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
223384740|NCT04820660|OTHER|Balance training exercises|"1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s."
223384741|NCT04492657|OTHER|no intervention|Natural exposure of iodine.
224002027|NCT03898167|BEHAVIORAL|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
224002028|NCT03180034|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
223425543|NCT02637895|DRUG|Placebo|Placebo pill matching Vortioxetine.
224002029|NCT03180034|OTHER|Questionnaire Administration|Ancillary studies
224002030|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent Vaccine|Given IM
224002031|NCT03180034|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
224002032|NCT04265144|BIOLOGICAL|Blood samples|62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
224002033|NCT04265144|OTHER|Biopsy|Skin biopsies only for volunteers among patients
224002034|NCT04265144|OTHER|Bronchoalveolar samples|50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients
224002035|NCT04265144|OTHER|Biopsy|Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients
224002036|NCT04557748|OTHER|Observational|"Treatment:~Up to five interactions: In-person visits at Baseline, 3 months, and 12 months after initial visit, and phone/online interaction at 6 months and 9 months after initial visit.~Each in-person follow up visit is expected to last up to 2 hours and each phone/online interaction is expected to last up to 1½ hours.~Answering questions about your general health and urinary symptoms - may be done remotely Physical exam Completing Self- Reported Measures questionnaires - may be done remotely Completing voiding/intake and food diaries, either online or on paper Weekly text message survey regarding symptom and treatment changes~Biosample collection:~At baseline: Up to 4 tablespoons of whole blood, dried blood spots, and urine At baseline: Whole blood will be collected with other biospecimens At 3 months: Up to 4 tablespoons of blood, dried blood spots and urine At 12 months: Dried blood spots"
224002037|NCT04557748|OTHER|Observational Controls|One in-person visit that is expected to last up to 2 hours Answering questions about your general health and urinary history Physical exam Completing Self- Reported Measures questionnaires Completing voiding/intake and food diaries, either online or on paper Biosample collection of up to 4 tablespoons of whole blood, dried blood spots, and urine
224002038|NCT04557748|OTHER|Central Sensitization|"One in-person visit expected to take up to 30 minutes, that include:~Segmental Mechanical Hyperalgesia - a hand-held device with a small flat rubber surface will be placed above the pubic bone and forearm, and will apply pressure. Participant will be asked about the intensity and unpleasantness that they experience.~Pinprick Temporal Summation - participant will receive tactile stimulation by a pointed skin probe (pinprick stimulator) being placed above the pubic bone and forearm. Participant will be asked to rate the sensation they are feeling.~Current treatment information including prior surgery or procedures, medication use, other current treatment/therapy used at the time of the visit.~Self-reported measures questionnaires"
224002039|NCT04557748|OTHER|Physical Activity and Sleep Tracker|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period starting at baseline prior to treatment and again at 3 months. During each 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
224002040|NCT04557748|OTHER|Physical Activity and Sleep Tracker Controls|"A physical activity and sleep monitor (Fitbit Charge 3 or similar) will be worn for a 2 week period at baseline prior to treatment. During the 2 week period:~The Fitbit will be worn both day and night to collect the most information. Text message reminders to wear the Fitbit will be sent. Daily text messages asking the number of nighttime voids you had."
224002041|NCT04557748|OTHER|Organ-Based|"One in-person visit involving:~Urethral vibratory sensation threshold Urethral Pressure Profilometry Cystometry Uroflowmetry Lidocaine Pre-Treatment Cystometry"
224124215|NCT03747835|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
224124216|NCT03747835|BEHAVIORAL|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
224124217|NCT00824187|DRUG|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
224124218|NCT00824187|DRUG|Placebo|Inert tablet
224124219|NCT01672606|DRUG|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
224124220|NCT01429792|DRUG|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
224124221|NCT01429792|DRUG|ribavirin [Copegus]|standard treatment, orally daily
223425544|NCT02637895|DRUG|Vortioxetine|Immediate Release 10 mg. Vortioxetine Pill
223425545|NCT06008197|DRUG|Finerenone|Oral finerenone
223425546|NCT06008197|DRUG|Placebo|Matching oral placebo
223545475|NCT02153437|DRUG|Placebo for BMS-919373|
224002042|NCT04557748|OTHER|Qualitative Assessment of Patients with Urinary Urgency|"Participation will include two interviews with a research assistant over the phone and are expected to take up to 60 minutes for each interview. The first interview will be done within four weeks from enrollment, before the start of treatment. The interview will include questions about participant's urinary urgency, including symptoms experienced, the onset of symptoms and other factors that affect urgency.~Approximately three months after the start treatment the participant will be interviewed again. This interview will cover changes in symptoms and experience with treatment, such as side effects and satisfaction with treatment."
224002043|NCT06136481|OTHER|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT). CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. Prior to engaging in therapy, one session will be devoted to gathering information regarding psychosocial history, trauma, and current functioning. The following sessions will follow the standard outpatient CPT protocol. The standard outpatient CPT consists of 12 one-hour sessions conducted over a 6- to 12-week period. An additional 3 weeks will be provided in case of participant and therapist vacation and/or sick days. CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
224002044|NCT05773586|DRUG|APG-5918|oral tablets 10mg, 50mg, 200mg.
224002045|NCT05773586|DRUG|Placebo|Matching placebo
224002046|NCT01370798|DRUG|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
224002047|NCT01370798|DRUG|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
224002048|NCT01370798|PROCEDURE|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
224002049|NCT01370798|RADIATION|Wrist X ray|Wrist X ray to follow the degree of bone maturation
224002050|NCT01370798|PROCEDURE|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
224002051|NCT04726618|DRUG|Hyperpolarized 129-xenon gas and Perfluoropropane gas|"Hyperpolarized 129-xenon gas will be used as a contrast agent for MRI. Xenon will be inhaled by the participant at a maximum dose volume of 1/6 of the participant's total lung capacity.~Perfluoropropane will also be used as a contrast agent for MRI. Perfluoropropane will be inhaled as a normoxic mixture (21% O2 and 79% perfluoropropane)."
224002052|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY987808)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
224002053|NCT05062044|DIETARY_SUPPLEMENT|Multivitamins (Elevit, BAY2906300)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
224002054|NCT05062044|DRUG|Multivitamins (Elevit, BAY987386)|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
224002055|NCT05062044|DIETARY_SUPPLEMENT|Folic acid|Following the manner of observational study, no intervention will be provided in the study. Participants follows approved clinical guidelines, without interference by the study initiator or study protocol.
224002056|NCT04949646|OTHER|Pelvic Intraoperative Neuromonitoring|Pelvic Intraoperative Neuromonitoring (pIONM) allows mapping of the pelvic autonomous plexus during total mesorectal excision (TME).
224002057|NCT06398418|DRUG|R-5780|Probiotic
224002058|NCT05093959|DRUG|Metformin|An extended release formulation will be used which improves compliance and reduces GI side effects.
224002059|NCT05093959|DRUG|Placebo|Placebo is a biologically inert substance placed in capsules to match appearance of active intervention
224002060|NCT01681615|DRUG|Acetylsalicylate|1-2 drops
224002061|NCT01681615|DRUG|Isotonic NaCl|1 drop
224002062|NCT02579395|BEHAVIORAL|Collaborative implementation Intentions|With spouse/romantic partner
224002063|NCT02579395|BEHAVIORAL|Individual implementation Intentions|Without spouse/romantic partner
224002064|NCT02579395|BEHAVIORAL|Control|
224002065|NCT02265809|DRUG|Aldesleukin|
224002066|NCT05870488|DEVICE|Use of iFuse TORQ|Use of iFuse TORQ for the treatment of SI Joint dysfunction
224124222|NCT03432910|OTHER|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
224124223|NCT04179968|DRUG|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
224124224|NCT04179968|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
224002067|NCT02593799|PROCEDURE|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
224002068|NCT03653000|PROCEDURE|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
224002069|NCT03653000|DRUG|local anaesthetic injection|Local anesthetic injection (ropivacaine) at this new site
224002070|NCT00455897|DRUG|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
224002071|NCT00455897|DRUG|CHOP|Administered as part of standard care
224002072|NCT00455897|DRUG|Rituximab|Administered as part of standard treatment
224002073|NCT01072708|OTHER|Prospective cohort with an annual follow-up|"Annualfollow-up including :~* oral glucose tolerance test~* dietary survey~* biological evaluation~* bacteriological and respiratory measures~* dual-energy x-ray absorptiometry~* physical activity survey"
224002074|NCT01607151|OTHER|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
224002075|NCT01607151|OTHER|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
224002076|NCT02646956|OTHER|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
223384742|NCT04697082|PROCEDURE|Open surgery|Each patient entered the operating room, and after the administration of general anaesthesia, the patient was placed in the prone position. Then, the buttocks were stretched to the lateral sides using adhesive bands to remove the disease area. The sacrococcygeal region was cleaned and disinfected with 10% povidone iodine. After covering the area around the region, the sinus tract was examined by using a thin-steel cane. The length and wealth of the cavity were noted. Then, the sinus tract was removed. The depth of the cavity was noted. Then, 50 cc of 0.9% saline solution (SS) was taken into a syringe and applied to the cavity until it filled the whole space, allowing the cavity volume to be measured accurately. The measurement was performed by subtracting the remaining saline-solution volume in the syringe from the whole syringe volume, which was 50 cc.
224002077|NCT00998842|DEVICE|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
224002078|NCT00998842|DEVICE|GE 5000 ECG Monitor System|Wired ECG system
224002079|NCT00004449|BEHAVIORAL|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
224002080|NCT00004449|BEHAVIORAL|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
224002081|NCT05164380|OTHER|Picture naming tasks|PWA and CG had to name 128 pictures presented on a tablet, in addition to 8 trial images.
224002082|NCT06177392|PROCEDURE|Secondary TAVI access|The randomization will determine whether radial or femoral artery puncture will be employed as the secondary access in the TAVI procedure.
224002083|NCT05048212|DRUG|Nivolumab|Given by IV
224002084|NCT05048212|DRUG|Ipilimumab|Given by IV
224002085|NCT05048212|DRUG|Cabozantinib|Given by IV
224002086|NCT05177354|DEVICE|Inceptiv|Implantable Neurostimulator with Neuro Sense
224002087|NCT05817240|DRUG|taladegib|100 mg per tablet, dosed once daily
224002088|NCT05817240|DRUG|nintedanib|100 mg per capsule, dosed once daily
224002089|NCT05318859|OTHER|Pharmacopuncture|Registry (observational study)
224002090|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (10G-A)|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth per day (10 total grams of R-1,3-Butanediol) for 2 weeks
224002091|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (20G-A)|Study participants will take two 35mL dose of HVMN Ketone-IQ by mouth per day (20 total grams of R-1,3-Butanediol) for 2 weeks
224002092|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (30G-A)|Study participants will take three 35mL dose of HVMN Ketone-IQ by mouth per day (30 total grams of R-1,3-Butanediol) for 2 weeks
224002093|NCT06578637|DIETARY_SUPPLEMENT|R-1,3-Butanediol (30G-B)|Study participants will take one 35mL dose of HVMN Ketone-IQ by mouth three times per day (30 total grams of R-1,3-Butanediol) for 12 weeks, with a possible additional 12 week extension
224002094|NCT05141643|DIAGNOSTIC_TEST|PET Scan|Participants will receive a minimum of 4 mCi (148 MBq) and up to a maximum of 10 mCi (370 MBq) of \[18F\]-FAC intravenously. Injection is performed in conjunction with a dynamic PET acquisition over a site of the disease (pre-selected based on the findings from a previous CT or MRI and FDG PET/CT study done for clinical purpose such as staging). Patients will be offered a second \[18F\]-FAC PET scan procedure during their SOC treatment. This second scan will be optional.
224002095|NCT03469401|OTHER|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
224002096|NCT05444205|BEHAVIORAL|Text4Baby or Bright by Text Referral|Passive texting programs where participants receive free text messages on topics such as child development and parenting tips three times per week. Text4Baby serves parents of children under one year. Bright by Text serves parents of children under eight years of age.
224002097|NCT05444205|BEHAVIORAL|Nurture Program Warm Referral|Nurture Program is a nonprofit organization that promotes healthy development in young children by pairing moms with experienced and knowledgeable mentors who use text messaging to answer questions and provide helpful information, while offering support and encouragement throughout the child's first few years of life.
224002098|NCT05444205|BEHAVIORAL|Video Interaction Project|The Video Interaction Project is a program to support parents and their young children. Video Interaction Project is typically offered at a convenient location, such as a pediatric clinic. Parents are observed and videotaped for 3 to 5 minutes while interaction with their child. The Video Interaction Project coach then watches the video with the parent and talks about their interaction, highlighting how best to support the child's growth and language development.
224002099|NCT05444205|BEHAVIORAL|Family Check-UP|"The Family Check-Up is brief, taking place over the course of three sessions, each about an hour long. A Family Check-Up family coach will spend time getting to know the family during an Initial Interview. Second, parents complete questionnaires that assess child and family adjustment, relationships, and other areas that influence children and families. The assessment includes videotaped family interaction tasks, where parents take part in activities with their child like playing together with toys and puzzles. Third, the Feedback session consists of sharing feedback - including strengths and challenges - about child and family well-being based on survey responses and video clips. Parents are invited to set goals for their family to support and maintain strengths and address areas of concern. Parents are paid 25 dollars after the Feedback Session. Parents have the option to continue meeting with the family coach to support the child's development and improve parental well-being."
224002100|NCT05444205|BEHAVIORAL|Smart Beginnings|Smart Beginnings consists of delivering both Video Interaction Project and the Family Check-up packed together as a single intensive intervention.
224002101|NCT05444205|BEHAVIORAL|Healthy Families America Warm Referral|As part of Healthy Families America, professionally trained Nurse Home Visitors provide information during weekly home visits so that parents can provide the best for your new baby. Topics addressed are ways to keep the baby safe, how to take care of the baby, and activities parents can enjoy with their babies.
224002102|NCT05444205|BEHAVIORAL|Family Center Warm Referral|There are 27 Family Centers across Allegheny County provide services to families of young children 5 and under. These centers focus on three primary activities: 1. enhancing child development; 2. facilitating parent education, and 3. ensuring parents are supported and connected.
224002103|NCT05919394|DRUG|To compare in both treatment arms the percentage of patients controlled at week 52.|Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
223384743|NCT04697082|PROCEDURE|Minimal invasive surgery|In the operating room, after the patient was placed in the prone position, the region was removed by stretching the buttocks with adhesive bands and cleaning the area with 10% povidone iodine. The largest pit was excised, and hairs in the cavity were removed with forceps. Then, the whole cavity was curetted meticulously and irrigated with SS. After haemostasis, the cavity volume was measured
223384744|NCT04697082|OTHER|Platelet rich plasma administration|Platelet rich plasma (PRP) was administered by filling the whole space from the lateral side of the cavity. After the first implementation of PRP, the second one was applied at 48 hours. Until that time, the dressing was not uncovered. PRP was applied on the 3rd, 4th and 5th days postoperatively.
223384745|NCT02329626|DEVICE|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
223384746|NCT03349086|BEHAVIORAL|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
224002104|NCT02342938|PROCEDURE|MEG or fMRI And INtracranial EEG|
224002105|NCT02342938|PROCEDURE|fMRI|
224002106|NCT06472804|OTHER|Non-Interventional Study|Non-interventional study
224002107|NCT04542733|DRUG|Everolimus|Everolimus will be given with tacrolimus.
224002108|NCT04542733|DRUG|reduced dose tacrolimus and Leflunomide|Reduced dose tacrolimus will be given with leflunomide
224002109|NCT00462605|DRUG|entinostat|Given PO
224002110|NCT00462605|DRUG|sargramostim|Given SC
224002111|NCT00002539|BIOLOGICAL|filgrastim|
224002112|NCT00002539|DRUG|cisplatin|
224299198|NCT04583449|BEHAVIORAL|Mental imagery|"Mental imagery involves the mental representation of a future event, action, or task. By imitating or rehearsing this mental event or series of events (Taylor et al., 1998, p. 430) mental imagery interventionists theorise that an individual's preparation for, and motivation toward, a future action can be made more likely. Mental imagery involves an individual following a set of pre-defined exercises involving thinking about, visualising and writing about a health-related action. Mental imagery exercises can involve focusing on anticipated positive/beneficial outcomes of an action (outcome imagery) or imagery relating to the anticipated strategies/preparation that would be required to successfully execute a pre-defined action (process imagery)."
224002113|NCT00002539|DRUG|doxorubicin hydrochloride|
224002114|NCT00002539|PROCEDURE|conventional surgery|
224002115|NCT04439188|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
224002116|NCT06360354|DRUG|AMG 193|Administered Orally
224002117|NCT06360354|DRUG|Gemcitabine|Administered IV
224002118|NCT06360354|DRUG|Nab-paclitaxel|Administered IV
224002119|NCT06360354|DRUG|Modified FOLFIRINOX|Modified FOLFIRINOX consists of irinotecan, 5-FU, LV, and oxaliplatin administered IV
223384747|NCT02826512|DRUG|Niraparib|niraparib 300 mg QD continuously
223384748|NCT03048552|BEHAVIORAL|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
223384749|NCT06080854|DRUG|Toripalimab|Toripalimab 240mg administered intravenously on Days 1 of every 3 weeks
223384750|NCT06080854|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks
223384751|NCT06080854|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
223384752|NCT06080854|OTHER|SBRT|SBRT Radiotherapy plan: Planning gross tumor volume (PGTV) 5Gy\*10 fractions, Planning target volume (PTV) 3Gy\*10 fractions
223425547|NCT05415605|DEVICE|Lung Strain|The main objective of this study is to describe the physiological values of lung strain in healthy volunteers as well as its variations induced by non-invasive positive pressure ventilation and their correlation with tidal volume.
223425548|NCT05033730|DEVICE|Flow Controlled Ventilation|Mechanically ventilated using Flow Controlled Ventilation (FCV)
224002120|NCT06360354|DRUG|RMC-6236|Administered orally
224002121|NCT03548220|DRUG|Placebo|Placebo matching AG-348 tablets, administered to maintain the blind.
224002122|NCT03548220|DRUG|AG-348|AG-348 tablets.
224002123|NCT00501657|DRUG|Sitagliptin|100mg mane for 2 days
224002124|NCT00501657|DRUG|Placebo|100mg mane for 2 days
224002125|NCT04837365|OTHER|Three dimensional gait analysis with eyetracking|An emotional impregnation and eye pursuit assessment are specific to the study. Emotional impregnation involves making the patient look at images from the International Affective Picture System (IAPS) on a screen before initiating walking. The equipment will be identical to that of the patient during walking tasks. Eye movement analysis is performed using a pair of eyetracking glasses.
224002126|NCT06534502|DRUG|Zonisamide Oral Product|Zonisamide oral suspension
224002127|NCT05723523|OTHER|CI-CDS|The CI-CDS system is a clinical decision support tool that assists clinicians in the diagnosis and management of cognitive impairment.
224002128|NCT02906007|DRUG|Bedaquiline|Participants received bedaquiline (BDQ) once per day through intensive PK sampling visit, then 3 times per week on Monday, Wednesday and Friday through the week 24 visit.
224002129|NCT03560375|BEHAVIORAL|Circuit resistance training (CRT)|"Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27"
223384753|NCT04667754|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
223384754|NCT03172494|DRUG|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
223384755|NCT03172494|DRUG|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
223384756|NCT03172494|DRUG|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
223384757|NCT00351455|BEHAVIORAL|smoking cessation|
223384758|NCT00351455|BEHAVIORAL|tighter diabetic control|
223384759|NCT00351455|BEHAVIORAL|diet and exercise program|
223384760|NCT03281395|PROCEDURE|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
223730005|NCT05767645|DEVICE|Mistral Procedure|"The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).~The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators."
223730006|NCT01954602|PROCEDURE|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
224002130|NCT03560375|BEHAVIORAL|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
224002131|NCT03560375|DRUG|Empagliflozin 10 MG|Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
224002132|NCT04669496|DRUG|Neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
224002133|NCT05795855|BEHAVIORAL|ADEPT|Prenatal providers will participate in trainings that will lay the foundation for an effective vaccination recommendation. After the completion of training, prenatal care providers will begin making recommendations promoting the importance of maternal and childhood vaccinations to pregnant individuals, as part of routine prenatal care. The core component of ADEPT is prenatal provider training to enable a vaccination recommendation, encouraging pregnant individuals to receive vaccines during pregnancy and for their child after birth. Pregnant individuals who remain vaccine hesitant despite the provider recommendation, will be eligible to receive the adaptive components of ADEPT in the form of evidence-based educational materials on vaccinations and phone consultations with a vaccine navigator to discuss residual concerns.
224124225|NCT06126874|OTHER|Patient Education|Individuals in both study groups will be provided with patient education through verbal and visual presentations. In the content of patient education; information about the importance of the research topic and the content of the study through anatomical models and short animations, lifestyle recommendations for urinary incontinence symptoms (avoiding bladder irritants such as alcohol, caffeine, tea, spicy foods, acidic foods and chocolate, regulating water / fluid consumption, recommendations for attention to bowel regularity and increasing physical activity levels) and recommendations for sexual functioning (coitus positions that facilitate erection, recommendations for reshaping the sexual schema, recommendations for the physical dimension of sexual health) will be given.
224124226|NCT06126874|OTHER|Pelvic Floor Muscle Training|In PFMT, voluntary maximal and submaximal contractions for strength and endurance training of pelvic floor muscles will be taught and individuals will continue PFMT as a home exercise program. In the first 2 weeks of PFMT, individuals will perform 3 sessions of exercise per day. In each 2-week control, the number of sessions will be increased by 1 session and PFMT application will be completed with 5 sessions per day in the study.
224124227|NCT06126874|OTHER|Aerobic Exercise Training|Aerobic exercise training will be planned 3 days a week, 1 day on the routine clinic day with a treadmill ergometer and 2 days as a home program in the form of brisk walking outside the clinic (e.g. outdoors or in a suitable environment).The intensity of aerobic exercise training will be planned according to the Maximal Heart Rate (MHR) method and Modified Borg Scale (MBS). In the first 2 weeks in the clinic, training will be started with 50 min (+10 min warm-up and cool-down) at 60% of the MHR, the exercise intensity will be increased by 5% every 2 weeks, and the program will be terminated by providing exercise training at 85% of the MHR in the 10th-12th week. Patients will be asked to adjust the intensity of aerobic exercise outside the clinic to correspond to the 12-14 (slightly difficult) degree of perceived fatigue according to the MBS.
224299199|NCT00158600|BIOLOGICAL|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
224299200|NCT00158600|DRUG|Placebo|Placebo Comparator; qow for 78 weeks.
224299201|NCT04163978|DRUG|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
224299202|NCT04163978|DRUG|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
223730007|NCT01954602|PROCEDURE|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
223384761|NCT03281395|PROCEDURE|No rapid ventricular pacing|
224002134|NCT05593302|BEHAVIORAL|Trauma-Focused Art Therapy (TFAT)|"Individual Trauma Focused Art Therapy (TFAT) consisting of 10 sessions. Each session lasts 60 minutes. Sessions are aimed at trauma recovery using visual art therapy. The sessions cover an introduction, making pieces of artwork, and reflection. Three phases can be distinguished:~Phase 1: 'stabilization and symptom reduction', i.e. exploring traumatic and positive memories, imagining a lifecourse, and expressing a safe haven (4 sessions).~Phase 2:'uttering and expressing memories', i.e. expressing chosen memories by making 5 pieces of artwork. Materials that can be used include clay, paint, graphite pencil or crayons and if needed with support of imagination using relevant photographs or objects (5 sessions).~Phase 3: 'integration and meaning attribution', i.e. ordering and assembling of the 5 pieces of artwork. Patients are asked to appraise the memories in the here-and-now present (c.f. mindfulness-based cognitive therapy) (1 session)."
224002135|NCT05764954|DEVICE|NovoTTF-200T System|The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
224002136|NCT06467175|BIOLOGICAL|blood sampling for high molecular weight DNA extraction|2 EDTA tubes will be taken for the index case, and the DNA will be extracted for sequencing into long-fragments and short-fragments. 1 EDTA tube will be taken for each relative.
224002137|NCT06385496|PROCEDURE|Biopsy Procedure|Undergo biopsy
224002138|NCT06385496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224002139|NCT06385496|PROCEDURE|Computed Tomography|Undergo CT scan
224124228|NCT06126874|OTHER|Resistance Exercise Training|Resisted exercise training will be planned 2 days a week, 1 day in the clinic and 1 day outside the clinic as a home program, and 12 different exercises for large muscle groups with dumbbells and weight sets, resistance bands (therabands) will be used in the training. These exercises are leg press, leg extension, leg curl, squat, seated row, lateral pull down, biceps curl, triceps extension, dumble fly, lateral raises, bench press and abdominal crunch. Exercises will be performed with free weights (dumbbells), resistance bands (therabands) or body weight.
223384762|NCT05478577|OTHER|Motor rehabilitation|Treatments for upper limb recovery (e.g. occupational therapy, technology devices, conventional therapy)
223384763|NCT02764151|DRUG|PF-06840003|Daily Oral PF-06840003
223384764|NCT03912597|DEVICE|Virtual Reality|The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.
224002140|NCT06385496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224002141|NCT06385496|DRUG|Sapanisertib|Given PO
224002142|NCT05820204|BEHAVIORAL|Pain reprocessing therapy (PRT)|A promising new psychotherapy for chronic pain
224002143|NCT05820204|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)|A psychotherapy for chronic pain that has 30+ years of research support.
224002144|NCT05820204|OTHER|Usual care|Participants will be asked to continue to do whatever they are currently doing to manage their pain
224002145|NCT04759976|BEHAVIORAL|Robotic motor training|The experiments consist in performing motor tasks with upper-limb robotic devices.
224124229|NCT04218916|DRUG|Rhodiola Rosea Capsules|0.28g per capsule, 0.56g once (2 capsules), three times a day
224124230|NCT04218916|DRUG|Placebo|2 placebo capsules once, three times a day
224124231|NCT04119726|BEHAVIORAL|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
224124232|NCT04119726|BEHAVIORAL|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
223384765|NCT03912597|DEVICE|Brochure|Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.
223384766|NCT03912597|DEVICE|Standard Video Control|The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
223384767|NCT01315327|DRUG|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
223384768|NCT01315327|DRUG|Olive oil|Placebo
223384769|NCT04860180|PROCEDURE|adrenalectomy|
223384770|NCT03131804|OTHER|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
223384771|NCT01091324|DRUG|Dextromethorphan|60 mg, bid
224002146|NCT05534425|BEHAVIORAL|GenX intergenerational mentoring program|GenX trains older adults to collaborate with K-3rd grade teachers in mentoring high-need elementary school students in core reading and math skills.
223384772|NCT01091324|DRUG|Silymarin|150 mg , tid
223384773|NCT01091324|DRUG|sugar pill|placebo
223425549|NCT03495674|BEHAVIORAL|Exercise Intervention|Complete cycling classes
224002147|NCT02919631|DRUG|Triheptanoin|Anaplerotic dietary oil
224002148|NCT02919631|DRUG|Placebo oil|Safflower oil
224002149|NCT04915820|DIETARY_SUPPLEMENT|Ferinject|intravenous iron carboxymaltose
224002150|NCT06507293|PROCEDURE|Paravertebral block|Before the general anesthesia induction, paravertebral block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
224002151|NCT06507293|PROCEDURE|Erector spiane plane block|Before the general anesthesia induction, erector spinae plane block will be performed at T5 with 0.25% bupivacaine (20 mL) using ultrasound.
224002152|NCT05997316|BEHAVIORAL|Time restricted eating|Participants will work with a psychologist towards achieving a 16 hour fasting period, 2-3 days per week. The intervention will last 12 weeks, with different intervention materials gradually introduced over the course of the 12 weeks.
223384774|NCT04871256|PROCEDURE|Septorhinoplasty|This intervention will be performed by the same surgeon, after signing of patient inform consent.
223730008|NCT07132047|OTHER|Mulligan Mobilization SNAG with Home Exercise|This intervention combines manual mobilization and self-exercise. The therapist applies sustained postero-anterior glides to the second cervical vertebra for 10-30 seconds, up to six repetitions if pain decreases. The home program involves C1-C2 self-SNAG with a towel, maintaining end-range rotation for 10 seconds before returning to neutral. Exercises are completed twice daily for 10 repetitions each session. Participants receive illustrated instructions to promote correct execution and compliance.
224002153|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
224002154|NCT02384876|DRUG|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
224002155|NCT06606210|DEVICE|InnovaMatrix® AC|Weekly dressing applications
224002156|NCT06986772|DRUG|[14C]TGRX-678|Healthy subjects will be given TGRX-678 240 mg orally on day 1.
224002157|NCT06664034|BEHAVIORAL|Multi-component reproductive health care intervention|"The multi-component reproductive health care intervention includes:~1. Young cancer patients presenting to oncology visits will complete a clinic-based reproductive health needs screen with a member of the clinical team. This needs screen assesses i) desire to have a child in the future and ii) need for contraception.~2. Reproductive health patient navigation consists of one telehealth or in-person session with a social worker to: i) assess the patient's reproductive health needs, ii) provide individualized patient education and counseling on a) infertility risk related to cancer type and treatment and b) screening and management strategies for reproductive health needs, iii) provide support with the goal of engaging in goal-concordant reproductive health care.~3. Telehealth reproductive health consultation will occur between the patient and reproductive specialist. Each consultation is estimated to be 1 hour."
223384775|NCT05194098|DEVICE|TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil|Active Session: Single session of standard iTBS of 50Hz triplet bursts, 5 times each second with a 2 s on / 8 s off duty cycle for 600 pulses per hemisphere (1200 pulses total) will be applied for a total stimulation time of 6:40 minutes
223384776|NCT05194098|DEVICE|SHAM (inactive) TMS stimulation|Sham neurostimulation (SHAM) entails use of the sham side of the D-B80 A/P placed over the same anatomical target, without any active stimulation.
223730009|NCT07132047|OTHER|Active Release Technique with Home Exercise|This approach integrates manual soft tissue release with targeted exercise. ART is applied to the neck and shoulder region, focusing on pectoralis major, upper trapezius, and levator scapulae. Exercises include wall angles, doorway stretches, Brugger's stretch, and head/neck retractions. Strengthening activities target rhomboids, deep neck flexors, and serratus anterior. The home routine consists of neck stretches, chin tucks, and postural drills, performed regularly to enhance muscle balance, posture, and headache relief.
223730010|NCT06877169|OTHER|Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.|During combined heart and kidney transplantation, heart and kidney allografts may be implanted during a single operative event, or with delayed kidney implantation in a second operative event. Timing of the delay is often determined by recipient stability and kidney availability; however, clinicians must balance recipient factors with accumulating cold ischemic time of the kidney allograft. This study uses hypothermic oxygenated machine perfusion to reduce ischemic injury to the kidney allograft and allow for improved recipient stability with planned delayed implantation of the kidney graft. Delays will allow for at least 6 hours of hypothermic oxygenated machine perfusion prior to implantation.
224002158|NCT06597279|BEHAVIORAL|Web-based dialysis decision support tool|"The intervention in this study is the Kidney Care Roadmap, a web-based dialysis decision support tool designed to assist patients with advanced chronic kidney disease and their caregivers."
223384777|NCT03366441|OTHER|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
223384778|NCT03366441|OTHER|SMS|Text messages were sent to an equal number of donors in the SMS group
224002159|NCT06588608|DEVICE|auricular nerve stimulation (aVNS)|The Spark Sparrow system stimulates the auricular branch of the Vagus nerve using a low-voltage electrical signal comprising a 1 Hz - 150 Hz biphasic square wave with a pulse width of 50s - 750s. Stimulation current is controlled with a maximum voltage of 95 V and 1-5 milliamperes (mA) output current. The device is positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Stimulation will occur for 30 minutes. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
224002160|NCT06588608|DEVICE|sham aVNS|The Spark Sparrow system device will be positioned at the auricular branch of the Vagus nerve on the ear with the outer electrode in front of the ear and the inner electrode into the hollow area of the ear, just above the ear canal. Subjects will wear the device for 30 minutes during which no stimulation will be emitted. Participation will last up to 2 weeks and requires 2 separate in-person visits. Each visit will be up to 3 hours.
224002161|NCT06997718|OTHER|RV5075A MF6793|Twice daily applications on both feet. The product will be applied according to randomization on the entire feet in a sufficient amount.
224002162|NCT06997718|OTHER|CO5075A|Twice daily applications on both feet. The product will be applied according to randomization on the entire feet in a sufficient amount.
223425550|NCT03495674|OTHER|Informational Intervention|Receive information about exercise guidelines
223730011|NCT06736418|DRUG|225Ac-ABD147|A delta-like ligand 3 (DLL3)-targeting antibody fragment conjugated with a linker-chelator that effectively coordinates Ac-225
224002163|NCT00786552|DRUG|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
224002164|NCT06004037|DRUG|Delpazolid|"Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks.~After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total."
224002165|NCT03549858|OTHER|Quality of life measure (survey)|The QoL tool is a questionnaire
223425551|NCT03495674|DEVICE|Monitoring Device|Wear Fitbit
223384779|NCT06633627|OTHER|Recording of brain activity using electroencephalography (EEG)|Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
224002166|NCT06369298|DRUG|JK07|JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
224002167|NCT06369298|DRUG|Placebo|0.9% sodium chloride
224002168|NCT07016165|DRUG|Ceftazidime|Ceftazidime 150 mg/kgBW/24 hours divided into 3 doses.
224002169|NCT07016165|DRUG|Ciprofloxacin|Ciprofloxacin 10 mg/kgBW/12 hours
224002170|NCT06691464|DIAGNOSTIC_TEST|PET|FAPI - PET/CT
224002171|NCT01796600|DEVICE|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
224002172|NCT04432571|BEHAVIORAL|SOC-REC/SOC-OIC|Standard of care - routine education and counseling (SOC-REC)/SOC-Outreach and Intensified Counseling (OIC). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
224002173|NCT04432571|BEHAVIORAL|SOC-REC/CCT|SOC-REC/Conditional Cash Transfer (CCT). SOC-REC is a stage 1 intervention to prevent lapses in HIV engagement through routine care. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following per current MOH guidelines).
224002174|NCT04432571|BEHAVIORAL|SOC-REC/IP-NAV|SOC-REC/In-Person Peer Navigation (IP-NAV). SOC-REC is a stage 1 intervention (routine care) to prevent lapses in HIV engagement. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement. Trained peer navigators will develop rapport with the participants and provide psychosocial support, case management, and assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers. The peer navigator will meet with the participant at least monthly, and no more than weekly, until HIV care engagement is demonstrated.
224002175|NCT04432571|BEHAVIORAL|E-NAV/SOC-OIC|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. SOC-OIC is a stage 2 intervention to treat lapses in HIV engagement through routine care which may include tracing and counseling to return to the clinic.
224002176|NCT04432571|BEHAVIORAL|E-NAV/CCT|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) who have unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. CCT is a stage 2 intervention to treat lapses in HIV engagement by providing a small cash incentive for on-time clinic attendance and/or viral load suppression (following current MOH guidelines).
224124233|NCT04119726|BEHAVIORAL|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
224124234|NCT01583998|BEHAVIORAL|e-MBC|antidepressant treatment
224124235|NCT04184622|DRUG|Tirzepatide|Administered SC
224124236|NCT04184622|DRUG|Placebo|Administered SC
224124237|NCT06300619|BEHAVIORAL|Pilates+4|12 weeks of seated Pilates twice weekly. In weeks 1-3, participants receive training on hip and shoulder cuff activation. This occurs through active isometric pressure on the stabilizing limb (not the moving limb during a Pilates movement) for 3 seconds at 30% strength using the participants' own hand (e.g., pressure on the outside of the knee with knee pressing against hand) prior to engaging in each exercise. Following the first 3 weeks, participants in the Pilates+4 group engage in the same Pilates protocol as the comparator group, however, they receive 4-quadrant cues for hip and shoulder cuff activation as they learned in weeks 1-3.
224124238|NCT06300619|BEHAVIORAL|Pilates|12 weeks of seated Pilates twice weekly. 18 exercises standard in Pilates instruction will be provided with standard Pilates cues (i.e., core activation, cuing the moving limb, breathing synchronization).
223384780|NCT04015310|DEVICE|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
223384781|NCT01984827|DRUG|Moxifloxacin|"1. a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~2. a single oral dose of 400mg Moxifloxacin plus C-peptide~3. a single oral dose of 400mg Moxifloxacin~4. placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
223384782|NCT01984827|OTHER|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
223384783|NCT03762694|DEVICE|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
224002177|NCT04432571|BEHAVIORAL|E-Nav/IP-NAV|E-Nav is a stage 1 intervention to prevent lapses in HIV engagement. Trained e-peer navigators will develop rapport and provide support through phone calls and/or patient preferred social media platforms. They will meet once in person and then weekly electronically for 8 weeks, and then monthly. If an adolescent (1) misses an appointment \>14 days, or (2) has unsuppressed HIV RNA as per current MOH viral load threshold or (3) clinically documented non-adherence after \>3 months of treatment he/she is re-randomized to a stage 2 intervention. IP-NAV is a stage 2 intervention to treat lapses in HIV engagement by providing in person navigation and counseling to a cash incentive for on-time clinic attendance and/or viral load suppression (MOH guidelines). Trained peer navigators will provide psychosocial support, case management, assess retention and adherence barriers in a systematic manner and work with the participant to develop social support and clear, feasible plans to address barriers
224002178|NCT06693752|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]|Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
224002179|NCT07014007|DEVICE|RV4421B- EV0407|Medical device. Product application on studied areas, 5 to 15 minutes after corticosteroids application, if applicable. The maximum duration of application of medical device is 87 days.
224002180|NCT06596135|DRUG|Setmelanotide|Open-label daily injections of setmelanotide
224002181|NCT05706610|BEHAVIORAL|Tailored Program|Participants in the tailored program will participate in 4 sessions with a coach, 1 every other week. During these sessions, the AYA will work with their coach to identify a barrier to adherence to target and create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text including a reminder about the action plan and a calendar of the AYA's eCAP adherence data.
224002182|NCT05706610|BEHAVIORAL|Feedback Program|Participants in the Feedback Program will receive weekly text messages including: a calendar depicting their weekly adherence (per eCAP data) and guidance for requesting additional support as desired.
224002183|NCT03570892|DRUG|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
224002184|NCT03570892|DRUG|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~\*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
224002185|NCT06782347|BEHAVIORAL|Proactive Care|The proactive care intervention was designed to be similar to proactive care approaches used successfully in the tobacco control area. These proactive care procedures have not yet been adequately evaluated in the exercise promotion area.
224002186|NCT07075406|DRUG|Luspatercept|According to product label
224002187|NCT07138001|COMBINATION_PRODUCT|KH617+TMZ|use KH617 and TMZ(5/28) as Combination Product.
224002188|NCT07138001|DRUG|KH617|Single Clinical trial investigational drug
224002189|NCT07138001|DRUG|TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16|"Comparator product, Two treatment options for physicians and subjects to choose from:~1. use TMZ(7/7)~2. Use Platinum (cisplatin or carboplatin)+VP-16"
224124239|NCT04319289|OTHER|aerobic interval training and Vitamin D supplementation,|"The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day ."
224124240|NCT04319289|DRUG|Vitamin D supplementation only|One capsule containing (cholecalciferol 400 IU) was taken every day .
224124241|NCT04319289|OTHER|aerobic interval training only|"The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks"
224124242|NCT05420467|DRUG|Docetaxel|75 mg/m2, d1, q3w,6 cycles
224124243|NCT05420467|DRUG|Carboplatin|AUC 6, d1, q3w,6 cycles
223384784|NCT02297256|PROCEDURE|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
223384785|NCT02297256|PROCEDURE|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
223384786|NCT01845727|DRUG|Topical Amphotericin B at 3%|
223384787|NCT01959373|PROCEDURE|electroencephalograms (EEG)|
223384788|NCT01959373|PROCEDURE|electro-myography (EMG)|
223425552|NCT03495674|OTHER|Questionnaire Administration|Complete questionnaire
223730012|NCT06897696|DRUG|Dexmedetomidine+propofol+remifentanyl group|The dexmedetomidine+TIVA group will receive a bolus of 0.8-1 µg/kg dexmedetomidine for 10 minutes followed by continuous dexmedetomidine infusion at a rate of 0.3-0.5 µg/kg/hour.
223730013|NCT06897696|DRUG|propofol+remifentanyl group|propofol 5-8 mg/kg/h and remifentanil 5-10 µg/kg/h will be administered to all patients
223730014|NCT06848140|DEVICE|Active Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim 20 or 32. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
224002190|NCT07136220|OTHER|Consumption of soy protein bar|The participants will be provided one soy protein bar to consume after dinner on day 1.
224002191|NCT07136766|DRUG|Facial Toner|Brightening Toner
224002192|NCT07136766|OTHER|Placebo Toner|Placebo Control Toner
224002193|NCT07135765|PROCEDURE|Additional 5 minutes of lying down position during MRI|During axial MRI for scoliosis assessment, additional 5 minutes of lying down position in order to performing a specific sequence for the study of the vertebral muscles (Diffusion Tensor Imaging).
224002194|NCT07137065|BEHAVIORAL|PRImary care MultilEvel intervention for low back pain (PRIME)|"The multilevel intervention includes four main components:~1\. GP training. GPs will receive training to improve their confidence in LBP guidelines, diagnostic triage and best practice. Furthermore, they will be trained to provide both general and cognitive reassurance to patients, use a stratified care strategy and improve interprofessional communication. 2. Reminders. GPs will receive regular reminders by email to reinforce the integration of high-value care into practice. 3. Patient education. GPs will reassure patients, help them understand their LBP in the initial consultation and target unhelpful beliefs about LBP. 4. Clinical pathway. The clinical pathway includes a gradual stratified care pathway based on risk factors for chronicity. The core interventions of this 3-step clinical pathway are education and self-management, individual sessions with a trained physiotherapist, and multidisciplinary group management. GPs remain free to make all clinical decisions."
224002195|NCT07137065|OTHER|Usual Care|In this arm, general practitioners will treat their patients as usual. They can prescribed any treatment or diagnostic tests to their patients.
224002196|NCT07136454|DRUG|Rugonersen|Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).
224002197|NCT07136805|DRUG|VVN461 Ophthalmic Solution 1.0%|1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
224002198|NCT07136805|DRUG|1.0% prednisolone acetate|1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days
224002199|NCT02627443|DRUG|Berzosertib|Given IV
224002200|NCT02627443|DRUG|Carboplatin|Given IV
224002201|NCT02627443|DRUG|Gemcitabine Hydrochloride|Given IV
224002202|NCT02627443|OTHER|Laboratory Biomarker Analysis|Correlative studies
224002203|NCT02627443|OTHER|Pharmacological Study|Correlative studies
224002204|NCT07076615|DRUG|Dapagliflozin (DAPA)|Receives dapagliflozin 10 mg once daily + standard intravenous diuretic therapy
224002205|NCT07076615|DRUG|Diuretic|Arm B (Control Group): Receives standard intravenous diuretic therapy alone
224002206|NCT04111172|BIOLOGICAL|Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE|Given as intramuscular injection
224002207|NCT06840886|DRUG|PHST001|"* PHST001 will be administered as IV infusions in a 3-week (Q3W) dosing interval. The dosing day will be on Day 1, 21 days cycle.~* Other Names:~* Dose Level 1~* Dose Level 2~* Dose Level 3~* Dose Level 4~* Dose Level 5~* Dose Level 6~* Dose Level 7~Drug: PHST001~* PHST001 will be administered as IV infusions in a 3-week (Q3W) dosing interval. The dosing day will be on Day 1, 21 days cycle.~This study is an open label, Phase 1 dose escalation trial with three expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 40-80 in total will be in enrolled in part A, covering 7 dose level.~* Part B: Expansion cohorts will be added as an amendment as further preclinical data and clinical data from Part A become available."
224002208|NCT06767111|DEVICE|Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm in vitro diagnostic (IVD) device|Digital cervical cytology slide imaging system with artificial intelligence (AI) algorithm to be used for AI-assisted review
224002209|NCT06755827|BEHAVIORAL|Emotion regulation and self-monitoring to treat pediatric obesity|Participants will attend telehealth group sessions once weekly and be asked to self-monitor their mood and health behaviors daily between sessions.
224124244|NCT05420467|DRUG|Trastuzumab|starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles
224124245|NCT05420467|DRUG|Pertuzumab|starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles
224124246|NCT05420467|DRUG|Nab paclitaxel|220 mg/m2, d1, q3w,6 cycles
224124247|NCT05420467|DRUG|Epirubicin|90 mg/m2, d1, q3w ,4 cycles ,followed by docetaxel
224124248|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
224002210|NCT06755827|OTHER|Psychoeducation|Participants who are randomized to the control group will receive an online, one-time, self-led psychoeducation program with information about current daily sleep, diet, and physical activity recommendations (e.g., information about sleep hygiene, the food pyramid, and recommendations for 60 minutes of moderate-to-vigorous physical activity daily).
224124249|NCT05420467|DRUG|Docetaxel|100 mg/m2, d1, q3w × 4 cycles
224124250|NCT05420467|DRUG|Epirubicin|90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
224124251|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
224124252|NCT05420467|DRUG|Nab paclitaxel|125 mg/m2, d1,8,15, q3w× 4 cycles
224124253|NCT05420467|DRUG|Cyclophosphamide|600 mg/m2, d1, q3w × 6 cycles
223384789|NCT03672591|OTHER|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
223384790|NCT05884502|DRUG|combination of high-dose rosuvastatin and ezetimibe|combination of rosuvastatin 20mg and ezetimibe 10mg
223384791|NCT05884502|DRUG|high-dose rosuvastatin single administration|rosuvastatin 20mg monotherapy
223384792|NCT00852202|DRUG|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
223384793|NCT00852202|DRUG|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
224002211|NCT07084051|BEHAVIORAL|I-MAS|Participants will receive a one-to one session with the pharmacy technician that involves two parts; the first part include education on ischemic stroke and risk factors such as practical strategies to improve hypertension control (i.e., appropriately taking medications, necessity of treatment, and consequences of not taking medicine, etc., making healthier dietary choices, exercising regularly, smoking cessation, alcohol intake, and managing blood sugar. The second part involves an interview to collect information on socio-demographics, clinical factors, co-morbidities, medications, and medication adherence barriers. During the second part of the session, the pharmacy technician will identify barriers to medication adherence for secondary prevention of stroke medications including antihypertensives, antithrombotic agents, and statins. The pharmacist will collaborate with the pharmacy technician to develop an action plan to address medication adherence barriers
223384794|NCT00852202|DRUG|placebo|placebo capsules, oral administration, once daily dosing
223384795|NCT00022113|DRUG|cilengitide|Given IV
223384796|NCT00022113|OTHER|pharmacological study|Correlative studies
223384797|NCT00022113|OTHER|laboratory biomarker analysis|Correlative studies
223384798|NCT03980535|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224002212|NCT06122870|BIOLOGICAL|CampETEC HBC product|Immunoglobulin from bovine milk/colostrum and challenge strain
223384799|NCT03980535|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223384800|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
223384801|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
223384802|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
223384803|NCT01838473|PROCEDURE|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
223384804|NCT02442180|DRUG|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
223384805|NCT02442180|DRUG|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
224002213|NCT06122870|BIOLOGICAL|ProMilk 85|Placebo ProMilk 85
224002214|NCT06122870|BIOLOGICAL|C. jejuni CG8421 Challenge strain|Challenge strain C. jejuni CG8421
224002215|NCT02726711|DRUG|Trimethaphan|Trimethaphan will be infused (0.5 - 4.0 mg IV)
223384806|NCT02442180|DRUG|placebo|equivalent to G-CSF doses
223384807|NCT03513094|OTHER|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
223384808|NCT00372840|OTHER|educational intervention|
223384809|NCT00372840|PROCEDURE|psychosocial assessment and care|
223384810|NCT00372840|PROCEDURE|quality-of-life assessment|
223384811|NCT05379244|BEHAVIORAL|CBT-i|Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
223384812|NCT02972892|DEVICE|Et Control Feature|Subjects using Et Control option; the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the wellbeing of the subject. The clinician must continuously monitor measured inspired and end tidal oxygen and anesthetic concentrations to assess individual responses and compare to the target concentrations.
223384813|NCT02972892|DEVICE|Conventional Fresh Gas|"Subjects to undergo a surgical procedure with inhaled anesthesia meeting the American Society of Anesthesiologists status classification system 1-3. Subjects using conventional option; the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature. Machine log data collection will end, when an end case is confirmed on the Aisys CS2 at the end of the anesthesia case."
223384814|NCT05054504|DEVICE|Butterfly iQ|The primary intervention under study is the Butterfly iQ point-of-care ultrasound device, embedded in a larger program of training, iterative ANC service delivery design, and a final program evaluation.
223384815|NCT05022212|DRUG|LACTIN-V|administered vaginally
223384816|NCT05022212|DRUG|Placebo|administered vaginally
223384817|NCT03104712|OTHER|Glucose #1|50g available carbohydrate
224002216|NCT02726711|DRUG|Placebo|0.5 - 4.0 mg IV to be infused
224002217|NCT05511467|BEHAVIORAL|Visuomotor learning task|Participants undergo functional magnetic resonance imaging during the performance of the visuomotor learning task. The visuomotor learning task involves holding a device in the hand that measures the strength of the grip when squeezing the 'gripper'.
224002218|NCT07081633|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
224002219|NCT07081633|DRUG|Tremelimumab|Tremelimumab IV (intravenous infusion)
224002220|NCT07081633|COMBINATION_PRODUCT|Lenvatinib|Lenvatinib Oral
223384818|NCT03104712|OTHER|Glucose #2|50g available carbohydrate
223384819|NCT03104712|OTHER|Glucose #3|50g available carbohydrate
223384820|NCT03104712|OTHER|Spaghetti|50g available carbohydrate
223384821|NCT03104712|OTHER|Rice|50g available carbohydrate
223384822|NCT03104712|OTHER|Spaghetti + Tomato Sauce|50g available carbohydrate
223384823|NCT03104712|OTHER|Rice + Tomato Sauce|50g available carbohydrate
223384824|NCT03104712|OTHER|Spaghetti + Pesto|50g available carbohydrate
224002221|NCT07083271|OTHER|Administration of validated questionnaires with established Turkish versions|Participants will complete validated Turkish versions of three self-administered instruments: the Zarit Caregiver Burden Scale (ZCBS), the EORTC QLQ-C30, and the Hospital Anxiety and Depression Scale (HADS). Financial toxicity will be assessed via self-reported socioeconomic data. No clinical, behavioral, or pharmaceutical intervention will be applied.
224002222|NCT07086664|DRUG|Placebo|Oral tablet
224002223|NCT07086664|DRUG|PF-07258669|Oral tablet
224002224|NCT06926075|DRUG|A novel hGIIA-Vimentin Inhibitor|Phase I, dose escalation includes 4 increasing doses, 10mg, 30mg, 60mg and 120mg.
224124254|NCT03852888|BIOLOGICAL|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
224124255|NCT05553756|DIETARY_SUPPLEMENT|Maltodextrin|200 ml maltodextrin given 2 hours before cesarean section
223384825|NCT03104712|OTHER|Rice + Pesto|50g available carbohydrate
224002225|NCT06926075|DRUG|Dose expansion|Phase II will enrol participants in selected indication(s) and will be given one of the two recommended doses by the SMC.
224002226|NCT06927505|OTHER|Bobath based trunk control training|Participants in the Bobath based trunk training group will undergo a comprehensive intervention encompassing strengthening exercises, stretching exercises, and motor training. This group will experience a 60-minute session, including 40 minutes of Bobath based exercises along with 20 minutes routine physical therapy. 1. Strengthening the oblique abdominals 2. Weight Shifting (Side-to-Side \& Forward-Backward) 3. Pelvic Tilts 4. Functional strengthening of trunk extensors 5. Reaching 6. Latissimus dorsi stretching exercise 7. Bridging 8. Trunk rotation (supine and standing position) 9. Sitting to Standing Transitions (with emphasis on trunk control) 10. Standing Weight Shifts There will be a rest of 1 minute between each set of exercise. Progression of exercises with increase in intensity and resistance.
224002227|NCT06927505|OTHER|Unstable surface trunk training|"This group will receive 60-minute training session that consists of 40 minutes of unstable surfaces exercises and 20 minutes of routine physical therapy 3 days per week for a total of 12 weeks.~Hook-lying position: (1) Abdominal draw-in maneuver with ball under the buttocks.~(2) Abdominal muscles isometric contraction. (3) Bridging combining with abdominal draw-in maneuver. Each exercise will be performed with 5-8 repetitions. Sitting: (1) Seated balance (2) Weight shifting e.g. anterior, posterior, lateral (3) Pelvic tilts e.g. anterior and posterior tilt (4) Trunk flexion, extension and lateral flexion on both sides (5) trunk rotation on both sides (6) Reaching e.g. lateral, forward and upward reach (7) Marching while seated Each exercise will be performed with 5-8 repetitions."
224002228|NCT07077434|DRUG|BMS-986504|Specified dose on specified days
224002229|NCT05374577|OTHER|pulmonary vascular dysfunction|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, left heart function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity. Further examinations will be performed in patients with still unclear cause of persistent shortness of breath after 3 months of follow-up (subgroup RHC)
224124256|NCT05163990|OTHER|transcutaneous acupoint electrical stimulation|The corresponding transcutaneous acupoint electrical stimulation is given to different groups before spinal anesthesia, which last from 10 minutes before anesthesia to 30 minutes after subarachnoid administration.
223384826|NCT02754843|DEVICE|Phonak's equivalent newly developped power BTE|
223384827|NCT02754843|DEVICE|Equivalent competitor device|
223384828|NCT01362543|OTHER|Cognitive behavioural therapy (stress management)|Following a manual
223730015|NCT06848140|DEVICE|Sham Transcranial direct current stimulation|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim 20 or 32. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
224124257|NCT02664636|PROCEDURE|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
224124258|NCT02664636|PROCEDURE|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
223384829|NCT01362543|OTHER|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
223384830|NCT00191607|DRUG|Gemcitabine|
223384831|NCT00191607|DRUG|liposomal doxorubicin|
223384832|NCT00367978|DRUG|Amlodipine/benazepril|
223384833|NCT03189992|DRUG|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
223384834|NCT03189992|DRUG|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
223425553|NCT00217776|BEHAVIORAL|Open Airways Educational Intervention|
223425554|NCT00217776|BEHAVIORAL|Peer Asthma Action Educational Intervention|
223425555|NCT06358846|BEHAVIORAL|Self-care behavior to promote foot care through educational guidance among individual with diabetes|Apart from physician consultation, individuals will received structured training of how to care their foot to avoid ulcer and inflammation.
223384835|NCT01979991|PROCEDURE|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
223384836|NCT04525937|OTHER|Patient Questionnaire|Patient Questionnaire
223384837|NCT04525937|OTHER|Provider Questionnaire|Provider Questionnaire
223384838|NCT03426189|PROCEDURE|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
223384839|NCT03426189|PROCEDURE|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
223384840|NCT06384833|DRUG|Ascorbic acid|Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
224002230|NCT05374577|OTHER|pulmonary vascular function|Right ventricular function determined by echocardiography at rest and during exercise (non-invasive estimation of ventilation-perfusion mismatch), systemic endothelial function, and plasma levels of vasoactive biomarkers compared with clinical parameters of dyspnea and exercise capacity.
224002231|NCT06905275|BIOLOGICAL|3M-052-AF + Alum|Intramuscular (IM) injection
224002232|NCT06905275|BIOLOGICAL|UVAX-1107|IM injection
224002233|NCT06905275|BIOLOGICAL|UVAX-1197|IM injection
224002234|NCT06836739|DEVICE|Genital nerve stimulation|Genital nerve stimulation (GNS) will be administered via non-invasive surface skin electrodes. In men, two surface electrodes (1 cm diameter) will be placed on the dorsum of the penile shaft 2 cm apart. In women, one surface electrode will be placed near the clitoris and a second surface electrode will be placed on the labia majora or inner thigh. The electrodes will be connected to an electrical stimulator device.
224002235|NCT07090876|DIETARY_SUPPLEMENT|Standardized Grape Seed Extract|Grape seed dry extract standardized to provide: ≥95.0% of proanthocyanidins by spectrophotometry, ≥5.0% ≤15.0% of catechin and epicatechin by High-Performance Liquid Chromatography (HPLC)
224002236|NCT07090876|OTHER|Placebo|Placebo
224002237|NCT06908447|BEHAVIORAL|Cold-water immersion|Single 10-minute acute full-body head-out single arm-out cold-water immersion at 10-16°C on the experimental day
224002238|NCT06908447|BEHAVIORAL|Warm-water immersion (Control)|Single 10-minute acute full-body head-out single arm-out cold-water immersion at 30-36°C on the experimental day
224002239|NCT06907524|BEHAVIORAL|Longitudinal, Individualized Health Coaching|During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.
223384841|NCT06384833|DRUG|N-acetyl cysteine|NAC (effervescent) 600mg 1 tab PO OD for 45 days
223384842|NCT06384833|OTHER|placebo|pharmacologically inactive substance
223384843|NCT00917774|DEVICE|Standard LPS flex TKA|TKA by Standard LPS flex TKA
223384844|NCT00917774|DEVICE|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
224002240|NCT07103512|OTHER|Scalene Hold Relax Technique|Scalene Hold Relax Technique Scalene Hold for 10 Second 10 Repetition. Hold your arms behind your back to keep them from rising then slowly tilt your head trying to touch your ear to your shoulder. Bend your neck only as far as it is comfortable, and hold for 5 to 10 seconds. Relax your neck and repeat 2-3 times on each side. The treatment will be provided for 1-4 weeks as per need
224299203|NCT06187493|DRUG|lisinopril, enalapril|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
223384845|NCT06278480|DEVICE|MegaCarti®|Medical devices containing allogeneic cartilage
223384846|NCT06278480|PROCEDURE|microfracture|microfracture
223730016|NCT04405037|DRUG|Alvimopan|Alvimopan will be given to patients who are diagnosed with postoperative ileus after surgery
223730017|NCT07133074|DIAGNOSTIC_TEST|RENEW-IN Algorithm for assessment of a beta-lactam intervention|The RENEW-IN intervention includes a detailed assessment of the participant's beta-lactam allergy history and determination of a risk-level for allergy-delabeling.
223384847|NCT02385474|DRUG|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
223384848|NCT02385474|DRUG|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
223384849|NCT03708094|DIAGNOSTIC_TEST|molecular diagnosis|whole exome sequencing and data analysis to elucidating molecular diagnosis
223384850|NCT00779831|DRUG|120 mg Pseudoephedrine hydrochloride extended release tablets|
223384851|NCT00001630|DEVICE|Isolex 300i|
223384852|NCT02890355|DRUG|Fluorouracil|Given IV
223384853|NCT02890355|DRUG|Fluorouracil|Given IV bolus
223384854|NCT02890355|DRUG|Irinotecan Hydrochloride|Given IV
223384855|NCT02890355|OTHER|Laboratory Biomarker Analysis|Correlative studies
223384856|NCT02890355|DRUG|Leucovorin Calcium|Given IV
223384857|NCT02890355|DRUG|Veliparib|Given PO
223384858|NCT06138873|PROCEDURE|Ablation-index guided ventricular tachycardia ablation|As described in arms descriptions
224002241|NCT07103512|OTHER|Conventional Physical Therapy|"Diaphragmatic Breathing Exercise Inhale through nose about 4 Seconds, hold Breath for 2 Seconds, repeat 5 times, exercise repeated for 2-3 days per week followed up to 4 weeks.~\+ Buteyko Breathing Exercise Exhale slowly and then hold that breath. Use index figure and thumb to plug nose hold that breath until there is an urge to breathe and then inhale Breathe normally at least 10 second repeat several. Frequency 2-3 days per week with Moderate Intensity follow-up to 4weeks"
224002242|NCT07126327|DEVICE|Peristeen Light - trans anal irrigation system|Subjects naive to TAI will use Peristeen Light trans anal irrigation
223384859|NCT06138873|PROCEDURE|Ventricular tachycardia ablation with no AI-guidance|As described in arms descriptions
223384860|NCT05707377|DRUG|Zanubrutinib|Zanubrutinib capsules administered orally.
223384861|NCT05707377|DRUG|Tacrolimus|Tacrolimus capsules administered orally.
223384862|NCT06575673|BEHAVIORAL|Internet-based dialectical behaviour therapy-informed skills training|Adaptive applications of DBT-ST for smokers with psychological distress
224002243|NCT07135440|DEVICE|OCT angiography RTVue XR Avanti; Optovue, Inc, Fremont, California, USA|OCTA is a fast, non-invasive, and contactless imaging technique that enables detailed visualization of the retinal microvasculature by tracking erythrocyte movement within blood vessels in real time. It provides layer-by-layer analysis of the retina and choroid without the need for intravenous contrast, significantly reducing patient risk and improving accessibility. Increasing evidence suggests that neurodegenerative and vascular changes precede clinically visible signs of disease, making OCTA a valuable diagnostic tool for early detection of diabetic retinopathy before it can be confirmed through standard fundus examination. The MoCA test includes assessments of executive functions, high-level language abilities, and complex visuospatial tasks, making it suitable for detecting even mild cognitive dysfunction.
224002244|NCT05951985|BEHAVIORAL|HIFT|Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity. Exercises will be tailored/modified to meet the needs of each participant.
224002245|NCT06935084|OTHER|ASTHMAXcel Voice platform|ASTHMAXcel Voice is a mobile health application with a multi-level approach to address barriers with intervention components and facilitate health behavior change through the use of push notifications and interactive educational content.
224002246|NCT07135258|DRUG|Ivabradine + Usual Care|For patients in the ivabradine arm targeting for strict rate control, ivabradine is started at 5mg BID, and titrated at follow-up visits if needed, up to 7.5mg BID to aim at the target heart rate \<80bpm. Uptitration of other existing or additional conventional rate control agents will considered after maximally tolerated dose of ivabradine. Conversely, if not tolerated, or if resting heart rate is persistently \<50bpm, ivabradine will be reduced to 2.5mg BID, followed by reassessment.
224002247|NCT07135258|DRUG|Placebo + usual care|For patients in the lenient rate control arm, medications will be adjusted, bidirectionally as appropriate, with a maximum heart rate that is tolerable by patient which is at \<110bpm. Routine heart rate control agents included betablockers, nondihydropyridine calcium channel blockers, or digoxin. All patients will be prescribed a matching placebo (morphologically identical to the comparison arm: ivabradine) that contains pharmacologically inactive cellulose.
224124259|NCT02664636|PROCEDURE|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
224124260|NCT01531491|PROCEDURE|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
224124261|NCT01531491|PROCEDURE|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
224124262|NCT01171547|DRUG|Daptomycin|once daily over 5 days
223384863|NCT06575673|BEHAVIORAL|Monthly health education|General health information and sharing sessions
223384864|NCT06560359|DIETARY_SUPPLEMENT|F&V|The intervention includes the healthy breakfast plan (daily delivery of balanced breakfast containing at least one piece of fruits, vegetables and other regular diet). Meals were centrally prepared by a professional catering service and delivered every morning, seven days a week, to participants' homes, ensuring consistency in portion size and quality. The selection of fruits and vegetables will consider seasonal availability to ensure freshness and variety. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
223384865|NCT06560359|DIETARY_SUPPLEMENT|No F&V|The intervention only includes breakfast plan (daily delivery of balanced breakfast containing regular diet without fruits and vegetables) for 12 weeks. Meals were centrally prepared by a professional catering service and delivered every morning, seven days a week, to participants' homes, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
223384866|NCT04886661|OTHER|CHRONIC NECK PAIN|Demographic information will be collected. Neck Disability Index will be filled. Physical examination will be performed.
223384867|NCT06551883|PROCEDURE|different bowel preparation regime|Patients in Group B receive the 3L of PEG in a single dose
223384868|NCT06551883|PROCEDURE|traditional bowel preparation regime|Patients in Group A receive the 3L of PEG in a split dose
223384869|NCT02694328|DRUG|ALKS 3831|Daily dosing
223384870|NCT02694328|DRUG|Olanzapine|Daily dosing
223384871|NCT03357744|OTHER|distress barometer|not applicable, observational study
224124263|NCT03311607|DRUG|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
224124264|NCT03653611|OTHER|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
223384872|NCT00413881|PROCEDURE|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
224002248|NCT07136740|DEVICE|Cerebri-TTH biofeedback|Cerebri-TTH biofeedback device is a therapist-independent home-based smartphone treatment application (app). Cerebri-TTH is a medical device in risk class IIa, according to MDR, and includes two non-invasive wireless sensors and a smartphone application. Both sensors shall be in contact with the skin: one sensor is applied on the index finger and measures heart rate (HR), heart rate variability (HRV) and peripheral skin temperature. The second sensor is applied on the trapezius muscle using adhesive electrodes and measures muscle tension. The sensors transmit the measurements to the user's smartphone where the user is instructed to perform a biofeedback session. The sensors are to be used for 10 minutes per session per day. The user can choose to use the device more frequently if desired - up to 6 sessions per day.
224002249|NCT07136740|OTHER|headache diary|"Participants randomized to the wait-list arm, are instructed to keep daily eDairy entries for 12 weeks.~The wait list control group will be offered active treatment for 12 weeks after the initial 12-week wait-list period is completed in an extension phase."
224002250|NCT07136155|PROCEDURE|Hall Technique|preformed metal crowns (PMCs) cemented with no local anesthesia, caries removal or tooth preparation in one side.
224002251|NCT07136155|PROCEDURE|Indirect pulp capping|Selective caries removal to hard dentin followed with G.I base material and subsequent preformed metal crown (PMC).
224002252|NCT06942819|DEVICE|VersaWrap Nerve Protector|VersaWrap Nerve Protector is applied to the nerve root to protect the surrounding tissues
224002253|NCT05323123|DRUG|Pre-Exposure Prophylaxis (PrEP)|FDA-approved oral medication to reduce the risk of HIV infection
224002254|NCT05323123|BEHAVIORAL|SPARK|SPARK is delivered in a clinic setting by a counselor using motivational interviewing techniques (e.g., open-ended questions, affirmations).
224124265|NCT03653611|OTHER|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
223384873|NCT00413881|PROCEDURE|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
223384874|NCT01845480|BEHAVIORAL|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
224002255|NCT05323123|BEHAVIORAL|HealthMpowerment|PrEP adherence support app that utilizes engaging social networking and game-based elements, with an in-app portal for individualized live adherence counseling.
224002256|NCT07143474|DRUG|RhizomK|RhizomK 50 mg once daily
224002257|NCT07143474|OTHER|Plcebo|Placebo matching to RhizomK
224002258|NCT00466154|DRUG|Aspirin|
224002259|NCT07141459|DEVICE|810 nm diode laser disinfection|810 nm diode laser (Elexxion clarosdental laser, Singen Deutschland, Germany) in a continuous wave mode with a power of 1.5 Watts in 4 cycles of 5 seconds with 20 seconds intervals in between each. A 200 μm fiber optic tip (Lite medics, Italy) will be inserted 1 mm from the working length, activated and moved in slow helical motion from the apex to the cervical third with alternating between clockwise and counterclockwise direction at speed of about 2 mm/s
224002260|NCT07141459|DRUG|Calcium Hydroxide Intracanal medication|Calcium hydroxide paste (MetaBiomed, Chungcheongbuk-do, Korea) will be placed inside the root canal and left for 1 week.
224124266|NCT03653611|OTHER|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
224124267|NCT03653611|OTHER|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
223384875|NCT00890604|OTHER|Stepwise normothermia protocol|Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
223384876|NCT00890604|DRUG|Ibuprofen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
223384877|NCT00890604|DRUG|Acetominophen|It is not the intent of the study to evaluate this drug but may be provided in conjunction with the Stepwise normothermia protocol.
223384878|NCT01260701|DRUG|Akt Inhibitor MK2206|Given PO
223384879|NCT03558438|OTHER|No interventions|No interventions
223384880|NCT00855907|OTHER|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
223384881|NCT05755347|OTHER|General health survey questionnaires|Patient-reported outcome survey will be offered at baseline.
223384882|NCT05755347|OTHER|PROMIS Cancer Function Brief 3D profile questionnaires|Patient-reported outcome survey will be offered at baseline.
223384883|NCT05755347|OTHER|FACT-G questionnaires|Patient-reported outcome survey will be offered at baseline.
223384884|NCT05755347|OTHER|Godin Leisure-Time Exercise Questionnaire|Patient-reported outcome survey will be offered at baseline.
223384885|NCT05755347|OTHER|REAP-S questionnaires|Patient-reported outcome survey will be offered at baseline.
223384886|NCT05411146|DRUG|[14C]-etrumadenant|Administered as specified in the treatment arm.
224002261|NCT07143643|OTHER|Excape room game|"Application of Research:The escape room game scenario prepared by the researchers was designed according to the steps of the Nursing Process. The game consists of five stages, each conducted at different stations, and each stage includes various clues and activities. The stages were organized to cover the steps of the Nursing Process: Assessment, Nursing Diagnosis, Planning, Implementation, and Evaluation. Before starting the game, the students who will participate will be informed about the expected objectives, the game rules, and the duration. In addition, it will be stated that each group must select a group leader. The students will be given a total of 60 minutes to answer the questions in each stage, assemble puzzle pieces, unlock locked boxes, follow the clues, and find the exit key in order to leave the room. The students will be expected to complete the tasks at the stations prepared in accordance with the Nursing Process stages and to exit the room within the allotted time."
224002262|NCT07147192|DEVICE|AAL-FAIOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject. Laser energy to specified locations can be used to allow a change in power for far distances.
224002263|NCT07147192|DEVICE|BAL-FAIOL|Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.
224002264|NCT07147192|PROCEDURE|Phacoemulsification|Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.
224002265|NCT07155694|DRUG|Finerenone 10 MG|Take Finerenone 10 mg orally daily
224002266|NCT07155694|DRUG|Empagliflozin 10 MG|Take Empagliflozin 10 mg orally daily for 4 months
224002267|NCT07155850|DEVICE|Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas|YntraDose™ is a locoregional therapy device used for percutaneous radio-ablation of solid tumours
224002268|NCT07155902|OTHER|The community-to-facility integrated strategy|The community-to-facility integrated strategy will focus on a joined-up T2D care delivery across the primary, secondary, and healthcare facilities, and urban communities.
224002269|NCT07154212|DIAGNOSTIC_TEST|Hepatitis B virus infection|anti-hepatitis B virus core antigen positive serologic status
223384887|NCT00134004|DRUG|cyclophosphamide|
223384888|NCT00134004|DRUG|fludarabine phosphate|
223384889|NCT00134004|DRUG|mycophenolate mofetil|
223384890|NCT00134004|DRUG|tacrolimus|
223384891|NCT00134004|PROCEDURE|allogeneic bone marrow transplantation|
223384892|NCT00134004|RADIATION|radiation therapy|
223384893|NCT06138691|COMBINATION_PRODUCT|Ketamine Infusion plus RO DBT|The participant will receive 4 weeks of 0.5mg/kg intravenous ketamine given over 40 minutes, as is routinely done in ketamine treatment and four months of RO DBT treatment.
223384894|NCT00720382|DRUG|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
223384895|NCT00720382|DRUG|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
223384896|NCT05440201|OTHER|Amount of anticoagulant Clexane|Change (increase/decrease) the amount of Clexane administered at the dialysis start.
223384897|NCT01443897|DIETARY_SUPPLEMENT|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
224002270|NCT07155603|BEHAVIORAL|Animated Video Group 1|The animated video intervention provides a clear and engaging multimedia explanation of the colonoscopy procedure in multiple languages. It includes visual aids to help explain the process, preparation instructions, risks, and expected outcomes, aiming to improve patient comprehension and adherence.
224002271|NCT07155837|DEVICE|TENS group|The intervention group received TENS twice a day.
224002272|NCT07153757|DRUG|Endocrine Therapy of Physician's Choice|This study employs a 2-3 year de-escalated endocrine therapy regimen in the experimental group, which distinguishes it from other escalation therapy studies.
224124268|NCT03653611|OTHER|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
223384898|NCT01443897|DIETARY_SUPPLEMENT|placebo capsule|0 IU vitamin D2
223384899|NCT01443897|OTHER|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
223384900|NCT01443897|OTHER|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
223384901|NCT01443897|OTHER|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
223384902|NCT03493256|OTHER|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
223425556|NCT03946683|RADIATION|Cyberknife for Early Stage Breast Cancer|Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
223730018|NCT07133074|OTHER|EMR Review|Electronic medical record review for comparative analysis
224002273|NCT07153523|OTHER|High intensity interval training|High intensity interval training provides time efficient benefits for strength and endurance training. It comprises of high burst training with rest periods. For experimental group HIIT training will be applied comprising of burpees, squats, arm walking and lunges. For experimental group HIIT training will be applied comprising of burpees, squats, arm walking and lunges. The exercise will be given 3 times/ week 4 weeks and total number of sessions will be 12
224002274|NCT07153523|OTHER|Routine physical therapy|For control group routine physical therapy will be applied for strength training using weights and running drills for endurance training. The exercise will be given 3 times/ week 4 weeks and total number of sessions will be 12
224124269|NCT03411746|OTHER|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
223384903|NCT07164612|OTHER|Occupation-Based Bilateral Upper Limb Training (OBBT)|Intervention sessions for experimental group will be conducted 5 times per week over 6 weeks. OBBT will be used to engage both upper limbs simultaneously in simulate real-life functional tasks which tailored to individual needs, focusing on improving the patient's ability to perform daily activities such as dressing, washing, and cooking. The training will emphasize occupation-specific repetitive practice for at least two selected occupations and encouraged active participation of both hands during functional tasks to improve use of both upper limb motor functions and activity participation. Additionally, it will seek to support stroke survivors in their pursuit of an independent, productive, and functional recover.
224002275|NCT07155941|BEHAVIORAL|Training of reward processing/sensitivity|"Participants in the experimental group complete a two-week ecological momentary intervention (EMI) consisting of three brief training units per day, each delivered via a smartphone. The exercises target different aspects of reward processing and are scheduled at specific times throughout the day.~The morning unit (to be completed between 10:00 and 12:00 a.m.) involves a positive mental imagery task guided by audio recording. Participants are guided to vividly imagine a future situation with the most pleasurable and meaningful outcome possible. They are encouraged to mentally activate all senses, thoughts, and emotions associated with this scenario.~The afternoon unit (to be completed between 3:00 and 5:00 p.m.) consists of a savoring exercise guided by audio recording. Participants recall a positive experience from the past and are instructed to re-experience and savor it mentally by focusing on its sensory details, emotional quality, and personal significance.~The evening unit (to be"
223384904|NCT07164612|OTHER|Conventional therapy group|Conventional therapy includes passive and active range of motion exercises, strengthening exercises, basic functional activities and mobility training, and activities designed to improve muscle tone and mobility in the affected upper limb among stroke survivors. The conventional therapy sessions will be delivered 5 times per week for 90 minutes over 6 weeks. Therapy sessions will be individualized to the participant's needs and will be provided by senior occupational therapists.
223384905|NCT07186075|BEHAVIORAL|Phubbing and Mental Health Literacy Education for Adolescents|Phubbing and Mental Health Literacy Education for Adolescents
223384906|NCT07186075|BEHAVIORAL|no training was provided|no training was provided
223384907|NCT07184905|BIOLOGICAL|Oral administration of inactive Bifidobacterium longum group|1×10\^11 CFU of inactive Bifidobacterium longum was given orally once daily for one month
223384908|NCT07184905|BIOLOGICAL|Oral Bifidobacterium longum group|1×10\^11 CFU of Bifidobacterium longum was given orally once daily for one month
223384909|NCT07184502|DRUG|ZT003|ZT003 is administered as a single subcutaneous injection at different dose levels.
223384910|NCT07184502|DRUG|ZT003|ZT003 administered as multiple subcutaneous injections at different dose levels.
223384911|NCT07184502|DRUG|Placebo|Matching placebo administered subcutaneously.
223384912|NCT05296174|OTHER|cognitive-oriented intervention program|The experimental group was offered six 40-minute courses once a week.
224002276|NCT07155941|BEHAVIORAL|Relaxation Training (PMR)|"Participants in the control group complete a two-week progressive muscle relaxation (PMR) program designed to match the reward training in both frequency and duration. The intervention consists of three daily units, each delivered via a smartphone app and guided by audio recordings.~The first and second units of each day consist of short audio-guided PMR sessions (approximately 5 minutes each). These exercises systematically guide participants through alternating tension and relaxation of different muscle groups to promote physical and mental relaxation.~The third unit of the day focuses on reflection. Participants are asked to evaluate their experiences with the relaxation exercises over the course of the day. They reflect on their ability to engage with the exercises, the perceived effects (e.g., feelings of relaxation), any difficulties they encountered, and strategies to enhance the effectiveness of relaxation in their daily life beyond the intervention."
224124270|NCT00035425|DRUG|linezolid|600mg every 12 hours
223384913|NCT05296174|OTHER|health education activities program|The control group was offered health education activities once a week.
223384914|NCT04536376|BEHAVIORAL|Resilience Program|Subjects receive program devices, and will be asked to wear during rest and sleep on a nightly basis along with active use during daytime. Notifications are sent daily, individualized approach developed and sent to participants to participate on.
223384915|NCT07185750|OTHER|Questionnaire application for JIA cases and their parents|Scales will be applied to cases diagnosed with JIA and their parents
223384916|NCT07185113|DRUG|GEn-1124|GEn-1124 will be administered to one single dose group of subjects dosed under fed (standardized meal) conditions. GEn-1124 will be administered as an oral capsule formulation containing GEn-1124.
223384917|NCT07185503|DRUG|liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole|The intervention in this study is a tailored antifungal regimen combining liposomal amphotericin B (L-AmB) (3-5 mg/kg/day IV) with posaconazole or isavuconazole (300 mg/200 mg daily, oral or IV), designed to optimize efficacy and safety in immunocompromised adults with blood cancers and mucormycosis. Dosing and duration are personalized based on clinical response, immune recovery, and organ function, with a focus on transitioning to oral therapy to reduce hospitalization. The study emphasizes rigorous safety monitoring, prohibited unauthorized antifungal co-medications, and explores prognostic factors to advance treatment strategies for this high-risk population.
223384918|NCT07187219|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - active|rTMS session active on the primary motor cortex
223384919|NCT07187219|DEVICE|Repetitive transcranial magnetic stimulation (rTMS) - inactive|rTMS session inactive on the primary motor cortex
223384920|NCT07184645|DRUG|OPA-15406|0.3% foam or 1% foam, topical, twice daily, for 8 weeks
223384921|NCT07184645|DRUG|Vehicle|vehicle, topical, twice daily, for 8 weeks
223384922|NCT06525207|DEVICE|Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography|Global morpho-functional assessment of the anal sphincter complex using Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
223730019|NCT04777994|DRUG|ABBV-CLS-484|Oral Capsule
223730020|NCT04777994|DRUG|Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)|Oral Tablet
223730021|NCT04777994|DRUG|Programmed Cell Death-1 (PD-1) Inhibitor|Intravenous (IV) infusion
223730022|NCT06504901|DRUG|Tislelizumab|Tislelizumab 200mg ivd D1
223730023|NCT06504901|DRUG|Interleukin-2|Interleukin 2 100IU HD,QOD d1-d14
224002277|NCT07155941|OTHER|Psychoeducation|All participants receive a psychoeducation session on the day before the respective intervention starts. In this session, a graduate-level study team member introduces the rationale behind the training (PMR or reward-training), and demonstrates each exercise. Participants also practice each task.
223384923|NCT05496491|RADIATION|Neoadjuvant Chemoradiotherapy|5-week neoadjuvant radiotherapy regimen (28 x 1.8 Gy) combined with Capecitabine (bid 800 mg/m2, twice daily, on days 1-33-38)
223384924|NCT05496491|DRUG|Adjuvant Chemotherapy|8 cycles of CAPOX (Capecitabine bid 1000 mg/m2, twice daily, day 1-14, every 3 weeks and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively, 12 cycles of folinate, fluorouracil and oxaliplatin (FOLFOX)
223384925|NCT05496491|DRUG|Consolidation Chemotherapy|CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
223384926|NCT06629038|BEHAVIORAL|observation alone|observation of maximal mouth opening, lateral excursion, and range of motion of shoulder abduction, neck joint
223384927|NCT06362265|DRUG|LY3209590|Administered SC.
223384928|NCT05291091|DRUG|Sevasemten 10 mg|Sevasemten is administered orally once per day
223384929|NCT05291091|DRUG|Sevasemten 5 mg|Sevasemten is administered orally once per day
223384930|NCT05291091|DRUG|Sevasemten 12.5 mg|Sevasemten is administered orally once per day
223384931|NCT05291091|DRUG|Placebo|Placebo is administered orally once per day
224002278|NCT07154563|DIAGNOSTIC_TEST|NIR-II probe (i.e ICG-CK) incubation solution|After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.
224002279|NCT07153809|PROCEDURE|FMT|FMT bacterial solution will be injected through a nasojejunal nutrition tube once a day for five days.
224002280|NCT07153809|PROCEDURE|Placebo|Physiological saline placebo will be injected through a nasojejunal nutrition tube once a day for five days.
224002281|NCT07154043|PROCEDURE|Complete Decongestive Therapy (CDT)|Manual lymph drainage, multilayer bandaging, skin care, and exercise. 75 minutes per session, 5 sessions per week, for 3 weeks.
224124271|NCT00035425|DRUG|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
223384932|NCT05861999|DRUG|Risdiplam|Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
223384933|NCT05292664|DRUG|Venetoclax|Tablet taken orally
223384934|NCT05292664|DRUG|Azacitidine|Taken intravenously
223384935|NCT05292664|DRUG|Cytarabine|Lumbar Puncture
223384936|NCT05292664|DRUG|Methotrexate|Lumbar Puncture
223384937|NCT05292664|DRUG|Hydrocortisone|Lumbar Puncture
223384938|NCT05292664|DRUG|Leucovorin|Taken Orally or intravenously
223384939|NCT05292664|DRUG|Dexamethasone|Taken Orally or intravenously
223384940|NCT05292664|DRUG|Vincristine|Taken intravenously
223730024|NCT06504901|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-d14
223730025|NCT06504901|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 ivd, d1
223730026|NCT06504901|DRUG|Neupogen|rhG-CSF 5mcg/kg HD, QD d1-d14
224002282|NCT07154043|PROCEDURE|CDT + Intermittent Pneumatic Compression (IPC)|Complete decongestive therapy program including manual lymph drainage, multilayer bandaging, skin care, and exercise, plus intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 115 minutes per session, 5 sessions per week, for 3 weeks.
224002283|NCT07154043|PROCEDURE|CDT without Manual Lymph Drainage plus Intermittent Pneumatic Compression|Complete decongestive therapy consisting of multilayer bandaging, skin care, and exercise, with manual lymph drainage replaced by intermittent pneumatic compression at 20-50 mmHg for 40 minutes per session. Total duration: 75 minutes per session, 5 sessions per week, for 3 weeks.
224002284|NCT07154095|DRUG|Sustained-Release Tablets|A single-center, randomized, open-label, two-sequence, two-period, crossover design was employed. Forty healthy participants were enrolled and randomized (1:1) into two sequences (AB and BA) to receive both the test and reference formulations across two periods, separated by a washout interval of at least 5 days.
224124272|NCT00587821|OTHER|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
224124273|NCT03514303|DIAGNOSTIC_TEST|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
223384941|NCT05292664|DRUG|Doxorubicin|Taken intravenously
223384942|NCT05292664|DRUG|Dexrazoxane|Taken intravenously
223384943|NCT05292664|DRUG|Calaspargase Pegol|Taken intravenously
223384944|NCT05292664|DRUG|Erwinia asparaginase|Given as intramuscular injection
223384945|NCT06524401|DEVICE|Limpet|Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.
223384946|NCT06524401|DEVICE|Control|Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.
223384947|NCT05740059|OTHER|Adjusted Transfusion|Patients assigned to the SvO2 group will be transfused if Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65%. Transfusion will be repeated whenever Hb concentration is lower than 9 g/dL and central SvO2 ≤ 65% during surgery and in the ICU (until day 5). Central SvO2 will be measured on a blood sample obtained from the distal lumen of the central venous catheter. Oximetry will be used for measurement with a point-of-care of gas analysis.
223425557|NCT05528198|DRUG|Montelukast sodium oral thin films without water (A)|Single-dose montelukast sodium oral thin film 5mg under fasted condition without water
223384948|NCT06191965|DRUG|MitoQ|"MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality\_safety/quality\_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ."
224002285|NCT07154095|DRUG|Immediate-Release Tablets|A single-center, randomized, open-label, two-sequence, two-period, crossover design was employed. Forty healthy participants were enrolled and randomized (1:1) into two sequences (AB and BA) to receive both the test and reference formulations across two periods, separated by a washout interval of at least 5 days.
223384949|NCT06191965|DRUG|Placebo|Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
223384950|NCT06029244|DEVICE|EyeControl-Pro|Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
223384951|NCT06029244|OTHER|Control|No intervention
224002286|NCT07156110|PROCEDURE|Traditional prosthetic procedure|Three months later, after an impression, haling abutment will be removed and a screw-retained restoration will be seated using a Ti-Base abutment.
223545476|NCT03128489|BIOLOGICAL|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
223545477|NCT02924259|DEVICE|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
223545478|NCT04149496|COMBINATION_PRODUCT|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
223545479|NCT05313763|OTHER|conventional physical therapy|A hotpack will be applied to the neck area for 15 minutes in the prone position of the patients. Conventional type Tens with a frequency of 50 Hz and a pulse duration of \<150 microseconds will be applied for 20 minutes, taking the painful area to the center. Ultrasound will be applied to the patients for 5 minutes with a dosage of 1-1.5 watts/cm2. Cervical joint range of motion exercises, stretching exercises for trapezius, scalenia, rhomboid, levator scapulae, pectoral and suboccipital muscles will be applied, then cervical isometric strengthening exercises and stabilization exercises will be carried out in a controlled manner. Conventional physical therapy will be applied by the same physiotherapist 5 days a week for 3 weeks.
224002287|NCT07156110|PROCEDURE|one abutment-one time|Three months later, after an impression, a screw-retained restoration will be seated directly on the connect healing
224002288|NCT07153549|DIETARY_SUPPLEMENT|Biolizin|Oral zinc-containing syrup taken per age-based dosing specified in the protocol, once or twice daily for 42 consecutive days. Product is dispensed at baseline (with refill if needed); batch and expiry are recorded. Caregivers receive instructions for use and complete dosing diaries; adherence is checked by diary review and returned bottle counts. Concomitant zinc products or pharmacologic appetite stimulants are not allowed. Safety is monitored through adverse event review and routine laboratory tests at baseline and Day 42.
223545480|NCT05313763|OTHER|Active Kinesiotaping|For kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, and the application will be started from the midline of the upper thoracic vertebrae. Initially, 4-5 cm stretching will be applied, and the arms of the Y strip will be adhered to the cervical paravertebral muscles without stretching. I strip will be applied to the painful area with the area correction technique, with maximum stretching in the middle and without stretching the ends. The applications will be made by the same physiatrist with 7 years of clinical experience.
224002289|NCT07153549|BEHAVIORAL|Standardized caregiver counseling on responsive feeding|Structured counseling delivered to caregivers at each clinic visit (Day 0, Day 7, Day 21, Day 42). Content includes mealtime routines, recognizing hunger/satiety cues, age-appropriate portions and textures, repeated exposure to diverse foods, and strategies to manage refusal or prolonged meals. A brief checklist guides delivery to ensure consistency across visits. No dietary supplement is provided in this intervention.
224002290|NCT07154277|PROCEDURE|Small bite closure|Small bite suturing is small tissue bite of 0.5cm depth x 0.5cm travel x 0.5cm apart, on the aponeurosis away from midline using Prolene 2/0
224002291|NCT07154277|PROCEDURE|Large bite closure|Large bite closure is defined as tissue bite of 1cm depth x 1 cm travel x 1cm apart, on the aponeurosis away from midline using Prolene 0
224002292|NCT07155772|PROCEDURE|Extracorporeal CardioPulmonary Resuscitation (eCPR)|The intervention of this study consists of moving the current eCPR program out of the hospital to reduce the time from collapse to ECMO flow (low-flow time).
224002293|NCT07156045|BIOLOGICAL|anti-PSMA CAR-NK|Targeting PSMA CAR-NK cells
224002294|NCT07154342|BIOLOGICAL|GR1802 injection|Recombinant fully human anti-IL4Rα monoclonal antibody drug.
224002295|NCT07154342|BIOLOGICAL|Placebo|Placebo
224124274|NCT03899129|PROCEDURE|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
223384952|NCT03516279|DRUG|Dasatinib|Given PO
223384953|NCT03516279|DRUG|Imatinib Mesylate|Given PO
224002296|NCT07155447|DIETARY_SUPPLEMENT|CEAA supplementation|(including calcium beta-hydroxy-beta- methylbutyrate monohydrate, L-Arginine, L-Glutamine and Ciltruline) Supplementation will be started within 72 hours of presentation and continued for a period of 28 days.
224002297|NCT07155447|OTHER|Placebo|a neutral powder containing the non- essential amino acid Alanine which will be indistinguishable from the CEAA supplement powder in in regards to packaging and supplement appearance.
224002298|NCT07153926|DIAGNOSTIC_TEST|Serum ferritin|Serum ferritin is a protein that stores iron, and high serum ferritin levels can suggest iron overload, but are also a common indicator of other conditions like inflammation, liver disease, or metabolic syndrome.
224002299|NCT07153926|DIAGNOSTIC_TEST|Serum hepcidin|"Hepcidin hormone has been found to be a key regulator of iron homeostasis. It controls plasma iron levels by regulating two key steps in iron metabolism, namely digestive iron absorption in enterocytes and iron recycling in macrophages.~Hepcidin is synthesized predominantly in the hepatocytes, which is physiologically increased by elevated serum iron level and decreased by erythropoietic activity. Recently, hepcidin has been used as a new marker for evaluation of liver fibrosis in patients with thalassemia major."
224002300|NCT07154667|PROCEDURE|Use of AuryzoN™ EAR 2.0 device|AuryzoN™ EAR 2.0 is an investigational non-significant risk device developed to improve cartilage construct shape and stability prior to use in ear reconstructive surgery.
224002301|NCT07154667|PROCEDURE|Hand carving|Standard hand carving using standard surgical blades will be performed in this intervention arm of the study.
223384954|NCT03516279|OTHER|Laboratory Biomarker Analysis|Correlative studies
223384955|NCT03516279|DRUG|Nilotinib|Given PO
224002302|NCT07155200|DRUG|Cirtuvivint|Cirtuvivint will be supplied by Biosplice.
224002303|NCT07155200|DRUG|Irinotecan|Irinotecan is commercially available.
224002304|NCT07155811|DIAGNOSTIC_TEST|test immunitaire fonctionnel automatisé VIDAS® STIMM™ T RUO|"The functional assessment of T lymphocytes is based on the use of the VIDAS® STIMM™ T RUO test, which will be performed on freshly collected whole blood in lithium heparin tubes without gel separators. Blood samples will be sent to the Immunology Laboratory at E. Herriot Hospital (Prof. Guillaume Monneret). T lymphocytes will be stimulated ex vivo for 3.5 hours (non-antigen-dependent stimulation by PHA) on the VIDAS®3 automated system (bioMérieux).~The automated system then performs a assay (immunofluorescence technique) to quantify the concentrations of IFN-γ in the supernatant of each sample. The entire process is automated, and results are obtained within 4 hours."
224002305|NCT00523861|DIETARY_SUPPLEMENT|Moderate alcohol consumption|
224124275|NCT03899129|PROCEDURE|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
224124276|NCT01649739|DRUG|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
223384956|NCT03516279|BIOLOGICAL|Pembrolizumab|Given IV
223384957|NCT03750708|DEVICE|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
223384958|NCT06138587|BIOLOGICAL|Cytokine Induced Memory-like Natural Killer Cells|Allogeneic, cytokine induced memory-like natural killer cells, via intravenous infusion per protocol.
224002306|NCT04164121|DRUG|Phenlarmide Tablets|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
224002307|NCT04164121|DRUG|Placebos|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
224002308|NCT00075842|DIETARY_SUPPLEMENT|Valeriana officinalis extract|Given orally
224002309|NCT00075842|OTHER|placebo|Given orally
224002310|NCT05400577|DRUG|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)|Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
224002311|NCT03915847|PROCEDURE|Single layer closure|Uterine incision will be approximated with continuous unlocked suture, including a narrow band of the endometrial layer, without trimming incision edges.
224124277|NCT02231658|DRUG|Liraglutide|
224124278|NCT02231658|DRUG|Lixisenatide|
224124279|NCT01057199|GENETIC|RNA analysis|
224124280|NCT01057199|GENETIC|gene expression analysis|
224124281|NCT01057199|GENETIC|mutation analysis|
224124282|NCT01057199|GENETIC|protein expression analysis|
223384959|NCT06138587|BIOLOGICAL|Interleukin-2|Recombinant, human glycoprotein, single-use 22 MIU vials, via subcutaneous injection per protocol.
223384960|NCT04190706|OTHER|bioactive components fortified food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
223384961|NCT04190706|OTHER|control food products intake (biscuits and cookies)|Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
223384962|NCT05453942|DRUG|SAR441566|Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
223384963|NCT05453942|DRUG|Placebo|Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
223425558|NCT05528198|DRUG|Montelukast sodium oral thin films with water (B)|Single-dose montelukast sodium oral thin film 5mg under fasted condition with water 240 mL
223425559|NCT05528198|DRUG|Montelukast sodium chewable tablets with water (C)|Single-dose montelukast sodium chewable tablet 5mg under fasted condition with water 240 mL
223425560|NCT00369070|BIOLOGICAL|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
223425561|NCT00369070|DRUG|AMG 706|subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
223425562|NCT00369070|DRUG|Paclitaxel|All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
223384964|NCT06894849|BEHAVIORAL|Text-based depression screening|Starting 1 week prior to the scheduled clinic appointment, patients will receive a text message invitation from HCC to complete depression screening. Participants will be asked to click to continue to the screening PHQ-2. For text message screening cadence, reminder texts will be sent daily for 3 days. Those who screen positive (PHQ-2 \>/= 3) will complete the remainder of the items (i.e., PHQ-9).
223384965|NCT06894849|BEHAVIORAL|Usual care (UC)|Usual care (UC) will consist of in-person assessment of depression using a validated brief screening tool (e.g., PHQ-2) synchronous with a clinical encounter with the outpatient oncology team. Although the person completing the screening (e.g., nurse, medical assistant) and other workflow may vary slightly across settings, the 2-items are generally presented orally to the patient during routine intake for a clinical encounter and entered into the EHR. Patients who screen positive will be asked to complete the full PHQ-9.
223384966|NCT06964009|DRUG|DT2216|A proteolysis-targeting chimera (PROTAC) degrader, single-use vial, via intravenous (into the vein) infusion.
223384967|NCT06964009|DRUG|Paclitaxel|An antimicrotubule agent, multi-dose vial, via intravenous (into the vein) infusion per institutional standard.
223384968|NCT05645861|PROCEDURE|Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg|Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
224002312|NCT03915847|PROCEDURE|Double layer closure|The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
224002313|NCT03915847|PROCEDURE|Doble layer closure with trimming|Uterine incision will be trimmed and old scar tissue will be removed. The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
224002314|NCT03311477|DRUG|ABBV-399|Intravenous infusion
224002315|NCT01886859|DRUG|Ibrutinib|Given PO
224002316|NCT01886859|DRUG|Lenalidomide|Given PO
224002317|NCT03663543|DRUG|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
224002318|NCT03663543|DRUG|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
224002319|NCT01901432|DRUG|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
224002320|NCT05859516|DIAGNOSTIC_TEST|Ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and blood flow of peripheral arteries by ultrasound，compared with EtCO2.
224002321|NCT00379288|DRUG|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
223384969|NCT04204915|PROCEDURE|Aortic valve replacement|Participants will be assessed by a member of the surgical team performing aortic valve replacement (AVR), and by any other relevant medical professionals identified by the doctors overseeing their care in hospital. When deemed ready for AVR, a member of the surgical team will ask for consent to proceed with the AVR. They will discuss the surgical procedure, covering information on the basic technical procedure, risks and expected recovery time.
223384970|NCT05355532|GENETIC|different variants of SNPs that may be associated with the coronary microvascular obstruction development|Some variants of SNPs determine endothelial function, microcirculation, hemostasis, and inflammation in MI patients. They may be associated with the development of coronary microvascular obstruction during emergency PCI. A link between the different SNPs and the CMVO development will be established. SNP will be determined by real-time polymerase chain reaction with high-resolution melting curve analysis using TaqMan fluorescent probes.
223384971|NCT06311721|DRUG|ABP 234|Intravenous administration
223384972|NCT06311721|DRUG|Pembrolizumab (US)|Intravenous administration
223384973|NCT06311721|DRUG|Pembrolizumab (EU)|Intravenous administration
223384974|NCT06443567|DEVICE|impedance threshold device|impedance threshold device (ResQPOD, Zoll) applied to airway
224002322|NCT00379288|DRUG|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
224002323|NCT00379288|DRUG|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
224002324|NCT00379288|DRUG|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
224002325|NCT03898232|RADIATION|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
224002326|NCT05457075|DIAGNOSTIC_TEST|Immune checkpoint measure|The measurement of soluble immune checkpoints of stage II-III rectal cancer before neoadjuvant treatment
224002327|NCT04318106|DEVICE|Precision tinted spectacle lenses|Precision tinted spectacles lenses (Cerium Technologies TM)
224002328|NCT06429098|DRUG|Venetoclax|Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.
224002329|NCT06429098|DRUG|azacitidine|Given SC
224002330|NCT06429098|DRUG|decitabine|Given IV
224002331|NCT06429098|DRUG|Cytarabine|Given IV
224002332|NCT03304197|DIETARY_SUPPLEMENT|Hypotonic|N/A: see arm description
224002333|NCT03304197|DIETARY_SUPPLEMENT|Isotonic|N/A: see arm description
223384975|NCT03244072|DRUG|Moxifloxacin|Intracameral injection
223384976|NCT03244072|DRUG|Placebo|intracameral injection
223384977|NCT05808634|DRUG|BA3182|Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
223384978|NCT06448572|DRUG|EXL01|1 capsule / day
223384979|NCT04205812|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
223384980|NCT04205812|DRUG|Placebo|Placebo administered intravenously every 3 weeks on Day 1 of each cycle for up to 35 cycles.
224002334|NCT03304197|DIETARY_SUPPLEMENT|Placebo|N/A: see arm description
224002335|NCT03304197|OTHER|Dehydrated|N/A: see arm description
224002336|NCT00685139|DRUG|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
224002337|NCT00685139|DRUG|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
224002338|NCT06162663|DRUG|Suvorexant Tablets|Suvorexant initially with 10-20 mg for 28 days
224002339|NCT06162663|OTHER|Placebo Control|Matched Placebo Control for 28 days
223384981|NCT04205812|DRUG|Pemetrexed|Pemetrexed administered intravenously every 3 weeks on Day 1 of each cycle.
223384982|NCT04205812|DRUG|Cisplatin|Cisplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
223384983|NCT04205812|DRUG|Carboplatin|Carboplatin administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
223384984|NCT04205812|DRUG|Paclitaxel|Paclitaxel administered intravenously every 3 weeks on Day 1 of each cycle for 4 cycles.
223384985|NCT04205812|DRUG|nab-Paclitaxel|nab-Paclitaxel administered intravenously every 3 weeks on Days 1, 8, and 15 of each cycle for 4 cycles.
223384986|NCT04111809|BIOLOGICAL|Blood and urine collection|collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
223384987|NCT05221320|DRUG|Ulixertinib|small molecule ERK 1/2 inhibitor
223384988|NCT05221320|DRUG|Hydroxychloroquine|Autophagy inhibitor
223384989|NCT05063708|DEVICE|Experimental: traditional dysphagia therapy plus Neuromuscular electrostimulation|In the present study, VitalStim equipment will be used (VitalStim Therapy; Chattanooga Group, Chattanooga, TN, USA). Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation.
223384990|NCT05063708|DEVICE|Sham Comparator: Traditional dysphagia therapy plus sham Neuromuscular electrostimulation|Therapists received additional training and information on NMES by an experienced laryngologist certified to use surface electrical stimulation. The training was given according to the manual of the manufacturer, the VitalStim certification course (http://www.vitalstim.com).
223384991|NCT06473519|BIOLOGICAL|RSVpreF MDV|RSVpreF with 2-PE formulated in an MDV
223384992|NCT06473519|BIOLOGICAL|RSVpreF SDV|RSVpreF without 2-PE formulated in an SDV
223384993|NCT03976843|DRUG|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
223545481|NCT05313763|OTHER|Sham Kinesiotaping|For Sham kinesio-tape application, a 20 cm long Y strip and a 15 cm long I strip tape will be prepared. The patient will flex his neck, the application will be started from the midline of the upper thoracic vertebrae, and the Y and I bands will be applied without stretching. The applications will be made by the same physiatrist with 7 years of clinical experience.
223545482|NCT04149483|DRUG|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
224002340|NCT03619447|DRUG|ESP block group|USG guided Erector spinae block (ESP) will perform bilaterally.
224002341|NCT03619447|DRUG|serratus block group|USG guided serratus plane block will perform bilaterally
224002342|NCT04223804|DRUG|ABBV-181|Intravenous (IV) Infusion
223384994|NCT05924763|DEVICE|Biphasic Cartilage Repair Implant (BiCRI)|The Biphasic Cartilage Repair Implant (BiCRI) is a two-phase scaffold composed of poly(lactic-co-glycolic acid) (PLGA) and β-triCalcium phosphate (TCP).
223545483|NCT04149483|DRUG|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
224002343|NCT04223804|DRUG|Placebo|Intravenous (IV) infusion
224002344|NCT05824598|BEHAVIORAL|Multifunctional rehabilitation treatment|multidisciplinary approach with (OMT, psychological counseling, and therapists dedicated to swallowing disorders)
224124283|NCT01057199|OTHER|fluorescence activated cell sorting|
224124284|NCT01057199|OTHER|laboratory biomarker analysis|
224124285|NCT06387888|OTHER|Listening to mother's voice|During the care, from the beginning to the end, mother's voice was played to the newborns. It took about 20 minutes. The mini Bluetooth speaker and the decibel meter were disinfected with the rapid surface disinfectant used in the clinic. The speaker was placed 30 cm away from the infant's ear and the sound level in the incubator was adjusted to be 50-60 dB by using a decibel meter (Official Gazette, 2018). Mother's voice was played from the beginning of the provision of care and continued for 15 minutes after the end of the provision of care. During the provision of care, COMFORTneo scores, pain scores, and vital signs were measured and recorded on the vital signs follow-up form.
223384995|NCT05630469|OTHER|Electroconvulsive therapy|repetitive induction of a generalized seizure under controlled conditions (muscle relaxation and sedation)
223384996|NCT05238623|DIAGNOSTIC_TEST|additional EIT Measurement|Patients who receive standard CT and pulmonary function testing also receive electroimpedance tomography measurement. The lunghealthy Patients in the control group only receive a EIT.
224002345|NCT03149809|DRUG|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
224002346|NCT03149809|BEHAVIORAL|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
224124286|NCT04426825|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg intravenously on Day 1 of each 21-day cycle.
224124287|NCT04426825|DRUG|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
224124288|NCT05081648|PROCEDURE|CT MuST|Multiple Single Cannulation Technique (MuST): Experimental technique
224124289|NCT05081648|PROCEDURE|Rope-ladder cannulation technique|Standard cannulation technique( Rope-ladder)
224124290|NCT01380106|DRUG|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
224002347|NCT03486860|BEHAVIORAL|Parent Psychoeducation|6-session parent psychoeducation group on child anxiety, following their children's lead, and encouraging approach behaviors.
224002348|NCT03486860|BEHAVIORAL|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
224002349|NCT05591014|DEVICE|Novel ROTEM interpretation software|Clinicians will be asked to interpret ROTEM studies before and after exposure to a novel ROTEM interpretation software.
224002350|NCT03787056|OTHER|Blood draws|"Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 25 mL for progastrin measurements and 5 mL for the dosage of the other tumor markers. The frequency depend to the cancer and treatment administered :~* Baseline at diagnosis : Local radical treatment : within 24h before surgery, within 24h after surgery and at the post-surgery follow up visit~* Chemotherapy treatment : every 3 or 4 weeks~* Radiotherapy : start day and at the end of radiation (end of treatment visit)~* Palliative systemic treatment (only palliative cohorts) : every 3 to 12 weeks. Follow until the third progression or change of treatment line, or alternatively up to 5 years after inclusion~* In case of PD or TOX~* Follow up: at each visit scheduled (every 3 months) for the first 2 years, then every 6 months for 3 years~* Relapse : withdrawn from the study and last progastrin measurement. Patient could be enrolled in the non-curative intent cohort"
224002351|NCT05701527|DRUG|EBC-129|EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.
224002352|NCT05701527|DRUG|Pembrolizumab|Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.
224002353|NCT01608126|PROCEDURE|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
224002354|NCT01692951|OTHER|serum sample|Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
224002355|NCT06043258|OTHER|Bond Apatite|composite graft formed of biphasic calcium sulphate and hydroxyapatite at a ratio of 2:1
224002356|NCT06043258|OTHER|Bio-Oss|xenograft bone substitute
223384997|NCT06246253|PROCEDURE|Virtual implant placement following safe angle concept|Virtual implant placement following safe angle concept in anterior maxillary teeth.
224002357|NCT02867215|OTHER|Barley bread|120g barley bread per day for 3 weeks.
224002358|NCT02867215|OTHER|Wheat bread|120g wheat bread per day for 3 weeks.
224002359|NCT01174576|OTHER|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
224002360|NCT01108926|DRUG|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
224002361|NCT01365936|DRUG|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
224002362|NCT01365936|DRUG|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
224002363|NCT06395025|DEVICE|Insoles|Insoles At Day 0, the patient received the insoles and adapted them to his shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled a usability's questionnaire at Day14.
224002364|NCT04616872|DRUG|Methotrexate-LDE|MTX-LDE 40mg/m2 (250mL total volume) IV and Folic acid 5mg by mouth (the day after MTX-LDE) weekly for 12 weeks
224002365|NCT04616872|DRUG|Placebo-LDE|Placebo-LDE (250mL total volume) IV and Folic acid 5mg by mouth (the day after Placebo-LDE) weekly for 12 weeks
224002366|NCT00237731|DRUG|morphine|morphine 0.05
224002367|NCT00237731|DRUG|morphine|morphine 0.10
224002368|NCT03789175|DIETARY_SUPPLEMENT|Nicotinamide Riboside (NR)|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
224002369|NCT04035902|DRUG|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
224002370|NCT04035902|DRUG|control|Ferric carboxymaltose is not administered
224002371|NCT00515671|BEHAVIORAL|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
224002372|NCT00515671|BEHAVIORAL|Problem Solving|Weekly problem-solving support group
224002373|NCT06479031|OTHER|Occupational Therapy|Occupational Therapy intervention, once a day, for 5 days, for 40 minutes each session.
223384998|NCT06246253|PROCEDURE|actual implant placement following safe angle concept|actual implant placement following safe angle concept in anterior maxillary teeth
223384999|NCT04582149|DEVICE|EyeControl Eye-tracking Device|The EyeControl is a new, wearable, eye-tracking device that facilitates communication by means of internal feedback to the patients with a bone-conducting speaker. In this way, the device can ask the patient what he or she wants to say, and the patient replies by eye gestures such as blinking or moving the eyes in a certain direction. Once the patient is able to operate the device, it will stay on the patient for as long as she or he would like it on, or until the patient is successfully extubated or discharged from the ICU, whichever is earliest.
224002374|NCT00678613|DRUG|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
224002375|NCT00678613|DRUG|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
224002376|NCT00814177|DRUG|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
224002377|NCT00814177|DRUG|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
223385000|NCT05220163|DIAGNOSTIC_TEST|CAD|It is an artificial intelligence (AI) system for detection of TB on CXR images. The system input is a frontal CXR, and the outputs are 1) a heatmap indicating suspicious regions on the image; and 2) a score (0-100) which implies the likelihood that the x-ray image shows TB.
223385001|NCT05220163|DIAGNOSTIC_TEST|Xpert|A novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at POC in a mobile van.
223385002|NCT02514447|DRUG|Trilaciclib|
223385003|NCT02514447|DRUG|Placebo|
224002378|NCT03955562|OTHER|Footbridge|Access to a pedestrian footbridge.
224002379|NCT03955562|OTHER|Comparison villages|Villages that do not receive a footbridge.
224002380|NCT03790553|RADIATION|Radiotherapy|Different total radiotherapy dose between two arms.
224002381|NCT04530097|PROCEDURE|RFA|Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
224002382|NCT00288639|DRUG|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
224002383|NCT02894970|DEVICE|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
224002384|NCT02952534|DRUG|Rucaparib|Rucaparib will be administered daily
224002385|NCT01244932|DRUG|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
224002386|NCT02698943|PROCEDURE|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
224002387|NCT02686177|DRUG|Liraglutide|
224002388|NCT02686177|DRUG|Metformin or sulfonylurea|
224002389|NCT02779114|DRUG|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
224002390|NCT02779114|OTHER|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
224002391|NCT02779114|OTHER|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
224002392|NCT03245853|DRUG|Riboflavin 5'-Phosphate|Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
224002393|NCT04284605|OTHER|Aerobic exercise combined with strength training|30 minute aerobic exercise training with warm-up and cool down followed by 30 minute strength training for specific muscles.
224002394|NCT04284605|OTHER|Yoga|60 minute yoga intervention including different asanas, breath control and meditation
224002395|NCT03691272|DEVICE|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
224124291|NCT01380106|DRUG|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
223545484|NCT03112291|PROCEDURE|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
224124292|NCT00227383|DEVICE|Electroacupuncture (device)|
223385004|NCT02514447|DRUG|Topotecan|
223385005|NCT05644548|OTHER|No intervention|No intervention
224124293|NCT01763905|BIOLOGICAL|Evolocumab|Subcutaneous injection
223385007|NCT06395168|OTHER|Combined Newborn and Lactation Visit|See Arm/Group Description
223385008|NCT05706558|PROCEDURE|Esophagectomy|Esophagectomy
223545485|NCT00335309|PROCEDURE|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
223545486|NCT00335309|DRUG|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
224124294|NCT01763905|DRUG|Placebo to Evolocumab|Subcutaneous injection
224124295|NCT01763905|DRUG|Ezetimibe|Tablet for oral administration
224124296|NCT01763905|DRUG|Placebo to Ezetimibe|Tablet for oral administration
224124297|NCT00314756|DRUG|imiquimod|
224124298|NCT02640846|DRUG|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
224124299|NCT02640846|DRUG|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
224124300|NCT02640846|DRUG|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
224124301|NCT00200499|DRUG|Nebivolol|
224124302|NCT04761887|DRUG|Cool Ropivacaine Block|Ropivacaine is cooled.
223385009|NCT06400329|OTHER|Pain Neuroscience Education|PNE focuses more on the neurophysiology of pain and approaches it from the perspective that knee OA pain is manageable, using neutral to positive language and emphasizes the importance of physical function and staying active
224002396|NCT03691272|DEVICE|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
224002397|NCT02385240|DRUG|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
224124303|NCT04761887|DRUG|Room Temp Ropivacaine Block|Room Temp Block
224124304|NCT05274113|DRUG|Dexamethasone 4mg|4 mg of Dexamethasone will be given before surgery
224124305|NCT05274113|DRUG|Ropivacaine|Ultrasound guided supraclavicular block with ropivacaine will be given to patients before surgery
224124306|NCT01405313|DEVICE|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
224124307|NCT01405313|DEVICE|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
224124308|NCT03456713|BIOLOGICAL|LY3074828|Administered SC
224124309|NCT01057719|OTHER|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
223385010|NCT06400329|OTHER|Standard Pain Education|In Standard Pain Education, the emphasis is on the structural pathology of knee OA and the outdated but common understanding of the disease process as a degenerative one, potentially conveying negative and threatening language
223385011|NCT05405790|PROCEDURE|thoracic endovascular aortic repair|In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
223545487|NCT03678051|BEHAVIORAL|Treatment as Usual (TAU)|Standard of care residential treatment
224002398|NCT02385240|DRUG|Brimonidine Topical Gel, 0.33 percent (Reference)|
224002399|NCT02385240|DRUG|Placebo gel|
224002400|NCT03341325|OTHER|animal-assisted activity|a live animal (small dog and/or rabbit)
224002401|NCT03341325|OTHER|control activity|a stuffed toy animal
224002402|NCT01014208|DRUG|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
224002403|NCT01014208|DRUG|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
224124310|NCT03025334|DEVICE|High-definition transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
224124311|NCT00318903|DRUG|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
224124312|NCT00318903|DRUG|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
224124313|NCT00318903|PROCEDURE|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
224124314|NCT00318903|PROCEDURE|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
224124315|NCT03848221|DRUG|Systane Complete|Systane Complete is an artificial tear.
224124316|NCT03848221|DRUG|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
224124317|NCT03505138|DEVICE|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
224124318|NCT03505138|OTHER|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
224124319|NCT00064467|DRUG|Extended-release bupropion (HCl)|
224124320|NCT01263691|BIOLOGICAL|BioThrax|BioThrax
224124321|NCT01263691|BIOLOGICAL|AV7909 Formulation 1|AV7909 Formulation 1
224124322|NCT01263691|BIOLOGICAL|AV7909 Formulation 2|AV7909 Formulation 2
224124323|NCT01263691|BIOLOGICAL|AV7909 Formulation 3|AV7909 Formulation 3
224124324|NCT01263691|BIOLOGICAL|AV7909 Formulation 4|AV7909 Formulation 4
224124325|NCT01263691|DRUG|Control|Saline control
224002404|NCT04651478|BEHAVIORAL|Action Observation+Motor Imagery through BCI|Patients will undergo the treatment through the NeuRow platform. NeuRow is a gamified Brain-Computer Interface training paradigm in Virtual Reality (or neurogame) that allows patients to perform the same actions as they would do in real-life by imaging the movement. In NeuRow, patients will see a boat and two high fidelity virtual arms gripping two oars in the first-person view. Patients will have to imagine the movement of each corresponding hand to rotate each oar and progress, observing the movement imagined on screen. The goal of the task is to collect as many flags as possible in a fixed amount of time. In order to improve adherence, the number of flags collected will be recorded in each session. It will be able to adapt the boat speed, turn speed, and cut-off angle, to help patients not to deviate in excess from the target. The treatment itself will be performed for 20 minutes each session, divided into 4 series of 5 minutes to prevent fatigue.
224002405|NCT04651478|BEHAVIORAL|Action Observation through non-related with movement illustrations|The same configuration will be applied to simulate a BCI task, but playing a video about graphic illustrations, people's faces, and landscapes, never related to human movement. They will address interesting and changing topics to avoid patient's boredom. The control session will last 20 minutes, also divided into 4 series of 5 minutes and the therapist will give the instructions of observing and relax.
224002406|NCT03730129|DRUG|Hizentra|Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
224002407|NCT06274931|PROCEDURE|Bronchoscopy|Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.
224002408|NCT00133562|DRUG|Alanyl-glutamine|
224002409|NCT00133562|DRUG|Glycine|
224002410|NCT05474495|OTHER|Pelvic floor muscle training|Pelvic floor muscle training. Two sessions a week for 6 weeks, each session lasting 45 mins.
224124326|NCT01111201|BEHAVIORAL|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
224124327|NCT05187806|BEHAVIORAL|motivational interview|After the pretest, the experimental group was intervened with a motivational interview (MI) method that consisted of four sessions.The pretest and posttest Diabetes Self-Management Scale total scores and HbA1c values of the patients in the experimental and control groups were compared.
224124328|NCT01139385|PROCEDURE|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
224124329|NCT01139385|PROCEDURE|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
224124330|NCT03913624|OTHER|Neuromuscular electrical stimulation|
224124331|NCT05943977|DRUG|MB-102 DMID|130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
224124332|NCT05943977|DRUG|MB-102 OMID|130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.
224124333|NCT05943977|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
224124334|NCT01028651|DRUG|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
224124335|NCT06271070|OTHER|Non-intervention|Non
224124336|NCT06305104|BIOLOGICAL|2.5μg/ml EEC|0.1ml ,one time, containing low dose of 2.5μg/ml of active ingredients
224124337|NCT06305104|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
224124338|NCT06305104|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
224002411|NCT05474495|OTHER|Transverse abdominas strength training|Transverse abdominas strength training will be given 5 days a week and continued for 6 weeks.
224124339|NCT01554956|BIOLOGICAL|Human Plasminogen|Eye Drops
224002412|NCT00801762|DEVICE|Fibered confocal microscope|
224002413|NCT01985451|DRUG|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
224124340|NCT04156997|OTHER|No intervention is involved in this study|No intervention is involved in this study
224124341|NCT05257408|DRUG|Nab-paclitaxel 80 mg/m^2|Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle.
224002414|NCT01985451|DRUG|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
224002415|NCT01290289|OTHER|Epidura, CSE & IV|"Gp 1: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia \& a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl \& a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg."
223545488|NCT03678051|BEHAVIORAL|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
224002416|NCT03919604|PROCEDURE|Extracorporeal Life Support|Any extracorporeal blood treatment technique for respiratory and/or cardiac support
224002417|NCT05070585|DIETARY_SUPPLEMENT|Isothiocyanate rich sprouts|Isothiocyanate rich sprout juice consumption for 1 week
224002418|NCT05070585|DIETARY_SUPPLEMENT|Placebo Juice|Sprout juice devoid of isothiocyanates for 1 week
224002419|NCT01695252|OTHER|MEMOS|Patient informed clinical outcomes supervision
224002420|NCT06088459|BIOLOGICAL|1mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
224002421|NCT06088459|BIOLOGICAL|4mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
224002422|NCT06088459|BIOLOGICAL|8mg NWRD06 administered by electroporation|DNA plasmid delivered via IM injection + electroporation using TERESA device
224002423|NCT04334200|BEHAVIORAL|Cultivate yourself: support for caregivers of dementia persons|The Chinese cultural values, including philosophical thoughts, will be included in the intervention. Chinese philosophical thoughts including the concepts of moderation, improving oneself, and harmony with nature will be used in the intervention. Confucianism, Taoism and Buddhism are the foundation for Chinese for concepts of health and illness, health promotion, and health-seeking behavior. Therefore, it is necessary to incorporate such philosophies in the sessions of the program.
224002424|NCT03745911|COMBINATION_PRODUCT|Paclitaxel and TAK-228|Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
224002425|NCT03103984|OTHER|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
224002426|NCT06126003|OTHER|Observation|No Intervention
224002427|NCT00220051|DRUG|Oxaliplatin, Capecitabine|
224002428|NCT00220051|PROCEDURE|Pre operative radiotherapy|
224002429|NCT00220051|PROCEDURE|Surgical Resection|
223545489|NCT02261207|DRUG|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
224002430|NCT00130260|BIOLOGICAL|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
224002431|NCT00130260|BIOLOGICAL|placebo|placebo to match StaphVAX
223545490|NCT03350451|DRUG|Lumasiran|Multiple doses of lumasiran by SC injection
223545491|NCT02639247|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
223545492|NCT02639247|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
223545493|NCT04798222|DRUG|Treatment A|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin tablet in fasted condition.
223545494|NCT04798222|DRUG|Treatment B|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fasted condition.
224002432|NCT03823157|BEHAVIORAL|Tai Chi|mind-body exercise
224002433|NCT03733990|BIOLOGICAL|FP-1305 (bexmarilimab)|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
224002434|NCT05339412|BEHAVIORAL|Training Tool for Preventing HIV/AIDS among Teens (PHAT) Life|The technology-based training tool will train facilitators to deliver the behavioral health intervention PHAT Life, which is an innovative HIV/STI, substance use, and mental health intervention for juvenile offenders. The training tool reviews each of PHAT Life's 8 sessions. The curriculum targets broad psychosocial factors implicated in HIV/STI-risk behavior, including promoting positive attitudes toward HIV/STI prevention, self-efficacy to reduce risk, and less substance misuse and sexual risk taking. Content emphasizes the importance of emotion regulation skills to manage strong feelings, uses goal setting and training in positive thought processes to plan ahead, encourages recognition of personal responsibility in future outcomes, and helps youth identify strategies and behaviors to accomplish short- and long-term goals.
224002435|NCT06011018|OTHER|Mirror Therapy|"Sitting, mirror place at the midline between the legs. Unaffected leg is placed in front of the mirror and perform ankle dorsiflexion exercises.~Duration: 5 seconds, Rest: 5 seconds"
224002436|NCT06011018|OTHER|Mirror Therapy + Electrical Stimulation|Same as the mirror therapy protocol. Affected leg: electrical stimulation on tibialis anterior muscle. Frequency: 35 Hz, Pulse width: 250µs, Duration: 5 seconds, Rest: 5 seconds.
224002437|NCT06011018|OTHER|Mirror Therapy + Binaural Beat|Same as the mirror therapy protocol. Listen to music (pink noise), with 14Hz binaural beat stimulation
224002438|NCT06632756|BEHAVIORAL|Individual and Group Treatment for Smoking Cessation|Positive psychology-based individual treatment and groups
224002439|NCT06218823|DRUG|Transdermal Nicotine Patch|a stop smoking aid, 21 milligrams(mg), 14mg, or 7mg of nicotine delivered over 24 hours
224002440|NCT06218823|BEHAVIORAL|Standard Telephone Counseling|3 brief telephone-based smoking cessation counseling sessions
224124342|NCT05257408|DRUG|Relacorilant 150 mg once daily (QD)|Relacorilant is administered as capsules for oral dosing.
224002441|NCT06218823|DRUG|Varenicline|12 weeks of an oral smoking cessation medication
224002442|NCT06218823|BEHAVIORAL|Cancer-Targeted Telephone Counseling|7 telephone-based smoking cessation counseling sessions adapted for cancer patients
224002443|NCT06218823|OTHER|Mailed Information about Standard Care Resources|Publicly funded treatment resources including the SmokefreeTXT program sponsored by the National Cancer Institute and the Wisconsin Tobacco Quit Line.
224002444|NCT05574699|OTHER|Social Risk Score and CDS Tool|A social risk score, which helps to identify patients with high social needs based on the risk score in the CDS tool and a closed loop referral, which helps to refer the patients to CBOs, if needed.
224124343|NCT05257408|DRUG|Nab-paclitaxel 100 mg/m^2|Nab-paclitaxel is administered as IV infusion on Day 1, 8, and 15 of each 28-day cycle.
223385012|NCT05820438|DEVICE|Electromyography|"Disposable bipolar surface electrodes will be used.~The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres.Doing so the position of the electrodes results as follows:~Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient."
223385013|NCT06561334|PROCEDURE|Botulinum toxin injections|Botulinum toxin injection to ease spasms of vocal cord
223385014|NCT05403216|OTHER|no intervention|
223385015|NCT03784781|BIOLOGICAL|Biopsy|Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
223385016|NCT03784781|BIOLOGICAL|Blood collection|Blood collection (+15mL/ current care)
224002445|NCT05574699|OTHER|Standard of Care|Currently available process for screening, assessment, and addressing social needs in the clinic setting, which may include providing a sheet of various educational resources, or a list of organizations that can address the identified social need.
224002446|NCT04662723|DRUG|Corticosteroid|To reduce the progression of renal damage in IgAN Patients
223385017|NCT03784781|BIOLOGICAL|Bronchoalveolar lavage|Bronchoalveolar lavage fluid (3mL/Kg)
223385018|NCT06397378|OTHER|short videos related to HPV and the HPV vaccine|"Eight college students created and developed four videos on human papillomavirus (HPV) and the HPV vaccine, designed to increase their knowledge and attitude, shape subjective norms, enhance perceived behavioral control, and strengthen intentions to receive the HPV vaccine. Two months after the video intervention, we will follow up with participants to collect their self-reported vaccine uptake status.~Outcomes will be compared with those of another group whose participants will watch a video presenting CDC information on HPV and the HPV vaccine, adapted into a narrated voiceover format."
223385019|NCT06397378|OTHER|CDC HPV Fact Sheet|"We did not develop this intervention. Instead, we will use information from the CDC website on HPV and the HPV vaccine and convert it into a video with a narrated voiceover format.~Because our student advisory board will develop four short videos, participants who are randomly assigned to the CDC fact sheet group will watch the converted CDC video four times to ensure that all groups are exposed to the same number of videos.~Here is the CDC link: https://www.cdc.gov/hpv/vaccines/?CDC\_AAref\_Val=https://www.cdc.gov/hpv/parents/vaccinesafety.html"
224002447|NCT04662723|DRUG|Renin-angiotensin sytem blockers|To reduce the progression of renal damage in IgAN Patients
224002448|NCT04662723|DRUG|Sodium-glucose cotransporter 2 inhibitor|To reduce the progression of renal damage in IgAN Patients
224002449|NCT05143697|BEHAVIORAL|Wellness Coaching for Families and Kids|The investigators propose to conduct a cluster-randomized pragmatic trial in 49 pediatric clinics in Kaiser Permanente Southern California (KPSC), to test the effectiveness of mBMI2Kids (a modified version of the BMI2 interven-tion) in pediatric clinics (randomization unit). Clinics serve over 45,000 children aged 2-8 yrs who are obese and have high racial/ethnic and socioeconomic diversity (53% Hispanic; 23% state-subsidized insurance). Clinics will be randomized into either 24 intervention or 25 usual care + attention control (enrolling 6,600 children). KP's long-standing electronic medical record (EMR) and stable membership, a research team embedded in care, existing team of lifestyle coaches, and ability to rapidly disseminate findings makes us uniquely positioned to conduct this study.
224002450|NCT06375629|DEVICE|FocalOne|The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device. This study is a non-interventional study. All the data will be collected from routine care. Data as indicated in the table below will be systematically recorded on the e-CRF to coincide with the scheduled follow-up visits at 3, 6 and 12 months.
224002451|NCT06223269|DRUG|Skin Xenotransplant|"realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area."
224002452|NCT06223269|PROCEDURE|Autograft(ing)|Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
224002453|NCT05905419|OTHER|Opioid Phase|"Opioid-taking patients are assigned to take their prescribed opioid medication before (peak opioid phase) during 1 scan and after (trough opioid phase) during the other MRI scan"
224002454|NCT06457451|OTHER|DIAPASOM program|A program of adapted physical activity carried out remotely by a specialist instructor, combined with personalized dietetic care by a dietician for one year.
224002455|NCT06263023|OTHER|Sub-Normothermic Machine Preservation and Assessment|Human kidneys from HTP deceased donors will be transported to the Sponsor's central preservation and assessment facility and placed onto a machine perfusion system in a sterile operating room for a brief period of Sub-Normothermic Machine Perfusion (SNMP). Basic parameters including internal renal resistance, oxygen, and electrolyte levels will be recorded using standard point-of-care hospital analyzers. Accepted kidneys will be transported to a participating transplant center using a portable oxygenated LifePort Hypothermic Machine Preservation (HMP) device.
224002456|NCT00330252|DRUG|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
224002457|NCT00330252|DRUG|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
223385020|NCT06567249|PROCEDURE|Intracoronary hypothermia|This trial stands apart from other studies of intracoronary hypothermia, mainly because it will establish the role of intracoronary hypothermia in reducing infarct size not only in the left anterior descending artery territory but in other vessels as well, including the right coronary artery and circumflex coronary artery.
223385021|NCT06567249|OTHER|Standard percutaneous coronary intervention|Percutaneous coronary intervention is performed in a standard manner.
223385022|NCT06538324|DIETARY_SUPPLEMENT|Omega-3|Dietary Supplement: Omega-3 In the marine Omega-3 fatty acid period, the participants will receive a capsule with 250 mg of EPA per day during 6 weeks.
223385023|NCT06538324|DIETARY_SUPPLEMENT|HOSO|Dietary Supplement: HOSO In the HOSO period, the participants will receive a capsule with the similar weight of HOSO per day during 6 weeks.
224002458|NCT04414202|PROCEDURE|tumorectomy with axillary dissection (sentinel lymph node)|All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
224002459|NCT04414202|RADIATION|per-operative partial irradiation|20 Gy of per-operative partial irradiation at the tumor site during the surgery
224002460|NCT01012401|OTHER|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
224002461|NCT06409234|OTHER|Transthoracic Echocardiography Recieved|Transthoracic Echocardiography Recieved
224002462|NCT00527787|DRUG|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
223385024|NCT05253339|PROCEDURE|target-controlled infusion (one of the administration methods)|a method of administering cefoxitin while maintaining a constant target concentration.
223385025|NCT05253339|PROCEDURE|Standard administration method|Standard method of administering cefoxitin in the current clinical setting
223385026|NCT04946370|DRUG|225Ac-J591|Alpha-emitter Actinium-225 conjugated to the anti-PSMA antibody J591.
223385027|NCT04946370|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously, 400mg every 6 weeks. Patients may receive maximum 18 cycles of therapy, approximately 2 years.
223385028|NCT04946370|DRUG|Androgen receptor inhibitor|Patients will receive an oral androgen receptor inhibitor (ARI). Examples include enzalutamide, apalutamide, darolutamide. Dosing will be the standard dosing, as described by the package insert.
223385029|NCT04946370|DIAGNOSTIC_TEST|68Ga-PSMA-11|\[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening and 12 weeks. Imaging agent for PSMA PET/CT.
223385030|NCT04843436|DEVICE|Symani Surgical System|Robotically Assisted Microsurgery
223385031|NCT03937635|BIOLOGICAL|Daratumumab|Given IV
223545495|NCT04798222|DRUG|Treatment C|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 1 in fed condition
223385032|NCT03937635|DRUG|Dexamethasone|Given PO
223385033|NCT03937635|DRUG|Lenalidomide|Given PO
223545496|NCT04798222|DRUG|Treatment D|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fasted condition.
223545497|NCT04798222|DRUG|Treatment E|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 2 in fed condition.
223545498|NCT04798222|DRUG|Treatment F|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 3 in fasted condition.
224002463|NCT00527787|DRUG|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
224002464|NCT05672901|DEVICE|StrataMGT|StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
224002465|NCT05672901|DRUG|Estrace 0.01% Vaginal Cream|Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
223385034|NCT03937635|OTHER|Quality-of-Life Assessment|Ancillary studies
223385035|NCT03937635|OTHER|Questionnaire Administration|Ancillary studies
223425563|NCT00369070|DRUG|Carboplatin|All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
223425564|NCT02530411|DRUG|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
223425565|NCT02530411|DRUG|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
223425566|NCT06620575|PROCEDURE|Atrial fibrillation ablation|Persistent atrial fibrillation ablation
223425567|NCT02031640|DRUG|Beclomethasone dipropionate|
223425568|NCT02031640|DRUG|Placebo|
223425569|NCT02031640|DRUG|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
223545499|NCT04798222|DRUG|Treatment G|Participants will receive oral AZD9977 Dose A capsule and 10 mg dapagliflozin capsule 4 in fasted condition.
223545500|NCT04798222|DRUG|Treatment H|Participants will receive oral dose of dapagliflozin capsule in fasted condition.
224002466|NCT04677218|PROCEDURE|Arthroscopic ACL reconstruction with retensioned hamstring autograft|After diagnostic arthroscopy, an oblique, 5-cm oblique skin incision is made below the joint line over the proximal edge of the pes anserine.Then fascia will be incised the fascia in an L-shaped fashion. After the releasing the distal end of tendons ,tendons will be harvested in their direction via tendon strippers.During the graft preparation phase firstly femoral tunel will be drilled from AM portal with knee flexed to 120 degrees. The drill will be aligned parallel to the tibial plateau and exit through LFC.Then tibial guide wire will be sent from graft incision to the tibial tunel and drilled for desired direction.Once the adjustable loop button is deployed to the graft, it will be pulled through the tunnels and the button is slipped on lateral femoral cortex. Then tibial fixation will be provided with one bioabsorbable screw and staple.After tibial fixation, the femoral loop will be retensioned in group 2 patients.
224002467|NCT04677218|PROCEDURE|Arthroscopic ACL reconstruction with retensioned and knotted hamstring autograft|After the same preparation procedure as in retensioned autograft group, after tibial fixation of graft, femoral loop will be retensioned and knotted in 3. group .
224002468|NCT04939701|DRUG|ASP0739|Intravenous (IV)
224002469|NCT06159699|OTHER|Online Survey|The participants of the study undergo the online survey at www.zdorov.tpu.ru and www.zdorov.expert.
224002470|NCT06159699|DIAGNOSTIC_TEST|Genetic Testing|Genetic testing will be performed in subgroup of survey respondents willing to participate in the study of polymorphisms of genes involved in drug metabolism or affecting biological effects of medications including CYP2D6, ACE, UGT1A1, CYP2C9, and CYP2C19.
224002471|NCT04579783|DRUG|Triamcinolone Acetonide|Group A: 40mg triamcinolone acetonide (1mL) + 4mL normal saline
224002472|NCT04579783|DRUG|Dextrose 5% in water|Group B: 5mL 5% dextrose
223385036|NCT06350721|DEVICE|DizzyVR|Each patient will receive a total of 8 sessions of vestibular rehabilitation with the DizzyVR system. Each session will last for 50 minutes, with a frequency of one session per week. The total duration of the intervention will be 10 weeks, with the initial assessment/T0 taking place in the first week and the final assessment/T2 in the tenth week. Similarly, the total expected participation time for each participant is set at 12 weeks (T3).
223385037|NCT04694248|DRUG|Rivaroxaban|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
224002473|NCT02565524|OTHER|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
224002474|NCT02308787|DEVICE|Spectra Optia Apheresis System|Platelet Depletion
224002475|NCT00040651|DRUG|Fludarabine|
224002476|NCT00040651|DRUG|Cyclophosphamide|
224002477|NCT00040651|DRUG|Thymoglobulin|
224002478|NCT00040651|PROCEDURE|Leukapheresis|
224002479|NCT00040651|PROCEDURE|Self bone marrow transplant|
223385038|NCT04694248|DRUG|Aspirin|For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
223385039|NCT02668510|BIOLOGICAL|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
224002480|NCT02672852|DRUG|Risankizumab|Risankizumab administered by subcutaneous injection
224002481|NCT02672852|DRUG|Placebo|Placebo for risankizumab administered by subcutaneous injection
224002482|NCT05532514|OTHER|MICRONUCLEI COUNT|MICRONUCLEI COUNT IN PRECBCT and POSTCBCT EXPOSURE
224002483|NCT02839525|DIETARY_SUPPLEMENT|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
224002484|NCT02839525|DIETARY_SUPPLEMENT|Isolate whey protein|23g of protein of whey protein
223385040|NCT02668510|DRUG|Normal saline|placebo injection of normal saline immediately following shockwave therapy
223385041|NCT06470815|PROCEDURE|Transcarotid Artery Revascularization (TCAR)|Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
224002485|NCT02839525|DIETARY_SUPPLEMENT|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
224002486|NCT02839525|OTHER|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
224002487|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
224002488|NCT06077240|BEHAVIORAL|E-cigarette with 2.4% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
224002489|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
224002490|NCT06077240|BEHAVIORAL|E-cigarette with 5% Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
224002491|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
224002492|NCT06077240|BEHAVIORAL|Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with lower nicotine concentration.
224002493|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors|Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
224002494|NCT06077240|BEHAVIORAL|Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only|Flavor availability is tobacco/unflavored only with higher nicotine concentration.
224002495|NCT05364372|BEHAVIORAL|Symptom assessment only|Dyads will receive 12 weekly phone calls to assess symptom management.
224002496|NCT05364372|BEHAVIORAL|Symptom management and lifestyle intervention|Survivor and caregiver dyads will work together with a coach to establish diet and physical activity change SMART goals. Motivational interviewing based weekly coaching sessions will review symptom management and goal attainment and then enact strategies to modify goals to be more relevant and achievable.
224002497|NCT02142868|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
224002498|NCT02142868|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
224002499|NCT00702962|DRUG|Vorinostat, Carboplatin, Etoposide|"Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total."
224002500|NCT00210145|BEHAVIORAL|Aesthetic care|
224002501|NCT04064996|OTHER|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
224002502|NCT04064996|OTHER|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
224002503|NCT01741805|OTHER|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
223385042|NCT04578483|OTHER|ERDS group|After anesthesia, extended-release dinalbuphine sebacate (ERDS) is injected into gluteus maximus with ultrasound guidance.
223385043|NCT05022147|DEVICE|High-Frequency-Only Stimulation|Control condition, constant high-frequency DBS stimulation (130Hz)
223385044|NCT05022147|DEVICE|Low-Frequency-Only Stimulation|Experimental condition, constant low-frequency DBS stimulation (60 Hz)
223385045|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 10 seconds for low, respectively.
223385046|NCT05022147|DEVICE|Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 50 seconds for high, and 50 seconds for low, respectively.
223385047|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 50 seconds for low, respectively.
223545501|NCT01751672|BEHAVIORAL|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
224002504|NCT02219165|DRUG|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
224002505|NCT02219165|DRUG|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
224002506|NCT03808142|OTHER|myBETAapp|Patients choosing to use the myBETAapp were required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number was not interfere with the process of continuously allocating data to a single patient; each patient had a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data were stored in the database once the mobile device was connected to the internet.
224002507|NCT03808142|OTHER|PEAK|Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
224002508|NCT03808142|DRUG|Betaferon, BAY86-5046|Injection
224002509|NCT03808142|DEVICE|BETACONNECT|BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
224002510|NCT02175641|BEHAVIORAL|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
224002511|NCT02175641|BEHAVIORAL|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
224002512|NCT00821951|DRUG|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
224002513|NCT00821951|RADIATION|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
224002514|NCT03791554|PROCEDURE|Group A (Lateral closed tunnel subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
224002515|NCT03791554|PROCEDURE|Group B (Tunnel procedure with subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
223385048|NCT05022147|DEVICE|Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation|Experimental condition where stimulation frequency is changed from high (130Hz) to low (60Hz) frequency. The time interval for each frequency is 10 seconds for high, and 10 seconds for low, respectively.
223385049|NCT05022147|DRUG|OFF Dopaminergic Medication|All six device interventions will be performed in medication OFF state
223385050|NCT05022147|DRUG|ON Dopaminergic Medication|All six device interventions will be performed in medication ON state
224002516|NCT05049577|DEVICE|Analgesia/Nociception Index (ANI)|V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
224002517|NCT03724058|DEVICE|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
224002518|NCT03724058|DEVICE|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
224002519|NCT01923467|BEHAVIORAL|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
224124344|NCT05398003|DEVICE|Implantation of the WAVEWRITER ALPHA ™ device|"The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)"
224124345|NCT02846376|DRUG|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
223385051|NCT04015596|DRUG|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
223385052|NCT04015596|OTHER|Placebo|Participants take placebo pills twice daily, for 8 weeks.
223385053|NCT05585164|BEHAVIORAL|Engage & Connect (E&C)|"Engage \& Connect, is a remotely-delivered extension of Engage psychotherapy. It is aimed to increase engagement in rewarding social activities and in turn, reduce postpartum depression. In each session, the therapist will work with the patient to develop action plans to pursue rewarding social activities of their choice with the goal of reducing social isolation."
223385054|NCT05585164|BEHAVIORAL|Symptom Review and Psychoeducation (SRP)|SPR is a remotely-delivered intervention aimed to increase knowledge of postpartum depression and monitor mental health changes. In each session, the therapist will review the participant's symptoms and discuss information related to postpartum depression and changes after birth.
223385055|NCT05806164|DRUG|Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]|The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
223385056|NCT05806164|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
223545502|NCT01751672|BEHAVIORAL|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
223545503|NCT03553537|DRUG|Decitabine|10mg/m² iv on day 1-5
223545504|NCT03553537|DRUG|Cyclophosphamide|750mg/m² iv on day 6
223545505|NCT03553537|DRUG|Doxorubicin|DOX
223545506|NCT03553537|DRUG|Vincristine|1.4mg/m² iv on day 6
223545507|NCT03553537|DRUG|Prednisone|100mg/m² po on day6-10
223545508|NCT02955238|BEHAVIORAL|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
223545509|NCT02638714|BIOLOGICAL|Stem Cells|Intervention: Transplantation of autologous purified stem cells
223545510|NCT02982655|PROCEDURE|Individualized BP lowering|
223545511|NCT02964806|DIETARY_SUPPLEMENT|Ordinary Diet|
223545512|NCT02964806|DIETARY_SUPPLEMENT|Modified Atkin's Diet|
223545513|NCT02964806|DIETARY_SUPPLEMENT|Ketogenic Diet|
223545514|NCT04803513|DRUG|Galcanezumab|Galcanezumab according to clinical indication in real life
223545515|NCT06090058|DIAGNOSTIC_TEST|Measurement of neurofilament light chain|Serum samples will be collected into a serum gel with clotting activator tube (Sarstedt). After delivery to the laboratory, the serum samples were centrifuged at 2500 × g for 6 min at 4 Celsius degree, then aliquoted into at least three vials (0.3 mL per vial) and stored at -70 Celsius degree until the analysis.
223545516|NCT05985707|DRUG|KN026|KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
223545517|NCT05985707|DRUG|KN046|KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
224002520|NCT01923467|DRUG|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
224002521|NCT04548323|BEHAVIORAL|Motor imagery|Subjects will perform motor imagery tasks on the motor gestures of running and walking.
224002522|NCT02518035|DRUG|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
224002523|NCT00963612|PROCEDURE|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
224002524|NCT00967902|DEVICE|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
224002525|NCT00974194|PROCEDURE|Single Trocar CCK|CCK using Triport
224002526|NCT00974194|PROCEDURE|Standard CCK|CCK using three or four ports
224002527|NCT02145338|DRUG|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
224002528|NCT02145338|OTHER|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
224002529|NCT06114303|OTHER|Stool sampling|1 stool sample is taken during the study with a stool sample kit
224002530|NCT05781412|DEVICE|tDCS|Anodal and Sham cerebellar tDCS will be used in each participant in a counterbalanced order
223385057|NCT06644846|RADIATION|Spatially fractionated radiation therapy|"Spatially fractionated radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of hot and cold spots within the tumour, thereby sparing nearby organs at risk."
223385058|NCT06577636|PROCEDURE|Propofol anesthesia|EEG-guided infusion of anesthestetics
223385059|NCT05160597|PROCEDURE|Biopsy of Prostate|Undergo image-guided prostate biopsy
223385060|NCT05160597|OTHER|Gallium Ga 68 Gozetotide|Given IV
223385061|NCT05160597|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo standard of care TRUS
223385062|NCT05844033|OTHER|Screening|Blood tests
224002531|NCT01162070|OTHER|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
224124346|NCT02846376|DRUG|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
224124347|NCT03993691|DEVICE|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
224124348|NCT03993691|DEVICE|Radiograph|Standard of Care radiographic imaging of wrist.
223385063|NCT03909737|DRUG|Azithromycin to pregnant women|Azithromycin to pregnant women at antenatal care visits and during delivery
223385064|NCT03909737|DRUG|Azithromycin to infants|Azithromycin to infants at 6 and 14 week EPI visits
224002532|NCT01162070|OTHER|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
224002533|NCT01876901|PROCEDURE|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|"2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
223385065|NCT03909737|OTHER|Placebo to pregnant women|Placebo to pregnant women at antenatal care visits and during delivery
223385066|NCT03909737|OTHER|Placebo to infants|Placebo to infants at 6 and 14 week EPI visits
223385067|NCT03909737|OTHER|No intervention to pregnant women|No intervention to pregnant women
223385068|NCT05510622|OTHER|Vaginal swab and endometrial biopsy|A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
223385069|NCT05626231|BEHAVIORAL|Training Intervention|"The training intervention is a modular online asynchronous training intervention designed to increase mental health providers' use of evidence-based practices with youth patients (ages 12-25). It was developed using community-engaged and human-centered design methods with key stakeholders (youth, their parents, mental health providers). In this open trial, the training will be offered to mental health providers at a multisite mental health clinic in the U.S. (referred to as pilot site herein)."
223385070|NCT06527404|DRUG|Rocatinlimab|SC Injection
223385071|NCT06527404|DRUG|Placebo|SC Injection
223385072|NCT06486376|BEHAVIORAL|Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia|Intervention components include teacher training, stepdown training of teachers to children and distribution of IEC materials.
224002534|NCT01876901|PROCEDURE|Colo-anal anastomosis (CAA)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
223385073|NCT06121375|DRUG|OCA|OCA will be administered.
223385074|NCT06121375|DRUG|Matching Placebo|Matching Placebo will be administered.
224002535|NCT03660644|BEHAVIORAL|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
224002536|NCT05805709|OTHER|Study Physician/Advance Practice Provider|The nephrologist and/or nephrology-associated advanced practice provider (APP) at each site will lead the intervention team for the duration of the study. The study physicians will fulfil two main roles: (a) Provide supervision to the rest of the study team and (b) conduct a discharge assessment to triage and make recommendations for follow-up care.
224124349|NCT04118686|OTHER|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
224124350|NCT04118686|OTHER|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
223385075|NCT03015246|DRUG|Extended release morphine|Dose (tailored to each participant based on his/her pre-experimental opioid use amount) is administered in 3 divided daily doses.
223385076|NCT03015246|DRUG|Buprenorphine/Naloxone low dose|Buprenorphine/Naloxone dose of 1.4/0.36 mg/day
224002537|NCT05805709|OTHER|Nurse Navigator|The nurse navigator will be the primary contact for the participants assigned to the intervention group for the study. The navigator will obtain contact information, information about the patient's usual care providers and pharmacy, review medications, show the participant how to use the home blood pressure machine and scales and arrange for follow-up visits. The role of the nurse navigator will be to monitor the participant's medical condition; facilitate scheduling of needed medical follow-up including both routine (pre-scheduled) and ad hoc (urgent or emergency); enhance adherence with prescribed medical care and follow-up appointments; and serve as a resource to the patient to answer questions about their AKI-related management, facilitate medical and associated care and provide enhanced psychosocial support.
223385077|NCT03015246|DRUG|Buprenorphine/Naloxone moderate dose|Buprenorphine/Naloxone dose of 4.2/1.08 mg/day
223385078|NCT03015246|DRUG|Buprenorphine/Naloxone high dose|Buprenorphine/Naloxone dose of 12.8/3.16 mg/day
223385079|NCT03015246|DRUG|Active stressor|Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet
223385080|NCT03015246|DRUG|Placebo stressor|Lactose
223385081|NCT05383612|PROCEDURE|Warm compresses|Commercial eye patch, 10 min before lid massage.Warm compresses and lid massage every 2 weeks，5 times in total（0，2, 4, 6, 8W）.
223385082|NCT05383612|DRUG|3% Diquafosol Sodium Eye Drops|3% Diquafosol Sodium Eye Drops (DIQUAS ophthalmic solution 3%; Santen Pharmaceutical Co. Ltd, Osaka, Japan)，3% diquafosol was administered six times a day for 12 weeks.
223385083|NCT01258140|RADIATION|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
223385084|NCT01258140|RADIATION|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
223385085|NCT02653625|DRUG|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning.
223385086|NCT03860974|DRUG|Serratus Plane block (single injection)|A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
223385087|NCT03860974|DRUG|Paravertebral block (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
223385088|NCT01348048|OTHER|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
223385089|NCT03707626|OTHER|Wellens Sign|presence or absence in presence of coronary collaterals to LAD
223385090|NCT05377749|BEHAVIORAL|FACT|Families Addressing Cancer Together (FACT) is a web-based intervention that provides tailored communication support for parents with cancer.
223385091|NCT00174304|DRUG|Amlodipine/atorvastatin single pill|
223385092|NCT03194269|DEVICE|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
224124351|NCT04867135|DRUG|Amikacin Sulfate Injection|The dose and frequency of amikacin was defined by each hospital.
223385093|NCT00096629|BIOLOGICAL|human prostate-specific membrane antigen plasmid DNA vaccine|
223385094|NCT00096629|BIOLOGICAL|mouse prostate-specific membrane antigen plasmid DNA vaccine|
223385095|NCT06150248|OTHER|Education Intervention|"This intervention is based on the Social Cognitive Theory (SCT) and The Health Belief Model (HBM) to improve knowledge and promote lifestyle adherence in terms of healthy diet behaviour and physical activity among the undergraduate students. This program will include educational booklets and educational classes include six weeks of in-person education sessions and six weeks of social media messaging. The course will include six weekly teaching units (lectures and group discussions, 45-60 minutes each):~Topic 1: To understand the causes and prevention strategies for overweight and obesity.~Topic 2: To understand food based approaches to reduce or prevent overweight and obesity.~Topic 3: To understand the importance of regular physical activity. Topic 4: To demonstrate how snacking can be a healthy habit. Topic 5: To learn how to read and interpret food labels. Topic 6: To understand how to prepare healthy meals."
223385096|NCT06150248|OTHER|No intervention|They will have their regular curriculums and normal physical activity routine.
223545518|NCT05985707|DRUG|XELOX|XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
223545519|NCT03462758|DEVICE|IUD|Postpartum IUD placement
223545520|NCT05744856|BEHAVIORAL|Self-care with informal support|"The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition."
223385097|NCT04413786|DRUG|oxytocin treatment|intranasal administration of oxytocin (24IU)
223385098|NCT04413786|DRUG|placebo treatment|intranasal administration of placebo (24IU)
223385099|NCT00314704|DRUG|dopamine versus norepinephrine|
223385100|NCT00218946|DRUG|Sucrose|30 % sucrose
223385101|NCT00218946|DEVICE|Pacifier|
223385102|NCT00218946|OTHER|sterile water|
223385103|NCT05517421|DRUG|Batoclimab|Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
223385104|NCT05517421|DRUG|Placebo|Matching Placebo
223385105|NCT02724514|OTHER|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
223385106|NCT04234308|DRUG|Polyglycolic Acid|Periodontal and periimplant flaps closed with at least one suture with Polyglycolic Acid Absorbable suture, synthetic, 4-0. (TAGUM®).
223385107|NCT04234308|DRUG|Catgut|Periodontal and periimplant flaps closed with at least one suture with Chromic Gut Absorbable suture, natural, 4-0. (TAGUM®)
223385108|NCT04234308|DRUG|Polytetrafluoroethylene|Periodontal and periimplant flaps closed with at least one suture with expanded Polytetrafluoroethylene Non absorbable suture, synthetic, 4-0. (TAGUM®)
223385109|NCT04234308|DRUG|Polyamide|Periodontal and periimplant flaps closed with at least one suture with Nylon Non absorbable sutures, synthetic, 4-0. (TAGUM®)
223385110|NCT04688645|DRUG|Balanced crystalloid solution|Balanced crystalloid solution (Plasmalyte) given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
223385111|NCT04688645|DRUG|Normal saline|0.9% sodium chloride solution given as an initial bolus of 10 ml/kg body weight within the first 60 min after randomization, and then continued at a rate of 2 ml/kg body weight during the next 72 hours. If needed boluses may be repeated.
223385112|NCT01817296|PROCEDURE|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
223385113|NCT01287806|DRUG|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
223385114|NCT01287806|DRUG|blank group|standard treatment
223385115|NCT04040036|BEHAVIORAL|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
223385116|NCT03617094|DEVICE|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
223385117|NCT03617094|DEVICE|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
223385118|NCT02762929|DRUG|HTX-011A|HTX-011A (bupivacaine/meloxicam), via injection.
223385119|NCT02762929|BIOLOGICAL|Saline Placebo|Saline placebo via injection.
223385120|NCT02762929|DRUG|HTX-011B|HTX-011B (bupivacaine/meloxicam), via injection or instillation.
223385121|NCT02762929|DRUG|HTX-002|HTX-002, via injection.
223385122|NCT02762929|DRUG|Bupivacaine HCl|Bupivacaine HCI, via injection.
223385123|NCT02762929|DRUG|HTX-009|HTX-009, via injection.
223385124|NCT01278186|PROCEDURE|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
223385125|NCT01278186|PROCEDURE|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
223385126|NCT03248687|OTHER|Follow up|The intervention will be method of follow up.
223385127|NCT01834625|DIAGNOSTIC_TEST|PET scan|
223385128|NCT00422825|DRUG|imatinib|
223385129|NCT04812301|RADIATION|Egg-white sandwich|1 mCi of Tc-99m sodium phytate is added into the egg-white sandwich
224002538|NCT05805709|OTHER|Pharmacist|The pharmacist will complete the medication reconciliation and medication regimen review per the predetermined checklist, via telemedicine if agreeable to the patient. The goal of the patient/caregiver-pharmacist interaction is to cover the following: avoidance of nephrotoxins when possible and appropriate, appropriate dosing of renally cleared drugs, review for drug-drug interactions, monitoring appropriate use of chronic medications, medication adherence, monitor for adverse drug reactions, evaluation of non-prescription medication use, medication/disease education and social support.
224002539|NCT05805709|OTHER|Patient Education|Written information about kidney disease, nephrotoxins to be avoided and importance/need for follow up with a physician will be provided.
224002540|NCT05945823|DRUG|Futibatinib|TAS-120 20 mg tablets, oral; once daily
224002541|NCT05945823|DRUG|Pembrolizumab|400 mg once every 6-week-cycle, via IV infusion.
224002542|NCT05945823|DRUG|Cisplatin|80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy
224002543|NCT05945823|DRUG|5-FU|"4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.~2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy."
223385130|NCT04812301|RADIATION|Abbott Vital®|1 mCi of Tc-99m sodium phytate is added into the Abbott Vital®
223385131|NCT02771769|OTHER|blood draw|Participants will have a venous blood draw of \~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
223385132|NCT03505086|DIAGNOSTIC_TEST|Blood withdrawal|"* Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~* Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~* Urine sampling will be for a maximum of 5 times per admission.~* Urine can be sampled from a catheter when present, or collected regular."
223385133|NCT03505086|OTHER|Questionnaire for former bleeding events|Questionnaire to investigate a bleeding tendency before diagnosis.
223385134|NCT05855603|PROCEDURE|Cardioneuroablation|"Ganglionated plexi will be localized using an empirical anatomical approach and/or a fractionated electrogram-based strategy.~Point-by-point ablation will be performed using radiofrequency energy and an irrigated tip contact force sensing ablation catheter in a power control mode (35-50 W; AI, 350-500; LSI, 4.5-5.5). The right superior GP (RSGP), left superior GP (LSGP) and posterior left GP (PMLGP) will be targeted during CNA. Radiofrequency applications in other GPs will be left at the discretion of the operator.~At the end of the procedure, another EP study and atropine test will be performed. Clinical endpoints for completion of the CNA will be: 1) a HR increase \>20% if the CNA was performed under general anesthesia/deep sedation; 2) improved electrophysiological parameters; 3) significant reduction in atropine response (HR increase \<10% after atropine); and 4) in case of using extracardiac vagal stimulation, lack of response."
223385135|NCT05855603|DEVICE|Permanent pacemaker therapy|All patients in the pacemaker group will receive a dual-chamber pacemaker that has the ability to be programmed in the DDD-CLS algorithm mode (or failing this, a dual-chamber pacemaker with RDR algorithm).
223385136|NCT02574832|DRUG|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
223385137|NCT01248676|OTHER|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
223385138|NCT06033391|DEVICE|GGOC-AD (GG Obsessive-Compulsive Disorder - Adolescents)|"GGOC was originally designed to challenge maladaptive beliefs that underline OCD symptoms in adult population. It was adapted to adolescent population. It consists of statements that are presented to the user, and that can portray either negative (I can't trust myself) or positive beliefs (I have a lot of good characteristics). Users have to respond by either pulling these towards Accept or Reject."
223385139|NCT06033391|DEVICE|GGN-AD (GG Neutral - Adolescents)|"it was designed to have a comparison group. It consists of neutral statements such as Madrid is a Spanish city, that ought not to produce changes in the direction of our hypothesis. These have to be Accepted or Rejected based on their veracity."
223385140|NCT04159246|DEVICE|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~* Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~* The patient will be examined before and after finishing the treatment course"
223385141|NCT04159246|DRUG|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
223545521|NCT02820844|DRUG|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
224002544|NCT05945823|DRUG|Oxaliplatin|85 mg/m\^2 Q2W via IV infusion, as part of mFOLFIRINOX or mFOLFOX6 chemotherapy. 2400 mg/m\^2 Q2W via continuous IV infusion, as part of mFOLFIRINOX chemotherapy.
224002545|NCT05945823|DRUG|Leucovorin|400 mg/m\^2 Q2W as part of mFOLFIRINOX or mFOLFOX6 chemotherapy.
224002546|NCT05945823|DRUG|Levoleucovorin|200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
224002547|NCT05945823|DRUG|Irinotecan|150 mg/m\^2 Q2W as part of mFOLFIRINOX chemotherapy.
224002548|NCT02242097|DRUG|ibrutinib|Given PO
224002549|NCT02242097|OTHER|laboratory biomarker analysis|Correlative studies
224002550|NCT05714124|PROCEDURE|Embolization|Endovascular treatment for patients with primary and secondary liver tumors
224002551|NCT04688697|PROCEDURE|prepectoral implant-based reconstruction|In this group, patients receive breast reconstruction with prosthesis placed to anterior pectoralis major, synthetic mesh is used to enclose the prosthesis and place it to anterior pectoralis major.
224002552|NCT04688697|PROCEDURE|subpectoral implant-based reconstruction|In this group, patients receive breast reconstruction with placed to posterior pectoralis major, part of the mesh is placed under the pectoralis major during the operation, and the mesh is used to cover the suture of the prosthesis on the inferior plica, or to directly enclose the lower part of the implant.
224002553|NCT01562041|DRUG|Ranolazine 500 mg|Ranolazine 500 mg, oral tablet, b.i.d.
224002554|NCT00188942|DRUG|Fluoxetine+Olanzapine|
224002555|NCT00188942|DRUG|Olanzapine|
224002556|NCT00188942|PROCEDURE|Functional Magnetic Resonance Imaging|
224002557|NCT00002477|DRUG|carboplatin|
224002558|NCT00002477|DRUG|cisplatin|
224002559|NCT00002477|DRUG|cyclophosphamide|
224002560|NCT00002477|DRUG|doxorubicin hydrochloride|
224002561|NCT04296266|DRUG|Alda-341|Dietary supplement d-limonene orally administered as a drug.
224002562|NCT02793271|BEHAVIORAL|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
224002563|NCT02793271|BEHAVIORAL|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
224002564|NCT06065982|OTHER|Questionnaires|Health-related quality of life will be measured using the 12-item Short Form (SF-12) and EQ5D-5L questionnaires. The SF-12 is summarized into two component scores, the Physical Component Score (PCS) and Mental Composite Score (MCS).
224002565|NCT04651790|BIOLOGICAL|SARS-CoV-2 inactivated vaccine|The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
223385142|NCT04030208|DEVICE|Umbulizer|Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
223385143|NCT04030208|DEVICE|Traditional Mechanical Ventilator|A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
223385144|NCT05938114|OTHER|Bonalive|Bonalive® is a bioactive glass synthetic bone substitute material that has been shown to have a low substitution rate and antibacterial properties. It has been used successfully in the orthopaedics, craniofacial and ear nose and throat (ENT) specialities for the treatment of osteomyelitis, sinusitis and bony cyst cavities. There have also been a few maxillofacial surgery case reports on its usage in the jaws.
223385145|NCT05938114|OTHER|Bio-Oss®|Bio-Oss® is a bovine xenogeneic bone graft substitute that is widely used in regenerative dentistry. Bio-Oss® is very similar to human bone in its structure and chemical make-up. The material's porosity allows for vascularisation and new bone formation.
223385146|NCT01088958|DIETARY_SUPPLEMENT|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
223385147|NCT00599365|OTHER|Pharmacy care arm|"* The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~* You will need to give a complete list of medications to the pharmacist.~* You will need to describe how you take these medications.~* The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~* The pharmacist will give you a medication schedule, and other papers about your medications."
223385148|NCT02550301|OTHER|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
223385149|NCT00786214|OTHER|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
223385150|NCT00786214|OTHER|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
223385151|NCT03514095|OTHER|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
223385152|NCT03757858|DEVICE|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
223385153|NCT03757858|BIOLOGICAL|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
223385154|NCT03757858|DRUG|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
223385155|NCT03757858|DRUG|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
223385156|NCT00960219|DRUG|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
223385157|NCT00960219|DRUG|placebo|1# BID, oral, for 6 weeks
223385158|NCT05460702|DIAGNOSTIC_TEST|Soluble immune checkpoints|Blood collection from breast cancer patients with stage I-II
223385159|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
223385160|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
223385161|NCT01325402|OTHER|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
223385162|NCT03652337|DEVICE|BlephEx|Electronic lid margin debridement
223385163|NCT03652337|DEVICE|Manual debridement|Manual lid margin debridement
223385164|NCT06582537|PROCEDURE|Participants sample collection|A skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.
223385165|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
223385166|NCT01037452|DRUG|Lansoprazole|Tablet
223385167|NCT01037452|DRUG|Calcium carbonate/magnesium hydroxide|Tablet
223385168|NCT01037452|DRUG|Placebo|Tablet
223385169|NCT05423132|DRUG|Ropivacaine injection|The patients will receive 15 ml of Ropivacaine 0.375 % on each side.
223385170|NCT05423132|DRUG|Physiological serum injection|The patients will receive 15 ml of physiological serum (NaCl 0.9 %) on each side.
223385171|NCT04123405|DRUG|acetylcysteine|600 mg tablet
223385172|NCT04123405|DRUG|Placebo|Placebo to acetylcysteine
223385173|NCT06366763|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (CIVIQ-14 and VCSS scores )
223545522|NCT02820844|DRUG|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
223385174|NCT06582290|DIAGNOSTIC_TEST|Oxford Virtual Autism Assessment Tool (OVAAT)|The OVAAT is an online ASD diagnostic tool that has been designed to identify both the external/observable features of autism but also the internal/experiential features of autism.
223385175|NCT05027152|OTHER|Resistance training|The resistance training group will perform traditional resistance exercises with an intensity of 30%-60% of a voluntary repetition maximum and 1 to 2 sets of 10 repetitions each exercise. The repetitive task training group will carry out exercises involving upper and lower limbs.
223545523|NCT02820844|DRUG|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
223385176|NCT05027152|OTHER|Repetitive task training|The repetitive task training group will carry out exercises involving upper and lower limbs.
224002566|NCT03282825|DRUG|Decitabine|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
223385177|NCT01927900|DIETARY_SUPPLEMENT|HMO|
223385178|NCT01927900|DIETARY_SUPPLEMENT|Glucose|
223385179|NCT02172807|DRUG|Tiotropium low|Tiotropium 18 µg inhalation capsule
223385180|NCT02172807|DRUG|Tiotropium high|Tiotropium 36 µg inhalation capsule
223385181|NCT02172807|DRUG|Placebo MDI|Placebo metered dose inhaler (MDI)
223385182|NCT02172807|DRUG|Placebo inhalation capsule|
223385183|NCT02172807|DRUG|Oxitropium|Oxitropium MDI (100 µg/puff)
224002567|NCT03282825|DRUG|Paclitaxel|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
224002568|NCT06135740|DEVICE|Fitbit wearing, with notification for sleep, activity and nutrition based fitbit data|Notification on Nutrition, Sleep, and Physical Activity based on fitbit-based data, and Nutritional supplementation and Promotion of Exercise
224002569|NCT06135740|DEVICE|Routine care|Regular Care on sleep, activity and nutrition
224002570|NCT02184975|PROCEDURE|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
224002571|NCT02184975|PROCEDURE|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
224002572|NCT00064740|BEHAVIORAL|relaxation response|
224002573|NCT00770887|PROCEDURE|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
224002574|NCT02791997|OTHER|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
224002575|NCT02791997|OTHER|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
224002576|NCT04297631|DRUG|Tobramycin Powder|Everyone gets tobramycin powder.
224002577|NCT04297631|DEVICE|Vancomyscin|Everyone gets the vancomyscin powder.
224002578|NCT00322075|DRUG|insulin glargine|
224002579|NCT01694316|BEHAVIORAL|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
223385184|NCT02581605|DEVICE|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
223385185|NCT02713685|PROCEDURE|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
223385186|NCT02713685|PROCEDURE|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
223385187|NCT01026194|DRUG|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
223385188|NCT01026194|DRUG|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
223385189|NCT05675098|DRUG|Methylphenidate|This medication is a psychostimulant medication and is usually prescribed for individuals with Attention-Deficit/Hyperactivity Disorder to manage ADHD behavioral symptoms
223385190|NCT05675098|DRUG|Modafinil|This medication is a Central Nervous System stimulant and is usually used to treat neurological conditions, including Narcolepsy
223385191|NCT05675098|OTHER|Placebo|Participant will receive placebo tablets (Methylphenidate and Modafinil shape)
223385192|NCT05081050|OTHER|Only Follow-up|No intervention is planned.
223385193|NCT01750190|DRUG|Roxadustat|Oral tablets
223385194|NCT01750190|DRUG|Placebo|Oral tablets
224002580|NCT00002950|BIOLOGICAL|sargramostim|
224002581|NCT00002950|DRUG|topotecan hydrochloride|
224002582|NCT02702323|DRUG|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
224002583|NCT02702323|PROCEDURE|TACE|one times every 4-6 weeks.
224002584|NCT01575600|OTHER|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
224002585|NCT01598662|DEVICE|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
223385195|NCT01851252|DEVICE|Methacetin (with Breath testing device)|The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
223385196|NCT05387889|BEHAVIORAL|Mindfulness Meditation for Pulmonary Hypertension (MMPH)|Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.
224002586|NCT04193540|OTHER|ACE questionnaire|Regardless of the result of the ACE questionnaire, physician, resident and nurse in charge of the patient will be asked their clinical opinion on decision-making capacity of the patient, based on a 4 steps Lickert scale and blindly of ACE result.
224002587|NCT02574845|DRUG|Rosuvastatin|
224002588|NCT02574845|DRUG|Metformin HCl|
224002589|NCT02574845|DRUG|Furosemide|
224002590|NCT01164618|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
224002591|NCT01164618|OTHER|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
224002592|NCT01538641|DRUG|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
224002593|NCT00845962|DRUG|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
224002594|NCT00845962|DRUG|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
224002595|NCT02374723|DEVICE|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
224002596|NCT02374723|DEVICE|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
224002597|NCT01581502|OTHER|This is an observational study.|This is an observational, not intervention, study.
223385197|NCT00208442|DEVICE|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
223385198|NCT00208442|DEVICE|Enduron|Standard polyethylene liner in a modular acetabular component
223385199|NCT00634868|OTHER|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
223385200|NCT00634868|DEVICE|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
223545524|NCT02820844|OTHER|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
224002598|NCT04246021|DRUG|Ferric carboxymaltose (FCM)|intravenous iron formulation
223385201|NCT02276456|BEHAVIORAL|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
223385202|NCT05519748|BEHAVIORAL|Online psychoeducational program|The intervention group will receive an online psychoeducational program for 8 weeks. The psychoeducation package consists of 16 different sets of reading materials and post-session writing/reflection exercises, which will be delivered to the participants twice a week.
223385203|NCT05777993|DRUG|Mitapivat|Tablets
223385204|NCT00458744|DRUG|talotrexin|
223385205|NCT00458744|PROCEDURE|chemotherapy|
224002599|NCT01035359|PROCEDURE|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
224002600|NCT01035359|PROCEDURE|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
224002601|NCT00981877|DRUG|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
224002602|NCT00981877|DRUG|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
224002603|NCT00981877|DRUG|GC (placebo)|Placebo 1 gram twice daily for 5 days.
224002604|NCT00350038|DRUG|Irbesartan|
224002605|NCT00350038|DRUG|Ciprofibrate|
224002606|NCT04974762|PROCEDURE|Wound infiltration|Surgical wound infiltration by proceduralist
224002607|NCT04974762|PROCEDURE|Truncal blocks|Truncal blocks provided by anesthesiology team for device placement
224002608|NCT06317467|OTHER|Blood sampling|Four blood samples will be collected, in conjunction with the collection of samples already programmed for assistance during pregnancy: blood sampling for the B-test (within the 13th week of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo; blood sampling for toxoplasmosis or blood sugar level, upon execution of the morphological ultrasound scanning (around the 20th and 34th weeks of gestation), at the blood test centre of the Institute for Maternal and Child Health, IRCCS Burlo Garofolo, as well. Finally, 40 days after delivery, during routine gynaecological control after the puerperium.
224002609|NCT06317467|OTHER|Blood sampling|For patient of group 2, the blood sample will be collected at the time of the diagnosis of PE and 40-50 days after delivery in Obstetrics and Gynaecology Department of the institute or in Department of Biomedical Sciences, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
224002610|NCT03689777|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
224002611|NCT03689777|PROCEDURE|gastric bypass|gastric bypass
224002612|NCT04412928|PROCEDURE|mid-urethral sling procedure|mid-urethral sling procedure
224002613|NCT01093677|DRUG|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
223385206|NCT03327844|DRUG|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
223385207|NCT03327844|DRUG|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
223385208|NCT01769248|DEVICE|Fine needle aspiration|Fine needle aspiration
223385209|NCT01769248|DEVICE|Fine needle biopsy|FNB
223385210|NCT02303457|PROCEDURE|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
223385211|NCT02303457|PROCEDURE|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
223385212|NCT02368964|DRUG|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
223385213|NCT02368964|DRUG|high dose hCG 500 mcg|Treatment for triggering
223385214|NCT03044028|DEVICE|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
223385215|NCT06372717|DRUG|APL-4098|APL-4098 is administered orally in 28-day cycles
223385216|NCT06372717|DRUG|Azacitidine and APL-4098|Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
223385217|NCT06461026|BIOLOGICAL|L9LS|Administered intramuscularly one time.
223385218|NCT06461026|OTHER|Normal Saline|Administered intramuscularly one time.
223385219|NCT04149821|DRUG|Umbralisib|"* Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~* Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)"
223385220|NCT04149821|DRUG|Ublituximab|-Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6
223385221|NCT04383262|DRUG|Fosamprenavir Calcium|A repurposing approach, prospective, placebo-controlled clinical trial of FOS-SA (used at 1,400 mg fosamprenavir calcium, twice daily) for 12 weeks in medically refractory patients with clinically diagnosed moderate/severe LPR (RSI \> 13, RFS \> 7 and MII-pH confirmed laryngeal reflux event\[s\]).
223385222|NCT04383262|OTHER|Placebo|Non-active placebo pill formulation
223385223|NCT06838689|OTHER|Comparison of two standard of care regimens|Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involvement (PPCI) in Qualitative Research: PAQ and CAB (Community Advisory Boards)
223385224|NCT05695001|DEVICE|Efferon CT|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross-linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886.
223385225|NCT01472692|DRUG|Febuxostat|80mg PO daily for 8 weeks
224295713|NCT05253924|DIAGNOSTIC_TEST|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1, Piezo1, Piezo2, TRPV1 andTRPM8) will be investigated. Saliva sample will be collected for PT and FT. Genomic DNA will be extracted from aliquots of 0. 4 ml of each saliva sample with the Oragene OG575 (DNA Genotek) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
223385226|NCT03934541|BIOLOGICAL|MPER-656 Liposome Vaccine|Administered by intramuscular injection
223545525|NCT02820844|OTHER|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
224002614|NCT01093677|DRUG|Placebo|Oral solution placebo BID for 14 days.
223385227|NCT03934541|BIOLOGICAL|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
223385228|NCT06236425|BIOLOGICAL|TBio-4101|TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells. A T-cell is a type of lymphocyte, or white blood cell.
223385229|NCT06236425|DRUG|Pembrolizumab|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
223385230|NCT06236425|DRUG|Platinum based chemotherapy|Will be administered as per standard of care. Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
223385231|NCT06236425|DRUG|Cyclophosphamide|Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
223385232|NCT06236425|DRUG|Fludarabine|Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
223385233|NCT06236425|DRUG|Aldesleukin|After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
223385234|NCT05515536|DRUG|Vatiquinone|Vatiquinone will be administered per dose and schedule specified in the arm.
223385235|NCT01926405|PROCEDURE|saliva collection|collection of saliva
224002615|NCT04941053|DIAGNOSTIC_TEST|laboratory test|seroprevalnce
224002616|NCT03435692|PROCEDURE|Lumbar Plexus Catheter|lumbar plexus catheter placed intraoperatively for perioperative pain control
224002617|NCT03435692|PROCEDURE|Lumbar Epidural Catheter|lumbar epidural catheter placed intraoperatively for perioperative pain control
224002618|NCT03435692|PROCEDURE|Patient Controlled Analgesia|Patient Controlled Analgesia (PCA) was started post operatively for perioperative pain control
224002619|NCT03435692|DRUG|Fentanyl|Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and occurring more than 30 minutes after the block if applicable.
224002620|NCT03435692|DRUG|Morphine|In the operating room patients, intravenous morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and after fentanyl had been administered. Intravenous Morphine was also administered in the operating room if the patient was randomized to the Patient Controlled Analgesia (PCA) arm of the study. Post operatively intravenous Morphine was administered as needed for severe pain.
224002621|NCT03435692|DRUG|Lorazepam|Intravenous Lorazepam was administered as needed for muscle spasm post operatively.
224002622|NCT03435692|DRUG|Ondansetron|Intravenous Ondansetron was administered as needed for nausea and vomiting post operatively.
224002623|NCT03435692|DRUG|Diphenhydramine|Intravenous Diphenhydramine was administered as needed for itching postoperatively.
224002624|NCT03435692|DRUG|Acetaminophen|Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
224002625|NCT03435692|DRUG|Oxycodone|Oral Oxycodone was administered as needed for breakthrough pain post operatively.
224002626|NCT03435692|DRUG|Ropivacaine|Intravenous Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
224002627|NCT02687438|DEVICE|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
224002628|NCT02687438|OTHER|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
224002629|NCT03999801|GENETIC|RGX-314|AAV8 vector containing a transgene for anti-VEGF Fab
224002630|NCT04091061|DRUG|PF-06865571 100 mg|PF-06865571 in 100 mg oral tablet will be administered on Day 1
224002631|NCT00031668|RADIATION|radiation therapy|
224002632|NCT01620918|PROCEDURE|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
224002633|NCT01620918|PROCEDURE|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
224002634|NCT00969826|DRUG|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
224002635|NCT05811962|OTHER|No intervention|No intervention, only comparison
224002636|NCT04885985|DEVICE|DEB catheter|"Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)"
224002637|NCT06010927|DRUG|ketamine/midazolam|premedication
224002638|NCT06010927|DRUG|Ketofol|Pre-extubation
224002639|NCT05905627|BEHAVIORAL|exercise|intervention group
224002640|NCT00821587|DRUG|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
224002641|NCT00821587|DRUG|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
224002642|NCT00596882|OTHER|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
224002643|NCT00596882|OTHER|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
224124352|NCT01735747|RADIATION|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
224124353|NCT01735747|DRUG|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
223385236|NCT03992365|DRUG|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
223385237|NCT03992365|DRUG|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
223385238|NCT05889429|DIAGNOSTIC_TEST|MRI scans|The MRI protocol will include standard anatomical, functional, and diffusion imaging, and spectroscopy sequences.
223385239|NCT05889429|BEHAVIORAL|clinical assessments|Several clinical assessments will be performed to evaluate the recovery of motor functions. Initially and for screening, the cognitive ability will be assessed using the Montreal Cognitive Assessment (MoCA), and visuospatial neglect will be assessed using the Star Cancellation Test (SCT). eligible participants that meet all inclusion criteria will undergo a series of clinical function tests during each test session (t1-t4) to assess clinical outcomes.
223385240|NCT00349219|DRUG|erlotinib|erlotinib 150 mg taken orally daily until disease progression
224002644|NCT01693900|PROCEDURE|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
224124354|NCT01735747|DRUG|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
224124355|NCT01735747|DRUG|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
223385241|NCT00349219|DRUG|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
223385242|NCT00349219|DRUG|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
223385243|NCT00349219|DRUG|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
223545526|NCT02820844|OTHER|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
223545527|NCT02820844|OTHER|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
223545528|NCT04231097|OTHER|MBCT intervention for ACS patients|The MBCT intervention will involve 8 virtually-delivered MBCT sessions (approximately 1.5 hours each), during which participants will be taught how to use evidence-based mindfulness skills to regulate distress and choose healthy behaviors, as well as learn about cardiac health. Participants involved in the intervention will be asked to complete a brief survey following each session. Within one week before and after the intervention and 3-months post-intervention participants will be asked to complete a series of questionnaires and provide self-collected blood samples. Upon completion of the intervention participants will complete an audio-or video recorded exit interview (approximately 30 minutes).
223545529|NCT02266147|DRUG|SD-101|
223545530|NCT02266147|RADIATION|Radiation therapy|
223545531|NCT04676893|DRUG|D418 Tab.|1T
223545532|NCT04676893|DRUG|CKD-388 Tab.|1T
223545533|NCT04298294|OTHER|injectable platelet rich fibrin|biologic activator
223545534|NCT02177630|OTHER|Endomyocardial Biopsy|
223545535|NCT04363242|BIOLOGICAL|SYN125|Administered by IV infusion
223545536|NCT04363242|BIOLOGICAL|SYN004|Administered by IV infusion
223545537|NCT00267306|DRUG|Visilizumab|
223545538|NCT01916486|BEHAVIORAL|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
223545539|NCT01916486|BEHAVIORAL|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
223545540|NCT01916486|BEHAVIORAL|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
223545541|NCT03133585|DEVICE|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
223545542|NCT01456130|DRUG|Alogliptin|Alogliptin tablets
223545543|NCT01456130|DRUG|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
223545544|NCT06260605|OTHER|Education|Nursing students learning about diabetes complications
223545545|NCT00507585|DRUG|Fluorouracil|300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
223545546|NCT00507585|DRUG|Avastin|10 mg/m\^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
224124356|NCT04153006|DEVICE|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
224124357|NCT06141213|DIAGNOSTIC_TEST|Ultrasound screening|Ultrasound screening for fetal membrane thickness at 18-24 weeks of pregnancy.
223385244|NCT00349219|DRUG|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
223385245|NCT00349219|DRUG|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
223545547|NCT00507585|DRUG|Leucovorin|200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
223545548|NCT00507585|DRUG|Oxaliplatin|60 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
223545549|NCT00871663|DRUG|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
223545550|NCT03931499|DIAGNOSTIC_TEST|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
224124358|NCT03165136|DRUG|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
224124359|NCT03165136|DRUG|Placebo|placebo of hydroxychloroquine
224124360|NCT02004912|OTHER|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
224002645|NCT01693900|PROCEDURE|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
224002646|NCT03524196|OTHER|Manage Your Life Online (MYLO)|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
224002647|NCT01597609|DRUG|sibutramine|10 mg, taken orally once per day for 12 weeks
224002648|NCT01597609|OTHER|sibutramine placebo|taken orally once per day for 12 weeks
224002649|NCT05590442|OTHER|Tests|Cognitive assessments and olfactory tests
224002650|NCT04694170|OTHER|additional therapy|Using conventional physiotherapy together with additional yoga exercising and regimen restriction acc to TCM.
224002651|NCT04694170|OTHER|conventional physiotherapy|Using conventional physiotherapy only.
224002652|NCT04199559|DRUG|Autologous dendritic cells pulsed with antigen|peptide(WT1-H/K-HELP, Survivin-H/K-HELP,MAGE-A4-H ⁄ K-HELP and MUC1-22) . Each dose contains of 10 million activated autologous DCs. Route of Administration: Intradermal
224002653|NCT06295198|OTHER|Single lep drop jump test|All evaluations will be repeated before and after the treatment.
224002654|NCT02958046|DRUG|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
224002655|NCT00693940|BEHAVIORAL|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
224002656|NCT00693940|OTHER|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
224002657|NCT06629181|OTHER|Education|"The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training"
224002658|NCT02781090|BEHAVIORAL|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
224002659|NCT02781090|BEHAVIORAL|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
224002660|NCT02781090|DRUG|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
224002661|NCT04712136|OTHER|MRI|MRI cardiac
223545551|NCT02930707|DRUG|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
223545552|NCT02930707|DRUG|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
224002662|NCT00643617|RADIATION|CyberKnife Stereotactic Radiosurgery - Low Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate
224002663|NCT00643617|RADIATION|CyberKnife Stereotactic Radiosurgery - Intermediate Risk|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally
224002664|NCT05027035|OTHER|"surgical plication or nocturnal non-invasive ventilation"|10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.
224002665|NCT03045965|PROCEDURE|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
224002666|NCT03871582|OTHER|No intervention|Cross-sectional
224002667|NCT00000689|DRUG|Bleomycin sulfate|
224002668|NCT00000689|DRUG|Vincristine sulfate|
224002669|NCT00000689|DRUG|Doxorubicin hydrochloride|
224002670|NCT00000689|DRUG|Cyclophosphamide|
224002671|NCT00000689|DRUG|Methotrexate|
224002672|NCT00000689|DRUG|Cytarabine|
224002673|NCT00000689|DRUG|Leucovorin calcium|
224002674|NCT00000689|DRUG|Sargramostim|
224002675|NCT00000689|DRUG|Dexamethasone|
224124361|NCT05485272|OTHER|Silver Diamine Fluoride combined with Potassium Iodide.|Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.
224124362|NCT05485272|OTHER|Silver Diamine Fluoride.|A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.
224124363|NCT05485272|OTHER|High-Viscosity Glass Ionomer.|A Glass Hybrid material.
224124364|NCT03034304|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
224124365|NCT03034304|DRUG|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
224124366|NCT03034304|DRUG|PD1 antibody|200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.
224124367|NCT03034304|DRUG|Adriamycin|60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles
224124368|NCT03034304|DRUG|Gemcitabine|1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle
223385246|NCT06972069|PROCEDURE|Combined Kidney/Bone Marrow Transplant|The conditioning regimen to be used in this protocol consists of an ordered series of procedures and treatments including thymic irradiation, low-dose cyclophosphamide, antibody administration (Siplizumab, rituximab and tegoprubart), and bone marrow cell infusion.
223385247|NCT06972069|PROCEDURE|Donation of Kidney / Bone Marrow|The donor will undergo nephrectomy and under general anesthesia. Donors will undergo bone marrow harvested under general anesthesia. Sufficient marrow will be obtained to provide at least 2 x 108 nucleated cells per kilogram weight of the recipient.
223385248|NCT06972069|DRUG|Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart)|Recipients will receive a conditioning regimen that includes rituximab on study day -6 and -2, Siplizumab (0.6mg/kg) on day -6, -1, 0 and +1, cyclophosphamide (CP, 22.5mg/kg) on days -5 and -4. Tegoprubart (Fc-modified anti-CD154 mAB, Eledon Pharm) 20mg/kg will be administered on days 0, 2, 5, 12 and 19).
224002676|NCT03684278|DRUG|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
224002677|NCT03684278|DRUG|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
224002678|NCT03684278|OTHER|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
223385249|NCT02845648|DRUG|anticholinergic|Initial anticholinergic therapy to all patients
223385250|NCT06685029|DEVICE|Clear aligner treatment|Clear aligners are appliances that allow the teeth to be gradually moved to the desired final position, as planned in the computer program, in a way that each aligner will perform a part of the total movement with its use.
223385251|NCT06685029|DEVICE|Fixed Orthodontic Appliance Treatment|Fixed orthodontic treatment is a type of orthodontic treatment performed by applying brackets and wires to the teeth and is considered the gold standard for orthodontic treatments.
223385252|NCT02673775|OTHER|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
223385253|NCT02673775|OTHER|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
223385254|NCT04660994|OTHER|Educational game|"The Yapouni educational game is based on a hot air balloon that will fly according to the number of hours the child has slept with his/her CPAP / NIV. Thus, the longer the child sleeps with his/her CPAP / NIV, the farther and higher his/her hot air balloon will fly in the sky. The game includes wild cards and rewards that are worked out with the child and his/her parents for an optimal individualized adaptation.~The game is explained at Necker Hospital during the therapy education for CPAP/NIV and used at home for 1 month."
223385255|NCT03740347|BEHAVIORAL|Questionnaires|"Response to questionnaires evaluating chronic pain and its repercussion :~* anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~* depression questionnaire (Children's Depression Inventory score),~* sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~* quality of life questionnaire (Pediatric Quality of Life inventory score)."
223545553|NCT03001661|DEVICE|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
223545554|NCT03001661|DRUG|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
224002679|NCT05817552|DIAGNOSTIC_TEST|Geomagic Control X|3D Surface matching and compare
224002680|NCT02472990|OTHER|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
224002681|NCT02162797|DIETARY_SUPPLEMENT|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
223385256|NCT04682145|DRUG|Turoctocog alfa pegol|Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
223385257|NCT04850755|DRUG|Selinexor in combination with nivolumab and ipilimumab|Patients will commence at dose level 1. One cycle is 42 days (6 weeks) for all three agents. At dose level 1, selinexor will be dosedorally weekly, and nivolumab at 2 weekly + ipilimumab 1mg/kg 6 weekly. Patients can have dosing interruptions or reductions of any drug independently of one another, depending on the drug causing the toxicity
223385258|NCT05108298|OTHER|Questionnaires|Patients will complete questionnaires online through EASEE-PRO. There will be a set of fixed questionnaires at each timepoint for both arms. The patients will be asked to rank the 15 types of PROs according to their importance. The participants randomized to the choice arm will be asked to choose 5 of the 15 PROs to complete. The participants randomized to the fixed arm will be given a fixed 5 of the 15 PROs at each time point.
223385259|NCT02441686|DRUG|Bortezomib|
223385260|NCT02441686|DRUG|Lenalidomide|
223385261|NCT02441686|DRUG|Dexamethasone|
223385262|NCT02441686|PROCEDURE|Stem Cell Mobilization|
223385263|NCT02441686|PROCEDURE|Autologous Stem Cell Transplant|
223545555|NCT00017069|DRUG|arsenic trioxide|
223545556|NCT00017069|DRUG|dexamethasone|
223545557|NCT00382265|DRUG|tamsulosin|tamsulosin 0.4mg po qd for 28 days
223545558|NCT00382265|OTHER|Placebo|placebo po qd for 28 days
223545559|NCT05480735|BEHAVIORAL|Prehabilitation|Multimodal prehabilitation program
223545560|NCT01896687|DEVICE|Scrambler|Electrotherapy
223385264|NCT02501733|DEVICE|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
223385265|NCT04875702|DRUG|Allopurinol|"For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial."
223385266|NCT04875702|DRUG|Naproxen 250 MG|Naproxen 250 mg p.o. twice daily
223385267|NCT04875702|DRUG|Colchicine 0.6 mg|Colchicine 0.6 mg p.o. once daily
223385268|NCT04875702|DRUG|Colchicine 1.2 mg|Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
223385269|NCT04875702|DRUG|Naproxen 500 Mg|dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
223385270|NCT04875702|DRUG|Prednisone 40 mg|For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
223385271|NCT03005743|RADIATION|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines \[Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A\]
223385272|NCT03005743|RADIATION|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder \& rectum ICRU point dose constraints
223385273|NCT01326468|DRUG|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
223385274|NCT01326468|DRUG|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
223385275|NCT01326468|DRUG|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
224002682|NCT02162797|DIETARY_SUPPLEMENT|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
224002683|NCT02280369|DEVICE|Automated abdominal binder|Inflatable abdominal binder
224002684|NCT01145898|DRUG|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
224124369|NCT03034304|DRUG|Cisplatin|70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;
224124370|NCT03034304|DRUG|Carboplatin|5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
224124371|NCT05951738|PROCEDURE|Blood and saliva collection|Blood and saliva samples from pregnant women; saliva samples from babies.
223385276|NCT01326468|DEVICE|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
223425570|NCT04514640|BEHAVIORAL|The Calm app|"All participants (n=100) will be asked to download the Calm app to their phone. Participants will then receive an email containing 4-weeks of free access to Calm. All participants be asked to use Calm once per day for at least 10 minutes based on their group assignment (i.e., general meditation during daytime, sleep meditation before bed, or sleep stories before bed). Participants will be asked to turn on the take a moment feature in the Oura app in order for the Oura ring to collect neurophysiological measures before, during, and after meditations. Additionally, participants will be asked to complete sleep diaries every day throughout the intervention."
223425571|NCT02395640|DRUG|Epirubicin|50mg/m2 ivgtt d1
224002685|NCT00023894|DRUG|alvocidib|
224002686|NCT06503302|DIAGNOSTIC_TEST|ultrasound Doppler function detection|Doppler function detection is an ultrasound technique that measures and visualizes blood flow within an object, such as vessels and soft tissue. It can be used to check for the inflammation status of calcifications by detecting blood flow around the calcified areas before performing an ultrasound-guided injection.
224002687|NCT03506659|DEVICE|SUDO-SCAN Device|Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
224124372|NCT05951738|BEHAVIORAL|Psychometric scales|A battery of psychometric scales and questionnaires.
224124373|NCT05951738|OTHER|Smartphone app|A smartphone application has been developed in the context of the study as a potential preventive and screening strategy.
224124374|NCT05279833|DRUG|dronedarone|Pharmaceutical form is tablet and route of administration is oral
224124375|NCT05279833|DRUG|sotalol|Pharmaceutical form is tablet and route of administration is oral
224124376|NCT00913978|DEVICE|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
224002688|NCT06803745|RADIATION|200 cGy or 400 cGy total body irradiation (TBI)|Either 200 or 400cGy will be given as part of reduced-intensity conditioning prior to consolidative allogeneic bone marrow transplant (alloBMT)
223385277|NCT06372119|PROCEDURE|Letrozole-stimulated cycle strategy|"Letrozole (Femara® 2.5 milligrams, Novartis, Switzerland or Lezra® 2.5 milligrams, Actavis, Rumani) 5 milligrams/day for 5 days, starting on the second to fourth day of the menstrual cycle.~Post-letrozole, ultrasound checks follicle growth. If ≥18mm, Ovitrelle® 250 mcg (Merck, Kenilworth, New Jersey, USA) induces ovulation.~Luteal phase support with vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day starting two days post-hCG.~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: no follicle development on day 21 from the day of starting letrozole, spontaneous ovulation, letrozole intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
223385278|NCT06372119|PROCEDURE|Artificial cycle strategy|"Oral estradiol valerate (Progynova® 2 milligrams, Bayer Pharma AG, Germany or Valiera® 2 milligrams, Laboratories Recalcine, Chile) 6 milligrams/day for 10 days, starting on the second to fourth day of the menstrual cycle.~Post-estradiol, ultrasound checks endometrial thickness. If ≥7mm, start vaginal micronized progesterone (Cyclogest® 400 milligrams, Actavis, UK or Utrogestan® 200 milligrams, Besins, Belgium) 800 milligrams/day. If \<7mm, increase the dose of oral estradiol valerate to 8 milligrams/day (5-6 days) and 12 milligrams/day (5-6 days).~Embryo transfer, 5 days post-progesterone. Ultrasounds use Samsung HS-30, vaginal probe, and ≥7.5MHz frequency. Hormonal support until the 12th gestational week with vaginal micronized progesterone 800 milligrams/day.~Cycle cancellation criteria: endometrial thickness \<7mm on day 21 of using estradiol, spontaneous ovulation, oral estradiol valerate intolerance, fluid retention. Cycle cancellation will be noted as a study's outcome."
223385279|NCT05565638|BEHAVIORAL|Prolonged Fasting Intervention|promote a 14-hour fast during the nighttime hours
223385280|NCT05565638|BEHAVIORAL|EDUCATION CONTROL|introductory session with a health coach and educational information will be provided. Participants will also receive one email and one text message per week with tips on healthy living
223385281|NCT06488911|DRUG|FDC tablet (OCA 5 mg + BZF 400 mg SR)|Participants will be administered with FDC tablets once daily.
223385282|NCT06211036|DRUG|Tarlatamab|Intravenous (IV) infusion
223385283|NCT06211036|DRUG|Durvalumab|IV infusion
223385284|NCT06307613|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
223385285|NCT06307613|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
223385286|NCT06574984|DRUG|Turoctocog alfa|Turoctocog alfa was administered intravenously.
223385287|NCT01137994|DRUG|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
223385288|NCT01137994|BIOLOGICAL|Trastuzumab|monoclonal antibody directed to HER2 receptor
223385289|NCT01137994|DRUG|Docetaxel|Taxane chemotherapy
224002689|NCT01712061|DRUG|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
224002690|NCT01712061|DRUG|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
224002691|NCT05994469|BEHAVIORAL|Copenhagen Adduction Exercise|The CAE is performed by side-lying on the floor with the dominant lower limb supported in the air by a teammate, the hip is adducted until the body forms a straight line from the ankles to the shoulders (concentric phase), then the player is instructed to lower the body slowly (eccentric phase) until reaching the floor to start the next repetition.
224002692|NCT06202963|DRUG|Triamcinolone Acetonide|"1. group will receive ultrasound-guided hydrodilatation~2. group will receive ultarsound-guided coracohumeral hydrorelease in addition to the ultrasound-guided hydrodilaltation of shoulder"
224002693|NCT04547647|RADIATION|X- Ray|X-Ray with A-P and lateral view of the whole spine.
224002694|NCT05092074|DRUG|Vosevi 400/100/100 Oral Tablet|Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX, Vosevi) 400/100/100 oral tablet: 1 table per os per day for 12 weeks
223385290|NCT01137994|DRUG|Paclitaxel|Taxane chemotherapy
223385291|NCT01137994|DRUG|Vinorelbine|Vinka alkaloid
223385292|NCT05272423|DIAGNOSTIC_TEST|FoundationOne® Liquid CDx|The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
223545561|NCT04377503|DRUG|Tocilizumab 180 MG/ML|Tocilizumab 8 mg/kg diluted in 100 ml of saline administered in 60 minutes. The dose will be repeated after 12 hours.
223545562|NCT04377503|DRUG|Methylprednisolone Sodium Succinate|Patients will receive methylprednisolone at a dose of 1.5 mg / kg / day divided into 2 daily doses for 7 days. Then they will receive 1 mg / kg / day for another 7 days. Finally 0.5 mg / kg / day until 21 days of use
223545563|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
223545564|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
223545565|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
223545566|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
223545567|NCT00413660|DRUG|CP-690,550|4 blinded tablets administered BID
223545568|NCT00413660|DRUG|CP-690,550|Oral tablets
223545569|NCT00413660|OTHER|placebo|Placebo
223545570|NCT05292690|DEVICE|Powered Wheelchair Obstacle Alerting System|Evaluation of an Obstacle Alerting System
223545571|NCT05439551|DIAGNOSTIC_TEST|MeMed BV®|Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
223545572|NCT02229786|DRUG|Buscopan® plus|
223545573|NCT02229786|DRUG|Buscopan®|
224002695|NCT04470947|DIAGNOSTIC_TEST|Next generation functional drug screening|High-throughput image based in-vitro drug screening on primary patient tumor cells
224002696|NCT04470947|DIAGNOSTIC_TEST|Comprehensive genomic profiling|Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
224124377|NCT00913978|DEVICE|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
224124378|NCT03446534|DRUG|Amoxicillin|Imacillin mixture
223385293|NCT03735004|DEVICE|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
224002697|NCT02108769|BEHAVIORAL|Yogic Breathing|"1. Chanting Om~   1. Sharp deep inhalation through nostrils~  2. Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~   Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~2. Yogic Breathing:~   1. Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~  2. Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~  3. Hold breath in this position for about 16 seconds.~  4. Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~  5. Go to step a)."
224002698|NCT02108769|BEHAVIORAL|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
224002699|NCT00345098|DRUG|SR58611A|
224002700|NCT00879775|DRUG|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
223385294|NCT03151304|DRUG|Pracinostat|45 mg capsule
224002701|NCT00879775|DRUG|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
224002702|NCT04791098|OTHER|Specific infectious diseases consultation|"Specific infectious diseases consultation at Clermont Ferrand Hospital with a specialist doctor :~* Update vaccinations~* Advice to travelers~* Diagnostic and treatment of latent tuberculosis infection"
224002703|NCT02771379|DRUG|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
224002704|NCT03680352|DRUG|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
224124379|NCT03446534|DRUG|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
224002705|NCT02461004|DRUG|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
224002706|NCT02461004|DRUG|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
224002707|NCT02282553|DEVICE|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
224002708|NCT02282553|DEVICE|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
224002709|NCT00905320|PROCEDURE|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
224002710|NCT00905320|PROCEDURE|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
224002711|NCT03026959|BEHAVIORAL|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, \& Bédard, (2015).
224002712|NCT03117764|DEVICE|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
224124380|NCT06475989|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224124381|NCT06475989|DRUG|Cabozantinib|Given PO
224124382|NCT06475989|PROCEDURE|Computed Tomography|Undergo CT scan
224124383|NCT06475989|DRUG|Dabrafenib|Given PO
224124384|NCT06475989|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224124385|NCT06475989|OTHER|Questionnaire Administration|Ancillary study
224124386|NCT06475989|DRUG|Trametinib|Given PO
224124387|NCT02869854|BEHAVIORAL|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
223385295|NCT03151304|DRUG|Azacitidine|SC or IV injection
223385296|NCT06115083|OTHER|Pelvic floor re-education using bio-feedback and home training|Pelvic floor re-education using bio-feedback and home training
223385297|NCT03694899|BEHAVIORAL|phone contact|patients will be called prior to their outpatient appointment
223385298|NCT04529837|OTHER|Gauze|placement of gauze
223385299|NCT04529837|OTHER|No gauze|no gauze
223385300|NCT02290457|BEHAVIORAL|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
223425572|NCT02395640|DRUG|Oxaliplatin|
224124388|NCT02869854|BEHAVIORAL|PAP|Physical Activity on Prescription, after 3 months a new prescription
224124389|NCT03610256|PROCEDURE|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI \< 50
224002713|NCT03117764|BEHAVIORAL|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
224002714|NCT03117764|DEVICE|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
224002715|NCT05946603|DRUG|Administration of IS-002|Intravenous administration of IS-002 approximately 24 hours prior to surgery
223545574|NCT02229786|DRUG|Paracetamol|
223545575|NCT02229786|DRUG|Placebo|
224002716|NCT05946603|DEVICE|Firefly fluorescent imaging|Near-infrared fluorescence imaging using Firefly technology will allow fluorescence imaging of IS-002
224002717|NCT05946603|PROCEDURE|robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection|Subject will undergo robotic-assisted laparoscopic prostatectomy with pelvic lymph node dissection
224002718|NCT05342805|PROCEDURE|Narrow gastric tube|At the lesser curvature, the resection began at the point that was 5-cm from the pyloric, toward to the greater curvature, then the stomach was divided along 3 cm from the greater curvature using linear stapler
224002719|NCT02551653|DRUG|[11C]-GSK2256098 500 MBq|\[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
224002720|NCT00000219|DRUG|Buprenorphine|
224124390|NCT03610256|PROCEDURE|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects"
224124391|NCT06368830|DIAGNOSTIC_TEST|3-ounce water swallow test|Bedside water swallow dysphagia screen where vocal quality of the participant is assessed before and after swallowing 3 ounces of water
224124392|NCT06368830|DIAGNOSTIC_TEST|Kayser-Jones Brief Oral Health Status Examination (BOHSE)|Scored assessment of the lymph nodes, lips, tongue, tissue inside of cheek, floor and roof of mouth, gums between teeth and/or under artificial teeth, saliva, condition of natural/artificial teeth, chewing position of teeth, and oral cleanliness
224124393|NCT06368830|DIAGNOSTIC_TEST|Tongue pressure|"Maximum isometric lingual pressure at the front and back of tongue will be measured by placing an air-filled pressure bulb on the surface of the oral tongue and having participants press the bulb as hard as possible against the hard palate"
224124394|NCT06368830|DIAGNOSTIC_TEST|Test of Masticating and Swallowing Solids (TOMASS)|Measurement of bites, masticatory cycles, swallows, and time taken to consume a cracker
224124395|NCT06368830|DIAGNOSTIC_TEST|Respiratory function tests|Participants will take a maximum inhalation and forcefully exhale into a spirometer to measure maximum expiratory pressure (MEP), fully exhale their air and take a maximal inhalation into the spirometer to measure maximum inspiratory pressure (MIP), and produce a single strong cough into to spirometer to measure peak expiratory flow (PEF) and forced expiratory volume (FEV1)
224124396|NCT06246058|BEHAVIORAL|Partner support|The intervention group's survey vignette will include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
224124397|NCT06246058|BEHAVIORAL|Formal recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~FORMAL dress code of the recruiter is the intervention in this case, defined as clinical attire alluding to some clinical authority."
224124398|NCT06246058|BEHAVIORAL|Without Partner support|The intervention group's survey vignette will NOT include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.
224124399|NCT06246058|BEHAVIORAL|Casual recruiter attire|"The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~CASUAL dress code of the recruiter is the intervention in this case."
224124400|NCT05806385|DEVICE|Cryoablation|Tumor ablation before neoadjuvant chemotherapy
224124401|NCT05806385|COMBINATION_PRODUCT|Cryoablation combined with PD1 Inhibitor|Combination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
224124402|NCT00235846|PROCEDURE|vein harvest|Conventional open vein harvest or endoscopic vein harvest
224124403|NCT05411198|DEVICE|XEN45 (Glaucoma Gel Stent)|Ab externo implant
223385301|NCT06325605|DRUG|Bifidobacterium|3 capsules, 3 times a day, for 8 consecutive weeks
223385302|NCT06325605|DEVICE|High-frequency rTMS|"In the rTMS treatment, the transcranial magnetic stimulation device with an 8-shaped coil with a diameter of 70mm was placed on the dorsolateral area of the left prefrontal lobe of the patient. The motor threshold was set to 90%. A 10-Hz pulse sequence was applied for 4 secs followed by a 20 secs interval. 10 pulses per train were used, and the total stimulation time was 30mins per day, 4 times a week, for 8 consecutive weeks."
223385303|NCT06325605|DRUG|Escitalopram Oxalate|Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
223385304|NCT06215235|OTHER|Bright light therapy|for 2 weeks the patient will take place for a 10.000lux lamp for 20-30 minutes.
223385305|NCT04805515|BEHAVIORAL|Nicotine Corrective Messages|Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.
223385306|NCT05676515|OTHER|culture media|spliting of biological material and use of three culture media
224002721|NCT03161613|OTHER|Non-Interventional|Non-Interventional
224002722|NCT02683785|DRUG|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
223385307|NCT03491657|BEHAVIORAL|virtual reality distraction (Yes VR)|
223730027|NCT05786885|PROCEDURE|Microneedling will be done with application of topical vitamin C paste for depigmentation|"A Dermapen device will be used to microneedle the gingival tissue (model M8) with 24 microneedles arranged in rows, which is adjusted with 1.5 mm depth at the 6th mode speed of 700 cycles/min.~It will be used in intermittent motion on the affected area for 30-40 seconds / tooth.~Once bleeding points are observed on all areas of the pigmented gingiva, it will be irrigated using saline solution and dried using sterile gauze.~Topical vitamin C powder (1000 mg/ml) will be mixed with saline, and the resultant slurry mix will then be applied to the gingiva for 10 minutes."
223730028|NCT05786885|PROCEDURE|Vitamin C injection|"1-1.5 ml Vitamin C will be injected into the gingiva, using an insulin syringe, once weekly, for 3 weeks.~All the injection procedures will be performed by the same operator. The treated area will be left without dressing in both groups."
224002723|NCT02683785|DRUG|Placebo|Matching placebo will be administered as above.
224002724|NCT03610347|DEVICE|Bare metal Stent plus Paclitaxel Balloon|
224002725|NCT03610347|DEVICE|Drug Eluting Stent|
224002726|NCT00403936|PROCEDURE|OA decompression manipulation|
224002727|NCT04806204|OTHER|music therapy|Music therapy will be applied to one group before angiography and to the other group during angiography. Patients who will listen to music before angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played with headphones for 15-20 minutes. Patients who will listen to music during angiography will be offered Turkish Folk, Classical, Turkish Art and Sufi Music as an option, and the music preferred by the patients will be played through a speaker that will be placed in the angiography hall during the angiography procedure.
224002728|NCT05941247|DRUG|Hemay005 60 mg|"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."
224002729|NCT00000331|DRUG|Test Drug|
224002730|NCT00000331|DRUG|Placebo Drug|
224002731|NCT00418548|DRUG|Etanercept|
224124404|NCT04472260|PROCEDURE|Verticalization and Prone position|"The randomly selected study sequence (Arm1, Arm2, Arm3 or Arm4) will begin after the supine roll-over at the end of the first PP session (out-of-study sequence). This allows all patients to initially have the positioning technique that has been proven beneficial in ARDS.~The chronology of the treatment periods in each of the 4 arms allocated by randomization will be as follows: Each PP must be started within 4 to 8 hours after the end of the previous PP or after the end of the verticalization that just preceded it. Each verticalization must be performed within 4 to 8 hours after the end of the previous PP or the previous verticalization. Each PP period will last between 12 and 20 hours."
223385308|NCT03491657|BEHAVIORAL|music distraction (No VR)|
223385309|NCT03080870|OTHER|Art|Multicomponent art intervention
223385310|NCT01960309|OTHER|Minimal invasive cardiac imaging|"* Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography"
223385311|NCT02443987|OTHER|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
223385312|NCT04194645|DRUG|BI 474121 tablet|BI 474121 tablet
223385313|NCT04194645|DRUG|Placebo tablet|Placebo tablet
223385314|NCT04194645|DRUG|BI 474121 oral solution|BI 474121 oral solution
223385315|NCT04194645|DRUG|Placebo solution|Placebo solution
223385316|NCT06462521|PROCEDURE|Cold Snare Piecemeal Resection (CSPR)|Qualifying polyps randomized to Cold Snare Piecemeal Resection (CSPR) will be removed using cold snare techniques (no electrocautery, no submucosal injection.)
223385317|NCT06462521|PROCEDURE|Cold Snare Endoscopic Mucosal Resection (Cold EMR)|Qualifying polyps randomized to Cold Snare Endoscopic Mucosal Resection (Cold EMR) will be removed using cold snare techniques (no electrocautery, with submucosal injection.)
223385318|NCT00645892|DRUG|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
223385319|NCT00645892|DRUG|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
223385320|NCT01601340|DRUG|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
223385321|NCT01601340|DRUG|Placebo|Placebo tablets, twice daily for 48 weeks
223385322|NCT05982171|DEVICE|Exo + TSCS|Participants will receive TSCS delivered with the ONWARD Lift system at 1ms using a 10kHz carrier frequency delivered at 30Hz, with an amplitude set for each participant based on their ability to increase voluntary movement output.
223385323|NCT05982171|DEVICE|Exo + Sham|The ONWARD Lift system will also be used to deliver sham stimulation which will also be delivered at 1ms using a 10kHz carrier frequency delivered at 30Hz, and an amplitude of 1ma which has been used in other sham stimulation protocols and is not sufficient to induce activation of lumbosacral neuronal pools.
223425573|NCT02395640|DRUG|Capecitabine|1000mg/m2 po d1-14
223425574|NCT05409001|DIAGNOSTIC_TEST|tomography pan scan|This is a retrospective chart review
223425575|NCT06416410|DRUG|JAB-21822|JAB-21822 administered orally as a tablet
224002732|NCT01823705|DEVICE|Exilis Implantable Gastric Electrical Stimulation (GES)|
224002733|NCT01195623|PROCEDURE|preoperative duplex examination|
224002734|NCT01195623|PROCEDURE|Preoperative duplex|
224002735|NCT00867295|DRUG|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
224002736|NCT00867295|DRUG|placebo|placebo
224002737|NCT06017739|DEVICE|Bronchial Clearance A|EFA technology: the patient has to breathe at tidal volume by a mouthpiece at level 5 for half an hour twice a day.
224124405|NCT06501534|DRUG|Febuxostat|Tablets, Once a day (QD), Per oral
224002738|NCT06017739|DEVICE|Bronchial Clearance B|High Flow Technology: patient has to wear nasal cannula and breathe his nose for one hour twice a day. After he has to use EFA technology level 5 for half an hour twice a day.
224124406|NCT06501534|DRUG|IBI128|Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral
223385324|NCT03076775|OTHER|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
223385325|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
223385326|NCT01783886|BIOLOGICAL|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
223385327|NCT01783886|PROCEDURE|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
223385328|NCT01140165|OTHER|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
223385329|NCT00866944|DRUG|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
223385330|NCT00866944|DRUG|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
223385331|NCT00866944|DRUG|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
223385332|NCT04542057|DRUG|Ensifentrine|"Dosage Formulation:~Ensifentrine Nebulizer suspension Dosage 3mg Frequency: Twice Daily for 24 weeks"
223385333|NCT04542057|DRUG|Placebo|"Dosage Formulation:~Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks"
223385334|NCT00104572|DRUG|Androgel (Testosterone Gel)|1 mg tablet for 12 months
224002739|NCT03285698|DEVICE|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
224002740|NCT03285698|DEVICE|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
224002741|NCT06068751|OTHER|Aerobic Exercise|The initial group will receive instructions to increase their moderate to high-intensity physical activity frequency to at least 60 minutes per day (in episodes exceeding 10 minutes) by 50%, with a minimum of three days per week. They will be encouraged to engage in enjoyable and age-appropriate activities, including jogging, brisk walking, swimming, dancing, cycling, as well as sports like basketball, football, and tennis.
224124407|NCT04261543|OTHER|High protein and early exercise|High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization
224124408|NCT04261543|OTHER|Usual Care|Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
224124409|NCT01327651|DRUG|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
224124410|NCT01327651|DRUG|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
224124411|NCT01327651|DRUG|Event-driven dosing|TDF/FTC as needed with a post exposure dose
224124412|NCT03708965|DRUG|JR-141|IV infusion (lyophilized powder)
224124413|NCT06361641|DIAGNOSTIC_TEST|Monocytes signatures in myeloproliferative neoplasms at diagnosis|The monocytes signatures will be perform from a peripheral blood sample. The signature will be derived from (i) surface marker expression, (ii) cytokines profiles, (iii) genes expression.
224124414|NCT00260585|PROCEDURE|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
224124415|NCT00260585|PROCEDURE|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
223385335|NCT00104572|DRUG|Anastrozole (Aromatase Inhibitor)|
223385336|NCT00104572|DRUG|Placebo tablet|Daily for 12 months
223385337|NCT00104572|DRUG|Placebo gel|Daily for 12 months
223385338|NCT00104572|DIETARY_SUPPLEMENT|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
223385339|NCT04045353|BEHAVIORAL|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
223385340|NCT04045353|BEHAVIORAL|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
223385341|NCT04167111|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D
223385342|NCT04469777|DRUG|erythropoietin|Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
223385343|NCT02934464|DRUG|RAMUCIRUMAB|
223385344|NCT02934464|DRUG|Paclitaxel|Paclitaxel
223385345|NCT02934464|DRUG|FOLFOX 4|
223385346|NCT02934464|DRUG|mFOLFOX 6|
223385347|NCT02934464|DRUG|XELOX|
223385348|NCT02914353|DRUG|EP=7041|Factor X!a Inhibitor
223385349|NCT02914353|DRUG|Placebo|Normal Saline
223385350|NCT03104855|DRUG|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
223385351|NCT01918566|DIETARY_SUPPLEMENT|tap water|
223385352|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
223385353|NCT01918566|DIETARY_SUPPLEMENT|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
223385354|NCT01918566|DIETARY_SUPPLEMENT|25g Fructose in 300ml tap water|
223385355|NCT01918566|DIETARY_SUPPLEMENT|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
223385356|NCT01918566|DIETARY_SUPPLEMENT|300ml tap water with 450ppm lactisole|
223385357|NCT00940316|BIOLOGICAL|panitumumab|Given intravenously 6mg/kg every 2 weeks
223385358|NCT00940316|DRUG|erlotinib hydrochloride|Given orally 150mg daily
224002742|NCT06068751|OTHER|Neck Exercises|The second group, focused on neck exercises, will receive guidance from an experienced physiotherapist and their families. The physiotherapist will demonstrate a series of stretching and isometric strengthening exercises for specific muscle groups: upper trapezius, levator scapula, sternocleidomastoid, cervical flexors, and extensors, which have been associated with migraines in prior studies. Each patient will perform 3 sets of 10-15 repetitions for both stretching and isometric strengthening exercises per muscle group, with a 1-minute break between sets. Patients will be advised to maintain a gentle stretch during stretching exercises, avoiding excessive force to prevent discomfort. Static stretching and isometric strengthening exercises will involve holding each position for 5-10 seconds. In the initial week, a reduced set of 5 repetitions will be allowed for adaptation. Throughout the intervention, participants will follow this exercise regimen for 3 days weekly.
224002743|NCT05447234|BIOLOGICAL|Tcrx T cell|Sequential IV infusion
224002744|NCT01293942|DRUG|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
224002745|NCT04457349|PROCEDURE|Therapeutic Plasma Exchange (TPE)|Treatment with Therapeutic Plasma Exchange (TPE)
224002746|NCT01870947|BEHAVIORAL|Exercise on stationary recumbent exercise cycle|
224002747|NCT01870947|BEHAVIORAL|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
224002748|NCT01870947|BEHAVIORAL|Questionnaires|
224002749|NCT01870947|PROCEDURE|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
224002750|NCT01870947|PROCEDURE|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
224002751|NCT02278484|DEVICE|XprESS device and PathAssist confirmation tools|
224002752|NCT00441259|BIOLOGICAL|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged \> 3 years and 0.5 ml to children and infants aged \< 3 years administered subcutaneously
224124416|NCT00260585|PROCEDURE|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
224124417|NCT00260585|PROCEDURE|Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies|Tissue from the biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushings are collected intraoperatively.
224124418|NCT06335121|BEHAVIORAL|POWER Up strategies -|Clinics will implement adapted POWER Up intervention strategies when a patient is flagged as PrEP eligible.
224124419|NCT03484533|BEHAVIORAL|HIV self-test kit|Women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
224124420|NCT03484533|BEHAVIORAL|Standard of Care (invitation letters for fast-track HIV testing in the clinic)|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
224124421|NCT03249792|DRUG|MK-2118 (IT)|IT injection
224124422|NCT03249792|DRUG|MK-2118 (SC)|SC injection
224124423|NCT03249792|BIOLOGICAL|Pembrolizumab|IV infusion
224124424|NCT04702711|OTHER|No intervention|No intervention
223730029|NCT04020198|OTHER|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.
224002753|NCT00441259|BIOLOGICAL|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged \> 3 years and 0.5 ml is given to children and infants aged \< 3 years administered subcutaneously
224002754|NCT01839097|DRUG|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~* Cohort 1: belinostat 1000 mg/m2 IV on Day 1~* Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~* Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~* Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~* Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
224002755|NCT01839097|DRUG|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
224002756|NCT04689945|DRUG|Morphine|"PREOPERATIVE ANALGESIA: None~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Morphine 0,1 mg/kg IV~POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol"
224002757|NCT04689945|PROCEDURE|Erector Spinae Block|"PREOPERATIVE ANALGESIA:~Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
224002758|NCT04689945|DRUG|Control|"PREOPERATIVE ANALGESIA: none~INTRAOPERATİVE ANALGESIA:~1. Paracetamol 1000 mg IV~2. Dexketoprofen 50 mg IV~POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol"
224002759|NCT04081870|DIAGNOSTIC_TEST|3D power doppler US|Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
224002760|NCT00795275|DRUG|Sitagliptin Phosphate|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
224002761|NCT05303389|PROCEDURE|Fixation of 2,3 or 4 column pilon fracture of the tibia|anterior to posterior screws in classic arm and posterolateral approach in new arm group
224124425|NCT05344508|DRUG|Brensocatib|Brensocatib tablets
223385359|NCT00940316|DRUG|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
223385360|NCT01907256|PROCEDURE|inverted V incision|It is a type of incision
224002762|NCT05003024|DEVICE|TOF SCAN|"For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~Once 2 contractions of the adductor pollicis muscle will be observed on the TOF Scan side following train of four stimulation, 2 mg/kg sugammadex will be injected. Train of four ratio (delivered every minute) will be recorded.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover."
224002763|NCT05003024|DEVICE|ITF|"For each included patient, 2 monitorings (TOF Scan and ITF device) will be placed, one on each hand.~On the ITF device side, 3 minutes after sugammadex administration, a tetanus 100 Hz stimulation will be done followed 2 minutes later by a tetanus 50 Hz stimulation.~This sequence (tetanus 100 Hz followed by tetanus 50 Hz) will be repeated 5 times For each tetanus stimulation, the ratio between the residual force and the maximum force generated by the adductor pollicis muscle will be recorded (this ratio illustrates the fade phenomenon). At the end of this period lasting 23 minutes after sugammadex administration, anesthetic drug delivery will be stopped and the patient wil be allowed to recover."
224002764|NCT01940432|DEVICE|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
223385361|NCT01907256|PROCEDURE|stair step incisions|It is a type of incision
223385362|NCT00425204|DRUG|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
223385363|NCT03897634|DEVICE|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
223385364|NCT02375165|PROCEDURE|phlebotomy|phlebotomy for collection of plasma and serum, \~30 cc
223385365|NCT00685386|OTHER|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
223385366|NCT00685386|OTHER|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
223385367|NCT04097873|OTHER|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
223385368|NCT04097873|OTHER|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
223385369|NCT06359912|DRUG|EPCs|IV
223385370|NCT06359912|BEHAVIORAL|Clinical standard treatment (CST)|Clinical standard treatment
224002765|NCT01940432|BEHAVIORAL|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
224002766|NCT00842244|DRUG|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
224002767|NCT00842244|DRUG|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
224002768|NCT00842244|DRUG|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.
223385371|NCT04457037|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells
223385372|NCT05146648|DEVICE|Gondola AMPS|One treatment session lasts about two minutes and consists of the application of a mechanical pressure pulses on each of the points, one after the other, for a set duration (a few seconds), which is repeated several times in sequence.
223385373|NCT04927143|BEHAVIORAL|App-Based Contingency Management|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
223385374|NCT04927143|BEHAVIORAL|Sham Control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
223385375|NCT02976948|OTHER|No intervention|
223385376|NCT04309617|PROCEDURE|nephrectomy|Surgery performed within the study period
223385377|NCT05748587|DIAGNOSTIC_TEST|Serum Iron|Serum iron levels in study groups
223385378|NCT05748587|DIAGNOSTIC_TEST|RBCs Alpha-synuclein|α-syn levels in RBCs
223385379|NCT05748587|DIAGNOSTIC_TEST|Serum Soluble lymphocyte activation gene|sLAG-3 in the serum of study groups
223385380|NCT05748587|RADIATION|Brain computed tomography|Brain CT of patients after admission
223385381|NCT05748587|DIAGNOSTIC_TEST|Brain Iron|Iron in brain homogenate of rats
223385382|NCT05748587|DIAGNOSTIC_TEST|Brain Alpha-synuclein|α-syn expression in rat's brain
224002769|NCT00430729|DRUG|Roflumilast|
223385383|NCT05748587|DIAGNOSTIC_TEST|Brain lymphocyte activation gene|LAG-3 expression in rat's brain
223385384|NCT05748587|DRUG|Deferoxamine|intramuscular deferoxamine (200 mg/kg) injection to rats
224002770|NCT04207580|OTHER|Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,|"The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients.~A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment)."
223385385|NCT03595046|PROCEDURE|erector spinae plane block (20 mL of 0.25% ropivacaine with dexamethasone 5mg)|In group E, The patient was placed in a sitting position and a high-frequency linear ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the thoracic spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle was inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between transverse process and erector spinae muscles, as evidenced by visible linear spread of fluid between erector spinae muscles and the bony acoustic shadows of the transverse process. A total of 20 mL of 0.25% ropivacaine with dexamethasone 5mg was injected here.
223385386|NCT03595046|PROCEDURE|thoracic paravertebral block(10 mL 0.25% ropivacaine with dexamethasone 5mg)|2\) In group P, an appropriate thoracic spinous precess is located by positioning the probe in the transverse plane. Then the probe is moved laterally to locate the transverse process. The probe is manipulated slightly caudad or cephala to locate the intercostal space. The transverse process is visualized medially with the pleura dipping under the inferolateral aspect. The internal intercostal membrane, which is contiguous with the superior costotransverse ligament, was generally seen as a thin, radiopaque line extending from the transverse process, creating a wedge-shaped pocket, which represents the thoracic paravertebral space. A 22-gauge, facet-tip needle is advanced, in plane, from the lateral aspect of the ultrasound probe. When the needle pierced the internal intercostal membrane, and after aspiration demonstrated the absence of air or blood, 10 mL 0.25% ropivacaine with dexamethasone 5mg deposited in 5-mL increments.
223730030|NCT01334268|DEVICE|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
224002771|NCT01701102|PROCEDURE|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
224124426|NCT01071044|DRUG|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
223730031|NCT01334268|DEVICE|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
223730032|NCT05030974|BIOLOGICAL|mRNA-1273|SARS-CoV-2 vaccination
223730033|NCT05030974|BIOLOGICAL|Ad26.COV2.S vaccine|SARS-CoV-2 vaccination
224002772|NCT01701102|PROCEDURE|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
224295714|NCT05253924|DIAGNOSTIC_TEST|EEG acquisition|Both PT and FT infants will have their EEG signal recorded during mother-baby interaction according to a modified version of the Still Face paradigm; the EEG signal will be recorded by means of the medical system eego mylab (AntNeuro), using special headphones equipped with 32 electrodes and suitable to acquire the EEG signal since early childhood. After spectral analysis of the EEG signal, the difference in signal strength in the alpha band recorded by two homologous electrodes (or electrode clusters) (i.e. right alpha - left alpha) will be calculated to obtain the FAA index. Because the alpha frequency band is associated with cortical inhibitory activity, a lower asymmetry reflects less left hemisphere activation than right hemisphere activation. The analysis of EEG data will be performed in MatLab environment using the eeglab software and algorithms developed ad hoc.
224295715|NCT00537108|BEHAVIORAL|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support \& skills-building for school continuation, higher education, and job readiness.
224295716|NCT06402201|BIOLOGICAL|CDR404|IV infusions
224002773|NCT01701102|PROCEDURE|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
224002774|NCT01701102|PROCEDURE|Mepivacaine|Mepivacaine 37.5 mg
224002775|NCT03156972|PROCEDURE|Replacment of mitral valve|Mitral valve replacment by prothsis
224002776|NCT04314141|PROCEDURE|Evaluation of surgical outcomes, quality of life and patient's satisfactions with phalloplasty|"Send a questionnaire to patients to collect informations about:~* Sexual quality of life before and after the surgery~* Satisfaction after surgery~Data collection in medical file :~* Surgery outcomes~* Functional outcomes"
224002777|NCT03132831|OTHER|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
224002778|NCT02233803|DRUG|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
224002779|NCT02233803|DRUG|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
223385387|NCT03282500|BEHAVIORAL|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
223385388|NCT02827734|DEVICE|multiple breath washout tests|
223385389|NCT02827734|DEVICE|impulse oscillometry|
223385390|NCT02827734|DEVICE|body plethysmography|
223385391|NCT01924559|OTHER|standard clothing|
223385392|NCT01924559|OTHER|Biohazard gear|
223385393|NCT01924559|DEVICE|Direct Laryngoscopy|
223385394|NCT01924559|DEVICE|Glidescope|
223385395|NCT01924559|DEVICE|Supraglottic Airway|
223385396|NCT01660425|BEHAVIORAL|Enhancement with psychosocial intervention|
223385397|NCT04265703|PROCEDURE|Internal jugular vein catheterization|Catheterization of internal jugular vein with real-time (in-plane) method, with neutral neck position. Standard aseptic technique.
223385398|NCT04265703|PROCEDURE|Subclavian vein catheterization|Catheterization of subclavian/axillary vein with infra-clavicular approach with real-time (in-plane) method, without shoulder retraction. Standard aseptic technique.
223385399|NCT04265703|PROCEDURE|Innominate vein catheterization|Catheterization of innominate vein with supra-clavicular approach with real-time (in-plane) method, with neutral shoulder position and no shoulder retraction. Standard aseptic technique.
223385400|NCT05548387|DRUG|HCP2202|Take it once per period.
223385401|NCT05548387|DRUG|RLD2202|Take it once per period.
224002780|NCT02233803|DRUG|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
224002781|NCT02233803|DRUG|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
223385402|NCT05548387|DRUG|RLD2203|Take it once per period.
223385403|NCT02290405|BEHAVIORAL|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
223385404|NCT03916705|OTHER|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
223385405|NCT00005805|DIETARY_SUPPLEMENT|St. John's wort|
223385406|NCT02012270|PROCEDURE|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions~* closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~* the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~* the SL/WL ratio should be at least 4/1~* SL/WL = (150cm x number of sutures used) - (the suture remnants)~* the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
223385407|NCT02012270|PROCEDURE|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
223385408|NCT02460146|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
223385409|NCT02460146|OTHER|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
223385410|NCT03789929|BEHAVIORAL|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
224002782|NCT04247477|OTHER|Ventilation strategy|Patients are ventilated in randomized order with three different ventilation strategies (A,B and C)
224002783|NCT02457377|PROCEDURE|laparoscopic cerclage|The vesico-uterine peritoneum is opened \& the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right \& left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right \& left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots \&
223385411|NCT03789929|BEHAVIORAL|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
223385412|NCT01609868|DIETARY_SUPPLEMENT|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
223385413|NCT01609868|DIETARY_SUPPLEMENT|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
223385414|NCT04393714|PROCEDURE|Alveolar ridge preservation after extraction|atraumatic extraction followed by graft material insertion
223385415|NCT02016183|DRUG|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
223385416|NCT01832571|DRUG|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
223385417|NCT05925998|OTHER|Observational study: no interventions|Not applicable as observational study with no intervention
223385418|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, one single dose
223385419|NCT01224197|DRUG|TMC435|100 or 200 mg capsule, once daily for 5 days
223385420|NCT06490978|RADIATION|CT Brain|Patient needs follow up ct brain , cbc , CRP
223385421|NCT02535689|DRUG|Tofacitinib|Oral administration of tofacitinib, 5 mg
223385422|NCT02535689|DRUG|Placebo|
224002784|NCT03474926|PROCEDURE|Routine Template-based lymphadenectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
224002785|NCT03474926|PROCEDURE|LND only for lymph nodes enlargement found in preoperative image or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
224002786|NCT04870008|PROCEDURE|Suture|The side of patient's scar that will receive the sutures placed at 2 or 5 mm from wound edge.
224002787|NCT05727189|DRUG|TR-01-XRR (1)|Extended-release form
224002788|NCT05727189|DRUG|TR-01-XRR (2)|Extended-release form
224002789|NCT05727189|DRUG|TR-01-XRR (3)|Extended-release form
224002790|NCT05727189|DRUG|TR-01-XRS|Extended-release form
224002791|NCT05727189|DRUG|TR-01-XR|Extended-release form
224002792|NCT05727189|DRUG|TR-01-IR|Active comparator
224002793|NCT05727189|DRUG|Placebo|Placebo comparator
224002794|NCT03578653|BEHAVIORAL|Merging Yoga and Occupational Therapy for Parkinson disease|The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
224124427|NCT01071044|DRUG|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
223385423|NCT00996489|DEVICE|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
223385424|NCT05149391|BIOLOGICAL|CD19/CD20-directed Chimeric Antigen Receptor T Cells|Autologous 2nd generation CD19/CD20-directed Chimeric Antigen Receptor T Cells, single infusion intravenously
223385425|NCT03142191|DRUG|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
223385426|NCT03142191|OTHER|Placebo|Placebo
223730034|NCT04487639|DIAGNOSTIC_TEST|SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics|a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
224002795|NCT04596839|DRUG|Remdesivir|Remdesivir INN 100 mg lyophilized powder for infusion
224002796|NCT04596839|OTHER|Standard of Care|Standard of Care Treatment for COVID-19 Infection
224002797|NCT00569023|DIETARY_SUPPLEMENT|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
223385427|NCT05855824|OTHER|Applesauce Pouch|One 90 g pouch of applesauce provides 0 mg carotenoids/d and 40 kcal, 10 mg vitamin C, and 1 g dietary fiber.
223385428|NCT05855824|OTHER|Fruit-vegetable puree blend|One 120 g pouch of fruit-vegetable puree blend provides 5 mg mixed carotenoids, 70 kcal, 4 mg vitamin C, and 2 g dietary fiber.
223385429|NCT06329739|DIAGNOSTIC_TEST|Clinical examinations and clinical scales administration|Psychometric assessment of cognitive and behavioral outcomes
223385430|NCT05682612|OTHER|outcome|hospital survivors and nonsurvivors
224002798|NCT03427151|DRUG|IPP-201101|200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
224002799|NCT05049135|DEVICE|Somnofy® sleep monitor|Registration of sleep score and apneas with radar sensor technology at time of primary investigation and 12 weeks after treatment initiation with continuous positive airway pressure (CPAP)
224002800|NCT03586934|DRUG|Acetaminophen|Acetaminophen Tablet
224002801|NCT03586934|DRUG|Celecoxib 200mg|Celecoxib Tablet
224002802|NCT03586934|DRUG|Celecoxib 400 mg|Celecoxib Tablet
224002803|NCT03586934|DRUG|Ropivacaine|Ropivicaine nerve block (injection)
224002804|NCT03586934|DRUG|Ketorolac|ketorolac injection
223385431|NCT05682612|OTHER|Subtype of COVID-19|Different subtype of COVID-19
223385432|NCT00825786|DRUG|Ropivacaine|ropivacaine (15 ml).
223385433|NCT00825786|DRUG|Mepivacaine|One syringe will contain mepivacaine (15 ml)
223385434|NCT02257281|DEVICE|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
223385435|NCT02257281|DEVICE|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
224002805|NCT03586934|DRUG|Acetaminophen Injectable Product|Acetaminophen injection
224002806|NCT03586934|DRUG|Oxycodone|oxycodone tablet
223385436|NCT06582550|PROCEDURE|Minor Hand Procedure|Unilateral minor hand procedure (carpal tunnel release, trigger finger A1 pulley release, lesion excision)
223425576|NCT06416410|DRUG|Tislelizumab|Tislelizumab administered as an intravenous (IV) infusion
223425577|NCT06416410|DRUG|JAB-3312|JAB-3312 administered orally as a tablet or capsule
223425578|NCT06416410|DRUG|Pemetrexed|Pemetrexed administered as an intravenous (IV) infusion
223425579|NCT06416410|DRUG|Carboplatin|Carboplatin administered as an intravenous (IV) infusion
224002807|NCT03586934|DRUG|Tramadol|Tramadol tablet
224002808|NCT03586934|DRUG|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
224002809|NCT03586934|DRUG|hydrocodone bitartrate and acetaminophen|Norco tablet
224002810|NCT03586934|DRUG|Morphine|morphine injection
224002811|NCT03586934|DRUG|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
224002812|NCT03586934|DRUG|Meloxicam|meloxicam tablet
224002813|NCT06507280|PROCEDURE|Periodontal theraphy|periodontal therapy
223385437|NCT02166710|DEVICE|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
223385438|NCT02166710|DEVICE|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
223385439|NCT02569190|DEVICE|Walkbot|Robot assisted gait training
223385440|NCT02445534|BIOLOGICAL|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
223385441|NCT04652778|DEVICE|Pulsed Field Ablation (PFA) using the Centauri System|cardiac ablation using pulsed electric field energy to cause pulmonary vein isolation; cavo-tricuspid isthmus (CTI) line ablation may be performed as needed
223385442|NCT02547532|OTHER|collection of sputum|
223385443|NCT01946932|OTHER|Temperature treatment|
223730035|NCT00991666|PROCEDURE|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
224002814|NCT01261117|DRUG|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
224002815|NCT02642692|PROCEDURE|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
224002816|NCT02642692|PROCEDURE|Hamstring Graft|Acl reconstruction with hamstring graft
224002817|NCT03163927|OTHER|Simulation-based training|See arm description
224002818|NCT03846453|BIOLOGICAL|HL036 Ophthalmic Solution|HL036 Ophthalmic Solution
224002819|NCT03846453|BIOLOGICAL|Placebo|Placebo vehicle solution
223385444|NCT00676832|DRUG|Placebo|Placebo solid capsule dosage form administered orally once daily.
223385445|NCT00676832|DRUG|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
223385446|NCT05766137|PROCEDURE|Alveolar ridge preservation|Socket preservation
223385447|NCT04298632|BEHAVIORAL|Safety Education Program|this is a pesticide safety education program
223385448|NCT05574361|DEVICE|Hypothermic Machine Perfusion|Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
223385449|NCT00428233|PROCEDURE|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
223385450|NCT05975528|DRUG|SGLT2 inhibitor|"For the SGLT2 inhibitor group, total drug adminstration days are 180 days, but non-SGLT2 inhibitor administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.~For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered."
223385451|NCT05975528|DRUG|Glimepiride|For non-SGLT2 inhibitor (glimepiride) administration period is 3 months, and then changed to the SGLT2 inhibitor another 3 months.
223385452|NCT03688633|DRUG|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
223385453|NCT03688633|OTHER|Usual care|patients will be followed as usual
223385454|NCT00770328|DRUG|Pentoxifylline|400mg PO TID x 8 weeks
223385455|NCT00770328|DRUG|Placebo|PO TID x 8 weeks
223385456|NCT05208489|OTHER|there is no intervention involved in this study|there is no intervention involved in this study.
223385457|NCT05709210|OTHER|Recording of smartphone usage data|Recording of smartphone usage data
224002820|NCT00757627|DRUG|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
224002821|NCT02303600|DRUG|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
224002822|NCT02303600|OTHER|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
224002823|NCT01173965|DEVICE|MEA|Microwave endometrial ablation device
224002824|NCT01173965|DEVICE|Novasure|Bipolar impedence control system
224002825|NCT02888574|DRUG|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
224002826|NCT02888574|DRUG|Placebo|Placebo nasal spray
224002827|NCT00472849|DRUG|Oxaliplatin|Oxaliplatin 30 mg/m\^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
224002828|NCT00472849|DRUG|Fludarabine|Fludarabine 30 mg/m\^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
224002829|NCT00472849|DRUG|Cytarabine|Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
224002830|NCT00472849|DRUG|Rituximab|Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses).
224002831|NCT00472849|DRUG|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
224002832|NCT04313257|OTHER|Monocular Active Occlusion|Occlusion treatment of one hour daily with action video game.
224002833|NCT04313257|OTHER|Monocular Passive Occlusion|Occlusion treatment of two hour daily.
224002834|NCT00468143|DRUG|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
224295717|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
224002835|NCT00468143|DRUG|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
224002836|NCT05240326|OTHER|exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.
224002837|NCT05240326|OTHER|control training group|The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
224002838|NCT04085484|DIETARY_SUPPLEMENT|More concentrated parenteral nutrition solution|This study is a single-center retrospective observational study comparing two cohorts of very low birth weight (VLBW, birth weight \< 1500 grams) infants who received parenteral nutrition (PN) either before or after a concentrated PN regime was implemented into clinical use. Both PN regimes were based on standardized PN solutions.
224002839|NCT04664075|BIOLOGICAL|Respiratory infections|With biological samples and longitudinal observations, the aim is to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection.
224002840|NCT04210167|BEHAVIORAL|web-based training and telephone monitoring|web-based training and telephone monitoring and short message
224002841|NCT03659864|OTHER|diesel exhaust particulate|aerosolised diesel exhaust particulate
224002842|NCT03659864|OTHER|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
224002843|NCT03659864|OTHER|small graphene oxide|aerosolised 'small' graphene oxide
224002844|NCT03659864|OTHER|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
224002845|NCT03659864|OTHER|filtered air|control: filtered air
224002846|NCT02466464|DEVICE|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
224002847|NCT02466464|DEVICE|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
223385458|NCT04500717|DRUG|Almonertinib|Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
223385459|NCT04500717|DRUG|Almonertinib plus carboplatin and pemetrexed|Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
223385460|NCT05015829|DIAGNOSTIC_TEST|Dobutamine Stress Echocardiography|Change in echocardiographic 2D and doppler measurements during infusion with Dobutamine 5 µg/kg/min till max dosage of 20 µg/kg/min.
223385461|NCT03452943|DRUG|TEV-50717|6, 9, 12, 15, and 18 mg oral tablets
223385462|NCT03452943|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
224002848|NCT01240421|DRUG|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
224002849|NCT03723018|BEHAVIORAL|Meditation|10 minutes a day of meditation, done on your own time.
224002850|NCT02951520|PROCEDURE|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
224002851|NCT05247905|DRUG|Lutetium Lu 177 Dotatate|Given IV
224002852|NCT05247905|DRUG|Capecitabine|Given PO
224002853|NCT05247905|DRUG|Temozolomide|Given PO
223385463|NCT01130493|DRUG|IPX066|experimental product
223385464|NCT01130493|DRUG|CLE|active comparator
223385465|NCT02589730|DEVICE|Welltang App|This App is a large platform of individualized diabetic management
224002854|NCT05247905|OTHER|Quality-of-Life Assessment|Ancillary studies
224002855|NCT05247905|OTHER|Questionnaire Administration|Ancillary studies
224002856|NCT01585077|BIOLOGICAL|P. vivax infected mosquito bites|All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
224002857|NCT00261976|DRUG|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
224002858|NCT01383655|DRUG|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
224002859|NCT01383655|DRUG|Placebo|NaCl
224002860|NCT03968380|OTHER|Population survey with biological and physical measurements.|Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
224002861|NCT06250959|DRUG|Blinatumomab Injection [Blincyto]|Reduced-intensity chemotherapy followed by Blinatumomab
224002862|NCT06250959|DRUG|Doxorubicin|HyperCVAD regimen
224002863|NCT00770900|DRUG|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children \>15 years took 10mg tablet of montelukast"
224124428|NCT06823271|OTHER|Resting and exercise right heart catheterization|At rest and after different modes of exercise, exercise right heart catheterization will be performed.
224124429|NCT06823271|OTHER|Right ventricular mapping|At the beginning and at the end of the exercise modes right ventricular mapping will be performed.
224295718|NCT00812422|DRUG|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
224002864|NCT00770900|DRUG|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
223385466|NCT01531088|BEHAVIORAL|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
224002865|NCT04508127|DEVICE|Spinal cord stimulation|
224002866|NCT01529320|DRUG|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
224002867|NCT03878277|DRUG|Starbucks® Cold brew - 325ml bottle|Starbucks® Cold brew 325ml bottles daily \[205mg caffeine\] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
224002868|NCT06185231|OTHER|Percussion Massage Group|In addition progressive exercise program, The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group. The application will be done to the Quadriceps and Hamstring muscle groups before exercise. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
224002869|NCT06185231|OTHER|Conventional Group|"Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes."
224002870|NCT00968071|DRUG|Decitabine|20 mg/m\^2 IV over an hour and half daily for 5 days.
224295719|NCT00812422|DRUG|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
224295720|NCT01426035|DRUG|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
224295721|NCT06441461|OTHER|Primary informal caregiver at work.|Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
224295722|NCT03082170|DEVICE|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
223385467|NCT04138381|DRUG|Selinexor|oral selinexor given once weekly (Cohort A), oral selinexor given BIW (Cohort B)
223385468|NCT04138381|DRUG|Imatinib|imatinib 400 mg, once daily (Cohort A)
224295723|NCT03082170|DIAGNOSTIC_TEST|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
224295724|NCT03082170|BEHAVIORAL|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
224295725|NCT03106558|DEVICE|Total Knee Arthroplasty using Manual Instrumentation|
224295726|NCT03106558|DEVICE|Total Knee Arthroplasty using Robotic Arm|
223385469|NCT02920801|DRUG|saxagliptin|5mg per day for 12 weeks
223385470|NCT02920801|DRUG|Metformin|1500mg per day for 12 weeks
224295727|NCT02944370|BEHAVIORAL|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
224295728|NCT04436978|DRUG|30-day DAPT|DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.
224295729|NCT04436978|DRUG|Guideline-directed therapy|Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
224295730|NCT00031083|GENETIC|Interferon-beta|
224002871|NCT00968071|DRUG|Gemtuzumab Ozogamicin|3 mg/m\^2 IV on day 5.
224002872|NCT00353041|DRUG|lidocaine topical|
224002873|NCT01559129|DRUG|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
223385471|NCT06451185|OTHER|A haemostatic mineral powder product.|The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.
224002874|NCT01559129|DRUG|Placebo|Matching placebo capsules taken orally once a day
224002875|NCT00368927|DRUG|sulindac|Given orally
224002876|NCT00368927|OTHER|placebo|Given orally
224002877|NCT02392052|BEHAVIORAL|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
224002878|NCT02392052|BEHAVIORAL|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
224002879|NCT00009659|DRUG|CDB 2914|
224002880|NCT04606108|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with Liposome doxorubicin and Ifosfamide
224002881|NCT00872755|PROCEDURE|Nissen|Laparoscopic Nissen Fundoplication
224002882|NCT00872755|PROCEDURE|Gastropexy|posterior gastropexy
224002883|NCT03525392|DRUG|177Lu-3BP-227 (also called 177Lu-IPN01087)|The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
224002884|NCT03750786|DRUG|Arfolitixorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous bolus; Arfolitixorin 60 mg/m2 intravenous bolus; 5-FU 2400 mg/m2 intravenous infusion; Arfolitixorin 60 mg/m2 intravenous bolus
224002885|NCT03750786|DRUG|Leucovorin|Bevacizumab 5 mg/kg intravenous infusion; Oxaliplatin 85 mg/m2 intravenous infusion; Leucovorin 400 mg/m2 intravenous infusion; 5-FU 400 mg/m2 intravenous infusion; 5-FU 2400 mg/m2 intravenous infusion
224002886|NCT01922388|DEVICE|Bilateral deep brain stimulation of the subthalamic nucleus|
223385472|NCT04894370|BIOLOGICAL|Sample collection|"PBMC collection at baseline, after radiotherapy 8 Gy (gray), at 6 months and at 12 months from inclusion: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell \[PBMC\] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection at baseline, after radiotherapy 8 Gy, at 6 months and at 12 months from inclusion: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection at baseline, at 2, 6 and 12 months from inclusion: two EDTA tube of 4 ml should be frozen in each investigation center for ctDNA collection."
223385473|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
223385474|NCT03541317|BEHAVIORAL|Stage 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
224002887|NCT03170687|DEVICE|short foot cast|metatarsal foot cast
224002888|NCT03170687|DEVICE|short leg cast|full short leg cast
224002889|NCT06172192|PROCEDURE|Core Strengthening|"1. Warm up phase Following exercise would be performed in warm up. Jump rope, Cross jacks, Standing side crunch, Mountain climbers, Scissor skier, Criss cross crunches, Reverse lunge high kick, Inchworm, Hip circles, Bent over.~2. Core Strengthening:~   Abdominal bracing, Bracing with heel slides, Bracing with leg lifts, Bracing with bridging, Bracing in standing, Bracing with standing row exercise, Quadruped arm lifts with bracing, Quadruped leg lifts with bracing, Quadruped alternate arm and leg lifts with bracing , Oblique abdominals~3. Cool down phase: Following exercise would be performed for cood down: child pose, Ab stretch, cat cow stretch, hip stretch, oblique stretch, standing forward bend.~After performance of core strengthening protocol, group A will perform self-diaphragmatic breathing exercises while group B will perform resistive diaphragmatic breathing exercise."
224002890|NCT06172192|PROCEDURE|Self-Diaphragm breathing exercises|"Participants will place one hand on the chest and other on the abdomen, feeling the swelling of the stomach and the movement of the chest. It will be performed in supine position.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
223385475|NCT03541317|BEHAVIORAL|Stage 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
223385476|NCT03541317|BEHAVIORAL|Stage 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
224002891|NCT06172192|PROCEDURE|Resistive-Diaphragm breathing exercises|"Participants will place one hand on the chest and another on the sand bag placed over abdomen. This sand bag weighing 3-5 Kgs will provide resistance to breathing. These exercises will be performed in supine position. We will adjust the weight of the sandbag as per individual's level of 11-13 of 'Rating of Perceived Exercise (RPE)'.~Supervised breathing exercises in two sets for 15 minutes with 5 minutes break between sets and 10 minutes rest after it will be performed"
224002892|NCT02240953|DRUG|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
224002893|NCT02240953|DRUG|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
224002894|NCT02240953|DRUG|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
224124430|NCT03415477|DRUG|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
224124431|NCT04093739|DEVICE|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
224295731|NCT00003748|DRUG|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
224124432|NCT03909763|DRUG|Berberine plus danazol|Oral BBR (0.3g thrice daily) plus oral danazol (200 mg twice daily) for 16 weeks
224124433|NCT02151006|DRUG|DHEA|
224124434|NCT02840487|BIOLOGICAL|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
224124435|NCT02053272|DRUG|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
224124436|NCT02053272|DRUG|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
224124437|NCT05420272|BEHAVIORAL|Trunk performance and endurance lower extremity biomechanic|Trunk performance and endurance lower extremity biomechanic
224124438|NCT03127215|DRUG|Olaparib|Olaparib 150 mg tablet
224124439|NCT03127215|DRUG|Physician's choice|treatment according to current guidelines
224124440|NCT03127215|DRUG|Trabectedin|Trabectedin 1.1mg/m² infusional solution
224124441|NCT03632681|DRUG|Intranasal Insulin|Intranasal insulin
224124442|NCT03632681|DRUG|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
224124443|NCT00793702|BIOLOGICAL|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
224124444|NCT06623461|DRUG|Standard of Care Immune Checkpoint Blockade|Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
224002895|NCT02240953|DRUG|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
223385477|NCT04359394|OTHER|biological sampling|In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.
223385478|NCT04359394|OTHER|Phenotypic description|Phenotypic characterization of the patient's clinical features
223385479|NCT04359394|OTHER|Photography|All affected areas will be photographed at each visit with 2-dimensional standardized photography
223385480|NCT02959125|OTHER|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
223385481|NCT02959125|DIETARY_SUPPLEMENT|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
223385482|NCT02959125|BEHAVIORAL|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
223385483|NCT02959125|OTHER|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
223385484|NCT02959125|DIETARY_SUPPLEMENT|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
223385485|NCT03422614|DIAGNOSTIC_TEST|Diagnostic Test|Characterisation of cellular and functional phenotype in different PIDs
224002896|NCT00667316|BEHAVIORAL|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
224002897|NCT06228209|BEHAVIORAL|Tier - Palliative Care|TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
224002898|NCT06403189|OTHER|Biologic samples and MRI|"* blood sample~* lumbar punction~* MRI"
224002899|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
224002900|NCT04078763|BEHAVIORAL|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
224124445|NCT06623461|DRUG|LND101|Approximately 40 capsules (total of 80-100g of processed fecal material) taken by mouth 7 days prior to the ICG agent(s) administered following bowel preparation.
224124446|NCT01226420|DRUG|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
224124447|NCT05437341|BIOLOGICAL|bi-4SCAR PSMA/CD70 T cells|Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
223385486|NCT04970303|DRUG|Methylphenidate|Retina or Concerta
223385487|NCT01805843|OTHER|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
223385488|NCT06459024|OTHER|Registration into the STREAM platform|All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.
223385489|NCT02286843|RADIATION|89Zr-trastuzumab|
223385490|NCT02286843|DEVICE|PET/CT scan|
223385491|NCT02286843|RADIATION|89Zr-pertuzumab|
223385492|NCT06115993|DRUG|AHB-137 injection|AHB-137 injection will be administered subcutaneously.
223385493|NCT06115993|DRUG|Placebo|Placebo will be administered subcutaneously.
223385494|NCT04574687|OTHER|Neurodevelopmental Techniques|)Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
223385495|NCT04574687|OTHER|Action observation Therapy|(a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
223385496|NCT06307626|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
223385497|NCT06307626|OTHER|Placebo PH20 SC|Subcutaneous placebo given by prefilled syringe
223385498|NCT04826692|DRUG|Metformin|Metformin oral: 425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
223385499|NCT04826692|DRUG|Placebo|425 mg twice daily (initial dose) and 850 twice daily (maximum dose)
223385500|NCT04274257|DRUG|Double-Blind Placebo|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of placebo will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
223385501|NCT04274257|DRUG|Double-Blind Rituximab|"The 4-week treatment period (four 375 mg/m2 doses at 1-week intervals) and subsequent 20-week follow-up period constitute one cycle of treatment.~In the double-blind period, one cycle of rituximab will be administered. In the active drug period, one additional cycle (rituximab) will be administered."
224124448|NCT02388516|DIETARY_SUPPLEMENT|Vitamin D3|
223385502|NCT00775619|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
224124449|NCT02388516|DIETARY_SUPPLEMENT|Placebo|
224124450|NCT05526794|PROCEDURE|Analgesic consumption|1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
224002901|NCT04078763|BEHAVIORAL|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
223385503|NCT02536846|DRUG|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
223385504|NCT04607057|DRUG|Parenteral Nutrition Solutions|"* Day0 : fasting(NPO) + crystalloid fluid~* POD#1 : Keep fasting, then start sips of water in the evening + crystalloid fluid~* POD#2 : Semifluid diet (SFD) + crystalloid fluid~* POD#3 : Semifluid diet (SFD) + PN~* POD#4-7: Soft blended diet (SBD) + PN"
224002902|NCT04078763|BEHAVIORAL|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
223385505|NCT05575232|BEHAVIORAL|Application Group (GA)|The main focus of the application is to assist in the treatment of patients with SAH. The application will address the components of adherence to medication use, blood pressure monitoring and promotion/monitoring of physical activity. In addition, health education tips will be provided, including guidelines for reducing sodium consumption, adopting an adequate and healthy diet, controlling body weight, moderate alcohol consumption and stress management, in accordance with the recommendations of the main guidelines related to the theme¹ ³. The intervention will last eight weeks.
224002903|NCT04078763|BEHAVIORAL|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
224002904|NCT02712164|DEVICE|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
224002905|NCT02712164|DEVICE|Tegaderm|Standard of care for STSG donor sites.
224295732|NCT04310839|PROCEDURE|Colectomy|colectomy due to neoplastic (stage 1) or diverticulosis
223385506|NCT06287398|DRUG|Epcoritamab|"Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg"
223385507|NCT04940572|DRUG|Depakine|Refer to arm description.
223385508|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using Gow-Gates anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using Gow-Gates anesthesia technique. Patients were monitored for TCR during the procedure.
223385509|NCT06499532|PROCEDURE|Monitoring and Surgical removal of mandibular impacted wisdom teeth, using inferior alveolar nerve block anesthesia technique|The surgical removal of impacted mandibular wisdom teeth in patients included in the study arms was performed using inferior alveolar nerve block anesthesia technique and supplemental anesthesia (buccal- mylohyoid). Patients were monitored for TCR during the procedure.
224002906|NCT06021626|DRUG|CRD3874|"Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05"
224002907|NCT02441868|BEHAVIORAL|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
224002908|NCT00318539|DRUG|Quetiapine|
224002909|NCT02654652|DIETARY_SUPPLEMENT|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
224002910|NCT02654652|DIETARY_SUPPLEMENT|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
224002911|NCT05703906|BEHAVIORAL|Telerehabilitation - VRRS Khymeia|Participants will receive an individualized, multidomain exercise program set up by the therapist, based on their needs. The intervention applied will consist of 20 sessions of motor, language and/or cognitive training distributed in five sessions for week, each lasting 1 hour. Remotely, the therapist will supervise the participant's exercise program.
224002912|NCT03349502|DRUG|MG4101|Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
224002913|NCT01868425|DRUG|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
224002914|NCT01868425|DRUG|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane plus placebos of intervention arm meds
224295733|NCT04375930|OTHER|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION|STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
224295734|NCT04375930|OTHER|Control|It consists of only skills and discharge education
224295735|NCT00931268|DEVICE|Macrolane VRF 30|One administration
224295736|NCT01388166|PROCEDURE|Education|Education
224295737|NCT04999033|OTHER|no intervention|This is a cross-sectional study, and no intervention will be included
224295738|NCT05236920|DEVICE|Resuscitative Endovascular balloon occlusion of the aorta using a REBOA catheter device|In-hospital use of a REBOA catheter device during advanced cardiac life support
223385510|NCT06442046|OTHER|Active Case Management|A case manager will work with families post-discharge to ensure that youth are connected to an appropriate community support. Case managers will also work with families to identify any social needs and provide support in accessing services as needed.
223385511|NCT06442046|OTHER|Treatment as usual|Subjects will receive a list of youth serving community service agencies and provided a recommendation to connect to them.
223385512|NCT05152147|DRUG|Zanidatamab|Administered IV
223385513|NCT05152147|DRUG|Tislelizumab|Administered IV
223385514|NCT05152147|DRUG|Trastuzumab|Administered intravenously (IV)
223385515|NCT05152147|DRUG|Capecitabine|Administered orally (PO bid)
223385516|NCT05152147|DRUG|Oxaliplatin|Administered IV
223385517|NCT05152147|DRUG|Cisplatin|Administered IV
224002915|NCT04538612|DEVICE|measure capillary refill time|"Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~* Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~* Veinous vascular occlusion test (30mmHg),~* Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb."
224002916|NCT00443170|DRUG|GSK626616, placebo, midazolam|
224002917|NCT00443170|DRUG|omeprazole, caffeine, flurbiprofen, rosiglitazone|
224002918|NCT02082171|OTHER|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
224002919|NCT05550662|DRUG|129Xenon|There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.
224002920|NCT01712620|DRUG|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
224002921|NCT01712620|DRUG|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
224002922|NCT06400225|PROCEDURE|Biopsy Procedure|Undergo biopsy
224002923|NCT06400225|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224002924|NCT06400225|PROCEDURE|Computed Tomography|Undergo CT scan
224002925|NCT06400225|PROCEDURE|Echocardiography Test|Undergo ECHO
224002926|NCT06400225|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223385518|NCT05152147|DRUG|5-Fluorouracil|Administered IV
223385519|NCT05467085|DEVICE|BX Pulsar 1002|Imaging-Guided Low Intensity Focused Ultrasound Pulsation (LIFU) device
223385520|NCT06399744|PROCEDURE|sclerotherapy|injection of sclerosing agent (tetracycline or polidocanol) into ovarian cyst after aspiration of its contents
223385521|NCT06459492|BEHAVIORAL|puzzle game strategies|"One innovative approach uses puzzle game strategies, including crosswords, Sudoku, and other brain-teasing activities. These strategies have been shown to help maintain attention, improve memory, and keep older adults' thoughts clear and sharp. Additionally, engaging in these activities can provide psychological benefits by offering a sense of achievement, reducing stress, and fostering social interactions.~Given puzzle games' potential to enhance cognitive and psychological health, exploring their effectiveness as a non-pharmacological intervention for community-dwelling older adults is essential. This research aims to fill the gap by empirically investigating the impact of puzzle game strategies on cognitive functioning and psychological well-being in this demographic."
223545576|NCT03856463|BEHAVIORAL|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
223545577|NCT03856463|OTHER|Usual Care|Usual care as provided by local oncologists
224002927|NCT06400225|PROCEDURE|Radionuclide Imaging|Undergo nuclear study
224002928|NCT06400225|DRUG|Ulixertinib|Given PO
224002929|NCT06500429|DRUG|NG101|NG101 20 mg BID
224002930|NCT06500429|DRUG|Placebo|Placebo BID
224002931|NCT06500429|DRUG|Semaglutide Injectable Product|Semaglutide 0.5 or 1 mg
224002932|NCT03993262|DRUG|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
224002933|NCT03993262|DRUG|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
224002934|NCT05572021|DEVICE|Propspective VHR with Fortiva|Ventral hernia repair using Fortiva biologic mesh
224002935|NCT05572021|DEVICE|RetroSpective VHR with Strattice|Retrospective cohort of ventral hernia repair patients using Strattice mesh
224002936|NCT01946529|DRUG|vincristine|Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
224002937|NCT01946529|DRUG|doxorubicin|Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
224002938|NCT01946529|DRUG|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
224002939|NCT01946529|DRUG|ifosfamide|Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
224002940|NCT01946529|DRUG|etoposide|Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
224002941|NCT01946529|DRUG|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
224002942|NCT01946529|DRUG|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
224002943|NCT01946529|DRUG|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
223385522|NCT05019287|BIOLOGICAL|Allogeneic human menstrual blood stem cells secretome|This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.
223385523|NCT05019287|OTHER|Intravenous saline injection|Intravenous saline injection in addition to standard care
224002944|NCT01946529|DRUG|sorafenib|Dosage and route of administration: 90 mg/m\^2/dose PO BID
224002945|NCT01946529|PROCEDURE|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
224002946|NCT01946529|RADIATION|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
224002947|NCT06493162|PROCEDURE|Intubation|Patients will be intubated with 5mm sized endotracheal tube for microscopic laryngeal surgery
224002948|NCT06493162|DEVICE|Flow Controlled Ventilation|Patients in FCV group will be ventilated with flow controlled ventilation mode
223385524|NCT02593110|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
224002949|NCT06493162|DEVICE|Volume Controlled Ventilation|Patients in VCV group will be ventilated with volume controlled ventilation mode
224002950|NCT06511310|OTHER|Exercise|High Intensity Exercise
224002951|NCT05177835|DRUG|ABX464|All subjects will receive ABX464 given at 25 mg QD.
224002952|NCT04218773|DRUG|Phenylephrine|Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.
224002953|NCT04218773|DRUG|Norepinephrine|As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
224002954|NCT06408142|DIAGNOSTIC_TEST|HIV testing|Point of Care HIV testing universally regardless of risk factors
224002955|NCT06408142|OTHER|In-depth interview|In-depth interviews of providers using Normalization Process Theory semi-structured interview guide to assess provider perspectives of PrEP delivery in the ED
224002956|NCT02920112|BEHAVIORAL|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
224002957|NCT06373068|OTHER|Resuscitation orders|Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
224295739|NCT01587586|BIOLOGICAL|PEGASYS 180 µg Q1W|48 doses, solution, 48 weeks
224295740|NCT01587586|BIOLOGICAL|P1101 180 µg Q1W, 48 doses|48 doses, solution, 48 weeks
224295741|NCT01587586|BIOLOGICAL|P1101 270µg Q1W, 48 doses|48 doses, solution, 48 weeks
224295742|NCT01587586|BIOLOGICAL|P1101 450µg Q2W, 24 doses|24 doses, solution, 48 weeks
224295743|NCT05046665|DRUG|89Zr-Girentuximab|Administration of 89Zr-girentuximab as per protocol.
224002958|NCT06655558|DEVICE|custom knee orthosis|The custom knee orthosis will be worn for 8 weeks (56 days).
224002959|NCT06603324|DEVICE|CVVHD treatment in paediatric mode with multiFiltratePRO|Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO
224002960|NCT04482933|BIOLOGICAL|Biological G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
224295744|NCT02138019|PROCEDURE|Fibrin Glue assisted external eye surgery|
224295745|NCT02138019|DEVICE|Fibrin glue|
224295746|NCT00345059|DRUG|docetaxel|
224295747|NCT00345059|DRUG|vinorelbine|
223385525|NCT02593110|DRUG|Telmisartan|Participants randomized to the telmisartan arm of the study will take 20 mg or 40 mg of telmisartan daily based on the results of their study run-in. Participants will have their dose increased to up to 80 mg as tolerated.
223385526|NCT02593110|OTHER|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
223385527|NCT02593110|DRUG|Placebo|
223385528|NCT02554162|OTHER|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
223385529|NCT02885402|OTHER|MRI Sodium ( 23Na )|
223385530|NCT05450419|DIETARY_SUPPLEMENT|Vitamin D3|8pc (576,000 IU/40ml) vitamin D3 on week 1, then 1pc (72,000 IU/5ml) vitamin D3 on week 2, week 3 \& week 4.
223385531|NCT05450419|DIETARY_SUPPLEMENT|placebo|8pc placebo on week 1, then 1pc placebo on week 2, week 3 \& week 4.
223385532|NCT00562523|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
223385533|NCT04198259|PROCEDURE|interventional devascularization|Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.
224295748|NCT00345059|DRUG|gemcitabine|
224295749|NCT00345059|DRUG|capecitabine|
224295750|NCT00376974|BEHAVIORAL|American Academy of Ophthalmology Glaucoma Educational Tape|
224295751|NCT01272362|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
224295752|NCT04823962|DRUG|rhGM-CSF + hydrogel|The active substance: molgramostim (rhGM-CSF)
224295753|NCT04823962|DRUG|Placebo hydrogel|Placebo hydrogel
224295754|NCT04823962|OTHER|Standard care|Compression therapy and neutral dressings
224295755|NCT02541162|BEHAVIORAL|Oral information and interviews|interviews about sexuality and self experience during the disease
223385534|NCT04198259|PROCEDURE|TIPS|TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.
224002961|NCT04866004|BEHAVIORAL|Contingency Management - Cannabis|Participants in the contingency management program will be provided financial incentives for 28-days of cannabis abstinence. At every visit, participants will provide urine samples for the biochemical verification of cannabis abstinence). Participants with evidence of cannabis abstinence will be provided a financial incentive that increases across subsequent study visits.
224002962|NCT06817902|DEVICE|Intermittent theta burst stimulation active coil|MagVenture TMS Therapy active coil with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
224002963|NCT06817902|DEVICE|Sham coil|MagVenture TMS Therapy sham coil
224002964|NCT06293794|OTHER|Personalized Clinical Decision Support (CDS)|The personalized CDS intervention evaluates clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. This is done through a nudge in the electronic health record that addresses common prescribing misconceptions for heart failure.
224002965|NCT06293794|OTHER|Traditional Clinical Decision Support (CDS)|The traditional CDS is the usual care intervention, which is patient-specific but are not clinician-specific.
224002966|NCT02525601|DEVICE|Triathlon CR cemented|Implantation of Knee Prosthesis
224002967|NCT02525601|DEVICE|Triathlon CR uncemented|Implantation of Knee Prosthesis
224002968|NCT06396078|DRUG|Ceftriaxone 1000 MG|Ceftriaxone 1 g IV q 24 hours x 7 days (in addition to clarithromycin and metronidazole)
224002969|NCT06396078|DRUG|Clarithromycin 500mg|Clarithromycin 500 mg PO BID x 7 days (in addition to ceftriaxone and metronidazole)
224002970|NCT06396078|DRUG|Metronidazole 500 mg|Metronidazole 500 mg PO q 12 hours x 7 days (in addition to clarithromycin and ceftriaxone)
224002971|NCT06396078|DRUG|Ampicillin 2 GM Injection|Ampicillin 2 g IV q 6 hours x 48 hours (prior to amoxicillin and in addition to either azithromycin or erythromycin)
224002972|NCT06396078|DRUG|Amoxicillin 250 MG|Amoxicillin 250 mg q 8 hours for an additional 5 days (following ampicillin and in addition to either azithromycin or erythromycin)
223385535|NCT04237935|DRUG|Ticagrelor 90mg|Ticagrelor 90 mg dispensing claim is used as the exposure group
224002973|NCT06396078|DRUG|Azithromycin|Azithromycin 1 g PO x 1 dose (in addition to ampicillin and amoxicillin)
224295756|NCT02273791|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
223385536|NCT04237935|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
224002974|NCT06396078|DRUG|Erythromycin|Erythromycin 250 mg IV q 6 hours x 48 hours followed by erythromycin 333 mg PO TID for an additional 5 days (in addition to ampicillin and amoxicillin)
224002975|NCT04154982|DRUG|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
224002976|NCT06590467|DEVICE|Amplatzer™ Occlusion Devices|The Amplatzer™ Occluders are devices intended for the occlusion of multiple septal heart defects.
224002977|NCT06590467|DEVICE|Epic™ Surgical Tissue Heart Valve devices|The Epic™ valves are indicated for patients requiring replacement of a diseased, damaged, or malfunctioning native aortic/mitral heart valve. It may also be used as a replacement for a previously implanted aortic/mitral prosthetic heart valve.
224002978|NCT06591091|DRUG|Clemastine Fumarate|Listed in arm/group description
224002979|NCT06591091|DRUG|Placebo|Listed in arm/group description
224002980|NCT06604234|DIETARY_SUPPLEMENT|Probiotic|Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 in concentration of 1E09 CFU/capsule
224002981|NCT06604234|OTHER|Placebo|Placebo comparator containing maltodextrin
224002982|NCT06990087|DRUG|Application of T-lymphocytes|Dosage form: Infusion; Route of administration: Intravenous; Cell dose: 1-2 x 10.000 viable CD3+ T-lymphocytes per kg bodyweight; Application at three timepoints: baseline, after two weeks, after 6 weeks
224002983|NCT06994468|DIAGNOSTIC_TEST|Flow-cytometry tetramer-based antigen-bait assay|"For tetramer assembly, recombinant biotinylated PLA2R will be incubated with either streptavidin-PE (Agilent) or streptavidin-APC (Agilent) conjugates according to the NIH protocol (https://tetramer.yerkes.emory.edu/support/protocols#10).~PBMCs will be thawed and resuspended in antibody cocktail medium containing 7.5ug APC- and PE- PLA2R tetramers. Multicolor flow cytometry will be used to identify B-cell subsets with standard technique and equipment (FACS FortessaX20, BD Biosciences and FlowJo software). PLA2R-specific B cells will be determined as Tetramer double (PE/APC) positive B cells that bind with proportional fluorescent intensities to each tetramer. Each sample will be incubated with only streptavidin-PE/APC conjugates to exclude B cells binding to the fluorochrome portion of the tetramers. T cell- and NK/NKT cell phenotyping will be assessed by FACS using ad-hoc antibody panels."
224002984|NCT05702684|OTHER|electronic Holistic Needs Assessment (eHNA)|eHNA to be completed within 31 days of diagnosis (standard care). ARC clinic previously offered 6-24 months post-diagnosis.
224295757|NCT02273791|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
224295758|NCT05712525|DIAGNOSTIC_TEST|G-Tech Wireless Patch System (WPS)|Noninvasive monitoring of myoelectrical signals
223385537|NCT02986477|OTHER|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
223385538|NCT01168752|DRUG|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
223385539|NCT00000691|DRUG|Foscarnet sodium|
223385540|NCT02831426|DEVICE|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
223385541|NCT02831426|DEVICE|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
223385542|NCT05488093|DEVICE|X-sens sensor|"the procedure will include:~* 7 to 8 sensors (Foot, leg, thigh, pelvis and chest possibly).~* 5 movements/exercises for the patients, each exercise performed 3 times except walking~* Analysis of 20m walking cycle (normal speed, most natural arm movement, 4 return trips of 20m):~* Climbing up and down stairs (using the public stairs of the rheumatology access department, 6 steps of 20 cm height, at normal speed, without using the handrail)~* Getting up from a chair without the help of hands (start standing, then the patient sits, leans and stands up, feet together, without taking the feet off the floor, using one and the same chair for each patient with a height of 50 cm)"
223385543|NCT02796053|DRUG|TAB08|The TAB08 will be administered intravenously, by infusion.
223385544|NCT02796053|OTHER|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
223385545|NCT06397495|OTHER|Education|Cervical region manual therapy training will be given with flipped learning models.
223385546|NCT04625244|OTHER|Video assisted home therapy|Subjects will follow along with prerecorded therapy videos.
223385547|NCT00426439|DRUG|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
224002985|NCT06597656|GENETIC|delandistrogene moxeparvovec|Single IV infusion of delandistrogene moxeparvovec
224002986|NCT06597656|PROCEDURE|Plasmapheresis|Therapeutic plasma exchange procedure
223385548|NCT00426439|DRUG|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
223385549|NCT06712082|DRUG|PF-07264660|PF-07264660 solution for injection (single use only)
223385550|NCT06712082|OTHER|Placebo|Placebo solution for injection (single use only)
223385551|NCT06887192|DRUG|ML-007C-MA|ML-007C-MA dosed as 105/1.5 mg (one tablet of 105/1.5 mg ML-007C-MA), or 210/3 mg (two tablets of 105/1.5 mg ML-007C-MA )
223385552|NCT06887192|DRUG|Placebo|Placebo Tablets
223730036|NCT02007876|BEHAVIORAL|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
224002987|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 1，IVI
223385555|NCT06619769|BEHAVIORAL|eSense-Cancer CBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer CBT is an online, cognitive behavioural therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer CBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
223385556|NCT06619769|BEHAVIORAL|Navigator support for eSense-Cancer|The eSense digital health tool has been previously tested alongside the support of treatment navigators - trained undergraduate students, not licensed therapists, who provide encouragement and answer any questions users may have as they work through eSense.
224002988|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 2，IVI
224002989|NCT06672536|DRUG|SCT520FF|SCT520FF dose level 3，IVI
224002990|NCT06672536|DRUG|EYLEA 2 MG|EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period
224002991|NCT06858137|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in four weeks using a single Polydioxaone thread. Needles have a gauge size of 30G, a shaft length of 26mm, folded in half, and are applied to nine acupoints, including Yintang (EX-HN3), Yingxiang (LI20) on both sides of the body. Needles with a gauge size of 29G, a shaft length of 30mm, and a thread length of 50mm, folded in half, are used for three acupoints, which included Hegu (LI4), Zusanli (ST36), Feishu (BL13), on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
223385557|NCT06619769|BEHAVIORAL|Behavioral: eSense-Cancer MBT: an online cognitive-behavioural therapy based intervention for sexual health concerns after gynecologic cancer|eSense-Cancer MBT is an online, mindfulness-based therapy based intervention for sexual health concerns after gynecologic cancer. eSense-Cancer MBT contains 8 modules and is intended to be completed over 8-16 weeks. It contains theoretical content, case-based learning, and at-home exercises.
223385558|NCT06628947|OTHER|Placebo (Sterile Saline or Balanced Salt Solution)|A control 50 μl injection of clear sterile saline or balanced salt solution (BSS) liquid.
223385559|NCT06628947|DRUG|100 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
223385560|NCT06628947|DRUG|50 μg KIO-301|KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
223385561|NCT04286711|DRUG|Albumin-paclitaxel, Apatinib, Camrelizumab|Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
223385562|NCT07045740|OTHER|PT Navigator|Participants assigned to the intervention group will meet with the PT Navigator withing the first month of starting cancer treatment. Following a one-hour initial assessment, the PT Navigator will follow up every two-three weeks for a total of six sessions. The PT Navigator will administer outcome measures to screen for complications or side effects of treatment. If any complications or side-effects are identified, the PT Navigator will facilitate referrals to other health care practitioners, provide exercise and/or rehabilitation treatment, or provide education and continue monitoring.
223385563|NCT07046559|DRUG|LY4066708|Administered IV
223385564|NCT07046559|DRUG|Placebo|Administered IV
223385565|NCT07046559|DRUG|LY4066708|Administered SC
224002992|NCT06858137|OTHER|Standal treatment|Inhaled corticosteroid spray - fluticasone propionate patients were permitted to use Fluticasone propionate 1 or 2 sprays (50 mcg/spray) in each nostril once a day as needed in four weeks and participants must change life style attaches including smoke and traffic pollution avoidant, preventing pets going into the bedroom, washing clothes.
224002993|NCT04446728|BEHAVIORAL|Training Webinar|The training webinar is a three hour training. The purpose of the study is to implement the Psychosocial Assessment Tool (PAT) in their center.
224002994|NCT04446728|BEHAVIORAL|Training Webinar Plus Implementation Enhanced Resources (TIER)|In addition the Training Webinar, sites randomized to Strategy II will identify a Champion and will participate in monthly consultation calls in support of implementation of the PAT
224002995|NCT07127692|DIAGNOSTIC_TEST|Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F) questionnaire|Self-administered screening tool for sarcopenia
224002996|NCT07127692|DIAGNOSTIC_TEST|Hand grip strength|Used to assess sarcopenia
224002997|NCT07127692|DIAGNOSTIC_TEST|Timed Up and Go test|Screening test for falls in elderly
224002998|NCT07127692|DIAGNOSTIC_TEST|Gait speed|Assessment to check for functional mobility and risk of falls.
223385566|NCT07046559|DRUG|Placebo|Administered SC
223385567|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
223385568|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
223385569|NCT01012310|DRUG|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
223385570|NCT01012310|DRUG|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
224002999|NCT07127692|DIAGNOSTIC_TEST|Clinical Frailty Scale (CFS)|Used to assess level of frailty.
224003000|NCT05582499|DRUG|Dalpiciclib|an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
224003001|NCT05582499|DRUG|Pyrotinib|an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
224003002|NCT05582499|DRUG|SHR-A1811|an anti-HER2 antibody-drug conjugate (ADC)
224003003|NCT05582499|DRUG|SHR-1316|an anti-programmed death ligand 1 (PD-L1) antibody
224003004|NCT05582499|DRUG|Camrelizumab|an anti-programmed death-1 (PD1) antibody
224003005|NCT05582499|DRUG|SHR-A1921|Trophoblast cell-surface antigen 2 (TROP2) ADC
224003006|NCT05582499|DRUG|Pertuzumab|Pertuzumab
224003007|NCT05582499|DRUG|Trastuzumab|Trastuzumab
223385571|NCT02568839|DRUG|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
223385572|NCT02568839|DRUG|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
223385573|NCT06451211|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered systemically on day 1 of each cycle in all participants
223385574|NCT06451211|DRUG|Oxaliplatin|Oxaliplatin 150 mg will be administered systemically on day 1 of each cycle in all participants
223385575|NCT06451211|DRUG|S-1|S-1 40 mg will be administered orally on day 1-14 of each cycle in all participants
223385576|NCT06451211|DRUG|Capecitabine|Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
223385577|NCT06740253|DEVICE|Placebo intravaginal ring (IVR)|Antibody-Based Nonhormonal Placebo Contraceptive Intravaginal Ring
223385578|NCT00930163|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
224003008|NCT05582499|DRUG|Goserelin|goserelin
224003009|NCT05582499|DRUG|Letrozole|letrozole
224003010|NCT05582499|DRUG|Nab paclitaxel|Albumin paclitaxel
224003011|NCT05582499|DRUG|Carboplatin|Carboplatin
224003012|NCT05582499|DRUG|Epirubicin|Epirubicin
224003013|NCT05582499|DRUG|Cyclophosphamide|Cyclophosphamide
224003014|NCT05582499|DRUG|Fluzoparib|an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
224003015|NCT05582499|DRUG|Apatinib|tyrosine kinase inhibitors
224003016|NCT05582499|DRUG|Famitinib|tyrosine kinase inhibitors
223385579|NCT00930163|DRUG|placebo|Subcutaneous repeating dose
223385580|NCT00745784|BEHAVIORAL|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
223385581|NCT01499433|DRUG|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
223385582|NCT01670591|BEHAVIORAL|PS - Prevention in School|
223385583|NCT03086551|DEVICE|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
224003017|NCT05582499|DRUG|HB1801|Albumin docetaxel
223385584|NCT03086551|DEVICE|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
223385585|NCT03086551|BEHAVIORAL|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
223385586|NCT00933361|DRUG|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
223385587|NCT02389231|DRUG|Interleukine-2|"Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
223385588|NCT00364936|PROCEDURE|Palliative care service|
223385589|NCT04848727|OTHER|Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)|"The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support."
223385590|NCT00100880|DRUG|lenalidomide|Given PO
223385591|NCT00100880|PROCEDURE|perfusion-weighted magnetic resonance imaging|Correlative studies
223385592|NCT00100880|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
223385593|NCT00100880|OTHER|laboratory biomarker analysis|Correlative studies
223385594|NCT02487225|DRUG|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
223385595|NCT02487225|DRUG|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
224003018|NCT05582499|DRUG|LEM|liposome-entrapped mitoxantrone
224003019|NCT05582499|DRUG|TQB2102|an anti-HER2 ADC
224003020|NCT05582499|DRUG|Benmelstobart|an anti-PDL1 antibody
224003021|NCT05582499|DRUG|Anlotinib|an tyrosine kinase inhibitor
224003022|NCT05582499|DRUG|TQB2868|anti-PD-1/TGF-βRII
224003023|NCT05582499|DRUG|Ivonescimab|an anti-PD-1/VEGF bispecific antibody
224003024|NCT05582499|DRUG|JS207|an anti-PD-1/VEGF bispecific antibody
223385596|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
223385597|NCT00625872|DRUG|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
224003025|NCT05582499|DRUG|JSKN003|an anti-HER2 ADC
224003026|NCT05582499|DRUG|HRS-4508|an HER2 inhibitor
224003027|NCT05582499|DRUG|SHR-4602|an anti-HER2 ADC
224003028|NCT05582499|DRUG|paclitaxel|paclitaxel
224003029|NCT06603363|DRUG|Rosuvastatin 40mg|Participants will receive 40 mg of rosuvastatin once a day for 3 months. After the 3-month visit, the dose will be reduced to a dose per standard of care.
224003030|NCT06603363|DRUG|Placebo|Participants will receive a placebo for rosuvastatin once a day for 3 months. After the 3-month visit, standard rosuvastatin will be initiated.
224003031|NCT06603363|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography (Coronary CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography at baseline, 3-month, and 24-month visits with a PCD-CT scanner.
224003032|NCT06603363|DIAGNOSTIC_TEST|Blood test|Blood test at baseline, 3-month, and 24-month visits.
224295759|NCT03858595|DEVICE|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
224124451|NCT06576011|BEHAVIORAL|Gamified Social Norms Marketing Campaign|This intervention is a gamified social norms marketing campaign (SNMC) primarily disseminated via advertisements on Instagram. These advertisements will invite students to participate in a game about student life at their university, during which misperceived alcohol norms will be corrected. The gamified SNMC spans the first full six weeks of students' first fall semester in college and includes three rounds of play. Round one occurs during the first two weeks, round two during the third and fourth weeks, and round three during the fifth and sixth weeks. In the game, participants are asked to identify whether normative facts related to a variety of topics are true or false. Correct feedback is then provided, intended to reinforce accurate norms related to alcohol use, which are embedded alongside other facts about college life.
224003033|NCT07015385|DEVICE|Lip Bumper with Integrated Distal Shoe|This novel appliance integrates a traditional lip bumper with a distal shoe extension designed to engage the mesial surface of the unerupted second permanent molar. The goal is to prevent mesial movement of the first molars and guide proper eruption of the second molars while simultaneously addressing anterior deep bite by eliminating lip pressure and promoting vertical incisor development. The device will be custom-fabricated for each participant and will be worn for 12 months, with clinical and radiographic evaluations conducted every 6 weeks.
224003034|NCT07015385|DEVICE|Conventional Lip Bumper|The conventional lip bumper is an interceptive orthodontic appliance used to alleviate lower anterior crowding, eliminate perioral muscle pressure, and promote dental arch expansion. It does not include a distal shoe component and therefore offers no guidance for second molar eruption. This device will also be custom-fabricated and worn for 12 months, with scheduled monitoring every 6 weeks to assess treatment progress and compare outcomes with the experimental device.
224003035|NCT06689267|DIAGNOSTIC_TEST|computed tomography myocardial perfusion|The diagnostic value of CT perfusion (CTP) has been established in patients with stable coronary artery disease, but relevant studies have not yet been conducted in suspected NSTEMI patients. This study aims to explore the diagnostic and therapeutic value of an initial CTP strategy for suspected NSTEMI patients.
224003036|NCT06689267|PROCEDURE|Invasive Coronary Angiography|Patients enrolled in the Invasive Coronary Angiography group will directly undergo coronary angiography. If necessary, intracoronary imaging (including IVUS and OCT) will be performed.
224003037|NCT03649178|OTHER|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
224003038|NCT02030613|GENETIC|Blood test|
224003039|NCT03270631|OTHER|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
224003040|NCT03270631|OTHER|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
224003041|NCT03270631|OTHER|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
224003042|NCT03270631|OTHER|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
224003043|NCT07030179|OTHER|Frailty status|This was an observational study with no intervention measures. The exposure factor was the frailty status of the patients.
224003044|NCT07030166|OTHER|No intervention measures were used.|The exposure factors were the perioperative related operations experienced by the patients and their individual conditions
224003045|NCT06876259|DIAGNOSTIC_TEST|Standard Clinical Ear Exam|The clinician will examine the child's ear with a standard otoscope and give a clinical diagnosis and decision to treat with antibiotics.
224124452|NCT06576011|BEHAVIORAL|Social Norms Marketing Campaign|This intervention is a social norms marketing campaign that is primarily delivered via advertisements on Instagram. These advertisements will contain normative facts related to student life at their university, during which misperceived alcohol norms will be corrected.
224003046|NCT06876259|DIAGNOSTIC_TEST|AI app ear exam and diagnosis|Using a standard otoscope with a cell phone mounted to it, research personnel will record a video image of the tympanic membrane and send it to the cloud for analysis using AI enhanced classification software to render a diagnosis and treatment recommendation
224003047|NCT06877793|DIAGNOSTIC_TEST|Administration of indocyanine green (ICG) and fluorescence imaging|Patients with clinical and lab findings consistent with a diagnosis of NSTI who consent to this study will receive a one-time, weight-appropriate dose of ICG (0.2 mg/kg, in accordance with FDA-approved recommendations). Each patient will undergo fluorescence imaging immediately before and after administration of ICG.
224003048|NCT07138482|OTHER|Survey using a questionnaire.|REDCap Survey
224003049|NCT07135479|OTHER|Youth Mental Health First Aid|This Youth Mental Health First Aid training has been adapted for South Asian American adults working with South Asian American youth. This training is a full-day, 5.25 hour blended course (some self-paced work and some live, virtual participation).
224003050|NCT07137000|OTHER|Art therapy|Five different art therapy methods (making bead jewelry, pencil drawing, painting, mandala, making clay figures) be used for people in this group.
224003051|NCT07137988|DIETARY_SUPPLEMENT|600 mg grape seed extract|Each participant took either GSE (300 mg, 2 capsules) or a placebo (300 mg, 2 capsules filled with starch) 2 hours before their scheduled lab visit. The supplements were made to look identical to prevent any bias from the participants or the testers. There was a washout period of at least 72 hours, but no more than a week, between each trial.
224003052|NCT07137988|DIETARY_SUPPLEMENT|600 mg Starch|Each participant took either GSE (300 mg, 2 capsules) or a placebo (300 mg, 2 capsules filled with starch) 2 hours before their scheduled lab visit. The supplements were made to look identical to prevent any bias from the participants or the testers. There was a washout period of at least 72 hours, but no more than a week, between each trial.
224124453|NCT06285552|BEHAVIORAL|Positive parenting PAIF program|Psychoeducational intervention in a group format driven by a practitioner with 6 to 12 sessions where caregivers learn parenting competences
224124454|NCT01016106|GENETIC|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
224124455|NCT04906655|DRUG|Glycopyrronium 2.4 % Medicated Cloth|The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
224124456|NCT01631279|DRUG|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
223385598|NCT01015469|PROCEDURE|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
223385599|NCT01015469|PROCEDURE|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
223385600|NCT00043810|PROCEDURE|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10\^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
223385601|NCT00043810|DRUG|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
223385602|NCT00043810|DRUG|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
223385603|NCT05429866|DRUG|Checkpoint Blockade, Immune|Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.
223385604|NCT04208750|DEVICE|Vision R-800 Phoropter|Refraction utilizing the Vision R-800 Phoropter with resulting glasses
223385605|NCT04208750|DEVICE|Standard Phoropter|Refraction utilizing the standard phoropter with resulting glasses
223385606|NCT00108706|DRUG|Candesartan|
224003053|NCT06721585|DRUG|Tecovirimat Oral Capsule [Tpoxx]|"Tecovirimat Oral Capsule 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
224003054|NCT06721585|OTHER|Standard of Care (SOC)|Participants are provided SOC for mpox
224003055|NCT07041736|DEVICE|diode laser|980 nm diode laser with optical fiber 200 µm (Lite medics, Italy) and power setting 1.2 watt in pulsed mode. The irradiation protocol will be a 5 sec. irradiation followed by a 10 sec. rest, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth.
224003056|NCT07041736|OTHER|conventional irrigation|After each file use, the root canal will be irrigated with 5ml of freshly prepared 2.5% sodium hypochlorite (NaOCl) solution (Alex. Deteregents and Chemical Co., Egypt) for 1 minute using a 31-gauge Navi-Tip flexible irrigating needle (Navi-Tip, Ultradent product, South Jourdan, UT). 5 ml of 17% EDTA (Colgate Oral Care Company, Waverly, Australia) for 1 min will be used for smear layer removal. 5 ml of saline solutio
223385607|NCT01119664|DRUG|SCH 721015|
224003057|NCT07041736|DEVICE|Diode laser|980 nm diode laser with optical fiber 200 µm (Lite medics, Italy) and power setting 1.2 watt in pulsed mode. The irradiation protocol will be a 5 sec. irradiation followed by a 10 sec. rest, which constituted one lasing cycle. The lasing cycle will be performed four times for each tooth.
224003058|NCT07041736|DEVICE|Ultrasonic|The needle will be operated using Satelec P5 Piezoelectric Ultrasonic Unit (Acteon, Mount Laurel, NJ, USA.) at power setting of 5. The stopper on the PiezoFlow needle will be set 1 mm short of binding in the canals, but not more than 75% of the WL. A syringe containing 5 mL of 2.5% NaOCl will be attached to the Piezoflow activation needle and the inactive needle will be inserted in the canal, and irrigant flow will be started before activation. During activation, the needle will be moved up and down passively in the canal
224295760|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
224295761|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
223385608|NCT02201277|DEVICE|Filter Placed|
223385609|NCT03590054|DRUG|Abexinostat|Given orally (PO) twice a day (BID) days 1-4, 8-11 of every 21 day cycle
223385610|NCT03590054|BIOLOGICAL|Pembrolizumab|Given IV on day 1 of every 21 day cycle
223385611|NCT00869076|OTHER|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
223385612|NCT00869076|OTHER|Usual care|Patient was managed by their primary care physician as usual
223385613|NCT02637531|DRUG|IPI-549 (eganelisib)|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
223385614|NCT02637531|DRUG|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
223385615|NCT05965973|OTHER|Low fat diet|During 3 days, subjects eat a diet low in fat (percent of total caloric intake: 15.0% from proteins; 65.0% from carbohydrates; 20.0% from fat: 4.0% from saturated fat; 10.0% from monounsaturated fat; 6.0% from polyunsaturated fat
223385616|NCT05965973|OTHER|High fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 45.0% from carbohydrates; 40.0% from fat: 8.0% from saturated fat; 22.0% from monounsaturated fat; 10.0% from polyunsaturated fat
223385617|NCT03451214|OTHER|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
223385618|NCT03777163|BIOLOGICAL|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
223385619|NCT03777163|BIOLOGICAL|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (\> 60 years),11,12 children (six months to three years) 13 and pregnant women.
223385620|NCT05967884|DRUG|Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab|Arm A: Cemiplimab: 350mg IV x 1 dose administered prior to surgery Arm B: Cemiplimab + Dupilumab: Cemiplimab 350mg IV x 1 dose + Dupilumab 600 mg SC x 1 dose administered prior to surgery
223385621|NCT03649984|BEHAVIORAL|Symptom Navi© Program|Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
223385622|NCT01049646|DRUG|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
223385623|NCT01049646|DRUG|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
223385624|NCT01958138|DRUG|comparison of group-I (low dose propofol with isoflurane)|Prior to LMA removal in group-I, isoflurane MAC awake (MAC less than 0.5) will be achieved in expiratory gases with 60% nitrous oxide and 40% oxygen. Propofol 1 mg/Kg will be combined with Isoflurane MAC awake and LMA will be removed after 20 seconds of propofol administration in group-I. The group-II LMA will be removed at end expiratory isoflurane MAC of 1.2% with 60% nitrous oxide and 40% oxygen
223385625|NCT00272051|DRUG|SR57746A|
224003059|NCT07031388|COMBINATION_PRODUCT|1-Hydrogen peroxide and hyaluronic acid|"Hydrogen Peroxide (1.80%): Acts as an antiseptic agent, releasing oxygen that helps in reducing bacterial load and disrupting biofilms associated with gingivitis.~* Hyaluronic Acid (0.10%): A naturally occurring polysaccharide known for its anti-inflammatory and tissue-regenerative properties, aiding in the healing of gingival tissues Clinical studies have demonstrated the efficacy of Perhyal in managing gingivitis. In a randomized controlled trial, Perhyal showed a significant reduction in gingival inflammation compared to placebo, with no reported adverse effects over 21 days."
224003060|NCT07031388|COMBINATION_PRODUCT|2- Hyaluronic acid|This intervention involves the use of a mouthwash containing hyaluronic acid (0.12%) of high molecular weight, without any additional active agents. Hyaluronic acid is a naturally occurring substance known for its anti-inflammatory and wound-healing properties. It supports gingival tissue regeneration and hydration, which may contribute to reducing signs of gingivitis such as redness, swelling, and bleeding. Participants assigned to this arm will rinse with 10 mL of the solution twice daily for three weeks, following standardized oral hygiene instructions. This arm serves to evaluate the independent therapeutic effect of hyaluronic acid in managing gingival inflammation.
224003061|NCT07031388|COMBINATION_PRODUCT|Chlorhexidine|This intervention uses a commercially available chlorhexidine gluconate 0.12% mouthwash, widely recognized for its strong antimicrobial properties. Chlorhexidine is considered a gold-standard agent for chemical plaque control and is effective in reducing bacterial load, gingival inflammation, and bleeding. Participants in this group will rinse with 10 mL of the solution twice daily for three weeks, in addition to maintaining regular oral hygiene practices.
224003062|NCT07031388|COMBINATION_PRODUCT|Placebo mouthwash|This placebo mouthwash was specially formulated to visually and sensorially resemble the active mouthwash products without containing any active therapeutic ingredients. It was prepared in the AwaMedica laboratory using 1 liter of distilled water, 98.5% distilled water, 2 mL of glycerin for mild viscosity, 5 mL of vanilla flavoring for taste masking, and 8 mL of brown food coloring to match the appearance of chlorhexidine. The solution was stored in 120 mL opaque brown bottles, each labeled only with the participant number to ensure blinding. Participants will use 10 mL of the placebo rinse twice daily for three weeks, following the same oral hygiene protocol as other groups.
224003063|NCT01734733|OTHER|NTCELL|
224003064|NCT00365170|DRUG|human insulin|
224003065|NCT00365170|DRUG|insulin aspart|
224003066|NCT06724003|OTHER|Computer-based virtual reality simulation|The computer-based virtual practice simulation was created as a single scenario for oral care practice in the unconscious patient. The scenario software was created and designed by the researcher who is an IT specialist. In the formation phase of the scenario, the software was realized by working together with the researcher, the expert faculty member, the nurse and the informatics specialist for the photographs required for the virtual reality application and the steps of the scenario software.
224003067|NCT06390865|PROCEDURE|Biopsy Procedure|Undergo biopsy
224003068|NCT06390865|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224003069|NCT06390865|PROCEDURE|Computed Tomography|Undergo CT scan
223385626|NCT00273897|DEVICE|Phoresor II|
223385627|NCT05808478|BEHAVIORAL|AAC + Eye Tracking|The AAC treatment will be supported by the use of an innovative high-tech tool, such as Eye Tracking. The duration of treatment will be 6 months, with sessions of 45 minutes twice a week.
223385628|NCT05808478|BEHAVIORAL|AAC|Treatment involves the use of conventional AAC, with low-tech tools, such as PECS or sign language. The duration of treatment will be six months, twice a week, with sessions of 45 minutes.
223385629|NCT02561117|DRUG|Metronidazole|Administration once daily
223385630|NCT03778073|DRUG|Cosibelimab|Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
223385631|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-6 Days 1\&15, Cycles 7-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
223385632|NCT03778073|DRUG|Cosibelimab + Ublituximab + Bendamustine combination|"Cosibelimab (Intravenous infusion):~Cycle 1-12 Day 1, Cycles 15-24 Day 1 every 3 cycles;~Ublituximab (Intravenous infusion):~Cycles 1-6 Day 1, Cycles 9-24 every 3 Cycles;~Bendamustine (Intravenous infusion):~Cycle 1 Days 2\&3, Cycles 2-6 Days 1\&2."
223385633|NCT01320501|DRUG|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
223385634|NCT01512160|DRUG|PF-04531083|2000 mg oral solution
223385635|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
223385636|NCT01512160|DRUG|PF-04531083|1000 mg oral solution
223385637|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
223385638|NCT01512160|DRUG|Ibuprofen|2 x 200 mg tablets
223385639|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
223385640|NCT01512160|OTHER|Placebo|Placebo solution for PF-04531083
223385641|NCT01512160|OTHER|Placebo|Placebo tablets for Ibuprofen
223425580|NCT01654653|DRUG|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
223385642|NCT07055165|BEHAVIORAL|Prostate Cancer Genius App|Participants assigned to use the Prostate Cancer Genius App will receive a combination of (a) scheduled and (b) on-demand content prostate cancer for one month. Scheduled content will be delivered on specific days each week using app notifications. Participants will also receive tailored navigation for ordering a home-based PSA kit, including receiving follow-up information from trained medical professionals about their test results.
223385643|NCT07055165|BEHAVIORAL|US Prevention Taskforce App|Participants assigned to use the US Prevention Task Force app will download the app from Google Play and will be instructed to use the app for one-month to to become more informed about prostate cancer. They will also be instructed to download a companion app from the Google Play store. This companion app will be used to deliver weekly assessments and order a home-based PSA test kit if the participant chooses to so. Participants assigned to the Prevention Taskforce app will receive a brochure providing details about the purpose of the home-based PSA test.
223385644|NCT05708430|DRUG|SVF injection into wrist|Intra-articular injection of autologous cells from the stromal vascular fraction derived from adipose tissue
223385645|NCT01246310|DIETARY_SUPPLEMENT|Inositol|
224003070|NCT06390865|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223385646|NCT01246310|DIETARY_SUPPLEMENT|Placebo|
223385647|NCT07053917|DRUG|Psilocybin (Usona Institute)|Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.
223385648|NCT05725863|OTHER|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is a structured group intervention developed by Segal et al. (2002). The intervention consisted of eight weekly 2.5-hr sessions and one 3-hr silent session. First, psycho-education focused on the importance of recognizing personal feelings and the relationship between stress, postpartum blues, mother-infant attachment and breastfeeding symptoms, and stress management, stress, postpartum blues, mother-infant attachment and breastfeeding. Additionally, postpartum mothers' experiences of stress, postpartum blues, mother-infant attachment, and breastfeeding were central during the study and were a recurring topic for the purpose of the study in general. Postpartum mothers were given homework assignments, including audio CDs with formal exercises, and were asked to practice for 30 min per day.
224003071|NCT06390865|DRUG|Sapanisertib|Given PO
223385649|NCT03878212|OTHER|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
223385650|NCT03878212|OTHER|mHealth application|a mHealth device
223385651|NCT01971047|DRUG|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG \>180 per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
223385652|NCT01971047|DRUG|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose \> 180, per the following formula:~1. Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~2. Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~3. Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~4. Consider repeating dose if BG\>240 mg/dl after 2 hours of initial dose"
223385653|NCT04610333|BEHAVIORAL|Modified MBSR programme|1 hour group session once a week in 10 weeks
224003072|NCT06726928|DEVICE|Sinus Stenting|Stenting of symptomatic sinus stenosis
224003073|NCT03004053|DEVICE|Reflectance Confocal Microscopy (RCM) endoscope device|
224003074|NCT06379542|DRUG|XC8|40 mg/day or 80 mg/day for 7-14 days
224003075|NCT06379542|DRUG|Placebo|2 tablets/day for 7-14 days
223385654|NCT06191029|BEHAVIORAL|Urdu translated cognitive failure questionnaire|Urdu Translated version of cognitive failure questionnaire will be given to adults to fill it accordingly and then it's reliability and validity will be checked
223385655|NCT02163057|BIOLOGICAL|INO-3112|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered intramuscularly (IM) followed immediately by electroporation (EP) with CELLECTRA™-5P device for a total of 4 doses of immunotherapy.
223385656|NCT02163057|DEVICE|CELLECTRA™-5P|CELLECTRA™-5P device was used for EP following IM delivery of INO-3112 for a total of 4 doses of immunotherapy.
223385657|NCT06758310|OTHER|Individualized Exercise|Each participant will be prescribed an individualized exercise program related to their fitness testing results and personal interests.
223385658|NCT03807570|DIETARY_SUPPLEMENT|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
224003076|NCT02995759|OTHER|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
224003077|NCT06256328|DRUG|ONO-4578|Specified dose, once daily
224003078|NCT06256328|DRUG|Oxaliplatin|Specified dose on specified days
224003079|NCT06256328|DRUG|Capecitabine|Specified dose on specified days
224003080|NCT06256328|DRUG|S-1|Specified dose on specified days
224003081|NCT06256328|DRUG|Nivolumab|Specified dose on specified days
224003082|NCT06256328|DRUG|Placebo|Specified dose, once daily
224003083|NCT06729632|DEVICE|Cold pack-delivered mild therapeutic hypothermia|Mild therapeutic hypothermia (cooling), delivered non-invasively to the structures of the inner ear (cochlea) for 30 minutes, using headband-style proprietary device, ReBoundRx.
224003084|NCT06728605|DEVICE|Enhanced External Counterpulsation (EECP)|Patients randomly assigned to EECP received 3 1/2-h sessions of EECP for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 300 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
224295762|NCT00430495|DRUG|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
224295763|NCT00430495|DRUG|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
223385659|NCT03807570|DIETARY_SUPPLEMENT|Placebo|Placebo 30 ml/day for 12 weeks.
223385660|NCT04652960|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223385661|NCT04652960|PROCEDURE|Computed Tomography|Undergo CT scan
223385662|NCT04652960|DRUG|Duvelisib|Given PO
223385663|NCT04652960|BIOLOGICAL|Nivolumab|Given IV
224003085|NCT06728605|DEVICE|Sham Comparator|Patients randomly assigned to sham group received 3 1/2-h sessions of sham treatment for 3 days before surgery. Three pneumatic cuffs will be placed around the lower limbs and buttocks and will be inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure will be 70 mm Hg and was reached within 5 min of the initiation of treatment. Pulse oximetry will be monitored continuously during the treatment session, and the subject's clinical status will be re-evaluated if the oxygen saturation drops by 4%.
224003086|NCT06889324|OTHER|Vibration therapy|Its therapy uses mechanical vibrations delivered via a specialized device called Thrive vibrator device model 717 to stimulate the calf muscles, which can help reduce the severity of restless legs syndrome and sleep disturbances among patients undergoing hemodialysis.
224003087|NCT06728046|OTHER|ESPB|Participants will receive ultrasound-guided ESPB preoperatively, using 40 ml of 0.3% ropivacaine.
224003088|NCT06728046|DEVICE|PCA|Participants will receive postoperative PCA with a formulation of 200 µg sufentanil diluted to 100 ml. The PCA settings will include a background dose of 3 ml/hour, a lockout time of 15 minutes, and a bolus dose of 2 ml.
223385664|NCT04652960|PROCEDURE|Positron Emission Tomography|Undergo PET
224003089|NCT07045402|OTHER|Kangaroo Care + Maternal Voice + Fetal Position Group|After ethical approval, all infants with a gestational age between 30-34 weeks in Neonatal Intensive Care Unit will be assessed. Parents of eligible infants will be informed about the study and asked to provide written consent. The infants will then be assigned to one of two groups: kangaroo care + mother's voice + fetal position (n=34) or fetal position only (n=34). In the first group, after tube feeding, infants will receive one hour of kangaroo care with the mother, including reading a story for the first 15 minutes. After finishing kangaroo care,they will then be placed in a fetal position in an incubator for 30 minutes. Comfort levels, weight, length, and head circumference will be measured daily until oral feeding begins, and the impact of kangaroo care and the mother's voice on the transition to full oral feeding will be assessed. All procedures will occur between 08:00 and 16:00.
224003090|NCT07045402|OTHER|control group|After ethical approval, all infants with a gestational age between 30-34 weeks in the Neonatal Intensıve Care Unit will be assessed. Parents of eligible infants will be informed about the study and asked to provide written consent. If infant is in the fetal position group, after being fed by a oral gastric tube, they will be placed in an incubator and positioned in a fetal position similar to that in the womb for one and a half hours. During all these procedures, infant's comfort levels will be assessed using a scale (form), and their weight, length, and head circumference will be measured every morning until they begin oral feeding. Additionally, the effect of the fetal position on infant's transition to full oral feeding will be evaluated.All procedures will take place between 08:00 and 16:00.
224295764|NCT03858738|DEVICE|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
224295765|NCT02857738|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
223385665|NCT04652960|PROCEDURE|Punch Biopsy|Undergo punch biopsies
223385666|NCT06719141|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
223385667|NCT06719141|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
223385668|NCT07079735|DRUG|Letermovir|CMV prophylaxis
223385669|NCT07079735|DRUG|Valganciclovir|Standard therapy for CMV prophylaxis
223385670|NCT06682780|DRUG|LM-2417|Q2W/Q3W,Intravenous Drip
223385671|NCT06682780|DRUG|Docetaxel|Q3W,Intravenous Drip
223385672|NCT06682780|DRUG|Toripalimab/Tirelizumab|Q3W,Intravenous Drip
223385673|NCT06682780|DRUG|Carboplatin|Q3W,Intravenous Drip
223385674|NCT06682780|DRUG|Niraparib|QD,Oral Administration
223385675|NCT06682780|DRUG|Lenvatinib|QD,Oral Administration
223385676|NCT01739712|BEHAVIORAL|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
223385677|NCT01739712|BEHAVIORAL|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
223385678|NCT07086131|DEVICE|Powerbreathe|The breathing training will consist of using the PowerBreathe for 12 weeks. The PowerBreathe is an inspiratory pressure threshold trainer. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
223385679|NCT07083011|DRUG|68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)|68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan
223385680|NCT06899750|BEHAVIORAL|E3 Multidisciplinary Team|The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, and nurse working together with patients via a remote monitoring, educational hypertension phone app to overcome barriers to hypertension control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.
223385681|NCT06899750|BEHAVIORAL|E3 Self-Guided Hypertension Education Program|Patients will receive timed, mailed educational materials on hypertension self-monitoring, diet and lifestyle modifications to supplement usual clinic-based hypertension care with their primary care doctor. A research assistant will ensure patients have home blood pressure monitors on enrollment, and will remind patients to check their blood pressures and follow-up with their primary care doctors at 3 months and 6 months.
223385682|NCT06930638|DEVICE|Ischemic Conditioning|The cuff will be placed around the proximal, non-affected thigh and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
223385683|NCT06930638|DIETARY_SUPPLEMENT|Antioxidant Supplement|MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. As MitoQ reaches peak concentrations at \~40 to 60 minutes after ingestion, we will wait 45 minutes (time matched to Ischemic conditioning).
223385684|NCT07084818|DEVICE|Reia System pessary self-care management|The Reia-System pessary is an FDA-cleared device to manage pelvic organ prolapse which is collapsible and intended to be more easily removed, with less discomfort.
224003091|NCT06029907|OTHER|Smoking cessation and pain management intervention|Patients will receive a behavioral smoking cessation and pain management intervention
223385685|NCT07084818|DEVICE|Standard pessary office-based management|These subjects will continue with the current pessary they are using to manage their prolapse, with office-based care.
224003092|NCT06029907|DRUG|Varenicline|Patients will receive varenicline prescribed by their oncologist
224003093|NCT00896935|OTHER|biologic sample preservation procedure|biologic sample preservation procedure
224003094|NCT06514339|DRUG|shenhuang granule|"Traditional Chinese medicine compound Shenhuang Granules is developed by Professor Fang Bangjiang, a scholar in the team of Qi-Huang, which is composed of ginseng, rhubarb, dandelion, etc., with the effect of Fuzheng Guben, clearing heat and detoxification, promoting qi and promoting blood and detumification."
224003095|NCT06514339|DRUG|placebo|Placebo was provided by Tianjin Hongri Pharmaceutical Co., LTD., and was given orally or nasally (through gastric tube or intestinal tube) after dissolution of 100ml warm water (temperature about 40°) in 1 package twice a day.
224003096|NCT06854731|BEHAVIORAL|Balance and Strength Training Exercises with Health Coaching|The OEP+ intervention integrates the OEP with health coaching by a physical therapists or kinesiologist. The OEP is an individualized home-based balance and strength exercise training program delivered by a PT or kinesiologist coach over 5 home visits.
224003097|NCT06854731|OTHER|Education Session|All active comparator participants will be invited to join monthly interactive social and education sessions via Zoom or in-person (hybrid delivery).
224003098|NCT07154745|DRUG|Pozelimab|Administered per the protocol
224003099|NCT07154745|DRUG|Cemdisiran|Administered per the protocol
224124457|NCT02018952|OTHER|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~* Information of patient and no opposition getting~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~* Clinical exam~* Laboratory tests~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~* Clinical exam~* Laboratory tests~* Radiography of the targeted joint~* Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~* Functional outcome"
224124458|NCT02512003|DEVICE|Fantom Scaffold|
223385686|NCT01959295|DRUG|ASP2151|200 mg once daily
223385687|NCT01959295|DRUG|ASP2151 placebo|once daily
224003100|NCT07155954|DIAGNOSTIC_TEST|SRUS imaging of the lymph nodes before surgery or biopsy|Ultrasound contrast agent (Sonovue/Sonazoid) is administered to the patients through a peripheral vein. When the micro-bubbles enter the lymph nodes, super-resolution ultrasonography imaging will initiate immediately, to capture the trajectory of the micro-bubbles, thus construct a map of the microvascular distribution.
224003101|NCT07155681|DEVICE|Virtual Reality intervention|Virtual Realtiy intervention with biofeedback for 10 minutes during a shift on the ward for healthcare professionals
224003102|NCT07154251|OTHER|Community Health Worker|Community Health Worker will meet with families monthly (and more often as needed) in the role of a diabetes technology coach
224003103|NCT07154069|RADIATION|Radical radiotherapy of nasopharynx and neck|Radical radiotherapy of nasopharynx and neck
224124459|NCT04402268|DEVICE|Cardioverter-defibrillator|We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.
223385688|NCT02698033|DRUG|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
223385689|NCT02698033|OTHER|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
224003104|NCT07154069|DRUG|Capecitabine|Adjuvant metronomic capecitabine (650 mg/m² twice daily) for one year
224003105|NCT07154069|DRUG|Concurrent chemoradiotherapy (cCRT)|Concurrent chemoradiotherapy
224003106|NCT07154069|DRUG|Toripalimab|Adjuvant Toripalimab (240mg day1, Q3W )
224003107|NCT07154407|OTHER|AI-assisted Mastisting Training App|An artificial intelligence (AI) recognition system for the 'AI-assisted Masticatory Muscle Training,' tailored to train masticatory muscles in patients with schizophrenia. By finishing certain exercise per day, expecting the experimental oral hygience, masticating and swallowing fuction could be advanced,
224003108|NCT07154199|DEVICE|sham transcranial ultrasound stimulation|In the sham group, the transducer power was turned off, pre-recorded pulse repetition sounds were played to control for auditory confounds. The equipment appearance is consistent with the test device. Single stimulation, 60 seconds.
224124460|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
224124461|NCT00444886|DRUG|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
223385690|NCT00457548|BEHAVIORAL|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
223385691|NCT00612092|RADIATION|Spiral image acquisition|standard spiral scan protocol
223385692|NCT00612092|RADIATION|sequential image acquisition|sequential CT scan protocol
223385693|NCT04280640|OTHER|Blood Draw|A blood sample will be collected once, prior to treatment.
223385694|NCT06468241|OTHER|Progressive relaxation exercise|For the progressive relaxation exercise group, a progressive relaxation exercise session will be applied to the participants 3 times a week for four weeks.
223385695|NCT06468241|OTHER|Listening to music|"For the music listening group, the participants will listen to the Turkish music makams (uşşak and rast) three times a week for four weeks."
223385696|NCT06932250|OTHER|Leg heating|Participants will perform home-based leg heating using a portable sauna blanket set at different temperature.
223385697|NCT04526847|BEHAVIORAL|Intermittent energy restriction (IER) : 5:2 diet pattern|Participants in the IER group will be provided menus on fasting day that provide \~25% of the individual energy requirement (400 kcal/day for females and 600 kcal/day for males) that means \~75% energy restriction per week (Sundfør et al., 2018; Svendsen, 2018; Templeman, Gonzalez, Thompson, \& Betts, 2020). The recommended fasting day may be on two non-consecutive days (Mondays and Thursdays) per week and remaining five days of the week will be based on the usual diet plan. All participants will be instructed to complete all food by 12 pm and then fast until 8 am the following day (Svendsen, 2018).Thus, the weekly average calorie intake will correspond to \~75% of the normal energy requirements. They will receive a diet plan that recommended \~50 gm protein/day from chicken breast, lean meat, lean fish, fat-free yogurt, cottage cheese, egg or legumes, and vegetables to increase satiety on fasting days.
223385698|NCT04526847|BEHAVIORAL|Continuous energy restricted (CER) group|Participants in the CER group will be advised to reduce total energy intake to 1200-1550 kcal in all seven days a week. They will be provided diet plan calculated in relation to each person's estimated energy requirements. Menus will be divided into breakfast, lunch, dinner, and snacks in line with their individualized energy recommendations. They will be requested to consume \~75% of the individual energy requirements daily (25% energy restriction of calculated baseline energy requirements daily) over six months. Thus, the overall energy restriction will similar between the groups at an estimated reduction of 25% of requirements. Participants will be randomized in a 1:1 ratio, and assigned to an intermittent or continuous energy restriction group randomly.
223385699|NCT03459456|BEHAVIORAL|Provocation OC task (Provoc)|used to evoke OC-related distress
224003109|NCT07154199|DEVICE|real transcranial ultrasound stimulation|Ultrasound stimulation was delivered using TPO-203 and H-104MR\_4AA-4CH transducer (Sonic Concepts, Woodinville, WA, USA). In the real stimulation group, theta-burst TUS (Yaakub et al., 2024; Yaakub et al., 2023) was performed with the following parameters: pulse duration = 20 ms; pulse repetition interval = 200 ms; total duration = 80 s. The target free-field spatial peak pulse-average intensity was maintained at 33.85 W/cm². The stimulation target was defined as the overlapping region between the source localisation results and the right inferior insula in the Destrieux atlas
224003110|NCT07155824|DIETARY_SUPPLEMENT|Whey and plant protein blend|The 12 week intervention will involve 2 weekly group exercise sessions incorporating strength and balance exercises, along with home-based exercise focused on increasing time spent walking.
224124462|NCT02683616|DEVICE|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
224124463|NCT01201798|DRUG|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
223385700|NCT03459456|BEHAVIORAL|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
223385701|NCT03459456|BEHAVIORAL|Exposure provocation task|used to elicit overt OCD rituals
223385702|NCT02971020|OTHER|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
223385703|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with the ultrasound. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
223385704|NCT04037709|PROCEDURE|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done only on one side of mouth using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
223385705|NCT01298414|GENETIC|RNA analysis|
223385706|NCT01298414|OTHER|laboratory biomarker analysis|
223385707|NCT07165041|PROCEDURE|SPSIP Block|Ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block performed prior to cardiac implantable electronic device (CIED) implantation. A total of 30 mL of 0.25% bupivacaine will be injected into the interfascial plane between the rhomboid major and serratus posterior superior muscles under sterile conditions.
223385708|NCT07165041|PROCEDURE|Sham procedure|Sham procedure with 1 mL saline injection at the same anatomical site, without administration of local anesthetic, prior to CIED implantation.
223385709|NCT07171125|DRUG|Liposomal bupivacaine (local infiltration)|"Patients will receive a pre-closure local infiltration of 266 mg liposomal bupivacaine (20 mL for single-level surgery; 30 mL for two-level surgery) combined with 25 mg bupivacaine hydrochloride (10 mL total volume). The drug will be injected bilateral into the paraspinal muscles and subcutaneous tissues prior to wound closure. This provides both immediate (bupivacaine HCl) and prolonged (liposomal) analgesia."
223385710|NCT07171125|DRUG|ropivacaine (local infiltration)|Patients will receive 120 mg ropivacaine diluted to 30 mL (single-level) or 40 mL (two-level) with normal saline. The solution will be infiltrated bilateral into the paraspinal muscles and subcutaneous tissues using the same technique as the experimental arm, ensuring consistent injection depth and distribution.
223385711|NCT07163845|BIOLOGICAL|Live-attenuated CHIKV vaccine VLA1553|Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is carried out after this observational study.
223385712|NCT07176559|BEHAVIORAL|Chaplain Intervention Group|Eligible and consented participants that are randomized to the Chaplain Intervention Group will receive a total of 4 visits with a board-certified or board-eligible chaplain. These visits will occur weekly for approximately 4 weeks either in person, by telephone, or through a HIPAA compliant video platform. The visits will last an average of 30 minutes each.
223385713|NCT07173361|DRUG|Micronized progesterone (oral capsules)|Two doses of 400 mg total micronized progesterone, administered as 2 × 200 mg capsules \~34 hours and \~10 hours prior to infusion trial, taken with a standardized nutritional drink.
223385714|NCT07173361|DRUG|placebo capsule|Matched oral placebo capsules administered on the same schedule (\~34 and \~10 hours prior to infusion trial) with a standardized nutritional drink.
223385715|NCT00054457|DRUG|capecitabine|
224003111|NCT07153640|OTHER|1 ) Wim Hof Breathing Exercise|"1. Subjects will be asked to breathe deeply for an average of 20-30 breaths then exhale, (deep rapid inhalations and relaxed expirations)~2. Hold their breath in an unforced manner for one minute or longer until they feel the urge to breathe (retention phase).~   (For safety, they were instructed not to hold their breath longer than 3.5 min).~3. Take deep inhalation breath and hold again for 15 seconds (recovery breath).~4. This procedure was repeated a total of three times.~5. After the last cycle, subjects were instructed to return to their natural rhythm of breathing and remain lying down without moving to relax for five minutes.~6. Done every day in the morning or at least three hours postprandial for four weeks.~(Marko et al., 2022)"
224003112|NCT07153640|OTHER|2) Aerobic exercises|Aerobic exercises were performed by walking on the treadmill for 30 minutes a day (5 days/week) and at least 150 minutes per week of moderate-intensity aerobic activity at 60-75% of the maximum heart rate (HR) for four weeks. Maximum heart rate is taken from 220 - to age. Both the warm-up and cool-down were performed for five minutes. Each session concluded with stretching the calf, hamstring, quadriceps, gluteus, back, neck, and shoulder muscles (Acar et al., 2024; Shandu et al., 2023a)
224003113|NCT07155044|DRUG|NAC|Participants in NAC+RNU cohort will receive 3-4 cycles of neoadjuvant chemotherapy (NAC) with the gemcitabine and cisplatin (GC) regimen prior to undergoing definitive surgery. Gemcitabine (1000 mg/m²) will be administered on Day 1 and Day 8, and cisplatin (70 mg/m²) will be administered on Day 2 of each 21-day cycle.
223385716|NCT00054457|DRUG|docetaxel|
223385717|NCT02303912|DRUG|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
223385718|NCT07192224|DEVICE|Hypothermia|This study involves the comparison of 2 groups, one receiving warm fluids while the other group receiving room temperature fluids during surgeries.
223385719|NCT07192224|DEVICE|Hotline|Used as a fluid warmer.
223385720|NCT07192328|DEVICE|rTMS and rTLSMS administered using a Magstim Rapid2 repetitive stimulator at pre-identified hotspots (cortical, lumbar, and sacral regions bilaterally).|rTMS and rTLSMS administered using a Magstim Rapid2 repetitive stimulator at pre-identified hotspots (cortical, lumbar, and sacral regions bilaterally. rTMS delivered with 250 pulses via the same double-cone coil used for the neurophysiological study, at either 1 Hz or 5 Hz. For rTLSMS (lumbar and sacral), 2400 pulses (600 per hotspot) were applied at 1 Hz, 5 Hz, or 10 Hz using a 70mm refrigerated air film coil (Magstim, UK). Each dose and stimulation site (cortical or peripheral) were tested in separate sessions.
223385721|NCT07192991|OTHER|Observational study|This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
223385722|NCT07192159|DEVICE|Quantitative ultrasound (DeepUSFF)|"\*\*Novel Quantitative Ultrasound Technology Assessment\*\*~This study evaluates Samsung Medison's proprietary DeepUSFF (Deep Learning-based Ultrasound Fat Fraction) technology, a next-generation quantitative ultrasound method for liver fat assessment that differs from conventional ultrasound approaches in several key aspects: advanced RF data analysis, proprietary technology, standardized protocol, direct MRI-PDFF correlation, specific MSALD poopulation and multicenter design."
223385723|NCT07193394|DRUG|Tucatinib (ONT-380)|Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
223385724|NCT07193394|DRUG|Trastuzumab (Herceptin)|Patients with a HER2-not amplified metastatic or unresectable breast cancer harboring an activating ERBB3 mutation will receive experimental treatment with tucatinib and trastuzumab combination
223385725|NCT07191587|DIETARY_SUPPLEMENT|Vitamin B Complex|Vitamin B complex given as prophylaxis in prophylactic arm and as treatment in non-prophylactic arm.
223385726|NCT07192900|BIOLOGICAL|locally manufactured adoptive cellular therapy (ACT) product|Single dose, intrapleural delivery (via indwelling pleural catheter) of adoptive cellular therapy (ACT) product derived from autologous pleural infiltrating T-cells.
223385727|NCT07192900|DRUG|Interleukin-2|Low dose Interleukin-2 (IL-2) will also be administered intrapleural at the dose of 20 milliliters (mL) at 1 x 10⁵ International Units (IU)/mL starting approximately 2 hours after ACT infusion and every 8 to 16 hours thereafter, as tolerated, for up to 4 doses (total 8 x 10⁶ IU).
223545578|NCT02021786|BEHAVIORAL|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
224295766|NCT02857738|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
223385728|NCT07193420|DRUG|Cyclophosphamide 35mg/kg/day|Cyclophosphamide will be administered intravenously (IV) post-HSCT at the experimental dose (70 mg/kg, divided into two doses of 35 mg/kg/day on days +3 and +4).
223385729|NCT07193420|DRUG|Cyclophosphamide 50mg/kg/day|Cyclophosphamide will be administered intravenously (IV) post-HSCT at the standard dose (100 mg/kg, divided into two doses of 50 mg/kg/day on days +3 and +4).
223545579|NCT02607124|DRUG|Ribociclib|
223385730|NCT07191691|DIAGNOSTIC_TEST|Bayley Scales of Infant and toddler Development, fourth edition (BSID-4)|"The BSID-4 is a test that evaluates three areas of child's development, divided into three scales:~* The Motor Scale, which includes the fine motor and gross motor subtests;~* The Cognitive Scale, which consists of items assessing sensorimotor development, object exploration and manipulation, concept formation, memory, and other primary functions from which the child's reasoning abilities emerge;~* The Language Scale, which includes the receptive communication and expressive communication subtests.~The administration of the BSID-4 involves the standardized delivery of items. The BSID-4 standardization does not specify a fixed order for administering the scales: depending on the child's temperament and spontaneous interest, the examiner adapts the order in which the motor, language, and cognitive scales are administered."
223385731|NCT07191925|BEHAVIORAL|Community Co-designed Physical Activity and Diet Intervention Package|A package of 4-6 diet and physical activity interventions selected from a long-list of potential interventions and adapted to the unique school and neighborhood context via consultation with community stakeholders. Intervention packages are multi-level (i.e. targeting at least two of individual, external and structural environments), target elements of both diet and physical activity, and are health equity oriented in terms of both access and improvement. Long-list potential interventions include items related to school intramural programming, active transport, health education, community recreational programming, and structural/public space design improvements.
223385732|NCT07192848|DRUG|Adebrelimab + Apatinib|"Adebrelimab: A fixed dose of 1200 mg is administered as an intravenous infusion over 30 minutes (not less than 20 minutes and not more than 60 minutes, including the flushing phase), once every 3 weeks (Q3W). The interval between two administrations should not be less than 12 days.~The maximum treatment duration is 6 courses.~Apatinib: 250 mg, once daily (QD), taken orally within half an hour after a meal, continuously, with a 3 - week (21 - day) cycle.~The maximum treatment duration is 6 courses."
223385733|NCT07192263|DRUG|IN-B00009|Test drug
224003114|NCT07154238|OTHER|No treatment given|No treatment given
224003115|NCT07154537|BIOLOGICAL|2-dose PCV13|2 doses PCV13 with one month apart
224003116|NCT07154537|BIOLOGICAL|1-dose PCV13|1 dose PCV13
224003117|NCT07155499|BIOLOGICAL|GNR-127, 20 mcg|GNR-127, 20 mcg in 0.5 ml administered 5 times every 4 weeks
224003118|NCT07155499|BIOLOGICAL|GNR-127, 40 mcg|GNR-127, 40 mcg in 0.5 ml administered 5 times every 4 weeks
224003119|NCT07155499|BIOLOGICAL|GNR-127, 80 mcg|GNR-127, 80 mcg in 0.5 ml administered 5 times every 4 weeks
224003120|NCT07155499|BIOLOGICAL|GNR-127 placebo|GNR-127 placebo 0.5 ml administered 5 times every 4 weeks
224003121|NCT07153393|DEVICE|Type I Bovine Collagen (HTIC)|HTIC is a sterile collagen powder (100 mg) contained in a glass vial, which is diluted by adding 5 ml of saline solution (0.9% sodium chloride solution) to obtain a suspension. This suspension will be prepared immediately before treatment. The procedure consists of performing a few microinjections of the product (0.1 ml per injection) into the dermis at intervals of approximately 2 cm, using a very fine needle (30G/32G, 4 mm) in the areas to be treated (face, neck, décolleté, and hands).
224003122|NCT07155109|OTHER|Low pressure group|In laparoscopic gyneco-oncological surgeries, low pressure group will receive below 12 mmHg intraperitoneal pressure.
224003123|NCT07155109|OTHER|Normal pressure group|In laparoscopic gyneco-oncological surgeries, normal pressure group will receive 12 and abowe 12 mmHg intraperitoneal pressure.
224003124|NCT07156019|DRUG|Sintilimab+Temozolomide+Surufatinib|After fully informed and signed informed consent, subjects will receive Sintilimab (200mg each fixed dose, once every 21 days) combined with Temozolomide (BSA≤1.7m2; BSA \&amp;amp;gt; 1.7m2 was administered with 300mg, QD, d1-d5, and with Surufatinib (250mg, QD, continuous administration). A treatment cycle of 21 days until disease progression, death, toxicity intolerance or withdrawal of informed consent, with a maximum treatment period of 24 months.
224003125|NCT07154914|DRUG|Abiraterone + ADT|Patients receiving androgen deprivation therapy (ADT) combined with abiraterone. Abiraterone is a CYP17A1 inhibitor used in combination with prednisone and ADT for metastatic hormone-sensitive prostate cancer (mHSPC). This combination is given in real-world practice according to clinical guidelines.
223385734|NCT07192263|DRUG|Placebo|Placebo drug
224003126|NCT07153627|OTHER|Rectal ozone sessions|Patients will receive 40 Rectal ozone sessions or until improvement (maximum 80 sessions), in addition to their conventional rehabilitation program.
224003127|NCT07153627|OTHER|Conventional rehabilitation program|Patients will receive their conventional rehabilitation program only (physiotherapy sessions three times per week for the treatment period (six months).
224003128|NCT07153718|PROCEDURE|Electrogram-guided ablation|pulmonary vein ioslation; target electrograms ablation, including (1) Spatial-temporal Dispersion Activation, (2) Locally Short Cycle Length Activity, (3) High-Frequency Potentials, (4) Focal Activity.
224003129|NCT07153718|PROCEDURE|Anatomical-guided Ablation|pulmonary vein isolation; LA roof, posterior inferior wall and mitral isthmus linear lesion; Vein of Marshall (VOM) ethanol infusion.
224003130|NCT07153718|PROCEDURE|Extensive electrogram-anatomical guided ablation|pulmonary vein isolation; target electrogram ablation; linear ablation
224003131|NCT07154316|RADIATION|LCRT|50Gy/25Fx
224003132|NCT07154316|RADIATION|SCRT|25Gy/5Fx
224003133|NCT07154316|DRUG|CAPOX|1000mg/m2 bid d1-14
224003134|NCT07154316|DRUG|PD-1|300mg d1，q3w
224003135|NCT07154316|DRUG|Celecoxib|200mg, bid
224003136|NCT07155135|DIAGNOSTIC_TEST|MRI|Magnetic resonance imaging (MRI) is a vital diagnostic tool in modern medicine due to its ability to produce detailed images of the body's internal structures without using ionizing radiation.
224003137|NCT07154511|DRUG|Tributyrin|Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.
224003138|NCT07154511|DRUG|Placebo|Participants will take 500mg TID placebo for 90 days +/- 7 days.
224003139|NCT07155733|DEVICE|Transcutaneous Vagus Nerve Stimulation|Participants receive 10 sessions of transcutaneous vagus nerve stimulation over 3 weeks using a TENS device. stimulation is applied to the auricular branch of the vagus nerve (cymba conchae/tragus) for 30 minutes per session. Participants continue usual medical care. Parameters (frequency, pulse width, intencity) are standartized according to safety guidelines. This intervention specifically targets the auricular branch of the vagus nerve, distinguishing it from other device-based intervention such as conventional TENS for pain management or non-auricular vagus stimulation used in other studies.
223385735|NCT07192185|DRUG|FOLFOX|oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W
223385736|NCT07192185|DRUG|Atezolizumab & Bevacizumab|Atezolizumab 1200mg iv.drip + Bevacizumab 15mg/kg iv.drip Q3w
223385737|NCT07191522|PROCEDURE|Mechanical debridment with titanium curettes and ultrasounds|Removal of deposits above and below the gum line using hand or ultrasonic tools to reduce the inflammatory parameters
223385738|NCT07191522|PROCEDURE|Mechanical debridment with titanium curettes and ultrasounds + aPDT (antimicrobial photodynamic therapy)|Non-invasive treatment that uses a combination of a light-sensitive compound (photosensitizer), specific light and oxygen to generate reactive oxygen species (ROS) that kill bacteria
223385739|NCT07193121|DEVICE|Inspiratory Muscle Warm-Up|The POWERbreathe device (IMT Technologies Ltd., Birmingham, UK) was used for inspiratory muscle warm-up (IWU). For the IWU protocol, the resistance of the POWERbreathe device was set to 40% of the participant's maximal inspiratory pressure (MIP). While standing, participants were instructed to perform two sets of 30 breaths (inspiratory and expiratory), with a 60-second rest interval between sets (Koizumi \& Ohya, 2023).
223385740|NCT07193121|DEVICE|Control|No intervention
224003140|NCT07155733|BEHAVIORAL|Myofascial Release Exercises|Participants receive 10 supervised session over 3 weeks focusing on myofascial release of cervical muscles. in addition to their usual medical management for tinnitus. Exercises are designed to reduse muscle tensionpotentially contributing to tinnitus. This intervention is distinct from general physical therapy or standart relaxation exercises beacause it specifically targets myofascial structures implicated in tinnitus pathophysiology.
224003141|NCT07155733|OTHER|Standard medical treatment|Participants continue their usual medical management for tinnitus without additional interventions. This group serves as a control to compare the effects of tVNS and myofascial exercises. It differs from sham or placebo interventions used in oter studies because no active or stimalated treatment is provided.
224003142|NCT07154797|COMBINATION_PRODUCT|Bimatoprost Implant System / IOL Combination|Bimatoprost Implant System used in combination with the SpyGlass intraocular lens
224003143|NCT07156058|OTHER|MiniPDX group|Personalized treatment for guided by mini-PDX. The MiniPDX test can provide drug sensitivity results in as little as 7 days. Drugs including but not limited to the following agents: capecitabine, gemcitabine + cis-platinum, gemcitabine + capecitabine, 5-FU + oxaliplatin, gemcitabine, 5-FU, capecitabine + cis-platinum, 5-FU + cis-platinum.
224003144|NCT07156058|DRUG|Capecitabine|Drug: Capecitabine
224124464|NCT01201798|DRUG|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
224124465|NCT00934557|DRUG|ATG Fresenius|
224124466|NCT00934557|DRUG|ATG Fresenius|
224124467|NCT00934557|DRUG|ATG Fresenius|
224124468|NCT00934557|DRUG|ATG Fresenius|
223385741|NCT07192718|BEHAVIORAL|Empowered Relief|The participants will attend a pain relief skills intervention (Empowered Relief). The two-hour session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
223385742|NCT07192718|OTHER|Education|Educational content: Participants view videos online focusing on specific areas of postpartum recovery (Sleep, Mental Health, Physical Therapy, Obstetric care).
223385743|NCT07191626|PROCEDURE|PFA - PV + SVCI|Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins AND the superior vena cava.
223385744|NCT07191626|PROCEDURE|PFA - PVI only|Catheter ablation procedure using a Pulsed Field Ablation system to achieve electrical isolation of all four pulmonary veins only. No ablation is performed in the superior vena cava.
223385745|NCT07191847|BIOLOGICAL|eye drops|apply 2 drops 3 times daily for 12 weeks
223385746|NCT07191808|OTHER|Low Level Laser Therapy|cluster method
223385747|NCT07191717|DRUG|Abemaciclib|Given PO
223385748|NCT07191717|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223385749|NCT07191717|DRUG|Imlunestrant|Given PO
223385750|NCT07191717|OTHER|Questionnaire Administration|Ancillary studies
223385751|NCT07191717|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic scans
223385752|NCT07193316|OTHER|no intervention|no intervention
223385753|NCT07192211|BIOLOGICAL|Mesenchymal stem cell|ADR-002K administration
223385754|NCT07192211|BIOLOGICAL|Placebo|Placebo
223385755|NCT07193225|DEVICE|Ultrasound localization microscopy, circle of Willis|Ultrasound localization microscopy sequences coupled with SonoVue® injection of the circle of Willis before carotid endarterectomy
223385756|NCT07193225|DEVICE|Ultrasound localization microscopy, coronary arteries|ultrasound localization microscopy sequences coupled with SonoVue® injection of coronary arteries before carotid endarterectomy
224003145|NCT07153367|DRUG|REKOVELLE (Follitropin Delta)|"Each patient will start the ovarian stimulation with a fixed dose of 3,66 mcg of Rekovelle ® on day 4 of the natural cycle (Stimulation day 1-S1). The stimulation period will last a maximum of 13 days.~Patients will be regularly evaluated to monitor the response to stimulation with ultrasound scan and blood sampling"
224124469|NCT00934557|DRUG|ATG Fresenius|
224124470|NCT00934557|DRUG|ATG Fresenius|
224124471|NCT00934557|DRUG|ATG Fresenius|
224124472|NCT00934557|DRUG|ATG Fresenius|
224124473|NCT04272216|DEVICE|Treatment with HydroPearl via radial access|This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
224124474|NCT02198287|DRUG|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
224124475|NCT02198287|DRUG|Placebo|
224124476|NCT01750398|DRUG|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
224124477|NCT01750398|DRUG|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
224124478|NCT01750398|DRUG|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
224003146|NCT07155512|BEHAVIORAL|Mindfulness based intervention|A mindfulness intervention was designed especially for this study and delivered by a RD also qualified as a mindfulness teacher. The intervention was delivered synchronously online and consisted of 4 x 50 minute sessions delivered across 4 weeks.
224003147|NCT07155928|BEHAVIORAL|Cardiac Rehabilitation|"* The cardiac rehabilitation program include supervised exercise training, patient education, and risk factor modification.~* CR starts 1-3 weeks after PCI (based on the patient's general condition) and lasting 12 weeks thereafter.~* Patients will undergo a supervised CR program based on published guidelines (FITT principle). The core will be a moderate-intensity aerobic exercise regimen (e.g. treadmill or cycle ergometer) 2-3 times per week for 12 weeks. Each session will last \~20-60 minutes of exercise followed by cool-down, with intensity gradually increased to High intensity interval training (HIIT) in low-moderate risk individuals. Resistance exercises (e.g. light weights or band exercises) will also be included twice weekly. Exercise dose (frequency, intensity, time) will be tracked. Physical therapists will supervise all sessions in an outpatient CR facility or affiliated gym. Patients' vitals and ECG will be monitored during initial sessions for safety."
224124479|NCT00525148|DRUG|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
223385757|NCT07191509|DEVICE|Speaking Valve ，Tracheostomy Tube Occlusion ，Tracheostomy Tube Ventilation|"Speaking Valve:~Participants are assessed while breathing through a one-way speaking valve attached to the tracheostomy tube. The valve directs exhaled air through the upper airway, restoring phonation and more closely simulating post-decannulation airflow. The assessment is performed for up to 4 hours to evaluate tolerance and respiratory function prior to tracheostomy tube removal.~Tracheostomy Tube Occlusion:~Participants undergo a capping trial, in which the tracheostomy tube is completely occluded. During this intervention, patients must breathe entirely through their natural upper airway, which increases airway resistance and tests their ability to tolerate decannulation. The capping trial is conducted for 24-48 hours, with monitoring for signs of intolerance.~Tracheostomy Tube Ventilation:~This intervention involves assessment of respiratory function while the participant breathes directly through the open tracheostomy tube, representing the baseline state prior to any decannu"
223385758|NCT07193303|OTHER|mental imagination|The Nine-Hole Peg Test (9 DPT) will be performed with a mental chronometer.the duration between actually physically performing the movement and mentally imagining the same movement will be recorded.
223425581|NCT01654653|DRUG|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
224003148|NCT07155928|PROCEDURE|Primary Percutaneous Coronary Intervention|Patients will undergo Primary Percutaneous Coronary Intervention (PPCI) within 24 hours of symptom onset for urgent revascularization of the occluded coronary artery.
223425582|NCT05356533|BEHAVIORAL|Drinking to Cope CBT skills|Young adults who drink to cope with negative affect will receive 8 web-based modules with cognitive behavioral skills
224003149|NCT07155018|PROCEDURE|Micro-osteoperforations (MOPs)|Maxillary canine retraction with miniscrew anchorage and NiTi closed-coil springs, without micro-osteoperforations.
224003150|NCT07155018|PROCEDURE|Conventional Canine Retraction|Maxillary canine retraction with miniscrew anchorage and NiTi closed-coil springs, without micro-osteoperforations
224003151|NCT07155759|DIAGNOSTIC_TEST|PSA/Stockholm3/MRI|Stockholm3+PSA followed by MRI of the prostate
224003152|NCT07155759|DIAGNOSTIC_TEST|PSA|PSA followed by standard biopsies
224003153|NCT07153510|OTHER|Post-Isometric Relaxation|Participants will undergo Post-Isometric Relaxation technique targeting the hamstring muscles. The technique involves an isometric contraction of the hamstring followed by a passive stretch. Participant will be in supine position; hip at 90° flexion, Isometric contraction of hamstrings for 7 seconds, Followed by 15 seconds of passive stretch, 10 repetitions, 3 times/week for 4 weeks
224003154|NCT07153510|OTHER|Active Static Stretching|Participants will perform Active Static Stretching exercises for the hamstrings, where the stretch is held actively without assistance.Seated long sitting position. Participant actively stretches hamstrings for 30 seconds. 10 repetitions, 3 times/week for 4 week
224003155|NCT07153965|DRUG|Sacituzumab Tirumotecan plus Tagitanlimab|Sacituzumab Tirumotecan 5mg/kg intravenously (IV) infusion every 2 weeks on Day 1, Tagitanlimab 900mg IV every 2 weeks on Day 1, until disease progression, unacceptable toxic effects, withdrawal from the trial, or death, whichever occurred first.
224003156|NCT07154355|BEHAVIORAL|community-based exercise training|The patients will engage in 40-60 minutes of exercise training, either at home or in the community, five times a week, for eight weeks. Brisk walking, jogging, swimming, cycling, and trekking were among the exercise modalities that were chosen mostly based on the patient's individual preferences and habits. To guarantee safe and efficient exercise, exercise intensity was modified based on each person's subjective effort level and the results of their individual cardiorespiratory exercise tests.
224003157|NCT03578887|BEHAVIORAL|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
224003158|NCT03578887|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Subjects undergoing Roux-en-Y Gastric Bypass or Sleeve Gastrectomy with their own surgical team
224003159|NCT05464615|DRUG|Amoxicillin|We will initially administer 1/5th (56 mg) of the goal dose of amoxicillin (256 mg) by oral route following the procedure outlined below. The total goal dose to be administered is amoxicillin 256 mg (3.2 ml of 400 mg/5 ml). These were numbers that came about for significance in relabeling penicillin allergies in patients in previous studies.
224124480|NCT06461611|BEHAVIORAL|Health Diary Program|The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.
224124481|NCT06461611|BEHAVIORAL|Traditional Health Education|Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
224124482|NCT05674045|DRUG|EG017 3mg|EG017 3mg/day Oral administration for 12 weeks, once daily
224124483|NCT05674045|DRUG|EG017 6mg|EG017 6mg/day Oral administration for 12 weeks, once daily
224124484|NCT02125487|BEHAVIORAL|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
223385759|NCT07193238|OTHER|The Ethics and Moral Course based on the Ashridge training model|Based on the three-stage characteristics of the Ashridge training model, the developed the content of this ethics course. (1) Discrete stage (within 3 months of employment): This stage aims to initially cultivate the professional identity of new nurses, stimulating humanistic awareness. It primarily involves self-study, supplemented by instructor supervision and implicit positive guidance. (2) Integrated stage (4-6 months of employment): This stage combines professional identity with actual work, enhancing humanistic care abilities in practice. It emphasizes mutual sharing between instructors and new nurses, utilizing diverse training methods to promote experience and reflection. (3) Cumulative stage (7-12 months of employment): This stage develops critical thinking and ethical problem-solving abilities. It focuses on assessing comprehensive abilities in complex nursing situations, providing feedback on the teaching plan, and evaluating training effectiveness.
223385760|NCT07192744|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
223385761|NCT07192562|BEHAVIORAL|Virtual Reality-Based Exercise Program|"Participants in the VR Exercise Group received a virtual reality-based physical activity intervention using the Meta Quest 2 headset. Two exergames, Beat Saber and PowerBeatsVR, were implemented twice a week for six weeks, totalling 12 exercise sessions. Each session lasted 30-35 minutes and was conducted individually during work hours. Beat Saber provided rhythm-based tasks involving block slicing and obstacle dodging, while PowerBeatsVR included high-intensity punching, squatting, and side-stepping movements. Game difficulty increased weekly."
223385762|NCT05308927|DRUG|Norditropin|Patients will be treated with commercially available Norditropin® according to routine clinical practice at the discretion of the treating physician.
223385763|NCT04956640|DRUG|LY3537982|Oral
223385764|NCT04956640|DRUG|Pembrolizumab|Intravenous
223385765|NCT04956640|DRUG|Cetuximab|Intravenous
223385766|NCT04956640|DRUG|Pemetrexed|Intravenous
223385767|NCT04956640|DRUG|Cisplatin|Intravenous
223385768|NCT04956640|DRUG|Carboplatin|Intravenous
223385769|NCT05552625|DRUG|TADIOS|TADIOS is a combination extract which composed of three herbs, and each herbal medicine has been traditionally used as a food or a herbal medicine treating various respiratory diseases in Asia
223385770|NCT05552625|DRUG|Placebo|Combination of the following Lactose hydrate, Microcrystalline cellulose, Colloidal silicone dioxide, Povidone, Croscarmellose sodium, Magnesium stearate, Tabshield(79O245)
223385771|NCT06294821|DRUG|4-Aminopyridine|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
224003160|NCT06118957|DRUG|Enoxaparin|Participants will receive weight-based dosing of enoxaparin at 0.5 mg/kg rounded to the nearest 10 mg every 12 hours based on delivery admission weight. Participants will receive therapy for 14 days.
224003161|NCT04193826|DEVICE|Left Atrial Appendage Closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the LAAC device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
224003162|NCT05421741|DRUG|Antibiotic coated intramedullary Nail|"Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube."
223385772|NCT06294821|OTHER|Placebo|Subjects will receive either the active study drug (4-aminopyridine) or placebo to determine the effects of 4AP on carpal tunnel syndrome
223385773|NCT06775704|DEVICE|Hip resurfacing system|Hip resurfacing with ROMAX system
223385774|NCT06275555|DRUG|bivalirudin|bivalirudin as an anticoagulant
224124485|NCT02125487|BEHAVIORAL|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
223385775|NCT06275555|DRUG|unfractionated heparin|unfractionated heparin as an anticoagulant
223385776|NCT04186039|DIAGNOSTIC_TEST|Functional magnetic resonance imaging - Blood Oxygenation Level Dependent|"First Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence under ambient air.~Oxygenation of 5 minutes at a rate of 12 l / min. Second Functional magnetic resonance imaging - Blood Oxygenation Level Dependent sequence."
223385777|NCT05208216|DEVICE|Geko device|A small battery powered device that provides neuromuscular stimulation to the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
223385778|NCT05208216|DEVICE|Flowtron DVT|A pneumatically powered pair of calf boots device that intermittently compress the muscles of the lower leg to enhance venous return from the leg and reduce the risk of patient developing VTE.
224003163|NCT05421741|OTHER|Standard Intramedullary Nail|Standard Intramedullary Nail
224124486|NCT00114283|DRUG|lapatinib ditosylate|Given PO
224124487|NCT00114283|OTHER|laboratory biomarker analysis|Correlative studies
224124488|NCT05174039|DRUG|Miglustat 100 milligrams (mg) Oral Capsule|Subjects will initiate miglustat at Week 1 and dosing will be escalated until 600mg/d. If a subject has not reached the maximum dose (600 mg/d) by Week 8, the Week 8 dose will be subject's MTD.
224124489|NCT05378425|DRUG|NTX-1088|IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
223385779|NCT04523987|DRUG|Ciprofloxacin|Subjects enrolled will be administered oral ciprofloxacin twice a day throughout the course of each 28-day cycle of gemcitabine and nab-paclitaxel chemotherapy.
223425583|NCT00635453|BEHAVIORAL|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
224003164|NCT05576753|PROCEDURE|Hernia repair|Robot assisted laparoscopic preperitoneal repair (vTAPP: ventral transabdominal preperitoneal hernia repair) of a midline ventral hernia
223385780|NCT05494346|DEVICE|Measurement of peak nasal flow.|Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
223385781|NCT06070233|RADIATION|stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation|"Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system"
223385782|NCT06070233|OTHER|Sham|Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
223385783|NCT05760612|DRUG|Trastuzumab and neratinib|Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.
223385784|NCT05760612|DRUG|Trastuzumab and Pertuzumab|Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.
223385785|NCT06218550|DRUG|Delta-9-THC|Acute self-administration of inhaled or oral ∆9-THC by healthy adult research volunteers
223385786|NCT06218550|DRUG|Delta-8-THC|Acute self-administration of inhaled or oral ∆8-THC by healthy adult research volunteers
224003165|NCT05718466|DRUG|Bevacizumab|
224003166|NCT05718466|DRUG|Chemotherapy|
224003167|NCT05718466|RADIATION|Fractionated radiosurgery|
224003168|NCT02159508|BEHAVIORAL|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
224003169|NCT05947032|OTHER|Supervised endurance exercise training + Patient Education|"ENDURANCE TRAINING:~Treadmill Walking:~Frequency: 15 to 20 sessions for 3 to 5 days per week. Intensity: 40% to 60% of HRR Time: 15 Min Type: aerobic training~Recumbent Bike:~Frequency: 15 to 20 sessions for 3 to 5 days/week. Intensity: 40% to 60% HRR Time: 15 Min Type: aerobic training~\+ Patient Education"
224003170|NCT05947032|OTHER|Home exercises + Patient Education|"HOME EXERCISES:~CONVENTIONAL Treatment:~Walking:~Frequency: 2 times/ day Intensity: as tolerated Time: 30 Min Type: aerobic training~Stair climbing:~Frequency: 1 flight/ day Type: aerobic training~\+ Patient Education"
224003171|NCT00386282|DRUG|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
224003172|NCT04695912|DEVICE|The SENS motion® sensor|"The sensor is a wearable physical tracker giving investigators feedback about daily activity~The SENS motion® system consists of:~The sensor 'SENS Motion Patch' A smart-phone application 'SENS motion´~SENS motion cloud storage database, a web-based visualization of data for the healthcare team~The iSpine app shows activity-information recorded by the sensor to the patient and gives nudges to activity."
224003173|NCT04009733|BIOLOGICAL|Blood sample|A study specific blood sample will be collected.
224003174|NCT04009733|BIOLOGICAL|Blood sample|Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.
224003175|NCT01562223|OTHER|motexafin gadolinium|
224003176|NCT03861026|DEVICE|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
223385787|NCT06218550|DRUG|Placebo|Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers
223385788|NCT03404024|BIOLOGICAL|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
223385789|NCT03404024|BIOLOGICAL|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
223385790|NCT03404024|BIOLOGICAL|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
223385791|NCT03404024|DRUG|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
223385792|NCT03404024|BIOLOGICAL|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
224003177|NCT06316310|OTHER|acupoint thread embedding|Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
224003178|NCT02548286|DRUG|Candesartan 8mg|PO, 1day or 22day
224003179|NCT02548286|DRUG|Amlodipine 5mg|PO, 1day or 22day
224003180|NCT02548286|DRUG|CKD-330 8/5mg|PO, 1day or 22day
224003181|NCT00036127|DRUG|aripiprazole|
223385793|NCT03404024|BIOLOGICAL|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
223425584|NCT06090409|OTHER|Implementing free/subsidized agricultural produce to encourage a plant-based diet.|Providing educational material on the benefits of a plant-based diet, simple recipes, food swaps and free/subsidized produce.
223385794|NCT03404024|DEVICE|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
223385795|NCT05621096|RADIATION|Bridging radiation therapy|Days -20 to -7: Patients will receive 2 fractions of 2 gray (Gy) for a total of 4 Gy received.
223385796|NCT05621096|BIOLOGICAL|Liso-cel|"Day 0: Patients will receive an infusion of liso-cel CAR T-cell product.~Prior to the liso-cell infusion (Days -5 to -3), patients will receive lymphodepleting chemotherapy using fludarabine 30mg/m2 and cyclophosphamide 300mg/m2 per institutional standard procedures."
223385797|NCT05621096|RADIATION|Post-infusion radiation|Days 30 to 80: Patients eligible for post-infusion radiation will receive a total dose of up to 32 Gy.
223385798|NCT04710043|DRUG|BNT152|intravenous
223385799|NCT04710043|DRUG|BNT153|intravenous
223385800|NCT04681131|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
223385801|NCT04681131|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
223385802|NCT05078957|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and annually during 5 years
223385803|NCT05078957|OTHER|Frailty phenotype|According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
223385804|NCT05078957|OTHER|Blood plasma collection|Blood plasma collection to measure persistent inflammation and immune activation
223385805|NCT02015117|OTHER|Laboratory Biomarker Analysis|Correlative studies
224003182|NCT01099215|BIOLOGICAL|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
223385806|NCT02015117|OTHER|Pharmacological Study|Correlative studies
224003183|NCT04203095|DIAGNOSTIC_TEST|the level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs.
224003184|NCT00252109|BEHAVIORAL|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
224003185|NCT02896075|OTHER|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
224003186|NCT02896075|OTHER|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
224003187|NCT02695342|BEHAVIORAL|Home balance exercise program|
224003188|NCT03408405|DRUG|Acthar Gel 80 UNT/ML Injectable Solution|Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
224003189|NCT03065257|PROCEDURE|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
224003190|NCT03435679|PROCEDURE|one-stage|one-stage surgery
224003191|NCT03435679|PROCEDURE|two-stage|two-stage surgery
224003192|NCT04358601|DEVICE|Triathlon PS Knee System with all-polyethylene tibial components|Primary Total Knee Replacement
224003193|NCT04358601|DEVICE|Triathlon PS Knee System with metal-backed modular components|Primary Total Knee Replacement
223385807|NCT02015117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
223385808|NCT02015117|DRUG|Trametinib|Given PO
223385809|NCT02015117|RADIATION|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
223385810|NCT06330441|PROCEDURE|endoscopic ultrasonography|endoscopic ultrasonography - frequency defined by arm
223385811|NCT06330441|PROCEDURE|magnetic resonance|magnetic resonance - frequency defined by arm
223385812|NCT06330441|DIAGNOSTIC_TEST|laboratory examination|hematology, biochemistry, Na+, K+, Cl-, Ca2+, bilirubin, ALT, AST, GGT, ALP, lactate dehydrogenase, creatinine, urea, fasting glycemia, HbA1c, alpha-amylase, LPS, albumin, total protein, CA19-9, CEA
223385813|NCT05336695|DIAGNOSTIC_TEST|PET/MR Imaging|PET/MRI Scan with \[64Cu\]FBP8 as directed by protocol
223385814|NCT05336695|DRUG|64Cu-FBP8|Will be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center
223385815|NCT05587127|BEHAVIORAL|Cognitive Behavioral Therapy|Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.
223385816|NCT05705570|DRUG|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
223385817|NCT05705570|DRUG|Fludarabine|Fludarabine 25mg/m\^2 IV on days -5 to -3
223385818|NCT05705570|BIOLOGICAL|"Chimeric antigen receptor T cells to be implemented in a 3 + 3 design on day 0"|"Level -1 (1 x 105 cells/kg)~Level 1 \[Starting dose\] (5 x 105 cells/kg)~Level 2 (1 x 106 cells/kg)~Level 3 (2 x 106 cells/kg)"
224003194|NCT01109641|DEVICE|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
223385819|NCT06157814|OTHER|STOMA Care web-based application|The STOMA Care App, with program software developed in collaboration with the Information Technology Department at Mount Sinai, is organized in a web-based app accessible on any smart-phone (e.g., Android and iOS), tablet, or computer device and consist of: 1) provision of information through text, and graphics; 2) videos of physicians and nurses answering questions; and 3) videos of patients describing their experiences and modelling competencies 4) mental health, support group, and ostomy supplier resources.
223385820|NCT06157814|OTHER|Usual Care|Patients and caregivers NOT given access to the web-based application.
224003195|NCT02801695|DRUG|Citrulline|Citrulline supplementation
224003196|NCT02801695|DRUG|Placebo|Placebo
224003197|NCT04593953|PROCEDURE|TLIP|Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
224003198|NCT01736943|DRUG|Bortezomib|Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
223385821|NCT05932199|DRUG|Durvalumab / tremelimumab|"Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
223385822|NCT05932199|DRUG|Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab|"Cisplatin 75mg/ m2 (or carboplatin AUC 5-6) + pemetrexed 500 mg/m2 will be provided as per standard of care.~Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL.~Tremelimumab concentrate for solution for infusion will be supplied in glass vials containing 400 mg or 25 mg tremelimumab at a concentration of 20 mg/mL."
223385823|NCT06221007|PROCEDURE|Use of bone cement in otosclerosis surgery|Surgical technique; It involves separating the sclerosed stapes from the oval window and incus under an endoscope or microscope and replacing it with a Teflon piston, which is a middle ear prosthesis. In this way, a new connection between the incus and the oval window ensures the transmission of sound to the inner ear. Bone cement has long been used in primary and revision ossiculoplasty, including stapedotomy of the middle ear. During stapedotomy, the part of the Teflon piston that places the teflon piston on the incus is fixed with bone cement, aiming to keep the prosthesis in place for a long time and prophylactic treatment of incus necrosis.
223385824|NCT06344000|OTHER|inapplicable|inapplicable
223385825|NCT04130893|BEHAVIORAL|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
223385826|NCT04130893|BEHAVIORAL|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
223385827|NCT06430866|DRUG|ABP 234|Administered by intravenous (IV) injection.
223385828|NCT06430866|DRUG|Pembrolizumab|Administered by IV injection.
223385829|NCT05102760|PROCEDURE|Nerve Block using FIC Proceedure|Ultrasound Guided Nerve Block for Hip Fracture Patients using the FIC Proceedure
223385830|NCT05102760|PROCEDURE|Nerve Block using PENG Proceedure|Ultrasound Guided Nerve Block for Hip Fractures Patients using the PENG Procedure
223385831|NCT04903288|GENETIC|Eladocagene Exuparvovec|Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
223385832|NCT03274492|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
223385833|NCT03274492|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
224003199|NCT01736943|DRUG|Doxil|Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
224003200|NCT01077453|DRUG|letrozole|Given orally
224003201|NCT01077453|OTHER|quality-of-life assessment|Ancillary studies
223385834|NCT03274492|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
223385835|NCT03274492|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
223385836|NCT03274492|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
223385837|NCT03274492|DRUG|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
223385838|NCT03274492|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223385839|NCT03274492|DRUG|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
223385840|NCT06474182|PROCEDURE|Blood sampling|Blood sampling
223385841|NCT06474182|DRUG|Apixaban|Treatment by Apixaban
223385842|NCT06452407|OTHER|Implementation of elleFA smartphone application|Participants will download the elleFA application on their smartphone. Through this application, the user will be prompted to complete a short modified Biberoglu and Behrman (B\&B) questionnaire and a longer EHP-30 questionnaire monthly, for a period of 6 months. Optionally, patients may complete an additional weekly summary of their mental health symptoms, pain localization, and other symptoms. Also optionally, they may record any daily symptoms, separated into categories from lifestyle to physical pain, objectified through a 5-point Likert scale.
223385843|NCT06636864|PROCEDURE|Intrathecal morphine|The patient was asked to lie on the side, the needle insertion point was located under the guidance of color ultrasound, and after local anesthesia, the needle was inserted into the subarachnoid space at the puncture point and morphine was injected.
223385844|NCT06636864|PROCEDURE|Intrathecal saline injection|After the patient was asked to lie on his side, the injection point was determined under the guidance of color ultrasound. After local anesthesia, the needle was injected into the subarachnoid space and then normal saline was injected.
224003202|NCT01077453|OTHER|laboratory biomarker analysis|Correlative studies
224003203|NCT00387426|DRUG|sunitinib malate|Given PO
224003204|NCT03680339|PROCEDURE|cesarean section|CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
224003205|NCT03680339|DRUG|Misoprostol|The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
224003206|NCT03680339|DRUG|Oxytocin|10 IU of oxytocin with fetal delivery
224003207|NCT00910377|BEHAVIORAL|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
224003208|NCT00282672|DEVICE|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
224124490|NCT05378425|DRUG|Pembrolizumab|IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
223385845|NCT06636864|PROCEDURE|TAPB|The patient was in a supine position. The rectus muscle was confirmed to be warping under the guidance of color photography, and the needle was injected with bupivacaine liposomes
223385846|NCT04770935|DRUG|efanesoctocog alfa (BIVV001)|Pharmaceutical form:solution for injection Route of administration: intravenous injection
223385847|NCT06557863|BEHAVIORAL|WeCareToFeedDysphagia web tool|The web tool uses written and video content, care-partner testimonials, frequently asked questions, and resource links to provide accurate information (e.g., dysphagia diets), set realistic expectations, identify/support feeding goals (quality of life considerations), acknowledge/support care-partner feelings, and provide competencies/skills for oropharyngeal dysphagia (OD) management.
224003209|NCT00282672|DEVICE|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
224003210|NCT03046108|DEVICE|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
224003211|NCT03046108|DRUG|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
224003212|NCT03046108|DRUG|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
224003213|NCT03046108|DEVICE|ultrasound guided injection|Introduction of a needle based guided by ultrasound
223385848|NCT04069312|DRUG|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months
223385849|NCT04069312|DRUG|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months
223385850|NCT06582693|OTHER|Refer2Quit|The Refer2Quit intervention consists of automatic connection to the adult participant's choice of any or all of four evidence-based tobacco treatment options (varenicline, NRT, quitline, and/or smokefreeTXT), as well as motivational counseling provided by the study team. Supportive and motivational text messaging is also included in the intervention to connect or reconnect adult participants to treatments as needed. Text messaging and support would also focus on supporting appropriate use of NRT and/or varenicline if indicated.
223385851|NCT05399992|OTHER|Inclisiran|Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
223385852|NCT03367572|DRUG|Dexamethasone|Given PO
223385853|NCT03367572|OTHER|Laboratory Biomarker Analysis|Correlative studies
223385854|NCT03367572|DRUG|Netupitant/Palonosetron Hydrochloride|Given PO
223385855|NCT03367572|DRUG|Olanzapine|Given PO
224003214|NCT03046108|DRUG|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
224003215|NCT03046108|DRUG|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
224003216|NCT04403087|DRUG|Trimebutine 100 MG|Trimebutine 100mg three times a day
224003217|NCT01852318|DRUG|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
224124491|NCT01734512|DRUG|Everolimus|Everolimus tablet will be taken daily by mouth with water. All participants will be given a dose of 5 mg/m2/dose daily.
223385856|NCT03367572|OTHER|Placebo|Given PO
223385857|NCT03367572|DRUG|Prochlorperazine|Given PO
223385858|NCT03367572|OTHER|Quality-of-Life Assessment|Ancillary studies
224003218|NCT01852318|DRUG|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
224003219|NCT01852318|DRUG|placebo|
224003220|NCT03247387|DEVICE|MC10 BioStampRC|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
224003221|NCT03247387|DEVICE|APDM actigraphy device|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
224124492|NCT04258059|DEVICE|Active household UV water treatment device|This point-of-entry treatment device will use germicidal UV to treat all of the well water used in the home.
223385859|NCT05229718|OTHER|Diabetes Collaborative Care Model for Young Adults|We designed a diabetes collaborative care model for young adults that incorporates a mental health provider alongside a diabetes care provider during joint office visits to facilitate screening and treatment of psychosocial determinants of diabetes management. The Massachusetts General Hospital (MGH) Diabetes Center will be piloting this model with a multi-disciplinary team of diabetologists, nurse practitioners, diabetes nurse educators, and mental health provider. Patients scheduled to be seen in the diabetes collaborative care model will continue to follow in the diabetes collaborative care model, with follow up visits every 3-4 months. All patients will receive routine diabetes care with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers.
224003222|NCT03247387|DEVICE|GENEActiv watch|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
224003223|NCT02525718|DRUG|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
224003224|NCT02525718|DRUG|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
224003225|NCT01621308|OTHER|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
224003226|NCT00211068|DRUG|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
224003227|NCT00747227|DEVICE|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
224003228|NCT00747227|DEVICE|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
224003229|NCT02777476|DEVICE|B-Lite- Light Weight Breast Implants|
224003230|NCT01715662|DEVICE|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
224003231|NCT01715662|DEVICE|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
224003232|NCT06426212|DRUG|Use of teicoplanin three times a week|retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
224003233|NCT03917862|COMBINATION_PRODUCT|TDM-621|The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
224003234|NCT01612598|OTHER|counseling intervention|Undergo PCI
224003235|NCT01612598|PROCEDURE|quality-of-life assessment|Ancillary studies
224003236|NCT01612598|OTHER|questionnaire administration|Ancillary studies
224003237|NCT01612598|OTHER|educational intervention|Undergo PCI
224003238|NCT05169398|DEVICE|EUS-guided hepaticogastrostomy|EUS-guided hepaticogastrostomy would be performed with the MG-biliary stent (Niti-S, Taewoong Medical, Gyeonggi-do, Korea)
224003239|NCT02309931|PROCEDURE|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
224003240|NCT02309931|PROCEDURE|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
224003241|NCT03440957|OTHER|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
224003242|NCT03554629|DEVICE|Capnography CO2 cannula sampling Flexiterline (CCSF) designs with supplemental O2|Use of 8 post-market nasal CO2 cannula sampling filterlines; 4 nasal only sampling ports manufactured by Medtronic, Salter, Hudson/Teleflex and FlexiCare) and 4 post-market oral/nasal sampling ports manufactured by Medtronic, Salter, Dispo-Med and Westmed during scripted activity with supplemental O2.
224003243|NCT06422000|DRUG|Pentoxifylline|Pentoxifylline 30 mg/kg given over 6 hours daily
223385860|NCT05229718|OTHER|Usual Care Model|Patients enrolled in this arm will receive routine diabetes care per usual care at the Massachusetts General Hospital (MGH) Diabetes Center, with lab testing, medical interventions, therapies and referrals performed at the discretion of the patients' providers. In the usual care model, behavioral/mental health and social work services are available on a referral basis and are not integrated into a patients' routine appointment. Screening and treatment of psychosocial determinants of diabetes management are at done at the discretion of the patients' provider. Frequency of follow up visits is at the discretion of the patients' provider.
223385861|NCT05849259|OTHER|Dementia Care Quality at Home|Each of the two HBPC practices will identify at least two trained Dementia Care Quality at Home Champions who will be trained in the intervention comprised of 1) a standardized assessment tool to assess PLWD and caregiver needs; 2) six modules created to optimize the well-being of the PLWD and their caregiver; and 3) regular team-based review of persons participating in the program to address care challenges and a team-based case conference approach to solve these challenges.
223425585|NCT02940093|OTHER|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
223425586|NCT05212688|OTHER|Acupuncture|Weekly treatment of 15 minutes for 6 weeks using Seirin 36 g 30 mm needles applied to two upper midline sternal points, thoracic paravertebral points, 5 pairs, 2 bilateral Trapezius trigger points, LI4, TE5, ST36, GB34, SP6, LR3 bilaterally, GV20 \& GV24 midline.
223425587|NCT05212688|OTHER|Active Control|Weekly contact once per week for 6 weeks for a semi-structured telephone consultation.
224003244|NCT06422000|DRUG|Probiotic Formula|probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
224003245|NCT06455735|DRUG|68Ga-JH04|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-JH04. Tracer doses of 68Ga-JH04 will be used to detect tumors by PET/CT.
224003246|NCT06455735|DRUG|68Ga-FAPI/18F-FDG|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
224003247|NCT03186053|DRUG|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
224003248|NCT03186053|DRUG|saline|.Loading dose followed by continuous infusion in operation
224003249|NCT05726240|DRUG|Ghrelin|Treatment in the intervention group will consist of intravenous acylated ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term) infusion in 30 minutes, twice daily, for five days. This treatment will be additional to standard treatment, including intravenous thrombolysis, if indicated.
224003250|NCT02880787|DRUG|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
224003251|NCT02880787|DEVICE|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
224003252|NCT06144021|DIETARY_SUPPLEMENT|Whey postbiotics derived from kefir lactic acid bacteria|Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
224003253|NCT06144021|DIETARY_SUPPLEMENT|Placebo powder|A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
224003254|NCT02297659|PROCEDURE|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
224003255|NCT02297659|DEVICE|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
223385862|NCT06472973|OTHER|Post-transplant addiction intervention|The first addiction consultation will be conducted using the BRENDA method which allows the addiction specialist to carry out a psychosocial assessment, to entrust the results of this assessment to the participant, to answer their questions and to evaluate their reactions. Risk factors for alcohol relapse will be collected: social determinants, male gender, psychiatric comorbidities, duration of alcohol abstinence before LT(≥ or \< 6 months) and young age (\< 40 years). If the addiction specialist notes the presence of at least 3 risk factors for alcohol relapse, targeted addiction follow-up will be proposed to the participant including outpatient consultations with motivational interview at least every 4 weeks +/- pharmacological treatment of alcohol use disorder.In case of alcohol relapse or a period of high vulnerability to relapse, specific hospitalizations can be scheduled. If the participant has \<3 risk factors, an addictology consultation every 6 months at most will be proposed.
223385863|NCT05866432|DRUG|Datopotamab deruxtecan|Will be given until PD or withdraw
223385864|NCT03504644|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223385865|NCT03504644|PROCEDURE|Computed Tomography|Undergo CT scan
223385866|NCT03504644|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223385867|NCT03504644|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223385868|NCT03504644|DRUG|Venetoclax|Given PO
223385869|NCT03504644|DRUG|Vincristine Liposomal|Given IV
223385870|NCT03504644|DRUG|Vincristine Sulfate|Given IV
223385871|NCT05186116|PROCEDURE|Living donor liver transplant, Split liver transplant, RAPID, DDLT|Transplantation of part of the liver from a living donor, or entire cadaveric graft
223385872|NCT05967624|OTHER|Teleconsultation|Each subject will be remotely assessed by a Medical Control Physician (MCP) using Zoom Pro (HIPAA-compliant video-conferencing software) on tablet devices as a low-cost mobile telemedicine platform and the Respiratory Observation Checklist, validated for telemedicine use in emergency settings. All prehospital clinical decision making will be made at the discretion of evaluating paramedics as per standard state-approved protocols and procedures, independent of checklist results.
223385873|NCT06961331|DRUG|Tucatinib|As provided in real world practice.
223385874|NCT06961331|DRUG|Trastuzumab|As provided in real world practice.
223385875|NCT06961331|DRUG|Capecitabine|As provided in real world practice.
223385876|NCT06453213|DRUG|Cenobamate|"The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day).~The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day)."
224003256|NCT03468062|DRUG|Dexmedetomidine|Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.
224003257|NCT00918879|DRUG|Saxagliptin|Oral tablet, once daily for 24 weeks
224003258|NCT00918879|DRUG|Placebo|Oral tablet, once daily for 24 weeks
224003259|NCT00003397|BIOLOGICAL|filgrastim|
224003260|NCT00003397|BIOLOGICAL|rituximab|
224124493|NCT04258059|DEVICE|Inactive household UV water treatment device|This sham device will use a lamp not emitting germicidal UV.
224003261|NCT00003397|BIOLOGICAL|sargramostim|
224003262|NCT00003397|DRUG|carmustine|
224003263|NCT00003397|DRUG|cisplatin|
224124494|NCT00347711|DRUG|Intravitreal injection|
223385877|NCT06479070|OTHER|Blood samples|"A blood sample of 20 mL (2 tubes of 10 mL) for research purposes will be collected during:~* The day of the centering scan (Visit 1);~* During treatment at Week 2 and Week 6 (+/- 1 week) (Visit 2 and 3);~* The day of the post-therapeutic visit scheduled between 3 and 5 weeks after the end of radiotherapy, whether or not associated with concomitant treatment (Visit 4);~* At each monitoring visit following radiotherapy associated or not with concomitant treatment (every 3 months for 24 months (V5 to V12 ; V12 = final visit)~* When the disease progresses before initiation of the 2nd line of treatment."
224003264|NCT00003397|DRUG|cyclophosphamide|
223545580|NCT00689897|PROCEDURE|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
224003265|NCT00003397|DRUG|dexamethasone|
223545581|NCT00689897|PROCEDURE|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
223545582|NCT01645774|PROCEDURE|10s injections duration|10s injections duration
223545583|NCT01645774|PROCEDURE|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
224003266|NCT00003397|DRUG|etoposide|
224003267|NCT00003397|DRUG|gemcitabine hydrochloride|
224003268|NCT00003397|DRUG|melphalan|
224003269|NCT00003397|DRUG|paclitaxel|
224003270|NCT00003397|PROCEDURE|bone marrow ablation with stem cell support|
224003271|NCT00003397|PROCEDURE|peripheral blood stem cell transplantation|
224003272|NCT04606186|DIETARY_SUPPLEMENT|Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289)|Supplementary intake of Lactobacillus reuteri Prodentis®-lozenges (DSM 17938, ATCC PTA 5289) 2 times per day for 12 weeks
224003273|NCT04606186|DIETARY_SUPPLEMENT|Placebo-lozenges (BioGaia)|Placebo-lozenges (BioGaia)
224003274|NCT00259623|DEVICE|Radiofrequency ablation|
224003275|NCT00031642|BIOLOGICAL|rituximab|
224124495|NCT00114972|DEVICE|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
224124496|NCT00114972|PROCEDURE|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
224124497|NCT00830037|DRUG|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
224124498|NCT00830037|DRUG|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
224003276|NCT00031642|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
224003277|NCT01532804|DRUG|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
224003278|NCT01532804|DRUG|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
224003279|NCT03149575|DRUG|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
224003280|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
223385882|NCT01742975|DEVICE|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
223385883|NCT06312020|DRUG|HZN-1116|Subcutaneous Administration
224003281|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
223385884|NCT06312020|DRUG|Placebo|Subcutaneous Administration
223385885|NCT06352411|DRUG|BI 456906|Solution for injection
223385886|NCT04007562|DRUG|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
223385887|NCT06850805|DRUG|OPN-375|OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID
223385888|NCT06850805|DRUG|Placebo|Placebo solution administered via exhalation delivery system (EDS).
224003282|NCT03149575|DRUG|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
224003283|NCT00357110|DRUG|Fulvestrant|intramuscular injection
224003284|NCT00357110|DRUG|Anastrozole|1 mg oral tablet
224124499|NCT05854615|BIOLOGICAL|Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells|• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
223385889|NCT03830775|PROCEDURE|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
223385890|NCT05269004|DRUG|Ocrelizumab|Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
223385891|NCT02498613|OTHER|18F-Fluoromisonidazole|Correlative studies
223385892|NCT02498613|DRUG|Cediranib Maleate|Given PO
223385893|NCT02498613|OTHER|Laboratory Biomarker Analysis|Correlative studies
223385894|NCT02498613|DRUG|Olaparib|Given PO
223385895|NCT02498613|PROCEDURE|Positron Emission Tomography|Correlative studies
223385896|NCT05168202|DRUG|CC-95251|Specified dose on specified days
223385897|NCT05168202|DRUG|Azacitidine|Specified dose on specified days
223385898|NCT05168202|DRUG|Venetoclax|Specified dose on specified days
223385899|NCT06963112|DRUG|Midazolam|The intervention group patients were given 2mg midazolam injection (Jiangsu Enhua Pharmaceutical Co., Ltd.) during anesthesia induction
223385900|NCT06963112|DRUG|Saline|The control group patients were given 2 mL physiological saline.
223385901|NCT06516510|DRUG|lutetium (177Lu) rhPSMA 10.1 and Pluvicto®|Radiopharmaceutical
223385902|NCT06801834|DRUG|Sacituzumab Govitecan (SG)|Administered intravenously
223385903|NCT06801834|DRUG|Topotecan|Administered intravenously
223385904|NCT06801834|DRUG|Amrubicin (Japan only)|Administered intravenously
223385905|NCT06433219|DRUG|Tuvusertib (M1774)|Tuvusertib will be administered orally.
223385906|NCT06433219|DRUG|Niraparib|Niraparib will be administered orally. If selected from Part A, Niraparib will be administered orally in combination with Tuvusertib.
223385907|NCT06433219|DRUG|Lartesertib (M4076)|Lartesertib will be administered orally. If selected from Part A, Lartesertib will be administered orally in combination with Tuvusertib
223385908|NCT06242912|BEHAVIORAL|QOL - quality of life|QOL assessments using EQ5D (Euroqol 5 dimension) +/- ESAS (Edmonton Symptom Assessment Scale) +/- CPC (Canadian Problem Checklist) every 4-8 weeks +/- 2 weeks
223385909|NCT06242912|DIAGNOSTIC_TEST|Radiographic or laboratory evaluation|Radiographic or laboratory evaluation every 12 weeks +/- 2 weeks
223385910|NCT05770622|OTHER|First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)|CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is \<10mg/L or \>20mg/L) and, if required, recommends a new adjusted dose.
223385911|NCT06628440|OTHER|oral condition assessment tool|Use of the Mat assessment tool by a nurse on the participant
224003285|NCT00688129|BEHAVIORAL|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
224003286|NCT00301678|BEHAVIORAL|behavioral dietary intervention|
224003287|NCT00301678|OTHER|educational intervention|
224003288|NCT00301678|OTHER|preventative dietary intervention|
224003289|NCT01303653|PROCEDURE|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
223385912|NCT05864521|DIETARY_SUPPLEMENT|Active Beetroot Juice Supplement (aBRJ)|aBRJ will consist of 70ml concentrated beetroot juice with 6.45-7.26mmol inorganic nitrate (range for inter-batch variability) taken orally.
223385913|NCT05864521|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Supplement (pBRJ)|pBRJ will consist of 70ml concentrated beetroot juice and will be chemically devoid of inorganic nitrate taken orally.
223385914|NCT03191682|DRUG|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
223385915|NCT06256588|DRUG|Dostarlimab|Dostarlimab will be administered as an intravenous (IV) infusion
224003290|NCT06138613|DRUG|Tradipitant|Oral Capsule
224003291|NCT00350597|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
224003292|NCT03942484|DEVICE|rPMS device|Pelvic floor muscle contractions will be induced by the device.
224003293|NCT03240705|BEHAVIORAL|Gratitude journaling|Gratitude journaling 3 times a week during surgical rotation
224003294|NCT01813877|RADIATION|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
224003295|NCT04799743|DRUG|Resveratrol|Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.
224003296|NCT04799743|DRUG|Placebo capsules|The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
224003297|NCT01242579|DRUG|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
224003298|NCT01242579|DRUG|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
224003299|NCT01242579|DRUG|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
224003300|NCT01242579|DRUG|Matching Placebo Gel|Matching placebo gel containing 2.5g
224003301|NCT04523389|BIOLOGICAL|analysis (protein, lipid, RNA ...) of circulating exosomes, size and number|use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
224003302|NCT04523389|OTHER|Gathering additional information about the patient's cancer|Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
224003303|NCT04523389|DIAGNOSTIC_TEST|Diagnostic test|Diagnostic test
224003304|NCT01010347|PROCEDURE|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
224003305|NCT01010347|PROCEDURE|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
224003306|NCT01008553|DRUG|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
224003307|NCT01008553|DRUG|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
224003308|NCT05894395|BIOLOGICAL|MMR booster vaccination (as M-M-R-VaxPro)|a single dose of MMR-containing vaccine (as M-M-R-VaxPro), in adults having previously received 2 lifetime doses of MMR-containing vaccine
224003309|NCT00219700|DRUG|Ibuprofen-PC|
224003310|NCT01534143|OTHER|pharmacological study|Correlative studies
224003311|NCT01534143|DRUG|tacrolimus|Given IV
224003312|NCT01534143|DRUG|sirolimus|Given PO
224003313|NCT01534143|BIOLOGICAL|anti-thymocyte globulin|Given IV
224003314|NCT01534143|DRUG|fludarabine phosphate|Given IV
224003315|NCT01534143|DRUG|busulfan|Given IV
224003316|NCT01534143|DRUG|bortezomib|Given IV
224003317|NCT01534143|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
224124500|NCT05151341|DIAGNOSTIC_TEST|Urine collection (150ml)|Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)
224124501|NCT05151341|OTHER|Blood sample (20 ml)|"Blood sample will be tacken at inclusion, ONLY for case patients that agreed upon this. This sample will be addition to the collection for further research."
224124502|NCT05092815|DRUG|HLX208|HLX208 450mg bid po
224124503|NCT06357975|PROCEDURE|Biopsy Procedure|Undergo biopsy
224124504|NCT06357975|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224124505|NCT06357975|DRUG|Crizotinib|Given PO
224124506|NCT06357975|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
224124507|NCT06973551|BEHAVIORAL|Brain Health Nostalgic VR Program|"The Brain Health Nostalgic VR Program is a culturally tailored virtual reality intervention integrating nostalgic content from Taiwanese culture (e.g., vintage photographs, familiar objects, historical TV clips, traditional settings) with interactive cognitive training tasks. The program targets seven cognitive domains: attention, imagination and creativity, observation, memory, reasoning, reading comprehension, and thinking. Each weekly session spans 60-90 minutes, with 10-30 minutes of actual VR use based on participant tolerance, each participant will use VR for no more than 30 minutes per session before taking a break. The intervention is delivered once per week over a 12-week period in long-term care settings, with researcher support provided throughout."
224124508|NCT01433458|DRUG|RLX030A|RLX030 is administered as a continuous 24 hour infusion
223385916|NCT06256588|DRUG|Placebo|Placebo will be administered as an IV infusion
223385917|NCT04954261|DIAGNOSTIC_TEST|CAPD|CAPD evaluation every day per 12hours during their stay in PICU
223385918|NCT05878093|DRUG|Dupilumab|solution for subcutaneous injection
223385919|NCT05878093|DRUG|Placebo|solution for subcutaneous injection
223385920|NCT05878093|DRUG|Budesonide|nasal spray (suspension)
224003318|NCT01534143|OTHER|laboratory biomarker analysis|Correlative studies
223385921|NCT04190563|BEHAVIORAL|Pain De-Catastrophizing|Experimenter-administered education and skill practice.
223385922|NCT04190563|BEHAVIORAL|Pain Education|Experimenter-administered education.
224003319|NCT01008410|DRUG|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
223385923|NCT06173388|OTHER|Structured exercise training program + The swallow resistance exercise program.|Structured exercise training program + The swallow resistance exercise program.
223385924|NCT06173388|OTHER|Only the swallow resistance exercise program.|Only the swallow resistance exercise program.
223385925|NCT05353322|BEHAVIORAL|Sedentary Break (Walking) Condition|For the sedentary break (walking) condition, participants will be randomized to 1 of 25 combinations of frequency (5 doses: sedentary break every 30, 45, 60, 90, or 120 minutes) and duration (5 doses: sedentary break duration of 1, 3, 5, 7, or 10 minutes). Participants will complete a 9-hour study visit and will remain seated throughout the lab visit and will take regular sedentary breaks by walking on a treadmill at 2.0 mph and 0% incline at specific frequency and duration (as determined by the randomization method) for the entirety of the visit.
224003320|NCT01008410|DRUG|Placebo|Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
224003321|NCT01477164|BEHAVIORAL|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at \~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
224003322|NCT01477164|BEHAVIORAL|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
224003323|NCT01477164|BEHAVIORAL|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
224003324|NCT01129544|BIOLOGICAL|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
224003325|NCT01151852|DRUG|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
224124509|NCT04425772|DRUG|FNC+Standard of Care|FNC + Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
224124510|NCT04425772|DRUG|FNC dummy tablet+Standard of Care|FNC dummy tablet+ Standard of Care according to the to the latest version of the National Health and Medical Commission Diagnostic criteria
224124511|NCT04571008|OTHER|Placebo|Intervention will last at least 16 weeks in the form of two capsules.
224124512|NCT04571008|DIETARY_SUPPLEMENT|Treatment|Intervention will last at least 16 weeks in the form of two or three NMN capsules (total of 300 or 450 mg/day).
224124513|NCT06286319|DEVICE|Angel Cooler|Device that provides cooled oxygen (between 4-8°C) directly to the lung airways along with external cooling to lung surfaces using cold preservation solutions.
223385926|NCT05353322|BEHAVIORAL|Sitting (Control) Condition|While completing the sitting (control) condition, participants will complete the 9-hour study visit by remaining seated and only standing up/walking to use the restroom at specified times.
223385927|NCT05353322|BEHAVIORAL|Controlled Diet|Participants in both the experimental and control groups will eat a controlled diet (breakfast, lunch, dinner, snacks) for two full days before each lab visit. They will also eat a controlled diet (breakfast, lunch) during each of the two lab visits. Participants will choose 1 of 3 dietary menus to eat for the study duration. Each meal will be individualized to meet 33% of daily estimated energy requirements. Target macronutrient profile will be 12-15% energy from protein, 55-58% from carbohydrate and 29-31% from fat; as well as 55 mmol of sodium and 24 mmol of potassium.
223385928|NCT06227052|DEVICE|Num Vapocoolant Spray|This is the study arm. Partipants in this arm will receive Num vapocoolant spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Num Vapocoolant spray is currently FDA approved to be used on skin prior to injections. The investigators are using it in the same fashion but in the vagina on the cervix to help with the pain of the paracervical block injection.
223385929|NCT06227052|OTHER|Placebo|This is the placebo. This group will receive Natures tear normal saline spray.
223385930|NCT05351983|PROCEDURE|Surgical biopsy of tumoral tissue for organoid generation|In surgically-resectable lesions, tumoral samples will be collected from the main surgical specimens, before sending it for final pathological examination. Patients with metastatic disease, will be offered to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic lesions. Intraoperative frozen section will confirm the presence of malignant cells in the sample. Part of the specimen will be sent for assessment of contamination by bacterial and/or fungal flora by the Microbiology Laboratory. The remaining tumour sample will be sent for patient-derived organoid (PDO) formation. Two patients' blood samples will be retrieved in ethylenediaminetetraacetic acid (EDTA) tubes and will be sent with the surgical specimen. All patients will then receive the standard of care (SOC) treatment according to the clinical judgement of the oncologist in charge, always within the framework of the international guidelines.
224003326|NCT01151852|DRUG|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
224003327|NCT01069653|BIOLOGICAL|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
223385931|NCT03751566|OTHER|Acupuncture|"Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture."
223385932|NCT03751566|DRUG|Standard supportive therapy|Standard supportive therapy
223385933|NCT04886895|OTHER|Let's Move Motor Intervention|Let's Move intervention will be administered and videotaped with infant/caregiver dyads. Therapy will occur weekly (30-60 minutes per session) for 16 weeks, alternating between clinic and home (video telehealth) sessions. Each month, we will attempt to schedule two clinic-based sessions followed by 2 telehealth-based sessions
223385934|NCT05144828|DEVICE|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
223385935|NCT05144828|DRUG|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
223385936|NCT06479135|DRUG|Navtemadlin|Navtemadlin is an investigational MDM2 inhibitor
223385937|NCT06479135|DRUG|Navtemadlin placebo|Navtemadlin placebo
224003328|NCT04998760|DRUG|ATG-008|ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.
224003329|NCT04998760|DRUG|ATG-010|ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
224003330|NCT02022787|OTHER|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
223385938|NCT06479135|DRUG|Ruxolitinib|Ruxolitinib is a janus kinase 1/2 inhibitor
223385939|NCT03690388|DRUG|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib once daily orally.
223385940|NCT03690388|DRUG|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.
223385941|NCT04291703|DRUG|Antithymocyte Globulin|Thymoglobulin
223385942|NCT04291703|DRUG|Placebo (for ATG)|Normal Saline administered by IV infusion to mimic ATG
223385943|NCT05453461|DIAGNOSTIC_TEST|Validation of new COMs for non ambulant FSHD patients|Monitoring of commonly used and news COMs in non ambulant patients with facioscapulohumeral muscular dystrophy
223545584|NCT01645774|PROCEDURE|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
224003331|NCT05671627|DRUG|DMARDs|Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
224003332|NCT02807935|DEVICE|Optical coherence tomography imaging|
224003333|NCT03056300|DEVICE|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
224003334|NCT02888210|DEVICE|MD-15 Intraocular Lens|
224003335|NCT05042908|DRUG|LBL-003 Injection|LBL-003 was given every two weeks for treatment
224003336|NCT01571401|BEHAVIORAL|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
223385944|NCT06274411|PROCEDURE|Standby cannulated ECMO|Femoral cannulas are inserted and connected to the primed circuit. Clamps are kept on circuit, and ECMO is on standby during PCI. ECMO is initiated if needed.
223385945|NCT06274411|PROCEDURE|Prophylactic ECMO|Prophylactic ECMO procedures are performed in the catheterization laboratory before PCI.
223385946|NCT06544733|DRUG|GS-1720|Tablets administered orally without regard to food
223385947|NCT06544733|DRUG|GS-4182|Tablets administered orally without regard to food
223385948|NCT06544733|DRUG|Placebo to Match BVY|Tablets administered orally without regard to food
224003337|NCT05870839|BIOLOGICAL|VXCO-100|Sterile liquid for injection
223385949|NCT06544733|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|Tablets administered orally without regard to food
223385950|NCT06544733|DRUG|GS-1720/GS-4182 FDC|Tablets administered orally without regard to food
223385951|NCT06544733|DRUG|Placebo to Match GS1720/GS-4182 FDC|Tablets administered orally without regard to food
224003338|NCT05670353|DRUG|Cannabis Derivatives|CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
224003339|NCT05670353|DRUG|Placebo|Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks
224003340|NCT05670353|DRUG|Hormonal Contraceptive Agents|All participants will be given hormonal contraceptive.
224003341|NCT05540106|BEHAVIORAL|Nature Coloring Packet|Coloring packet containing nature scenes
224003342|NCT05540106|BEHAVIORAL|Geometric Shape Coloring Packet|Coloring packet containing geometric shapes
224003343|NCT05540106|BEHAVIORAL|Activity Book|Pages containing word searches, connect the dots, etc.
224003344|NCT05540106|BEHAVIORAL|Blank Paper and Pencil|Blank sheets of paper and a pencil.
224003345|NCT03563157|BIOLOGICAL|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
223385952|NCT06425510|BEHAVIORAL|Translation: Living the Advantages of Technological Assistance (VIVE-AT)|It comprises 2-hour small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected assistive technology devices (ATDs). The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding, and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals; providing information on ATDs, resources, and services; reflection on the advantages and disadvantages of using these ATDs; hands-on practice with selected ATDs; goal setting and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
223385953|NCT06425510|OTHER|Attention calls|Ten minutes of attention calls, once a week for six weeks, to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
223385954|NCT03211663|DEVICE|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
223385955|NCT06649695|DRUG|Teclistamab|Teclistamab will be administered via a subcutaneous injection (SC)
224003346|NCT03563157|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]
224003347|NCT03563157|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223425588|NCT03785613|DRUG|Test Product T1: Buprenorphine patch (9 mg)|Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
223425589|NCT03785613|DRUG|Test Product T2: Buprenorphine patch (3.8 mg)|Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
223425590|NCT03785613|DRUG|Reference Product R: Transtec patch (20 mg)|Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
224003348|NCT03563157|BIOLOGICAL|ETBX-021|Ad5 \[E1-, E2b-\]-\[HER2\]
224003349|NCT03563157|BIOLOGICAL|ETBX-051|Ad5 \[E1-, E2b-\]-Brachyury
224003350|NCT03563157|BIOLOGICAL|ETBX-061|Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]
224003351|NCT03563157|BIOLOGICAL|GI-4000|RAS yeast
224003352|NCT03563157|BIOLOGICAL|GI-6207|CEA yeast
224003353|NCT03563157|BIOLOGICAL|GI-6301|Brachyury yeast
224003354|NCT03563157|BIOLOGICAL|haNK|haNK™, NK-92 \[CD16.158V, ER IL-2\]
224003355|NCT03563157|DRUG|Avelumab|BAVENCIO® injection
224003356|NCT03563157|DRUG|Capecitabine|XELODA® tablets
224003357|NCT03563157|DRUG|Cetuximab|ERBITUX® injection
224003358|NCT03563157|DRUG|Cyclophosphamide|Cyclophosphamide Capsules
224003359|NCT03563157|DRUG|5-Fluorouracil|5-FU; Fluorouracil Injection
224003360|NCT03563157|DRUG|Leucovorin|Leucovorin Calcium
224003361|NCT03563157|DRUG|Nab-paclitaxel|ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
224003362|NCT03563157|DRUG|Oxaliplatin|ELOXATIN® injection
224003363|NCT03563157|DRUG|Regorafenib|STIVARGA® tablets
224003364|NCT03563157|PROCEDURE|SBRT|Stereotactic body radiation therapy
224124514|NCT05228002|OTHER|sFlt-1/PlGF ratio - Active Comparator: Standard|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation"
224003365|NCT02860494|DRUG|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
224003366|NCT02860494|DRUG|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
224003367|NCT05039216|BIOLOGICAL|Blood sampling|4 tubes of 7 mL will be sampled
224003368|NCT04045964|DRUG|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
224003369|NCT04045964|BEHAVIORAL|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
224003370|NCT04045964|BEHAVIORAL|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
223385956|NCT03708302|PROCEDURE|Unilateral serratus plane block|Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration. Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sternum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.5% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration.
223385957|NCT03708302|PROCEDURE|Unilateral parasternal infrapectoral block|"Ultrasound guided unilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration.~Ultrasound guided unilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration."
223385958|NCT01221610|DEVICE|Passeo-18 Lux DRB|
224003371|NCT04521569|DRUG|Regadenoson|If the donor lungs are randomized the experimental arm, the administration of Regadenoson will be performed at each study site by a qualified medical professional. The donor lungs will be perfused with Regadenoson at a dosage of 1.44 microgram/kg/min (based on donor's weight) for a minimum of three hours and maximum of four hours, using a pediatric syringe pump into the EVLP circuit (XVIVO Perfusion System). The infusion will begin within 10 minutes of the start of the EVLP procedure. Once the EVLP is complete the lungs are re-flushed with Perfadex solution (removing the Steen™ solution and Regadenoson; standard for EVLP).
223385959|NCT01221610|DEVICE|Standard PTA (POBA)|
224003372|NCT04521569|DRUG|Placebo|If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
223425591|NCT03785613|DRUG|Matching placebo patch to T1|Placebo patch to T1.
223425592|NCT03785613|DRUG|Matching placebo patch to T2|Placebo patch to T2.
224003373|NCT00700700|DEVICE|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~1. Insync Sentry 7298 \& 7299~2. Concerto C174 ASK (Most frequently implanted)~3. Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~1. Contak Renewal 4 H190 \& H199~2. Contak Renewal 3 H127~Devices by ELA/Sorin:~1\. Ovatio CRT 6750"
224003374|NCT02683551|PROCEDURE|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
224003375|NCT04218149|DRUG|Bupivacaine Injection|Block with bupivacaine
224003376|NCT06797336|DRUG|PT0253|PT0253 injection.
224003377|NCT03711032|BIOLOGICAL|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W for BCG Post-Induction Cohort (Cohort A), or IV infusion of 400 mg Q6W for BCG Naïve Cohort (Cohort B), according to randomization
224003378|NCT03711032|BIOLOGICAL|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
224003379|NCT06833372|DEVICE|ESWT group|During each session, participants will receive 2000 pulses at a frequency of 4 Hz and an EDF between 0.02 and 0.2 mJ/mm2.
224003380|NCT06833372|OTHER|exercise group|daily exercise program
224003381|NCT04881383|DIAGNOSTIC_TEST|OGTT and HbA1c|An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
224003382|NCT04795765|PROCEDURE|SpineJack system|For use in the reduction of painful osteoporotic vertebral compression fractures.
224003383|NCT04795765|PROCEDURE|Balloon kyphoplasty|Treatment of osteoporotic vertebral compression fractures.
224003384|NCT04795765|PROCEDURE|Vertebroplasty|Treatment of osteoporotic vertebral compression fractures.
224003385|NCT06460259|BEHAVIORAL|Breathing Exercise|He individual will be seated in a quiet environment in a semi-fowler or fowler position with their feet pointing forward. Then, they will be asked to join their hands on their abdomen and breathe normally while focusing on their breath. They will ensure their shoulders are relaxed, their body is loose, and they will inhale and exhale slowly and deeply through the nose without rushing.Next, while sitting upright with relaxed muscles, they will close their eyes, block their right nostril with their thumb or ring finger, inhale as much air as possible through the left nostril, and hold their breath. Then, they will block the left nostril with their ring finger or thumb and exhale slowly through the right nostril. The same process will be repeated for the left nostril. They will continue this process for approximately 2 minutes.
224003386|NCT05046613|OTHER|Rimegepant|75mg
224003387|NCT05046613|OTHER|Not taking Rimegepant|No rimegepant
224003388|NCT00537589|PROCEDURE|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
224003389|NCT05854472|OTHER|smartphone based application use|A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
223425593|NCT03785613|DRUG|Matching placebo patch to R|Placebo patch to R.
223425594|NCT03595813|PROCEDURE|Blood sample collection|Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
224003390|NCT05602727|DRUG|MK-1942|MK-1942 oral capsule
224003391|NCT05602727|DRUG|Placebo|Placebo oral capsule
224003392|NCT02087449|DEVICE|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
224003393|NCT00309205|DRUG|dapivirine (TMC120) vaginal gel|
224124515|NCT05228002|OTHER|sFlt-1/PlGF ratio - Experimental: Biomarkers|"Blood test for biomarkers (sFlt-1/PlGF ratio) For patients in the standard group, the biomarker results will be masked and then revealed afterwards for statistical analysis.~For the biomarkers group, the monitoring decision will be made based on the ratio calculation."
223385960|NCT03514290|RADIATION|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
223385961|NCT03514290|OTHER|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
223385962|NCT03514290|OTHER|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
223385963|NCT05608395|DRUG|11C-Methionine PET/CT|11C-Methionine PET/CT will be applied in patients in 11C-Methionine PET/CT Arm, based on planning MRI, prior chemo/radiotherapy (2 weeks prior C1D1)
223385964|NCT04100018|BIOLOGICAL|Nivolumab|Specified dose on specified days
224003394|NCT03729401|DRUG|Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily|DAPT with aspirin and ticagrelor
224003395|NCT03729401|DRUG|Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily|Ticagrelor monotherapy
224003396|NCT03729401|DRUG|Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily|Personalized therapy based on risk score and genotyping
224124516|NCT04857112|DRUG|Low Dose MT-1303|MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
224124517|NCT04857112|DRUG|High Dose MT-1303|MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
223385965|NCT04100018|DRUG|Prednisone|Specified dose on specified days
223385966|NCT04100018|DRUG|Docetaxel|Specified dose on specified days
223385967|NCT04100018|OTHER|Placebo|Specified dose on specified days
223385968|NCT06550414|DRUG|Dexmedetomidine|Active comparator: dexmedetomidine group
223385969|NCT06550414|DRUG|Bupivacain|Placebo comparator: bupivacaine group
223385970|NCT03196843|DRUG|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
223385971|NCT03196843|RADIATION|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
224003397|NCT00319462|DEVICE|hemoclip|
223385972|NCT04814095|BEHAVIORAL|QOL|QOL assessments using the ESAS, CPC, EQ5D every 4-8 weeks +/- 2 weeks
223385973|NCT04814095|DIAGNOSTIC_TEST|CT imaging|CT radiographic imaging every 12 weeks +/- 2 weeks
223385974|NCT02257775|GENETIC|n/a - observational|
223385975|NCT05736861|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
223385976|NCT05736861|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
223385977|NCT03583476|DRUG|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
223385978|NCT04622748|BEHAVIORAL|Trier Social Stress Test|8-min oral calculation and 5-min speech
223385979|NCT00036361|DRUG|Aripiprazole|
223385980|NCT00966472|DRUG|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
223385981|NCT06034119|BEHAVIORAL|Split belt treadmill|Participants will walk on a dual belt treadmill with each belt moving at a different speed which is known as a split belt treadmill to provide implicit modifications of the walking pattern
223385982|NCT06034119|BEHAVIORAL|Biofeedback|The Gait Real-time Analysis Interactive Lab (GRAIL) system has an immersive virtual reality screen that provides real-time information to participants of their walking pattern and provides visual instructions on how to walk more symmetrically
223385983|NCT00865761|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
223425595|NCT03595813|PROCEDURE|Biopsy collection|Optional biopsy collection at baseline and progression
224003398|NCT03495843|DIAGNOSTIC_TEST|Spinal stiffness|Spinal stiffness will be assessed with a device, which measures tissue compliance according to the concept of impulse-response
224003399|NCT02187159|DRUG|DS-5565|DS-5565 15 mg tablet for oral administration
224003400|NCT02187159|DRUG|Pregabalin|Pregabalin 150 mg capsule for oral administration
224124518|NCT04857112|DRUG|Placebo|Matching placebo, QD (Day 1-85)
224124519|NCT04857112|DRUG|MT-1303|0.4 mg MT-1303 QD for 36 weeks for those participants who continue on to the OLE period from the double-blind portion of the clinical study
224124520|NCT05438563|PROCEDURE|MRI-Guided Transurethral Ultrasound Ablation|Undergo MRI-Guided TULSA
224124521|NCT05438563|OTHER|Questionnaire Administration|Ancillary studies
224124522|NCT05438563|PROCEDURE|Digital Rectal Examination|Undergo DRE
224124523|NCT05438563|PROCEDURE|Cystoscopy|Undergo cystoscopy
224124524|NCT05438563|PROCEDURE|Biopsy|Undergo biopsy
224124525|NCT05438563|PROCEDURE|Bone Scan|Undergo bone scan
224124526|NCT05438563|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
224003401|NCT02187159|DRUG|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
224003402|NCT02187159|DRUG|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
224003403|NCT02204332|DRUG|Cabazitaxel|
224003404|NCT02204332|OTHER|Best Supportive Care|
224003405|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Population Health Management (PHM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM who can access and existing registry of patients with possible or confirmed AUD to examine quality metrics for patients with an AUD on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide performance metric data that indicates the proportion of patients on their primary care panel who are initiating and engaging in AUD treatment. Additionally, the PHM will circulate a weekly report of higher risk patients on the clinician's panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. PHM does not directly help clinicians with implementation of care with individual patients, and has no direct patient contact.
224003406|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). The clinician will be supported by a CCM who will assist in identifying patients who need further assessment on the clinician patient panel. The CCM will conduct outreach to patients regarding alcohol use care, and will communicate with the clinician to help decide potential care plans, and then assist in implementing those plans for patients. The CCM has expertise on how to provide appropriate care to patients and can help patients navigate the complex care system. Further assistance by the CCM may include facilitating prescriptions for clinician sign-off, assuring refills, finding, selecting and coordinating specialty AUD care, and contacting patients to make appointments.
224003407|NCT05492942|BEHAVIORAL|Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM)|A clinician will have continued access to the existing Epic BPA that provides clinical decision support and management for risky alcohol use and alcohol use disorder (AUD). Additionally, a clinician will be supported by a PHM and clinical care manager CCM. The PHM can access and existing registry of patients with possible or confirmed alcohol use disorder to examine quality metrics for patients with an alcohol use disorder on the provider panel. The PHM will circulate quarterly reports to the clinicians in this group to provide summaries of data of those who have initiated or engaged in treatment for alcohol use, as well as a weekly report of higher risk patients on their panel who recently had an acute care visit for AUD and could benefit from outreach for follow-up care. The CCM will assist in identifying patients who need further assessment, and will assist in conducting outreach and implementing care to those patients regarding alcohol use care.
224003408|NCT03930862|DEVICE|Locator Attachment (positioner)|intra oral attachment
224003409|NCT02776839|DEVICE|Mobile sensing|
224003410|NCT04973501|BEHAVIORAL|Manual physiotherapeutic correction (MFK) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
224003411|NCT04973501|BEHAVIORAL|Dynamic Neuromuscular Stabilization (DNS) Method|Patients undergo ambulatory physiotherapy :1-hour duration, twice a week for one month and once a week for next two months (16 therapies in total).Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
224003412|NCT03475654|BEHAVIORAL|Technology-assisted rehabilitation|The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.
224003413|NCT03475654|BEHAVIORAL|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
224003414|NCT04020185|DRUG|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
224003415|NCT04020185|DRUG|Immune checkpoint inhibitor (ICI)|Administered according to product label
224003416|NCT04020185|DRUG|Immuno-oncology (IO) therapy|Administered according to product label
224003417|NCT01868932|OTHER|hypertonic saline|inhaled nebulized 3%NaCl
223385984|NCT00865761|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under fasting conditions
224003418|NCT01868932|OTHER|saline|inhaled nebulized 0.9% NaCl
223385985|NCT00879255|BEHAVIORAL|Cognitive Processing Therapy Group Videoteleconference|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
223385986|NCT00879255|BEHAVIORAL|Cognitive Processing Therapy Group In-Person|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
224003419|NCT06075186|OTHER|A survey to assess anesthesiologists' secondary victim experience and quality of support resources.|cross-sectional descriptive questionnaire
224003420|NCT00618176|DRUG|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W\>60Kg)125mg bid (W\<60Kg) Nevirapine (NVP) 200mg bid
224003421|NCT00618176|DRUG|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W\>60Kg)20mg bid (W\<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
224124527|NCT05438563|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
223385987|NCT00038077|DRUG|Seloken ZOK/Toprol-XL|50 mg
223385988|NCT00038077|DRUG|Seloken ZOK/Toprol-XL|200 mg
223385989|NCT00038077|DRUG|Placebo|
223385990|NCT00063024|BEHAVIORAL|Increased calcium intake|
223385991|NCT00063024|BEHAVIORAL|Weight-bearing physical activity|
223385992|NCT00467974|PROCEDURE|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
223385993|NCT00467974|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
223385994|NCT06428396|DRUG|Belzutifan|Belzutifan 120 mg administered QD as an oral tablet.
223385995|NCT06428396|DRUG|Fulvestrant|Fulvestrant 500 mg administered as an IM injection.
223385996|NCT06428396|DRUG|Everolimus|Administered at 10mg via oral tablets QD.
223385997|NCT06428396|DRUG|Exemestane|Administered at 25 mg via oral tablets QD.
224003422|NCT00618176|DRUG|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
224003423|NCT06563999|DRUG|Sunvozertinib|300 mg orally once a day, 28 days as one cycle.
224003424|NCT06563999|DRUG|Crizotinib|300 mg orally once a day, 28 days as one cycle.
224003425|NCT06563999|DRUG|Pralsetinib|400 mg orally once a day, 28 days as one cycle.
224003426|NCT06563999|DRUG|Larotrectinib|100 mg orally twice daily, 28 days as one cycle.
224003427|NCT06563999|DRUG|Savolitinib|600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
224003428|NCT06563999|DRUG|Pyrotinib|400 mg orally once a day, 28 days as one cycle.
224003429|NCT06563999|DRUG|Dabrafenib+Trametinib|Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
224003430|NCT06563999|DRUG|Glecirasib|800 mg daily orally, 28 days as one cycle.
224003431|NCT06563999|DRUG|Ensartinib|225 mg daily orally, 28 days as one cycle.
223385998|NCT01665001|OTHER|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients \<55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD\>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD \<0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients \>55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
223385999|NCT01257620|DIETARY_SUPPLEMENT|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
224295767|NCT01075841|DRUG|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
224295768|NCT01739621|DRUG|Proellex 12 mg|
223386000|NCT04821726|DEVICE|Drug eluting balloon (Vmoky)|Use Vmoky Drug Eluting Balloon to treat patients with symptomatic intracranial atherosclerosis stenosis
223386001|NCT05397080|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia."
223386002|NCT05397080|BEHAVIORAL|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
223386003|NCT05397080|BEHAVIORAL|TAU + multicomponent treatment VIRTUAL FIBROWALK + 4 face-to-face sessions|"Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (15 min.)~* Cognitive restructuring (15 min.)~* Mindfulness techniques (15 min.)~* Physical exercise(15 min.)~* Treatment as Usual (TAU)~* 4 face-to-face sessions (1 per mounth) Standard pharmacological treatment usually provided to patients with fibromyalgia."
223386004|NCT05610540|DEVICE|TECNIS Synergy IOL|Implanted in one eye
223386005|NCT05610540|DEVICE|AcrySof PanOptix Trifocal IOL|Implanted in one eye
223386006|NCT00795262|DRUG|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
224003432|NCT05022901|COMBINATION_PRODUCT|Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)|Melphalan administered directly to the liver via the Hepatic Delivery System (HDS) infused over a 30 minute period, followed by a 30 minute washout period
224003433|NCT05829798|DEVICE|SYNOLIS VA 80/160|Single 4mL intra-articular injection of SYNOLIS VA 80/160
224003434|NCT05829798|DEVICE|SYNOLIS VA 40/80|Single 2mL intra-articular injection of SYNOLIS VA 40/80
224003435|NCT00652769|PROCEDURE|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
224003436|NCT00652769|PROCEDURE|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
224003437|NCT06569303|BEHAVIORAL|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, the participants learn how to be more positive and nurturing through academic, social and emotional coaching.
224003438|NCT06569303|BEHAVIORAL|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
224003439|NCT04586231|DRUG|Belzutifan|Immediate-release 40 mg tablet
224003440|NCT04586231|DRUG|Lenvatinib|Capsule available in 4 mg and 10 mg dosages
224003441|NCT04586231|DRUG|Cabozantinib|Tablet available in 20 mg, 40 mg and 60 mg dosages
224003442|NCT04035278|BIOLOGICAL|Dengusiil|Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
223386007|NCT00795262|DRUG|accupril, placebo|accupril 40 mg
223386008|NCT00795262|DRUG|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
223386009|NCT04636476|PROCEDURE|Modified Nesbit's procedure and dorsal dartos flap|Modified Nesbit's procedure to correct the penile curvature and dorsal dartos flap to correct the associated penile torsion
223386010|NCT04251104|OTHER|Images' personal relevance effectiveness in objective and subjective mood recovery|"After completing the PANAS, the negative mood induction phase (viewing a film clip) phase will begin. Before this phase, the participants will be encouraged to experience the feelings generated by the clip as intensely as possible. After viewing the film clip, participants will be asked to complete the PANAS again in order to assess the effectiveness of the negative mood induction procedure.~Following the negative mood induction phase, the emotional recovery phase will be initiated, in which the participants will look at a total of six pictures previously selected according to their experimental condition in order to generate specific positive autobiographical memories. At the end of this phase, participants will once more complete the PANAS in order to assess the effectiveness of the emotional recovery."
223386011|NCT04850339|BIOLOGICAL|ANXV|Intravenous infusion
223386012|NCT04850339|OTHER|Placebo|Intravenous infusion
223386013|NCT03499639|DRUG|Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet|"* Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~* Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks."
223386014|NCT02090725|DRUG|3-4 Diaminopyridine|
224003443|NCT04035278|BIOLOGICAL|Placebo|Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
223386015|NCT01512017|DEVICE|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
223386016|NCT01512017|DEVICE|Vaseline|External use
223386017|NCT03885843|PROCEDURE|Renal nerve stimulation, mapping and denervation|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.
223386018|NCT03885843|PROCEDURE|Sham Procedure: Renal angiography|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
223386019|NCT04358081|DRUG|HCQ|Hydroxychloroquine Monotherapy
223386020|NCT04358081|DRUG|HCQ+AZT|Hydroxychloroquine with azithromycin
223386021|NCT04358081|DRUG|Placebo|Placebo
223386022|NCT01348256|DRUG|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
224295769|NCT01739621|DRUG|Proellex 24 mg|
224295770|NCT06067321|OTHER|abdominal ultrasound, insertion of naso-gastric tube|measurement antral cross sectional area, volume and pH of residual stomach contents
223386023|NCT02346656|DEVICE|Implantation with the commercially available Axium neurostimulator|
223386024|NCT04314453|OTHER|percutaneous endoscopic lumbar discectomy|Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
223386025|NCT05124470|OTHER|cognitive remediation by musical training sessions|"The musical learning method Diapason \& Metronome is unprecedented. It was specially created by Florent Cholat. It aims an apprenticeship of a musical practice adapted to subjects with schizophrenia. The method does not require the handling of a musical instrument; it is based on the voice and the body. It is built on the three essential dimensions of music, which are rhythm, single sound and harmony. Rhythm concerns the division and management of time. The single sound allows work on the representation of a sound object as a singularity. Harmony allows you to work on the positioning of a sound in the globality of the chord to which it belongs and in the collective polyphony exercises."
223386026|NCT03652402|PROCEDURE|kidney transplantation|samples additional to the standard of care' (SOC)will be taken at each visit (Day 0, Month 3, Month12, clinical indication)
223386027|NCT00626353|OTHER|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
223386028|NCT00626353|OTHER|Standard care|Standard care during hospital stay and in the municipality after discharge
223386029|NCT00431470|BEHAVIORAL|Six classroom based character building education lessons|
224295771|NCT01626521|OTHER|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
223386030|NCT02600975|BIOLOGICAL|R21 with ASO1B|R21 with ASO1B
223386031|NCT01130532|DRUG|Tadalafil|Administer orally
223386032|NCT01130532|DRUG|Placebo|Administer orally
223386033|NCT00404287|DRUG|Fluvastatin|
223386034|NCT02691754|OTHER|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
223386035|NCT03649672|DEVICE|TOF Watch SX|Neuromuscular monitoring via the TOF Watch SX device
223386036|NCT02656303|BIOLOGICAL|Ublituximab|Ublituximab IV infusion
223386037|NCT02656303|DRUG|Umbralisib|Umbralisib tablets
223386038|NCT01479075|DRUG|intransal insulin|4x 40mU intranasal insulin
223386039|NCT01479075|DRUG|Placebo|
223386040|NCT01479075|DEVICE|taVNS|
223386041|NCT01479075|DEVICE|sham stimulation|
224003444|NCT02423278|PROCEDURE|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1\&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
224295772|NCT00782821|DRUG|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
223386042|NCT03041311|DRUG|Trilaciclib|Trilaciclib IV
223386043|NCT03041311|DRUG|Placebo|Placebo IV
223386044|NCT03041311|DRUG|Carboplatin|Carboplatin IV
223386045|NCT03041311|DRUG|Etoposide|Etoposide IV
223386046|NCT03041311|DRUG|Atezolizumab|Atezolizumab IV
223386047|NCT06383494|DEVICE|LMA supreme group|Patient in this group received LMA supreme (one of laryngeal airway management device) for airway management during general anesthesia
223386048|NCT06383494|DEVICE|I-gel group|Patient in this group received I-gel laryngeal (one of laryngeal airway management device) for airway management during general anesthesia
223386049|NCT06383494|DEVICE|GMA-Tulip|Patient in this group received GMA-Tulip (one of laryngeal airway management device) for airway management during general anesthesia
223386050|NCT01842438|BEHAVIORAL|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
223386051|NCT01622257|DEVICE|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm\^2 adjustable, 60W with 20cm\^2 active surface).
223386052|NCT01622257|DRUG|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
223386053|NCT01622257|OTHER|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
223386054|NCT00782626|DRUG|everolimus|
223386055|NCT02126514|DRUG|AZD3293|7 subjects will receive AZD3293
223386056|NCT05439096|OTHER|Functional Exercise|Among Functional Exercises, cobra position is most effective in reducing pelvic pain while others are cat and fish position.Kegel exercises along with other strengthening activities for pelvic floor muscles have been accounted for in writing to favorably affect primary dysmenorrheal.
223386057|NCT05439096|OTHER|High Frequency Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation, best treat primary dysmenorrhea. Transcutaneous Electrical Nerve Stimulation is proposed as an incredible spasm decrease, lessening torment, decline of analgesics and improving personal satisfaction in primary dysmenorrhea patients.
224003445|NCT02423278|PROCEDURE|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1\&2 LNs) and para-aortic lymph nodes must be removed during the operation."
224003446|NCT02423278|DRUG|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
224003447|NCT04212637|OTHER|MRI|Examine BOLD activity in relation to eye movements measures
224003448|NCT00567567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
223386058|NCT00562848|DRUG|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
223386059|NCT00562848|DRUG|Placebo|Subjects will receive placebo.
223386060|NCT04909853|DRUG|PF-07321332/ritonavir|PF-07321332 in combination with the PK boosting agent, ritonavir, being developed for the treatment of COVID-19
223386061|NCT01323400|DRUG|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
223386062|NCT01323400|OTHER|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
223386063|NCT02253511|DRUG|Cidan capsule|
224003449|NCT00567567|DRUG|Carboplatin|Given IV
224003450|NCT00567567|DRUG|Cisplatin|Given IV
224003451|NCT00567567|DRUG|Cyclophosphamide|Given IV
224295773|NCT00782821|DRUG|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
223386064|NCT05089383|DRUG|Utrogestan|PROSPECTIVE STUDY
223386065|NCT04054765|DEVICE|videogame|Invite Only VR videogame
223386066|NCT04054765|OTHER|treatment as usual|treatment as usual
223386067|NCT02264678|DRUG|Administration of ceralasertib|An oral formulation of ceralasertib will be used. In Module 2 Part A1, patients will receive a single dose of ceralasertib on Day 1, followed by 4 to 6 days washout, before multiple dosing.
223386068|NCT02264678|DRUG|Administration of ceralasertib in combination with olaparib|An oral formulations of ceralasertib and olaparib will be used. In Module 2 Part A2, patients will receive either a single or twice daily dose of ceralasertib followed by 4 to 6 days washout, before multiple dosing with ceralasertib and olaparib. In Module 2 Part B, patients will receive ceralasertib and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2. Cycle 0 may be omitted at the discretion of the sponsor.
224003452|NCT00567567|DRUG|Doxorubicin Hydrochloride|Given IV
224003453|NCT00567567|DRUG|Etoposide|Given IV
224003454|NCT00567567|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224003455|NCT00567567|BIOLOGICAL|Filgrastim|Given IV or SC
224003456|NCT00567567|DRUG|Isotretinoin|Given orally
224003457|NCT00567567|OTHER|Laboratory Biomarker Analysis|Correlative studies
224295774|NCT00782821|DRUG|Rituxan|Given via IV per group assignment.
224295775|NCT03514654|PROCEDURE|Mastectomy|Removal of the whole breast.
224003458|NCT00567567|DRUG|Melphalan|Given IV
224003459|NCT00567567|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
224003460|NCT00567567|OTHER|Pharmacological Study|Correlative studies
224003461|NCT00567567|DRUG|Thiotepa|Given IV
224003462|NCT00567567|DRUG|Topotecan Hydrochloride|Given IV
224003463|NCT00567567|DRUG|Vincristine Sulfate Liposome|Given IV
224003464|NCT04216563|DRUG|Asciminib|Given PO
224003465|NCT05017662|OTHER|Data collection|Participants will have surveillance visits every 3 months up to 5 years after their first dose of 177Lu-IPN01072 in Study OPS-C-001.
224003466|NCT06244576|BEHAVIORAL|Radically Open Dialectical Behaviour Therapy (RO-DBT)|RO-DBT is a trans diagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
224003467|NCT03237442|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2\*10\^6 cells) subconjunctival injection
224003468|NCT03237442|BIOLOGICAL|placebo|Saline injection
224003469|NCT02209493|BEHAVIORAL|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
224003470|NCT02209493|BEHAVIORAL|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
224295776|NCT03514654|PROCEDURE|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
224295777|NCT03257475|RADIATION|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
223386069|NCT02264678|DRUG|Administation of ceralasertib in combination with durvalumab|An oral formulation of ceralasertib will be used. Durvalumab is given via IV infusion. In Module 3 Part A, patients will receive an initial single dose of ceralasertib on Day 1, followed by multiple dosing in combination with durvalumab. In Module 3 Serial Tumour Biopsy Extension and Part B expansion cohorts, patients will receive ceralasertib at the dose, frequency and schedule recommended from Module 3 Part A, in combination with durvalumab.
223386070|NCT02264678|DRUG|Administration of ceralasertib monotherapy|Module 4 Part A and Module 4 Part B Cohort 3: During C0, patients will receive ceralasertib monotherapy orally once a day on 3 non-consecutive days and ceralasertib twice a day on 5 consecutive days. After the patients have completed C0 (Part A) they may transition to Module 4 Part B cohort 3 where they will continue to receive ceralasertib monotherapy
223386071|NCT02264678|DRUG|Administration of ceralasertib and olaparib|"Module 4 Part B Cohort 1:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with olaparib as decided by the investigator."
223386072|NCT02264678|DRUG|Administration of ceralasertib and durvalumab|"Module 4 Part B Cohort 2:~After completion of Part A (C0), the patient may transition to Part B and be allocated to receive ceralasertib in combination with durvalumab as decided by the investigator."
223386073|NCT02264678|DRUG|Administration of ceralasertib in combination with AZD5305|An oral formulations of ceralasertib and AZD5305 will be used. In Module 5 Part A, patients will receive a single dose of ceralasertib on cycle 0 Day 1 as per dose level cohort. In Module 5 Part B, patients will receive ceralasertib and AZD5305: C1 onwards (as per dose level cohort allocated).
223386074|NCT02264678|DRUG|Administration of ceralasertib in combination with carboplatin|An oral formulation of ceralasertib will be used. In Module 1 Part A, patients will receive a single dose of ceralasertib on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive ceralasertib and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
223386075|NCT03485560|COMBINATION_PRODUCT|ACE CSD|Topical application of the ACE CSD 4 times daily.
224003471|NCT04825405|PROCEDURE|hand motor coordination in a sitting position after use TipStim Glove|The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
224003472|NCT05087251|BEHAVIORAL|Five Psycho-educational Session(s)|5 psychoeducational sessions focused on skills for enhancing wellbeing, relationships, social support, and ability to cope with uncertainty
224003473|NCT05087251|BEHAVIORAL|One Psycho-educational Session(s)|1 session focused on exploring goals and expectations for post-treatment quality of life, including supportive listening; assessment of unmet needs; preferences for support, and tailored referral recommendations
224003474|NCT02075281|BIOLOGICAL|HM11260C|Glucagon-like peptide-1 analogue
224003475|NCT02075281|BIOLOGICAL|Placebo|
224003476|NCT02562443|DRUG|rigosertib|Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
224003477|NCT02562443|DRUG|Any approved or standard-of-care therapy|Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
224003478|NCT02562443|DRUG|best supportive care (BSC)|Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
224003479|NCT02562443|DRUG|best supportive care (BSC)|Patients will receive best supportive care (BSC).
224003480|NCT05852665|DEVICE|Ultrasound-guided resection|Ultrasound-guided resection of buccal squamous cell carcinomas
224295778|NCT05767606|BIOLOGICAL|NVX|Administration of NVX
224295779|NCT05767606|BIOLOGICAL|PCV20|Administration of PCV20
224295780|NCT05767606|BIOLOGICAL|Placebo|No intervention
224138501|NCT04198103|DEVICE|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.
223386076|NCT04945395|DEVICE|FES and Conventional training|The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke. Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
224003481|NCT04406415|DRUG|Nafamostat Mesilate|Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days
224003482|NCT04406415|DRUG|Placebo|Oral placebo administered three times daily for up to 5 days
224003483|NCT06153342|DRUG|TL-925|TL-925 is an eye drop.
224003484|NCT06153342|DRUG|Placebo|The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
224003485|NCT03126669|DEVICE|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
224003486|NCT03126669|DEVICE|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
223386077|NCT04945395|DEVICE|AFO and Conventional training|The control group will be fitted with an ankle-foot-orthosis (AFO) according to clinical practice to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions during 4 weeks of inpatient rehabilitation including walking and mobility training in the subacute phase after hemiplegic stroke
223386078|NCT04994769|DEVICE|Epitomee Capsule|Epitomee Capsule combined with lifestyle counseling.
223386079|NCT06118801|DIETARY_SUPPLEMENT|Probiotic Product Supplement|Mothers of preterm babies who feed their babies only with breast milk will be given a probiotic product supplement once a day (80 ml probiotic product support containing the Actregularis (5×106 CFU\\mL) (lactobacillus bulgaricus, streptococcus thermophilus, lactococcus lactis and bifidobacterium lactis) strain)
223386080|NCT01198769|BIOLOGICAL|Rotarix TM|Oral, 2 doses
223386081|NCT00077207|DRUG|carboplatin|Given IV
223386082|NCT00077207|DRUG|temozolomide|Given orally
223386083|NCT00077207|DRUG|vincristine sulfate|Given IV
223386084|NCT05809960|OTHER|Nursing support program|It was discussed about the operation and surgical menopause that the woman will undergo after hospitalization for the operation. Education was given including the problems experienced during menopause and the approaches used to cope with them. Progressive relaxation exercises were taught and practiced. In order to carry out these procedures, an interview of approximately 45-60 minutes was held with each woman. During the program, four planned meetings were held. One of them was face-to-face and the others were phone calls. During the phone calls, the symptoms experienced by the women and their coping methods were discussed and the questions of the women were answered. The average of each phone call was 20-30 minutes.
223386085|NCT05809960|OTHER|Routine nursing care|Routine nursing care was given to the control group. The clinical routine has not been exceeded. It includes discharge training for the surgery.
223545585|NCT01645774|PROCEDURE|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
224003487|NCT04609488|DIAGNOSTIC_TEST|Surfactant assessment|To determine surfactant levels in lung fluid
224003488|NCT03433677|DRUG|LY900014|Administered by CSII
224003489|NCT03433677|DRUG|Insulin lispro|Administered by CSII
224003490|NCT03570567|DEVICE|Piranha Treatment|The piranha device is used with an endoscope to breakup/dislodge the food bolus.
224003491|NCT01786226|DRUG|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
224003492|NCT01786226|DRUG|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
224003493|NCT06184126|DEVICE|Virtual Reality Headset and Hand-Held Controllers|Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.
224003494|NCT06184126|OTHER|Blindfolding and Noise Cancelling|Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.
224003495|NCT00281060|PROCEDURE|primary stenting|
224003496|NCT01227837|DIETARY_SUPPLEMENT|placebo|placebo given to patients
224003497|NCT01227837|DIETARY_SUPPLEMENT|omga3|use of omega 3
224003498|NCT00508053|PROCEDURE|Small stitches|
224003499|NCT00508053|PROCEDURE|Mass closure|
224003500|NCT03330405|DRUG|Avelumab Phase 1b|Avelumab
224003501|NCT03330405|DRUG|Talazoparib Phase 1b|Talazoparib
224003502|NCT03330405|DRUG|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
224003503|NCT03330405|DRUG|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
224003504|NCT05594381|DRUG|Sintilimab|"Neoadjuvant treatment method: Sintilimab 200 mg, i.v., d1 + oxaliplatin 130 mg/m2, d1, i.v., + Tegafur 40 mg po, bid, d1-14; 3-week course; Neoadjuvant therapy: 3 courses of preoperative SOX chemotherapy (oxaliplatin+Tegafur) + PD-1 monoclonal antibody (Sintilimab).~After the 2nd and 3rd cycles of neoadjuvant therapy (6-9 weeks from the start of treatment), imaging effects and feasibility of radical surgery were performed respectively; The operation time is arranged within 2-6 weeks after the last administration of neoadjuvant therapy, and the operation method is selected by the surgeon according to the actual needs; The postoperative treatment plan is the same as the preoperative neoadjuvant treatment plan, and the SOX+Sintilimab will continue to be given until the full 8 cycles (including the preoperative 3 cycles)."
224003505|NCT03585010|BEHAVIORAL|Supportive Parenting for Anxious Childhood Emotions|12 sessions with parents
224003506|NCT03585010|BEHAVIORAL|Parent Educational Support|12 sessions with parents
224138502|NCT03350178|DRUG|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
224138503|NCT00101491|BEHAVIORAL|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
223386086|NCT04857658|PROCEDURE|extraction orthodontic treatment plan|patients will be referred for extraction of the upper and lower first premolars then orthodontic treatment will follow.
223386087|NCT05128825|DRUG|azenosertib|Azenosertib (ZN-c3) will be administered orally.
223386088|NCT06128447|DRUG|ZP5-9676 600 mg dose|oral, chewable tablet formulation of flubendazole
223386089|NCT06128447|DRUG|Placebo|Matching placebo
224003507|NCT03585010|BEHAVIORAL|Cognitive-Behavioral Therapy|12 sessions with child
224003508|NCT01582841|PROCEDURE|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
223386090|NCT06290934|DRUG|GS-1427|Administered orally
224003509|NCT00198770|DIETARY_SUPPLEMENT|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
224003510|NCT04772859|BEHAVIORAL|Online Lifestyle Intervention|"The intervention will be based on the Planet Nutrition program. This program was previously designed by the present research group and has a handbook that includes nutrition topics, framed by different behavior change strategies. The nutrition education and physical activity sessions will be offered 3 days a week, in the same 1-hour class: 30 minutes for each.~Nutrition education: presentations based on the Planet Nutrition program, a dedicated website, and the Zoom application, will be used to deliver the intervention. The website will be used to upload the nutrition materials and the recorded sessions. Participants will work on self-monitoring of different health behaviors.~Physical activity: The classes will be delivered by the Physical Activity team through the Zoom application. A website will be used to upload the recorded sessions.~Parents participation. The same website and a private Facebook group will be used to upload nutrition information once a week."
224003511|NCT04772859|OTHER|Control Group|They will receive one digital brochure with general information on a healthy diet, at the beginning of the program.
224003512|NCT03390764|PROCEDURE|4:1 closure group|In this arm the incisions are closed by the 4:1-technique
224003513|NCT03390764|PROCEDURE|RTL plus 4:1 closure group|In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
224003514|NCT02330705|DRUG|HCG|Women will be given HCG before IUI
224003515|NCT03889704|DEVICE|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
224003516|NCT03482466|BEHAVIORAL|Neurofeedback|Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
224003517|NCT04847206|DRUG|3,4-methylenedioxymethamphetamine|A moderate dose of 100 mg MDMA will be administered.
224003518|NCT04847206|DRUG|3,4-methylenedioxyamphetamine|A moderate dose of 93.9 mg MDA will be administered.
224003519|NCT04847206|DRUG|lysine-3,4-methylenedioxymethamphetamine|A moderate dose of 171.7 mg lysine-MDMA will be administered.
224003520|NCT04847206|DRUG|lysine-3,4-methylenedioxyamphetamine|A moderate dose of 165.6 mg lysine-MDA will be administered.
224003521|NCT04847206|OTHER|Placebo|Placebo (Mannitol)
224003522|NCT00847067|PROCEDURE|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
223386091|NCT06290934|DRUG|Placebo-to-match GS-1427|Administered orally
223386092|NCT04446962|DRUG|Lenalidomide|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
224003523|NCT00847067|PROCEDURE|Sham injections|Sham injections with Normal Saline
224003524|NCT04335591|DRUG|75 mg linzagolix tablet|For oral administration once daily
224003525|NCT04335591|DRUG|200 mg linzagolix tablet|For oral administration once daily
224003526|NCT04335591|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
223386093|NCT04446962|DRUG|Ibrutinib|Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.
224003527|NCT04335591|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
224003528|NCT04335591|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
224003529|NCT04335591|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
224003530|NCT04688619|BEHAVIORAL|"Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
224003531|NCT04688619|BEHAVIORAL|"Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
224003532|NCT00239551|DRUG|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 \& EGD with biopsy at 8 weeks
224003533|NCT05721547|OTHER|Assessment|Assessment
224003534|NCT05816304|BEHAVIORAL|Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)|Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
224003535|NCT03268603|DRUG|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
224003536|NCT02060370|DRUG|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
224003537|NCT02060370|BEHAVIORAL|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
224138504|NCT05250193|DEVICE|DK ScoreTM Coronary Scoring Balloon|After pre-dilation balloon is used (if any), DK Score is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
224003538|NCT05270369|BEHAVIORAL|digital CBTI|The app-based intervention will consists of 6 weekly sessions and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
224003539|NCT05270369|BEHAVIORAL|group CBTI|The group-based CBT-I intervention will consist of 6 weekly sessions (90-min, 5-8 adolescents in each group) and will be delivered within a 10-week window. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psycho-education about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention
224003540|NCT03240822|PROCEDURE|Penile Transplant|Penile Allotransplantation
224124528|NCT06194136|DEVICE|PBM light therapy|The PBM machine consists of a dual light emitting diode (LED) cluster array with 105 light diodes within the 660 nanometer (nm) red light wavelength and the 850 nm near-infrared light wavelength. These wavelengths are both within the ranges noted in previous literature for neuropathic pain (1) and are within the World Association for Photobiomodulation (Laser) Therapy (WALT) guidelines for PBM therapy (2). Dosage will be determined according to the following equation: Laser output Power (Watts) x Time (seconds) divided by Beam Area (cm2)= J/cm2 (1). The PBM unit generates energy equal to 115 mW/cm2 with a surface area of 54.6 cm x 17 cm. Thus, for a target power output of 3.45 J, the participant will have a continuous irradiation duration of 30 seconds for each application (1). The participant will be asked to utilize the PBM device on breast tissue post-mastectomy for 30 seconds 3 times per week with at least 24 hours between each session. The duration of treatment will be 6 weeks.
224124529|NCT04591912|BEHAVIORAL|mind. body. voice|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
224124530|NCT06079268|OTHER|the initial gastric ultrasound|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
224124531|NCT06079268|OTHER|the gastric ultrasound last 3 minutes|Non-invasive gastric antrum ultrasound examinations will utilize a probe with a frequency of 2-5.5 MHz and a linear probe with a frequency of 10 MHz, enabling the evaluation of the gastric antrum's appearance
224124532|NCT05669001|BIOLOGICAL|TCD601|Investigational Product
224124533|NCT05669001|BIOLOGICAL|belatacept|Study Product
224124534|NCT05669001|DRUG|ATG|Comparator
224124535|NCT05669001|DRUG|TAC|Comparator
224124536|NCT05669001|DRUG|MPA|Immunosuppression Therapy
224124537|NCT05669001|DRUG|Corticosteroids|Immunosuppression Therapy
224124538|NCT04026438|DRUG|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
224124539|NCT02639793|PROCEDURE|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
224124540|NCT04740268|DEVICE|Straberi|"The patient's entire face will be treated with the Straberi microneedling devise.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
224124541|NCT00931671|OTHER|Exercise training|aerobic exercise training
224124542|NCT03147144|OTHER|Ultrasonographic imaging|Ultrasound pelvic scan
224124543|NCT01425190|DRUG|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
224003541|NCT03240822|BIOLOGICAL|Monoclonal Antibody (Humanized Anti-CD52)|
224124544|NCT04111276|DEVICE|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
224124545|NCT04111276|OTHER|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
224124546|NCT04111276|DIAGNOSTIC_TEST|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
224124547|NCT04111276|DIAGNOSTIC_TEST|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
224124548|NCT02648412|DRUG|ketamine|bolus 1 mg/kg
224124549|NCT02648412|PROCEDURE|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
223425596|NCT02898324|OTHER|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
224003542|NCT03240822|DRUG|Tacrolimus|
224003543|NCT05503199|DEVICE|Combination of one Perclose ProGlide or ProStyle (Abbott Vascular) and one Angio-Seal (Terumo).|Combined suture- and plug-based VCD strategy after TF-TAVI.
224124550|NCT04097756|DRUG|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
224138505|NCT05250193|DEVICE|Non-Slip Element Coronary Dilatation Catheter|After pre-dilation balloon is used (if any), NSE is used as final dilatation balloon before Drug Eluting Stent implantation or Drug Coated Balloon deployment.
224003544|NCT05503199|DEVICE|Combination of two ProGlides or ProStyles (Abbott Vascular).|Pure suture-based VCD strategy after TF-TAVI.
224003545|NCT01684189|OTHER|Patient registry|Patient registry without study intervention
224003546|NCT06487130|OTHER|N/A Observational Registry|Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.
224003547|NCT00017368|BIOLOGICAL|filgrastim|
224003548|NCT00017368|BIOLOGICAL|sargramostim|
224003549|NCT00017368|DRUG|carboplatin|
223386095|NCT05116072|PROCEDURE|total pancreatectomy|"The total pancreatectomy will be performed in two steps: The pancreatectomy will begin by a standard pancreaticoduodenectomy procedure.~The section margin will be sent for intraoperative histological analysis to confirm the absence of invasion of the left remnant pancreas.~When absence of tumor invasion is confirmed and the high-risk of postoperative pancreatic fistula is validated intraoperatively, the extended left distal pancreatectomy will be performed, with splenic preservation when possible.~Then, the left side of the pancreas will be resected and cooled (4-6°) in the preservation solution and shipped to Lille Biotherapy platform to perform islet isolation and purification. The reconstruction after total pancreatectomy will be done as usually performed by center expert surgeon."
223386096|NCT05116072|BIOLOGICAL|intraportal islet autotransplantation|The final islet preparation will be cultured and shipped 48 hours after total pancreatectomy from the Lille laboratory to the surgical center, and finally transplanted into the patient through a venous catheter placed in the portal trunk (91% of the total islet mass) and at the same time, a small fraction of the isolated islet (5% of the total islet mass) will be transplanted into the forearm muscle.
223386097|NCT05303337|OTHER|Stool sampling|Stool samples will be collected from participants at baseline and W52
223386098|NCT05303337|OTHER|Blood plasma collection|Blood plasma collection to assess persistent inflammation, immune activation and HIV reservoir at baseline,W24,W52
223386099|NCT04927832|OTHER|SUDOSCAN and EMG (electromyogram)|The participants are evaluated clinically by a neurologist with evaluation by DN4 questionnaire, treatments and comorbidities (alcohol consumption, diabetes, etc.). They undergo from exploration by SUDOSCAN according to the already established methodology and an EMG
223386100|NCT04821453|DEVICE|NAVA|NAVA mode of mechanical ventilation provide the trigger for a spontaneous breath from the diaphragmatic movement instead of diaphragm and allows the patient to control the dynamics of the breath generally set in CMV mode.
224003550|NCT00017368|DRUG|cisplatin|
224003551|NCT00017368|DRUG|cyclophosphamide|
224003552|NCT00017368|DRUG|doxorubicin hydrochloride|
224003553|NCT00017368|DRUG|etoposide|
224003554|NCT00017368|DRUG|etoposide phosphate|
224003555|NCT00017368|DRUG|ifosfamide|
224003556|NCT00017368|DRUG|isotretinoin|
224003557|NCT00017368|DRUG|melphalan|
224124551|NCT04597034|PROCEDURE|AN69-Oxiris|To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
223386101|NCT04821453|DEVICE|CMV|CMV mode of mechanical ventilation that provides a trigger for a spontaneous breath from the airway flow sensor with dynamics of the breath set as required by the mode
224003558|NCT00017368|DRUG|thiotepa|
224003559|NCT00017368|DRUG|vincristine sulfate|
224003560|NCT00017368|PROCEDURE|conventional surgery|
224124552|NCT04597034|PROCEDURE|AN69-Standard|Standard treatment.
224124553|NCT04236206|BEHAVIORAL|Mobile Phone Short Message Service|"SMS content will be adopted from the validated Arabic national and international diabetes educational materials (Centers for Disease Control (CDC), 2018; Diabetes Australia, 2004; Diabetes Queensland, 2012; Utah Diabetes Control Program, 2005).~* The mobile phone SMSs will be pre-tested for clarity on a sample of 10 patients similar to the study population and their comments on the SMSs wording will be used to modify them to ensure acceptance.~* The SMS will be sent to participants using the internet, open-source software for bulk messages and a local telephone network provider.~* Patients will be encouraged to send messages/call the researcher for any queries encountered."
224124554|NCT04592432|OTHER|SIGN@L-A|Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).
224124555|NCT04592432|OTHER|SIGN@L-B|The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
224124556|NCT06072872|DEVICE|Use of portable CPAP|Patients use portable CPAP during exercise
224003561|NCT00017368|PROCEDURE|peripheral blood stem cell transplantation|
224003562|NCT00017368|RADIATION|radiation therapy|
224003563|NCT02507453|OTHER|parabolic flight|
224003564|NCT02507453|OTHER|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
224003565|NCT02507453|DEVICE|ESA short-arm human centrifuge (SAHC)|
224003566|NCT04893252|DRUG|durvalumab and vactosertib|durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)
224003567|NCT01575301|DRUG|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
224003568|NCT03412201|OTHER|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
224003569|NCT03412201|OTHER|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
224003570|NCT03028727|PROCEDURE|Ultrasonic Scaling and root planing|Procedure of scaling and root planing at day 0 and at 1 week
224003571|NCT03028727|PROCEDURE|980 nm diode laser irradiation|Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
224003572|NCT00356408|BIOLOGICAL|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
224003573|NCT05457751|PROCEDURE|Rocuronium injection pain|1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath
224003574|NCT00405366|DRUG|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
224003575|NCT03971383|DRUG|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
224124557|NCT05283083|DRUG|Dexmedetomidine|A highly-selective alpha-2 agonist with sedative, analgesic, and sympatholytic effects.
224124558|NCT02818153|OTHER|Self questionnaire for allergic rhinitis control|
224124559|NCT03272477|DRUG|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
224124560|NCT03272477|DRUG|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
224124561|NCT03272477|DRUG|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
224124562|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
224124563|NCT03272477|DRUG|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
224124564|NCT03272477|DRUG|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
224124565|NCT03272477|DRUG|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
224124566|NCT03272477|DRUG|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
223386102|NCT05813652|OTHER|Pre-pandemic time period (Jun 22, 2018 to March 12, 2020)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
223386103|NCT05813652|OTHER|Peri-pandemic time period (March 13, 2020 to December 3, 2021)|The primary exposure is the time period of the pandemic (March 13, 2020 to Dec 3, 2021), compared to pre-pandemic (Jun 22, 2018 to pandemic onset March 12, 2020)
224003576|NCT03971383|DRUG|Placebo|3 tablets one time, 3 times a day(tid)
224003577|NCT02625051|PROCEDURE|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
224124567|NCT03272477|DRUG|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
224124568|NCT03272477|DRUG|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
224124569|NCT03272477|DRUG|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
224124570|NCT03272477|DRUG|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
224124571|NCT03272477|DRUG|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
224124572|NCT03272477|DRUG|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
223386104|NCT05930496|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223386105|NCT05930496|OTHER|Exercise Intervention|Receive exercise intervention
223386106|NCT05930496|OTHER|Exercise Intervention|Receive tele-coaching intervention
223386107|NCT05930496|BEHAVIORAL|Health Education|Receive health-related information
223386108|NCT05930496|OTHER|Interview|Ancillary studies
223386109|NCT05930496|OTHER|Questionnaire Administration|Ancillary studies
223386110|NCT05806567|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
223386111|NCT05806567|DRUG|UGT1A1 victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
223386112|NCT05806567|DRUG|P-gp victim drug|Pharmaceutical form: Capsule; Route of administration: Oral
223386113|NCT05806567|DRUG|OATP1B1/BCRP victim drug|Pharmaceutical form: Tablet; Route of administration: Oral
223425597|NCT05768750|OTHER|Rehabilitation|X
224124573|NCT03272477|DRUG|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
224124574|NCT03272477|DRUG|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
224124575|NCT03272477|DRUG|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
224124576|NCT03272477|DRUG|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
224003578|NCT02625051|PROCEDURE|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
224003579|NCT05762913|OTHER|Manual Diaphragm Release Technique|The therapist passes his fingers under the costal arch, during inspiration the therapist accompanies the movement of the ribs, while during expiration he takes his fingers deeper, increasing his pressure. The therapist progresses progressively deeper into the costal arch with each breath. The maneuver will be performed in two sets of 10 deep breaths. The diaphragm release technique will be applied in 3 sessions, with 2 days of rest in between.
224003580|NCT03177499|PROCEDURE|Invasive PPG|Invasive PPG obtained by means of catheterization.
224003581|NCT00069173|BEHAVIORAL|Project FAB (Fitness and Bone)|
224003582|NCT05880537|OTHER|Nexeon Arterial Venous Allograft|Nexeon AVX allograft for hemodialysis access in end stage renal disease
224003583|NCT05215964|PROCEDURE|Renal artery embolization|After catheterization of renal arteries, multiple coils are applied to embolize renal arteries until blood flow stasis
224003584|NCT06834594|DRUG|Micronized progesterone 200 MG|Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle
224003585|NCT06834594|DRUG|Micronized Progesterone 100 MG|Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
224003586|NCT05258396|OTHER|MRI without injection of contrast product|MRI without injection of contrast product
224003587|NCT05959759|DRUG|Dimethyl fumarate|dimethyl fumarate enteric capsule (the initial dose is 120 mg twice a day, and after 7 days, the dose will be increased to the maintenance dose of 240 mg twice a day, for 6 months), 30 patients for this arm.
224003588|NCT05959759|DRUG|Placebo|placebo with the same appearance (color, taste, size, shape), 30 patients for this arm.
224003589|NCT03203330|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
224003590|NCT03203330|BIOLOGICAL|Placebo Control|2 mL normal saline injection
224003591|NCT04011488|OTHER|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
224003592|NCT04180033|DIAGNOSTIC_TEST|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
224003593|NCT05487586|DRUG|ceftazidime avibactam group|Non-Interventional Study
224003594|NCT01493427|DRUG|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
224003595|NCT02157389|OTHER|Administration of a pharmacological placebo|
224003596|NCT05045651|PROCEDURE|Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA|gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
224003597|NCT05979441|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
224124577|NCT03272477|DIAGNOSTIC_TEST|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
224003598|NCT00565773|DRUG|Belatacept|Belatacept will be given within 24 hours of transplantation via a peripheral intravenous catheter at a dose of 10mg/kg (actual body weight) infused over 30 mins. The dose will be repeated on study days 4 (post op day 3) and 8 (post op day 7), then every 2 weeks for 5 additional doses. Thereafter, belatacept will be given once every 4 weeks (+/- 3 days) at 10mg/kg through 6 months then at 5mg/kg indefinitely.
224003599|NCT00565773|DRUG|Sirolimus|Sirolimus will be started on postoperative day 1 at a dose of 2 mg per day orally. Doses will be adjusted to maintain 24-hour trough levels of 8-10ng/ml until the drug is weaned. Toxicity attributable to sirolimus (e.g., mouth ulcers, arthralgias) will prompt dose reduction to address clinical concerns in this regard. If sirolimus trough levels need to be reduced below 4ng/ml to control drug side effects, the patient will be considered intolerant to the drug and will be changed to other medications.
224003600|NCT00565773|DRUG|Alemtuzumab|All participants will receive a single dose of 30 mgs of alemtuzumab on the day of transplantation.
224003601|NCT03864198|DIETARY_SUPPLEMENT|Genante|A dietary supplement for male infertility
224003602|NCT01390662|DIETARY_SUPPLEMENT|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
224124578|NCT03272477|PROCEDURE|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
224124579|NCT03312140|DRUG|Choline Chloride|
224124580|NCT05598996|BEHAVIORAL|COT-Based Intervention|The COT-based approach uses a controller that runs case-by-case dynamical systems simulations modeling based on answers to daily questions rooted in social cognitive theory to produce ambitious but achievable daily adaptive step goal recommendations. The process for the COT-based approach is as follows: Phase 1) 2-week measurement only; Phase 2) open-loop system identification experiment (meant to create individualized dynamical models for each participant); Phase 3) closed-loop experiment to optimize for PA initiation, and Phase 4) closed-loop experiment to optimize for PA maintenance.
224124581|NCT03491163|DIAGNOSTIC_TEST|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
224124582|NCT01555463|DRUG|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
224124583|NCT01555463|DRUG|Vehicle foam|twice daily topical application
223386114|NCT06412874|OTHER|Screening tool|Participants will complete a screening tool survey
224003603|NCT01390662|DIETARY_SUPPLEMENT|placebo|one tablet of sugar pill pr. day, for 24 weeks.
224003604|NCT04798781|DRUG|Telatinib|900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
224003605|NCT04798781|DRUG|Keytruda|200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
224003606|NCT05061368|DRUG|Sildenafil Citrate|Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
224003607|NCT05061368|OTHER|Placebo|Placebo
224003608|NCT01601522|PROCEDURE|Peanut protein|500 mg
223386115|NCT06958822|DRUG|Ferric Carboxymaltose (FCM)|As this is an observational study, ferric carboxymaltose recipients are determined based on routine medical care practices. The researchers do not define which participants will receive ferric carboxymaltose.
224003609|NCT01601522|PROCEDURE|Oat flour|500 mg Oat flour
224003610|NCT01601522|DRUG|Antihistamine|Desloratidine 5 ml po od (0.5mg/ml = 2.5 mg) Ranitidine 5ml (15mg/ml=75 mg) po bid
224124584|NCT02491658|BIOLOGICAL|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
224124585|NCT04728971|DRUG|Micafungin Sodium 50 MG Injection|Give Micafungin 150 mg/d within 24 hours after liver transplantation.
224124586|NCT04728971|DRUG|Caspofungin Acetate|Give Caspofungin 35 mg/d lasts 1 week after liver transplantation.
224124587|NCT02026271|BIOLOGICAL|Ad-RTS-hIL-12|"* 2.0 x 10\^11 viral particles (vp) per injection or 1.0 x 10\^12 viral particles (vp) per injection~* one intratumoral injection of Ad-RTS-hIL-12"
224124588|NCT02026271|DRUG|veledimex|"* 4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~* 14 oral daily doses of veledimex~* 1 Expansion cohort at a single dose level at or below MTD"
224003611|NCT01219907|BIOLOGICAL|HER-2/neu peptide vaccine|Given intradermally
224003612|NCT01219907|DRUG|cyclophosphamide|Given IV
224003613|NCT01219907|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
224003614|NCT01219907|OTHER|laboratory biomarker analysis|Correlative studies
224124589|NCT02154269|DRUG|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
224124590|NCT02154269|DRUG|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
223386116|NCT04182490|BIOLOGICAL|LMN-101|VHH-derived binding protein designed to bind and inhibit FlaA, flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, spirulina biomass
224124591|NCT00832754|DEVICE|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
223386117|NCT04182490|DRUG|Placebo|Identical appearing placebo
223386118|NCT04925960|DRUG|Epalrestat|Epalrestat is a noncompetitive and reversible aldose reductase inhibitor (ARI) used for the treatment of diabetic neuropathy in Japan. The drug's ability to safely improve symptoms of neuropathy alone by reducing oxidative stress, increasing glutathione levels, and reducing intracellular sorbitol accumulation make it a desirable medication for PMM2-CDG patients who commonly suffer with various neuropathies. However, work recently conducted by Perlara, a public benefit company with the mandate to screen existing commercially available drugs for possible application in rare diseases, has demonstrated that Epalrestat can also elevate the level PMM2 produced endogenously. This may reduce the severity of the morbidities associated with PMM2-CDG.
223386119|NCT04925960|DRUG|Placebo|The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
224003615|NCT01219907|OTHER|flow cytometry|Correlative studies
224003616|NCT01219907|OTHER|immunoenzyme technique|Correlative studies
224003617|NCT03214770|DRUG|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
224003618|NCT03214770|DRUG|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
224003619|NCT04555785|DRUG|Wilate|Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
224003620|NCT04555785|OTHER|Placebo|Empty placebo will be given with platelets in cases of severe bleeding.
224003621|NCT00868153|DRUG|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
224003622|NCT04558398|OTHER|Resistance exercise training|"Each session will be performed at home, with resistance bands used to provide resistance. Participants will be guided to increase the resistance if over 15 repetitions can be performed prior to fatigue. Weekly contact will be made with participants to encourage participation and to guide the exercise.~Each session will include:~2 min warm-up jogging on the spot~2 sets of 12-15 repetitions of:~Squats~Hip flexion~Hip extension~Hip abduction~Seated row~Bench press~Lateral raises~2 min jogging on the spot cooldown."
224003623|NCT04558398|OTHER|High-intensity interval training|"Each session will include:~* 2 min warm-up: jogging on the spot~* Each of the following exercises performed for 60seconds, interspaced by 90 seconds rest~  * Star jumps~ * Standing squats~ * On-the-spot sprints~ * Standing squats~ * Star jumps~* 2 min cool-down: jogging on the spot~Participants will be contacted weekly to encourage participation and to guide the exercise"
224124592|NCT00832754|OTHER|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
224124593|NCT04370028|DRUG|Divaza|Oral administration.
224124594|NCT00540449|DRUG|TMC278|25 mg tablet once daily for 96 weeks
224124595|NCT00540449|DRUG|Efavirenz|600mg once daily for 96 weeks
224124596|NCT05873101|DIAGNOSTIC_TEST|Mobilization With Movement (MWM)|Mobilization With Movement
223386120|NCT05645549|BEHAVIORAL|Centering Pregnancy with Care Navigation|Centering Pregnancy is a group based prenatal care intervention. Centering Pregnancy is an evidenced based intervention that has 10 group sessions for pregnant women. Each session has dedicated educational material relative to pregnancy, birth, and infant feeding. In addition, all participants will be provided a bilingual Marshallese care navigator to aid in enrolling them in social support services.
223386121|NCT00853099|BIOLOGICAL|adalimumab|
223386122|NCT00853099|DRUG|placebo|
223386123|NCT02489097|DRUG|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
223386124|NCT02489097|OTHER|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
223386125|NCT00511823|DRUG|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
223386126|NCT00511823|DRUG|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
224003624|NCT03120468|DRUG|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
224003625|NCT03120468|DRUG|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
224003626|NCT01217853|DEVICE|SENSIMED Triggerfish|Contact lens-based device for continuous intraocular pressure monitoring
224003627|NCT05762393|BIOLOGICAL|Sm-p80 + GLA-SE|Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
224003628|NCT05653063|OTHER|A web-based artificial intelligence (AI) auto-planning tool|"The CT scan taken at the time of treatment planning is uploaded to a web server called the Radiotherapy planning assistant which automates the contouring of target organs and areas of high-risk disease as well as defining the size, shape and number of radiotherapy beams to treat the cancer. The final plan is downloaded to the local treatment planning system where the doses are recalculated and clinical peer review is undertaken before the plan can be used clinically.~In this study patients will not be treated with the AI tool but the manual plan created by the local teams."
224003629|NCT02252770|DIETARY_SUPPLEMENT|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
224003630|NCT02252770|DIETARY_SUPPLEMENT|Placebo|Placebo will not contain nitric oxide supplement.
224003631|NCT01852461|DRUG|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
224003632|NCT01852461|DRUG|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
224003633|NCT00645268|DRUG|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
224003634|NCT00645268|DRUG|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
224003635|NCT00645268|DRUG|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
224003636|NCT05735171|PROCEDURE|GTR surgery|Gross total resection of the enhancing tumor volume
224003637|NCT05735171|PROCEDURE|AI-guided surgery|Supramarginal resection including high-risk areas of recurrence
224003638|NCT04153422|DRUG|Panzyga IVIG|Immune Globulin Infusion 10% (Human)
224003639|NCT04153422|DRUG|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
224003640|NCT03417544|DRUG|ATEZOLIZUMAB|(IV) every 3 weeks
224003641|NCT03417544|DRUG|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
224003642|NCT03417544|DRUG|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
224003643|NCT06518785|DEVICE|Low Intensity Focused Ultrasound|An inhibitory LIFU protocol that allows suppression of neuronal activity in the basal ganglia and thalamus will be used.
224003644|NCT00919191|DRUG|Tretinoin gel|Tretinoin gel 0.04% used once daily in a split-face model
224003645|NCT00919191|DRUG|Adapalene and Benzoyl peroxide|Adapalene .1% and Benzoyl peroxide 2.5%
224003646|NCT05844670|DRUG|Vincristine|"The initial vincristine dosage will be according to institutional treatment protocol. After vincristine administration, three blood samples will be taken at T=1, T=1.5 and T=4 hours. The concentration of vincristine will be analyzed in the samples. If the concentration of 2 or more samples is lower than the reference concentration and there is no toxicity, an advice will be given to increase dosage by 20%. Whether or not a dosage is given, vincristine concentrations will be measured again for the next dose administration.~For the feasibility study, both venous blood samples and finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 2 times.~For the rest of the study, finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 3 times.~Toxicity will be monitored through physical exam and questionnaire, bilirubin levels and clinical status of the patient."
224003647|NCT00953186|DEVICE|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
224003648|NCT00953186|DEVICE|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
224003649|NCT02475512|OTHER|Wash wipes (3M)|
224003650|NCT02475512|OTHER|water and pH neutral soap|
224003651|NCT03894072|DEVICE|CPAP|Conventional CPAP
223386127|NCT00511823|DRUG|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
223386128|NCT00511823|DRUG|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
223386129|NCT02353910|PROCEDURE|Ultrasound|
223386130|NCT00313079|DRUG|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
223386131|NCT00313079|DRUG|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
223386132|NCT06582979|BEHAVIORAL|Computer-Based Game Therapy|Computer-based game intervention will be done three times a week, every morning before school lessons begin or during break time. Researchers will give a brief explanation of the rules on how to play the game before the intervention begins. In the game, participants will act as a fruit truck delivery driver and will have to sort out fruit delivery to different houses according to the instructions of the game. For example, the instruction starts with delivering a yellow-colored banana to a house with a red-colored roof, or delivering a purple-colored grape to a house with a blue-colored roof. Participants will first have to finish a minimum of three tutorial rounds reaching ≥75% correct delivery. Instructions will be divided into four stages; visual stimulus, auditory stimulus, visual stimulus with an obstacle, auditory stimulus with an obstacle. Each round will last for 2 minutes. Total time needed to complete a single computer-based intervention session is around 30-45 minutes.
223386133|NCT06582979|BEHAVIORAL|High-Intensity Interval Training|HIIT will be done two times a week during physical education hours (in the school's sports field) led by the school's physical education teacher and also certified physical trainers who have undergone training supervised by a sports medicine physician. Before the start of each HIIT session, participants will have their pulse rate assessed with a pulse oximetry and then undergo warm-up for 5 minutes. The duration of each HIIT session will be continuously extended starting at around 4 minutes (1 tabata block/8 moves) during the first week to 8 minutes (2 tabata block/16 moves) during the final week. A single tabata block moveset incorporates 8 total moves; squat jump, push up, high skipping, burpees, isometric front plank, multi jumps on bench, mountain climber in hand plank and lateral sprint (5m). Each move will be done for 20 seconds, followed by a 10 second rest. Pulse rate will be assessed again after the HIIT session and then participants will undergo cooling down and relaxation.
223386134|NCT05509517|DIAGNOSTIC_TEST|Photoplethysmography based smartphone application for heart rhythm analysis (FibriCheck™)|Heart Rhythm assessment using the FibriCheck™ application with the patient's proprietary smartphone, three times daily, from discharge until follow-up consultation (day 21-91 after discharge).
224003652|NCT03894072|DEVICE|HFHO|A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
224003653|NCT04417842|DIAGNOSTIC_TEST|Respimetrix flow-volume monitoring device|The Respimetrix flow-volume monitoring device is being tested to validate its ability to measure Inspiratory Capacity
223386135|NCT02641652|DRUG|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
223386136|NCT02641652|DRUG|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
224003654|NCT05908851|DRUG|100 mL of 0.9% normal saline (57ml), 0.5% ropivacaine (40 ml), 10 mg morphine (10 mg/ml), 0.1 mg of epinephrine (0.1 mg/ml), and 30 mg of ketorolac (30 mg/ml)|Ultrasound guided brachial plexus blockade
224124597|NCT05873101|DIAGNOSTIC_TEST|Kelternborn Treatment Technique|Kelternborn Treatment Technique
224124598|NCT03801304|DRUG|Atezolizumab|Atezolizumab in IV infusions
224124599|NCT03801304|DRUG|Vinorelbine|Vinorelbine capsules
223425598|NCT01192113|DRUG|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
224003655|NCT00019175|BIOLOGICAL|aldesleukin|
224003656|NCT00019175|BIOLOGICAL|fowlpox virus vaccine vector|
224003657|NCT00019175|BIOLOGICAL|gp100 antigen|
224003658|NCT00564746|DRUG|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"\[14C\] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) \[14C\] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of \[14C\]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter \[14C\] SB-681323 oral solution will be dosed."
224124600|NCT03160404|DRUG|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
224003659|NCT02251769|DRUG|Tipranavir|
224003660|NCT02251769|DRUG|Ritonavir|
224003661|NCT02251769|DRUG|Clarithromycin|
224003662|NCT02251769|OTHER|High-Fat Test Meal|
224124601|NCT03160404|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
224124602|NCT05108909|DEVICE|MRI, CT, and serum biomarkers|magnetic resonance image Imaging data were collected in a strong magnetic field, and collected the serum of participants.
224124603|NCT05360277|DRUG|Tislelizumab + Capecitabine|"Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy."
224124604|NCT05360277|OTHER|Best supportive care|Best supportive care
224124605|NCT06150105|OTHER|Exercise training|Intense endurance training
224124606|NCT02041546|DRUG|Lung lavage with surfactant|
224124607|NCT02041546|DRUG|Bolus surfactant|
224124608|NCT05681741|PROCEDURE|current versus high pump flow|during each phase of randomized pump flow, arterial pressure will be increased from 40 to 90 mmHg with vasodilators and/or vasoconstrictors
224124609|NCT02458079|DRUG|Pentoxiphylline|
224124610|NCT02458079|DRUG|Stool microbiota transplantation|
224124611|NCT06671093|GENETIC|Tune-401|Epigenetic gene silencing therapy
224124612|NCT06673069|DRUG|ION269|Administered as intrathecal (IT) injection.
224124613|NCT03684161|DIAGNOSTIC_TEST|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
224124614|NCT03689283|OTHER|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
224003663|NCT06039020|DRUG|Anti-human thymocyte immunoglobulin, equine|Usually, 40 mg of anti-human thymocyte immunoglobulin, equine per kilogram of body weight should be slowly administered by intravenous drip infusion once daily. The duration of treatment should be 4 days.
224124615|NCT03689283|OTHER|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
224124616|NCT00263302|DRUG|dexamethasone|
224124617|NCT00121355|DEVICE|safety glide|
224124618|NCT00121355|DEVICE|autocover needle|
224124619|NCT05075096|OTHER|No intervention.|No intervention observational study.
223386137|NCT04710615|DEVICE|Synapse platform|"The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.~The Synapse platform offers a panel of functions to help the doctor to prescribe medication."
224003664|NCT05701267|DEVICE|MRI research|3T MRI protocol of \~1 hour
224003665|NCT02960698|OTHER|IRM and comportemental tasks|
224003666|NCT05481476|DRUG|Surufatinib|250mg, qd, po, 21 days for a cycle
224003667|NCT05481476|DRUG|Sintilimab|200mg, ivgtt, d1, 21 days for a cycle, up to 2 years
224003668|NCT05481476|DRUG|AG|nab-paclitaxel (125mg/ m2, ivgtt, d1, 8), Gemcitabine (1000mg/ m2, intravenous infusion over 30min, d1, 8), 21 days for a cycle, up to 6 cycles
224003669|NCT01727284|PROCEDURE|MR-guided cryoablation|
224003670|NCT03870360|BEHAVIORAL|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
224003671|NCT03870360|BEHAVIORAL|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
224003672|NCT03870360|BEHAVIORAL|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
224003673|NCT03870360|BEHAVIORAL|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
224003674|NCT03870360|BEHAVIORAL|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
224003675|NCT05964647|DRUG|LSD (150 µg) + ketanserin (40 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"
224003676|NCT05964647|DRUG|LSD (150 µg) + olanzapine (10 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"
224124620|NCT02292199|DEVICE|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
224124621|NCT02292199|DEVICE|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
224124622|NCT02292199|DEVICE|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
224124623|NCT02659683|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
224124624|NCT02659683|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
223386138|NCT04676360|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
224003677|NCT05964647|DRUG|LSD (150 µg) + lorazepam (2 mg)|"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"
224003678|NCT05964647|DRUG|LSD (150 µg) + placebo|"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
224003679|NCT05964647|DRUG|Placebo + placebo|"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"
224003680|NCT06309290|OTHER|Prehabilitation with resistance-exercise training|The volunteers in the intervention group will be subjected to 16 - 20 weeks of whole-body resistance-type exercise training (2x/wk).
224003681|NCT06309290|OTHER|Usual care program|The volunteers in the intervention group will be subjected to usual care (diagnosis confirmation, chemotherapy treatment planning and an initial education session).
224003682|NCT06435494|OTHER|Systematic use of patient reported outcome measures in clinical work with the patients|Se description of the arms
224003683|NCT03921723|DRUG|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
224003684|NCT03921723|DRUG|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
224003685|NCT03921723|DRUG|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
224003686|NCT01461811|DEVICE|Nelfilcon A toric contact lenses (with comfort additives)|
224003687|NCT01461811|DEVICE|Nelfilcon A toric contact lenses|
224003688|NCT03015129|DRUG|Durvalumab|
224003689|NCT03015129|DRUG|Tremelimumab|
224003690|NCT04090177|BEHAVIORAL|TEAM Wheels|A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
223386139|NCT03513991|OTHER|Infant formula|
223425599|NCT01192113|DRUG|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
224003691|NCT05917847|OTHER|Awake intubation|Awake videolaryngoscopic intubation with dexmedetomidine for sedation
224003692|NCT05594134|OTHER|Automatic toothbrush with nylon bristle|The automatic toothbrush with nylon bristles will be used for 10 seconds per dental arch
224003693|NCT05594134|OTHER|Automatic toothbrush with silicone bristle|The automatic toothbrush with silicone bristles will be used for 10 seconds
224003694|NCT05594134|OTHER|Manual toothbrush used for 2 minutes|A conventional manual toothbrush will be used for 2 minutes
224003695|NCT05594134|OTHER|Manual toothbrush used for 45 seconds|A conventional manual toothbrush will be used for 45 seconds
224003696|NCT01986270|DRUG|Placebo|Matching Placebo
224003697|NCT01986270|DRUG|Eletriptan 40 mg|40mg oral
224003698|NCT01986270|DRUG|Eletriptan 80 mg|80mg oral
224003699|NCT01986270|DRUG|Sumatriptan 25 mg|25mg oral
224003700|NCT01986270|DRUG|Sumatriptan 50 mg|50mg oral
224003701|NCT03330145|BEHAVIORAL|Scales, questionnaires and inventory|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
224003702|NCT04454931|DEVICE|Root® with O3® Regional Oximetry|"May help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.~It was aimed to determine the appropriate head height that should be given to patients in order to correct the endotracheal suctioning sequence, which is the most important care application of the neurosurgery patients who are followed up in the intensive care unit after surgery, and the possibility of subsequent disruption of cerebral perfusion. Therefore, cerebral oxygenation status, which is the most important parameter that shows the cerebral perfusion status of patients during and after the application, will be followed up by nurses with a non-invasive cerebral oximeter device."
224003703|NCT06150352|DEVICE|Continuous Positive Airway Pressure or other management for OSA per clinical indications.|PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria
224124625|NCT03477565|DEVICE|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
224003704|NCT00527462|PROCEDURE|Bronchoscopy|bronchoscopy with segmental allergen challenge
224003705|NCT00527462|OTHER|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
224003706|NCT05318573|DRUG|Pembrolizumab|Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
224003707|NCT05318573|DRUG|FF-10832|Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
224003708|NCT06146205|PROCEDURE|Direct lateral approach|The hip joint is approached from laterally, and parts of the gluteus medius tendon is released from the greater trochanter before the hip joint is entered from the anterior side.
224003709|NCT06146205|PROCEDURE|SPAIRE|The hip joint is entered from posterior, and the approach preserves the external rotators of the hip joint.
224003710|NCT06412991|BEHAVIORAL|Cycle Therapy|The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.
224003711|NCT05047068|DEVICE|OCS Heart System|"The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation."
224003712|NCT03783416|DRUG|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
224124626|NCT04371731|OTHER|Care4todayheart failure platform|Platform allowing patients to enter information about their health at home, namely weight and BP and medications
223386140|NCT02295501|BIOLOGICAL|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
224003713|NCT00968825|DRUG|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
224003714|NCT00968825|DRUG|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
224003715|NCT04439149|DRUG|PI3K-beta Inhibitor GSK2636771|Given PO
224003716|NCT04559373|OTHER|Virtual Reality and Field Training (VRFT)|The VRFT intervention involves the intensive practice of community ambulation skills. Some of the training sessions will be performed in a virtual environment, while others will consist of field training exercises in the community. During the intervention, stroke participants will be invited to practice different dimensions of community ambulation, such as postural transitions, avoiding other pedestrians, dual-task walking, etc.
224003717|NCT00376077|DRUG|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
224003718|NCT00376077|DRUG|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
224003719|NCT02954744|PROCEDURE|HIFU treatment|High intensity focused ultrasound
224003720|NCT03788759|DRUG|Alpha-lipoic acid|Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
224003721|NCT03788759|DRUG|Placebo Oral Tablet|Administration of placebo, as an adjunct to antipsychotic medication.
224003722|NCT04037176|DRUG|Omalizumab|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
224003723|NCT04037176|OTHER|Placebo|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
224003724|NCT02594657|PROCEDURE|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
224003725|NCT02594657|PROCEDURE|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
224003726|NCT02234505|PROCEDURE|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
224003727|NCT06381544|OTHER|Aromatherapy application|Applying lemon, orange and frankincense oils via inhalation
224003728|NCT05850728|DRUG|TLC-ART|TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
224003729|NCT03500991|BIOLOGICAL|HER2-specific chimeric antigen receptor (CAR) T cell|Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
224003730|NCT02291939|PROCEDURE|Parotidectomy|Surgical Intervention with the FMwand Surgical System
224003731|NCT01250561|DRUG|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
224003732|NCT01250561|DRUG|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
224003733|NCT01068275|PROCEDURE|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
224003734|NCT01068275|PROCEDURE|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
224003735|NCT01068275|PROCEDURE|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
224003736|NCT00406692|DRUG|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
224003737|NCT02361268|BEHAVIORAL|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
224003738|NCT02361268|BEHAVIORAL|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
224003739|NCT02941900|GENETIC|MC1R genotyping|
224003740|NCT02941900|BEHAVIORAL|MC1R Testing Website|The website includes three educational modules about genetic testing with corresponding knowledge questions.
224003741|NCT02941900|BEHAVIORAL|Baseline Survey|
224003742|NCT00069537|DEVICE|The GlucoWatch® G2™ Biographer (GW2B)|
224003743|NCT00069537|DEVICE|The Continuous Glucose Monitoring System (CGMS™)|
224003744|NCT03856983|OTHER|Point light display|Experimental group who will do usual rehabilitation and visualization of point-light human actions
224003745|NCT02879526|DRUG|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
224003746|NCT04706299|OTHER|Resistance Exercise|Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
224003747|NCT04964349|DRUG|Corticosteroids Acting Locally|topical application of jessener solution
224003748|NCT00002775|DRUG|docetaxel|
224003749|NCT00002775|DRUG|estramustine phosphate sodium|
224003750|NCT01675453|DRUG|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
224003751|NCT01675453|DRUG|0.9% NaCl|
224003752|NCT02193490|DRUG|DNase|DNase 0.1% eye drops four times a day for 8 weeks
224003753|NCT02193490|DRUG|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
224003754|NCT06003322|PROCEDURE|non - Incised Papilla surgical approach NIPSA for intrabony defect|"As described by Rodríguez and Caffesse in 2018, a single incision apical to the defect ,on the buccal aspect, only one apical horizontal or oblique incision will be made in the alveolar mucosa, as far removed as possible from the interdental papillae and marginal keratinized tis- sues.~Following flap reflection, the bony defect will be examined carefully. Root planing is performed,. Flap closure will be performed by horizontal mattress sutures, placed 3 mm away from the borders, will be used as the first line of closure, promoting connective tissue contact between both edges of the incision, and single interrupted sutures will then be placed as a second line of closure. Using 5/0 polypropylene monofilament suture, Assut, Swiss"
224003755|NCT06003322|PROCEDURE|single-flap approach SFA|"As described by Trombelli et al 2010, A horizontal, butt-joint incision will be performed at the interdental papilla 1-2 mm coronal to the bone crest (as detected through pre-operative bone sounding).~-A buccal mucoperiosteal envelope flap will be elevated by using a microsurgical periosteal elevator, leaving the residual portion of the interdental supracrestal soft tissues undetached.Flap closure will be performed by a horizontal internal mattress suture,will be performed at the base of the papilla, and a second internal mattress suture (vertical or horizontal) was performed between the most coronal portion of the flap and the most coronal portion of the palatal/lingual papilla. Using a resorbable suture"
224003756|NCT05407181|OTHER|Blood and Liver Function test|Data was collected through routine blood and liver function tests using a hematology analyzer and ELISA, respectively.
224003757|NCT04913467|OTHER|Groningen Anti-Inflammatory Diet (GrAID)|Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.
224003758|NCT04913467|DIETARY_SUPPLEMENT|ColoVit capsule|Vitamin B2/B3/C supplement in a ColoPulse-coated capsule
224003759|NCT04913467|OTHER|ColoPulse-placebo capsule|A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
224003760|NCT02299414|DRUG|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
224124627|NCT02843867|OTHER|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
224124628|NCT01225640|DRUG|PNU-100480|600 mg twice daily (BID) for 14 days
223730037|NCT03712319|BEHAVIORAL|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
224003761|NCT02299414|OTHER|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
223730038|NCT03712319|BEHAVIORAL|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
224003762|NCT01869023|DRUG|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
224003763|NCT01869023|DRUG|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
224003764|NCT02273258|DRUG|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
223730039|NCT06173921|PROCEDURE|robotic system|Implant placement will be navigated by robotic system based on a digital plan
223730040|NCT06173921|PROCEDURE|Static navigation system|Implant placement will be navigated by static navigation system based on a digital plan
223730041|NCT03323931|BEHAVIORAL|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
224003765|NCT02273258|DRUG|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
224003766|NCT02273258|DRUG|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
224003767|NCT00299442|BEHAVIORAL|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
224003768|NCT04098562|DRUG|LL37|cream
224003769|NCT04098562|PROCEDURE|Standard Wound Care|Standard wound debridement
224003770|NCT04958200|BEHAVIORAL|mhealth-pc for alcohol and pain|Smartphone-based intervention that includes in-person initial session and 8 video lessons, daily activities, and weekly check-ins.
224003771|NCT04958200|BEHAVIORAL|Treatment As Usual|psychoeducation on pain and alcohol use and treatment resource information
224124629|NCT01225640|DRUG|PNU-100480|1200 mg once daily (QD) for 14 days
224003772|NCT04531098|BIOLOGICAL|Sci-B-Vac-Lot B|Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml
224003773|NCT04531098|BIOLOGICAL|Sci-B-Vac-Lot A|Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml
224003774|NCT04531098|BIOLOGICAL|Engerix-B|Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection
224003775|NCT05038605|DRUG|Topical metronidazole|Topical application of metronidazole cream on the anal verge every 8 hours after surgery
224124630|NCT01225640|DRUG|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
224124631|NCT02802059|DRUG|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
224003776|NCT05038605|DRUG|oral metronidazole|Patients received oral metronidazole 500 mg tablets every 8 hours after surgery
224003777|NCT00543023|DRUG|teriparatide 20 micrograms/day subcutaneous|
224003778|NCT00543023|DRUG|salmon calcitonin 100 IU/day subcutaneous|
224003779|NCT05025592|DRUG|Regorafenib|patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not
224003780|NCT05025592|DEVICE|cTACE/DEB-TACE-HAIC|conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion
224003781|NCT02628028|DRUG|LY3337641|Administered orally
224003782|NCT02628028|DRUG|Placebo|Administered orally
224003783|NCT05639712|DRUG|Placebo|The patient is given standardized questions about their well-being and affective state before and after the administration of placebo intravenously. This is carried out on the operating table right before anesthesia
224003784|NCT05639712|DRUG|Morphine 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of 2.5 mg morphine intravenously. This is carried out on the operating table right before anesthesia
224003785|NCT05639712|DRUG|Morphine 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 5 mg intravenously . This is carried out on the operating table right before anesthesia
223386141|NCT00629018|BIOLOGICAL|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
223386142|NCT00629018|DRUG|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
223386143|NCT00629018|BIOLOGICAL|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
224003786|NCT05639712|DRUG|Morphine 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of morphine 10 mg intravenously . This is carried out on the operating table right before anesthesia
223386144|NCT04364776|DRUG|Durvalumab|In this observational study, durvalumab will be administered according to current indications (PACIFIC phase III trial).
224003787|NCT05639712|DRUG|Oxycodone 2.5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 2.5 mg intravenously . This is carried out on the operating table right before anesthesia
224003788|NCT05639712|DRUG|Oxycodone 5 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 5 mg intravenously . This is carried out on the operating table right before anesthesia
224003789|NCT05639712|DRUG|Oxycodone 10 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of oxycodone 10 mg intravenously . This is carried out on the operating table right before anesthesia
224003790|NCT05639712|DRUG|Fentanyl 0.025 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.025 mg intravenously . This is carried out on the operating table right before anesthesia
224003791|NCT05639712|DRUG|Fentanyl 0.05 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.05 mg intravenously . This is carried out on the operating table right before anesthesia
224003792|NCT05639712|DRUG|Fentanyl 0.1 mg i.v.|The patient is given standardized questions about their well-being and affective state before and after the administration of fentanyl 0.1 mg intravenously . This is carried out on the operating table right before anesthesia
224003793|NCT02145468|DRUG|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
224003794|NCT02145468|DRUG|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
224003795|NCT02145468|DRUG|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
224003796|NCT01073644|DRUG|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
224003797|NCT03796377|DRUG|St Johns Wort Extract|20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
223386145|NCT06487169|DIAGNOSTIC_TEST|Urine analysis to determine the presence of hexafluoroisopropanol|analysis of sevoflurane metabolites in urine
223386146|NCT05193838|DRUG|Allopurinol Tablet|examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
223386147|NCT06404918|PROCEDURE|Erector spinae plane group|The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.
223386148|NCT06404918|PROCEDURE|Serratus anterior plane group|Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
223386149|NCT03749889|OTHER|100 g carbs|Participants will be assigned a diet of 100g carbs max for the day
223386150|NCT03749889|OTHER|MyPlate|40-65% of daily intake is from carbohydrates
223386151|NCT05389787|DEVICE|Transcranial Magnetic Stimulation|The TMS will be administrated using the MagVenture Mag Pro R30 device equipped with a B-70 coil. The FDA-approved iTBS sequence will be applied: 10 bursts of three biphasic pulses at 50 Hz, repeated at 5 Hz, for 10 seconds for a total of 600 pulses, and will be repeated for three times. The total stimulation time is \~10 min per session (day). Patients will receive five sessions (days) of rTMS each week, and the total treatment will last for four weeks.
224003798|NCT03796377|DRUG|Rivaroxaban|20 mg rivaroxaban.
224003799|NCT02512731|DEVICE|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
224003800|NCT00673621|DRUG|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
224003801|NCT00673621|DRUG|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
224124632|NCT02802059|DRUG|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
224003802|NCT00673621|DRUG|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
224003803|NCT00218270|DRUG|Tobacco free snuff|Tobacco free snuff
223386152|NCT02045446|RADIATION|Stereotactic Body Radiation Therapy|
223386153|NCT02045446|DRUG|Maintenance chemotherapy|Maintenance chemotherapy
223386154|NCT03937505|DRUG|IS-001|intravenous injection of IS-001 investigational drug
223386155|NCT03937505|DRUG|No treatment|no drug injection
223386156|NCT00567008|DRUG|varenicline|1.0 mg BID for 8 weeks
223386157|NCT00567008|DRUG|placebo|placebo BID for 8 weeks
223386158|NCT04090125|BEHAVIORAL|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
223386159|NCT04090125|BEHAVIORAL|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
223386160|NCT00634946|DRUG|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
223386161|NCT00634946|DRUG|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
223386162|NCT01134250|DRUG|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
223386163|NCT01482416|DRUG|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
223386164|NCT01482416|DRUG|Placebo|Placebo group will use placebo once/day during 30 days
223386165|NCT04549350|OTHER|PSQI|Assessment of sleep quality using Pittsburgh Sleep Quality Index (PSQI): It is a simple tool which assess the sleep quality over one month period. It included seven components with a global PSQI score \> 5 is indicative of poor sleep quality
223386166|NCT01342081|DRUG|DE-111 ophthalmic solution|
223386167|NCT01342081|DRUG|Tafluprost ophthalmic solution 0.0015%|
223386168|NCT01342081|DRUG|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
223386169|NCT03236090|DIETARY_SUPPLEMENT|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
223386170|NCT06042543|DIAGNOSTIC_TEST|Screening with HPV test|Women aged 25-49 yrs will be screened with a validated HPV test. They will also provide urine samples for HPV test. Women HPV positive in either sample will be referred to colposcopy for disease ascertainment.
223386171|NCT03432143|OTHER|Community Reviewers|Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
223386172|NCT01228058|PROCEDURE|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
223386173|NCT05609513|OTHER|HTN-BASIC|The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
223386174|NCT05609513|OTHER|HTN-PLUS|In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
224003804|NCT00135473|DRUG|10% Hemohes® (10% Hydroxyethyl starch)|
224003805|NCT00135473|DRUG|Sterofundin® (Ringer lactate solution)|
224003806|NCT00135473|DRUG|Actrapid® (Insulin)|
224003807|NCT02352519|PROCEDURE|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
224003808|NCT02352519|PROCEDURE|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
224003809|NCT05713903|PROCEDURE|Laparoscopic right colectomy|Resection of the ascending colon via a laparoscopic approach, adhering to the CME principles
224003810|NCT05713903|PROCEDURE|Open right colectomy|Resection of the ascending colon via an open approach, adhering to the CME principles
224003811|NCT06052709|OTHER|Occupational balance assessment|There is no intervention. The presence and severity of temporomandibular disorders, occupational balance, and stress levels of individuals will be evaluated.
224003812|NCT00573053|OTHER|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
223386175|NCT02790437|DRUG|IdeS|One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.
223386176|NCT02790437|PROCEDURE|Kidney transplantation|Performed following IdeS treatment
224003813|NCT00573053|OTHER|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
223386177|NCT04719442|BEHAVIORAL|Building Healthy Families|Building Healthy Families (BHF) is a family based obesity treatment program which includes key behavior change strategies including goal setting for both behavior change and weight loss, self-monitoring, rewards/contingency management, role modeling, and stimulus control/ modifying the environment. BHF includes a minimum of 32 contact hours consisting of three main program components: nutrition education, behavior modification, and physical activity. Participants and parents are expected to attend 12 continuous weeks of education (2 hours/session) followed by 12 weeks of relapse prevention refresher courses. Relapse prevention refresher sessions are every three weeks for one hour to re-evaluate goals, discuss rewards/contingency management and changes in stimulus control with seasonal changes and holidays. A final follow-up check-in session is conducted at 12 months for approximately 1 hour.
223386178|NCT03727074|DRUG|5-FU Cream|topical cream twice a day
223386179|NCT03727074|DRUG|Efudex®|topical cream twice a day
223386180|NCT03727074|DRUG|Vehicle|topical cream twice a day
223386181|NCT01631760|GENETIC|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
223386182|NCT05314231|DRUG|ALXN1720|All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
223386183|NCT00004667|DRUG|von Willebrand factor|
223386184|NCT04991246|OTHER|Antigenic tests (on saliva samples)|SARS-CoV-2 screening tests: two massive antigenic tests campaigns (on salivary samples).
223386185|NCT04991246|OTHER|Individual electronic sensor port|Individual electronic sensor recording contacts but not their location (in the form of a bracelet, a key ring or a badge) Contact data collection points (5 maximum, located at compulsory passage points for participants). When a sensor is close to one of these terminals, it discharges its contacts in seconds.
223386186|NCT04991246|OTHER|Atmospheric measurements of CO2|Atmospheric measurements of CO2 in the relevant closed places of the faculty (lectures / practical work / BU / refectory): battery operated sensors. When a sensor is installed in a place, the ventilation conditions (number of open windows, etc.) as well as the number of people present will be noted.
223386187|NCT05012046|OTHER|Orange juice|Matched for volume (240 mL/ 8 oz) of other test beverages. 100% orange juice.
223386188|NCT05012046|OTHER|Orange flavoured drink|Matched for volume (240 mL/ 8 oz) of other test beverages. Orange flavoured drink
223386189|NCT05012046|OTHER|Water|Matched for volume (240 mL/ 8 oz) of other test beverages. Water control
223386190|NCT02426502|DRUG|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
223386191|NCT02426502|DRUG|conversion of non-immunosuppressant drugs to once daily|"* Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
223425600|NCT01192113|DRUG|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
224003814|NCT01241825|OTHER|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
224003815|NCT01241825|OTHER|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
224003816|NCT03055429|OTHER|Full Scale Unit|Pre-test, usability, post-test
224003817|NCT04157400|DEVICE|Intraoperative Parameter Testing|"Step 1: Recording and stimulation of spinal potentials during insertion of epidural spinal stimulator paddle~Once the epidural paddle is placed, study procedures will begin by connecting the terminals of the paddle to an electrophysiological recording device for signal amplification and filtering. Using this recording setup, motor evoked potential (MEP) and somatosensory evoked potential (SSEP) protocols will be performed to determine motor and sensory thresholds, respectively. Next, the surgical procedure will resume and after the implantable pulse generator (IPG) has been placed, study procedures will begin again and include activation of both low-frequency tonic stimulation (LFTS) and high-frequency burst stimulation (HFBS) patterns from the inserted paddle while recording EMG signals."
224003818|NCT04157400|DEVICE|Proprioception Testing During Stimulation|"Step 3: Proprioception testing~The research team will investigate the perceived change in knee joint angle and direction of movement reported by the subject in a Threshold to Detect Passive Movement (TTDPM). The TTDPM protocol will begin with the subject sitting in the Biodex testing seat, with the non-tested leg hanging freely and the tested leg strapped to the rotating arm of the dynamometer at the lower shank. The subject will be blinded as to the mode and intensity of stimulation: HFBS, LFTS, or no stim. The TTDPM will consist of at least 10 trials for each stimulation condition chosen based on SCM outcomes. The subject has control of a kill-switch that immediately halts movement of the rotating arm, which is to be activated once the subject perceives movement OR if the subject begins to feel any pain or discomfort throughout the task."
224124633|NCT04247022|OTHER|Health care product (intimate gel)|heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days
224124634|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
224124635|NCT01002625|DRUG|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
224124636|NCT05158595|OTHER|Exergaming low intensity group|wobble board-based Exergame balance training, the game intensity will be low for this group (Size of goal will be kept small for 3 times a week, 30 minutes per day for 8 weeks.
223425601|NCT01254838|BIOLOGICAL|HLA-A02 restricted HIG2|
223425602|NCT03195023|DRUG|Lisinopril|
224003819|NCT04157400|DEVICE|Gait Analysis During Stimulation|"Step 4: Body weight support and treadmill (BWST) testing~Similar to step 2, LFTS and HFBS patterns will be compared by systematically testing each individual contact on the paddle while investigating for changes in stepping speed, pattern and EMG moduling complexity. Regarding EMG module analysis, muscle activity will be recorded bilaterally via surface EMG from lower extremity musculature. Furthermore, subjects will also have active LED markers placed over their clothes in order to track whole body kinematics throughout this portion of the study.~To optimize capture of steady state data on the treadmill, each subject will walk for approximately 10 sec prior to the 30 sec of data collection (40 sec per trial). This will allow capture of at least 10 consecutive steady state gait cycles (depending on cadence) per each amplitude selection for each stimulation delivery technique, which will be defined by parameters found during walking SCM."
224003820|NCT04917640|RADIATION|Radiation Therapy|Either SBRT or IMRT radiation therapy
224003821|NCT01809834|DEVICE|Etafilcon A|
224003822|NCT01809834|DEVICE|Stenfilcon A|
224003823|NCT05834062|DRUG|Qsymia and lifestyle management therapy|Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.
224003824|NCT05834062|BEHAVIORAL|Placebo and lifestyle management therapy|Placebo will be used in lieu of Qsymia to maintain the blind. Participants will be offered lifestyle management therapy.
224003825|NCT00713505|OTHER|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
224124637|NCT05158595|OTHER|Exergaming moderate intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept medium).for 3 times a week, 30 minutes per day for 8 weeks.
224124638|NCT05158595|OTHER|Exergaming high intensity group|Wobble board-based Exer- game balance training, the game intensity will be moderate for this group (size of goal will be kept high).for 3 times a week, 30 minutes per day for 8 weeks.
224124639|NCT05158595|OTHER|control group exergaming|Exer games training with soccer heading and penguin slide games(Wii Fitt balance games) for 3 times a week, 30 minutes per day for 8 weeks.
224124640|NCT04398017|PROCEDURE|Transesophageal echography|Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
224124641|NCT03436446|OTHER|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
223386192|NCT02426502|DRUG|Conversion to once daily MPA|"* Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose."
223386193|NCT02530502|OTHER|Laboratory Biomarker Analysis|Correlative studies
224124642|NCT03017924|DEVICE|Q collar|q-collar concussion prevention device
224124643|NCT05129813|BEHAVIORAL|Recovery Guide Counseling|Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling
224124644|NCT05029544|OTHER|Dynamic taping|The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.
224124645|NCT05029544|OTHER|Kinesio taping|The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.
223386194|NCT02530502|BIOLOGICAL|Pembrolizumab|Given IV
223386195|NCT02530502|RADIATION|Radiation Therapy|Undergo focal RT
223386196|NCT02530502|DRUG|Temozolomide|Given PO
223386197|NCT03694509|OTHER|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
223386198|NCT03694509|OTHER|Water|Water 250ml.
223386199|NCT05362071|OTHER|Remote Exercise Group|The intervention will have a weekly frequency of two sessions on non-consecutive days during the first six weeks and three sessions on non-consecutive days for the remaining six weeks. The exercise intervention will consist of four 3-week mesocycles. The session's structure will consist of a warm-up, the main part, in which a combined training program will be carried out, consisting of three distinct blocks, and at the end, stretching. Blocks 1 and 2 will consist of three strength exercises with bodyweight and alternative materials and aerobic training. Between blocks 1 and 2, and later in block 3, participants will take a free walk with displacement in the space they have available in their own home. The session will end with stretching exercises for the main muscle groups. The sessions will last 37 to 57 minutes over 12 weeks, with approximately 5 min of warm-up and stretching, and the main part ranging from 27 min to 47 min throughout the intervention.
224003826|NCT00713505|PROCEDURE|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
224124646|NCT05029544|OTHER|Physiotherapy and Rehabilitation|exercise, manuel therapy, mobilization, massage, sensorimotor control
224124647|NCT00914836|DRUG|Betamethasone Sodium Phosphate|1cc:2cc
224124648|NCT00914836|DRUG|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
224124649|NCT00914836|DRUG|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
224138506|NCT02928926|OTHER|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
224138507|NCT01951690|DRUG|defactinib (VS-6063)|
224138508|NCT02383680|BIOLOGICAL|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
224003827|NCT00623805|DRUG|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
224003828|NCT00623805|DRUG|Capecitabine|Capecitabine was supplied as film-coated tablets.
224003829|NCT00623805|DRUG|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
224003830|NCT03725527|PROCEDURE|Rectus Sheath Block|Sonar guided RSB will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
224003831|NCT01800890|DEVICE|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
224003832|NCT01800890|DEVICE|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
224003833|NCT01800890|DEVICE|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
224003834|NCT01800890|DEVICE|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
224003835|NCT00635128|BIOLOGICAL|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
224003836|NCT02296736|RADIATION|Computerised tomography (CT) scan|Retrospective review of CT scans
224003837|NCT02169544|DRUG|Abatacept|
224003838|NCT04920942|DRUG|Ivermectin 0.4mg/kg/day for 5 days|Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
224003839|NCT04818008|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
224003840|NCT04032184|OTHER|Fluoride toothpaste|regimen using fluoride toothpaste
224124650|NCT02149836|DRUG|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
224124651|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
224124652|NCT01204658|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
224124653|NCT01204658|BIOLOGICAL|Synflorix|Intramuscular injection
224124654|NCT01204658|BIOLOGICAL|Prevenar 13|Intramuscular injection
224124655|NCT01204658|BIOLOGICAL|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
224124656|NCT00916500|DRUG|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
224124657|NCT04136353|DRUG|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
224124658|NCT04136353|DRUG|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
223386200|NCT05362071|OTHER|Group control|"Participants allocated to the GC will receive recommendations for the practice of physical activity based on information from three specific chapters of the Physical Activity Guide for the Brazilian Population (2021). The GC will receive through Whatsapp the information that is available in chapters 1, 4, and 5, which address the following topics: Understanding Physical Activity, Physical Activity for Adults, and Physical Activity for the Elderly. If sending via Whatsapp is not possible, the booklet will be printed and delivered to the participant. At the end of the 12 weeks, the same booklet will be made available to IG participants."
224003841|NCT04032184|OTHER|fluoride toothpaste and chlorhexidine mouthwash|regimen using fluoride toothpaste and chlorhexidine mouthwash
224124659|NCT04136353|DRUG|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
224124660|NCT04136353|RADIATION|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
224003842|NCT04032184|OTHER|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
224003843|NCT01949389|BEHAVIORAL|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
224003844|NCT01012297|BIOLOGICAL|Bevacizumab|Given IV
224003845|NCT01012297|DRUG|Docetaxel|Given IV
224003846|NCT01012297|BIOLOGICAL|Filgrastim|Given SC
224003847|NCT01012297|DRUG|Gemcitabine Hydrochloride|Given IV
224003848|NCT01012297|BIOLOGICAL|Pegfilgrastim|Given SC
224124661|NCT01977053|OTHER|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
224003849|NCT01012297|OTHER|Placebo|Given IV
224003850|NCT05504252|DRUG|Nivolumab|"Q2W~Nivolumab: 240 mg fixed dose over 30 minutes, IV administration every 2 weeks"
224003851|NCT05504252|DRUG|Oxaliplatin|FLOX, Q2W
224003852|NCT02870049|BEHAVIORAL|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
224003853|NCT02870049|BEHAVIORAL|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
224003854|NCT02870049|BEHAVIORAL|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
224003855|NCT02870049|BEHAVIORAL|Usual care|Usual care: FIT kit delivery as part of usual care
224003856|NCT06405360|DIETARY_SUPPLEMENT|Egg consumption|Participants in the intervention group will be provided two eggs to consume daily.
223386201|NCT01146171|DRUG|BMS-844203 (CT-322)|Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
223386202|NCT02711631|BEHAVIORAL|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
223386203|NCT04395820|DIAGNOSTIC_TEST|Lung function test|MBW
224295781|NCT05726461|DEVICE|AndroidAPS-rt-CGM;|Insulin therapy (aspart, lispro or glulisine) with AndroidAPS-rt-CGM.AndroidAPS-rt-CGM consists of three components:1) AiDEX G7 continuous glucose monitoring (an rt-CGM);2) Equil® insulin patch pump;3) AndroidAPS algorithm implemented in Android smartphone.
223386204|NCT04395820|DIAGNOSTIC_TEST|Imaging|MP-MRI
223386205|NCT06271148|OTHER|Interview|We made multiple interviews with randomly selected surgical candidates
223386206|NCT03771092|DIETARY_SUPPLEMENT|SunActive®Fe|SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.
223386207|NCT03771092|DIETARY_SUPPLEMENT|Lipofer®|Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.
223386208|NCT03771092|DIETARY_SUPPLEMENT|Intravenous ferric gluconate|Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
223386209|NCT04174274|OTHER|ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
224003857|NCT01527591|BIOLOGICAL|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
224003858|NCT06453811|OTHER|Self-efficacy Theory-based Childbirth Preparation Program|According to the block randomisation method, the couples who are included in the experimental group by applying the pre-test will be included in the programme in groups of 3-4 couples by planning the day and time they can participate in the programme. At the end of the sessions, the training guide reflecting the training content will be given to the couples and they will be asked to read it at home and do their homework by using the relevant parts of the guide. At the same time, these couples will continue their routine pregnancy controls in the hospital. It is planned to complete the trainings once a week, twice in total and for two weeks. After the trainings are completed, it is planned to send at least three reminders by text message until the calculated delivery date. Brochures and text message content related to the training content will be used in the reminder.
224003859|NCT04694534|DIAGNOSTIC_TEST|Serious game|"The serious game is accessible via an online platform, on a tablet: 4 20-minutes activities sessions per week must be carried out.~The program format in the serious game form makes possible to simultaneously understand a large number of cognitive functions."
224003860|NCT04694534|DIAGNOSTIC_TEST|Usual HAS care|The control group patients will follow the care they need, according to the HAS recommendations. Non-specific cognitive activities notebooks will be provided to them. They will be instructed to perform the 4 20-minutes sessions per week for 4 months.
224003861|NCT04231760|DRUG|Inhaled Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
224003862|NCT04231760|DRUG|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
224003863|NCT03037437|DRUG|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
224003864|NCT03037437|DRUG|Hydroxychloroquine (HCQ)|400mg by mouth daily
224003865|NCT06964685|DEVICE|Impella|US commercially approved Impella CP is the device that study inclusion will be based on. Only patients with AMICS who receive Impella CP as the first Impella device after cardiogenic shock onset will be included in the study.
224003866|NCT06542250|DRUG|AZD5492|CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously
224003867|NCT06592508|OTHER|Remote Virtual Cardiology Program|Ventricle Health Program, which is a remote, virtual, cardiology program that provides heart failure education to patients, monitors for worsening heart failure, and rapidly titrates heart failure medical therapy.
224003868|NCT06533748|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
224003869|NCT06533748|DRUG|Vincristine|Given IV.
224003870|NCT06533748|DRUG|Inotuzumab|Given IV.
224003871|NCT06533748|DRUG|Blinatumomab|Given IV.
224003872|NCT06533748|DRUG|Dasatinib|Given PO.
224003873|NCT06533748|PROCEDURE|IT MHA|Given Intrathecal (IT), Age adjusted.
224003874|NCT06533748|DRUG|Cyclophosphamide|Given IV.
224003875|NCT06533748|DRUG|Cytarabine|Given IV or IT.
224003876|NCT06533748|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
224003877|NCT06533748|DRUG|6-Mercaptopurine|Given PO.
224003878|NCT06533748|DRUG|Calaspargase|Given IV.
224003879|NCT06533748|DRUG|Daunorubicin|Given IV.
224003880|NCT06533748|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
224003881|NCT03777852|DIAGNOSTIC_TEST|First Questionnaire application|Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.
224003882|NCT03777852|DIAGNOSTIC_TEST|Second Questionnaire application|Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
224003883|NCT05245591|DRUG|Pentosan Polysulfate Sodium 100 MG Oral Capsule|Pentosan Polysulfate Sodium 100 mg three times daily (tid) for 0-8 weeks Pentosan Polysulfate Sodium 100 mg twice daily (bid) for 9-16 weeks
224003884|NCT05245591|DRUG|Placebo|Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
224295782|NCT05726461|DEVICE|sensor augmented pump(SAP);|Insulin therapy (aspart, lispro or glulisine) with sensor augmented pump(SAP).SAP includes only Equil® insulin patch pump and AiDEX G7 continuous glucose monitoring.
224295783|NCT00158756|BIOLOGICAL|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
224003885|NCT06415604|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving."
223386210|NCT04174274|OTHER|not ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
224003886|NCT06415604|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
223386211|NCT02026401|BIOLOGICAL|NGM282|
223386212|NCT02026401|BIOLOGICAL|Placebo|
223386213|NCT05248737|DIETARY_SUPPLEMENT|DHA/EPA fortified chicken plus Placebo|For participants who received DHA/EPA fortified chicken
223386214|NCT05248737|DIETARY_SUPPLEMENT|non-25(OH)D fortified chicken/eggs plus vitamin D3 supplement|Provided to participants in the group where they consumed non-fortified chicken/eggs
223386215|NCT05248737|DIETARY_SUPPLEMENT|non-DHA bio-enhanced chicken plus supplement DHA Omega-3|Used in the crossover part of the study given to the group who did not received DHA bio-enhanced chicken
223386216|NCT05248737|DIETARY_SUPPLEMENT|25(OH)D bioenhanced chicken and eggs plus placebo|participants will receive 25(OH)D bioenhanced chicken and eggs plus a placebo as a dietary intervention
223386217|NCT05248737|DIETARY_SUPPLEMENT|Dietary Supplement: DHA/EPA fortified eggs plus Placebo|For the participants who received DHA/EPA fortified eggs
223386218|NCT05248737|DIETARY_SUPPLEMENT|non-DHA bio-enhanced eggs plus supplement DHA Omega-3|for the participants who received non-DHA bio-enhanced eggs plus supplement DHA Omega-3
223386219|NCT05248737|OTHER|non-25(OH)D fortified chicken/eggs plus placebo|Provided to participants in the group where they consumed non-fortified chicken/eggs + placebo pills
223386220|NCT02144714|BIOLOGICAL|SB5|
224003887|NCT03628547|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
223386221|NCT02144714|BIOLOGICAL|EU sourced Humira®|
223386222|NCT02144714|BIOLOGICAL|US sourced Humira®|
223386223|NCT05027308|DRUG|Teduglutide|Teduglutide 0.05 mg/kg SC injection
223386224|NCT01001650|BIOLOGICAL|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If \> 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
223386225|NCT00718874|OTHER|Dietary|modification of macronutrient content
223386226|NCT00683865|DRUG|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
223386227|NCT00683865|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
223386228|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose
223386229|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo single dose with food effect
224003888|NCT06052358|DEVICE|LAAC with Watchman FLX device|LAAC with Watchman FLX device
224003889|NCT04259827|OTHER|Neuronation|Online cognitive training app, with exercises created for patients with mild cognitive impairment
224003890|NCT04259827|OTHER|Aspecific online games|Online gaming without cognitive training
224003891|NCT04956705|DIETARY_SUPPLEMENT|Vitamin D and calcium|Either as tablets, droplets or sprays. Preferably daily doses of 20 µg of vitamin D and 800-1000 mg of calcium as recommended.
224003892|NCT02336451|DRUG|Ceritinib|LDK378 is a gelatin capsule, administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule on an empty stomach.
224003893|NCT04045847|BIOLOGICAL|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
224003894|NCT05418634|OTHER|point of care EEG|For pocEEG, scalp electrodes are applied in five locations.
224003895|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
224003896|NCT05703607|BIOLOGICAL|Candidate 1: PF-07915234: VZV modRNA Suspension for Injection|Intramuscular injection
224003897|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Suspension for Injection|Intramuscular injection
224003898|NCT05703607|BIOLOGICAL|Candidate 3: PF-07921186: VZV modRNA Suspension for Injection|Intramuscular injection
224003899|NCT05703607|BIOLOGICAL|Shingrix|Intramuscular injection
224003900|NCT05703607|BIOLOGICAL|Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection|Intramuscular injection
224003901|NCT05570630|BEHAVIORAL|VAX-MOM COVID-19 Intervention|The multi-component VAX-MOM COVID-19 intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
224295784|NCT00158756|BIOLOGICAL|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
223386230|NCT05638126|DRUG|HRS-1780 table or placebo|HRS-1780 table or placebo multiple dose
223386231|NCT01750801|DRUG|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
223425603|NCT03195023|DRUG|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
223386232|NCT01750801|DRUG|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
223386233|NCT03908125|DEVICE|Eversense® CGM System|Continuous Glucose monitoring device
223386234|NCT04677335|DIETARY_SUPPLEMENT|AB-LIFE with Monacolin K|Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
223386235|NCT04677335|OTHER|Placebo|Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).
223386236|NCT00578591|DRUG|Rituximab|"Rituximab 375 mg/m\^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
223386237|NCT03074578|BEHAVIORAL|Watching Video-clip 1|Video -clip 1 contains violent images and text
223386238|NCT03074578|BEHAVIORAL|Watching Video-clip 2|Video -clip 2 contains neutral images and text
224003902|NCT05570630|OTHER|Standard of Care|Standard vaccine education and processes provided to patients by obstetric practices.
224003903|NCT07134010|OTHER|perineural injection|"Intervention The procedure will be performed by a rehabilitation physician who has obtained hospital-level credentialing and privileging to practice Perineural Injection Therapy (PIT). The physician has undergone hands-on training with Dr. Lyftogt-certified trainers in Malaysia.~PIT will be administered weekly for six week (Total 6 sessions). In addition to this intervention, patient will also receive conventional therapy which is monthly outpatient physiotherapy with supplementary home-based exercise program, and oral analgesia (except NSAIDs).~Solution: Buffered 5% dextrose.~Pre injection: Chronic constriction injury points will be identified by palpation along the shoulder's cutaneous nerves - the suprascapular, supraclavicular, axillary, musculocutaneous, and radial nerves. These points will be marked to ensure precise targeting. Taking into account these nerve pathways, the maximum injection area for this research is set at 10 sites per session."
224003904|NCT07134010|OTHER|Physiotherapy|Patients will be receiving a structured home-based exercise program and will be instructed on how to perform these exercises at home. The exercise regime will be 30 minutes, 3 times a day to enhance shoulder mobility and strength in addition to the regular monthly outpatient physiotherapy session. Oral analgesics exclude NSAIDs will be prescribed as needed to manage pain.
224003905|NCT02726984|DRUG|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
224003906|NCT00393497|DRUG|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
224003907|NCT06591221|PROCEDURE|Chuna Maintenance Therapy|"it is conducted every two weeks for a total of 20 weeks for individuals. The technique follows the guidelines of the Society of Chuna Manual Medicine and is based on Chuna Medicine (2.5th edition), which is utilized as a textbook in Korean Medicine colleges.~The treatment is selectively administered based on the clinical judgment of the practitioner."
224003908|NCT06593093|OTHER|a bundled intervention|a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.
224003909|NCT06593093|OTHER|control group|participants will not be intervened with this bundled treatment, but continue the usual care that has been established at UAB ED.
224003910|NCT05811598|DEVICE|repeated ultra low lever red light|Myopia indoor lighting therapy
224003911|NCT06987981|DEVICE|Chitosan-based dressing|Chitosan-based dressing for wound and scar treatment will be used (e.g. ChitoCare® medical Wound Healing Gel)
224003912|NCT06987981|DEVICE|Silver-based dressing|Silver-based dressing (e.g. AQUACEL® Ag), followed by a cosmetic lotion (e.g.: Bepanthol® DERMA) will be used
224003913|NCT06825364|OTHER|auricular stimulation|Different points on both ears will be repeatedly stimulated with a plastic filament. This will be felt, but not be painful and should not result in lasting irritation.
224003914|NCT06470360|OTHER|Surgycal procedure|surgical technique
224295785|NCT00158756|BIOLOGICAL|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
223386239|NCT01071915|DRUG|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
223386240|NCT05738733|DEVICE|MsChief Classic Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
223386241|NCT05738733|DEVICE|MsChief Ylang Ylang Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
223386242|NCT05738733|DEVICE|MsChief Vanilla & Citrus Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
224295786|NCT00158756|BIOLOGICAL|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
223386243|NCT05738733|DEVICE|MsChief Tea & Peach Natural Lubricant|Apply the desire amount of lubricant on the body to make it more sensitive.
223386244|NCT02242253|DRUG|Tiotropium|administered via HandiHaler®
223386245|NCT02242253|DRUG|Salmeterol|administered via metered dose inhaler (MDI)
223386246|NCT02242253|DRUG|Placebo-MDI|
223386247|NCT02242253|DRUG|Placebo HandiHaler®|
224295787|NCT00158756|BIOLOGICAL|Engerix™-B|GSK Biologicals' hepatitis B vaccine
224295788|NCT00158756|DRUG|Placebo|Placebo for the Rotarix™ vaccine
224003915|NCT06200272|COMBINATION_PRODUCT|Germ and Carob Molasses Pulp added standard whole wheat breads|Test bread (bread with soluble pulp added, bread with added germ, and bread with soluble pulp + germ added) containing 50 g carbohydrate, samples taken from all four types of bread were collected for moisture, ash, fiber, protein, fat, digestible carbohydrate, and antioxidant capacity analysis will be performed. This experimental group consists of the group that will eat the test bread.
224003916|NCT06824168|DRUG|Quizartinib High Dose|Participants in Arm 1 will receive oral daily higher dose of quizartinib,
224003917|NCT06824168|DRUG|Quizartinib Low Dose|Participants in Arm 2 will receive oral daily lower dose of quizartinib
223386248|NCT02094482|DEVICE|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
223386249|NCT01510951|DRUG|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
223386250|NCT03866889|OTHER|Strength|"In the performance of the squat exercise (Back Squat), the subjects will be standing, with an Olympic bar behind their neck, supported on both trapezoids, while the hands will help to hold and stabilize the bar, taking it from below.~For hamstring curl, the subject will be in the prone position, clinging to the backrest, with the legs under the arm that lifts the weight.~The deadlift exercise will be performed from the standing posture, holding the bar with your arms extended and the trunk straight, while your hands will hold the bar at the height and separation of the hips.~Finally, in the quadriceps chair the subject will find himself sitting with his back straight and supported on the back of the seat, while the legs will go under the arm that lifts the weight."
223386251|NCT03866889|OTHER|Normal activity|The subjects included in the control group will continue to perform the same strength training plan that they did before starting this one. The periodicity will be the same (4 days / week) and with the same intensity.
223386252|NCT03327701|DRUG|Benralizumab|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
224003918|NCT06106542|OTHER|assessment|assessment of motor imagery on muscle oxygenation
224003919|NCT06611371|BIOLOGICAL|IVT GBS-06|Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.
224003920|NCT06611371|BIOLOGICAL|Placebo|0.9% sodium chloride
224003921|NCT06612710|DRUG|extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles derived from human induced neural stem cell for intravenous injection（4×10\^9 particles/kg）
224003922|NCT06612710|DRUG|a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection|extracellular vesicles placebo (4×10\^9 particles/kg)
224124662|NCT04983329|OTHER|Telemedicine intervention|Following education, the telemedicine center will subsequently monitor operating rooms included in this trial for protocol adherence for three-months. The telemedicine center is staffed by attending anesthesiologists, resident anesthesiologists, certified registered nurse anesthetists (CRNAs) and student registered nurse anesthetists (SRNAs) and is currently providing evidence-based support to clinicians in a subset of operating rooms and post-anesthesia care unit (PACU) beds at Barnes-Jewish Hospital.
224124663|NCT06918977|DEVICE|InPen Smart insulin pen|InPen is a reusable pen injector which allows the user to dial the desired dose of insulin to be administered. The dose calculator a component of the InPen app calculates an insulin dose or carbohydrate intake based on user entered data. Prior to use, the patient -specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters are to be programmed into the software.
224124664|NCT06918977|OTHER|traditional/standard insulin pen|personal prescribed insulin pen
224295789|NCT01485666|OTHER|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
224003923|NCT05820295|BEHAVIORAL|Care coordination delivered based on perceived need|If patients in intervention group report on the survey that they experience difficulty coordinating care among their providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.
224003924|NCT05820295|BEHAVIORAL|Care coordination delivered based on usual care (e.g. discharge from hospital)|If a patient is discharged from a hospital, the patient will be selected for care management services.
224003925|NCT04089358|OTHER|Educational Intervention|Receive educational materials
224124665|NCT06677892|OTHER|No Intervention|This is non-interventional study.
224124666|NCT07007559|DRUG|Evorpacept (ALX148)|IV infusion
224124667|NCT07007559|DRUG|Trastuzumab|IV infusion
224003926|NCT04089358|DEVICE|FitBit|Wear a Fitbit
224003927|NCT04089358|OTHER|Goal Setting|Set goals
224003928|NCT04089358|OTHER|Health Promotion and Education|Receive text message about goal setting
224003929|NCT04089358|OTHER|Media Intervention|Follow Instagram group
224124668|NCT07007559|DRUG|Paclitaxel|IV infusion
224003930|NCT04089358|BEHAVIORAL|Telephone-Based Intervention|Receive phone call about goal setting
224003931|NCT06662149|OTHER|Pleasant Smell|The participants will be in an environment with an assumed pleasant smell while consuming the meal.
224003932|NCT06662149|OTHER|Unpleasant Smell|Participants will be in an environment with an assumed unpleasant smell while consuming the meal.
224003933|NCT00739115|OTHER|Heliox gas|Heliox gas used in conjunction with nasal CPAP
224003934|NCT00542542|PROCEDURE|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
224124669|NCT07007559|DRUG|Capecitabine|Oral administration
224299204|NCT06187493|DRUG|dapagliflozin, empagliflozin|"1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia."
224124670|NCT07007559|DRUG|Eribulin|IV infusion
223386253|NCT00114140|DRUG|Temozolomide|"Concurrent chemoradiotherapy temozolomide given 75 mg/m\^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles."
223386254|NCT00114140|RADIATION|Radiation therapy|One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
223386255|NCT04150172|DRUG|Rebamipide SR 150mg|Test drug
223386256|NCT04150172|DRUG|Rebamipide IR 100mg|Reference Drug
223386257|NCT02261272|BEHAVIORAL|CBT for insomnia SHUTi|SHUTi
224003935|NCT00542542|DRUG|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
224003936|NCT00542542|DRUG|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
224003937|NCT00542542|DRUG|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
224003938|NCT00542542|DRUG|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
224003939|NCT06994767|OTHER|The Canary Application|The CANARY application will use clinically validated survey instruments and voice recordings to measure user MCI status /Alzheimer's data. These tests are designed to evaluate a user's voice characteristics and potentially identify disease-specific patterns.
224003940|NCT06674616|OTHER|Replicating Effective Programs|Replicating Effective Programs (REP), based on Social Learning Theory and Rogers' Diffusion of Innovations, incorporates program packaging, training, and technical support
224003941|NCT06674616|OTHER|Coaching|Coaching is based on the Positive Behavior Interventions and Supports model, addresses staff barriers by building implementers' evidence-based practice (EBP) knowledge, self-efficacy, and skills through clinical support and feedback.
224003942|NCT06674616|OTHER|Facilitation|Facilitation addresses potential organizational barriers to delivery, including leadership support and acceptance among other staff.
224003943|NCT06121336|DIAGNOSTIC_TEST|Plasma levels of BD-tau|Plasma levels of BD-tau will be assessed using a single-molecule array assay.
224003944|NCT05043454|OTHER|High Intensity Interval Training (HIIT) Exercise|Participants will exercise 4 days/week for 10 weeks using the High Intensity Interval Training (HIIT) protocol. Sessions can be conducted at home or at a gym with access to a cycle ergometer. Participants will undergo 2 supervised training sessions to learn the HIIT protocol. To record heart rate, session duration, and time at each exercise intensity, participants will be provided with an H10 Polar TM heart rate chest strap monitor and a Polar Beat/Polar Flow account. Participants will download the Polar Beat/Flow smart phone application to record exercise sessions and allow the researcher to conduct remote data monitoring. Research staff will contact participants twice per week to provide feedback.
224003945|NCT07135089|DRUG|Intravenous tirofiban before endovascular thrombectomy|The tirofiban was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
224003946|NCT07135089|DRUG|Intravenous placebo before endovascular thrombectomy|The placebo was administrated as a bolus dose of 10 μg/kg, followed by continuous infusion of 0.15 μg/kg/min for up to 24 hours.
224003947|NCT07126470|PROCEDURE|CTR implantation|Device: CTR (275001G, OPHTEC BV, Netherlands) All patients undergo uneventful phacoemulsification by a 2.2 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL (J\&J Tecnis DCB00) is implanted.
224003948|NCT07008963|OTHER|non-interventional|This is a non-interventional, observational study
224003949|NCT05765487|DRUG|Sildenafil|Sildenafil Cream, 3.6%
224003950|NCT05765487|DRUG|Vehicle|No Active or experimental ingredients
224003951|NCT05765487|DRUG|Placebo|Cream with only L-arginine
224124671|NCT07007559|DRUG|Gemcitabine|IV infusion
223386258|NCT02261272|BEHAVIORAL|passive patient education/sleep hygiene|
223386259|NCT00600730|PROCEDURE|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
223386260|NCT00600730|PROCEDURE|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
223386261|NCT01878357|DRUG|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
223386262|NCT01878357|DRUG|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
224003952|NCT03004716|OTHER|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
224003953|NCT06676488|DEVICE|Re-Timer glasses|Morning bright light therapy (BLT) will be administered through a safe wearable glasses device called a Re-Timer, purchased from the manufacturer Re-Timer.
224003954|NCT06676488|DEVICE|Placebo Device|Placebo glasses not providing Bright Light Therapy
224003955|NCT04998812|DRUG|Ocrelizumab|Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
224003956|NCT06619236|DRUG|Rina-S|Intravenous (IV) infusion
224003957|NCT06619236|DRUG|Paclitaxel|IV infusion
224124672|NCT07007559|DRUG|Vinorelbine|IV infusion
224124673|NCT07132385|BEHAVIORAL|Guidelines-based moderate-intensity continuous exercise|Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity (total intervention is 6 weeks)
224124674|NCT07132385|BEHAVIORAL|High-intensity interval training|Through a combination of exercise trainer-led in-person and virtual sessions, participants will be guided to achieve 75 weekly minutes of high-intensity interval training.
223386263|NCT03618550|DRUG|pembrolizumab|Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
223386264|NCT03618550|DRUG|gemcitabine|1000mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
224003958|NCT06619236|DRUG|Topotecan|IV infusion
224003959|NCT06619236|DRUG|Pegylated liposomal doxorubicin (PLD)|IV infusion
224003960|NCT06619236|DRUG|Gemcitabine|IV infusion
224003961|NCT06867848|PROCEDURE|laminar bone membrane for labial bone augmentation|adding laminar bone membrane in one group and pericardium membrane in another group with sticky bone by using vestibular incision in both groups to augment the labial bone over dental implant
224003962|NCT03446001|DRUG|TRx0237 16 mg/day|Oral TRx0237 4-mg tablets administered twice daily
224124675|NCT07132385|BEHAVIORAL|Stretching exercise|Twice weekly virtual instructor-led whole-body stretching class.
224124676|NCT05513612|BIOLOGICAL|Autologous CAR-T cells|CAR-T cells will be infused intravenously.
224124677|NCT05513612|DRUG|Fludarabine|Administered according to package insert
224124678|NCT05513612|DRUG|Cyclophosphamide|Administered according to package insert
224124679|NCT04951648|DRUG|Almonertinib|Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
224124680|NCT04951648|DRUG|chemotherapy|Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
224124681|NCT06866262|PROCEDURE|Biopsy|Undergo biopsy
224124682|NCT06866262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224295790|NCT06323486|DEVICE|active accelerated bilateral sequential theta burst stimulation and sham treatment|"We shall use the Magpro device (Magventure) employing the specialized Active/Sham B70 coil.~absTBS shall be administered consisting of 6 sessions daily (with a 50-minute interval between treatment sessions) on Mondays to Fridays or for a maximum of 5 working days of daily treatment. The target stimulation intensity will be set at 90 to 120% of the subject's resting motor threshold (RMT). Each session shall be composed of administration of continuous theta burst stimulation (triplet burst pulses at 50 Hz, repeated at 5 Hz, for a total of 600 pulses per session over 40 seconds administered on the right dorsolateral prefrontal cortex) and then intermittent theta burst stimulation (triplet burst pulses at 50 Hz bursts, repeated at 5 Hz, 2 s on and 8 s off, for a total of 600 pulses per session over about 3 min, administered on the left dorsolateral prefrontal cortex).~The sham treatment will be conducted for the same number of sessions and duration as the absTBS treatment sessions."
224295791|NCT01799863|DRUG|Ketorolac trometamol 0.45% with carboxymethylcellulose|
224295792|NCT01799863|DRUG|Preservative free artificial tear|
224295793|NCT02152735|PROCEDURE|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
224299205|NCT02737332|DRUG|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart
224299206|NCT02737332|DRUG|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
223386265|NCT03618550|DRUG|vinorelbine|20mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
223386266|NCT03618550|DRUG|liposomal doxorubicin|15mg/m\^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
223386267|NCT03618550|PROCEDURE|Stem cell mobilization and collection|Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
223386268|NCT04899154|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.
223386269|NCT04899154|OTHER|stool sampling|Participants will provide one stool sample at inclusion
223386270|NCT03321318|DRUG|AK-R215|Investigational product is prescribed to all ofrandomized subjects
223386271|NCT03321318|DRUG|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
224003963|NCT03446001|DRUG|Control|Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
224003964|NCT03446001|DRUG|TRx0237 8 mg/day|Oral TRx0237 4-mg tablet administered twice daily
224003965|NCT03987295|DRUG|AL001|60 mg/kg of AL001 every 4 weeks
224003966|NCT06696079|DRUG|Early Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 5th postoperative day following burr-hole surgery for chronic subdural hematoma. This early resumption strategy is compared to the standard practice of resuming anticoagulation therapy on the 30th postoperative day.
224003967|NCT06696079|DRUG|Late Resumption of Oral Anticoagulation Therapy|The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma. This standard resumption strategy is compared to the early approach of resuming anticoagulation therapy on the 5th postoperative day.
224003968|NCT05785949|PROCEDURE|Microfracture|Use of standard tool kit to drill vertically from the periphery to the center with a hole spacing of 3\~4 mm with care to prevent penetrating adjacent holes. The hole depth should be 3\~5 mm and fat droplets or blood oozing is seen after loosening the tourniquet. However, no blood oozing is observed in some holes and in such case, the hole depth should be deepened to 5\~7 mm.
224003969|NCT05785949|DEVICE|Chondro-Gide bilayer collagen membrane|After the Microfracture, the porous layer of the bilayer collagen membrane faces the bone surface. The already trimmed, cut and wetted membrane is insert into the defect and fixed symmetrically with absorbable surgical suture with needle. Knots are put on the pinhole of collagen membrane to avoid tearing of surrounding cartilage or collagen membrane during knotting.
224003970|NCT06719609|OTHER|Ankle tape|The influence of ankle tape on gait biomechanics
224124683|NCT06866262|PROCEDURE|Computed Tomography|Undergo CT
224124684|NCT06866262|DIETARY_SUPPLEMENT|Inulin|Given PO
223386272|NCT03321318|DRUG|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
223386273|NCT05485831|DRUG|Epidiolex 100 mg/mL Oral Solution|As prescribed in routine clinical practice in Italy.
223386274|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub A)|The algorithms act upon the digital audio signal received by the microphones and other sensors to enhance speech and attenuate noise prior to encoding the signal for delivery to a cochlear implant via the specified system.
223386275|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Automatic Gain Control, SNR-NR, Forward Focus
223386276|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub B)|Spatial Automation profile
223386277|NCT06100393|DEVICE|Investigational pre-processing algorithm (Sub D)|Microphone miscalibration profile with applied correction method
223386278|NCT06100393|DEVICE|Cochlear Limited standard-of-care pre-processing algorithms|Standard microphone calibration profile
223386279|NCT06100393|DEVICE|Investigational Pre-Processing Algorithm (Sub C)|Spatial Automation profile and DNR algorithm
224003971|NCT06719609|OTHER|Standard lace-up ankle brace|The influence of lace-up ankle brace on gait biomechanics
224003972|NCT06719609|OTHER|Standard high ankle-sprain (HAS) brace|The influence of standard HAS brace on gait biomechanics
224003973|NCT06719609|OTHER|Low-profile HAS brace|The influence of low-profile HAS brace on gait biomechanics
224003974|NCT06719609|OTHER|No ankle brace or tape|The influence of no ankle tape or brace on gait biomechanics
224003975|NCT06729879|OTHER|Yoga eye exercises group:|Yoga eye exercises
224003976|NCT06729879|OTHER|Myofascial release-postural correction exercises group|Myofascial release-postural correction exercises
224003977|NCT06729879|OTHER|Yoga eye exercises, myofascial release-postural correction exercises group|Yoga eye exercises, myofascial release-postural correction exercises group
224003978|NCT06729879|OTHER|control group|no intervention
224003979|NCT07046260|OTHER|Blood sample collection|The study will collect up to 40 mL of whole peripheral blood in Streck Cell-Free DNA BCT® tubes from each Subject.
224124685|NCT06866262|BIOLOGICAL|Ipilimumab|Given IV
224124686|NCT06866262|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224124687|NCT06866262|BIOLOGICAL|Nivolumab|Given IV
224124688|NCT06866262|OTHER|Questionnaire Administration|Ancillary studies
223386280|NCT03449732|DEVICE|PDR measurement|"PDR measurement at two standardized times perioperatively:~1. Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~2. Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth"
223386281|NCT02957383|OTHER|Wavelength|wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
224003980|NCT06747273|DRUG|SRP-9004|Intravenous (IV) infusion.
224003981|NCT04990713|PROCEDURE|Serratus Plane Block (Local Anesthetic) and Intercostal Block (Local Anesthetic)|Patients will receive local anesthetic via serratus plane block as opposed to saline placebo
223386282|NCT02957383|OTHER|Intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
223386283|NCT05434988|PROCEDURE|appendectomy|Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
224003982|NCT04990713|PROCEDURE|Serratus Plane Block (Placebo) and Intercostal Block (Local Anesthestic)|Patients will receive saline placebo via serratus plane block
224003983|NCT06761898|DRUG|BGB-43395|Administered orally as solid dispersion tablet or salt tablet
224003984|NCT06761898|DRUG|BGB-43395|Administered orally as solid dispersion tablet or salt tablet
224003985|NCT07059312|DRUG|JADE101|JADE101 is supplied as sterile solution to be administered by SC injection.
224003986|NCT07059312|DRUG|Placebo|Placebo solution to be administered at a matching volume by SC injection.
224003987|NCT07053865|DEVICE|Surface Electromyography (dia-BRUXO)|Participants will undergo 24-hour surface electromyographic recording of the left masseter muscle using the dia-BRUXO portable device to quantify sleep bruxism activity through Bruxism Work Index (BWI) and Bruxism Time Index (BTI).
224003988|NCT07055542|DIAGNOSTIC_TEST|Observational|Prospective observational study
224124689|NCT06244537|RADIATION|MR-linac|Patients enrolled will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4 cycles of mFOLFOX6 or 3 cycles of XELOX chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mFOLFOX6 or 5 cycles of XELOX chemotherapy.
224124690|NCT03566108|PROCEDURE|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
224003989|NCT06313710|OTHER|head down position|-10° Trendelenburg
224003990|NCT07062133|PROCEDURE|Electrical pudendal nerve stimulation|Electrical Pudendal Nerve Stimulation (EPNS) delivered by four deep acupuncture needles targeting bilateral sacrococcygeal points near the pudendal nerve. Connected to G6805-2 electrical stimulator, 2 Hz, 60 minutes/session, three times per week for 4 weeks.
224003991|NCT07062133|OTHER|Conventional conservative treatment|Conventional conservative treatment including medications (e.g., oxybutynin), clean intermittent catheterization, and diaper use as needed
224124691|NCT03566108|PROCEDURE|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
224124692|NCT06686797|DRUG|PF-08049820|Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).
224124693|NCT06686797|DRUG|Placebo|Oral solution/suspension for Part A (Cohorts 1 to 3). Tablets for Part B (Cohorts 4 to 7).
224124694|NCT04626245|BEHAVIORAL|Mindfulness training|Phone-delivered brief mindfulness training based on principles of MBSR
223386284|NCT01831661|DRUG|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
223386285|NCT01831661|DRUG|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
223386286|NCT00644215|DRUG|5-FU and Mitomycin|"* 5-FU injection 5mg~* Mitomycin drop 0.02%"
223386287|NCT04085237|DRUG|Ropivacaine injection|30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
223386288|NCT04085237|OTHER|Sham|Saline will be used at the same amounts as the ropivacaine arm.
223386289|NCT00218387|DRUG|Modafinil|200mg Modafinil
223386290|NCT00218387|DRUG|Modafinil|400mg Modafinil
223386291|NCT00218387|DRUG|Matching Placebo|Matching Placebo
224003992|NCT06770270|DRUG|Pucotenlimab|"Pucotenlimab combined with long-course concurrent chemoradiotherapy, followed by two cycles of pucotenlimab combined with chemotherapy, and then based on tumor response, TME surgery or a watch and wait strategy will be adopted."
224003993|NCT02049853|DEVICE|"NTproBNP measurement with point of care device Cobash232 in the POCT group"|
224003994|NCT06770660|BEHAVIORAL|Telemedicine|"A 10-week telemedicine-based exercise programme consisting of 90-minute sessions conducted weekly via a video conferencing platform.~All participants will also be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form."
224003995|NCT06770660|BEHAVIORAL|Lifestyle|All participants will be educated on physical activity recommendations, including achieving a minimum of 12,000 steps daily, and required to perform weekly check-in for number of daily steps via online survey form.
224124695|NCT04122001|DEVICE|Active, in-person HD-tDCS or active remote tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes. In the active, in-person HD-tDCS the current is delivered in a ring configuration. In the active remote tDCS current is delivered in one electrode patch.
224124696|NCT04122001|DEVICE|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
224124697|NCT04122001|OTHER|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
224124698|NCT06875479|DIAGNOSTIC_TEST|Five Seasons [5S] Sleep Tracking Mat|The Five Seasons \[5S\] Sleep Tracking Mat consists of a main control box, monitoring mat, temperature/humidity sensor, power adapter, and light sensor. It utilizes Ballistocardiogram (BCG) technology to detect heartbeat, respiration, body movements, and snoring. The collected data is analyzed by a proprietary pre-trained AI model, enabling automatic detection of respiratory events, calculation of the Apnea-Hypopnea Index (AHI), and sleep stage interpretation. Compared to other sleep monitoring devices, it is non-contact and requires no wearable components, making it particularly suitable for long-term, daily home use.
224124699|NCT06899204|DRUG|Abrocitinib|Study Drug for Observational Data Collection.
224124700|NCT05100056|OTHER|No Intervention|This is a non-interventional study.
224124701|NCT06771674|DRUG|Pembrolizumab|Given as monotherapy.
224124702|NCT06771674|DRUG|Nivolumab|Given in combination with chemotherapy.
224124703|NCT06771674|DRUG|Nivolumab|Given without chemotherapy.
224124704|NCT06771674|DRUG|Pembrolizumab|Given in combination with chemotherapy.
223386292|NCT03525561|DRUG|Acetazolamide Pill|Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
223386293|NCT03525561|DRUG|Placebo pill|Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
223386294|NCT00821561|DRUG|Nexagon®|
223386295|NCT00821561|DRUG|Nexagon® vehicle|
223386296|NCT00666328|DRUG|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
223386297|NCT06025123|DEVICE|Early transnasal evaporative cooling with the RhinoChill device|Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours
223386298|NCT04145128|DRUG|AG881|AG-881 tablets.
223386299|NCT04466280|DRUG|Hydroxychloroquine|200 mg of hydroxychloroquine daily for participants in the intervention group 1
224003996|NCT07067684|OTHER|Low Tidal Volume Ventilation During CPB|"Group Low: Patients in this group will receive low tidal volume mechanical ventilation during cardiopulmonary bypass (CPB).~Ventilation settings will be:~Tidal Volume: 3-4 mL/kg (ideal body weight)~PEEP: 5-8 cmH₂O~Respiratory Rate: adjusted to maintain normocapnia (PaCO₂ 35-45 mmHg)"
224003997|NCT06269627|DRUG|Acamprosate calcium|Two oral capsules (packaged as one) containing 666 mg of acamprosate calcium will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
224003998|NCT06269627|OTHER|Placebo|Two oral capsules (packaged as one) containing 666 mg of inactive substance (e.g., sugar) will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.
224124705|NCT06771674|DRUG|Pembrolizumab|Given without chemotherapy.
224124706|NCT06772896|OTHER|Reordered PHQ-8|Participants will be administered the PHQ-8 somatic items separately from the psychological items, outside the context of a depression questionnaire.
223386300|NCT04466280|DRUG|Mucodentol|Intervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.
223386301|NCT04466280|DEVICE|Personal protective equipment|Personal protective equipment such as masks, gloves, protective shields
223386302|NCT01031329|PROCEDURE|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
223386303|NCT01350362|DRUG|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
223386304|NCT01350362|DRUG|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
223386305|NCT01350362|DRUG|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
223386306|NCT01350362|DRUG|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
223386307|NCT00918866|DRUG|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
224003999|NCT06756074|DRUG|Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)|pancreaticojejunostomy was done with application of glubran 2: The blister pack was opened, and the sterile single-dose vial was released directly onto the operating table in a sterile environment, Draw the Glubran 2 out of the single-dose vial using a sterile syringe then put the syringe into applicator Glubran 2 was applied into anastomosis by applicator in spraying manner . Whenever possible, the area to be treated should be cleaned before application. When applied in such a minimal amount, once it had polymerized, Glubran 2 formed a thin adhesive layer. It was therefore essential not to apply more than one drop in the same point. A second layer of Glubran 2 may not be applied until the first had polymerized. Any excess product was removed using a dry swab within 5-6 seconds after application. Glubran 2 was not touched after application until the polymerization reaction is complete, as it may detach or not produce the desired effect.
224004000|NCT06756074|PROCEDURE|Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)|Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)
224004001|NCT06547151|DRUG|AMOR-1|Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
224004002|NCT06547151|DRUG|Crystalline Calcium Carbonate|Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
224004003|NCT06900647|DRUG|Bortezomib (B)|1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
224004004|NCT06900647|DRUG|Cisplatin (CDDP)|50mg/m2, IV, D1-3, every 3 weeks
223386308|NCT05663125|PROCEDURE|Laser interstitial thermal therapy|Ablation of the tumor will be done by MRI-guided laser interstitial thermal therapy with the assistance of neuro-navigation.
223386309|NCT05663125|DRUG|Temozolomide|Temozolomide will be administered continuously from the 1st to the 21st day after LITT surgery. The oral dose of temozolomide is 75 mg/m2. And then, it will be given at a routine dose from the second month after surgery.
223386310|NCT03885661|DRUG|Icosapent Ethyl 1000 MG [Vascepa]|Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
223386311|NCT02054052|DRUG|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
223386312|NCT01893515|DRUG|PRC-4016|
223386313|NCT01893515|DRUG|Placebo|
223386314|NCT05064397|DRUG|Eptinezumab|Eptinezumab will be administered per schedule specified in the arm description.
223386315|NCT01023009|PROCEDURE|vitrectomy|
223386316|NCT04820725|DIAGNOSTIC_TEST|Plantar pressure and gait|Gait analyses (cadence, stride length, swing phase duration, step duration and double stand duration) will be evaluated using Win-Track platform (MEDICAPTEURS Technology, France).
224124707|NCT03949049|DRUG|Citicoline|Citacoline as neuroprotector
224124708|NCT03949049|OTHER|Placebo|placebo group
223386317|NCT02607046|OTHER|Exercise training|The exercise program includes supervised and home-based walking and strength exercise.
223386318|NCT02607046|OTHER|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
223386319|NCT06300203|BIOLOGICAL|Interleukin-4 receptor responders|Interleukin-4 receptor was injected subcutaneously.
223386320|NCT06300203|OTHER|Placebo|Placebo was injected subcutaneously.
223386321|NCT06388785|OTHER|No Intervention|This is a non-interventional study.
223386322|NCT06538116|DRUG|Mevidalen|Administered orally
223386323|NCT06538116|DRUG|Placebo|Administered orally
224124709|NCT03645460|GENETIC|Direct intravenous injection of ivlv-ADA lentiviral vector|Injection of ivlv-ADA lentiviral vector at \~1x10\^9 per kg body weight
223386325|NCT05270200|DRUG|Azacitidine|Patients will recieve six courses of azacitidine 50mg/m2 through a needle under skin on Days 1-3.Each course is 28 days long.
223386326|NCT05270200|DRUG|Chidamide|Patients will recieve oral chidamide 5mg per day for no more than 2 years.
223386327|NCT05797610|DRUG|Sefaxersen (RO7434656)|Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified.
223545586|NCT05237362|BEHAVIORAL|Saga Stories|Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
223545587|NCT01616277|BIOLOGICAL|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
224124710|NCT07067775|DRUG|Vicagrel Capsules|Vicagrel Capsules qd per period, for two periods
224124711|NCT07067775|DRUG|Clopidogrel Tablets|Clopidogrel Tablets qd per period, for two periods
223386328|NCT05797610|DRUG|Placebo|Matching placebo will be administered as SC injection per schedule as specified.
223386329|NCT02665104|DEVICE|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
223545588|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
223545589|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
224004005|NCT06900647|DRUG|Bortezomib (B)|1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
224004006|NCT06900647|DRUG|Bortezomib (B)|1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks
224004007|NCT06900647|DRUG|Cisplatin (CDDP)|70mg/m2, IV, D1-3, every 3 weeks
224004008|NCT07076030|DRUG|Petrelintide|Solution administered with a syringe
224004009|NCT05170399|BIOLOGICAL|Fluzone|Annual Influenza Vaccine
224004010|NCT05170399|BIOLOGICAL|Shingrix|Recombinant, adjuvanted Zoster Vaccine (RZV)
224124712|NCT06023589|BIOLOGICAL|Tezepelumab|Participants will be receiving subcutaneous injection of tezepelumab
224004011|NCT05170399|BIOLOGICAL|Flucelvax|Annual Influenza Vaccine
224004012|NCT05170399|BIOLOGICAL|Afluria|Annual Influenza Vaccine
224124713|NCT06023589|OTHER|Placebo|Participants will be receiving subcutaneous injection of matching placebo
223545590|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
223545591|NCT01616277|BIOLOGICAL|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
224004013|NCT05170399|BIOLOGICAL|PREVNAR 13|Pneumococcal Conjugate Vaccine (PCV13)
223545592|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
223545593|NCT01616277|BIOLOGICAL|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
223545594|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
224004014|NCT05170399|BIOLOGICAL|Heplisav -B|Recombinant, adjuvanted Hepatitis (HepB-CpG)
224004015|NCT05170399|BIOLOGICAL|Pfizer-COVID-19 Vaccine|COVID-19 Vaccine
224004016|NCT05170399|BIOLOGICAL|FluLaval|Annual Influenza Vaccine
224004017|NCT05170399|BIOLOGICAL|Fluarix|Annual Influenza Vaccine
224004018|NCT05170399|BIOLOGICAL|PNEUMOVAX 23|Pneumococcal Polysaccharide Vaccine (PPSV23)
224004019|NCT05170399|DRUG|PREVNAR 20|Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
224004020|NCT05170399|DRUG|AREXVY, ABRYSVO|Respiratory Syncytial Virus Vaccine
223545595|NCT01616277|BIOLOGICAL|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
224004021|NCT00900198|PROCEDURE|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
224004022|NCT07077122|PROCEDURE|Scaling and Root Planing|Mechanical debridement of tooth surfaces using hand and ultrasonic instruments
224124714|NCT06203392|OTHER|Very low carbohydrate ketogenic diet|Very low carbohydrate ketogenic diet provided for six weeks
224124715|NCT06203392|OTHER|Mediterranean diet|Mediterranean diet provided for six weeks
224124716|NCT06331377|OTHER|Non-Interventional Study|Non-interventional study
224124717|NCT06926764|PROCEDURE|Intertransverse process block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 25 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same v
224138509|NCT01194869|DRUG|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
223545596|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
223545597|NCT01616277|BIOLOGICAL|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
224004023|NCT07077122|DRUG|antibiotic prophylaxis|2g Amoxicillin given 1 hour prior to instrumentation
224004024|NCT07077122|DEVICE|810nm Diode Laser|Laser applied at base of gingival pockets prior to mechanical debridement.
224004025|NCT07077122|PROCEDURE|Air Polishing|air flow-based mechanical debridement with erythritol powder
224004026|NCT06903897|OTHER|WE CARE SDOH System|The WE CARE System: A family-centered, highly efficacious approach for addressing adverse SDOH in the clinical setting. Arvin Garg, MD, MPH developed and conceptualized the WE CARE (Well-Child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) intervention in 2005. This approach relies on existing clinical processes and infrastructure and social service resources, thereby making implementation, dissemination, and sustainability feasible. The intervention components include brief training of the clinical team; administration of a short screening tool to parents/patients identifying their desire for help with specific unmet social needs; and provider/clinic staff access to a physical or electronic family resource book containing community- resource listings. Providers generate referrals for families who indicate that they want help with unmet social needs on the WE CARE screener. Existing staff members may assist patients in connecting to referred resources.
224004027|NCT06903897|OTHER|Standard Pediatric Care|Standard pediatric care includes any existing screening practices, which can vary at each clinic.
224004028|NCT06805994|BIOLOGICAL|Nasal Microbiota Transplant (NMT)|nasal microbiota transplant
224004029|NCT06805994|BIOLOGICAL|Placebo|Placebo sterile swab
224004030|NCT06906731|DRUG|SHR-9803|SHR-9803
224138510|NCT01194869|DRUG|Cisplatin|75 mg/m² given IV
224138511|NCT01194869|DRUG|Paclitaxel|175 mg/m² given IV
223386330|NCT04206917|DEVICE|Multi Pulse Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
223386331|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
224004031|NCT07137351|DIAGNOSTIC_TEST|The Biosensor Using the Target Urine Volatile Organic Compounds|"The authors opted to utilize five distinct commercially available semiconductors (metal oxide sensors) to detect all the targeted VOCs which were manufactured by Figaro company.~Urine samples from patients were placed in a urine container, which was then placed into the VOCs detection device. The lid was closed, and the system was set to operate in a closed-loop mode at a room temperature of 25 degrees Celsius. The device then vacuumed VOCs from the urine samples of the patients through a gas tube into the biosensor chamber located on top, where analysis was performed."
223386332|NCT04661644|BIOLOGICAL|Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)|Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
223386333|NCT03996811|OTHER|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
223386334|NCT05754749|DRUG|Iohexol 350 Mg/mL Injectable Solution|Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
224004032|NCT07091955|DIETARY_SUPPLEMENT|Lacticaseibacillus rhamnosus CRL1505|Probiotic product containing Lacticaseibacillus rhamnosus CRL1505 formulated in a vegetable hydroxymethylpropyl-cellulose capsule of size 2
223386335|NCT00144729|PROCEDURE|Bone marrow transplant|
224004033|NCT07091955|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo product containing cornstarch, in a vegetable hydroxymethylpropyl-cellulose capsule of size 2
224004034|NCT04074057|OTHER|Conventional Cardiac Rehab Classes|conventional weekly CR programme lasting 8-12 sessions.
224004035|NCT04074057|DEVICE|Heart Track|"Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness."
224004036|NCT05014568|DRUG|tapinarof cream, 1%|applied topically once daily
224004037|NCT05014568|DRUG|Vehicle cream|applied topically once daily
224004038|NCT06904222|BIOLOGICAL|Low dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
224004039|NCT06904222|BIOLOGICAL|Low dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
224004040|NCT06904222|BIOLOGICAL|Middle dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
224004041|NCT06904222|BIOLOGICAL|Middle dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
224004042|NCT06904222|BIOLOGICAL|High dose antigen of LYB005 without A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
224004043|NCT06904222|BIOLOGICAL|High dose antigen of LYB005 with A01B adjuvant|0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
224004044|NCT06904222|BIOLOGICAL|Placebo|0.5 mL 0.9% sodium chloride (normal saline) injection per dose
224004045|NCT04893460|BEHAVIORAL|CoQuit App|The CoQuit App is a cognitive dissonance based app for smoking cessation.
224004046|NCT07101419|OTHER|Long PRT|PRT (in seconds) set at 75% of inspiratory time (in seconds)
224004047|NCT07101419|OTHER|Short PRT|PRT (in seconds) set at 33% of inspiratory time (in seconds).
224004048|NCT07110584|DRUG|MDX2004|MDX2004 intravenous infusion
224004049|NCT07111481|BEHAVIORAL|Mozart music|Participants will be played Mozart's Sonata for Two Pianos in D Major, K. 448 during their surgical simulation training session with an AI tutor.
224004050|NCT06738121|PROCEDURE|Infra-umbilical incision|Traditional curvilinear infra-umbilical incision is used to repair the umbilical hernia
224004051|NCT06738121|PROCEDURE|Transumbilical incision|The incision for the repair of the umbilical hernia will be carried through the umbilicus itself.
224004052|NCT06132256|DRUG|Axatilimab|Administered as intravenous (IV) infusion
223386336|NCT01400542|DEVICE|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
223386337|NCT01400542|DEVICE|No treatment|no treatment
223386338|NCT05624879|BEHAVIORAL|Accelerated Resolution Therapy|A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.
223386339|NCT05624879|OTHER|Information and Support|4 sessions of a standardized social work intervention. Standard of care including education and active listening.
223386340|NCT00383253|BEHAVIORAL|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
223386341|NCT00383253|BEHAVIORAL|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
223386342|NCT00383253|BEHAVIORAL|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
223545598|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
224004053|NCT06132256|OTHER|Placebo|Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.
224004054|NCT07107841|OTHER|Autologous Hair Follicle-Derived Secretome|Hair follicles are plucked, cultured and the product is the resulting cell secretions (secretome) collected from the conditioned media.
223386343|NCT00383253|BEHAVIORAL|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
223386344|NCT05669664|PROCEDURE|Biopsy Procedure|Undergo biopsy
223386345|NCT05669664|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223386346|NCT05669664|PROCEDURE|Computed Tomography|Undergo CT
223386347|NCT05669664|DRUG|Darolutamide|Given PO
223386348|NCT05669664|DRUG|Leuprolide Acetate|Given IM
223386349|NCT05669664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223386350|NCT05409729|BEHAVIORAL|retrospective charts reviewing|
223386351|NCT01996930|DRUG|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
223386352|NCT01996930|DRUG|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
223386353|NCT06144944|DRUG|Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Pyrotinib 320 mg orally once daily, and epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
223386354|NCT06144944|DRUG|Epirubicin or doxorubicin, cyclophosphamide, paclitaxel|Epirubicin 90 mg/m² or doxorubicin 60 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 for four 3-week cycles followed by paclitaxel 175 mg/m² intravenously on day 1 or four 3-week cycles.
224004055|NCT07107841|OTHER|Placebo Control|The same saline used for diluting the active treatment in will be used as a control.
224004056|NCT07109505|DIETARY_SUPPLEMENT|Nutritional Shake|The shake mixes will be dry shelf -stable powders prepared with ingredients readily available in the US food supply and contain a minimum of 990 mg total cocoa flavanols, with a profile to support general nutritional health including 10 g protein. Accordingly, each shake contains approximately 95 mg of caffeine, equivalent to a medium-sized cup of coffee. Based on prior studies of cognition, additional composition specifications are: 1600 mg DHA and up to 400 mg EPA and 550 mg choline; \>250 mg epicatechin and epigallocatechin (plant polyphenols); multivitamin/mineral fortification to ensure 50-100% of all essential micronutrients except calcium (to prevent competitive absorption with other divalent cations). Participants will be given a supply of pre-portioned daily servings upon discharge from the hospital, for 30 days after surgery.
224124718|NCT06926764|PROCEDURE|Sham Block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 25 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
224124719|NCT06926764|DRUG|Levobupivacaine 0.25%|Drug used for intertransverse process block (intervention group)
224124720|NCT06926764|DRUG|Sodium Chloride (NaCl) 0.9 %|As placebo for sham block group
224124721|NCT06926764|DEVICE|Ultrasound guided injection with local anaestethic|Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany)
224124722|NCT07083830|DEVICE|ECP-DL treated mononuclear cell infusion|Participants in this study will undergo the infusion of donor white blood cells treated with ECP one week before their living donor kidney transplant, combined with standard of care antirejection medications. You will also then have ECP treatments using your own blood on two consecutive days once per month for 6 months. This combination is intended to cause your immune system to create a state called tolerance to the donor kidney. The ECP procedure has not been approved to prevent rejection after kidney transplant and the use of ECP to prevent rejection of transplanted organs is experimental, and is not a part of standard treatment which is based on the long term use of anti-rejection drugs such as tacrolimus (Prograf), everolimus, and prednisone.
224124723|NCT06930131|BEHAVIORAL|Semantic rehabilitation|Semantic rehabilitation, consisting of validated lexico-phonological training exercises
223386355|NCT05881304|DEVICE|Standardized research e-cigarette (SREC)|Patients will be provided with NIDA's standardized research electronic cigarette (SREC) for 8-weeks and asked to attempt to substitute the SREC for combusted cigarettes during the 8 weeks. Participants will be randomized in a 1:1 ratio to 1 of 2 conditions for 8 weeks: 1) immediate standardized research e-cigarette provision (iSREC) or 2) delayed SREC provision waitlist control (WLC). Those randomized to the iSREC group will be provided a free 8-week supply of SRECs and asked to try to switch completely to the SREC. Those in the WLC condition will receive SREC provision after an 8-week delay.
223386356|NCT05716737|RADIATION|Irradiation|3 Gy in 6 fractions to the TMJ, every other day, LINAC based
223386357|NCT04699591|DRUG|Domperidone|Domperidone taken 4 times a day, dose based on body weight
223386358|NCT03740529|DRUG|Pirtobrutinib|Oral
223386359|NCT03740529|DRUG|Venetoclax|Oral
223386360|NCT03740529|DRUG|Rituximab|IV
223386361|NCT03907475|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223386362|NCT03907475|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223386363|NCT03907475|DRUG|Capecitabine|Given PO
223386364|NCT03907475|DRUG|Carboplatin|Given IV
223386365|NCT03907475|PROCEDURE|Computed Tomography|Undergo CT
223386366|NCT03907475|BIOLOGICAL|Durvalumab|Given IV
223386367|NCT03907475|PROCEDURE|Echocardiography Test|Undergo ECHO
223386368|NCT03907475|DRUG|Gemcitabine Hydrochloride|Given IV
223386369|NCT03907475|DRUG|Nab-paclitaxel|Given IV
223386370|NCT03907475|DRUG|Paclitaxel|Given IV
223386371|NCT03907475|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223386372|NCT06518447|DEVICE|Digital occlusal splints (CAD/CAM)|Consists of occlusal stabilization intra-oral splints fabricated using a fully digital workflow, involving intraoral scanning, virtual design, and 3D printing to ensure precise fit and comfort.
223545599|NCT01616277|BIOLOGICAL|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
224004057|NCT07109505|OTHER|Nutritional Instructions Only|The control arm receives the Nutrition After Surgery instructions, which provide guidelines for healthy eating after surgery but not the nutritional shake. The intervention arm receives the same instructions along with the nutrition shake mix and accompanying postoperative supplementation
224124724|NCT06929715|OTHER|Intervention for Teaching the First Link in the Chain of Survival to 7- and 8-Year-Old Children|Unlike traditional CPR training programs designed primarily for older children or adults, this intervention is uniquely tailored for 7- and 8-year-old schoolchildren. It employs a narrative-based, age-appropriate educational approach that incorporates storytelling, interactive activities, and practical simulation exercises aligned with the cognitive and motor development of young learners. Delivered by school nurses in a classroom setting, the program not only focuses on teaching the first link in the chain of survival but also ensures that its content and methods are rigorously validated by experts. Moreover, the intervention includes a follow-up evaluation at three months to assess the retention of knowledge and skills, distinguishing it from other clinical studies that lack such long-term assessment.
223386373|NCT06518447|DEVICE|Conventional occlusal splints|Consists of occlusal stabilization splints fabricated using traditional analog methods, including physical impressions, plaster models, and manual processing with heat-cured acrylic resin to achieve the desired occlusal arrangement.
223386374|NCT04563520|DRUG|Emicizumab|HEMLIBRA® is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
223386375|NCT04563520|DRUG|FEIBA|"FEIBA™ is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia patients with inhibitors for: control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.~The max dose allowed for aPCC will be 50 U/kg dose given at a single visit."
223386376|NCT04563520|DRUG|rFVIIa|rFVIIa is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents with hemophilia with inhibitors.
224004058|NCT06398964|DIETARY_SUPPLEMENT|3-hydroxybutyrat|The intervention is administered as a drink.
224004059|NCT06398964|DIETARY_SUPPLEMENT|Isocaloric placebo drink|The intervention is administered as a drink.
224004060|NCT07119268|DEVICE|SPARK Healthy Sleep|SPARK-Healthy Sleep is a single-session digital intervention delivered via smartphone that combines stigma reduction with evidence-based sleep improvement strategies.
224004061|NCT06920251|DRUG|Letermovir|"Elranatamab: Participants will receive SC administration of elranatamab QW, Q2W or Q4W. The initial doses of elranatamab will be 12 mg (C1D1) and 32 mg (C1D4) and will serve as the 2 step-up priming regimen.~Dexamethasone: Dexamethasone is administered at the dose of 20 mg/day on C1D1, C1D4 and C1D8 as a premedication for elranatamab~Letermovir: Letermovir is administered at the dose of 480mg/day PO from C1D15 (W3) to C4 (W16) (total of 98 days)."
224004062|NCT06923748|DEVICE|Superfloss|Use of Superfloss daily as the interproximal cleaning device, combined with an electronic toothbrush, as part of a tailored oral hygiene protocol in patients with peri-implant disease.
224004063|NCT06923748|DEVICE|Interdental brush|Use of interdental brush once daily as the interproximal cleaning device, combined with an electronic toothbrush, within a professional oral hygiene maintenance program for peri-implant disease
224004064|NCT07131007|BEHAVIORAL|Immunotherapy Monitoring and Sample Collection|For cancer patients receiving immune checkpoint inhibitors (ICIs), we conduct behavioral monitoring: collect blood, urine, and feces samples before medication and 7 days after medication for multi - omics analysis. Monitor organ function indicators at 24 hours, 72 hours, and 1 week post - medication. No interference with standard ICI treatment; focus on observational data collection to construct an organ damage early - warning system.
224004065|NCT07139938|PROCEDURE|Isolated lumbar decomression|"All patients will undergo microsurgical decompression of stenosed neural structures of the lumbar canal at all clinically significant levels with saving the posterior spinal column (type of decompression may be as unilateral, bilateral, or bilateral from a unilateral approach (over-the-top)).~Degenerative lumbar stenosis may be caused by thickened yellow and posterior longitudinal ligaments, facet joints hypertrophy, vertebral body osteophytes posteriorly, synovial (facet joints cysts) and disc cysts."
224138512|NCT04362449|COMBINATION_PRODUCT|Shortened hydration time and dispensary of Akynzeo|Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.
224138513|NCT04362449|COMBINATION_PRODUCT|Standard of care|Hydration remains at around 6 hours and 30 minutes due to no oral fluids being consumed prior to treatment and normal saline being administered for 90 minutes before cisplatin and then for 2 hours after cisplatin and before gemcitabine administration
223386377|NCT06975722|DRUG|SAR442970|Route of administration: Subcutaneous
224138514|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
224138515|NCT00313950|BIOLOGICAL|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
223386378|NCT06975722|DRUG|Placebo|Route of administration: Subcutaneous
223386379|NCT05249283|OTHER|Questionnaire Measures|Patients will complete the following questionnaires: CDS questionnaire, Niigata PPPD questionnaire, HAD (Hospital Anxiety and Depression) scale and DHI (Dizziness Handicap Inventory)
223386380|NCT04772079|DRUG|Deucravacitinib|Specified dose on specified days
223386381|NCT04772079|OTHER|Placebo matching deucravacitinib|Specified dose on specified days
223545600|NCT01616277|DRUG|Placebo|Placebo for PF-06252616, IV infusion, single dose
223545601|NCT01791660|DEVICE|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
223386382|NCT05685797|PROCEDURE|Herpes zoszter (acute)with inter vention|nerve block
223545602|NCT01396356|PROCEDURE|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
223545603|NCT03842046|PROCEDURE|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
224124725|NCT06929715|OTHER|Placebo Intervention - First Aid (Excluding Basic CPR)|In the control arm, participants receive a structured first aid educational program that intentionally excludes any training on the first link in the chain of survival. This intervention focuses on general first aid skills-such as wound care, management of minor injuries, and other non-cardiac emergency procedures-ensuring that no content related to recognizing a cardiac emergency or activating the emergency response system is provided. Delivered in a classroom setting by qualified personnel, the program is designed to mirror the overall structure, duration, and engagement level of the CPR intervention without overlapping its core content. Expert validation has been obtained to confirm that the curriculum remains neutral and strictly adheres to general first aid, thereby serving as a robust comparator to isolate the specific effects of CPR training in young schoolchildren.
224124726|NCT04902703|DRUG|Sargramostim|Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
224124727|NCT04902703|DRUG|Saline - placebo comparator|Saline will be administered subcutaneously, 5 days/week, for 24 weeks
224124728|NCT06910124|BIOLOGICAL|Linvoseltamab|"Participants will receive Linvoseltamab intravenously (IV) according to the following schedule and regimen, for up to 24 cycles, each cycle lasting 28 days:~* Cycle 1 Day 1: 5mg~* Cycle 1 Day 8: 25mg~* Cycle 1 Days 15, 22: 100mg~* Cycles 2 and 3, Days 1, 8, 15, 22: 100mg~* Cycles 3 and 6, Days 1 and 15: 100mg~* Cycles 7 through 24: 100mg"
224124729|NCT06910124|DRUG|Lenalidomide|Participants will take 10mg of Lenalidomide maintenance therapy standard of care by mouth daily from days 1 through 21 of each 28 day cycle of Linvoseltamab therapy. Lenalidomide therapy will begin on Cycle 2 Day 1 of Linvoseltamab therapy.
224124730|NCT07099560|PROCEDURE|Ultrasound-guided sacral erector spinae plane block (sESPB)|After induction of general anesthesia, bilateral sESPB is performed under ultrasound guidance. Needle advanced to the sacral interfascial plane near the median sacral crest; after negative aspiration, bupivacaine 0.25% at 0.5-1 mL/kg (max total 20 mL) is injected. Standardized perioperative care; rescue pethidine 0.5 mg/kg if FLACC ≥4.
223386383|NCT06575153|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
223386384|NCT03346954|OTHER|[11C]-Methionine PET/MRI|Implementation \[11C\]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The \[11C\]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
223386385|NCT06284954|BIOLOGICAL|Empasiprubart IV|Intravenous infusion with Empasiprubart IV
223730042|NCT03323931|BEHAVIORAL|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
224004066|NCT07135310|BEHAVIORAL|STROKE 120 multifaceted intervention campaign|"Based on the existing usual health policy, the intervention group will implement a STROKE 120 multifaceted intervention campaign in the intervention community units for a continuous period of 12 months (3-month intensive period and 9-month maintenance period).~The detailed implementation plan for the STROKE 120 multifaceted intervention campaign in the intervention group is as follows:~1. Training medical workers in stroke center;~2. Training emergency center staff and primary care physicians;~3. Conducting public education;"
223386386|NCT06284954|OTHER|Placebo IV|Intravenous infusion with Placebo IV
223386387|NCT00707473|DRUG|Carboplatin|Given IV
224004067|NCT01963637|DEVICE|gastric tomodensitometry with gas at 3 months and 12 months|
224004068|NCT07145983|BEHAVIORAL|Structured Diabetes Education on medication Adherence and self care|Lived-experience facilitation, goal setting, real-world problem solving, and ongoing peer accountability not provided in standard clinician-led education. Peer-led, group-based sessions emphasizing lived experiences, problem-solving, and mutual support. Participants meet regularly in small groups facilitated by trained peers with diabetes. Includes structured booster follow-ups and SMS reminders to reinforce adherence and self-care.
224004069|NCT07139743|BIOLOGICAL|Obecabtagene autoleucel (obe-cel)|Obecabtagene autoleucel (obe-cel) given as a single infusion.
224004070|NCT07154264|DRUG|DZD8586|DZD8586 will be taken orally once daily on days 1-28 of each cycle.
223730043|NCT01848587|OTHER|acupuncture|
223730044|NCT01848587|OTHER|usual care|
224004071|NCT07154264|DRUG|Venetoclax|Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.
224138516|NCT00313950|BIOLOGICAL|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
223386388|NCT00707473|OTHER|Chemoradiotherapy|Undergo chemoradiotherapy
223386389|NCT00707473|DRUG|Cisplatin|Given IV
223386390|NCT00707473|PROCEDURE|Definitive Surgical Resection|Undergo surgery
223386391|NCT00707473|DRUG|Docetaxel|Given IV
223386392|NCT00707473|DRUG|Fluorouracil|Given IV
223386393|NCT00707473|PROCEDURE|Quality-of-Life Assessment|Correlative studies
223386394|NCT00707473|RADIATION|Radiation Therapy|Undergo radiation therapy
223386395|NCT04895709|DRUG|BMS-986340|Specified dose on specified days
223386396|NCT04895709|DRUG|BMS-936558-01|Specified dose on specified days
223386397|NCT04895709|DRUG|Docetaxel|Specified dose on specified days
223386398|NCT05272826|DRUG|Iberdomide|Available as formulated capsules and administered as oral medication
223386399|NCT05272826|DRUG|Bortezomib|Administered as subcutaneous injection
223386400|NCT05272826|DRUG|Dexamethasone|Administered as oral medication
223386401|NCT05272826|DRUG|Isatuximab|Administered as subcutaneous injection
223386402|NCT03520647|DRUG|Cyclophosphamide|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
223386403|NCT03520647|OTHER|Peripheral Blood Stem Cells|This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
223386404|NCT02470338|PROCEDURE|MBP plus arthroscopy (Group A)|
223386405|NCT02470338|PROCEDURE|MBP alone (Group B)|
223386406|NCT06002828|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223386407|NCT06002828|OTHER|Quality-of-Life Assessment|Complete questionnaires
224124731|NCT07099560|PROCEDURE|Ultrasound-guided caudal epidural block|After induction of general anesthesia, caudal epidural injection via sacral hiatus under ultrasound guidance; after negative aspiration, bupivacaine 0.25% at 0.5-1 mL/kg (max total 20 mL) is injected. Standardized perioperative care; rescue pethidine if FLACC ≥4.
224124732|NCT03321552|PROCEDURE|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
223386408|NCT06002828|OTHER|Questionnaire Administration|Complete questionnaires
223386409|NCT06285253|COMBINATION_PRODUCT|miroliverELAP treatment|Subject's blood will be perfused through a bioengineered liver graft via an extracorporeal blood circuit.
224124733|NCT03321552|DEVICE|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
223386410|NCT05490446|DRUG|Tebapivat|Tebapivat Tablet
223386411|NCT04141826|DIETARY_SUPPLEMENT|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
223386412|NCT04141826|DIETARY_SUPPLEMENT|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
223386413|NCT04141826|DIETARY_SUPPLEMENT|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
223386414|NCT03164538|BEHAVIORAL|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
223386415|NCT03164538|BEHAVIORAL|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
223386416|NCT00535405|DRUG|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
223386417|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
223386418|NCT00535405|DRUG|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
223386419|NCT00535405|DRUG|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
223386420|NCT00535405|DRUG|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
223386421|NCT00327756|DRUG|Coenzyme Q10|
223386422|NCT01404676|DRUG|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
223386423|NCT01404676|DRUG|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
223545604|NCT03842046|PROCEDURE|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
223545605|NCT03762460|OTHER|Online eHealth tool|Mobile-optimized online eHealth tool to support MBC.
223545606|NCT03762460|OTHER|Informational website|Participants randomized to this group will receive information about online resources for mental health
224124734|NCT06943495|DRUG|177Lu-PSMA-617|6 cycles of personalized activity (1st cycle based on BSA and eGFR; cycles 2-6 based on renal dosimetry), maximum 22.2 GBq, every 6 weeks
224124735|NCT06943495|DRUG|177Lu-PSMA-617|6 cycles of 7.4 GBq every 6 weeks
224124736|NCT07151118|OTHER|Blood Sampling for ctDNA Analysis|Approximately 20 mL of peripheral blood will be collected from patients with advanced biliary tract cancer. Samples will be obtained prior to systemic therapy initiation (in about two-thirds of patients) or prior to subsequent therapy (in about one-third of patients). Additional blood draws may be performed at progression in patients with FGFR2 fusion, IDH1 mutation, or HER2 amplification. Collected samples will be centrally analyzed for genomic alterations using ctDNA profiling.
224138517|NCT05971953|OTHER|Muscle Energy Technique|"They would be receiving treatment as follow:~The patient is instructed to gently attempt to push down on the practitioner's shoulder with the leg against the practitioner's resistance( 75% of his and her available strength). After the relaxation, the muscle is lengthened more aggressively beyond the barrier and held for up to 15 seconds. Frequency: 10 reps for 4 times/week for 2 consecutive weeks. Intensity: moderate intensity (pain free) Time: 20 mins"
223545607|NCT03689569|DIETARY_SUPPLEMENT|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
223545608|NCT03689569|BEHAVIORAL|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
223730045|NCT04346537|DEVICE|INGEVITY+™ Pace/Sense Lead|The INGEVITY+ lead is indicated for chronic pacing and sensing in the right atrium and/or right ventricle when used with a compatible pulse generator.
224004072|NCT07155642|OTHER|yoga|"Participants in the yoga group received a total of 8 weeks of intervention, conducted 3 days a week, for 60 minutes per day. The program components were: • 8 minutes of meditation practice. • 40 minutes of Yin and Yang yoga postures. (It's highly recommended to briefly explain what Yin and Yang yoga postures specifically entail in the full paper's methodology section, e.g., Yin yoga focuses on holding passive poses for longer durations to target deep connective tissues, while Yang yoga incorporates more active, flowing sequences to build strength and flexibility.) • 2 minutes of breathing exercises (pranayama). • 10 minutes of deep relaxation (savasana)."
224004073|NCT07155642|OTHER|conventional physiotheraphy|"Participants in the conventional physiotherapy group also underwent an 8-week program, 3 days a week, for 60 minutes per day. This program included:~* Aerobic exercises.~* Stretching exercises.~* Strengthening exercises.~* Spinal stabilization exercises.~* Balance exercises."
224004074|NCT02537210|DRUG|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
224004075|NCT02537210|DRUG|Placebo oral capsule|Patients will be prescribed placebo 5 capsules daily for 12 months
224004076|NCT02558127|GENETIC|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
224004077|NCT01253135|BIOLOGICAL|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
224004078|NCT01253135|OTHER|White Petrolatum|Topical application
224004079|NCT02816775|DEVICE|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
224004080|NCT02816775|DEVICE|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
224004081|NCT02712073|OTHER|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
224004082|NCT03788603|DRUG|Rogaratinib (BAY1163877)|Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
224004083|NCT02285296|OTHER|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
224004084|NCT04532229|DRUG|Nimotuzumab+CRT(concurrent IMRT and TMZ)|"Drug: Nimotuzumab Concurrent radiochemotherapy period, 150mg/m2, weekly, for 6 weeks; Maintenance period, from the 7th to the 52nd week, 150mg/m2, every two weeks until disease progression or intolerable toxicity.~Other Names: h-R3~Drug: Temozolomide Concurrent radiochemotherapy period, 75mg/m2, daily, for 6 weeks; Maintenance period, rest from the 7th to 10th weeks, from the 11th week, 150-200mg/m2, day1 to day5, 21 days for a cycle, for 6 cycles.~Other Names: TMZ"
224004085|NCT05702697|DEVICE|focus extracorporeal shock wave therapy|F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.
224004086|NCT05702697|BEHAVIORAL|Home stretching program|The leaflet on hamstring stretching exercises (in a sitting posture)
224004087|NCT05290753|DRUG|Prokinetic Motility Agents as primpiram and gastreg|Prospective cohort study to evaluate the effect of pro kinetic use in emergency intestinal anastomosis
224004088|NCT02567760|DIETARY_SUPPLEMENT|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
224004089|NCT02567760|OTHER|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
224004090|NCT01802151|DIETARY_SUPPLEMENT|B. subtilis R0179|B. subtilis R0179 for a period of 4 weeks. One capsule per day.
224004091|NCT01802151|DIETARY_SUPPLEMENT|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
224004092|NCT00129480|BEHAVIORAL|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
224004093|NCT06298240|OTHER|nursing procedure for acute health problems of low complexity|An agreed nursing procedure is applied for users of a primary care emergency center who spontaneously consult for 5 acute health problems of low complexity: gastroenteritis, cystitis in women, dental pain, upper respiratory tract affections and acute wounds
223425604|NCT03085238|DEVICE|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity. Up to three (3) M-Trap devices will be surgically implanted via laparotomy in the right and left paracolic (pelvic) gutters and behind segment 6 of the liver within the peritoneal cavity of the patient at the time of surgical resection. Patients will receive standard platinum-based chemotherapy. If the cancer is diagnosed to have recurred, M-Trap devices with captured tumor cells will be removed via minimally invasive surgery (laparoscopy).
224004094|NCT06390852|PROCEDURE|Biopsy Procedure|Undergo biopsy
224004095|NCT06390852|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223425605|NCT05896527|DRUG|DC-806|DC-806 was supplied as tablets to be administered orally.
224004096|NCT06390852|PROCEDURE|Computed Tomography|Undergo CT scan
224004097|NCT06390852|DRUG|Larotrectinib|Given PO
224004098|NCT06390852|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223730046|NCT01134783|BEHAVIORAL|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
223730047|NCT04829903|DRUG|Dulaglutide|Dulaglutide injections
223730048|NCT04829903|DRUG|Liraglutide|Liraglutide injections
223730049|NCT04221009|BEHAVIORAL|MI and CBT 4-session manualized intervention|This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
223425606|NCT05896527|OTHER|Placebo|Matching placebo was supplied as tablets to be administered orally.
224004099|NCT03997175|OTHER|Biodiversity powder|Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
224004100|NCT03997175|OTHER|Placebo|Sand that looks like intervention sand but does not have high biodiversity
224004101|NCT00491166|DRUG|Bromfenac ophthalmic solution|
224004102|NCT05321277|DIETARY_SUPPLEMENT|Walnuts|Participants will consume 56 g of walnuts daily for 3 weeks. Participants will also follow a diet devoid of ellagitannin-rich, high fiber, and fermented foods.
224004103|NCT05321277|DIETARY_SUPPLEMENT|No-nut diet|Participants will exclude all nuts and nut-derived products; high-fiber, fermented and ellagitannin-rich foods will also be excluded.
224004104|NCT00833261|DRUG|cetuximab|cetuximab
224004105|NCT00833261|DRUG|cisplatin|cisplatin
224004106|NCT00833261|RADIATION|intensity-modulated radiation therapy|IMRT
224004107|NCT00833261|DRUG|Nab-Paclitaxel|Nab-Paclitaxel
224004108|NCT04716777|BEHAVIORAL|Brief Transdiagnostic group-based Cognitive-Behavioral Treatment|Weekly group-based transdiagnostic CBT sessions for eight weeks.
224004109|NCT04151589|BEHAVIORAL|ANGEL Intervention Package and Toolbox|The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
224004110|NCT03544853|DEVICE|Prosthetic socket for transtibial amputee|To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
224124737|NCT07151716|DRUG|Dexmedetomidine|"For patients with endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.2 μg/kg/h dexmedetomidine and increased/decreased by 0.1 μg/kg/h dexmedetomidine every 15 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches 0.7 μg/kg/h dexmedetomidine, or adverse reactions occur. Daytime (06:00-20:00) sedation is provided as above when considered necessary, with a target RASS score of -2 to +1.~For patients without endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.10 μg/kg/h dexmedetomidine and increased/decreased by 0.05 μg/kg/h dexmedetomidine every 15 min, until the RASS reaches -1, maximal infusion rate reaches 0.2 μg/kg/h dexmedetomidine, or adverse reactions occur. Daytime (06:00-20:00) sedation is typically not provided."
224004111|NCT03753698|DEVICE|eCoin|"Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient."
224004112|NCT02930395|PROCEDURE|serum S100B assay|
224004113|NCT05500677|DRUG|Lidocaine topical|Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
224004114|NCT04496245|DRUG|Broncho-Vaxom®|Broncho-Vaxom adult capsules® (OM85)
224004115|NCT06126458|OTHER|shooting performance|collecting total points after 72 target shootings done
224004116|NCT04850872|BEHAVIORAL|PLAYwithHEART Programme for adolescent athletes|PLAYwithHEART programme for adolescent athletes is an intervention programme based on Mindfulness, Acceptance, and Compassion for adolescent athletes
224004117|NCT04542213|DRUG|Linagliptin tablet|Linagliptin 5mg once daily plus a basal-bolus insulin scheme
224138518|NCT05971953|OTHER|Conventional PT|"They would be receiving conventional treatment as follow:~including hot pack for 10 mins ischemic compression for 60 seconds .Frequency: 5 reps with 60 sec hold for 4 times/week for 2 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 mins"
224299207|NCT02423356|PROCEDURE|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
224004118|NCT04542213|DRUG|Insulin|Basal-bolus insulin scheme
224004119|NCT05758948|DIAGNOSTIC_TEST|NGS in blood and Formalin-Fixed Paraffin-Embedded (FFPE) tissue|In patients with denovo metastatic breast cancer blood and tissue sample will be collected and then further analysed using NGS in order to detect somatic and germline pathogenic variants
223425607|NCT02666196|DRUG|DAA-I|
223425608|NCT02666196|DRUG|Placebo|
224004120|NCT02863770|OTHER|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
224004121|NCT02490033|DEVICE|Ablation Catheter|
223425609|NCT01279070|BEHAVIORAL|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
223545609|NCT03689569|BEHAVIORAL|Starch|Patients will be given 30 grams of corn starch
223545610|NCT06281977|DRUG|Dexmedetomidine|Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
223545611|NCT06281977|DRUG|Normal saline|Programed as dexmedetomidine on infusion pump.
223545612|NCT00400517|BIOLOGICAL|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
223545613|NCT00400517|DRUG|thalidomide|doses up to 400 mg/day
223545614|NCT00400517|PROCEDURE|conventional surgery|SOC care surgery
223545615|NCT00400517|PROCEDURE|neoadjuvant therapy|post radical prostatectomy
223545616|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
223545617|NCT01692743|BEHAVIORAL|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
223545618|NCT04404673|PROCEDURE|Evaluation of urinary and sexual dysfunction after rectal resection|Comparison among the 4 different surgical approaches for urinary and sexual function
223386424|NCT03298217|DEVICE|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
224004122|NCT00954889|DRUG|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
224004123|NCT00954889|DRUG|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
224004124|NCT00962377|PROCEDURE|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
224004125|NCT00962377|PROCEDURE|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
224004126|NCT05912829|DEVICE|IOL Master 700|Biometry using the IOL Master 700
224004127|NCT05912829|DEVICE|Casia-2|Anterior segment-OCT to evaluate lens tilt
224004128|NCT05912829|DEVICE|MS-39|Corneal Topography using the MS-39
224004129|NCT05912829|DEVICE|OSIRIS|Abberometry using the OSIRIS-Abberometer
224124738|NCT07151716|DRUG|Dexmedetomidine-esketamine combination|"For patients with endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.1 μg/kg/h dexmedetomidine and 0.05 mg/kg/h esketamine, increased/decreased by 0.05 μg/kg/h dexmedetomidine and 0.025 mg/kg/h esketamine every 15 min, until the RASS reaches -2 to -1, maximal infusion rate reaches 0.35 μg/kg/h dexmedetomidine and 0.175 mg/kg/h esketamine, or adverse reactions occur. Daytime (06:00-20:00) sedation is provided as above when considered necessary, with a target RASS score of -2 to +1.~For patients without endotracheal intubation, nighttime (20:00-06:00) sedation is initiated with 0.05 μg/kg/h dexmedetomidine and 0.025 mg/kg/h esketamine, and increased/decreased by 0.025 μg/kg/h dexmedetomidine and 0.0125 mg/kg/h esketamine every 15 min, until the RASS reaches -1, maximal infusion rate reaches 0.1 μg/kg/h dexmedetomidine and 0.05 mg/kg/h esketamine, or adverse reactions occur. Daytime (06:00-20:00) sedation is typically not provided."
224124739|NCT07160621|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Receive mobile CBT
224124740|NCT07160621|BEHAVIORAL|Education|Receive educational materials
224124741|NCT07160621|OTHER|Questionnaires|Ancillary studies
223386425|NCT01340131|DRUG|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
223386426|NCT01340131|DRUG|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
223386427|NCT03858010|DIAGNOSTIC_TEST|Wheeze and me questionnaire|validation of questionnaire assessing disease control and quality of life in preschool children with recurrent wheeze
223386428|NCT00264901|DRUG|insulin detemir|
223386429|NCT00173511|DEVICE|24 hr Holter monitor|
223386430|NCT02819089|DRUG|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
223386431|NCT02819089|OTHER|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
223386432|NCT05469334|BEHAVIORAL|DeStress for Health Program Participants|Behavioral: DeStress for Health Program The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals, with an additional class five as a check in that will be used for survey completion. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
223545619|NCT00104338|DRUG|FK778|
223545620|NCT00353301|DRUG|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
224004130|NCT05912829|DEVICE|Autorefractor|Evaluation of Refraction using an Autorefractor
224004131|NCT05912829|DIAGNOSTIC_TEST|Subjective Refraction|Refraction performed by experienced staff
224004132|NCT05912829|DIAGNOSTIC_TEST|Biomicroscopy|Slit Lamp Examination
224004133|NCT02116790|DRUG|Naproxen|Subjects will take one 250mg Naproxen capsule
224004134|NCT02116790|DRUG|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
224004135|NCT02116790|DRUG|Sinemet|Subjects will take one 25mg/100mg Sinemet.
224004136|NCT02116790|DRUG|Placebo|Subjects will take two placebos.
224004137|NCT05245552|BIOLOGICAL|Quadrivalent influenza vaccine(0.25ml)|7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
224004138|NCT05245552|BIOLOGICAL|Quadrivalent influenza vaccine(0.5ml)|15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
224004139|NCT05245552|BIOLOGICAL|Trivalent influenza vaccine(BV)|7.5μg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
224004140|NCT05245552|BIOLOGICAL|Trivalent influenza vaccine(BY)|7.5μg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses of quadrivalent influenza vaccine on day 0, 28.
223386433|NCT06429293|BEHAVIORAL|Cognitive processing therapy|The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician
223386434|NCT02765256|DRUG|Fluconazole|400mg orally once daily (Day 1-14)
223386435|NCT02765256|DRUG|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
223386436|NCT02765256|DRUG|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
223386437|NCT02765256|DRUG|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
223386438|NCT02765256|DRUG|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
223386439|NCT02765256|DRUG|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
223386440|NCT02765256|DRUG|Fluconazole placebo|Once daily
224004141|NCT06335485|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will attend 4 CBT sessions prior to surgery and 2 optional sessions after surgery.
224004142|NCT03675373|BEHAVIORAL|Mobile chat-based instant messages|"Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques."
224004143|NCT03675373|BEHAVIORAL|Alcohol brief intervention|Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
224004144|NCT04292353|OTHER|Cognitive tests and Patient Reported Outcome|
224004145|NCT06097351|OTHER|Grouping based on previous laboratory results, no intervention.|The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken
224004146|NCT01914601|DEVICE|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
224004147|NCT01914601|DEVICE|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
224004148|NCT00008359|DRUG|caspofungin acetate|
224295794|NCT02590835|PROCEDURE|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
224004149|NCT00008359|DRUG|liposomal amphotericin B|
224004150|NCT04422327|DIETARY_SUPPLEMENT|Probiotic capsule|"Each probiotic capsule contains 5 x 10\^8 CFU B. longum 35624® and 5 x 10\^8 CFU B. longum 1714™ with corn starch and magnesium stearate.~The probiotic capsule will be supplied by PrecisionBiotics Ltd."
224299208|NCT03326609|DRUG|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
223545621|NCT00353301|DRUG|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
223386441|NCT01915030|OTHER|High protein diet|controlled feeding trail. Both arms are caloric restricted
223386442|NCT01915030|OTHER|standard protein diet|
223386443|NCT02534389|DIETARY_SUPPLEMENT|omega-3 fish oil|2,4g of EPA + DHA
223386444|NCT00478517|DRUG|Erythropoetin (rHuEPO, EPREX®)|
223386445|NCT02969044|DRUG|Placebo|
223386446|NCT02969044|DRUG|PF-06651600|200mg pill every day (QD) for 8 weeks
223386447|NCT04139824|DRUG|Xanthine Oxidase Inhibitor|LC350189 200mg qd
223386448|NCT04139824|DRUG|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
223386449|NCT04662814|OTHER|shock wave therapy|Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.
223545622|NCT02831855|DRUG|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
223545623|NCT02831855|DRUG|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
223545624|NCT02831855|DRUG|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
223545625|NCT02785783|DEVICE|Standard colonoscopy|
223545626|NCT02785783|DEVICE|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
223386450|NCT04662814|OTHER|dietary modification|Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months
223386451|NCT04728802|DRUG|Proxalutamide|Proxalutamide 300mg q.d
223386452|NCT04728802|DRUG|Placebo|Placebo pill
223386453|NCT01176513|DRUG|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
223386454|NCT06188221|DRUG|Lidocaine|The group with the lidocaine will get a combined injection with a corticosteroid and lidocaine. The dosages depend on the disease.
224004151|NCT01695031|BEHAVIORAL|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
224004152|NCT01695031|BEHAVIORAL|Generic web-based education|Generic, web-based asthma education
224004153|NCT00559312|DRUG|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
224004154|NCT00559312|DRUG|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
224004155|NCT00678431|DIETARY_SUPPLEMENT|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
224004156|NCT00678431|DIETARY_SUPPLEMENT|Placebo|Liquid placebo
224004157|NCT00902928|DRUG|YM150|oral
224004158|NCT00902928|DRUG|enoxaparin|SC injection
224004159|NCT06151028|OTHER|No intervention|This is an observational study and did not involve interventions.
224004160|NCT03248882|DRUG|Placebo|Placebo
224004161|NCT03248882|DRUG|PF-05221304|PF-05221304, Experimental Drug
224004162|NCT01457482|OTHER|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
224004163|NCT01457482|OTHER|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
224004164|NCT03625180|BIOLOGICAL|NAMIC: nanofractured autologous matrix-induced chondrogenesis|the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
224004165|NCT00269438|DRUG|5 ASA, enemas, suppositories, corticosteroids|
224004166|NCT03813277|DRUG|Dexmedetomidine|infusion
224004167|NCT02557529|BEHAVIORAL|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
223386455|NCT06188221|DRUG|Corticoids|The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
223545627|NCT04475159|PROCEDURE|Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)|Pressurized Intraperitoneal Aerosol Chemotherapy will be delivered to the abdominal cavity by means of laparoscopy.
224004168|NCT02557529|BEHAVIORAL|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
224004169|NCT02557529|BEHAVIORAL|Diet diary|Weekly diet diary during the 12-weeks intervention
224004170|NCT01917721|DRUG|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
224004171|NCT01917721|DRUG|Placebo|Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
224004172|NCT00626626|DRUG|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
224124742|NCT07158632|BEHAVIORAL|handwashing education|Arm A: This arm receive handwashing education using social and behavioral change communication
224124743|NCT07158632|BEHAVIORAL|water chlorination|Arm B: This arm receives water chlorination intervention
224124744|NCT07158632|BEHAVIORAL|combined intervention|Arm C: This arm receives combined handwashing and water chlorination intervention
224299209|NCT02775474|DRUG|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
223386456|NCT04588168|DRUG|Chemotherapy|Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.
223386457|NCT04588168|DIAGNOSTIC_TEST|Immediate Multiparametric MRI|Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.
223386458|NCT04588168|PROCEDURE|Cystectomy and Lymphadenectomy|The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.
223386459|NCT04588168|DIAGNOSTIC_TEST|conventional Multiparametric MRI|After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.
223545628|NCT05794737|BIOLOGICAL|Immunohistochemical staining|Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
223386460|NCT04588168|DIAGNOSTIC_TEST|Baseline Multiparametric MRI|Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.
223386461|NCT00316758|DRUG|GK Activator (2)|Escalating doses bid
223386462|NCT00316758|DRUG|Metformin|As prescribed, in patients who were in study BM18249
223386463|NCT06492122|DRUG|[225Ac]Ac-FL-020|\[225Ac\]Ac-FL-020 injected intravenously
223386464|NCT06492122|DRUG|Blood samples for PK|Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
223386465|NCT06492122|DRUG|[111In]In-FL-020|A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation
224004173|NCT00626626|DRUG|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
224004174|NCT02625688|OTHER|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
224004175|NCT02625688|OTHER|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
224004176|NCT02625688|OTHER|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
224004177|NCT04235829|PROCEDURE|Laparoscopic sleeve gastrectomy|Form of obesity surgery
224004178|NCT02553967|DEVICE|Functional MRI|Functional MRI
224004179|NCT05358041|DEVICE|Robotic Bronchoscopy|Replace the Super-D EMN navigational platform with Ion Robotic bronchoscopy platform guided with shape sensing technology
224004180|NCT01156376|DEVICE|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
224004181|NCT01156376|DEVICE|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
224004182|NCT01156376|DEVICE|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
224004183|NCT05293977|BEHAVIORAL|Routine care by the dispensing pharmacist|Patients in the control group received routine care by the dispensing pharmacist and seen by research assistant for data collection only
224004184|NCT05293977|BEHAVIORAL|Pharmaceutical education/counseling about prescribed antibiotic|Patient in the intervention group was provided with pharmaceutical education about his/her prescribed antibiotic by the trained clinical pharmacist. To prepare the education about antibiotics, the 10 most commonly prescribed antibiotics were determined in advance from hospital records: Amoxicillin or Amoxicillin/Clavulanic acid, Ciprofloxacin, Levofloxacin, Azithromycin, Cefuroxime, Cephalexin, Clindamycin, Doxycycline, Metronidazole, Trimethoprim/Sulfamethoxazole. Standard education points about antibiotics include (i) mechanism of action and/or use, (ii) correct administration method, (iii) correct timing, (iv) possible adverse effect and self-management intervention methods when faced with side effects, (v) what to do in case of missing any dose.
224004185|NCT03858829|OTHER|Psychometric analysis|Psychometric analysis
224004186|NCT04495075|OTHER|Visuomotor Therapy|"The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed visuomotor therapy. Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback."
224004187|NCT04495075|OTHER|Passive Motion|The knee is passively moved through a range of motion.
223386466|NCT06492122|PROCEDURE|Blood and urine samples collection|For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020
223386467|NCT06492122|PROCEDURE|SPECT/CT images|For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
223386468|NCT04423952|OTHER|COMQ-12 questionnaire|Subjects respond to COMQ-12 questionnaire twice at 15 days apart. COMQ-12 : quality of life measurement questionnaire related to chronic otitis media.
223386469|NCT03714919|DRUG|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
223386470|NCT03714919|DRUG|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
223386471|NCT03714919|DRUG|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
223386472|NCT03714919|DRUG|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
223386473|NCT06529471|OTHER|Massage group|The patient in the massage group will be visited by the practitioner 3 times at 10:00-14:00-20:00 on the first day after surgery and a back massage will be applied. The patient in the massage group will be placed in an orthopnea position during the application. The massage procedure lasts an average of 30 minutes and is applied to the cervical 3 and thoracic 12 vertebrae.
223386474|NCT03282916|DRUG|Valacyclovir|Valacyclovir hydrochloride 500mg caplet
223386475|NCT03282916|DRUG|Placebo|Placebo sugar pill 500mg caplet
223730050|NCT02498860|DRUG|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
223386476|NCT06350578|PROCEDURE|Hall Crown Technique|The Hall technique (HT) involves cementing Stainless Steel Crowns SSC on carious primary teeth without using rotary instruments nor local anaesthesia, thus eliminating discomfort, and increasing child's behavior.
224004188|NCT02997826|OTHER|Infantil formula|
224004189|NCT02005575|DRUG|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
224004190|NCT02005575|DRUG|Placebo|
224124745|NCT07162558|BEHAVIORAL|Child-Centered Empowerment Intervention|"Participants in this group receive the child-centered empowerment program, a structured behavioral intervention designed to enhance coping skills, promote self-efficacy, and improve lifestyle in children with leukemia. The program is based on four dimensions of empowerment:~Perceived Threat: Increasing awareness of illness, its complications, and the treatment process through group discussions.~Self-Efficacy: Practicing problem-solving and self-management techniques to strengthen self-belief, self-control, and confidence in handling illness-related challenges.~Educational Participation: Children receive educational cards at the end of each session and are encouraged to share the learned content with family members to reinforce responsibility and engagement.~Evaluation: Continuous follow-up and assessment of learning after each session to ensure understanding and active participation."
224124746|NCT07162064|DRUG|Heparin - Therapeutic dosage|Intra-arterial sheath injection of heparin 2500 units before operation
224124747|NCT07162064|DRUG|Saline (0.9% NaCl)|Intra-arterial sheath injection of 2mL saline (0.9% sodium chloride)
224124748|NCT07163234|DEVICE|Cardiac surgery|cardiac surgery
224124749|NCT07162883|DRUG|QL2107|IV infusion.
224124750|NCT07162883|DRUG|Keytruda®|IV infusion.
224124751|NCT07163572|DRUG|Intravenous brivaracetam|Patients received intravenous brivaracetam as a loading dose of 2 mg/kg (maximum 100 mg) diluted in 100 ml of normal saline infused over 10 minutes.
224124752|NCT07163572|DRUG|Intravenous levetiracetam|Patients received intravenous levetiracetam as a loading dose of 40 mg/kg (maximum 3000 mg) diluted in 100 ml of normal saline infused over 10 minutes.
224124753|NCT07161791|DRUG|Camrelizumab Combined With Pirfenidone and Chemotherapy|"Treatment Regimen:~Camrelizumab: 200 mg intravenous (IV) every 3 weeks (q3w). Pirfenidone: 200 mg three times daily (tid), escalated to 600 mg tid based on tolerability.~Chemotherapy: Investigator's choice of standard regimens (e.g., paclitaxel 175 mg/m² IV q3w or capecitabine 1000 mg/m² orally bid on days 1-14 of a 21-day cycle)."
224124754|NCT07164118|BEHAVIORAL|Pranayama Breathing Exercise|Pranayama breathing technique consisting of 6 cycles, demonstrated by the researcher before the operation, supported by the brochure, and lasting 8-10 minutes every 2 hours from the 4th post-operative hour.
224124755|NCT07164118|BEHAVIORAL|Deep Breathing Exercise|Deep breathing exercise, demonstrated one-on-one before surgery and supported by a guide, applied 6 times every 2 hours from the 4th post-operative hour onwards.
224124756|NCT07162285|DEVICE|Delivery Room Bubble CPAP|delivery room bubble CPAP initiated within 10 minutes of birth for preterm neonates \<34 weeks, using water-seal oscillation system via nasal prongs.
224124757|NCT07162285|OTHER|Delivery Room Supplemental Oxygen|Standard oxygen therapy initiated within 10 minutes of birth via mask/tubing, without positive pressure support.
224124758|NCT07162311|DEVICE|tDCS|Home-Based Transcranial Direct Current Stimulation
224124759|NCT07163325|DRUG|EP102|EP102 will be administered orally
224124760|NCT07163910|DRUG|homoharringtonine|Intravenous infusion of 1mg homoharringtonine plus 250ml of 5% glucose injection, administered once daily for two consecutive days.
224124761|NCT07163910|PROCEDURE|Radical prostatectomy|All patients will undergo radical prostatectomy within 3 weeks (±7 days) after the completion of treatment.
224124762|NCT07163312|PROCEDURE|Endovenous Ablation for Varicose Veins|Participants will receive standard endovenous treatment for lower limb varicose veins as part of their routine clinical care. The procedure may include radiofrequency ablation (RFA), endovenous laser ablation (EVLA), or other accepted thermal ablation techniques, with or without adjunctive phlebectomy or foam sclerotherapy if clinically indicated. The intervention is performed under tumescent local anesthesia by vascular surgeons according to established guidelines. No experimental techniques or investigational devices are used.
224124763|NCT07163351|OTHER|CAD/CAM allogenic bone block|CAD/CAM allogenic bone block augmentation with immediate non-functional implant loading
224124764|NCT07162961|DRUG|Nintedanib|Participants will be randomly assigned to one of two groups: the Experimental Group will receive oral nintedanib (100 mg twice daily) plus progesterone therapy for three months; the Control Group will receive progesterone therapy only.
223730051|NCT02498860|DRUG|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
224124765|NCT07162961|DRUG|Progesterone|For control group
224124766|NCT07161986|BEHAVIORAL|Mindfullness based Sobriety (MBS)|MBS is combination of Mindfullness , Relapse prevention, motivational interviewing , acceptance and commitment therapy. It helps in dealing underlying depression and anxiety issues among Polysubstance use. it Cover most of underlying problem faced by person with addiction.
224124767|NCT07163338|OTHER|Collectio nof blood|Collection of an additional volume of blood in the initial blood test.
223730052|NCT05780333|PROCEDURE|TAP block|Bilateral tap block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
223730053|NCT05780333|PROCEDURE|ESP block|Bilateral esp block with 20 ml of mixture 2:1:1 (0.5% bupivacaine: 0.9%NaCl: 2% lidocain) for each
223730054|NCT00133614|PROCEDURE|Prone Positioning|
223730055|NCT01080352|DRUG|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
223730056|NCT05371028|OTHER|Non-interventional Study|This is non-interventional study.
224004191|NCT01616004|DRUG|N2O|
223386477|NCT06350578|PROCEDURE|Conventional SSC Technique|The conventional technique involves complete removal of the carious lesion using rotary instruments and local anesthesia, then restoring the tooth with Stainless Steel Crown SSC.
224004192|NCT01616004|DRUG|Air|sham comparator
224004193|NCT00304304|BEHAVIORAL|Asthma education|Research assistant worked with CCC staff on asthma prevention
224004194|NCT03808701|DRUG|SCT200|Recombinant Anti-EGFR Monoclonal Antibody
224004195|NCT00292422|DRUG|BG9924|
224004196|NCT02073240|BEHAVIORAL|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~1. Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~2. Audits and Feedback of performance~3. A TB IC collaborative membership~4. A standardized unit-level daily checklist of critical IC activities"
224124768|NCT07161752|DEVICE|Anatomical face mask 1|Providing face mask ventilation in a neonatal manikin using a model of anatomical face mask
224124769|NCT07161752|DEVICE|Anatomical face mask 2|Providing face mask ventilation in a neonatal manikin using another model of anatomical face mask
224124770|NCT07161752|DEVICE|Round face mask|Providing face mask ventilation in a neonatal manikin using a model of round face mask
224295795|NCT02590835|PROCEDURE|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
224295796|NCT01915693|RADIATION|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
224299210|NCT02775474|DRUG|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
223386478|NCT06854224|DRUG|Suvorexant (dual orexin receptor antagonist)|Veteran patients with Major Depressive Disorder and elevated risk of suicide will receive the FDA-approved drug Suvorexant (brand name: Belsomra), a dual orexin receptor antagonist, for four weeks. Participants will take 10mg of Surovexant nightly for the first two weeks and 20mg of Surovexant nightly for the second two weeks.
223386479|NCT06813924|DRUG|Etavopivat|Participants will receive a daily dose of etavopivat orally.
224004197|NCT05025670|BEHAVIORAL|Supportive psychotherapy|Participants will receive monthly 30-45 minute supportive psychotherapy sessions. Supportive psychotherapy is an integrative and eclectic psychotherapeutic approach, based upon the individual's needs and symptoms. It draws from elements of a variety of psychotherapeutic disciplines, including cognitive-behavior, psychodynamic, and interpersonal therapies.
223386480|NCT06813924|DRUG|Digoxin|Participants will receive a single dose of digoxin orally.
223386481|NCT06813924|DRUG|Pitavastatin|Participants will receive a single dose of pitavastatin orally.
223386482|NCT06813924|DRUG|Metformin|Participants will receive a single dose of metformin orally.
223730057|NCT04232124|BEHAVIORAL|Hypertension Management Model|"1. Blood Pressure readings by barbers~2. Clinical Pharmacist evaluation and counseling~3. Blood pressure measurement~4. Point of care basic metabolic panel measurement"
223386483|NCT06813924|DRUG|Midazolam|Participants will receive a single dose of midazolam orally.
223386484|NCT06813924|DRUG|Rosuvastatin|Participants will receive a single dose of rosuvastatin orally.
223386485|NCT06982859|DRUG|Retatrutide|Administered SC
223386486|NCT06982859|DRUG|Semaglutide|Administered SC
223730058|NCT00572702|PROCEDURE|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
223730059|NCT00572702|PROCEDURE|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
223730060|NCT04557397|DRUG|Fruquintinib|oral VEGFR inhibitor
223386487|NCT06982859|DRUG|Placebo|Administered SC
223386488|NCT06126315|DRUG|Acetyl-l-carnitine|Acetyl-l-carnitine
223730061|NCT04557397|DRUG|Itraconazole|a synthetic triazole antifungal agent
223730062|NCT04557397|DRUG|Rifampin|a semisynthetic antibiotic derivative of rifamycin SV
224004198|NCT05049057|DRUG|Erenumab 140 Mg/mL Subcutaneous Solution|Active erenumab delivered via subcutaneous injection.
224004199|NCT05049057|DRUG|Placebo|Placebo delivered via subcutaneous injection.
224004200|NCT03553199|DEVICE|TRS, Tissue Retraction System|Tissue Retraction System
223386489|NCT06126315|DRUG|Placebo|placebo
223386490|NCT03164616|DRUG|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
223386491|NCT03164616|DRUG|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
223386492|NCT03164616|DRUG|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
223730063|NCT06245330|DRUG|AST-001|liquid formulation for Intravenous infusion
223730064|NCT05253170|RADIATION|Hypofractionation|Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions
224004201|NCT03733314|DRUG|E6011|E6011, infusion, intravenously.
224004202|NCT03733314|DRUG|Placebo|Placebo, infusion, intravenously.
223730065|NCT05253170|RADIATION|Conventional Fractionation|Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
224004203|NCT04204746|OTHER|We will observe and evaluate the temperature and moisture in the respiratory circuit by a thermo-hygrometer.|
224004204|NCT05304455|DRUG|Apixaban 2.5 MG|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
224004205|NCT05304455|DRUG|Dipyridamole 25Mg Tab|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
224124771|NCT07162610|DEVICE|Rejuviel V® with lidocaine|Crosslinked hyaluronic acid (HA) 22 mg/mL + 0.3% lidocaine hydrochloride.
224124772|NCT07162610|DEVICE|JUVEDERM® VOLUMA® with lidocaine|Crosslinked hyaluronic acid (HA) 20 mg/mL + 0.3% lidocaine hydrochloride.
224004206|NCT05304455|DRUG|subcutaneous Low Molecular Weight Heparin|From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
223386493|NCT03164616|DRUG|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
224004207|NCT05955508|DRUG|Linvoseltamab|Administration by intravenous (IV) infusion
224004208|NCT01240915|DRUG|placebo|once every 7 days for 1- 3 doses
224004209|NCT01240915|DRUG|MultiStem low dose|1-3 doses
224004210|NCT01240915|DRUG|placebo|Single dose at week 8
224004211|NCT01240915|DRUG|MultiStem low dose|Single dose at week 8
224004212|NCT01240915|DRUG|placebo|Single dose Day 1
224004213|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
224004214|NCT01240915|DRUG|placebo|Single dose at week 8
224004215|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
224004216|NCT01240915|DRUG|placebo|Single dose Day 1
224004217|NCT01240915|DRUG|MultiStem high dose|Single dose Day 1
224004218|NCT01240915|DRUG|placebo|Single dose at week 8
224004219|NCT01240915|DRUG|MultiStem high dose|Single dose at week 8
224124773|NCT07163949|OTHER|Performance-based tests (such as TUG, foot posture measurements, Tandem Gait test) will be administered to children with ASD.|Children with ASD underwent balance and foot measurement tests that they could perform only by following instructions.
224124774|NCT07163754|DIAGNOSTIC_TEST|Automated Sperm Selection|This group of oocytes will be microinjected with sperm selected by the second version of SID TM (SID V2.0) wich analyses additional sperm parameters than first version of SID TM (SID V1.0).
224124775|NCT07163754|DIAGNOSTIC_TEST|Conventional Sperm Selection|Half of the oocytes will be microinjected with sperm selected by the embryologist without SID assistance, based on the conventional and visual assesment of seminal samples located at ICSI dishes.
224124776|NCT07162935|OTHER|Cigarillo brand 1|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
224124777|NCT07162935|OTHER|Cigarillo brand 2|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
224124778|NCT07162935|OTHER|Cigarillo brand 3|Participants will be assessed on puffing behavior, subjective effects, and exhaled carbon monoxide when assigned to using one of three cigarillo brands. Additives and ingredients of the cigarillo used will also be assessed
223386494|NCT03164616|DRUG|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).
223386495|NCT03164616|DRUG|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
223425610|NCT06621797|DIETARY_SUPPLEMENT|Intervention 1: Dietary Supplement - Caffeine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) taken orally 45 minutes before performance testing. No additional interventions will be administered.
224004220|NCT02441478|RADIATION|functional magnetic resonance imaging exam|
224004221|NCT02982551|DRUG|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
224004222|NCT02982551|OTHER|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
224004223|NCT02982551|OTHER|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
224004224|NCT02982551|DRUG|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
224004225|NCT03847792|DRUG|Group DB/Dexamethasone-Bupivacaine|The patient were received an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
224004226|NCT03847792|DRUG|Group FB /Fentanyl-Bupivacaine|The patient were received an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
224004227|NCT03847792|DRUG|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
224004228|NCT00682981|DRUG|Obatoclax|IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
224004229|NCT00682981|DRUG|Carboplatin/etoposide|Carboplatin/etoposide combination
224004230|NCT04571788|PROCEDURE|Foldable Capsular Buckle|Intraoperatively, the location and size of the fissure hole is located under the microscope to determine the location and extent of the conjunctival incision. Once local infiltration anesthesia is complete, a 2 ml needle is inserted into the outer surface of the sclera \>10 mm behind the corneoscleral rim, and a cotton swab is used to apply light pressure on the side of the wound to help drain the fluid. Under the microscope, the emptied and folded FCB was inserted vertically into the external scleral channel and the drainage valve was sutured with 5.0 non-absorbable sutures 8-10 mm behind the angular scleral rim. The balloon was then filled with 1 ml of alkaline Ringer's solution using a 1 ml syringe through the drainage valve. Subconjunctival injection of tobramycin and dexamethasone was followed by gentle pressure and bandaging of the eye.
223386496|NCT03164616|DRUG|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.
224004231|NCT04571788|PROCEDURE|Silicone scleral padding|Intraoperatively, the location and size of the fissure is located under the microscope to determine the location and extent of the incision of the bulbar conjunctiva. When the fissure hole is located microscopically, a retrobulbar block anesthesia is performed and fluid is released according to the degree of retinal detachment. Silicone was then implanted on the scleral surface as an external cushion and intraocular pressure was applied, and the opening was finally sutured, with laser closure performed within a week after surgery. After the surgery, subconjunctival injection of tobramycin and dexamethasone was routinely performed, and the operated eye was bandaged, with observation of the fundus and closure of the aperture.
224004232|NCT04514510|DRUG|Isoquercetin|"Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.~Isoquercetin given at 1000 mg, once daily by mouth for 28 days."
224004233|NCT04514510|DRUG|Placebo|"Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days."
224004234|NCT05892705|DRUG|Dexmedetomidine Injection [Precedex]|intrathecal injection of 5 mcg dexmedetomidine
224004235|NCT00202917|DRUG|Fludarabine|
224004236|NCT00202917|DRUG|Thiotepa|
224004237|NCT00202917|DRUG|Melphalan|
224124779|NCT07163390|COMBINATION_PRODUCT|Sideral Folico|Pregnant women will be enrolled from 24 to 32 weeks of gestation whether their hemoglobin levels are comprised between 8.5 and 10.5 g/dl. They start oral supplementation with Sucrosomial iron® 30 mg (Sideral® Folico), 2 sticks for twice a day for 15 days, followed by Sucrosomial iron ® 30 mg (Sideral® Folico), 1 stick for twice a day for the next 15 days
224124780|NCT07163793|DRUG|Azacitidine|Given Day 1-7 with Venetoclax Day 1-14 every 28 days until off study
224124781|NCT07163793|DRUG|Decitabine|Given Day 1-5 with Venetoclax Day 1-14 every 28 days until off
224124782|NCT07163793|DRUG|Venetoclax|Venetoclax up to 400mg a day on Day 1-14 every 28 days until off in combination with Azacitidine or Decitabine
224124783|NCT05310227|DEVICE|Nerivio|The device is a wireless wearable battery-operated stimulation unit controlled by a dedicated smartphone application. Treatments with Nerivio™ are self-administered by the user at the onset of a headache
224124784|NCT05625360|OTHER|eHealth Mindful Movement and Breathing|The self-directed intervention includes an approximately 20-minute eMMB will teach synergistic components: (a) Mindful Meditation - 2 minutes of observing the current state of the body, emotions, thoughts, energy, and breath. Mindful attention may facilitate safe physical movements; (b) Mindful Movement - 10 minutes of gentle movements coordinated with and intended to enhance the breath; (c) Breathing and Relaxation - 3 minutes of placing the hands above the navel (rather than on the belly to avoid discomfort) and noticing them rise and fall with a focus on slightly extending the exhale, which will prepare participants for meditation); (d) Meditation - 5 minutes of observing the natural breath without reacting to it.
224124785|NCT05625360|OTHER|Life Impacts Reflection|"This self-directed intervention will focus on active listening, reflection of statements, and avoiding negative judgments. Participants will write brief diary entries daily for four weeks postoperatively and as they choose thereafter. Participants will be given the option of completing diaries on the tablet computer or paper. The instructions for daily diary entries will be, What were some of the events or circumstances that affected you in the past day? Think back over the past day and write down on the lines below up to five events that had an impact on you. A study team member will call participants to encourage diary completion two days (Postop Day 3) and two weeks after the synchronous session."
224124786|NCT05625360|OTHER|PROMIS Questionnaires|Various PROMIS questionnaires will be completed by participants (Pain Interference, Sleep Disturbance, Physical Function, Anxiety and Depression)
224124787|NCT05459077|BEHAVIORAL|Hypertension control through education and monitoring|Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
224124788|NCT05137262|OTHER|Abiraterone acetate|Given by IV
224124789|NCT05137262|DRUG|Durvalumab|Given by IV
224124790|NCT05137262|DRUG|Methotrexate|Given by IV
224124791|NCT05137262|DRUG|Vinblastine|Given by IV
224124792|NCT05137262|DRUG|Doxorubicin Hydrochloride|Given by IV
224004238|NCT00202917|DRUG|OKT-3|
224004239|NCT00202917|PROCEDURE|CD3/CD19 depletion on CliniMACS|
224124793|NCT05137262|DRUG|Cisplatin|Given by IV
224124794|NCT06826079|DRUG|Sorbitol|During the neoadjuvant treatment week, oral sorbitol 2-4g/ time, three times a day (with meals)
224124795|NCT06826079|OTHER|Placebo|During the neoadjuvant treatment week, oral placebo 2-4g/ time, three times a day (with meals)
223386497|NCT06655883|DRUG|Suvorexant|Oral Tablet
223386498|NCT06655883|DRUG|Placebo|Oral Tablet
224004240|NCT02146404|OTHER|hypoglycemia|Blood glucose levels will be kept at \~3.0 mmol/l
224004241|NCT02146404|OTHER|euglycemia|Blood glucose levels will be kept at \~5.0 mmol/l
224004242|NCT04871880|BEHAVIORAL|Dietitian led life style modification intervention|All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.
224004243|NCT04871880|BEHAVIORAL|Conventional care (control)|Receive routine care
224004244|NCT03846180|DRUG|Terlipressin|Continuous or intermittent intravenous infusion of terlipressin was given.
224124796|NCT04145115|BIOLOGICAL|Ipilimumab|Given IV
224124797|NCT04145115|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223386499|NCT06649851|DRUG|Granulocyte Colony Stimulating Factor (G-CSF)|Subcutaneously injected study drug; standard target dose of 5-7 µg/kg/d.
223386500|NCT06649851|RADIATION|Radiation Therapy + Temozolomide|Standard of care chemoradiation is radiation therapy + Temozolomide (TMZ). Chemoradiation (chemo-RT) includes an initial 6-week cycle, followed by a 4-week break, and up to 6 additional cycles of TMZ.
223386501|NCT06660394|DRUG|LP352|LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
223386502|NCT06660394|DRUG|Placebo|Participants will be administered with matching placebo orally or through G-tube/ PEG tube
223386503|NCT06481293|DEVICE|Diode laser therapy|Dual wavelength laser diode therapy device
223386504|NCT06481293|COMBINATION_PRODUCT|Alveogyl dressing|Alveogyl is a haemostatic-analgesic alveolar dressing
223386505|NCT03452774|OTHER|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
223386506|NCT05443295|OTHER|MoveUS Program|The MoveUS Program have 5 stages: 1 (approach stage), based on analytical movements, isometric peak contractions and learning/motor control; 2 (structural stage), based on muscular strength or resistance training through a cumulative work of short efforts, following with the analytical work of pushing or lifting/pulling; and ending in a closed kinetic chain; 3 (neural stage), that has two stage: 3A, based on a structural work that serves as a continuation of stage 2 and the work is focused on the training of increase cross-sectional muscular area; and 3B, based on a neural work focursed in an intra neuromuscular system highlighted motoneuron unit workout. Finally, stage 4 (functional stage), based on a functional readaptation to sports activity and/or work activity; or, failing that, to the activity of daily life with the highest demand.
224004245|NCT03846180|DRUG|Somatostatin|Continuous or intermittent intravenous infusion of somatostatin was given.
224004246|NCT03846180|DRUG|Octreotide|Continuous or intermittent intravenous infusion of octreotide was given.
224004247|NCT03838120|OTHER|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
224004248|NCT05719740|DIAGNOSTIC_TEST|osteocrin|laboratory routine test
224124798|NCT04145115|BIOLOGICAL|Nivolumab|Given IV
223386507|NCT05443295|OTHER|Control intervention|The control intervention is based on following the conventional treatment guidelines for glenohumeral instability, where immobilization, taking non-steroidal anti-inflammatory drugs, cryotherapy, passive kinesitherapy and self-assisted, pendular exercises stand out and education.
224004249|NCT06130670|OTHER|nerve block|Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery.
224004250|NCT03217695|BEHAVIORAL|Mindfulness-based Yoga Arm|
224124799|NCT06113445|DRUG|Povorcitinib|Oral, Tablet
224124800|NCT06113445|DRUG|Placebo|Oral, Tablet
224299211|NCT00858962|DRUG|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
223730066|NCT06326567|OTHER|C4 Program|C4 program aims to provide a multi-level intervention program (Patient Level, Healthcare Team and Healthcare System Level) that improves the coordination of care with supportive/ancillary care providers and community services through the use of patient navigation and a digital needs assessment and a closed-loop referral system and improves patient-centered communication and engagement in care through skills training for the healthcare team and provision of culturally appropriate patient educational tools and resources. The program components incorporate three areas that are critical to improving patient-centered care: coordination of care, patient-centered communication and engagement, and psychosocial care and other supportive services.
223730067|NCT00677612|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
224004251|NCT00662142|DIETARY_SUPPLEMENT|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
224004252|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
224004253|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
224004254|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
224004255|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
224004256|NCT01298687|DRUG|Travoprost Ophthalmic Solution, 0.004%|
224004257|NCT01298687|DRUG|Travoprost Vehicle|Inactive ingredients used as an active comparator
224004258|NCT00003187|BIOLOGICAL|filgrastim|
224004259|NCT00003187|DRUG|cyclophosphamide|
224004260|NCT00003187|DRUG|cyclosporine|
224004261|NCT00003187|DRUG|cytarabine|
224124801|NCT04582383|DRUG|Spironolactone|Dispensation of spironolactone according to the arm description.
224124802|NCT04582383|DRUG|Doxycycline Hyclate|Dispensation of doxycycline hyclate according to the arm description.
224124803|NCT04038255|DRUG|Nicoderm C-Q Transdermal Product|6 weeks of nicotine replacement therapy patches
224124804|NCT04038255|BEHAVIORAL|Orientation session|This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide electronic informed consent which will be audio-recorded with their permission, and complete the baseline assessment.
223730068|NCT04048031|DIETARY_SUPPLEMENT|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
223730069|NCT04048031|OTHER|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
223730070|NCT02213016|DEVICE|Transcranial Magnetic Stimulation|
223730071|NCT02213016|DEVICE|Sham Transcranial Magnetic Stimulation|
223386520|NCT05203328|DEVICE|Vapotherm|Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula
223386521|NCT05203328|DEVICE|Regular nasal canula|Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
224004262|NCT00003187|DRUG|methotrexate|
223386522|NCT04768686|DRUG|FLX475|tablet
223386523|NCT04768686|DRUG|Pembrolizumab|IV infusion
223386524|NCT06860243|DRUG|Opevesostat|Oral film-coated tablet
223386525|NCT06860243|DRUG|Prednisone|Oral tablet
223730072|NCT04066673|DIAGNOSTIC_TEST|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
223730073|NCT05000177|OTHER|30-minute computer typing task|The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
223730074|NCT05000177|OTHER|30-minute rest|Rest for 30 minutes
224004263|NCT00003187|DRUG|methylprednisolone|
224004264|NCT00003187|PROCEDURE|allogeneic bone marrow transplantation|
224004265|NCT00003187|PROCEDURE|in vitro-treated bone marrow transplantation|
224004266|NCT00003187|RADIATION|radiation therapy|
224004267|NCT04393870|OTHER|Foccusing on Maryam's Flower|Effect of Focusing on Maryam's Flower During the First Phase of the labor
224004268|NCT01378689|OTHER|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
223386526|NCT06860243|DRUG|Fludrocortisone acetate|Oral tablet
223386527|NCT02419534|DRUG|Polyethylene glycol|Laxative to treat constipation
223386528|NCT02419534|DRUG|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
223386529|NCT06989424|DEVICE|Magnetic Flexible Endoscope (MFE)|The Magnetic Flexible Endoscope (MFE) is a single-use endoscope intended to integrate with other commercially available devices for visualization of the human colon in order to eliminate the need for passage of the much stiffer, non-intuitive, risk prone standard colonoscope. The MFE will be introduced into the colon and traverse from the rectum to the cecum.
223386530|NCT03522025|DEVICE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
223386531|NCT06606106|DRUG|LY3537031|Administered SC
223386532|NCT06606106|DRUG|Placebo|Administered SC
223386533|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping is used to map the atrial tachycardia mechanism. Using the scar thresholding technique the Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
223730075|NCT03381846|PROCEDURE|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
224004269|NCT05565495|DRUG|Hydromorphone|Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
224004270|NCT04488770|DRUG|GSK3882347|Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
224004271|NCT04488770|DRUG|Placebo|Matching strength placebo capsules will be provided
224004272|NCT04746885|DIETARY_SUPPLEMENT|DHA|Oral supplement
224004273|NCT06629740|DEVICE|Measurements with a eHealth system|The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
223386534|NCT03915691|PROCEDURE|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
223386535|NCT05934396|BEHAVIORAL|Safety Planning|Prior to discharge and following the conclusion of all Virtual Reality (VR) sessions, the participant will develop a safety planning intervention for school settings in collaboration with relevant individuals (e.g., the researcher, a school professional).
224004274|NCT05000840|BEHAVIORAL|Enrollment in existing SDRI diabetes education programs|Education will be based on a modification of the existing Ocho Pasos education program provided by SDRI.
224004275|NCT06063434|BEHAVIORAL|Night Shift|"The player must not only manage the patients who present to the emergency department of the hospital, gaining experience with the consequences of trauma triage, but also solve the mystery of the grandfather, gaining an emotional connection with the character and making the feedback that Andy receives more relevant. Embedded within Night Shift 2024 is a mini-game (Graveyard Shift) that contains a series of puzzles that reinforce the lessons of the overarching game: transfer severely injured patients expeditiously."
224004276|NCT06063434|BEHAVIORAL|Usual education|Standard continuing medical education, including Advanced Trauma Life Support, and the American Board of Emergency Medicine educational modules (e.g., trauma resuscitation).
224004277|NCT03264911|DRUG|Amoxicillin or Placebo|Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
224004278|NCT02138708|OTHER|Pharmacological test of pulmonary endothelial|
224004279|NCT00573638|DEVICE|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
224004280|NCT00776217|DRUG|loratadine 10 mg orally disintegrating tablets|
224004281|NCT00913848|DRUG|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
224004282|NCT00913848|DRUG|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
224004283|NCT01867333|BIOLOGICAL|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
224004284|NCT01867333|BIOLOGICAL|PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.
224004285|NCT01867333|BIOLOGICAL|Enzalutamide|An androgen receptor inhibitor.
224004286|NCT00564577|BIOLOGICAL|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
224004287|NCT06418945|COMBINATION_PRODUCT|Tinidazole oral microneedle patch|Ultrasonic teeth cleaning: After gargling with compound chlorhexidine gargle or 3% hydrogen peroxide gargle for 1 minute, the teeth were cleaned by ultrasonic wave. After the teeth were cleaned, the wound was rinsed with 3% hydrogen peroxide to stop bleeding. Immediately after the ultrasonic cleaning, two pieces of tinidazole oral composite microneedle patch were applied to the upper and lower gums close to the inside of the first molar, especially on the tooth loss or damage, and the mouth was kept closed for 15 minutes. After the microneedle was fully degraded, the room could be left.
224004288|NCT06240923|DEVICE|Maxillary molars distalization|Maxillary molars distalization by using a nickel titanium open coil spring as an posterior displacement device.
224004289|NCT03390582|DRUG|Methimazole Pill|Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
224004290|NCT06235437|BIOLOGICAL|ASD141|Subjects will receive one of 4 dose levels of ASD141.
224004291|NCT06808022|BEHAVIORAL|Preoperative Resistance Exercise|Participants will have been deemed to be medically safe to participate in exercise-based physical therapy based on their physician recommendation and may also undergo an in-person evaluation by a licensed physical therapist to evaluate their physical capacity. This will inform the frequency and intensity of exercise prescription according to a participant's identified physical impairments and activity tolerance levels. Based on this information, an exercise program will be implemented either via web-based HIPAA compliant platforms (e.g. Zoom or WebEx) or in the clinic(e.g if the participant does not have internet access) on a 1-2x/week basis for the 4-6 week pre-operative duration. Each exercise session will be approximately 30 minutes. During these sessions, exercises including gravity-assisted, body-weighted, or body-weight-augmented resistance exercises targeting the paraspinal extensor muscles (multifidus, erector spinae, latissimus dorsi, lower trapezius) will be performed at a mo
224004292|NCT01157767|OTHER|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
224004293|NCT05439382|PROCEDURE|Gingival recession regenerative surgery|Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
224004294|NCT02876822|DIETARY_SUPPLEMENT|Vitamin D|
224004295|NCT05287464|DRUG|pembrolizumab plus axitinib|collect global experiences with the use of immuno-combinations in patients with metastatic RCC
224004296|NCT03956693|BEHAVIORAL|HEADS: UP|"HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories."
224004297|NCT00521066|DEVICE|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
224124805|NCT04038255|BEHAVIORAL|Craving-to-Quit app|The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
224124806|NCT04038255|BEHAVIORAL|Two brief follow-up phone calls|The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.
223386536|NCT05934396|BEHAVIORAL|VR Enhanced Affect Regulation|Participants will receive an overview of affect regulation in VR and then have the opportunity to practice using affect regulation in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
224004298|NCT02313389|DRUG|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
224004299|NCT04481568|BEHAVIORAL|PES-4-BPSD Model|We will conduct a non-randomized preliminary efficacy trial, enrolling N=158 patients (79 control and 79 intervention). The primary outcome will be presence of BPSD as measured by a patient's total score on the Neuropsychiatric Inventory-Questionnaire (NPI-Q) during hospitalization. A multi-modal approach (including chart review and HCG questionnaires) will be used to determine the presence and severity of BPSD.
224004300|NCT04481568|BEHAVIORAL|The attention control condition|On this unit, the management of patients who display BPSD is performed by nurse assistants, rather than PES. Therefore, in order to test the added layer of PES staff, the nurse assistants on the control unit will receive equivalent dementia care education and training as well as staff support (please refer to NCT# 04179721 for more details on this aim).
224004301|NCT05312281|DEVICE|Device : Lombastab immo. wear for 6 weeks post-surgery the Lombastab Immo|Wear for 6 weeks post-surgery
224004302|NCT04162379|DRUG|Oral tablet|Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
224004303|NCT03878329|BEHAVIORAL|remote home monitoring|Will use telemedicine to guide behavior changes in outcomes
224004304|NCT03842540|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~1. Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~2. Digital materials for recipients to keep and/or share with friends.~3. Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~4. Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut."
224124807|NCT04038255|BEHAVIORAL|Group MT sessions|Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.
224124808|NCT04038255|BEHAVIORAL|Brief advice on quitting smoking|Standard advice on how to quit smoking.
224124809|NCT04038255|BEHAVIORAL|Self-help smoking cessation materials|Written materials on how to quit smoking including contact info for state tobacco quitline.
224124810|NCT06226571|DRUG|SNDX-5613|Participants will receive SNDX-5613 orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.
223386537|NCT05934396|BEHAVIORAL|VR Enhanced Cognitive Restructuring|Participants will receive an overview of cognitive restructuring in VR and then have the opportunity to practice using cognitive restructuring in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
223386538|NCT05934396|BEHAVIORAL|VR Enhanced Problem Solving|Participants will receive an overview of problem solving in VR and then have the opportunity to practice using problem solving in a brief immersive experience designed to mimic difficult school experiences. Each session begins with goal setting prior to the VR experience and concludes with a debrief summary following the VR experience.
223386539|NCT05934396|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Worksheets|The researchers will provide instructions for participants to complete a packet of worksheets teaching introduction to cognitive behavioral therapy (CBT), affect regulation, cognitive restructuring, and problem solving.
223386540|NCT06004050|DRUG|Delgocitinib|Topical administration
223386541|NCT06004050|OTHER|Vehicle cream|Topical administration
223386542|NCT03740841|BEHAVIORAL|Interactive story teller LUNII|Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
223386543|NCT04687969|DRUG|[18F]DCFPyL|will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination
223386544|NCT04687969|RADIATION|PET/MRI scanner|PET/MRI Scan with \[18F\]DCFPyL as directed by protocol
223386545|NCT06614946|BEHAVIORAL|Electronic Safety Plan (ESP)|Participants will receive an electronic safety plan in the ED. ESP focuses on developing a personalized coping plan to manage suicidal thoughts and urges.
223386546|NCT06614946|BEHAVIORAL|Text support|Those in the text-based support program will receive up to 2 texts per day for a month with varying levels of tailoring, based on ESP and dynamic personalized feedback.
223425611|NCT06621797|DIETARY_SUPPLEMENT|Intervention 2: Dietary Supplement - Caffeine + L-Theanine Supplement|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) along with L-theanine in a 1:2 ratio taken orally 45 minutes before performance testing.
223545629|NCT01722994|DEVICE|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
223545630|NCT01722994|DEVICE|Chromic Gut Sterile absorbable Suture (Ethicon)|
223545631|NCT04858841|DRUG|Levetiracetam Oral Product|Administer levetiracetam powder once a day in eligible patients
223545632|NCT04858841|DRUG|Perampanel Oral Product|Administer perampanel powder once a day in eligible patients
223545633|NCT04858841|DRUG|Placebo|Administer placebo powder once a day in eligible patients
223545634|NCT00858325|DRUG|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
224124811|NCT06226571|DRUG|Chemotherapy Regimen|Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.
223386547|NCT06998498|BEHAVIORAL|Ready for Recovery|The Ready for Recovery program is a 6-week, multicomponent, tailored, prehabilitation intervention to promote the optimization of medical and psychological status prior to surgery. Its key components include education, enhancement of beneficial health behaviors, reduction of negative psychological symptoms, and the promotion of social support. Following an initial session, the team will develop a customized prehabilitation plan for each participant. Participants will work towards goals each week and will discuss progress with their study trainer via weekly phone sessions, which will continue until the scheduled surgical procedure.
224004305|NCT03842540|BEHAVIORAL|PartyWise|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
224004306|NCT06016218|DRUG|Simvastatin|Comparing Simvastatin powder with PRF to Bone Powder with PRF on Peri-implant Bone
224004307|NCT02373579|DRUG|Omega-3 Fatty Acids|"study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
224124812|NCT06226571|DRUG|HiDAC|Consolidation: Participants will receive HiDAC IV.
224295797|NCT01207648|DRUG|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
223386548|NCT07007442|OTHER|Instrument assisted soft tissue mobilization|for application of IASTM. the patient will sit on chair in comfortable position, apply lubricant material on treated area (trapezius muscle). Apply IASTM in 30-60 angle for 40 to 120 sec until hyperemia occur for each side+ conventional therapy
223386549|NCT07007442|OTHER|dry cupping|the dry cupping will be aplied by using plastic cups that are placed over localized areas of skin. A vacuum suction is achieved with a manual handheld pump device to create a negative pressure, drawing localized skin and soft tissue structures into the cup+ conventional therapy
223386550|NCT07007442|OTHER|conventional therapy|the patients will receive Isometric strengthening exercises for cervical Extensors, Flexors, bilateral side Flexors and Rotators (resistance was about 50% of the patient's maximum strength, hold for 10 seconds, for 10 repetitions.Stretching of the upper fibers of trapezius (stretching was held for 30 seconds and repeated 3 times). postural correction exercises in the form of ; 1) Chin tucks exercise is quick and easy to do and it helps strengthening upper thoracic extensors, the muscles that align head over shoulders.2)Corner stretch: provides a deep stretch of the chest and shoulders, which can help maintain good posture.
223386551|NCT07127159|BEHAVIORAL|Intentional Music Listening|Participants will receive an iPad with Spotify (for music listening) and FaceTime. For 4 weeks (excluding weekends; 20 sessions), participants will listen to music for one hour per session, without multitasking (e.g., no chores or cooking), and will be encouraged to listen attentively. The investigators will collaborate with each participant to co-create a personalized playlist composed of self-selected, culturally relevant songs. This playlist can be updated at any time by the participant, either independently or with assistance from the team. During the music-listening session, participants will be on FaceTime with a team member, who will be available to provide support as needed. A custom Python script will continuously track the songs played by participants through Spotify, logging playback activity for research purposes.
223730076|NCT03381846|PROCEDURE|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
223730077|NCT02906059|DRUG|AZD1775|
223730078|NCT02906059|DRUG|Irinotecan|
224004308|NCT02373579|DRUG|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
224124813|NCT05031910|OTHER|Medical Device Usage and Evaluation|Undergo virtual reality imaging via VR/3D-CEPs
224124814|NCT05031910|OTHER|Best Practice|Receive standard of care
224124815|NCT05031910|PROCEDURE|Resection|Undergo surgical resection
224124816|NCT01027910|DRUG|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
224124817|NCT01027910|DRUG|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
224124818|NCT01027910|DRUG|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
224124819|NCT05243290|DIETARY_SUPPLEMENT|Nicotinamide Riboside|The product under investigation, Nicotinamide riboside (NR), is a naturally occurring NAD+ precursor and a member of the vitamin B3 family.
224124820|NCT05243290|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured NR capsules, with the exception of any NR compound.
224124821|NCT05973487|BIOLOGICAL|TSC-204-A0201|Escalating doses of TSC-204-A0201 as a monotherapy
224124822|NCT05973487|BIOLOGICAL|TSC-204-C0702|Escalating doses of TSC-204-C0702 as a monotherapy
224124823|NCT05973487|BIOLOGICAL|TSC-200-A0201|Escalating doses of TSC-200-A0201 as a monotherapy
224124824|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-C0702|Escalating doses of TSC-204-A0201 in combination with TSC-204-C0702
224124825|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-200-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-200-A0201
224124826|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-200-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-200-A0201
224295798|NCT03008486|DEVICE|Real soft splint (6 cm)|
224295799|NCT03008486|DEVICE|Placebo soft splint (1 cm)|
224299212|NCT02181426|DRUG|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
223386552|NCT07127159|BEHAVIORAL|Audiobook Listening|Participants will be provided with an iPad equipped with a Spotify (for audiobook listening) and FaceTime. For 4 weeks (excluding weekends; 20 sessions), participants will be asked to listen to an audiobook of their choice for one hour per session, without engaging in other activities such as chores or cooking. Participants will be instructed to listen attentively and avoid multitasking during the session. A team member will connect with each participant via FaceTime to offer support. Participants may update or change their audiobook selections at any time, either independently or with help from the team. A custom Python script will be used to continuously track audiobook playback activity for research and analysis.
223386553|NCT05314010|DRUG|MIL62|"Phase 1b: Participants will receive intravenous (IV) infusions of MIL62 at doses of 500 mg or 1000 mg on Week (W) 1 Day (D) 1, W3D1, W25D1, W27D1, W53D1, W79D1, W105D1, W131D1, W157D1, W183D1, and W209D1. Participants initially assigned to the 500 mg dose group who exhibit good tolerance may be escalated to the 1000 mg dose starting from W25D1.~Phase 3 (Randomised Controlled Period \[RCP\]): Participants will receive IV MIL62 1000 mg or placebo matched to MIL62 on W1D1, W3D1, W25D1, and W27D1. The administration protocol for placebo is identical to that of MIL62.~Phase 3 (Open-Label Period \[OLP\]): Participants who enter the OLP will receive IV MIL62 1000 mg on W1D1, W27D1, W53D1, W79D1, W105D1, and W131D1, along with matching placebo on W3D1."
223386554|NCT05314010|OTHER|Placebo|"Phase 3 (RCP): Participants will receive IV placebo matched to MIL62 on W1D1, W3D1, W25D1, and W27D1.~Phase 3 (OLP): Participants entering the OLP will receive IV MIL62 1000 mg on W1D1, W3D1, W27D1, W53D1, W79D1, W105D1, and W131D1."
223386555|NCT06465069|DRUG|LY4052031|Intravenous
223386556|NCT03752697|BEHAVIORAL|metacognitive performance|Paper and pencil/computerized tests of metacognition
223386557|NCT04417465|DRUG|ABBV-CLS-579|Oral Capsule
224004309|NCT05899803|DIAGNOSTIC_TEST|Posture Analysis|This analysis consists of 13 different body parts and evaluates the body in terms of current posture changes. Our study evaluated children from two angles: posterior (head, shoulders, back, hips, feet, and arches) and lateral (neck, chest, shoulders, upper back, trunk, abdomen, and waist). In the scoring system, correct posture was recorded as five points, a moderate amount of deformity posture as three points, and severe deformity posture as one point. The total score calculated at the end of the questionnaire was a maximum of 65 points and a minimum of 13 points. The results of the analysis were evaluated as follows: ≥ 45 points, very good, 40-44 points good, 30-39 points moderate, 20-29 points poor, and a total score of ≤ 19 points.
224124827|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-203-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-203-A0201
224124828|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-203-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-203-A0201
224124829|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-203-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-203-A0201
224124830|NCT05973487|BIOLOGICAL|TSC-203-A0201|Escalating doses of TSC-203-A0201 as a monotherapy
224124831|NCT05973487|BIOLOGICAL|TSC-204-A0101|Escalating doses of TSC-204-A0101 as a monotherapy
224124832|NCT05973487|BIOLOGICAL|TSC-201-B0702|Escalating doses of TSC-201-B0702 as a monotherapy
224124833|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-204-A0101|Escalating doses of TSC-204-A0201 in combination with TSC-204-A0101
224299213|NCT04570540|DIAGNOSTIC_TEST|Sleep Study|Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry
223386558|NCT04417465|DRUG|PD-1 inhibitor|Intravenous (IV) infusion
223386559|NCT04417465|DRUG|VEGFR TKI|Oral Tablet
223386560|NCT06671236|BIOLOGICAL|Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)|Regulatory T cell therapy, intrathecal injection
223730079|NCT06530225|OTHER|Education and Mentoring for Prescribing Pharmacists|Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
223730080|NCT00327678|DRUG|Rituximab|
224124834|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-201-B0702|Escalating doses of TSC-204-A0201 in combination with TSC-201-B0702
224124835|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-204-A0101|Escalating doses of TSC-204-C0702 in combination with TSC-204-A0101
224124836|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-201-B0702|Escalating doses of TSC-204-C0702 in combination with TSC-201-B0702
224299214|NCT04570540|DIAGNOSTIC_TEST|Pulmonary Function Test|Bodyplethysmographic assessment
223730081|NCT00327678|DRUG|Imatinib Mesylate|
223730082|NCT03421119|DRUG|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
224124837|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-204-A0101|Escalating doses of TSC-200-A0201 in combination with TSC-204-A0101
223386565|NCT06683092|OTHER|RETRIAL-MH|Participants will complete: daily diaries for 6 weeks, from about 2 weeks prior to starting VTD to about 4 weeks after; biweekly surveys, from about 2 weeks prior to starting VTD to 6 months after, and 2 quarterly surveys (at 9mo and 12mo post-initiation of VTD).
223386566|NCT06683092|OTHER|RETRIAL-Liver|Participants may have a research liver function test done prior to starting VTD and 28 days after, if not done clinically.
224124838|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-201-B0702|Escalating doses of TSC-200-A0201 in combination with TSC-201-B0702
224124839|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-204-A0101|Escalating doses of TSC-203-A0201 in combination with TSC-204-A0101
223386567|NCT06683092|OTHER|RETRIAL-Neuro|participants will complete a neurocognitive assessment prior to starting VTD and 28 days after.
223386568|NCT04416282|DRUG|Terlipressin|Injection terlipressin 2 mg/24 hours infusion
223386569|NCT04416282|BIOLOGICAL|Albumin|i/v albumin 1g/Kg/day
224124840|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-201-B0702|Escalating doses of TSC-203-A0201 in combination with TSC-201-B0702
224124841|NCT05973487|BIOLOGICAL|TSC-202-A0201|Escalating doses of TSC-202-A0201 as a monotherapy
224124842|NCT05973487|BIOLOGICAL|TSC-204-A0201 + TSC-202-A0201|Escalating doses of TSC-204-A0201 in combination with TSC-202-A0201
224124843|NCT05973487|BIOLOGICAL|TSC-204-C0702 + TSC-202-A0201|Escalating doses of TSC-204-C0702 in combination with TSC-202-A0201
224124844|NCT05973487|BIOLOGICAL|TSC-200-A0201 + TSC-202-A0201|Escalating doses of TSC-200-A0201 in combination with TSC-202-A0201
224004310|NCT05899803|DIAGNOSTIC_TEST|Physical activity level|This questionnaire, administered to children aged 4-14, evaluates the activities performed during a week. The questionnaire consisted of nine questions, each of which was evaluated on a 5 points. One point indicated a low physical activity level and five points indicated a high physical activity level. Dividing the total score of the selected items by the number of items gives a summary score for the PAQ-C questionnaire. In our study, we used the Turkish version of the questionnaire, which was found to be reliable and valid.
224004311|NCT05899803|DIAGNOSTIC_TEST|Muscle strength|"Our study objectively measured muscle strength using the JTech Commander PowerTrack Muscle Dynamometer.~Right and left muscle tests: Hip flexors/hyperextensors/adductors/abductors/internal rotators/external retractors, knee flexors/extensors, and foot plantar flexors/dorsiflexors were evaluated. The measurement results were recorded in Newtons, the measurements were repeated three times, and the average of these three repetitions was recorded."
223730083|NCT03421119|DRUG|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
223730084|NCT03421119|DRUG|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
223730085|NCT05595356|DEVICE|transcranial direct current stimulation|"Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
223730086|NCT05595356|DEVICE|sham transcranial direct current stimulation|"Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session."
224004312|NCT02876042|DEVICE|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
224004313|NCT01404364|DRUG|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
224004314|NCT01404364|DRUG|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
224004315|NCT03789331|OTHER|Anogenital distance measurement|"The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used."
224004316|NCT02636725|DRUG|Axitinib|5 mg tablets twice daily oral dose administered for 7 consecutive weeks on Cycle 1. A safety lead-in consisting of the initial five patients, intrapatient dose escalation of Axitinib will be permitted based on the absence of predefined toxicities. Twice daily oral dose between 2 mg to 10 mg Axitinib tablets will be administered on subsequent 6 week cycles until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
224004317|NCT02636725|DRUG|Pembrolizumab|200 mg intravenous infusion administered every 21 weeks beginning week 2 of Cycle 1 for a maximum of up to 2 years or until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
224004318|NCT00003705|DRUG|BMS-184476|
224004319|NCT00241553|DRUG|Esomeprazole|
224004320|NCT03370744|DIAGNOSTIC_TEST|Neuropsychological scale|Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
224004321|NCT03556956|DRUG|Masitinib|Tyrosine kinase inhibitor
223386570|NCT07022678|OTHER|Best Practice|Given standard chemotherapy
223386571|NCT07022678|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
223386572|NCT07022678|DRUG|Cytarabine|Given IV
224004322|NCT00883064|DRUG|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
224004323|NCT00883064|DRUG|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
224004324|NCT02826928|BIOLOGICAL|blood sample withdrawn|
224004325|NCT05010343|RADIATION|carbon ion irradation|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
224004326|NCT05010343|RADIATION|Carbon Ion Irradiation With SIB|All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
224004327|NCT04767100|DEVICE|Social telepresence robot|Use of a social telepresence robot at home, during three months with the aim of reducing the feeling of loneliness and social isolation among the elderly.
224004328|NCT01681121|DRUG|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
223386573|NCT07022678|OTHER|Electronic Health Record Review|Ancillary studies
223386574|NCT07022678|DRUG|Placebo Administration|Given intraorally
223386575|NCT07022678|OTHER|Xylitol-containing Oral Wipe|Given intraorally
223386576|NCT07021547|DRUG|LY3867070|Administered orally
223386577|NCT07021547|DRUG|Placebo|Administered orally
223386578|NCT03555292|DRUG|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
223386579|NCT04164290|DRUG|Jiashen Tablets|1 tablet
223386580|NCT04164290|DRUG|Jiashen Tablets|2 tablets
223386581|NCT04164290|DRUG|Jiashen Tablets|4 tablets
223386582|NCT04164290|DRUG|Jiashen Tablets|6 tablets
224004329|NCT01681121|DRUG|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
224004330|NCT05330676|PROCEDURE|coronary artery bypass grafting, valve repair/replacement|cardiovascular surgery with cardiopulmonary bypass
224004331|NCT00920322|DEVICE|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
224004332|NCT00920322|DEVICE|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
224004333|NCT03653208|DRUG|hzVSF-v13|Dosage form: 10mg / 20mg / 50mg / 100mg / 200mg / 400mg / 800mg / 1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1 (single administration)
224004334|NCT03653208|DRUG|Placebo|Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1 (single administration)
224004335|NCT00436605|DRUG|dasatinib|
224004336|NCT03545477|OTHER|Novel locomotion treatment: curved-walking training|"Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)"
224004337|NCT03545477|OTHER|Standard locomotion treatment: straight-walking training|It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
223386583|NCT04164290|DRUG|Jiashen Tablets|8 tablets
223386584|NCT04164290|DRUG|Jiashen Tablets|9 tablets
223386585|NCT04164290|DRUG|Jiashen Tablets Placebo|1 tablet
223386586|NCT04164290|DRUG|Jiashen Tablets Placebo|2 tablets
223386587|NCT04164290|DRUG|Jiashen Tablets Placebo|4 tablets
223386588|NCT04164290|DRUG|Jiashen Tablets Placebo|6 tablets
223386589|NCT04164290|DRUG|Jiashen Tablets Placebo|8 tablets
223386590|NCT04164290|DRUG|Jiashen Tablets Placebo|9 tablets
223386591|NCT06694389|BIOLOGICAL|mRNA-1083|Suspension for injection
224004338|NCT03545477|OTHER|Standard physical therapy|It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
224004339|NCT03752970|DRUG|Spesolimab|Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
224004340|NCT03752970|DRUG|Placebo|Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
224004341|NCT00355303|DRUG|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
224004342|NCT00355303|DRUG|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
224004343|NCT04058275|OTHER|Draw blood (phlebotomy, 83 ml)|Draw 83 ml of blood
224004344|NCT06345651|DEVICE|Transcranial Magnetic Stimulation|Individually MR-neuronavigated TMS, 600 pulses, 120% RMT
224004345|NCT01013038|PROCEDURE|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
224004346|NCT01013038|PROCEDURE|conventional PCI|balloon angioplasty and/or stent implantation
224004347|NCT03417570|PROCEDURE|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
224004348|NCT03417570|DEVICE|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
224004349|NCT05133349|DRUG|Anlotinib|Anlotinib 12mg capsules given orally on once daily in 21-day cycle until disease progression or treatment intolerance(14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21), the dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
224004350|NCT01638143|DIETARY_SUPPLEMENT|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
224004351|NCT01638143|DIETARY_SUPPLEMENT|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
223386592|NCT06694389|OTHER|Placebo|0.9% sodium chloride suspension for injection
223386593|NCT06694389|BIOLOGICAL|Licensed Influenza Vaccine|Aqueous injectable (SC) or suspension for injection (IM)
223386594|NCT06694389|BIOLOGICAL|SARS-CoV-2 Vaccine|Suspension for injection
223386595|NCT05722418|BIOLOGICAL|CB-011|CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion
223386596|NCT07032909|BEHAVIORAL|comfortable reading mode|Subjects are asked to read a terminal display device for 45 minutes, featuring texts with different reading mode treatments. Specifically, they will read the same text content for 45 minutes with different background and text color. The participants will complete a total of 4 sets of tests in a random order.
223386597|NCT06713837|DRUG|High intensity therapies|"* High and intermediate dose Cytarabine~* Mitoxantrone - Etoposide - Cytarabine (MEC)~* fludarabine - cytarabine - idarubicin - G-CSF (FLAG-IDA)~* cladribine - high dose cytarabine (2CDA+HDAraC)~* mitoxantrone - intermediate dose cytarabine (MiDAC)~* fludarabine - amsacrine - cytarabine (FLAMSA)~* Mitoxantrone - Intermediate-dose Cytarabine (HAM)~* 3+7 (cytarabine and daunorubicine or idarubicine)"
224004352|NCT01638143|DIETARY_SUPPLEMENT|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
224004353|NCT01696045|BIOLOGICAL|Ipilimumab|
224004354|NCT04337671|OTHER|Moderate intensity aerobic training|"The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks."
224004355|NCT00573859|DRUG|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
224004356|NCT00573859|DRUG|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
224004357|NCT01184040|BEHAVIORAL|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
224004358|NCT00193752|OTHER|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
224004359|NCT03265171|BIOLOGICAL|Plasminogen (Human)|
224004360|NCT00484484|DRUG|Ketamine|Ketamine
224004361|NCT01432587|DRUG|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
224004362|NCT04703998|PROCEDURE|Arthroscopic rotator cuff repair|A double-row rotator cuff repair will be performed.
224004363|NCT04703998|BIOLOGICAL|platelet rich plasma|A single dose of 10 ml of autologous platelet rich plasma at the bone-tendon interfase will be administered.
224124845|NCT05973487|BIOLOGICAL|TSC-203-A0201 + TSC-202-A0201|Escalating doses of TSC-203-A0201 in combination with TSC-202-A0201
224124846|NCT05973487|BIOLOGICAL|TSC-204-A0101 + TSC-202-A0201|Escalating doses of TSC-204-A0101 in combination with TSC-202-A0201
224124847|NCT05973487|BIOLOGICAL|TSC-201-B0702 + TSC-202-A0201|Escalating doses of TSC-201-B0702 in combination with TSC-202-A0201
224124848|NCT05376345|BIOLOGICAL|LCAR-BCDR cells product|Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
224124849|NCT05183867|DEVICE|Healthy Minds Program|HMP is a 4-week mobile health (mHealth) meditation training program.
224124850|NCT05215769|BEHAVIORAL|Health Education|Participate in a video intervention
224124851|NCT05215769|OTHER|Questionnaire Administration|Complete questionnaires
224004364|NCT03260777|DEVICE|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
224004365|NCT03017898|PROCEDURE|Laser Coagulation|Laser coagulation of anal fistula
224004366|NCT04398823|DRUG|Sclerosing foam of Lauromacrogol|Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
224004367|NCT04398823|DRUG|Sclersing liqiud of Lauromacrogol|Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
224004368|NCT00144495|DRUG|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
224124852|NCT03561220|RADIATION|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
224124853|NCT03561220|RADIATION|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
224295800|NCT05739214|DEVICE|laser therapy|"All patients received 2 sessions of laser therapy / week in two consecutive months of treatment aiming complete wound closure , patients received \& infrared laser therapy plus traditional wound care:~(I) Use red \& infrared laser therapy device with 4 different wavelengths in a synchronized mode:~1. 980 nm for wound decontamination, improve circulation, lymphatic drainage~2. 915 nm enhances O2 delivery~3. 810 nm increases ATP production~4. 650 nm accelerate surface healing, tissue regeneration plus traditional wound treatment mentioned before"
224299215|NCT04570540|DIAGNOSTIC_TEST|Hypercapnic ventilatory response|Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag
224299216|NCT04570540|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
224004369|NCT00144495|DRUG|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
224004370|NCT00878683|DEVICE|silicone catheter boot|silicone device using Dermabond
224004371|NCT00881062|DRUG|Proellex|A single oral dose administered after at least a 10 hour fast
224004372|NCT05741138|OTHER|Core strengthening|"Plank 1-3 sets of 10-15 reps per side at a slow tempo Side plank Draw in and lift, holding for 5 seconds with purposeful engagement of the core and leg musculature. Keep the head, shoulders, hips, knees and feet in a straight line.~Bridges - Lie supine with your knees bent and the feet flat on the floor. Lift your pelvis off the ground while supporting on your feet and shoulders. The bridge can be progressed by lifting one foot off the ground end extending the knee Leg rises - Lie on your back with your legs straight and your arms by your sides. Then lift one leg 4 inches of the ground. Your back has to stay flat on the floor. Don't allow it to arch. Alternate. The exercise can be progressed by lifting both legs at the same time."
224004373|NCT05741138|OTHER|Conventional treatment|Hot pack and TENS for 10 minutes (lumbar region and calf muscles) Ultrasound for 10 mins (lumbar region and calf muscles) Gentle passive stretching (calf muscles) Isometric exercises (lumbar region)
224004374|NCT02294526|OTHER|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
224004375|NCT01521936|DIETARY_SUPPLEMENT|cholecalciferol|Given PO (lower dose)
224004376|NCT01521936|OTHER|pharmacological study|Correlative studies
224004377|NCT01521936|DIETARY_SUPPLEMENT|cholecalciferol|Given PO (higher dose)
224004378|NCT01521936|OTHER|laboratory biomarker analysis|Correlative studies
224004379|NCT05319912|DRUG|ALXN1840 Enteric-coated Tablet|ALXN1840 (60 milligrams) was administered orally as EC tablets at Hour 0 on Day 1.
224124854|NCT03561220|RADIATION|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
224124855|NCT03561220|RADIATION|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
224124856|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMRT
224124857|NCT01629498|RADIATION|Image Guided Radiation Therapy|Undergo image-guided IMPT
224124858|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
224124859|NCT01629498|RADIATION|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
224124860|NCT01629498|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224124861|NCT01629498|RADIATION|Photon Beam Radiation Therapy|Undergo image-guided IMRT
224124862|NCT01629498|RADIATION|Proton Beam Radiation Therapy|Undergo image-guided IMPT
224124863|NCT01629498|OTHER|Questionnaire Administration|Ancillary studies
224004380|NCT05319912|DRUG|ALXN1840 Non-coated Capsule|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
224004381|NCT05319912|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
224004382|NCT03720951|RADIATION|pudendal nerve|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
224004383|NCT03720951|RADIATION|sacral n roots|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
224004384|NCT01266551|DEVICE|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
224004385|NCT04488523|BEHAVIORAL|Family-based Telehealth Intervention|"The Family Telehealth intervention focuses on improving parent-child relationships and communication.~For the dyadic version, the intervention involves eleven hours of intervention material; it includes motivational interviews, individual and joint sessions co-led by two separate clinicians. The sessions will be delivered on a weekly basis.~For the caregiver-only version, the intervention involves six hours of intervention material; it includes a motivational interview and individual sessions led by a single clinician. The sessions will be delivered on a weekly basis."
224004386|NCT01148329|DEVICE|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
224004387|NCT04445740|BEHAVIORAL|i♥rhythm project|behavioral mobile health intervention, targeting parents of 5-8 year olds, designed to promote consistent behavioral rhythms in children through consistent bedtimes, light exposure, meal timing, and physical activity.
224004388|NCT03560024|OTHER|PACAP27|PACAP27 is vasodilator of cerebral vessels
224004389|NCT03560024|OTHER|Placebo|Saline
224004390|NCT02320981|DIAGNOSTIC_TEST|Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance|
224004391|NCT05512689|DEVICE|Ventilations while using a respiratory function monitor|Healthcare professionals are able to use a feedback device to guide their ventilations.
224004392|NCT03101839|DRUG|AZD4785|KRAS Antisense Oligonucleotide
224004393|NCT05945589|BEHAVIORAL|Singapore A-Health Intervention|The Singapore A-Health Intervention spanned 12 weeks, with each weekly session lasting for two hours. The program is structured around three thematic domains of the past, present, and future. In each thematic domain consisting of four weeks, participants were tasked with creating an artwork related to the theme and incorporating the learned art techniques. The structure of each thematic domain follows the same structure: the first week involved a 45-minute docent-led gallery tour on three selected pieces of artworks, followed by a 75-minute artist-led brainstorming session where participants were introduced to the techniques and discuss ideas on the artwork to be created. The subsequent three sessions involved further guidance from the artist and a scaffolded delivery of art techniques for participants to incorporate their learning to their artwork. At the end of each domain, there was a showcase where participants present their artwork.
224004394|NCT00728897|DRUG|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
224004395|NCT00728897|DRUG|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
224004396|NCT02145559|DRUG|Metformin XR|
224004397|NCT02145559|DRUG|Delayed Metformin|
224004398|NCT02145559|DRUG|Sirolimus|
223730087|NCT05595356|DEVICE|run-in sham transcranial direct current stimulation|In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.
224004399|NCT03162562|BIOLOGICAL|Oregovomab|Monoclonal antibody against CA 125
224004400|NCT03162562|DRUG|Poly ICLC|Immune adjuvant
224004401|NCT01802177|PROCEDURE|UVB excimer light|
224004402|NCT05151900|BEHAVIORAL|Support Group for Caregivers|"Engage parents in the community via this support group, so they can be supported by other parents who know the system, can advise them on how to proceed, and empower them to help their children. Parents will learn psychoeducation about eating disorders and how to support their children."
224004403|NCT03454126|DRUG|BIIB095|Administered as specified in the treatment arm.
224004404|NCT03454126|DRUG|Placebo|Administered as specified in the treatment arm.
224004405|NCT02229851|DRUG|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
224004406|NCT02229851|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
224004407|NCT02229851|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
224004408|NCT03284203|DEVICE|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
224004409|NCT04395300|OTHER|Web Based Survey|On line survey distributed electronically
224004410|NCT03541200|DRUG|MT-8554|MT-8554 Oral
224004411|NCT02519140|DRUG|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
224004412|NCT02297100|DRUG|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
223386598|NCT06713837|DRUG|Low intensity therapies|"* Venetoclax+hypomethylating agent (decitabine, azacitidine)~* Venetoclax+low dose cytarabine~* Gilteritinib alone or in combination with low dose hypomethylating agent or low dose cytarabine~* 2CDA 5mg/sqm + low dose cytarabine~* Glasdegib+low dose cytarabine~* Ivosidenib alone or in combination with low dose hypomethylating agent or low dose cytarabine~* Single agent Gemtuzumab or Gemtuzumab in combination with alone or in combination with low dose hypomethylating agent or low dose cytarabine"
223386599|NCT07030127|DRUG|LY3985863|Administered SC
224004413|NCT02297100|PROCEDURE|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
223386600|NCT07030127|DRUG|Placebo|Administered SC
223386601|NCT07123480|BEHAVIORAL|Usual Care Group|Standard of care to encourage cardiac rehabilitation attendance.
223386602|NCT07123480|BEHAVIORAL|More Support and Tools|More Support and Tools includes the following: monetary incentive, text messages, case management, and physical activity coaching. The investigators will start providing support and tools while patients are still in the hospital and continue this support weekly after discharge. Intervention participants will receive a monetary incentive both in the hospital and upon attending cardiac rehabilitation. The support (case management) and tools (physical activity coaching and text messages) will continue for up to 3 months or until the individual attends cardiac rehabilitation, whichever occurs first. Participants can decline any or all support or tools.
224004414|NCT02297100|PROCEDURE|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
224004415|NCT04215445|DRUG|Empagliflozin 25 MG|Tab.empagliflozin 25mg once daily for 28 days
224004416|NCT04215445|DEVICE|OCT-A|Optical coherence tomography angiography (OCT-A) is a non-invasive method to study the microvasculature of the retina and choroid.
224004417|NCT04198064|PROCEDURE|Bag Squeeze|"Participants will receive a bag squeeze of irrigation fluid (500 ml/\~2 cups of % 0.9 saline solution) during the insertion of the cystocopy tube during their cystocopy."
224004418|NCT04198064|PROCEDURE|No Bag Squeeze|Participants will receive a standard cystocopy procedure as per standard of care.
224004419|NCT03377478|DRUG|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
224004420|NCT01120730|DRUG|fluid resuscitation|fluid resuscitation with HES
224004421|NCT01120730|DRUG|Fluid resuscitation|Fluid resuscitation in standardized fashion
224004422|NCT00876577|DRUG|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
224004423|NCT04349839|DEVICE|Acrodat software|Acrodat is a newly developed software medical device to access disease activity in acromegaly based on five parameters: IGF-I, tumour size, comorbidities, symptoms and quality of life.
224004424|NCT02972268|DRUG|Tamsulosin 0.2mg + Solifenacin 5mg|Tamsulosin 0.2mg + Solifenacin 5mg for 12wks
224004425|NCT02972268|DRUG|Tamsulosin 0.2mg + Placebo(Solifenacin)|Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
224004426|NCT05984836|BEHAVIORAL|Implement health education|"Implement health education class for the rural mothers in the for of one session will take about 30 minutes and it will include the following:~First aid (fracture, burn, bleeding, injuries and food poising). Critique malpractice for injuries management behavior at home.~About 10 mothers will be included in the session. Each session will take 30 minutes (in the family health center), to cover all theoretical contents.~The researcher will use different teaching methods as demonstration and discussion, learning aids as handout, video and pictures."
224004427|NCT01913834|DRUG|Forsteo|Subcutaneous administration 20 micrograms
224004428|NCT01913834|DRUG|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
224004429|NCT02632604|BEHAVIORAL|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
224004430|NCT02632604|BEHAVIORAL|Computer games|
224004431|NCT05526131|OTHER|Questionare|"Assessing the presence or the absence of depression:~By structured clinical interview for DSM-IV Axis disorder (SCID-I) and Hamilton Depression Rating Scale (HAM-D) for diagnosing depression and exclusion of other psychiatric disorders."
224004432|NCT03738644|OTHER|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
224004433|NCT03818360|BEHAVIORAL|an evidence-based smoking cessation intervention comprising brief advice plus active referrals|The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
224004434|NCT04374214|PROCEDURE|Complete Pulpotomy using Mineral Trioxide Aggregate|Inflammed coronal pulp tissue will be removed till the canal orifices and mineral trioxide aggregate placed over the amputated pulp stump.
224004435|NCT04374214|PROCEDURE|Complete Pulpotomy using Simvastain -alphatricalcium phosphate|Inflammed coronal pulp tissue will be removed till the canal orifices and Simvastatin -alpha tricalcium phosphate placed over the amputated pulp stump.
224004436|NCT03198468|DEVICE|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).
224004437|NCT01333813|BIOLOGICAL|Engerix-B™ Kinder|Intramuscular, single dose
224004438|NCT04716062|PROCEDURE|Open or Laparoscopic-assisted Colorectal surgery|Colorectal surgery
224004439|NCT00285025|DRUG|SR57667B|
224124864|NCT06962891|DIAGNOSTIC_TEST|CKD progression biomarker|We will evaluate the CKD progression biomarker at baseline and evaluate 1-year CKD progression afterwards.
224004440|NCT02237729|BIOLOGICAL|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
224299217|NCT04253496|OTHER|Tumor samples and MRI|We will use DNA and RNA tumor samples. We will not use germline or blood DNA. These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
223730088|NCT05595356|BEHAVIORAL|Psychoeducation video|Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.
223730089|NCT05595356|BEHAVIORAL|Tutorial video|Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
223730090|NCT00543556|DRUG|MK0767|
224004441|NCT02237729|BIOLOGICAL|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
224004442|NCT02237729|BIOLOGICAL|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
224004443|NCT04278014|PROCEDURE|ultrasound-guided continuous sciatic block with longitudinal approach|ultrasound-guided continuous sciatic block with longitudinal approach
224004444|NCT00306267|DRUG|epoetin alfa|
224004445|NCT00464984|BEHAVIORAL|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
224004446|NCT02429453|DRUG|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
224004447|NCT02429453|BIOLOGICAL|Fresh Frozen Plasma|A pooled collection of plasma from donors
224004448|NCT01992601|DRUG|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|"For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period."
224004449|NCT04368364|DRUG|Intrathecal morphine sulfate (ITM)|Spinal anesthesia with ITM + US guided QLB single shot sham block + QLB catheters with no continuous infusion
224004450|NCT04368364|DRUG|Bupivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters with no continuous infusion
224004451|NCT04368364|DRUG|ropivacaine hydrochloride|Spinal anesthesia without ITM + US guided QLB single shot with bupivacaine hydrochloride + QLB catheters continuously infusing 0.2% ropivacaine hydrochloride
224124865|NCT06433128|DRUG|Fosmanogepix solution for infusion|Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
223730091|NCT00656344|OTHER|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
223730092|NCT05667545|DRUG|Peptide|it is about synthetic protein acting on tooth structure help information apatite crystals
224004452|NCT03947307|DEVICE|lymphtaping using Easytape®|lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
224004453|NCT03947307|PROCEDURE|compression treatment|manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
224004454|NCT03947307|DEVICE|sham taping|sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
224004455|NCT04068233|OTHER|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
224004456|NCT00619749|DIETARY_SUPPLEMENT|juice rich in polyphenols|juice during 2 weeks
224004457|NCT00619749|DIETARY_SUPPLEMENT|juice poor in polyphenols|juice during 2 weeks
224004458|NCT04906629|BIOLOGICAL|INO-4201|One dose of 1 mg of INO-4201 in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
224004459|NCT04906629|BIOLOGICAL|Placebo|One dose of normal saline in 0.1 ml injected intradermally followed by electroporation with CELLECTRA2000
224004460|NCT06363682|PROCEDURE|ERCP|ERCP of the biliary duct ou the pancreatic duct, with or without the use of a stent, in a context of gallstone or tumor or other
224004461|NCT06363682|PROCEDURE|endoscopic ultrasound|The use of endoscopic ultrasound in diverse situation with the necessity of using X rays
224004462|NCT06363682|PROCEDURE|gastroscopy|"The diverse procedure in witch scopy is use in orders to place or switch or remove an oesophageal or gastroduodenal stent during a gastroscopy.~Or for oesophageal or gastroduodenal dilatation."
224004463|NCT06363682|PROCEDURE|Colonoscopy|The diverse procedure in witch scopy is use during a colonoscopy
224004464|NCT06363682|PROCEDURE|placement of a nasojejunal tube|placement of a nasojejunal tube for enteral nutritional support
224004465|NCT04404127|DRUG|Basiliximab 20 milligram [Simulect]|Basiliximab
224004466|NCT04404127|OTHER|Normal Saline|No-Induction
224004467|NCT00495105|BEHAVIORAL|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
224004468|NCT03339739|OTHER|Isometric mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars
224004469|NCT03339739|OTHER|Isotonic mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors
224004470|NCT03339739|BEHAVIORAL|Counseling group|subjects included in this group get an education brochure about the disorder and receive no further interventions
224124866|NCT06433128|DRUG|Fosmanogepix 400 mg tablets|Fosmanogepix 400 mg tablets for oral administration
224124867|NCT05232279|DRUG|Testofen 300mg|Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
224124868|NCT05232279|DRUG|Testofen 600mg|Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
224124869|NCT05232279|DRUG|Placebo comparator|The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
223386603|NCT05518084|OTHER|Liponovo tissue product|Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
224004471|NCT05052788|DEVICE|Optical coherence tomography angiography|"OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine ."
224004472|NCT04095559|DIAGNOSTIC_TEST|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
224004473|NCT04095559|DIAGNOSTIC_TEST|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
224004474|NCT04095559|DIAGNOSTIC_TEST|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
224004475|NCT03749018|DRUG|Cyclophosphamide|Given IV
224004476|NCT03749018|DRUG|Doxorubicin Hydrochloride|Given IV
224004477|NCT03749018|DRUG|Etoposide|Given IV
224004478|NCT03749018|BIOLOGICAL|Nivolumab|Given IV
224004479|NCT03749018|DRUG|Prednisone|Given PO
224004480|NCT03749018|BIOLOGICAL|Rituximab|Given IV
224004481|NCT03749018|DRUG|Vincristine Sulfate|Give IV
224004482|NCT00856440|DRUG|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
223386604|NCT00766740|DEVICE|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
223386605|NCT00766740|DEVICE|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
223730093|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
224004483|NCT00856440|DRUG|Colyte|Lavage preparation for colonoscopy
224004484|NCT00856440|DRUG|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
224004485|NCT03212495|DRUG|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
224004486|NCT03212495|DRUG|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
224004487|NCT06502886|PROCEDURE|combined protocol of retention (bonded lingual retainer and vacuum formed retainers)|Combined bonded retainer and vacuum formed retainer
224004488|NCT06502886|PROCEDURE|Bonded lingual retainer|Bonded retainer
224004489|NCT01098318|DIETARY_SUPPLEMENT|Herbal extract|340-1,360 mg daily
224004490|NCT01098318|DRUG|Sertraline|50-200 mg daily
224004491|NCT01098318|OTHER|Lactose monohydrate|1-4 capsules daily
224004492|NCT01675245|DRUG|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
224004493|NCT02878707|DRUG|Dexmedetomidine|Intraoperative dexmedetomidine infusion
224004494|NCT00513487|DRUG|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
224004495|NCT04698759|OTHER|No Intervention|no Intervention
224004496|NCT02538159|DEVICE|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
224004497|NCT02538159|DEVICE|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
224004498|NCT05901909|BEHAVIORAL|Educational intervention based on the Precede-Proceed Model for individuals caring for stroke home care patients|Home visits will be made to 70 stroke patients identified during the implementation phase of the research, and training based on the Precede-Proceed model will be given to 70 individuals who care for these patients in the meeting room of the hospital where the research will be conducted. In the research, pre-education evaluation will be collected at the hospital before the training for the caregivers and home visits for the patients. In the second stage, the training program planned for the caregivers will be implemented in the meeting room of the hospital. After the training program reaches all of the caregivers in the determined number, the first evaluation will be made for the caregivers and the patient in the 8th week after the training is over. The third stage is the 16th week after the completion of the training, and the final evaluation will be made for the patients and caregivers.
223386606|NCT06881992|DRUG|Ersodetug|Ersodetug (9 mg/kg) + SOC
223386607|NCT06881992|DRUG|Ersodetug|Ersodetug (9 mg/kg) + SOC
223386608|NCT06881992|DRUG|Placebo|Placebo (9mg/kg) + SOC
223386609|NCT06551207|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
224004499|NCT03186573|DIETARY_SUPPLEMENT|Grape juice|400ml diary of grape juice
224004500|NCT03186573|DIETARY_SUPPLEMENT|Maltodextrin|400ml diary of maltodextrin
224004501|NCT05865132|DRUG|Palbociclib|120mg/125mg po qd on day 1 to 21, every 28 days
224004502|NCT05865132|DRUG|Afatinib|30mg/40mg po qd on day 1 to 28, every 28 days
224004503|NCT02824354|DRUG|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
224295801|NCT06195696|BEHAVIORAL|employs questionnaires|The first phase is a quantitative study that employs a questionnaire to investigate the current state of illness perception and the distribution of coping styles in kidney transplant recipients, and to explore the differences in illness perception between positive coping and negative coping patients after kidney transplantation; The second phase involves a descriptive qualitative study that utilizes face-to-face, semi-structured, in-depth interviews to investigate the causes of differences in illness perceptions of different coping styles in kidney transplant recipients who experience idiosyncrasies.
224299218|NCT04029441|OTHER|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
224004504|NCT02824354|DRUG|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
223386610|NCT06551207|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
223386611|NCT06551207|RADIATION|SBRT|SBRT:8-10Gy×5F, god, in 10 days
223386612|NCT03875547|DRUG|Refixia®|Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
223386613|NCT01650701|DRUG|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
223386614|NCT01650701|DRUG|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
224004505|NCT02080559|BIOLOGICAL|4CMenB|0.5ml IM
223386615|NCT01650701|DRUG|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
223386616|NCT01650701|DRUG|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
223386617|NCT01650701|DRUG|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
223386618|NCT07041203|DRUG|sodium oxybate|Oral administration of sodium oxybate (1.5g, 2.0g, 2.5g, 3.0g)
223386619|NCT06731907|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg IV Infusion.
223386620|NCT06731907|DRUG|Carboplatin|Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.
224004506|NCT05838378|OTHER|Package image sorting with pictorial warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with pictorial warnings on each pack.
224004507|NCT05838378|OTHER|Package image sorting with Surgeon General text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with Surgeon General text-only warnings on each pack.
224004508|NCT05838378|OTHER|Package image sorting with FDA text-only warnings|Weekly for four weeks participants will complete an image-sorting task based on sorting cigarillos by flavor categories \[fruit (e.g., Grape), alcohol (e.g., Wine) desserts/candy (e.g., Sticky Sweets), mint (e.g., Menthol), color (e.g., Blue Crush), and other\]. Participants will sort 18 images of cigarillo packages from various brands with FDA text-only warnings on each pack.
224004509|NCT06147908|DRUG|DW5221|megestrol acetate
224004510|NCT06147908|DRUG|DW5221-R|megestrol acetate
224004511|NCT00864253|DRUG|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
224004512|NCT00864253|DRUG|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
224004513|NCT03089138|DRUG|Regan Tangjiang|The treatment duration is 3 consecutive days.
224004514|NCT01896726|DRUG|Baricitinib|Administered orally
224004515|NCT01896726|DRUG|Microgynon|Administered orally
224004516|NCT01128114|DRUG|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
224004517|NCT06078228|DRUG|Propofol - Fentanyl- Atracurium|investigate the reliability of preanesthetic ultrasound measurements of the carotid artery FTc and the internal jugular vein collapsibility index in predicting hypotension during the induction of general anesthesia.
224004518|NCT05414344|BEHAVIORAL|Standard Brief Intervention|Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.
223386621|NCT06731907|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 IV infusion.
223386622|NCT06731907|DRUG|Nab-paclitaxel|Nab-paclitaxel 100mg/m\^2 IV infusion.
223386623|NCT06731907|DRUG|Pemetrexed|Pemetrexed 500mg/m\^2 IV infusion.
223386624|NCT06731907|BIOLOGICAL|HER3-DXd|HER3-Dxd 5.6mg/kg IV infusion.
223386625|NCT05703269|RADIATION|single fraction stereotactic radiosurgery (SSRS)|SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions.
223386626|NCT05703269|RADIATION|fractionated stereotactic radiosurgery (FSRS)|FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions.
223386627|NCT06919809|DEVICE|A microsurfaced ADM (acellular dermal matrix)|X A-DERM™ ADM has been resurfaced (Microsurfaced) instead of currently utilized smooth surface reconstructive grafts. Microsurfacing of regenerative tissue grafts increases the surface area at the graft-to-host interface and results in quicker absorption of blood into the graft, greater cellular infiltration, improved seal and wound bed preparedness.
224004519|NCT05414344|BEHAVIORAL|Trauma-Informed and Peer-Supported Brief Intervention|In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
224004520|NCT05414344|BEHAVIORAL|Assessment only|Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
224004521|NCT04532567|DRUG|GLPG1205|GLPG1205 film-coated tablets
224295802|NCT02023736|OTHER|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
224295803|NCT02023736|OTHER|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
223386628|NCT07047326|DRUG|Urokinase thrombolysis|The intravenous thrombolysis group was administered urokinase dissolved in 100 mL of saline via continuous intravenous infusion for 30 min, and the treatment was given within 6 h of stroke onset. The dose escalation plan includes the following increments: 15,000 IU/kg (maximum dose: 1.5 million IU), 20,000 IU/kg (maximum dose: 2.0 million IU), and 25,000 IU/kg (maximum dose: 2.5 million IU).
223386629|NCT03958292|DEVICE|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
223386630|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
223545635|NCT05317650|OTHER|Multi-gravitational suspension-based therapy (M-Gravity)|Multi-gravitational suspension-based therapy (M-Gravity) is a comprehensive discipline based on the principles of non-gravity, which serves to increase the quality of life and holistic health of the individual with the rehabilitation content of non-pressure inversion therapy.
224004522|NCT04532567|DRUG|Placebo|placebo film-coated tablets
224004523|NCT00208325|DEVICE|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
224004524|NCT00208325|DEVICE|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
224004525|NCT06436638|DEVICE|Non-invasive ventilation support equipment|Non-invasive ventilation support is provided by nasal airway and nasal CPAP mask to avoid respiratory complications such as hypoxia, desaturation, hypercarbia, respiratory depression etc. during extraction of impacted molars under deep sedation.
224004526|NCT04258683|DRUG|Pembrolizumab|Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
224004527|NCT02574962|DRUG|H.P. Acthar® Gel|
224004528|NCT02623751|DRUG|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
224004529|NCT02623751|DRUG|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily."
224299219|NCT01021358|DRUG|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
224004530|NCT01913262|BEHAVIORAL|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
224004531|NCT03877861|DEVICE|Readiband Sleep Tracking|Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
224004532|NCT04650399|BIOLOGICAL|Active|Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose
224004533|NCT04650399|BIOLOGICAL|Placebo|Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo
224004534|NCT04606498|OTHER|Observational|Observational study only - no intervention
224004535|NCT01063608|BIOLOGICAL|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
224004536|NCT03460808|DRUG|atorvastatin|Atorvastatin was used in combination with acetylcysteine and danazol.
224004537|NCT03460808|DRUG|Acetylcysteine|Acetylcysteine was used in combination with atorvastatin and danazol.
224004538|NCT03460808|DRUG|Danazol|Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
223386631|NCT04446923|DRUG|Hand antisepsis by scrub|Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
223386632|NCT00489255|DRUG|Tigan®|Oral capsule, 300mg three times daily
223386633|NCT00489255|DRUG|Placebo|Oral capsule, three times daily
223386634|NCT01171261|BEHAVIORAL|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
223386635|NCT07054606|DRUG|Perfluorohexyloctane ophthalmic solution|Eligible subjects will receive Miebo up to 4 times bilaterally on Day 1/Visit 1 (1 drop instilled bilaterally by site staff in-clinic while wearing contact lenses and the rest self-administered throughout the remainder of the day while wearing contact lenses). Starting on Day 2, subjects will self-administer the first drop of Miebo bilaterally before inserting contact lenses for the day. Subjects will wait 30 minutes after the first dose of Miebo to insert their contact lenses and will then instill 3 additional drops of Miebo while wearing contact lenses approximately evenly spaced throughout the rest of the day. Subjects will continue to self-administer Miebo QID bilaterally following the dosing schedule from Day 2 for approximately 30 days. Subjects are expected to record daily VAS assessments throughout the study. The VAS assessments will be collected by the sites at Visits 2, 3, and 4.
224004539|NCT00249964|DRUG|Combination Treatment - Cohort 1|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6."
224004540|NCT00249964|DRUG|Combination Treatment - Cohort 2|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6."
224004541|NCT00249964|DRUG|Combination Treatment - Cohort 3|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6."
224004542|NCT00249964|DRUG|Combination Treatment - Cohort 4|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6."
224004543|NCT04562740|DEVICE|ABLUMINUS DES drug eluting stent|Following successful plain balloon angioplasty of the arterial lesion, (defined as \<30% residual stenosis after treatment at rated burst pressure of the angioplasty balloon), the ABLUMINUS stent will be deployed at the lesion as per Instructions for Use (IFU) after appropriate sizing using the diameter of the plain balloon angioplasty. After deployment of the ABLUMINUS stent, further balloon angioplasty of the stent will be performed, using the same diameter standard balloon catheter at 2 minutes inflation, to ensure adequate moulding and expansion of the stent.
224004544|NCT04332159|PROCEDURE|Closed nasal fracture reduction|Closed nasal fracture reduction is performed under local anesthesia with addition of Methoxyflurane or placebo
224004545|NCT04052295|PROCEDURE|surgical diaphragmatic plication|The plication was done by the same surgeon either via a 7-8 cm long lateral thoracotomy and entrance to the pleural cavity through the eighth intercostals space on the affected side or using VATS (video-assisted thoracoscopic surgery) procedure. It was performed under single lumen intubation general anaesthesia. The diaphragm with the abdominal content was pushed caudally till the normal position of the copula achieved. At this position a fold of about 5 cm is made using traction forceps of the reluctant diaphragm. Polypropylene sutures (zero or 1) were used to perform the plication of the diaphragm. in making a fold on itself. The plication was performed using interrupted polypropylene U-stitches; usually, it started from posterior part to the anterior part of the diaphragm. We merged every two rows with continuous polypropylene sutures. The diaphragm became tough and firm and returned to its normal position. An intercostal tube was inserted, and the thoracotomy was closed in layers.
224004546|NCT02206061|BEHAVIORAL|School-Based Asthma Care for Teens (SB-ACT)|
224004547|NCT02206061|BEHAVIORAL|Directly Observed Therapy|
224004548|NCT02206061|BEHAVIORAL|Asthma Education|
224004549|NCT03873168|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
224004550|NCT06437951|DRUG|Fexuprazan Injection|20/40/80 mg
224004551|NCT06437951|DRUG|Fexuprazan Injection placebo|20/40/80 mg
224004552|NCT06437951|DRUG|Fexuprazan Injection_part 2|20mg
224004553|NCT06437951|DRUG|Fexuprazan Injection_part 3|40mg
224004554|NCT06437951|DRUG|Fexuprazan tablet|40mg
224004555|NCT03617900|DRUG|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
224004556|NCT03617900|DRUG|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
224004557|NCT03617900|DRUG|Paracetamol|500 mg paracetamol. use in need
224004558|NCT04351035|PROCEDURE|Tumour resection|It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.
224295804|NCT05288036|OTHER|Proprioceptive Neuromuscular Rehabilitation group|The PNF technique was performed in the supine position with the hip joints of the patients in 30° flexion and the lower extremities in semi-flexion. The application was performed in 2 different diagonal and 4 different patterns (flexion-abduction-external rotation/extension-abduction-internal rotation, and flexion-adduction-external rotation/extension-abduction-internal rotation) of the upper extremity. When starting the exercise, the muscles were first brought to their longest position and the patient was asked to move in the direction of the pattern with resistance (concentric contraction) and to maintain this position for 6 seconds at the end of the pattern (isometric contraction). Then, while the therapist was taking the patient's arm to the starting position, the patient was asked to prevent movement (eccentric contraction). All of these moves counted as one repetition. 3 sets of 8-12 repetitions were performed for each pattern.
224004559|NCT01883102|DRUG|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
224004560|NCT01883102|DRUG|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
224004561|NCT06042413|OTHER|Personalized CPC Prehabilitation|Patients for elective surgery randomized to the intervention group will be scheduled for a preoperative evaluation (3-6 weeks prior to the surgical date) and will receive standardized and personalized assessment and prehabilitation according to UPMC's established disease-specific algorithms.
224004562|NCT06042413|BEHAVIORAL|Cognitive Training|Participants will be provided with access to the Lumosity (Lumos Labs) software for installation on a home device. They will be trained to navigate the touchscreen tablet and guided through an introductory series of brain exercise games focused on 5 main categories: memory, speed, attention, flexibility, and problem-solving. Patients will be asked to complete a cognitive exercise dosage of a minimum of 20 minutes a day for ≥5 days prior to their date of surgery. Research coordinators and volunteers from UPMC's Hospital Elder Life Program (HELP) will reach out to participants daily for a quick social check-in and to remind them to perform their training. Compliance data will be retrieved from the Lumosity app.
224004563|NCT06042413|BEHAVIORAL|Meditation|A single guided meditation session with instructions will be provided using a smart device. The meditation session will last for at least 10 minutes daily starting at least 1-week prior to surgery. If the subject does not own a smart device, one will be provided or meditation will be completed in-person or over the phone.
224004564|NCT06042413|BEHAVIORAL|Daily Exercise|Participants in the intervention group will meet with an occupational or physical therapist approximately 1-6 weeks before surgery who will discuss the potential benefits of exercise and give directions for an easy strength training exercise. Participants will then be provided with a video link for a guided exercise and encouraged to walk or perform a seated strength exercise for ≥ 5 minutes each day for at least 1 week before surgery and after surgery. Patient reported frequency, fitness app compliance and exercise duration with REDCap email or mobile link or over telephone will be collected before and after surgery. Patients will be cleared by an occupational or physical therapist to perform the upper-extremity exercises and will confirm the exercises are not contraindicated after surgery. An occupational or physical therapist will see subject again post-surgery to mitigate risk of injury.
224004565|NCT06042413|BEHAVIORAL|Enhanced Social Support|"Research coordinators and volunteers from HELP will reach out to patients daily prior to their surgery to discuss concerns they may have, provide daily social touchpoints, and remind them to perform their cognitive exercises. In addition, the importance of social support will be discussed with family members and other caregivers and they will be encouraged to participate.~e. Proactive depression treatment: All patients will receive preoperative interventions to manage their depression under their CPC prehabilitation program."
224004566|NCT06042413|OTHER|Proactive Bundle Interventions|Participants randomized to the proactive bundled intervention group (Group D) will receive a routine intraoperative SSEP and EEG monitoring as well as optimization of intraoperative physiology by maintaining normal blood pressure, oxygen levels, opioid sparing analgesia, avoiding deep anesthesia and benzodiazepines. For example, increasing mean arterial pressure can stabilize SSEP (Fig. 6). If persistent focal changes in SSEP and EEG, (i.e., changes in one hemisphere) occur efforts will be made to increase brain perfusion by ensuring and maintaining hematocrit \>30, MAP \>70, and anesthetic BIS \>50-60; soon after surgery, patients will get stroke management and thrombectomy if indicated.
224004567|NCT06042413|PROCEDURE|Pre-operative Standard of Care|Patients in the control group will receive standard of care pre-operative treatment, which may or may not include a visit to the CPC.
224004568|NCT06042413|PROCEDURE|Intra-operative Standard of Care|This includes routine intraoperative SSEP and EEG monitoring. Physician oversight and interpretation of real-time neuromonitoring data will be performed using a combined on-site and remote model at UPMC. In the event that changes in EEG or SSEP are considered significant by the oversight neurophysiologists, the surgical team will be immediately informed so that immediate appropriate action can be taken to reverse the change.
224004569|NCT01607476|DRUG|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
224004570|NCT01607476|DRUG|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
224004571|NCT04445987|DRUG|ARQ-154|ARQ-154 foam 0.3% applied once daily for 52 weeks
224004572|NCT01114880|BIOLOGICAL|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
224004573|NCT01114880|OTHER|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
224004574|NCT03656224|OTHER|Survey Administration|Ancillary studies
224004575|NCT00288002|BIOLOGICAL|trastuzumab|
224004576|NCT00288002|DRUG|capecitabine|
224004577|NCT00288002|DRUG|cyclophosphamide|
224004578|NCT00288002|DRUG|docetaxel|
224004579|NCT00288002|DRUG|epirubicin hydrochloride|
224004580|NCT00288002|PROCEDURE|adjuvant therapy|
224004581|NCT00288002|PROCEDURE|conventional surgery|
224004582|NCT00288002|PROCEDURE|neoadjuvant therapy|
224004583|NCT04960904|DEVICE|Dental implant surgery with implants|Adult patients who have had dental implant surgery.
224004584|NCT01260818|DRUG|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
224004585|NCT01260818|DRUG|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
224004586|NCT00397670|DRUG|Drug: BufferGel® with diaphragm|
224004587|NCT02539459|DRUG|Everolimus|10 mg tablets
224299220|NCT01021358|DRUG|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
224004588|NCT00543231|DRUG|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
224004589|NCT05871320|DRUG|[99mTc]Tc-TECANT1|only one arm - the administration of \[99mTC\]-Tc-TECANT1 in all patients included
224004590|NCT03000205|DEVICE|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain at Week0
224004591|NCT03000205|DEVICE|Normal saline and Lidocaine.|Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
224004592|NCT01728311|DRUG|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
224004593|NCT02773173|PROCEDURE|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
224004594|NCT02773173|PROCEDURE|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
224004595|NCT02005042|BEHAVIORAL|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
224004596|NCT00749957|BIOLOGICAL|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
224004597|NCT01533753|DRUG|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
224004598|NCT01533753|DRUG|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
224004599|NCT04218786|DRUG|Colchicine|The tablet will be given once daily for the span of the study
224004600|NCT04218786|DRUG|Placebo oral tablet|The tablet will be given once daily for the span of the study
224004601|NCT01623193|OTHER|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
224004602|NCT01623193|PROCEDURE|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
224004603|NCT05508204|DRUG|BION-1301|A solution for SC injection administered as a single dose
224004604|NCT05413239|BEHAVIORAL|Psychoeducation to reduce diabetes distress and improve glycemic outcomes|The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting \~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
224004605|NCT02865239|PROCEDURE|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium"
224004606|NCT03582787|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
224004607|NCT03582787|DEVICE|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
224004608|NCT05684718|DRUG|BV100 (300 mg)|Intravenous solution
224004609|NCT05684718|DRUG|Itraconazole 200 mg|Oral solution
224004610|NCT04323540|PROCEDURE|Peri-implantitis reconstructive surgery|"For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap."
224004611|NCT04655027|DRUG|Roxadustat|The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to \< 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to \< 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.
224004612|NCT04655027|DRUG|rHuEPO|The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU \[dosing will BIW\], and patients on weekly dose of \>6000 IU \[dosing will TIW\]) and on patient's haemoglobin levels.
224004613|NCT03698110|BEHAVIORAL|Intervention Group|PUEDES program included eight hours in groups and activities to practice at home.
224004614|NCT01297153|DEVICE|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
224004615|NCT01297153|DEVICE|No IOL|No IOL will be implanted in these eyes
224004616|NCT03350932|BEHAVIORAL|Sensory imagination about foods|In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
224004617|NCT02860689|OTHER|using questionnaires - International Index Erectile Function|using questionnaires
224004618|NCT01169922|BEHAVIORAL|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
224004619|NCT01169922|BEHAVIORAL|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
224004620|NCT04781413|DRUG|Nab-PTX, Sintilimab, S-1|This is a single-arm study with all patients receiving these three drugs.
224004621|NCT05298059|RADIATION|Laser of low frequncy|Apply the laser at three points on each tooth.
224004622|NCT05298059|DRUG|CPP-ACPF|Apply MI paste plus for five minutes, in the vestibular surface os teeth. During this time patientes should be with closed mounth ad should not talk or to split.
224004623|NCT00232453|PROCEDURE|Combined Radiation and Chemotherapy|
224299221|NCT00759135|DRUG|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
224299222|NCT00759135|DRUG|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
224124870|NCT05170438|DRUG|Lenvatinib Pill,Paclitaxel|Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.
224124871|NCT06068270|PROCEDURE|Micro-ostoperforations (MOPs)|3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
224124872|NCT01286272|DRUG|Bendamustine Hydrochloride|Given IV
224004624|NCT02245022|DRUG|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
224124873|NCT01286272|DRUG|Bortezomib|Given IV or SC
224124874|NCT01286272|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET
224124875|NCT01286272|OTHER|Laboratory Biomarker Analysis|Correlative studies
224124876|NCT01286272|BIOLOGICAL|Ofatumumab|Given IV
224124877|NCT01286272|PROCEDURE|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
224124878|NCT05352893|DRUG|Imsidolimab high dose|intravenous
224124879|NCT05352893|DRUG|Imsidolimab low dose|intravenous
224124880|NCT05352893|OTHER|Placebo|intravenous
224124881|NCT05205954|BEHAVIORAL|Hepatology Home Hospital|The Hepatology Home Hospital intervention entails the following: patient-reported symptoms and vital signs with appropriate triggers for phone calls and home visits, and regular communication with hepatology clinicians regarding care delivered at home to ensure continuity of care.
224124882|NCT05386394|DEVICE|Active tDCS + Language Therapy|Active tDCS stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 milliamps (mA)/cm2; estimated total charge 0.048 Coulombs (C)/cm2) in a ramp-like fashion for a maximum of 20 minutes. Language therapy will be conducted in conjunction with stimulation and will target oral and written naming.
224124883|NCT05386394|DEVICE|Sham tDCS + Language Therapy|During sham stimulation, current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Language therapy targeting oral and written naming will be administered during sham tDCS stimulation.
223386636|NCT01625091|DRUG|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
223386637|NCT01625091|DRUG|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
223386638|NCT03126448|DIAGNOSTIC_TEST|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
224004625|NCT02245022|DRUG|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
224124884|NCT04966351|BEHAVIORAL|Time-restricted feeding|Each subject will participate in both conditions (CM and CM+TRF)--one in which food is allowed during the nighttime period and one in which food will be restricted to the daytime only. Food intake will be matched across conditions and designed to keep participants weight stable.
224124885|NCT04966351|BEHAVIORAL|Circadian Misalignment|Healthy lean subjects will undergo circadian misalignment induced using a simulated night shift-work protocol in both conditions of the study. Each condition will last approximately 6 days.
224124886|NCT06795373|DRUG|Ritlecitinib|Once daily dose of 100mg of ritlecitinib taken orally for 12 weeks
224124887|NCT06795438|DIETARY_SUPPLEMENT|Green tea|Green tea tablets 1000mg 1 x per day
224124888|NCT06795438|OTHER|Placebo|Placebo control 1 x blinded placebo tablet per day
224299223|NCT00759135|DRUG|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
223425612|NCT06621797|BEHAVIORAL|Intervention 3: Dietary Supplement - Caffeine Supplement + Diaphragmatic Breathing Exercises|Participants in this group will receive a caffeine supplement (3 mg/kg body weight) 45 minutes before performance testing, followed by a 10-minute session of diaphragmatic breathing exercises.
224004626|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.
224124889|NCT06076499|DEVICE|NTX100|NTX100 Tonic Motor Activation (TOMAC) System - a non-invasive peripheral nerve stimulation device programmed to deliver active stimulation.
224124890|NCT06839976|BIOLOGICAL|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.
224124891|NCT05420129|DEVICE|MAD Therapy|Participants will be treated with a Mandibular Advancement Device therapy
224124892|NCT05420129|DEVICE|CPAP Therapy|Participants will be treated with a Continuous Positive Airway Pressure therapy
224124893|NCT04058457|DEVICE|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
224124894|NCT01415037|PROCEDURE|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
224124895|NCT01127126|DRUG|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
224124896|NCT01671969|OTHER|very low calorie diet|medically supervised diet
224124897|NCT01360944|DRUG|LAS41004|once daily, topical, 100 microgram
224124898|NCT01360944|DRUG|reference|once daily, 100 microgram
224124899|NCT00793676|OTHER|spirometry|
224124900|NCT00793676|OTHER|blood test|
224124901|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
224004627|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 14 and week 26 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.
224004628|NCT05126472|DRUG|anti-CD40 antibody 2141-V11|Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
224004629|NCT05887115|BEHAVIORAL|Nurse Family Partnership|During NFP visits, the nurse: 1) engages in a therapeutic nurse-client relationship focused on promoting client abilities and behavior change to protect and promote her own health and child's health; 2) provides service coordination based on client's identified needs, referring to available community services; 3) follows NFP Visit Guidelines tailoring them to the strengths and challenges of each family; 4) works with client to support a healthy pregnancy by recognizing and reducing risk factors and promoting prenatal health care, healthy diet, exercise, and stress management; and 5) gathers data on program implementation and maternal and child health. The visits include content from six domains: personal health, environmental health, life-course, maternal role, family and friends, and health and human services. Nurses use educational materials to address the content from the six domains with their clients.
224004630|NCT02753179|OTHER|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
224004631|NCT02753179|OTHER|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
224004632|NCT02753179|OTHER|VEMPs & VEMPo|VEMPs \& VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
224004633|NCT02753179|OTHER|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
224004634|NCT02753179|OTHER|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
224004635|NCT03519997|DRUG|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
224004636|NCT03519997|DRUG|Bavituximab|Bavituximab 3mg/kg IV weekly
224004637|NCT05082961|OTHER|Collection of blood samples|Samples to evaluate the circulating CD8+ T cell count.
224004638|NCT05543707|DRUG|PBI-0451 (Pomotrelvir)|2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
224004639|NCT05543707|DRUG|Placebo|2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
224004640|NCT00186888|PROCEDURE|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
224004641|NCT00186888|DRUG|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage\< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
224124902|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
224124903|NCT02498561|PROCEDURE|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
224124904|NCT02498561|PROCEDURE|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
224299224|NCT01423136|DEVICE|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
223386639|NCT07067398|BEHAVIORAL|Peer Coaching Delivered Life's Essential 8 Program|This intervention includes structured bi-weekly peer coach (PC) Zoom or telephone sessions and a cardiovascular health curriculum including links to AHA resources. During the 1:1 session, PCs will elicit participants' challenges and successes from the previous week, track progress, and set goals (behavioral targets). PCs will use cognitive training techniques to teach participants how to manage negative thinking and replace it with positive thinking and goal setting. They will be encouraged to work towards these goals and monitor their progress (i.e. getting more physical activity on the job).
224299225|NCT02252718|OTHER|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
223425613|NCT05497479|DRUG|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic (per randomization), before and after instillation of 0.003% AR-15512
223425614|NCT05497479|DRUG|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed without anesthetic, before and after instillation of Vehicle
223386640|NCT06811545|DEVICE|Neuromuscular Electrical Stimulation (NMES)|Children with CP can have trouble with daily tasks such as walking. This raises their risk of disability as they age into their teens. Current treatments are not very effective. In this study, children with CP will walk on a treadmill while receiving NMES on their lower limb muscles, using surface electrodes, while their gait dynamics are assessed. Our proposed study aims to gather preliminary evidence to support the potential efficacy of NMES assistance to muscles across all lower limb joints during walking, i.e., multi-joint NMES assistance. Additionally, the investigators aim to investigate the optimal level of intensity.
224004642|NCT00186888|PROCEDURE|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
224004643|NCT00186888|RADIATION|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
224004644|NCT00186888|DRUG|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml\*hr, daily for 5 consecutive days, infused over 30 minutes.
224004645|NCT00186888|DRUG|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
224004646|NCT00186888|DRUG|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: \< 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin \< 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
224004647|NCT00186888|DRUG|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: \< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, \< 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
224004648|NCT00186888|PROCEDURE|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
224004649|NCT00186888|OTHER|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is \> 2,000/mL in one occasion after the expected nadir.
224004650|NCT05691205|OTHER|PEEP|After a recruitment maneuver three levels of PEEP (14\>10\>6cmH2O) will be tested
224004651|NCT04752722|DRUG|EG-70 (phase 1)|Patients will receive up to four cycles of EG-70 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes.One cycle lasts approximately 12 weeks and consists of either a 2-dose (Day 1 and Day 8) or 4-dose (Day 1, Day 8, Day 29 and Day 36) regimen.
224124905|NCT01136668|PROCEDURE|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
224124906|NCT01136668|PROCEDURE|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
224124907|NCT02251444|PROCEDURE|outpatient rehabilitation program|
224124908|NCT02251444|PROCEDURE|physical therapy|
224124909|NCT01923233|BIOLOGICAL|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
224124910|NCT04611763|DRUG|Flurbiprofen axetil preoperatively|give Flurbiprofen axetil 15 min before surgery
224124911|NCT04611763|DRUG|Flurbiprofen axetil postoperatively|give Flurbiprofen axetil at the end of surgery
223386641|NCT04639284|DRUG|Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies|Combination therapies with an anti-angiogenic agent (tyrosine kinase inhibitor or VEGF/VEGFR antibody) and an anti-PD-1/PD-L1 antibody.
224124912|NCT03172611|OTHER|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
224124913|NCT02775760|BEHAVIORAL|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
224124914|NCT02775760|BEHAVIORAL|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
223386642|NCT04729114|DRUG|PRL-02 injection|abiraterone decanoate for intramuscular injection
223386643|NCT04729114|DRUG|prednisone|Oral dose
223386644|NCT04729114|DRUG|dexamethasone|Oral dose
224124915|NCT01760941|RADIATION|Radiation Therapy|Undergo standard of care radiation therapy
224124916|NCT01760941|OTHER|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
224299226|NCT04481321|BIOLOGICAL|Biological/Vaccine|
223386645|NCT04729114|DRUG|enzalutamide|Oral capsule
224004652|NCT04752722|DRUG|EG-70 (phase 2)|Patients will receive during Treatment Period, up to 4 cycles of EG-70 at the RP2D defined in Phase 1 administered as a bladder instillation of a 50 mL volume of study drug via catheter with a targeted retention time of 60 minutes. One cycle lasts approximately 12 weeks. For Maintenance treatment 2 doses of EG-70 will be administered as a bladder instillation per 12-week cycle.
224004653|NCT05020535|DRUG|MW189|MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
224004654|NCT05020535|OTHER|Saline|Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
224004655|NCT06073002|OTHER|home-based concurrent exercise|3 weekly sessions of home-based concurrent exercise on non-consecutive days. Resistance exercise is comprised of lunges, hip thrusts, pushups, resistance band rows, core and performed for 3 sets with 15-20 repetitions at an RPE of 14-18 (6-20 BORG scale). Endurance exercise can be done by the mode of choice and is monitored by heartrate zones. Sessions are of low to moderate intensity (below VT2) and the duration will be slowly increased for 20-40min.
224004656|NCT03006848|DRUG|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
224004657|NCT03006848|OTHER|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
224004658|NCT04712591|DIAGNOSTIC_TEST|Auditory stimuli|Auditory stimuli (passive, active perturbations)
224004659|NCT06963658|OTHER|Multiple repetition isometric wall squat|Participants were directed to rest their backs against the wall with shoulder width apart and feet parallel, then descend until they achieve an angle of 100 degrees at knee joint. The knee joint angle was assessed using a goniometer placed on the lateral epicondyle of the knee, aligned with the femur, while the anchor arm was aligned with the lateral malleolus. They were instructed to maintain the isometric hold for up to three minutes, or until volitional fatigue was reached.with a 30-second rest period between each squat hold.
224004660|NCT06963658|OTHER|Multiple Isometric wall squat exercise + Double Leg Lower with Isometric Hold|Participants were directed to rest their backs against the wall with shoulder width apart and feet parallel, then descend until they achieve an angle of 100 degrees at knee joint. The knee joint angle was assessed using a goniometer placed on the lateral epicondyle of the knee, aligned with the femur, while the anchor arm was aligned with the lateral malleolus. They were instructed to maintain the isometric hold for up to three minutes, or until volitional fatigue was reached.with a 30-second rest period between each squat hold. Immediately post 60 second rest, Determine the participant's maximum angle using the double leg lowering test from supine position let the participant with both legs straightened before lifting the posterior hip, lowering the legs to a specific angle. Turn on the stopwatch. Hold the position near--maximally, try to achieve on (IES=9/10) and hold for the longest duration. They should reach 4 minutes for 3 repetition with 30 seconds rest between repetition
224004661|NCT06963658|OTHER|Control quiet seated rest|The control group served as the control group and did not perform any exercise. Participants were instructed to sit quietly in a standard height stationary clinical room patient chair for the entire eight minutes.
224004662|NCT01602029|DRUG|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
224004663|NCT01602029|DRUG|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
224004664|NCT01602029|DRUG|Placebo|Placebo added to TAU
224004665|NCT01602029|DRUG|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
224004666|NCT04836169|DEVICE|InCaveo's EOA system with integrated mobile CBT|integrated pain management therapeutic and tapering system including a software apt that manages and tracks patient-reported outcomes, including pain levels, medication use, quality of life
224004667|NCT00131105|BEHAVIORAL|The Stanford Active Choices program|
224004668|NCT05250427|OTHER|No treatment given|No treatment given
224004669|NCT06415097|DEVICE|Insulin Smart Pen|Retrospective analysis of electronic health records for individuals with type 1 diabetes receiving multiple daily doses of insulin, combined with glucose monitoring devices and who have used or are currently using insulin smart pens.
224004670|NCT01622062|BIOLOGICAL|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
224004671|NCT01622062|BIOLOGICAL|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
224004672|NCT01622062|BIOLOGICAL|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
224004673|NCT00407862|DRUG|Telmisartan 80 mg|
224004674|NCT00407862|DRUG|Losartan 50 mg|
224004675|NCT06266208|PROCEDURE|Exostectomy|Patients diagnosed with dorsal osteophyte and experiencing pain were advised to proceed with osteophyte removal surgery during their initial visit.The surgical procedure, following protocol occurred during the second visit and involved the following steps: a 2-4 mm incision using a Beaver-64-MIS scalpel on the distal surface wall of the toe, parallel to its longitudinal axis, followed by careful osteophyte drilling; precise delineation of the osteophyte contour using a blunt elevator to prevent nailbed damage; resection executed through medial and lateral movements facilitated by a mini-Shannon drill; and finally, pressure application with a surgical spoon to extract the bone paste resulting from the drilling process.
224004676|NCT06266208|PROCEDURE|Cut fingernail|Patients diagnosed with dorsal osteophyte and experiencing pain underwent nail cut fingernail
224004677|NCT03812042|DIAGNOSTIC_TEST|Enzyme assay and molecular sequencing|Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
224004678|NCT06417710|OTHER|Neurological Assessment|Clinical neurological assessment performed by 2 raters
224004679|NCT02630680|DRUG|Eziclen®/Izinova®|
224124917|NCT01760941|OTHER|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
224124918|NCT05279014|OTHER|Meal timing|A high-carbohydrate (1 g/kg body mass) meal to be consumed either 1.5-3 hours before or immediately after exercise. Those consuming the meal after exercise will have fasted for at least 8 hours before exercise.
224004680|NCT03322839|BEHAVIORAL|Multifaceted implementation strategies|The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
224004681|NCT03322839|BEHAVIORAL|Single implementation strategy|The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
224004682|NCT04058834|DRUG|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
224004683|NCT04058834|DRUG|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
224004684|NCT03297502|DRUG|pimecrolimus cream 1%|
224004685|NCT03297502|DRUG|Elidel (pimecrolimus) cream 1%|
224004686|NCT03297502|DRUG|placebo|
224004687|NCT05036980|DRUG|Trans Sodium Crocetinate|Single IV bolus
224004688|NCT00720031|BIOLOGICAL|autologous Melan-A/MART-1 specific CTL clones|"By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.~After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12."
224004689|NCT04080037|OTHER|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication."
224004690|NCT00587691|BIOLOGICAL|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
224124919|NCT03300752|BEHAVIORAL|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
224124920|NCT03300752|BEHAVIORAL|Control Intervention|PCP will provide discussion of healthy lifestyles.
224124921|NCT04502810|RADIATION|High-level laser therapy|Nd:Yag 1064 nm pulsed high-level Laser will be applied to the vulvar area.
223386649|NCT03008759|OTHER|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
223386650|NCT03008759|OTHER|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
223386651|NCT03008759|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
223386652|NCT06901505|DRUG|Erythropoiesis-Stimulating Agent (ESA)|Administered by intra-venous (IV) infusion.
223386653|NCT06901505|DRUG|Vadadustat|300mg, oral tablets
223386654|NCT06908304|DRUG|6-Thio-2'-Deoxyguanosine|small molecule telomere targeting agent
223386655|NCT06908304|DRUG|Cemiplimab|programmed cell death protein 1 (PD-1) inhibitor
224004691|NCT02868606|OTHER|Physiologic Insulin Therapy|
224004692|NCT02868606|OTHER|Sliding-Scale Insulin Therapy|
224004693|NCT06341140|OTHER|Breastfeeding support and Booklet containing information about breastfeeding|Pregnant women in the intervention group were given individual counseling with a wearable breastfeeding model. During postnatal home visits, mothers were given support on breastfeeding, breast problems were addressed, and information was given to support the mother's self-efficacy.
224004694|NCT06341140|OTHER|Booklet containing information about breastfeeding|Pregnant women in the control group were given only a breastfeeding booklet, breastfeeding status, breast problems and breastfeeding self-efficacy were evaluated during postnatal home visits and telephone interviews, and risky situations were referred to health professionals.
224124922|NCT05164406|PROCEDURE|Blood salvage therapy|In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met
224124923|NCT01371487|DRUG|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
224124924|NCT01350960|DRUG|SPC5001|3 weekly SC injections
224124925|NCT01350960|DRUG|Saline 0.9%|3 weekly SC injections
224124926|NCT01350960|DRUG|SPC5001|3 weekly SC injections
224124927|NCT01350960|DRUG|SPC5001|3 weekly SC injections
224124928|NCT01350960|DRUG|SPC5001|3 weekly SC injections
224124929|NCT01350960|DRUG|SPC5001|3 weekly SC injections
223386656|NCT06908304|DRUG|Docetaxel|Chemotherapy drug; inhibits cell division by stabilizing microtubules. Used for breast, lung, and prostate cancers.
223386657|NCT06908304|DRUG|Vinorelbine|Chemotherapy drug; disrupts microtubule formation, inhibiting cell division. Used for non-small cell lung cancer and breast cancer.
223386658|NCT06908304|DRUG|Gemcitabine alone|Chemotherapy drug; inhibits DNA synthesis. Used for pancreatic, lung, breast, and ovarian cancers.
223386659|NCT04872985|DRUG|Pyrotinib|400 mg orally once per day. Pyrotinib starts with a dose of 240 mg once daily for one week, followed by 320 mg once daily for the next week, before transitioning to 400 mg once daily as maintenance therapy.
224004695|NCT05891951|OTHER|Fluid therapy under the guide of Carotid ultrasound|Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient. If volume is sufficient, no fluid therapy will be given.
224004696|NCT03960047|BEHAVIORAL|Virtual Reality Training|This group gets trained to cross streets using virtual reality
224004697|NCT03960047|BEHAVIORAL|Streetside Training|This group is trained to cross streets based on streetside experiences
224004698|NCT05157243|DRUG|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
224004699|NCT05157243|DIETARY_SUPPLEMENT|Vitamin Super-B Complex|Vitamin Super B-Complex administered orally twice daily for 5 days to maintain the blind
224004700|NCT05157243|DRUG|Placebo|Two matching placebo tablets administered orally with food twice daily for 5 days
224004701|NCT05157243|OTHER|Standard of Care|Local standard of care for COVID-19
224004702|NCT06355934|OTHER|no intervention|not applicable, this is an observational retrospective data analysis study; no interventions in the study
224004703|NCT06604650|BEHAVIORAL|Active older Adults|The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.
224004704|NCT02172677|BEHAVIORAL|Episodic memory task|
224004705|NCT02172677|DEVICE|fMRI|
224004706|NCT06853431|DRUG|dexmedetomidine|esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.
224004707|NCT06853431|DRUG|Esketamine|esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.
224004708|NCT05615766|DEVICE|Experimental: Device Intervention|The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
224004709|NCT06606054|OTHER|Educational and implementation Neurocardiology tool|Sites in this arm will be provided with an educational and implementation Neurocardiology tool aiming to improve adherence to best practice recommendations for secondary stroke prevention of cardioembolic strokes, as defined by the WSO Systematic Review and Synthesis of Global Stroke Guidelines or more recent high-quality evidence published after the last stroke guidelines1.
224004710|NCT06606054|OTHER|No educational or implementation tool will be provided|Participants will be followed for up to 12 months. No educational or interventional tool will be provided to sites in this arm until the follow-up period has ended.
224004711|NCT06987903|PROCEDURE|Pre- and post-operative physical exercise programme|"Pre- and post-operative physical exercise programme during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants.~A program will be designed according to the needs and preferences of the individual and will include:~Aerobic exercise: Activities that mobilize large muscle groups for prolonged periods of time.Walking, running at a slow or moderate pace (especially on a treadmill), cycling, cycloergometer, etc. In addition, due to the characteristics of the patients, the recommended exercises will be of low impact.~Strength exercise: Exercises of large muscle groups with intensities adapted to patients using body weight or elastic bands of different resistances.~Flexibility exercise: Stretching exercises will be included during the warm-up and cool-down of each exercise session of the program."
224004712|NCT06987903|PROCEDURE|Pre- and post-operative respiratory physiotherapy|"Pre- and post-operative respiratory physiotherapy during 4 weeks before bariatric surgery and during 8 weeks after bariatric surgery for arm 1 participants.~Breathing exercises:~Abdomino-diaphragmatic respiratory control exercises, costo-diaphragmatic respiratory control exercises, costo-diaphragmatic breathing control exercises, exercises with costal expansion and arm elevation and breathing exercises with pursed lips in different positions.~Incentive spirometry:~Incentive spirometry with the performance of slow, deep breaths in a volumetric incentive device."
224004713|NCT06858280|DRUG|Patiromer 8400 MG [Veltassa]|Randomized patients will receive one 8.4 g packet of patiromer per day or one identical packet containing a placebo. To minimize the possibility of interference with gastrointestinal absorption of other orally administered medications, administration of patiromer will be separated by at least 3 hours from other oral medicinal products. Throughout the whole study period, the study drug will be administered every day in the morning.
223386660|NCT04872985|DRUG|Epirubicin|100 mg/m2,q3W\*4
223386661|NCT04872985|DRUG|Doxorubicin Hydrochloride Liposome Injection|30mg/m2, q3w\*4
223386662|NCT04872985|DRUG|Cyclophosphamide|600 mg/m2, q3w\*4
223386663|NCT04872985|DRUG|Docetaxel|100 mg/m2, q3w\*4
224004714|NCT06858280|DRUG|Placebo|Randomized patients will receive one packet of placebo identical to that of patiromer. Following the same treatment sequence of patiromer, administration of the placebo will be separated by at least 3 hours from any other oral medicinal products. As for patiromer, the placebo will be administered every day in the morning.
224124930|NCT00857753|DRUG|Fentanyl patch 25 ug/nr Sandoz|
224124931|NCT00857753|DRUG|Duragesic|
223386664|NCT04872985|DRUG|Nab paclitaxel|120mg/m2 qw\*12 or 260mg/m2 q3w\*4
223386665|NCT04872985|DRUG|Placebo|400 mg orally once per day
223386666|NCT06938399|DEVICE|Silicone gel-filled breast implants - Motiva Implants®|Breast Surgery
223386667|NCT06938399|OTHER|Aesthetic Surgery|Aesthetic procedure other than breast implant surgery
223386668|NCT06954948|BEHAVIORAL|pulmonary rehabilitation (PR)|PR is an exercise and education programme designed for people with lung disease who experience symptoms of breathlessness.
223386669|NCT07157930|BEHAVIORAL|The Beighton Scoring system|The Beighton Scoring System is widely used to distinguish individuals with generalized joint hypermobility from those without. The Beighton Scoring System consists of: • Passive dorsiflexion of the fifth metacarpophalangeal joint • Passive hyperextension of the elbow • Passive hyperextension of the knee joint • Passive placement of the thumb on the flexor side of the forearm • Forward flexion of the trunk In adults up to 50 years of age, a score of ≥5 out of 9 indicates joint hypermobility, while in adults over 50, a score of ≥4 out of 9 is considered positive for joint hypermobility.
224004715|NCT06661785|PROCEDURE|large orbital floor fracture|Twenty two patients with large orbital floor fracture will be reconstructed with interlocking polyetheretherketone patient-specific implant
224004716|NCT06297213|DRUG|R-2487|R-2487 DP
224124932|NCT06545747|RADIATION|DCE-MRI based split-course hypo-RT|Tumor delineation will be based on DCE-MRI and CT. MRI help define the tumor boundary. Different radiation doses will be delivered based on the Ktrans value of the tumor area on DCE-MRI.
224124933|NCT06545747|RADIATION|CT based split-course hypo-RT|Tumor delineation will be based on CT. The total dose for both the first and boost courses of hypo-RT to the tumor area will be constant.
224004717|NCT04372121|DRUG|75 mg linzagolix tablet|For oral administration once daily
224004718|NCT04372121|DRUG|200 mg linzagolix tablet|For oral administration once daily
223425615|NCT05497479|DRUG|0.003% AR-15512 to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of 0.003% AR-15512
223730094|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
224004719|NCT04372121|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
224124934|NCT06545747|DRUG|Concurrent chemotherapy|Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.
224124935|NCT06545747|DRUG|Consolidative immunotherapy|Consolidative PD-1/PD-L1 inhibitors
223730095|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
224004720|NCT04372121|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
224004721|NCT04372121|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
224004722|NCT04372121|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
224124936|NCT05955209|DRUG|Disitamab Vedotin（RC48-ADC）|Participants will receive RC48-ADC intravenous injection (2.0 mg/kg, Q2W) until disease progression or death.
224124937|NCT06500494|DRUG|Vinorelbine Tartrate Oral|The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.
224124938|NCT06414499|DRUG|rhTNK-tPA|rhTNK-tPA 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds. Additionally, placebo oral aspirin and clopidogrel are given. Aspirin 100 mg and clopidogrel 300 mg are administered within 6 ± 2 hours following thrombolytic therapy.
224124939|NCT06414499|DRUG|Control group (Aspirin combined with clopidogrel)|Dual antiplatelets with aspirin 100mg and clopidogrel 300mg, plus placebo intravenous rhTNK-tPA. Placebo oral aspirin and clopidogrel are administered within 6 ± 2 hours following intravenous placebo.
224124940|NCT02729558|RADIATION|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
224124941|NCT03938441|OTHER|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
224124942|NCT05247619|DRUG|Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin|Tisleliumab 200mg, Bevacizumab 7.5mg/kg, Paclitaxel 175mg/m2, and Cisplatin 50mg/m2 (or Carboplatin AUC5) IV on day 1 of every 21-day cycle.
224124943|NCT00189241|DRUG|imiquimod|
224124944|NCT02527551|OTHER|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
224124945|NCT04674618|DEVICE|US-assisted nusinersen administration|Ultrasound identification of intervertebral space (L2-L3 or L3-L4)
224124946|NCT00358995|BEHAVIORAL|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
223425616|NCT05497479|DRUG|Vehicle to be administered in both eyes|Two rounds of Schirmer tests, performed with anesthetic (per randomization), before and after instillation of Vehicle
223425617|NCT03926364|OTHER|Patients with referred pain|The project does not affect treatment or does not offer any intervention.
224004723|NCT06658093|DRUG|Rapamycin|mTOR inhibitor
224004724|NCT06658093|DRUG|Everolimus|mTOR inhibitor
224004725|NCT06658093|OTHER|Placebo|Inert placebo for rapamycin or everolimus
224004726|NCT06613984|BIOLOGICAL|Bretovameran|Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.
224004727|NCT05874401|DRUG|Trilaciclib|Participants will receive intravenous trilaciclib infusion
224004728|NCT05874401|DRUG|Placebo|Participants will receive intravenous placebo infusion
224004729|NCT05874401|DRUG|Topotecan|Participants will receive intravenous topotecan infusion
224124947|NCT00358995|BEHAVIORAL|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
224004730|NCT06999772|DEVICE|Active rTMS|A figure-of-8 coil connected to a biphasic Magstim Rapid 2 stimulator (The MagstimCo, Whitland, UK) will be used. Coil orientation and position will be guided throughout the experiment by a neuronavigation system (Brainsight, Rogue research, Montreal, QC, Canada). Stimulation parameters will be obtained by measuring the motor threshold of the first right interosseous muscle, then the rTMS intensity will be set at 110% of this motor threshold. High frequency (HF) rTMS consisting of 60 trains of 5 s at 10 Hz with 15 s intertrain intervals, for a total of 3000 pulses per session, will be used. The coil will be positioned over the left dorsolateral PFC using the BeamF3 methods.
223386670|NCT07157930|BEHAVIORAL|2D:4D Digit Ratio|The lengths of the second (2D) and fourth (4D) digits will be measured separately on both hands. Measurements will be taken with the participants' hands placed on a flat surface with the palms facing upward. Digit length will be defined as the distance from the midpoint of the proximal crease at the base of the finger to the distal tip of the finger. A digital caliper with a precision of 0.01 mm will be used, and two separate measurements will be obtained for each finger, with the mean value recorded. Based on these measurements, the 2D:4D digit ratio will be calculated for each hand by dividing the length of the second digit by that of the fourth digit. To enhance reliability, assessments will be performed independently by two different researchers, and inter-rater agreement will be evaluated.
223386671|NCT07157930|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index is a self-report questionnaire that assesses sleep quality over a one-month period. The measure consists of 19 items divided into 7 components that produce a single overall score and takes 5-10 minutes to complete. Component scores are as follows: • Subjective sleep quality • Sleep latency (time to fall asleep) • Sleep duration • Habitual sleep efficiency (percentage of time spent in bed) • Sleep disturbances • Use of sleeping pills • Daytime dysfunction Each item is scored on a 0-3 scale. The seven component scores are then summed to create an overall score ranging from 0-21, with lower scores indicating better sleep quality
223425618|NCT06622369|OTHER|Virtual Reality-Game group|Children in the play group will be allowed to choose a game that is compatible with virtual reality. Children in this group will be allowed to play the game they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use
224004731|NCT06999772|DEVICE|Sham rTMS|A sham coil will be used (e.g. equipped with a magnetic shield that blocks the magnetic field). The sham stimulation will last the same duration as the active rTMS and will be located over the same area (dorso-lateral prefrontal cortex).
224004732|NCT06999772|OTHER|Psychologically-informed physiotherapy (PiP)|Participants will receive 6 intervention sessions (45 min) over 6 weeks by a physiotherapist. The objective of this intervention is to identify biopsychosocial factors that may impede recovery and to address these factors within the physiotherapist's scope of practice. Physiotherapists will use strategies such as the establishment of common goals and therapeutic alliance, the use of behavior change model, motivational interview, education on pain neurophysiology, gradual exposure to movement and stress management strategies (e.g. breathing techniques). Participants allocated to PiP groups will have access to a website offering support information related to understanding their pain (e.g. pain neuroscience education), myths and false beliefs related to back pain, understanding the impact of psychological factors on their pain, self-management strategies, and healthy lifestyle habits. This site will be freely available to participants during the course of the study.
224004733|NCT06999772|OTHER|Usual physiotherapy|Participants will receive 6 intervention sessions (45 min) over 8 weeks by a physiotherapist. This is a pragmatic group that aims to represent real-word clinical practice i.e. interventions commonly used in physiotherapy to manage CLBP. All interventions that a physiotherapist can deliver in the province of Quebec will be allowed (e.g. manual therapy, exercises). No training will be provided to better reflect usual clinical practice in physiotherapy.
224004734|NCT02344290|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
224004735|NCT02344290|DRUG|Placebo|One tablet taken once daily, orally with or without food
224004736|NCT06729047|DRUG|normal Saline|patients will receive placebo (normal saline)
224004737|NCT06729047|DRUG|Neostigmine|patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)
224004738|NCT06729047|DRUG|Ketorolac|patients will receive ketorolac (0.5 mg/kg)
223425619|NCT06622369|OTHER|Virtual Reality-Cartoon-video group|Children in the cartoon-video group will be allowed to choose a cartoon they want compatible with virtual reality. Children in this group will be allowed to watch the cartoon they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
224004739|NCT06727474|DIAGNOSTIC_TEST|Health-Related Quality of Life (HRQoL) with EQ-5D-3L|The EQ-5D-3L and EQ-VAS questionnaires, administered at all visits, evaluated five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Responses generated a Health Status sequence and calculated the EQ-5D-3L Index. A visual analogue scale (VAS) rated health from 0 (worst) to 100 (best). Functional capacity was assessed using the Katz Index (IK) and Timed Up and Go (TUG), which measured the time to rise from a chair, walk 3 meters, and return. Anthropometric variables, measured by the same researcher (LP) at 1 month and 1 year, included limb circumferences using specific techniques. Muscle strength, evaluated with the EF-MRC scale, involved verbal commands for movement tests. Calf circumference was measured on the largest circumference area. Living conditions and work reintegration were recorded. Health issues detected during follow-up were referred to the clinic's coordinating physician for appropriate care.
224124948|NCT04940442|BEHAVIORAL|Outreach|Active: Outreach offering FIT or colonoscopy. Sequential: Outreach offering FIT first, and then offering colonoscopy to those still unscreened
224124949|NCT00423085|DRUG|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm\^2 (4.5 mg), 5 cm\^2 (9 mg), 7.5 cm\^2 (13.5 mg), and 10 cm\^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
223386672|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 350 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min.
223386673|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 500 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by another 5 min of infusion at the original rate.
223425620|NCT05115188|DIETARY_SUPPLEMENT|Dex4/ dextrose|Participants will be asked to ingest 21 Dex4® tablets and no more than 300ml of water within 5 minutes. Blood draws will be performed at fasting (before ingesting the dextrose monohydrate tablets), as well as 1 hour after (+/- 15 minutes) and 2 hours (+/- 15 minutes) after ingesting the dextrose monohydrate tablets.
224004740|NCT04545736|DRUG|Metformin hydrochloride|Metformin is commercially produced in immediate and extended release. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach a goal of 2000mg daily maximum. Once participants \>=17 years of age reach 2000mg metformin immediate release they will switch to an extended-release formulation (1000mg twice a day by mouth). Participants \>= 17 years of age that cannot tolerate 2000mg will be permitted to reduce their daily dose to a minimum of 1000mg/day. Because metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation. For these participants who remain on standard formulation, the maximum tolerated dose between 1000mg and 2000mg/day will be given.
224004741|NCT06892418|BEHAVIORAL|Ketoflex 12/3 Diet|A plant-based ketogenic diet combined with intermittent fasting (12/3)
223730096|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
224004742|NCT06894537|OTHER|Experimental (percutaneous echo-guided electrical nerve stimulation)|The protocol applied in this study will consist of: 10 stimulations of 10 seconds at 10Hz with a rest of 10 seconds between one stimulation and the next one. The intensity of the current (mA) will be adapted to each of the subjects until the greatest possible muscle contraction is achieved without reaching the painful threshold.
223730097|NCT02329730|BIOLOGICAL|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
224004743|NCT06894537|OTHER|Control (placebo) group|For the subjects in the control group, the same process shall be carried out without increasing the intensity of the current. It shall be explained to the subjects that the current will reach a non-perceptible stimulus.
224004744|NCT07051655|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|Participants will undergo two test days separated by 3-7 days. On both test days, participants will arrive fasted and consume a single dose of ketone monoester or placebo (357 mg/kg of body weight) in random order. Drinks will be prepared by non-study personnel and matched in taste, texture, and appearance to maintain blinding. Thirty minutes after consuming the ketone monoester or placebo, cognitive assessments will be completed including NIH Toolbox cognitive assessments, Senaptec Sensory Station, and driving simulation.
224004745|NCT07051655|DIETARY_SUPPLEMENT|Placebo|Participants will undergo two test days separated by 3-7 days. On one test day, participants will consume a single dose of placebo (357 mg/kg of body weight). Thirty minutes after consuming the placebo, cognitive assessments will be completed including NIH Toolbox cognitive assessments, Senaptec Sensory Station, and driving simulation.
224124950|NCT00423085|DRUG|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
224124951|NCT04561713|PROCEDURE|Virtual reality task|Virtual reality application in an immersive room (CAVE) in three dimensions to assess child's sustained attention in a dynamic environment that is as close as possible to everyday situations.
224124952|NCT02260466|OTHER|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
224124953|NCT06048406|COMBINATION_PRODUCT|Health education|The intervention group will receive a health education intervention focused on influenza vaccination literacy, while the control group will continue with their standard school health education without any additional intervention. An influenza vaccination health education including topics such as the importance of influenza vaccination, benefits of vaccination, and vaccination methods, will be developed and reviewed by an expert group. The package for the intervention group will include educational activities, distribution of promotional materials, vaccination services, and distribution of vaccination souvenirs.
224299227|NCT00846521|DRUG|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
224004746|NCT07049328|DRUG|HCW9302, an IL-2 fusion protein|Injection
224004747|NCT05204290|DRUG|Pembrolizumab|Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
224004748|NCT05204290|RADIATION|Stereotactic Body Radiation Therapy|patients will undergo CT simulation and will be immobilized in either a BodyFix® or long thermoplastic mask depending on the location of the lesion. 1.25mm slices will be acquired. Dose and fractionation will be at the discretion of the treating radiation oncologist (as will the constraint to the spinal cord).
224004749|NCT05204290|OTHER|Blood draws|Patients will have a blood draw at baseline and at 2-months post-SBRT, and 6 months post-stereotactic body radiation therapy.
224004750|NCT05822583|DRUG|abatacept infusion|The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
224004751|NCT05822583|DRUG|Placebo group|Placebo group (IV infusion of normal saline) + baseline IM
224004752|NCT01934751|OTHER|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
224004753|NCT01934751|OTHER|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
223425621|NCT05115188|DIETARY_SUPPLEMENT|Glucose beverage|For the 2 hour oral glucose tolerance test (OGTT), women fast for 8 hours and then consume 75g of glucose beverage, and serum glucose levels are taken at fasting, 1 and 2 hours after drinking the glucose beverage. The 75g OGTT is the gold standard and is performed for GDM diagnosis.
223425622|NCT06412185|BIOLOGICAL|CM383|CM383 Injection
223425623|NCT06412185|OTHER|Placebo|Placebo
223425624|NCT03789578|DRUG|NNC0148-0287sema|Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
223730098|NCT02329730|BIOLOGICAL|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
224004754|NCT06053164|DRUG|Exertional Oxygen|Use of a portable oxygen concentrator for exertional activities lasting \>2 minutes
224004755|NCT06053164|BEHAVIORAL|Education and Support|Participants will receive disease-specific educational material (Living Well with Pulmonary Fibrosis: Oxygen), and will have scheduled phone appointments with a certified respiratory educator after 1, 3, and 5 weeks of oxygen therapy in order to address individual barriers to oxygen use and facilitate the optimal use of portable oxygen.
224004756|NCT06546800|BIOLOGICAL|RSVpreF vaccine|Injection in the muscle, 1 dose 0.5mL
224004757|NCT07073885|OTHER|Ultra-Low Tidal Volume Ventilation|Ventilation continued during CPB using volume-controlled mode with ultra-low tidal volume (3-4 mL/kg IBW(Ideal Body Weight)), 12-14 breaths/min, 5 cm H₂O PEEP, and 50% FiO₂.
224004758|NCT07073885|OTHER|Apnea Group|In this group, mechanical ventilation will be discontinued after aortic cross-clamping during CPB, and apnea will be maintained throughout the bypass period.
224004759|NCT06878365|DRUG|BI 3000202_low dose|BI 3000202\_low dose
224004760|NCT06878365|DRUG|BI 3000202_high dose|BI 3000202\_high dose
224004761|NCT07074288|DEVICE|MAD|MAD intervention involves the use of a mandibular advancement device, which is designed to reposition the lower jaw and tongue to keep the airway open during sleep.
224004762|NCT07074288|DEVICE|HGNS|HGNS intervention involves a surgical procedure to implant a device that stimulates the hypoglossal nerve to prevent airway collapse during sleep.
224004763|NCT07135531|DEVICE|Continuous Glucose Monitoring (CGM)|Continuous glucose monitors will be placed subcutaneously every 14 days.
224004764|NCT07128576|DRUG|Romiplostim N01|Romiplostim N01: 3-10 μg/kg(Initial dose 3 μ g/kg), qw, H.
224004765|NCT03826030|DEVICE|Sham|Sham group only receives 30 seconds of stimulation at 2mA in the beginning to create a sensory perception to the scalp in order to blind the subject.
224004766|NCT03826030|DEVICE|Low dose tDCS|The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
224004767|NCT03826030|DEVICE|High dose tDCS|The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
224004768|NCT03826030|BEHAVIORAL|mCIMT|All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
224004769|NCT07076862|DRUG|A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging.
224004770|NCT07076862|DRUG|A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
224004771|NCT07076862|DRUG|B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)|Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging.
224004772|NCT07076862|DRUG|B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)|Participants receive 5 mCi (±20%) of \[¹⁸F\]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.
224004773|NCT07086768|DRUG|BSI-082|BSI-082 is a sterile solution for injection which contains the active ingredient at the nominal concentration of 50.0 mg/mL. T
224004774|NCT07086768|OTHER|Trastuzumab deruxtecan|T-DXd: Administrate as per the drug package insert and Investigator's guidance, and T-DXd can be continued after the patients been taken off from the study.
224004775|NCT02745353|DRUG|naloxegol|
224004776|NCT06852209|PROCEDURE|Cognitive remediation therapy|Cognitive remediation therapy as treatment as usual
223386674|NCT07163299|PROCEDURE|Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).|According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 650 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by intermittent infusion at the original rate for another 5 min twice. The interval between two times is also 5 min.
224004777|NCT06852209|PROCEDURE|Neuropsychological assessment|Neuropsychological assessment to measure cognitive performances
224004778|NCT06852209|PROCEDURE|Real-time functional MRI neurofeedack (rt-fMRI NF)|Real-time functional MRI neurofeedack (rt-fMRI NF) is a procedure of brain-machine interface supporting self-regulation of brain activity, with promising results in the treatment of mental disorders. The main objective of the study is to evaluate in a pilot study, the ability of stroke patients to learn to self-regulate their brain activity in a priviledged direction.
223386675|NCT07170891|DEVICE|Morning Running and IMT|Inspiratory muscle training was performed in addition to morning running
223386676|NCT07170891|DEVICE|Inspiratory muscle training and evening running|Inspiratory muscle training was performed in addition to evening running
223386677|NCT07170891|OTHER|Control|non-exercise group
223386678|NCT07179523|COMBINATION_PRODUCT|Hemostatic gelatin sponge|Colisorb® exhibits optimal pore structure, number and size, which results in its structure being highly porous with low density. In addition, Colisorb® possesses optimal mechanical integrity allowing it to swell to its maximal absorption capacity while maintaining mechanical stability. The sponge can absorb fluids in the blood resulting in prompt recruitment of clotting factors, hence accelerating the body's natural blood clotting cascade. Colisorb® was configured in a way to imitate natural adhesive mechanism without the use of co-agulants, it provides a safer and a more efficient alternative for minimizing post-operative complications and enhancing recovery. Upon performing the tooth extraction, oral surgeon instantly applied the sponge. Patients were prescribed, antibiotics, and antacid, if needed, for 3 days and analgesics for 5 days, followed by a mouth wash routine of warm water with salt to enhance healing outcomes. Patients visited the clinic three days after surgery.
223386679|NCT07179523|COMBINATION_PRODUCT|Hemostatic Agent|"Gelatin sponge that may be soaked with sterile physiological solution. Biocompatible and easy to use for 5 to 10 minute bleeding control rate.~Upon performing the tooth extraction, oral surgeon instantly applied the sponge in the socket where the tooth was extracted to facilitate hemostasis. Patients were prescribed, antibiotics, and antacid, if needed, for 3 days and analgesics for 5 days, followed by a mouth wash routine of warm water with salt to enhance healing outcomes. Patients visited the clinic three days after surgery."
223386680|NCT07183826|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (Internet-delivered)|A 6-week (42 days), unguided online adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program. The intervention consisted of six sequential modules delivered through a secure web platform, including guided mindfulness meditations, body scan, mindful movement, and cognitive-behavioral exercises. Participants received audio recordings, written materials, and reflective tasks, along with automated reminder emails. No therapist guidance was provided.
223386681|NCT07183826|BEHAVIORAL|No intervention|Participants in this arm received no active intervention during the 6-week waitlist period but completed all study assessments on the same schedule as intervention arms. After the waiting period, participants were offered to take part in the online MBCT program.
223386682|NCT07185308|DIETARY_SUPPLEMENT|Postbiotics, 2.5 g per dose, three times per day|Postbiotics oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
223386683|NCT07185308|DIETARY_SUPPLEMENT|Placebo, 2.5 g per dose, three times per day|Placebo made of cyclodextrine, oral powder, 2.5 g per dose, administered three times daily for a total duration of 90 days (four 21-day chemotherapy cycles).
223386684|NCT07186465|DRUG|Nitrofurantoin|Nightly oral nitrofurantoin 100 mg for 6 months as prophylaxis for recurrent UTI in postmenopausal women. If symptomatic UTI occurs, treat per standard care and, once resolved, continue assigned prophylaxis to complete 6 months. Monitoring per protocol: baseline and month-6 visits with urinalysis, urine culture, urinary microbiome, and kidney function; twice-weekly phone/Line check-ins for adherence, symptoms, and adverse events.
223386685|NCT07186465|DRUG|Gynoflor|Vaginal tablet containing Lactobacillus with ultra-low-dose estriol. Insert 1 tablet nightly for 14 days, then twice weekly through month 6 as prophylaxis against recurrent urinary tract infection. If a symptomatic UTI occurs, treat per standard of care; after resolution, continue assigned prophylaxis to complete 6 months. Monitoring identical to comparator.
223425625|NCT03789578|DRUG|Semaglutide|Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
224004779|NCT06852209|PROCEDURE|fMRI sessions|fMRI sessions but without receiving feedback
224004780|NCT06363890|DIAGNOSTIC_TEST|TAQMan Array Card|Real time PCR test to detect diarrheal pathogens.
224004781|NCT07088900|PROCEDURE|caudal block using dexmedetomidine with bupivacaine|Patients will receive a single-shot caudal block with 1 mL/kg of 0.25% bupivacaine mixed with 1 µg/kg of dexmedetomidine (diluted in 1 mL of normal saline).
224004782|NCT07088900|PROCEDURE|caudal block with bupivacaine|Patients will receive a single-shot caudal block with 1 mL/kg of 0.25% bupivacaine mixed with 1 mL of normal saline
224004783|NCT07105371|BIOLOGICAL|AlloEx exosomes|This is an intranasal treatment of exosomes derived from mesenchymal stem cells.
224004784|NCT07099404|OTHER|PET/CT imaging with rubidium-82|PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.
224004785|NCT07102407|OTHER|Contructivist|Implementation of constructivist training on VAP in small groups
224004786|NCT07102407|OTHER|Routine training|Implementation of routine training on VAP in large groups
224124954|NCT05992363|DEVICE|ureteral stent\s insertion|ureteral stent\\s insertion in the operating room
224004787|NCT06518707|OTHER|Phrenic nerve stimulation|A commercial phrenic nerve stimulation equipment will be used during surgery. Phrenic nerve stimulation intensity will be determined before surgery, ensuring significant diaphragm contraction under stimulation. The use of an electric knife will be avoided during surgery. Tidal volume, airway pressure, and vital signs will be monitored continuously.
224004788|NCT06256354|OTHER|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An upper- or lower-body forced-air cover will be positioned over an appropriate non-operative site but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further. The target nasopharyngeal temperature is 35.5°C.
224004789|NCT06256354|OTHER|Target temperature management|"Pre-warming is performed with a full-body forced-air cover and electrically heated blanket for about 30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to about 43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be warmed during surgery using two forced-air covers or combining forced-air covers with electric heating blanket when clinically practical. All intravenous fluids will be warmed to body temperature. There is no need to control ambient temperature since ambient temperature has little effect on core temperature in patients warmed with forced air. The target nasopharyngeal temperature is 36.8℃."
224004790|NCT04015869|DRUG|Allopregnanolone|neurosteroid
224004791|NCT04015869|DRUG|Placebos|placebo
224004792|NCT06826794|OTHER|Clinicians|Clinicians will determine respiratory parameters for mechanical ventilation upon arrival in the intensive care unit.
224004793|NCT06826794|DEVICE|VenitlO|VentilO application (or web platerform) will determine respiratory parameters for mechanical ventilation upon arrival in the intensive care unit.
224124955|NCT03084575|PROCEDURE|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
224124956|NCT03084575|DRUG|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
224124957|NCT03084575|DEVICE|Thermal RF lesioning is done using Bailys RF generator|
224124958|NCT02719418|DRUG|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
224124959|NCT05590234|DRUG|Dexmedetomidine injection|1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%
224124960|NCT05590234|DRUG|Bupivacaine 0.25% Injectable Solution|20 ml of bupivacaine 0.25%,
224004797|NCT07105670|OTHER|Controlled dietary intervention|Participants will complete a 2-week baseline period consuming their standard diet without any food or beverages provided followed by a randomized, crossover-controlled feeding study of a lacto-ovo vegetarian diet versus the same diet with 20% of the protein replaced by red meat. In between the two diets, there will be a five-week washout where participants will consume their standard diet without any food or beverages provided.
224124961|NCT05590234|DRUG|normal saline|20 ml of normal saline 0.9%.
224124962|NCT00769704|BIOLOGICAL|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
223425626|NCT03789578|DRUG|NNC0148-0287|Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
224004798|NCT03820947|DEVICE|VenaSeal™ System|The VenaSeal™ System is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
224004799|NCT03820947|DEVICE|Endothermal Ablation (ETA)|"ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein.~Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice."
224004800|NCT03820947|PROCEDURE|Surgical Stripping|Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.
224004801|NCT07107568|DIAGNOSTIC_TEST|Standard Invasive Coronary Angiography|Standard invasive coronary angiography performed routinely for all participants in this arm to assess coronary artery disease before TAVR.
224004802|NCT07107568|DIAGNOSTIC_TEST|PCD-CT-Guided Diagnostic Strategy|Participants randomized to this arm will undergo coronary artery disease (CAD) assessment using photon-counting detector computed tomography (PCD-CT). Invasive coronary angiography (ICA) will only be performed if PCD-CT shows significant CAD, defined as ≥70% diameter stenosis in vessels ≥2.5 mm or ≥50% in the left main artery.
224124963|NCT00769704|BIOLOGICAL|GM-CSF|125 µg/m² subcutaneous injection
224124964|NCT00011193|BEHAVIORAL|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
224124965|NCT04051593|OTHER|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
224124966|NCT01351077|OTHER|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
224124967|NCT02743403|DEVICE|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
224124968|NCT02743403|DEVICE|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
224124969|NCT02743403|DEVICE|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
224124970|NCT03548597|DEVICE|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
223386686|NCT07181031|BEHAVIORAL|High-Intensity Interval Training (HIIT)|Participants in the HIIT group engaged in a 12-week resistance-based high intensity interval training program, designed to target both aerobic and anaerobic energy systems. Training sessions were conducted twice per week in addition to the athletes' regular volleyball practice schedule. Each session commenced with a standardized 10-minute warm-up involving low-intensity jogging and dynamic stretching, and concluded with a 5-minute cool-down of light jogging and static stretching to promote recovery. The main training component consisted of short, repeated high intensity bouts (30 s) of multi-modal exercises-including sprint drills, plyometric movements, functional bodyweight resistance exercises, multi-joint strength movements, agility drills, and aerobic conditioning-performed at 85-95% of maximal heart rate (HRmax) \[28,13\]. Each bout was followed by 30 s of active recovery (e.g., walking or light movement).
224004803|NCT06626035|DRUG|Methadone based ERAS|Children randomized to the methadone arm will include standardized perioperative care and analgesia, including intraoperative intravenous methadone (1st dose: 0.1 mg/kg up to a maximum of 5 mg before incision; 2nd dose: 0.1 mg/kg up to a maximum of 5 mg 4 hours after 1st dose) and postoperatively, up to 4 oral or IV doses of methadone (0.1 mg/kg up to a maximum of 5 mg) every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
224004804|NCT06626035|DRUG|Non-methadone based group|Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
224004805|NCT06915220|BEHAVIORAL|mobile health app|HeartSteps is an innovative mobile health (mHealth) app designed for cardiac rehabilitation patients. The app features dynamic push notifications, daily and weekly surveys to capture psychosocial data, and an in-app dashboard that provides feedback on activity levels, goal progress, and reminders. Integrated with a Fitbit Charge tracker, HeartSteps emphasizes behavioral changes through engaging features. The intervention is personalized to meet individual needs and preferences, enhancing patient engagement and promoting sustained physical activity.
224004806|NCT07115953|DEVICE|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
224004807|NCT06905964|BEHAVIORAL|Eccentric cycling exercise (ECC)|"Performed exercise training 5 days a week for 5 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~After each training session, rest in sitting position for 20 min. Exercise intensity: Firstly, set at 80% Wmax, and progressively increased 5% per week to 120 % Wmax in the last week."
224004808|NCT06905964|BEHAVIORAL|Eccentric cycling exercise with assistive devices (ECA)|"Performed exercise training 5 days a week for 5 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~After each training session, receive NMES in sitting position for 20 min.~Intensity: Firstly, set at 80% Wmax, and progressively increased 5% per week to 120 % Wmax in the last week."
224004809|NCT01217788|DRUG|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
224004810|NCT06953089|DRUG|DB-1311/BNT324|Administered I.V.
224004811|NCT06953089|DRUG|BNT327|Administered I.V.
224004812|NCT06953089|DRUG|DB-1305/BNT325|Administered I.V.
224004813|NCT07140939|DRUG|CBL-514 Injection|Provided as a ready for use injectable CBL-514 solution
224004814|NCT07140939|OTHER|0.9% Sodium Chloride|Injectable 0.9% Sodium Chloride solution as placebo
224004815|NCT07155174|DRUG|ABBV-706|Intravenous (IV) Infusion
224004816|NCT07155174|DRUG|Atezolizumab|IV Infusion
224004817|NCT07155174|DRUG|Etoposide|IV Infusion
223425627|NCT06683040|DRUG|Oxacom|Lyophilisate for solution for intravenous administration, 6.3 mg
223425628|NCT06683040|DRUG|Placebo|0.9% sodium chloride
223425629|NCT06002529|OTHER|HFR|patient received HFR treatment
224004818|NCT07155174|DRUG|Carboplatin|IV Injection
224004819|NCT07155174|DRUG|Carboplatin|IV Infusion
224004820|NCT07155174|DRUG|Lurbinectedin|IV Infusion
224004821|NCT07153731|DRUG|Shenkangling|Chinese herbal tonics taken orally: Shenkangling, one dose, 2 times a day, 1 time before breakfast and 1 time 30 minutes after dinner.
224004822|NCT07153952|RADIATION|radiotherapy|The surgical method is determined by the gynecological oncologist, including total hysterectomy, pelvic exenteration, or radical total hysterectomy. The specific surgical choice needs to be comprehensively judged based on the patient's residual tumor location, size, and other complications. Supplementary radiotherapy is mainly image-guided brachytherapy ± external irradiation. The irradiation range and dose must be comprehensively considered based on the location and size of the residual lesions. The best local treatment plan is jointly determined by gynecological oncologists and radiotherapists.
224004823|NCT07153952|DRUG|Systemic treatment|Systemic treatment regimens include chemotherapy ± targeted therapy ± immunotherapy. According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel and cisplatin/paclitaxel. The addition of immunotherapy can be determined based on the PD-L1 expression level. The specific chemotherapy regimen will be determined by the gynecological oncologist based on the residual tumor site, the number of lesions, and other complications. In addition, if the patient's pathological results indicate HER2 positivity or the genetic test results show PIK3CA mutation, targeted therapy, such as neratinib or apelisimab, can be considered as a second-line regimen after the first-line chemotherapy regimen progresses.
224004824|NCT07153614|PROCEDURE|Intrathecal Morphine Block|Morphine 150 mcg
224004825|NCT07153614|PROCEDURE|Bilateral Quadratus Lumborum Block|30 mL of 0.25% bupivacaine and 4mg of dexamethasone
224004826|NCT07153614|PROCEDURE|Bilateral Transverse Abdominis Plane Block|Exparel-based solution mixed with 50mL of saline
224004827|NCT07154693|DEVICE|Combination 70% FDBA and 30% DFDBA|A combination freeze-dried bone allograft consisting of 70% mineralized FDBA and 30% demineralized FDBA
224004828|NCT07154693|DEVICE|OsteoGen Plug|A synthetic calcium apatite material combined with Type 1 bovine collagen (in a sponge-like product)
223425630|NCT00800605|BIOLOGICAL|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
223425631|NCT00800605|BIOLOGICAL|Placebo: Phosphate-buffered saline|Single intramuscular injection
224004829|NCT07153744|DRUG|Aspirin|Patients in the Shexiang Baoxin Pill(MUSKARDI) group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
224004830|NCT07153744|DRUG|Shexiang Baoxin Pill|Patients in the Shexiang Baoxin Pill group initiated treatment immediately after randomization. They received 2-4 pills of Shexiang Baoxin Pill preoperatively before PCI, followed by a maintenance dose of 2-4 pills orally three times daily (TID) with warm water for 12 months postoperatively, concurrently with standard guideline-directed therapy.
224124971|NCT04200170|DEVICE|Rose|Rose is a patient-centric, mobile mental health platform designed for in-between clinical mental health monitoring in form of mood tracking, clinical surveys and daily journaling. Rose is used as a participant-facing mobile app and clinician-facing dashboard. Each day, they complete mood and anxiety scales and update their journals. Biweekly, they are also asked to complete the PHQ-9 and GAD-7 assessments as well. The Rose mobile app sends timely self-help articles and notifications for users. The curated insights are selected based on participant responses to the daily mood and anxiety surveys, as well as a built-in sentiment analysis of the journaling. The clinical dashboard is a secure, web-based portal that has a unique login for each provider. Providers have access to only their patients through the system and are able to see all the health metrics collected with the Rose mobile app and the summarized metrics produced by our models.
224004831|NCT07154147|DRUG|Alprazolam|Participants will take oral alprazolam 0.5 mg 15 to 90 minutes before surgery to promote relaxation and reduce anxiety. An IV placebo (normal saline) will be administered to maintain blinding.
224295805|NCT05288036|OTHER|Progressive Resistance Exercise Group|"Strengthening exercises targeting the upper extremity main muscles were applied to the PRE group with progressive resistance. Dumbbells and sandbags were used as resistance equipment. resistance intensity; 50-80% of a repetition maximum (RM) was determined according to the patient's tolerance. The exercises were applied as 8-12 repetitions and 3 sets. A rest period of 60-90 seconds was allowed between each set. After the 4th week of the training, 1 RM was measured again and the resistance density was updated. The 8 strengthening exercises to be applied were created by taking examples from the literature and in accordance with the Guidelines for implementing exercise programs exercise programs for cancer patients. These exercises are: dumbbell fly, triceps extension, biceps curl up, one-arm bent over row, dumbbell sides rise, lifting the arm forward, wrist curl and side lying shoulder internal -external rotation."
224124972|NCT04801537|OTHER|normal body temperature and warm extremities|environmental temperature is set according to the standard method to keep normal body temperature and warm extremities
224124973|NCT04801537|OTHER|normal body temperature and cold extremities|environmental temperature is set according to the standard method to keep normal body temperature, but cold extremities
223386687|NCT07181031|BEHAVIORAL|High-Intensity Functional Training (HIFT)|Participants completed a 12-week high intensity functional training program aimed at developing aerobic capacity, anaerobic power, muscular strength, and agility. Training sessions were performed twice weekly in addition to regular volleyball practices. Each training session followed a standardized structure, beginning with a 10-minute warm-up of light jogging and dynamic mobility exercises, followed by a main training phase consisting of circuit-style functional workouts that combined sprint drills, plyometric exercises, bodyweight resistance movements, multi-joint strength exercises, agility drills, and aerobic activities; each exercise was performed for 30 seconds at maximal effort with no fixed rest between exercises (≤10 seconds transition allowed), and participants completed 4-6 sets per session with 1-2 minutes of rest between sets, while emphasizing maximal movement speed and explosive execution of all repetitions, and concluding with a 5-minute cool-down of low-intensity joggi
223386688|NCT07193277|DRUG|Butylphthalide|Butylphthalide soft capsules (0.1g per capsule) manufactured by CSPC NBP Pharmaceutical Co., Ltd. Participants take 2 capsules (0.2g total) orally three times daily, 15-30 minutes before meals, for 48 weeks. This represents off-label use for cognitive impairment comorbid with epilepsy, as the drug is currently approved in China only for acute ischemic stroke treatment.
224124974|NCT05853562|OTHER|structured vestibular rehabilitation program|The structured Vestibular rehabilitation protocol consisted of a structured vestibular rehabilitation program that included vestibular adaptation exercises, oculomotor exercises, static and dynamic balance exercises, and posture exercises.
224295806|NCT05288036|OTHER|Control Group|The patients in the control group were instructed to continue their usual daily lives (not changing their physical activity levels, diet, drug use, etc.) until the date of re-evaluation after the initial evaluation. Information was given about the upper extremity normal range of motion exercises that they could apply at home, and a brochure was given.
223386689|NCT07193277|DRUG|Placebo|Matching placebo capsules identical in appearance, weight, and odor to butylphthalide soft capsules, manufactured by the same company following GMP standards. Participants take 2 capsules orally three times daily, 15-30 minutes before meals, for 48 weeks. Placebo contains starch and appropriate excipients.
223386690|NCT07192003|DEVICE|Floss Band Group (FBG)|Participants in this arm will perform the standardized Floss Band (FBG) protocol. While seated with the shoulder at 90° abduction, the researcher will apply a compressive elastic band made of 100% polymer gel (T.P.E), measuring 210 cm in length, 5 cm in width, and 1.3 mm in thickness. The first anchor is placed two fingers medial to the acromion, and the band is wrapped around the shoulder until the second anchor at the end of the band is fixed. After the application, the participant will perform sport-specific movements (spike and serve) for 2 minutes. Following the completion of the compression period, the band will be removed. Assessments will be conducted at baseline and immediately post-intervention, including shoulder range of motion using a digital inclinometer, perception of movement fluency using a Visual Analogue Scale (VAS), and sport-specific performance tests (One-arm Seated Shot Put Test and Functional Throwing Performance Index).
223425632|NCT05862883|DRUG|Rutan 25 mg|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose."
223730099|NCT02329730|BIOLOGICAL|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
224004832|NCT07154147|DRUG|Midazolam|Participants will receive IV midazolam 1 mg immediately before surgery to promote relaxation and reduce anxiety. An oral placebo pill will be used to maintain blinding.
224004833|NCT07156136|DRUG|IMC-P115C|IV infusion
224004834|NCT07154771|OTHER|First with the arm circumference measurement tool, then with the traditional tape measure|Patients and nurses in this group will measure both arms (at four different anatomical reference points) first using the newly developed arm circumference measurement device, followed by the traditional tape measure.
224004835|NCT07154771|OTHER|First with the traditional tape measure , then with the arm circumference measurement tool|Patients and nurses in this group will measure both arms (at four different anatomical reference points) first using the traditional tape measure, and then using the newly developed arm circumference measurement device.
224004836|NCT07154849|DRUG|Hydrocortisone|received 2mg/kg.
224004837|NCT07154849|DRUG|Dexmedetomidine|received 1 µg/kg
224004838|NCT07154030|PROCEDURE|Micro needle injection|"* Disinfection: the affected area by alcohol 70 %.~* Topical anaesthetic cream will be applied: pridocaine (lidocaine 2.5% and prilocaine 2.5%) for 30 minutes under occlusion.~* Microneedling with tretinoin 0.025% of the affected area will be done by dermapen that will be applied on the affected area as follows: inserting the sterilized needle into the dermapen tip, turning on using speed setting and adjusting speed on 5, needle depth of dermapen will be adjusted to (2- 2.5mm) according to the site of the striae, passing vertically over the striae with dermapen in a stamping pattern until pin point bleeding appear."
224004839|NCT07154030|PROCEDURE|Micro needle injection only|"* Disinfection: the affected area by alcohol 70 %.~* Topical anesthetic cream will be applied: pridocaine (lidocaine 2.5% and prilocaine 2.5%) for 30 minutes under occlusion.~* Microneedling with timolol 0.5% of the affected area will be done by derma pen that will be applied on the affected area as follows: inserting the sterilized needle into the derma pen tip, turning on using speed setting and adjusting speed on 5, needle depth of derma pen will be adjusted to (2- 2.5mm) according to the site of the striae, passing vertically over the striae with derma pen in a stamping pattern until pin point bleeding appear."
224004840|NCT07153666|DRUG|Ruxolitinib 1.5% Cream BID|ruxolitinib twice per day
224004841|NCT07154108|BIOLOGICAL|recombinant human endostatin adenovirus|Recombinant Human Endostatin Adenovirus: Administered via intratumoral injection twice every 3 weeks for a total of eight doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first.
224004842|NCT07154108|DRUG|PD-1 Inhibitor|PD-1 inhibitor: Administered via intravenous infusion once every 3 weeks.
224004843|NCT07155720|OTHER|Intervention (Kinesio Taping) group|No studies have been found in the literature examining whether kinesio taping increases happiness in women with PMS.
224004844|NCT07155343|COMBINATION_PRODUCT|Bulk Fill Composite|Orthodontic brackets will be bonded using a bulk fill composite resin, which is formulated for faster application and reduced polymerization shrinkage compared to conventional composites. This material will be used to assess its bond strength, failure rate, and overall clinical performance.
224124975|NCT03200457|DEVICE|1,5 Tesla abdominal MRI|Measurement of the fat and iron
223386691|NCT07192003|OTHER|Mobilization with Movement (MWM) Group|Participants in this arm will perform the standardized Mobilization with Movement (MWM) protocol. While seated in a chair with back support and hips, knees, and ankles at 90° flexion, the researcher will stabilize the scapula with one hand and apply a posterolateral glide to the anterior humeral head with the other hand during active shoulder elevation in the scapular plane. The intervention consists of 3 sets of 10 repetitions, with a 1-minute rest interval between sets. Assessments will be conducted at baseline and immediately post-intervention, including shoulder range of motion using a digital inclinometer, perception of movement fluency using a Visual Analogue Scale (VAS), and sport-specific performance tests (One-arm Seated Shot Put Test and Functional Throwing Performance Index).
223386692|NCT07193459|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily
223386693|NCT07193459|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily
223386694|NCT07193459|DRUG|Placebo|Placebo tablets, once daily
224004845|NCT07155343|COMBINATION_PRODUCT|Conventional Composite|Orthodontic brackets will be bonded using a conventional light-cured orthodontic composite resin that requires careful incremental application and standard curing time. This material is commonly used in routine clinical practice and serves as the benchmark for comparison.
224004846|NCT07153692|DEVICE|tDCS|The IS200 intelligent electrical stimulator, manufactured in Chengdu, Sichuan, will be used. The electrode pads are 4cm × 6cm in size. The anode of the electrode pad will be placed on the swallowing sensorimotor cortex (S1/M1). The specific positioning will follow the international 10-20 electroencephalographic system: the left S1/M1 area is located at the midpoint of the line connecting C3 and T3 in the left hemisphere; the right S1/M1 area is located at the midpoint of the line connecting C4 and T4 in the right hemisphere. The cathode will be placed on the contralateral supraorbital margin. The S1/M1 areas of the left and right hemispheres will be stimulated alternately, with a current intensity of 1.6mA. The treatment will be given once daily, 20 minutes per session, 5 times a week, for 2 consecutive weeks, totaling 10 sessions (5 sessions for each hemisphere).
224004847|NCT07153692|BEHAVIORAL|Conventional Dysphagia Treatment|"1. Training for perioral muscles, tongue sensory and motor functions, including ice cotton swab stimulation, gustatory stimulation, tongue muscle movement training, etc.;~2. Airway protection training, including Mendelsohn maneuver, supraglottic swallow training, etc.;"
224004848|NCT07153692|DEVICE|sham tDCS|According to previous literature, the electrode positions and treatment frequency of sham tDCS will be the same as those of real tDCS. The current will be adjusted to 0.05mA.
224124976|NCT03200457|DEVICE|3 Tesla abdominal MRI|Measurement of the fat and iron
224124977|NCT02083510|DRUG|Colchicine|
224124978|NCT02882399|OTHER|Shortystrap|
224124979|NCT02145299|DEVICE|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
223425633|NCT05862883|OTHER|Control group|Taking basic therapy without Rutan
224004849|NCT07155187|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
224004850|NCT07155187|DRUG|Standard of Care|Standard of Care
224124980|NCT02145299|DEVICE|CROSSER CTO Device|
224004851|NCT07155278|DRUG|Elravie Re2O|Elravie Re2O is a particulated human Acellular Dermal Matrix (phADM), with each 5 mL syringe containing 150 mg of phADM. This product is classified as a human tissue product and received its approval via a tissue bank establishment permit from the Ministry of Food and Drug Safety.
224004852|NCT07155278|DRUG|Elravie Balance|Elravie Balance is a gel-type hyaluronic acid (HA) skin booster. It contains HA at a concentration of 20mg/ml in a 2.5 cc syringe with a volume of 1.5 mL.
224004853|NCT07155083|OTHER|Survey using a questionnaire.|REDCap Survey
224004854|NCT07155252|DIAGNOSTIC_TEST|GTT@Home|self-administered fingerstick based glucose tolerance test
224004855|NCT07154485|DRUG|NS101 IV infusion|NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
224004856|NCT07154485|DRUG|Placebo IV Infusion|Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
224004857|NCT05655273|DRUG|Prograf|Participants randomized to the Prograf (control) arm will continue with their current twice daily dosing of Prograf.
224004858|NCT05655273|DRUG|Envarsus|Participants randomized to Envarsus arm will have their current daily dose of Prograf converted to once-daily Envarsus dose according to the following ratio: 0.7 x the current daily Prograf dose. Envarsus is available in 3 dose strengths- 0.75mg, 1.0mg, and 4.0mg. The actual dose of Envarsus will be rounded to an amount that can be administered using the above tablet strengths.
224004859|NCT04500769|BEHAVIORAL|Acute Resistance Exercise|Participants will perform three sets of eight repetitions, with a 90-120 second rest between sets, with a fourth set performed to failure. All resistance exercise will be performed on pneumatic resistance devices (Keiser Sports Health Equipment, Fresno, CA).
224004860|NCT04642807|PROCEDURE|Long arm soft cast|Participants in group 2 will have a long arm soft cast applied without clinical or radiological follow up.
224004861|NCT04642807|PROCEDURE|Long arm full cast|Participants in group 1 will have a long arm full cast applied.
224124981|NCT03191656|DEVICE|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
224124982|NCT00147732|RADIATION|Accelerated radiotherapy|68 Gy over 5.5 weeks
224124983|NCT00147732|RADIATION|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
224124984|NCT00260637|PROCEDURE|Acupuncture|
224124985|NCT04346628|DRUG|Favipiravir|Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).
224004862|NCT01967147|DRUG|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
224124986|NCT04346628|DRUG|Placebo|Placebo to match favipiravir administered orally through day 10.
224124987|NCT04346628|OTHER|Standard of care treatment|Standard of care treatment for COVID-19 infection
224124988|NCT03163199|DEVICE|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
224124989|NCT00646971|DEVICE|CPAP device|for 4 weeks
224004863|NCT01967147|DRUG|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
224004864|NCT03986164|DEVICE|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
224004865|NCT03986164|DEVICE|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
224124990|NCT00646971|DEVICE|Placebo device|for 4 weeks
224124991|NCT00878657|DRUG|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
224124992|NCT00878657|RADIATION|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
224295807|NCT03656874|OTHER|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
224124993|NCT02364206|DRUG|LY2228820|
224124994|NCT02364206|DRUG|Temozolomide|
224124995|NCT02364206|RADIATION|radiotherapy|
224124996|NCT06122428|DRUG|modified hyaluronic acid 0.1% covalently linked to Riboflavin|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
223386695|NCT07192965|RADIATION|Non-ECG-gated computed tomography|Scanning with a Revolution Apex Elite system (GE Healthcare, WI, USA), using hyperdrive pulmonary CT angiography (523mm/s with 0.28s/rotation gantry speed). Images will be acquired using the ECG-less Cardiac software (GE Healthcare, WI, USA), without the need for patient-attached ECG leads. The system uses a wide detector coverage of 160mm to provide full heart coverage and a fast gantry speed of 0.23 seconds per rotation to perform imaging in a single cardiac cycle. An estimation of the heart rhythm must be provided, based on the heart rhythm the scanner simulates an ECG signal. This simulated ECG signal provides virtual gating of the scan. Advanced software tools including SmartPhase (automated phase selection) and SnapShot Freeze 2 (optimized volume registration) will be used. After a short delay of 5-12 sec, allowing contrast to pass from the pulmonary circulation into the aorta and coronary arteries, a coronary CT angiography will be performed using the same contrast bolus.
223386696|NCT07193433|OTHER|CSNAT-I|CSNAT-I will be conducted in five stages, including an introduction of the CSNAT, family caregivers' consideration of needs, prioritize needs, a shared care plan, and a shared review for effectiveness and subsequent actions .
223386697|NCT07192783|OTHER|Lavender|Participants receive lavender oil inhalation three times per week for one month (total of 12 sessions) using a standardized diffuser. This intervention is provided in addition to routine care for primary hypertension. Outcomes measured include anxiety, sleep quality, and blood pressure before and after the intervention.
223386698|NCT07192094|BEHAVIORAL|Mindfulness Sessions - 8 Week Program|A culturally, and developmentally adapted Mindfulness-Based Stress Reduction (MBSR) program for Hispanic (self-identified) emerging adult (EA) participants (ages 18-25 years old) over 8 weeks (1.5 hours/week).
223386699|NCT07193212|OTHER|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a hands-on approach where a trained physician uses techniques such as gentle pressure, stretching, and guided movements to improve mobility, reduce pain, and support the body's natural healing. It focuses on the interconnectedness of muscles, joints, and fascia to restore balance and function.
223386700|NCT07192107|DRUG|MHB042C for Injection|IV administration of MHB042C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223386701|NCT07192029|PROCEDURE|Balloon guide catheter combined with conventional thrombectomy treatment|The experimental group will use balloon guide catheter combined with conventional thrombectomy treatment.
223386702|NCT07192029|PROCEDURE|Standard guide catheter or neurovascular sheath combined with conventional thrombectomy treatment|use standard guide catheter or neurovascular sheath combined with conventional thrombectomy treatment
223386703|NCT07189845|DIAGNOSTIC_TEST|BIS GROUP|In the BIS group, monitoring will be visible and anesthesia depth will be maintained within a BIS value range of 40-60.
223386704|NCT07189845|DIAGNOSTIC_TEST|CONTROL GROUP|In the control group, the BIS monitor will be applied with the screen concealed from the investigator, and anesthesia depth will be guided solely by clinical parameters.
223386705|NCT07192198|DRUG|Methoxyflurane|Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
224004866|NCT05212727|DEVICE|Eye-tracking|Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
224004867|NCT04255199|BEHAVIORAL|Control|Clinicians randomized to the control group will receive a single visit with a standardized patient instructor (SPI) scheduled during usual office hours. SPIs will portray a patients with acute back pain but will deliver no formative training or feedback to the primary care physicians randomized to the control arm.
224004868|NCT04255199|BEHAVIORAL|Intervention|Clinicians randomized to the intervention group will receive 2-3 visits with a standardized patient instructor (SPI) scheduled during usual office hours over \~3 month period. For intervention physicians, SPIs will portray patients with acute back pain and will provide formative feedback to physicians and specific instruction in communication techniques to facilitate patient acceptance of a watchful waiting strategy with respect to spinal imaging. The specific communication techniques and sequence will be determined based on pre-trial literature review, patient focus groups, and interviews of primary care physicians who will not participate in the trial.
224004869|NCT06009484|PROCEDURE|Colon resection|Colon cancer resection
224004870|NCT06475963|OTHER|surveys|telephone survey
224004871|NCT01038375|BEHAVIORAL|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
224004872|NCT03953924|OTHER|Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)|The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
224124997|NCT06122428|DRUG|hyaluronic acid 0.1%|The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
224124998|NCT04514237|DRUG|BOS172767 enantiomer E1 or E2|Oral tablets
224295808|NCT00857792|DRUG|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
224004873|NCT02218606|DRUG|Abiraterone acetate 1000 mg po daily|
224124999|NCT04514237|DRUG|Placebo|Oral tablets
224125000|NCT06502470|DEVICE|ellacor® Micro-Coring procedure|ellacor® Micro-Coring Technology is FDA approved for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I-IV.
224125001|NCT00083070|DRUG|temozolomide|
224125002|NCT02514928|PROCEDURE|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
223386706|NCT07192198|OTHER|Control|This intervention will be the control group, only receiving local infiltration.
223386707|NCT05995899|DRUG|Tenapanor|IBS-C patients will ingest one capsule of tenapanor (50 mg per dose), twice daily, before breakfast and dinner for a total of 8 weeks
223386708|NCT03922724|DRUG|ATL-RIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, low-dose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5mcg /kg/day subcutaneous on days -12, -8, and -4, ruxolitinib 45 mg/day from day -12 through day -2, and zidovudine 300mg orally three times a day from day -1 through day +50.
224004874|NCT02218606|DRUG|Cabazitaxel 25 mg/m2 IV|
224004875|NCT02218606|DRUG|prednisone 5 mg po BID|
224004876|NCT03203473|DRUG|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
224004877|NCT03203473|DRUG|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
224004878|NCT06013553|OTHER|Control Group|It comprised of parameters such as early mobilization and ambulatory training, pulmonary physiotherapy, active and passive normal joint movement exercises.
224004879|NCT06013553|OTHER|Aerobic Exercises group|"Standard physiotherapy + bicycle ergometer: In addition to the standard therapy, a bicycle ergometer for 20 minutes 5 days a week will be given.~Patients will turn the pedals of the bicycle while sitting on the edge of the bed.~In this protocol, a portable bicycle with adjustable pedal system, which can be placed on the edge of the bed, will be used.~Ratings of perceived exertion (RPE) will be used to determine the intensity of aerobic activity. According to the RPE, 10-12 strength exercises will be given"
224004880|NCT01431495|DRUG|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
224004881|NCT01431495|DRUG|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
224004882|NCT01844024|OTHER|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
224004883|NCT04666623|DRUG|esketamine nasal spray|unlabeled nasal injectors, each device will deliver 28mg of esketamine in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
224004884|NCT04666623|DRUG|placebo nasal spray|unlabeled nasal injectors, each device will deliver 28mg of placebo in a 200 μL solution, so in order to achieve the 56mg dose two devices will be required. On each dosing day during the trial, participants will self-administer at 2 time points 1 spray of the nasal spray into each nostril. Each administration will be separated by 5 minutes. The participants will receive the intervention twice weekly for 4 consecutive weeks.
224004885|NCT04492449|OTHER|congenital malformation|congenital malformation
224004886|NCT02226861|DEVICE|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
224125003|NCT02514928|PROCEDURE|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
223386709|NCT03922724|DRUG|mRIC|e-ATG 40 mg/kg/day IV on days -14 and -13, pentostatin 4 mg/m2/day IV on days -11 and -7, lowdose cyclophosphamide (5 mg/kg) orally daily on days -11 through -4; busulfan IV, pharmacokinetically dosed, on days -3 and -2, filgrastim or biosimilar drug 5 mcg/kg/day subcutaneous on days -12, -8, and -4.
223386710|NCT03922724|PROCEDURE|allo HCT|Stem cell transplant
223386711|NCT03922724|DRUG|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
223386712|NCT03922724|DRUG|GVHD prophylaxis|"High-dose, post-transplantation cyclophosphamide (PTCy) on days +3~and +4 ( 25 mg/kg/day on both arms), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on~days +5 through +25."
224004887|NCT02226861|BIOLOGICAL|ULD IL-2|sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
224004888|NCT03222713|OTHER|Program Self-regulation in health|The intervention program with children will be run by teachers and health professionals (Condition Group II) in 50-minute biweekly sessions which will take place in class in school year. During these sessions, the children will complete the following tasks: the reading of the chapters of Yellow Trials and Tribulations (one chapter per week) and the discussions and activities related to the topics of healthy eating and oral health.
224004889|NCT00004853|BIOLOGICAL|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC \>=10,000/microliter
224004890|NCT00004853|BIOLOGICAL|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
223386713|NCT03922724|DRUG|IOC|e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2
223386714|NCT02630628|DRUG|Tacrolimus|Dosage: start at 2mg twice a day, then titrated according to therapeutic drug level monitoring using 12-hour post-dose blood sampling
224004891|NCT02081430|PROCEDURE|CT Manipulation|
224125004|NCT03051334|OTHER|diagnosed as bicuspid aortic valve|
224125005|NCT01236612|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
224125006|NCT01236612|BIOLOGICAL|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
224125007|NCT01236612|BIOLOGICAL|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
223386715|NCT02630628|DRUG|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
223386717|NCT04416568|DRUG|Nivolumab|"Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle"
223386718|NCT04416568|DRUG|Ipilimumab|Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
223386719|NCT05977218|OTHER|FoodSwitch|Access to the 'DiabetesSwitch' filter of the FoodSwitch app when grocery shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
223386720|NCT06404099|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
224004892|NCT02081430|PROCEDURE|Upper trapezius stretch|
224004893|NCT00890695|DIETARY_SUPPLEMENT|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
224004894|NCT05462158|BEHAVIORAL|Impact of Nudges on CKD Testing|The investigators will examine the impact of different messages on different dimensions of testing for CKD
224004895|NCT04420949|BEHAVIORAL|Sensory re-weighting|During training, sensory re-weighting is driven by priming upregulation of somatosensory cues. Two rounds of training, each lasting 15 minutes and block-randomized in sets of 10 trials, are conducted per training visit. In each training trial, participants must determine the direction of gravity and then indicate if the rod being displayed is aligned with gravity or if it needs to rotate clockwise or counterclockwise for that to be so. Participants will be instructed to pay attention to what they feel from their feet, legs, and gut during training and to use that pressure, stretch, movement, and muscle tension feedback to help them sense gravity. Immediate auditory and non-orienting, visual feedback is provided after each trial. A staircase method is used to adapt the level of difficulty based on response accuracy. After two consecutive correct responses, the difficulty increases. After each incorrect response, the difficulty decreases. This process is repeated in each round.
224004896|NCT01718808|DRUG|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
224004897|NCT01718808|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
224004898|NCT06188897|OTHER|Self-stretching of the masticatory musculature|"If the subject belonged to the Treatment group, he was instructed to self-stretch the masticatory muscle.~This stretch consisted of introducing three knuckles of the non-dominant hand between the incisors for two minutes while sitting."
224004899|NCT06188897|OTHER|Control group intervention|The control group was asked to introduce only two knuckles in the oral cavity and perform a mandibular occlusion, an intervention that serves as a simulated stretch in said group.
224004900|NCT01325311|DRUG|Cholecalciferol|Given PO
224125008|NCT01236612|BIOLOGICAL|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
223386721|NCT06404099|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
223386722|NCT06404099|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
223386723|NCT06404099|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
223425634|NCT01279174|OTHER|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
224004901|NCT01325311|DRUG|Genistein|Given PO
224004902|NCT01325311|OTHER|Laboratory Biomarker Analysis|Correlative studies
224125009|NCT01236612|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
224125010|NCT06519006|PROCEDURE|Pelvic floor exercise|Exercises aimed at this issue consist of identification and isolated contraction of the pelvic floor muscles as well as their activation during complex movements and daily activities. During the engagement of the pelvic floor muscles, the correct engagement of the respiratory activity is important. Within the exercise units, exercises are used from sphincter contraction, through the gradual activation of individual pelvic floor layers in various ways, to their complex involvement in movement activities. Exercises are practiced repeatedly, at different frequencies and intensities that gradually increase, 4-5 times per day.
224004903|NCT01325311|OTHER|Pharmacological Study|Correlative studies
224004904|NCT01325311|OTHER|Placebo|Given PO
224004905|NCT06342414|DIAGNOSTIC_TEST|ELUCIDATE|ELUCIDATE (Evaluation of Liver Cholangiocarcinoma Intrahepatic)
224004906|NCT06079619|OTHER|Analysis of photos of pigmented tumours by the three groups|Analysis of photos of pigmented tumours by the three groups with different techniques for each group to compare them.
224004907|NCT00023296|DRUG|Nitric Oxide|
224004908|NCT00023296|DEVICE|INO Pulse - NO Delivery System|
223386724|NCT03935997|OTHER|Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program|"Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff."
223386725|NCT06790017|OTHER|body temperature|Body temperature measurement will be performed in the preoperative and intraoperative periods.
223386726|NCT06958536|DRUG|SAR442970|Route of Administration: Subcutaneous
223386727|NCT06958536|DRUG|Placebo|Route of Administration: Subcutaneous
223386728|NCT05277168|DRUG|SHR-A1904|Single Arm ：It is a dose-escalation and dose-expansion study of SHR-A1904 in subjects with advanced solid tumors
223386729|NCT05108831|DEVICE|ePOCT+|ePOCT+ is an electronic clinical decision support algorithm
224004909|NCT02470156|BEHAVIORAL|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
224004910|NCT02470156|BEHAVIORAL|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
224004911|NCT06013696|OTHER|Adding household bleach to urine sample|Adding household bleach to urine sample
224004912|NCT06132542|BIOLOGICAL|stem cell therapy|The fat derived stem cell will be transplanted by a reproductive gynecologist who does routine ovarian puncture.
224004913|NCT05814588|OTHER|Anodal TDCS|"RehaCom software is a computer assisted cognitive rehabilitation, it targets six programs of brain including attention, memory, and higher executive function, visuo-motor abilities, visual filed, vocational abilities, each module is divided into further subsections there is 36 total subsections, we will work on 6 subsections in every week.~The aTDCS device is a battery operated, with a pair of rubber conductive electrodes (size 7×5cm) enclosed with sponge saturated pockets (pads)."
224004914|NCT05814588|OTHER|Sham Anodal TDCS|rehacom cognitive therapy will be provided to this group participants
224004915|NCT03599258|DEVICE|Skylife|Newly FDA approved device
224004916|NCT03599258|DEVICE|Standard Therapy|Both devices are considered standard therapy
224004917|NCT02869529|OTHER|Data collection|
224004918|NCT01581177|DRUG|Albuterol DPI 25 mcg/inh|Albuterol DPI with 25 mcg Albuterol/inhalation
223386730|NCT03184571|DRUG|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor
224004919|NCT01581177|DRUG|Albuterol DPI 90 mcg/inh|Albuterol DPI with 90 mcg Albuterol/inhalation
224125011|NCT02814968|DRUG|Enzalutamide|
224125012|NCT02814968|DEVICE|18-FDG PET/CT|
224125013|NCT02814968|DEVICE|Whole body MRI|
223386731|NCT03184571|DRUG|Bemcentinib|Bemcentinib is a selective Axl kinase inhibitor;
224004920|NCT01581177|DRUG|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
224004921|NCT01581177|DRUG|Albuterol MDI 90 mcg/inh|Albuterol MDI with 90 mcg Albtuerol/inhalation
224004922|NCT02144792|DRUG|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
224004923|NCT01255631|DEVICE|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
224004924|NCT01255631|DEVICE|Sham PEMF Device|Inactive PEMF device, delivers no PMF
224125014|NCT02814968|DEVICE|Bone scan|
224125015|NCT02810262|OTHER|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
224295809|NCT01310673|DRUG|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
223386732|NCT05247580|OTHER|Hicks self-confidence scale, Karasek survey, Maslach Burnout Inventory|Questionnaires (Hicks self-confidence scale, Karasek questionnaire, Maslach Burnout Inventory) sent to hospital staff caregivers before and after (at 3 and 6 months) their SUrVIS training.
223386733|NCT03855111|OTHER|Standard Acupuncture / Moxibustion|Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
223386734|NCT03855111|OTHER|Individualized (Tailored) Active Acupuncture / Moxibustion|Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
223386735|NCT06493383|DEVICE|Lotrafilcon B plano cosmetic contact lenses|Commercially approved colored contact lenses worn for cosmetic purposes to alter or enhance the apparent color of the eye
223386736|NCT05239468|DRUG|Bezafibrate 100 mg|One tablet of bezafibrate 100 mg IR once daily
224125016|NCT00016874|DRUG|cisplatin|
224125017|NCT00016874|DRUG|paclitaxel|
224125018|NCT00016874|DRUG|triapine|
224125019|NCT04336592|BEHAVIORAL|Non-pharmacological Options in post-operative Hospital and Rehabilitative Management (NOHARM)|Gathers patient preferences for non-pharmacological pain management strategies through medical record and inform clinicians (via prompts, orders, etc.) of these preferences and encourages conversation about these preferences throughout their routine pre- and post-surgical interactions with patients. Resources will be provided to bedside clinicians as they assist patients in identifying a personalized post-discharge pain management strategy.
224125020|NCT00002789|DRUG|busulfan|
224125021|NCT00002789|DRUG|cyclophosphamide|
224125022|NCT00002789|DRUG|cyclosporine|
224125023|NCT00002789|DRUG|methotrexate|
224004925|NCT04393194|DRUG|Vaginal Cream with Applicator [Dose Form]|Patients with symptomatic POP will be assigned as outpatients. After the initial pessary fitting, the patients will be followed up in 2 weeks. If the prolapse is supported, no discomfort, and the patient decides to continue to use the pessary, the pessary fitting is successful. Patients with successful ring pessary fitting, who agree to participate and sign written consent, will be randomized into the vaginal estrogen group and the placebo group. The patients will be followed up every 3 months after wearing pessary combined with vaginal medication, until 1 year after wearing the pessary.
224004926|NCT00313092|DEVICE|nCPAP treatment|treatment with positive air pressure during night
224004927|NCT00384774|DRUG|Lasmiditan|Administered as intravenous infusion
224004928|NCT00384774|DRUG|Placebo|Administered as intravenous infusion
224004929|NCT04921475|DEVICE|Regional oxygen saturation monitoring|Regional oxygen saturation of kidney is monitored using near infrared spectroscopy
224004930|NCT04631159|BEHAVIORAL|Health2Sync app and report blood glucose data weekly|Patients will need to download and use the Health2Sync app and report blood glucose data weekly
224004931|NCT04631159|OTHER|self-manage|Patients will be asked to self-manage and there is no intervention during the tracking process
224004932|NCT04695522|BIOLOGICAL|ADR-002K administration|ADR-002K administration
224004933|NCT05473559|PROCEDURE|Adductor canal block with Ipack block or selective tibial nerve block|Ultrasound guided
224004934|NCT04215484|DIAGNOSTIC_TEST|serum BNP assessment|serum BNP assessment in pregnant women with placenta previa, associated or not to a suspected abnormal placental invasion, compared to a control group
224004935|NCT04604574|OTHER|Indigenous Healing and Seeking Safety|Indigenous Healing and Seeking Safety Intervention: Initial 90-minute meetings will be conducted with the participants; during these meetings, participants will receive information about IHSS, traditional healing, sharing circles, sweat lodge ceremonies, and program details. The sharing circles will take place at Benbowopka Residential treatment Centre in Blind River, Ontario. Each of the sharing circles will be cofacilitated by two Indigenous health-care workers. These facilitators will organize and lead sharing circles daily throughout the 28-day treatment cycle. Each sharing circle will be two hours long. The Seeking Safety program consists of up to 25 treatment topics that aim to teach participants a variety of skills. The majority of topics address the cognitive, behavioral, interpersonal, and case management needs of persons with SUD and posttraumatic stress disorders (PTSD) (Najavits, 2002a). The treatment will adhere to the concept of Two-Eyed Seeing and cultural sensitivity.
224004936|NCT02420951|DRUG|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
224004937|NCT02420951|OTHER|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
224004938|NCT01674829|BIOLOGICAL|MA09-hRPE|Transplantation of MA09-hRPE cells accoding to the assigned dose group
224004939|NCT05698576|DEVICE|TRANBERG® Transperineal Fusion Laser--Induced Thermal Therapy of Prostate Cancer (TPF-LITT)|A perineal local anesthesia block is performed with patient on lithotomy. The ultrasound probe is advanced, secured to digital stepper. The live ultrasound image feed is visible on the FOCALYX® Fusion device. Image co-registration (MR/US) will be performed. The FOCALYX® Fusion device shows outline of the prostate on the MRI and the target area(s) in real-time. The urologist advances laser fiber introducer, temperature probes to indicated coordinates. Target treatment - applying TRANBERG® laser energy over the treatment area and controlling delivery with a pedal. Treatment is monitored using FOCALYX® Fusion device in real-time. One laser fiber will be used and a single or multiple applications may be required. The fiber will be relocated to other targets if present. Patient will be dismissed to the MRI center where a multiparametric MRI will be conducted. After this study is completed, the patient will be discharged home with instructions and contact information.
224004940|NCT03561662|DIETARY_SUPPLEMENT|Alpro soya drinks|12 weeks
223730100|NCT02329730|BIOLOGICAL|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
223730101|NCT04563923|DRUG|Avdoralimab (IPH5401)|Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.
224004941|NCT00568178|DRUG|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed \<50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
224004942|NCT00568178|OTHER|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
224125024|NCT00002789|PROCEDURE|allogeneic bone marrow transplantation|
224125025|NCT00002789|PROCEDURE|peripheral blood stem cell transplantation|
224125026|NCT03161938|DRUG|Dexamethasone|intravenous
224125027|NCT04664595|DRUG|Propofol Fresenius|final dose of Propofol (mcg/kg) to reach the target effect-site concentration
224125028|NCT03531177|BEHAVIORAL|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
224125029|NCT03531177|BEHAVIORAL|Control|Participants receive usual care from their healthcare team.
224125030|NCT03615755|OTHER|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
223425635|NCT00005601|BIOLOGICAL|rituximab|
224004943|NCT00568178|DRUG|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
223386737|NCT05239468|DRUG|Bezafibrate 200 mg|Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
223730102|NCT04563923|OTHER|Control|"Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion"
224004944|NCT00568178|OTHER|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
224004945|NCT00568178|OTHER|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
224004946|NCT00568178|DRUG|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
224004947|NCT01531673|DRUG|VX-661|
224004948|NCT01531673|DRUG|Ivacaftor|
224004949|NCT01531673|DRUG|Placebo matched to VX-661|
224004950|NCT01531673|DRUG|Placebo matched to ivacaftor|
224004951|NCT02760875|BEHAVIORAL|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
224004952|NCT02290808|BEHAVIORAL|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
224004953|NCT02880410|DEVICE|NeuroBlate System|Laser Interstitial Thermal Therapy
224004954|NCT02880410|DRUG|Radiation therapy and temozolomide|Radiation therapy and temozolomide
224004955|NCT02032589|BEHAVIORAL|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
224004956|NCT01508624|OTHER|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
224004957|NCT01508624|OTHER|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
224004958|NCT01508624|BEHAVIORAL|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
224004959|NCT01508624|BEHAVIORAL|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
223386738|NCT05239468|DRUG|Obeticholic Acid 5 mg|One tablet of obeticholic acid 5 mg tablet once daily.
223386739|NCT05239468|DRUG|Obeticholic Acid placebo|One tablet of obeticholic acid placebo tablet once daily
223386740|NCT05239468|DRUG|Bezafibrate Placebo|One tablet of bezafibrate placebo tablet once daily
223386741|NCT04876781|DRUG|Tofacitinib XR|Tofacitinib XR 11mg
224125031|NCT06279897|OTHER|Skin Surface Rewarming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~90°F and held here for the duration of the LBNP test.
224125032|NCT06279897|OTHER|Skin Surface Warming|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~93°F and held here for the duration of the LBNP test.
223425636|NCT00005601|DRUG|cisplatin|
223425637|NCT00005601|DRUG|cytarabine|
223425638|NCT00005601|DRUG|dexamethasone|
223425639|NCT00005601|DRUG|sargramostim|
223730103|NCT00435292|DRUG|Naproxen|nonsteroidal anti-inflammatory drug
223730104|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 250 mg|flavonoid mixture
223730105|NCT00435292|DIETARY_SUPPLEMENT|flavocoxid 500 mg|flavonoid mixture
224004960|NCT05651152|DRUG|JZP441|Nighttime oral dose
224004961|NCT05651152|DRUG|Placebo|Nighttime oral dose
224004962|NCT01618253|DRUG|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
224004963|NCT01618253|RADIATION|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or \>10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If \>1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions \>10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
224004964|NCT04819659|DEVICE|Pharyngeal packing|Placing gauze-like material in the nasal cavity to absorb blood or other fluids right after tracheal intubation.
224004965|NCT02823197|OTHER|Active transport lesson|
224004966|NCT02823197|OTHER|Active transport lesson and Facebook group|
224004967|NCT00264303|DRUG|Levocetirizine|5mg oral capsules, once daily, 4 week duration
224004968|NCT00264303|DRUG|Desloratadine|5mg oral capsules, once daily, 4 week duration
224004969|NCT02815579|OTHER|Shamba Maisha Intervention|A) A loan (\~$175) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
224004970|NCT02255253|DRUG|Telmisartan|capsule,40mg per day,2 months
224004971|NCT02255253|DRUG|Hydrochlorothiazide|tablet, 25mg per day, 2 months
224004972|NCT02389452|DRUG|Synvisc-One|intraarticular injection
224004973|NCT01855971|DIETARY_SUPPLEMENT|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
224004974|NCT01855971|DIETARY_SUPPLEMENT|Placebo|Same capsules containing rice flour. No active treatment is given.
224004975|NCT01855971|OTHER|Cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
224004976|NCT00943839|DRUG|sunitinib malate|
224004977|NCT00943839|OTHER|laboratory biomarker analysis|
224004978|NCT00943839|OTHER|pharmacological study|
223386742|NCT03130777|DEVICE|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
223386743|NCT04677569|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes
223386744|NCT04677569|DRUG|Azithromycin|Oral tablet
223386745|NCT04677569|DRUG|Ethambutol|Oral tablet
224004979|NCT02311673|DRUG|Setmelanotide|subcutaneous injection
224004980|NCT02311673|DRUG|Placebo|Subcutaneous injection
224004981|NCT03995862|OTHER|Questionnaire|A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
224004982|NCT01006252|DRUG|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
224004983|NCT01006252|DRUG|Paclitaxel|80 mg/m\^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
224004984|NCT02878226|PROCEDURE|repair of rupture|
224004985|NCT05003518|BEHAVIORAL|ParentText|ParentText delivers content, aligning with children's developmental stages (0-23 months, 2-9 years, 10-17 years). ParentText content is delivered through text messages, images, audio and video for parents/ caregivers and their children. Parents receive parenting content surrounding three themes: 1) relationship building by spending time together, 2) positive reinforcement, 3) stress reduction for parents and caregivers. Further supportive content is available for parents of children living with disabilities, child development, online child safety, talking about COVID-19 with children, family budgeting, family harmony, helping with schoolwork and sexual violence prevention.
224004986|NCT05907525|DRUG|Remimazolam|"To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
224004987|NCT05907525|DRUG|1% propofol|"To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg."
224004988|NCT04136821|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
223386746|NCT04677569|DRUG|ELC (matching placebo for ALIS)|Inhalation via nebulization over approximately 6 to 15 minutes
224004989|NCT04136821|OTHER|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
224004990|NCT04595851|OTHER|Patient Reported Outcome Measure (PROM)|Participants will complete a PROM (Michigan Oncology Quality Consortium, Patient Assessment Tool for Oral Chemotherapy) for their oral anticancer agent (OAA) at two timepoints over 2 months, to assess patient symptoms and adherence to OAA.
224004991|NCT04595851|OTHER|Comprehensive Medication Review (CMR)|Following the first PROM, participants will be contacted by the primary care pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. If warranted, a follow-up CMR will take place after the second PROM.
224004992|NCT04595851|OTHER|Communications between oncology and primary care pharmacists|Throughout the study, the oncology and primary care pharmacists will communicate about medications through the electronic medical record.
224125033|NCT06279897|OTHER|Skin Surface Heating|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will be increased to \~95°F and held here for the duration of the LBNP test.
224125034|NCT06279897|OTHER|Skin Surface Cooling|Sixty seconds after the onset of lower body negative pressure (LBNP) skin temperature will remain lowered to \~82°F for the duration of the LBNP test.
224295810|NCT01310673|DRUG|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
223386747|NCT06199921|DRUG|Atorvastatin 20mg|Participants will receive oral atorvastatin 20mg daily for 16 weeks
223386748|NCT06199921|DRUG|Atorvastatin 40mg|Participants will receive oral atorvastatin 40mg daily for 16 weeks
223386749|NCT06199921|DRUG|Atorvastatin 60mg|Participants will receive oral atorvastatin 60 mg daily for 16 weeks
223386750|NCT06199921|DRUG|Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)|Participants will receive 8 weeks of daily oral treatment with rifampin, isoniazid, pyrazinamide, ethambutol, followed by 16 weeks of daily oral treatment with rifampin, isoniazid
223386751|NCT05910840|OTHER|Support-t|Support-t plus usual diabetes care for 18 months
224004993|NCT05064527|DEVICE|wearable biosensor|The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.
224004994|NCT05064527|BEHAVIORAL|Treatment as usual (TAU)|Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.
224004995|NCT05064527|BEHAVIORAL|Exposure and response prevention (ERP)|One ERP session will be offered in Week 0 and Week 8.
224004996|NCT04425759|DIAGNOSTIC_TEST|Blood sample|Blood sammples for the serological analysis will be collected at 0/90/180/270/360 days.
224004997|NCT03156881|OTHER|Global Osteopathic Treatment|"The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.~Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance."
224004998|NCT02566044|OTHER|Placebo|Placebo
224004999|NCT02566044|DRUG|QBW276|0.3 mg and 1.5 mg strengths
224005000|NCT06114316|BEHAVIORAL|individualized nursing interventions based on the Roy Adaptation Model /experimental|"The personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. The interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the support coping interventions under the title of the behavioral area in the Nursing Intervention Classification (NIC). A total of 10 individual interviews were made twice a week for about 45 to 60 minutes. The interviews were evaluated by determining the area specific Nursing outcome classification (NOC) (self respect, social support, mood management, role performance)."
224005001|NCT01077427|DEVICE|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3\* and 16, 17\* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3\*, and 16, 17\* of each course~\* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
224005002|NCT01077427|DRUG|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
224005003|NCT01355861|BEHAVIORAL|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
224005004|NCT01364792|DRUG|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
224005005|NCT00285662|DRUG|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
224005006|NCT02683772|DEVICE|Astral|Astral ventilator
224005007|NCT02380924|DRUG|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
224005008|NCT02380924|DRUG|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
223386752|NCT02835612|OTHER|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
223386753|NCT02835612|OTHER|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
223386754|NCT06549179|DIAGNOSTIC_TEST|AMSE|Evaluation of the performance of the French-language AMSE tool used by non-expert psychiatrists and psychologists, trained in the tool, in the identification of ASD in adults.
223386755|NCT06295367|OTHER|Best Practice|Receive PAF brochure describing financial navigation services
223386756|NCT06295367|OTHER|Financial Navigation|Receive CostCOM financial counseling
223386757|NCT06295367|OTHER|Interview|Participate in a 1 on 1 in-depth interview
223386758|NCT06295367|OTHER|Survey Administration|Ancillary studies
224125035|NCT06324994|DRUG|Linperlisib in combination with Obinutuzumab and Venetoclax|Combined induction period: Linprixate: 80 mg, oral (pre - and post meal), once a day; Otuzumab: 1000 mg/dose, intravenous infusion, administered on the first day (1st cycle is 1, 8, 15 days); (Up to 6 cycles, administration cycle can be adjusted according to clinical treatment conditions); Vineclavone: increase from 40mg, 100mg, and 200mg to 400mg within 4 weeks, followed by a treatment cycle of 400mg orally once a day; (Starting from the third cycle), one cycle every 28 days, for a total of 6 cycles。 Maintenance treatment period: Linprixate: 80 mg, oral (both before and after meals), once a day; Vinecala: 400 mg, oral, once daily; Cycle every 28 days.
224125036|NCT04898374|DRUG|Gemcitabin/cisplatin|chemotherapy combination
224125037|NCT04053543|DRUG|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
223386759|NCT05144256|DRUG|Mitapivat|Tablets or granules
223386760|NCT05144256|DRUG|Mitapivat-matching placebo|Tablets or granules
223386763|NCT04696731|GENETIC|ALLO-316|ALLO-316 is an allogeneic CAR T cell therapy targeting CD70
223386764|NCT04696731|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
223386765|NCT04696731|DRUG|Fludarabine|Chemotherapy for lymphodepletion
223386766|NCT04696731|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
223386767|NCT04760353|DIETARY_SUPPLEMENT|Probiotic mixture (OMNi-BiOTiC STRESS)|OMNi-BiOTiC STRESS containing 9 human bacterial strains \[Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactobacillus plantarum W62, Bifidobacterium bifidum W23, with at least 7,5 billion CFU per one dose (3 g) and 15 billion CFU per two doses (6 g)\] and vitamin B (B2, B6, B12),
223386768|NCT04760353|OTHER|Placebo|"one powder portion bag self-administered orally twice a day for 8 weeks, identical in all aspects (organoleptic) as investigational product (IP) but containing excipient only.~* Powder portion bags are suitable for participants with intolerance to yeasts or lactose~* Each patient will receive a container with 112 powder portion bags (IP or placebo depending on the randomization) at the randomization period (0 weeks)."
223386769|NCT05239780|PROCEDURE|Brain stimulation|Brain stimulation will be performed after collection of clinical seizure data. Bipolar stimulation to one or several adjacent electrodes will be applied. Stimulation design will be either determined prior to testing or designed according to results from neurobehavioral assessments. Stimulation will consist of biphasic, constant-current trains of stimulation pulses at 100 Hz, with 100 ms pulse width or a sinusoidal wave of a predefined mean band frequency (i.e. 6Hz for θ, 11Hz for α, 20Hz for β, etc.). Stimulation intensity will be ≤6 mA, consistent with parameters used for clinical mapping, for the duration of the behavioral task or for short (2-3 s) periods of time at given epochs during the task (i.e. outcome evaluation). Clinical personnel will be available during stimulation to help monitor stimulation-induced after-discharges; if any are detected, stimulation intensity will be dialed down or terminated.
223386770|NCT04546971|BEHAVIORAL|Brief Intervention|Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking
223386771|NCT04546971|BEHAVIORAL|Telehealth Counseling|5 sessions of counseling on alcohol use based on Motivational Interviewing.
223386772|NCT04546971|BEHAVIORAL|Text messaging|A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.
224005009|NCT05396534|PROCEDURE|Atrial Fibrillation transcatheter ablation|We perform pulmonary veins isolation that remains remains the cornerstone of all catheter-based treatment strategies in atrial fibrillation
224005010|NCT00769652|BEHAVIORAL|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
224005011|NCT00769652|BEHAVIORAL|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during \& after treatment."
224005012|NCT00271726|PROCEDURE|Osteosynthesis with palmar locking plate|
224005013|NCT00271726|PROCEDURE|Osteosynthesis with external fixator|
224005014|NCT00271726|PROCEDURE|Osteosynthesis with Kirschner wires|
224005015|NCT00414908|DRUG|Pancrelipase delayed release capsule|24,000 unit capsule
223386773|NCT05057234|DIAGNOSTIC_TEST|FoundationOne liquid CDx|FoundationOne liquid CDx testing
223386774|NCT05057234|BEHAVIORAL|Quality of life questionnaires|Quality of life questionnaire - EQ5D
224125038|NCT02078882|BIOLOGICAL|abatacept|125 mg subcutaneously each week for 24 weeks
224125039|NCT00449111|DRUG|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
223386775|NCT05109611|DRUG|Nitric Oxide|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
223386776|NCT05109611|DEVICE|Nasal spray with isotonic saline|The Sponsor designed a dual chamber nasal spray bottle for NORS administration. The bottle will be filled with normal saline before being provided to the participant.
223386777|NCT02557438|PROCEDURE|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
223386778|NCT02557438|PROCEDURE|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
223386779|NCT05081024|PROCEDURE|Biopsy|Undergo biopsy
223386780|NCT05081024|PROCEDURE|Biospecimen Collection|Undergo collection of blood and/or tissue samples
223386781|NCT05081024|OTHER|Electronic Health Record Review|Medical records are reviewed
223386782|NCT06389396|DEVICE|CP362 Test Catheter|The investigational device is intended to perform TAI procedures together with the CE-marked Peristeen Plus TAI system.
224005016|NCT00414908|DRUG|Placebo Comparator|Placebo
224005017|NCT04945889|DIAGNOSTIC_TEST|Quick Sequential Organ Failure Assessment (qSOFA)|Clinical bedside tool that evaluates three vital parameters, scoring one point each if altered: respiratory rate (RR) ≥22 breaths/minute, systolic blood pressure (SBP) ≤100 mmHg and altered mental status (defined in our study as either Glasgow Coma Scale (GCS) score \<15 or any worsening in the Italian Oriented, Disoriented, Agitated, Sleepy scale). A qSOFA score ≥2 points is considered indicative of sepsis.
224005018|NCT04945889|DIAGNOSTIC_TEST|Modified Early Warning Score (MEWS)|Clinical bedside tool that evaluates five vital parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), body temperature (0-2 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A MEWS score ≥5 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
224005019|NCT04945889|DIAGNOSTIC_TEST|National Early Warning Score (NEWS)|Clinical bedside tool that evaluates seven parameters, with multiple scoring according to alteration: respiratory rate (0-3 points), oxygen saturation (0-3 points), need for any supplemental oxygen (0-2 points), body temperature (0-3 points), heart rate (0-3 points), systolic blood pressure (0-3 points), mental status (0-3 points, evaluated using the Alert, Verbal, Pain, Unresponsive - AVPU scale). A NEWS score ≥7 points is considered indicative of an acute condition at risk of sudden clinical deterioration.
224005020|NCT04245059|DEVICE|Multi-channel Transcranial direct current stimulation|A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
224005021|NCT01367925|DEVICE|Stryker Triathlon® CS Tibial Insert|
224005022|NCT01367925|DEVICE|Stryker Triathlon® PS Tibial Insert|
224005023|NCT03679715|OTHER|participatory art-based activity|"The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work.~In Montreal, Canada, participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops.~In Tokyo, Japan, participants will meet once per week for a 2h workshop at the Tokyo Fuji Museum in a dedicated room during a three month-period defining a session. The session will be composed of 12 consecutive workshops."
223386783|NCT01002495|BIOLOGICAL|VM202|Endocardial injections on Day 0.
224005024|NCT00204321|DRUG|sirolimus (drug), mmf (drug)|
224005025|NCT02069652|BEHAVIORAL|Lifestyle Counseling|Lifestyle Counseling
223386784|NCT04132206|OTHER|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
224005026|NCT01076153|DRUG|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
224005027|NCT00080353|DRUG|IL-2|
224005028|NCT00080353|DRUG|gp100:209-217|
224005029|NCT00080353|DRUG|OKT3|
224005030|NCT00080353|DRUG|rF-go 100P209|
224005031|NCT00080353|DRUG|Montanide ISA 51|
224005032|NCT04601675|DRUG|Ranibizumab Ophthalmic and Intravitreal Dexamethasone|Pro re nata patients with macula edema due to diabetes will receive Ranibizumab. Group A will continue to receive Ranibizumab depending on their clinical status of macular edema
224005033|NCT04601675|DRUG|Ranibizumab Ophthalmic only|Group B will initially receive intravitreal Dexamethasone and Ranibizumab and then depending on their clinical status of macular edema, Ranibizumab will be injected.
224005034|NCT06010277|DRUG|Folinic acid|Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
224005035|NCT05691803|BEHAVIORAL|Exercise intervention|"The 6 month intervention consists of usual care (PaP) plus an initial 12 weeks of instructor led exercise (described below) followed by a 12 week period in where the participant will have to conduct their physical activity on their own.~Exercise intervention:~Participants are invited to a 12 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first three weeks and then two sessions per week for week 4-12. A follow-up session is also included after 12 weeks in where a physiotherapist contact the participant and discuss how they will adhere to their Physical activity on prescription."
224005036|NCT03780218|OTHER|Respiratory function|Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
224005037|NCT04069481|OTHER|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
224005038|NCT04069481|OTHER|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
224005039|NCT02808078|DEVICE|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
224005040|NCT02808078|DEVICE|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
224125040|NCT06198049|OTHER|Pilates Training|This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week
224125041|NCT06198049|OTHER|Balance Proprioception Exercises|This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
223386785|NCT06171659|DRUG|FDG radiotracer|Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
223386786|NCT06171659|DEVICE|PET/MRI|positron emission tomography and magnetic resonance imaging
223386787|NCT06171659|DEVICE|PET/CT imaging|positron emission tomography and computed tomography imaging
223386788|NCT06168578|DEVICE|ultrasound|Optic nerve diameter will be measured by ultrasound at certain stages of the operation in Group I (ARM-) and Group II (ARM+)
223386789|NCT06195930|DRUG|Vericiguat (BAY1021189) 5 mg|Vericiguat (BAY1021189) will be taken as 5 mg tablet 1x daily over at least 14 days up to 18 days (+ 4 days time window allowed)
223386790|NCT05506683|OTHER|MotoMeds pediatric telemedicine and medication delivery service (TMDS)|The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.
223386791|NCT04995029|DRUG|Transmucosal Buprenorphine|Transmucosal (TM) buprenorphine as selected by the Investigator per local prescribing guidelines, administered either under the tongue (sublingual) or between the gum and cheek (buccal)
223386792|NCT04995029|DRUG|Extended-release Buprenorphine|Administered by subcutaneous injection
223386793|NCT06075537|DRUG|tividenofusp alfa|Intravenous repeating dose
224005041|NCT06272552|OTHER|PROMs and PREMs|"Participants are administered PROMs and PREMs at a given timeline adequate to each participant conditions for a duration of 2 years. The administration of PROMs is done by email using the REDCap platform. The research team and health care professionals have access to their patient\&amp;amp;#39;s results to aid in the patients clinical care.~Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
224005042|NCT06272552|OTHER|PREMs|"Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit."
224005043|NCT06272552|OTHER|Control|At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
224005044|NCT06272552|OTHER|Healthcare professionals|Healthcare professionals participating in the study answer an evaluation questionnaire before the implementation starts at their service and two years later to measure their perceptions about the implementation.
224005045|NCT00817713|DRUG|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~* Praziquantel 2400mg single dose~* Ivermectin 12 mg, single dose~* Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
224005046|NCT02823990|BIOLOGICAL|TG4010|Given SC
224005047|NCT02823990|BIOLOGICAL|Nivolumab|Given IV
224005048|NCT02201615|OTHER|Perineal massage in childbirth|
224005049|NCT04633525|PROCEDURE|Optimum Cup Orientation|Participants will have X-rays taken before surgery to determine the target optimal zone for orientation of the cup implant, using EBRA software. The surgeon may or may not implant in this target zone, depending on what they believe is in the patient's best interest. X-rays will be taken at 12 months after surgery to determine if they target cup orientation was achieved.
224005050|NCT05138354|OTHER|Low Level laser therapy|MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
224005051|NCT05138354|OTHER|Myofascial release|Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
224125042|NCT03540134|DEVICE|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
224125043|NCT05489822|DEVICE|VERTICALE® Cervical System|"All measures and devices mentioned in the study protocol correspond to routine clinical practice with the exception of the following questionnaires:~NDI (Neck Disability Index) NRS (Numerical Rating Scale) neck pain (cervical spine) and NRS arm pain mJOA (modified Japanese Orthopaedic Association) Score"
224125044|NCT04264455|DEVICE|Biomonitor|Patients receive a Biomonitor only
224125045|NCT04264455|DEVICE|Life Vest|Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
224005052|NCT05138354|OTHER|Standard care|"1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles."
224005053|NCT04411693|DRUG|Dexamethasone implant|A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.
224005054|NCT04411693|DRUG|Aflibercept|A single dose, 2mg, drug administered by intravitreal injection.
224005055|NCT00039390|DRUG|capecitabine|Given orally (PO)
224005056|NCT00039390|DRUG|gefitinib|Given PO
224005057|NCT00039390|OTHER|pharmacological study|Correlative studies
224005058|NCT00039390|OTHER|laboratory biomarker analysis|Correlative studies
224125046|NCT04264455|DEVICE|Implantable Cardioverter-Defibrillator (ICD)|Patients receive an Implantable Cardioverter-Defibrillator (ICD)
224005059|NCT00818168|BIOLOGICAL|Infliximab|"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"
224125047|NCT04792437|PROCEDURE|surgery|surgery
224125048|NCT02391090|DEVICE|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
224125049|NCT02391090|DEVICE|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
224125050|NCT02391090|PROCEDURE|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
224125051|NCT02391090|OTHER|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
224125052|NCT02391090|PROCEDURE|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
224125053|NCT02391090|PROCEDURE|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
223386794|NCT05407636|GENETIC|ABBV-RGX-314 Dose 1|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
223386795|NCT05407636|GENETIC|ABBV-RGX-314 Dose 2|AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
223386796|NCT05407636|BIOLOGICAL|Aflibercept (EYLEA®)|2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections
223386797|NCT06276010|DRUG|nafamostat mesilate|Use nafamostat mesilate as an anticoagulant
223386798|NCT06276010|DRUG|unfractionated heparin group|Use unfractionated heparin as an anticoagulant
223386799|NCT03915652|BEHAVIORAL|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
223386800|NCT06264921|DRUG|NKT3447|Oral CDK2 inhibitor
223730106|NCT05989789|DEVICE|Radioactive Seed Implantation|In patients where initially the tumour lesion could not be identified, a radioactive seed was implanted and intraoperatively detected with a geiger counter sonde.
224005060|NCT01015040|DRUG|solifenacin succinate suspension|Oral
224005061|NCT01015040|DRUG|solifenacin succinate tablet|Oral
224005062|NCT00399191|DRUG|stable isotope of iron, dysprosium|
224005063|NCT05383144|OTHER|Complete Positioning scans|Entire treatment zone imaging at mi-treatment and at end of treatment
223386801|NCT05478239|DRUG|ArtemiCoffee|3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
223386802|NCT04569734|PROCEDURE|WATCHMAN device implant procedure utilizing ICE probe|The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation.
223386803|NCT03767660|DRUG|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
223386804|NCT04279210|DEVICE|Platelet-rich plasma|The RegenKit-THT (RegenLab SA, Switzerland) was used to separation of plasma and blood cells. 3mL PRP was extracted from the bottom of the plasma. PRP was injected into anterior vaginal wall, near external urethral sphincter, and into endopelvic fascia.
223386805|NCT05541081|DIAGNOSTIC_TEST|Point-of-care STI testing|"Testing for:~* Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid)~* Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics)~* HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd)~* Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)"
223386806|NCT01593774|DRUG|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
223386807|NCT01593774|DRUG|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
223386808|NCT02655913|DRUG|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
223425640|NCT03781583|DEVICE|SmartHMD version 1|First version of the SmartHMD device, which used custom software running on commercially available ODG R7 smart glasses and accompanying earbuds.
223730107|NCT02341053|OTHER|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
223730108|NCT02423577|DRUG|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
223730109|NCT02423577|DRUG|Placebo|Placebo dry powder administered by nasal inhalation
223730110|NCT04236011|BIOLOGICAL|GC012F injection|GC012F injection is a autologous dual CAR-T targeted BCMA and CD19. A single infusion of CART cells will be administered intravenously.
223730111|NCT00004482|DRUG|Cyclosporine|
223730112|NCT00004482|DRUG|methylprednisolone|
223730113|NCT00004482|DRUG|Muromonab-CD3|
223730114|NCT00004482|DRUG|prednisone|
224005064|NCT00846729|PROCEDURE|CT angiogram of the remaining kidney.|
224005065|NCT00846729|PROCEDURE|Kidney Function study using Iothalamate & PAH as clearance markers|
224005066|NCT06415539|OTHER|classical physical therapy program|Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.
224005067|NCT06415539|OTHER|exercises|Children in this group will be given vestibular and proprioceptive exercise training in addition to the classical physiotherapy program. Skateboard, swing, hammock, bowl, ball, sensory pads, ball pool, slide, climbing bar, trampoline and balance board will be used as materials in vestibular and proprioceptive exercise training. In addition, at the end of the training sessions, parents will be informed about the application of exercise training to daily activities.
224005068|NCT05586477|DRUG|Placebo|A placebo pill (i.e., sugar) will be consumed 2 h before intervention.
224005069|NCT05586477|DRUG|Diphenhydramine|Extra strength Benadryl (DIN 02470144) will be consumed 2 h before intervention
224005070|NCT00173992|BEHAVIORAL|Balance and Exercise|
224005071|NCT04476251|BIOLOGICAL|E7 T-Cell Receptor (TCR)|Patients will receive up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).
224005072|NCT02334982|DRUG|TAK-137|TAK-137 tablets
224005073|NCT02334982|DRUG|Placebo|TAK-137 placebo-matching tablets
224005074|NCT00480402|DRUG|200 mg of Progesterone|Administration of 200 mg of Progesterone
224005075|NCT00480402|DRUG|400 mg Progesterone|Administration of 400 mg Progesterone
224005076|NCT00480402|DRUG|Placebo|Administration of a Placebo
224005077|NCT00921687|BEHAVIORAL|Education only|The education will consist of a lecture and distribution of a CKD reference card.
224005078|NCT00921687|BEHAVIORAL|Multifactorial intervention|Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
224005079|NCT02652325|DRUG|Saline|
224005080|NCT02652325|DRUG|Povidone-Iodine|
223386809|NCT02655913|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
223386810|NCT02655913|OTHER|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
223386811|NCT05202314|DRUG|Immunotherapy (Camrelizumab)|After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
223386812|NCT05067283|DRUG|MK-1084|Oral dose
223730115|NCT03198949|DRUG|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
224005081|NCT02652325|DRUG|5% Povidone-Iodine USP swabs|
224005082|NCT01133795|DRUG|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
224005083|NCT02966327|DEVICE|Bilateral leg compression stockings|Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
224005084|NCT02966327|BEHAVIORAL|Individualized exercise|Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
224005085|NCT02966327|BEHAVIORAL|Lymphedema risk reduction|Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
224005086|NCT00316602|BIOLOGICAL|IMVAMUNE|Subjects receiving two subcutaneous vaccinations
224005087|NCT01681901|PROCEDURE|ultrasound imaging|Undergo ultrasound
224005088|NCT02710318|BEHAVIORAL|Electronic immunization alert|Immunization alert in the electronic health record
224005089|NCT04807673|BIOLOGICAL|Pembrolizumab|"Neoadjuvant period: pembrolizumab 200mg IV D1, Q3W, and preoperative therapy with three cycles.~Adjuvant period: pembrolizumab 200 mg IV D1, Q3W, up to one year, which should be performed within 3-6 weeks after surgery."
224005090|NCT04807673|DRUG|Paclitaxel|Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
224005091|NCT04807673|DRUG|Cisplatin|Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
223386813|NCT05067283|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
223386814|NCT05067283|DRUG|carboplatin|Per label
223386815|NCT05067283|DRUG|pemetrexed|Per label
223386816|NCT05067283|BIOLOGICAL|cetuximab|Per label
223386817|NCT05067283|DRUG|oxaliplatin|Per label
223730116|NCT00000633|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
224125054|NCT02391090|PROCEDURE|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
224125055|NCT02103790|DEVICE|Home NIV installation|
223386818|NCT05067283|DRUG|leucovorin|Per label
223386819|NCT05067283|DRUG|5-fluorouracil|Per label
223386820|NCT02562118|DRUG|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
223386821|NCT04859205|BEHAVIORAL|Intervention|"Participants will have access to the SUPPORT-Pro self-guided online training platform addressing many aspects of type 1 diabetes care. The SUPPORT-Pro content was developped by a team of health professionals specialized in type 1 diabetes as well as patient partners. It's content is regularly updated, evidence-based and divided into 6 categories (medication, blood glucose monitoring, diet, physical activity, hypo and hyperglycemia, health and other particularities). In each category, users can pick between 3 levels (beginner, intermediate and advanced) according to their level of confidence and knowledge.~Participants will be asked to fill out questionnaires at baseline, 3-month, and 12-month of the intervention which include the following: Eligibility assessment, identification, background, confidence, platform satisfaction."
223386822|NCT03091374|DRUG|Somatotropin (Human)|
223730117|NCT00000633|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
224005092|NCT04807673|RADIATION|neoadjuvant chemoradiotherapy|neoadjuvant chemoradiotherapy 41.4Gy(1.8Gy×23 fractions) with five cycles of TP(Paclitaxel 50mg/m\^2 on D1 and Cisplatin 25mg/m\^2 D1, repeated every week
224005093|NCT01142232|DRUG|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
224125056|NCT00448253|BIOLOGICAL|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
224125057|NCT04281160|DEVICE|BeCare Mobile App|The BeCare App is a mobile application that will perform routine assessments of neurological function in individuals with MS and address the most relevant domains that are affected in MS: cognition, afferent visual functioning, motor functioning, fine motor functioning, coordination, gait, and endurance
224125058|NCT00948662|DRUG|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
224125059|NCT00948662|DRUG|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
224125060|NCT00948662|DRUG|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
224005094|NCT01142232|DRUG|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
224005095|NCT01663922|DRUG|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
224005096|NCT01663922|DRUG|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
224005097|NCT05350280|DEVICE|electric current|Electric current will be applied in this group of patients using removable device.
224005098|NCT05350280|DEVICE|Traditional treatment|No acceleration method will be performed in this group.
224005099|NCT00732862|PROCEDURE|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
224005100|NCT00732862|PROCEDURE|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
224005101|NCT05983380|OTHER|Hand Mobility and Grip Strengthening Exercises|Addition of hand mobility and grip strengthening exercises to the usual care for breast cancer-related lymphedema to assess changes in limb volume, quality of life, and hand function.
224005102|NCT05983380|OTHER|Usual Care|Manual lymphatic drainage, compression, exercise, skin hygiene.
224005103|NCT00626990|DRUG|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
224005104|NCT00626990|GENETIC|DNA methylation analysis|O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
224005105|NCT00626990|OTHER|laboratory biomarker analysis|Prognostic factor analyses
224005106|NCT00626990|PROCEDURE|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
224005107|NCT00626990|PROCEDURE|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
224005108|NCT00626990|RADIATION|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
224005109|NCT01507987|DEVICE|Implanted with one or more of the following SJM leads: Riata leads, RiataST leads, Durata leads, and QuickSite/QuickFlex leads|"Riata leads implanted between 2002-2009 Riata ST leads implanted between 2006-2009 Quicksite or QuickFlex leads implanted between 2006-2010 Durata leads implanted between 2008-2010~Subjects were followed for three years and cinefluoroscopy imaging was done annually to determine prevalence of externalized conductors or other visual lead anomalies"
224005110|NCT02270541|OTHER|Telemedicine|In-ambulance telemedicine
224005111|NCT04357054|DIAGNOSTIC_TEST|Darwish test|Infertile women planned for combined laparoscopy and hysteroscopy as an integral part of infertility wok-up.
224005112|NCT00484081|PROCEDURE|Microdissection Testicular Sperm Extraction|
224005113|NCT00484081|PROCEDURE|ICSI|
224005114|NCT04449328|DEVICE|Computerized Mirror Therapy (CMT)|"Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand."
224125061|NCT01202227|DRUG|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
224295811|NCT03564041|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
224295812|NCT03564041|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
224295813|NCT00008151|DRUG|cyclosporine|
224005115|NCT04449328|DEVICE|Tendon vibration|Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
224005116|NCT01249716|DIETARY_SUPPLEMENT|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
224005117|NCT02154464|DRUG|Paracetamol|
224005118|NCT02154464|DRUG|Placebo|
224005119|NCT00297427|PROCEDURE|Acupuncture|Acupuncture twice weekly for 6 weeks.
224295814|NCT00008151|DRUG|fludarabine phosphate|
223730118|NCT06507449|DEVICE|Lithotripsy|Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent
224005120|NCT00297427|OTHER|Sham acupuncture|Twice a week for 6 weeks
224005121|NCT01951352|OTHER|Soap|
224005122|NCT04377685|OTHER|CT-Scan|Chest CT scan on admission to the hospital
224005123|NCT00847925|DRUG|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
224005124|NCT00285428|DRUG|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
224005125|NCT05537168|PROCEDURE|Pediatric cardiac surgery under cardiopulmonary bypass|All patients with pediatric cardiac surgery under cardiopulmonary bypass between 2008 and 2018 operated at our institution
224005126|NCT00475124|DEVICE|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
224005127|NCT00475124|DEVICE|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
224125062|NCT02152592|DRUG|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
224125063|NCT02152592|DRUG|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
224125064|NCT00643487|PROCEDURE|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
224295815|NCT00008151|DRUG|gemtuzumab ozogamicin|
224295816|NCT00008151|DRUG|methotrexate|
224295817|NCT00008151|DRUG|mycophenolate mofetil|
224295818|NCT00008151|PROCEDURE|allogeneic bone marrow transplantation|
224295819|NCT00008151|PROCEDURE|peripheral blood stem cell transplantation|
224295820|NCT00008151|RADIATION|radiation therapy|
224005128|NCT00597246|DRUG|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
224005129|NCT00597246|OTHER|PET Scan|GE Advance PET scanner for sequential body imaging
224005130|NCT04410601|PROCEDURE|Total thyroidectomy|DRT-diet modification, compensation strategies, oral motor exercises such as laryngeal elevation, masseters / tongue hold / exercise, bolus transition exercise; chin-down/up, head rotation, and other maneuvers with tactile stimulation.
224005131|NCT04481308|DRUG|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula|propofol (2 mg/kg) and fentanyl (1ug/kg) and 4 liters O2 flow through nasal cannula
224005132|NCT00449618|DRUG|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
224005133|NCT00449618|DEVICE|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
224005134|NCT00449618|PROCEDURE|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
224005135|NCT00449618|DRUG|Placebo|Use of placebo on awakening versus bedtime
224005136|NCT00092287|DRUG|lanreotide Autogel (somatostatin analogue)|
224005137|NCT00092287|DRUG|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
224005138|NCT01385852|PROCEDURE|microcoaxial phacoemulsification|conventional longitudinal ultrasound
224125065|NCT04402008|DRUG|Poziotinib Once Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
224125066|NCT04402008|DRUG|Poziotinib Twice Daily Dosing|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
224125067|NCT04402008|DRUG|Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
224125068|NCT01972009|PROCEDURE|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
224125069|NCT01693133|OTHER|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
224125070|NCT01693133|OTHER|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
224125071|NCT03816410|PROCEDURE|LAA amputation|complete surgical amputation of the left atrial appendage
224125072|NCT01970930|PROCEDURE|Blood specimen|4 green top tube 40 cc of blood draw
224125073|NCT04300491|OTHER|Suspension walking training|Physiotherapy session, objective wlaking with body weight support using a specific device
224125074|NCT05821257|OTHER|Evaluation of the arm swing during gait|Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.
224125075|NCT05821257|OTHER|Functional Tests|To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
224125076|NCT05920187|OTHER|Mediterranean diet and Anti-inflammatory diet|"Cases will be randomly allocated to two groups: Mediterranean diet group (following dietary intervention based on MD), and Anti\_inflammatory diet group(following dietary intervention based on IBD-AIF). Patients of the control group will not be instructed to follow a specific dietary intervention.~Evaluation of adherence of cases to dietary intervention will be at two points of time: after four weeks and after 12 weeks by using Mediterranean Diet Serving Score (MDSS) for MD adherence and Anti- Inflammatory Diet Serving Score for IBD- AID adherence. The AID Serving Score (AIDSS) is based on the latest update of the Anti-Inflammatory Diet Pyramid, using the recommended consumption frequency of foods and food group."
224125077|NCT06288672|OTHER|True avoidance diet|Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic
224125078|NCT06288672|OTHER|Sham avoidance diet|Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy
224125079|NCT02930798|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-116)"
224125080|NCT03633786|PROCEDURE|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung \& Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
224125081|NCT03633786|PROCEDURE|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
224125082|NCT03633786|DIAGNOSTIC_TEST|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
224125083|NCT03633786|DIAGNOSTIC_TEST|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
224125084|NCT03633786|DIAGNOSTIC_TEST|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
224125085|NCT06364228|DRUG|Placebo|Placebo intranasal spray liquid with no oxytocin will be delivered in 2 puffs to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
223386823|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
223386824|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
223386825|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|"Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56"
223386826|NCT05289687|DRUG|Daratumumab / Hyaluronidase Injection|All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
223386827|NCT01295112|DRUG|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
223386828|NCT01295112|DRUG|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
224005139|NCT05611112|BEHAVIORAL|Problem Solving Therapy|Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
224005140|NCT04300751|DRUG|Alcohol|Active alcohol or placebo, administered orally
224005141|NCT04300751|DRUG|Opioid Agonist|Active opioid agonist or placebo, administered orally
224005142|NCT03932305|DIETARY_SUPPLEMENT|Lutein|Lutein is a common oral supplement that may have neuroprotective effect on the human retina
224005143|NCT03932305|DIETARY_SUPPLEMENT|Placebo|Inactive placebo tablet
224005144|NCT01684787|DRUG|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
224005145|NCT01684787|DRUG|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
224005146|NCT05519098|DEVICE|COLO-SW-1|Patient will undergo a CADe-assisted colonoscopy procedure with use of the COLO-SW-1 software.
224125086|NCT06364228|DRUG|Oxytocin Intranasal Spray 12 International Unit (12IU)|Participants weighing less than 40 kg (88 pounds) will receive 12 IU of oxytocin delivered as 1 puff (6 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
224125087|NCT06364228|DRUG|Oxytocin Intranasal Spray 24 International Unit (24IU)|Participants weighing more than 40 kg (880 pounds) will receive 24 IU of oxytocin delivered as 2 puffs (12 IU) to each nostril daily for 21 days. The first single dose will be administered at the clinic (Visit 1).
224125088|NCT06364228|PROCEDURE|Functional MRI|Functional MRI (fMRI) scan with affective Stroop and Empathy and Theory of Mind task (EmpaTom task will administered pre- and post-administration of oxytocin.
224005147|NCT06797258|DEVICE|FlexHD® Pliable|Acellular Dermal Matrix
223386829|NCT03071692|DRUG|K-877|0.2mg tablet
223386830|NCT03071692|DRUG|Placebo|K-877 matching placebo tablet
223386831|NCT04110730|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
224005148|NCT06797258|OTHER|No intervention|Historical Control Arm
224125089|NCT03783650|BEHAVIORAL|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
224125090|NCT03783650|BEHAVIORAL|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
223425641|NCT03781583|DEVICE|SmartHMD version 2|Second version of the SmartHMD device, which uses RGB-D smart glasses, custom software running on a laptop, and bone-conducting earphones.
223425642|NCT03781583|DEVICE|SmartHMD version 3|Third iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and custom software.
224005149|NCT05789056|DRUG|QRX003, 4% Lotion|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
224005150|NCT05656235|DRUG|Enfortumab vedotin|Enfortumab vedotin 1.25mg/kg on Days 1 and 8 every 3 weeks for up to 35 weeks (each cycle = 21 days)
224005151|NCT05656235|DRUG|Pembrolizumab|Pembrolizumab 200mg on Day 1 every 3 weeks for up to 35 weeks (each cycle = 21 days)
224125091|NCT03783650|BEHAVIORAL|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
224125092|NCT03783650|BEHAVIORAL|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
224125093|NCT03783650|BEHAVIORAL|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
224125094|NCT01533935|DRUG|Placebo|placebo matching tiotropium + olodaterol
223386832|NCT04110730|BEHAVIORAL|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
223386833|NCT04520269|DRUG|Pacritinib|3+3 design Dose Level 1 :200mg BD every 4 weeks Dose Level -1 :200mg OM, 100mg ON every 4 weeks Dose Level -2 :100mg BD every 4 weeks
224005152|NCT05946187|BEHAVIORAL|Apolo_Bari Stepped-care intervention|"Step 1 - Low-intensity intervention that will run on a private Facebook® group. Weekly, a subtopic and related activities are posted as short text/images. Patients are encouraged to participate by viewing publications, commenting, and posting their content.~Step 2 - Will consist of an adjusted version of the Cognitive Behavior Treatment (CBT) program developed by Conceição et al. (2016). The intervention will last for 12-months and be delivered online by Facebook's functionalities, namely chat and calls. The intervention offered includes three components: 1) a psychoeducational cognitive-behavioral-based self-help manual that consists of 12 different modules. Each month a different topic will be covered and divided into four weekly sub-topics, which are supported with a set of related CBT tasks; 2) interactive call sessions with a psychologist (30 min at the beginning of each month); 3) monthly monitoring of risk-behaviors responded every session."
223386834|NCT00108004|DRUG|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
224005153|NCT05946187|OTHER|Treatment as Usual for Bariatric Surgery|Treatment as Usual for bariatric surgery in portuguese public hospitals.
224005154|NCT05440916|RADIATION|Palliative Radiotherapy: 5 x 4Gy|Palliative irradiation of 2 to 5 sites (metastatic sites or/and primary lung tumour) in one week before systemic therapy. Systemic therapy should be given as soon as possible after irradiation.
224005155|NCT05440916|DRUG|chemotherapy + immune checkpoint inhibitors|Systemic therapy according to national/European recommendations.
224005156|NCT02393300|DRUG|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
224005157|NCT02393300|DRUG|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
224005158|NCT02393300|DRUG|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
224005159|NCT02787044|BIOLOGICAL|High Dose Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine
224005160|NCT02787044|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine
224005161|NCT04900571|DRUG|Nitrofurantoin 100 MG|Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
224005162|NCT01056952|PROCEDURE|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
224005163|NCT01056952|PROCEDURE|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher \& Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 \> 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
224005164|NCT01056952|PROCEDURE|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 \> 90%
224005165|NCT01528553|DEVICE|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
224005166|NCT01528553|DEVICE|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
224005167|NCT05401006|DRUG|Acitretin 25Mg Cap|Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
224005168|NCT05401006|RADIATION|Narrowband ultraviolet B|Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
224005169|NCT02048475|OTHER|desflurane|changing concentration
224125095|NCT01533935|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
223386835|NCT05516186|OTHER|Scapular-focused exercise protocol with EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback
223386836|NCT05516186|OTHER|Control Therapy|manual and exercise therapy
224005170|NCT02324608|BIOLOGICAL|cetuximab|Given IV
224005171|NCT02324608|OTHER|laboratory biomarker analysis|Correlative studies
224125096|NCT01533935|DRUG|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
224125097|NCT01533935|DRUG|Tiotropium|tiotropium
224125098|NCT01533935|DRUG|Olodaterol|Olodaterol 5 mcg once daily
224125099|NCT01533935|DEVICE|Respimat|Respimat inhaler
224125100|NCT03430245|DEVICE|VelaShape III|The VelaShape III device combines controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum.
223386837|NCT05516186|OTHER|Scapular-focused exercise protocol without EMGBF|Scapular-focused exercises, based on the dos Santos et al (2021) protocol
223386838|NCT01200173|OTHER|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
223386839|NCT01200173|OTHER|2-Non fermented dairy product (control)|
223386840|NCT02413567|DEVICE|DMR Procedure (Fractyl)|Endoscopic procedure
224005172|NCT03434990|OTHER|Spinal manipulation/myofascial release|The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.
223386841|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
223386842|NCT01379157|DRUG|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
224005173|NCT03434990|OTHER|Spinal manipulation|The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
224005174|NCT04338659|BIOLOGICAL|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection|IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
224005175|NCT05374200|OTHER|Mind-body intervention with 1-1 support from study personnel|"The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (\~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered."
224005176|NCT02591953|PROCEDURE|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
224005177|NCT02591953|PROCEDURE|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
224005178|NCT02591953|DRUG|Methylprednisolone|Corticosteroid used in injection (40 mg)
224125101|NCT03430245|DEVICE|UltraShape Power|The UltraShape Power device uses focused ultrasound energy for lipolysis (breakdown of fat) via a non-thermal mechanism of action.
224125102|NCT01208896|DRUG|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
224125103|NCT05983003|PROCEDURE|endoscopic sinus surgery|Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
223386843|NCT00970593|DRUG|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
223386844|NCT00970593|DRUG|placebo comparator|Group 1 \& 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
223386845|NCT00897182|GENETIC|microarray analysis|
223386846|NCT00897182|GENETIC|polymerase chain reaction|
223386847|NCT02180048|DIETARY_SUPPLEMENT|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
223386848|NCT02180048|DIETARY_SUPPLEMENT|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
224005179|NCT02591953|DRUG|Lidocaine 1%|Anesthesic used in injection
224005180|NCT03732742|PROCEDURE|TOF repair with trans-annular patch VS preservation of PV|One group study
224005181|NCT00673959|OTHER|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
224005182|NCT00673959|OTHER|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
224005183|NCT02753153|PROCEDURE|Control surgical protocol|"A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0)."
224005184|NCT02753153|PROCEDURE|Test surgical protocol|The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
224005185|NCT02753153|PROCEDURE|Socket preservation|"An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied."
224005186|NCT00615745|DRUG|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
224125104|NCT06129604|DRUG|TPST-1495|Eligible subjects will receive study treatment of 50mg TPST-1495 taken orally, once a day for 7 days prior and discontinued 3 days prior to scheduled surgery.
224295821|NCT01598350|DEVICE|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
224005187|NCT05353205|DRUG|Flumatinib mesylate tablets (400mg)|Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.
224005188|NCT05353205|DRUG|Flumatinib mesylate tablets (600mg)|Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
224005189|NCT01517295|DRUG|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
224005190|NCT02819427|DEVICE|Near Infra Red Spectroscopy (NIRS)|
224005191|NCT02819427|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
224005192|NCT05110027|DRUG|Enpatoran|Participants will receive single oral dose of enpatoran tablet on Day 1
224005193|NCT05110027|DRUG|[14C]enpatoran microtracer|Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of \[14C\]enpatoran on Day 1 of Period 1.
224005194|NCT05110027|DRUG|[14C]enpatoran microdose|Participants will receive intravenous \[14C\]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.
224005195|NCT05076084|PROCEDURE|QUICK questionnaire and 6 additional questions|QUICK questionnaire and 6 additional questions
224005196|NCT05076084|OTHER|Retrospective collection of clinical data from the patients' medical records|Retrospective collection of clinical data from the patients' medical records
224005197|NCT03818724|DEVICE|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
224125105|NCT05628181|BEHAVIORAL|Educational nudge intervention|This project will adapt the EMPOWER educational brochure for PLWD receiving CNS polyRx. The educational brochure will be mailed to intervention participants identified through EHR at Michigan Medicine and Henry Ford Health System. The brochure will describe what CNS polyRx is, present information about the associated risks, and suggest that participants speak with the prescribing clinician or pharmacist about ways to potentially simplify the medication regimen. The tool will be adapted through three successive rounds of focus groups (AIM one of this project) of PLWD.
224005198|NCT02156726|DRUG|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
224005199|NCT01800734|OTHER|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1\. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
224005200|NCT02182947|DEVICE|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
224125106|NCT05453396|BIOLOGICAL|Loncastuximab Tesirine|Given IV
224125107|NCT02532361|DEVICE|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
224125108|NCT02532361|PROCEDURE|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
224125109|NCT03613415|OTHER|Expansion|non invasive technique to increase thickness of thin ridge
224299228|NCT02618408|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 low dose (18 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
223386849|NCT02180048|DIETARY_SUPPLEMENT|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
223386850|NCT01935830|RADIATION|[11c] LAAM|intravenous administration of 15-20 mCi of \[11c\] LAAM.
223386851|NCT01935830|DRUG|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
223386852|NCT01935830|DRUG|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
223386853|NCT05966415|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily.
223386854|NCT05966415|OTHER|placebo|4 capsules once daily OR 2 capsules twice daily
223386855|NCT04402411|PROCEDURE|Quadratus lumborum block|The patient will be placed in a lateral position with the side to be blocked facing upwards. The ultrasound probe will be properly sterilized and with sterile covers. An 18-20 gauge blunt tipped block needle or a Tuohy needle is advanced under ultrasound guidance on the posterior aspect of the Quadratus Lumborum. The QL muscle is identified with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the QL muscle adherent to the apex of the transverse process, a well recognisable pattern of a shamrock with three leaves can be seen.
223386856|NCT04402411|PROCEDURE|Transversus abdominis plane block|"The patient will be supine while performing the block and sterilization of the site of the ultrasound and needle entry will be performed.~The ultrasound probe is placed in a transverse plane to the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest.~The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles."
224125110|NCT03925389|PROCEDURE|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
223386857|NCT04402411|DRUG|Intravenous opioid|Patients will receive morphine 0.1 mg/kg
224005201|NCT01656200|BIOLOGICAL|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
224005202|NCT03546400|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
224005203|NCT01449500|DIETARY_SUPPLEMENT|L. reuteri|Chewable tablet, one tablet/day for 28 days
224005204|NCT01449500|DIETARY_SUPPLEMENT|Placebo|Chewable tablet, one tablet per day for 28 days
224005205|NCT00735631|DEVICE|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
224005206|NCT03570489|BEHAVIORAL|Exercise|Patients will bicycle for 20 minutes per day for 5 days per week for 6 months
224005207|NCT03570489|BEHAVIORAL|Relaxation|Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
224005208|NCT04985786|BEHAVIORAL|Cognitive Behavioral Therapy for reducing risk behaviors|Cognitive Behavioral Therapy to reduce risk behaviors and increase risk perception that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. For SZ the target risk behavior is medication non-adherence and for AUD and AUD \& SZ it is alcohol use.
224005209|NCT04985786|BEHAVIORAL|Cognitive Behavioral Therapy for increasing non-risk behaviors|Cognitive Behavioral Therapy to increase non-risk behaviors that combines a standardised face-to-face group therapy before discharge from in-patient treatment and a standardised ecological momentary intervention delivered by mobile phones during the four weeks after discharge. In this control intervention for patient groups the target behavior is cognitive exercises.
224005210|NCT04887779|BEHAVIORAL|Pathologist intervention|viewing explanted organ and microscopy
224005211|NCT02734576|DEVICE|Venous Sinus Stenting with the Precise Pro Stent|Enrolled patients will undergo a minimally invasive procedure that involves placement of a stent in the cerebral venous sinuses (large veins of the brain).
224005212|NCT02067559|BEHAVIORAL|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
224005213|NCT02067559|BEHAVIORAL|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
224005214|NCT01652495|DRUG|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
224005215|NCT01652495|DRUG|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
224005216|NCT01382368|DRUG|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
224005217|NCT06518031|OTHER|meditation|meditation practices were administered by the meditation expert for 6 weeks, three times a week for 20 minutes each session, totaling 60 minutes per week
224005218|NCT00512655|BEHAVIORAL|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
224005219|NCT05435482|BEHAVIORAL|Education|Participants will receive two small group meetings and two follow-up calls
224005220|NCT05435482|OTHER|COVID-19 testing kits|Participants will receive two COVID-19 at-home antigen test kits.
224005221|NCT05435482|OTHER|Instruction|Participants will receive a written guide and a video clip guide to the test kit.
224005222|NCT02410460|DRUG|clonidine|
224005223|NCT02410460|DRUG|glycopyrrolate|
224005224|NCT02410460|DRUG|propofol|
224005225|NCT02410460|DRUG|ketamine|
224005226|NCT02410460|DRUG|marcaine|
224005227|NCT02410460|DRUG|scopolamine|
224005228|NCT02410460|DRUG|midazolam|
224005229|NCT02410460|DEVICE|ondansetron|
224005230|NCT02410460|DRUG|metoclopramide|
224005231|NCT02410460|DRUG|glycopyrrolate|
224005232|NCT02410460|DRUG|lidocaine|
224005233|NCT02410460|DRUG|famotidine|
224005234|NCT02410460|DRUG|desflurane|
224005235|NCT02410460|DRUG|sevoflurane|
224125111|NCT06142422|PROCEDURE|stimulation device|"The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation."
224125112|NCT04150822|OTHER|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
224005236|NCT05511064|DEVICE|Blood circulation device|Blood circulation device of CGM MB-1701
224005237|NCT04155047|COMBINATION_PRODUCT|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
224005238|NCT04155047|DRUG|Placebo administered by Magnair|Placebo Inhalation Solution
224005239|NCT03988738|OTHER|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
224005240|NCT01770977|DEVICE|Light-emitting diode therapy|
224005241|NCT01770977|DEVICE|Placebo light-emitting diode therapy|
224005242|NCT00867984|OTHER|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
224005243|NCT00867984|OTHER|Usual Care|AV optimization (VTI) only
224005244|NCT04441177|DEVICE|PlayStation®VR training|Participants in the study group receive conventional rehabilitation therapy over 50 minutes on weekdays and 7 sessions (flexible schedule in different day) of PlayStation®VR of 20 minutes each in the main 16-day study period.
224005245|NCT05905107|OTHER|Neurodynamic Slider Technique from Proximal to Distal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
224005246|NCT05905107|OTHER|Neurodynamic Slider Technique from Distal to Proximal|Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
224005247|NCT01875029|DEVICE|sham-tDCS + back school|sham tDCS + back school
224005248|NCT01875029|DEVICE|real-tDCS + back school|real tDCS + back school
224005249|NCT02121964|PROCEDURE|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
224125113|NCT05518305|DIAGNOSTIC_TEST|Medical Imaging|magnetic resonance imaging
223386858|NCT04177407|PROCEDURE|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
223386859|NCT03027960|DRUG|Empagliflozin|10mg empagliflozin for a 2-week period
223386860|NCT03027960|DRUG|Placebo Oral Capsule|10 mg placebo for a 2-week period
223386861|NCT00118326|BIOLOGICAL|filgrastim|
223386862|NCT00118326|PROCEDURE|allogeneic bone marrow transplantation|
223386863|NCT01648530|OTHER|No Treatment|No Treatment
223386864|NCT02591524|OTHER|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
224005250|NCT02121964|PROCEDURE|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
224005251|NCT02489240|DRUG|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
224005252|NCT02489240|DRUG|placebo|2000 IU placebo tablets were taken daily for 6 days
224005253|NCT00414167|DRUG|bupropion|300 mg per day for 8 weeks
224005254|NCT00414167|OTHER|Placebo|Placebo
224005255|NCT02604082|OTHER|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
224005256|NCT02604082|OTHER|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
224005257|NCT02604082|OTHER|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
224125114|NCT02085239|DRUG|Lidocaine Ropivacaine|"* 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection"
223386865|NCT03225417|DRUG|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
223386866|NCT03225417|DRUG|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
223386867|NCT03225417|DRUG|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
224005258|NCT03361605|DRUG|Propofol|Propofol administration
224005259|NCT02713477|DRUG|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224005260|NCT02713477|DRUG|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224005261|NCT02713477|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224005262|NCT05418751|OTHER|Manual therapy|Participants will received a manual therapy protocol consisting of the following techniques: manipulation of the occipito-atlanto-axial joint (C0-C1-C2), suboccipital inhibition technique, manipulation of the thoracolumbar hinge (T12-L1), global manipulation of the bilateral pelvis, global abdominal hemodynamic technique, functional technique of the pelvic diaphragm and stretching of the lumbopelvic musculature.
224005263|NCT05418751|OTHER|Placebo treatment|Participants will receive light contact on the same points and for the same amount of time as the experimental group, with no intention to treat.
224005264|NCT04477395|DIETARY_SUPPLEMENT|fish oil|SRP will be supplemented with the dietary fish oil rich in omega-3 PUFAs EPA and DHA for 6 months. Fish oil (BioMarine Medical, 200 ml liquid), obtained from Tasmanian deep sea shark and Norwegian cod liver and sardine, anchovy and mackerel muscle, will be administered two times a day at a dose 10 ml. Daily dose of 20 ml provides 2.6 g of EPA and 1.8 g of DHA.
224005265|NCT04477395|PROCEDURE|SRP only|Scaling and root planing will be the only method of treatment.
224005266|NCT00227942|DRUG|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
224005267|NCT00227942|DRUG|Zolpidem|10 mg/day, po qhs
224005268|NCT00227942|DRUG|placebo|placebo
224125115|NCT02085239|DRUG|Lidocaine alone|
224125116|NCT03697928|OTHER|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
224125117|NCT01428063|DRUG|Daclatasvir|
224125118|NCT01428063|DRUG|Asunaprevir|
224295822|NCT01345435|PROCEDURE|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
224295823|NCT01345435|PROCEDURE|Telemonitoring & Telemedicine|The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
224295824|NCT01345435|OTHER|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
224295825|NCT02148341|OTHER|Community of Practice Facilitation|
224125119|NCT01428063|DRUG|Pegylated interferon alfa-2a|
224125120|NCT01428063|DRUG|Ribavirin|
224125121|NCT01326169|BEHAVIORAL|Brief intervention|Telephone-delivered counseling
224125122|NCT01326169|BEHAVIORAL|Standard care|No intervention
224295826|NCT02148341|OTHER|Usual Care|
224005269|NCT03711292|BEHAVIORAL|Antibiotic Stewardship|For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
223386868|NCT03225417|DRUG|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
224005270|NCT02799394|OTHER|Activity modification, exercises and gradual return to sport|
224005271|NCT05963477|PROCEDURE|laparatomy|all abdominal procedures which are approached by different incisions
224005272|NCT02243670|DEVICE|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
224005273|NCT03921099|DRUG|Ascorbic Acid|ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
224005274|NCT04654767|OTHER|Tissue sampling|"Blood collection via venipuncture into citrate- or ethylenediaminetetraacetic (EDTA)-containing vacutainer tubes and into serum tubes. Explant lung tissue obtained from patients that underwent lung transplantation.~Non-transplanted donor lungs that had been harvested for transplantation, but not implanted because of size-reduction serve as controls."
224005275|NCT01055847|DRUG|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
224005276|NCT01055847|DRUG|Placebo|Saline Placebo
224005277|NCT00513877|DRUG|bortezomib|
224005278|NCT00513877|PROCEDURE|quality-of-life assessment|
224005279|NCT00827099|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin
224125123|NCT03793140|DRUG|CPI-613|CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
224125124|NCT02557971|DRUG|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
224125125|NCT06037356|DEVICE|Prostatic Urethral Lift|Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel
224125126|NCT06037356|PROCEDURE|TURP|Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH
224125127|NCT06370455|PROCEDURE|comparison of septal advancement flap effect on nasal tip in primary rhinoplasty to columellar strut technique|All patients will be operated on under general anesthesia through an open rhinoplasty then will undergo 2 different procedures according to each group.
224125128|NCT05282953|DRUG|KIO-301|KIO-301 intravitreal injection at ascending doses
224125129|NCT05888090|OTHER|Prone, right lateral, and semi-elevated supine positions|Each participant will be followed during three feedings and the prone, right lateral, and semi-elevated supine positions will be applied once.
224125130|NCT05888090|OTHER|Semi-elevated supine, prone, and right lateral positions|Each participant will be followed during three feedings and the semi-elevated supine, prone, and right lateral positions will be applied once.
224125131|NCT05888090|OTHER|Right lateral, semi-elevated supine, and prone positions|Each participant will be followed during three feedings and the right lateral, semi-elevated supine, and prone positions will be applied once.
224125132|NCT05813431|OTHER|FRENCH grid (classification for emergency nurses in French hospitals)|Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.
224125133|NCT05813431|OTHER|QuickSOFA|Rapid score that consists of an evaluation based on 3 clinical criteria (blood pressure, respiratory rate and consciousness) to quickly establish a severity score.
223386869|NCT01561716|DEVICE|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
223386870|NCT03942601|DRUG|Temsirolimus|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
224005280|NCT00827099|DRUG|fludarabine phosphate|fludarabine phosphate
224005281|NCT00827099|DRUG|Melphalan|melphalan
224005282|NCT00827099|DRUG|mycophenolate mofetil|mycophenolate mofetil
224005283|NCT00827099|DRUG|tacrolimus|tacrolimus
224005284|NCT00827099|PROCEDURE|umbilical cord blood transplantation|umbilical cord blood transplantation
224005285|NCT04678505|DRUG|MK-3402|"MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2"
224005286|NCT01613482|RADIATION|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
224005287|NCT01613482|DRUG|Trastuzumab|Weekly, 2mg/kg of corporal weight
224005288|NCT01613482|DRUG|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
224005289|NCT02015364|PROCEDURE|Controlled early mobilization|1\. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
224005290|NCT00056277|DRUG|lamotrigine|
224125134|NCT05813431|OTHER|Capillary lactate assessment|Collect a drop of blood from the fingertip (less than 1 ml)
224125135|NCT02284906|DRUG|Pioglitazone|Pioglitazone tablets
224125136|NCT02284906|DRUG|Placebo|Pioglitazone placebo-matching tablets
224125137|NCT00461266|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
224125138|NCT00461266|DRUG|Antiretroviral therapy|As prescribed
224125139|NCT03501706|BEHAVIORAL|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
224125140|NCT03501706|BEHAVIORAL|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
224125141|NCT03501706|BEHAVIORAL|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
223386871|NCT03942601|DRUG|Temsirolimus and dexamethasone sodium phosphate|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
223386872|NCT03684850|OTHER|Home-based exercise|Home-based exercises three times per week.
223386873|NCT03684850|DEVICE|Knee brace|Progressive use of knee brace each day during activities of daily living.
223386874|NCT03684850|DEVICE|Biomechanical footwear device|Progressive use of footwear each day during activities of daily living.
224005291|NCT05385380|BEHAVIORAL|Safe motherhood Promotion|Interventions included the training of community members, who subsequently led participatory educational sessions on safe motherhood topics with pregnant females. The project staff identified 2 community health workers and 15 female volunteers from each kebele cluster and trained them as research implementers. The implementers received 2 days of training led by the project team. The project staff and research implementers conducted safe-motherhood training comprising 2 h of information presentations and discussions with pregnant females in the intervention clusters. In addition to the pregnant-female intervention strategy, we also conducted a four-day training programme on clinical skills for local maternal and child healthcare providers in the study area. MWH intervention was also implemented in the intervention group, including upgrades to existing MWH services per national guidelines to standardize services and create a homelike environment for pregnant females.
224005292|NCT02003222|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
224005293|NCT02003222|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224005294|NCT02003222|BIOLOGICAL|Blinatumomab|Given IV
224005295|NCT02003222|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224125142|NCT03501706|BEHAVIORAL|Verbal Memory--Visual|word recognition AT memory component
224125143|NCT06555055|OTHER|CT trochlear thickness change|"Preoperative and postoperative CT scan measuring trochlear thickness of PFJ was defined as distance from deepest part of trochlea and line tangential to the anterior aspect of the femoral cortex. It was assessed on the sagittal cuts.~CT images will be viewed using Sante DICOM viewer version 5.4.2 and image fusion will be done using Overlay multiple image software.~Two observers will measure the angles and the intraobserver and interobserver reliabilities will be assessed for consistency by the intraclass correlation coefficient (ICC) and reliability coefficient using the SPSS software"
224125144|NCT05974735|BEHAVIORAL|Wellness trail|"Setting up wellness trails based on four distinct themes:~* Food, Nutrition and Micronutrition~* Physical activity~* Sleep~* Stress and well-being"
224125145|NCT02407951|BEHAVIORAL|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
223386875|NCT02801123|BEHAVIORAL|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
223425643|NCT03781583|DEVICE|SmartHMD version 4|Fourth iteration of the SmartHMD device, which uses RGB-D smart glasses, bone-conducting earphones, a Jetson mobile computer, and a specific version of custom software.
223425644|NCT06388616|DRUG|Balcinrenone|50 mg, Immediate release capsule to be taken orally.
223425645|NCT01925235|PROCEDURE|remote ischemic preconditioning|
223425646|NCT00005836|DRUG|oxaliplatin|
223425647|NCT05535075|DEVICE|Vancomycin model-informed precision dosing|A dosing calculator is used for a posteriori calculation of vancomycin dose using a target AUC/MIC between 400-600 mg\*h/L
224005296|NCT02003222|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224005297|NCT02003222|DRUG|Cyclophosphamide|Given IV
224005298|NCT02003222|DRUG|Cytarabine|Given IT, IV, or SC
224005299|NCT02003222|DRUG|Daunorubicin|Given IV
224005300|NCT02003222|DRUG|Daunorubicin Hydrochloride|Given IV
224005301|NCT02003222|DRUG|Dexamethasone|Given PO
224005302|NCT02003222|DRUG|Etoposide|Given IV
224005303|NCT02003222|DRUG|Leucovorin Calcium|Given IV or PO
224005304|NCT02003222|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224005305|NCT02003222|DRUG|Mercaptopurine|Given PO
224005306|NCT02003222|DRUG|Methotrexate|Given PO, IT or IV
224005307|NCT02003222|DRUG|Pegaspargase|Given IM or IV
224005308|NCT02003222|DRUG|Prednisone|Given PO
224005309|NCT02003222|BIOLOGICAL|Rituximab|Given IV
224005310|NCT02003222|DRUG|Vincristine|Given IV
224005311|NCT02003222|DRUG|Vincristine Sulfate|Given IV
224005312|NCT02003222|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224005313|NCT01365481|DRUG|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
224005314|NCT01365481|DRUG|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
224005315|NCT01365481|DRUG|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
224005316|NCT00077831|BEHAVIORAL|neurobehavioral development|observational study of infant and child development
223386876|NCT02801123|BEHAVIORAL|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
223386877|NCT06583252|DEVICE|multimodal monitoring cluster management|All patients will be monitored for baseline TCD at admission and at least once a day during treatment to assess changes in cerebral blood flow dynamics. Brain Oxygen Monitoring, Equipment \&amp;amp; Frequency: Continuous monitoring of partial pressure of oxygen (PbtO2) in brain tissue using near-infrared spectroscopy (NIRS). qEEG monitoring，Frequency and timing of monitoring. Baseline monitoring: All patients will undergo a baseline qEEG test at the time of admission. Continuous monitoring: In the ICU, for critically ill patients, qEEG will be performed continuously to monitor changes in EEG activity in real time. Monitoring brain activity: qEEG is able to detect subtle changes in brain waves that can be used to assess brain functional status, such as EEG quiescence, abnormal electrical discharges (e.g., epileptiform activity), etc. Abnormal parameters: focus on abnormal rhythms (e.g., high-amplitude slow-wave activity), acute asymmetric activity, and epileptiform discharge.
223386878|NCT01186237|PROCEDURE|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
223386879|NCT05079048|OTHER|PEEK retentive elements|received implant-supported mandibular overdenture retained by PEEK retentive element and housings
223386880|NCT04671589|DRUG|Meropenem Injection|"Administration Intravenous meropenem 1gram every 8 hours together with standard care;~."
223386881|NCT05626842|OTHER|Total Diet Replacement (800kcal/day)|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly for a further 36 weeks. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks.
223386882|NCT00379392|BEHAVIORAL|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
223386883|NCT00379392|PROCEDURE|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
223386884|NCT03701893|DIETARY_SUPPLEMENT|Lactobacillus PS11610|7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1\*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1\*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
223386885|NCT06227039|OTHER|Vibroacoustic stimulation on|Mechanical stimulus is provided to the patient through a vibroacoustic device via vibration around the neck.
224005317|NCT05702385|OTHER|Educational Materials for a new diagnostic test|These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
224005318|NCT01745575|DRUG|Alprazolam 2mg tablets|Reference product
224005319|NCT01745575|DRUG|Alprazolam 2 mg tablets|Test product
224005320|NCT03221166|DRUG|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
224005321|NCT03221166|DRUG|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
224005322|NCT02341742|DEVICE|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
224005323|NCT00031070|DRUG|Abacavir sulfate, Lamivudine and Zidovudine|
224005324|NCT00031070|DRUG|Cyclosporine|
224295827|NCT04683666|PROCEDURE|Bariatric surgery|Laparoscopic Roux-en-Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG), as primary bariatric procedures, were performed. \^Postoperative complications were assessed.
224295828|NCT00937820|DRUG|YM150|oral
224295829|NCT06026020|OTHER|Biological samples collection|Samples of blood, faeces, saliva are collected for analysis.
224295830|NCT02398357|DRUG|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
224295831|NCT01093664|BIOLOGICAL|AFFITOPE AD02|s.c. injection
224005325|NCT00031070|BIOLOGICAL|Hepatitis A Vaccine (Inactivated)|
224005326|NCT00031070|DRUG|Efavirenz|
224005327|NCT00031070|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
224005328|NCT00031070|BIOLOGICAL|Rabies Vaccine|
224005329|NCT02297490|DRUG|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
224295832|NCT03018808|OTHER|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
224295833|NCT03018808|OTHER|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
224295834|NCT03018808|OTHER|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
224005330|NCT02297490|BIOLOGICAL|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
224005331|NCT06191055|DIETARY_SUPPLEMENT|Beta Alanine high dose|4 intakes of 5 g of beta alanine every 3 hour.
224295835|NCT03018808|PROCEDURE|Blood test|Blood samples will be collected at indicated time points
224005332|NCT06191055|DIETARY_SUPPLEMENT|Beta Alanine low dose|4 intakes of 2.5 g of beta alanine every 3 hour.
224295836|NCT03018808|OTHER|anthropometric measures|Anthropologic measures will be performed.
224005333|NCT06191055|OTHER|Control group|4 intakes of 2.5 g of wheat semolina every 3 hour.
224295837|NCT03018808|OTHER|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
224295838|NCT03660293|DRUG|Atorvastatin|cardio-protective agents
224295839|NCT03660293|DRUG|Captopril|cardio-protective agents
224295840|NCT03660293|DRUG|L-carnitine|cardio-protective agents
223386886|NCT06227039|OTHER|Augmented Reality on|Visual stimulus is provided through augmented reality glasses in the form of a game.
224295841|NCT00003093|BIOLOGICAL|filgrastim|
224295842|NCT00003093|BIOLOGICAL|sargramostim|
224295843|NCT00003093|DRUG|carboplatin|
224295844|NCT00003093|DRUG|cyclophosphamide|
224295845|NCT00003093|DRUG|doxorubicin hydrochloride|
224295846|NCT00003093|DRUG|etoposide|
224295847|NCT00003093|PROCEDURE|conventional surgery|
224295848|NCT00003093|PROCEDURE|neoadjuvant therapy|
224295849|NCT01703884|DRUG|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
223386887|NCT06227039|OTHER|Vibroacoustic stimulation off|Vibroacoustic device is worn but turned off.
224005334|NCT03271853|DEVICE|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
224295850|NCT01574482|OTHER|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
224295851|NCT01574482|OTHER|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
224295852|NCT04360044|DRUG|THC ~5%|4 puffs of vaporized flower containing THC \~5%
224295853|NCT04360044|DRUG|CBD ~12%|4 puffs of vaporized flower containing CBD \~12%
224295854|NCT04360044|DRUG|THC ~5% and CBD ~12%|4 puffs of vaporized flower containing THC \~5% and CBD \~12%
224295855|NCT04360044|DRUG|Sham Cannabis|4 puffs of vaporized flower from which the THC and CBD have been extracted
223386888|NCT06227039|OTHER|Augmented reality off|Augmented reality glasses are worn but turned off.
223386889|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
223386890|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
223386891|NCT03889886|DRUG|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
224005335|NCT00260286|BEHAVIORAL|Energy availability|
224005336|NCT05871684|DRUG|BTK inhibitor|Intervention were given during bridging therapy and maintanance treament of CAR-T cell therpay.
224005337|NCT05871684|DRUG|PD-1 inhibitor|Intervention were given during maintanance treament of CAR-T cell therpay.
224005338|NCT00355290|BEHAVIORAL|Changes on Oral Vitamin K Intake|
224005339|NCT01962532|DRUG|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
224005340|NCT01962532|DRUG|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
224005341|NCT05254080|DEVICE|Active taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath).
224005342|NCT05254080|DEVICE|Sham taVNS|Electrodes will be attached to the participant's ear with a small sticker or clip, which will deliver mild stimulation. These electrodes will be plugged into the Digitimer DS7a device, which is a device that delivers transcutaneous auricular vagus nerve stimulation or taVNS. Stimulation will be delivered randomly to participant's tragus (the small cartilage knob before the ear canal) for up to 5 minutes while you participate in the stress induction test (by putting both feet into an ice bath). During sham (placebo) stimulation, ear electrodes will be attached to the participant's ear but they will not receive any stimulation.
224005343|NCT04646967|DRUG|Bupivacain|See active comparator description
224005344|NCT04646967|DRUG|Sevoflurane|See active comparator description
224005345|NCT04646967|DRUG|Acetaminophen|See active comparator description
224005346|NCT04646967|DRUG|Ibuprofen|See active comparator description
224005347|NCT04646967|DRUG|Ketorolac|See experimental arm description
224005348|NCT02803008|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation number - SR15-46-Z13-072)
224005349|NCT03719417|PROCEDURE|Unicompartmental Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery.
224005350|NCT03719417|PROCEDURE|Extensive Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
224005351|NCT05821582|OTHER|Stool Collection and Survey Completion|Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact. The biospecimens collected from participants on this study are stool samples.
223386892|NCT03889886|DRUG|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
223386893|NCT03572686|DRUG|Ropivacaine 0.5% 20mL|In Group RH, participants received supraclavicular brachial plexus block with ropivacaine 0.5% 20ml at the end of surgery.
223386894|NCT03572686|DRUG|Ropivacaine 0.25% 20ml|In Group RL, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml at the end of surgery.
223386895|NCT03572686|DRUG|Ropivacaine 0.25% 20ml + dexamethasone 8mg|In Group RLD, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml + dexamethasone 8mg at the end of surgery.
223386896|NCT05334030|DEVICE|High Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
224005352|NCT05287490|DEVICE|FormaV and VTone|Eligible subjects will receive 3 treatments(every 2 weeks) with the FormaV and VTone Applicators according to the study protocol.
223386897|NCT05334030|DEVICE|Neutral Swing Assistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
224125146|NCT02407951|BEHAVIORAL|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
224125147|NCT04786873|DRUG|Macimorelin|Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.
224125148|NCT04786873|DIAGNOSTIC_TEST|Arginine|For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.
224125149|NCT04786873|DIAGNOSTIC_TEST|Clonidine|"For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally."
224125150|NCT01262300|BIOLOGICAL|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
223386898|NCT05334030|DEVICE|High Swing Resistance|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - 2Free;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
223386899|NCT05334030|DEVICE|Max Trajectory Control|"On this study, four settings are going to be evaluated being that High Swing Assistance, Neutral Swing Assistance, High Swing Resistance and Max Trajectory Control. The following settings will be used in all three conditions:~* Sitting program - Min lean;~* Standing program - Auto lean;~* Step initiation program - ProStep+,~* Training mode - Off,~* SmartAssist option - Bilateral;~* Stance support - Low. The level of stance support and swing assistance will be set symmetrically for the affected and non-affected side.~Each patient is going to walk 7 min (or min 25 gait cycles) with every setting"
223386900|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
223386901|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
223386902|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
223386903|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
223386904|NCT04176250|DRUG|TBA-7371|Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
223425648|NCT05535075|DRUG|Vancomycin|Vancomycin treatment
223730119|NCT06507449|DEVICE|Orbital atherectomy|Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent
224125151|NCT05553431|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a CRT device or dual-chamber pacemaker through the pacing lead at left bundle branch region
224125152|NCT04017988|DIETARY_SUPPLEMENT|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
224005353|NCT01353118|BIOLOGICAL|gastric bypass|Optimise glucose control within 3 months before operation
224005354|NCT05114486|COMBINATION_PRODUCT|Pilocarpine Ophthalmic administered with the Optejet dispenser|Pilocarpine 2% ophthalmic spray administered with the Optejet dispenser
224005355|NCT05114486|COMBINATION_PRODUCT|Placebo administered with the Optejet dispenser|Vehicle ophthalmic solution administered with the Optejet dispenser
224125153|NCT04017988|DIETARY_SUPPLEMENT|Placebo|Placebo for 8 week
223386905|NCT04176250|DRUG|HRZE|Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
224125154|NCT02275689|PROCEDURE|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
224125155|NCT02275689|PROCEDURE|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
224125156|NCT05605379|BIOLOGICAL|Next Generation Sequencing (DNA and RNA)|Targeted Next Generation Sequencing (DNA and RNA)
224125157|NCT04332640|DEVICE|VERITAS Vision System|The investigators or designees will perform routine small-incision cataract surgery via phacoemulsification and use the VERITAS Vision system. The Investigator or designee will then complete a questionnaire regarding the clinical use of the VERITAS Vision system. The system log files automatically generated by the VERITAS Vision system after completion of each surgery will be collected.
224125158|NCT05426707|DEVICE|RIC|RIC is a non-invasive therapy that is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol includes five cycles of 5-min inflation to 200mmHg and 5-min deflation.
224125159|NCT05426707|DEVICE|Sham-RIC|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
223386906|NCT01339403|OTHER|non-interventional trial|No study specific intervention, non-interventional trial
223386907|NCT01339403|OTHER|non-interventional trial|No study specific intervention, non-interventional trial
224005356|NCT05202392|OTHER|Myofascial release with isometric exercises|Patients in group A will receive 40 minutes of combined therapy treatment session including myofascial release of muscles with trigger point release and 5 isometric exercises of neck at alternative 3 days/week for 4 weeks.
224005357|NCT05202392|OTHER|Myofascial release with scapular stabilization exercise|Patients in group B will get 40 minutes of myofascial therapy same as the first group combined with scapular stabilization exercise in 5 different positions and this treatment session will be at alternative 3 days/week for 4 weeks.
224005358|NCT05078593|DRUG|HLX26|Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
224005359|NCT00003124|DRUG|flutamide|
224005360|NCT00003124|DRUG|leuprolide acetate|
224005361|NCT00003124|RADIATION|radiation therapy|
224005362|NCT00709267|DRUG|Folic acid|
224005363|NCT05297006|DIETARY_SUPPLEMENT|The infants who drank milk powder were given a dietary intervention four months before|The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients
224005364|NCT00403767|DRUG|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
224005365|NCT00403767|DRUG|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
224005366|NCT00403767|DRUG|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
224005367|NCT00403767|DRUG|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
224005368|NCT01696955|BIOLOGICAL|Cetuximab|Given IV
224125160|NCT03023982|DRUG|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
223386908|NCT05175105|DRUG|Mitapivat|Tablets or granules
223386909|NCT05175105|DRUG|Mitapivat-matching placebo|Tablets or granules
224005369|NCT01696955|OTHER|Laboratory Biomarker Analysis|Correlative studies
224005370|NCT01696955|DRUG|Tivantinib|Given PO
224005371|NCT04860362|BEHAVIORAL|PEERS|Structured social skills curriculum including didactics, behavioral rehearsal, parent coaching, and parent coaching support.
224005372|NCT03192475|BEHAVIORAL|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
224005373|NCT03192475|BEHAVIORAL|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
224005374|NCT06310408|DEVICE|nasal mask|Give interface nasal mask
224005375|NCT06310408|DEVICE|nasal prong|give interface nasal prong
224005376|NCT03187964|DIAGNOSTIC_TEST|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
224125161|NCT03023982|DEVICE|Ultrasound|All blocks will be done under ultrasound
224125162|NCT03023982|PROCEDURE|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
224125163|NCT03023982|DRUG|Opioids|standard pain control with opioids
224125164|NCT03023982|DRUG|NSAID|standard pain control with NSAIDs
224125165|NCT00850759|DEVICE|virtual pedestrian environment|a computer-driven virtual pedestrian environment
224125166|NCT00850759|DEVICE|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
224005377|NCT03187964|DIAGNOSTIC_TEST|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
224005378|NCT02436434|DEVICE|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
224005379|NCT01641159|DRUG|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
224005380|NCT01641159|DRUG|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
224005381|NCT04484116|DIAGNOSTIC_TEST|Intraoperative Paratohormone|Three IOPTH determinations were withdrawn: at anesthetic induction (PTH0), 15 minutes (PTH15), and 30 minutes (PTH30) after completion gland resection. Another sample was taken 24 hours after the procedure (PTH24), values \<150pg/mL defined a successful surgery and patients were assigned to the successful or unsuccessful group. IOPTH drop was analyzed to predict successful surgery with drops of 70% and 90% at 15 and 30 minutes.
224005382|NCT00632489|DRUG|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
224005383|NCT00632489|DRUG|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
224005384|NCT00632489|DRUG|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
224005385|NCT01939444|DRUG|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
224005386|NCT01939444|DRUG|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
224005387|NCT04408703|DIAGNOSTIC_TEST|Red Density|Image analysis of endoscopic images in patients with ulcerative colitis
224005388|NCT02893384|DRUG|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
224005389|NCT03235752|DRUG|TJ301 300mg|TJ301 300mg IV infusion
224005390|NCT03235752|DRUG|TJ301 600mg|TJ301 600mg IV infusion
224005391|NCT03235752|DRUG|Placebo|Placebo IV infusion
224005392|NCT00831129|DRUG|Rosiglitazone|4 mg daily
224005393|NCT00831129|DRUG|Placebo Rosiglitazone|1 tab daily
224005394|NCT00831129|DRUG|Simvastatin|40 mg daily
224005395|NCT02818725|DRUG|Chemotherapy|METHOTREXATE: 30 mg/m² on day 1 VINBLASTINE: 3 mg/m² on day 2 DOXORUBICIN: 30 mg/m² on day 2 CISPLATIN: 70 mg/m² on day 2
223386910|NCT03277443|PROCEDURE|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
223730120|NCT06507449|DEVICE|High-pressure non-compliant balloon|Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent
224005396|NCT02818725|DRUG|Panitumumab|PANITUMUMAB: 6 mg/kg on day 2
224005397|NCT05845281|PROCEDURE|Bupivakain + deksametazon Adjuvant|In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
224005398|NCT04647552|DRUG|Drug Steroid|hydrocortisone injection
224005399|NCT04094441|OTHER|chest physiotherapy|chest physiotherapy
224005400|NCT01283516|DRUG|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
224005401|NCT01204710|BIOLOGICAL|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
224005402|NCT01204710|DRUG|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
224005403|NCT01204710|DRUG|Prednisone|5 mg orally (PO) twice daily (BID) on each day
224005404|NCT00002001|DRUG|Zidovudine|
224005405|NCT00002001|DRUG|Zalcitabine|
224005406|NCT00002001|DRUG|Didanosine|
224005407|NCT03039101|PROCEDURE|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
224005408|NCT03039101|PROCEDURE|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
224005409|NCT03039101|PROCEDURE|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
224005410|NCT03039101|PROCEDURE|Peripheral blood|Peripheral blood draw
224005411|NCT03039101|DRUG|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
224005412|NCT03039101|DRUG|Placebo Oral Tablet|one pill orally, daily, for 1 week
224005413|NCT05129228|DEVICE|OCT-guided saphenous vein CABG|OCT examination of harvested saphenous vein conduits will indicate pathology. Under the surgeon's discretion the conduit segments with pathology will not be grafted.
224005414|NCT04270396|BEHAVIORAL|Presence or absence of implant|We procedure to observed clinically the sample size, to be able to determine if the dental implant was present or no. If the implant was absent we recorded if it was early( prior to restoration) or late ( after prosthesis was delivered).
224005415|NCT06188429|DIAGNOSTIC_TEST|DSM-5|Using DSM-5 for diagnostic testing of the children in the study group.
224005416|NCT00476073|DRUG|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
224005417|NCT02639832|DEVICE|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
224005418|NCT01689571|DRUG|CHF6001|
224005419|NCT01689571|DRUG|Placebo|
224005420|NCT01303679|DRUG|Paclitaxel|IV, 80mg/m² at d1, d8, d15
224125167|NCT00850759|BEHAVIORAL|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
224125168|NCT05369416|OTHER|Low sodium diet|Subjects will be started on a low sodium (food will be provided) for two weeks.
224125169|NCT05369416|OTHER|high sodium diet|Subjects will be started on high sodium diet (regular diet supplemented with salt tablets to reach a daily intake of \> 4200 mg/Day) for two weeks.
224295856|NCT06420544|BEHAVIORAL|JAPI: Cognitive, Emotional and Social Stimulation for Preschool Children|"Those children in the intervention group will play with the gaming platform Japi using a tablet device in a designated time given from schools' authorities. Early Year Educators will be present to help with the discipline and motivation of the students and Research Assistants will be there as well to provide technical support for the use of the equipment.~The intervention has 24 sessions, and the dosage will be two sessions of 15 minutes each per week for 12 weeks. Sessions number 1 to number 8 are focused on emotional regulation and inhibitory control. Sessions number 9 to 16 work on working memory and problem-solving. Sessions number 17 to 24 promote empathy and planification skills. Each session will have eight activities with increasing levels of difficulty."
224295857|NCT04008966|DRUG|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
224295858|NCT04008966|DRUG|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
224295859|NCT04008966|DRUG|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
224295860|NCT04008966|DRUG|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
224295861|NCT04008966|DRUG|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
224295862|NCT04008966|DRUG|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
224295863|NCT04008966|PROCEDURE|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
224295864|NCT04008966|PROCEDURE|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
224295865|NCT04008966|DRUG|natural Progesterone|400 mg twice daily per vagina
224295866|NCT03317665|DEVICE|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
224295867|NCT01829841|DRUG|Famitinib|Famitinib 25 mg p.o. qd
224295868|NCT01829841|DRUG|Sunitinib|Sunitinib 50 mg p.o. qd
224295869|NCT05657236|OTHER|medical treatment|traditional medical treatment and regular follow-up
224295870|NCT05657236|OTHER|plyometric exercise|Each session starts with a 5-minute warm-up of flexibility exercises (active range motion and stretching exercises).The main plyometric exercise set will be applied for 20-30 minutes and consisted of 10 exercises directed at the lower body that gradually progress by increasing the set/repetition number in two exercise blocks, each continue for 1 month .The cool down period is 5 minutes and includes walking at self-preferred speed and static stretches of the major muscle groups.
223730121|NCT06507449|DEVICE|Optical coherence tomography|Optical coherence tomography assessment of coronary arteries.
224005421|NCT01303679|DRUG|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
224005422|NCT01303679|DRUG|Exemestane|daily 25 mg (1 pill) oral intake
224005423|NCT00509431|DRUG|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
224005424|NCT03537547|OTHER|GeneSight Psychotropic test|GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
224005425|NCT03537547|DRUG|FDA-approved antidepressant or antipsychotic treatment|Participant is treated with medications included in the GeneSight Psychotropic product.
224125170|NCT03062904|DRUG|Inhaled Bronchodilators +/- Inhaled Methacholine|"1. Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~2. Inhaled Methacholine based on international recommendations"
224125171|NCT00456963|BEHAVIORAL|Diet|total fat \< 5%, saturated fat \< 10%, vegetables, fruit
224125172|NCT00456963|BEHAVIORAL|Moderate exercise|30 min at least 5 times/week
224125173|NCT00456963|DRUG|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
224125174|NCT00456963|DRUG|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
224125175|NCT00456963|DRUG|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
224125176|NCT00065741|DRUG|silymarin|
224005426|NCT01276379|DRUG|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
223386911|NCT03277443|PROCEDURE|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
223386912|NCT03277443|DEVICE|2D cephalometric radiograph|2D cephalometric radiograph
224005427|NCT01276379|DRUG|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~* Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~* l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~* One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~* 5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
224005428|NCT01276379|DRUG|Cetuximab|\- 500 mg/m2 i.v. Every 2 weeks.
224005429|NCT01376232|DRUG|GSK1278863|GSk1278863 100mg
224005430|NCT01376232|DRUG|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
224005431|NCT01376232|DRUG|Gemfibrozil|600 mg Gemfibrozil
224005432|NCT04228926|DRUG|ZKY001 eye drops 0.3g:0.006mg|ZKY001 eye drops of 0.002% continuously for up to 14±2 days after Corneal endothelial transplantation
224005433|NCT04228926|DRUG|ZKY001 eye drops 0.3g:0.012mg|ZKY001 eye drops of 0.004% continuously for up to 14±2 days after Corneal endothelial transplantation
224005434|NCT04228926|DRUG|ZKY001 simulated eye drops|ZKY001 simulated eye drops continuously for up to 14±2 days after Corneal endothelial transplantation
224005435|NCT06459700|DIETARY_SUPPLEMENT|Probiotic supplements|See arm/group description
224005436|NCT06459700|DIETARY_SUPPLEMENT|Placebo supplements|See arm/group description
224005437|NCT02613234|DEVICE|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
224005438|NCT02613234|DEVICE|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
224005439|NCT00055588|PROCEDURE|Locomotor training|
224005440|NCT03178370|DEVICE|Gastric Electrical Stimulation|Temporary and permanent gastric electrical stimulation
224005441|NCT00447564|DRUG|Probuphine|4 implants
224005442|NCT00447564|DRUG|placebo|4 implants
224005443|NCT05381545|BEHAVIORAL|laser puncture, energy expenditure programming, and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34\&28, ST25\&36\&40, SP6, and CV4\&9\&12.
224005444|NCT05381545|BEHAVIORAL|energy expenditure programming and low-calories recommended diet programming|This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
224005445|NCT03613025|DIAGNOSTIC_TEST|Sampling of non-invasive and/or non-targeted respiratory tract specimens|Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
224125177|NCT00532948|DRUG|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
224005446|NCT00222872|DRUG|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
224125178|NCT00374374|BEHAVIORAL|Administration of probiotic|
224125179|NCT01103817|DIETARY_SUPPLEMENT|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
224125180|NCT02575079|DEVICE|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
224295871|NCT03840616|DRUG|Oteseconazole (VT-1161) 150mg capsule|600mg administered on Day 1 and 450mg administered on Day 2, followed by 150mg administered once weekly for 11 weeks staring on Day 14.
224295872|NCT03840616|DRUG|Fluconazole 150mg capsule|150mg administered every 72 hours in 3 sequential doses starting on Day 1.
224295873|NCT03840616|DRUG|Placebo|Administered once weekly starting on Day 14.
224295874|NCT03949803|BEHAVIORAL|Chocolate 100gr|"Evening/Night Chocolate:~Eating 100gr of milk chocolate within 1 hours of habitual bedtime~Control Chocolate:~Eating no milk chocolate or other chocolate~Chocolate Morning:~Eating chocolate within one hour of habitual waketime."
224295875|NCT03166683|OTHER|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
224005447|NCT00222872|DRUG|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
224005448|NCT00330148|DRUG|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
224005449|NCT00330148|DRUG|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
224125181|NCT04891991|DRUG|Intravitreal infliximab|1 mg/0.05 mL of infliximab will be injected intravitreally at the end of pars plana vitrectomy.
224125182|NCT04891991|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy
224125183|NCT02918266|DRUG|Scopolamine|Scopolamine subcutaneous injection
224295876|NCT03166683|OTHER|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
223386913|NCT03277443|DEVICE|3D computerized tomography|3D computerized tomography
223386914|NCT03495375|DIETARY_SUPPLEMENT|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
224005450|NCT00330148|DRUG|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
223730122|NCT06507449|DEVICE|Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire|A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
224005451|NCT02903563|OTHER|observational|
224005452|NCT02302170|BIOLOGICAL|H. pylori vaccine|
223386915|NCT03495375|OTHER|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
223386916|NCT05641298|DRUG|Sodium Fusidate|Tablets
223386917|NCT05641298|DRUG|Placebo|Tablets
223386918|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
223386919|NCT03423797|DRUG|25% AgNO3 solution followed by 5% NaF with fTCP|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
223386920|NCT00633997|DRUG|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
223386921|NCT00633997|DRUG|Vildagliptin|
224005453|NCT02302170|BIOLOGICAL|placebo|
224125184|NCT02918266|DRUG|TAK-071|TAK-071 DIC
224125185|NCT02918266|DRUG|Donepezil|Donepezil over-encapsulated tablet
224125186|NCT02918266|DRUG|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
223386922|NCT03304145|OTHER|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
223386923|NCT01144611|DRUG|bIAP bolus and 8h infusion|intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
223386924|NCT01144611|DRUG|placebo bolus and 8h infusion|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
223386925|NCT03304405|DIAGNOSTIC_TEST|Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
223386926|NCT04406077|DEVICE|Ligasure|Using ligasure to treat hydrocele
223386927|NCT05217576|DEVICE|NBM-200|Finger Prick and Venipuncture
223386928|NCT03241992|BEHAVIORAL|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
223386929|NCT05990829|DRUG|Ozurdex|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of Ozurdex will be performed at the end of the surgery.
224005454|NCT05812742|BEHAVIORAL|Early intervention programme|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
224005455|NCT05812742|BEHAVIORAL|Enhanced usual care|For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
224005456|NCT02839889|DRUG|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
224005457|NCT02839889|DRUG|Placebo|Placebo once daily for two weeks, followed by two week open-label period
224005458|NCT02001064|BEHAVIORAL|Care4Today v2.0 mobile application + electronic monitoring of adherence|Care4Today mobile application will send automated medication alert messages to HIV-infected persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV-infected persons who experience adherence difficulties over standard of care.
224125187|NCT02918266|DRUG|TAK-071 Placebo|TAK-071 placebo-matching DIC
223386930|NCT05990829|DRUG|Aflibercept|Standard 25-gauge pars plana vitrectomy (PPV) will be performed under retrobulbar anaesthesia using high-speed vitrectomy system. Clear all the vitreous hemorrhage and proliferative membrane during PPV operation, panretinal photocoagulation (PRP) should be completed. The vitreous cavity will be filled with balanced salt solution. An injection of aflibercept will be performed at the end of the surgery.
223386931|NCT03983980|DRUG|Tapinarof|Tapinarof cream, 1%, applied once daily
223730123|NCT03935009|BEHAVIORAL|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
224005459|NCT04890548|DRUG|AZD3427|Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
224005460|NCT03892252|OTHER|No intervention|No intervention
224125188|NCT02918266|DRUG|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
224125189|NCT03235596|DEVICE|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
224125190|NCT01914419|DRUG|Oxytocin|
224125191|NCT01897961|OTHER|Anticorps anti-PLA2R1|
224125192|NCT00300469|DRUG|ABT-335|135 mg, daily, 12 weeks
224125193|NCT00300469|DRUG|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
224125194|NCT00300469|DRUG|Placebo|daily, 12 weeks, see Arm Description for placebo information
224295877|NCT06062797|DEVICE|Mixed Reality Viewer|The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.
224005461|NCT00409721|DRUG|Memantine|
224005462|NCT01406470|DRUG|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
224005463|NCT05624905|PROCEDURE|Percutaneous coronary intervention|Percutaneous Coronary Intervention Procedure
224005464|NCT02602639|DEVICE|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
224005465|NCT04936477|OTHER|Calculation of ventilation-perfusion ratio|"Three to five paired measurements of fraction of inspired oxygen and peripheral oxygen saturations.~Insertion of mainstream capnograph with combined pressure and flow sensor to perform end-tidal capnography measurement.~Echocardiogram to assess intra-cardiac shunting."
224005466|NCT05034159|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Same as is described previously.
224005467|NCT00413205|DRUG|Placebo|po daily
224005468|NCT00413205|DRUG|RAR Gamma|5mg po daily
224005469|NCT05512351|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks.
224005470|NCT02387190|OTHER|Telenursing monitoring|"The telenursing program protocol is based on:~1. Contact the patient by telephone, weekly;~2. Distribution and explanation of the educational booklet;~3. Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support."
224005471|NCT05276908|PROCEDURE|Thoracolumbar interfascial plane block (TLIP)Technique|A curvilinear array ultrasound probe (Siemens ACUSON X300 Ultrasound System) will be placed at the targeted lumbar level.The corresponding spinous process and interspinal muscles will be identified, and the probe will be slided laterally to identify the longissimus muscle and iliocostalis muscle. Under ultrasound guidance, A 38-mm 22-gauge (22-G, 50-mm 'Stimuplex; BBraun, Melsung, Germany) regional block needle will be advanced in plane to the ultrasound beam in a medial to lateral orientation through the belly of longissimus muscle toward the iliocostalis muscle. Hydro-dissection with 2-3 ml of isotonic saline solution will confirm the correct needle tip position and, after negative aspiration, 0.25 % bupivacaine will be injected slowly whilst carefully monitoring the spread of local anesthetic into the fascial plane between the longissimus and iliocostalis muscles. The same procedure will be repeated on the contralateral side.
224005472|NCT05276908|PROCEDURE|Anesthetic Management|"Induction:~Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of atracurium.~Maintenance:~Anesthesia will be maintained with inhaled isoflurane 0.8% in oxygen enriched air (FiO2=0.5). Maintenance doses of 0.1 m\\kg atracurium will be provided every 30 minutes. Then the patient will be placed in prone position."
224125195|NCT02405234|DEVICE|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
224125196|NCT02405234|DEVICE|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
224005473|NCT05276908|DRUG|Bupivacaine Injection 10ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 20 ml 0.25%bupivacaine (10 ml on each side).
224005474|NCT05276908|DRUG|Bupivacaine Injection 20ml|patients will receive single shot of bilateral modified thoracolumbar interfascial plane block at the mid-level of the operative intervention with 40 ml 0.25%bupivacaine (20 ml on each side).
224005475|NCT00644163|BEHAVIORAL|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
224005476|NCT00644163|BEHAVIORAL|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
224125197|NCT01259856|DRUG|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
224005477|NCT01109680|DRUG|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
224125198|NCT01259856|DRUG|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
224125199|NCT01259856|DRUG|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
224125200|NCT01758393|DRUG|Prednisone|
223386932|NCT03983980|DRUG|Vehicle Cream|Vehicle cream applied once daily
223386933|NCT04801992|DEVICE|MINI WELL Ready (SIFI SpA, Italy)|Implantation during cataract surgery of the progressive extended depth of focus intraocular lens for the posterior chamber to replace the crystalline lens in the correction of aphakia in adult patients.
223386934|NCT05580250|DRUG|LY3526318|Administered orally.
223386935|NCT05580250|DRUG|Placebo|Administered orally.
223386936|NCT05580250|DRUG|Iohexol|Administered intravenously (IV).
223386937|NCT05580250|DRUG|Simvastatin|Administered orally.
224005478|NCT00565487|DRUG|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
224005479|NCT04321421|OTHER|hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
224005480|NCT02789644|DRUG|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
224005481|NCT03953755|PROCEDURE|Tricuspid valve repair|Tricuspid valve repair
224005482|NCT00081822|DRUG|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
224005483|NCT00081822|DRUG|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 \& 3.
224005484|NCT00659555|DRUG|pazopanib eye drops|Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
224005485|NCT00659555|DRUG|Ketoconozole tablets|Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
224005486|NCT04866953|OTHER|Blood transfusion|Number of units of blood received within 24 hours of admission
224005487|NCT02944201|DRUG|Carvedilol|Carvedilol will give twice daily until prostatectomy
224005488|NCT02893787|OTHER|Speckle Tracking Echocardiography|Echocardiography analyses
224005489|NCT01941147|DEVICE|pulsed ELF-MF|(75 Hz, 1,8 mT)
224005490|NCT04061460|PROCEDURE|mechanical plaque control|supra and sub gingival debridment ( plaque control)
224005491|NCT00311987|DRUG|3,5-Diiodothyropropionic acid (DITPA) therapy|
224005492|NCT03568643|DRUG|Azithromycin|Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
224005493|NCT03568643|DRUG|Amoxicillin|Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.
224005494|NCT00701649|BIOLOGICAL|CYT006-AngQb|s.c.
224125201|NCT02555761|DRUG|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
223386938|NCT05580250|DRUG|Metformin|Administered orally.
223386939|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
224005495|NCT00701649|BIOLOGICAL|Placebo|s.c.
224125202|NCT00412698|DRUG|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
224125203|NCT00412698|DRUG|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
223386940|NCT02074150|DRUG|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
223386941|NCT02074150|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
224005496|NCT04684017|DRUG|Anlotinib hydrochloride|anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
224005497|NCT04684017|DRUG|Etoposide|100mg/m2 iv on days 1-3 every 21 days for 4 cycles
224005498|NCT04684017|DRUG|Carboplatin|AUC 5 iv on day 1 every 21 days for 4 cycles
223386942|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
223386943|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
223386944|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
224005499|NCT01368029|BIOLOGICAL|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
224005500|NCT01368029|BIOLOGICAL|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
224005501|NCT05249738|DIAGNOSTIC_TEST|Measuring tongue cross-sectional area by submental ultrasonography|The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
224125204|NCT01636752|BEHAVIORAL|Deprexis|Online self-help with and without e-mail-support
224125205|NCT04405505|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
224125206|NCT04405505|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
223386945|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
224005502|NCT01741103|DRUG|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
224005503|NCT01741103|DRUG|Placebo|Take one by mouth daily for 12 weeks
224005504|NCT05293665|BIOLOGICAL|UB-612|UB-612 (100µg), 0.5mL suspension, intramuscular injection
224005505|NCT05293665|BIOLOGICAL|BNT162b2 vaccine|BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
224005506|NCT05293665|BIOLOGICAL|ChAdOx1-S vaccine|ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
224005507|NCT05293665|BIOLOGICAL|Sinopharm BIBP|Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
224005508|NCT01500811|BIOLOGICAL|cell injection|Intra articular injection of chondrocyte
224005509|NCT01060839|BEHAVIORAL|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
224005510|NCT03018522|OTHER|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
224005511|NCT04969068|DRUG|Remimazolam|Interventions:The dose of remimazolam for each patient was determined by the response of the previously tested patients using the modified Dixon's up-and-down method.The first patient was tested at 0.2mg/kg remimazolam (0.025mg/kg as a step size). Duodenoscopy insertion was conducted when MOAA/S≤1.The response of the patients to the duodenoscopy insertion during ERCP was categorized as either 'success (no movement)' or 'failure (movement).' Movement was defined as duodenoscopy insertion a failure was as gross purposeful muscular movement, coughing or vomiting occurring during or within 2 minutes of insertion of duodenoscopy. No movement was depicted when the reactions mentioned earlier were absent. If BIS\>75 and MOAA/S \> 1 when 3 min after the intravenous injection of remimazolam, it was considered a failure, and the patient received rescue sedation.
224005512|NCT05697263|OTHER|Periodization of training|Participants in the three arms will exercise the same dose and number of sessions distributed in three different ways.
224005513|NCT00152984|DRUG|Tiotropium inhalation capsules|
224005514|NCT00152984|DRUG|Placebo inhalation capsules|
224005515|NCT04204252|DRUG|Alpha 1-Antitrypsin|Kamada's alpha 1-antitrypsin product given by inhalation using the eFlow® electronic nebulizer manufactured by PARI Pharma GmbH
224005516|NCT04204252|DRUG|Placebo|Preparation of NaCl in phosphate buffer solution with 0.01% TWEEN-80
224005517|NCT05095207|DRUG|Abemaciclib|100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
224005518|NCT05095207|DRUG|Bicalutamide|150 mg orally daily, day 1 to 28.
224005519|NCT02108964|DRUG|EGF816|EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
224005520|NCT06418295|OTHER|Unilateral thoracotomy|Unilateral thoracotomy to proceed as per standard of care guidelines. Thoracic epidural analgesia, or patient controlled analgesia (PCA) pumps will be offered to each study participant as per standard of care. Pre- and post-operative (post-operative day 1 and 3 months) pain scores and blood samples will be collected. Blood samples will be analyzed to determine the concentration of cytokines, chemokines, and growth factors that are potentially associated with CPSP (epidermal growth factor, eotaxin, fibroblast growth factor basic, G-CSF, GM-CSF, human growth factor, IFN-α, IFN-γ, IL-1ra, IL-1β, IL-2, IL-2r, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40/p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIG, MIP-1α, MIP-1β, RANTES, TNF-α, and VEGF). DNA promotor methylation for these targets will also be investigated.
224005521|NCT01735227|DRUG|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
224005522|NCT01735227|DRUG|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
224005523|NCT04685837|OTHER|therapeutic exercise|"As soon as the study investigators have obtained a significant sample of patients with non-specific sub-acute low back pain, the intervention will begin.~The principal investigator will perform an individual assessment of the patients. At the end of the assessment, he will randomly distribute them into two groups. Tele-rehabilitation group and face-to-face group.~On the one hand, the main researcher will explain the application works to the tele-rehabilitation group. For 8 weeks, they have to perform 2 therapy exercise training sessions following the instructions on the application.~On the other hand, the researcher will explain the protocol to be followed by the group face to face. In addition, he will provide a schedule to follow a correct development of the protocol. Like the tele-rehabilitation group, they will carry out 16 sessions over 8 weeks.~At the end of the protocol, the principal investigator will perform an individualized assessment of each of the study participants."
224005524|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
224005525|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224005526|NCT00384397|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224125207|NCT04405505|DRUG|Paclitaxel for Injection (albumin bound)|a anti-microtubule drug.
223386946|NCT02074150|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
224005527|NCT03197168|BEHAVIORAL|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
223386947|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
224005528|NCT03197168|BEHAVIORAL|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
223386948|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
223386949|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
224005529|NCT03455244|DEVICE|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
223386950|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
223386951|NCT02074150|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
224125208|NCT03988257|DIETARY_SUPPLEMENT|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
223386952|NCT02074150|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
224005532|NCT01214642|DRUG|pegfilgrastim|Administered subcutaneously
224005533|NCT01214642|DRUG|LY2523355|Administered intravenously
224005534|NCT00896597|DRUG|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
224005535|NCT00007670|DRUG|Carbamazepine|
224005536|NCT00007670|DRUG|Gabapentin|
224005537|NCT00007670|DRUG|Lamotrigine|
224125209|NCT03988257|DIETARY_SUPPLEMENT|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (\< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
224125210|NCT04912037|DEVICE|artificial intelligence assistance system|the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
224125211|NCT04825236|OTHER|MyVoice:CF|"Participants will be given access to MyVoice:CF, a web-based decision aid (DA). This tool includes information about fertility, genetics, parenting, pregnancy, and breastfeeding within the context of cystic fibrosis (CF). The tool includes interactive elements designed to give users the ability to assess and reflect on their own reproductive goals and experiences and promote self-efficacy to engage in shared decision-making with their CF and women's health providers.~Upon completion of use of the decision aid, a summary sheet is generated based on the user's interaction with the tool. This summary is supplied to the provider prior to the next appointment."
224125212|NCT00788775|DRUG|Nilotinib|
224125213|NCT00088868|DRUG|alvespimycin hydrochloride|
224295878|NCT06062797|DEVICE|X-ray or CT scan|X-ray or CT scan enables the visualization of the fracture in 2D.
224295879|NCT00302120|PROCEDURE|Contrast-enhanced MR mammography|
223386953|NCT02074150|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
224005538|NCT00099749|DRUG|FTY 720|
223386954|NCT01121250|BEHAVIORAL|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
223386955|NCT01121250|BEHAVIORAL|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
223386956|NCT04827823|OTHER|Retrospective evaluation of amalgam and composite restorations|Multi-surface restorations that were performed by dental students and that are in function for the last five years will be clinically evaluated with mirrors and probes according to the modified USPHS criteria.
223386957|NCT00354913|DRUG|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
223386958|NCT00354913|DRUG|imatinib mesylate|"Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately."
223386959|NCT03864419|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
223386960|NCT03864419|DRUG|Cyclophosphamide|Given IV
224005539|NCT04554719|DRUG|68Ga-DOTA-FAPI|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-FAPI dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
224005540|NCT04554719|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
224005541|NCT04554719|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
224005542|NCT03758547|DEVICE|in-exufflator technique|application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation
224005543|NCT03758547|DEVICE|percussion technique|sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
224005544|NCT06203353|DIAGNOSTIC_TEST|diaphragm ultrasound monitoring|Ultrasound measure the diaphragm excursion, thickening fraction and maximal contraction and relaxation velocities
224125214|NCT05505968|OTHER|Virtual Reality Headset|Virtual Reality Headset of the society Healthy Mind and is a CE Class 1 medical device. This virtual reality headset is a Pico G2 4K and corresponds to the model A7510 and is connected to a Bose Sound Link 2 AE headset.
224125215|NCT00578864|DRUG|Protracted Oral Etoposide|"Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~* Hour 0: Etoposide 50 mg/m2 po daily~* Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~* Etoposide 50 mg/m2 po once daily"
223386961|NCT03864419|DRUG|Vincristine|Given IV
223386962|NCT03864419|DRUG|Methotrexate|Given IV
223386963|NCT03864419|DRUG|Doxorubicin|Given IV
223386964|NCT03864419|DRUG|Doxorubicin Hydrochloride|Given IV
224005545|NCT03942692|OTHER|Phone call questionnaire|"Questionnaire for parents of subject about :~* the frequency of consultations with an allergist~* the information of the general practitioner or pediatrician~* the prescription of epinephrin auto-injector~* the frequency of renewal of epinephrin auto-injector~* the specialty of doctor who prescribed the renewal~* the implementation of specific measures in schools~* the frequency of renewal of specific measures in schools~* the number of recurrence of anaphylactic reaction~* the use of medical advice in case of recurrence of anaphylactic reaction"
224005546|NCT03255005|DEVICE|Endomina|Endoscopic sleeve reduction
224005547|NCT03255005|BEHAVIORAL|Diet|Multidisciplinary follow-up
224005548|NCT03095469|DRUG|Dexmedetomidine|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
224005549|NCT03095469|DRUG|0.9%NaCl solution|when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
224125216|NCT00578864|DRUG|Doxorubicin|"Given together with cyclophosphamide for cycle 3 and 5 of induction chemotherapy Day 1 and 2~* Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if \< 12 kg) with Mesna 400 mg/m2 (13 mg/kg if \< 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~* Hours 6 to 6.25: Doxorubicin 37.5 mg/m2 (1.25 mg/kg if \< 12 kg) IV over 15 minutes"
223386965|NCT03864419|DRUG|Prednisone|Given PO
223386966|NCT03864419|DRUG|Etoposide|Given IV
223386967|NCT03864419|BIOLOGICAL|Rituximab|Given IV
223386968|NCT03901313|DRUG|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
223386969|NCT03901313|DRUG|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
223386970|NCT03901313|DRUG|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
223386971|NCT03379402|OTHER|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
223386972|NCT03845205|BEHAVIORAL|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
223386973|NCT02041819|DRUG|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
223386974|NCT02659423|BEHAVIORAL|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
223386975|NCT02659423|BEHAVIORAL|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
223386976|NCT02659423|BEHAVIORAL|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
223386977|NCT05206123|OTHER|Interview|Patients will be interviewed with a semi-structured qualitative interview in order to know how they lived their first sexual experiences and their sex lives during their adolescence
223386978|NCT02611908|DRUG|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
224125217|NCT00578864|DRUG|IV Bolus Etoposide|"Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
224125218|NCT00578864|DRUG|Cisplatin|Cycle 1, 2, and 4
223386979|NCT02611908|DRUG|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
223386980|NCT03063008|DEVICE|PEEK|"Procedure/Surgery:~TLIF fusion with common PEEK cages."
224125219|NCT00578864|DRUG|Cyclophosphamide|Cycle 3 and 5 with doxorubicin
224125220|NCT00578864|DRUG|Mesna|Standard weight-based dosing with cyclophosphamide
224125221|NCT00578864|DRUG|Hematopoietic Factor|Standard weight-based dosing after cycle 3 and 5 and if needed for neutropenic recovery after cycles 1,2 and 4
223386981|NCT03063008|DEVICE|TiPEEK|"Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages."
223386982|NCT01221870|DRUG|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
224125222|NCT00578864|PROCEDURE|Primary tumor resection|Resection of primary tumor after cycle 3, 4, or 5 as clinically appropriate
224295880|NCT03251963|DRUG|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
223386983|NCT01221870|DRUG|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
224125223|NCT01233401|OTHER|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
224125224|NCT00149656|DIETARY_SUPPLEMENT|Multivitamins|dietary supplement of multivitamins
224125225|NCT00149656|DIETARY_SUPPLEMENT|Selenium|dietary supplement of selenium only
224125226|NCT00149656|OTHER|Placebo|placebo pill
224125227|NCT05111899|BEHAVIORAL|Newborn Health Education|Community influencers will receive training and give community education to women and their families regarding newborn health.
224125228|NCT04332029|BEHAVIORAL|CBT + WGP + CM|The intervention will be implemented in 8-week group-based sessions and includes: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating, and 3) a Contingency Management procedure reinforcing smoking abstinence. This component will consist on providing vouchers to reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
224295881|NCT03251963|DRUG|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
224295882|NCT03308539|RADIATION|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
224295883|NCT03867799|DRUG|Nivolumab|Immunotherapy
224295884|NCT00290836|DRUG|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
224295885|NCT00198653|BEHAVIORAL|Newborn Thermal Care Practice|
224295886|NCT04505293|DEVICE|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
223386984|NCT06086106|PROCEDURE|caudal block|The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
223386985|NCT06086106|PROCEDURE|Dorsal Penile Nerve Block DPNB|DPNB is A type of pain control post-operative, often performed as a circumferential infiltration of the root of the penis (ring block). Two skin wheals are raised at the dorsal base of the penis, one on each side just below and medial to the pubic spine. A 25-gauge, 37.5-mm needle is introduced on each side, and the bupivacaine (1 to 1.5 mL) maximum dose 2 ml concentration 0.25% for infants is injected superficially and deep along the lower border of the pubic ramus to anesthetize the dorsal nerve. For a complete ring of infiltration,
223730124|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
224005550|NCT06595251|OTHER|Fit2Play curriculum|Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
224005551|NCT01220245|PROCEDURE|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
224005552|NCT01220245|PROCEDURE|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
224005553|NCT06605807|OTHER|Clinical Decision Framework for Managing older adults' chronic conditions during hospitalization.|All clinicians will attend an educational session where they will be provided a clinical decision framework for management of chronic conditions in hospitalized older adults, reviewing guiding principles for managing chronic disease in the hospital, and working through case-based hypothetical examples.
224005554|NCT06727968|PROCEDURE|Compression Stocking|Wear the compression stockin at least 6-8 hours/day
224005555|NCT06727968|PROCEDURE|Therapeutic exercise|Home-based exercise programm based on calf strengthening, mobility and stretching of lower limbs performed in standing, sitting, and laying position. Each exercise was performed 15-20 repetitions, 1 set, 3-4 days at week. In addition to these exercises, patients were instructed to walk, at least, 20 minutes at day.
224005556|NCT06727968|PROCEDURE|Self-massage|Self-massage techniques alterne manual lymphatic drainage maneuvers with superficial techniques that follow the path of saphenous veins, their respective cayaids and the anastomotic system.
224005557|NCT06727968|PROCEDURE|Prevention measures|"General preventive recommendations, and they were explained to the patient by the primary care physician. Those recommendations were based on the reduction in risk factors described in the Guide of Recommendations for the management of Chronic Venous Disease in Primary Care published by Semergen and semFYC."
224005558|NCT06891560|DRUG|Enfortumab Vedotin|intravenously on Days 1, 8 and 15 of a 28-day cycle
224005559|NCT05303792|DRUG|Cyclophosphamide|Given IV
224005560|NCT05303792|DRUG|Vincristine|Given IV
224005561|NCT05303792|DRUG|Dexamethasone|Given IV or PO
224005562|NCT05303792|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
224005563|NCT05303792|DRUG|Methotrexate|Given IV or PO
224005564|NCT05303792|DRUG|Cytarabine|Given IV
224005565|NCT05303792|DRUG|Methylprednisolone|Given IV
224005566|NCT05303792|BIOLOGICAL|Rituximab|Given IV
224005567|NCT05303792|DRUG|Prednisone|Given PO
224005568|NCT05303792|DRUG|Mercaptopurine|Given PO
224005569|NCT05303792|DRUG|Doxorubicin|Given IV
224005570|NCT06567925|BEHAVIORAL|Customized Sleep Coaching|Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.
224005571|NCT06567925|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy
224005572|NCT07055945|OTHER|Experimental group|Individuals in both groups will receive a physiotherapy program for 3 sessions per week, 60 minutes per day, for a total of 8 weeks.The study consists of two groups: the experimental group and the control group. Both groups will receive a physiotherapy program of 3 sessions per week, each lasting 60 minutes, for a total of 8 weeks. Within the 60-minute physiotherapy session, patients from both groups will undergo 30 minutes of exercises based on the Neurodevelopmental Treatment (NDT) method. In addition, a 12-minute training session will be conducted using a light-based trainer system (Light Trainer® Exercise System).
224125229|NCT04332029|BEHAVIORAL|CBT + WGP|The intervention will be implemented in 8-week group-based sessions and will include only the first two components of the experimental intervention: 1) A Cognitive Behavioral Treatment (CBT) for smoking cessation with quit date occurring at sixth session. Patients will be asked to reduce their nicotine intake gradually (i.e., 20% each week); 2) A Weight Gain Prevention module (WGP) which will consist on providing CBT and Dialectical-Behavioral Therapy (DBT) techniques targeting weight stability and associated disordered eating.
224125230|NCT02796534|OTHER|Diagnosis of sleep apnea by oxymetry|
224125231|NCT03796091|BEHAVIORAL|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
224295887|NCT05172466|DEVICE|BeCare application|Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
224295888|NCT04657926|DRUG|APPA|APPA, an oral combination of two isomers: 4-hydroxy-3-methoxyacetophenone (4H3MA) \& 2-hydroxy-4-methoxyacetophenone (2H4MA).
224295889|NCT04657926|DRUG|Placebo|Placebo capsules
224005573|NCT07055945|OTHER|Control group|"In addition to the full-body exercises mentioned, individuals in the control group will also receive upper extremity exercises based on the Neurodevelopmental Treatment approach. These exercises are as follows:~* Functional reaching activities at the table in a sitting position (e.g., pushing objects, wiping the table, touching various points)~* Ball sliding on the wall in a standing position~* Touching different targets on the wall in a standing position~* Drawing shapes on the wall in a standing position~These exercises will be performed bilaterally and on the hemiparetic side. The exercises will be given for approximately 12 minutes, in line with the exercises given to the experimental group. The difficulty level will not be increased during the training."
224005574|NCT06750432|DRUG|PMN310|A humanized immunoglobulin G1 (IgG1) monoclonal antibody
223386986|NCT06086106|DRUG|Systemic opioids|Systemic opioids belong to a class of analgesics, they act by attaching to opioid receptors in the brain and spinal cord. For relief of pain, they are frequently utilized in a variety of surgical procedures and can be given intravenously, and in intramuscular injections. Although opioids are considered highly effective in pain control, they can lead to several adverse effects, such as nausea, vertigo, and respiratory depression, some of which can be dangerous.
224005575|NCT06750432|DRUG|Placebo|0.9% NaCl 100 mL
224005576|NCT06804109|DEVICE|Active nVNS|2-min transcutaneous nVNS stimulation using portable Truvaga Plus Device (electroCore Inc., Rockaway, NJ).
224005577|NCT06804109|DEVICE|Control nVNS|2-min control stimulation using portable Truvaga Plus Device (electroCore Inc., Rockaway, NJ).
224005578|NCT07066293|PROCEDURE|Unilateral alveolar cleft repair|10 patients in whom unilateral alveolar cleft will be repaired using sticky bone grafting combined with concentrated growth factor membrane
224005579|NCT07070336|OTHER|Neuroathletic exercise|After warm-up and resetting exercises, it will start with eye muscle training with a star chart. It then consists of exercises that regulate the accommodation reflex, balance the right and left lobes, regulate the vestibular system and rhythm exercises.
224005580|NCT04666792|DRUG|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
224005581|NCT07153653|BEHAVIORAL|Prenatal Baduanjin Exercise Program|A structured 12-week program featuring Baduanjin, a traditional Chinese mind-body exercise involving gentle, flowing movements. Participants receive 24 online instructional sessions (approximately 2 s
224125232|NCT03796091|BEHAVIORAL|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice \& Shaw, 2001).
224125233|NCT03796091|BEHAVIORAL|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
224125234|NCT00651976|DRUG|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
224125235|NCT00651976|OTHER|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
224125236|NCT00651976|PROCEDURE|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
224125237|NCT03167580|PROCEDURE|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
224125238|NCT03167580|PROCEDURE|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
224125239|NCT01860053|BEHAVIORAL|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
224125240|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
224125241|NCT02949115|DIETARY_SUPPLEMENT|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
224125242|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
224125243|NCT02949115|DIETARY_SUPPLEMENT|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
223730125|NCT03935009|BEHAVIORAL|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
223730126|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
224005582|NCT07154550|DEVICE|Mastisol|a liquid adhesive used to secure dressings for extended periods of time
224005583|NCT07154888|OTHER|Fast Track to Fertility Algorithmic Text Messaging Platform|"The Fast Track to Fertility algorithmic text messaging platform uses branching logic based on our standard workup protocol to text patients to schedule blood tests and an ultrasound timed to their menstrual cycle, as well as remind male partners to schedule blood and semen analyses.~The platform will use an algorithmic approach to facilitate two-way communication, and any queries with no available responses will be escalated to the clinical team. Patients are not dependent on structured messages to progress through their journey; they can ask relevant questions in real time, and they are supported with fewer reminders. Response categories include clinical guidance and FAQs (e.g., how to determine cycle start or uterine cavity evaluation pre-appointment instructions), administrative guidance and FAQs (when to schedule test/appointment or clinic locations or phone numbers), and conversational pleasantries."
224125244|NCT02195791|DRUG|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
224125245|NCT02195791|DRUG|Placebo|Placebo (oral) 1 tab once daily for 7 days
224125246|NCT02307344|DIETARY_SUPPLEMENT|Nigella Sativa|
224125247|NCT02307344|DIETARY_SUPPLEMENT|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
224125248|NCT02858609|OTHER|Nasopharyngeal Swab|
224125249|NCT00426114|DRUG|Administration of an IV glucose-injection|
224125250|NCT03219593|DRUG|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
224125251|NCT01930812|PROCEDURE|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
224125252|NCT01930812|PROCEDURE|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
224125253|NCT01930812|DRUG|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
223386987|NCT01608100|DEVICE|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
223386988|NCT04747470|DRUG|GS-3583|Administered as an intravenous (IV) infusion
223386989|NCT04747470|DRUG|Zimberelimab|Administered as an IV infusion
223386990|NCT04747470|DRUG|Cisplatin|Administered as an IV infusion
224005584|NCT07154082|DRUG|TACE (transarterial chemoembolization) combined with targeted/immunotherapy|Patients in the neoadjuvant treatment group will receive TACE treatment within one week after enrollment. One week after the resolution of the TACE treatment syndrome, they will be given Camrelizumab (200 mg, once every two weeks, for a total of 4 cycles) and oral Apatinib mesylate tablets (250 mg, once a day, for a total of 2 months).To ensure surgical safety, Camrelizumab should be discontinued at least two weeks before surgery, while Apatinib should be discontinued at least one week before surgery.
224005585|NCT07153419|DEVICE|Laparoscopic and robotic (DaVinci) RYGB|Laparoscopic and robotic (DaVinci) Roux-en-Y Gastric Bypass
224005586|NCT07155356|DEVICE|Red light exposure|Patients in the red light group received red light therapy concurrently with standard care.
224125254|NCT01253044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
224125255|NCT01253044|BEHAVIORAL|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
224125256|NCT00664300|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
224125257|NCT06234735|BEHAVIORAL|Physical activity in the community|Supervised and guided PA sessions in the community setting using public resources such as parks, sports facilities, etc.
224125258|NCT06234735|BEHAVIORAL|Conventional intervention|Conventional protocol for lung cancer and PA recommendations.
223386991|NCT04747470|DRUG|Carboplatin|Administered as an IV infusion
223386992|NCT04747470|DRUG|5-Fluorouracil|Administered as an IV infusion
224005587|NCT07155356|DEVICE|Red-blue light exposure|Patients in the red and blue light group received combined red and blue light therapy concurrently with standard care。
224125259|NCT04368806|DRUG|JointStem|Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
224125260|NCT04368806|OTHER|Placebo Control|Normal Saline with autologous Serum
224125261|NCT03288272|RADIATION|Whole Brain Radiotherapy|Radiotherapy of the whole brain
224125262|NCT03288272|OTHER|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
224125263|NCT04090281|GENETIC|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
223386993|NCT04747470|DRUG|Docetaxel|Administered as an IV infusion
223386994|NCT01202175|DRUG|Nebivolol|Oral nebivolol 2.5-5mg once daily
224125264|NCT02327286|BEHAVIORAL|Promote and support healthy behaviors|"* Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~* Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~* Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~* A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
224125265|NCT04151537|BEHAVIORAL|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
224125266|NCT04151537|BEHAVIORAL|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
223386995|NCT04089449|DRUG|PRT811|PRT811 will be administered orally
223386996|NCT03923140|DRUG|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
223386997|NCT05544474|OTHER|Delphi questionnaire|"An invitation email, including a link to the survey, will be sent to the panel of experts in the field of radical right colectomy. The Delphi questionnaire will be administered via www.surveymonkey.com.~In the first survey, panel members will agree on surgical steps, definition of surgical steps and nomenclature for radical right colectomy In subsequent surveys, panel expert will agree on a common definition, nomenclature and reporting for right colectomy. Multiple rounds will be conducted until consensus is reached. After each round, the study team will calculate the agreement and distribution of responses. Likert responses will be dichotomized with positive values indicating agreement and neutral or negative values indicating disagreement.~For the questions that do not reach a consensus of more than 70% in the first round or need further explanation, additional rounds of the survey may be performed."
223386998|NCT06155201|BEHAVIORAL|functional training|Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
224005588|NCT07156006|DIAGNOSTIC_TEST|Mammography|Participants will undergo mammographic imaging using a digital full-field mammography system, following standard clinical practices and blood sampling.
224125267|NCT03326219|PROCEDURE|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
224125268|NCT00006222|DRUG|cilengitide|
223386999|NCT06155201|OTHER|Observation|Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
224005589|NCT07155655|BEHAVIORAL|Motor Imagery (MI)|Participants followed an audio-guided motor imagery protocol describing the lumbopelvic dynamometer movement. The audio was played three times per session, with pauses for visualization. Training was delivered online via Microsoft Teams, twice weekly for four weeks, in a quiet and focused environment.
224005590|NCT07155655|BEHAVIORAL|Action Observation (AO)|Participants viewed three videos of the lumbopelvic dynamometer movement (two third-person, one first-person perspective). Each video was watched three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks, with participants instructed to remain silent and focused.
224005591|NCT07155655|BEHAVIORAL|Motor Imagery with Motivation (MIm)|Participants followed the MI protocol, combined with a motivational strategy. Intrinsic motivation was provided through self-talk statements, and extrinsic motivation through an audio simulating a weightlifting competition. Each motivational audio was played three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks.
224005592|NCT07155655|BEHAVIORAL|Action Observation with Motivation (AOm)|Participants followed the AO protocol, combined with the same motivational strategy described for the MIm group (self-talk + extrinsic audio simulation). Each motivational audio was played three times per session. Training was delivered online via Microsoft Teams, twice weekly for four weeks.
224005593|NCT07155980|DRUG|GSM-779690T|Opaque capsules for oral consumption.
224005594|NCT07155980|OTHER|Placebo|Opaque capsules for oral consumption.
224005595|NCT07153601|DRUG|Norepinephrine 4mcg|Norepinephrine 4 mcg IV bolus diluted in 2 mL normal saline, administered upon onset of hypotension during spinal anesthesia.
224005596|NCT07153601|DRUG|Phenylephrine 50 mcg|Phenylephrine 50 mcg IV bolus diluted in 2 mL normal saline, administered upon onset of hypotension during spinal anesthesia.
224005597|NCT07153874|OTHER|Physical exercise rehabilitation intervention|12 weeks of physical exercise intervention, including aerobic snd anaerobic exercise at home. 36 sessions of monitorized training with distance supervision.
224005598|NCT07154290|DRUG|Ubamatamab|Administered per the protocol
223387000|NCT03440840|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Application of a small electrical current (1-2 mA) across the head.
224005599|NCT07154290|DRUG|REGN7075|Administered per the protocol
224005600|NCT07154290|DRUG|Sarilumab|Administered per the protocol
224125269|NCT03105440|OTHER|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
224125270|NCT03105440|OTHER|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
224295890|NCT04295135|BEHAVIORAL|Chronic Pain OneSheet|The Chronic Pain OneSheet (OneSheet) is an EHR decision support tool that uses behavioral economics to increase adoption of chronic pain guideline recommendations. OneSheet works by aggregating and structuring information that is already collected, that PCPs often need while caring for patients with chronic pain conditions. By aggregating and structuring this information in a more convenient manner, the goal of OneSheet is to make the information that is important in clinical decision making more readily available, and to reduce the amount of time that PCPs need to spend locating this information.
224295891|NCT02327416|DRUG|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
224295892|NCT02327416|DRUG|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
224295893|NCT02327416|DRUG|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
224295894|NCT01517659|DEVICE|The Zeltiq CoolSculpting System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
224295895|NCT05177874|DEVICE|Traumacel FAM Trium|Absorbable Hemostat (oxidized non-regenerated cellulose)
224295896|NCT05177874|DEVICE|Surgicel Fibrillar|Absorbable Hemostat (oxidized regenerated cellulose)
224295897|NCT00474474|PROCEDURE|Virtual patient is NOT introduced|
224295898|NCT00048204|DRUG|GW597599B|
224295899|NCT00048204|DRUG|paroxetine|
224295900|NCT00376025|DIETARY_SUPPLEMENT|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
224295901|NCT00698893|BIOLOGICAL|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
224295902|NCT03525925|DRUG|Ibrutinib|Given PO
223387001|NCT03440840|BEHAVIORAL|Computer-based Cognitive Training|Use of computer-delivered games or exercises with the goal of improving cognitive performance.
224005601|NCT07153588|OTHER|Level of awareness|"This study uses a structured, interviewer-assisted questionnaire as the main intervention. The questionnaire is designed to assess patients' awareness and perception of glaucoma. It includes four sections:~Sociodemographic information (age, gender, education, occupation, residence, family history)~Ocular history (diagnosis of glaucoma, history of eye disease, surgery, or previous eye checkups)~Awareness of glaucoma (understanding of risk factors, symptoms, prevention, and treatment options)~Perceptions and attitudes (beliefs about curability, reversibility of vision loss, and willingness for screening and education).~For illiterate participants, trained research staff will administer the questionnaire verbally without influencing responses. The data collection method distinguishes this intervention from treatment-based studies, as it focuses on knowledge assessment and perception analysis rather than a medical or surgical procedure."
224005602|NCT07155408|DRUG|Povidone-Iodine 10%|Preoperative skin antisepsis performed with 10% povidone-iodine solution according to standard surgical preparation guidelines before hair transplantation.
223387002|NCT03440840|BEHAVIORAL|Watching Educational Videos|Watching educational videos and answering questions about them
224005603|NCT07155408|DRUG|Povidone-Iodine + Rifampicin|Preoperative skin antisepsis performed with a combination of 10% povidone-iodine and rifampicin solution according to study-specific preparation guidelines before hair transplantation.
224005604|NCT07155551|DEVICE|Lens A|Lens A of Study P/883/24/MO
224005605|NCT07155551|DEVICE|Lens B|Lens B of Study P/883/24/MO
224005606|NCT07155551|DEVICE|Lens C|Lens C of Study P/883/24/MO
224005607|NCT07155369|BIOLOGICAL|UCAR-T cells|UCAR-T cells will be administered intravenously as per the schedule specified in the protocol.
224005608|NCT07155369|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
224005609|NCT07155369|DRUG|Fludarabine|Fludarabine will be administered intravenously.
224005610|NCT07155668|DRUG|VRDN-003|VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
224005611|NCT07155668|DEVICE|Autoinjector|The autoinjector is a single-dose, disposable, ready-to-use delivery device
224005612|NCT07155915|DIETARY_SUPPLEMENT|Sweet cherries, 280 g daily for 42 days|Participants will consume 280 grams of fresh sweet cherries daily for 42 consecutive days. Cherries are provided in pre-weighed portions to be consumed in the morning on an empty stomach
224005613|NCT07154017|OTHER|Combination of Movement Representation Techniques with neural mobilization exercises|The experimental intervention will be an exposition of movement representation techniques in an established sequential order, consisting of action observation, implicit/explicit motor imagery and visual feedback with a mirror in combination with neural mobilization exercises.
224125271|NCT03105440|OTHER|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
224125272|NCT03105440|OTHER|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
223387003|NCT00743925|DRUG|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
223387004|NCT05760963|OTHER|Collection of datas|"Analysis lumbar echographies results by Trident ans Shamrock techniques.~Costiform processes on T12 to L5 were spotted and noted. For Trident technique, quality of image, depth of lumbar plexus and presence of vessels were noted.~Shamrock technique was performed, the projection of C line (line obtained with a probe put on the iliac crest) was noted with the invisible ink pen. Then the probe was oriented cephalically (for line \>C) and caudally (line \<C). For each lines, quality of image, depth of lumbar plexus and presence of vessels were also noted.~The projections of C, \>C, \<C on the costiform processes were noted."
223387005|NCT04688671|DRUG|ETX-018810|Study Drug
223387006|NCT04688671|DRUG|Placebo|Matching Placebo
223387007|NCT01807403|PROCEDURE|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
224005614|NCT07154017|OTHER|Neural mobilization exercises|The control intervention will consist in three series of active neural mobilization exercises
224005615|NCT07155226|DRUG|AZD3632|AZD3632 will be administered orally.
224005616|NCT07155226|DRUG|Posaconazole|Posaconazole will be administered orally.
224005617|NCT07153861|PROCEDURE|Oral mucosal graft|Patients will be admitted for the surgical management by the oral mucosal graft urethroplasty with the anterior onlay technique.
224005618|NCT07153861|PROCEDURE|Labial graft|Patients will be admitted for the surgical management by the labial graft urethroplasty with the anterior onlay technique.
224005619|NCT07154173|PROCEDURE|Biospecimen Collection Procedure|Collection of fecal samples from healthy volunteers, non-metastatic (M0) and metastatic (M1) colorectal cancer patients. Additionally, collection of tissue samples during surgery from operable patients (M0 and M1) for subsequent research analysis.
224005620|NCT07153679|DEVICE|1064-nm Nd:YAG Picosecond Laser|Treatment was performed using 1064 nm Nd:YAG microlens array picosecond laser (Picocare 450, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.
224005621|NCT07153679|DEVICE|1927-nm Fractional Thulium Laser|Treatment was performed using 1927-nm thulium fractional laser (Lavieen, WONTECH, Daejeon, South Korea). Received three treatments, with a 4-week interval between each treatment.
224005622|NCT07154602|OTHER|3D printed hybrid resin ceramic crowns|3D printed hybrid resin ceramic crowns in anterior and premolar maxillary teeth
224005623|NCT07154602|OTHER|milled hybrid resin ceramic crown|milled hybrid resin ceramic crown on implants in anterior and premolar maxillary teeth
224125273|NCT03105440|OTHER|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
224295903|NCT03525925|OTHER|Laboratory Biomarker Analysis|Correlative studies
223387008|NCT02329509|PROCEDURE|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
224005624|NCT07155005|DEVICE|CVAC® SYSTEM|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
224005625|NCT07155005|DEVICE|FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)|Group/Cohort Description: FANS is designed to incorporate suction to facilitate stone fragment removal through its lumen and is used with a separate ureteroscope. FANS is fitted with a Y connector with a pressure control vent and connects to a standard vacuum device. A separate ureteroscope provides direct visualization and irrigation and a separate specimen collector captures stone debris.
224005626|NCT07155005|DEVICE|DIRECT IN-SCOPE SUCTION (DISS) IN FLEXIBLE URETEROSCOPY (FURS)|DISS is a system that integrates controlled suction into the working channel of a standard flexible ureteroscope during ureteroscopic lithotripsy. A suction adapter is attached externally to the ureteroscope's working port, which connects to a standard hospital suction source.
224005627|NCT07155005|PROCEDURE|URETEROSCOPY (URS) WITHOUT SUCTION|URS allows the surgeon to visualize the stone by inserting the ureteroscope into the ureter, most often a flexible scope that allows them to accommodate to the shape of the ureter and renal collecting system. A laser fiber is advanced through the working channel of the ureteroscope to perform stone fragmentation (dusting or breaking up the calculi). Once the stones are dusted or fragmented, the pieces can be removed by active extraction of individual stone fragments using a retrieval basket or using the concept of stone dusting where the fragments are small enough to be passed after the procedure.
224005628|NCT07155005|PROCEDURE|PERCUTANEOUS NEPHROLITHOTOMY (PCNL)|This is a surgical procedure under general anesthesia, where a rigid probe is placed through the flank, creating a percutaneous tract into the renal collecting system under fluoroscopy. Via nephoscopy, stones are fragmented, pulverized, and extracted.
224005629|NCT07154056|DEVICE|Lead(s) and Implantable Pulse Generator implantation|8-contact lead(s) will be radiologically positioned within the spinal foramen under awake anesthesia in order to optimize paresthesia coverage. Awake anesthesia will allow patients to be tested during the surgery in order to determine the sweet spot and the optimal paresthesia coverage using the PREDI-P platform for a single lead. A trial phase will be performed for a period of 7 days in order to assess the benefits of stimulation according to the HAS (French Health Authority) guidelines. Subjects who succeed the lead trial will receive a permanent implant depending on the patient electrical consumption during the lead trial period or according to the implanter decision.
224005630|NCT07153978|DEVICE|Effectivity of TFL on large renal stone|While literature studies on TFL have focused on the effect of stone size on laser efficacy parameters, the present study is important as it is a prospective study examining the effects of TFL lithotripsy on SFRs in stones \>1000 mm3.
223387009|NCT02329509|PROCEDURE|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
223387010|NCT04332315|PROCEDURE|Vaginally assisted laparoscopic sacrocolpopexy|"The VALS procedure consists of two steps. First, vaginal hysterectomy or laparoscopically assisted vaginal hysterectomy performed, anterior vaginal wall dissected up to bladder neck starting from initial vaginal incision, posterior vaginal wall dissected from rectum starting from initial vaginal incision up to distal third of posterior vaginal wall.The free arms of fixed meshes are introduced to the peritoneal cavity and the vaginal vault is closed with absorbable polyglactin suture. laparoscopy phase was performed with one intraumbilical (10 mm), 3 lateral abdominal (5 mm) trocars. Two mesh strips fixated to anterior longitudinal ligament of the sacrum with two separate no: 1 polypropylene sutures without tension.~AS was performed via Pfannenstiel incision after total or subtotal abdominal hysterectomy"
223387011|NCT00806429|PROCEDURE|transvaginal appendectomy|patient undergoes transvaginal appendectomy
224005631|NCT07153939|DEVICE|Velocity Percutaneous Arteriovenous Fistula|The Velocity pAVF is a catheter-based device used to create an arteriovenous fistula for hemodialysis access through a minimally invasive, percutaneous procedure. Unlike surgical AVF creation or other pAVF systems, Velocity is designed to simplify the procedure and improve consistency of maturation and long-term function. All participants in this study will undergo AVF creation using the Velocity pAVF.
224005632|NCT07153835|DRUG|Paliperidone extended-release (ER)|Paliperidone extended-release (ER) tablets will be administered orally once daily at flexible doses ranging from 6 mg to 12 mg, based on the clinical judgment of the treating psychiatrist. The treatment duration is 12 weeks. Dose adjustments may be made throughout the study period depending on patient response and tolerability.
223387012|NCT02317003|BEHAVIORAL|Intervention PPIL|
223387013|NCT02317003|BEHAVIORAL|Control OR|
223387014|NCT00738179|DEVICE|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
223387015|NCT00738179|OTHER|Standard care|Standard care of cardiovascular risk factors
223387016|NCT03879785|OTHER|Screening|Screening and validation of assessment tool translated into Spanish
224005633|NCT07153445|DRUG|Atezolizumab|Patients will receive atezolizumab administered by intravenous infusion in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
223387017|NCT03530683|DRUG|Maplirpacept (PF-07901801)|maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
223387018|NCT03530683|DRUG|Azacitidine|intravenous (IV) or subcutaneous (SC) daily for 7 days, repeated every 4 weeks
224125274|NCT03105440|OTHER|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
224125275|NCT01087528|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
224125276|NCT03775018|PROCEDURE|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
224125277|NCT03775018|DRUG|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
224295904|NCT03525925|BIOLOGICAL|Nivolumab|Given IV
223387019|NCT03530683|DRUG|Venetoclax|orally daily for each day of each cycle (first 7 doses taken in clinic). The ramp-up and target dose of venetoclax will be adjusted per the package insert in subjects who are taking concomitant moderate or strong CYP3A4 inhibitors or posaconazole
223387020|NCT03530683|DRUG|Carfilzomib|Days 1, 8, and 15 of 28-day cycles; starting dose IV given on Cycle (C) 1 Day (D) 1, and if tolerated, then increased dose via IV given starting on C1D8 and subsequent doses thereafter.
223387021|NCT03530683|DRUG|Dexamethasone|starting dose via IV on Days 1, 8, 15, and increased dose via IV on 28-day cycles
223387022|NCT03530683|DRUG|Anti-CD20 Targeting agent|Days 1,8,15, and 22 of the first 28-day cycle and then on Day 1 of subsequent 21-day cycles. The anti-CD20 targeting agent will be administered for a total of eight doses, and then Cohort F1, F2 and F3: TTI-622 + isatuximab, carfilzomib and dexamethasone Cohort C1, C2 and C3: TTI-622 + Carfilzomib and Dexamethasone will be continued as single-agent therapy.
223545636|NCT03012191|DRUG|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
223730127|NCT00421187|DRUG|Liposomal amphotericin B (AmBisome®)|
224005634|NCT07153445|DRUG|Paclitaxel|"Neoadjuvant / induction treatment:~Atezolizumab Paclitaxel Carboplatin~Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery.~Route of administration Paclitaxel: Intravenous infusion.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml."
224005635|NCT07153445|DRUG|Carboplatin|"Neoadjuvant / induction treatment:~Atezolizumab Paclitaxel Carboplatin\*~\*Infusion according to the standard of each center~Neoadjuvant / induction treatment 3 cycles will be administered prior to the assessment for surgery.~Route of administration Carboplatin: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center."
224005636|NCT07153770|DRUG|Bozitinib|Participants will receive bozitinib in combination with standard platinum-based doublet chemotherapy for 8 weeks. Following investigator-assessed operability, surgical resection will be performed approximately 4 weeks after completion of neoadjuvant therapy. The first MRD assessment will be conducted after completion of neoadjuvant therapy and before surgery.A second MRD assessment will be performed within 7 days to 1 month after surgery. Based on a comprehensive evaluation of MRD status, tumor markers, and imaging results, if molecular abnormalities are detected., patients will receive bozitinib within 3 months after surgery. If CEA remains within the normal range and blood cfDNA-MRD is negative, patients will enter a regular follow-up program, with MRD assessments every 3 months during the first 2 years and every 6 months from years 3 to 5. If MRD conversion to positive, abnormal CEA, or abnormal CT findings occur within 5 within 5 years, bozitinib will be administered.
224005637|NCT07154758|OTHER|Screening for need of HFrEF GDMT implementation through SwedeHF|Screening for need of HFrEF GDMT implementation through SwedeHF
224005638|NCT07154641|PROCEDURE|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer is a surgical procedure that aims to restore active range of motion and stability of the shoulder in patients with massive rotator cuff tears. The tendon of the latissimus dorsi muscle is dettached from its insertion in the midbicipital groove of the humerus and reattached to the greater tubetosity. Therefore, the muscle acts as an external rotator, while the forces created pull the humeral head down and stabilize it in the glenoid.
224005639|NCT07154641|PROCEDURE|Superior capsular reconstruction|Superior capsular reconstruction is a surgical procedure that aims to restore shoulder stability in patients with massive rotator cuff tears. The superior capsule of the shoulder joint is attached to the greater tuberosity and is therefore often torn in cases of supraspinatus or infraspinatus tears. A fascia lata autograft is used to reconstruct the torn capsule, between the greater tuberosity and the glenoid. Thus, superior migration of the humeral head is prevented, and pain and functionality are improved.
224005640|NCT07154004|OTHER|Test Serum 897222 210|Repeated application
224005641|NCT07154004|OTHER|Test Serum 897222 212|Repeated application
224005642|NCT07154004|OTHER|Test Serum 897250 39|Repeated application
224005643|NCT07154004|OTHER|Test Serum 897250 102D|Repeated application
224005644|NCT07154004|OTHER|Test Serum 774569 67|Repeated application
224005645|NCT07155486|OTHER|Interview|Interview
224005646|NCT07154134|DIAGNOSTIC_TEST|Serum endocan|Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
224005647|NCT07154134|DIAGNOSTIC_TEST|Serum copeptin|Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
224005648|NCT07155616|OTHER|Blood flow measurement|Intraoperative blood flow measurement
224005649|NCT07155473|DIAGNOSTIC_TEST|C-peptide dosage|Measurement of C-peptide at 5 time points during a standard oral glucose tolerance test (OGTT)
224005650|NCT07155265|DRUG|Remimazolam Besylate|Continuous IV infusion; start 0.10 mg/kg/h and titrate every 15-30 minutes in 0.025-0.05 mg/kg/h steps to target RASS -3 to -5 (allowable range -2 to -5 for clinical safety). Maximum typical rate 0.20 mg/kg/h; temporary higher rates permitted per protocol for breakthrough agitation.
224005651|NCT07155265|DRUG|Midazolam|Continuous IV infusion; start 0.04 mg/kg/h and titrate every 15-30 minutes in 0.01-0.03 mg/kg/h steps to target RASS -3 to -5 (allowable range -2 to -5). Maximum typical rate 0.20 mg/kg/h per protocol.
224005652|NCT07155291|BEHAVIORAL|Abdominal Self-Massage|Daily self-administered visceral abdominal massage consisting of circular motions and pressure point techniques, performed for 5-20 minutes in total based on participant preference. The massage includes two parts: belly exercises (10 exercises) and pelvic exercises (3 exercises), with each exercise repeated 5-10 times or until the area feels relaxed. The app provides instructional videos and written step-by-step guides with drawings in English and German. Participants are recommended to use oil/cream, find a comfortable position, and integrate the massage into a daily routine.
224005653|NCT07153406|DRUG|Experimental regimen|Esketamine intranasal spray at flexible doses (28, 56 and 84 mg) once or twice a week
224005654|NCT07153406|DRUG|Control regimen|Oral aripiprazole 5-30 mg daily, once or twice daily for the duration of the study
224005655|NCT07154459|OTHER|Breastfeeding Education|Breastfeeding Education
224005656|NCT07156097|OTHER|Mediterranean-style Diet (SAFF)|Participants followed a 4-week Mediterranean-style dietary pattern (SAFF), characterized by high intake of vegetables, fruits, whole grains, olive oil, and lean protein sources. This arm served as a comparator for the boron-rich diet.
224005657|NCT07156097|OTHER|Boron-rich Diet|Participants assigned to this arm will follow a boron-rich dietary pattern for 4 weeks. The diet includes foods naturally high in boron (e.g., dried fruits, nuts, legumes, and boron-rich water). Daily dietary intake will be monitored and adjusted to ensure consistent boron exposure.
224005658|NCT07154420|DIAGNOSTIC_TEST|Diagnostic Test: Periodontal Examination|Diagnostic Test: Periodontal Examination
224005659|NCT07154420|DIAGNOSTIC_TEST|Diagnostic Test: Periodontal Examination|Periodontal Examination
224005660|NCT07155304|PROCEDURE|percutaneous sigmoid colon fixation|after endoscopic sigmoid colon untwisting , percutaneous colon fixation using anchor device
224005661|NCT07154680|DIAGNOSTIC_TEST|GPT-4o mini;Claude 3 Haiku;Gemini 1.5 Flash;Llama 3.1 7OB;GPT-4o;Claude 3.5 Sonnet;Gemini 1.5 Pro;Llama 3.1 4O5B|Input all the patient's information into the large language model and process it using a pre-defined prompt.
224005662|NCT07155785|DRUG|Lidocain spray|Lidocaine spray as a local anaesthetic agent was applied to the cervix before intrauterine device application.
224005663|NCT07154836|OTHER|Telephone calls|Regular telephone reminders and health information will be sent to help mothers or caregivers of children 0-23 months to remind them to go vaccine their children
224005664|NCT07153575|PROCEDURE|suprainguinal fascia iliaca block|The ultrasound-guided suprainguinal fascia iliaca block (SFIB) procedure was first described by Hebbard et al. in 2011. It is a prevalent regional anesthesia technique employed in surgical procedures involving the hip joint and femur. Local anesthetics are administered in close proximity to the fascia iliaca. The primary objective is to obstruct the femoral, obturator and lateral femoral cutaneous nerve in a simultaneous manner. In clinical practice, it is a safe and simple alternative to lumbar plexus blocks and femoral blocks. A 30-ml solution of 0.25% bupivacaine was injected between the iliac muscle and the iliac fascia. The bupivacaine dosage administered in the study was standardized for the groups by employing equal concentrations and volumes.
224005665|NCT07153575|PROCEDURE|Pericapsular nerve group (PENG) block|In pericapsular nerve group (PENG) block the local anesthetic agent is injected into the musculofascial plane between the psoas muscle tendon and the pubic ramus. The primary objective of this technique is to obstruct the genicular branches of the femoral, obturator, and accessory obturator which innervate the hip capsule. Therefore, a comparison with the SFIB was undertaken. A 30-ml block of 0.25% bupivacaine solution was injected between the pubic ramus and the iliopsoas muscle tendon. The bupivacaine dosage administered in the study was standardized for the groups by employing equal concentrations and volumes.
224005666|NCT04388163|DRUG|Gentian Violet|Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
224125278|NCT01899404|BIOLOGICAL|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
224125279|NCT04443127|DEVICE|Virtual Reality Training Session|VR based motor priming intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
224125280|NCT04443127|BEHAVIORAL|Motor-Relearning Program|Motor-Relearning Program intervention will be given for 16 sessions, comprising of 45 minutes, 4 times/week for the duration of 4 weeks on two VR environments.
224005667|NCT06180642|OTHER|Assessment of soft tissue properties|Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
224005668|NCT06180642|OTHER|Retest assessment of soft tissue properties|Retest Assessment of soft tissue properties at the upper limb region with clinical assessments and ultrasound
224005669|NCT06272500|OTHER|oral administration of receives only oral administration of placebo|receives oral administration of placebo, with two capsules before each meal.
224005670|NCT06272500|DIETARY_SUPPLEMENT|oral administration of Betaine hydrochloride|receives oral administration of Betaine hydrochloride(BHCL), with two capsules before each meal.
224005671|NCT04270591|DRUG|Glumetinib|The investigational product will be orally administrated when fasting at dose level of 300mg QD
223387023|NCT03530683|DRUG|Isatuximab|"F1: IV dose C0D1, C0D8, C0D15 and C0D22 (lead in phase);weekly during Cycle 1; Cycle 2 and beyond will be administered on Days 1 and 15 (Q2W).~F2 and F3: IV dose C0D1 and C0D8 (lead in phase); C1D1, C1D8, C1D15 and C1D22; Cycle 2 and beyond will be administered on days 1 and 15 (Q2W). Carfilzomib: IV dose on days 1 and 2 of cycle 1; then increased IV dose on days 8, 9, 15, and 16 of cycle 1; cycle 2 and beyond: increased IV dose on days 1, 2, 8, 9, 15, and 16. Dexamethasone IV or PO on days 1, 2, 8, 9, 15, 16, 22, and 23 starting cycle 1."
224005672|NCT01980680|DRUG|hCG|
224005673|NCT01980680|DRUG|Progesterone and Estradiol|
224005674|NCT01788553|OTHER|remission prevalence of generalized anxiety disorder|
224005675|NCT01696552|PROCEDURE|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
224005676|NCT01696552|PROCEDURE|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
224005677|NCT01732822|DRUG|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
224005678|NCT01732822|DRUG|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
224005679|NCT02912923|OTHER|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
224005680|NCT02912923|OTHER|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
224005681|NCT01620268|DRUG|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
224005682|NCT02315300|DEVICE|medilog® DARWIN FD12|
224005683|NCT02315300|DEVICE|Continuous Glucose Monitoring|
224005684|NCT02314780|DRUG|Heme arginate 3mg/kg|
224005685|NCT02314780|DRUG|Heme arginate 1mg/kg|
224005686|NCT02314780|DRUG|Placebo|
224005687|NCT00109330|BIOLOGICAL|Combined diphtheria, tetanus, acellular pertussis vaccine|
224005688|NCT04579718|OTHER|Zeus Cloud TPS V1.0|Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.
224005689|NCT04579718|OTHER|Eclipse|Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.
224005690|NCT06224127|DEVICE|active heat|Users receive an active Soovu heating pod(s).
224005691|NCT06224127|DRUG|Active c tactile fiber stimulation|Hair brushes that activate c tactile fibers
224005692|NCT06224127|DEVICE|sham heat|A Soovu heating pod(s) in the subtherapeutic temperature range
224005693|NCT06224127|DEVICE|Sham c tactile fiber stimulation|Hair brushes that do not activate c tactile fibers
224005694|NCT04998929|OTHER|complementary therapy|traditional techniques of treatment including, (a)cupping therapy, (b)Backstroke for young people, (c)Sitting on all fours while the other person holds both knees firmly with the hands, the patient is asked to bend at the back so that the abdominal muscles are stretched, (d)taking a nerve that passes under the armpit with two index fingers and thumbs and applying intense pressure to the extent that the patient goes unconscious due to the severity of the pain, (e)Hanging the patient from the horizontal bar and stretching the abdominal muscles, (f)Tie an onion-sized object such as, a bag of wheat or salt, with a scarf on the navel for one hour, (g) taking the gum of mountain pistachio tree which is the same as turpentine and halve a walnut and fill it with raw turpentine and put it inside the navel for 72 hours, and then move it in the umbilical region by twisting hand movements, (h)cupping therapy.
224005695|NCT02083107|DRUG|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
224005696|NCT02083107|OTHER|Placebo|
224005697|NCT04725877|BIOLOGICAL|VIR-1111|VIR-1111 is administered as a 1 mL subcutaneous injection in the deltoid area of the upper arm on Day 1 and Day 57.
224005698|NCT04725877|DRUG|Placebo|A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
224005699|NCT02504983|DRUG|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
224005700|NCT02504983|PROCEDURE|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
224005701|NCT01056900|PROCEDURE|Autologous Chondrocyte Implantation|"* Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
224005702|NCT01115127|DIETARY_SUPPLEMENT|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
224005703|NCT01115127|DIETARY_SUPPLEMENT|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
224005704|NCT01115127|DIETARY_SUPPLEMENT|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
224005705|NCT00310934|DRUG|methadone|
224005706|NCT00310934|DRUG|buprenorphine / methadone sequence|
224005707|NCT00310934|BEHAVIORAL|Relapse prevention|
224005708|NCT00310934|BEHAVIORAL|Contingency management|
224005709|NCT04023773|DEVICE|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
224005710|NCT02468219|BEHAVIORAL|cardiovascular rehabilitation program|"Phase I: 2-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at hospital).~Phase II: 6-weeks of respiratory muscle training and neuromuscular electrical stimulation (daily at home).~Phase III: 8-weeks of supervised, structured, combined aerobic and resistance training."
224005711|NCT05922059|DEVICE|Transcutaneous vagus nerve stimulation|Auricular transcutaneous vagus nerve stimulation will be used in the left cavity of the external ear with a stimulation frequency of 20-30 Hz for half hour. Monophasic rectangular waveforms will be used, and the intensity will be adjusted below the patient's pain threshold.
224005712|NCT05922059|DEVICE|Heart rate variability biofeedback|The patient will receive visual HRV feedback during resonance frequency breathing. Finally, the patient will be instructed to maximize their peak-to-peak HRV and attain the phase between respiration and HRV changes as closely as possible
224005713|NCT05922059|OTHER|Standard-care physiotherapy|consists of cervical mobilization on the painful segment, isometric exercise for neck flexors, and a combination of strengthening and stretching exercises from sitting position; cervical extensors strengthening exercise using red color Thera-band and stretching exercises upper trapezius of the painful side.
224005714|NCT00215137|DRUG|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
224005715|NCT00215137|DRUG|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
224005716|NCT00082875|DRUG|cilengitide|Given IV
224005717|NCT00082875|OTHER|pharmacological study|Correlative studies
224005718|NCT00082875|OTHER|laboratory biomarker analysis|Correlative studies
224005719|NCT03154853|OTHER|Behavioral: short foot exercise|Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
224005720|NCT03392259|BEHAVIORAL|Smartphone app|Installment and use of smartphone app
224005721|NCT01948700|BEHAVIORAL|Motivational Interviewing|
224005722|NCT01948700|OTHER|Education|
224005723|NCT01241487|DRUG|valsartan/amlodipine|160/10 mg
224005724|NCT02754739|DRUG|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
224005725|NCT02754739|DRUG|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
224005726|NCT02754739|BEHAVIORAL|Nutritional education only|Only nutritional education by a nutritionist
224005727|NCT05180331|BEHAVIORAL|Mobile Application to Prevent Suicide (MAPS)|Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
224005728|NCT00296985|DEVICE|Fresenius Cellsaver|
224005729|NCT00336700|DRUG|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
224005730|NCT00336700|DRUG|Erlotinib|150 mg/d Daily, oral 12 months
224005731|NCT04458805|DRUG|NX-13 250 mg|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
224125281|NCT01831934|BIOLOGICAL|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
224125282|NCT00436969|DEVICE|Orthovisc|Orthovisc injection
224125283|NCT00436969|DRUG|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
224005732|NCT04458805|DRUG|Placebo|"Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days."
224005733|NCT02644395|DRUG|Chlorthalidone|Drug
224005734|NCT02644395|DRUG|Amlodipine|Drug
224005735|NCT00244998|DRUG|fulvestrant|IM
224005736|NCT02655068|OTHER|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
224005737|NCT02655068|OTHER|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings"
224005738|NCT05684263|OTHER|Weight Science Educational Video|Educational videos on the topic of weight science created by a registered clinical psychologist.
224005739|NCT05684263|OTHER|Healthy Eating Educational Video|Educational videos on the topic of healthy eating created by a registered clinical psychologist.
224005740|NCT05684263|OTHER|Healthy Sleep Educational Video|Educational videos on the topic of healthy sleep created by a registered clinical psychologist.
224125284|NCT03020758|DIETARY_SUPPLEMENT|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
224125285|NCT03020758|OTHER|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
224125286|NCT01601054|DEVICE|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
224125287|NCT03838172|OTHER|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
224125288|NCT01223872|OTHER|interview|"* Standard Interview (2-15 years from last treatment)~* Demographic data interview (pre-initial study interview)"
224005741|NCT01320059|DRUG|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
224125289|NCT01223872|OTHER|clinic visit and interview|"* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
224125290|NCT01223872|OTHER|interviews and clinic visit|"* Pre-REACH Clinic Interview(2-15 yrs from last treatment)~* REACH Clinic Visit(initial or regular)~* Post-REACH Clinic Interview(1mo from initial clinic visit)~* Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~* Demographic data interview(pre-initial study interview)"
224125291|NCT03085641|DEVICE|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
224125292|NCT05749926|BIOLOGICAL|Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
224125293|NCT05749926|BIOLOGICAL|VidPrevtyn® Beta vaccine (Sanofi/GSK)|A single administration of COVID-19 vaccine will be performed at D0, depending on randomization
224125294|NCT00905307|DRUG|OPC-34712|oral, once daily
224125295|NCT00905307|DRUG|Placebo|Placebo
224125296|NCT00905307|DRUG|Aripiprazole|oral, once daily
224125297|NCT05556733|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4, week 8
224125298|NCT00005117|DRUG|pravastatin|
224125299|NCT03978819|DEVICE|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI\>80 + Remifentanil \>6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
224125300|NCT05255705|OTHER|Observation only|Observation only
224125301|NCT02671695|DRUG|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
224005742|NCT01320059|PROCEDURE|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
224005743|NCT02777138|OTHER|Maintaining a normal daily living lifestyle|participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
224125302|NCT02671695|DRUG|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
224125303|NCT01757782|DRUG|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be \<10% of previous value and SpO2 was not increasing \>5 of previous value) and blood pressure remained stable
224125304|NCT01757782|DRUG|Placebo (distilled water)|Distill water oral
224125305|NCT04060667|COMBINATION_PRODUCT|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
224005744|NCT02844218|OTHER|Age of patient|"* Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~* Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~* Improvement of Treatments Over Time~* Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
224005745|NCT04963790|BEHAVIORAL|Tailored COVID-19 vaccine messages|Survey responses from participants will be aggregated to create hesitant patient segments. Then, specific content messages will be created following the health belief model, in a way that is meaningful to the recipients in the different segments, to persuade them to receive the COVID-19 vaccine.
224005746|NCT04963790|OTHER|Other health messages|Other health messages unrelated to COVID-19 will be sent to participants in the control arm
224005747|NCT03581604|DIAGNOSTIC_TEST|Allergy work-up|Allergy work-up
224005748|NCT03581604|OTHER|Blood samples|Blood samples
224005749|NCT03002220|DRUG|radium-223|Radium-223 at a dose of 55 kBq
224005750|NCT06253078|DRUG|Ciprofol dose 0.4mg/Kg|The initial dose of ciprofol was 0.4mg/Kg for induction in this group.
224005751|NCT06253078|DRUG|Ciprofol dose 0.3mg/Kg|The initial dose of ciprofol was 0.3mg/Kg for induction in this group.
224005752|NCT06253078|DRUG|Ciprofol dose 0.2mg/Kg|The initial dose of ciprofol was 0.2mg/Kg for induction in this group.
224005753|NCT05530759|PROCEDURE|Biopsy Specimen|Undergo collection of tissue samples
224005754|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal swab samples
224005755|NCT05530759|PROCEDURE|Biospecimen Collection|Undergo collection of archived tissue and blood samples
224005756|NCT05530759|OTHER|Medical Chart Review|Review of medical record
224005757|NCT05720845|PROCEDURE|VESPA|Using Ventilatory strategy of prevent atelectasis for General Anesthesia.
224005758|NCT05720845|PROCEDURE|conventional mechanical ventilation|Conventional mechanical ventilation for General Anesthesia.
224125306|NCT00142012|BEHAVIORAL|Nutrition Intervention|
224125307|NCT06053606|DEVICE|cryoablation of atrial fibrillation using only 28 mm size balloon|all applications in all PVs are done with 28 mm balloon
224125308|NCT06053606|DEVICE|cryoablation of atrial fibrillation using expandable balloon (28 / 31 mm)|first applications in LSPV and RSPV are done with 31 mm balloon
224125309|NCT00767156|OTHER|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
224005759|NCT04871854|DRUG|Tocilizumab|patients treated with Tocilizumab for Covid-19 infection
224005760|NCT04871854|DRUG|traditional Covid -19 therapy|patients treated with traditional therapy for Covid-19 infection
224005761|NCT04523428|DRUG|Venetoclax/Acalabrutinib|All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
224005762|NCT03082404|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
224005763|NCT04497064|OTHER|survey|survey asking questions regarding breakfast habits and composition, sports nutrition knowledge and exercise habits
224005764|NCT00371189|DRUG|Placebo|Normal saline.
224005765|NCT00371189|BIOLOGICAL|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10\^8 viral particles (vp)/mL, 10\^9 vp/mL, 10\^10 vp/mL and 10\^11 vp/mL.
224005766|NCT06208449|PROCEDURE|Robotic repair for EA|The paitents with EA were repaired by Da Vinci robot
224005767|NCT06208449|PROCEDURE|Thoracoscopic repair for EA|The patients with EA were repaired by thoracoscopy
224005768|NCT06208449|PROCEDURE|Thoracotomy repair for EA|The patients with EA were repaired by traditional open thoracotomy.
224005769|NCT02812693|DRUG|Imatinib Mesylate|Given PO
224005770|NCT02812693|OTHER|Laboratory Biomarker Analysis|Correlative studies
224005771|NCT02812693|BIOLOGICAL|Pembrolizumab|Given IV
224005772|NCT00926497|OTHER|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
224005773|NCT04630392|OTHER|Treadmill Training|Ten minutes of treadmill walking at 110% self-selected overground walking speed
224125310|NCT00767156|OTHER|Base cream|The subjects use the base cream on the face, twice per day
224125311|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
224125312|NCT00767156|DIETARY_SUPPLEMENT|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
224125313|NCT03420378|DIETARY_SUPPLEMENT|vitamin D|Vitamin D replacement
224125314|NCT00016523|DRUG|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
224125315|NCT00016523|DRUG|Placebo|Started at 5 ppm and could be increased to 10 ppm
224125316|NCT05462769|DEVICE|Percutaneous vascular closure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device
224295905|NCT03484117|BEHAVIORAL|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
224295906|NCT00002752|RADIATION|iodine I 131 monoclonal antibody 81C6|
224295907|NCT00054600|DRUG|Methoxsalen|
224295908|NCT00054600|PROCEDURE|Extracorporeal Photopheresis|
223387024|NCT04720053|DEVICE|Wearable brain sensing wellness device headband system|Brain sensing headband that measures brain activity by detecting electrical impulses created by the brain.
223387025|NCT01091194|OTHER|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
223730128|NCT01396707|DRUG|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~* Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~* Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Oxaliplatin 130 mg/m2 i.v. on day 1"
224005774|NCT04630392|OTHER|Whole Body Vibration & Treadmill Training|Eight bouts of 90 seconds of vibration at 20 Hz and an amplitude of 2 mm on a Galileo Med-L side-to-side-alternating WBV plate (StimDesigns LLC, Carmel, CA, USA) followed by ten minutes of treadmill walking at 110% self selected overground walking speed.
224005775|NCT03107338|DRUG|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
224005776|NCT03107338|OTHER|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
224005777|NCT00127686|DRUG|Dextromethorphan|
224005778|NCT00127686|DRUG|Buckwheat Honey|
224005779|NCT00433212|DEVICE|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
224005780|NCT00433212|DEVICE|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
224005781|NCT03029221|OTHER|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
224005782|NCT03029221|OTHER|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
224295909|NCT04578652|DRUG|Metformin 850 mg oral tablet bid|MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
224005783|NCT03029221|OTHER|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
224005784|NCT05505240|OTHER|Respiratory analysis at cold temperature|Respiratory analysis at an ambient temperature of 18°C
224005785|NCT05505240|OTHER|Respiratory analysis at room temperature|Respiratory analysis at an ambient temperature of 22°C
224005786|NCT05505240|OTHER|Respiratory analysis at thermoneutral temperature|Respiratory analysis at an ambient temperature of 28°C
224005787|NCT05505240|OTHER|Respiratory analysis at hot temperature|Respiratory analysis at an ambient temperature of 38°C
224005788|NCT02294903|PROCEDURE|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
224005789|NCT05709340|OTHER|proprioceptive neuromuscular facilitation exercises|PNF exercises will be done for Masseter, Temporalis, Lateral pterygoid and medial pterygoid muscles. Each contraction will be held for 10 seconds, and each stretch (relaxation phase) will be allowed to continue as long as the muscle tension continued to give away.
224005790|NCT05709340|OTHER|traditional physical therapy treatment|"* Ultrasound: Continuous ultrasound at 1MHZ to temporomandibular joint at 1.0-1.25 W/CM2 for 5 min over each affected TMJ and masseter area, with the mouth in a slightly open position.~* Forward head posture correction exercises including: chin tuck exercise, Strengthening shoulder retractors, stretching of sternocleidomastoid muscle, and Stretching of pectoralis muscle."
224005791|NCT00207610|BEHAVIORAL|Daily iron supplements of 65 mg a day for 3 months|
224005792|NCT00207610|BEHAVIORAL|Universal anemia screening and treatment|
224005793|NCT00207610|BEHAVIORAL|Selective anemia screening and treatment|
224005794|NCT05680038|DRUG|Penpulimab|Penpulimab is a modified PD1 inhibitor, which innovated the use of IgG1 subtype. On the basis of ensuring the stability of the antibody, it eliminated ADCC, ADCP, CDC and other effects that were not conducive to the efficacy of T cells and reduced the effect of ADCR by modifying the Fc segment
224005795|NCT04110704|PROCEDURE|Insertion of transvaginal cerclage|Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
224005796|NCT04252443|OTHER|Evaluation of nurses' knowledge and attitudes about opioid analgesics working in a university hospital|Interventions involving nurses' pharmacological level
223387026|NCT05362604|PROCEDURE|scheduled delivery at a tertiary center|Neonatal units in French hospitals are classified in three levels. The intention is for infants requiring high level care to receive it in a tertiary neonatal unit within the same network when appropriate. In case of known fetal gastro-intestinal artesia, the prenatal care includes obstetric consultation and level 3 ultrasound scheduled every four weeks at our unit until the end of the pregnancy, antenatal consultations with a specialized multidisciplinary team, and an antenatal visit of the birth center to reduce the parental anxiety.
223387027|NCT02497586|RADIATION|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
223730129|NCT05654753|DRUG|active FMT|MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
223730130|NCT05654753|DRUG|Placebo|Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
224005797|NCT04712695|OTHER|Exercise Based Interventions|Proprioception Training Interventions
224005798|NCT03143647|OTHER|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
224005799|NCT01183260|DEVICE|Trabecular Metal Revision Cup|Revision of the acetabular cup
224005800|NCT01183260|DEVICE|Trabecular Metal Modular Cup|Revision of the acetabular cup
224005801|NCT01805453|DRUG|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg\*2/day until the halting for any reason
224005802|NCT01805453|DRUG|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
224005803|NCT05403112|PROCEDURE|Bone ring with open sinus lifting|All patients involved in this study will be divided in to two group each group will receive a different technique of sinus lifting use autogenous bone ring technique with study group and autogenous sticky bone with control group.
224005804|NCT05055505|DIAGNOSTIC_TEST|Take home saliva kits|Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
224005805|NCT06446986|OTHER|Single and Dual-Task Timed Up and Go Test|Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.
224005806|NCT06446986|OTHER|Single and Dual-Task Tandem Walking Test|"The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards"
224005807|NCT06446986|OTHER|Simple Shoulder Test|Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.
224005808|NCT06025760|OTHER|patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness|All patients after ICU admission will be started enteral nutrition through a nasogastric tube within 24-48 hours. The target caloric intake is 25-30 kcal/kg/day. patients in the interventional group will receive 2 gm protein/kg/day, while patients in the control group will receive 1.2 gm protein/kg/day. Quadriceps thickness and Diaphragm thickening fraction will be assessed by ultrasound from the time of admission on days 0, 3, 5, and 7 then weekly till the fourth week.
224005809|NCT03667430|DIETARY_SUPPLEMENT|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
224005810|NCT03667430|DIETARY_SUPPLEMENT|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
224005811|NCT00730275|DRUG|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
224005812|NCT00730275|DRUG|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
224005813|NCT02448433|DEVICE|Phototherapy light-emitting glasses|"The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m\^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls."
224005814|NCT00251901|DRUG|Esomeprazole|
224005815|NCT04326322|DIETARY_SUPPLEMENT|Methionine Intake|Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
224005816|NCT04482309|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
224125317|NCT03007953|BEHAVIORAL|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
223387028|NCT02802410|DEVICE|IQ-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
223387029|NCT02802410|DEVICE|Kinesiotape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
223387030|NCT02802410|OTHER|No-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
223545637|NCT06503822|DEVICE|Long peripheral venous catheter|In this study, patients eligible for admission were subjected to peripheral vein long catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data were collected.
223730131|NCT00878085|DEVICE|Robot Therapy Device|3x a week for 4 weeks
223387031|NCT02283723|OTHER|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
224005817|NCT02631759|DRUG|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
224005818|NCT02631759|DRUG|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~* A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~* Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
223387032|NCT02283723|OTHER|Usual care|While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
223387033|NCT04818125|OTHER|Patients with breast cancer (stage I, II III or IV)|"Blood samples will be collected at different times:~* at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients);~* at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV)~For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study."
224005819|NCT03147703|BEHAVIORAL|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
224005820|NCT03674580|BEHAVIORAL|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
224005821|NCT01417624|OTHER|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
224125318|NCT05174312|DEVICE|Reprieve Decongestion Management System|The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
224125319|NCT05174312|DRUG|Diuretic|Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
223387034|NCT01582035|DRUG|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
223387035|NCT01582035|DRUG|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
223387036|NCT01582035|DRUG|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
223387037|NCT01582035|DRUG|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
224125320|NCT02797041|DRUG|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
224125321|NCT02817542|DEVICE|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
223387038|NCT01582035|DRUG|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
223387039|NCT01582035|DRUG|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
223387040|NCT01582035|DRUG|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
223730132|NCT00878085|BEHAVIORAL|Occupational Therapy|3x a week for 4 weeks
224125322|NCT03438422|DIETARY_SUPPLEMENT|Pollen extract|1 tablet a day
224125323|NCT04575662|RADIATION|STAR Treatment|Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
224125324|NCT03400670|DEVICE|ventilator NCPAP|infants will be randomized into two different NCPAP groups
224125325|NCT00003356|BIOLOGICAL|aldesleukin|
224125326|NCT00003356|BIOLOGICAL|rituximab|
223387041|NCT00750425|DRUG|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
223387042|NCT02016534|DRUG|AMG 337|AMG 337 300mg orally daily.
223387043|NCT03349021|DEVICE|Bougiecap|Treatment of esophagel Stenosis by Bougiecap
223387044|NCT04467502|OTHER|cognitive-behavioral therapy for gambling disorder|6 sessions of cognitive-behavioral therapy for gambling disorder
224005822|NCT02757872|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
223387045|NCT04467502|OTHER|imaginal exposure therapy focus on gambling cues|6 sessions of imaginal exposure therapy focus on gambling cues
223387046|NCT04467502|OTHER|virtual reality exposure therapy focus on gambling cues|6 sessions of virtual reality exposure therapy focus on gambling cues
223387047|NCT01495299|DEVICE|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
224005823|NCT02757872|DRUG|Omega-3 Fatty acids|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\])
224005824|NCT02757872|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
224125327|NCT01904877|BEHAVIORAL|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
224125328|NCT01332929|DRUG|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
224125329|NCT04489524|BEHAVIORAL|individualized counselor-led MI sessions|Intervention consisted of four 60-min in-person sessions of AMI counseling and a packet of self help smoking cessation materials.
224125330|NCT04489524|BEHAVIORAL|general health education session|four in-person 60-min health education sessions and packets of general health self-help information, nutrition, exercise, and the harmful effects of tobacco.
224125331|NCT04489524|BEHAVIORAL|NRT|nicotine replacement therapy
224125332|NCT01554878|PROCEDURE|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
224125333|NCT06302205|OTHER|Physical activity|The home-based training intervention consists of two phases of each three months in duration. It consists of three weekly aerobic training sessions on the one hand, and two weekly training sessions focused on strength, balance, and flexibility on the other hand.
224125334|NCT06302205|OTHER|Sham intervention|2 times a week, flexibility and balance training
224125335|NCT03196297|DRUG|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
223387048|NCT05494996|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet and the five-item relationship satisfaction scale(RS5) .
223387049|NCT02633007|DRUG|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
223387050|NCT02633007|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
223387051|NCT02633007|OTHER|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
223387052|NCT01706406|BEHAVIORAL|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
223387053|NCT05471999|PROCEDURE|surgery|interventional or surgical treatment
224005825|NCT02757872|DIETARY_SUPPLEMENT|Fish oil placebo|Fish oil placebo
224125336|NCT03196297|DRUG|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
224125337|NCT00002706|PROCEDURE|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
224125338|NCT00002706|OTHER|Quality-of-Life Assessment|Ancillary studies
224125339|NCT00002706|PROCEDURE|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
224125340|NCT00829166|DRUG|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
224125341|NCT00829166|DRUG|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
224125342|NCT00829166|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
224125343|NCT02954835|DEVICE|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
224125344|NCT02954835|DEVICE|Traditional Dressing|Sterile gauze dressing secured by tape.
224125345|NCT01635933|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
224125346|NCT01635933|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
224125347|NCT03510663|DRUG|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
224125348|NCT03510663|DRUG|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
224125349|NCT03510663|DRUG|Moxifloxacin|400mg tablet will be administrated once a week.
224125350|NCT03510663|DRUG|Placebos|Placebo will be intravenously administered once a week.
224125351|NCT04942483|DIAGNOSTIC_TEST|Blood eosinophil count|Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
224125352|NCT04942483|DIAGNOSTIC_TEST|Atopic sensitization|Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
223387054|NCT04931693|DRUG|paracetamol|iv post operative analgesia
223387055|NCT04931693|PROCEDURE|modifiedPECs block|sonar guided pectoral nerve block
223387056|NCT04654793|DEVICE|Robot assisted inclined bed treatment and FES|FES was performed at the same time as the robot-assisted inclined bed treatment once a day for 30 minutes, 5 days a week for 4 weeks.
223387057|NCT04654793|DEVICE|conventional inclined bed treatment|conventional inclined bed treatment for 30 minutes once a day for 4 weeks, 5 days a week
223387058|NCT01522911|DEVICE|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
223387059|NCT03258411|DEVICE|Rapid Expansion of palatal suture|
223387060|NCT02764593|DRUG|Nivolumab|Anti-PD-1 targeted immunotherapy
223387061|NCT02764593|DRUG|Cisplatin|Anti-cancer alkylating agent
223387062|NCT02764593|DRUG|Cetuximab|Epidermal Growth Factor Receptor (EGFR) antagonist
223387063|NCT02764593|RADIATION|IMRT|High-precision radiotherapy
223387064|NCT05289505|DEVICE|MUSIC-CARE|This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.
223387065|NCT02716961|DRUG|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
223387066|NCT01942993|DRUG|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
223387067|NCT00977093|OTHER|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
224005826|NCT03652727|DEVICE|ECG-EM Guidance|"ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) \[CE marked device, C. R. Bard, Inc.\].~At the end of procedure, a chest x-ray is performed to assess the PICC position"
224005827|NCT03652727|DEVICE|FX Guidance|"FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position"
223387068|NCT00977093|OTHER|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
224005828|NCT00318162|DRUG|low dose naltrexone|
224125353|NCT04942483|DIAGNOSTIC_TEST|FeNO (offline method)|The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
224005829|NCT00146367|BEHAVIORAL|Active Living Every Day|
224005830|NCT00327262|DRUG|Imatinib|
224125354|NCT04764123|DIAGNOSTIC_TEST|AVNRT mapping|AV annuli mapping during AVNRT
224125355|NCT00110383|BEHAVIORAL|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
224005831|NCT03395262|DIETARY_SUPPLEMENT|Active with caffeine|Novel formula with caffeine
224005832|NCT03395262|DIETARY_SUPPLEMENT|Active without caffeine|Novel formula without caffeine
224125356|NCT00278265|DRUG|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
223387069|NCT01350271|DRUG|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
223387070|NCT01350271|DRUG|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
223387071|NCT01350271|DRUG|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
224005833|NCT03395262|DIETARY_SUPPLEMENT|Placebo|Dextrose placebo
224005834|NCT02653612|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
224005835|NCT02005770|DRUG|Sevoflurane|
224005836|NCT02005770|DRUG|Propofol|
224125357|NCT02965534|DEVICE|Spectacle/Glasses|
224125358|NCT05203133|DIETARY_SUPPLEMENT|Energy Balance|Energy balance phase to elicit weight-maintenance
224005837|NCT03046121|BEHAVIORAL|Family-centered Function-focused Care (Fam-FFC)|"An educational empowerment model for family CGs that includes a care pathway, provided within a social-ecological in-patient framework promoting specialized care to patients with ADRD. The intervention creates an enabling milieu for the person with ADRD through environmental and policy assessment/modification, staff education, unit-based champions, and individualized goal setting that focuses on functional recovery during hospitalization and the immediate post-acute period."
224005838|NCT00910039|DRUG|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
224005839|NCT00910039|OTHER|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
224005840|NCT03151993|DRUG|Recombinant staphylokinase|10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
224005841|NCT03151993|DRUG|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
224005842|NCT00385177|DRUG|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
224005843|NCT00004426|DRUG|gonadotropin releasing hormone|
224005844|NCT00004426|DRUG|leuprolide|
224005845|NCT04221672|DRUG|Terlipressin plus standard care|All the participants received routine care after surgery. Intraoperative 1 mg, and 1 mg q12h from post-operative day 1 through day 4.
224005846|NCT04221672|OTHER|Standard care|All the participants received routine care after surgery only.
224005847|NCT06151093|OTHER|Video-based games intervention|"These games are applied via using Nintendo Wii~1st - 2nd Week Applications~* Basic Step~* Penguin slide (right-left weight transfer)~* Snowball flight (right-left weight transfer)~* Tilt city (right-left weight transfer)~  3rd-4th Week Applications~* Advanced Step~* Snowball flight (right-left weight transfer)~* Penguin slide (right-left weight transfer)~* Table tilt (weight transfer in 4 directions)~  5th-6th Week Applications~* Advanced Step~* Table tilt (weight transfer in 4 directions)~* Balance bubble (weight transfer to 4 directions)~* Ski slalom (weight transfer in 4 directions)"
224005848|NCT06151093|OTHER|Balance exercises|"1st-2nd Week Applications On a flat-hard surface;~* Standing on 2 legs~* Stepping forward and backward (separately for both feet)~* Getting into the tandem position and maintaining the position (separately for both feet)~* Standing on one leg (separately for both feet)~* Weight transfer in four directions~* Taking a step back towards the step~* Stepping on the stability ball~  3rd-4th Week Applications All exercises which applied in 1st and 2nd week are applied on mat.~  5th-6th Week Applications On the balance board;~* Standing on 2 legs~* Stepping forward and backward (separately for both feet)~* Getting into the tandem position and maintaining the position (separately for both feet)~* Standing on one leg (separately for both feet)~* Weight transfer in four directions~* Catching balls thrown by the enforcer"
224005849|NCT01143870|OTHER|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
224005850|NCT06431815|DEVICE|FARAPULSE™ Pulsed Field Ablation System|De-novo pulmonary vein isolation (PVI) will be performed with the FARAPULSE Pulsed Field Ablation (PFA) System.
224005851|NCT02689843|DRUG|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
224005852|NCT02689843|DRUG|Metformin|Metformin 500mg three times daily
224005853|NCT02689843|DRUG|Pioglitazone|Pioglitazone 30mg once daily
224005854|NCT00131729|BEHAVIORAL|Educational programme|
224005855|NCT05705323|BEHAVIORAL|Internet-delivered cognitive behavioral therapy (iCBT)|This CBT is specifically adapted for individuals experiencing tinnitus
224005856|NCT05705323|BEHAVIORAL|Internet-delivered mindfulness-based tinnitus stress reduction (iMBTSR)|This is a mindfulness-based intervention specifically adapted for individuals experiencing tinnitus
224005857|NCT00528619|DRUG|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg\*min/mL until progression or unacceptable toxicity.
224125359|NCT05203133|DIETARY_SUPPLEMENT|Energy Deficit|Energy deficit phase to elicit weight-loss
224125360|NCT05203133|DIETARY_SUPPLEMENT|Baseline Assessment|Free-living assessment of energy status
224125361|NCT00003859|DRUG|carboplatin|
224125362|NCT00003859|DRUG|cyclophosphamide|
224125363|NCT00003859|DRUG|etoposide|
224125364|NCT00003859|DRUG|vincristine sulfate|
224125365|NCT00003859|PROCEDURE|surgical procedure|
224125366|NCT00003859|RADIATION|radiation therapy|
224125367|NCT03061123|OTHER|Questionnaire|
224125368|NCT05436938|COMBINATION_PRODUCT|Jing Si herbal tea liquid packets use|with or without Jing Si herbal tea liquid packets use
224125369|NCT01147315|PROCEDURE|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
224125370|NCT02354170|DRUG|Mifepristone|
224125371|NCT02354170|DRUG|Placebo|
224125372|NCT02431585|DIETARY_SUPPLEMENT|gluten|
224125373|NCT02431585|DIETARY_SUPPLEMENT|placebo|
224125374|NCT02213198|BEHAVIORAL|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
224125375|NCT02213198|BEHAVIORAL|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
223387072|NCT02143128|OTHER|Efficacy Safety Score|Evaluation using the score for postoperative patients
223387073|NCT02143128|OTHER|Verbal Numeric Rating Scale|Patients assessed for postoperative pain using VNRS (0-10)
224005858|NCT05893368|OTHER|Sharing all key aspects associated with the quality of life in a single digital environment|"A digital platform called DNMLAB (DNMLAB) offers the possibility of sharing all key aspects associated with the quality of life in a single digital environment by activating:~* a digital narrative diary in which the patient has the opportunity to share with the multidisciplinary team her needs, critical issues~* report Patient-Reported Outcome Measures (PROMs) aimed at detecting health-related quality of life (i.e. QLQ-C30-B23 EORTC).~* digital narrative diary focused on three main areas of health-related behavior-nutrition, physical activity, and sleep habits-aimed at personalizing and reshaping lifestyle, daily behaviors and, if required, the care pathway.~The patient will be guided by narrative prompts, but at the same time will always be free to share all aspects related to her lifestyle that she deems useful, in addition to those detected, to benefit from a personalized care approach."
224005859|NCT05341401|DRUG|Budesonide MMX|Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis
224005860|NCT05341401|DRUG|Prednisolone|It is a corticosteroid used as a standard therapy for management of ulcerative colitis
224005861|NCT01454687|PROCEDURE|Grafting of Autologous Cultured Revertant Keratinocytes|Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
224005862|NCT05041010|DRUG|Neu2000KWL group|1st infusion of 750mg in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 ± 1 hours, twice a day.
224005863|NCT05041010|DRUG|Placebo group|1st infusion of the same volume of saline in patients receiving endovascular therapy within 12 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 ± 1 hours, twice a day
224005864|NCT06487117|DRUG|Huafu Shengji Ointment|"Huafu Shengji Ointment~1. The experimental group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The experimental group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, Huafu Shengji Ointment is applied topically with a coverage thickness of 1mm, followed by sterile gauze dressing. The dressing is changed every other day. The treatment period is 4-8 weeks."
224005865|NCT06487117|DRUG|ethacridine lactate solution|"ethacridine lactate solution~1. The control group received conventional medical treatment: diabetes-related knowledge education, blood sugar control, blood pressure reduction, blood lipid regulation, antiplatelet drugs, vasodilation, nerve nutrition, and the use of antibiotics.~2. The control group receive local debridement: iodophor disinfection, saline cleaning, removal of necrotic tissue, and wound exposure.~3. After debridement, the wound is cleaned and disinfected with ethacridine lactate solution, then covered and dressed with sterile gauze. The dressing is changed every other day. The treatment period is 4-8 weeks."
224005866|NCT04590157|DEVICE|Low Level Laser Therapy|Laser Acupuncture application on Neurogenic Acupoints: the treatment based upon the use of low power laser light to stimulate acupuncture points
224005867|NCT04590157|OTHER|Pelvic floor muscle training|exercise prodram as follow: from supine lying position with legs slightly apart the patient asked to contract the pelvic muscles as hard as possible and hold for 10 seconds
224005868|NCT06396351|PROCEDURE|Laparoscopic surgery|effect of carbondioxide insufflation on abdominal compliance was evaluated
224005869|NCT03727542|DEVICE|adjustment of atrioventricular delay in DDD packers|Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
223387074|NCT02906670|DRUG|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes or domains on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
224005870|NCT06012227|DIETARY_SUPPLEMENT|kent'erbas cheese study|"Nutritional intervention with kent'erbas pecorino from extensive farming with crossover and industrial pecorino from intensive farming"
224005871|NCT01911390|DIETARY_SUPPLEMENT|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
224005872|NCT01911390|DIETARY_SUPPLEMENT|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
224005873|NCT01911390|DIETARY_SUPPLEMENT|Control arm|No bean or rice bran additive in smoothie or muffin.
223387075|NCT05092789|OTHER|Kinesio taping group|"Participants in this group will receive treatment through standardised therapeutic kinesio taping along with conventional therapy.~Tape will place over the posterior cervical extensor muscle, from insertion to the origin, with the patient's neck in cervical contralateral side-bending and rotation.~Duration of kinesio tape will be of 48 hours with 50-100% tension.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions."
224005874|NCT01911390|DIETARY_SUPPLEMENT|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
224005875|NCT05308706|DEVICE|8 weeks of home based use.|Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.
224005876|NCT01066429|DRUG|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
224005877|NCT00591539|PROCEDURE|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
224005878|NCT00181870|DRUG|carbamazepine ER (Equetro)|
224295910|NCT04578652|DIETARY_SUPPLEMENT|Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.|The first week of treatment will use 1/3 the daily treatment dose; then 2/3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.
224295911|NCT03403166|BEHAVIORAL|DASH diet|Diet intervention
224295912|NCT03403166|BEHAVIORAL|Fruits and vegetables diet|Diet intervention
223387076|NCT05092789|OTHER|Cervical thrust manipulation group|"Participants of this group will receive treatment via cervical thrust manipulation along with conventional therapy.~For mid cervical spine thrust manipulation, the patient will be in supine lying position,with cervical spine in neutral position.~The therapist will cradle the patients head with the other hand. Gentle ipsilateral cervical side flexion and contralateral rotation will introduce until tension will perceive in target tissues at contact point. A high velocity, low amplitude thrust manipulation, will direct upward and medially in direction of subject's contralateral eye.~Participants of this group will also receive conventional therapy which will include:~Hot pack for 10 minutes Stretching exercises of the neck muscles. This intervention protocol is for 6 weeks. The sessions will be given twice a week making it a total of 12 sessions with 1 month follow up."
223387077|NCT05092789|OTHER|Conventional therapy group|"Participants of this group will receive only conventional therapy which will include:~Hot pack for 10 minutes Stretching Exercises of neck muscles. For sternocleidomastoid stretching, the subject will ask to sit or stand facing forward, exhale and slowly turn your head to right, by keeping shoulder relaxed and down,inhale and return to the center, then turn to look at your left shoulder, ask to hold this position for 30 seconds and do 3 repetitions.~For Trapezius stretching, patient is seated upright, therapist then passively move right ear to right shoulder.~This study includes interventional protocol of 6 weeks. The session will be given twice a week making it a total of 12 sessions with 1 month follow up."
223387078|NCT01349192|DRUG|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: \<40kg : 15mg/kg daily for 14 days divided every 12 hours.
223387079|NCT01349192|DRUG|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: \<40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
223387080|NCT01349192|DRUG|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: \< 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
223387081|NCT01349192|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
223387082|NCT01349192|DRUG|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
223387083|NCT01349192|DRUG|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
223387084|NCT01349192|BEHAVIORAL|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks."
224125376|NCT06472505|DEVICE|polyglycolic acid(Neoveil)|This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
224125377|NCT00606697|DRUG|GR205171|10 milligrams (mg)
223387085|NCT03566030|DRUG|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
223387086|NCT03566030|DRUG|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
223387087|NCT04383548|OTHER|hyper immunoglobulins containing anti-Corona VS2 immunoglobulin|Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
223545638|NCT06503822|OTHER|Control group (Short peripheral venous catheter)|In this study, the patients eligible for admission will undergo peripheral venous short catheter puncture according to the operating standards, daily routine maintenance until catheter removal, and relevant data will be collected.
224005879|NCT03174431|DEVICE|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
224005880|NCT03174431|DEVICE|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
224005881|NCT04969315|DRUG|TT-10|TT-10 orally administered BID
224005882|NCT04969315|DRUG|TT-4|TT-4 is orally administered QD
224005883|NCT04208490|OTHER|HN-STAR Intervention|The Head and Neck Survivorship Tool (HN-STAR) is a web-based tool used to assist clinicians in implementing the ACS/ASCO HNC survivorship guidelines.
224125378|NCT00606697|DRUG|GW597599|15 mg
224125379|NCT04844047|OTHER|Exercise|refer to arm descriptors
223545639|NCT02485509|DRUG|VM-1500/Placebo|VM-1500 or Placebo
223545640|NCT01803880|DEVICE|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
223545641|NCT01803880|DEVICE|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
224125380|NCT04844047|OTHER|Exercise|refer to arm descriptors
224138519|NCT03154151|BEHAVIORAL|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
224295913|NCT03403166|BEHAVIORAL|Control diet|Diet intervention
223545642|NCT03685981|OTHER|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
223730133|NCT04683536|PROCEDURE|Obturator nerve blockade|We performed spinal anesthesia combined with ultrasound guided obturator nerve blockade according to the localization of bladder cancer in patients with lateral wall localized non-muscle invasive bladder cancer
224005884|NCT03547739|BEHAVIORAL|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
224005885|NCT03547739|BEHAVIORAL|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
224005886|NCT00558038|DRUG|AST-120|AST-120
224005887|NCT00558038|DRUG|lactulose|lactulose
224005888|NCT06124469|DIAGNOSTIC_TEST|US-guided fine needle aspiration (FNA)|This study enrolled consecutive patients in follow-up for DTC history who underwent US-guided fine needle aspiration (FNA) of the LNs for suspicious metastatic cervical
224005889|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under popliteal sciatic nerve
224005890|NCT05734469|OTHER|Forefoot bone surgery|Elective forefoot bone surgery under an ankle block
224005891|NCT02137889|DRUG|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
224005892|NCT04650139|PROCEDURE|PCI - percutaneous coronary intervention|percutaneous coronary intervention
224005893|NCT02075073|BIOLOGICAL|SB3|
224005894|NCT02075073|BIOLOGICAL|EU sourced Herceptin®|
224005895|NCT02075073|BIOLOGICAL|US sourced Herceptin®|
224005896|NCT01708304|BEHAVIORAL|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
224005897|NCT04473898|OTHER|Aerobic Exercise Training|Aerobic exercises using all body muscles and that one can do on their own after being shown online
224005898|NCT04473898|BEHAVIORAL|Patient Education|Patient education about covid-19 and hygiene education
224005899|NCT04473898|OTHER|Respiratory Exercise Training|Respiratory exercises that one can do on their own after being shown online
224005900|NCT04253873|DRUG|Apatinib|Apatinib mesylate (0-14 days, 500 mg, qd), taken half an hour after a meal (the daily dose should be as much as possible), one week apart, and then given temozolomide (150mg/m2 for 5 Days); every 28 days is a cycle, medication to disease progression, intolerable toxicity, etc.
224005901|NCT00510640|DRUG|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
224005902|NCT05923515|DRUG|JMKX000197|for injection
224005903|NCT05731999|DEVICE|Previct Drugs|Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
224005904|NCT06588855|DRUG|Afimkibart|Participants will receive afimkibart IV followed by afimkibart subcutaneous SC injection.
224005905|NCT06588855|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
224005906|NCT04577456|DEVICE|The Insides System|Novel pump designed to return effluent from the ostomy bag to the distal gut
224005907|NCT00785993|OTHER|Vitrification of oocytes for IVF treatment|
224005908|NCT00785993|OTHER|Protocolary IVF treatment with fresh donor oocytes|
223387088|NCT03749330|BEHAVIORAL|CICU Team And Loved Ones Communicating (CICU TALC)|When the necessary pre-intervention clinical encounters are completed, clinicians will go through the interprofessional team training to improve communication skills and teamwork in developing care plans and communicating with families in family meetings. The first step in the study is co-design of the intervention, so it will evolve as the study continues.
223387089|NCT03364101|DIETARY_SUPPLEMENT|Placebo Capsule|Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.
224005909|NCT00629733|DRUG|RO-14|
224005910|NCT02786550|DRUG|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
224005911|NCT02786550|OTHER|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
224005912|NCT04073446|DEVICE|Spinal Cord Stimulation|Patients eligible for SCS
224005913|NCT04124029|DEVICE|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
224005914|NCT04124029|PROCEDURE|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
224005915|NCT02686684|DRUG|Dimethyl fumarate|
224295914|NCT00930254|PROCEDURE|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
223387090|NCT03364101|DIETARY_SUPPLEMENT|POWEROFF Capsule|blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
224295915|NCT01138865|DEVICE|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
223387091|NCT01973439|OTHER|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
224005916|NCT00540865|BEHAVIORAL|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
224005917|NCT00540865|BEHAVIORAL|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
224005918|NCT02592993|DEVICE|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
224005919|NCT04458129|DRUG|Treatment with polyethylene glycol (Macrogol 4000)|3-month treatment with polyethylene glycol (Macrogol 4000), powder for oral solution, in 4g and 10g sachets. Dosage of 0.7 g/kg/day, with a maximum dose of 20 g/day.
224005920|NCT05922384|DRUG|KL-7SHRNA injection solution|Patients continue to receive HAART throughout treatment until meet the criteria of interruption of HAART.
224005921|NCT02491515|DRUG|Denosumab|every 6 month injection
224005922|NCT02586428|OTHER|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
223387092|NCT01973439|OTHER|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
224005923|NCT04928287|BIOLOGICAL|HB-adMSCs|HB-adMSCs will be administered intravenously to study participants who qualify.
224005924|NCT04928287|OTHER|Placebo|Placebo will be administered intravenously to study participants who qualify.
224005925|NCT06349356|DEVICE|Intense pulsed light with C.STIM device|4 flashes per treatment session
224005926|NCT05527262|BEHAVIORAL|Queen Square Upper Limb Neurorehabilitation Programme|A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
224005927|NCT05527262|DEVICE|Immersive gaming therapy|The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
224005928|NCT00211302|DRUG|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
224125381|NCT06442917|BEHAVIORAL|Breathing Exercise|"32 the Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth was completed before the pregnancy intervention and the VAS was measured. Breathing exercise training and application were carried out during the latent phase process. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made.~During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed every 30 minutes from the beginning of contraction until the end of contraction. During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 15 minutes from the beginning of contraction to the end of contraction."
224138520|NCT03154151|BEHAVIORAL|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
223387093|NCT05474014|PROCEDURE|superior trunk block|Local anesthetic injection will be applied to the superior trunk of the brachial plexus accompanied by ultrasonography.
223387094|NCT05474014|DRUG|intravenous patient-controlled analgesia|Analgesics will be given using a patient-controlled analgesia device.
223387095|NCT01354210|BEHAVIORAL|SMS Text Message Reminder|Daily
223387096|NCT05577559|PROCEDURE|intermediate cervical plexus block|patients will receive bilateral ultrasound guided intermediate cervical plexus block using 15 ml of bupivacaine 0.25% for each side.
223387097|NCT05577559|PROCEDURE|Cervical Erector spinae block|patients will receive bilateral ultrasound guided cervical erector spinae plane block using 15 ml of bupivacaine 0.25% for each side at the level of C6.
223387098|NCT01472861|PROCEDURE|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
223387099|NCT01472861|OTHER|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
223387100|NCT04406428|PROCEDURE|NKI followed by EBD|Needle-knife incision therapy followed by endoscopic bougie dilation
223387101|NCT03365362|DRUG|Long-Term Varenicline|Varenicline tablet x 24 weeks
223387102|NCT03365362|DRUG|Short-Term Varenicline|varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
224005929|NCT05431374|OTHER|Measurement Based Care (MBC)|"Patients in both groups will receive either open-label paroxetine (10-40mg/day) or open-label mirtazapine (7.5-45mg/day), within the therapeutic dosage range recommended by the US Food and Drug Authority (Paxil -Highlights of Prescribing Medication, 2022; Remeron -Highlights of Prescribing Medication, 2022). Paroxetine, a selective serotonin reuptake inhibitor, is chosen because it has been one of the most commonly prescribed antidepressants, and mirtazapine, an alpha-2 antagonist, is chosen because it has a different mechanism of action. The treating psychiatrists will decide which of the antidepressants and dosages to prescribe, as long as they were within the study's recommended dosage ranges.~patients in the MBC group will receive treatment according to a schedule that includes individualized starting dosages, dosage adjustment, and medication changes to minimize side effects, maximize safety, and optimize the therapeutic benefit for each patient."
224005930|NCT05431374|OTHER|Control/Standard-care|Local medical, psychiatric and family medicine services provide routine care according to their clinical judgment and available resources. Standard-care will be ascertained by the participant's treating physician. Research staff will record the nature and intensity of standard-care delivered to each participant. In current practice, MDD patients are not routinely referred for any psychological therapies in Pakistan. Standard-care in Pakistan largely comprises of pharmacotherapy.
223387103|NCT03365362|BEHAVIORAL|Directly Observed Therapy|Varenicline doses are administered by opioid treatment program nurses
223387104|NCT03365362|BEHAVIORAL|Self Administered Therapy|Varenicline doses are self-administered
223387105|NCT05302960|DEVICE|Fitbit|The use of Fitbit sensors to see if activity levels can be improved to track recovery from COVID
223387106|NCT04881474|DRUG|Ibuprofen 800 mg|30-minute lasting iv infusion of 800 mg ibuprofen diluted with 0,9% saline via intravenous route every 6 hours.
223387107|NCT05839444|OTHER|BioPB-01|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
223387108|NCT05839444|OTHER|Placebo|2 sachets/day, one to be taken orally with (4±1 mins prior) at breakfast and one (4±1 mins prior) at dinner
223387109|NCT02352701|DRUG|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
223387110|NCT02352701|DRUG|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
223387111|NCT02352701|DRUG|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
223387112|NCT01275846|DEVICE|Health Guide using AHA heart failure protocols and content|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
223387113|NCT04748640|PROCEDURE|Gamma Knife VIM thalamotomy|Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).
223387114|NCT02262325|RADIATION|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
223387115|NCT02262325|DRUG|cisplatin|Given IV
223387116|NCT02262325|DRUG|etoposide|Given IV
223387117|NCT02262325|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
224005931|NCT03949855|DRUG|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
224005932|NCT03949855|DRUG|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose:~Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously."
224005933|NCT03949855|DRUG|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
223387118|NCT02262325|OTHER|laboratory biomarker analysis|Correlative studies
224005934|NCT04501120|DRUG|Lisaftoclax (APG-2575)|Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.
224005935|NCT04501120|DRUG|Reduced-dose HHT|1mg IV QD on Days 1-14 (28-day cycle).
224005936|NCT04501120|DRUG|standard-dose HHT|2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
223387119|NCT01695616|DRUG|Placebo|
223387120|NCT01695616|DRUG|Active drug|
223730134|NCT02853591|PROCEDURE|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
223730135|NCT03114813|DRUG|Carvedilol|Non-selective beta-blocker as per routine clinical care
224005937|NCT04501120|DRUG|Azacitidine|75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
224005938|NCT04501120|DRUG|Lisaftoclax (APG-2575)|Lisaftoclax (APG-2575) orally once daily for 14 days, every 28 days as a cycle.
224005939|NCT04501120|DRUG|olverembatinib|orally, with meals, QOD, every 28 days as a cycle.
223387121|NCT02815995|DRUG|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
223387122|NCT02815995|DRUG|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
223387123|NCT06494475|DRUG|GBS-NN/NN2 vaccine|Intramuscular injection.
223387124|NCT06494475|DRUG|Tdap vaccine|Intramuscular injection.
223387125|NCT06494475|DRUG|Placebo|Intramuscular injection.
223730136|NCT03114813|OTHER|MRI scan|One hour non-invasive MRI scan
223387126|NCT04507399|BEHAVIORAL|Liquid Model|"To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages."
224005940|NCT02797080|DRUG|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
223387127|NCT01296087|DRUG|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
223387128|NCT01296087|DRUG|Placebo|Matching placebo capsule given once daily on Days 1 to 28
223387129|NCT00795899|DRUG|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
223387130|NCT06550999|PROCEDURE|Laceration repair with adhesive strips|Repair of the patient's facial laceration with adhesive strips
223387131|NCT06550999|PROCEDURE|Laceration repair with sutures|Repair of the patient's facial laceration with sutures
224005941|NCT00768170|DRUG|MK0633|MK0633 (50 mg) Oral, single dose
224005942|NCT05145543|DRUG|Saline 0.9%|0.9 NaCl % (Saline) (5 ml) will be applied
224005943|NCT05145543|DRUG|Levobupivacaine Hydrochloride|0.25 % levobupivacaine (5 ml) will be applied.
224005944|NCT05145543|DRUG|Fentanyl|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
224005945|NCT05145543|DRUG|Dexamethasone|Dexamethasone plus levobupivacaine (5 ml) will be applied.
224125382|NCT06442917|BEHAVIORAL|Affirmation Method|"32 pregnant women who were admitted to the hospital for childbirth and were in the latent phase (0-3 cm) filled out the pre-intervention Pregnant Identifying Characteristics Form, the Short Version of the Self-Efficacy Scale in Childbirth, and the VAS was measured. During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained. During the active phase process (4-7 cm), the Innatal Period Evaluation Form was filled out and the VAS was measured, and the affirmation phrases were repeated and used by the researcher every 30 minutes from the beginning of the contraction until the end of the contraction.~During the transition phase (8-10 cm), the Innatal Period Evaluation Form, the Short Version of the Self-Efficacy Scale in Childbirth were filled out and the VAS was measured, and affirmation sentences and support sentences were said every 15 minutes from the beginning of the contraction to the end of the contraction."
224125383|NCT06442917|BEHAVIORAL|Breathing Exercise and Affirmation Method|During the latent phase, affirmation phrases were shown to the pregnant women and the application was explained and the application was made with breathing exercise training. In this training, the importance of proper breathing was explained and diaphragmatic breathing application was made. During the active phase process (4-7 cm), the Congenital Period Evaluation Form was filled out and the VAS was measured, and diaphragmatic breathing exercise was performed once every 30 minutes from the beginning of contraction to the end of contraction, and the affirmation phrases were repeated and used by the researcher
224125384|NCT00471367|DRUG|AZD4877|intravenous infusion administered twice a week for 2 weeks
224125385|NCT00069082|DRUG|Civamide (Zucapsaicin)|Nasal Solution 0.01%
223387132|NCT05834556|BEHAVIORAL|Prehabilitation|Everyone will participate in a home-based prehab program with individual video sessions with a physiotherapist at 4 time points over a period of 3 weeks. The initial session will take an hour and consist of a subjective and physical assessment followed by an individualized exercise program demonstration and education. Patients will be instructed to complete the exercises independently 3x/week. The second and third sessions will be 30 minutes in duration and will check in on activity progress, the presence of abnormal responses to exercise, review exercise technique, address barriers and facilitators to activity completion as well as provide support and encouragement for the current level of activity. The final session will take 30 minutes and will review exercise progress, presence of abnormal responses to exercise followed by a reassessment of physical function.
223387133|NCT05435027|DRUG|GRT-R912, samRNA-Spikebeta-TCE11|IM injection of GRT-R912. Doses will be decided after safety review of Part A.
224005946|NCT06319885|BEHAVIORAL|Text messaging|Participants receive text messages related to their alcohol consumption.
224005947|NCT02443831|PROCEDURE|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19+CD22 CAR T-cells
224125386|NCT00069082|DRUG|Sodium Chloride|Nasal Solution 10%
223387134|NCT05435027|DRUG|GRT-R914, samRNA-Spikebeta-TCE9|"Part A: 3 microgram (mcg), 10 mcg, or 30 mcg intramuscular (IM) injection of GRT-R914.~Part C: IM injection of GRT-R914. Doses decided after safety review of Part A."
223387135|NCT05435027|DRUG|GRT-R918, samRNA-SpikeOmicron-N-TCE11|IM injection of GRT-R918. Doses will be decided after safety review of Part A.
223387136|NCT02623062|DRUG|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
223387137|NCT02623062|DRUG|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
223387138|NCT01499264|DEVICE|MySkin patch|Hydrogel and polyurethane film
223387139|NCT01499264|DEVICE|Traditional Dressing|Gauze and Patch
223387140|NCT04110015|DEVICE|virtual visual field|Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
223730137|NCT03114813|PROCEDURE|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
224005948|NCT02443831|RADIATION|Total Body Irradiation (TBI)|Participants will receive total body irradiation delivered as a single fraction (2Gy) on day -7 prior to CD19+CD22CAR T-cell infusion.
224005949|NCT02443831|DRUG|Lymphodepletion with Fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -6 to -3 prior to CD19+CD22CAR T-cell infusion.
224005950|NCT02443831|DRUG|Lymphodepletion with Cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -6 to -5 prior to CD19+CD22CAR T-cell infusion.
224125387|NCT02055027|OTHER|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
223387141|NCT05576688|OTHER|Balance|Balance was evaluated with Berg Balance Scale (BBS), Functional Reach Test (FRT), One Leg Stance Test (OLST) and Five-Repeat Sit-and-Stand Test (5STS). BBS consists of 14 functional tasks of increasing difficulty, each scored on a scale ranging from 0 to 4. The maximum possible score is 56, indicating no identifiable balance difficulties. FRT measures the maximum distance that participants can reach forward with their dominant arm raised to 90 degrees without moving their feet, which were positioned 10 cm apart. OLST measures the time one is able to stand on one lower limb without support. The test was repeated for both sides. 5STS assesses the time it takes to get up and sit from the chair five times. Measurements were repeated 3 times and the average duration was calculated as a patient score.
224005951|NCT02443831|BIOLOGICAL|CD19+CD22 CAR T-cells|Dose level 1: 2 doses of 4 x 10\^5 CD19+CD22 CAR T-cells/kg Dose level 2: 2 doses of 1 x 10\^6 CD19+CD22 CAR T-cells/kg given as a split dose as an intravenous injection through a Hickman line or PICC line (peripherally inserted central catheter) on day 0 and day 14.
224005952|NCT06225440|DIETARY_SUPPLEMENT|Levagen+® Palmitoylethanolamide (PEA)|Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
223387142|NCT05576688|OTHER|Trunk control|Trunk control was evaluated with Trunk Impairment Scale (TIS).TIS evaluates static sitting balance, dynamic sitting balance, and trunk coordination on a scale from 0 to 23 points, a higher score indicating a better performance.
223387143|NCT05576688|OTHER|Gait|Gait was evaluated with Dynamic Gait Index (DGI). DGI has 8 items: walking, walking while changing speed, walking while turning the head horizontally and vertically, walking with pivot turn, walking over and around obstacles, and stair climbing. The scoring of the DGI is based on a 4-point scale ranging from 0 to 3, with 0 indicating severe impairment and 3 indicating normal ability. The best performance total score is 24. A low composite DGI score indicates greater impairment in gait.
224005953|NCT06225440|DIETARY_SUPPLEMENT|Placebo|Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
224005954|NCT02638597|DRUG|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
224005955|NCT02638597|BEHAVIORAL|smoking cessation counseling|smoking cessation counseling
224005956|NCT00448942|BEHAVIORAL|Daily bathing with Chlorhexidine based product|
224005957|NCT00493740|PROCEDURE|chocolate cake|
224005958|NCT04035499|BEHAVIORAL|GO-EXCAP Mobile App|A mobile app delivery platform and the EXCAP©® exercise program
224005959|NCT00951015|DRUG|GSK1349572|investigational HIV-1 integrase inhibitor
224005960|NCT00951015|DRUG|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
224005961|NCT02249572|RADIATION|gamma knife radiosurgery|Leksell Perfection model gamma knife.
224005962|NCT04408352|DEVICE|selective bladder denervation using RF energy|RF ablation of the trigone for the treatment of UUI
224005963|NCT02180750|OTHER|Memory Work Therapy|
223387144|NCT05576688|OTHER|Functional mobility|Functional mobility was evaluated with Timed Up and Go Test (TUG). TUG is a test of the time required for an individual to stand up from a chair with armrests, walk 3 m, turn, walk back to the chair, and sit down. The stopwatch timing started when the participant's bottom left the chair and ended when the bottom made contact with the chair after the walk.
224005964|NCT02180750|OTHER|Standard care|Pediatric clinic, ART
224005965|NCT01611597|OTHER|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
224005966|NCT02635893|DRUG|D-Cycloserine|100 mg of Seromycin by mouth will be administered
224005967|NCT02635893|DRUG|Placebo|placebo pill will be administered instead of medication by mouth
224005968|NCT02635893|OTHER|Training|walking around a designated track at different speeds both forward and backward
224005969|NCT02635893|OTHER|Stimulation|magnetic stimulation and electrical stimulation may be applied
224005970|NCT02635893|OTHER|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
224005971|NCT05842499|PROCEDURE|Line Set Strategy|Substrate-guided ablation procedure of atypical atrial flutter
224005972|NCT05842499|PROCEDURE|Conventional strategy|Electrical activation-guided ablation
224005973|NCT01167452|DRUG|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
224005974|NCT02398669|DRUG|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
224295916|NCT01138865|DEVICE|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
224005975|NCT00081575|DRUG|Tigecycline|
224005976|NCT00081575|DRUG|Levofloxacin|
224005977|NCT06541496|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of muscle regions.
224005978|NCT03315013|PROCEDURE|SLATE II|The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
224005979|NCT01208103|BIOLOGICAL|Bevacizumab|Given IV
224005980|NCT01208103|DRUG|Capecitabine|Given PO
224005981|NCT01208103|DRUG|Oxaliplatin|Given CVC
224005982|NCT01766115|DRUG|Telaprevir|HCV Protease Inhibitor
224005983|NCT03819634|DEVICE|Inset II with Lantern Technology|Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
224005984|NCT00305838|DRUG|tamoxifen citrate|
224005985|NCT00305838|OTHER|diagnostic laboratory biomarker analysis|
224005986|NCT01804868|OTHER|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
224005987|NCT01804868|OTHER|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
224005988|NCT03912051|DEVICE|asymmetric balloon|Asymmetric balloon for treatment of intranasal bleeding
224005989|NCT00368342|DRUG|Erythromycin, Azithromycin , Clarithromycin|
224005990|NCT05440253|DEVICE|dry needling|Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.
224005991|NCT05440253|PROCEDURE|ischemic compression|Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
224005992|NCT03128281|BEHAVIORAL|Questionnaires|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete."
224005993|NCT03128281|DEVICE|Conventional Insufflation System (CIS)|CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
224005994|NCT03128281|DEVICE|ConMed AirSeal Insufflation System (AIS) at Low Pressure|AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
224125388|NCT04389476|OTHER|Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)|"Establish standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) for the different tiers of medical staff, patients, and community residents.~Then explore the psychological impact and mental disabilities under the intervention and controlling related factors."
224125389|NCT04743635|DEVICE|Avéli device|Minimally invasive single procedure with the Avéli device for reduction in the appearance of cellulite in the thighs and buttocks.
224125390|NCT06377644|DIAGNOSTIC_TEST|Kinesio taping|Kinesio taping is a physiotherapy method employed to provide support and stability to muscles and joints while allowing freedom of movement (ROM). The elastic nature of kinesio tape closely resembles that of human skin. After application, kinesio tape rebounds, generating a pulling force that acts as the primary stabilizer for the specific area. Physiotherapy treatments often involve a combination of stretching and strengthening exercises, along with electrotherapy modalities. Additionally, Joint mobilization is a form of passive movement in a broad spectrum of exercise used to treat painful and stiff synovial joints.
224125391|NCT06377644|DIAGNOSTIC_TEST|Dry Needling|Dry needling is a minimally invasive technique involving the use of a single filament or acupuncture needle to penetrate painful soft tissue areas. From a neurophysiological standpoint, Dry Needling might stimulate A-delta nerve fibers (group III), which could activate inhibitory dorsal horn interneurons containing enkephalin, leading to pain suppression and relief through opioid mechanisms. (DN) may affect microcirculation. Numerous studies have shown that inserting needles into muscles can increase blood flow in both the skin and the muscle in the treated area. It can lead to an immediate reduction in local and referred pains, as well as enhance range of motion (ROM) and correct muscle activity patterns.
224125392|NCT04002440|COMBINATION_PRODUCT|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
224125393|NCT04002440|DEVICE|HomeChoice PRO|Usual care
224125394|NCT01044277|DRUG|Glutathione supplementation|500 mg, two times daily
224125395|NCT01044277|DRUG|Gluthathione peroxidases|125 mg, two times daily
224125396|NCT01044277|OTHER|Placebo|2 times daily
224125397|NCT00782925|OTHER|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
224125398|NCT00782925|OTHER|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
224125399|NCT00782925|OTHER|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
224125400|NCT03332108|OTHER|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past \[x\] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
224295917|NCT05913466|DRUG|Tranexamic Acid group|Patients in this group will receive 1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline
224295918|NCT05913466|DRUG|Distilled water group|This group will receive 10 mL of distilled water (placebo) in 1 L of irrigation solution sterile wash (glycine).
224005995|NCT03128281|DEVICE|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
224005996|NCT00771992|PROCEDURE|Bronchoscopy|Bronchoscopy with segmental allergen challenge
224005997|NCT04601025|DIETARY_SUPPLEMENT|Yoghurt|200 ml plain full-fat yoghurt
224005998|NCT04601025|DIETARY_SUPPLEMENT|Chickpea+Yoghurt|80 ml plain full-fat yoghurt + 70 gr cooked chickpea
224005999|NCT04601025|DIETARY_SUPPLEMENT|Oat+Yoghurt|80 ml plain full-fat yoghurt + 100 gr cooked oat
224006000|NCT01428427|DRUG|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
224006001|NCT01428427|DRUG|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
224006002|NCT04016012|DIETARY_SUPPLEMENT|Local Zambian Foods|Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site. The packs will be adjusted according to the weight of the participant and daily recommended allowances. Packaging of foodstuffs will be done in the food service lab at the Mukuba University. Instructions on how to prepare and use the food will be given to the participants. All food Items will be labelled diabetic food to avoid intra-household sharing.
223387145|NCT05576688|OTHER|Fear of falling|Fear of falling was evaluated with the Falls Efficacy Scale-International (FES-I). FES-I was used to assess the level of concern about falls during 16 activities of daily living, ranging from basic to more demanding activities including social activities that may contribute to quality of life. It was administered as a self-report questionnaire.
224006003|NCT05769946|DRUG|Hemay005|A PDE-4 inhibitor
224006004|NCT04481698|OTHER|Mesoglycan|Prisma® 30 mg 2 vials i.m./day for the first 5 post-operative days and then Prisma® 50 mg 1 oral tablet twice/day for an additional 30 days
224006005|NCT01169376|GENETIC|DNA analysis|
224006006|NCT01169376|GENETIC|DNA methylation analysis|
223387146|NCT04298944|DIAGNOSTIC_TEST|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
223387147|NCT04298944|DIAGNOSTIC_TEST|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep
223387148|NCT04298944|DIAGNOSTIC_TEST|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
223387149|NCT04298944|BEHAVIORAL|Emotional/ Behavioural assessments|Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
223387150|NCT03632369|DIAGNOSTIC_TEST|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
223387151|NCT00608101|DRUG|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
223387152|NCT00608101|DRUG|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
223387153|NCT06147193|OTHER|with baseline intervention and power training interventions|"Group A (with power training ) was treated with~* squats jump,~* change of direction speed,~* countermovement jump,~* bench press,~* Romanian deadlift~* barbell squats,~* resistance band sprints,~* stair sprints~* weighted sled pulls"
223387154|NCT06147193|OTHER|baseline interventions and without power training interventions|"Group B (without power training) was treated with~* squats jump~* change of direction speed~* countermovement jump~* barbell squats~* resistance band sprints~* stair sprints~* Weighted sled pulls."
223387155|NCT03885986|RADIATION|Ultrasound|role of ultrasound in comparison to magnetic resonance imaging in diagnosis of benign cystic lesions of knee
223387156|NCT00387335|DRUG|sunitinib malate|Given orally
223387157|NCT05583461|PROCEDURE|Positive end-expiratory pressure titration|Positive end-expiratory pressure level
223387158|NCT02481206|DEVICE|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
223387159|NCT03571828|DRUG|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
223387160|NCT03797170|OTHER|Gut microbiota samples|Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy
224006007|NCT01169376|GENETIC|RNA analysis|
224006008|NCT01169376|GENETIC|comparative genomic hybridization|
224006009|NCT01169376|GENETIC|mutation analysis|
224006010|NCT01169376|GENETIC|polymorphism analysis|
224006011|NCT03787342|PROCEDURE|Double Flap Incision|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
224006012|NCT03787342|PROCEDURE|Modified Periosteal Releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
224125401|NCT03332108|OTHER|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
224125402|NCT03382899|BIOLOGICAL|Pegilodecakin|Pegilodecakin plus Pembrolizumab
224125403|NCT03382899|DRUG|Pembrolizumab|Pembrolizumab Alone
224125404|NCT05663996|OTHER|locally applied to the skin|Applying St John's wort oil locally on the knee three times a day for three weeks.
223387161|NCT01901640|DRUG|DA-8159 (Udenafil)|
223387162|NCT02088762|PROCEDURE|surgical excision|comparison of safety margin 1 versus 2 cm
223387163|NCT04681716|OTHER|ELDOA|For Spinal Segment L4-L5 and L5-S1 proper ELDOA position was instructed to the experiment group patients.ELDOA stands for Elongation Longitudinaux Avec Decoaption Osteo Articulaire, or LOADS (Longitudinal Osteo-articular De-coaptation Stretching). ... They can be described as fascial stretch that localizes tension at the level of a specific spinal segmental.
224006013|NCT03787342|PROCEDURE|Coronally Advanced Lingual Flap|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
224006014|NCT03787342|PROCEDURE|Periosteal releasing incision|
223387164|NCT04681716|OTHER|CONVENTIONAL PHYSIOTHERAPY|"Transcutaneous Electrical Nerve Stimulation (TENS):~120Z dual channel TENS unit made in Japan was used in the research. Electrodes of TENS were placed on lumbar region and TENS was given for 15 minutes on Constant mode. Intensity was adjusted according to patient's comfort.~Hot pack was applied on the lumbar region for 10 - 15 minutes.Lumbar Mobilization (CPA) was given on spinous process of L1- L5 vertebrae and L5-S1. For every session given 3 sets of 10 repetitions of each lumbar vertebra was performed."
223387165|NCT05900778|BEHAVIORAL|HABIT-ILE|2 weeks HABIT-ILE
223387166|NCT05900778|BEHAVIORAL|Conventional intervention|2 weeks usual intervention (waitlist group)
223387167|NCT00769379|OTHER|Laboratory Biomarker Analysis|Correlative studies
223387168|NCT00769379|BIOLOGICAL|Trastuzumab|Given IV
223387169|NCT00769379|RADIATION|Whole Breast Irradiation|Undergo standard whole breast irradiation
223387170|NCT05021835|DRUG|Ziltivekimab B|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
223387171|NCT05021835|DRUG|Ziltivekimab C|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
223387172|NCT05021835|DRUG|Placebo (Ziltivekimab B)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
223387173|NCT05021835|DRUG|Placebo (Ziltivekimab C)|Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.
224006015|NCT05976373|DRUG|Dupilumab (SAR231893)|injection solution subcutaneous
224006016|NCT02299947|DRUG|Haemocomplettan P|
224006017|NCT02299947|DRUG|Placebo|
223387174|NCT06440239|DRUG|PMS-101|PMS-101
223387175|NCT06440239|OTHER|Standard treatment|Standard treatment according to physicians
223387176|NCT05514470|OTHER|Skin biopsy|"A skin biopsy performed on the forearm or thigh depending on the patient's age and wishes, with a biopsy punch with a diameter of 3 to 4 mm depending on the child's age (3 for children under 3 years, 4 beyond).~Culture of fibroblasts and immortalization."
223387177|NCT06007716|OTHER|reflexology massage|5 minutes of classic message on the left foot, 15 minutes of reflexology message, and 5 minutes of classic message on the right foot, 15 minutes of reflexology message, a total of 40 minutes of massage. 30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, reflexology massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
224006018|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
224006019|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
224006020|NCT00299494|DRUG|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
224006021|NCT00299494|DRUG|Rituximab|rituximab 375 mg/m\^2 via IV infusion on Day 1
224006022|NCT03247868|COMBINATION_PRODUCT|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
224006023|NCT02764047|DIETARY_SUPPLEMENT|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
224006024|NCT04957147|OTHER|12 months of guideline-directed heart failure therapy|Standard guideline-directed heart failure drug +/- device therapy
224006025|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
224006026|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
224006027|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
224125405|NCT05663996|OTHER|locally applied to the skin|Applying olive oil locally on the knee three times a day for three weeks.
224125406|NCT03387124|OTHER|Breastfed infants|Breastmilk
223387178|NCT06007716|OTHER|Placebo massage|Placebo reflexology massage was applied to each foot for 20 minutes, for a total of 40 minutes.30 minutes after the massage, evaluation was recorded with the Vital Signs Registration Form, McGill Pain Scale Short Form, State Anxiety Inventory, General Comfort Scale Short Form, and Fatigue and Quality Sleep Visual Comparison Scale. Thus, Placebo massage is performed once a day for each patient for 2 consecutive days, for a total of 2 sessions.
223730138|NCT05295043|DRUG|(CDK)4/6 inhibitor|CDK4/6 inhibitor + AI/fulvestrant therapy，According to clinical guidelines or drug instructions, the treating physician will adjust the drug dose in accordance with the clinical reality and the patient's personal situation.
223730139|NCT05158933|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223730140|NCT05016973|DRUG|RC48-ADC|2.0mg/kg, Intravenous drip on days 1 every 21 days
224006028|NCT00383539|BIOLOGICAL|Inactivated Split-virion influenza vaccine|Control Vaccine
224006029|NCT05109767|DEVICE|Virtual reality|The Virtual Reality Glass game application reduces anxiety by distracting attention..The virtual reality glass game was played to intervention group for 15 minutes before surgery.
224006030|NCT05109767|DEVICE|Smartphone|The Smartphone game application reduces anxiety by distracting attention. Smartphone game was played to intervention group for 15 minutes before surgery.
224006031|NCT00416195|DRUG|E2007|
224006032|NCT00416195|DRUG|Placebo|
224006033|NCT00033618|DRUG|ixabepilone|Given IV
224006034|NCT00033618|OTHER|laboratory biomarker analysis|Correlative studies
224006035|NCT01882764|DRUG|HMPL-004|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.
224125407|NCT04249141|OTHER|Survey and concept mapping|ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
224125408|NCT05557890|BEHAVIORAL|System Constellation VR-Seminar|individual-centered intervention in a group VR-setting, duration 2 to 3 days
223387179|NCT01795417|DEVICE|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
223387180|NCT01795417|DEVICE|XP200 RF device|4 RF treatments of periorbital region on one side of the face
223387181|NCT02770482|BIOLOGICAL|spinal fluid collection|
223387182|NCT04632576|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will given.
223387183|NCT06368011|BEHAVIORAL|acceptance and commitment therapy|Psychoeducation was delivered in 8 sessions lasting 90 minutes to two separate groups of 8-10 individuals in the experimental group.Group sessions were conducted once a week at the community mental health center under the leadership of the researcher.In total, the psychoeducation lasted 10 weeks, including make-up sessions.
224006036|NCT01882764|DRUG|Placebo|Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.
224006037|NCT04347057|OTHER|Bed bathing with 2% CHG solution|Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with CHG solution for each period. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions.
224006038|NCT04347057|OTHER|Bed bathing with soap and water|Patients were bathed from the neck down, avoiding contact with face, mucous membranes and wounds by wiping with soap and water. The patient's skin bathed in the order of clean area to dirty area. Additionally, if patients in both arms became soiled after the daily baths, contaminated body areas were wiped using water and disposable washcloths. Patients were assessed daily for localised or body-wide skin reactions. During control period, patients were washed with soap and then rinsed with water, and dried with disposable towels
224006039|NCT02372838|PROCEDURE|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
224006040|NCT02089568|DRUG|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
224006041|NCT02089568|DRUG|Normal Saline|Placebo - 0.9% saline
224006042|NCT00733252|PROCEDURE|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
224006043|NCT00733252|PROCEDURE|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
224138521|NCT05221788|PROCEDURE|Goal-directed hemodynamic therapy|Compounded sodium lactate 3 ml/kg/h was given intravenously as a basal rehydration volume before induction, and 200 ml of electrolyte solution was given after induction. If SV increased \>10%, 200 ml of electrolyte solution was continued until SV increased \<10%. After fluid shock, if SV increases \<10% but mean arterial pressure (MAP) \<65 mmHg and/or cardiac index (CI) \<2.5l/min/m2 give low-dose norepinephrine continuous pumping and/or dobutamine continuous pumping. If hypotension was accompanied by hypovolemia (defined as urine output \<0.5 ml /kg/h and/or heart rate more than 20% above baseline), plasma was administered until urine output and/or HR returned to normal. Fluid responsiveness and hemodynamic variables were reassessed at least every 15 minutes, and more frequently in cases of hemodynamic instability.
223387184|NCT06184945|BEHAVIORAL|Realtime audit and feedback|ICUs randomized to this arm will receive and electronic dashboard that displays realtime ABCDEF bundle performance data
223387185|NCT06184945|BEHAVIORAL|RN Implementation Facilitator|ICUs randomized to this arm will receive a RN who will assist with ABCDEF bundle implementation
223387186|NCT02671929|BEHAVIORAL|self-help program|Access to the internet-based self-help program
223387187|NCT02671929|BEHAVIORAL|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
223387188|NCT03875924|OTHER|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
223387189|NCT03404674|BIOLOGICAL|CssBA|Recombinant enterotoxigenic Escherichia coli (ETEC) surface antigen 6 containing modified structural subunits A and B
223387190|NCT03404674|BIOLOGICAL|dmLT|Escherichia coli double mutant heat-labile toxin with mutations at amino acids 192 and 211
224006044|NCT00733252|PROCEDURE|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
224006045|NCT00733252|PROCEDURE|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
223387191|NCT03091179|DEVICE|THRIVE|active nasal oxygen delivery system
223387192|NCT03091179|DEVICE|Endotracheal tube|a plastic tube for mechanical ventilation
223387193|NCT04459741|DIETARY_SUPPLEMENT|Dietary salt (Sodium chloride)|Dietary salt used was sodium chloride tablets (from the research consolidated midland corporation division, New York, USA) which participants crashed and put in their food and/or ingested. Each tablet weighed one (1) gram and contained 394 mg of sodium and 606 mg of chloride.
223387194|NCT01311323|PROCEDURE|PCI|Percutaneous Coronary Intervention with contemporary drug eluting stent, fractional flow reserve or iFR measurement and optimisation with intravascular imaging
223387195|NCT01311323|PROCEDURE|CABG|Coronary Artery Bypass Graft
223387196|NCT03904290|OTHER|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
223387197|NCT00523939|DRUG|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
223387198|NCT00717717|BEHAVIORAL|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
223425649|NCT03724903|PROCEDURE|Ductal lavage|The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
223730141|NCT05016973|DRUG|Triplizumab|240mg, Intravenous drip on days 1 every 21 days
223387199|NCT06488287|DEVICE|Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). The 2mA continuous current will be applied during the active stimulation condition via gradual ramps that start and stop after 30 seconds of stimulation (current ramps). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
224006046|NCT01538966|DRUG|Pegvisomant|
224006047|NCT01538966|DRUG|Octreotide LAR|
224006048|NCT01538966|DRUG|Lanreotide|
224125409|NCT04350658|PROCEDURE|Transcatheter aortic valve implantation required for symptomatic aortic stenosis|The procedure is performed via transfemoral or transcarotid access; Patients were confirmed to be eligible for TAVR by a multidisciplinary heart team including at least an interventional cardiologist, a cardiothoracic surgeon and an anesthetist. All TAVR implantation procedures were performed with the Edwards SAPIEN 3 THV or the MEDTRONIC CoreValve EVOLUT . For all patients, both vascular access and aortic valve were evaluated before the procedure by multislice computerized tomographic angiography (MSCT) of the entire aorta using vascular windows settings. The prosthesis and the vascular access were left to the discretion of the operating team. Transfemoral access was the first choice when possible. All TAVR procedures were performed in the same hybrid room (in Montpellier University Hospital), Most TAVR were performed under sedation or general anesthesia using mild low profile 14-16 French delivery systems and using percutaneous or surgical vascular access.
224125410|NCT04527016|PROCEDURE|Microbiota and eosinophils based therapy|"1. Blood eosinophils ≥3%+ mixed airway microbiota: 3 month course of FP 50 ug twice daily via spacer~2. Blood eosinophils\<3%+ Moraxella species\>40% in airway microbiota: Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~3. Blood eosinophils ≥3%+ Moraxella species\>40% in airway microbiota: 3 month course of FP 50 ug twice daily via spacer and Azithromycin 10mg/kg per day for 3 consecutive days a week for 4 weeks;~4. Blood eosinophils\<3%+ mixed airway microbiota: intermittent budesonide inhalation suspension (1mg twice daily) and terbutaline inhalation suspension for 7 days during wheeze episode.~The participants will be followed up for one year after the intervention."
224138522|NCT06169930|OTHER|This was an observational study without any intervention|This was an observational study without any intervention
224138523|NCT05957497|BIOLOGICAL|Biological samples transport and analysis|Biological samples transport and analysis
223387200|NCT06488287|DEVICE|sham Transcranial direct current stimulation (brain stimulation)|The intervention will be applied using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise left DLPFC anodal or sham stimulation. The reference (cathodal) electrode will be placed over the right supraorbital ridge, and the anodal electrode will be placed over the region corresponding to the left DLPFC (F3 of the EEG10-20 international system). For sham stimulation, the electrodes will remain in place for the whole session, but the current will only be applied for the first 36 seconds of the stimulation. Each tDCS session will last for 20 minutes.
223387201|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
223387202|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
223387203|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
223387204|NCT00954343|PROCEDURE|Extracorporeal Shock Wave|
223387205|NCT02770378|DRUG|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
223387206|NCT02770378|DRUG|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
223387207|NCT02770378|DRUG|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
223387208|NCT02770378|DRUG|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
223387209|NCT02770378|DRUG|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
223387210|NCT02770378|DRUG|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
224006049|NCT00526253|BIOLOGICAL|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
224006050|NCT00526253|BIOLOGICAL|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
224006051|NCT00526253|PROCEDURE|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
224006052|NCT02283476|DRUG|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
224006053|NCT02283476|DRUG|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
224006054|NCT02283476|DRUG|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
224006055|NCT02283476|DRUG|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
224006056|NCT00451724|DRUG|Intranasal ketamine|
224006057|NCT01417104|DRUG|Aliskiren|150 mg/300mg
224006058|NCT01417104|DRUG|Placebo|150mg/300mg
224006059|NCT04149431|DRUG|Derinat|desoxyribonucleate sodium
224006060|NCT03335657|OTHER|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
224006061|NCT03335657|OTHER|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
223387211|NCT02770378|DRUG|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
224006062|NCT02727855|BIOLOGICAL|Shanchol|Oral Cholera Vaccine
224006063|NCT03225690|DRUG|Morphine|Prevention of remifentanil induced hyperalgesia
224006064|NCT03225690|DRUG|Serum physiologic|For placebo, serum physiologic will use
224006065|NCT04823676|DIETARY_SUPPLEMENT|Probiotic composition|Mixture of two Lactoplantibacillus plantarum strains (formerly Lactobacillus plantarum) and one Levilactobacillus brevis strain (formerly Lactobacillus brevis), in a maltodextrin carrier (E1400)
224006066|NCT04823676|OTHER|Placebo|Maltodextrin (E1400, qs)
224006067|NCT05775172|PROCEDURE|Sleeve gastrectomy|laparoscopic sleeve gastrectomy was done under general anesthesia by the same surgeon in the SBAHC. Routine preoperative, and postoperative care (including early post-operative dietary management) were done. Baseline assessment was taken within the last week before the surgery during the preoperative preparation and the final assessment was recorded 6 months after the surgery date.
224006068|NCT05775172|DIETARY_SUPPLEMENT|Lifestyle intervention|balanced 500 to 1000-calorie-deficit diet, personalized physical activity plan, and customized behavioral modification
224006069|NCT05775172|OTHER|Control|No interventions were applied
223730142|NCT06221540|BEHAVIORAL|"Myth busting information leaflet"|A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
224006070|NCT03042923|DRUG|lactulose:mannitol (L:M) oral challenge|
224006071|NCT05150977|OTHER|Polysomnography|Reviewing collected data
224125411|NCT04527016|DRUG|Clinical guidelines based therapy|"The children will be treated as directed by their paediatrician ( The clinical practice is based on the guideline for the diagnosis and optimal management of asthma in children of China 2016).The treatment protocols include:~1. regular inhaled FP 50 ug twice daily via spacer for 3 months;~2. montelukast(4mg od for 3 months)~3. intermittent budesonide inhalation suspension (1mg twice daily for 7 days during wheeze episode).~The participants will be followed up for one year after the intervention."
224125412|NCT02915861|OTHER|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
224125413|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
224125414|NCT02915861|OTHER|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
223387212|NCT02770378|DRUG|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
224006072|NCT04708951|DEVICE|ENDOCUFF VISION® device|ENDOCUFF VISION® is a disposable cap placed on the tip of a standard colonoscope, intended to flatten colonic folds and assist in controlling the colonoscope's field of view and tip positioning
224006073|NCT04708951|DEVICE|G-EYE® colonoscope|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning
224006074|NCT00909831|DRUG|hydroxychloroquine|
223387213|NCT02770378|DRUG|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
224006075|NCT00909831|DRUG|temsirolimus|
224006076|NCT00909831|OTHER|electron microscopy|
224006077|NCT00909831|OTHER|high performance liquid chromatography|
224006078|NCT00909831|OTHER|immunologic technique|
224006079|NCT00909831|OTHER|laboratory biomarker analysis|
223387214|NCT02770378|DRUG|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
223387215|NCT06817590|DRUG|deoxycytidine|Oral administration, in combination with deoxythymidine
223387216|NCT06817590|DRUG|deoxythymidine|Oral administration, in combination with deoxycytidine
223730143|NCT06214104|BEHAVIORAL|Acupressur|Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
223730144|NCT01051024|DIETARY_SUPPLEMENT|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
224006080|NCT00909831|OTHER|mass spectrometry|
224006081|NCT00909831|OTHER|pharmacological study|
224006082|NCT00909831|PROCEDURE|autophagy inhibition therapy|
224006083|NCT05090670|OTHER|Incrediwear Germanium-Embedded Knee Brace following Knee Arthroscopy|Germanium-Embedded Knee Brace will be applied to the effected limb following Knee Arthroscopy
224006084|NCT05090670|OTHER|Replica Knee Brace|Replica Knee brace will be applied to the effected limb following Knee Arthroscopy
224006085|NCT00377689|BEHAVIORAL|high intensity functional exercise|high intensity functional exercise
224006086|NCT02760095|DRUG|3 mg zinc sulfate supplement|
224006087|NCT02760095|DRUG|0.5 mg of 13C10-retinyl-acetate|
224006088|NCT01305408|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
224006089|NCT01305408|DRUG|Placebo|Matching placebo tablets, taken orally, once daily in the morning
224006090|NCT02899351|DEVICE|Respiratory Volume Monitor|
224006091|NCT01589159|DRUG|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
224006092|NCT01589159|DRUG|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
224125415|NCT02915861|OTHER|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
224125416|NCT03524677|DIAGNOSTIC_TEST|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
223387217|NCT06991205|BEHAVIORAL|Web-TIRELESS|This is a self-administered web-based intervention that consists of 4 on-demand sessions, each \~30 minutes long, that teach mind-body skills, cognitive-behavioral strategies (e.g., reframing, pain and substance use urge surfing), activity pacing, acceptance and commitment skills, and psychoeducation on the association between substance use and pain. The program aims to increase patients' physical and emotional functioning and decrease pain intensity and maladaptive substance use behaviors.
223387218|NCT06991205|OTHER|Web-MEUC|An educational information web-based pamphlet, containing brief, summarized information tailored for the respective patient population that follows topics including the trajectory of pain and adaptation after non-traumatic painful upper extremity conditions, the role of relaxation strategies to manage pain, and the importance of returning to engagement in activities of daily living.
224006093|NCT02864277|PROCEDURE|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
224125417|NCT01231633|DRUG|Ozurdex|Ozurdex, 0.7mg dexamethasone
224125418|NCT01231633|DRUG|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
224125419|NCT04016883|OTHER|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model.
224125420|NCT04016883|OTHER|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
223387219|NCT01954862|OTHER|Air Insufflation method.|Air Insufflation method.
223387220|NCT01954862|OTHER|CO2 insufflation|CO2 insufflation.
223387221|NCT01954862|OTHER|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
223387222|NCT01954862|OTHER|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
223387223|NCT01954862|OTHER|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
223387224|NCT01954862|OTHER|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
223387225|NCT04323943|DEVICE|Ankle Foot orthosis (AFO)|"The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed"
223387226|NCT06860542|DRUG|Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care|Budesonide (Pulmicort® Turbuhaler®) 800ug inhaled twice daily (BID) will be taken in addition to usual care for 36 weeks.
223387227|NCT06860542|OTHER|Arm 1- Usual care|The comparison arm will be usual care (UC) for Checkpoint inhibitor pneumonitis (CIP) (steroids).
224006094|NCT02864277|PROCEDURE|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
224006095|NCT01075295|BEHAVIORAL|Behavioural Intervention for the Prevention of Weight Gain|"The intervention consists of four steps:~* STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~* STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake \& physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~* STEP 3 (Nutrition \& Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~* STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)"
224006096|NCT01075295|OTHER|TAU|Treatment as provided by individuals' existing healthcare providers
224006097|NCT04523753|PROCEDURE|emergency endoscopy|emergency endoscopy for gastrointestinal bleeding situation before or after surgery
224006098|NCT01315470|DRUG|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
224006099|NCT03101462|BIOLOGICAL|Inactivated Influenza Vaccine|
224006100|NCT03101462|BIOLOGICAL|Live Attenuated Influenza Vaccine|
224006101|NCT05017428|DIETARY_SUPPLEMENT|Spermidine|Spermidine in the form of a 0.1% spermidine wheat germ extract
224006102|NCT05017428|DIETARY_SUPPLEMENT|Nicotinamide|Nicotinamide given as niacinamide
224006103|NCT05017428|DIETARY_SUPPLEMENT|PEA|Palmitoylethanolamide given at 98% purity
224006104|NCT05017428|DIETARY_SUPPLEMENT|OEA|Oleoylehtanolamide given at 90% purity
224006105|NCT05017428|DIETARY_SUPPLEMENT|Wheat Flour|Wheat flour given as a placebo control
224125421|NCT00148460|DRUG|TNK-tPA|
224125422|NCT00148460|DRUG|rt-PA|
224125423|NCT04154267|PROCEDURE|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
224125424|NCT06050863|BIOLOGICAL|silk fibroin|silk fibroin extracted from bombyx mori silk worm is processed in laboratory to form silk fibroin films
224125425|NCT06050863|DRUG|Chlorhexidin|chlorhexidine is used
224125426|NCT06050863|BIOLOGICAL|combination of silk fibroin and chlorhexidine|combination of silk fibroin and chlorhexidine is used
224125427|NCT03736746|BEHAVIORAL|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
224006106|NCT05269953|DEVICE|Active stimulation|Participants assigned to the active stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 120% the intensity needed to produce a visible contraction within the thenar muscle.
223387228|NCT06993792|DRUG|Orforglipron|Administered orally
223387229|NCT06993792|DRUG|Placebo|Administered orally
223387230|NCT06541379|OTHER|No intervention|
223387231|NCT03869957|DIETARY_SUPPLEMENT|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
223387232|NCT05027204|DRUG|Docetaxel|Docetaxel for Injection (Albumin-bound), Q3W, i.v. 60 min
223387233|NCT05027204|DRUG|Nivolumab|Nivolumab, Q3W, i.v. 30 min
224006107|NCT05269953|DEVICE|Sham stimulation|Participants assigned to the sham stimulation arm will receive rhythmic MNS 2 minutes on and 1 minute off for 15 minutes. The strength of the stimulation will be set to 50% the intensity needed to produce a visible contraction within the thenar muscle.
224006108|NCT04391998|DRUG|Iron Supplement|oral tablet twice daily after meals
224006109|NCT04391998|DRUG|Metronidazole Oral|500 mg oral twice daily
224006110|NCT04391998|DRUG|Albendazole|200 mg oral single dose
224006111|NCT02699138|DRUG|Trazodone|100mg of trazodone to be administered orally once.
224006112|NCT02699138|DRUG|Placebo|Compounded sugar pill
224006113|NCT02699138|DEVICE|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
224006114|NCT03156192|BEHAVIORAL|Survey|Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
224006115|NCT00582413|BEHAVIORAL|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
223387234|NCT06598943|DRUG|Eltrekibart|Administered
223387235|NCT06598943|DRUG|Mirikizumab|Administered
223387236|NCT06598943|DRUG|Placebo|Administered
223387237|NCT06528314|DRUG|Efruxifermin|Administered by subcutaneous injection
223387238|NCT06528314|DRUG|Placebo|Administered by subcutaneous injection
224006116|NCT02119442|DEVICE|Transcather Valve Implantation|Transcather Valve Implantation
224006117|NCT04875299|OTHER|The study is observational|The study is observational
224006118|NCT02770612|OTHER|Prescribed opioids|Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
224006119|NCT01223547|OTHER|Education|Participants are taught the principles of carb counting
224006120|NCT01223547|OTHER|Education|Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
224006121|NCT01367470|DIETARY_SUPPLEMENT|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
224006122|NCT01367470|OTHER|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
223387239|NCT06069583|BEHAVIORAL|Support platform|"The study will be conducted over a 12-month period. This should allow participants to see their medical team 2 to 3 times during this timeframe. Participants of arms 1 and 2 will have access to the Support platform and will receive a monthly newsletter, informing them of news on the platform and acting as a reminder to log in. Several features are included in this responsive-designed platform to enhance participation, such as a visual of personal progress, ability to bookmark content, change their avatar.~Support contains 3 main components: Educational material, News blog written by HCPs weekly in collaboration with patient-partners on up-to-date topics related to T1D, a peer-to-peer discussion forum which is moderated daily by a HCP specializing in T1D."
223387240|NCT05016739|DEVICE|CADISS|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5~2. Reusable stainless steel non-cutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
223387241|NCT06672549|DRUG|Orforglipron|Administered orally. ISA specific interventions will be listed in the ISA.
223387242|NCT06672549|DRUG|Placebo|Administered orally. ISA specific interventions will be listed in the ISA.
223425650|NCT03724903|DRUG|Corticosteroid therapy|Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
224006123|NCT05816772|DRUG|Endosequence Bio ceramic Sealer|Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide
224006124|NCT05816772|DRUG|Sealapex Calcium hydroxide Based Sealer|KERR Dental, an original eugenol-free root canal sealant based on calcium hydroxide.
224006125|NCT04213742|OTHER|Thanksgiving diary intervention|Record gratitude.
224006126|NCT04365231|DRUG|Hydroxychloroquine and azithromycin treatment|"hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~\- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days."
224006127|NCT04365231|OTHER|conventional management of patients|conventional management of patients
224006128|NCT03599102|BEHAVIORAL|LOVED Intervention|
224006129|NCT02060877|OTHER|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
224006130|NCT00417742|BEHAVIORAL|Service delivery through a Headache Management Program|
224006131|NCT01492153|DRUG|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
224006132|NCT01492153|DRUG|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
224006133|NCT01492153|DRUG|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
224006134|NCT04646863|RADIATION|laser therapy|performed by MLS® Laser Therapy (ASA Srl, Vicenza, Italy). It is designed to synchronize between two modules. One is emitting at 905 nm, with peak optical power = 25 W; each pulse is composed of a pulse train (single pulse width = 100 ns, maximum frequency 90 kHz). The frequency of the pulse trains varied between 1 and 2000 Hz. The other one is emitting at 808 nm in a continuous mode (power 1.1 W) or pulsed mode (pulses repetition rate 1-2000 Hz).
224006135|NCT04646863|OTHER|exercise|"The exercises were applied on a floor mat to achieve a full body workout with 10 repetitions for each exercise and rest for one minute before beginning the next exercise to avoid muscle fatigue as the following.~1. Modified Hundred~2. Modified Single Leg Stretch~3. One Leg Circle~4. Modified Scissors"
224006136|NCT04646863|OTHER|combination|laser therapy + Pilates exercises
224006137|NCT04080453|OTHER|Septic shock|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
224006138|NCT04080453|OTHER|Systemic Inflammatory Response Syndrome|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
224006139|NCT01005069|DRUG|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
224006140|NCT01005069|DRUG|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
224006141|NCT01005069|DRUG|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
224006142|NCT01005069|DRUG|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
224125428|NCT01975766|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
224125429|NCT01975766|DEVICE|External beam radiation therapy|
223387243|NCT06593860|BEHAVIORAL|Remote speech rehabilitation|Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.
224125430|NCT01259752|DEVICE|compression stockings|compression stockings
224125431|NCT01259752|OTHER|standard non compressive stockings|standard non compressive stockings
223387244|NCT07005284|DRUG|LY3981314|Administered SC
223387245|NCT07005284|DRUG|Placebo|Administered SC
223387246|NCT07128524|DIETARY_SUPPLEMENT|Treatment with Ketone Supplement|Participants (n=25) will receive three doses of a ketone supplement drink daily for seven days.
223387247|NCT07128524|DIETARY_SUPPLEMENT|Treatment with Placebo|Participants (n=25) will receive three doses of a placebo drink for seven days.
224125432|NCT04129684|OTHER|Probiotics|subgingival delivery and lozenges
224125433|NCT05313932|OTHER|Sleep deprivation|Participants wake after six hours so that they are deprived of 2 hours of sleep
224006143|NCT01005069|DRUG|Placebo capsule|Placebo capsules once daily and lifestyle modification
224125434|NCT02514460|DEVICE|plaque excision system|
224125435|NCT02514460|DEVICE|Stent|
224125436|NCT02426658|OTHER|Laboratory Biomarker Analysis|Correlative studies
223387252|NCT06987201|DEVICE|DigiVibe Vibration Anesthesia|DigiVibe Vibration Anesthesia
223387253|NCT03972345|DRUG|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
223387254|NCT07017712|PROCEDURE|Complex esophageal surgery for carcinoma|Appropriate combination of ICD-10 code (C15, C16.0) and medical procedure code (5-423, 5-424, 5-425, 5-426, 5-427.0, 5-427.1, 5-438.0, 5-438.1, 5-438.x)
223387255|NCT07017712|PROCEDURE|Rectum resection for carcinoma|Appropriate combination of ICD-10 code (C19, C20, C218, D011, D012) and medical procedure code (5-484, 5-485)
223387256|NCT07017712|PROCEDURE|Colon resection for carcinoma|Appropriate combination of ICD-10 code (C18, D01.0) and medical procedure code (5-455, 5-456, 5-458)
223387257|NCT07017712|PROCEDURE|Pancreatic resection for carcinoma|Appropriate combination of ICD-10 code (C25, C24.1) and medical procedure code (5-524, 5-525.0, 5-525.1, 5-525.2, 5-525.x, 5-525.y, 5-528)
223387258|NCT07017712|PROCEDURE|Gastric resection for carcinoma|Appropriate combination of ICD-10 code (C16) and medical procedure code (5-436, 5-437, 5-438)
224125437|NCT02426658|DRUG|Pemetrexed Disodium|Given IV
224125438|NCT02426658|OTHER|Quality-of-Life Assessment|QOL studies
224125439|NCT00524316|DRUG|doxorubicin hydrochloride|Transarterial chemoembolization
224125440|NCT00524316|DRUG|sunitinib malate|Given Orally
224125441|NCT00524316|OTHER|laboratory biomarker analysis|Correlative Study
224125442|NCT00524316|PROCEDURE|hepatic artery embolization|Surgical procedure
224125443|NCT00524316|PROCEDURE|quality-of-life assessment|Correlative Study
224125444|NCT01402284|DRUG|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
224125445|NCT01402284|DRUG|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
223387259|NCT07016711|BEHAVIORAL|Lifestyle and Nutrition Promotion|Adherence to the Mediterranean diet
223387260|NCT02558530|OTHER|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
223387261|NCT06738628|PROCEDURE|(Esophageal or Gastric) Per-Oral Endoscopic Myotomy|Performing Per-Oral Endoscopic Myotomy for the treatment of either achalasia of the esophagus, or gastroparesis of the stomach.
223387262|NCT00596076|BEHAVIORAL|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
223387263|NCT00950131|OTHER|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
223387264|NCT03452878|BEHAVIORAL|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
223387265|NCT03656588|DRUG|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
223387266|NCT03656588|DRUG|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
223387267|NCT00736437|DRUG|ME-609|Cream applied topically 6 times daily over the UVR exposed area
223387268|NCT00736437|DRUG|Vehicle|Treatment applied 6 times daily over the UVR exposed area
223387269|NCT01761760|BEHAVIORAL|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
223387270|NCT03785327|DEVICE|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
223387271|NCT03785327|BEHAVIORAL|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
223387272|NCT04935229|DRUG|SD-101|SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device
223387273|NCT04935229|BIOLOGICAL|Nivolumab|During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101
223387274|NCT04935229|BIOLOGICAL|Ipilimumab|During Cohort C, ipilimumab will be administered together with nivolumab and SD-101
223387275|NCT04935229|BIOLOGICAL|Nivolumab and Relatlimab|During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
223387276|NCT00143390|DRUG|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
223387277|NCT00143390|DRUG|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
223387278|NCT00041132|BIOLOGICAL|filgrastim|5 ug/kg
223387279|NCT00041132|BIOLOGICAL|rituximab|375 mg/m\^2 on day 1 of cycles 1-6
223387280|NCT00041132|DRUG|cyclophosphamide|300 mg/m\^2 on days 2-4 of cycles 1,3,5,7
223387281|NCT00041132|DRUG|cytarabine|12 g/m\^2 over days 3-4 of cycles 2,4,6,8
223387282|NCT00041132|DRUG|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
223387283|NCT00041132|DRUG|doxorubicin|16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7
223387284|NCT00041132|DRUG|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
223387285|NCT00041132|DRUG|methotrexate|1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8
223387286|NCT00041132|DRUG|vincristine|1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7
223387287|NCT03848494|PROCEDURE|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
223387288|NCT03417687|DRUG|129Xe MRI|Evaluation of pulmonary function
223387289|NCT03417687|DRUG|133 Xe scintigraphy|Evaluation of pulmonary function
223387290|NCT03620045|BEHAVIORAL|Acute moderate physical activity|For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
223387291|NCT05607745|OTHER|FMT and placebo|Similar healthy diet counseling is given to all participants in both FMT and placebo group. FMT to placebo is given in 2:1.
223387292|NCT03180645|OTHER|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
223387293|NCT03180645|OTHER|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
223387294|NCT03180645|OTHER|No treatment|No treatment
223387295|NCT01028482|DRUG|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
223387296|NCT01028482|DRUG|placebo|placebo
223387297|NCT01028482|OTHER|psychotherapy|psychotherapy
223387298|NCT01774162|DEVICE|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
223387299|NCT01774162|DEVICE|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
223387300|NCT04273191|DRUG|Brexanolone|Brexanolone will be initiated and administered per the USPI and the associated REMS.
224006144|NCT06399562|DIAGNOSTIC_TEST|carbon-13 urea breath test (13C-UBT)|The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), a delta over baseline (DOB) of ≥4.0 was considered positive for H. pylori, and a DOB\<4.0 was considered negative.
224006145|NCT06399562|BEHAVIORAL|questionnaires|The related factors of H. pylori infection were investigated by questionnaire survey. The physical examination population participated in the questionnaires of the physical examination center, which included basic demographic characteristics and living habits, and filled out the questionnaires on the use of serving chopsticks at the same time. In the community, members of each eligible family were asked to complete a questionnaire including the details such family general information, basic information of every family member, personal living habits, past medical history, and so on.
224006146|NCT02822430|OTHER|Pain scales|"* Visual analogic scale of pain~* Pain behaviour scale~* Short-FormHealth Survey (SF-36)~* Clinical Global impression~* Mini International Neuropsychiatric Interview (MINI)"
224006147|NCT04853641|PROCEDURE|Cadaveric|Cadaveric Organ Transplant
224006148|NCT04853641|PROCEDURE|Living Donor|Living Donor Organ Transplant
224006149|NCT01655953|DIETARY_SUPPLEMENT|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
224006150|NCT01655953|OTHER|Control: high NaCl|7.7 mmol Na/kgBW/d
224006151|NCT04940338|DRUG|Bromfenac Ophthalmic 0.09% Ophthalmic Solution|topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery
224006152|NCT04940338|DRUG|Dexamethasone Ophthalmic|topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery
224006153|NCT04940338|DRUG|Placebo|topical placebo (artificial tears substitute) 2x daily before the surgery
224006154|NCT04940338|PROCEDURE|Phacoemulsification surgery (PHACO)|About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).
224006155|NCT02712268|OTHER|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
224006156|NCT03202953|PROCEDURE|ventilation strategy 1|"In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.~* Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
224006157|NCT03202953|PROCEDURE|ventilation strategy 2|"In group A, after trendelenburg position, patients will be applied autoflow VCV.~\- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
224125446|NCT01402284|DRUG|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
224125447|NCT01402284|DRUG|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
223387301|NCT00773474|DRUG|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
224006158|NCT03586011|BEHAVIORAL|Predicting factors for increased physical activity|
224006159|NCT05315739|DEVICE|Non-invasive transcutaneous vagus nerve stimulation (tVNS)|tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.
224006160|NCT05315739|DEVICE|Sham vagus nerve stimulation|"The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period."
224006161|NCT03834324|DEVICE|FES|Functional Electrical Stimulation during cycling with Virtual Reality Feedback
224006162|NCT05097196|OTHER|Moderate-intensity aerobic activities|The exercise intensity of the individual is planned at 50-60% heart rate reserve using the Karvonen method.
224125448|NCT01402284|DRUG|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
223387302|NCT06400030|PROCEDURE|Root canal treatment with AH Plus sealer|\- AH Plus sealer Group: the base and accelerator of AH Plus Sealer was mixed, then the walls of the canal were coated with the AH Plus sealer using K-File, then lateral condensation was performed through a number of gutta-percha cones.
223387303|NCT06400030|PROCEDURE|Root canal treatment with BioCeramic sealer|\- BioCeramic Sealer Group: the canals in this group were filled using BioCeramic-based sealer and a single gutta-percha cone, and gently insert it into the root canal to the preselected working length without applying pressure.
223387304|NCT00288730|DRUG|nesiritide|
223730145|NCT01051024|DIETARY_SUPPLEMENT|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
224006163|NCT00047697|DRUG|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
224006164|NCT00047697|DRUG|Placebo|Placebo used in placed of Donepezil HCL
224006165|NCT03698253|DRUG|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
224006166|NCT03698253|GENETIC|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
224006167|NCT03698253|GENETIC|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
224006168|NCT03698253|GENETIC|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
224125449|NCT02619019|DRUG|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
224125450|NCT02619019|DRUG|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
224125451|NCT02619019|DRUG|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
224125452|NCT01199263|OTHER|Laboratory Biomarker Analysis|Correlative studies
224125453|NCT01199263|DRUG|Paclitaxel|Given IV
224006169|NCT05315505|OTHER|Maintenance programme|"Continuous educational support, exercise training, behaviour change intervention, and self-management.~Maintenance home-based pulmonary rehabilitation programme for ten months with alternate supervision"
223387305|NCT05133674|DRUG|Tamoxifen 20 mg|i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
223387306|NCT01828801|DEVICE|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
223387307|NCT06582667|PROCEDURE|PENG block|US guided PENG block in hip fracture without anti thrombotic therapy
223387308|NCT02729909|DRUG|Lubiprostone|Lubiprostone capsules
223387309|NCT02729909|DRUG|Placebo|Lubiprostone placebo-matching capsules
223387310|NCT04597697|DRUG|Insulin icodec|Insulin icodec will be investigated in participants with impaired liver function and subjects with normal liver function. Administered as a single dose subcutaneously (under the skin) The study will last for about 8 weeks.
223387311|NCT03219827|OTHER|Human biological samples|Blood samples collection
224006170|NCT05315505|OTHER|Usual Care|No maintenance programme, and the patient has the usual follow-up and medical appointments
223387312|NCT02471040|DRUG|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
223387313|NCT02471040|OTHER|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
223387314|NCT06578728|DRUG|Methotrexate|25mg/mL intralesional injection into nail bed/nail matrix
223387315|NCT06578728|DRUG|Triamcinolone Acetonide 10mg/mL|10mg/mL intralesional injection into nail bed/nail matrix
223387316|NCT06578728|DRUG|Saline|saline intralesional injection into nail bed/nail matrix
223387317|NCT06746883|OTHER|Non-interventional|Non-interventional
223387318|NCT07058974|DRUG|lamivudine|Lamivudine (Epivir) is a drug used typically to treat HIV and Hepatitis B Virus (HBV). It has not been studied when given in combination with spermidine.
223387319|NCT07058974|DRUG|rapamycin|Rapamycin (Rapamune, Sirolimus) is an FDA-approved drug and indicated for use as an immune modulator.
223387320|NCT07058974|BEHAVIORAL|Exercise Regimen|All experimental groups will receive an exercise regimen combining high-intensity interval training (HIIT) (targeting aerobic fitness) and resistance training (targeting strength and skeletal muscle mass preservation). The HIIT exercise component will consist of 2 sessions per week totaling 20 minutes per session. The resistance training component will consist of 3 sessions per week totaling 40 minutes per session.
223387321|NCT07058974|DIETARY_SUPPLEMENT|Spermidine|Spermidine is a polyamine that forms naturally in plants, animals, and microorganisms as a byproduct of protein breakdown. Participants will take an oral dosage of 2mg/day for 180 days.
223387322|NCT03832205|DEVICE|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
223387323|NCT01548105|OTHER|Blood draw for the study participants|"These will include:~* Procollagen 1-N propeptide levels (PINP)~* Matrix metalloproteinase (MMP9)~* Plasma Vitamin C levels"
223387324|NCT01605747|DIETARY_SUPPLEMENT|Culturelle|one capsule 2x per day per feeding tube
223387325|NCT01605747|DIETARY_SUPPLEMENT|Placebo|one placebo 2x per day per feeding tube
223387326|NCT05250297|OTHER|no intervention|standard prenatal care
223387327|NCT03258580|DEVICE|Medoc thermal stimulator|Heat pain stimulation for substudy 1
223387328|NCT03258580|DEVICE|Electric shock stimulator|Electric pain stimulation for substudy 1
224006171|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
224006172|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
224006173|NCT01644084|DRUG|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
224006174|NCT02369068|DRUG|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
224006175|NCT02369068|DRUG|Kenalog|Intravaginal pelvic floor injection one series
224006176|NCT01745692|DEVICE|Mechanical thrombectomy|
224006177|NCT01745692|DRUG|Intravenous rtPA|All patients receive IV alteplase
224006178|NCT06401070|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
224006179|NCT06401070|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
224125454|NCT01199263|BIOLOGICAL|Pelareorep|Given IV
224125455|NCT03691402|BEHAVIORAL|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
223387329|NCT03258580|DEVICE|Cold water bath|Cold pain stimulation for substudy 1
223387330|NCT03258580|BEHAVIORAL|Pain assessment performance feedback|Participants in substudy 3's Feedback Group will be informed about their performance after every trial when making judgments about other people's pain.
223730146|NCT05715593|OTHER|health education intervention|health education intervention
224006180|NCT01291030|DIETARY_SUPPLEMENT|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of \> 1,9 mg/dl.
224006181|NCT05416944|OTHER|Personalized blood pressure management|Personalized blood pressure management: Intraoperative mean arterial pressure will be maintained at least at the mean nighttime mean arterial pressure (assessed using preoperative automated blood pressure monitoring) with a minimum mean arterial pressure of 65 mmHg, and maximum mean arterial pressure of 110 mmHg.
224006182|NCT05648929|OTHER|Patient Satisfaction Questionnaire|During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders
224006183|NCT05648929|DIAGNOSTIC_TEST|Pregnancy test|Pre-op; to sufficiently check pregnancy as exclusion criteria
224006184|NCT05648929|PROCEDURE|Blood draw|pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed
224006185|NCT05648929|PROCEDURE|Expander based breast reconstruction|implantation of 2 different expanders intraindividually
224006186|NCT05648929|PROCEDURE|Ultrasound of breast|Measurement of capsular thickness pre- expander removal
224006187|NCT05648929|OTHER|S(AE )monitoring|(S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
224006188|NCT00958841|DRUG|pasireotide LAR|Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
224006189|NCT05219994|OTHER|Hyperoxia Exposure|2 hours of hyperoxia exposure during OGTT
223387331|NCT04447560|PROCEDURE|Erector Spinae Plane Block|One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
223387332|NCT03289819|DRUG|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
223387333|NCT03289819|DRUG|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
223730147|NCT02577731|OTHER|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
224006190|NCT05219994|OTHER|Normoxia Exposure|2 hours of normoxia exposure during OGTT
224006191|NCT02402153|DEVICE|Hyposafe device|Subcutaneous EEG recorder for EEG measurements
224006192|NCT05732753|OTHER|Mindfulness + Education in Neurophysiology of pain|An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
224006193|NCT03908957|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
224006194|NCT04160026|DRUG|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
224006195|NCT04160026|DRUG|Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
224006196|NCT04160026|DRUG|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer|Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
224006197|NCT00932542|DRUG|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
224006198|NCT00932542|DRUG|placebo|placebo
224006199|NCT00932542|DRUG|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
224006200|NCT02915484|DEVICE|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
224006201|NCT00484029|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
224006202|NCT00484029|OTHER|Air|Air (Medical Grade)
224006203|NCT02928497|DEVICE|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
224006204|NCT02928497|DRUG|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
224006205|NCT03466905|OTHER|Ambulant assessment|
224006206|NCT04148664|PROCEDURE|Catheter ablation with Standard RF ablation settings|"Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard."
224006207|NCT04148664|PROCEDURE|Catheter ablation with High Power Short Duration RF ablation settings|"High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard."
224138524|NCT02603354|DRUG|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
223730148|NCT02577731|OTHER|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
223387334|NCT03289819|DRUG|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
224006208|NCT02909218|OTHER|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
224006209|NCT04224857|DRUG|AMT-101|Single or daily dosing at doses A, B, C, D, E, F
224006210|NCT04224857|DRUG|Placebos|Single or daily dosing at doses A, B, C, D, E, F
224006211|NCT03325491|DIETARY_SUPPLEMENT|Acipimox|Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
224006212|NCT03325491|DIETARY_SUPPLEMENT|Placebo|Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
224006213|NCT05591261|BEHAVIORAL|ePREP|6-session online psychoeducational program with supporting coach calls
224006214|NCT04641676|DIAGNOSTIC_TEST|NGS testing|NGS test will be performed
224006215|NCT03183505|DRUG|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
224006216|NCT03183505|DRUG|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
224006217|NCT04792619|OTHER|Bobath Approach|The patients in both groups were treated with the exercise program according to the Bobath concept was planned taking the functional needs of the survivors into account, including stretching and facilitation of latissimus dorsi muscle, facilitation of abdominal muscles, placing exercises, training of lumbar spine stabilizers, functional reach of shoulder in different directions. Five sessions of about an hour each were provided to the patients
224006218|NCT04792619|OTHER|Isometric scapular exercises|Isometric scapular exercises were performed to the patients included to the study group in a sitting position and at 900 of the shoulder flexion and 900 of the shoulder abduction. The patients were exercised by a physiotherapist using isometric contraction in protraction and retraction by a physiotherapist. Isometric contractions lasted 5 seconds and each exercise was repeated 2x15 times. One minute rest period was given between sets
224006219|NCT00483990|DRUG|PSD502|
224006220|NCT00799981|DEVICE|A=SpeediCath Compact 7 cm and B=POBE 10 cm|Catheterization should resemble the daily use as far as possible and at least 2 hours had to pass between 2 catheterizations.The study centre decided whether the subject performed all four catheterizations on one or several days.
224006221|NCT03296670|DRUG|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
224006222|NCT03296670|DRUG|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
224006223|NCT06186921|DRUG|Dexamethasone|After endodontic instrumentation and placement of temporary restoration, the patients shall receive intraligamentary injections.
223387335|NCT03289819|DRUG|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
223387336|NCT00866359|DRUG|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
224006224|NCT03041974|PROCEDURE|Red Blood Cell transfusion|
224006225|NCT03041974|PROCEDURE|Microparticles quantification|Flow cytometric quantification of microparticles in transfused blood
224006226|NCT02449551|DRUG|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
224006227|NCT04680806|DEVICE|Er,Cr:YSGG laser 2780 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
224006228|NCT04680806|DEVICE|Diode laser 940 nm|The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
224006229|NCT00452777|DRUG|BVT.115959|
224006230|NCT00452777|DRUG|Placebo|
224006231|NCT06415149|PROCEDURE|High power short duration ablation with 50 W|Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.
224006232|NCT06415149|PROCEDURE|High power short duration ablation with 45 W|Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
224006233|NCT01249027|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
224006234|NCT04101630|BEHAVIORAL|Activity Monitoring|Monitoring with FitBit
224125456|NCT03691402|BEHAVIORAL|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
224125457|NCT02928406|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
224138525|NCT06446414|BEHAVIORAL|Choose to Move|As described under study arm description
224138526|NCT03428802|OTHER|Laboratory Biomarker Analysis|Correlative studies
224138527|NCT03428802|BIOLOGICAL|Pembrolizumab|Given IV
224006235|NCT03778268|PROCEDURE|sentinel lymph node biopsy|"1. Injecting carbon nanoparticles (CNP)\[Not Equipped with near-infrared fluorescent vascular imager\] or CNP combining Indocyanine Green(ICG)\[Equipped with near-infrared fluorescent vascular imager\].~2. Identifying and removing sentinel lymph nodes.~3. Staining all nodes using hematoxylin-eosin staining."
224006236|NCT02690259|PROCEDURE|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
224006237|NCT04625699|DRUG|Durvalumab|4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
224006238|NCT04625699|DRUG|Tremelimumab|2 doses of Tremelimumab 300 mg IV Day 1, q56 days
224006239|NCT02984722|DRUG|Metformin|
224006240|NCT04889105|BEHAVIORAL|Smart MOVE!|"Multi-component behavioral intervention of PAD consisting of:~1. guideline-directed HBET prescription~2. active behavioral coaching (via MOVE! program or other)~3. mobile health monitoring"
224125458|NCT06459531|BEHAVIORAL|Virtual Reality (VR) Therapy|"Patients in this group will receive therapy using VR technology. This involves engaging in various sensorimotor training exercises and tasks in an immersive virtual environment. The VR sessions are designed to be interactive and adaptive, providing real-time feedback to the user. The exercises will target the improvement of motor functions, coordination, and strength of the affected upper extremity.~Duration and Frequency: The specific regimen may involve sessions several times a week, with each session lasting between 30 to 60 minutes, over a period of several weeks or months, depending on the study design."
224125459|NCT06459531|OTHER|Conservative Treatment|"Patients in this group will receive traditional rehabilitation therapies, which may include:~Physical Therapy (PT): Exercises and activities aimed at improving strength, flexibility, and coordination of the upper limb.~Occupational Therapy (OT): Functional task training to enhance daily living skills and independence, focusing on the use of the upper extremity.~Manual Therapy: Techniques such as massage or joint manipulation to improve mobility and reduce pain.~Home Exercise Programs: Prescribed exercises to be performed at home to reinforce therapy sessions.~Duration and Frequency: Similar to the VR group, this regimen may involve regular sessions several times a week, with each session lasting between 30 to 60 minutes, over a comparable period."
224125460|NCT03003416|DRUG|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
224125461|NCT03859986|DRUG|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
224125462|NCT03859986|DRUG|ALX-101 Gel 5%|ALX-101 Gel 5%
223387337|NCT00866359|DRUG|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
223387338|NCT01050959|DEVICE|bion|
223387339|NCT02245087|DRUG|Atorvastatin|20 mg of atorvastatin daily
224125463|NCT03531437|DRUG|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
224125464|NCT03531437|DRUG|15 µg ethinylestradiol and 60 µg gestodene|
224125465|NCT00002333|DRUG|Saquinavir|
224125466|NCT00002333|DRUG|Zalcitabine|
224125467|NCT00697047|BEHAVIORAL|Automated Mailing|Usual Care plus Automated mailing
224125468|NCT00697047|BEHAVIORAL|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
224125469|NCT00697047|BEHAVIORAL|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
224125470|NCT02061722|RADIATION|PET Imaging with [18F]MNI-659|"The radioligands \[11C\]raclopride and \[18F\]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of \[11C\]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of \[18F\]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
223387340|NCT01790087|DRUG|ANX-188 Therapeutic Dose|
223387341|NCT01790087|DRUG|ANX-188 Supratherapeutic dose|
223387342|NCT01790087|DRUG|Saline|
223387343|NCT01790087|DRUG|Moxifloxacin|
224125471|NCT02305901|DRUG|repaglinide|single dose on day 1 of visits 2 and 3
224125472|NCT02305901|DRUG|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
224125473|NCT02305901|DRUG|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
224006241|NCT04889105|BEHAVIORAL|General walking advice|Basic guidance on performing walking exercises for PAD according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.
224006242|NCT04889105|BEHAVIORAL|Performance evaluation|"Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include:~1. Provider and stakeholder interviews~2. PAD patient interviews~2\) N-of-1 trials to refine the intervention"
224006243|NCT03117829|BEHAVIORAL|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
224125474|NCT03653702|DRUG|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
224125475|NCT03302416|DRUG|Hydrocortisone|
224125476|NCT03302416|RADIATION|[C-11]NOP-1A|
224125477|NCT00434863|DRUG|botulinum toxin type A|
224125478|NCT04761094|DEVICE|Insulin pump|Treatment with continuous subcutaneous insulin infusion
224138528|NCT01684475|DRUG|CJH1 (CLR4001)|
224138529|NCT00546793|BIOLOGICAL|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
224138530|NCT03908710|OTHER|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
224138531|NCT05480254|OTHER|clamped catheter|Q3 clamped catheter protocol is applied before urinary catheter removal
223387344|NCT01747954|OTHER|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
224006244|NCT05215028|DEVICE|web-application|web application multi-domain familial digital health record PRO The aim is to help for early screening of neurodevelopmental disorders of toddler after birth to 3 years of age and mother's postnatal depression, to improve vaccinations rate of toddlers and to provide advice to parents for child development.
224006245|NCT00685451|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|
224006246|NCT02158923|PROCEDURE|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
223387345|NCT01747954|OTHER|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
223387346|NCT00295997|BIOLOGICAL|anti-thymocyte globulin|
223387347|NCT00295997|BIOLOGICAL|filgrastim|
223387348|NCT00295997|BIOLOGICAL|graft-versus-tumor induction therapy|
223387349|NCT00295997|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223387350|NCT00295997|DRUG|busulfan|
223387351|NCT00295997|DRUG|cyclophosphamide|
223387352|NCT00295997|DRUG|fludarabine phosphate|
223387353|NCT00295997|DRUG|methotrexate|
223387354|NCT00295997|DRUG|mycophenolate mofetil|
223387355|NCT00295997|DRUG|tacrolimus|
223387356|NCT00295997|PROCEDURE|allogeneic bone marrow transplantation|
224006247|NCT02158923|PROCEDURE|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
224006248|NCT02158923|PROCEDURE|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI\> 30) with a FiO2 of 0.5 will be applied.
224006249|NCT03478904|DRUG|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
224006250|NCT03478904|DRUG|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
224006251|NCT01986764|DRUG|Lisdexamfetamine|
224006252|NCT01986764|DRUG|Estradiol|
224006253|NCT01986764|DRUG|Placebo|Placebo capsules will be filled with lactose powder.
224006254|NCT00193167|DRUG|Topotecan|
224006255|NCT01152814|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
224006256|NCT04682860|DRUG|Hyoscine N Butylbromide|Hyoscine N butylbromide injection for the treatment of abdominal pain in acute gastroenteritis
224006257|NCT04682860|OTHER|Placebo|2 ml of normal saline injection as placebo
224006258|NCT04525794|DEVICE|BRight DCB|The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.
223387357|NCT00295997|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223387358|NCT00295997|PROCEDURE|peripheral blood stem cell transplantation|
223387359|NCT02046811|BEHAVIORAL|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
223387360|NCT02046811|BEHAVIORAL|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
223387361|NCT02046811|BEHAVIORAL|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
223387362|NCT02431377|OTHER|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
224006259|NCT01486290|BEHAVIORAL|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
224006260|NCT02167009|DEVICE|Embosphere Microspheres|Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
224006261|NCT00111410|DRUG|Anakinra (r-metHuIL-1ra)|
224138532|NCT00030615|DRUG|decitabine|Given IV
224138533|NCT00030615|OTHER|pharmacological study|Correlative studies
224138534|NCT00030615|OTHER|laboratory biomarker analysis|Correlative studies
224138535|NCT04584853|DRUG|Abemaciclib|Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
223387363|NCT00136227|BEHAVIORAL|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
224006262|NCT01877239|OTHER|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
224006263|NCT01353651|DEVICE|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
224006264|NCT01353651|DEVICE|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
224006265|NCT01669577|PROCEDURE|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
224006266|NCT03369327|DRUG|sofosbuvir and daclatasvir|"Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~1. Daclatasvir 30 mg and sofosbuvir 400 mg~2. Daclatasvir 60 mg and sofosbuvir 400 mg~3. Daclatasvir 90 mg and sofosbuvir 400 mg"
224006267|NCT02009098|DRUG|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
224006268|NCT02328859|OTHER|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
224006269|NCT02328859|OTHER|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
224006270|NCT00444275|DRUG|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
224006271|NCT00444275|DRUG|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
224006272|NCT03001375|PROCEDURE|Laparoscopic high anterior resection splenic flexure mobilization|
224006273|NCT03001375|PROCEDURE|Laparoscopic high anterior resection without splenic flexure mobilization|
224006274|NCT01048801|DEVICE|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
224006275|NCT01048801|OTHER|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
224006276|NCT04690894|PROCEDURE|erector spinae block - caudal block|the child placed in lateral position identification of spinous process of 10th thoracic vertebral then the transducer was moved 2.5 cm laterally to visualize the transverse process and a total of 0.4mg/kg of 0.25%bupivacaine was adminstered
224006277|NCT05313659|DRUG|Ketamine Hydrochloride|intramuscular ketamine hydrochloride at dose of 0.7 mg/kg at the time of turning the inhalational agent off
223387364|NCT06280339|BEHAVIORAL|Test two food cravings strategies during dietary weight loss|The intervention includes 12 online nutrition education sessions using the MealPlot App to track food intake and view the daily weight charts. Participants need to weigh themselves daily using a Wi-Fi scale. Participants will complete 12 asynchronous online diet improvement sessions (eText) lasting 45 minutes each. The 12 sessions will be conducted weekly for the intervention period (12 weeks). The following four sessions will be focused on creating consistent eating and sleeping patterns related to timing, frequency, and portion, as well as daily self-monitoring of weight. After that, participants will continue to complete the rest of asynchronous online diet improvement sessions, including personalized weight loss diets from their kitchen based on their diet practice and food preference, safe and efficient weight loss, weight maintenance and healthy eating, skills to select foods and create meals that prevent overeating, all to be completed by the end of 12 weeks.
224006278|NCT04224376|DEVICE|App based Serious Gaming with the Genu Sport knee trainer|The Genu Sport knee trainer has a strength monitoring unit with three integrated sensors which is placed in the popliteal area and a tablet with the application which allows to transfer the raised force into the game modus. Each training session in our study takes around 5 minutes and is performed autonomously by the patient in his bed with 45° degrees of upper body evaluation while the patient holds the tablet in both hands. By simply pushing his knee downward onto the measuring unit the patient can apply the force.
224006279|NCT06474819|DEVICE|Pacemaker implant|All patients in the study will have a clear indication for a permanent pacemaker. The type of device (single or dual chamber) will be chosen as per clinical practice. The only difference between the two groups of the study will be the position of the ventricular lead.
224006280|NCT01124331|PROCEDURE|Higher oxygen saturation target range (91%-95%)|higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
224006281|NCT01124331|PROCEDURE|Lower oxygen saturation (85%-89%)|Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
224006282|NCT01038739|DRUG|Mesalazine|3 g per day
224006283|NCT01038739|DRUG|Mesalazine|1.5 g per day
224006284|NCT01038739|DRUG|Placebo|0 g per day
224006285|NCT05880901|BEHAVIORAL|After school program|The after school program are existing community-based programs that take place immediately after the regular school day (typically 3:00-6:00pm); are located in a school; are available daily throughout the academic year (Monday through Friday); and provide a combination of scheduled activities, which include a snack, homework assistance/tutoring, enrichment activities (e.g., arts and crafts, music), and opportunities for children to be physically active.
224006286|NCT05880901|BEHAVIORAL|Summer day camp|The summer day camp programs are existing camps which take place at schools from which children will be recruited. The camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks.
224006287|NCT04531501|DIAGNOSTIC_TEST|Saliva and NPS test|N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
224006288|NCT00105599|BEHAVIORAL|End of life care coordination|
224006289|NCT00105599|PROCEDURE|FairCare System|
224006290|NCT02160236|DRUG|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
224006291|NCT02160236|DRUG|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
224006292|NCT02160236|DRUG|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
224006293|NCT00743431|DRUG|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
224006294|NCT01671397|BEHAVIORAL|Diet and exercise counseling|Not needed
224006295|NCT01671397|BEHAVIORAL|Diet, exercise, sleep hygiene counseling|None needed
224006296|NCT04104828|BIOLOGICAL|Allergovit|Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis
224006297|NCT04104828|BIOLOGICAL|Polvac|Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis
224006298|NCT04104828|BIOLOGICAL|Pollinex Quattro|Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
224006299|NCT05978206|DRUG|Nandrolone Decanoate|Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
224006300|NCT05978206|BEHAVIORAL|Physiotherapy Intervention|"The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate."
224006301|NCT05978206|BEHAVIORAL|Nutritional Intervention|An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.
224006302|NCT05978206|DRUG|Placebo|Placebo
223425651|NCT05139303|DEVICE|Orthoapnea NOA®|The efficacy of the appliance for the management of OSA will be stablished based on two criteria. Criterion I: \> 50% reduction of AHI/RDI. Criterion II: AHI/RDI \< 5 events/hour or \<15 events/hour with a significative reduction of OSA associates symptoms as defined before. Therapeutic failure will be established when at 100% of advancement of the device, there is less than 50% of reduction of the AHI/RDI with a residual AHI/RDI \>5 events/hour with OSA associates symptoms.
224006303|NCT03291288|DRUG|Tolbutamide|Commercially available tolbutamide
224006304|NCT03291288|DRUG|Midazolam|Commercially available midazolam
224006305|NCT03291288|DRUG|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules
224006306|NCT04276415|DRUG|DS-6157a|Administered as a single agent intravenously (IV) every 3 weeks
224006307|NCT04385550|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
224006308|NCT04385550|DRUG|AK105 injection|AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.
224125479|NCT02934048|OTHER|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
223425652|NCT02754687|DRUG|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
224006309|NCT04385550|DRUG|Paclitaxel injection|Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
224006310|NCT04385550|DRUG|Docetaxel injection|Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
224006311|NCT06137326|DEVICE|Pulsed Electromagnetic Field Therapy|Participants in this arm will receive pulsed electromagnetic field (PEMF) therapy to the pelvic floor area along with pelvic floor muscle training. The PEMF device generates a pulsed magnetic field with the following parameters: frequency 10 Hz, intensity 200 μT, pulse duration 250 μs. It will be applied over the pelvic floor for 20 minutes per session, 5 days per week for 8 weeks.
224006312|NCT06137326|DEVICE|Laser Acupuncture|Participants in this arm will receive low-level laser acupuncture to pelvic floor trigger points along with pelvic floor muscle training. A continuous wave 810 nm diode laser will be used at 100 mW power and 0.5 J/point, delivered to 6 pelvic floor acupoints bilaterally (12 points total) for 15 seconds per point. Acupuncture will be performed 3 days per week for 8 weeks.
224006313|NCT01353768|OTHER|retrospective chart review|retrospective chart review
224006314|NCT03887949|DEVICE|Group VCV|Volume controlled ventilation
224006315|NCT03887949|DEVICE|Group PCV|Pressure controlled ventilation
224006316|NCT03887949|DEVICE|Group PCV-VG|Pressure controlled ventilation with volume guarantee
224006317|NCT04434573|OTHER|Observation study|French-speaking digestive surgeons are invited to respond to an online survey consisting of 13 common clinical situations concerning primary or asymptomatic incisional hernia pathology where a therapeutic decision is requested.
224006318|NCT02461784|PROCEDURE|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
224125480|NCT02934048|OTHER|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
224125481|NCT02934048|OTHER|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
223387365|NCT06280339|BEHAVIORAL|Dietary weight loss program +Food cravings strategies|The intervention includes 12 online nutrition education sessions using the MealPlot App to track food intake and view the daily weight charts. Participants need to weigh themselves daily using a Wi-Fi scale. Participants will complete 12 asynchronous online diet improvement sessions (eText) lasting 45 minutes each. The 12 sessions will be conducted weekly for the intervention period (12 weeks). The following four sessions will be focused on creating consistent eating and sleeping patterns related to timing, frequency, and portion, as well as daily self-monitoring of weight. After that, participants will continue to complete the rest of asynchronous online diet improvement sessions, including personalized weight loss diets from their kitchen based on their diet practice and food preference, safe and efficient weight loss, weight maintenance and healthy eating, skills to select foods and create meals that prevent overeating, all to be completed by the end of 12 weeks.
224006319|NCT04173351|BEHAVIORAL|Education and Counseling|Following the pretests between the 28th and the 34th gestational weeks, nulliparous women in the intervention group received a presentation on childbirth preparation at a room of the obstetrics clinic. The education was completed in two sections in a single day. Each session took about 45 minutes there was a 15-minute break between the sessions. Following the education, the questions of the participants were responded and educational brochures on childbirth preparation were given to the participants. One of the researchers of this study telephoned the participant women in the intervention group one week after the childbirth education and provided counseling service about the demands and the points that the nulliparous women wondered.
224006320|NCT00074477|DRUG|R092670|
224006321|NCT03309813|DEVICE|Transcranial ExAblate|ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
224125482|NCT06555926|OTHER|Acupressure|The pregnant women will receive acupressure on the (Pc-6/Lung-7 )acupoints one minute for each point with 3 repetitions on both side( about 30minutes /session),2 times per week in addition to advices for 12 weeks.
224125483|NCT06555926|OTHER|advices for relieving carpal tunnel syndrome|"The pregnant women will receive advices for 12 weeks as follows:~* Avoid heavy lifting.~* Avoid repetitive tasks.~* Sit on chairs with armrests and elevate affected hand on the armrest~* Avoid sleeping on the side of the affected hand.~* Keep the wrist in a neutral (straight) position.~* Avoid positions of full flexion and extension.~* Reduce general swelling by:~  * eating less salty food .~ * elevating legs when sitting .~ * wearing compression garments.~* Apply cold water over the wrist."
224125484|NCT04018469|OTHER|No Interventions|No Interventions
224125485|NCT05837078|PROCEDURE|ridge splitting with implant placement|ridge splitting of mandibular denture followed by two implant placement
224125486|NCT03564171|COMBINATION_PRODUCT|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
223387366|NCT03051672|DRUG|Pembrolizumab|Pembrolizumab (formerly MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD1 and its ligands, PD-L1 and PD-L2.
223387367|NCT03051672|RADIATION|Palliative radiotherapy|Palliative radiotherapy aims to shrink cancer, slow down its growth or control symptoms.
223387368|NCT00768248|DRUG|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
223387369|NCT00768248|DRUG|normal saline (placebo)|the basal rate will be set at 7 mL/h
223387370|NCT00469924|PROCEDURE|Real Time Clinical Alerting|
223387371|NCT02962986|DRUG|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
223387372|NCT02962986|DRUG|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
224006322|NCT03309813|DEVICE|Sham Transcranial ExAblate|Sham ExAblate Thalamotomy procedure
224006323|NCT03309813|DEVICE|Crossover Transcranial Exablate|Subjects randomized to the Sham Exablate could opt for the Crossovover Transcranial Exablate Arm (Exablate Thalamotomy) after completing the Month 3 visit in the Sham Arm.
223387373|NCT05806892|OTHER|Thera Pearl|"You can apply Thera°Pearl warm breast therapy before breastfeeding or during milking. You should do this application 4 times a day, in the morning, at noon, in the evening and at night before going to bed. Each application should be done on both breasts and should last at least 20 minutes.~Thera°Pearl Warm Breast Therapy has been developed to open milk ducts and accelerate milk flow.~Thermogel packs for Thera°Pearl hot therapy can be heated inside the fabric covers in the microwave for a maximum of 15 seconds or in hot water by removing the fabric covers. Packages that have been removed from the cover should be kept in boiling water for 1-2 minutes and then applied by putting them into the sheath."
223387374|NCT04092140|DEVICE|ultrasound|easy new non invasive tool
224006324|NCT06283966|DRUG|BGF MDI 320/14.4/9.6 μg|Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension
224006325|NCT06283966|DRUG|GFF MDI 14.4/9.6 μg|Glycopyrronium and formoterol fumarate pressurized inhalation suspension
224006326|NCT03981328|DEVICE|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
224006327|NCT03981328|DEVICE|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
224125487|NCT02738437|DEVICE|Kryptonite-bone cement|
224125488|NCT05909215|DRUG|Normal saline|Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
224125489|NCT05909215|DRUG|Dexmedetomidine 0.5 microgram/kg|Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
224125490|NCT05909215|DRUG|Dexmedetomidine 0.75 microgram/kg|Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
224125491|NCT06064708|BEHAVIORAL|Mindfulness-based intervention|"The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes)."
223387375|NCT04006002|OTHER|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
223387376|NCT01547390|DRUG|Aspirin|
223387377|NCT01547390|DRUG|placebo|
224125492|NCT03047863|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
223387378|NCT04530643|DRUG|HY209 0.3%|25 subjects will be assigned to drug (HY209 0.3% gel).
223387379|NCT04530643|DRUG|HY209 0.5%|25 subjects will be assigned to drug (HY209 0.5% gel).
223387380|NCT04530643|DRUG|Placebo|25 subjects will be assigned to drug (Placebo).
223387381|NCT03406754|BEHAVIORAL|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
223387382|NCT01459783|BEHAVIORAL|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
223387383|NCT03248427|DRUG|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
223387384|NCT03248427|DRUG|Letrozole 2.5mg|Daily continuous
223387385|NCT03248427|DRUG|Doxorubicin|60 mg/m2 as a continuous IV perfusion
224006328|NCT04551404|OTHER|transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.
224125493|NCT03047863|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
224125494|NCT00849264|DRUG|chemotherapy with endostar|15mg/d×14d
223387386|NCT03248427|DRUG|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
223387387|NCT03248427|DRUG|Paclitaxel|80 mg/m2, in one hour IV infusion
223387388|NCT06370611|DEVICE|Early mobile health intervention supplemented by weekly calls from a physiotherapist|"Six-week home-based rehabilitation program using the ICURA app and sensor-based technology (ICURA ApS, Copenhagen, Denmark). During the hospital stay patients in the intervention group are introduced to the app's usage, and an individualized training plan is collaboratively created and subsequently tailored by a physiotherapist.~The comprehensive mobile health intervention includes customized training programs, activity tracking, visualization of exercises with videos, and a password-protected webpage for physiotherapists to customize training programs and track patient activity.~The patients will receive two calls from a physiotherapist per week for the first two weeks and as required the following four weeks."
223387389|NCT03231111|OTHER|Preventive Multimedia Teaching Program|Preventive Multimedia Teaching Program
223387390|NCT00488189|DRUG|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
224006329|NCT04551404|OTHER|transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)|The study intervention consists of a bilateral tRNS application over temporal regions
224125495|NCT00849264|DRUG|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
224125496|NCT00849264|DRUG|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
224125497|NCT02592629|DRUG|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
224125498|NCT02592629|DRUG|ethyl chloride|topical spray
224125499|NCT02592629|DRUG|Kenalog|used with lidocaine in shoulder injection
224125500|NCT04129749|PROCEDURE|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
224125501|NCT00905021|DRUG|Exemestane|Exemestane 25 mg by mouth every day.
224125502|NCT00905021|DRUG|Sutent|Sunitinib 37.5 mg by mouth every day.
224125503|NCT01918098|DRUG|Oxycodone/naloxone prolonged release tablets|
224125504|NCT00214851|DRUG|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
224125505|NCT00606762|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
224125506|NCT02893774|OTHER|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~* QLQ-C30~* SWLS (Satisfaction with Life Scale)~* PTGI (Post-Traumatic Growth Inventory)~* HADS (Hospital Anxiety and Depression Scale)~* Brief COPE~* MHLCS (Multidimensional Health Locus of Control Scale)"
223387391|NCT06748976|OTHER|Positive sham neurofeedback|Participants receive simulated positive reinforcement feedback designed to mimic successful modulation of EEG alpha rhythms, despite the feedback not being directly based on their actual neural activity. This condition aims to create the perception of improved attentional control.
223387392|NCT06748976|OTHER|Negative sham neurofeedback|Participants receive simulated negative reinforcement feedback that mimics unsuccessful modulation of EEG alpha rhythms, regardless of their actual neural activity. This condition is intended to simulate reduced attentional control.
223387393|NCT06748976|OTHER|Control|Participants perform the same attentional task but without receiving any feedback. This condition serves as a baseline to evaluate the effects of the sham neurofeedback interventions on EEG alpha rhythm modulation.
223387394|NCT02398266|DRUG|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
223387395|NCT00479986|DRUG|pioglitazone|
223387396|NCT00479986|DRUG|placebo|
224006330|NCT01632540|DRUG|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
224006331|NCT01780259|DRUG|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
224125507|NCT06023173|DIAGNOSTIC_TEST|Deep radiomics-based fusion model|This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
224295919|NCT00289874|DRUG|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
224295920|NCT00289874|DRUG|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
223387397|NCT01328184|DRUG|levonorgestrel|multiple doses
223387398|NCT01328184|DRUG|levonorgestrel|multiple doses
223387399|NCT01328184|DRUG|Ethinylestradiol|multiple doses
223387400|NCT01328184|DRUG|Microgynon + BI 10773|multiple doses BI 10773
223387401|NCT01328184|DRUG|Ethinylestradiol|multiple doses
223387402|NCT06890403|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover human papillomavirus (HPV) disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
223387403|NCT06890403|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
224006332|NCT01780259|DRUG|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
224006333|NCT01780259|DRUG|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
224006334|NCT04561778|DEVICE|HOT-CRT|Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.
224125508|NCT02750657|GENETIC|Molecular Profiling|Whole Genome Sequencing
223387404|NCT06766747|OTHER|Intermittent Fasting|Participants in the alternate-day fasting group will receive biweekly telecounseling to ensure adherence to the prescribed dietary plan and to monitor for potential adverse events. During the 12-week weight loss phase, patients are instructed to restrict calories to 75% of usual intake 2 days per week. A daily intake of at least 2 liters of low-energy beverages (water, caffeine- and sugar-free beverages) is generally recommended on fasting days. Usual physical activity is encourage
223425653|NCT02754687|DRUG|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
224125509|NCT02058134|DEVICE|cardioPAT cell saver|
224125510|NCT01160055|PROCEDURE|Middle ear fluid and urine.|Middle ear fluid and urine collection.
224125511|NCT00786838|DRUG|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
224125512|NCT00786838|DRUG|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
224125513|NCT04937816|DRUG|Placebo|Placebo
224125514|NCT04937816|DRUG|Empagliflozin|Empagliflozin once daily
224125515|NCT06618235|BIOLOGICAL|THEO-260|Oncolytic Virus
224125516|NCT06677229|DRUG|Eletriptan HBr 40 mg|Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.
224125517|NCT06683014|DRUG|MDMA|Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
224125518|NCT06622434|BIOLOGICAL|immunization|One month after completion of concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide with subcutaneous injections of the vaccine formulation (D0, W2, W4, W6, and then every 2 months until progression) consisting of 2 tumor antigens (TERT and PTPRZ1) adjuvanted with synthetic melanin and a TLR9 agonist (CpG-ODN).
224125519|NCT06881459|OTHER|Placebo|Saline
223425654|NCT05474170|OTHER|AHA resuscitation sequence|Starting the cardiopulmonary resuscitation by following the AHA guideline, meaning starting with 15 chest compressions, followed by 2 ventilations
224295921|NCT05594303|BIOLOGICAL|Autologuos transplantation of bronchial basal cells|Autologuos transplantation of bronchial basal cells
224295922|NCT03577483|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
224299229|NCT02618408|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 high dose (36 mg) twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
223387405|NCT06766747|OTHER|Continuous calorie restriction|Participants in the continuous calorie restriction group will receive biweekly nutritional counseling via Telecoaching to ensure adherence to the prescribed dietary plan. Based on weekly caloric intake obtained from the 7-day log, a model menu will be prescribed with a 25% daily calorie restriction divided among 3 meals every day consisting of macronutrient intake, with 20% of energy as fat, 40 to 50% as carbohydrate, and 20 to 30% as protein. They will be instructed to continue their usual physical activity.
223387406|NCT07064707|DRUG|Mesalamine|Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.
223387407|NCT07064707|DRUG|Rupatadine|Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions
224006335|NCT04561778|DEVICE|Biventricular Pacing|Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
224006336|NCT06266624|DIAGNOSTIC_TEST|Tourniquet Test|Tourniquet Test was performed in patients with HHT
224006337|NCT00312598|DRUG|Aripiprazole|
224006338|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
224006339|NCT01030432|DRUG|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
224006340|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
224006341|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
224125520|NCT06881459|DRUG|Oxytocin|Oxytocin
224125521|NCT06512207|DRUG|Leuprorelin acetate + Sintilimab|Leuprolide, an FDA-approved GnRH agonist, reduces sex hormone production and is widely used in clinical practice.
224125522|NCT06512207|DRUG|Sintilimab|PD-1 inhibitor
224125523|NCT07042516|DRUG|Asimadoline|Asimadoline TP0052 2.5 mg two (2) tablets bid (two on awakening and two before bed), total of four (4) tablets daily (10 mg) for 8 weeks.
224125524|NCT05513391|BIOLOGICAL|Recombinant influenza vaccine (RIV4)|Pharmaceutical form: solution for injection Route of administration: intramuscular
224295923|NCT06258603|OTHER|oral care bundle|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, an oral care bundle containing an oral care combination was applied to the experimental group. According to this bundle application, patients were received tooth brushing (with chlorhexidine solution) and ice water application twice a day and moisturizing attempts 4 times a day.~In the 3rd stage, saliva pH, dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
224299230|NCT02618408|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day (BID) with or without food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if after noon, the evening dose.
224299231|NCT01792219|OTHER|Interprofessional collaboration in health care module|An educational module
223387408|NCT07066176|DRUG|Aspirin|Aspirin 650mg prior mixed meal beverage
223387409|NCT07066176|DIETARY_SUPPLEMENT|Mixed meal beverage|Mixed meal beverage
223387410|NCT06786637|DRUG|Nociceptin Receptor Antagonist (LY-2940094)|Participants in the experimental arms will receive 40 mg of the nociceptin receptor antagonist LY-2940094. Peak concentrations are achieved 2-4 hours post-administration.
223387411|NCT06786637|DEVICE|DS8R Biphasic Constant Current Stimulator|As part of the fear conditioning task, electrotactile stimulation will be used. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). This model has been safely implemented in studies within McLean Hospital and Massachusetts General Hospital.
223387412|NCT06589986|DRUG|Afimkibart|Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.
223387413|NCT06589986|DRUG|Placebo|Placebo matching IV afimkibart. Placebo matching SC afimkibart.
223387414|NCT07072585|PROCEDURE|Biopsy Procedure|Undergo biopsy
223387415|NCT07072585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223387416|NCT07072585|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223387417|NCT07072585|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223387418|NCT07072585|PROCEDURE|Bone Scan|Undergo bone scan
224006342|NCT01030432|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
224006343|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
224006344|NCT01030432|DRUG|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
224006345|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
224006346|NCT01030432|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
224006347|NCT02686619|DRUG|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
224125525|NCT05513391|BIOLOGICAL|Quadrivalent influenza vaccine (IIV4)|Pharmaceutical form: suspension for injection Route of administration: intramuscular
224125526|NCT07051915|DRUG|Avatrombopag|Daily tablets
224125527|NCT07051915|DRUG|Rituximab (Arm B)|I.V.
224125528|NCT07051954|OTHER|Core Stabilization|12-week supervised core stabilization training, 3 sessions per week, 45 minutes per session.
224125529|NCT07051954|OTHER|Functional Inspiratory Muscle Training (IMT)|IMT using a portable inspiratory muscle training device at 60% MIP, progressively increased over 12 weeks.
224006348|NCT02686619|DRUG|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
224006349|NCT02686619|DRUG|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
224006350|NCT02686619|DRUG|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
224006351|NCT02686619|DRUG|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
224006352|NCT03752086|PROCEDURE|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
224006353|NCT03752086|PROCEDURE|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
224006354|NCT04419922|BEHAVIORAL|Smartphone Contingency Management Intervention|Participants will provide baseline data on their recent substance use and smoking habits/severity. Participants will 1) download the DynamiCare Rewards app, and 2) receive a Carbon Monoxide breath testing device (iCO™ Smokerlyzer®) and reloadable debit card for receiving financial incentives. Participants will follow instructions on the app to take breath tests and receive incentives if the carbon monoxide breath result is less than 6 ppm (Cessation mode) or lower than 3 of the last 4 tests (Shaping mode). The app will use GPS to track if patients have attended their scheduled BrightView appointments (GPS is not used at any other time) and reward them for all kept appointments. The participant will also be able to view Cognitive Behavioral Therapy (CBT) modules on the app and receive incentives upon completing each module. At all times, the participant retains the right to choose whether to use and when to use the app, device, and funds for a total period of 4 months.
224006355|NCT00251706|DRUG|amiodarone|
224006356|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
224006357|NCT00636740|DRUG|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
224006358|NCT00636740|DRUG|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
224006359|NCT01070446|DIETARY_SUPPLEMENT|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
224006360|NCT05914051|OTHER|Colloid preload|250 cc of colloid preload solution will be infused in the intervention group
224006361|NCT01989169|DRUG|Midazolam|
224125530|NCT06751056|DEVICE|Cervical Traction Device|"Participants will use their home neck traction devices daily for 12 weeks, while continuing their prescriptions for gabapentin or pregabalin.~At study initiation and every 2 weeks thereafter for a total of 12 weeks, they will receive an electronic survey assessing their itch score. Based on survey results, they will receive a call from the study team to adjust their dosage of gabapentin or pregabalin by up to 33%."
224125531|NCT06895408|OTHER|Intravenous Infusion|Glucose-dependent Insulinotropic Polypeptide
224125532|NCT06895408|OTHER|Intravenous Infusion|Glucagon-Like Peptide 1
224006362|NCT01989169|DRUG|SSP-004184SS|
224006363|NCT01580553|DRUG|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
224006364|NCT01580553|DRUG|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
224006365|NCT00106301|DRUG|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
224006366|NCT02749110|DEVICE|Vaginal self-sampling brush|Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
224006367|NCT00936572|PROCEDURE|Probiotics (La1, BB536)|
224006368|NCT00936572|BIOLOGICAL|probiotics (La1, BB536)|
224006369|NCT00936572|BIOLOGICAL|placebo|Maltodoxtrin
224006370|NCT04761432|DEVICE|neoGuard|NeoGuard is a wireless wearable vital signs monitor that continuously measures temperature, pulse rate, respiratory rate and oxygen saturation.
224006371|NCT05912205|DRUG|Disitamab Vedotin|Four cycles of neoadjuvant therapy with Vidiximab (2.0mg/kg) were administered first, followed by bladder sparing therapy using maximized TURBT combined with radiotherapy and chemotherapy. The patient will receive vidiximab combined with local radiotherapy after maximizing TURBT surgery. The subjects received treatment with Vidixitol every two weeks for six consecutive treatment cycles, and simultaneously received 1 month of radiation therapy (SBRT, total dose of bladder irradiation field greater than 50 Gy)
224006372|NCT05912205|RADIATION|radiotherapy|radiotherapy
224006373|NCT00139880|DRUG|Parcopa|
224006374|NCT05099432|PROCEDURE|CARMA technique|Once standard polyp resection and assessment of the polypectomy site without magnification is completed, the CARMA technique will be applied. This will involve an assessment of the entire polypectomy margin using cap assisted magnification endoscopy with the ability to also use NBI (at the endoscopist's discretion) and documentation of any residual polyp noted.
224006375|NCT00948649|DRUG|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
224006376|NCT00948649|DRUG|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
224125533|NCT06895408|OTHER|Intravenous Infusion|Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide 1
224125534|NCT06895408|OTHER|Intravenous Infusion|Saline
224125535|NCT02924506|DEVICE|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
224125536|NCT02924506|DEVICE|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
224125537|NCT00005051|DRUG|carboplatin|
224125538|NCT00005051|DRUG|cisplatin|
224125539|NCT00005051|DRUG|paclitaxel|
223387419|NCT07072585|DRUG|Bortezomib|Given IV or SC
224006377|NCT02406677|OTHER|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
224006378|NCT05754164|BEHAVIORAL|Attention Control Training|Mobile app-based attention control training is an effective training method that can help people improve their ability to control attention. It is generally recommended to undergo 4 weeks of training, with 3-4 sessions per week and one day between each session. The specific operational method of this training may vary depending on different applications, but generally, training is presented in the form of a series of tasks. These tasks may involve aspects such as focusing attention, inhibiting interference, and reacting quickly.
224006379|NCT03807960|OTHER|written form|The written form which include PCA usage information.
224006380|NCT03807960|OTHER|video|The video about PCA usage
224006381|NCT03807960|OTHER|routine care|The routine description about PCA usage
224006382|NCT02766101|BEHAVIORAL|Aerobic Exergaming PE Curriculum|Sustained aerobic exercise.
224006383|NCT02766101|BEHAVIORAL|Standard PE|Non-aerobic skill building.
224006384|NCT02654353|PROCEDURE|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
224125540|NCT00005051|DRUG|topotecan hydrochloride|
224125541|NCT04182659|DEVICE|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
224125542|NCT04182659|DEVICE|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
224125543|NCT06911073|DIETARY_SUPPLEMENT|Postbiotic|"Active ingredients:~Vitamin D (as cholecalciferol) - 10 mcg Vitamin B12 (as methylcobalamin) - 200 mcg Chromium (as chromium picolinate) - 600 mcg resM™ Postbiotic (L. plantarum RSB11® HI - 16B cells) - 40 mg White mulberry (Morus alba) leaf extract - 250 mg Fenugreek (Trigonella foenum-graecum) seed extract - 200 mg~Inactive ingredients:~Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate"
224125544|NCT06911073|DIETARY_SUPPLEMENT|Placebo|"Active ingredients:~N/A~Inactive ingredients:~Microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, silica, water, carrageenan, potassium acetate"
224125545|NCT04552873|DRUG|Urea|"the experimental group will be treated during 5 days by urea dose per administration : 1g / kg / 24 hours in 2 or 3 doses morning, noon and evening (dose adjustment of urea according to weight)~If hyponatremia persists beyond D8 after initiation of the study treatment (urea or placebo), that is to say after the date of the collection of the primary endpoint, it will be possible to introduce corticosteroids (fludrocortisone or others). These treatments will be collated.~If during patient monitoring the serum sodium exceeds 145 mmol / L, treatment should no longer be administered."
224125546|NCT04552873|OTHER|PLACEBO|the control group will be treated during 5 days by ergytonyl dose per administration : 5mL
224006385|NCT06528847|DRUG|Benmelstobart|The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.
224006386|NCT04672785|BEHAVIORAL|SF36 questionary|patients who underwent a posterior fossa craniectomy for a cerebellar hematoma at Grenoble University Hospital between 01/01/2010 and 01/01/2020 were enrolled in this study. The main objective is to assess the level of disability and the quality of life of patients who have had a posterior cranial fossa craniectomy.
224006387|NCT04531904|DEVICE|EMBOVAC Aspiration Catheter|The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature.
224006388|NCT02251249|DRUG|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
224006389|NCT03585803|DRUG|KMRC011 5μg or Placebo|Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
224125547|NCT06833281|DRUG|SPG302|small synthetic molecule
224138536|NCT04584853|DRUG|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)|Standard of care endocrine therapy for a minimum of 5 years from randomisation
224138537|NCT05960110|DRUG|Fluoride varnish|Fluoride varnish 26200 ppm
224138538|NCT05960110|DRUG|Fluoride toothpaste|Fluoride toothpaste 1450 ppm
224138539|NCT01174953|DRUG|finasteride|"Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)"
223387420|NCT07072585|DRUG|Calaspargase Pegol|Given IV
223387421|NCT07072585|PROCEDURE|Computed Tomography|Undergo CT
223387422|NCT07072585|DRUG|Cyclophosphamide|Given IV
224006390|NCT03585803|DRUG|KMRC011 10μg or Placebo|Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
224006391|NCT03585803|DRUG|KMRC011 15μg or Placebo|Intramuscular Injection of KMRC011 15μg or Placebo(Normal Saline) 0.3ml
224006392|NCT03585803|DRUG|KMRC011 20μg or Placebo|Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.4ml
224138540|NCT02524756|PROCEDURE|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
223387423|NCT07072585|DRUG|Cytarabine|Given IT or IV or SC
223387424|NCT07072585|BIOLOGICAL|Daratumumab|Given IV
223387425|NCT07072585|DRUG|Daunorubicin Hydrochloride|Given IV
223387426|NCT07072585|DRUG|Dexamethasone|Given PO or IV
223387427|NCT07072585|DRUG|Doxorubicin Hydrochloride|Given IV
223387428|NCT07072585|PROCEDURE|Echocardiography Test|Undergo ECHO
223387429|NCT07072585|PROCEDURE|Lumbar Puncture|Under lumbar puncture
223387430|NCT07072585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223387431|NCT07072585|DRUG|Mercaptopurine Oral Suspension|Given PO
223387432|NCT07072585|DRUG|Methotrexate|Given IT or IV or PO
223387433|NCT07072585|DRUG|Methylprednisolone|Given IV
223387434|NCT07072585|DRUG|Nelarabine|Given IV
223387435|NCT07072585|DRUG|Pegaspargase|Given IV or IM
224006393|NCT03585803|DRUG|KMRC011 25μg or Placebo|Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.5ml
224006394|NCT00566189|PROCEDURE|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
224006395|NCT04997772|DEVICE|Digital Gaucher Platform|Digital platform specified for Gaucher patients.
224006396|NCT04461444|GENETIC|Skin biopsy|"COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure:~* risk of pain due to the procedure performed under local anaesthesia~* can leave a visible scar (about 2 x 1 cm)"
224006397|NCT02870829|DRUG|menaquinone-7|Oral supplement given post dialysis 3x/week
224006398|NCT02260323|OTHER|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
224006399|NCT02260323|OTHER|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
224006400|NCT06272396|DEVICE|Smart watch|ECG 1D/6D
224006401|NCT00283244|DRUG|erlotinib hydrochloride|given orally
224006402|NCT00283244|DRUG|gemcitabine hydrochloride|given IV
224006403|NCT05670015|DRUG|Low dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.2% concentration.
224006404|NCT05670015|DRUG|High dosage selective alpha-2 receptor agonists topical eyedrop|Using selective alpha-2 receptor agonists eyedrop in both groups with 0.02% concentration.
224006405|NCT01934348|BEHAVIORAL|Psychological First Aid|
224006406|NCT01934348|BEHAVIORAL|Usual victim advocacy Services|
224006407|NCT02397382|DRUG|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.
224125548|NCT04283032|PROCEDURE|Multiparametric magnetic resonance|MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
224295924|NCT06258603|OTHER|clinical oral care|"In the first stage, oral health was evaluated and data about the patient was collected.~In the second stage, routine oral care protocol used in intensive care unit was applied to patients by the patients' primary nurse. According to this application, patients were received oral care using tongue depressor with wrapped in gauze and chlorhexidine solution 4 times a day.~In the 3rd stage, saliva pH (power of hydrogen), dry mouth (amount of salivation) and ventilator associated pneumonia development status of the experimental group patients were evaluated.~Measurements were made by the researcher using the Bedside Oral Exam scale, pH (power of hydrogen) strip and Schirmer Tear Test Strip.~Data regarding whether patients were diagnosed with ventilator associated pneumonia were obtained from the Infection Control Committee."
224125549|NCT01562015|DRUG|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
224125550|NCT06921772|BEHAVIORAL|PNF Stretching Exercise|Proprioceptive Neuromuscular Facilitation (PNF) stretching exercises were applied three times per week for six weeks. The intervention included contract-relax and hold-relax techniques targeting lower extremity muscle groups, conducted in addition to regular volleyball training.
224299232|NCT04404452|DEVICE|Use of Eko CORE and Eko DUO electronic stethoscopes|Auscultation of heart and lung sounds using electronic stethoscopes
224299233|NCT02551432|DRUG|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
224299234|NCT03816215|BEHAVIORAL|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
223730149|NCT02577731|OTHER|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
224006408|NCT02397382|DRUG|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
224006409|NCT02397382|DRUG|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
224006410|NCT02397382|DRUG|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
224006411|NCT02397382|DRUG|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
224006412|NCT02397382|DRUG|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
224006413|NCT00450541|BEHAVIORAL|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
224006414|NCT00450541|BEHAVIORAL|Interview|Interview lasting about 30 minutes.
224006415|NCT00586612|BIOLOGICAL|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
224006416|NCT00586612|BIOLOGICAL|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
224006417|NCT00586612|BIOLOGICAL|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
224006418|NCT00586612|BIOLOGICAL|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
224125551|NCT03662464|OTHER|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
224125552|NCT03137394|OTHER|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
224125553|NCT07117734|OTHER|An Evaluation of the Quality and Informational Content of Balance Exercise Training Videos Published on YouTube.|"In the study, there will be no participant groups; YouTube videos searched using the keyword balance exercise will be evaluated based on specific criteria."
224299235|NCT02912585|BIOLOGICAL|Oropharyngeal administration of own mother's colostrum|
224006419|NCT00315991|BEHAVIORAL|Blood Glucose Awareness Training for Parents|
224006420|NCT01609062|DRUG|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
224006421|NCT01609062|DRUG|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
224006422|NCT02738853|DEVICE|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.
224006423|NCT02929277|OTHER|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
224006424|NCT01940133|DRUG|PQR309|Dosing will be orally, once a day for the duration of the trial.
224125554|NCT06924801|BEHAVIORAL|Snipperfingers|Snipperfinger is a self developed engagement focused software platform designed to encourage participation in pediatric physical therapy.
224125555|NCT06922032|DEVICE|Mystics Pet|Participants will receive the game intervention and be instructed to wear a Oculus Quest 2 headset (Meta, Inc., Menlo Park, CA) and participate in Mystic Pets software game (Stanford Chariot Program, Palo Alto, CA) that is specifically designed to promote overall distraction and emotional distress reduction.
224125556|NCT06923358|OTHER|Virtual Nature intervention (VN)|The intervention will consist of a 12-week virtual nature program in which participants will engage in two sessions per week. During each session, they will watch a 10-minute 360° video depicting a natural setting. Participants will select videos from a curated library of nature scenarios filmed by researchers in locations near or within the same region as their nursing homes. The videos will showcase various seasons in Norway (spring, summer, fall, and winter) and include popular activities such as hiking and cross-country skiing. The videos will be played using a Meta Quest 3 headset, with sessions conducted in participants' rooms by nursing home staff-except for the first session, which will be facilitated by the researchers.
224125557|NCT00436215|DRUG|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
224125558|NCT00436215|DRUG|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
224125559|NCT06930521|DIAGNOSTIC_TEST|Intervention - Low Risk Group OR Intermediate Risk Group|"Participants will be randomized to judicious imaging (decreased imaging frequency based on HF risk category) or SOC (imaging every 3 months). Participants who do not have any HF risk factors will be categorized as low risk, while participants with at least one risk factor will be categorized as intermediate risk for HF.~Low Risk (zero risk factors): imaging before cycles 1 and 9 of HER2-TT (i.e., at baseline and near the halfway mark, corresponding to 2 fewer studies than SOC in Year 1), then after the end of HER2TT. This translates to imaging every 6 months for uninterrupted adjuvant HER2TT.~Intermediate Risk (any risk factors): imaging before cycles 1, 6, and 12 of HER2-TT (i.e., at baseline and near the 1/3 and 2/3 marks, corresponding to 1 fewer study than SOC in Year 1), then at end of HER2TT. This translates to imaging every 4 months for uninterrupted adjuvant HER2TT."
224125560|NCT06929702|DRUG|Beta-lactam antibiotic|amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment
224125561|NCT06929702|DEVICE|Beta-lactam model-informed precision dosing|A dosing calculator is used for the prediction of starting doses (a priori dose predictions) and follow-up doses (a posteriori calculations), using a target 100% fT\>MIC.
224125562|NCT06928844|DRUG|Progesterone|Women will receive low dose progesterone 5 mg intramuscularly as a study group. (Letrozole 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
224125563|NCT06928844|DRUG|Placebo|Women will receive placebo as a control group. (Placebo 2.5 mg/day will be given from cycle day 3 onwards for only 5 days).
224125564|NCT06930118|DRUG|chidamide, regorafenib, and iparomlimab/tuvonralimab|All patients were treated with the following regimen: Chidamide: 30mg per dose, twice a week; Regorafenib: 80mg per dose, once a day, orally for 3 weeks, followed by a 1-week rest, and repeated every 4 weeks; Iparomlimab/Tuvonralimab: 5mg/kg, once every 3 weeks, intravenous infusion.
224125565|NCT07132775|DEVICE|Active full-body stimulation|Participants will receive active stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
224125566|NCT07132775|OTHER|Sham full-body stimulation|Participants will receive sham stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
224125567|NCT01808703|DEVICE|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
224125568|NCT01808703|PROCEDURE|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
223387436|NCT07072585|PROCEDURE|Positron Emission Tomography|Undergo PET or PET-CT
224006425|NCT06020183|DEVICE|Hybrid hyrax|these patents will be treated using Four mini-screws supported hybrid hyrax
224006426|NCT01891942|PROCEDURE|twitch by magstim|
224006427|NCT01008800|BEHAVIORAL|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey \& Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
223387437|NCT07072585|DRUG|Prednisolone|Given PO or IV
223387438|NCT07072585|DRUG|Prednisone|Given PO or IV
223387439|NCT07072585|OTHER|Questionnaire Administration|Ancillary studies
223387440|NCT07072585|RADIATION|Radiation Therapy|Undergo radiation therapy
223387441|NCT07072585|DRUG|Therapeutic Hydrocortisone|Given IT
223387442|NCT07072585|DRUG|Thioguanine|Given PO
223387443|NCT07072585|PROCEDURE|Ultrasound Imaging|Undergo ultrasound
223387444|NCT07072585|DRUG|Vincristine Sulfate|Given IV
223387445|NCT04537871|PROCEDURE|Bioelectric Impedance Analysis|Undergo bioelectric impedance analysis
223387446|NCT04537871|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223387447|NCT04537871|PROCEDURE|Cardiopulmonary Exercise Testing|Undergo cardiopulmonary exercise test
223387448|NCT04537871|PROCEDURE|Echocardiography|Undergo echocardiogram
223387449|NCT04537871|PROCEDURE|Physical Performance Testing|Undergo physical function tests
223387450|NCT04537871|PROCEDURE|Pulmonary Function Test|Undergo pulmonary function test
223387451|NCT04537871|OTHER|Questionnaire Administration|Ancillary studies
224006428|NCT01008800|BEHAVIORAL|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy \& Grusec, 2001).
224006429|NCT06143592|OTHER|Inspiratory Muscle Training|Inspiratory muscle training is performed using POWERbreathe® (Powerbreathe, POWERbreathe International Ltd.Warwickshire, England) with a working range of 10-90 cmH2O with the inspiratory threshold pressure loading method. The device is given to each participant to use at home, so Gazi University Scientific Research Projects Coordination Unit (BAP) was applied for the supply of the devices. At the end of the session in which the initial evaluations of all participants are made, the participants are told how to work with the device, the resistance levels of the device and the points to be considered during the application. A sample application session is performed with the participants under the supervision of a specialist physiotherapist. Participants are called by the same physiotherapist every two days by phone to ensure their compliance with the training.
224006430|NCT02922504|BEHAVIORAL|Music intervention group|
224006431|NCT02922504|BEHAVIORAL|Controlled group|
224006432|NCT00072137|BIOLOGICAL|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
223387452|NCT04537871|PROCEDURE|Ultrasound|Undergo musculoskeletal ultrasound
224006433|NCT00072137|BIOLOGICAL|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
224006434|NCT00072137|PROCEDURE|Therapeutic Conventional Surgery|Undergo cystectomy
224006435|NCT00072137|OTHER|Pharmacological Study|Correlative studies
224006436|NCT00072137|OTHER|Laboratory Biomarker Analysis|Correlative studies
224006437|NCT03330626|DEVICE|InBody group|As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
224006438|NCT03330626|OTHER|IO group|Fluid removal are guided by intake-output balance.
224006439|NCT04502017|DRUG|ASA plus Clopidogrel|OAC (6 weeks) + DAPT (until 6 months) + ASA
224125569|NCT05437029|DRUG|Q-Griffithsin 3.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of low dose Q GRFT intranasal spray DP
224125570|NCT05437029|DRUG|Q-Griffithsin 6.0|This is an open-label dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of a multiple dosing schedule of high dose Q GRFT intranasal spray DP
224138541|NCT02524756|PROCEDURE|laparoscopic radical hysterectomy (type III/C2).|
224138542|NCT00368498|DRUG|teicoplanin|
223387453|NCT06830746|DEVICE|LBBAP Implant with a CSP ICD Lead|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
223387454|NCT04729959|BIOLOGICAL|Atezolizumab|Given IV
223387455|NCT04729959|PROCEDURE|Biospecimen Collection|Undergo blood sample and tumor tissue collection
223387456|NCT04729959|PROCEDURE|Conventional Surgery|Undergo surgery
223387457|NCT04729959|RADIATION|Fractionated Stereotactic Radiation Therapy|Undergo FSRT
223387458|NCT04729959|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223387459|NCT04729959|BIOLOGICAL|Tocilizumab|Given IV
223387460|NCT06018129|BIOLOGICAL|GEN3017|Subcutaneous injection
223387461|NCT06782087|DRUG|nano chitosan|nano chitosan
223387462|NCT07075640|DRUG|AG-236|Subcutaneous (SC) Injection
223387463|NCT07075640|DRUG|Placebo|SC Injection
223387478|NCT07074886|DRUG|Ocrelizumab Test Formulation|Ocrelizumab test formulation will be administered as per the schedule specified in the respective arm.
223387479|NCT07074886|DRUG|Ocrelizumab Reference Formulation|Ocrelizumab reference formulation will be administered as per the schedule specified in the respective arm.
223387480|NCT05196984|DEVICE|GENUS device (Active Settings)|Participants in the active condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to active 40Hz settings for 30-60 minutes.
223387481|NCT05196984|DEVICE|GENUS device (Sham Settings)|Participants in the control condition within the Down Syndrome participant group and the Cognitively Normal Control group will use the GENUS device configured to sham settings for 30-60 minutes.
223387482|NCT07086248|DEVICE|Radiesse|Radiesse injections diluted 1:2 with sterile saline.
223387483|NCT06805773|OTHER|Educational videos|Participants will be provided with four educational videos in clinic prior to their initial medical oncology consult.
224006440|NCT04502017|DRUG|Genetic-Tailored AntiThrombotic Strategy|Half-Dose OAC or Clopidogrel in combination with ASA on the basis of CYP2C19 Genotype
223730150|NCT00505843|DRUG|MK0657|7mg MK0657 capsules
224006441|NCT04502017|DRUG|Half-Dose of novel OAC|Half Dose of novel OAC post-device Implantation
224006442|NCT00538317|DRUG|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
224006443|NCT00538317|DRUG|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
224006444|NCT03193775|BIOLOGICAL|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
224006445|NCT02235311|DRUG|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
224006446|NCT03636191|DIETARY_SUPPLEMENT|Probiotic strain|Lactobacillus
223730151|NCT00505843|DRUG|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
224125571|NCT02279589|BIOLOGICAL|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
224125572|NCT02279589|BIOLOGICAL|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
223730152|NCT00505843|DRUG|Comparator: levodopa|levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
224006447|NCT03636191|DIETARY_SUPPLEMENT|Placebo|Placebo
224125573|NCT02279589|BIOLOGICAL|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
224125574|NCT00309777|DRUG|Pitavastatin|Pitavastatin once daily
224125575|NCT00309777|DRUG|Simvastatin|Simvastatin once daily
224125576|NCT07148063|OTHER|Measurement of Preoperative Inflammatory Biomarkers|Blood samples will be collected preoperatively to measure inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index, monocyte-to-lymphocyte ratio (MLR), and systemic inflammation response index. These values will be analysed in relation to the incidence of postoperative nausea and vomiting within the first 6 hours after pediatric orchiopexy. No experimental drug or device will be administered as part of the study; all procedures will be conducted within the scope of standard perioperative care.
224125577|NCT07162792|DEVICE|bioresorbable scaffold|75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of BRS.
224125578|NCT07162792|DEVICE|drug-coated balloon|75 subjects with de novo large vessel coronary lesions who met the inclusion/exclusion criteria were enrolled; subjects were assigned to the treatment group of DCB.
224125579|NCT07162597|DEVICE|Pulsed Field Ablation|Pulsed Field Ablation
224299236|NCT02912585|OTHER|Oropharyngeal administration of sterile water (placebo)|
224299237|NCT02912585|BIOLOGICAL|Oropharyngeal administration of donor human milk|
223387484|NCT06805773|OTHER|Standard of Care|Participants in the control arm will be provided with the educational videos after their consult with the medical oncologist.
223730153|NCT00505843|DRUG|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
223730154|NCT04056676|PROCEDURE|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
223730155|NCT04056676|PROCEDURE|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
223730156|NCT04056676|PROCEDURE|GA with ETT|General anesthesia with endotracheal intubation
224006448|NCT00449722|DRUG|mesalazine|
224006449|NCT00658788|DRUG|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
223730157|NCT01770548|GENETIC|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
223730158|NCT01770548|GENETIC|DNA collection|DNA collection
223730159|NCT01770548|OTHER|Auditory evoked potentials|auditory evoked potentials
223730160|NCT05599568|OTHER|Exercise|Either concentric or excentric exercise
223730161|NCT01108705|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
224006450|NCT00658788|DRUG|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
224006451|NCT04496934|BEHAVIORAL|Exercise|Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
224006452|NCT05384938|BIOLOGICAL|Benralizumab|Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
224006453|NCT06003218|DRUG|Dexmedetomidine-esketamine combination|Dexmedetomidine-esketamine mixture will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
224006454|NCT06003218|DRUG|Remifentanil|Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
224006455|NCT06003218|DRUG|Oxycodone|Oxycodone will be injected intravenously 10-15 min before puncture.
224006456|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of ≥65 mmHg|The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.
224006457|NCT06451133|OTHER|Mean arterial blood pressure (MAP) goal of 85-90 mmHg|The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.
224006458|NCT06451133|OTHER|Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg|The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
224006459|NCT03517943|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
224006460|NCT03517943|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
223387485|NCT03630380|OTHER|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
223387486|NCT03630380|OTHER|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
223387487|NCT03630380|OTHER|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
223387488|NCT03630380|OTHER|Lung Ultrasound|We will perform lung ultrasound on all patients.
223387489|NCT06538740|PROCEDURE|Ventilating the patient with lower (40 or 70%) oxygen concentration during the wash out phase, before extubation|The investigated intervention is the application of 70% inspired oxygen compared to 100% inspired oxygen during the anesthetic washout, right before extubation of the patient for the first 24 enrolled patients, and 40% inspired oxygen compared to 100% inspired oxygen for the subsequently enrolled 24 patients. Before and after the intervention EIT measurements are performed at designated time points to assess lung aeration and calculate the center of ventilation. This information allows assumptions on atelectasis formation in the patients' lung.
223387490|NCT07089485|OTHER|effects of sound|The surgical trainees will perform four 15-minute surgical sequences in a controlled environment, with varying sound levels (64, 67, 73, and 75 dB(A)) randomized across the sequences to assess the surgeons' responses.
223387491|NCT04917861|BIOLOGICAL|mRNA-1893|Solution for injection
223387492|NCT04917861|BIOLOGICAL|Placebo|0.9% sodium chloride solution for injection
223387493|NCT06906601|PROCEDURE|magnetic clip localization|magnetic clip localization for preoperative localization for breast cancer surgery
224006461|NCT02626455|DRUG|Copanlisib (BAY80-6946)|"Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Treatment with copanlisib/placebo will be continued up to 12 months.~Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days."
224006462|NCT02626455|DRUG|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
224006463|NCT02626455|DRUG|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
224125580|NCT07162688|DRUG|Omega-3 Lipid Emulsion|Intravenous Omega-3 lipid emulsion administered at a dose of 2 mL/kg/day (equivalent to 0.2 g/kg of fish oil), starting from the conditioning phase prior to hematopoietic stem cell infusion and continuing daily until neutrophil and platelet engraftment or up to Day +35 post-transplantation. The emulsion is infused over 4-6 hours and combined with medium- and long-chain triglyceride emulsion as part of parenteral nutrition.
224125581|NCT07163364|DRUG|Hydroxocobalamin Chloride Injection|1 - 20 mg per dose, 1 - 5 times per week
223387494|NCT06906601|PROCEDURE|metallic wire localization.|metallic wire localization for preoperative localization for breast cancer surgery
223387495|NCT06906601|PROCEDURE|Breast cancer surgery|Patient with invasive or in situ breast carcinoma, presenting with a unifocal and unilateral lesion, requiring a first-line breast-conserving treatment with preoperative localization, regardless of the associated lymph node procedure
223387496|NCT07091851|BEHAVIORAL|Group medical visits and home blood pressure monitoring|This arm will receive instructions for home blood pressure monitoring but also be enrolled in group medical visits.
223387497|NCT06887569|BEHAVIORAL|Rewards|Financial rewards for attending therapy
223387498|NCT06887569|BEHAVIORAL|Screening|Information about screening for depression and anxiety
223387499|NCT06389487|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1.
223387500|NCT04585711|DRUG|Etanercept Optimal dosing|Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.
223387501|NCT06908096|BIOLOGICAL|EBV gp350-ferritin vaccine with ALFQ adjuvant|The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.
223387502|NCT06908096|BIOLOGICAL|EBV gH/gL/gp42-ferritin nanoparticle vaccine with ALFQ adjuvant|The adjuvanted gH/gL/gp42-ferritin nanoparticle vaccine is given with gp350-ferritin intramuscularly into the deltoid muscle at 0, 1, and 4 months.
223387503|NCT07107737|BEHAVIORAL|Physician Consultation|Every other month will be randomized to either Physician Consultation or Standard of Care. During the months designated for Physician Consultation, direct communication between the patient and a designated physician by phone will be implemented when a patient refuses transport in cases where the EMS clinician feels that physician consultation is warranted for further guidance. The physician will attempt to address patient concerns and provide additional medical advice.
223425655|NCT05474170|OTHER|ERC resuscitation sequence|Starting the cardiopulmonary resuscitation by following the ERC guideline, meaning starting with 5 initial ventilations, then alternating 15 chest compressions with 2 ventilations
223730162|NCT01108705|DRUG|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
224006464|NCT02626455|DRUG|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
224006465|NCT02626455|DRUG|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
224125582|NCT07161804|DRUG|Homoeopathic medicines|Thuja officinalis Vaccininum Causticum Argentum nitricum Tuberculinum Stramonium Staphysagria Arum triphyllum Bacillinum Cina Carcinocin Cuprum Metallicum Ambera grisea Calcarea carbonica Crocus sativus Hepar sulphur Hyoscymus Kali Bromatum Lac Vaccininum Medorrhinum Natrum phosphoricum Thyroidinum
224006466|NCT02626455|DRUG|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
224006467|NCT02626455|DRUG|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
224006468|NCT02626455|DRUG|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
224006469|NCT00043953|DRUG|Lopinavir/ritonavir|
224006470|NCT00043953|DRUG|Saquinavir mesylate|
224125583|NCT07161804|BEHAVIORAL|Therapy|Occupational Therapy / Speech Therapy
224125584|NCT07161804|DRUG|Placebo|Saccharum lactis
224125585|NCT07161687|DRUG|Marstacimab|For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcutaneously at a dose of 300 mg as the initial dose, followed by 150 mg once weekly. If the patient weighs 50 kg or more and shows an inadequate response, the dose may be increased to 300 mg once weekly for subcutaneous administration.
224125586|NCT07162987|BEHAVIORAL|Prehabilitation|Please refer to arm description
224125587|NCT07163702|DRUG|High-dose Xinglou Chengqi granules|Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
224125588|NCT07163702|DRUG|Low-dose Xinglou Chengqi granules and placebo|Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.
224125589|NCT07164027|PROCEDURE|Biopsy of Prostate|Undergo biopsy
224125590|NCT07164027|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224125591|NCT07164027|PROCEDURE|Computed Tomography|Undergo PET/CT
224125592|NCT07164027|RADIATION|Flotufolastat F-18 Gallium|Given IV
224125593|NCT07164027|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224125594|NCT07164092|DRUG|Atropine 0.05% Eye drops|The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.
224125595|NCT07164092|DRUG|Placebo ophthalmic solution|The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.
224125596|NCT07162740|PROCEDURE|Right atrial ablation|Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to right atrial ablation. The patients receive a right atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.
224125597|NCT07162740|PROCEDURE|Bi-atrial ablation|Eligible patients receive the implantation of a LuxDx® ILR and are monitored for one month by means of the Latitude Clarity data management system of the device. The usual practice of the centres is unchanged. According to their usual practice, the centre is assigned to bi-atrial ablation. The patients receive a bi-atrial procedure accordingly. As per pragmatic design, cross-over are permitted according to investigator judgment. The ablation methods and techniques are left to investigator's decision. They are reported in the CRF.
223387504|NCT07107737|BEHAVIORAL|Standard of Care|Every other month will be randomized to either Physician Consultation or Standard of Care. During the months designated for Standard of Care, physician intervention will not be provided. For safety reasons, if physicians or EMS MEDIC clinicians feel that speaking with the patient is important to provide additional clinical benefit, they may do so without hesitation and can override the designated intervention month.
223387505|NCT07105878|PROCEDURE|Epidural Electrical Stimulation|Epidural Electrical Stimulation (EES) is a medical technology that involves delivering controlled electrical impulses to the spinal cord through electrodes implanted in the epidural space-the area between the outermost membrane of the spinal cord (dura mater) and the vertebrae. This technique aims to modulate the activity of spinal neural networks, thereby regulating neurological functions and promoting functional recovery, particularly in individuals with spinal cord injuries or certain neurological disorders.
223387506|NCT07105878|PROCEDURE|Standard Rehabilitation Therapy|A structured, multidisciplinary rehabilitation program designed to improve motor function, mobility, and independence in participants with paralysis. The therapy typically includes physical Therapy and occupational Therapy.
223387507|NCT07105878|RADIATION|positron emission tomography-computed tomography (PET-CT)|PET-CT is an advanced hybrid imaging modality that combines metabolic information from positron emission tomography with anatomical details from computed tomography.
223730163|NCT01080521|PROCEDURE|Cognitive Assessment|Ancillary studies
223730164|NCT01080521|OTHER|Quality-of-Life Assessment|Ancillary studies
224006471|NCT00043953|DRUG|Lamivudine/zidovudine|
224006472|NCT01224470|DRUG|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
224006473|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete expressive disclosure writing
224006474|NCT02339870|OTHER|Psychosocial Support for Caregiver|Complete benefit finding writing
224006475|NCT02339870|OTHER|Questionnaire Administration|Ancillary studies
224125598|NCT07161921|OTHER|lymph node metastasis|Histopathological examination confirmed the presence of at least one lymph node metastasis
224125599|NCT07162896|DRUG|Crisaborole 2%|Apply thin layer to affected skin daily for 28 days.
224125600|NCT07162896|DRUG|Tacrolimus 0.1%|Apply thin layer to affected skin daily for 28 days.
224125601|NCT07163871|BEHAVIORAL|Postpartum hygiene, breast milk, and breastfeeding education have been provided for new mothers.|During the first ten days after birth, the first month, and the third month, new mothers received detailed care and education through home visits in addition to routine postnatal education. Information was shared at the mother's request as needed.
224125602|NCT07161817|BEHAVIORAL|Lateral positioning|Patients allocated to lateral positioning were placed at 90° on a horizontal bed, supported with a pillow to maintain neutral alignment of the spine and avoid hyperextension or forward flexion of the neck. No preference was specified for left or right lateral decubitus positioning, allowing flexibility based on patient comfort and surgical requirements.
224125603|NCT07161817|BEHAVIORAL|Semirecumbent positioning|Patients in the semi-recumbent position were placed in the bed and the head of the bed was raised by 30 °, allowing flexibility based on patient comfort and surgical requirements.
224299238|NCT05693207|DEVICE|EMG|wearables EMG
224299239|NCT00930371|OTHER|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
223387508|NCT07105878|RADIATION|Diffusion Tensor Imaging (DTI)|DTI is an advanced MRI technique that maps white matter tracts by measuring the directionality (anisotropy) and magnitude of water molecule diffusion in neural tissues. It provides quantitative metrics of fibers.
223387509|NCT07105878|PROCEDURE|Somatosensory Evoked Potentials (SEPs)|SEPs are electrophysiological responses recorded from the central or peripheral nervous system following electrical stimulation of sensory nerves. They assess the functional integrity of somatosensory pathways.
223387510|NCT07105878|PROCEDURE|Motor Evoked Potentials (MEPs)|MEPs are electrophysiological responses elicited by transcranial magnetic stimulation or electrical stimulation of the motor cortex, recorded from peripheral muscles or the spinal cord. They evaluate the integrity of corticospinal tracts.
223387511|NCT06923306|BEHAVIORAL|Virtual reality exposure|This is a single case design and there is only one intervention. In the no-treatment arm, participants will only have assessment but no virtual reality exposure therapy.
223387512|NCT06926699|PROCEDURE|Medial Patellofemoral Ligament Reconstruction|An initial evaluation with a diagnostic knee arthroscopy is done to ensure there are no loose bodies or osteochondral lesions missed on MRI that require removal or fixation. Graft harvest and preparation is done using either an autograft or allograft tendon as per a shared decision-making approach between the surgeon and patient. A 2cm longitudinal incision is made over the anteromedial aspect of the patella and dissection done between the second and third layers. Fixation (variable depending on surgeon preference) is performed over the proximal half of the patella. Another skin incision is then made over the medial femoral epicondyle with a guide pin passed through Schottle's point. The proximal femoral cortex is then drilled overtop of the guide pin to a diameter equal to the graft diameter with the remainder of the femoral tunnel drilled to 4.5mm.The graft ends are tied to the patellar fixation and shuttled through the second and third layers and fixed to the femur.
224006476|NCT02339870|OTHER|Sham Intervention|Complete writing on an emotionally neutral topic
224006477|NCT06546722|PROCEDURE|Transversus Thoracic Plane Block|The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.
224006478|NCT04126252|DRUG|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
224006479|NCT04126252|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
224006480|NCT04126252|COMBINATION_PRODUCT|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
224006481|NCT04126252|OTHER|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
224125604|NCT07163104|BEHAVIORAL|Kaleidoscope|"Immediately before the procedure, children will be given the opportunity to examine the kaleidoscope and asked what shapes they see. The kaleidoscope distraction will begin immediately before the immunotherapy procedure and continue throughout the procedure. Children will be asked detailed questions such as, What shapes do you see in the picture? What colors are there? How many eyes do you see in the picture?, which the child can only accurately answer after careful examination. After the procedure, the kaleidoscope will be wiped with 70% alcohol and preserved by the researcher for the next session. A Zapp Flex Kaleidoscope (31.5 cm) will be used in this study."
224006482|NCT04165044|PROCEDURE|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
224125605|NCT07163104|BEHAVIORAL|Buzzy|The device contains a wing-shaped ice pack on the skin-contact portion. The ice pack is stored in a deep freezer and inserted into the device before application. After application, the ice pack is wiped with 70% alcohol and kept in the freezer until it freezes again. Cold application and vibration begin before the procedure and continue until the end. When vibration is applied, it reduces or eliminates pain by causing numbness, paresthesia, and anesthesia. Cold application reduces pain by slowing or blocking conduction in peripheral nerves. It also reduces pain by activating the gate-control mechanism, stimulating touch receptors, and increasing the release of endogenous opioids.
224125606|NCT07163104|BEHAVIORAL|Cognitive behavioral intervention|The researcher will suggest various distraction techniques (counting, singing, reading poetry, answering questions, etc.) to shift the child's focus during the procedure. The distraction technique chosen by the child will be used during the procedure. This method will be chosen during the preparation and briefing phases of the procedure. Cognitive behavioral intervention application will begin before subcutaneous application and will last 15-20 minutes, after which subcutaneous application will begin. After subcutaneous administration, children will rate their pain levels during and after the procedure with the Wong Baker Scale, their anxiety levels with the Children's State Anxiety Scale (CSA), and their fear levels with the Children's Fear Scale (CFS). A parent present with the child will observe the child's behavioral state during the procedure and will rate the child's fear level during and after the procedure with the CFS and their anxiety level with the CSA.
224125607|NCT07162714|RADIATION|radiotherapy|The patients receive pelvic radiotherapy: Intensity-Modulated Radiation Therapy (IMRT) or Volumetric Modulated Arc Therapy (VMAT), with a total dose of 25 Gy delivered in 5 fractions. Radiotherapy is to start on day 1 and to finish on day 5.
224125608|NCT07162714|DRUG|Ivonescimab (20mg/kg Q3W)|The first dose of vonescimab (AK112) was administered 1 week after the completion of radiotherapy. Ivonescimab (AK112) was initiated at a dose of 20 mg/kg via intravenous infusion on Day 1 of each 21-day cycle, for a total of 6 cycles.
224125609|NCT07162714|OTHER|Non-operative Management|Subjects who achieve cCR after radiation and 6 cycles treatment of Ivonescimab can, after discussion with the local investigator, decline surgery and opt for a non-operative management.
224299240|NCT00930371|OTHER|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
224125610|NCT07162714|PROCEDURE|Surgery|For patients who do not achieve cCR at the end of 6 cycles treatment of Ivonescimab, TME surgery is recommended.
223387513|NCT06926699|OTHER|Rehabilitation|Patients will be initially placed in a patellar stabilizing brace and told to remain non weight-bearing for the first two weeks. Subjects will be permitted to perform gentle ROM exercises while in the knee brace with progressive weight-bearing as tolerated permitted at the 2-week mark. Formal physiotherapy commences at 2-weeks post-enrollment, with a goal of return to activities or sport at 6-months post-enrollment.
223387514|NCT07140679|PROCEDURE|Biopsy Procedure|Undergo biopsy
223387515|NCT07140679|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223387516|NCT07140679|PROCEDURE|Colonoscopy|Undergo colonoscopy
223387517|NCT07140679|PROCEDURE|Computed Tomography|Undergo CT
223387518|NCT07140679|OTHER|Questionnaire Administration|Ancillary studies
223387519|NCT07140679|DRUG|Toripalimab|Given IV
223387520|NCT04004403|OTHER|Alternate day fasting|"The diet involves consuming 600 kcal on the fast day and eat ad libitum at home on alternating feed days."
223387521|NCT04004403|OTHER|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session, 60-85% HRmax.
223387522|NCT07143604|DRUG|AZD0901|Participants will receive AZD0901 IV, Q3W
224006483|NCT04165044|PROCEDURE|Connective tissue graft plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
224006484|NCT00724165|BEHAVIORAL|Intervention|Culturally-modified, individually tailored physical activity print materials
224006485|NCT00724165|BEHAVIORAL|Control|Bilingual health education booklets
224125611|NCT07161843|DRUG|QRX-3|Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
224125612|NCT07162376|BEHAVIORAL|Personal Information Disclosure|Each profile also contains non-health related personal information that the patient has disclosed (e.g., nickname, hobbies).
224125613|NCT07162389|DEVICE|Shallow-Threaded Short Implant (SHI)|A 7mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) Macrodesign, surgically placed in the jawbone to restore missing teeth
224125614|NCT07162389|DEVICE|Shallow-Threaded Standard Implant (SDI)|A 11mm long, 4.2mm diameter dental implant with shallow thread (\<0.5mm depth) macrodesign, surgically placed in the jawbone to restore missing teeth.
224295925|NCT06058286|OTHER|Continuous quality improvement|Continuous quality improvement (CQI) is an approach to develop healthcare providers' capacity to improve quality of care processes and improve adherence to clinical guidelines. Key features of CQI include systematic, data-guided activities, designing interventions (or changes to facility processes) with local conditions in mind, and iterative development and testing of interventions. The approach is based on the premise that valuable improvement in organisational processes can be achieved through bottom-up initiatives of stakeholders and providers. It requires a 'team-based' culture of staff working together to collect and use available data to evaluate the effect of local solutions. Facility staff drive the development of solutions to quality of care shortcomings that they feel are best suited to the local context, and CQI works within existing resource constraints so it does not require large long-term investments to sustain improvements.
224295926|NCT05500196|DEVICE|Per Oral Endoscopy Myotomy (POEM)|POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
223387523|NCT07144293|DRUG|Dasatinib|Dasatinib will be administered as one 100 mg capsule.
223387524|NCT07144293|DRUG|Quercetin|Quercetin will be administered as five 250 mg capsules.
223387525|NCT07144293|OTHER|Placebo - Dasatinib|Matching Placebo for Dasatinib will be administered as one 100 mg capsule.
223387526|NCT07144293|OTHER|Placebo - Quercetin|Matching Placebo for Quercetin will be administered as five 250 mg capsules.
223387527|NCT06946056|OTHER|biofiller prp|Ten ml of the patient's blood was drawn in a syringe pre-filled with 1 mLacid citrate dextrose(anticoagulant). It wascentrifuged firstat 3500 rotations per minute (RPM)for 15 min and thenat 1500 RPM for 5 min. The upper part,i.e.,platelet-poor plasma (PPP) waswithdrawn in a 5 mL syringe. PPP wasincubated in hot water at 100a °C for 5 min and then cooled in a refrigerator for 5 min.The PRP injection was performed in a standardized manner and injected into the IA surface of the affected knee joint
223387528|NCT01942421|PROCEDURE|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
223387529|NCT07148024|DEVICE|ETT cuff pressure 0 mmHg|In this group, the endotracheal tube (ETT) cuff pressure will be maintained at 0 mmHg during cardiopulmonary bypass (CPB)
223387530|NCT07148024|DEVICE|ETT cuff pressure 20-30 mmHg|In this group, the endotracheal tube (ETT) cuff pressure will be maintained at 20-30 mmHg during cardiopulmonary bypass (CPB)
223387531|NCT06953453|DRUG|Inhaled Fentanyl Aerosol|The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg Fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg Fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
223387532|NCT06953453|DRUG|Fentanyl Citrate Injection|The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.
223730165|NCT04774874|DRUG|Topical formulation|Topical administration on the scalp once daily for 16 weeks
223730166|NCT03821298|OTHER|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
224006486|NCT04822077|RADIATION|Proton radiation|"* Patients with radical surgery and unfavourable histology (B2, B3, C) and/or Masaoka-Koga stage III, IVa: 2 Gy(RBE), once daily, five days a week to a total dose of 50 Gy(RBE).~* Patients with non-radical surgery (R1 resection) regardless of stage and histology: 2.3 Gy(RBE), once daily, 5 days a week to a total dose of 57.5 Gy(RBE)~* Inoperable patients regardless of stage and histology and patients with R2 non-radical resection: 2.5 Gy (RBE), once daily, 5 days a week to a total dose of 62.5 Gy(RBE)"
224006487|NCT06142110|OTHER|Funcional movement screen|FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.
224006488|NCT06142110|DIAGNOSTIC_TEST|Respiratory muscle strength|Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
224006489|NCT06573749|DIETARY_SUPPLEMENT|Bioactive whey protein concentrate|Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.
224006490|NCT06573749|DIETARY_SUPPLEMENT|Whey protein isolate supplement|Every day for 12 weeks, participants will mix 1 scoop of supplement with \~350ml of water and consume the resultant drink alongside their breakfast.
224006491|NCT03442153|DIETARY_SUPPLEMENT|Solgar No7 Complex|Solgar No7 Capsules
224006492|NCT03442153|DIETARY_SUPPLEMENT|placebo|Placebo tablets Cellulose
224006493|NCT01470053|DRUG|mometasone furoate plus azelastine HCl|
224006494|NCT01470053|DRUG|mometasone furoate|
224006495|NCT01470053|DRUG|azelastine HCl|
224006496|NCT01663051|DEVICE|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
224006497|NCT02906163|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
224295927|NCT05597735|DRUG|Tecovirimat|"The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days."
224295928|NCT05597735|DRUG|Placebo|The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
223730167|NCT02862613|PROCEDURE|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
224006498|NCT02906163|DRUG|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
224006499|NCT06725069|OTHER|Neuromuscular Electrical Stimulation|NMES was performed using the Enraf Nonius Myomed 632X device. Both applications were performed 5 days/week for 4 weeks. NMES was performed with the patients in a sitting position and the affected arm resting on a table with the forearm supinated (Agonist group) / forearm pronated (Antagonist group). Surface electrodes (50x50 mm self-adhesive) were placed on the wrist and finger flexor/extensor muscle group. NMES parameters; Symmetric biphasic, pulse width 200 μs, on time 6 seconds (ramp up 1 second, ramp down 2 seconds), off time 12 seconds, stimulation intensity according to the patient's tolerance (not exceeding 90 mA), frequency 50 Hz and was adjusted to elicit contraction in the flexor and extensor muscles of the wrist and fingers.
224006500|NCT06725069|OTHER|Control (Standard treatment)|In addition to conventional treatment, participants were included in an occupational rehabilitation program for 20 minutes to improve upper extremity functions.
224006501|NCT06728111|OTHER|High sensitive Troponin T|The baseline population will consist of all patients who underwent a form of non-cardiac surgery. Baseline variables, medication use, type of surgery and perioperative hemodynamic and laboratory variables will be extracted from the hospital information system. One year mortality is registered, as well as major vascular events. This is in line with previous publications from our group. The adjudication strategy used for patients with myocardial injury. For the adjudication process minimal two senior anesthesiologists will be invited. Two members with at least one senior anesthesiologist will receive a sample of patients to adjudicate. Together the entire panel will adjudicate all patients. The goal to investigate the differences between the raters.
224006502|NCT06731803|DRUG|Trastuzumab deruxtecan + 5FU/LV|trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
224006503|NCT06731803|DRUG|Trastuzumab deruxtecan + FLO|trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles FLO: oxaliplatin 85 mg/m2 and leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
224006504|NCT06897150|DRUG|Carotegrast methyl|a dosage of 960 mg three times daily
224006505|NCT01477580|BIOLOGICAL|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006506|NCT01477580|BIOLOGICAL|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006507|NCT01477580|BIOLOGICAL|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
224006508|NCT01477580|BIOLOGICAL|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006509|NCT01477580|BIOLOGICAL|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224295929|NCT06079697|OTHER|Electronic Health Record Review|Ancillary studies
224295930|NCT06079697|OTHER|Exercise Intervention|Receive prehabilitation exercise intervention
224295931|NCT06079697|OTHER|Medical Device Usage and Evaluation|Wear Fitbits
224295932|NCT06079697|OTHER|Survey Administration|Ancillary studies
224006510|NCT01477580|BIOLOGICAL|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
224006511|NCT01477580|BIOLOGICAL|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
224295933|NCT03026907|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
223387533|NCT07143838|DEVICE|Transcranial Electrical Stimulation (TES)|Using the Sleep WISP device, transcranial electrical stimulation will be delivered during sleep as 0.5 Hz sine wave, 0.5 mA, between frontal (frontopolar and inferior lateral frontal) and posterior (mastoid and occipital) electrodes.
223387534|NCT07142252|DRUG|Rezpegaldesleukin|Rezpegaldesleukin will be dosed at 12 μg/kg for subcutaneous injection. Rezpegaldesleukin will be provided as a 1.5 mg/mL sterile solution in a vial for injection preparation. Study agent injections will be administered in the abdomen, back of the upper arm or the upper thigh of the participant.
223387535|NCT07142252|DRUG|Placebo|Sterile saline for injection. Placebo will be administered in the same volume and as the active comparator to maintain treatment masking.
223387536|NCT07149350|BEHAVIORAL|FAVORes Workshop|The FAVORes (Food Access, Value, and Optimization of Resources) Workshop is a 4-week, in-person group coaching program for caregivers of children in food-insecure households. The intervention focuses on financial and nutrition literacy, community resource navigation, healthy eating habits, and setting family goals.
223387537|NCT07152132|PROCEDURE|Trabeculectomy|Trabeculectomy with mitomycin c application
224006512|NCT01477580|BIOLOGICAL|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006513|NCT01477580|BIOLOGICAL|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006514|NCT01477580|BIOLOGICAL|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006515|NCT01477580|BIOLOGICAL|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006516|NCT01477580|BIOLOGICAL|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
224006517|NCT01477580|BIOLOGICAL|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
224006518|NCT05020457|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
224006519|NCT05020457|DRUG|AP or TP|AP or TP should be administered immediately after SI-B001 is completed. The administration of AP or TP should refer to the drug instructions and standard usage.
224006520|NCT05020457|DRUG|Docetaxel|Docetaxel should be administered immediately after SI-B001 is completed. The administration of Docetaxel should refer to the drug instructions and standard usage.
224006521|NCT00146094|PROCEDURE|BMD Measurement|
224006522|NCT00146094|DRUG|antiretrovirals|Treated with antiretrovirals
224006523|NCT05812820|COMBINATION_PRODUCT|LiveSpo DIA30|LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
224006524|NCT05812820|COMBINATION_PRODUCT|LiveSpo CLAUSY|LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam
224006525|NCT05812820|OTHER|RO|"Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle"
224006526|NCT06477250|BEHAVIORAL|Empathy-based socio-emotional mental training|The goal of the EmCo dyad practice is to enhance coping with difficult emotions, empathic and compassionate listening, social sharing, acceptance, and gratitude. It involves a daily partner-based practice and weekly coaching sessions with expert teachers.
224006527|NCT06398457|DRUG|Darzalex Faspro (Daratumumab and hyaluronidase-fihj)|Darzalex Faspro will be administered weekly as a subcutaneous injection on Days -42, -35, -28 and -21 (+/- 1 day) for a total of four doses at 1800 mg each.
224006528|NCT06398457|DEVICE|JH-DSA Semi-Quant Screen and Response Score|Serum based semi-quantifiable investigational testing regimen used to screen for high DSA level or assess response to desensitization. It is based on results from cross-matched flow cytometric assessment cellular-based and solid phase immunoassays (SPI) that estimates antibody level.
224006529|NCT04917107|BEHAVIORAL|Qigong|"The Five Element Qigong Healing Movements practice includes five gentle horizontal and vertical arm and leg movements performed with guided breathing."
224006530|NCT05501769|DRUG|ARV-471 in combination with Everolimus|ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
224006531|NCT06834724|OTHER|Standard OSA care|All people will undergo standard care.
223387538|NCT07152132|PROCEDURE|Slow coagulation trans-scleral cyclophotocoagulation|Slow coagulation trans-scleral cyclophotocoagulation
223387539|NCT07160257|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be administered SC.
223387540|NCT07160257|DRUG|Placebo|Placebo will be administered SC.
224006532|NCT04965675|DRUG|Eptinezumab|Eptinezumab will be administered per dose and schedule specified in the arm.
224295934|NCT03026907|DRUG|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
224295935|NCT02924636|BEHAVIORAL|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
224295936|NCT06324799|OTHER|phototherapy treatment|The newborns in the study group will be subjected to position changes (supine, prone, lateral) every 2 hours
224295937|NCT06294236|BIOLOGICAL|SC291|SC291 is an allogeneic CAR T cell therapy
224125615|NCT07163897|DEVICE|Cobra Ankle Arthrometer|This is a prototype portable ankle arthrometer designed to measure the laxity of the ankle joint.
224125616|NCT07162103|OTHER|GMART|Group Mandala Art Therapy
223387541|NCT07161960|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the definite treatment for acute cholecystitis. According to Tokyo Guideline 2018, the proper timing of delay LC remains unclear due to lack to proper evidence.
224006533|NCT04965675|DRUG|Placebo|Placebo matching to eptinezumab will be administered per schedule specified in the arm.
224006534|NCT06632483|DRUG|Vericiguat (Verquvo, BAY1021189)|Prescibed as per local label
224006535|NCT04693546|DIAGNOSTIC_TEST|LifeKit Prevent Colorectal Neoplasia Test|Procedure: Colonoscopy
224006536|NCT04693546|DIAGNOSTIC_TEST|FIT Test|Procedure: Colonoscopy
224006537|NCT05038735|DRUG|Alpelisib|Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
224006538|NCT05038735|DRUG|Fulvestrant|Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).
224006539|NCT05038735|DRUG|Alpelisib-matching placebo|"Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~After Protocol Amendment 5 is implemented, alpelisib matching-placebo will no longer be supplied or administered once participants have been unblinded."
224006540|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed of POCT results for CT and NG|Molecular, PCR based near-POCT performed by the research assistant on self -collected urine. The outcome is positive or negative
224125617|NCT06238466|DRUG|AZD1705|Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.
224125618|NCT06238466|OTHER|Placebo|Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.
224125619|NCT06525701|OTHER|Execise Group|SCORE workout: eight exercises done sequentially: bicycles, balancing dog, windshield wipers, three-point plank, kayaker, super push-ups, bridge, and side plank. These workouts are modified from the core regimen recommended by Steve House and Scott Johnston in their book Training for the New Alpinism: A Manual for the Climber as Athlete (House 2014). Each exercise is done until fatigue: when the individual is no longer able to complete the exercise with good form. The participant then rests for approximately thirty to sixty seconds before beginning the next exercise. Passive stretching can be performed during the rest periods. The workout is complete at twenty minutes. Those individuals who complete all eight exercises in less than twenty minutes begin again with the first exercise (bicycles) and continue until reaching twenty minutes. The workout is thus adaptive-seamlessly increasing in repetitions as an individual's strength and endurance increase.
224125620|NCT06525701|OTHER|Control Group|No additional exercises or tasks are requested of control participants. Control group participants will perform or not perform exercise as they otherwise would outside of the study.
224125621|NCT06023680|BEHAVIORAL|Continuous sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days."
223387542|NCT07176286|DRUG|18F-MFBG|Intravenous injection of 222-370 MBq (6-10 mCi) 18F-mFBG followed by whole body PET imaging.
223425656|NCT05862337|DRUG|Anlotinib hydrochloride capsules, Penpulimab injection|"Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1)."
224006541|NCT05977491|DIAGNOSTIC_TEST|Health care practitioner is informed about POCT result for TV and BV|The pH of vaginal secretion is measured from a self-collected swab by the research assistant, and if above 4.5 a dropp of KOH is added. If it smells fishy, the whiff test is positive.
224006542|NCT05977491|OTHER|addressing psycholsocial problems|"1. Participants screening positive for anxiety, depression or domestic violence will be offered psychological counseling or referral to a crisis management center in the POCT-PLUS arm~2. All participants of the POCT-PLUS arm receive audio- visual and written education on vaginal discharge and antibiotics"
224006543|NCT05245513|BEHAVIORAL|Recovery Community Center Linkage (RCCL)|A certified recovery coach will meet with participants to educate them on recovery support services, including recovery community centers, and link them to a recovery community center, with the aid of a facilitated connection to a volunteer recovery community center member (e.g., calling a standby peer, scheduling a meet-up at the center). The coach will also provide the participant with a brochure of recovery support resources.
224006544|NCT05245513|BEHAVIORAL|Control Condition (CC)|A certified recovery coach will meet with participants to educate them on recovery support services more broadly, including recovery community centers, and will provide them with a brochure of recovery support resources.
224006545|NCT06225908|PROCEDURE|Serratus posterior superior intercostal plane block|application of local anestesic under serratus posterior superior muscle at the level of second costa
224006546|NCT06003231|DRUG|disitamab vedotin|Given into the vein (IV, intravenous) every 2 weeks
224125622|NCT06023680|BEHAVIORAL|Bouted sedentary reduction intervention|"During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts).~During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days."
224125623|NCT05513053|BIOLOGICAL|Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH|Pharmaceutical form: Solution for injection Route of administration: intramuscular
224125624|NCT04239703|DIAGNOSTIC_TEST|MMDx|Portion of kidney transplant indication biopsy
224125625|NCT04239703|DIAGNOSTIC_TEST|Prospera|Transplant patient blood sample
224125626|NCT04239703|DIAGNOSTIC_TEST|HLA antibody|Transplant patient blood sample
224125627|NCT06811233|DRUG|DMSA|Given PO
224125628|NCT06811233|DRUG|Ca-EDTA|Given by IV
224125629|NCT06811233|DRUG|Magnesium Sulfate|Given by infusion
224125630|NCT06811233|DRUG|Multivitamin|Given PO
224125631|NCT03124173|OTHER|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
224299241|NCT02871271|DIETARY_SUPPLEMENT|IQP-AS-121|
224006547|NCT04852341|DEVICE|Collect ocular biological parameters including age, corneal diameter, eye axis, intraocular pressure, steep&flat axis of corneal curvature, corneal thickness, lens thickness, anterior chamber depth|observation
224006548|NCT06601699|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
224125632|NCT03124173|OTHER|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
224125633|NCT03124173|OTHER|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
224125634|NCT03124173|OTHER|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
224125635|NCT04696159|PROCEDURE|Pyloromyotomy|Endoscopic Per-Oral Pyloromyotomy (POP)
224125636|NCT05361122|DIETARY_SUPPLEMENT|Maternal Use of Xylitol Chewing Gum During Pregnancy|There are no current interventions within this follow-up study. However, the mothers enrolled in the parent PPaX trial received xylitol-containing chewing gum (1 gram per stick of gum and instructed to chew 1-2 sticks of gum twice daily for a total dose of 2-4 grams/day of xylitol throughout pregnancy starting pre-conception or at \<20 weeks gestation).
224125637|NCT05361122|DIETARY_SUPPLEMENT|No Maternal Xylitol Chewing Gum Use During Pregnancy|There are no current interventions within this follow-up study. Children born to mothers who received access to a dentist and prenatal education (oral health, prevention of preterm birth) are in the active comparator group
224125638|NCT06797375|DRUG|RLYB116 for Injection|RLYB116 is a small protein composed of an Affibody® Z-domain that binds with high affinity to C5, inhibiting terminal complement activation, and an albumin binding domain (ABD) that extends the effective plasma half-life of the protein by targeting serum albumin.
224006549|NCT06601699|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
224006550|NCT05253157|OTHER|Virtual Reality Augmented remote rehabilitation|XRHealth offers remote skilled therapy treatments such as education, exercise, and VR-augmented activities. The platform consists of the VRHealth portal with multiple immersive applications for measurement, motor-cognitive training, and mindfulness/cognitive behavioral applications for symptom relief, the external control application, and the XR Health data portal with real-time analytics for evaluating performance. Contraindications for VR use are assessed. Treatment sessions are 60 min long. Duration and frequency are based on clinical judgement. VR interventions used are; VR motor-cognitive: ReAct, Color Match, Memorize, Rotate, and Balloon Blast; VR Reliever: Relax 8, Luna, and Mindset. An external VR portal and mirroring software allows the clinician to view patient activities in real time. Additionally, the clinician can remotely monitor patient performance via the external portal and adjust parameters accordingly.
224006551|NCT02523859|DRUG|Propofol|Hypnotic drug used for anesthesia
223387543|NCT07184229|BEHAVIORAL|motivational interviewing-based family planning counseling|This intervention consists of motivational interviewing-based family planning counseling aimed at women currently using traditional contraceptive methods. The counseling sessions are designed to enhance participants' motivation and readiness to adopt modern contraceptive methods by addressing their concerns, increasing knowledge, and resolving ambivalence. The comparator group will receive only standard family planning counseling.
224006552|NCT02523859|DRUG|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
224006553|NCT04505423|PROCEDURE|Blind CSF Drain Placement|CSF Drain placement without fluoroscopic image guidance.
224006554|NCT04505423|PROCEDURE|Fluoroscopy-guided Drain Placement|CSF Drain placement utilizing fluoroscopic image guidance.
224006555|NCT06957327|DRUG|ERAS-601|ERAS-601 40mg BID, 3-weeks on 1-week off (3/1), as monotherapy
224006556|NCT00898209|GENETIC|protein expression analysis|Blood and exhaled breath condensate will be collected.
224006557|NCT00898209|GENETIC|proteomic profiling|Blood and exhaled breath condensate will be collected.
224006558|NCT00898209|OTHER|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
224006559|NCT00898209|OTHER|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
224006560|NCT00898209|OTHER|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
224125639|NCT03050359|DRUG|TAK-438|TAK-438 tablets
223387544|NCT07184229|BEHAVIORAL|standard family planning counseling.|The comparator group will receive only standard family planning counseling.
223425657|NCT05862337|DRUG|Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo|placebo control, no active substance.
224006561|NCT00898209|OTHER|questionnaire administration|Questionnaire will be completed.
224006562|NCT05799651|BIOLOGICAL|Glycovax-002|Intramuscular injection of vaccine against SARS-CoV-2
224006563|NCT03455803|DEVICE|CPAP|Continuous positive airway pressure
224006564|NCT05302492|DEVICE|CPAP|CPAP: continue positive airway pressure ventilator is the standard treatment of OSA.
224006565|NCT05302492|DEVICE|Light box|Light box: is the treatment choice for circadian rhythm disorders. now apply to sleep disturbance without OSA or PLMS.
224006566|NCT00544310|BIOLOGICAL|Anti adhesion agent|Adhesions prevention
224125640|NCT03050359|DRUG|Lansoprazole|Lansoprazole capsules
224125641|NCT03050359|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets.
224125642|NCT03050359|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
224125643|NCT03050359|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
224299242|NCT04406597|DEVICE|the New Tissue Containment System|Laparoscopic Ovarian Cystectomy using the New Tissue Containment System
224006567|NCT05550545|OTHER|cohort study|Please note that this is an observational study; not applicable
223387545|NCT07180212|DIAGNOSTIC_TEST|utDNA testing + Urine Cytology|Participants undergo urine tumor DNA (utDNA) testing and urine cytology every 3 months, and cystoscopy once per year. If either utDNA or urine cytology is positive, an additional cystoscopy will be performed. If urine cytology is positive but cystoscopy is negative, or if two consecutive utDNA tests are positive while cystoscopy remains negative, participants will undergo computed tomography urography (CTU) to evaluate the upper urinary tract.
224006568|NCT00223639|DRUG|Topiramate|200mg twice a day
224006569|NCT00979550|DRUG|Imiquimod|commercially available topical antiviral drug
224006570|NCT00979550|DRUG|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
224006571|NCT04147520|BEHAVIORAL|Brief Motivational Interview|Single (60 min) session discussion of alcohol use and associated experiences.
224006572|NCT04963452|OTHER|Dural puncture epidural|Parturients, between 18 and 45 years of age, with cervical dilation less than 5 cm were consented to receive a DPE technique, with a single dural puncture with a 26-gauge spinal needle. After successful placement of the epidural catheter and puncturing the dura; 20 mL of bupivacaine 0.25% was administered through the epidural catheter and a patient-controlled epidural infusion of bupivacaine was initiated.
224006573|NCT05301647|DIAGNOSTIC_TEST|Nasal cytology|The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
224006574|NCT05301647|OTHER|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)|The validated Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) consists of 23 questions in 5 domains (nasal symptoms, ocular symptoms, practical issues, limitation of activities, other symptoms) that are answered on a 7-point scale (0-6), where 0 represents the absence of problems and 6 the greatest symptom distress. Children will complete the questionnaire together with a parent at baseline and during the study. A Total Score was calculated as the mean of the 5 domains.
224006575|NCT05301647|OTHER|Total symptom score (TSS)|Total symptom score was the sum of 3 domains: i) nasal symptoms (TNSS) included itching, sneezing, rhinorrhea, nasal congestion; ii) ocular symptoms (TOSS): itching, hyperemia of the conjunctiva, tearing; and iii) throat symptoms (TTSS): itching, coughing. With the help of their parents, patients scored symptoms severity on a 4-point scale: 0 = absent or irrelevant, 1 = mild, 2 = moderate, 3 = severe. Total symptom score was assessed at 12 hours (TTS 12h) and two weeks (TTS 2W) before the visits. TSS represents the doctor's point of view of symptom severity
224125644|NCT06512948|PROCEDURE|High tibial osteotomy|Surgical treatment for patients with osteoarthritis and indications for high tibial osteotomy
224125645|NCT05579912|PROCEDURE|Esophageal and gastric resections requiring an anastomosis|Distal gastrectomies, total gastrectomies, bariatric gastric bypasses, subtotal esophagectomies, proximal gastrectomies, palliative bypasses, and total esophagectomies.
224125646|NCT01556802|DRUG|Minocicline|Minocicline 100mg oral twice a day for 5 days
224006576|NCT05301647|OTHER|Visual analogic scale (VAS)|A visual analogic scale (VAS) measured the parental perception of symptom severity (0=no symptom; 10=very severe symptoms).
224006577|NCT02862587|DRUG|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
224006578|NCT02862587|BIOLOGICAL|precision cells|precision cells DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
224006579|NCT06146127|OTHER|phenotyping|Large scale molecular phenotyping
224006580|NCT04997681|BEHAVIORAL|Combined Aerobic Exercise and Resistance Training (AE + RT)|AE + RT will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. AE + RT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 strength training exercises (that progressively increase in resistance intensity over time) will be completed followed by a break. Aerobic exercises that safely increase the participant's heart rate will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the AE + RT exercise session is approximately 65 minutes.
224125647|NCT01556802|DRUG|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
224125648|NCT06097767|DRUG|Caffeine citrate|It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.
223387546|NCT07180212|DIAGNOSTIC_TEST|Cystoscopy + Urine Cytology|Participants undergo cystoscopy and urine cytology every 3 months as per standard high-risk NMIBC surveillance. If urine cytology is positive but cystoscopy is negative, participants will undergo computed tomography urography (CTU) to evaluate the upper urinary tract.
224125649|NCT06097767|DRUG|Amikacin|it includes preterm infants with respiratory distress syndrome who received amikacin in regular intervention therapy in control group
224125650|NCT01430572|DRUG|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
224125651|NCT01430572|DRUG|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
224125652|NCT02614287|DRUG|Galcanezumab|Administered SC
224138543|NCT04321252|DRUG|KAE609|"* iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)"
224138544|NCT04321252|DRUG|Placebo|matching placeo for iv administration
224138545|NCT03004469|DRUG|P-3074|
224138546|NCT03004469|DRUG|Finasteride|
224138547|NCT03004469|DRUG|P-3074 Vehicle|
224138548|NCT03004469|DRUG|Finasteride Placebo|
224006581|NCT04997681|BEHAVIORAL|Cognitive Training (NeuropeakTM)|NeuropeakTM is a program which will be completed by participants remotely using a tablet or computer. It consists of cognitive training including dual-task training that requires participants to maintain and prepare for many response alternatives (working memory) and to share attention between two concurrent tasks (divided attention). Difficulty of cognitive training is tailored to their individual functioning level. During each session, participants perform one of two different visuo-motor tasks, which include sets of visual stimuli (e.g., letters, numbers, animals, vehicles, fruits, celestial bodies) and respective hand-button correspondences (i.e., keys that are to be tapped on either the right or the left side of the screen). Participants are instructed to perform these tasks as fast as possible, while maintaining accuracy. Training also includes online feedback and a histogram of daily performance to encourage improvement. NeuropeakTM takes approximately 30 minutes to complete.
224125653|NCT01303809|OTHER|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~1. Pre-op carbohydrate loading~2. No pre-op GIK while NBM~3. Pre-medication~4. Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~5. Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~6. Fluid restriction~7. Standardised method of anaesthesia~8. Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~9. 10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~1. Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~2. Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~3. Post operative oxygenation~4. Incentive spirometry~5. Drains (e.g. IDC) removed in recovery~6. Full mobilisation 4-8 hours post op)~7. Early Follow up"
224125654|NCT00536042|DRUG|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
224125655|NCT06129318|BEHAVIORAL|Clinical Pharmacist Led Pharmaceutical Care|Within the scope of pharmaceutical care, medication review services for past and current medication use were provided by the clinical pharmacist. The patients in the intervention group were given verbal information about the definition of stroke, symptoms, how to manage risk factors, and their medications by the clinical pharmacist on the day of discharge, in addition to the neurologist. Each patient in the intervention group had a scheduled meeting with the clinical pharmacist. During the 1-year follow-up the patient education given by the clinical pharmacist was repeated every 3 months.
224125656|NCT01711320|DRUG|Placebo|
224125657|NCT01711320|DRUG|Omeprazole|
224125658|NCT03571841|BEHAVIORAL|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
224125659|NCT03571841|BEHAVIORAL|Telephone Booster|One month following the group session, women will receive a telephone booster session (\<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
224125660|NCT02620462|DEVICE|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
224125661|NCT02811536|DEVICE|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
224125662|NCT02261168|OTHER|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
224125663|NCT04684550|DRUG|Stabilized hypochlorous acid|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
224125664|NCT04684550|DRUG|Placebo|Application of 2 puffs and gargles every 8 hours of a solution with low concentrations of S-HCLO (3-5 ppm).
224125665|NCT05390424|DIAGNOSTIC_TEST|Blood collection using Dried Blood Spot|Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
224125666|NCT05023655|DRUG|Tazemetostat|800mg po twice daily
224125667|NCT06182475|BEHAVIORAL|EPPComm Provider Training|A curriculum will be developed to educate patients about LDKT and promote the search of potential living donors while supporting patients' values and cultural preferences. The curriculum will consist of two components: didactic education and skills-based communication. The didactic component provides evidence of the impact of patient-provider communication and LDKT process outcomes for Black and Caucasian patients. The skills-based component will build communication confidence leading discussions about LDKT. It provides instructions for the key communication skills needed to confidently assuage patients' concerns about LDKT/live donation and motivates patients to search for living donor. The following will be covered: providing LDKT information/answering questions, highlighting LDKT benefits, refuting live donation misinformation, and encouraging patients to seek living donors.
224125668|NCT00492856|DRUG|mercaptopurine|Given orally
224125669|NCT00492856|DRUG|methotrexate|Given orally
224125670|NCT00492856|DRUG|tretinoin|Given orally
223730168|NCT02862613|BIOLOGICAL|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
223730169|NCT04334291|COMBINATION_PRODUCT|Observational (registry)|Observational study.
223730170|NCT02723032|DEVICE|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
223730171|NCT02392247|DEVICE|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
224125671|NCT06347341|DIETARY_SUPPLEMENT|Clinical study comparing a gluten-containing diet to a gluten-free diet|The study includes a basal period of 2 weeks, 2 test periods of a maximum duration of 1 week and a wash-out period of 2 to 3 weeks.
224125672|NCT02513368|DEVICE|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
224125673|NCT02513368|PROCEDURE|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
224138549|NCT05429177|DRUG|QY101 ointment or vehicle|QY101 ointment or vehicl topical applied to skin
223387547|NCT07183436|DRUG|Intra-articular Hyaluronic Acid and Ketorolac|Single intra-articular injection containing 2 mL moderate-molecular-weight hyaluronic acid (20 mg/2 mL), 1 mL ketorolac (30 mg/mL), and 2 mL lidocaine (10 mg/mL), total volume 5 mL. Administered under aseptic technique (ultrasound-guided or landmark-based) followed by standardized rehabilitation program.
223730172|NCT04690543|PROCEDURE|z-plasty|Z-plasty: It will be defined as a local transposition flap that will be used to improve the functional and cosmetic appearance of scars. It will be involved creating two triangular flaps of equal dimensions that will be transposed.
224006582|NCT04997681|BEHAVIORAL|Control Cognitive Training of Website Searching and Video Watching (WS+V)|During the WS + V task, participants alternate between 2 different tasks (touristic searching using internet and video watching). For the touristic searching using internet, participants are required to find 3 hotels, 3 touristic places, and 3 restaurants of their own preference in a city assigned by the instructor (a new city will be selected each session). They will also need to include the respective addresses of those places on their log sheet. For the video watching task, participants watch a National Geographic video on YouTube selected by the instructor with a different video selected for each session. They will watch the video for 20 minutes and during the remaining 5 minutes they will answer the following questions on their log sheet: 1) What is the video about? 2) What is the most important information in your opinion? 3) Create a question based on the video and answer your own question. WS + V sessions take approximately 30 minutes to complete.
224006583|NCT04997681|BEHAVIORAL|Control Balance and Toning Exercise Training (BAT)|BAT exercises will be conducted via a video-conferencing platform under the direct supervision and coaching of a certified exercise physiologist with certification from the Canadian Society for Exercise Physiology (CSEP; or equivalent certification). These certified trainers will administer the exercise interventions in a one trainer to one participant ratio. BAT includes a set of warm up exercises, which will be completed in approximately 5 minutes, followed by a break. Next, 6 balance and toning exercises will be completed followed by a break. Stretching exercises will follow for 30 minutes followed by a break and a set of cool down exercises for 5 minutes. In total the BAT exercise session is approximately 65 minutes.
224006584|NCT01350284|DIETARY_SUPPLEMENT|Cinnamon|acute oral administration of 3 g cinnamon
224006585|NCT01350284|DIETARY_SUPPLEMENT|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
224006586|NCT01293045|DIETARY_SUPPLEMENT|hydrolyzed collagen|10g/day at breakfast during 90 days
224006587|NCT01293045|DIETARY_SUPPLEMENT|wheat protein|10g/day at breakfast during 90 days
224006588|NCT01733537|OTHER|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
224006589|NCT01733537|BEHAVIORAL|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
224006590|NCT03976492|DIAGNOSTIC_TEST|diagnostic of specific biomarkers|Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
224006591|NCT04237025|OTHER|Nordic walking exercise|Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
224006592|NCT04752410|PROCEDURE|Selective Brachial Plexus Block|It is one type of peripheral nerve blocks for upper extremity surgery. In this study, the block will be done under the ultrasound guidance and the local anesthetic agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 25ml) will be injected at the trunks of the brachial plexus in order to produce the surgical anesthesia of the whole upper extremity of the patients scheduled for upper limb surgeries.
224006593|NCT05626114|BIOLOGICAL|OpRegen|OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space
224006594|NCT01497353|PROCEDURE|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
224006595|NCT01497353|PROCEDURE|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
224006596|NCT05470647|BIOLOGICAL|Interleukin-4 receptor responders 1|Interleukin-4 receptor was injected subcutaneously.
224006597|NCT05470647|BIOLOGICAL|Interleukin-4 receptor responders 2|Interleukin-4 receptor was injected subcutaneously.
224006598|NCT05470647|BIOLOGICAL|Placebo|Placebo was injected subcutaneously.
224006599|NCT00550589|DRUG|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
224006600|NCT00550589|GENETIC|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
224006601|NCT00550589|GENETIC|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
224006602|NCT00550589|GENETIC|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
224006603|NCT00550589|PROCEDURE|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
223387548|NCT07183436|DRUG|Intra-articular Ketorolac|single intra-articular injection containing 1 mL ketorolac (30 mg/mL), 2 mL lidocaine (10 mg/mL), and 2 mL normal saline, total volume 5 mL. Administered under aseptic technique (ultrasound-guided or landmark-based) followed by standardized rehabilitation program.
224006604|NCT00550589|PROCEDURE|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
224006605|NCT06029894|DIETARY_SUPPLEMENT|Citicoline Supplement|Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
224006606|NCT06029894|OTHER|Placebo|Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
224006607|NCT02333305|DIETARY_SUPPLEMENT|CoQ10|• 2 dosages according to patient weight: Weight \< 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
224006608|NCT02333305|OTHER|Sanomit Placebo|• according to patient weight: Weight \< 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
224006609|NCT03164694|DRUG|Apatinib|Apatinib was given 850 mg per day orally.
224006610|NCT03164694|DRUG|Pemetrexed|pemetrexed (500 mg/m2)
224006611|NCT03164694|DRUG|Carboplatin|carboplatin (AUC =5)
224006612|NCT00166712|DRUG|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
224006613|NCT00166712|DRUG|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
224006614|NCT00166712|DRUG|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
224006615|NCT00166712|DRUG|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
224006616|NCT00350350|DEVICE|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
224006617|NCT00350350|DEVICE|medical device. Spray containing essentially oxygenated oil|"protective oral spray containing :~* 94.4% of oxygenated oil~* Silicium dioxide~* aspartame artificial flavoring"
224006618|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
224006619|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
224006620|NCT01803412|DRUG|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
224006621|NCT02432508|DEVICE|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
224006622|NCT02432508|DEVICE|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
224006623|NCT04764461|OTHER|Use of customised GROW Charts|Intervention group will follow the same antenatal visit plan and two ultrasounds will be offered (NT 11-13+6 weeks \& anomaly scan 19-22 weeks of gestation) in routine. A third trimester scan will not be offered in routine to Intervention group. Serial SFH measurements will be plotted against estimated date of delivery at each review from 26 weeks of gestation on the customized GROW chart already attached in the maternity notes. On each visit patient will be examined after emptying bladder in a semi-recumbent position, using non-elastic tape with cm side hidden; measurement will be taken from the fundus to upper margin of pubic symphysis. Abnormal SFH measurements, when plotted below the 10th or does not follow its trajectory on customized growth charts will be referred for growth scan suspecting SGA. SFH plotted above 90th centile will also be referred for growth scan, as a part of antenatal care.
224006624|NCT05630820|DRUG|Bepirovirsen|Bepirovirsen will be administered.
224006625|NCT05630820|OTHER|Placebo|Matching placebo will be administered.
224006626|NCT06115629|OTHER|Surveillance protocol|Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.
224006627|NCT03986944|DRUG|75 mg linzagolix tablet|For oral administration once daily
224006628|NCT03986944|DRUG|200 mg linzagolix tablet|For oral administration once daily
224006629|NCT03986944|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
224006630|NCT03986944|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
224006631|NCT03986944|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
224006632|NCT03986944|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
224006633|NCT05973786|DRUG|Escitalopram|See arm description
224006634|NCT05973786|DRUG|Sertraline|See arm description
224006635|NCT05973786|DRUG|Venlafaxine|See arm description
224006636|NCT05973786|DRUG|Lithium|See arm description
224006637|NCT05973786|DRUG|Valproate acid|See arm description
224006638|NCT05973786|DRUG|Quetiapine|See arm description
224006639|NCT05973786|DRUG|Bupropion|See arm description
224006640|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft combined with injectable PRF loaded with metronidazole|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid as particulate demineralized dentin graft and processed with injectable platelet rich fibrin. The injectable PRF will be mixed with 5mg/ml metronidazole first then added to the particulate demineralized dentin graft forming sticky demineralized tooth graft with slowly released metronidazole then inserted in the extraction socket and covered then suturing
224006641|NCT05470673|PROCEDURE|Alveolar ridge preservation using autogenous demineralized dentin graft alone|Atraumatic extraction of non-restorable teeth, then the extracted tooth will be prepared and demineralized using hydrochloric acid (HCL) acid inserted in the extraction socket as particulate demineralized dentin graft
224006642|NCT04771754|DRUG|Dolutegravir|50 mg once daily orally
224006643|NCT00245921|DRUG|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
224006644|NCT05808881|DRUG|Nalmefene Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
224006645|NCT05808881|DRUG|Naloxone Hydrochloride Injection|for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
224006646|NCT03866291|OTHER|No intervention, observational|See above
224006647|NCT02409069|DEVICE|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
224006648|NCT02409069|DEVICE|Sham stimulation (Nemos®, Cerbomed GmbH)|
224006649|NCT02420197|BEHAVIORAL|High-intensity resistance training|
224006650|NCT02420197|BEHAVIORAL|General physical activity|
224006651|NCT02420197|BEHAVIORAL|Multidisciplinary rehabilitation program|
224006652|NCT02037633|DRUG|Fentanyl|Fentanyl IV
224006653|NCT02037633|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
224006654|NCT02037633|DRUG|ropivacaine|
224006655|NCT06150482|OTHER|No intervention|No intervention
224006656|NCT04201054|DRUG|Fluconazole|50 mg of fluconazole administered orally in a single dose.
224006657|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC tablet for oral administration.
224006658|NCT06299709|DRUG|VNZ/TEZ/D-IVA|FDC granules for oral administration.
224006659|NCT05113745|DRUG|AXS-12 (reboxetine)|AXS-12 tablets, taken twice daily
224006660|NCT05113745|DRUG|Placebo|Placebo tablets, taken twice daily
224006661|NCT01015560|DRUG|anti-CCR2 monoclonal antibody MLN1202|
224006662|NCT01015560|GENETIC|polymorphism analysis|
224006663|NCT01015560|OTHER|laboratory biomarker analysis|
224006664|NCT00640133|DEVICE|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
224006665|NCT00640133|DEVICE|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
224006666|NCT02717221|OTHER|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-\[18F\] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
224006667|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMATRIX trial using single agent idasanutlin.
224006668|NCT05952687|DRUG|Idasanutlin|Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.
224006669|NCT05952687|DRUG|Selinexor|Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.
224006670|NCT01847677|DRUG|Bevacizumab|
224006671|NCT01847677|DRUG|Paclitaxel|
224006672|NCT01847677|DRUG|Carboplatin|
224006673|NCT01096654|OTHER|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
224006674|NCT04854876|DIETARY_SUPPLEMENT|5-ALA-Phosphate + SFC (5-ALA+SFC)|The food supplement 5-Aminolevulinic acid phosphate and Sodium ferrous citrate (5-ALA-Phosphate + SFC) will be administered orally daily for 28 days. The dose will be in total 3 capsules of 50 mg 5-ALA-Phosphate and 28.68 mg SFC (3.04 mg as Fe) per day, 2 capsules in the morning and 1 capsule in the evening resulting in 150 mg 5-ALA-Phosphate and 86.04 mg SFC ( 9.12 mg as Fe).
224006675|NCT03704623|DRUG|Paracetamol|Paracetamol 1g IV
224006676|NCT03704623|DRUG|Parecoxib|Parecoxib 40 mg IV
224006677|NCT05213897|DEVICE|SARS-CoV-2 Antigen Assay|To demonstrate that non-laboratory personnel can accurately perform the SARS-CoV-2 Antigen assay in the intended use environment using nasopharyngeal samples by demonstrating that the assay can achieve a ≥ 80% sensitivity and specificity when it is compared to the results of a high sensitivity EUA SARSCoV-2 RT-PCR assay using nasopharyngeal samples.
224006678|NCT05926440|BIOLOGICAL|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
224006679|NCT05926440|BIOLOGICAL|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection|SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
224006680|NCT00589589|DEVICE|Endo Tool|Computer tool to help achieve glucose control
224295938|NCT05118087|PROCEDURE|Webril Padded Plaster Splint|Patients in the coaptation splint group will have a webril padded plaster splint that is placed around the humerus. The forearm and wrist are then suspended in a cuff and collar.
224295939|NCT05118087|PROCEDURE|Pre-Fabricated Fracture Brace|Patients in the sarmiento group will be given a fitted pre-fabricated fracture brace with a cuff and collar for the forearm. The patients will be educated on brace maintained, tightening, and care during at the time of the ER encounter.
223387549|NCT07180849|PROCEDURE|Fluoride varnish|Group A will receive conventional fluoride varnish for antiplaque effects.Plaque will be assessed quantitatively by modified plaque index.
223387550|NCT07180849|PROCEDURE|Novel titania nanoparticle infused fluoride varnish|Group B will receive topical application of titania nanoparticle infused fluoride varnish for antiplaque effects.Plaque will be assessed quantitatively by modified plaque index.
223387551|NCT07181668|DEVICE|Low-Level Light Therapy|The intervention consists of non-invasive periocular photobiomodulation using the Eye-light® device (Espansione Marketing S.p.A., Italy), which delivers low-level monochromatic red light (633 ± 10 nm) through a specially designed mask. Participants receive two 15-minute sessions, one 7 days before and one 7 days after femtosecond laser-assisted in situ keratomileusis (Femto-LASIK). The treatment is designed to stimulate meibomian gland activity, improve tear film stability, and reduce ocular surface inflammation. This protocol is unique compared to standard post-refractive surgery care because it targets cellular mitochondrial activity to enhance tissue repair and anti-inflammatory effects. It is non-pharmacological, non-contact, and well-tolerated, making it suitable for perioperative application. The light is delivered through closed eyelids, ensuring safety and comfort, and the device used is CE-marked for ophthalmic applications.
223387552|NCT07181668|DEVICE|Sham (No Treatment)|Participants in the Control group underwent the same procedural setup as the LLLT group, using the Eye-light® device (Espansione Marketing S.p.A., Italy). Instead of delivering therapeutic light energy, the device operated in demo mode, emitting less than 30% of the full treatment power. This configuration mimicked the visual and sensory aspects of a low-level light therapy session without producing biologically effective photobiomodulation. Sham treatment consisted of two 15-minute sessions, one 7 days before and one 7 days after Femto-LASIK. This design ensured masking of participants and investigators while preventing active therapeutic exposure in the control group.
223387553|NCT07181148|DRUG|MSP01-R|Total 20 tablets, split-dose administration over 2 days: 14 tablets the day before colonoscopy, 14 tablets on the morning of colonoscopy, oral intake.
223387554|NCT07181148|DRUG|MSP01-T|Total 20 tablets, split-dose administration over 2 days: 10 tablets the day before colonoscopy, 10 tablets on the morning of colonoscopy, oral intake.
223387555|NCT07186530|OTHER|Best Practice|Receive usual care
223387556|NCT07186530|OTHER|Communication Intervention|Receive portal message
223387557|NCT07186530|OTHER|Electronic Health Record Review|EHR reviewed to assess whether recommended follow-up was completed, if follow-up was indicated.
223387558|NCT07186530|PROCEDURE|HPV Self-Collection|Complete HPV self-collection
223387559|NCT07186530|PROCEDURE|Standard Follow-Up Care|Receive standard follow-up care
224006681|NCT05298722|DIAGNOSTIC_TEST|Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.|"* The images from CT scans and MRI with DWI will be processed using specialized software to determine the direction of diffusion tensors. This will indicate the diffusion direction using color coding (red, green, and blue for the x, y, and z components of the vector) and the intensity using anisotropy (brightness of voxels). Further analysis will be performed using fiber tracking, which provides a clear representation of the functional connectivity of adjacent tissues.~* Genetic profiling of liquid biopsies: Multi-omics profiling of liquid biopsies (blood samples) will be conducted, followed by cell phenotyping, longitudinal analysis of driver mutations and epigenetic changes in cfDNA, and genotyping of germline variations.~* Questionnaires for patient-reported outcomes and health economic analysis:~EQ-5D-5L PAN 26 HADS"
224006682|NCT00924690|OTHER|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
224006683|NCT00924690|OTHER|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
224006684|NCT03795753|DEVICE|F2S Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
224006685|NCT03795753|OTHER|Non-functioning Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
224006686|NCT03990116|PROCEDURE|Lateral|Posture lateral kangaroo care
224006687|NCT03990116|PROCEDURE|Prone|Posture prone kangaroo care
224006688|NCT00128102|DRUG|Vorinostat|Vorinostat 100 mg oral capsules
223387560|NCT07186205|DIAGNOSTIC_TEST|Standard blood test|Blood test will measure haemoglobin and other parameters
224006689|NCT00128102|DRUG|Placebo|Vorinostat-matching placebo oral capsules
223387561|NCT07186205|OTHER|Imaging and videography of anatomical sites|Images and videos of anatomical sites will be collected to develop algorithms to estimate iron status
223387562|NCT07178782|OTHER|Dual-Task Training Program|the participant will receive dual task program in form of balance and hand function program
223387563|NCT07178782|OTHER|rehabilitation program|designed rehabilitation program
223387564|NCT07192510|OTHER|Pancake oral immunotherapy|The baked egg tolerant group underwent a 4-dose initial escalation (at intervals of 20-30 minutes) with pancakes in hospital (37.5 mg, 75 mg, 150 mg, 300 mg egg protein) to determine the home starting dose of pancake. The dose tolerated was one which resulted in no more than mild transient (not lasting more than 20 minutes) symptoms (e.g. itchy mouth) - transient Grade 1 symptoms. The home starting dose (taken daily at home) was one step below the tolerated dose, to minimise risk of allergic reactions at home, particularly as the presence of co-factors might decrease reaction threshold. Those reacting at 37.5 mg or 75 mg would not begin OIT with pancakes but instead began with cookies. Updosing visits were performed in the hospital at approximately 4 weekly intervals. Participants were kept at the pancake daily maintenance dose (2500 mg) for a minimum of 16 weeks, or total OIT duration of 18 months, whichever earlier
223387565|NCT07193017|DEVICE|BIPAP|After BIPAP Prescribed By A Physician, Diaphragmatic Functions Will Be Evaluated With Ultrasound In The Early And Late Periods
223387566|NCT07193186|DRUG|Anlotinib and Benmelstobart|Patients will receive Benmelstobart (1200mg, d1, q3w) in combination with Anlotinib (12mg, qd, d1-14, q3w). Treatment will continue until disease progression, voluntary withdrawal of informed consent, intolerable toxicity, or until the investigator determines that the patient no longer benefits.
223387567|NCT07193108|DEVICE|Inspiratory Muscle Warm-Up|Inspiratory Muscle Warm-Up (IWU) The POWERbreathe® device (IMT Technologies Ltd., Birmingham, UK) was used for the inspiratory muscle warm-up (IWU). For the IWU protocol, the resistance of the POWERbreathe® device was set to 40% of the participant's maximal inspiratory pressure (MIP). While standing, participants were instructed to perform two sets of 30 breaths (inspiratory and expiratory), with a 60-second rest interval between sets (Yılmaz et al., 2025).
223387568|NCT07193108|DEVICE|Control|Inspiratory Muscle Warm-Up Non-treated group, Control
224006690|NCT00693667|DRUG|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
224006691|NCT04929275|PROCEDURE|Enhanced recovery program|12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
224006692|NCT02225132|DRUG|Hydroxyurea|"The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium."
224006693|NCT01202903|DRUG|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
224006694|NCT01202903|DRUG|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
224006695|NCT04808752|DRUG|Almonertinib|Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
224006696|NCT00352326|DEVICE|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
224006697|NCT04586764|DEVICE|Non-Invasive Cardiac System|Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.
224006698|NCT05229276|OTHER|Sternum Guard|"The intervention being assessed is a surgical drape used as a cover of sternal bones and the neighboring structures exposed during median sternotomy named Sternum Guard.~Sternum guard® is a single use, sterile surgical drape with modified cellulose designed specifically to reduce the risk of surgical site infection (SSI).~It is made of 4 parts, the main part is in contact with the retractors and the sternum edge. It is made of carboxymethylated cellulose (CMC) spunlace which makes direct contact with the sternum edges. It contributes to blood absorption, to decreasing of pH environment, and to haemostatic action through a physical effect (compression); another part was made from hydrophilic spunbond (swabs) allowing blood absorption, comfort and protection"
224006699|NCT05229276|OTHER|Bone Wax|patients in this group were given Bone Wax as the hemostatic material during sternotomy. Midline sternotomy with an oscillating saw was conducted after standard aseptic surgical techniques. Bone wax was applied to both spongiosa surfaces of resected sternal bones until bleeding had ceased.
224006700|NCT03081364|OTHER|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
224006701|NCT01302080|DRUG|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
224006702|NCT01302080|BEHAVIORAL|psychotherapy|Non-interventional study- as above
224006703|NCT02117453|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day
224006704|NCT02117453|DRUG|Placebo|Placebo
224006705|NCT00085553|DRUG|Erlotinib Hydrochloride|Given PO
224006706|NCT00085553|OTHER|Laboratory Biomarker Analysis|Correlative studies
224006707|NCT00085553|OTHER|Pharmacological Study|Correlative studies
224006708|NCT00085553|DRUG|Tipifarnib|Given PO
224006709|NCT05781191|BIOLOGICAL|COMIRNATY|Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors
224006710|NCT03425097|DRUG|Fexofenadine|Fexofenadine 180 mg in the morning
224006711|NCT03425097|DRUG|Placebo - Cap|Placebo cap in the morning
224299243|NCT02641197|DEVICE|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
223387569|NCT07192523|OTHER|Restrictive fluid therapy|Group Restrictive (Group R) received 3ml/kg/hr, crystalloid (Ringer Lactate).
223387570|NCT07192523|OTHER|Liberal fluid therapy|Group Restrictive liberal received 8ml/kg/hr, crystalloid (Ringer Lactate).
223387571|NCT07192120|DRUG|MHB048C for Injection|IV administration of MHB048C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223387572|NCT07193485|OTHER|Buteyko breathing|twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.
224125674|NCT05165511|BEHAVIORAL|PBT-EF|PBT-EF will be delivered to parents only. Parents will be taught general behavioral weight loss skills to apply to their child and themselves including decreasing caloric intake and increasing physical activity, self-monitoring, and goal setting. Additionally, parents will learn compensatory strategies surrounding organization, habit learning, planning, and problem-solving to generalize FBT skills to real-world behaviors (e.g., self-monitoring of food intake). Each session will include interactive exercises to help train an aspect of EF. Skills taught will be presented to be practiced with real-world applications.
224125675|NCT06451380|PROCEDURE|orthopaedic surgery|orthopaedic surgery of the upper limb under anaesthesia
224006712|NCT02768532|DRUG|Vedolizumab|"During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed."
224006713|NCT03339245|OTHER|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
224125676|NCT06451380|DRUG|propofol anesthesia|The initial dose of propofol and the refractory period will be determined according to a standardized protocol used in current practice.
224125677|NCT01520324|DEVICE|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
224125678|NCT03488472|DEVICE|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
224125679|NCT03488472|RADIATION|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
223387573|NCT07193485|OTHER|usual care|twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.
224006714|NCT03339245|OTHER|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
224006715|NCT02897050|DRUG|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
224006716|NCT02897050|DRUG|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
224006717|NCT02897050|DRUG|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
223387574|NCT07192640|DRUG|After induction of anaesthesia tranexamic acid will be administered at the start of surgery to reduce intraoperative bleeding. loading dose of 10 mg/kg for high BMI patients who are undergoing bariatr|This intervention will be applied for High-risk patients, with obesity, BMI more than 45, Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.
223387575|NCT07192055|BEHAVIORAL|Self-sampling|Self-sampling instructions will be provided to participants who will insert the swab into the anus to collect cells. Then the participant will put the swab in a vial of transport fluid for assessment at a laboratory.
224006718|NCT02897050|DRUG|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
224006719|NCT02897050|DRUG|Epirubicin|Epirubicin 100mg/m2, iv, d1
223387576|NCT07192055|OTHER|Nylon-flocked Swab|At the cytology appointment, participants may receive self-sampling or clinician sampling with 1 of 2 kinds of swabs. The nylon-flocked swab is the intervention and will be assessed on patient acceptability and patient and clinician ability to collect an adequate sample.
224006720|NCT02897050|DRUG|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
224006721|NCT00633646|DIETARY_SUPPLEMENT|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
224006722|NCT03916679|BIOLOGICAL|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
224006723|NCT00964275|PROCEDURE|diagnostic procedure|Standard diagnostic procedures followed
224006724|NCT00964275|RADIATION|fludeoxyglucose F 18|PET with flueoxyglucose F 18
224006725|NCT06182553|OTHER|Expiratory Rib Cage Compression|Expiratory rib cage compression (ERCC) In this study, ERCC is a technique consisting of bilateral manual compression of the lower rib cage (anterolateral region of the chest at the level of the six last ribs) gradually during the expiratory phase of the ventilatory cycle and release from the compression at the end of the expiration.
224006726|NCT06182553|OTHER|PEEP-ZEEP Maneuver|PEEP-ZEEP maneuver In this study, PEEP-ZEEP maneuver refers to PEEP which stands for positive end-expiratory pressure, and ZEEP which stands for zero end-expiratory pressure. In this maneuver PEEP will be incremented to 15 cmH2O throughout five consecutive respiratory cycles, then immediately after the inspiratory phase of the fifth cycle has been ended ZEEP should be done by abruptly reducing PEEP value to 0 cmH2O. The PEEP-ZEEP maneuver should be performed in two sets, consisting of a total of 10 consecutive breathing cycles. Subsequently, the patient is ventilated according to his/her baseline ventilator parameters.
224006727|NCT06182553|OTHER|ERCC + PEEP-ZEEP maneuver|\- The ERCC technique will be applied as mentioned above, then followed by PEEP-ZEEP maneuvers according to the standard steps mentioned before.
224006728|NCT01570959|DRUG|Quetiapine Fumarate|300 mg tablet
224006729|NCT04389151|DRUG|Toripalimab|Toripalimab union CAPEOX scheme： Toripalimab 240mg, ivgtt, Q3w Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w
224006730|NCT05154877|DEVICE|OMNI PET/CT Scan|The subject will undergo two PET/CT scans: one on the standard of care scanner and one on the OMNI scanner.
224125680|NCT03121222|DRUG|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
224125681|NCT03121222|DRUG|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
224125682|NCT03779035|DRUG|Gemcitabine|1000mg/m2
223387577|NCT07193251|OTHER|Core Stabilization Exercises|Participants will receive supervised core stabilization exercises twice weekly for 8 weeks (≈50 min: 10 min warm-up, 30 min stabilization, 10 min cool-down), progressing from basic trunk activation and bridging to plank and ball-assisted tasks. A daily 60-min home program with illustrated handouts will be prescribed.
224006731|NCT04630041|BEHAVIORAL|211 Referral|Patients with one or more reported social need will be referred to 211 for community based services. 211 will reach out and contact patients for follow-up.
224006732|NCT05557175|DEVICE|Repetitive transcranial magnetic stimulation|The active rTMS group will receive a 1 Hz inhibitory low-frequency rTMS protocol hotspot of the contra-lessional primary motor cortex (M1), will deliver a continuous pulse of 1 pulse per second totalling 1200 pulses of 80% active motor threshold stimulation. The duration of the stimulation will last for 20 minutes thrice a week for four weeks (12 sessions). The motor threshold will be the minimum single-pulse TMS intensity necessary to elicit a motor-evoked potential greater than 50μV in more than 5 out of 10 consecutive trials. The standard 70 mm figure-of-eight air-cooled coil handle (MagPro) will be held at right angle to the skull for effective M1 stimulation. The participants in the active rTMS groups will receive a subthreshold stimulation intensity for muscle contraction with no painful peripheral sensation
224006733|NCT05557175|DEVICE|Sham rTMS|The sham rTMS will be applied using the same parameters as the active rTMS but the coil will be rotated 90° away from the scalp so that minimal or no flow of current will be induced
224006734|NCT04143945|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
224006735|NCT04143945|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
224006736|NCT04370548|DRUG|DARE-BV1clindamycin phosphate vaginal gel, 2%|One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
224006737|NCT04850677|OTHER|Observational Cohort|Observational study
224006738|NCT00306670|DRUG|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
224006739|NCT00306670|DRUG|prednisone|\<30 mg/day
224006740|NCT00159939|PROCEDURE|prone positioning|prone positioning
224006741|NCT03450837|DIAGNOSTIC_TEST|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
224006742|NCT03450837|DIAGNOSTIC_TEST|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
224125683|NCT03779035|DRUG|Capecitabine|1250mg/m2
224125684|NCT04185480|DEVICE|Hemopatch|Before closure of the wound this hemostatic sealant (Hemopatch), a pad of collagen derived from bovine dermis will be applied in the axilla
224125685|NCT01883934|OTHER|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
224125686|NCT01883934|OTHER|Control|
224125687|NCT03798145|PROCEDURE|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
224125688|NCT02583802|DRUG|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
223387578|NCT07193251|OTHER|Connective tissue massage|each supervised session will include 20 min of connective tissue massage (CTM) applied bilaterally to lumbar and lower thoracic regions using oblique and transverse pulls at connective tissue reflex zones. CTM will be performed in seated or prone position depending on patient comfort
223387579|NCT07191912|DRUG|Govorestat|Govorestat will be provided as a liquid suspension (200mg/mL) for weight-based administration and administered orally at 20 mg/kg QD (every 24 hours)
223387580|NCT07191912|DRUG|Placebo Control|Placebo will also be provided as a matching liquid suspension to be taken orally QD
224125689|NCT02583802|DRUG|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
224125690|NCT02533518|PROCEDURE|Rigid bronchoscopy with ultraviolet transmission|
224125691|NCT02533518|OTHER|Biopsy|
224125692|NCT00186745|DRUG|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
224125693|NCT02658994|BEHAVIORAL|Thinking Healthy Program Peer Delivered Plus|
224125694|NCT02658994|OTHER|Enhanced Usual Care|
224125695|NCT02955134|DRUG|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
224125696|NCT02955134|DRUG|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
224125697|NCT02955134|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
223387581|NCT07192016|DRUG|fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg|The investigational drug is a single Ellipta inhaler containing 100 ug fluticasone furoate(inhaled corticosteroid), 62.5 ug umeclidinium(long-acting muscarinic antagonist) and 25 ug vilanterol(long-acting β2-adrenergic agonist). The drug is delivered in an Ellipta inhaler in a single dose once daily.
223387582|NCT07184554|PROCEDURE|us-guided espb|Hemodynamic monitoring is provided. The lumbar region where the procedure will be performed is cleaned with povidone iodine. Sterile draping is provided. For the lumbar erector spinae plane block application, a 5 Hz convex ultrasound probe is first placed sagittally over the desired level of the lumbar vertebra. After the spinous processes are visualized, the ultrasound probe is laterally shifted in the sagittal plane, first visualizing the laminae, then the facet joints, and finally the transverse processes. The erector spinae muscles are visualized over the transverse processes. The skin and subcutaneous tissue are then anesthetized with 2 cc of 2% lidocaine. A spinal needle is inserted from the anesthetized area in the same plane as the ultrasound probe (in plane) and contacts the relevant transverse process. Thanks to the real-time imaging advantage of ultrasound, a certain distance is maintained from the nerves and vascular structures. Once the appropriate location is reached, a m
223387583|NCT07184554|PROCEDURE|fl-guided Ilesi|For lumbar interlaminar epidural steroid injection, the anterior view of the desired level is obtained under fluoroscopy to visualize the relevant interlaminar epidural space. The skin and subcutaneous tissue are anesthetized with a local anesthetic. A paramedian approach is used to enter the target interlaminar space with an epidural needle using a negative pressure injector. The lateral view is checked using fluoroscopy. 2 cc of opaque material is administered, and its presence in the epidural space is confirmed from the lateral and anterior-posterior views. A mixture of steroid and local anesthetic (8 mg dexamethasone, 3 cc 5mg/ml bupivacaine, and SF for a total of 10 cc) is injected. The needle is removed in a controlled manner and the needle site is closed. After the procedure, patients are monitored in the recovery unit for 60 minutes and then transferred to the ward for follow-up. Patients who have completed their 1-hour follow-up in the ward are discharged.
223730173|NCT04690543|PROCEDURE|square flap|Square flap: It will be defined as is another local transposition flap which will be used for release of contractures. Square will be marked on one side of the contracture, and two triangles will be marked on the other side, with the length of all the flaps equal, which will be then transposed.
223730174|NCT01479153|PROCEDURE|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
224006743|NCT02776722|OTHER|fructose, allulose, tagatose, or sorbose|Single-bolus feeding of fructose, allulose, tagatose, or sorbose given together with a reference carbohydrate(s) compared with the same reference carbohydrate(s) alone for acute feeding trials or chronic feeding of fructose, allulose, tagatose, or sorbose provided in substitution for other reference carbohydrates or added to a control diet compared with the reference carbohydrate(s) alone or the control diet alone for chronic feeding trials.
224006744|NCT00106210|BEHAVIORAL|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
224006745|NCT00106210|BEHAVIORAL|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
224006746|NCT00072228|DRUG|gemcitabine|
224006747|NCT00072228|DRUG|soblidotin|
224006748|NCT00072228|PROCEDURE|chemotherapy|
224125698|NCT02955134|DRUG|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
224125699|NCT03015922|DRUG|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
224125700|NCT03015922|BIOLOGICAL|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
224006749|NCT02735655|OTHER|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
224006750|NCT02169362|DEVICE|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
224125701|NCT02648958|DRUG|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
224125702|NCT02648958|DRUG|normal saline|The control group received the normal saline infusion
224125703|NCT02622100|DEVICE|Bioresorbable Vascular Scaffold|
224125704|NCT03363243|OTHER|STOP Therapy Treatment group|Testing of the STOP Therapy protocol
224125705|NCT03363243|OTHER|Treatment as usual (TAU) group|Treatment as usual in the community through group therapy
224125706|NCT00441441|DRUG|fluticasone propionate|fluticasone propionate 100mcg HFA
224006751|NCT01178697|DRUG|Bevasizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
224125707|NCT00441441|DRUG|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
224006752|NCT01178697|DRUG|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
224125708|NCT04467177|OTHER|30% glucose|Male neonates will receive 2 ml of 30% glucose two minutes prior to circumcision
224125709|NCT04467177|OTHER|Placebo|Male neonates will receive 2 ml of sterile water two minutes prior to circumcision
224125710|NCT00262080|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
224125711|NCT00262080|DRUG|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
224299244|NCT00902720|OTHER|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
223387584|NCT07193446|BEHAVIORAL|D-stress study: The detection, prevention and management of diabetes distress for adults living with type 1 diabetes.|Enhanced Usual Care intervention aims to train health care professionals to detect and prevent, and manage diabetes distress in routine diabetes care, in the UK NHS. The REDUCE programme aims to prevent and manage elevated diabetes distress.
224006753|NCT06229652|BEHAVIORAL|RASMUS Resilience Training|"RASMUS stands for Resilience through mindfulness, self-compassion and self-care and is a German-language 10-week group resilience program with one training unit per week. The main content of the RASMUS is based on seven resilience factors, i.e. acceptance, optimism, taking responsibility, solution orientation, future orientation, role clarity, and network orientation including the aspects of mindfulness, self-compassion, and self-care.~RASMUS has been tested and certified according to the German Prevention Standard. The Central Prevention Test Center has awarded the seal of approval for the areas of exercise, nutrition, stress management/relaxation, and addictive substance consumption. Accordingly, this training program has been certified as a prevention course that is recognized by the German statutory health insurance companies. Furthermore, RASMUS can and is already offered as a (group) online course."
224006754|NCT06229652|OTHER|Body-oriented Yoga|"Body-oriented Yoga following the Ashtanga style will be held by certified yoga teacher parallel to the experimental one hour per week 10 times.~Each yoga session will start with the proper warming up of the whole body with some stretching exercises (20 min). The main part will last about 30 minutes and consist of dynamic and active yoga sequencing containing sun salutation with a mix of exercises. A relaxation phase with controlled breathing and meditation-elements will finish the class (10 min). Each exercise has different complexity levels of implementation and will be adapted to the performance abilities of each participant."
224006755|NCT03695939|BIOLOGICAL|realSKIN (skin xenotransplant)|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.
224006756|NCT03695939|BIOLOGICAL|Human Cadaver Allograft|HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
224006757|NCT03275597|DRUG|Durvalumab|Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
224006758|NCT03275597|DRUG|Tremelimumab|Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.
224006759|NCT03275597|RADIATION|Stereotactic Body Radiotherapy|SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
224006760|NCT03690583|DRUG|Zinc sulfate|Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
224125712|NCT04815304|DIAGNOSTIC_TEST|peripheral lymphocytes subsets|The data were collected during the first and the second wave of epidemic in COVID-19 patients with acute respiratory distress syndrome. At the moment of hospitalization, at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans (lung ultrasound score, diaphragmatic thickness and motion), arterial blood gas analysis parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation ), and pain assessed by using numeric rating scale. Macroscopic and microscopic hypopharynx and larynx damages were also evaluated by video-laryngoscopy and light miscoscopy.
224125713|NCT03660813|DIAGNOSTIC_TEST|Follicle measurment|Follicle will be measured before aspiration
224125714|NCT03660813|DRUG|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
224125715|NCT03660813|DRUG|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
224125716|NCT03284294|DRUG|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
224125717|NCT03284294|DRUG|Placebo|Oral placebo daily for 8 weeks
224125718|NCT03863236|DIETARY_SUPPLEMENT|regular diet|The control group (group 1) will continue their regular diet.
224125719|NCT03863236|DIETARY_SUPPLEMENT|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
224125720|NCT03580382|DRUG|Trametinib daily Until PD|1.0 mg daily
224125721|NCT03580382|DRUG|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
223387585|NCT07191665|OTHER|Acute nutrition intervention|The products (investigational and placebo) consists of three capsules that should be taken with water at two separate visits, with a wash-out period in between. The placebo product will comprise of microcrystalline cellulose (bulk). The investigational products will contain either caffeine and microcrystalline cellulose or caffeine, L-Arginine, and microcrystalline cellulose.
223545643|NCT02063685|DRUG|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
223545644|NCT02063685|DRUG|Observation|not maintenance therapy and followed-up with MRD monitoring.
223545645|NCT02063685|DRUG|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
223545646|NCT02063685|DRUG|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
223387586|NCT07192601|BEHAVIORAL|E-cigarette Cessation Manual|E-cigarette cessation manual development. Empirically supported treatment content. We anticipate grounding the intervention in an empirically supported psychosocial smoking cessation program (i.e., Cognitive Behavior Therapy; CBT), which has been found to be effective with both adults and adolescents to quit cigarette smoking (Vinci, 2020). We anticipate including sessions that teach CBT skills to help adolescents quit e-cigarette use. These CBT skills and format will be adapted from prior manualized CBT smoking cessation interventions for adolescent smoking cessation and manualized CBT e-cigarette intervention for adolescents and young adults that are currently ongoing (e.g., Kong et al., 2017; Kong et al., 2021; Bold et al., 2022). The structure and content of the e-cigarette cessation manual will be further informed by themes and sub-themes from the focus group data analysis relating to both surface and deep structure cultural modifications.
224006761|NCT03690583|OTHER|Glucose|The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
224006762|NCT06359925|PROCEDURE|Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine|After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL of\[ 5\]µg dexmedetomidine. The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
224006763|NCT06359925|PROCEDURE|Suprazygomatic maxillary nerve block using Bupivacaine|After induction of general anaesthesia blockade of the contents of the pterygopalatine fossa is performed bilaterally before starting surgery as follows: After complete aseptic skin preparation and under ultrasound guidance images are obtained with a high-frequency linear array probe. The ultrasound transducer is placed in the infrazygomatic area, over the maxilla, angled \[45 \]degree cephalad. This probe position allows visualization of the pterygopalatine fossa,The needle is advanced using an out-of-plane approach, and the needle tip can usually be identified during movements. the injectate consisted of \[4\]mL of \[0.5% \]Bupivacaine combined with \[1\]mL normal saline . The injectate is delivered over \[15-20 \] seconds, while observing the spread of the local anesthetic under ultrasoundThe same procedure is then repeated on the contralateral side.
224006764|NCT01827475|DRUG|Ibuprofen|single dose
224006765|NCT01827475|DRUG|Acetaminophen|single dose
224006766|NCT01827475|DRUG|Ibuprofen-acetaminophen combination|single dose
224006767|NCT01640470|DEVICE|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
224006768|NCT01640470|DEVICE|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
224006769|NCT01800682|DRUG|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
224006770|NCT02735577|DRUG|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
224006771|NCT04340791|BEHAVIORAL|Increased proportion of lower energy density items|The proportion of lower energy density vs. higher energy density items will be reversed (67% lower - 33% higher) relative to the default proportion condition (D and DL) (33% lower - 67% higher). Lower energy density items will be defined as lower energy density ≤ median of energy density distribution within a food category.
224006772|NCT04340791|BEHAVIORAL|Labelling|"When energy density of an item ≤ median of ED distribution within a food category, healthier choice badges will be added to the food item pictures on the online supermarket. Instructions when logging-into the platform will introduce the badges to the participants: In the online supermarket, the green tick allows you to see which products (e.g. muesli) in each product category (e.g. cereals) are healthier choices with fewer calories per gram than most other products in the same category."
224006773|NCT00833833|DRUG|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
224006774|NCT00833833|DRUG|Dexamethasone|oral dexamethasone
224125722|NCT03849040|PROCEDURE|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
224125723|NCT00442247|DEVICE|Pelvicol|
224125724|NCT04840654|PROCEDURE|Caudal Block|"A caudal block is a procedure that will help lessen a child's pain after an operation.~100 subjects will be randomized to this block procedure."
224125725|NCT04840654|PROCEDURE|Pudendal Block|"form of local anesthesia commonly used in the practice of obstetrics to relieve pain during the delivery of baby by forceps.~100 Subjects will be randomized to this block procedure."
224125726|NCT06958653|DEVICE|Brief-BESTest assessment|Uses the traditional Brief-BESTest to assess the balance ability of the participants.
223387587|NCT07185841|DRUG|HX9428 tablet|Subjects will receive HX9428 orally every day. The total treatment period is tentatively set at 25 weeks..
223387588|NCT07192302|PROCEDURE|Arthroscopy|Early Surgical Intervention in Patients with Partial Rotator Cuff Tears and Concomitant Shoulder Stiffness.
223387589|NCT07192302|DRUG|Drugs administration|Oral Medication for Conservative Management of Partial Rotator Cuff Tears with Concomitant Shoulder Stiffness.
223387590|NCT07192497|OTHER|DRY NEEDLING|Myofacial trigger point dry needling used to treat taught bands superficial or deep inside of muscles .
223545647|NCT02063685|DRUG|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
224006775|NCT00833833|DRUG|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
224125727|NCT06958653|DEVICE|Digital balance assessment tool|Uses the digital balance assessment tool, which is the digitalized Brief-BESTest, to assess their balance ability.
224125728|NCT06836401|PROCEDURE|Root scaling|Scaling and root planing is a deep cleaning below the gumline used to remove plaque and tartar that cover the root in the periodontal pockets. This intervention is carried out in both control and experimental sites
223387591|NCT07192497|OTHER|Acupressure|Acupressure therapy based on traditional Chinese principles
223387592|NCT07192497|OTHER|Dry needling and Acupressure therapy|combination of dry needling and acupressure therapy on cervical trigger points
223387593|NCT07192497|OTHER|Hot Pack|Hot fermentation will be applied on cervical pain area
223387594|NCT07192835|DIETARY_SUPPLEMENT|Juice from untreated control fruits|Participants will consume 300 g of juice prepared from untreated fruits (lemon, blood orange, or sweet cherry) under fasting conditions on the intervention day. Urine samples will be collected at 0-3.5 h, 3.5-12 h, and 12-24 h post-consumption to assess absorption and metabolism of bioactive compounds.
223387595|NCT07192835|DIETARY_SUPPLEMENT|Juice from melatonin-treated fruits|Participants will consume 300 g of juice prepared from fruits (lemon, blood orange, or sweet cherry) treated preharvest with melatonin (0.1, 0.3, or 0.5 mM). Juice will be consumed under fasting conditions on the intervention day. Urine samples will be collected at 0-3.5 h, 3.5-12 h, and 12-24 h post-consumption to assess absorption and metabolism of bioactive compounds.
223387596|NCT07193368|BIOLOGICAL|Polyacrylamide hydrogel 2.5% intra-articular injection|A single intra-articular injection of 2.5% cross-linked polyacrylamide hydrogel (iPAAG), composed of 2.5% polyacrylamide and 97.5% non-pyrogenic water. The product (Arthrosamid®, Contura, Denmark) was administered under ultrasound guidance into the knee joint. Patients were followed retrospectively for 12 months to evaluate safety and effectiveness in reducing pain (VAS) and improving function (WOMAC).
223387597|NCT07192692|DIETARY_SUPPLEMENT|fast|fast state
223387598|NCT07192692|DIETARY_SUPPLEMENT|low fat meal|take HSK47388 with low fat meal
223387599|NCT07192692|DIETARY_SUPPLEMENT|take meal after HSK47388 administration|take meal after HSK47388 administration at specific time
223387600|NCT07193134|DRUG|Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS)|Wound debridement will be performed, followed by the application of temporary allogeneic skin grafts for 3-5 days. The allografts will then be removed, and the GMEB-SASS grafts will be applied.
223387601|NCT07191782|BEHAVIORAL|Universal, classroom-based, Bullying and Aggression Prevention Program|PRAISE is a universal, classroom-based aggression and bullying prevention program that addresses all forms (physical, verbal, relational, cyber), with a strong focus on the relational and reactive behaviors. All emotional and social skills taught focus on applying and practicing the skills within peer relationships. This program has gone through iterative development and adaptations using a community-based participatory approach whereby the elementary students and staff were active partners with researchers in refining the program. Specific attention was paid to ensuring that the program is feasible for schools to implement and sustain while also being relevant and relatable for students from a variety of backgrounds and school communities (e.g., under-resourced, higher levels of community violence). This updated PRAISE includes \~14 sessions (amounts can vary by grade) and training and coaching for school-based facilitators of the program.
223387602|NCT07191873|DRUG|Tirzepatide|Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
223387603|NCT07191873|DRUG|Tirzepatide Placebo|Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
223545648|NCT03058198|DIAGNOSTIC_TEST|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
223545649|NCT00964951|BIOLOGICAL|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
224006776|NCT02365727|DRUG|Liposomal bupivacaine|
224125729|NCT06836401|DRUG|Topical Gel|A gel (experimental: metronidazole VS control: carbopol) is introduced in the recently cleaned periodontal pocket. The allocation of either experimental or control gel was distributed randomly, being masked both the patient and the clinician.
223730175|NCT05558163|PROCEDURE|transverse scrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
224006777|NCT02365727|DRUG|Ropivacaine|
224006778|NCT02365727|DRUG|Epinephrine|
224006779|NCT02365727|DRUG|Clonidine|
224006780|NCT02365727|DRUG|Saline|
224006781|NCT02814084|DEVICE|Bilateral Internal Mammary Artery grafts|Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts
224006782|NCT02814084|DEVICE|Prevena|The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
224006783|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
223387604|NCT07192549|DRUG|Sevoflurane group|Patients fasted for 6 hours and abstained from clear fluids for 3 hours preoperatively. Upon entering the operating room, oxygen was administered via an appropriately sized face mask at a flow rate of 6-8 L/min. Anesthesia was induced by sequential intravenous injection of remimazolam, sufentanil, and rocuronium. A laryngeal mask was inserted after the disappearance of the eyelash reflex. Anesthesia was maintained with sevoflurane (Inhalation Sevoflurane, Brand: Kaiteli, Specification: 120 mL, Approval Number: National Drug Approval H20070172, Manufacturer: Shanghai Hengrui Pharmaceutical) combined with continuous intravenous infusion of remifentanil. During surgery, vital signs and body movement responses were closely monitored, and the inhaled concentration of sevoflurane was adjusted as needed (maintained at 1%-3%). Administration of anesthetics was discontinued 5 minutes before the end of surgery.
223387605|NCT07192549|DRUG|Propofol group|Preoperative preparation was identical to that of the Sevoflurane Group. Anesthesia induction was performed using the same sequence of intravenous injections of remimazolam, sufentanil, and rocuronium, followed by laryngeal mask insertion after the disappearance of the eyelash reflex. Anesthesia was maintained with remifentanil combined with continuous intravenous infusion of propofol at a maintenance dose of 0.5 mg/(kg·h). The infusion rate was dynamically adjusted based on intraoperative vital signs. Administration of anesthetics was stopped 5 minutes before the end of surgery.
223387606|NCT07191769|PROCEDURE|general anaesthesia|Patients undergoing general anaesthesia
224006784|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
224006785|NCT00989625|DRUG|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
224006786|NCT05715021|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
224006787|NCT01994837|DRUG|ABT-199|Tablet
224006788|NCT04135690|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
224006789|NCT04135690|DRUG|Toripalimab|240mg intravenously every 3 weeks
224006790|NCT04135690|DRUG|Sorafenib|400mg bid po
224006791|NCT04135690|DRUG|systemic treatment|atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on
224006792|NCT00518544|DRUG|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
223387607|NCT07191769|PROCEDURE|regional anaesthesia|Patients undergoing regional anaesthesia
223387608|NCT07193095|BEHAVIORAL|Brief Mindfulness Oriented Recovery Enhancement|B-MORE is a 2-hour, single session adaptation of the traditional MORE program.
223387609|NCT07193095|BEHAVIORAL|Empowered Relief|ER is an evidence-based 2-hour single session intervention for chronic pain.
223387610|NCT07193095|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|MORE is an 8-week evidence-based treatment for chronic pain.
223387611|NCT07185828|BEHAVIORAL|Contact your PCP|Text messages will be sent and discharge paperwork will be modified to encourage contacting a primary care provider.
223545650|NCT00964951|BIOLOGICAL|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
224006793|NCT02630108|PROCEDURE|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
224006794|NCT02630108|DRUG|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
224006795|NCT02630108|DRUG|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
224006796|NCT02630108|OTHER|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
224006797|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
224006798|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
224006799|NCT01127893|BIOLOGICAL|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
224006800|NCT02913053|BEHAVIORAL|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
224006801|NCT02913053|BEHAVIORAL|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
224006802|NCT03356782|BIOLOGICAL|Sarcoma-specific CAR-T cells|1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
224006803|NCT02928276|OTHER|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
224006804|NCT02905071|OTHER|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
224006805|NCT02905071|OTHER|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
224006806|NCT02905071|OTHER|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
224125730|NCT05972070|DEVICE|ROMTech Portable Connect|The ROMTech PortableConnect Rehab System is a continuous rehabilitative exercise therapy device that uses assisted movement to measure, evaluate, exercise, re-educate and strengthen muscles, and to increase joint range of motion.
224006807|NCT00574873|DRUG|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
224006808|NCT00574873|DRUG|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
223387612|NCT07185828|BEHAVIORAL|Use Intelligent Triage|Text messages will be sent and discharge paperwork will be modified to encourage using Intelligent Triage.
224006809|NCT05316272|BEHAVIORAL|Exercise|Supervised bone-loading exercise on 3 days per week for 36 weeks
224006810|NCT05316272|DIETARY_SUPPLEMENT|DHEA|DHEA in pill form 50 milligrams taken daily for 36 weeks
224006811|NCT04603287|DRUG|SI-B001|Administration by intravenous infusion.
224006812|NCT05621577|DEVICE|MANDIBULAR ADVANCEMENT DEVICE|orthodontically treating obstructive sleep apnea
224006813|NCT02043964|PROCEDURE|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
224006814|NCT05628805|DEVICE|iTBS|intermittent theta burst stimulation with TMS
224006815|NCT06504160|DRUG|ShA9 Topical Gel|The ShA9 topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose containing lyophilized ShA9 bacteria. The ShA9 bacteria is derived from a healthy donor-derived (allogeneic) commensal Staph species. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
224006816|NCT06504160|DRUG|Hydrocortisone Ointment|All participants will apply hydrocortisone ointment 2.5% alongside the study product in sensitive body areas (e.g., face, neck, intertriginous regions) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
223387613|NCT07191613|BEHAVIORAL|HAPPY GO GO Somatosensory Game|"Participants in the intervention group will engage in the HAPPY GO GO somatosensory exergame program. The intervention consists of structured game-based physical activity sessions, conducted once per week for a total duration of 12 weeks. Each session includes interactive, movement-based tasks designed to promote physical health, and mental well-being among community-dwelling older adults."
223387614|NCT07186634|DRUG|Liberal inspired oxygen|The concentration of Oxygen will differ according to the randomisation
223387615|NCT07186634|DRUG|Conservative inspired oxygen|Conservative inspired oxygen
223387616|NCT07186634|DRUG|Intermediate inspired oxygen|Intermediate inspired oxygen
223387617|NCT07192250|PROCEDURE|short segment TPF|short segment transpedicular screw fixation with one or two screws in fractured vertebra
223387618|NCT07192250|PROCEDURE|conservative management|brace and bed rest with mobilization as tolerated
223387619|NCT07192315|OTHER|Bloodsampling|Blood will be sampled At Visit 1, 2, 3 and 4. For patients presenting immuno-induced adverse events (iRAEs), an additionnal visit V tox will be planned will a blood sampling.
223387620|NCT07192315|OTHER|Pharyngeal swab sampling|Pharyngeal swab will be sampled at visit 4 for patients without immuno-induced adverse events (iRAEs) Pharyngeal swab will be sampled at visit Tox for patients presenting immuno-induced adverse events (iRAEs)
223387621|NCT07192315|OTHER|Cuteanous swab sampling|"Cuteanous swab will be sampled at visit 1, 2, 3 and 4 for patients without immuno-induced adverse events (iRAEs).~Cuteanous swab will be sampled at visit 1, 2, 3 and tox for patients presenting immuno-induced adverse events (iRAEs)."
223387622|NCT07192315|OTHER|Stools sample collection|"Stools sample will be collected at visit 1, 2, 3 and 4 for patients without immuno-induced adverse events (iRAEs).~Stools sample will be collected at visit 1, 2, 3 and tox for patients presenting immuno-induced adverse events (iRAEs)."
223387623|NCT07193290|OTHER|Lifestyle Questionnaire|All subjects will complete the lifestyle questionnaire
223387624|NCT07193290|OTHER|Self-portrait image (Face and Hair)|All subjects will take one self-portrait image of their face and hair
223387625|NCT07193290|DIAGNOSTIC_TEST|Skin microbiome collection|Subjects randomly assigned in the skin microbiome subset will complete the skin microbiome collection
223387626|NCT07192354|OTHER|Questionnaire and Physical Exam|Participants will be administered the Cyberchondria Severity Scale Short Form (CSS-12), Health Perception Scale, and State and Trait Anxiety Scale online via Google form.
223387627|NCT07193160|DRUG|Sacituzumab Tirumotecan|fixed dosage 4mg/kg iv, D1, D15, each 4 weeks one cycle. Drug reduction will be implemented according to the research plan.
223387628|NCT07193160|DRUG|Furmonertinib|160mg QD or 80mg QD, each 4 weeks one cycle, according to the safety run-in phase, until confirmed by the investigator as imaging disease progression, intolerable toxicity, subject's request to terrminate treatment, or other treatment termination criteria specified in the protocol. Drug reduction will be implemented according to the research plan.
223387629|NCT07191951|OTHER|Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.|Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.
223545651|NCT00723151|BEHAVIORAL|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
223730176|NCT05558163|PROCEDURE|penoscrotal approach for PPI|penile prothesis implantation through penoscrotal approach outcome
224006817|NCT06504160|DRUG|Clobetasol Ointment|All participants will apply clobetasol ointment 0.05% alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It will be applied twice daily to lesional skin and selected sampling areas from Baseline to Week 2. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
224125731|NCT03443726|PROCEDURE|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
224125732|NCT03443726|PROCEDURE|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
224006818|NCT06504160|DRUG|Fluocinonide Ointment|Participants with a past intolerance to clobetasol or who become too sensitive to clobetasol in the initial two-week cotreatment period will apply fluocinonide ointment 0.05% as an alternative. In these cases, fluocinonide ointment 0.05% will be applied alongside the study product in non-sensitive body areas (e.g., arms, legs, torso) for the first two weeks of the trial. It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 2 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 2 Visit.
223387630|NCT07192172|DEVICE|Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes|"Device: Twin Internally Cooled-Perfusion (TICP) Electrodes~Two 17-gauge internally cooled-perfusion electrodes Multichannel RF generator (RF Medical Co., Seoul, Korea) Bipolar mode application Saline perfusion rate: approximately 1 cc/min"
223387631|NCT07192536|DEVICE|Transcranial magnetic stimulation|Intermittent theta burst stimulation (iTBS) will be delivered via the Magstim Horizon 3.0 Transcranial Magnetic Stimulation device. This device has been authorized by Health Canada (License No.: 111334, Type: System, Device class: 3 Device first issue date 2024-06-04, License name: HORIZON 3.0 TMS THERAPY SYSTEM) and is indicated for use in treating mild depressive disorder. The device will be used off-label as a potential treatment for Post-Traumatic Stress Disorder (PTSD) and chronic pain in this Investigator-Initiated study. rTMS will be delivered using modified intermittent theta burst accelerated bilateral treatments (MITAB), combining low frequency 1HZ to the right dorsolateral prefrontal cortex (dlPFC) with high frequency intermittent theta burst to the left dlPFC, up to 6 times per day for 5 days.
223387632|NCT07192445|OTHER|Reading of Mental Health Graphic Novels|Participants read carefully selected excerpts from graphic novels focused on mental health. These excerpts integrate written narratives with visual storytelling to illustrate daily life challenges, symptoms, interpersonal relationships, and treatment experiences in mental health contexts. The intervention is conducted individually in a supervised classroom environment. Along with the graphic novel, a guide is provided with questions designed to encourage focused and reflective reading.
224006819|NCT06504160|DRUG|Placebo (Vehicle) Topical Gel|The placebo (vehicle) topical gel contains phosphate-buffered saline solution (PBS), Glycerol, and hydroxyethylcellulose. The gel is manufactured and packaged by University of California San Diego (UCSD). It is applied twice daily to all areas identified as actively lesional during the Baseline Visit, regardless of ongoing lesional status, until the Week 14 Visit. If new lesions arise during this time, these areas will also be treated, regardless of ongoing lesional status, until the Week 14 Visit.
224006820|NCT06370520|BEHAVIORAL|Validated Questionnaires|Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-8 (PHQ-8), The Rivermead Post Concussion Symptom Questionnaire (Rivermead), Pediatric Quality of Life Inventory (PedsQL), Strengths and Difficulties Questionnaire (SDQ)
224006821|NCT06370520|BEHAVIORAL|Questionnaires|Early Physical Activity/Return to School Questionnaire, Mental Health Utilization Questionnaire
224006822|NCT06370520|OTHER|Clinician / Medical Record Variables|Medical History, Emergency Department Clinical Variables
224006823|NCT06512675|OTHER|Resistance combined with cardiovascular training|Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
224006824|NCT05277571|BIOLOGICAL|UCB1381|UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B
224006825|NCT05277571|DRUG|Placebo|Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
224006826|NCT03674359|DIAGNOSTIC_TEST|BDG analysis|BDG analysis
224125733|NCT03443726|DRUG|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
224125734|NCT03443726|PROCEDURE|Third molar extraction|Third molar extraction under local anesthesia.
224125735|NCT04255186|DEVICE|Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
224125736|NCT04255186|DEVICE|Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency|Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
224125737|NCT04255186|DEVICE|Sham stimulation|a simulated stimulation protocol so that the device does not emit current
224125738|NCT03583762|DIAGNOSTIC_TEST|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
224125739|NCT03583762|DIAGNOSTIC_TEST|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
224295940|NCT05496387|OTHER|Sciatic nerve neuromobilization techniques|Sciatic nerve neuromobilization techniques (tension and sliding) was applied to the dominant side lower extremities of all participants in the study. While the participant was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to dorsiflexion. After waiting 30 seconds in this tense position, the ankle, head and neck returned to neutral position and relaxed. 3 sets were repeated with 1 minute rest breaks. Sciatic nerve sliding was applied in the same starting position as tension. While the participants was trying to bring her chin closer to her chest by flexing her head and neck, she simultaneously brought her foot to plantar flexion.
223387633|NCT07191535|DRUG|linvemastat|Matrix Metalloproteinase-12 inhibitor
223545652|NCT04535102|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
224006827|NCT01440998|DRUG|Carboplatin|Given IV
224006828|NCT01440998|DRUG|Dasatinib|Given PO
224006829|NCT01440998|OTHER|Laboratory Biomarker Analysis|Correlative studies
224006830|NCT01440998|DRUG|Paclitaxel|Given IV
224006831|NCT01808937|OTHER|Morphea|
224295941|NCT04967872|OTHER|Implementing risk management and control plan for the elderly during perioperative period|Visualization technology is used for preoperative evaluation, anesthesia management, bedside real-time monitoring and intervention, etc., to achieve accurate perioperative management of elderly patients and whole-process whole-person management
224006832|NCT04195139|DRUG|Nivolumab|Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
224006833|NCT04195139|DRUG|Temozolomide|Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
224006834|NCT03283254|BEHAVIORAL|Practical Resources for Effective Postpartum Parenting (PREPP)|A preventive psychotherapy intervention for PPD: Participants in this arm of the study receive PREPP (Practical Resources for Effective Postpartum Parenting). PREPP is a brief preventive intervention for Postpartum Depression that focuses on the birthing parent-infant dyad and consists of 5 sessions that take place during pregnancy through 6 weeks postpartum carried out by study clinicians referred to as 'coaches.' The sessions of this preventive psychotherapy are comprised of three components: (a) mindfulness and self-reflection skills, (b) parenting skills and (c) psycho-education.
224006835|NCT03283254|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|"Psychoeducation, Clinical Assessment, Potential Referral: Participants receive usual care along with Postpartum Depression psychoeducation and enhanced support for finding perinatal mental healthcare treatment when appropriate by meeting with a study clinician specifically assigned to provide ETAU in this study at three times that are aligned with PREPP sessions that span from pregnancy to 6 weeks postpartum. At the first contact, participants meet with their assigned ETAU clinician and are given information about PPD, a brief clinical mental health assessment, and a referral for treatment if warranted or requested; the second session is a follow-up mental health clinical assessment with the study clinician and a referral for treatment if warranted or requested; at the third session, participants meet again with their study clinician and receive a mental health assessment, review relevant psychoeducation on PPD and are referred to treatment when appropriate."
224006836|NCT02541955|DRUG|Acthar|Injections will be self administered
224006837|NCT05689710|DIETARY_SUPPLEMENT|Inositol and alpha-lactalbumin|The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)
224006838|NCT05132231|BIOLOGICAL|Brodalumab|Brodalumab
224006839|NCT05132231|BIOLOGICAL|Matched cohort|Matched cohort
224125740|NCT04109235|OTHER|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
224125741|NCT04109235|OTHER|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4\&5 from: http://csep.ca/CMFiles/Guidelines/CSEP\_PAGuidelines\_0-65plus\_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for a research assistant who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, the research assistant will respond to these over the phone.
224125742|NCT00264316|PROCEDURE|bone marrow-derived stem cell transfer|
223387634|NCT07191535|DRUG|Placebo|Placebo
223387635|NCT07191483|DRUG|KYN-5356 low dose|oral tablet
223387636|NCT07191483|OTHER|Placebo|Oral tablet
223387637|NCT07191483|DRUG|KYN-5356 Medium Dose|oral tablet
223387638|NCT07191483|DRUG|KYN-5356 High Dose|oral tablet
223387639|NCT07192289|PROCEDURE|Using advanced platelet-rich fibrin (A-PRF+) or injectable platelet-rich fibrin (i-PRF) in regenerative endodontic treatment in mature permanent teeth.|"After obtaining informed consent, the study will be conducted over 2 appointments, 2-4 weeks apart.~The first appointment will focus on infection control and inflammation reduction. The canal will be instrumented with a single-file system. The canal will be then irrigated sequentially with 3% sodium hypochlorite (NaOCl), saline, and 17% ethylenediaminetetraacetic Acid (EDTA) to ensure thorough disinfection. Finally, a temporary filling of Glass Ionomer Cement will be placed over an intracanal dressing of calcium hydroxide.~At the second appointment, the final treatment will be performed based on the patient's group:~Control Group - Blood clot method for regenerative endodontics. Experimental Group 1 - Regenerative endodontics using advanced platelet-rich fibrin (A-PRF+).~Experimental Group 2 - Regenerative endodontics using injectable platelet-rich fibrin (i-PRF).~All three groups will be then sealed with mineral trioxide aggregate (MTA) and a final composite resin filling."
223545653|NCT05421676|DEVICE|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
223545654|NCT00541112|BIOLOGICAL|cetuximab|
223545655|NCT00541112|DRUG|capecitabine|
224006840|NCT05869812|DRUG|CaHMB (Dietary supplement, not Drug)|The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.
224006841|NCT05869812|DIETARY_SUPPLEMENT|CaLa|Comparative placebo
224125743|NCT03643822|DRUG|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
223545656|NCT00541112|DRUG|fluorouracil|
223545657|NCT00541112|DRUG|leucovorin calcium|
223545658|NCT00541112|DRUG|oxaliplatin|
223545659|NCT00541112|PROCEDURE|adjuvant therapy|
223545660|NCT00541112|PROCEDURE|conventional surgery|
223545661|NCT00541112|PROCEDURE|neoadjuvant therapy|
223545662|NCT00541112|RADIATION|radiation therapy|
224006842|NCT05293756|BEHAVIORAL|OPTIMA-BP Intervention|"Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor."
224006843|NCT06133153|DEVICE|THIODERM ELATE|Thiomer-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
224006844|NCT06133153|DEVICE|Juvéderm Ultra 3|BDDE-crosslinked Hyaluronic Acid Dermal Filler with Lidocaine for Injection into Lips
224006845|NCT04907565|BIOLOGICAL|Blood sampling|4 tubes of 7 mL of blood will be collected
224006846|NCT04907565|BIOLOGICAL|white adipose tissue sampling|At the beginning of the surgery, samples of white adipose tissue from the surgical wound will be collected.
224006847|NCT01899898|OTHER|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~1. Pictorial representation of various food items and exchange lists will be provided.~2. Instead of weights, we will provide standardized measures~3. We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~4. We will formulate recipes and diets based on locally available and culturally acceptable foods.~5. We will develop a parent instruction manual.~6. We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~7. We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
224006848|NCT01899898|DRUG|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
224006849|NCT05104775|DRUG|GNC-035|Administration by intravenous infusion.
224006850|NCT02508220|DRUG|Syntocinon|Oxytocin nasal spray
224125744|NCT03643822|DRUG|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
224125745|NCT03643822|OTHER|Saline|Control/Placebo intervention
224295942|NCT00505648|DRUG|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
224295943|NCT01091272|DRUG|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
224295944|NCT01091272|DRUG|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
223387640|NCT07192081|DRUG|Labetalol|Labetalol 0.25 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.
223387641|NCT07192081|DRUG|Lignocaine|Lignocaine 1.5 mg/kg intravenous bolus over 60 seconds, administered 3 minutes before laryngoscopy.
223387642|NCT07192484|BEHAVIORAL|KT group|Receiving additional KT
224006851|NCT02508220|DRUG|Placebo|distilled water in nasal spray
224006852|NCT02093949|PROCEDURE|Routine substrate ablation without pulmonary vein Isolation|
224006853|NCT02093949|PROCEDURE|Routine conventional ablation with pulmonary vein Isolation|
223387643|NCT07192484|BEHAVIORAL|Conventional group|Conventional physical therapy
223387644|NCT07192796|BEHAVIORAL|Pilates Exercise Program|A 6-week supervised Pilates exercise program, with 18 sessions. Exercises focused on core stabilization, posture, and lower limb alignment using mat-based and resistance band movements.
223387645|NCT07192796|BEHAVIORAL|Neuromuscular Exercise Program|A 6-week supervised neuromuscular training program, 18 sessions . Training emphasized balance, proprioception, dynamic stability, and strengthening of lower extremity muscles.
224006854|NCT06241898|DRUG|BB-1709|Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
223387647|NCT07192367|BEHAVIORAL|Virtual Reality Exposure Therapy|Participants receive structured Virtual Reality Exposure Therapy sessions using a VR headset. The intervention provides simulated social situations (e.g., public speaking, group interactions) to gradually expose participants to anxiety-provoking scenarios. The sessions are guided and standardized to target symptoms of social anxiety disorder.
223545663|NCT00001034|DRUG|Ganciclovir|
224006855|NCT06184581|DRUG|Lithium Carbonate|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
224006856|NCT06184581|DRUG|Lamotrigine|The trial is designed as a single-blinded two-armed, parallel randomized trial with randomization 1:1 to lamotrigine versus lithium.
224006857|NCT02450045|PROCEDURE|Continuous femoral nerve block|
224006858|NCT02450045|DRUG|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
224125746|NCT04592614|BEHAVIORAL|Choose to Move - Next Steps|Choose to Move - Next Steps consists of a series of group meetings delivered virtually for 2 years. Group meetings (1-hr each) of 6-11 older adults will be facilitated by a trained Activity Coach and delivered remotely via the Zoom or GoToMeeting platform (password protected; access through phone or internet). Each group meeting will provide information on a health-related topic of interest and will include time for goal setting, discussion and sharing among participants. Older adults will have the option to sign up for a bi-weekly CTM electronic newsletter containing health information and ideas and resources for older adults to be physically active and socially connected at home (and elsewhere as local restrictions permit). Activity Coaches will also facilitate social connections between participants to encourage contact (by phone or online) outside of group sessions (for interested participants only).
224125747|NCT05619172|DRUG|Nanrilkefusp alfa|Subcutaneous (SC) injection
224125748|NCT05619172|DRUG|Cetuximab|Intravenous (IV) infusion via peripheral or central venous line
224006859|NCT03917056|PROCEDURE|Cap-assisted endoscopic sclerotherapy using long needle|Participants were treated with CAES using long needle.
223387648|NCT07192367|DRUG|Sertraline (Oral Antidepressant)|Participants receive pharmacological treatment with Sertraline, a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for social anxiety disorder. Dosage and administration will follow clinical guidelines and physician judgment.
223387649|NCT07191938|PROCEDURE|Ultrasound guided penile block|The penile block is performed supine. After skin disinfection, the Buck's fascia is sonographically located, and the local anesthetic is injected close to the dorsal nerve of the penis in the plane after a negative aspiration test (16). The recommended dose is 0.1 ml/kg per side of ropivacaine 2 mg/ml (8). Injection is performed bilaterally. A subcutaneous injection of 1ml ropivacaine 2mg/ml (i.e. 2mg) is made at the base of the penis to ensure blockage of the perineal fibers.
223387650|NCT07191938|PROCEDURE|Neurostimulation guided pudendal block|The pudendal block is performed in the supine position, with the legs flexed. After skin disinfection and palpation of the ischial tuberosity, the neurostimulator needle, set at 0.5 mA, is inserted 1 cm medial to the tuberosity. Contraction of the anal sphincter enables the proximity of the pudendal nerve, originating from the S2, S3 and S4 roots, to be identified. Once contraction has been obtained, local anaesthetic is injected using ropivacaine 2 mg/ml at a dose of 0.2 ml/kg per side, in the absence of blood reflux.
224006860|NCT03917056|PROCEDURE|Cap-assisted endoscopic sclerotherapy using short needle|Participants were treated with CAES using short needle.
224006861|NCT05331573|DEVICE|apomorphine pump|observationnal
224006862|NCT05490238|PROCEDURE|Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)|Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
224006863|NCT02590900|DRUG|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
224006864|NCT05141500|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|"Reprocessed noninvasive pulse oximeters~* 1859 \& 2329~* MAX-A \& MAX-N"
224006865|NCT03819790|DRUG|Basal insulin glargine and lixisenatide|Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
224006866|NCT03819790|DRUG|Basal insulin Basaglar/Lantus + gliclazide MR|basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
224006867|NCT03819790|DRUG|Metformin|Patients can be administered with most tolerant dose of metformin
224006868|NCT06420518|OTHER|Ketogenic diets|During the outpatient phase of the study, all participants will undergo a very low-carbohydrate diet (less than 50grams/day) and, a fasting diet (12 hours) in a randomized order. Both diets are 6 days in duration and, will be interspaced by an inpatient insulin-suspension period. These ketogenic diets are implemented to drive higher ketone levels, within a safe threshold, to assess the accuracy of the CKM sensor. All the while, study participants will be wearing the CKM and, taking multiple daily ketone measurements with a standard point-of-cate ketone meter.
224006869|NCT06420518|OTHER|8-hour insulin-suspension period|Interspaced between both ketogenic diets, on day 8 of the study, participants will have their insulin pumps suspended for 8 hours; therefore, participants will not receive any basal or bolus insulin. Ketone levels will be monitored on-site every 30 minutes with standard point-of-care capillary ketone meters and, if ketones measurements exceed the safety threshold, participants will be treated accordingly. Clearly defined stopping criteria and corrective treatments have been outlined in the study protocol to ensure participants safety.
223387651|NCT07193043|BEHAVIORAL|Body Image Program (BIP)|The Body Image Program (BIP) is a culturally adapted, dissonance-based group intervention derived from the Body Project. It is delivered in two weekly sessions of 120 minutes each, in small groups of 7-10 participants, by trained health professionals with experience in eating disorders. Activities include verbal, written, and behavioral exercises to critique sociocultural appearance ideals, reduce thin-ideal internalization, and promote more adaptive body image. Each session ends with homework: after Session 1, tasks include a behavioral challenge and reflective writing; after Session 2, a commitment activity (e.g., self-affirmation or body activism) is completed within one week and submitted by email. Participants in the waitlist control arm complete the same assessments but receive the BIP between weeks 6 and 8, after the final follow-up.
224006870|NCT02140255|DRUG|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
224006871|NCT02140255|DRUG|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
224006872|NCT02140255|DRUG|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
224006873|NCT02140255|DRUG|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
224006874|NCT02140255|DRUG|VRC01|40 mg/kg administered subcutaneously.
224006875|NCT02140255|DRUG|DTG|Administered orally. Dosed according to participant's weight.
224006876|NCT02140255|DRUG|VRC07-523LS|40 mg/kg administered subcutaneously.
224006877|NCT03568318|DRUG|Placebo|Tablets taken orally once a day
224006878|NCT03568318|DRUG|Upadacitinib|Tablets taken orally once a day
224006879|NCT03568318|DRUG|Topical corticosteroids (TCS)|"Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.~Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid."
224006880|NCT04806438|OTHER|Group A|Patient will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
224125749|NCT04009096|BIOLOGICAL|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
224125750|NCT03153215|OTHER|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
224295945|NCT01091272|DRUG|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
224006881|NCT04806438|OTHER|Group B|Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice
224006882|NCT00897117|GENETIC|gene expression analysis|Blood and lung tissue collection
224006883|NCT00897117|GENETIC|microarray analysis|Blood and lung tissue collection
224006884|NCT00897117|GENETIC|protein expression analysis|Blood and lung tissue collection
224006885|NCT00897117|OTHER|biologic sample preservation procedure|Blood and lung tissue collection
224006886|NCT00897117|OTHER|laboratory biomarker analysis|Blood and lung tissue collection
224006887|NCT00897117|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
224006888|NCT06377553|DRUG|Radiotracer Injection|"An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably."
224006889|NCT06377553|DIAGNOSTIC_TEST|Imaging|"MRI and PET scanner to be used:~3.0 T Laboratory (Bay 7) Siemens Biograph mMR.~Magnetic resonance images of the pelvis and abdomen will be acquired using the Martinos Center's combined 3 Tesla PET/MRI scanner. The image quality on these 3 Tesla devices will be very high, equivalent to or better than any other standard clinical MRI system. PET images of the target body site will be acquired when necessary, the data acquisition will be started shortly before radiotracer injection; Coincidence event data will be acquired and stored in list mode or compressed (i.e., sinogram space) format. Subjects will be asked to lie still for the duration of the study. The entire imaging session will last up to 120 minutes"
224006890|NCT06377553|OTHER|Rectal Ultrasound Gel Injection|About 50ml of ultrasound gel will be placed into the vagina using the blunt end of the ultrasound gel tube or a Foley catheter or a syringe with a blunt Christmas tree end. No ultrasound probe will be inserted into the vagina, no external ultrasound probe will be used. No ultrasound study will be performed. The ultrasound gel will only be used to distend the vagina and improve the quality of MRI images; this is standard of practice in MRI for endometriosis and for several other gynecological diseases.
224006891|NCT05594797|DRUG|Human BCMA Targeted T Cells Injection|A single dose of predetermined level CAR-positive T cells will be infused.
224006892|NCT00449605|DRUG|Rimonabant|Tablet, oral administration
224006893|NCT00449605|DRUG|Glimepiride|Tablet, oral administration
223387652|NCT07192471|DRUG|KK2223|Intravenous infusion
223387653|NCT07191899|DRUG|KN060|The dose was calculated based on the fasting body weight of the subject D1, and the corresponding volume of KN060 was drawn and added to 0.9% sodium chloride injection to prepare a 100 ml solution by intravenous drip every two weeks
223387654|NCT07191899|DRUG|0.9% Sodium Chloride Injection|0.9% sodium chloride 100ml was administered as placebo by intravenous drip every two weeks
224006894|NCT00449605|DRUG|Metformin|Metformin continued at stable dose as background therapy
223387655|NCT07192757|DEVICE|transcutaneous auricular vagus nerve stimulation|active electrical stimulation applied to the cymba conchae of the left ear
223387656|NCT07192757|DEVICE|Sham Control|electrical stimulation applied to a location on the ear not innervated by the auricular vagus
223387657|NCT07192809|OTHER|Stabilisation exercise, resistance exercise and distraction task|The 8-week exercise intervention consists of 25 minutes non supervised training while distracting their attention with a knowledge based application
223387658|NCT07192809|OTHER|stabilisation exercise and resistance exercises|The 8-week exercise intervention consists of 25 minutes non supervised training without distracting their attention with a knowledge based application
224006895|NCT05246527|BEHAVIORAL|Physical Exercise|30 min of cycling on an ergometer, moderate or high intensity
224125751|NCT03153215|OTHER|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
223387659|NCT07191977|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
223387660|NCT07191977|DRUG|Palbociclib|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
223387661|NCT07191795|OTHER|Gait analysis|Participants with unilateral amputations and a control group will undergo a comprehensive walking analysis. In a lab setting (on a treadmill or floor), their gait will be recorded using inertial sensors, EMG, force plates, and motion capture, while an EEG cap and a NASA-TLX questionnaire will assess cognitive load. Capable participants will also perform a walking test on a real-world outdoor course with varied terrain. The data will be analyzed to compare walking patterns between groups (amputees vs. controls, and amputees with vs. without phantom limbs). Finally, participants will describe any interactions they perceived between their phantom sensations and walking during the tests.
223545664|NCT00353080|DRUG|risedronate (HMR4003)|
223545665|NCT05384834|BEHAVIORAL|#HerHeart tool|An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
223545666|NCT03225248|DRUG|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
223545667|NCT03225248|DRUG|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
224006896|NCT05246527|BEHAVIORAL|Control Intervention|30 min of watching a movie
224006897|NCT00794144|DRUG|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
224006898|NCT00794144|DRUG|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
224006899|NCT04063475|DRUG|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
224006900|NCT06364787|BIOLOGICAL|γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδ T cells from donors will be adoptively transfused.
224125752|NCT05151471|DRUG|MT-1186|Oral edaravone
224125753|NCT05151471|DRUG|Placebo|Oral
224125754|NCT02679248|DIETARY_SUPPLEMENT|Neo40 Daily®|
224125755|NCT02679248|DIETARY_SUPPLEMENT|Placebo|
224295946|NCT01091272|DRUG|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
223387662|NCT07191795|OTHER|Mapping of referred sensations.|Participants reporting referred sensations in gait analysis phase will undergo further testing. The study will investigate whether prosthesis pressure or a specific socket interaction causes these sensations. A 3x3 cm grid will be drawn on the residual limb to systematically map referred sensations using various stimuli (brush, pressure tip, electrical stimulation). Participants will rate the intensity and describe the location of any resulting phantom sensations. This mapping will be repeated after 6 months to assess the stability of these sensations over time, with the ultimate goal of potentially using them to provide sensory feedback for prosthesis users. The session will last approximately 2 hours.
223387663|NCT07191795|OTHER|Exploration of the areas of the brain activated during referred sensations|Unilateral transfemoral amputees with detailed referred sensation maps will have their brain activity recorded using a 64-electrode EEG cap. Non-invasive stimuli will be applied to four specific sites: an area on the residual limb that elicits a referred sensation, the corresponding location on the intact foot, a neutral area on the residual limb, and its corresponding location on the intact thigh. This process, involving 400 total stimulations, will be repeated after 6 months to track cortical changes. Non-amputee participants will also be tested as a control group to check for symmetry in brain responses to thigh stimulation. Each session lasts about 2 hours.
224006901|NCT06364787|DRUG|Targeted drugs|Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
224006902|NCT06364787|DRUG|PD-1 monoclonal antibody|Humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
224006903|NCT04909398|BEHAVIORAL|Dynamic pupillometry sessions|"The evaluation protocol will include the following steps:~* Installation of the subject, adaptation of the chin rest for the best comfort of the participant~* Calibration of the oculometer consisting of ocular fixation of 9 fixation points distributed on the stimulation screen~* Final validation of the eligibility of the subject in the study according to the success or not of the calibration."
224006904|NCT01638429|DRUG|Neomycin|Neomycin: 500mg po bid for 10 days
224006905|NCT01638429|DRUG|Rifaximin|Rifaximin: 550mg po tid for 10 days
224006906|NCT01281059|DEVICE|BreathID - Breath Test - 13C Octanoate|
224006907|NCT06426420|DIAGNOSTIC_TEST|FTIR spectroscopy analysis|ATR-FTIR Spectroscopy analysis combined with machine learning algorithms.
224006908|NCT03483259|DRUG|Sulfatinib T capsule|Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.
224006909|NCT03483259|DRUG|Sulfatinib R capsule|Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
224125756|NCT04263142|DRUG|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
224125757|NCT04263142|DRUG|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
224125758|NCT00638326|DRUG|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
224125759|NCT00638326|DRUG|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
223387664|NCT07191795|OTHER|Evaluation of the effects of socket modifications on phantom sensations and walking|This phase will evaluate how socket modifications affect phantom sensations and walking in 10 transfemoral amputees. First, the best material to comfortably induce referred sensations will be determined in a small sub-study. Then, each participant will be tested under four conditions: their usual socket and a socket with different rigidity, both with and without a specific local pressure point added inside. The location of this pressure point is based on the user's sensation map. Participants' walking will be analyzed in both lab and real-world environments for each condition, and they will provide feedback on their sensations and which setup they find most helpful. The evaluation involves 4 sessions over 2-3 months
224006910|NCT02703181|DRUG|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
224006911|NCT02703181|DRUG|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
224006912|NCT05880602|DIETARY_SUPPLEMENT|Nettle and Cranberry complex capsules|A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.
224006913|NCT05880602|DIETARY_SUPPLEMENT|Placebo(starch)|A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
224006914|NCT03823573|BEHAVIORAL|Walk within 24 hours|Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
224006915|NCT04610541|DRUG|Remdesivir-HU|Remdesivir-HU 100 mg concentrate for solution for infusion
224006916|NCT03207451|DRUG|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
224006917|NCT03207451|DRUG|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
224125760|NCT00038701|DRUG|TNP-470|
224125761|NCT04093518|DRUG|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
224125762|NCT04093518|DRUG|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
224125763|NCT02308345|OTHER|Pre-chemotherapy visit summary Video|
224125764|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
224125765|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
224125766|NCT00162305|DRUG|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
224125767|NCT00162305|DRUG|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
224125768|NCT05641792|DEVICE|CGM (Dexcom G6)|Dexcom G6 system consists of a transmitter and sensor that measure interstitial glycaemia every 5 minutes. Measurements are transmitted via Bluetooth to a compatible device, that uploads the data on a virtual drive. This allows for remote real-time glycaemia monitoring on another device.
224295947|NCT02707926|DRUG|Anti-HIV Agents|Therapy to treat HIV infection
224295948|NCT03939325|RADIATION|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
224006918|NCT03207451|DRUG|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
224006919|NCT03207451|DRUG|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
224006920|NCT04116580|OTHER|RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol|
224006921|NCT04333251|BIOLOGICAL|high-titer anti-Sars-CoV-2 plasma|Recipients will receive 1-2 units of ABO matched donor plasma at neutralization antibody titer \>1:64 vs best supportive care
224006922|NCT04333251|OTHER|oxygen therapy|oxygen therapy
224006923|NCT02486276|DRUG|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224006924|NCT02486276|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224006925|NCT02486276|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224006926|NCT02240459|DRUG|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
224006927|NCT02240459|DRUG|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
224006928|NCT02240459|DRUG|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
224006929|NCT02240459|DRUG|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
224006930|NCT04761900|DIAGNOSTIC_TEST|the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases|
224006931|NCT05044897|DRUG|SI-B001|administration weekly by intravenous infusion（QW）.
224006932|NCT06308887|DRUG|Triamcinolone Hexacetonide|Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 0.5 mg/5 ml of triamcinolone acetonide was injected.
224006933|NCT06308887|DRUG|Dextrose 5% in water|Ultrasound-guided periarticular (perimeniscal) injection: The injections were administered using ultrasonic guidance on the longitudinal axis while the patient was in a supine position with the knee flexed at approximately 20°-30°. The transducer was positioned longitudinally in the region where extrusion was seen along the medial collateral ligament. Subsequently, employing a free-hand method, a 0.60x60 mm 23 G needle was inserted directly into the meniscus wall with the use of sonographic guidance. After the needle made contact with the medial meniscus wall, it was pulled back by 1 mm and placed between the medial collateral ligament and the medial meniscus, and a dose of 5 ml of 5% dextrose was injected.
224006934|NCT05635201|DRUG|Anesthesia induction with propofol|After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.
224006935|NCT05635201|DRUG|Anesthesia induction with remimazolam|After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
224006936|NCT06475430|BIOLOGICAL|fecal microbiota transplantation|During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the experimental group receiving FMT solution matched to the patient's microbiota for intra-intestinal administration.
223387665|NCT07191795|OTHER|Phantom limb interview|A semi-structured interview will be conducted to ask participants to describe their phantom limb sensations (type, location, intensity) under three conditions: without their prosthesis, while standing with it, and while walking with it. This aims to identify factors influencing these sensations. Additionally, a brief physical examination of the residual limb will be performed to see if touch in specific areas triggers any referred sensations.
223387666|NCT07186699|OTHER|Non-Interventional Study|Non-interventional study
224125769|NCT04790474|DRUG|ixazomib-pomalidomide-dexamethasone|"Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23"
223387667|NCT07193147|DRUG|GZR4|GZR4 s.c., single-dose
223387668|NCT07191600|BEHAVIORAL|Talking Pen Audio-Interactive Oral Frailty Care Program|Participants in the intervention group will receive a structured oral frailty delay care program integrated with talking pen audio-interactive technology. The program includes bilingual (Mandarin and Taiwanese) teaching materials with audio support to enhance comprehension and engagement. Training sessions will focus on oral frailty prevention, oral function exercises, and related health education. The intervention is delivered over 3 to 6 months, with outcomes measured at baseline, 3 months, and 6 months.
223387669|NCT06431269|OTHER|Screening for neurodevelopmental disorders by an advanced practice nurse|Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale
223387670|NCT00595491|BIOLOGICAL|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
224006937|NCT06475430|DIETARY_SUPPLEMENT|Formulated probiotic supplements|During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the control group receiving a standardized probiotic formula.
224006938|NCT03257943|DRUG|Ivermectin Lotion, 0.5%|Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
224125770|NCT00812916|PROCEDURE|RF ablation, using specialized CFAE software|RF ablation
224125771|NCT00450372|BIOLOGICAL|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
224125772|NCT00450372|OTHER|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
224125773|NCT03010423|DRUG|Nicorandil|Participants received Nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks.
224125774|NCT05445297|DRUG|Pharmacological cardioversion with Amiodarone|"Patients in this group will receive intravenous amiodarone according to the following scheme:~1. administration of 5 mg/kg body weight of amiodarone diluted in 250 ml of 5% glucose solution intravenously for 20-60 minutes, depending on the tolerability of the drug.~2. if there is no effect (recovery of SR did not occur within 60 minutes from the start of the drug administration), continue the infusion of amiodarone intravenously at a dose of 100 mg/hour until a total dose of 1200 mg is reached."
224125775|NCT05445297|DRUG|Pharmacological cardioversion with Refralon|"Patients in this group will receive intravenous refralon according to the following scheme:~1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur), after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
224125776|NCT05157672|DIETARY_SUPPLEMENT|Cinnamon (2 g)|oral capsules, 2 g
224125777|NCT05157672|DRUG|Nicotine gum (2.5 mg)|gum, 2.5 mg
223387671|NCT01191450|DRUG|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
223387672|NCT01191450|DRUG|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
223387673|NCT05357170|OTHER|Human feces collection|Oral swab and saliva, human feces collection and blood sampling
223387674|NCT02598050|OTHER|No Interventions as this is a observational study|
224006939|NCT03257943|DRUG|SKLICE (ivermectin) Lotion, 0.5%|SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
224125778|NCT05157672|DRUG|Letrozole (2.5 mg)|tablet, 2.5 mg
224125779|NCT05927389|OTHER|Adapted Physical Activity program|The Adaptated Physical Activity program consists of a Personalized Training Program adapted to each patient's condition and capacities
223387675|NCT06544499|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
223387676|NCT06544499|OTHER|Placebo IV|Intravenous infusion of placebo
224006940|NCT03257943|DRUG|Vehicle of the Test product|Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
224006941|NCT00841217|DRUG|GW501516|2.5mg/day
224006942|NCT00841217|DRUG|placebo pill|
224006943|NCT01261065|DRUG|carvedilol|Patients with heart failure and LVEF \< 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight \> 80 kg.
224295949|NCT06166238|PROCEDURE|Millard and Tension Randal Technique|Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.
224295950|NCT00313456|DRUG|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
224295951|NCT04247152|OTHER|Intraoperative Aberrometry vs preoperative biometry|Hypothesis: Intraoperative aberrometry measures lower levels of astigmatism more accurately than preoperative biometry in patients undergoing cataract surgery.
224295952|NCT04218500|OTHER|Niacinamide 4%|cream moisturizer
224295953|NCT04218500|OTHER|Virgin Coconut oil 30%|cream moisturizer
223387677|NCT05191277|DRUG|Treatment 'discontinuation of antidepressant medication'|Pharmacological intervention: Participants will discontinue their antidepressant medication.
223387678|NCT05191277|DRUG|Treatment 'continuation of antidepressant medication'|Pharmacological intervention: Participants will remain on their antidepressant medication.
224006944|NCT04398290|DRUG|Inhaled nitric oxide (iNO)|iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
224006945|NCT04398290|DRUG|Nitrogen gas|250 mcg/kg ideal body weight (IBW)/hour
224006946|NCT04398290|DRUG|Oxygen gas|Supplemental oxygen administered via nasal cannula
224006947|NCT04421443|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups every three months until two years after post-treatment, all of them will be conducted online.
224006948|NCT00859729|BIOLOGICAL|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
224006949|NCT00859729|DEVICE|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
224006950|NCT04439162|PROCEDURE|retrograde cardioplegia protection|antegrade-retrograde cardioplegia
224006951|NCT06306716|DEVICE|RENASYS Film with AIRLOCK Technology|RENASYS Film with AIRLOCK Technology intended for use with Smith+Nephew RENASYS NPWT Systems
224006952|NCT05838560|DRUG|Dasatinib|dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
224006953|NCT05838560|DRUG|quercetin|The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
224006954|NCT02885324|DRUG|Cabozantinib|Subjects will receive Cabozantinib
224006955|NCT02040584|DRUG|Minimisation of TAC|•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted
224125780|NCT00637364|PROCEDURE|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
224125781|NCT06046716|BEHAVIORAL|Mindful compassion based on behavioural change taxonomy experimental group|Since this is a waitlist control study both groups get the same intervention. This is a mindful compassion intervention which is based on the behavioural change taxonomy techniques to support the reliability of the intervention. This will include sensate, mindful exercises, relaxation and attending to the critical voice. The intervention consists of behavioural, cognitive and mindful compassion constructs.
224125782|NCT03546179|OTHER|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded.
224125783|NCT03546179|OTHER|Volume loading|After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight).
223387679|NCT05191277|BEHAVIORAL|Expectation 'high'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).
223387680|NCT05191277|BEHAVIORAL|Expectation 'moderate'|Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
223545668|NCT00675831|DEVICE|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
223545669|NCT00091663|DRUG|Tarceva (erlotinib HCl)|
224006956|NCT02040584|DRUG|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
224125784|NCT02012608|DRUG|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
224295954|NCT04414306|OTHER|In-person cancer screening education|Participants will receive verbal instruction covering the key messages, including risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. These in-person programs will take place in a variety of settings such as community-based organizations (e.g., community businesses, libraries, faith-based organizations, senior centers), fairs and community events, and clinical centers (e.g., health centers, local hospitals). Depending on the setting, education will be facilitated with one or more of the following educational tools: inflatable colon exhibit, PowerPoint presentation, flip chart/flip book, written materials/handouts, and displays. Data will be collected via pre- and post-tests. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
224006957|NCT00628576|DRUG|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
224006958|NCT00628576|DRUG|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
223387681|NCT06014112|DEVICE|Freestyle Libre Pro iQ|"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."
223387682|NCT05156970|DRUG|Camrelizumab|Camrelizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months
224006959|NCT03457870|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet.
224006960|NCT03457870|BEHAVIORAL|Chewing|Asked to chew 1 piece of gum for 10 minutes 3 times a day.
224006961|NCT03457870|BEHAVIORAL|Chewing + Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
224006962|NCT05094024|DIETARY_SUPPLEMENT|Central kitchen-prepared version of MDCF-2|Kitchen-prepared MDCF-2 containing chickpea flour, peanut flour, soybean flour, green banana pulp, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be freshly prepared in central kitchens on a daily basis and provided to participants on the same day. Every child in this arm will be offered 25g of the MDCF-2 formulation twice daily.
224006963|NCT05094024|DIETARY_SUPPLEMENT|MDCF-2 shelf-stable foil pouch prototype with green banana powder|This shelf-stable foil pouch prototype of MDCF-2 contains chickpea flour, peanut flour, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix, prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 21.77g of the formulation twice daily.
224006964|NCT05094024|DIETARY_SUPPLEMENT|MDCF-2 shelf-stable foil pouch prototype with sweet potato|This shelf-stable MDCF prototype contains chickpea flour, peanut flour, soybean flour, sweet potato, sugar, soybean oil and micronutrient mix. This version of MDCF-2 will be prepared by an industry partner following the formulation developed at icddr,b. Every child in this arm will be offered 23.34g of the MDCF formulation twice daily.
224006965|NCT05094024|DIETARY_SUPPLEMENT|Freshly reconstituted MDCF-2 ingredients|This version of MDCF-2 is comprised of its individually packaged ingredients. Separate premeasured sachets of chickpea flour, peanut paste, soybean flour, green banana powder, sugar, soybean oil and micronutrient mix will be combined and reconstituted prior to each feeding session. Every child in this arm will be offered 21.72g of the formulation twice daily.
224006966|NCT05094024|DIETARY_SUPPLEMENT|Ready-to-use supplementary food (RUSF) arm|Locally-produced ready-to-use supplementary food (RUSF) is used as part of a nutritional program to treat moderate acute malnutrition in children over 6 months-of-age. RUSF is eaten directly from the package with no dilution, mixing or cooking. RUSF contains rice, lentil, powdered low-fat milk, soybean flour, sugar, and micronutrient mix. Every child in this arm will be offered 25g of the formulation twice daily.
224006967|NCT06466720|BEHAVIORAL|Neurocognitive testing|The MoCA is a brief tool developed to screen mild cognitive impairment and has been validated in patients aged 55-85 years old. It has been tested and validated in patients with brain metastases, and its acceptability has been tested in the general brain tumour population. The paper version of the MoCA is available in nearly 100 languages. The online version is available currently in 5 languages.
224006968|NCT06466720|BEHAVIORAL|Quality of Life questionnaire|The EORTC-QLQ-C30 is a quality-of-life questionnaire that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) for use in clinical trials. It is a 30-item questionnaire that incorporates the following five scales: physical, role, cognitive, emotional and social. It has also been validated and is available in more than 100 languages. The EORTC-QLQ-BN20 is a questionnaire that was developed for use specifically with patients that have brain cancer. The BN20 is a 20-item questionnaire and addresses four different scales (multi-item): future uncertainty, visual disorder, motor dysfunction and communication deficit. There are seven items that assess physical symptoms: headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs and bladder control. The questionnaire has been validated in over 15 languages. The two questionnaires are meant to complement each other when used in patients with brain cancer.
224006969|NCT06466720|RADIATION|Stereotactic radiosurgery|This is a Standard of Care treatment for all the patients that will be recruited in both cohorts. Stereotactic radiosurgery will be delivered to one or more sites and in the prospective cohort can be delivered more than once.
224006970|NCT04285138|OTHER|phantom limb exercise|phantom limb exercises (that is, active imaginal efforts to move the phantom), under the assumption that the neural pathways involved in performing actual movements are activated when using one's imagination to move the phantom extremity
224125785|NCT02012608|DRUG|Placebo|For subjects undergoing breast conserving therapy
224125786|NCT06291116|DRUG|standard care + rotigotine at 4 mg/24h for 24 months.|standard care + rotigotine at 4 mg/24h for 24 months.
224125787|NCT06291116|DRUG|standard care for 24 months.|standard care for 24 months.
224125788|NCT03625427|DIETARY_SUPPLEMENT|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
224125789|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
223387683|NCT05156970|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 or Carboplatin AUC5 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
223387684|NCT05156970|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV on Day 1 of each 3-week cycle (4 to 6 cycle maximum)
224125790|NCT03625427|DIETARY_SUPPLEMENT|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
223387685|NCT05156970|DRUG|Apatinib Mesylate|Apatinib 250mg qd for up to 24 months
223387686|NCT05156970|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum)
223387687|NCT06109948|DRUG|ABX1100 injection for IV infusion|Centyrin protein-siRNA conjugate
223387688|NCT06109948|DRUG|Placebo injection for IV infusion|placebo saline injection
223387689|NCT05536258|OTHER|Fluid|The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period.
223387690|NCT06789731|BEHAVIORAL|Mindfulness Meditation|Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a loving kindness meditation adapted to apply to college communities and designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
223387691|NCT06789731|OTHER|Psychoeducation|In the psychoeducation arm, participants will receive information related to creating connections with campus community and managing anxiety and/or depression through a presentation. They will also receive information on resources for connecting with their community and treating anxiety and/or depression.
223387692|NCT04574089|DRUG|Experimental: Baofukang Suppository 7 days|Experimental: Baofukang Suppository 7 days
223387693|NCT04574089|DRUG|Experimental: Baofukang Suppository 14 days|Experimental: Baofukang Suppository 14 days
223387694|NCT06378996|DIAGNOSTIC_TEST|14-day rhythm monitoring|Eligible patients will be monitored during 14 days using the Byteflies patch ambulatory rhythm monitor.
223387695|NCT06397950|OTHER|Assessment of potential fatigue factors|"3 visits will be carried out: V0: Inclusion V1: Familiarization visit V2: Experimental visit~V1~* Completion of MFI-20 questionnaire for familiarisation.~* Information about accelerometry and activity journal use will be delivered to the patient.~* The participant will be equipped with an accelerometer and asked to complete the activity journal for seven days.~V2~* Completion of questionnaires: MFI-20, GATS tobacco consumption questionnaire, caffeine consumption questionnaire, Fatigue Catastrophizing Scale, PSQI.~* Assessment of cognitive function: Sustained Attention to Response Task (SART), AX-Continuous Performance Task (AX-CPT) and verbal fluency test (animals and P categories).~* Assessment of physical evaluation: isometric evaluation of maximal handgrip strength, one-minute sit-to-stand test, isometric evaluation of maximal quadriceps strength, QIF test.~Negative symptoms will be assessed. Calf circumference will be measured for sarcopenia risk."
223387696|NCT05650476|DRUG|Talazoparib|capsules
223387697|NCT04595773|OTHER|Aerobic Exercise Training|Aerobic exercise training will consist of 10 weeks of aerobic exercise, performed 3 times/week for 30 minutes. Each session will include a warm-up and cool-down period. The intensity will be guided by heart rate and gradually increased from light-moderate to moderate-high intensity as safely tolerated by the subject. All sessions are supervised by credentialed RMD staff members.
223387698|NCT04595773|OTHER|Education|Education consisting of weekly lectures lasting approximately 1 hour for 10 weeks. Topics related to exercise programming, safety and well-being will be covered. Conducted remotely by credential RMD staff members.
223387699|NCT06514547|BIOLOGICAL|Conjugate Pneumococcal Vaccine 20 (PCV20)|Vaccine
223387700|NCT06415058|DEVICE|HemoIV|A sterile, single use device. It is a non-patient stick blood collection device that attaches to a peripheral IV catheter (PIV catheter) and allows for blood sample collection to occur during continuous IV infusion therapy. The control blood sampling will occur via standard of care blood draws either through peripheral IV catheter or standard venipuncture.
223387701|NCT05351164|DRUG|Metreleptin|Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
223387702|NCT03568266|PROCEDURE|Biospecimen Collection|Undergo collection of saliva
223387703|NCT05854498|DRUG|Liposomal irinotecan|50mg/m2 IV on days 1 and 15
223387704|NCT05854498|DRUG|TAS102|35mg/m2 PO BID on days 1-5 and 15-19
223387705|NCT05854498|DRUG|Bevacizumab|5mg/kg IV on days 1 and 15
223387706|NCT06392386|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injections
224125791|NCT01151592|DRUG|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
224295955|NCT04414306|OTHER|Online educational video and website module|Participants will receive online education via a video and website. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
223387707|NCT03493685|DRUG|sparsentan|Double-blind period: target dose of 800 mg daily; Open-label extension: target dose based on dosage from week 114 daily
223387708|NCT03493685|DRUG|Irbesartan|target dose of 300 mg daily
223387709|NCT05969821|OTHER|observational cohort study|observational cohort study
223387710|NCT05814627|DRUG|Upadacitinib|Oral Tablets
223387711|NCT05814627|DRUG|Adalimumab|Subcutaneous Injection
223387712|NCT05814627|DRUG|Upadacitinib Matching Placebo|Oral Tablets
224125792|NCT00066664|GENETIC|proteomic profiling|
224295956|NCT04414306|OTHER|Online educational video|Participants will receive online education via a video and website about lung cancer screening. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
223387713|NCT05814627|DRUG|Adalimumab Matching Placebo|Subcutaneous Injection
223387714|NCT04000880|BEHAVIORAL|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
223387715|NCT04000880|OTHER|Diet-Exercise|Diet-Exercise
224125793|NCT06098209|DRUG|Dexmedetomidine|Patient will receive dexmedetomidine 0.2-1.4 μg/kg/h.
224125794|NCT06098209|DRUG|Propofol|Patient will receive propofol 0.3-4 mg/kg/h.
224125795|NCT02637791|DEVICE|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
224125796|NCT06121700|RADIATION|Radiotherapy targeted to the primary lesion|5 to 7 fractions of short course hypofractionated radiotherapy (HFRT) targeted to the primary lesion.
224006971|NCT04285138|OTHER|conventional treatment|"Mirror therapy uses a flat mirror placed parasagittally in front of the patient's body with the reflective surface toward the sound limb so that the amputee sees the reflection of the sound limb in the mirror \[Figure 1\]. This reflection mimics the amputated limb, and with the movement of the intact limb, the mirror provides an optical illusion that the phantom limb is moving simultaneously.~Equipment:~Therapy mirror: A standing mirror (130 cm × 46 cm) with wooden frame and base (62 cm × 65 cm) Routine physiotherapy The general exercise programme consisted of strengthening, stretching, dynamic, and isometric exercises based on the level of amputation and their assessment results. Participants allocated to the control group were advised to continue rehabilitation at their respective physiotherapy out-patient departments as frequently as possible. Participants were given a diary and advised to record their activities, specifying the nature, frequency and duration of each activity"
224006972|NCT01410123|OTHER|Integrated Stepped Care (ISC)|"1. At risk drinking:~   Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~2. Alcohol abuse/dependence:~   Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~3. Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
224006973|NCT01410123|OTHER|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
224006974|NCT06436443|OTHER|SMS Counseling|In addition to routine physician check-ups, an SMS group was created for the individuals in the intervention group, and basic information messages for diabetes control were sent to this group at regular intervals. In addition, individuals asked questions via this group. At the end of the eight-week follow-up, the data collection forms were filled out again and the study was terminated.
224006975|NCT04290559|PROCEDURE|Reveal LINQ ILR implant before AF ablation|Patients will undergo insertion of a LINQ ILR before the atrial fibrillation ablation performed according to standard clinical practice.
224006976|NCT06040593|OTHER|No drug|This is a non-interventional study and no study drug will be provided.
224006977|NCT01802567|DEVICE|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
224006978|NCT02488538|DRUG|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
224006979|NCT02488538|DRUG|Fluoxetine|women will receive oral fluoxetine 20 mg daily
224006980|NCT02488538|DRUG|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
224006981|NCT02488538|DRUG|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
224006982|NCT02488538|PROCEDURE|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
224006983|NCT02626988|BEHAVIORAL|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
224006984|NCT00588978|BEHAVIORAL|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
224295957|NCT04414306|OTHER|Message from healthcare system and online educational video and website module|Patients at one or more healthcare systems will receive a message from their healthcare provider or healthcare system indicating that they are due or overdue for colorectal cancer screening and receive information on how to schedule a related care (e.g. appointment with primary care provider to discuss screening options) and have the option of receiving education via on online video and website module with or without research study participation. Only recipients of this information who opt into the study through a consenting process will be considered study participants. Key messages will include information on risk factors, prevention, screening recommendations, and screening options pertaining to colorectal cancer. Some participants will be asked to participate in three and/or six-month follow-up surveys administered online or by telephone.
223387716|NCT04000880|OTHER|Exercise-Diet|Exercise-Diet
223387717|NCT04000880|OTHER|Combined Diet and Exercise|Combined Diet and Exercise
224006985|NCT01001182|OTHER|non interventional|non interventional
224295958|NCT05559775|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
223387718|NCT04223518|DIETARY_SUPPLEMENT|Serum bovine immunoglobulin|Serum bovine immunoglobulin (SBI), also known by the brand name of Enteragam (Proliant Biologicals, Ankeny, Iowa) is derived from bovine serum and classified as a medical food composed of \>90% protein which consists primarily of immunoglobulins (\>50% of IgG) along with other bovine proteins and peptides similar to those commonly consumed by humans in beef products.
223387719|NCT04223518|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed Collagen
224006986|NCT03825731|BIOLOGICAL|GC022|GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10\^5 to 1×10\^7 CAR+T/Kg.
223387720|NCT04452669|DRUG|VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)|VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
223387721|NCT03300817|OTHER|Laboratory Biomarker Analysis|Correlative studies
223387722|NCT03300817|BIOLOGICAL|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
224006987|NCT06788600|DRUG|EBV mRNA vaccine (WGc-043)|"Each subject will be infused with EBV mRNA vaccine per administration, including 5 doses for the primary immunization regimen and subsequent optional personalized treatment. For the primary immunization, the first 4 doses will be administered weekly, with the 5th dose given 4 weeks after the 4th dose.~The specific dose of mRNA vaccine will be determined according to the experimental group."
224006988|NCT04371120|DIAGNOSTIC_TEST|BICS Q|assess perceived self-efficacy (PSE) regarding a person's brain injury and proved responsive to treatment effects in the original BICS study.15-16 Specifically, it measures a person's perceptions about his or her ability to both understand the effects of brain injury, as well as, perceived capability of managing BI-related challenges. As the literature suggests, it is important to utilize a measure that would assess PSE specific to the person's challenge, rather than a general PSE scale.
224006989|NCT01603901|DEVICE|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
224006990|NCT05870605|OTHER|No Intervention|This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.
224006991|NCT06325644|OTHER|Ketogenic Diet|The diet intervention will start after all baseline testing is complete
224006992|NCT06325644|BIOLOGICAL|Ketone/Glucose Monitoring|KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
224006993|NCT06325644|BIOLOGICAL|CGM/CKM|Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
224006994|NCT06325644|BIOLOGICAL|Blood Draw|Blood samples will be collected according to the schedule in Figure 1
224006995|NCT06325644|OTHER|Body Composition|DEXA Scanning will be done pre-, mid-, and post- intervention.
224006996|NCT06325644|OTHER|Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .|Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
224006997|NCT04157725|DRUG|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
224006998|NCT04157725|DRUG|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
224006999|NCT04028089|BEHAVIORAL|Diet Modification Group|The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
223387723|NCT05117476|DRUG|CLN-619|Anti-MICA/MICB monoclonal antibody
223387724|NCT05117476|DRUG|Pembrolizumab|Keytruda
223387725|NCT05117476|DRUG|Paclitaxel|Taxane
223387726|NCT05117476|DRUG|Carboplatin AUC 6|Platinum compound
224007000|NCT04028089|OTHER|Regular Diet Group|"Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study."
224007001|NCT03969381|RADIATION|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
224125797|NCT06121700|RADIATION|Radiotherapy targeted to the metastatic lesions|Hypofractionated radiotherapy (HFRT) or stereotactic body radiotherapy (SBRT) targeted to metastatic lesions. The target dose will be adjusted based on the lesion's site and diameter and organs at risk, with high-dose irradiation of 4-8 fractions. All metastatic lesions should be irradiated as much as possible, and partial lesion irradiation should be allowed when technically impractical.
224125798|NCT06121700|BIOLOGICAL|Anti-PD-1 monoclonal antibody|"The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status.~The commonly used anti-PD-1 mAb usages are as follows: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W."
224295959|NCT01131572|DRUG|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
223387727|NCT05117476|DRUG|pemetrexed|antifolate
223387728|NCT05117476|DRUG|Datopotamab deruxtecan-dlnk (Dato-DXd)|TROP-2 antibody-drug conjugate (ADC)
223387729|NCT04599647|BIOLOGICAL|PVSRIPO|PVSRIPO (5x10\^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).
223387730|NCT06437015|DIAGNOSTIC_TEST|Constraint-Induced Movement Therapy|patient's unaffected hand is tied with a triangular bandage or splint and the patient asks to perform the exercise through the affected hand. for up to 6 hours a day for 5days week /4 weeks and the patient nonparetic arm restrained from the use by having the patient placing a mitt on the hand or a sling on the unaffected hand, forcing the use of the affected limb to promote purposeful movements when performing functional tasks.
223387731|NCT06437015|OTHER|Mirror Therapy|In this group training was given for 45min a day for 5 days a week for 4 weeks. Mirror box which was of 18×24inch \[was placed on the learning table and exercises were carried out by the patient looking into the mirror where an unaffected limb is placed in front of the mirror, through looking into the mirror patient assumes the reflection of the unaffected limb as the paretic limb. Exercises performed were hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation
224295960|NCT05854082|DRUG|Lidocaine 2% Polyampoule|Three intervention conditions in a repeated measures design - lidocaine; no perturbation, candy (lollipop)
224295961|NCT02404688|DRUG|Active delta-9-THC|"Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes."
223387732|NCT01159730|DRUG|VB-201 or Placebo|
223387733|NCT04838730|DEVICE|Surgical procedure|Standard cataract extraction procedure will be performed under local anesthesia (at physician discretion) and CleaRing device will be implanted together with SeeLens AF IOL.
223387734|NCT04430959|DRUG|Candesartan|Candesartan 4 mg, tablets, orally, once daily for 4 weeks
223387735|NCT04430959|DRUG|Placebo|Candesartan placebo-matching tablets, orally, once daily for 4 weeks
223387736|NCT03847467|DRUG|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
224007002|NCT03167359|RADIATION|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
224007003|NCT03339583|BEHAVIORAL|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
224007004|NCT03339583|DRUG|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
223387737|NCT03847467|OTHER|Placebo|Dextrose
224007005|NCT00162448|DRUG|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
224007006|NCT00162448|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
224007007|NCT03649438|DRUG|131 I-Metaiodobenzylguanidine|"* Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
224007008|NCT03649438|DRUG|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
224007009|NCT03649438|DRUG|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
224007010|NCT05820165|RADIATION|high-resolution 3D-T1|Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
224007011|NCT05820165|RADIATION|diffusion tensor imaging (DTI)|Subjects undergo a DTI imaging to obtain images of white matter lesions
224007012|NCT05820165|RADIATION|resting-state functional magnetic resonance imaging (rs-fMRI)|Subjects undergo rs-fMRI to investigate the differences in intra-regional brain activity and inter-regional functional connectivity
224007013|NCT05820165|RADIATION|arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI)|Subjects undergo arterial spin labeling (ASL) perfusion magnetic resonance imaging (MRI) to clarify the difference of cerebral blood flow (CBF) perfusion in certain regions
224007014|NCT05820165|RADIATION|susceptibility-weighted images (SWIs)|Subjects undergo susceptibility-weighted images (SWIs) to segment the vein network
224007015|NCT03805542|COMBINATION_PRODUCT|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
224007016|NCT04974125|PROCEDURE|Drain|A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).
224007017|NCT04974125|PROCEDURE|Manual exsufflation|Exsufflation through the trocar opening.
224007018|NCT03961347|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
224295962|NCT02404688|DRUG|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
223387738|NCT04225156|BIOLOGICAL|efgartigimod|Intravenous infusion of efgartigimod
223387739|NCT06021405|PROCEDURE|Tape stripping|a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
223387740|NCT03122730|COMBINATION_PRODUCT|VentaProst|epoprostenol for inhalation via custom drug delivery system
223387741|NCT04135677|DRUG|Rivaroxaban|Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)
224007019|NCT03961347|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
224007020|NCT01896557|DRUG|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
224007021|NCT01896557|DRUG|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
224007022|NCT01896557|DRUG|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
224007023|NCT02811718|BEHAVIORAL|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
224007024|NCT02811718|BEHAVIORAL|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
224007025|NCT03635203|DEVICE|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
224007026|NCT01221636|DRUG|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
224007027|NCT00013247|BEHAVIORAL|Prostate Cancer Screening Education|
224007028|NCT01205854|DEVICE|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
224007029|NCT01230346|OTHER|questionnaire administration|Ancillary studies
224007030|NCT01230346|OTHER|survey administration|Ancillary studies
224007031|NCT01230346|OTHER|counseling intervention|Telephone intervention
224007032|NCT01230346|OTHER|educational intervention|Telephone intervention
224007033|NCT05597813|PROCEDURE|microneedling|15 patients will be subjected to microneedling alone. Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
224007034|NCT05597813|PROCEDURE|microneedling with topical timolol 0.5%|15 patients will be subjected to microneedling with topical timolol 0.5%.Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
224007035|NCT04449380|DRUG|Interferon-ß-1a|IFNβ-1a will be administered subcutaneously at a dose of 44 mcg (equivalent to 12 million international units), three times per week at least 48 hours apart, for a total of two weeks. All patients will receive a total dose of 264 mcg (72 million international units) under physician control
224007036|NCT04449380|COMBINATION_PRODUCT|Standard of Care (SOC)|Any pharmacological (e.g. antibiotics, etc.) and non-pharmacological (e.g. oxygen, ventilation, etc.) treatments prescribed on clinical grounds
224007037|NCT02564380|DRUG|Pembrolizumab|
224007038|NCT02564380|DRUG|Placebo|
224007039|NCT00681148|DRUG|Botox injection|Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for \> 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
224007040|NCT00681148|DRUG|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
224007041|NCT05990803|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
224007042|NCT05990803|DRUG|SI-B003|SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
224007043|NCT04371523|DRUG|Apo-Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO BID on day one, then 400mg PO weekly, to be taken with meals for two months total.
224007044|NCT04371523|DRUG|Matched Placebo|Matching Placebo
224007045|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (250 mg)|Quercetin LipoMicel® soft-gels. Total dose of 250 mg of quercetin
224007046|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (500 mg)|Quercetin LipoMicel® soft-gels. Total dose of 500 mg of quercetin
224007047|NCT05611827|DIETARY_SUPPLEMENT|Quercetin LipoMicel (1000 mg)|Quercetin LipoMicel® soft-gels. Total dose of 1000 mg of quercetin
224007048|NCT05611827|DIETARY_SUPPLEMENT|Regular/standard Quercetin (500 mg)|Total dose of 500 mg of quercetin
224007049|NCT00013260|PROCEDURE|Integrated model of primary care|
224007050|NCT00734591|DRUG|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
224007051|NCT00734591|OTHER|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
224007052|NCT01514708|BIOLOGICAL|AdimFlu-S Influenza Vaccine|Suspension for injection
224295963|NCT02404688|DRUG|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
224295964|NCT02404688|DRUG|Placebo|Control: no alcohol, administered for a total of 80 minutes.
224295965|NCT00576654|DRUG|Irinotecan Hydrochloride|Given IV
224007053|NCT03183219|PROCEDURE|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
224007054|NCT03183219|BIOLOGICAL|γδ T cell|γδ T cells will be used against Liver Cancer
224007055|NCT03183219|OTHER|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
224295966|NCT00576654|OTHER|Laboratory Biomarker Analysis|Correlative studies
223387742|NCT04135677|DRUG|DAPT|Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
224007056|NCT00281515|DRUG|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
224007057|NCT05881993|DRUG|CBP-4888|siRNA therapeutic
224007058|NCT05881993|OTHER|Placebo|Normal Saline
224007059|NCT06031103|PROCEDURE|mini-PCNL procedure|"Mini-PCNL~. A 12 Fr rigid nephroscope and a Holmium:YAG laser as energy source was used for surgery Percutaneous renal puncture was achieved with an 18 Ga needle after displaying renal collecting system with contrast material. and tract dilatation was achieved using Amplatz dilators up to 16-18 Fr according to patient age"
224007060|NCT06031103|PROCEDURE|RIRS procedure|RIRS Technique the 9.5 Fr ureteral access sheath (UAS). UAS was inserted over the guide wire under fluoroscopy control. A flexible ureteroscope was passed through the UAS. If the UAS did not pass over the guide wire, the investigator moved the flexible ureteroscopy over the guide wire without access sheat
224295967|NCT00576654|OTHER|Pharmacological Study|Correlative studies
224295968|NCT00576654|DRUG|Veliparib|Given PO
223387743|NCT06353373|OTHER|Application of the modified DeVTEcare system|The modified DeVTEcare system, which incorporates bundled guideline-based VTE prevention measures, will be utilized to assist healthcare providers in VTE prophylaxis after September 2024.
223387744|NCT05798182|DIAGNOSTIC_TEST|Ultrasound measurement|Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
224007061|NCT01749111|DRUG|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
223387745|NCT01437436|PROCEDURE|ventilation tube|ventilation tube insertion
223387746|NCT05642897|BEHAVIORAL|Mind|ACT, mindfulness, and compassion-based intervention
224007062|NCT01749111|DRUG|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
224007063|NCT00958503|DRUG|Thiamphenicol|750 and 1500 mg/day;tablets
223387747|NCT05642897|BEHAVIORAL|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening and a sense of community between participants.
223387748|NCT06404398|OTHER|OMNICHROMA, Ceram. x spectra|Each patient had two types of veneers.
223387749|NCT01861223|DRUG|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
223387750|NCT01581437|PROCEDURE|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
223387751|NCT04203342|DRUG|Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
223387752|NCT04203342|DRUG|Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)|Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
224007064|NCT00958503|DRUG|Placebo|Matched tablets without active ingredient
223387753|NCT04203342|DRUG|Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)|Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
224007065|NCT03966768|DEVICE|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
223387754|NCT03729596|BIOLOGICAL|vobramitamab duocarmazine|Anti-B7H3 antibody drug conjugate
223387755|NCT03713593|DRUG|lenvatinib|Administered orally once a day
224007066|NCT03966768|DEVICE|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
224007067|NCT02840344|BEHAVIORAL|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
224007068|NCT02840344|BEHAVIORAL|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
224007069|NCT01511783|DRUG|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
224007070|NCT01511783|DRUG|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
224007071|NCT03798782|PROCEDURE|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
224007072|NCT03798782|PROCEDURE|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
224125799|NCT06121700|BIOLOGICAL|Trastuzumab|For patients with HER2-positive cancer (defined as IHC 3+ or 2+/ISH+), trastuzumab is used along with chemotherapy and anti-PD-1 antibody. The 3-weekly schedule of trastuzumab starts with a loading dose of trastuzumab of 8 mg/kg, followed by 6 mg/kg trastuzumab every 21 days.
224125800|NCT06121700|DRUG|Chemotherapy|"The investigator's choice of chemotherapy regimens included SOX, XELOX or FOLFOX. Their usages are as follows:~SOX: S-1 twice a day, days 1-14, the dose of S-1 is accorded to body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily; and oxaliplatin 130 mg/m2, day 1, every 3 weeks; XELOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks; FOLFOX: Leucovorin 400 mg/m2, day 1, fluorouracil 400 mg/m2, day 1 and 1200 mg/m2, days 1-2, and oxaliplatin 85 mg/m2, day 1, every 2 weeks."
224125801|NCT06121700|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For primary lesions, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper-third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle-third tumors, the gastric margin is recommended to be more than 5 cm, and total gastrectomy is performed. For lower-third tumors, a 2 cm duodenal margin is recommended, and subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
224295969|NCT03835325|DIETARY_SUPPLEMENT|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
223387756|NCT03713593|BIOLOGICAL|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
224007073|NCT04110353|OTHER|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
223387757|NCT03713593|DRUG|saline placebo|Administered as an IV infusion on Day 1 Q3W
223387758|NCT06014931|BEHAVIORAL|Telemedicine ICU Recovery Clinic Visit|Multidisciplinary clinic visit that encompasses a medical examination, medication management, neuropsychological exam with focused psychotherapy, case management, and patient-centered consultation.
223387759|NCT06496295|DEVICE|Vaginal Speculum Exam|Evaluating the visibility of the cervix, ease-of-use, and comfort of a new vaginal speculum.
223387760|NCT05394909|DRUG|Tocilizumab 162Mg/0.9Ml Autoinjector|Patients will receive high-dose pulse intravenous methylprednisolone (500 mg ) for 3 consecutive days (Day 0-1-2) and subsequently will be treated weekly with Tocilizumab 162 mg s.c. for 52-weeks and then following according to SOC
223387761|NCT05790213|DRUG|Androgen Deprivation Therapy (ADT)|ADT will be given for 3 months. Participants will receive a standard ADT as chosen by their study doctor.
223387762|NCT05790213|PROCEDURE|Focal prostate ablation (focal therapy)|Focal prostate ablation (focal therapy) is a surgical procedure to destroy cancer cells by destroying a portion of the prostate instead of the whole prostate.
224007074|NCT04110353|OTHER|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
223387763|NCT05319509|DEVICE|gameChange|Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus. Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete. The participant will put on the Oculus headset, and go through a preliminary orientation game. The headset will be casted to an external monitor. Once they start gameChange, it will take the participants to the virtual therapist's room. They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario. Research staff will be taking event sampling-style observations of the participant. After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
223387764|NCT03492944|DRUG|Ultrasound Microbubble Contrast Agent|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
224007075|NCT04110353|OTHER|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
224007076|NCT01955967|DRUG|Lidocaine|
224007077|NCT04237168|DIAGNOSTIC_TEST|IgNGS from circulating tumor DNA|3 longitudinal plasma samples will be evaluated at three different time points per patient: 0 (pre-treatment), end of treatment, and at 6 months after treatment.
224007078|NCT05622916|DRUG|Topical Ethanol Extract (Piper crocatum)|Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section
224007079|NCT05622916|DRUG|Trichloroacetic Acid Topical|Trichloroacetic acid topical 90%
224007080|NCT00639782|DEVICE|On-X Heart valve replacement|On-X Heart valve replacement
224007081|NCT00639782|DEVICE|SJM Heart valve replacement|SJM Heart valve replacement
224007082|NCT06092424|BEHAVIORAL|Relocation from HA to LA|Patients will be relocated by bus from Quito (2840m) to Pedernales (sea level) and have investigations at both altitudes
224007083|NCT05410639|OTHER|online education program|The training we provided was to give exercises and advice to parents according to the age of the baby in order to stimulate the motor and social development of the baby,and then, an improvement in the stress state of the parents by their participation in the care of their baby.The training, which began with the discharge of the baby from the hospital, was in the form of slide presentations and videos.
224007084|NCT05410639|OTHER|no online education program|Parents and their infants in the control group did not receive any online education program
224007085|NCT05451823|DEVICE|Post auriclar-frontal|"Frontal sensors will be applied with lead 1 at the center of the forehead; lead 2, 2.8 cm lateral to lead 1; and lead 3 at the temporal area between the lateral canthus and the hairline.~Post auriclar sensors will be applied to the same side of the face, with lead 1 approximately 2.5 cm medial to the mastoid area, post-auricularly next to the hairline. Lead 2 will be attached at the mastoid area and lead 3 will be attached on the same side at the temporal area between the lateral canthus and the hairline."
224007086|NCT01644448|OTHER|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
224007087|NCT01644448|OTHER|Standard Therapy|Topical Applications as directed by the investigator
224007088|NCT03024905|BEHAVIORAL|Village meeting and travel vouchers|"The interventions are:~1. Village meetings by community health workers to educate women and their families about safe birthing.~2. Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery."
224007089|NCT03024905|DEVICE|Birth kit with misoprostol|Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
224007090|NCT01940068|DIETARY_SUPPLEMENT|Amino acid based formula|
224007091|NCT04669015|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
224125802|NCT06121700|PROCEDURE|Metastasectomy|For patients with a good response to preoperative treatment, surgical resection of primary and metastatic lesions is recommended. For metastatic lesions, the surgical procedure and resection range are determined by the surgeon.
224125803|NCT06121700|PROCEDURE|Local ablative therapies|Local ablative therapies such as radiofrequency ablation (RFA) and microwave ablation (MVA) achieve high rates of complete tumor eradication of small metastases, and can be seen as alternatives if a widely invasive surgical approach is required or patient is inoperable.
224125804|NCT00861484|DRUG|GSK958108|Coated Tablets 1 mg
224125805|NCT00861484|DRUG|Placebo|Coated tablets
224125806|NCT02876939|OTHER|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
224125807|NCT02876939|OTHER|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
224007092|NCT04669015|BIOLOGICAL|Placebo|Formulation vehicle
224007093|NCT05847673|BEHAVIORAL|Online Smoking Cessation Intervention|Receive EQQUAL A intervention
224007094|NCT05847673|BEHAVIORAL|Online Smoking Cessation Intervention|Receive EQQUAL B intervention
224007095|NCT05847673|OTHER|Questionnaire Administration|Ancillary studies
224007096|NCT05847673|OTHER|Health Promotion and Education|Receive motivational messages and smoking cessation information via SMS text messages
224007097|NCT05444023|PROCEDURE|Pubocervical fascia reconstruction|Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
224007098|NCT03872024|DEVICE|For the first 60 patients: 3 XXL probe prototypes of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes."
224007099|NCT03872024|DEVICE|From patient 61 to patient 120: 1 XXL probe prototype of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~* An ultrasound examination~* One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~* One examination with the FibroScan® 630 Expert - Research model fitted with 1 adjusted XXL+ probe prototype (H+F prototype probe)."
224125808|NCT02843334|BIOLOGICAL|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
224125809|NCT02311855|BIOLOGICAL|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
223387765|NCT03492944|DEVICE|Ultrasound Imaging|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
223387766|NCT06297265|OTHER|Lymphedema Management|Undergo MLD breast massage
223387767|NCT06297265|OTHER|Questionnaire Administration|Ancillary studies
223387768|NCT06297265|RADIATION|Adjuvant breast radiation therapy|Using standard 3D conformal or intensity modulated techniques, patients will receive standard fractionation or moderate hypofractionation radiation therapy. The radiation treatment will last for 3 to 6 weeks, with the length of treatment depending on patient's specific clinical situation.
223387769|NCT04653454|DEVICE|Continuous Glucose Monitor (CGM)|CGM data will be downloaded prior to discharge and it will be compared with hospital glucometer readings taken at the same time.
223387770|NCT05513001|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
223387771|NCT05513001|DRUG|Placebo|Placebo
223387772|NCT05513001|DRUG|LOU064 (open label)|LOU064 (open-label) active treatment
223387773|NCT05616793|BIOLOGICAL|AAV8.hLCA5|Adeno-associated virus vector expressing human LCA5 gene
223387774|NCT03620708|BEHAVIORAL|Motivational Interviewing|Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
223387775|NCT03620708|DRUG|Nicotine Replacement Therapy Sampling|Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
224007100|NCT04627779|DRUG|preemptive analgesia with flurbiprofen axetil|give flurbiprofen axetil 15 min before surgery
224007101|NCT04427059|PROCEDURE|Transversus Abdominis Plane (TAP) block|"The laparoscopic-assisted Transversus Abdominis Plane (TAP) block will be done just after the optic trocar placement as follow: as landmarks we use the anterior axillary line, in the middle between the iliac crest and the costal margin. After insertion of the optic trocar the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. Laparoscopy allows to confirm that the needle did not pass the peritoneum.~A solution of 20 ml of Ropivacaine (0.25%) is then injected, observing the formation of a bulge posterior to the transversus abdominis muscle.~The procedure is then repeated identically on the contralateral side."
224007102|NCT04427059|PROCEDURE|Port-Site Infiltration (PSI)|The Port-Site Infiltration (PSI) will be performed by infiltrating the subcutis and the skin at the trocar site before the trocar placements with a solution of local anesthetic (Ropivacaine 0.25%), a total of 40 ml will be administered.
223387776|NCT03620708|BEHAVIORAL|Referral Only|Participants are provided with a written referral for tobacco dependence treatment.
223387777|NCT06191796|DRUG|zanzalintinib|Specified doses on specified days
223387778|NCT06191796|DRUG|AB521|Specified doses on specified days
223387779|NCT06191796|BIOLOGICAL|Nivolumab|Specified doses on specified days
223730177|NCT04841902|OTHER|Life Style Intervention Manual (With Exercise Under Supervision)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.
223387780|NCT06481033|BEHAVIORAL|Real Time fMRI Neurofeedback|The proposed pilot study is designed to collect feasibility and acceptability data regarding the utility of real-time functional magnetic resonance imaging (rt-fMRI) feedback in reducing suicide-specific rumination in veterans. Fifteen veterans will receive 2 rt-fMRI neurofeedback sessions while attempting to alter connectivity in brain regions that play a role in rumination. Pre- and post-treatment assessments of suicide, disability, functional impairment, and quality of life will be collected.
223387781|NCT04209218|DRUG|Dexamethasone|Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
223387782|NCT04209218|OTHER|Targeted blood pressure management|Blood pressure is maintained within ±10% from baseline.
223387783|NCT04209218|DRUG|Placebo|Placebo (2 ml normal saline) is administered before anesthesia induction.
223387784|NCT04209218|OTHER|Routine blood presure management|Blood pressure is maintained according to routine practice.
223387785|NCT06034405|DIAGNOSTIC_TEST|Tc99-PYP or Tc99-HDMP Scan|Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.
224007103|NCT01609244|DEVICE|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
224007104|NCT01609244|DEVICE|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
224007105|NCT02236988|DRUG|Apremilast Immediate Release|30 mg immediate release tablets
224007106|NCT02236988|DRUG|Apremilast Modified Release 1|75 mg oral tablet of prototype modified release (MR) 1
224007107|NCT02236988|DRUG|Apremilast Modified Release 2|75 mg oral tablet of prototype MR 2
224007108|NCT02236988|DRUG|Apremilast Modified Release 3|75 mg oral capsule of prototype MR 3
224125810|NCT06154031|BEHAVIORAL|Dyad learning|All participants will perform a gamified exercise using a dyad learning protocol. This means that all participants will practice the gamified exercise in pairs (dyads), for 60 minutes on two consecutive days.
224125811|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
224125812|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
224125813|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
224125814|NCT00879814|BIOLOGICAL|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
224125815|NCT01281852|DRUG|Cisplatin|Given IV
224125816|NCT01281852|OTHER|Laboratory Biomarker Analysis|Correlative studies
224125817|NCT01281852|DRUG|Paclitaxel|Given IV
224125818|NCT01281852|DRUG|Veliparib|Given PO
223387786|NCT06384885|DIAGNOSTIC_TEST|Ultrasound|Lung ultrasound
223387787|NCT05126693|OTHER|Botulinum Toxin treatment combined with a post-BoNT intensive physical therapy period guided by individualized treatment goals.|BoNT treatment combined with a follow-up period of intensive physical therapy of 8-10 weeks. During this intensive physical therapy post BoNT injections, the children in the intervention group will work on individualized treatment goals, which will be defined based on the baseline measurements during a multidisciplinary discussion with the treating physician (planned prior to the BoNT injections).
223387788|NCT04483583|DRUG|Ticagrelor 60mg|Patients will be administered a 180 mg loading dose followed by a 60 mg bid for the duration of the study.
223387789|NCT04483583|DRUG|Clopidogrel|Patients will be administered a 600 mg loading dose followed by a 75 mg daily for the duration of the study.
223387790|NCT04011722|DEVICE|Portico™ NG (Navitor) Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the new generation Portico NG (Navitor) valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
224007109|NCT02236988|DRUG|Apremilast Modified Release 4|75 mg oral capsule of prototype MR 4
224007110|NCT02236988|DRUG|Apremilast Modified Release 5|75 mg oral capsule of prototype MR 5
224007111|NCT02236988|DRUG|Apremilast Modified Release 6|75 mg oral capsule of prototype MR 6
224007112|NCT02236988|DRUG|Apremilast Modified Release 8|80 mg oral capsule of prototype MR 8
224007113|NCT02236988|DRUG|Apremilast Modified Release 9|80 mg oral capsule of prototype MR 9
224007114|NCT02236988|DRUG|Apremilast Modified Release 11|80 mg oral capsule of prototype MR 11
224007115|NCT02236988|DRUG|Apremilast Modified Release 12|80 mg oral capsule of prototype MR 12
224007116|NCT02236988|DRUG|Apremilast Modified Release 13|80 mg oral capsule of prototype MR 13
224007117|NCT02236988|DRUG|Apremilast Modified Release 14|80 mg oral capsule of prototype MR 14
224007118|NCT02920489|DRUG|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
224007119|NCT02920489|DRUG|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
224007120|NCT05368792|DIETARY_SUPPLEMENT|Complex Carbohydrate (PREcovery)|Each serving of the complex carbohydrate drink is a clear, colorless, 12.5% maltodextrin drink with a citrus taste, prepared by mixing 54 g of powder (50g carbohydrate) with 400mL of cold water. Participants will consume 2 servings of the complex carbohydrate drink the evening before colonoscopy (100g carbohydrate, 800mL fluid), and 1 serving 2 hours before their colonoscopy (50g carbohydrate, 400mL fluid)
224125819|NCT03258346|OTHER|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
224125820|NCT03258346|DIETARY_SUPPLEMENT|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
224125821|NCT03258346|DIETARY_SUPPLEMENT|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
224007121|NCT00480935|DRUG|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
224007122|NCT06198348|OTHER|Aerobic Exercise|"Treatment Protocol to Group A It consists of patients who will receive aerobic exercise sessions 3 times per week for 8 weeks. Every session will be of 30 minutes.~It will include warm up phase, active phase and cool down phase Warm-up phase:~In which each participant will walk at 80 m/min at for 5 min.~Active phase:~Brisk walking or treadmill:~In which each participant will perform brisk walking for 15 mints initially. After that gradually duration of brisk walking will increase."
224007123|NCT06198348|OTHER|Aerobic Exercises with Resistance training|"These groups will perform these exercises:~Aerobic exercise +resistance exercises Exercise~Session: 3 days per week Time of exercise session: 30-45 min~After following protocol of aerobic exercise as mentioned above the subjects will perform resistance exercises. These Exercises will perform:~1. Leg press (dual leg press):~   Leg press targets the Glutes Quadriceps or quads .but they also work your Hamstrings.~2. Crunches:~   Crunches Target the abdominal muscles specifically rectus abdominis and obliques.~3. Squats:~Squats targets the adductor muscles of the hip, glutes and rectus abdominis muscle Leg Extension~Total Exercise plan for 12 weeks:~1-2 weeks: Repitations: 10-15 times~No of sets: 1 set Resistance: minimum 3-4 weeks:~Repitations: 10-15 times~No of sets: 2 set Resistance: moderate 5-6 weeks:~Repitations: 15-16 times~No of sets: 2 set Resistance: moderate 7-8 weeks:~Repitations: 15-16 times No of sets: 2 set"
224007124|NCT01843153|DRUG|Ropivacaine|
224007125|NCT05727384|DRUG|Clazakizumab|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
224007126|NCT05727384|DRUG|Placebo|5 mg, subcutaneous injection, every 4 weeks for 24 weeks
224007127|NCT06224062|BIOLOGICAL|SARS-CoV-2|Circulating strains of SARS-CoV-2 (including variants of concern) were already collected, cultured and purified. The Wuhan reference strain will be used in the VIRCHILLD study to infect cells.
224007128|NCT06224062|BIOLOGICAL|Adenovirus (AdV)|Infection with C-type viruses (e.g. HAd-C5) using bronchial epithelium from adult donors
224007129|NCT06224062|BIOLOGICAL|Rhinovirus|RV is a member of the picornaviridae family; small non-enveloped viruses with a single strand positive RNA genome protected by an icosahedral capsid. They are divided in more than 160 serotypes classed in subtype A, B and C. RV-A and RV-C infections will be used in the VIRCHILLD study
224007130|NCT06224062|BIOLOGICAL|No Intervention|no infection
224007131|NCT06576089|OTHER|Supported, women-centred and aphasia-friendly recruitment and enrollment process (ORDER)|"Participants randomized into ORDER will be approached by the Site Coordinator for interest in the host trial. The Coordinator will introduce the trial and share a brief, women-centred, aphasia-friendly, close-captioned video that further describes the trial procedures and an accompanying leaflet.~ORDER recruitment materials will be saved to a mobile tablet. The Coordinator will watch the video together with the potential participant, engage in discussion about the host trial and answer any questions they may have. The Coordinator will offer to leave the tablet with the potential participant, along with printed copies of the leaflet and participant information letter. The Coordinator will encourage them to share these materials with their family members, friends or member of their healthcare team who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial."
224007132|NCT06576089|OTHER|Traditional recruitment and enrollment processes (TRAD)|Participants randomized into the traditional recruitment process (TRAD) will be approached by the Site Coordinator for interest in the CAMAROS trial and presented with the standard participant information letter and full informed consent form. The information letter and consent form will be left with the potential participant to view again; the Coordinator will encourage them to share these materials with their family members or friends who may assist with decision making. The Coordinator will return in the following days to address any further questions and determine the decision whether to enroll in the trial.
224007133|NCT04202367|DRUG|1 mg.kg-1 bupivacaine 0.25%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
224007134|NCT04202367|DRUG|1 mg.kg-1 bupivacaine 0.125%|Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.
224007135|NCT05228743|PROCEDURE|Comparing Hyperthermic Intraperitoneal Chemotherapy|After laparoscopic exploration, HIPEC was started immediately: the temperature was 43 ℃ and the duration was 60 min. paclitaxel (PTX) was used with a dose of 50mg / m2. The second HIPEC was completed 24-48 hrs after the first HIPEC, and at least 4 HIPEC was completed.
224007136|NCT05228743|DRUG|Paclitaxel|A natural anticancer drug that has been widely used in the treatment of breast, ovarian and some head and neck and lung cancers.Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
224125822|NCT05625386|DEVICE|transcranial magnetic stimulation|TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
224125823|NCT01879670|DEVICE|CircuLite Synergy left ventricular assist device|
223387791|NCT04011722|DEVICE|Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor Titan valve and large FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
224125824|NCT01289626|DRUG|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
224125825|NCT01289626|DRUG|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
224125826|NCT00702156|DRUG|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
224125827|NCT00702156|DRUG|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
224125828|NCT04712656|DEVICE|CPAP therapy|CPAP treatment of obstructive sleep apnea.
223730178|NCT04841902|OTHER|General Advice|General advice to stay healthy and active
224007137|NCT05228743|DRUG|S1|S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase, which degrades 5-FU), and oteracil (which inhibits the phosphorylation of 5-FU in the gastrointestinal tract, thereby reducing the toxic effects of 5-FU in the intestinum).Three to six weeks after HIPEC was completed, chemotherapy was started:: PTX: 50mg / m2 IV, D1, D8; PTX: 20mg / m2 IP, D1, D8; q3w; S-1: 60mg / m2, bid, d1-14, repeated every 3 weeks.
224007138|NCT06801756|OTHER|Questionnaire|The patients will respond to a questionnaire about their parental project, the occurence or not of complications during the pregnancy, and the impact of pregnancy on craniopharyngioma.
224007139|NCT05915949|DRUG|Dapagliflozin 10mg Tab|Forxiga 10mg Tab once daily will be given to participants for 24 weeks.
224007140|NCT05915949|DRUG|Lobeglitazone 0.5 mg|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
224007141|NCT05915949|DRUG|Dapagliflozin + Lobeglitazone|Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
224007142|NCT01021618|DRUG|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
224007143|NCT01021618|OTHER|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
224007144|NCT00939822|DRUG|Simvastatin|40 mg Simvastatin/day
224007145|NCT00939822|DRUG|Placebo|Matching Placebo
224007146|NCT05045274|DRUG|Dapagliflozin 10Mg Tab|"1. Dapagliflozin: It will be given in a dose of 10 mg once daily within 24 hours after PPCI.~2. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~3. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~4. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
224007147|NCT05045274|DRUG|Placebo|"1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload."
224007148|NCT04705116|BIOLOGICAL|COVID-19 vaccine|At least one dose of a COVID-19 vaccine.
224007149|NCT05563350|DIAGNOSTIC_TEST|Blood samples|p-chlordiazepoxide and metabolites, p-omeprazole and metabolites, p-midazolam and metabolites, CYP3A4 and CYP2C19 genotyping
224007150|NCT03014011|OTHER|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
224007151|NCT03014011|OTHER|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
224125829|NCT02251704|DIAGNOSTIC_TEST|Assessment of body temperature|Axillary body temperature of all participants recorded by a digital thermometer at the time of survey.
224125830|NCT02251704|PROCEDURE|Blood sampling|Capillary blood samples collected by finger/heel prick for determination of parasite prevalence at the time of survey.
224295970|NCT06321991|DRUG|Vitamin E-creme (Remederm®) vs Vaseline (Placebo)|Louis Widmer Remederm® Face Cream Without Perfume 50 ml is a skin care product that contains vitamin E as an active ingredient. Before applying Remederm®, the following are advised: On dry clean skin thoroughly before applying Remederm®, apply a layer of cream cutaneous to the hand palm, twice a day: morning and evening, massage cream into skin until absorbed. This procedure is applied by the patient treated with Vaseline or Remederm®.
224007152|NCT00805805|DRUG|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
224007153|NCT00805805|OTHER|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
224007154|NCT00556465|DRUG|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
224007155|NCT00354575|DRUG|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
224125831|NCT05377177|DEVICE|Accelerated Theta Burst Stimulation|B65 magnetic coil stimulation applied to the dorsal lateral prefrontal cortex.
224125832|NCT03810209|DRUG|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
224125833|NCT03810209|DRUG|Normal saline|adding normal saline to local anaesthetic in SAP block
224125834|NCT05154266|BEHAVIORAL|Taking it Further|This programme is offered to individuals who have already completed a Mindfulness-Based Cognitive Therapy (MBCT) or Mindfulness-Based Stress Reduction Programme (MBSR). In this programme, participants explore weekly themes (i.e. 'Responding not reacting' and 'Taking care of ourselves, taking care of others'). These themes reinforce the learning from the eight-week MBCT/MBSR courses whilst also providing new learning opportunities. The programme makes some of the dimensions that are implicit in MBCT/MBSR more explicit; for example, the cultivation of attitudes of mindfulness (such as equanimity, joy, and kindness). These attitudes of mindfulness require a foundational mindfulness practice and thus this is an additive learning theme from traditional MBCT/MBSR programmes.
224125835|NCT00489840|DRUG|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
224125836|NCT00489840|DRUG|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
224007156|NCT04344080|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)
224007157|NCT03551327|BEHAVIORAL|Experimental: Intervention plus information|The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.
224007158|NCT03551327|OTHER|Active Comparator: Information only|Participants in this arm will be provided with information about fatigue.
224007159|NCT00956176|DRUG|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
224007160|NCT04479228|DEVICE|Endosonography guided transmural drainage|The procedures would be performed by experienced endoscopists. All procedures will be performed with the patient in the left lateral position under propofol sedation after administration of intravenous antibiotics (third generation cephalosporins) A therapeutic linear echo-endoscope (UCT-180; Olympus Ltd, Tokyo, Japan) will be used; the PFC assessed for size, wall maturity, thickness, interposing collaterals and percentage of solid debris
224007161|NCT02605551|PROCEDURE|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~1. OM Occipitomastoid release technique~2. Sub-Occipital Release Technique~3. Rib Raising Technique~4. Rotatory stimulation of posterior Chapman's Reflexes~5. Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
224007162|NCT02605551|BEHAVIORAL|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
224007163|NCT04179916|DIAGNOSTIC_TEST|stimulation in virtual reality|"HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
224007164|NCT02416453|BIOLOGICAL|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.
224007165|NCT02416453|BIOLOGICAL|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
224007166|NCT02416453|BIOLOGICAL|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
224007167|NCT04573088|BEHAVIORAL|ACCEPTANCE-BASED INTERVENTION|24 hours prior to surgery the patients undergo acceptance-based intervention, incorporating questions about their subjective perception about the surgery, the domains of their lives that have been affected, and on their own expectations from surgery and its effects on their lives. They will be asked to express their fears and worries about their condition and they will be discussed about the likelihood of experiencing postoperative pain.
224007168|NCT02630589|DEVICE|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
224007169|NCT01955408|OTHER|Questionnaires, anticholinergic treatment, urodynamic study|
224007170|NCT03385590|DIETARY_SUPPLEMENT|Soy-fiber-maize|Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.
224007171|NCT03385590|DIETARY_SUPPLEMENT|Maize|Two servings of maize porridge will be consumed by the children each day for a period of six months.
224007172|NCT00418769|DRUG|Nilotinib|
224007173|NCT04521751|DRUG|EMP16-02 120 mg orlistat/40 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
224007174|NCT04521751|DRUG|EMP16-02 150 mg orlistat/50 mg acarbose|EMP16-02 capsules are composed of three pharmaceutical fractions (granules denoted G1, G2 and G3). G1= Prolonged release of acarbose, G2= Enteric-coated granule fraction containing orlistat and acarbose, G3= Orlistat with a delayed on-set release mechanism.
224007175|NCT04521751|DRUG|Placebo|Matching oral placebo capsules
224125837|NCT00681538|DRUG|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
224125838|NCT00681538|DRUG|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
224295971|NCT06321991|PROCEDURE|Ultrasound measurement|Nodule evolution will be measured with ultrasound.
224295972|NCT06003751|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
224295973|NCT06003751|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
224125839|NCT03587038|DRUG|OKN 007|400 mg OKN-007/mL in a phosphate buffer
224125840|NCT03587038|DRUG|Temozolomide|75 mg/m2
224125841|NCT03587038|RADIATION|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
224295974|NCT06003751|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
224007176|NCT04839822|OTHER|edupression.com®|"Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, App) at any time."
224007177|NCT04839822|OTHER|Health tips|Interventions that do not directly target depression: general health tips (diet, lifestyle, smoking, etc.), occupational health interventions (back pain prevention, breaks,...), etc.
224007178|NCT04839822|DIAGNOSTIC_TEST|Surveys|Quizzes and surveys for course monitoring (including suicidality), but without extensive reports.
224007179|NCT04839822|OTHER|Popular psychological interventions|Popular psychological interventions, which have not been shown to be effective in studies: Affirmation phrases, motivational sayings and quotes (known also from calendars), tests (e.g., Rorschach interpretation), exercises (emotion recognition of faces), multimedia content (pleasant music, landscape images, interviews of famous people with depression), etc.
224007180|NCT04314635|BEHAVIORAL|Brief family engagement intervention for CHR|The individual sessions, done with the caregiver and the teen separately, include a review of symptoms and a qualitative interview exploring treatment priorities, attitudes, and perceived barriers. The first family session focuses on psychoeducation. The second family session focuses on motivational enhancement, to promote ongoing engagement in services after discharge, including outpatient treatment and case management through the CSC.
224007181|NCT04314635|BEHAVIORAL|Treatment as usual (TAU)|The TAU group will receive treatment as usual on the adolescent inpatient unit. This includes individual therapy, psychiatric care, skills groups, and family therapy meetings.
224007182|NCT01143181|DRUG|Brincidofovir|Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
224007183|NCT00359983|BIOLOGICAL|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
224007184|NCT00359983|BIOLOGICAL|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
224007185|NCT01593475|RADIATION|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~\- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
224007186|NCT04025489|DIETARY_SUPPLEMENT|Randomized control trial of vitamin D supplementation|This open-label randomized placebo-controlled prospective trial will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. Anthropometry, body composition, levels of vitamin D, blood glucose (including oral glucose tolerance test) and dietary assessments will be assessed periodically (every 3 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. Diet and exercise will be recommended as per the regular norms for overweight and obese subjects. Clinical and dietary profile, sunlight exposure, glycemic and lipid profile other metabolic parameters, body composition, hand grip strength, leukocyte telomerase length and telomerase activity will be assessed at enrolment time and one-year intervention. As mentioned above, genes related to ageing will be evaluated. Effects on polymorphisms of pro-ageing genes will be assessed.
224007187|NCT00183157|BEHAVIORAL|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
224007188|NCT00183157|BEHAVIORAL|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
224007189|NCT00183157|BEHAVIORAL|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
224007190|NCT04473599|BEHAVIORAL|Uniform random message delivery|In this arm, the categories and timings of text-messages will be delivered to participants using a random schedule
224007191|NCT04473599|BEHAVIORAL|Reinforcement learning message delivery|In this arm, the categories and timings of text-messages will be chosen by a reinforcement learning algorithm
224007192|NCT04473599|BEHAVIORAL|Mood ratings only|In this arm, participants will monitor their mood daily and receive feedback on that mood randomly
224125842|NCT05434689|DRUG|Iberdomide|Iberdomide (Iber, CC-220) is a novel cereblon E3 ligase modulator (CELMoD) in development for treatment of multiple myeloma and other conditions.
224125843|NCT05434689|DRUG|Daratumumab|Anti-CD 38 monoclonal antibody established in the treatment of multiple myeloma
224125844|NCT05434689|DRUG|Dexamethasone|Corticosteroid active against multiple myeloma in combination with other agents
224125845|NCT05434689|DRUG|Carfilzomib|Second generation proteasome inhibitor with activity in multiple myeloma
224125846|NCT00630812|DRUG|inhaled mannitol|400 mg BD for 26 + 26 weeks
223387792|NCT06030804|DRUG|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
224007193|NCT04369781|DIAGNOSTIC_TEST|transcutaneous oxygen pressure recording at rest|Recording of limb and chest transcutaneous oxygen pressure
224007194|NCT06444204|DRUG|Rilzabrutinib|Rilzabrutinib tablet administered orally
224007195|NCT00599573|DRUG|ondansetron|Ondansetron 4mg BID for six weeks
224007196|NCT00860847|DIETARY_SUPPLEMENT|Aged garlic extract and Coenzyme Q10|AGE (1200 mg) and CoQ10 (120 mg)
224007197|NCT00697645|DEVICE|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
224007198|NCT00697645|DEVICE|Brainsway Deep TMS|Deep TMS applied over the motor strip
224007199|NCT00874692|OTHER|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
224007200|NCT03593551|COMBINATION_PRODUCT|five relaxation treatments and one control|Five treatments are relaxation meditation tape, music tape, relaxation lighting, meditation tape plus lighting, and music plus lighting. The control session have no intervention, participants will just be asked to sit comfortably for 10 minutes.
224007201|NCT04445727|COMBINATION_PRODUCT|Vitamin C|Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.
224007202|NCT04445727|COMBINATION_PRODUCT|spinal manipulation|Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.
224007203|NCT04445727|COMBINATION_PRODUCT|Transcutaneous electrical nerve stimulation (TENS)|Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.
224007204|NCT05614193|DIAGNOSTIC_TEST|Deep learning imaging enhancement|Conventional imaging or down-sampling imaging from CT or MR are enhanced by approved deep learning method.
224007205|NCT04076189|PROCEDURE|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
224007206|NCT04076189|PROCEDURE|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
224007207|NCT05833100|DEVICE|CareSens PRO GK Blood Glucose/b-Ketone Monitoring system|"All BG results were compared to YSI 2300 reference method results obtained from subjects' capillary blood.~All Ketone results were compared to Randox Imola D-3-Hydroxybutyrate analyzer."
223387793|NCT06030804|DRUG|Placebo|Volume-matched normal saline will be administered in the same rate and volume for the same duration as in the dexmedetomidine group during anesthesia. Patient-controlled sufentanil analgesia will be provided after surgery: the formula contains sufentanil (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
224007208|NCT00132873|DRUG|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
224007209|NCT02045875|DRUG|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
224007210|NCT03798041|BEHAVIORAL|Debridement Within 24 Hours After Surgery|Debrided within 24 hours after surgery
224007211|NCT03775928|DRUG|Apatinib|apatinib 425mg qd po
224007212|NCT03775928|DRUG|capecitabine|capecitabine 1000mg/m2 bid d1-d14
224007213|NCT04184232|BIOLOGICAL|Dendritic cells|Autologous dendritic cells primed with muc-1/wt-1 peptides
224007214|NCT04184232|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder cancer according to the Clinical protocols
224007215|NCT03030859|OTHER|Usual Care|Undergo usual care only
224007216|NCT03030859|OTHER|Usual Care plus LEF-SCP|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos
224125847|NCT00630812|DRUG|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
223387794|NCT04528680|DEVICE|Sonication for opening of blood-brain barrier|Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
223387795|NCT04528680|DRUG|Chemotherapy, albumin-bound paclitaxel|Intravenous infusion of ABX over 30 minutes
223387796|NCT04528680|DRUG|Chemotherapy, carboplatin|Intravenous infusion of carboplatin over 30 minutes
224007217|NCT03030859|OTHER|Usual Care plus LEF-SCP plus Follow-up|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
224295975|NCT05020314|BEHAVIORAL|Healthy Weight Clinic|Patients meet with a multi-disciplinary team over a 12 month period. In addition to the clinical visits, group visits, and phone calls, patients will also receive education materials, community resources, and an optional text messaging/social media library of messages.
224125848|NCT03868709|DRUG|Penehyclidine inhalation|Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
224007218|NCT00195468|DRUG|CYCLOSPORINE|
224007219|NCT01803282|DRUG|Andecaliximab|Administered intravenous infusion
224007220|NCT01803282|DRUG|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
224125849|NCT03868709|DRUG|Placebo inhalation|Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
224125850|NCT04937478|OTHER|Observation|Only observational study, no intervention.
224125851|NCT00610727|DRUG|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
224295976|NCT06583018|BEHAVIORAL|In-Person Mindfulness-based Group Sessions|The 3-hour group-based session in week 1 focuses on experiential mindfulness practices, and a booster session in week 5 further consolidates these mindfulness techniques, reinforces mindful, healthy lifestyle, and provides peer support. Participants will enhance their self-awareness of positive, neutral, and negative body sensations, feelings, and thoughts while engaging in healthy behaviors, particularly physical activity.
223387797|NCT03593590|DRUG|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
223387798|NCT06639828|DIAGNOSTIC_TEST|Contrast-Enhanced Ultrasound|Following unenhanced (pre-contrast) ultrasound imaging of the target focal liver lesions (FLL), Sonazoid™ will be intravenously administered and a contrast-enhanced examination will be performed.
223387799|NCT06525246|DRUG|ONO-7475|Specified dose, once daily
223387800|NCT06525246|DRUG|Osimertinib Mesylate|Specified dose, once daily
223387801|NCT05327894|DRUG|Blinatumomab|1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.
223387802|NCT05327894|DRUG|Blinatumomab|2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
223387803|NCT05961527|DRUG|MDMA|Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose
223387804|NCT05961527|BEHAVIORAL|Group Therapy|Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
223387805|NCT05061134|DRUG|Ceralasertib|Ceralasertib (240 mg) will be administered orally twice daily.
223387806|NCT05061134|BIOLOGICAL|Durvalumab|Durvalumab (1500 mg) will be administered intravenously once every 28 days for participants who weight above \> 30 kgs. For participants who weigh below ≤ 30 kgs, weight-based dosing equivalent to 20 mg/kg of durvalumab will be administered.
223387807|NCT04640259|OTHER|Online Survey|Epidemiological Survey (approx 200 questions)
223387808|NCT06154239|DEVICE|DAYE Diagnostic Tampon|The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746). The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion.
223387809|NCT06154239|DIAGNOSTIC_TEST|Vaginal self-swab|A vaginal self-swab typically consists of a long, slender, and flexible stick or handle, often made of plastic or a similar material. At one end, there's a soft, absorbent tip made of cotton or synthetic material. This tip is designed to collect a sample from the vaginal walls or cervix.
224007221|NCT01803282|DRUG|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
224007222|NCT01803282|DRUG|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
224007223|NCT01803282|DRUG|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
224007224|NCT01803282|DRUG|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
224007225|NCT01803282|DRUG|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
224007226|NCT01803282|DRUG|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
224007227|NCT01803282|DRUG|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
224007228|NCT01803282|DRUG|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
224007229|NCT01803282|DRUG|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
224007230|NCT01743989|DRUG|Nilotinib|Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
224007231|NCT00515723|DRUG|risperidone|randomized to 12 week trial of risperidone.
224007232|NCT00515723|DRUG|olanzapine|randomized to 12 week trial of olanzapine.
224007233|NCT00515723|DRUG|quetiapine|randomized to 12 week trial of quetiapine.
224007234|NCT00515723|DRUG|ziprasidone|randomized to 12 week trial of ziprasidone.
224007235|NCT00566605|PROCEDURE|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty \[IEK\])
224007236|NCT00566605|PROCEDURE|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
224007237|NCT00515684|DRUG|bevacizumab (Avastin)|
224007238|NCT04944745|OTHER|Myofascial Release|Moderate pressure manual treatment to the pectoral fascia.
224125852|NCT00610727|DRUG|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
224125853|NCT00610727|DRUG|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
224125854|NCT00610727|DRUG|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
224125855|NCT00610727|DRUG|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
224125856|NCT00610727|DRUG|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
224125857|NCT00610727|DRUG|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
224125858|NCT00610727|DRUG|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
224125859|NCT06565338|DRUG|Dexmedetomidine|drug
224125860|NCT06565338|DRUG|Vitamin D3|drug
224007239|NCT04944745|OTHER|Soft-touch Control|No pressure manual treatment to the pectoral fascia.
223387810|NCT06154239|DIAGNOSTIC_TEST|Clinician vaginal swab|"A clinician vaginal swab is a medical tool used by healthcare professionals to collect samples from the vaginal canal for diagnostic purposes. It's typically a long, thin, and flexible instrument. At one end, there's a cotton, rayon, or synthetic tip designed to collect cells, discharge, or other materials from the vaginal walls, cervix, or other areas within the vaginal canal.~The clinician swab is not taken in sub-study participants."
223387811|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Pre-training)|handgrip and treadmill walking 4 days per week
223387812|NCT06042439|BEHAVIORAL|6 weeks of exercise training (Post-training)|handgrip and treadmill walking 4 days per week
224007240|NCT05827913|DEVICE|Polylevolactic Acid Injection|The patient was placed in a flat recumbent position and subjected to topical anesthesia with lidocaine cream for those who were unable to tolerate pain. According to the location and degree of indentation of the atrophic stria, a conventional disinfection towel is placed and injected into the subcutaneous and deep dermis. Use left thumb and index finger to press or tighten the skin from both sides to the middle. Depending on the location of the SD, determine the injection direction. During linear injection, the injection starts from the distal end of the SD, and then the injection is withdrawn until the SD subsides. Apply uniform force and withdraw the needle at a uniform speed. Stop the injection before the needle is pulled out of the skin, To avoid too shallow an injection.
224125861|NCT05374174|DIAGNOSTIC_TEST|Tardieu Scale for Spasticity|The clinician will rotate the elbow joint at various speeds while the participant sits relaxed.
224125862|NCT05583474|DRUG|OPC-1085EL|one drop for each eye, once per day
224125863|NCT05583474|DRUG|0.005% Latanoprost|one drop for each eye, once per day
224125864|NCT05627622|BEHAVIORAL|WhatsApp health education message|stone-prevention information on a monthly basis, using personal WhatsApp messages
224295977|NCT06583018|BEHAVIORAL|Ecological Momentary Interventions (EMI)|Participants will receive personalized instant messages with chat-based support throughout the 8-week intervention period. The message content is guided by existing international lifestyle modification guidelines and the Integrated Body-Mind-Spirit Model. The pre-set frequency of regular message delivery is five times per week. The schedule of message delivery will be personalized according to the participants' on-going needs/preferences over the intervention period. Chat-based support will be provided by trained research assistants, who will utilize motivational interviewing techniques to enhance participant compliance and effectiveness.
224295978|NCT06583018|BEHAVIORAL|In-person Lifestyle Education Session|A 3-hour group-based session in week 1 focused on general education on lifestyle modification based on the HEARTS technical package as recommended by the WHO, and will only receive reminder messages for the two assessment follow-ups. No chat-based support will be provided.
224295979|NCT06583018|DEVICE|Activity Monitoring|All participants will wear an accelerometer-based wristband activity tracker to monitor their physical activity in daily life.
223387813|NCT04865107|BIOLOGICAL|UC-MSCs|3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)
223387814|NCT04865107|BIOLOGICAL|Placebo|PlasmaLyte A and 5% Human Albumin
223387815|NCT01013077|OTHER|Optive, Soothe, New Emulsion|One week without artificial tear use followed by Optive use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by Soothe use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the New Emulsion use a minimum of 2 drops per day for 1 month.
223387816|NCT01013077|OTHER|Soothe, New Emulsion, Optive|One week without artificial tear use followed by Soothe use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by New Emulsion use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the Optive use a minimum of 2 drops per day for 1 month.
223387817|NCT01013077|OTHER|New Emulsion, Optive, Soothe|One week without artificial tear use followed by New Emulsion use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by Optive use a minimum of 2 drops per day for 1 month. One week without artificial tear use followed by the Soothe use a minimum of 2 drops per day for 1 month.
223545670|NCT02012036|DRUG|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
224125865|NCT03656926|DRUG|Liposomal Cyclosporine A|"This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm.~The L-CsA was administered as 10 mg/2.4 mL inhalation via the PARI eFlow device BID (morning/evening, approximately 12 hours apart) for 48 weeks. Nebulization time per inhalation dose was approximately 6 to 17 minutes.~Patients received training on the use of the device and the first dose of L-CsA was self-administered by each patient under the supervision of trained personnel. In addition, during all subsequent scheduled visits the L-CsA inhalation was self-administered by the patient and under the supervision of trained study personnel."
224295980|NCT06439602|DRUG|AR882 50 mg|Solid Oral Capsule
224295981|NCT06439602|DRUG|AR882 75 mg|Solid Oral Capsule
224295982|NCT06439602|DRUG|Placebo|Matching Solid Oral Capsule Placebo
224295983|NCT04725058|OTHER|Medical Group Visit|A group of 20 or more participants will receive obesity management through endocrinologist and registered dietitian in a group seetting.
224295984|NCT04725058|OTHER|Dietitian Individual Visit|Participant receives obesity management individually from a registered dietitian.
224295985|NCT03284866|OTHER|Laboratory Biomarker Analysis|Correlative studies
224295986|NCT03284866|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
224295987|NCT03284866|OTHER|Saline|Given IM
224295988|NCT06414954|DRUG|NMD670|Tablets taken twice a day for 21 days
224295989|NCT06414954|DRUG|Placebo|Tablets taken twice a day for 21 days
224295990|NCT04890093|DRUG|PEN-866|PEN-866 will be given as an IV infusion once every week for the first two consecutive weeks out of every three-week (21 day) cycle.
224295991|NCT04890093|DRUG|Vincristine|Vincristine will be given at a dose of 1.5 mg/m2 by IV on days 1 and 8 of each 21-day cycle
224125866|NCT03656926|DRUG|Standard of Care|"Standard of Care Therapy (SoC). The SoC included maintenance immunosuppressive medication including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent; but also a prophylaxis against common opportunistic infections, and all other necessary medications and therapies for the optimal care of the patient.~This also included vaccination against COVID-19 All changes in concurrent treatment or medication were administered according to site's SoC.~The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, should be on a stable regimen for a least 4-weeks prior to randomization and continued to receive azithromycin during the trial as deemed appropriate by the investigator."
224125867|NCT05472233|PROCEDURE|Suture removal after Coronally Positioned Flap|Sutures are removed after different healing period post coronally positioned flap surgery, this latter is a procedure that aims at surgically advancing the gingiva in order to cover dehiscences of the soft tissues uncovering dental roots.
223387818|NCT05989841|BEHAVIORAL|RISE Guide|Brief cognitive behavioral intervention completed in the 3 weeks post-assault delivered via Internet on participants' smartphones targeting anxiety sensitivity, or fear of anxious arousal. Patients learn psychoeducation regarding the nature of stress, cognitive retraining to reduce negative interpretations of stress, and how to complete interoceptive exposures to reduce anxiety sensitivity. These skills are supported by 6 concurrent then subsequent weeks of ecological momentary intervention to deliver personalized intervention reminders based on symptoms.
223387819|NCT05989841|BEHAVIORAL|Relaxation Control|"Patients will download the Breathe2Relax app, which delivers information about how to use diaphragm breathing (taking slow, deep breaths through the diaphragm) to manage stress. Participants will receive reminders to engage with the intervention. Participants will also receive ecological momentary intervention reminders to engage with the relaxation intervention."
224007241|NCT05827913|DEVICE|1565nm Non-ablative Fractional Laser|M22-ResurFx laser (Lumenis Medical Company, USA) was used for treatment, with a wavelength of 1565 nm, a selected energy of 45 mJ, and a lattice density of 200 dots/cm2. The end point reaction was erythema and wind masses at the treatment site.
224007242|NCT05827913|DEVICE|Polylevolactic Acid Injection combined with 1565nm Non-ablative Fractional Laser|combination of the two treatments described above
224007243|NCT04190836|BEHAVIORAL|Self-Managed Exercise Strategy|The intervention is a personalised supported self-management intervention which emphasises dynamic, progressively loaded exercises for the shoulder. The intervention consisted of 1-5 individual sessions provided over 3 months, with a duration of 1 hour for the first session and 45 minutes for the following. The participants will have the opportunity to contact the physiotherapist by phone, text message or e-mail for advice during the treatment period (12 weeks). The personalised supported self-management intervention will be based on the components of the self-management framework, provided by Lorig and Holman (2003). The five self-management skills and the operationalization of these will be described when publishing the study. For specific content reporting of the self managed exercises we will follow the Consensus on Exercise Reporting Template.
224007244|NCT05181059|DIAGNOSTIC_TEST|Dual-layer spectral computerized tomography (DLSCT)|Contrast enhanced DLSCT scan using a 128-slice dual-layer detector (IQon Spectral CT, Philips Health Systems) will be performed. Patients will be placed in prone position during the DLSCT scan in order to improve the visualisation of breast tissue and comparability with MRI images. During the examination we will administer a nonionic low-osmolar iodinated contrast agent (Optiray©) in order to visualise tumor angiogenesis.
224007245|NCT01891201|DRUG|Oxytocin|Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
224007246|NCT00653523|DRUG|Ezetimibe|Ezetimibe 10 mg once daily
224007247|NCT00653523|DRUG|Simvastatin|Simvastatin 20 mg daily
224007248|NCT03909438|PROCEDURE|Endovascular Thrombectomy|Endovascular therapy includes direct mechanical thrombectomy or intravenous thrombolysis with mechanical thrombectomy. Endovascular Thrombectomy Device: Trepo trevor Retriever Device: SolitaireTM FR Revascularization Device
224007249|NCT05286827|DRUG|Olaparib|Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.
224007250|NCT05439590|BEHAVIORAL|High dose CSO|Participants in the high-dose CSO arm of the study will consume two smoothies containing a total of 60 g of CSO per day for 4 weeks.
224007251|NCT05439590|BEHAVIORAL|Low dose CSO|Participants in the low-dose CSO arm of the study will consume two smoothies containing a total of 30 g of CSO per day for 4 weeks.
224007252|NCT05439590|BEHAVIORAL|Low dose OO|Participants in the low-dose OO arm of the study will consume two smoothies containing a total of 30 g of OO per day for 4 weeks.
224295992|NCT04890093|DRUG|Temozolomide|temozolomide will be given at a dose of 100 mg/m2, orally on days 1-5, of each 21-day cycle
224007253|NCT05439590|BEHAVIORAL|High dose OO|Participants in the high-dose OO arm of the study will consume two smoothies containing a total of 60 g of OO per day for 4 weeks.
224007254|NCT03271242|OTHER|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
224295993|NCT02172196|DRUG|BI 10773|
224295994|NCT02172196|DRUG|Sitagliptin|
224295995|NCT06617572|GENETIC|Non-conforming afamitresgene autoleucel|Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration
224295996|NCT02117388|BEHAVIORAL|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
224295997|NCT02117388|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
224295998|NCT02117388|BEHAVIORAL|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
224295999|NCT05201638|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
224007255|NCT03271242|OTHER|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
224007256|NCT00854893|DEVICE|transcranial direct current stimulation|1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
224007257|NCT04251507|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.
224007258|NCT02425904|DRUG|Clofarabine|second-generation purine nucleoside analog
224296000|NCT05201638|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
224007259|NCT05461768|DRUG|BL-M07D1|Administration by intravenous infusion
224007260|NCT05393427|DRUG|BL-B01D1|Administration by intravenous infusion
224007261|NCT03663257|DEVICE|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
223387820|NCT06520449|DRUG|68Ga-NTA-476|The novel Prostate Specific Membrane Antigen (PSMA) targeting molecule, NTA-476, is comprised of a small peptide targeting moiety that is attached to a linker and dodecane tetraacetic acid (DOTA) cage which enables chelation of the radionuclide 68Ga for Positron Emission Tomography (PET) imaging.
223545671|NCT01453491|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
223545672|NCT01942824|BEHAVIORAL|Text Messages|
224007262|NCT06511453|DEVICE|Acupressure (using AcuWand or pencil eraser)|"The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure."
224007263|NCT02603653|DEVICE|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
224007264|NCT04713891|DRUG|KF-0210 tablets, 120 mg|KF-0210 tablet will be orally administered as a single agent at 120 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
224007265|NCT04713891|DRUG|KF-0210 tablets, 240 mg|KF-0210 tablet will be orally administered as a single agent at 240 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
224007266|NCT04713891|DRUG|KF-0210 tablets, 450 mg|KF-0210 tablet will be orally administered as a single agent at 450 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
224007267|NCT04713891|DRUG|KF-0210 tablets, 600 mg|KF-0210 tablet will be orally administered as a single agent at 600 mg once daily (QD) continuously, until the disease progression, intolerance, or informed consent withdrawal.
224007268|NCT04713891|DRUG|KF-0210 (dosage RP2D-2) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-2 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
224296001|NCT03758573|OTHER|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT)
224296002|NCT03758573|OTHER|Intensive Physiotherapy (IPT)|Intensive Physiotherapy (IPT)
224296003|NCT00172419|DRUG|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
224296004|NCT06035484|OTHER|Seat height|Seat height of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
224296005|NCT06035484|OTHER|Seat inclination|Seat inclination of a manual wheelchair will be changed according the different arms specified. The participant will complete a course in the manual wheelchair with each arm.
224296006|NCT04593342|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
223545673|NCT02381314|BIOLOGICAL|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
224007269|NCT04713891|DRUG|KF-0210 (dosage RP2D-1) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D-1 once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
223387822|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
223387823|NCT05742776|OTHER|Assessment of Sleep Quality|Assessment of Sleep Quality
223387824|NCT05432284|DRUG|Placebo|Placebo (ambient air)
223387825|NCT05432284|DRUG|THC|Pure THC vapor
223387826|NCT05432284|DRUG|Beta-Myrcene|Pure beta-myrcene vapor
223387827|NCT05144685|DEVICE|OTX-202|Experimental Pscyhoeducation and Intervention App
223387828|NCT05144685|DEVICE|OTX-000|Other Pscyhoeducation App
224007270|NCT04713891|DRUG|KF-0210 (dosage RP2D) + Atezolizumab|KF-0210 tablet will be orally administered at dosage RP2D once daily (QD) in combination with Atezolizumab that will be administered at 1200 mg every 3 weeks via intravenously infusion.
224007271|NCT06336252|BEHAVIORAL|Digital nudging intervention target to change behavior|"In hospital Participants in the intervention group will receive usual hospital care and be provided with a sensor collecting data on physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing, and walking. This information will be visible to the health personnel, the patients, and their relatives. This feedback system is developed and provided by SENS Innovation.~After discharge The visual feedback system from SENS will be continued after discharge and include an E-sport biking system provided by 4Mvideo. This integrated new system will combine an ergometer bike or sofa bike installed in the patient's own home or nursing home, and data from the sensor that the participants continue to wear after discharge will go into the SENS system, feeding back a visual track of their activities"
224125868|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME.
224296007|NCT04593342|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
224007272|NCT04711109|DRUG|Denosumab|Given SC
224007273|NCT04711109|DRUG|Placebo|Given SC
224007274|NCT04711109|OTHER|Quality-of-Life Assessment|Ancillary studies
224007275|NCT05540613|BEHAVIORAL|Health Education|A 26 weeks brain health and general health education program with two 1.5-hour sessions weekly.
224007276|NCT05540613|BEHAVIORAL|Conventional Exercise|A 26 weeks Conventional Exercise training with two 1.5-hour sessions weekly.
224007277|NCT05540613|BEHAVIORAL|Tai Chi|A 26 weeks Tai Chi training with two 1.5-hour sessions weekly.
224007278|NCT03730649|DRUG|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
224007279|NCT03730649|RADIATION|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
224007280|NCT06620848|DRUG|HRS-4642 monotherapy|HRS-4642 will be administrated per dose level in which the patients are assigned.
224007281|NCT06620848|DRUG|HRS-4642 and adebrelimab combination therapy|HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.
224007282|NCT04092010|BEHAVIORAL|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
224007283|NCT04092010|BEHAVIORAL|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
224296008|NCT00775606|DRUG|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
224296009|NCT00775606|DRUG|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
224296010|NCT01012141|DIETARY_SUPPLEMENT|phytochemical|
224296011|NCT01012141|DRUG|Docetaxel|
223387829|NCT05144685|BEHAVIORAL|Treatment as Usual|Treatment as usual may include appointments with psychiatrists and other mental health clinicians, suicide risk assessment, supportive listening, crisis resources, clinician assessment, and referral to outpatient treatment.
223387830|NCT02446249|BIOLOGICAL|AAV2hAQP1|Infusion of gene therapy
223387831|NCT06407323|DIAGNOSTIC_TEST|Personalized vibration therapy powered by AI|A target frequency of either 20 Hz or 25 Hz, and amplitude 2-4 mm The whole treatment session will be around 20 minutes along with hot pack as a baseline treatment, consisted of 6 sessions per week for total 8 weeks of duration
224007284|NCT04092010|BEHAVIORAL|Usual care|Normal services provided children and their mothers in Head Start
224007285|NCT01744470|DRUG|Tacrolimus targeted half-dose|
224007286|NCT01744470|DRUG|Tacrolimus targeted plain dose|
224296012|NCT04063982|OTHER|none, only assessment at different time points|assessment at different time points
224296013|NCT00284804|DRUG|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
224296014|NCT05732259|OTHER|Percussion therapy|Participant lying in prone position on the couch will receive percussion therapy with Theragun PRO using standard ball head at speed of 1750 rpm, for total of 90 seconds, split into 3 sets of 30 seconds with 10 seconds rest.
224296015|NCT05732259|OTHER|Manual Myofascial Release technique|Manual myofascial release technique for 90 sec continuous.
223387832|NCT06407323|OTHER|Physical therapy treatment|A selected physical therapy treatment program for spastic diplegic CP.
223387833|NCT04233138|OTHER|SUPPORT online platform for people with type 1 diabetes|"All participants accepting the SUPPORT study will receive the full intervention for 6 months. Their learning is individualized depending on the way they take their insulin (injection or pump) and the way they measure their blood sugar (finger prick or continuous glucose monitoring).~The training program starts with mandatory module on hypoglycemia. Once completed, participants will unlock all level 1 (out of 3 levels) modules from the 6 categories (medication, blood sugar monitoring, nutrition, physical activity, hypo- and hyperglycemia, health and other situations). The platform contains functionalities such as discussion forum, quizzes, videos, downloadable forms, etc. During the first 6 months, participants will receive a bi-weekly newsletter to inform them about what's new on the platform."
223545674|NCT03898271|OTHER|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
223387834|NCT00194402|DRUG|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
223387835|NCT05012371|DRUG|Cabozantinib|Given PO
223387836|NCT05012371|DRUG|Everolimus|Given PO
223387837|NCT05012371|DRUG|Lenvatinib|Given PO
223387838|NCT05012371|OTHER|Questionnaire Administration|Ancillary studies
223387839|NCT01122485|OTHER|PG201|two tablets
223387840|NCT01122485|OTHER|Placebo|two tablets
223387841|NCT06280703|DRUG|LY3938577|Administered Intravenously (IV)
224007287|NCT04237311|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as following: after greater curvature dissociating, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using linear cutting stapler of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
224007288|NCT04237311|PROCEDURE|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass is performed as following: a gastric pouch of approximately 30mL was obtained using linear cutting stapler, the sum of the length of the alimentary limb and the biliopancreatic limb\> 200 cm (can be adjusted according to the incidence of the patient's BMI, type 2 diabetes mellitus and the specific situation).
224007289|NCT01344551|DIETARY_SUPPLEMENT|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
223387842|NCT06280703|DRUG|Placebo|Administered Intravenously (IV)
223387843|NCT06280703|DRUG|Insulin Degludec|Administered Intravenously (IV)
223387844|NCT06280703|DRUG|Insulin Lispro|Administered Intravenously (IV)
223387845|NCT06280703|DRUG|LY3938577|Administered subcutaneously (SC)
223387846|NCT06280703|DRUG|Placebo|Administered subcutaneously (SC)
223387847|NCT06280703|DRUG|insulin degludec|Administered SC
223387848|NCT05839626|DRUG|SAR445514|Powder for solution for injection. Sub Cutaneous administration.
223387849|NCT03056170|DEVICE|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
224007290|NCT02127138|DEVICE|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
224007291|NCT01937026|DRUG|Baricitinib|Administered orally
224007292|NCT01937026|DRUG|Probenecid|Administered orally
223387850|NCT04479852|DRUG|SP-624|Oral capsule
223387851|NCT04479852|DRUG|Placebo|Oral capsule
223387852|NCT06475703|DEVICE|Isla wound prioritisation module|The intervention group will use the artificial intelligence enabled platform with the new wound prioritisation module for 30 days after surgery in addition to standard post-operative wound follow-up care for 60 days after surgery.
223387853|NCT06475703|OTHER|Standard follow-up|Standard care, mapped during the economic scoping exercise may include; out-patient appointments, advised to contact GP, or no follow-up.
223387854|NCT00001521|DRUG|Fludrocortisone|Mineralocorticoid needed to replace aldosterone deficiency. Patients will continue to receive an optimal fludrocortisone dose
223545675|NCT02223052|DRUG|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
224007293|NCT04902183|DRUG|CovenD24|The drug will be administrated once daily for 5 days
223387855|NCT00001521|DRUG|Hydrocortisone|Glucocorticoid needed to replace cortisol deficiency. Reduced hydrocortisone dose might normalize the growth and adult stature of children with congenital adrenal hyperplasia
223387856|NCT00001521|DRUG|Letrozole|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
223387857|NCT00001521|DRUG|Flutamide|Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
223387858|NCT00001521|DRUG|Testolactone|Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.
223387859|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
223545676|NCT02223052|DRUG|Vidaza|75mg/m\^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
223545677|NCT03396887|OTHER|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
223545678|NCT03396887|OTHER|Control group|The control group will receive treatment as usual.
223545679|NCT02388880|DEVICE|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
223545680|NCT01881789|DRUG|Oprozomib|Extended release (ER) tablets administered orally
223545681|NCT01881789|DRUG|Lenalidomide|Administered orally at a dose of 25 mg on days 1 through 21 of each 28-day cycle for a maximum of 24 cycles.
223545682|NCT01881789|DRUG|Dexamethasone|Administered at 20 mg, orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. After the first cycle the dose may be decreased to 10 mg/day in participants \> 75 years of age, at the discretion of the investigator.
223545683|NCT01881789|DRUG|Cyclophosphamide|Administered orally at 300 mg/m² (up to a maximum of 600 mg) on days 1, 8, and 15 of each 28-day cycle for a maximum of 8 cycles of therapy (approximately 8 months).
223545684|NCT00664482|BIOLOGICAL|AGS-006|Autologous Therapy for Pancreatic Cancer
224007294|NCT02447653|DEVICE|G7 HA Acetabular Component|G7 HA Acetabular Component
224007295|NCT02447653|DEVICE|G7 PPS Acetabular Component|G7 PPS Acetabular Component
224007296|NCT05550753|BEHAVIORAL|Better Together Physician Coaching Program|thought-based coaching. This type of coaching focuses on thoughts and beliefs. It combines a cognitive behavioral therapy (CBT) model with mindfulness-based awareness and integrates theories of acceptance and commitment therapy (ACT), nonattachment, and radical questioning from Socratic and Greek philosophies.4 BT delivers a robust coaching experience via a 4-month web-based, group-coaching model. This novel program allows residents to participate as actively as they are inclined and able, offering flexibility via multiple modalities of coaching: twice weekly group coaching calls, unlimited anonymous written coaching, and weekly self-study modules that are housed on a secure members-only website.
224007297|NCT05550753|BEHAVIORAL|No intervention - placebo control|No intervention - placebo control
224007298|NCT04168281|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|instead of PCI patients will be followed-up with MRI
224007299|NCT06195462|OTHER|Laying on of hands with intention health (LHHI)|The participants will receive systemic acupuncture. The no healers will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
224007300|NCT06195462|OTHER|Laying on of hands by spiritist passe|The participants will receive systemic acupuncture. The healers will prepare before the start with prayer for connection with Good Spirits and will move their hands in a longitudinal direction, starting at the top of the patient's head, slowly lowering their hands along the body, 5 times and asked to send thoughts of health and healing to the participant. Then, they will place their hands on the patient's head, distance about 10 to 15 cm, during 5 minutes. Weekly sessions.
224125869|NCT06473155|BEHAVIORAL|Experimental: Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)|Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME. Also, participants will answer the Geniotype questionnaire and the results will be worked with the adolescents.
224125870|NCT01194557|DEVICE|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
224125871|NCT01194557|DRUG|Lumartem|Presumptive treatment of malaria/fever
224125872|NCT03965663|DEVICE|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
224125873|NCT02114333|BIOLOGICAL|Zostavax|0.65ml, subcutaneous
224125874|NCT02114333|BIOLOGICAL|HZ/su vaccine|0.5ml, intramuscular
224125875|NCT02114333|BIOLOGICAL|Placebo|0.65ml, subcutaneous
224125876|NCT03764202|OTHER|Detection of sufentanil concentration|"* Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~* The volume of human breast milk was detected at each fixed time point"
224125877|NCT02558816|DRUG|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients receive the combination of Ibrutinib + GA101 Step B : 24 patients receive the combination of Ibrutinib + GA101 + GDC-0199 Step C : 15 untreated patients receive the combination of Ibrutinib + GA101 + GDC-0199
224125878|NCT06205147|DEVICE|Elastic Band|Using the newly patented product, the Muscle Exercise and Falling Prevention Elastic Strap (Patent Certificate No. M585601), the procedure involves securing the elastic strap to a high-back chair to administer elastic band intervention exercises for patients.Guided by continuous contextual action demonstration videos, participants will engage in the elastic band resistance intervention twice a day, each session lasting 20 minutes, over a span of five days. These videos are designed to provide a continuous contextual demonstration, incorporating them within the video itself.
224125879|NCT05065801|COMBINATION_PRODUCT|GEMBRAX/FOLFIRINOX Arm A|Patients in the experimental arm received sequential treatment: A maximum of 6 cycles (12 months) of chemotherapy; One cycle = 3 administrations of GEMBRAX followed by 2 administrations of FOLFIRINOX
224125880|NCT05065801|COMBINATION_PRODUCT|FOLFIRINOX Arm B|Patients in this arm received : A maximum of 3 cycles (6 months) of chemotherapy. One cycle = 4 administrations of FOLFIRINOX
224125881|NCT06214910|OTHER|Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)|Participants randomized to this arm will receive the entire supply of TB preventive therapy (TPT) at enrollment.
224125882|NCT06214910|OTHER|Clinic-link TPT|Participants receive 2-week supply of TPT at initiation, then continue to receive remainder of TPT course at clinic (including refills).
224125883|NCT04995224|OTHER|Assessment of Psychophysiological factors|Investigating the presence of psychophysiological factors (depression, anxiety, catastrophizing) by questionnaires.
224125884|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating autonomic nervous function using heart rate recording, colon biopsy samples, microbiota, and blood cytokines levels. (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons. Blood samples and stool samples will be taken when participants come to the hospital for colonoscopy)
224299245|NCT06064292|DEVICE|INSPIRATORY MUSCLE TRAINING|After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
224299246|NCT02468063|DRUG|Low dose terlipressin|Terlipressin-2mg (low dose )
224007301|NCT06195462|OTHER|Control|The participants will receive systemic acupuncture and they not receive the laying on of hands.
224007302|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
224125885|NCT04995224|GENETIC|Assessment of Genetics|Genetic data investigated by another cohort study (IBD BioResource study) will be utilized in the analysis of this study.
224125886|NCT04995224|BEHAVIORAL|Assessment of Quality of Life|Investigating QOL by questionnaires.
224125887|NCT04995224|BIOLOGICAL|Assessment of Biological factors|Investigating colon biopsy samples (Colon biopsy samples are obtained when colonoscopy is performed for clinical reasons).
224296016|NCT04884061|OTHER|NBI images and/or videos|A library of NBI images and/or videos will be established from previously recorded bronchoscopies in 30 patients (10 with a SARS-CoV2 infection, 10 with a lower respiratory tract infection not related to SARS-CoV2, and 10 in patients with pulmonary nodule). NBI images and/or videos of the bronchial tree will then be analysed by three experimented interventional pulmonologists blinded to the patient ID. Each investigator will describe the vasculature pattern according to a prespecified grid: Normal mucosal vascularity / increased capillary density / presence of capillary loops / presence of dotted vessels / complex vascular networks of tortuous vessels or abrupt ending vessels / dilated longitudinal vessels. In case of discordance between the investigators, images will be reviewed to obtain a consensus.
224007303|NCT00652483|DRUG|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
224007304|NCT05569213|DIAGNOSTIC_TEST|motor evoked potentials|see previous descriptions
224007305|NCT04232267|DEVICE|MEB-001|Software medical device used to aid in the screening of patients with potential depressive burden symptoms.
224007306|NCT05333874|DRUG|Neoadjuvant chemotherapy administered before surgical extraction of a tumor|SignateraTM is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The Signatera methodology is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor tissue. This maximizes accuracy for detecting the presence or absence of disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and quantify how much cancer is left in the body, to improve prognosis and help optimize treatment decisions, based on the tissue-informed testing of mutations.
224007307|NCT05333874|OTHER|Observational|In participants, undetectable ctDNA at fourteen days will be in the observation arm (observation defined as TNBC: No adjuvant chemotherapy. Participants may complete checkpoint inhibitor from neoadjuvant setting; HER2 positive BC: Completed one year of anti-HER2 therapy from the neoadjuvant setting). No investigational drugs will be used. Samples of ctDNA will be collected at time points described in the study arm.
224007308|NCT03228147|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given PO
224007309|NCT03228147|OTHER|Questionnaire Administration|Ancillary studies
224007310|NCT04455503|DRUG|EVX-02A|Up to 8 patients will receive EVX-02A administered IM.
224007311|NCT04455503|DRUG|EVX-02B|Up to 8 patients will receive EVX-02B administered IM.
224007312|NCT04455503|DRUG|EVX-02A OR EVX-02B|EVX-02A or EVX-02B will be used. Patients: 24 to 30
224125888|NCT05610176|DEVICE|Amvia Sky pacemaker or CRT-P device|Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
224125889|NCT04207619|OTHER|hyperinsulinemic-hypoglycemic clamp|An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.
224125890|NCT04207619|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
224125891|NCT05929755|DRUG|Depo-Medrol|steroid
224125892|NCT05929755|DRUG|Gel-Flow NT|hemostatic agent
224125893|NCT06549257|BIOLOGICAL|Pfs25-IMX313, Pfs48/45|Two soluble protein vaccines.
224125894|NCT01353833|DRUG|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
224125895|NCT06601712|OTHER|Adherence support strategy A|Community health worker (CHW) support through monthly home visits to remind the caregiver to administrate the PDMC drugs
224125896|NCT06601712|OTHER|Adherence support strategy B|SMS/phone reminders from the qualified community health officers (ASCQ) to the community health workers (CHW) to administrate the PDMC drugs
224299247|NCT02468063|DRUG|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
224299248|NCT02468063|DRUG|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
224299249|NCT01305395|DRUG|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
224299250|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
223387860|NCT02487966|BEHAVIORAL|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
224007313|NCT03166995|OTHER|Low impact aerobic exercise|The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
224125897|NCT06601712|OTHER|Control|No reminders
224125898|NCT06349616|OTHER|Intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment. At 2 time points in the experiment, participants will place their hands and forearms in a bucket of cold tap water for 10 minutes.
224125899|NCT06349616|OTHER|No intermittent cold-water hand and forearm immersion|Participants will be seated at rest in a hot and humid environment.
224125900|NCT01180374|DRUG|Cannabidiol|Active Cannabidiol 5mg.
223387861|NCT02487966|DEVICE|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
223387862|NCT02487966|BEHAVIORAL|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
223387863|NCT03089710|OTHER|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
223387864|NCT06336434|DRUG|CAB LA 600mg|600mg (3mL) IM Injection
223387865|NCT06336434|DRUG|RPV LA 900mg|900mg (3mL) IM Injection
224007314|NCT03166995|OTHER|Postural exercises|The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
224007315|NCT00000367|DRUG|Treatment of depression|
224007316|NCT00000367|BEHAVIORAL|Suicide prevention intervention|
224007317|NCT00000367|DRUG|Suicide prevention treatment|
224007318|NCT04816123|DRUG|[14C]Donafenib|Each volunteers received a single 300 mg dose of \[14C\]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.
224007319|NCT04911478|GENETIC|ADI-001|No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy
224007320|NCT03381677|DEVICE|Pedicle Lengthening Osteotomy with Altum® Device|Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.
224007321|NCT03381677|DEVICE|Control|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~1. DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~2. DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
224007322|NCT01187381|DRUG|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
224007323|NCT01853267|PROCEDURE|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
224007324|NCT01853267|PROCEDURE|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
224007325|NCT00482157|DRUG|Vitamin D (Calcitriol)|
224007326|NCT02353364|OTHER|PGS|Embryos screened by the validated NGS technology CNV-Seq
224007327|NCT05764135|BEHAVIORAL|SCI-Lynx Mobile Application|. The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
224007328|NCT00380302|DRUG|AVE1625|
224007329|NCT01293253|BEHAVIORAL|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
224125901|NCT01180374|DRUG|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
224125902|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
224125903|NCT01180374|DRUG|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
224125904|NCT06034938|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]|Switch previous therapy with DOR/TDF/3TC
224125905|NCT03257072|BIOLOGICAL|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
224125906|NCT03257072|BIOLOGICAL|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
223387866|NCT06336434|DRUG|CAB LA 400mg|400mg (2mL) IM Injection
223387867|NCT06336434|DRUG|RPV LA 600mg|600mg (2mL) IM injection
223387868|NCT03582462|DRUG|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
223387869|NCT03582462|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
223387870|NCT00834509|DEVICE|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
223387871|NCT02632266|DIETARY_SUPPLEMENT|Powder HMF|powder human milk fortifier
223730179|NCT04841902|OTHER|Life Style Intervention Manual (Home Based)|Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.
224296017|NCT01033578|OTHER|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
224007330|NCT03435302|DRUG|Temozolomide Plus Cisplatin|"Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide."
223387872|NCT02632266|DIETARY_SUPPLEMENT|Liquid HMF|Liquid human milk fortifier
224007331|NCT03435302|DRUG|High-Dose IFN-a2b|Interferon belongs to the large class of glycoproteins known as cytokines.
224007332|NCT03008798|DRUG|Herbal Medicine C-117|C117 formula including 2 herbals and 2 insects
224007333|NCT03008798|DRUG|The Placebo of Herbal Medicine C-117|
224007334|NCT04287699|OTHER|labor dance|The pregnant women and their spouses/partners who wanted to perform the practice were asked to inform the researcher when the labor started. The researcher stayed with the pregnant women and their spouses during the practice and labor process. The pregnant women started to dance with their spouses during the active phase of the labor process accompanied by meditation music in a dim, silent environment. The spouse or partner massaged the pregnant woman's sacral area while dancing.
224007335|NCT00157027|PROCEDURE|Extracorporeal photochemotherapy with UVADEX|"Photopheresis (or extracorporeal photoimmunetherapy \[ECP\]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
224007336|NCT05355857|DIAGNOSTIC_TEST|brain PET-MRI with 18F-FDG|Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers
224007337|NCT00994175|DRUG|Pioglitazone|
224007338|NCT00994175|DRUG|Placebo|
224007339|NCT00003072|DRUG|amifostine trihydrate|
224125907|NCT03257072|BIOLOGICAL|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
224125908|NCT00398541|DRUG|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
224125909|NCT06247592|PROCEDURE|Greater occipital nerve block|Pulse Radiofrequency application to the greater occipital nerve will be applicated after radiofrequency cannula placed near the greater occipital nerve location at 42 degree, for 240 seconds.
224125910|NCT06247592|PROCEDURE|Greater occipital nerve pulse radiofrequency|The greater occipital nerve will be blocked with 5 cc 2% prilocaine.
224125911|NCT01375504|BEHAVIORAL|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
224296018|NCT03212794|BEHAVIORAL|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
224007340|NCT00003072|DRUG|carboplatin|
224007341|NCT00003072|DRUG|paclitaxel|
224007342|NCT05802316|DEVICE|tracheal intubation using videolaryngoscope with a hyperangulated blade or standard intubation videolaryngoscopy (VL) and direct laryngoscopy (DL)|In the awake group tracheal intubation performed by an videolaryngoscope with a hyperangulated blade. In the asleep group the standard intubation were performed by videolaryngoscopy (VL) and direct laryngoscopy (DL)
224125912|NCT01375504|BEHAVIORAL|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
224125913|NCT04591470|DIAGNOSTIC_TEST|Mar test|Study of antisperm antibodies
224125914|NCT00506077|DRUG|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
224125915|NCT00506077|DRUG|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
224125916|NCT04500314|DEVICE|whole body vibration device|20 patients will receive vibration training on vibration platform (Power Plate International, Irvine, California, USA) at a frequency of 25-30 Hz and amplitude of 3-5mm, plus traditional physical therapy program 3 sessions per week for total period of 8 weeks. The total duration of the WBV training stimulus will 10 min in first week and progress gradually to 25 min in the 8th week with regular increase by 5 minutes after each 2 successive weeks
223387873|NCT04885881|PROCEDURE|Ozone therapy|Patients in the ozone therapy group will be treated with ozone (O2-O3) in a volume of 5 ml and a dose of 10 µg / ml for three consecutive weeks in a weekly session to the most painful trigger point.
223387874|NCT04885881|PROCEDURE|Lidocaine injection group|Patients in the lidocaine injection group will be applied to the most painful trigger point in a volume of 2 ml of 1% lidocaine for three consecutive weeks, once a week.
223387875|NCT04487613|DRUG|Moringa oleifera leaf|450 mg capsule
223387876|NCT04487613|DRUG|Placebo|placebo capsule
223545685|NCT05228405|OTHER|All of the disabled children's caregivers will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness|All of the different type of disabled children's caregivers (cerebral palsy, muscular dystrophy, spina bifida and down syndrome) will answer the Questionnaire of Disease, Physiotherapy and Sports Awareness
223545686|NCT02972229|RADIATION|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
224007343|NCT02954198|DRUG|Tacrolimus|goal trough level 5-12ng/mL
224007344|NCT02954198|DRUG|Prednisone|goal dose 5mg QD
224007345|NCT02954198|DRUG|Mycophenolate mofetil|goal dose 1g BID
224007346|NCT02954198|DRUG|Everolimus|goal trough level 3-8ng/mL
224007347|NCT03800953|DRUG|Avelumab|The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
224007348|NCT06402565|DRUG|NOX1416 and SOC|Topical Nitric Oxide
224007349|NCT06402565|PROCEDURE|SOC (Standard of care)|SOC as provided in the Arm/Group description.
224007350|NCT06686758|DIETARY_SUPPLEMENT|Sugar cane polysaccharide|Sugar cane polysaccharide
224007351|NCT06686758|DIETARY_SUPPLEMENT|Control|placebo
224007352|NCT06703229|DRUG|The Transversus Abdominis Plane (TAP) block|or injectate preparation, utilizing ultrasound guidance while the patient was supine. In the D1 group, patients were administered 20 mL of 0.25% isobaric bupivacaine with 0.5 mcg/kg of dexmedetomidine.
224007353|NCT06703229|DRUG|The transverse abdominis plane (TAP) block|Patients in the D2 group received 20 mL of 0.25% isobaric bupivacaine with 1 mcg/kg of dexmedetomidine.
224007354|NCT06688799|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
223730180|NCT04597996|OTHER|web based education for students|"Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help"
223730181|NCT04085133|DIAGNOSTIC_TEST|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
224007355|NCT04537533|DRUG|Tranexamic acid|Intraoperative infusion
224007356|NCT04537533|OTHER|Normal saline|intravenous infusion
224007357|NCT02304692|DEVICE|Bone anchored hearing aid|
224007358|NCT06715878|PROCEDURE|Zero Ischemia Robot-Assisted Laparoscopic Microwave Ablation Assisted suture-less Enucleation|Under the visualization of ultrasound contrast imaging through the operative channel, a microwave ablation probe was inserted into the tumor (at the interface between the tumor and kidney, close to the tumor base). The microwave ablation device was used, with a power setting of 70 W for initiating microwave ablation. Depending on the tumor volume and depth, 1-3 ablation cycles were performed, with each cycle lasting 1-3 minutes. After reaching the pseudocapsule of the tumor, a combination of blunt dissection, sharp cutting, and blunt dissection was employed to separate the tumor from the renal parenchyma . The renal artery was not occluded during the procedure.If intraoperative injury to the collecting system is suspected, the collecting system should be sutured normally, while simultaneously suturing the outer layer of renal parenchyma to prevent urine leakage.
224007359|NCT06715878|PROCEDURE|robotic-assisted laparoscopic partial nephrectomy|robotic-assisted laparoscopic partial nephrectomy
224007360|NCT06729398|DEVICE|NIRS|NIRS is placed on the frontoparietal once the neonates born in the delivery room until 72 hours
224007361|NCT06729398|OTHER|SafeboosC|SafeboosC treatment guideline is used to maintain normal value of cerebral rStO2.
224007362|NCT06729008|DIETARY_SUPPLEMENT|Diabetes-specific nutrition formula (DSNF)|The diabetes-specific nutrition formula to be used in this study will be Glucerna (Abbott Laboratories). It features an advanced blend of low-glycemic carbohydrates for steady energy release, a dual fiber blend to support digestive health, and a unique lipid blend free from trans fats, cholesterol, and low in saturated fat. Additionally, Glucerna is enriched with 4x more inositol and high levels of trivalent chromium, which contribute to maintaining normal blood glucose levels. It provides 28 essential vitamins and minerals, is low in lactose, and gluten-free, making it a suitable option for various dietary needs. 5 scoops will be mixed in 200 mL of water, and this amounts to 228 calories, with 30.01g of carbohydrates, 10.16g of protein, and 8.70g of fat. This will be given twice, as a breakfast replacement and an afternoon snack replacement.
224007363|NCT06729008|OTHER|Medical Nutrition Therapy|Medical Nutrition Therapy is the standard of care for the management of metabolic syndrome
224007364|NCT06728514|PROCEDURE|Erector spinae plane block group.|In ESPB technique the linear transducer will be placed over the spinous process of the vertebra and a point 3 cm lateral to it are marked at the T10-T11 level before performing the block. Under aseptic precautions, the 23G spinal needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra. The transverse process of the thoracic vertebra lies at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, local anesthetic is injected in 3-5 ml aliquots. A volume of 20-25 ml of 0.25% bupivacaine will be used for analgesia on each side depending upon the surgery and requirements. The number of attempts will be noted.Time taken to perform block in minutes will be noted from placing transducer to taking out needle after injecting drug in plane.
224125917|NCT04500314|OTHER|routine physical therapy treatment|The program consists of 60 minutes supervised and individualized stretching exercise to all involved muscles followed by strengthening for affected muscles, mobilizing exercise for the joints involved to increase the joint range of motion, in addition to scar management techniques including pressure garments, inserts, and physical agent modalities , to avoid scar or contracture formation
224125918|NCT01013948|OTHER|Non-Interventional|Non-Investigational Product (Survey Study)
224125919|NCT02891031|DRUG|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
224125920|NCT02891031|DRUG|Placebo|500 mg twice daily after meal for 6 weeks
223545687|NCT02972229|RADIATION|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
223545688|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
224125921|NCT00339014|DRUG|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
224125922|NCT00339014|OTHER|Placebo|Identical placebo
223545689|NCT03084848|OTHER|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
223545690|NCT02592421|DRUG|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
223545691|NCT02592421|DRUG|Placebo|Placebo Comparator
223545692|NCT03925987|BEHAVIORAL|Exposure therapy|10 weekly sessions of group-based exposure therapy
223545693|NCT00005989|DRUG|tipifarnib|
224007365|NCT06728514|PROCEDURE|Paravertebral Nerve Block|In PVB technique the patient will be placed in the lateral position, and the superior aspect of the T9,T10 and T11 spinous processes will be identified. Under complete aseptic precautions and after skin infiltration with LA, 23G spinal needle will be inserted perpendicular to the skin, with the goal of contacting the tranverse process. Once the TP is contacted, generally at a depth of 2 to 5 cm in adults, the needle is withdrawn into the subcutaneous tissue, redirected in a caudal direction, and then slowly advanced with the purpose of entering the PVS at an approximate depth of 1.0 to 1.5 cm past the initial contact with the TP. After perforating the costotransverse ligament and negative aspiration for blood, air, or spinal fluid,10 mL of 0.25% bupivacaine will be injected at each level superficial to to the pleural line. Displacement of the pleura line anteriorly will be confirmed proper injection of the local anaesthetic solution. The number of attempts will be noted.
224007366|NCT06728514|DRUG|Inj Bupivacaine|Inj Bupivacaine 0.25% (10ml) in both groups
224007367|NCT06727942|DEVICE|V-TARGET intervention|V-TARGET intervention will be delivered through a 360 degree self-paced treadmill in a university clinical laboratory for 5-weeks (2 days/week, 30 minutes/session) with total 10 sessions. The treadmill is the first-of-kind motion platform that an individual can walk and run at self-paced speed in 360 degree (i.e., forwards, sideways and backwards) without risk of falling or colliding with other people. During the V-TARGET intervention, participants will self-pace their locomotor action (walking/running) while they wear the HTC vivo headset and experience daily exercises/games augmented by the VR Therapy System. Therapy System is a library of VR exercises/games targeted on neurological rehabilitation, balance improvement training as well as cognitive therapy suited for variety of conditions, and includes various daily living simulation activities such as Retail Shopping, Gait Training, Cafeteria Experience, and Nature Walk.
224007368|NCT06897033|BEHAVIORAL|Health education followed by AI-generated Whatsapp reminders|Participants will receive dental health education in a one to one personal session followed by Text messages generated by AI large language model (ChatGPT free version) about oral hygiene practices for three month in a tapering frequency. These messages will be designed based on Fogg's Behavior Model, focusing on enhancing motivation, ability, and providing clear triggers for action.
224007369|NCT06897033|BEHAVIORAL|Oral Health Education|Oral health education in a one to one session explaining the importance of oral hygiene measures and demonstrating teeth brushing techniques and healthy dietary guidelines and recommendations.
224007370|NCT06897813|DRUG|WD-910 tablet|Administered P.O.
224007371|NCT06897813|DRUG|WD-910 Tablets Placebo|Administered P.O.
224007372|NCT02379377|BIOLOGICAL|Fluorine F 18 L-glutamate Derivative 18F-FSPG|Undergo 18F-FSPG PET scan
224007373|NCT02379377|BIOLOGICAL|Carbon C 11 Acetate|Undergo 11C-acetate PET scan
224007374|NCT02379377|PROCEDURE|Positron Emission Tomography|Undergo 18F-FSPG, 11C-acetate, or 18F-FDG PET
224007375|NCT02379377|OTHER|Laboratory Biomarker Analysis|Correlative studies
224007376|NCT02379377|BIOLOGICAL|Fluorine F 18 2-deoxy-2-(18F)fluoro-D-glucose|Undergo 18F-FDG PET scan
224007377|NCT06900218|DRUG|Sintilimab|Sintilimab 200 mg, administered on Day 1, every 3 weeks for a total of 9 cycles
223730182|NCT01947439|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
224007378|NCT06900218|DRUG|Capecitabine|Capecitabine 650 mg/m², taken orally twice daily, continuously from Day 1 to Day 21, every 3 weeks, for a maximum of 1 year.
224007379|NCT06926920|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
224007380|NCT06900257|PROCEDURE|Pregnant women who present for routine antenatal follow-up between 24-34 weeks of gestation.|All singleton uncomplicated pregnancies that present to our hospital for routine antenatal follow-up between 24-34 weeks of gestation will be included in this study.
224007381|NCT06623136|DRUG|ES102|ES102 is administered via intravenous infusion, once every 21 days.
224007382|NCT06623136|DRUG|Toripalimab|Toripalimab is administered via intravenous infusion, once every 21 days.
224125923|NCT06262555|PROCEDURE|Transbronchial PDT peripheral lung tumor ablation|Transbronchial lung tumor ablation with Photodynamic therapy
224125924|NCT05655390|BEHAVIORAL|Safety Intervention Planning|The therapy is based on the iFightDepression platform implemented by the European Alliance against Depression. The aim of this specific therapy is to help individuals to acquire strategies to regulate emotions and learn to tolerate discomfort preventing the imminent risk for suicidal behavior. The safety planning intervention will be conducted by identifying warning signs and provide each individual with personal and individualized coping strategies and sources of support. Main skills to be acquired and integrated for the individual are as it follows: 1) Contingency plan by five steps (identification of warning signs; applying internal coping strategies; network as distraction; safe environment; reasons for living and contact professionals), 2) Mindfulness, 3) Discomfort tolerance, and 4) Regulating emotions.
224125925|NCT02180503|DRUG|BI 1356 BS PIB - low dose|
224125926|NCT02180503|DRUG|BI 1356 BS tablet - low dose|
223730183|NCT03010254|DEVICE|ACRYSOF® IQ Extended Depth of Focus IOL|Implantable IOL intending to extend the depth of focus and provide continuous functional vision from distance to near while maintaining distance vision and a visual disturbance profile comparable to a monofocal IOL; intended for long-term use over the lifetime of the pseudophakic subject
223730184|NCT03010254|DEVICE|ACRYSOF® IQ Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the pseudophakic subject
224125927|NCT02180503|DRUG|BI 1356 BS PIB - high dose|
224125928|NCT02180503|DRUG|BI 1356 BS tablet - high dose|
224125929|NCT02180503|DRUG|BI 1356 BS tablet - high dose with food|
224125930|NCT04856436|DRUG|Benzodiazepine|Exposure to benzodiazepine during early pregnancy
224125931|NCT03064776|DEVICE|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
224125932|NCT03064776|DEVICE|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
224125933|NCT00316303|DRUG|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
224299251|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
224299252|NCT01305395|DRUG|Sirolimus|Will start sirolimus after they develop CAV by angiogram
223387877|NCT06069219|DRUG|Epidural administration of sufentanil|The epidural cannulations were placed by anesthesiologists before general anesthesia. Correct positioning of the catheters were tested and confirmed by negative aspiration and injection of 3 mL of 2% Lidocaine. The epidural infusion (solution of 0.2 % ropivacaine 5 ml with 25 to 50 mcg sufentanil in 50 ml of 0,9% NaCl) was started with bolus of 5 ml over 5 minutes and then continuous infusion was maintained was throughout the surgery at 3-12 mL/h and 2-12 mL/h after the surgery. Single dose of sufentanil was given when needed.
223387878|NCT03200990|DEVICE|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
224007383|NCT04962997|OTHER|Data collection|"Investigator will ensure the completion of a hetero-administered questionnaire which will be carried out in French, English, Portuguese or Spanish depending on the language spoken by the participant, including informations related to Demography and socio-economic conditions, Addictions, Work and studies, Housing, Health coverage, Gender and sexuality, Vulnerabilities and violence, Recourse to care, State of physical health, Mental Health, Prevention and Sexually Transmitted Infections (STIs), Checkup, Transition path and clinical complications and Dermatological problems.~Investigator will collect the data relating to the clinical examination, dermatological examination and the search for STIs (blood and / or urine) carried out in the routine care of the participant in a case report form (CRF).~The estimated duration of the interviews and the consultation is approximately 1 hour and 30 minutes per patient."
224007384|NCT06907927|BEHAVIORAL|Control group|the radiologists enrolled in the study will be randomly divided into two groups: the experimental group used AI(Artificial Intelligence) software to assist in the submission of radiology reports and the control group did not use any AI software to submit their reports
224007385|NCT06907927|BEHAVIORAL|Experimental group|the radiologists enrolled in the study will be randomly divided into two groups: the experimental group used AI(Artificial Intelligence) software to assist in the submission of radiology reports and the control group did not use any AI software to submit their reports
224007386|NCT06906380|OTHER|Non interventional study|Non Intervention, an observation LTFU study
224007387|NCT07154498|BEHAVIORAL|Conventional physiotherapy with Cognitive Behavior Therapy|Gentle exercises include stretching and strengthening exercises. Cognitive-behavioral therapy (CBT) sessions.
224007388|NCT07154498|COMBINATION_PRODUCT|Conventional physiotherapy|Gentle exercises include stretching and strengthening exercises mobilisation, soft tissue mobilisation Interventions was applied at two sessions per week, each session is about an hour total of 24 sessions. Assessment was done at baseline in the 6th week and 12th week.
224007389|NCT07154719|DRUG|Tirzepatide|GLP-1 based treatment for obesity
224007390|NCT07154719|BEHAVIORAL|Lifestyle toolkit|2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.
224007391|NCT05385692|DRUG|BL-M02D1|Administration by intravenous infusion
224007392|NCT05630703|BEHAVIORAL|Mindfulness-based Attention Training in IBS|The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.
224007393|NCT05630703|OTHER|Low FODMAP Diet|Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
224007394|NCT03843554|OTHER|Standard of Care Oral Hygiene|Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
224007395|NCT03843554|PROCEDURE|Oral mucosal deterging and dental prophylaxis|Subjects will receive a professional dental prophylaxis including periodontal surface debridement \[a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum\] and deterging of the oral mucosal surfaces.
224007396|NCT05944978|DRUG|GNC-035|GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
224125934|NCT00316303|BEHAVIORAL|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
224125935|NCT04536740|DEVICE|PDT treatment device|All patients will be treated under general anesthesia. After carefully covering the normal skin, hematoporphyrin monomethyl ether (HMME; Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Shanghai, China) was i.v. transfused at a dose of 5 mg/kg for 20 min at a constant rate. Five to 10 min after the onset of HMME transfusion, continuous irradiation at 532 nm (532-nm light-emitting diode green-light therapeutic apparatus; Wuhan Yage Optic and Electronic Technique, Wuhan, China) was applied with a power density of 80- 95 mW/cm2 for 20-30 min. Concomitant forced air cooling was applied during irradiation for epidermal protection. Post-treatment skin cooling was performed by intermittent application of ice packs over a 3-day period, to minimize pain and potential thermal damage. To prevent the effects of photosensitivity, patients were instructed to avoid exposure to strong light for at least 14 days after treatment.
224125936|NCT06475235|DRUG|Pembrolizumab|Humanized immunoglobin G4 monoclonal antibody, 4 mL vials, via intravenous infusion (into the vein) per protocol.
224125937|NCT06475235|DRUG|Methotrexate|Anti-metabolite, 50 mL vials, via intravenous infusion per protocol.
223387879|NCT04347577|DRUG|duloxetine|open-label study
224125938|NCT06475235|DRUG|Temozolomide|Alkylating agent, 5, 20, 100, 140, 180, or 250 mg capsules, taken orally per protocol.
223730185|NCT03010254|PROCEDURE|Cataract surgery|IOL bilateral implantation
223730186|NCT03556007|DRUG|LY3471851|LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
224007397|NCT00988767|BIOLOGICAL|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
224007398|NCT01882543|DRUG|AQX-1125|Synthetic SHIP1 activator
224125939|NCT06475235|DRUG|Rituximab|Anti-CD20 antibody, 10 or 50 mL single-use vials, via intravenous infusion per standard of care.
224125940|NCT01636024|DRUG|AZD7594|Suspension inhaled via Spira nebuliser
224125941|NCT01636024|DRUG|Placebo to match|Matching placebo inhaled via Spira nebuliser
224125942|NCT02604927|DIETARY_SUPPLEMENT|Beta-alanine|
224125943|NCT02604927|DIETARY_SUPPLEMENT|Dextrose|
224007399|NCT01882543|DRUG|Placebo|Double blind placebo capsule
224007400|NCT05189600|DEVICE|Mechnical Insufflation:Exsufflation|Cough Augmentation device
224007401|NCT00012324|DRUG|doxorubicin hydrochloride|
224007402|NCT00012324|DRUG|nolatrexed dihydrochloride|
224007403|NCT01774877|DRUG|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
224007404|NCT01774877|DRUG|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
224007405|NCT05199987|BEHAVIORAL|Standard Occupational Therapy|Standard occupational therapy sessions include patient therapeutic education (implementation of strategies and/or technical aids promoting autonomy and independence), walking and stair exercises in real-life conditions (weighted shopping bag, unstable ground, ...), as well as work on activities of daily living aiming to improve toileting skills (includes individual assessment, the use of technical aids depending of this assessment, and personalised strategies to conserve energy).
224007406|NCT05199987|BEHAVIORAL|Occupational Therapy with Breathing Control Exercises|Includes the same treatment than the one described in standard occupation therapy but with the addition of 30-minute sessions per day on breathing control exercises. These exercises included the reproduction of gestures reproducing daily activities and simultaneous explanations of breathing techniques that the patient can perform in order to set up strategies for saving breath during exercise.
224007407|NCT06429059|DRUG|Astaxanthin|Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).
224007408|NCT06429059|DRUG|Protandim|Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.
224007409|NCT06429059|DRUG|Melatonin|Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.
224007410|NCT06429059|DRUG|MitoQ|The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.
224007411|NCT04222764|DIAGNOSTIC_TEST|Real-time three-dimensional echocardiography|"The initial hemodynamic assessment and monitoring using echocardiography will be performed within 12h following ICU admission. TTE will be performed systematically as first-line examination and TEE will be performed only on ventilated and sedated patients for whom additional information is required for their management, according to the standards of care of the participating centers. In that case, TEE will be performed immediately after TTE.~3D echocardiographic measurements will be performed after the examination by two independent intensivists expert in critical care echocardiography who will be blinded from the usual parameters of RV systolic functions; these parameters will be measured during the examination to guide the management of patients, according to the standard of care of the participating centers."
224007412|NCT04777370|OTHER|posterior glide mobilization|The participant will be positioned supine on a plinth, with their scapula stabilized against a firm wedge on the table, and the shoulder joint in the resting position (approx. 55 degrees abduction, 30 degrees horizontal adduction, and slight external rotation). With the extremity held in the same position, the researcher will then apply a grade III (into tissue stretch) PG mobilization. This will consist of five 30-second bouts of sustained gr III posterior glide mobilizations.
224007413|NCT04777370|OTHER|Sleeper stretch|All participants randomized to the stretching group will perform five 30-second holds of the sleeper stretch. This is performed by lying on the side to be stretched, elevating the upper arm to 90° on the support surface with the elbow bent 90°, then passively internally rotating the shoulder with force provided by with the opposite arm.
224125944|NCT02686606|DIETARY_SUPPLEMENT|Vital 1.5|Oral nutritional supplement
224125945|NCT02686606|DIETARY_SUPPLEMENT|Ensure Plus|Oral nutritional supplement
224125946|NCT03535233|DRUG|Triamcinolone Acetonide|
224125947|NCT03535233|DRUG|Minoxidil 5 % Topical Spray|
224125948|NCT03535233|DRUG|clobetasol propionate|
224125949|NCT01753076|DRUG|Ozanezumab|Ozanezumab injection solution
224125950|NCT01753076|DRUG|Placebo|Normal saline (0.9% sodium chloride) infusion
223730187|NCT03556007|DRUG|Placebo|The placebo dosing solution is 0.9% sodium chloride for injection (USP).
224125951|NCT00678106|DRUG|Dalbavancin|Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
224125952|NCT06113185|OTHER|survey|Demographic and clinical information of the participants will be recorded using a standardized form. The cognitive status of the patient will be evaluated according to the answers to the questions asked to the patient during the questioning of demographic data and reading and signing the consent form. The participants will be asked to complete a series of questionnaires to assess pain intensity and characteristics, pain-related functional disability, and pain-related fear-avoidance behavior. To record the presence and severity of pain behaviors exhibited during physical performance tests, patients will be asked to complete 5 functional tests (repetitive trunk flexion, repetitive sit-to-stand, timed get-up-and-go test, reach with load, 50-step walk test) and observers will simultaneously complete the Pain Behavior Scale. Each participant will be asked to attend two testing sessions separated by one week and occurring before the start of treatment.
223730188|NCT06095427|BIOLOGICAL|LY06006 (Denosumab Biosimilar)|single dose of 60 mg LY006006 s.c.
224007414|NCT04777370|OTHER|thoracic manipulation|"Individuals will then undergo a single supine grade V thrust manipulation. All manipulations will take place at the T3-4 segment. If a cavitation (pop) is not heard or felt by either the subject or examiner, a second thrust will be performed."
224007415|NCT03505177|DIETARY_SUPPLEMENT|Chitin-glucan fiber|4.5g per day of chitin-glucan during 3 weeks
224007416|NCT06791109|DIAGNOSTIC_TEST|Primary care physicians|For participants in Group A, a nonblinded independent staff member will first collect medical history, followed by sequential auscultation and CHD assessment by a specialist physician and a primary care physician, with an echocardiogram performed last.
224007417|NCT06791109|DIAGNOSTIC_TEST|AI + Primary care physicians|For participants in Group B, after medical history collection, both a specialist physician and a primary care physician will perform auscultation and CHD assessment. Subsequently, the primary care physician will use an electronic stethoscope to collect heart sound data according to the protocol and upload the recordings to a cloud platform. The AI model will analyze the data on the cloud platform and provide a diagnostic result within 5-10 seconds for the primary care physician's reference. The primary care physician may reassess the findings based on the AI model's feedback, and the participant will then undergo an echocardiogram.
224007418|NCT01788462|DRUG|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
224007419|NCT04122976|DRUG|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
224007420|NCT02070939|DRUG|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
224007421|NCT02070939|DRUG|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
224007422|NCT02070939|DRUG|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
224007423|NCT02070939|DRUG|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
224007424|NCT02070939|DRUG|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
224007425|NCT02070939|DRUG|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
224007426|NCT00389701|DRUG|bortezomib|
224007427|NCT00389701|DRUG|dexamethasone|
224007428|NCT04396652|PROCEDURE|Adductor canal block (ACB) group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
224007429|NCT04396652|PROCEDURE|Peri-articular injection group|"Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL"
224125953|NCT02801630|DEVICE|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
223387880|NCT01666626|PROCEDURE|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
223387881|NCT05295225|DEVICE|Green Light Emitting Diode|GLED exposure for two hours
223387882|NCT05295225|DEVICE|White Light Emitting Diode|WLED exposure for two hours
223387883|NCT04134533|OTHER|Gross Motor Function Measurement|These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
223387884|NCT01158235|DRUG|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
223387885|NCT06521060|PROCEDURE|tru cut biopsy|Proving that preoperative TCB could provide accurate information about the histological nature of the tumor would have great impact for setting an adequate, tailored, oncologically safe treatment approach.
223387886|NCT05430243|DRUG|Empagliflozin 10 MG|once daily empagliflozin 10mg+/- diuretics
223387887|NCT05430243|DRUG|Diuretics|diuretics as clinically indicated
223387888|NCT03482518|OTHER|custom slippers with perforated synthetic leather cover.|the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.
223387889|NCT05459246|OTHER|Virtual reality glasses|"Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes)."
224007430|NCT04396652|PROCEDURE|Adductor canal block and IPACK block group|Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal IPACK block in which The ultrasound probe will be positioned in the popliteal crease, and needle will be inserted into the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur and 15 ml of 0.25% Levobupivacaine will be injected
224007431|NCT02413853|DRUG|CBP/beta-catenin Antagonist PRI-724|Given IV
224007432|NCT02413853|BIOLOGICAL|Bevacizumab|Given IV
224007433|NCT02413853|DRUG|Leucovorin Calcium|Given IV
224007434|NCT02413853|DRUG|Oxaliplatin|Given IV
224007435|NCT02413853|DRUG|Fluorouracil|Given IV
224007436|NCT02413853|OTHER|Laboratory Biomarker Analysis|Correlative studies
224125954|NCT04708652|OTHER|No intervention|No intervention
224125955|NCT00652431|DRUG|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
224125956|NCT00652431|DRUG|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
224125957|NCT00652431|DRUG|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
224125958|NCT00301782|BIOLOGICAL|bleomycin sulfate|
223387890|NCT01356823|BIOLOGICAL|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
224007437|NCT04659577|BEHAVIORAL|ICBT for panic and depression|The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks. As for depression, the most known type of CBT for treating depression consists of two major strategies: cognitive restructuring, the relationship between thoughts and feelings, behavioural activation, sleep hygiene and relaxation. Each ICBT program includes six modules, containing psychoeducation, cognitive restructuring exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress
224007438|NCT00001629|DRUG|Angiotensin II type 1 receptor antagonists|
224007439|NCT05205187|PROCEDURE|Healthy control specimen collection|Collecting blood and feces from healthy population.
224125959|NCT00301782|DRUG|carboplatin|
224125960|NCT00301782|DRUG|cisplatin|
224125961|NCT00301782|DRUG|etoposide phosphate|
224125962|NCT00301782|DRUG|vincristine sulfate|
224125963|NCT05520814|DRUG|PD-1 inhibitors|treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg \* q21d (until the disease progresses, intolerable toxicity or the investigator / subject decides to withdraw from the study, and the duration of PD-1 inhibitor is not more than 96 weeks)
224125964|NCT05520814|RADIATION|chemoradiotherapy|"Chemotherapy：~1. GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1~   \* Treatment courses every 3 weeks~2. Cisplatin 80mg/m2 d1 or carboplatin area under the curve 5mg/ml/min \* Treatment courses every 3 weeks~Radiotherapy： All the metastatic lesions received radiation dose from 30 to 60Gy according to different metastatic sites."
224125965|NCT02251054|OTHER|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
224125966|NCT02251054|OTHER|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
224125967|NCT01212172|DEVICE|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
224125968|NCT01212172|DEVICE|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
224296019|NCT02551393|BEHAVIORAL|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
224296020|NCT06324058|PROCEDURE|Transurethral cryoablation|Using an intracavitary cryoablation balloon, cryoablation is performed on the wound surface after tumor resection. The wound surface is frozen for 2 rounds, with each round lasting 3 minutes, to fully cover the wound surface.
223387891|NCT01356823|BIOLOGICAL|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
223387892|NCT01356823|BIOLOGICAL|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
224007440|NCT05205187|PROCEDURE|Non-Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.
224007441|NCT05205187|PROCEDURE|Borrmann IV patient specimen collection|Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
224007442|NCT00329147|DRUG|desvenlafaxine SR|
224007443|NCT00329147|DRUG|desipramine|
223387893|NCT01356823|BIOLOGICAL|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
223387894|NCT03098719|BEHAVIORAL|Active Mobility|see detailed discription
223545694|NCT06113757|DEVICE|Signal Therapy provided by Dr.Biolyse device|Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.
224007444|NCT00329147|DRUG|paroxetine|
224007445|NCT05958875|DRUG|Clozapine|Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
224007446|NCT05958875|DRUG|Second-line Antipsychotics (treatment as usual)|Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
224007447|NCT01502683|PROCEDURE|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
223730189|NCT06095427|BIOLOGICAL|US-Prolia (Denosumab)|single dose of 60 mg US-Prolia s.c.
224007448|NCT01502683|PROCEDURE|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
224007449|NCT01502683|PROCEDURE|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
224007450|NCT01502683|PROCEDURE|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
224007451|NCT06090188|OTHER|A Culture-Based Multicomponent Cognitive Training Program|Activities of the program were structured, cognitive, leisure activities based on Chinese and Taiwanese culture for cognitively impaired older people. Activities contained structured brain-exercise activities and musical activities. The structured brain-exercise activities included playing musical instruments or singing, playing board games, and classes in Chinese, sciences, sociology, physical education, cooking, and math. Chinese and Taiwanese cultures were included within the structured brain-exercise activities curriculum, such as food, clothing, architecture, places of interest, folklore, etiquette, celebrations, religion, art, etc. Participants began with a musical exercise, then had 20-30 minutes of physical exercise with 5 minutes of warm-up at the beginning and 5 minutes of cool down. The program was provided for at least 40-60 minutes, twice a week, for 8 weeks via RAs and day centre caregivers.
224007452|NCT02885844|PROCEDURE|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
224007453|NCT02885844|PROCEDURE|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
223387895|NCT03973736|OTHER|application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)|Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
223387896|NCT01159808|DRUG|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
223387897|NCT01159808|DRUG|Placebo|matching placebo capsules, oral administration, single dose
224007454|NCT04396366|DRUG|QBW251|QBW251, 300 mg, oral use, one capsule, twice daily.
224007455|NCT04396366|DRUG|Placebo|Matching placebo, 300 mg, oral use, one capsule, twice daily.
224007456|NCT06835972|DRUG|Abemaciclib|twice a day, orally
224007457|NCT06835972|DRUG|Cabozantinib|once daily, orally
224007458|NCT01425905|OTHER|The Blues Program|
224007459|NCT01425905|OTHER|Hey Durham|
224007460|NCT03729375|DRUG|10cc injection of bupivacaine|10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
224007461|NCT03729375|DRUG|20cc injection of bupivacaine|20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
224007462|NCT00503139|DRUG|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
224007463|NCT06845852|DRUG|varegacestat|Single oral dose of varegacestat
224007464|NCT06609824|BEHAVIORAL|Leer te Durven!|'Leer te Durven!' is an eight-week preventative group training for children between the ages of 8 and 12. This training is evidence-based and is based on the principles of Cognitive Behavioral Therapy. With this program children learn to stand up for themselves in a safe environment, to face the situations that they find exciting and to be more confident in their own abilities. The training consists, among other things, of psychoeducation, exposure, and relaxation.
223387898|NCT05389137|BIOLOGICAL|Inavtivated Quadrivalent Influenza Virus Split Vaccine|Prevent influenza caused by H1N1, H3N2, B (V), B (Y) strain virus infection.
224007465|NCT00056992|DRUG|ADI-PEG 20|
224007466|NCT05434052|OTHER|Turkish Validity and Reliability of The CIQ-R Scale|The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society and to make its validity and reliability in Turkish. It has 18 questions. This study will be conducted with stroke patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
224007467|NCT05589805|DEVICE|Extracorporeal shock wave therapy|In addition to wrist splint, ESWT treatment (1.5 bar, 5Hz, 1000 beats) will be applied to the patients with Elmed Vibrolith Ortho brand ESWT device, which we routinely use in the treatment of carpal tunnel syndrome, for 3 weeks, once a week.
224007468|NCT05589805|DEVICE|Laser therapy|In addition to the wrist splint, the patients will be treated with the BTL-4110 Laser Topline model low-intensity laser device, which we routinely use in the treatment of carpal tunnel syndrome in our hospital, 5 days a week for 15 sessions of laser treatment.
224007469|NCT05589805|OTHER|Control group|Patients will only be given a wrist splint to keep the wrist in neutral position.
224007470|NCT04763317|GENETIC|Prostate cancer risk gene panel|A list of genes created by study experts, thought to increase the risk of prostate cancer from from review previous research, this list is regularly reviewed for accuracy
224007471|NCT00996476|DRUG|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
224007472|NCT00996476|DRUG|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
224007473|NCT00996476|DRUG|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
223545695|NCT06113757|OTHER|Liquid Support Treatment|The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
223730190|NCT06095427|BIOLOGICAL|EU-Prolia|single dose of 60 mg EU-Prolia s.c.
223730191|NCT01404325|DRUG|standard therapy|centre specific CNI-based triple drug immunosuppression
224007474|NCT06291675|DRUG|gender-affirming hormone therapy|We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.
224007475|NCT01322802|BIOLOGICAL|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
224007476|NCT01322802|OTHER|laboratory biomarker analysis|Correlative studies
224007477|NCT05540717|BIOLOGICAL|PQ Grass|Suspension for Injection
224007478|NCT05540717|BIOLOGICAL|Placebo|Solution for injection
224007479|NCT00519519|DRUG|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
224007480|NCT04538911|DRUG|BCG-PPD|BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
224007481|NCT01940939|DEVICE|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
224007482|NCT01470001|DRUG|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
224007483|NCT01895101|DRUG|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
224007484|NCT01895101|DRUG|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
224007485|NCT02077101|OTHER|Questionnaire|
224125969|NCT02065310|OTHER|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
224125970|NCT01687738|OTHER|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
224125971|NCT01687738|OTHER|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
224125972|NCT06418672|BEHAVIORAL|Go Sun Smart Georgia (GSSG)|"Go Sun Smart Georgia (GSSG) is an educational, train-the-trainer, and technical assistance program for Georgia worksites that employ outdoor workers.~GSSG is delivered through personal contacts with senior worksite managers, employee training, and distribution of educational materials. In meetings with managers, trained coaches work to increase perceived need for workplace sun safety, cite advice from national authorities (e.g., CDC and NIOSH), plan for policy implementation, alter policies/education and/or workplace to improve fit, clarify changes to other managers/ employees, and bundle sun safety with worksite safety.~The intervention period will last 12-16 weeks in each of the groups."
224125973|NCT06527612|OTHER|Pulmonary rehabilitation exercise programme|In addition to standard medical treatment, the EGr will undergo an exercise program. The initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. From the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. Compliance with the exercise regimen will be assessed through a weekly survey shared in a WhatsApp group established for the exercise group patients.
224125974|NCT01426399|DRUG|LC15-0444|LC15-0444 50mg qd (8 days once daily)
223387899|NCT00815932|DEVICE|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
224296021|NCT06324058|PROCEDURE|Transurethral resection of bladder tumor|Resection of bladder tumor using resectoscopy, which is a standard procedure to treat non-muscle invasive bladder cancer
224296022|NCT06324058|DRUG|Bcg Intravesical|Bacillus Calmette-Guerin instillation of bladder after surgery according to the NCCN bladder cancer guidelines. At least 6 weeks induction instillation is required for high-risk NMIBC patients. At least 1 year maintenance instillation is recommended.
224007486|NCT02077101|OTHER|Interview|
223387900|NCT02366689|DRUG|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
223387901|NCT02366689|DRUG|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
224007487|NCT02126761|BIOLOGICAL|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
224007488|NCT02126761|BIOLOGICAL|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
224007489|NCT02126761|BIOLOGICAL|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
224007490|NCT02126761|BIOLOGICAL|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
223387902|NCT02366689|DRUG|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
223730192|NCT01404325|DRUG|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
224007491|NCT03246776|DRUG|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
224007492|NCT05826470|DEVICE|"TRANBERG®|Thermal Therapy System"|Focal laser ablation.
224007493|NCT03085173|BIOLOGICAL|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.
224007494|NCT03619551|DRUG|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
224007495|NCT03619551|DEVICE|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
224007496|NCT04786964|DRUG|Cosibelimab|IV infusion
224007497|NCT04786964|DRUG|Cisplatin|IV infusion
224007498|NCT04786964|DRUG|Carboplatin|IV infusion
224007499|NCT04786964|DRUG|Pemetrexed|IV infusion
224007500|NCT04786964|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
224007501|NCT04786964|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
224007502|NCT04786964|DRUG|Dexamethasone 4mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
224007503|NCT04836403|OTHER|Sinus and nasal quality of life survey questionnaire (SN-5)|"The SN-5 consists of five questions on a 7-point scale that assesses the frequency of the following symptoms: (1) nasal obstruction, (2) sinus infection, (3) allergies, (4) emotional distress, and (5) activity limitations. The scoring system is as follows: 1 indicates none of the time, 2 indicating hardly any time at all, 3 indicates a small part of the time, 4 indicates some of the time, 5 indicates a good part of the time, 6 indicates most of the time, and 7 indicates all of the time. Higher scores indicate more severe sinonasal symptoms. One item from a global faces scale scored from 0 to 10 is used to evaluate overall QoL related to nasal or sinus disease. Higher scores on this scale indicate a less severe impact of nasal or sinus disease. The scores from the first five items (1-7 each)"
224007504|NCT01835691|DIETARY_SUPPLEMENT|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
224007505|NCT01835691|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
224007506|NCT03568968|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
224007507|NCT03568968|OTHER|Placebo|Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.
224007508|NCT05304234|DIAGNOSTIC_TEST|Ultrasound or abbreviated MRI|Abdominal ultrasound or abbreviated MRI
224007509|NCT01885520|DIETARY_SUPPLEMENT|fasting condition|eperisone SR tablet 75mg administrated under fasting
224007510|NCT01885520|DIETARY_SUPPLEMENT|fed condition|eperisone SR tablet 75mg administrated fed condition
224007511|NCT03735589|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
224007512|NCT03735589|BIOLOGICAL|Autologous Natural Killer Cell-like CTLs|Given IP
224007513|NCT03021980|BEHAVIORAL|SuperFIT|Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
224007514|NCT00734357|PROCEDURE|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
224007515|NCT01134068|OTHER|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
224007516|NCT04032613|OTHER|Vascular Access Navigation and Education Quality Improvement Program|A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
224007517|NCT00011752|DRUG|FCWAY|
224007518|NCT03526276|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
224007519|NCT03526276|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily
224007520|NCT03526276|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
224007521|NCT02404727|PROCEDURE|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
224007522|NCT02404727|DEVICE|Avantage® Cup|
224007523|NCT04334187|BEHAVIORAL|Mindfulness Based addition treatment|The intervention is comprised of 8 weekly group MBAT sessions. Two weekly groups of about 10 participants each will be conducted. All participants will also have the option to receive nicotine patches, gum, or lozenges for four weeks as part of their time in the study. Participants will complete surveys at enrollment (baseline), immediately after their last MBAT session (around 2 months after enrollment) and one month after completing treatment (3 months post-enrollment). Surveys will assess primary and secondary outcomes and satisfaction with the intervention.
224007524|NCT01659853|DRUG|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
224007525|NCT01659853|DRUG|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
224007526|NCT00961480|DRUG|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
224007527|NCT00961480|DRUG|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
224007528|NCT00961480|DRUG|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
224007529|NCT00961480|DRUG|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
223387903|NCT02366689|DRUG|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
224007530|NCT00961480|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
224007531|NCT00961480|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
224007532|NCT00961480|DRUG|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
224007533|NCT00961480|DRUG|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
224007534|NCT04556903|COMBINATION_PRODUCT|Bilateral Arm Training|First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
224007535|NCT04556903|COMBINATION_PRODUCT|modified constrained induce movement therapy|"BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~* Block placement- 10minutes~* Peg targeting- 10 minutes~* Peg inversion-10miutes~* Transferring objects- 10minutes"
223387904|NCT02366689|DRUG|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
223387905|NCT06338501|OTHER|Specifical Functional Training Exercises|"Strength Training: Include compound exercises like squats, deadlifts, lunges, and bench presses to build overall strength and muscle mass. Focus on functional movements that mimic the actions used in Muay Thai.~Core Stability Exercises: A strong core is essential for generating power and maintaining balance during strikes and defensive maneuvers.~Plyometric Training: Jumping exercises such as box jumps, squat jumps, and split jumps help improve explosive power and enhance muscular endurance, crucial for delivering swift and powerful strikes.~Flexibility and Mobility Training: Incorporate stretching exercises to improve flexibility, joint range of motion, and prevent injuries.~Interval Training: Perform high-intensity interval training (HIIT) sessions that combine cardiovascular exercises."
223387906|NCT03535792|DRUG|Fentanyl/Hyperbaric bupivacaine|Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
224007536|NCT01085968|BEHAVIORAL|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
224007537|NCT03053518|DEVICE|Abbott Freestyle Libre Pro|A professional, blinded, continuous glucose monitoring device will be inserted on the back of the upper arm to measure interstitial glucose every 5 min for 4 times / day.
224007538|NCT03053518|BEHAVIORAL|LifeStyle|Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
224007539|NCT05949866|BEHAVIORAL|Movement and Cognition Intervention Group|"Preschool centers assigned to the Movement and Cognition (MAC) group will receive the 6-month intervention, which will be implemented 4 days per week. To ensure consistency of intervention delivery, centers will be provided with the MAC modules on a bi-weekly basis. The MAC intervention will be implemented using a train-the-trainer (gradual release) model. This will be a gradual release model, in which interventionist will first serve as a co-provider and will eventually serve in a support role, as providers become primary implementers.~The MAC intervention will consist of gross motor skill curriculum consists of 30 individual lesson plans. The number of days needed to instruct each lesson plan activities ranges between 3 to 5 days. In each lesson, specific instruction and activities are designed to teach fundamental movements (e.g., running, leaping, kicking, jumping, throwing, catching)."
224007540|NCT05949866|BEHAVIORAL|Health Tracker Group (Control Group)|Preschool centers assigned to the health tracker g group will be asked to maintain their usual daily schedule and to not participate in other physical activity programs during the 6-month intervention.
224007541|NCT02071290|DEVICE|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
224007542|NCT04938167|OTHER|95% - 99% SpO2 target|If the infant is randomized to the intervention arm, the oxygen saturation goal will be changed from the standard goal of 91% - 95% to the experimental goal of 95%-99%. The treating medical team will then adjust the oxygen and respiratory support to maintain these goals (SpO2 alarm levels will be set at 93% and 100%).
224007543|NCT04852042|BEHAVIORAL|mHealth|Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.
224007544|NCT04852042|BEHAVIORAL|CHW support|The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
224007545|NCT03535506|DRUG|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
224007546|NCT00656708|OTHER|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
224125975|NCT01426399|DRUG|Metformin|Metformin 1000 mg bid (8 days twice daily)
223387907|NCT03535792|DRUG|Nalbuphine/Hyperbaric bupivacaine|Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
223387908|NCT06013475|DRUG|Apalutamide|Decision by the treating physician
223387909|NCT06013475|DRUG|Darolutamide (BAY 1841788)|Decision by the treating physician
223387910|NCT06013475|DRUG|Enzalutamide|Decision by treating physician
224125976|NCT01426399|DRUG|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
224125977|NCT05393817|DRUG|caffeine citrate|caffeine citrate administration, dosage decided by the the physician on duty, within the range of routine management (5mg/kg/day \~ 20mg/kg/day)
224125978|NCT03355287|OTHER|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
224125979|NCT03355287|OTHER|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
224007547|NCT06502730|BEHAVIORAL|Creating Opportunities for Parent Empowerment (COPE) Program|It helps to recognize the critical role of parents and encourage taking an active role in their neonate's care, engaging in dyadic interaction with their neonate. COPE program consists of two types of educational information; as teaching parents about normal physical, developmental and behavioral characteristics of their preterm infants and the best ways to interact with them and facilitate their development.
224007548|NCT04578353|DEVICE|The AquaPass System|The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
224125980|NCT03355287|OTHER|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
224125981|NCT05097053|BIOLOGICAL|MVC-COV1901(3 Months)|MVC-COV1901 vaccine after a 3-month Interval
224125982|NCT05097053|BIOLOGICAL|MVC-COV1901(6 Months)|MVC-COV1901 vaccine after a 6-month Interval
224007549|NCT06121206|OTHER|Altitude-like hypoxia (12% O2)|Fresh air with 12% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. After participants enter the room, the O2 levels will be reduced from 16% to 12% (≈ 4,400 meters altitude) in a 30 minutes lead-in phase. The target O2 level of 12% will be maintained over three hours
224007550|NCT06121206|OTHER|Normoxia (20% O2)|Fresh air with 20% O2, is blown into a sealed 20 m³ room by a 4kW air compressor with a safety-approved system developed by HöhenBalance, Austria. The target O2 level of 20% will be maintained over 3.5 hours
224125983|NCT00370695|DEVICE|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
224125984|NCT03885726|DEVICE|Precision Flow Plus|High velocity nasal insufflation
224125985|NCT03885726|DEVICE|Treatment as Usual|Conventional therapy per institution
224125986|NCT01217190|DRUG|Ondansetron (ODFS)|Test Article
224125987|NCT01217190|DRUG|Zofran (ODT)|Comparator
223387911|NCT06172712|OTHER|Variations in daily life activity signals detected by unobtrusive sensors|Patients will be equipped with unobtrusive devices for a duration of 12 months. Throughout this period, they will attend scheduled visits every three months following the baseline visit. These assessments will focus on determining the frequency of exacerbations, evaluating exercise capacity, measuring the severity of dyspnea, and assessing health-related quality of life. The data gathered from the sensors embedded in these unobtrusive devices will be instrumental in developing AI-based models. These models aim to accurately predict COPD exacerbations and effectively estimate the progression of the previously mentioned health outcome.
223387912|NCT06578221|OTHER|Kegel Pelvic Floor Muscle Exercise Group|After the surgery, the patients will be taken to the clinic room in a supine position and the researcher will perform the Kegel pelvic floor muscle exercises three times at the 1st, 4th and 7th hours within the first 8 hours after the patients are taken to the clinic room.
223387913|NCT01576679|DRUG|Cathflo (Alteplase)|
223387914|NCT01576679|DRUG|Saline|
223387915|NCT03283566|DRUG|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
223387916|NCT03283566|DRUG|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
223387917|NCT01231646|OTHER|No intervention|No intervention. This is a cross-sectional study.
223387918|NCT02934672|OTHER|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
224125988|NCT06291246|BEHAVIORAL|Virtual Family Navigation|Participants randomized to the Family Navigation condition will receive up to 4 research-based individual sessions with a trained navigator to support them in identifying and enrolling in recommended autism early intervention services. All navigation sessions will be delivered virtually via phone/Zoom.
224125989|NCT06291246|BEHAVIORAL|Educational Materials|"The comparison condition (Educational Materials) consists of providing the participant's caregivers information about early intervention and community-based supports (i.e., infant-toddler programs, transition to school-based supports, family support groups, local organizations. Families in this condition will receive this information throughout 4 timepoints in the first 3 months after enrolling."
224125990|NCT03915899|BEHAVIORAL|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
224125991|NCT02306993|OTHER|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
224125992|NCT02306993|OTHER|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
224125993|NCT02306993|OTHER|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
224125994|NCT00210015|DRUG|INS37217 Nasal Spray|
224125995|NCT01905319|OTHER|Blood collecting for storage of samples|
224125996|NCT04683198|DRUG|camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
224125997|NCT04683198|DRUG|Apatinib Mesylate|Apatinib capsules 250 mg given orally , once daily in 21-day cycle and maintenance phase,until PD.
224125998|NCT04683198|DRUG|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6).
223387919|NCT03288714|DEVICE|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
224007551|NCT06121206|BEHAVIORAL|Cognitive training|The web-based cognitive training (Happy Neuron Pro) is grounded on principles of neuroplasticity-based learning by being intensive, neuroadaptive, engaging and rewarding. The active training involves parametric task adjustment by decreasing stimuli presentation time, increasing working memory load, decreasing time to respond, and increasing the number of non-target items (distractors).
224007552|NCT06121206|BEHAVIORAL|Sham training|Participants in the no training control condition receive computer games similar to Happy Neuron Pro but with low cognitive demand that produce no cognitive benefits. Specifically, this sham procedure involves the exact same stimuli as the active condition but with changes from trial to trial only in the appearance of the tasks.
224007553|NCT06190210|DIAGNOSTIC_TEST|electroencephalography|Pre-, per- and postoperative electroencephalography
224007554|NCT06190210|DIAGNOSTIC_TEST|Near-Infrared Spectroscopy|Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation
224007555|NCT06190210|DIAGNOSTIC_TEST|neuronal cell-free DNA|CfDNA which is characterized based on methylation patterns to determine the tissue of origin
224007556|NCT06527937|DRUG|DESF|DESF administered in the sublingual space.
224007557|NCT06527937|DRUG|Epinephrine Injection|Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
224007558|NCT04907019|DRUG|rifampicin，SY-004|"On the morning of D1, the subjects will take orally 80 mg of SY-004 Capsules on an empty stomach.Fasting will be performed within 4 hours after taking the medicine. From D8 to D14, the subjects will take orally 600 mg rifampicin before breakfast every day. On the day of D15, the subjects will take orally 600 mg rifampicin and 80 mg SY-004 Capsules on an empty stomach.~From D16 to D21, subjects will take orally 600 mg of rifampicin before breakfast every day.The patient can be discharged from the hospital after completing the safety examination on D22."
224007559|NCT00873028|OTHER|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
224007560|NCT04374539|BIOLOGICAL|Plasma exchange|"Plasma exchanges with 5% human albumin and fresh frozen plasma in patients with quick \<50% or only with 5% albumin in patients with quick of 50% or more. We will exchange between 1.2 and 1.5 plasma volumes, that will vary according to sex, weight, height and hematocrit.~Polyclonal immunoglobulin will be administered at a dose of 100 mg / kg ev after each plasma exchange.~Standar Medical treatment Kaletra:~lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d"
224007561|NCT04374539|DRUG|Standar medical treatmen|"Kaletra: lopinavir/ritonavir: 2c/12h 7 days~* Hydroxychloroquine sulfate 400 mg/12h the first day followed by 200 mg /12h 4 days~* Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)~* Tocilizumab 400 mg (weight \<75Kgs) or 600 mg (weight ≥ 75 Kg)~* Methylprednisolone 250 mg EV three days and 30 mg/d another 3 days~* Anakinra 200mg/ 12h SBC first day, 200mg / 24h SBC two more days~* Clexane 40-60 mg/d"
224007562|NCT05156151|OTHER|Relex-Smile|
224007563|NCT05268536|OTHER|core stabilization exercise|Patients will perform Plank, Bird dog, Double leg lifts, Prone cobra, Oblique twists exercises under the supervision of experienced Physiotherapist. All the participants will perform exercise for 6 weeks, 2 days a week for approximately 30-45 (including warm-up and cool-down).
224007564|NCT05268536|OTHER|resistance exercise|resistance exercise
224007565|NCT03374449|PROCEDURE|continuation of the RAS-inhibitors|drug intake
224007566|NCT03374449|PROCEDURE|discontinuation of the RAS-inhibitors|no drug intake
223387920|NCT03288714|DEVICE|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
224007567|NCT05951270|DIETARY_SUPPLEMENT|Apple Polyphenols|ApplePhenon® is prepared from unripe green apples (malus domestica) and contains a large amounts of polyphenols. The supplement contains 63.8% procyanidins, 12.4% flavon-3-ols, 6.5% chalcones and 10.8% phenolcarboxylic acids
223387921|NCT05846035|DIAGNOSTIC_TEST|Triphasic C.T abdomen and pelvis|for cirrhotic patients to ensure hepatocellular carcinoma
223387922|NCT00023413|DRUG|Rifabutin|
223387923|NCT00023413|DRUG|Efavirenz|
223387924|NCT05596656|DIAGNOSTIC_TEST|skin prick test|"Skin prick testing was performed to all diabetic child with history of allergy. The recommended method of prick testing includes the appropriate use of specific allergen extracts, positive and negative controls, interpretation of the tests after 15 - 20 minutes of application, with a positive result defined as a wheal ≥3 mm diameter more than negative control for detection of specific IgE to one or more of common aeroallergens.~The location of each allergen was marked with a pen on the volar aspect of forearm to properly identify test results, at least 2 cm from the wrist and the antecubital fossae. The distance between two skin prick tests should be appropriate to avoid false-positive reactions due to direct contamination of a nearby test. A drop of each test solution should be placed on the skin in identical order for each subject tested and immediately pricked with a single-head metal lancet."
223387925|NCT00814476|OTHER|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
223730193|NCT02144233|PROCEDURE|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
223387926|NCT00814476|OTHER|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
223387927|NCT03689465|DRUG|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
223387928|NCT03689465|DRUG|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
223387929|NCT03689465|DRUG|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
224007568|NCT05951270|OTHER|Control|The placebo used in this study is 1100 mg maltodextrin (Avebe, Veendam, the Netherlands). This product is an enzymatically converted potato starch. The flavor and color will have a similar/identical appearance and taste as all mentioned antioxidants.
224007569|NCT04472416|DEVICE|VRD in addition to standardized analgesic protocol|Use of VRD in addition to standardized analgesic protoco for abdominal VAC dressing change
224007570|NCT06029348|BEHAVIORAL|Paced Auditory Serial Addition Task|Study volunteers will be asked to complete a 4-minute Paced Auditory Serial Addition Task, which is a standardized task that is widely used to study cardiovascular responses to acute psychological challenges (or stressors) in a laboratory setting.
223387930|NCT03689465|DRUG|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
223387931|NCT03689465|DRUG|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
224007571|NCT06341686|DRUG|Letermovir 480 MG|Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection
224007572|NCT06341686|DRUG|Ganciclovir|The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
224007573|NCT04489953|OTHER|Viral Load|For the Clinical and Immunologic criteria, viral load was done retrospectively on stored plasma samples. Whereas for the Clinical, Immunologic and Virologic criteria, viral load was done in real-time
224007574|NCT06042894|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
224007575|NCT06042894|DRUG|SI-B003|SI-B003 was administered by intravenous infusion on D1 in a 3-week cycle.
224007576|NCT06431048|OTHER|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure.|Naso-enteral nutrition will be stopped when the patient is called to the OR for scheduled procedure (tracheostomy + PEG or PEG only).
224007577|NCT06431048|OTHER|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure.|Naso-enteral nutrition will be stopped 2 hours before the scheduled procedure (tracheostomy + PEG or PEG only).
224007578|NCT06145854|DRUG|Cabotegravir Injection [Apretude]|Apretude for PrEP
224007579|NCT04702321|OTHER|Procedure: Biospecimen Collection|Collection of saliva, buccal swabs, blood, or other sample adequate for germline DNA extraction
224007580|NCT04702321|OTHER|Procedure: Medical Chart Review|Collection of clinical data
224007581|NCT06161727|OTHER|HPV exposure|According to group descriptions
224007582|NCT06250712|DEVICE|Continous ECG Patch|Using a continuous patch ECG for 1 week during 1 month
224007583|NCT06250712|DEVICE|Intermittent handheld ECG|Using a handheld ECG twice daily and when symptoms are present during 1 month
224007584|NCT05187364|BEHAVIORAL|COPE|The COPE therapy is a talk-therapy in which individuals are asked about their trauma, alcohol use, mood, and behavior. The therapy occurs over 12 sessions and will be paired with a telehealth technology system to determine if it enhances the COPE therapy. The telehealth system is worn on the arm and hand during the out-of-office COPE homework assignments. It consists of a small camera (about the size of a pencil eraser), Bluetooth earpiece with microphone, monitors to measure and record heart rate and skin conductance, and a breathalyzer to assess blood alcohol content. The device will connect to an application on password protected cell phone that will monitor and record the above listed information as well as reported subjective units of distress and craving. A study coach will virtually guide participants through one out-of-office assignment per week using this technology. Interviews and surveys will be collected at study baseline and weekly during treatment.
224007585|NCT05870774|PROCEDURE|Soft tissue augmentation with CTG|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Harvesting of free connective tissue graft from the maxilla tuberosity area~4. Fixation of the graft to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
224296023|NCT02316158|OTHER|Web-based support|Comparison between the efficacy between webb-based support and informational support
223387932|NCT01917682|PROCEDURE|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
223387933|NCT02706444|DEVICE|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
223730194|NCT02144233|PROCEDURE|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
223730195|NCT02389088|DRUG|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
223387934|NCT02706444|DEVICE|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in \> 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
223387935|NCT01806194|BEHAVIORAL|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
223387936|NCT01806194|BEHAVIORAL|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
223387937|NCT01027325|OTHER|Dietary Intervention|Starch digestibility and carbohydrate quantity
224007586|NCT05870774|PROCEDURE|Soft tissue augmentation with CM|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech dental implant (Dentsply, Germany)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular mucosal-periosteal flap~5. Suturing the wound tightly"
224007587|NCT06120985|DEVICE|Countertop pitcher water filter|Point-of-use drinking water filter
224007588|NCT05803018|DRUG|BL-B01D1|Administration by intravenous infusion
224007589|NCT05560243|BEHAVIORAL|Tobacco cessation|Tobacco cessation program consisting of cognitive-therapy sessions and pharmacological management
224007590|NCT06504394|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|SC injection
224007591|NCT04903262|PROCEDURE|Ultraprotective ventilation with Extracorporeal CO2 removal|HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.
224007592|NCT04903262|PROCEDURE|Conventional protective ventilation|"Conventional lung protective mechanical ventilation, as described in the arm description (standardized ventilation)"
224007593|NCT04004468|BEHAVIORAL|Resistance Training|Standard barbell resistance training programs
224007594|NCT06010433|DEVICE|CERAMENT G|"* Primary mode of action is to be a resorbable ceramic bone graft substitute intended to fill gaps and voids in the skeleton system to promote bone healing. CERAMENT ™\|G provides a void/gap filler that during the surgical procedure can augment hardware and bone alignments.~* Secondary mode of action is to prevent colonization of Gentamicin sensitive microorganisms in order to protect bone healing."
224125999|NCT04683198|DRUG|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m\^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6).
224296024|NCT00498342|DRUG|N-acetylcysteine|
223387938|NCT01169792|DRUG|tamoxifen|
223387939|NCT05506670|OTHER|Diagnostic test and phone call|Viral diagnostic test will be performed at inclusion. In case of RSV positive results, follow up phone calls will be scheduled at day 14 and day 30 to collect data.
223387940|NCT05506670|DIAGNOSTIC_TEST|Diagnostic test|Viral diagnostic test will be performed at inclusion. In case of RSV negative result, no more intervention will be required.
223387941|NCT04882241|BIOLOGICAL|Pembrolizumab|IV infusion
223387942|NCT04882241|DRUG|Placebo|IV infusion
223387943|NCT04882241|DRUG|Cisplatin|IV infusion
223387944|NCT04882241|DRUG|Capecitabine|Oral tablets
223387945|NCT04882241|DRUG|5-fluorouracil|IV infusion
223387946|NCT04882241|DRUG|Docetaxel|IV infusion
223387947|NCT04882241|DRUG|Oxaliplatin|IV infusion
223387948|NCT04882241|DRUG|Leucovorin|IV infusion
223387949|NCT04553393|DRUG|Chidamide|Chidamide will be added 1 month after responding to CART cells infusion
223387950|NCT04553393|DRUG|Decitabine|Decitabine will be added 1 month after responding to CART cells infusion
223387951|NCT04553393|DRUG|Chidamide and Decitabine|Both chidamide and decitabine will be added 1 month after responding to CART cells infusion
223387952|NCT04553393|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|Tandem CAR19/20 engineered T cells
224007595|NCT04116892|PROCEDURE|the Cover group|The internal limiting membrane around the MH was left to cover the hole
223387953|NCT04766645|DEVICE|Robotic assisted intervention|Conventional rehabilitation and Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
223387954|NCT04766645|GENETIC|epigenetic analyses|Epigenetic study: evaluation of methylation levels of ACE2 promoter and miR-200c-3p levels.
223387955|NCT04766645|DIAGNOSTIC_TEST|biochemical analyses|Biochemical analysis: the evaluation of serum levels of angiotensin II, ACE2 and Vitamin D.
224007596|NCT04116892|PROCEDURE|the Fill group|The internal limiting membrane around the MH was left to fill the hole
224007597|NCT04116892|PROCEDURE|the peeling group|the internal limiting membrane was discarded
224007598|NCT06612645|BIOLOGICAL|B7H3-IL7Ra CAR-T cells|Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion
224296025|NCT04090970|DEVICE|Briagen|Natural complex carbohydrate wound dressing for skin wounds
224296026|NCT00426010|DRUG|caffeine/placebo|caffeine or placebo, either overt or covert
224296027|NCT01973023|OTHER|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
224296028|NCT02725775|DIETARY_SUPPLEMENT|100% Florida OJ|
224296029|NCT02725775|DIETARY_SUPPLEMENT|Placebo Equicaloric Orange Drink|
224296030|NCT04904159|PROCEDURE|Thyroidectomy|total thyroidectomy
224296031|NCT04904159|PROCEDURE|Lobectomy|Lobectomy
224296032|NCT01566019|PROCEDURE|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
224296033|NCT03674502|DRUG|ADU-1604|anti-CTLA-4 monoclonal antibody
224296034|NCT05822245|DRUG|PER-001 Intravitreal Implant - Low Dose|PER-001 Low Dose Intravitreal Implant
224296035|NCT05822245|DRUG|PER-001 Intravitreal Implant - High Dose|PER-001 High Dose Intravitreal Implant
224296036|NCT05822245|DRUG|PER-001 Intravitreal Implant - Sham|PER-001 Intravitreal Sham
224007599|NCT03335839|DRUG|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
224007600|NCT03335839|OTHER|Saline|Placebo
224007601|NCT06643728|DRUG|Bimagrumab|Administered SC
224007602|NCT06643728|DRUG|Tirzepatide|Administered SC
224007603|NCT06643728|DRUG|Bimagrumab Placebo|Administered SC
223387956|NCT05436730|DEVICE|Ambulatory blood pressure measurement device|Assessment of the 24-h blood pressure profile
224007604|NCT06643728|DRUG|Tirzepatide Placebo|Administered SC
224007605|NCT05868954|BEHAVIORAL|MedDiet Program|Subjects allocated to the MedDiet Program group will receive counseling based on the principles of the traditional MedDiet with a focus on a general change in diet instead of micronutrients or macronutrients. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional MedDiet meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive olive oil and nuts during their enrollment visit and during their routine 26-30 week prenatal visit.
224007606|NCT05868954|BEHAVIORAL|ACOG-based Dietary Program|Following ACOG recommendation, subjects allocated to the ACOG-based Dietary Program group, will receive routine counseling on healthy eating. This will include advice on the consumption of grains, fruits, vegetables, protein, and dairy foods recommended during pregnancy. Diet adherence will be assessed using a questionnaire. Participants will receive 6, free traditional healthy meals every 3 weeks between enrollment and until the subject is approximately 38 weeks pregnant. In addition, participants will receive canola oil and healthy snacks during their enrollment visit and during their routine 26-30 week prenatal visit.
224007607|NCT05485753|DRUG|GNC-038|Administration by intravenous infusion
224007608|NCT06152627|BEHAVIORAL|Standard of care voice therapy with novice clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will be trained to use the RTSS-Voice in their clinical documentation.
224007609|NCT06152627|BEHAVIORAL|Standard of care voice therapy with expert clinician RTSS-Voice documentation|Voice therapy is individually tailored to each patient and typically includes behavioral ingredients (e.g., applying pressure to the anterior neck, practice voicing in various ways, feedback on performance, provide information on the importance of therapy concepts) to modify the patient's auditory, somatosensory, vocal, musculoskeletal, respiratory, and mental functions. During this time, the treating clinicians will have completed their RTSS-Voice training and using the RTSS-Voice in their clinical documentation.
224007610|NCT06131450|DRUG|BL-M07D1|Administration by intravenous infusion
224007611|NCT01783964|DRUG|[14C]-Elacytarabine|Single intravenous administration
224007612|NCT01072630|DRUG|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
224007613|NCT01072630|DRUG|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
224007614|NCT03301441|OTHER|questionnaire ef-ID Migraine|"All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status."
224007615|NCT05183529|DEVICE|Vitals Monitoring Pill System|The Celero Vitals Monitoring Pill (VM Pill) uses 3 axis accelerometry to measure physiological signals from within the GI tract.
224007616|NCT01232738|DRUG|rasagiline|rasagiline 2 mg daily for 12 months
223387957|NCT05436730|DEVICE|Sphygmocor|Assessment of the arterial stiffness
224007617|NCT01341054|OTHER|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
224007618|NCT01341054|OTHER|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
224007619|NCT00683683|BEHAVIORAL|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
224007620|NCT00338962|DRUG|paroxetine|paroxetine (40mg/day)
224007621|NCT00338962|DRUG|desipramine|200 mg per day
223387958|NCT05436730|DEVICE|VaSera-VS|Assessment of the arterial stiffness
223730196|NCT03160534|OTHER|preoperative exercise|Each intervention session contains a stretching part and aerobic training
223730197|NCT03025867|DRUG|Niraparib|
223730198|NCT03472027|BIOLOGICAL|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
224007622|NCT00338962|DRUG|Naltrexone|50 mg per day
224007623|NCT00338962|DRUG|Placebo|placebo
224007624|NCT05178069|DRUG|: Placebo for Probiotic|Capsule manufactured without active ingredients.
224007625|NCT05178069|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus G
223387959|NCT05436730|DEVICE|Somnocheck|Assessment of the sleep breath disturbances
223387960|NCT03530839|PROCEDURE|Arthrodesis|see study group description
223387961|NCT03530839|PROCEDURE|Resection arthroplasty|see study group description
223387962|NCT03590210|DRUG|Trabectedin|Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
223387963|NCT03590210|DRUG|Nivolumab|Cycle 2 to 16 240 mg IV over 30 minutes, q3w
223730199|NCT03134989|DEVICE|Cochlear implant|Study involves measuring using Electrocochleography to measure the CM response in patients undergoing cochlear implant surgery
224007626|NCT03121209|PROCEDURE|Revascularization|Patients in this arm are randomized to CEA/CAS plus IMM
223387964|NCT01436955|DRUG|Placebo|multiple oral doses
224007627|NCT03121209|OTHER|Intensive Medical Management (IMM) alone|Patients in this arm are randomized to intensive medical management (IMM) alone
224007628|NCT03214640|DEVICE|Rivanna Accuro US Device|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group C-R or L-R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
224007629|NCT03214640|OTHER|Palpation|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Palpation method using conventional landmarks (spinous process and iliac crest). For subjects in group C-P or L-P, the needle insertion site will be the site identified by the Palpation method. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
224007630|NCT03214640|PROCEDURE|Neuraxial Analgesia|Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
224007631|NCT03214640|PROCEDURE|Spinal Block|Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
224007632|NCT03415737|OTHER|Questionnaire|Profile Fitness Mapping Neck Questionnaire
224007633|NCT04529772|DRUG|acalabrutinib|Investigational Product
224007634|NCT04529772|DRUG|placebo|Placebo comparator
224007635|NCT04529772|DRUG|Prednisone|Investigational Product
224007636|NCT04529772|DRUG|Rituximab|Investigational Product
224007637|NCT04529772|DRUG|Cyclophosphamide|Investigational Product
224007638|NCT04529772|DRUG|Vincristine|Investigational Product
223730200|NCT03451344|OTHER|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
224007639|NCT04529772|DRUG|Doxorubicin|Investigational Product
224007640|NCT04565275|DRUG|Drug ICP-192|"1. Dose Escalation Phase ICP-192 will be taken by patients with advanced solid tumor and will be treated follow the 3+3 dose escalation scheme~2. Dose Expansion Phase ICP-192 will be taken by patients with urothelial carcinoma or cholangiocarcinoma with FGFR gene alterations and will be treated at a single dose defined from the Dose Escalation Phase."
224007641|NCT02147899|DRUG|SYM-1219|Oral
224007642|NCT02147899|DRUG|Placebo|Oral
224007643|NCT06340477|OTHER|Thoracic SNAGs with conventional therapy|"Thoracic (T1- T5) SNAGs 3 repetitions x 1 set, 2 days/week Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
224007644|NCT06340477|OTHER|conventional therapy|"Hot pack for 10 minutes Stretching of upper trapezius, levator scapulae, 5 reps x 1 set x 15 sec hold 2 days/week and Pectoralis Major 10 reps x 1 set x 10 sec hold~Strengthening of deep neck flexors and shoulder retractors (rhomboids) 10 reps x 1 set x 10 sec hold 2 days/week 2 days/week"
224007645|NCT04329468|DEVICE|DS-MCE|"The subjects swallowed the MCE to investigate the esophagus repeatedly by pulling up or down the string. After completion of the esophageal examination, MCE reached the stomach and was lifted away from the posterior wall, rotated if necessary and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination, the capsule would enter the duodenum due to peristalsis when the pylorus opened. Then DS-MCE tried to inspect the duodenum repeatedly under the string and magnetic field control, including view of major papilla in the descending part of duodenum and retrograde view of pylorus in duodenal bulb with a 360-degree automatic scanning mode. After completion of the duodenum examination, the capsule started to view the small bowel."
224007646|NCT03303768|DIAGNOSTIC_TEST|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
224007647|NCT03342989|BEHAVIORAL|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
224007648|NCT03342989|BEHAVIORAL|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
224007649|NCT05716295|DRUG|MDK-703|MDK-703 will be administered as specified under Arm description.
223387965|NCT01436955|DRUG|RG1662|Cohorts receiving multiple oral doses
223387966|NCT02262455|DRUG|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
224007650|NCT05716295|DRUG|Checkpoint Inhibitor, Immune|Checkpoint inhibitor will be administered as specified under Arm description.
224007651|NCT02580721|DEVICE|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
224007652|NCT01791075|DEVICE|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
224296037|NCT06123260|DIAGNOSTIC_TEST|renal function tests|BUN, eGFR , CBC , Electrolytes , Liver function tests
224296038|NCT05886231|OTHER|music sound therapy|investigate the effects of music on intraoperative hemodynamic parameters, anesthesia depth, muscle relaxant consumption, analgesic consumption and pain and side effects (nausea, vomiting, tremor) in the early postoperative period in patients undergoing thyroidectomy operation under general anesthesia.
224296039|NCT03221231|DRUG|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
224296040|NCT03221231|DRUG|Placebo Oral Tablet|twice daily, placebo
223387967|NCT02262455|DRUG|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
224007653|NCT01791075|DEVICE|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
224007654|NCT04538560|PROCEDURE|polar body biopsy|Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.
224007655|NCT00036387|DRUG|Infliximab|
224007656|NCT05684744|DRUG|Roflumilast|The patients will receive oral roflumilast in a dose of 500 mcg per day for 12 weeks
224007657|NCT05684744|DRUG|Methotrexate|The patients will receive methotrexate in a dose of 0.2- 0.4 mg/kg/week for 12 weeks
224007658|NCT06198322|OTHER|Platelet-rich Fibrin|Platelet-rich Fibrin will be injected distal to the canine on the experimental side
224007659|NCT06198322|OTHER|Vitamin D3|Vitamin D3 will be injected distal to the canine on the experimental side
224007660|NCT03401008|OTHER|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
224007661|NCT02982824|DIETARY_SUPPLEMENT|Magnesium|Oral magnesium
224007662|NCT02982824|DRUG|Placebo - Concentrate|Placebo will be given
224007663|NCT03472716|PROCEDURE|Biological Samples|"5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)"
224007664|NCT01998074|DIETARY_SUPPLEMENT|extensively hydrolyzed rice protein formula|
223387968|NCT00442208|DRUG|PN 200|
223387969|NCT00074308|DRUG|imatinib mesylate|Given orally
223387970|NCT00074308|BIOLOGICAL|bevacizumab|Given IV
223387971|NCT00074308|OTHER|pharmacological study|Correlative studies
223387972|NCT00074308|OTHER|laboratory biomarker analysis|Correlative studies
224007665|NCT04734054|DEVICE|Modified Hyrax Palatal Expander|The rapid maxillary expansion will be performed. The expansion should be accomplished between 10 to 15 days at most. The screw is going to be turned in a rapid manner.
224007666|NCT04734054|DEVICE|Removable Palatal Expander|The slow maxillary expansion will be performed. The expansion will be performed in a slow manner. Patients may need between 6 to 8 months to achieve the required expansion.
223387973|NCT01910818|DEVICE|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
223387974|NCT01910818|OTHER|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
223387975|NCT05669235|DIAGNOSTIC_TEST|Questionnaires|A series of questionnaires will be carried out that assess both respiratory problems, depression and strength.
223387976|NCT03595956|OTHER|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
223387977|NCT02521415|DRUG|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
223387978|NCT02521415|DRUG|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
223387979|NCT02521415|DRUG|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
223387980|NCT04068493|BEHAVIORAL|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
223387981|NCT00614640|BIOLOGICAL|DermaVir patch|DNA Vaccine
223387982|NCT00614640|BIOLOGICAL|Placebo patch|10% dextrose (D-glucose) solution
223387983|NCT02543944|DRUG|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detoxification and transition to depot naltrexone.
223387984|NCT02543944|DRUG|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
223387985|NCT02543944|DRUG|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
223387986|NCT02543944|DRUG|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
224007667|NCT01580891|DRUG|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
224007668|NCT01580891|DRUG|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
224007669|NCT01580891|DRUG|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
224007670|NCT02427945|BEHAVIORAL|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
224007671|NCT02427945|BEHAVIORAL|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
224007672|NCT03479853|PROCEDURE|Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
224007673|NCT01129700|RADIATION|Radiation: short-course preoperative chemoradiotherapy|"Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day)."
224007674|NCT02917603|BEHAVIORAL|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
224007675|NCT01941433|BEHAVIORAL|Arthritis Health Journal|
224296041|NCT03221231|OTHER|Magnetic Resonance Imaging|
224296042|NCT03221231|OTHER|Neurocognitive measures|
224296043|NCT03221231|OTHER|Neuro-inflammatory measures|
223387987|NCT02543944|DRUG|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
223387988|NCT02543944|DRUG|Placebo|Microcrystalline cellulose
223387989|NCT00172029|DRUG|Zoledronic acid|
223387990|NCT01612065|DRUG|Misoprostol|200 ug
223387991|NCT01612065|DRUG|Misoprostol|Misoprostol vaginally, 400 ug
223387992|NCT04555434|DIETARY_SUPPLEMENT|Probiotics|"* Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose"
223387993|NCT03266796|BEHAVIORAL|goal setting process|goal setting process during the first consultation
223387994|NCT05963724|DEVICE|Real-Time Computer Aided Detection|This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)
224007676|NCT05619757|BEHAVIORAL|Compliance with medical treatment for endometriosis|"During their scheduled consultation at the Hôpital Femme Mère Enfant (HFME), women who meet the eligibility criteria will be presented with the study and given the written information note. If they agree to participate, the investigator will give them a QR code redirecting them to the online self-questionnaire.~Patients will be included once they log in and complete the questionnaire."
224007677|NCT03714087|DEVICE|T1 before aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
224007678|NCT03714087|OTHER|T2 after the aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
223387995|NCT05963724|PROCEDURE|Stanford Colonoscopy|This involves white-light colonoscopy
223387996|NCT06191588|PROCEDURE|INFANT CIMT/BIT|Constraint induced movement therapy (CIMT) and Bimanual Intensive therapy (BIT)
223387997|NCT01117974|PROCEDURE|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
223387998|NCT00149474|BEHAVIORAL|Peak Flow Monitoring|
223387999|NCT04163965|DEVICE|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
223388000|NCT03347201|DEVICE|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
223388001|NCT02766114|PROCEDURE|Carpal tunnel release through Mini Transverse Approach|Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
223730201|NCT03451344|OTHER|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
223730202|NCT00569296|BIOLOGICAL|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
224007679|NCT03714087|OTHER|Historic control group|
224007680|NCT02006524|DEVICE|'MyDiagnostick|
224007681|NCT01253018|BEHAVIORAL|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
224007682|NCT01253018|BEHAVIORAL|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
224007683|NCT01555476|DRUG|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
224007684|NCT01555476|DRUG|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
224296044|NCT00962884|DEVICE|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
223388002|NCT04001036|DRUG|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
223388003|NCT04001036|DRUG|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
223388004|NCT00200902|DRUG|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
223388005|NCT00200902|OTHER|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
223388006|NCT00200902|BEHAVIORAL|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
223388007|NCT05924321|DRUG|Carbetocin|Single infusion of Carbetocin
223730203|NCT00569296|BIOLOGICAL|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
224126000|NCT05267353|BEHAVIORAL|Exercise intervention program|"It was developed, along with usual care, to prevent restricted ROM in both upper body and limited general physical functioning. Patients in exercise intervention group received verbal instructions about stretching major muscles and phsical activity recommendations from a trained nurse (intervenor), and then received the booklet plus DVD.~The physical therapist who developed and adjusted this program also trained the intervenor. After verifying the intervenor has performed exercise interventions were consistent with the physical therapist, he/she was responsible for all interventions. Therefore, if pain or discomfort persists for more than an hour, the patient should inform the intervenor. The intervention group patients also received telephone follow-up from the intervenor every two weeks until the end of the intervention."
224296045|NCT00962884|DEVICE|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
224296046|NCT04858659|DRUG|PK101|1 tablet at each time, 2 times a day
224296047|NCT04858659|DRUG|PK101-002|1 tablet at each time, 2 times a day
223388008|NCT05924321|DRUG|Placebo|Single IV infusion of matching placebo
223388009|NCT05924321|DRUG|Placebo and Moxifloxacin|Single IV infusion of matching placebo in combination with Single Oral dose of Moxifloxacin
223388010|NCT06382532|DIAGNOSTIC_TEST|Niacin skin reaction test|Nicotinic skin reaction, also known as nicotinic flush reaction, occurs when a solution of nicotinic acid methyl ester briefly contacts the skin. Following penetration through the skin barrier into the subcutaneous tissue, it generates nicotinic acid (vitamin B3). Under the action of phospholipase A2 (PLA2), cyclooxygenase (COX), and other enzymes, arachidonic acid (AA) on the cell membrane is cleaved to produce prostaglandins, leading to local vasodilation, increased blood perfusion, and the transient appearance of erythema on the skin.
223388011|NCT00470535|DRUG|erlotinib hydrochloride|Oral
223388012|NCT00470535|OTHER|immunohistochemistry staining method|Correlative Study
223388013|NCT00470535|OTHER|laboratory biomarker analysis|Correlative Study
223388014|NCT04648787|BEHAVIORAL|family-integrated care|One week after admission, the parents of premature infants were informed by telephone one day in advance to enter the ward for family participation nursing, and the guidance of daily life nursing for premature infants was given on the same day, including hand hygiene, breast feeding, pacification, changing diapers, bathing and establishment of parent-child relationship. Before discharge, theparents of premature infants should be informed by telephone one day in advance to enter the ward again for family participation nursing, and half a day's guidance was given, including observation and treatment of common symptoms and signs, guidance of home safety prevention and learning to write diary of premature infants.
224007685|NCT03520101|PROCEDURE|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is \>18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
223388015|NCT04648787|BEHAVIORAL|traditional nursing|In hospital education: the health education manual for premature infants will be issued at the time of discharge; the patient's condition will be answered by telephone from 14:00 to 16:00 every day.
224007686|NCT03520101|PROCEDURE|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
224007687|NCT06000033|DRUG|Disitamab Vedotin+Anlotinib|Disitamab Vedotin:2 mg/kg，ivgtt，d1-14/28day/cycle Anlotinib: 12mg once daily (taken before meals) orally, continuously for 2 weeks followed by a 1-week break. Each cycle consists of 21 days.
224007688|NCT03331913|DRUG|Botulinum Toxin type A (intradermal / submucosal injection at pain area)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
224007689|NCT03331913|DRUG|Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
223388016|NCT06392529|DRUG|Voriconazole Powder|The drug will be topically applied for vagina of patients suffering from vaginal Candidasis albican
224296048|NCT04858659|DRUG|PK101 placebo|1 tablet at each time, 2 times a day
224296049|NCT04858659|DRUG|PK101-002 placebo|1 tablet at each time, 2 times a day
224296050|NCT01702077|PROCEDURE|Neurofeedback|
223388017|NCT02531529|DRUG|dexmedetomedine|intraoperative infusion
223388018|NCT02531529|DRUG|Fentanyl|
223388019|NCT06551792|OTHER|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection|Effect of Serum Magnesium Level on the Success of Transforaminal Epidural Steroid Injection
223388020|NCT01299012|DRUG|Liraglutide|Liraglutide s/c 0.6mg once daily.
223730204|NCT00569296|BIOLOGICAL|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
224007690|NCT00002248|DRUG|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
224296051|NCT01702077|PROCEDURE|Sham feedback|
224296052|NCT01216098|BEHAVIORAL|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
224296053|NCT00168090|DRUG|Blood coagulation Factor VIII and vWF, human|
224299126|NCT06408883|DEVICE|Vibrabot capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
224007691|NCT03449901|DRUG|pegylated arginine deiminase|-Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
224007692|NCT03449901|DRUG|Gemcitabine|-Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
224007693|NCT03449901|DRUG|Docetaxel|-Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
224007694|NCT03449901|PROCEDURE|Tumor biopsy|"* Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~* Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort"
224007695|NCT03449901|PROCEDURE|Research blood draw|-Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
224007696|NCT02185001|PROCEDURE|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
224007697|NCT02185001|PROCEDURE|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
224007698|NCT06424431|PROCEDURE|stapler combined with electrocautery|Closure with a closure device combined with electrocoagulation for pancreatic stump closure in distal pancreatectomy
224007699|NCT06424431|PROCEDURE|simple closure with a closure device|Simple closure with a closure device for pancreatic stump closure in distal pancreatectomy
224007700|NCT06046105|DRUG|Administering intraperitoneal bupivacaine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
224007701|NCT06046105|DRUG|Administering intraperitoneal bupivacaine plus Dexmedetomidine for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Dexmedetomidine injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
224007702|NCT06046105|DRUG|Administering intraperitoneal bupivacaine plus Ibuprofen for pain control after laparoscopic gynecological procedures|"All patients will receive a standardized general anesthetic. Intravenous induction will be achieved with propofol, fentanyl (up to 2 µg/kg), rocuronium 0.6 mg/kg, and ondansetron 4 mg.~Anesthesia will be maintained with 50% oxygen/ air mixture and isoflurane, intravenous fentanyl boluses (up to 3 µg/kg), rocuronium to maintain muscle relaxation, and intravenous fluids administered as Ringer's lactate (minimum of 20 mL/kg).~All incision sites were infiltrated with 0.25% bupivacaine, and CO2 insufflation pressure was limited to a maximum of 15 mmHg.~At the end of the procedure bupivacaine plus Ibuprofen injection will be given by the surgeon through trocars intraperitoneally.~Patients will be transferred to the post-anesthetic care unit (PACU) and the Modified Aldrete Score will be assessed and discharged after fulfilling an Aldrete score of ≥9.~During the first 24 hr. after surgery, all patients will receive 1 gm paracetamol i.v. every 8 hr."
224007703|NCT03466073|DRUG|Recombinant Human Plasma Gelsolin|Recombinant human plasma gelsolin lyophilized for reconstitution, reconstituted in sterile water
224126001|NCT00528346|BEHAVIORAL|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies-allowing them to view their brain activity.
224299127|NCT02982798|DRUG|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
223388021|NCT01108614|BEHAVIORAL|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
223388022|NCT01951924|DRUG|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
223388023|NCT01951924|DRUG|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
223388024|NCT05688917|DIETARY_SUPPLEMENT|Green coffee been extract|supportive treatment
223388025|NCT05688917|OTHER|Placebo|Placebo capsule
224007704|NCT03466073|OTHER|Normal Saline Placebo|Normal saline in volume equivalent to drug
224007705|NCT03269682|DEVICE|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
224126002|NCT00528346|BEHAVIORAL|placebo|Some participants will see simulated data that does not come from their own brains.
224126003|NCT02500199|DRUG|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
224126004|NCT05580172|DRUG|RH324|polymolecular
224299128|NCT02982798|DRUG|JLP-1310|administration of JLP-1310
224299129|NCT05019820|OTHER|Knee strengthening exercises with isokinetic dynamometer|18 sessions of strengthening exercises around the knee with an isokinetic dynamometer 3 days a week
223388026|NCT04463758|OTHER|An auto-questionnaire comprising three psychometric scales|"three psychometric scales validated in French: \_depression (Edinburgh Postpartum Depression Scale (EPDS)), anxiety (State-Trait Anxiety Inventory (STAI)~\- and Impact of Event Scale (Revised) (IES-R)"
223388027|NCT04016519|OTHER|Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
223388028|NCT03348332|BEHAVIORAL|Exercise pregnant women|A supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
223388029|NCT00308178|DRUG|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
223388030|NCT04658134|DIETARY_SUPPLEMENT|Glycine|Oral glycine tablets (100 mg/kg/day) in divided doses
223388031|NCT01669187|OTHER|Education brochure|
223388032|NCT01669187|OTHER|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
223388033|NCT00186732|PROCEDURE|Subcuticular Suture|
223388034|NCT00186732|PROCEDURE|Surgical Staples|
223388035|NCT05262387|DRUG|Lyumjev with 50% basal rate reduction|Administered SC.
223388036|NCT05262387|DRUG|Humalog with 50% basal rate reduction|Administered SC.
224007706|NCT00744757|DRUG|Decitabine|Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
224007707|NCT02249598|BIOLOGICAL|lactamica|
223388037|NCT05262387|DRUG|Humalog with 100% basal rate reduction|Administered SC.
223388038|NCT05262387|DRUG|Lyumjev with 100% basal rate reduction|Administered SC.
223388039|NCT06128161|DEVICE|Hearing Aid|Contralateral Hearing Aid to Cochlear Implant
223388040|NCT02941471|DEVICE|Interferential Stimulation|Transabdominal interferential electrcial stimulation
224007708|NCT02249598|BIOLOGICAL|Placebo|
224007709|NCT01600248|BEHAVIORAL|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
224007710|NCT03682302|DRUG|Exparel|EXPAREL 4mg/kg (maximum 266 mg)
224299130|NCT05019820|OTHER|Strengthening around the knees with home exercise programe|18 sessions of strengthening exercises for the muscles around the knee at home, 3 days a week
223388041|NCT02941471|DEVICE|TENS stimulation|Transabdominal standard electrical stimulation
223388042|NCT01437293|DRUG|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
223388043|NCT00055731|DRUG|bicalutamide|
223388044|NCT00055731|DRUG|Goserelin Acetate|
223388045|NCT00055731|DRUG|docetaxel|
223388046|NCT00055731|DRUG|Estramustine phosphate sodium|
223388047|NCT00055731|DRUG|acetylsalicylic acid|
223388048|NCT00055731|PROCEDURE|conventional surgery|
223388049|NCT00055731|RADIATION|radiation therapy|
223388050|NCT02070965|DRUG|DFD01 Spray|
223388051|NCT02070965|DRUG|Comp01 Lotion|
223388052|NCT03256604|DIAGNOSTIC_TEST|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
223388053|NCT03693417|DEVICE|Heated circuit on|Heated circuit will be turned on.
223388054|NCT03693417|DEVICE|Heated circuit off|Heated circuit will be turned off.
223388055|NCT05523115|DIETARY_SUPPLEMENT|Heights Smart Supplement|"The ingredient list of the product includes the following:~Algae oil Blueberry Extract Methylcobalamin (Vitamin B12) Cholecalciferol (Vitamin D3) Ascorbic acid (Vitamin C) Retinol acetate (Vitamin A) Calcium L-methylfolate (Folic Acid) D-biotin Pyridoxine hydrochloride (Vitamin B6) Calcium pantothenate (Vitamin B5) Nicotinamide (Vitamin B3) Riboflavin (Vitamin B2) Thiamine hydrochloride (Vitamin B1) D-Alpha tocopheryl acetate (Vitamin E) Chromium picolinate Potassium iodide Iron Citrate Sodium selenite Zinc citrate"
223388056|NCT04756947|PROCEDURE|surgical treatment according to standard indication criteria|internal fixation according to standard indication criteria
224007711|NCT03682302|DRUG|0.5% Bupivacaine HCl|Bupivacaine HCl 2mg/kg
224007712|NCT02832401|DRUG|Caffeine|
224007713|NCT02832401|DRUG|Placebo|
224007714|NCT02707549|DRUG|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
224007715|NCT02707549|DRUG|0.9% sodium chloride|
224007716|NCT03083418|DEVICE|control group|No EDP treatment
224007717|NCT03083418|DEVICE|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
223388057|NCT04756947|PROCEDURE|conservative treatment according to standard indication criteria|conservative therapy according to standard indication criteria
223388058|NCT00771498|DRUG|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
223388059|NCT02515331|DRUG|LHW090|Capsule - oral dose
224007718|NCT02054559|DRUG|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
224007719|NCT02054559|RADIATION|Radiotherapy|
224007720|NCT03091231|DIAGNOSTIC_TEST|mpUS multiparametric Ultrasound|compare the mpUS to other methods
224007721|NCT06305754|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg via IV infusion
224007722|NCT06305754|DRUG|Pemetrexed|500 mg/m\^2 via IV infusion
224007723|NCT06305754|DRUG|Carboplatin|AUC 5 mg/mL\*min via IV infusion
224007724|NCT06305754|DRUG|H1 Receptor Antagonist|Administered as rescue medication per approved product label
224007725|NCT06305754|DRUG|H2 Receptor Antagonist|Administered as rescue medication per approved product label
224007726|NCT06305754|DRUG|Acetaminophen (or equivalent)|Administered as rescue medication per approved product label
224007727|NCT06305754|DRUG|Dexamethasone (or equivalent)|Administered as rescue medication per approved product label
224007728|NCT06305754|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered as rescue medication per approved product label
224007729|NCT05010018|BEHAVIORAL|Web-based application connecting small food store owners and suppliers of healthier foods and beverages|The primary intervention is a web-based app that connects small food store owners in low income Baltimore with suppliers of healthier foods and beverages. To reduce costs associated with small purchasing quantities by corner stores, and high delivery charges, the BUD app uses collective purchasing and shared delivery strategies. BUD will be implemented in four stages, where each stage promotes different food/beverage items and introduces new features. The app will be bundled with a small subsidy in stages 1-2 to encourage initial use, increase familiarity with the app and reduce risk. Trainings in the use of the app will take place at the beginning of each phase. BUD will use collective purchasing at stage 2 of implementation (BuddyUp!). The BuddyLift! feature will start in stage 3, enabling small store owners to deliver BuddyUp! deals to other stores for an additional discount. Participating stores and wholesalers will receive point of purchase materials to promote BUD products.
224007730|NCT05271604|BIOLOGICAL|Ozuriftamab Vedotin|Conditionally active biologic anti-ROR2 antibody drug conjugate
224126005|NCT01519622|OTHER|Questionnaire|Questionnaire to be distributed among sick elderly in the community
224126006|NCT05685368|BEHAVIORAL|ACT for Race Related Stress|This intervention will be guided by: Payne, J. S. (2022). Out of the Fire: Healing Black Trauma Caused by Systemic Racism Using Acceptance and commitment Therapy New Harbinger Publications, Inc.
223388060|NCT02515331|DRUG|Placebo|Capsule - oral dose
224007731|NCT05271604|BIOLOGICAL|Pembrolizumab|PD-1 inhibitor
224007732|NCT05271604|BIOLOGICAL|Evalstotug (BA3071)|Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody
224007733|NCT05271604|BIOLOGICAL|Cetuximab|Epidermal growth factor receptor (EGFR) antagonist
224007734|NCT03863015|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
224007735|NCT03863015|DRUG|isotonic saline|A one hour infusion of 100mL isotonic saline
224007736|NCT03655457|DEVICE|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
224007737|NCT03655457|DEVICE|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
224007738|NCT06053450|OTHER|Oil Inhalation Patch|Each participant will wear a patch for a work week (3 worked shifts) and then no patch is worn for a week. This alternates for a total of a month.
224007739|NCT05781126|DIAGNOSTIC_TEST|The Spatial Hearing Questionnaire, MINI-MENTAL STATE EXAMINATION, International Outcome Inventory - Hearing Aid, Glasgow Hearing Aid Benefit Profile, BECK-II and STAI questionnaires|a) medical history record, b) ENT examination, c) pure tone audiogram and speech audiometry (with and without the hearing amplification) d) listening effort evaluation (with and without the hearing amplification) Self-report and behavioral methods will be used: Evaluation of subjective performance (Spatial Hearing Questionnaire (SHQ) Evaluation of time response in auditory message Evaluation of speech comprehension with background noise or a competitive speaker e) cognitive function evaluation by using the Greek version of Mini-Mental State Examination, f) evaluation of hearing-aid satisfaction, by using the Glasgow Hearing Aid Benefit Profile (GHABP), and International Outcome Inventory - Hearing Aid (IOI-HA), questionnaires and g) evaluation of stress level and depression by using BECK-II and STAI questionnaires.
224007740|NCT04812197|PROCEDURE|Biospecimen Collection(Punch Biopsy)|Punch Biopsy of Skin
224126007|NCT03116399|BEHAVIORAL|PRISM 2.0 Condition|Access to the PRISM 2.0 program
224126008|NCT03116399|BEHAVIORAL|Tablet Condition|Access to the tablet
224126009|NCT03450369|BIOLOGICAL|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
224126010|NCT05873153|BEHAVIORAL|Health Education|Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.
224126011|NCT05873153|OTHER|Home Blood Pressure Monitor|Blood pressure cuff for home use
224126012|NCT01237808|DRUG|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
224126013|NCT01237808|DRUG|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
224299253|NCT01305395|DRUG|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
224007741|NCT06445764|OTHER|e-learning|Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.
223388061|NCT06551597|PROCEDURE|Extremely low frequency electromagnetic fields stimulation|"* In Group MT1, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - head, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* In Group MT2, patients will undergo 10 sessions (over 10 consecutive days excluding weekends) of low-frequency magnetotherapy (exposure site - pelvis, 40 Hz, 5 mT) as addition to standard neurological rehabilitation.~* The control group participants will receive only neurological rehabilitation."
223388062|NCT00124748|DRUG|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
223388063|NCT05125640|DRUG|"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"|Orally, with 240 mL of water at dosing in sitting position
224007742|NCT06445764|OTHER|Virtual reality training|Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
224126014|NCT01237808|DRUG|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
224126015|NCT03860727|DIAGNOSTIC_TEST|Welch Allyn IExaminer|Fundus Examination
224296054|NCT06817538|BEHAVIORAL|Physiotherapy/Exercise Program|"Arm 1: Scoliosis-Specific Exercises Combined with Dual-Task Cognitive Training Participants with idiopathic scoliosis in this group received scoliosis-specific physiotherapeutic exercises combined with dual-task cognitive training. The intervention included motor exercises performed on balance boards and stability trainers to enhance postural control. While engaging in these motor exercises, participants simultaneously performed cognitive tasks such as word recall, identifying cities or countries starting with a given letter, and other memory-based games. This dual-task approach aimed to improve both motor and cognitive functions.~Arm 2: Scoliosis-Specific and Motor Exercises Only~Participants with idiopathic scoliosis in this group performed scoliosis-specific physiotherapeutic exercises along with motor exercises aimed at improving postural stability. The motor exercises were conducted using balance boards and stability trainers, focusing solely on physical performance without the"
224296055|NCT00443482|DRUG|formoterol|
224296056|NCT04224727|BEHAVIORAL|Group Commitment Contract|A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
224296057|NCT04224727|BEHAVIORAL|Individual Monetary Rewards|Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
224296058|NCT04224727|BEHAVIORAL|Individual Commitment Contract|Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
224296059|NCT04224727|OTHER|Information|"In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates."
224007743|NCT00175201|PROCEDURE|Proactive care and rehabilitation|
224007744|NCT04812002|DRUG|PD-1 inhibitor， bevacizumab|Both drugs are given intravenously
224007745|NCT01585155|DRUG|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
223388064|NCT05125640|DRUG|Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)|Orally, with 240 mL of water at dosing in sitting position
224007746|NCT00422812|DRUG|Inhaled Placebo|Inhaled Staccato Placebo
223388065|NCT04069650|PROCEDURE|Free flap|Free flap reconstruction of the oral cavity
224007747|NCT00422812|DRUG|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
224007748|NCT00422812|DRUG|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
224007749|NCT00422812|DRUG|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
224007750|NCT02318459|OTHER|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
224007751|NCT02318459|OTHER|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
224007752|NCT05660291|BEHAVIORAL|Early time-restricted eating|Subjects can eat whatever they want between the hours of 8:00 AM and 4:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 4:00 PM to 8:00 AM).
224007753|NCT05660291|BEHAVIORAL|Late time-restricted eating|Subjects can eat whatever they want between the hours of 12:00 PM and 8:00 PM and can only consume water, black coffee/tea, or other zero calorie drinks (artificial sweeteners are okay) outside your designated eating window (from 8:00 PM to noon).
224007754|NCT03921385|DEVICE|Augmented Reality Headset|Patients undergoing navigated cranial or spine procedures will acquire standard of care clinical high-resolution imaging to be used for registration purposes intraoperatively. VGA output on the navigation machine will be utilized to project imaging information to the augmented reality headset. The holographic image will then be recorded to assess feasibility and ease of use.
224007755|NCT02140840|DRUG|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
224007756|NCT03772587|DRUG|M281|M281 administered as IV infusion
224007757|NCT03772587|OTHER|Placebo|Placebo administered as intravenous (IV) infusion
224007758|NCT06150274|DEVICE|Percutaneous Balloon Mitral Valvulotomy|Stenotic mitral valve will be dilated to open the commissures
224007759|NCT06259578|BIOLOGICAL|INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg|1 dose of 0.5 ml containing inactivated SARS-CoV-2 virus (5 μg ), Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride
224007760|NCT04613544|DEVICE|Voice Assist Arrhythmia Monitoring (VAAM)|application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
224126016|NCT02304536|DRUG|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
224126017|NCT02304536|PROCEDURE|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
223388066|NCT05620446|PROCEDURE|endoscopy|the technique was done by two doctor the patients were sedated then colonoscopy was done for the patients while the patients were put in lithotomy position , we identified the site of sigmoid colon fixation by radiological colongraphy then tip of artery forceps was moved at outer skin at anterior abdominal wall at left lower quadrant to meet tip of colonscopy at multiple point where fixation was done . fixation was done by exploratory puncture of skin by scalpel about (2-3 mm puncture) at site of these points then widening the puncture by artery forceps at level of subcutaneous tissue. A 2- shot anchor device was used to fix the sigmoid colon against anterior abdominal wall. The 2-shot anchor device was passed through the puncture to be entered inside the sigmoid colon and the thread with a metal T-bar was detachd and pulled towards the anterior abdominal wall. This was repeated at multiple point of fixation .
223388067|NCT06195137|DIETARY_SUPPLEMENT|Caffeine|caffeine supplementation
223388068|NCT06195137|DRUG|Alpha Lipoic Acid|600-800 mg ALA
223388069|NCT04582032|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|intravenous dexketoprofen (KETAVEL 50 mg/2 ml)
223388070|NCT04582032|DRUG|Saline (Isotonic Saline Solution 0.9% )|intravenous 2 ml of saline
223388071|NCT00758524|DRUG|LCI699|LCI699 oral capsules
223388072|NCT00758524|DRUG|Eplerenone|Eplerenone oral capsules
224007761|NCT03613376|OTHER|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
224007762|NCT05355948|DEVICE|MEMO Patch PLUS for 1 day|Individuals randomized to one-day monitoring will wear MEMO Patch PLUS for 1 day. After that, confirm the monitoring result and carry out a fixed schedule.
224007763|NCT05355948|DEVICE|MEMO Patch PLUS for More than 8-days|Individuals randomized to More than 8-days monitoring will wear MEMO Patch PLUS for 8 days \~ 14 days at their voluntarily. After that, confirm the monitoring result and carry out a fixed schedule.
224007764|NCT03691909|BIOLOGICAL|HB-adMSCs|Hope Biosciences autologous adipose-derived mesenchymal stem cells
224007765|NCT05510687|DEVICE|Glasses to correct presbyopia|Participants will receive eyeglasses to correct presbyopia, as per the power determined in the eye examination.
224296060|NCT05125562|DRUG|ExoFlo|Patients will be randomized to one of three infusions: (1) Normal Saline 100 mL, (2) Normal saline 90 mL and ExoFlo 10 mL, which is 7x1011 EVs, and (3) Normal saline 85 mL and ExoFlo 15 mL, which is 10.5x1011 EVs. The study intervention will only be dosed on day=1
224296061|NCT02758860|PROCEDURE|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
223388073|NCT00758524|DRUG|LCI699-matching Placebo|LCI699-matching placebo oral capsules
223388074|NCT00758524|DRUG|Eplerenone-matching Placebo|Eplerenone-matching placebo oral capsules
223388075|NCT06025071|DRUG|colchicine|Dosage form: Tablets; Dosage: 0.5mg; Frequency: Once daily; Duration: From randomization to one-year follow-up is completed.
223388076|NCT00190762|DRUG|Pemetrexed|
223388077|NCT06551532|OTHER|Multicomponent program|Lumbopelvic training (foam rolling, manual therapy, mobility, posture, and strength training) and sprint technique program.
223388078|NCT01269918|DRUG|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
223545696|NCT05285228|BEHAVIORAL|effect of choice on cooperation (pseudoalternative)|For the test group, before the standard check-up starts, the participant is given the choice of selecting the taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint), which will be applied at the end of the visit. Post-placement instructions provided by the manufacturer will be given to the caregiver and the child and questionnaires will be handed out.
224007766|NCT05631964|DRUG|BL-M07D1|Administration by intravenous infusion
224007767|NCT05238376|BEHAVIORAL|Exercise training|12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
224007768|NCT06356311|BIOLOGICAL|Sacituzumab tirumotecan|Participants will receive sacituzumab tirumotecan as 4mg/kg IV infusion on days 1, 15, and 29 of every 42-day cycle.
224007769|NCT06356311|DRUG|Trifluridine-Tipiracil|Trifluridine-tipiracil will be administered at 35 mg/m\^2 as tablet orally twice a day on days 1-5 and 8-12 of every 28-day cycle.
224007770|NCT06356311|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m\^2 by IV infusion on days 1 and 15 of every 28-day cycle.
224007771|NCT06356311|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m\^2 by IV infusion on days 1, 8 and 15 of every 28-day cycle.
224007772|NCT06356311|DRUG|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m\^2 by IV infusion on day 1 of a 21-day cycle.
224007773|NCT06356311|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
224126018|NCT02868216|BEHAVIORAL|anger management training|
224126019|NCT06084325|DEVICE|Respiration resistance sensitivity task (RRST)|The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
224299254|NCT02599636|OTHER|None intervention|Investigators will study the usual medical assistance
223545697|NCT05285228|BEHAVIORAL|given fluoride varnish (control)|For the control group the participant is provided with a given taste of the fluoride varnish (Profluorid VOCO, Germany) from a range of about five flavors (Melon, Caramel, Cherry, Bubble gum, Mint) according to the randomization list.
224007774|NCT06356311|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Supportive care measures may include but are not limited to antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
224007775|NCT04655976|BIOLOGICAL|Cobolimab|Cobolimab will be administered.
224007776|NCT04655976|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
224007777|NCT04655976|DRUG|Docetaxel|Docetaxel will be administered.
224007778|NCT05452278|OTHER|Product A|Tobacco-free pouch, 14 mg nicotine/pouch, used for 20 minutes
224007779|NCT05452278|OTHER|Product B|Tobacco-free pouch, 16 mg nicotine/pouch, used for 20 minutes
224007780|NCT05452278|OTHER|Product C|Tobacco-free pouch, 20 mg nicotine/pouch, used for 20 minutes
224007781|NCT05452278|OTHER|Product D|Tobacco pouch, 16.6 mg nicotine/pouch, used for 20 minutes
224126020|NCT06084325|BEHAVIORAL|Heartbeat Tracking (HBT)|The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
224126021|NCT06084325|DEVICE|Heartbeat evoked potential (HEP)|The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
224296062|NCT04475250|DEVICE|Tetragraph (TM) NMT Monitor|TetraGraph is a unique, EMG-based portable device for quantitative (objective) monitoring of neuromuscular function. It is a precise and easy to use tool for monitoring depth of block, ensuring adequate recovery of muscle function, and aiding the clinician to reduce the incidence of residual block.
224007782|NCT06616363|BEHAVIORAL|Questionnaires to be competed|"* The Pain Coping Questionnaire short form~* Functional Disability Inventory (FDI), the primary clinical outcome measure.~* COMPASS-31 and orthostatic hypotension modified for POTS.~* The Pain Response Inventory (PRI)PROMIS Depression~* GAD-7 for anxiety~* Varni/Thompson Pediatric Pain Questionnaire~* Child and Parent Reports of Post-Traumatic Symptoms (CROPS/PROPS)~* Pain Catastrophizing Scale (PCS-C)~* Detailed account of natural history and evolution of POTS and COPCs through MEDYSA (facilitates the assessment of specific syndromic diagnoses based on published criteria, rather than organ-based classification of symptoms)"
224007783|NCT06616363|BEHAVIORAL|Provide list of medication and lifetime events|Participants will provide a list of all medications taken at each visit time, lifetime history of infections, traumas, and other significant life events.
224007784|NCT06616363|BEHAVIORAL|Use phone App to record new life events|Subjects will also record new life events, minor traumas, entrance into a flare and menses in Ilumivu's EMA (Ecological Momentary Assessment) phone App
224007785|NCT06616363|DEVICE|Will wear an activity monitor|Participants will have an activity monitor loaned for the duration of the study to track their physical activity.
224126022|NCT06084325|DEVICE|Libet task|Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
224126023|NCT05370599|DRUG|Anti-hypertensive agent: amlodipine|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
223545698|NCT02950103|DRUG|Phosphoethanolamine|Phosphoethanolamine PO daily
224007786|NCT06616363|OTHER|Periodic 24-hour urine sodium check|POTS patients will have a periodic 24-hour urine sodium check to determine compliance to intake of salt.
224007787|NCT06616363|DIAGNOSTIC_TEST|A fMRI scan|• Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
224007788|NCT06616363|DIAGNOSTIC_TEST|A bedside tilt test will be performed|A bedside tilt test will be performed where blood pressure will be recorded supine and upright positions to confirm/exclude POTS.
224007789|NCT06616363|OTHER|IV placed to collect blood samples|• An IV will be place for collection of 4 blood samples, about 12 mL of blood. For each position (lying and standing) the study team will draw 2 tubes each times with 3 mL of blood, for a total of 4 lab tubes (12 mL). Physical exams to assess the 18-tender points described by the American College of Rheumatology for the diagnosis of fibromyalgia and hypermobility/Ehlers-Danlos Syndrome (EDS) exam will be performed in all subjects.
224007790|NCT06616363|OTHER|Stool Sample|• Participants will provide a stool biospecimen sample at each in-person visit. Stool will be collected in a hat and sample will be swabbed with the swab placed directly into PrimeStore collection tube and the remainder of the sample discarded
224007791|NCT06463587|OTHER|Placebo|Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
224007792|NCT06463587|DRUG|Cladribine Low Dose|Participants will receive cladribine low dose in two courses separated by 4 weeks.
224007793|NCT06463587|DRUG|Cladribine High Dose|Participants will receive cladribine high dose in two courses separated by 4 weeks.
224126024|NCT05370599|DRUG|Anti-hypertensive agent: Chlorthalidone|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
224296063|NCT05273931|OTHER|Lifestyle intervention|Documents explaining the strategies to achieve and maintain recommended behaviours as part of a healthier lifestyle
224296064|NCT04845620|DRUG|ARQ-151 Active|ARQ-151 Cream 0.05% - Active
224296065|NCT04845620|DRUG|ARQ-151 Vehicle|ARQ-151 Cream - Vehicle
224296066|NCT00597116|DRUG|Vinorelbine|
224296067|NCT00597116|DRUG|Vandetanib|once daily oral dose
223388079|NCT01269918|DRUG|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
223388080|NCT05001893|DEVICE|S53P4 bioactive glass putty|Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.
223388081|NCT04990453|OTHER|RPD frameworks fabricated from PEEK material|extracoronal precision attachment RPD frameworks fabricated from PEEK material using milling machine (CAD/CAM technology)
224007794|NCT05260021|DRUG|Tirzepatide Dose 1|Administered SC
224007795|NCT05260021|DRUG|Tirzepatide Dose 2|Administered SC
224007796|NCT05260021|DRUG|Placebo|Administered SC
224007797|NCT04958031|DRUG|CVL-871 1.0 mg|CVL-871 1.0 mg, oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-7)
224007798|NCT04958031|DRUG|CVL-871 3.0 mg|CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
224007799|NCT04958031|DRUG|Placebo|Placebo QD, oral (tablet), once per day for 12 weeks
224007800|NCT05705479|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
224007801|NCT05705479|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
224007802|NCT06291922|BEHAVIORAL|Exercise Intervention|See arm description.
224007803|NCT06291922|BEHAVIORAL|Usual Care|See arm description.
224007804|NCT06556407|DEVICE|renal denervation|ultrasound based renal denervation
224007805|NCT05804747|DRUG|Edoxaban|This is observational, non-interventional study. No study drug will be administered during this study.
224007806|NCT06143345|BEHAVIORAL|High-intensity interval training and eucaloric diet|Intervention participants will complete 24 supervised high-intensity interval training (HIIT) sessions over 8 weeks, with 3 sessions per week on alternate days. Each HIIT session will consist of a 5-minute warm-up, followed by an interval-based workout phase that includes steady up-tempo cadences, sprints, and climbs, interspersed with recovery periods. The session will conclude with a 5-minute cooldown. The workout sessions will initially last 20 minutes and will progressively increase in time based on participants\&amp;#39; tolerance and instructor recommendations. Intensity will start at 75% of estimated maximal heart rate reserve and will increase by 5% weekly, as tolerated and/or deemed necessary by the instructor, over the 8-week intervention period. Participants will receive instructions to maintain a eucaloric diet throughout the study.
224007807|NCT06143345|BEHAVIORAL|No intense physical activity and eucaloric diet|Control participants will be instructed to refrain from engaging in intense physical activities during the study period. They will also receive instructions to maintain a eucaloric diet throughout the study.
224126025|NCT05370599|DRUG|Anti-hypertensive agent: Losartan|Patients with hypertension will be randomly assigned to be treated with amlodipine, chlorthalidone, or losartan. All drugs will be initiated at the lowest dose and uptitrated as needed to achieve standard BP targets.
224126026|NCT05370599|DEVICE|Home BP monitoring with cuffed device|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
224296068|NCT04658316|BEHAVIORAL|Iowa Oral Performance Instrument|Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
224299255|NCT05089318|DIETARY_SUPPLEMENT|Flexofytol PLUS|2 tablets in the morning and in the evening for minimum 6 weeks.
223388082|NCT01928472|BIOLOGICAL|H7N9c low dose with adjuvant|
223388083|NCT01928472|BIOLOGICAL|H7N9c medium dose with adjuvant|
223388084|NCT01928472|BIOLOGICAL|H7N9c high dose with adjuvant|
223388085|NCT01928472|BIOLOGICAL|H7N9c high dose without adjuvant|
223388086|NCT04117438|OTHER|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
223388087|NCT02301013|PROCEDURE|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
223388088|NCT02301013|DRUG|300 cc saline|
223388089|NCT06134687|PROCEDURE|Endoscopic Submucosal Dissection|Removal of study eligible lesions per endoscopic submucosal dissection
223388090|NCT06134687|DEVICE|Novel Rigidizing Overtube|Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection
223388091|NCT06174766|DRUG|HGP2102-1|Test drug
223388092|NCT06174766|DRUG|HGP2102-2|Test drug
223388093|NCT06174766|DRUG|RLD2209-1|Control drug
223388094|NCT06174766|DRUG|RLD2209-2|Control drug
224007808|NCT06143345|DEVICE|Continuous glucose monitoring (CGM) (Dexcom G6 Pro CGM sensor)|The continuous glucose monitoring (CGM) system comprises a sensor, a transmitter, and a receiver. The sensor measures interstitial fluid glucose levels every 5 minutes, and the transmitter wirelessly sends this glucose data to the receiver. Both intervention and control participants will wear the CGM device in a blinded mode for 10 days before starting the intervention, throughout the 8-week intervention period, and for 10 days post-intervention.
224007809|NCT05044819|DRUG|Cannabidiol|Oral Cannabidiol solution 100 mg/mL
224007810|NCT02332447|DRUG|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
224126027|NCT05370599|DEVICE|Home BP monitoring with cuffed device + BP patch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
224126028|NCT05370599|DEVICE|Home BP monitoring with cuffed device + BP watch|Patients will be randomized to monitor their blood pressure either with a BP cuffed device alone, versus with either or use of a BP monitoring patch or BP monitoring watch.
224126029|NCT04898738|OTHER|Alcohol based hand sanitizer|Provision of ABHS to randomly selected households
224299256|NCT05322499|DRUG|Camrelizumab|200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);
224299257|NCT05322499|DRUG|Irinotecan|100-125mg/m2，d1，d8；q21d
223388095|NCT04111731|PROCEDURE|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
223388096|NCT04111731|PROCEDURE|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
224007811|NCT02332447|DRUG|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
224007812|NCT03842358|DEVICE|Hand-held hybrid probe|Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
224007813|NCT06034262|BIOLOGICAL|SclerFIX-IP|Decellularized, viro-inactivated, freeze-dried and sterile allogeneic graft of amniotic membrane of umbilical cord used as an interposition implant in the PIPJ
224007814|NCT05567172|DEVICE|Left atrial appendage closure device WM FLX Pro|Left atrial appendage closure
224007815|NCT04606472|DRUG|SI-B003|Administration by intravenous infusion.
223388097|NCT04111731|PROCEDURE|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
224126030|NCT06039761|PROCEDURE|Digestive or gynecological surgery by laparoscopy|Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
224299258|NCT05322499|DRUG|Paclitaxel|135-175mg/m2，d1，Q3W
224299259|NCT05322499|DRUG|Paclitaxel-albumin|100-135mg/m2, d1、d8，Q3W
224299260|NCT05322499|DRUG|Docetaxel|60-75mg/m2，d1，Q3W
223388098|NCT04111731|PROCEDURE|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
223388099|NCT05809479|OTHER|No intervention|No intervention
223388100|NCT01308424|DRUG|BTL TML HSV|Sublingual micro-dosing for 7 days
223388101|NCT01308424|DRUG|Matching placebo|sublingual dosing for 7 days
223388102|NCT00713037|PROCEDURE|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
223388103|NCT04877522|DRUG|Asciminib single agent|Taken orally, twice daily (BID) or once daily (QD), in fasting state
223388104|NCT04877522|DRUG|Imatinib|Taken orally, once daily, in the morning with low-fat meal
223388105|NCT04877522|DRUG|Nilotinib|Taken orally, twice daily, on an empty stomach
223388106|NCT04877522|DRUG|Bosutinib|Taken orally, once daily, with food
223388107|NCT04877522|DRUG|Dasatinib|Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
223388108|NCT04877522|DRUG|Asciminib single agent pediatric formulation|Pediatric participants receive a body weight adjusted dose of 1.3 mg/kg of pediatric film coated granules with food twice daily (b.i.d.) or 2.6 mg/kg once daily (q.d.) in the morning.
223388109|NCT04215887|DEVICE|Contactless Portable Respiratory rate Monitor|Novel hand-held respiratory rate monitor
224007816|NCT03269669|DRUG|Bendamustine Hydrochloride|Given IV
223388110|NCT05355376|PROCEDURE|Bundle of measures to decreased SSI|
223388111|NCT00095446|DRUG|insulin aspart|
223388112|NCT04757974|DRUG|Fostemsavir 600 mg|Fostemsavir tablets will be administered via oral route.
223388113|NCT04757974|DRUG|Fostemsavir 200 mg|Fostemsavir tablets will be administered via oral route.
224007817|NCT03269669|PROCEDURE|Biopsy Procedure|Undergo biopsy
224007818|NCT03269669|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224007819|NCT03269669|PROCEDURE|Computed Tomography|Undergo PET/CT scans
224007820|NCT03269669|DRUG|Cyclophosphamide|Given IV
224007821|NCT03269669|DRUG|Doxorubicin Hydrochloride|Given IV
224007822|NCT03269669|PROCEDURE|Echocardiography Test|Undergo ECHO
224007823|NCT03269669|DRUG|Lenalidomide|Given PO
224007824|NCT03269669|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224007825|NCT03269669|BIOLOGICAL|Obinutuzumab|Given IV
224007826|NCT03269669|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scans
223388114|NCT00399126|DRUG|Perifosine|Perifosine oral dose
223388115|NCT00399126|DRUG|Paclitaxel|Paclitaxel IV
224007827|NCT03269669|DRUG|Prednisone|Given PO
224007828|NCT03269669|DRUG|Umbralisib|Given PO
224126031|NCT05219617|DRUG|Carisbamate|"Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]).~Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\])."
224126032|NCT03403998|OTHER|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
224299261|NCT05322499|DRUG|Anlotinib|12mg，qd，d1-d14，q3w
224299262|NCT00376311|DRUG|oral salmon calcitonin|
224299263|NCT00057083|OTHER|Telemedicine Care|
223388116|NCT02007525|BEHAVIORAL|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
223388117|NCT03970577|DRUG|Rituximab|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
223388118|NCT03970577|DRUG|Prednisone|exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
223388119|NCT06297590|DRUG|LY3954068|Administered IT
223388120|NCT06297590|DRUG|Placebo|Administered IT
223388121|NCT06297590|DRUG|Flortaucipir F18|Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan
224007829|NCT03269669|DRUG|Vincristine Sulfate|Given IV
224007830|NCT06387355|DIAGNOSTIC_TEST|Coronary computed topography (CT) angiography with FFR-CT|The investigational treatment strategy will have a coronary CT angiography diagnostic imaging with computational analysis FFR-CT (Fractional Flow Reserve from the coronary CTA)
224007831|NCT04505566|DRUG|Ketorolac 0.45% ophthalmic solution|Ketorolac 0.45% ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
224007832|NCT04505566|DRUG|Placebo - Preservative-free artificial tears|Preservative free artificial tears ophthalmic solution 1 drop instilled in both eyes twice daily for 3 years in double-masked fashion.
224007833|NCT04505566|OTHER|Aqueous PGE2 and inflammatory cytokines measurements|After topical anesthetic, antibiotic and 5% povidone-iodine application, a 30 gauge needle on a 1 ml tuberculin syringe will be inserted into the anterior chamber and used to collect 0.1 ml of aqueous fluid from each eye. Aqueous PGE2 and Inflammatory cytokines will be measured
224007834|NCT06404879|OTHER|determining scores with tests|"Parents of children preparing for the operation will be given a child and family information form and STAI-I and STAI-II (State-Trait Anxiety Scale) scale forms and will be asked to fill them out themselves.~An anesthesia technician blind to the content of the study will calculate and take notes on the children\&#39;s anxiety levels, according to the m-YPAS (modified Yale Preoperative Anxiety) scale, in the preoperative waiting room (T1) and when the anesthesia ventilation mask is shown (T4).~FLACC (Face, Legs, Activity, Cry, Consolabilityscale) scores and spO2, pulse values and complications such as nausea, vomiting and desaturation at the 5th, 10th, 20th and 30th minutes of all children taken to the recovery unit in the postoperative period will be recorded by the recovery unit nurse. . Children who are thought to have pain according to the FLACC score will be given 0.5 mg/kg meperidine as rescue analgesia and a note will be taken."
223388122|NCT01253902|DRUG|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
223388123|NCT01253902|DRUG|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
223388124|NCT01253902|DRUG|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
223388125|NCT02412553|OTHER|Specific carbohydrate diet|
223388126|NCT02412553|OTHER|Elemental diet|
223545699|NCT04904107|DIAGNOSTIC_TEST|modified HEART score (including POC hs cTnI analysis)|"The modified HEART score was developed in 2007 and has been validated to stratify the risk of short-term adverse cardiac events in patients with chest pain at the ED. Negative predictive value (NPV) of the modified HEART score for ACS as well as positive predictive value (PPV) for major adverse cardiac events (MACE) within 6 weeks after presentation is high.~The modified HEART score is an acronym for history, ECG, age, risk factors and troponin at arrival.The components can be rated 0,1 or 2 points each and result in a total score between 0 and 10."
224007835|NCT05143554|DEVICE|Auricular percutaneous neurostimulation|Percutaneous neurostimulation
224007836|NCT05143554|DEVICE|Sham percutaneous neurostimulation|Sham percutaneous neurostimulation
224126033|NCT03403998|OTHER|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
223388127|NCT05842603|BEHAVIORAL|Cardiac Lifestyle Program|12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
223388128|NCT03202940|DRUG|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
223388129|NCT03202940|DRUG|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
223388130|NCT04053088|DEVICE|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
224007837|NCT03158922|GENETIC|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
224007838|NCT03158922|OTHER|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
224007839|NCT03158922|PROCEDURE|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
224126034|NCT06526858|DEVICE|HyperQureTM Renal Denervation (RDN) System:|"The HyperQure RDN System consists of a Generator that generates RF energy and a Laparoscopic Instrument that delivers the RF energy generated by the generator to the treatment area. Through a extravascular(laparoscopic) approach, the renal artery is accessed through the retroperitoneum, which is the closest path to the renal artery. After wrapping 360 degrees of renal artery, RDN is performed as per the preset parameters of 50 degrees and 70 seconds.~The target blood vessels will be planned by CTA before the procedure, and the proximal and distal areas of the right and left main renal artery are treated once at a distance of at least 3 mm respectively, and RDN will be also performed on the branch or accessory vessels confirmed to be suitable for the procedure by CTA."
224126035|NCT06172777|DIAGNOSTIC_TEST|suspected asthma|enrollment 200 asthma patients
224126036|NCT06172777|DIAGNOSTIC_TEST|suspected COPD|enrollment 200 COPD patients
223388131|NCT06196879|DRUG|Verekitug (UPB-101)|Verekitug (UPB-101) formulated solution
224007840|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - maximum|"Breathing assistance from the breathing assist machine using a method in which doctors try to find the pressures that expands the lungs the best. This is based on measurements of one's respiratory pressures and volumes. This is done by adjusting the pressure settings. This allows one's lungs to expand with the least amount of change in pressure during breathing.~PEEP (positive end-expiratory pressure) will be set at the maximum static respiratory system compliance (Crs) during a descending PEEP titration curve."
223388132|NCT06196879|DRUG|Placebo|Verekitug (UPB-101) matching placebo
224007841|NCT05977153|PROCEDURE|PEEP (positive end-expiratory pressure) - standard|"Breathing assistance from the breathing assist machine using the pressure settings typical for your disease.~Standard ARDSNet low-stretch PEEP (positive end-expiratory pressure) protocol: PEEP will be set following a routinely used PEEP table according to patients' blood oxygenation status."
224007842|NCT05983588|DRUG|RAVICTI 1.1 g/ml|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
224007843|NCT05983588|DRUG|Placebo|"Duration of Treatment: 26 weeks, twice daily~Dosage:~* weeks 0 - 3: 3 ml/day (1,5ml - 0 - 1,5ml) (≙ 3,3 g glycerol phenylbutyrate/placebo)~* weeks 4 - 26: 6 ml/day (3 ml - 0 - 3 ml) (≙ 6,6 g glycerol phenylbutyrate/placebo)"
224007844|NCT06295536|DEVICE|Comparator device, Closed-field autorefractometer|"* Objective refraction without cycloplegia~* Distance visual acuity with objective refraction without cycloplegia~* Objective refraction with cycloplegia~* Distance visual acuity with objective refraction with cycloplegia"
224007845|NCT06326697|DRUG|Azacitidine|Azacitidine 300 mg Film coated tablets
224007846|NCT06326697|DRUG|Onureg|Azacitidine 300 mg Film coated tablets
224007847|NCT05160545|DRUG|GNC-035|Administration by intravenous infusion
224007848|NCT06176001|OTHER|psychoeducation in groups|Group-based psychoeducation for relatives. Group size: 20-40 relatives. Duration of intervention: six sessions, each two hours long with a 15 minutes break, over a period of 6-10 weeks. The sessions are held by experienced clinicians from the Copenhagen Affective Disorder Clinic, one chief physician and one nurse. Each session focuses on a specific topic, which the clinicians present and discuss using a presentation viewer. The sessions are interactive, and the participants are encouraged to ask questions during the presentations. During each session the participants will have some discussions in smaller groups to reflect on a topics and issues raised during the session.
224007849|NCT05097274|OTHER|MRI pelvis or CT imaging under clinical management for Pr Ca|Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.
224007850|NCT05097274|OTHER|Whole body bone scan imaging|bone scan of the whole body (under clinical diagnosis).
224007851|NCT05097274|OTHER|PET-CT imaging|Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
224007852|NCT05696496|DEVICE|night recording|"The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera."
224007853|NCT05913479|DEVICE|Mucogyne Gel|At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)
224007854|NCT04838769|DEVICE|REZŪM|Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
224007855|NCT04838769|DRUG|alpha blocker and 5-alpha reductase inhibitor|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
223388133|NCT06973291|DRUG|Zasocitinib|Zasocitinib tablets.
224126037|NCT06172777|DIAGNOSTIC_TEST|confirmed asthma|enrollment 200 patients
224126038|NCT06172777|DIAGNOSTIC_TEST|confirmed COPD|enrollment 200 patients
223388134|NCT06973291|DRUG|Deucravacitinib|Deucravacitinib capsules.
223388135|NCT06973291|DRUG|Placebo to match zasocitinib|Zasocitinib matching placebo tablets.
223388136|NCT06973291|DRUG|Placebo to match deucravacitinib|Deucravacitinib matching placebo capsules.
223388137|NCT05989711|DRUG|Pemvidutide|Administered by subcutaneous injection
223388138|NCT05989711|DRUG|Placebo|Administered by subcutaneous injection
223388139|NCT04154683|DEVICE|Cellvizio®|use of the Cellvizio® optical biopsy
223388140|NCT04471428|DRUG|Cabozantinib|Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.
223388141|NCT04471428|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
223388142|NCT04471428|DRUG|Docetaxel|Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.
223388143|NCT01654172|DIETARY_SUPPLEMENT|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is \~900mg
223388144|NCT01654172|DIETARY_SUPPLEMENT|Low Flavanol Cocoa|
223388145|NCT06243848|PROCEDURE|Minimal Incision Surgery for median nerve decompression|Classic minimal incision surgical technique for median nerve decompression in patients diagnosed with mild, moderate, and severe carpal tunnel syndrome.
223388146|NCT06243848|PROCEDURE|Ultrasound-guided perineural injection with 5 cc 5% Dextrose|The median nerve will be identified using ultrasound at the proximal entrance of the carpal tunnel. Using an ulnar approach with the in-plane technique, it was planned to inject 5 cc of 5% dextrose around the median nerve.
223545700|NCT04904107|OTHER|Standard care and triage according to the local (EMT)protocol.|Standard care and triage of chest pain patients according to the local (EMT)protocol.
223545701|NCT03363178|BIOLOGICAL|GC3107|BCG Vaccine, 0.1mL
223545702|NCT00006132|DRUG|acyclovir|
223545703|NCT00817934|DRUG|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
223388147|NCT05184881|OTHER|Retrolaminar block|2- Cervical retrolaminar block: will be performed on prone-positioned patients. Under fluoroscopic visualization, after identification of the lamina at the desired level, a 25-gauge, 3.5-inch spinal needle was introduced and when the needle tip will be confirmed at the posterior aspect of the cervical lamina corresponding to cervical facet arthropathy level. 5 mL of a mixture of 3 mL 1% lidocaine and 2 mL dexamethasome (8mg/2ml) will be injected.
223388148|NCT05184881|OTHER|Medial Branch Block|1- Cervical medial branch block: will be performed on prone-positioned patients using a posterior approach. Under fluoroscopic visualization, after identification of the waists of the articular pillars at the desired levels, each medial branch block was administered with a 25-gauge, 3.5-inch spinal needle. When the place of the needle tip will be confirmed at the mid-point of the waists of articular pillars, 1 ml of the mixture of 0.5 mL 1% lidocaine and 0.5 mL dexamethasome (8mg/2ml) will be injected at each level.
223388149|NCT04856046|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223388150|NCT04856046|OTHER|Electronic Health Record Review|Review of medical records
223388151|NCT05167097|OTHER|ASSIST-linked Brief Intervention|WHO's ASSIST-linked Brief Intervention (with and without Steps 6-9, the decisional balance element)
223388152|NCT05167097|OTHER|Mindset Intervention|Standard mindset manipulation as used in research by Peter M. Gollwitzer and colleagues
224007856|NCT04561362|DRUG|BT8009|Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
224007857|NCT04561362|DRUG|Pembrolizumab|Participants in Cohorts A-2 and B-7 will receive 200 mg IV over 30-minute infusion of pembrolizumab on Day 1 of each Q3W.
223388153|NCT00226096|DRUG|Labetalol Hydrochloride|
224007858|NCT06965582|DEVICE|ALPFA BPH PFA System|PFA system for treatment of Benign Prostatic Hyperplasia
224007859|NCT00261456|DIAGNOSTIC_TEST|PSA test|Patients tested for their level of Prostate Specific Antigen.
224007860|NCT00261456|PROCEDURE|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
224007861|NCT05906381|DIETARY_SUPPLEMENT|Probiotics|A specific probiotics capsule product, containing Streptococcus thermophilus will be given to participants for oral intake for 35 days.
224007862|NCT05906381|DIETARY_SUPPLEMENT|Placebo|A specific capsule product, containing microcrystalline cellulose will be given to participants for oral intake for 35 days.
224007863|NCT05457283|DRUG|Finerenone (Kerendia, BAY94-8862)|Finerenone in different doses, treatment duration will be 540 ±7 days.
224126039|NCT04472923|PROCEDURE|Traditional Treatment|"Patients belonging to the control group received conventional physical therapy program in the form of:~1. Dietetic Regulation: The diet was given in the form of the bulk-forming diet, fruits, vegetables, cereals, and bran.~2. Pelvic floor muscle exercises (Kegal exercises): The patient was instructed to lie crock lying position with knees bent. He/she was instructed to pull his/her pelvic muscles upward and inward and hold the contraction for 6 seconds as if to hold back a defecation movement, followed by relaxation for 6 seconds. The exercise was repeated 25 times. Gradually increase the time until reaching 10 seconds of contraction and relaxation for each with repetition up to 30 times. The exercises applied twice per week for 3 months."
223388154|NCT00226096|DRUG|Metoprolol tartrate|
223388155|NCT00226096|DRUG|Hydralazine Hydrochloride|
223388156|NCT00226096|DRUG|Glycerol Trinitrate|
223388157|NCT00226096|DRUG|Phentolamine mesylate|
223388158|NCT00226096|DRUG|Nicardipine|
223388159|NCT00226096|DRUG|Urapidil|
224007864|NCT04905069|DEVICE|SpaceOAR Vue System|"The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time."
224007865|NCT06381115|BEHAVIORAL|SleepWell24 Application|The SleepWell24 application will use connections with a Shelly smart plug and a Fitbit Charge 4 along with weekly questionnaires to monitor CPAP usage.
224007866|NCT06540391|BIOLOGICAL|MB097|Live bacterial therapeutic for oral administration
224007867|NCT06540391|BIOLOGICAL|Pembrolizumab|IV infusion
224007868|NCT06540391|DRUG|Vancomycin|Antibiotic
224007869|NCT03964090|DRUG|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
223388160|NCT00226096|DRUG|Esmolol|
223388161|NCT00226096|DRUG|Clonidine|
223388162|NCT00226096|DRUG|Enalaprilat|
223388163|NCT00226096|DRUG|Nitroprusside|
223388164|NCT05037825|DRUG|Checkpoint Inhibitor, Immune|anti-PD-1, anti-PD-L1, or anti-CTLA-4 as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
223388165|NCT03591042|DIAGNOSTIC_TEST|cervical length screening|transvaginal ultrasound cervical length
223388166|NCT01289145|BEHAVIORAL|Motivational intervention|The motivational intervention promotes positive outcome expectancies on physical activity.
223388167|NCT01289145|BEHAVIORAL|Volitional intervention|The volitional intervention promotes the formulation of action plans for physical activity.
223388168|NCT01289145|BEHAVIORAL|Active Control|Participants receive a quiz on physical activity and sports.
223388169|NCT03788343|DIETARY_SUPPLEMENT|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
223388170|NCT03788343|DRUG|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
224007870|NCT03964090|DRUG|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
223388171|NCT06372210|DRUG|Placebo IEM tablet|Oral placebo-embedded IEM tablet.
223388172|NCT06372210|DRUG|Abilify MyCite®|Oral aripiprazole-embedded IEM tablet.
223388173|NCT06372210|DEVICE|D-Tect Patch|The D-Tect patch is a wearable sensor (WS) capable of detecting the ingestion of the IEM and measuring physiologic parameters. The WS automatically logs and stores the time when the IEM reaches the stomach and transmits the data to a smartphone.
223388174|NCT00129545|DEVICE|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
224007871|NCT03964090|DRUG|Ibrutinib|For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
224007872|NCT03964090|DRUG|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
223388175|NCT00129545|DRUG|Warfarin|Subjects receive warfarin
224007873|NCT03964090|DRUG|Isavuconazole|Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
224007874|NCT03964090|DRUG|Methotrexate|Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
224007875|NCT06067802|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg triheptanoin
224007876|NCT02963025|PROCEDURE|PEEP level|
224007877|NCT02963025|PROCEDURE|Use of recruitment maneuvers|
224007878|NCT06564506|DEVICE|Disposable acupuncture needles (0.30 × 75 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
224007879|NCT06564506|DEVICE|Placebo needles (0.30 × 25 mm)|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.
224007880|NCT06564506|DEVICE|SDZ-V electroacupuncture devices|Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
224007881|NCT05929183|DEVICE|Repetitive Transcranial magnetic stimulation|"Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of depressive symptom was dorsolateral prefrontal cortex (DLPFC). In this study, we use high frequency rTMS in the occipital lobe are precisely targeted by navigation, by stimulating the primary visual cortex（V1), can affect the orbitofrontal cortex (OFC), which is functionally connected to V1, and thus affect the entire nerve ring pathway excitability, thereby rapidly, effectively and safely improving mood symptoms in the acute phase of bipolar depressive episode.~After the target was determined by fMRI navigation and positioning, the subjects were subjected to rTMS for 20 minutes per day with the stimulation intensity of 10Hz and 100% of the motion threshold(MT),stimulation time of each sequence was 5 seconds, stimulation interval was 15 seconds, 3000 pulses per day for 15 days, and the total number of pulses was 45000."
224007882|NCT05929183|DEVICE|Sham Repetitive Transcranial magnetic stimulation|The stimulus intensity was 20% of MT in the Sham Comparator arm, and the remaining parameters were the same as the Active Comparator arm.
224007883|NCT06046014|OTHER|BI Focused writing|BI Focused writing program
224007884|NCT06046014|OTHER|Control|Attention Control Writing
224007885|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
224007886|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
224007887|NCT01525238|DRUG|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
224007888|NCT06575699|PROCEDURE|Rectus sheath block|bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.
224007889|NCT06575699|PROCEDURE|Thoracic Epidural Analgesia|Low thoracic Epidural Analgesia.
224126040|NCT04472923|DEVICE|Biofeedback|"Patients belonging to the study group were subjected to the same conventional physical therapy program in addition to biofeedback training.~Biofeedback was planned after full guardians' education. Local hygiene for perianal skin for soiling episodes and using zinc oxide cream to prevent excoriation. Biofeedback was done using two types of catheters; a 24-channel water-perfused catheter with latex balloon for sensory training and a double-lumen rectal PVC balloon clothed catheter (MMS U-72210) for strength training. Each biofeedback session took 30 minutes with two sessions per week for 3 months."
224126041|NCT05465733|DRUG|Envafolimab;Pemetrexed|single agent, 300mg Q3W IH until disease progressed,The duration of treatment with Envafolimab should not exceed 2 years.
223545704|NCT04118725|DIAGNOSTIC_TEST|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
224126042|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
224126043|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement B|4 capsules daily of oral supplement B for 3 days
224126044|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
223388176|NCT05528978|BEHAVIORAL|Shambhavi Kriya|"The intervention investigators propose for the study includes an Online Course with 7 modules, or a 10 hours long course, and a 1-2 day In-Person Course, in which participants will learn a simple 21 minute practice called Shambhavi Mahamudra Kriya, also known as Shambhavi Kriya.~Shambhavi Kriya is a powerful and purifying energy technique incorporating the breath. This practice is said to align the participants system such that their body, mind and emotions function in harmony."
223388177|NCT03315078|BIOLOGICAL|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
223545705|NCT01667341|BIOLOGICAL|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
223545706|NCT01667341|BIOLOGICAL|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
223545707|NCT01667341|BIOLOGICAL|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
223388178|NCT03315078|DRUG|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
223388179|NCT03315078|DRUG|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
223388180|NCT06443229|BEHAVIORAL|Graded Activity based in exercises and educational approach|"Exercises for warming up, strengthening, and relaxation, along with informational sessions incorporating an educational approach for low back pain using Telerehabilitation platform. Participants will be randomized into two groups: the Experimental Group (EG), which will receive graded activity along with the educational approach, three times a week, over 12 sessions, totaling 4 weeks.~The intervention will involve adapting a protocol from an exercise program based on gradual activity with progressively increasing exercise intensity using web applications from Physitrack® Ltd., LDN, United Kingdom (used by the physiotherapist/researcher) and Physiapp® (used by the participant). Participants will be provided with (i) a welcome letter outlining the intervention/group components they are allocated to; (ii) instructions on how to use the Physiapp® web application (web browser, Android or iOS app) at home."
223388181|NCT06443229|OTHER|Educational Approach|Educational approach for low back pain using Telerehabilitation platform. Participants will receive educational materials with an isolated educational approach, with the delivery of the materials occurring three times a week.
223388182|NCT01841593|DRUG|Raltegravir|Isentress 400mg tablet taken twice daily
223388183|NCT01841593|DRUG|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
223388184|NCT04584411|DIAGNOSTIC_TEST|Cardiac Magnetic resonance imaging|"The following basic sequences will be conducted:~* Cine imaging using SSFP sequence for cardiac structure and function.~* Tissue characterization imaging, T1 and T2.~* Myocardial perfusion imaging.~* Late gadolinium enhancement.~Diagnosis of myocarditis will be based on the modified Lake Louise criteria:~T2-weighted: any of the following standard T2 sequences: regional high signal standard T2 sequences: global signal intensity ratio (myocardium/skeletal muscle) ≥2 T2 mapping: increased T2 relaxation times T1-weighted: any of the following late enhancement imaging: non-ischemic (subepicardial or mid myocardial) late enhancement native T1 mapping: increased T1 relaxation times or extracellular volume supportive criteria: signs of pericarditis: effusion or pericardial late enhancement regional or global wall motion abnormalities\[5\]"
224007890|NCT06575699|DRUG|Liposomal bupivacaine|133 mg liposomal bupivacaine per side for rectus sheath block
224007891|NCT06575699|DRUG|Bupivacaine Hydrochloride|20 mL bupivacaine 0.25% per side for rectus sheath block
224007892|NCT06575699|DRUG|Bupivacaine-Hydromorphone Cassette|Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
224007893|NCT04002297|DRUG|zanubrutinib|Administered as two 80 mg capsules by mouth twice a day
224007894|NCT04002297|DRUG|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
224126045|NCT03707652|DIETARY_SUPPLEMENT|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
224126046|NCT03707652|DIETARY_SUPPLEMENT|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
224126047|NCT04989829|DRUG|SHR6390、Omeprazole|SHR6390 tablet single dose、Omeprazol single dose.
224126048|NCT02702193|BEHAVIORAL|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
224126049|NCT04516018|OTHER|Cold exposure|Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
224126050|NCT05517603|DRUG|AJ201|Administered orally
224007895|NCT04002297|DRUG|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
224007896|NCT06265272|DRUG|Injection of a gadolinium contrast agen|"All patients will be requested to have an injection of a gadolinium contrast agent, which may be either Gadavist (Bayer, Whippany, NJ, USA), Eovist (Bayer, Whippany, NJ, USA), or Dotarem (Guerbet, Princeton, NJ, USA) (ancillary drugs).~* About halfway through the examination, the same intravenous catheter used to inject the radiotracer will be used to inject the MRI contrast agent;~* After being positioned on the PET/MRI table, the nuclear medicine technicians will connect the patient to the MRI-safe power-injector; - The catheter will be flushed before and after injection with 0.9% saline solution;"
224126051|NCT05517603|DRUG|Placebo|Administered orally
224126052|NCT04077970|BIOLOGICAL|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
224126053|NCT02486510|DRUG|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
224126054|NCT03644940|DIAGNOSTIC_TEST|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
224126055|NCT04342715|DRUG|Sodium stibogluconate / paramomycin|Treatment with Sodium stibogluconate / paramomycin
224126056|NCT05735717|DRUG|Fludarabine|Fludarabine 25mg/m2 IV on days -8 to -6 or days -4 to -2. 40mg/m2 IV on days -5 to -2.
224126057|NCT05735717|DRUG|Busulfan|Busulfan 82.1 mg\*hr/L IV on days -5 to -2 or days -8 to -5
224126058|NCT05735717|DRUG|Melphalan|Melphalan 50 mg/m2 IV on days -4 to -2
224126059|NCT05735717|DRUG|Rituximab|200 mg/m2 intravenous given once on day-1
223388185|NCT00548613|BIOLOGICAL|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
223388186|NCT00548613|BIOLOGICAL|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
224126060|NCT05735717|DRUG|Levetiracetam|As seizures have occurred following high dose busulfan, all patients will be treated with Keppra beginning day -6 and continuing until day -1 per institutional guidelines.
223388187|NCT03561649|DRUG|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
223388188|NCT06354517|OTHER|SENSE group|Parents of babies in this group will be given SENSE program training. After the training, parents will care for their babies within the scope of the SENSE program. These babies will receive care from their parents with positive sensory exposures within the scope of the SENSE program from admission to the clinic until discharge. Data collection forms will be administered to babies and their parents.
224007897|NCT06265272|DRUG|Radiotracer Injection|"All patients will be requested to have a radiotracer injection of Ga-PSMA (Illucix, Telix Pharmaceuticals). An intravenous catheter will be placed in an arm or hand vein for injection of the Ga-PSMA;~* The catheter will be flushed post-injection with 0.9% saline solution~* The injected dose and the time of injection will be recorded.~* The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used to enable the patient to comfortably maintain his/her position throughout the scan"
224007898|NCT06265272|DIAGNOSTIC_TEST|Imaging|PET, MRI and fused PET/MRI images will be qualitatively assessed in comparison to standard of reference data. For PET, standard of reference will be PET images as obtained by standard PET acquisition mode. Attenuation correction of the PET images will be performed using a 2-point Dixon MRI sequence and a vendor-specific atlas-based attenuation map. 3D scatter correction by single scatter simulation is also performed using the MRI-derived attenuation data. MRI images will be compared to dedicated 3 Tesla MR upper abdominal protocol images acquired at the MGH in patients with liver cirrhosis, including those undergoing imaging follow-up after systemic or local regional therapies. For PET/MRI fused images, the standard of reference will be co-registered and fused PET/MRI images as obtained by standard MRI sequences/reconstructions.
224007899|NCT05054439|DRUG|SI-B001|Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
224007900|NCT05054439|DRUG|Paclitaxel|The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
224007901|NCT04141735|DIAGNOSTIC_TEST|ultrasound|no intervention
224007902|NCT05486572|OTHER|Abbreviated Magnetic Resonance Imaging with serum AFP|Abdominal aMRI+ serum AFP every 6 months from the time of recruitment until the end of year 8
224007903|NCT05486572|OTHER|Abdominal Ultrasound Screening with serum AFP|abdominal ultrasound (US)+serum alpha fetoprotein (AFP) every 6 months from the time of recruitment until the end of year 8
224007904|NCT04625413|BEHAVIORAL|Behavioral: UR-GOAL communication tool|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awarene
224126061|NCT05735717|BIOLOGICAL|Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells|Patients will be treated on the most medically appropriate regimen followed by an infusion at Day 0 of Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells.
224126062|NCT05735717|DRUG|Thymoglobulin|rabbit anti-thymocyte globulin (rATG). Used in conditioning regimens for in vivo depletion of T cells, and the use of fludarabine model-based dosing to optimize dosing.
224126063|NCT05735717|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV over 2 hours on days -3 and -2
224126064|NCT06053268|DEVICE|Headspace|The intervention will be delivered via the Headspace mobile application. The basic application program includes daily 10-minute sessions in guided mindfulness meditation that include mindful breathing, body awareness, emotion and thought recognition, and attentional control
224126065|NCT05562037|OTHER|Stepped Care|Patients meeting a non-response criterion will be stepped up to the next step
224126066|NCT04188873|DRUG|Preparation Varenicline and Standard Duration Varenicline|16 weeks of varenicline starting 4 weeks pre-quit
224126067|NCT04188873|DRUG|Preparation Varenicline and Extended Duration Varenicline|28 weeks of varenicline starting 4 weeks pre-quit
223388189|NCT00307086|DRUG|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
223388190|NCT00307086|DRUG|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
223388191|NCT00307086|PROCEDURE|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
223388192|NCT02263963|DRUG|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
223388193|NCT02263963|PROCEDURE|TAP Block|no intervention will be done to this arm.
223388194|NCT00327418|DRUG|Atorvastatin|
223388195|NCT00890617|PROCEDURE|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
223388196|NCT00890617|DRUG|Prednisone|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
223388197|NCT04943133|DEVICE|Blood pressure measurement and collection of the oscillometric curve for later SFATI analysis|Brachial systolic arterial blood pressure will be systematically taken with acquisition of the oscillometric curve for analysis and measurement with the SFATI system and simultaneous electronic recording of the Korotkoff sound (auscultatory method) and a search for SFATI arterial stiffness markers for all patients. Brachial systolic arterial blood pressure will be measured with the help of a cuff equipped with a Biopac SS30L electronic stethoscope and a MA-300 phonocardiographic microphone, placed side-by-side immediately downstream from the brachial occlusion cuff. The various signals (pneumatic cuff, oscillometric signal and Korotkoff sounds) will be digitalized by an MP35 system.
223545708|NCT04631315|DRUG|Difluprednate Ophthalmic Emulsion 0.05%|1 drop, 2 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, once a day for the next 2 weeks.
224126068|NCT04188873|DRUG|Standard Duration Varenicline|12 weeks of varenicline
223388198|NCT04943133|DEVICE|Blood pressure measurement with the usual equipment used in the department|Brachial systolic blood pressure will be taken via the conventional oscillometric method, only for hospitalized women. Blood pressure will be measured on the same arm with the help of a conventional Dinamap-type automat (GE), with at least 2 minutes between the end of the first measurement and the start of the second inflation.
224126069|NCT04188873|DRUG|Extended Duration Varenicline|24 weeks of varenicline
223388199|NCT04943133|DEVICE|systematic measurement of pulse wave velocity (aortic and brachial)|"Carotid to femoral and carotid to radial pulse wave velocity (Complior) will be systematically determined for hospitalized women and offered to all women seen for consultation.~Pulse wave velocity will be measured with the help of a Complior tonometric system (Alam Medical, Vincennes, France), with which the aorta and the arterial axes of the upper limb used to measure blood pressure can also be measured."
224296069|NCT05339646|DRUG|SSD8432 dose 1~7 and Ritonavir|"Cohort 1 Period 1 single dose of SSD8432 dose 1 or placebo, on day 1. Period 2: single dose of SSD8432 dose 2 or placebo , on day 7. Period 3: single dose of SSD8432 dose 3 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 2:~Period 1 single dose of SSD8432 dose 4 or placebo, on day 1 Period 2: single doses of SSD8432 dose 5 or placebo , on day 7 Period 3: single dose of SSD8432 dose 6 on day 13, ritonavir or placebo, before SSD8432 dose 3 and BID on SSD8432 dosing date~Cohort 3:~single dose of SSD8432 dose 7 or placebo on day1. ritonavir or placebo, before SSD8432 dose 7 and BID on SSD8432 dosing date."
224296070|NCT05339646|DRUG|SSD8432 dose 8~9|Cohort 4: SSD8432 dose 8 or placebo, on day 1 \~day6. Cohort 5: SSD8432 dose 9 or placebo, on day 1 \~day6.
224007905|NCT04679935|BIOLOGICAL|Brolucizumab|Intravitreal injection
224007906|NCT02683980|DEVICE|Lumenis Pulse P120H and Xpeeda side firing fiber|
224007907|NCT06814028|DEVICE|Volta System|The Volta System will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. During the Second and Third Menstruations, participants will self-administer daily active tAN sessions Volta System Device beginning Day 1 of menstruation through the final day of menstruation.
223388200|NCT01870778|DRUG|RLX030|1 mg/mL solution in 6 mL vials
223388201|NCT01870778|DRUG|Placebo|Matching placebo solution to serelaxin
223388202|NCT05782777|DRUG|ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
223388203|NCT05782777|DRUG|high-intensity statin monotherapy (atoravastatin 40mg)|The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
223388204|NCT01304056|DEVICE|Ventilatory therapy|
224007908|NCT05022654|DRUG|SI-B001|Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
223388205|NCT03809689|OTHER|68Ga-NODAGA-RGD PET/CT|intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
224007909|NCT05022654|DRUG|Irinotecan|The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
223388206|NCT03809689|DIAGNOSTIC_TEST|82-Rb PET/CT as part of standard care, not a comparator|2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
224007910|NCT06985940|OTHER|Visual stimulation|Participants will watch a 10-minute snow- or fire-themed video
224007911|NCT06985940|OTHER|Acoustic stimulation|Participants will listen to a natural sound from fire burning or snow falling
224007912|NCT06985940|OTHER|Combination|Participants will undergo both visual and acoustic stimulation
224007913|NCT06820463|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
224007914|NCT06820463|DRUG|Fluorouracil|IV Infusion; IV Injection
224007915|NCT06820463|DRUG|Oxaliplatin|IV Infusion
224007916|NCT06820463|DRUG|Leucovorin|IV Infusion; IV Injection
224007917|NCT06820463|DRUG|Bevacizumab|IV Infusion
224007918|NCT06820463|DRUG|Panitumumab|IV Infusion
224007919|NCT04504019|DEVICE|USCTR|Ultrasound guided CTR via a single \< 1 cm wrist or palmar incision. The procedure will be performed using the SX-One MicroKnife®, also known as UltraGuideCTR
224007920|NCT04504019|PROCEDURE|mOCTR|Mini-open CTR via a single 1-3cm palmar incision
224007921|NCT02993146|OTHER|Laboratory Biomarker Analysis|Correlative studies
223388207|NCT00258726|BIOLOGICAL|MMR-II|
223388208|NCT00258726|BIOLOGICAL|Pro-Quad|
223388209|NCT00258726|BIOLOGICAL|Varivax|
223388210|NCT03881293|DRUG|lidocaine 2% gel|Transurethral instillation of 5 ml lidocaine 2% gel
223388211|NCT03881293|DRUG|water soluble lubricant|Transurethral instillation of 5 ml water soluble lubricant
223388212|NCT00312338|DRUG|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
223388213|NCT03308214|DRUG|Imipenem|Imipenem 1.0 q 8h
223388214|NCT00262028|BIOLOGICAL|MenACWY-CRM Vaccine|
223388215|NCT00262028|BIOLOGICAL|MenACWY-PS Vaccine|
223388216|NCT02292693|DEVICE|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
223388217|NCT02292693|DEVICE|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
224007922|NCT02993146|OTHER|Pharmacological Study|Correlative studies
224007923|NCT02993146|OTHER|Quality-of-Life Assessment|Ancillary studies
224007924|NCT02993146|DRUG|Ropidoxuridine|Given PO
224126070|NCT04188873|DRUG|Preparation Combination NRT and Standard Duration Combination NRT|16 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
224126071|NCT04188873|DRUG|Preparation Combination NRT and Extended Duration Combination NRT|28 weeks of nicotine patch + nicotine mini-lozenge starting 4 weeks pre-quit
224126072|NCT04188873|DRUG|Standard Duration Combination NRT|12 weeks of nicotine patch + nicotine mini-lozenge
224126073|NCT04188873|DRUG|Extended Duration Combination NRT|24 weeks of nicotine patch + nicotine mini-lozenge
223388218|NCT02292693|DEVICE|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
223388219|NCT04968613|DRUG|Madopar monotherapy|In addition to basic treatment, the patient also received Madopar treatment
223388220|NCT04968613|DRUG|senfrol monotherapy|In addition to the basic treatment, the patient also received the rofosson treatment
223388221|NCT04968613|DRUG|placebo monotherapy|In addition to basic treatment, the patient also received selegiline treatment
223388222|NCT02960009|DEVICE|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients. After 20-minute stimulation, EMG-driven robot hand training will be conducted.
223388223|NCT05148221|OTHER|Questionnaires|Once each participant signs an informed consent form upon agreeing to participate in the study, they will be asked to complete a simple demographic questionnaire including year in program, work schedule, self-reported height and weight, age, and sex. They will also be interviewed by a faculty of university of Wisconsin-Eau Claire (UWEC) regarding their current and past exercise habits, exercise preferences, and perceived exercise barriers. Two questionnaires listed above (Occupational Fatigue Exhaustion Recovery (OFER 15) and Maslach Burnout Inventory (MBI)) will also be completed by each participant on Qualtrics online platform.
223388224|NCT05148221|OTHER|Actigraph and activPAL devices|Actigraph and activPAL devices will be set up based on the demographic information and will be provided to each participant to wear for 7 consecutive days during all waking hours and sleep, except when bathing or swimming. If the first 7-day monitoring period was an overnight inpatient week, the second 7-day monitoring period will be scheduled during a non-overnight week. A day before the first day of the second monitoring period, a new set of Actigraph and activPAL devices will be delivered to each participant. Once the second monitoring period ends, devices will be retrieved from each participant, and data will be downloaded from devices.
223388225|NCT04708704|DIETARY_SUPPLEMENT|Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be obtained from Roxy \& Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
223388226|NCT04708704|DIETARY_SUPPLEMENT|SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)|Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with \~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
223388227|NCT04708704|DIETARY_SUPPLEMENT|Iodine, prepared in drinking water 0.075 mg/kg bw/day)|Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
224007925|NCT02993146|RADIATION|Whole-Brain Radiotherapy|Undergo WBRT
224007926|NCT06824662|DRUG|Quisinostat|a highly potent and orally active HDAC inhibitor
224007927|NCT06817356|DRUG|Mazdutide|Administered SC
224007928|NCT06817356|DRUG|Placebo|Administered SC
224007929|NCT05470348|DRUG|BL-B01D1|Administration by intravenous infusion
224007930|NCT04362189|BIOLOGICAL|HB-adMSC|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
224126074|NCT04188873|BEHAVIORAL|Intensive Counseling|4 phone or video counseling sessions
224296071|NCT05339646|DRUG|SSD8432 dose 10~12 and ritonavir|Cohort 6: SSD8432 dose 10 or placebo, on day 1 \~day6. Cohort 7: SSD8432 dose 11 or placebo, on day 1 \~day6. Cohort 8: SSD8432 dose 12 or placebo, on day 1 \~day6 Cohort 9: to be decided
223388228|NCT01679990|BIOLOGICAL|PLX-PAD Low dose|
223388229|NCT01679990|BIOLOGICAL|PLX-PAD high doses|
223388230|NCT01679990|BIOLOGICAL|Double Placebo|
223388231|NCT01679990|BIOLOGICAL|high dose +Placebo|
223388232|NCT02922920|OTHER|Tart cherry juice|16 fl. oz of tart cherry juice
224007931|NCT04362189|OTHER|Placebo|Saline
224007932|NCT02111681|DEVICE|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
224007933|NCT06597474|BEHAVIORAL|Food-Body-Mind|The Food-Body-Mind intervention includes 3 main components: 1) a school-based mindfulness component delivered by daycare teachers to equip preschoolers with knowledge and skills in mindful eating and movement (e.g., yoga, deep breathing exercises) to reduce emotional eating and increase F/V intake and physical activity; 2) a home-based mindfulness component to increase caregivers' skills in practicing mindful eating, movement, and parenting behaviors at home to foster a more positive, mindful, and healthy home environment; and 3) a preschooler school learning and caregiver home practice connection component to improve caregiver-preschooler relationships.
224007934|NCT05500391|OTHER|Oncological Follow-up|Post-cancer surveillance (including biological, clinical and imaging exams depending on the condition)
224007935|NCT06603571|DRUG|LY3841136|Administered SC
224007936|NCT06603571|DRUG|Tirzepatide|Administered SC
224126075|NCT04188873|BEHAVIORAL|Minimal Counseling|2 brief phone or video counseling sessions
224126076|NCT05112458|OTHER|Cope 360 mobile health application|Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).
223388233|NCT02922920|OTHER|Placebo|16 fl. oz of placebo
223388234|NCT05712499|BEHAVIORAL|mindfulness-based psychoeducation program|Mindful awareness is a mind and body practice that involves increasing attention to what is happening at the moment and accepting what is perceived without judgment. Mindfulness includes awareness and attention; Awareness is the mechanism that constantly controls the of the state of consciousness. Mindfulness-based cognitive therapies are evidence-based psychoeducation. Psychoeducation was organized in 2 consecutive sessions once a week for 8 weeks, and each session was 60 minutes, in total 16 sessions. The content of the psychoeducation program was explained in detail, and techniques such as presentation and question-answer narrative techniques, video, audio recording, mindfulness assignments for the next session were used in the training.
224007937|NCT06603571|DRUG|Placebo|Administered SC
224007938|NCT04258449|DEVICE|DOvEEgene Fleur Sampling|Patients will undergo uterine sampling with DOvEEgene Fleur endometrial sampling device prior to surgical intervention, in addition to standard of care treatment.
224007939|NCT05588011|DEVICE|Terumo|A low pressure oxygenator (Terumo) will be used during cardiopulmonary bypass.
224126077|NCT05112458|OTHER|Usual care|Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
224126078|NCT02934412|DRUG|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
224126079|NCT02934412|DRUG|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
224126080|NCT00660504|DRUG|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
224126081|NCT00660504|DRUG|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
223388235|NCT05712499|BEHAVIORAL|ongoing life|The control group continued with their lives without any intervention. Only pre-test and post-test were applied. While the program was applied to the experimental group, no intervention was made to the control group.
223388236|NCT02401269|DRUG|Aspirin|
223388237|NCT02401269|DRUG|Placebo|
223545709|NCT04631315|DRUG|Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution|1 drop, 4 times a day, starting the day before surgery and continuing for 14 post-surgical days and 1 drop, twice a day for the next 2 weeks.
223545710|NCT01023152|PROCEDURE|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
223545711|NCT02797912|OTHER|No intervention|
224007940|NCT05588011|DEVICE|LivaNova|A high pressure oxygenator (LivaNova) will be used during cardiopulmonary bypass.
224007941|NCT06824675|OTHER|Teledidactic Training|Participants will take part in a tele-didactic training session, matching the duration of the control group's training. This workshop will cover the same content as the control group's session, but instead of in-person instruction, teaching experts will deliver the training remotely using telemedicine software.
224007942|NCT06824675|OTHER|In-Person Hands-on Training|Participants will attend a face-to-face, hands-on workshop led by experts to learn the eFAST protocol.
224007943|NCT06825000|BEHAVIORAL|neuro-education|30 minutes of videos about the neuroscience of stress, fear, emotion-regulation, and therapy.
224007944|NCT06825000|BEHAVIORAL|psycho-education|30 minutes of videos about the psychological science of stress, fear, emotion-regulation, and therapy.
224007945|NCT06859177|DEVICE|Remote eCTG|"Device: Remote eCTG monitoring~A remote self-administered electrophysiological cardiotocography (eCTG) monitoring (using Nemo Remote®), daily in a Home@Hospital setting, or at least twice weekly at the outpatient clinic, between 32 and 37 weeks of pregnancy."
224007946|NCT06859970|DEVICE|PAS-C System|All patients will undergo catheterization with the PAS-C System to create an interatrial shunt to reduce left atrial pressure in the heart.
224007947|NCT06857253|DRUG|HRS-1301|HRS-1301.
224007948|NCT06857253|DRUG|HRS-1301 placebo|HRS-1301 placebo.
224126082|NCT03878017|PROCEDURE|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
224126083|NCT06286956|DEVICE|Treatment of rectal lesions with UNI-VEC|Polyp resections
224126084|NCT06524999|BEHAVIORAL|Progressive muscle relaxation|This intervention consists of two parts. The first part gives short information about the content and how exercises should be done. It consists of information about deep relaxation. In the second part, there are relaxation exercises accompanied. Both the briefing and the intervention lasted 30 minutes for each patient.
224126085|NCT05429099|PROCEDURE|Virtual Surgical Planning (VSP)|The 3D reconstruction model, not requiring sterilization, will be sent directly to the SS. Prior to surgery, the SS will prebend a titanium fixation plate to the reconstruction model. Both the surgical cutting guides and titanium plate will be sterilized prior to use in surgery. If the planned resection cannot proceed (possibly due to tumour growth), the surgical team will note the reason for abandonment and conduct a standard FHS. Intraoperatively, the SS will apply the mandibular cutting guide to make the resection, remove the resected component and apply the pre-bent plate. Next, either the fibular or scapular cutting guide is applied to harvest the transplant which is then secured to the plate. The flap is re-vascularized by joining it to blood vessels in the neck.
224126086|NCT05429099|PROCEDURE|Free-Hand Surgery|The SS will adopt their standard procedure for the mandibular resection and reconstruction. This typically involves bending a titanium fixation plate, harvesting of the bony flap, and shaping of the segments all intraoperatively based on the SS's judgement.
224126087|NCT06432907|OTHER|motor tasks|"During the study session, the patient will sit at a table in front of a computer monitor. The stereoEEG electrodes will be connected to the Neurovisor-BMM52 electroencephalograph (Medical Computer Systems, Russia) and to a computer with a software for recording and decoding brain signals (BCI classifier). One microsensor (Ascension TrekStar, Ascension Technology, USA) and two disposable cutaneous electrodes (connected to the Neurovisor-BMM52 system) will be put on each patient's hand for electromyogram recording.~The session consists from 3 blocks (1-3). The participant is asked to:~1. execute simple motor tasks (thumbs up, open hand or clench hand into fist - 30 times with each hand with 5-second brakes), according to the instruction on the computer screen;~2. to imagine the same movements - 30 times with each hand with 5-second brakes;~3. to imagine the same movements with the feedback (brain-computer interface control).~The blocks are separated by 5-minute brakes."
224126088|NCT05750498|OTHER|No interventions|There are no interventions
223388238|NCT05878457|DEVICE|MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System|Treatment will consist 12 approximately-three-minute sessions on each of three treatment days within a seven-day period. To promote participant adherence and retention, treatment days will not need to be contiguous. A single session consists of 600 pulses delivered to the dmPFC at an intensity of 120% resting motor threshold (rMT). 50 hz triphasic bursts will be delivered for two seconds, followed by an 8 second inter-train interval. Trains will be repeated every 10 seconds, 10 times total, for a total of 190 seconds per session. An intersession interval of at least 15 minutes will be employed between each of the 12 sessions. Each treatment day will thus last approximately 3-4 hours in duration.
223388239|NCT05590364|DEVICE|Profhilo® Body|Dosage form: Profhilo® Body (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 3.25 ml non-pyrogenic pre-filled syringe, containing 3 ml of 3.2% hyaluronic acid for intradermal use (48 mg H-HA + 48 mg L-HA) dissolved in 3 ml of saline buffered sodium chloride.
223388240|NCT05702944|DRUG|Phenoxybenzamine|Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
223388241|NCT01308801|DEVICE|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
223388242|NCT01308801|DEVICE|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
223388243|NCT01897805|DRUG|Heart-protecting Musk Pill|
224007949|NCT04728204|BEHAVIORAL|Depresijos terapija|Intervention is based on the principles of cognitive behavioral therapy and culturally adapted to elderly Lithuanian population. The main purpose of the intervention is to reduce the symptoms of depression and increase psychological well-being. Intervention contains psychoeducation, examples, exercises and consultation with a psychologist.
224007950|NCT05753501|DRUG|ABBV-101|Oral:Tablet
224007951|NCT06595602|DEVICE|Artificial intelligence based decision support system (AI-DSS); software|"The device is intended for monitoring and recommending ventilator settings, ventilation mode to qualified Intensive Care Unit (ICU) health care professionals (HCP). This is for medical indications that require invasive mechanical ventilation of the respiratory system in the ICU under international / EU guidelines.~The device receives clinical data via the ICU's data integration platform that includes patient physical and demographic data as well as current vital signs, ventilation parameters, blood gas analysis, general blood laboratory reports, fluid balance and medication. Prediction models based on artificial intelligence algorithms are used to deduce therapy suggestions from received data. The algorithm is carried out on a secured cloud platform."
224007952|NCT06596694|BIOLOGICAL|Patritumab deruxtecan|Administered via intravenous (IV) infusion
224007953|NCT05406622|DEVICE|MOTIV Sirolimus-Eluting Bioresorbable Scaffold|Participants will receive the MOTIV device
224007954|NCT05406622|DEVICE|Percutaneous Transluminal Angioplasty (PTA) Device|Participants will receive PTA treatment
224007955|NCT06274190|DIAGNOSTIC_TEST|bowel e-diary|This bowel diary will be available on the smartphone in the form of an application.
224007956|NCT00809172|DRUG|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
224007957|NCT00809172|DRUG|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
224007958|NCT06677060|DRUG|Baxdrostat and dapagliflozin|baxdrostat tablet and dapagliflozin tablet
224007959|NCT06677060|OTHER|Placebo and dapagliflozin|placebo tablet and dapagliflozin tablet
223388244|NCT01897805|DRUG|Placebo|
223388245|NCT01679652|DRUG|Nebivolol|Tablet i blinded in capsula
223388246|NCT01679652|DRUG|placebo|
223388247|NCT02308124|DRUG|Midodrine|
224007960|NCT07001293|BEHAVIORAL|MomMA Intervention|The MomMA program is a CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings.
224007961|NCT07001293|OTHER|Treatment as Usual (TAU)|Participants will receive treatment as usual, including but not limited to medication and behavioral therapy. No participation in treatment is required.
224007962|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
224126089|NCT05413616|BEHAVIORAL|FITFOOD lifestyle intervention|Lifestyle intervention with a nutritional and exercise component.
224126090|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 1.0 mg/kg/week
223388248|NCT02308124|DRUG|Pyridostigmine Bromide|
223388249|NCT02308124|DRUG|Midodrine + pyridostigmine|
223388250|NCT03020771|BIOLOGICAL|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
223388251|NCT03020771|OTHER|Placebo|
223388252|NCT03716856|GENETIC|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
223388253|NCT03716856|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223388254|NCT03716856|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion
223388255|NCT00455156|DRUG|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
223388256|NCT01029743|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
224126091|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 2.0 mg/kg/week
224126092|NCT03359213|DRUG|JR-141|IV infusion (lyophilized powder), 4.0 mg/kg/week
224126093|NCT03919292|DRUG|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
224126094|NCT03919292|DRUG|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
223388257|NCT01029743|DRUG|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
224007963|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
224007964|NCT03331198|BIOLOGICAL|JCAR017 (lisocabtagene maraleucel) + venetoclax|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
223388258|NCT03567928|DEVICE|Sedation with Gastro Cuff Pilot Laryngeal Mask|This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.
224007965|NCT05116540|BIOLOGICAL|HB-adMSCs|Autologous product
224007966|NCT05116540|DRUG|Placebo|Normal Saline
224007967|NCT06858878|DRUG|Maridebart cafraglutide|Maridebart cafraglutide will be adminstered SC.
224007968|NCT06858878|DRUG|Placebo|Placebo will be adminstered SC.
223388259|NCT03567928|DRUG|Propofol|Target controlled infusion (TCI) with propofol
224007969|NCT04684563|BIOLOGICAL|huCART19-IL18|autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)
224007970|NCT05949606|DRUG|SI-B001|Administration by intravenous infusion
223388260|NCT03674398|BEHAVIORAL|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
223545712|NCT00610259|BEHAVIORAL|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
223545713|NCT00610259|OTHER|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
223545714|NCT01778959|DEVICE|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
223545715|NCT01778959|DEVICE|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
224007971|NCT05949606|DRUG|SI-B003|Administration by intravenous infusion
224007972|NCT06478017|DRUG|Belatacept|"Patients will receive 10mg/kg on Day 3 post-transplant (72 hours +/- 12 hours post-transplant)~Day 7 post-transplant (+/- 6 hours)~Day 16 (End of Week 2 after 1st dose of belatacept) post-transplant (+/- 2 days)~Day 30 (End of Week 4 after 1st dose of belatacept) post-transplant (+/- 3 days)~Day 58 (Week 8) post-transplant (+/- 3 days)~Day 86 (Week 12) post-transplant (+/- 3 days)~Patients will receive 5mg/kg Every 28 days (+/- 3 days) thereafter"
224007973|NCT06478017|DRUG|Tacrolimus|Prograf (tacrolimus) or tacrolimus generic
224007974|NCT06478017|DRUG|Mycophenolate Mofetil/Sodium|CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)
224007975|NCT06478017|DRUG|Prednisone|Prednisone
224007976|NCT06680232|BIOLOGICAL|PBGENE-HBV|PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.
224126095|NCT02668237|OTHER|OptiPAC|Molecular and urinary tests.
224126096|NCT02668237|OTHER|Usual care|Antibiotics for prevention.
224007977|NCT06869018|DRUG|LY3549492|Administered orally
224007978|NCT06869018|DRUG|Placebo|Administered orally
224007979|NCT05627856|DRUG|GNC-038|Administration by intravenous infusion
224007980|NCT06869889|PROCEDURE|Retrolaminar plane block|Retrolaminar plane infiltration with the local anesthetic mixture.
224007981|NCT06869889|PROCEDURE|Local wound infiltration|Local infiltration along the surgical incision.
224007982|NCT06674460|DRUG|Edaravone Dexborneol Sublingual Tablets|One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.
224126097|NCT04028492|DRUG|Tradipitant|BID
224126098|NCT04028492|DRUG|Placebo|BID
224126099|NCT04028492|DRUG|Open Label Tradipitant|BID
224126100|NCT05153733|DEVICE|RIFRAM implant|Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
224126101|NCT04742946|OTHER|Digital Physiotherapy Practice (Telerehabilitation)|Online Physiotherapy services
224296072|NCT05339646|DRUG|SSD8432 dose 13 and Ritonavir|"Cohort 10:~Group A: SSD8432 dose 13, on day1 under fasting condition, on day 6 under fatty food condition, ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date.~Group B: SSD8432 dose 13, on day1 fatty food condition, on day 6 under fasting condition ,Ritonavir, before SSD8432 dose 13 and BID on SSD8432 dosing date"
223545716|NCT01778959|DEVICE|standard OVD|use of a standard cohesive OVD during cataract surgery
223545717|NCT01778959|DEVICE|OVD|use of a highly cohesive OVD during cataract surgery
223545718|NCT05159258|OTHER||
224126102|NCT05610995|DEVICE|SENSIUM Patch|The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
224007983|NCT06674460|DRUG|Placebo|One placebo tablet, to be taken sublingually, twice daily
224007984|NCT07010978|BEHAVIORAL|Recovery Community Center Participation|Recovery community centers are brick and mortar buildings that house recovery-oriented organizations, located in the heart of their communities. They act as recovery hubs, offering a variety of recovery support services in house as well as connecting participants to resources in their area. They are peer-led organizations that are open to anyone in early or long-term recovery from substance use and that recognize that there are multiple pathways to recovery. Study participants will be provided with information about their local RCC (including a video link, contact information, a monthly calendar of events, a list of services and activities offered by the RCC, transportation options, etc.) and will be asked to visit the RCC on two different occasions within one month of enrollment.
224007985|NCT07010978|BEHAVIORAL|Enhance Treatment as Usual|In this study, the enhanced treatment as usual intervention will encompass providing participants with information about diverse recovery activities (e.g., mutual help group meetings, exercise, job search, recovery coach meetings, etc.) and then to assign participants to complete a recovery activity of their choosing one two different days within one month after enrollment. Participants can do the same activity twice, or different activities on each of the two days assigned.
224007986|NCT05145400|DRUG|Isatuximab|Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab:10 mg/kg intravenous or 1400 mg subcutaneous (SC) via on-body delivery system (OBDS) will be administered in cycles 1-24.
224007987|NCT05145400|DRUG|Lenalidomide|"Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death."
224007988|NCT05145400|DRUG|Dexamethasone|Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
224007989|NCT07009522|BEHAVIORAL|Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents - HEART|The group program for adolescents with ASD takes place weekly. Each session lasts 100 minutes (including a break), and the training includes a total of 12 sessions. The intervention is manualized and is based on the theoretical foundations of Cognitive Behavioral Therapy, Mindfulness-Based Therapy, and the TEACCH approach (Mesibov et al., 2005). Parallel to the adolescents, their parents will participate in a separate group training, which will be conducted in five sessions of 100 minutes each and is closely linked in content to the adolescent group training.
224296073|NCT05339646|DRUG|SSD8432 dose 14 and Ritonavir|Cohort 11: to be decided
224296074|NCT04272203|DRUG|ABBV-184|Intravenous (IV) infusion
224296075|NCT04030494|DIAGNOSTIC_TEST|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
224296076|NCT04030494|DIAGNOSTIC_TEST|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
224296077|NCT04030494|DIAGNOSTIC_TEST|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
224296078|NCT04392557|DRUG|Metformin / alogliptin Oral Product|850 or 1000 mg/ 12.5 mg every 12 hours for 12 months
224296079|NCT04392557|DRUG|Metformin / Pioglitazone Pill|(850 mg/15 mg every 12 hours) for 12 months
224296080|NCT04392557|DRUG|triple therapy|Metformin / Alogliptin/ Pioglitazone
224296081|NCT06273020|DRUG|Cerebrolysin|Cerebrolysin would be prepared according to manufacturer's instructions: 30 mL of cerebrolysin in 100 ml of saline solution every 24 hours to a minimum of 10 days and a maximum of 14 days
224296082|NCT06273020|PROCEDURE|Brain-MRI with contrast after 10-14 days of cerebrolysin|Blood-brain barrier (BBB) disruption will be measured using dynamic susceptibility contrast (DSC) magnetic resonance imaging. DSC MRI is collected during the injection of a gadolinium bolus and the majority of the change in recorded signal in this T2-weighted sequence is due to intravascular contrast. However, in the setting of gadolinium leakage through the BBB into the brain parenchyma, the recorded signal is altered by a T1 effect. An arrival time correction is performed to account for regional difference in blood flow after which the signal is separated into an intravascular and an extravascular component using a comparison with unaffected tissue.The extravascular component is captured with the metric K2 which reflects the fraction of the recorded signal that is due to gadolinium leakage and is a measure of BBB disruption.
224296083|NCT06388837|OTHER|Injectable Platelet Rich Fibrin|Patients underwent mandibular symphysis Onlay bone graft mixed with injectable platelet rich fibrin (I-PRF) placement.
224296084|NCT06388837|OTHER|Xenograft|Patients underwent mandibular symphysis Onlay bone graft mixed with Xenograft (InterOss® Anorganic Cancellous Granules).
224296085|NCT04303702|DRUG|Continue Oxytocin|The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
224296086|NCT04303702|OTHER|Discontinue Oxytocin|Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
224296087|NCT01677013|OTHER|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
224296088|NCT02135406|BIOLOGICAL|CART-19 T cells|
223388261|NCT03674398|BEHAVIORAL|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
223388262|NCT00564512|BIOLOGICAL|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
223388263|NCT00564512|BIOLOGICAL|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
223388264|NCT00564512|DRUG|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
224007990|NCT05319730|DRUG|Paclitaxel|80-100 mg/m\^2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
224007991|NCT05319730|DRUG|Irinotecan|180 mg/m\^2 IV infusion, administered on day 1 of every 14-day cycle.
224007992|NCT05319730|BIOLOGICAL|Pembrolizumab|200 mg IV infusion, administered every Q3W up to 35 infusions.
224007993|NCT05319730|BIOLOGICAL|MK-4830|800 mg IV infusion, administered Q3W up to 35 infusions.
224007994|NCT05319730|DRUG|Lenvatinib|20 mg oral administration every day.
224007995|NCT05319730|BIOLOGICAL|Sacituzumab tirumotecan|4 mg/kg or 5 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
224007996|NCT05319730|DRUG|Antihistamine|Administered per product label.
224007997|NCT05319730|DRUG|H2 Receptor Antagonist|Administered per product label.
224007998|NCT05319730|DRUG|Acetaminophen (or equivalent)|Administered per product label.
224007999|NCT05319730|DRUG|Dexamethasone (or equivalent)|Administered per product label.
224008000|NCT05319730|DRUG|Steroid Mouthwash (dexamethasone or equivalent)|Administered per product label.
224008001|NCT05319730|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or ointment may be given as a supportive care for Ocular Surface Toxicity.
224008002|NCT06624982|OTHER|observational study|Observational study; alveolar ridge preservation
224008003|NCT06672939|DRUG|Orforglipron|Administered orally
224008004|NCT06672939|DRUG|Placebo|Administered orally
224008005|NCT04348435|BIOLOGICAL|HB-adMSCs|Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
224008006|NCT04348435|OTHER|Placebos|Saline
224008007|NCT05668637|OTHER|Artificial Intelligence-based Decision support|Decision support to optimise invasive mechanical ventilation settings
224008008|NCT07012135|DIAGNOSTIC_TEST|Tests of sympathetic inhibition|Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
224008009|NCT07012135|DIAGNOSTIC_TEST|Tests of sympathetic activation|Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
224008010|NCT07012135|DIAGNOSTIC_TEST|Testing of autonomic dysreflexia|Cold pressor test of the foot and bladder pressor response will be tested.
224008011|NCT07014111|BEHAVIORAL|Fight Fatigue|Combined progressive muscle relaxation and walking (increasing step count) 12-week intervention that consists of education/training followed by text messages.
224008012|NCT07014111|OTHER|Attention Control|End-stage kidney disease education
224126103|NCT04222439|DEVICE|AI for the Diagnosis of Gastrointestinal Diseases|After receiving standard preparation regimen, patients go through colonoscopy or gastroscopy under the AI monitoring device. The whole procedure is monitored by AI associated recognition system. Gastrointestinal diseases will be detect and diagnosis in which the AI device will automatically captured relevant images and report the site of each segment on the screen. Histology analysis is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
224126104|NCT06973642|DEVICE|Software as a Medical Device (WizeCare)|Telehealth services will be provided through a telerehabilitation platform with AI capabilities and markerless motion capture.
224126105|NCT03644277|OTHER|Acute Intermitted Hypoxia|Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
224296089|NCT03352752|DEVICE|HTC Vive|Wearing VR helmet before operation
223388265|NCT00564512|DRUG|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
224008013|NCT06170606|DEVICE|Boston Scientific Cardiac Cryoablation System|"The Boston Scientific Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The main devices and components of the system consists of the following:~* POLARx™ or POLARx™ FIT Cryoablation Catheter~* POLARMAP™ Catheter~* POLARSHEATH™~* SMARTFREEZE™ Console~* Diaphragm Movement Sensor (DMS)~* Related Accessories"
223388266|NCT02248987|OTHER|patients treated with antipsychotics|
223388267|NCT04499469|PROCEDURE|Spreader Graft|To place and attach with 5.0 PDS suture 2 grafts in the middle third of the nose
224008014|NCT06875206|DEVICE|Low-intensity focused ultrasound|Low-intensity focused Ultrasound (LIFU) is a noninvasive brain stimulation technique that uses low-intensity ultrasound to stimulate specific parts of the brain.
224008015|NCT06875206|DEVICE|Immersive virtual reality|IVR is a noninvasive, computer-based audiovisual therapy designed to enhance visual function. Using a VR headset, the system delivers targeted visual stimulation through an interactive game that the participant engages with during each session.
224296090|NCT03352752|OTHER|Without HTC Vive|Wearing a blindfold before operation
224296091|NCT05610592|PROCEDURE|total mesorectal exicision|
223388268|NCT06810726|DEVICE|Platelet Rich Plasma|Tropocells(R) Autologous Platelet-Rich Fibrin
223388269|NCT06841770|BIOLOGICAL|OPC1|One injection of 10 million LCTOPC1 cells will be delivered to the target injection site of the damaged spinal tissue.
224008016|NCT06875206|DEVICE|Inactive Low-intensity focused ultrasound|High acoustic impedance disk placed between LIFU and scalp that mimics the audible sensation of a slight buzzing but attenuates more than 95% of the energy into the brain.
224008017|NCT06686394|BIOLOGICAL|Patritumab deruxtecan|Patritumab deruxtecan administered via IV infusion
224008018|NCT06686394|BIOLOGICAL|Trastuzumab|Trastuzumab administered via IV infusion
224008019|NCT06686394|BIOLOGICAL|Trastuzumab Biosimilar|Trastuzumab biosimilar administered via IV infusion
224008020|NCT06686394|BIOLOGICAL|Pertuzumab|Pertuzumab administered via IV infusion
224008021|NCT06686394|BIOLOGICAL|Tucatinib|Tucatinib administered as oral tablets
224008022|NCT07025291|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated salivav was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224008023|NCT05085782|DRUG|Propranolol Hydrochloride|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
224008024|NCT05085782|DRUG|Placebo|6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
224008025|NCT05085782|BEHAVIORAL|Reactivation procedure|Description/visualization of painful movements/activities
224008026|NCT05085782|BEHAVIORAL|Pain neuroscience education|In the form of 10 videos that participants will watch on their own time
224008027|NCT07017179|DRUG|AZD6234|Participants will receive a subcutaneous injection weekly
224008028|NCT07017179|DRUG|Placebo|Participants will receive a subcutaneous injection weekly.
224008029|NCT07017179|DRUG|AZD9550|Participants will receive a subcutaneous injection weekly
224008030|NCT07017179|DRUG|Plocebo|Participants will receive a subcutaneous injection weekly
224008031|NCT07017179|DRUG|AZD6234 in combination with AZD9550|Participants will receive a subcutaneous injection weekly
224008032|NCT07017179|DRUG|Placebo|Participants will receive a subcutaneous injection weekly
224008033|NCT06697600|BEHAVIORAL|UR-GOAL|Patients will view an AML video, complete the best/worst scaling, will be provided with a summary report, and will be asked to review and discuss at upcoming clinical visits. Caregivers, if available, will view an AML video, will be provided with a summary report, and will be asked to review. Oncologists will be provided with a summary report and will be asked to review and discuss at upcoming clinical visits.
224008034|NCT05335369|BEHAVIORAL|UR-GOAL|UR-GOAL helps conducts assessments of fitness, elicits patient values via Best-Worst Scaling, and elicits preferences for prognostic information and assesses prognostic awareness. The tool also includes an AML educational video.
224008035|NCT05513547|OTHER|LE protocol 1: exposure to artificial light|Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
224008036|NCT05513547|OTHER|LE protocol 2: natural daylight|Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
224008037|NCT05513547|OTHER|LE protocol 3: natural daylight with reduced short-wavelength proportions|Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
224008038|NCT07028905|PROCEDURE|Total caries removal|Total caries removal and application of bioactive material
224296092|NCT05920564|OTHER|Upper fibers of trapezius stretching|The Upper fibers of trapezius stretching intervention involves specific stretching exercises designed to target the upper fibers of the trapezius muscle. The stretching exercises will be performed under the guidance of a licensed physical therapist and will involve extending the neck while gently pulling the head downward to stretch the upper fibers of the trapezius muscle. The intervention is designed to improve neck range of motion, reduce pain intensity, and reduce disability in patients with cervical spondylosis. The duration and frequency of the stretching exercises will be standardized across participants, and adherence will be monitored throughout the study period.
224008039|NCT07028905|PROCEDURE|Partial caries removal|Partial caries removal then application of biodentin
224008040|NCT07029711|DRUG|Ritlecitinib higher dose|Study intervention will be provided as oral capsules centrally by the sponsor in high-density polyethylene (HDPE) bottles.
224008041|NCT07029711|DRUG|Ritlecitinib lower dose|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
224008042|NCT07029711|DRUG|Placebo|Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.
224008043|NCT06698770|OTHER|Anticipated long-term use of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life.
224008044|NCT06698770|OTHER|Period re-evaluation of medication|In this hypothetical scenario, the doctor anticipates that the participant will take this medication for the rest of their life but will periodically re-evaluate the benefits and risks of the medication.
224008045|NCT07030530|DEVICE|Virtual Glasses Group|Virtual Glasses Group; Pregnant women in the virtual reality group will be shown a virtual reality video in VR mode via smartphone during the NST procedure (with the pregnant woman lying on her left side). It will be watched with virtual reality glasses containing nature sounds (streams, birds, etc.). Pregnant women will be informed about the use of virtual reality goggles before being shown the virtual reality video and will be asked to stop watching the video if they feel any discomfort. It is recommended to watch virtual reality videos for 5-20 minutes because they may cause nausea and vomiting (23). Since this study includes pregnant women, it is planned to play the virtual reality videos for 5-10 minutes.
223388270|NCT06588439|OTHER|Cognitive-motor training|Cognitive-motor training is that cognitive tasks incorporated into motor tasks.
224008046|NCT07030530|OTHER|Mandala Coloring activity group;|Mandala Coloring activity group; In studies examining the effect of art therapy on the reduction of psychological symptoms, it has been shown that the use of round patterns is more effective in symptom management. In line with these studies, ready-made mandala coloring templates with round shapes will be used in our study. Each participant will be asked to choose one of the mandala coloring templates. Each participant will be given colored pencils and asked to color the mandala template of their choice during the NST
224008047|NCT07029555|BIOLOGICAL|PIT565|Study treatment will be provided in vials as open-label participant specific supply.
224008048|NCT06710132|DRUG|M9140|All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.
224008049|NCT06715241|COMBINATION_PRODUCT|combination of relatlimab and nivolumab wich are two immunotherapy treatments|Induction: Nivolumab 360 mg/relatlimab 360 mg fixed dose combination, IV, 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab 480 mg/relatlimab 480 mg fixed dose combination, IV 13 cycles (Q4W): 52 weeks
223730205|NCT04951245|PROCEDURE|UC group: ultrasound-assisted CNSs guided|1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast. The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla. During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used. Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle . A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters. Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region. Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
224008050|NCT06715241|OTHER|Nivolumab alone|Induction: Nivolumab alone 360 mg, IV2 cycles (Q3W): 6 weeks Off treatment period: 4 to 6 weeks Maintenance: Nivolumab alone 480 mg, IV, 13 cycles (Q4W): 52 weeks
224008051|NCT06875427|DRUG|Ropivacaine 2-2.5mg/kg + dexmedetomidine 1 mcg/kg delivered via a single-shot adductor canal block under ultrasound guidance|The local anesthetic (ropivacaine) + dexmedetomidine will be administered via single-shot adductor canal block under ultrasound guidance
224008052|NCT07033117|OTHER|Performance Feedback Reports on Referral and Evaluation Closures|Performance feedback reports will reflect each transplant center's performance related to kidney transplant evaluation initiation and referral closure. These reports aim to help centers understand common reasons why patients do not initiate the evaluation process or failed to proceed beyond the evaluation process, and to identify patterns in referral and evaluation closure practices. Reports will be individualized and distributed quarterly to the transplant center champion by the intervention lead.
224008053|NCT07033117|OTHER|Dialysis Facility Awareness Campaign|As part of the intervention, dialysis centers will participate in an Awareness Campaign designed to educate staff about transplant center quality improvement efforts and how they may be contacted as part of the project. This campaign may include brief webinars or informative documents distributed via platforms such as IPRO Learn.
224008054|NCT07033117|OTHER|Patient Contact via Preferred Method|Transplant centers will contact patients using their preferred method of communication.
224008055|NCT07033117|OTHER|Phone Call to Dialysis Facility During the Patient's Dialysis Session|Facilities will enhance their patient communication procedures by making a phone call to the dialysis facility during the patient's dialysis session if the patient has not responded to initial outreach attempts. This additional step increases the likelihood of reaching the patient during a time when they are accessible and can engage in scheduling or follow-up.
224008056|NCT07033117|OTHER|Phone Call to Provider|"Transplant centers will enhance their outreach procedures by making a phone call to the referring provider (e.g., nephrologist, medical assistant) or another provider involved in the patient's care (e.g., primary care provider) in the event of self-referral if the patient has not responded to initial outreach attempts or no-shows an initial evaluation appointment. This additional step ensures that the referring provider is informed of the patient's progress and can assist in re-engagement or decision-making prior to referral closure."
224008057|NCT07033117|OTHER|Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show|Transplant center staff will utilize transplant referral communication platforms and/or email to communicate updates to dialysis staff regarding patient status (e.g., unable to contact the patient or no-show) before referral closure.
224008058|NCT07033117|OTHER|Audit and Tracking of Patient Contact Attempts Prior to Referral Closure|Transplant center staff will continue internally tracking the frequency that a patient is contacted before closure and the date of closure, in alignment with center standard practice. This intervention introduces an audit process to be conducted before closure to ensure that all contact attempts (including one or more attempts to contact the patient directly, one or more phone calls to the alternate preferred contact, or one or more attempted contacts to the dialysis unit to connect with the patient), in alignment with center communication procedures, are appropriately executed.
224008059|NCT07036835|PROCEDURE|LASIK Surgery|Laser assisted in situ keratomileusis (LASIK) surgery conducted for the purpose of correcting refractive error
224008060|NCT07036835|DEVICE|UV fs-Laser|WaveLight Ultraviolet Femtosecond Laser used for creating a corneal flap during LASIK surgery
224008061|NCT07036835|DEVICE|IR fs-Laser|WaveLight FS200 Infrared Femtosecond Laser used for creating a corneal flap during LASIK surgery
224008062|NCT07036835|DEVICE|Anesthetic 1 eye drops|Topical anesthetic used to numb the surface of the eye
224008063|NCT07036835|DEVICE|Anesthetic 2 eye drops|Topical anesthetic used to numb the surface of the eye
224008064|NCT07032038|DRUG|Otic neural progenitors|Advanced Cell Therapy - tissue engineered product
224008065|NCT07032038|DEVICE|cochlear implantation|cochlear implant
224008066|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex|TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern
223388271|NCT06588439|OTHER|Conventional physiotherapy|Conventional physiotherapy includes stretching, ROM exercise, strengthening exercise, and eye-hand coordination.
223388272|NCT04806516|DEVICE|Summit RC+S System with ECoG Paddles|"Summit RC+S System with ECoG Paddles consists of:~* Olympus RC+S implantable pulse generator (IPG), Model B35300R: 2 per subject x 5 subjects = 10 units~* Extension Leads, Model 37087: 2 per subject X 5 subjects = 10 units~* DBS Leads, Model 3387: 2 per subject X 5 subjects = 10 units~* Patient Therapy Manager (PTM), Model 4NR009: 1 per subject x 5 subjects = 5 units~* Recharge Therapy Manager (RTM), Model 97755: 1 per subject x 5 subjects = 5 units~* Clinician Telemetry Module (CTM), Model 4NR011: 1 per subject x 5 subjects = 5 units~* Research Lab Programmer (RLP), Model 4NR010: 1 unit~* Research Software Development Kit (RDK), Model 4NR013: 2 units~* Subdural Quadripolar Paddle Lead, Model 09130: 2 per subject x 5 subjects = 10 units"
223388273|NCT04806516|OTHER|One Month Blinded Discontinuation Period:|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
223545719|NCT02008994|OTHER|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
224008067|NCT05931913|BEHAVIORAL|Exposure with Response Prevention|ERP will be delivered daily, immediately following TMS
224008068|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: Sham|Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex
224008069|NCT05931913|DEVICE|Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area|TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
224008070|NCT07044622|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The TENS 7000 digital TENS unit is a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
224008071|NCT07044622|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The TENS 7000 digital TENS unit is a low cost, over the counter, battery operated device with high consumer ratings. The handheld device works by transmitting an electronically generated topical stimulus to a specified area on the body to alter response to pain signals and promote endogenous endorphin release for pain reduction.
224008072|NCT06885658|BEHAVIORAL|Visual Storytelling Intervention for Antibiotic Adherence|The intervention involves the use of a visual storytelling approach designed to improve antibiotic adherence in patients diagnosed with urinary tract infections (UTIs). The intervention consists of a sticker featuring simple, visually appealing illustrations and a narrative highlighting the importance of completing the full course of prescribed antibiotics. The story contrasts the positive outcomes of adhering to the treatment with the negative consequences of stopping early, such as increased bacterial resistance. Key messages are reinforced through bold text and visual cues. This intervention aims to engage patients emotionally and cognitively, promoting behavior change by making the concept of antibiotic adherence more relatable and memorable.
224008073|NCT06709820|DRUG|LY4060874|Administered SC
224008074|NCT06709820|DRUG|LY4060874|Administered IV
224008075|NCT06709820|DRUG|Placebo|Administered SC
224008076|NCT06709820|DRUG|Placebo|Administered IV
224008077|NCT06451055|BEHAVIORAL|Low-calorie diet|The low-calorie diet consists of approximately 1,300 kcal/day (37% carbohydrates, 25% protein, 39% fat, and 7 g of fiber per meal) over an eight-week period. Participants receive weekly pre-prepared meals from Trifecta Nutrition (Trifecta Inc. California, USA) with options for breakfast, lunch, and dinner, meticulously crafted by certified dieticians and expert chefs. Participants are encouraged to consume 1-2 liters of water daily and maintain their habitual physical activity levels.
224008078|NCT06451055|BEHAVIORAL|Routine dietary and physical activity habits|Participants are asked to maintain their habitual dietary and physical activity habits for the 8-week study period.
224008079|NCT06725329|BEHAVIORAL|A tailored psychosocial education intervention|"Participants will get ten 60-minute psychoeducational group sessions about chronic pain and its management. The group sessions will be conducted by the PI and a bilingual project director at Korean churches or daycare centers in Baltimore-Washington Metropolitan area.~The psychoeducational group session will be adapted from LAMP intervention that has been previously developed. The intervention provides biopsychosocial education sessions about chronic pain and its management. For example, sessions focus on providing information regarding: (1) pain and the biological stress response and the gate control theory of pain, (2) the psychological impact of thoughts and emotions on pain and (3) facilitated group discussions to help participants develop a new understanding of pain through shared social experiences, all of which have been shown to improve pain outcomes."
224296093|NCT05920564|OTHER|Standard care|The Control Group in this study will receive standard care, including heat treatment and strengthening exercises, but will not receive the specific Upper fibers of trapezius stretching intervention that is being tested in the Treatment Group.
223545720|NCT02041299|DRUG|Deferiprone|
224008080|NCT07048197|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of Rapcabtagene autoleucel
224008081|NCT04806347|BIOLOGICAL|TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft|After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.
224296094|NCT05841147|DRUG|Tirofiban|Intravenous administration of tirofiban
223545721|NCT02041299|DRUG|Deferoxamine|
223545722|NCT02034643|PROCEDURE|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
223545723|NCT04464811|DIAGNOSTIC_TEST|Furosemide stress test|Furosemide stress test is performed by administration of intravenous furosemide 1 mg/kg in patients who do not receive oral furosemide before and 1.5 mg/kg patients who have never received oral furosemide.
223730206|NCT04951245|PROCEDURE|GC group: CNSs plus ICG dual-tracer-guided|The preparation of CNSs mapping was identical to that of the UC group. 1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast. A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs. All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed. The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
224008082|NCT04806347|DEVICE|CliniMACS® System|The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
224008083|NCT05973851|DRUG|Esketamine Nasal Product|See arm description
224008084|NCT05973851|DRUG|Ketamine Hydrochloride|See arm description
224008085|NCT05973851|DRUG|Esketamine hydrochloride|See arm description
224008086|NCT05973851|DRUG|Second-line Antidepressants|See arm description
224008087|NCT07049900|DEVICE|NeoBelly Band|The DandleLion NeoBellyBand (NBB) is an FDA listed Class 1 medical device that is 510k exempt and is categorized under therapeutic medical binders. This device is indicated to be used while the infant is receiving CPAP support in order to reduce CBS. The NBB is made of a medical-grade blend of fabric and foam that is latex and neoprene-free and is reported as safe to use on premature infant skin. There are two sizes available and the outer fabric is attached with adjustable Velcro. It is a single baby use and may be hand washed and reused. This device is currently in use in multiple NICUs around the country, and as it has already been FDA-approved for the purpose of our investigation.
224008088|NCT06745843|OTHER|Questionnaire|The patient information, informed consent form and questionnaire will collectively be distributed digitally or by mail to all patients.
224008089|NCT07044817|BEHAVIORAL|Stroke Rehabilitation Guideline Adherence Survey|"This intervention consists of a structured online survey, the Stroke Rehabilitation Guideline Adherence Survey, designed to assess physiotherapists' and physiotherapy internship students' adherence to stroke rehabilitation clinical practice guidelines, their attitudes toward implementing evidence-based post-stroke care, and the perceived barriers-such as time constraints, limited resources, or insufficient training-that influence their compliance. No clinical treatments or procedures are administered; the sole intervention is the delivery of this comprehensive questionnaire."
224008090|NCT06739122|DRUG|Dulaglutide|Administered SC
224008091|NCT06482073|OTHER|Non-Interventional Study|Non-interventional study
224008092|NCT07051330|OTHER|Healthy Minds Program (HMP) app|"All participants will complete baseline surveys, weekly questionnaires (for 4 weeks) through the HMP app intervention, and will be surveyed again at 3-months post-intervention. Participants are randomized to each of the following binary conditions.~1. Introduction video for the app (yes / no)~2. Introduction video for the training modules (yes / no)~3. Module order based on ACIP score (highest-first / lowest-first)~4. Practice-nudging text messages (yes / no)~5. Microsupport messages during the intervention period (yes / no)~6. Microsupport messages during the follow-up period (yes / no"
224008093|NCT06090669|DRUG|imatinib|Imatinib at 300-400 mg PO QD based on arm assignment/dose level
224126106|NCT03644277|PROCEDURE|Massed Practise|"Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve \>100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded."
224296095|NCT05841147|DRUG|normal saline|Intravenous administration of normal saline
224296096|NCT04828798|DEVICE|Deep brain stimulation of the VIM Thalamic nuclei|Deep brain stimulation of the thalamus, in a directional and nondirectional manner
224296097|NCT02025231|RADIATION|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
223730207|NCT04469114|DRUG|Tofacitinib 10 mg|Tofacitinib 10mg administered orally twice daily for 14 days or until hospital discharge
223730208|NCT04469114|DRUG|Placebo|Tofacitinib-matching placebo administered orally twice daily for 14 days or until hospital discharge
223730209|NCT05762003|DRUG|interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab|Administered as part of routine clinical practice.
223730210|NCT00945139|DRUG|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
223730211|NCT00945139|DRUG|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
224008094|NCT06090669|DEVICE|TruSight Oncology|Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA
224008095|NCT06813274|DRUG|hypoglycemic treatment|"The diabetes management adheres to the The 2025 Guidelines for Standards of Diabetes Care issued by the American Diabetes Association (ADA)."
224008096|NCT06813274|DRUG|Tangshen'an Granules|Tangshen'an Granules comprises a meticulously blended mix of Astragalus, Prepared Rehmannia Root, Dodder Seed, Kudzu Root, Millettia Speciosa Champ, Salviae Miltiorrhizae Radix et Rhizoma, Poria Cocos, and Polygala Tenuifolia. Tangshen'an Granules is administered at a dosage of 9g, dissolved in boiling water, and taken three times daily.
224008097|NCT06813274|DRUG|Ginkgo Leaf Tablets|The primary active ingredients of Ginkgo Leaf Tablets are ginkgo flavonoid glycosides and terpene lactones. The prescribed oral dosage is one tablet each time, administered three times a day.
224008098|NCT06813274|DRUG|Mecobalamin Tablets|Mecobalamin Tablets primarily contain mecobalamin, which is a coenzyme-active form of vitamin B12. The prescribed oral dosage is 0.5mg, administered three times a day.
224008099|NCT06813274|DRUG|placebo|The placebo contains 10% of the active ingredients in Tangshen'an Granules, formulated by controlling the concentration to mimic Tangshen'an Granules. The placebo is administered at a dosage of 9g, dissolved in boiling water, and taken three times daily.
224008100|NCT05668858|DRUG|SI-B001|Administration by intravenous infusion
224008101|NCT05668858|DRUG|SI-B003|Administration by intravenous infusion
224126107|NCT03644277|OTHER|Rapael Glove|The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
224126108|NCT06408025|OTHER|Syrenity App|"Currently, the Syrenity App has two active interventions. One is an exposure-based intervention called Face your fears. Another is an intervention based on behavioral activation called Get better. The app also provides self-report questionnaires for tracking mood along with psychoeducation on a variety of topics relevant to mental health."
224126109|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.~Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment."
224296098|NCT02422914|BEHAVIORAL|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
224299264|NCT06168877|DIAGNOSTIC_TEST|Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.|PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).
224299265|NCT00040053|DRUG|Ondansetron|
224299266|NCT01524614|PROCEDURE|nasal mask|nasal mask use instead of face mask
223388274|NCT06367985|OTHER|Air Oxygen Concentration CAPA-IVM culture|"* Group 1A: COC will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 1B: COCs will be cultured in the CAPA step at an air oxygen concentration (20%) for 24 hours and in the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
223545724|NCT03123770|DRUG|Pegylated liposomal doxorubicin|a new kind of doxorubicin
223545725|NCT03123770|DRUG|Cyclophosphamide|traditional chemotherapy drug
223545726|NCT03123770|DRUG|Epirubicin|traditional chemotherapy drug used in breast cancer
223545727|NCT03123770|DRUG|Docetaxel|traditional chemotherapy drug used in breast cancer
223730212|NCT03370354|BEHAVIORAL|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
224008102|NCT06550388|BEHAVIORAL|Nutritional Education|In addition to the traditional course of CBT-I, the PI will provide education and materials regarding the Mediterranean Diet. Patient will be provided with the Mayo Clinic booklet on Mediterranean Diet and asked to increase their daily intake in two categories assessed by the Mini-EAT.
223730213|NCT01797003|OTHER|High tibial osteotomy|
224008103|NCT06550388|BEHAVIORAL|Physical Activity|In addition to the traditional course of CBT-I, the PI will recommend patient to increase physical activity minutes per week. The increase in physical activity will be based on patient's current level of physical activity.
224008104|NCT03598257|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224008105|NCT03598257|DRUG|Olaparib|Given PO
224008106|NCT03598257|RADIATION|Radiation Therapy|Undergo radiation therapy
224008107|NCT03598257|OTHER|Survey Administration|Ancillary study
224008108|NCT05563220|DRUG|Elacestrant|Elacestrant 86 mg, 172 mg, 258 mg or 345 mg once daily in cycles of 28 days
224008109|NCT05563220|DRUG|Alpelisib|Alpelisib 150 mg or 250 mg once daily in cycles of 28 days
224008110|NCT05563220|DRUG|Everolimus|Everolimus 5 mg, 7.5 mg, or 10 mg once daily in cycles of 28 days
224008111|NCT05563220|DRUG|Ribociclib|Ribociclib 400 mg or 600 mg once daily for 21 days followed by 7 days off in cycles of 28 days
223545728|NCT01738633|BEHAVIORAL|nutritional counseling|
223545729|NCT01738633|BEHAVIORAL|respirology counseling|
224008112|NCT05563220|DRUG|Palbociclib|Palbociclib 100 mg or 125 mg once daily for 21 days followed by 7 days off in cycles of 28 days
224008113|NCT05563220|DRUG|Capivasertib|Capivasertib 200 mg or 320 mg or 400 mg twice daily for 4 days on, 3 days off in cycles of 28 days
224008114|NCT05563220|DRUG|Abemaciclib|Abemaciclib 100 mg or 150 mg twice daily in cycles of 28 consecutive days
224008115|NCT06768827|OTHER|Lactulose Oral Product|Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
224008116|NCT06898242|OTHER|Manual myofascial treatment direct to upper and lower limb|Manual treatment direct specifically on fascia connective tissue
224008117|NCT06898242|OTHER|Rehabilitative treatment following rehabilitation project|Intensive multidisciplinary rehabilitation program for at least 180 minutes/day, 6 days a week, following rehabilitation project
224008118|NCT06808217|DEVICE|FARAPULSE Pulsed Field Ablation System|Subjects who have provided written informed consent are considered enrolled. Subjects who have received ablation treatment with the FARAPULSE™ System are assigned to the 'TREATMENT' group.
223388275|NCT06367985|OTHER|Low Oxygen Concentration CAPA-IVM culture|"* Group 2A: COC will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and 6% carbon dioxide at 37 degrees Celsius.~* Group 2B: COCs will be cultured in the CAPA step at a low oxygen concentration (5%) for 24 hours and the IVM step at an air oxygen concentration (20%) for 30 hours; all two steps combine 6% carbon dioxide at 37 degrees Celsius."
223388276|NCT01447043|DRUG|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
223388277|NCT03354715|DEVICE|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
224008119|NCT06834932|DRUG|Placebo|Administered orally as tablets
223388278|NCT03354715|DEVICE|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
224008120|NCT06834932|DRUG|Rosuvastatin Dose 1|Administered orally as tablets
224008121|NCT06834932|DRUG|Rosuvastatin dose 2|Administered orally as tablets
224126110|NCT05661383|DEVICE|Non-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.|"Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks).~One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session."
224126111|NCT04278729|DRUG|Apixaban 5 MG|1 - 5 mg tablet taken orally twice a day
224126112|NCT06552364|DRUG|LABA+LAMA|1 dose per day (AM)
224126113|NCT06552364|DRUG|LABA+LAMA+ICS|1 dose per day (AM)
224126114|NCT06552364|OTHER|Filtered Air|Exposure to HEPA filtered air, as a control
223388279|NCT04077580|DRUG|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
223388280|NCT02074007|DRUG|AR01|drops administered as needed for pain
223388281|NCT02074007|DRUG|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
223388282|NCT01573104|OTHER|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
223388283|NCT01573104|OTHER|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
223388284|NCT01573104|OTHER|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
223388285|NCT05082974|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 (varenicline 0.6mg/ml) nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of Drye Eye Disease. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production to bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
223388286|NCT05082974|DRUG|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray \[control\]
223388287|NCT00028977|DRUG|herba scutellaria barbata|
223388288|NCT00028977|OTHER|herba scutellaria Barbatae (HSB)|
223388289|NCT04640870|DRUG|Afatinib|Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
224008122|NCT06834932|DRUG|AZD0780|Administered orally as tablets
224008123|NCT06876766|DEVICE|Lung Ultrasound|Lung ultrasound (LUS) is a non-invasive, radiation-free imaging technique that uses sound waves to visualize the lungs. It will be used in the experimental arm to help guide decisions regarding antibiotic therapy in hospitalized children and adolescents with lower respiratory tract infections (LRTIs). The LUS will be performed within 24 hours of enrollment.
224008124|NCT06876766|DEVICE|Sham|In the sham group, participants will undergo a mock or placebo version of the lung ultrasound. This involves performing the procedure in a way that mimics the real ultrasound process but does not provide any diagnostic results or influence clinical decision-making regarding antibiotic therapy.
224008125|NCT07069725|DRUG|AZD2389|Doses of AZD2389 will be administrated orally
224008126|NCT07069725|DIAGNOSTIC_TEST|PET scan and radioligand|PET scan and radioligand
224008127|NCT04536584|OTHER|Personalized Coaching (Arm A)|Patients will receive personalized physical activity coaching with an online digital platform to take online educational workshops and interact with other peers of the cohort with a online private forum. They will also have a connected watch that will measure several physical activity metrics.
224008128|NCT04536584|OTHER|Standard supportive approach (Arm B)|Patients will receive the standard recommendations during their visits with the oncologist. The exercise recommendations include strength training and aerobic activities.
224126115|NCT06552364|OTHER|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
224126116|NCT05071716|DRUG|Rifaximin SSD|Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily
224126117|NCT05071716|DRUG|Placebo|Placebo Twice Daily
224126118|NCT06556277|DRUG|Metyrapone And Hydrocortisone|"Drug: Metyrapone 250 mg Oral Tablets~During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Hydrocortisone 19,9mg/12mg s.c., pulsatile with a flow rate of 10μl/s~Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 in a total daily dose of 19.9mg and 12mg on day 7"
223388290|NCT02251899|BEHAVIORAL|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
224008129|NCT06900374|DEVICE|GynWave-360|"For patients randomized to the experimental group:~3 sessions of 20 minutes each, spaced 4 to 6 weeks apart (M0, M1, M2) ideally, with +/- 1 maintenance session between 8 and 12 months after the first session (M8-12)."
224008130|NCT06900374|OTHER|Local hydratation|Reference treatment combining local hydration (hyaluronic acid-based treatment, 3 times a week), with the possibility of using associated measures at the investigator's discretion (physiotherapy, vaginal dilators, etc.).
224008131|NCT07069569|DRUG|AHB-137|AHB-137 will be injected.
224008132|NCT07069569|DRUG|Peg-IFN|Peg-IFN will be administered .
224008133|NCT07069569|DRUG|Hepatitis B Vaccine|Hepatitis B vaccine will be administered.
224008134|NCT06816329|BEHAVIORAL|Computer Task Manipulation|Participants will complete computer tasks.
224008135|NCT06822569|OTHER|Cue reactivity paradigm|Participants will be exposed to cues in a fixed sequence while they answer questions about their emotions and thoughts. The cues will include everyday items (e.g., an ink pen) and substance-related items (e.g., a vape pen).
224008136|NCT06634719|DEVICE|Juveena Hydrogel System|The Juveena Hydrogel System is a single-use device that is instilled into the endometrial cavity as a liquid and sets up as a gel intrauterine tamponade within seconds.
224126119|NCT06556277|DRUG|Placebo|"Drug: Placebo 250 mg Tablets~During another phase of the study: identical looking placebo pills starting Day 1 During one phase of the study: Metyrapone (pills of 250mg) on full stomach: Day 1 0-1-2, day 2 1-2-2, day 3 3-3-4 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-0-0~Drug: Placebo (0,9% NaCl solution)~Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 6 and 12mg on day 7"
224126120|NCT06277154|BIOLOGICAL|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.
224126121|NCT06277154|DRUG|Doxorubicin|Commercially approved for cancer treatment
224126122|NCT06277154|DRUG|Ifosfamide|Commercially approved for cancer treatment
224008137|NCT05310448|DEVICE|Optune device|Wear Optune device
224126123|NCT05674747|DEVICE|Swift Microwave treatment - weekly x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
224126124|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 4wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
224126125|NCT05674747|DEVICE|Swift Microwave treatment - Every other week x 24wks|"Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.~Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions)."
224126126|NCT01217281|PROCEDURE|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
224126127|NCT06268886|DRUG|BMS-986446|Specified dose on specified days
224126128|NCT06268886|OTHER|Placebo|Specified dose on specified days
224126129|NCT03897920|OTHER|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
224126130|NCT04481425|OTHER|SMS intervention|SMS intervention
224008138|NCT06215066|DEVICE|Virtual reality|The VR goggles and headset phone were placed on the patient's head, straps secured, and lens spacing adjusted for a clear visual field. Patients were instructed to use head movements to control the cursor and interact with the virtual content. The 3D video clips with natural sceneries and background music were played to create a relaxing experience.
224008139|NCT06215066|OTHER|Modified Progressive Muscle Relaxation|The exercises applied to specific body parts while patients closed their eyes and practiced deep breathing, accompanied by background music.
224126131|NCT03946423|PROCEDURE|Bariatric Surgery with Sleeve Gastrectomy|Standard of care bariatric surgery with sleeve gastrectomy
224126132|NCT03946423|BEHAVIORAL|Lifestyle Intervention|All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
224008140|NCT06533826|DRUG|Trastuzumab Deruxtecan|A HER2-directed ADC, 100mg/vial, via intravenous (into the vein) infusion per protocol.
224008141|NCT06533826|DRUG|Datopotamab Deruxtecan|A TROP2-directed antibody drug conjugate, 100mg/vial, via intravenous (into the vein) infusion per protocol.
224008142|NCT06040086|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study.
224008143|NCT06040086|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study.
224008144|NCT06621524|DEVICE|EucaLimus coronary stent system|The EucaLimus coronary stent system is a drug-coated coronary stent system, indicated for use in patients with symptomatic ischaemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries.
224008145|NCT06900725|DRUG|edoxaban|edoxaban 15 mg daily will be administered to the patients as secondary stroke prevention.
224008146|NCT06900725|DRUG|Edoxaban 30 mg|edoxaban 30 mg daily will be administered to the patients as secondary stroke prevention.
224008147|NCT05886621|BEHAVIORAL|Smiling instead of Smoking - HIV|"Participants will be onboarded to the smartphone app Smiling instead of Smoking - HIV (SiS-H) and will be asked to complete the integrated SiS-H program while they quit smoking. The integrated SiS-H treatment consists of: (1) face-to-face onboarding to the SiS-H app, (2) one face-to-face session discussing app usage and antiretroviral therapy (ART) adherence (Life Steps), with direct linkage to tools in the app supporting ART adherence, and (3) an 8-week course of the SiS-H app. The SiS-H app is a smoking cessation app that uses a positive psychology framework in conjunction with with the US Clinical Practice Guidelines for smoking cessation to guide participants through the process of quitting smoking."
223388291|NCT01258309|DRUG|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
224008148|NCT05886621|BEHAVIORAL|QuitGuide|"Participants will be onboarded to the NCI smartphone app QuitGuide(QG) and will be asked to use it for 8 weeks to support them in quitting smoking. The QuitGuide app follows the US Clinical Practice Guidelines. The app is freely available on NCI's Smokefree.gov website, which is a recommended resource for treating smokers in the healthcare setting. The QuitGuide app is frequently used as a comparison app in smartphone app smoking cessation studies. It asks participants to set a quit day, track their mood and cravings, and log their cigarettes. It provides app users with guidance on quitting (i.e., Learn to Quit information), offers strategies to counter smoking triggers, and allows users to set reminders to stay smoke free (time and location based)."
224008149|NCT06906757|DRUG|Erythromycin 250mg + placebo|Antibiotic.
224008150|NCT06906757|DRUG|Azithromycin 500mg + placebo|Antibiotic.
223730214|NCT04284618|DIAGNOSTIC_TEST|assessment of standardized and off axis view radiographs|Radiographic assessment of hallux valgus interphalangeus angles is performed on preoperative standing anteroposterior and on off axis view radiographs. These radiographs are taken by equalizing the hyperpronation of the greater toe.
223388292|NCT01258309|DRUG|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
223730215|NCT05847231|BEHAVIORAL|Perceived Stress, Mandala application|Mandala
224008151|NCT06906757|DRUG|Erythromycin 250mg and Amoxicillin 500mg|Antibiotics.
224008152|NCT06906692|DIAGNOSTIC_TEST|Serum Bactericidal Assay|The Serum Bactericidal Assay (SBA) will be used for the analysis of the antibody titer, which represents a valid surrogate for the efficacy of the tetravalent vaccine. Subjects' sera will be serially diluted and incubated with a solution containing a certain strain of meningococcus. At this point, an exogenous source of rabbit complement will be added. Bactericidal activity will be assessed against controls. Neutralizing antibody titers will be defined as the highest dilution of sera at which at least 50% of bacteria death occurs. Antibody titers will be considered protective with a cut-off greater than or equal to 1:8.
224126133|NCT06810843|DRUG|Remazolam combined with afentanil for non-intubated thoracoscopic surgery|Remazolam combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,
224126134|NCT06810843|DRUG|Propofol combined with afentanil in non-intubated thoracoscopic surgery|Propofol combined with afentanil for sedation in patients undergoing non-intubated thoracoscopic surgery,
223388293|NCT01595685|DRUG|Telbivudine|Telbivudine 600 mg Daily Oral
223388294|NCT01595685|DRUG|Entecavir|Entecavir 0.5 mg Daily Oral
223388295|NCT01627678|DRUG|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
223388296|NCT01627678|DRUG|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
223388297|NCT06357585|OTHER|Web based education|Web-based training will be provided to the parents in the experimental group regarding care practices for children diagnosed with leukemia.
223388298|NCT06357585|OTHER|inactive group|Parents in the control group will continue to receive routine care and treatment.
223388299|NCT01050439|PROCEDURE|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
223388300|NCT01050439|OTHER|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
223388301|NCT03081780|BIOLOGICAL|FATE-NK100|"Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
224126135|NCT03523832|DRUG|Celecoxib and Pregabaline|Single dose versus repetition dose
223388302|NCT00207519|BEHAVIORAL|weekly behavioral modification group|
223388303|NCT00207519|BEHAVIORAL|liquid meal replacements|
223388304|NCT02642172|DIETARY_SUPPLEMENT|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
223388305|NCT02642172|DIETARY_SUPPLEMENT|Placebo|Participants will consume 16 g/day maltodextrin
223388306|NCT03333434|DEVICE|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
224126136|NCT03523832|OTHER|Placebo|Placebo
224126137|NCT00083239|DRUG|talabostat (PT-100) tablets|
224299267|NCT04202809|DRUG|Durvalumab|Durvalumab is given earlier as registered, during chemotherapy and radiotherapy in treatment Arm A
224299268|NCT05206292|DIAGNOSTIC_TEST|Sulfitest|Urine strip to detect the presence of sulfites in urine. Immediate result.
223388307|NCT03333434|DEVICE|Hinged AFO|
223388308|NCT00248872|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
223388309|NCT02176265|DEVICE|Qvanteq bioactive coronary stent|PCI
223388310|NCT01974973|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
223388311|NCT00255554|BEHAVIORAL|Dialectical Behavioral Therapy|
223388312|NCT00255554|DRUG|Escitalopram|
223388313|NCT04032015|DEVICE|TMS|Device used to administer electromagnetic fields to the brain to alter connectivity patterns
223388314|NCT02881684|DEVICE|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
223388315|NCT02881684|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
224008153|NCT07094685|PROCEDURE|Biopsy Procedure|Undergo biopsy
224126138|NCT02610400|COMBINATION_PRODUCT|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) \> 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
224126139|NCT02610400|COMBINATION_PRODUCT|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
224126140|NCT02610400|COMBINATION_PRODUCT|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) \> 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
224126141|NCT01123278|DRUG|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
224126142|NCT01123278|DRUG|Placebo|Placebo transdermal gel (5 gr)
224126143|NCT01716468|OTHER|Ketogenic Diet|modified ketogenic diet
224299269|NCT00119067|BIOLOGICAL|Anthrax Vaccine Adsorbed|
224299270|NCT00119067|BIOLOGICAL|Saline injection|
223388316|NCT05361590|DEVICE|Lumoral device|The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
223388317|NCT02961998|DRUG|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
224008154|NCT07094685|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224008155|NCT07094685|PROCEDURE|Computed Tomography|Undergo PET-CT and CT scan
224008156|NCT07094685|BIOLOGICAL|Ivonescimab|Given IV
224008157|NCT07094685|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224008158|NCT07094685|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
224008159|NCT07094685|PROCEDURE|Surgical Procedure|Undergo surgical dissection
223388318|NCT02961998|DRUG|Sorafenib|Each group will receive sorafenib as basic treatment.
223388319|NCT01506388|DEVICE|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
223388320|NCT01506388|DRUG|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
223388321|NCT01506388|DRUG|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
223388322|NCT04350411|DEVICE|Conventional diathermy|Abdominal free flap raise performed with conventional diathermy. Settings: cutting 40 Watt, coagulation 40 Watt.
223388323|NCT04350411|DEVICE|PEAK PlasmaBlade™|Abdominal free flap raise performed with PEAK PlasmaBlade™ Settings: cutting 7 (35 Watt), coagulation 7 (35 Watt)
223388324|NCT01564043|BEHAVIORAL|website and pedometer|use of pedometer and website
224008160|NCT07099898|BIOLOGICAL|GSK5764227|GSK5764227 will be administered
223388325|NCT06861478|DRUG|Omeprazol 40 mg IV|Daily until discharge
223730216|NCT02378701|BEHAVIORAL|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
223730217|NCT02378701|BEHAVIORAL|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
224008161|NCT07099898|DRUG|Topotecan|Topotecan will be administered
224008162|NCT03553511|PROCEDURE|Vaginal vault suspension to the uterosacral ligaments|Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments
224008163|NCT03553511|PROCEDURE|McCall culdoplasty|Vaginal hysterectomy with McCall culdoplasty
224008164|NCT06937229|DRUG|KarXT|Specified dose on specified days
224008165|NCT06937229|DRUG|KarX-EC|Specified dose on specified days
224008166|NCT07144306|DIAGNOSTIC_TEST|Smartphone-based AI skin lesion analysis (NuvanaDx platform).|Smartphone-based AI skin lesion analysis (NuvanaDx platform).
224008167|NCT07153991|DRUG|Donepezil group|Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months
224008168|NCT07153991|DRUG|Placebo group|35 Pacients with tinnitus received for 3 months placebo medication
224008169|NCT07154966|OTHER|Standard Chemotherapy (Carboplatin-Paclitaxel)|Standard-of-care chemotherapy with carboplatin (AUC 5, every 21 days) and paclitaxel (175-200 mg/m², every 21 days) for six cycles. No additional drugs, dose modifications, or alternative regimens introduced.
224008170|NCT07150247|DRUG|Iparomlimab and Tuvonralimab|3mg/kg，ivdrip
224008171|NCT07150247|DRUG|Bevacizumab|5mg/kg，ivdrip
224008172|NCT07150247|DRUG|5-Fluorouracil|400mg/m2 iv followed by 2.4g/m2 civ 48h
224008173|NCT07150247|DRUG|Irinotecan (drug)|180mg/m2
223388326|NCT06657937|OTHER|Questionnaire|"An initial questionnaire is completed on D0, the day of the patient's admission to the emergency department, by the practitioner in charge of the patient, and covers the patient's anamnesis, clinical examination, radiological examinations and treatment.~A follow-up telephone visit is then carried out at 30 days by an investigator, to gather information on the clinical and therapeutic evolution, and to evaluate the recovery and evolution of symptoms experienced by the patient in relation to the initial management."
223388327|NCT03622424|DEVICE|Gelesis200|Gelesis200: Three (3)Gelesis200 capsules (2.10 g) three (3) times per day (i.e., breakfast, lunch, and dinner)
223388328|NCT03622424|DEVICE|Placebo|Placebo: Three (3)placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)
223388329|NCT03622424|DEVICE|Gelesis200 and Placebo|Placebo and Gelesis200: Three (3) placebo capsules at breakfast,and three (3) Gelesis200 capsules (2.10 g)two (2) times per day (i.e., lunch and dinner)
223388330|NCT05510284|OTHER|Doula-coordinated, midwife-delivered postpartum care|A doula will coordinate all postpartum care and provide support to the participant. A midwife will be available on-site in the NICU to provide postpartum care.
223388331|NCT01738451|DRUG|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
223388332|NCT01738451|DRUG|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
223388333|NCT00530205|OTHER|physiologic testing|
223388334|NCT00530205|OTHER|questionnaire administration|
223388335|NCT00530205|PROCEDURE|management of therapy complications|
223388336|NCT00530205|RADIATION|radiation therapy|
224126144|NCT03716232|DEVICE|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~\- Stent will be extracted endoscopically after 6 months."
223388337|NCT04201197|DRUG|Inje cocktail|Acute drug exposure
223388338|NCT04201197|DRUG|THC Cannabis extract|Acute drug exposure
223388339|NCT04201197|DRUG|THC/CBD Cannabis Extract|Acute drug exposure
223388340|NCT05308433|DEVICE|Functional MRI|The volunteer will have to imagine the smells evoked by different visual aids. This task will be carried out during 2 acquisition runs of about 10 minutes each. The volunteer should note (on a scale from 1 to 4) the pleasantness of the smell evoked.
223388341|NCT05308433|OTHER|Virtual Reality: control|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. In the center of the maritime scene, it will be visible the black outlines of a frame. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
223388342|NCT05308433|OTHER|Virtual Reality: experimental|The volunteer will be immersed in a virtual maritime environment with nauseating characteristics. The visual support inserted in the center of the virtual scene will be the one defined as being the most facilitator of the olfactory imagination during the fMRI examination. The volunteer will be asked to concentrate on the smell evoked by this support. Every minute, the volunteer will be asked to verbalize the level of his general condition via the Fast Motion Sickness Scale (1 to 20).
223388343|NCT04810715|OTHER|Patients with Ankylosing Spondylitis|Observational study, not applicable
223388344|NCT04722497|OTHER|Sound Education|All physicians and nurses involved in cesarean births will be given an education intervention explaining the impact of noise levels on stress and focus. The SoundEar device will be used as an intervention tool to inform operating room physicians and nurses when the noise level is above the desired level.
223388345|NCT06079892|PROCEDURE|radiofrequency|haemorrhoidal removal using radiofrequency
223388346|NCT06530797|DRUG|First-line Adebrelimab regiment for advanced stage ES-SCLC|First-line Adebrelimab in any regiment for advanced stage ES-SCLC
224008174|NCT07155798|DEVICE|bamboo toothbrush|recent toothbrush
224008175|NCT07155798|DEVICE|conventional toothbrush|conventional toothbrush
224008176|NCT07155460|DEVICE|HDC-GCog|Surface electromyography records
224008177|NCT07156032|DEVICE|Starpen automatic injection device|Starpen device will be used on high speed 45-150s with the conventional carpule of articaine HCL 4% with 1:100,000 epinephrine and short needle
224126145|NCT03716232|DEVICE|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
223388347|NCT06530797|DRUG|Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC|Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC
223388348|NCT00033085|DRUG|Ondansetron|
223388349|NCT00028171|DRUG|Tacrolimus|
223388350|NCT02553772|DRUG|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
223388351|NCT02553772|DRUG|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
223388352|NCT03035188|DRUG|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
224008178|NCT07156032|PROCEDURE|conventional syringe|injection will be done using conventional metal syringe with articaine HCL 4% with 1:100,000 epinephrine and short needle
223388353|NCT00002422|DRUG|HE2000|
223388354|NCT01295398|DEVICE|nebulisations|
223388355|NCT05724589|DRUG|Epidermal Growth Factor|Apply facial twice daily.
224008179|NCT07154303|DIAGNOSTIC_TEST|Computer algorithms|Computer algorithms that are designed to perform heart sound, ECG, and/or facial photoplethysmography analysis on data collected from smartphone's internal hardware and/or external accessories.
224008180|NCT07153471|DRUG|Orforglipron|Administered orally
224008181|NCT07153471|DRUG|Placebo|Administered orally
224126146|NCT06189001|DRUG|Oxytocin|Intravenous oxytocin 0.2 IU/min during experimental days
223388356|NCT00786409|BIOLOGICAL|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
223388357|NCT01970137|DRUG|KPS-0373, High dose|
223388358|NCT01970137|DRUG|KPS-0373, Low dose|
223388359|NCT00031148|DRUG|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
223388360|NCT00610129|DRUG|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
223388361|NCT07128342|DEVICE|CGM Group|This group of patients will receive a CGM device to monitor their blood glucoses
223388362|NCT07128342|DEVICE|FSBG group|This group of patients will receive a fingerstick blood glucose (FSBG) device for glucose monitoring
224008182|NCT07158593|OTHER|Claudia carraro prevention program|"The Claudia Carraro prevention program is grounded in a cognitive-behavioral conceptualization of the development of eating disorders or disordered eating. The program was designed to address specific and non-specific risk factors that appear relevant: body dissatisfaction and unhealthy weight control behaviors. Its dual objective is to help participants reduce the importance they place on body weight and shape in self-evaluation while simultaneously promoting healthy weight regulation through adherence to Mediterranean dietary guidelines and an active lifestyle.~The strategies and procedures used are derived from cognitive behavioral therapy protocols for eating disorders (Dalle Grave \& Calugi, 2020). The intervention is delivered by psychologists specialized in eating and weight disorders using an interactive, rather than didactic, format, involving small group activities and assigned homework tasks between sessions."
224008183|NCT07162181|DRUG|Pirtobrutinib|Administered orally.
223388363|NCT06865664|DRUG|fludarabine|30 mg/m2 per day IV on days -5, -4, -3, -2
223388364|NCT06865664|DRUG|cyclophosphamide|500 mg/m2 per day IV on days -4, -3, -2
223388365|NCT06865664|DRUG|cetuximab|"Participants Age \>=18 years, based on FDA approved dosing: Loading dose of 400 mg/m2 IV, followed by 250 mg/m2 IV weekly for a total of 4 doses.~Participants Age \<18 years, based on phase I data of cetuximab in children: Dose of 250 mg/m2 IV administered over 1 hour weekly for a total of 4 doses."
223388366|NCT06865664|BIOLOGICAL|FGFR4-CAR T Cells|Single intravenous (IV) infusion on Day 0
224008184|NCT07165015|DRUG|LY3537031|Administered SC
224008185|NCT07169747|DRUG|Psilocybin|The intervention consists of two oral doses of 25 mg synthetic psilocybin administered in a controlled clinical setting, combined with psychological support. The psychological support includes preparatory sessions prior to psilocybin administration, support during the drug experience and integration sessions following each dosing session.
224126147|NCT06189001|OTHER|Placebo (saline)|Intravenous saline during experimental days
223388367|NCT07008768|PROCEDURE|Cataract surgery and refractive lens exchange surgery|Cataract surgery or refractive lens exchange surgery was performed with standard phacoemulsification procedure using micro coaxial surgical technique. After superior clear corneal incision, anterior capsulorexis and lens phacoemulsification, the IOL was implanted into the capsular bag using an injector in all cases. Ophthalmic Viscosurgical Device (OVD) was completely removed by irrigation and aspiration. All incisions were self-closing.
223388368|NCT07008768|DEVICE|TRIFOCAL IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, trifocal
223388369|NCT07008768|DEVICE|EROV IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, extended range of vision (EROV)
223388370|NCT07008768|DEVICE|BIFOCAL IOL|1-piece aspheric hydrophobic presbyopia-correcting intraocular lens, bifocal with low addition
223388371|NCT07008768|DEVICE|MONOFOCAL IOL|Control lens: 1-piece aspheric hydrophobic monofocal aspheric IOL
223388372|NCT05552118|PROCEDURE|Cochlear™ Remote care|"Cochlear™ Remote Check is a virtual assessment tool which helps the clinician to monitor the participant hearing progress remotely. It allows the participant to complete a series of hearing tests using the Cochlear™ Nucleus® Smart App then electronically send the results to the clinician for review.~Cochlear™ Remote Assist enables a video call appointment through the Cochlear™ Custom Sound® Pro software and the Nucleus® Smart App. When remote check requires further follow-up, it allows the clinician to make programming adjustments and sound processor settings without a clinic visit."
223388373|NCT05552118|PROCEDURE|Standard of care|Routine in clinic face-to-face care and sound processor programming using Cochlear™ Custom Sound® Pro
223388374|NCT05552118|DEVICE|Compatible Implant Series and Compatible Sound Processors|Individuals who are implanted with a compatible cochlear implant series and compatible sound processor are eligible to participate.
223388375|NCT02216097|DRUG|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
224008186|NCT07190131|DIAGNOSTIC_TEST|Investigational Flu A/B And Covid-19 Diagnostic Test|A diagnostic test in lateral flow cassette format designed to detect Influenza A, Influenza B and SARS-CoV-2 from anterior nasal swab specimens.
224008187|NCT07188896|DRUG|Fianlimab|Fianlimab will be co-administered by IV.
224008188|NCT07188896|DRUG|Ipilimumab|Ipilimumab will be administered by IV.
224008189|NCT07188896|DRUG|Nivolumab|Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.
224126148|NCT02833649|DEVICE|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
223388376|NCT02216097|DRUG|Placebo|Matching placebo tablet taken once daily for 7 days.
223388377|NCT02449278|RADIATION|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
223388378|NCT02449278|RADIATION|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15\~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20\~25 fractions of 2 Gy 5 days per week for partial response (PR)."
223388379|NCT02449278|DRUG|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
223388380|NCT02449278|DRUG|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
223388381|NCT02449278|DRUG|vincristine|Patients in both arms will be given vincristine chemotherapy
223388382|NCT02449278|DRUG|prednisone|Patients in both arms will be given prednisone chemotherapy
223388383|NCT07011680|DIETARY_SUPPLEMENT|Phospholipid-rich dairy milk extract|Dietary phospholipid-rich dairy milk extract 500 mg/day for 12 weeks
223388384|NCT07011680|DIETARY_SUPPLEMENT|Placebo|Placebo (Grape seed oil) 500 mg/day for 12 weeks
223388385|NCT07007702|DEVICE|T2769|Preservative-free combination of trehalose, sodium hyaluronate and N-Acetyl Aspartyl Glutamic Acid
223388386|NCT07011121|BEHAVIORAL|CenteringPregnancy|. CenteringPregnancy, a group prenatal care model, is a promising alternative that challenges the standard model of one-on-one prenatal counseling. Previous research has documented that group prenatal care is associated with a lower prevalence of preterm birth and low birth weight infants. 18,39 Group prenatal care also has been associated with improved maternal mental health, breastfeeding, optimal pregnancy weight gain, improved postpartum weight loss, better birth spacing, and higher patient satisfaction. 18,39 All participants will attend routine one-on-one prenatal appointments prior to the intervention. The sessions occur from week 14 of pregnancy through birth with women of similar gestational age, following the same schedule as standard care. Once the groups of women are formed (5 per group), the participants attend all appointments together for the duration of their pregnancies. Mobile health clinic located at FBOs will provide a location for providers to provide brief one-on-
224008190|NCT07188896|DRUG|Cemiplimab|Cemiplimab will co-administered by IV.
224126149|NCT00000271|DRUG|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
224126150|NCT00000271|DRUG|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
224126151|NCT05345834|BEHAVIORAL|Patient Navigation|Participants in arm 2 will receive patient navigation provided by humans (rather than e-navigation) to provide personalized care to include support, resources, and referrals to address psychosocial issues that arise during the perinatal period. Patient navigation is available to participants through 12 months postpartum.
223388387|NCT04400539|DEVICE|intrapleural photodynamic therapy with videothoracoscopy|MPM patients will be first administrated 20 mg/kg of oral photosensitizer, 5-Aminolevulinic Acid (5-ALA) {Gliolan®}, 4 to 6 hours prior undergoing thoracoscopy (VATS). During VATS procedure, after a qualitative control of the fluorescence of tumor lesions and some guided pleural tumor biopsies, the pleural cavity will be illuminated using a flexible probe and laser source at a specific wavelength for 5-ALA (400-500 nm; 25 J/cm2) during 15 minutes (6 fractions of 2.5 minutes separated by 5 pauses of 2 minutes each to improve tissue oxygenation for the PDT reaction). An IPC device (but no talc) will be inserted and used for pleurodesis and may permit to collect further pleural effusion samples. As 5-ALA has a short half-life and thus does not need extensive precautions to avoid patient photosensitivity, the patient would not stay longer than a standard procedure (about 2-3 days in the hospital)
223388388|NCT04400539|DRUG|Nivolumab Injection|Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
223388389|NCT00707616|OTHER|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
223388390|NCT04640415|DEVICE|Active Alarms|Intervention consists of actively alerting staff personnel if physiologic vital signs, deviates from certain thresholds for more than a set duration. Continuous vital sign data will also be available to clinical staff.
223388391|NCT07018427|DRUG|Sacituzumab Govitecan Monotherapy or Combination Therapy|The interventions in this study comprised either Sacituzumab Govitecan monotherapy or combination therapy. The specific combination regimens were determined based on real - world clinical practice patterns.
223388392|NCT07017920|DIAGNOSTIC_TEST|Vitamin D Levels measurement|Patient will have a vitamin D level drawn with their other prenatal labs during an OB visit. If vitamin D insufficiency (less than 30 ng/mL) or deficiency (less than 20 ng/mL) is detected, the patient will be prescribed and provided a supplementation of 2000 IU of vitamin D daily for the remainder of the pregnancy.
223730218|NCT04273646|BIOLOGICAL|UC-MSCs|4 times of UC-MSCs(0.5\*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).
223730219|NCT04273646|DRUG|Placebo|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).
224008191|NCT07195422|DEVICE|Japet.W+|Current care of low back pain and wearing the Japet.W+
224126152|NCT05345834|BEHAVIORAL|Adapted Cognitive-Behavioral Therapy|Participants who do not meet diagnostic criteria (Group 2a) will participate in a prevention group which includes 8 sessions based on culturally adapted CBT for Black/ of African descent populations facilitated by mental health professionals. Participants who meet diagnostic criteria (Group 2b) will participate in individual treatment which includes 12 sessions based on culturally adapted CBT for Black/ of African descent populations.
224126153|NCT03213613|BEHAVIORAL|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
224008192|NCT07195422|DEVICE|Control (Standard treatment)|Current care of low back pain
224008193|NCT07195513|BEHAVIORAL|ePRO-Directed Referral and Navigation to Palliative/Supportive Care|This intervention combines routine electronic patient-reported outcome (ePRO) symptom monitoring with additional components designed to connect patients more directly to palliative/supportive care. In addition to weekly ePRO symptom surveys, participants complete a monthly palliative care-focused ePRO survey, receive structured palliative care education from a trained study coordinator, and are offered navigation support to facilitate access to palliative/supportive care services. Severe or persistent symptoms or unmet needs reported on ePROs generate an alert to the oncology team along with a recommendation for palliative care referral. This multicomponent approach is intended to address gaps in timely referral and access to palliative/supportive care that are not addressed through symptom monitoring alone.
224008194|NCT07195513|OTHER|ePRO Symptom Monitoring with Usual Palliative Care Referral|Participants complete weekly electronic patient-reported outcome (ePRO) symptom monitoring surveys. Survey results are shared with the oncology team to support routine care. Referral to palliative/supportive care is made according to usual clinical practice at the discretion of the oncology team. Unlike the intervention arm, participants do not receive structured palliative care education, a monthly palliative care-focused ePRO survey, navigation support, or referral alerts generated from persistent or severe symptoms and unmet care needs.
224008195|NCT07193563|DRUG|ENX-102|oral capsule
224008196|NCT07193563|OTHER|Placebo|oral capsule
224126154|NCT03213613|BEHAVIORAL|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
224126155|NCT03213613|BEHAVIORAL|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
224008197|NCT07187479|OTHER|Physiologic Insulin Resensitization (PIR)|PIR is a physician-directed treatment that uses an exterior infusion pump to deliver insulin intravenously.
224126156|NCT03914820|PROCEDURE|HIPEC CO2 surgery|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
223388393|NCT07017738|OTHER|Corrective exercises|The corrective exercise program will include various positions: in standing, scapular retraction and arms overhead; in sitting, chin tuck and thoracic extension; in supine, arms in a W shape and horizontal abduction with external rotation; in side-lying, forward flexion starting with arms parallel to the body; and in prone, scapular retraction and depression in a T shape, extension from 90° forward flexion, and horizontal abduction at 90° with external rotation. Exercises will start with three repetitions held for 10 seconds and progress to six repetitions held for 25 seconds, based on overload principles and individual needs. Participants experiencing pain may stop and rest until symptoms subside.
223388394|NCT07017738|OTHER|Neural mobilization|Median nerve mobilization will be performed with the patient in a supine position, shoulder abducted to 90°, elbow flexed at 90°, and both wrist and head in a neutral position. The therapist will mobilize the nerve by extending the elbow to 45°, while the patient performs ipsilateral cervical lateral flexion to unload the nervous system.
224008198|NCT07194187|DEVICE|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound (HIFU) works with an image-guided transrectal probe that utilizes 3-10 MHz ultrasound waves at very high powers (200W). These waves can be very precisely directed at target tissue. Through both thermal and mechanical forces (shearing motion and mechanical energy leading to hyperthermia) the focal point core temperature can be raised significantly (\> 80°C) leading to coagulative necrosis to the target tissue while sparing surrounding tissue. The degree of tissue injury is based on the temperature and the duration of exposure, with the cooling off time allowing for the heat to dissipate to prevent the damage to surrounding tissues. The most common device involves a transrectal transducer with ultrasound guidance that can be performed under either general or spinal anesthesia. The device has been FDA approved to be used in ablation of prostatic tissue since 2018.
224008199|NCT07194590|DRUG|Equol|This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).
224126157|NCT03914820|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
224126158|NCT03914820|DRUG|Mitomycin|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
224126159|NCT03909191|DIAGNOSTIC_TEST|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
223388395|NCT07012668|PROCEDURE|Interventional or surgical treatment|Simultaneous interventional or surgical treatment/staged interventional or surgical treatment
223388396|NCT07012668|PROCEDURE|Interventional or surgical treatment|Interventional or surgical treatment
223388397|NCT07018687|OTHER|day hospital|This multidisciplinary day hospital consists of 3 information workshops focused on balanced nutrition, oral nutritional supplements and enrichments as well as artificial feeding. During this day hospital, patients will meet with an endocrinologist nutritionist, a dietitian, and a teacher in adapted physical activity.
223388398|NCT07018687|OTHER|dietician consultation|dietician consultation
223545730|NCT01635998|DEVICE|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
223545731|NCT06287372|OTHER|Cardioplegic solution|Patients were randomly assigned to undergo surgery using one of two methods for myocardial protection
224008200|NCT07194590|DRUG|Placebo|This group will receive 2 placebo capsules per day.
224008201|NCT07193589|DRUG|The high-dose group of ZL-82 tablets|Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.
224126160|NCT01035255|DRUG|LCZ696 200 mg BID|LCZ696 200 mg BID
224126161|NCT01035255|DRUG|Enalapril 10 mg BID|Enalapril 10 mg BID
224008202|NCT07193589|DRUG|The low-dose group of ZL-82 tablets|Participants will take the investigational drug orally for 16 weeks, 100mg each time, once a day.
224126162|NCT06420648|OTHER|Early passive mobilization|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
224126163|NCT06420648|OTHER|Controlled active motion|a rehabilitation protocol for post-surgical repair of flexor tendons of the hand
224126164|NCT01912729|BEHAVIORAL|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
223388399|NCT07016737|DRUG|Sintilimab Combined With Docetaxel Monotherapy|79 patients will receive treatment with a PD-1 inhibitor (sintilimab or camrelizumab 200mg, d1, q3w) combined with monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w) for 4 cycles, followed by a 2-year maintenance treatment with PD-1 inhibitors. During this period, patients diagnosed with esophageal wall thickening and identified as having progressive disease (PD) have the option to undergo salvage radiotherapy (45-50.4 Gy/25-28/F/5-5.5 weeks) in conjunction with a dual-agent chemotherapy (paclitaxel 50 mg/m2, d1 + carboplatin AUC 2, d1, qw) for 5 cycles.
223388400|NCT07018115|OTHER|Basic Preoperative Information|Participants receive a brief, non-detailed explanation of the surgical procedure.
223388401|NCT07018115|OTHER|Detailed Verbal Preoperative Information|Participants receive a detailed verbal explanation covering the surgical procedure, including anesthesia, incision, bone removal, tooth sectioning, and suturing.
223388402|NCT07018115|OTHER|Visual Preoperative Information (2D Animation)|Participants receive a 2D animated video illustrating the surgical procedure in addition to the detailed verbal explanation.
223388403|NCT07018115|DRUG|Articaine 4% with epinephrine 1:100,000|A local anesthetic solution (Ultracain D-S; Aventis) administered in a dose of 2 ml for all patients. The anesthetic was injected to achieve regional nerve block anesthesia (inferior alveolar, lingual, and buccal nerves) prior to the surgical extraction of impacted mandibular third molars. The solution contains epinephrine as a vasoconstrictor to prolong anesthetic effect and minimize intraoperative bleeding.
223388404|NCT07018115|PROCEDURE|Surgical extraction of impacted mandibular third molar|A standardized surgical protocol was followed for the removal of impacted mandibular third molars. All procedures were performed under local anesthesia using a mucoperiosteal flap approach. The surgery included a linear or triangular incision, elevation of the mucoperiosteal flap, ostectomy using rotary instruments as needed, and tooth sectioning in cases of difficult extraction. The socket was irrigated with sterile saline solution, and hemostasis was achieved. Wound closure was performed with 4.0 silk sutures. All surgeries were conducted by experienced oral and maxillofacial surgeons without sedation or premedication. The entire procedure was monitored for hemodynamic parameters including heart rate, blood pressure, and oxygen saturation.
223388405|NCT07018115|DEVICE|Multiparameter patient monitor|A hospital-grade multiparameter monitor was used to measure and record patients' vital signs at five defined surgical stages: before surgery, after information delivery, after local anesthesia, during tooth extraction, and postoperatively. The monitor continuously recorded heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), and peripheral oxygen saturation (SpO₂). The collected data were used to evaluate physiological responses associated with anxiety and surgical stress.
223388406|NCT07018388|DEVICE|NervioX-2400|To design the individualized STN-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data are used to determine the STN-tTIS montage and stimulation settings through computational modeling.
224008203|NCT07193589|DRUG|The placebo group|The participants will take the investigational drug orally for 16 weeks, 2 tablets each time , once a day.
224008204|NCT07194577|DIETARY_SUPPLEMENT|Moringa oleifera|5.6 grams of Moringa oleifera Lam dried leaf powder administered orally per day (as nine 0.5 g capsules), divided into three doses (three capsules with breakfast, three with lunch, and three with dinner) for 8 weeks.
224008205|NCT07194577|DIETARY_SUPPLEMENT|Placebo|Starch placebo administered orally per day (as nine 0.5 g capsules), divided into three doses (three capsules with breakfast, three with lunch, and three with dinner) for 8 weeks.
224008206|NCT07194278|DEVICE|Blue-blocking glasses|The intervention will last for 7 days, during which patients are required to wear the glasses from 6 p.m. to 8 a.m. and whenever a light is turned on during this interval. Additionally, patients will be asked to wear an actimeter and fill out a sleep diary each day. Doctors will conduct daily interviews to assess manic symptoms, with more in-depth assessments scheduled on days 0, 3, and 7 to evaluate other clinical characteristics.
224126165|NCT01912729|BEHAVIORAL|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
223388407|NCT07018388|DEVICE|NervioX-2400|To design the individualized GPi-tTIS, each patient completes a T1-weighted anatomical magnetic resonance imaging (MRI) scan. The individual's structural brain MRI data is used to determine the GPi-tTIS montage and stimulation settings via computational modeling.
223545732|NCT06073197|PROCEDURE|erector spinae plane block|Erector spinae plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block. Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
224008207|NCT07195370|OTHER|peripheral iridotomy|This procedure involves using a neodymium-doped yttrium aluminum garnet (YAG) laser to create a small hole in the temporal region of the iris in one eye. It aims to relieve intraocular pressure in patients with primary angle-closure glaucoma by improving the flow of aqueous humor. The procedure is performed under local anesthesia in a clinical setting, with patients unaware of which eye receives this treatment. Outcomes, including laser power, intraocular pressure, visual symptoms, and complications, are monitored over six months.
224008208|NCT07195097|DRUG|Oral intake of sildosin|Oral intake of sildosin in male non hormonal contraception
224008209|NCT07195097|OTHER|Oral intake of placebo|Intake of placebo to compare effecacy of other group
224008210|NCT07194980|DRUG|Nemtabrutinib|Given PO
224126166|NCT00619411|BEHAVIORAL|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
224126167|NCT00399984|BEHAVIORAL|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
224126168|NCT00904826|DRUG|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
224126169|NCT04207957|DRUG|Olorofim|150 mg
223388408|NCT07016893|OTHER|Healthy aging interventions|In our study workshop activities conducted for eight weeks and included an Exercise Workshop (Music-Based Exercise Workshop, Exercise Training with Active Video Games (Exergaming), Clinical Pilates Training Workshop, Cognitive Exercise Therapy Approach Workshop, Nordic walking, dance therapy), Skill-Oriented Art Workshop (Systemic Calligraphy Therapy Workshop, soap-candle making workshop, culinary arts workshop), and Disease Awareness Studies (disease awareness information and education, the process from diagnosis to acceptance, experiences of patients and relatives, use of daily life technologies, home adjustments against falls, introduction of municipal services for the elderly).
224008211|NCT07194980|BIOLOGICAL|Lisocabtagene Maraleucel|Given IV
224008212|NCT07194343|PROCEDURE|Laparoscopic colposacropexy with levator ani muscle mesh fixation|The standard technique includes dissection of the rectovaginal space and bilateral mesh fixation to the levator ani muscle at the deep limit of the pararectal fossae dissection.
224008213|NCT07194343|PROCEDURE|Simplified modification of laparoscopic colposacropexy|Rectovaginal dissection is avoided, and the mesh is anchored to the posterior aspect of the cervix or vaginal vault rather than to the levator ani muscle, representing the specific modification from the standard technique.
224008214|NCT07195071|DEVICE|Natera empower comprehensive hereditary cancer panel|Natera Empower Comprehensive Hereditary Cancer Panel to screen for hereditary cancers
224008215|NCT07195071|DEVICE|Obstetrical carrier screening|Obstetrical carrier screening for genetic conditions
223388409|NCT05836051|OTHER|Flavor|E-liquid flavor chemicals
223388410|NCT04153019|OTHER|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
224008216|NCT07195305|PROCEDURE|Radiofrequency endometrial ablation|Radiofrequency endometrial ablation
224008217|NCT07195305|PROCEDURE|Uterine artery embolization|Uterine artery embolization
224008218|NCT07195305|PROCEDURE|Hysterectomy|Hysterectomy
224008219|NCT07194304|DRUG|alpha-Tocopherol|patients in the intervention group received parenteral alpha-tocopherol at a dose of 4 mg/kg body weight
224008220|NCT07194304|DRUG|Sterile Water for Injection|the control group received a placebo (sterile water for injection/aquabidest)
224008221|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 1)|2.5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
224008222|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 2)|5 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
224008223|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 3)|10 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
224008224|NCT07193628|BIOLOGICAL|EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy (Dose level 4)|20 × 10⁶ EPC-003 CAR-T cells will be administered into the Ommaya reservoir of the subjects weekly.
224126170|NCT06982937|OTHER|High-Intensity Half-Squat|Participants in the conditioning arm perform a single set of two to three half-squats with a free-weight barbell set at 90% of their one-rep max (1RM). Each squat is taken down until the thigh is parallel to the floor (knee at \~90°) and then driven upward as explosively as possible.
223388411|NCT07017348|OTHER|Clinical assessments|dermatitis atopic scores will be evaluated on the entire body and on target areas by the investigator
223388412|NCT07017348|OTHER|Biometrological measurements|Measurements will be performed on the target areas
224008225|NCT07195643|OTHER|Drain|We want to put a assess the predictive factors for prophylactic drain after cholecystectomy.
224008226|NCT07195344|BIOLOGICAL|Pharmacokinetics blood samples|Blood samples will be collected at different time points during the first four treatment cycles and at the end of T-DXd treatment or at 24 months after inclusion in case of T-DXd continuation beyond this time period.
224126171|NCT06982937|OTHER|Treadmill running|Participants engaged in a standardized 5-minute treadmill warm-up. Participants were instructed to walk at a moderate, self-selected pace of approximately 7-9 km/h, maintaining an incline of 0%. Heart rate and perceived exertion were monitored to ensure that the activity remained within a light-intensity range (Borg scale: 6-11).
224126172|NCT02426411|DRUG|EMA401 200 mg|
224126173|NCT02426411|DRUG|EMA401 600 mg|
224126174|NCT02426411|DRUG|Placebo|
224126175|NCT01893190|DRUG|Nimodipine|Based upon Investigator Judgement
224126176|NCT01893190|DRUG|Nimodipine Microparticles|Based upon Investigator Judgement
223388413|NCT07017348|OTHER|Biological sampling|Skin and faecal samples will be performed
223388414|NCT07017348|OTHER|Questionnaires|dietary habits, health and lifestyle, and digestive health
223388415|NCT07017101|OTHER|PILATES BASED EXERCISE TRAINING WITH REFORMER|"Participants will only be given training on pilates-based exercises with reformers. Breathing, which are the 5 key elements of clinical pilates exercises after the first evaluation to individuals,~Focus, rib cage placement, shoulder placement, head and neck placement will be taught. Whole~Participants will be informed about the reformer instrument and work schedule. Exercises 2 days a week, 6~Will be applied throughout the week."
224008227|NCT07193836|DRUG|Normal Saline (0.9% NaCl)|Participants in the control group received a single intravenous injection of 0.9% normal saline at induction of anesthesia.
224126177|NCT01308320|DRUG|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
224126178|NCT01308320|DRUG|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
224008228|NCT07193836|DRUG|Lidocaine|Participants in this group received a single intravenous bolus of lidocaine (1.5 mg/kg) at anesthesia induction. No additional lidocaine was administered thereafter.
224008229|NCT07193836|DRUG|Lidocaine Bolus + Infusion|Participants in this group received a bolus of lidocaine (1.5 mg/kg) at induction followed by continuous intravenous infusion of lidocaine (2 mg/kg/h) until the end of surgery.
224126179|NCT06177782|DEVICE|Tooth modified scan bodies|Tooth modified scan bodies are used during scanning for full arch implant cases.
223388416|NCT07017101|OTHER|NEUROPHYSIOLOGICAL FASCILITATION TECHNIQUES|"In addition to reformer-based pilates training, participants will be given Neurophysiological facilitation techniques training. Neurophysiological facilitation techniques are non-invasive, easy to apply, the physiotherapist is active~It consists of exercises made with guidance and active participation of the patient. These techniques are any~Does not contain an electrotherapy current. In this study, the neurophysiological~Facilitation techniques, perioral stimulation, intercostal tension, anterior basal lift, vertebral pressure, medium~Graded manual pressure and abdominal co-contraction techniques and each technique for 15 seconds~Will be applied. Neurophysiological facilitation techniques are used to repeat 10 sessions each session throughout the treatment.~It will be done."
223388417|NCT07017426|DRUG|Fuzheng Huayu tablets|Fuzheng Huayu Tablets are composed of various medicinal ingredients such as Salvia miltiorrhiza, Prunus persica seed, Gynostemma pentaphyllum, pine pollen, Cordyceps sinensis, and Schisandra chinensis. They have the functions of promoting blood circulation and removing blood stasis, nourishing the liver and enriching essence, and can be used to treat chronic liver diseases, anti-fibrosis, and patients with liver cirrhosis.
223388418|NCT07017426|OTHER|Placebo Comparator|placebo combined with conventional antiviral therapy
224008230|NCT07194772|OTHER|Low-calorie sweeteners (LCS)|"Consumption of sucralose-sweetened beverages (LCS) using doses and formulations reflecting real-world conditions.~Individualized dose equivalent volume (mL) to SSB group. Average dose received of 150 mg (±30 mg) of pure sucralose per day (2.00 ± 0.23 mg/Kg BW) among participants, which is below Acceptable Daily Intake for sucralose (5 mg/Kg BW/day). LCS matched for sweetness to SSB based on the manufacturer's information."
224008231|NCT07194772|OTHER|Refined sugars (SSB)|"Consumption of sugar-sweetened beverages (SSB) using doses and formulations reflecting real-world conditions.~Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada. SSB matched total free sugar concentration of 100% natural orange juice (FJ)."
224008232|NCT07194772|OTHER|Natural sugars (FJ)|"Consumption of natural fruit juice (100% natural orange juice) using doses and formulations reflecting real-world conditions.~Individualized dose of 15% Ereq representing estimated free sugars consumption in Canada."
224008233|NCT07193706|BEHAVIORAL|Traditional group training program|This intervention consists of two supervised plyometric training sessions per week, each lasting about 40 minutes. It represents the traditional approach with fewer but longer sessions. The total weekly training volume is equivalent to the micro-dosed group but distributed differently.
224008234|NCT07193706|BEHAVIORAL|Micro-dosed group training program|This intervention consists of three to four shorter supervised plyometric sessions per week, each lasting about 20 minutes. It represents a micro-dosed approach, with higher frequency but shorter duration per session. The total weekly training volume is equivalent to the traditional group but distributed across more frequent sessions.
223388419|NCT07018414|BEHAVIORAL|Abdominal Massage|Non-pharmacological intervention involving manual massage of the abdomen to support gastric motility and reduce gastric residual volume and abdominal distension in enterally fed surgical ICU patients.
223388420|NCT07024173|DRUG|HRS-8080 Tablet|HRS-8080 tablet orally administered.
223388421|NCT07024173|DRUG|Fulvestrant injection|Fulvestrant injection.
223388422|NCT07024173|DRUG|Exemestane tablets|Exemestane tablets orally administered.
223388423|NCT07024173|DRUG|Everolimus Tablets|Everolimus tablets orally administered.
224008235|NCT07193862|COMBINATION_PRODUCT|Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373|"Patients with diagnosed liver metastasis from a colorectal primary deemed resectable. The study intervention will be limited to the percutaneous placement of up to 2 IMDs per lesion with a maximum of 4 devices total, with the subsequent en bloc resection of the tumor plus IMD within 3 (+2) days after placement. The microdevices will remain in the tumor for a minimum of a 2-day incubation period, although ideally for 3 days.~The IMD is a small cylindrical device approximately 750 um in diameter and 5 mm in length (Figure 2), housing up to 21 reservoirs. It is made of PEEK, biocompatible material used in other implantable constructs, including joint replacements. 11-13 Drugs are solubilized with poly-ethylene glycol (PEG) and loaded into the individual reservoirs. The drug diffusion has been mapped extensively to ensure that the weight of PEG is selected such that drug diffusion is limited and will not mix or interfere with another drug."
224008236|NCT07195435|BEHAVIORAL|Genital Hygiene Education|Genital Hygiene Training: Young girls who agree to participate will receive two sessions of two hours of genital hygiene training on a predetermined date, as appropriate. Genital hygiene training will be delivered via PowerPoint presentation, and at the end of the training, a training booklet and brochure, developed in accordance with the relevant literature, will be distributed to the participating girls to ensure retention. The training booklet and brochure will be prepared by the researcher based on current literature sources. Expert opinions will be sought from obstetrics and gynecology nursing experts regarding the training content and will be revised as necessary. The content of the training booklet will cover the female internal and external genital organs, the importance of genital infections for women's health, factors affecting genital hygiene, characteristics of normal and abnormal genital discharge, common genital infections, signs and symptoms of genital infection, and pro
224008237|NCT07194928|OTHER|We will monitor patient's response to medical marijuana as alternative to opioid for chronic pain.|We will monitor patient response to medical marijuana as opioid alternative. This will be given to patient who otherwise could not get intervention secondary to cost. We want to show that medical marijuana is a safer alternative to opioids in this population of patients
224008238|NCT07195136|BEHAVIORAL|Essential Oil|essential oil
224008239|NCT07195019|BEHAVIORAL|Integrative Yoga & Mindful Self-Compassion training|Group Integrative Yoga \& Mindful Self-Compassion training for women with a history of interpersonal violence exposure and distress
224008240|NCT07195019|BEHAVIORAL|Women's Wellbeing Education|Group women's wellbeing education for women with a history of interpersonal violence exposure and distress
223388424|NCT04699240|DRUG|clotrimazole vaginal tablets|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
223388425|NCT04699240|DRUG|Clotrimazole vaginal tablets+ Lactobacillus|Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
224126180|NCT06177782|DEVICE|Conventional scan bodies|Conventional scan bodies will be used for scanning the full arch implant cases.
223388426|NCT04854161|BEHAVIORAL|Empathic Attunement to Affect Training|"Empathic Attunement to Affect:~Empathy and neuroscience Therapeutic Presence~Opening receptivity channels Empathic reflections and landscapes (external, meaning and feeling)~Types of emotions: Primary (adaptive, maladaptive), Secondary. Emotion Scheme Types of experiential responses: conjectures, exploration.~Working with Core emotions Types of experiential responses: Evocation and Empathic affirmation,~Empathy and Emotion Productivity Types of experiential responses: Empathic formulation, process suggestion Difficult situations: working on assertive anger and self-soothing Types of experiential responses: Facilitative Congruence"
223388427|NCT04854161|BEHAVIORAL|Compassion Training|Compassion Training Introduction to Mindfulness Compassion toward a significant other Compassion toward a generic other Self-compassion Tonglen Compassion toward a difficult other
223388428|NCT04854161|BEHAVIORAL|Focusing Oriented Therapy Training|Focusing-Oriented Therapy training Introduction to focusing Acceptance and empathy as the main focusing attitudes Fels-sense markers Felt sense, handle and resonance Hakomi Therapy The Safe Place. Focusing with a challenging person
223388429|NCT02273388|DRUG|BI 6727|BI 6727
223388430|NCT01042093|DRUG|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
224008241|NCT07194408|OTHER|Sunscreen RV4620A RP2552|"Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product.~Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon."
224008242|NCT07193810|BIOLOGICAL|CC312|CC312 is administered twice weekly (BIW) on Day 1 and Day 4 of each week for a 4-week treatment period. After Day 28, subsequent dosing (including the decision to continue treatment, dosing frequency, and treatment duration) will be determined based on the subject's clinical response and B-cell depletion status. The maximum planned treatment period is 24 weeks, followed by a follow-up phase.
224008243|NCT07193888|DEVICE|Navitor Transcatheter Aortic Valve Implantation|Subjects will undergo transcatheter aortic valve implantation (TAVI) with the Navitor valve, the FlexNav Delivery system and the Navitor Loading System.
224008244|NCT07195058|BEHAVIORAL|Trauma Informed Obstetric Care (TIOC)|"TIOC providers will receive a training that was developed for this study. Elements of trauma-informed care described in the literature -combined with the experience of the study team, with deep expertise in trauma-informed obstetric care, were used to create three training modules, each of which includes didactics and role-plays to help participants practice and embody skills they learn. The three modules are:~1. Effects of trauma on physiological and psychological process relevant to pregnancy and childbirth.~2. Body language and verbal language for safety, respect, and patient agency~3. Recognizing and responding to distress and dissociation"
224008245|NCT07194083|BEHAVIORAL|Function-Based Elopement Treatment|"FBET is a structured, caregiver-implemented behavioral intervention targeting elopement in children. It includes:~* Psychoeducation and Behavioral Assessment-caregivers receive training on elopement, behavioral principles, and assessment strategies~* Functional Analysis Coaching-therapists guide caregivers through a latency-based functional analysis to identify the function of elopement~* Individualized Treatment Implementation-caregivers apply a function-based plan using differential reinforcement, providing preferred items/activities contingent on safe behavior~* Treatment Modification-therapists support caregivers in adjusting the plan based on child's response.~There will be 12 2-hour, caregiver-mediated sessions across 20 weeks Caregivers also learn safety and prevention strategies, including the use of resources like the Big Red Safety Toolkit."
224008246|NCT07194083|BEHAVIORAL|Treatment as Usual|TAU consists of ongoing Applied Behavior Analysis (ABA) services, including caregiver training as it normally exists, provided by the family's Board Certified Behavior Analyst (BCBA), independent of the study protocol. The BCBA determines session frequency, content, and focus based on clinical judgment and the child's individual needs. Topics may include skill acquisition, behavior reduction (including elopement), or other areas deemed relevant to the child's care. The research team does not influence or standardize the TAU content, but will monitor and document the services delivered for descriptive and comparative purposes
224126181|NCT03472378|DRUG|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
224126182|NCT03472378|OTHER|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
223388431|NCT01042093|DRUG|Toradol|Toradol 30mg/ml (1 ml)
223388432|NCT01042093|DRUG|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
223388433|NCT01042093|DRUG|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
223388434|NCT07016984|OTHER|standard phototherapy eye patches|Following the mydriasis procedure performed prior to ROP examination, the eyes were covered with these patches.
223388435|NCT04331808|DRUG|Tocilizumab|Tocilizumab 8mg/kg on day 1 and if no response (no decrease of oxygen requirement) a second injection at day 3 (fixed dose of 400 mg)
223388436|NCT07031336|DEVICE|Photon-counting CT|The participants will receive a photon-counting CT scan as part of this protocol.
223388437|NCT07031336|DEVICE|Energy-integrating CT|The participants will receive an energy-integrating CT scan as part of the main study (NCT00608764).
223388438|NCT07035288|DEVICE|EAM based Pulmonary Vein Isolation|"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to EAM by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"
223388439|NCT07035288|DEVICE|Fluoro based pulmonary vein ablation|"20 patients with symptomatic paroxysmal or persistent AF will be scheduled for pulmonary vein isolation (PVI) based to Fluoroscopy by means of the PulseSelect catheter.~Ablation will be performed in a deep sedation setting and additional ablation within the pulmonary veins will be assessed"
223388440|NCT06884462|RADIATION|High-intensity laser (HIL)|The wavelength measured 1064 nm, accompanied by a power output of 5.00 W. The frequency employed was 25 Hz
223388441|NCT06884462|PROCEDURE|moderate-intensity aerobic exercise|walking on a treadmill at a speed of 3-4 miles per hour on a flat surface (0% incline) for 40 minutes, 3 times weekly over eight weeks
223388442|NCT06728423|OTHER|Temporary target during an anaerobic training session|Temporary target during an anaerobic training session
223388443|NCT06728423|OTHER|SmartGuard during an anaerobic training session|SmartGuard during an anaerobic training session
223388444|NCT06924970|DRUG|Tebapivat|Oral tablets.
223388445|NCT06924970|DRUG|Tebapivat Matched Placebo|Oral tablets.
223388446|NCT06730633|BEHAVIORAL|Heart Matters|Heart Matters is a lifestyle modification intervention guided by the theory of planned behavior. Designed to mitigate cardiovascular disease risk factors, the program strives to help participants consume nutritious foods, engage in a more active lifestyle, lose weight and lower their systolic or diastolic blood pressure. Lifestyle modifications can include weight loss, a reduction in percent calorie fat consumption and total sodium intake, improving diet and increasing physical activity, and reducing daily alcoholic beverage consumption.
224008247|NCT07195383|OTHER|Nutrion plan based on GUSS-ICU scale|To ensure a rapid and accurate transition to post-extubation nutrition, patients will be assessed using the GUSS-ICU scale at 4 hours after extubation. A nutrition plan will be created based on the patient's GUSS-ICU score and will be maintained for 4 days.
224008248|NCT07195539|OTHER|Tranexamic Acid sprinkle with CO2 LASER|tranexamin acid will be sprayed after CO2 LASER
224008249|NCT07195474|DIETARY_SUPPLEMENT|Yogurt Smoothie (1 per day)|Children consume one yogurt smoothie per day for 4 weeks (93 mL and \~70 kcal).
224008250|NCT07195474|DIETARY_SUPPLEMENT|Yogurt Smoothie (2 per day)|Children consume two yogurt smoothies per day for 4 weeks (186 mL and \~140 kcal).
224008251|NCT07195474|DIETARY_SUPPLEMENT|Fruit Juice Control|Children consume one fruit juice per day for 4 weeks (\~140 kcal, isocaloric with 2 yogurt smoothie).
224008252|NCT07193667|DRUG|CD19 CAR-T cells were administered to patients with relapsed/refractory autoimmune diseases|"This is a prospective, single-center, open, single-arm, dose-escalation clinical trial to evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed/refractory autoimmune diseases. Intravenous infusion will be used, and the trial procedure will be divided as follows:~1. Screening period (D-28 to D-6):~   After subjects voluntarily sign an informed consent form, a screening period will be conducted to determine whether subjects are eligible for the trial based on inclusion and exclusion criteria.~2. Lymphocyte depletion pretreatment (Study D-5 to Study D-3):~   Subjects will be pre-treated with Lymphocyte depletion starting 5 days prior to CAR-T cell infusion (FC regimen)~3. Rest and Observation (Study D-2 to Study D-1):~   Follow the study procedures and perform the relevant examinations during the rest and observation period.~4. Cell Infusion and Primary Study Endpoint Observation Period (Study D0 to W12 post-infusion):Subjects will undergo CAR-T cell infusion at 2-da"
224008253|NCT07194031|OTHER|Ankle Exercise|In the literature, studies have evaluated ankle proprioception following interventions applied to the knee. However, no studies report the effects of ankle exercises on knee proprioception
224008254|NCT07194031|OTHER|Knee Exercise|The literature emphasizes that long-term and multidirectional exercise programs provide proprioceptive improvements
224008255|NCT07195240|DIETARY_SUPPLEMENT|Active: Lemongrass|200mg of lemongrass extract
224008256|NCT07195240|DIETARY_SUPPLEMENT|Control: Placebo|microcrystalline cellulose
224008257|NCT07188675|OTHER|Functional Inspiratory Muscle Training (FIMT)|Participants will begin with Inspiratory Muscle Training (IMT) at 50% of maximal inspiratory pressure (MIP) for 4 weeks. Training will be performed once a week face-to-face, while adherence will be monitored on other days via WhatsApp. During each face-to-face session, MIP will be reassessed and training loads adjusted. Participants will perform 30 dynamic inspiratory efforts twice daily. In the following 4 weeks, Functional Inspiratory Muscle Training (FIMT) will be applied: once face-to-face, twice online under physiotherapist supervision, and twice unsupervised IMT. FIMT exercises will be performed with the POWERbreathe Classic Light Resistance device, consisting of 10 breaths lasting 15-30 seconds in 2 sets. Each session will include warm-up (diaphragmatic breathing and trunk stretches), loading (core stabilization exercises), and cool-down (trunk stretches). IMT intensity will be adjusted weekly using MIP measurement
224126183|NCT00195260|DRUG|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
224126184|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
224008258|NCT07188675|OTHER|Inspiratory Muscle Training (IMT)|Participants will perform IMT daily for 8 weeks. Training will be conducted once a week face-to-face, while on other days adherence will be monitored via WhatsApp. The group will complete 30 dynamic inspiratory efforts twice daily. The POWERbreathe Classic Light Resistance device (PowerBreathe, IMT Technologies Ltd, Birmingham, UK) will be used to strengthen the diaphragm and chest wall muscles by breathing against a set pressure load. Training intensity will be set at 50% of maximal inspiratory pressure (MIP). After 10-15 consecutive breaths, participants will perform 3-4 recovery breaths before continuing. IMT intensity will be re-adjusted weekly during face-to-face sessions using MIP measurements to maintain 50% loading.
224008259|NCT07193602|DEVICE|VR-based dexterity training in MS|Training of limited manual dexterity in people with multiple sclerosis through a specially developed home-based dexterity training programm using a virtual headset
224008260|NCT07193602|OTHER|mediation program|Sham Training is the comparator. The Sham group is performing a commercially available mediation programm TRIPP:
224008261|NCT07193784|BEHAVIORAL|Reiki|Reiki therapy applied by trained practitioner for 30 minutes.
224008262|NCT07193784|BEHAVIORAL|Sham reiki|Sham Reiki applied by same practitioner, mimicking Reiki without actual energy technique.
224008263|NCT07195461|DEVICE|Magnetic Bead Tracking System|The Magnetic Beads will be implanted in a subject during either an already required revision of an existing unilateral or bilateral transtibial amputation or during the performance of a unilateral or bilateral transtibial amputation.
224126185|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
224126186|NCT00195260|DRUG|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
224126187|NCT00880672|DRUG|dutasteride|5mg, oral, daily, 2-4 weeks
224126188|NCT00226681|BEHAVIORAL|Nursing Telephone Support Protocol|
224126189|NCT00226681|BEHAVIORAL|Usual Care|
224126190|NCT06452628|OTHER|Mulligan mobilizations|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with Mulligan mobilizations.
224126191|NCT06452628|OTHER|Active Release Technique|The duration of the intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with the Active release technique.
223388447|NCT06732440|BEHAVIORAL|Subthreshold Vestibular Conditioning|The subthreshold vestibular conditioning protocols will be performed while seated on a motion platform in a dark room. A 0.5Hz whole-body tilt conditioning stimulus will be delivered. The stimulus will consist of whole-body sinusoidal motions (similar to those used when measuring tilt perceptual thresholds) delivered at 57.4% of the measured baseline threshold (e.g., 0.574°/s for a 1 °/s threshold); the frequency (0.5Hz) was chosen to match the baseline threshold tasks. The participants and experimenter will be blinded to the nature of the condition and will be informed that while the chair may vibrate or move slightly, the motion will not occur in any particular direction. Music, audiobooks, or podcasts of the subject's choosing will be played to further discourage attention to the conditioning stimulus.
223388448|NCT06732440|BEHAVIORAL|Balance Training|Balance training will consist of progressive exposure to continuous pseudorandom platform perturbations delivered using a 6DoF motion platform. Participants will stand on a MOOG hexapod motion platform and will be secured using a safety harness tethered to the ceiling and a full enclosure of safety rails. Balance training will be progressed by (a) gradually increasing the number of degrees of freedom (e.g., 1DOF to 6DOF) in the perturbation, (b) removing visual cues, (c) narrowing the base of support, and (d) increasing the amplitude, velocity, and/or acceleration of the platform motion. In the event that subject experiences a loss of balance, the level of difficulty will be modified accordingly. Each balance training block will include 5 minutes of perturbations followed by 3 minutes of rest, repeated 5 times for a total of 40 minutes of training.
223388449|NCT06634173|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated Cancer associated fibroblasts as a marker of Tumor Micro-Environment and indirectly as a marker for malignancies.
223388450|NCT04932057|OTHER|Action observation Training|Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.
223388451|NCT04932057|OTHER|Action Practice|Participants perform an upper extremity functionality test a couple of times.
223388452|NCT04932057|OTHER|Observation|Participants will watch a slide show of landscape
223388453|NCT03609320|BEHAVIORAL|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
223388454|NCT05275920|OTHER|Best Practice Alert (BPA)|A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
224008264|NCT07194967|DEVICE|Virtual Reality Hypnosis for Labor Pain and Anxiety Management|"For patients randomized to the intervention arm, the investigator will provide a clear explanation of the procedure and the use of the HypnoVR virtual reality headset. The investigator will remain present throughout the session to supervise the experience, using the companion tablet to monitor the visualization in real time.~Participants will be invited to select one of eight immersive visual environments designed to promote relaxation and analgesia during labor. Available options include: Tropical Beach, Underwood, Underwater Dive, Zen Garden, Astral Travel, Winter Landscape, Aurora Borealis, and Oasis.~Patients will be informed that they may discontinue the use of the headset at any time and for any reason, without any consequences for their standard medical care."
224008265|NCT07194109|DRUG|Remimazolam based total intravenous anesthesia|For patients who aged between 3 and 6 years old undergoing tonsillectomy or/and adenoidectomy, anesthesia induction will performed with remimazolam in a dose of 0.4 - 0.5 mg/kg anesthesia maintenance was administered with remimazolam at a rate of 1.0 - 3.0 mg/kg/h.
224008266|NCT07194109|DRUG|Propofol based general anesthesia|For patients who aged between 3 and 6 years old undergoing tonsillectomy or/and adenoidectomy, anesthesia induction will performed with propofol in a dose of 2.0 - 3.5 mg/kg , anesthesia maintenance was administered with propofol at a rate of 4 - 12 mg/kg/h.
224008267|NCT07193524|DEVICE|3D Fracture Analysis Tool|"Based on a pre-operative computed tomography (CT) scan, fractured bone fragments of a proximal tibia are segmented and aligned to achieve adequate fracture reduction.~Bone material properties for each fragment are derived from Hounsfield Units (HU) of the CT scan, based on internal density calibration with air, fat, muscle, and cortical bone. Screws and implants are then modelled based on the manufacturer's design and material properties Placement of off-the-shelf plate and screws can be analyzed and support a personalized plan on how to individually treat a patient with a specific fracture pattern and anatomical biometric data.~Surgeons can define up to three approaches (different placement of implants and screws) to be visualized and analyzed for construct stability.~The surgeons will receive a visualization of the fracture, fracture-reduction, implant and screw placement in 3D as well as a comparison of construct stabilites of the submitted approaches"
224008268|NCT07194395|DEVICE|PatenSee System|Contactless AV access monitoring device
224008269|NCT07194551|COMBINATION_PRODUCT|Vaginal DNA swab, microbiome swab and pH test|Participants will receive up to three at-home collection kits with a vaginal swab for DNA collection, a vaginal swab for microbiome sampling, a vaginal pH testing kit, and instructions on how to perform the sample collection. Vaginal DNA will be collected using Zymo DNA/RNA Shield, vaginal microbiome DNA will be collected using Genotek OMNIgene, and vaginal pH will be collected using GYNEX pHem-Alert. Those with abnormal findings will be referred to a gynecologist or gynecologic oncologist for appropriate clinical assessment. Those with negative pathology will remain in the study. The self-collection will be repeated up to two more times, at eight-to-nine-month intervals, up to three successful self-collections.
224008270|NCT07194668|BIOLOGICAL|10μg R21/50μg Matrix-M|Adults and adolescents receiving the standard adult vaccine dose: 10μg R21/50μg Matrix-M (n=125)
224008271|NCT07194668|BIOLOGICAL|5μg R21/50μg Matrix-M with adaptor preservative free|Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with adaptor Preservative Free (n=125)
224126192|NCT06452628|OTHER|Mulligan mobilizations with active release technique|The duration of intervention will be 4 weeks, 3 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes. Conventional physical therapy will be given to participants along with mulligan mobilizations with active release technique.
223388455|NCT05275920|OTHER|In-Basket Message|An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
223388456|NCT00424229|DRUG|LENALIDOMIDE|
223388457|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
223388458|NCT01184079|BIOLOGICAL|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
223388459|NCT04060290|OTHER|Observational study|Observational study of this study, no interventions involved
223388460|NCT01213277|OTHER|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
224008272|NCT07194668|BIOLOGICAL|5μg R21/50μg Matrix-M with 2PE preservative|Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with 2PE Preservative (n=125)
224008273|NCT07195318|DIETARY_SUPPLEMENT|Fisetin|One capsule (100 mg) daily
223388461|NCT01213277|OTHER|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
224008274|NCT07195318|DIETARY_SUPPLEMENT|Placebo|One capsule daily
224008275|NCT07194876|OTHER|No Intervention (subjects were previously treated with Onglyza®)|no intervention
224126193|NCT05841134|DRUG|Tislelizumab|"Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months."
224126194|NCT03119116|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
223388462|NCT04810065|OTHER|SingStrong: Strong lungs through Song|"Participants who have been clinically diagnosed with Covid-19 and who continue to suffer residual adverse effects on the lung health will be invited to participate in the study.~The intervention will involve biweekly hour-long breathing and singing classes that are designed to correct dis-ordered breathing, and retrain the principal muscles of respiration.~Pre and post evaluation of participant bio-psychosocial health and wellness will be conducted. Triangulation of data using focus groups and individual interviews will be conducted after conclusion of the intervention,"
223388463|NCT04880473|DEVICE|PrevisEA device|The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
224008276|NCT07193901|DRUG|Low Dose PRT042 nasal spray|two times a week, for 4 weeks
224008277|NCT07193901|DRUG|median Dose PRT042 nasal spray|two times a week, for 4 weeks
224008278|NCT07193901|DRUG|high dose PRT042 nasal spray|two times a week, for 4 weeks
224008279|NCT07193901|DRUG|placebo|two times a week, for 4 weeks
224008280|NCT07195253|DIAGNOSTIC_TEST|Polysomnography (PSG) to explore OSA|"Patients will undergo full-night PSG (including electrocardiogram to monitor heart rate and the JAWAC system to record mandibular movements) in the sleep unit of Hôpital Femme-Mère-Enfant (Bron, France) to explore OSA, included in the routine care of children with DS.~OSA diagnosis will be made based on the obstructive apnea-hypopnea index (OAHI) resulting from the PSG. OSA will be diagnosed when OAHI ≥1.5/hour."
224008281|NCT07195253|BEHAVIORAL|Oro-myo-functional clinical evaluation|Orofacial myofunctional evaluation will be conducted by a physiotherapist according to the OMES-E (Orofacial Myofunctional Evaluation with Scores for Nursing Infants).
224008282|NCT07195253|OTHER|Sleep Disturbance Scale for Children|"The Sleep Disturbance Scale for Children is a short questionnaire answered by parents about their child's sleep disorders.~Total score and scores for each sleep disorder will be calculated, according to the classical procedures during hospitalization of all children in our sleep unit."
224008283|NCT07195253|OTHER|Non-nutritive sucking recording|Non-nutritive sucking performance will be recorded through an experimental method using a classical pacifier, equipped with pressure sensors. Recording will last about 10 minutes. Variables related to sucking performance (maximum amplitude, frequency of sucking bursts, etc.) will be recorded.
224126195|NCT03119116|DRUG|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
224126196|NCT03119116|DRUG|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
224126197|NCT02853734|OTHER|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
224126198|NCT02853734|OTHER|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
224126199|NCT03860311|DEVICE|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
223388464|NCT04233073|DRUG|andexanet alfa|Andexanet is a recombinant version of human FXa
224008284|NCT07195253|OTHER|Neurocognitive evaluation|The Brunet-Lézine test will be administered by a neuropsychologist. Global score will be calculated along with its four subscores (posture, hand-eye coordination, language, sociability).
224008285|NCT07195253|OTHER|PedsQL-Infants|The PedsQL-Infants questionnaire is designed to evaluate quality of life in infants. It will be given to parents during their child's hospitalization.
224008286|NCT07194993|OTHER|Nonradioactive stable oral isotope|"NaH13CO3 \[99% atom percent excess (APE) and L-\[1-13C\]Leu (99% APE) will be given orally.~Isotope administration will begin with the fifth meal on each study day with each remaining meal.~The nonradioactive stable oral isotope is being administered to study the physiological process of amino acid oxidation."
223388465|NCT02307773|DRUG|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
223388466|NCT04980989|DEVICE|Mobile software for follow-up of early breast cancer|The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer
223388467|NCT01534130|DEVICE|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
223388468|NCT01534130|DEVICE|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
223388469|NCT04357548|DEVICE|FEEDBACK|Once the sample was selected, a test was performed in which the professionals performed 2 minutes of CPR on the dummy without any feedback system, after 5 minutes they performed 2 minutes of CPR with feedback system through the Zoll® monitor with CPR patch -D padz training, to later compare the pretest-posttest results.
223388470|NCT02198963|DRUG|Hypochlorous acid solution 106 mg/L|test product
223388471|NCT02198963|DRUG|0.1% (w/v) Sodium Lauryl Sulfate|positive control
223388472|NCT02198963|DRUG|0.9% Physiological Saline, USP|negative control
223388473|NCT03982992|DRUG|Blinatumomab in combination with donor lymphocyte infusion|Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
223388474|NCT06632119|DEVICE|high-intensity laser therapy|high-intensity laser therapy (HILT) machine, ASA laser
223388475|NCT06632119|DEVICE|Sham-HILT|Sham-HILT, HILT machine without laser release
223388476|NCT03350607|OTHER|Non interventional study|Non interventional study (collect of data)
223388477|NCT00146276|DRUG|gemcitabine|
223388478|NCT04053127|DEVICE|RAVANS|Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
223388479|NCT00681031|BIOLOGICAL|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
223388480|NCT04957030|DIAGNOSTIC_TEST|ULDCT group|underwent ultralow-dose chest CT
223730220|NCT03695679|BEHAVIORAL|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
224008287|NCT07194993|OTHER|Test diet|"Test diets will be provided on study days in 8 hourly isocaloric and isonitrogenous meals to maintain a metabolic steady state.~Each meal will provide one-twelfth of the participant's daily needs to model a 12-hour fasted and 12-hour fed feeding pattern.~The diet will be composed of PFD2 (Mead Johnson), Tang and Kool-Aid (Kraft), corn oil, and protein-free wheat starch cookies. Each participant will receive 1 of 7 test protein intakes (0.2-3.2 g ⋅ kg-1 ⋅ d-1) on each study day. Protein will be provided as a crystalline L-amino acid mixture based on an egg protein pattern. Phe will be provided separately based on the Phe tolerance for each patient established by the metabolic dietitian listed on the IRB protocol. Leucine will be provided at a constant amount of 82.6 mg/kg/day as it is used as the indicator amino acid. The medical food used in this study is being fed to subjects for nutritional purposes to study the oxidation of the nonradioactive oral isotope."
224126200|NCT03860311|OTHER|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
223388481|NCT04684472|BIOLOGICAL|Modified anti-CD19 CAR T cells|intravenous infusion
223388482|NCT02210624|BIOLOGICAL|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
223388483|NCT01476514|OTHER|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
223388484|NCT05019950|DRUG|NIM-1324|Once daily oral tablet
223388485|NCT05019950|DRUG|Placebo|Once daily oral tablet
224126201|NCT03262597|OTHER|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
224126202|NCT03262597|OTHER|Pedialyte|Subjects will consume Pedialyte
224126203|NCT03262597|OTHER|Gatorade|Subjects will consume Gatorade
224126204|NCT03262597|OTHER|Water|Subjects will consume water as the control beverage
223388486|NCT02300155|DRUG|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
224126205|NCT01418664|DIETARY_SUPPLEMENT|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
224126206|NCT01107756|DRUG|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
223388487|NCT02300155|DRUG|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
223730221|NCT01743131|DRUG|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
223730222|NCT01743131|DRUG|placebo|
224126207|NCT03559244|OTHER|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
224126208|NCT03559244|OTHER|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
224126209|NCT00427583|DRUG|imatinib mesylate|
224126210|NCT03118531|DEVICE|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
223388488|NCT02457923|OTHER|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
223388489|NCT00396643|DRUG|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
223388490|NCT01290159|OTHER|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
223388491|NCT06265259|DRUG|Initiation of vasopressine as a first vasoconstrictive drug|The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.
223388492|NCT06265259|DRUG|Initiation of noradrenaline as a first vasoconstrictive drug|ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
223388493|NCT05329259|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|One dose of 13vPnC (0.5mL) will be administered intramuscularly.
224008288|NCT07194057|GENETIC|Whole genome sequencing|Whole genome sequencing (WGS) is an advanced genomic technique that allows for the comprehensive analysis of an individual's entire DNA sequence, including both coding and non-coding regions. In the context of pediatric transplantation, WGS offers a powerful tool for uncovering underlying genetic disorders that may influence transplant eligibility, donor-recipient compatibility, immune response, or risk of post-transplant complications. It enables the identification of rare monogenic diseases, pharmacogenomic markers relevant to immunosuppressive therapy, and potential genetic predispositions to graft rejection or infection. Integrating WGS into transplant evaluation process enhances personalized medicine approaches, contributing to improved long-term outcomes in pediatric transplant recipients.
224008289|NCT07194057|GENETIC|Polygenic Risk Score Calculation|A polygenic risk score (PRS) calculation will be performed to quantitatively estimate the an individual's genetic predisposition to the original disease that led to transplantation. These scores are calculated by aggregating the weighted sum of risk alleles-most commonly single nucleotide polymorphisms (SNPs)-each of which contributes a small effect size as determined by genome-wide association studies (GWAS).
224008290|NCT07194057|DIAGNOSTIC_TEST|Methylome and episignatures|"Methylomic analysis in paediatric transplantation refers to the comprehensive profiling and study of DNA methylation patterns across the genome to understand epigenetic modifications associated with transplant-related outcomes.~This epigenetic approach enables the identification of differentially methylated regions (DMRs) that may correlate with clinical phenotypes, such as graft acceptance or rejection, infectious complications, or immune dysregulation.~The studies withjin the Protect\_Child\_101 project will be aimed at: 1) Refinement of episignatures, to increase specificity, sensitivity and robustness of those episignatures that already exist and 2) Discovery and validation of new disease, gene or variant specific mDNA signatures."
224008291|NCT07194512|OTHER|Taekwondo-Specific Agility Test (TSAT), Frequency Speed of Kick Test (FSKT), Frequency Speed of Kick Test (FSKT10s), Multiple Frequency Speed of Kick Test (FSKTmult), Kick Decrement Index (KDI)|After pre-test measurements, the experimental group performed an eight-week high-intensity interval training (HIIT) program three times per week (Monday, Wednesday, Friday) alongside their regular taekwondo training. The control group continued with their regular taekwondo training only. After the eight-week intervention, post-tests were administered to both groups, and the results were recorded by the researchers.
224008292|NCT07193407|DEVICE|Sacral Neuromodulation System|INOPASE Sacral Neuromodulation System (INO-SNM-01) for treatment of overactive bladder.
224008293|NCT07195578|OTHER|Three Dimensional Puzzle Game (3D puzzle)|Individuals in the intervention group were exposed to the 3D puzzle game three days a week for a total of 10 weeks. Three-dimensional puzzle figures, ranging in size from 20 to 50 pieces, were used in 30 sessions, each with a different figure.
224008294|NCT07194655|OTHER|Acupuncture at the Yanglingquan point|Acupuncture at the Yanglingquan point
224008295|NCT07194655|OTHER|Acupuncture at the Xiabai Point|Acupuncture at the Xiabai Point
224008296|NCT07194655|OTHER|Acupuncture at non-meridian points|Acupuncture at non-meridian points
224008297|NCT06069817|DEVICE|High flow nasal cannula|home treatment with HFNC after airway stent placement both for malignant and benignant central airway obstruction
224008298|NCT06069817|DEVICE|nebulized normal saline|home treatment with nebulized normal saline after airway stent placement both for malignant and benignant central airway obstruction
224008299|NCT01464372|DEVICE|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
224008300|NCT01464372|DEVICE|Sham Nerve Stimulation Device|Use of the sham device
224008301|NCT05498987|DEVICE|Monopolar 448 kilohertz radiofrequency stimulation|448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant Achilles Tendon
224126211|NCT03206034|BEHAVIORAL|Stylistic Memory Enhancement|
224126212|NCT06442852|OTHER|exposure|The observed exposure factor was the expression level of synaptic associated mirna in the serum of patients with Alzheimer's disease and healthy volunteers
223388494|NCT01892280|BEHAVIORAL|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
223388495|NCT01892280|BEHAVIORAL|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
223388496|NCT05052112|OTHER|E-PR-01|Active arm
223388497|NCT05052112|OTHER|E- PR-02|Placebo arm
223388498|NCT05243446|DRUG|Losartan|losartan treatment
224008302|NCT06357325|OTHER|a qualitative study.|"Before the interview process began, an interview form was created in accordance with the study design. In the study, care was taken to use open-ended general questions that would allow the participant to provide detailed information on the subject and did not require short answers such as short and clear questions, multiple choice questions, and yes-no questions.~For the analysis and reporting phase, an introduction was made in the form of a conversation with the participant before starting the interview, and then the interview was started if the participant was available. During the transcription phase, the questions were asked during the interview in such a way as to allow the participant to express themselves in detail without any direction or comment. The interview was conducted individually by calling each woman by telephone. During the interview, the researcher transcribed the interviewee's sentences exactly as she expressed them."
224008303|NCT02261987|OTHER|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
224008304|NCT02261987|OTHER|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
224008305|NCT02261987|OTHER|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
224008306|NCT03333876|DEVICE|Nasal Dilator|Mute is a pair of nasal dilators that fit snugly in the nose of the snorer dilating the nostrils to help reduce or eliminate snoring. This is an over-the-counter (OTC) product and is cleared by FDA for use in the United States. The introduction video for Mute is located at http://mutesnoring.com/how-to-use/.
224008307|NCT03333876|DEVICE|Mandibular Advancement|"For purposes of this trial, we will be using an investigational myTAP V, which is not available for commercial use. The changes from the released product are: a vertical offset (+3mm) has been added to the design of the adjustment post and mechanism to improve overall comfort.~myTAPTM is a mandibular advancement device used for snoring relief. The product requires a prescription and is cleared by FDA for use in the United States."
224008308|NCT03333876|DEVICE|Positional Therapy|Sleep Positional Trainer (SPT) is a small device worn around the chest with an ergonomic band that continuously monitors the sleep position of the snorer. When the snorer is supine, it emits a gentle vibration to remind them to turn to the side to help reduce or eliminate their snoring.
224008309|NCT01587859|PROCEDURE|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
224008310|NCT00095498|DRUG|placebo|placebo subcutaneous injection
224008311|NCT00095498|DRUG|denosumab|For subcutaneous injection
224008312|NCT05020327|DRUG|Graded Oral Amoxicillin Challenge|Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
223388499|NCT00508131|OTHER|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
224008313|NCT05020327|OTHER|De-labelling in electronic medical record|Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
224008314|NCT05020327|OTHER|Referral to Allergy Immunology/Retention of Allergy Label|Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
224008315|NCT04684394|BIOLOGICAL|GEM103|GEM103 500 mcg/50 mcL intravitreal injection
224008316|NCT04684394|DRUG|Aflibercept|"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"
224008317|NCT04684394|DRUG|Sham|Sham intravitreal injection
224008318|NCT05749484|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
224008319|NCT01094210|DRUG|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
224008320|NCT01558401|OTHER|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
224126213|NCT04276311|DEVICE|Percutaneous transluminal angioplasty|The purpose of this study is to evaluate the efficacy and the feasibility of atherectomy, using the Jetstream™ artery preparation associated to DCB treatment (Ranger™ Paclitaxel-Coated balloon), in symptomatic patients with claudication (Rutherford 2 and 3) and with complex de novo femoropopliteal arterial lesions (TASC C).
224126214|NCT01952834|DIETARY_SUPPLEMENT|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
224126215|NCT01952834|DRUG|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
224126216|NCT02249234|DRUG|Botox|
224126217|NCT02249234|DRUG|Placebo|
224299271|NCT03340363|BEHAVIORAL|environmental change|"1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store."
223388500|NCT06432816|DIETARY_SUPPLEMENT|NANO-PSO|NANO-PSO or Oil of pomegranate seed with nanotechnology, they are capsules with a net content of 640 mg with a dosage indicated by sponsor of 2 capsules in fast
223388501|NCT06432816|OTHER|PLACEBO|"Placebo physically identical to NANO-PSO capsules:~Soft gelatin capsules 640 mg edible oil 35for PLACEBO Oil edible, oval shape, 640 mg."
223388502|NCT04359797|OTHER|Prone|Provider-recommended guidance on prone positioning of patients
223388503|NCT04359797|OTHER|Usual Care|No provider-recommendation, patients will remain in their natural choice of position
223388504|NCT04615351|DRUG|Metformin|Medication
224126218|NCT06652568|DEVICE|ThinkSono System|The ThinkSono Guidance System is a guidance software expected to help non-radiology specialist healthcare professionals produce compression ultrasound image data that meet or exceed the minimal image quality criteria for a remote diagnosis by an expert (e.g. radiologist).
224126219|NCT04229498|DRUG|Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)|In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
224126220|NCT06269341|OTHER|No intervention|No intervention
224126221|NCT02432287|DRUG|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
224126222|NCT02432287|DRUG|Placebo|there is no other name we used for the placebo
224126223|NCT02153450|DRUG|metformin hydrochloride|Given PO
224126224|NCT02153450|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
223388505|NCT01108627|DRUG|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
224008321|NCT05199415|BEHAVIORAL|Health and Well-being Committee|Health and Well-being Committees (HaWCs) will be introduced in treatment sites as a means to facilitate on-going problem identification and collaborative processes for developing action plans, implementing small-scale, site-based improvements. HaWCs will involve 10-14 workers and frontline supervisors, with a worker and manager co-chair. HaWCs will identify challenges to safety, health, and well-being spanning physical hazards, COVID-19 protocols as relevant, other conditions of work (e.g., schedules, pace of work), and policies (e.g., absenteeism, performance management). They will then design and implement mitigating solutions and track outcomes. As such, HaWCs have a broader scope than traditional safety committees and will actively solicit worker voice regarding policies and practices that are not labeled as health and safety policies.
224008322|NCT05599503|BEHAVIORAL|Behavioral Interventions|Traditional SimpleC Wellness
224008323|NCT05599503|BEHAVIORAL|Robot Interventions|Robot interventions
224126225|NCT03682510|PROCEDURE|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
224126226|NCT03682510|PROCEDURE|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
223388506|NCT01108627|DRUG|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
223388507|NCT01108627|DRUG|foradil|open-labeled inhaled corticosteroids (ICS); foradil
223388508|NCT03423940|BEHAVIORAL|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
223388509|NCT03714243|DEVICE|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
224126227|NCT03682510|PROCEDURE|N&H sandwich technique|In the N\&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
224126228|NCT03041194|OTHER|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
224126229|NCT06065527|BEHAVIORAL|Map Our Life|The intervention takes participants through the process of planning using the Preparation for Future Care Model stages: care expectation, awareness, information gathering, decision making, and concrete planning. The intervention has 8 modules: (1) Letter of Intent for Your Loved One, (2) Caregiver Support and Well-Being, (3) Medical Decision Making for Your Loved One, (4) Daily Routines and Medical Management, (5) Medicaid Waiver for Your Loved One, (6) Financial Planning for Your Loved One, (7) Emergency Planning for Your Loved One, and (8) Managing Jobs, Day Programs, and Transportation. Map Our Life takes users - the caregiver alongside the individual with intellectual disability - through the stages of planning in each of the 8 modules until a concrete care plan is developed. The last component of the intervention is that this Care Plan is subsequently saved and shared with others such as care managers, clinicians, friends or family members.
224126230|NCT06065527|BEHAVIORAL|Attention Control|The control group will have access to a CDC Website, CDC Healthy Living with a Disability.
224126231|NCT00610935|DRUG|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
224126232|NCT00610935|DRUG|Placebo|Single intramuscular injection
224126233|NCT04749979|DRUG|Agonist (decapeptyl )|giving agonist
224008324|NCT03407937|BEHAVIORAL|Hypnosis|Hypnosis is a therapeutic method in which the experimenter or therapist make suggestions to individuals after they have undergone a hypnotic induction. This induction is a relaxation procedure designed to focus one's mind and to induce a hypnotic trance in individuals. The hypnotic trance consists in a state of deep absorption, concentration and altered sensations, cognitions and behaviors. Hypnosis can be used for pain control in experimental and clinical settings. In this study, standardized hypnosis including a relaxation technique for the hypnotic induction and a direct hypnotic analgesia technique for the hypnotic suggestions will be used.
224008325|NCT03407937|BEHAVIORAL|Meditation|Meditation is a relaxation method that can be used to reduce pain symptoms and pain perception in clinical and experimental situations. In this study, a standardized mindfulness meditation session of 20 minutes will be used to induce a relaxation and an analgesic effect in participants. Mindfulness meditation is a practice intended to increase mindfulness and awareness of the self and the environment by techniques of controlled breathing, focus on neutral elements, and observation of one's thoughts and emotions without judgment.
224008326|NCT03407937|OTHER|Conditioned pain modulation|Conditioned pain modulation (CPM) is a pain inhibition mechanism that is used to assess endogenous analgesia capacity. The method to evaluate CPM in healthy individuals and patients with pain includes both a conditioning stimulus (a noxious stimulus that induces CPM) and a test stimulus (a noxious stimulus used to evaluate the analgesic response to the conditioning stimulus). In this study, the conditioning stimulus will be a cold pressor test (two-minutes immersion of one hand in ice water) and the test stimulus will be a two-minutes thermal noxious stimulus delivered by a contact thermode.
224008327|NCT03407937|DRUG|Placebo Oral Tablet|A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
224008328|NCT03143621|DIETARY_SUPPLEMENT|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
224008329|NCT03143621|OTHER|Water|Tap water heated to same temperature as coffee
224008330|NCT04874285|DIETARY_SUPPLEMENT|HA|hyaluronic acid, alpha-lipoic acid, vitamin D and vitamin B6
224008331|NCT00482690|DRUG|nicotine polacrilex|
224008332|NCT00482690|DRUG|nicotine transdermal system|
224008333|NCT00482690|DRUG|nicotine inhaler|
224008334|NCT02932566|DRUG|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
224008335|NCT02932566|DRUG|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
224126234|NCT04749979|DRUG|HCG ( eg. Choriomon )|giving HCG
224126235|NCT06512467|DRUG|Donafenib|200 mg BID,oral administration will start before the first HAIC treatment .
224126236|NCT06512467|DRUG|Sintilimab|200 mg Q3W,Intravenous infusion will perform before HAIC treatment.
224126237|NCT06512467|OTHER|HAIC|HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
224126238|NCT03369301|DRUG|Gammanorm|Gammanorm given per standard of care
224126239|NCT03369301|DRUG|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
224126240|NCT03792776|OTHER|cuff inflation with air|Endotracheal tube cuff inflation with air
224296099|NCT02422914|BEHAVIORAL|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
224008336|NCT05747300|OTHER|Premixed bioceramic paste wellroot PT|Vital pulpotomy primary Molars using premixed bioceramic paste wellrootPT
224008337|NCT00591370|DRUG|Temozolomide (TMZ)|One group treatment study
224008338|NCT03439254|DRUG|Obeticholic acid (10 mg)|Tablets administered orally once daily.
224008339|NCT03439254|DRUG|Obeticholic acid (10 mg to 25 mg)|Tablets administered orally once daily.
224008340|NCT03439254|DRUG|Placebo|Tablets administered orally once daily.
224008341|NCT04101214|OTHER|Dry needling|Dry needling into spastic muscle
224008342|NCT04101214|OTHER|Sham dry Needling|Sham dry needling into spastic muscle
224008343|NCT02442492|DRUG|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
224126241|NCT03792776|DRUG|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
224126242|NCT03792776|DRUG|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
224126243|NCT03792776|OTHER|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
224126244|NCT03792776|OTHER|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
224126245|NCT03792776|OTHER|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept \< or = 20 centimeter of water (cmH2O).
224126246|NCT03792776|OTHER|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
224126247|NCT06553144|PROCEDURE|control|Canals were irrigated with only10 mL of 5% NaOCl
224126248|NCT06553144|PROCEDURE|methylene blue|0.1 mg/mL methylene blue solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
224008344|NCT02442492|DRUG|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
223388510|NCT03132233|DIETARY_SUPPLEMENT|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
224008345|NCT04556292|DRUG|SC10914|SC10914 400mg tid
224008346|NCT00080457|DRUG|sitaxsentan sodium|
224008347|NCT06531993|DRUG|Pectin|Using pectin as tablets 600 mg per day for 6 months
224008348|NCT02780154|BIOLOGICAL|PfSPZ (7G8) Challenge|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
224008349|NCT02780154|BIOLOGICAL|PfSPZ (NF54) Challenge|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
224008350|NCT00271960|BEHAVIORAL|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
224008351|NCT00271960|BEHAVIORAL|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
224008352|NCT00271960|BEHAVIORAL|Usual care|Participants will receive usual prenatal care.
224008353|NCT03232580|DRUG|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
224008354|NCT04362943|DRUG|Baricitinib or Anakinra|Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
223388511|NCT03132233|OTHER|placebo powder|matched placebo powder to the IMP.
223388512|NCT03169088|OTHER|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~* survey like FFQ, IPAQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers"
223388513|NCT02905032|BEHAVIORAL|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
224008355|NCT05331313|GENETIC|DNA sequencing|The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
224008356|NCT02851888|DRUG|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
224008357|NCT02851888|OTHER|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
224008358|NCT02851888|PROCEDURE|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
224008359|NCT02265289|DRUG|Lefradafiban|
224008360|NCT02265289|DRUG|Clopidogrel|
224008361|NCT06281106|DRUG|Deucravacitinib|Daily drug intake for 4 weeks.
223388514|NCT01723475|BIOLOGICAL|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
224008362|NCT06254937|OTHER|Reproductive Life Plan training|Reproductive Life Plan trainings; It will be done in the form of group training, which is considered an advantageous health education method in terms of low cost, wide scope and practicality. During the training, after the power point presentation to the initiative group, question-answer, discussion, brainstorming and visualizations will be made with the Pecha Kucha Technique. Presentations prepared in line with the Reproductive Life Plan Training Booklet will be used as training tools. Training will be given to participants face to face for 40 minutes, once a week for five weeks. Each training session will include two topics in booklet.
224008363|NCT02392520|DRUG|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
224008364|NCT02392520|DRUG|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
223388515|NCT01723475|BIOLOGICAL|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
223388516|NCT02660905|DRUG|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
223388517|NCT02660905|DRUG|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
223388518|NCT00932672|BEHAVIORAL|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
223388519|NCT07067229|DEVICE|Personalized rTMS|Personalized repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
223388520|NCT07067229|DEVICE|Standard rTMS|Standard repetitive transcranial magnetic stimulation (TMS) together with mixed-reality (MR) exercise
223388521|NCT07067229|DEVICE|Sham rTMS|Sham rTMS together with mixed-reality (MR) exercise
224008365|NCT03282669|DRUG|Intrathecal Morphine|Intrathecal Morphine administered in the operating room.
224008366|NCT03282669|DRUG|Intravenous hydromorphone|Intravenous hydromorphone administered via IV in the post operative area.
224008367|NCT04506645|DRUG|REGN5381|Single dose REGN5381 administered via IV infusion
224008368|NCT04506645|OTHER|Placebo|Placebo matching single dose REGN 5381 administered via IV infusion
224008369|NCT05490901|DIAGNOSTIC_TEST|Exercise hemodynamic test|Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
224008370|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
224008371|NCT02492022|DIETARY_SUPPLEMENT|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
224008372|NCT02492022|OTHER|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
224126249|NCT06553144|PROCEDURE|erythrosine b|0.3 mg/mL eryrhtosine b solition delivered into the canal and irradiated with a 100mW diode laser at a wavelength of 660 nm
223388522|NCT05325827|PROCEDURE|ultrasound-guided high fascia iliaca compartment block|H-FICB was guided by ultrasound before general anesthesia. The patient was supine. First, the probe is placed transversely above the groin. Then slide the probe up and down to reveal a clear image of the internal oblique and sartorius muscles. There is a bowtie-like iliac fascia space at the junction of these two muscles. After the scanning, the needle was inserted behind the probe with the tip pointed to the ventral side under the guidance of real-time ultrasound; the tip passed through the skin into the iliac fascia space and advanced to the inguinal ligament. After no blood was extracted, 1 \~ 2 ml of normal saline was firstly injected to determine whether the tip position was correct. If the needle tip was correctly positioned, 0.375% ropivacaine 30 mL of local anesthetic was injected. The H-FICB was performed under ultrasound guidance by the same anesthesiologist.
223388523|NCT02649712|DEVICE|biliary stent|Self-expandable biliary nitinol alloys stent
223388524|NCT04927845|BEHAVIORAL|StriveWeekly|"The intervention (app.striveweekly.com) delivers content via independent modules. Principles covered in content modules: Psychoeducation; Self-monitoring; Values-based goal-setting; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Relaxation strategies; Maintenance planning. Modules get released week-by-week, and participants are self-guided through content. To facilitate skills practice, every module is accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displays user progress, including self-rating graphs and a history log of skills practice. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity."
223388525|NCT07104838|PROCEDURE|Non-intubated spontaneous ventilation anesthesia|Non-intubated spontaneous ventilation anesthesia
223388526|NCT07192939|DRUG|HRS-9813 capsules|HRS-9813 capsule; High dose
223388527|NCT07192939|DRUG|HRS-9813 capsules|HRS-9813 capsule; Low dose
223388528|NCT07192939|DRUG|HRS-9813 capsule mimetic|HRS-9813 capsule mimetic
224008373|NCT05139251|OTHER|Recovering from Intimate partner violence through Strengths and Empowerment (RISE)|RISE intervention will be implemented for a period of 4 weeks at the beginning of the program. Four components/modules of the RISE intervention which includes a) education on health effects of violence, b) improving coping and self-care, c) enhancing social support, and d) addressing sexual violence will be used. Toward the beginning of each session the participant will complete a brief survey including a 10-item general self-efficacy scale to be graphed and discussed together to provide more immediate feedback to women about their progress, and at times, inform module selection. At the conclusion of each RISE session, women are asked to set a goal related to the topic in consultation with the clinician
223388529|NCT03258502|DRUG|RV521|RV521 drug in capsules
224008374|NCT05139251|OTHER|ePALS|"Participants and their children will then receive 6 weekly sessions of ePALS. The ePALS sessions include rapport building, recognizing and understanding children's signals, contingently responding to signals, labeling objects and actions, learning book reading strategies, maintaining children's focus of attention, helping children with self-regulation, and language scaffolding techniques. Each parent will have a personal parenting coach who remotely supports their progress through the program.~After a parent views a PALS coaching session, they will videotape themselves trying the strategy for that week with their child. Then their coach sets up a zoom call and together they talk about the PALS strategy and view the video. The coach facilitates parental appraisal of their behavior and discuss what they thought worked with their child and what they want to do differently."
223388530|NCT03258502|DRUG|Placebo|Placebo in capsules
223388531|NCT05954988|DRUG|LTI-03|Caveolin-1-Scaffolding-Protein-Derived Peptide
223388532|NCT05954988|DRUG|Placebo|Matching placebo
223388533|NCT06263179|BEHAVIORAL|Target Heartrate Aerobic Exercise|Exercise program
223388534|NCT03528642|OTHER|Questionnaire Administration|Ancillary studies
223388535|NCT03528642|RADIATION|Radiation Therapy|Undergo RT
223388536|NCT03528642|DRUG|Telaglenastat Hydrochloride|Given PO
223388537|NCT03528642|DRUG|Temozolomide|Given PO
223388538|NCT04150783|PROCEDURE|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
223388539|NCT03328884|DRUG|Irinotecan (CPT-11) liposome|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan free base, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered 50 mg/m2 on D1 of a 14-day cycle in monotherapy."
223388540|NCT05491915|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|The SPRINT System delivers mild electrical stimulation to the occipital nerves. The SPRINT System includes up to two leads (small wires) that are placed through your skin at the top of your neck. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
224008375|NCT04379362|PROCEDURE|Focal laser ablation|Focal laser ablation
224008376|NCT02084563|DRUG|Induction Chemotherapy|"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~* Cytarabine 200 mg/m2 IV continuous infusion days 1-7~* Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"
223388541|NCT05471856|DRUG|BI 1703880|BI 1703880
223388542|NCT05471856|DRUG|Ezabenlimab|Ezabenlimab
223388543|NCT04797039|PROCEDURE|MR guided cryoablation|MR guided cryoablation of focal biopsy proven prostate cancer
223388544|NCT06297941|DRUG|REM-422|"REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~REM-422 will be administered orally once daily"
223388545|NCT02603146|DRUG|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
223388546|NCT02603146|DRUG|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
223388547|NCT05343260|DRUG|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
223388548|NCT05343260|DRUG|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
224008377|NCT02084563|DRUG|Consolidation Chemotherapy|"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"
224008378|NCT02084563|DRUG|Autologous Stem Cell Transplantation|"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"
224126250|NCT06553144|PROCEDURE|curcumin|5.0 mg/mL curcumin solition delivered into the canal and irradiated with a 200mW diode laser at a wavelength of 450 nm
224126251|NCT05427825|OTHER|ERAS anesthetic care|The ERAS anesthetic care includes EEG spectrum-guided multimodal anesthesia and HPI-guided hemodynamic therapy.
223388549|NCT06476730|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased
223388550|NCT06476730|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
223388551|NCT06288282|OTHER|No Intervention|No intervention will be used.
223388552|NCT04059952|DEVICE|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
223388553|NCT06290765|DRUG|Ropeginterferon alfa-2b|"Ropeginterferon alfa-2b subcutaneously (SC) every two weeks (± 3 days), 250 µg at Day 1, 350 µg at Week 2, and target optimal dose of 500 µg at Week 4.~Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value."
223388554|NCT06290765|PROCEDURE|Phlebotomy and aspirin|Phlebotomy should be conducted if confirmed Hct ≥48%, or confirmed Hct ≥45% that is ≥3% higher than baseline Hct value, or confirmed Hct ≥45% according to the standard of care for phlebotomy at the institution regardless of the magnitude of the increase compared with the baseline. The same standard or criteria for phlebotomy eligibility should be applied for patients during the study at each study site or institution.
224008379|NCT02084563|DRUG|Allogeneic Stem Cell Transplantation|"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"
224008380|NCT02084563|DRUG|Low Dose Cytarabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
223388555|NCT03829540|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
223388556|NCT00265759|DRUG|anastrozole|Given PO
223388557|NCT00265759|DRUG|exemestane|Given PO
223388558|NCT00265759|DRUG|letrozole|Given PO
223388559|NCT00265759|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
223388560|NCT03802526|DRUG|NVP-1805-R1|1 tablet, multiple oral dosing
224008381|NCT02084563|DRUG|Decitabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
223388561|NCT03802526|DRUG|NVP-1805-R2|1 tablet, multiple oral dosing
223388562|NCT03802526|DRUG|NVP-1805-R1 and NVP-1805-R2|NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
223730223|NCT05503641|OTHER|Cognitive and psychomotor stimulation|"Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users."
223730224|NCT04840238|DRUG|Cholecalciferol|30,000IU cholecalciferol
223730225|NCT04840238|DRUG|Placebo|Placebo tablets
224126252|NCT05427825|OTHER|Standard anesthetic care|The standard anesthetic care includes bispectral index guided general anesthesia and arterial line monitored hemodynamic care.
224126253|NCT01234012|BIOLOGICAL|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
224126254|NCT03737968|DRUG|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
224299272|NCT03340363|BEHAVIORAL|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
223730226|NCT03613935|OTHER|Product 1|Comparison with products 2, 3, and 4
223730227|NCT03613935|OTHER|Product 2|Comparison with products 1, 3, and 4
223730228|NCT03613935|OTHER|Product 3|Comparison with products 1, 2, and 4
223730229|NCT03613935|OTHER|Product 4|Comparison with products 1, 2, and 3
223388563|NCT04009759|DRUG|Morphine|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
223388564|NCT04009759|DRUG|Ketamine Injectable Solution|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
224008382|NCT02371291|BEHAVIORAL|Memory Flexibility Training|As in experimental arm description.
224008383|NCT02371291|BEHAVIORAL|Psychoeducation|As in experimental arm description.
224008384|NCT01051934|DRUG|SS1 (dsFv) PE38|
223388565|NCT04009759|DRUG|Saline 0.9%|Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
223388566|NCT04704453|DRUG|Capsaïcin patch (Qutenza®)|Treatment by application of capsaicin 8% (Qutenza®) patches 3 months apart (Month 1, Month 4 and Month 7).
223388567|NCT04704453|DRUG|Amitriptyline (Laroxyl®)|Treatment by amitriptyline (oral solution 40mg/ml), for 9 months at the recommended dose of 25 mg to 75 mg daily.
223388568|NCT04467840|DRUG|Opaganib|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
224008385|NCT01051934|DRUG|Paclitaxel|
224008386|NCT01051934|DRUG|Carboplatin|
224008387|NCT01051934|DRUG|Bevacizumab|
224008388|NCT02075476|PROCEDURE|Hemiarthroplasty|
224126255|NCT03737968|DRUG|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
224126256|NCT01131221|OTHER|laboratory biomarker analysis|
224126257|NCT02572128|OTHER|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
223388569|NCT04467840|DRUG|Placebo|Study participants will receive either opaganib 2 x 250 mg capsules (500 mg) every 12 hours, or matching placebo, in addition to standard of care (pharmacological as defined above and/or supportive) at any given institution. Study drug will be administered every day for 14 days (Day 1 to Day 14).
223730230|NCT06475482|OTHER|Lip hydrant|lip hydrant containing peppermint oil, perilla frutescens, and Emblica fruit extract or petroleum gel.
223388570|NCT05749055|DRUG|ENX-102|Selective GABA-A alpha2,3,5 positive allosteric modulator
223730231|NCT06475482|OTHER|Petroleum gel|Vaseline
223730232|NCT00224055|DRUG|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
224126258|NCT04161586|DRUG|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
223388571|NCT05749055|DRUG|Placebo|Placebo
223388572|NCT04961515|DRUG|Orelabrutinib|Orelabrutinib: 150 mg orally once daily
224126259|NCT04651725|OTHER|Exercises|Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
223388573|NCT04961515|DRUG|Sintilimab|Sintilimab: 200 mg intravenously every 3 weeks
223388574|NCT04961515|DRUG|Temozolomide (TMZ)|Temozolomide: 150 mg/m² orally on days 1-5 of each 21-day cycle
223388575|NCT06625177|DRUG|TEV-53408|TEV-53408 injection administered subcutaneously
223730233|NCT00224055|DRUG|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
223730234|NCT02983331|PROCEDURE|complications during procedure|patients may have anesthesia related complications during procedure
223730235|NCT02391740|OTHER|Questionnaire|
223730236|NCT02068443|DRUG|Alogliptin|Alogliptin tablets
223730237|NCT02068443|DRUG|Metformin hydrochloride|Metformin hydrochloride tablets
224008389|NCT02075476|PROCEDURE|reverse arthroplasty|
224008390|NCT00301587|DRUG|Norgestimate-ethinyl estradiol, with or without folic acid|
224008391|NCT06042322|OTHER|Educational intervention|Multidisciplinary educational intervention was performed by orthopedic, anesthesia, and nursing team. This included a discussion of the patient's pain plan and a patient visit.
224126260|NCT06819566|PROCEDURE|Endoscopic variceal ligation (EVL)|"1. EVL for high-risk varices will be performed by experienced endoscopists, certified in gastroenterological endoscopy, within two weeks prior to the initiation of the Atezo/Bev.~2. A follow-up EGD will be conducted one week after the Atezo/Bev #3. If any of the following criteria are met, additional EVL will not be performed, and anticancer treatment will proceed two weeks later. Otherwise, an additional on-demand EVL session will be conducted:~   * The esophageal varices have improved to F1 or less.~  * The red color sign has disappeared.~3. On-demand EVL will be considered after 5th, and 7th consecutive doses of Atezo/Bev, with EGD follow-up performed to assess eligibility. The maximum number of EVL sessions is limited to three sessions."
224008392|NCT05882409|BEHAVIORAL|Education|Education covers women's education on violence, conflict and awareness.
224008393|NCT05894902|DRUG|SM-001|The Investigational New Drug SM-001 is formulated as a hot water decoction of two proprietary clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV).
224008394|NCT00567203|DRUG|PF-3463275|PF-3463275 10mg
224008395|NCT00567203|DRUG|PF-3463275|PF-3463275 25mg
224008396|NCT00567203|DRUG|Placebo|Placebo
224008397|NCT00000444|DRUG|nicotine replacement patch|
224008398|NCT01015859|DEVICE|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
223388576|NCT06556199|DRUG|Selinexor|Selinexor dose escalation: 40,60,80mg respectively every week, and dose expansion at the RP2D of Selinexor,every 3 weeks for 6 cycles.
223388577|NCT06556199|DRUG|Temozolomide|Temozolomide 150mg/m2 po d1-5 every 3 weeks for 6 cycles.
223388578|NCT06556199|DRUG|Anti-PD-1 monoclonal antibody|The dose of anti-PD-1 monoclonal antibody is fixed dose 200 mg intravenously every 3 weeks until until disease progression or recurrence, intolerance of toxicity, death, loss of follow-up, withdrawal of notification (whatever happened first).
223388579|NCT06650007|DRUG|HRS9531 Injection|HRS9531 Injection
223388580|NCT06650007|DRUG|HRS9531 Placebo Injection|HRS9531 Placebo Injection
223388581|NCT04025905|BEHAVIORAL|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
223388582|NCT04025905|BEHAVIORAL|Informations|informations about work environment, social environment, stress management, sleep management, treatments
223388583|NCT05445999|DEVICE|High-Definition transcranial electrical stimulation|The first and final sessions will include clinical assessments and acquisition of MRI and EEG data. To minimize variability, each patient will undergo tDCS at a consistent time in the afternoon or evening and will remain lying in bed with eyes closed throughout stimulation. Stimulation will be delivered using the GTEN 200 system (Magstim EGI, Oregon, USA), which also enables simultaneous EEG recording. The stimulation current will be limited to 1.5 mA, with a maximum of 0.15 mA per electrode (up to 20 electrodes). Electrode placement and current intensity will be individualized to achieve the targeted electric field strength (0.1 or 0.2 V/m at SMHC;). Each session will include 5 min of resting-state EEG immediately before and after stimulation to assess tDCS-induced changes in brain dynamics. Current onset and offset will be gradual, with 2-s ramp-up and ramp-down periods.
223388584|NCT04408183|DRUG|GLS-1200|GLS-1200 is given as a nasal spray using an atomizer
223388585|NCT04408183|DRUG|Placebo|Placebo is given as a nasal spray using an atomizer
223388586|NCT06261970|BEHAVIORAL|Connect|Community level enhancements
223388587|NCT06794658|DEVICE|software|Caaring is an electronic data collection notebook that allows patients to confidentially fill out data/questionnaires on their mobile phone and report them through an application that will be installed on the patient's mobile phone. Besides, This group (G\_CAARING) will receive educational and prevention recommendations relative to diabetes.
223545733|NCT06073197|PROCEDURE|combined deep and superficial serratus anterior plane block|Combined deep and superficial serratus anterior plane block was implemented on preoperative course on 35 patients. Intraoperative analgesic (Fentanyl) consumption was measured for intraoperative effects of the erector spinae plane block Postoperative Visual Analogue Scale (VAS, from 0 to 10) scores and postoperative analgesic (Morphine) consumption was measured using Mann-Whitney test.
223545734|NCT03150147|OTHER|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
223545735|NCT03150147|OTHER|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
223545736|NCT03706768|OTHER|Glycocalyx|Measure Degradation of the Glycocalyx
223730238|NCT02068443|DRUG|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
223388588|NCT02593565|OTHER|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
223388589|NCT05536219|DIAGNOSTIC_TEST|Serum anti-IFN-I antibodies|Anti-IFN-I autoantibodies presence will be assessed through serological methods (ThermoFisher Kit)
223388590|NCT06447103|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223388591|NCT06447103|PROCEDURE|Bone Scan|Undergo bone scan
223388592|NCT06447103|PROCEDURE|Computed Tomography|Undergo CT, PET/CT, and CT of the brain
223388593|NCT06447103|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI of the brain
223545737|NCT03855345|PROCEDURE|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
223730239|NCT03407378|DRUG|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
223730240|NCT03407378|GENETIC|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
223730241|NCT03407378|OTHER|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
223730242|NCT03407378|OTHER|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
224126261|NCT06612034|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223388594|NCT06447103|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223388595|NCT06447103|OTHER|Questionnaire Administration|Ancillary studies
223388596|NCT06447103|DRUG|Zirconium Zr 89 Girentuximab|Given IV
223388597|NCT05732064|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
223388598|NCT05732064|DRUG|Esketamine|Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
223388599|NCT05732064|DRUG|Normal saline|Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
223388600|NCT05419492|DRUG|ETX101|ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
223388601|NCT06482749|DEVICE|Repetitive transcranial magnetic stimulation|"Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 6-8 pm\], no intervention on the day of the surgery). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
223545738|NCT03855345|RADIATION|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F \& A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
223545739|NCT00243191|DRUG|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
223545740|NCT04361448|OTHER|samling of oropharynx and nasopharynx|Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
223545741|NCT02076854|BEHAVIORAL|Text-Message Intervention|
223545742|NCT05475977|DIAGNOSTIC_TEST|MSCT chest|Multi slice Computed Tomography of the chest
224008399|NCT05201391|BEHAVIORAL|"Eat Right Now (ERN) mobile application"|"Eat Right Now (ERN) is an app-based (28 daily modules, self-paced) Mindfulness-Based Intervention (MBI), which uses mindfulness to target craving-based eating. The program is designed to take 6-8 weeks to complete."
224008400|NCT02166996|PROCEDURE|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
224008401|NCT02166996|PROCEDURE|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
224008402|NCT05617664|DRUG|desmopressin 120 mcg oral tablets|treatment for three months then will stop
224008403|NCT05617664|DRUG|Mirabegron 25 MG Oral Tablet, Extended Release|treatment for three months then will stop
224008404|NCT05617664|BEHAVIORAL|behavioral therapy alone|no medications will be given to the patient
224008405|NCT06191822|OTHER|Nutrition|Interact with mobile app and work toward personalized nutrition goals
224008406|NCT06191822|OTHER|Fitness|Interact with mobile app and work toward personalized fitness goals
224008407|NCT06191822|OTHER|Sleep|Interact with mobile app and work toward personalized sleep goals
224008408|NCT02780908|OTHER|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
224008409|NCT02780908|OTHER|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
224008410|NCT00095056|DRUG|sitagliptin|One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
224126262|NCT06650176|BEHAVIORAL|Lifestyle Management|The Metrikamind intervention features a unique digital ecosystem designed to manage mental health specifically in workplace contexts, with a focus on aiding recovery and facilitating the return to work for employees on sick leave. This innovative tool employs bifactor models to enhance the accuracy of self-reported data, effectively countering potential faking behaviors. Through continuous, real-time data collection on a user-friendly platform, Metrikamind tracks and assesses various mental health conditions, including stress, anxiety, and depression. The intervention\&amp;#39;s advanced analytics enable personalized feedback and targeted interventions, improving the detection, management, and ultimately, the mitigation of mental health issues. By focusing on individuals currently unable to work due to mental health challenges, Metrikamind aims to support their recovery and accelerate their readiness to return to work, thus addressing both immediate and long-term recovery trajectories.
223388602|NCT06482749|DEVICE|Sham stimulation|"Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 6-8 pm\], no intervention on the day of the surgery). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes."
223388603|NCT04213625|OTHER|Surgeon Personal Background|"Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~* Favorite outdoor activity/form of exercise~* Favorite hobby~* Family information (children, pets)~* Single sentence about how the clinician conceptualizes excellent patient care"
223545743|NCT04091191|DIETARY_SUPPLEMENT|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
223545744|NCT05115565|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation) Application|Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
224008411|NCT00095056|DRUG|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance \<30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to \<50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
224008412|NCT00095056|DRUG|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
223388604|NCT04204798|DRUG|Dexmedetomidine|"1. Dexmedetomidine is infused from 4 pm to 8 am during ICU stay for no more than 3 days.~2. For non-intubated patients, the infusion rate is adjusted to reach a Richmond Agitation-Sedation Scale (RASS) of -1, or a maximal rate of 0.2 microgram/kg/h, or the occurrence of any adverse events.~3. For intubated patients, the infusion rate is adjusted to reach a RASS of -1, or a maximal rate of 0.7 microgram/kg/h, or the occurrence of any adverse events."
223388605|NCT04204798|DRUG|Placebo|"1. Normal saline is infused in the same rate for the same duration as in the dexmedetomidine group.~2. Propofol sedation is administered when considered necessary."
223388606|NCT05201794|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
223388607|NCT05201794|DRUG|Placebo|Matching placebo for each dose level as tablet will be administered orally.
224008413|NCT00095056|DRUG|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
224008414|NCT05452200|BEHAVIORAL|Solicitation for lung cancer screening|3 levels of solicitation will be cumulated. First : a Simple collective solicitation of all staff via internal media 4 months later : Personalized indirect solicitation of at-risk groups with information posted in identified areas 4 months later : Personalized direct solicitation of at-risk groups
224008415|NCT05452200|OTHER|added exams to the usual lung cancer screening|"* spirometry examination~* Questionnaires~* Blood samples and breath samples to find biomarkers"
224008416|NCT03918499|DRUG|Cyclophosphamide|Given IV
224008417|NCT03918499|BIOLOGICAL|Cytokine-based Biologic Agent IRX-2|Given SC
224008418|NCT03918499|BIOLOGICAL|Pembrolizumab|Given IV
223388608|NCT05537155|PROCEDURE|Buccal acupuncture in addition to routine care|"Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed."
223388609|NCT05537155|OTHER|Routine care|Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
224008419|NCT06245148|OTHER|Observation|Observation
224008420|NCT04019990|OTHER|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
224008421|NCT01882205|DEVICE|Virtual chromoendoscopy|
224008422|NCT01882205|PROCEDURE|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
224008423|NCT05775081|OTHER|Regenerative endodontic procedues|Treating non-vital immature permanent teeth with either treated dentine matrix paste or platelet rich fibrin
224008424|NCT02321202|DRUG|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
224126263|NCT06661291|OTHER|Pip Care Digital Health Platform|Pip Care Digital Health Platform is a smartphone application granting access to a health coach who will assist the patient in completing a health intake, creating personalized perioperative care plans, and meets regularly with the patient to encourage goal accomplishments and supports healthy surgical recovery.
223545745|NCT05626179|DRUG|[14C] IBI351|The oral formulation of \[14C\] IBI351 was formulated as a suspension for subjects to take orally in drinking water under fasting conditions
223545746|NCT02822742|DRUG|DE-117 ophthalmic solution|
223545747|NCT02822742|DRUG|Latanoprost ophthalmic solution 0.005%|
223545748|NCT04224922|DRUG|Paclitaxel|
223545749|NCT04224922|DRUG|Carboplatinum|
223545750|NCT04224922|DRUG|Epirubicin|
224008425|NCT02321202|DRUG|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
224008426|NCT03498859|OTHER|Physiotherapist-supervised training|The intervention is physiotherapist-supervised training once per week during 10 weeks.
224008427|NCT03498859|OTHER|Home-based training|The intervention is home-based training during 10 weeks
224008428|NCT01169740|PROCEDURE|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
224008429|NCT02999802|BEHAVIORAL|Exercise|Progressive resistance exercise training
224008430|NCT06162962|OTHER|Retrospective analysis|Retrospective analysis
224008431|NCT02209662|DEVICE|APIC-PRP|APIC-PRP
224008432|NCT02209662|OTHER|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
223545751|NCT04224922|DRUG|Cyclophosphamide|
223545752|NCT00362882|DRUG|docetaxel|Given IV
223545753|NCT00362882|DRUG|bortezomib|Given IV
223545754|NCT00362882|OTHER|laboratory biomarker analysis|correlative study
224008433|NCT00363350|DRUG|rituximab (anti-CD20)|2 infusions of 1000 mg
224008434|NCT00682851|DEVICE|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
224126264|NCT06661291|OTHER|Standard of Care Protocol|Subjects in this intervention group will receive routine, standard of care throughout their surgery and hospital stay as determined by their acting clinical care team.
223545755|NCT00362882|OTHER|immunoenzyme technique|correlative study
223730243|NCT03407378|OTHER|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
223388610|NCT05793151|BEHAVIORAL|ENDURE|ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
223545756|NCT00362882|OTHER|immunohistochemistry staining method|correlative study
223730244|NCT03407378|OTHER|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
223730245|NCT06186531|DIETARY_SUPPLEMENT|PhytoSERM|PhytoSERM, a formulated dietary supplement, will be an ovalized tablet measuring 8.51 mm x 15.49 mm. Each pill will contain a white PEG coating and an equal mixture of, daidzein, genistein, and S-equol.
223730246|NCT06186531|DRUG|Placebo|Placebo product is of identical shape, size and color with a white PEG coating but without S-equol, daidzein and genistein.
224008435|NCT00682851|DEVICE|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
223545757|NCT00362882|OTHER|pharmacological study|correlative study
223545758|NCT01366573|DRUG|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
223545759|NCT01366573|OTHER|Placebo|Placebo
223545760|NCT04074226|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
223730247|NCT05178966|BEHAVIORAL|Bp OneDay psychoeducation program|"The BP One-Day Psychoeducation program is based on a single day of psychoeducation . This program was carried out by members of the bipolar expert center network in various hospitals of the network and included :~* Representation of BD~* Definition, diagnosis and awareness of the disorder~* Depressive, hypo / manic symptoms~* Vulnerability to BD causes of BD, risk factors for relapses~* Drug treatments, drug compliance and non-drug treatments~* Early detection of prodromal signs~* Communication techniques~Each BP One-Day psychoeducation session welcomes an average of ten participants (5 patients / 5 caregivers). At the end of the day, participants receive a booklet containing the main information of the day.~BP One-Day program is delivered by a nurse and a psychologist specialized in both BD and therapy group facilitation. A specialized psychiatrist intervenes in the section Medication treatments and medication adherence for a period of approximately one hour."
223730248|NCT02699528|DRUG|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
223730249|NCT01986855|DRUG|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
223730250|NCT01986855|DRUG|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
223730251|NCT01986855|DRUG|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
223730252|NCT01986855|DRUG|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
224008436|NCT03114839|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of LcS.
224008437|NCT02746432|DRUG|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
223388611|NCT02205047|DRUG|Cisplatin|
223388612|NCT02205047|DRUG|5-fluorouracil or Capecitabine|
223388613|NCT02205047|DRUG|Trastuzumab|
223388614|NCT02205047|DRUG|Pertuzumab|
223388615|NCT02205047|PROCEDURE|gastrectomy|D2 gastrectomy
223545761|NCT04074226|PROCEDURE|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
223545762|NCT04680624|PROCEDURE|Fecal sample collection|During the study, patients will be ask to collect fecal samples using sample collection kits. A total of 4 stool samples per patient will be collected.
223545763|NCT04420052|OTHER|Osteopathic manipulative treatment|"Osteopaths will executed several high velocity low amplitude (HVLA) techniques on the upper thoracic spine and cervical spine. These techniques are assumed to modulate the sympathetic cervical ganglia and reduce inflammation in chronic rhinosinusitis.~This procedure takes around 15 minutes."
223545764|NCT04420052|OTHER|Placebo manipulation|"The osteopath will lay hands without movement on the nose, the throat and the thorax of patients.~This procedure takes around 15 minutes."
223545765|NCT00004744|DRUG|immune globulin|
223545766|NCT00817765|DRUG|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
223545767|NCT00817765|DRUG|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
223388616|NCT04765514|OTHER|Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)|Temozolomide or Radiotherapy
223388617|NCT04765514|COMBINATION_PRODUCT|Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.|Temozolomide will be administered at a dose of 75 mg/m2 daily for a total of 21 days. This will be followed by adjuvant temozolomide (150-200 mg/m2 daily for 5 day
223388618|NCT06349382|DIETARY_SUPPLEMENT|carbohydrate-rich beverage|Patients in the OCHL group will drink a high-carbohydrate beverage (12.6% carbohydrates, 50 kcal/100 mL, 285 mOsm/kg; PreOp®, Nutricia, Zoetermeer, The Netherlands) 800 mL in the evening before surgery (between 9 p.m. and 11 p.m.), and 400 mL two hours before the induction of anesthesia.
224008438|NCT03700112|OTHER|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
223388619|NCT05730283|DRUG|ORC-13661|High-dose intervention (30mg daily)
223388620|NCT05730283|DRUG|ORC-13661|Low-dose intervention (12mg daily)
224008439|NCT03700112|OTHER|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
224008440|NCT03700112|OTHER|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
224126265|NCT00740779|DRUG|Silodosin 8 mg|Silodosin 8 mg daily
223388621|NCT05730283|DRUG|Placebo|Placebo intervention
223388622|NCT05079568|DEVICE|Oculus Go VR headset|Virtual reality programs consisting of interactive games, meditation and deep breathing exercises, and passive virtual reality experiences designed to facilitate relaxation.
223388623|NCT05079568|DEVICE|Sham Oculus Go VR headset|Virtual reality program with two-dimensional nature video
223388624|NCT05527041|DEVICE|EyeBOX Lens (EBLens)|"The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz:~* Gaze coordinates~* Pupil sizes~* Accelerometer data~* Gyroscopic data~* Rotation data~* Blink data"
223388625|NCT06540196|DIAGNOSTIC_TEST|NodeAI|The ultrasound video and images of each LN will be analyzed by NodeAI, which will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
223388626|NCT06540196|DIAGNOSTIC_TEST|Surgeon|The ultrasound video and images of each LN will first be analyzed by the surgeon, who will assign a CLNS for each LN based on the four ultrasonographic features of the CLNS, predict LN malignancy, and determine whether to biopsy it or not.
223388627|NCT06095986|DRUG|Aramchol meglumine|Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
223388628|NCT06418529|DRUG|tofacitinib|New index treatment of tofacitinib
223388629|NCT06418529|DRUG|tumor necrosis factor inhibitors (TNFi)|New index treatment of TNFi
223388630|NCT06418529|DRUG|abatacept|New index treatment of abatacept
223388631|NCT06418529|DRUG|tocilizumab or sarilumab|New index treatment of tocilizumab or sarilumab
223388632|NCT05841862|DEVICE|2C-QD|Quantum Dot
223388633|NCT05841862|DEVICE|Sham 2C-QD|Sham Intravitreal Injection
223388634|NCT04537741|PROCEDURE|Coronary CT angiography|all patients being included will undergo CCTA before invasive coronary angiography
224126266|NCT00740779|DRUG|Placebo|Placebo
223388635|NCT04537741|PROCEDURE|Invasive coronary angiography|all patients being included will undergo CCTA before invasive coronary angiography
223388636|NCT05758506|DEVICE|Primary Immunodeficiency (PID) Rapid Diagnostic Test (RDT)|We are evaluating the accuracy of a new rapid diagnostic screening test. There is no medical intervention with the participants in this study.
223388637|NCT06566469|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
223388638|NCT06566469|DRUG|Esketamine|Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
223388639|NCT06566469|DRUG|Normal saline|Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
223388640|NCT04027647|DRUG|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
223545768|NCT00817765|DRUG|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
223545769|NCT05771805|OTHER|Vagus nerve stimulation with task oriented training|VNS Group will receive non-invasive vagus nerve stimulation at left auricle of ear for 30 mins during the task-oriented training. Subjects will receive protocol 3 days per week for 12 weeks.
223545770|NCT05771805|OTHER|Task oriented training|Task oriented group will receive task oriented training and placebo effect with vagus nerve stimulator.
223730253|NCT00664742|DRUG|Fluvastatin XL®|Fluvastatin extended release 80 mg
224008441|NCT03700112|OTHER|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
224008442|NCT03700112|OTHER|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
224008443|NCT03700112|OTHER|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
224008444|NCT03700112|OTHER|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
224008445|NCT03700112|OTHER|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
224126267|NCT00740779|DRUG|Silodosin 4 mg|Silodosin 4 mg daily
224126268|NCT05118958|DRUG|KVD824 Prototype 1 modified-release tablet|300 mg modified-release tablet
224126269|NCT05118958|DRUG|KVD824 Prototype 2 modified-release tablet|300 mg modified-release tablet
223388641|NCT04436757|BEHAVIORAL|IPS program : Self-image and body representation|"The IPS program consists in 13 sessions of 2 hours over a 13-weeks period.~Sessions content is as follows :~1. : Introduction~2. : Sensory approach workshop~3. : Self presentation and personal hygiene~4. : Organisation of well-being, planning and pictograms~5. : Becoming aware of my body, my envelope~6. : Presentation and self-esteem (photolanguage)~7. : Self-presentation in social interactions: Social codes~8. : My ideas and desires for change~9. : Places of well-being and clothing hygiene~10. : Vocational insertion devices~11. : Daring change : presence of a Socio-hairdresser~12. : The awakening of color : presence of a Socio-aesthetician~13. : Development of practice sheets and the network"
223388642|NCT04436757|BEHAVIORAL|TAU|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by the health service. No additional session will be proposed.
223388643|NCT05958368|OTHER|Avocado|The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).
223388644|NCT05958368|OTHER|Other Fruit(s)|The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).
223388645|NCT04500119|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system; Blackrock Cerestim stimulator|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried), apply intermittent electrical stimulation (Blackrock Cerestim)
224008446|NCT01242735|BEHAVIORAL|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
223388646|NCT02555579|BEHAVIORAL|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
223388647|NCT04673175|DRUG|Ceftolozane / Tazobactam Injection|Zerbaxa (ceftolozane/tazobactam) for injection is supplied as a white to yellow sterile powder for reconstitution in single-use vials; each vial contains 1 g ceftolozane (equivalent to 1.147 g of ceftolozane sulfate) and 0.5 g tazobactam (equivalent to 0.537 g of tazobactam sodium).
223388648|NCT04049591|DRUG|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
223388649|NCT04049591|DRUG|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
223730254|NCT01940679|DIETARY_SUPPLEMENT|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
224008447|NCT01242735|BEHAVIORAL|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
224008448|NCT04539080|PROCEDURE|transversus abdominis plane block|transversus abdominis plane block group
224008449|NCT03601377|BEHAVIORAL|Training away from threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
224126270|NCT05118958|DRUG|KVD824 Immediate-Release Capsule|300 mg immediate-release capsule
224126271|NCT05118958|DRUG|Placebo to KVD824 Prototype 1|Placebo to 300 mg KVD824 Prototype 1 modified-release tablet
223388650|NCT05781399|DRUG|JNT-517 Suspension|JNT-517 in on-site compounded suspension
223388651|NCT05781399|DRUG|Placebo Suspension|On-site compounded placebo suspension
223388652|NCT05781399|DRUG|JNT-517 Tablet|JNT-517 tablets, 25 mg and 75 mg
223388653|NCT05781399|DRUG|Placebo Tablet|Matching film-coated placebo tablet
223388654|NCT05150704|DRUG|Methylprednisolone|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
223545771|NCT02653339|DRUG|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
223545772|NCT02653339|DRUG|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
224126272|NCT05118958|DRUG|KVD824 Prototype 3 modified-release tablet|300 mg modified-release tablet
224126273|NCT03834571|DRUG|Carboplatin|Given IV
223388655|NCT05150704|DRUG|saline solution|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
223388656|NCT04761926|DEVICE|Audiometry|"Audiometry: Thresholds from the audiogram obtained when Ponto 4 were fitted. Pure tone air conduction (AC) and bone conduction (BC) audiometry conducted at the visit.~Speech recognition in quiet: Speech intelligibility is measured in a soundproof room using the Matrix sentences presented from a loudspeaker. The Matrix test includes five-word sentences with a fixed syntactical structure and limited contextual cues. A list of 20 sentences is compiled from these words, ensuring that no sentence is repeated twice. This test will be obtained both unaided and aided (with and without the Ponto 4(s)).~Sound field Audiometry: Detection of sound field thresholds presented from a loudspeaker. Thresholds will be obtained both unaided and aided and the test order will be balanced between subjects. During these measurements, the Ponto 4 will be programmed in omni-directional mode, with noise reduction and feedback management system turned off."
223545773|NCT02705612|DRUG|Cisplatin|
223545774|NCT02705612|RADIATION|External Beam Radiation Therapy|
223545775|NCT02705612|RADIATION|Internal Radiation Therapy|
223730255|NCT06161220|DRUG|Carbidopa capsule|Dose: 4x 100 mg
223730256|NCT06161220|DRUG|Moxifloxacin Tablets, USP|Dose: 400 mg
223730257|NCT06161220|DRUG|Placebo|Placebo capsules matching the carbidopa capsules
224126274|NCT03834571|DRUG|Cisplatin|Given IV
224126275|NCT03834571|DRUG|Paclitaxel|Given IV
224126276|NCT03834571|PROCEDURE|Patient Monitoring|Undergo active monitoring
224126277|NCT03834571|RADIATION|Radiation Therapy|Undergo radiation
223388657|NCT05755932|DRUG|HFO-1234ze(E)|"* Dose formulation: metered dose inhaler (MDI)~* Unit dose strength(s): Experimental (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment A in 1 of 2 possible treatment sequences: AB or BA"
223545776|NCT02705612|DRUG|nimotuzumab|
223545777|NCT01214473|DIETARY_SUPPLEMENT|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
223545778|NCT01214473|DIETARY_SUPPLEMENT|Maltodextrin|Only maltodextrin as placebo
223545779|NCT00005739|BEHAVIORAL|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
223730258|NCT04317066|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on day 1 of each 3-week cycle.
223730259|NCT01907503|PROCEDURE|Evaluation of the balance of force platform|
224008450|NCT03601377|BEHAVIORAL|Training towards threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
224008451|NCT03601377|BEHAVIORAL|Placebo|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
224008452|NCT02731690|DRUG|Aceneuramic Acid Extended-Release|oral tablets
224008453|NCT04723914|BIOLOGICAL|dual target CAR-T cell therapy|CD19/CD20 dual target CAR-T cell therapy
224008454|NCT03293160|OTHER|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
224008455|NCT05253300|OTHER|Positioning the patient|"The patients' vital signs, pain and analgesic drug use were recorded in the Pain Follow-up Form at the time they came to the clinic, at the 6th and 12th hours after the surgery, by recording from the end-of-operation file. In case the patient had pain, the time when the pain started was recorded, the experimental group was given the semi-recumbent position with analgesic drug and the patient was asked to maintain this position for 2 hours. If the patient has pain again, this position is given again. Patient Satisfaction Evaluation Form was filled in at the 12th hour after the surgery for the patients in the experimental group."
224008456|NCT00535756|DRUG|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
224008457|NCT00535756|DRUG|Placebo|Placebo
223388658|NCT05755932|DRUG|HFA-134a|"* Dose formulation: metered dose inhaler (MDI)~* Unit dose strength(s): Reference (propellant only)~* Dosage level(s): 6 inhalations, BID~* Route of administration: Oral inhalation~* Participants will receive treatment B in 1 of 2 possible treatment sequences: AB or BA."
223730260|NCT01864447|BEHAVIORAL|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
224008458|NCT04734743|OTHER|cystic fibrosis|Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
223388659|NCT03172897|DRUG|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
223388660|NCT03172897|DRUG|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
224126278|NCT03161769|PROCEDURE|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
224126279|NCT03161769|DEVICE|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
223388661|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-10 mg/kg per dose
223388662|NCT05478720|DRUG|Placebo|Single intravenous dose of saline
223545780|NCT00005739|BEHAVIORAL|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
223545781|NCT01738685|BEHAVIORAL|Behavioral Intervention.|
223545782|NCT01738685|OTHER|Nutritional Education.|
223545783|NCT02655276|OTHER|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
223545784|NCT02655276|OTHER|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
223545785|NCT04914156|OTHER|Genetic based dietary advice|Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
223545786|NCT04914156|OTHER|Personalised population based dietary advice|Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
223730261|NCT03072628|OTHER|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
223730262|NCT03072628|OTHER|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
223730263|NCT03072628|OTHER|nicotine inhaler|use a nicotine inhaler for 30 minutes
223730264|NCT03072628|OTHER|sham control|use an empty e-cigarette for 30 minutes
223388663|NCT05478720|DRUG|6-diazo-5-oxo-L-norleucine (DON)|Single intravenous dose ranging from 0.1-1.0 mg/kg per dose
223545787|NCT05009576|OTHER|silver alginate|silver alginate hydrofiber dressing
224008459|NCT06316453|OTHER|Evaluating ASCVD risk over 10 and 30 year and lifetime|Utilizing validated tools such as the Pooled Cohort Equations (PCE) for 10-year ASCVD risk, the 30-year ASCVD risk prediction tool, and lifetime ASCVD risk categories, participants will undergo a thorough risk assessment. This multi-dimensional approach ensures a nuanced understanding of short and long-term cardiovascular risks. Further, The genetic risk for ApoB will be meticulously assessed by genotyping the APOB rs1042031 variant. Subsequently, the calculation of the genetic risk score (GRS) based on risk alleles will provide personalized insight into genetic predispositions related to ASCVD risk. Moreover, Participants will receive personalized management recommendations derived from the ACC/AHA Cardiovascular Risk Assessment Guidelines. These tailored suggestions may encompass dietary programs, lifestyle modifications, and, when indicated, pharmaceutical therapies like statins, aiming to mitigate identified risks effectively
224008460|NCT02886273|OTHER|Group 1|Observation
224008461|NCT02886273|OTHER|Group 2|Observation
224008462|NCT02886273|OTHER|Group 3|Observation
224008463|NCT02886273|OTHER|Group 4|Observation
224008464|NCT00396760|DRUG|aprotinin or tranexamic acid|
224008465|NCT01291823|DRUG|gefitinib|gefitinib 250mg/day
224008466|NCT01291823|RADIATION|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
224296100|NCT02422914|BEHAVIORAL|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
224296101|NCT00164749|DRUG|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
223388664|NCT05336877|DEVICE|Aveir VR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention is required in this study.
223388665|NCT05336877|DEVICE|Single-Chamber Transvenous Pacemaker|This study will utilize real-world data from patients implanted with a single-chamber transvenous pacemaker as a comparator to the Aveir VR LP system study arm. No device intervention is required in this study.
223388666|NCT06454734|DEVICE|Extracorporeal shock wave therapy by radial device|Patients will receive treatment by extracorporeal shock waves therapy (ESWT).
224296102|NCT00164749|DRUG|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
223388667|NCT06454734|DEVICE|Placebo extracorporeal shock wave therapy by radial device|Patients will receive treatment sham extracorporeal shock waves.
223388668|NCT06454734|OTHER|DLT|Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
223545788|NCT05009576|OTHER|VAC dressing without silver alginate|vaccum assisted dressing
223545789|NCT05789459|DEVICE|Stapler|Stapler
223545790|NCT05789459|OTHER|Suture|Suture
223545791|NCT05324592|DRUG|9MW0813|"The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~One dose(2mg) of the drug will be injected intravitreously."
223545792|NCT05324592|DRUG|Aflibercept|"Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~One dose(2mg) of the drug will be injected intravitreously."
224008467|NCT00687687|DRUG|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
224008468|NCT00687687|DRUG|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
224008469|NCT00687687|DRUG|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
224008470|NCT00923260|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
224008471|NCT00923260|PROCEDURE|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
224008472|NCT02914340|DEVICE|Spiration Valve System|
224008473|NCT03704675|DRUG|TEW-7197|Administered orally
224008474|NCT06213259|DRUG|KD6005|Biological: KD6005, SQ
224008475|NCT06213259|DRUG|Placebo|Placebo, SQ
224008476|NCT03100643|OTHER|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
224296103|NCT00164749|DRUG|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
224296104|NCT00965770|DEVICE|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
224296105|NCT00465049|OTHER|PRIMARY CLOSRE|SUTURE
224296106|NCT00465049|OTHER|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
224296107|NCT00465049|OTHER|SPONTANEOUS HALING|SECONDARY HEALING AFTER I\&D
224008477|NCT04997447|BEHAVIORAL|Step-reduction/Exercise Rehab|2-week limited daily steps (\<2000), and then 4 weeks of typical strength+endurance exercise for older adults
224008478|NCT05617729|OTHER|Saline applied via swab|sterile saline applied via swab
224008479|NCT05617729|OTHER|Povidone-iodine based gel|gel applied via swab
224008480|NCT03260257|OTHER|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
224008481|NCT00660543|DRUG|Gadolinium|Given IV
223388669|NCT06451003|BEHAVIORAL|Exposure to clinical decision support system and education|"Surgeons will receive education regarding post-discharge venous thromboembolism after cancer surgery. An electronic medical record based decision support tool with be initiated that will identify patients who have undergone major abdominopelvic cancer surgery. The tool will permit use of a risk stratification score and advise guideline concordant post-discharge venous thromboembolism prophylaxis strategies.~Patients will receive dedicated venous thromboembolism education at the time of discharge."
223388670|NCT05844449|DRUG|VNZ/TEZ/D-IVA|Fixed-dose combination tablets or granules for oral administration.
223388671|NCT04556188|PROCEDURE|Cardiac surgery|
223388672|NCT06082843|DRUG|Placebo|Placebo-matching Avenciguat
223388673|NCT06082843|DRUG|Avenciguat|1 millligram (mg), 2 mg, or 3 mg film-coated tablet
223388674|NCT06220513|PROCEDURE|erector spinae plane block (ESP)|patients will receive Ultrasound-guided erector spinae plane block (ESP) block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
223388675|NCT06220513|PROCEDURE|transversus abdominis plane block(TAP)|patients will receive Ultrasound-guided transversus abdominis plane block(TAP) Block for postoperative analgesia of adult patients undergoing laparoscopic appendectomy.
223388676|NCT03326791|DRUG|Acetylsalicylic acid|Trombyl 160 mg once daily
223388677|NCT03326791|DRUG|Placebo Oral Tablet|Placebo one tablet daily
223388678|NCT00765687|DRUG|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
223388679|NCT05473182|OTHER|IndieTrainer system|The IndieTrainer system is comprised of the IndieGo device and video-game modules. The IndieGo device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. The video-game modules are integrated into the IndieGo device such that the video games can be played on a TV screen using the specific access method used to control the IndieGo (i.e., switch or joystick). The IndieTrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills.
223388680|NCT06577935|DRUG|AGA2118|Subcutaneous injection
223388681|NCT06577935|OTHER|Placebo|Subcutaneous injection
224008482|NCT00660543|DRUG|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
224008483|NCT00660543|OTHER|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
224008484|NCT00660543|OTHER|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
224008485|NCT00660543|OTHER|Diffusion Weighted Imaging|Undergo DWI
224008486|NCT00660543|OTHER|MRI-Based Angiogram|Undergo TOF MR angiography
224008487|NCT03429829|DEVICE|Flairesse varnish|"Flairesse is applied to enamel and dentine as protective varnish to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.~During the application, children sat upright; their teeth were first cleaned and dried with cotton wool rolls. After mixing the fluoride varnish, it was applied as a thin layer to all surfaces of the lower and upper dentition, including proximal surfaces (using floss in case of tight contact points) as well as pits and fissures (using a small brush that was provided together with the varnish by the manufacturer). Children were advised not to drink or eat directly after the application, while this could not be controlled."
224008488|NCT06019624|BEHAVIORAL|Fresh Takes!|Receipt of a fresh produce box, nutritional education and support in a 6 month program
224008489|NCT02116673|OTHER|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
224008490|NCT02116673|OTHER|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
224008491|NCT06056791|BIOLOGICAL|INKmune|INKmune is a patented biologic delivery system and method for cancer treatment using in vivo priming and activation of natural killer (NK) cells in order to achieve tumor cell lysis. INKmune is a suspension of INB16 cells which have been rendered replication incompetent that does not require donor matching.
224008492|NCT03206892|DEVICE|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
224126280|NCT05773716|BEHAVIORAL|Pelvic floor muscle training|Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.
224126281|NCT05773716|OTHER|Electroacupuncture|Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.
224126282|NCT05773716|OTHER|Sham electroacupuncture|Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
223388682|NCT06437054|DRUG|Dexamethasone|Dexamethasone 5mg/ml
223388683|NCT06437054|DRUG|Hyaluronic acid|Hyaluronic Acid 20mg/2ml
224008493|NCT00522405|PROCEDURE|TACE|"* Under local anesthesia, the Femoral artery would be punctured~* A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~* Superselective catheterization of the hepatic artery feeding the tumor would be done~* By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~* Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~* The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~* Gelfoam particles would be injected following this for embolization"
224008494|NCT06463665|BIOLOGICAL|Olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
224008495|NCT06463665|DRUG|Platinum chemotherapy: carboplatin or cisplatin|Administered according to local practice.
224008496|NCT06463665|DRUG|Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC|Administered according to local practice.
224126283|NCT06054035|DRUG|Dapagliflozin (Forxiga®)|Dapagliflozin 10 mg once daily for 6 months. Route of administration: oral.
224126284|NCT06054035|DRUG|Placebo matching Dapaglifolzin|Placebo matching Dapaglifolzin once daily for 6 months. Route of administration: oral.
224126285|NCT06054035|BEHAVIORAL|Lifestyle Intervention|Patients receive a conventional lifestyle intervention (one in depth individual session at the beginning and standard care information on a healthy lifestyle at every visit thereafter).
224126286|NCT03392753|PROCEDURE|Mechanochemical ablation|Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
224296108|NCT04894071|DRUG|QA102|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
223388684|NCT06437054|OTHER|Indocyanine green(ICG)|ICG 25mg
223388685|NCT04194775|DRUG|Nofazinlimab (CS1003)+Lenvatinib|Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily
223388686|NCT04194775|DRUG|Nofazinlimab (CS1003) Placebo+Lenvatinib|Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily
223388687|NCT06078137|OTHER|Usual PROMs and new PROMs strategy|Patients randomized to intervention receive both usual PROMs and new PROMs strategy
223388688|NCT06377241|DEVICE|ScentAware|ScentAware is a smell test
223388689|NCT06377241|DEVICE|UPSIT|UPSIT is a smell test
224008497|NCT06463665|DRUG|Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab|Administered according to local practice.
223388694|NCT05859490|BIOLOGICAL|17D|Vaccine administration in subjects previously vaccinated with 17D.
223388695|NCT02732730|DRUG|Truvada|400 women who accept to initiate PrEP
223388696|NCT02732730|BEHAVIORAL|Drug level counseling at Weeks 8 and 13|Women who are randomized to enhanced counselling will have adherence monitoring based on plasma TFV levels obtained 4 and 8 weeks after PrEP acceptance
223388697|NCT02769520|DRUG|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
223388698|NCT06430086|OTHER|Walnut consumption|Participants will add one serving (1 oz) of walnuts at their self-defined breakfast, lunch, and dinner for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.
224008498|NCT06463665|DRUG|Docetaxel|Administered according to local practice.
224126287|NCT03392753|PROCEDURE|Cyanoacrylate adhesive|Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
224126288|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
224126289|NCT00533637|DRUG|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
224126290|NCT00533637|DRUG|Placebo|Citrate buffer with preservatives
224126291|NCT03737318|BEHAVIORAL|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
224299273|NCT03155386|OTHER|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
223545793|NCT05881681|BEHAVIORAL|App-Delivered Mindfulness Training (MT)|Unwinding Anxiety is an app-delivered mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
224008499|NCT06363071|OTHER|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
224008500|NCT06363071|PROCEDURE|Paired associative stimulation|Use TMS combine ES to stimulate TA nerve and M1 cortical
224008501|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
224008502|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
224008503|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
224008504|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
224008505|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
224008506|NCT01262677|DRUG|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
224008507|NCT01262677|DRUG|placebo|matched to the active drug
224008508|NCT05180929|DEVICE|Dual M1-tDCS|In the M1- dual tDCS montage, the anodal electrode will be placed above ipsilesional M1 and the cathode will be positioned over contralesional M1.
224008509|NCT05180929|DEVICE|a-tDCS over contralesional PMC|In the anodal-tDCS for PMC, the anodal electrode will be placed over the contralesional PMC. The PMC is defined as being 2.5 cm anterior to the M1. The cathodal electrode will be positioned over the contralateral suborbital region
224008510|NCT05180929|DEVICE|Sham tDCS|For sham stimulation, there is no particular electrode configuration to be followed, thus, 6 participants will receive sham stimulation with the configuration will be used in group A, and 5 participants will receive sham stimulation with the configuration will be used in group B. By pressing the sham button, the current will automatically ramped up over 10 sec. till reaching 1 mA, then it will be decreased gradually over 30 seconds till turning off the apparatus. This is to ensure the typical initial itching sensation
224008511|NCT04512703|DEVICE|µCor|Sensor Monitor for arrhythmia and other bio-metric markers
224008512|NCT05416073|DRUG|Esketamine|"PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
223388699|NCT06430086|OTHER|HCHS consumption|"Participants will add one HCHS food (one PopTarts® pastry) to each of their 3 main meals of the day for 4 days. The study will provide study foods at 3 main meals each day to evaluate a temporal effect of the food on melatonin concentrations throughout the day.~An energy-matched high-carbohydrate, high-sugar (HCHS) alternative, representative of a common US snack food, on sleep quality in adults with habitually poor sleep quality."
223388700|NCT05699200|OTHER|Arterial Tonometry|We will measure arterial stiffness using arterial tonometry.
223388701|NCT05699200|DIAGNOSTIC_TEST|Echocardiogram|We will collect limited ultrasound images of the heart.
223388702|NCT05699200|DIAGNOSTIC_TEST|Carotid Ultrasounds|We will perform ultrasound imaging of the carotid artery.
223388703|NCT05699200|DIAGNOSTIC_TEST|Elastography|We will measure the elastic properties of the arteries using elastography.
223388704|NCT05699200|OTHER|Ankle-Brachial Index|We will measure the ankle-brachial index to assess peripheral artery blood flow.
224008513|NCT05416073|DRUG|Sufentanil|"PCIA formula：100ml analgesic solution was prepared by adding 2 μ g/kg sufentanil and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition."
224008514|NCT06493357|BEHAVIORAL|PAC-Man|"PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach high risk MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings."
224008515|NCT06493357|BEHAVIORAL|Standard of Care|Routine care as provided by Ministry of Health.
223388705|NCT05699200|OTHER|Microneurography with sympathoexcitatory maneuvers|We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
223388706|NCT05342675|PROCEDURE|Rapid Rollover|Repositioning of the participant post biopsy
223545794|NCT00969163|DRUG|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
223545795|NCT00969163|DRUG|Comparator: placebo|transdermal placebo gel for 6 weeks
223545796|NCT01495533|DEVICE|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
223545797|NCT01495533|COMBINATION_PRODUCT|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
224008516|NCT05571579|BIOLOGICAL|blood and/or csf collection|"blood and/or collection~Only once :~* 1 tube of blood of 4 mL on dry tube with or without gel,~* 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection."
224008517|NCT03581383|BEHAVIORAL|PREP-C|The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.
224008518|NCT03581383|BEHAVIORAL|Modified ECHO|The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.
224008519|NCT03581383|BEHAVIORAL|Patient Telemedicine Questionnaire|The patient questionnaire includes questions about patient experiences with telemedicine visits with providers
224008520|NCT02055781|DRUG|Pacritinib|
224008521|NCT02055781|DRUG|Best Available Therapy|
224008522|NCT03831126|DRUG|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
224008523|NCT03623945|OTHER|Collection of blood|Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
224008524|NCT03017573|PROCEDURE|Tumor biopsies / Tumor surgery|"Tumoral tissues samples must be collected at different times points :~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)~OR~* before neoadjuvant therapy~* at the time of surgery~* before first cycle of adjuvant treatment (if possible)~* at progression (if possible)"
224008525|NCT03017573|PROCEDURE|Blood withdrawal|"Blood samples must be collected at different times points :~* at the time of surgery or before the beginning of chemoradiotherapy~* after surgery or after chemoradiotherapy~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression~OR~* before neoadjuvant therapy~* during neoadjuvant therapy (post cycle 1)~* at the time of surgery~* 6 months after surgery if non recurrence~* before first cycle of adjuvant treatment or before radiotherapy~* before second cycle of adjuvant treatment or after radiotherapy~* at progression"
224008526|NCT05286684|PROCEDURE|Consultation|History of the disease, anatomopathological and molecular biological data concerning the initial tumor; Collection of treatments received and/or in progress by the patient for her meningeal tumor (chemotherapy, targeted therapy, radiotherapy, surgery, corticosteroids, antiepileptics); Evaluation of the general condition and neurological status.
224008527|NCT05286684|PROCEDURE|Cerebral and medullary MRI, lumbar puncture, CSF sampling|diagnosis of leptomeningeal involvement
224008528|NCT05286684|BIOLOGICAL|biological test|5 ml of additional CSF after diagnostic lumbar puncture for proteomic analysis, 50-100 µl of breast aspiration fluid (NAF) for patients with an existing breast tumor, for proteomic analysis 10 ml of blood for proteomic analysis
224008529|NCT06204445|DIETARY_SUPPLEMENT|Green coffee|Each cup of coffee provides approximately 400 mg of hydroxycinnamic acids.
224008530|NCT06204445|DIETARY_SUPPLEMENT|Roasted coffee|Each cup of coffee provides approximately 150 mg of hydroxycinnamic acids.
224008531|NCT05745922|BEHAVIORAL|Moderate intensity exercise|Treadmill walking/running with moderate intensity
224008532|NCT05745922|BEHAVIORAL|High intensity exercise|Treadmill walking/running with high intensity
224008533|NCT02246153|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
224008534|NCT02246153|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
224008535|NCT06195540|DRUG|Rivaroxaban 10 MG|"Administration of rivaroxaban 10 mg once daily to prevent venous thromboembolic events in patients with trauma to a lower limb.~Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose is rivaroxaban 10 mg orally once a day (no dosage adjustment).~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
224296109|NCT04894071|DRUG|Placebo|"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."
224296110|NCT05264961|BEHAVIORAL|voice therapy|sessions of voice therapy
223545798|NCT05582148|DEVICE|Hearing aids fitting|Fitting hearing aids and evaluating the results at 6 months
223545799|NCT06120686|OTHER|Biofeedback method|Study group - implementing a conventional therapy program supplemented additionally with visual and auditory biofeedback training on a dynamic balance platform
223545800|NCT06120686|OTHER|Conventional therapy program|Control group - rehabilitation management aimed at improving cognitive and motor functions in children with mild intellectual disabilities.
223545801|NCT03747796|OTHER|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
223545802|NCT03747796|OTHER|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
224008536|NCT06195540|DRUG|Low Heparin Molecular Weight|"Administration of standard prophylactic anticoagulant treatment with LMWH for the duration of immobilisation (i.e. until full mobilisation with weight-bearing). Consecutive patients with lower limb trauma and a TRiP(cast) score ≥ 7 are assessed for possible participation in the study. At the inclusion visit, if the patient meets the study's selection criteria, the investigator provides oral and written information (information letter written in a language the patient can understand) and answers any questions the patient may have. Depending on randomisation, the patient will receive either LMWH or rivaroxaban. The dose of LMWH is free, given according to local practices and national recommendations.~Treatment is started in the emergency department and continued at home for the duration of the immobilisation (i.e. until mobilisation with weight-bearing). The duration of treatment will be determined by the physician."
223545803|NCT01162473|DIETARY_SUPPLEMENT|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
223545804|NCT01162473|DRUG|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
223545805|NCT01162473|OTHER|Food Challenge|
224008537|NCT06233890|DEVICE|Motion watch|Actigraphy watch to be worn for 14 days
223545806|NCT05329337|DIAGNOSTIC_TEST|Blood test|Sixteen mL of blood will be collected on EDTA for the purpose of this study
223545807|NCT00440492|DRUG|PLA-695|
223545808|NCT03456219|OTHER|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
223545809|NCT03456219|OTHER|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
223545810|NCT04770558|OTHER|Interactive Exergame|The one-to-one supervised training session consists of 10 min warm-up exercise, 40 min interactive exergame, and 10 min cool-down exercise. Both physical (muscle strength, coordination and balance in lower limbs) and cognitive functions (visuospatial, attention, short-term memory, calculation, reaction and executive function) will be trained through the interactive exergame.
223545811|NCT01478932|BEHAVIORAL|diaphragmatic breathing retraining|In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
223545812|NCT01478932|BEHAVIORAL|Health Promotion|n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
223545813|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
223545814|NCT00910494|RADIATION|Photon Radiosurgery System IORT|
223545815|NCT05568563|DRUG|Ethyl chloride|Ethyl chloride is an agent that is widely used in dental practice as the standard modality for pulp vitality tests .
224008538|NCT00736905|DRUG|TMC278|
224008539|NCT05769556|OTHER|Brain Gym Exercises|Brain gym exercises is a collection of simple movements that function to stimulate the development of all parts of the brain synergistically.
224008540|NCT05769556|OTHER|Traditional physiotherapy|A Group of exercises
224008541|NCT01791387|DRUG|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
224008542|NCT00242905|BEHAVIORAL|Study of memory using MRI|Study of memory using MRI
224008543|NCT00201643|DRUG|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
224008544|NCT00201643|DRUG|Placebo|Course of Placebo (NS)
224126292|NCT03737318|BEHAVIORAL|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
223545816|NCT05568563|OTHER|Honey|Honey is a natural dietary product
223545817|NCT01072136|OTHER|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
223545818|NCT01072136|DRUG|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
223545819|NCT01072136|DRUG|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
223545820|NCT03983720|OTHER|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
224008545|NCT04330001|DEVICE|Alcon Fluid Accommodating Intraocular Lens|Intraocular lens intended to treat presbyopia by dynamically adjusting power, resulting in a continuous range of vision from distance to near.
223388707|NCT03407820|PROCEDURE|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
223388708|NCT03407820|PROCEDURE|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
223388709|NCT04848480|DRUG|insulin icodec|insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
224008546|NCT04330001|OTHER|Top Con Autorefractor|Device intended to automatically determine the focusing characteristics of the eye
224008547|NCT01355900|PROCEDURE|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
224008548|NCT01231009|DRUG|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
224008549|NCT01231009|OTHER|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
223388710|NCT04848480|DRUG|insulin degludec|insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
224126293|NCT03737318|BEHAVIORAL|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
224126294|NCT00850460|DRUG|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
223388711|NCT04848480|DRUG|insulin aspart|insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
223388712|NCT03441074|BEHAVIORAL|Odor Enrichment|Patients in intervention group will get odor enrichment during perioperative period (3 days before the surgery and 7 days after the surgery). Odor-enriched participants were exposed daily for 24 hours to different aromatic fragrances (phenyl ethyl alcohol - rose; eucalyptol - eucalyptus; citronellal - lemon; eugenol - cloves) referred to previous studies. Odors were changed for each subject after 24 hours. According to previous studies, 10 drops of the 100% essential oil (0.5 ml) were dropped on a fabric which was placed in tea bags hanging at the hospital bedside.
223388713|NCT03176134|DRUG|Tedizolid phosphate|Tedizolid phosphate IV solution or oral suspension
224008550|NCT04199832|DIETARY_SUPPLEMENT|Dietary guidance|Dietary guidance for feeding tube patients with food homogenate，dietary guidance for patients with oral feeding.
224008551|NCT01671254|DIETARY_SUPPLEMENT|FishOil|
224008552|NCT01671254|DIETARY_SUPPLEMENT|CBE75|
223388714|NCT03176134|DRUG|Comparator|Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
223388715|NCT02498912|PROCEDURE|Production of Genetically-modified T cells|
223388716|NCT02498912|DRUG|Cyclophosphamide|
223388717|NCT02498912|DEVICE|IP Catheter Insertion|
223388718|NCT02498912|GENETIC|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
223388719|NCT02498912|DRUG|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
223388720|NCT00293787|DRUG|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
223388721|NCT00293787|OTHER|Timolol Vehicle|Placebo
223388722|NCT00293787|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
223388723|NCT00293787|DRUG|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
224008553|NCT01671254|DIETARY_SUPPLEMENT|CBE150|
224008554|NCT01671254|DIETARY_SUPPLEMENT|placebo|
224008555|NCT03837210|DRUG|Pylorin|Poly Herbal formulation
224008556|NCT04344652|DEVICE|Photoscreening -|external picture taken with a an phone based app
224008557|NCT04681599|DEVICE|Filter|Filter is used to capture any individual bacteria or viruses that might be suspended within inhaled or exhaled gases
224008558|NCT04681599|DEVICE|Scavenger face tent|A face tent is connected to a vacuum resource to continuously suction the exhaled gas from the subject, in order to reduce the transmission risk of virus or bacteria
224008559|NCT03883139|BEHAVIORAL|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child.
224008560|NCT03883139|BEHAVIORAL|DTT (Discrete Trial Training)|"DTT is an adult-led, highly structured, behavioral teaching approach, is considered to have the strongest evidence as a standard of care for young children with autism. DTT emphasizes didactic, adult-led instruction."
224126295|NCT00850460|DRUG|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
224126296|NCT01474330|DRUG|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
224126297|NCT01474330|DRUG|Placebo|Placebo capsule
224126298|NCT05882604|DRUG|Mesna Injection|1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.
224126299|NCT05882604|DRUG|Arthrocentesis with ringer solution|Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid
223388724|NCT01368497|DRUG|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
224008561|NCT05137132|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
224008562|NCT05137132|DIETARY_SUPPLEMENT|Placebo|MCT oil
224008563|NCT05830864|DRUG|Isoflurane|no other intervention
224008564|NCT05225428|BEHAVIORAL|Video Education|Investigator-developed, professionally animated and produced 8-minute video (Video Education) summarizing the core educational components of a genetic counseling visit
224008565|NCT05225428|BEHAVIORAL|Genetic Counseling|Standard genetic counseling
224008566|NCT03866798|BIOLOGICAL|Panzyga|Immune Globulin, intravenous, human-ifas
224008567|NCT06629649|OTHER|Glaucoma screening using an AI-algorithm and screening for diabetic retinopathy, cataract, and visual acuity impairment.|Participants who have the glaucoma screening will undergo an Artificial Intelligence Remote Optic Nerve Assessment (AI-RONA). The AI information may or may not be used by the FQHC provider to refer their patient for follow-up eye exam. It is information that the provider may find useful in making a referral.
224008568|NCT04142359|BIOLOGICAL|BCG in Combination with N-803|BCG in Combination with N-803
224126300|NCT06600165|PROCEDURE|Ex vivo confocal microscopy|The aim is to use AI to assist surgeons in analyzing CLSM tissue slide images obtained during BCC surgeries with the aim to integrate it in real time. We plan to use AI to analyze CLSM images of BCCs and distinguish between tumor tissue, inflammatory tissue, and non-tumor/non-inflammatory tissue. This approach would provide surgeons with real-time feedback and automated image analysis, leading to a more targeted and efficient approach to tissue analysis. By improving the accuracy and speed of tissue analysis, our proposal could ultimately improve operative patient outcomes and benefit healthcare professionals.
224126301|NCT05299502|BEHAVIORAL|Nutritional Intervention|4 individual 1-hour in person (or virtual, according to potential public health restrictions and patients' preference) motivational interviews (12, 18, 24 and 30 weeks) with a registered dietitian will be conducted to elaborate S.M.A.R.T. (Specific,Measurable, Attainable, Relevant, Timely) goals regarding diet, based on the 2019 Canada's Food Guide. Between those individual follow-ups, 4 phone calls with the registered dietitian will be provided (15, 21, 27, 33 weeks). Throughout the study, 10 informative nutritional video clips will also be provided. Participants receiving the intervention will have access to an online Facebook private community to discuss and share experiences, thus maintaining motivation and providing social support.
224126302|NCT02773914|OTHER|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
224126303|NCT04374825|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|This intervention consists of 8, 90-minute online group sessions delivered via video conference. Content will be developed by tailoring an ACT intervention to the specific needs of women with MBC, by using qualitative data gathered in patient focus groups. The intervention will incorporate key concepts of ACT (i.e., creating meaning and purpose in life via coping skills, activities in line with patients' values, and mindfulness meditation).
224126304|NCT04374825|BEHAVIORAL|Cognitive Behavioral Stress Management (CBSM)|This intervention consists of 8, 90-minute online group sessions delivered via videoconference. Content is drawn from a standard published CBSM intervention previously tested in other studies. The intervention incorporates key concepts of CBSM (i.e., managing stress via deep breathing and relaxation, identifying distorted thoughts,cognitive restructuring, and effective interpersonal communication).
224008569|NCT04142359|DRUG|N-803 alone|N-803 alone
224008570|NCT05663970|BEHAVIORAL|VG Social ABCs|The Social ABCs is an evidence-based caregiver-mediated early intervention. This trial examines the 6-week Virtual Group Social ABCs; an adapted model of the existing evidence-based Social ABCs. The targets are functional directed vocalizations and positive emotion sharing with a caregiver. It is provided to small groups of parents (4-8 per group) who meet virtually for a series of 6 didactic learning sessions led by two trained Coaches, supported by the programs Parent Manual, PowerPoint slides, facilitated discussion, reflection, and idea generation. Each family is assigned a Coach, and one parent per family receives 9 individualized, 1:1 live coaching sessions over a 6-week period via the virtual platform with the goal of learning to implement the Social ABCs strategies with their child. 10-min video recordings of caregiver and child are taken at baseline(time 0), post intervention (time 1),and follow up (time 2) as a measurement of fidelity of implementation and child responsivity.
224008571|NCT03786042|BEHAVIORAL|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
224008572|NCT03786042|OTHER|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
224008573|NCT05924841|DRUG|BL-B01D1|Administration by intravenous infusion
224008574|NCT05924841|DRUG|SI-B003|Administration by intravenous infusion
224008575|NCT05263388|DRUG|REKOVELLE (Follitropin Delta)|REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE was 15 μg fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose could be increased or decreased by 5 μg based on the participant's response. The minimum REKOVELLE dose was 5 μg and the maximum REKOVELLE was 20 μg. Participants could be treated for a maximum of 20 days.
224126305|NCT04857073|OTHER|Glucose Monitoring|Glucose monitoring consists of finger stick fasting and 2 hours post prandial
223388725|NCT02729298|DRUG|TP-0903|Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
223388726|NCT00218933|BEHAVIORAL|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
223388727|NCT00218933|BEHAVIORAL|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
223388728|NCT00459563|DRUG|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
223388729|NCT00459563|DRUG|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
223388730|NCT00459563|DRUG|Placebo|Placebo once a week for 3 weeks
223388731|NCT05335824|OTHER|The platelet-rich plasma (PRP)|"Twenty ml of venous blood was drawn from each patient with the use of PRP tubes that contain anticoagulant citrate dextrose. The double-spin technique was used to prepare the PRP. The injection areas were anesthetized with lidocaine 2% with epinephrine 1/80000 and left for 10 minutes. 15 units (0. 15 mL) of PRP were injected interaligamentlly in the middle, distobuccal, and distopalatal areas of the distal surface of the upper canines (5 units in each area) together with submucosal injections buccally and palatally (100 units and 50 units~, respectively)."
223388732|NCT05335824|OTHER|The injectable platelet-rich fibrin (I-PRF) group|"Twenty ml of venous blood was drawn from each patient in this experimental group.~I-PRF was prepared with the use of 20 ml of blood drawn from the patient in dry sterile tubes without anticoagulant (quickly before coagulation starts) by following the centrifugation protocol requires one cycle only (700 RPM for 3 minutes) Injection procedures, sites, and time were similar to the PRP group."
223388733|NCT05335824|DEVICE|The control group|NiTi closed-coil springs (American Orthodontics, Sheboygan, WI) were used to impose 150 g force from the first molar band hook to the bracket of canine on each side on 0.019\*0.025-in SS archwire Patients' follow-up appointments were two weeks intervals; at each visit, the force produced by the coil was checked and readjusted when needed in order to keep it at 150-g level and the appliances were examined for any deformation or change in the position because of chewing. Canine retraction continued until achieving Class I canine relationship.
224008576|NCT05263388|OTHER|GONAL-F (Follitropin Alfa)|GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F was 225 IU fixed for the first four stimulation days. Dose adjustments could be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, could occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose could be adjusted by 75 IU based on the participant's response. The minimum GONAL-F dose was 75 IU and the maximum GONAL-F dose was 300 IU. Participants could be treated for a maximum of 20 days.
223388734|NCT01383720|DEVICE|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
223388735|NCT03397030|OTHER|Home-Based Exercise Program|The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.
223388736|NCT00270946|DEVICE|Bilayered Cellular Matrix (OrCel)|
223388737|NCT01435850|PROCEDURE|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
223388738|NCT04378972|OTHER|curcumin, homotaurine, vitamin D3|ELISA tests on supernatants of 25 vitreous biopsies incubated with bioactive molecules at 37 ° C for 20 h. The concentration of soluble mediators was calculated from a calibration curve.
223388739|NCT04378972|OTHER|control|ELISA tests on supernatants of 25 vitreous biopsies. The concentration of soluble mediators was calculated from a calibration curve.
223388740|NCT04335890|BIOLOGICAL|Vaccination with IKKb matured Dendritic Cells|IKKb matured autologous monocyte derived dendritic cells loaded with RNAs; intravenous Infusion with a dose escalation starting with 7.5 mio Dendritic Cells for the first vaccination up to 30 mio cells per vaccination
223388741|NCT04937413|DRUG|Evolocumab|Evolocumab subcutaneous injection
224008577|NCT06080243|BIOLOGICAL|R21/Matrix-M1|10 µg of R21 and 50 µg of Matrix-M1
224008578|NCT06080243|BIOLOGICAL|Saline and R21/Matrix-M1|Saline and 10 µg of R21 and 50 µg of Matrix-M1
224008579|NCT06080243|OTHER|Sterile isotonic (0.9%) normal saline|Saline
224126306|NCT06666426|DEVICE|PureWick System|The PureWick System consists of the PureWick Urine Collection System used with the PureWick Flex Female External Catheter, which are intended for non-invasive urine output management.
223388742|NCT03523741|DRUG|Clozapine|Clozapine is administered orally according to individual prescribed dosing regimens.
223388743|NCT05989672|BIOLOGICAL|HSVTI Formulation 1|This investigational intervention was administered intramuscularly to HSVTI\_F1 Group.
224008580|NCT06200168|DEVICE|Electroacupuncture|"The acupuncturists will insert needles into the acupoints and manipulate the needles untilde qisensation is achieved and reported by the participants. Electrical stimulation will be delivered for 30 minutes at alternating frequencies of 2/10Hz."
224008581|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.
224008582|NCT06200168|DEVICE|Sham electroacupuncture|"The sham acupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive minimal acupuncture treatment without electrical stimulation at the same time as the intervention group.Care was taken to avoid de qi sensation."
223388744|NCT05989672|BIOLOGICAL|HSVTI Formulation 2|This investigational intervention was administered intramuscularly to HSVTI\_F2 Group.
223388745|NCT05989672|BIOLOGICAL|Placebo|This intervention was administered intramuscularly to Placebo group.
223388746|NCT00254787|DRUG|IR (Immediate-Release) quetiapine fumarate (drug)|
223388747|NCT00443729|DRUG|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
223388748|NCT00443729|DRUG|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
223388749|NCT00443729|DRUG|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
223388750|NCT00443729|DRUG|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
223388751|NCT04182178|OTHER|10 years follow up|Questionnaires
223388752|NCT03526328|OTHER|EMR and RFA effect on stem cell marker expression in BE/EAC|Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
223388753|NCT01582490|DRUG|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
223388754|NCT01582490|DRUG|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
223388755|NCT06353464|OTHER|Ensure and Water|Ensure, a liquid meal with 9 grams of protein in 8 ounces consumed 20 minutes before eating pizza; and water, 8 ounces consumed 20 minutes before eating pizza
224126307|NCT06666426|DEVICE|Hollister Female Urinary Pouch External Collection Device|The Hollister Female Urinary Pouch External Collection Device is intended to collect and contain urine for individuals with urinary incontinence.
223388756|NCT04311372|BEHAVIORAL|Educational Sesssion+Material+Videos|n =50 participants (Educational Session + Material from Educational Session (Handout form) + Access to Online Video Library)
223388757|NCT04311372|BEHAVIORAL|Educational Sesssion+Material ONLY|n =50 participants (Educational Session + Material from Educational Session (Handout form) ONLY)
223545821|NCT03983720|OTHER|Questionnaires|"* Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)"
223545822|NCT03983720|BIOLOGICAL|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
223545823|NCT03983720|OTHER|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
223545824|NCT03983720|DEVICE|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
223545825|NCT03983720|DEVICE|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
223545826|NCT03983720|DEVICE|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
223545827|NCT03983720|OTHER|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation"
223545828|NCT04836611|PROCEDURE|1 blood sample|2 groups of subjects (group 1 : with diagnosis of CHS - group 2 : no diagnosis of CHS) will have 2 blood and 1 urine samples + 1 questionnaire
223545829|NCT03555877|DRUG|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
223545830|NCT03555877|DRUG|Anastrozole|1mg once daily as indicated in the SmPC
223545831|NCT03555877|DRUG|Letrozole|2,5mg once daily as indicated in the SmPC
223545832|NCT03555877|DRUG|Exemestane|25mg once daily as indicated in the SmPC
223545833|NCT03555877|DRUG|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
223545834|NCT02797314|OTHER|Bone biopsies|Bone biopsies
223545835|NCT03503396|BEHAVIORAL|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
224008583|NCT06200168|DRUG|Standard antiemetic treatment|Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg IV or ondansetron 8 mg IV or tropisetron 5 mg IV (the previously mentioned medication, which includes fosaprepitant or aprepitant combined with palonosetron or ondansetron or tropisetron, can also be taken orally in a fixed combination of netupitant (300 mg) and palonosetron (0.50 mg))+ dexamethasone 10 mg IV 30 minutes prior to chemotherapy on Day 1, dexamethasone 8 mg IV on days 2, 3, 4 post chemotherapy. Dexamethasone doses may be individualized based on the doctor's judgment.All the antiemetic drugs used are the same as those in the true acupuncture group.
224008584|NCT05720156|OTHER|99mTc-tilmanocept SPECT/CT scanning|99mTc-Tilmanocept SPECT/CT allows for visualization of macrophage-specific arterial infiltration
224008585|NCT06034509|OTHER|No intervention. This is an observational study.|There are no interventions being tested in the Cognitive and Vascular Functioning Following TBI study.
224008586|NCT06385249|DEVICE|Navina Mini|Trans-anal irrigation (TAI) with a new CE-marked device, Navina Mini
224008587|NCT05147558|DRUG|Pembrolizumab|Pembrolizumab (200mg every 3 weeks, intravenously)
224008588|NCT05147558|DRUG|Lenvatinib|Lenvatinib (20mg once daily orally)
224008589|NCT06440291|PROCEDURE|Cardioneuroablation|Cardioneuroablation procedure performed according to the protocol
224008590|NCT03387748|BEHAVIORAL|Gesture elicitation|"* Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~* Participants retell a cartoon to the researcher~* The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded."
224008591|NCT03446781|BIOLOGICAL|EN3835|Collagenase clostridium histolyticum
224008592|NCT03446781|BIOLOGICAL|Placebo|Placebo
224008593|NCT05550090|DRUG|Chemotherapy|All patients were given 2 cycles of chemotherapy, including the chemotherapy recommended by the clinical treatment guidelines for advanced metastatic breast cancer, which can be combined with targeted or immune or endocrine therapy.
223388758|NCT02673736|DRUG|PLX73086|
223388759|NCT04485442|OTHER|data collection by questionnaires|psychological well-being in patients evaluated by Patient Reported Outcomes (PRO)
223388760|NCT04485442|OTHER|data collection (photos of the patients' tumors)|photos of the patients' tumors will be taken at baseline and at follow-up after the surgery
223388761|NCT03244761|PROCEDURE|The modified HFT|The HFT was modified by increasing the expiratory resistance.
223388762|NCT02708628|DRUG|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
224008594|NCT05856305|DRUG|Chlorophyllin, Sodium Copper Complex|Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
224008595|NCT05856305|DRUG|Placebo|Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose
224008596|NCT05262491|DRUG|BL-B01D1|Administration by intravenous infusion
224008597|NCT06169722|DRUG|TDI01 suspension|200mg or 400mg oral once a day
224008598|NCT04712461|OTHER|SUPPORTS|The SUPPORTS implementation model will be developed and refined based on community feedback. It will likely include a combination of strategies demonstrated to reduce burnout and secondary traumatic stress in the occupational health literature, such as psychoeducation about burnout, mindfulness training, or changes in scheduling or the physical environment. As the most effective interventions have been shown to involve an integration of both individual- and organization-directed strategies supporting each other, SUPPORTS will aim to include both. For example, the model may include provider-directed strategies such as group peer consultation meetings, and organizational-directed strategies such as increasing communication and providers' involvement in organizational decisions. Through this approach, SUPPORTS will aim to target therapist burnout and turnover at the provider and organizational level.
224008599|NCT01158482|PROCEDURE|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
224008600|NCT02551718|OTHER|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
224008601|NCT02551718|OTHER|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
224008602|NCT02551718|GENETIC|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
223388763|NCT02708628|PROCEDURE|Scar excision|Scar excision in second c-section
223388764|NCT02332629|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
223388765|NCT02332629|DRUG|Isotonic Sodium Chloride|Placebo
223388766|NCT04146792|BEHAVIORAL|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
223388767|NCT04146792|BEHAVIORAL|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
223388768|NCT02363218|RADIATION|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
223388769|NCT03718832|OTHER|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
223388770|NCT03190525|OTHER|Quality of life questionnaires|QLQ-C30
223388771|NCT04140305|DRUG|RPC-1063|Oral capsule
223388772|NCT05492643|BIOLOGICAL|one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)|all the 1000 participants enrolled will be given one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
223388773|NCT05492643|OTHER|Cellular Immunity|the first 30 participants enrolled in each group will take extra blood samples for specific cellular immune response as measured by ELISpot.
223388774|NCT05492643|OTHER|Humoral Immunity|the first 100 participants enrolled in each group will take extra blood samples for humoral immunity testing and laboratory examination.
223388775|NCT05492643|OTHER|Safety|all the 500 participants enrolled will undergo safety observation
223388776|NCT06574451|DEVICE|VR-assisted postoperative analgesia|Patients will receive postoperative analgesic adjunctive therapy software to assist in pain control, with one postoperative analgesic adjunctive therapy software intervention at 24 hours and 48 hours after surgery, and pain evaluation within 30 minutes.
223388777|NCT04948346|OTHER|diagnosed with ALS|diagnosed with ALS
223388778|NCT04126538|DRUG|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
223388779|NCT04126538|DRUG|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
223388780|NCT03503669|BEHAVIORAL|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
224008603|NCT02551718|GENETIC|Genetic Variation Analysis|Analysis of leukemia cell genes to identify possible drug targets
224008604|NCT02551718|DRUG|In Vitro Sensitivity-Directed Chemotherapy|"Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"
224008605|NCT00858377|DRUG|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
224008606|NCT00858377|DRUG|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
224008607|NCT05879133|BEHAVIORAL|Questionnaires|Survey
224008608|NCT05879133|OTHER|Fit Bit|measures physical activity
224008609|NCT05177991|DRUG|Liposomal Bupivacaine|20cc of Liposomal Bupivacaine for TAP block
224008610|NCT05177991|DRUG|Bupivacaine|20cc of Bupivacaine for TAP block
224126308|NCT02593747|DRUG|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
224008611|NCT05875805|BEHAVIORAL|Telehealth Serious Illness Care Program|The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
224008612|NCT05875805|OTHER|Education Control|"Education materials developed by the NCI on Communication in Cancer Care (PDQ®) - Patient Version"
224008613|NCT02796300|DEVICE|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
224008614|NCT02796300|DEVICE|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
224008615|NCT00957177|DRUG|Pregabalin|300mg pregabalin orally 1 hour before operation
224008616|NCT00957177|DRUG|Placebo|Placebo
224008617|NCT02078843|DRUG|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
224008618|NCT02078843|DRUG|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
224008619|NCT05339685|DRUG|BL-M02D1|Administration by intravenous infusion
224008620|NCT06520826|DRUG|Vadadustat|A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
224008621|NCT06520826|DRUG|Erythropoiesis Stimulating Agent|Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
224126309|NCT02593747|DRUG|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
223388781|NCT03503669|BEHAVIORAL|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
223388782|NCT00100672|DRUG|LErafAON-ETU|
223388783|NCT04793711|DEVICE|EpiCeram|protective emollient
223388784|NCT04837040|DRUG|Paltusotine|Paltusotine, tablets, once daily by mouth
223388785|NCT04837040|DRUG|Placebo|Placebo, tablets, once daily by mouth
223388786|NCT06002984|DEVICE|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
223388787|NCT04038463|BEHAVIORAL|EFP|This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).
223388788|NCT04038463|BEHAVIORAL|LFP|The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).
223388789|NCT04038463|BEHAVIORAL|ELP|The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).
223388790|NCT04038463|BEHAVIORAL|LLP|The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
223388791|NCT06961864|BEHAVIORAL|Visual Adaptation|Presentation of visual stimuli to quantify the appearance of visual snow or its effects in the visual system of the brain.
223388792|NCT06961864|BEHAVIORAL|Assessments and Questionnaires|Administration of clinical assessments and questionnaires to gather information about visual and mental symptoms, cognitive, and sensory function.
223388793|NCT06961864|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|7 tesla fMRI data will be acquired during visual paradigms designed to measure neural responses with and without adaptation.
223388794|NCT06961864|DEVICE|Magnetic Resonance Imaging (MRS)|7 tesla MRS data will be acquired to quantify the concentrations of different brain chemicals in brain regions including visual cortex.
223388795|NCT04901455|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
223388796|NCT04968834|GENETIC|Genomic profiling|Genomic profiling using CLIA assay
224008622|NCT04534972|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Intervention for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \> 100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
224008623|NCT04790370|DRUG|Anticoagulation with heparin|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
224008624|NCT04790370|DEVICE|EkoSonicTM Endovascular System|EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]
224008625|NCT00542776|OTHER|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
224008626|NCT05185934|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Patients with COVID-19 infection will be randomized to receive food supplement Endocalyx for 4 months.
224008627|NCT05185934|DIETARY_SUPPLEMENT|Placebo|Patients with COVID-19 infection will be randomized to receive placebo for 4 months.
224008628|NCT06078345|OTHER|Carbohydrate|400 Kcal glucose (100g oGTT)
224008629|NCT06078345|OTHER|Fat|400 Kcal glucose rapeseed oil.
224008630|NCT06078345|OTHER|Protein|400 Kcal Moltein PURE (111g)
224008631|NCT02625961|BIOLOGICAL|Pembrolizumab|Participants with CIS with or without papillary tumors (Cohort A) and participants with papillary tumors only, without CIS (Cohort B) receive pembrolizumab 200mg via IV infusion once every 3 weeks for up to 35 administrations
223388797|NCT04213495|OTHER|Anesthesia|Patients undergoing anesthesia from the cooperating Anesthesia center
223388798|NCT04696536|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate cavity protection toothpaste for brushing teeth twice daily.
223388799|NCT04696536|OTHER|American Dental Association (ADA) Referenced Toothbrush|Participants will brush teeth at least one minute with provided toothbrush twice daily.
223388800|NCT04696536|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse as negative control for 30 sec twice a day after brushing.
223545836|NCT03503396|BEHAVIORAL|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
223545837|NCT01930604|DRUG|Botox (onabotulinumtoxinA)|
223545838|NCT01930604|DRUG|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
224008632|NCT02625961|BIOLOGICAL|Pembrolizumab/vibostolimab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion once every 3 weeks for up to 35 administrations
224008633|NCT02625961|BIOLOGICAL|Favezelimab/pembrolizumab coformulation|Participants with CIS with or without papillary tumors (Cohort C) receive favezelimab/pembrolizumab (coformulation of 800mg favezelimab and 200 mg pembrolizumab) via IV infusion once every 3 weeks for up to 35 administrations
224008634|NCT01881555|PROCEDURE|invasive coronary angiography|
224008635|NCT01881555|PROCEDURE|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
224008636|NCT05987800|DIAGNOSTIC_TEST|Titration procedure|"The NAVA level will be reduced to 0,5 cmH2O/microvolt (µV) for 3 minutes as a starting point. Limit peak pressure will be set to 35 cmH2O (the maxi-mum pressure that can be delivered to the patient is cut off at 30 cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 2,5 cmH2O/µV."
224008637|NCT05987800|DIAGNOSTIC_TEST|Electrical impedance tomography|This is a non-invasive technique consisting of the application of a non-adhesive single-use patient belt to monitor regional changes in lung aeration at the bedside.
223388801|NCT04696536|OTHER|REACH Dental Floss|Participants after brushing, rinse mouth with water and floss using Reach dental floss once a day.
223388802|NCT04696536|OTHER|Alcohol-containing Essential Oil (AEO) Mouth Rinse (Listerine Cool Mint, marketed)|Participants after brushing, rinse with 20mL of the AEO mouth rinse for 30 seconds twice a day.
223388803|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
223545839|NCT01930604|DRUG|NaCl (placebo)|
223545840|NCT01591408|DEVICE|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
223545841|NCT03662282|DRUG|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
223545842|NCT04444739|OTHER|radiographic data collection|From existing radiological Images (upright standing X-ray and supine MRI of the lumbar spine), specific radiographic parameters will be extracted
224008638|NCT05987800|DIAGNOSTIC_TEST|Lung and diaphragm ultrasound|"Lung ultrasound is a non-invasive technique used to diagnose lung pathology and to monitor lung condition. This technique is part of the standard of care for preterm infants in our neonatal unit. Lung ultrasound scores are calculated at each time an ultrasound is performed.~Ultrasound of the diaphragm consists of a short additional measurement of diaphragm thickness and thickening fraction and will be done at the same time of the lung ultrasound following a standardized procedure."
224008639|NCT05010590|DRUG|Romosozumab|Monthly romosozumab
224008640|NCT05010590|DRUG|Denosumab|Every 6 months denosumab
224008641|NCT03093376|BEHAVIORAL|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
224008642|NCT00044265|DRUG|ramipril|
223388804|NCT02802813|DRUG|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
223388805|NCT00544635|DEVICE|no intervention|no intervention
223388806|NCT00544635|DEVICE|light|scars will be treated with light
223545843|NCT02108756|DRUG|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
223545844|NCT02108756|DRUG|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
223545845|NCT05214430|OTHER|3 months exclusive enteral nutrition after surgery|patients underwent intestinal resection and anastomosis in this arm will given over 3 months exclusive enteral nutrition,and free diet after 3 months.
223545846|NCT05419752|DRUG|bioceramic sealer|bioceramic based obturating sealer
223545847|NCT05419752|DRUG|MTA|MTA based obturating sealer
223545848|NCT05419752|DRUG|resin sealer|resin based obturating sealer
224008643|NCT00249262|DRUG|Taxoprexin|Administered by intravenous infusion over 1 hour infusion weekly for the first five weeks of a six week cycle.
224008644|NCT04410523|DRUG|CSJ117|"CSJ117 inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device.~CSJ117 = inhaled monoclonal antibody fragment"
224008645|NCT04410523|DRUG|Placebo|"Run-in period (all arms): Placebo inhaled once daily (in the morning) for 4 weeks. Placebo dosing extended to 8 weeks in case of asthma exacerbation or respiratory tract infection during this period.~Treatment period (Placebo arm only): Placebo inhaled once daily (in the morning) for 12 weeks. Delivered via Concept1 device."
224008646|NCT05396833|DRUG|Tuvusertib|Tuvusertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, and Part B1 until disease progression, death, discontinuation, or end of study.
224008647|NCT05396833|DRUG|Lartesertib|Lartesertib will be administered orally once daily over a defined period of time in Part A1, A1.1, A1.2, A2, A3, A2/A3, until disease progression, death, discontinuation, or end of study.
224008648|NCT05396833|DRUG|Avelumab|Avelumab will be administered by intravenous infusion once a day over a defined period of time in Part B1 until disease progression, death, discontinuation, or end of study.
223545849|NCT00405730|DRUG|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
223545850|NCT00405730|DRUG|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
224008649|NCT00490490|DRUG|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
223388807|NCT05778461|DRUG|L-ornithine L-Aspartate|LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
224008650|NCT00490490|PROCEDURE|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
224008651|NCT00490490|DRUG|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~* Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~* Lugol's solution 20 drops orally 3-times-a-day, OR~* KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
223545851|NCT00405730|OTHER|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
223545852|NCT01983007|PROCEDURE|High-intensity exercise|Performance of high-intensity exercise
224008652|NCT04681768|DRUG|Abemaciclib|Abemaciclib tablets 150 mg, 100 mg, 50 mg as clinical routine: 150 mg twice daily per os, in-label administration in combination with endocrine therapy (aromatase inhibitor or Fulvestrant)
224008653|NCT06233344|DRUG|Psilocybin plus mindfulness training|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists. The psilocybin dosing session will take place approximately halfway through an 8-week mindfulness training course. The mindfulness training course will consist of weekly 2-hour classes with experienced mindfulness teachers; participants will be encouraged to practice mindfulness for 45 minutes per day between classes.
224008654|NCT06233344|DRUG|Psilocybin|Participants will receive a single 25 mg dose of psilocybin under the supervision of study therapists.
224008655|NCT01205334|BIOLOGICAL|Autologous CMV-specific CTL|"CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.~At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion."
224008656|NCT06281821|BEHAVIORAL|mhealth-pc|Participants meet with an interventionist who explains the rationale for the mobile app. They complete video and survey-based intervention content each week for 8 weeks. App-based sessions are supplemented with brief chat-based coaching weekly.
224008657|NCT01507519|DEVICE|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
224008658|NCT01475279|DRUG|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
224008659|NCT02415673|DEVICE|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
224008660|NCT04307771|BEHAVIORAL|m-Health application|Dental Buddy is a mobile application that has been designed to improve oral hygiene maintenance behaviours in teenagers
224008661|NCT02881320|DRUG|B/F/TAF (Adult Strength)|50/200/25 mg FDC tablets administered orally once daily without regard to food.
224008662|NCT02881320|DRUG|B/F/TAF (Low Dose)|30/120/15 mg FDC tablets administered orally once daily without regard to food.
224008663|NCT02881320|DRUG|B/F/TAF (TOS)|2 x B/F/TAF 15/60/7.5 mg (total daily dose 30/120/15 mg) FDC tablets administered orally as TOS, once daily.
224008664|NCT02881320|DRUG|B/F/TAF (TOS)|2 x B/F/TAF 3.75/15/1.88 mg (total daily dose 15/60/7.52 mg) FDC tablets administered orally as TOS, twice daily.
224008665|NCT02881320|DRUG|B/F/TAF (TOS)|1 x B/F/TAF 3.75/15/1.88 mg (total daily dose 7.5/30/3.76 mg) FDC tablets administered orally as TOS, twice daily.
223388808|NCT05778461|DRUG|Placebo|Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
223388809|NCT04898699|DEVICE|UrSure Rapid Urine Tenofovir Test|A point of care urine immunoassay to measure PrEP drug levels for adherence in participant urine samples over the preceding seven days will be done at all follow-up visits. At enrollment, study staff will explain the use of this experimental measurement of PrEP drug level in urine samples. Participants will receive results of the test at the same study visit during which it is performed.
223545853|NCT01983007|PROCEDURE|Low-intensity exercise|Performance of low-intensity exercise
223545854|NCT05554276|COMBINATION_PRODUCT|neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy|All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical radiotherapy.
223545855|NCT01176877|BEHAVIORAL|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
223545856|NCT00640003|DRUG|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
223545857|NCT00640003|DRUG|Placebo|placebo drug
223545858|NCT01653444|DRUG|GC1119|biweekly, IV infusion
224008666|NCT02881320|DRUG|B/F/TAF (TOS)|1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
224008667|NCT01851499|DIETARY_SUPPLEMENT|Ultramicronized PEA (Normast)|600 mg
223388810|NCT04898699|DEVICE|OraQuick Rapid HIV Self-test kit|Participants will be provided with HIV self-testing kits to use at their discretion and, in case of multi-month dispensing, prior to start of new bottle of PrEP medication, in between study visits. HIV self-testing kits will be provided to confirm their HIV-negative status and make a connection between PrEP use and protection against HIV. Participants will receive detailed, interactive training on HIVST with pictorial elements, including instructions to contact study staff immediately in event of a reactive test for confirmation as per Kenya guidelines.
223388811|NCT04898699|DRUG|Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]|Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
223388812|NCT04898699|BEHAVIORAL|2-way text message reminders|"All participants will receive weekly SMS visit reminders to support PrEP adherence. Participants will be asked at study enrollment for a primary contact telephone number and an alternate number for contact. Participants without cell phones will be provided an inexpensive cell phone (although cell phone ownership is very high in Kenya). Participants will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, use of HIV self-test kit, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with any questions, concerns or messages that they have for the study staff."
223388813|NCT04898699|BEHAVIORAL|HIV risk-reduction counseling|All study participants will be provided with brief interactive counseling at each study visit, tailored to the results of their urine assay.
223388814|NCT00276484|DRUG|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
223388815|NCT00276484|DRUG|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
223388816|NCT00276484|DRUG|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
223388817|NCT03333993|OTHER|Pilates Exercise|The Mat Pilates exercise will be performed twice a week and the duration of the sessions will be 60 minutes, consisting of 5 minutes of warm-up exercises, 50 minutes of strengthening exercises followed by 5 minutes of relaxation and stretching.
224008668|NCT05527652|DEVICE|Self-Supporting Nasopharyngeal Airway (ssNPA)|The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.
224008669|NCT00473265|DRUG|PTH|
224008670|NCT00692276|DEVICE|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
224008671|NCT00692276|DEVICE|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
224008672|NCT04513652|DRUG|AG-920|AG-920 Sterile Topical Ophthalmic Solution
224008673|NCT04513652|DRUG|Placebo|Placebo Topical Ophthalmic Solution
224008674|NCT05612503|OTHER|Traditional physical therapy program|resistance-based diaphragm strengthening exercises, breathing exercises to increase costal or chest breathing, and breathing exercises to relax the breathing muscles.
224008675|NCT05612503|OTHER|Virtual reality-based exercises|Virtual reality exercise using Nintendo Wii systems. As game interfaces, the Nintendo Wii systems employ haptic sensor-based controllers and a balance board.
224008676|NCT01828489|DRUG|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
224008677|NCT01828489|DRUG|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
224008678|NCT00363688|DRUG|Penicillin test and challenge|
224008679|NCT04158232|OTHER|Method|treatment of mature teeth with apical periodontitis
224008680|NCT00717327|OTHER|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
224008681|NCT04546490|OTHER|Pressure Release technique|Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
224008682|NCT04546490|OTHER|Ischemic pressure technique|Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
224008683|NCT04500795|PROCEDURE|Middle meningeal artery embolization|"MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure."
224008684|NCT03879369|DIAGNOSTIC_TEST|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
224008685|NCT04635969|BEHAVIORAL|Sexual Health and Development Education for Children With Intellectual Disability|Sexual Health and Development Education for Children With Intellectual Disability: It is aimed to eliminate the problems related to personal care and cleaning of children with mental retardation, to learn the symptoms of adolescence and to learn the methods of protection from abuse.
223388818|NCT03333993|OTHER|Home exercises|Exercises for upper limbs according to the institutional routine.
223388819|NCT03726060|OTHER|control group|In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months
223388820|NCT03726060|OTHER|test group|In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
223388821|NCT04800081|DRUG|Sacubitril/Valsartan|Patients will be randomized to receive once-daily treatment with 100-400 mg of Sacubitril/Valsartan.
223388822|NCT04800081|DRUG|Valsartan|Patients will be randomized to receive once-daily treatment with 80-320 mg of Valsartan.
223388823|NCT00004012|DRUG|capecitabine|
223388824|NCT00348725|DRUG|fenofibrate and metformin fixed combination (drug)|
223388825|NCT06282939|DEVICE|OPTIMA and OPTIMAX Coils manufactured by Balt USA|\*Percentage from protocol
223388826|NCT00974116|BEHAVIORAL|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
223388827|NCT00974116|BEHAVIORAL|Control Group|No intervention
223388828|NCT00002019|DRUG|Amphotericin B, Lipid-based|
224008686|NCT06358638|DRUG|Daratumumab|Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.
224008687|NCT06358638|DRUG|Alemtuzumab|Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.
224008688|NCT06358638|DRUG|Sirolimus|Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.
224008689|NCT06358638|RADIATION|Total Body Irradiation|Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
224008690|NCT05871606|DRUG|iNO|Inhaled Nitrous Oxide
224008691|NCT06472102|PROCEDURE|Cardioneuroablation|Endocardial radio-frequency ablation of areas of ganglionated plexi in the left and the right atrium
224008692|NCT06639464|DRUG|Semaglutide|This intervention will consist of the FDA-approved dosing schedule, with terminal dosage based on manufacturer's recommendation to titrate to 1mg over 12 weeks. Participants will receive 0.25mg for the first 4 weeks, 0.5mg for the next 4 weeks, and 1.0mg for the final 4 weeks. IDS will extract semaglutide an draw the doses into syringes for matching placebo doses to also be produced and maintain blind.
224008693|NCT06639464|OTHER|Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
224008694|NCT05501873|DEVICE|FARAPULSE Pulsed Field Ablation system|Any subject who has signed the informed consent and for whom the FARAPULSE Pulsed Field Ablation system has been inserted into the body, and pulsed field ablation treatment has been received, are assigned to the treatment group.
224008695|NCT04254822|PROCEDURE|Transjugular intrahepatic portosystemic shunt|The TIPS procedures will be performed by experienced interventional radiologists. polytetrafluroethylene-covered stents were used with initial balloon dilatation to 8 mm, aiming for a decrease in portal-venous pressure gradient to less than 12 mm Hg.
224008696|NCT04254822|DRUG|Carvedilol|Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.
223388829|NCT00002019|DRUG|Amphotericin B|
223388830|NCT05293119|DRUG|JAK-2 inhibitor|In this trial, one group will receive the tofacitinib 5 mg twice daily
223388831|NCT05293119|DRUG|Topical corticosteroid|Mometasone furoate 0.1% ointment once daily
223388832|NCT03926299|DEVICE|FotonaSmooth SP® Spectro laser device|dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.
223388833|NCT03926299|DRUG|Clobetasol propionate 0.05% ointment|6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
223388834|NCT06346301|BEHAVIORAL|Imagery rescripting|In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 90 minutes.
223388835|NCT06582069|DEVICE|Bleaching|Bleaching
223388836|NCT00995917|OTHER|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
223388837|NCT00995917|OTHER|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
223388838|NCT00202371|PROCEDURE|Red Blood Cell transfusion|
223388839|NCT02969252|DRUG|Rifamycin SV-MMX® 600|
223388840|NCT01626690|DEVICE|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
223388841|NCT01626690|DEVICE|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
223388842|NCT02251093|DRUG|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
223388843|NCT02251093|DRUG|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
223388844|NCT02771873|BEHAVIORAL|Integrated cardiovascular disease risk management.|Health promotion intervention
223388845|NCT02009189|DRUG|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
223388846|NCT02009189|DRUG|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
223388847|NCT04762667|PROCEDURE|reverse shoulder arthroplasty|"In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique."
223388848|NCT05957601|OTHER|No intervention was made as it was a descriptive epidemiological study.|No intervention was made as it was a descriptive epidemiological study.
223388849|NCT05902507|DIAGNOSTIC_TEST|Magnetic Resonance Imaging Simulation|Radiographic Image Simulation
223388850|NCT01708577|DEVICE|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
224008697|NCT04254822|PROCEDURE|Endoscopic variceal ligation|For endoscopic variceal ligation, the first elective session will be carried out within 7 days of randomisation. Then EBL sessions were scheduled every 10-14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device).
224008698|NCT02728739|PROCEDURE|Transthoracic Echocardiogram (TTE) Assesment|Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (\>30 pg/ ml) for grading of MR severity within 7 days.
224008699|NCT06008054|DRUG|SI-B003|Administered by intravenous infusion every 3 weeks (Q3W).
224008700|NCT06008054|DRUG|BL-B01D1|Administered by intravenous infusion for a cycle of 3 weeks.
224008701|NCT06008054|DRUG|PD-1 Monoclonal Antibody|Administration by intravenous infusion for a cycle of 3 weeks.
224008702|NCT04293003|OTHER|fasting|6-hour fasting
223388851|NCT00150605|DRUG|Extended-release carbamazepine|
223388852|NCT05383183|DRUG|Choline Alfoscerate 400mg|Oral administration
223388853|NCT05383183|DRUG|Placebo|Oral administration
223388854|NCT01856725|PROCEDURE|Hemodynamic measurements for CRT device programming|
223388855|NCT01856725|DEVICE|CRT device implant with MultiPoint Pacing|
223388856|NCT03076840|OTHER|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
223388857|NCT04166786|DRUG|Testosterone gel|Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
223388858|NCT04166786|DRUG|Ethanol Solution|Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
223388859|NCT04166786|DRUG|Testosterone placebo (vaseline)|Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
223545859|NCT04966234|DRUG|Posaconazole 100 MG [Noxafil]|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
223545860|NCT04966234|DRUG|Posaconazole 40 MG/ML|"Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile"
223545861|NCT02789085|DEVICE|ULF TENS stimulation|
223388860|NCT04166786|DRUG|Ethanol placebo (lemon-flavoured water)|Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
223388861|NCT04868825|DEVICE|Ivory Dentin Graft|Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 900 μm porous particles or granules of hydroxyapatite and collagen which retain the natural form of the source porcine dentin and protein matrix. (Packed Vial: 1.00 gr; Packed Syringe: 1.0 gr)
223388862|NCT04868825|DEVICE|OsteoBiol Gen-Os|Comparator control device A natural porcine origin cortico-cancellous heterologous bone mix consists of sterile 250 - 1000 μm porous particles of hydroxyapatite and collagen (Packed Vial: 1.0 gr)
223388863|NCT01589458|DRUG|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
223388864|NCT00110396|BIOLOGICAL|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
223388865|NCT02414958|DRUG|Empagliflozin|
223545862|NCT00741169|DRUG|TMC435350|200 mg taken by mouth once daily for 7 days
223545863|NCT00741169|DRUG|Rifampin|600 mg taken by mouth once daily for 7 days
223545864|NCT00741169|DRUG|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
223545865|NCT02977338|OTHER|Retrospective review|
223545866|NCT04487197|PROCEDURE|blood sample for seroepidemiological investigation|blood sample for seroepidemiological investigation
224008703|NCT04293003|OTHER|Low carbohydrate|Consumption of a zero-carbohydrate breakfast
224296111|NCT03475628|DRUG|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
223388866|NCT02414958|DRUG|Empagliflozin|
223388867|NCT02414958|DRUG|Placebo|
224008704|NCT04293003|OTHER|Mediterranean|Consumption of a Mediterranean-type breakfast
224008705|NCT06138652|BEHAVIORAL|App|Participants completed games on an app and sessions with a mentor focused on alleviating anxiety over 8 weeks.
224008706|NCT04435678|DIAGNOSTIC_TEST|ALEX² test using the MAX 45k automated laboratory system|"The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays."
224126310|NCT06856005|OTHER|Music intervention|"to evaluate the effectiveness of personalized music playlists in reducing procedural anxiety among young dentists performing crown preparations for porcelain-fused-to-metal (PFM) crowns and to compare the crown preparation performance of students who listened to music with those who did not.~• Experimental Group:~o Participants in the experimental group were asked to use personalized music playlists during the procedure. These playlists were already available on their personal devices (e.g., smartphones) and reflected their individual music preferences. Participants selected music they found relaxing or enjoyable, ensuring the intervention was tailored to their unique tastes."
223388868|NCT03524443|BEHAVIORAL|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
224126311|NCT02399813|DRUG|Axalimogene filolisbac|
224126312|NCT03833674|OTHER|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
223388869|NCT04305132|DEVICE|Electroconvulsive therapy|Thymatron System IV electroconvulsive therapy device
224126313|NCT03833674|OTHER|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
224126314|NCT03833674|OTHER|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
223388870|NCT03786588|OTHER|Observation|The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
223388871|NCT00300807|DRUG|XTL 6865|
223388872|NCT00923741|DRUG|Talactoferrin|
223388873|NCT00923741|PROCEDURE|Apheresis|
223388874|NCT01163864|BEHAVIORAL|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
223388875|NCT01163864|BEHAVIORAL|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
223388876|NCT05466045|OTHER|Olive oil application in hemodialysis patients with pruritus|Experimental group: In addition to routine care, a brown glass bottle containing extra virgin olive oil was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
223388877|NCT05466045|OTHER|Normal saline application in hemodialysis patients with pruritus|Control group: In addition to routine care, a brown glass bottle containing normal saline was applied on the itchy skin every 12 hours by rubbing (after washing the patient's face in the morning and after dinner). The intervention duration was 28 days.
224008707|NCT00823576|DRUG|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
224126315|NCT03833674|OTHER|AIH + Strength Training Block|AIH followed by respiratory strength training.
224126316|NCT04009174|OTHER|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~* \[18F\]-FCH PET + Dynamic CT~* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~* 3D-Transrectal ultrasound~* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~* \[18-F\]-DCFPyL PET+Dynamic CT~* PET/MRI with endorectal coil~* 3D-Transrectal Ultrasound~* Optional Sodium (23Na) MRI"
224126317|NCT06376604|OTHER|Fasting Mimicking Diet|Subject will consume 6 cycles of 5-day fasting mimicking diet: 3 days prior to, the day of, and 1 day following chemotherapy treatments.
224126318|NCT06376604|DRUG|Chemotherapy|6 cycles of standard chemotherapy for the gynecologic malignancy.
224126319|NCT00003943|BIOLOGICAL|filgrastim|5 ug/kg
224126320|NCT00003943|DRUG|carboplatin|AUC 5
224126321|NCT00003943|DRUG|cyclophosphamide|3 gm/m2
224126322|NCT00003943|DRUG|paclitaxel|250 mg/m2
224126323|NCT00003943|DRUG|topotecan hydrochloride|10 mg/m2
224126324|NCT00003943|PROCEDURE|peripheral blood stem cell transplantation|harvest via apheresis
224126325|NCT01658696|BIOLOGICAL|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 2 x 10\^8 pfu heterologous prime-boost immunisation
224126326|NCT01658696|BIOLOGICAL|Rabies vaccine|2 x 2.5IU Verorab
224126327|NCT00988559|BIOLOGICAL|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
224126328|NCT00988559|DEVICE|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
224126329|NCT00988559|BIOLOGICAL|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
223388878|NCT01097512|DRUG|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
223388879|NCT01097512|DRUG|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
223388880|NCT00481117|DRUG|LY2405319|
223388881|NCT00481117|DRUG|Placebo|
223388882|NCT01748201|PROCEDURE|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
223388883|NCT04762004|BEHAVIORAL|Maternal speech|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
223388884|NCT04762004|BEHAVIORAL|Maternal singing|In both intervention conditions, speaking and singing, the mothers were asked not to touch the baby but to pay close attention to his/her reactions and to modulate the voice accordingly. A nurse was present during all procedures.
223388885|NCT04762004|BEHAVIORAL|Standard care|the newborn was placed by the nurse in the incubator in the standard care conditions recommended for painful procedures (supine position, wrapped and contained by the nest).
224008708|NCT02632435|DEVICE|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
224008709|NCT02632435|DEVICE|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
224008710|NCT00370682|BIOLOGICAL|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
223388886|NCT06462755|OTHER|No intervention|no intervention
223388887|NCT03354598|DRUG|Sulopenem-Etzadroxil/Probenecid|Treatment of uncomplicated urinary tract infection
223388888|NCT03354598|DRUG|Ciprofloxacin|Treatment of uncomplicated urinary tract infection
223388889|NCT00476190|DRUG|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
223388890|NCT00476190|DRUG|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
224008711|NCT00370682|BIOLOGICAL|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
223388891|NCT00476190|DRUG|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
223388892|NCT00476190|DRUG|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
223388893|NCT00476190|DRUG|Cyclophosphamide|Consolidation IB: Intravenously on day 1
224008712|NCT00370682|OTHER|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
224008713|NCT03293875|BEHAVIORAL|Community Events|The coalitions in collaboration with CABs and peer leaders in their respective cities convened community meetings and events and invited PWID who had participated in other intervention components, who were receiving services at the partner organizations, and members at-large to participate. Events and meetings were advertised at the partner organizations offices, by staff during delivery of harm reductions supplies at places where PWID congregated to use drugs, and through social media. Events and meetings took place at community venues including parks, neighborhood gathering spaces, and at organizations. Events covered topics about HIV, sexual health, and human rights and included health fairs.
223388894|NCT00476190|DRUG|Methylprednisone|Prophase: Intravenously on days 1-3
223388895|NCT00476190|DRUG|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
223388896|NCT00476190|DRUG|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
223388897|NCT00476190|DRUG|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
223388898|NCT00476190|DRUG|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
223388899|NCT00476190|DRUG|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
223388900|NCT00476190|DRUG|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
223388901|NCT00476190|PROCEDURE|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
223388902|NCT00476190|DRUG|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
223388903|NCT03616457|DEVICE|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
224008714|NCT03293875|BEHAVIORAL|Social Network HIV Testing|The social network HIV testing intervention consisted of offering rapid HIV tests to PWID using a social network referral methodology.
224008715|NCT03293875|BEHAVIORAL|Peer Network Intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 PWID.
224008716|NCT06091293|BEHAVIORAL|Narrative Intervention for Long COVID-19 (NICO)|The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
224008717|NCT03585491|PROCEDURE|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
224008718|NCT03585491|PROCEDURE|Bankart + Remplissage Procedure|Participants will undergo arthroscopic stabilization.
224008719|NCT05109572|OTHER|Hospitalized|It was developed by Addington et al. (1994) to measure the presence of depression and the severity of depressive symptoms in patients with schizophrenia. The scale consists of 9 items to assess depression and is answered with a four-point Likert scale. The validity and reliability of the scale in schizophrenia patients in the Turkish population was determined by Oksay et al. by (2000). In the reliability study, the Cronbach's alpha coefficient was found to be 0.88. The cut-off point of the scale was stated as 11.
224008720|NCT05109572|OTHER|Non-hospitalized with emergency care|It is adapted from the Buss-Durkee Hostility Inventory by Buss and Perry (1992), the scale consists of 29 items and five-point Likert types. The scale is physical and verbal aggression, hostility, and anger. Questions 9 and 16 on the scale are reverse scored. The score value on the scale varies in direct proportion to the aggression, that is, the higher the score, the higher the aggression. The Cronbach Alpha internal consistency coefficients of the original version of the scale is defined as; 0.89 for physical aggression, 0.85 for physical aggression, 0.72 for verbal aggression, 0.77 for hostility, 0.83 for anger subscale.
224008721|NCT05109572|OTHER|Non-hospitalized and non-emergency care|"Developed by Cull and Gill (1989), it evaluates the probability of suicide in adolescents and adults. The Turkish validity and reliability of the scale were performed by Atlı et al (2009). The scale consists of 36 items and is answered as a four-point Likert-type scale as never or rarely, sometimes, often and often or always."
224008722|NCT00002870|BIOLOGICAL|filgrastim|
224008723|NCT00002870|DRUG|cyclophosphamide|
224008724|NCT00002870|DRUG|epirubicin hydrochloride|
223388904|NCT05012020|DEVICE|mHealth Remote Monitoring platform|Clinic Portal and Mobile Application for remote monitoring of Chronic Kidney Disease patients and patients on Peritoneal Dialysis
223388905|NCT03357185|PROCEDURE|Femoral eversion|"The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique.~The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up."
223388906|NCT00561119|DRUG|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 \& 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
224008725|NCT00002870|DRUG|fluorouracil|
224008726|NCT00002870|DRUG|thiotepa|
224008727|NCT00002870|PROCEDURE|peripheral blood stem cell transplantation|
224008728|NCT03223831|OTHER|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 \& 12cm.
224008729|NCT03223831|OTHER|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
224008730|NCT03651622|BEHAVIORAL|Hypocaloric, low carbohydrate diet|Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
223388907|NCT02502032|DRUG|Cisatracurium|Different groups received different pretreatments of cisatracurium.
223388908|NCT00302653|DRUG|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
223388909|NCT04680572|PROCEDURE|arthroplasty|arthroplasty for fracture neck of femur
223388910|NCT06998069|DRUG|Arm I Carboplatin, Paclitaxel, Pembrolizumab|Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
223545867|NCT01177124|BEHAVIORAL|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
223545868|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
224008731|NCT03651622|BEHAVIORAL|Hypocaloric, moderate low fat diet|Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
224008732|NCT03651622|BEHAVIORAL|Mediterranean diet, no caloric restriction|Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
224008733|NCT03096080|DRUG|Tesevatinib|One dose of the study drug in liquid form
224126330|NCT00988559|BIOLOGICAL|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
223388911|NCT06998069|DRUG|Arm II Carboplatin, Paclitaxel, Cetuximab|Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Cetuximab 400 mg/m2, day 1 of the first cycle and then 250 mg/m2 days 1, 8, 15 every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
223388912|NCT06998069|DRUG|Arm III Pembrolizumab|Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
223388913|NCT04480242|DRUG|Inhaled Corticosteroids (ICs)|Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
224008734|NCT01519089|DRUG|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
224008735|NCT01519089|DRUG|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
224008736|NCT05649722|DRUG|Treprostinil Palmitil Inhalation Powder|Oral inhalation using a capsule-based dry powder inhaler device.
224008737|NCT05649722|DRUG|Placebo|Oral placebo inhalation using a capsule-based dry powder inhaler device.
224008738|NCT06006169|DRUG|BL-B01D1|BL-B01D1 was administered by intravenous infusion on D1, D8, or D1 in 3-week cycles.
224008739|NCT06006169|DRUG|SI-B003|SI-B003 was administered intravenously every 3 weeks (Q3W).
224008740|NCT00165204|DRUG|Tibolone|
224008741|NCT00127205|DRUG|clodronate disodium|Given orally
224008742|NCT00127205|DRUG|ibandronate sodium|Given orally
224008743|NCT00127205|DRUG|zoledronic acid|Given IV
224008744|NCT00673036|OTHER|Blood sample|60 ml of whole blood
224008745|NCT00822211|DRUG|Vildagliptin 50 mg bid|
223388914|NCT04480242|DRUG|Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)|Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
223388915|NCT04480242|DRUG|Other treatments|Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
223388916|NCT04480242|DRUG|Inhaler device|Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers.
223388917|NCT04480242|BEHAVIORAL|Regularly monitoring of the Inhalation technique through mobile app|App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2).
224008746|NCT00822211|DRUG|Vildagliptin 50 mg qd|
224008747|NCT00822211|DRUG|Placebo|
224008748|NCT00126802|PROCEDURE|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
223545869|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
224008749|NCT04343287|DRUG|BRM421|The active control with BRM421 solution
224008750|NCT04343287|DRUG|Placebo|The vehicle solution
224008751|NCT03582943|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
224008752|NCT03582943|BEHAVIORAL|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
224008753|NCT03582943|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
224008754|NCT02708563|PROCEDURE|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
224008755|NCT02708563|PROCEDURE|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
224008756|NCT04149977|BEHAVIORAL|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
224008757|NCT04149977|BEHAVIORAL|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
224008758|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing 100% Xylitol as sweetener|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
224008759|NCT04420780|DIETARY_SUPPLEMENT|Administration of sugar-free gums sugar-free gums containing containing a polyols mixture plus a low amount of Xylitol (22%)|The subjects will be instructed to chew a total of 6 pellets for 5 min divided into 3 intakes a day (2 in the morning, 2 after the midday meal and 2 in the afternoon)
224008760|NCT01373073|OTHER|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
224008761|NCT01373073|OTHER|Control human milk fortifier|Control human milk fortifier to be added to human milk
224008762|NCT04656496|BEHAVIORAL|NOURISH-T+|NOURISH-T+ (Nourishing Our Understanding of Role Modeling to Improve Support and Healthy - Transitions) is a 6 session, psychoeducational program designed to teach parents of childhood cancer survivors with overweight/obesity knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
224008763|NCT04656496|BEHAVIORAL|Brief NOURISH-T+|Enhanced Usual Care (or Brief NOURISH-T+) is an abbreviated version of the full NOURISH-T+ intervention in which parents are engaged in a one-time information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
224008764|NCT04747327|BEHAVIORAL|mandate public|mandate by airlines, bars, restaurants
224008765|NCT04747327|BEHAVIORAL|employer mandate|your employer requires vaccination
224008766|NCT04747327|BEHAVIORAL|incentive reward|$1,000 tax credit
224008767|NCT04747327|BEHAVIORAL|penalty|$1000 tax penalty
224008768|NCT04747327|BEHAVIORAL|incentive lottery small|100,000 smaller monetary amount
224008769|NCT04747327|BEHAVIORAL|incentive lottery medium|200,000 mid monetary amount
224008770|NCT04747327|BEHAVIORAL|incentive lottery large|1 million dollar lottery
224008771|NCT04747327|BEHAVIORAL|cash small|smaller guaranteed cash amount
224008772|NCT04747327|BEHAVIORAL|cash medium|mid sized quarenteed cash amount
224008773|NCT04747327|BEHAVIORAL|cash large|large quarenteed cash amount
224008774|NCT04747327|BEHAVIORAL|invitation for exercise financial incentive study|financial incentives earned when increasing exercise behaviors
224008775|NCT04747327|BEHAVIORAL|invitation for exercise social incentive study|social incentives earned when increasing exercise behaviors
224126331|NCT00988559|PROCEDURE|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
223388918|NCT01765335|DEVICE|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
223388919|NCT06254456|DIAGNOSTIC_TEST|End expiratory occlusion test|Fluid responsiveness test
224008776|NCT04747327|BEHAVIORAL|invitation for sleep social incentive study|social incentives earned when increasing sleep
224008777|NCT04747327|BEHAVIORAL|invitation for sleep financial incentive|Financial incentives earned when increasing sleep
224126332|NCT00988559|DRUG|imiquimod|imiquimod applied to the cervix by the physician
224126333|NCT01193192|OTHER|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
223388920|NCT07017517|DEVICE|Motomed Letto® servo-assisted cycling + standard physiotherapy|Servo-assisted cycling using the Motomed Letto® device with a cadence target of 30 revolutions per minute (rpm), performed for 60 minutes twice daily for 7 days. This intervention is administered in addition to standard ICU physiotherapy to critically ill patients at risk of critical illness myopathy (CIM).
224008778|NCT00171717|DRUG|Cyclosporine - cyclosporine microemulsion|
224008779|NCT03592810|OTHER|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
224008780|NCT05526066|BIOLOGICAL|ARCT-810|ARCT-810 is messenger RNA (mRNA) coding for Ornithine Transcarbamylase (OTC) formulated in a lipid nanoparticle (LNP).
224008781|NCT05526066|OTHER|Placebo|Normal Saline
224008782|NCT06088654|DRUG|IPH6501|phase 1 (dose finding) and phase 2 (dose expansion)
224008785|NCT03907644|DEVICE|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
224008786|NCT05126563|BIOLOGICAL|HB-adMSCs (allogeneic)|HB-adMSCs allogenic
224008787|NCT05126563|OTHER|Placebo|Placebo comarator
224008788|NCT05081882|DRUG|Kava|Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
224008789|NCT05081882|DRUG|Placebo|Participants on this arm will take one placebo capsule orally three times daily for 28 days.
224008790|NCT04284267|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive tool for modulating patterns of brain activation and circuit connectivity. It uses electromagnetic pulses to induce electric currents over the cortex that serve to depolarize or hyperpolarize neurons, thereby changing patterns of synaptic activity. This study will use intermittent theta burst stimulation (iTBS), an efficient TMS protocol that uses high frequency (50Hz) triplets of TMS given every 200 milliseconds (i.e. at 5 Hz).
224008791|NCT06612255|DRUG|Delafloxacin|Delafloxacin tablet
224008792|NCT06612255|DRUG|Delafloxacin Powder|Delafloxacin powder for oral suspension formulation
224008793|NCT06190509|BIOLOGICAL|Vaccine|The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart, with adjuvant.
224008794|NCT06190509|BIOLOGICAL|Vaccine|The candidate pentavalent bioconjugate vaccine (Candi5V) is administered twice, 2 months apart without adjuvant
224008795|NCT06190509|BIOLOGICAL|Vaccine|The placebo is administered twice, 2 months apart
224008796|NCT04891705|DEVICE|Lung Ultrasound Scan|Ultrasound scan of subjects in up to 14 lung zones
224008797|NCT02545829|DRUG|HIP1302|Tenofovir 292mg
224008798|NCT02545829|DRUG|HGP1406|Tenofovir 300mg
224126334|NCT01193192|OTHER|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
224126335|NCT02825264|DEVICE|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
224126336|NCT05516901|PROCEDURE|The erector spinae plane block group|The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
224126337|NCT05516901|PROCEDURE|Control group|Patients in this group will receive general anesthesia alone.
224126338|NCT01856634|DRUG|100 mg Delamanid|100 mg Delamanid BID for 10 days
224126339|NCT01856634|DRUG|50 mg Delamanid|50 mg Delamanid BID for 10 days
224126340|NCT01856634|DRUG|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
224008799|NCT04797143|DEVICE|multidisciplinary consultation program|The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
224008800|NCT06420752|DEVICE|Calf Plantar flexion|Daily passive calf stretching
224008801|NCT06420752|DIETARY_SUPPLEMENT|Dietary nitrate|Weekday 140 ml dietary nitrate consumption two hours prior to passive stretching
224008802|NCT04202640|PROCEDURE|Mechanical Stimulation|The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.
224008803|NCT04202640|PROCEDURE|Massages|"Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~* One part muscle exercise~* One part skin work (drainage)"
223388921|NCT07017517|BEHAVIORAL|Standard physiotherapy|Standard physiotherapy including mobilization and passive/active range-of-motion exercises, delivered during routine ICU care for 7 days.
224008804|NCT01172470|DRUG|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
224008805|NCT01172470|DRUG|Pemetrexed|"Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes"
224008806|NCT01172470|DRUG|Carboplatin|"Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour."
224008807|NCT00004572|PROCEDURE|Sustacal challenge|
224008808|NCT05709470|OTHER|No-intervention|Observational cross-sectional study design with no intervention
223388922|NCT07018154|OTHER|Musculoskeletal Assessment|Patients underwent a musculoskeletal Assessment.
223388923|NCT07016828|DEVICE|guided surgery technique|"* Clinical examination will be performed and preoperative CBCT will be taken for all the patients prior to the surgery to evaluate the posterior maxilla for the placement of the pterygoid implants.~* Ideal pterygoid implant placement will be planned using the BlueSky Bio software (USA) which will be mostly to emerge from the third molar position and to engage the dense pillar of bone formed by the pyramidal process and pterygoid process of sphenoid bone.~* surgical guide will be fabricated which will be either soft tissue without flap elevation."
223388924|NCT07016828|PROCEDURE|Free hand technique|the surgery will be done without the use of the surgical guides depending on the anatomical landmarks.
224008809|NCT05926453|OTHER|Maximal cardiorespiratory exercise test|previously described
224008810|NCT04848389|PROCEDURE|Skin Adhesive procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.
223388925|NCT07018622|DRUG|Dapagliflozin 10 MG Oral Tablet|Participants in this arm will receive oral dapagliflozin 10 mg daily starting one day before platinum-based chemotherapy infusion (cisplatin or carboplatin) and continuing for 72 hours. The intervention aims to assess the potential nephroprotective effect of SGLT2 inhibition. Standard supportive care including hydration and magnesium supplementation will be provided to all participants.
223388926|NCT07018622|DRUG|Placebo Oral Tablet|Participants in this arm will receive a matched oral placebo starting one day before platinum-based chemotherapy infusion (cisplatin or carboplatin) and continuing for 72 hours. Standard supportive care including hydration and magnesium supplementation will also be provided. Investigators and participants will remain blinded to the group assignments.
223388927|NCT07017283|DEVICE|Tracheal intubation general anesthesia|Endotracheal intubation with general anesthesia was administered to the patient during the ERCP procedure.
223388928|NCT07017283|DEVICE|Nasopharyngeal airway ventilation|Nasopharyngeal airway-assisted anesthesia was employed for the patient during the ERCP procedure.
223388929|NCT05106192|DEVICE|Med-Jet Injector|The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue
224008811|NCT04848389|PROCEDURE|Standard suture procedure|The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
224008812|NCT01996462|DRUG|Escitalopram Oxalate Tablets|
224008813|NCT02950610|DEVICE|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
224008814|NCT05020769|DRUG|SI-B001|SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended).
224008815|NCT05020769|DRUG|Osimertinib|Osimertinib is administered at the recommended dose of 80mg daily.
224008816|NCT06401889|OTHER|Non-Interventional Study|Non-interventional study
224008817|NCT00870077|DIETARY_SUPPLEMENT|ProWHEY 94 CFM, SponserR|3 times 20g per day
224008818|NCT01603134|DRUG|Allopurinol|300 mg tablet once a day
224008819|NCT01603134|DRUG|Allopurinol|300 mg tablet once a day
224008820|NCT06150859|DRUG|Ayahausca-Assisted psychotherapy|"Drug: Two ayahuasca administrations (0.75 mg/kg DMT), after 3rd and 6th therapeutic session. Ayahuasca is a psychoactive mixture of plants which contains DMT as an active principle.~Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions."
224008821|NCT06150859|BEHAVIORAL|Constructivist Psychotherapy|Constructivist Psychotherapy will be delivered over 9 online psychotherapeutic sessions
224008822|NCT06150859|OTHER|No treatment|No treatment during the control period
224008823|NCT05183789|DIAGNOSTIC_TEST|Evaluation of serum levels of IL-6 and IL-8|Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits).
224008824|NCT04399759|BEHAVIORAL|Approach-Instrumental Activities of Daily Living|Individualized instrumental activities of daily living training
224008825|NCT04399759|BEHAVIORAL|Home health education|Individualized home health education
224008826|NCT03231280|DEVICE|SB-061|delivered via intra-articular injection
224008827|NCT03231280|OTHER|Placebo|Placebo delivered via intra-articular injection
224008828|NCT00263016|DRUG|Docetaxel|
224008829|NCT03415373|DEVICE|Microneedle Adapter (Model UAR-2S)|Investigational device
224008830|NCT03415373|DEVICE|Hypodermic needle + syringe|Control device
224008831|NCT05032872|BEHAVIORAL|Social Exergame Treatment Group|"* Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit, use the app, and share stories to unlock new flowers to grow~* Includes social features: like, reply, and see other's stories, and share their stories; Access to other people's gardens~* In-app rewards (unlock new flowers to grow each week) if participants post stories"
224008832|NCT05032872|BEHAVIORAL|Control Group|"* Physical activity tracking, walk to grow flowers and plant their own garden~* Follow workout tutorials~* Daily steps tracked by Fitbit and workout log tracked by the app~* Daily reminders to wear Fitbit and use the app"
224008833|NCT01155089|DRUG|Anastrozole|1 mg tablet
224008834|NCT06233227|DRUG|Dutasteride-Test product|Dutasteride soft capsule 0.5 mg Test product Manufactured by: Phil Inter Pharma Co., Ltd., Vietnam
224008835|NCT06233227|DRUG|Dutasteride-Reference product|Dutasteride soft capsule 0.5 mg Reference product Manufactured by: DELPHARM POZNAN S.A., Poland
224008836|NCT06393387|DRUG|DTG/3TC versus BIC/F/TAF|A new-user, active comparator, retrospective cohort study design will be employed using inverse probability of treatment weighting to adjust for measured confounders. This study will be conducted as a retrospective chart review and the organization's electronic health record (EHR) will be utilized. Subjects identified as having previously been or currently receiving DTG/3TC or BIC/F/TAF will be assessed for eligibility based on inclusion/exclusion criteria. Subject eligibility will be confirmed by the Principal Investigator (PI).
224008837|NCT05130294|DIETARY_SUPPLEMENT|CARDIO®|"CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA"
224008838|NCT05130294|DIETARY_SUPPLEMENT|Placebo|MCT oil
224296112|NCT04508920|OTHER|Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)|Interventions were recorded in two groups of patients, who were randomly selected, in two different periods of time. The basal group was intervened from 15 May to 15 June 2019, a pandemic-free period. The outbreak group from 15 May to 15 June 2020, corresponding to increased activity of contagiousness and mortality associated with COVID-19, in general population in Mexico14 Basal measurement was performed in a face to face method. In Outbreak period, under social isolation conditions, patients were evaluated by telephone. The assessments were performed out by medical staff with specialized training, with evaluations to which patients were accustomed by regular cohort assessments. The questions were ordered and systematized in a patient evaluation, care, and follow-up guide (appendix). A causality association question of emotional distress perception was added. We recorded mortality and rehospitalization
223388930|NCT05106192|DRUG|Triamcinolone Acetonide|The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).
223388931|NCT05106192|DRUG|Bexarotene 1% Top Gel|Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.
223388932|NCT05106192|DRUG|Nitrogen Mustard|Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.
223388933|NCT05106192|DEVICE|Conventional syringe|A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.
223388934|NCT05860738|OTHER|sterilization|autoclaving using the rapid cycle (4 mins, 134 oC) and the universal cycle (20 mins, 121 oC). The autoclave used in this study is (Anthos A-17 Autoclave, Italy).
223388935|NCT02435524|BEHAVIORAL|A&T infant and young child feeding intervention|"1. Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~   * Increase mother's knowledge about optimal breastfeeding and its benefits~  * Increase mother's self-efficacy related to breastfeeding~  * Improve mother's perceptions about social norms relating to breastfeeding~2. Community mobilisation activities to:~   \- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~3. Enhanced training of government health workers in infant and young child feeding to:~   * Improve their ability to support mothers and provide timely information about infant feeding"
223388936|NCT00489632|BEHAVIORAL|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
224008839|NCT00956553|BIOLOGICAL|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
224008840|NCT00956553|BIOLOGICAL|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
224008841|NCT05870228|BEHAVIORAL|Strathclyde Sleep Intervention|Manual-based CBT-I
224008842|NCT02974777|DRUG|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
224008843|NCT02974777|DRUG|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
224008844|NCT02974777|DRUG|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
224008845|NCT03099564|DRUG|Pembrolizumab|pembrolizumab 200mg IV every three weeks
224008846|NCT03099564|DEVICE|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
224296113|NCT03978091|DRUG|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
223388937|NCT05621876|DEVICE|IgG deficiency rapid screening test|We will be testing patients who have already been diagnossed iwth primary immunodeficiency (PID) disease. there are 400 types of PID. We will test their blood before they receive antibody transfusion to evaluate the accuracy of our new screening test. We are trying to develop easy to use, low-cost screening tests for doctors to use with patients to detect those with low IgG levels before they are given the oral polio vaccine. These patients must be prioritized for intramuscular injections of a polio vaccine to prevent potential spread of wild type polio.
224008847|NCT06249958|OTHER|Rehabilitation|Specific rehabilitation exercises
224008848|NCT06249958|OTHER|Verticalisation|Day of patient verticalisation after surgery
224008849|NCT01481987|PROCEDURE|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
224008850|NCT04522622|DRUG|Teriparatide|20 micrograms
224008851|NCT04522622|DIAGNOSTIC_TEST|DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT|All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
224008852|NCT04522622|PROCEDURE|Bone biopsy|All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.
224008853|NCT04522622|DIAGNOSTIC_TEST|Cardiac tests|All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.
224008854|NCT04522622|OTHER|Blood and urine samples and physical examination|All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
224008855|NCT00078000|DRUG|SU011248|
224008856|NCT06636110|DEVICE|Jun mHealth app|The intervention will be a mHealth app, JUN, across 3 months during pregnancy.
224008857|NCT00488475|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
224008858|NCT04620343|PROCEDURE|A: Breathing advice with bio-feedback|Information and breathing advice with biofeedback will serve as an active comparator in this study, and time allowed for IBA and biofeedback in this study will be max 30 min. The teaching will be provided by the attending physician and the test leader. The session will follow a strict checklist. After the laryngoscope has been secured in correct position the patient will be shown his/her larynx on the screen, providing the patient with basic knowledge on laryngeal anatomy and function in a calm atmosphere before the CLE-test. After, the patients will be trained to make any symptoms abate, and a good breathing posture and how to optimally use their breathing muscles.
224008859|NCT04620343|PROCEDURE|B: Breathing advice with bio-feedback, Inspiratory muscle training (IMT)|Breathing advise and IMT. The inspiratory muscle training (IMT) will build on the information the patients have obtained during the IBA and biofeedback session. The IMT will focus on training endurance and coordination of the PCA muscle, aiming to reduce fatigue of the abducting capacity of the larynx and to enhance coordination and create a sense of laryngeal control. When performing the IMT sessions, it is of utmost importance that a functional diaphragmatic breathing pattern has been established, and that this breathing pattern is maintained throughout all the IMT sessions. Once the patient has demonstrated that he/she is able to perform breathing according to these principles, the IMT session will follow a detailed protocol while wearing a flexible laryngoscope and settings and techniques are adjusted to ensure max open larynx. The patient will perform IMT training at home as instructed and have video meetings one and three weeks after initial training to observe progress.
224008860|NCT04620343|PROCEDURE|C: Breathing advice with bio-feedback, Speech Therapy|The training period with the speech therapist takes three days, divided into 6 sessions. The training is continued at home, implementing the techniques during physical activity and at rest. The aim of the speech therapy is to help the patients to develop a strategy on how to control his/her larynx during exercise, and to be able to continue exercising without experiencing dramatic EILO incidents. They will be informed that the best approach is to start practicing while performing low to moderate intensity exercise, and then gradually increase the intensity as they become more confident. It will be emphasized that the new breathing technique they are about to adopt will need to be repeated until it becomes adapted as a part of their automated breathing pattern. Patients will be followed up with video meetings one and three weeks after initial training to observe progress.
224008861|NCT04620343|PROCEDURE|D: Breathing advice with bio-feedback, IMT and Speech Therapy|All treatments as described above.
224008862|NCT04620343|PROCEDURE|A: If CLE-test unchanged, additional IMT and Speech Therapy|All treatments as described above.
224008863|NCT04620343|PROCEDURE|Surgery 1: Supraglottoplasty - full procedure under general anesthesia|Endoscopic supraglottoplasty with carbon dioxide laser and cold steel microlaryngeal instruments. The patient is intubated with an armored laser-tube which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot is utilized. Releasing incisions are made at the anterior border of both AEFs. The depth of the incisions are limited to the cranial border of the ventricular folds. The cuneiform tubercles including their surrounding mucosa are removed in a circular pattern before the two incisions are adjoined, thus creating a drop shaped excision. Care is taken to avoid scarring. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. In case of perioperative edema of the laryngeal mucosa, corticosteroids are administrated to prevent laryngeal edema post-operatively.
224126341|NCT01856634|DRUG|10 mg Delamanid Pediatric Formulation|Patients \> 10 kg will receive DPF 10 mg BID for 10 days
224126342|NCT01856634|DRUG|5 mg Delamanid Pediatric Formulation|"Patients \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
224126343|NCT01856634|DRUG|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
223388938|NCT04567420|DRUG|Palbociclib|4 week cycles
223388939|NCT04567420|DRUG|Fulvestrant|4 week cycles
223388940|NCT04567420|DRUG|Adjuvant Therapy|Standard of Care
224008864|NCT04620343|PROCEDURE|Surgery 2: Supraglottoplasty - mini-invasive procedure under general anesthesia|"Endoscopic supraglottoplasty with carbon dioxide laser. The patients are intubated with an armored laser-tube, which is positioned in the posterior midline to protect this area from laser injury. The laryngoscope (Benjamin/Lindholm) is positioned into the vallecula and the surgery is visualized through an operation-microscope. CO2-laser beams of 2-4W focused with micro spot are utilized. Four punctures will be made along the lateral borders of both aryepiglottic folds bilateral, thus creating a row of small punctures parallel to the rim of the aryepiglottic folds. The punctions should not be deeper than the incision in the full procedure (above); i.e. less than 5 millimeter, and care must be taken to avoid heat affecting the nervus recurrens posteriorly. Care is taken to avoid scarring and collateral thermal injury. It is recommended to protect the posterior commissure and the piriform sinus with wet tissue cloths. No antibiotic prophylaxis is administered."
224008865|NCT05192486|DRUG|GNC-038|Administration by intravenous infusion
224008866|NCT04606433|DRUG|GNC-038|Administration by intravenous infusion.
224008867|NCT06534957|OTHER|Online mindfulness-based stress reduction|The online MBSR intervention sessions will be available in a website created specifically for this purpose, where each pre-recorded session will be uploaded so that each patient can begin the intervention at the same time as their chemotherapy regimen. Each session will last approximately 1 hour, for a total of 6 sessions. The topics that will be covered in these sessions include: mindfulness overview, stress and suffering, emotional regulation, meditation, management of stressful situations, self-compassion and acceptance. Participants will watch 1 session per week following the order that will be indicated on the website; patients will be encouraged to watch the sessions during their chemotherapy infusions. During these sessions, patients will be instructed in mindfulness practice and will perform targeted exercises to promote complete consciousness, including mindful body awareness (body scan), gentle yoga exercises, and meditation.
224008868|NCT04883242|DRUG|Carfilzomib|Given IV
224008869|NCT04883242|DRUG|Dexamethasone|Given PO or IV
224008870|NCT04883242|BIOLOGICAL|Isatuximab|Given IV
224008871|NCT04883242|DRUG|Pomalidomide|Given PO
224008872|NCT04883242|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224008873|NCT04883242|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224008874|NCT04883242|PROCEDURE|Skeletal Survey X-Ray|Undergo skeletal x-ray
224008875|NCT04883242|PROCEDURE|Computed Tomography|Undergo CT
224008876|NCT04883242|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
224008877|NCT04883242|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224008878|NCT00263341|COMBINATION_PRODUCT|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
224008879|NCT01525654|BEHAVIORAL|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
224008880|NCT00267085|BIOLOGICAL|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
224126344|NCT05788068|BEHAVIORAL|Cognitive behavior therapy|"Participants will receive CBT intervention for smoking cessation via wechat-based mini-program developed by a professional team."
224126345|NCT06312007|OTHER|Semi seated position|The patient is positioned 45-90 degrees
224126346|NCT06312007|OTHER|side lying position|Side lying position
224126347|NCT05585437|PROCEDURE|gastric cancer specialist training program|The gastric cancer specialist training program includes technical training and non-technical training. The technical training includes 1. The whole process of laparoscopic gastric cancer surgery technical teaching 2. Operation practice 3. Operation video review, non-technical training includes 1. Difficult case discussion 2. Specialists Session 3. Lymph node sorting training.
224126348|NCT05942898|OTHER|The present study does not contain any intervention|The present study does not contain any intervention
224126349|NCT05762939|BEHAVIORAL|Chatbot|Participants in this condition were asked to use Fido, a Polish therapy chatbot, for two weeks. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
224126350|NCT05762939|BEHAVIORAL|Control (book)|Participants in this condition were told to read selected chapters from a self-help book during the two-week intervention period. No minimal requirements of usage time were enforced, but participants had to fill in five engagement check surveys during the intervention period. Each survey had to be completed in less than 24 hours.
224126351|NCT00003210|BIOLOGICAL|recombinant interleukin-12|Given subcutaneously
224296114|NCT03978091|DRUG|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
223545870|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
224126352|NCT00003210|OTHER|laboratory biomarker analysis|Correlative studies
224126353|NCT03223038|OTHER|No intervention|No intervention - exposure is mechanical ventilation in PICU
224126354|NCT02203838|DRUG|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
224126355|NCT02806778|OTHER|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
223388941|NCT06702969|DEVICE|Intra oral scanner|Immediate implant placement with customized healing abutment and after three months placement all ceramic crown by digital impression using intra oral scanner
223388942|NCT06702969|DEVICE|impression analog|Immediate implant placement with customized healing abutment and after three months placement of all ceramic crowns by conventional impression
223388943|NCT03173209|BEHAVIORAL|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
223388944|NCT01329900|DRUG|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
223388945|NCT01329900|DRUG|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
223388946|NCT01329900|DRUG|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
223388947|NCT01329900|DRUG|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
223388948|NCT01329900|DRUG|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
224008881|NCT03894618|DRUG|SL-279252|The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
224008882|NCT05530317|BEHAVIORAL|Cardiac Rehabilitation|Exercise prescriptions will be based on the heart rate performance during the baseline CPET. The intensity of the exercise prescription and level of monitoring will be tailored to the individual participant's performance on their baseline CPET according to guidelines. Exercise will be prescribed by a Cardiac Exercise Physiologist in accordance with standard cardiac rehabilitation protocols with special attention to post-exertional malaise. Resistance exercise activities will also be incorporated. Recumbent exercise will be utilized based on assessment by exercise physiologist and patient. Dietary counseling, smoking cessation counseling for smokers, and medication counseling will be incorporated according to standard cardiac rehabilitation protocols. Most participants will participate in a hybrid approach (12-16 sessions in person), but participants will be allowed to select a fully in-person approach (36 sessions).
224008883|NCT03250442|DEVICE|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
224008884|NCT03250442|OTHER|Standard Dry Dressing|These are customary dry dressings.
224008885|NCT02074189|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
224008886|NCT04515290|DRUG|TSG-01|Two tablets of TSG-01 (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; High dose group.
224008887|NCT04515290|DRUG|TSG-01 and Placebo|One tablet of TSG-01 (0.35g/tablet) and one tablet of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks; Low dose group.
224008888|NCT04515290|DRUG|Placebo|Two tablets of placebo (0.35g/tablet) were given by oral with 3 times a day for 12 weeks.
224126356|NCT02806778|OTHER|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
224126357|NCT02831491|DRUG|Ramucirumab|Administered IV
224126358|NCT02831491|DRUG|Docetaxel|Administered IV
224126359|NCT00002826|DRUG|paclitaxel|
224126360|NCT00002826|DRUG|valspodar|
224126361|NCT01310595|PROCEDURE|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
224126362|NCT01310595|PROCEDURE|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
224126363|NCT02188121|DRUG|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
224126364|NCT02188121|DRUG|Losartan|Angiotensin II receptor antagonist
224126365|NCT03345836|DRUG|Matching Placebo for Upadacitinib|Matching placebo tablets
224126366|NCT03345836|DRUG|Upadacitinib|Upadacitinib tablets
224126367|NCT04652687|OTHER|VIA Disc NP (HCT/P)|VIA Disc NP - Allograft tissue injection
224126368|NCT00672542|BIOLOGICAL|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
224126369|NCT02610088|DRUG|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
224126370|NCT02610088|DRUG|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by \> 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
224126371|NCT04678167|DIAGNOSTIC_TEST|Caloric test|Lying, patientwill be placed so that he can introduce water (hot then cold) into his external ear canal. It is the reaction of the vestibular system (sensory organ responsible for balance) which is then measured with a helmet placed over his eyes and which measures the nystagmus (movement of the eye) which reflects vestibular activity.
224126372|NCT04678167|DIAGNOSTIC_TEST|Measurement of the speed of Nystagmus|A helmet with an infrared camera will be placed in front of patient eyes. This will allow visualizing on screen and measuring eye movements spontaneous or induced in the dark by various tests.
223388949|NCT01329900|PROCEDURE|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
223388950|NCT06403254|PROCEDURE|There isn't an intervention name because the study is observational and has only one group.|Follow-up after surgey
223388951|NCT03997851|DRUG|Acetaminophen|Topical acetaminophen gel
223388952|NCT03997851|DRUG|Carbomer 980|Topical vehicle gel
223388953|NCT04252339|DRUG|RLY-1971|RLY-1971 is an oral inhibitor of SHP2.
223545871|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
224008889|NCT04242043|DIAGNOSTIC_TEST|intel@med-feasibility|"Initial evaluation by the Nurse using the AI tool which enters into MEDVIR the patient's symptoms or functional complaints and comorbidities and is complemented by a telemedicine solution for data transmission to the remote tele-expert physician located in a regulatory center or health center. The remote doctor (a geriatrician from Prevention Care for Elderly Unit (UPSAV) platform of the Clinical Gerontology Division of the Limoges University Hospital) analyses the data collected by the Nurse and establishes a symptom severity criterion and a diagnosis with the help of the AI technology.~Both the geriatrician and the NHs nurse are not aware of the proposals made by AI.~The geriatrician can nevertheless initiate a visit to the resident's place of residence in order to verify the information necessary to establish the diagnosis and thus improve the relevance of the algorithm. For the resident, this study doesn't interfere with the usual care."
224008890|NCT04493775|DEVICE|Brainwave Entrainment|Alpha frequency visual and auditory stimulation delivered through a smartphone application, with the use of a virtual reality headset and earphones respectively.
224008891|NCT01584960|BEHAVIORAL|endurance training|2 years of home-based endurance training
224008892|NCT02946853|PROCEDURE|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
224008893|NCT02946853|DEVICE|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
224008894|NCT04073992|BEHAVIORAL|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
224008895|NCT05441644|DEVICE|Bispectral index|A new placemewnt to monitor intraoperative BIS
224008896|NCT05252442|OTHER|Pre-COVID-19|Pre-COVID-19 period
224008897|NCT05252442|OTHER|COVID-19|COVID-19 period
224008898|NCT05252442|OTHER|COVID-19 vaccination roll-out|COVID-19 vaccination roll-out period
224008899|NCT00002305|DRUG|Flucytosine|
224008900|NCT00002305|DRUG|Fluconazole|
224008901|NCT00002305|DRUG|Amphotericin B|
224126373|NCT04678167|DIAGNOSTIC_TEST|Angle of deviation at Fukuda|The patient will be asked to trample on the spot (30 steps) with the indexes pointed forward. In the event of vestibular asymmetry, the patient turns at a varying angle to the right or to the left. This will then measure what is called the angle of deflection of the fukuda.
224126374|NCT04678167|DIAGNOSTIC_TEST|Alexander's degree of nystagmus|"there are 3 degrees:~* Degree I: nystagmus that exists only when the eyes are turned to the right.~* Degree II: also exists when the eyes are to the right or to the front.~* Degree Ill: exists when the eyes are on the right, front, or left"
223388954|NCT03097146|OTHER|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
223388955|NCT02308995|PROCEDURE|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
223388956|NCT02308995|PROCEDURE|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
223388957|NCT02308995|DEVICE|V-Loc (Covidien, Mansfield, MA)|
223388958|NCT02308995|DEVICE|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
223388959|NCT00695305|DRUG|rilapladib|250 mg oral dose once daily
223388960|NCT00695305|DRUG|placebo|placebo
223388961|NCT00695305|OTHER|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
223545872|NCT00365339|DRUG|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
223545873|NCT02116842|DRUG|0.1% bupivacaine|Epidural block in early labour.
223545874|NCT02116842|DRUG|0.075% bupivacaine|Epidural block in early labour.
223545875|NCT02116842|DRUG|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
224008902|NCT02854878|DEVICE|The Lucy ultrasonic comb models A and B combined with the LucyGel|
224008903|NCT04716270|PROCEDURE|Electrophysiology Study and Ablation|Electrophysiology Study and Ablation of Supraventricular Arrhythmias
224008904|NCT01158079|DRUG|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
224008905|NCT00798590|DRUG|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
224008906|NCT00798590|DRUG|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
224126375|NCT04678167|OTHER|EHTEV questionnaire|Handicap Scale for Balance Disorders and Vertigo
224126376|NCT04678167|OTHER|EEV questionnaire|European Vertigo Assessment Questionnaire
224126377|NCT04678167|OTHER|anxiety VAS|visual analog scale of anxiety
223388962|NCT02336646|DRUG|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
223388963|NCT02336646|DRUG|Normal saline|
224126378|NCT03321292|DRUG|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
223545876|NCT05111288|DEVICE|Pulsed electromagnetic field therapy (PEMF)|Pulsed electromagnetic field (PEMF) therapy is a noninvasive technique, which provides low field electromagnetic stimulation. The therapy of PEMF is achieved by altering biological and physiological systems via low energy and non-ionizing electromagnetic fields.
224126379|NCT03321292|DRUG|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
224126380|NCT03586843|DRUG|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
224126381|NCT04618393|BIOLOGICAL|EMB-02|EMB-02 is a FIT-Ig® bispecific antibody against PD-1 and LAG-3.
224126382|NCT03934593|BEHAVIORAL|Faith-Based (FB, BHT DSMS)|BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
224126383|NCT03934593|OTHER|Faith-Placed (FP, Stanford DSMP)|Standard Stanford DSMP delivered by health professional
224126384|NCT05611684|DRUG|Polyethylene Glycol Losenatide|Treatment 0.2mg QW for 12 weeks
224126385|NCT01943864|DRUG|Trametinib (single tablet)|The drug substance is blended with inert
224126386|NCT01943864|DRUG|Trametinib (Multiple tablet)|The drug substance is blended with inert
224126387|NCT04005443|OTHER|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
224126388|NCT04534426|DRUG|: Arnica montana|In Arnica group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
224296115|NCT01197157|DRUG|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
223388964|NCT02914860|DEVICE|Cardiac CT|"* Cardiac CT - contract enhanced cardiac CT according to standard protocol~* D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~* Merge CT and D-SPECT image data to generate SUMO map."
223388965|NCT02914860|PROCEDURE|Ablation Procedure|"1. CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~2. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~3. RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~4. Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~5. Control HFS~6. At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~7. Exit and entrance block confirmation~8. Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
223388966|NCT02914860|DEVICE|D-SPECT|
223388967|NCT00619060|DRUG|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
223388968|NCT00619060|DRUG|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
223545877|NCT05111288|DEVICE|Inactive Pulsed electromagnetic field therapy (PEMF)|PEMF device that turns on but does not provide any electromagnetic stimulation
223545878|NCT06315192|DEVICE|Stroke Alarm|Patients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.
224126389|NCT04534426|DRUG|Mucopolysaccharide polysulfate|In Arnica group and MPSP group, patients were given an unlabelled tube containing cream to be applicated topically on skin surface of masseteric and submandibular region, 2 cm in length cream for each 8 hours, starting immediately after surgery and continued for 10 days
224126390|NCT04534426|OTHER|Control group|In Control group, only standard therapy was performed after surgery
224126391|NCT03415724|PROCEDURE|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
224126392|NCT00003019|DRUG|methotrexate|
224126393|NCT00003019|DRUG|vinblastine sulfate|
224126394|NCT02151500|BEHAVIORAL|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
224126395|NCT04289103|BIOLOGICAL|Inolimomab (Leukotac)|"* Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion."
224126396|NCT03304483|OTHER|246-km running|Spartathlon 2017
224126397|NCT05886647|OTHER|Active non-invasive stimulation and inspiratory muscle training|Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
224126398|NCT05886647|OTHER|Sham compatorator and inspiratory muscle training|As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
224126399|NCT03175744|DEVICE|Stellarex DCB|Intervention with the Stellarex DCB
223388969|NCT00858182|DRUG|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
223388970|NCT00858182|DRUG|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
223388971|NCT05327231|DRUG|IN10018|IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
223388972|NCT05327231|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days a cycle.
223388973|NCT00178282|PROCEDURE|Pelvic Floor Muscle exercises|
223388974|NCT03016273|PROCEDURE|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
223388975|NCT02892929|BEHAVIORAL|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
223388976|NCT02892929|BEHAVIORAL|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
223388977|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
223388978|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
223388979|NCT00995774|DEVICE|robotic therapy|12 sessions of robot therapy for arm and hand function
223388980|NCT00995774|OTHER|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
223388981|NCT00247780|PROCEDURE|Pulmonary vein isolation and cavotricuspid ishtmusblock|
223388982|NCT01808573|DRUG|neratinib|
223388983|NCT01808573|DRUG|capecitabine|
223388984|NCT01808573|DRUG|lapatinib|
223388985|NCT00004212|BIOLOGICAL|filgrastim|
223388986|NCT00004212|DRUG|exatecan mesylate|
223388987|NCT04524195|DRUG|[18F]F-AraG Injection|Single dose of 5 mCi+/- \[18F\]F-AraG IV injection followed by the PET/CT scan. A baseline \[18F\]F-AraG PET/CT will be performed at about 0-7 days before patient receives the first dose of PD-1/PD-L1 immunotherapy. A second \[18F\]F-AraG PET-CT will be performed at less than 14 days after the first dose of PD-1/PD-L1 immunotherapy is administered and before the second dose of PD-1/PD-L1 immunotherapy is given.
224008907|NCT01404429|DRUG|Methotrexate|Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
223388988|NCT02513212|DEVICE|Potassium Oxalate|Professionally applied liquid
223388989|NCT02513212|DRUG|Stannous fluoride paste|SnF2 Paste
223388990|NCT02513212|DEVICE|Manual toothbrush|Marketed manual toothbrush
223388991|NCT02513212|DEVICE|Power toothbrush|Marketed power toothbrush
223388992|NCT06318312|OTHER|Hypoxia|Hypoxic exposure: FiO2 = 11% Hypoxic exposure: FiO2 = 13% Hypoxic exposure: FiO2 = 15% Hypoxic exposure / placebo: FiO2 = 21%
223388993|NCT03709212|OTHER|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
223388994|NCT03353012|DRUG|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
223388995|NCT03353012|DRUG|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
223388996|NCT05863169|DEVICE|fNIRS-Neurofeedback|Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
223388997|NCT05273450|BEHAVIORAL|Quitline Information with Reinforcement|The intervention arm involves direct referral to the Ohio Tobacco Quitline, with up to two brief follow-up telephone calls from the research team to elicit motivation to quit, emphasize benefits of calling the quitline, encourage use and address concerns. Participants are surveyed at baseline and at 3-month follow-up to assess awareness and use of the quitline.
223388998|NCT01523002|DRUG|Metoprolol and pyronaridine-artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with pyronaridine-artesunate at the above dose.~On Days 98 - 100, subjects will receive pyronaridine-artesunate once daily at the same dose described above. Followed by a 40 day follow-up period."
223388999|NCT01523002|DRUG|pyronaridine-artesunate|"On Days 1 to 3, subjects will receive 3 days of pyronaridine-artesunate as follows:~55 - \< 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Days 61 to 63, subjects will be redosed with a 3 day course of pyronaridine-artesunate at the above dose.~Followed by a 40 day follow-up period."
223389000|NCT05904002|DRUG|pulmicort inhaler|Each woman in both groups (A\&B) will receive pulmicort inhaler on needs.
223389001|NCT05904002|DEVICE|Incentive spirometer treatment|Each patient in group B will be instructed about the effects of incentive spirometer to gain their cooperation during the study course.
223389002|NCT03420521|DRUG|Nivolumab|240mg IV over 60 minutes Q2W
223389003|NCT03420521|DRUG|Ipilimumab|1mg/kg IV over 30 minutes Q6W
224008908|NCT03934177|DIETARY_SUPPLEMENT|Blueberry powder|Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.
224008909|NCT03934177|DIETARY_SUPPLEMENT|Placebo powder|A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.
224008910|NCT02276144|OTHER|Liver ultrasound|For evaluate whether fatty liver is exist or not
224008911|NCT00599703|OTHER|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
223389004|NCT03245866|OTHER|Observational/ no intervention|
223389005|NCT01256502|DEVICE|SERI® Surgical Scaffold|Breast reconstruction surgery
223389006|NCT02797197|PROCEDURE|handgrip strength test|
223730265|NCT06052007|BEHAVIORAL|LC-Based Debriefing|LC-based debriefing encourages reflection by allowing learners to identify and explore topics of particular interest. The model is defined as a structured post-event LC, which is useful for improving competence, professional development, and clinical judgment among intensive care unit and trauma nurses. The model is useful not only for one recipient by allowing reflection on positive and negative experiences but also for the whole group by allowing them to make connections to their own practice that day or to previous experiences, supporting teamwork. It also helps them understand what good practice is by doing their own self-assessment with peers' benchmarking.
224008912|NCT03882580|DRUG|Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
224008913|NCT06196320|DRUG|Tenecteplase|Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion
224008914|NCT06196320|DRUG|Best Practice (which may include intravenous Alteplase)|Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
224008915|NCT01280357|DEVICE|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
223389007|NCT02797197|DRUG|chemotherapy|
223389008|NCT05348447|DEVICE|cryoanalgesia|intraoperative intercostal nerve freezing for post-operative pain control
223389009|NCT05348447|OTHER|Standard of Care Pain Control|Standard of Care Pain Control Post-operatively
224008916|NCT01280357|DEVICE|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
223389010|NCT05927597|DRUG|INS1007|Oral tablets.
223389011|NCT05927597|DRUG|Placebo|Oral tablets.
223545879|NCT01547156|DEVICE|Intervention group|
223545880|NCT05985837|DEVICE|KalobaGOLA spray (1)|Oral spray, 2-4 spray, till 8 times per day
223730266|NCT06052007|BEHAVIORAL|3D Model-Based Debriefing|The model has three parts: defusing, discovering, and deepening. The experiential learning theory on which this model is based facilitates learning goals. This model allows its participants to create new mental models for future practice, develop critical thinking skills, and identify knowledge gaps. In the model, a debriefing session starts with preliminary information and ends with a summary of what has been learned. Participants' gaps in understanding and learning are identified, and how they can apply their learnings to practice is discussed.
224008917|NCT02818244|DEVICE|Fit Bit Blaze Heart Rate Monitoring Device|
223730267|NCT02434731|DEVICE|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
223730268|NCT02152579|DRUG|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
224008918|NCT02818244|DEVICE|Garmin Forerunner 235 Heart Rate Monitoring Device|
224008919|NCT02818244|DEVICE|Tom Tom Spark Cardio Heart Rate Monitoring Device|
224008920|NCT02818244|DEVICE|Apple Watch Heart Rate Monitoring Device|
224008921|NCT02818244|DEVICE|Scosche Rhythm + Heart Rate Monitor|
224008922|NCT01259089|DRUG|erlotinib hydrochloride|Given orally
224008923|NCT01259089|DRUG|Hsp90 inhibitor AUY922|Given IV
224008924|NCT01259089|OTHER|laboratory biomarker analysis|Correlative studies
224008925|NCT01259089|PROCEDURE|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
224008926|NCT01259089|GENETIC|mutation analysis|Correlative studies
223389012|NCT05709197|PROCEDURE|Braun anastomosis|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. In addition to the reconstruction technique used, a side-to-side anastomosis will be created between the afferent and efferent jejunal limbs of the gastrojejunostomy (GJ) at 20 cm distance from the GJ. The anastomosis will be hand-sewn with monofilament PDS 3-0 one-layer running suture.
223389013|NCT05709197|PROCEDURE|Standard Child reconstruction|Participants will undergo open pancreatoduodenectomy (PD). The reconstruction technique will not be standardized. The surgeon is able to perform the PD as normally would be done (antecolic, retrocolic, pylorus-preserving or with distal gastric resecting).
223389014|NCT03437473|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
223389015|NCT03414476|OTHER|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
223389016|NCT05186792|OTHER|Test:mycoplasma|Retrospective analysis of records of recruits to a previous mycoplasma study.
223389017|NCT03377101|DRUG|Copanlisib|Given IV
223389018|NCT03377101|DRUG|Fulvestrant|Given IM
223389019|NCT03377101|OTHER|Laboratory Biomarker Analysis|Correlative studies
223545881|NCT05985837|DEVICE|KalobaGOLA spray (2)|Oral spray, 2-4 spray, till 4 times per day
223545882|NCT05985837|DEVICE|KalobaGOLA tablets|1 tablets, 6 times per day
223545883|NCT05221645|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD 1. Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of indications because of its mechanism of action to bind the PD-1 receptor on the T cell.
224008927|NCT01259089|OTHER|pharmacological study|Correlative studies
224008928|NCT00886795|DRUG|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
224008929|NCT05890001|DRUG|BLI5100|Patients will take BLI5100 once daily, orally, for up to 29 weeks.
224008930|NCT02310100|DEVICE|TactiCath Quartz treatment|
224008931|NCT02837003|DRUG|Aspirin|Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
223389020|NCT03377101|DRUG|Palbociclib|Given PO
223389021|NCT00269984|DRUG|Epoetin alfa|
224008932|NCT02837003|DRUG|Thienopyridine|Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
224008933|NCT05020587|BEHAVIORAL|Open pilot trial of a group therapy manual.|Open pilot trial of a group therapy manual.
224008934|NCT03262662|DRUG|Varenicline|oral varenicline tablets
224008935|NCT03262662|BEHAVIORAL|Brief smoking cessation counseling|\~10-minute individual counseling at each of 6 clinic visits
224008936|NCT00688870|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
224008937|NCT00688870|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
224008938|NCT01828762|BIOLOGICAL|DC-TC+GM-CSF|
224008939|NCT02905448|OTHER|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
224008940|NCT00937677|DRUG|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
224008941|NCT03537495|DRUG|Linezolid|"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."
224008942|NCT02878005|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
224008943|NCT02878005|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
224008944|NCT00625547|DRUG|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
224008945|NCT00625547|DRUG|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
224008946|NCT00477659|DRUG|Donepezil hydrochloride|Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks
224008947|NCT00329173|DRUG|Rosuvastatin|
224008948|NCT00329173|DRUG|Atorvastatin|
224008949|NCT03924440|DIAGNOSTIC_TEST|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
224008950|NCT05833477|DRUG|Recombinant human erythropoietin|Recombinant human erythropoietin treatment three times per week for three weeks
224008951|NCT06194552|DRUG|NTRX-07|Investigational orally administered CB2 agonist
224008952|NCT06194552|DRUG|Placebo|Matched placebo administered orally
224008953|NCT04059302|BEHAVIORAL|Internet-delivered Cognitive Behavioral Therapy for Insomnia|The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
224008954|NCT06333353|DEVICE|Real RepetitiveTranscranial Magnetic Stimulation 5 sessions|"5 consecutive treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
224008955|NCT06333353|DEVICE|Sham RepetitiveTranscranial Magnetic Stimulation 5 sessions|"5 consecutive sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximately 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention"
223389022|NCT01593046|DRUG|GSK1265744 Oral|30mg tablet
223389023|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
223389024|NCT01593046|DRUG|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
223389025|NCT01593046|DRUG|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
223730269|NCT02930421|OTHER|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
224008956|NCT06333353|DEVICE|Real RepetitiveTranscranial Magnetic Stimulation 10 sessions|"10 consective treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
224126400|NCT03175744|DEVICE|PTA Catheter|Intervention with an uncoated Standard PTA
224126401|NCT02805218|DRUG|PEG-rhG-CSF|
224126402|NCT03553329|DRUG|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
223389026|NCT01593046|DRUG|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
224008957|NCT06333353|DEVICE|Sham RepetitiveTranscranial Magnetic Stimulation 10 sessions|"10 consective sham treatment sessions will be provided using a protocol based on the updated guideline (Lefaucheur, 2014) and on Pinot-Monange et al. (2019). Each treatment session will last approximatly 30 minutes.~Acceptability, adverse events and side effects will be recorded after each session, while the researchers will also record the total treatment time, difficulties encountered during implementation, and any modifications to the intervention."
223389027|NCT01593046|DRUG|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
223389028|NCT01593046|DRUG|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
223389029|NCT01593046|DRUG|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
223389030|NCT00641446|DRUG|budesonide|
223389031|NCT00641446|DRUG|varicella zoster virus|
224008958|NCT02571153|DRUG|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
224008959|NCT02571153|DRUG|Normal saline|Intravenous normal saline 0.9% 5 mL
224008960|NCT02571153|DRUG|Ketamine 0.2 mg/kg|Intravenous ketamine 0.2 mg/kg after induction of anesthesia
224008961|NCT02324400|DEVICE|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
224008962|NCT02324400|DEVICE|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
224008963|NCT05723159|DEVICE|Clinical Validation of the Hyfe Cough Monitoring System|The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.
224008964|NCT05751954|RADIATION|Postero-anterior weight-bearing full-leg radiograph|Full leg standing X ray of the involved lower extremity (postero-anterior direction)
224008965|NCT05751954|DEVICE|Pedobarographic analysis|Foot pressure analysis during gait on pedobarographic device
224008966|NCT01821352|DEVICE|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
224008967|NCT01821352|DEVICE|Placebo Laser|Emits light that has no therapeutic effect
224008968|NCT06270043|PROCEDURE|Focal Therapy|"Focal ablation of prostate cancer using different modalities. These modalities include:~* Cryoablation or Cryotherapy~* Irreversible Electroporation - Nanoknife~* High Intensity Frequency Ultrasound - FocalOne~* Transurethral Ultrasound Ablation - TULSA - PRO"
224008969|NCT02094287|DRUG|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
224008970|NCT02094287|BEHAVIORAL|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
224008971|NCT02094287|OTHER|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
224008972|NCT01140295|DRUG|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age \>12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
224008973|NCT04419376|DEVICE|driving pressure|Mechanically ventilated patients (via ETT or trachestomy) were recorded for patients whose ventilation duration lasted at least 24 hours.We divided the patients into two groups by calculating the oxygenation index (OI): \[mean airway pressure(MAP) × fraction of inspired oxygen (FiO2) \]/ partial pressure of oxygen in arterial blood (PaO2) × 100) used in the classification of PALICC, including pARDS and non-pARDS.
224008974|NCT05180643|BEHAVIORAL|Mindfulness-Based Stress Reduction-based program (MBSR).|The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.
224008975|NCT01966172|DRUG|Ibuprofen|oral ibuprofen 400mg 4 times daily
223389032|NCT03905616|DEVICE|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
223389033|NCT03953612|DRUG|Pregnenolone (PREG)|2 doses of PREG (300 or 500 mg/day)
223389034|NCT03953612|DRUG|Placebos|placebo
223389035|NCT03885583|PROCEDURE|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
223389036|NCT03885583|PROCEDURE|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
223389037|NCT02404480|DRUG|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
223545884|NCT05221645|DRUG|Rituximab|Rituximab is a chimeric mouse/human monoclonal antibody that binds to CD20, on pre-B and mature B lymphocytes and eliminates these cells potentially via a number of different mechanisms. Anti-CD20 mAbs, like rituximab, are classified by their CD20-binding characteristics, ability to induce complement-dependent cytotoxicity (CDC), and immune effector cell effects.
223545885|NCT05221645|DRUG|Ifosfamide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
224008976|NCT01966172|DRUG|Gabapentin|Oral Gabapentin 300mg twice daily
224008977|NCT01966172|DRUG|Morphine|10 mg morphine orally 4 times daily
224008978|NCT01966172|DRUG|Paracetamol|oral paracetamol 1000mg four times daily
224008979|NCT00163280|DRUG|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
224008980|NCT02753569|OTHER|Imaging - DW-MRI|
224008981|NCT02753569|RADIATION|FDG PET-CT|
224008982|NCT02604303|OTHER|No Intervention|No intervention; prospective observational study
224008983|NCT01862380|OTHER|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
224008984|NCT01862380|OTHER|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
224008985|NCT04582136|DRUG|Sirolimus|In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
224008986|NCT04582136|DRUG|Placebo|In the double-blinded phase, placebo plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate are switched to receive sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
224008987|NCT00375440|DRUG|Tranexamic Acid|
224126403|NCT05628467|DRUG|Antidepressive Agents|Compare the signal obtained from the pharmacovigilance database study between adults over 65 who fall on antidepressants versus those who fall on other drugs
224126404|NCT05029076|DRUG|Liraglutide injection|Human glucagon-like peptides-1 analogue
224126405|NCT05029076|DRUG|Victoza|Human glucagon-like peptides-1 analogue
224126406|NCT02689219|DRUG|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
224126407|NCT04956822|OTHER|Basic information|Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
224126408|NCT04956822|OTHER|Functional scores|depending on the diseases enrolled, ALS and KD chose ALS-FRS functional scores and CMT chose CMTNS2 functional scores
224126409|NCT04956822|DEVICE|MINUX|MUNIX examination was performed on all subjects. A total of eight bilaterally symmetrical muscles were selected, bilateral abductor little finger or abductor pollicis brevis, bilateral biceps or deltoid muscles, bilateral tibialis anterior muscles, and bilateral femurs. For quadriceps, choose a muscle with less muscle atrophy.
224126410|NCT03650348|DRUG|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
224126411|NCT01822041|DRUG|ARN-509|Single oral dose of 240 mg ARN-509
224126412|NCT01665755|DEVICE|Upstroke Compression Defibrillation|
224126413|NCT01665755|DEVICE|Precompression Defibrillation|
224296116|NCT01197157|DRUG|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight \< 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
224008988|NCT02405143|DEVICE|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
224008989|NCT02405143|DEVICE|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
224126414|NCT03535324|BEHAVIORAL|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
224126415|NCT03535324|OTHER|Control|There will be no intervention
224126416|NCT04507438|DRUG|Donepezil 5-10 Mg Oral Tablet|Donepezil 5mg or 10mg oral tablet administered daily for an 8 week period
224126417|NCT04507438|DRUG|Placebo Oral Tablet|Placebo oral tablet administered daily for an 8 week period
224126418|NCT00169988|DRUG|risperidone|
224126419|NCT00169988|DRUG|sertraline-primary|
224126420|NCT03064295|DEVICE|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
224126421|NCT03064295|DRUG|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
224126422|NCT03064295|DRUG|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
224126423|NCT00276978|DRUG|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
224126424|NCT01176097|DRUG|AZD5658|oral suspension, escalating single doses
224126425|NCT01176097|DRUG|Placebo|oral suspension,single doses
224126426|NCT03673241|DEVICE|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
223389038|NCT04277962|DEVICE|Triton L and D system for estimation of blood loss at time of vaginal delivery|The Triton L\&D system (Gauss Surgical, Inc., Menlo Park, CA) is an FDA-cleared mobile application on a tablet computer (iPad) that facilitates quantification of blood loss (QBL) by providing an easy to use process and user interface. Dry weights of all potential blood containing substrates are built-in to the device allowing batch weighing with automatic subtraction of dry weights. There is also a V-drape simulator accounting for collected fluids with automatic subtraction of a measured amount of amniotic fluid.
223389039|NCT02317029|DEVICE|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
223389040|NCT02317029|PROCEDURE|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
223545886|NCT05221645|DRUG|Carboplatin|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
224008990|NCT04981171|PROCEDURE|Electro-thumbtack Needle Therapy|Each treatment session starts with sterilizing acupoints. Dazhui (GV14), bilateral Wangu (GB12), bilateral cervical Jiaji (at C4 and C6 level), two Ashi points and bilateral Houxi (SI3) have been selected in accordance with the principle of acupuncture prescription making and the consensus of experts on treating neck pain. Electro-thumbtack needles (0.25×2 mm) will be held by the acupuncturist between thumb and forefinger, vertically inserted into skin instantly and taped well on skin. Then assemble the gel electrodes to the surface of the conductive adhesive tape, also assemble the portable stimulation devices, adjust the current intensity from level 1 to a proper level that the participant can tolerate. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
223389041|NCT02317029|DEVICE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
224008991|NCT04981171|PROCEDURE|Sham electro-thumbtack needle therapy|Each treatment session starts with sterilizing acupoints. Sham electro-thumbtack needles (0.25×0.2 mm) will be held by the acupuncturist between thumb and forefinger, taped well on skin without penetration. The adhesive tape of needles are also produced with conductive material, after assembling the gel electrodes and the portable stimulation devices, adjust the current intensity to level 1 for a minimal stimulus which will last for only 30 seconds. By this time the acupuncturist will turn the device off to cut the current. Participants will receive three 30-min treatment sessions per week every other day for 4 consecutive weeks.
224008992|NCT00707759|DRUG|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
224008993|NCT00707759|DRUG|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
224008994|NCT01579331|DEVICE|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
224008995|NCT00399243|DRUG|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
224008996|NCT02027636|BEHAVIORAL|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
223389042|NCT02317029|PROCEDURE|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
223545887|NCT05221645|DRUG|Etoposide|Ifosfamide, Carboplatin and Etoposide (ICE) is proven to be an effective regimen in the relapsed refractory NHL population. In a study of 163 transplant eligible patients with relapsed/refractory disease, 66.3% of patients obtained CR/PR after 3 cycles of ICE chemotherapy at two weekly intervals.
223545888|NCT04881682|DEVICE|Immunoadsorption|see arm/group description
223545889|NCT04881682|BIOLOGICAL|Immunoglobulins|see arm/group description
223545890|NCT06567002|DRUG|MK-6552|Oral Administration
223545891|NCT02157909|DEVICE|Lotrafilcon B sphere modified design contact lenses|
223545892|NCT02157909|DEVICE|Lotrafilcon B sphere contact lenses|
223425658|NCT03884699|PROCEDURE|Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant|"Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique."
223425659|NCT01248052|DRUG|LY2979165|administered orally
223425660|NCT01248052|DRUG|Placebo|administered orally
223545893|NCT00943761|DRUG|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
223545894|NCT00943761|DRUG|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
223545895|NCT00943761|DRUG|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
224008997|NCT02027636|BEHAVIORAL|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
224008998|NCT01769326|OTHER|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
224008999|NCT01769326|DEVICE|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
224009000|NCT01769326|OTHER|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
224009001|NCT01769326|DEVICE|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
224009002|NCT01278173|DRUG|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
224009003|NCT01657786|DIETARY_SUPPLEMENT|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100\_-102delAAG).
224009004|NCT00857129|PROCEDURE|Normal Unit|low-risk patients randomised to Normal Unit
224009005|NCT00857129|PROCEDURE|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
224009006|NCT01549938|DIETARY_SUPPLEMENT|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
224009007|NCT01549938|DIETARY_SUPPLEMENT|Placebo|Microcellulose capsule identical in appearance to treatment
223545896|NCT00943761|DRUG|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
223545897|NCT00287781|DRUG|Lidocaine|
223545898|NCT02268383|DRUG|Luspatercept|Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
223545899|NCT01911468|DRUG|metformin|
224009008|NCT02713087|DRUG|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
224009009|NCT02713087|DRUG|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
224009010|NCT04064073|DRUG|DWP16001|Tablets, Oral, once daily single dose
224009011|NCT04064073|DRUG|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
224009012|NCT04064073|DRUG|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
224009013|NCT03085654|DRUG|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
224009014|NCT03085654|DRUG|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
224126427|NCT04897555|DEVICE|LLLT|This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
224009015|NCT05745701|DRUG|PF-07081532|Oral Tablet
224009016|NCT05745701|DEVICE|Cyclosporine|Oral Solution
224009017|NCT05745701|DRUG|Itraconazole|Oral Capsule
224009018|NCT04501913|PROCEDURE|Patient Monitoring|Undergo remote perioperative telemonitoring
224009019|NCT04501913|OTHER|Questionnaire Administration|Complete questionnaires
223545900|NCT01911468|DRUG|liraglutide|
223545901|NCT01911468|DRUG|metformin and liraglutide|
223545902|NCT03099473|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
223545903|NCT03099473|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
224126428|NCT01648543|PROCEDURE|lumbar sympathetic ganglion block|
224126429|NCT02746393|OTHER|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
224126430|NCT02746393|OTHER|211 Information Sheet|Receive a printed list of community resources to address social needs.
224009020|NCT04662931|DRUG|crizanlizumab|Crizanlizumab 5.0 mg/kg i.v. initial dose on Week 1 Day 1, second dose on Week 3 Day 1. Subsequently, Day 1 of every 4 weeks until Week 51, in addition of standard of care.
224009021|NCT00046969|BIOLOGICAL|epoetin beta|
224009022|NCT00046969|DRUG|cisplatin|
223389043|NCT02028676|OTHER|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
223389044|NCT02028676|OTHER|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
223389045|NCT02028676|DRUG|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
223425661|NCT00943956|DRUG|bicalutamide|
223425662|NCT00943956|DRUG|everolimus|
224009023|NCT00046969|RADIATION|brachytherapy|
224009024|NCT00046969|RADIATION|radiation therapy|
224009025|NCT03736226|DEVICE|SYNERGYTM Stent System|no intervention design in the study
224009026|NCT06485635|DRUG|Nintedanib|Nintedanib
224009027|NCT06485635|DRUG|Pirfenidone|Pirfenidone
224009028|NCT01186822|DEVICE|Lung Flute|Used twice daily
224009029|NCT02705846|OTHER|Observation of treatment outcomes via Questionnaire|Collection of treatment data from participants
224009030|NCT05893186|OTHER|Deep Brain Stimulation, STN|DBS of the STN, within FDA-approved limits and labeling, for symptoms of PD
223425663|NCT00943956|DRUG|leuprolide acetate|
223425664|NCT00943956|RADIATION|external beam radiation therapy|
223425665|NCT03013907|BEHAVIORAL|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping \& Relaxing Session 4: Attention \& Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure \& the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
223545904|NCT03099473|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
224009031|NCT05893186|OTHER|GP Deep Brain Stimulation|PD with GP DBS, within FDA-approved limits and labeling, for symptoms of PD.
224009032|NCT03420248|DEVICE|Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere|One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
224009033|NCT01504477|DRUG|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
224009034|NCT03064399|PROCEDURE|without lateral ligament repairment|microfracture without repairment of the lateral ligament
224009035|NCT03064399|PROCEDURE|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
224126431|NCT06295081|OTHER|Exercise exposure|"Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km"
224009036|NCT05399537|DRUG|Prismocitrate 18|Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
224009037|NCT05399537|DEVICE|PrisMax System Version 3.x with calcium line accessory|The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.
223425666|NCT03013907|BEHAVIORAL|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
224126432|NCT04226859|OTHER|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
224126433|NCT07015151|DIAGNOSTIC_TEST|Low-dose Chest CT Screening|Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
223389046|NCT02028676|DRUG|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
224009038|NCT02275429|PROCEDURE|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
224009039|NCT04366531|BEHAVIORAL|START-VET|prison reentry program
224009040|NCT04366531|OTHER|Treatment as usual|This intervention involves no additional services above what is provided by the local health care system
224009041|NCT01397422|DRUG|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
224009042|NCT05039294|BEHAVIORAL|School-Based Physical Activity Educational Program|The structure of the educational sessions includes physical education lectures, group discussions, videos, training sessions, physical activities diaries, short quizzes, and feedback after each session. The educational programs were conducted among students with intervention groups at two-level individually and in school. The individual-level includes classroom lectures that mainly emphasized the health benefits of physical activity and provided necessary information about physical activity fitness for 60 minutes and were given weekly for four weeks. In coordination with the school sports teacher, training sessions included moderate to vigorous physical activities for 45 minutes twice weekly for four weeks
224009043|NCT03311464|DRUG|adalimumab|Study drug will be administered subcutaneously.
224126434|NCT07015151|DIAGNOSTIC_TEST|Spirometry|Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
224126435|NCT07015151|DIAGNOSTIC_TEST|Cardiovascular Risk Assessment|Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
224009044|NCT00596700|DEVICE|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
224009045|NCT03446833|DEVICE|The LFP Beta aDBS System|The LFP Beta aDBS System is intended for use in patients receiving DBS for Parkinson's Disease where LFPs may be recorded and analyzed.
224009046|NCT03075423|DRUG|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd or 4th week
224126436|NCT07015151|BEHAVIORAL|Smoking Cessation Support|Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
224296117|NCT03218891|BEHAVIORAL|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation."
224296118|NCT01184248|BEHAVIORAL|Sound stimulation|Listening to sound stimuli at the lowest audible level.
223389047|NCT02028676|DRUG|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
223389048|NCT02028676|DRUG|Once-daily ABC+3TC|
224009047|NCT03075423|DRUG|Standard Therapy|Standard of Care therapy is administered according to the physician´s decision.
224009048|NCT05051462|BEHAVIORAL|Family / systemic constellation therapy|Family / systemic constellation therapy is a short-term group counseling intervention aiming to help clients better understand and resolve their conflicts within their personal systems, which in turn might lead to a decrease in psychopathological or functional somatic symptoms. The personal system addressed is most often the family but other inter- or intrapersonal systems (e.g., ego parts, victim-perpetrator dyads) can also be the target of the intervention.
223389049|NCT02028676|DRUG|Twice-daily ABC+3TC|
223389050|NCT02028676|DRUG|Continued cotrimoxazole prophylaxis|
223389051|NCT02028676|OTHER|Stopped cotrimoxazole prophylaxis|
223389052|NCT00971373|OTHER|Vestagen scrubs|antimicrobial impregnated textile
223389053|NCT00626457|BEHAVIORAL|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
223545905|NCT02576873|OTHER|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
223545906|NCT02338388|PROCEDURE|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
223545907|NCT03246607|DEVICE|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
224009049|NCT05608499|DRUG|Duobrii|topical contains active drug lotion, once daily for 4 weeks then twice daily for 8 weeks
224009050|NCT05608499|DRUG|Placebo|Topical does not contain active properties of study drug
224009051|NCT05608499|DRUG|Bryhali|Bryhali will only be used as a rescue treatment - in case of irritation with Duobrii. Bryhali lotion once daily up to 12 weeks only if Duobrii is not tolerated.
224126437|NCT07015151|OTHER|Optional Biospecimen Collection (Bio-ILYAD)|Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.
223389054|NCT02748148|OTHER|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
223389055|NCT02720848|DEVICE|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
223389056|NCT02720848|DEVICE|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
223389057|NCT03008174|OTHER|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
224009052|NCT04823663|DEVICE|Implant|In the scope of the CRM procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific CRM products/components and combination of those products/components with competitor product(s) per hospital's standard of care.
224009053|NCT04823663|PROCEDURE|Electrophysiologic procedure|In the scope of the EP procedure and subsequent follow-up, the registry will provide information on the use of the Boston Scientific Electrophysiology products/components and capital equipment products and combination of those products/components with competitor product(s) per hospital's standard of care.
224009054|NCT05785039|DRUG|BL-B01D1|Administration by intravenous infusion
224126438|NCT03312946|DEVICE|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
224126439|NCT06693349|DRUG|the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to give superior effects than other procedure used in this study
223389058|NCT06633874|DIAGNOSTIC_TEST|TD Playing the Serious Game APSOU|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then, the child may interact with the Serious Game. Typically developed (TD) children engage under the clinician's face-to-face supervision with the serious game APSOU, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for TD children to play the whole game is estimated to be 45 minutes.
223389059|NCT06633874|DIAGNOSTIC_TEST|Non-TD Playing Serious Game|After parents participate in informative meetings, they proceed with written consent, SmartSpeech enrollment, and child developmental history. Then the child may interact with the serious game. Non-typically developed (non-TD) children engage under the clinician's face-to-face supervision with the serious game Apsou, which assesses developmental domains, including speech, language, psychomotor, cognitive, psychoemotional, and hearing abilities. The average time for non-TD children to play the whole game is estimated to be over an hour.
223389060|NCT05847348|DRUG|68Ga-PSMA-11|A single dose of 111 - 259 MBq administered intravenously over 3 -5 minutes
223389061|NCT05847348|OTHER|PET/CT or PET/MRI|PET/CT or PET/MRI will be acquired no sooner than 50 minutes post injection and not later than 100 minutes post injection with 68Ga-PSMA-11
223389062|NCT04727801|DEVICE|Verily Patch|The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
223389063|NCT02565940|OTHER|biopsy|
223389064|NCT04469504|OTHER|Prehabilitation program|4-week trimodal prehabilitation program: Exercise, nutritional supplementation, and psychological support
223389065|NCT04469504|DIETARY_SUPPLEMENT|Oral Impact|perioperative immunonutrition by ORAL IMPACT
224126440|NCT06693349|DRUG|the effect of apexification in treatment of contaminated and uncontaminated immature permanent teeth|this procedure was anticipated to be replaced by other procedure be used in this study
224126441|NCT06692010|DRUG|Bupivacaine with Dexamethasone Solution|10 to 15 ml %0.25 bupivacaine \& 4 mg Dexamethazone
224126442|NCT01911182|OTHER|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
224126443|NCT05239286|PROCEDURE|General anaesthesia|"All patients in supine position will receive breathing 100% oxygen, induction of anaesthesia will be achieved using propofol (2 mg/Kg), 1-2 mcg/kg of fentanyl and atracurium (0.5 mg/Kg). Endotracheal tube will be inserted after 3 minutes of mask ventilation. Patients who will experience prolonged airway instrumentation due to a difficult intubation will be excluded from further data analysis because of excessive stimulation. Then mechanical ventilation will be performed using a tidal volume of 6-8 mL/kg of ideal body weight at an inspiratory to expiratory ratio of 1:2 without positive end-expiratory pressure. The ventilatory frequency will be adjusted to maintain an end-tidal carbon dioxide tension of 35-40 mmHg.~Anaesthesia will be maintained by isoflurane (1-1.5%), atracurium 10 mg intravenous increments every 20 minutes and morphine 0.1 mg/kg intravenous will be given as a long acting analgesia."
224296119|NCT02114957|DIETARY_SUPPLEMENT|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
223389066|NCT05282563|PROCEDURE|double and a half layered esophagojejunal anastomosis|After the end of esophagojejunostomy, 3/0 barbed suture or absorbable suture was used. First, the anastomotic site was sutured continuously for one circle, with the suture spacing of 3-4 mm and the width of 4-5 mm. Then, the continuous horizontal mattress type seromuscular layer varus suture was used to embed the anastomotic stoma for one circle, and the suture width was 5\~8 mm above and below the anastomotic stoma. After the completion of esophagojejunostomy, the full-thickness reinforcement of the anastomosis and the embedding of the seromuscular layer can ensure the complete anastomosis of the mucosal layer of the anastomosis. The embedding of the seromuscular layer can also improve the anti-pressure and anti-tension of the anastomosis, and provide a guarantee for the primary healing of the anastomosis.
223389067|NCT00973063|BEHAVIORAL|Routine sterile gloving|routinely new sterile gloving just before sampling
223389068|NCT01244503|DRUG|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
223389069|NCT02459938|DRUG|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
223389070|NCT02459938|DRUG|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
223389071|NCT02523261|PROCEDURE|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
224296120|NCT02324673|DRUG|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
223389072|NCT02523261|PROCEDURE|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
223389073|NCT01912261|DRUG|Placebo|one capsule orally daily times 84 days
223389074|NCT01912261|DRUG|Polysaccharide iron complex|150 mg daily orally times 84 days
223389075|NCT01587287|DEVICE|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
223389076|NCT01609205|BIOLOGICAL|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
223389077|NCT03691727|DRUG|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
223389078|NCT03691727|DIAGNOSTIC_TEST|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
223545908|NCT04355650|OTHER|Clinical decision support tool|Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
223730270|NCT01593488|DRUG|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
223730271|NCT02771990|DEVICE|Sham transcranial direct current stimulation|sham stimulation
224009055|NCT04458207|PROCEDURE|Oral prosthetic rehabilitation|Individual treatment options will be discussed with the participants individually and rehabilitation will be provided as agreed by the dentist and the participant. The rehabilitation will include fixed prosthodontics. The procedures will involve a control phase involving scaling, root planing oral hygiene instructions etc., extractions and bone augmentation when needed and temporary removable dentures. Restoration of the lost vertical dimension (if needed) with occlusal splints, tooth preparations, placement of dental implants (if needed) and finally cementation of dental crowns. The rehabilitation phase is estimated to take approximately 3-18 months, or more.
224009056|NCT05479032|DRUG|Amantadine|2x100 mg Amantadine for 3-5 days (dosage can be doubled in case of missing response to treatment after 48 hours)
224009057|NCT05437575|DRUG|Ketamine Hydrochloride|ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
224009058|NCT05437575|DRUG|Fentanyl Citrate|fentanyl citrate 10mcg/ml packaged in pre-filled syringe
224296121|NCT01484184|DRUG|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
223389079|NCT03691727|DIAGNOSTIC_TEST|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
223389080|NCT03691727|BEHAVIORAL|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
223389081|NCT03691727|DIAGNOSTIC_TEST|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
223389082|NCT03691727|OTHER|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
223389083|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with ALL plasty|ACL reconstruction with hamstrings combined anterolateral plasty using the ALL reconstruction technique (Gracilis throught the femur tunnel of the ACL graft and fixed to the tibia by an anchor on its point of isometry on the tibia).
223730272|NCT02771990|DEVICE|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
224009059|NCT04937062|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|"Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda\_docs/label/2017/203284s005lbl.pdf)."
224009060|NCT06252493|DRUG|Radiotracer Injection|"Injection of Gallium-68 labeled collagen binding probe 8 (\[68Ga\]CBP8):~All subjects will undergo placement of an intravenous catheter (IV). The catheter will be flushed post-injection of \[68Ga\]CBP8 with 0.9% saline solution.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used as needed to enable the patient to comfortably maintain his/her position throughout the scan; Up to 15 mCi of \[68Ga\]CBP8 will be administered. The injected dose and the time of injection will be recorded;~Post scan:~The catheter will be removed. The subject will be asked to void again immediately after the scan and he/she will be counseled on the importance of continuing to drink fluids for several more hours in order to increase urine flow rate and minimize the radiation dose to the bladder wall."
224009061|NCT06252493|DRUG|Contrast Media, Magnetic Resonance|Dotarem 20ml will be injected during acquisition of contrast enhanced T1weighted fat saturated sequences, in keeping with standard of care MR enterography.
224296122|NCT02171390|DRUG|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
223389084|NCT06147427|PROCEDURE|ACL reconstruction with hamstrings combined with modified Lemaire's LET|ACL reconstruction with hamstrings combined with modified Lemaire's lateral extra-articular tenodesis technique (Fascia lata strip pedicled to the Gerdy and fixed to the femur throught the tunnel of the ACL graft).
223389085|NCT05522127|OTHER|Colonoscopy|Colonoscopy
223389086|NCT05522127|OTHER|Sedoanalgesia|Ketamine, fentanil, midazolam, propofol
223389087|NCT02083627|DRUG|rosuvastatin|Oral
223389088|NCT02083627|DRUG|fidaxomicin|Oral
223389089|NCT00006760|BIOLOGICAL|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
223389090|NCT00006760|DRUG|ifosfamide|V over 24 hours on days 1-4
223389091|NCT00006760|DRUG|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
223389092|NCT01093092|DIETARY_SUPPLEMENT|Calcitriol|Given PO
223389093|NCT01093092|DRUG|Cisplatin|Given IV
223389094|NCT01093092|DRUG|Gemcitabine Hydrochloride|Given IV
223389095|NCT01093092|OTHER|Pharmacological Study|Correlative studies
223389096|NCT01807312|DEVICE|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
223389097|NCT01807312|DEVICE|Placebo|
223389098|NCT03200717|DRUG|Pazopanib|Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.
223389099|NCT02110784|DRUG|Eurartesim tablets|dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
223389100|NCT03254264|BEHAVIORAL|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
223389101|NCT03254264|BEHAVIORAL|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
223389102|NCT01590303|DRUG|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
223389103|NCT01590303|DRUG|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
223389104|NCT05446259|OTHER|Standard clinical care procedures and outcome measurements.|Standard of care surgical interventions, imaging impressions, laboratory results, and outcome measurements will be collected and analyzed.
223389105|NCT00034008|BEHAVIORAL|Healing Touch|
223389106|NCT01461538|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
223389107|NCT01461538|DRUG|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
223389108|NCT01461538|DRUG|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
223389109|NCT01884038|DRUG|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
224296123|NCT02171390|DRUG|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
223389110|NCT01884038|DRUG|Placebo|
223389111|NCT05225779|DIAGNOSTIC_TEST|12- derivation Electrocardiography|6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
223389112|NCT04892537|DEVICE|Coronary Sinus Reducer|Coronary Sinus Reducer implantation according to standard clinical protocols
223389113|NCT04892537|PROCEDURE|Placebo Procedure|A placebo procedure involving venous sheath implantation in the right internal jugular vein without proceeding to CSR implantation
223389114|NCT05209607|OTHER|Mobile Medical and bundle management|Based on the current follow-up management platform of respiratory disease, the WeChat official account will be designed and used to provide health education for patients, such as smoking cessation, reasonable diet, appropriate exercise, etc., and monitor some physiological indicators (such as body temperature, weight, the score of mMRC, etc.) and guide patients to standardize medication and pulmonary rehabilitation.
223389115|NCT05209607|OTHER|Mobile Medical and standard of care|Based on the mobile medical, participants will receive advice on standard medication only.
223389116|NCT05816109|DIAGNOSTIC_TEST|superficial cervical block|After anesthesia and surgical procedures, bilateral superficial cervical plexus block will be applied to the lower border of the sternocleidomastoid muscle, accompanied by ultrasonography. After cleaning the area with povidone iodine before the block, the sternocleidomastoid muscle and carotid artery and other vascular structures are determined using a linear ultrasound probe. Local anesthetic will be administered between the lower border of the sternocleidomastoid muscle and the upper border of the prevertebral fascia with the help of an insulated needle designed for peripheral block procedures. The location of the needle will be confirmed by hydrodissection method with saline before local anesthesia is given. After the location of the needle is confirmed, 2 ml of saline will be injected, followed by 10 ml of 0.5% bupivacaine. The deep cervical fascia of the superficial lamina will appear to open.
223389117|NCT05816109|DIAGNOSTIC_TEST|without superficial cervical block|patients who underwent anterior cervical surgery and did not undergo superficial cervical block
223389118|NCT00141778|DRUG|Placebo|Matching placebo taken once a day
223389119|NCT00141778|DRUG|Ramipril|Taken orally, once a day
223389120|NCT00141778|DRUG|Spironolactone|Taken orally, once a day
223545909|NCT00693888|BEHAVIORAL|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
224296124|NCT03507413|DRUG|Metformin Glucophage 500mg (IR) tablets M90|oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
223389121|NCT02100488|DEVICE|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
223389122|NCT02100488|OTHER|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
223389123|NCT04763954|OTHER|Rethink therapeutic game|The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
223389124|NCT00003183|BIOLOGICAL|filgrastim|
223389125|NCT00003183|DRUG|mitoxantrone hydrochloride|
223389126|NCT03220854|RADIATION|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
223389127|NCT03220854|OTHER|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
223389128|NCT03220854|OTHER|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
223545910|NCT02708680|DRUG|Entinostat|An orally available histone deacetylases inhibitor (HDAC).
223545911|NCT02708680|DRUG|Atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
223545912|NCT02708680|DRUG|Placebo|A pill containing no active drug ingredient
223389129|NCT00368797|DRUG|XRP0038 (NV1FGF)|
223389130|NCT06353698|DIETARY_SUPPLEMENT|fasting mimicking diet|Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
223545913|NCT05894603|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir/ritonavir
223545914|NCT05894603|DRUG|Molnupiravir|Molnupiravir
223545915|NCT01342926|DRUG|GSK933776|GSK933776
224009062|NCT06252493|DIAGNOSTIC_TEST|Blood Draw|All subjects will undergo placement of an intravenous catheter (IV). Through the same catheter, 10 mL of venous blood will be collected to evaluate blood markers for fibrostenosis.
224009063|NCT06252493|DRUG|Glucagon|Glucagon will be injected into the subject's indwelling i.v. catheter (0.3-0.5 mg) before imaging acquisition; or intramuscularly (1-2 mg) prior to imaging the abdomen and pelvis. A second administration of IV glucagon (0.3-0.5mg) may take place during image acquisition.
224296125|NCT03507413|DRUG|Placebo Oral Tablet|Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
223389131|NCT00082277|DRUG|Anastrozole|1mg/Day Oral
223389132|NCT00082277|DRUG|Risedronate Sodium|35mg/week, oral
223389133|NCT01321827|DRUG|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
223389134|NCT01321827|DRUG|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
223730273|NCT02691299|DRUG|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
223730274|NCT02691299|DRUG|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
224009064|NCT06252493|DIAGNOSTIC_TEST|Imaging|MR and PET images of the abdomen and pelvis will be acquired using the Siemens 3 Tesla Biograph mMR scanner. Multiple anatomical and functional imaging sequences may be run to assess specific image quality measures in addition to those used for anatomical diagnosis. Among the sequences, patients will undergo a full set of standard of care MR enterography sequences to ensure they get at least same quality of study and of clinical information they would gain from a clinical study. Certain MR sequences scans may be repeated after varying a limited range of pulse sequence parameters to assess their effect on the image contrast, image artifacts and signal to noise ratio.
224126444|NCT05239286|DRUG|Conventional fluid managment|Ringer solution at the dose of 5 ml/kg/h infused throughout the surgical procedure by taking the parameters such as Heart rate (HR), mean arterial pressure (MAP) and urine output, Hypotension was defined as a condition in which the MAP was below 30% of the baseline MAP of the patient. In this case, bolus of 250 ml crystalloids (0.9% NaCl) was given and in case of hypotension persistence, 5 mg I.V. ephedrine administered and repeated every 5 min till the MAP increased over 70% of baseline.
224296126|NCT05212064|DEVICE|high-flow oxygen nasal cannula therapy|Heated and humidified oxygen of 40L/minute through high-flow nasal cannula (HFNC) therapy machine.
224296127|NCT05212064|OTHER|nasal cannula oxygen therapy|Heated and humidified oxygen of 6L/minute through high-flow nasal cannula (HFNC) therapy machine.
223389135|NCT03580473|DRUG|SATURNO II association|opthalmic solution, 4 times a day
223389136|NCT03580473|DRUG|Vigadexa®|opthalmic solution, 4 times a day
223545916|NCT01342926|DRUG|Placebo|Placebo
223545917|NCT04162470|DRUG|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
223545918|NCT00394264|PROCEDURE|Soft Tissue|
223545919|NCT00394264|PROCEDURE|Myofascial release|
223545920|NCT00394264|PROCEDURE|Counterstrain|
223545921|NCT00394264|PROCEDURE|Muscle energy|
223545922|NCT00394264|PROCEDURE|Sacro-iliac articulation|
223545923|NCT00394264|PROCEDURE|High-velocity, low amplitude|
223545924|NCT02568722|OTHER|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization."
223730275|NCT00002007|DRUG|Zidovudine|
223730276|NCT00002007|DRUG|Sargramostim|
223389137|NCT03660176|DRUG|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
223389138|NCT03660176|OTHER|routine management|the colonic irrigations
224009065|NCT06252493|DRUG|Oral contrast media application|Patients will be invited to drink as much as possible of an oral contrast solution consisting of a mixture of 1500-2000 ml of dilute barium or sorbitol (VoLumen or Breeza) and water. Breeza, and in the past VoLumen, is routine clinical practice at MGH. The solution comes already prepared in bottles, so there is no need to dilute or prepare. The investigators will just hand the bottle to the patient and will ask the patient to start drinking \~1 hour before the scan. By routine practice at MGH, the investigators give 3-4 bottles of Breeza, about 1500-2000ml.
224009066|NCT05421728|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
224009067|NCT05421728|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
224009068|NCT05742438|DRUG|Lidocaine IV|Continuous intravenous infusion of lidocaine
224009069|NCT05742438|DRUG|Dexmedetomidine IV|Continuous intravenous infusion of dexmedetomidine
224009070|NCT05742438|DRUG|intrathecal morphine|intrathecal morphine injection
223389139|NCT04663230|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|right atrial late gadolinium enhancement in % and cm2
223389140|NCT00922740|DRUG|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
223389141|NCT00922740|DRUG|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
223389142|NCT03657225|DEVICE|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
223389143|NCT03657225|DRUG|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
223389144|NCT00079430|PROCEDURE|adjuvant therapy|
223389145|NCT00079430|DRUG|paclitaxel|Given IV
223389146|NCT00079430|DRUG|carboplatin|Given intraperitoneally
223389147|NCT00079430|BIOLOGICAL|bevacizumab|Given IV
223389148|NCT03529201|PROCEDURE|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
223389149|NCT03529201|DEVICE|PCA|Patient-controlled analgesia
223389150|NCT03529201|PROCEDURE|GA|General anesthesia
223389151|NCT03529201|DRUG|Oxycodone|administered by PCA
223389152|NCT03529201|DRUG|Sevoflurane|Inhalational anesthetic during GA
223389153|NCT03529201|DRUG|Fentanyl|painkiller during GA
223389154|NCT03529201|DRUG|Rocuronium|muscle relaxant during GA
223389155|NCT03959969|OTHER|Educational video|An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
223389156|NCT03959969|OTHER|Standard of care|The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
223389157|NCT03959969|DRUG|Ibuprofen|Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
223389158|NCT03959969|DRUG|Oxycodone|Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
223389159|NCT06090201|OTHER|3-Tesla brain MRI and a comprehensive neuropsychological assessment|Patients with a moderate to severe form of congenital haemophilia A or B or a severe form of von Willebrand disease will be consecutively recruited in the study during a routine follow-up visit at the Haemostasis and Transfusion Department of the Lille University Hospital.
223389160|NCT02730663|DEVICE|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
223389161|NCT02258763|DRUG|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
224009071|NCT05456906|OTHER|No intervention|No interventions
224009072|NCT05565378|DRUG|Pembrolizumab|Pembrolizumab will be administered.
223389162|NCT02258763|DRUG|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
223389163|NCT00016081|DRUG|ribavirin|
223389164|NCT01308502|DEVICE|Dx-pH probe|Dx-pH probe with 24 hour recording
223389165|NCT04580264|BEHAVIORAL|REINTERVENTION|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
223389166|NCT05919615|DRUG|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
223389167|NCT05919615|DRUG|Normal saline|0.9% sodium chloride normal saline
224009073|NCT05565378|DRUG|Dostarlimab|Dostarlimab will be administered
224009074|NCT05565378|DRUG|Belrestotug|Belrestotug will be administered.
224009075|NCT05565378|DRUG|Nelistotug|Nelistotug will be administered.
223389168|NCT02829645|OTHER|Clinical assessment|Clinical assessment with questionnaires
223389169|NCT05843747|OTHER|Sampling|During thier bariatric surgery, samples of adipose tissue will be done
223389170|NCT06471374|BEHAVIORAL|Circadian rhythm assessment|Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.
223545925|NCT02568722|OTHER|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
224009076|NCT04557150|DRUG|Forimtamig|Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I.
224009077|NCT04824859|BEHAVIORAL|Behavioral|eGAP that allows patients to complete validated questionnaires, and these questionnaires will be summarized and recommendations provided to the treating team
224009078|NCT04876456|DRUG|Cabozantinib|Patients will be treated with Cabozantinib 60mg orally daily continuously until disease progression, unacceptable toxicity, or trial closure.
223389171|NCT06471374|BEHAVIORAL|Light sensitivity assessment|Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
223389172|NCT05851027|DRUG|QL0911|Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
224009079|NCT05745038|BEHAVIORAL|SONATA|The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
224009080|NCT02966665|OTHER|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
224126445|NCT05239286|DRUG|PVI dependant goal directed fluid therapy|"After the induction of anesthesia, Ringer solution infused at the dose of 2 ml/kg/h started as a basal rate of infusion. If the PVI was higher than 13% for more than 5 min, a 250-ml bolus of crystalloids administrated. If the PVI was still higher than 13% after the bolus, it was repeated every 5 min until the PVI was less than 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~In the cases where PVI was less than \< 13% and if MAP was below 30% of the baseline MAP of the patient 5 mg iv ephedrine was applied and repeated every 5 min to keep the MAP increased over 70% of baseline.~Then the patient was turned to prone position and the same steps according to Massimo readings were repeated."
224126446|NCT06829420|BEHAVIORAL|Mirror speech entrainment|Speech entrainment with the user's own voice using auditory-only and auditory-visual modalities.
224126447|NCT06829420|BEHAVIORAL|Traditional speech entrainment: auditory-only|Traditional speech entrainment (speech entrainment using an external agent's voice) using the auditory-only modality (users only listen and speak along to auditory stimuli)
224126448|NCT06829420|BEHAVIORAL|Traditional speech entrainment: auditory-visual|Traditional speech entrainment (speech entrainment using an external agent's voice) using the auditory-visual modality (users listen and speak along to both auditory and visual stimuli (mouth movements)
224296128|NCT03511170|DRUG|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
223389173|NCT01288404|DRUG|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
223389174|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
223389175|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
223389176|NCT01288404|DRUG|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
223389177|NCT06628804|DIETARY_SUPPLEMENT|Artemisia and green tea extracts|Artemisia and green tea extracts 700 mg/day for 8 weeks
224009081|NCT02966665|DRUG|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
224296129|NCT03511170|DRUG|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
223389178|NCT06628804|DIETARY_SUPPLEMENT|Placebo|Placebo 700 mg/day for 8 weeks
223389179|NCT03204448|DEVICE|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
223389180|NCT01649986|BEHAVIORAL|Non-pharmacologic intervention|Diet and physical exercise
223389181|NCT01649986|DRUG|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
223389182|NCT05114733|BEHAVIORAL|InVEST|Individualized vocational and educational support and training -- participant works with BA level school/ work coach for four months
223389183|NCT04970628|OTHER|Medical records collection|Patient's medical records before and after surgery.
223389184|NCT04718454|DEVICE|dental attachment|This research aimed to evaluate the retentive power and wear of the smart box attachment use with tilted two implant assisted mandibular overdenture
223389185|NCT04217954|DRUG|OXA, 5-FU and bevacizumab plus Toripalimab|"1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks."
223389186|NCT06187805|DEVICE|OSSIX Volumax|OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
223545926|NCT01062698|DRUG|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
224009082|NCT02966665|DRUG|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
224009083|NCT02966665|DRUG|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
224009084|NCT02966665|OTHER|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
224009085|NCT02966665|DRUG|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
224009086|NCT02966665|DRUG|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
224009087|NCT06972446|DRUG|Lutikizumab|Subcutaneous (SC) injection
224009088|NCT06972446|DRUG|Placebo|Subcutaneous (SC) injection
224009089|NCT06972446|DRUG|Ravagalimab|Subcutaneous (SC) injection
224009090|NCT05148962|BIOLOGICAL|GRT-R910|Injection administered intramuscularly
224296130|NCT03338179|BEHAVIORAL|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
224296131|NCT00838942|BEHAVIORAL|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
223389187|NCT04379427|DEVICE|Sanmina Biosensor|non-invasive blood glucose measurement using the Sanmina Biosensor referenced with the invasive reference blood glucose device YSI 2400 Plus.
224009091|NCT05806151|DIAGNOSTIC_TEST|Genetic and immunologic assessments|Definitive Local Therapies including surgery, radiotherapy, radio-frequency ablation of metastases.
224009092|NCT02595580|DEVICE|Glucopred|
224009093|NCT01200290|DRUG|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
224009094|NCT05838521|DRUG|Sacituzumab govitecan|This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).
224009095|NCT04199845|DIETARY_SUPPLEMENT|PS128|PS128 or placebo will be given twice daily for 8 weeks.
224009096|NCT03549390|BEHAVIORAL|Physical activity|Light-moderate intensity physical activities
224009097|NCT01144377|DRUG|LY2541546|Administered subcutaneously
223389188|NCT01370031|DRUG|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
223389189|NCT01370031|DRUG|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
223389190|NCT01370031|DRUG|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
223389191|NCT01370031|DRUG|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
223389192|NCT03768362|PROCEDURE|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
223389193|NCT03768362|PROCEDURE|Resection strabismus surgery|resection strabismus surgery
223389194|NCT02345876|OTHER|no intervention|
223389195|NCT03263676|DEVICE|Icon resuable underwear|Reusable incontinence underwear
224009098|NCT01144377|DRUG|Placebo|Administered subcutaneously
224009099|NCT05867277|OTHER|music|The students in the intervention group listened to music for 15 min before and during the peripheral intravenous catheter placement skill practice.
224009100|NCT05623696|DEVICE|Sham or actual non-invasive (Magnetic) brain stimulation|5 Hz rTMS applied using an actual or sham coil over the left or right DLPFC
224009101|NCT01640405|DRUG|modified FOLFOX6 + bevacizumab|"* Bevacizumab 5 mg/kg iv, day 1, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~* 5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~  * LV 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
224009102|NCT01640405|DRUG|FOLFOXIRI + Bevacizumab|"* Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~* LV 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
224296132|NCT04016337|DIETARY_SUPPLEMENT|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
224296133|NCT04710537|OTHER|AlloDerm|Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.
223389196|NCT03263676|DEVICE|Disposable pad|Standard market disposable pad
223389197|NCT06048276|DRUG|Herbal medicines (e.g., Yunkang granules, Duzhong granules)|Herbal medicines (e.g., Yunkang granules, Duzhong granules) exposure at the early gestation.
223389198|NCT02058329|OTHER|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
223389199|NCT05347329|DIETARY_SUPPLEMENT|Tongkat Ali Maca Plus|Tongkat Ali and Maca (Tongkat Ali: powdered extract 200 mg (from roots of Eurycoma longifolia Jack) + Maca: powdered extract 100 mg (from dried tuberous root of Lepidium meyenii).
223389200|NCT03623191|OTHER|Clinical examination|
224009103|NCT00151281|DRUG|PEPC|"Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC \< 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis"
224009104|NCT00151281|DRUG|Thalidomide|"Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)"
224009105|NCT00151281|DRUG|Rituximab|"Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
224009106|NCT05666921|OTHER|psychological assessment|The intervention consists in the assessment of some psychological aspects (emotional awareness, attachment style and the ability to abstract and symbolize (IQ)) of pediatric patients who present with somatic symptom disorders. , through specific tests. Each patient fills out the test battery during the psychological consult. At the same time, it is involved a parent to collect personal and clinical data through an ad hoc questionnaire.
224126449|NCT07077902|DRUG|Topical roflumilast 0.3% foam|Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis
224296134|NCT04710537|OTHER|DermACELL|Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
224296135|NCT03501537|PROCEDURE|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
223389201|NCT06398379|OTHER|Fecal Virome Transplantation|The primary steps of the production of fecal virome transplantation capsules is the same as when producing fecal microbiota transplantation capsules. Through an subsequent proces of filtering bacterial parts of the material are removed. The material, now called fecal virome transplanation material, has then been moved to capsules and stored in -80c untill use.
223389202|NCT06398379|OTHER|Fecal microbiota Transplantation|Donor fecal material is mixed with cryoprotectant and NaCl. Following processing the material transfered to capsules and is stored at -80c prior to use.
223389203|NCT00767403|BEHAVIORAL|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
223545927|NCT01062698|PROCEDURE|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
223545928|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
223545929|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
223545930|NCT02333812|OTHER|Stroboscopic nasopharyngeal laryngoscopy|
223545931|NCT01818843|OTHER|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
224126450|NCT07084740|DIAGNOSTIC_TEST|PeriCam and PeriFlux measurements|PeriCam and PeriFlux measurements
224126451|NCT07083895|BEHAVIORAL|Modified RICHH|"The RICHH intervention is an educational-behavioral and counseling intervention that promotes caregivers' knowledge, skills and motivation to engage in CVD risk reduction. The intervention is delivered individually to caregivers in their homes using video-conferencing technology on mini-iPads. The program consists of 12 weekly sessions \[30-45 minutes\] that will be held at the caregivers' preferred times. RICHH consists of 6 interactive modules (i.e., self-management for heart health, depressive symptom management, heart healthy eating, physical activity, co-morbid condition management, and adherence to medication and smoking cessation).~The modified RICHH intervention utilizes focus group outcomes to employ modifications needed to target custodial grandparents from varied backgrounds (e.g., high ACEs, SDoH groups)."
224126452|NCT07083895|BEHAVIORAL|Standard of Care (SOC)|Referral to primary care provider
223545932|NCT04475107|DRUG|Pyronaridine-Artesunate|Pyramax
223545933|NCT04475107|DRUG|Placebo|Placebo
223730277|NCT03807869|PROCEDURE|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
223730278|NCT00848081|DRUG|Tadalafil|5 mg taken by mouth once daily for 12 weeks
223730279|NCT00848081|DRUG|Placebo|By mouth once daily for 12 weeks
223730280|NCT03032731|BEHAVIORAL|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
223730281|NCT03032731|OTHER|Control|Standard, publicly available NHS resources for healthy lifestyles.
224009107|NCT06464549|DIAGNOSTIC_TEST|EEG-EOG recording at rest and during an auditory oddball paradigm|Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
224009108|NCT04150068|DRUG|Oral Lenacapavir|Tablets administered without regard to food
224009109|NCT04150068|DRUG|Oral Lenacapavir Placebo|Tablets administered without regard to food
224009110|NCT04150068|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
224009111|NCT04150068|DRUG|Failing ARV Regimen|Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
224009112|NCT04150068|DRUG|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
224009113|NCT06455787|DEVICE|J-Valve Transfemoral (TF) System|Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.
224009114|NCT04112667|OTHER|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
224009115|NCT04112667|OTHER|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
224009116|NCT04112667|OTHER|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
224009117|NCT05760001|OTHER|Assigned Interventions|"Financial well-being interventions:~• Tax preparation; access to public benefits; financial counseling and microgrants~Place-based interventions:~• Vacant lot greening; abandoned house remediation; trash cleanup; tree planting"
224009118|NCT04816591|DEVICE|Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System|Standard of Care Surgery + Embolization
224009119|NCT04816591|OTHER|Standard of Care Surgery|Standard of Care Surgery Only
224009120|NCT04816591|DEVICE|Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System|Standard of Care Medical Management + Embolization
224009121|NCT04816591|OTHER|Standard of Care Medical Management|Standard of Care Medical Management Only
224009122|NCT06357533|DRUG|Datopotamab Deruxtecan|Datopotamab Deruxtecan IV (intravenous)
224009123|NCT06357533|DRUG|Rilvegostomig|Rilvegostomig IV (intravenous)
224126453|NCT07083427|OTHER|CAPA-IVM|In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
224126454|NCT07085052|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|10-week online MBSR program, involving 10 weekly 2.5-hour group sessions, a day-long online retreat, and approximately 45 minutes of home practice assignments six days per week.
224299274|NCT04229524|PROCEDURE|Fluorescence angiography|After the tube and stomach were made during surgery, the predetermined anastomosis position was marked with sutures in advance according to the doctor's experience, and then 0.04ml / kg indocyanine green injection was injected into the central vein. Next, dynamic observation and recording of the tube-gastric anastomosis area in 136 seconds using a fluorescent imaging system with a fixed focal length till the fluorescence reaching range and intensity. If the average value of the fluorescence value of the anastomosis position is greater than 30, then the anastomosis position may be according to the original plan or moved to the proximal part. If the average fluorescence value of the predetermined anastomosis position is less than 30, the anastomosis must move to proximal part ensure anastomosis with fluorescence value at least\> 30.
224009124|NCT06357533|DRUG|Pembrolizumab|Pembrolizumab IV (intravenous)
224009125|NCT06138067|BEHAVIORAL|High intensity approach|PEM, cancer center support services material, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the participants appointment with the medical oncologist. If enrolled in a clinical trial, the patient navigator will call the participant biweekly, or more often if they are working to resolve any needs identified in the needs assessment) until the participant is successfully enrolled in the therapeutic clinical trial. The patient navigator will call the participant once weekly for 4 weeks, or less than 4 weeks in other cases including withdrawal from the clinical trial or this navigation study, disease progression, or death. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
224009126|NCT06138067|BEHAVIORAL|Low intensity approach|The participant will receive PEM, and community resources and services available to cancer patients material. The PEM will be reviewed with the patient navigator before the appointment with the medical oncologist. The patient navigator will call the participant 4 weeks after enrollment on the trial. The participant will receive a call 3 months after enrollment on the therapeutic clinical trial to complete the Exit Questionnaire
224009127|NCT06818643|BIOLOGICAL|MK-3120|IV infusion
224009128|NCT06817668|RADIATION|ePURT 5Gy x 5 fractions with single HDR boost of 15Gy|ePURT 5Gy x 5 fractions delivered on noncontiguous weekdays with single HDR boost of 15Gy.
224126455|NCT07083778|PROCEDURE|Laser Fistula Surgery (FiLaC - Fistula-tract Laser Closure)|A minimally invasive procedure using a radial fiber diode laser probe to ablate the fistula tract. Laser energy (10W in pulsed mode) is applied circumferentially as the probe is slowly withdrawn, leading to shrinkage and closure of the fistula tract. The internal opening is closed with absorbable sutures. The procedure is done under spinal or general anesthesia.
223389204|NCT00767403|BEHAVIORAL|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
224009129|NCT06784466|DEVICE|Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System|Ablation using the Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
224009130|NCT06471361|DRUG|Zilucoplan|Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
224009131|NCT06896669|DIETARY_SUPPLEMENT|vitamin D3|600IU of vitamin D3 and 1.5 to 2g of calcium will be provided for time period of 6 weeks once daily. In addition, Participants dietary intake will be assessed through 24 hours dietary recall.
223389205|NCT00767403|BEHAVIORAL|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
224009132|NCT07136077|DRUG|Tislelizumab|Given by IV
224009133|NCT07136077|DRUG|Fruquintinib|Give by PO
224009134|NCT05304767|DRUG|Xanomeline and Trospium Chloride Capsules|KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
224009135|NCT06223568|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 will be administered over 60 (+/-10) minutes.
224009136|NCT06223568|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 will be administered over 120 (+/-10) minutes.
224009137|NCT06223568|DRUG|PRGN-2009|PRGN-2009 will be administered in Arm 2 participants only as an SQ injection in the arm at a dose of 1 mL nominally containing 5x10\^11 viral particles (VP) on Day -7 (+/-3 days) of Cycle 1, Day 11 (+/-3 days) of Cycles 1, 2, and 3.
224009138|NCT07115576|PROCEDURE|Radiofrequency ablation alone|Radiofrequency ablation (RFA) is a minimally invasive procedure used to treat benign thyroid nodules without surgery. It involves inserting a thin, needle-like electrode into the nodule under ultrasound guidance. Using high-frequency alternating current, the electrode generates heat to destroy targeted thyroid tissue, causing the nodule to shrink over time.
224009139|NCT07115368|DRUG|GS-1219|Administered orally
224009140|NCT07115368|DRUG|BVY|Administered orally
224009141|NCT07115368|DRUG|Standard of Care|Antiretroviral therapy, administered orally non nonnucleoside reverse transcriptase inhibitor (NNRTIs), examples: ABC/ DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
224009142|NCT06919003|BIOLOGICAL|Berinert|Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
224009143|NCT06919003|OTHER|Placebo for Berinert|Administered as a 10 ml renal artery infusion approximately 1-2 hours before implantation and reperfusion of the allograft
224009144|NCT07124650|DRUG|Hydrocortisone Acetate 1% Ointment|Endotracheal tubes will be coated with 1% hydrocortisone acetate ointment prior to intubation. The ointment will be applied uniformly to the outer surface of the tube. This intervention aims to reduce postoperative throat inflammation and pain.
224009145|NCT07124650|DRUG|Lidocaine hydrochloride 0,05% with chlorhexidine|Endotracheal tubes will be treated with 0.05% lidocaine hydrochloride solution combined with chlorhexidine (Cathejell). The solution will be applied to the tube surface before intubation to provide local anesthesia and reduce postoperative throat discomfort.
224126456|NCT07083778|PROCEDURE|Open Fistula Surgery (Fistulotomy, Fistulectomy, or LIFT Procedure)|"Patients in this group will undergo standard open surgical treatment for fistula-in-ano. Based on the type and location of the fistula (intersphincteric or transsphincteric), the surgical procedure may be:~* Fistulotomy: Laying open the fistula tract.~* Fistulectomy: Excision of the entire fistulous tract.~* LIFT Procedure: Ligation of the intersphincteric fistula tract, preserving the sphincter complex. This sphincter-sparing technique is chosen for transsphincteric fistulas when appropriate.~All procedures are performed under spinal anesthesia. The choice of technique is individualized based on MR fistulogram findings and intraoperative assessment. Wounds are managed with regular dressings and allowed to heal by secondary intention. Standard postoperative care includes antibiotics, analgesia, and sitz baths. Follow-up is done at 1 week, 1 month, 3 months, and 6 months."
224126457|NCT06635629|DRUG|Desmopressin|Stimulates ACTH release in Cushing disease
224126458|NCT06635629|DRUG|Dexamethasone|Inhibits ACTH release in Cushing disease and healthy volunteers
223730282|NCT01739478|OTHER|Packing of abscess cavity|
223730283|NCT01739478|OTHER|External dressing|Application of external dressing whilst abscess cavity heals
224009146|NCT06931093|BEHAVIORAL|Group Guided Written Exposure Therapy for CPTSD (GWE-C)|"Group Guided Written Exposure Therapy for CPTSD (GWE-C) is a manualized, exposure-based therapeutic program consisting of 7 to 10 sequential sessions. The intervention follows a structured sequence of trauma processing that addresses trauma details, associated emotions, cognitions, and impacts. Writing tasks incorporate imagery dialogues, self-compassion exercises, and resource identification to help participants alleviate C-PTSD symptoms.~The interval between two consecutive sessions ranges from 0 to 2 days, with participants expected to complete all sessions within 1 to 2 weeks. The first and last sessions are scheduled to last 1.5 hours each, while the intermediate sessions are 60 minutes in duration. Each group will consist of 6 to 10 participants and will be facilitated by one counselor and one assistant."
224009147|NCT06931093|BEHAVIORAL|Supportive counselling|Supportive counselling, the comparator intervention, is a non-trauma-focused treatment based on the Rogerian psychotherapy model and has been used as an active comparator in previous trials of trauma-focused therapies. The program comprises seven sessions: the first two employ group activities such as card games and interactive drawing to build a sense of belonging; sessions three to six focus on stress management and emotion regulation skills through methods including expressive drawing, relaxation training, and resource identification; the final session emphasizes reflection and sharing. Throughout, counsellors provide supportive guidance to encourage emotional expression, mutual listening, and peer support, while discussions deliberately exclude participants' individual traumatic experiences.
224009148|NCT06944379|DRUG|ORKA-002|ORKA-002 is supplied as sterile solution to be administered by SC injection
223389206|NCT00006038|DRUG|cisplatin|
223389207|NCT00006038|DRUG|docetaxel|
223389208|NCT00006038|DRUG|floxuridine|
224009149|NCT06944379|OTHER|Placebo|Placebo solution to be administered at a matching volume by SC injection
224009150|NCT06939478|DEVICE|Arrhythmia Mapping|vMap is indicated for analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.
224009151|NCT07184983|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (19 minutes), and then ramp down (for 30 seconds) at the end.
224126459|NCT06931041|DRUG|insulin lispro|1 UI/ml of insulin added to the autologous serum formulation.
224126460|NCT06931041|OTHER|Autologous serum|Autologous Serum
223389209|NCT00006038|DRUG|fluorouracil|
223389210|NCT00006038|DRUG|leucovorin calcium|
224009152|NCT07184983|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 18 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end.
224009153|NCT07184983|BEHAVIORAL|Mindfulness meditation|Participants will follow an audio track for guided mindfulness during the stimulation.
223389211|NCT00006038|PROCEDURE|conventional surgery|
223389212|NCT05873790|DRUG|Serplulimab plus chemotherapy|"Serplulimab: 4.5 mg/kg via intravenous infusion on Day 1 of each 21-day cycle. Chemotherapy drugs: etoposide + carboplatin/cisplatin Etoposide: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Carboplatin: 300 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles.~Cisplatin: 75 mg/m2 via intravenous infusion, administered in 3-week (21 days) cycles for a maximum of 6 cycles."
224009154|NCT07195032|DRUG|Commercial measles, mumps, and rubella (MMR) vaccine|Participants will receive the commercial MMR vaccine if they are deemed eligible for the study.
224009155|NCT07194421|OTHER|Sunscreen RV4620A RP2552|Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon.
223389213|NCT01245283|OTHER|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
223389214|NCT01245283|OTHER|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
223730284|NCT02753101|DRUG|[18F]-FTC-146|10 mCi± 1 mCi of \[18F\]FTC-146 intravenously
224009156|NCT07194174|OTHER|Strength exercise|3 weekly supervised trainings with specific strengt exercises
224009157|NCT02952118|DEVICE|Forrest Snoring device|
224009158|NCT00770705|DRUG|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
224009159|NCT00770705|OTHER|Standard surgical approach|Historical controls
224009160|NCT04399070|DRUG|S-ketamine|The depression patients received propofol and S-ketamine before ECT
224009161|NCT04399070|DRUG|ketamine|The depression patients received propofol and ketamine before ECT
224009162|NCT04399070|DRUG|saline|The depression patients received propofol and saline before ECT
224009163|NCT00530140|BIOLOGICAL|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
224009164|NCT04565093|PROCEDURE|iPACK|"Interspace between the popliteal artery and the capsule of the posterior knee (iPACK):~This is basically ultrasound guided peripheral nerve block performed by the anesthesiologists at the posterior side of the knee to control pain after TKA."
224009165|NCT04565093|PROCEDURE|Periarticular local infiltration analgesia (LIA)|A mixture of Bupivacaine 0.25% 20 ml + epinephrine 100 mics ± lornoxicam 8 mg ± morphine 10 mg ± tranexamic acid 1 gm in 40 ml normal saline (NS) will be injected into the posterior capsule and the medial and lateral ligaments just before implantation: after insertion of the implants and into the capsule and retinacular tissues. The remaining solution (approximately 20 mL) will be used to infiltrate the muscle and subcutaneous tissues. This intervention is commonly performed by the operating orthopedic surgeon to control pain after TKA.
224009166|NCT03388697|DIAGNOSTIC_TEST|Quantose IR and Quantose IGT analysis|Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).
224009167|NCT03388697|DIAGNOSTIC_TEST|HOMA IR the standard testing for insulin resistance|Testing using HOMA IR: Investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing. The investigators will be using the following computation to calculate HOMA.
224009168|NCT04242836|DIAGNOSTIC_TEST|MNREAD testing|One randomly selected eye is included for each study participant. Participants respond to the near vision chart with defined environmental circumstances at 40cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.
223389215|NCT01245283|OTHER|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
224126461|NCT06929351|PROCEDURE|otago exercise|"Otago exercise program group 40 min/ thrice a week/ 8 weeks~1st week strengthening of knee flexors( prone lying), extensors ( in sitting) ,abductors( in standing) with 1-2 kg ankle cuff. Dorsi flexors, planter flexors(in standing on weight)/ hold 5-10 sec 5 reps/ 2 sets 2nd week Strengthening same as week 1 balance exercises.Knee bending( standing),tandem stance,sit to stand / with support/ 5-10 reps/2 sets 3rd week strengthening of all above Ms group with increase weight 2-3 kg ankle cuff or participant (The exercises are of moderate intensity; the person should not get unduly tired) balance exercise as 2nd week 4th week strengthening exs as in 3rd week balance exs: Knee bending, tandem stance( without support), forward walk,walking and turning around, side walk, one leg stand,sit to stand, stair climb( all with support)/5-10 reps 5th week strengthening exs of above ms group increase either weight 3-4 kg or repetitions 10-15 or hold time 10-15 sec 6th week strengthening same as 5"
224009169|NCT05999695|OTHER|self-management|"The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts."
224009170|NCT05999695|OTHER|regular care|"gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text."
224009171|NCT00689975|BEHAVIORAL|behavioral dietary intervention|
224126462|NCT06929351|PROCEDURE|Dual task exercise|"Balance exercises and secondary cognitive task simultaneously 40 min/ thrice a week/ 8 weeks~1. st week Balance exercises: Narrow-base standing on the floor (firm surface) with eyes open and closed, Tandem standing on the floor with eyes open and closed, Single-leg standing on the floor with eyes open and closed, Wide-base walking on the floor, Chair sitting to standing transfer Cognitive tasks: Naming a group of cities; foodstuff; boy names; or girl names starting with A,I, S, and T sounds/ 3 trails~2. nd week Balance exercise: Narrow-base standing on the floor with open eyes while moving arms, Forward lunge standing on the floor with eyes open, Narrow-base walking on the floor, keeping balance while sitting on a ball and moving arms in different directions Cognitive task: Backward counting from 50,Count by multiple(3,6,9…….)/3trails Week 3 Balance exercises: Narrow-base standing on a foam with eyes open and closed, Tandem standing on a foam with eyes open and closed, Backward walking on"
224126463|NCT06929208|DEVICE|Electrocardiogram (ECG) monitor|"A novel AI-based risk stratification algorithm incorporated into portable platform will be used to monitor and measure patient's ECG, blood pressure, SpO2, and HRV parameters. The platform comprises a tablet application that the clinicians interface with, and coupled with a patient monitoring device with the app that received the real-time patient vital signs to be processed. It requires only a 5-minute 12-lead ECG recording and provides a diagnostic report and risk score on major adverse cardiac events in patients with chest pain complaints. The device is approved as a Class C Medical device by Health Science Authority Singapore for clinical use in Singapore.~Three ECG samples for HRV data will be recorded before, during and after music listening, with a sampling rate of 1000Hz, 5-10-minute duration in the supine position and breathing spontaneously to minimise influence from external factors."
224126464|NCT06929208|OTHER|Music listening|Patients will be given a mobile phone to choose their preferred music to be played during surgery. The music list contains songs across pre-saved playlists spanning different music genres compiled by the institution's music therapist to ensure adequate coverage of the various music genres and to promote relaxation and serenity.
224126465|NCT06018025|DRUG|CGRP antibody|treatment with CGRP antibody for 4 months
224126466|NCT06892756|DRUG|CHF6001 dry powder inhaler (DPI)|CHF6001 DPI single dose administration followed by a 14 to 17-day wash-out period before Treatment Period 2
224299275|NCT05628519|BEHAVIORAL|Captain Sonar Exposition|Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
223389216|NCT00091611|DRUG|IL-2 (interleukin-2)|
224009172|NCT00689975|BEHAVIORAL|exercise intervention|
224126467|NCT06892756|DRUG|Cyclosporine|Oral cyclosporine single dose administration
224126468|NCT06892756|DRUG|CHF6001 DPI|CHF6001 DPI single dose administration after oral cyclosporine single dose administration
224126469|NCT07084376|OTHER|Enhanced Educational Program for Intermittent Catheterization|Participants in this group receive an enhanced educational program for intermittent catheterization (IC), including an informational booklet, a specifically designed video tutorial, and standard clinical practice training. The program aims to improve psychological acceptance, adherence, and self-efficacy by providing comprehensive and patient-centered educational materials in addition to standard care.
224299276|NCT05628519|BEHAVIORAL|Monopoly Exposition|Participant will be invited to play to Monopoly during 60 min
224299277|NCT00242619|DRUG|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
224299278|NCT02143635|DRUG|HDM201|
223389217|NCT00091611|DRUG|OKT3|
223389218|NCT00091611|DRUG|Cyclophosphamide|
223389219|NCT00091611|DRUG|Fludarabine|
223389220|NCT00091611|DRUG|Mesna|
223389221|NCT03672227|BEHAVIORAL|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
223389222|NCT07057557|OTHER|Aloe Vera Gel Dressing|Participants in this arm will receive Aloe Vera gel applied directly to the split-thickness skin graft (STSG) donor site immediately after graft harvesting. The Aloe Vera gel will be applied in a sterile manner, followed by secondary dressing with dry gauze and crepe bandage. Pain will be assessed on postoperative day 7 using the Visual Analogue Scale (VAS).
224009173|NCT00689975|OTHER|counseling intervention|
224009174|NCT00689975|OTHER|flow cytometry|
224009175|NCT00689975|OTHER|immunoenzyme technique|
224009176|NCT00689975|OTHER|laboratory biomarker analysis|
224009177|NCT00689975|PROCEDURE|complementary or alternative medicine procedure|
224009178|NCT00689975|PROCEDURE|standard follow-up care|
224009179|NCT03930290|DIAGNOSTIC_TEST|Vaginal tactile imager|Vaginal elasticity evaluation by vaginal tactile imaging analysis.
224009180|NCT05261919|PROCEDURE|Acupuncture manipulation|The investigator used directional supplementation and draining manipulation. The supplementation manipulation is defined as the angle of needle insertion to skin as 45 degrees with the needle tip in the same direction as the meridian. While the draining manipulation is defined as the angle of needle insertion at 45 degrees with the needle tip direction opposite to that of the meridian.
224009181|NCT03646591|DRUG|Chemotherapy|Patients will receive four cycles of the standard dose of FLOT chemotherapy prior to curative gastrectomy. And four cycles of the FLOT chemotherapy is recommended after surgery. Preventive antiemetic and dexamethasone are allowed before chemotherapy, growth factor, or other supportive medicines are allowed for treatment only. Surgical intervention is allowed for acute bleeding or other surgical emergencies.
224009182|NCT00197587|DRUG|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
224009183|NCT00197587|DRUG|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
224009184|NCT03022253|BIOLOGICAL|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~1. PDA closes or~2. A maximum of 120 hours after the point of randomisation"
224009185|NCT03022253|BIOLOGICAL|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:~(i) Platelet count is \< 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count \< 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count \< 1, 00,000 per microliter and requires a neurosurgical procedure"
224009186|NCT03022253|DRUG|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
224009187|NCT03022253|DRUG|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
224126470|NCT07084376|OTHER|Standard Education Group|Participants in this group will receive standard clinical practice training for intermittent catheterization (IC), as routinely provided in participating healthcare centers. This training focuses on basic procedural skills and practical education necessary to perform IC independently, without additional enhanced educational materials such as booklets or video tutorials.
224009188|NCT02717351|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-07)
224009189|NCT04585854|OTHER|Caffeine|Consumption of 3 shots of espresso
224009190|NCT01451892|OTHER|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
224009191|NCT01451892|OTHER|patient education|overweight individuals participating in a patient education program
224126471|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Containing Milk|"Participants will be asked to drink 1% regular milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
224299279|NCT02143635|DRUG|ancillary treatment|
224299280|NCT02637921|OTHER|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
224299281|NCT02637921|OTHER|Ambulatory|Participants hava a standardized activity level throughout the intervention
224299282|NCT02637921|OTHER|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
223730285|NCT03590587|DRUG|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
223730286|NCT03590587|DEVICE|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
224009192|NCT02480959|PROCEDURE|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
224009193|NCT04838951|DEVICE|ENDO-AID CADe|ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
224009194|NCT01276938|RADIATION|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
224009195|NCT01276938|RADIATION|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
224009196|NCT00886496|BIOLOGICAL|recombinant human mannose-binding lectin|
224009197|NCT04576403|DEVICE|activated mittens|activated mittens (with electronic heat)
224009198|NCT04576403|DEVICE|deactivated mittens|deactivated mittens (without electronic heat)
224009199|NCT05442905|DRUG|propofol|Anesthesia will be induced with propofol 2-3mg/kg
224009200|NCT05442905|DRUG|Atracurium Besylate|Atracurium 0.15mg/kg used for muscle relaxation before intubation
224009201|NCT05442905|DRUG|sevoflurane|sevoflurane(1%-2%) used during anesthesia
223389223|NCT07057557|OTHER|Paraffin-Based Tulle Dressing|Participants in this arm will receive a conventional paraffin-based tulle dressing impregnated with chlorhexidine applied to the STSG donor site. The dressing will be followed by secondary coverage with dry gauze and crepe bandage. Pain will be assessed on postoperative day 7 using the Visual Analogue Scale (VAS).
223545934|NCT01102920|BEHAVIORAL|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
223545935|NCT01102920|DEVICE|CPAP|CPAP-treatment as usual (during nights)
223545936|NCT06173505|COMBINATION_PRODUCT|Vudalimab + Carboplatin + Pemetrexed|Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous
223545937|NCT06173505|COMBINATION_PRODUCT|Pembrolizumab + Carboplatin + Pemetrexed|Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
224009202|NCT06431100|BIOLOGICAL|TCR T-cells|The strengthened T cells are re-infused into the patient to achieve the killing effect
224009203|NCT01316406|DRUG|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
224009204|NCT03603249|DRUG|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in \>80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several-not yet fully understood-mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
224009205|NCT00039312|OTHER|Papanicolaou test|
224009206|NCT00039312|OTHER|cytology specimen collection procedure|
224126472|NCT06513026|DIETARY_SUPPLEMENT|Lactose-Free Milk|"Participants will be asked to drink 1% lactose-free milk for 12 weeks as follows:~* Weeks 1-4: ½ cup milk per day~* Weeks 5-8: 1 cup milk per day~* Weeks 9-12: 2 cups milk per day~Participants will continue drinking 2 cups milk/day for 2 weeks after the 12-week follow-up visit."
224126473|NCT04649528|BEHAVIORAL|Effective endurance 4x4 training - Supervised|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
224126474|NCT04649528|DEVICE|Effective endurance 4x4 training - APP|Exercise intervention utilizing 4x4min aerobic high-intensity interval training
223389224|NCT01610492|DRUG|belimumab|10mg/kg administered intravenously
223545938|NCT03552016|DRUG|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
223545939|NCT00066053|PROCEDURE|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
224126475|NCT07084454|OTHER|GAIN-S Multidisciplinary Telehealth Intervention|This intervention delivers a comprehensive geriatric assessment (GA) via telehealth to older adults with cancer. Based on the GA results, a multidisciplinary team including oncologists, geriatricians, psychiatrists, psychologists, nutritionists, and certified fitness trainers provide personalized supportive care recommendations and consultations remotely. The goal is to improve physical function, reduce depressive symptoms, and enhance quality of life during cancer treatment.
224296136|NCT06107478|OTHER|Self-report questionnaires (only for parents)|"Quantitative part (all investigating centers): When they come to the various timepoints (T0, T1, T2), participants will be asked to fill in self-questionnaires, either electronically or on paper. If they are unable to come to the center at T1 and/or T2, they will be offered the option of completing the self-questionnaires online. These can also be sent by e-mail or postal mail and received by the same means if necessary.~The tools:~* Quality of life: Pediatric Quality of Life Inventory~* Anxiety: Edmonton Symptom Assessment System; Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Scale~* Depression: Edmonton Symptom Assessment System; PROMIS depression scale~* Parent-child relationship: Ad hoc questionnaire~* Parent-caregiver relationship: Enabling Practices Scale Socio-demographic data on parents and children, data relating to supportive care will be collected at inclusion. Massage habits will be collected at T1 and T2."
224299283|NCT02637921|OTHER|Bed Rest|Participants remain on supine bed rest throughout the intervention
223389225|NCT06054321|DRUG|stepwise pharmacotherapy|In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
223389226|NCT06054321|DRUG|antidepressant monotherapy group|In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
223545940|NCT00066053|PROCEDURE|Referral|
223545941|NCT06473051|OTHER|Original set|The original set of implementation strategies will include the same strategies as applied in the INTERCARE study by the research group but will be updated to fit the current practice field.
223545942|NCT06473051|OTHER|Adapted set|The adapted set of implementation strategies will contain similar implementation strategies that are expected to achieve the same outcomes as the first set, but with less resources required (for instance, by providing group coaching sessions rather than single sessions).
223545943|NCT05575466|DIAGNOSTIC_TEST|Blood samples|Hemostatic biomarkers
223545944|NCT05575466|DIAGNOSTIC_TEST|Questionnaires|Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
223730287|NCT00310128|DRUG|cisplatin|
223730288|NCT00310128|DRUG|cytarabine|
223730289|NCT00310128|DRUG|etoposide|
223730290|NCT00310128|DRUG|methylprednisolone|
223730291|NCT00310128|DRUG|rituximab|
223730292|NCT00310128|DRUG|yttrium Y 90 ibritumomab tiuxetan|
224009207|NCT00039312|PROCEDURE|annual screening|
224009208|NCT00039312|PROCEDURE|colposcopic biopsy|
224009209|NCT00039312|PROCEDURE|comparison of screening methods|
224009210|NCT03829475|DRUG|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
224009211|NCT03829475|DRUG|Placebo|placebo is an infusion of normal saline.
224009212|NCT03829475|DRUG|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
224009213|NCT04978272|DRUG|Dihydroartemisinin-piperaquine (DP)|Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
224009214|NCT04978272|OTHER|DP Placebo|Placebos will be identical appearance to DP.
224009215|NCT03472053|DRUG|BIO-11006 plus standard of care|BIO-11006 is administered 125mg BID plus standard of care.
224009216|NCT03472053|DRUG|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
224009217|NCT04500249|DRUG|infiltration rescue intraoperative analgesia|in the case of intraoperative pain perception, rescue infiltration analgesia using 1 % lidocaine administered by the operator into the operation field.
224009218|NCT04500249|DRUG|rescue IA|in the case of intraoperative pain perception, rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist
224126476|NCT07084454|OTHER|Standard Oncology Care|Participants receive the usual oncology care provided by their treating physicians without a structured geriatric assessment-driven intervention. Geriatric assessment results are shared with the treating oncologist, who may refer patients to supportive care services based on clinical judgment. No coordinated multidisciplinary telehealth intervention is provided.
224126477|NCT02859545|BEHAVIORAL|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
224126478|NCT02859545|BEHAVIORAL|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
224126479|NCT06766500|DRUG|Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets|1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablet
224126480|NCT06766500|DRUG|Synjardy® 5 mg/850 mg film-coated tablets|1 tablet of Empagliflozin+Metformin 5 mg/850 mg filmcoated tablets
224126481|NCT06893653|DEVICE|Focal muscle vibration|FMV will be applied to the muscle belly along with the conventional physical therapy
224126482|NCT06893653|DEVICE|tDCS|tDCS will be applied to M1 area of brain along with the conventional physical therapy
224009219|NCT04500249|DRUG|rescue antyhypertensive medication|in the case of intraoperative hypertension reluctant to rescue analgesia, rescue intravenous antihypertensive medication using 10 mcg of urapidil will be administered by anaesthesiologist
224009220|NCT04500249|DRUG|rescue antyemetic medication|in the case of postoperative nausea and vomitting, rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist
224126483|NCT06893653|OTHER|Physical Therapy|Conventional physical therapy will be provided
224126484|NCT06893653|DEVICE|Focal muscle vibration & tDCS|Focal muscle vibration with tDCS and conventional physical therapy will be provided.
224126485|NCT07084519|RADIATION|hypofractionated radiotherapy|43.5 Gy in 15 fractions (2.9 Gy/fraction, 3 weeks)
224126486|NCT07084519|RADIATION|conventional fractionated radiotherapy|50 Gy in 25 fractions, 2 Gy/fraction, 5 weeks
224296137|NCT06107478|OTHER|Interview (only for parents)|"Qualitative part (exclusively at CLB):~Participants (parents) in the qualitative part of the study will be asked to complete a self-administered questionnaire on socio-demographic data when they come to the center at T0. Clinical data will also be collected at T0. At T1, an interview will be organized with a researcher dedicated to the study. Qualitative interviews will preferably take place face-to-face, although videoconferencing may be used in certain circumstances."
224296138|NCT06107478|OTHER|Clinical data collection (only concerning Children)|The children's medical data (patients) will be collected in a Case Report Form (CRF; e.g. type of cancer, date of diagnosis, anti-cancer treatments received, symptoms) at T0.
223389227|NCT06753955|DRUG|ART5803|A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
223389228|NCT06753955|DRUG|Intravenous immunoglobulin (IVIG)|Administered as background treatment prior to the investigational product
223389229|NCT01982955|DRUG|Tepotinib|Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.
224009221|NCT04500249|DRUG|rescue antyhypotensive medication|in the case of intraoperative hypotension, rescue intravenous antihypotensive medication using 10 mg of ephedrine will be administered by anaesthesiologist
223730293|NCT00310128|PROCEDURE|antibody therapy|
224009222|NCT04500249|DRUG|rescue antyhypotensive medication|in the case of intraoperative bradycardia, rescue intravenous antihypotensive medication using 500 mcg of atropine will be administered by anaesthesiologist
224009223|NCT00836745|OTHER|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
224126487|NCT07094204|DRUG|ASP5834|Intravenous infusion
224126488|NCT07094204|DRUG|panitumumab|Intravenous infusion
224126489|NCT06926140|DEVICE|Acupuncture|Both groups have a standard anti-tumor Western medical treatment regimen (PD-1/PD-L1 inhibitor combined with chemotherapy); the acupuncture group is combined with acupuncture treatment. The day of starting antitumor treatment for each cycle was D1; D1-D5 was performed by the investigator on the patient for 2 times of acupuncture treatment, once a day; D8-D13 and D15-D20 were operated by patients or family members, and the investigator remotely assisted via video to complete the press needle treatment 4 times each, once a day, for four consecutive synergistic cycles, for a total of 24 times. The main acupuncture points are Guanyuan (Ren Mai 4), Shangyintang (EX-HN3), Taiyang (EX-HN5), Taichong (Liv-3), Zusanli (ST-36), and Xin (CO-15).
223389230|NCT01982955|DRUG|Gefitinib|Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
223389231|NCT01982955|DRUG|Pemetrexed|Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
223389232|NCT01982955|DRUG|Cisplatin|Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
223389233|NCT01982955|DRUG|Carboplatin|Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
223545945|NCT06293937|BEHAVIORAL|Numerical label|Labels that list the amount and percent of daily value of added sugar, sodium, or saturated fat, modeled after Guideline Daily Amounts labels.
223545946|NCT06293937|BEHAVIORAL|Interpretive text-only label|Interpretive text-only labels that state when a product contains high amounts of added sugar, sodium, or saturated fat.
224009224|NCT02060539|DEVICE|Biofinity XR|
224009225|NCT00082940|BIOLOGICAL|denileukin diftitox|
224126490|NCT06926140|DEVICE|Sham Comparator|Both groups have a standard anti-tumor Western medical treatment regimen (PD-1/PD-L1 inhibitor combined with chemotherapy); the sham acupuncture group is combined with sham acupuncture treatment. The day of starting antitumor treatment for each cycle was D1; D1-D5 was performed by the investigator on the patient for 2 times of sham acupuncture treatment, once a day; D8-D13 and D15-D20 were operated by patients or family members, and the investigator remotely assisted via video to complete the sham press needle treatment 4 times each, once a day, for four consecutive synergistic cycles, for a total of 24 times. The main acupuncture points are Guanyuan (Ren Mai 4), Shangyintang (EX-HN3), Taiyang (EX-HN5), Taichong (Liv-3), Zusanli (ST-36), and Xin (CO-15).
224126492|NCT07102121|PROCEDURE|luting material applaication with Modified Glass Ionomer Cement (RMGIC)|The intervention involves the use of two different types of luting cements-resin-modified glass ionomer cement (RMGIC) and conventional glass ionomer cement (GIC)-for the cementation of fixed dental prostheses. The objective is to compare post-cementation sensitivity between the two materials. All clinical procedures, including tooth preparation, isolation, and cementation, will follow standardized protocols. Sensitivity will be measured using the Visual Analog Scale (VAS) at 24 hours and 7 days post-procedure. The study will maintain consistency across both groups, with the only variable being the type of cement used.
224126493|NCT01996345|PROCEDURE|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
224126494|NCT06797063|BEHAVIORAL|BEST4Baby|BEST4Baby consists of prenatal and post-delivery breastfeeding education and support for mothers provided by community-based peer counselors who are trained in a modified 5-day WHO/UNICEF Breastfeeding Counselling Course and supported by an mHealth application.
224009226|NCT04844619|DRUG|4mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
224296139|NCT04888676|PROCEDURE|Class II Restoration|A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
224296140|NCT00480623|DRUG|Satraplatin plus radiation therapy|
224299284|NCT02637921|OTHER|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
223389234|NCT02449850|OTHER|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
224009227|NCT04844619|DRUG|16mg/ml KDR2-2 suspension eyedrop|"KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eyedrop is developed for the treatment of iris neovascularization."
224009228|NCT05183126|DRUG|Paclitaxel|Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
224009229|NCT05183126|DRUG|Paclitaxel|"Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time."
224009230|NCT05458947|PROCEDURE|pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing
224009231|NCT05458947|PROCEDURE|electrical stimulation (ES)|high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
223545947|NCT06293937|BEHAVIORAL|Interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon.
223545948|NCT06293937|BEHAVIORAL|Separated interpretive magnifying glass icon label|Interpretive labels that state when a product contains high amounts of added sugar, sodium, or saturated fat, containing a magnifying glass icon. Each nutrient will be on a separate label.
223730294|NCT00310128|PROCEDURE|biological therapy|
223730295|NCT00310128|PROCEDURE|chemotherapy|
223730296|NCT00310128|PROCEDURE|monoclonal antibody therapy|
223730297|NCT00310128|PROCEDURE|radiation therapy|
223730298|NCT00310128|PROCEDURE|radioimmunotherapy|
223730299|NCT00310128|PROCEDURE|radioisotope therapy|
223730300|NCT05264077|DRUG|Dexmedetomidine Hydrochloride|Inj dexmedetomidine and inj midazolam given to two groups of participants and effects of both drugs will be observed for 24 hrs
223730301|NCT03670303|BEHAVIORAL|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~1. Lectures on importance of spectacles use including visual materials such as pictures and videos.~2. An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~3. Posters~4. Brochures"
224009232|NCT05458947|PROCEDURE|electrical stimulation (ES) and pulsed wound irrigation (PWI)|necrotic wound is irrigated with normal saline (0.9%) with an 8-12 pounds per square inch pressure (PSI) to provide a mechanical force to loosen necrotic tissue for wound healing and high volt pulsed current (HVPC) is most effective in wound healing while decreasing risk of adverse skin reactions or mild burns under the electrodes
224009233|NCT00588991|DRUG|Carboplatin|Given IV
224009234|NCT00588991|OTHER|Laboratory Biomarker Analysis|Correlative study
224009235|NCT00588991|DRUG|Topotecan Hydrochloride|Given IV
224009236|NCT00588991|DRUG|Veliparib|Given orally
224296141|NCT04158349|DRUG|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
224296142|NCT04158349|DRUG|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
224296143|NCT02234206|DRUG|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs \& cosmetic act 1940"
224296144|NCT02247219|BEHAVIORAL|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
224296145|NCT01976013|DEVICE|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
224296146|NCT00117403|DRUG|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
224296147|NCT00117403|DRUG|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
224296148|NCT00117403|DRUG|Placebo capsules|one placebo capsule three times per day with meals
224296149|NCT00117403|DRUG|Placebo wafers|two placebo wafers three times per day with meals
224296150|NCT01348984|DRUG|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
224296151|NCT01348984|DRUG|placebo patch|group 2 = placebo patch
224296152|NCT05310799|OTHER|Shared Decision Making (SDM)|The intervention is a structured SDM discussion between physician and family, occurring at the time of the child's JIA diagnosis and clinic visit. Discussion will be guided by a discussion guide and the PERSON-JIA Report, which is generated in real time on the physician's smart phone.
224296153|NCT05333237|DIETARY_SUPPLEMENT|Intervention #1: ProvideXtra Drink|Fasted subjects will be offered 200 ml of ProvideXtra and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
224296154|NCT05333237|DIETARY_SUPPLEMENT|Intervention #2: Fresubin Energy Drink|Fasted subjects will be offered 200 ml of Fresubin Energy Drink and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
224296155|NCT05333237|DIETARY_SUPPLEMENT|Intervention #3: Generic Glucose Solution|Fasted subjects will be offered the glucose solution and will be asked to ingest it at a comfortable rate. Subsequent gastric ultrasound examinations will be performed half-hourly (up to 6 hours) to determine the volume of the gastric contents. The intervention ends when the stomach appears to be empty again on ultrasound.
223389235|NCT02449850|OTHER|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
223389236|NCT04996979|DRUG|Ropivacaine 0.5% Injectable Solution|Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)
223389237|NCT04996979|DRUG|Placebo|Standard care
224009237|NCT04835337|BEHAVIORAL|Air Purifiers|Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.
224009238|NCT04835337|BEHAVIORAL|Sham Air Purifiers|The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.
223389238|NCT02719275|BEHAVIORAL|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
223389239|NCT04599075|DRUG|Insulin|IV Insulin Infusion
223389240|NCT04599075|DRUG|Insulin|Continuous Subcutaneous Insulin Infusion (Pump)
223389241|NCT04834609|PROCEDURE|Injection of autologous adipose tissue in anal fistula|
223389242|NCT02951754|DRUG|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
223389243|NCT02557763|DEVICE|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
223389244|NCT04190121|DIETARY_SUPPLEMENT|prosure|The study group will receive the dietary supplement preoperatively and for three months after the operation
224009239|NCT04967807|DIAGNOSTIC_TEST|Cardiac PET/MRI|An imaging technique that combines the strengths of both MRI and PET into one comprehensive study. This technique allows for detailed myocardial tissue characterization with MRI (including assessment of myocardial edema and fibrosis) and metabolic changes (including myocardial inflammation).
224126495|NCT06797063|BEHAVIORAL|Usual Care|Participants in the control clusters will continue with local practice for antenatal breastfeeding support and referral to facilities. It is expected that they will receive routine health education recommended by the national health system during the prenatal and postnatal period and offered through PHC and community level workers, including ASHAs. ASHAs may visit a woman after delivery to provide lactation support, as needed, with visits ceasing at 42 days post-delivery. Breastfeeding mothers requiring advanced lactation support may be referred to a community subcenter for care with more skilled clinicians.
224296156|NCT06310928|OTHER|Thermal Blanket|Thermal blankets, a passive heating blanket, have a silver surface to prevent heat loss through radiation. Thermal insulation is achieved thanks to the fact that they are covered with a reflective surface to reflect light radiation, i.e. thermal radiation. It is a cost-effective, easy-to-clean, flexible material that takes the desired shape. Thermal blankets generate heat by providing thermal insulation with infrared radiation and can provide thermal vasodilation or thermotherapy. In 2013, Lima et al. used infrared thermal blankets to provide thermal vasodilation and as a result, it was found to reduce vascular resistance. Therefore, FORCLAZ brand blanket, also known as emergency blanket, used in natural disaster management, peripheral vascular resistance studies and hypothermia prevention studies was used in this study.
223389245|NCT06582108|GENETIC|DNA, RNA, ctDNA, metabolomics|The use of specific assays or global molecular profiling to identify novel biomarkers based on DNA, RNA, protein, lipids, or metabolites obtained from tumor tissue or body fluids
223389246|NCT06581679|DRUG|Triptorelin|GnRHa will be given as a subcutaneous injection of triptorelin in a dose of 3.75 mg monthly for three months.
223389247|NCT06581679|DEVICE|levonorgestrel-releasing intrauterine system|The levonorgestrel-releasing intrauterine system releasing 20 levonorgestrel daily.
223389248|NCT06581679|PROCEDURE|frozen embryo transfer|"Frozen embryo transfer (FET) where a previously frozen embryo is thawed and transferred into a woman's uterus.~The FET process involves hormone preparation to prepare the uterus for the transfer, embryo thawing, and the actual transfer of the embryo into the uterus. If the embryo implants and develops successfully, pregnancy can occur."
223389249|NCT03087500|OTHER|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
223389250|NCT06583200|DIAGNOSTIC_TEST|End Expiratory Occlusion Test|All studied mechanically ventilated patients under post operative sedation. EEO test will be applied to predict probable responder and probable non-responder according to pulse pressure variation in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of 5% or more
223389251|NCT06583200|DIAGNOSTIC_TEST|Passive Leg Raising Test|All studied mechanically ventilated patients under post operative sedation.Passive leg raising test will be applied to predict probable responder and probable non-responder according to the PPV in accordance to previous study where the response to volume expansion was defined as an increase in pulse pressure of at least 10%
223389252|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
223389253|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
223389254|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
224009240|NCT04967807|DIAGNOSTIC_TEST|Blood Biomarkers|Markers of cardiac damage, inflammation, circulating microRNA profiles, and COVID antibody levels will be evaluated in patients after COVID-19 vaccination.
224009241|NCT04981795|DRUG|Tafasitamab|Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
224009242|NCT05459376|OTHER|Exercises and dry cupping|Participants in the intervention group will receive an assessment, classification as to MDT syndrome and indication of the preferred direction of movement, whether flexion, extension or lateral displacement of the spine
224009243|NCT05299814|BEHAVIORAL|Behavioral Parenting Intervention|8 session evidence based parenting intervention
224009244|NCT01330849|BEHAVIORAL|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
223389255|NCT00810147|DRUG|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
223389256|NCT00810147|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
223389257|NCT03950154|DRUG|Bevacizumab Injection [Avastin]|Bevacizumab injection
223389258|NCT03950154|DRUG|Oxaliplatin|Oxaliplatin injection
223389259|NCT03950154|DRUG|Capecitabine|Capecitabine oral agent
223389260|NCT03950154|BIOLOGICAL|PD1-T cells|PD1-T cells injection
223389261|NCT03309098|DIAGNOSTIC_TEST|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
223389262|NCT03487289|PROCEDURE|natural orifice|laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
223389263|NCT01395927|DRUG|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
223389264|NCT01395927|DRUG|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
224009245|NCT01330849|OTHER|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
223389265|NCT04386382|PROCEDURE|ridge splitting flapless technique using interchangeable guide followed by implant placement|"An informed consent is taken from all the patients~I. Presurgical phase:~1. Proper dental and medical history.~2. Scaling and oral hygiene measurements.~3. Clinical examination.~4. Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~1. Optical scanning of the dental casts was done using Ceramill map 400~2. surgical stent was designed using Mimics Innovation Suite 19 ™ software.~3. Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately"
224009246|NCT04488393|DEVICE|MaterniT21 PLUS and GENOME Laboratory-Developed Tests|Both the MaterniT21 PLUS and GENOME are intended for use as laboratory developed test that analyze ccfDNA extracted from a maternal blood sample utilizing Massively Parallel Sequencing (MPS) technology.
224009247|NCT04709289|OTHER|Aminolevulinic acid, photodynamic therapy|Aminolevulinic acid, photodynamic therapy
224009248|NCT02133222|PROCEDURE|blood sample|
224009249|NCT06051136|BEHAVIORAL|Pulmonary rehabilitation|"The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise.~The exercise program is individualized and can be delivered in telerehabilitation."
224009250|NCT02898077|DRUG|Ramucirumab|Administered IV
224009251|NCT02898077|DRUG|Paclitaxel|Administered IV
224009252|NCT02898077|DRUG|Placebo|Administered IV
224296157|NCT00578071|DRUG|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
223389266|NCT00317629|DRUG|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
223389267|NCT00317629|DRUG|meglumine antimoniate|20mg/kg daily during 20 days
224296158|NCT00578071|DRUG|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
224296159|NCT00578071|DRUG|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
223730302|NCT06359470|OTHER|Positioning technique|"First time of testing: Firstly, the patients were scanned in the conventional neutral supine position and a 3D-CT scan was taken.~Second time of testing: after 10 minutes, the patients were scanned in the modified reversed contralateral rotation (side-lying on a hard pillow with side bending to the non-affected side and rotation to non affected side). This is achieved through instructing the participant to first lie on the side lying on a wedge pillow (that is flexible with dimensions of 30 cm in height and 75 cm in length) to achieve trunk side bending to non-affected side this pillow is the same for all patients, then the patient/participant rotated to the affected side (pelvis on the trunk rotation), and 3D-CT scan.~Third time of testing: after 48 hours, the patients were scanned in the modified reversed contralateral rotation."
223730303|NCT03415191|DRUG|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
223730304|NCT03415191|DRUG|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
223730305|NCT00660998|DRUG|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
223730306|NCT00660998|DRUG|Placebo|Matching placebo
223730307|NCT04931862|DRUG|WVE-004|WVE-004 is a stereopure antisense oligonucleotide (ASO)
224296160|NCT00578071|RADIATION|Radiation Therapy (RT)|Daily for 6 weeks
223389268|NCT05311189|DRUG|HLX10, Trastuzumab and Chemotherapy|HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
223389269|NCT04211831|DRUG|URO-902|intradetrusor injection
223389270|NCT04211831|DRUG|Placebo|intradetrusor injection
223730308|NCT04931862|DRUG|Placebo|Artificial cerebrospinal fluid (aCSF)
223730309|NCT02635945|DRUG|PBF-680|
223730310|NCT02635945|DRUG|Placebo|
223730311|NCT04475653|BEHAVIORAL|Physical Activity using an Activity Tracker|
224009253|NCT04845204|OTHER|Relaxation Treatment|Relaxation Group recieve progressive muscle relaxation exercises additional to the standard exercises. The relaxation exercises are applied two times a day till the discharge day starting on the postoperative day one. Progressive muscle relaxation included the relaxing of different muscle groups along with deep breathing. The maximal contraction period consist of the contraction of muscle groups around ankle, calf, knee, hip, lumbar, thoracic and cervical regions, shoulder, arm, forearm for 5 s and continued with a relaxation period for 30 s while focusing on breathing. These two periods ware repeated for each muscle groups and lasted approximately 30 min
224009254|NCT04845204|OTHER|Standard Exercises|The physiotherapy protocol is applied under the supervision of the same physiotherapist within a progressive manner immediately after surgery. Continued passive range of motion is applied twice a day starting with 45º of knee flexion range of motion and increased gradually as tolerated. All patients performed same isometric, isotonic and active exercises. Patients were instructed to bear weight as tolerated on the postoperative day 1
224009255|NCT04288102|BIOLOGICAL|UC-MSCs|3 does of UC-MSCs(4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
224009256|NCT04288102|BIOLOGICAL|Saline containing 1% Human serum albumin（solution without UC-MSCs）|3 does of placebo（intravenously at Day 0, Day 3, Day 6）
224009257|NCT03584542|OTHER|No interventional study|No Interventional study - Only one questionnaire will be done for patients and for general practitioners
224009258|NCT00752947|DRUG|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
224009259|NCT00752947|DRUG|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
224009260|NCT00752947|DRUG|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
224296161|NCT03605251|DRUG|TAS5315 low dose|Oral administration for 12 or 36 weeks
224296162|NCT03605251|DRUG|TAS5315 high dose|Oral administration for 12 or 36 weeks
223389271|NCT00898287|DRUG|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
223389272|NCT00898287|DRUG|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
223389273|NCT05717569|DRUG|Vitamin D|o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
223389274|NCT03697031|DRUG|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
223389275|NCT01256879|DRUG|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
223389276|NCT00397514|PROCEDURE|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
223545949|NCT06358521|OTHER|Physiotherapist-led primary care model for hip and knee pain|"1. Initial assessment and screening: The PT will provide a comprehensive assessment according to established clinical practice guidelines.~2. Brief individualized intervention at first visit: The PT intervention will be at the discretion of the PT to reflect real-world PT intervention.~3. Health services navigation: Participants will be provided with options available to them in their community for rehabilitation. For example, they may be referred to community PT for ongoing management. Participants will be assessed regarding the need for specialist referrals or resources available to manage complex clinical presentations. Participants may be referred to the primary care provider if no specialized services are needed or when the PT cannot provide a direct referral.~4. Additional PT care: Patients who require community PT but do not have the appropriate coverage for community-based services will be managed by the PT who provided the assessment in the primary care setting."
223545950|NCT06358521|OTHER|Usual physician-led primary care model for hip and knee pain|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
224009261|NCT00621777|DRUG|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
224009262|NCT00621777|DRUG|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
224009263|NCT06363760|OTHER|Safety and efficacy assessments|Assessed throughout the duration of the study.
223545951|NCT05580614|DEVICE|Sham|MRI (Magnetic Resonance Imaging) paired ERP/Sham YBOCs(Yale-Brown Obsessive Compulsive Scale) (4,8,12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
223730312|NCT02534870|DRUG|ABT-450/r/ABT-267|Tablet
224009264|NCT05016362|PROCEDURE|medial fat preservation upper blepharoplasty|medial fat preservation upper blepharoplasty increasing volumetric upper eyelid skin fold
224009265|NCT04905459|DIAGNOSTIC_TEST|ARDA software application|Subject images will be sent to the investigational ARDA software
224009266|NCT02533817|DIETARY_SUPPLEMENT|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
224009267|NCT04687059|BIOLOGICAL|PQ Grass|Suspension for injection
224009268|NCT04687059|DRUG|Placebo Option 1|Suspension for injection
224009269|NCT04687059|DRUG|Placebo Option 2|Solution for injection
223730313|NCT02534870|DRUG|ABT-333|Tablet
224009270|NCT03492749|DIAGNOSTIC_TEST|Saliva monitoring|The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
224009271|NCT04394208|DRUG|Silymarin|Silymarin Oral at a dose of 420 mg/day in 3 divided doses.
224009272|NCT04394208|DRUG|Placebo|Placebo comparator
224009273|NCT02138955|DRUG|Liposomeal curcumin|
224009274|NCT01239043|BIOLOGICAL|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
224009275|NCT01239043|BIOLOGICAL|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224009276|NCT01952353|PROCEDURE|Preoprative TACE|
224009277|NCT01952353|PROCEDURE|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
224296163|NCT03605251|DRUG|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
224009278|NCT04155736|BEHAVIORAL|Renew|Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
224126496|NCT06930482|BEHAVIORAL|Safe early intervention|The SAFE early intervention approach, an activity-focused, sensory intervention program, was applied to the babies in the intervention group in an enriched environment. As part of the intervention, coaching was provided in collaboration with the family on how to support the baby's development. For this purpose, family visits were made 15 days after the initial assessment and once a month. During these visits, the suggestions given to the family were repeated and all questions about the process were answered. It was discussed how the home environment should be structured in a way that is appropriate for the baby's development. The aims of the approaches applied were explained and information was provided about the follow-up process. In order to follow up on whether the family implemented the intervention, the family was interviewed by phone and the family was asked to keep an activity diary.
224126497|NCT06930482|BEHAVIORAL|early intervention approach based on neurodevelopmental treatment|Within the scope of the study, NGT-based applications were applied to the babies included in the control group by their families. After the first assessment, activities were planned to support skills appropriate to the child's developmental level. The treatment movements, how to facilitate the baby's movements, and how to provide hand contact were demonstrated to the families in practice. The applicability of the intervention program was monitored with weekly phone calls. The babies were called to the clinic environment for a check-up every month to revise the intervention program and teach new movements, and an evaluation was made. Two home visits were made to evaluate the families' home environments and parental attitudes (pre- and post-intervention).
224126498|NCT07128121|BIOLOGICAL|Respiratory Syncytial Virus IN006 Bivalent mRNA Vaccine (IN006)|Formulation for injection
224126499|NCT07128121|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224126500|NCT04924985|OTHER|Non-Physiological Feedback CPR|Non-physiologically guided CPR using AV feedback (integrated into defibrillators)
224126501|NCT04924985|OTHER|Physiological Feedback CPR|Physiological feedback CPR using an optimal regional O2 Saturation (rSO2), End-tidal CO2 (ETCO2) or combined (rSO2/ETCO2) target
224126502|NCT04961190|BEHAVIORAL|Prolonged Exposure Therapy|A form of cognitive-behavioral psychotherapy focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
224126503|NCT04961190|DRUG|Pharmacotherapy with paroxetine or venlafaxine XR|Standard dosing with paroxetine, a selectiveserotonin reuptake inhibitor that is FDA approved to treat PTSD and depression, or venlafaxine extended-release, a serotonin-norepinephrine reuptake inhibitor that is FDA approved to treat anxiety and depression
224126504|NCT04909736|OTHER|Music Exposure|Music will be played for participants.
224296164|NCT03987347|OTHER|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
224296165|NCT00336128|BEHAVIORAL|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
224296166|NCT00336128|BEHAVIORAL|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
224296167|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator flaps|closure of myelomeningocele defect by perforator island flap after complete incision of the flap all around based on perforator vessel .
224296168|NCT06405698|PROCEDURE|surgical closure of myelomeningocele defects by perforator-plus flaps|closure of myelomeningocele defect by perforator-plus island flap harvesting leaving skin bridge connecting to the flap and dissection of the perforator vessel
224296169|NCT01609621|DEVICE|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
224296170|NCT06611085|OTHER|cold application group|The index finger of the child will be used in the cold application group. In this group, cold application will be performed by placing the index finger of the designated hand on a 10 x 10 cm ice pack for 30 seconds and then removing the ice pack immediately.
224296171|NCT06611085|OTHER|vibration group|The middle finger of the child will be used in the vibration group. In this group, vibration was applied by targeting the tip of the middle finger area using a vibrator device measuring 2x1x3 cm. The insertion of the needle will coincide with the application of the vibration stimulation.
224296172|NCT06611085|OTHER|vibration and ice group|In the vibration and ice group, cold and vibration stimulation will be applied to the child simultaneously. The ring finger of the designated hand was placed on a 10x10 cm ice pack for 30 seconds and subjected to cold application. Simultaneously, vibration stimulation will be applied to the tip of the middle finger area using a vibrator device with dimensions of 3x1 cm and 2x1 cm. After 30 seconds, the ice bag will be removed and the lancet pen will be adjusted for drilling from the fingertip while vibration stimulation continues.
224296173|NCT06859853|DRUG|Placebo|Sub cutaneous injection on the abdomen by a qualified member of study staff.
224296174|NCT06859853|DRUG|Subcutaneous single and mutiple dose|Sub cutaneous injection on the abdomen by a qualified member of study staff.
223545952|NCT05580614|DEVICE|tVNS|MRI (Magnetic Resonance Imaging) paired ERP/tVNS YBOC's (Yale-Brown Obsessive Compulsive Scale) (4, 8, 12) OCI-R (every other session). YBOCs and OCI-R will also be administered at intake and 4 weeks post treatment.
224126505|NCT05922878|DRUG|ALTO-300|ALTO-300 capsule QD
224126506|NCT05922878|DRUG|Placebo|Placebo capsule QD
223545953|NCT04372875|BEHAVIORAL|SHS-derived CDS|This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
224126507|NCT06781983|DRUG|IPH4502|Part 1 (dose escalation) and Part 2 (dose optimization)
224126508|NCT06017765|BEHAVIORAL|Meditation Training|"The Meditation Training consists of 8 weekly sessions of Mindfulness Training and is adapted from the group-based Stress Management and Resiliency Training - Relaxation Response Resiliency Program, SMART-3RP. This training is structured around the following four goals:~1. Education about stress response~2. Elicitation of the Relaxation Response through Mindfulness Training~3. Creating adaptive perspectives~4. Coping strategiest."
224009279|NCT05961787|DEVICE|SeQuent® Please drug coating balloon(DCB)，Firehawk family drug eluting stent(DES)|"Investigation on DCB vs DES on Symptomatic or silent ischemic coronary artery disease with indications for PCI~* Lesions ≤35 mm in length (visual), diameter 3-4 mm.~* A maximum of 2 target lesions on 2 major epicardial coronary target vessels can be treated during baseline procedure. (e.g., one target lesion on one target vessel, or two target lesions on the same target vessel but separated ≥ 15 mm; Or 1 target lesion on each of the target vessels)"
224009280|NCT01756768|RADIATION|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of \[14C\]-PD-0332991.
224126509|NCT06017765|BEHAVIORAL|Waitlist|The waitlist consists of a waiting time of 12 weeks during which participants will nog receive any type of intervention.
224009281|NCT00359216|DRUG|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
224126510|NCT05367063|DRUG|Canagliflozin 100mg or Sitagliptin 100mg|Eligible type 2 diabetes patients at high risks of cardiovascular diseases will be randomly assigned by a 1:1 ratio to either Canagliflozin 100 mg once daily or Sitagliptin 100 mg once daily.
224126511|NCT06030206|BEHAVIORAL|Investigator-designed lung transplant education resource (Research Intervention)|Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.
224126512|NCT06030206|BEHAVIORAL|Publicly available transplant education resource (Attention-control)|Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
224126513|NCT03890952|DRUG|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
224126514|NCT03890952|DRUG|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
224126515|NCT01156597|DRUG|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
224126516|NCT03785496|DRUG|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
224126517|NCT01116219|BIOLOGICAL|bevacizumab, erlotinib|"* Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~* Erlotinib 150 mg p.o. daily until progression."
224296175|NCT04072276|BIOLOGICAL|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
224296176|NCT06617273|DEVICE|Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation|Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
223389277|NCT02833337|RADIATION|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
223730314|NCT01817998|OTHER|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
223730315|NCT06295770|DRUG|Obinutuzumab|Obinutuzumab 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6.
224009282|NCT00359216|DRUG|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
224009283|NCT02121301|DRUG|Low Dose 0.155µg/mL SkQ1 ophthalmic solution|eyedrops
224009284|NCT02121301|DRUG|High Dose 1.55µg/mL SkQ1 ophthalmic solution|eyedrops
224009285|NCT02121301|DRUG|Placebo (Vehicle) opthalmic solution|eyedrops
224126518|NCT01116219|DRUG|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. and~* Cisplatin\* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~* Bevacizumab 7.5 mg/kg i.v. and~* Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
224126519|NCT05821153|DRUG|Aldesleukin|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
224126520|NCT01814683|DRUG|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
224126521|NCT01814683|DRUG|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
224126522|NCT01814683|DRUG|Placebo|14 days placebo.
224126523|NCT02476682|OTHER|blood or stool samples will be collected|blood or stool samples will be collected
224126524|NCT00660036|DRUG|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m\^2, 6 mg/m\^2 or 9 mg/m\^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
224296177|NCT04544020|DIETARY_SUPPLEMENT|NG feeding|NG feeding
224296178|NCT00449982|DRUG|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
224296179|NCT00257920|DRUG|Zemplar® injection|6 mcg QOD
223389278|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
223389279|NCT00640315|DRUG|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
223730316|NCT06066554|DEVICE|Puva (psoralin and uva )|Intervention will be given for 48 sessions or till coplete resolution of biopsied plaque
224009286|NCT01473446|PROCEDURE|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV\> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV \<10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding \>1000ml. By fall in blood pressure and SVV \<10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
224009287|NCT05323760|DEVICE|Cardiopulmonary exercise test (CPET)|A symptom-limited test on a treadmill will be performed, using incremental ramp Bruce protocol up to exhaustion. Patients who will not be able to perform the test on a treadmill will be tested on a cycle ergometer beginning with a no-resistance warm-up lasting 2-3 minutes, followed by incrementing resistance (8-30 Watts/minute).
224009288|NCT05142852|DEVICE|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
224009289|NCT05142852|OTHER|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
224009290|NCT01769768|DRUG|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
224009291|NCT01769768|DRUG|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
223389280|NCT05536063|PROCEDURE|bilateral erector spinae plane block in pediatric cardiac surgeries|The ESPB will be performed after induction of anesthesia, endotracheal tube insertion and before the start of operation, with the child in a right lateral decubitus position under aseptic precautions. A high frequency linear ultrasound transducer will be placed over the T4 transverse process lateral to the spinous process. After identifying the muscles above the hyperechoic transverse process image, a 5-cm 22 gauge needle will be inserted in-plane in a cephalo-caudad direction. The endpoint is defined as the needle pointing to the tip of transverse process piercing the erector spinae muscle. The local anesthetic will be deposited at this position, After careful negative aspiration, local anesthetic, according to study groups , The process will be repeated on thecontralateral side
224009292|NCT01769768|DRUG|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
224009293|NCT00334464|DRUG|Standard of care or genotyping dosing of warfarin dosing|
224009294|NCT00180063|DRUG|L-NMMA(drug)|
224009295|NCT00476970|BEHAVIORAL|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
223389281|NCT01259479|DRUG|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
224009296|NCT04311528|BIOLOGICAL|9-valent HPV vaccine|9-valent HPV vaccine
224009297|NCT04721535|DRUG|DWJ1248|Orally, 1 tablet of DWJ1248 TID, up to 14 days
223389282|NCT03437408|DEVICE|Mapping and ablation|High density substrate map. Data collection during ablation
223389283|NCT00366795|DRUG|Satavaptan|oral administration once daily
224009298|NCT04721535|DRUG|Placebo|Orally, 1 tablet of placebo TID, up to 14 days
224009299|NCT01033422|DRUG|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
224009300|NCT01033422|DRUG|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
224009301|NCT04129697|DRUG|Dexamethasone or Methylprednisolone|steroids
224009302|NCT03805620|OTHER|Combined physical-cognitive training|combined physical-cognitive training
224009303|NCT03805620|OTHER|Physical training|Multi-component physical exercise
224009304|NCT03805620|OTHER|Cognitive training|cognitive training
224009305|NCT02663518|DRUG|PF-0791800 (TTI-621)|Monotherapy
224009306|NCT02663518|DRUG|PF-07901800 (TTI-621) plus Rituximab|Combination therapy
224009307|NCT02663518|DRUG|PF-07901800 (TTI-621) plus Nivolumab|Combination therapy
224009308|NCT04392661|PROCEDURE|Laparoscopic Sleeve Gastrectomy|bariatric surgeries and data collection
224126525|NCT00660036|DRUG|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
224296180|NCT00257920|DRUG|Hectorol® injection|3.6 mcg QOD
223389284|NCT00366795|DRUG|placebo|oral administration once daily
223389285|NCT02183779|PROCEDURE|post-occlusive hyperemia|
223389286|NCT02183779|PROCEDURE|cooling box|
223389287|NCT02183779|DRUG|L-NMMA and Fluconazole dermic injection|
223389288|NCT01834833|OTHER|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
224009309|NCT04174794|DEVICE|Lung ultrasound|The two different lung ultrasound protocols are performed initially within 48 hours of internal medicine ward admission by a pair of expert-beginner echographers. In case of admission during non-working days, the first scan can be done within 72 hours from admission. Follow-up scans are repeated 4 to 6 days later or on the day of discharge if it occurs before de fourth day. Experts and beginners execute the lund ultrasound protocols in sequence, reciprocally blinded, without accessing to clinical data files.
224009310|NCT00353522|DRUG|Placebo|po daily for 24 weeks
224009311|NCT00353522|DRUG|dalcetrapib|900mg po daily for 24 weeks
224009312|NCT02935725|DRUG|Low dose AUT00206 800mg|
224296181|NCT01757574|DRUG|Alemtuzumab infusion|
223389289|NCT06181773|BEHAVIORAL|EPO Feeding Program|The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
223389290|NCT02891668|DRUG|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
223389291|NCT07097701|DRUG|Granular powder in unit dose foil-lined sachet Mexiletine (PR)|Mexiletine (PR)
223389292|NCT07097701|DRUG|Oral Capsule Mexiletine (IR)|Mexiletine (IR)
223389293|NCT07097259|COMBINATION_PRODUCT|Test: Follitropin alfa|It is a solution for injection in prefilled pen. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of at least 23 days will be maintained between period 1 and 2.
223389294|NCT07097259|DRUG|Reference: Follitropin alfa|It is a powder and diluent for solution for injection in multidose vial. Participants will receive follitropin alfa on Day 1 in Study Period 1 or Study Period 2. A washout period of 23 days will be maintained between period 1 and 2.
224009313|NCT02935725|DRUG|High dose AUT00206 2000 mg|
224009314|NCT02935725|DRUG|Placebo|
224009315|NCT02935725|DRUG|Ketamine|
224009316|NCT02935725|OTHER|Saline|
224126526|NCT00660036|DRUG|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
224126527|NCT01830361|DRUG|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
223389295|NCT07097259|DRUG|Zoladex|It is a auxiliary medicinal product. Participants will receive Zoladex injection on Day -11 in down regulation period, and on Day 17 prior to the start of Period 2.
223730317|NCT05237154|OTHER|Intervention with intermittent fasting.|Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
224009317|NCT04713800|DEVICE|Monolithic zirconia screw retained implant-supported cantilever reconstruction supported by titanium base abutments, in a full digital workflow (ZR-TiB)|In group ZR-TiB the implant impressions will be taken using an intra-oral scanner and the respective scanbody. The restorations will be manufactured by means of CAD/CAM procedures using monolithic zirconia. For sufficient aesthetics, the zirconia restorations can be manually veneered with veneering ceramic only at the buccal surface, while the occlusal surface will remain monolithic and will be high-gloss polished. The zirconia restorations will be extra-orally cemented onto titanium base abutments (Straumann® Variobase® for crown, Straumann AG), correctly polished and delivered to the patient, by screw-retention onto the implant.
224009318|NCT04713800|DEVICE|porcelain fused-to metal screw retained implant-supported cantilever reconstruction supported by a gold-abutment, in a conventional workflow (PFM-GA)|In group PFM-GA implant impression will be taken using a polyvinyl siloxane or polyether impression material in a conventional manner with the use of stock trays and corresponding impression copings. The framework will be manufactured by the lost wax-technique using a gold-abutment (Straumann® Gold abutment for crown, Straumann AG) and a gold-alloy. All metal frameworks will be manually veneered with veneering ceramic, polished and glazed, and delivered to the patient, by screw-retention onto the implant.
224126528|NCT00255684|BIOLOGICAL|graft-versus-tumor induction therapy|
224009319|NCT02289092|BEHAVIORAL|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
224126529|NCT00255684|DRUG|cyclophosphamide|
224126530|NCT00255684|DRUG|cyclosporine|
224126531|NCT00255684|DRUG|fludarabine phosphate|
223389296|NCT06345807|OTHER|Individuals activity programs|activity program will be adjusted every week by practitioner for each patient following data coming from the wearable device ( connected whatch and bellt for 12 months)
223730318|NCT05237154|OTHER|Intervention with high-intensity interval training.|Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
223730319|NCT03608501|DRUG|Ixazomib|Ixazomib capsules.
223730320|NCT03608501|DRUG|Thalidomide|Thalidomide capsules.
223730321|NCT03608501|DRUG|Dexamethasone|Dexamethasone tablets.
224126532|NCT00255684|DRUG|mycophenolate mofetil|
224126533|NCT00255684|PROCEDURE|umbilical cord blood transplantation|
223389297|NCT06345807|OTHER|activity program|pre established program without adjustement. The patient has connected whatch and bellt for 12 months
223389298|NCT06345807|OTHER|no Physical Activity program|no Physical Activity (PA)program but just PA recommendations.PA is carried out independently (common practice).The patient has connected whatch and bellt for 12 months
223389299|NCT06765070|DEVICE|EXPLORER|Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.
223730322|NCT01876030|DEVICE|FES|
223730323|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: exposure in vivo|Behavioral, chronic pain rehabilitation therapy
224126534|NCT00255684|RADIATION|radiation therapy|
224126535|NCT02728440|DRUG|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
224126536|NCT00211588|DRUG|galantamine|
224126537|NCT05394740|DRUG|Regorafenib|"90 mg administered orally, once daily for 21 consecutive days followed by 7 days off~\*Repeat every 4 weeks as Regorafenib therapy"
223389300|NCT06819254|DRUG|Fisetin followed by Placebo|Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over placebo-controlled dosing regimen to be taken twice daily on two consecutive days for two consecutive weeks.
224009320|NCT04167527|DEVICE|Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device|"Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
223389301|NCT06819254|DRUG|Placebo followed by Fisetin|Placebo twice daily on two consecutive days for two consecutive weeks. Participants will return on day 14 for a blood draw followed by a 14-day wash-out. At the 4-week visit participants will receive a cross-over Fisetin 20 mg/kg per dose twice daily on two consecutive days for two consecutive weeks.
223389302|NCT06849713|DRUG|Zanubrutinib|Bruton's Tyrosine Kinase (BTK) inhibitor
223389303|NCT06849713|DRUG|Sonrotoclax|B-cell lymphoma 2 (BCL2) protein inhibitor
223389304|NCT06849713|DRUG|Obinutuzumab|Anti-CD20 monoclonal antibody
223389305|NCT07077447|PROCEDURE|Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma|"This is an observational cohort study with no direct intervention assigned by the investigators. The study compares two groups of patients in our cohort diagnosed with high-risk pTa upper tract urothelial carcinoma (UTUC), as defined by the European Association of Urology (EAU) guidelines. The experimental group includes patients who, due to imperative indications (e.g., solitary kidney, impaired renal function, or comorbidities), undergo kidney-sparing surgery. These patients are compared to a reference group treated with radical nephroureterectomy, which is considered standard of care."
223389306|NCT06087029|PROCEDURE|TEVAR|Thoracic endovascular aortic repair
223389307|NCT06087029|OTHER|Guideline directed medical therapy and surveillance of dissection|Routine clinical care with suggested antihypertensive therapy and cardiovascular risk factor reduction as per appropriate cardiovascular guidelines.
223389308|NCT07095504|BEHAVIORAL|Virtual World-based Cardiac Rehabilitation (VWCR) program|36 Virtual World-based Cardiac Rehabilitation sessions over the course of 12 weeks (3 sessions/week)
224009321|NCT04167527|COMBINATION_PRODUCT|Initial medical management (iMM)|"Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.~All subjects, regardless of randomization arm, will receive best medical management based on current American Heart Association, Canadian, or European guidelines according to their geographic location."
224009322|NCT06002633|OTHER|Alcohol|Participants will consume beverages containing alcohol.
224009323|NCT06002633|OTHER|Placebo|Participants will consume beverages containing a very low dose of alcohol (placebo condition).
224009324|NCT02569593|DIETARY_SUPPLEMENT|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
223389309|NCT01004744|DRUG|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
223389310|NCT03576079|DEVICE|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
223389311|NCT03576079|DEVICE|anterior re-positioning splint|hard acrylic anterior re-positioning splint
223389312|NCT03576079|DEVICE|inactive Laser therapy|sham Laser, with inactive beam
223389313|NCT05608473|OTHER|Posture Exercises|A 10-minute video consisted of 14 cervical and thoracal postural exercises was uploaded to the computers of the participants. Participants were asked to do these exercises simultaneously with the video, 3 days in a week for 6 weeks. During theese weeks, the participants were checked by sms and they were asked to keep an exercise diary. For progression, the number of repetitions was increased in the 3rd week and the number of sets in the 5th week.
223389314|NCT01611779|DEVICE|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
223389315|NCT00262665|DRUG|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
223389316|NCT00262665|DRUG|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
223389317|NCT03475992|DEVICE|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
223389318|NCT03791684|DEVICE|Cross linking|Cross linking strategy either standard or accelerated
223389319|NCT02644915|DRUG|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
223389320|NCT02644915|DRUG|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)\> 6 mmHg"
223389321|NCT07100106|DRUG|GDC-4198|GDC-4198 will be administered orally.
223389322|NCT07100106|DRUG|Giredestrant|Giredestrant will be administered orally.
223389323|NCT07100106|DRUG|Abemaciclib|Abemaciclib will be administered orally.
223389324|NCT07101328|DRUG|LY4152199 - IV|Administered by IV infusion
223389325|NCT07101328|DRUG|LY4152199 - SC|Administered by SC injection
223389326|NCT02698111|DRUG|Donafenib|donafenib 200mg，bid
224009325|NCT04820218|DEVICE|With Try-on glasses|Subjects will be asked to measure their visual acuity with their try-on glasses
224009326|NCT01658332|OTHER|blood samples|3 tubes (15 ml)
224009327|NCT02469103|DEVICE|C2|C2 and colonoscopy will be performed one after another on the same day
224009328|NCT02469103|PROCEDURE|colonoscopy|
224009329|NCT00553072|DRUG|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
224009330|NCT00553072|DRUG|Normal saline|1 ml/kg/dose
224009331|NCT01066520|DRUG|Traumeel S ointment|2 g, 3 times daily topical during 14 days
223389327|NCT05026827|OTHER|Iyengar Yoga|Participation in Iyengar Yoga classes
223389328|NCT05026827|OTHER|Socialization Control|Participation in socialization control group sessions
223389329|NCT06747949|DRUG|Dazodalibep|Dazodalibep will be given intravenously (IV).
223389330|NCT05409976|DEVICE|GORE® VIAFORT Vascular Stent|Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
223389331|NCT04743960|DIETARY_SUPPLEMENT|Time-of-day of parenteral nutrition provision|Parenteral nutrition will be provided during the nighttime followed by daytime.
223730324|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: graded activity|Behavioral, chronic pain rehabilitation therapy
223730325|NCT05798949|BEHAVIORAL|Chronic pain rehabilitation: acceptance and commitment therapy|Behavioral, chronic pain rehabilitation therapy
223389334|NCT06917222|PROCEDURE|Slide tracheoplasty|Management of tracheal stenosis by slide tracheoplasty
223389335|NCT06917222|PROCEDURE|Tracheal resection anastomosis|Management of tracheal stenosis by tracheal resection anastomosis
223389336|NCT07106658|OTHER|TEAS + Urgent Endoscopy|Participants receive real Transcutaneous Electrical Acupoint Stimulation (TEAS) delivered via surface electrodes bilaterally at four predefined acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]). Stimulation (dense-disperse wave, 2/100Hz frequency, intensity 5-15mA based on tolerance) begins 30 minutes before urgent endoscopy and continues throughout the procedure. All participants receive standard medical management and urgent endoscopy.
223389337|NCT07106658|OTHER|Sham TEAS + Urgent Endoscopy|Participants receive placebo TEAS. Electrodes are placed identically to the Active TEAS Group at the same four acupoints (Hegu \[LI4\], Neiguan \[PC6\], Zusanli \[ST36\], Gongsun \[SP4\]) using the same device, but no electrical current is delivered. The device appears active to maintain blinding. All participants receive standard medical management and urgent endoscopy.
223389338|NCT07106658|OTHER|Urgent Endoscopy Only|Participants receive standard urgent endoscopy care only, with no TEAS electrodes or device applied. They receive identical standard medical management and urgent endoscopy as the other groups.
223389339|NCT07112742|DEVICE|High-Intensity Laser Therapy and Exercise|High-intensity laser therapy will be applied to the painful and affected joint of the participants. A Class IV high-intensity laser device will be used. The parameters to be applied have been determined based on the relevant guidelines: average power 3 W, in analgesic mode, wavelength of 1064 nm, frequency of 2 Hz, energy dose of 75 J per session, spot size of 5 cm², and treatment will be administered three times per week for a total of 4 weeks. The total treatment duration will be 160 seconds. A standard exercise program including range of motion, stretching, and strengthening exercises will be administered to the participant during the treatment sessions. Strengthening exercises will be performed using a therapy ball to improve grip and pinch strength.
223389340|NCT07112742|DEVICE|High-Intensity Laser Therapy at a Non-Therapeutic Dose Combined With Exercise|Participants will receive high-intensity laser therapy at an ineffective dose to the painful and affected joint. Due to the absence of a placebo mode in the laser device used in hospital, the lowest possible parameters will be applied to simulate an ineffective dose. For the ineffective dose, the device parameters will be set as follows: average power 0.5 W, in analgesic mode, wavelength of 1064 nm, frequency of 1 Hz, energy dose of 12 J per session, spot size of 5 cm², and treatment will be administered three times per week for a total of 4 weeks. The treatment duration will be the same as that of the intervention group. A standard exercise program including range of motion, stretching, and strengthening exercises will be administered to the participant during the treatment sessions. Strengthening exercises will be performed using a therapy ball to improve grip and pinch strength.
223389341|NCT06932263|DRUG|Tozorakimab|The drug will be administered subcutaneously.
223389342|NCT06932263|DRUG|Placebo|Placebo will be administered subcutaneously.
223389343|NCT07128368|OTHER|Resistance Exercise Training|Participants will undergo resistance exercise training 3 days a week for approximately 1 hour each day for 8 weeks.
223730326|NCT03111901|DRUG|Pembrolizumab|Pembrolizumab solution
223730327|NCT03111901|DRUG|Interleukin-2|Interleukin-2 solution
223730328|NCT03331419|BEHAVIORAL|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
223730329|NCT01711970|DRUG|Paclitaxel|
223730330|NCT05783778|DIAGNOSTIC_TEST|Free testosterone levels and toxoplasma igG|Free testosterone levels and toxoplasma igG in serum by ELISA
223730331|NCT02014597|DEVICE|HOCD|feasibility of HOCD and comparison of HOCD results between subjects with and without glaucoma
224009332|NCT01066520|DRUG|Traumeel S gel|2 g, 3 times daily topical during 14 days
224009333|NCT01066520|DRUG|Diclofenac gel|2 g, 3 times daily topical during 14 days
224009334|NCT05210751|OTHER|Physical and psychosocial assessments|Dual Task Test, 6 min Walking Test, the Baecke Habitual Physical Activity Questionnaire, Multidimensional Fatigue Inventory-20, Tracking Test, General Self-Efficacy Scale the Toronto Alexithymia Scale, the Revised FM Impact Questionnaire, the Social Support Scale.
224009335|NCT02163005|DRUG|Gadolinium|-agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
224009336|NCT03896152|DRUG|LNP023|approximately 2 year of Treatment with LNP023
224009337|NCT01296802|DRUG|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
224009338|NCT00436852|DRUG|ABT-751|Given orally
224009339|NCT00436852|PROCEDURE|quality-of-life assessment|Ancillary studies
224126538|NCT05394740|DRUG|Nivolumab|CohotA:360 mg administered intravenously, every 3 weeks \*Administered on the same day as CapeOX therapy Cohort B: 240 mg administered intravenously, every 2 weeks \*Administered on the same day as FOLFOX therapy
223389344|NCT06942910|DRUG|Zibotentan/Dapagliflozin|Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
223389345|NCT06942910|DRUG|Dapagliflozin|Participants will receive dapagliflozin in fixed-dose combination as per the arms they are randomized to
223389346|NCT06942078|PROCEDURE|Cryoneurolysis|Targeting of specific nerves related to surgical procedure using very low temperatures
223389347|NCT07139314|DRUG|Early anticoagulation|Early initiation of direct oral anticoagulants will be started within 4 weeks after symptom onset.
223389348|NCT07139314|DRUG|Delayed anticoagulation|Delayed initiation of direct oral anticoagulants will be started between 4-8 weeks after symptom onset.
223389349|NCT07146581|BEHAVIORAL|SIRENS|The SIRENS intervention is a technology intervention designed specifically for caregivers of those with dementia, providing them with easy access to expert-reviewed information and helpful resources. The content includes take-home messages summarizing the main points discussed and a goal-setting feature that encourages the care givers to establish small, actionable goals.
223389350|NCT00251121|OTHER|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
223730332|NCT02825992|DEVICE|AcQMap System|3D imaging and mapping system for cardiac chambers
223730333|NCT00020475|DRUG|gp100 antigen|
224009340|NCT01698190|PROCEDURE|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
224009341|NCT01629732|DRUG|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
224009342|NCT01629732|DRUG|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
224009343|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
224009344|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
224009345|NCT01629732|DRUG|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
224009346|NCT01629732|DRUG|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
224126539|NCT05394740|DRUG|CapeOX|"For Cohort A only~* Capecitabine 1,000 mg/m\^2 administered orally, twice daily (Days 1 to 14 continuous dosing of CapeOX therapy)~* Oxaliplatin 130 mg/m\^2 administered intravenously (Day 1 of CapeOX therapy) \*Repeat every 3 weeks as CapeOX therapy"
223389351|NCT00251121|OTHER|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
224126540|NCT05394740|DRUG|FOLFOX regimen|"For Cohort B only~* Leucovorin 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy)~* Fluorouracil 400 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) and 1,200 mg/m2 administered intravenously (Days 1 to 2 of FOLFOX therapy)~* Oxaliplatin 85 mg/m\^2 administered intravenously (Day 1 of FOLFOX therapy) \*Repeat every 2 weeks as FOLFOX therapy"
224126541|NCT03375359|DIAGNOSTIC_TEST|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
224126542|NCT03200873|DEVICE|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
223389352|NCT04207307|BEHAVIORAL|Multimodal exercise program|Multimodal exercise intervention (machine-based resistance, coordination and endurance training).
223389353|NCT04207307|BEHAVIORAL|Usual Care|General recommendations for healthy ageing, no machine-based strength training intervention.
223389354|NCT07192913|DEVICE|Transcranial Magnetic Stimulation|"TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.~Device: Transcranial Magnetic Stimulation (Sham)~TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used."
223730334|NCT00020475|DRUG|interleukin-2|
223730335|NCT00020475|DRUG|MART-1 antigen|
223389355|NCT07192653|PROCEDURE|nonanatomical anastomosis|In Period 1 (2016-2019, n=41), nonanatomical anastomosis was performed if portal flow was insufficient.
223389356|NCT07192653|PROCEDURE|LTH-based EVT|In Period 2 (2019-2024, n=34), patients with persistent hypoperfusion underwent additional LTH-based EVT (stenting or shunt occlusion)
223730336|NCT00020475|DRUG|Montanide ISA-51|
223730337|NCT03025503|OTHER|nipple stimulation|
223730338|NCT02028624|BEHAVIORAL|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
224009347|NCT01629732|DRUG|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
224009348|NCT04135768|PROCEDURE|Wrist joint haematoma washout|After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
224009349|NCT04135768|PROCEDURE|Volar locking plate insertion of the distal radius|An anatomical locking plate is applied to the distal radius fracture using screws
224126543|NCT00462098|DEVICE|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
223389357|NCT07192627|PROCEDURE|Endoscopic mucosal dissection|Removal of lesions extending down to submucosa
223730339|NCT00823394|BEHAVIORAL|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
224126544|NCT00462098|DEVICE|non-treated control group|no change from routine care, no HBO
224126545|NCT03363048|BEHAVIORAL|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
223389358|NCT07191756|DRUG|Amphotericin B|This is a retrospective observational study. Patients in this cohort received various formulations of amphotericin B as part of their standard medical care.
223389359|NCT07191756|DRUG|Isavuconazole|This is a retrospective observational study. Patients in this cohort received isavuconazole as part of their standard medical care.
223389360|NCT07193342|PROCEDURE|computer controlled automatic injection (Star pen® system)|local anesthesia will be administered using computer controlled automatic injection(Star pen® system ) to provide slow and consistent anesthetic flow, aiming to reduce pain and anxiety during pediatric dental treatment.
223389361|NCT07193342|PROCEDURE|conventional anesthetic syringe|local anesthesia will be administered using a standard manual dental syringe , following conventional injection techniques for pediatric dental patients.
223389362|NCT07192575|BEHAVIORAL|Perioperative Pulmonary Physiotherapy in Laparoscopic Liver Surgery|The intervention includes pulmonary physiotherapy training 7 days prior to surgery and 7 days postoperatively. Patients receive physiotherapy education in a single session preoperatively or via an educational video, to guide pulmonary training at home. The pulmonary training includes deep breathing, and coughing, pursed lip breathing and positive expiratory pressure (PEP) therapy. The exercise session (10min) is to be performed two times daily for a total of 14 days.
223389363|NCT07193355|OTHER|Mental Imagery Application Protocol|"Before the GYKO test, the patient will be asked to perform mental imagery to visualize a 3-meter distance for five cycles, and the time will be recorded. The TKYT will be administered according to standard protocols.~Mental Imagery Application Protocol:~1. Awareness:~   The therapist will show a video of a typical normal gait for an adult male or female without pathology and compare it with a video of the patient's own gait.~2. Problem Identification/Explanation In the EG, subjects will identify gait problems and compare their gait with their typical gait. They will then use the comparative information for feedback.~3. Progressive Relaxation~4. Mental Imagery of Gait~5. Physıcal Performance Of The gait This protocol will be implemented the day after the initial assessment and will be conducted in 12 training sessions of no more than 90 minutes, three times per week for 4 weeks."
223389364|NCT07192380|DEVICE|Electroencephalogram|EEG measurement to assess attentional state
223389365|NCT07192380|DEVICE|Actigraphy|Evaluation of sleep-wake phases 24 hours prior to eye tracking measurement
223389366|NCT07192380|DEVICE|Eye Tracking|"Assessment of ocular parameters during controlled eye tracking: guided saccade task followed by analysis of chest scans to detect pulmonary embolism. Measurement of ocular saccade parameters (distance, velocity), fixation time and pupil diameter.~Measurements performed twice: after a night on call and after a night of rest."
224009350|NCT00167167|PROCEDURE|Donor Lymphocyte Infusion|"Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer."
224009351|NCT04218045|PROCEDURE|Laparoscopic single anastomosis sleeve ileal bypass|a simple loop gastro-ileal bypass is added to the sleeve procedure.
224009352|NCT04218045|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional sleeve gastrectomy using endoscopic stapler
224009353|NCT02883998|OTHER|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
223389367|NCT07192380|OTHER|Questionnaires|"Measurements of sleepiness (Karolinska Sleep Scale KSS, Epworth Sleep Scale ESS), mental fatigue (EVA Scale), insomnia (Insomnia Severity Index, ISI) and chronotype (Morningness Eveningness Questionnaire, MEQ)~* Inclusion visit: MEQ~* Before the first evaluation: ISI, KSS, ESS, EVA~* Before the second evaluation: ISI, KSS, ESS, EVA"
223389368|NCT07192666|DRUG|Exosome Preparation|Each subject will have a single designated study eye; this eye will receive multiple instillations-one drop four times daily for 14 consecutive days.
223389369|NCT07192822|BEHAVIORAL|Virtual Reality distraction|Participants goes into an immersive virtual reality during a brief painful stimulus
223389370|NCT07192822|BEHAVIORAL|No Virtual Reality|Participant receives a brief thermal stimulus during no treatment
223389371|NCT07192822|BEHAVIORAL|One brief pain stimulus|patient receives one brief pain stimulus with no simultaneous second stimulus
223389372|NCT07192822|BEHAVIORAL|Two simultaneous brief thermal stimuli|Participants receive two brief thermal stimuli at the same time
224009354|NCT02883998|OTHER|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
223389373|NCT07192068|DRUG|Zanidatamab|"Single arm study where the experimental regimen used for all patients will be zanidatamab, administered intravenously every 3 weeks :~* Patients \<70 kg: 1800 mg IV Q3W on Day 1 of each 21-day cycle~* Patients ≥70 kg: 2400 mg IV Q3W on Day 1 of each 21-day cycle."
223389374|NCT07191639|OTHER|completion of the QOL-HHT questionnaire|filling in the QOL-HHT questionnaire when they come for consultation
223389375|NCT07191860|COMBINATION_PRODUCT|The Airiver Pulmonary drug-coated balloon (DCB) dilation|drug coated balloon dilation
223389376|NCT07191860|DEVICE|Commercial airway balloon dilation|uncoated airway balloon dilation
223730340|NCT00823394|OTHER|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
224009355|NCT02934256|DRUG|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
224009356|NCT05953649|DEVICE|Extracorporeal Diaphragm Pacing|In the EDP group, a pacer using the extracorporeal diaphragm pacemaker provided by Guangzhou Xueliang Biotechnology Developing Co., Ltd., the pacing electrode is pasted on the body surface closest to the phrenic nerve at the outer edge of the lower end of the sternocleidomastoid muscle under ultrasound guidance, and the auxiliary electrode is placed between the second intercostal of the midline of the clavicle. The intensity of treatment parameters was set from low to high, and the intensity of treatment was increased when the patient could tolerate it, pacing 12-18 times/min at a frequency of 40 hertz (Hz)/30min/time, and performed every 12 hours for a week.
224009357|NCT05953649|DEVICE|Tilt Table Verticalization|VitalGo bed (VitalGo Systems Ltd., Fort Lauderdale） is used for verticalization. Verticalization was set to minimum 30°, depending on cardiopulmonary parameters (respiratory rate, heart rate, blood pressure, oxygen saturation), vertical position was gradually increased (in 5° steps) to a maximum of 90°, as long as the above-named cardiopulmonary parameters of the patient remained stable and remain this position for 30 minutes simultaneously with extracorporeal diaphragm pacing for a week.
223389377|NCT07192588|DRUG|GR1014-CG 2.4%|Topical gel formulation of amifostine thiol (GR1014) at 25 mg/mL
223389378|NCT07192588|DRUG|Vehicle Gel|The same topical formulation as GR1014-CG without the active ingredient amifostine thiol
223389379|NCT07192588|RADIATION|Radiation Therapy|Ultra hypofractionated RT, 26 Gy in 5 daily fractions (5.2 Gy) given over 1 week on the whole breast
223389380|NCT07192588|DRUG|GR1014-CG 4.7%|Topical gel formulation of amifostine thiol (GR1014) at 50 mg/mL
224009358|NCT05953649|OTHER|Conventional Physiotherapy|Patients receive early mobilization, which refers to a series of clinical intervention protocols (such as passive movement or active exercises, etc.) that confers physical benefits at an early period in collaboration with a multidisciplinary team (intensive care physicians, rehabilitation physicians, physical therapists, occupational therapists, respiratory therapists, and nurses). The study intervention take place during working time between 8 a.m. and 17 p.m. Patients of all three study groups receive this rehabilitation program until they transfer out of ICU.
224009359|NCT02938026|PROCEDURE|Bariatric surgery|
224009360|NCT02938026|BEHAVIORAL|Telephone Intensive Lifestyle Counselling|
224009361|NCT05195502|DIAGNOSTIC_TEST|Biopsy|Participants included in the study, will have additional biopsies performed during their colonoscopy
224009362|NCT00943852|DRUG|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
224009363|NCT00943852|DRUG|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
224009364|NCT00943852|DRUG|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
224009365|NCT00943852|DRUG|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
223389381|NCT07191990|PROCEDURE|Final irrigation by cryotreated NaOcl.|Final irrigation by cryotreated NaOcl (2.6%) at 2-4 °C for 1 min
223389382|NCT07191990|PROCEDURE|Final irrigation by preheated NaOcl|Final irrigation by preheated 60°C(15) NaOcl (2.6%) for 1 min.
223389383|NCT07191990|PROCEDURE|Final irrigation with ultrasonic activation of NaOcl|Final irrigation with ultrasonic activation of NaOcl(2.6%) for 1 min
223389384|NCT07191990|PROCEDURE|Final irrigation by NaOcl at room temperature|Final irrigation by NaOcl (2.6%) at room temperature 24 °C for 1 min
223389385|NCT04934046|OTHER|Additional acquisition|Additional SPECT acquisition (30min added time approximately), with no added radiation
223389386|NCT04957628|BEHAVIORAL|Harmful alcohol use treatment|Patients identified through routine hospital screening as having a potentially harmful alcohol use (AUDIT-C 4-6 points (men) / 3-5 points (women) will receive information about the possible harmful effects of their drinking and will be advised to reduce their consumption. Patients identified with more excessive drinking patterns (AUDIT-C \> 6 (men) / \> 5 (women) will be assessed with blood sample analysis of relevant alcohol biomarkers, psychological assessments for alcohol addiction and withdrawal symptoms, and if necessary referral to alcohol addiction treatment. Patients with severe withdrawal symptoms will be put in CIWA-Ar observation.
223730341|NCT00823394|BEHAVIORAL|Self-help Materials|Information on how to lower risk for developing cancer.
223730342|NCT00754624|DRUG|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
224009366|NCT00943852|DRUG|Comparator: Placebo|Single dose placebo only in one of five treatment periods
224009367|NCT02548975|DRUG|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
224009368|NCT02548975|OTHER|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
224009369|NCT05461833|BIOLOGICAL|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
224009370|NCT05461833|DRUG|OTILONII BROMIDUM|OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
224009371|NCT05461833|DIETARY_SUPPLEMENT|multi-strain probiotic|multi-strain probiotic, oral, 1 capsule BID for 1 month
224009372|NCT04640831|DRUG|5 Methoxy N,N Dimethyltryptamine|GH001 administered via inhalation
223389387|NCT04957628|BEHAVIORAL|Non-prescribed psychoactive medicinal use treatment|Patients with prescription on psychoactive medicinal drugs are pharmacologically assessed using serum sample analysis. Patients identified with discrepancy in prescribed doses and serum concentrations will have doses adjusted, or be referred to addiction treatment. Patients identified with psychoactive medicinal drugs other than those prescribed will be advised to quit those medications, or be referred to addiction treatment.
224009373|NCT00733876|BIOLOGICAL|Multipotent Stromal Cells|Post-operative administration of MSC
224009374|NCT00733876|BIOLOGICAL|Administration of MSC|Dose escalation protocol
224009375|NCT01062802|DRUG|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
224009376|NCT01062802|OTHER|Placebo|Placebo given once daily for 4 weeks.
224009377|NCT02141620|DRUG|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
224009378|NCT02141620|DRUG|n-Acetylcysteine|
224126546|NCT03363048|BEHAVIORAL|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
224009379|NCT02141620|DRUG|Placebo|
224009380|NCT04777877|OTHER|Pain Neuroscience Education delivered via a Virtual Reality Headset|Pain educational videos (5) and guided imagery 360 degree nature videos (5)
224009381|NCT06546917|BEHAVIORAL|bWell Cognitive Remediation|"Patients will take part in the bWell cognitive remediation protocol, consisting of 40-minute sessions of bWell, administered 2 times a week for 8 weeks. These sessions consist of tasks that target various cognitive domains and increase in complexity and difficulty as training progresses. The tasks are as follows:~1. Lab Exercise: participant alternates between two different, increasingly complex 'recipes', targeting executive functioning and divided attention.~2. Egg Exercise: In an office environment, participants must seek out and maintain their gaze on certain objects in order to collect them in the presence of visual distractors, targeting sustained attention.~3. Mole Exercise: participants must strike moles with the matching coloured hammer as fast as possible, targeting selective attention.~4. Theatre Exercise: participants must remember objects presented on stage and recreate the sequence after the curtains close, targeting working memory."
224126547|NCT03201510|OTHER|Observational|HPTN 075 is an observational study in sub-Saharan MSM
223389388|NCT06507527|OTHER|Collection of variables|This is an observational study, so no interventions that are not routine clinical practice are performed. It is only about collecting information on variables that are already collected in normal clinical practice.
223389389|NCT05837845|DRUG|MDMA|Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
224009382|NCT06546917|BEHAVIORAL|VR Experience|Patients will take part in the viewing of VR scenes which contain no instructed cognitive tasks. This consists of 40-minute sessions of viewing VR scenes, administered 2 times a week for 8 weeks.
223389390|NCT05837845|BEHAVIORAL|Cognitive Processing Therapy|Participants will receive 8-15 (average of 12) sessions of Cognitive Processing Therapy
223389391|NCT05837845|BEHAVIORAL|MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT)|Participants assigned to MDMA-aCPT will undergo a therapeutic approach administered by trained therapists. MDMA seems to engender internal awareness that even painful feelings that arise are an important part of the therapeutic process. MDMA can elicit feelings of empathy, love, and deep appreciation, along with a clearer perspective of the trauma as a past event, a more accurate perspective about its significance, and a heightened awareness of the support and safety that exists in the present. A combined treatment of MDMA and therapy may be especially useful for treating PTSD because MDMA can attenuate the fear response of a perceived threat to one's emotional integrity and decrease defensiveness without blocking access to memories or preventing a deep and genuine experience of emotion.
223389392|NCT05287230|BEHAVIORAL|CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging)|Investigators will use concepts from the LIFT and REFLECT interventions.
223389393|NCT05287230|BEHAVIORAL|Control|Participants will watch HIV and health related videos and discuss how it is related to aging with HIV.
223389394|NCT06146361|BEHAVIORAL|COVID-19 Group Problem Solving|"This group will have three core components to be delivered at the corner by trained data collectors. Interactive dialogue component that incorporates popular education activities aimed at developing social cohesion among LDLs, building awareness about COVID-19 risks and protective behaviors and developing a plan of action to reduce their and their peers' risk for COVID-19 transmission. Navigation Component will consist of providing information and linking LDLs with social service providers that can help buffer some of the social and economic effects of the COVID-19 pandemic and the Multiplicador de salud/Health Multiplier component that builds from the theoretical and practice-based method of mobilizing social networks and social support, defined as encouraging social networks to provide informational, emotional, appraisal, and instrumental support as cited in the Taxonomy of Behavior Change Methods."
223389395|NCT06146361|BEHAVIORAL|Standard of Care|This group will receive a COVID-19 prevention flyer and social resources list only
223389396|NCT06146361|BEHAVIORAL|Booster session|"Participants will have a 10 - 15 minute booster' session about a week after engaging in the small group intervention. They will be contacted by phone and the booster will consist of brief prompts to engage participants in a discussion to encourage them to act on their personal commitments to protect themselves and others against COVID. They will also be encouraged to seek COVID related resources based on the information provided during the small group intervention."
223389397|NCT04952922|OTHER|Treatment for recurrent oropharyngeal cancer (curative/ palliative)|Open salvage surgery, transoral robotic surgery, palliative chemotherapy, immunotherapy.
224009383|NCT02051959|DEVICE|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
224009384|NCT02051959|DEVICE|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
224009385|NCT02051959|DEVICE|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
224009386|NCT02051959|DEVICE|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
224009387|NCT02757040|DRUG|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
224009388|NCT02757040|DRUG|ibrutinib|ibrutinib
224009389|NCT02940587|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
224009390|NCT02718430|DRUG|VXM01|Oral immunotherapy targeting VEGFR2
224009391|NCT04459117|DRUG|Acetaminophen|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
224126548|NCT04991454|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
224126549|NCT00401622|BEHAVIORAL|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
224126550|NCT00401622|BEHAVIORAL|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
224126551|NCT03874598|PROCEDURE|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
224126552|NCT03874598|BEHAVIORAL|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
224126553|NCT03555903|OTHER|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
224126554|NCT00781781|DRUG|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
224126555|NCT00520676|DRUG|pemetrexed|500 mg/m\^2, IV, q 21 days x 6 cycles maximum
224126556|NCT00520676|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days x 6 cycles maximum
224009392|NCT04459117|DRUG|NACL 0.9%|"In the 27-28 weeks gestational age group, the dosage is 2 ml/kg loading dose within 12 hours after birth followed by 0.75 ml/kg/ 6 hours during 5 days (total = 20 doses).~In the 23-26 weeks gestational age group, the dosage will be minimum effective dose of acetaminophen to close the ductus arteriosus before or at day 7, found during the phase II."
224009393|NCT04239469|DRUG|KL16-012|Standardized cannabis sativa extract of THC and CBD, with each drop containing 1 mg of THC and 0.45 mg of CBD
224009394|NCT04239469|DRUG|Placebo|Placebo
224009395|NCT03856190|OTHER|Fasting and plant-based nutrition|The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
224009396|NCT03856190|OTHER|Standard Nutrition Counselling|The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
224009397|NCT03377699|DRUG|Insulin degludec|Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
224009398|NCT03377699|DRUG|Insulin Aspart|Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
224009399|NCT03377699|DRUG|Insulin detemir|Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
224009400|NCT03784001|BEHAVIORAL|Gratitude + No Expectations Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
224296182|NCT00521274|BIOLOGICAL|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
224296183|NCT00521274|DRUG|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
223389398|NCT05878015|DRUG|Acetaminophen|1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
223389399|NCT04067037|DRUG|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
223389400|NCT04067037|DRUG|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
223389401|NCT04067037|DRUG|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
224009401|NCT03784001|BEHAVIORAL|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
224009402|NCT03784001|BEHAVIORAL|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
224009403|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
224009404|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with sarcoma.
224009405|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
224009406|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with breast cancer.
224009407|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with esophagus cancer.
224009408|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with lung cancer.
224009409|NCT05602792|BIOLOGICAL|T3011|T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
224009410|NCT03517813|DEVICE|Contrast-enhanced Spectral Mammography (CESM)|Dual energy mammography images obtained after the administration of an intravenous contrast agent
224009411|NCT00307684|DRUG|double blind placebo|matching placebo tablets once daily for 4 weeks
223389402|NCT04067037|DRUG|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
224009412|NCT00307684|DRUG|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
224009413|NCT00307684|DRUG|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
224296184|NCT01727687|BEHAVIORAL|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
224296185|NCT03508687|DRUG|300mg Gemcabene|300mg Gemcabene
224296186|NCT03508687|DRUG|600mg Gemcabene|600mg Gemcabene
223389403|NCT05645003|DEVICE|High-frequency real-time rTMS protocol|It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
224009414|NCT01189175|DRUG|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
224009415|NCT01189175|DRUG|BI 113823|single oral dose
224009416|NCT04068961|OTHER|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
224009417|NCT02580305|DRUG|SUVN-502|Once-daily, tablets, orally
224009418|NCT02580305|DRUG|Placebo|Once-daily, tablets, orally
224009419|NCT02580305|DRUG|Donepezil|Donepezil HCl (10 mg, once a day)
224126557|NCT00520676|DRUG|carboplatin|AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum
224296187|NCT00563680|DRUG|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
224296188|NCT05177562|OTHER|No intervention|There is no intervention in this study
223389404|NCT05645003|DEVICE|Sham rTMS Protocol|It was planned to apply a to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.
224009420|NCT02580305|DRUG|Memantine|Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
224009421|NCT00004487|DRUG|chondrocyte-alginate gel suspension|
224009422|NCT03525067|OTHER|Bile sampling for bacterial examination|At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
224009423|NCT00224887|BEHAVIORAL|In home nutrition counseling|In home family-based behavioral counseling
224009424|NCT00224887|OTHER|standard nutrition education curriculum|video and lesson plans based on USDA Food Guide Pyramid
223389405|NCT05969041|DRUG|MT-302 (A)|MT-302 is an investigational drug
223389406|NCT06022822|PROCEDURE|Biopsy Procedure|Undergo biopsy
223389407|NCT06022822|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223389408|NCT06022822|DRUG|Placebo Administration|Given PO
223389409|NCT06022822|DIETARY_SUPPLEMENT|Urolithin A Supplement|Given PO
223389410|NCT06478251|DRUG|NW-301V|TCR-T cell targeting KRAS G12V mutation
223389411|NCT06478251|DRUG|NW-301D|TCR-T cell targeting KRAS G12D mutation
223389412|NCT05525520|DRUG|EP547|Once daily
223389413|NCT05525520|DRUG|Placebo|Once daily
223545954|NCT05196308|DRUG|Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)|"Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator."
223545955|NCT05196308|DRUG|Placebo administration|"For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator."
223545956|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
223545957|NCT01468545|OTHER|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
224009425|NCT02370927|OTHER|Control|Non pulse extruded cereal
224009426|NCT02370927|OTHER|Pea protein|Pulse extruded cereal
224009427|NCT02370927|OTHER|Pea Starch|Pulse extruded cereal
224009428|NCT02370927|OTHER|Pea fibre + pea starch|Pulse extruded cereal
224009429|NCT02370927|OTHER|Pea protein + pea starch|Pulse extruded cereal
224009430|NCT02370927|OTHER|Pea fibre + pea starch + pea protein|Pulse extruded cereal
224009431|NCT03199118|PROCEDURE|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
224009432|NCT03199118|OTHER|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
224009433|NCT02309151|PROCEDURE|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
224009434|NCT05831722|PROCEDURE|Rapid Maxillary Expansion|Rapid Maxillary Expansion consists in the mid palatal suture opening through temporary anchorage mini implants placed in the palatal area.
224009435|NCT02277353|OTHER|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
224009436|NCT00348530|DRUG|Verapamil|
224009437|NCT05625451|DEVICE|Elastic Tension Digital Neoprene Orthosis|The treatment consisted of an exercise program in conjunction with the use of an extension elastic tension digital neoprene orthosis to generate two different daily total end range time doses. Group A patients used a dose of twenty to twenty-two hours of daily total end range time while group B patients used the extension elastic tension digital neoprene orthosis to achieve a daily total end range time between eleven and thirteen hours for a mean of twenty hours a day. The exercise program was the same for both groups.
224126558|NCT00475280|PROCEDURE|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
224126559|NCT00475280|PROCEDURE|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
224126560|NCT02793167|DEVICE|AKI alert|
224126561|NCT04030052|DRUG|Nuwiq (low dose protocol)|After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
223389414|NCT05574868|DEVICE|Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis|Treatment: Erectile dysfunction
224009438|NCT00754364|DRUG|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
223389415|NCT05806138|DRUG|Vericiguat|A starting dose of vericiguat 2.5 mg will be administered in-clinic at the Day 1 visit. Titration visits will occur on Days 14 and 28, with dose escalation to 5 mg and 10 mg.
223389416|NCT05806138|OTHER|Optimal medical therapy|All subjects will be followed by a cardiologist throughout the study period and will receive optimal medical therapy for cardiomyopathy/heart failure following the ACCF/AHA and ESC Guidelines for the Management of Heart Failure recommendations, applied individually at the discretion of the treating investigator and in line with individual tolerability. This includes medications such as ßblockers, angiotensin converting enzyme inhibitors(ACEI), angiotensin receptor/neprilysin inhibitor (ARNI), angiotensin receptor blockers (ARB), and mineralocorticoid antagonists
223389417|NCT06117332|DEVICE|Visual prosthesis|"In response to the stimulation/image on the monitor, subjects will be asked to either make a perceptual judgment or perform a simple behavioral task. Examples include detecting a stimulus ('did you see a light on that trial'), reporting size by drawing on a touch screen, or walking to a target location. Both patient response and reaction time will be recorded.~In some cases, the investigators will also collect data measuring subjects' eye position. This is a noninvasive procedure that will be carried out using standard eye-tracking equipment via an infra-red camera that tracks the position of the subjects' pupil. Only measurements like eye position or eye blinks will be recorded, so these data do not contain identifiable information."
223389418|NCT06404034|DRUG|Gallium Maltolate|GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed
223389419|NCT06529068|BEHAVIORAL|Isometric handgrip exercise|The participants will perform isometric handgrip exercises without blood flow restriction.
223389420|NCT06529068|BEHAVIORAL|Isometric handgrip exercise with a narrow-elastic band|The participants will perform isometric handgrip exercises with blood flow restriction using a narrow-elastic band.
223389421|NCT06529068|BEHAVIORAL|Isometric handgrip exercise with a wide-rigid cuff|The participants will perform isometric handgrip exercises with blood flow restriction using a wide-rigid cuff.
223389422|NCT04603625|OTHER|postural management|postural management in sitting position
223389423|NCT06041880|DEVICE|Passive calf muscle stretching device|Modified night splints will be used to passive stretch the calf muscle.
223389424|NCT06424184|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|"The rTMS protocol implemented in this study will include approximately 10-minute long sessions of intermittent theta burst stimulation (iTBS) with at least 50 minutes in between iTBS sessions.~Study participants will receive the rTMS intervention for up to 50 sessions across a three-week period. The total of 50 sessions will be administered as up to 4 sessions each day, up to 5 days per week over an up to 3-week-long period."
223389425|NCT05957848|DRUG|Guanfacine Extended Release Oral Tablet|Target dose 4 mg daily
223389426|NCT05957848|BEHAVIORAL|Residential withdrawal|4-14 days in residential withdrawal treatment
223389427|NCT05957848|BEHAVIORAL|Engagement with alcohol and other drug services|Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study
223389428|NCT05957848|DRUG|Placebo|Placebo capsule taken daily
223389429|NCT04541082|DRUG|ONC206|ONC206 is a member of the imipridone class of anti-cancer small molecules that share a unique tri-heterocyclic core chemical structure and target G protein-coupled receptors.
223389430|NCT05636020|BEHAVIORAL|ICARE Treatment|The treatment is 12 teletherapy sessions lasting approximately 60-90 minutes. Of the 12 treatment sessions, 7 of them will focus on training skills to help the participant with TBI better recognize emotions from facial expressions. The remaining 5 sessions will teach skills important for empathizing with others' thoughts and feelings, and how to be emotionally supportive. Role-playing will be a big part of these last 5 sessions. The care-partner will be expected to attend as many of these 5 empathy sessions with the participant with TBI as possible.
223389431|NCT06306300|DRUG|Specialist - Epclusa 400Mg-100Mg Tablet|HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.
223389432|NCT06306300|DRUG|Non- specialist - Epclusa 400Mg-100Mg Tablet|HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.
223389433|NCT00000525|DRUG|hydrochlorothiazide|
223389434|NCT00000525|BEHAVIORAL|diet, potassium supplementation|
223389435|NCT00000525|BEHAVIORAL|diet, magnesium supplementation|
223389436|NCT00000525|DRUG|triamterene|
223389437|NCT00000525|DRUG|chlorthalidone|
223389438|NCT02621866|DEVICE|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
223389439|NCT02621866|DEVICE|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of \<500nm, but permits visible light to pass.
223389440|NCT03657797|DRUG|NCX 470|NCX 470 Ophthalmic Solution
223389441|NCT03657797|DRUG|Latanoprost 0.005%|Latanoprost 0.005% Ophthalmic Solution
223389442|NCT05981235|BIOLOGICAL|AZD6422 CLDN18.2 CAR-T product|AZD6422 CAR-T product infusion after pre-conditioning
223389443|NCT00118157|OTHER|Laboratory Biomarker Analysis|Correlative studies
223389444|NCT00118157|DRUG|Lapatinib Ditosylate|Given PO
223389445|NCT00118157|DRUG|Tamoxifen Citrate|Given PO
223389446|NCT03685916|OTHER|Control|Plain rice with plain water
223389447|NCT03685916|OTHER|Cumin Rice|Cumin rice with plain water
223389448|NCT03685916|OTHER|Cumin Drink|Cumin drink with plain rice
223389449|NCT03685916|OTHER|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
223389450|NCT03685916|OTHER|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
223545958|NCT00788814|BEHAVIORAL|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
224009439|NCT00754364|DRUG|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
224009440|NCT01422551|BEHAVIORAL|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
224009441|NCT01422551|BEHAVIORAL|a psycho-educational control|a single-day psycho-educational seminar
224009442|NCT00419978|PROCEDURE|Colectomy|
224009443|NCT00270140|DRUG|epoetin alfa|
224009444|NCT00720772|DRUG|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
224009445|NCT02874417|BEHAVIORAL|CAST psychoeducation|
224009446|NCT02874417|BEHAVIORAL|PHET|
224009447|NCT06373523|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin 10mg daily will be given to the treatment arm.Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups.
224009448|NCT06373523|DRUG|Placebo|The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).
224009449|NCT06373523|DRUG|Levothyroxine Replacement daily|Levothyroxine Replacement daily for 28 weeka
224126562|NCT04030052|DRUG|HEMLIBRA|Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
224126563|NCT04030052|DRUG|Nuwiq (Atlanta protocol)|After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
224126564|NCT02152865|DRUG|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
224126565|NCT02152865|DRUG|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
224126566|NCT00928473|BEHAVIORAL|A family-centered, multidisciplinary obesity treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
224126567|NCT04705025|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBSM using the BNT001 app
224126568|NCT04705025|OTHER|Interview|Complete interview
224126569|NCT04705025|OTHER|Quality-of-Life Assessment|Ancillary studies
224126570|NCT04705025|OTHER|Questionnaire Administration|Ancillary studies
224126571|NCT02179515|BIOLOGICAL|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
224126572|NCT03484923|DRUG|PDR001|400 mg of PDR001 administered every 4 weeks intravenously
224126573|NCT03484923|DRUG|LAG525|600 mg of LAG525 administered every 4 weeks intravenously
224126574|NCT03484923|DRUG|INC280|400 mg of INC280 administered twice daily orally
223389451|NCT03685916|OTHER|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
223389452|NCT03685916|OTHER|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
223389453|NCT03685916|OTHER|Tamarind Rice|Tamarind rice with plain water
224009450|NCT03114787|OTHER|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
224009451|NCT02347423|BIOLOGICAL|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
224009452|NCT02347423|BIOLOGICAL|IPV Vaccine SSI|
223389454|NCT03685916|OTHER|Tamarind Drink|Tamarind drink with plain rice
223389455|NCT01308203|DRUG|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
224009453|NCT03916939|OTHER|osteopathy|osteopathy treatment
224009454|NCT03916939|OTHER|simulated osteopathy|simulated osteopathic sessions
224009455|NCT05861700|OTHER|Group 1: B) Dbic 35 -30 mmol/L C) Dbic 30- 35 mmol/L|A change Dbic in a middle of hemodialysis
224009456|NCT05861700|OTHER|Group 2: C) Dbic 30 -35 mmol/L B) Dbic 35- 30 mmol/L|A change Dbic in a middle of hemodialysis
224009457|NCT04134988|OTHER|Medimoov|The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
224009458|NCT04134988|OTHER|Standard psychomotor therapy|Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
224126575|NCT03484923|DRUG|ACZ885|200 mg of ACZ885 administered every 4 weeks subcutaneosuly
224126576|NCT03484923|DRUG|LEE011|600 mg of LEE011 orally taken once daily on Days 1-21 of a 28-day cycle
224126577|NCT00556361|DRUG|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
224126578|NCT00556361|DRUG|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
224126579|NCT03165357|DIETARY_SUPPLEMENT|Sodium bicarbonate supplementation|
224126580|NCT03165357|DIETARY_SUPPLEMENT|Placebo treatment|
224126581|NCT00335504|DRUG|oligofructose-enriched inulin|Given orally
224126582|NCT00335504|DRUG|sulindac|Given orally
224126583|NCT00335504|DRUG|placebo|Given orally
224126584|NCT00335504|DRUG|atorvastatin calcium|Given orally
223545959|NCT03338985|GENETIC|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
223545960|NCT04185350|DRUG|68Ga-NOTA-MAL-Cys39-exendin-4|After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
224009459|NCT03942900|OTHER|Additional biological samples|"* Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~  * at baseline,~ * at first tumor assessment (phase 2 in OPTIMANAL study),~ * at second tumor assessment (phase 4 in OPTIMANAL study),~ * at end-point visit.~* A tumor biopsy or archived tumor sample will be mandatory at baseline."
224009460|NCT04073251|DIETARY_SUPPLEMENT|KalobaTuss children|Syrup, dosage: 5 ml for 4 times a day for 8 days.
224009461|NCT04073251|DIETARY_SUPPLEMENT|Placebo|Syrup, dosage: 5 ml for 4 times a day for 8 days.
224009462|NCT00575120|OTHER|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
224009463|NCT04916093|DRUG|Vildagliptin 50 MG|Galvus 50 mg oral tablets
224009464|NCT04916093|DRUG|Sitagliptin 100mg|Januvia 100mg oral tablets
224009465|NCT04916093|DRUG|MetFORMIN 1000 Mg Oral Tablet|Glucophage 1000 mg oral tablets
224009466|NCT01744938|PROCEDURE|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
224009467|NCT01253109|DEVICE|SENSIMED Triggerfish|Contact lens-based device for continuous IOP monitoring
224009468|NCT05422404|PROCEDURE|Anti-Reflux Mucosectomy|ARMS will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. The upper gastrointestinal tract will be evaluated in detail first. Then Endoscopic mucosal resection(EMR) will performed at E-C junction, gastric cardia side. About 50%-70% of the EGJ circumference will be resected to create artificial ulcer which will lead to mucosal contraction during the healing process.
224009469|NCT05422404|PROCEDURE|Anti-reflux mucosal ablation|ARMA will be performed using gastroscope . The preparation and endoscopy procedure will be done as in regular practice with conscious sedation. Mucosal ablation will be performed in retroflex fashion following. Then APC with soft coagulation(effect 2, 40W) will be used to mark the area that not going to be ablated at gastric carida over the great curvature direction, about 1.5 scope width. Then submucosa injection with saline and indigo carmine dye will be performed using a 25 guage needle.
224009470|NCT05310305|COMBINATION_PRODUCT|Radiotherapy for targeted lesions and PD-1 antibody|Radiotherapy for targeted lesions in all enrolled participants, with concurrent PD-1 antibody. Patients may or may not accept subsequent PD-1 as maintenance therapy.
224009471|NCT05880745|DIAGNOSTIC_TEST|Nine-Hole Peg Test (NHPT)|Ataxia Rating and Rating Scale (SARA) for coordination Nine-Hole Peg Test (NHPT) and Dexterity Questionnaire-24 (DextQ-24) for manuel dexterity Beck Depression Inventory (BDI) for depression level The Fatigue Severity Scale (FSS) and Fatigue Impact Scale (FIS) for general fatigue level Static and dynamic fatigue levels for hand fatigability
224009472|NCT00620295|DRUG|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m\^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
224009473|NCT00620295|DRUG|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m\^2) on day 1 and day 8 of a 21 day cycle.
224009474|NCT04487704|OTHER|camrelizumab|camrelizumab 200 mg, intravenous infusion (no need for prophylactic administration), no less than 30 min ，No more than 60 min, one cycle every 2 weeks (14 days) or one cycle every 3 weeks (21 days). Try to complete the administration before the ECG
223545961|NCT04035343|BEHAVIORAL|Face down positioning|See description of the face down positioning group
223545962|NCT04035343|BEHAVIORAL|Supine positioning|See description of the supine positioning group
223545963|NCT02270281|DRUG|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
223545964|NCT00962871|DRUG|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
224009475|NCT00574756|DRUG|ranolazine|extended release 500 mg twice a day for two weeks
224009476|NCT03596333|OTHER|Retrospective chart review|We conducted a retrospective chart review to evaluate the stored ultrasound images used during labor epidural placement, as well as demographic and anesthetic variables.
224009477|NCT05949073|PROCEDURE|Non-impregnated retraction cords/ less than 10 minutes|lower first molar will be prepared for full coverage restoration, plain retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
224126585|NCT00335504|OTHER|laboratory biomarker analysis|Correlative studies
224126586|NCT03430687|OTHER|Laboratory Biomarker Analysis|Correlative studies
224126587|NCT03430687|BIOLOGICAL|Talimogene Laherparepvec|Given intravesically
224126588|NCT05270538|DEVICE|Mask Zero Seam Virus Bac-Off Lupo® 98% Polyamide and 2% Elastane|The 26 participants allocated as G2 had to perform the physical exercise using the Zero Sewing Virus Bac-Off Virus® 98% Polyamide and 2% Elastane, in order to totally seal the nose and mouth.
224126589|NCT04569474|DEVICE|Transparent dressing|Use of sterile transparente dressing
224126590|NCT04861480|BIOLOGICAL|C-4-29 Cells|Drug: C-4-29 Cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
224126591|NCT02493816|DRUG|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
223545965|NCT00962871|DRUG|tenofovir|300mg po daily for 2 weeks
223545966|NCT01544348|OTHER|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
223545967|NCT01544348|BIOLOGICAL|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
223545968|NCT01544348|BIOLOGICAL|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
223545969|NCT01544348|BIOLOGICAL|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
223730343|NCT04762433|DEVICE|Kegel Exercise Pregnancy Training - app|"KEPT-app is designed to educate pregnant women on PFMT via the step-by-step training with the capability element to improve their confidence and skills (beginner, intermediate and advance skills). Pregnant women are encouraged to continue adopt the PFMT throughout pregnancy until postpartum period.~The details of the mHealth app content was developed based on the need assessment gathered from the cross-sectional study (Jaffar et al., 2020). It was conducted to identify the need of PFMT by looking at the prevalence of the UI among pregnant women and to understand their knowledge, attitude, and practices towards PFMT."
223730344|NCT00193154|DRUG|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
224009478|NCT05949073|PROCEDURE|Non-impregnated retraction cords/ more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then a plain retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
224009479|NCT05949073|DRUG|impregnated gingival retraction cord - less than 10 minutes|lower first molar will be prepared for full coverage restoration, Aluminum chloride-impregnated retraction cord will be placed in the sulcus just before impression recording (less than 10 minutes).
224009480|NCT05949073|DRUG|impregnated gingival retraction cord - more than 10 minutes|the preparation of the lower first molar for full coverage restoration will be initiated - occlusal reduction, contact points breaking, and preparation with the roughest bur- then an Aluminum chloride-impregnated retraction cord will be placed and kept in the sulcus until finishing the preparation and impression recording which will take more than 10 minutes.
224009481|NCT02261259|PROCEDURE|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
224296189|NCT03749629|OTHER|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
224009482|NCT01493843|DRUG|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
224009483|NCT01493843|DRUG|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
224009484|NCT01493843|DRUG|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
224009485|NCT01493843|DRUG|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
224009486|NCT01493843|DRUG|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
224009487|NCT05330689|BIOLOGICAL|PRP injection dose (<5 billion platelets)|PRP injection with a dose of platelets that is less than 5 billion platelets
224009488|NCT05330689|BIOLOGICAL|PRP injection dose (between 5 and <10 billion platelets)|PRP injection with a dose of platelets that is between 5 and \<10 billion platelets
224296190|NCT03749629|OTHER|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
224296191|NCT05196360|DRUG|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
224296192|NCT00770692|DRUG|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
224296193|NCT00770692|DRUG|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
224296194|NCT00770692|DRUG|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
224296195|NCT00770692|DRUG|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
224296196|NCT04167176|PROCEDURE|Erector spinae plane block|Patients will be placed on their right side. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10-cm needle will be inserted using an in-plane approach in a cranial to caudal direction. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
223730345|NCT00193154|DRUG|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
224009489|NCT05330689|BIOLOGICAL|PRP injection dose (between 10 and <20 billion platelets)|PRP injection with a dose of platelets that is between 10 and \<20 billion platelets
224009490|NCT05330689|BIOLOGICAL|PRP injection dose (20 billion or greater platelets)|PRP injection with a dose of platelets that is 20 billion platelets or greater
224009491|NCT05330689|OTHER|Saline injection control|Saline control
224009492|NCT01107821|DEVICE|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
223389456|NCT01308203|DRUG|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
223545970|NCT01544348|BIOLOGICAL|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
223545971|NCT01544348|BIOLOGICAL|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
223545972|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
224009493|NCT03811262|PROCEDURE|ESP BLOCK|local anesthetic will be injected between transverous process and erector spinae muscle
224009494|NCT03811262|PROCEDURE|PECS BLOCK|local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
224009495|NCT03663491|PROCEDURE|Nasal Gastroscopy|Use of transnasal endoscopes for routine gastroscopy in adults.
224009496|NCT03663491|PROCEDURE|Oral Gastroscopy, unsedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
224009497|NCT03663491|PROCEDURE|Oral Gastroscopy, sedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
224009498|NCT03663491|PROCEDURE|Oral Gastroscopy with transnasal endoscope, sedated|Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
223545973|NCT01544348|BIOLOGICAL|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
224009499|NCT05182281|DEVICE|Whole Body Vibration and Infrared Therapy|Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
224009500|NCT05182281|DEVICE|Infrared Therapy|Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
224009501|NCT05182281|OTHER|Classical Treatment|1000 mg Ca and 880 IU vitamin D treatment were given
224009502|NCT05784831|DEVICE|Reappraisal training|The EMI developed and tested here is based on theoretical and empirical findings and consists of several items and repeated training using various individual scenarios from participants' life that will be presented to participants via an app on their smartphones.
224296197|NCT04167176|PROCEDURE|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
224296198|NCT04167176|DEVICE|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio-Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
224296199|NCT04167176|DRUG|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
224296200|NCT04167176|DRUG|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
223389457|NCT01546818|BIOLOGICAL|SAV001-H|A whole-killed HIV
223389458|NCT00944099|BEHAVIORAL|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
223545974|NCT04196725|OTHER|Physical therapy treatment|Two weeks rehabilitation programme focusing on physical therapy treatment, e.g. manual lymphatic drainage and compression bandaging
223545975|NCT04196725|BEHAVIORAL|Lifestyle treatment|Two weeks rehabilitation programme focusing on physical activity
223545976|NCT02705092|OTHER|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
223545977|NCT02705092|OTHER|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
223545978|NCT05871580|RADIATION|Low frequency laser activated photobiomodulation|"Infravermelho: analgesia, tissue biostimulation. The number of laser application points will be determined based on the areas referred by the patients.~* apex tongue: 3 points~* lateral edge of the tongue: 4 points~* tongue dorsum: 10 points~* jugal mucosa: 8 points~* labial mucosa: 5 points~* hard palate: 8 stitches~* soft palate: 3 stitches~* gingiva or alveolar mucosa: 3 stitches per sextant.~Time of 30 seconds in each application point, with dosage: 3 J/point."
223730346|NCT02272920|PROCEDURE|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
223389459|NCT02670616|DRUG|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
223545979|NCT05871580|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
223545980|NCT00777348|DRUG|Combination DSCG and Reproterol|1:
223730347|NCT04049396|OTHER|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
224009503|NCT05784831|DEVICE|Ecological Momentary Assessment|The EMA tested here collects data on participants' mood and behavior.
224009504|NCT00417105|PROCEDURE|hemodialysis|group 1: twice weekly, four hours
224009505|NCT00417105|PROCEDURE|hemodialysis|group 2: twice weekly, eight hours
224009506|NCT00417105|PROCEDURE|hemodialysis|group 3: every other day, eight hours
224009507|NCT00417105|PROCEDURE|hemodialysis|group 4: six days a week, eight hours
224009508|NCT02083120|DEVICE|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
223389460|NCT02670616|DRUG|Rituximab|375 mg/m2 IV, day 1
223389461|NCT02670616|DRUG|Cyclophosphamide|750 mg/m2 IV day 1
223389462|NCT02670616|DRUG|Doxorubicin|50 mg/m2 IV day 1
223389463|NCT02670616|DRUG|vincristine|1.4 mg/m2 IV on day 1
224009509|NCT02083120|OTHER|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
223389464|NCT02670616|DRUG|Prednisolone|100mg per day on day 1-5
223389465|NCT03262428|OTHER|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
223545981|NCT06337981|DRUG|(AJU-S56 5% and placebo)|(AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
224009510|NCT03871673|DIETARY_SUPPLEMENT|Sweet manioc starch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
224009511|NCT03871673|DIETARY_SUPPLEMENT|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
224009512|NCT05499845|DIAGNOSTIC_TEST|butanol threshold test and smell identification tests|no additional intervention
224009513|NCT00094289|DRUG|Disulfiram|
223389466|NCT00102219|DRUG|Pemetrexed|
223389467|NCT00102219|DRUG|Doxorubicin|
223389468|NCT01813617|DRUG|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
223389469|NCT00929968|BIOLOGICAL|Placebo|
223389470|NCT00929968|BIOLOGICAL|VAK694|
223389471|NCT00929968|DRUG|Fluticasone|
223389472|NCT01224405|DRUG|Docetaxel + LH-RH analogues|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration."
223389473|NCT01224405|DRUG|Docetaxel|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues."
223389474|NCT01224405|DRUG|Docetaxel|Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced \>50%. Docetaxel treatment will be resumed when the serum PSA will rise by \>50% from the lowest PSA level recorded and will be \>10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
223389475|NCT01224405|DRUG|Continuous Docetaxel|Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
223389476|NCT01224405|DRUG|Continuous Docetaxel|Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
223389477|NCT00696423|BIOLOGICAL|Infanrix™|Intramuscular injection, one dose
223389478|NCT00696423|BIOLOGICAL|Hiberix™|Intramuscular injection, one dose
223389479|NCT02897778|DRUG|Entinostat|Single, supratherapeutic dose of entinostat given orally.
223389480|NCT02897778|DRUG|Placebo|Single dose of placebo-matching entinostat (containing inactive ingredients matching the appearance of the active product).
223545982|NCT06337981|DRUG|AJU-S56 5%|(AJU-S56 5%), 1drop/1times, 6times in a day
223545983|NCT06337981|DRUG|Placebo(Vehicle)|Placebo(Vehicle), 1drop/1times, 6times in a day
223545984|NCT01237431|DIETARY_SUPPLEMENT|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
223545985|NCT00752414|DRUG|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
223545986|NCT00752414|DRUG|Placebo|same frequency as MP-376
224009514|NCT02321332|PROCEDURE|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
224009515|NCT02321332|PROCEDURE|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
224009516|NCT04573829|PROCEDURE|Home visit|Psychologist come once a week for the carer and three times a week for the patient
224009517|NCT06129578|DIETARY_SUPPLEMENT|Mediterranean diet supplement with 20 g / day of hemp protein.|"All participants followed a low-energy diet (1315 kcal/daily) based on Mediterranean diet for 12 weeks, supplement with 20 g / day of hemp protein. The specific menu was designed by a trainee nutritionist. The program prescribed five meals a day, with the time customized to fit the lifestyle of each patient. Based on the baseline metabolism, the energy and nutritional parameters of every patient were computed. Patients reported the dietary intake data daily.~The intervention included face to face visit every two weeks, individual nutrition counseling and education sessions."
224009518|NCT06268548|OTHER|Manual diaphragmatic activation|Manual diaphragm release on diaphragm
224009519|NCT02797431|DRUG|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR\>2.5 or platelet count \< 35,000
224009520|NCT02797431|DRUG|Placebo|IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
224126592|NCT06515041|OTHER|brain well-being|Each volunteers will be subjected to an evaluation of his well-being using a previously well established well-being scale, through a list of questions, prior, during and after the visit to the museum. All volunteers will be also equipped with a non invasive NIRS system to measure their emotions (measure of tissus oxygenenation), with a non invasive system of eye tracking glasses to measure where their eyes are looking and with a non invasive system to measure their heart rate.
224009521|NCT04617977|BEHAVIORAL|I-BMS for families with children suffering from eczema|It is a strength-based, family system approach to aid empowerment of individuals. It focuses on the interplay between physical and emotional well-being, the spiritual transformation of adverse life experiences, and the acceptance of adversity through reflection on the philosophical concepts of forgiveness and letting go. It integrates Western therapeutic techniques and Eastern philosophies to develop spiritual transformation through suffering and pain under a meaning-oriented framework. It consists of six three-hour consecutive weekly sessions: (1) awareness of body-mind connection; (2) regulation of emotion; (3) acknowledgement of the gains and losses in the caregiving or illness experience; (4) appreciation of self and others; (5) cultivation of acceptance; and (6) meaning reconstruction of caregiving or illness experience.
224009522|NCT04617977|BEHAVIORAL|Health education for parents whose children have eczema|It focuses on practical eczema management. It serves as a control for group effect between conditions. It consists of six three-hour sessions: (1) information about the physiology of eczema and its health impact; (2) recognition and avoidance of trigger factors and daily skin care; (3) dealing with itching and scratching; (4) stage-related treatment of symptoms and unconventional therapies; (5) general child nutrition, food allergies in eczema, and different forms of diets; and (6) self-management plan and problems in integrating into daily routine.
224009523|NCT01315210|DRUG|D-Ribose Powder|5 g TID for 12 Weeks
224009524|NCT01315210|DIETARY_SUPPLEMENT|Placebo Powder|5 g TID for 12 Weeks
224299285|NCT06088056|DRUG|Combination use of SRT with T-DXd|"Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.~Dose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg"
224299286|NCT00327288|DRUG|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
223389481|NCT01090778|DRUG|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
223389482|NCT03075371|OTHER|Glucose|75 g of glucose dissolved in 300 ml of water
223389483|NCT03075371|OTHER|Placebo|300 ml of tap water
223389484|NCT03444311|DIETARY_SUPPLEMENT|A: 1 dosis|"1 dosis (3E+09 cfu/d + 6 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
224009525|NCT03502031|DRUG|Renin-Angiotensin (RAAS) alone|maximal RAAS blockade alone for 24months.
224009526|NCT03502031|DRUG|Renin-Angiotensin (RAAS) blockers in combination with Spironolactone|maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
224009527|NCT00700427|DRUG|atomoxetine hydrochloride|Oral 40-100 mg/day
224009528|NCT00700427|DRUG|Placebo|Oral delivery of matching placebo
224009529|NCT06419400|BEHAVIORAL|Supportive text messages|The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency.
224126593|NCT04414657|OTHER|blood sampling for biobank|blood sampling for biobank
224126594|NCT02292303|DIETARY_SUPPLEMENT|zinc-enriched yeast|
224126595|NCT02292303|DIETARY_SUPPLEMENT|Zinc references|
224126596|NCT02179528|DRUG|Etoposide|
224126597|NCT03165721|DRUG|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m\^2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
224126598|NCT01863849|BIOLOGICAL|Vaccination with Fluval AB suspension for injection|Single intramuscular injection with Fluval AB suspension for injection in both age groups
224126599|NCT01457118|DRUG|NKTR-102 145 mg/m2|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
224126600|NCT01457118|DRUG|NKTR-102 120 mg/m2|A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
224126601|NCT01457118|DRUG|NKTR-102 95 mg/m2|A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
224126602|NCT01457118|DRUG|NKTR-102 50 mg/m2|A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
224126603|NCT06092242|DRUG|Tas-102(Suyuan) combined with bevacizumab|Tas-102: po 35 mg/m2, bid, d1-5, d8-12, Q4 wks; bevacizumab: intravenous drip 5 mg/kg, D1, D15, Q4 wks.
224126604|NCT00256048|PROCEDURE|Nasojejunal feeding|
224126605|NCT00115349|DRUG|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
224126606|NCT00115349|DRUG|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
224126607|NCT06423287|DIETARY_SUPPLEMENT|Lactobacillus plantarum LP-KFY04|Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.
224126608|NCT06423287|OTHER|Take placebo in addition to the limited diet.|Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks'trial.
224126609|NCT01980108|OTHER|water|water
224126610|NCT02804412|OTHER|Control group|This is the control group with 14 h treatment over 10 workdays.
224126611|NCT02804412|OTHER|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
224126612|NCT02804412|OTHER|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
224126613|NCT01887899|DEVICE|transcranial direct current stimulation|
224126614|NCT01887899|DEVICE|sham stimulation|
224009530|NCT03025685|PROCEDURE|TRUST technique|A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
224009531|NCT03025685|PROCEDURE|Anchoring Technique|A standard endovascular technique of coronary wire support improvement
224009532|NCT03025685|PROCEDURE|Coronary stenting|A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
224009533|NCT05962801|DEVICE|Lumoral device, Lumorinse|Regular use of dual-light photodynamic therapy at home
224009534|NCT00484133|DRUG|Dopamine|
224009535|NCT00484133|DRUG|dobutamine|
224009536|NCT00484133|DRUG|enoximone|
224009537|NCT00484133|DRUG|nitroglycerine|
224009538|NCT00484133|DRUG|noradrenaline|
224009539|NCT03482401|DIETARY_SUPPLEMENT|Polyphenol|Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
224009540|NCT00579267|OTHER|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
224009541|NCT05269745|OTHER|Stretching through immobilisation (IG)|The immobilization group (IG) will receive the standard treatment, a dynamic ankle-foot orthosis (AFO) for night and day use (23 hours per day)
224009542|NCT05269745|OTHER|Stretching through immobilisation and activity (IAG)|The Immobilization/Activity Group (IAG) will be treated with the same type of ankle-foot orthosis at night (8 hours) and for 6 hours during the day (altogether orthosis treatment 14 hours per day). The rest of the day (10 hours) children and adolescents will be using only the foot shell of orthoses (FS) without the lower leg shell, to secure the correct position of the foot and to allow a free motion at ankle joint with a good correction of the foot deformity (e.g. Pes equinovarus / equinovalgus, midfoot-break).
224009543|NCT05269745|OTHER|Control Phase|Before the intervention with the orthotic treatment starts, a control phase of 8 weeks is planned. During this time, the individual orthoses for each subject are manufactured.
224296201|NCT02447926|PROCEDURE|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
224296202|NCT05559112|OTHER|Vitamin D-enriched mushrooms|Participants will consume their usual, unrestricted, self-selected diet plus 84 g of vitamin D-enriched mushrooms twice daily (for a total of 168g per day) for 12 weeks.
224296203|NCT05559112|OTHER|Study Powder|Participants will consume their usual, unrestricted, self-selected diet plus 1 tsp of dried study powder twice daily (2 tsp total per day) for 12 weeks. Study powder is a commercially available carbohydrate.
224009544|NCT03093103|DRUG|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
224009545|NCT03093103|DRUG|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
224009546|NCT00457860|DRUG|Immunotoxin therapy|
224009547|NCT00457860|DRUG|CAT-8015 immunotoxin|
224296204|NCT03915665|DRUG|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
224296205|NCT03915665|DEVICE|Air-powder|Erythritol powder using air-powder device
223730348|NCT01432886|DRUG|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
224009548|NCT00457860|PROCEDURE|Biological therapy|
224009549|NCT02384265|BEHAVIORAL|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
224009550|NCT05816226|DRUG|Hydrocortisone 2.5%|Applied four times daily to TMJ with arthralgia
224009551|NCT05816226|DRUG|Diclofenac 1% topical|Applied four times daily to TMJ with arthralgia
224009552|NCT01828632|PROCEDURE|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
224009553|NCT00730873|DEVICE|Continuous positive airway pressure|
224009554|NCT04585867|DRUG|Exparel|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
224299287|NCT00327288|DRUG|docetaxel|IV once every 21 days for duration of study
224299288|NCT01390285|DEVICE|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
223389485|NCT03444311|DIETARY_SUPPLEMENT|B: 2 dosis|"1 dosis (3E+09 cfu/d + 12 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
223389486|NCT02069639|OTHER|no treatment|
224009555|NCT04585867|DRUG|Bupivacaine|The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure
224126615|NCT02123160|BEHAVIORAL|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
224126616|NCT02123160|BEHAVIORAL|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
224126617|NCT01337531|DRUG|Gonal-F, Fostimon|dosage form
224126618|NCT01337531|DRUG|Gonal-F, Fostimon|injection, daily, 10-15 days
224009556|NCT01244529|DEVICE|galy A Plus|galyfilcon A Plus, BC: 8.3 or 8.7
224009557|NCT01244529|DEVICE|seno A|senofilcon A, BC:8.4 or 8.8
224009558|NCT01244529|DEVICE|galy A|galyfilcon A , BC: 8.3 or 8.7
224009559|NCT03746782|DIAGNOSTIC_TEST|Flow Cytrometry; Thrombin Generation Assay|Apixaban combined with blood specimens (in vitro) of study participants
224126619|NCT04341675|DRUG|Sirolimus|Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
224299289|NCT01390285|DEVICE|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
223545987|NCT03911297|OTHER|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
223545988|NCT03695887|DRUG|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
223545989|NCT03695887|DRUG|Placebo|Inactive comparator
223545990|NCT05200559|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
224009560|NCT03974139|DRUG|Metformin Oral Tablet|Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
224009561|NCT00351208|DEVICE|Medtronic Manufactured Spinal Cord Stimulators|
224126620|NCT04341675|DRUG|Placebo|Matching placebo
224126621|NCT06400836|OTHER|Carbohydrate timing - carbohydrate intake before or after exercise|The study aims to investigate how pre- or post evening exercise carbohydrate ingestion influences glucose metabolism and substrate oxidation (fat/CHO) during exercise and after exercise in athletes during the nocturnal period (21:00-06:00) and the morning after during an 120 minute oral glucose tolerance test (OGTT).
224126622|NCT02300415|BIOLOGICAL|blood sample|Dosage of presepsine
224009562|NCT04940819|BEHAVIORAL|Mobile Application for Dietary Management|A mobile application developed by a multi-disciplinary team will be used in the dietary management of CKD patients. The application is patient orientated. It has 4 core features including food searching, dietary logging, personalized key nutrient intake feedback and patient-caregiver interaction.
224009563|NCT03583567|DRUG|Chlorpheniramine and ranitidine|Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
224126623|NCT01718509|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
224126624|NCT01718509|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
224126625|NCT05263102|DEVICE|Vaginal Moisturizing Gel|All eligible subjects will received the Vaginal Moisturizing Gel twice per week, total in 8 weeks
224126626|NCT00804258|DRUG|intraperitoneal chemotherapy|
224299290|NCT02693093|DRUG|NI-03|
224299291|NCT02693093|DRUG|Placebo|
223389487|NCT03920514|DRUG|hCG|Women will be given hCG before or with IUI
223389488|NCT02363543|DEVICE|Hyalomatrix|
223389489|NCT02363543|DEVICE|Integra|
224009564|NCT03583567|DRUG|0.9% Normal Saline|Patient will receive normal saline as placebo.
224009565|NCT00941070|DRUG|triapine|Given IV
224009566|NCT00941070|DRUG|cisplatin|Given IV
223389490|NCT03989102|BIOLOGICAL|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
223389491|NCT03989102|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
223389492|NCT03642262|DRUG|Mucinex®|Mucinex® 600 mg single dose ER bi-layer tablet
223389493|NCT00000520|DRUG|immunoglobulins, intravenous|
223389494|NCT00000520|DRUG|aspirin|
223389495|NCT04047667|PROCEDURE|cone beam CT guided transbronchial cryobiopsy|CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
223545991|NCT05200559|DRUG|E7777|E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
223545992|NCT05006066|OTHER|Temporal Summation|4 type of stimulations applied on the right arm
224009567|NCT00941070|RADIATION|external beam radiation therapy|Undergo pelvic external beam radiation therapy
224009568|NCT00941070|PROCEDURE|quality-of-life assessment|Ancillary studies
223545993|NCT01204957|DIETARY_SUPPLEMENT|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
224009569|NCT00941070|OTHER|questionnaire administration|Ancillary studies
224009570|NCT00941070|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET/CT
224009571|NCT00941070|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
224009572|NCT00941070|PROCEDURE|computed tomography|Undergo FDG-PET/CT
224009573|NCT04143958|DRUG|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
224009574|NCT04143958|DRUG|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
224009575|NCT01984138|DRUG|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
224009576|NCT01984138|DRUG|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
224009577|NCT05158816|PROCEDURE|ECMO|Patients undergoing extracorporeal membrane oxygenation
224009578|NCT01998503|DRUG|Bortezomib|
224126627|NCT00804258|OTHER|educational intervention|
224009579|NCT01998503|DRUG|dexamethasone|Given orally
224009580|NCT01998503|BIOLOGICAL|filgrastim|Given subcutaneous
224009581|NCT01998503|PROCEDURE|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
224009582|NCT01998503|DRUG|Melphalan|
224009583|NCT03510494|BEHAVIORAL|Augmented physical education program|Augmented physical education program
224009584|NCT03182192|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
224126628|NCT00804258|OTHER|medical chart review|
224126629|NCT00804258|OTHER|questionnaire administration|
224126630|NCT00804258|PROCEDURE|assessment of therapy complications|
224126631|NCT00804258|PROCEDURE|end-of-life treatment/management|
224126632|NCT00804258|PROCEDURE|psychosocial assessment and care|
223389496|NCT06490848|PROCEDURE|Diagnostic cerebral angiography|In transradial access, no preprocedural upper extremity collateral blood supply testing was completed. When the radial access is unsuccessful, it is shifted to ulnar or femoral access. All right arms were secured in the fully supine position to allow access to both radial and ulnar arteries. At the conclusion of radial access procedures, a TR band was applied to close the access. Neurological exams as well as radial artery pulse and pulse oximeter of the right first finger were assessed during and on discharge by trained recovery nurses. Femoral access was performed in a standard manner. After the access (femoral or radial), a cerebral angiogram was performed in a standard manner using appropriate catheters (vertebral, bern, Simmons 2 or 3) according to the access. For the radial access, the patient was slightly sedated.
223545994|NCT01204957|DIETARY_SUPPLEMENT|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
223545995|NCT03695445|DRUG|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
224126633|NCT00804258|PROCEDURE|quality-of-life assessment|
223545996|NCT01710566|DRUG|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
224009585|NCT01247285|DRUG|Fluoxetine Hydrochloride|90 mg Capsules
224009586|NCT01247285|DRUG|PROZAC WEEKLY®|90 mg Capsules
224009587|NCT01896323|DRUG|CC-223|CC-223 20 mg tablets
224009588|NCT01896323|DRUG|Ketoconazole|Ketoconazole 400 mg tablets
224009589|NCT03803124|DRUG|Tolvaptan|1 tablet before renography
224009590|NCT03803124|DRUG|Placebo|1 tablet before renography
224009591|NCT05551533|OTHER|Kampung Care App|Please refer to the previous session
224009592|NCT01141647|BEHAVIORAL|Vocational Rehabilitation|SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
224009593|NCT04677829|BIOLOGICAL|PNT001|30 minute infusion for PNT001 1000mg; 60 minute infusion for PNT001 4000mg
224009594|NCT04677829|BIOLOGICAL|%5 dextrose for infusion|30 min placebo infusion for 1000mg; 60 minute placebo infusion for 4000mg
224009595|NCT04727892|PROCEDURE|epilepsy surgery|Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
224126634|NCT04823208|DRUG|LY3437943|Administered SC
224126635|NCT04823208|DRUG|Placebo|Administered SC
224126636|NCT05209932|BEHAVIORAL|Online New Beginnings Program (eNBP)|The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group-based NBP that can be used on a smart phone, tablet or computer. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations.
224009596|NCT00418340|DRUG|probiotic (bacterial/dietary supplement)|
224009597|NCT01729442|OTHER|Shear-wave ultrasound elastography (SWUE)|
224009598|NCT03684668|BEHAVIORAL|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
224009599|NCT04127851|DRUG|TJO-018 (HA 0.15%)|TJO-018 / one drop / 6 times daily in both eyes
224009600|NCT04127851|DRUG|Cyclosporine Ophthalmic Emulsion 0.05% standard therapy (CMC 0.5% add)|Cyclosporine / one drop / twice daily in both eyes carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes
224009601|NCT04127851|DRUG|TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%|TJO-018 (HA0.15%)/ one drop 6 times daily in both eyes Cyclosporine 0.05% /one drop twice daily in both eyes
224009602|NCT02120287|DRUG|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
224009603|NCT02120287|PROCEDURE|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
224296206|NCT01528020|BEHAVIORAL|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
224009604|NCT02120287|PROCEDURE|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
224009605|NCT03905343|DRUG|Ribociclib|Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.
224009606|NCT03905343|OTHER|Mono-chemotherapy|mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.
224009607|NCT03905343|OTHER|Endocrine-Therapy|The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
224009608|NCT04549649|OTHER|Dual triggering|Adding GnRH agonist (0.2 mg Triptorelin (Decapeptyl; Ferring GmbH) to routine oocyte triggering (two ampoules of Ovitrelle®, 250 μg/0.5 ml, Merck, Serono, Inc) is defined as dual triggering.
224009609|NCT01579500|DRUG|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
224009610|NCT01579500|DRUG|normal saline|Subcutaneous injection of normal saline
224009611|NCT06065254|OTHER|Efficacy of free gingival grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Two vertical incisions will be made in the previously elevated flap against the placed implant , where these two incisions will be 10 mm apart from each other, and the free graft to will be placed in this distance (10 x 10 mm). The graft will be obtained from the donor site (the hard palate), and will be thinned to obtain a regular graft with the required thickness. After that, the graft will be moved to its correct place accurately, while avoiding leaving a distance between the graft and the tissue underneath, and the graft will be sutured well to ensure its stability and correct placement.
223545997|NCT01710566|DRUG|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
224009612|NCT06065254|OTHER|Efficacy of connective tissue grafts during in the increasing of peri-implant keratinized tissue width and soft tissues thickness|Vertical incisions will not be made in the previously elevated flap against the placed implant, where there is no need to suture the flap apically of the grafting place because the graft will be covered with it after fixing it in place. The area will be washed with the serum to remove the clot before fixing the graft.The graft will be obtained from the donor site according to the previously mentioned method. Then the epithelium will be removed to leave the connective tissue underneath, and then the graft will be moved to its place (buccally dental implant site) and the flap will be sutured over it.
224009613|NCT06065254|OTHER|No types of grafts will be made to improve the quality of the peri-implant mucosa|The simple suturing of the two surgical incisions will be done after the completion of the dental implant process, with no procedure will be made to improve the quality of the peri-implant mucosa.
224009614|NCT06347328|PROCEDURE|echo-guided infiltration|the subjects will receive their injection in the ultrasound room. a glucocorticoid injection is given at the time of consultation, using anatomical ultrasound scan to guide needle placement
224009615|NCT06347328|PROCEDURE|non-echo-guided infiltration|"the subjects will receive their injection in the ultrasound room.~a glucocorticoid injection is given at the time of consultation, using anatomical landmarks to guide needle placement.~The investigator simulate an ultrasound scan with a film shown on the screen."
224126637|NCT05600192|OTHER|Aerobic or anaerobic exercise|Aerobic or anaerobic exercise in the morning or in the afternoon
224126638|NCT04552379|BIOLOGICAL|Peginterferon beta-1a|"Administration of trial drug: PLEGRIDY is given by an injection under the skin (subcutaneous injection). It will be administered to participants in accordance with product insert instructions by appropriately trained trial staff for whom administration of subcutaneous injections is within their normal scope of practice (e.g. RN or MD). They will wait for 20 mins after the last individual receives the interferon before leaving a residence. Administering staff will be supplied with appropriate PPE, trained in the use of this equipment and protocols for infection control, and will always attend in pairs.~PLEGRIDY will be administered in the home of the participants. Due to the heat-labile nature of the trial product (storage required at \~4oC) a verified English Spanish version of the product label will be printed by a GMP certified company and applied to the product and patient band just at the time of use."
224126639|NCT00103545|BIOLOGICAL|ACA 125|
224126640|NCT06256783|DRUG|Baozhu Keli|Once enrolled, participants will be administrated Baozhu Keli
224299292|NCT01333371|PROCEDURE|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
224299293|NCT03580083|GENETIC|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
224299294|NCT00822341|DRUG|TG-0054|0.10, 0.14, 0.28, 0.56, 1.12, 2.24, 3.14, and 4.40 mg/kg of TG-0054/placebo via 15 min IV infusion
223389497|NCT06150586|OTHER|Skin Conductance (SC) Measurement|SC will be measured using a specific monitor and three self-adhesive electrodes on one foot of the infant (one plantar and two on the ankles). Peaks per second (the rate of firing in the sympathetic nerves), average amplitude (mean peaks) and area under curve (forcefulness of sympathetic nerve firing) will be automatically analyzed. Corresponding data will be transferred to a separate tablet computer via bluetooth.
223545998|NCT02257320|DEVICE|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
224009616|NCT00004242|DRUG|fluorouracil|
224009617|NCT00004242|DRUG|gemcitabine hydrochloride|
224009618|NCT00004242|DRUG|oxaliplatin|
224126641|NCT06362499|DEVICE|Experimental Group|After the initial assessment, all volunteers will receive a POWERbreathe® classic light resistance device (POWERbreathe®, Nsc, Brazil), to carry out the training, and will be individually guided on how to use it and how to complete the protocol. They will perform a trial session to familiarize themselves with the device that will not be considered for analysis. Every week, volunteers will receive a telephone call from researcher 2, who will not participate in the evaluation, to confirm whether the exercise with the POWERbreathe® will be performed appropriately at the recommended frequency, intensity, and duration and whether there are any questions regarding the protocol. At the end of each week, participants will receive a video call from researcher 2 to adjust the device according to G1's weekly load progression.
224126642|NCT00803010|DRUG|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
224126643|NCT00803010|DRUG|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
224126644|NCT00803010|DRUG|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
224126645|NCT04346264|DIAGNOSTIC_TEST|NO intervention planned due to the observational study design only a diagnostic testing|Only a diagnostic test (serum blood and antibody measurement) is planned
224126646|NCT02985502|OTHER|pancreatogenic diabetes|pancreatogenic diabetes
224126647|NCT02717065|OTHER|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
224126648|NCT02717065|OTHER|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
224126649|NCT05800106|DRUG|Sunitinib malate capsules generic product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
224126650|NCT05800106|DRUG|Sunitinib malate capsules reference product|Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
224126651|NCT04234126|PROCEDURE|ERCP|Routine ERCP for CBD stone with the gallbladder in situ, the chronic gallbladder status was defined as gallbladder wall thickness≥4mm, chronic cholecystitis, polyps,crudely or calculus .
223389498|NCT06150586|OTHER|Video Recording|The video recording for later N-PASS assessment will be done by a camera fixed above the incubator / resuscitation unit, not interfering with the LISA procedure. The video will show the full body of the newborn as well as the hands / forearms of the treating clinical team with the awareness and oral consent of the treating team.
223389499|NCT01961219|PROCEDURE|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
223389500|NCT01961219|PROCEDURE|Arthroscopic capsular release|Arthroscopic capsular release
223545999|NCT01647854|PROCEDURE|Teleconsultation|Teleconsultation in prehospital emergencies
224126652|NCT04503928|DRUG|Euphorbia kansui Pill|1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
223546000|NCT04079660|DIAGNOSTIC_TEST|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
223546001|NCT03649802|DIETARY_SUPPLEMENT|Low dose vitamin D3|Low dose arm-800 IU given daily
224126653|NCT05880407|PROCEDURE|SERI osteotomy|Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
224126654|NCT05880407|PROCEDURE|percutaneous osteotomy according to Chevron|Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
223546002|NCT03649802|DIETARY_SUPPLEMENT|High dose vitamin D3|High dose arm-5000 IU given daily
223546003|NCT03790748|PROCEDURE|Standard Lumbar Epidural Technique|Standard Lumbar Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
224009619|NCT05956275|DRUG|Tramadol|ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
224009620|NCT05956275|DRUG|Morfin|No block was applied to the patients in control
224009621|NCT05841992|DRUG|Al18F-PSMA-617|Intravenous injection of one dosage of 0.1mCi/kg Al18F-PSMA-617. Tracer doses of Al18F-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
224009622|NCT05841992|DRUG|68Ga-PSMA-617|Intravenous injection of one dosage of 148-185 MBq (4-5 mCi) 68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.
224009623|NCT04235153|OTHER|Evaluation of the 9 dimensions of the CANUT-QVA questionnaire|"Evaluation of the contribution of a new questionnaire by patients with solid or hematological cancer according to 9 dimensions:~1. Making food~2. Place where the meals are eaten~3. Eating and drinking: Nutrition~4. Eating and drinking: The pleasure of tasting, chewing~5. Eating and drinking: Satiated, well being~6. Food preparation: Supply, choice, presentation~7. Eating and drinking: Feelings~8. After eating: heaviness, discomfort, hunger~9. Taste/Odour Problems to confirm the number and structure of factors obtained at the end of the pre-study and to remove redundant questions."
224009624|NCT03975751|DIAGNOSTIC_TEST|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
223389501|NCT04142736|OTHER|Prone Position|The best-fitting and most-tolerated oxygen interface will be used in the prone position--this could be different from patient to patient, and different from what is used in the supine position, and could differ between patients but also institutions (i.e., depending on the availability of masks with or without a reservoir bag and with or without the Venturi system, HFNO, CPAP or NIV). The patient will be placed in the prone position for at least 2 hours, which may be prolonged if the patient is comfortable or interrupted if the patient presents any criteria for prone position discontinuation. After the prone position period, the patient will be rotated to the semi-recumbent supine position for at least 2 hours and a maximum of 4 hours. This 2-hour time frame will depend on nursing availability, need for hygiene, complementary explorations, or diet.
223389502|NCT01365819|DRUG|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
223389503|NCT01365819|DRUG|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
223389504|NCT01783990|DRUG|Hydroxyurea|Parents and child's doctor may plan to use or not to use hydroxyurea.
223389505|NCT00242138|BEHAVIORAL|Erectile Dysfunction|
223389506|NCT00001041|BIOLOGICAL|rgp120/HIV-1MN|
223389507|NCT03063788|DRUG|3BNC117-Copper-64|3 mg/kg 3BNC117 combined with radio-isotope Copper-64
223389508|NCT00288535|PROCEDURE|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
223389509|NCT02453932|DRUG|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
223389510|NCT02453932|DRUG|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
223389511|NCT02453932|DRUG|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
223389512|NCT03721861|DEVICE|Intra-operative neural cuff stimulation|A feasibility study consists of placing 2 electrodes around the radial or medial nerves intraoperatively. The movements caused by the electrical stimulation of these nerves are observed.
223389513|NCT01629628|DRUG|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
223389514|NCT01629628|DRUG|6 Mercaptopurine|"6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~\--------------------------------------------------------------------------------"
223389515|NCT03452761|DIETARY_SUPPLEMENT|Ketone Salts|Subjects will take 2 servings of ketone salts daily for 6 weeks
223389516|NCT03045211|DEVICE|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
223389517|NCT06381206|DRUG|Silodosin|Selective Alpha Blocker drug
223389518|NCT00564642|DRUG|N Acetylcysteine|1200 mg, BD, 2weeks
223389519|NCT06549842|DRUG|Heparin|The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
223389520|NCT06549842|DEVICE|Terumo Radial Band|Group 1 will receive TR band post cardiac catheterization for radial hemostasis.
224009625|NCT02643472|BEHAVIORAL|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
224126655|NCT00107770|DRUG|sodium phenylbutyrate|histone deacteylase inhibitor
224126656|NCT02260167|OTHER|A mix of natural treatments and medications|
223389521|NCT06549842|DEVICE|Vaosband|Group 2 will receive Vasoband post cardiac catheterization for radial hemostasis.
223389522|NCT01858844|OTHER|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
223389523|NCT02989220|OTHER|Positive Reappraisal Coping Intervention|
223389524|NCT00902772|DRUG|Lorazepam|mg, oral dose
223389525|NCT00902772|DRUG|AZD7325|mg, oral dose
223389526|NCT00902772|DRUG|Placebo|
223389527|NCT03227081|BEHAVIORAL|Sleep Deprivation|Sleep Deprivation
224009626|NCT02643472|BEHAVIORAL|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
224126657|NCT00900250|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224126658|NCT02773719|OTHER|True Biofield therapy|
224126659|NCT02773719|OTHER|Fake Biofield therapy|
224126660|NCT01332812|DRUG|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
223389528|NCT02223962|BEHAVIORAL|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
223389529|NCT03863782|OTHER|No intervention|No specific intervention. Collection of clinical data
223389530|NCT06198231|OTHER|Pilates exercises|Pilates exercises
223730349|NCT03873233|DEVICE|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
223730350|NCT03873233|DEVICE|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
223730351|NCT06508073|OTHER|Neural Therapy|The injection was prepared using a solution of lidocaine 2% and saline 0.9%. A 0.4% lidocaine solution was prepared by diluting 1 cc of lidocaine with 4 cc of saline.
224009627|NCT05955300|OTHER|Training program|The GLAD training program consists of neuromuscular exercises for the core, the knee and the hip muscles and patient education. The New Nordic Diet is a plant-based nutrition thats aims to reduce systematic low-grad inflammation.
224009628|NCT05955300|OTHER|Nutrition therapy|Nutrition therapy based on the New Nordic Diet
224009629|NCT02830126|OTHER|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
223389531|NCT06198231|OTHER|Flexibility ,strength and endurance excercises|flexibility ,strength and endurance excercises
223389532|NCT03823170|RADIATION|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
223389533|NCT03823170|PROCEDURE|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
223389534|NCT03823170|COMBINATION_PRODUCT|Laser therapy and Fluorotherapy|This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
223389535|NCT02809313|DIETARY_SUPPLEMENT|Treatment Gingivitis with Probiotic|gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months
223389536|NCT02809313|OTHER|Treatment Gingivitis conventional|gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
223389537|NCT04672837|PROCEDURE|Pediatric Integrative Manual Therapy and educational therapy|Pediatric Integrative Manual Therapy is a soft Orthopedic Manual Therapy approach por infants and children. It integrates joints soft mobilisation, myofascial release and neurodynamic mobilisation. Also the educational therapy.
223389538|NCT04672837|PROCEDURE|Stretching and educational therapy|It is a protocol of stretching based on literature research. Also the educational therapy with counter positioning, stimulation in prone position, positional care, etc.
223389539|NCT05342350|OTHER|GALAD Score|GALAD score, a blood-based biomarker panel (gender, age, AFP, AFP-L3%, DCP)
223389540|NCT05440123|OTHER|screening for bronchopulmonary cancer|The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
223389541|NCT05481853|PROCEDURE|One Anastomosis Gastric Bypass|
223546004|NCT03790748|PROCEDURE|25G Dural Puncture Epidural Technique|25G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
223546005|NCT03790748|PROCEDURE|27G Dural Puncture Epidural Technique|27G Dural Puncture Epidural Technique at L4-5 inter-space using 0.5%Bupivacaine and Fentanyl.
223546006|NCT02004301|DRUG|Radiolabelled T4 Tablet|
224009630|NCT01215188|BIOLOGICAL|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
224009631|NCT01215188|BIOLOGICAL|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
224126661|NCT01332812|OTHER|control group|General anesthesia, without additional interventions
224126662|NCT04855565|DRUG|ALY688-SR|single dose subcutaneous injection
223546007|NCT02004301|DRUG|Radiolabelled T6 Tablet|
223546008|NCT02314442|DRUG|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
223546009|NCT02314442|DRUG|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
223546010|NCT00626041|OTHER|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
223730352|NCT06363968|DEVICE|RETeval|as previous
224126663|NCT03916250|DRUG|PF-06700841 cream|PF-06700841 will be applied topically
224126664|NCT03916250|DRUG|White petrolatum|White petrolatum will be applied topically
224126665|NCT01316601|DRUG|QAX567|
223730353|NCT02545790|PROCEDURE|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
223730354|NCT02545790|BIOLOGICAL|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
223389542|NCT03983525|DIETARY_SUPPLEMENT|Goji berry|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
223389543|NCT03983525|DIETARY_SUPPLEMENT|Lutein + zeaxanthin supplementation|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
223389544|NCT05526638|RADIATION|ultraviolet phototherapy|thrice weekly sessions of ultraviolet phototherapy
223389545|NCT02760004|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"* Access to MCPAP for Moms~* PRogram In Support of Moms Toolkit with Stepped Care Algorithms~* Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~* Customization of depression screening for each practice~* Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~* Employ psychoeducation and Motivational Interviewing to engage patients with depression~* medical assistant champion and psychiatrist contact bi-weekly to review cases~* Stepped care treatment to depression screening/assessment"
223546011|NCT03532022|DRUG|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
223546012|NCT03532022|DRUG|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
223546013|NCT03768323|OTHER|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
223546014|NCT03768323|OTHER|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
223546015|NCT00251992|DRUG|Esomeprazole|
223730355|NCT04882267|BEHAVIORAL|Team and Technology|Subjects will receive access and instruction on multiple home exercise apps. They will receive phone calls once a week from care team members for motivational interviewing to encourage exercise.
224009632|NCT01215188|BIOLOGICAL|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
224009633|NCT05072028|DRUG|[14C]DBPR108|\[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
224009634|NCT01217177|DRUG|everolimus|
224126666|NCT01600183|DEVICE|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
224126667|NCT01600183|PROCEDURE|cast|casting of the infant legs
224126668|NCT01596959|PROCEDURE|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
223730356|NCT05802667|DIAGNOSTIC_TEST|Tryptase|Serum samples were collected from patients within 24 hours, 1 month, 3 months and 12 months after myocardial infarction, and trypsin-like enzymes were determined by elisa
223730357|NCT00045500|DRUG|7-hydroxystaurosporine|
224009635|NCT01018238|DRUG|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
224126669|NCT01596959|PROCEDURE|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
224126670|NCT00390416|DRUG|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
223389546|NCT02760004|BEHAVIORAL|MCPAP for Moms|"* 30-60 minute presentation on perinatal depression~* Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~* Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~* Access to assessment and treatment protocols in Provider Toolkit~* Resource provision/referrals"
223389547|NCT00128401|DRUG|D-Cycloserine|
223389548|NCT00128401|DRUG|Placebo|
224009636|NCT01018238|DRUG|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
224009637|NCT01258842|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
224126671|NCT02940717|OTHER|Vita suprinity|New glass ceramic material
223546016|NCT01445847|DRUG|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
223546017|NCT01445847|OTHER|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
223546018|NCT03332147|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
223546019|NCT03332147|DEVICE|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
223546020|NCT03834896|OTHER|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
223546021|NCT02962921|DRUG|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
223730358|NCT00045500|DRUG|prednisone|
223730359|NCT00715078|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
223730360|NCT06503419|OTHER|non-intervention|non-intervention
223389549|NCT05193955|OTHER|Laughter Yoga|Laughter yoga is one of the methods that is among the complementary therapy and supportive care practices in the world and is used increasingly. Laughter yoga is a non-invasive and non-pharmacological method that combines unconditional laughter with yoga breathing techniques. In laughter yoga, one can laugh without being humorous, joking, or funny. Laughter is simulated by starting out as a physical exercise and making eye contact with other members of the group and playing games with them. The body cannot distinguish between real and unreal laughter and laughter begins.
223389550|NCT02203357|BIOLOGICAL|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
223389551|NCT06581315|DRUG|Donafenib|Donafenib 100 mg twice daily (BID)
223389552|NCT04464850|DRUG|Intravenous iron|"Iron sucrose will be given by continuous infusion for 1 hour during the last 1 hour of dialysis session. Iron sucrose will be given for 24 weeks during study period.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~The dosage of intravenous iron will be adjusted according to serum ferritin levels as follows.~Serum ferritin \<500 mg/dl: iron sucrose 100 mg every 2 weeks Serum ferritin 500-800 mg/dl: iron sucrose 100 mg every 4 weeks Serum ferritin \>800 mg/dl: discontinue iron sucrose"
223546022|NCT01166035|DRUG|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
223730361|NCT05029674|DEVICE|Whoop|Wear WHOOP Strap, complete surveys
224009638|NCT01258842|DIETARY_SUPPLEMENT|Placebo|Placebo sachet, consumed once per day for 12 weeks
224009639|NCT00853944|DRUG|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
224009640|NCT04909827|PROCEDURE|3D-printed endocrown|pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
224009641|NCT04909827|PROCEDURE|Zirconia crown|pulpotomy and restoration with prefabricated zirconia crown
224009642|NCT01691170|OTHER|Stretching Hamstring|
224009643|NCT01691170|OTHER|Quadriceps Strengthening|
223389553|NCT04464850|DRUG|Oral iron|"1 tablet, three times a day, of iron fumarate will be prescribed for 24 weeks of study period.~The dosage of iron fumarate will be adjusted according to serum ferritin levels as follows.~Serum ferritin will be monitored at 4, 12, and 24 weeks after randomization.~Serum ferritin \<500 mg/dl: iron fumarate 200 mg three times daily Serum ferritin 500-800 mg/dl: iron fumarate 200 mg once daily Serum ferritin \>800 mg/dl: discontinue iron fumarate"
223389554|NCT05944471|OTHER|Providing breastfeeding support with Telehealth|After discharge, training videos on the importance of breast milk and breastfeeding prepared in line with the literature and explained by experts, and written documents (e-brochure, plain text version of breastfeeding trainings) were sent to individual mothers once a week between 10.00-14.00 hours via telehealth application. At the same time intervals, visualised messages explaining breastfeeding and that breast milk is sufficient for the baby were sent via telehealth application five days a week. In addition, if the mothers requested at 10.00-17.00 on weekdays, they were given live support by the researcher for the issues they were curious about breastfeeding by calling the researcher via telehealth application.
223389555|NCT02504528|OTHER|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
223389556|NCT04335513|OTHER|Early CGM-guided education and initiation of insulin therapy.|Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.
223730362|NCT06441344|DRUG|Toripalimab plus Anlotinib|For patients who did not progress after standard chemotherapy, toripalimab plus anlotinib maintenance therapy was used
224009644|NCT01127763|DRUG|RAD001|
224009645|NCT01127763|DRUG|Carboplatin|
224009646|NCT01680640|DIETARY_SUPPLEMENT|Synbiotic|The synbiotic to be used is fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
224009647|NCT01680640|DIETARY_SUPPLEMENT|Maltodextrin|
224009648|NCT01249950|OTHER|feasibility|feasibility
224009649|NCT00528931|BIOLOGICAL|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
224009650|NCT06132438|DRUG|PEP-CMV vaccine|The PEP-CMV vaccine is a long synthetic peptide (PEP) made up of 26 amino acids that is derived from the human cytomegalovirus (CMV) matrix protein pp65 and has both MHC class I and II epitopes. A vaccine platform that initially consists of TMZ-induced lymphopenia and Td pre-conditioning will be used, with serial vaccinations of up to 12 times (maximum 20) being applied. To ensure the effectiveness of the future Td pre-conditioning, which is given right before the initial PEP-CMV vaccine, a Td booster is required at enrollment.
224009651|NCT03262142|DRUG|Piperacillin/tazobactam|Intravenous Piperacillin/tazobactam four times daily
224009652|NCT03262142|DRUG|Ciprofloxacin|Oral Ciprofloxacin twice daily
224009653|NCT00480480|BEHAVIORAL|Trauma and Grief Component Therapy for Adolescents (Group Version)|
224009654|NCT02605655|DRUG|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
224009655|NCT02605655|OTHER|Placebo|Instant noodles without drug
224009656|NCT02459002|BEHAVIORAL|QOL Questionnaire|Participant outcomes assessed with survey
224009657|NCT02459002|BEHAVIORAL|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
224009658|NCT03835351|DEVICE|Urinary Catheter|An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
224009659|NCT01823939|DRUG|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
224009660|NCT05841329|DEVICE|tDCS|High-definition tDCS (HD-tDCS, 4×1 montage, with 1 anode and 4 cathodes, (Soterix Medical, New York, NY, USA) was applied with battery-driven electrical stimulator (2001\&4×1-C3A). The center electrode was anode and placed over FPz (according to the EEG 10-20 system in order to target the medial prefrontal cortex). The reference electrodes were cathodes and placed over AF7, AF8, F3, F4(see fig. 3). Participants were randomized to receive 20 minutes of active(1.5mA) or sham (0 mA) tDCS in a single-blind design. In order to ensure that participants can gradually adapted to the current change, there was a 15-second current rising process before the stimulation and, a 15-second current falling process after the stimulation. For sham tDCS, the device was automatically turned off after current reached 1.5 mA, thus providing 30s of ramping current stimulation, which made it difficult for participants to distinguish which kinds of stimulation they received.
224009661|NCT05841329|BEHAVIORAL|virtual reality exposure therapy|The VRET was adapted on the basis of Öst's single exposure treatment paradigm and conducted by experienced psychotherapists following a standard exposure treatment manual.. An exposure therapy was divided into three parts: psychological education, exposure intervention and summary. Each scene started with a 10-min psychological education followed up with the tDCS stimulation. In exposure trail, participants ought to take an elevator to 100th, observe the environment and look down on the platform. The psychotherapist guided participants to be exposed to the VR environment and helped them experience the process of anxiety decline in the exposure trail.
224009662|NCT03764527|DRUG|Artemether-lumefantrine|Two doses a day for 3 days, under supervision
224009663|NCT03764527|DRUG|Coadministered Artesunate plus Amodiaquine|One dose a day for 3 days, under supervision
224009664|NCT00291642|DRUG|Placebo drops|"* Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use"
224009665|NCT00291642|DRUG|Placebo tablets matching to levocetirizine|"* Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use"
224009666|NCT00291642|DRUG|Placebo tablets matching to cetirizine|"* Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use"
224009667|NCT00291642|DRUG|Levocetirizine drops|"* Pharmaceutical form: Drops for oral administration~* Concentration: 5 mg/ml~* Route of administration: Oral use"
224126672|NCT02940717|OTHER|Emax CAD|standard etchable glass ceramic used for laminate venneers
224126673|NCT01219959|DRUG|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
224126674|NCT01219959|DRUG|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
224009668|NCT00291642|DRUG|Levocetirizine tablets|"* Pharmaceutical form: Tablets for oral administration~* Concentration: 5 mg~* Route of administration: Oral use"
224126675|NCT04604314|DEVICE|CEREC Tessera|Full ceramic endocrown restorations will be made from the high strength ceramic, CEREC Tessera
224126676|NCT05291871|BIOLOGICAL|HPV vaccine|One-fifth dose bivalent HPV Vaccine or One-fifth dose nonavalent HPV Vaccine
224126677|NCT06458439|DRUG|Epcoritamab|"* C1D1: fixed priming dose of 0.16 mg subcutaneous injection~* C1D8: fixed intermediate dose of 0.8 mg subcutaneous injection~* C1D15 onward: fixed full dose of 48 mg subcutaneous injection"
224126678|NCT04373642|DRUG|Pebrolizumab + QUADSHOT Radiotherapy|"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."
224126679|NCT05946395|DEVICE|Hearing aid|Fitting a hearing aid
224126680|NCT05946395|OTHER|Speech therapy session|As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
224126681|NCT06122675|DEVICE|DBS|Implanted in the cerebellum.
223389557|NCT04335513|OTHER|Usual care: glucometer surveillance and basic education.|"* Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK.~* Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes."
223389558|NCT01431079|BEHAVIORAL|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
223389559|NCT05032300|DEVICE|Focused shockwave|Procedure: Focused shockwave therapy received shock wave therapy once a week: first locate, touch on the heel of the patient Tenderness points, take tenderness points as treatment points;Then ask the patient to take the lower limbs straight sitting or prone position, Target intensity will be within a range of 0.15-0.25 mJ/mm2 at maximum Hz, Total of 3000 pulses; rest for 20 minutes after the treatment
223389560|NCT05032300|OTHER|Home therapy|Stretching and ice massage
223389561|NCT03617666|DRUG|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
223730363|NCT06441344|DRUG|Toripalimab|For patients who did not progress after standard chemotherapy+toripalimab, toripalimab maintenance therapy was used
224009669|NCT00291642|DRUG|Cetirizine drops|"* Pharmaceutical form: Drops for oral administration~* Concentration: 10 mg/ml~* Route of administration: Oral use"
224126682|NCT06043700|OTHER|No Intervention|No treatment intervention will be administered.
224126683|NCT01728584|DRUG|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
224126684|NCT01728584|OTHER|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~* Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~* Low insufflation pressure - a starting pressure of 8 mmHg will be used."
224299295|NCT01948713|OTHER|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
224009670|NCT00291642|DRUG|Cetirizine tablets|"* Pharmaceutical form: Tablets for oral administration~* Concentration: 10 mg~* Route of administration: Oral use"
224009671|NCT00230880|BEHAVIORAL|follow-up phone counseling|9 calls over 12 months
224009672|NCT02341729|DRUG|ticagrelor|crushed tablets and non-crushed tablets
224009673|NCT01875289|PROCEDURE|obturator nerve block|
224009674|NCT02881346|DRUG|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
224009675|NCT02028078|DRUG|Insulin human|Induces hypoglycaemia
224009676|NCT03904225|DRUG|Tegafur-Gimeracil-Oteracil|oral administration for 12 months
224009677|NCT02157701|DIETARY_SUPPLEMENT|Polyherbal capsule|
224009678|NCT02157701|DIETARY_SUPPLEMENT|Placebo capsule|
224009679|NCT02977273|OTHER|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
224009680|NCT02977273|OTHER|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
224009681|NCT02977273|OTHER|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
224009682|NCT02977273|OTHER|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
224009683|NCT00224679|DRUG|Aspirin|
224009684|NCT02870374|BEHAVIORAL|Answering specific quality of life questionnaire in kidneys transplantation population|
224009685|NCT02936882|PROCEDURE|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
224009686|NCT05009784|OTHER|Baseline|5-min urban park video clip (Presented on a TV)
224009687|NCT05009784|OTHER|Fatigue Manipulation|20-min 2-back task (Presented on a computer)
224009688|NCT05009784|OTHER|Traffic Sound|Active Comparator: Traffic Sound (Played through speakers)
224009689|NCT05009784|OTHER|Traffic and Masking Sound|Experimental: Traffic and Masking Sound (Played through speakers)
224296207|NCT01528020|BEHAVIORAL|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
224296208|NCT02235220|OTHER|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
224296209|NCT05623631|OTHER|Survey|Surveys were distributed using REDCap, and participants were asked to complete these within 5 weeks of receiving the invitation.
224296210|NCT01200940|OTHER|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
224299296|NCT01948713|OTHER|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
224009690|NCT05009784|OTHER|Silence|No Intervention: No sound (Played through speakers)
224009691|NCT03328104|DRUG|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
224009692|NCT03328104|DRUG|Nelarabine|650 mg/m2 IV daily x Day 1-5
224009693|NCT03328104|DRUG|Cyclophosphamide|440 mg/m2 IV x Day 1-5
224009694|NCT03328104|DRUG|Etoposide|100 mg/m2 IV x Day 1-5
224009695|NCT04589481|OTHER|Intake of 3 different candies against bad breath|Intake of 3 different candies against bad breath on three different days (2-days interval each) after artificially creating a temporary bad breath (by eating of chips and cheese); analysis of breathing during intake of candy both subjectively and objectively
224009696|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Tandem Stance Test (ATST) and Physical Therapist's Measurements of Tandem Stance Test (PTST)|For the Tandem Stance Test comparisons, the Azure Kinect-based Tandem Stance Test system quantified the distance traveled by the pelvic point to X, Y, and Z coordinates over a 30-second duration while the physical therapist measured the time elapsed until the participant lost balance was measured with a maximum of 30 seconds. Participants remained a tandem stance, positioning their preferred leg in front such that the heel of the front foot touched the toes of the back foot, ensuring both feet were aligned as straight as possible. They stood with holding on to two chairs each placed on their sides for stability and safety. Upon the cue to 'start', the participants let their hands go and both the Azure Kinect-based system and the physical therapist's stopwatch initiated their measurements. Participants tried to maintain their stance for 30 seconds. The participants had to reposition themselves when they stepped, used hands or lose balance for 30 seconds
224037810|NCT03861819|BEHAVIORAL|Vigorous-intensity interval training (VIIT)|Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
223389562|NCT02851784|BIOLOGICAL|adoptive immunotherapy|HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
223389563|NCT02851784|PROCEDURE|MWA|ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
224009697|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Five Times Sit-to-Stand Test (AFTSS) and Physical Therapist's Measurements of Five Times Sit-to-Stand Test (PFTSS)|The Five Times Sit-to-Stand Test (FTSS), standardized by Csuka and McCarty, has been designed to assessing lower limb strength as well as balance and postural control among elder population with high level of reliability. A previous study reported excellent intra-rater reliability (ICC=.914-.933) and inter-rater reliability (ICC=.988-.995) among healthy older adults. In addition, Five Times Sit-to-Stand Test more than 11.50 seconds had been reported to represent risk of falls among elders over 65-year-old. To assess Five Times Sit-to-Stand Test , a chair, 45cm in height and fixed to the ground, was placed three meters from the camera. Participants began seated, and on start cue, repeatedly stood up and sat down five times. The Azure Kinect-based system automatically ended its measurement as the participant completed the fifth stand, whereas the physical therapist manually measured time using the stopwatch. The time measures from the system and therapist were compared.
224037811|NCT04119973|OTHER|standard treatment|standard medical treatment
224037812|NCT05145335|DEVICE|Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
224126685|NCT01728584|DRUG|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
223389564|NCT04136314|BEHAVIORAL|Decision-Framed Survey|Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to \[A\] a gain-framed message or \[B\] a loss-framed message.
223389565|NCT05857683|PROCEDURE|cextension pin block|this is the technique for mallet finger where 2 pins are used, one for the extension block and other intramedullary for the extension posture
223389566|NCT05857683|PROCEDURE|pin orthosis- extension block pin|this is the technique for mallet finger where only 1 pin is used for extension block and an orthosis is applied for the extension posture
223389567|NCT01605851|DEVICE|Closure, Foramen Ovale|
223389568|NCT04055740|DEVICE|IVUS Imaging|IVUS or radial-ICE (intracardiac echocardiography) is a visualization tool used in many cardiac procedures including electrophysiology procedures (catheter ablation). Its utility in identifying ILA will be assessed in this study.
223389569|NCT01525329|DRUG|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
223389570|NCT06035692|DRUG|Ropivacaine|According to the results of the preliminary experiment, the BPB group was given ultrasound-guided BPB with 0.15% ropivacaine 20ml.The ropivacaine concentration was the 90% minimum effective concentration(MEC90) for preventing vasospasm during operation.
223389571|NCT02038010|DRUG|PI3K inhibitor BYL719|Given PO
223389572|NCT02038010|BIOLOGICAL|ado-trastuzumab emtansine|Given IV
223389573|NCT02038010|OTHER|pharmacological study|Correlative studies
223389574|NCT02038010|OTHER|laboratory biomarker analysis|Optional correlative studies
223389575|NCT02000726|DRUG|Placebo|
223389576|NCT02000726|DRUG|Citalopram|
223389577|NCT02000726|DRUG|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
223389578|NCT02042157|BEHAVIORAL|Bidet use|Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
223389579|NCT02042157|OTHER|Regular toileting|Patients in the control arm will toilet as usual.
224126686|NCT05195333|OTHER|The exercise program|The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.
224126687|NCT05195333|OTHER|The exercise program|The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
224126688|NCT04824196|OTHER|vestibular visual cues therapy|Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear
224126689|NCT04824196|OTHER|propriocetion exercise|"1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball"
224126690|NCT02894047|BIOLOGICAL|blood|measurement of CaSR expression levels on synovial fluid monocytes
224126691|NCT02935634|BIOLOGICAL|Nivolumab|Specified dose on specified days
223546023|NCT01166035|DRUG|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy"
223546024|NCT04052165|PROCEDURE|Glaucoma Implant|
223546025|NCT00222820|DRUG|escitalopram|
223546026|NCT00222820|BEHAVIORAL|Interpersonal Psychotherapy|
223730364|NCT01516320|PROCEDURE|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
224009698|NCT06519864|DIAGNOSTIC_TEST|Azure Kinect-based Timed Up and Go Test (ATUG) and Physical Therapist's Measurements of Timed Up and Go Test (PTUG)|The Timed Up and Go test (TUG) has been employed as a straightforward assessment of an individual's mobility, necessitating both static and dynamic balance. A Timed Up and Go test duration exceeding 9.50 seconds has been identified as indicative of a heightened fall risk in individuals aged 65 and older. A previous study reported excellent intra-rater reliability (ICC=.97) and inter-rater reliability (ICC=.96). Initiating in a seated position, participants stood upon commencement of the test. Simultaneously, the Azure Kinect-based system and stopwatch began the time measurements. Participants then walked a distance of three meters, turned around, retraced their steps, and resumed their seated position. The Azure Kinect-based system automatically terminated its timing once the participant was seated, while the physical therapist manually stopped the stopwatch. The time measures from the system and therapist were compared.
224009699|NCT06519864|DIAGNOSTIC_TEST|Short Physical Performance Battery (SPPB)|The assessment includes three tests: a Timed Up and Go test test where participants walked a distance of 3 meters at their comfortable pace; a Five Times Sit-to-Stand Test which the duration is also measured; and the standing balance test which determines a participant's capacity to maintain three different stances of side-by-side, semi-tandem, and full tandem, each for 10 seconds.
224009700|NCT06519864|DIAGNOSTIC_TEST|Berg Balance Scale (BBS)|Participants are scored on a 5-point scale for each task, where a score of 0 signifies an inability to perform, while a 4 denotes independence in execution. A perfect score of 56 is a marker of excellent balance. Administering the Berg Balance Scale is efficient, taking between 10 to 20 minutes, and requires only basic equipment such as a chair, stopwatch, ruler, and step within a small space.
224126692|NCT02935634|BIOLOGICAL|Ipilimumab|Specified dose on specified days
224126693|NCT02935634|BIOLOGICAL|Relatlimab|Specified dose on specified days
224126694|NCT02935634|BIOLOGICAL|BMS-986205|Specified dose on specified days
223389580|NCT01108172|OTHER|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
223389581|NCT01108172|OTHER|Usual care|The usual care provided to patients after discharge from hospital
224126695|NCT02935634|DRUG|Rucaparib|Specified dose on specified days
224126696|NCT04699903|DIAGNOSTIC_TEST|POC SARS-Cov-2 IgG Antibody test|All patients will undergo a Point of care (POC) SARS-Cov-2 IgG Antibody test in fingerstick whole blood
224126697|NCT06638021|BEHAVIORAL|Targeted EHR-based Communication of Diagnostic Uncertainty (TECU)|The Targeted EHR-based Communication about Uncertainty (TECU) strategy will be activated in the electronic health record (Epic) every time an ED clinician enters an uncertain diagnosis for a patient being discharged, and will notify the clinician to counsel the patient about uncertainty while additionally triggering automated 1) insertion and printing of the patient handout and 2) provision of a hyperlink for the clinician-facing checklist to guide the discharge conversation.
224126698|NCT05647902|DIAGNOSTIC_TEST|Serum samples will be collected. Asprosin levels will be determined by biochemical analysis|Serum samples will be collected from both groups for biochemical analysis.
224126699|NCT02014935|OTHER|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
224126700|NCT06511999|DEVICE|Continuous SjO2 monitoring with a PediaSat Oximetry Catheter|The PediaSat Oximetry Catheter is capable of continuous, indwelling measurement of venous oxygen saturation, which is displayed on a bedside monitor connected by an optical cable. Enrolled participants will undergo continuous SjO2 measurement for 72 hours. Clinical care will not be directed by the continuous SjO2 values.
224126701|NCT06511999|DIAGNOSTIC_TEST|Intermittent SjO2 monitoring with a PediaSat Oximetry Catheter|The PediaSat Oximetry Catheter is also capable of intermittent blood sampling enabling measurement of SjO2 on a laboratory blood gas analyzer. Enrolled participants will undergo intermittent SjO2 measurement every 4-6 hours for 72 hours. Clinical care will be directly by the intermittent values.
224126702|NCT05906732|DRUG|LQT-1213|LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
224126703|NCT05906732|DRUG|Placebo|Matching Placebo
224126704|NCT05906732|DRUG|Dofetilide 250 μg Cap|Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker
223389582|NCT04138901|PROCEDURE|Ultrasound guided subcostal transversus abdominis plane block (TAPB)|At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
223389583|NCT04138901|DRUG|Ropivacaine 0.75% Injectable Solution|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
223389584|NCT04138901|DEVICE|21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
223389585|NCT05653557|OTHER|Shen Que Moxibustion|Herb-partitioned moxibustion was administered at RN8 (Shen Que), once every 72 hours from the beginning of previous menstrual cycle day 2 until oocyte retrieval. Approximately 10 moxa cones will be used for this procedure, which will take approximately two hours. It is recommended that patients close their eyes during the procedure and rest. Following moxibustion, the umbilicus will be affixed and sealed with a medical applicator and removed after 24 hours.
224009701|NCT06519864|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|Participants, standing barefoot, aligned the side of their body with a wall, ensuring no contact. Their stance was parallel with feet comfortably spaced. With their shoulders flexed at a 90° angle adjacent to the wall, they kept their elbows straight and hands clenched. The starting point on a horizontally affixed measuring tape, level with the floor, was determined by where the third metacarpal touched. This tape was aligned with each participant's acromion height. Without taking a step, lifting heels or losing balance, participants leaned forward to their maximum extent. The difference between the initial and final third metacarpal positions on the tape denoted the reach distance.
224037813|NCT05145335|DEVICE|Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)|This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
224126705|NCT04821310|DRUG|Full dose Pantoprazole plus matching placebo|Full healing dose of pantoprazole plus matching placebo
223389586|NCT00446693|DEVICE|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
223389587|NCT02764671|BIOLOGICAL|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
223389588|NCT03239093|OTHER|No intervention|Observational study using official data from the Federal Office of Statistics
223389589|NCT00815880|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
223389590|NCT03246451|DRUG|Placebo Oral Tablet|2-4 tablets in 14 days
223389591|NCT03246451|DRUG|Metformin|1000-2000 mg in 14 days
223389592|NCT03246451|DRUG|Saline|9 mg/ml saline infusion during experimental days
223389593|NCT03246451|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist used as a tool during experimental days
223389594|NCT04655560|OTHER|no intervention|qualitative study
223389595|NCT01375062|OTHER|analyse and proliferate the cells|"1. Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~2. Digestion of the biopsies through controlled enzymes~3. Replication of the cells~4. Selection undifferentiated cells~5. Expansion of the purification cells population~6. Characterization of the cell population~7. Assessment of pluripotent and germinal cell potential.~8. Possible maturation of the cells."
223389596|NCT01601418|DRUG|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
223389597|NCT01601418|DRUG|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
223389598|NCT04688437|RADIATION|standard standing-sitting posteroanterior and lateral whole spine X-ray and lumbar MRI examination|Routine examination
223546027|NCT04527835|DIAGNOSTIC_TEST|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.|ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB.
224037814|NCT02537535|OTHER|survey|This is a cross-sectional study without specific intervention
224037815|NCT06096207|DEVICE|Medtronic SenSight Directional DBS lead|At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
224037816|NCT05183750|PROCEDURE|High tibial osteotomy|Opening wedge high tibial osteotomy will be done according to the measurement preoperatively and fixation will be by plate and screws.
223389599|NCT00246818|PROCEDURE|Tai Chi Chuan|
223389600|NCT02101944|DRUG|Carfilzomib|Given IV
223389601|NCT02101944|DRUG|Dexamethasone|Given IV
223389602|NCT02101944|OTHER|Laboratory Biomarker Analysis|Correlative studies
223389603|NCT02101944|BIOLOGICAL|Pelareorep|Given IV
223389604|NCT02150226|DEVICE|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
224037817|NCT06451614|DEVICE|SpaceIT Hydrogel System|"SpaceIT Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceIT Hydrogel System to reduce the radiation dose delivered to the anterior rectum. The SpaceIT Hydrogel System is composed of a radiopaque, biodegradable material designed to maintain space for approximately 12 weeks and be absorbed in about 6 months, sufficient time to support the intended use.~SpaceIT has an iodinated PEG powder making it radiopaque."
224037818|NCT06451614|DEVICE|Commercially available Boston Scientific Spacer|Boston Scientific's commercially available SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System to reduce the radiation dose delivered to the anterior rectum. SpaceOAR and SpaceOAR Vue are both perirectal spacers. SpaceOAR Vue specifically has an iodinated PEG powder making it radiopaque. SpaceOAR does not contain iodinated PEG powder and is not radiopaque. The SpaceOAR Hydrogel System or SpaceOAR Vue Hydrogel System maintains space during prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
224037819|NCT06804226|BEHAVIORAL|Video conversation aid|A video conversation aid which provides information regarding life-sustaining care and encourages further goals of care discussions with a healthcare provider will be shown to patients or their surrogates (for those incapacitated and unable to make their own decisions) on admission or within 48 hours whenever feasible
224037820|NCT06804226|BEHAVIORAL|Usual Care|Participants and/or surrogates will participate in discussions surrounding life-sustaining care at healthcare provider discretion.
224037821|NCT04284293|BIOLOGICAL|CNS10-NPC implantation|All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
224009702|NCT06519864|DIAGNOSTIC_TEST|Four-Square Step Test (FSST)|During the Four-Square Step Test, participants were instructed to step over four straight tapes, each 90 cm in length, laid out in a cross-shape configuration on the floor. Beginning in square 1 and facing square 2, participants followed a specific sequence: they stepped forward into the next quadrant, then to the right, backward, and finally to the left, moving in a clockwise direction. This sequence was then retraced in a counterclockwise manner. It was essential for both feet to touch down in each quadrant. Participants aimed to complete this pattern as fast as they could, avoiding stepping the tapes. The duration taken to finish the sequence was recorded.
224126706|NCT04821310|DRUG|Half Dose Pantoprazole plus matching placebo|Half healing dose of pantoprazole plus matching placebo
224126707|NCT06374264|DEVICE|MR-C-014|Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
224126708|NCT06095518|DIAGNOSTIC_TEST|DIC markers and Thrombin Generation Parameters|Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
224126709|NCT04855201|DRUG|Bocidelpar|Oral
224126710|NCT04855201|DRUG|Placebo|Oral
224126711|NCT05815433|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
224126712|NCT04779229|BEHAVIORAL|Parent Activation|Parent Activation (PA) is comprised of concrete social learning theory steps (i.e., direct instruction, modeling, practice opportunities, and reinforcement) that aim to enhance a parent's confidence, knowledge, and ability to manage his/her child's health. PA is applicable across a range of conditions, including behavioral and psychiatric problems, and it can be delivered by varied providers, including paraprofessionals.
224126713|NCT04779229|BEHAVIORAL|Usual Services|This intervention refers to the typical techniques that JPOs employ to monitor the juveniles on their caseloads (e.g., regular meetings with youth and parents to ensure the youth is following conditions of probation and issuing swift sanctions \[community service; detention\] if conditions are not being followed).
224296211|NCT01200940|OTHER|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
224296212|NCT01200940|OTHER|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
224296213|NCT01200940|OTHER|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
224296214|NCT05587335|BEHAVIORAL|PREP|Relationship intervention to improve communication and conflict resolution for couples
224296215|NCT05587335|BEHAVIORAL|OurRelationship|Relationship intervention to improve communication and conflict resolution for couples
224296216|NCT06449755|DIAGNOSTIC_TEST|Radiologic examination|Posoperative first week, month and third month On the x-ray of Hand AP view: metacarpal shortening On the x-ray of Hand 30 degree pronation view: dorsal angulation
224296217|NCT06449755|PROCEDURE|Grip Strength|Postoperative first month and third month grip streng compare with Cambry hand dinamometer.
224296218|NCT06449755|OTHER|Quick DASH Questionnaire|Quick DASH is an 11-question questionnaire that assesses upper extremity functionality.
224296219|NCT03668821|OTHER|Questionnaire|Quality of life and frailty questionnaires
224126714|NCT04493411|PROCEDURE|WBMRI|"WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
224126715|NCT04493411|PROCEDURE|Positron Emission Tomography/Computed Tomography (PET/CT)|"PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)"
224296220|NCT03166813|PROCEDURE|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
224296221|NCT03166813|OTHER|Control|Placement of blood pressure cuff without inflation for 30 minutes.
224296222|NCT06326502|DRUG|ETN101|Oral administration
224296223|NCT03288974|DRUG|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
224296224|NCT02469779|BEHAVIORAL|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
224296225|NCT02469779|BEHAVIORAL|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
224296226|NCT02469779|BEHAVIORAL|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
224009703|NCT06519864|DIAGNOSTIC_TEST|Grip Strength (GS)|The strength of the dominant hand's maximal grip force, indicative of upper extremity muscle strength, was gauged using a digital isometric hand dynamometer.
223389605|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
223389606|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
224009704|NCT02102607|OTHER|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
224009705|NCT05624671|OTHER|bupivacaine,fentanyl|According to our institution protocol, intravenous (iv) hydration will not be given as preload and afterload and vasopressor infusion will not be initiated before spinal anesthesia. After the skin is prepared sterile and local infiltration with 2% lidocaine is done, from L3-L4 OR L4-L5 range on midline with the 16 gauge Tuohy needle and the loss of resistance technique epidural space is identified and then 26 gauge pencil point needle is passed trough the Touhy and the dura will be drilled. After the cerebrospinal fluid (CSF) is seen the fluid containing 5mg isobaric bupivacaine and 15µg fentanyl will be given in 30 seconds to patients. After the spinal needle is removed, the epidural catheter is placed 3-5 cm in the epidural space through Tuohy, and after the catheter is fixated, the patients will be placed in the supine position by placing a height under their right hip with a 15 ° angle.
224009706|NCT00213889|OTHER|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
224009707|NCT05054803|DRUG|WJ-MSC (XCEL-UMC-BETA)|Administration of 2 Intrathecal infusions of WJ-MSC at day 1 and at 3 months
224009708|NCT05054803|DRUG|Placebo|Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
224009709|NCT04950595|OTHER|Plant-based mince|Spaghetti bolognaise meal made with plant-based mince
224126716|NCT05403944|BEHAVIORAL|Standard of Care Rehabilitation (SOC)|6 weeks of standard of care rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
224296227|NCT02469779|BEHAVIORAL|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
223389607|NCT00245466|DRUG|Degarelix|Given as a subcutaneous injection once every 4 weeks.
223389608|NCT03671161|DEVICE|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c \>9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
223389609|NCT01958437|DEVICE|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
223389610|NCT03469635|OTHER|Nutritional deficiencies in pregnant women after bariatric surgery|compare maternal nutritional parameters and neonatal outcomes after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) and to assess the impact of nutritional alterations on fetal growth.
223389611|NCT04408729|OTHER|PrEP My Way|"Intervention components may be modified pending the input from Aim 1. As currently planned, the peer delivering the PrEP My Way kit will be trained to provide basic education and support use of the kit components. The peer will also have a smart phone to show an instructional video. Participants will communicate with peers via mobile phones (e.g., SMS, WhatsApp) to arrange for kit delivery at Months 1, 3, and 6 via unmarked vehicles at home or a preferred safe site during reasonable hours. Two-way mobile phone communication will also be used to convey test results and provide on-going support and empowerment. Follow-up with the clinic will occur at Month 6 and as needed (e.g., treatment for positive tests).~This intervention aims to increase adherence/persistence on PrEP. We hypothesize that removing the structural barriers and stigma associated with going to the clinic, women may be more likely to continue on PrEP."
223389612|NCT05048901|DRUG|Cabozantinib|Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
223389613|NCT05048901|DRUG|Lanreotide|Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
223389614|NCT06273319|DRUG|OXYGEN THERAPY|15 AND 30 LT OXYGEN TREATMENT
223546028|NCT00125788|DRUG|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
223546029|NCT00125788|DRUG|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
223546030|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
223546031|NCT00690326|BEHAVIORAL|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
223546032|NCT03098095|BEHAVIORAL|Physical Activity|Moderate physical activity
223546033|NCT02060981|BEHAVIORAL|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
223546034|NCT02060981|BEHAVIORAL|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
224009710|NCT04950595|OTHER|Beef mince|Spaghetti bolognaise meal made with beef mince
224009711|NCT05843422|DRUG|0.1% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
224009712|NCT05843422|DRUG|0.3% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
224009713|NCT05843422|DRUG|0.8% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
224009714|NCT05843422|DRUG|1.5% QY211 Gel or placebo|QY211 Gel or placebo topical applied to skin
224009715|NCT00301938|DRUG|7-hydroxystaurosporine|Given IV
224126717|NCT05403944|BEHAVIORAL|Strength Training Rehabilitation Incorporating Power Exercises (STRIPE)|6 weeks of STRIPE rehabilitation will be given designed to target the core, hip, and quadriceps muscles. Each participant will be expected to complete 3 supervised telehealth sessions per week.
224126718|NCT06075706|BIOLOGICAL|MC0518|MC0518 will be intravenously infused immediately after thawing.
224296228|NCT03201679|PROCEDURE|Repair of hip fracture|Patients undergoing hip fracture surgery
224126719|NCT06075706|BIOLOGICAL|BAT|BAT including ECP, ATG, etanercept, infliximab or RUX will be administered based on Investigator's decision.
223546035|NCT02060981|BEHAVIORAL|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
224009716|NCT00301938|DRUG|perifosine|Given orally
224009717|NCT00301938|OTHER|pharmacological study|Correlative studies
224009718|NCT00929942|DEVICE|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
224009719|NCT06616025|COMBINATION_PRODUCT|NTX-001 (PEG-Fusion)|One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
224009720|NCT01546675|OTHER|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
224009721|NCT04730817|DEVICE|Virtual Reality Motor-Cognitive Training System|Immersive VR training system tailor-made for the daily living experiences in the Hong Kong context to provide interactive experiences for older people in Hong Kong. The VR training system is designed as a game with 16 progressive levels (anticipating intervention group participants to complete 2 levels per week for 8 weeks) which aim to train their motor and cognitive functions.
224009722|NCT05474053|DRUG|Ticagrelor 90mg (Brilique)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
224009723|NCT05474053|DRUG|Ticagrelor 90mg (Ticaloguard)|compare the efficacy and safety of ticagrelor generically named Ticaloguard® compared to its brand Brilique® in healthy volunteers
224126720|NCT05701904|OTHER|Local mechanical vibration|Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
224126721|NCT05701904|OTHER|Shotblocker group|It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
224126722|NCT05415358|OTHER|Blood and tissue samples|Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of immune checkpoint inhibitor treatment discontinuation.
224126723|NCT06580106|OTHER|Biospecimen samples|Buccal swabs and Blood samples will be collected throughout study.
224126724|NCT03207022|PROCEDURE|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
224126725|NCT03789604|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
224126726|NCT03789604|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
224126727|NCT06266533|BEHAVIORAL|Conventional Ultra-processed Food Nutrition Education|The participants will receive a conventional nutrition education session with slides, flyers/handouts, and a lecture with discussion.
224126728|NCT06266533|BEHAVIORAL|Arts-based Ultra-processed Food Nutrition Education|The participants will receive an arts-based nutrition education session with video, animation, music, and discussion.
224126729|NCT06235476|DIETARY_SUPPLEMENT|whey protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
224126730|NCT06235476|DIETARY_SUPPLEMENT|mixed plant-based protein supplement|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
224126731|NCT06235476|OTHER|e-health application|Daily use of an e-health application with dietary intake counselling to increase protein intake. The overall goal of these advices is to increase protein intake from \<1.0g/kg/bw/d to \>1.2g/kg/bw/d which is approximately 30 grams of additional protein per day (similar to the other arms of the intervention).
224126732|NCT06235476|DIETARY_SUPPLEMENT|isocaloric carbohydrate control|Daily dosage of the supplements will be 30 gram, preferably consumed in the morning and post-exercise or prior to sleep.
224126733|NCT02353260|DEVICE|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
224126734|NCT02353260|DRUG|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
224126735|NCT00287326|DRUG|Bupivacaine, Clonidine, Morphine|
224126736|NCT00977327|DEVICE|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
224126737|NCT00977327|DEVICE|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
224296229|NCT06194006|OTHER|Follow-up|Follow-up grafted patients as long as their condition allows
224299297|NCT05797818|DEVICE|Methylene Blue Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Methylene Blue (0.01%) + 4 minutes of light treatment"
224009724|NCT03242967|DRUG|Vadadustat|Oral tablet
223546036|NCT04443114|OTHER|Organ Donation Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Biomedical Aspects of Living Donation Didactic Session 2: Organ Donation and Transplantation in the US- Statistics and Procedures Moderated Debate: Living Organ Donation: Halal or Haram? Facilitated Group Discussions with Peer Educators
223730365|NCT01516320|PROCEDURE|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
224009725|NCT03242967|DRUG|Darbepoetin alfa|subcutaneous or intravenous
224009726|NCT01721928|DEVICE|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
224009727|NCT00680992|DRUG|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
224009728|NCT04690153|OTHER|Patients with three vertical Hayman Sutures|Patients who are referred to our clinic due to postpartum hemorrhage between the ages of 18-45 and who need to undergo a surgical procedure (not responding to medical treatment) due to abnormal uterine bleeding in our clinic will be included. Patients with a previously known diagnosis of bleeding and coagulation disorders will not be included in the study. Considering that we are one of the primary referral centers in Istanbul in terms of deliveries and post-partum bleeding in our hospital, it is aimed to terminate the study with approximately 50 participants.
224009729|NCT04337853|DEVICE|Intraoral stent|Radiotherapy with intraoral stent
224009730|NCT04337853|OTHER|No intraoral stent|Radiotherapy without intraoral stent
224009731|NCT06226272|DEVICE|Spinal Fusion|Cervical Spinal Fusion
224009732|NCT06226272|DEVICE|Spinal Fusion|Thoracic / Lumbar Spinal Fusion
224009733|NCT06226272|DEVICE|Spinal Deformities Correction|Spinal Deformities Correction
224009734|NCT03464851|DIAGNOSTIC_TEST|Carotid Stenotic Scan (CSS)|"Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart."
224009735|NCT00636805|DRUG|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
224009736|NCT04642248|OTHER|Personalized Run Practice|A combination of drills, flexibility, and strength activities combined with a gait retraining program
224009737|NCT02367547|DRUG|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
224009738|NCT02367547|DRUG|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
223389615|NCT04886596|BIOLOGICAL|Placebo|Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.
223389616|NCT04886596|BIOLOGICAL|RSVPreF3 OA vaccine|RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.
223389617|NCT03702127|DEVICE|Transcranial magnetic stimulation|NIBS is applied to the brain.
224009739|NCT02367547|DRUG|Methylaminolevulinate cream|In the study we use Metvix.
224009740|NCT05008939|DRUG|Sevoflurane|Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
224009741|NCT05008939|DRUG|Placebo|Patients received 30% oxygen for 1 hour.
224009742|NCT05576246|DIAGNOSTIC_TEST|airway pressure occlusion measurement|Flow, airway pressure (Paw), and esophageal pressure (Pes) will be recorded for 10 minutes on different NIV settings: during each one, three end-expiratory airway occlusions will be applied at random intervals. Each occlusion was maintained for the duration of a single breath deflection in Paw from PEEP, confirmed by the return of Paw to baseline.
224009743|NCT06168539|OTHER|Emboless|Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.
224009744|NCT06168539|OTHER|Standard|Standard dialysis set is used as comparative
224009745|NCT06690996|DRUG|LY4005130|Administered IV
224009746|NCT06690996|DRUG|LY4005130|Administered SC
224009747|NCT06690996|DRUG|Placebo|Administered IV
224009748|NCT06690996|DRUG|Placebo|Administered SC
224037822|NCT05915000|DIAGNOSTIC_TEST|Lumbar CSF protein marker determination|The cerebrospinal fluid levels of the Aβ1-42 amyloid, h-tau and phospho-tau proteins will be assessed. The response of patients to the possible implantation of a ventricular peritoneal shunt will be assessed through neuropsychological, gait and ventricular size studies assessed through cerebral magnetic resonance studies.
224037823|NCT06510361|DRUG|Epcoritamab|Humanized IgG1 bispecific antibody, 5 or 60 mL vial, via subcutaneous (under the skin) injection per protocol.
224037824|NCT04833322|DIETARY_SUPPLEMENT|D-Galactose|Galactose supplementation, once per day, up to 1.5g/kg per day
224037825|NCT05950139|BIOLOGICAL|Peptide vaccine|Peptide vaccine
224037826|NCT04869059|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
224037827|NCT04869059|DEVICE|sham tDCS|Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.
224037828|NCT06507813|DRUG|ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 45 mg ADC189 tablets once; patients weigh over 80 kilograms, given 90 mg ADC189 tablets once.
224037829|NCT06507813|DRUG|Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 40 mg Baloxavir marboxil tablets once. Patients weigh over 80 kilograms, given 80 mg Baloxavir marboxil tablets once.
224037830|NCT06507813|DRUG|Placebo of ADC189 tablets|Patients weigh between 20 to 80 kilograms, given 1 tablet of placebo once; patients weigh over 80 kilograms, given 2 tablets of placebo once.
224037831|NCT06507813|DRUG|Placebo of Baloxavir Marboxil tablets|Patients weigh between 20 to 80 kilograms, given 2 tablets of placebo once; patients weigh over 80 kilograms, given 4 tablets of placebo once.
223546037|NCT04443114|OTHER|End of Life Care Workshop|Discussion Moderated by Peer Educators Didactic Session 1: Critical Theological Concepts about Sickness and Health in Islamic Bioethics Didactic Session 2: Islamic Rulings about Brain Death, and Withdrawing/Withholding Life Support Moderated Panel Discussion: End-of-life Decision Making Facilitated Group Discussions with Peer Educators
223546038|NCT01987466|BIOLOGICAL|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
224009749|NCT05535881|BEHAVIORAL|Strengths to Grow Program|In an online, self-directed format, the Strengths to Grow program will present the principles of strength-based parenting using videos, pictures, reflection questions, and written text. The intervention will communicate that a) every child has a unique set of strengths and that b) noticing and developing these strengths can enhance child and family well-being. It will also provide concrete steps that parents can follow to talk with their child about strengths, and it will provide ideas for family activities that would allow family members to express strengths. Participants will be invited to respond to reflection questions at various points throughout the program.
224009750|NCT05905328|DRUG|CTO1681 10 μg|Administered 3 times daily for 15 days (initial cohort).
224009751|NCT05905328|DRUG|CTO1681 20 μg|Administered 3 times daily for 15 days (successive cohort).
224009752|NCT05905328|DRUG|CTO1681 30 μg|Administered 3 times daily for 15 days (successive cohort).
224009753|NCT06069375|DRUG|Sodium phenylbutyrate|Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day
224009754|NCT05308030|DRUG|Rivaroxaban and Aspirin|After the endovascular intervention, Anticoagulant therapy plus Antiplatelet therapy will be maintained (Aspirin 100 mg once daily and Rivaroxaban 2.5 mg twice daily) for 3 months, and then Aspirin alone indefinitely
224009755|NCT04534959|OTHER|Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)|Post-implementation of targeted normoxemia through oxygen titration for individual patients. Interventions for treatment of hypoxemia will follow usual local practice. Interventions for treatment of hyperoxemia (SpO2 \>96% or PaO2 \>100 mmHg) will involve down titration of FiO2 (or supplemental oxygen for non-mechanically ventilated patients) within a time frame based on local site preferences-typically in increments of no greater than 0.10 until goal oxygenation in the normoxemia range is achieved (including room air \[no supplemental oxygen\] for non-mechanically ventilated patients).
224009756|NCT03329859|PROCEDURE|High resolution standardized laparoscopic cholecystectomy|High resolution standardized laparoscopic cholecystectomy
224009757|NCT01363570|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
224126738|NCT06331923|DEVICE|Continuous glucose monitoring (CGM) device|Continuous glucose monitoring (CGM) will be prescribed by the attending physician for at least 6 hours before surgery. The supervising nurse will educate the patient and their family on the correct wearing and connection of the CGM device. The calibration frequency and interval of glucose monitoring devices before and after surgery should be determined according to institutional treatment guidelines and the requirements of the monitoring device used. Intraoperative glucose calibration should be done immediately upon entering the operating room, immediately after skin incision, every 2 hours after skin incision, and at the end of wound closure. Glucose monitoring should be continued until the 7th day after surgery or discharge.
224126739|NCT05560841|DEVICE|topical treatment|Topical application of Nailner brush 2in1 for toenail onychomycosis
224126740|NCT03857763|COMBINATION_PRODUCT|Apatinib,Paclitaxel,Cisplatin,RT|Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
224126741|NCT02351245|OTHER|observation|
224126742|NCT00330655|DRUG|memantine|
224126743|NCT00455260|DRUG|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
224296230|NCT03957187|DIAGNOSTIC_TEST|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
223546039|NCT00128999|PROCEDURE|Intensity-Modulated Radiation Therapy|
224009758|NCT04906395|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.
223546040|NCT05353413|DEVICE|Neuroimaging|Magnetic resonance diffusion tensor imaging of the brain
223546041|NCT05353413|DIAGNOSTIC_TEST|VEP - visual evoked potential|Electrophysiology of the visual pathway.
223546042|NCT05353413|DIAGNOSTIC_TEST|Ophthalmology examination.|Full ophthalmological examination (visual acuity, color vision, measurement of intraocular pressure, evaluation of the anterior chamber and the fundus of the eye using a slit lamp and the Volk lens, optical coherence tomography examination of the macula and optic nerve disc (OCT), neurological field vision)
224009759|NCT04906395|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet or solution
224009760|NCT04906395|DRUG|Letrozole Tablets|One 2.5 mg tablet taken orally once daily
223546043|NCT05805163|BEHAVIORAL|FABI tailored COVID-19 testing pamphlet|FABI adapted COVID-19 educational pamphlet
224009761|NCT04906395|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
223546044|NCT05805163|BEHAVIORAL|Standard COVID-19 home-based test kit|Standard COVID-19 home-based test kit
223546045|NCT02374229|PROCEDURE|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
223546046|NCT02374229|PROCEDURE|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
223546047|NCT05807126|PROCEDURE|Biopsy|Undergo biopsies
223546048|NCT05807126|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223546049|NCT05807126|PROCEDURE|Computed Tomography|Undergo CT
223389618|NCT01106079|DRUG|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
223389619|NCT01106079|DRUG|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
223389620|NCT04442464|DEVICE|Scleral Lens|15.0 mm diagnostic spherical rigid contact lens
223389621|NCT00948155|DRUG|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
223546050|NCT05807126|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223546051|NCT05807126|BIOLOGICAL|Magrolimab|Given IV
224009762|NCT04906395|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
224009763|NCT01519505|BEHAVIORAL|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
224299298|NCT05797818|DEVICE|Chlorhexidine Gluconate Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
223389622|NCT06345911|BEHAVIORAL|Experimental group|The animal characters were shown to the child before the bloodletting procedure. The child was asked to choose one of them and the one chosen by the child was attached to the vacutainer. The child and their parents were taken to the blood collection room. During the bloodletting procedure, the child was asked to focus on the animal character they had chosen.
223389623|NCT04610190|DEVICE|Training with Gait Enhancing and Motivating System (GEMS-H) Robot|Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
223389624|NCT02406690|OTHER|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
223389625|NCT03473925|DRUG|Navarixin|Oral capsules
223389626|NCT03473925|BIOLOGICAL|Pembrolizumab|Intravenous infusion
223389627|NCT02614326|BEHAVIORAL|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
223389628|NCT02614326|BEHAVIORAL|Psychoeducation|As in experimental arm description
223389629|NCT05477784|OTHER|Educational Intervention|Receive EC-PC program
223389630|NCT05477784|OTHER|Informational Intervention|Receive education booklet
223389631|NCT05477784|OTHER|Questionnaire Administration|Ancillary studies
223389632|NCT06823349|DRUG|Dexmedetomidine|5 mic dexmedetomidine will be given intrathecally added to 2.5 mg bupivacaine
223389633|NCT06823349|DRUG|fentanyl|25 mic of fentanyl will be given intrathecally added to 2.5 mg bupivacaine
223389634|NCT06823349|DRUG|Saline 0.9%|0.5 ml of saline 0.9% will be given intrathecally added to 2.5 mg of bupivacaine
223389635|NCT02691234|DEVICE|Extracorporeal Shockwave Therapy and debridement|
223389636|NCT02691234|OTHER|debridement and cleaning|
223389637|NCT06492109|BEHAVIORAL|Sleep manipulation|"This study will collect the MMSE results as a supplement to the MoCA. The sleep status of subjects will be screened using the Morningness-Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), and Epworth Sleepiness Scale (ESS).~Subjects must maintain regular sleep and diet before sample collection. Peripheral blood samples will be taken the day before, the day of, and the day after acute sleep deprivation, whether experimentally induced (controlled) or naturally occurring (passive), along with assessment scales including anxiety and depression assessments.~For chronic sleep deprivation (≥7 days), blood samples will be collected before and after the deprivation period, with anxiety, depression, and cognitive assessments.~Experimentally induced sleep deprivation takes place under controlled laboratory conditions, whereas passive sleep deprivation arises from external factors such as aging or shift work."
223389638|NCT04584502|BEHAVIORAL|Mindful Moms Yoga Mindfulness Intervention|MMORE is an 8-session yoga-mindfulness intervention protocol, offered via Zoom over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
223546052|NCT05807126|DRUG|Olaparib|Given PO
224009764|NCT05766384|DRUG|Hyperpolarized Xe129|Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
224009765|NCT04435288|DRUG|week 24|"At the week 24 timepoint, there are 3 possible scenario's:~1. In patients that do not reach a state of clinical remission at week 24, blinded study medication will be interrupted and all patients will start open-label SC golimumab for an additional 36 weeks (up to max. week 60).~2. In patients that achieve sustained clinical remission at week 24, defined as absence of clinical arthritis, enthesitis and dactylitis at both week 12 and week 24, all study medication will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B.~3. In patients that reach a state of clinical remission at week 24, but that did not yet reach this status at week 12, blinded study medication will be continued without any change in the treatment schedule for another 12 weeks."
223546053|NCT01027429|DRUG|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
223546054|NCT01027429|DRUG|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
223546055|NCT01027429|DRUG|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
224009766|NCT04435288|DRUG|week 36|"At week 36, patients that have continued the blinded study medication, will be re-assessed regarding sustained clinical remission (at week 24 and 36): if yes, all study medication will again be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. If no, these patients will start open-label SC golimumab for an additional 24 weeks (up to max. week 60).~If patients were in the open-label golimumab treatment arm, effectiveness of the treatment will be assessed by using the PASSI-question. Inadequate responders will be discontinued from the study and will be treated with standard-of-care medication at the discretion of their treating rheumatologist, whereas patients with an acceptable improvement in signs and symptoms will continue with the same (open-label) medication schedule."
224009767|NCT04435288|DRUG|Week 48|"At week 48, all patients still remaining in SPARTACUS Phase A will have been treated with open-label golimumab (for a minimum of 12 weeks, but potentially up to 48 weeks). In patients reaching at this timepoint sustained clinical remission (at week 36 and 48), golimumab will be discontinued and prospective follow-up will be planned in SPARTACUS Phase B. For the other patients there are 3 possible scenarios:~1. If clinical remission for the first time at week 48, continuation without any change in the treatment schedule for another 12 weeks.~2. If an inadequate response (based on the PASSI-question), discontinuation from the study and standard-of-care medication~3. If an acceptable improvement (but no clinical remission), continuation open-label golimumab for an additional 12 weeks, with open-label methotrexate (unless contra-indicated) to fulfil Belgian reimbursement criteria for TNFi."
224009768|NCT04435288|DRUG|Week 60|At week 60 (final study visit of SPARTACUS Phase A), patients reaching sustained clinical remission (at week 48 and 60), will roll-over into SPARTACUS Phase B. All other patients will be discontinued and will be treated with standard-of-care medication (including TNFi, if in accordance with Belgian reimbursement criteria).
224126744|NCT00455260|DEVICE|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
224126745|NCT03741894|DRUG|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
224126746|NCT03741894|OTHER|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
224126747|NCT03741894|DRUG|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
224126748|NCT06206668|OTHER|Action observation videos|The participant will see videos of balance exercises performed by the assigned reference, depending on their group, without performing any physical movement.
224126749|NCT01368341|DRUG|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
224126750|NCT01368341|DRUG|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
224126751|NCT01368341|DRUG|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
224126752|NCT05653206|PROCEDURE|Nonsurgical treatment|Cervical collar, Halo ring, Halo vest, cervical braces, skeletal skull traction, MAP, steroids, observation or bedrest
224126753|NCT05653206|PROCEDURE|Surgical treatment|Anterior discectomy and instrumented fusion (single level), Anterior discectomy and instrumented fusion (multi-level), Posterior decompression-laminectomy, Posterior decompression-laminoplasty, Posterior decompression and instrumented fusion, Combined anterior and posterior decompression and instrumented fusion
224126754|NCT05337813|DEVICE|"Storz Medical Extracoporeeal Shock Wave Therapy System"|A. B. C. D. groups need to Low Energy Extracorporeal Shock Wave (LiESWT) therapy once a week, duration 8 weeks(B.、C. groups needs to be combined PRP treatment at 1, 5, 9 weeks)
224126755|NCT02197429|OTHER|Acupuncture|
224126756|NCT02336594|DRUG|RDEA3170 10 mg|
223546056|NCT02789852|DEVICE|Orthosis|use orthosis
224009769|NCT05924750|DRUG|BL-M11D1|Administration by intravenous infusion
224126757|NCT02336594|DRUG|RDEA3170 2.5 mg|
224009770|NCT03065062|DRUG|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
224126758|NCT00471536|DRUG|pazopanib hydrochloride|800 mg Given orally
224126759|NCT00679679|DRUG|Metformin|Metformin 750 mg BID for 4 months
224126760|NCT00679679|DRUG|Placebo|Diet counseling and exercise
224126761|NCT02651194|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
223389639|NCT04852406|DRUG|Protocol-based management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to the latest expert consensus published in the Chinese Medical Journal, 2020.
223546057|NCT05843331|PROCEDURE|implants|Four implants in the maxilla with locator attachments
223389640|NCT04852406|DRUG|Routine management of perioperative antithrombotic therapy|Perioperative antithrombotic therapy is managed according to current routine practice.
223389641|NCT02777372|DRUG|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
223389642|NCT06262204|PROCEDURE|Hallux Valgus Treatment with Shark Screw®|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
223389643|NCT06262204|PROCEDURE|Hallux Valgus Treatment with metal screw|This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.
223389644|NCT04661150|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 3 cycles prior to surgery and 5 cycles after surgery.
223546058|NCT01677871|DRUG|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
224009771|NCT03065062|DRUG|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
224009772|NCT06665919|OTHER|CYP2C19 Genotype-Guided Clopidogrel Treatment|Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
224009773|NCT06665919|OTHER|CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel|An antiplatelet drug alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor, or prasugrel).
224009774|NCT06665919|OTHER|The Conventional Clopidogrel Treatment|Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or clopidogrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
224009775|NCT05433090|BEHAVIORAL|Inpatient serious illness care program|Inpatient advance care planning intervention that will be delivered by advanced care practitioners or hematology/oncology fellow physicians. The intervention will be an adapted version of the serious illness care program.
224009776|NCT06320067|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR)|SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 27-30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
224126762|NCT05060666|DRUG|Ivermectin|"2 doses of Ivermectin will be administered with 48 hours time interval.~The dosage is based on body weight calculated as follows:~* 15 mg for 40-60 kg = 5 tablets à 3 mg~* 18 mg for 60-80 kg = 6 tablets à 3 mg~* 24 mg for \> 80 kg = 8 tablets à 3 mg each~This corresponds to an ivermectin dose of about 300 µg / kg."
224126763|NCT05060666|DRUG|Placebo|"An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin."
224126764|NCT00966758|PROCEDURE|Computed Tomography|1 low dose CT scan is taken
224126765|NCT00966758|PROCEDURE|Single Photon Emission Computed Tomography|1 SPECT scan is taken
224126766|NCT02144454|DIETARY_SUPPLEMENT|Saturated fat|
224126767|NCT02144454|DIETARY_SUPPLEMENT|Monounsaturated fat|
224296231|NCT03840252|DIAGNOSTIC_TEST|3D gait analysis|Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
224126768|NCT02144454|DIETARY_SUPPLEMENT|n-6 polyunsaturated fat|
224126769|NCT00320736|DRUG|galantamine|
224126770|NCT02496585|DRUG|Nintedanib|
224126771|NCT02496585|DRUG|Prednisone|
224126772|NCT02496585|OTHER|Placebo|
224126773|NCT01051375|BEHAVIORAL|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
224126774|NCT04005820|OTHER|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
224126775|NCT04005820|OTHER|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
224296232|NCT03840252|DIAGNOSTIC_TEST|rsfMRI|MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
224296233|NCT03840252|DIAGNOSTIC_TEST|Montreal Cognitive assesment (MoCA)|Standard clinical questionnaire
224296234|NCT06358287|PROCEDURE|cryogenic auriculotherapy|Compressed nitrogen is used to create a 'cryonic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point.
224009777|NCT06320067|OTHER|177Lu-PSMA-617|177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
224009778|NCT06320067|DRUG|Androgen Deprivation Therapy (ADT)|Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
224037832|NCT06507813|DRUG|ADC189 granules|"For patient 5-11 years old, patients weigh between 20 to 80 kilograms, given 45 mg ADC189 granules once; patients weigh over 80 kilograms, given 90 mg ADC189 granules once.~For patient 2-4 years old, patients \<10kg, given 15mg ADC189 granules once. 10kg \~ \<15kg, given 25mg ADC189 granules once. 15kg \~\<20 kg, given 35mg ADC189 granules once. 20kg \~ \<80kg, given 45mg ADC189 granules once."
224037833|NCT06507813|DRUG|Placebo of ADC189 granules|Placebo. Given once only.
224037834|NCT06507813|DRUG|Placebo of Oseltamivir granules|For patients 2-4 years old. Placebo. Given 10 times (5 days, BID).
224126776|NCT03057834|BEHAVIORAL|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
224126777|NCT04490265|BEHAVIORAL|Problem-solving treatment|included in arm descriptions
224126778|NCT04490265|BEHAVIORAL|Supportive Psychotherapy|included in arm descriptions
224126779|NCT06157502|DRUG|Shuxuening Injection|Receiving 20 ml Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days
224126780|NCT06157502|OTHER|Placebo|Receiving 20 ml placebo Shuxuening injection plus 250ml 0.9% sodium chloride injection, intravenous drip once a day, for 10-14 days.
223389645|NCT04661150|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg IV loading dose and then 6 mg/kg IV on Day 1 of a 21-day cycle for 3 cycles before surgery, and administration will continue after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
223389646|NCT04661150|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered twice orally on Days 1-14, repeated every 3 weeks.
223389647|NCT04661150|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m\^2 will be administered by IV on Day 1 of a 21-day cycle.
224296235|NCT00562770|DRUG|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
224296236|NCT00562770|DRUG|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
223546059|NCT01677871|DRUG|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
223546060|NCT01677871|DRUG|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
223546061|NCT01677871|DRUG|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
224126781|NCT01864018|DRUG|Cyclophosphamide|Given PO
224126782|NCT01864018|DRUG|Dexamethasone|Given PO
224126783|NCT01864018|DRUG|Ixazomib Citrate|Given PO
224126784|NCT01864018|OTHER|Laboratory Biomarker Analysis|Correlative studies
224126785|NCT01864018|OTHER|Pharmacological Study|Correlative studies
224126786|NCT01864018|OTHER|Quality-of-Life Assessment|Ancillary studies
224126787|NCT01864018|OTHER|Questionnaire Administration|Ancillary studies
224126788|NCT03316391|OTHER|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
224126789|NCT02777775|PROCEDURE|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~* The skin area will be cleaned~* The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~* Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~* A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
224126790|NCT06300060|DIETARY_SUPPLEMENT|Synbiotic|Combination of a probiotic and prebiotic. Daily administration in a single dose in powder form.
224126791|NCT06300060|DIETARY_SUPPLEMENT|Placebo|Placebo. Daily administration in a single dose in powder form.
224126792|NCT03013777|BEHAVIORAL|8-week CBT Program|
223546062|NCT02224534|DRUG|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
223546063|NCT02224534|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
224126793|NCT00962000|OTHER|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
224126794|NCT00962000|OTHER|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
224126795|NCT06138795|DRUG|AZD2389|Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
224126796|NCT06138795|DRUG|Placebo|Participants will receive placebo matching the AZD2389 dose orally as a single ascending dose or multiple ascending dose.
224126797|NCT06822010|DRUG|Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)|"Drug: Gemcitabine (endoluminal administration)~Drug: Jelmyto (gel-based mitomycin, endoluminal administration)"
224126798|NCT05057702|OTHER|Specialized Tumor Board Treatment Plan|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
224126799|NCT05057702|OTHER|Combinations|Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
224126800|NCT04906889|DRUG|Dexmedetomidine Hydrochloride|dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia
224296237|NCT01861236|DRUG|Firmagon® (degarelix)|Monthly subcutaneous injections
224296238|NCT01147978|BEHAVIORAL|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
224296239|NCT05110807|DRUG|TQB3617|TQB3617 is a BET inhibitor.
224009779|NCT06320067|DRUG|Androgen Receptor Signalling Inhibitor (ARPI)|"Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines.~Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess.~Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles.~Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring.~Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles."
224009780|NCT06320067|RADIATION|Radiotherapy to Prostate ± Pelvic Nodes|Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 44-47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
224009781|NCT06320067|DRUG|Docetaxel|Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
224009782|NCT05377996|DRUG|XMT-1660|XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)
224009783|NCT05965856|DRUG|BL-B01D1|Administration by intravenous infusion
224009784|NCT05965856|DRUG|SI-B003|Administration by intravenous infusion
224009785|NCT05858281|BEHAVIORAL|Survey|Black adolescent girls (aged 12-17) will participate in an online survey and will be asked questions regarding their strengths, family, school and community experiences, sexual education knowledge, physical health and mental wellbeing, etc.
224009786|NCT05858281|BEHAVIORAL|Interviews|Parents/guardians of Black girls (aged 12-17) and Black emerging adult women aged 18-22 will participate in individual interviews and will be asked questions about their understanding of Black girls' strengths and resources.
224009787|NCT05858281|BEHAVIORAL|Focus group|Black adolescent girls (aged 12-17) will participate in a focus group and will be asked questions regarding their strengths, family, school and community resources, etc.
224009788|NCT00181142|DRUG|Zenapax|
224126801|NCT04906889|DRUG|Remifentanil Hydrochloride|remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia
224126802|NCT04906889|DRUG|Lidocaine Hydrochloride|lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
224009789|NCT05375097|OTHER|Erenumab|Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses
224009790|NCT06292442|OTHER|traditional physical therapy|This group received conventional physical therapy treatment including Range of Motion (ROM) exercises for the affected hip, knee, and ankle joints, as well as stretching exercises for tight lower limb muscles, administered 3 times per week for 4 weeks, with each session lasting approximately 20-30 minutes.
224009791|NCT06292442|OTHER|High intensity interval training|This group received High Intensity interval training along with conventional treatment for lower limb muscles, performed 3 times per week fr 4 weeks.
224009792|NCT05722639|DEVICE|X-Trodes acquisition system|No intervention. The participants will sit passively while electrophysiology signals are captured from two devices in order to evaluate the signal quality.
224126803|NCT01507610|DRUG|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
224126804|NCT06257238|DEVICE|Fully immersive Head-Mounted Display Virtual Reality|patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
224126805|NCT06257238|BEHAVIORAL|Traditional Physical Therapy Program|patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
224126806|NCT02379741|BIOLOGICAL|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
224126807|NCT06316622|DEVICE|ultrasound|measured by ultrasound
224126808|NCT02283606|DEVICE|Accuvix SnonAce UGEO|vaginal ultrasonography
224126809|NCT04757779|DRUG|anlotinib hydrochloride combined with irinotecan or docetaxel|From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
224126810|NCT03136757|OTHER|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~* to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~* to identify new intracellular signaling pathways that could lead to new therapeutic"
224126811|NCT03264482|PROCEDURE|M-TURP|endoscopic resection of the prostatic adenoma
224126812|NCT03264482|PROCEDURE|THUVAP|vaporization of prostatic adenoma via THULIUM laser
224126813|NCT05948410|BEHAVIORAL|The State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.
224126814|NCT05948410|BEHAVIORAL|Perceived Stress Scale|The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale
223389648|NCT06970652|DEVICE|virtual reality|Participants in the intervention group received access to the MR smartphone application and a smartphone-compatible VR headset, both developed by MindCo Health.32 The application contained a stress reduction program that comprised a structured sequence of 77 modules designed to be completed over the course of 8 weeks. Each module was designed to be completed in approximately 7 minutes, and each module needed to be completed before progressing to the next module. Forty modules used VR, and for these modules, participants placed their personal smartphones running the MR application in the VR headset, and the smartphone provided all audiovisual content. All other modules used smartphones without the VR headset.
223389649|NCT06362421|GENETIC|Pre-Radiation Dental Evaluation/Sample Collection|Collection of saliva samples and mouth swabs and pre-cancer dental evaluation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
223389650|NCT06362421|OTHER|Pre-Study Visit|Collection of vital signs, medical history and current medications
224009793|NCT06450847|OTHER|Soleus Muscle Push Up Exercise|"Members will be asked to do the SPUs for 270 minutes/day for most days of the week (minimum 5 days) for 3 months:~1. Begin seated on a bench or chair so knees form a 90-degree angle with feet flat on the floor and toes pointed forward. Keep spine straight and shoulders back (not hunched or rounded forward).~2. Using a slow and controlled tempo, push toes into the floor and lift heels off the ground.~3. Hold for one to two seconds, pushing down on the balls of feet. Keep your thigh muscles relaxed.~4. Slowly lower heels and return to start. That's 1 rep. Without shoes Educational session will be given before the intervention time WhatsApp messages will be sent 1-2 times/day to remind the participants to continue doing the exercise and ascertain compliance. Also, the participants are required to daily fill logbook about the duration (in minutes) of the SPU that they did."
224009794|NCT06450847|OTHER|Other Exercise|Participants will be asked to continue their regular lifestyle
224009795|NCT06248437|OTHER|innovative nutraceutical-type food product that we designed called HIC1® from coffee mucilage|All participants completed a survey on sociodemographic data (age, sex, respiratory problems, smoking, among others). Weight, height, skin folds, and a blood sample were taken to quantify the Oxygen Radical Absorption Capacity (ORAC) units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and lipid profile. At that time, they were explained how they should eat the nutraceutical food, starting the next day and for five consecutive days. During those 5 days, a nurse made contact calls to verify that the participant took the corresponding dose for the day. After 5 days of ingesting the nutraceutical compound, a blood sample was taken again to quantify post-ingestion levels of ORAC units, amino acids, vitamin B12, vitamin D, phosphorus, magnesium, calcium, and the lipid profile. In the case of the participants in the ICU, control visits were made to the unit to verify that the dose was delivered to the participant
224126815|NCT05948410|BEHAVIORAL|Visual Analog Scale|The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
223389651|NCT06362421|GENETIC|Oral Medicine Consultation Visit/Sample Collection|Collection of saliva samples and mouth swab, complete oral medicine consultation by study staff. Unstimulated saliva will be collected then a buccal swab sample will be obtained. Participants will be asked to rinse their mouth with water, wait 10 minutes, then 1-2 mL of unstimulated saliva will be captured into sterile centrifuge tube. Next, a buccal swab sample will be collected using a sterile cotton swab and immediately placed in a transport tube containing buffer (Tris with low EDTA)
223389652|NCT05767905|DRUG|PF-06821497 Treatment A|A single dose of PF-06821497 administered under fasting conditions.
223389653|NCT05767905|DRUG|PF-06821497 Treatment B|A single dose of PF-06821497 administered under fasting conditions.
224126816|NCT02207699|DRUG|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
224126817|NCT02207699|DRUG|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
224126818|NCT02207699|DRUG|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
223389654|NCT05767905|DRUG|PF-06821497 Treatment C|A single dose of PF-06821497 administered under fasting conditions.
223389655|NCT05767905|DRUG|PF-06821497 Treatment D|A single dose of PF-06821497 administered under fasting conditions.
223730366|NCT01516320|PROCEDURE|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
223730367|NCT03652844|PROCEDURE|AAM|Subcutaneous injection procedure
223730368|NCT05122520|OTHER|Questionnaire|The HMBT-Q is a 26-item questionnaire, split into four main sections: food related symptoms; general digestive symptoms; extra-intestinal symptoms and co-morbidities and Medication and onset.
224126819|NCT02207699|DRUG|Placebo|8 placebo perles given by mouth once
224126820|NCT03811678|DRUG|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
224126821|NCT03811678|DRUG|placebo|Tablet，administered orally once daily
224126822|NCT04571710|DRUG|SHR1258|Drug: SHR1258 400mg
224126823|NCT05428358|DIAGNOSTIC_TEST|Preoperative MRI|Preoperative MRI performed between outpatient visit at the surgical clinic and scheduled date of resection
224126824|NCT06502964|DRUG|ALTO-101|ALTO-101 patches
224126825|NCT06502964|DEVICE|ALTO-101 Transdermal Delivery System|ALTO-101 transdermal delivery system
224126826|NCT06502964|DRUG|Placebo|Inactive placebo patches
224126827|NCT06502964|DEVICE|Placebo Transdermal Delivery System|Placebo transdermal delivery system
224126828|NCT05574647|DIAGNOSTIC_TEST|bpMRI|biparametric MRI takes 30-40 minutes and requires a contrast injection called gadolinium (like a dye). This is also called long MRI and is most commonly used in the NHS.
224296240|NCT01698437|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
223730369|NCT05642754|OTHER|Overall uncertainty language|Researchers are testing different forms of information about overall study uncertainty and margin of error around main result
224296241|NCT00560937|DRUG|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
224296242|NCT00560937|DRUG|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
224296243|NCT03676751|DRUG|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
224296244|NCT03676751|DRUG|Placebo|Oral suspension of placebo for azithromycin
224296245|NCT01868711|BEHAVIORAL|Cognitive Behavior Therapy|
223389656|NCT05767905|DRUG|PF-06821497 Treatment E|A single dose of PF-06821497 administered after low fat meal
223389657|NCT05767905|DRUG|PF-06821497 Treatment F|A single dose of PF-06821497 administered after high fat meal.
223389658|NCT04157595|OTHER|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
224009796|NCT06240013|OTHER|Foam Rolling|Participants will take a long sitting position on a solid and flat surface, positioning their arms back and transferring their body weight to their palms. The foam roller to be applied to the dominant side will be placed under the hamstrings and slowly moved back and forth from the ischial tuberosity to the popliteal fossa, applying pressure for 2 minutes.
224296246|NCT03486054|DEVICE|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
224296247|NCT03486054|DEVICE|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
224296248|NCT05023577|DRUG|Rabeprazole|20mg bid
223389659|NCT06045689|DRUG|Luspatercept|Specified dose on specified days.
223389660|NCT03762239|OTHER|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
223389661|NCT03762239|OTHER|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
223389662|NCT06183983|DIAGNOSTIC_TEST|Extended or additional MRI-scan (with contrast) prior to radiotherapy|The MRI-protocol before radiotherapy is extended with 20 minutes. Patients who would not have received an MRI-scan prior to radiotherapy, will get an extra MRI-scan when participating.
223389663|NCT06122363|DEVICE|hysteroscopy|uterine hysteroscopy right after Novasure endometrial ablation
223389664|NCT06304883|DRUG|Experimental: ALZ-801|ALZ-801 265 mg BID tablet orally.
223546064|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
223546065|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
223730370|NCT02350725|DRUG|Furosemide injection solution for subcutaneous administration (80 mg)|
223730371|NCT02350725|DRUG|Oral Furosemide tablets (80 mg)|
223730372|NCT05898815|DIAGNOSTIC_TEST|Medical record collection|Medical record collection
223389665|NCT05588024|DEVICE|Head Up CPR based bundle of care|All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
224009797|NCT06240013|OTHER|Proprioceptive Neuromuscular Facilitation Stretching|A PNF stretching protocol will be implemented with each participant assuming a tall sitting position on a solid, flat surface with their knees extended as much as possible. At this moment, the participant will be asked to perform maximum isometric hamstring muscle contraction for 5 seconds, followed by 5 seconds of relaxation and 20 seconds of stretching.
224009798|NCT05847907|DEVICE|Implant placement|Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
224009799|NCT05974670|DEVICE|Consumer wearable device|The subjects are required to wear the consumer wearable devices continuously during the whole study period. The device can provided several physiological parameters, including pulse rate, blood oxygen saturation, physical activity, electrocardiogram, and sleep.
224009800|NCT04747197|DRUG|EYP-1901|Intravitreal injection
224009801|NCT03883646|BEHAVIORAL|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
224009802|NCT03883646|BEHAVIORAL|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
224009803|NCT00607724|DRUG|GDC-0449|
224009804|NCT00555529|PROCEDURE|radial artery applanation tonometry (RAAP)|non-invasive tonometry
224009805|NCT02156323|DRUG|CMS|Multiple doses of CMS over 2.5 days
224009806|NCT02156323|DRUG|RO7033877|Multiple doses of RO7033877 over 2.5 days
224009807|NCT02156323|DRUG|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
224009808|NCT01419327|DRUG|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
224296249|NCT05023577|DRUG|Bismuth potassium citrate|0.6g bid
224009809|NCT03738423|DRUG|REGN3500|Administered subcutaneous (SC)
224009810|NCT03738423|DRUG|REGN3500-Matching Placebo|Administered subcutaneous (SC)
224009811|NCT06519084|OTHER|Home based exercise training|"Intervention: home based physical exercise performed 4 times a week, each session lasting 40 minutes each. Aerobic and muscular resistance exercises, using body weight and elastic bands.~The sessions were proposed through video classes, in total 12 video classes during the 12 weeks of physical training. Patients monitored their heart rate during exercise and wrote it down on spreadsheets that were monitored weekly."
224009812|NCT04311710|DRUG|ipilimumab|Specified Dose on Specified Days
224009813|NCT04311710|DRUG|nivolumab|Specified Dose on Specified Days
224296250|NCT05023577|DRUG|Metronidazole|0.4g qid
224296251|NCT05023577|DRUG|Clarithromycin|0.5g bid
224296252|NCT05023577|DRUG|Levofloxacin|0.5g qd
224296253|NCT01026259|OTHER|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
224296254|NCT01026259|OTHER|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
224296255|NCT04785157|BIOLOGICAL|serology testing profiles description|SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)
224296256|NCT04785157|BIOLOGICAL|immune response characterization|systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)
224009814|NCT04311710|DRUG|ENHANZE (rHuPH20)|Specified Dose on Specified Days
224009815|NCT04311710|DRUG|nivolumab|Specified Dose on Specified Days
224009816|NCT05194982|DRUG|BL-B01D1|Administration by intravenous infusion.
223389666|NCT06004674|DRUG|Lovenox 40mg|Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
223389667|NCT04416581|DRUG|PPI|rabeprazole 20mg + tegoprazan 50 mg placebo, once daily.
223389668|NCT04416581|DRUG|P-CAB 50|tegoprazan 50 mg + rabeprazole 20mg placebo, once daily.
223389669|NCT04175041|DEVICE|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
223389670|NCT05357846|DRUG|Sintilimab|Sintilimab 200mg, IV (in the vein) on day 1 and day 22
223389671|NCT05357846|RADIATION|Preoperative radiotherapy|External radiation with a total dose of 40.0 or 45.0 Gy is given in 20 fractions,5 fractions a week.
223389672|NCT05357846|DRUG|Paclitaxel|50mg/m2, IV (in the vein) on day 1,day 8,day 15 and day 22
223389673|NCT05357846|DRUG|Cisplatin|25mg/m2,IV DRIP on day 1,day 8,day 15 and day 22
223389674|NCT05357846|PROCEDURE|esophagectomy|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 6-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
224009817|NCT06578741|DEVICE|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)|Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
224009818|NCT04095923|BEHAVIORAL|Social media game|Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
224009819|NCT04095923|BEHAVIORAL|Standard self-regulation|Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
224037835|NCT06507813|DRUG|Oseltamivir granules|For patients 2-4 years old. Patients \<15kg, given 30mg×10 times (5 days, BID) Oseltamivir granules. 15kg \~ \<23kg, given 45mg×10 times (5 days, BID) Oseltamivir granules. 23kg \~ \<40kg, given 60mg×10 times (5 days, BID) Oseltamivir granules. ≥40kg, given 75mg×10 times (5 days, BID) Oseltamivir granules.
224037836|NCT00396435|DRUG|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
224037837|NCT06027983|DRUG|Chimeric receptor T-cells + Trastuzumab|Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.
224037838|NCT06027983|DRUG|Fludarabine and Cyclophosphosphamide|3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
224037839|NCT07130175|DEVICE|Radiofrequency Catheter Ablation|An invasive procedure performed under local anesthesia. An electroanatomic mapping system (CARTO 3) was used to identify the arrhythmogenic substrate of the PMVT. Radiofrequency energy was delivered via an irrigated-tip catheter (30-35 W, 43°C, 17 mL/min saline irrigation) to ablate the target sites. The procedural endpoint was the non-inducibility of the clinical arrhythmia. Post-procedure, patients were prescribed amiodarone.
224037840|NCT07130175|DRUG|Guideline-Directed Medical Therapy (GDMT)|Standard medical therapy for heart failure, including spironolactone (20 mg once daily), metoprolol succinate (25 mg twice daily), and sacubitril/valsartan (50 mg twice daily). Doses were titrated according to patient tolerance and clinical guidelines.
224037841|NCT02458014|BIOLOGICAL|Blinatumomab|Given IV
224037842|NCT02458014|OTHER|Laboratory Biomarker Analysis|Correlative studies
224037843|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
224037844|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
224009820|NCT00558077|DRUG|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
224009821|NCT00558077|PROCEDURE|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
224009824|NCT05223608|OTHER|ImmuCCo Cohort|Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
224009825|NCT01133418|OTHER|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
224009826|NCT01133418|OTHER|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
224009827|NCT06474091|OTHER|Non-Interventional Study|Non-Interventional Study
224009828|NCT05316701|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
224296257|NCT04785157|OTHER|in vivo brain PET-TSPO acquisitions|in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)
224296258|NCT04785157|OTHER|brain MRI assessment|structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)
224296259|NCT04785157|BEHAVIORAL|neurocognitive assessment|multi-domains neurocognitive assessment
224296260|NCT00384007|PROCEDURE|Hydrodiscectomy with Spinejet|
224009829|NCT05316701|BIOLOGICAL|Standard-of-Care|unmanipulated donor allograft
224009830|NCT04696653|OTHER|Comprehensive Unit Based Safety Program (CUSP)|CUSP is a quality improvement strategy developed by the Johns Hopkins University Armstrong Institute for Patient Safety and Quality that is used to improve care delivery.
224296261|NCT00793741|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
224296262|NCT03046719|DRUG|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
224296263|NCT03046719|DRUG|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
224296264|NCT04637633|DRUG|topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,|topical preservative free artificial tears Q.I. D.
224296265|NCT04116905|BEHAVIORAL|Intensive Lifestyle Intervention|"The intensive lifestyle intervention program employs a structured, multi-component approach under professional supervision to achieve and sustain 15% weight reduction from baseline. This 12-month intervention features:~1. A weight loss phase (months 1-5) incorporating:~   Individualized calorie restriction using partial meal replacement (carbohydrate energy supply ratio is 20\~25%, and the daily calorie intake is 22.5\*70% kcal/kg/d); exercise recommends at least 150 min of moderate intensity and 2 to 3 resistance training per week; with monthly follow-ups；~2. A maintenance phase (months 6-12) focusing on:~   Healthy balanced diet, total daily calorie intake is 20-25 kcal/kg/d; exercise recommends at least 150 minutes of moderate intensity and 2-3 resistance training per week; with follow-ups every 2 months；~3. Digital health integration:~Mobile application-based monitoring of metabolic parameters; real-time feedback and adherence tracking."
223389675|NCT05195801|DEVICE|USG|Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
223389676|NCT03645863|DRUG|MT-6548|Oral tablet
224009831|NCT04615130|OTHER|Rehabilitation|Rehabilitation, exercise training
224009832|NCT05013632|DRUG|Antiviral Agents|Antiviral medications indicated for the treatment of mild to severe COVID-19
224009833|NCT05013632|DRUG|Monoclonal antibody|Monoclonal antibodies indicated for the treatment of mild to severe COVID-19
224037845|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
224037846|NCT07118943|OTHER|Face care product|The topical product will be applied twice daily (morning and night).
224037847|NCT07118852|DEVICE|Remote Human Milk Sample Collection|"Three commercially available products will be evaluated for their ability to preserve RNA in human milk samples.~* RNAlater (ThermoFisher©) (ratio variable)~* DNA/RNA Shield (Zymo©) (ratio variable)\*~* NucleoProtect RNA (Takara©) (ratio variable)\*~  * Product volume mixed with human milk samples will vary by product and may be titrated as part of protocol development."
224037848|NCT06223555|OTHER|Fixed Mixed Meal Test|a FIXED dose meal that will be 900 kcal of a liquid meal
224037849|NCT06223555|OTHER|Adjusted Mixed Meal Test|"a body weight ADJUSTED dose liquid meal.~(30% of total daily energy requirements)"
224037850|NCT04378855|OTHER|Questionnaire|Quality of life assessment
224037851|NCT04115878|DRUG|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
224009834|NCT05890898|BEHAVIORAL|Virtual Reality Headset|To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
224009835|NCT05890898|DRUG|Nitrous Oxide|Nitrous Oxide is the current standard of care being used and will be compared to the use of the VR headsets.
224009836|NCT06318390|DIETARY_SUPPLEMENT|XO Genius|This is a beverage powder that is high in healthy ingredients that are believed to be beneficial for physiological health
224126829|NCT05574647|DIAGNOSTIC_TEST|Image-Fusion targeted and systematic Biopsy|During image fusion targeted biopsy, the biopsy operator uses the MRI scans that were taken beforehand but laid on top of the live ultrasound images during the biopsy. This uses software and takes a few minutes longer to perform. Once the MRI images and ultrasound images are 'fused', the actual biopsies are taken as normal.
224126830|NCT05619497|OTHER|Clinic-wide Trainings|The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.
224138550|NCT04161274|PROCEDURE|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
224296266|NCT04116905|BEHAVIORAL|Conventional Treatment|"The conventional treatment arm receive standardized metabolic syndrome management through monthly group education sessions and peer support, with a target of 7% weight reduction from baseline. The program incorporates:~1. A weight loss phase (months 1-5) incorporating:~   Structured lifestyle education; limit the total energy diet (total daily calorie intake is 22.5\*85% kcal/kg/d), with carbohydrates, fat, proteins accounting for 45-55%, 20-30%, and 20-30%, respectively, for the daily energy intake.; physical activity(150 min medium intensity exercise and 2 to 3 resistance training); with monthly follow-ups;~2. A maintenance phase (months 6-12) focusing on:~   Healthy balanced diet, total daily calorie intake is 20\~25 kcal/kg/d; physical activity(150 min medium intensity exercise and 2 to 3 resistance training);with follow-ups every 2 months;~3. Digital health integration:~Mobile application-based monitoring of metabolic parameters; real-time feedback and adherence tracking."
224296267|NCT00492765|DRUG|Interferon-beta-1a|dosage and frequency as per label
224296268|NCT00492765|DRUG|Simvastatin|dosage and frequency as per Biogen Idec protocol
224296269|NCT00492765|DRUG|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
224296270|NCT02359201|DRUG|V0018|Oromucosal - Single dose
223730373|NCT02968745|OTHER|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
224296271|NCT02359201|DRUG|Placebo|Oromucosal - Single dose
224296272|NCT03858218|OTHER|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
224296273|NCT03043118|OTHER|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
224296274|NCT06204419|DRUG|XH-S002 （A）|XH-S002 powder will be administered orally as per assigned treatment regimen.
224296275|NCT06204419|OTHER|Placebo（B）|XH-S002 Placebo (matched) will be administered orally as per assigned treatment regimen.
224009837|NCT04580368|DRUG|CFTR Modulators|Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
224009838|NCT02577120|DEVICE|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
224009839|NCT02577120|BIOLOGICAL|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
224009840|NCT06973577|DRUG|Centanafadine|Centanafadine QD XR fixed dose 328.8mg
224009841|NCT06973577|OTHER|Placebo|Placebo
224009842|NCT06575426|COMBINATION_PRODUCT|OPF-310|"Dose(Part1): 6,000 islet equivalents (IEQ)/kg or 12,000 islet equivalents (IEQ)/kg~Dose(Part2): Recommended Phase II Dose(RP2D), which will be determined based on the data of Part1~* In Part1, three subjects will be enrolled into the first dosing cohort (Cohort 1: 6,000 IEQ/kg) and they will undergo safety monitoring. Three subjects in Cohort 2 will be dosed with 12,000 IEQ/kg and will undergo safety monitoring.~* In Part2, 7 subjects will be enrolled into the Part 2 dose-expansion part."
224296276|NCT03822364|DRUG|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
224296277|NCT03822364|DRUG|active comparator|commercially available apomorphine injector
224296278|NCT03822364|DRUG|009-0|Inhaled placebo via Staccato device
223730374|NCT05514691|DIAGNOSTIC_TEST|iStatis COVID-19 Ag Rapid Test|SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
223730375|NCT05514691|DIAGNOSTIC_TEST|"COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)"|The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
224009843|NCT05085210|DEVICE|transcranial random noise stimulation (tRNS)|noninvasive current stimulation for 20 - 30 minutes stimulation on visual cortex (electrodes on surface of scalp, positioned O1 / O2 on EEG cap). 1mA max amplitude noise stimulation, frequencies from 100 Hz - 640 Hz.
224296279|NCT03822364|DRUG|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
224296280|NCT03822364|DRUG|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
224296281|NCT03822364|DRUG|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
224009844|NCT05085210|BEHAVIORAL|Computer Based Visual Training|Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center of screen during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
224009845|NCT05085210|DEVICE|Sham stimulation|20-30 minutes sham stimulation on visual cortex. Participants receive identical setup to real stimulation. The device provides a short ramp on period to simulate the feeling of real stimulation at the start but no current is delivered otherwise.
224009846|NCT05085210|BEHAVIORAL|Virtual Reality Based Visual Training|• Dynamic visual stimuli are presented on specific locations of the visual field. Participant holds fixation on center point within the VR headset during presentation of visual stimuli. Participants will be presented with multiple trials of a motion discrimination task. Training will be performed for 2 weeks (10 consecutive weekdays), 30 minutes each day.
224009847|NCT06853665|DRUG|Adderall XR (mixed salts amphetamine)|Capsule
224009848|NCT06853665|DRUG|Placebo|Capsule
224009849|NCT06597773|OTHER|Online patient navigation and supportive care referrals|In the online patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to web-based, systematic supportive care resources consisting of pre-recorded videos led by specialists and which will be available on a study-specific website, allowing each participant to access the resources as soon as they receive a referral. Additionally, online support groups will be held monthly to complement the supportive care programs.
224009850|NCT06597773|OTHER|In-person patient navigation and supportive care referrals|In the in-person patient navigation program, a navigator will use validated instruments to identify participants\&amp;#39; need for nutrition, psychology, and sexology counseling, and will refer them to the required services. Referrals will be made to supportive care services available at their healthcare institution.
224009851|NCT03598595|DRUG|Docetaxel|Given IV
224009852|NCT03598595|DRUG|Gemcitabine|Given IV
224126831|NCT05619497|OTHER|Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)|"The clinic-wide trainings combine principles of shared decision-making and trauma informed care to inform providers and clinic staff of an equitable approach to offering HIV prevention information. These care delivery approaches have been used in health education and counseling in a range of contexts and are effective strategies for care provision. Participants in this arm will receive care from providers and staff who received training.~The DST is founded on principles of decision-science and will address barriers to PrEP delivery. The DST will present HIV prevention information through a tablet in the clinical setting. The tool provides information about vulnerabilities to HIV and core characteristics of different HIV prevention methods, and the opportunity to explore these characteristics in depth, including efficacy, safety and side effects. The tool emphasizes the highly variable and individual nature of baseline risk."
224126832|NCT05619497|OTHER|Standard Care with the HIV Prevention Decision Support Tool (DST)|Participants in this arm will receive usual care at a clinic that has not received training in shared decision making and trauma informed care. These participants will view the decision support tool. These participants were recruited in Aim 1 of this study.
224126833|NCT04813042|BEHAVIORAL|Working Out Dads|"The WOD is a manualised group intervention underpinned by solution-focused therapy and social cognitive theories. Psychoeducation about the transition to fatherhood and its potential impacts on wellbeing and family relationships is provided. Fathers are encouraged to share practical ideas for managing stress, revisit previous strategies, validate what they are doing well, and explore solutions.~The group discussion is followed by a structured group fitness session provided by a personal trainer. This session focuses on body weight exercises, cardio-based activities, stretching, mobility and incidental activity.~Fathers in the WOD study arm receive 10 weeks of encouraging text messages - one each week during the intervention, and four in the weeks after. These will be sent via the WhatsApp group created for each WOD group. These text messages and the WhatsApp group are designed to facilitate fathers' active engagement with the intervention, and to maintain contact with each other."
224296282|NCT03822364|DRUG|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
224296283|NCT03866018|OTHER|Adapted physical activity|12 sessions of one hour of adapted physical activity.
223389677|NCT03645863|DRUG|Iron supplement A|Oral tablet
224009853|NCT03598595|DRUG|Hydroxychloroquine|Given PO
224009854|NCT00317733|DRUG|Ketoprofen in Transfersome|
224009855|NCT06698042|BIOLOGICAL|Pembrolizumab (+) Berahyaluronidase alfa|Administered subcutaneously on Day 1 of each cycle
224009856|NCT06698042|BIOLOGICAL|Pembrolizumab|Administered intravenously on Day 1 of each cycle
224009857|NCT06697314|DEVICE|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System|Single Arm Study - Use of AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 for the treatment of acute pulmonary embolism
223389678|NCT03645863|DRUG|Iron supplement B|Oral tablet
223389679|NCT03645863|DRUG|Iron supplement C|Oral tablet
223389680|NCT03645863|DRUG|Iron supplement D|Oral tablet
224009858|NCT06710197|DRUG|Anakinra (Kineret®)|100 mg/daily subcutaneously
224009859|NCT05956587|DRUG|BL-B01D1|Administration by intravenous infusion
224009860|NCT05956587|DRUG|SI-B003|Administration by intravenous infusion
224009861|NCT06744712|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing will be completed by the vendor. The vendor is certified under CLIA-88 and accredited by the College of American Pathologists as qualified to perform high-complexity testing. Genomic DNA extracted from the swab will be analyzed by PCR using Thermo Fisher TaqMan® and/or LGC Biosearch BHQ® probe-based methods to interrogate the variant locations listed in (See Appendix II). Twenty-seven genes are evaluated and reported.
224009862|NCT06893705|OTHER|Conventional Therapy|Conventional Therapy Group: Group A will be control group which will receive conventional physical therapy program for the affected neck like stretching exercises, active range of motion exercise, and neck isometrics for 6 weeks (3 sessions per week).
224009863|NCT06893705|OTHER|Pilates+Conventional Therapy|Group B will be experimental group, which will receive Pilate's exercises like cat stretch, swan dive/roll up along with conventional therapy for 6 weeks(3 sessions per week). In each session there will be 25 minutes of conventional therapy and 25 minutes of Pilate's exercises program.
224126834|NCT04813042|BEHAVIORAL|Usual care|The Usual Care arm, also known as 'Talking about being dad' comprises a telephone consultation with a qualified mental health professional. Topics including in this consultation include: (a) discuss family and fathering; (b) health and wellbeing; (c) mental health symptoms and conduct a risk assessment for suicidal ideation; (d) current supports and support needs; (e) provide referral options to telephone support services (PANDA; MensLine); and (f) encourage a general practitioner visit to discuss a mental health care plan.
224009864|NCT05897320|DRUG|Eptinezumab|Solution for infusion
224009865|NCT05897320|DRUG|Placebo|Solution for infusion
224009866|NCT07053774|DRUG|Intravenous oxytocin|Oxytocin, 10 International Units (IU) will be administered by IV infusion over 30 minutes and, 30 minutes later, a second 10 IU will be administered over 30 min, for a total dose of 20 IU. The first infusion will be at a rate of 0.125 IU/min for the first 5 min, then at 0.375 IU/min for the remaining 25 min. The second 30-min infusion will be at a fixed rate of 0.333 IU/min.
223546066|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
223546067|NCT01052883|DRUG|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
223546068|NCT00947128|DRUG|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
223546069|NCT00947128|DRUG|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
223546070|NCT01545596|BEHAVIORAL|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
223546071|NCT05006105|DEVICE|seven-day ECG Holter|Participants receive a seven-day ECG Holter after hospital discharge.
224009867|NCT07053774|DRUG|Intravenous placebo|Saline will be administered as two 30-min IV infusions separated by 30-min, using the same volume of infusion solution and rates of administration as in the intravenous oxytocin intervention.
224009868|NCT07053774|DRUG|Intranasal oxytocin|Oxytocin will be self-administered at the time the first IV infusion begins as a single 0.1 mL spray (20 IU) in each nostril followed in 5 min by another spray in each nostril. The total dose of oxytocin is 80 IU.
224009869|NCT07053774|DRUG|Intranasal placebo|Placebo (solution containing the excipients in the oxytocin solution but without oxytocin) will be self-administered at the time the first IV infusion begins as a single 0.1 mL spray in each nostril followed in 5 min by another spray in each nostril.
224009870|NCT07063095|DRUG|Ceftazidime± avibactam with fosfomycin|"The intervention will last 72h (±6h). Ceftazidime will be administered intravenously in 5% glucose serum (per hospital standard), either intermittently (divided into three doses daily) or as continuous infusion; doses will be adapted to renal function. The decision to administer CAZ by continuous infusion and to add AVI will be left to the attending physician. CAZ±AVI will be adjusted for renal insufficiency per internal guidelines of dosing and international recommendations.~The use of CAZ with its paired beta-lactamase inhibitor avibactam, i.e., the use of ceftazidime-avibactam (Zavicefta®) instead of CAZ will occur in case of suspicion of infection by either extended-spectrum-beta-lactamase-producing Enterobacterales (ESBL-E), cephalosporinase-carrying Enterobacterales (ampC-E) or carbapenem-resistant Enterobacterales (CRE), as determined by treating physician and/or the infectious diseases consultant."
224126835|NCT04117685|OTHER|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
224126836|NCT03716986|DIAGNOSTIC_TEST|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
224126837|NCT03065634|BEHAVIORAL|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
224126838|NCT03065634|BEHAVIORAL|socio-legal counseling|"Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker"
224126839|NCT02422550|DEVICE|MRI or CT|Participants enrolled on this protocol may undergo multiple MRI or CT examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
224126840|NCT01064466|DRUG|ETOPOSIDE - Usual|Etoposide Capsule
224126841|NCT01064466|DRUG|ETOPOSIDE - Study|China Import Etoposide Capsule
224126842|NCT06663956|BEHAVIORAL|a patient self-reporting applet|"We propose to develop a patient self-reporting applet that is easy to use and simple to operate. The program is embedded with questionnaires related to cancer pain and quality of life assessment, so that patients can fill out the questionnaires to report their symptoms and changes in their conditions to primary care doctors in a timely manner. At the same time, the background of the program will monitor the patient's indicators in real time. When the patient's pain reaches moderate-to-severe level, or when the patient experiences side effects of drugs, or when the patient's adherence to medication is poor, the primary care doctor can immediately receive relevant alerts through the app, so as to intervene in the patient's cancer pain treatment. When the patient has an alarm value, primary care doctors can provide feedback to doctors in higher-level hospitals and implement comprehensive and standardized treatment for cancer pain patients."
223546072|NCT05006105|DEVICE|24-hour blood pressure monitor|Participants receive a 24-hour blood pressure monitor, approximately four weeks after hospital discharge.
223546073|NCT05006105|OTHER|Questionnaire: vision of mHealth|Participants receive a questionnaire concerning their vision of mHealth, approximately four weeks after hospital discharge.
223546074|NCT05006105|OTHER|Questionnaire: user experience & feeling of safety|Participants receive a questionnaire concerning their user experience and feeling of safety of using mHealth, after using mHealth for six months.
223546075|NCT05006105|DEVICE|Insertable loop recorder|Participants receive an insertable loop recorder, approximately six weeks after hospital discharge.
224009871|NCT07063095|DRUG|Ceftazidime± avibactam with placebo|Participants randomized to the control arm will receive placebo infusion. Placebo will be 5% glucose serum and will be administered IV with the same frequency as FOS would be for the participant's renal function.
224009872|NCT06777368|DEVICE|Medtronic TAV|Medtronic TAV where commercially available
224009873|NCT06777368|DEVICE|Edwards TAV|Edwards TAV where commercially available.
224009874|NCT07062614|OTHER|Hair sampling and questionnaires answers for Patients with Lamivudine or Emtricitabine treatment|at inclusion, 3 months and 6 months of follow-up, patients must answer the Girerd compliance questionnaire. After 6 months of follow-up, two strands of hair will be taken from the base of the skull using scissors
224009875|NCT07071948|DEVICE|Multifunctional Integrated Flexible Ureteroscope|"Investigational ureteroscope with three integrated functions:~1. Real-time pressure control: Continuous renal pelvic pressure monitoring with auto-adjustment of irrigation/aspiration flow to maintain pressure \<30 mmHg (safety threshold)~2. Simultaneous lithotripsy \& fragment removal: Holmium laser lithotripsy (200-365 μm fiber) coordinated with suction through working channel~3. Single-pass stone clearance: Designed to reduce residual fragments requiring secondary procedures~Distinguishing features vs conventional ureteroscopes:~1. Eliminates need for separate suction devices~2. Prevents intraoperative washout failure causing obscured vision~3. Patent-pending pressure sensor"
224009876|NCT04993508|DIAGNOSTIC_TEST|PSA test|testing for blood levels of PSA
224009877|NCT04993508|DEVICE|multiparametric prostate Magnetic Resonance Imaging (mpMRI)|mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD \> 0.15 will considered suspicious for csPCa.
224009878|NCT04993508|PROCEDURE|targeted MRI/US fusion-guided biopsy|Targeted MRI/US fusion-guided biopsy (TB) are performed using transrectal ultrasound (max. 4 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
224009879|NCT04993508|PROCEDURE|combined prostate biopsy (systematic biopsy plus targeted MRI/US fusion-guided biopsy)|The combined biopsy comprises systematic biopsy (SB) and targeted MRI/US fusion-guided biopsy (TB). They are performed using transrectal ultrasound (number of cores: SB 12 cores, TB max. 4 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
224009880|NCT04993508|PROCEDURE|MRI inbore biopsy|MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
224009881|NCT07093281|BIOLOGICAL|Live Attenuated Influenza Vaccine|Nasal spray
224009882|NCT04392908|OTHER|Communication memory|All groups will undergo audio-recorder interviews. Only adults will complete a self-report questionnaire on phenomenological aspects of autobiographical memories.
224009883|NCT07095933|DRUG|Everolimus|Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 2.5 mg per dose for BSA \<1.2 m², 5 mg per dose for BSA 1.3-2.1 m², and 7.5 mg per dose for BSA \>2.2 m².
224009884|NCT07136857|DRUG|EPTACOG BETA|"Eptacog beta (SEVENFACT®; EB) is a lyophilized powder in single-use vials (1, 2, or 5 mg) of coagulation factor VIIa (recombinant)-jncw. It is reconstituted with sterile water (provided in the kit) and administered intravenously.~SEVENFACT® may be administered by a healthcare provider (HCP) at the study site or home, or by a trained participant/caregiver. Participants will be monitored in a healthcare facility for 60 minutes after the first dose for hypersensitivity."
224009885|NCT06910566|PROCEDURE|Chemoradiotherapy or radiotherapy alone|Patients included in the study receive standard treatment with chemoradiotherapy or radiotherapy alone for their head and neck cancer or lung cancer. These treatments are part of their routine care and are not part of the observational study.
224009886|NCT07134972|DRUG|Ozone treatment|Ozone treatment was administered to study group only. 90 ml of blood was collected into a vacuum sterile glass bottle (Ozonosan). To prevent clotting, 10 ml of 3.8% Na Citrate solution was added to the glass vial. The blood to citrate volume ratio is 9:1. After blood collection, the O3 concentration is ozonized to 20-50 mcg/ml. After at least 5 minutes of mixing, ozonized blood was infused over 20 minutes. Ozone/oxygen mixture was administered intravenously. Ozone therapy was administered twice a week for a total of 16 sessions.
224009887|NCT06762717|DEVICE|FARAPULSE™ Pulsed Field Ablation system|no intervention design in the study
224009888|NCT04349631|BIOLOGICAL|HB-adMSCs|Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
224009889|NCT06706284|DRUG|Semaglutide Injectable Product|A GLP-1 inhibitor used to control T2DM
224009890|NCT06706284|OTHER|Placebo|Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.
224126843|NCT03609359|DRUG|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
224126844|NCT03609359|DRUG|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, every 3 weeks (25 minutes to 40 minutes are acceptable).
223389681|NCT04756115|PROCEDURE|Vascular Surgery.|Open Vascular, endovascular or hybrid procedures.
223389682|NCT05321004|OTHER|Semi-structured interviews will be conducted - there will be no intervention.|The use of semi structured interviews and questionnaires
223546076|NCT03670849|DEVICE|LapAR|LapAR system will map (transform) the live LUS image in the reference frame of the laparoscopic camera, and fuse it with the live laparoscopic video in real time. For thermal ablations that involve a needle, we also track the needle and overlay its path on the AR view.
224009891|NCT06832631|DEVICE|Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon|Balloon angioplasty for the treatment of symptomatic peripheral arterial disease with a paclitaxel drug-coated balloon
224009892|NCT05949684|BIOLOGICAL|Luspatercept|Specified dose on specified days
224009893|NCT05949684|BIOLOGICAL|Epoetin Alfa|Specified dose on specified days
224009894|NCT04009499|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
224009895|NCT06916078|DRUG|Lepodisiran|Lepodisiran administered SC
224009896|NCT07104578|DIAGNOSTIC_TEST|Pleuropulmonary ultra sound|pleuropulmonary ultrasound performed as part of the treatment
224009897|NCT06921928|DRUG|AZD4360|Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)
224009898|NCT07119593|OTHER|Intradialytic Cycling|Intradialytic exercise has emerged as a safe and effective non-drug therapeutic approach to improve cardiovascular health and is now recommended for people undergoing hemodialysis treatment. Administration of a higher intensity exercise could offer better cardio-protective mechanisms and if the efficacy of cardiovascular protection is proven, it could be developed as a therapeutic option in the dialysis population.
224009899|NCT07122102|DRUG|Cofrogliptin|10mg administered once every two weeks
224009900|NCT07122102|DRUG|Acarbose|50mg administered 3 times daily
224009901|NCT06919497|BEHAVIORAL|Spatial audio stimulation|"Study RA will affix the thermode to the dorsum of the participant's dominant or non-dominant hand. Participants will undergo heat-pain-inducing thermode exposure. The intervention will be randomized to receive spatial audio stimulation or not for the first HPT trial, then crossed over to the other study condition for the second HPT trial.~Participants will be randomized to expose their dominant or non-dominant hand first. Between each levels test, the thermode will be moved to the other hand (ex: VR: DH, NDH, DH; Nothing: NDH, DH, NDH). There will be a 30 second break between each levels test and a five-minute washout period between each intervention."
224009902|NCT06919497|BEHAVIORAL|No spatial audio stimulation|"Study RA will affix the thermode to the dorsum of the participant's dominant or non-dominant hand. Participants will undergo heat-pain-inducing thermode exposure. The intervention will be randomized to receive spatial audio stimulation or not for the first HPT trial, then crossed over to the other study condition for the second HPT trial.~Participants will be randomized to expose their dominant or non-dominant hand first. Between each levels test, the thermode will be moved to the other hand (ex: VR: DH, NDH, DH; Nothing: NDH, DH, NDH). There will be a 30 second break between each levels test and a five-minute washout period between each intervention."
224009903|NCT06933732|DEVICE|Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (2 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 2 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
224009904|NCT06933732|DEVICE|Device: Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (4 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 4 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
224009905|NCT06933732|DEVICE|Virtual Reality Intervention for Preoperative Anxiety and Postoperative Pain Management (6 hours)|The Virtual Reality intervention involves participants wearing a VR headset at least one hour prior to their surgery to watch immersive, pre-recorded educational videos showing the operating room with a nurse explaining the process aimed at reducing pre-operative anxiety and nature videos with distraction effect after surgery for pain management. The intervention for pain management will be delivered 6 hours after surgery. The videos to be shown to patients will be limited to a maximum of 30 minutes. In addition, all participants will be reminded that they can remove the glasses or leave the study at any time.
224126845|NCT04641364|DRUG|recombinant human albumin injection|single dose or multiple doses of intravenous infusion
224126846|NCT04641364|DRUG|Placebo|Single dose intravenous infusion of 0.9% sodium chloride injection
224126847|NCT04641364|DRUG|human albumin injection|multiple doses of intravenous infusion
224126848|NCT06643845|PROCEDURE|arthroplasty|In the surgery arm, patients will have their surgery (arthroplasty), as originally planned.
223389683|NCT02171195|DRUG|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
223389684|NCT02171195|DRUG|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
223546077|NCT03008070|DRUG|IVA337|1200mg
224126849|NCT06643845|OTHER|Medical and non-medical treatments|In the medical care arm, patients will follow multimodal medical strategies to prevent surgery in a population of patients with knee osteoarthritis having a first indication of knee prosthesis
224299299|NCT05797818|DEVICE|Methylene Blue + Chlorhexidine Gluconate|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- Methylene blue (0.01%) + chlorhexidine gluconate (0.25%) + 4 minutes of light treatment"
223389685|NCT05814731|DRUG|MA-BUCY2|Mitoxantrone liposome 20mg/m2，ivgtt，d-11 ；Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
223546078|NCT03008070|DRUG|IVA337|800mg
223546079|NCT03008070|DRUG|Placebo|Placebo to match
223389686|NCT05814731|DRUG|BUCY2|Ara-C 4g/m2.d ，ivgtt，d-10- -9； BU 0.8 mg/kg q6h，ivgtt，d-8- -6； CTX 1.8 g/m2.d ，ivgtt，d-5- -4； me-CCNU 250 mg/m2，p.o，d-3； ATG 2.5 mg/Kg.d，d-5 -2
223389687|NCT03112473|BEHAVIORAL|Task-orientated training|Task-Oriented Training (TOT) is a goal-directed exercise therapy, which help the people derive optimal control strategies for solving specific motor problems in real environment. In this study, TOT included stretching exercises, mobilizing exercise, strengthening exercises, seated reaching tasks, dexterity training and bimanual practice.
223546080|NCT04631809|PROCEDURE|Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
223546081|NCT04631809|PROCEDURE|CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention|Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
223546082|NCT00841412|BEHAVIORAL|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
224009906|NCT06929559|OTHER|Pain expectation conditioning|Participants receive application of a neutral cream (MEDICAFARM) with verbal and behavioral suggestions that it may cause localized pain. Researchers wear gloves during application and emphasize potential discomfort, stating effects may intensify with movement.
224009907|NCT06929559|OTHER|Comparator (Control Group)|Participants receive identical application of the neutral cream but are informed it is inert and harmless. Researchers apply the cream without gloves and provide neutral instructions.
224009908|NCT06929559|OTHER|Intervention: Gait|"Participants undergo assessment procedures including:~* Pre- and post-application gait analysis (GAITRite mat, Zebris treadmill)~* Physiological monitoring (EMG, HRV, EDA)~* Identical questionnaires (BPI, TSK, FACS, PCS, VAS)"
224009909|NCT06935604|BEHAVIORAL|VR with a trained facilitator|"Intervention Group 1 - VR with a facilitator:~Each participant in the intervention group will undergo a structured VR session, consisting of:~Duration: 20 minutes Content: Immersive VR experience designed to promote relaxation and reduce pain.~Facilitator training: The facilitator group will include trained healthcare professionals skilled in VR technology, C-I-CARE, and empathetic patient engagement. All facilitators also complete the Creative \& Healing Arts Heart-to-Heart training which includes observation, empathy training, and reflection to support complex communication, and companionship needs of adult patients ."
224009910|NCT06935604|BEHAVIORAL|VR without a trained facilitator.|"Intervention Group 2 - VR without an inperson facilitator:~Each participant in the intervention groups will undergo a structured VR session, consisting of:~Duration: 20 minutes Content: Immersive VR experience designed to promote relaxation and reduce pain.~Instructional video: A research assistant will use C-I-CARE to give the patient an instructional video and the headset to engage in the VR technology.~Patients will take a surveys before and after the intervention"
224296284|NCT05692284|OTHER|routine care group|Firstly, informed consent was obtained from the patients in the control group, a pre-test was applied with the existing data collection methods, and routine nursing care continued. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
224296285|NCT05692284|OTHER|Care in accordance with Orem's theory group|Firstly, informed consent was obtained from the Intervention group, for which the pre-test was applied, and then care was given during their stay in the hospital in accordance with Orem's theory. This care was performed when the patient came to each chemotherapy cycle. After discharge, patient follow-up and care continued with the mobile application designed with Orem's theory, which will ensure the continuity of this care given in the clinic. At the end of the 6-week follow-up period, the data collection process was ended with the post-test application.
223389688|NCT03112473|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|The stimulator was 120z Dual-Channel TENS Unit (ITO PHYSITHERAPY\&REHABILITION CO., LTD, Tokyo, Japan). The parameter (100 Hz, 0.2 ms square pulses, intensity barely below the motor threshold) of TENS followed our previous study
223389689|NCT03112473|DEVICE|Sham electrical nerve stimulation|A identical-looking TENS devices that electrical circuit has been disconnected.
224296286|NCT00287859|DRUG|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
223389690|NCT04660331|OTHER|Communication Intervention|Undergo communication strategy intervention
223389691|NCT04660331|OTHER|Communication Skills Training|Undergo communication training sessions
223389692|NCT04660331|BEHAVIORAL|Healthcare Activity|Participate in interview
223389693|NCT04660331|BEHAVIORAL|Healthcare Activity|Undergo environmental scan
223546083|NCT00841412|BEHAVIORAL|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
223546084|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered transdiagnostic emotion regulation treatment|Please see description of experimental arm (arm one)
223546085|NCT05032547|BEHAVIORAL|Therapist-supported digitally delivered supportive treatment|Please see description of active comparator arm (arm two)
223546086|NCT04409834|DRUG|Unfractionated Heparin IV|Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an aPTT of 1.5-2.5 times the control as per institutional therapeutic target for treatment of VTE
223546087|NCT04409834|DRUG|Enoxaparin 1 mg/kg|Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours
223546088|NCT04409834|DRUG|Clopidogrel|Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily orally on subsequent days
223546089|NCT04409834|DRUG|Unfractionated heparin SC|Heparin 5,000 units administered subcutaneous three times daily
223389694|NCT04660331|OTHER|Survey Administration|Complete survey
223389695|NCT03624192|DEVICE|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
223389696|NCT03624192|OTHER|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
223389697|NCT02143544|DEVICE|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
223389698|NCT01491451|DEVICE|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
223389699|NCT01491451|DEVICE|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
224126850|NCT05610462|BEHAVIORAL|Guided Exercise Training Program|The guided exercise program training consists of: a video demonstration, an exercise training session or group session, a follow up home visit, and virtual check-ins. The exercises include treadmill, wall sits, straight leg raise, bicep curls, hand grips with dynamometer at 40% maximal voluntary contraction (MVC), and Stationary cycling at moderate intensity (100 Watts).
224009911|NCT03974204|PROCEDURE|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
224009912|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
224009913|NCT03974204|PROCEDURE|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
224009914|NCT06938074|DIAGNOSTIC_TEST|CT and MRI|All participants will undergo both CT imaging and MRI imaging to identify areas of ischemic scar. Treatment plans will be created based on CT scans, for all participants using various treatment delivery and motion management techniques.
224009915|NCT06508931|DRUG|zamtocabtagene autoleucel (MB-CART2019.1)|Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
224126851|NCT05610462|BEHAVIORAL|Usual Care|Usual care consists of routine clinic visits and standardized counseling about exercise, including an exercise pamphlet that is given to all thoracic aortic dissection (TAD) patients.
224126852|NCT04827238|DIAGNOSTIC_TEST|Standardized Invasive Hemodynamics|The SIH technique is a standardized, reproducible and efficient way of obtaining hemodynamic measurements.
224126853|NCT00675974|DEVICE|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
224126854|NCT00675974|DEVICE|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
224296287|NCT05465642|OTHER|Collect stool and blood samples from patients|Collect stool and blood samples from patients
223546090|NCT04409834|DRUG|Enoxaparin 40 mg SC|Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if CrCl\<30 ml/min)
223546091|NCT00668759|DRUG|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
223546092|NCT00668759|DRUG|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
224009916|NCT06943755|DRUG|Zanzalintinib|Administered as specified in the treatment arm.
224009917|NCT06943755|DRUG|Everolimus|Administered as specified in the treatment arm.
224009918|NCT07136350|OTHER|Communication Coaching|Nurses in this group will receive caring communication coaching (2 CEUs).
224126855|NCT04950582|DIAGNOSTIC_TEST|Spectral characteristics assessment|Urine sample analysis for evidence of urinary tract infection
224126856|NCT04747483|OTHER|Extension Oriented Treatment Approach|"The EOTA intervention involves three components.~The first component is a series of active extension- oriented exercises:~Prone lying: Able to tolerate for 5 minutes, no pillow Prone lying on elbows: Able to tolerate for 5 minutes Prone press up exercise: 3 sets of 10 repetitions, move to end-range extension Repeated extension in standing: 3 sets of 10 repetitions, move to end-range extension The second component of the EOTA is subject education. Subjects are educated to maintain the natural lordosis of the lumbar spine while sitting, and are instructed to avoid prolonged sitting for greater than 20-30 minutes whenever possible.~The third component of the EOTA is mobilization of the lumbar spine to promote lumbar extension. The mobilization component consist of a series of up to 20 graded oscillatory mobilizations performed with the subject prone by using a grade I - IV mobilization force as described by Maitland."
224126857|NCT04747483|OTHER|EOTA+ Traction|"Subjects in the EOTA + traction group receive the EOTA components described above with Mechanical lumbar traction.~Intermittent traction being applied (30-sec hold, 10-sec rest) for 15 minutes. Traction started with 25% of the patients' body weight and increased until the patient indicated that the tolerance for pulling was reached, with a maximum of 50% of the total body weight.~2 sessions being given per week for 3 weeks."
224126858|NCT00562003|PROCEDURE|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
224126859|NCT00562003|DRUG|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
224126860|NCT06596369|DEVICE|Transcutaneous spinal cord stimulation|Continuous, sub motor threshold stimulation is delivered through surface electrodes placed over the cervical spine region.
224126861|NCT06596369|OTHER|Upper extremity rehabilitation|Using the ReJoyce system individuals will engage in upper extremity rehabilitation.
224126862|NCT06469762|OTHER|Dry Cupping|Dry cupping treatment session, using 4 regular plastic cups on the lumbar spine for 10 minutes.
224296288|NCT02728752|DRUG|Octagam 10%|Patients to be treated with Octagam 10%
224296289|NCT02728752|OTHER|Placebo|Patients to be treated with a Placebo
224296290|NCT02025751|DRUG|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
224296291|NCT02025751|DRUG|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
224296292|NCT01709734|DRUG|galeterone|
223389700|NCT04952350|DRUG|Atorvastatin 40 Mg Oral Tablet|Patients will receive Atorvastatin 40 mg orally within 24 hrs after hospital admission after evaluation of the clinical and laboratory inclusion criteria.
224009919|NCT07136350|BEHAVIORAL|Implement S.M.A.R.T. Discharge Tool|Implement the S.M.A.R.T. discharge tool.
224009920|NCT07142551|DRUG|Testosterone cypionate|Intermittent intramuscular testosterone cypionate (T) at a dose of 400 mg every 4 weeks.
224009921|NCT07142551|DRUG|Luteinizing hormone-releasing hormone (LHRH) analogue|Eligible patients will initiate combined androgen deprivation therapy (ADT) with an LHRH agonist or antagonist (e.g. Eligard, Zoladex, Lupron, Orgovyx) in combination with standard dose darolutamide (600 mg twice daily) for a total of 6 months.
224009922|NCT07142551|DRUG|Darolutamide|600 mg twice daily during the lead-in phase and on darolutamide cycle.
224009923|NCT07140900|DRUG|Xaluritamig|Participants will receive xaluritamig intravenously.
224009924|NCT07140900|DRUG|Darolutamide|Participants will receive darolutamide orally.
224009925|NCT07140900|DRUG|Abiraterone|Participants will receive abiraterone orally.
224009926|NCT07148765|DEVICE|Fitbit Sense 2|Continuous biometric monitoring (e.g., heart rate, pulse oximetry, respiratory rate, etc.) that will trigger alerts based on predefined threshold criteria for health care providers to respond to by contacting patients within 24 hours of alert.
224126863|NCT06469762|OTHER|Placebo Dry Cupping|Dry cupping treatment session, using 4 plastic cups with two 2 mm holes drilled in either side of them, on the lumbar spine for 10 minutes.
224126864|NCT05428072|OTHER|Sugar test|All participants will take two sugar tests ( sugar cocktail consisting of mannitol \& lactulose) subjects within 2-3 days of the initial sugar test.
224126865|NCT05428072|DRUG|Aspirin Challenge|All participants will take a sugar test after 2 doses of aspirin, 1.3 g each given at 12 \& 1 hour before the sugar drink.
224126866|NCT02244450|BIOLOGICAL|SCID screening|
224296293|NCT02546843|DRUG|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
223389701|NCT04952350|OTHER|Placebo|A formulary similar to the drug tablets and labels but without the active ingredients (Atorvastatin).
223389702|NCT00000714|DRUG|Trimetrexate glucuronate|
223389703|NCT00000714|DRUG|Leucovorin calcium|
223389704|NCT02635984|DRUG|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
223389705|NCT02635984|DRUG|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
224009927|NCT07148765|OTHER|Smartphone application survey|Daily questionnaire to record PROs will be administered via patient smartphones. Concerning PROs will trigger alerts which health care providers will respond to by contacting patients within 24 hours of alert.
224009928|NCT07152002|DRUG|LY4064912|Administered SC
224126867|NCT03930953|DRUG|CC-99282|Specified dose on specified days
224126868|NCT03930953|DRUG|Rituximab|Specified dose on specified days
223389706|NCT06581744|OTHER|[18F]AlF-NOTA-Pentixather|inject 185\~370MBq \[18F\]AlF-NOTA-Pentixather
223389707|NCT04020523|OTHER|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
223546093|NCT05419245|OTHER|Guided Health History for Freeman-Burian Syndrome Questionnaire|Completed during the interview. The Guided Health History for Freeman-Burian Syndrome Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
223546094|NCT05419245|OTHER|Freeman-Burian syndrome Semi-Structured Quality of Life Interview|Completed during the interview. Freeman-Burian syndrome Semi-Structured Quality of Life Interview is a quality of life interview for Freeman-Burian syndrome, taking into consideration individual's total health.
224009929|NCT07152002|DRUG|LY4064912|Administered IV
224126869|NCT03930953|DRUG|Obinutuzumab|Specified dose on specified days
224126870|NCT03930953|DRUG|Tafasitamab|Specified dose on specified days
223389708|NCT05729490|RADIATION|Coronary computed tomography angiography|"All patients will be subjected to:~Two CT scans (coronary calcium scoring and angiography) using 128 or 160-row scanners with a slice thickness of 0.5 mm (Revolution Evo 128, GE Health care, Chicago, Illinois, USA) or (Aquilion 160, Canon Medical Systems, Tochigi, Japan). Calcium scoring will be performed with the use of prospective electrocardiographic gating with 400-ms gantry rotation, 120-kV tube voltage, and 300-mA tube current. For CTA, retrospective electrocardiographic gating will be used, with heart rate adjusted gantry rotations of 350 ms to 500 ms to enable adaptive multisegmented reconstruction.~Iopromide (Ultravist 370, Bayer AG, Berlin, Germany) is the intravenous contrast medium that will be used for CTA. Beta-blockers will be given if the resting heart rate is 70 beats/min."
223389709|NCT06030375|DRUG|KAND567|Continuous intravenous infusion for 6 hours
223389710|NCT06030375|OTHER|Placebo|Continuous intravenous infusion for 6 hours
224009930|NCT07152002|DRUG|Placebo|Administered SC
224009931|NCT07152002|DRUG|Placebo|Administered IV
224126871|NCT03930953|DRUG|Valemetostat|Specified dose on specified days
224126872|NCT02973841|DEVICE|Sono-ease device|insertion of US guided IJV using sono-ease device
224126873|NCT02768649|DRUG|RBP-7000|Sequential dosing of each cohort
224126874|NCT02768649|DRUG|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
224126875|NCT04285346|DRUG|Ganaxolone|titration followed by maintenance and extension period
224126876|NCT05057273|DRUG|BT-11|Oral once daily tablet
224126877|NCT05057273|DRUG|Active comparator|Biologic
224126878|NCT03823417|DRUG|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
224126879|NCT03823417|DRUG|Normal saline|Normal saline infusion
224126880|NCT02277899|OTHER|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
224126881|NCT02277899|OTHER|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
224126882|NCT02277899|OTHER|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
224296294|NCT02546843|DRUG|Cisatracurium|cisatracurium 0.15mg/kg intravenously
224296295|NCT02546843|DRUG|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
223389711|NCT00291317|DEVICE|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
223389712|NCT06152432|DEVICE|Maxillary implant overdenture|Patients with an edentulous maxilla and problems with their conventional denture are treated with an implant overdenture either retained by bars or Locators
223389713|NCT01640249|DRUG|Placebo|Capsules administered orally
224009932|NCT07155876|OTHER|Aromatherapy plus standard of care|"The participant is offered an aromatherapy scented tab that is attached to their gown based on symptoms (anxiety, pain, and/or nausea/vomiting):~1. Pain or anxiety: lavender or lavender sandalwood,~2. Nausea/vomiting: orange ginger, or~3. Despite the type of discomfort, the participant may request the alternate scent if the scent offered is not to their liking.~Plus, the patient receives SoC for treatment based on symptoms (anxiety, pain, and/or nausea/vomiting) as prescribed by the physician."
224009933|NCT07155876|OTHER|Standard of Care Only|Participant receives symptom management medications for pain, nausea/vomiting, and/or anxiety as prescribed by the physician.
224009934|NCT05095415|OTHER|Occupational Therapy Pre-operative Consult|Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.
224009935|NCT05095415|OTHER|Typical Pre-Operative Education|Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
224009936|NCT07167706|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|BBTI is a multi-component intervention consisting of techniques from sleep restriction and stimulus control therapy. It targets behavioral elements of insomnia using four techniques: 1) reduce time in bed, 2) get up at the same time every day, 3) do not go to bed unless sleepy, and 4) do not stay in bed unless asleep.
224009937|NCT07167706|BEHAVIORAL|Sleep Hygiene Therapy|SHE consists of education on lifestyle factors (diet, exercise, substance use) and enviromental variables (noise, light, temperature) affecting sleep quality.
224009938|NCT07171840|DRUG|10 cc of oxygen-ozone plus thumb splint|Oxygene-Ozone therapy plus splint therapy
224009939|NCT07171840|DEVICE|thumb splint|thermoplastic splint
224009940|NCT07174583|DRUG|IDE849|IV administration
223389714|NCT01640249|DRUG|LY3006072|Capsules administered orally
223389715|NCT01776632|BEHAVIORAL|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
223389716|NCT01776632|BEHAVIORAL|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
223389717|NCT01683396|DRUG|Placebo|Solution for subcutaneous injection
223389718|NCT01683396|DRUG|gevokizumab|Solution for subcutaneous injection
223389719|NCT02321059|DEVICE|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
223389720|NCT05481671|OTHER|Questionnaires|Participants will be asked to respond to the Demographic Information Sheet, Tampa Scale for Kinesiophobia, Numeric Rating Scale, Pain Catastrophizing Scale, Hospital Anxiety and Depression Scale, Resilience Scale , Pain Self-efficacy Questionnaires and Functional Exercise Compliance Scale for Orthopaedic Patients.
223389721|NCT02190370|BEHAVIORAL|Resources activation|
223389722|NCT02315911|PROCEDURE|ATE|surgical removal of adenoids and tonsils
223389723|NCT02315911|PROCEDURE|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
223546095|NCT05419245|OTHER|Medical Records Review|Review of medical records will be used, along with Guided Health History for Freeman-Burian Syndrome Questionnaire to assess patient histories and outcomes.
224009941|NCT07183319|DRUG|Pembrolizumab & Enfortumab Vedotin (PEV)|Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.
224126883|NCT02277899|OTHER|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
224126884|NCT02277899|OTHER|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
224126885|NCT01778387|PROCEDURE|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
224009942|NCT07183319|DRUG|Pembrolizumab|Patients will receive 400 mg of pembrolizumab every 42 days. During the de-escalation period from PEV.
224009943|NCT07183319|DRUG|Pembrolizumab & Enfortumab Vedotin (PEV)|If patients experience radiographic progression on pembrolizumab monotherapy, they will undergo rechallenge with PEV.
224009944|NCT07194629|DRUG|Silver diamine Fluoride 38%|SDF 38%, applied on tooth surface for arrestation of active carious lesions and prevention of development of new carious lesions
224009945|NCT07194629|DRUG|placebo solution|bluish liquid designed to mimic the appearance of SDF 38%
224009946|NCT07193654|DRUG|Intrathecal injection of thiotepa|Intrathecal injection of thiotepa: Administered via lumbar puncture or OMMAYA reservoir according to the study protocol.
224009947|NCT07193654|DRUG|Stupp regimen (oral temozolomide)|Stupp regimen (oral temozolomide)::75 mg/m² daily during radiotherapy; 150-200 mg/m² daily for 5 days every 28 days for 6 cycles after radiotherapy;
224009948|NCT07193654|RADIATION|Radical radiotherapy|Radical radiotherapy: Delivery of 60 Gy of radiation, typically divided into 30 fractions of 2 Gy each;
224009949|NCT07193654|PROCEDURE|Maximal surgical resection|Maximal surgical resection: Removal of as much tumor as possible while preserving neurological function;
224009950|NCT07195617|DRUG|BCMA-GPRC5D CART|The entire study process was as follows: Screening period (V1) : Informed consent was signed, screening was checked, criteria were evaluated, and baseline demographic information and subject status were recorded. Blood collection period (V2) : For subjects who meet the inclusion and exclusion criteria, the blood required for CAR-T preparation will be obtained by leukocyte isolation monopexy or intravenous collection according to the conditions of the subjects. Preconditioning phase (V3) : cytokine and cell changes. Pre-transfusion assessment (V4) : The investigator assessed that the test results met the cell transfusion criteria, and D0 CAR T cell infusion could be performed with investigator permission. Infusion phase (V5) : CAR-T cells were transfused according to the dosage and method specified in the protocol. Safety and efficacy were followed up on D1, D4, D7, D10, D14, D21, D28, M3, M6, M9, M12, and M24.
224009951|NCT07194707|OTHER|Intraoperative Noise Monitoring|Noise levels will be passively measured during surgery using a calibrated sound level meter (CEM DT-8850) placed near the patient's head. Measurements will be taken every 10 minutes without physical contact or interference with clinical care. The procedure is purely observational and does not modify anesthesia or surgical practice.
224009952|NCT07194902|BEHAVIORAL|"HIVST for Partners and PrEP uptake for HIV-uninfected Postpartum Women (H4P)."|"For female participants, the intervention includes a 30-45 minute counseling session that will cover (1) SOC PrEP information, (2) communications skills training for HIVST kit distribution, (3) Motivational interviewing strategies (e.g., PrEP/HIVST pros/cons), (4) problem-solving barriers to PrEP uptake or HIVST distribution, (5) linkage enablers (e.g., care sites, transportation, asking questions of providers). For their male partners, an informative video will cover geographically diverse HIV treatment resources, as well as on why linkage to HIV care is needed in the context of the relationship with his female partner and gender norms. The video will also demonstrate a brief motivational exercise whereby men are asked to consider the pros and cons of linking to HIV care versus not (with examples), as well as a step-by-step guide to generate a concrete plan for linkage to care based on linkage enablers."
224009953|NCT07195149|DRUG|High-Dose Aspirin 300 mg|High-dose Aspirin 300 mg once daily taken orally for three months
224009954|NCT07195149|DRUG|DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)|"Drug: Prasugrel 10 mg~Prasugrel 10 mg once daily taken orally for 3 months~Drug: Low-Dose Aspirin~75 mg once daily taken orally"
224009955|NCT07195149|DRUG|Low-Dose Aspirin 75 mg|Low-Dose Aspirin 75 mg once daily taken orally
224009956|NCT07195357|OTHER|epidemiological|collection of data from all participating subjects involving tooth erosion examinations, tooth sensitivity and questionnaire data collection
224009957|NCT07195201|DEVICE|3D Printed Onlay Restoration|Onlay restorations will be fabricated using a 3D printer and a biocompatible permanent resin (Bego VarseoSmile TriniQ). Digital intraoral scans will be used for design. Restorations will be placed in vital posterior teeth and evaluated at (1 week), 6 months, 12 months, and 18 months according to FDI criteria.
224009958|NCT07195201|DEVICE|CAD/CAM Onlay Restoration|Onlay restorations will be fabricated using a CAD/CAM milling unit and hybrid ceramic blocks (GC Cerasmart 270). Digital intraoral scans will be used for design. Restorations will be placed in vital posterior teeth and evaluated at (1 week), 6 months, 12 months, and 18 months according to FDI criteria.
224126886|NCT04427787|DRUG|Cabozantinib|Cabozantinib will be administered orally at a dose of 60 mg/day
224126887|NCT04427787|DRUG|Lanreotide|Lanreotide will be administrated 120 mg injection every 28 days
224126888|NCT01599468|DRUG|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
224126889|NCT01599468|DRUG|saline serum|The Placebo group received normal saline with the same volumes
224126890|NCT01975272|DRUG|Ferinject|
224126891|NCT01975272|DRUG|Ferrous fumarate|
224126892|NCT01975272|DRUG|Placebo for ferrous fumarate|
224126893|NCT01975272|DRUG|Placebo for ferinject|
224126894|NCT04661930|DRUG|TriCor® 145mg tablets|Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
224126895|NCT04661930|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
224126896|NCT04661930|OTHER|Usual care|All participants will otherwise receive usual medical care
224126897|NCT05872971|DEVICE|Dry Needling|Dry Needling: The technique will be used by a physiotherapist experienced in orthopedic conditions and with specific training in DN. The application will be through the deep technique, above 10mm deep, the therapist will score trigger points regions of the muscles of the posterolateral region of the hip with application duration of 30 to 60 seconds. Eight points of application will be standardized in the region of the muscles of the posterolateral region of the hip.
224126898|NCT05872971|DEVICE|Lasertherapy|Lasertherapy: The application of the Laser will be performed by a physiotherapist specialized in traumato-orthopedics. The equipment will be infrared laser (904 nm), by point technique. Eight points of application will be standardized in the region of muscles of the posterolateral region of the hip. The time, dose and amounts of application points will be guided according to the dosimetry criteria of the World Association for Photobiomodulation Therapy.
224299300|NCT05797818|DEVICE|Light Only|"All subjects will have a baseline sample taken of their nasal microbiome and undergo the administration of the following:~\- 4 minutes of light treatment only"
224009959|NCT07193953|DEVICE|Next Generation Dome Helmet Focused Ultrasound|Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening.
224009960|NCT07193953|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|"Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening. Cohort I will receive 0.2g/kg of IVIg at each dose. Cohort II will receive 0.4g/kg of IVIg at each dose.~Privigen® IVIg comes in vials containing 10% active ingredient. It is supplied in 2.5 g (25 mL bottle), 5 g (50 mL bottle), 10 g (100 mL bottle), 20 g (200 mL bottle) or 40 g (400 mL bottle). The IVIg dose will be determined based on the patient's ideal body weight."
224009961|NCT07193953|DRUG|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure on the day of the second IVIg dose.
223389724|NCT02226211|DEVICE|Air-Q intubation laryngeal airway|"The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet ."
223389725|NCT02226211|DEVICE|Ambu-Aura i laryngeal mask|"The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (\> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT."
224009962|NCT07188922|OTHER|Non-invasive intraocular pressure measurement during ventilator weaning Description: Intraocular pressure will be measured using a portable non-invasive tonometer before and after the transition from|Intraocular pressure will be measured using a portable non-invasive tonometer before and after the transition from mechanical ventilation to spontaneous breathing. Measurements will be performed as part of routine clinical care and will not involve any experimental intervention.
224009963|NCT07194824|OTHER|Pragmatic allergy management according to risk stratification|"Intervention based on allergy risk stratification. Tipus A) Patients in this group can undergo direct delabeling without the need for exposure, with this being documented in the EMR. If the patient refuses, an exposure to penicillin and/or cephalosporin will be performed. Once completed, de-labeling can proceed without the need for re-exposure.~Tipus B) Indication for use of a penicillin: Oral exposure to 250 mg of amoxicillin.~\- Indication for cephalosporin : administration of a cephalosporin that exhibits the lowest level of cross-reactivity with penicillin.~Re-exposure to penicillin/ cephalosporin or both is performed at least 2 weeks after the first tolerated exposure. De-labeling is performed when tolerance to re-exposure is verified.~Tipus C) These high-risk patients are managed following the protocol for the treatment of patients with beta-lactam allergy, referring them to allergy consultation for further specific test."
224009964|NCT07194850|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
224009965|NCT07194850|OTHER|Placebo IV|Intravenous infusion of placebo
224009966|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 1|10g single oral dose dissolved in water
224009967|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 2|10g single oral dose dissolved in water
224009968|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 3|10g single oral dose dissolved in water
224126899|NCT04874909|OTHER|Blood sample|"Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max"
224126900|NCT04874909|OTHER|Urine sample|Urine sample (500 ml) once time
224126901|NCT02437097|OTHER|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
224126902|NCT02437097|OTHER|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
224009969|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 4|10g single oral dose dissolved in water
224009970|NCT07195396|DIETARY_SUPPLEMENT|Collagen hydrolysate 5|10g single oral dose dissolved in water
224009971|NCT07195331|DRUG|Intravenous injection of indocianine green at least three hours before surgery at a dose of 2.5 mg per subject.|A dilution will be prepared by dissolving 25 mg of ICG in 10 mL of water for injectable solutions, yielding a concentration of 2.5 mg/mL. Once the solution is prepared, 1 mL will be administered directly via a peripheral venous line in the patient's upper limb.
223546096|NCT05419245|OTHER|PTSD Checklist for DSM-5|"Completed by patients before the interview. The PTSD Checklist for DSM-5 is a 20-item questionnaire. Each item is rated 0-4, with 0 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms."
223546097|NCT05419245|OTHER|Modified Flanagan Quality of Life Scale|"Completed by patients before the interview. The Modified Flanagan Quality of Life Scale is a 16-item survey designed for use in persons with chronic illness. Each item is rated 1-7, with 1 being Terrible and 7 being Delighted. Higher scores suggest the person may be experiencing a better quality of life."
223546098|NCT05419245|OTHER|Center for Epidemiologic Studies Depression Scale|"Completed by patients before the interview. The Center for Epidemiologic Studies Depression Scale is a 20-item survey that asks about depressive feelings and behaviours in the past week. Each item is rated 0-3, with 0 being Rarely or none of the time (less than 1 day) and 3 being Most or all of the time (5-7 days). Lower scores suggest the person may be experiencing fewer symptoms."
223546099|NCT05419245|OTHER|Review of Systems|Completed during the interview. A review of systems is a checklist of medical problems.
224009972|NCT07195331|DRUG|Intravenous injection of indocianine green 15 to 30 minutes before surgery at a dose of 0.25 mg per subject.|A dilution will be prepared by dissolving 25 mg of ICG in 25 mL of water for injectable solutions, yielding a concentration of 1 mg/mL. Subsequently, 0.25 mL will be administered as a direct intravenous injection via a peripheral venous line in the patient's upper limb.
224126903|NCT02437097|OTHER|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
224126904|NCT02437097|OTHER|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
224126905|NCT03886727|DEVICE|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
224126906|NCT03886727|DEVICE|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
224126907|NCT02126904|DRUG|IVA group|
224126908|NCT04202861|DIAGNOSTIC_TEST|In vitro antibiotic combination testing (iACT)|CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
224126909|NCT03695432|BIOLOGICAL|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
224126910|NCT03695432|DIETARY_SUPPLEMENT|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
224126911|NCT03695432|OTHER|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
223546100|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance of the Face"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance of the Face is a 9-item questionnaire. Each item is rated 1-4, with 1 being Not at All and 4 being Very Much. Lower scores suggest the person may be less pleased with the appearance of their face."
224009973|NCT07195175|DRUG|MAR002|subcutaneous injection
224009974|NCT07195175|DRUG|Placebo|Subcutaneous injection
224296296|NCT02546843|DRUG|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
224296297|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
224296298|NCT02546843|DRUG|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
223389726|NCT03817645|OTHER|Zeolite|The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb\^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
223546101|NCT05419245|OTHER|"FACE-Q | Craniofacial - Appearance Distress"|"Completed by patients. The FACE-Q \| Craniofacial - Appearance Distress is an 8-item questionnaire. Each item is rated 1-4, with 1 being Always and 4 being Never. Lower scores suggest the person may be experiencing more distress related to the appearance of their face."
224009975|NCT07194434|OTHER|No.intervrntion|No intervention
224299301|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
224299302|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
224299303|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
224009976|NCT07194252|OTHER|Guided imagery technique application|Intervention is a guided imagery technique designed for patients undergoing total joint arthroplasty. It will be administered in a total of 4 sessions: once daily on the day before surgery, twice daily on the day of surgery, and once daily on the 2nd and 3rd days after surgery, accompanied by imagery scenarios developed in accordance with the Compact Disc (CD) and literature developed by the Turkish Psychological Association. The study aims to examine its effects on surgical anxiety levels, postoperative pain intensity, and analgesic consumption. This approach is structured as a non-pharmacological method specific to surgical nursing practice and differs from previous similar studies in that it is applied in both the preoperative and postoperative periods using the same sample in the literature.
224009977|NCT07195188|BEHAVIORAL|"Let's Learn Diabetes Game-Based Education"|"Participants in the experimental group will receive diabetes education using the Let's Learn Diabetes board game. The program consists of four weekly sessions, each lasting two hours, over one month. The intervention is designed to improve diabetes knowledge, reduce anxiety, and enhance treatment adherence among patients with Type 2 Diabetes Mellitus on insulin therapy."
224009978|NCT07195188|BEHAVIORAL|Traditional Diabetes Education|Participants in the control group will receive standard diabetes education through traditional lecture-based presentations. The education schedule matches the experimental group with four weekly sessions, each lasting two hours, over one month.
224126912|NCT03695432|OTHER|Placebo probiotic|Capsul
224126913|NCT01245426|DRUG|GW870086 2mg|oral inhalation
224126914|NCT01245426|DRUG|GW870086 4mg|oral inhalation
224126915|NCT01245426|DRUG|GW870086 Placebo|oral inhalation
224296299|NCT02996045|OTHER|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored \>4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
224296300|NCT00817076|DRUG|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
224296301|NCT03146182|BEHAVIORAL|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
224296302|NCT03146182|BEHAVIORAL|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
224299304|NCT01008852|DRUG|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
223389727|NCT06581445|BEHAVIORAL|Birdsongs|The participants listened to a clip of birdsongs from laughing thrushes.
223389728|NCT06581445|BEHAVIORAL|Music|The participants listened to a cheerful Cuckoo Waltz music.
224009979|NCT07193966|BIOLOGICAL|NG2 and DLL3 CAR-T cells|Infusion of NG2 and DLL3-specific CAR-T via intravenous route
224009980|NCT07194616|PROCEDURE|Primary Surgery|Patients undergo radical surgical resection with TME without preceding neoadjuvant therapy
224009981|NCT07194616|PROCEDURE|Neoadjuvant radiochemotherapy and surgery|Neoadjuvant treatment: long-course pelvic radiotherapy (conventional fractionation) with concurrent chemotherapy (standard fluoropyrimidine-based regimen)
224126916|NCT01245426|DRUG|GW870086 1mg|oral inhalation
224126917|NCT01245426|DRUG|GW870086 3mg|oral inhalation
224126918|NCT00696865|DRUG|AZD2624|oral suspension, 3 doses
224126919|NCT00696865|DRUG|Placebo|
223389729|NCT00065156|DRUG|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
223389730|NCT04356989|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.
223389731|NCT02735109|OTHER|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
223389732|NCT02735109|PROCEDURE|biopsy normal area|biopsy done to compare with abnormal area
223389733|NCT05592457|DIAGNOSTIC_TEST|MSCT|multislice computed tomography
223389734|NCT01363193|DRUG|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = \[9270 x weight (kg)\] / \[6680+216 x BMI\] Female = \[9270 x weight (kg)\] / \[8780+244 x BMI\]"
224126920|NCT03220048|DRUG|PrEP-001|
224126921|NCT03220048|OTHER|Placebo Comparator|
224126922|NCT04111887|BEHAVIORAL|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
224126923|NCT01759329|DIETARY_SUPPLEMENT|test coffee|test coffee with higher alkyl pyridine content
224126924|NCT01759329|DIETARY_SUPPLEMENT|control coffee|control coffee with regular alkyl pyridine content
224126925|NCT00635947|OTHER|isotonic solution|1.5 L- during 2-4hours
224126926|NCT00635947|OTHER|water|1.5 L- during 2-4hours
224126927|NCT00635947|OTHER|water|200mL- during 2-4hours
224126928|NCT06515652|DRUG|rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun|Comparing allopathic and herbal group of drugs for metabolic syndrome
224126929|NCT03223324|DEVICE|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
224126930|NCT02075762|PROCEDURE|Transbronchial biopsy|
224126931|NCT02075762|PROCEDURE|Cryoprobe biopsy|
224126932|NCT02075762|PROCEDURE|VATS biopsy|
224126933|NCT00136747|DRUG|Memantine|Two capsules of Memantine twice daily for 12 days.
224126934|NCT00136747|DRUG|bupropion|
224126935|NCT00136747|DRUG|placebo|
224126936|NCT02224846|DRUG|Tadalafil|Administered orally
223389735|NCT00711295|BIOLOGICAL|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
224009982|NCT07193849|DRUG|MEBO Wound Ointment|both are used for second pressure ulcer
224009983|NCT07193849|DRUG|zinc oxide|both are used to treat second degree pressure ulcer but with no superiority
224009984|NCT07194200|BIOLOGICAL|Lactobacillus plantarum|Intervention measures for the experimental group: Apply 5ml of Lactobacillus plantarum solution extracted from the skin surface of healthy individuals to the psoriatic lesions daily, for a duration of 2 months.
224009985|NCT07194200|BIOLOGICAL|inactivated Lactobacillus plantarum|Intervention measures for the control group: Apply 5ml of inactivated Lactobacillus plantarum solution to the psoriatic lesions daily, for a duration of 2 months.
224009986|NCT07193576|DRUG|flunotinib|100mg
224009987|NCT07195487|OTHER|Fermented Extract Hair Growth and Scalp Health Serum|"Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.~Frequency: Apply the treatment twice daily- once after morning shower and once before bed time. immediately after shower and at night before bed.~Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
224009988|NCT07195487|OTHER|Placebo Hair Growth and Scalp Health Serum|"Mode of Usage: Apply the serum directly to the scalp using the rollerball applicator. Gently roll the ball over thinning or affected areas of the scalp. Gently massage the serum into the scalp with clean fingertips to help it absorb fully. Ensure liquid is visible on the scalp and reapply until you feel a cooling wet sensation during application - this confirms the mechanism is working and that a good amount of product is being delivered.~Frequency: Apply the treatment twice daily - once after morning shower and once before bed time. immediately after shower and at night before bed.~Route of administration: Topical Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight"
224009989|NCT07195604|DRUG|HRS-2162|HRS-2162
224009990|NCT07195604|DRUG|Placebo|Placebo
223389736|NCT00711295|BIOLOGICAL|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
223389737|NCT02336321|DEVICE|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
223389738|NCT05469672|OTHER|Low-level laser therapy|For LLLT, laser treatment will be applied using gallium-aluminum-arsenide (GaAIAs, infrared laser) diode laser (Chattanooga, Mexico, USA) at a wavelength of 904 nm, output power of 240 Mw and a frequency of 5000 Hz. The spot area is about 0.5 cm2. A total of 9 points will irradiated along the glenohumeral joint, with a power density of 3 j/cm2 at each point. The application time was 50 seconds to each point. The total dose per shoulder was 27 J per treatment. Three sessions of LILT therapy per week will administered over a three-week period.
223389739|NCT05469672|OTHER|High-intensity laser therapy|HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the shoulder area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first three sessions consisted of a 75-second intermittent phase analgesic effect at 8 W and 10 J/cm2 for a total energy of 100 J. The following six sessions consisted of a continuous 30-second bio stimulating effect with a dosage of 12 W 120 J/cm2. Over the course of three weeks, nine treatment sessions of HILT will be given.
224009993|NCT07193641|RADIATION|Spatially Fractionated Radiotherapy (SFRT)+Stereotactic Body Radiation Therapy (SBRT)|"The intervention includes SFRT for larger oligoprogressive lesions (≥4.5 cm in diameter), utilizing image-guided CT, including 4D-CT, with Lattice technique planning. The dose fractionation will be determined by the radiation oncologist based on clinical parameters, with peak doses ranging from 6-15 Gy/Fx and valley doses from 1.8-4 Gy/Fx, typically in 1-5 fractions.~For smaller oligoprogressive lesions, stereotactic body radiotherapy (SBRT) or intensity-modulated radiotherapy (IMRT) will be selected based on clinical parameters."
224009994|NCT07193641|DRUG|The systemic therapy|Continuation or switch of prior standard regimen (chemotherapy, targeted TKI, or PD-1/PD-L1 inhibitor) at investigator discretion until further progression or intolerable toxicity.
224009995|NCT07194382|DRUG|AP02|Oral inhalation solution
224009996|NCT07194382|DRUG|Placebo|Placebo oral inhalation solution
224009997|NCT01982448|DRUG|Cisplatin|
224009998|NCT01982448|DRUG|Paclitaxel|
224009999|NCT07195279|OTHER|Experimental Group|The VR intervention consisted of a simulated driving experience delivered over nine sessions, three times per week, each lasting 20 minutes, over a three-week period. The virtual reality (VR) therapy employed a full immersion approach, delivering intense multisensory visual-auditory stimulation. Patients were exposed to diverse driving scenarios, specifically: urban streets (featuring intersections, traffic lights, and pedestrians to simulate complex urban environments), ring roads (designed for practicing smooth and confident high-speed driving in dense traffic), and tunnels (sections aimed at gradually desensitizing users to claustrophobic responses during driving).
224010000|NCT07195279|OTHER|Control Group|Conventional cardiac rehabilitation protocol consisted of 1.5-hour group calisthenics sessions with a 10-minute break, held six times per week. This was accompanied by aerobic reconditioning exercises on a stationary bike or treadmill, depending on medical prescription and the patient's health status.
224010001|NCT07195266|BEHAVIORAL|Strategic Psychoterapy|Strategic psychotherapy as described in scientific literature
224296303|NCT03021694|DIETARY_SUPPLEMENT|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
224296304|NCT03200691|RADIATION|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
224299305|NCT01008852|DRUG|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
223389740|NCT03975933|DIAGNOSTIC_TEST|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
223546102|NCT05419245|OTHER|"FACE-Q | Craniofacial - Facial Function"|"Completed by patients. The FACE-Q \| Craniofacial - Facial Function is a 10-item questionnaire. Each item is rated 1-3, with 1 being I cannot do this and 3 being I can do this. Lower scores suggest the person may be experiencing more problems with facial muscle functioning."
223546103|NCT06607263|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
223546104|NCT06607263|DRUG|Essential oils mouthrinse|Essential oils mouthrinse
224010002|NCT07195591|DEVICE|GammaTile®|GammaTiles are a U.S. FDA-cleared, surgically targeted radiation therapy for patients with certain brain tumors. GammaTile consists of bioresorbable collagen tiles embedded with Cesium-131 (Cs-131) radioactive seeds
224010003|NCT07195591|RADIATION|External Beam Radiation Therapy|External beam radiation therapy (EBRT) is a type of radiation therapy that is standard of care. EBRT uses a machine outside the body to deliver high-energy beams of radiation to cancerous areas within the body
224010004|NCT07195591|DRUG|Temozolomide|TMZ (Chemotherapy) is used as a first-line treatment, often in combination with radiation therapy after surgical resection of the tumor
223389741|NCT03975933|DIAGNOSTIC_TEST|Free pregnancy test for the future use|We will provide a free pregnancy test in for the future use.
223389742|NCT03975933|DIAGNOSTIC_TEST|Pregnancy test for the future use with randomzied price|We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
223389743|NCT04700670|BIOLOGICAL|measurement of anti-Xa activities|"The measurement of anti-Xa activities will be carried out on frozen-defrosted plasma citrate and CTAD with 4 reagents~* STA-Liquid anti-Xa (STAGO) (not containing dextran)~* Biophen Heparin LRT (Hyphen) (reactive containing dextran)~* Berichrom (Siemens) with dextran~* Berichrom (Siemens) without dextran~The dosage of platelet factor 4 and of the beta-TG will be carried out on frozen-defrosted plasma with the asserachrom PF4 and Asserachrom beta-TG (Diagnostica Stago) kits."
223389744|NCT03119779|DRUG|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
223546105|NCT06607263|DEVICE|Dental floss|Dental floss
223546106|NCT06607263|DRUG|Toothpaste|A commercially available fluoride toothpaste
223546107|NCT06607263|DEVICE|Toothbrush|A commercially available adult toothbrush
223546108|NCT06712017|DEVICE|Yttrium-90 (Y-90) resin microspheres|selective internal radiation therapy
224010005|NCT07194239|BEHAVIORAL|Lifestyle medicine Health coaching|Participants assigned to this group will have 4 face-to-face sessions with the health coach. Lifestyle modifications with the aim of pain reduction will be determined in a shared decision-making approach. Lifestyle modifications will be based on the 6 pillars of lifestyle medicine: Physical activity, Healthy eating, Stress reduction, Sleep restoration, Social Support, and Avoiding risky substances. The health coach will make use of motivational techniques such as motivational interviewing to guide and assist participants in realizing the lifestyle modifications.
224010006|NCT04359043|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.
223546109|NCT06716164|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.
223546110|NCT06715046|DIAGNOSTIC_TEST|Sample collation for cfDNA methylation analysis|Sample collation for cfDNA methylation analysis
223546111|NCT06715046|DIAGNOSTIC_TEST|Sample collection for EV phenotype analysis|Analysis of the EV phenotype to evaluate their potential value as markers for GVHD, relapse and engraftment.
224010007|NCT04359043|BEHAVIORAL|Treatment as Usual|Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
224010008|NCT01572168|OTHER|Acupuncture|Eight session of weekly acupuncture
224010009|NCT05589324|BEHAVIORAL|3D-printed writing aids task|Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
224010010|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
223546112|NCT02856022|DEVICE|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1\~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
224010011|NCT01198756|BIOLOGICAL|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
224010012|NCT01198756|BIOLOGICAL|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
224010013|NCT01198756|BIOLOGICAL|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
224010014|NCT02992821|PROCEDURE|Bed-side pocket size ultrasound imaging|
223389745|NCT03119779|DRUG|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
223389746|NCT03385317|BEHAVIORAL|Mindfulness|
223389747|NCT04967326|DRUG|Optimizing therapy with antiepileptic drugs (carbamazepine, phenytoin, valproic acid)|
224010015|NCT02992821|PROCEDURE|High frame rate tracking doppler|
224010016|NCT00004444|DRUG|paromomycin|
224126937|NCT03280550|DRUG|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
224126938|NCT03280550|DRUG|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
224126939|NCT06862791|DRUG|AZD9550|IMP injected subcutaneous, once weekly. Unit dose strength as per CSP
224126940|NCT06862791|DRUG|AZD6234|IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.
224299306|NCT00003875|DRUG|busulfan|Given PO or IV
223730376|NCT02781051|BEHAVIORAL|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
224299307|NCT00003875|DRUG|etoposide|Given IV
223389748|NCT00044408|DRUG|Ruboxistaurin mesylate|
223389749|NCT03518008|DEVICE|verofilcon A contact lenses|Investigational daily disposable soft contact lenses
223389750|NCT03518008|DEVICE|somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
223389751|NCT05611866|PROCEDURE|Fecal Microbiota Transplantation|FMT at Week 0
223389752|NCT00107848|DRUG|Modafinil|
223389753|NCT03376919|DEVICE|CLs++ gait training|CLs++ gait training
223389754|NCT05712083|DRUG|BCMA CAR-T cells|Each subject receive BCMA CAR T-cells by intravenous infusion
223730377|NCT02781051|DEVICE|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
224010017|NCT00004444|DRUG|streptomycin|
223389755|NCT05976880|OTHER|Conventional treatment of isometric hand grip training exercises|In control group, conventional treatment perform by using isometric hand grip training exercises (putty grip and squeeze exercise, thumb pinch z strengthening exercises, isometric Hooks exercises, rubber band abduction and c thumb exercises) for 3times a week in one month.
223730378|NCT02781051|BEHAVIORAL|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
223730379|NCT02781051|OTHER|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
224010018|NCT05676853|DRUG|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
224010019|NCT02402673|OTHER|Temporary activity modification and graded exercises|
224010020|NCT03462173|DRUG|yimitasvir|Capsule administered orally once daily
224010021|NCT03462173|DRUG|placebo|Matching Placebo Capsule
224010022|NCT00670631|COMBINATION_PRODUCT|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 \& 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
224010023|NCT02124447|DRUG|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
224010024|NCT02124447|DRUG|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
224010025|NCT02124447|DRUG|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
224010026|NCT02124447|DRUG|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
224010027|NCT04822493|OTHER|Counseling Aid|Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
224010028|NCT05837962|BEHAVIORAL|Nursing intervention to improve knowledge and self-care behaviors in the face of HDP|"The nursing professional will perform 1 session weekly, for 4 weeks, lasting 90 minutes each. The contents that make up each of the sessions are:~Session 1. Knowledge about the risk factors, signs and symptoms, maternal and fetal complications of HDP.~Session 2. Control over behaviour, positive attitude and family and social support: essential components for conducting self-care behaviour.~Session 3. Nutritional recommendations: eating healthy helps prevent or reduce the risk of developing HDP.~Recommendations to improve sleep, rest and physical exercise: key routines in my health to prevent or reduce the risk of developing HDP.~Session 4. Mental health promotion: managing my stress, anxiety and depression levels help prevent or decrease the risk of HDP"
224010029|NCT00269360|PROCEDURE|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
224010030|NCT00269360|PROCEDURE|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
224010031|NCT00269360|BEHAVIORAL|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
224010032|NCT06433973|PROCEDURE|Test group 1 - CM+LLLT+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique. LLLT will be applied on the site for 10 sec.
224010033|NCT06433973|PROCEDURE|Test group 2 - CM+VISTA|After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts. Adequate size of CM will be trimmed and applied over the recession defect using minimally invasive technique and secured with sutures.
224010034|NCT06433973|PROCEDURE|Control group - SCTG+VISTA|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
224010035|NCT04669353|DRUG|Platelet rich plasma|approximately 15 cm of whole blood was drawn from the uninvolved arm of each patient in the intervention group (group I) into a 20 ml sterile syringe containing citrate for anticoagulation. The blood was immediately centrifuged at 3200 Revolutions per Minute (PRM). Following 15 minutes of centrifugation, 4 - 5 mL of PRP was obtained. Then, the PRP was buffered by using sodium bicarbonate.
224010036|NCT01386762|OTHER|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
224010037|NCT02909530|DEVICE|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
224010038|NCT02909530|DEVICE|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
224010039|NCT01670955|DIETARY_SUPPLEMENT|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
224010040|NCT01670955|DRUG|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
224010041|NCT02896049|DEVICE|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
224010042|NCT02716818|DRUG|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
224010043|NCT02716818|DRUG|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
224010044|NCT00901186|DRUG|RFB002|0.5 mg
224010045|NCT00901186|PROCEDURE|Laser photocoagulation|
224010046|NCT01016743|DEVICE|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
224010047|NCT00541060|GENETIC|mutation|a mutation of a gene coding
224010048|NCT03980600|DEVICE|FibDex wound dressing|Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
224010049|NCT03980600|DEVICE|NFC wound dressing Types 1-3|Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
224010050|NCT03980600|DEVICE|Suprathel (comparator)|Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
224010051|NCT05222724|DRUG|Tachifene|paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
224010052|NCT05222724|DRUG|Brufen|ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
224010053|NCT01597141|BEHAVIORAL|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
224010054|NCT01597141|BEHAVIORAL|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
224010055|NCT02299154|BEHAVIORAL|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
224010056|NCT01762319|DRUG|Misoprostol|
224010057|NCT01762319|DRUG|Vitamin B6|
224010058|NCT00294203|DRUG|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
224010059|NCT00294203|OTHER|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
224010060|NCT00581555|DRUG|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
224010061|NCT00581555|OTHER|Placebo|Randomized to placebo during taper of ciclosporin
224010062|NCT05816330|BIOLOGICAL|L9LS (VRC-MALMAB0114-00-AB)|Administered one time via subcutaneous route.
223730380|NCT03590145|DIAGNOSTIC_TEST|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
223730381|NCT00255827|BIOLOGICAL|HyperAcute-Pancreatic Cancer Vaccine|
224010063|NCT05816330|OTHER|Placebo|Normal saline administered one time via subcutaneous route.
224010064|NCT03900416|BEHAVIORAL|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
224010065|NCT04445532|OTHER|Gene expression analysis|Gene expression analysis
224010066|NCT04445532|OTHER|Genomic analysis|Genomic analysis
224010067|NCT04445532|OTHER|Protein expression analysis|Protein expression analysis
224010068|NCT04445532|OTHER|Proteomic profiling|Proteomic profiling
224010069|NCT04445532|OTHER|Polymerase chain reaction|Polymerase chain reaction
224010070|NCT04445532|OTHER|Mass spectrometry|Mass spectrometry
224010071|NCT04445532|OTHER|Immunohistochemistry|Immunohistochemistry
224010072|NCT04445532|OTHER|Metabolomics profiling|Metabolomics profiling
224010073|NCT04445532|OTHER|Methylation and epigenetic analysis|Methylation and epigenetic analysis
224010074|NCT04445532|OTHER|Liquid biopsy analysis|Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
223730382|NCT03569540|DRUG|Glibenclamide|Placebo-controlled; Double blind test
224010075|NCT04445532|OTHER|Laboratory biomarker analysis|Laboratory biomarker analysis (such as AFP, CA19-9, CEA)
224010076|NCT01699659|OTHER|allergen immunotherapy|allergy shots
224010077|NCT00899782|OTHER|cytology specimen collection procedure|correlative studies
224010078|NCT04837651|DEVICE|Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test|Subjects will receive an Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test within 4 weeks of receiving their first COVID-19 injection. Within 3-4 weeks of receipt of their final COVID-19 vaccine dose, subjects will receive another Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test.
224010079|NCT04837651|DEVICE|T-Detect COVID T-cell blood test|A select number of subjects will also receive a qualitative SARS-CoV-2 t-cell immunity test, the T-Detect COVID test, within 3-4 weeks of receipt of their final COVID-19 vaccine dose.
224010080|NCT03141697|DEVICE|Carbon Dioxide|Insufflation of Carbon Dioxide
224010081|NCT03141697|DEVICE|Room air|Insufflation of room air
224010082|NCT06371859|BEHAVIORAL|"XAI feedback on MCA/UA Doppler spectral curves and gate placement suggestions"|"This study includes 1840 ultrasound images, split into UA and MCA flow and spectrum images, each duplicated for a total of 3680 images to compare explainable AI (XAI) feedback vs. no feedback. The investigators will provide matched sets of 40 images (one for the XAI group and one for the non-XAI group) to participants. Participants are matched based on their level of experience within each hospital (Resident physicians, obstetricians, and gynecologists with obstetric ultrasound experience).~All participants are instructed to place gates on the flow images of the umbilical artery and the middle cerebral artery and to assess the quality of the resulting flow curves. Specifically, for flow images, participants must identify the most appropriate gate placement. For spectral flow curves, they are to decide if the curves are of sufficient quality to guide medical management decisions."
224010083|NCT00978523|DRUG|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
224010084|NCT00699049|DRUG|Alpha blocker|oral
224296305|NCT03200691|DRUG|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
224296306|NCT04429529|BIOLOGICAL|TY027|TY027 Injection, (100 mg/5 mL/Vial), SARS-CoV-2 Monoclonal Antibody (mAb)
224296307|NCT04429529|OTHER|0.9% Saline|Placebo
224296308|NCT05387174|BEHAVIORAL|: Nursing intervention in two risk factors of the Metabolic Syndrome, abdominal obesity and arterial hypertension and quality of life in the climacteric period.|Nursing intervention with technological support (Metamorphosis) in two risk factors of Metabolic Syndrome, abdominal obesity and hypertension and quality of life in the climacteric period, developed in 3 months, in the experimental group that includes individual nursing counseling, group education virtually and physical activity sessions for 12 weeks virtually.
223730383|NCT03569540|OTHER|Placebo|Amylum
223730384|NCT04726423|OTHER|transcranial direct current stimulation|5 daily sessions of tDCS (2mA, 20 min) were recommended to all patients. Physical exercises were also done at the physiotherapy clinic. Physical exercises program was recommended to be continued at home after the week of physiotherapy visits.
224296309|NCT02947074|BEHAVIORAL|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
224296310|NCT04851431|BEHAVIORAL|one-to-one peer mentoring|Weekly meetings with a peer family caregiver
224010085|NCT00699049|DRUG|placebo|oral
224010086|NCT00699049|DRUG|solifenacin|oral
224010087|NCT02984293|DRUG|Atorvastatin|Atorvastatin 80 mg once daily for 28 days.
224010088|NCT02984293|DRUG|Placebo|Placebo once daily for 28 days.
224010089|NCT02527642|OTHER|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
224010090|NCT04403464|BEHAVIORAL|HABIT-ILE with REAtouch®|65h HABIT-ILE including 30h REAtouch®
224010091|NCT04403464|BEHAVIORAL|HABIT-ILE without REAtouch®|65h HABIT-ILE
224010092|NCT01854853|BEHAVIORAL|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
224010093|NCT01854853|BEHAVIORAL|Health Promotion|Health promotion intervention
224010094|NCT05865015|OTHER||
224010095|NCT01959997|PROCEDURE|Redo PVI|
224010096|NCT01959997|PROCEDURE|PVI + RDN|
224010097|NCT01883232|DEVICE|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
224010098|NCT01883232|DEVICE|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
224010099|NCT06261632|OTHER|Blood flow restriction|The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will include performing squats and knee extension for 5-10 and 10 minutes respectively. In both exercises, 4 series will be performed (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
224010100|NCT00772330|DEVICE|Glaucoma Drainage Device|Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
224299308|NCT00003875|BIOLOGICAL|aldesleukin|Given SC
223730385|NCT00002925|DRUG|ara-C|
224010101|NCT01056497|DRUG|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
224010102|NCT01269723|DIETARY_SUPPLEMENT|Broccoli sprout homogenate|Subjects will drink the broccoli shake homogenate
224010103|NCT01269723|DIETARY_SUPPLEMENT|Alfalfa sprout homogenate|Subjects will drink the alfalfa sprout homogenate.
224010104|NCT02742402|OTHER|Diagnostic imaging|Abdominal ultrasound, followed by abdominal computed tomography when necessary
224010105|NCT02742402|OTHER|Observation|Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
224010106|NCT02654301|DIETARY_SUPPLEMENT|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
224010107|NCT02654301|DIETARY_SUPPLEMENT|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
224010108|NCT02654301|DIETARY_SUPPLEMENT|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
224010109|NCT02654301|DIETARY_SUPPLEMENT|Control|sucrose 50 g + deionized water 100 g
224010110|NCT06009757|DEVICE|GUIDEX® guiding catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
224010111|NCT06009757|DEVICE|Launcher™ coronary guide catheter|"The main steps of the procedure Percutaneous Coronary Intervention are :~* The patient should prepare for angioplasty using standard techniques. Appropriate anticoagulation and vasodilation therapy should be administered.~* The Guiding Catheter must be introduced into the vascular system by cut-down or percutaneous techniques.~* The guiding catheter will be introduce over a previously placed standard angiographic wire. It will be aspirate and flush after the removal of the angiographic wire following established angiographic technique.~* The catheter should should address the selected vascular site~* The guiding catheter will be removing. The procedure is performed in a healthcare facility, in an operating room under fluoroscopic monitoring. The users are trained practiticoners for PCI."
224010112|NCT01291940|OTHER|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
224010113|NCT01291940|OTHER|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
224010114|NCT01786759|DRUG|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
224010115|NCT01786759|DRUG|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
224010116|NCT01353859|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
224010117|NCT01353859|DRUG|methotrexate|10-25 mg orally weekly
224010118|NCT02541877|DEVICE|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
224010119|NCT02541877|DEVICE|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
224010120|NCT02541877|DEVICE|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
224010121|NCT00469573|DRUG|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
223730386|NCT00002925|DRUG|Daunorubicin|
223730387|NCT00002925|DRUG|Etoposide|
223730388|NCT00002925|DRUG|PSC-833|
223730389|NCT00002925|BIOLOGICAL|Aldesleukin|
224010122|NCT03887078|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks pre and or post-surgery.
224010123|NCT02849522|PROCEDURE|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
224010124|NCT02849522|PROCEDURE|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
224126941|NCT06862791|DRUG|Placebo comparator|Placebo matching IMP dose injected subcutaneously, once weekly.
224299309|NCT00003875|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
223389756|NCT05976880|OTHER|Conventional treatment along with power ball training|In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
224010125|NCT02849522|PROCEDURE|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
224010126|NCT02849522|PROCEDURE|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
224010127|NCT01870908|DRUG|tacrolimus|
224010128|NCT01870908|DRUG|biological agents|
224010129|NCT02935985|OTHER|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
224010130|NCT01792050|DRUG|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
224010131|NCT01792050|OTHER|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
224010132|NCT01792050|DRUG|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
224010133|NCT01792050|DRUG|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
224010134|NCT01348568|DIETARY_SUPPLEMENT|low glycemic index diet with canola oil bread|
224010135|NCT01348568|DIETARY_SUPPLEMENT|High fiber diet|
224010136|NCT00625261|OTHER|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
224010137|NCT00373477|PROCEDURE|Generalist Care Manager vs Usual Care|
224010138|NCT05907109|BEHAVIORAL|Remotely monitored parent-mediated hybrid home and clinic based multidisciplinary Early Intervention protocols.|"* Parents receive manualized protocols, instructional videos, and toy and material kits to administer EIs at home.~* New modules are provided according to infant age or stage of intervention during the length of brief interventions or 12-months.~* The families will be monitored by clinical researchers weekly. -High risk infants will receive supplemental EI services at the clinic according to developmental needs.~* Infants will receive outcome evaluations within a 42-month follow-up clinic."
224010139|NCT00582686|PROCEDURE|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
224010140|NCT00582686|PROCEDURE|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
224010141|NCT06130280|RADIATION|MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)|40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance.
224010142|NCT00319410|PROCEDURE|vaginoscopic hysteroscopy|
224010143|NCT03231800|DRUG|dasotraline|dasotraline 2mg capsule once daily
224010144|NCT03231800|DRUG|Placebo|Placebo capsule once daily
224010145|NCT00034060|DRUG|Etanercept|
224299310|NCT03282474|DRUG|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
223389757|NCT01215136|DRUG|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
223389758|NCT01215136|DRUG|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
223389759|NCT01215136|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
223389760|NCT05398328|DEVICE|active metal appliance|fixed metal labial orthodontic appliance MBT 0.022'' slot
223389761|NCT05398328|DEVICE|active esthetic appliance|fixed ceramic labial orthodontic appliance MBT 0.022'' slot
224010146|NCT00859222|DRUG|LBH589|
224010147|NCT00859222|DRUG|bevacizumab|
223389762|NCT05398328|COMBINATION_PRODUCT|retention fixed appliance|fixed lingual metal retention appliance
223389763|NCT05398328|COMBINATION_PRODUCT|retention removable appliance|removable clear termoplastic retention appliance
223389764|NCT02851628|DEVICE|Alternative sizing model based trial mask|A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
224010148|NCT00400725|DRUG|Clobex® Shampoo|Clobex® Shampoo 0.05 % (W/W) topically to scalp for 4 weeks.
224010149|NCT00400725|DRUG|Clobex® Vehicle Shampoo|Clobex® Vehicle Shampoo 0.05 % (W/W) topically to scalp up to 6 months.
224010150|NCT00400725|DRUG|Clobex® Shampoo|Clobex® Shampoo 0.05% (W/W) topically to scalp up to 6 months.
224010151|NCT01081600|OTHER|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
224010152|NCT04436575|DEVICE|Point-of-care ultrasound|Point-of-care ultrasound prognostic performance : echocardiography mainly
224010153|NCT03428529|DRUG|Capecitabine Oral Product|Neoadjuvant Capecitabine concomitant to external beam radiotherapy
224010154|NCT03428529|DRUG|5Fluorouracil|Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
224010155|NCT04025541|BIOLOGICAL|Blood sampling|blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
223389765|NCT02851628|DEVICE|Prototype Full Face Mask|A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
223389766|NCT01644851|BEHAVIORAL|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
223389767|NCT06421766|DEVICE|BAHS|Implantation of a percutaneous bone-anchored hearing system
223389768|NCT03862924|DEVICE|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
223389769|NCT03438019|DEVICE|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
223389770|NCT03438019|DEVICE|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
223389771|NCT05748951|DEVICE|Canalicular occlusion device|Occlusive device is inserted into the tear duct to block tear drainage
223389772|NCT04124445|PROCEDURE|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
223389773|NCT00708110|DRUG|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
224010156|NCT04025541|BIOLOGICAL|Blood sampling C3|"Blood samples will be collected at four key time points:~* baseline (T1),~* first scan assessment (T2),~* second scan assessment (T3),~* and progression (T4)."
224010157|NCT04025541|BIOLOGICAL|Blood sampling C4/7/10/13|Blood samples will be collected before any treatment
224010158|NCT04025541|BIOLOGICAL|Blood sampling C5|"Blood samples will be collected at four key time points:~* At the inclusion (T1)~* Before the beginning of the treatment (cycle 1 day 1) (T2)~* After the first cycle of T-DXd (cycle 2 day 1) (T3)~* At progression or at the end of the follow-up (after 3 years) (T4)"
224010159|NCT04025541|BIOLOGICAL|Blood sampling C6|"Blood samples will be collected at three key time points:~* At the inclusion (T1)~* For patients starting treatment at the time of inclusion (T2):~* Chemotherapy: 3 months after inclusion,~* Concurrent chemoradiotherapy with Temozolomide: 4-6 weeks after completion of radiotherapy,~* For patients starting treatment at the time of inclusion: at the time of tumor progression if occurring within one year of inclusion, or 12 months after inclusion in the absence of progression (T3)."
223389774|NCT00708110|DRUG|Placebo|Placebo is a tablet with no drug in it.
223389775|NCT01910428|DRUG|L-asparaginase encapsulated in RBC|"* 50 IU/kg IV~* 100 IU/kg IV~* 150 IU/kg IV~* 200 IU/kg IV"
223389776|NCT04801511|DRUG|Vitamin C|High-dose Intravenous Vitamin C will be delivered on the day of radiotherapy, in order to reduce the acute toxicity of chemoradiotherapy.
223389777|NCT00036153|DRUG|Tacrolimus (Prograf®)|
223389778|NCT00036153|DRUG|Methotrexate|
223389779|NCT00929851|DRUG|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
223389780|NCT00929851|DRUG|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
223389781|NCT05712174|DRUG|[18]F-PSMA-1007|\[18\]F-PSMA-1007 is a diagnostic radiopharmaceutical for use with PET/CT or PET/MRI scanning to diagnose prostate cancer.
223546113|NCT02856022|PROCEDURE|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
223546114|NCT01365455|DRUG|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
223546115|NCT01365455|DRUG|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
224010160|NCT04025541|BIOLOGICAL|Blood sampling C8|"Blood samples will be collected at five key time points:~* At the inclusion~* At follow-up visit 2 to 6, every 3 months"
224010161|NCT04025541|BIOLOGICAL|Blood sampling C9|"Blood samples will be collected at four key time points:~* At the inclusion before the beginning of the treatment (Cycle 1 Day 1)~* After the first cycle of the first chemo-immunotherapy sequence (Cycle 2 Day 1)~* After the first cycle of the second chemotherapy sequence (Cycle 2b Day 1)~* After the end of the whole neo-adjuvant chemo-immunotherapy protocol, before surgery"
224010162|NCT04025541|BIOLOGICAL|Blood sampling C11 + FFPE|"Blood samples will be collected at five key time points:~* At the inclusion (T1)~* At first clinical evaluation (T2): 4th week after start of treatment~* At first scan evaluation (T3a): 8th week after start of treatment~* At the Nth scan evaluation (T3b, c, ...)~* At progression (T4)~Tumor sampling :~* At the inclusion~* At tumor progression"
223389782|NCT06972810|OTHER|A/Texas/71/2017, clade 3C3a H3N2 influenza virus|The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device. Participants will be admitted into an inpatient facility prior to the administration of the flu virus. Following inoculation, they will be quarantined for a minimum of 8 days prior to discharge. Participants will receive supportive care and PCR positive participants will receive an effective antiviral medication. Participants will be followed for a total of 6 months.
223389783|NCT06649344|DRUG|HRS9531 Injection|HRS9531 injected subcutaneously once weekly.
223389784|NCT06649344|DRUG|Semaglutide Injection|Semaglutide injected subcutaneously once weekly.
223546116|NCT04632017|DIAGNOSTIC_TEST|Computerized cardiotocography|To compare Dawes and Redman indices as determined by computer analysis of the fetal heart tracing
224010163|NCT04025541|BIOLOGICAL|Blood sampling C12|"Blood samples will be collected at several points :~* Inclusion: at the time of suspected leptomeningeal metastases, prior to any specific treatment,~* Every 4 weeks until meningeal progression, or for a maximum of 4 months,~* Then every 3 months beyond 4 months until meningeal progression."
224010164|NCT04041674|BIOLOGICAL|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
224010165|NCT04041674|BIOLOGICAL|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
224010166|NCT04041674|BIOLOGICAL|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
224126942|NCT06142747|DIAGNOSTIC_TEST|Super-Resolution Ultrasound Imaging of Erythrocytes (SURE)|Research ultrasound sequence for tracking erythrocytes and thereby generating a super-resolution image of the vasculature.
224126943|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder.
224126944|NCT04433520|DEVICE|Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder|Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder.
224126945|NCT06203678|OTHER|Kinesio taping|therapeutic tape application
224126946|NCT06203678|OTHER|Exercise|Cervical stretching and strengthening exercises home program
224126947|NCT06203678|OTHER|Sham taping|patch tape application
224126948|NCT04624893|DRUG|Polatuzumab Vedotin-Piiq|Patients will receive a total of six cycles of Pola in combination with rituximab and bendamustine or in combination with only rituximab. A cycle is typically 21 days for DLBCL.
224126949|NCT03115801|DRUG|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
224126950|NCT03115801|DRUG|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
224126951|NCT03115801|RADIATION|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
224296311|NCT05467163|DEVICE|Biventricular pacemaker implantation|Implantation of permanent pacemaker with biventricular stimulation with or without defibrillator lead placement using standard techniques. The right ventricle lead will be positioned in the RV apex or septum, while the left ventricle lead will be delivered to the most appropriate coronary sinus tributary, preferably posterolateral or lateral vein.
224299311|NCT02257463|DRUG|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
224299312|NCT02257463|OTHER|peripheral muscles exercise training|
224299313|NCT02257463|DEVICE|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
223389785|NCT06319560|DRUG|Hydroxychloroquine Oral Tablet|200mg daily
223389786|NCT04548440|DRUG|Sintilimab|Route of administration: Intravenous
224010167|NCT04041674|BIOLOGICAL|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
224299314|NCT00006466|DRUG|beta alethine|
223389787|NCT04548440|DRUG|Nab paclitaxel|Route of administration: Intravenously over 30min
223389788|NCT04548440|DRUG|Cisplatin|Route of administration: Intravenous
224010168|NCT04041674|BIOLOGICAL|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
224010169|NCT03026699|BEHAVIORAL|eSNAP|Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
224126952|NCT03115801|DRUG|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
224126953|NCT01073748|DRUG|paracetamol|single dose of paracetamol 15mg/kg.
224126954|NCT01312792|OTHER|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
224126955|NCT01312792|OTHER|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
224126956|NCT04688567|BEHAVIORAL|Patient-driven iCBT|1\) Participants who are randomized to the experimental condition are asked to make choices regarding the structure of their treatment by the time of the randomization call. The participant can choose which of the available treatment programs (targeting anxiety, worry, stress, sleep disorders or depression) they want to undergo, how many modules in the treatment program they want to complete and in what order, for how many weeks they want to complete the treatment as well as how much telephone contact and how much written contact they want to have with their therapist.
224126957|NCT04688567|BEHAVIORAL|Standardized iCBT (TAU)|2\) Patients who are randomized to the control condition (standardized iCBT) undergo the usual iCBT program available for anxiety disorders for 8 weeks. The psychologist provide weekly feedback on the patient's exercises and interact with the patient via secure encrypted messages in the treatment program. A follow-up telephone call takes place at the middle of treatment and at the end of the treatment.
223389789|NCT05441592|DRUG|Tranexamic acid injection|The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
224010170|NCT03026699|BEHAVIORAL|Questionnaires|Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
224126958|NCT05869344|DIETARY_SUPPLEMENT|Black bean protein hydrolysates (BPH)|Participants were blinded to treatment and received BPH (5 g powder) dissolved in 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of BPH.
224296312|NCT05467163|DEVICE|Conduction system pacing device implantation|Left bundle branch pacing (LBBP) will be the preferred pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory. If LBBP will be unobtainable, His bundle pacing (HBP) implantation will be attempted. His bundle potential mapping will be performed with the use of the electrophysiological system and under fluoroscopic guidance. Distal HB potential with a large ventricular signal and a small atrial signal will be targeted before the pacing lead will be screwed into position. Backup RV lead will be mandatory for all patients receiving HBP devices.
224299315|NCT04236726|OTHER|Questionnaire|HRQoL questionnaires
224299316|NCT02967796|DIETARY_SUPPLEMENT|Proteochoc|
224010171|NCT00150865|DRUG|ropivacaine|
224010172|NCT06218160|DRUG|Hydromorphone combined with ropivacaine|1mg hydromorphone was added to 0.375% ropivacaine for a total of 30ml to perform quadrat block
223389790|NCT05441592|OTHER|No additional irrigation|There will be no additional irrigation after the standard surgical procedure.
223389791|NCT02212314|BEHAVIORAL|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
224010173|NCT06218160|DRUG|Ropivacaine|A mixture of 0.375% ropivacaine for a total of 30ml was used for quadrate block
224010174|NCT05422664|DRUG|Lacosamide|Patients with autoimmune related epilepsy were included. After obtaining informed consent, lacosamide was given according to the weight of the patients, and the efficacy and safety were observed.
224010175|NCT06121167|DIAGNOSTIC_TEST|urinary partial oxygen pressure|arterial blood gas
224010176|NCT04075994|BEHAVIORAL|Relational Agent and heart rate and rhythm monitor|Use of the Relational Agent and heart rate and rhythm monitor daily for 120 days.
223389792|NCT05248204|DEVICE|Scotchbond™ Universal Plus Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU+ treatment group will undergo restoration with Scotchbond™ Universal Plus Adhesive using self-etch mode and Filtek Universal Restorative
224010177|NCT04075994|BEHAVIORAL|Usual Care|Use of the WebMD app and heart rate and rhythm monitor daily for 120 days.
224010178|NCT04668430|OTHER|imaging and motion analysis|performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
224010179|NCT01452373|DRUG|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
223389793|NCT05248204|DEVICE|Scotchbond™ Universal Adhesive|Eligible tooth with Class I or Class II carious lesion randomized to the SBU control group will undergo restoration with Scotchbond™ Universal Adhesive using self-etch mode and Filtek Universal Restorative
223389794|NCT06987513|DRUG|Pemvidutide|Pemvidutide 2.4mg
223389795|NCT06987513|OTHER|Placebo|Subcutaneous injection
223389796|NCT06659263|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
223389797|NCT00951496|BIOLOGICAL|Bevacizumab|Given IV
223389798|NCT00951496|DRUG|Carboplatin|Given IV
223389799|NCT00951496|DRUG|Carboplatin|Given IP
223389800|NCT00951496|DRUG|Cisplatin|Given IP
223389801|NCT00951496|OTHER|Laboratory Biomarker Analysis|Correlative studies
223389802|NCT00951496|DRUG|Paclitaxel|Given IV
223389803|NCT00951496|DRUG|Paclitaxel|Given IP
223389804|NCT00951496|OTHER|Quality-of-Life Assessment|Ancillary studies
223389805|NCT02792920|DEVICE|CoCr-EES|
223546117|NCT04858113|OTHER|Blephaclean|Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
223546118|NCT04858113|OTHER|Baby Shampoo|Conventional baby shampoo
224010180|NCT01452373|DRUG|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
224010181|NCT02722642|BIOLOGICAL|Bronchial basal cells|Patients will receive 10\^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
224010182|NCT02750982|OTHER|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
224010183|NCT05416190|DIAGNOSTIC_TEST|Lupus anticoagulant testing|The patient will have a visit during which a blood sample will be taken, a clinical examination will be performed, and data will be collected.
224010184|NCT04850794|BEHAVIORAL|Decision Support Tool|The decision support tool is an observational checklist with recommendations for specific specialist referrals based on what the provider observed during the feeding evaluation.
224010185|NCT04081623|DEVICE|Raydiant Oximetry Sensing System|The investigational device is used to record fetal pulse signals.
224010186|NCT00371332|DRUG|Minocycline HCL Microspheres|
224010187|NCT02436473|DRUG|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
224010188|NCT02436473|OTHER|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
224126959|NCT05869344|OTHER|Commercial non-caloric beverage|Participants were blinded to treatment and received 120 mL of a commercial non-caloric beverage and immediately after an oral glucose tolerance test was performed to evaluate the postprandial effect of placebo.
224126960|NCT00722540|DRUG|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
224010189|NCT02436473|DRUG|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
224010190|NCT02436473|DRUG|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
224010191|NCT04625387|OTHER|Dry Needle and Exercise|"A 0.25 X 15 mm acupuncture needle was used for sub occipital muscle and 0.25 X 40 mm needle was used for paraspinal and trapezius muscle. All the necessary precautions were maintained before inserting the needle. Therapists wore hand gloves for all purposes.~The exercise for the muscles of cervical group, for group A was carried out by elevating head from lying in supine position repeating 20 times in three sets and pressing a theraband forward in one set of 15 repetitions, to right side and to left side and back side"
224010192|NCT00816478|DRUG|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
224010193|NCT00577876|PROCEDURE|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
224010194|NCT04775199|BEHAVIORAL|Language Intervention|The examiners will target vocabulary and grammar in the context of preschool science instructions.
224010195|NCT00461513|BEHAVIORAL|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
224010196|NCT04416373|DIAGNOSTIC_TEST|RT PCR SARS-CoV-2|Positive SARS-CoV-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samples
224010197|NCT03316820|DRUG|K0706|Study treatment with water after an overnight fast
224010198|NCT03316820|DRUG|K0706|Study treatment with water after food
224010199|NCT02645227|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
224010200|NCT02645227|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
224010201|NCT02645227|PROCEDURE|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
224010202|NCT01009151|BEHAVIORAL|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
224010203|NCT01009151|BEHAVIORAL|Heart Care Self Tracker|Web-based Home Tele-monitoring System
224010204|NCT02811731|DRUG|CKD-330 16/5mg - B|
224010205|NCT02811731|DRUG|Candesartan 16mg and Amlodipine 5mg|
224010206|NCT06204874|PROCEDURE|Pulsed radiofrequency ablation|See left.
224010207|NCT06204874|PROCEDURE|Sham ablation|See left.
224126961|NCT00722540|DRUG|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
224126962|NCT00722540|DRUG|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
224126963|NCT00722540|DRUG|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
224126964|NCT00722540|DRUG|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
224126965|NCT00722540|DRUG|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
223546119|NCT00928187|DRUG|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
224010208|NCT01075802|DRUG|Tamoxifen|Dose escalation
224010209|NCT03435354|BEHAVIORAL|Physical activity counselling|Clinician counselling about physical activity using standardized tools to promote daily physical activity.
224010210|NCT06419426|OTHER|Battery incidence|Incidence of batteries from negative Gram germs; Incidence of batteries from gram positive germs; Incidence of fungemie; Incidence of septic shock; Incidence of batteries from colonising germs; Incidence of resistance to the main classes of antibiotics
224010211|NCT05151705|DRUG|HR17031 injection|Treatment group A:HR17031 injection; 10U/0.024mg
224010212|NCT05151705|DRUG|HR17031 injection|Treatment group B: HR17031 injection; 10U/0.024mg
224010213|NCT05151705|DRUG|HR17031 injection|Treatment group C: HR17031 injection; 10U/0.024mg
224126966|NCT00722540|DRUG|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
224126967|NCT00722540|DRUG|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
224126968|NCT00722540|DRUG|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
224126969|NCT00722540|DRUG|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
224126970|NCT00118170|DRUG|sorafenib tosylate|Given orally
224126971|NCT00118170|OTHER|pharmacological study|Correlative studies
224126972|NCT06403384|DEVICE|Vibration|Local vibration was applied
224126973|NCT01167595|OTHER|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
224126974|NCT01915849|DRUG|LIK066|LIK066 15 mg, 50 mg and 150 mg
224126975|NCT01915849|DRUG|Placebo|
224010214|NCT04160065|BIOLOGICAL|IFx-Hu2.0|"The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.~Therapeutic Classification:~* Immunomodulatory Agent~Route of Administration:~* Intralesional (i.e. injection of cutaneous, subcutaneous or nodal lesions)~Mechanism of Action:~* Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells.~Physiological Effect:~* Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses."
224010215|NCT03108456|DEVICE|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
224010216|NCT03108456|DEVICE|Balloon|Vessel preparation with conventional and/or specialty balloons
224010217|NCT01941719|BEHAVIORAL|Enhanced foot care education|In addition to the standard foot care education, personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
224010218|NCT01941719|BEHAVIORAL|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
224010219|NCT00252577|DRUG|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
224010220|NCT00243048|DIETARY_SUPPLEMENT|soy protein isolate|
224010221|NCT00243048|RADIATION|radiation therapy|
224010222|NCT03929172|BIOLOGICAL|AAVLP-HPV|20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
224010223|NCT03929172|DRUG|Placebo|0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
224010224|NCT02138084|DRUG|BMS-663068|BMS-663068
224010225|NCT02138084|DRUG|Rifabutin|Rifabutin
224010226|NCT02138084|DRUG|Ritonavir|Ritonavir
224010227|NCT01480219|DRUG|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
224126976|NCT03777956|DRUG|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
224126977|NCT03777956|DRUG|Placebo|Identical placebo are given as capsules and taken orally twice a day.
224126978|NCT05823909|DEVICE|fabian Therapy evolution ventilators with PRICO (Predictive Intelligent Control of Oxygenation)|12 hours Automated PRICO FiO2 control
224126979|NCT05823909|DEVICE|fabian Therapy evolution ventilators with manual FiO2 control|12 hours Manual PRICO FiO2 control
223546120|NCT00928187|DRUG|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight \< 60 kg, 400 mg if weight \> 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
223546121|NCT00928187|DRUG|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
224010228|NCT01480219|OTHER|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
224010229|NCT02046889|BEHAVIORAL|Bicycle Training Intervention|
224010230|NCT00251823|DRUG|Eptifibatide facilitated PCI|
224126980|NCT04961801|DRUG|Acalabrutinib, tacrolimus, methotrexate|For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
224126981|NCT03864172|DIETARY_SUPPLEMENT|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
224126982|NCT03864172|DIETARY_SUPPLEMENT|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
224126983|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
224126984|NCT03864172|DIETARY_SUPPLEMENT|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
224126985|NCT01729364|DRUG|crystalloid|
224126986|NCT01729364|DRUG|colloid|
224126987|NCT00668343|DRUG|simvastatin|40 mg/ day
224126988|NCT00668343|DRUG|placebo|80 mg /day
224126989|NCT03222479|BEHAVIORAL|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
224126990|NCT02444897|DRUG|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
224126991|NCT02444897|DRUG|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
224126992|NCT05828264|BEHAVIORAL|Quantum touch|this group by the nurse who is included in the study and who has a practice certificate before vascular access is established. In this process, the treatment process of the patient will continue and will not create an obstacle. While the child is in a comfortable position (lying or sitting position) during the application, the child's back/shoulder/head will be touched by the practitioner and guantum touch energy will be applied. Then, vascular access will be performed by the nurse included in the study. The child will be asked to rate the level of pain during the procedure with 'FPS-R', the level of fear with 'CDS', and the level of anxiety with 'ÇAS-D'.
224126993|NCT03611959|OTHER|Non Applicable|
224126994|NCT04628559|DRUG|Dexmedetomidine|dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
224126995|NCT04628559|DRUG|Ketamine|In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
223730390|NCT04387175|DEVICE|Carriere Motion 3D Class III Appliance|The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
224010231|NCT05774743|OTHER|Consent with Visual Aid|Participants who receive the study intervention will receive the standard anesthesia consent procedure with the addition of the visual aid. The visual aid is a poster with pictorial representations of the information that is verbally communicated to participants during the standard consent process.
224010232|NCT01744392|BEHAVIORAL|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
224010233|NCT06344546|DIAGNOSTIC_TEST|Metabolomics|Analysis of the metabolome in plasma samples.
224010234|NCT00851838|DRUG|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
224010235|NCT04024774|BIOLOGICAL|Biological samples|blood samples, urine samples, tissue samples
224010236|NCT04024774|GENETIC|Genetic test|anamnesis and NGS sequencing
224010237|NCT00334672|BIOLOGICAL|anti-thymocyte globulin|
224010238|NCT00334672|DRUG|busulfan|
224010239|NCT00334672|DRUG|cyclophosphamide|
224010240|NCT00334672|DRUG|cyclosporine|
224010241|NCT00334672|DRUG|dexamethasone|
224010242|NCT00334672|DRUG|etoposide|
224010243|NCT00334672|DRUG|methotrexate|
224010244|NCT00334672|DRUG|mycophenolate mofetil|
224010245|NCT00334672|DRUG|therapeutic hydrocortisone|
224010246|NCT00334672|OTHER|laboratory biomarker analysis|
224010247|NCT00334672|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224010248|NCT00334672|PROCEDURE|biopsy|
224010249|NCT05145959|DEVICE|Maskin Probe|The eyelids are examined using meibography to evaluate which eyelids are more severe (right or left). A drop of proparacaine 0.5% solution is added and a bandage contact lens is placed. To avoid patient discomfort, anesthetic ointment is instilled using a sterile cotton-tipped applicator. In some cases, 4% lidocaine can be directly applied to the lid margin. The Maskin probe will be passed through the gland orifice perpendicular to the lid margin. After first using a 1-mm probe, a 2- or 4-mm probes may be used in cases of persistent resistance. The BCL is removed and the eyes are rinsed with sterile preservative-free saline. The patient is given preservative-free artificial tears to use every hour. A brief slit lamp exam will performed in order to ensure that there is no unanticipated damage to the lid or cornea. The probing device will be properly disposed of in the sharps containers.
224126996|NCT04628559|DRUG|Saline|Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
224296313|NCT05467163|PROCEDURE|AV node ablation|Atrioventricular node ablation (AVNA) will be performed following pacemaker implantation (preferably during the same hospitalization). After femoral vein access will be obtained, the ablation catheter will be positioned to the presumed area of the AV node in the mid-septum under fluoroscopy. The location will be optimized according to the intracardiac electrograms. Ablation will be performed in a temperature-controlled mode. Successful AVNA will be recognized with an abrupt drop of heart rate to 40 bpm and will continue for 60 seconds thereafter.
224296314|NCT02794857|DRUG|NP001|
224296315|NCT02794857|DRUG|Placebo|
224296316|NCT01846273|DRUG|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
224010250|NCT06371638|DRUG|Dexmedetomidine|General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml
224010251|NCT06371638|DRUG|Sevoflurane|General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.
224010252|NCT01416389|DRUG|LY2523355|Administered intravenously as a one hour infusion
224010253|NCT01416389|DRUG|ixabepilone|Administered intravenously
224010254|NCT01416389|DRUG|pegfilgrastim|Administered intravenously
224010255|NCT01416389|DRUG|filgrastim|Administered intravenously
224010256|NCT03711422|DRUG|Afatinib|40mg daily
224010257|NCT03711422|DRUG|Afatinib|160mg for 3 days every 3 weeks
224010258|NCT02927197|BEHAVIORAL|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
224010259|NCT00538694|DRUG|daptomycin|
224010260|NCT04650542|DRUG|HBI-3000|small molecule, multi-ion channel blocker
224010261|NCT04650542|DRUG|Paroxetine|serotonin uptake inhibitor, CYP2D6 inhibitor
224010262|NCT00151580|DRUG|Ribavirin|18 months of oral ribavirin maintenance treatment
224010263|NCT00151580|DRUG|Placebo|18 months oral placebo treatment
224010264|NCT04306016|OTHER|Sensory stimulation|Sensory stimulation can be formed in different aspects, and the most important ones are visual stimulation and auditory stimulation. Visual stimulation interventions involved providing a calendar, clock or familiar objects such as photographs of family caregivers; while auditory stimulation included calling the name of patients, helping to orientate the time and location, introducing hospital information, the ICU surrounding and treatment, and communicating with patients, who could not talk due to artificial airway, through a blackboard and use of gestures.
224010265|NCT01125514|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
224010266|NCT01125514|DRUG|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
224010267|NCT01125514|DRUG|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
224010268|NCT01125514|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet
224010269|NCT02033083|DEVICE|Laminaria|
224010270|NCT02033083|DEVICE|Dilapan-S|
224010271|NCT04864262|OTHER|Photovoice|Photovoice is a method that uses photographs and dialogue to share experiences, understand an issue and promote positive change. Group meetings will be held four times throughout the photovoice intervention. The goals of the group meetings are to share knowledge about falls and fall prevention, identify commonalities in the issues raised by the participants, and discuss ways in which these issues could be addressed, both at individual and societal levels. For two photo assignments, participants will be asked to take 4-6 pictures for an assigned question. The question for photo assignment #1 will be 'What decreases your likelihood of falling?' The question for photo assignment #2 will be 'How do you reduce the risk of falling so that you can participate in meaningful activities?' Following each photo assignment, participants will complete an individual semi-structured interview with the peer mentor and the research trainee, who will have a background in physical or occupational therapy.
224010272|NCT02512640|PROCEDURE|Volume-controlled ventilation|a tidal volume of 8 ml/kg
224010273|NCT02512640|PROCEDURE|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
224010274|NCT00858364|DRUG|Darbepoetin alfa|Administered subcutaneously once every 3 weeks
224010275|NCT00858364|DRUG|Placebo|Administered subcutaneously once every 3 weeks
224010276|NCT05833490|OTHER|Repetitive Peripheral Magnetic Stimulation (rPMS)|Repetitive Peripheral Magnetic Stimulation (rPMS) is an external device that delivers repetitive pulsed magnetic fields of sufficient magnitude, will be applied on the tibialis anterior muscle belly at \~ 10% of motor threshold, in order to induce neural action potentials in the lower extremities.
224010277|NCT05833490|OTHER|Sham Priming|Sham Priming using the Repetitive Peripheral Magnetic Stimulation (rPMS), it will be applied on the dorsal part of the foot with a minimal intensity at 5% of maximum stimulator output, that is of insufficient magnitude to induce changes in the muscle or nerves of lower extremities.
224010278|NCT01971801|DIETARY_SUPPLEMENT|Vitamin D3 50,000 IU|Capsule given by mouth once a week
224296317|NCT01846273|DRUG|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
224296318|NCT01846273|DRUG|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
224010279|NCT01971801|OTHER|Placebo|One capsule given by mouth weekly
224010280|NCT04716335|DRUG|DMT|DMT
224296319|NCT01298713|DRUG|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
224296320|NCT01298713|DRUG|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
223389806|NCT04628091|OTHER|Sampling on surgery day|"In the morning, the day of the surgery (the patient will be fasting):~* Occipital hair sample (without roots)~* Venous blood sample (3 tubes of 7mL)~During the surgery:~* Sample of 0.5 to 1 cm3 of subcutaneous adipose tissue during laparoscopic umbilical access~* Collection of a portion of Ampulla proximal part and Isthmus distal part in order to obtain a piece of approximately 4 cm long (2cm of ampulla and 2 cm of isthmus) for each tube."
223389807|NCT00808951|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
223389808|NCT00808951|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
224010281|NCT04716335|DRUG|Harmine|Harmine
224010282|NCT04716335|DRUG|Placebo (Harmine)|Placebo for Harmine
224010283|NCT04716335|DRUG|Placebo (DMT)|Placebo for DMT
224010284|NCT02850289|DRUG|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
224010285|NCT02850289|DRUG|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
224010286|NCT00214552|DRUG|rabeprazole|
223389809|NCT02422134|OTHER|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
224010287|NCT02680990|BEHAVIORAL|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
224010288|NCT02680990|OTHER|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
224010289|NCT05485545|OTHER|Electrophysiological exploration of the right ventricle|"* CARTO electrophysiological mapping system~* 3D echocardiography~* High Resolution MRI"
224010290|NCT00157508|DRUG|nitroaspirin|
224010291|NCT04061044|DRUG|Ophthalmic Insert|Travoprost, 0.32 mg
224010292|NCT03913923|BIOLOGICAL|BCD-217|Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
224010293|NCT03913923|BIOLOGICAL|BCD-100|Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
224010294|NCT03913923|OTHER|Placebo|Placebo
224010295|NCT00677599|DIETARY_SUPPLEMENT|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
224010296|NCT00677599|DIETARY_SUPPLEMENT|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
224010297|NCT02794415|OTHER|Community-based exercise|"Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for \~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly."
224010298|NCT02755818|DRUG|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
224010299|NCT02741323|DRUG|Maraviroc|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
224010300|NCT02741323|DRUG|Placebo|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
224010301|NCT05521815|OTHER|Coma arousal therapy|early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
224010302|NCT05521815|OTHER|Selected physiotherapy program|selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
224010303|NCT00001145|DRUG|Bacteriophage|
224010304|NCT00001145|DRUG|rhuCD40L|
224010305|NCT00001145|DRUG|KLH|
224010306|NCT00324558|DRUG|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
224010307|NCT03693859|BEHAVIORAL|Cognitive enhancement program|The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
224010308|NCT03693859|BEHAVIORAL|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
223389810|NCT02791451|DEVICE|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
223389811|NCT02020278|DRUG|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets. Dosage: Depending on age and weight, Tablet (3.75 mg - 60 mg daily). Frequency: Once daily.~Duration: Participants may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
224010309|NCT04602559|DEVICE|MOBIDERM Panty group|"In the MOBIDERM Panty group, patients wear the MOBIDERM Panty during day and night for 3 months with the possibility to add the PAD.~The protocol includes 3 visits.~Visit 1 at day 0, corresponding to the inclusion visit, includes device delivery and some clinical evaluations (clinical examination, characteristics of lymphedema, self questionnaires, pain assessment, perimeter data).~Visit 2 at 30 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).~Visit 3 at 90 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance)."
224010310|NCT00972660|BIOLOGICAL|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
223389812|NCT03575377|OTHER|Disposal Aid|Deterra® drug deactivation system
223389813|NCT00920491|BIOLOGICAL|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
223730391|NCT04387175|DEVICE|Facial mask|The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
224010311|NCT00972660|DRUG|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
224010312|NCT00357331|DRUG|potassium citrate|20 meq by mouth in capsule form twice daily
224010313|NCT03369171|DEVICE|Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)|"MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2)."
224010314|NCT05271721|DRUG|epidural transforaminal injection of magnesuim sulfate|transforaminal fluroscopic guided
224010315|NCT05271721|DRUG|epidural transforaminal injection of dexmedtemodine|transforaminal fluroscopic guided
224010316|NCT05271721|DRUG|transforaminal epidural injection of dexamethasone|transforaminal fluroscopic guided
223389814|NCT06401135|OTHER|Inspiratory muscle training|IMT will be conducted using a pressure threshold-loading device (POWERbreathe® Classic Low Resistance). The groups will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department. physiotherapist
223389815|NCT01526057|BIOLOGICAL|PF-05280586|1000 mg, IV on days 1 and 15
224010317|NCT03573076|COMBINATION_PRODUCT|Photodynamic therapy|Photodynamic therapy with Methyl Aminolevulinate creme and red light.
224010318|NCT03573076|DEVICE|Non-ablative Thulium laser (NAFL)|Non-ablative Thulium laser (NAFL).
224010319|NCT03573076|DEVICE|Radio-frequency microneedles (RF-MN)|Radio-frequency microneedles (RF-MN).
224010320|NCT05850559|DIAGNOSTIC_TEST|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer|evaluation of diagnostic importance of insulin like growth factor binding protein3 in patient with recently diagnosed as Colorectal cancer by Enzyme-linked immunosorbent assay (ELISA
224010321|NCT04618562|OTHER|Revival Active Program|Program comprised of physical activities, group play, mind games, reasoning and discussion on sleeted topics, breath work and relaxation techniques, 60 minutes all together.
224010322|NCT01170676|BEHAVIORAL|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
224010323|NCT01170676|BEHAVIORAL|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
224010324|NCT03297424|DRUG|PLX2853|tablets
224010325|NCT02015208|DRUG|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
224010326|NCT04419272|DRUG|Methylphenidate|10mg twice per day, at 8am and 12pm, for one week, then increased to 20mg twice daily, at 8am and 12pm, for the next 7 weeks during the double-blinded period.
224010327|NCT04419272|OTHER|Placebo|When assigned to receive the placebo during the double-blinded period, subjects will be given a sugar pill for 8 weeks. The sugar pill will be taken twice per day, at 8am and 12pm.
224010328|NCT04419272|DRUG|Methylphenidate|During the open-label extension phase, dosing will begin at 10mg twice per day, at 8am and 12pm, for one week. The dosage will then increase to 20mg twice daily, at 8am and 12pm, for the next 7 weeks.
224037852|NCT05506072|OTHER|Blood flow restriction therapy|Blood Flow Restriction involves the application of a tourniquet to an extremity to partially restrict the arterial and venous blood flow to stimulate localized cellular and systemic hormonal changes that occur in high intensity exercise. BFR Training may produce similar cellular and muscular responses to cause hypertrophy when exercise is performed at low intensity. Studies have compared BFR therapy in the lower extremities with light load resistance exercise to light load resistance alone and observed greater improvements in the BFR group. A recent systematic review further identified that adding BFR to exercise effectively augments muscle strength and size. Additionally, BFR has been shown to be applied in a safe manner with low risk for complications. With this growing body of evidence supporting BFR, it is becoming increasingly common in rehabilitation
223389816|NCT01526057|BIOLOGICAL|MabThera|1000 mg, IV on days 1 and 15
223389817|NCT01526057|BIOLOGICAL|Rituxan|1000 mg, IV on days 1 and 15
224126997|NCT05212194|OTHER|examination|Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.
224126998|NCT04841629|OTHER|PreBioGyn Gel|Cellulose-based prebiotic gel developed to optimize vaginal health and reduce the risk of cervical cancer in women.
224126999|NCT04841629|OTHER|Trimosan Gel|Carbomer-based gel
224127000|NCT04841629|OTHER|RepHresh Gel|Carbomer-based gel
224127001|NCT05091060|DEVICE|Erchonia HLS|56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks.
224127002|NCT03769740|DEVICE|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
223389818|NCT01486225|DEVICE|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
223389819|NCT01486225|OTHER|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
224127003|NCT02484573|DRUG|Propanolol|
224127004|NCT04201769|DRUG|Netupitant/Palonosetron|NEPA is adiministered 60 minutes before chemotherapy, on day 1
223389820|NCT04880486|OTHER|Education|Usual pulmonary rehabilitation education and pharmacological therapies, and taught them some limbs exercise, using social application to contact and suggestion giving as supervision.
223389821|NCT04880486|OTHER|Supervision upper limb weight training exercise with VR|Participant is supervised by physical therapist to conduct upper limb weight training exercise with VR.
223730392|NCT01229059|DIETARY_SUPPLEMENT|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
223389822|NCT00546663|DRUG|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
224010329|NCT05155176|BEHAVIORAL|Intensive Day Monitoring|During intake, a research assistant will demonstrate how to place the HRV monitor, BACtrak Skyn, and provide instructions on completing the saliva samples at home. Participants will wear the HRV and Skyn monitors for three consecutive, randomly selected days twice for individuals with Alcohol Use Disorder and once for social drinkers during the study (72 hours each). Participants will be provided with six saliva sample collection tubes per day with explicit directions on when the saliva sampling should occur (hours since waking: +0, +1, +2, +4, +6, +10 hours, and before going to sleep). Participants will also complete a subjective report using similar questions included in the survey prompts at the same scheduled time as the saliva sample. Individuals with Alcohol Use Disorder would complete a total of 6 such days during the study, and social drinkers would complete a total of 3 such days during the study.
224010330|NCT02716259|PROCEDURE|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
224010331|NCT02716259|PROCEDURE|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
224010332|NCT03794700|OTHER|Hospice Decision Aids|Paper and video hospice decision aid
224010333|NCT06182891|DRUG|Dulaglutide Injection|Dulaglutide injection was injected subcutaneously at standard dose and frequency for consecutive 12 months in patients with type 2 diabetes and diabetic kidney disease. Other hypoglycemic agents not including GLP-1 receptor agonists were used at standard dose and frequency for consecutive 12 months.
224010334|NCT04097353|BEHAVIORAL|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
223389823|NCT00584324|COMBINATION_PRODUCT|BIS 40|"Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
223389824|NCT00584324|COMBINATION_PRODUCT|BIS 60|"Mini-mental state exam: For subjects \> 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
223546122|NCT05729906|OTHER|psychological and physical tests|"Once included (T0), participants will be reviewed at 6 (T1), and 12 (T2) months. At the three measurement times, research professionals (belonging to the PAVeA laboratory) will carry out, within the nursing home the physical and psychological measurements (classic standardized tests for the population). These measurements will be carried out in parallel with the routine biological explorations performed in the institution.~At each visit, the remaining blood sampled in routine will be frozen in 2 aliquots for metabolomic and spectrometric analyses at the end of the study by the iBrain and Research Center for Respiratory Diseases laboratories."
224010335|NCT04097353|BEHAVIORAL|Surviving Strong for Kids (SS4K)|Enhanced usual care
224010336|NCT00293501|DRUG|tinzaparin sodium|
224010337|NCT00744562|DRUG|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
224010338|NCT05857189|DEVICE|Digitalized printed paper|Patients will receive a newly formed digitalized printed paper inserted into eyeglasses
224010339|NCT05857189|DEVICE|Traditional drawing image|Patients will receive eyeglasses that hold a traditional drawing image of the eye
224010340|NCT05857189|OTHER|Healthy controls|Patients will include volunteering participants with un defected eye
224010341|NCT00517400|DEVICE|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
224010342|NCT00311389|DRUG|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
224010343|NCT00311389|DRUG|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
224010344|NCT01555840|DEVICE|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
224010345|NCT02535091|DRUG|YKP3089|see above
224010346|NCT01482923|BEHAVIORAL|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
224010347|NCT01482923|BEHAVIORAL|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
224010348|NCT03045835|DEVICE|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
223389825|NCT04386850|DRUG|Oral 25-Hydroxyvitamin D3|Subjects in the case group will receive 25 mcg of 25(OH)D3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months.
224010349|NCT03045835|DEVICE|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
224010350|NCT05617430|DRUG|HAIC|"Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W"
224010351|NCT05617430|DRUG|Sintilimab|200mg IV d1, Q3W
224010352|NCT05617430|DRUG|Bevacizumab Biosimilar IBI305|7.5mg/kg IV d1, Q3W
224010353|NCT04179942|DIAGNOSTIC_TEST|Fractional exhaled nitric oxide and CRP levels|measurement of FeNO and Hs-CRP after 3months of CPAP
224010354|NCT03223662|OTHER|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
224010355|NCT03223662|PROCEDURE|Esophagectomy|Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
224010356|NCT05691751|PROCEDURE|primary unilateral total knee arthroplasty with limited application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be cruciate scarifying cemented DePuy Synthes PFC Sigma without resurfacing of the patella, intramedullary guides will be used for the femoral and tibial cuts as seen appropriate by the surgeon, however, the application time of the tourniquet during surgery will be as the allocation of each patient imply.
224010357|NCT05691751|PROCEDURE|primary unilateral total knee arthroplasty with full application of tourniquet|the tourniquet will be applicated around the proximal thigh in all patients before the incision, all patients will undergo primary unilateral TKA by the same surgeon using the medial para-patellar approach, and the prostheses used in all patients will be
224010358|NCT03581903|BIOLOGICAL|H7N3 pLAIV|Approximately 10\^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device
224010359|NCT03581903|BIOLOGICAL|H7N9 pIIV|30 micrograms administered by intramuscular (IM) injection
224010360|NCT06024434|OTHER|Exercises|Experimental Group Exercises for Core: Crunches, Glute bridges Crunches Glute bridge Week 1-2 (set/rep/sec) Week 3-4 (set/rep/sec) Week 5-6 (set/rep/sec) Exercises for upper body: Push up (4), Bicep curls Exercises Weeks Reps/sets Push up walk out Bicep curls 1-3 16-20\*3 Push up Bicep curl with Dumbbell 4-6 12-15\*3 Exercises for Lower body: Lunges and Squats Exercises Weeks Reps/set Split Squat with body weight Body weight Squat 1-3 16-20\*3 Split Squat with Dumbbell Squat with Dumbbell 4-6 12-15\*
224010361|NCT06024434|OTHER|Walking|Walking for 30min, 5 days a week
224010362|NCT05833204|PROCEDURE|Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)
223389826|NCT02108184|DRUG|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
223389827|NCT02108184|DRUG|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
223389828|NCT02108184|DRUG|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
223389829|NCT02108184|DRUG|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
224010363|NCT05833204|PROCEDURE|Laparoscopic colporrhaphy with standard 0-caliber absorbable suture|After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)
224010364|NCT04276753|OTHER|Terminalia Chebula Fruit Extract|Standardized fruit extract
224010365|NCT04276753|OTHER|Placebo|Placebo
224010366|NCT02217475|DRUG|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
224010367|NCT02217475|DRUG|Placebo|Placebo administered orally once daily and taken every morning with food.
224010368|NCT00506441|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
224010369|NCT00506441|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
224010370|NCT01012414|DRUG|paricalcitol|2 mcg oral paricalcitol daily
224010371|NCT01012414|DRUG|placebo|placebo
224010372|NCT02601300|DRUG|GED-0301|
224010373|NCT04177043|DIAGNOSTIC_TEST|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
224010374|NCT04177043|DRUG|DAAs|Treatment with different regiments with DAAs
224010375|NCT02506075|DEVICE|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
224010376|NCT02506075|BEHAVIORAL|Visual inattention training|
224010377|NCT03656172|BIOLOGICAL|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
224010378|NCT04955782|BEHAVIORAL|samples will be analyzed for semen volume, pH, count, concentration, motility, morphology and viability|"The volume will be measured by weighing the sample in the container in which it has been collected, it will be a pre-weighed container. The volume will be assessed by aspirating the sample using a non-toxic pre scaled surgical pipette.~The samples will be liquified in an incubator at 37 C. Complete ejaculate liquefaction is normally achieved within 15-30 minutes at room temperature (WHO2010).~pH will be analyzed 30 minutes after collection. pH test strips in range of 6.0-10.0 will be used. A value under 7.0 will indicate lack of alkaline seminal vesicular fluid (pH-Fix 0-14 from Macherey-Nagell,Germany).~The samples concentration and motility will be analyzed in laboratory by Neubauer chamber, morphology will be assessed by RAL Diff-Quik kit (3x0.5L) from RAL Diagnostics, France as per the manufacturers' recommendation.~Vitality will be analyzed by Vital screen, FertiPro N.V. Belgium,as per guidelines of manufacturer"
224010379|NCT00673400|PROCEDURE|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
224010380|NCT05787327|DRUG|Chinese Herb|Yinqiaosan-Maxingganshitang granules
224010381|NCT05787327|DIAGNOSTIC_TEST|Placebo|Placebo
224010382|NCT00335933|DRUG|Gabapentin extended-release tablets|
224010383|NCT05447572|OTHER|FIT + FC|FIT + FC
224010384|NCT02920437|BEHAVIORAL|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
224010385|NCT02920437|OTHER|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
224010386|NCT00992225|DRUG|LY573636-sodium|Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
224127005|NCT04201769|DRUG|Dexamethasone|"Intravenous dexamethasone 12 mg is administered 30 minutes before chemotherapy initiation, on day 1.~The administration of DEX in the subsequent days (2-4) depends on the randomly assignement to treatment arm"
224296321|NCT00891839|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
224296322|NCT00891839|DRUG|Rituximab|Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
224296323|NCT03014336|DEVICE|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
224296324|NCT01858987|PROCEDURE|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
224296325|NCT01858987|PROCEDURE|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
224296326|NCT01858987|DEVICE|Ligasure|
223546123|NCT02895178|BEHAVIORAL|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
223546124|NCT01682356|DIETARY_SUPPLEMENT|Beetroot juice|double-blind placebo-controlled cross-over study
223546125|NCT05393245|DRUG|Tiotropium+Olodaterol|Tiotropium+Olodaterol
224010387|NCT01208649|DRUG|Exenatide|Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
224010388|NCT02756221|DIETARY_SUPPLEMENT|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
224010389|NCT02756221|OTHER|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
224010390|NCT03644303|RADIATION|SBRT + ADT|Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
224127006|NCT02979795|PROCEDURE|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
224127007|NCT05162612|DIAGNOSTIC_TEST|abtominal CT|standard basic Abdominal Ct scan
224127008|NCT04146584|DEVICE|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
224296327|NCT01858987|OTHER|vascular staple|
224296328|NCT03370822|DEVICE|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
224296329|NCT00132834|DEVICE|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
224296330|NCT00004135|BIOLOGICAL|filgrastim|
224296331|NCT00004135|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224296332|NCT00004135|DRUG|cyclophosphamide|
224296333|NCT00004135|DRUG|fludarabine phosphate|
224296334|NCT00004135|PROCEDURE|peripheral blood stem cell transplantation|
224296335|NCT03801941|DEVICE|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
223546126|NCT05393245|DEVICE|Spiolto Respimat|Spiolto Respimat Inhaler device
223546127|NCT05393245|DRUG|Long-acting muscarinic antagonists (LAMAs)|Long-acting muscarinic antagonists (LAMAs)
223546128|NCT05393245|DRUG|Long-acting β2-agonists (LABAs)|Long-acting β2-agonists (LABAs)
223389830|NCT00571324|DRUG|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
223389831|NCT00571324|OTHER|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
223389832|NCT06207721|DRUG|Polyethylene Glycols|Polyethylene Glycols syrup (0.7 g/kg daily)
223389833|NCT06207721|OTHER|Physical therapy program|The physical therapy program includes exercises and massage
224010391|NCT05216159|BEHAVIORAL|HAPA behavioural counselling + weekly HAPA worksheets|Behavioural counselling grounded in the Health Action Process Approach (HAPA; ie., action planning and coping planning) paired with weekly HAPA based worksheets delivered through a mobile application, SEMA3, to reduce consecutive workplace sedentary behaviour.
224010392|NCT02064348|DRUG|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
224010393|NCT02064348|DRUG|placebo|Solution for s.c. injection or tablets for oral administration
224010394|NCT02064348|DRUG|moxifloxacin|Tablets for oral administration
224010395|NCT03032432|DEVICE|Dynamic Elastic Garment (DEG) brace|Improve function of the shoulder
224010396|NCT03032432|DRUG|Corticosteroid injection|Injection to improve rotator cuff tendinosis pain and functional score
224010397|NCT02943239|DRUG|REGN1033|REGN1033
224127009|NCT02775864|DRUG|Antipsychotic|New initiation of any antipsychotic medication
223389834|NCT03660995|BEHAVIORAL|Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.|"Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child."
224010398|NCT02943239|DRUG|REGN2477|REGN2477
224010399|NCT02943239|OTHER|Placebo|Placebo
224010400|NCT06065683|PROCEDURE|surgery|Surgical procedures performed in the study period
224010401|NCT06400940|DRUG|ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).|Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).
224010402|NCT06400940|DRUG|combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).|Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
224010403|NCT00684723|DRUG|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
224010404|NCT00684723|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
224010405|NCT00924118|DRUG|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
223389835|NCT01719614|DRUG|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
223389836|NCT01719614|DRUG|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
223389837|NCT03328975|DRUG|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
223389838|NCT03328975|OTHER|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
223389839|NCT06632821|OTHER|No intervention will be used.|University students' health literacy, physical activity, back pain and posture habits will be evaluated.
223389840|NCT01555697|DRUG|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
223389841|NCT01555697|DRUG|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
223389842|NCT01232933|DEVICE|VPS System|Use of the navigational VPS system during catheter placement
223389843|NCT05001646|DEVICE|In-home resonance-based electromagnetic field protection device|Participants will have an in-home EMF protection device
223546129|NCT04790279|DRUG|Amlodipine|Initiation of amlodipine 2.5 mg
223546130|NCT04790279|DRUG|NIFEdipine ER|Initiation of nifedipine ER 30 mg
223546131|NCT03851887|COMBINATION_PRODUCT|TAI combine SBRT|TAI combine SBRT
224010406|NCT03013075|PROCEDURE|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
224010407|NCT03013075|DRUG|Bupivacaine heavy and Morphine|
224010408|NCT03013075|DRUG|General Anesthetics|
224010409|NCT04440852|BEHAVIORAL|TEACCH|The Treatment and Education of Autistic and Communication Handicapped Children
224010410|NCT03540563|OTHER|Blood draw|Blood will be drawn to assess ctDNA
224010411|NCT05770518|BEHAVIORAL|Biofeedback|Biofeedback is a strategy used in the treatment of PVFM, which involves allowing patients to directly visualize their breathing patterns during laryngoscopy.
224127010|NCT02775864|DRUG|Antidepressant|New initiation of any antidepressant medications
224127011|NCT02775864|DRUG|Benzodiazepine|New initiation of any benzodiazepine
224127012|NCT02775864|DRUG|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
224296336|NCT03801941|OTHER|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
223389844|NCT05721911|GENETIC|whole genome sequencing|Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes
224010412|NCT05770518|BEHAVIORAL|Laryngeal control therapy (LCT)|This treatment typically involves 2 guided therapy sessions that include patient education, relaxation techniques, and training in specific breathing techniques.
224010413|NCT03055052|OTHER|Standard formula for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
224010414|NCT03055052|OTHER|Formula with higher protein and new fat blend for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
224010415|NCT02576587|OTHER|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI \>=15) will be place on CPAP therapy.
224010416|NCT00341432|BEHAVIORAL|Nicotine Replacement Therapy|
224010417|NCT00532493|DRUG|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
224010418|NCT00532493|OTHER|placebo|"sugar pill"
224010419|NCT05187143|DEVICE|DENTAL IMPLANT|The study implants were 3.5, 3.75 or 4.5 mm implant diameter, Straumann® BLX implant SLActive® Roxolid® (Institut Straumann AG, Basel, Switzerland) and the abutment was a 0 °, 2.5 mm of height Straumann® Screw-retained Abutment. The length of the implants was 6, 8 and 10 mm. The 6 mm implant is only commercially available in 3.75 and 4.5 diameter.
224010420|NCT00100087|DEVICE|Ocular Brachytherapy|
223389845|NCT04368338|DIAGNOSTIC_TEST|COVID-19 RT-PCR|Polymerase chain reaction tests after reverse transcription for the detection of viral Covid-19 RNA (RT-PCR)
223389846|NCT04368338|PROCEDURE|lung ultrasound|lung ultrasound is standard practice to diagnose acute respiratory failure in Emergency room
223389847|NCT03171012|OTHER|Lower limbs CRT|cycle ergometer for lower limbs
223389848|NCT03171012|OTHER|Upper limbs CRT|cycle ergometer for upper limbs
223546132|NCT04874883|DIETARY_SUPPLEMENT|Simbyotic|6 grams of the symbiotic will be administered twice a day
224010421|NCT04394468|DEVICE|PlasmaJet|Data will be collected during two contact moments, in particular during her admission for surgical laparoscopy, and during her postoperative check-up. Both of these are standard of care. No additional questionnaires will be taken. During the admission the postoperative pain scoreswill be monitored and collected. The duration of her stay in the hospital will also be recorded. During the postoperative check-up, which takes usually place six weeks after the surgery, complications will registered.
224010422|NCT00351663|DRUG|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~1. Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~2. Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~3. Subcutaneous Enoxaparine 40mg x1/day"
224010423|NCT04937972|DRUG|SHR-1701 Combined With Fluazopalil|SHR-1701 +fluzoparib
224010424|NCT05613387|DRUG|ZP8396|"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."
224010425|NCT05613387|DRUG|Drug: Placebo (ZP8396)|"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."
223389849|NCT03171012|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
223389850|NCT03171012|OTHER|respiration|respiration
224010426|NCT02773563|OTHER|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
224010427|NCT02773563|OTHER|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
224127013|NCT05547373|BEHAVIORAL|Infection prevention and control (IPC)|The intervention will be developed by matching behavioral change components identified in the gap analysis stage with the intervention components extracted from a systematic review. The investigators will use the Behavior Change Wheel (BCW) model as a guide to design this infection control prevention and control intervention. In brief, the intervention development processes will follow eight steps based on the BCW. The steps will include defining the problem in behavioral terms, selecting the target behaviors, specifying the target behaviors, identifying what needs to change, identifying intervention functions, identifying policy categories, identifying behavior change techniques, and identifying the mode of delivery.
223546133|NCT04874883|DEVICE|Control Group|6 grams of the maltodextrin will be administered twice a day
223546134|NCT05972421|OTHER|High Intensity Proactive Outreach|phone calls + mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
223546135|NCT05972421|OTHER|Low Intensity Proactive Outreach|mailed letter to eligible patients to describe and offer enrollment into the FLEX Nutrition Program
223546136|NCT03930771|DRUG|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
223546137|NCT03930771|DRUG|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
223546138|NCT00589706|DRUG|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
224296337|NCT00655278|DRUG|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
224010428|NCT05460403|RADIATION|Adjuvant Radiotherapy|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
224010429|NCT00655018|DIETARY_SUPPLEMENT|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
224010430|NCT00655018|DIETARY_SUPPLEMENT|Placebo|placebo and lifestyle intervention \[hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity\].
224010431|NCT02842801|OTHER|Hip manipulation|High-amplitude and low-velocity thrust mobilization
224010432|NCT01036438|DEVICE|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
224010433|NCT01036438|DEVICE|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
224010434|NCT05714345|BIOLOGICAL|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
224010435|NCT05714345|DRUG|Fludarabine|Chemotherapy for lymphodepletion
224010436|NCT05714345|DRUG|Cyclophosphamide|Chemotherapy for lymphodepletion
224127014|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
224127015|NCT02868749|DEVICE|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
224127016|NCT02839967|OTHER|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
224010437|NCT05714345|GENETIC|ALLO-501A|ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
224296338|NCT05069155|BEHAVIORAL|Gamification|Each participant signs a pre-commitment contract agreeing to try their best to achieve their daily step goal. Each week over the 12 week intervention period, participants are endowed 70 points (10/day). Participants are informed they will lose 10 points for each day the step goal is not met. Points are replenished at the start of the week. At the end of the week, if the participant has 40 points or more, he/she will advance one level, or drop one level if they have less than 40 points. The levels include: blue (lowest), bronze, silver, gold, platinum (highest). Each participant begins in the middle (silver). Each participant will also select a spouse, family member, or friend that they see often to serve as a supportive sponsor that receives a weekly email participants progress including points, game level, and average step countThis supportive sponsor will help to enhance social incentives to motivate the individual towards his or her goal.
224296339|NCT01987726|OTHER|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
224127017|NCT02839967|OTHER|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
224010438|NCT00659659|DRUG|MEDI-563|1.0 mg/kg IV: MEDI-563
224010439|NCT00659659|DRUG|MEDI-563|100 mg, 200 mg SC
224010440|NCT00659659|OTHER|Placebo Comp.|Placebo SC
224010441|NCT00659659|OTHER|Placebo|Placebo as a single IV infusion (Certain number of subjects)
224010442|NCT03350373|DRUG|FYU-981|Single administration of FYU-981 under Fasted and fed conditions in the morning.
224010443|NCT00888927|BIOLOGICAL|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
224010444|NCT01291459|DRUG|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
224010445|NCT03459443|DRUG|Danicopan|Danicopan was to be administered as an oral tablet.
224010446|NCT04656704|DRUG|hyaluronidase injected intradermally|Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
224010447|NCT06249659|PROCEDURE|Extubation in operative room|Extubation takes place in operative room
224010448|NCT06249659|PROCEDURE|Extubation in post anesthesia care unit|Extubation takes place in post anesthesia care unit
224010449|NCT02440945|DEVICE|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
224010450|NCT05812417|DRUG|DA-8010|DA-8010 5mg single dose administration
224010451|NCT02806648|DRUG|Palbociclib|Palbociclib
223564100|NCT06410261|BEHAVIORAL|Exercise rehabilitation program|"* The sessions will consist of a customized low-impact, resistance-base rehabilitation regime to increase muscle strength and functionality by focusing on isolating each targeted muscle, without increasing the participant's fatigue or pain level.~* The goal of phase one will be to start muscle activation without increasing fatigue or pain. Low intensity, single set of 30-35 repetitions for each of the targeted muscles will be performed by the participants, followed by stretching; the goal of phase two will be to progressively develop muscle strength, without increasing pain or fatigue. A single set of 20-25 repetitions for each muscle will be prescribed, followed by stretching; during phase three, the emphasis will be on further development of muscle strength, function, and endurance."
224010452|NCT03702231|BIOLOGICAL|Zoster Vaccine Recombinant, Adjuvanted|A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.
224010453|NCT02443454|DEVICE|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
224127018|NCT05215392|BEHAVIORAL|Family Connections program|Family members in the experimental group of this study will receive an ecological momentary intervention (EMI) derived from an ecological momentary assessment (EMA) via the Family Connections smartphone app. Family members in this condition will receive the manual of Family Connections which contains all the information on the program sessions conducted and the skills training strategies in writing.
224127019|NCT01276067|DRUG|Donepezil|10 mg Tablet
224127020|NCT00953550|DRUG|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
224127021|NCT00953550|DRUG|Succinylcholine|1 mg/kg
224127022|NCT02937103|BIOLOGICAL|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
224127023|NCT01506414|DRUG|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
223389851|NCT02060812|PROCEDURE|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
223389852|NCT02060812|PROCEDURE|Group II, SSNB alone|This is same as the Group I, SSNB \& ANB, but ANB was performed with placebo(10mL normal saline).
223564101|NCT04824911|DRUG|Clopidogrel|300mg loading and 75mg/day from day 2
224010454|NCT02443454|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
224010455|NCT05131269|DRUG|Dextrose 15 % in Water|A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
224010456|NCT05131269|DRUG|Normal Saline 20 mL Injection|A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
224010457|NCT03018431|OTHER|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
224010458|NCT03590366|BIOLOGICAL|B244|B244 Suspension
224010459|NCT03590366|BIOLOGICAL|Vehicle|Vehicle suspension
224010460|NCT00151632|DRUG|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
224127024|NCT06149312|OTHER|Advance Care Planning Intervention|Standardized interview based on The letter Project (Stanford Medicine) and Questions Prompt List
224127025|NCT02209233|OTHER|Massage Therapy|
224127026|NCT00619684|DRUG|lenalidomide|Given PO
224127027|NCT03552549|BIOLOGICAL|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
224127028|NCT03552549|BIOLOGICAL|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
224127029|NCT03273075|DRUG|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
224127030|NCT03273075|DRUG|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
224127031|NCT03273075|DRUG|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
224127032|NCT03273075|DRUG|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
224127033|NCT00382889|DRUG|beclomethasone/salbutamol combination|
224127034|NCT00382889|DRUG|beclomethasone|
224127035|NCT00382889|DRUG|salbutamol|
224127036|NCT03403504|DRUG|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
224127037|NCT03403504|DRUG|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
224127038|NCT02094586|BIOLOGICAL|PXVX0200 Lot A|Lot P700-1CA03
224127039|NCT02094586|BIOLOGICAL|PXVX0200 Lot B|Lot P700-3CA03
224127040|NCT02094586|BIOLOGICAL|PXVX0200 Lot C|Lot P700-6BA03
224127041|NCT02094586|BIOLOGICAL|Placebo|Placebo
224127042|NCT03242278|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
224010461|NCT00151632|DRUG|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
224010462|NCT06377046|DEVICE|Accelerated pacing|The lower rate of the pacemaker will be programmed to 80 bpm in DDDR mode with mode switch to DDIR mode.
224010463|NCT06377046|DEVICE|Current standard of care|The lower rate of the pacemaker will be programmed to the current standard of care which is 60 bpm in DDDR mode with mode switch to DDIR mode.
224010464|NCT06108011|OTHER|Lollipop|sucking of lollipop after operation
224010465|NCT05106413|OTHER|BiCROS fitting|Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible hearing device on the other ear.
224010466|NCT05106413|OTHER|Monaural fitting|"Each participant will be fitted with a hearing aid on the better hearing ear and no device on the poorer, unaidable ear.~Monaural hearing aid fitting acts as control intervention."
224010467|NCT05106413|OTHER|Unaided condition|"No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention."
224010468|NCT05106413|OTHER|CROS baseline|"Each participant will be fitted with the experimental CROS device on the poorer, unaidable ear and with a compatible device on the other ear. The difference to the BiCROS condition is the setup of the microphones in the CROS device and the compatible hearing device.~This test condition is only tested for speech intelligibility in diffuse noise and acts as control intervention."
224010469|NCT04326166|DRUG|Evogliptin|Evogliptin
224127043|NCT02761993|BIOLOGICAL|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
224127044|NCT02761993|DRUG|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
224127045|NCT02461485|OTHER|Fermented milk product containing Probiotics|2 pots/day during 28 days
224127046|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
224127047|NCT02461485|OTHER|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
224127048|NCT02461485|OTHER|Non fermented Milk Product|2 pots/day during 28 days
224127049|NCT06531382|OTHER|Nurses attitudes toward adressing sexual health in patients with cancer|"Health professionals, within the field of cancer, attitude towards addressing sexual health with patients is unknown.~The aim is to investigate the attitudes of Danish cancer nurses towards addressing sexual health in their clinical work, as well as to assess differences in perceived competences and knowledge.~Method: The questionnaire Health professionals Attitudes towards Sexual Health-Danish version (PA-SH-D) is sent out to Danish cancer nurses via the Professional Society for Cancer Nurses. The questionnaire is sent out via a link via the RedCap database.~The questionnaire link is sent out to members of the Professional Association for Cancer Nurses under the Danish Nursing Council, and it is sent out via their membership register."
224296340|NCT01987726|OTHER|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
224296341|NCT01946074|DRUG|paclitaxel|Paclitaxel will be administered by intravenous infusion.
224296342|NCT01946074|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
223389853|NCT00006464|DRUG|7-hydroxystaurosporine|
223389854|NCT00006464|DRUG|cisplatin|
223389855|NCT02063750|OTHER|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
224010470|NCT04326166|DRUG|Evogliptin|Evogliptin
224010471|NCT04326166|DRUG|Metformin and Evogliptin|Metformin and Evogliptin
224010472|NCT05305924|DRUG|Fulvestrant Run-In|The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.
224010473|NCT04570215|OTHER|Gotcha! Therapy application|"Gotcha! will provide an app-based therapy for people with dementia who have difficulty naming people they know well.~The therapy element works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. This DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item."
224010474|NCT04570215|OTHER|Gotcha Therapy application: Maintenance|Gotcha! Maintenance therapy is identical to Gotcha! but takes place over a longer period of time in an attenuated form.
224010475|NCT02597647|BIOLOGICAL|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
224010476|NCT02597647|OTHER|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
224010477|NCT01275781|DRUG|[14C]-AZD9742|1000 mg intravenous over 2 hours
224010478|NCT03211117|DRUG|Docetaxel|Given IV
224010479|NCT03211117|DRUG|Doxorubicin Hydrochloride|Given IV
224010480|NCT03211117|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224010481|NCT03211117|OTHER|Laboratory Biomarker Analysis|Correlative studies
224010482|NCT03211117|BIOLOGICAL|Pembrolizumab|Given IV
224127050|NCT03778177|PROCEDURE|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
224127051|NCT06298292|DIETARY_SUPPLEMENT|Zero minis (range of protein substitutes in tablet form)|Intervention: range of protein substitute tablets. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemias or alkaptonuria, homocystinuria, or MSUD will be recruited. Subjects will take the study product for 7 days. Daily questionnaires will be completed (ease of preparation,administration; any problems or gastrointestinal effects). Subjects will replace some or their entire usual protein substitute with the new product suitable for their diagnosed rare metabolic disease. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Additional questions at the beginning and end of the study will record information on organoleptic properties, presentation and packaging of the product. Routine weekly blood samples will be collected and analysed for amino acids typically for the metabolic control of the individual specified metabolic disorders as is usual clinical practice.
224127052|NCT00817986|DRUG|Arbaclofen placarbil, 20 mg|tablets
224127053|NCT00817986|DRUG|Placebo|tablets
224127054|NCT00817986|DRUG|Arbaclofen placarbil, 30 mg|tablets
224127055|NCT00817986|DRUG|Arbaclofen placarbil, 40 mg|tablets
224127056|NCT02995681|OTHER|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
224127057|NCT02995681|OTHER|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
224127058|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
224296343|NCT01946074|DRUG|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
224296344|NCT01946074|DRUG|ABBV-181|ABBV-181 will be administered by intravenous infusion.
223564102|NCT04824911|DRUG|Aspirin|Aspirin(100-300mg/day)
224010483|NCT03211117|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224010484|NCT05232747|DIAGNOSTIC_TEST|Diagnostic Test|Diagnostic Test
224010485|NCT04927247|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
224010486|NCT04927247|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
224127059|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
224127060|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intramuscular Injection|Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
224127061|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
224127062|NCT04993586|BIOLOGICAL|AG0302-COVID19 for Intradermal Injection|Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
224127063|NCT01442129|BIOLOGICAL|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
224127064|NCT01442129|BIOLOGICAL|Control Solution|Injection of control solution during the LVAD implantation.
224127065|NCT00701740|DRUG|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
224127066|NCT00701740|DRUG|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
224127067|NCT04210336|DEVICE|PAPILOCARE|"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."
223389856|NCT02063750|OTHER|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
223564103|NCT04824911|DRUG|Atorvastatin|Atorvastatin 40-80mg/day
223564104|NCT04824911|DRUG|Rosuvastatin|Rosuvastatin 20 mg/day.
224010487|NCT01485146|DRUG|ETC-1002|escalating doses
224010488|NCT01170390|DRUG|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
224010489|NCT01170390|DRUG|Portia|30 mcg EE/0.15 mg LNG cyclically
224010490|NCT01170390|DRUG|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
224010491|NCT04548102|OTHER|Fetal movement count|Pregnant women in the study group received verbal information regarding normal fetal movements (i.e. description of the changing pattern of movement as the fetus develops, normal sleep/wake cycles, and factors which may modify the mother's perception of movements such as maternal weight and placental position), and its importance to be followed during the third trimester. A chart for fetal movements counting provided and to ensure proper performance of this task, women telephoned once a week. They also asked to show the fetal movements chart to the researcher and the health care providers in each visit. Women followed according to her antenatal visits schedule till delivery.
224010492|NCT06450860|OTHER|Nutrition Interventions|Individualized food provision and/or supplemental referral based on participant's unique needs/responses to assessment (NSAT). Food provision interventions include medically tailored meals, home delivered prepared meals, grocery boxes, grocery delivery services, food pantries, and soup kitchens/meal sites. Supplemental interventions include SNAP benefit enrollment support, nutrition education, and cooking education.
224296345|NCT02614963|DRUG|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
224296346|NCT02614963|DRUG|placebo|Irritable bowel syndrome patients treated with placebo
224296347|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
224010493|NCT02790827|BEHAVIORAL|CETA|CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
224010494|NCT02790827|BEHAVIORAL|Treatment as usual|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
224127068|NCT04210336|DEVICE|PLACEBO|The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
224127069|NCT03259542|DRUG|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
224127070|NCT03259542|DRUG|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
224127071|NCT06207500|PROCEDURE|Pharmacist-led Medication Reconciliation|The best possible medication history (BPMH) at hospital admission was obtained from medical and pharmacy records and by interviewing the patient or carers. The BPMH - an accurate and complete (or as close as possible) list of medications the patient is currently taking - was documented in the medication information system. At hospital admission the BPMH was compared with the therapy in hospital to identify discrepancies. All discrepancies were discussed with the treating physician, unintentional discrepancies were reconciled. Intentional discrepancies were documented in the medical records. Prior to discharge from hospital, the BPMH and the medications planned in the discharge therapy were compared again to ensure that all unintentional discrepancies were corrected. Intentional discrepancies were explained in the discharge letter. Individual patient counselling on discharge medications and pharmacotherapy changes was conducted and coupled with written instructions in lay language.
224127072|NCT00199264|DRUG|Albaconazole oral solution|
223389857|NCT03359408|BEHAVIORAL|Dementia Care Management (DCM)|"A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes."
224010495|NCT04197362|OTHER|Evaluation|Subjects will be asked to walk across the gait laboratory floor at their self-selected walking speed. They will complete a 3-5 minute warm up period, as it was found to produce stable estimates of kinetic parameter mean values during treadmill activity. The positions of each marker will be recorded through the motion capture system. Ground reaction force will be obtained in real time from the gait laboratory force plates as marker dimensions are recorded. For walking data, two trials of 15 seconds each will be recorded. The second trial will be a redundancy in the setting of potential significant marker dropout.
224127073|NCT05323786|PROCEDURE|The combined topical anesthesia induction group|Inhalation of aerosolized surface anesthesia with 10 ml 2% lidocaine would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia with 3ml 2% lidocaine.
224127074|NCT05323786|PROCEDURE|The routine induction group|Inhalation of 10 ml 0.9% normal saline would be administered with an atomizer for 15 minutes prior to intravenous anesthesia. After the intravenous induction, 3ml 0.9% normal saline would be administered into subglottic airway with a catheter.
224127075|NCT01465178|DIETARY_SUPPLEMENT|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
224127076|NCT01465178|DIETARY_SUPPLEMENT|Placebo|matching placebo
224127077|NCT06189677|OTHER|Observation of biological characteristics of fertile men|Sampling in outpatient settings, after biopsy or after surgery and collection of biological samples in fertile subjects
224127078|NCT03732872|DIAGNOSTIC_TEST|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
223389858|NCT03561038|DEVICE|Franseen Needle|Comparing 2 needles designed for tissue acquisition
223389859|NCT03561038|DEVICE|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
223389860|NCT02436343|OTHER|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
223389861|NCT01875978|DIETARY_SUPPLEMENT|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
223564105|NCT02357472|DIETARY_SUPPLEMENT|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d. Patients in these group will take one capsule each time and three times a day for three months before entering into IVF cycles.
224010496|NCT04337541|OTHER|Surgical facial mask|Participants will follow normal Authority recommendations AND wear mask outside their homes, or when receiving visits in their home.
224127079|NCT03732872|DIAGNOSTIC_TEST|Saliva analysis|Saliva samples for miRNA 21 expression analysis
224127080|NCT06672094|DIETARY_SUPPLEMENT|NeuroQ|Two (2) capsules of NeuroQ taken once a day for 60 days.
224127081|NCT06672094|OTHER|Placebo|Two (2) capsules of placebo taken once a day for 60 days.
224127082|NCT02027298|DRUG|Abatacept|by SC injection of 125 mg weekly for 6 months
224010497|NCT03660423|OTHER|Integrative Dance|Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
224296348|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
223389862|NCT05662176|OTHER|Experimental: Supportive Care based on trauma informed care|Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care based on trauma informed care was provided to the experimental group during birth.
223389863|NCT05662176|OTHER|Standart care|Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
223389864|NCT04311294|DRUG|ANS-6637 Low Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
223389865|NCT04311294|DRUG|ANS-6637 High Dose|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
223389866|NCT04311294|DRUG|Matched Placebo|ANS-6647 is a selective, reversible, and orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor. It will be tested at a low dose (200mg) and a high dose (600mg) against matched placebo.
223389867|NCT02574182|RADIATION|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
223389868|NCT06213376|BEHAVIORAL|Melodic Intonation Therapy|Melodic Intonation Therapy uses intonation and melody to aid individuals with aphasia with producing words.
223564106|NCT04704505|RADIATION|radium-223|Radium-223 is an alpha-particle-emitting bone-targeted therapy. All patients will receive Treatment with Radium-223 at a dose of 55 kBq per kilogram of body weight IV every 28 days, for 6 cycles,
224010498|NCT02627053|DRUG|rivaroxaban|
224010499|NCT00297505|DRUG|citalopram|
224010500|NCT04730193|DRUG|Caffeine|Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient
224010501|NCT04730193|DRUG|Placebo|Placebo pill will be formulated with a non active ingredient such as rice flour powder
224010502|NCT03529682|OTHER|exercise|10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
224010503|NCT03529682|OTHER|control group|60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
224010504|NCT06005545|DEVICE|Passive Ultrasonic Irrigation (PUI) group|Passive ultrasonic irrigation is the current golden standard in root canal cleaning and irrigation devices. It is used after root canal shaping using manual or rotary instruments. It uses sodium hypochlorite which is mobilized in the canal using ultrasonic non-cutting tips to clean, debride, disinfect, and prepare the root canal for obturation.
224010505|NCT06005545|DEVICE|Endoclean (EC) group|Endoclean is a novel device that uses hydraulic inertial cavitation with the help of pressure and saline solution to debride the root canal after minimal shaping using manual or rotary shaping instruments. It is used to effectively clean, debride and prepare the root canal before obturation in the root canal treatment procedure.
224010506|NCT06005545|DEVICE|Conventional group|Conventional root canal preparation uses manual or rotary files along with manual irrigation using syringes and irrigant solutions like sodium hypochlorite or EDTA to clean, debride and prepare the root canal for obturation.
224010507|NCT01456572|DIETARY_SUPPLEMENT|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
224010508|NCT01456572|DIETARY_SUPPLEMENT|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
224010509|NCT04293458|DEVICE|EsoGuard|EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
224010510|NCT01827644|DRUG|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
224010511|NCT01827644|DRUG|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
224010512|NCT01827644|DRUG|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
224010513|NCT01827644|DRUG|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
224127083|NCT02487849|PROCEDURE|HIPEC|secondary cytoreductive operation
224127084|NCT02487849|DRUG|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
224127085|NCT04806932|PROCEDURE|The modified approach|The first three attempts via the modified approach will be performed. If the first three attempts failed, the location or operator of the subsequent attempts of artery puncture will be changed.
224127086|NCT04806932|PROCEDURE|The conventional approach|The conventional approach
223389869|NCT06213376|BEHAVIORAL|Video Feedback Performance Review|Participant will view recording to judge correct and incorrect productions of trained words and to identify motor techniques increasing intelligibility
223564107|NCT04704505|DRUG|Bipolar Androgen Therapy (BAT)|All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
223564108|NCT00719498|DRUG|Epo-alpha|
224010514|NCT01827644|DRUG|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
224010515|NCT01827644|DRUG|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
224010516|NCT00513305|DRUG|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
224010517|NCT00513305|DRUG|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m\^2 subcutaneously (sc) twice a day (bid).
224010518|NCT02856100|DRUG|18F DCFPyL- Radiopharmaceutical|
224010519|NCT05640271|DRUG|Tocilizumab|Tocilizumab 80 mg IV dose (one time per patient)
224010520|NCT00830505|DRUG|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
224010521|NCT00830505|DRUG|fluticasone|2 puffs twice a day for 2 weeks
224010522|NCT01065142|PROCEDURE|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
224010523|NCT00929747|DEVICE|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
224010524|NCT00929747|PROCEDURE|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
224010525|NCT02918305|DEVICE|PRDS-001 Renal Denervation Ultrasound System|
224010526|NCT02918305|PROCEDURE|Sham Procedure|
223389870|NCT01669291|DRUG|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
223389871|NCT01669291|DRUG|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
223389872|NCT01669291|DRUG|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
223389873|NCT03738072|DIAGNOSTIC_TEST|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
223389874|NCT04876638|DRUG|Minocyclin|10mg/kg minocycline up to 700mg for 4 days following aneurysmal subarachnoid hemorrhage
223389875|NCT00047450|DRUG|Citalopram (Celexa)|Citalopram for 3 months
223389876|NCT00047450|DRUG|Placebo|Placebo for 3 months
223389877|NCT04840381|BEHAVIORAL|Questionnaire administrations|Administration of an ad hoc questionnaire to register food frequency consumption and meal time, main recipes; phisical activity questionnaire and list of questions concerning the previous and actual health status of participants
223389878|NCT04429945|DEVICE|Virtual Reality|Virtual Reality Headset with Virtual Reality Applications
223389879|NCT06577233|DRUG|Bupivacaine Hydrochloride|10cc of 0.25% Bupivacaine Hydrochloride will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
223730393|NCT06088550|DIETARY_SUPPLEMENT|BCAA|a branched-chain amino acid (BCAA) formula: taken by oral route in the form of 2 scoops of Protofit BCAA daily on 200 cc water, (manufactured by Dulex lab company). Each scoop contains 5 gm BCAA (2.5 gm leucine, 1.25 gm isoleucine \& 1.25 gm valine).
224010527|NCT05930613|DRUG|Certolizumab (CIMZIA® ; TNF-α antagonist)|400mg of certolizumab injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
224010528|NCT05930613|DRUG|Placebo (NaCl 0.9 % solution)|NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
224010529|NCT00710905|DEVICE|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
224010530|NCT02461953|DEVICE|hemoperfusion apparatus|
224127087|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
224296349|NCT01642199|BEHAVIORAL|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
223389880|NCT06577233|DRUG|Normal saline|10cc of 0.9% normal saline will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
223389881|NCT06821100|DRUG|Thymalfasin (Thymosin alpha 1, Ta1)|Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases. Ta1 has been shown to provide increased response to vaccines.
223389882|NCT03367195|DRUG|Omeprazole|1 Omeprazole 20 mg capsules twice daily
223389883|NCT03367195|DRUG|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
223389884|NCT03367195|DRUG|Placebo capsule of Omeprazole|1 placebo capsule of omeprazole, twice daily
223389885|NCT03367195|DRUG|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
224010531|NCT02461953|DEVICE|low flux dialyzer|
224010532|NCT02461953|DEVICE|high flux dialyzer|
224010533|NCT02888652|DRUG|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
224010534|NCT03776539|DRUG|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
224010535|NCT00052000|DRUG|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
224010536|NCT05901064|PROCEDURE|Axillary clearance|Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
224010537|NCT04765332|OTHER|DLQI and PSO-TARGET QoL grid|At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid
223389886|NCT05475197|DEVICE|Kinesio taping|We planned to perform two different taping applications to evaluate the acute effect of kinesio taping application on the carpal tunnels of individuals with carpal tunnel syndrome.
224010538|NCT00821717|DRUG|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
224127088|NCT01135953|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
224127089|NCT01135953|OTHER|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
223389887|NCT04870710|DEVICE|transcranial electrical stimulation|Electrical stimulation to the extrastriate visual cortex.
223389888|NCT00710268|DRUG|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
223389889|NCT00710268|DRUG|Bevacizumab|IV administration10 mg/kg every 14 days
223389890|NCT06662968|OTHER|Lollipop group|In the Lollipop group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were given lollipops for sucking without chewing after waking up.Throughout the entire sucking process, we continuously monitor vital signs.
223389891|NCT06662968|OTHER|Control group|In the Control group,children were sent to the recovery room (PACU) for observation after extubation after surgery.They were received routine nursing treatment.
223389892|NCT02245607|BEHAVIORAL|Compensatory Cognitive Training|
223546139|NCT06017960|OTHER|Dry needling + usual care|"Participants assigned to the dry needling group will receive a weekly session for four weeks of ultrasound-guided dry needling in the inner gastrocnemius muscle with disposable stainless-steel needles, according to the depth of the muscle to be treated. For the realization of the technique, the diagnostic criteria of the Dry Needling in Hypertonia and Spasticity technique (DNHS®) developed by Herrero et al. will be applied adapted to the characteristics of the study, as well as the procedure for its application.~The ultrasound guidance will be the same ultrasound device than in the assessments. This ultrasound-guided intervention allows to guarantee the safety of the approach, to have the certainty in the location of the target structure and to see the responses of local spasm. During the application of the technique, patient will not look at the ultrasound screen to ensure the blindness of the patient to the group allocated."
223546140|NCT06017960|OTHER|Sham dry needling + usual care|"Participants assigned to this group will receive the same assessments, the same number of sessions, and the sham dry needling at the same site as the dry needling group, but with a sham intervention, where the needle is dropped through the guide tube and touch the skin. The patient will not feel anything, or at most that the needle touches the skin, since it does not get into the subcutaneous cell tissue, as placebo interventions were performed in similar studies. The context will be simulated in its entirety, using the same ultrasound and disposable needles for the intervention.~Both groups will continue their daily motor rehabilitation treatment during the 4 weeks, which consists of strength training, balance, motor control, gait training, and mass practice oriented to tasks of intensity and duration appropriate to each patient, allowing the fastest possible clinical improvement, as recommended by clinical practice guidelines."
223389893|NCT02245607|BEHAVIORAL|Recreational Therapy|
223546141|NCT04832789|DEVICE|Venovenous ECMO|Venovenous ECMO
223546142|NCT02026674|DEVICE|FloRite|Disposable home use urine flow meter.
223730394|NCT06088550|OTHER|home-based graded exercise program|home-based graded exercise program comprises both aerobic and resistance exercise. The exercise was done by the patients themselves aided by a physiotherapist, a nurse or patients' relatives
224010539|NCT00821717|DRUG|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
224127090|NCT02916498|DEVICE|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
224296350|NCT03829137|DEVICE|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
224296351|NCT03829137|DEVICE|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
224296352|NCT02925585|OTHER|Pre/post imaging|
224296353|NCT00712985|DRUG|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
224296354|NCT02700711|DRUG|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
223389894|NCT03443349|DEVICE|Vibwife One|"Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control."
223389895|NCT03123068|DRUG|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
223389896|NCT03123068|OTHER|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
224010540|NCT04904939|PROCEDURE|Bronchoscopic mucosal biopsy|Endobronchial forceps biopsy using flexible bronchoscope
224010541|NCT00685906|DRUG|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
223389897|NCT04493164|DRUG|Ivosidenib|Given PO
224010542|NCT00685906|DRUG|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
224010543|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
224127091|NCT00647777|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fed
224296355|NCT02700711|DRUG|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
224296356|NCT02700711|DRUG|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
224296357|NCT02674061|BIOLOGICAL|Pembrolizumab|Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle
223389898|NCT04493164|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223389899|NCT01427699|DRUG|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
223389900|NCT02329015|BEHAVIORAL|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
223389901|NCT02329015|BEHAVIORAL|Physical Education Class|Standard physical education
223389902|NCT06919432|DEVICE|Active-tACS|Participants were comfortably positioned on a lounge chair and received alternating current stimulation using an FDA-approved tACS device (Nexalin Technology, Inc., Houston, TX, USA). Electrodes were evenly placed across the forehead and mastoid regions. Trained nurses administered the tACS according to standardized protocols.
223389903|NCT06919432|DEVICE|Sham-tACS|The sham tACS device will resemble the active stimulation device in appearance, weight, size, color, and odor, ensuring indistinguishability for the patients. Throughout the entire intervention period, each participant will be allocated to the same tACS device, regardless of whether it delivers active or sham stimulation.
223389904|NCT06546826|PROCEDURE|BARP|deep layers of collagen, medium-superficial heterologous bone graft, superficial collagen layer
223389905|NCT06546826|PROCEDURE|simple tooth extraction|tooth extraction without grafting procedure.
223389906|NCT06546826|PROCEDURE|tooth root and PRF|Autogenous roots derived from the extracted hopeless tooth and stabilized with osteosynthesis screws to reconstruct the missing buccal wall of the socket. The defect was then filled with PRF.
223389907|NCT06546826|PROCEDURE|Ice cream cone technique|xenogeneic granules and a resorbable collagen membrane
223389908|NCT07128316|DEVICE|Contoura Topolyzer with Phorcides|LASIK calculated ablation using Contoura Topolyzer with Phorcides
223389909|NCT07128316|DEVICE|iDesign|LASIK calculated ablation using iDesign Refractive Studio 2.0
224010544|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
223389910|NCT06997900|DRUG|Combination therapy : Follitropin delta and HP-hMG|Follitropin delta dose will be determined by age. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight.
223389911|NCT07005921|BEHAVIORAL|qEEG-neurofeedback|The participants will be submitted to a qEEG-neurofeedback intervention in order to verifify its feasibility to enhance cognition. The theta/beta ratio reduction protocol at electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4 will be performed, with 10 sessions of qEEG-neurofeedback training, 2 sessions for pre and post test, and 1 session for follow-up after 30 days of intervention. Each session will last approximately 1 hour. The Psychological Battery of Attention 2 (BPA-2) and Digit Span Test will be employed to measure attention and working memory levels. The Montreal Cognitive Assessment (Moca) will be used for neurological and cognitive assessment. Participants will receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
223546143|NCT01222117|BIOLOGICAL|Plasmin|Plasmin prepared in 0.9% saline for injection
223546144|NCT01222117|BIOLOGICAL|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
224010545|NCT01282853|PROCEDURE|endoscopic biopsy|endoscopic biopsy for rapid urease test
224010546|NCT01453400|DRUG|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
224010547|NCT01453400|DRUG|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
224010548|NCT01453400|DRUG|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
224296358|NCT01856361|DRUG|Ramipril|Angiotensin Converting Enzyme Inhibitor
224296359|NCT01856361|DRUG|Placebo|Placebo pill that will match the treatment pill
224010549|NCT03676491|OTHER|Music Intervention|Music intervention
224010550|NCT03545802|BEHAVIORAL|Home-HIT|Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
224010551|NCT01423227|BEHAVIORAL|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
224010552|NCT01423227|BEHAVIORAL|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
224010553|NCT02025959|BEHAVIORAL|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
224010554|NCT04044898|DRUG|ALA 5%|prepare 5% ALA solution, apply topically to the affected area for 1.5 hours, single dose
224010555|NCT04044898|DRUG|ALA 10%|prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
224127092|NCT00647777|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fed
224127093|NCT01395589|DRUG|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels \< 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
224127094|NCT03827473|DRUG|Abiraterone Acetate|Given PO
224127095|NCT03827473|DRUG|Antiandrogen Therapy|Given per standard of care
224127096|NCT03827473|DRUG|Docetaxel|Given IV
224127097|NCT03827473|DRUG|Prednisone|Given PO
224127098|NCT03827473|OTHER|Quality-of-Life Assessment|Ancillary studies
224296360|NCT01753947|OTHER|Deliberate Practice|
224296361|NCT01299805|DRUG|Vortioxetine|Encapsulated tablet
224296362|NCT01299805|DRUG|Placebo|Vortioxetine placebo-matching capsules.
223389912|NCT07005921|BEHAVIORAL|SHAM qEEG-neurofeedback|The participant will be submitted to an inactive qEEG-neurofeedback that appears to be the same as a functional procedure or device. Participants will not receive feedback based on their theta/beta ratio in the frontal and central cortical areas (electrodes Fp1, Fp2, Fz, F3, F4, Cz, C3, C4).
224010556|NCT05476302|OTHER|Cognitive digital treatment|The remote cognitive-rehabilitation treatment was based on Parkinson's adapted cognitive stimulation therapy (CST). Fourteen twice-weekly sessions were planned, followed by one session per week for a duration of six months for maintenance therapy. The treatment took place in groups of 4 patients in remote mode through the Microsoft-Teams platform. All subjects maintained the prescribed drug therapy and regular physiotherapy activity during the intervention.
224010557|NCT03007446|DRUG|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
224010558|NCT03007446|DRUG|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
224010559|NCT03007446|DRUG|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
224010560|NCT03994354|PROCEDURE|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
224010561|NCT03367429|DRUG|Botox|THE PROTOCOL DESCRIPTION ATTEMPTED TO OUTLINE A CONTINGINECY PLAN- MOVING TO ONE OF TWO METHODOLOGOIES DPENDING ON PRELIMINARY FINDINGS. UNFORTUNATLEY, OVER 2 YEARS RECRUITMENT WAS GROSSLY INADEQUATE PREVENTING ANY TYPE OF EVEN CURSURY PRELIMINARY DATA ANALYSIS AND FORCING THE EARLY TERMINATION OF THIS STUDY. MICHAEL W. O'DELL, MD
224010562|NCT04788043|DRUG|Magrolimab|45 mg/kg with dose escalation starting at 1 mg/kg IV Infusion
224010563|NCT04788043|DRUG|Pembrolizumab|200 mg IV infusion
224010564|NCT04788043|PROCEDURE|PET/CT|Scan
224010565|NCT04730154|BEHAVIORAL|Pain Neuroscience Education (PNE)|PNE is a cognitive behavioural intervention, including educating patients that pain is an output product of the brain resulting from input from multiple central and peripheral nervous system processes and leading to threat perception. Transferring that knowledge to patients, allows them to understand, accept and effectively cope with their pain. In order to obtain the targeted behavioural change, motivational interviewing is used as the communication process throughout PNE.
224010566|NCT04730154|BEHAVIORAL|Motivational Interviewing (MI)|Motivational interviewing is a directive, collaborative, patient-centered communication approach for eliciting and enhancing motivation for behaviour change by helping clients to resolve ambivalence and uncertainty.
224010567|NCT04730154|BEHAVIORAL|Biomedically-focused education|The traditional biomedical-focused education programme explains patient's pain experience from a tissue (injured versus healthy tissue) and biomechanical perspective.
224010568|NCT06089096|DIAGNOSTIC_TEST|Home Sleep Apnea test (HSAT)|Patient will received HSAT at baseline
224010569|NCT05417958|OTHER|Extremely thick blenderized tube feed|Commercial blenderized tube feed, not diluted
224127099|NCT03827473|OTHER|Questionnaire Administration|Ancillary studies
224010570|NCT05417958|OTHER|Mildly thick blenderized tube feed|Commercial blenderized tube feed, diluted with ingredients contained in blend
224127100|NCT02167568|GENETIC|Genetic|
224127101|NCT04081844|DRUG|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
224127102|NCT04081844|DRUG|HGP0904|Amlodipine 5mg(Norvasc)
224127103|NCT04081844|DRUG|HGP0608|Losartan 100mg(Cozaar)
223389913|NCT03578302|DEVICE|BI Anterior Segment Mode|Single eye measurement in Anterior Segment Mode
223389914|NCT03578302|DEVICE|BI Anterior Segment and IOL Biometry Mode|Eye measurement 3 times with and without dilation in IOL biometry and Anterior Segment mode
223389915|NCT06668987|DRUG|B10 L-BPA Injection|The investigational product is B10 L-BPA Injection, is a boron-containing compound in which 10B replaces a position on L-phenylalanine at the para position with dihydroxyboron.
223389916|NCT05024773|DRUG|ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)|Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
223389917|NCT00324220|DRUG|MGCD0103|MGCD0103 Oral administration 3 times per week.
223389918|NCT02984371|PROCEDURE|Coronary artery bypass grafting|
223389919|NCT02984371|PROCEDURE|Epicardial ganglionated plexi ablation|
223389920|NCT02984371|PROCEDURE|implantable loop recorder|
223389921|NCT05248347|DEVICE|Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
223389922|NCT05248347|DEVICE|The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)|Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
224127104|NCT03468192|OTHER|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
224127105|NCT00875017|DRUG|Lanthanum Carbonate|1 x 1000mg tablet
224127106|NCT00875017|DRUG|Sevelamer|3 x 800mg tablets
224127107|NCT00377624|DRUG|sodium hyaluronate|
224127108|NCT03342469|OTHER|Artificial Food Coloring|225mg mixed powdered Artificial Food Coloring (AFC)
224127109|NCT03342469|OTHER|Placebo|Placebo chocolate cookies
224127110|NCT02767141|BEHAVIORAL|Coping Strategies|Coping strategies for households in the US with food insecurity
224127111|NCT02674581|DRUG|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
224127112|NCT04855123|OTHER|retinal imaging|OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer
224127113|NCT04855123|OTHER|paraclinical surveillance|blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)
223389923|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
223546145|NCT01222117|OTHER|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
224010571|NCT06211322|DEVICE|"Urika, a self-management application for patients with gout"|The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
224010572|NCT06260683|DRUG|Nicotine Replacement|Given nicotine patches and nicotine lozenges
224010573|NCT06260683|OTHER|Questionnaire Administration|Ancillary studies
224010574|NCT06260683|DEVICE|Vaping|Given Preferred Flavor e-liquid
224010575|NCT06260683|DEVICE|Vaping|Given Tobacco flavored e-liquid
224010576|NCT06417697|DRUG|XEN-101|capsule formulation
224010577|NCT06417697|DRUG|Placebo|capsule formulation
224010578|NCT04375072|DEVICE|active tDCS paired with active MBM|Active tDCS with a constant current intensity of 2 milli ampere( mA)will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
224010579|NCT04375072|DEVICE|sham tDCS paired with active MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2(milli ampere) mA current for 30 seconds. The meditation intervention will be applied simultaneously with tDCS for 20 minutes per session daily for 2 weeks by a recorded meditation.
224010580|NCT04375072|DEVICE|active tDCS paired with sham MBM|Active tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
224010581|NCT04375072|DEVICE|sham tDCS paired with sham MBM|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
224010582|NCT05597787|BEHAVIORAL|HIV Connect|online education and clinical skills
224010583|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention|education and clinical skills
224010584|NCT05597787|BEHAVIORAL|Project ECHO for HIV Prevention and Stigma Reduction|education, clinical skills and contact
224010585|NCT06520124|DEVICE|Essilor® Stellest® spectacle lens|Spectacle lens with highly aspherical lenslets.
224010586|NCT06520124|DEVICE|Single-vision spectacle lens|Standard single-vision distance spectacle lens.
224010587|NCT06222580|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223389924|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
223389925|NCT01205360|DRUG|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
223389926|NCT03972761|DEVICE|Magnetic Resonance Imaging (MRI) 3 tesla|Functional neuroimaging objectifies the activation of specific areas of the brain
223546146|NCT05337982|OTHER|Downhill Eccentric Treadmill Training with Electrical Stimulation|Participants will walk on a treadmill with a downward incline with support from a harness and assistance from trainers as needed. Participants will also simultaneously receive stimulation to their muscles including their trunk and legs. Each session will include 20 minutes of walking divided into 5 minute bouts with 5 minute rest breaks in between for 3 sessions per week for 12 weeks.
223546147|NCT01536028|DRUG|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
223546148|NCT01536028|DRUG|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
224010588|NCT06222580|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224010589|NCT06222580|DRUG|Gilteritinib|Given PO
224010590|NCT06222580|DRUG|Revumenib|Given PO
224010591|NCT04827901|DRUG|XEN1101|two 10 mg capsules
224010592|NCT04827901|DRUG|Placebo|matching placebo
224010593|NCT04512430|DRUG|Atezolizumab|"Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~* No premedication administered for atezolizumab specifically is permitted~* Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~* If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles \> 2 at the discretion of the treating physician.~* If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes."
224010594|NCT04512430|DRUG|Bevacizumab|Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
224010595|NCT04512430|DRUG|Carboplatin|"Structure: The cis-diamino (cyclobutan-1, 1 dicarboxilate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosaline or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion Patients will receive Carboplatin AUC6 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Guidelines of Carboplatin administration: According to the standard of each center"
224010596|NCT04512430|DRUG|Pemetrexed|"Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase.~Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrolo\[2,3 d\]pyrimidine-based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center"
224010597|NCT05598281|DRUG|AMG 510|Oral tablet
224010598|NCT05598281|DRUG|Digoxin|Oral tablet
224010599|NCT05453201|BEHAVIORAL|Long COVID Coping and Recovery (LCCR) Intervention|Veterans will participate in a LCCR (1x/week for a total of 16 sessions) via the HIPAA-compliant telehealth platform VA Video Connect (VVC) and/or VA WebEx with two co-therapists.
224010600|NCT04168970|PROCEDURE|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
224010601|NCT03798691|BIOLOGICAL|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
224010602|NCT03437395|DEVICE|Balloon Brachytherapy|The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
224010603|NCT03437395|RADIATION|3D Conformal External Beam Irradiation|3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
224010604|NCT01372839|DRUG|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
224010605|NCT01372839|DRUG|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
224010606|NCT05241353|BEHAVIORAL|Reduced Frequency Self-Monitoring|Participants will be asked to record only a subset of daily eating throughout the intervention, with the prescription for self-monitoring individually tailored at baseline dependent on participants' self-reported eating patterns.
224010607|NCT05241353|BEHAVIORAL|Full-Frequency Self-Monitoring|Participants will be asked to record all contents of their diet throughout the intervention.
224010608|NCT05241353|BEHAVIORAL|Standard Behavioral Treatment|Participants will receive four individual coaching calls over 12 weeks. During coaching calls, participants will receive guidance on lowering calorie intake, increasing physical activity and use of specific behavioral strategies to increase the probability of success with weight loss.
224010609|NCT03725111|DEVICE|venous compression|venous compression
224010610|NCT02944812|DRUG|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
224010611|NCT01115179|DRUG|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
224010612|NCT01115179|DRUG|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
224010613|NCT01115179|DRUG|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
224010614|NCT04419727|PROCEDURE|arterial reconstructive open surgery|Patients with peripheral artery disease (PAD) will undergo arterial reconstructive open surgery. Samples obtained from diseased arteries of lower limbs of patients undergoing arterial reconstructive open surgery will be collected and immediately preserved at -80°. Briefly, the arterial tissues will be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using Trizol reagent (Invitrogen, Milan Italy), according to the manufacturer's instructions. The expression of ER-alpha, ER-beta,and GPER will be quantified by real-time PCR using the Step One ™ sequence detection system (Applied Biosystems Inc. Milan, Italy), following the manufacturer's instruction
224010615|NCT04478136|DIAGNOSTIC_TEST|Blood test of factor levels|Blood draw from central line to check coagulation factors
224010616|NCT05371106|OTHER|exposure to mycotoxins|self-report eating questionnaire
224010617|NCT04155203|DRUG|Mupirocin Calcium|mupirocin cream
224010618|NCT04155203|DRUG|Mupirocin Calcium|Reference mupirocin cream
224010619|NCT04155203|DRUG|Vehicle|vehicle control cream
224127114|NCT04032496|BEHAVIORAL|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
224010620|NCT00576563|DRUG|FDG|contrast medium
224127115|NCT04032496|BEHAVIORAL|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
224010621|NCT03776708|OTHER|Spinal manipulation|Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain
224127116|NCT01477892|DRUG|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
224127117|NCT00409604|DEVICE|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
224127118|NCT01528800|DRUG|Vitamin K1|10mg orally three times a week for 12 months
224127119|NCT01528800|DRUG|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
223389927|NCT00004263|DRUG|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
223389928|NCT00004263|DRUG|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
223389929|NCT02297997|DRUG|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
223389930|NCT02297997|DRUG|Placebo|Control group takes the placebo for the same period.
223546149|NCT01536028|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
224010622|NCT03776708|OTHER|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires"
224010623|NCT05173389|OTHER|TechnoBody|"1\. Group-TechnoBody balance training (15 min / 5 days a week, 4 weeks) In the study, the first group will be included in the balance program with the TechnoBody device Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes"
224010624|NCT05173389|OTHER|Thera-Trainer|"2\. Group-Thera-Trainer balance training (15 min / 5 days a week, 4 weeks) the second group will be taken into the balance program with the Thera-Trainer device and the results of both groups will be compared after 4 weeks.~Patients will be applied 5 days of week~1. Exercise bike with visual feedback, which allows active-assisted or resistant work according to the condition of the patient, will be done in the lower limb for 10 minutes.~2. Nmes- (Neuromuscular electrical stimulation) will be applied to the hemiparetic limb for 10 minutes.~3. Bobath Method- 30 minutes"
224010625|NCT02489968|DRUG|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
224010626|NCT02489968|DRUG|empagliflozin 10 mg|empagliflozin low dose once daily
224010627|NCT02489968|DRUG|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
224010628|NCT02489968|DRUG|empagliflozin 25 mg|empagliflozin high dose once daily
224010629|NCT02489968|DRUG|Placebo|
224010630|NCT03011762|DEVICE|Computer controlled mandibular positioner|Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
224010631|NCT05359887|OTHER|standardized liquid mixed meal Nutridrink®|Administration of food in controlled situation
224010632|NCT04668040|OTHER|Muscle energy technique|Muscle energy technique for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of contraction was 10 sec, rest interval was 5 sec, stretch duration was 30 sec, number of repetition of stretch was 5, number of set was 1, frequency per week was 3
224010633|NCT04668040|OTHER|Stretching|Stretching exercises for illiopsoas, rectus femoris, erector spinae \& hamstrings muscles duration of stretch was 15 sec, rest interval was 5 sec, number of repetition was 5, number of set was 1, frequency per week was 3
224010634|NCT03539588|DEVICE|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
224127120|NCT02672319|PROCEDURE|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
223546150|NCT01536028|DRUG|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
224127121|NCT05336526|DEVICE|ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants|Bilateral brest augmentation in primary intention
224127122|NCT02714673|DRUG|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
224127123|NCT00791713|DRUG|Paliperidone ER|
224127124|NCT02361203|BEHAVIORAL|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
224127125|NCT01476176|DRUG|Experimental paracetamol|experimental paracetamol with caffeine
224010635|NCT03539588|DEVICE|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
224010636|NCT02844634|DRUG|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
224010637|NCT02844634|DRUG|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
224010638|NCT02844634|DRUG|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
224010639|NCT04224012|OTHER|Exercise and respiratory therapy|Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
224010640|NCT05785377|DRUG|Bupivacaine-Neostigmine|20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)
224010641|NCT05785377|DRUG|Bupivacaine|20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%
224010642|NCT01974778|DIETARY_SUPPLEMENT|Meal|Meal
224010643|NCT02296333|DRUG|ondansetron|8 mg intravenous in the skin closure
224010644|NCT02296333|DRUG|isotonic|8 mg intravenous in the skin closure
224010645|NCT04002843|OTHER|paraclinical evaluation of single fibre|ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
224010646|NCT00588900|DRUG|cediranib maleate|
224010647|NCT00588900|DRUG|irinotecan hydrochloride|
224010648|NCT02828787|OTHER|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night."
224010649|NCT05526651|OTHER|true electroacupuncture|the investigators use stainless steel acupuncture needle, disposable : Huanqiu® 0.25 x 0.40 mm Electroacupuncture device : Hwato-SDZ V®, continuous wave, 2 Hz, for 30 minutes
224010650|NCT05526651|OTHER|sham electroacupuncture|"the investigators use the same device like true electroacupuncture group, but the acupuncture needle not puncture on the skin and only attached.~electroacupuncture device, with no electrical stimulation"
224010651|NCT01279213|DRUG|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
224010652|NCT00816790|DRUG|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR \< 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
224127126|NCT01476176|DRUG|Paracetamol marketed formulation|marketed formulation containing caffeine
224299317|NCT00003708|DRUG|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
224010653|NCT00816790|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
224010654|NCT04996446|DRUG|Tislelizumab|In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, treated with Tislelizumab 2-4 weeks after stage I surgery, and receive ALPPS stage II surgery 2-4 weeks after Tislelizumab treatment, and treated with Tislelizumab q3W 6-12 months after stage II surgery.
224010655|NCT04996446|PROCEDURE|ALPPS surgery|In experimental group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 4-8 weeks after stage I surgery; In control group, patients who meet the inclusion criteria will receive ALPPS stage I surgery, and receive ALPPS stage II surgery 3-6 weeks after stage I surgery.
224127127|NCT00102505|DRUG|Motexafin Gadolinium Injection|
224127128|NCT04836143|DRUG|Intravitreal anti-vascular endothelial growth factor injection|Intravitreal injection of either ranibizumab or aflibercept
224127129|NCT01452126|DRUG|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
224127130|NCT01449357|DRUG|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
224127131|NCT03762122|DRUG|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
224127132|NCT02385825|BIOLOGICAL|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
224127133|NCT00086658|DRUG|mepolizumab|
224127134|NCT01967667|DIETARY_SUPPLEMENT|Liposomal glutathione|Escalating dose steps
224127135|NCT01967667|DIETARY_SUPPLEMENT|Placebo|escalating dose steps
224127136|NCT04969640|OTHER|Optical coherence tomography|Anterior segment optical coherence tomography examination of corneas with infective keratitis
224127137|NCT00465153|DIETARY_SUPPLEMENT|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
224127138|NCT00465153|BEHAVIORAL|Resistance exercise training|Resistance training
224010656|NCT01717742|DRUG|TPA (Tissue Plasminogen Activator)|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
224010657|NCT01717742|DRUG|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (\>10 kg) normal saline once daily for 3 days
224010658|NCT01717742|OTHER|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (\>10 kg)
224010659|NCT01865747|DRUG|Cabozantinib tablets|
224010660|NCT01865747|DRUG|Everolimus (Afinitor) tablets|
224010661|NCT02592876|DRUG|denintuzumab mafodotin|Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
224010662|NCT02592876|DRUG|rituximab|375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
224010663|NCT02592876|DRUG|ifosfamide|5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
224010664|NCT02592876|DRUG|carboplatin|AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
224010665|NCT02592876|DRUG|etoposide|100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
224010666|NCT04196127|OTHER|Bite force testing|Maximum bite force examination with a force intra-oral measuring device
224010667|NCT06215885|DIAGNOSTIC_TEST|Mass spectrometry-based proteomics|Detecting genomic and proteomic information
224127139|NCT06146712|OTHER|Asutra's 'Dream the night away' nighttime lotion|Product contains Water (Aqua), Magnesium Chloride, Dimethyl Sulfone (MSM), Prunus Amygdalus Dulcis (Sweet Almond) Oil, Butyrospermum Parkii (Shea Butter), Sodium Lactate, Cetearyl Alcohol, Glyceryl Stearate Citrate, Glycerin, Undecane, Cetyl Palmitate, Polyglyceryl-3 Diisostearate, Pentylene Glycol, Glyceryl Stearate, Magnesium Sulfate, Melatonin, Tridecane, Potassium Chloride, Sodium Chloride, Calcium Chloride, Tocopheryl Acetate, Xanthan Gum, Hydroxyacetophenone, Sodium Hydroxide, Cymbopogon Flexuosus (East-Indian Lemongrass) Oil, Citral, Geraniol, Linalool
223389931|NCT01652547|DRUG|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
224010668|NCT04527432|OTHER|Survey|Survey at baseline, 6 and 12 months
224010669|NCT04527432|DIAGNOSTIC_TEST|SARS-CoV-2 antibody test|SARS-CoV-2 antibody test results and testing again at 6 and 12 months
224010670|NCT01464775|OTHER|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
224010671|NCT01464775|OTHER|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
224010672|NCT02859740|OTHER|SIGAM Questionnaire|
224010673|NCT00611975|DRUG|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
224010674|NCT00611975|DRUG|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
224010675|NCT05609903|DRUG|Atezolizumab in combination with nab-paclitaxel|Treatment of patients with stage IV triple negative breast cancer with Atezolizumab in combination with nab-paclitaxel
224010676|NCT03066349|OTHER|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
224010677|NCT04299022|OTHER|Vivigen Cellular Bone Matrix|Allograft bone matrix
224010678|NCT01970722|DRUG|Carboplatin|Given IP or IV
224010679|NCT01970722|DRUG|Cisplatin|Given IP
224010680|NCT01970722|DRUG|Gemcitabine Hydrochloride|Given IP or IV
224010681|NCT01970722|OTHER|Laboratory Biomarker Analysis|Correlative studies
224010682|NCT01970722|DRUG|Paclitaxel|Given IP or IV
224010683|NCT01970722|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IP or IV
224010684|NCT01970722|OTHER|Quality-of-Life Assessment|Ancillary studies
224010685|NCT01970722|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224010686|NCT03465904|DEVICE|Verum Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.
224010687|NCT03465904|DEVICE|Sham Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
224010688|NCT01916148|DRUG|18F-DOPA|18F-DOPA is a PET (Positron Emission Tomography) scan radiotracer.
224010689|NCT06430476|OTHER|EMI|A phone-based intervention containing exercises meant to reduce ruminative thoughts carried out on an experience sampling platform m-Path
224010690|NCT06430476|OTHER|EMA|A phone-based exercise containing relaxation videos carried out on an experience sampling platform m-Path
224127140|NCT04517617|OTHER|The level of air pollution|The intervention measure is the level of air pollution, it is a non-human interventional measure based on the weighted average of various air pollutants monitored by air pollution monitoring stations during different period of pregnancy.he perinatal period.
224127141|NCT01081223|BIOLOGICAL|Cancer vaccine plus immune adjuvant|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
223546151|NCT05089552|OTHER|1-WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale|WHOQOL-BREF(WHO-Quality of life-BREFF) Arabic version Scale The WHOQOL-BREF is composed of 26 self-administered items. Using a 5-point Likert response scale ranging from 1 (very dissatisfied/very poor) to 5 (very satisfied/very good), family caregivers were asked to rank each item accordingly. Caregivers were asked to respond to the items indicating their assessment of QOL during the preceding 2 weeks, Ohaeri and Awadalla developed and tested the Arabic version of the WHOQOL-BREF among an Arab population in Kuwait. The translated Arabic WHOQOL-BREF has considerable reliability and validity indices . As reported in the Kuwaiti study, a satisfactory (≥0.7) Cronbach's alpha was reported for the full questionnaire and the domains
223546152|NCT05089552|OTHER|SCL-90-R(Symptoms Checklist-90-Revised) Arabic version scale|"developed by Derogatis et al. and El-Behairy. established the validity and reliability of the Arabic version.SCL-90-R is a 90-item self-report symptom inventory, and reflect the psychologic symptom pattern of psychiatric and medical patients. Each item of the 90 is rated on a five-point scale of distress (0-4), ranging from not at all to extremely.Under usual circumstances, SCL-90-R requires between 12 and 15 minutes to be completed.SCL-90-R is a measure of the current psychologic symptom status. It is not a measure of personality, except indirectly, in that certain personality disorders may manifest a characteristic profile on the primary symptom dimensions."
224010691|NCT05962554|BEHAVIORAL|iJobs|iJobs is a 2-week intervention consisting of 5 modules focusing on discovering job skills, job search strategies, preparing effective resumes, exercising different types of interviews, and overcoming setbacks in the job search process. This is an adaptation of the JOBS program.
224010692|NCT05167669|DEVICE|HIFU-MRI guided|HIFU application under MRI guiding to deliver hypothermia to eligible bone metastases before clinical indicated radiotherapy
224010693|NCT06472336|PROCEDURE|Intracranial stenting|Intracranial stenting (+/- balloon dilatation) will be performed. Decisions regarding intracranial stenting are solely made by the treating physician. This means in specific, that the treating physician decides based on his/her judgement or based on local standards (as reported in the literature) on the devices and/or concomitant medications (including infusion/administration of antiplatelet medicine) used for intracranial stenting.
224010694|NCT06472336|PROCEDURE|Continuation of conventional endovascular therapy (EVT)|Patients undergo either (a) continued stent retriever or contact aspiration based endovascular treatment manoeuvres, (b) infusion/administration of antiplatelet medication or (c) stop of the procedure depending on local standard treatment approaches.
224127142|NCT06276608|DIAGNOSTIC_TEST|Iron status|Iron status will be based on preoperative ferritin levels: a ferritin \< 10 mcg/L will be considered as iron deficiency, ferritin levels \> 10 mcg/L will be considered normal
224127143|NCT02391506|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
224127144|NCT03393364|DRUG|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
224127145|NCT03393364|DRUG|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
224127146|NCT02187094|DRUG|TC-6499|
224127147|NCT02187094|DRUG|Placebo|
224127148|NCT05515601|DRUG|Mirikizumab|Administered SC.
224127149|NCT00777491|DRUG|induction cisplatin|15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
224299318|NCT03591523|DIAGNOSTIC_TEST|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
223389932|NCT01652547|DRUG|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
223389933|NCT06623994|BEHAVIORAL|Task sharing with Epilepsy Medical Record Systems|Training multiple cadres of healthcare workers in epilepsy treatment and management to enable a team-based approach to address access to care. Task sharing will be supported by epilepsy medical records system with patient tracking data to support care retention
223389934|NCT07003724|OTHER|Questionaire|Questionnaire evaluating level of awareness of patients towards using AI in dentistry
223389935|NCT07005414|DRUG|Bumetanide|Participants will receive bumetanide (0.5mg bid) for a period of three months.
224127150|NCT00777491|DRUG|induction 5-fluorouracil|400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
224127151|NCT00777491|DRUG|induction gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
224127152|NCT00777491|RADIATION|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
224127153|NCT00777491|RADIATION|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
224127154|NCT00777491|RADIATION|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
224127155|NCT00777491|RADIATION|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
224296363|NCT05080647|BEHAVIORAL|Mightier online gameplay|"Mightier is a video-game-based biofeedback intervention that capitalizes on children's love of video games to increase emotional awareness and facilitate emotion regulation practice through heart rate (HR) control. Each family receives a Mightier Kit (Mighty Band heart rate monitor, dedicated Mightier tablet unless the family prefers to use their own device) and the Mightier App. Children wear a Mighty Band heart rate monitor on their arm while they play any one of 26+ games. As their heart rate rises the games become more difficult. For example, during a cooking game, smoke may appear on the screen and obscure the player's view. Children can either opt into an explicit cool down activity (deep breathing, progressive muscle relaxation, crossing the midline, or visualization) or cool down on their own. By simply playing Mightier, children are motivated to practice calming strategies in moments of challenge."
223546153|NCT05089552|OTHER|addiction severity index|a semi-structured interview that takes approximately 45 minute. developed to evaluate treatment outcome in substance abusers. The instrument focuses on seven areas that are typically affected in the lives of substance abusers: medical status, employment, drug use, alcohol use, legal status, family/social status, and psychiatric status. Information regarding frequency, duration, and severity of problems in these seven areas is collected for both lifetime and recent (past 30 days) history. The ASI provides two types of scores: severity and subjective ratings of the client's need for treatment, and composite scores of problem severity during the prior 30 days. Specific alcohol-related questions include total lifetime years of use, money spent on alcohol, and number of days that alcohol problems are experienced.
224010695|NCT03696797|PROCEDURE|Blood Donation|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
224010696|NCT03696797|PROCEDURE|Sham Blood Donation|Participants will have a needle inserted their arm, however, no blood will be drawn.
224010697|NCT05397691|OTHER|Modified Family Talk|The Modified Family Talk intervention consists of six modules, each lasting approximately 60 minutes. Family Talk is intended to be delivered over a period of 12 weeks, with meetings occurring every 1-2 weeks.
224010698|NCT05397691|OTHER|Control-like parameter estimation|Parameter estimation is designed to emulate best practices around comprehensive, high quality, patient-centered care for adults and youth. Participants will have access to collaborative adult Office Based Addiction Treatment (OBAT) clinical services, multidisciplinary adolescent primary care clinics with co-located adolescent substance use specialists, high quality social work services, integrated behavioral health, and access to patient navigators for assistance connecting to community resources.
224010699|NCT05816538|PROCEDURE|Paravertebral nerve block (PVB)|PVB is a regional anesthetic technique applied at the thoracic (Th) level of Th2, Th3, and Th4 at a dose of 0.3ml/kg 0.5% levobupivacaine total, divided into levels. Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
224010700|NCT05816538|PROCEDURE|Pectoralis and Serratus Plane Nerve Blocks (PECS 2)|Pectoralis and Serratus Plane Nerve blocks (PECS 2) is a regional anesthetic technique applied in the space between the large and small pectoral muscles (10 ml of 0.5% levobupivacaine), and in the space between the small pectoralis muscle and the serratus anterior muscle (with 15 ml of 0.5% levobupivacaine). Block will be performed with ultrasound-guided in-plane technique and neurostimulation.
224010701|NCT05816538|DEVICE|Regional anesthetic technique with ultrasound guidance|The device that will be used is an ultrasound with an 8 Hz ultrasonic linear probe for both regional anesthetic techniques.
224010702|NCT05816538|DEVICE|Regional anesthetic technique with peripheral nerve stimulation.|The 22G neurostimulator needle (Stimuplex D®, B. Braun Melsungen AG)\], and neurostimulator (Stimuplex HNS 12, B. Braun, Melsungen AG, Germany) will be used for both regional anesthesias.
224010703|NCT05816538|DRUG|Levobupivacaine 0.5%|Local anesthetic levobupivacaine 0.5% will be used for regional anesthetic technique with ultrasound guidance and peripheral nerve stimulation. For the paravertebral block at a dose of 0.3ml/kg total, applied at the thoracic (Th) level of Th2, Th3, and Th4 and divided into levels. For the PECS 2 block levobupivacaine 0.5% 10 ml will be applied in the space between the large and small pectoral muscles and 15 ml in the space between the small pectoralis muscle and the serratus anterior muscle.
224010704|NCT05816538|PROCEDURE|General anesthesia|In both groups for induction of general anesthesia we will use 1% propofol 2 - 2.5 mg/kg (10 mg/ml, Fresenius), sufentanil (Sufentanil® Altamedics) 0.2 μg / kg, rocuronium \[Zemuron®, Schering - Plow\] 0.8 mg/kg. We will use a laryngeal mask (I - gel supraglottic airway) of appropriate sizes for airway maintenance. All subjects will be ventilated by controlled mechanical ventilation with a volume of 8 ml/kg, a frequency of about 12 breaths per min with a mixture of oxygen and air in a 40: 60% ratio. Maintenance of anesthesia and sedation in group 1 will be performed with continuous infusion of 1% propofol (10 mg / ml, Fresenius) (25 - 150 mcg / kg / min.) and rocuronium \[Zemuron®, Schering - Plow\] 0.01 mg / kg / min per perfusor.
224127156|NCT00777491|DRUG|consolidation gemcitabine|27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
224127157|NCT00777491|DRUG|consolidation 5-fluorouracil|400 mg/m\^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
224127158|NCT00777491|DRUG|consolidation cisplatin|15 mg/m\^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
224127159|NCT00777491|PROCEDURE|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
224127160|NCT00777491|PROCEDURE|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
224127161|NCT00777491|DRUG|adjuvant gemcitabine|1000 mg/m\^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
224127162|NCT00777491|DRUG|adjuvant cisplatin|70 mg/m\^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
224127163|NCT00398710|DRUG|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
224127164|NCT04398849|BIOLOGICAL|Licenced 4CMenB Vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 2 months apart to be given to consenting 14-19 year olds
223389936|NCT07005414|BEHAVIORAL|Treatment as usual (TAU)|Participants will undergo treatment as usual, such as behavioral interventions
223389937|NCT03047161|DEVICE|fetal MCG|assess fetal heart rate and rhythm
223389938|NCT07006077|BIOLOGICAL|Recombinant human IL-21-expressing oncolytic vaccinia virus injection|hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
223389939|NCT06866288|BEHAVIORAL|Meditation|Each person will participate in seated meditation, then walking meditation, then return to seated meditation.
223389940|NCT06866288|BEHAVIORAL|Yoga|Each person will participate in a yoga sessions.
223389941|NCT04813276|BEHAVIORAL|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants receive weekly notifications for 12 weeks alerting them that a new serious game session is available and encourage them to complete one session per week.
223389942|NCT04813276|BEHAVIORAL|Enhanced Care as Usual|A self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
223389943|NCT07011927|DEVICE|Cochlear Implant|Eligible Cochlear Americas devices eligible for inclusion in this study include any Cochlear Americas device that has two ground electrodes.
223389944|NCT07011927|DEVICE|Modified Implant Procedure|Implant procedure will be modified to place ground electrode (ECE1) near Arnold's nerve.
223389945|NCT07012967|OTHER|Kinesiology Taping|"For thoracic kinesiology taping (KT), a 5 cm wide, 100% cotton, latex-free elastic tape will be used. Application sites will follow the technique and principles described by Kase. Participants will sit upright in an armless chair with knees at 90° flexion, feet flat on the floor, and arms relaxed.~The tape will be applied to the front and back of the body to facilitate respiratory muscles, primarily the diaphragm. On the anterior side, an I-shaped strip will be applied with 50-75% tension at the xiphoid process along the linea alba, and the tails will be laid over the subcostal area without tension. Posteriorly, another I-shaped strip will be applied from the projection of the 12th thoracic vertebra with 50-75% tension, and the ends placed toward the ribs without tension. Additionally, two more strips will be applied to the upper trapezius region between the neck and acromion bilaterally."
223389946|NCT07012967|OTHER|Diaphragmatic Breathing Exercises|Participants in the control group will receive diaphragmatic breathing exercises. Exercises will be taught and supervised by a physiotherapist. Sessions will be conducted twice weekly for four weeks, and participants will be instructed to continue home practice between sessions.
223389947|NCT07010627|PROCEDURE|Auriculotherapy for chronic pain treatment with laser stimulation of acupoints using red light|"This arm of the study will analyze the effectiveness of the treatment protocol for chronic pain in the shoulder, knee, or lumbar spine region in elderly individuals, using the application of laser acupuncture with low-power laser and red light on acupoints of Auriculotherapy.~As a criterion for the qualitative evaluation of the study, the McGill questionnaires (Annex A) and the Visual Analog Scale (Annex B) will be used to assess chronic pain, while the SF-36 instrument (Annex C) will allow for the evaluation of participants' quality of life before and after the treatment protocol.~For quantitative evaluation, thermographic images and the Ryodoraku System will be used. All proposed tools will be applied before the first treatment session (A1), before the fifth session (A2), and at the end of the tenth session (A3)."
223389948|NCT07010627|PROCEDURE|"Auriculotherapy for chronic pain treatment with stimulation of acupoints using mustard seeds."|"This arm of the study will analyze the effectiveness of the treatment protocol for chronic pain in the shoulder, knee, or lumbar spine regions in elderly individuals, utilizing the application of mustard seeds on Auriculotherapy acupoints.~As criteria for the qualitative evaluation of the study, the McGill questionnaires (Annex A) and the Visual Analog Scale (Annex B) will be used to assess chronic pain, while the SF-36 instrument (Annex C) will allow for the evaluation of participants' quality of life before and after the treatment protocol.~For quantitative evaluation, thermographic images and the Ryodoraku System will be utilized. All proposed tools will be applied before the first treatment session (A1), before the fifth session (A2), and at the end of the tenth session (A3)"
223546154|NCT06035172|BEHAVIORAL|guided imagery|The guided imagery technique, which is one of these methods, is used in the method of pain by establishing a connection between mind and body. In the technique, a peaceful scene is depicted in which positive energy is reflected in the person to ensure complete relaxation and relaxation.
224127165|NCT04176432|OTHER|No intervention|Retrospective observational study with no intervention
224127166|NCT01801137|DRUG|Everolimus (Afinitor®)|
224127167|NCT03152916|DEVICE|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
224127168|NCT00088634|DRUG|Lurasidone|80 mg AM dosing once daily
224127169|NCT00088634|DRUG|Placebo|Matching Placebo to 40mg lurasidone tablets
224127170|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily
224127171|NCT02150824|DRUG|Placebo|BI 187004 medium dose matching placebo once daily
224127172|NCT02150824|DRUG|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
224127173|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily add on to background metformin
224127174|NCT02150824|DRUG|Placebo|BI 187004 low dose matching placebo once daily
224127175|NCT02150824|DRUG|BI 187004|BI 187004 medium dose once daily
224127176|NCT02150824|DRUG|BI 187004|BI 187004 low dose once daily
224127177|NCT02150824|DRUG|BI 187004|BI 187004 high dose once daily
224127178|NCT04671914|DRUG|Hyaluronic Acid 20 MG/ML Injectable Solution|Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C
224127179|NCT04671914|OTHER|Dilation and curretage|After abortion in II trimester we do D\&C.
224127180|NCT01803763|DRUG|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
224127181|NCT01803763|DRUG|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
224010705|NCT06414603|DIAGNOSTIC_TEST|The Prospera™ Test|"The Prospera™ test is a non-invasive test intended to detect and quantify the fraction of donor-derived cell-free DNA (dd-cfDNA) to supplement management and surveillance of allograft rejection in patients who have undergone organ transplantation. It employs Next Generation Sequencing (NGS), which is performed on cell-free DNA (cfDNA) that is extracted from the patient's plasma to discriminate between the patient's DNA and the solid organ-allograft DNA.~In study 23-069-TRP, the Prospera test is indicated for heart allograft rejection surveillance in lieu of surveillance endomyocardial biopsy. Prospera results should be considered together with clinical evaluations and other diagnostic testing or imaging results. Prospera will be run as a centralized laboratory developed test that is developed and validated under Design Controls. The test will be run within Natera's CLIA-certified and CAP-accredited laboratory."
224010706|NCT05119179|DRUG|Semaglutide|Glucagon-like Peptide 1 Receptor Agonist
224010707|NCT05997199|DIETARY_SUPPLEMENT|Vitamin D replacement|Group 1 with vitamin D deficiency will be getting a standart vitamin D replacement of 50.000 IU/week for 8 weeks.
224010708|NCT05924438|DRUG|Delstrigo|Treatment Group 1 Participants will receive Doravirine, as part of a fixed-dose oral combination with lamivudine and tenofovir disoproxil fumarate (DOR/3TC/TDF, Delstrigo)tablets which are to be administered orally and once daily.
224010709|NCT05924438|DRUG|KOCITAF|Treatment Group 2 Participants will receive dolutegravir, as part of a fixed-dose oral combination with tenofovir alafenamide plus emtricitabine (DTG/TAF/FTC, KOCITAF) tablets which are to be administered orally and once daily.
224010710|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at ET|Ultrasound scan
224010711|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at HCG|Ultrasound
224010712|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at TVOR|Ultrasound
224010713|NCT03860636|DIAGNOSTIC_TEST|Endometrial Pattern on Ultrasound at co-ordination scan|Ultrasound
224010714|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at HCG|Ultrasound
224010715|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at TVOR|Ultrasound
224010716|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at ET|Ultrasound scan
224010717|NCT03860636|DIAGNOSTIC_TEST|Endometrial thickness at coordination scan|Ultrasound scan
224010718|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at HCG|Ultrasound scan
224010719|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at TVOR|Ultrasound scan
224010720|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at ET|Ultrasound scan
224127182|NCT01592279|DRUG|liraglutide|
224127183|NCT01592279|DRUG|Insulin injections|
224127184|NCT06227390|PROCEDURE|partial pulpotomy|2-3 mm of the coronal pulp tissue is removed leaving healthy vital pulp tissue that is dressed with a dental biomaterial that maintains pulpal vitality and promotes repair
224127185|NCT06674096|DRUG|RLC-CRCHOP|"Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:~rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.~Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.~maintenance treatment period: chidamide d1,4,8,11"
224010721|NCT03860636|DIAGNOSTIC_TEST|Endometrial volume at coordination scan|Ultrasound scan
224010722|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at HCG|Blood test
224010723|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at TVOR|Blood test
224010724|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at ET|Blood test
224010725|NCT03860636|DIAGNOSTIC_TEST|Blood test for progesterone at coordination scan|Blood test
224010726|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between TVOR and ET|Ultrasound scan
224010727|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at HCG|Blood test
224010728|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at TVOR|Blood test
224010729|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at ET|Blood test
224010730|NCT03860636|DIAGNOSTIC_TEST|Blood test for estradiol at coordination scan|Blood test
224010731|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at HCG|Ultrasound scan
224010732|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at TVOR|Ultrasound scan
224010733|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at ET|Ultrasound scan
224010734|NCT03860636|DIAGNOSTIC_TEST|Endometrial blood flow (doppler) at coordination scan|Ultrasound scan
224010735|NCT03860636|DIAGNOSTIC_TEST|Contractility at embryo transfer on a subgroup of participants|Ultrasound scan
224010736|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between coordination scan and ET|Ultrasound scan
224010737|NCT03860636|DIAGNOSTIC_TEST|Change in endometrial pattern between HCG and ET|Ultrasound scan
224010738|NCT04423523|DIAGNOSTIC_TEST|Blood drop sampling|For each patient included, 1 additional EDTA blood tube (2 ml) will be collected for research purposes at different times (4 visits), and 1 PAXgene-type tube adapted for pediatric collection of only 500 μl (2 visits).
224010739|NCT06115603|DRUG|Cannabigerol|1 mL of 80mg Cannabigerol once during experimental session
224010740|NCT06115603|OTHER|Placebo|1 mL of placebo once during experimental session
224010741|NCT05087758|OTHER|Matrion|Decellularized placental membrane applied to Wagner 1 and 2 diabetic foot ulcers
224010742|NCT05087758|OTHER|Conventional Care Wound Management|Advanced wound care with debridement and dressings
224010743|NCT05543382|DEVICE|Axonics System|The Axonics System will be implanted as standard care
224010744|NCT05284695|PROCEDURE|Bariatric surgery|Patients undergoing elective bariatric surgery
224010745|NCT03342833|DEVICE|Blood flow restriction|Occlusion of venous flow between bouts of HIIT training exercise
224010746|NCT03621787|DEVICE|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
224010747|NCT05339386|DRUG|Hyperpolarized Xe129|Lung MRI using gaseous contrast agent hyperpolarized 129Xe.
224127186|NCT00540436|DRUG|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
224127187|NCT04292405|DEVICE|Wearable Cardioverter Defibrillator|Use of the Wearable Cardioverter Defibrillator and AUDICOR AM to evaluate accuracy of cardiac acoustic biomarker recordings.
224127188|NCT00398151|DRUG|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
223389949|NCT07011537|BEHAVIORAL|Digital Musculoskeletal (MSK) Program|"Hinge Health is a digital MSK program to help participants manage chronic MSK pain through offering exercise therapy sessions, educational articles, and personal health coaching. Hinge Health delivers exercise therapy sessions and education through playlists accessed through the program app. Each playlist consists of three to seven exercises specific to the body region(s) the participant experiences pain in. Animations and videos, while paired with sensors and computer vision, demonstrate how to perform exercises, the number of repetitions for each exercise, and how long to hold positions. Playlists present more challenging exercises and/or more repetitions as participants progress further along in the program. After participants complete the exercises, the playlist delivers educational articles and resources focused on MSK pain-related topics, including lifestyle changes, pain neuroscience, and social support."
224010748|NCT06342479|BEHAVIORAL|Discharge Education|Discharge education will be provided.
224010749|NCT01305200|DRUG|supersaturated calcium phosphate rinse|Mouth rinse
224010750|NCT01305200|OTHER|placebo|Mouth rinse
224010751|NCT01305200|OTHER|questionnaire administration|Ancillary studies
224010752|NCT01305200|PROCEDURE|quality-of-life assessment|Ancillary studies
224010753|NCT04639297|DEVICE|NeuroVision® IONM|Using NeuroVision® prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
224127189|NCT01884454|BEHAVIORAL|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
224127190|NCT05362851|DRUG|YYC301-1 & YYC301-2 & YYC301-3|"YYC301-1: Subjects take the investigational products once a day~YYC301-2: Subjects take the investigational products once a day~YYC301-3: Subjects take the investigational products once a day"
224296364|NCT03182582|DEVICE|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
224296365|NCT03182582|PROCEDURE|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
224296366|NCT04463290|OTHER|No intervention, Patients selection based on clinical symptoms and radiological imaging|No intervention
224296367|NCT00449826|PROCEDURE|Computed Tomographic Angiography|CT scan
224296368|NCT03631082|OTHER|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
224296369|NCT03631082|OTHER|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
224296370|NCT00266357|DRUG|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
224296371|NCT00266357|DRUG|Placebo / Duration of Treatment: 2 days for screening period|
224296372|NCT03814330|DIAGNOSTIC_TEST|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
224296373|NCT03814330|DIAGNOSTIC_TEST|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
224296374|NCT03814330|OTHER|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
224296375|NCT03814330|DEVICE|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
224296376|NCT03218163|DRUG|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
224010754|NCT04639297|DEVICE|Hospital Based IONM|Using hospital based IONM prior to surgery SSEP and tcMEP and values are recorded. A deficit of SSEP tracking is defined as an amplitude reduction of more than 10% or a latency increase more than 50%. Similarly, a CMAP amplitude reduction demonstrates problematic tcMEP monitoring.
224010755|NCT01828905|DEVICE|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
224010756|NCT01828905|PROCEDURE|Autologous cancellous bone graft|autologous cancellous bone graft
224010757|NCT06658405|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine, Recombinant|HPV vaccine administered in three doses: first dose on day 1, second dose 2 months later, and third dose 4 months after the second dose, within a one-year period.
224010758|NCT06609109|DRUG|THC High Dose|Low dose of THC (30 mg)
224127191|NCT05362851|DRUG|YYC301 placebo & Celecoxib 200mg|comparator medication
224127192|NCT03255291|BEHAVIORAL|Risk Assessment App|The App provides participants with personalized risk results for colon cancer, breast cancer (women), heart disease, diabetes, and stroke.
224296377|NCT04378517|OTHER|psychosocial education in parents groups|psychosocial education
224296378|NCT04378517|OTHER|psychosocial parents support, interviews with APN|Family strength-oriented therapy conversation
224296379|NCT00933517|DRUG|vectibix|9mg/kg at D1 of each 21-days cycle
224296380|NCT00933517|DRUG|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
224296381|NCT00933517|DRUG|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
224296382|NCT00933517|DRUG|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
224296383|NCT00933517|DRUG|docetaxel|100 mg/m2 at D1 of each 21 days cycle
224296384|NCT04461119|DRUG|Evenamide|oral capsules for 4 weeks of treatment
224296385|NCT04461119|DRUG|Placebo|oral capsules for 4 weeks of treatment
224010759|NCT06609109|DRUG|THC Low Dose|Low dose of THC (5 mg)
224010760|NCT06609109|DRUG|THC 0mg|Placebo dose of THC (0 mg)
224010761|NCT06609109|DRUG|E-Cigarette Full Nicotine|E-Cigarette with Nicotine
224010762|NCT06609109|DRUG|E-Cigarette Placebo Nicotine|E-Cigarette with No Nicotine
224010763|NCT05917028|DEVICE|Transcatheter Arterial Micro-Embolization|Participants will undergo TAME with Nexsphere-F.
224010764|NCT07165002|DRUG|LY3537031|Administered SC
224010765|NCT07169851|DRUG|LY3537021|Administered SC
224010766|NCT07169851|DRUG|Placebo|Administered SC
224010767|NCT07169851|DRUG|Standard of Care Antiemetic Therapies|5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally
224010768|NCT07169851|DRUG|Background Chemotherapy|Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV
224010769|NCT07167966|DRUG|AADvac1|Subcutaneous injection of AADvac1
224010770|NCT07167966|DRUG|Anti-amyloid Monoclonal Antibody (mAb)|Active comparator: intravenous infusion of an anti-amyloid mAb
224296386|NCT05789719|BIOLOGICAL|STEM-OA|Combination of autologous or allogeneic MSC(AT)s and fat
224296387|NCT00123955|DRUG|Spironolactone|25mg tablet daily for 9 months
224296388|NCT00123955|DRUG|Placebo|Placebo tablet daily for 9 months
224296389|NCT00270049|DRUG|epoetin alfa|
224296390|NCT00692718|DRUG|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
224296391|NCT04356118|DRUG|Recombinant Human Endostatin|endostatin 7.5mg/㎡/d，Once a day for two weeks, take a week off,start the next cycle, up to four cycles .We advocate a highly individualized treatment plan according to each patients specific manifestations of the disease process.
224296392|NCT04356118|DRUG|intrathcal methotrexate|Intrathecal chemotherapy specified dose on specified days.
223389950|NCT07011537|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|The Enso is a strong complement/enhancement to the Hinge Health program, as it helps users to better manage their pain in order to work through their exercise sessions in the program. The Enso device is not intended to be a stand-alone solution; it provides pain relief, but exercise therapy provides important long-term benefits. Participants will use the digital MSK program (Hinge Health) in combination with a pain management device (Enso).
223389951|NCT07011537|OTHER|Standard of Care (SOC)|The control group will continue to receive the access to traditional medical care for their MSK needs through their healthcare provider. Upon study completion, control group members who complete all follow-up surveys will receive Hinge Health membership and an Enso device for free for 12 months, starting at the conclusion of their participation in the study.
223389952|NCT07013071|DRUG|2% Mepivacaine with 1:100,000 epinephrine|A standard vasoconstrictor-containing local anesthetic used in dental procedures to minimize bleeding and prolong anesthetic effect.
223389953|NCT07013071|DRUG|2% Mepivacaine with 1:55,000 Epinephrine Bitartrate|An alternative formulation of vasoconstrictor-containing local anesthetic evaluated for its safety and analgesic effectiveness in dental extractions.
223389954|NCT03888963|PROCEDURE|PRF|patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
223389955|NCT03888963|PROCEDURE|SHAM|patients will be subjected to the same procedure like PRF group without giving PRF
223546155|NCT06035172|BEHAVIORAL|music recital|It is stated that the acemasiran tune (instrumental music) has a reducing effect on the duration of labor, as well as having labor pain and muscle relaxant properties.
223546156|NCT00810277|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
224010771|NCT07167862|DIAGNOSTIC_TEST|Butterfly iQ3 ultrasound system for determination of postpartum volume status|"A trained study staff member will perform point-of-care ultrasound (POCUS) of the lungs and the inferior vena cava (IVC). All POCUS assessments will be performed using either the curvilinear or phased array settings on a portable Butterfly iQ3 ultrasound system. Images obtained via the Butterfly iQ3 ultrasound system will be labeled according to the subject's unique identification number and transmitted directly to a digital study archive. The lead investigator or physician of record will review all captured ultrasound images to ensure that an appropriate therapy is selected moving forward.~Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider."
224010772|NCT07167862|DRUG|Oral furosemide|Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The first cohort of 48 patients will be treated with oral furosemide 20mg daily and oral potassium chloride 40mEq daily for a total of 5-days. As patients delivered vaginally are typically discharged 2-3 days after birth and delivered via cesarean are typically discharged 4-5 days after birth, patients who have not yet completed the medication course by the time of planned discharge will be prescribed the remainder of their medications before departing the hospital.
224010773|NCT07167862|DRUG|Intravenous furosemide|Any subject who is confirmed to have 3 or more B-lines, a maximum IVC diameter above 2.0cm, or an IVC collapsibility index less than 15% on POCUS will become a candidate for diuretic therapy, which will be ordered by the patient's primary inpatient provider. The second cohort of 48 patients will be treated with a single dose of intravenous furosemide 40mg and oral potassium chloride 40mEq on postpartum day 1.
224010774|NCT07172672|DIETARY_SUPPLEMENT|400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer|400 mL Fresubin Energy Drink and 100 mL heavy cream with the addition of the 18F-FTHA radiotracer
224010775|NCT07174986|DEVICE|Double sequential defibirllation|A second defibrillator will be applyed with electrodes placed in the A-P position and defibrillation will be performed with two defibrllators in a sequential manner
224010776|NCT07174986|DEVICE|Standard defibrillation|Standard defibrillation uning one defibrillator
224010777|NCT07174336|DRUG|LY4064809|Administered orally
224010778|NCT07174336|DRUG|Placebo|Administered orally
224010779|NCT07174336|DRUG|Ribociclib|Administered orally
224296393|NCT04356118|DRUG|Targeted drugs for non-small cell lung cancer|EGFR Mutation: Erlotinib，Afatinib，Osimertinib, et al. ALK ROS1 Mutation:Crizotinib,Ceritinib,Alectinib ,et al. BARF Mutation:Vemurafenib,et al. Other Mutation: other Targeted drugs .
224296394|NCT01418482|DEVICE|Mepilex Border Ag|a silver dressing
224010780|NCT07174336|DRUG|Palbociclib|Administered orally
224010781|NCT07174336|DRUG|Abemaciclib|Administered orally
223730395|NCT01741922|DRUG|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
224010782|NCT07174336|DRUG|Anastrozole|Administered orally
224010783|NCT07174336|DRUG|Letrozole|Administered orally
224010784|NCT07174336|DRUG|Exemestane|Administered orally
224127193|NCT03255291|BEHAVIORAL|Audio Recording - Sleep|-Participants imagine themselves improving sleep hygiene
224127194|NCT03255291|OTHER|Surveys|Assesses information comprehension, intentions, perceived risk and severity worry, self- efficacy, response efficacy, affect, race, education, age, numeracy, graph literacy, and exercise and sleep behaviors.
224127195|NCT03255291|BEHAVIORAL|Audio Recording - Exercise|Participants imagine themselves improving exercise
224127196|NCT03255291|OTHER|Text message reminders|-Reminders to practice mental imagery
224296395|NCT06927050|BEHAVIORAL|Visual Communication Tool|MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.
224296396|NCT03496857|DEVICE|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
223389956|NCT04508738|OTHER|ERP|"The ERP intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~ERP: 1) neck cooling with an iced gel pad, 2) drinking a ∼ 6% CHO solution, 3) mouth-rinsing with a ∼10% CHO, ∼6 mg ･ kg -1 caffeine solution, 4) performing submaximal squats and 5) hyperventilating a hyperoxic mixture"
223389957|NCT04508738|OTHER|Placebo|"The control intervention is applied in a randomized and counter-balanced order across visits 2-4 in each 3-min break in-between the six 30-s sprints, with one intervention per visit. The order and timing of the constituents of the interventions will be strictly constant within and between participants.~1\) neck cooling with room temperature gel pack, 2) drinking an artificially sweetened solution, 3) mouth-rinsing with artificially sweetened solution (containing no caffeine), 4) performing unloaded squat manoeuvres, 5) deep breaths with room air"
223389958|NCT04328090|OTHER|Computer based Antimicrobial stewardship (AMS) intervention system|"1. Re-evaluation alerts and decision support for the duration of antimicrobial treatment.~2. Re-evaluation alerts and decision support for the choice of antimicrobial.~3. Quality control audit and feedback."
223389959|NCT05117346|DRUG|CARDIX-101A, CARDIX-101B, CARDIX-101C|Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
223389960|NCT07017374|OTHER|Proteomic analysis, targeted temperature management|Biobank serum samples from patients that were included in the TTM trial will be used for proteomic analysis. TTM trial randomised patients to targeted temperature management of 33 °C or 36 °C.
223389961|NCT07016867|DRUG|l-carnitine|to compare the efficacy of medical treatment (l-carnitine and antioxidants) versus surgical treatment (varicocelectomy) versus surgical treatment and medical treatment (varicocelectomy with adjuvant medications) on pregnancy rate on varicocele related subfertility patients with isolated teratozoospermia.
223389962|NCT07018440|DIETARY_SUPPLEMENT|Low-Volume Oral Carbohydrate Loading (200 mL of 12.5% solution)|Patients were given Low Volume Oral Carbohydrate feeding (200 mL 12.5% solution) in the preoperative period.
224010785|NCT07174336|DRUG|Fulvestrant|Administered intramuscular
224010786|NCT07177339|DRUG|Depemokimab|Depemokimab will be administered.
224010787|NCT07177339|DRUG|Placebo|Matching placebo will be administered.
224010788|NCT07178288|OTHER|Physiological/measurement-validation study|"Protocols PPT Reliability The assessor measured Pressure Pain Threshold; PPT, using an electronic digital algometer. Measurements will be taken at two test sites wrist at baseline, at 1, 3 and 5 minutes. Three PPT measurements were taken at each time point with a 15-20 seconds interval between each. Mean values will then be used in analysis.~Conditioned Pain Modulation In order to assess CPM, PPT was used as a tested stimulus on the painful arm (elbow and wrist). Baseline PPTs will assessed three times with an interval of 30 seconds between the repetitions. A Cold Pressure Task (CPT) will be used as the conditioning stimulus. Participants will be instructed to immerse their uninvolved hand in the ice water for 2 minutes. PPT will be measured at baseline pre and 1 minute during immersion to calculate CPM response, and then at various time points post immersion (minutes: 1, 5, 15, 30, 45, and 60) to determine the time point at which PPT returns to baseline."
224010789|NCT07179250|DEVICE|Volume-Oriented Incentive Spirometer|Participants in the experimental group will perform volume-oriented incentive spirometry training twice daily (morning and evening) for 6 weeks. Each session consists of 10 deep inspirations using the spirometer, with the target volume initially set according to the participant's predicted maximum inspiratory capacity and increased by approximately 5% each week starting from week 2. For each breath, participants inhale to reach the target volume, hold their breath for 3-5 seconds, and then exhale. A rest period of 30-60 seconds is allowed between maneuvers, and the pace is adjusted according to individual tolerance. Training is performed in a seated or semi-recumbent position.
224127197|NCT03255291|OTHER|Text Message Survey|-Assesses exercise behavior, intentions, actions plans, self-efficacy, affect, imagery vividness, and practice.
224127198|NCT01790737|DRUG|Cyclophosphamide|
224127199|NCT01790737|DRUG|Filgrastim|
223389963|NCT07017491|OTHER|Orange candy melon (Cucumis melo)|Participants will consume a portion of melon A containing 50g of available carbohydrates to evaluate postprandial glycemic response.
223389964|NCT07017491|OTHER|Rock melon ( Cucumis melo var.cantalupensis)|Participants will consume a portion of melon B containing 50g of available carbohydrates to evaluate postprandial glycemic response.
223389965|NCT07017491|OTHER|honey dew (cucumis melo L.)|Participants will consume a portion of melon C containing 50g of available carbohydrates to evaluate postprandial glycemic response.
223546157|NCT04631198|OTHER|Thoracoabdominal rebalancing|the patients selected for the intervention group will be submitted to the handling of thoracoabdominal rebalancing as abdominal supports and / or in the ileo-costal space, inspiratory help, scapular waist release, thoracic swing, pectoralis major muscle release and deltoid together with aspiration if necessary.
223546158|NCT06306911|DIETARY_SUPPLEMENT|Aronia Melanocarpa extract|Aronia Melanocarpa extract (AME) consisting of a mixture of anthocyanins and other polyphenols
223546159|NCT02899455|DRUG|HGP0904|
223546160|NCT02899455|DRUG|HGP0608|
223546161|NCT02899455|DRUG|HGP0816|
223546162|NCT02899455|DRUG|HGP0904 Placebo|
223546163|NCT02899455|DRUG|HGP0816 Placebo|
223546164|NCT02644213|OTHER|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~* simulated road march using a virtual reality environment without additional load~* simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~* without physical or cognitive load (without march, waiting between performance evaluations) as control."
224010790|NCT07179250|BEHAVIORAL|Diaphragmatic Breathing Exercise (DBE)|Participants in the control group will perform diaphragmatic breathing exercises twice daily (morning and evening) for 6 weeks. During weeks 1-2, each session consists of 10 breaths per set; from week 3 to week 6, each session consists of 15 breaths per set. The exercise is performed without devices and includes the following sequence: slow inspiration through the nose with abdominal expansion, holding the breath for 5 seconds, followed by exhalation through the mouth with visible abdominal contraction. After each set, participants rest with natural breathing for 1-2 minutes to prevent hyperventilation or diaphragmatic fatigue. Training is conducted in a semi-recumbent position with both hands placed behind the head, focusing on abdominal movement control and breathing rhythm.
224010791|NCT07179250|BEHAVIORAL|Usual Care and Education|Participants in the control group will receive usual clinical care for gastroesophageal reflux disease (GERD) without structured breathing training. At study entry, participants are provided with standardized patient education regarding GERD and lifestyle modification strategies, along with an educational leaflet. No specific posture or breathing exercises are required during the study period.
224010792|NCT07178977|BEHAVIORAL|Psychoeducation group|"A structured, group-based psychoeducation program designed for parents of adolescents with anorexia nervosa. The intervention consists of four weekly sessions, each lasting 90 minutes, delivered in small groups (up to 7 families) at the Child Psychiatry Department, University Medical Centre Ljubljana. Each session follows a standardized structure. The session topics are: Understanding eating disorders; Maintaining factors in anorexia nervosa and strategies to address them; Establishing and supporting normal eating patterns, Promoting and sustaining change.~The program is adapted from evidence-based approaches, including family-based treatment (FBT) and enhanced cognitive-behavioral therapy (CBT-E), and is tailored to a psychoeducational group format for parents. The aim is to reduce parental distress, improve coping, and enhance adolescent treatment outcomes (BMI, eating disorder symptoms, anxiety, depression)."
224010793|NCT07181941|BIOLOGICAL|Linvoseltamab|Given IV
224010794|NCT07181941|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224010795|NCT07181941|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223389966|NCT07018076|DIAGNOSTIC_TEST|RS ratio|We will evaluate the non-culture, sputum-based assay RS ratio, which measures ongoing Mycobacterium tuberculosis activity by quantifying the abundance of precursor rRNA relative to mature rRNA (an indicator of active rRNA synthesis).
223389967|NCT07018076|DIAGNOSTIC_TEST|Blood-based host immune response assays|We will evaluate blood-based assays measuring host immune response parameters for predicting mycobacterial activity.
224010796|NCT07181941|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223389968|NCT07017062|OTHER|hybrid ceramic occlusal veneers|occlusal veneers cemented with self adhesive resin cements
223546165|NCT00318318|DRUG|Premarin|
224010797|NCT07181941|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224010798|NCT07181941|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224010799|NCT07186660|DRUG|CIR-0602K|mitochondrial pyruvate carrier inhibitor
223546166|NCT02836470|DRUG|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
223546167|NCT02836470|DRUG|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
223546168|NCT05804487|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
223546169|NCT06405438|OTHER|No intervention|No intervention.
223546170|NCT00005903|DRUG|GDNF & Synchro Med Infusion System|
223546171|NCT02342769|DRUG|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
223546172|NCT04289558|DRUG|Sodium Nitrite|Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
223546173|NCT01433406|DRUG|TAK-875|
223546174|NCT01433406|DRUG|TAK-875|
223546175|NCT03884153|DEVICE|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
223546176|NCT06184685|DRUG|Sahasthara Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
223389969|NCT07017127|BEHAVIORAL|Mediterranean diet|Exclusion of highly processed food products and beverages, introduction of a diet according to the modern pyramid of the Mediterranean diet (44). Subjects will be recommended to reduce as much as possible the use of plastic food and drinks containers. The nutritionist will create personalized nutritional recommendation, with a moderate reduction in caloric intake (quantified by calculating the basal metabolism and ideal body mass of each subject, and the whole day's energy consumption). The goal of this part of the intervention is to achieve a weight loss of at least 0.5 kg every week, by reducing caloric intake by 300-500 kcal. The nutritionist will create sample menus throughout the day, for 30 days, to make it easier for subjects to follow this part of the intervention. In addition, each subject of the experimental group will receive a total of six liters of extra virgin olive oil (one liter per month for 6 months).
224010800|NCT07186660|DRUG|Placebo|Placebo tablet
223389970|NCT07017127|BEHAVIORAL|Physical activity intervention|Participants will be involved in aerobic activities expertly guided by kinesiologist (Nordic walking) every day for 45-60 minutes, spent in nature or indoors in case of unfavorable weather. Along with Nordic walking, participants will be involved in organized muscle strength and endurance exercises twice a week for 60 minutes with the use of external loads (elastic bands, small weights), and mobility, balance and coordination will also be developed. All training programs will be conducted by trained kinesiologists who will instruct, monitor and correct participants in order to perform the exercises correctly and get the maximum effect on the targeted motor skills. Nordic walking, resistance exercise, and a combination of aerobic activity and resistance exercise have been shown to be effective in improving cardiometabolic parameters, physical fitness, and quality of life in people with DM2.
223389971|NCT07017127|BEHAVIORAL|Psychological intervention|Support group meetings discussing mental health topics and encouraging change through the adoption of healthy lifestyle habits. Psycho-educational component, stimulating group environment for sharing personal experiences, motivation and becoming aware of emotions and resistance. The specific topics of individual group meetings will be: stress and stress management, relaxation techniques (breathing techniques, autogenic training, progressive muscle relaxation techniques and guided fantasies), emotion management (recognition of negative beliefs and thought patterns, awareness and management of emotional reactions), interpersonal skills in the function of self-care (awareness and communication of one's own needs through assertive communication techniques), self-care through the adoption of healthy habits (motivation, adoption of habits and planning), conscious eating and the alike, creating a list of SMART goals (45).
223546177|NCT06184685|DRUG|Diclofenac Microemulsion|All patients were instructed to treat the knee with 2 ml, 3x/day, for 28 days. Each of the patients received the same appearance of drug packaging, which was not revealed until data analysis was completed, or medical emergency conditions would require an unblinding.
223546178|NCT05128071|DRUG|Progesterone|Randomized to 400 mg (200 mg twice daily) oral micronized progesterone daily
223546179|NCT05128071|DRUG|Placebo|Randomized to placebo twice daily
224010801|NCT07187765|DRUG|Oliceridine|Oliceridine will be administered intravenously at a dose of 1 mg for gastroscopy or 1.5 mg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
224127200|NCT03167086|BEHAVIORAL|"Empowered Relief (ER)"|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
224010802|NCT07187765|DRUG|Sufentanil|Sufentanil will be administered intravenously at a dose of 5 μg for gastroscopy or 7.5 μg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
224010803|NCT07184190|OTHER|Trancutaneous Auriculotemporal Nerve Stimulation|Trancutaneous Auriculotemporal Nerve Stimulation
224010804|NCT07185022|PROCEDURE|Intra-arterial Thrombolysis|rhTNK-tPA（Tenecteplase）dose: 0.4 - 0.8 mg/min, maximum dose: 16mg.
224010805|NCT07185022|DRUG|Best Medical Treatment|Patients in this group will receive standard medical therapy in accordance with the guideline-directed management for acute ischemic stroke.
224010806|NCT07194941|BIOLOGICAL|Freeze-dried product made of fresh feces|"FMT represents an ecological alternative for restoring the damaged intestinal ecosystem in this infection, increasing ecological diversity and thus limiting the spread of the pathogen. Recurrence of C. difficile is its only approved indication.~The impact of FMT on the intestinal ecosystem is attributable to intraspecific bacterial competition: commensal microorganisms (sensitive and non-virulent) have more effective growth rates than pathogenic bacteria (resistant and virulent), so FMT produces an ecological replacement in favor of grafting the donor microbiota and eliminating antibiotic-resistant clones."
224127201|NCT03167086|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading."
224010807|NCT07194226|OTHER|No intervention (observational study)|This is an observational survey; participants complete an anonymous questionnaire and no medical or behavioral intervention is applied.
224296397|NCT03496857|OTHER|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
224296398|NCT06175247|OTHER|Low Glycemic Index Diet|A low glycemic diet will be initiated with dietician support and guidance.
223389972|NCT07012083|OTHER|survey|"This cross-sectional survey study will be conducted on a consecutive sample of physicians who treat patients with animal bites potentially requiring post-exposure anti-rabies prophylaxis. The sample will include emergency physicians, general practice or family physicians, and surgeons of both sexes, with varying degrees of experience and post-graduate clinical training.~All participants will consent to submit an anonymous Google Form-based questionnaire. The designed questionnaire will include introductory personal, academic, and work experience data about the physicians as gender, age, specialty, workplace, highest achieved medical-academic or training degree, and number of years of postgraduate clinical work experience. Candidates will be asked to reflect on their pre and postgraduate education/training quality and their confidence level in prescribing anti-rabies post-exposure prophylaxis treatment. (as a linear scale)."
223389973|NCT07017881|BEHAVIORAL|Psychosocial Skills Training|The 24-person intervention group was divided into three separate groups of 8 people (Group 1, Group 2, Group 3). Group 1 and Group 2 attended sessions on Tuesdays at different times, while Group 3 attended sessions on Thursdays. Psychosocial Skills Training consisted of eleven sessions in total, one session per week. Sessions lasted an average of 60 minutes for each group. In each session, 5-10 minute breaks were given for rest and eating and drinking, considering the attention span and fatigue of the patients. Psychosocial Skills Training was applied two days a week (Group 1-2: Tuesday, Group 3: Thursday) in order to ensure that the patients could get more benefit from the application.
224010808|NCT07194746|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will receive a non-specific spine exercise program provided in a handout. The interventional group (Group B) will be asked to keep the standardised spine-specific exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain.
224010809|NCT07194746|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine-specific exercise program will be provided in a handout and given only to the intervention group (Group B), and will include specific spine basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study and referred for evaluation and treatment if necessary.
224010810|NCT07194603|PROCEDURE|Spinal mobilization (SM) of the neck|This cohort intervention study has only one arm and this arm has only one intervention, the one described above. Both SM and JM mean the same thing and are synonymous.
223389974|NCT07018609|BEHAVIORAL|Zen Den Experience|The Zen Den is a dedicated safe space for healthcare staff to decompress and recharge during shifts, addressing the growing issue of workplace stress. It has soft warm lighting, sound machines and aroma therapy, relaxing furnishings centered around a faux fireplace to create a stress-free environment.
223546180|NCT06174155|OTHER|physical therapy treatment|The control group will receive the physical therapy program and conduct five times per week over four consecutive weeks under the supervision of a physical rehabilitation specialist. The primary focus of the program was to improve scar malleability, lengthen muscles and tendons, enhance joint mobility, and to restore functionality. Each session lasted almost for 45 minutes and consisted of therapeutic paraffin application; deep tissue massaging (5 minutes); stretching exercises; active ROM exercises.
223546181|NCT06174155|OTHER|Botulinum toxin-A injection in addition to physical therapy program|Two injection procedures will be used. The first is an EMG-guided BTX-A administration (Botox®, Allergan PLC, Dublin, Ireland) that will be localized to the motor endplate zone of the wrist flexors, radial and ulnar deviators. The second is a meso-injection procedure, where the BTX-A will be injected subdermal, intradermal, and into the scar (around the periphery and into the center).
223546182|NCT06174155|OTHER|shock wave therapy in addition to physical therapy program|After wound and skin graft healing (\~ 90 days post-surgery), the unfocused shockwave will be applied to the site of burn injury on the volar aspect of the hand of the subjects and will allocate to the shock wave therapy intervention arm. The treatment will be delivered using a portable shockwave device (Zimmer enPuls, EMS physio Ltd, Germany).
223546183|NCT02533544|DRUG|tenofovir disoproxil fumarate|
224127202|NCT03167086|BEHAVIORAL|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
224127203|NCT06085846|DEVICE|Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application|Vivally® System Wearable, Non-Invasive Neuromodulation System and Mobile Application to treat patients with the conditions of urinary incontinence and urinary urgency.
224127204|NCT00219765|DRUG|Imatinib mesylate 600 mg|
224127205|NCT00219765|DRUG|Cytarabine|
223546184|NCT01032187|DRUG|Meglumine antimoniate|20mg/kg/day IV for 20 days
223546185|NCT01032187|DRUG|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
224010811|NCT07193797|OTHER|Phenotypes of ICU delirium|The included delirium patients will be divided into different phenotypes, according to delirium risk factors such as age, history of cerebrovascular accident, blood transfusion, surgery duration etc.
224010812|NCT07195006|OTHER|Malnutrition in pregnancy as exposure|MUAC ≤23 cm in pregnancy at least 20 weeks gestational age
224127206|NCT00219765|DRUG|Daunorubicine|
224127207|NCT05348265|OTHER|Low Intensity steady state training|Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
223389975|NCT07018609|BEHAVIORAL|Music Therapy Experience|The music therapy experience will consist of either Music Minutes which have music therapists available on specific units and circulating amongst staff across flexible shift times. Intervention choices will include relaxation songs, motivation songs, music, mindfulness, breathing to music, dance-a-minute, and brief song rewrites. Notes for Resilience will be scheduled group sessions that follow a more structured format and are 30 to 60 minutes in length. Involvement and coping will be emphasized through active forms of music participation, including drum circles, unit playlist creation, song writing, jam sessions, and song discussion.
224010813|NCT07195006|OTHER|Poor WASH living conditions as exposure|"Poor water (source, quality, access, reliability), sanitation (toilet type, cleanliness, number of people using toilet) and personal (hand wash practices) and household hygiene (dumpster availability and emptying frequency) index scores.~WASH Index score ranges; 1.Basic services (76-100%), 2.Semi-basic services (51-75%) 3.Poor services (26-50%) 4.No services (0-25%)"
224010814|NCT07195409|BEHAVIORAL|Out of School Time Coach (OST-Coach)|Four data coaching session (investigate, design, practice, reflect) will be conducted over an academic year. Each session will involve: a customized site level data report, goal setting and implementing strategies to address child physical activity, motor competence, and staff physical activity promoting behaviors.
224010815|NCT07193875|DRUG|Efavirenz 600mg|Take One pill daily for 6 months in addition to baseline combination antiretroviral therapy regimen
224010816|NCT07195552|DIETARY_SUPPLEMENT|Agaricus blazei|Agaricus blazei mushroom capsules. 2000 mg per serving
224010817|NCT07195552|DIETARY_SUPPLEMENT|Reishi|Reishi mushroom capsules. 2000 mg per serving.
224010818|NCT07195552|DIETARY_SUPPLEMENT|Turkey Tail|Turkey tail mushroom capsules. 2000 mg per serving.
224010819|NCT07195552|OTHER|Placebo|Placebo
224010820|NCT07194473|BEHAVIORAL|ZeroOCD|"The ZeroOCD app contains the following components:~psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention"
224010821|NCT07194473|BEHAVIORAL|Videoconferencing CBT|"Videoconferencing CBT contains the following chapters:~psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention"
224010822|NCT07194499|OTHER|No interventions|No intervention
224010823|NCT07194785|DIAGNOSTIC_TEST|AI-Assisted Cardiac Auscultation using the HearTech Smart Stethoscope|This intervention utilizes the HearTech smart stethoscope, where trained research personnel perform standardized examinations of four cardiac auscultation areas on subjects. The integrated AI algorithm analyzes heart sounds in real time and automatically generates reports. An initial positive detection triggers a repeat testing process, with the algorithm ultimately determining a positive screening result based on three detection outcomes (any two positive). This AI-assisted auscultation system is designed to achieve large-scale, standardized, and highly efficient preliminary heart murmur screening.
224010824|NCT07194447|DRUG|Simvastatin Gel|A single local application of 1.2% simvastatin incorporated into 4% methylcellulose gel, placed around the implant site immediately after implant placement and before flap closure.
224010825|NCT07194447|DRUG|Methylcellulose Gel|A single local application of 4% methylcellulose gel without simvastatin, placed around the implant site immediately after implant placement and before flap closure.
224010826|NCT07194291|OTHER|Follow up of female sexual function|We follow up menstrual changes in diabetic adolescent girls to improve the outcome
224010827|NCT07195526|BEHAVIORAL|Bicycle balance control training|The intervention involves three components: (1) training on an exercise bicycle, (2) a balance control training on a bicycle simulator, and (3) cycling on the public roads with a safe start-and-stop technique that was practiced on the bicycle simulator. In the bicycle simulator training, the difficulty of the balance control will be increased gradually, slowly approaching the difficulty of bicycle balance control on the public roads.
224010828|NCT07194356|PROCEDURE|Pericapsular nerve group (PENG) block|A single-shot PENG block was administered preoperatively using ultrasound guidance. The block was performed with the patient in the supine position, and 20 mL of local anesthetic (0.25% bupivacaine) was injected between the psoas tendon and the superior pubic ramus to achieve analgesia of the anterior hip capsule.
224010829|NCT07194356|PROCEDURE|Standard Spinal Anesthesia (Control)|Patients in this arm were managed according to standard care protocols for spinal anesthesia in hip fracture surgery. No preoperative regional block was performed. Pain scores and postoperative tramadol use were measured for comparison with the experimental arm.
224010830|NCT07193615|DRUG|YOLT-202|The IP is administered intravenously at the predetermined dose; Administration frequency: Once
224010831|NCT07195084|RADIATION|Hypervision proton surgery|Proton radiaotherapy (34GyE or 39GyE)
224010832|NCT07194317|DEVICE|Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)|55 participants will be recruited (target to complete the study n=50). The acceptability trial will be conducted remotely. A baseline questionnaire will capture demographic data. Over three weeks participants will be asked to record three random consecutive days of dietary intake each week using a different tool. Participants will be randomised to the order they complete the tools. To minimise potential biases. Participants will be randomly assigned to one of the six possible tool completion sequences (Table 1) using a relevant participant randomization package (e.g., rempsyc) in R (v4.4.2), which is a free, open-source statistical software used for data analysis and randomisation.
224127208|NCT05348265|OTHER|High intensity interval training|"Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches."
223389976|NCT07017504|DEVICE|proprioception-enhancing assistive orthosis|A wearable device that provides mechanical vibration to the tendons around the knee and ankle to enhance proprioceptive feedback. Vibration intensity and timing are controlled automatically based on body tilt measured by an IMU sensor. The device is applied during balance and joint sense assessments conducted across three visits.
223389977|NCT07018544|OTHER|semaglutide|Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
223389978|NCT07018674|DIETARY_SUPPLEMENT|Experimental|Brain Edge, a cognition supporting supplement beverage formulated from herbs, vitamins, and amino acids.
223389979|NCT07018674|OTHER|Placebo|A sensory-matched placebo beverage formulated from flavors, colors, fillers, and excipients.
223389980|NCT07018674|OTHER|Water|Bottled Water
223389981|NCT07016841|DEVICE|pHA130 hemoperfusion device|HP once every 2 weeks.
223389982|NCT07016841|DEVICE|HD/HDF|HD twice weekly, HDF once weekly, with each session lasting 4 hours.
223389983|NCT07016841|DEVICE|HA130 hemoperfusion device|HP once every 2 weeks.
223389984|NCT07017036|DRUG|IVIG-VImmune|V-Immune will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose
223389985|NCT07017036|DRUG|IVIG-Immuglo|Immuglo will be administered at 200-800 mg/kg dose as a single infusion every 3 or 4 weeks. Patients will be treated with V-Immune from Week 0 (first dose) till Week 48 at an investigator-recommended dose
223389986|NCT07018219|DEVICE|X ray device|X ray macjine : shimadzo corporation ( japan)
223389987|NCT07017049|BEHAVIORAL|Integrative Neuromuscular Training|Participants will receive a 12-week Integrative Neuromuscular Training (INT) program, conducted 3 times per week, each session lasting 1 hour. The intervention includes progressive exercises targeting balance, strength, plyometrics, speed, agility, and coordination. Training intensity increases from 55-65% HRmax in weeks 1-2, to 65-75% HRmax in weeks 3-5, and 70-85% HRmax in weeks 6-12. Exercises include single-leg balance, BOSU balance, box jumps (30-50 cm), lateral jumps, squats, Nordic hamstring exercises, sprints (20-30m), shuttle runs, and agility drills. Rest between sets is 30-60 seconds.
223389988|NCT07017049|BEHAVIORAL|Routine training intervention|"Participants in the control group will follow the standard physical training program of the school over a 12-week period, with sessions conducted 3 times per week, each lasting approximately 50 minutes (including warm-up and cool-down). The training intensity will progressively increase from 55%-65% HRmax in weeks 1-3, 65%-75% HRmax in weeks 4-8, and 75%-85% HRmax in weeks 9-12.~Each session includes:~Warm-up (10 minutes): Movement of hands and legs, small-sided games, ball handling, and stretching exercises.~Intervention (30 minutes):~Weeks 1-3: Barbell back squat, barbell deadlift, bench press, continuous broad jumps, continuous burpee jumps, frontal plank (60 sec), 50m sprinting (5 reps), 2 sets of each exercise with 30-60 seconds rest.~Weeks 4-5: Similar structure with increased repetitions (barbell exercises 6-10 reps, plank 70 sec).~Weeks 6-8: Barbell back squat, deadlift, bench press, broad jumps, each for 3 sets, 30-60 sec rest.~Weeks 9-12: Higher load with 8-12 reps per"
223389989|NCT07017699|DRUG|Deucravacitinib|According to product label
223389990|NCT07017699|DRUG|Other systemic treatments for PsO|According to product label
223389991|NCT07018726|BEHAVIORAL|Resilient Together-YOD|This is a 6 session dyadic (patient and spousal care-partner) intervention that teaches resiliency and interpersonal communication skills early after YOD diagnoses. It aims to decrease heightened symptoms of depression and anxiety among dyads to help them engage in important decisions around long term care-planning and optimize adjustment. The goal is to equip dyads with the necessary skills to cope and engage in meaningful, challenging conversations around care-planning, symptom deterioration, work/family planning to improve well-being in both members of the dyad.
223389992|NCT07018726|BEHAVIORAL|Health Enhancement Program-YOD|This is a 6 session program that will deliver educational information to dyads and will mimic the dose and duration of Resilient Together. The program will not teach any individual and dyadic interpersonal skills, but will contain education on psychological distress and healthy behaviors. Sessions will also be delivered virtually.
223389993|NCT07018375|DRUG|Oliceridine|postoperative patient-controlled analgesia (PCA)
224010833|NCT07194005|DRUG|Disitamab vedotin(RC48)|2.5 mg/kg, administered intravenously every 3 weeks (Q3W) on Day 1 of each cycle.
223389994|NCT07018375|DRUG|Sufentanil|Sufentanil
223389995|NCT07016659|DRUG|0.12% Chlorhexidine Mouthwash ( Hexitol )|About 10 ml will be administered, and participants will be asked to swish mouthwash for 30 seconds two times daily under the supervision of their parents, 30 to 45 minutes after toothbrushing for 2 weeks.
223389996|NCT07016659|DRUG|Triphila mouthwash|The participant will be instructed to administer 15 ml of the mouthwash and swish it for 30 seconds two times daily under the supervision of their parents, 30 to 45 minutes after toothbrushing for 2 weeks
223389997|NCT07017075|DEVICE|Transesophageal ultrasound|Transesophageal ultrasound with built-in ultrasound software (Philips QLAB 3D quantification advance, Philips Healthcare, USA, speckle tracking echocardiography (STE,Speckle tracking echocardiography) to evaluate stroke volume and cardiac output in traditional CPR location and the better position
223389998|NCT07018453|DRUG|SHR-3167|SHR-3167 Injection.
223389999|NCT07018453|DRUG|Insulin Degludec|Insulin Degludec Injection.
223546186|NCT05909033|PROCEDURE|Kasai procedure|All KPs were performed by a medical team. This technique involved creation of a 35-40 cm Roux loop to facilitate biliary drainage. After dissection of the hepatic vasculature at the hilum and excision of the hilar plate, hepaticojejunostomy was performed as an anastomosis extending from the bifurcation of the right hepatic artery into anterior and posterior branches to the Rex confluence of the left portal vein with the obliterated umbilical vein.
223546187|NCT00292071|DRUG|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
223546188|NCT04357184|OTHER|Blood flow restriction training|BFRT is done with 4 exercises with low load resistance of 30% 1 repetition maximum
223546189|NCT04509570|PROCEDURE|Biopsy|5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
224010834|NCT07194005|DRUG|Sintilimab|200 mg, administered intravenously, d1, every 3 weeks.
223390000|NCT02008812|DEVICE|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
223390001|NCT02577991|DRUG|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
223390002|NCT02577991|DRUG|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
223390003|NCT02513862|DEVICE|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
223390004|NCT03618251|DIAGNOSTIC_TEST|specific MRI sequences|MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
223390005|NCT00115076|DRUG|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
223390006|NCT05164692|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
223390007|NCT05164692|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
223390008|NCT07016997|DRUG|CBA-1535|Dosing is increased from 0.1 µg/body until DLT or disease progression occurs.
223546190|NCT04452747|PROCEDURE|Vaginal Dinoprostone system (Propess®)|Labour will be induced using the vaginal Dinoprostone system (Propess®) as a first strategy
223546191|NCT04452747|PROCEDURE|Dilatation balloon|Labour will be induced using a cervix dilatation balloon as a first strategy
223730396|NCT01741922|DRUG|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
223730397|NCT01741922|DRUG|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
223730398|NCT01741922|DRUG|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
223390009|NCT07016997|DRUG|CBA-1535+Pembrolizumab|"Drug：CBA-1535 First Dosing will be determined by Part 1. And dosing will be increased until DLT or disease progression occurs.~Drug：Pembrolizumab 200 mg/body"
223390010|NCT07016698|DEVICE|Rotarex(TM) Rotational Excisional Atherectomy System|Subjects treated with Rotarex(TM) Rotational Excisional Atherectomy System
223390011|NCT05290727|OTHER|Aquoral Lipo (Esteve)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
223390012|NCT05290727|OTHER|Hyabak (Thea)|15-day randomized treatment period of each of the clinical trial products (experimental and control) with a 1-week washout period prior to use of the study products
223390013|NCT06054165|OTHER|Clinical pathway|Evidence-based and expert-opinion-based clinical pathway regarding the diagnostic and treatment strategy
223390014|NCT04851873|GENETIC|OAV101|Gene Therapy - 1.1e14 vector genome (vg)/kg as a one-time IV infusion was administered over approximately 60 minutes.
223390015|NCT06634290|DEVICE|intramedullary nailing augmentation|Treatment of pertrochanteric hip fractures with intramedullary nailing with cephalic augmentation with bone cement
223546192|NCT04729153|DRUG|DAAD Compound|Sofosbuvir , Daclatasvir and ribavirin
223546193|NCT02079909|DRUG|T-817MA-H|224 mg or 448 mg T-817 MA once daily
223730399|NCT03090854|DIAGNOSTIC_TEST|ADASCog|Neuropsychological test
223730400|NCT01053689|DRUG|Glimepiride tablets 1 mg|
223390016|NCT06634290|DEVICE|intramedullary nailing|Treatment of pertrochanteric hip fractures with intramedullary nailing without cephalic augmentation
223546194|NCT02079909|DRUG|T-817MA-L|224 mg T-817 MA once daily
223546195|NCT02079909|DRUG|Placebo|Placebo
223546196|NCT02277249|DRUG|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
223546197|NCT02277249|DRUG|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
223390017|NCT06235827|DIETARY_SUPPLEMENT|Green tean group|Patients in Group A will have to consume two cups (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes. They are only allowed to consume as hot drink, not for iced tea. Any sweetener or sugar is not allowed to mix in the drink. The green tea bag will be distributed to patient at beginning of research and at every visit. Patient will be reminded weekly using text messages or phone call by a research assistant for green tea consumption.
223390018|NCT06235827|DIETARY_SUPPLEMENT|Control group|Patients in Group B will not be consuming green tea during 6 months of study period.
223546198|NCT05233501|PROCEDURE|low level laser therapy|adjunctive application of low level laser therapy to non-surgical periodontal treatment
223546199|NCT05233501|PROCEDURE|non-surgical periodontal treatment|standart periodontal therapy
223546200|NCT03040739|OTHER|use of O'ARM imaging system|use of O'ARM imaging system
224010835|NCT07194005|DRUG|S-1|Oral, 40-60 mg, twice daily (bid), d1-14, every 3 weeks.
224010836|NCT07194005|DRUG|Oxaliplatin|130 mg/m², administered intravenously on Day 1 (d1), every 3 weeks.
224010837|NCT07193914|OTHER|ECCCLORE program|2-hour sessions in groups of up to 10 people, once a week for 12 weeks plus 30-minute individual sessions after each group session At the beginning of each session, there will be a discussion about the past week and home practices. This will be followed by an alternation between presentations/explanations of key concepts and associated practices. In the individual sessions the previous session and any difficulties encountered during the group session will be reviewed, as well as to address the implementation of home practices.
224010838|NCT07195630|OTHER|Moderate-Intensity Continuous Exercise|15 recreationally active males completed the \~21 min of exercise at 55% of VO2max, consisting of a 3-minute warm-up and 3-minute cool-down at 60 W.
224010839|NCT07195630|OTHER|High-Intensity Interval Exercise|15 recreationally active males performed 10 x 1-minute intervals at 90% of VO2max, separated by 75 s of active recovery at 60 W, and a final 3-minute cool-down period at 60 W.
223730401|NCT02618434|DRUG|SPN-810 (18 mg)|Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
224010840|NCT07193537|OTHER|Virtual reality exercises|Thirty one subjects will receive virtual reality exercises by VR Training using Xbox Kinect. The Kinect sensor is an infrared camera that can recognize the positions and motions of the player without the need for special controller. The console controls the various games .For the VR training, the Xbox Kinect, console, and monitor will set up in a dedicated space. The patient will placed 1.5-2 m away from the Kinect sensor. Before the start of the training session, the research assistant adjusted the position of the sensor while the patient is sitting to ensure optimal position and motion capture, and loaded games into the system. After the setup is completed, the research assistant demonstrated games included in the Kinect adventure
224127209|NCT05323903|OTHER|Telesimulation|Telesimulation is an application that is a teaching process by which telecommunication and healthcare simulation resources are used to provide education, training and assessment to learners at an off-site location. In this study, simulation was recorded and this was shared with the students through means of telecommunication.
224127210|NCT05323903|OTHER|Kahoot Game|Kahoot is a game-based learning platform, used as educational technology in schools and other educational institutions.
224127211|NCT06336577|OTHER|lower respiratory tract disease|lower respiratory tract disease
224127212|NCT00002533|DRUG|fluconazole|
224127213|NCT00002533|RADIATION|radiation therapy|
224127214|NCT04993950|OTHER|sustained natural apophyseal glides|SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
223390019|NCT00240565|DRUG|Tositumomab 450 mg|Unlabeled TST
223390020|NCT00240565|DRUG|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
223390021|NCT03590769|DRUG|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
223390022|NCT02644473|DRUG|Tranexamic Acid|
223390023|NCT02644473|DRUG|Normal saline|Control
223390024|NCT00484640|DRUG|Coumadin|
223390025|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL ECT)|
223390026|NCT02583490|DEVICE|spectrum 5000Q ECT device (RUL LAP ECT)|
223390027|NCT03860324|PROCEDURE|Single-shot erector spinae plane block|Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.
223390028|NCT03860324|PROCEDURE|Single-shot fascia iliaca block|Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
223390029|NCT02628886|BIOLOGICAL|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
223546201|NCT06517368|DEVICE|MRI, Ultrasound|The patients will undergo both B-mode and sonoelastographic examinations in the supine and lateral decubitus position and will perform during breath-holding after deep inspiration. The elastogram was displayed over the B-mode image in a color scale: red (greatest strain, softest tissue component), green (average strain, intermediate tissue component), and blue (no strain, hardest tissue component) Patients will be examined by MRI with diffusion images and ADC values.
223564109|NCT06491745|OTHER|ESWT+PT+corticosteroid injection, ESWT group|ESWT group. Patients in the ESWT group will receive ESWT, physical therapy, and both shoulder joint (glenohumeral joint, GHJ) and SASD bursa injection for 2 times in a 2-week interval. 3ml triamcinolone (1ml triamcinolone= 10mg) will be added to 3ml 1% xylocaine to make 6ml injectate. Among them, 4ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. After withdrawing the needle to subcutaneous layer, another 2ml injectate will be injected into the SASD bursa of the affected shoulder under US guidance.
223564110|NCT06491745|OTHER|Sham ESWT+PT+corticosteroid injection, SHAM group.|SHAM group. The participants will receive the same dosage and technique of corticosteroid posterior GHJ and SASD bursa injection for 2 times at 2 weekly interval as participants do in the ESWT group. For creating a single-blinded condition, they will also receive 4 ESWT treatments at weekly interval except that the energy flux density is set at 0.04 mJ/mm2. For sham ESWT, the machine still makes a noise with every shock wave delivered in order to enhance the sham design.
223564111|NCT05221567|BEHAVIORAL|Psychotherapy|Intensive psychotherapy (i.e., greater number of treatment sessions per time unit)
223390030|NCT02628886|BIOLOGICAL|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
224127215|NCT04993950|OTHER|SNAGS with thoracic postural correction techniques|thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
224127216|NCT01968096|DEVICE|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
224127217|NCT05155475|PROCEDURE|Ultrasound endoscopy|After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
224127218|NCT03934086|DRUG|rimegepant|rimegepant 75 mg
224127219|NCT05347498|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 40mg qd + placebo of febuxostat tablets 40mg qd in Week 1 and 2, HR091506 tablets 80mg qd + placebo of febuxostat tablets 80mg qd in Week 3 and 4
224127220|NCT05347498|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 40mg qd + placebo of HR091506 tablets 40mg qd in Week 1 and 2, febuxostat tablets 80mg qd + placebo of HR091506 tablets 80mg qd in Week 3 and 4
224127221|NCT00471445|DRUG|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
223390031|NCT02628886|OTHER|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
224127222|NCT00471445|OTHER|placebo|Applied topically
224127223|NCT06608511|OTHER|Blood draw for the laboratory assessment|Participants will have 50 milliliters (3.5 tablespoons) of blood drawn
224127224|NCT00685620|BEHAVIORAL|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
224127225|NCT02330627|BEHAVIORAL|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
223390032|NCT03240263|PROCEDURE|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
223390033|NCT03240263|PROCEDURE|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
223390034|NCT00939016|OTHER|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
224127226|NCT01794494|PROCEDURE|Bypass surgery|Patients are treated with femoro-popliteal bypass
224127227|NCT01794494|PROCEDURE|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
224127228|NCT04323748|DRUG|rituxan|"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"
224127229|NCT03922360|BEHAVIORAL|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
224127230|NCT03922360|BEHAVIORAL|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
224127231|NCT04330755|DRUG|Saline Solution|Placebo
224127232|NCT04330755|DRUG|Levosimendan|Levosimendan
224127233|NCT04330755|DRUG|Magnesium Sulfate|Magnesium Sulfate
224127234|NCT03003780|BEHAVIORAL|Mindful Steps|Integrated website, activity tracker, and mind-body training
223390035|NCT03555110|BEHAVIORAL|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
223390036|NCT03555110|BEHAVIORAL|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
224127235|NCT01996137|DEVICE|VASST II treadmill|Supervised treadmill training under physiotherapist
224127236|NCT05397899|OTHER|Abdominal hypopressive Exercises (AHE)|Active and specific Therapeutic exercises will be used to treat postpartum low back pain in this study. AHE consisted of exhaling to their expiratory reserve volume, then holding their breath (apnea), and expanding their rib cage, to draw their abdominal wall inward and cranially without inhalation. Each exercise will have a specific frequency, intensity, and duration.
223390037|NCT00736632|DRUG|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
224010841|NCT07193537|OTHER|Motor control training|Thirty one subjects will receive motor control training two times a week for eight weeks in form of deep cervical flexors strengthening using pressure biofeedback unit (craniocervical flexor exercise) :Pressure biofeedback unit will be used to perform Cranio-cervical flexor muscle training. Through which an endurance and isometric exercise for DNFs in progressive range positions will be performed each session, the PBU's air bag will be positioned below the occiput, and the inflatable cuff pressure sensor will be inflated to a baseline of 20 mmHg. Participants will instruct to target five pressure levels between 22 and 30 mmHg by nodding. scapular exercises .With patient in prone position, pillow under the chest and upper limb in varying degree of shoulder abduction, the participant lifts the hand toward the ceiling while retracting the scapula
224010842|NCT07193537|OTHER|conventional treatment|"Thirty one subjects will receive conventional treatment for 3 times per week for 4 weeks. Conventional treatment will include the following:~1-Posture correction (chin tuck exercise) Stand with the upper back against the wall, with the feet shoulder-width apart. Tuck the chin in and hold for 5 seconds 10 repetitions .Return to the starting position and repeat a number of times. This can help stretch the muscles in the upper neck 2. Stretching exercise: Self-stretching exercise for most common tight muscles. These muscles include upper trapezius (by contralateral side bending), levator scapulae (flexion, contralateral side bending and rotation) and sternocleidomastoid muscle (slight flexion with ipsilateral side bending and rotation). Each position should be maintained for 30 seconds and repeated for 3 times."
224010843|NCT07194330|DIAGNOSTIC_TEST|None-placebo|Not be displayed, only retrospective data will be required
224010844|NCT07194135|DRUG|Tenoxicam|Intra-articular administration of tenoxicam, 20 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique.
224010845|NCT07194135|DRUG|Triamcinolone Acetonide|Intra-articular administration of triamcinolone acetonide, 40 milligrams as a single injection, delivered through an anterolateral approach under aseptic technique.
224010846|NCT06332963|BEHAVIORAL|Floatation-REST|Participants lay supine in one of two circular fiberglass pools that were custom-designed for research purposes. The floatation pools are 8 feet in diameter and contain 11 inches of reverse osmosis water saturated with \~1,800 pounds of Epsom salt (magnesium sulfate). This creates a dense saltwater solution with a specific gravity of \~1.26, allowing participants to effortlessly float on their back while the water hovers just above the ears. The temperature of the water and air is calibrated to approximate skin temperature (\~95.0 °F), helping to minimize the need for thermoregulation while reducing the boundary between air, body, and water. Clothing is usually not worn while floating since anything touching the body can generate somatosensory stimulation, detracting from the float experience. However, participants have the option to choose if they would prefer to float with a bathing suit or nude. During floatation-REST, visual, auditory, olfactory stimuli are minimized.
224010847|NCT06332963|BEHAVIORAL|IFT|Two ACT principles, contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the IFT condition, awareness and acceptance of bodily signals, thoughts, and emotions and being present with one's self (i.e., mindfulness focus is inward) are emphasized. All participants will engage in an introduction session. Followed by three IFT sessions. The experimental sessions are formatted the same for both conditions. Each begins with a clinician reviewing previous constructs and introducing a new skill. Then participants engage in their assigned condition intervention, followed by a debrief with a clinician. Practices in both conditions are matched as closely as possible for content. The mindful focus of IFT is internal toward thoughts, emotions, and body sensations. In the experimental sessions, participants will engage in a floatation-REST session while practicing acceptance and mindfulness-based skills presented to them.
224127237|NCT05397899|OTHER|General exercises|General exercises are therapeutic exercises for core muscles for the treatment of postpartum low back pain.
224127238|NCT05012319|DRUG|to be given as a treatment|"Nitric Oxide Nasal Spray Enovid"
224127239|NCT01067508|OTHER|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
224127240|NCT00962039|DRUG|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
224127241|NCT00962039|DRUG|Placebo|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
224127242|NCT06447025|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
224127243|NCT00526149|DRUG|BI 2536|
224127244|NCT00526149|OTHER|high performance liquid chromatography|
223390038|NCT00736632|DRUG|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
223390039|NCT03065946|OTHER|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
223390040|NCT00281957|DRUG|sorafenib tosylate|Given orally
224127245|NCT00526149|OTHER|mass spectrometry|
223390041|NCT00281957|DRUG|tipifarnib|Given orally
223390042|NCT00281957|DRUG|temsirolimus|Given IV
223390043|NCT04746144|PROCEDURE|Total knee arthroplasty|
223390044|NCT00797589|DRUG|HES|20ml/kg as prime fluid
223390045|NCT00797589|DRUG|Ringer lactate|
223390046|NCT02871544|OTHER|BNP and NGAL|
223390047|NCT03103516|PROCEDURE|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
223390048|NCT03103516|PROCEDURE|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
223390049|NCT02376816|BIOLOGICAL|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
223390050|NCT01876446|OTHER|Laboratory Biomarker Analysis|Correlative studies
223390051|NCT01876446|DRUG|Pegylated Irinotecan|Given IV
223390052|NCT01876446|OTHER|Pharmacological Study|Correlative studies
224010848|NCT06332963|BEHAVIORAL|EFT|Two acceptance and commitment therapy modules contact with the present moment and cognitive defusion were utilized in the development of the intervention. In the EFT condition, awareness and acceptance of thoughts and emotions and mindfulness of current experience are emphasized. The mindful focus of EFT is external, toward attending to experience as well as thoughts and emotions. During experimental sessions, participants will engage in a self-guided and computer-based practice of acceptance and mindfulness-based skills. These videos were created to ensure content was congruent with the material presented in the introduction sessions and represent skills that build from session to session.
224010849|NCT04840225|OTHER|Measurement of biomarkers for inflammation and anemia|Measurement of biomarkers for inflammation and anemia, in addition to standart clinical measurements
224127246|NCT00526149|OTHER|pharmacological study|
224127247|NCT03797040|BIOLOGICAL|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
224127248|NCT00444626|DEVICE|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
224127249|NCT00444626|DEVICE|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
224127250|NCT00444626|DRUG|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
224296399|NCT00951626|BEHAVIORAL|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
223390053|NCT01693510|BEHAVIORAL|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
223390054|NCT03277755|DRUG|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
223390055|NCT03277755|DRUG|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
223390056|NCT03277755|DRUG|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
223390057|NCT04226521|PROCEDURE|Extracoropreal photopheresis|Patients who sign informed consent form undergo prophylactic extracorporeal photopheresis after heart transplant according to predetermined protocol
223390058|NCT05999487|DRUG|Dobutamine|"Patient randomization will be done by a computer based generation , serial enveloped numbers will be taken for the patients. Cardiac assessment will be done by a blinded pediatric cardiologist. If at any time the randomly assigned therapy considered to be failed or unsafe to continue, the treating physician will discontinue randomization and will continue with the appropriate medication according to the patients need.~Milrinone will start by 0.25 , 0.5 , 0.75 we can titrate up with time interval 3 hours after re-assessment.~Dobutamine will start by 5, 10 , 15, 20 we can titrate with time interval 15 mins after re-assesment."
223390059|NCT02852577|DRUG|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
223390060|NCT02852577|DRUG|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
223390061|NCT00822692|DRUG|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
223390062|NCT00822692|DRUG|placebo|matched placebo 2 pills PO BID x 7 days
223390063|NCT00036192|DRUG|FK614|
223390064|NCT03680612|DRUG|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
223390065|NCT03680612|DRUG|cefepime 1 g or cefepime 2 g|cefepime monotherapy
223390066|NCT03216863|OTHER|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
223390067|NCT03740373|DRUG|BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
223730402|NCT02618434|DRUG|SPN-810 (36 mg)|Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
223390068|NCT03740373|DRUG|BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
223390069|NCT03149276|OTHER|Interpreter services|
223390070|NCT02986867|RADIATION|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
224010850|NCT07194018|DRUG|Use of cannabis oil|Use of cannabis oil on pain relief in patients suffering from fibromyalgia syndrome
223390071|NCT03322644|BEHAVIORAL|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
223564112|NCT00803400|DRUG|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
224010851|NCT07193732|BEHAVIORAL|Psychotherapy-Empathic Attunement Phase|The initial focus of our therapeutic intervention is on establishing empathic attunement to aid individuals in processing the inherent pain of grief in a constructive manner. For this phase, therapists will focus solely on adhering to the relationship formation and introspective exploration. Practitioners aimed at empathetically tuning into the patient's emotional experience, validating and reassuring the patient's emotional state, and adhering to the fundamental principles of empathy, sincerity, and positive regard for establishing and upholding a strong therapeutic alliance. Also, accompanying the patients to uncover and process the natural pain to gain self-awareness about their emotions.
224010852|NCT07193732|BEHAVIORAL|Psychotherapy - Chair-work intervention phase|During this phase, bereavement person will conduct imaginal conversation with a deceased. Practitioners utilized the resolution model including 5 components: (1) emotional reaction of the bereavement (blame, hurt, regret etc.) and enactment of the deceased; (2) differentiation of the bereavement's feelings and deceased's specific negative aspects accessed; (3) intense expression of the bereavement's specific emotions; (4) expression of the bereavement's previously unmet interpersonal needs from the deceased and the deceased validates bereavement's feelings; (5) understanding and forgiveness of the deceased or shift in view of the deceased.
224010853|NCT07193732|BEHAVIORAL|Psychotherapy - Cognitive consolidation and spiritually behavioral activation phase|Cognitive consolidation and spiritually behavioral activation complement the emotional interventions implemented in earlier stages. This cognitive process aids in the transformation and integration of adaptive growth, enabling patients to assimilate the knowledge and insights acquired during therapy. Therapists take a directive and co-constructivist approach, guiding patients to discover emotionally adaptive reconciliations and meanings that challenge and reshape their emotional and cognitive frameworks in the cognitive consolidation and spiritually behavioral activation phase. Aligned with this cognitive shift, spiritual behavioral activations involve creating plans to address unmet needs.
224010854|NCT07194460|DEVICE|Peripheral Magnetic Stimulation (PMS)|Treatment will be administered using a Peripheral Magnetic Stimulation (PMS) device. The intervention involves directing magnetic fields to stimulate specific peripheral nerve regions to regulate neural activity and improve symptoms.
224010855|NCT07194460|DEVICE|ham control group receiving PMS intervention|Identical to the experimental group in all procedures, except that no electrical stimulation is delivered.
224010856|NCT07194460|OTHER|Exercise|See previous sections
224010857|NCT07194460|OTHER|PMS＋Exercise|See previous sections
224296400|NCT00951626|BEHAVIORAL|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
223390072|NCT03629184|DRUG|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
224010858|NCT07193680|OTHER|Intervention arm: expectant management if sFlt-1/PlGF<38|If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.
224010859|NCT07193680|OTHER|Standard care: elective delivery at 37 weeks of gestation|In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.
224010860|NCT07194096|OTHER|no intervention|no intervention
224296401|NCT00951626|DIETARY_SUPPLEMENT|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
223390073|NCT03629184|DRUG|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
223390074|NCT01263938|DRUG|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
223564113|NCT00803400|DRUG|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association)."
223390075|NCT03732963|DRUG|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
224010861|NCT07194525|OTHER|A standardized treatment algorithm for postoperative ileus after abdominal surgery, based on nasogastric tube output and including stepwise use of water-soluble contrast, imaging, and prokinetic medic|"The Ileus Management Protocol (I-MAP) is a standardized algorithm for the treatment of postoperative ileus (POI) after abdominal surgery. Management decisions are based on nasogastric tube (NGT) output measured every 12 hours. Depending on output and tolerance, patients may receive:~Water-soluble contrast (Telebrix® gastro, ioxitalamic acid 300 mg/mL) administered via NGT, followed by a clamp test at 4 hours.~Diagnostic imaging (CT-scan or X-ray) if ileus persists or small bowel obstruction is suspected.~Intravenous Neostigmine® (2.5 mg diluted in 500 mL NaCl 0.9%, infused over 5 hours) as a prokinetic, only after small bowel obstruction is excluded.~The protocol is applied until resolution of POI or requirement of further intervention."
224010862|NCT00905515|DRUG|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
224010863|NCT00905515|DRUG|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
224010864|NCT00358176|DRUG|Risedronate (HMR4003)|
224010865|NCT00248482|DRUG|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
224010866|NCT00248482|DRUG|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
224010867|NCT00248482|DRUG|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
224010868|NCT04013048|DRUG|[14C]-Fluzoparib|Patients will receive single dose of orally \[14C\]- Fluzoparib on Day 1.
224010869|NCT01455389|DRUG|DOTAP:Chol-TUSC2|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
224010870|NCT01455389|DRUG|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
224010871|NCT01455389|DRUG|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-TUSC2 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
223390076|NCT03732963|DRUG|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
224010872|NCT01455389|DRUG|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol TUSC2
224010873|NCT04554524|DRUG|Chemotherapy+Pembrolizumab.|Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). After 4 cycles treatment, complete response subjects continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, some of partial disease and stable disease subjects can receive surgical treatment. And then continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab up to disease progression, other partial disease and stable disease subjects cannot be removed by surgery will continue carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab for 4 cycles and then pembrolizumab or Normal Saline up to disease progression.
224010874|NCT02227979|BEHAVIORAL|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
224010875|NCT02227979|BEHAVIORAL|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
224010876|NCT05161221|DRUG|OxyCODONE 5 mg Oral Tablet|Participants will receive 20 OxyCODONE 5 mg Oral Tablet post surgery for pain control
224010877|NCT05161221|DRUG|Naproxen 500 Mg|Participant will receive Naproxen 500 Mg post surgery for pain control
224010878|NCT05161221|DRUG|Tylenol Pill|Participants will be instructed to take up to 1000mg of Tylenol by mouth for pain control
224010879|NCT05161221|DRUG|Liposomal bupivacaine|Participants will receive pre-operative adductor canal block with liposomal bupivacaine (Exparel)
224010880|NCT05161221|PROCEDURE|Femoral Nerve Catheter|Participants will receive pre-operative femoral nerve catheter
224010881|NCT04187807|DRUG|Melatonin 5 mg|Placebo
224010882|NCT03057522|BEHAVIORAL|Change in running cadence|The intervention will involve a home exercise program designed to increase the running cadence in recreational runners.
224010883|NCT02736461|PROCEDURE|Floor repair surgery|
224010884|NCT01843127|DRUG|Ranolazine|
223390077|NCT05457777|BEHAVIORAL|Motivational interview in digital game addiction|Motivational interviewing, which is a technique developed by William Miller that aims to change behavior by revealing the contradiction of problematic behavior with the value judgments of the person and creating motivation by the counselor, will be applied to the individuals with digital game addiction.
223390078|NCT03385889|PROCEDURE|Cervical Spine Mobilization|C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
223390079|NCT03385889|PROCEDURE|Cervical Spine Manipulation|C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
223390080|NCT02000492|BEHAVIORAL|Football|
223390081|NCT02000492|BEHAVIORAL|Running|
224010885|NCT01843127|DRUG|Placebo|
223390082|NCT02000492|BEHAVIORAL|Circuit training|
223564114|NCT05837611|BEHAVIORAL|Deposit Contract|A deposit contract requires individuals to put down money that is earned back contingently upon meeting their goals.
224010886|NCT01843127|DRUG|Exenatide|
224010887|NCT05762289|OTHER|Thrust Manipulation (in weight bearing and non weight bearing)|Pain and Range of cervical motion was assessed before and after manipulation in both groups.
224010888|NCT03394001|PROCEDURE|Wound infiltration|Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
224010889|NCT03394001|DRUG|Lidocaine Hydrochloride|20 ml of 1% Lidocaine solution
224010890|NCT03394001|DRUG|Ketorolac tromethamine|20 mL of saline with 30 mg ketorolac
224010891|NCT00081627|DRUG|CoFactor and 5FU|
224010892|NCT05401825|BIOLOGICAL|pfizer, astrazeneca,moderna,sinofac|effect of COVID 19 vaccination on pregnancy outcomes
223390083|NCT03957044|OTHER|The education of sensory integration with vestibular education|"Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, trampoline, and balance board were used."
223390084|NCT00800267|DRUG|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
223390085|NCT00800267|DRUG|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
223390086|NCT00800267|DRUG|timolol 0.5%|one drop in the morning and evening
223390087|NCT02863796|DEVICE|WhiteSwell System|To promote movement of interstitial fluid to the intravascular space to allow for the body to remove it, in conjunction with a diuresis regimen.
223390088|NCT02548143|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|LR769
223390089|NCT00366431|DRUG|MOA-728|
223390090|NCT06770036|BEHAVIORAL|Implementation Resource Package for Caregivers|The implementation resource package for caregivers is a set of resources provided to caregivers that aims to support their use of evidence-based behavior management practices and home-school communication strategies.
223390091|NCT03440125|DRUG|Cayenne Pepper topical|20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
223390092|NCT03440125|DEVICE|Electrical stimulation|Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
223390093|NCT03440125|PROCEDURE|Massage|10 minutes of classical massage of low back pain area.
223564115|NCT05837611|OTHER|Transdermal Alcohol Monitoring|Using a SCRAM-Cam device participants will be monitored for their alcohol use.
223564116|NCT03643341|BEHAVIORAL|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
224010893|NCT01234077|DEVICE|CPC M1|CPC M1
224010894|NCT02980731|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
224010895|NCT05162989|DEVICE|iCare HOME2 vs iCare IC200|Measurement of IOP with iCare HOME2 compared with iCare IC200.
224010896|NCT03552432|DRUG|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
224010897|NCT04140019|DIAGNOSTIC_TEST|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
224010898|NCT04790656|OTHER|Conventional Therapy|Subjects will randomly placed into intervention group and control group . In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
224010899|NCT04790656|OTHER|Cycle ergometer combine with CPAP|Physical exercise on a cycle ergometer combine with CPAP will be performed in a single daily session from the second to the fourth postoperative days . The maximum exercise time for postoperative day 2 will be 20 min, and 30 min for the third and fourth postoperative days.
224010900|NCT04196491|BIOLOGICAL|bb2121|CAR-T Cell Therapy
224010901|NCT04196491|DRUG|Fludarabine|Lymphodepleting Chemotherapy
224296402|NCT00951626|OTHER|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
224296403|NCT00951626|OTHER|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
224296404|NCT00951626|PROCEDURE|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
223390094|NCT05493501|DRUG|Aumolertinib monotherapy|Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
223390095|NCT05493501|DRUG|Osimertinib monotherapy|80 mg tablet administered orally, once daily
223390096|NCT05493501|DRUG|Pemetrexed|Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
223390097|NCT05493501|DRUG|Cisplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
223390098|NCT05493501|DRUG|Carboplatin|Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
223390099|NCT05493501|DRUG|Paclitaxel|Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
223390100|NCT05493501|DRUG|Nab paclitaxel|Administered by IV Infusion given over 4 fixed cycles per prescribing information.
223390101|NCT05493501|DRUG|Gemcitabine|Administered by IV Infusion over 4 fixed cycles per prescribing information.
224010902|NCT04196491|DRUG|Cyclophosphamide|Lymphodepleting Chemotherapy
224010903|NCT04196491|DRUG|Lenalidomide|Maintenance Therapy
224010904|NCT01787149|DRUG|DMARDs|
224010905|NCT02016040|PROCEDURE|High Intensity Focused Ultrasound|
224010906|NCT02968316|OTHER|BIA measurement|observation only
224010907|NCT00134745|DRUG|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
224010908|NCT05396768|OTHER|Assessment using the ACTION-tool.|Participants will be assessed using the ACTION-tool while they are performing a CTI on a porcine rib model and Thiel embalmed human cadavers.
224296405|NCT00951626|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
224296406|NCT00951626|PROCEDURE|assessment of therapy complications|Collected throughout the 12 month study period
224010909|NCT01275950|BEHAVIORAL|Health Education|"1. Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.~2. Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.~3. Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
223390102|NCT01654692|DRUG|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
223390103|NCT06208540|DRUG|Cerebrolysin|Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.
223390104|NCT06208540|OTHER|olfactory and gustatory trainings|olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention
223390105|NCT02552901|DRUG|0.1 mg/kg ICG Dose|least efficacious dose
223390106|NCT02552901|DRUG|0.5 mg/kg ICG dose|per package insert
223390107|NCT06904872|DRUG|Crofelemer Powder for Oral Solution|Crofelemer Powder for Oral Solution
223390108|NCT06904872|DRUG|Matched Placebo Powder for Oral Solution|Matched Placebo Powder for Oral Solution
223390109|NCT03901976|DEVICE|bed exit detection|bed exit detection to avoid patients fall
224010910|NCT05322993|DEVICE|GI Genius|The use of artificial intelligence during colonoscopy to improve polyp detection.
224010911|NCT05322993|DEVICE|Standard white light colonoscope|Standard colonoscopy.
224010912|NCT03470246|BEHAVIORAL|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
224010913|NCT03470246|BEHAVIORAL|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
224010914|NCT03470246|BEHAVIORAL|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
224010915|NCT04393337|OTHER|Gestational Age Chart Method|The endotracheal tube insertion depth is obtained by the gestational age chart
224010916|NCT04393337|OTHER|Nasal-Tragus Length Method|The endotracheal tube insertion depth is obtained by the nasal-tragus method formula
224010917|NCT04341402|DRUG|Antifungal Nail Gel Study|Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.
224010918|NCT05497973|BEHAVIORAL|E-health ecosystem of stepped psychosocial care|"1. Screening and monitoring: weekly administration of an emotional state thermometer. If the score is \>5, participants are asked to complete the HADS. If HADS' score \>10, step 2 is assigned. The same procedure is followed for steps 3 \& 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~2. Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~3. Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q\&As.~4. Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available."
224296407|NCT00951626|PROCEDURE|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
223390110|NCT06344273|BEHAVIORAL|ROM exercises|Each individual in the case group will have lower extremity ROM exercises, each of which will last 20 minutes, at the beginning of the session and at the beginning of the hour until the end of the session.
223390111|NCT07095049|DRUG|Apo-Si-K170A-C76|Apo-Si-K170A-C76 is an small interfering RNA (siRNA) against SARS-CoV-2
223390112|NCT07095049|DRUG|Placebo|5% glucose, 0.5% benzyl alcohol in RNase free water
223390113|NCT07095803|DRUG|Ivonescimab (20mg/kg Q3W)|Patients received intravenous everciximab (20mg/kg Q3W) within 1 week before and after radiofrequency ablation.
223390114|NCT07095803|PROCEDURE|radiofrequency ablation|Patients received radiofrequency treatment for less than three lesions.
223390115|NCT07097064|COMBINATION_PRODUCT|standard radiotherapy with chemotherapy|intensity-modulated conformal radiotherapy (IMRT) 50-54 Gy in 25-30 fractions with concomitant Xeloda 800-825 mg/m2 morning and evening 5d/7.
223390116|NCT07097064|RADIATION|MRI-guided adaptive stereotactic radiotherapy (SMART)|MRI-guided adaptive stereotactic radiotherapy (SMART) 50 Gy / 5 fractions without concomitant chemotherapy.
223564117|NCT02302248|BEHAVIORAL|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
223564118|NCT02302248|BEHAVIORAL|Expressive writing intervention|3 week access to a web-based expressive writing platform.
223564119|NCT00884962|DEVICE|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
223564120|NCT01159925|PROCEDURE|Serum sample|Serum samples collected
223390117|NCT07097090|BEHAVIORAL|Emotion Recognition Training Program: A structured school-based intervention designed to enhance children's ability to recognize emotions through facial expressions, tone of voice, and body language.|"Emotion Recognition Training Program Integrated CASEL-based activities with CBT principles and digital tools to enhance emotional attribution and recognition in primary school children.~The intervention consisted of three structured activities based on the CASEL framework (Collaborative for Academic, Social, and Emotional Learning), integrated with cognitive-behavioral principles inspired by the model of Albert Ellis. Sessions included interactive use of digital whiteboards and narrative tools (e.g., emotion-themed interactive stories), aimed at improving children's ability to attribute emotions to others and to emotionally evaluate events.~In addition, a neurostimulative component was included, exposing children to visual stimuli with either neutral or fear-inducing emotional valence. Participants were asked to rate the perceived emotional intensity, supporting the development of self-regulation and emotional differentiation."
223390118|NCT07097090|BEHAVIORAL|No Intervention: Observational Cohort|Control group received no intervention in order to serve as a baseline for comparison, isolating the effects of the emotion recognition training on behavioral and cognitive outcomes.
223390119|NCT07097883|PROCEDURE|Percutaneous Nephrolithotomy|Patients underwent percutaneous nephrolithotomy (PCNL) for renal calculi \>2 cm.
223390120|NCT07097298|BEHAVIORAL|empathy and compassion training|A 6-week empathy and compassion training will be designed and delivered involving PD patients and caregivers. During the compassion training participants will do mindfulness, writing and poetry exercises
223390121|NCT07097597|DEVICE|Comparison 1: New Snoring Application|Measurements obtained from the snoring application under development
224010919|NCT05497973|BEHAVIORAL|Usual psychosocial care|Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
223390122|NCT07097597|DEVICE|Comparison 2: Commercially Available Snoring Application|Measurements from a commercially available snoring application
223390123|NCT07097597|DEVICE|Comparison 3: Polysomnography|Measures taken from home or in laboratory polysomnography
223390124|NCT07097805|BEHAVIORAL|GLITTER comprehensive management|The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.
223390125|NCT07095205|DRUG|Nicotine transdermal patch|The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).
223390126|NCT07095205|DRUG|PET Scan with [18F] VAT|All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.
224010920|NCT03090243|DEVICE|Virtual colonoscopy|Inserting a Foley catheter through the anus, and gas inflating of the bowel.
224010921|NCT04465253|OTHER|Best Practice|Undergo standard of care occupational therapy
224010922|NCT04465253|BEHAVIORAL|Motivational Interviewing|Participate in discussions via videoconferencing
224010923|NCT04465253|BEHAVIORAL|Motivational Interviewing|Participate in interview via videoconferencing
224010924|NCT04465253|OTHER|Quality-of-Life Assessment|Ancillary studies
224010925|NCT04465253|OTHER|Questionnaire Administration|Ancillary studies
224010926|NCT04031807|PROCEDURE|Single-Incision Sling|The women with stress urinary incontinence underwent single-incision sling procedure.
224010927|NCT01290315|DRUG|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
224010928|NCT01290315|DRUG|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
224010929|NCT02724059|PROCEDURE|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
224010930|NCT00828477|DRUG|Xibrom|Xibrom: two times a day for seven days in the first eye.
224010931|NCT00828477|DRUG|Nevanac|Nevanac: three times a day for seven days in the second eye.
224010932|NCT00591721|BEHAVIORAL|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
224010933|NCT00599911|DRUG|Lu AA24530|per oral, once daily for 6 weeks
224010934|NCT00599911|DRUG|Duloxetine|per oral, once daily for 6 weeks
224010935|NCT00599911|DRUG|Placebo|per oral, once daily for 6 weeks
224010936|NCT01953653|BEHAVIORAL|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
224010937|NCT05035784|DRUG|Fecal supernatant|Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
224010938|NCT05035784|DRUG|Placebo|a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
224010939|NCT02699086|DRUG|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
224010940|NCT05999643|DIAGNOSTIC_TEST|Drug: 68Ga-FAPI|Intravenous injection of one dosage of 111-185 MBq (3-5 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image SpA lesions in SI joints, spine, musculoskeletal and the extra-articular involvement by PET/CT.
223390127|NCT07097194|BEHAVIORAL|EX program|Quit plan with interactive exercises, educational videos, and tailored text messages and emails; peer support; coach chatting; nicotine replacement therapy (patches, gum, or lozenges). All components are self-selected.
223390128|NCT07096583|BIOLOGICAL|METR-NK cell（metabolic remodeling nature killer cells）|100 mL METR-NK cells were diluted in 500 mL 0.9% sodium chloride normal saline at 37℃, and the infusion volume of METR-NK cells was not less than 2×107 cells/kg for 1 day as a course of treatment, and the infusion time was maintained for 30 minutes on the 10th day before chemotherapy.
223390129|NCT07096609|DRUG|Lenvatinib Capsules|Lenvatinib will be administered orally once daily at a dose of 12 mg (for patients weighing ≥ 60 kg) or 8 mg (for patients weighing \< 60 kg). Each treatment cycle consists of 4 weeks (i.e., 28 days).
224010941|NCT06206187|OTHER|Automated detection of the intracardiac thrombus through deep learning|A deep learning model will identify the intracardiac thrombus. The AI model will produce an assessment of intracardiac thrombus using video based features.
224010942|NCT06206187|OTHER|Electrophysiologist judgment of the intracardiac thrombus|Cardiac electrophysiologists use their own experience to determine whether there is intracardiac thrombus
224010943|NCT01837784|OTHER|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
224127251|NCT02276157|DEVICE|Direct peroral cholangioscopy|"The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary."
224296408|NCT00951626|PROCEDURE|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
223564121|NCT05201430|DRUG|FOLFOXIRI|irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
224010944|NCT05972031|BEHAVIORAL|Person-centred integrated care intervention|See arm description.
224010945|NCT05577884|DIAGNOSTIC_TEST|noncontrast-enhanced whole-body CT|"noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~* conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~* ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software."
224010946|NCT03809429|DRUG|FE 999049 + GnRH agonist (GONAPEPTYL)|Pre-filled injection pen
224010947|NCT03809429|DRUG|FE 999049 + GnRH antagonist (CETROTIDE)|Powder and solvent for solution for injection
224010948|NCT02050711|BEHAVIORAL|Pulmonary rehabilitation|
224010949|NCT02050711|OTHER|Usual care|
224010950|NCT01251185|DEVICE|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
224010951|NCT02323282|DRUG|ropivacaine|
224010952|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 1 with Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day. Practice according to Nutrilite Lifestyle Guideline per day.
224010953|NCT05872360|DIETARY_SUPPLEMENT|Bundle Group 2 without Nutrilite Lifestyle|All-plant protein booster: 2 spoons (15g), twice per day. Calcium \& Magnesium：3 tablets one time per day. Glucosamine: 2 tablets two times per day. 20 minutes training with EMS (Electric Muscle Stimulation) per day.
224010954|NCT05872360|DIETARY_SUPPLEMENT|Control Group 1|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day.
224010955|NCT05872360|DIETARY_SUPPLEMENT|Control Group 2 with Nutrilite Lifestyle|Placebo: 2 spoons (15g), twice per day. Placebo for Calcium \& Magnesium：3 tablets one time per day. Placebo for Glucosamine: 2 tablets two times per day. Practice according to Nutrilite Lifestyle Guideline per day.
224010956|NCT04407871|OTHER|Acupuncture and Chinese Herbal Medicine|1\) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.
224010957|NCT04103060|DRUG|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
224010958|NCT04103060|DRUG|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
224010959|NCT03842722|DEVICE|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
224010960|NCT01543984|OTHER|Tailored Physical Activity|Tailored Physical Activity (3\*50 min/week in 10 weeks)
224010961|NCT01543984|BEHAVIORAL|Health Counselling|Health guidance (1,5h)
224010962|NCT03611413|PROCEDURE|ERAS care|ERAS PROTOCOL
224010963|NCT03336567|OTHER|Telephonic interview|Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
224010964|NCT05807529|DRUG|2ccPA|"2-carba-cyclic phosphatidic acid (2ccPA) is a first-in-class phospholipase autotaxin (ATX) inhibitor that may act as a disease-modifying drug and may relieve OA associated symptoms.~Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
224010965|NCT05807529|DRUG|Placebo|"Phase I: 2 dose cohorts (4800μg, 7200μg) single dose at Day 1~Phase II: 3 dose cohorts (2400μg, 4800μg, 7200μg) multiple dose at Day 1, 15, 29"
224010966|NCT05303220|DRUG|Branebrutinib|Specified dose on specified days
224010967|NCT05303220|DRUG|Placebo|Specified Dose on specified days
224010968|NCT05225727|BEHAVIORAL|Me & You - Tech|The 13 MYT lessons will train youth to adopt a zero tolerance approach to dating violence (DV) and contain activities to enable youth to recognize healthy (non-abusive) and unhealthy (abusive) relationships, assess their own relationships, and adopt and practice a lifestyle paradigm of select-detect-protect informed by SCT self-regulatory frameworks. Within this lifestyle paradigm, youth select their personal rules to have only healthy (non-abusive) relationships, detect unhealthy (abusive) relationships that might threaten their rules, and learn to protect their rules using communication, management, and avoidance skills. MYT will tailor content by gender, relationship status, and the youth's DV profile of perpetration or victimization based on the Conflict in Adolescent Dating and Relationship Inventory (CADRI).
224010969|NCT03828747|DRUG|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
224010970|NCT03828747|DRUG|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
224010971|NCT03828747|DRUG|[18F]GTP1|\[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
224010972|NCT04007380|OTHER|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
224010973|NCT00964587|BEHAVIORAL|Education + Problem-Solving Training Self-Study|"* Education + Problem-Solving Training Self-Study~* One session of Literacy-Adapted Diabetes and CVD Risk Education~* Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
224010974|NCT00964587|BEHAVIORAL|Education + Group Problem-Solving Training|"* Education + Group Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Group problem-solving training eight, 90-minute sessions"
224010975|NCT00964587|BEHAVIORAL|Education + Individual Problem-Solving Training|"* Education + Individual Problem-Solving Training~* One session of the Literacy-Adapted Diabetes and CVD Risk Education~* Individual problem-solving training (eight, 60-minute sessions)"
224010976|NCT00964587|BEHAVIORAL|Usual Care|"* Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~* Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
224010977|NCT05009953|DRUG|Irinotecan Liposome Injection|Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
224010978|NCT05009953|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
224010979|NCT05009953|DRUG|Fluorouracil|5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
224010980|NCT05009953|DRUG|Leucovorin|Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
224010981|NCT04465500|RADIATION|External Beam Radiation|EBRT will be administered every 5 consecutive days for 5 consecutive weeks. This is standard of care practice for this therapy. This may be revised as applicable per treating physician discretion. The dose of radiation will be in accordance with standard clinical practice guidelines for the treatment of prostate cancer.
224010982|NCT04465500|RADIATION|HDR Brachytherapy|HDR brachytherapy will be administered per standard clinical practice (per NCCN guidelines version 1.2020 for prostate cancer), however standard clinical practice may vary between clinicians. Therefore, the dose of 15Gy in 1 fraction and a set of dosimetry guidelines are to be followed for the purposes of this study. A diagnostic MRI will be co-registered with Transrectal Ultrasound (TRUS) to perform the HDR brachytherapy.
224010983|NCT04465500|DRUG|Androgen Deprivation Therapy|The dosing and administration of ADT will be in accordance with the drug label for the drug(s) used for this purpose. Participants may receive ADT before and/or during the course of this study.
224010984|NCT03534128|OTHER|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
224010985|NCT03069755|OTHER|No intervention|No intervention
224010986|NCT03939559|PROCEDURE|Static, dynamic and functional balance exercises|In the first group (G1), 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks
224010987|NCT03939559|PROCEDURE|Static, dynamic and functional balance exercises with dual task|In the second group (G2), 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
224010988|NCT06002893|DIETARY_SUPPLEMENT|Cholesfytol NG®) supplement|General Practitioner (GP) prescribed oral Cholesfytol NG®) supplement
224010989|NCT06492915|DRUG|Chiauranib|Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily
224010990|NCT06492915|DRUG|Albumin-paclitaxel Injection|Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
224010991|NCT06492915|DRUG|Gemcitabine Injection|Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
223564122|NCT05201430|DRUG|CapeOX|oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
224010992|NCT01375400|DRUG|Aspirin|Administration of 300 mg of aspirin, per os.
224010993|NCT01375400|BIOLOGICAL|blood sample|2 blood samples will be performed
224010994|NCT03666377|OTHER|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
224010995|NCT00641329|DRUG|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
224010996|NCT00641329|DRUG|Placebo|Matching placebo tablets
224010997|NCT00244816|DRUG|Taxoprexin|
224010998|NCT04744168|OTHER|Acupuncture|Puncture of 5 points 4GI, 6RP, 34VB, 36E, 3F
224010999|NCT04744168|OTHER|Placebo Acupuncture|Puncture of point HM
223546202|NCT01784367|DEVICE|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
223546203|NCT00470002|DRUG|Somatropin|
224011000|NCT00408239|DRUG|YM150|Oral
224011001|NCT00408239|DRUG|enoxaparin|Sub cutaneous
224011002|NCT03698500|OTHER|Removal of blood|10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw
224011003|NCT00092352|DRUG|MK0966, rofecoxib|
224011004|NCT00092352|DRUG|Comparator: celecoxib, placebo|
224011005|NCT03848013|DEVICE|Q switched Nd YAG laser|Laser device emitting Q switched Nd YAG aiming for skin toning
224011006|NCT03848013|DEVICE|Fractional CO2 laser|Laser device emitting fractionated ablative laser aiming for skin resurfacing
224011007|NCT03623854|BIOLOGICAL|Nivolumab|Given IV
224011008|NCT03623854|BIOLOGICAL|Relatlimab|Given via infusion
224011009|NCT01144052|DRUG|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units \[MIU\])
224011010|NCT01144052|DRUG|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
224011011|NCT04444973|PROCEDURE|Balloon pulmonary angioplasty|Balloon dilatation of sub segmental pulmonary artery web disease
224011012|NCT02206477|DRUG|Dimethyl Sulfoxide|
224011013|NCT02206477|DRUG|Saline 0.9%|
224011014|NCT03448770|DRUG|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
224011015|NCT03448770|DRUG|Lactulose : 20-30gm|Lactulose : 20-30gm
224011016|NCT00234845|DRUG|adalimumab|
224011017|NCT00234845|DRUG|methotrexate|
224011018|NCT04893343|OTHER|Antibiotic treatment|Antibiotic treatment
224011019|NCT04893343|OTHER|No antibiotic treatment|No antibiotic treatment
224011020|NCT05115643|BEHAVIORAL|Immobilization|Immobilization of left arm using a brace and sling.
223546204|NCT02457650|DRUG|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
224011021|NCT03082118|DEVICE|Vesair Bladder Control System|Intravesical balloon
224011022|NCT04033666|OTHER|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
224011023|NCT04033666|OTHER|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
224011024|NCT02232607|DRUG|Lacidipine, low dose|
224011025|NCT02232607|DRUG|Lacidipine, medium dose|
224011026|NCT02232607|DRUG|Lacidipine, high dose|
224011027|NCT02232607|DRUG|Placebo|
224011028|NCT01581359|DRUG|Triptorelin acetate|"* Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
224296409|NCT00951626|PROCEDURE|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
224011029|NCT00901433|DEVICE|Personal WheezoMeter|pulmonary sounds analyzer
224011030|NCT01805401|DEVICE|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
224011031|NCT04938700|DRUG|probiotics|Probiotics as granules can be used for infants and adolescents
224011032|NCT04938700|DRUG|conventional medical treatment|Treatment for allergic diseases includes anti-allergic drugs, nasal spray hormones, inhaled hormones, external hormones, etc
224011033|NCT00424385|DRUG|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
224011034|NCT05564416|BIOLOGICAL|Atezolizumab|Given IV
224011035|NCT05564416|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224011036|NCT05564416|PROCEDURE|Biospecimen Collection|Correlative studies
224011037|NCT05564416|PROCEDURE|Computed Tomography|Undergo CT
224011038|NCT05564416|PROCEDURE|Cystoscopy|Undergo cystoscopy
224011039|NCT05564416|DRUG|Erdafitinib|Given PO
224011040|NCT05564416|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224011041|NCT00355199|DRUG|Rituximab-HDS|Rituximab-HDS
224011042|NCT00355199|DRUG|Rituximab-CHOP|Rituximab-CHOP
224011043|NCT02104050|DRUG|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
224011044|NCT02104050|DRUG|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
224011045|NCT02503189|DRUG|KCT-0809 ophthalmic solution|
224011046|NCT02503189|DRUG|Placebo|
224011047|NCT06250244|DRUG|177Lu-LNC1011|\[177Lu\]Lu-LNC1011 is a novel long-circulating PSMA therapeutic probe.
224011048|NCT04241107|PROCEDURE|Laparoscopic repair of Uterine niche|Repair of uterine niche through Laparoscopic approach.
224011049|NCT04241107|PROCEDURE|Transvaginal repair of Uterine niche|Repair of uterine niche through Transvaginal approach.
223390130|NCT07095400|OTHER|strength training|"An intervention based on the application of a strength training protocol for multi-joint and single-joint muscles will be implemented, performed with a slow-moderate execution speed. This intervention will be carried out over 12 weeks, with a total of 24 sessions (2 sessions per week), each lasting 45 minutes. In all of these sessions, free weights will be used, performing three sets at 60-80% of 1RM for 8-12 repetitions.~The exercise protocol will include:~* Squats~* Deadlifts~* Rows~* Bicep curls~* Bench press~* Shoulder press~Each set will be performed to muscular failure, progressing in the number of repetitions (from 8 to 12). Once 12 repetitions are reached, the load volume will be increased by adding 5% to the weight."
223390131|NCT07095647|PROCEDURE|Hysteroscopy|Hysteroscopic-guided suction evacuation and double-layer laparoscopic repair of the niche were performed concomitantly and followed by second-look hysteroscopy to ensure the competence of the repair.
224011050|NCT02225210|DRUG|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2\~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
224011051|NCT02225210|DRUG|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05\~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
224011052|NCT02225210|DRUG|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
224011053|NCT01308138|BEHAVIORAL|Exercise training|exercise training
224011054|NCT01308138|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning
224011055|NCT00085787|DRUG|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
224011056|NCT02405728|DEVICE|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
224011057|NCT02405728|DEVICE|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
224011058|NCT01978327|DRUG|GSK2647544|repeat dose
224011059|NCT01978327|DRUG|drug-drug interaction|drug-drug interaction
224011060|NCT01035645|DRUG|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
224011061|NCT04120571|OTHER|Sleep Audiological Intervention Device (SleepAID)|subtle sound stimulation in phase with the slow oscillations
224011062|NCT04120571|OTHER|sham control|no noise
224011063|NCT02503852|DEVICE|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
224011064|NCT02503852|DEVICE|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
224011065|NCT02503852|PROCEDURE|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
224011066|NCT02503852|PROCEDURE|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
224011067|NCT00110877|DRUG|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
224011068|NCT00110877|DRUG|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
224011069|NCT00701831|DRUG|Insulin glargine|The dose is titrated according to patient needs
224011070|NCT05715385|PROCEDURE|laser photocoagulation|"Laser Parameters of grid photocoagulation Diffuse diabetic macular edema is treated by a grid pattern of laser. The grid is applied to areas of retinal thickening with diffuse leakage or capillary non-perfusion.~Spot size: 50-100 micron is utilized. The burn intensity for grid laser: barely visible (light grey). Power of laser burn is between 80-100 mw depending on the condition of the laser, the opacities in the media and background pigmentation.~Laser burns should be placed at least one burn width apart, wider if thickening is less severe. If necessary, the grid can extend up to 2 disc diameters superiorly, inferiorly, and temporally from the centre of the macula. One should avoid treating within 500 microns of the disc margin or the centre of the macula.~Duration of about 0.05-0.1 sec is used Number of spots- 100-500"
224011071|NCT05715385|DRUG|eye drop bromfenac 0.09%|twice daily e/d bromfenac 0.09% for 6 weeks
224011072|NCT05715385|DRUG|Placebo|Observation group. No intervention done. Only eye drop carboxymethyl cellulose 0.5% to be instilled thrice a day for 6 weeks.
224011073|NCT03670095|DRUG|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
224011074|NCT03670095|DRUG|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
224011075|NCT00942305|DRUG|Brincidofovir|Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
224011076|NCT00942305|DRUG|Placebo|"Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort."
224011077|NCT02342470|DRUG|Placebo|Drug : Placebo
224011078|NCT02342470|DRUG|PMK-S005 1|Drug : PMK-S005 1 (50mg)
224011079|NCT02342470|DRUG|PMK-S005 2|Drug : PMK-S005 2 (100mg)
224011080|NCT02342470|DRUG|PMK-S005 3|Drug : PMK-S005 3 (150mg)
224011081|NCT02668549|OTHER|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
224011082|NCT00018239|PROCEDURE|Exercise|
224011083|NCT03233139|DRUG|Cemiplimab|Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.
224011084|NCT03233139|DRUG|Ipilimumab|To be administered per protocol
224011085|NCT03233139|DRUG|Platinum-doublet chemotherapy|To be administered per protocol
224011086|NCT03233139|DRUG|Gemcitabine|To be administered per protocol
224011087|NCT03233139|DRUG|Pemetrexed|To be administered per protocol
224011088|NCT03233139|DRUG|Paclitaxel|To be administered per protocol
223390132|NCT07096154|BEHAVIORAL|Group CBT Anxiety Management|An 8-session Group Cognitive Behavioural Therapy for anxiety management.
223390133|NCT07095556|OTHER|Low-level laser therapy|"The low-level laser applications will be made on the same day as the standard of care treatment (day 1), and then day 3, and day 7 by a study team member who is trained in the use of the laser device.~The laser photobiostimulation will be applied using LightWalker® laser (FOTONA), with following settings, Nd:YAG laser 1064 nm, MSP modality (pulse duration), 0.5 W (power), 10 Hz (frequency), 1 min/ 1 cm2 spot using Genova handpiece from buccal, lingual, and occlusal aspects. The Genova handpiece will be placed 1 cm away from gingival tissue.~Participants and operators will wear glasses to protect their eyes from laser beam in all sessions."
224011089|NCT03233139|DRUG|Fianlimab|To be administered per protocol
224011090|NCT05303259|DRUG|Bevacizumab|Bevacizumab 2.5mg/kg, q2w, 4 cycles.
224011091|NCT04220840|PROCEDURE|Damage control strategy|"The damage control strategy constitutes a two stage procedure.~Emergency surgery:~limited resection oft he diseased colonic segment with oral and aboral blind closure, abdominal lavage, temporary vacuum assisted abdominal closure~Second look surgery (48-72 hours later):~reexploration with~1. definite reconstruction (Colorectal anastomosis -/+ diverting ileostomy vs. end colostomy)~2. lavage, vacuum assisted abdominal closure, third look 72 hours after emergency surgery"
224127252|NCT03578848|DEVICE|uAOBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
224127253|NCT03578848|DEVICE|Home BP|As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
224127254|NCT03578848|DEVICE|CBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
224127255|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, needle|Injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles
224127256|NCT04594239|DEVICE|Belotero Balance (+) Lidocaine, cannula|Injection of Belotero Balance (+) Lidocaine into the infraorbital hollows using cannulas
224127257|NCT04594239|DEVICE|Untreated-control / delayed-treatment, needle|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using needles)
224127258|NCT04594239|DEVICE|Untreated-control / delayed-treatment, cannulas|Untreated-control, followed by delayed-treatment with Belotero Balance (+) Lidocaine (injection of Belotero Balance (+) Lidocaine to the infraorbital hollows using cannulas)
224127259|NCT06671756|DIETARY_SUPPLEMENT|Fructose Ingestion|Participants will consume a beverage containing 75g of fructose dissolved in 225ml of water.
224127260|NCT06671756|DIETARY_SUPPLEMENT|Glucose Ingestion|Participants will consume a beverage containing 75g of glucose dissolved in 225ml of water.
223390134|NCT07095777|PROCEDURE|visual perceptual learning|Participants in the VPL group performed 40 minutes of daily monocular training at home for three months, with follow-up evaluations conducted at 1 month and 3 months after training initiation.
224011092|NCT04611308|OTHER|C1q tumor necrosis factor-related protein 6 levels|C1q tumor necrosis factor-related protein 6 is a tumor marker
224011093|NCT01593956|BEHAVIORAL|tDCS|
224011094|NCT05229042|DRUG|Ricolinostat|Oral
224127261|NCT06672731|DIAGNOSTIC_TEST|REMS: Radiofrequency Echographic Multi Spectrometry|it is a non invasive ultrasonographic evaluation of bone and muscle quality
224127262|NCT02408146|PROCEDURE|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
224127263|NCT02408146|DRUG|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
224127264|NCT02408146|PROCEDURE|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
224127265|NCT02408146|DRUG|fentanyl citrate+ ondansetron hydrochloride + normal saline|
224127266|NCT02408146|DRUG|celecoxib|
223390135|NCT07095257|DRUG|ZX-7101A for oral suspension|ZX-7101A will be administered as oral suspension in a single dose on Day 1. Oseltamivir phosphate matching placebo will also be administered as oral suspension twice daily (BID) for 5 days.
223390136|NCT07095257|DRUG|Oseltamivir phosphate for oral suspension|Oseltamivir phosphate will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive ZX-7101A matching placebo as oral suspension, single dose on Day 1.
224011095|NCT02721667|DEVICE|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
224011096|NCT02721667|OTHER|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
224011097|NCT03620916|PROCEDURE|Intravenous morphine|Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days
224127267|NCT06693700|OTHER|Indoor Air Quality Monitor AirGradient ONE|Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.
224127268|NCT00091390|RADIATION|High Dose brachytherapy boost|19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
224127269|NCT00091390|RADIATION|External beam radiotherapy|45 Gy as 1.8 Gy five days a week for five weeks.
224127270|NCT06693219|DIAGNOSTIC_TEST|ultrasonography to confirm the correct placement of a nasogastric tube in the stomach|The sonographic examination consisted of three parts: neck scan, epigastric scan, and injection test using a mixture of 25 mL NaCl 0.9% and 25 mL room air through the nasogastric tube to detect dynamic fogging
224127271|NCT06692023|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
224127272|NCT06692023|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
224127273|NCT06692790|OTHER|Venous Sinus Stenting Procedure|"Performed under general or local anesthesia. Targeted stenosis sites included the right transverse sinus, left transverse sinus, bilateral transverse sinuses, and right transverse and sigmoid sinuses.~Stents used included Venous Sinus Stent (CWS), CASPER, PRTCS, and multiple stents where necessary.~Post-procedure care included antiplatelet therapy and routine follow-up assessments"
224127274|NCT06693167|PROCEDURE|chirurgie canal carpien|study compares a group of patients who received a preoperative auriculotherapy session followed by standard analgesic treatment to a group who received only standard analgesic treatment, and this, during the three days following surgery (D1, D2, and D3).
224127275|NCT06200116|OTHER|Non-Interventional Study|Non-interventional study
224127276|NCT06742398|OTHER|Carbohydrate Dissolvable Strip|"Participants are provided with a carbohydrate dissolvable strip for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The carbohydrate dissolvable strip (Innsol Health Corp.) is primarily composed of sucrose and glucose; however, the full ingredient list includes pullulan, mannitol, menthol, hydroxyl propyl methyl cellulose, eucalyptol, polysorbate 80, glyceryl oleate, purified water."
224127277|NCT06742398|OTHER|Carbohydrate Mouth Rinse|"Participants are provided with a carbohydrate mouth rinse for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The sucrose solution will consist of 64g of sucrose dissolved in 1000 mL of water, with a bolus of 25 mL being used for each mouth rinse. Each mouth rinse solution will have 2mL of red food dye FD\&C Red No. 40 to ensure the same sensory response through appearance."
224127278|NCT06742398|OTHER|Water Mouth Rinse|"Participants are provided with a water mouth rinse for every 12.5% of the time trial that is completed (calculated based on the distance covered).~The water solution will consist of 1000 mL of water, with a bolus of 25 mL being used for each mouth rinse. Each mouth rinse solution will have 2mL of red food dye FD\&C Red No. 40 to ensure the same sensory response through appearance."
224127279|NCT06098261|DRUG|Test (T) Bilastine|Specification: Bilastine 20mg. Produced and supplied by Shandong Hubble Kisen Biological Technology Co., Ltd.
224127280|NCT06098261|DRUG|Reference (R) Bilastine|Specification: Bilastine 20mg. Produced by Menarini International Operations Luxembourg S.A.
224127281|NCT03229759|DRUG|Octenidine Dihydrocloride in aqueous solution|application of investigational product
224127282|NCT03229759|OTHER|Vehicle Control|application of vehicle control
224127283|NCT03229759|OTHER|Saline Control|application of placebo
224011098|NCT03620916|PROCEDURE|Intrathecal morphine|Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale\>4, at least 6 hour interval) over next two days in the postoperative period
224011099|NCT05367154|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (WNY, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
224011100|NCT04496531|DEVICE|Portable Neuromodulation Stimulator|
224011101|NCT05697952|DRUG|E1K 1,200 ㎍/joint|Injection of E1K 1,200 ㎍/joint/ml on target lesion
223390137|NCT07095465|DRUG|ACP-204|Provided as 1 capsule, to be taken orally once daily
223390138|NCT07097363|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223390139|NCT07097363|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223390140|NCT07097363|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223390141|NCT07097363|PROCEDURE|Computed Tomography|Undergo CT scan
223390142|NCT07097363|DRUG|Cyclophosphamide|Given IV
223390143|NCT07097363|DRUG|Doxorubicin|Given IV
223390144|NCT07097363|PROCEDURE|Echocardiography Test|Undergo echocardiography
223390145|NCT07097363|BIOLOGICAL|Epcoritamab|Given SC
223390146|NCT07097363|DRUG|Etoposide|Given IV
223390147|NCT07097363|OTHER|Fludeoxyglucose F-18|Given fludeoxyglucose
223390148|NCT07097363|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223390149|NCT07097363|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223390150|NCT07097363|DRUG|Prednisone|Given PO
223390151|NCT07097363|BIOLOGICAL|Rituximab|Given IV
223390152|NCT07095439|RADIATION|Total Neoadjuvant Treatment|Participants in this arm receive 4 cycles of induction chemotherapy CAPEOX (or 5 cycles of FOLFOX6), followed by short course radiotherapy (25 Gy in 5 fractions) delivered via IMRT technique ,then consolidation chemotherapy in the form of : 2 cycles of CAPOX (or, 4 cycles of FOLFOX6). Total mesorectal excision (TME) will be performed for non-metastatic patients within 8-12 weeks of the short course radiotherapy.
224011102|NCT05697952|DRUG|E1K 2,400 ㎍/joint|Injection of E1K 2,400 ㎍/joint/ml on target lesion
224011103|NCT05697952|DRUG|placebo|Injection of 3ml saline on target lesion
224011104|NCT00142077|DEVICE|Electronic health record and messaging system|
223390153|NCT07096466|OTHER|DHA stain|On day 1, the volar forearm test area will undergo DHA staining (250μl of 10% DHA solution applied under occlusion with Finn Chambers for 8 hours)
223390154|NCT07096466|OTHER|No DHA stain|On day 1, the volar forearm test area will not undergo DHA staining.
224011105|NCT02545023|OTHER|Quality-of-Life Assessment|Complete an in-person one-on-one interview
223390155|NCT07096466|OTHER|Cosmetic product application - forearm|The cosmetic product will be applied twice daily for two weeks to the volar forearm test area.
223390156|NCT07096466|OTHER|No cosmetic product application - forearm|The cosmetic product will not be applied for two weeks to the volar forearm test area.
223390157|NCT07096466|OTHER|Cosmetic products application - face|For two weeks on the face (excluding eye area), a cleansing cosmetic product containing Mitopure will be applied twice daily, and the cosmetic test product (that is used on forearms) will be applied once daily.
224011106|NCT02545023|OTHER|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
224011107|NCT04870684|OTHER|thromboelastometry test|This study does not modify the usual care of the patient. Only 5 citrated tubes (maximum 15 mL of blood) are collected in addition to the initial emergency department sample (routine care). The patient's care follows the classic thrombolysis alert pathway. There is no additional complementary examination or additional neurological evaluation. Clot formation kinetics will be evaluated by thromboelastometry to determine the predictive parameters of revascularization. Clot formation and lysis parameters as well as revascularization according to thrombo-inflammation processes will be studied.
224011108|NCT01375231|PROCEDURE|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
224011109|NCT01375231|PROCEDURE|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
224011110|NCT00142181|DRUG|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
224011111|NCT01949038|DRUG|Oral alprazolam|
224011112|NCT01949038|DRUG|Sublingual alprazolam|
223390158|NCT07097766|BEHAVIORAL|"HBM-Based Education and Motivational Interviewing"|This intervention consists of a structured 3-session educational program and motivational interviews based on the Health Belief Model (HBM). It aims to increase knowledge about HPV infection and improve HPV vaccination awareness among women aged 18-45.
223390159|NCT07095153|BEHAVIORAL|Neuroathletic Training (NAT)|The intervention group will undergo an 8-week Neuroathletic Training program, conducted three times a week. The program consists of exercises designed to enhance visual-motor coordination, reaction time, balance, and proprioception, integrated with classical judo training. Each session lasts approximately 20-25 minutes and includes 6 to 8 different exercises targeting cognitive and neuromotor skills.
223390160|NCT07095153|BEHAVIORAL|Routine Judo Training|The control group will continue with their usual judo training program, which follows the training plans and technical development programs set by the Turkish Judo Federation for athletes aged 10-18. This program focuses on maintaining and improving existing technical, tactical skills, physical conditioning, and sports culture without any additional neuroathletic training interventions.
224011113|NCT01949038|DRUG|Oral placebo|
223390161|NCT03398603|PROCEDURE|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
223390162|NCT07095608|BEHAVIORAL|Pressure and stretch sensitivity testing|"We will measure pressure sensitivity by applying gradual pressure (50 kPa/s) at the site of testing using a digital pressure algometer. In healthy subjects, we will perform these measurements on the lateral tongue on the left and the right side. In cancer patients, we will first test on the unaffected contralateral matched site and then at the site of the cancer. We will define pressure sensitivity as the mean of three threshold measurements.~For measuring stretch sensitivity, we will use a visual analog scale (VAS) recording of pain scores associated with tongue stretching. Participants will be asked to perform tongue range of motions (ROM): protrusion, elevation, right and left lateralization, and rate sensitivity score on the VAS scale after holding the tongue in position for five seconds. We will define stretch sensitivity as the sum of VAS scores for protrusion, elevation, right and left lateralization."
223390163|NCT00990925|BEHAVIORAL|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
223390164|NCT00990925|OTHER|Usual Care|Care as usual
223546205|NCT02457650|DRUG|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
223390165|NCT04598386|OTHER|PR Lotion - AMP Human Performance|Sodium Bicarbonate Topical Solution. For use of the PR Lotion solution, consumers are instructed to apply the lotion to areas of the body that have been identified as most likely to use during their activity (i.e. calves and thighs for runners, shoulders and forearms for swimmers, etc.). Moreover, the product can be applied up to 2 hours prior to beginning a workout or event with one use supporting a 4-6 hour workout. AMP Human has also verified the safety of their product as being well tolerated in consumers \>2 years of age unless there is a known allergy to an ingredient on the label. Moreover, to the company's knowledge no side effects have been reported per the SAFETY Section at https://amphuman.com/pages/faq.
223390166|NCT04598386|OTHER|Placebo Lotion|Placebo Topical Solution. Lotion will be created by the AMP Human Performance company and will include all ingredients similar to the PR Lotion product except for the exclusion of sodium bicarbonate.
223390167|NCT00226980|DRUG|Thalidomide|
223390168|NCT00226980|DRUG|Capecitabine|
223390169|NCT05620082|DIETARY_SUPPLEMENT|Standard liquid-based oral nutritional supplement|An anonymous ready-made drink supplement: 125g, 306kcal, 18.3g protein.
223390170|NCT05620082|DIETARY_SUPPLEMENT|Fortified porridge|Vital Daily High Protein Oats (Adams Vital Nutrition Ltd.): 157g, 230kcal, 15g protein.
223390171|NCT06011707|BEHAVIORAL|OPT-IN|Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).
223730403|NCT02618434|DRUG|Placebo|Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
224011114|NCT01949038|DRUG|Sublingual placebo|
224011115|NCT04773197|BEHAVIORAL|Beating the Blues (BtB)|Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
224011116|NCT04773197|BEHAVIORAL|Entertain Me Well (EMW)|Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
224011117|NCT04773197|BEHAVIORAL|Coaching|A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
224011118|NCT03253445|BEHAVIORAL|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
223390172|NCT06011707|OTHER|Psychoeducational control|This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
223390173|NCT03985540|BEHAVIORAL|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
223390174|NCT03985540|BEHAVIORAL|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
223390175|NCT03985540|BEHAVIORAL|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
223390176|NCT03985540|BEHAVIORAL|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
223390177|NCT04031469|OTHER|There is no intervention in this study|There is no intervention in this study
223390178|NCT05733416|DIAGNOSTIC_TEST|FDG PET/CT|F-fluorodeoxyglucose positron emission/computed tomography
223390179|NCT05733416|DIAGNOSTIC_TEST|Usual Care|Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care
223390180|NCT02360215|RADIATION|Whole brain radiation therapy with hippocampal avoidance|Intensity modulated radiation therapy (IMRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately two week; starting within 21 calendar days after randomization.
223390181|NCT02360215|DRUG|Memantine|Given PO daily during and after radiation therapy for a total of 24 weeks. Week 1: 5 mg in the AM, none in the PM; Week 2: 5 mg in the AM, 5 mg in the PM; Week 3: 10 mg in the AM, 5 mg in the PM; Weeks 4-24: 10 mg in the AM, 10 mg in the PM. Should start the same day as radiation therapy, at latest before the fourth radiation treatment.
223390182|NCT02360215|RADIATION|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) 30 Gy in 10 fractions once per day, 5 days per week for approximately 2 weeks
223390183|NCT06956560|RADIATION|PET/MRI or separate PET/CT and MRI|"PET/MRI or separate PET/CT and MRI using the following imaging protocol: 15O-H20 (myocardial perfusion, up to 10 min dynamic PET scan), \[68Ga\]Ga-DOTA-Cys-ATH001 (PDGFRß PET, up to 60 min dynamic + static full body PET scans), and Gd-MRI (extracellular volume in infarct, around 10 min MRI scan).~Cohort 1 and 2 are examined twice, first one week after PCI/stent and then a second examination 2 to 8 months after the first. Cohorts 3, and 4 are examined once."
223390184|NCT03897244|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
223390185|NCT03897244|DRUG|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
223390186|NCT03897244|DRUG|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
223730404|NCT05417061|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
223730405|NCT00488436|DRUG|Antithymocyte globulin|
223390187|NCT05210764|DRUG|propofol|General anesthesia is induced and maintained mainly with propofol.
223390188|NCT05210764|DRUG|sevoflurane|General anesthesia is induced and maintained mainly with sevoflurane.
224011119|NCT03253445|OTHER|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
224011120|NCT04406506|DEVICE|nasogastric|• The insertion of NG tubes were performed by the ICU physician and the position was checked by auscultation of gas from 50 ml syringe by injecting 20 ml of air in the NG and by X-ray abdomen to be sure from the site of NG tube
224011121|NCT04406506|DEVICE|nasojejunal|"* The nasojejunal tube is silicone or polyurethane tube with an inner stylet that is positioned (under fluoroscopic guidance) beyond the ligament of Treitz.~* Patients were placed in right lateral position"
224011122|NCT04406506|DRUG|(erythromycin 250 mg IV bolus)|prokinetic (erythromycin 250 mg IV bolus) given to assist the passage of the tube through the pylorus
224011123|NCT04037657|DRUG|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
224011124|NCT04037657|DRUG|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
224011125|NCT00254046|DRUG|TMC125|2 X100 mg tablets b.i.d.96 weeks
224011126|NCT00254046|DRUG|Placebo|2 tablets b.i.d.96 weeks
224011127|NCT03992131|DRUG|Rucaparib|Rucaparib will be administered per schedule specified in the arm description.
224011128|NCT03992131|DRUG|Lucitanib|Lucitanib will be administered per schedule specified in the arm description.
224011129|NCT03992131|DRUG|Sacituzumab govitecan|Sacituzumab govitecan will be administered per schedule specified in the arm description.
224011130|NCT05653102|DEVICE|Truliant Total Knee System|Total Knee Arthroplasty using Exactech's Truliant® branded components are compatible with Optetrak branded components.
224011131|NCT03980808|BEHAVIORAL|American Sign Language-Accessible Diabetes Education|Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
224011132|NCT03980808|BEHAVIORAL|Control Intervention|Non-health related video approximately the same length as ASL-ADE.
224011133|NCT01655693|DRUG|Doxorubicin 20 mg/m2|
224011134|NCT01655693|DRUG|Doxorubicin 30 mg/m2|
224011135|NCT01655693|DRUG|Best Standard of Care|
224011136|NCT01637948|DRUG|Listerine mouthrinse|For six months
224011137|NCT01637948|DRUG|Chinese Medicine mouthrinse|six months
224011138|NCT04348253|PROCEDURE|Berger|Treatment 1
224011139|NCT04348253|PROCEDURE|3LT|Treatment 2
224011140|NCT02904070|DEVICE|Vaginal swabbing|
224011141|NCT02604888|OTHER|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
224011142|NCT03189459|BEHAVIORAL|Home Visit Program|RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8
223390189|NCT05210764|DRUG|S-ketamine|General anesthesia is induced mainly with S-ketamine and maintained mainly with propofol.
223390190|NCT06819839|BEHAVIORAL|Village Health Worker (VHW) Care Model|VHW care model includes four components: (1) universal screening of all non-pregnant adults over 40 for elevated CVD risk (2) confirmatory visit to confirm diagnoses of hypertension, diabetes and elevated CVD risk (predicted 10-year risk \>10%) (3) monthly household visits by VHW; (4) an mHealth tool (tablet computer) to assist with determination of study eligibility and provide recommendations for initiation of medications according to local guidelines. VHW household visits include: health education on smoking cessation, healthy diet, physical activity and medication adherence; assessment of possible medication side effects, measurement of blood pressure and (when applicable) blood glucose; review monitoring results with the treating clinician household delivery of medications; and facilitate referral and transport to higher levels of care.
223546206|NCT02457650|BIOLOGICAL|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
223546207|NCT00720356|DRUG|bevacizumab|10mg/kg administered intravenously every 2 weeks
223546208|NCT00720356|DRUG|erlotinib hydrochloride|150 mg/daily orally
223546209|NCT04579406|PROCEDURE|non-cardiac surgery|All the patients are undergoing non-cardiac surgery.
223546210|NCT01869634|DRUG|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
223546211|NCT00290992|DRUG|rasburicase (SR29142)|
223546212|NCT04059081|DRUG|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
223546213|NCT02075294|DRUG|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
223546214|NCT03567967|BEHAVIORAL|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
223546215|NCT02210988|OTHER|acupuncture|Intervention with acupuncture
223546216|NCT01887730|BEHAVIORAL|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
223564123|NCT04695600|DRUG|Botulinum Toxin Type A Injection [Botox]|100 units of Botulinum toxin A (Botox, Allergan, CA) under endoscopic guidance will be injected in the cricopharyngeus muscle
223390191|NCT06796790|BEHAVIORAL|Media instruction|Caregivers will be asked to implement joint media sessions with their child four times per week for 12 weeks using lightly adapted versions of the commercially-available Super Why! program, which focuses on early literacy skills, including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week
224011143|NCT03189459|BEHAVIORAL|Caregiver Mentorship Program|"Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor"
224011144|NCT01756378|PROCEDURE|joint mobilization with movement|
224011145|NCT01756378|PROCEDURE|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
224011146|NCT04220619|DIAGNOSTIC_TEST|Tranesophageal Echocardiography|RescueTEE during ACLS versus Conventional ACLS
224011147|NCT00225823|DRUG|GW685698X|
224011148|NCT01240187|DRUG|perampanel|Single dose of 6 tablets 2 mg orally
224011149|NCT01240187|DRUG|perampanel|Single dose of 1 tablet 12 mg orally
224011150|NCT02416960|OTHER|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
224011151|NCT02416960|OTHER|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
224011152|NCT03993600|DIAGNOSTIC_TEST|Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)|"three groups:~1. Healthy volunteers~2. Patients with Cystic fibrosis~3. Heterozygous subjects"
224011153|NCT00929110|DRUG|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
224011154|NCT00929110|DRUG|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
224011155|NCT00929110|DRUG|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
224011156|NCT00236379|DRUG|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
224011157|NCT00236379|DRUG|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
224011158|NCT06525714|DRUG|cisplatin oxaliplatin tegafur|Within 48 hours postoperative, the first infusion was performed with 3000-4000 ml of saline and 50 mg/m2 cisplatin at 43°C, with an infusion rate of 600 ml/min for a duration of 2 hours. During treatment, close attention is given to the patient's heart rate, blood pressure, oxygenation, and other vital signs. A total of 2 HIPEC treatments were conducted, each 48 hours apart. Systemic chemotherapy is initiated 3-4 weeks postoperative for 6-8 cycles using SOX: intravenous injection of oxaliplatin (130 mg/m2) on the first day and oral administration of tegafur (40-60 mg twice daily, with doses adjusted for body surface area: \<1.25 m2, 40 mg; 1.25m2 ≤ body surface area ≤ 1.5m2, 50mg; body surface area \>1.5m2, 60 mg bid) from day 1 to 14.
224011159|NCT02757690|DEVICE|3-dimensional distal pancreatectomy|3D laparoscopy
224011160|NCT02757690|DEVICE|2-dimensional distal pancreatectomy|2D laparoscopy
223546217|NCT01887730|BEHAVIORAL|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
223546218|NCT01887730|BEHAVIORAL|Control|
224011161|NCT04385381|DEVICE|URECA CTO device|facilitating guidewire re-entry into the true lumen after passing occlusion(s) in the peripheral vasculature with the URECA CTO device.
223546219|NCT04737434|DEVICE|Extremely low frequency electromagnetic field device|with extremely low frequency electromagnetic wave deliver or not to participants during sleep.
223546220|NCT04737434|DEVICE|electromagnetic field with no wave|electromagnetic field with no wave
223546221|NCT04254692|DRUG|Liposomal bupivacaine|Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
223546222|NCT04254692|OTHER|Standard of care|Participants in the standard of care group will receive intraoperative injection of bupivacaine only to the abdominal wall
223546223|NCT03629665|BEHAVIORAL|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
223546224|NCT03629665|DEVICE|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
223546225|NCT05410925|DRUG|Recombinant staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
224011162|NCT02471105|DRUG|Preserved Bimatoprost 0.01%|Eye drops solution Topical use Once in the evening 3 months
224011163|NCT02471105|DRUG|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
224011164|NCT05945004|OTHER|ChatGPT-4|Subjects' clinical records will be read by ChatGPT-4 to write preoperative visit sheets.
224011165|NCT05945004|OTHER|Clinician|Subjects' clinical records will be read by clinicians to write preoperative visit sheets.
224011166|NCT02807818|BEHAVIORAL|Home visiting Program for Young Pregnant Women|
224011167|NCT04648644|OTHER|Application of ERAS protocol|Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
224011168|NCT02285153|DRUG|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
224011169|NCT02285153|DRUG|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
223564124|NCT01986192|DRUG|rivaroxaban|
223390192|NCT06796790|BEHAVIORAL|Storybook intervention|Caregivers will be asked to implement joint storybook reading sessions with their child four times per week for 12 weeks using adapted versions of the commercially -available Super-Why! storybooks, which focus on early literacy skills including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week.
223390193|NCT05962372|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
223390194|NCT05962372|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate For A Healthy Puerto Rico dietary recommendations.
223390195|NCT05344443|DRUG|Lemborexant|A dual orexin antagonist
223390196|NCT05344443|DRUG|Placebo|A placebo that looks and tastes like Lemborexant tablets
223390197|NCT03458117|GENETIC|Talimogene Laherparepvec (T-VEC)|a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
224011170|NCT00548262|DRUG|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
223390198|NCT02721732|OTHER|Laboratory Biomarker Analysis|Correlative studies
223390199|NCT02721732|BIOLOGICAL|Pembrolizumab|Given IV
223546226|NCT05410925|DRUG|Placebo|Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
223730406|NCT00488436|DRUG|Cyclosporine|
223730407|NCT02030392|BEHAVIORAL|Intervention group|Cognitive-behavioral intervention
223730408|NCT02030392|BEHAVIORAL|Active control group|Education and information
223730409|NCT01402544|DRUG|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
223730410|NCT01324765|BEHAVIORAL|TARGET|12-session group therapy twice weekly 6 weeks
224011171|NCT00548262|DRUG|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if \<40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if \<40 kg body weight).
224011172|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Subjects may continue to receive treatment until progressive disease (PD) or unacceptable toxicity.
224296410|NCT00951626|PROCEDURE|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
223390200|NCT02721732|OTHER|Questionnaire Administration|Ancillary studies
223390201|NCT00627159|OTHER|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
223390202|NCT00627159|OTHER|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
223390203|NCT04837820|PROCEDURE|Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
223390204|NCT04837820|PROCEDURE|Sham Acupuncture|Each participant will receive 10 treatments of acupuncture (real or sham) over the course of 10 weeks (i.e. one treatment a week) with a +/- 14-day window.
223390205|NCT04837820|OTHER|Wait-List Control (WLC)|Patients in the WLC group will continue to receive their standard medical care as prescribed by their oncologists/primary care physicians.
223390206|NCT04837820|OTHER|Questionnaires|Will follow patients for 26 weeks from baseline and collect assessments at baseline and Weeks 0, 10, and 26. Average time to complete the surveys is 30 minutes, which has been judged to be acceptable with minimal missing data; 20 minutes of these 30 minutes will be completed during the neurocognitive battery. Patients will complete PROs online using Research Electronic Data Capture (REDCap) or over the phone with the CRC. Biospecimens will be collected in person at assessment visits. The neurocognitive battery will be administered remotely.
223390207|NCT00725283|BIOLOGICAL|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|Intramuscular administration
223546227|NCT03145064|DRUG|Zanubrutinib|Administered at a dose of 160 mg BID orally.
223546228|NCT04651764|DEVICE|ColubrisMX Endoluminal Surgical (ELS) System|Robotically assisted transanal endoluminal resection of rectal lesion using the ColubrisMX Endoluminal Surgical (ELS) System
223564125|NCT01986192|DRUG|Warfarin|
223564126|NCT01980303|DRUG|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
223564127|NCT00211393|DRUG|ketoconazole|600mg. /day for 6 weeks
223564128|NCT05120973|PROCEDURE|multispectral imaging|Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein
223564129|NCT05120973|PROCEDURE|fluorescence for lymphatic mapping|Indocyanine green injected in abdominal wall
223564130|NCT04487535|OTHER|Cytokine level|Serum cytokine level will be measured before surgery, 72nd after surgery and 6 weeks after surgery
223564131|NCT02027467|DIETARY_SUPPLEMENT|StemAlive®|
223564132|NCT02027467|DIETARY_SUPPLEMENT|Placebo (For StemAlive®)|
223564133|NCT00054951|DRUG|MTC-DOX for Injection|
223730411|NCT01324765|BEHAVIORAL|SGT|12 sessions supportive group therapy twice weekly 6 weeks
224011173|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 30 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
224011174|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib: Ruxolitinib 40 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
224011175|NCT01712659|DRUG|Ruxolitinib|Ruxolitinib 50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Subjects may continue to receive treatment until progressive disease (PD) or dose limiting toxicity (DLT) or unacceptable toxicity.
224011176|NCT06263764|OTHER|Listening to Qur'an Recital|Listening to Surah Ar Rahman twice a day for minimum 15 minutes each for 40 days
224011177|NCT00939159|DRUG|LBH589|20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
224011178|NCT04549896|PROCEDURE|CT scan|Surgeon will perform a CT scan before the surgery procedure (CTO PCI) in order to increase the success rate of the surgery.
224011179|NCT04549896|PROCEDURE|No CT scan|The surgery procedure (CTO PCI) will be performed following the standard of care, meaning that the surgeon will not perform a CT scan before the surgery procedure.
224011180|NCT02888873|OTHER|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
224011181|NCT02888873|OTHER|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
224011182|NCT05068141|DRUG|SG001|Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 240 mg, i.v., q2w
224011183|NCT05068141|DRUG|Nab-paclitaxel|Paclitaxel for Injection (Albumin Bound), 100 mg/m\^2, i.v., D1, D8, D15 of every 4-week cycle
224011184|NCT04642300|PROCEDURE|Holmich Protocol|"Module 1 (1st two weeks):~i)Isometric adduction ii)Abdominal sit-ups iii)Isometric adduction iv)Compound abdominal sit-ups and hip flexion v)Balance exercise on wobble board vi)One-foot exercise on sliding board~Module 2 (from 3rd week):~i)Leg abduction and adduction exercise carried out in side lying ii)Low back extension exercise prone on the end of bench iii)One leg weight pulling abduction/adduction standing iv)Abdominal sit ups v)One leg coordination exercise vi)Training in sideways motion vii)Balance exercise on wobble board"
224011185|NCT04642300|PROCEDURE|Myofascial Release Technique|"1. Transverse friction massage: 10 mins on painful area of adductor-tendon insertion into pubic bone~2. Stretching of adductor muscles, hamstrings muscles and hip flexors:3 times and each stretch is 30s with Contract relax technique"
224011186|NCT01303029|DRUG|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
224011187|NCT01303029|DRUG|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
224011188|NCT01369771|DRUG|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
224011189|NCT02976571|DRUG|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
224011190|NCT01712945|DRUG|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
224011191|NCT01712945|DRUG|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
224011192|NCT05599841|PROCEDURE|PI solution|3,000 cc of \<2% concentrated povidone iodine solution will be used as irrigation solution at primary hip/knee arthroplasty. The PI solution was left in the joint for 3 minutes.
224011193|NCT05599841|PROCEDURE|Saline Solution|3,000 cc of 0.9% saline solution will be used as irrigation solution at primary hip/knee arthroplasty. The saline solution was left in the joint for 3
224011194|NCT01327443|BEHAVIORAL|Weight loss|Nutritional counseling
224011195|NCT01327443|BEHAVIORAL|Exercise|Under direct supervision
223546229|NCT01693250|BEHAVIORAL|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
224011196|NCT00948766|DRUG|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm\^2 patch which released 4.6 mg/24 h. Patches were changed daily.
224011197|NCT00948766|DRUG|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm\^2 patch which released 9.5 mg/24 h. Patches were changed daily.
224011198|NCT00948766|DRUG|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm\^2 patch which released 13.3 mg/24 h. Patches were changed daily.
224011199|NCT00948766|DRUG|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
224011200|NCT02810587|DRUG|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
224011201|NCT04469127|DRUG|Lutetium-177-DOTAGA-IAC|Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.
223546230|NCT01693250|BEHAVIORAL|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
223390208|NCT06156397|OTHER|Standard Physiotherapy Exercise Group|At the beginning of the treatment, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions. Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks.
223390209|NCT06156397|OTHER|Telerehabilitation Based Supervised Exercise Group|Exercises will be performed for 45 minutes, twice a week, for a total of 12 sessions, for a total of 6 weeks. In the telerehabilitation group, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied for the first 2 weeks at the beginning of the treatment, through a meeting with the patients via zoom application. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. In the following weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weights.
223390210|NCT06156397|OTHER|Mobile Application Supported Exercise Group|With the videos uploaded to the Becure application, breathing exercises, upper extremity pumping exercises, scar tissue massage and flexion movements up to 90 degrees will be applied in the first 2 weeks. 2-6. Between weeks, pendulum exercise, shoulder rotation, lifting overhead with clasped hands while sitting and lying down, wand exercise, snow angels, clock on the wall exercise, m. Pectoralis minor and major stretching, standing trunk rotation, and scapulo-thoracic joint stabilization exercises will be applied. 6-8. Between weeks, in addition to the previous exercises, strengthening exercises will be applied in all directions with theraband and weight. Exercises will start with 2 sets of 5-10 repetitions and progress to 10-15 repetitions.
223390211|NCT00659451|DRUG|Losartan|tablets; 50, 100 mg; od; 12 months
223390212|NCT00659451|DRUG|Amlodipine|tablets; 5, 10 mg; od; 12 months
223390213|NCT01837511|OTHER|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
223546231|NCT03530150|DRUG|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
224011202|NCT02769767|GENETIC|Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.|The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
224011203|NCT03803839|DRUG|Clodronate|
224011204|NCT03803839|DRUG|Saline|
224011205|NCT00841555|DRUG|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
224011206|NCT00841555|RADIATION|Hypofractionated radiation therapy|Patients will undergo HIMRT
224011207|NCT00841555|RADIATION|Intensity-modulated radiation therapy|Patients undergo HIMRT
224011208|NCT01757431|DRUG|Eculizumab|
224011209|NCT04592120|BEHAVIORAL|Coalition Check-Up|The Coalition Check-Up identifies and addresses coalition and implementation capacity deficiencies that frequently lead to failure, following recommendations from the audit and feedback literature.
224011210|NCT00566592|OTHER|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
223546232|NCT06375525|DEVICE|Janssen's icon Application (App)|
223546233|NCT01761513|DRUG|YH4808|"Group1~1. adminitration of YH4808 dose1, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, qd for 2weeks"
223546234|NCT01761513|DRUG|YH4808|"Group2~1. adminitration of YH4808 dose2, qd for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose1, bid for 2weeks"
224011211|NCT00566592|OTHER|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
224011212|NCT00566592|OTHER|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
224011213|NCT00566592|OTHER|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
224011214|NCT02153073|DRUG|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
224011215|NCT00537654|DRUG|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
224011216|NCT00537654|DRUG|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
224011217|NCT00537654|DRUG|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
224011218|NCT00537654|DRUG|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
224011219|NCT04141059|DIETARY_SUPPLEMENT|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
224011220|NCT04141059|DIETARY_SUPPLEMENT|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
224011221|NCT05438628|DIAGNOSTIC_TEST|Point of care ultrasound|Measurement of thickness of rectus abdominis, biceps brachii muscles
224011222|NCT05333692|DIETARY_SUPPLEMENT|Fresubin® Protein Energy DRINK|1-2 bottles of Fresubin® Protein Energy DRINK per day
224011223|NCT05333692|DIETARY_SUPPLEMENT|NEPRO® , Abbott|2-4 cans NEPRO® per day
224296411|NCT06928896|PROCEDURE|This interventional trial enrolled a total of 42 patients, dividing them into two age groups: group 1. Using the friction and group 2. Using the frictionless|Cone beam computed tomography (CBCT) was conducted before and after retraction to evaluate alveolar changes and speed.
224011224|NCT05958550|BEHAVIORAL|The tympanic membrane temperature of patients was measured.|After the patient entered the anesthesia recovery room ( PACU ) at the end of the operation, the ear canal was cleaned with cotton swabs by nurses trained in the use of ear temperature guns to avoid the impact of earwax. The patient was in a supine position, the patient 's head was fixed, the patient 's auricle was gently pulled back and up, the ear canal was straight, the ear temperature gun was put into the ear canal, the temperature of the patient 's left and right ears was measured uniformly, and the average value was taken as the final body temperature value. Thereafter, the same measurement was performed every 20 minutes until the patient left the resuscitation room.
224011225|NCT05924308|OTHER|electroacupuncture|every time 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
223390214|NCT01384474|OTHER|Diffusion of a surgical safety checklist|"* Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~* A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~  * First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~ * Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~* Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
223390215|NCT01446536|OTHER|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
223390216|NCT01686672|BEHAVIORAL|Web Intervention|Behavioral
223546235|NCT01761513|DRUG|YH4808|"Group3~1. adminitration of YH4808 dose2, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of Nexium tab 40mg, bid for 2weeks"
223546236|NCT01761513|DRUG|YH4808|"Group 4~1. adminitration of Nexium tab 40mg, bid for 2weeks~2. wash-out period for 3weeks between period1 and period2~3. adminitration of YH4808 dose2, bid for 2weeks"
223546237|NCT06003439|BEHAVIORAL|Virtual Reality Program|Behavioral: Virtual Reality Program The VR Program will be pre-installed on Meta Quest 2 headsets, which will be donned by students as a class to experience the intervention for approximately the length of one school class period (approximately 30-40 minutes). Each participant will experience the program once a week for 3 weeks. Participants who missed a week will complete the program by the 4th or 5th week.
223546238|NCT06003439|BEHAVIORAL|VR Program|VR program participants will be able to download a mobile app that complements and reinforces the school-based VR session.
223546239|NCT04450030|DRUG|Methyl Prednisolonate|2000mg intravenous methyl prednisolone per day for five consecutive days
223546240|NCT04450030|PROCEDURE|Immunoadsorption|6 courses of tryptophane-based immunoadsorption within up to 12 days
223546241|NCT06474520|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
223546242|NCT03048435|OTHER|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
223546243|NCT03048435|OTHER|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
224011226|NCT05924308|OTHER|sham acupuncture|Electroacupuncture was connected to the fixed place of Sishencong on the left and right sides of Baihui and Shenting, and the electroacupuncture instrument was returned to zero. Pull out the needle when informed patient for cotton on the above points, to make patients feel the needle was pulled out. The same treatment time of 30 min, 1 times a day, five times a week, 4 weeks for 1 course of treatment, treatment 3 period of treatment.
224011227|NCT02076438|DIETARY_SUPPLEMENT|Probiotics|Randomized to receive probiotics or placebo
224011228|NCT02039232|DEVICE|Pedicle screw system|
224011229|NCT03134794|BEHAVIORAL|Educational intervention applying the traffic light system (TLS)|The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
224011230|NCT02063373|OTHER|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
224011231|NCT03592745|DEVICE|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
224011232|NCT03592745|DEVICE|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
224011233|NCT06155994|DRUG|68Ga-DOTA-MGS5|intravenous administration
223546244|NCT06543459|DRUG|MY008211A tablets|Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
223546245|NCT06543459|DRUG|Placebo|Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.
224011234|NCT03301129|BEHAVIORAL|Smoke|See arm/group descriptions.
223730412|NCT05060055|PROCEDURE|Immediate dental implant placement|Immediate dental implant placement
223730413|NCT02448420|DRUG|Palbociclib|"Cohort A, B1 y B2: Palbociclib oral dose of 200 mg/day for 2 weeks, followed by 1 week off.~Cohort C1: Palbociclib oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles."
224011235|NCT02505386|DRUG|Ertapenem|
224011236|NCT03090828|BEHAVIORAL|app-based therapeutic education|Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.
224011237|NCT03090828|BEHAVIORAL|enhanced app-based therapeutic education|Patients in the enhanced app group will also have access to a social network. (forum, chat room)
224296412|NCT06928935|BEHAVIORAL|d-DBT|d-DBT is an 8-week self-led online intervention that teaches mindfulness, emotional regulation, distress tolerance, and interpersonal effectiveness skills. Participants receive weekly digital navigator check-ins.
223390217|NCT01996241|BEHAVIORAL|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
223390218|NCT04141241|DRUG|Ecklonia cava Phlorotannin|Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
223390219|NCT06362915|DRUG|Lidocaine|* Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.
224011238|NCT01367639|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
223390220|NCT06362915|DRUG|Bupivacain|• Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist
224011239|NCT00879073|DRUG|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
224011240|NCT00738894|DEVICE|Septal Occluder Device|PFO closure with study septal occluder device
224011241|NCT00738894|DRUG|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
224011242|NCT02297321|DEVICE|Describe patch|Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
224011243|NCT04449120|BEHAVIORAL|Mediterranean diet-based culinary intervention|The culinary intervention was developed integrating four culinary workshops that were given every week, once per week, during one-month intervention. The duration of each culinary workshop was 3,5 h, thus, the program provided a total of 14h of practice in cooking activities. The courses took place in a well-equipped kitchen from the Basque Culinary Center. Each culinary workshop was divided in two differentiated parts in order to work on the specific objectives established for each day. All cooking classes began with a theoretical introductory part that aimed to explain the main take-home messages from the workshop. Subsequently, every class was characterized by a hands-on part that included the demonstration and practical preparation of different elaborations based on the use specific cooking techniques and healthy ingredients. At the end of the session, participants were encouraged to taste the prepared meals, to share their preferences and their view about the cooking experience.
224011244|NCT04449120|BEHAVIORAL|Mediterranean diet-based nutritional education intervention|The patients in the nutritional intervention group will receive dietary advice on how to follow a Mediterranean diet. The dietary recommendations will be given at the beginning of the study by nutritionists using comprehensive written material.
223390221|NCT02496078|DRUG|Daclatasvir|Daclatasvir tablet 60mg
224011245|NCT03796962|DRUG|XEN1101|Oral dose
224011246|NCT00719329|DRUG|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
224011247|NCT00719329|BEHAVIORAL|Dry Cord Care|Educational messages regarding clean cord care
224296413|NCT06927908|PROCEDURE|Partial Cardiac Denervation|Expose the ligament of Marshall (LOM) between the left atrial appendage and left pulmonary veins, and transect it using an electrocautery knife. Expose the fatty pad along the Waterston groove between the right pulmonary veins and the right atrium, and completely resect it down to the myocardial surface, extending the superior margin beyond the ostium of the right superior pulmonary vein and the inferior margin to the inferior vena cava.
223390222|NCT02496078|DRUG|Asunaprevir|Asunaprevir soft capsule 100 mg
223390223|NCT03465059|DRUG|Zanubrutinib|A single oral dose of 80 mg Zanubrutinib will be administered.
223390224|NCT03822585|DIAGNOSTIC_TEST|CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study|"high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%."
223546246|NCT02782585|OTHER|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
223730414|NCT02448420|DRUG|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
223730415|NCT02448420|DRUG|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
224011248|NCT05351320|DRUG|WX-0593 Tablets|WX-0593 60 mg, tablets, orally, once daily for 7 days, followed by WX-0593 180 mg, tablets, orally, once daily
224011249|NCT05351320|DRUG|chemotherapy|Platinum-based chemotherapy
224011250|NCT05351320|RADIATION|Thoracic Radiation Therapy（TRT）|Five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy
224011251|NCT02649504|DRUG|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
224011252|NCT02649504|DRUG|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
224011253|NCT02649504|DRUG|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
224011254|NCT02649504|DRUG|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
223390225|NCT05751317|DIAGNOSTIC_TEST|Culture|"* Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium.~* Pink colonies will be inoculated on bile esculin agar medium.~* Enterococci produce blackening of the agar"
223390226|NCT05751317|DIAGNOSTIC_TEST|Staining:|The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
223390227|NCT05751317|DIAGNOSTIC_TEST|Biochemical reactions:|"* Catalase test.~* Salt tolerance test"
223390228|NCT05751317|DIAGNOSTIC_TEST|VITEK|Automated identification of Enterococci will be done with VITEK2 system.
223390229|NCT05751317|DIAGNOSTIC_TEST|Antibiotic sensitivity test|Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
223390230|NCT05751317|DIAGNOSTIC_TEST|nanoparticles effect|The effect of nanoparticles on Enterococci antimicrobial resistance pattern
223390231|NCT05751317|DIAGNOSTIC_TEST|The biofilm formation activity|The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
223390232|NCT05751317|DIAGNOSTIC_TEST|molecular diagnosis|Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
223390233|NCT06074224|OTHER|Sleep assessment score|The patients in the intervention group will include those for whom their clinician was given their sleep questionnaire result before the visit.
223390234|NCT06074224|OTHER|No Score|The patients in the control group will include those for whom their clinician was not given their sleep questionnaire result before the visit.
223390235|NCT04690595|BIOLOGICAL|BAFFR-CAR T cells|First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL
223546247|NCT02782585|OTHER|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
223546248|NCT02782585|OTHER|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
224011255|NCT02137317|DEVICE|LAPPE (locally adapted personal protective equipment)|"* Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~* Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~* Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
224011256|NCT02773004|OTHER|EPClin genomic test|
224011257|NCT05475275|PROCEDURE|pancreaticojejunostomy|"The experimental group underwent intraoperative measurements (A: short distance from the center of the pancreatic duct to the edge of the pancreas) and (B: pancreatic thickness). When the ratio of the thickness of the short distance from the center of the pancreatic duct to the edge of the pancreas at the pancreatic section was ≥0.401, it was divided into the N1 group (central pancreatic duct). If the ratio was \<0.401, it was divided into the N2 group (eccentric pancreatic duct). The central pancreatic duct group was given 1+1 mode pancreaticojejunostomy; the eccentric pancreatic duct group was given 1+1² mode pancreaticojejunostomy."
224011258|NCT05473611|PROCEDURE|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring|closed reduction percutaneous fixation with open reduction internal fixation of the posterior pelvic ring
224011259|NCT03878992|DRUG|Genotropin miniquick 0.5 mg, injection|GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
224011260|NCT01413503|RADIATION|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
223390236|NCT04515147|BIOLOGICAL|CVnCoV 6 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
223390237|NCT04515147|BIOLOGICAL|CVnCoV 12 μg|Participants will receive an intramuscular injection by needle in the deltoid area.
223390238|NCT04515147|BIOLOGICAL|Hepatitis A vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
223390239|NCT04515147|BIOLOGICAL|Pneumococcal vaccine|Participants will receive an intramuscular injection by needle in the deltoid area.
223390240|NCT04515147|BIOLOGICAL|CVnCoV 12μg|Participants will receive an intramuscular injection by needle in the deltoid area.
223546249|NCT02112643|DRUG|Sodium selenate|A 100 microgram pill will be orally administered twice a day for 6 months.
223546250|NCT02112643|DIETARY_SUPPLEMENT|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
223546251|NCT03939767|DRUG|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.
223546252|NCT02824393|BIOLOGICAL|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
223546253|NCT01741493|DRUG|ABT-494|Oral administration of ABT-494 capsules
223390241|NCT02866305|PROCEDURE|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
223730416|NCT02448420|DRUG|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
224011261|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 70 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution for safety assessment.
224011262|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 250 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by either an intradermal injection of 0.1 mL of a 2 µg/mL MOv18 IgE solution or a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
224011263|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 500 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
224011264|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 700 µg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
224011265|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 1.5 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
224011266|NCT02546921|DRUG|MOv18 IgE|The allocated dose of 3 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 6 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE. Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment.
224011267|NCT02546921|DRUG|MOv18 IgE|"Cycle 1 - The allocated dose of 6 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks.~Cycle 2 - The allocated dose of 12 mg MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for 3 weeks, followed by fortnightly for 6 weeks if the patient appears to be benefiting from MOv18 IgE.~Each IV infusion will be preceded by a skin prick test with 2 µg/mL MOv18 IgE solution, for safety assessment."
224011268|NCT00495443|DEVICE|Peterio|
224011269|NCT04255472|BEHAVIORAL|WHO Caregiver skills training (CST) program|Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
224296414|NCT06927596|PROCEDURE|Interventional therapy|The fistula was occluded by coil and NBCA glue.
224296415|NCT02605798|DRUG|Elbanovir|1 tablet contains 400 mg sofosbuvir
223390242|NCT02866305|PROCEDURE|Chest tube insertion|Conventional chest tube insertion.
223390243|NCT02866305|DRUG|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
223390244|NCT02866305|RADIATION|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
223390245|NCT04713605|DEVICE|Critical closing pressure detection|Observational study that determines the critical closing pressure (CrCP) of the brain by comparison of the cerebral blood flow velocity (measured by TCD) and invasive blood pressure measurement (IABP)
223390246|NCT06575205|BEHAVIORAL|Educational video|Participants will view a brief 3-to-5-minute educational video (VIDEO), covering information that is already printed on FDA labels for OTC NSAIDs, on their own device covering themes such as: defining OTC NSAIDs, potential harms of NSAIDs, and alternatives.
223390247|NCT04032405|PROCEDURE|CAF+CTG+i-prf|combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
223390248|NCT04066452|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
223390249|NCT04066452|DIAGNOSTIC_TEST|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
223390250|NCT03052751|DRUG|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)
223390251|NCT03052751|OTHER|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
223390252|NCT03232359|DIAGNOSTIC_TEST|immature platelets fraction|IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
223390253|NCT04468022|PROCEDURE|Toric Trifocal IOL|Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
223730417|NCT02448420|DRUG|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
223546254|NCT01741493|DRUG|Placebo|Oral administration of placebo capsules
223546255|NCT01741493|DRUG|Tofacitinib|Oral administration
223546256|NCT01470222|OTHER|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
224011270|NCT04255472|BEHAVIORAL|Treatment as usual|WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
224011271|NCT01373151|DRUG|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
224011272|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
224011273|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
224011274|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
224011275|NCT01373151|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
223730418|NCT04350840|BEHAVIORAL|feedback|feedback of optical diagnosis performance per 3 month
223730419|NCT06254586|PROCEDURE|Aerobic exercises|This group received a single session of low-intensity cycling for 20 minutes. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
224011276|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
224011277|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
224011278|NCT01373151|DRUG|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
224011279|NCT01373151|DRUG|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
224011280|NCT01373151|DRUG|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
224011281|NCT01373151|DRUG|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
224011282|NCT05271968|PROCEDURE|Global management of scabies|"For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes"
224011283|NCT04519866|OTHER|Electroacupuncture|"Manual acupuncture (see procedures below) will be administered first to obtain the de qi sensation. After de qi is obtained, the electroacupuncture unit will be connected to 1-3 pairs of acupoints. Current intensity used will be based on the tolerance of each patient. Needles with electrical stimulation will be retained for 30 min.~Main acupoints will be Jingjin points (meridian sinews) along the Bladder meridian of Foot - Taiyang, such as Shenshuci, as well as Jingjin points (meridian sinews) at transverse process from L2 to L4, iliac crest and spinous process from S1 to S4. Secondary acupoints will also be selected based on patients' syndromes and symptoms."
224011284|NCT04519866|OTHER|Manual acupuncture|"After disinfecting the acupuncture points, acupuncture will be performed with the patient lying prone. Depending on the acupuncture points, 0.25mm X 25-75 mm sterile acupuncture needle will be used. Needles will be inserted 10-50 mm and either rotating manipulation or lifting-thrusting manipulation will be used to achieve de qi (a compositional sensation including soreness, numbness, distention and heaviness).~Acupoints used will be similar to those mentioned for electroacupuncture (see above)."
224011285|NCT04779762|OTHER|Crohn's disease exclusion diet (CDED)|Dietary therapy for Crohn's disease
224011286|NCT04779762|DRUG|Ustekinumab Injection [Stelara]|Drug for Crohn's disease
224011287|NCT01363544|OTHER|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
224011288|NCT01363544|BEHAVIORAL|Exercise|30 sessions of individual sports training during 10 weeks.
224011289|NCT01363544|DRUG|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
224296416|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
223546257|NCT02948764|DEVICE|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
223546258|NCT02655718|OTHER|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
223546259|NCT02655718|DEVICE|MRI|
223546260|NCT02060929|DRUG|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
223546261|NCT04649216|DRUG|PCO371|PCO371 Capsule
223546262|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Oral solution
223546263|NCT04649216|DRUG|[14C]PCO371|\[14C\]PCO371 Solution for infusion
223546264|NCT04288856|DRUG|BIIB078|Administered as specified in the treatment arm.
223546265|NCT02576548|BIOLOGICAL|MEDI4276|MEDI4276 is an investigational product
223730420|NCT06254586|PROCEDURE|Resisted exercises|This group received four sets of 15 repetitions of knee extension, hamstring curls, and standing calf raises (20-40% 1RM) with 30 sec to 1 minute rest period between sets. A period of reperfusion (3 to 5 minutes) were provided in both groups after 10 minutes of exercise training by deflating the BFR cuffs. The cuffs were inflated after 5 minutes of reperfusion, and the exercises were completed in both groups.
223730421|NCT02430584|OTHER|Observational - no intervention|
223730422|NCT00516438|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
223730423|NCT00516438|DRUG|Topotecan|intravenous infusion
223730424|NCT00142584|DRUG|Nebivolol (NEB)|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
223390254|NCT03859167|OTHER|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
224011290|NCT04821024|DIAGNOSTIC_TEST|A self-administered questionnaire|A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
224011291|NCT05557500|DEVICE|Repitetive transcranial magnetic stimulation|Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
224011292|NCT06233604|DRUG|0.9%sodium chloride|unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
224011293|NCT06233604|DRUG|Dexamethasone|unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
224011294|NCT06233604|DRUG|Dexmedetomidine|unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
224011295|NCT00128531|DRUG|leuprolide acetate|
223390255|NCT02999750|OTHER|individual therapy|Patient will be treated with individual therapy.
223390256|NCT06425588|OTHER|Surgical/Procedure Mask Fit Testing|All participants will wear a surgical/procedure mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
224011296|NCT02186600|DRUG|Calcium Carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
223390257|NCT06425588|OTHER|KN95 Mask Fit testing|All participants will wear a KN95 mask and be fit tested using a modified version of the OSHA quantitative fit testing procedure.
223390258|NCT05285423|PROCEDURE|Novel technique of Vocal cord Laterlization with Prolene suture.|The procedure will be performed under General anesthesia, preferably with a tracheostomy so that the extent of vocal cord lateralization could be ascertained intraoperatively.
224011297|NCT02186600|DRUG|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
224296417|NCT02605798|DRUG|Sovaldi|1 tablet contains 400 mg sofosbuvir
223390259|NCT04634006|DEVICE|Home-based transcranial direct current (tDCS) device|tDCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes in order to modify the cerebral activity of the stimulated zones. Twenty sessions (active/sham) will be self-administered by parent or caregiver on twenty consecutive business days. The parameter of electrode size, current strength and current duration were previously tested for safety in children. The investigators use the Soterix Medical tDCS devices of the home-based miniCT 1x1 type.
223546266|NCT01424358|OTHER|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
223546267|NCT03166852|OTHER|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
223546268|NCT05120583|OTHER|Pilates exercises|Side kick internal/ external rotation with Pilate's band
223546269|NCT05120583|OTHER|Traditional physical therapy program|strength, flexibility
223546270|NCT06497751|BEHAVIORAL|Couple-based Dyadic Coping Group|"Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization."
223730425|NCT00142584|DRUG|Metoprolol (MET)|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
224011298|NCT02186600|DRUG|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
224011299|NCT02186600|BEHAVIORAL|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
224011300|NCT00763776|DEVICE|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
224011301|NCT00763776|DEVICE|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
224011302|NCT01647555|DRUG|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
224011303|NCT01647555|RADIATION|Radiotherapy|Curative dose: 66 to 70 Gy
224011304|NCT04557553|DIETARY_SUPPLEMENT|Lagenbone|Traditional Chinese medicine herbal formula
224011305|NCT03154970|DEVICE|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
224011306|NCT06311344|DIAGNOSTIC_TEST|Molecular biology analyses|Samples of M. perstans microfilariae will be processed by PCR to investigate the presence (or absence) of Wolbachia using a set of primers targeting the genes ftsZ and 16S and optimized using reference material during the first year of the study. Samples of Schistosoma eggs from urine and feces will be processed for DNA extraction. Each sample will be genetically characterised by multi locus analysis of the mitochondrial cox1 region and the nuclear ITS and 18S rRNA regions. PCR products will be analysed by agarose gel electrophoresis and selected amplicons will be purified and Sanger sequenced. For the individuation of Schistosoma hybrids, the nuclear DNA for each sample will be confirmed by analysis of the species-specific polymorphic positions of the ITS1+2 and 18S. The mitochondrial and nuclear DNA genetic profiles for each individual sample will be recorded to determine the species involved in the infections and also any hybrid schistosomes
224011307|NCT00677105|DRUG|JNJ-26481585|
224296418|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 8g protein/100kcal|Enteral feed containing 8g protein/100kcal
224296419|NCT04633421|DIETARY_SUPPLEMENT|PRECISe protocol EN 5g protein/100kcal|Enteral feed containing 5g protein/100kcal
223390260|NCT02439216|DRUG|Edasalonexent|
223390261|NCT02439216|DRUG|Placebo|
224296420|NCT06461481|DEVICE|Withings Scanwatch|Data captured by the used smartwatches (Withings Scanwatch) includes activity-related data (step count, minutes in certain intensity levels), basic cardiovascular measurements such as heart rate, and sleep-related data (total time asleep, sleep efficiency and quality etc.).
224011308|NCT02573389|DEVICE|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
224011309|NCT03026075|DEVICE|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter \& fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
224011310|NCT05195021|DEVICE|EDDY|EDDY (VDW) sonic irrigation activation system
224011311|NCT05195021|DEVICE|Diode Laser device|980-nm diode laser device
224011312|NCT05195021|DEVICE|Conventional irrigation|Conventional root canal irrigation with 31-guage side port needle
224011313|NCT03381339|DEVICE|Oscillating rotating power toothbrush|a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
224011314|NCT05478889|PROCEDURE|Minimally invasive pancreatoduodenectomy|Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
224011315|NCT04022512|RADIATION|computed tomography|thoracic CT examinations for pre-treatment staging and/or subsequent post-treatment follow-up.
224011316|NCT02387268|DEVICE|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
224011317|NCT00644670|DRUG|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
224127284|NCT07082790|OTHER|Music intervention|The music was provided to the pregnant women with wireless headphones worn over the head, an electronic acoustic device with sound-enhancing ear pads, and an adjustable headband. These headphones allowed the pregnant women to listen to music in isolation. The music played in the study was determined with the recommendation of the Research and Promotion of Turkish Music (TUMATA), which operates in Turkey and carries out treatment studies with Turkish music. Accordingly, pregnant women were made to listen to Acemashiran maqam, which is thought to have a positive effect on the uterus, the baby in the womb, and facilitate birth. According to TUMATA, Acemashiran Maqam has a fiery nature. It is a dry-hot makam. It is effective on bones and the brain. It helps balance fat in the body. It gives a sense of creativity and inspiration. Revitalizes stagnant thoughts and emotions. Facilitates childbirth in women. Helps to correct the wrong posture of the child in.
223390262|NCT02094300|DEVICE|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
223390263|NCT01892956|OTHER|Nutritional intervention|"2 dietary interventions~1. personalized diet based on algorithm predictions of glucose response to foods~2. Mediterranean-style diet"
223390264|NCT02091856|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
223546271|NCT01647698|BEHAVIORAL|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
224011318|NCT00644670|DRUG|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
224011319|NCT05679089|DEVICE|early detection test|Blood collection and early detection testing
224011320|NCT01714661|DRUG|EVP-6124|Arms 1, 2
224011321|NCT01714661|DRUG|Placebo|Arm 3
224011322|NCT00625651|DRUG|Placebo|Inactive dummy AMG 655 (to maintain blind)
224011323|NCT00625651|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
224011324|NCT00625651|DRUG|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)
224127285|NCT07082790|OTHER|Virtual Reality Intervention|Pregnant women in the VR group were given adaptive three-dimensional (3D) glasses that fit snugly on their heads to optimize image quality and provide full distance adjustment. All pregnant women in the group were allowed to wear the glasses for a few minutes before the application in order to get used to the glasses. The image to be projected on the glasses was provided by placing a smartphone compatible with the glasses on the front of the glasses. Pregnant women in the VR group were shown an image of a green landscape with a relaxing sound accompanying the 3D images. Pregnant women in the VR group were shown an image of green nature due to the proven psychologically relaxing effect of green. Since the content in question is prepared in 360 degrees, the person wearing the glasses finds herself in the virtual world and experiences the feeling of being there, no matter which direction she looks.
223390265|NCT04238078|DRUG|Contraceptive|Oral contraceptive pill
223390266|NCT03532529|OTHER|not applicable, it is an observational study|not applicable, it is an observational study
223546272|NCT01647698|BEHAVIORAL|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
223546273|NCT01647698|BEHAVIORAL|No training|No training during the experiment.
223546274|NCT03323138|PROCEDURE|Ex-PRESS and phacoemulsification|
224011325|NCT00625651|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
223390267|NCT04703595|GENETIC|To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.|"To determine the presence of biallelic expansion of AAGGG in RFC1 in patients with chronic cough, regardless of the presence of neurological symptoms.~For the molecular study of the DNA sample of the patients, two techniques will be used: standard Polymerase chain reaction amplification with primers flanking the intron 2 fragment of the RFC1 gene and amplification using Repeated Primed Polymerase chain reaction in 3 independent reactions."
223390268|NCT05702983|DRUG|STSA-1002 subcutaneous injection|Subjects will receive a single low dose on day 1 following protocol requirements.
224011326|NCT05675813|DRUG|CHOP+selinexor+5-Azacitidine|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T1 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and selinexor 40mg or 60mg qw (d-7, 1, 8) by traditional 3+3 dose escalation methods and decide RP2D of selinexor.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
224011327|NCT05675813|DRUG|CHOP+duvelisib+5-Azacitidine|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T2 genetic subtype, for the remaining 5 cycles, they will receive 5-Azacitidine ih d-7-d-1 and duvelisib 25mg or 50mg bid (d1-14) by traditional 3+3 dose escalation methods and decide RP2D of duvelisib.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T1 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
224011328|NCT05675813|DRUG|CHOP+chidamide+tislelizumab|"Phase I: Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle. If tumor NGS indicates T3 genetic subtype, for the remaining 5 cycles, they will receive tislelizumab 200mg d0 ivgtt and chidamide 20mg or 30mg biw (d1,4,8,11) by traditional 3+3 dose escalation methods and decide RP2D of chidamide.~Phase II: Patients will receive CHOP for the first cycle. If tumor NGS indicates T3 genetic subtype, then 1:1 randomized to experimental (CHOPX2) or standard CHOP regimen for 5 cycles of every 21-day cycle."
224011329|NCT05675813|DRUG|standard CHOP|Patients in this arm will receive cyclophosphamide 750 mg/m² IV, doxorubicin 50 mg/m² IV, and vincristine 1.4 mg/m² IV (maximum 2 mg) on day 1, and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the 6 cycles.
224011330|NCT00293059|DRUG|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
224011331|NCT00293059|DRUG|Placebo|Matching placebo to be taken orally daily.
224011332|NCT05630534|DRUG|Minocycline|Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.
224011333|NCT05630534|OTHER|starch|Use starch capsules as placebo
224011334|NCT00970762|DRUG|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
224011335|NCT00970762|DRUG|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
224011336|NCT00970762|DRUG|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
224011337|NCT00970762|DRUG|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
224011338|NCT00970762|DRUG|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
224127286|NCT07082504|BEHAVIORAL|Physical Exercise Program|Participants will complete supervised moderate-intensity physical exercise sessions three times per week for 12 weeks (totaling 150 minutes per week). The program includes balance, flexibility, strength, and mobility exercises designed according to WHO and ACSM guidelines for older adults. Sessions are delivered in small groups by trained physiotherapists.
224127287|NCT07082504|BEHAVIORAL|Cognitive Stimulation Program|Participants will attend cognitive stimulation sessions three times per week for 12 weeks. Activities include memory games, attention tasks, puzzles, orientation exercises, and problem-solving strategies. The sessions are led by a psychologist and a trained social educator, in small groups.
223390269|NCT05702983|DRUG|STSA-1002 subcutaneous injection|Subjects will receive a single high dose on day 1 following protocol requirements.
223390270|NCT03182426|DRUG|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
223390271|NCT03182426|DRUG|Alemtuzumab|T-cell depletion
223390272|NCT03182426|DRUG|Anakinra|Anti-inflammatory
223390273|NCT03182426|DRUG|Etanercept|Anti-inflammatory
223730426|NCT01482754|DRUG|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
224011339|NCT00970762|DRUG|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
224011340|NCT00970762|DRUG|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
224011341|NCT02731144|OTHER|Peptamen intense|
224011342|NCT02731144|OTHER|Novasource senior|
224011343|NCT03970538|DEVICE|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
224296421|NCT04064814|DRUG|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
224296422|NCT04064814|DRUG|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
223390274|NCT03182426|DRUG|Liraglutide|Beta-cell regeneration
223390275|NCT01050530|DRUG|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
223390276|NCT01050530|DRUG|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
223390277|NCT04505969|OTHER|Questionnaire to assess needs|Two questionnaires have been developed to assess the specific needs of healthcare professionals working with SCD patients and of SCD patients or parents of children with SCD
223390278|NCT02288312|DRUG|BIA 2-093|
223390279|NCT06458517|DEVICE|Photobiomodulation session - intraoral|use of CareMin650TM lightbox(NeoMedLight) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose
224127288|NCT07082504|BEHAVIORAL|Combined Physical Exercise and Cognitive Stimulation|Participants will receive both the physical exercise and cognitive stimulation interventions, conducted in parallel, over a 12-week period with three sessions per week. The combined program aims to improve physical and cognitive functions simultaneously and is delivered by a multidisciplinary team.
224011344|NCT05155670|DEVICE|WRL HX MCP|WRL HX MCP is a non CE marked class IIa medical device designed for clinical application in hand rehabilitation; it consists in a cable-driven robotic MCP orthosis providing flexion-extension of the metacarpo-phalangeal joint. WRL HX MCP features and a series-elastic actuators (SEA) architecture for compliant actuation of MCP flexion-extension and a self-aligning mechanism to absorb human/robot joint axes misplacement. Exoskeleton module is mounted on a dorsal hand support and connected to its electronic box through wires.
224011345|NCT01983189|PROCEDURE|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
224011346|NCT02408991|DRUG|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
224011347|NCT02408991|DEVICE|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
224011348|NCT05596253|PROCEDURE|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
224011349|NCT01640639|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
224127289|NCT07083713|BEHAVIORAL|Group Coaching|Group coaching using a protocol developed with Coaching in Context model
224127290|NCT07084649|DEVICE|TMS|accelerated intermittent theta burst stimulation
223390280|NCT06458517|DEVICE|Photobiomodulation session - transcutaneous|use of ATP38® phototherapy device (Swiss Bio Inov Europe) in preventive and in case of occurence of grade 1 oral mucositis, in curative purpose
224011350|NCT01640639|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
224127291|NCT06931067|BEHAVIORAL|OTAGO Exercise Program with motivational interviewing|OTAGO exercise home visits will be offered 7 times with 2 phone-based check-ins during the 6-month period. As part of OTAGO home visits, participants will receive OTAGO exercise instruction and MI. Each home visit will be approximately an hour.
224127292|NCT01915810|BEHAVIORAL|Exercise Intervention|Complete SCwPA intervention
224127293|NCT01915810|OTHER|Laboratory Biomarker Analysis|Correlative studies
224127294|NCT01915810|DRUG|Nicotine Patch|Receive nicotine patch
224127295|NCT01915810|OTHER|Questionnaire Administration|Ancillary studies
224127296|NCT01915810|OTHER|Tobacco Cessation Counseling|Receive smoking cessation counseling
224138551|NCT04161274|PROCEDURE|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
223390281|NCT05832203|OTHER|Counseling on planetary health diet with calorie restriction|Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application
223390282|NCT05832203|OTHER|Counseling on balanced nutrition diet with calorie restriction|Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
223390283|NCT03965195|BIOLOGICAL|Recombinant Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
223390284|NCT03965195|BIOLOGICAL|Standard Dose Quadrivalent Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
223390285|NCT05583695|BEHAVIORAL|mindfulness-based music therapy|eight weekly sessions with a combination of both mindfulness and music therapy
223390286|NCT05583695|BEHAVIORAL|mindfulness-based therapy|eight weekly sessions of mindfulness
223390287|NCT05583695|BEHAVIORAL|routine care|eight weekly sessions of routine care
223390288|NCT01276041|DRUG|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
223546275|NCT00660972|DRUG|Raltegravir|400 mg tablet taken orally twice daily
223546276|NCT00660972|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
223546277|NCT01396187|DRUG|PF-05231023|5 mg IV twice a week for 4 weeks
223546278|NCT01396187|DRUG|PF-05231023|25 mg IV twice a week for 4 weeks
223546279|NCT01396187|DRUG|PF-05231023|100 mg IV twice a week for 4 weeks
223546280|NCT01396187|DRUG|PF-05231023|200 mg IV twice a week for 4 weeks
224011351|NCT03058575|DIETARY_SUPPLEMENT|Dietary MACs|"All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement"
224011352|NCT03058575|OTHER|Control|No Intervention for 8 weeks
223390289|NCT01366118|DRUG|Therapeutic target tailored chemotherapy|"All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen"
223390290|NCT05087225|BIOLOGICAL|polyethelyene glycol|the excipients at covid-19 vaccines
223546281|NCT01396187|OTHER|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
223546282|NCT03126643|BIOLOGICAL|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
223546283|NCT05386147|DEVICE|Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)|see arm description
223546284|NCT04485845|DRUG|Vildagliptin|to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
223546285|NCT04485845|DRUG|Captopril Tablets|used to treat hypertension in metabolic syndrome patients and as a renal protector
224011353|NCT03506074|DIAGNOSTIC_TEST|Flavor test|The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
224011354|NCT04673370|BEHAVIORAL|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines techniques regulating body, breath and spirit. According to traditional Chinese theory, every movement of Ba Duan Jin has unique effect to different Zang-fu organs.
224011355|NCT04673370|BEHAVIORAL|Health education|Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.
224011356|NCT02753543|DRUG|Chidamide|
224011357|NCT04322903|BEHAVIORAL|Passport to Freedom (P2F)|During the P2F sessions, the women learn to understand and process the impact of multiple traumas on women's lives and health and learn specific strategies to overcome the symptoms of trauma and everyday stress. Each session will begin and end with a mindfulness exercise to provide different strategies the women can use when these women are in a stressful situation. At the end of each session, the participants will complete a session evaluation. The women will also have a home visit or telephone call with a community health navigator who will conduct a social determinant of health screenings assessment to determine what identified social barriers these women may have. The community health navigator will help with linking the participant to a community agency that addresses the identified problem. Four weeks after the completion of the program, the women will be contacted for a follow-up interview to learn the effectiveness of the program sessions.
224011358|NCT04469049|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
224011359|NCT03399851|DEVICE|Amplatzer Amulet for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
224011360|NCT03399851|DEVICE|Watchman/FLX for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
224011361|NCT04152057|DRUG|Pyrotinib Maleate Tablets|400mg/d,po qd,q3w, 4 cycles
224011362|NCT04152057|DRUG|Albumin Paclitaxel|125mg/m2,ivggt,d1,q3w,4 cycles.
224011363|NCT04152057|DRUG|Trastuzumab|The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
224011364|NCT00419081|DRUG|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
224011365|NCT00419081|DRUG|Forodesine Hydrochloride Capsules (100 mg)|
224296423|NCT03083821|DRUG|Baraclude|Specified dose on specified day
223546286|NCT04485845|DRUG|MetFORMIN 500 Mg Oral Tablet|antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
224011366|NCT02209870|BEHAVIORAL|E-checklist Group|The patient group after E-checklist system deployed
224011367|NCT02729064|DRUG|Humulin R|Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
224296424|NCT04969861|DRUG|Bempegaldesleukin|Specified dose on specified days
223390291|NCT01950221|DIETARY_SUPPLEMENT|POMx|"POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract."
223390292|NCT01950221|OTHER|Placebo|
223390293|NCT03888846|DRUG|Pentoxifylline|Topical gel version of pentoxifylline to be administered intraorally.
223546287|NCT03310359|DIETARY_SUPPLEMENT|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
223546288|NCT03310359|OTHER|Placebo|Matching placebo pill
223546289|NCT05323604|OTHER|Colectomy with anastomosis of any type|Patient with colonic resection followed by ileocolic, or colo colic, or colorectal, or coloanal anastomosis for cancer by laparoscopy or laparotomy
223546290|NCT01504295|DRUG|Metadoxine|Improve Liver Function and Reduce ALcohol Use
223546291|NCT05840835|DRUG|IMX-110 combined with Tislelizumab|Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
224011368|NCT02729064|DRUG|Normal Saline|Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
224011369|NCT04616729|DRUG|Triptorelin 3.75 MG Injection|Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.
224296425|NCT04969861|DRUG|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
224011370|NCT04616729|PROCEDURE|Transvaginal oocyte retrieval|Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.
224011371|NCT04616729|DRUG|Triptorelin Injection|Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
224011372|NCT04851353|BEHAVIORAL|GT+VC|Gentle touch and verbal comfort,
224011373|NCT04851353|BEHAVIORAL|Smell|Smell breast milk
224011374|NCT04851353|BEHAVIORAL|Taste|Taste breast milk
224011375|NCT02086305|BEHAVIORAL|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
224011376|NCT02086305|BEHAVIORAL|Usual care|Usual care is the routine practice in the hospital
224011377|NCT05539144|RADIATION|"Oropharyngeal mucosa"|"Oropharyngeal mucosa was delineated as OARs and limiting its dose"
224011378|NCT05539144|RADIATION|oropharynx|oropharynx was delineated as OARs and limiting its dose
224011379|NCT05539144|RADIATION|"oropharynx and oropharyngeal mucosa"|"oropharynx and oropharyngeal mucosawere delineated as OARs and limiting its dose"
224011380|NCT04389203|PROCEDURE|Unilateral tubal disconnection + Spontaneous follow up for pregnancy|Unilateral tubal disconnection + Spontaneous follow up for pregnancy
224011381|NCT04389203|PROCEDURE|Unilateral tubal disconnection + ICSI|Unilateral tubal disconnection + ICSI
224011382|NCT01810458|DEVICE|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
224127297|NCT06930053|OTHER|Core stability training|"The study group will receive core stability exercises, which consist of three levels. Each level took 4 weeks. The difficulty of each level varies in proprioception, balance, and stability as it started from exercising on a stable surface mat and ended with unstable surface physioball. The first simple level involves supine abdominal draw (3 sets per 20 repetitions), abdominal draw-in with a double knee to chest (3 sets/20 repetitions), and supine twist (3 sets per 20 repetitions). The second medium level involves pelvic bridging (3 sets per 3-5 repetitions) and twists with a medicine ball (3 sets per 10-20 repetitions). The third difficult level involves bridging with head-on physioball holding this position for 3-5 seconds, then slowly relaxing (3 sets per 10-20 repetitions), and prone bridging (3 sets per 3-repetitions). There was a 30-second rest between sets . The program will be applied 30 minutes a day for 3 days a week for 12 weeks. in addition to 30 minutes of a standard"
224127298|NCT06930053|OTHER|Action observation therapy|The examined group got 30 minutes of a standard,selected physical therapy program in addition to 30 minutes of AOT on the upper limb (total session time: 1 hour), 3 sessions per week for three consecutive months (total therapy time: 3 hours/week). Action observation was executed with therapist guidance and repeated practice (3 repetitions for each task). The child has been requested to perform the watched task with the same tool after observing a 3-minute video for each task on an adjustable monitor screen positioned one meter infront of him or her from forward, sideways, and backward directions. The therapist sat beside the child to provide verbal comments during the excursion and to guide the child's movement.The AOT for the examined group included six unimanual tasks and six bimanual tasks. The unimanual tasks included pressing a rubber stamp, stacking cups, drinking water from a cup, grabbing a pen, flipping cards, and putting things on a stick. The bimanual tasks were opening a bo
224127299|NCT06930053|OTHER|combination of Action observation therapy and core stability training .|combination of Action observation therapy and core stability training .
224127300|NCT06930261|DRUG|LBT-999|LBT-999 administration for PET imaging
224296426|NCT06920615|BEHAVIORAL|Fading and chaining combined with differential reinforcement|Intervention Treatment will involve backward chaining, fading and differential reinforcement.
223390294|NCT03888846|DRUG|Colchicine|Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
223390295|NCT03843060|DRUG|AZD9977|Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
223390296|NCT03843060|DRUG|Itraconazole|Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
223390297|NCT04902001|BEHAVIORAL|Multidisciplinary weight loss|The adolescents will follow a 12-week intervention combining nutritional education, physical activity 3 times per week and psychological supports.
224011383|NCT01810458|PROCEDURE|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
224011384|NCT01810458|PROCEDURE|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
224011385|NCT01810458|PROCEDURE|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
224011386|NCT01810458|OTHER|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
224011387|NCT01810458|PROCEDURE|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
224011388|NCT01810458|DRUG|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
223546292|NCT01898286|DRUG|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
223546293|NCT01274598|BIOLOGICAL|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10\^10 CFU by mouth twice daily for 28 days
223546294|NCT06167967|DIAGNOSTIC_TEST|ctDNA methylation|A blood-based circulating tumor DNA methylation assay that uses 6 different methylation markers, SEPT9 region1, SEPT9 region2, BCAT1, IKZF1, BCAN and VAV3.
223546295|NCT06167967|DIAGNOSTIC_TEST|standard treatment|This group was treated according to standard procedure
223546296|NCT01201928|DRUG|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
223546297|NCT01201928|DRUG|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
223546298|NCT03245346|DRUG|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
223546299|NCT03245346|DRUG|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
223546300|NCT03245346|DRUG|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
223546301|NCT03245346|DRUG|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
223546302|NCT02185261|DRUG|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
223546303|NCT02257242|DRUG|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
223546304|NCT02257242|DRUG|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
224011389|NCT01810458|DRUG|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
224011390|NCT01810458|DRUG|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
224011391|NCT01810458|DRUG|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
224127301|NCT01686503|DRUG|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
224127302|NCT06929585|PROCEDURE|Genicular artery embolization|The patient will receive GAE procedure and sham IA procedure.
224127303|NCT06929585|PROCEDURE|Intra-articular injection with corticosteroids.|The patient will receive IA procedure and sham GAE procedure.
224296427|NCT06920615|BEHAVIORAL|Differential reinforcement of high rate|This will be identical to baseline, except a DRH will be introduced: The participant will be instructed to complete his whole meal within set time criteria to receive an identified reinforcer.
223546305|NCT02257242|DRUG|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
223546306|NCT04968392|DRUG|Dexmedetomidine Hydrochloride|20 mL of 0.25% levobupivacaine plus 0.5 µg/kg dexmedetomidine
223546307|NCT04968392|DRUG|Levobupivacaine|20 mL of 0.25% levobupivacaine plus 1 mL normal saline
223546308|NCT06252844|BEHAVIORAL|Resistance exercise training|Supervised PRT will consist of leg extension, leg curl, leg press, and calf raises. Initially participants will start with a 4 weeks adaptation with low loads at 15 (repetition maximum, RM) conducting for 1-3 sets. Further on subjects will continue with a 5 month of PRT with intensity increasing every 2 weeks from 12 to 6 RM. Each exercise will be done for 3 sets with 2 min rest periods between sets. After the 2 weeks at 6 RM, 1 week of rest will be applied. After the rest week, the same cycle starting from 12 RM will be repeated until the end of intervention.
223546309|NCT06252844|BEHAVIORAL|Active control|Supervised static stretching exercises will be performed without causing an unpleasant feeling of stretching, up to pain, maintaining the stretching position for at least 30 s. Exercises will be performed slowly so that heart rate (HR) does not exceed 50% maximum. Subjects will calculate their HR before training, in the middle and after the training measuring the pulse for 10 s. Exercises will be repeated 3-5 times for each side of the body. The duration of the training will be match to PRT group and will take around 40 min. In order to keep the subjects interested and motivated, two of the stretching exercises will be changed every two weeks.
223546310|NCT00014274|DRUG|carboplatin|
223546311|NCT00014274|DRUG|gemcitabine hydrochloride|
223546312|NCT00014274|DRUG|methotrexate|
223546313|NCT00014274|DRUG|vinblastine sulfate|
223546314|NCT01350674|PROCEDURE|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
223546315|NCT02714491|OTHER|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
223390298|NCT01094704|DRUG|sodium chloride (7%)|4mL nebulized 7% sodium chloride
223390299|NCT00461916|DRUG|Half-Dose Depot Triptorelin|
223390300|NCT00461916|DRUG|Reduced-Dose Daily Buserelin|
223390301|NCT06294717|OTHER|Progressive relaxation exercises will be applied.|Progressive relaxation exercises will be not applied.
224127304|NCT00650429|DRUG|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
224127305|NCT00523822|OTHER|Spinal Manipulative Therapy|
224127306|NCT04416776|DRUG|Strabismus diagnostic system.|An AI platform based on corneal light-reflection photos to facilitate the diagnosis and angle evaluation of strabismus and to provide advice for surgical planning.
224127307|NCT07162077|PROCEDURE|Sodium hypochlorite 5.25%|In the test group, the investigators will be applied sodium hypochlorite 5.25% by using cotton wad on the opacity before treatment, then after the first and second etching cycles (application of the Icon-Etch (ICON® -Etch; DMG, Hamburg, Germany) and Icon-dry (ICON® -Dry; DMG, Hamburg, Germany) according to the manufacturer's recommendations) as irrigation step and following the third -Etch etching cycle Icon-infiltrant (ICON® -Infiltrant; DMG, Hamburg, Germany) will be applied.
224127308|NCT07162077|PROCEDURE|ICON resin infiltration Material group in vivo|In control group, the investigators will be applied the same protocol of test group but without using sodium hypochlorite
224127309|NCT07163143|DRUG|Isoniazid (H)|H, weight based, 150-375mg
224127310|NCT07163143|DRUG|Rifampicin (R)|R, weight based, 300-750mg
223390302|NCT01776710|BEHAVIORAL|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
223390303|NCT04989543|DIAGNOSTIC_TEST|vaginal swabs|"Nugent score: Vaginal swabbing with the dry swab, make two smears on slides.~Cytobacteriological examination: swabbing at the exo-endocrine junction using the swab~Evaluation of the vaginal microbiota: swabbing at the exo-endocrine junction using the swab"
223390304|NCT00245518|DRUG|Isoflavone|
223390305|NCT00245518|DRUG|Placebos|
223390306|NCT03936036|DRUG|Linagliptin|Linagliptin dispensing claim is used as the exposure
223390307|NCT03936036|DRUG|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
223390308|NCT00738387|DRUG|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
223390309|NCT00738387|DRUG|Placebo|Placebo i.v. on day 1 of each 21 day cycle
223390310|NCT00738387|DRUG|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
223390311|NCT01332487|DRUG|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
223390312|NCT03469232|DRUG|Huanglian-Jiedu Decoction|Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
223390313|NCT03593837|DRUG|Huang qi gui zhi wu wu granule|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
223390314|NCT03593837|DRUG|Huang qi gui zhi wu wu granule placebo|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
223390315|NCT01324778|DEVICE|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
223390316|NCT01324778|DEVICE|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
223390317|NCT00485264|DRUG|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
223390318|NCT00485264|DRUG|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of \~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
223390319|NCT00485264|DRUG|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of \~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
223390320|NCT00485264|DRUG|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants \< 25 kg were switched to a weight-based dose of the chewable tablet.
223390321|NCT05509530|OTHER|anti-BCMA/GPRC5D CAR-T CELL|anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy
223390322|NCT03977948|OTHER|semi-structured systemic interview|Semi-structured systemic interviews will be conducted with families who have benefited from the preparation for surgery through play. Other tools such as the logbook and the socio-demographic questionnaire will also be used. The themes that will emerge from these interviews will provide a better understanding of what these families are going through, how the proposed intervention may or may not have met their expectations, and provide insights so that health care services can build their own surgical preparation programs.
223390323|NCT03738046|BEHAVIORAL|Cognitive Behavioral Therapy|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, \& Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, \& Wykes, 2016).
223390324|NCT05447104|BEHAVIORAL|Mastication|Chewing sugar-free gum for 20 min
223390325|NCT04185155|BEHAVIORAL|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
224127311|NCT07163143|DRUG|Pyrazinamide (Z)|Z, weight based, 800-2000mg
223390326|NCT04185155|BEHAVIORAL|Attention placebo|Smartphone activity for same amount of time.
223390327|NCT03575208|BIOLOGICAL|hepatitis B immune globulin (HBIg)|HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.
223390328|NCT03575208|DRUG|Pegylated interferon alfa (pegIFN)|peginterferon alfa-2a 180 mcg weekly for 24 weeks
224011392|NCT01810458|DRUG|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
224011393|NCT01810458|DRUG|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
224011394|NCT01810458|DRUG|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
224011395|NCT02310867|DRUG|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
224011396|NCT02310867|PROCEDURE|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
224011397|NCT03787836|BEHAVIORAL|Maintained Exercise|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
224011398|NCT03787836|BEHAVIORAL|Increased Intensity|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
224296428|NCT06920615|BEHAVIORAL|Response interruption with redirection|RIRD involves physically blocking a movement from occurring using the least amount of physical contact for max 3 s, and then redirecting behavior to an ongoing activity or movement. Stereotypi that is verbal or not possible to block physically will involve a demand to answer a verbal question or a motor task that sufficiently interrupts the behavior and then redirecting.
224299319|NCT03591523|DIAGNOSTIC_TEST|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
223390329|NCT02441010|DEVICE|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
223390330|NCT02441010|OTHER|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
223390331|NCT02441010|DEVICE|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
223390332|NCT04004481|DRUG|Postoperative analgesia using tramadol|Tramadol 100 mg will be given to the patients in the postoperative period.
224299320|NCT02263781|PROCEDURE|Blood draw|Blood draw
223390333|NCT04527510|DIAGNOSTIC_TEST|Conventional-reading|Two radiologists interpret at least three views of each breast without AI independently.
223390334|NCT04527510|DIAGNOSTIC_TEST|Second-reading|One radiologist reads AB US images without AI first, then combines the indications of AI marks to make the final decision.
223390335|NCT04527510|DIAGNOSTIC_TEST|Concurrent-reading|One radiologist identifies CAD marks first, then quickly browses the entire AB US examination to make the final decision.
223546316|NCT02714491|OTHER|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
223390336|NCT04527510|DIAGNOSTIC_TEST|Tow views-reading|Two radiologists interpret only two views of each breast without AI independently.
223390337|NCT04527510|DIAGNOSTIC_TEST|Handheld US-screening|One radiologist screens the breast cancer using Handheld US and interprets images immediately.
223390338|NCT01977495|BEHAVIORAL|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
223390339|NCT00654095|DRUG|Ezetimibe|Ezetimibe 10 mg once daily
224011399|NCT00848939|DRUG|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
224011400|NCT00848939|DRUG|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
224011401|NCT04281459|OTHER|HIV Treatment Satisfaction Questionnaire status|Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.
224011402|NCT00606060|DRUG|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
224011403|NCT04451967|PROCEDURE|thrombolysis|transfer after thrombolysis for STEMI patients within 6h since onset
224011404|NCT04425304|BEHAVIORAL|Group counseling|4 times
224011405|NCT04425304|BEHAVIORAL|Intensive group counseling|14 times
224011406|NCT04425304|BEHAVIORAL|Persuasive ICT support|Weekly reminders for 12 months
224011407|NCT03403582|OTHER|Raspberries|250g frozen whole red raspberries
224011408|NCT00760968|DRUG|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
224011409|NCT00760968|DRUG|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
224011410|NCT00867204|PROCEDURE|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
224011411|NCT06058975|OTHER|Observational|Review the management of duodenal trauma in France
224011412|NCT05657652|DRUG|cladribine, cytarabine,venetoclax|Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
224011413|NCT05907707|DEVICE|Gamma transcranial alternating current stimulation|tACS (gamma frequency, 40Hz) during cognitive testing (about 40 minutes duration).
224011414|NCT05907707|DEVICE|Control transcranial alternating current stimulation|tACS (control frequency, 21Hz) during cognitive testing (about 40 minutes duration).
224011415|NCT05907707|DEVICE|EEG headband|At-home, ambulatory, single-channel EEG headband which records brain activity during sleep
224011416|NCT05907707|DEVICE|Actigraphy wristband|At-home, ambulatory, wrist-worn accelerometer which records levels of motor activity during the whole day
224011417|NCT05336630|DEVICE|Forceps|The forceps clears the redundant tissue to enable access to the papilla, as well as stabilizes the ampullary position to permit an easier cannulation. The forceps is an FDA approved instrument and does not put the patient at any higher risk for any adverse event. Please note that for the explicit purpose of the study the forceps will be used to grab tissue and not take biopsies. The forceps may still be used to take biopsies if the physician believes it is indicated.
223390340|NCT00654095|DRUG|atorvastatin|atorvastatin 20 mg once daily
223390341|NCT04353635|DEVICE|dolphin 3d|software
223390342|NCT05236335|DIETARY_SUPPLEMENT|Ketone ester|Commercially available ketone supplement
223390343|NCT05236335|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
224011418|NCT06027671|BEHAVIORAL|Group SPARCS Intervention|Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on their location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).
223390344|NCT00871208|DRUG|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
224011419|NCT06027671|BEHAVIORAL|ART-SPARCS Intervention|"ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs."
224011420|NCT02227199|DRUG|Brentuximab Vedotin|Given IV
224011421|NCT02227199|DRUG|Carboplatin|Given IV
223390345|NCT00871208|DRUG|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
224011422|NCT02227199|DRUG|Etoposide|Given IV
223390346|NCT03158103|DRUG|MEK162|MEK162 at 30mg twice daily
224011423|NCT02227199|DRUG|Ifosfamide|Given IV
224011424|NCT02227199|OTHER|Laboratory Biomarker Analysis|Correlative studies
224011425|NCT05003856|OTHER|Quality-of-Life Assessment|Ancillary studies
224011426|NCT05003856|PROCEDURE|Radiofrequency Ablation|Undergo RFA
224011427|NCT06414720|DRUG|Dienogest 2 MG|The patients will be started on progestin therapy after a saliva sample is collected from them for miRNA analysis.
224127312|NCT07163143|DRUG|Ethambutol (E)|E weight based, 550-1375mg
224127313|NCT07161739|BEHAVIORAL|Behavioural Nudge (Influenza Risk Reduction)|A behavioural nudge via mailed letter that discusses the benefits of the influenza vaccine in preventing influenza infection and reducing cardiovascular risk.
223390347|NCT03158103|DRUG|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
223390348|NCT02440464|PROCEDURE|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
223390349|NCT02440464|DRUG|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
223390350|NCT02440464|DRUG|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
223390351|NCT02440464|DRUG|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
223390352|NCT02440464|DRUG|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
223390353|NCT02440464|DRUG|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
223546317|NCT02714491|OTHER|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
224011428|NCT05183152|DEVICE|NMES Feedback|Electroencephalography (EEG) signals will be recorded from subjects as they perform cued tasks for flexing/extending their non-dominant hand. The signals will be processed and classified in real-time using machine learning algorithms to trigger electrical stimulation on the flexors/extensors of the targeted arm contingent to the detection of a subject-specific flexion/extension EEG patterns.
224127314|NCT07161739|BEHAVIORAL|Behavioural Nudge (Travel Vaccination Benefit)|A behavioural nudge via mailed letter that discusses the benefits of travel vaccines in preventing travel-related illnesses.
223546318|NCT00153413|BEHAVIORAL|Cookin' Up Health|A brief nutrition intervention designed to improve dietary habits
223546319|NCT03225391|BEHAVIORAL|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
223546320|NCT03225391|BEHAVIORAL|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
223546321|NCT04470882|BEHAVIORAL|Exposure with faded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during the first two trials, and will remove the protective gear during the last trial.
223546322|NCT04470882|BEHAVIORAL|Exposure without safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will not wear protective gear during any of the exposure therapy trials.
223546323|NCT04470882|BEHAVIORAL|Exposure with unfaded safety behaviors|Exposure therapy will involve three, 10-minute trials in which participants encounter a spider. Participants in this group will wear protective gear during all three exposure therapy trials.
223546324|NCT02433496|OTHER|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
223546325|NCT02659813|DEVICE|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
223546326|NCT03495726|BEHAVIORAL|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
223546327|NCT03216720|PROCEDURE|CABG|"* Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~* Grafting: pedicled left internal mammary artery, and no-touch~* saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~* Target activated coagulation time of \>400 seconds"
223546328|NCT03216720|PROCEDURE|Miniaturized extracorporeal circulation|"* Centrifugal pump to reduce mechanical stress~* Circuit coated with biosurface to increase haemocompatibilty.~* Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~* Collapsible soft-shell reservoir for blood volume management~* Cell-saving device~* Venous air removing device and electric clamp system to air embolism"
223546329|NCT03216720|PROCEDURE|Conventional extracorporeal circulation|"* Roller pump~* Circuit uncoated~* Hard-shell venous reservoir~* Intermittend cold blood Harefield cardioplegia"
223546330|NCT01597648|DRUG|Maraviroc|300 mg
223546331|NCT01597648|DRUG|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
223546332|NCT01597648|DRUG|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
223546333|NCT03069040|PROCEDURE|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
224127315|NCT07161934|BEHAVIORAL|Guided Imagery Training|Participants received guided imagery sessions of 15 minutes after each football training, three times per week for 12 weeks (36 sessions). Sessions included relaxation, visualization of technical movements, and reinforcement of motivation and confidence.
224299321|NCT02263781|PROCEDURE|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
223390354|NCT00965887|DRUG|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
223390355|NCT00965887|DRUG|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
223390356|NCT00290017|DRUG|talabostat|
223390357|NCT00290017|DRUG|pemetrexed|
223390358|NCT04482764|DRUG|Valproic Acid|Treatment of children with frequent cyanotic breath holding spells (at least 4 spells per week) with 5 mg/kg/day for 6 months.
223390359|NCT00741000|PROCEDURE|Cervical Stairstep|Cervical low force mobilization procedure.
224011429|NCT05183152|DEVICE|Visual Feedback|Electroencephalography (EEG) - recorded from subjects as they perform cued motor imagery (MI) tasks - are classified in real-time using a subject-specific BCI decoder,. The output classification probability of the decoder is accumulated using exponential smoothing and translated into continuous visual feedback by means of a bar - on a computer screen - that moves to the right or left in response to classification of one or the other MI task.
224011430|NCT05183152|DEVICE|TESS|Transcutaneous Electrical Spinal Stimulation (TESS) is applied over the C5-C6 spinal segment for 20 minutes at 30Hz with 5kHz carrier frequency.
224011431|NCT04613583|OTHER|SAFeR fetuses|NO active intervention performed.
224011432|NCT06784999|DRUG|sufentanil|1\. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)
224011433|NCT06784999|DRUG|methadone|2\. Intravenous methadone of 0.2 mg/kg IBW up to a maximum dose of 20mg, rounded to the nearest milligram. The methadone will be given at the beginning of the case, prior to surgical incision. n=64)
224011434|NCT06260397|PROCEDURE|serratus anterior plane block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles
224011435|NCT06260397|PROCEDURE|costotransverse block|using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib
224011436|NCT06260397|PROCEDURE|patient controlled analgesia|PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
224011437|NCT05717101|OTHER|Electronic Health Record Review|Review of medical records
224011438|NCT05676034|DRUG|AMX0035|AMX0035
224011439|NCT06202612|DRUG|SHR0302 quick release tablets|SHR0302 quick release tablets 8 mg
223546334|NCT03069040|PROCEDURE|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
223546335|NCT05722834|BEHAVIORAL|SOAR intervention|"This program intervention will be over 6 weeks and participants will have two group sessions and individual sessions, all conducted by an asthma health coach over Zoom (or phone). The two Zoom group sessions will be recorded so that all the information from the conversations will be maintained and used for research purposes. Additionally, participants will keep track of asthma symptoms and complete surveys at specified time-points (the last one at 6 months after participation).~Primary care physicians will be sent emails regarding the self-management goals of their patients."
223546336|NCT06090123|DRUG|TPN171H|"Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.~Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10."
223546337|NCT06090123|DRUG|Itraconazole|Sequence 1：Single dose of 10mg TPN171H on Day 1, 200mg Itraconazole(QD) on Days 3-5, 10mg TPN171H and 200mg Itraconazole on Day 6.
223546338|NCT06090123|DRUG|Rifampicin|Sequence 2：Single dose of 20mg TPN171H on Day 1, 600mg Rifampicin(QD) on Days 3-9, 20mg TPN171H and 600mg Rifampicin on Day 10.
224011440|NCT06202612|DRUG|SHR0302 sustained-release tablets|SHR0302 sustained-release tablets 10 mg
224011441|NCT05866822|OTHER|APA|24 APA sessions
224011442|NCT05866822|OTHER|PAE|8 individuals sessions of PAE
224011443|NCT04903197|DRUG|VAY736|VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
224011444|NCT04903197|DRUG|lenalidomide|Immune-modulatory agent that enhances activation of NK cells.
224011445|NCT04874818|DIAGNOSTIC_TEST|[89Zr]Df-IAB22M2C PET/CT scan|PET imaging procedure
224011446|NCT05646888|BIOLOGICAL|Blood sampling|the blood sample will be taken during a planned blood sampling
224011447|NCT04758065|OTHER|Radial pressure waves Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Experimental Group: Home-based cervical therapeutic exercise, manual therapy, and radial pressure waves."
224127316|NCT07161934|BEHAVIORAL|Standard Football Training|Participants received only regular football training three times per week for 12 weeks (36 sessions). Each session lasted 60 minutes and focused on technical skills. To match contact time, a 15-minute team evaluation meeting was held after each practice.
224127317|NCT07163650|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa was injected daily in the morning before meals Subcutaneous injection at a dose of 1 mg/week in the first two weeks, increased to 3 mg/week in week 3, increased to 6 mg/week in week 5, up to 9 mg/2 week in week 13.
224127318|NCT07163650|BEHAVIORAL|Diet and exercise guidelines|Participants followed a science-based diet and exercise program intervention.
224127319|NCT07163455|BEHAVIORAL|Balanced Diet|Participants will receive balanced dietary guidance informed by the Weight Management Manual (developed in line with the Dietary Guidelines for Chinese Residents) along with biweekly consultations with a nutritionist, with an emphasis on weight management education.
224138552|NCT04161274|PROCEDURE|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
224127320|NCT07163455|BEHAVIORAL|Artificial Intelligence-Assisted Time-Restricted Eating with Evening Caloric Restriction|"This intervention combines Artificial Intelligence-assisted Time-Restricted Eating (10-hour eating window) with Evening Caloric Restriction (\<20% of total daily energy intake at dinner). The recommended daily energy distribution is 40% for breakfast, 40% for lunch, and 20% for dinner. Al support will be provided via the Weight Manager app, which sends meal reminders ahead of each meal. Participants will log each meal by the app. If no log is recorded for seven consecutive days, the weight management AI will notify a study dietitian to contact the participant for follow-up and provide dietary counseling. Educational infographics and articles on the benefits of restricting the eating window and reducing dinner caloric intake will be pushed once a month via the Weight Manager app or WeChat. Dietary records collected during follow-up visits will be reviewed to reinforce education on lowering the proportion of daily energy consumed at dinner."
224127321|NCT07164144|BEHAVIORAL|Vaccine Communication Training|School personnel receive vaccine communication training + promotional materials
224127322|NCT07161869|PROCEDURE|Registration of all findings during preoperative Endoscopic Ultrasound|Using the improved POELH-III EUS format
224127323|NCT07163273|DRUG|NALIRIFOX|NALIRIFOX consists of 5-FU 2400 mg/m2 over 46 hours, liposomal irinotecan 50 mg/m2, and oxaliplatin 60 mg/m2, which would be given on Day 1 and Day 15
224127324|NCT07163273|DRUG|Gemcitabine plus nab-Paclitaxel (GnP)|GnP consists of gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2, given on Days 1, 8, and 15.
224127325|NCT07163247|BEHAVIORAL|Robotic pet (PARO) companionship|"The intervention is composed of the following components:~Duration: Robotic pet companionship lasting 30-120 minutes, depending on clinical goals during each spontaneous breathing trial (SBT).~Preparation and interaction: PARO is introduced 30 minutes before each SBT to establish emotional connection. Study staff will briefly introduce its interactive features, including responding to stroking, gentle tapping, head movements, and eye blinking. Participants may interact freely with PARO during the intervention.~Assessment: Outcome measurements are conducted during the intervention. If extubated successfully, a semi-structured interview is conducted three days later.~Early termination: The intervention is stopped if the participant becomes clinically unsuitable for further SBTs or experiences a serious adverse event (e.g., device dislodgement).~Additional information: After each SBT, PARO is sterilized and stored in a sealed container in the patient's room."
224127326|NCT03638089|BEHAVIORAL|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
224127327|NCT05416229|DRUG|Psilocybin|Psilocybin-assisted therapy
224127328|NCT05416229|DRUG|Maltodextrin|Placebo-assisted therapy
224127329|NCT04294810|DRUG|Atezolizumab|Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.
224127330|NCT04294810|DRUG|Tiragolumab|Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
224127331|NCT04294810|DRUG|Matching Placebo|Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
224127332|NCT05317429|OTHER|A meal delivering 75 g of carbohydrate|"The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity."
224127333|NCT06397690|BEHAVIORAL|My Choice for HIV Prevention (MyChoice)|My Choice for HIV Prevention (MyChoice) is a counselor-delivered shared decision-making approach for pregnant women considering PrEP
223390360|NCT02963779|DRUG|LY2775240|Administered orally
223390361|NCT02963779|DRUG|Placebo|Administered orally
223390362|NCT02963779|DRUG|Apremilast|Administered orally
223390363|NCT05433142|BIOLOGICAL|XmAb819|Monoclonal Bispecific Antibody
223390364|NCT02423200|DRUG|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
223390365|NCT00364767|DIETARY_SUPPLEMENT|A|Alcohol consumption (32 g/day) for 4 weeks
223390366|NCT00364767|DIETARY_SUPPLEMENT|B|Water
223390367|NCT00343525|DRUG|bavituximab|
223390368|NCT02892630|OTHER|No intervention|
223390369|NCT01722630|DRUG|Dopamine|
223390370|NCT04937881|DRUG|Tenofovir alafenamide|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 25 mg tenofovir alafenamide (TAF)
223390371|NCT04937881|DRUG|Tenofovir Disoproxil Fumarate|Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)
223390372|NCT06158893|DRUG|Salbutamol|inhalation anaesthesia
223390373|NCT06158893|DRUG|Budesonide|inhalation anaesthesia
223390374|NCT06158893|OTHER|Saline|saline
223390375|NCT03877835|PROCEDURE|Peripheral nerve blocks|LSIB + SSNB
223390376|NCT04512664|OTHER|cold application|cold application with gel pacs
223390377|NCT04394403|BEHAVIORAL|Internet-based guided self-help based on CBT principles|Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
223390378|NCT01280643|DRUG|fluorouracil|Given IV
223390379|NCT01280643|DRUG|leucovorin calcium|Given IV
223390380|NCT01280643|DRUG|oxaliplatin|Given IV
223390381|NCT01280643|DRUG|irinotecan hydrochloride|Given IV
223390382|NCT01280643|BIOLOGICAL|bevacizumab|Given IV
223390383|NCT01280643|BIOLOGICAL|cetuximab|Given IV
223390384|NCT01280643|DRUG|capecitabine|Given PO
223390385|NCT01280643|GENETIC|mutation analysis|Correlative studies
223390386|NCT01280643|GENETIC|gene expression analysis|Correlative studies
223390387|NCT01280643|OTHER|laboratory biomarker analysis|Correlative studies
223390388|NCT01280643|OTHER|immunohistochemistry staining method|Correlative studies
223390389|NCT01280643|GENETIC|nucleic acid sequencing|Correlative studies
224127334|NCT06397690|BEHAVIORAL|Standard of care (control arm)|Standard of care (control arm) participants will receive comprehensive education on both the advantages and limitations of each PrEP method, including guidance on potential side effects.
223546339|NCT00633763|DRUG|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
223546340|NCT00633763|DRUG|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration \<10 micrograms.
223546341|NCT04014699|PROCEDURE|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
223390390|NCT01280643|GENETIC|protein expression analysis|Correlative studies
223390391|NCT01280643|GENETIC|polymerase chain reaction|Correlative studies
223390392|NCT01280643|GENETIC|DNA analysis|Correlative studies
223390393|NCT01277783|DEVICE|Endocardial Left Ventricular pacing|Subjects receive an endocardial LV lead placement via superior approach using Medtronic Model 3830 lead and Medtronic Model 6227ATS deflectable delivery catheter and Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter, using trans esophageal echo (TEE) or intra-cardiac echo (ICE) to guide the procedure.
223546342|NCT04014699|PROCEDURE|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
223546343|NCT05830318|OTHER|P-STEP Mobile Application|A mobile application that allows you track your walking habits while keeping you up to date with air quality information.
223546344|NCT00106041|BEHAVIORAL|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
223546345|NCT00196690|DRUG|Donepezil|
223546346|NCT03460652|DRUG|KP415 oral capsule|Once-daily oral dose
223546347|NCT00548197|DRUG|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
223546348|NCT01602263|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
224011448|NCT04758065|OTHER|Therapeutic Exercise and Manual Therapy|"Combination of the usual physiotherapy treatment with the application of radial pressure waves compared with a control group in which only the usual treatment, in people with non-specific neck pain, will be applied.~During the first month, the participants will perform 3 weekly sessions of home-based cervical therapeutic exercise and will come to the facilities, once a week, to get a manual therapy session based on the Maitland Concept (15 minutes of posteroanterior mobilizations in the restricted and/or painful vertebrae of the cervical and thoracic spine). Besides this participants of the experimental group will receive a radial pressure waves treatment sessión.~Control Group: Home-based cervical therapeutic exercise and manual therapy."
224011449|NCT05169593|DRUG|Biological Drug|Biological therapy used in daily clinical practice in patients with Crohn's disease to prevent disease recurrence
224011450|NCT06199336|BIOLOGICAL|JHM03|Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.
224011451|NCT06199336|BIOLOGICAL|BOTOX®|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
224011452|NCT06199336|BIOLOGICAL|Placebo|Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.
224011453|NCT05920720|BEHAVIORAL|Self-guided Personalized Treatment|Women who endorse significant DE will complete two weeks of smart-phone self-monitoring to identify target problems and will be sent two self-guided modules of personalized treatment directly to their smart-phones.
224011454|NCT05937373|DEVICE|Continuous Glucose monitor|Perioperative glucose management beginning preoperative through postoperative monitoring
224011455|NCT05937373|OTHER|Standard of Care|no study intervention. participant follows current medical providers recommendations for glucose management
224011456|NCT04242069|BEHAVIORAL|Healthy for my Baby|"Participants will start the preconception intervention by meeting with a health professional for a motivational interview session on healthy lifestyle habits. Following this interview, participants will have access to a mobile phone application that will allow them to track daily lifestyle modification goals. After a month, they will meet the health professional for a second motivational interview and review their progression. Participants will continue to make lifestyle changes through the preconception period by accomplishing smart goals followed daily in the mobile phone application.~If the woman becomes pregnant, the couple will participate in two more in-person motivational interviews, a month apart. The mobile application will be put in pregnancy mode, and participants will adapt their daily lifestyle goals for the pregnancy. Participants will continue to make lifestyle changes throughout pregnancy by accomplishing smart goals followed daily in the mobile phone application."
223390394|NCT01715961|PROCEDURE|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
223390395|NCT04196283|DRUG|ABBV-368|Intravenous (IV) infusion
223390396|NCT04196283|DRUG|Tilsotolimod|Intratumoral (IT) injection
223390397|NCT04196283|DRUG|Nab-paclitaxel|Intravenous (IV) infusion
223390398|NCT04196283|DRUG|ABBV-181|Intravenous (IV) infusion
223390399|NCT04867005|BEHAVIORAL|Impact of a training program|Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
223546349|NCT05673824|DRUG|Huaier Granule|"Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher."
223730427|NCT05843981|DEVICE|Implant placement TS III|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.
224011457|NCT04242069|OTHER|Usual Care|"Participants in the control group will receive standard advice on healthy lifestyle habits as provided by their usual care provider. They will receive standard medical care in preconception and pregnancy.~To improve compliance with the study follow-up, participants in this group will have access to a simplified version of the mobile application that contains a fertility calendar and a research visit calendar. This version of the application does not include lifestyle goals or any information on healthy lifestyle habits."
224011458|NCT04040218|PROCEDURE|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
224011459|NCT04924166|DRUG|Placebo|Inactive dose of capsules that appear identical to active dose
224011460|NCT04924166|DRUG|Hydrocortisone|Hydrocortisone 180 mg in capsule form
224011461|NCT01934790|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
224011462|NCT03453853|DEVICE|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
224011463|NCT02284217|DEVICE|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
224011464|NCT04265352|OTHER|No intervension|There is intervention at all.
224011465|NCT02365090|OTHER|patching|covering the sound eye with a patch to force use of the amblyopic eye
224011466|NCT02365090|OTHER|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
224011467|NCT04073004|BEHAVIORAL|Rapid Resolution Therapy|psychotherapy that includes trance states
224011468|NCT06340360|DRUG|Rezpegaldesleukin|Pharmaceutical form: Injection solution Route of administration: subcutaneous
224011469|NCT06340360|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: subcutaneous
224011470|NCT04777201|DRUG|Faricimab|Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
224011471|NCT04777201|OTHER|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.
224011472|NCT00552929|DRUG|Sugammadex|"After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered."
224011473|NCT05701774|DRUG|DCCR|Once daily oral administration
224011474|NCT04809506|BIOLOGICAL|additional blood samples|2 additional blood samples (2 x 7ml) at every visit
224011475|NCT06050759|DIAGNOSTIC_TEST|CRP and Albumin level in blood sample|CRP and Albumin levels will be measured from blood samples of the patients to determine CRP/Albumin Ratio
224011476|NCT05881135|DRUG|Citicoline|i.v. bolus administration every 12 hours for 5 days.
224011477|NCT05881135|DRUG|Saline/Placebo|i.v. administered every 12 hours as a 10 ml bolus for 5 days.
224011478|NCT03532503|DEVICE|Foley catheter|Transcervical foley catheter will be applied
224011479|NCT05555147|DRUG|nerve block with 0.5% ropivacaine|After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
224011480|NCT05555147|OTHER|without any nerve block|Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
224011481|NCT03889145|DRUG|Telmisartan 80mg|Telmisartan 80mg
223390400|NCT03218020|OTHER|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
223390401|NCT06211101|OTHER|Providing training on kangaroo care guide|Online training was given to neonatal nurses on the kangaroo care guide created by the researcher in line with the literature.
224011482|NCT03889145|DRUG|Amlodipine10mg|Amlodipine 10mg
224011483|NCT03889145|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg
224011484|NCT03092817|DRUG|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
224011485|NCT03092817|OTHER|Placebo|"Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose"
224011486|NCT05845541|BEHAVIORAL|Technology Supported Meditation and Biofeedback|"Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.~During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed."
223546350|NCT05673824|DRUG|VEGFR-TKIs|Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib. Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
223546351|NCT00245388|DRUG|Muraglitazar|
223390402|NCT01350882|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
223390403|NCT01350882|DRUG|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
223546352|NCT00598923|DRUG|topiramate|100 mg twice per day for 3 months
223546353|NCT00598923|DRUG|topiramate|100 twice per day for 6 days after loading dose of phenytoin
223546354|NCT00598923|DRUG|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
223546355|NCT01650831|DEVICE|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
223546356|NCT04062747|DEVICE|I-gel|After standard anesthesia i-Gel was placed into the patient
223546357|NCT04062747|DEVICE|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
223546358|NCT03882437|BIOLOGICAL|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
223546359|NCT02614339|DRUG|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
223546360|NCT02614339|DRUG|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
223390404|NCT04200820|DIAGNOSTIC_TEST|Trampoline|During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
223390405|NCT00596791|DRUG|tafluprost|prostaglandine analoque
223390406|NCT06399835|DRUG|Enavogliflozin|Enavogliflozin 0.3mg once daily
223390407|NCT06399835|DRUG|Pioglitazone|Pioglitazone 15mg once daily
223390408|NCT01320995|PROCEDURE|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
223546361|NCT01303952|DRUG|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
223546362|NCT03377595|DRUG|Exparel|TAP (Transversus Abdominis Plane) block
223546363|NCT03377595|DRUG|Exparel|Wound infiltration
223546364|NCT01876303|OTHER|laboratory biomarker analysis|Correlative studies
223546365|NCT01876303|OTHER|questionnaire administration|Ancillary studies
223546366|NCT05156944|OTHER|physiotherapeutic intervention|"The intervention consists of a brief physiotherapeutic assessment, the short physical performance battery, a brief information on the expected course of the condition, a check of fall hazards at home using the Bundesamt für Unfallverhütung (bfu) checklist, and instructions on self-management (eg. staying active, adaptation of behavior and surrounding at home). Additionally, two exercises for daily self-guided therapy will be instructed, namely, sit-to-stand and balance performance exercises."
223546367|NCT01479244|BIOLOGICAL|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
223546368|NCT01479244|BIOLOGICAL|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
223546369|NCT03810547|DRUG|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
223546370|NCT01741298|BEHAVIORAL|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
223546371|NCT01495039|DRUG|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
223546372|NCT03774771|DRUG|Cinacalcet|Capsule for oral administration
223546373|NCT03774771|DRUG|Placebo|Capsules for oral administration
223546374|NCT05892497|OTHER|Tecartherapy|The tecartherapy intervention was with a deep diathermy machine applied to the patient's lower extremity for 30 minutes.
223390409|NCT06578793|PROCEDURE|Catheter Ablation Combined with Marshall Vein Ethanol Ablation|This study involves two procedures. The first procedure is a combination of catheter ablation with ethanol ablation of the Marshall vein. The second procedure is catheter ablation alone. Both procedures involve standard techniques used to treat persistent atrial fibrillation, with the addition of Marshall vein ethanol ablation in the experimental group aimed at potentially improving outcomes by targeting additional arrhythmogenic substrates.
223390410|NCT04666948|DEVICE|vancomycin model-informed precision dosing|A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg\*h/L
224011487|NCT05845541|OTHER|Standard Treatment|Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
223390411|NCT04666948|DRUG|Vancomycin|Vancomycin treatment
223390412|NCT02344667|RADIATION|Stereotactic Body Radiotherapy|
223390413|NCT04998565|OTHER|Routine care|Reverse pressure applied to the areola
223390414|NCT04998565|PROCEDURE|Electrical Acupuncture|Acupuncture on Hegu, Sanyinjiao, Zusanli and Taichong with electrical stimulation
223390415|NCT04998565|PROCEDURE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation over bil breasts
223390416|NCT01113372|DRUG|Clopidogrel|Clopidogrel 75mg daily.
223390417|NCT02507739|OTHER|no possibility to walk during labor|
223390418|NCT02507739|OTHER|possibility to walk during labor|
223390419|NCT04113161|OTHER|Standard Care|Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
223390420|NCT04113161|OTHER|Child Behavioral Health Navigator (cbhN)|CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
223390421|NCT03330561|DRUG|PRS-343|PRS-343
223390422|NCT03976271|PROCEDURE|hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp|For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
223390423|NCT00777387|PROCEDURE|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
223390424|NCT00777387|PROCEDURE|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
223390425|NCT03383965|BIOLOGICAL|ICAR30 T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
223390426|NCT05112081|DRUG|Botulinum toxin type A|The group will receive a solution of 100 units BTX with 10 ml sterile saline close to the superficial inguinal ring.
223390427|NCT05112081|OTHER|Sterile saline|The group will receive a solution of 10 ml sterile saline close to the superficial inguinal ring.
223390428|NCT04283630|DIETARY_SUPPLEMENT|Dietary nitrate in the form of beetroot juice for all participnats|participants asked to consume dietary nitrate in the form of beet juice everyday in the morning and then one hour later, the vitamin C capsules.
223390429|NCT04283630|DIETARY_SUPPLEMENT|Nature Made vitamin c 1000 mg|vitamin C and the placebo were provided as supplement capsules. Participants were asked to consume one dose/shot of sport Beet IT (70ml) that delivers on average 300-400mg of inorganic nitrate every day in the morning during the four-week study period, except for the test days and washout weeks. Accordingly, the participant were asked to consume the daily vitamin C supplement (1000 mg) or placebo one-hour post beetroot juice supplementation.
223390430|NCT04283630|DIETARY_SUPPLEMENT|Placebo|Vitamin C matched Placebo capsules that made from starch.
223546375|NCT05077839|DRUG|Trifluridine/Tipiracil|Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
224011488|NCT00728910|DRUG|Atorvastatin|10 mg QD for 4 weeks
223390431|NCT00751062|DRUG|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
223390432|NCT00751062|DRUG|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
223390433|NCT00981812|PROCEDURE|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
223390434|NCT04933695|DRUG|Sotorasib|Oral tablet
223390435|NCT02418884|DRUG|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
223390436|NCT04620746|DRUG|Penicillin Major Determinant (PrePen) Skin Testing|Skin testing followed by oral challenge with amoxicillin 250 mg single dose
223390437|NCT04620746|DRUG|Direct Oral challenge|Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
223390438|NCT03411863|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
223390439|NCT03411863|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
223546376|NCT03449849|OTHER|Base Diet|Base Diet
223546377|NCT03449849|OTHER|Kale Treatment|Base Diet plus Kale
223546378|NCT01007188|OTHER|1.5PD almonds|average American diet plus 1.5 oz per day almonds
224011489|NCT00728910|DRUG|ABT335|135 mg QD added to atorvastatin for 8 weeks
224011490|NCT00728910|DRUG|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
224011491|NCT00769262|OTHER|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
224011492|NCT00769262|OTHER|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
224011493|NCT05756270|DIAGNOSTIC_TEST|pCASL|Brain 3 Tesla MRI with pCASL sequence
224011494|NCT02368457|DRUG|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
224011495|NCT00669279|DRUG|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
224127335|NCT03431324|BEHAVIORAL|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
223390440|NCT04244461|BEHAVIORAL|Personalized Normative Feedback|The personalized normative feedback (PNF) focuses on behavioral norms, where participants see (1) how their perceptions compare to other same-gender veterans' actual drinking and (2) how their actual drinking compares to other same-gender veterans' actual drinking. The format of the intervention highlights typical days per week, drinks per occasion, and binge drinking as per traditional PNF interventions. PNF will also contain a video description of theories of normative influence (e.g., how individuals are affected by perceptions) and a description of the normative data sample. Participants also see enhanced PNF content that will focus on sharing with participants treatment information that the investigators obtained from a pilot sample.
223390441|NCT05015816|DIAGNOSTIC_TEST|Total body photography|3 monthly TBP imaging
223390442|NCT03535740|DRUG|Brigatinib|Brigatinib Tablets
223390443|NCT04894734|DEVICE|EES on|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
223390444|NCT04894734|DEVICE|EES off|Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
223390445|NCT06120153|DIAGNOSTIC_TEST|POC PCR-test device|"The analysis will follow an intention-to-treat principle, that is, contacts in the intervention period will be analyzed as randomized, regardless of whether the POC PCR test was actually performed for a given contact. As sensitivity analysis, the data will be analyzed in a per-protocol spirit, defining the intervention at the contact level as a POC PCR test performed."
223390446|NCT06974760|DEVICE|IVUS|The Participants will receive IVUS examinations from Pulse and Boston
223390447|NCT04481035|DRUG|N-acetylcysteine (NAC)|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the experimental phase/arm will receive 70 mg/kg/dose (max dose 900 mg) three times per day of NAC for eight (8) weeks.
223390448|NCT04481035|OTHER|Placebo|The study design is essentially a cross-sectional survey and then longitudinal evaluation of cognition and behavior, motor function, cortical function, and metabolomics profiles in NF1 before and after 8 weeks of treatment with an FDA approved medication, N-acetylcysteine (NAC) or placebo. This is a cross-over double-blind placebo controlled study. Participants in the placebo phase/arm will receive placebo (non-drug) three times per day for eight (8) weeks.
223390449|NCT06536465|DRUG|REC-3964|REC-3964 given at a dose of either 500 mg q12h or 250 mg q12h
223546379|NCT01007188|OTHER|3.0PD almonds|average American diet plus 3.0 oz per day almonds
223546380|NCT01007188|OTHER|Base (without almonds)|average American diet without almonds
223546381|NCT00632775|DRUG|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
224011496|NCT00669279|DRUG|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
224011497|NCT06052670|DIAGNOSTIC_TEST|fractional flow reserve (FFR); ultrasonic flow ratio (UFR); intravascular ultrasound (IVUS)|pressure wire-based fractional flow reserve (FFR); intravascular ultrasound (IVUS)-based ultrasonic flow ratio (UFR)
224011498|NCT04168983|OTHER|sophrology|Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
223546382|NCT00632775|DRUG|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing \<10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those \>20kg."
223546383|NCT02515344|OTHER|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
223546384|NCT02515344|OTHER|Providing general information about CRC sreening|
223546385|NCT01834599|DEVICE|cerebral oximetry|tissue saturation measurement in pregnant women
224011499|NCT01147536|BIOLOGICAL|HSPPC-96|
224011500|NCT03410004|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
224011501|NCT00116597|GENETIC|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
224011502|NCT00116597|BIOLOGICAL|Intranodal booster immunizations with synthetic melanoma associated epitopes|
223390450|NCT05437198|OTHER|collection of human exhalation|"the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device"
224127336|NCT03431324|BEHAVIORAL|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
224127337|NCT01044381|DRUG|Luliconazole Solution, 10%|28 days of daily application
224127338|NCT05909605|DEVICE|sphygmomanometer|Comparison to the ultrasound sensor
224127339|NCT05909605|DEVICE|Arterial Line|Comparison to the ultrasound sensor
224127340|NCT05388162|DEVICE|Mobile colposcope|It is a comparison trial - Comparing a standard colposcpoe with a smart-phone based colpsocpe.
224127341|NCT00724724|DRUG|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
224127342|NCT00724724|DRUG|Aspirin|Aspirin 100mg Qd for 1 year
223390451|NCT05807828|PROCEDURE|VR simulation on basic THA skills|The medical students' VR group will perform three VR simulation sessions on basic THA skills on the cup or stem implantation before actual implantation.
223390452|NCT06975683|BIOLOGICAL|Plasma Rich in Growth Factors (PRGF)|On the day of the ovarian puncture of the 1st IVF cycle, intraovarian instillation of plasma rich in growth factors will be performed.
223390453|NCT05198518|DEVICE|Microcurrent TENS device|The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
223390454|NCT05198518|DEVICE|Sham Device|The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
223390455|NCT05024825|DRUG|Gabapentin|Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
223546386|NCT06072625|DIETARY_SUPPLEMENT|Extra virgin organic olive oil (ULTRA PREMIUM)|Babies who have fully enteral feeding will take oral, 1 ml/kg/day of extra virgin olive-oil
223546387|NCT03475069|OTHER|Custom Designed Exercises|
223546388|NCT03475069|OTHER|Plates Exercises|
224011503|NCT04914429|DRUG|Guselkumab|Guselkumab 100 mg will be administered as a SC injection.
224011504|NCT04914429|DRUG|Placebo|Matching placebo will be administered as a SC injection.
224011505|NCT05963347|DRUG|Golidocitinib|Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.
224011506|NCT05963347|DRUG|CHOP Regimen|CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.
224011507|NCT05216822|DRUG|Racecadotril|racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
224011508|NCT00246220|DRUG|methylphenidate hydrochloride|
224011509|NCT06104813|OTHER|Interviews|Interview with volunteer, to ask them a series of open questions about sexual health in the deaf male population.
224011510|NCT03636529|DIETARY_SUPPLEMENT|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
224011511|NCT03636529|OTHER|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
224127343|NCT05844345|OTHER|Hydrocolloid barrier group|In the hydrocolloid barrier group, Comfeel Plus brand hydrocolloid tape will be used. Hydrocolloid tape is a dressing cover made of soft, flexible and economic material in the form of a semi-permeable film or foam-supported gel. Air exchange continues due to the semipermeable film on the top, while entry of harmful microorganisms to the region is prevented, healing is accelerated by creating a humid environment for the wound and exudate from the wound is absorbed. These features reduce the risk of developing infection and ensure patient comfort. There is no specific change time, though generally the tape is changed every 3-5 days; however, it may remain in place for up to 7 days.
224127344|NCT05844345|OTHER|Facial Massage group|Premature infants in the facial massage group will have facial massage applied by the researcher. For facial massage, physiological serum used for routine moisturizing in the clinic will be used. When performing facial massage, the fingers will be placed in the middle of the infant's forehead and massage will be performed towards the temples. The eyelids will be lightly rubbed toward the temples. Both thumbs will be placed in the center of the eyebrows and the ridge of the nose will be rubbed toward the lips. The sides of the nose will be rubbed with light pressure. The nasal septum will be rubbed toward the tip of the nose along the philtrum. The fingers will be placed on the philtrum region above the gums and the mouth will be rubbed toward the ears to make a smiling expression. The chin will be lightly massaged toward the back of the ears. The thumbs of both hands will rub from under the infant's chin toward the temples to give make a smiling face (smiling motion).
224127345|NCT00663728|DRUG|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
224127346|NCT00663728|DRUG|Placebo|Matching placebo
224127347|NCT02594397|OTHER|acupoints combination 1|
224127348|NCT02594397|OTHER|acupoints combination 2|
224127349|NCT02594397|OTHER|sham acupoints combination|
224127350|NCT06004141|BEHAVIORAL|Laguna Health|Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
224127351|NCT00173251|PROCEDURE|obtain surgical specimen for analysis|
224127352|NCT05494541|OTHER|Crizanlizumab|Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
223546389|NCT03475069|OTHER|Calisthenics Exercises|
223546390|NCT04377958|DIAGNOSTIC_TEST|Serum biomarker testing|Serum and sputum samples will be collected and biomarkers will be evaluated using ELISA
223546391|NCT00074139|DRUG|cyclophosphamide|
223546392|NCT00074139|DRUG|docetaxel|
223546393|NCT00074139|DRUG|doxorubicin hydrochloride|
223546394|NCT02315040|DEVICE|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
223546395|NCT02315040|OTHER|Standard Intrauterine Insemination|standard intrauterine insemination procedure
223546396|NCT01393210|DIETARY_SUPPLEMENT|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
223546397|NCT01393210|OTHER|low-calorie diet|low-calorie diet only for 12 weeks.
224011512|NCT01728337|DRUG|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
223390456|NCT05024825|DRUG|hydrocodone, acetaminophen and ibuprofen|Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
223390457|NCT06103045|OTHER|unilateral and bilateral mirror therapy|The mirror box is placed on a table in the sagittal plane of the participant. The affected upper extremity of the participant is hidden in the morror box and the unaffected upper extremity is placed symmetrically. During the unilateral or bilateral mirror therapy, the participant is requested to execute a serial of movements and tasks and pay attention on observing the reflection of the unaffected side in the mirror simultaneously. In the bilateral mirror therapy, the participant also has to move the affected upper extremity simultaneously; while in the unilateral mirror therapy, the participant only keeps the affected side relaxed.
224011513|NCT01728337|DRUG|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
224011514|NCT06045052|DRUG|Eltrombopag|Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.
224011515|NCT02932098|BEHAVIORAL|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
224011516|NCT02932098|BEHAVIORAL|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
224011517|NCT02932098|BEHAVIORAL|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
224127353|NCT01827059|DRUG|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
223390458|NCT04659369|DRUG|CMAB819|for injection only
223390459|NCT04659369|DRUG|Nivolumab|for injection only
223546398|NCT05604144|DEVICE|Cryoanalgesia (iovera°®)|iovera°® treatment will be administered via ultrasound guidance to 1-2 branches of the dorsal/digital/proper nerve/s that innervate the Morton's neuroma. The treatment will be completed one time per subject.
223546399|NCT02448355|DEVICE|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
223546400|NCT02089932|DRUG|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
223546401|NCT02089932|DRUG|Placebo|
223546402|NCT03417310|DEVICE|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
223546403|NCT03417310|PROCEDURE|Common reduction methods|Manual reduction methods without the assistance of any devices
223546404|NCT02559635|PROCEDURE|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
223546405|NCT02559635|DRUG|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
224127354|NCT01827059|DRUG|Placebo|
224127355|NCT03153735|DEVICE|CMDHA0101|Maximum injection dose : 22 ml
224127356|NCT03153735|DEVICE|PowerFill®|Maximum injection dose : 22 ml
224127357|NCT01534234|DEVICE|PARADYM RF SONR|SonR CRT Optimization
224127358|NCT01534234|DEVICE|PARADYM RF SONR|Echocardiography Optimization
223390460|NCT06021418|DEVICE|DKB-119|Experimental and Acitve Comparator are applied 4 times to each of crow's feet on both sides of the subject.
224127359|NCT04972916|OTHER|Patient navigation-based tobacco harm reduction intervention|At the first intervention interview, the patient navigators will educate participants about the benefits of quitting, introduce smoking cessation resources, motivate participants to link with treatment, help participants attend smoking cessation treatments, and assess barriers that prevented them from being able to consider smoking cessation. The cessation treatment resources will be discussed include PennState Health Smoking Cessation Clinic, Pennsylvania Quitline, or visiting their primary care provider (PCP) to discuss cessation, prescription medications, and/or nicotine replacement therapy. A follow-up call will be made 1 month later to further assist and motivate to use tobacco treatment services, and assess interim tobacco treatment engagement outcome.
224127360|NCT05141773|DEVICE|Computed adenoma detection system (CADe) plus endocuff|This is a computed system that helps the endoscopist to increase the detection of colorectal polyps. An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
224127361|NCT05141773|DEVICE|Endocuff|An add-on device (Endocuff) is also incorporated to the tip of the colonoscope
223390461|NCT05856851|DRUG|Alteplase|See arm/group descriptions.
223546406|NCT04005391|OTHER|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
223546407|NCT03344783|OTHER|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
223546408|NCT00002081|DRUG|Zidovudine|
223546409|NCT00002081|DRUG|Zalcitabine|
224011518|NCT02651532|DEVICE|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
224127362|NCT04774679|PROCEDURE|Endosonographic fine needle aspiration biopsy|An endoscopic ultrasound device will be inserted to the stomach and biopsy will performed with a needle
224127363|NCT05172193|BIOLOGICAL|SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated|SARS-CoV-2 vaccine (Vero cell) inactivated developed by Beijing Bio-Institute Biological Products Co., Ltd, can induce active immunity and prevent diseases caused by the SARS-CoV-2 virus by producing neutralizing antibody. The inactivated SARSCoV-2 Vaccine (Vero cell) is prepared by inoculating Verda Reno cells (Vero cell) with SARS-CoV-2 HB02 strain, culturing, harvesting, inactivating, clarifying, concentrating, purifying and adding aluminum hydroxide adjuvant.
224127364|NCT05268315|BEHAVIORAL|Brief Psychoeducational Intervention|The 1-session psychoeducational intervention is divided into three brief modules. Topics that are covered include thinking, learning, emotional, and behavioral functioning as they relate to childhood cancer, educational and school supports, and the role of neuropsychological and school-based assessments.
223546410|NCT00289172|BIOLOGICAL|Live attenuated human rotavirus vaccine|
223546411|NCT02236325|BEHAVIORAL|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
223546412|NCT02236325|BEHAVIORAL|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
224011519|NCT02371590|DRUG|Lenalidomide|"Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject."
224011520|NCT02371590|DRUG|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
224127365|NCT04574063|BEHAVIORAL|Lifestyle intervention to reduce breast cancer risk|Women will be educated about lifestyle factors which increase breast cancer risk. They will also be guided through an online goal setting process.
223390462|NCT02927470|DEVICE|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
223390463|NCT02927470|DEVICE|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
223546413|NCT01034501|DEVICE|sham procedure|non activated laser tip
223546414|NCT01034501|DEVICE|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
223546415|NCT01999244|BEHAVIORAL|Self-monitoring skills|
223546416|NCT01999244|BEHAVIORAL|Technology|
223546417|NCT01999244|BEHAVIORAL|Interventionist Contact|
223546418|NCT04068077|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
223390464|NCT02927470|DEVICE|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
224011521|NCT04637269|BIOLOGICAL|anti-BCMA CAR-T|5×10\^7 /KG 15×10\^7 /KG 45×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.
224011522|NCT06415526|PROCEDURE|OPERA|Robotic-assisted mastectomy and robotic assisted free DIEP flap harvest for breast reconstruction
223390465|NCT03168022|DRUG|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
223390466|NCT03168022|DRUG|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
223390467|NCT03214783|OTHER|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
223390468|NCT02188810|BIOLOGICAL|PAL|Single dose administered intramuscularly.
223390469|NCT02188810|BIOLOGICAL|TIV|Single dose administered intramuscularly .
223390470|NCT05209789|BEHAVIORAL|HUGS|Group therapy with the participation of two therapist positively encouraging mother-baby interactions in a non-judgmental manner
224011523|NCT03890003|DEVICE|AID System|AID system
224011524|NCT03890003|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
224011525|NCT00263367|OTHER|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
224011526|NCT06269094|OTHER|CGM|CGM use for 6 weeks during virtual focus groups
224011527|NCT04577001|DRUG|Letrozole|2.5 mg orally daily for 6 months
224011528|NCT04577001|DRUG|Placebo|No active ingredient taken orally daily for 6 months
224011529|NCT04558892|DRUG|Enoxaparin|
223390471|NCT05209789|BEHAVIORAL|Playtime|Very little intervention from the therapists
223390472|NCT02677350|DRUG|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
224011530|NCT00507403|DRUG|infliximab|
224011531|NCT05986500|OTHER|Galactose|The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)
224011532|NCT05986500|OTHER|No intervention|The participants will receive a saline infusion
224011533|NCT01241604|DEVICE|BiPAP S/T|Mechanical Non-invasive Ventilation
224011534|NCT01241604|DEVICE|BiPAP Auto SV3|Auto Servo Ventilation Device
224011535|NCT00360217|DRUG|docosahexanoic acid (DHA)|
223390473|NCT03910985|DRUG|Duovent HFA|bronchodilation
223390474|NCT04774484|OTHER|High Intensity Interval Training|After the acclimatization session and assessment of eligibility, a graded exercise test (GXT) will be given to the participant. After checking their vitals, the HIIT program will be performed on recumbent cycles. The first two weeks of training will consist of a gradual ramp where subjects will perform a moderate intensity cycling program consisting of a 5-minute warm up followed by progressively longer continuous cycling starting at 15 minutes and progressing up to 30 minutes prior to starting the HIIT training. For the HIIT training subjects will perform 5 minutes of low to moderate steady state cycling to warm up. Following the warm up, the subjects will complete the 4x4 HIIT program. This will consist of 4 minutes of cycling at 85% of the subject's maximum heart rate (HR) followed by 4 minutes of a low intensity cycling period for recovery.
223390475|NCT02521649|DRUG|G17DT|
223390476|NCT02223988|PROCEDURE|subglottic secretion removal|
223390477|NCT03427515|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10\^9 CFU/day
223390478|NCT03427515|DIETARY_SUPPLEMENT|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10\^9 CFU/day
223390479|NCT03427515|DIETARY_SUPPLEMENT|Placebo|30 days of supplementation
223390480|NCT02068313|RADIATION|Toxicity and outcome measures of IMRT|
223390481|NCT05228678|DIAGNOSTIC_TEST|cardiopulmonary exercise tests|"Spirometry~* forced expiratory volume in 1 second (FEV1) % predicted,~* forced vital capacity (FVC)% predicted,~* forced expiratory volume in 1 second /forced vital capacity FEV1 /FVC"
223390482|NCT04364178|BIOLOGICAL|Adenovirus Specific T- Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Adenovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
223390483|NCT04364178|BIOLOGICAL|Cytomegalovirus Specific T-Lymphocytes|Peripheral blood mononuclear cells will be collected from the donor and loaded onto our Miltenyi Biotec CliniMACS Prodigy® or CliniMACS® Plus where they will be stimulated in vitro with Cytomegalovirus viral-specific antigen(s). The cells are then immunomagnetically labeled with interferon gamma via the cytokine capture system, captured and infused.
223390484|NCT02756611|DRUG|Venetoclax|Tablets for oral administration
223390485|NCT02608411|DRUG|ARQ197|
224011536|NCT03093623|BEHAVIORAL|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points \* time of each exercise (hours) \* Number of times per week + moderate level 5 points \* time per activity (hours) \* number of times per week + low level 3 points \* time per activity (hours) \* number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (\>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
224011537|NCT05148910|DEVICE|Silver and copper IUD (TCu380Ag)|An intrauterine device containing 380mm² of copper with a silver core.
224011538|NCT05148910|DEVICE|Copper IUD (TCu380A)|An intrauterine device containing 380mm² of copper.
224011539|NCT02642562|DRUG|Ferric Derisomaltose|
224011540|NCT06170177|PROCEDURE|Radical Cystectomy|A radical cystectomy is an operation to remove the whole bladder
224011541|NCT03771794|DEVICE|ReguRate neurostimulation|"Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode"
223390486|NCT04942678|BEHAVIORAL|10-minute visit with therapy dog and child life specialist handler|A visit from a therapy dog and child life specialist will occur which will last for approximately 10 minutes. Parents and patients will be asked to sanitize their hand prior to the visit. The child life specialist will be instructed to have ad lib conversation with the family. The dog will remain on a leash during the visit. The patient will be free to pet the therapy dog if they wish.
224127366|NCT00582062|OTHER|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
223390487|NCT06365528|PROCEDURE|Subcutaneous tunnelling|The Subcutaneous tunnelling group will undergo PICC placement under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe and place with additional subcutaneous tunnelling. After vein puncture with the access needle, a Nitinol guidewire will be placed as usual. We will make a tunnel distal to the initial venepuncture site using an additional 14-gauge needle. After resolution of the loop over the venepuncture site, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction plus the subcutaneous tunnel before being inserted in the usual manner.
223390488|NCT06365528|PROCEDURE|Non-tunnelling|The Non-tunnelling group will have PICC placement with the traditional method under ultrasonography. Procedures will be implemented under hand hygiene, maximal sterile barrier, and chlorhexidine. The targeted arm will be sterilized with a mixture of chlorhexidine and isopropyl alcohol, and a sterile drape will be placed to cover the entire procedure feld from head to toe. After vein puncture with the access needle, a Nitinol guidewire will be placed. After, a peel-away sheath will be placed over the wire. The catheter will be trimmed to the distance between the venepuncture site and cavoatrial junction.
223390489|NCT06196489|BEHAVIORAL|adapted vaping cessation intervention|Behavioral intervention for vaping cessation
223390490|NCT02740192|PROCEDURE|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
223390491|NCT02740192|PROCEDURE|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
224011542|NCT02960243|DEVICE|Deep Brain Stimulation|"* DBS System Medtronic~* DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~* These settings will be used to evaluate effects of voice tremor as well"
224011543|NCT00631839|RADIATION|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies \>=6MV.
224011544|NCT05241600|BEHAVIORAL|Mindfulness-Based Childbirth and Parenting|MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.
223390492|NCT02740192|DRUG|Ropivacaine|Ropivacaine was used for the periarticular injection
223390493|NCT02740192|DRUG|Bupivacaine|Bupivacaine was used for the periarticular injection
223390494|NCT05545189|DIAGNOSTIC_TEST|colonoscopy,polypectomy|polyp removal during colonoscopy
223390495|NCT03125798|DEVICE|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
223390496|NCT03125798|DEVICE|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
223390497|NCT01470092|DRUG|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
224011545|NCT05241600|BEHAVIORAL|Non-Mindfulness-Based Childbirth Class|Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
224011546|NCT04353505|DRUG|Ketorolac|Intra-arterial delivery of Ketorolac in the internal maxillary artery, once
223390498|NCT05211648|DEVICE|Aktiia Bracelet|Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The optical signals at the wrist are recorded non-invasively by means by the Aktiia bracelet. The Blood Pressure measurements are further determined from these optical signals and are compared to weekly and monthly Blood Pressure averages measured manually by traditional Home Blood Pressure Monitoring.
223390499|NCT02023931|DRUG|Broccoli Sprout Extract (BSE)|"1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
223730428|NCT05843981|DEVICE|Implant placement ks|Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
223730429|NCT01573572|DRUG|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
223730430|NCT00337506|DRUG|Dexamethasone|
223390500|NCT03869944|DRUG|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a unsuppressed plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with unsuppressed plasma HIV-1 VL (\< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
223390501|NCT03412331|DEVICE|Ultrasonic|Cavitron® BOBCAT® Pro, Dentsply International, USA
224011547|NCT04353505|DRUG|Dexamethasone|Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
224011548|NCT04192253|DRUG|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
224011549|NCT05454332|DRUG|Early Caffeine administration|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
224011550|NCT05454332|OTHER|Control Group|Blinding will be done with the administration of saline solution. Patients in the early caffeine group will receive an attack dose of caffeine 20 mg/kg and begin maintenance dose 10 mg/kg/day. Patients in the late caffeine group, receive bolus of saline solution in the first 2 hours of life, starting, at 24 hours of life, the caffeine-loading dose 20 mg/kg and after maintenance dose 10mg/kg/day. The medical team will prescribe the medication, and the pharmacy will be responsible for randomly dispensing the caffeine or saline solution. The pharmacy will prepare syringes with the medication or saline solution identified by a code referring to the randomization without identifying which solution is being administered. The syringes will be sent to the neonatal ICU and will be administered according to the physician's prescription. The administration will be blinded.
224011551|NCT03899402|DRUG|Insulin|Standard of care insulin for pump or injection and serves as a control
224011552|NCT03899402|DRUG|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
224127367|NCT04765826|PROCEDURE|Autologous mini punch grafting|"All the medications will be administered for 3 months prior to surgery in addition to twice-weekly NB-UVB sessions following its standard protocol.and all patients will continue the treatment till the end of the follow up period Only stable non-responsive or poorly responsive patients (\<25% according to VASI score vitiligo area severity index) and image J measurement during the 1st 3 months phase will be included.~. Chosen lesions in all included patient's groups will undergo mini-punch grafting Mini punch grafting: Skin grafts will be harvested from the anesthetized (local inﬁltration of 2% lignocaine) donor site (the anterolateral aspect of the thigh, using 1mm sterile disposable punches. The grafts obtained will be placed in the slots made by removing the vitiliginous skin using 1mm punches at the recipient site"
224127368|NCT04822857|DIAGNOSTIC_TEST|AMH|The group was divided according to the level of Anti-Müllerian Hormone
224127369|NCT02581566|DRUG|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
224127370|NCT02581566|DRUG|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
224127371|NCT02581566|DRUG|Bupivacaine|Intrathecal Bupivacaine
224127372|NCT03230162|DRUG|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
224127373|NCT03230162|DRUG|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
224127374|NCT02326467|DRUG|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
223390502|NCT03412331|DEVICE|Hand Instruments|Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
223390503|NCT03412331|DEVICE|LED Source|LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
223390504|NCT05593744|OTHER|no intervention|This is an observational study so not involved intervention
223390505|NCT02463773|DEVICE|Ultrasound|Diaphragmatic excursion ultrasound assessment
223390506|NCT02688738|DRUG|Doxycycline|
223390507|NCT00784108|DEVICE|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
223390508|NCT00784108|OTHER|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
223390509|NCT01587157|PROCEDURE|capnography|
223390510|NCT00399048|DRUG|OROS hydromorphone HCL ; OxyContin|
223390511|NCT00401661|DRUG|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
223390512|NCT05446558|PROCEDURE|Intracorporeal anastomosis|"Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis."
223390513|NCT05446558|PROCEDURE|Extracorporeal anastomosis|"A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis."
223390514|NCT03472781|OTHER|No intervention. A retrospective case review|No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
223390515|NCT00332670|PROCEDURE|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
223390516|NCT00332670|PROCEDURE|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
223390517|NCT03135015|OTHER|Placebo capsules|250ml water with 16 x 250mg placebo capsules
223546419|NCT04660695|DEVICE|EUS-guided gastroenterostomy|Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
223546420|NCT05351177|OTHER|Exercise Training|Either of; 8-weeks twice-weekly High-Intensity Interval Training or Same-Session Concurrent Exercise Training.
223546421|NCT01048242|DRUG|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
223546422|NCT01048242|DRUG|Placebo|placebo
223546423|NCT02964273|DRUG|Tolvaptan|Tolvaptan spray-dried, immediate release tablets
223546424|NCT02964273|DRUG|Tolvaptan Matching-placebo|Tolvaptan matching-placebo tablets
223546425|NCT05023785|BEHAVIORAL|Cardio-oncology Rehabilitation (CORE)|Exercise therapy, CVD risk factor management for the first 6 months (as per current standards in CR models) and behavioural support for the entire 2-year intervention period
224011553|NCT03899402|DRUG|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
224011554|NCT03899402|DRUG|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
224011555|NCT03222804|DIETARY_SUPPLEMENT|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10\^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
224011556|NCT03877497|BEHAVIORAL|Adapted SBIRT-T for transgender women|Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
224011557|NCT06649331|DRUG|SHR-A1811|A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
224011558|NCT06649331|DRUG|SHR-A1921|A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.
224127375|NCT03347604|DIAGNOSTIC_TEST|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
224127376|NCT00395408|DRUG|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
224127377|NCT00395408|DRUG|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
224127378|NCT00434512|BIOLOGICAL|HIV vaccine 732461|
223390518|NCT03135015|OTHER|2g capsules|250ml water with 8 x 250mg capsules containing Axulin powder plus 8 x 250mg placebo capsules
223390519|NCT03135015|OTHER|4g capsules|250ml water with 16 x 250mg capsules containing Axulin powder
223390520|NCT03135015|OTHER|Water Control|250ml water
223390521|NCT03135015|OTHER|2g tablets|250ml water with 2 x 1g tablets containing Axulin powder
223390522|NCT03135015|OTHER|4g tablets|250ml water with 4 x 1g tablets containing Axulin powder
223546426|NCT03358355|DRUG|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
223546427|NCT03380637|OTHER|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
223546428|NCT01282255|DRUG|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
223546429|NCT01282255|DRUG|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
223546430|NCT04818307|OTHER|Macquarie Injury Management group|Group A was treated by MIMG (soft tissue mobilization) with base line treatment (Hot pack for 10 mint, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with extended knee, therapist places both hands on the knee and gently apply soft tissue release. This procedure was applied for 2 to 3 minutes.
223730431|NCT00337506|DRUG|velcade|
224011559|NCT06649331|DRUG|SHR-A2009|A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.
224011560|NCT06649331|DRUG|SHR-A2102|A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
224011561|NCT04210440|PROCEDURE|Core decompression procedure|Core Decompression with Bone Chips Allograft adjuvanted by Fibrin Platelet Rich-plasma (PRP) and Concentrated Autologous Mesenchymal Stromal Cells (MSCS), isolated from Bone Marrow
224127379|NCT02526758|DRUG|beclomethasone|
224127380|NCT02526758|DRUG|formoterol|
224127381|NCT02526758|DRUG|budesonide|
224127382|NCT00745186|DRUG|Glucagen|0.2 mg or 1 mg Glucagen single injection
224127383|NCT00745186|DRUG|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
224127384|NCT00004816|DRUG|monoclonal antibody M-T412|
224127385|NCT03570034|DEVICE|Obalon Balloon System|Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program
223390523|NCT03153358|DRUG|Icotinib|icotinib 125 milligram three times a day
223390524|NCT03153358|RADIATION|SBRT|given radiation for the primary lesion
223390525|NCT05560490|DEVICE|FibroFix Cartilage P Knee Implantation|The FibroFix Cartilage P instrument set (Drill set) is used for the preparation of an implant site and placement of the FibroFix Cartilage P Implant to resurface an articular cartilage lesion in the anterior and central regions of the femoral condyles of the knee.
223390526|NCT01172041|DEVICE|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
223390527|NCT01172041|DEVICE|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
223390528|NCT01172041|DRUG|18-FDG|15mCi
224011562|NCT04536870|DIAGNOSTIC_TEST|Echocardiography|Ultrasound of heart
224011563|NCT04536870|DIAGNOSTIC_TEST|ECG screening|Single lead ECG screening twice daily for two weeks
224127386|NCT00199134|DRUG|Letrozole|Size of the tumor is followed
224127387|NCT06258135|DIETARY_SUPPLEMENT|Galacto-oligosaccharide|Single 7g dose daily for 28 days
224127388|NCT06258135|DIETARY_SUPPLEMENT|Maltodextrin|Single 7g dose daily for 28 days
224127389|NCT03767296|DRUG|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease \< 20%)"
224127390|NCT03767296|DRUG|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease \< 20%)"
224127391|NCT05903937|DRUG|Autologous Tumor Infiltrating Lymphocytes|Administered via hepatic arterial infusion (HAI)
224127392|NCT05903937|DRUG|Melphalan|Administered via isolated hepatic perfusion
223730432|NCT05820308|BEHAVIORAL|Companion Dog Walking|Participants will be asked to walk their dog three times per week, for a minimum of 30 minutes each day of walking, over an 8-week period.
223730433|NCT05820308|BEHAVIORAL|Attention Control Group|Participants will be asked to read educational materials on dog health once per week, over an 8-week period.
224011564|NCT04536870|DIAGNOSTIC_TEST|ECG Screening|12-lead ECG screening
224011565|NCT05713955|DEVICE|Obsidian|To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
224011566|NCT06589700|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder.
224011567|NCT06610604|PROCEDURE|thermal ablation|thermal ablation including microwave ablation, radiofrequency ablation of thyroid nodules
224011568|NCT06610604|PROCEDURE|thyroidectomy|surgical resection of thyroid nodules
224011569|NCT06678880|BEHAVIORAL|Phase Advanced Intervention (PAI)|Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.
224011570|NCT06678880|BEHAVIORAL|Phase Delay Intervention (PDI)|Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.
224011571|NCT06243354|DRUG|Test product: HYP-2090PTSA|"Dosage form: Capsule. Strength: 2.5 mg, 5 mg. Method of administration: Oral; Dose escalation: a fixed dose QD is planned, and all other dose levels and administration methods are temporary with the exception of the initial dose. Dose expansion: the dose and method of administration are conducted as discussed by the sponsor and investigators.~Medication cycle: Take orally under fasting condition every morning, with 21 days as a cycle (tentative), and continue taking until disease progression, or intolerable toxicity, or withdrawal of informed consent, or treatment with another antitumor drug, or the death of the subject, or loss to follow-up (whichever occurs earliest)."
224011572|NCT03079453|DRUG|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
224011573|NCT06682481|OTHER|Measurement of biomarker|Measurement of blood levels of 1,5-anhydroglucitol
224011574|NCT03797690|PROCEDURE|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
224011575|NCT03797690|PROCEDURE|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
224011576|NCT02522559|OTHER|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
224011577|NCT05110690|BEHAVIORAL|Behavioral Activation|The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values
224127393|NCT05903937|DRUG|Interleukin-2|low-dose, administered s.c.
224127394|NCT05197478|OTHER|Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey|"To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire"
224127395|NCT00014378|DRUG|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
224296429|NCT06920615|BEHAVIORAL|Chained schedules|"The following procedures are based on Slaton et al. (2016): At the start of each session, the candidate or therapist will hold up the red card, prompt the participant to touch the card, while saying we are in red now, time to work. The participant will have to perform age- or function appropriate tasks without stereotypi to gain access to the green phase. Demand will be designated with a token economy, where each token represents completion of a certain amount of task-related responses. The participant will not be prompted to perform the tasks. If the participant makes an error in a task (e.g. answer a math question incorrectly), this will lead to an error correction and no token will be presented. If stereotypi occurs, it will be blocked for up to 3 s, and then all demands will be reset by removing all earned tokens."
223390529|NCT04488588|OTHER|Kaplan Meier analysis|Kaplan Meier survival analysis was conducted to calculate the cumulative overall survival rates using Log Rank test for comparison between age groups
223730434|NCT00416559|OTHER|clinical observation|
223730435|NCT04389567|DRUG|Famotidine|Use of oral Famotidine.
223390530|NCT04658966|OTHER|administration of a self-questionnaire|Women will have to fill in an online self questionnaire on pre-eclampsia
223390531|NCT03855982|DRUG|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
223390532|NCT05883124|DRUG|Rivastigmine twice-weekly 9,5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
223390533|NCT05883124|DRUG|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
223390534|NCT01174693|DRUG|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
223390535|NCT01174693|DRUG|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
223390536|NCT05681598|DRUG|Hydroxyurea|The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
223390537|NCT00179881|DRUG|Carboplatin|
223390538|NCT00179881|DRUG|Thalomid|
223390539|NCT00179881|PROCEDURE|External Beam Radiation Therapy|
223390540|NCT00100828|DRUG|irinotecan hydrochloride|
223390541|NCT00857571|DRUG|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
223390542|NCT00857571|DRUG|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
223390543|NCT00857571|DRUG|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
224011578|NCT05110690|OTHER|Medication Optimization|Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
224011579|NCT06870214|OTHER|relaxation|Women in the 3rd trimester will receive routine care only.
224011580|NCT06619756|BEHAVIORAL|Phonomotor Treatment (PMT)|Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
224011581|NCT06619756|BEHAVIORAL|Phonological Components Analysis (PCA)|Anomia treatment focuses on improving word-finding abilities. This intervention targets the phonology of words to improve word-finding.
223390544|NCT00857571|DRUG|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
223390545|NCT00857571|DRUG|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
223390546|NCT00857571|DRUG|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
223390547|NCT00857571|DRUG|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
223390548|NCT00857571|DRUG|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
223390549|NCT00857571|DRUG|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
223390550|NCT00857571|DRUG|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
223390551|NCT04583735|BIOLOGICAL|TEPEZZA|Intravenous infusion
223390552|NCT04583735|DRUG|Placebo|Intravenous infusion
224011582|NCT03091660|BIOLOGICAL|BCG Solution|Given intravesically
224011583|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Solution|Given intravesically
224011584|NCT03091660|BIOLOGICAL|BCG Tokyo-172 Strain Vaccine|Given ID
223390553|NCT00124917|RADIATION|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.\[1\]
223390554|NCT05899738|DRUG|Iberdomide|Specified dose on specified days
223390555|NCT03629262|DRUG|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
223390556|NCT03629262|DRUG|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
223390557|NCT00613171|DRUG|STI571|STI571 tablets taken orally once a day
223390558|NCT00220389|DRUG|SPM 907|
223390559|NCT01197911|DRUG|aleglitazar|single oral dose
223390560|NCT05330260|DIAGNOSTIC_TEST|neurocognitive test battery|Assessment of the incidence of late postoperative cognitive decline (LPOCD)
223390561|NCT05080153|DIETARY_SUPPLEMENT|Ocufolin forte|start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)
223390562|NCT05939765|DRUG|Antipsychotic|Participants will undergo a systematic neuropsychiatric assessement at regular intervals. Any change in medication, together with aggressive or dysfunctional behaviour will be continually recorded. The time period prior to the change in medication will be classified as control, the time after as case; therefore each patient becomes his own control.
223390563|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
223390564|NCT03198676|DRUG|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
223390565|NCT03198676|DRUG|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
224011585|NCT03091660|OTHER|Laboratory Biomarker Analysis|Correlative studies
224011586|NCT06872723|BEHAVIORAL|Lung Cancer Screening|Participants who agree to take part in this study, will participate in an interview. During the interview, participants may be asked about: • Participants background information, such as your race and level of education • Participants lung cancer diagnosis and your history of lung cancer screening • Participants experience with scheduling lung cancer screening • Any barriers that kept participants from completing screening
224011587|NCT06708832|DEVICE|SIMBA ingestion|Ingestion of 2 SIMBA capsules at the same time and their excretion.
224296430|NCT02804230|DEVICE|Neuro Ablation - Functional|MR-Guided Focused Ultrasound
224011588|NCT04939363|COMBINATION_PRODUCT|Obinutuzumab with Ibrutinib and Venetoclax|"1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"
223390566|NCT03198676|DRUG|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
223390567|NCT06552182|DRUG|HUC2-344|per oral
223390568|NCT06552182|DRUG|HUC2-344-R1, HUC2-344-R2|per oral
223390569|NCT02587091|BEHAVIORAL|Portable obstetric ultrasound|This intervention was advertised at the cluster level
224011589|NCT06715150|DRUG|Azithromcyin|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
224011590|NCT06715150|OTHER|Placebo|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
224011591|NCT02328235|OTHER|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
224011592|NCT01209234|BEHAVIORAL|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
224011593|NCT01209234|DRUG|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
224011594|NCT02928159|DEVICE|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
224011595|NCT06723184|BEHAVIORAL|The training|"Behavioral: Antenatal Education Education Hours: The training will be completed in a total of three weeks and six hours, two hours each week.~Method: The training will be in a total of three weeks and six hours, two hours each week. Informed Voluntary Consent Form will be obtained from individuals in both groups. Grandmothers in both the control and intervention groups will be asked to fill out the Introductory Information Form, Pharis Self-Confidence Scale, State-Trait Anxiety Scale and Knowledge Measurement Questionnaire for Grandchild Care measurement tools. The data of the intervention group will be filled in before and after the training. The data of the control group will be filled in parallel with the intervention group. At the end of the study, the same training will be applied to the control group.~Group to receive training: Grandmothers who are expecting a grandchild and have a grandchild will be included in the training."
224011596|NCT06723886|DIETARY_SUPPLEMENT|Experimental arm: Olive pomace oil|Participants will consume during 8 weeks either the test oil (olive pomace oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
224011597|NCT06723886|DIETARY_SUPPLEMENT|High-oleic acid sunflower oil|Participants will consume during 8 weeks either the test active comparator oil (high-oleic acid sunflower oil) as the only dietary fat. They will consume 45 g/day of oil, using it in salads, fried foods, as spread on toasts, etc.
224011598|NCT06729372|BEHAVIORAL|Deliberate Flawed Performance|Deliberate Flawed Performance during simulation-based training
224127396|NCT01814488|PROCEDURE|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if \<40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
224127397|NCT00797797|DRUG|No Treatment Added|No added treatment
224127398|NCT00797797|DRUG|Milnacipran Added|Milnacipran 100 mg/d added
223390570|NCT05727098|DRUG|Bupivacaine Hydrochloride|injection of Bupivacaine 0.25% in ESPB
223390571|NCT05727098|DRUG|Bupivacaine Hydrochloride and dexmedetomedine|injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
223390572|NCT05727098|DRUG|Bupivacaine Hydrochloride and ketamine|injection of Bupivacaine 0.25% and ketamine in ESPB
223390573|NCT01331993|DRUG|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
223390574|NCT01331993|DRUG|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
223390575|NCT01331993|DRUG|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
223390576|NCT02012426|BEHAVIORAL|Weight management program|
223390577|NCT02498002|DEVICE|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
223390578|NCT02498002|OTHER|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
223390579|NCT02498002|OTHER|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
223390580|NCT02498002|PROCEDURE|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
223390581|NCT02498002|PROCEDURE|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
223390582|NCT02498002|DRUG|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
224011599|NCT06729372|BEHAVIORAL|Error Avoidance Training|Error Avoidance during simulation-based training
224011600|NCT06729840|DRUG|Injection|Vitamin D , botox , tramcinolone intralesionally injected in keloid
224011601|NCT06886529|OTHER|ML-based intervention|ML model predicting a serious cardiac event in cardiac patients, defined as VAD procedure, being wait listed for heart transplant or death within the next three months.
224127399|NCT05133193|DRUG|three kinds of antibiotics|All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
223390583|NCT02498002|OTHER|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
223390584|NCT02498002|RADIATION|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
223390585|NCT02498002|OTHER|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
223546431|NCT04818307|OTHER|Mulligan Mobilization with Movement|Group B was treated by Mulligan Mobilization with movement with base line treatment (Hot Pack for 10 mints, Quadriceps Isometrics, Stretching). For the application of technique subject lies supine with 30 degree knee flexion, therapist places right hand below the knee and left hand above the knee. Apply the lateral glide on the joint. This procedure was applied for 3 times.
223546432|NCT05606848|OTHER|Nutrition Emulsion (TPF-T)|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake control product with recommended energy.~* 1-8 days after surgery: Patients gradually increase control product intake to reach the recommended energy."
224011602|NCT06735625|BIOLOGICAL|Measurement of AHSP concentration|"Pseudonymization and identification of research samples EDTA tube of 4 mL for patients over 15 and a half years old, and 2 EDTA tubes of 2 mL for children aged 3 to 15 and a half years, totaling 4 mL) by Team 4 according to the procedure in force at the URC.~The 4 mL research sample will then be divided into 1 mL fractions by a technician in the laboratory and stored at -80°C in the medical biology laboratory."
224011603|NCT06726707|COMBINATION_PRODUCT|Diaper with a copper-based product + usual care|The intervention is an incontinence aid product and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
224011604|NCT06726707|COMBINATION_PRODUCT|Barrier product with common diaper|The common diaper is an incontinence aid and its performance is related to its ability to absorb and contain urine/ feces as well as keeping the skin dry.
224011605|NCT06743685|BEHAVIORAL|HEALthy Beginnings|HEALthy Beginnings, an innovative, enhanced, trauma-informed, chronic disease self-care program and nurse-driven intervention, developed and tailored for middle-aged, and older, homeless women (MAO-HW).
224011606|NCT06896344|OTHER|In vitro culture|In vitro culture of bone marrow MNCs to obtain mesenchymal stromal cells
224011607|NCT06836856|DRUG|control|Patients will receive standard care with no interventions until end of treatment.
224011608|NCT06836856|DRUG|propranolol|starting at 20mg propranolol three times daily by mouth or per feeding tube. The dose was increased daily in 20mg three times daily increments (60mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 640mg/day in addition to standard care until end of treatment.
224011609|NCT06836856|DRUG|Carvedilol|starting at 6.25mg carvedilol three times daily by mouth or per feeding tube. The dose was increased daily in 6.25 mg three times daily increments (18.75 mg/day total) until heart rate (HR) was less than 100 beats per minute (bpm) with maximum dose of 100 mg/day in addition to standard care until end of treatment.
224127400|NCT02233205|DEVICE|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
224127401|NCT02233205|DRUG|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
224127402|NCT01575197|BIOLOGICAL|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
224127403|NCT01397305|DRUG|[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
224127404|NCT01397305|DRUG|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
224127405|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
224127406|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
224127407|NCT02820883|BIOLOGICAL|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
224127408|NCT04253834|DEVICE|Incentive spirometer|The incentive spirometer is a device that measures how deeply a person can inhale (breathe in). It helps with taking slow, deep breaths to expand and fill the lungs with air, which helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator to help users control their breathing.
224127409|NCT04253834|DEVICE|GO2 Mouthpiece|The GO2 Mouthpiece is a simple, comfortable, and straightforward silicone rubber-made, bidirectional oxygenation mouthpiece that effectively delivers PEEP with every breath.
224127410|NCT01630096|DRUG|Nu-Lytely|Bowl prep solution.
223390586|NCT02498002|OTHER|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
223546433|NCT05606848|OTHER|Foods for special medical purposes [FSMP] for patients with tumors|"All patients will be randomized to receive the FSMP or control product.~* Before the surgery: Patients daily intake FSMP with recommended energy.~* 1-8 days after surgery: Patients gradually increase FSMP intake to reach the recommended energy."
224011610|NCT06896617|DRUG|Estradiol + Progesterone|Pregnancies with absence of corpus luteum(PC-FET)
224011611|NCT06896617|DRUG|Ovitrelle ( Hcg 250 mcg)|NC-FET(natural cycle FET, endometrial preparation with presence of CL)
224127411|NCT00698061|BIOLOGICAL|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
224127412|NCT00698061|BIOLOGICAL|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
223390587|NCT02498002|OTHER|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
223390588|NCT02498002|OTHER|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
223390589|NCT01169350|RADIATION|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
223390590|NCT01169350|OTHER|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
223390591|NCT01169350|PROCEDURE|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
223390592|NCT01169350|PROCEDURE|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
223390593|NCT01169350|OTHER|laboratory biomarker analysis|Correlative studies
223390594|NCT04807920|DRUG|OnabotulinumtoxinA 100 UNT|Intravesical injection
223390595|NCT04807920|OTHER|Injectable saline|Intravesical injection
223546434|NCT06176781|DRUG|Edaravone Dexborneol Sequential Therapy|Sequential treatment started with intravenous injection of edaravone dextrocamphorol 37.5 mg, twice a day for 5-10 days. Then, Edaravone Dexborneol Sublingual Tablets 36.0 mg was taken sublingual twice a day for 14 days (the total course of the two drugs was 14 days, a total of 28 times).
223546435|NCT06176781|DRUG|Placebo|Injection Simulants(Edaravone Dexborneol concentrated solution for injections) administered intravenously for 5 - 10 days, and then followed by Sublingual Tablet Simulants(Edaravone Dexborneol Sublingual Tablets) BID administered sublingually for the last days, the total duration of treatment was 14 days
223546436|NCT01095081|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
223546437|NCT01453036|PROCEDURE|23S rRNA point mutation test of Helicobacter pylori|mutation test group\>\> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group \>\> no intervention
223546438|NCT01453036|PROCEDURE|UBT test & Gastroenterology with biopsy c silver stain|UBT test \& Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group \>\> intervention
223546439|NCT00559104|DRUG|carmustine|Unique to the Carmustine in Conditioning arm
224011612|NCT06900803|DEVICE|interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)|The dashboard serves as an interactive communication tool during education sessions, promoting real-time dialogue between patients and pharmacists. By collaboratively entering patient-specific data, patients gain insight into personalized visual representations of actionable risk factors. Initially, data specific to the patient are inputted to generate a baseline assessment, presenting hazard ratios that indicate the current condition and pinpoint areas needing improvement. To simulate potential changes, an alternative dataset is deliberately entered, portraying either improvement or deterioration in the patient's status, thereby acting as a motivational tool. Throughout the education session, the dashboard continuously updates hazard ratios, enabling direct comparisons of patient outcomes under varying conditions or treatment scenarios. This dynamic process clearly demonstrates individualized risk-benefit trade-offs in diverse treatment contexts.
223390596|NCT06445998|OTHER|task oriented training|Task-oriented training program: \[For study group\] Rocker board training Wobble board training Sit to stand Walk five steps forward Upstairs and downstairs three steps
223390597|NCT05830786|DEVICE|Immersive virtual reality (IVR)|Using Oculus Quest 2 (Reality Labs, Meta Platforms, United States) headsets the PrecisionOS platform version 3.0 (PrecisionOS Technology, Canada) virtual reality surgical modules will be utilized.
223390598|NCT05830786|OTHER|Traditional hands on orthopaedic workshop group|Hands-on orthopaedic workshop sessions (including arthroscopy simulators, cadaveric models, and Sawbones®) in differing orthopaedic subspecialties (including sports, arthroplasty, and spine surgery).
223390599|NCT00516659|BIOLOGICAL|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
224011613|NCT06816875|DEVICE|NozeBot Electric Nasal Aspirator|The NozeBot is a rechargeable, battery-operated baby nasal aspirator with a nosepiece that loops directly onto the caregivers fingers for ease of use, and is intended to be held so it sits just inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
224011614|NCT06816875|DEVICE|NoseFrida the SnotSucker|The NoseFrida is nose-to-mouth nasal suctioning device with a disposable hygienic filter. The nosepiece is a larger tube that is to be held so it sits against and not inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
224011615|NCT06816875|DEVICE|hydraSense Baby Nasal Care Nasal Aspirator Starter Kit|The hydraSense Baby Nasal Aspirator Starter Kit is a nose-to-mouth nasal suctioning device with a disposable hygienic filter. The kit contains pre-proportioned saline solution vials to liquify mucus prior to suctioning. The nosepiece is intended to be held so it sits inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
224011616|NCT06816875|DEVICE|Braun Nasal Aspirator|The Braun nasal aspirator is a battery-operated nasal suctioning device with a washable collection chamber for mucus. There are two nosepiece sizes to accommodate a best fit in the nose. It will be used according to its manufacturer's instructions for use in this study.
224011617|NCT06895720|OTHER|Myofascial Self-Release|Athletes will be asked to use the myofascial release roller for 2 minutes before training on each of the three muscle groups: anterior and posterior thigh and posterior leg. They will be instructed to roll while applying as much pressure as possible on the roller. For the anterior thigh, the roller will be moved along the entire front part of the thigh; for the posterior thigh, it will be rolled from just below the gluteal region to just above the knee; and for the posterior leg, it will be rolled from just below the knee to just above the heel.
224127413|NCT01527227|OTHER|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
223390600|NCT00516659|BIOLOGICAL|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
223546440|NCT00559104|DRUG|cyclophosphamide|Used in Both Arms
223546441|NCT00559104|DRUG|etoposide|Used in Both Arms
223546442|NCT00559104|PROCEDURE|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
223546443|NCT00559104|PROCEDURE|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
223546444|NCT00559104|RADIATION|total-body irradiation|Unique to the Radiation in Conditioning Arm
223546445|NCT00559104|DRUG|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
224011618|NCT06546020|DIETARY_SUPPLEMENT|Haskap berry smoothie|A smoothie blend of berries and water
224127414|NCT05220228|DRUG|Prucalopride|1mg prucalopride x 2d, 2mg prucalopride x 5-8d
224127415|NCT05220228|DRUG|Placebo|Lactose / sucrose placebo
224296431|NCT04451603|PROCEDURE|Surgery|Surgical resection of the liver
223390601|NCT03380065|DEVICE|Late deflation of TR band|"1. First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation."
223390602|NCT03380065|DEVICE|Early deflation of TR band|"1. First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~2. Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
223390603|NCT06211309|DRUG|co.mouthwas|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
223390604|NCT06211309|OTHER|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
223546446|NCT04879108|OTHER|Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation|"Physiotherapy rehabilitation and Transcutaneous Electrical Nerve Stimulation (TENS) group received TENS therapy in addition to physiotherapy rehabilitation after thoracic surgery.~Physiotherapy and rehabilitation program was started after surgery and it was performed for 30 min, twice a day, 5 day a week. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Transcutaneous Electrical Nerve Stimulation was performed with the a 2-channel portable TENS device and using disposable electrodes. TENS applied on both sides of the incision line. After surgery, TENS was performed before the Physiotherapy and Rehabilitation for 30 min, twice a day, 5 day a week.~Patients were evaluated before the surgery and the end of postoperative 5th day."
223546447|NCT04879108|OTHER|Physiotherapy Rehabilitation|"Physiotherapy and Rehabilitation was performed for 5 days after surgery, twice a day, for 30 min, 5 day a week after thoracic surgery. The program was included respiratory and posture exercises, coughing, enhancing mobility.~Patients were evaluated before the surgery and the end of postoperative 5th day."
223546448|NCT01957293|DRUG|Salbutamol|single oral administration, 4 mg
223546449|NCT01957293|DRUG|Placebo|single oral administration
223546450|NCT05544201|DEVICE|High-definition transcranial current stimulation|High-definition transcranial current stimulation (HD-tCS) is delivered by a battery driven direct current stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) through a central anodal electrode surrounded by four return cathodal electrodes.
223546451|NCT05294497|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
223546452|NCT05294497|OTHER|Product B|Flavor variant P1312914 of a nicotine pouch product with 4 mg of nicotine
223546453|NCT05294497|OTHER|Product C|Flavor variant P1312915 of a nicotine pouch product with 8 mg of nicotine
223546454|NCT05294497|OTHER|Product D|Flavor variant P1313014 of a nicotine pouch product with 4 mg of nicotine
223546455|NCT05294497|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
223546456|NCT05294497|OTHER|Product E|Flavor variant P1313015 of a nicotine pouch product with 8 mg of nicotine
223546457|NCT04740086|PROCEDURE|Calcium alginate hydrogel|"1. The external and internal fistulous orifice and fistulous tract were explored without applying any product, including hydrogen peroxide or povidone-iodine.~2. The seton was removed and FT cannulation was performed using a needle for cleaning with a gauze impregnated with saline.~3. Calcium chloride was applied through the EFO until it exits through the IFO, and then the IFO was obturated.~4. Alginate was applied, and the pressure at the IFO was stopped, until the alginate solution partial exits through the IFO.~5. The IFO was closed with a 3/0 braided resorbable suture.~6. The EFO was removed with an electric scalpel and closed with a 3/0 braided resorbable suture."
223546458|NCT04216849|BIOLOGICAL|human umbilical cord mesenchymal stem cells|human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
223546459|NCT04216849|OTHER|saline|Saline solution containing human serum albumin will be infused to the control group
223546460|NCT05044650|DIETARY_SUPPLEMENT|KOVIR capsule combined with background treatment|KOVIR is a hard capsule containing fine powder mixed medicinal herbs 600 mg
223546461|NCT00512850|DIETARY_SUPPLEMENT|Folic acid|Intervention group 1g folic acid per day
223390605|NCT06211309|OTHER|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
223390606|NCT06990711|DRUG|Siltuximab|Interleukin-6 blockade
223390607|NCT06990711|DRUG|Placebo|Siltuximab placebo IV
223390608|NCT04338022|DRUG|Teriflunomide|Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.
223546462|NCT00512850|OTHER|Placebo|One placebo pill per day
223546463|NCT02396108|DRUG|Paclitaxel + Carboplatin + ASLAN001|"Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
223546464|NCT00111449|DRUG|Etanercept|
223546465|NCT03355950|PROCEDURE|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
223546466|NCT03355950|PROCEDURE|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
223546467|NCT03766464|DIAGNOSTIC_TEST|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
224127416|NCT01087411|BEHAVIORAL|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
224127417|NCT01087411|BEHAVIORAL|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
224296432|NCT04451603|RADIATION|Radiation therapy|Y-90 radioembolization therapy is the main treatment
223390609|NCT04338022|DRUG|Evobrutinib|Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.
223390610|NCT06996795|BEHAVIORAL|music therapy|Music therapy will be applied with drums, maracas, cymbals and orf instruments. It will consist of body rhythms, breathing exercises and rhythm studies.
224011619|NCT06546020|DIETARY_SUPPLEMENT|Placebo comparator|A smoothie with no polyphenolic content and matched in carbohydrate composition to the experimental haskap smoothie
224011620|NCT03973931|BEHAVIORAL|Nudge|Interventions will include a variety of text messages aimed at improving medication adherence.
224011621|NCT06907316|DRUG|Cefixime 400mg|cefixime 400 mg taken orally two times a day for 14 consecutive days
223546468|NCT03766464|DIAGNOSTIC_TEST|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
224011622|NCT06907316|DRUG|Benzathine penicillin 2.4 million units|single dose of benzathine penicillin G 2.4 MIU intramuscularly
224011623|NCT06906003|OTHER|visual rehabilitation program|"I. meeting: coin recognition II. meeting: reading stories and audio books' listening III. meeting: installation of APPs on their smartphones and tablets and use of voice assistant IV. meeting: management of table activities V. meeting: meeting with caregivers."
224011624|NCT06907121|DRUG|Intra-Articular Injection of Growth Hormone and Platelet-Rich Plasma|Intervention will be an intra-articular injection of 10 units of HGH and 10 mL PRP conjunct. Three total injections/placements of HGH spaced 7 to 16 days apart on either the effected ankle or knee joint guided by ultrasound.
224011625|NCT06906484|DEVICE|echocardiography|analyse echocardiographic reports on cardiac abnomalies
224011626|NCT06906289|OTHER|resumption of enteral feeding within 24 hours of surgery|Patients will be subjected to resumption of enteral feeding within 24 hours of surgery
224011627|NCT06906289|OTHER|resumption of enteral feeding after 24-48 hours|Patients will be subjected to late resumption of enteral feeding after 24 to 48 hours of surgery
224011628|NCT06907589|DEVICE|Motor Data Analysis|The SensMode System includes wearable devices for upper and lower limb motion analysis. The upper limb device, SensHand, consists of 3 sensorized elements: 2 sensorized rings to be placed at the level of the distal phalanx of the thumb and forefinger of the hand and 1 sensorized wristband to be placed at the level of the distal portion of the forearm near the wrist. Each element of SensHand allows the acquisition of inertial data with respect to the biomechanics of the arm-forearm-wrist and the first three fingers of the hand, measuring the 3 components in space of linear acceleration, angular velocity, and magnetic field. The lower limb device, SensFoot, is a device that integrates the same electronic components as the bracelet and is placed in a plastic housing shaped like a small rectangular parallelepiped that is placed over the shoe.
224011629|NCT06907368|OTHER|Quantitative Gait Analysis|"The following explorations will be carried out pre-operatively (pre-OP), then post-operatively at 3 months (post-OP3) and 12 months (post-OP12) :~* Quantified gait analysis (QGA)~* Functional tests (mechanical analysis of everyday tasks):~  * SIT-TO-STAND test (test consisting of standing up and sitting down on a chair)~ * STEP INITIATION test (test consisting of walking up a step and then down)~* Proprioceptive tests :~  * Joint Position Sense (JPS) (angle memorization and reproduction test at the knee joint)~ * OBSTACLE CLEARANCE test (test consisting in simulating the clearance of an obstacle)~* Questionnaires :~  * Functional questionnaires :~ * KSS (Knee Society Score)~ * SKV (Simple knee value)~ * KOOS (Knee Injury and Osteoarthritis Outcome Score)~ * Quality of life (EQ5D-5L) The total duration of each exploration session is estimated at 1 hour ."
224127418|NCT01087411|DIETARY_SUPPLEMENT|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
224127419|NCT01087411|DIETARY_SUPPLEMENT|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
224127420|NCT03994263|DEVICE|ITind device implant|device implanted for 5-7 days
224127421|NCT00107068|PROCEDURE|[A] Aerobic isokinetic cycling exercise|
224127422|NCT00107068|PROCEDURE|[B] Progressive Resistance Training|
224127423|NCT00107068|PROCEDURE|[A] + [B]|
224296433|NCT04451603|DRUG|Drug treatment|Examples include tyrosine kinase inhibitors and immune checkpoint inhibitors
223390611|NCT06996795|BEHAVIORAL|sensory integration|Sensory integration will include sensory modulation activities, vestibular, proprioceptive, tactile, visual and auditory sensory studies.
223390612|NCT04278456|BEHAVIORAL|postpartum depression|melatonin levels in c-sections with different anesthesia modalities.
223390613|NCT02749617|DRUG|apixaban|2.5 mg PO BID
223390614|NCT02860546|DRUG|TAS-102|One Arm Only (of TAS 102 plus nivolumab)
223390615|NCT02860546|DRUG|nivolumab|One Arm Only (of TAS 102 plus nivolumab)
223390616|NCT01956474|OTHER|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
223546469|NCT03766464|DIAGNOSTIC_TEST|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
223546470|NCT01618058|DRUG|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
223546471|NCT04463563|OTHER|Physiological|Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.
223390617|NCT04267796|OTHER|Aerobic Exercise|Complete aerobic training
223390618|NCT04267796|OTHER|Dietary Intervention|Receive diet recommendations from health coach or registered dietitian
223390619|NCT04267796|OTHER|Quality-of-Life Assessment|Ancillary studies
223390620|NCT04267796|OTHER|Questionnaire Administration|Ancillary studies
223390621|NCT04267796|OTHER|Resistance Training|Complete high-resistance circuit training sessions
223390622|NCT06601764|OTHER|Circuit Training|"1. Warm-up, balance~2. Aerobic, balance~3. Muscle strength Upper Limbs~4. Muscle strength Lower Limbs~5. Stretching both Upper Limb and Lower Limb"
223390623|NCT06601764|OTHER|Progressive Resistance|"1. Muscle habituation exercises~2. Hypertrophic phase 1 exercises~3. Hypertrophic phase 2 exercises"
223390624|NCT06999460|PROCEDURE|Infraspinatus teres minor block group|Patients in this group will receive a unilateral ultrasound-guided Infraspinatus-teres minor (ITM) block with injection of local anesthetics (20 mL of bupivacaine 0.25% (50 mg), 50 mcg dexmedetomidine (0.5 ml) and 8 mg dexamethasone (2 ml)) before induction of general anesthesia
223546472|NCT01448889|DRUG|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
223546473|NCT01448889|DRUG|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
223546474|NCT06547697|OTHER|Dialysate sodium concentration|
223546475|NCT00862368|BEHAVIORAL|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
223546476|NCT00862368|BEHAVIORAL|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
223546477|NCT00862368|BEHAVIORAL|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
223546478|NCT01713647|DRUG|Amlodipin, losartan, HCTZ|
223546479|NCT01336712|PROCEDURE|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
223546480|NCT06368414|DRUG|Asciminib|that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
223546481|NCT02469701|DRUG|nivolumab and ablation|
224011630|NCT06906172|BEHAVIORAL|Plant-based intensive lifestyle intervention|The plant-based intensive lifestyle intervention has 2 phases. The first 12-weeks is a weight loss phase consisting of a plant-based, high-plant protein energy restricted total diet replacement (TDR), psyllium-based fibre and complete multivitamin supplements, and vegetable bouillon, with the option of continuing with this phase up to week 20. The second phase is weight-loss maintenance beginning with an 8-week (weeks 12-20) stepped food reintroduction phase with partial meal replacement, progressing towards the 32-week (weeks 20-52) full food introduction phase. These phases focus on introducing a plant-based, high-plant protein, energy balanced, weight loss maintenance diet, which will be supported by a digital program. At weeks 12-28, a 16-week in-person structured exercise training program will be delivered followed by 2-weekly motivational phone calls until the 52-weeks. A 19-session, group-based, structured behavioural support program will be delivered throughout the study.
224011631|NCT06906172|OTHER|Standard of Care|Participants will continue to receive usual diabetes and obesity management as per current Canadian clinical practice guidelines. The management will continue to be delivered to participants through their family doctor, nurse practitioner, or diabetes care team with standard frequency of contact. Participants will attend clinic visits on 5 occasions (weeks 0, 12, 28, 40 and 52) and will receive motivational phone calls between visits to provide reminders regarding follow-up with their diabetes care providers.
224011632|NCT06907069|DRUG|Intravenously atomized polycolistin E sodium mesylate|To explore the therapeutic effect of CMS combined with intravenous atomization in patients with carbapenem resistant gram-negative bacteria in lung infection.
223390625|NCT06999460|PROCEDURE|Control group|Patients in this group will receive general anesthesia
223390626|NCT07001735|BEHAVIORAL|Talking for Change Group Psychotherapy|Talking for Change (TFC) is a secondary prevention program that targets dynamic risk factors for child sexual abuse, including (1) atypical sexual interests and sexual self-regulation problems; (2) problems in relationships; (3) offense-supportive attitudes; and (4) general self-regulation deficits and related traits (e.g., impulsivity, emotion regulation deficits). Participants will complete 20 weekly, 120-minute sessions delivered via WebEx.
223546482|NCT03545308|DRUG|Rocuronium|Dose: 1 mg/kg
223546483|NCT05580263|BEHAVIORAL|aerobic exercise|The main AE program will be designed and controlled for at least moderate intensity of heart rate reserve (HRR) lasting 30 minutes. The goal of intensity will be set at least 40% of HRR during the first two weeks, and then progressively increase the targeted intensity at the end of 16 weeks with 60% HRR. The motions will design by involving core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).
224011633|NCT06906055|DEVICE|Multicath|Use of a multifunctional catheter for revascularization of blocked arteries below the knee
224011634|NCT06906055|DEVICE|Standard of Care (SOC)|Use of single function crossing catheters, diagnostic catheters, angioplasty balloon catheters
224011635|NCT06907810|OTHER|Blood sample + questionnaire|"* blood sample before tumor surgery and at every follow-up visit~* questionnaire before tumor surgery and at every follow-up visit"
223390627|NCT07001735|BEHAVIORAL|Healthier Me: Managing Risk and Stress in Everyday Life|The active therapeutic control is a non-directive supportive psychotherapy that targets general mental health concerns. It consists of psychoeducation about human sexuality and common mental health concerns, as well as instruction and practice in applied relaxation and stress management, and group discussions that will facilitate sharing and problem-solving current stressors. This active control intervention is equivalent in length to Talking for Change (TFC), consisting of 120-minute long occurring weekly over the course of 20 weeks.
223390628|NCT02466321|PROCEDURE|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
223390629|NCT07005765|BEHAVIORAL|Video-Based Stabilization Exercise Program|Participants will follow a 6-week home exercise program focusing on stabilization exercises. The instructions and demonstrations will be delivered through video format, which participants can watch at their convenience. The program aims to improve pain, functionality, exercise adherence, kinesiophobia, and quality of life.
223390630|NCT07005765|BEHAVIORAL|Brochure-Based Stabilization Exercise Program|Participants will follow the same 6-week home exercise program using illustrated printed brochures that provide step-by-step instructions for stabilization exercises. This format allows participants to perform exercises independently. The program's effects on pain, functionality, exercise adherence, kinesiophobia, and quality of life will be evaluated.
223390631|NCT07010562|DEVICE|Data collection|A supervised session that includes 10 minutes of patient information entry, 5 minutes of sensor recording time and 10 minutes of margin for setting up the system and patient, thus a total evaluation duration of approximately 25 minutes prior to the Right Heart Catheterization. No follow-up period for the subjects will be required for this clinical investigation. Patients will be followed as per standard of care, at the hospital. A single follow-up observational data collection will be conducted at 90 days, to collect the number of unplanned hospitalizations since the procedure visit. This does not involve active patient participation.
223390632|NCT07016958|BEHAVIORAL|Carbohydrate Counting Training|Advanced Carbohydrate Counting Training is a meal planning training where individuals can calculate the amount of carbohydrates in foods based on their portion sizes, and the insulin doses they need to take based on their plasma glucose levels and the amount of carbohydrates they consume.
223390633|NCT07016724|COMBINATION_PRODUCT|cadonilizumab combined with neoadjuvant radiochemotherapy|Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.
223390634|NCT07016724|COMBINATION_PRODUCT|neoadjuvant radiochemotherapy|Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.
223546484|NCT05580263|BEHAVIORAL|resistance exercise|"In the process, the participants will be instructed by resisting the weight smoothly, and peaking at hold. RE prescription consist of 2-4 sets with 10-15 repetitions per set with a rest interval of 1-2 minutes between sets to improve muscular fitness.~The first two weeks will start with two sets of 10-15 repetitions and then gradually progress on four sets of 15 repetitions at the end of 16 weeks. The total duration of RE will lasting around 15 minutes."
223546485|NCT04300504|OTHER|observational study|observational study
223546486|NCT03520296|OTHER|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
223546487|NCT00620373|DEVICE|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
223546488|NCT00620373|DEVICE|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
224011636|NCT06906224|DRUG|Control group (clozapine, placebo)|Patients received oral clozapine (Jiangsu Pharmaceutical Co., Ltd., Approval No. H32022963) in combination with a placebo. Each dose of the placebo was 1 mg, taken three times a day.
224011637|NCT06906224|DRUG|Low-dose group (buspirone tablets, clozapine)|Patients received oral buspirone tablets (Jiangsu Enhua Pharmaceutical Co., Ltd., Approval No. H19991024) in combination with clozapine. The total daily dose of buspirone was 15 mg, divided into three administrations. The dose remained unchanged throughout the entire study period.
224011638|NCT06906224|DRUG|High-dose group (buspirone tablets, clozapine)|Patients received oral buspirone tablets in combination with clozapine. The initial total daily dose of buspirone was 15 mg, divided into three administrations. One week later, the dose was increased to a total daily dose of 30 mg, also divided into three administrations.
223546489|NCT00620373|DRUG|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
224011639|NCT06907641|DRUG|64Cu-SAR-bisPSMA|All participants will receive a single administration of 200 MBq of 64Cu-SAR-bisPSMA
224011640|NCT06906211|DEVICE|low intensity focused ultrasound (LIFU)|Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.
224011641|NCT06907251|DRUG|Dapagliflozin (DAPA)|Dapagliflozin 10mg orally once a day for 12 months
224011642|NCT06907251|DRUG|Placebo|Participants will receive a matching placebo taken once daily by mouth for 12 months.
224127424|NCT00856479|DEVICE|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
224127425|NCT00856479|PROCEDURE|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
224127426|NCT01702662|DEVICE|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
223390635|NCT07017855|RADIATION|Stereotactic Arrhythmia Radioablation (STAR)|"Radiotherapy Implementation: During treatment on a TrueBeam™ linear accelerator (Varian Medical Systems, Palo Alto, CA, USA), a planned radiation dose of 25 Gy will be delivered to the defined planning target volume (PTV) using highly conformal stereotactic techniques. Image-guided radiotherapy (IGRT), respiratory gating, and Triggered Tracking will be utilized, targeting the previously delineated defibrillation lead of the implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), with position verification every 15 degrees of gantry rotation.~Patient positioning will be performed using kV-kV imaging, based on pre-determined fiducial markers on the ICD/CRT-D defibrillation lead, followed by verification using gated cone-beam computed tomography (CBCT). Continuous ECG monitoring will be conducted throughout the treatment, and the patient will remain under cardiologist supervision."
223546490|NCT03109743|BEHAVIORAL|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
223546491|NCT03109743|BEHAVIORAL|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
223546492|NCT04120246|DRUG|Alpha-tocopheryloxyacetic Acid|Given PO
223546493|NCT04120246|BIOLOGICAL|Trastuzumab|Given IV
223546494|NCT02869126|PROCEDURE|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"* During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~* Stress conventional acquisition with D.SPECT camera 20 min after injection~* 60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~* double isotope acquisition 5 min after thallium-201 injection~* injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~* rest conventional acquisition 20 min later"
223546495|NCT02869126|DRUG|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
223546496|NCT02869126|DRUG|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
223546497|NCT01144169|DRUG|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
223546498|NCT00475592|DEVICE|Esophageal Capsule Endoscopy|
223546499|NCT00475592|DEVICE|Upper Gastrointestinal Endoscopy|
224011643|NCT05762055|DEVICE|Titan nanoLOCK interbody cage|Medtronic Titan Endoskeleton TCS zero-profile, stand-alone interbody cages with nanoLOCK osseointegrative technology
224011644|NCT05762055|DEVICE|ACDF interbody cage|Anterior cervical discectomy and fusion (ACDF) is an alternative interbody cage system that does not employ nanoLOCK ossteointegrative technology
224011645|NCT06906354|PROCEDURE|Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection|Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
224011646|NCT06621576|DRUG|HM2002 injection|Eligible subjects under general anesthesia will undergo CABG surgery. After completing the distal anastomosis, 5mg of HM2002 injection solution drawn into a 1 ml syringe will be administered via multi-point injection using an OT needle or insulin needle (preferably a 30G needle). The injections will be spaced approximately 1 cm apart, with no more than 30 injection points, into the myocardium at the edge of the MI area (with obvious infarcts) or the area of the diseased coronary artery branches (without obvious infarcts) through the epicardium.
223546500|NCT03051464|PROCEDURE|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
223546501|NCT03051464|RADIATION|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
223546502|NCT03051464|RADIATION|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
223546503|NCT02225704|DRUG|Radium-223 and enzalutamide|
223546504|NCT04930861|DRUG|Covidir injections|administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
223546505|NCT04930861|DIAGNOSTIC_TEST|One Step Test|rapid test for the diagnosis of COVID-19 based on the detection of anti-SARS-CoV-2 in the blood.
223546506|NCT04930861|DIAGNOSTIC_TEST|IgM and IgG dosage|blood collection for dosage of Anti SARS-CoV-2 antibodies.
223546507|NCT04930861|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
223546508|NCT04930861|DIAGNOSTIC_TEST|Screening blood test|complete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; fibrinogen, Pregnancy test for non-sterile women.
224011647|NCT06296641|BEHAVIORAL|Needs navigation intervention|The investigator anticipates that this will include a baseline financial, education and vocational assessment, likely using a virtual platform. Participants who screen positive will be connected to community resources and for consultation. There will be a 1-month, 3-month and 6-month check-in to address any financial concerns through additional counseling/navigation.
224011648|NCT01185275|DEVICE|Alair system|Bronchial thermoplasty
224011649|NCT06906913|DIAGNOSTIC_TEST|HPV testing|Oropharyngeal and anal swab samples are evaluated in the Microbiology laboratory for the existence of HPV.
223390636|NCT07017855|PROCEDURE|Catheter Ablation|CA will be conducted in an electrophysiology laboratory and will routinely follow diagnostic procedures, including an electrophysiological study (EPS) and three-dimensional electroanatomical mapping (3D-EAM). Once sufficient data on the nature and location of the arrhythmic substrate have been obtained from the three primary mapping modules-voltage, activation, and propagation-spatial 3D-EAM maps will be integrated with a 3D left ventricular reconstruction from multislice computed tomography (MSCT) or cardiac magnetic resonance (CMR). Subsequently, ablation will be performed by delivering energy to predefined target sites identified as the arrhythmia source to close the sVT isthmus or eliminate late potentials (LPs) and/or low-amplitude ventricular activities (LAVAs). Following CA, a repeat induction attempt of sVT using programmed ventricular pacing (VP) will be conducted to verify procedural efficacy.
223390637|NCT07017296|OTHER|Placebo|150 mL of water during the breakfast
224011650|NCT03819608|DEVICE|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
224011651|NCT03819608|BEHAVIORAL|real APT|APT-III is an attention processing training program
224011652|NCT03819608|BEHAVIORAL|placebo APT|computerized cognitive training
224011653|NCT03819608|DEVICE|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
224011654|NCT05521438|DRUG|QRX003-2% Lotion|QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)
224011655|NCT05521438|DRUG|QRX003-4% Lotion QAM|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
224011656|NCT05521438|DRUG|Vehicle|Vehicle Lotion
224011657|NCT05521438|DRUG|QRX003-4% Lotion BID|QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)
224011658|NCT00550303|DRUG|bazedoxifene/conjugated estrogens combination|
224011659|NCT00925353|DRUG|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
224011660|NCT00006353|DRUG|temozolomide|
224011661|NCT00006353|RADIATION|radiation therapy|
224011662|NCT02275832|DRUG|3 % Minoxidil lotion|
224011663|NCT02275832|DRUG|Placebo|
223390638|NCT07017296|DRUG|Positive control|Normal antihypertensive in 150 ml of water during the breakfast
223390639|NCT07017296|DIETARY_SUPPLEMENT|Active comparator|20 g microencapsulated pomegranate juice in 150 mL water
223390640|NCT07017296|DIETARY_SUPPLEMENT|Control|150 mL fresh pomegranate juice
223546509|NCT04930861|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram with report.
223546510|NCT04930861|DIAGNOSTIC_TEST|Medical evaluation|evaluation by the principal investigator or assistant physician with a complete physical examination.
223546511|NCT04930861|DIAGNOSTIC_TEST|NEWS-2 score|assessment of the participant by the NEWS-2 score.
224011664|NCT00538915|BIOLOGICAL|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% \[Immune Globulin Intravenous (Human), 10%\] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
224011665|NCT00840151|BEHAVIORAL|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
224011666|NCT01181388|PROCEDURE|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
224011667|NCT01181388|PROCEDURE|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
224011668|NCT06799481|OTHER|Aerobic Exercise|Participate in personalized, progressive aerobic training
224011669|NCT06799481|BEHAVIORAL|Behavioral Intervention|Receive active lifestyle behavior coaching
224011670|NCT06799481|PROCEDURE|Follow-Up|Receive calls from the trainer
224011671|NCT06799481|OTHER|Internet-Based Intervention|Receive access to Physitrack
224011672|NCT06799481|OTHER|Medical Device Usage and Evaluation|Wear a Fitbit monitor
224011673|NCT06799481|OTHER|Questionnaire Administration|Ancillary studies
224011674|NCT06799481|OTHER|Resistance Training|Participating in strength training exercises
224011675|NCT02978378|OTHER|biomarker levels|The level of the biomarker hyaluronic acid will be measured
224011676|NCT02485782|DEVICE|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
224011677|NCT02485782|DEVICE|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
224011678|NCT02485782|DEVICE|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
224011679|NCT03111251|BEHAVIORAL|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
224011680|NCT03111251|BEHAVIORAL|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
223546512|NCT04930861|DIAGNOSTIC_TEST|WHO score|assessment of the participant by the score of the World Health Organization.
224011681|NCT03111251|BEHAVIORAL|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
224011682|NCT03111251|BEHAVIORAL|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
224011683|NCT03111251|BEHAVIORAL|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
223390641|NCT07017114|DRUG|Gel PKB171|"Subjects received a single dose of pentoxifylline PKB171 gel or placebo, in a one-dose form with an applicator device that allowed for vaginal administration following the randomisation list:~* First dose level: 2% (100 mg)~* Second dose level: 3% (150 mg)~* Third dose level: 4% (200 mg) The treatment was provided by a member of the investigator's staff and self-administered by volunteers under clinical supervision.~The dose-escalation process enabled to determine MTD or the highest dose that was safe to administer in later studies was determined. The results of this study helped to define the recommended doses to be used in the multiple-dose extension."
223390642|NCT07017114|DRUG|Gel PKB171 placebo|PKB vaginal gel at the MTD or placebo once every 24 hours for two consecutive days
223546513|NCT04069949|DRUG|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
223546514|NCT06374927|DEVICE|Rehabilitation Gaming System (VR-based mobile application)|The study intervention includes using the mobile phone technology RGSapp. This application integrates sensor data for delivering patient-tailored VR and AR-based training via gamified exercises for cognitive training.
223546515|NCT04514627|DEVICE|Auricular percutaneous neurostimulation|The BRIDGE/PENFS device manufactured by Key Electronics, consists of a battery activated generator and wire harness that connects to the generator. Four leads are also attached to the generator, each with a sterile 2 mm, titanium needle. The BRIDGE device settings are standardized and deliver 3.2 volts with alternating frequencies (1 ms pulses of 1 Hz and 10 Hz) every 2 s. This stimulation targets central pain pathways through branches of cranial nerves V, VII, IX, and X, which innervate the external ear. The PENFS device generator has a battery life of 5 days and delivers almost continuous stimulations throughout the 120 hours.
223546516|NCT00000870|DRUG|Indinavir sulfate|
223546517|NCT00000870|DRUG|Lamivudine|
223546518|NCT00000870|DRUG|Stavudine|
223546519|NCT00000870|DRUG|Zidovudine|
223546520|NCT00000870|DRUG|Didanosine|
223546521|NCT00000870|DRUG|Aldesleukin|
223546522|NCT05434793|DEVICE|RJ-LASER, LASERPEN®; Reimers & Janssen, Germany|The device was frequently used in laser acupuncture on the superficial skin of the acupuncture point Tsu San Li (St-36).
224011684|NCT01968993|DEVICE|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
223390643|NCT07017205|DEVICE|Application of oropharyngeal dye and tracheal aspirate collection|After intubation, 2 mL of blue dye will be applied to the oropharyngeal mucosa. Once hemodynamically stable (MAP \>65 mmHg), the first tracheal aspirate will be collected within 10 minutes by a blinded investigator for analysis.
223390644|NCT07018479|DIETARY_SUPPLEMENT|FemmeBalance Supplement Group|Participants will take two capsules daily of the FemmeBalance supplement with their evening meal for four menstrual cycles
223390645|NCT07018505|DIAGNOSTIC_TEST|SERS detection|"Incubation: A mixture of 20 μL (0.5 mg/mL) magnetic beads (MB@RB20115UD), 40 μL SERS nanotags (Au-IR808@RB20115UC), and prepared sample is incubated for 5 min.~Washing: The supernatant is removed after magnetic separation (30 s), followed by washing with PBST (pH 7.4, 0.05% Tween-20).~Detection: The separated pellet is resuspended in 10 μL ultrapure water. Then 2 μL solution is spotted onto a 2.5 mm × 2.5 mm gold substrate for air-drying. Raman spectra are acquired using a portable spectrometer (785 nm laser, 500 mW power, 5 s acquisition time, triplicate measurements). Peak areas within 540-570 cm-1 are quantified."
223390646|NCT07017543|OTHER|Psychotherapy Process-Outcome Study in Group Therapy|A manualized group dynamic psychotherapy conducted at the University Hospital in Kraków, focused on monitoring and enhancing therapeutic alliance and insight development. The intervention targeted patients diagnosed with neurotic and personality disorders. Psychological assessments were conducted at weeks 1, 4, 8, and 12 to track changes in symptoms, resilience, alliance, and insight. The psychotherapy emphasized the interplay between trait-like and state-like components of alliance and insight and their relationship to therapeutic outcomes (symptom reduction and resilience enhancement).
223546523|NCT02704624|DIETARY_SUPPLEMENT|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
223546524|NCT02704624|OTHER|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
224011685|NCT00601770|BIOLOGICAL|IC41|injection
224011686|NCT01354184|DRUG|CRD007|
223546525|NCT05850819|DRUG|Colloidal silver gelatin sponge|Augment the extraction socket with Gelatamp
223546526|NCT05850819|DRUG|Sterile gauze pack|Extraction socket allowed to heal without augmentation with any material
223546527|NCT01948219|DEVICE|ENTegral Artificial Larynx implant|
223546528|NCT04931914|OTHER|Clinical pharmacy sharing in the patient care regimen|antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.
224011687|NCT01354184|DRUG|CRD007 matching placebo|
224011688|NCT00169078|DRUG|Chloroquine|
223564134|NCT03150745|PROCEDURE|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
224011689|NCT03507777|DEVICE|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
224011690|NCT03507777|DEVICE|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
224296434|NCT01068379|PROCEDURE|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
224011691|NCT04719975|OTHER|Mental Fatigue (Stroop task)|"A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself."
224011692|NCT04719975|OTHER|Control (Documentary)|In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team. During the control task physiological and psychological measures will be assessed at the same time points as during the mental fatigue trial.
224011693|NCT00542243|DRUG|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
224011694|NCT00542243|DRUG|Placebo|Placebo will be given once a day for 6 months.
224011695|NCT03009552|PROCEDURE|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
223390647|NCT07016854|PROCEDURE|Endovascular treatment|Endovascular treatment could be performed with any recanalization strategy, such as thrombectomy with aspiration or stent and angioplasty with balloon dilation or stent implantation, depending on the operator's choice and anatomical and radiological circumstances. In the setting of emergency stenting, the use of antiplatelet agents will depend on operator preference, anatomy, and bleeding risk.
223390648|NCT07016854|DRUG|The best medical treatment|Medical treatment includes intravenous thrombolysis, anticoagulant or antiplatelet drugs, etc. which is determined by the attending physician according to the Chinese guidelines or expert consensus.
223390649|NCT07016945|BEHAVIORAL|Stress and Mindfulness Intervention|Participants will be randomized to either the race-related stress condition or the non-race-related stress condition and the experimental group (7-minute pre-recorded audio file of a guided mindfulness practice) or the control group (7-minute pre-recorded neutral audio file). Thus there are four conditions total (RRS/Control Audio, RRS/Mindfulness Audio, Control Stress/Control Audio, Control Stress/Mindfulness Audio)
223390650|NCT07017088|DIETARY_SUPPLEMENT|Leuconostoc mesenteroides|Control vs Experiment
223390651|NCT07017309|BEHAVIORAL|Telerehabilitation Protocol for Diastasis Recti|12-week telerehabilitation program combining synchronous (live, supervised by physiotherapists) and asynchronous (video -recorded) therapeutic exercise sessions focused on progressive inner core exercises (i.e. transversus abdominis, pelvic floor muscle retraining), outer core strengthening, and functional retraining.
223390652|NCT05743257|BEHAVIORAL|Questionnaire|Each participant completes a questionnaire (online or paper version) about socio-demographic characteristics, health outcomes (general health, respiratory health, and weight status), physical activity and sedentary behaviors, perception of neighborhood characteristics, air quality, and noise exposure.
223390653|NCT05743257|BEHAVIORAL|Food diary supply|Sample of participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops. For each food purchase, participants provided details of date, place of purchase and foods purchased (name, quantity and expense incurred). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary.
223390654|NCT05743257|BEHAVIORAL|Interviews (semi-structured)|Sample of participants was interviewed about their food provisioning practice and living conditions.
223390655|NCT05743257|BEHAVIORAL|air and noise|Sample of participant were instructed to wear air and noise sensors to record their daily environmental exposure for 7 consecutive days, except for sleeping, bathing and performing activities in the water. Particulate matter concentrations, the temperature, and the relative humidity were measured - the nitrogen dioxide (NO2) and ozone (O3) concentrations were determined with data loggers that integrate reliable electrochemical gas sensors. Noise levels was measured using noise dosimeters. Sensors were accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
223390656|NCT07017257|DEVICE|Active taVNS|Patients will receive active taVNS for 15 consecutive days, with each session lasting 30 minutes. The stimulation will target the cymba conchae of the left ear and will consist of alternating 30-second on and 30-second off periods. The current intensity will range from 1 to 3 mA, adjusted to the patient's pain threshold, with a pulse width of 250 μsec and a frequency of 25Hz.
223390657|NCT07017257|DEVICE|Sham taVNS|Patients will receive sham taVNS for 15 consecutive days, with each session lasting 30 minutes. The stimulation will target the cymba conchae of the left ear and will consist of alternating 30-second on and 30-second off periods. The current intensity will be fixed at 100 µA, with a pulse width of 250 μsec and a frequency of 25 Hz.
223390658|NCT07017530|OTHER|Cognitive training|Combined Intervention of Cognitive Training and Supervised Physical Exercise
223390659|NCT07017530|OTHER|Psychoeducational therapy|According to standard clinical practice
223546529|NCT02882061|PROCEDURE|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
224296435|NCT01068379|PROCEDURE|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
223390660|NCT07017140|DEVICE|Immersive Functional Virtual Reality Intervention using a Head-Mounted Display System for Spatial Neglect Rehabilitation|Participants receive 12 sessions (30 minutes each, 3 per week over 4 weeks) of immersive functional virtual reality (IFVR) using the KINESIX system, a CE-certified Class I head-mounted display device. The intervention targets visuospatial attention and upper limb function through progressively challenging, gamified exercises. All sessions are supervised by a physiotherapist or occupational therapist and delivered in a safe, controlled rehabilitation setting. Participants continue receiving usual care.
223390661|NCT07018011|PROCEDURE|Conventional open CTR|Conventional open CTR involved making a longitudinal incision in the wrist, typically along the median palmar crease, to access and release the transverse carpal ligament.
223390662|NCT07018011|PROCEDURE|Transverse mini-incision technique|Mini-incision CTR involved a smaller incision than traditional CTR procedures, aiming to minimize scarring and improve recovery time.
223546530|NCT03281031|PROCEDURE|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
223546531|NCT00331994|DRUG|Bacillus clausii|3 bacillus clausii vials/day for one month
223546532|NCT00331994|DRUG|Metronidazole|3 Metronidazole tablets/day for one week
223546533|NCT00601692|DRUG|cisplatin|Given IV
223546534|NCT00601692|DRUG|docetaxel|Given IV
223546535|NCT00601692|DRUG|irinotecan hydrochloride|Given IV
224011696|NCT05954507|DIAGNOSTIC_TEST|PET/MRI|PET/MRI is a new-generation hybrid camera capable of simultaneously performing FDG positron emission tomography and gadolinium-injected MRI. PET/MRI could be a relevant prognostic marker of progression, and could significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis.
224011697|NCT04321668|DEVICE|Synvisc-One|SYNVISC-ONE® (Hylan G-F 20), 10 mL single-injection viscosupplement Status : CE marked (CE 0086) class III Medical Device The IP is used according to its usual dosage, administration and indication
223390663|NCT07017452|DRUG|Methoxyflurane - Penthrox|Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
223390664|NCT07017452|OTHER|Control|This intervention will be the control group only, receiving deep IV sedation.
224011698|NCT06610721|DIAGNOSTIC_TEST|Urine Biomarkers|At baseline midstream urine will be collected in a sterile urine container.
224011699|NCT06245993|OTHER|EOS imaging|EOS imaging 3 years after skin traction treatment for femoral shaft fracture.
224296436|NCT04945772|BIOLOGICAL|Gene Therapy Product-MCO-010|The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
223390665|NCT07017452|DRUG|Percocet Pill|Percocet will be given in conjunction with methoxyfluorane and lorazepam
223390666|NCT07017452|DRUG|Lorazepam (drug)|Lorazepam will be given in conjunction with penthrox and percocet.
223390667|NCT07018128|OTHER|Study 2: deep breathing|Participants in the deep breathing group will be randomized to receive a diaphragmatic deep breathing program. They will be instructed to practice deep breathing at a rate of 6-10 breaths per minute for 15 minutes, twice daily, every day for a duration of 3 months.
223546536|NCT00601692|RADIATION|radiation therapy|Given 5 days a week for 3 weeks
223546537|NCT05770297|DIETARY_SUPPLEMENT|Propolis|intervention will use propolis extract (liquid-based) with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given to intervention group
223546538|NCT05770297|OTHER|placebo|intervention will use placebo with 1 drop/10kgBW/times, 2 times in a day for 12 weeks. propolis will be given control group
223546539|NCT04081662|BEHAVIORAL|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
223546540|NCT03870464|DIAGNOSTIC_TEST|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
223546541|NCT03870464|DIAGNOSTIC_TEST|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
223546542|NCT03870464|OTHER|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
223546543|NCT03870464|BEHAVIORAL|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
223546544|NCT02295631|DEVICE|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
224011700|NCT04925687|BIOLOGICAL|Intravitreal autologous CD34+ cells|Autologous CD34+ cells harvested from bone marrow injected intravitreal
224127427|NCT01895816|DIETARY_SUPPLEMENT|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus \& ZINGIBER OFFICINALE \& Onion \& Ocimum basilicum \& Cinnamomum zelanicum \& Citrullus lanatus \& Citrullus vulgaris \& Daucus carota
224127428|NCT05598294|PROCEDURE|Mobilization recommendations|Standard mobilization recommendations will be given to all patients, and feedback will be given to the intervention group to increase the number of steps 4 times a day according to the daily targeted number of steps.
224127429|NCT05142514|BIOLOGICAL|COVID-19 Vaccine HIPRA|Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
224127430|NCT05142514|BIOLOGICAL|Cominarty (Pfizer-BioNtech)|Subjects will receive 2 injections of Cominarty administered 21 days apart
224296437|NCT04945772|PROCEDURE|Sham Injection|Sham Injection
223546545|NCT02295631|DEVICE|ETView VivaSight SL|ETI with ETView VivaSight SL
223546546|NCT06407453|OTHER|control|There will be no interference ergonomics training
223546547|NCT06407453|OTHER|exercise|upper extremity strengthening exercises upper extremity stretching exercises ergonomics training posture training relaxation exercises
224127431|NCT04606654|OTHER|Handgrip strength training without Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contract his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training.
223390668|NCT07018128|OTHER|Study 2: 4-7-8 breathing|Participants in the 4-7-8 breathing group will be randomized to receive a 4-7-8 breathing program. They will follow the 4-7-8 breathing training program, which involves inhaling for 4 seconds, holding the breath for 7 seconds, and exhaling for 8 seconds, counted as one cycle. This pattern is to be repeated for 6 cycles to complete one set. They will perform 12 sets per day-6 sets in the morning and 6 sets in the evening-with normal breathing between each set. This routine will be carried out daily for a duration of 3 months.
223390669|NCT07018128|OTHER|Study 2: slow breathing with device|Participants in the slow breathing with device group will be randomized to receive a slow breathing with device. They will undergo deep breathing training using a resistance-based breathing device called BreathMax, set at 25% of their maximal inspiratory pressure. The breathing rate will be 6 breaths per minute, continuously for 15 minutes, twice a day. This routine will be performed daily for a duration of 3 months.
223390670|NCT07017218|DIETARY_SUPPLEMENT|IMPACT|immune enhanced formula enriched in arginine, n-3 PUFA and nucleotide
223390671|NCT07017894|COMBINATION_PRODUCT|Experimental: breast mask containing cabbage leaves extract group|apply breast mask to the breasts, avoiding the nipples, for 20 minutes, 2 times a day, for 3 days
223390672|NCT07017894|COMBINATION_PRODUCT|Sham Comparator|Apply a breast mask without cabbage leaves extract to the breasts, avoiding the nipples, for 20 minutes, 2 times a day, for 3 days.
223390673|NCT07018206|DRUG|Upadacitinib 15 MG [Rinvoq]|15mg tablet once per day
223390674|NCT07018648|DEVICE|Medical device|Adding Kardi Ai medical device for detection of heart rythm disorders
223390675|NCT07017868|DIAGNOSTIC_TEST|interleukin- 17|focused on the importance of IL-17 in SLE, and its relation to different disease activity
223390676|NCT07018596|DEVICE|CellFX nsPFA Endocardial Ablation Catheter System|The CellFX nsPFA Endocardial Ablation Catheter System includes the nsPFA 360 Endocardial Ablation Catheter, CellFX Console, switcher box/adapter, and sensing cable. The System is a proprietary endocardial catheter system designed for use in cardiac electrophysiology procedures to treat arrhythmias, including atrial fibrillation. The nano-PFA 360 Catheter ablates cardiac tissue using nonthermal nanosecond pulses of electrical energy. nsPFA is a cell-specific, nonthermal ablation technology that delivers nanosecond-duration pulses of high-amplitude electrical energy to tissue via bipolar electrodes. The pulses disrupt the cell's and internal organelles' ability to maintain cellular homeostasis by creating nanopores in lipid membranes, ultimately leading to regulated cell death (RCD).
223390677|NCT04152967|DEVICE|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
223390678|NCT04152967|DEVICE|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
223390679|NCT06071754|DEVICE|Masimo INVSENSOR00057|Masimo INVSENSOR00057 will be used to collect electrocardiogram measurements.
223390680|NCT07018271|DRUG|sulpegfilgrastim|On Day 1 of each oncological treatment cycle, after administration of the CD38 monoclonal antibody, a subcutaneous injection of Sulfubrolipoyl G-CSF will be given. The recommended fixed dose of Sulfubrolipoyl G-CSF is 6 mg per injection.
223390681|NCT04648267|OTHER|Cast and bolster placement duration|The intervention is increasing the duration of cast and bolster placement on split thickness skin graft sites.
223390682|NCT04648267|OTHER|Standard of care|This will be standard of care - the patient will have his cast and bolster on for 5-7 days
223390683|NCT04861623|OTHER|Orange juice|Orange juice will be purchased commercially.
223390684|NCT04861623|OTHER|Placebo juice (SunnyD)|SunnyD beverage will be purchased commercially.
223390685|NCT06153199|BEHAVIORAL|Self-management videos|Short video modules on self-management of back pain without medication and ergonomic adjustments for limiting back pain in nursery and landscape work
223390686|NCT06153199|BEHAVIORAL|Check lists for ergonomic options|Guidance on ergonomic choices appropriate for work tasks not currently being used that are the most difficult due to back pain, using a checklist
223390687|NCT06153199|BEHAVIORAL|Text reminders|Reminders to implement choices using graphics and gifs as well as motivational messages
223390688|NCT06153199|BEHAVIORAL|Video review|Participants will review videos of their movement during their most difficult work tasks to help problem solving to adjust ergonomic adjustments
223546548|NCT03073525|BIOLOGICAL|Vigil|The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
223546549|NCT03073525|DRUG|Atezolizumab|"Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters."
223546550|NCT03470350|DRUG|Galunisertib|treatment with capecitabine and galunisertib
223546551|NCT03569124|OTHER|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
223546552|NCT04140617|BEHAVIORAL|Exposure to aerosol of electronic cigarette|Exposure to aerosol of electronic cigarette (30 min)
223390689|NCT06265389|DRUG|Pentoxifylline Oral Tablet|50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
224011701|NCT05070442|BEHAVIORAL|Norm-based messaging and peer comparison features|"Participants are shown a version of NUSMart which includes Nutri-Score labels that are enabled and displayed besides all the products in the store. Additionally, they are shown a video that gives them background information about Nutri-Score labels and describes the following features enabled in this intervention:~* Norm-based messaging will be displayed in the form of a happy or sad emoticon based on whether the participant's current basket average Nutri-Score (weighted by number of servings) is above or below other shoppers (Nutri-Score=3.98).~* Peer comparison will be implemented as a vertical ruler display of the participant's current basket average Nutri-Score (weighted by number of servings) as well as that of their peers.~Nutri-Score=3.98 was chosen as it is 10% better than the mean Nutri-Score of baskets purchased by participants in the Nutri-Score labelled intervention arm of a prior study."
224011702|NCT05070442|BEHAVIORAL|Financial Incentives leveraging on loss aversion|"Participants are informed that they have received an additional $5 towards their participant reimbursement. However, this amount will be forfeited if they check-out with a basket average Nutri-Score (weighted by the number of servings) that falls below the average Nutri-Score of other shoppers i.e. 3.98. An indicator on the screen that informs the participants of this potential forfeiting will be included."
224011703|NCT01879722|DRUG|TAK-063|TAK-063 tablets
224011704|NCT01879722|DRUG|TAK-063 Placebo|TAK-063 placebo-matching tablets
224011705|NCT02099045|DEVICE|Point of Care Ultrasonography|
223390690|NCT05963581|BEHAVIORAL|Salsa Dancing|Participants will complete salsa dancing classes in central Oxford with instructor(s) from the Oxford University Salsa Society
223390691|NCT06103578|DIAGNOSTIC_TEST|GCF and saliva analysis|ELISA
223390692|NCT01171729|BIOLOGICAL|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
223390693|NCT00702988|DRUG|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
223390694|NCT00702988|DRUG|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
223390695|NCT06274866|OTHER|exercise program|Study group were followed up with a personalized home-based exercise program for 6 weeks. IThe exercise program of the individuals in the study group was checked at two-week intervals and adjustments were made in the exercise program
223390696|NCT06274866|OTHER|control group|Individuals in the control group were followed up with an exercise training brochure.
223390697|NCT07030231|RADIATION|Intraoperative|Intraoperative radiotherapy with any device after conservative surgery in early breast cancer
223390698|NCT07030907|BIOLOGICAL|OPB-101|An autologous mesothelin (MSLN) CAR T cell therapy with antigen-dependent expression of OUTSMART designed IL-2 cytokine
223390699|NCT00295425|DRUG|Cyclosporine A versus mycophenolate mofetil for psoriasis|
223390700|NCT06208137|BEHAVIORAL|Health monitoring and regular return follow-up reminders|Health monitoring \& reminders for blood tests and follow-up visits until 1 year post-transplant
223390701|NCT06882980|OTHER|Ciprofol group|In the Ciprofol group,children were given Ciprofol 0.6-0.8 mg/kg during anesthesia induction,and ciprofol 1.2-2 mg·kg-¹·h-¹for anesthesia maintenance.Throughout the entire process, we continuously monitor vital signs and IoC1/IoC2.
223390702|NCT06882980|OTHER|Propofol group|In the Propofol group,children were given Propofol 2.5-3.5 mg/kg during anesthesia induction,and propofol 6-10 mg·kg-¹·h-¹for anesthesia maintenance.Throughout the entire process, we continuously monitor vital signs and IoC1/IoC2.
223390703|NCT02966977|OTHER|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
224011706|NCT03012698|DEVICE|Ocular Repetitive Magnetic Stimulation (RMS) treatment|"First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."
223390704|NCT02966977|OTHER|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
223390705|NCT05137392|OTHER|oral hygiene instruction|The treatment process is identical for both test and control groups except for the methods of oral hygiene instructions. In the control group, the participants will receive the following oral hygiene instructions at completion of debridement, at week-1 and week-3. In the test group, apart from the standard oral hygiene instructions at completion of debridement, at week-1 and week-3 , additional analysis of brushing data and provision of targeted brief interventions will be provided on a daily basis for the first week, 3 times/week until week 6 and once a week thereafter until 6 months after the debridement.
223390706|NCT05850117|DRUG|esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin|Tetracycline combined with levofloxacin quadruple therapy
223390707|NCT05850117|DRUG|esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole|standard tincture quadruple therapy
223390708|NCT05850117|DRUG|esomeprazole, tripotassium dicitrate bismuthate , amoxicillin and levofloxacin|amoxicillin combined with levofloxacin quadruple therapy
223390709|NCT02189837|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223390710|NCT02189837|DRUG|Atorvastatin|Administered by mouth
223390711|NCT02189837|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
223390712|NCT02189837|DRUG|Placebo to Atorvastatin|Administered by mouth
223390713|NCT04991207|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
223390714|NCT04991207|DRUG|bosentan|Oral Tracleer (bosentan) 125 mg film coated tablets
223390715|NCT02421055|PROCEDURE|Laparoscopic Roux-en-Y Gastric Bypass|
223390716|NCT02421055|PROCEDURE|Laparoscopic Sleeve Gastrectomy|
223390717|NCT04900181|PROCEDURE|the same-day discharge surgery|the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
223390718|NCT06721871|DRUG|Crofelemer Powder for Oral Solution|Crofelemer Powder for Oral Solution
223546553|NCT03263403|BIOLOGICAL|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
223546554|NCT03263403|BIOLOGICAL|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo \[Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined\] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
223546555|NCT06100757|DEVICE|Micra Transcatheter Pacing System (TPS°|Implantation of a leadless pacemaker type Micra TPS. Echocardiographic and clinical follow-up during 12 months
223546556|NCT06100757|DEVICE|Conventional pacemaker type Medtronic Advisa ADSR03 or Azure XT VR|Implantation of a conventional ventricular pacemaker (VVI and VV(R) pacing mode) and right ventricular lead (Medtronic 5076-58)/ Echocardiographic and clinical follow-up during 12 months
223546557|NCT06097403|DIAGNOSTIC_TEST|Covid 19 swap|diagnostic tool
223546558|NCT06154616|DIETARY_SUPPLEMENT|Control Product|Lactose-free skimmed milk
223546559|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250|Lactose-free skimmed milk enriched with 250 mg aswaghanda
223546560|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 250 + TRP|Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan
224011707|NCT05149053|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
223390719|NCT06721871|DRUG|Placebo Powder for Oral Solution|Matching Placebo Powder for Oral Solution
223390720|NCT02665156|PROCEDURE|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
223390721|NCT04631354|DRUG|Radio-labelled S-770108|99mTc radio-labelled S-770108 supplied as a capsule containing 6 mg active pirfenidone for inhalation
223390722|NCT04631354|DEVICE|S-770108 Inhaler A1|Dry powder inhaler
223390723|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; first study group: 10E7\_TCID50
223390724|NCT00386633|BIOLOGICAL|MVA-mBN32|3 immunizations; second study group: 10E8\_TCID50
223390725|NCT00701961|DRUG|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
223390726|NCT01674218|DRUG|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
223390727|NCT01674218|DRUG|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
223390728|NCT01674218|OTHER|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
223390729|NCT00950365|DRUG|Erlotinib Hydrochloride|Given PO
223390730|NCT00950365|OTHER|Laboratory Biomarker Analysis|Correlative studies
223390731|NCT00950365|DRUG|Pemetrexed Disodium|Given IV
223390732|NCT00408746|BEHAVIORAL|palatal development|Impressions of preterm and term palates.
223390733|NCT01164696|DRUG|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
223390734|NCT03597659|GENETIC|phenome-wide association study (PheWAS)|Phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of TSH levels identified by a previously published genome-wide association study (GWAS) which included North American and European participants. A phenome-wide scanning of 1,318 phenotypes will be performed, using a cohort of 37,154 North American individuals of European ancestry with electronic-health-record (EHR) data.
224011708|NCT05149053|OTHER|Placebo|Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
224011709|NCT00191178|DRUG|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
223390735|NCT01769560|BEHAVIORAL|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
223390736|NCT04589663|DRUG|Mometasone furoate|Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
223390737|NCT04589663|DRUG|QMF149|Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
224011710|NCT00191178|DRUG|insulin glargine|
223390738|NCT04589663|DRUG|Standard of Care (Soc)|Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
223390739|NCT00275119|DRUG|fluorouracil|
223390740|NCT00275119|DRUG|gemcitabine hydrochloride|
223390741|NCT00275119|DRUG|oxaliplatin|
223390742|NCT00275119|RADIATION|radiation therapy|
224127432|NCT04606654|OTHER|Handgrip strength training with Blood flow restriction|Participants of this group will get exercise training through hand grip strengthener and DMOOSE fitness resistance bar. Participants will contracts his/her forearm at a rate of 15 times/min (1 contraction every 4 sec). The subjects will train for 20 min, 3 days per week for 2 weeks (total 6 sessions), under the supervision of a principle investigator. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training. However, for one of the limbs the pneumatic blood pressure cuff will be placed on the upper arm, 4 cm proximal to the ante-cubital fossa. The decision which arm would receive the occlusion during training will be randomized to avoid a dominant or non-dominant hand bias. During experimental group training blood pressure cuff will be partially inflated (80 mmHg) to ensure venous occlusion. Participants will be allowed to take 1 min rest periods, after the completion of 5 minutes of training while the cuff remained inflated.
224127433|NCT04865250|DRUG|Atezolizumab 1200 mg abs day 1 q22 (iv)|Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)
224127434|NCT03503682|RADIATION|standard treatment|3000 cGy in 10 daily fractions
224127435|NCT03503682|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
224127436|NCT04961814|OTHER|liberal fasting|preoperative fasting according to 6-4-0 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
224011711|NCT01559753|DRUG|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~* Beta-Lactams:~  * Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~ * Ceftriaxone : 2 g OD during 3 days, then 1 g OD~ * Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~* Aminoglycosides~  * Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~ * Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~ * Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
224127437|NCT04961814|OTHER|standard fasting|preoperative fasting according to 6-4-2 regimen then qualitative and quantitative preoperative gastric ultrasound assessment will be done to evaluate the proportion of patients with risky stomach
224011712|NCT01559753|DRUG|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
224011713|NCT02414737|DRUG|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
224011714|NCT02892695|BIOLOGICAL|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
224011715|NCT05141240|DRUG|Ribiciclib|Participants who initiated CDK4/6i therapy
224011716|NCT05141240|DRUG|Palbociclib|Participants who initiated CDK4/6i therapy
224011717|NCT05141240|DRUG|Abemaciclib|Participants who initiated CDK4/6i therapy
224011718|NCT01253304|DRUG|LY2189265|Subcutaneous (SC) injection
224011719|NCT00741559|DEVICE|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
224011720|NCT00741559|DEVICE|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
224011721|NCT00741559|DEVICE|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
224127438|NCT01695850|DRUG|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
224127439|NCT01695850|DRUG|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
224127440|NCT01695850|DRUG|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
224127441|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
224127442|NCT00849121|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
224127443|NCT05216848|OTHER|Wijma Delivery Expectancy Questionnaire|Simple questionaire identifying the level of fear of childbirth in pregnancy
224127444|NCT05216848|OTHER|Clinical data collection|Collection of the standard clinical data during hospitalization
224127445|NCT03007485|OTHER|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
223546561|NCT06154616|DIETARY_SUPPLEMENT|Experimental Product: 600|Lactose-free skimmed milk enriched with 600 mg aswaghanda
223546562|NCT01273038|DEVICE|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
223546563|NCT01273038|DEVICE|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
223390743|NCT04769531|OTHER|Hip Joint Mobilizations|i. Anterior-posterior glide ii. Posterior-anterior glide iii. Caudal glide iv. Posterior-anterior glide with Abduction, flexion, and lateral rotation
223390744|NCT04769531|OTHER|Hip joint Muscle strength training|i. Hip abduction in side-lying ii. Hip extension in the prone position iii. Sideways walk iv. Hip abduction in stand up position v. Hip hitching
223390745|NCT04769531|OTHER|knee strengthening and flexibility exercises|"i. STRENGTHENING EXERCISES: Knee extension static quads set, terminal knee extension while standing up, sitting leg press, partial squat, step-ups.~ii. STRETCHING EXERCISES:: stretching of the calf, hamstring, and quadriceps-femoris.~iii. RANGE OF MOTION EXERCISES: Knee in mid-flexion to full-extension, Knee in mid-flexion to full-flexion:"
223546564|NCT03248388|DEVICE|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
223546565|NCT03248388|DEVICE|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
224011722|NCT04492800|DEVICE|Paxman Scalp Cooling Device|Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).
224011723|NCT01327495|OTHER|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
224011724|NCT01327495|OTHER|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
224011725|NCT01327495|DRUG|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
224011726|NCT01327495|DRUG|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
224011727|NCT01327495|DRUG|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
224127446|NCT00792233|OTHER|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
224127447|NCT01848054|DRUG|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
223390746|NCT04243031|DEVICE|QFT Access|Measure of Interferon Gamma
223390747|NCT02137876|PROCEDURE|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
223390748|NCT03009773|OTHER|rehabilitation multitasking walking.|rehabilitation multitasking walking.
223546566|NCT02682459|DRUG|Lisinopril|
224011728|NCT01327495|DRUG|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
224011729|NCT01327495|DRUG|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
224011730|NCT01327495|DRUG|Acyline|300 ug/kg subcutaneous injection every 2 weeks
224011731|NCT00006011|DRUG|Doxorubicin Hydrochloride|Given IV
224011732|NCT00006011|DRUG|Cisplatin|Given IV
224011733|NCT00006011|BIOLOGICAL|Filgrastim|Given SC
224011734|NCT00006011|BIOLOGICAL|Pegfilgrastim|Given SC
224011735|NCT00006011|DRUG|Paclitaxel|Given IV
224127448|NCT01848054|DRUG|Buprenorphine|Buprenorphine sublingual tablets
224127449|NCT02634099|DEVICE|blood measurement|Hemoglobin measurement
223390749|NCT03009773|OTHER|Traditional walking rehabilitation|Traditional walking rehabilitation
223390750|NCT05176873|DRUG|DZD8586|Single dose of DZD8586. Starting dose of DZD8586 is 20mg. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
223390751|NCT05176873|DRUG|Placebo|A single oral dose of placebo will be given.
224011736|NCT01104597|PROCEDURE|Flow Mediated Doppler (FMD)|Non-invasive assessment of flow-mediated dilation (FMD) will be performed using brachial artery ultrasound.
223390752|NCT01153373|BEHAVIORAL|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
224011737|NCT01104597|DRUG|Nitroglycerin 0.4 mg sublingual|Nitroglycerin 0.4 mg (a small tablet that dissolves under the tongue) will be given to dilate the arteries. Images of the arm will be recorded via non-invasive flow-mediated doppler for 5 minutes to assess for endothelium dysfunction. as outlined above.
224011738|NCT04848701|OTHER|latent phase duration|latent phase duration in post term pregnancies
224011739|NCT04848701|OTHER|uterocervical angle (UCA)|uterocervical angle is the angle between lower segment of uterus and cervix
224011740|NCT06281899|DRUG|Dapagliflozin 10 mg Tab|Dapagliflozin 10 mg once daily
224011741|NCT06281899|BEHAVIORAL|Low protein diet|Plant based low protein diet (0.6 g/kg IBW)
224011742|NCT04781400|BEHAVIORAL|Mobile phone support|Mobile phone support (SMS)
224011743|NCT04781400|BEHAVIORAL|Remote service delivery model|ART treatment delivery via a courier service
224127450|NCT02634099|DEVICE|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
224127451|NCT02634099|DEVICE|hemoCue|non invasive method of hemoglobin measurement
223546567|NCT04116593|BEHAVIORAL|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
223546568|NCT05865951|OTHER|Isometric Exercises|Isometric (same length) strengthening exercises of the neck muscles will be performed.
223546569|NCT05865951|OTHER|Isotonic Exercises|Isotonic strengthening exercises for the neck muscles will be performed.
223546570|NCT01976299|DEVICE|AVERT|
224011744|NCT05161728|DIAGNOSTIC_TEST|PSMA-PET/CT|PSMA-PET/CT
224127452|NCT05738499|OTHER|Character strengths-based structured treatment and education programme (CSSTEP)|This CSSTEP intervention included both psychological and educational contents, and the intervention type was psycho-educational intervention. The implementation process lasted for three weeks. CSSTEP mainly includes two main components. The first part is character strengths-based intervention. The second part is educational intervention, which is structured treatment and education programme for stroke patients. The two components were combined and optimized on the basis of theoritical and empirical evidences, and then this kind of complex intervention suitable for Chinese clinical stroke patients was obtained.
224127453|NCT05738499|OTHER|Structured treatment and education programme (STEP)|The STEP programme is aimed at the treatment needs of stroke patients, considering the education level and cultural background of patients, screening important health education content, and planning and grading of patients' education. The intervention consisted of three educational sessions, focusing on patients' daily life, post-stroke rehabilitation and secondary prevention.
224127454|NCT03913221|DRUG|Caffeine Citrate 5 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
224127455|NCT03913221|DRUG|Caffeine Citrate 10 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
223390753|NCT01153373|BEHAVIORAL|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
223390754|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
223390755|NCT02443740|DRUG|BIIB118|Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
223390756|NCT02443740|DRUG|BIIB118|Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
223546571|NCT02402595|DRUG|AVP-923|
223546572|NCT02402595|DRUG|AVP-786|
224011745|NCT01841931|DRUG|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
224011746|NCT05882552|DIAGNOSTIC_TEST|Tilted Gaze Target Tast|Tilted gaze target tast is playing a small animated video with a visual mobile device at a distance of 33 cm and 3 m, respectively, to determine the optimal angle of head position improvement and the spatial tilt angle of the screen relative to the orthostatic position.It will be conducted during the first visit. Preoperative intervention will also be conducted before surgery. Postoperative interventions will be conducted at one day, one month, and six months after surgery.
224127456|NCT06285929|OTHER|ACS CARES Student Navigation|Student volunteers providing navigation support to patients, families and caregivers with a cancer diagnosis through an SDOH assessment.
223546573|NCT02402595|DRUG|Itraconazole|
223546574|NCT04982991|DRUG|RIPK1 inhibitor|Capsule Oral
223546575|NCT00977483|DRUG|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
224127457|NCT04626193|DRUG|Doxycycline|Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid
224127458|NCT04626193|DRUG|Levofloxacin 500mg|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
224127459|NCT02704494|DRUG|Resveratrol|Resveratrol 500mg daily
224127460|NCT02704494|DRUG|Placebo|Placebo 1 capsule daily
224127461|NCT02704494|DRUG|Losartan|Losartan 12.5mg daily
224127462|NCT05249231|DRUG|Silver diamine fluoride|Previous studies have recommended silver diamine fluoride (SDF) to exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. The result is useful in arresting early childhood caries (ECC)
223546576|NCT00977483|DRUG|Placebo|1 tablet once daily 4 years double-blind treatment period
223546577|NCT00649350|DRUG|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
223546578|NCT00649350|DRUG|Glucophage XR 750 mg|750mg, single dose fed
223546579|NCT04317235|DRUG|Ropivacaine 0.5% Injectable Solution|Is to put 3 ml or 5 ml and show the difference
223546580|NCT02735603|DRUG|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
223546581|NCT02735603|OTHER|Placebo|Naltrexone/bupropion placebo-matching tablets.
223546582|NCT02735603|DRUG|Moxifloxacin|Moxifloxacin tablet.
223546583|NCT02722213|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
223546584|NCT01306643|DRUG|Idelalisib|Tablet(s) administered orally twice daily
223546585|NCT05385211|OTHER|Frequency of hypoglycemia in people with type 1 diabetes and exocrine pancreatic insufficiency|Blood samplings; Glucose monitoring; CFTR variants
223390757|NCT02741414|DEVICE|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
223390758|NCT02741414|DEVICE|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
223390759|NCT02741414|DEVICE|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
223390760|NCT05411341|DEVICE|Argos (Alcon Laboratories, Inc.)|An ocular biometry examination will be performed on the affected eyes using the Argos device.
223390761|NCT05411341|DEVICE|IOLMaster 500 (Carl Zeiss Meditec AG)|An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
223390762|NCT01736969|DEVICE|RD047-023|Experimental hydrogel
223390763|NCT01736969|DEVICE|Predicate Device|
223390764|NCT02982837|DRUG|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
223390765|NCT02982837|DRUG|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
223546586|NCT01057537|DRUG|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
223546587|NCT01057537|DRUG|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
223390766|NCT01229137|DEVICE|SRD-1 conversion|
223546588|NCT00614419|DEVICE|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
223546589|NCT00614419|DEVICE|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
223546590|NCT02981056|OTHER|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
224011747|NCT05882552|DIAGNOSTIC_TEST|Conventional Examination Methods|The conventional examination methods include oculomotor examination, Bielschowsky head tilt test, alternate prism cover test, prism adaptation test, and monocular cover test. They will be conducted during the first visit. Preoperative intervention will also be conducted before surgery.Postoperative interventions will be conducted at one day, one month, and six months after surgery.
223390767|NCT06156332|DRUG|surufatinib、serplulimab|"surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment."
223546591|NCT02981056|OTHER|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
224011748|NCT02861547|OTHER|death|
224011749|NCT04619940|DIAGNOSTIC_TEST|iHandy application|The IHandy® app is a free app with a visual display similar to that of the digital inclinometer in terms of digital size. In this study, due to its prevalence in the literature and its use in clinics, manual goniometer (gold standard) was chosen to be compared with this iPhone application.
224011750|NCT04619940|DIAGNOSTIC_TEST|Standard Goniometer|While measuring with goniometer, the pivot point of the goniometer was placed on the olecranon, the immobile rod of the goniometer was kept parallel to the bed, while the moving rod was kept parallel to the ulna, the angle was recorded at the end point of the movement.
224011751|NCT04005573|DIETARY_SUPPLEMENT|VD3|VD3 50000 IU/ week for 8 weeks
224011752|NCT04005573|DIETARY_SUPPLEMENT|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
223390768|NCT03900052|DEVICE|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
224011753|NCT04005573|DIETARY_SUPPLEMENT|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
223390769|NCT03900052|DEVICE|typical cane|Typical training cane loading training
224011754|NCT04005573|OTHER|no intervention|no intervention is given
224011755|NCT03212989|DRUG|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
224011756|NCT03212989|BIOLOGICAL|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
224127463|NCT05249231|DEVICE|Hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method
223390770|NCT00456300|DRUG|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
223390771|NCT00456300|DRUG|Insulin|Each subject received a baseline study with insulin alone
223390772|NCT02784561|DRUG|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously \[i.v.\], days -10 to -8)
223390773|NCT02784561|DRUG|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
223390774|NCT02784561|DRUG|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
223390775|NCT02784561|DRUG|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
223390776|NCT02784561|DRUG|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
223390777|NCT05503576|DEVICE|reminder mobile application|After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
223390778|NCT01478373|DRUG|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
223390779|NCT03098082|DEVICE|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
223390780|NCT03928301|BEHAVIORAL|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
223390781|NCT03928301|BEHAVIORAL|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
223390782|NCT04793594|OTHER|Berg Balance Test|Patients evaluate with Berg Balance Test for balance
224011757|NCT00795366|DRUG|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
224011758|NCT00795366|DRUG|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
224011759|NCT05333952|PROCEDURE|Pulmonary vein isolation|The 3D geometry of the LA will be created using CARTO 3 system (version 6) with UDM Module and VISITAG Optimum Device Performance (ODP) module. Continuous circumferential lesions will then be created encircling the right and left PV ostia using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA).Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
223390783|NCT04793594|OTHER|Tinetti Balance And Gait Test|Patients evaluate with Tinetti Balance And Gait Test for balance
223390784|NCT04793594|OTHER|Time Up And Go Test|Patients evaluate with Time Up And Go Test for balance
223390785|NCT01467440|DEVICE|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
224011760|NCT05333952|PROCEDURE|Substrate ablation(PRISM based)|Substrate modification will be guided by waveform periodicity analysis. The User Defined Map of waveform periodicity analysis will be also created by CARTO 3 system (version 6) with and VISITAG ODP module. Pentaray catheter will be used and facilitate the high density mapping of atrial substrate (PentarayTM, Biosense Webster Inc., Diamond Bar, CA, USA). Substrate modification based on waveform periodicity analysis will be performed by using a 7.5F, 3.5-mm Thermocool SMARTTOUCH ablation catheter (Biosense Webster, Inc., Diamond Bar, CA, USA). The radiofrequency energy will be applied with contact force range 5-25 g continuously with a target Ablation Index target 380-400 on the posterior wall and 550 - 600 on the anterior wall and maximum power of 25-35W in a power control mode.
223546592|NCT02981056|OTHER|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
224011761|NCT03499470|OTHER|Protocol for structured discharge and follow-up|
224011762|NCT02302378|PROCEDURE|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
224011763|NCT02302378|PROCEDURE|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
224011764|NCT03047395|BIOLOGICAL|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
224011765|NCT04949061|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)|CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.
224011766|NCT04949061|OTHER|Enhanced Treatment as Usual (ETA-U)|Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
224011767|NCT04704583|BEHAVIORAL|SPACE parental-guidance|The treatment will be delivered to the parents in ten 50-minute sessions. The sessions are planned to be weekly and will be completed within 13 weeks of the first session. The sessions include instruction and education, acquiring skills, role-play, and simulations. Parents will be given exercises and goals in reducing accommodation to achieve at home (in cognitive behavioral therapy this is sometimes called 'homework') in some of the sessions. For example, parents to write down one or two things that they would most like to see their child handling better.
223390786|NCT01199380|BEHAVIORAL|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
223390787|NCT01199380|BEHAVIORAL|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
223390788|NCT01199380|DRUG|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
223390789|NCT03940131|DRUG|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
223390790|NCT05149326|DRUG|KN046|KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
223390791|NCT05149326|DRUG|placebo|placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
223546593|NCT01149330|DRUG|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
223546594|NCT03895294|OTHER|Health care under the strategic purchase-Clinical pathway|1\) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
223564135|NCT03150745|PROCEDURE|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
224011768|NCT04984447|DEVICE|TNIB Catheter|Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.
224011769|NCT06292052|DRUG|Immunotherapy|Received neoadjuvant chemotherapy plus immunotherapy
224011770|NCT06100081|DIAGNOSTIC_TEST|Detection of lesions using fluorescence molecular imaging|Using a fluorescence camera, lesions will be detected and biopsies will be taken to try and find cancer of unknown primary
224011771|NCT01566877|DRUG|AVI-7288|"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
223390792|NCT02371473|DRUG|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
223390793|NCT02371473|DRUG|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
223546595|NCT03895294|OTHER|Usual care process prior strategic purchase-clinical pathway|1\) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
223546596|NCT03852784|OTHER|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
223546597|NCT01958255|BEHAVIORAL|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
223546598|NCT01947335|DEVICE|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
223546599|NCT00852579|DRUG|Azithromycin|Daily dose 250mg
223546600|NCT00852579|DRUG|Placebo|Placebo
223546601|NCT00329823|DRUG|Etanercept sc 50mg per week for 12 weeks|
223546602|NCT01730911|OTHER|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
223730436|NCT05353231|BEHAVIORAL|Attention Feedback Awareness and Control Training (A-FACT)|"A-FACT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control.~Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Following a fixation que, the auditory neutral or negative simulated thought stimulus is delivered, and 500ms prior to termination of the auditory stimulus, a visual stimulus is presented until participants categorize the visual stimulus as greater than or smaller than 5 objects. Latency to disengage attention from each thought stimuli, at the trial-level, is repeatedly measured, and after each negative thought stimulus, trial-level feedback on the latency to disengage is delivered back to participants through a visual scale representing their attentional bias. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial."
224011772|NCT01566877|OTHER|Placebo|Normal Saline Solution (NSS)
224011773|NCT05299294|OTHER|Data collection|Collecting data on children receiving capsaicine 8% patch for localized neuropathic pain
224011774|NCT05343520|BEHAVIORAL|Pelvic floor muscle exercises|Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
224011775|NCT06461702|DRUG|YOLT-101|The IP is administered intravenously at the predetermined dose.
224011776|NCT03484273|DEVICE|LifeWrap Compression Garment|Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
223390794|NCT05600673|DRUG|Bimatoprost 0.03% solution|Topical Bimatoprost 0.03% solution
224011777|NCT06243692|DRUG|Lacosamide 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
224011778|NCT06243692|DRUG|Topiramate 50Mg Tab|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of treatment was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
223390795|NCT05600673|DEVICE|CO2 fractional laser|CO2 fractional laser treatment
223390796|NCT01088230|OTHER|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
223390797|NCT01088230|OTHER|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
223546603|NCT02071771|DEVICE|Nelfilcon A toric contact lenses|
223546604|NCT02071771|DEVICE|Etafilcon A toric contact lenses|
223546605|NCT04523584|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo MR imaging of the liver. Liver PDFF will be measured.
223546606|NCT04523584|DEVICE|Ultrasound Imaging|Participants will undergo ultrasound imaging of the liver. UDFF and shear wave speed (US-SWS) will be measured.
223546607|NCT04868383|BEHAVIORAL|Use of smart phone technology to support medication adherence and uptake|Use of smart phone technology to support medication adherence and uptake
223546608|NCT01450644|OTHER|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
223546609|NCT02746406|DEVICE|Peritron+|Peritron+ device to measure intravesical pressure
224011779|NCT02197559|PROCEDURE|DES group|all the participants in this group will be performed with drug -eluting stents
224011780|NCT02197559|PROCEDURE|BMS group|all the participants in this group will be performed with bare-metal stents
223546610|NCT06133881|DRUG|prilocaine|intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
223390798|NCT06578273|DEVICE|NeuroGlove|"The NeuroGlove is a plastic chamber with multiple apertures along its length to allow for puffs of air to be directed to the volar surface of the distal forearm, the palm, and the fingers. The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development. A pneumatic pump delivers intermittent puffs of air cycling between one second on and two seconds off. The hand with the palm facing up is placed within the device chamber on a gel pad to provide a comfortable resting surface for the duration of the treatment, which lasts approximately thirty minutes.~The device facilitates the rehabilitation, improvement, or restoration of motion in patients with neurological disorders."
223390799|NCT00682474|BEHAVIORAL|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
223390800|NCT00682474|BEHAVIORAL|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
223390801|NCT01445704|DIETARY_SUPPLEMENT|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
223546611|NCT06133881|DRUG|bupivacaine|intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
223546612|NCT01516632|BEHAVIORAL|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
223546613|NCT00700648|DRUG|insulin aspart|Intravenous NovoRapid dose \& frequency as decided by treating physician
223546614|NCT06326008|DRUG|Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy|Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.
223546615|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
223546616|NCT02245321|DIETARY_SUPPLEMENT|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
223546617|NCT02245321|OTHER|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
224011781|NCT00501839|DRUG|clomiphene citrate|
224011782|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
223390802|NCT01445704|DIETARY_SUPPLEMENT|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
223390803|NCT01074944|DRUG|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
223546618|NCT02245321|OTHER|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
223546619|NCT02245321|DIETARY_SUPPLEMENT|Placebo|Receive pills to take daily that contain 0 mg iron.
223546620|NCT00355368|DRUG|Succinylcholine|1mg/kg iv
223546621|NCT00355368|DRUG|Rocuronium|0.6mg/kg iv
223546622|NCT01889108|BEHAVIORAL|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
223546623|NCT05066126|BEHAVIORAL|Mixed-Presentation of Content|Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
223546624|NCT00844142|DRUG|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
223546625|NCT00844142|DRUG|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
223546626|NCT01344486|PROCEDURE|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
224011783|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase distress tolerance|Increase the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including more emotion exposure tasks, materials from Facing Your Feelings.
224011784|NCT06056232|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-decrease distress tolerance|Decrease the intervention dose of distress tolerance in Mindfulness Intervention for Emotional Distress (MIED). For example, including less emotion exposure tasks and interoceptive exposure tasks.
223546627|NCT01344486|PROCEDURE|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
223546628|NCT03263065|DIETARY_SUPPLEMENT|Bran|220g rice pudding meal with raspberry jam with added bran flakes
223546629|NCT03263065|DIETARY_SUPPLEMENT|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
223546630|NCT03263065|DIETARY_SUPPLEMENT|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
223390804|NCT05011604|DEVICE|Full-Digital Workflow in Single-Tooth Implant Rehabilitation|"For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented."
223390805|NCT03822104|DIETARY_SUPPLEMENT|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
223390806|NCT03822104|DIETARY_SUPPLEMENT|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
223390807|NCT00762112|DRUG|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
223390808|NCT02348112|DEVICE|Altis Single Incision Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
223390809|NCT02348112|DEVICE|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
223390810|NCT03181412|DIAGNOSTIC_TEST|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
223390811|NCT00745550|DRUG|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
223390812|NCT02103855|DRUG|Belatacept|
223390813|NCT03741400|DEVICE|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
223546631|NCT02680340|PROCEDURE|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
223546632|NCT04778748|DIAGNOSTIC_TEST|Under-mattress sleep monitor|Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
223546633|NCT02307240|DRUG|CUDC-907|CUDC-907 oral with meals.
223546634|NCT02897687|BEHAVIORAL|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
224011785|NCT06258226|DRUG|Conventional dosage reduction|The doctor will guide patients to adjust medication dosage once a week in the outpatient clinic. When patients experience withdrawal reactions such as worsening insomnia or anxiety symptoms due to drug reduction, they will be returned to the oral dose before the current reduction, and the dosage will be reduced again after evaluation in the next reduction cycle. The treatment for 4 weeks is one course and 1 course of treatment is required totally.
224127464|NCT05973643|OTHER|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (bitemporal) or unilaterally (or fronto-temporal) on the frontotemporal region under anesthesia.~The stimulation dose is determined by titration method, during the first ECT session. An ECT cure corresponding from 12 to 20 sessions of ECT. Patients will receive 2 sessions a week.~Blood samples will be done during the anesthesia process."
224127465|NCT00903747|DRUG|prucalopride|2-10 mg prucalopride
224127466|NCT00903747|DRUG|moxifloxacin|400 mg moxifloxacin (Group 2a)
224127467|NCT00903747|DRUG|placebo|placebo (Group 2b)
223390814|NCT04477070|PROCEDURE|Air-polishing with ultrasonic debridement|Use of air-polishing and ultrasonic device (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) to remove plaque and calculus from the surface of the roots of teeth.
223390815|NCT04477070|PROCEDURE|Conventional scaling and root planing|Use of scaling instruments to remove plaque and calculus from the surface of the roots of teeth.
223546635|NCT02897687|BEHAVIORAL|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
223546636|NCT02471053|OTHER|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
223546637|NCT02345616|DRUG|Nitric oxide|
223546638|NCT01195818|DRUG|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
223390816|NCT05019300|BIOLOGICAL|Exposure: COVID-19 severity|COVID-19 severity between 4 to 7 points according the seven-category scale of clinical status reported by Huang et al. (2021) and severe to critical symptomatic levels on spectrum of disease reported by Wu and McGoogan (2020).
223546639|NCT05901571|OTHER|acupuncture|"The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation."
223546640|NCT05901571|OTHER|escitalopram|Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
223546641|NCT05901571|OTHER|sham-acupuncure|In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
223546642|NCT05901571|OTHER|escitalopram placebo|Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
223546643|NCT06009822|OTHER|Postoperative outcome measurements|"Kinesiophobia; It will be assessed on the Tampa Kinesiophobia Scale. Function; Lysholm knee score, kujala knee score, single-leg hop test, Y balance test and single leg sway index will be evaluated.~Biodex Bio-balance system device will be used for single leg sway index."
223546644|NCT02257749|OTHER|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
223546645|NCT02257749|OTHER|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
223546646|NCT03202433|DEVICE|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
223564136|NCT03150745|PROCEDURE|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
223564137|NCT03745872|BEHAVIORAL|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
224011786|NCT06258226|PROCEDURE|Auricular acupressure|Auricular acupressure is a non-pharmacological therapy that involves applying acupressure on the surface of points in different parts of the ear. One side of the auricular acupoints will be treated first and the tapes will be kept in place for 3 days. On the fourth day, the tapes on the ear will be removed and new tapes will be applied to the opposite side of the ear. The purpose of replacing tapes is to reduce the adverse events (AEs) that may be caused by long-term stimulation unilaterally. In addition, the participants will be informed to press the tapes by themselves for 3 to 5 minutes vertically and appropriately to achieve the sensation, with a duration of 4 to 5 times a day. The treatment will last for 4 weeks, and the follow-up will be done after 1 month.
224011787|NCT06258226|PROCEDURE|Sham auricular acupressure|Based on the estazolam reduction method in the control group, the acupuncturist will place the same skin-colored adhesive tapes without vaccaria on the auricular points, but these tapes will not be pressed during treatment.
224011788|NCT03568396|DEVICE|Pupillometer|Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
223390817|NCT02319278|DRUG|Ferumoxytol|Infusion following between paired MRI scans
223390818|NCT03560128|DEVICE|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
223390819|NCT03560128|DEVICE|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
224011789|NCT02960750|BEHAVIORAL|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
224011790|NCT02960750|BEHAVIORAL|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
224011791|NCT00913315|DRUG|tolterodine|4 mg of tolterodine ER
224011792|NCT00913315|DRUG|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
224011793|NCT00913315|DRUG|placebo|placebo once a day for 8 weeks
224011794|NCT00445354|DRUG|cinnamon|
224011795|NCT03983629|OTHER|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
224011796|NCT01227382|PROCEDURE|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
223390820|NCT05871554|BEHAVIORAL|Mind-OP+|"Mind-OP is an online program designed to cultivate mindfulness and self-compassion developed by Beshai and his team. Mind-OP is self-guided, with four modules administered at a pace of one module per week (four weeks total). The version used for this study, Mind-OP+, is five weeks total, containing an extra module focused on connectedness.~The modules contain psychoeducational videos, guided audio meditations, goal-setting and motivational interviewing inspired exercises. Participants also have opportunities to engage with meditations and other exercises embedded within each module.~The first module (Week 1) introduces the concept of mindfulness. The second module (Week 2) focuses on attention to bodily sensations and thoughts. The third module (Week 3) introduces the concept of self-compassion. The fourth module (Week 4) focuses on the self-kindness component of self-compassion. The fifth module (Week 5) focuses on the concept of connectedness."
223390821|NCT05911061|BIOLOGICAL|High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
223390822|NCT05911061|BIOLOGICAL|Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)|boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
223390823|NCT05911061|BIOLOGICAL|control group|boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)
223390824|NCT05911061|BIOLOGICAL|Placebo group|saline
223390825|NCT03714828|DRUG|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
223390826|NCT03714828|DRUG|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
223390827|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
223390828|NCT03714828|DRUG|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
223390829|NCT01998841|DRUG|Crenezumab|Crenezumab will be administered as per the schedule specified in the treatment arm.
224011797|NCT01383460|DRUG|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
224011798|NCT01383460|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
224011799|NCT03099746|BEHAVIORAL|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
223390830|NCT01998841|DRUG|Placebo|Placebo will be administered as per the schedule specified in the treatment arm.
223564138|NCT03013387|RADIATION|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
224011800|NCT03099746|BEHAVIORAL|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
224011801|NCT03099746|BEHAVIORAL|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
224011802|NCT01788787|BEHAVIORAL|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
224011803|NCT01788787|BEHAVIORAL|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
224011804|NCT01788787|BEHAVIORAL|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
224011805|NCT01788787|BEHAVIORAL|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
224011806|NCT06096454|DRUG|Metformin|effect of life style modification and metformin on hypothyroidism with insulin resistance
224127468|NCT06457035|DRUG|immunosuppressant|No intervention was performed in this retrospective cohort study.
224127469|NCT01870219|DRUG|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
224127470|NCT01870219|DRUG|Ketamine|ketamine was given to 1mg/kg ıv bolus
223546647|NCT06266026|DIAGNOSTIC_TEST|ThermoBreast - AI-based evaluation of dynamic breast thermography imaging|"Index test: AI-based evaluation of dynamic breast thermography imaging (ThermoBreast). The ThermoBreast evaluation will be performed independently of the routine breast cancer diagnostic evaluation. Some baseline risk variables (e.g. patient age, hormonal status) may be included in the ThermoBreast evaluation.~Reference test: Routine breast diagnostics will serve as a reference test against which the ThermoBreast outcome will be compared. Depending on national guidelines and clinical scenarios, routine breast cancer diagnostics can consist of several routine procedures, including clinical examination, ultrasound, mammography, tomosynthesis, MRI, follow-up imaging, biopsy, surgical excision, and histopathologic evaluation. All procedures will be performed as indicated and specified by the respective, current national guidelines."
223546648|NCT04384471|OTHER|Online survey|Participants are invited to answer an online questionnaire including both close-ended and open-ended questions about their experience during this sanitary crisis
224011807|NCT03751046|BEHAVIORAL|Trial-Based Cognitive Therapy|Participants in the TBCT intervention arm will have 14 (fourteen) psychotherapy sessions over a period of 7 (seven) months. The frequency of the intervention is biweekly with a duration of approximately 90 minutes per session. We will have10 groups with 5 participants each. All participants will practice the learned techniques during the meetings, have a manual with a description summary of the sessions and the activities to practice at home. The main TBCT techniques that will be used are case conceptualization, intrapersonal thought record, consensual role-play, action plan, trial-based thought record and trial-based metacognitive awareness.
224011808|NCT03751046|OTHER|Control group. Standard healthcare.|"Participants with therapeutic failure, receiving the standard healthcare in the HIV / AIDS Program, which includes at least a half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each).~The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV"
224011809|NCT04916080|DRUG|N-acetyl cysteine|mucolytic and anti-oxidant. Dose 10mg/Kg/ 12 hours orally
224011810|NCT04715243|DEVICE|High flow nasal cannula (HFNC)|High flow nasal cannula as a form of non-invasive oxygen delivery
224011811|NCT04715243|DEVICE|Helmet NIV|NIV interface
224011812|NCT04715243|DEVICE|Face-mask NIV|NIV interface
224011813|NCT04230603|PROCEDURE|Hyperspectral imaging|Photos were taken with the hyperspectral camera of the human tissue
224011814|NCT04230603|DIAGNOSTIC_TEST|Lactate acid measurement|At the marked regions of the specimen, a lactate acid measurement was performed.
224011815|NCT04230603|DIAGNOSTIC_TEST|pathological examination|At the marked regions of the specimen, the pathological examination was performed.
224011816|NCT04700020|DIAGNOSTIC_TEST|ITT|In the context of this study, we will take two blood samples. In addition to the second blood sample, an insulin tolerance test (ITT) is also performed, even if the result of the blood values is normal. MRI will only be performed if the previous imaging was done more than two years ago or when the quality of the MRI was not good enough to measure the volume of the pituitary gland. This is needed for better analysis of the pituitary gland, as the pituitary volume could be important for the hormonal abnormalities.
224011817|NCT01670760|DEVICE|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
224011818|NCT03203395|BEHAVIORAL|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
224011819|NCT02496689|BIOLOGICAL|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
224011820|NCT01971710|BEHAVIORAL|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
224011821|NCT01971710|BEHAVIORAL|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
224011822|NCT01971710|BEHAVIORAL|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
224011823|NCT00560066|BIOLOGICAL|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
224011824|NCT00560066|BIOLOGICAL|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
224011825|NCT01748877|DRUG|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
224127471|NCT00243113|DRUG|docetaxel|
224127472|NCT00243113|RADIATION|radiation therapy|
224127473|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
224011826|NCT01748877|DRUG|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
224127474|NCT01490268|DRUG|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
224127475|NCT04439370|DIAGNOSTIC_TEST|Microneurography to measure muscle sympathetic nerve activity (MSNA)|Microneurography is a direct measurement of electrical activity of peripheral sympathetic nerves
223390831|NCT05706584|OTHER|control grup (skills lab.) and experimental group (mateverse skill lab.)|The universe of the study consists of students (N: 190) who took a pediatric nursing course in the 3rd year of the Teaching Department at Istanbul Medipol University. The sample of the study will consist of the students who took the 3rd year child health and diseases nursing course in the nursing department, accepted the study, and met the study criteria. It will try to reach the universe where the sample selection of the research will not be made. With the simple randomization method, students will be assigned to the experimental and control groups. Even the last digit of the student number will be randomized to the experimental group and odd ones will be randomized to the control group
223390832|NCT04539912|DEVICE|angulated screw retained crown|ASC abutment was used in AG;
223390833|NCT04539912|DEVICE|cemented crown|prefabricated Ti abutment was used in CG
223390834|NCT05994885|PROCEDURE|Root surface debridement|the included patients will undergo full-mouth supra- and subgingival debridement by using ultrasonic device and manual instrumentation at baseline. This is followed, after 1 week, by performing root surface debridement for all pockets with PPD = 4-6 mm for each patient. All patients will be instructed to brush their teeth twice daily and will be supplied with the same type of tooth paste and toothbrush, with suitable interdental aids.
223390835|NCT00559533|DRUG|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
223546649|NCT00355355|DRUG|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
223546650|NCT00355355|DEVICE|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
223546651|NCT00355355|PROCEDURE|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
223546652|NCT00355355|PROCEDURE|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
223546653|NCT03578107|BEHAVIORAL|improvement of quality of stroke care|"1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams"
223546654|NCT01864265|DRUG|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
223546655|NCT01864265|DRUG|Placebo|Placebo will be administered according to the label of the biological
223546656|NCT03032419|BIOLOGICAL|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
223546657|NCT03032419|BIOLOGICAL|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
223546658|NCT03685058|DEVICE|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
223546659|NCT03685058|OTHER|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
223546660|NCT01927263|BIOLOGICAL|NI-071|100mg/vial
223546661|NCT01927263|BIOLOGICAL|Infliximab|100mg/vial
223546662|NCT02584712|OTHER|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
224011827|NCT05033171|DIAGNOSTIC_TEST|3D Scanning|3D scanning of the rod using Artec Eva Spider type manual 3D scanner
224011828|NCT05033171|DIAGNOSTIC_TEST|EOS 2D/3D scanning|EOS Micro Dose imaging will be done on the third day after surgery, on the third, the sixth, the twelfth and twenty fourth month after surgery.
223390836|NCT04366947|DEVICE|NIO® (Intraosseous access)|obtaining intravascular access using a ready intravenous NIO needle set
223390837|NCT04366947|DEVICE|Standard of Care (Intravenous access)|obtaining intravascular access using a standard intravenous cannula
223546663|NCT04981847|BEHAVIORAL|Dietary Intervention Meetings|Participants will attend classes once per week for 3 months.
224011829|NCT05884177|OTHER|Short-term cold exposure|Short-term cold exposure
223546664|NCT02692963|BIOLOGICAL|BCG vaccination|BCG vaccine InterVax
223546665|NCT03974126|OTHER|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
223546666|NCT03974126|OTHER|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
223546667|NCT01487486|DRUG|IVF Antagonist Protocol|"1. Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~2. Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle \>14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~3. hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
223564139|NCT03013387|PROCEDURE|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
223390838|NCT05955183|DRUG|AZD5055|AZD5055 will be given orally to randomized participants as per the arm they are assigned.
223546668|NCT05695040|BEHAVIORAL|"dietary workshop proteins"|"The workshop will have 2 objectives:~* Information of the importance of protein after bariatric surgery and the different sources of protein in the diet.~* Manipulation of a tool in the form of a real size and shape stomach (before and after surgery) that patients will be able to fill and manipulate in order to visualize the quantities needed to achieve the sensation of satiety."
223546669|NCT00515528|BIOLOGICAL|4-peptide melanoma vaccine|Experimental cancer vaccine given as a shot under the skin once every two weeks
223390839|NCT05955183|DRUG|Placebo|Placebo will be given orally to randomized participants as per the arm they are assigned.
223390840|NCT06551233|DRUG|9MW2821|Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
224011830|NCT03697317|BEHAVIORAL|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
223390841|NCT01358747|DRUG|BEACOPPesc|
223390842|NCT01358747|DRUG|BEACOPPesc - ABVD - PET2|
223546670|NCT00515528|DRUG|Ontak|A single dose of Ontak given as an intravenous infusion over 30 minutes, 4 days before the first vaccine is given.
223730437|NCT05353231|BEHAVIORAL|Mindful Disengagement from Thoughts Training (MDTT)|MDTT is designed to promote meta-awareness of moment-to-moment biased internal attention allocation (e.g. toward negative thoughts) and thereby internal attentional control. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Participants will first learn and practice a focused attention on the breath meditation. Then, participants will practice pressing a button each time they notice an inhalation or exhalation during the focused attention meditation. Next, during the meditation, participants will be presented the auditory neutral or negative simulated thought stimuli and will train internal attentional control by repeatedly disengaging their attention from these stimuli and back to their breath MDTT will thus entail 80 trials (40 negative, 40 neutral, ITI ≈ 10sec) during the focused attention on the breath meditation.
224011831|NCT03697317|BEHAVIORAL|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
224011832|NCT04718779|OTHER|Digital Engagement Application (GD App)|This is a chart review (prospective) data analysis study to describe the effect of the treatment change on the clinical parameters and patient reported outcomes (PROs) with the use of a digital engagement application (GD app) (to evaluate participants clinical engagement, shared decision making, emotional wellbeing, activities of daily living, goal attainment and Gaucher Disease specific measures).
224011833|NCT04718779|OTHER|No Intervention|This is a chart review (retrospective) data analysis study to describe the effect of the treatment change on the clinical parameters.
224011834|NCT06263127|BEHAVIORAL|oral stimulation|Prefeeding OS is a 5-minute oral sensorimotor intervention, containing peri- and intra-oral stimulation for 3 minutes and pacifier sucking for 2 minutes.
224011835|NCT06263127|BEHAVIORAL|infants massage|IM is a 15-minute intervention, involving 5-min manual stroking on the infant's head, neck, back, upper limbs, and lower limbs twice and 5-min gentle flexion and extension exercises on the infant's arms and legs.
224011836|NCT00741390|DEVICE|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
224011837|NCT00741390|DEVICE|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
224011838|NCT00741390|DEVICE|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
224011839|NCT00741390|DEVICE|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
224011840|NCT00741390|DEVICE|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
224011841|NCT04197739|DRUG|Amikacin|"Patients in the intervention arm will receive a fixed, single daily dose of amikacin, 500 mg, a day.~Patients in the Comparator arm will receive a weight adjusted loading dose of amikacin (15 mg/kg adjusted body weight) and continue in adjusted intervals according to the Barnes Jewish Hospital nomogram"
224011842|NCT00031798|DRUG|methylphenidate hydrochloride|
224127476|NCT04439370|DIAGNOSTIC_TEST|Baroreflex sensitivity testing|Two arms of the baroreflex that will be tested in this study are sympathetic and cardiovagal. Static baroreflex is tested during baseline resting conditions and dynamic baroreflex is tested during Valsalva maneuvers.
224127477|NCT04439370|DIAGNOSTIC_TEST|Sympathoexcitatory Maneuvers|Cold Pressor Test (CPT) and Upper extremity fatiguing contraction with post exercise circulatory occlusion (PECO) will be performed
224127478|NCT04439370|DIAGNOSTIC_TEST|Blood tests|Serum FSH, estrogen, progesterone, and testosterone will be measured
223390843|NCT02658760|DRUG|Dexmedetomidine|dexmedetomidine plus placebo
223546671|NCT04237181|DEVICE|Filmarray PCR multiplex-PCT assay|Filmarray PCR multiplex gastro intestinal panel on stools and serum PCT dosage
223546672|NCT00681395|DRUG|ABT-143|once daily for 6 days
223546673|NCT00681395|DRUG|ABT-335|once daily for six days
223546674|NCT00681395|DRUG|Rosuvastatin|Once daily for 6 days
224127479|NCT06637865|DRUG|IMP761|intravenous
224127480|NCT06637865|DRUG|Placebo|intravenous
223390844|NCT02658760|DRUG|Bupivacaine|dexmedetomidine and Bupivacaine
223390845|NCT00329082|DRUG|LY2062430|"1. 100mg QW IV for 12 weeks~2. 100mg Q4W IV for 12 weeks~3. 400mg QW IV for 12 weeks~4. 400mg Q4W IV for 12 weeks"
223390846|NCT00329082|DRUG|Placebo|5: Placebo QW IV for 12 weeks
223390847|NCT04141982|DIAGNOSTIC_TEST|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
223390848|NCT00003274|BIOLOGICAL|gp100 antigen|
223390849|NCT00003274|BIOLOGICAL|incomplete Freund's adjuvant|
223390850|NCT00003274|BIOLOGICAL|sargramostim|
223390851|NCT00003274|BIOLOGICAL|tyrosinase peptide|
223390852|NCT00934167|BIOLOGICAL|heparin sodium - Hipolabor|5.000 UI/0,25mL
223546675|NCT04264520|BEHAVIORAL|PTSD Psychoeducation + Skills Intervention|A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
223546676|NCT02326727|DRUG|Ropivacaine|Epidural analgesia
224011843|NCT00031798|PROCEDURE|quality-of-life assessment|
224011844|NCT00031798|RADIATION|radiation therapy|
224011845|NCT00701857|DRUG|cisplatin|Standard weekly dose
224011846|NCT00701857|DRUG|Pemetrexed|Biweekly pemetrexed dose escalation
223390853|NCT00934167|BIOLOGICAL|Heparin sodium - APP|5.000 USP/mL
223390854|NCT02792582|RADIATION|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
223390855|NCT02792582|PROCEDURE|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
224011847|NCT00701857|RADIATION|radiation therapy|Weekly standard dose radiation therapy
224011848|NCT04990011|PROCEDURE|BioXclude amnion chorion membrane|The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
224011849|NCT04642313|OTHER|Magnesium and/ or Potassium|Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia
224011850|NCT05901623|OTHER|'Ages and Stages Questionnaries' (ASQ)|''ASQ' is a screening tool for assessing the development of infants and preschoolers in the areas of communication, fine motor, gross motor, problem-solving and personal-social development, and 'ASQ:SE' is a screening tool for social-emotional development
224011851|NCT00620282|DRUG|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
224011852|NCT00620282|DRUG|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
224011853|NCT00620282|DRUG|glimepiride|Tablets, 1 - 4 mg daily
224127481|NCT06637865|OTHER|keyhole limpet haemocyanin (KLH)|intramuscular immunization and intradermal challenge
224127482|NCT05019456|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine (mRNA or J\&J)
224127483|NCT03406286|DRUG|Tolvaptan|
224127484|NCT06026254|DRUG|IMSA101|Intra-tumoral administration on Days 1 and 15 of every 28-day cycle
223390856|NCT00153972|DRUG|Cabergoline|
223390857|NCT00153972|DRUG|Levodopa|
223390858|NCT01042769|DRUG|Aleglitazar|aleglitazar 150 micrograms po daily
223390859|NCT01042769|DRUG|Placebo|placebo control po daily
223390860|NCT03855267|DRUG|Propofol 20 MG/ML|Pump propofol to keep bispectral index within 40 # 60
223390861|NCT03855267|DRUG|Propofol 20 mg/ml , etomidate 2 mg/ml|Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
223546677|NCT02326727|DRUG|Fentanyl|General Anesthesia
223546678|NCT02326727|DRUG|Propofol|General Anesthesia
223390862|NCT00828165|DRUG|ARRY-300, MEK inhibitor; oral|single dose, escalating
223390863|NCT00828165|DRUG|Placebo|matching placebo
223390864|NCT01207310|BEHAVIORAL|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
223390865|NCT01207310|DRUG|Nicotine patch|8 weeks' worth of nicotine patches
223390866|NCT01207310|DEVICE|alphanumeric pager|therapeutic messages to be delivered for three months
223390867|NCT05101343|BEHAVIORAL|Breathing meditation|Daily, 5-minute breathing meditation for one week.
223390868|NCT02046603|DRUG|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
223546679|NCT02326727|DRUG|Isoflurane|General Anesthesia
223546680|NCT02326727|DRUG|Nitrous Oxide|General Anesthesia
223564140|NCT03013387|DRUG|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
223564141|NCT01764477|DRUG|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
224011854|NCT00647933|DRUG|Org 36286|Subcutaneous Org 36286
224011855|NCT00647933|DRUG|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
224011856|NCT02942524|OTHER|Communication Intervention|Complete TEPID
224011857|NCT02942524|OTHER|Questionnaire Administration|Ancillary studies
224011858|NCT02942524|OTHER|Survey Administration|Ancillary studies
224011859|NCT02199223|DRUG|regorafenib + panitumumab|
224011860|NCT03501602|DEVICE|LMA protector|In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
224127485|NCT06026254|DRUG|Immune Checkpoint Inhibitor|Administered according to product label
224127486|NCT02352116|OTHER|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
224127487|NCT02352116|OTHER|Standard of care management|Current standard of care at a major U.S. teaching hospital.
224011861|NCT03501602|DEVICE|I-gel LMA|In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
223390869|NCT02046603|DRUG|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
223390870|NCT02046603|DRUG|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
223390871|NCT02046603|DRUG|Methotrexate|Methotrexate per investigator's discretion.
224011862|NCT04671966|DRUG|Estradiol patch|Brand name Climara for estrogen add back portion of study. Premenopausal women treated with a GnRH antagonist will be randomized to estrogen add-back or placebo. Thus, for women without contradictions to estrogen use, the risks associated with their use for the duration proposed in these studies (i.e., 6 days) are small. The respective estradiol regimen is a standard approved dose for treatment of hot flashes and the prevention of osteoporosis, and this dose will increase E2 to concentrations typically observed during the mid to late follicular phase of the menstrual cycle.
224011863|NCT04671966|DRUG|Cetrotide|Premenopausal women will be treated with the gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix for 6 days in order to suppress ovarian sex hormones. Cetrorelix may cause an anaphylactic reaction in volunteers with hypersensitivity to cetrorelix, GnRH or any other GnRH analogs, or extrinsic peptide hormones or mannitol. It may also cause hot flashes, headaches, and nausea. These are typically transient and of mild intensity. These effects are all reversible upon cessation of cetrorelix. Absence of pregnancy will be confirmed before drug administration.
223390872|NCT03447743|DRUG|XR-NTX community location|XR-NTX will be administered at the local health care clinic
223390873|NCT03062761|OTHER|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
224011864|NCT04671966|OTHER|Fasting|Subjects will abstain from food for 48 hours. Subjects will be allowed water and/or an isotonic saline solution in order to maintain hydration status.
224011865|NCT04671966|OTHER|Lower Body Negative Pressure|This test simulates Earth's gravity. The subject will rest on his/her back, with their lower body sealed in an air-tight chamber from the waist down. The chamber is connected to a vacuum that sucks air from the chamber and creates negative pressure inside and around the subject's lower body. As a result, the subject's blood pool shifts towards their legs, away from their chest and arms.
224011866|NCT01226342|DEVICE|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
224011867|NCT03718351|PROCEDURE|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
223390874|NCT03062761|OTHER|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
223390875|NCT02671747|BEHAVIORAL|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
223390876|NCT00325247|DRUG|ZINC|
223390877|NCT01323361|PROCEDURE|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
223390878|NCT02390882|DRUG|Placebo|Placebo
223390879|NCT02390882|DRUG|HGP0412 capsule|Tamsulon high dose
223390880|NCT02390882|DRUG|HIP1402 capsule|Tamsulon high dose
223390881|NCT00714194|PROCEDURE|Normal continuous sedation|Normal continuous sedation.
223390882|NCT00714194|OTHER|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
223390883|NCT02065076|DRUG|Sodium polystyrene sulfonate|
223390884|NCT02065076|DRUG|Lactose with carob gum|
223390885|NCT04997863|DEVICE|Sericin hydrogel sheet impregnated with EBN extract|Sericin hydrogel sheet impregnated with EBN extract will be used as a primary dressing for preventing scar development at one-half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
223390886|NCT04997863|DEVICE|Placebo hydrogel sheet|Placebo hydrogel sheet will be used as a primary dressing for preventing scar development at another half of the STSG donor site. Then, the donor site will be covered with adhesive tape (secondary dressing). The application of primary and secondary dressings will be done once daily after shower in the morning or evening. Both dressings will be recommended to wear over the donor site for 8-12 hours per day. Patients will be advised to remove both dressings before shower to clean the donor site and the surrounding skin, and then replace them with new wound dressing sheets in the next day. The duration of the dressing application will be 6 months.
224011868|NCT03718351|PROCEDURE|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
224011869|NCT01044017|DRUG|Placebo|single oral dose
223546681|NCT03940079|DEVICE|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
223546682|NCT01152788|DRUG|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
223546683|NCT01152788|DRUG|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
223546684|NCT02957513|BEHAVIORAL|Text Messaging (TM)|As specified in the arm description above
223546685|NCT02957513|BEHAVIORAL|Health Coaching (HC)|As specified in the arm description above
223546686|NCT02957513|BEHAVIORAL|Enhanced Usual Care (EC)|As specified in the arm description above
223546687|NCT01984047|DRUG|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
223546688|NCT01984047|DRUG|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
223546689|NCT06121648|OTHER|hydrotherapy|30 degrees temperature pool balance and breathing therapy
223390887|NCT01949402|OTHER|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
223390888|NCT01949402|OTHER|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
223390889|NCT01949402|OTHER|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
223390890|NCT01949402|OTHER|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
223390891|NCT00193050|DRUG|Gemcitabine|Gemcitabine
223390892|NCT00193050|DRUG|Epirubicin|Epirubicin
223390893|NCT00193050|DRUG|Docetaxel|Docetaxel
223390894|NCT00712790|DRUG|Sorafenib|Tablet, 400mg orally, twice daily
223390895|NCT00712790|RADIATION|SIR-Spheres|one time treatment and capped at 3.0 Gbq
223390896|NCT01705379|BIOLOGICAL|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
223390897|NCT01373138|DRUG|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
223390898|NCT00121537|DEVICE|Wound Care -Wound Vacuum Assisted Closure (VAC)|
223390899|NCT00121537|PROCEDURE|Wound Care - Wet to Dry Dressing Changes|
223390900|NCT00061932|DRUG|bortezomib|Given IV
223390901|NCT00061932|DRUG|irinotecan|Given IV
223546690|NCT06121648|OTHER|neurological physiotherapy|Balance and neurological physiotherapy on land
223546691|NCT05156411|OTHER|eccentric arm-cranking training|Over the twenty training sessions, able-bodied participants will exercise on the KREHA device. An arm-crank has to be decelerated, which will be rotated by a prematurely defined revolution rate and training duration. During this intervention a certain power has to be applied. During the whole time of training a continous progression in power and training duration is applied
223546692|NCT04651205|DIETARY_SUPPLEMENT|vitamin B1 and magnesium supplements|vitamin B1 - 100 mg/day magnesium - 400 mg/day
223546693|NCT01282866|DEVICE|LightSheer Duet|LightSheer Duet HS handpiece
223546694|NCT00841061|DIETARY_SUPPLEMENT|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
224011870|NCT01044017|DRUG|RO4998452|single oral doses
224011871|NCT02141022|OTHER|plasticity-based computerized cognitive remediation program|
224011872|NCT02141022|DRUG|Gileyna|
223546695|NCT00841061|DIETARY_SUPPLEMENT|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
223546696|NCT03894696|DRUG|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
224011873|NCT05084170|PROCEDURE|Bilateral anterior cingulotomy|Stereotactic bilateral anterior cingulotomy is a brain operation with demonstrated efficacy in the treatment of intractable pain from a variety of causes, including a few cases of spinal cord injury related neuropathic pain.
224011874|NCT00412152|DRUG|Oxycodone nalaxone prolonged release tablets (OXN)|
224011875|NCT05423990|DIAGNOSTIC_TEST|Video-Electroencephalography|Three types of video EEG monitoring equipment produced by Nicolet, Bio-logic and Nihon Kohden were used to collect data in the multi-center. The 19-lead recording electrode was placed according to the international 10-20 system, and the average lead was used. The recording time was 24h. All patients underwent eyes open and closed test, intermittent photic stimulation and hyperventilation induction test.
223390902|NCT00886509|BIOLOGICAL|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
223390903|NCT00886509|OTHER|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
223390904|NCT05880511|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
223390905|NCT05880511|DEVICE|Augmented Reality Sensorimotor Training|Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
223390906|NCT05880511|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
223390907|NCT04902937|RADIATION|Adjuvant radiotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
223390908|NCT04902937|DRUG|neoadjuvant and adjuvant chemotherapy|Guideline-based therapy of primary non-metastatic early breast carcinoma
223390909|NCT03930537|DEVICE|Hip replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
223390910|NCT02732873|DEVICE|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
223390911|NCT03567980|DRUG|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
223390912|NCT05999214|DIAGNOSTIC_TEST|99mTc-H7ND SPECT/CT imaging performed|99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT discussion results.
223390913|NCT01398046|DRUG|Dasatinib|dasatinib (100mg) PO x1
223390914|NCT01398046|DRUG|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
223546697|NCT03235193|OTHER|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
224127488|NCT04281030|BEHAVIORAL|PMR (Progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension. The relaxation therapy should take about 20 minutes a day.
224127489|NCT04281030|BEHAVIORAL|Monitored Usual Care (MUC)|Subjects will be given basic migraine information such as evidence-based ways to treat migraine: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
224127490|NCT03442894|PROCEDURE|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
224296438|NCT00608192|BEHAVIORAL|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
223390915|NCT01398046|DRUG|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
223390916|NCT03700502|DIAGNOSTIC_TEST|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
223390917|NCT00580502|DEVICE|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m\^2
223390918|NCT05115175|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants engaged in meditation and self-led exercises to help them understand and cope with stress.
223390919|NCT03093259|DRUG|ABX464|ABX464 is a new Anti-inflammatory drug
223390920|NCT03093259|DRUG|Placebo oral capsule|Placebo matching with ABX464
223390921|NCT02575833|DRUG|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
223390922|NCT02575833|DRUG|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
223546698|NCT03235193|OTHER|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
224011876|NCT06441370|PROCEDURE|waterbirth|waterbirth: laboured for all or part of the first stage of labour and remained in the water for birth of newborn
223390923|NCT01456806|OTHER|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
223390924|NCT03352687|PROCEDURE|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
223390925|NCT03352687|PROCEDURE|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
223390926|NCT04881786|DEVICE|Orthodontic forces|56g force and 224g force
223390927|NCT03537131|DRUG|Dapagliflozin 10 MG Oral Tablet|taken once a day
223390928|NCT06751758|OTHER|C1-C2 Mobilization|Participants in both Group A and Group B will receive manual mobilization targeting the C1-C2 region. This specific mobilization technique is chosen for its potential to improve joint mobility and alleviate stiffness in the upper cervical spine. The mobilization will be performed by trained physiotherapists to ensure precision and safety.
223390929|NCT06751758|OTHER|Transcutaneous Electrical Nerve Stimulation (TENS)|Following C1-C2 mobilization, each participant will undergo a 20-minute session of TENS. TENS involves the application of low-voltage electrical currents through electrodes placed on the skin. This modality aims to modulate pain perception by stimulating nerve fibers, leading to the release of endorphins - the body's natural painkillers. The 20-minute duration is chosen based on established guidelines for effective TENS application.
223390930|NCT06751758|OTHER|Suboccipital Distraction|"Suboccipital distraction is a manual technique aimed at relieving tension in the upper cervical spine. This intervention involves the gentle separation of the suboccipital muscles and associated structures, promoting relaxation and reducing pain. The technique is intended to enhance the range of motion in the cervical region by targeting the upper cervical structures.~Procedure:~5-7 repetitions of intermittent distraction 20-30 seconds on, 10-15 seconds off~Administration:~Suboccipital distraction will be performed by skilled physiotherapists trained in this technique. Close monitoring will ensure correct application and participant safety."
223390931|NCT06751758|OTHER|Traction|"Traction is a therapeutic technique that involves applying a controlled, manual force to stretch and mobilize the cervical spine. The primary goal of this intervention is to reduce compression on the cervical structures, alleviate pain, and improve the range of motion. It is typically used for its potential to decompress the spine and relieve pressure on nerves.~Procedure:~Traction will be administered manually by trained physiotherapists, who will ensure that the correct amount of force is applied and that the treatment is both safe and effective. The application will be carefully tailored to the individual's needs.~Administration:~Participants will undergo traction treatments with close monitoring throughout the study period, allowing for necessary adjustments to the treatment plan based on individual responses."
223390932|NCT00445146|DRUG|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
223390933|NCT00445146|DRUG|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
223390934|NCT00445146|DRUG|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
223390935|NCT00625820|DRUG|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
223390936|NCT00625820|DIETARY_SUPPLEMENT|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
223390937|NCT02309307|DEVICE|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
223390938|NCT05717660|COMBINATION_PRODUCT|SBRT on all sites of metastatic disease+Apalutamide|oral Apalutamide 240 mg daily+ stereotactic body radiotherapy on all metastatic sites of disease, administered in 1-8 fractions for a total EQD2 of 50 Gy with an alpha/beta of 10.
223390939|NCT00115414|DRUG|pegfilgrastim|
223390940|NCT00115414|DRUG|docetaxel|
223390941|NCT00115414|DRUG|doxorubicin|
223390942|NCT00115414|DRUG|cyclophosphamide|
223390943|NCT04565574|DRUG|E7090|Oral tablet.
223390944|NCT04565574|DRUG|Rabeprazole 20 mg|Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
223390945|NCT04565574|DRUG|Rifampin 600 mg|Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
223390946|NCT00967330|DRUG|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
223390947|NCT00967330|DRUG|irinotecan|125mg/m2 iv every 2 weeks
223390948|NCT00967330|DRUG|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
223390949|NCT03759392|DRUG|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
223390950|NCT03759392|DRUG|Placebo|Oral placebo twice daily for up to 20 weeks
223546699|NCT02985177|DRUG|INF2.0 + IBU|Analgesics
223546700|NCT02985177|DRUG|INF1.0 + IBU|Analgesics
223546701|NCT03853967|OTHER|Low dose CT scan|low dose CT scan
223546702|NCT01405703|OTHER|xrays|xrays from 2 week postop to 5 year postop
223546703|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 single dose + paracetamol|Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol
223546704|NCT04536051|BIOLOGICAL|MenACWY single dose + paracetamol|Single dose of MenACWY + paracetamol
223546705|NCT04536051|BIOLOGICAL|ChAdOx1 nCoV-19 two dose + paracetamol|Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol
224011877|NCT01258595|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
224011878|NCT01258595|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
224011879|NCT02703259|DRUG|Gabapentin|
224011880|NCT02703259|DRUG|Acetaminophen|
224011881|NCT02703259|DRUG|Celecoxib|
224011882|NCT02682277|DEVICE|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
224011883|NCT02682277|OTHER|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
223390951|NCT02623725|BIOLOGICAL|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
224011884|NCT02643043|OTHER|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
224296439|NCT00608192|BEHAVIORAL|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
223390952|NCT02623725|BIOLOGICAL|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
223390953|NCT01243957|DRUG|LY2216684|LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
223390954|NCT01243957|DRUG|Fluoxetine|Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
223390955|NCT02814344|DEVICE|Electrohysterography|
223390956|NCT03573622|DRUG|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
223390957|NCT03573622|DRUG|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
223390958|NCT03902665|DRUG|Up-front allogeneic hematopoietic stem cell transplantation (HSCT)|"Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only."
223390959|NCT04183621|DIAGNOSTIC_TEST|high resolution impedance manometry|Two detailed swallow assessments to be carried out at between 2-4 months and 8-10 months of age
223390960|NCT03286153|OTHER|Ideal Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: \[50kg + (2.3kg\*every inch over 5 feet)\].
223390961|NCT03286153|OTHER|Actual Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
223390962|NCT00286104|DEVICE|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
223390963|NCT00286104|DEVICE|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
223390964|NCT02046044|DRUG|Digoxin|
223390965|NCT02046044|DRUG|Ivabradine|
223390966|NCT02120638|DRUG|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
223390967|NCT02120638|DRUG|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, \>70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, \>50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
223390968|NCT00542633|DRUG|VIAject™|Dosage as individually required
223390969|NCT00542633|DRUG|Regular Human Insulin|Dosage as individually required
223390970|NCT01237119|DRUG|Liraglutide|1.8 mg once daily, subcutaneous injection
223390971|NCT01237119|OTHER|Liraglutide-placebo|1.8 mg once-daily, subcutaneous injection
224296440|NCT00072072|DRUG|celecoxib|
223390972|NCT02284477|OTHER|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
223390973|NCT02284477|OTHER|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
223390974|NCT06071624|BIOLOGICAL|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
223390975|NCT04522440|OTHER|to relieve the pain of inpatients in the hospice Ward|This study will use pain scale, distress thermometer and POMS to understand whether the patient's pain status have changed.
223390976|NCT01780701|PROCEDURE|Magnetic Resonance Spectroscopy Imaging with rectal probe|
223390977|NCT00238017|DRUG|amodiaquine-artesunate versus amodiaquine|
223390978|NCT04385017|OTHER|COVID-19 patients|It will consist in the collection of 2 additional tubes at their blood draw. For DNA analysis, informed consent will be collected in writing
223390979|NCT00471679|DRUG|ethanol|
223390980|NCT06033937|DEVICE|PFO occlusion|Patients in PFO occlusion group received PFO closure using devices.
223390981|NCT05393167|DEVICE|Echo_CT_MRI_US_x ray|Examination: General and systemic examinations of the studied neonates. Investigation will be done to the neonates according to the clinical examination including imaging studies as X-rays, U/S, echocardiography, CT and MRI studies
223390982|NCT06772233|DRUG|regorafenib combined with envafolimab|"-Regorafenib: Specification: 40 mg/tablet Dosage: 120 mg, taken orally once daily for 3 weeks, followed by 1 week off, until disease progression or intolerable toxicity occurs.~* Envafolimab:~Specification: 200 mg/vial Dosage: 200 mg, administered via subcutaneous injection once every 2 weeks, until disease progression or intolerable toxicity occurs."
223546706|NCT04536051|BIOLOGICAL|MenACWY prime & saline placebo boost + paracetamol|MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol
223546707|NCT03125330|BEHAVIORAL|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
223390983|NCT06772233|DRUG|Control Group|The governing principle for physician decision-making in the control group was selection based on prior medication tolerability, genotype, etc.: a. Continued maintenance therapy with the originally effective TKI at the same dose: The patient achieved at least stable disease (SD) or partial response (PR) during prior treatment, with progression-free survival (PFS) exceeding 6 months, and the adverse reactions were tolerable. b. Combination therapy with two TKIs: Different drugs were selected for maintenance based on distinct actionable mutations identified in the patient's tissue or peripheral blood genetic testing, OR a combination of drugs previously effective and well-tolerated was used, OR the combination therapy was chosen by referencing past tolerability.
223390984|NCT01509274|BIOLOGICAL|Plasma|3 ml plasma injected once into the plantar fascia
223546708|NCT03765580|DIETARY_SUPPLEMENT|Fish|Lunch containing fish
223546709|NCT03765580|OTHER|Control|Lunch containing no fish
223546710|NCT03011112|PROCEDURE|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
223546711|NCT01144325|PROCEDURE|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
224011885|NCT02338180|OTHER|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
224011886|NCT02338180|OTHER|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
223546712|NCT01934907|OTHER|Washing of packed RBC by normal saline|
223546713|NCT04003844|DRUG|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
223546714|NCT04003844|DRUG|Acetylsalicylic acid|Coadministration
223546715|NCT06156852|OTHER|Mindfulness-based stress reduction group|Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
223546716|NCT06156852|OTHER|Cognitive behavioral-based stress reduction group|Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
223546717|NCT04684576|DEVICE|Permobil Explorer Mini|The use of powered mobility devices for young children with cerebral palsy is increasingly recommended. The Permobil Explorer Mini is a new pediatric powered wheelchair that has been cleared by the FDA. The Explorer Mini will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
224011887|NCT01763515|PROCEDURE|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
224011888|NCT06049992|DEVICE|Pacemaker implantation with conduction system pacing using Lumenless leads|Pacemaker implantation for conduction system pacing will be done using leads without internal lumen (Lumenless; Medtronic Selectsecure 3830, Minneapolis, USA).
224011889|NCT06049992|DEVICE|Pacemaker implantation with conduction system pacing using Stylet-driven leads|Pacemaker implantation for conduction system pacing will be done using leads with internal lumen and retractable helix (Tendril STS 2088TC, Abbott, Inc., USA; Solia S60, Biotronik, SE \& Co., KG, Germany; Ingevity +, Boston Scientific, Marlborough, MA, USA)
223546718|NCT04684576|DEVICE|Modified Ride-On Car|Access to commercial powered mobility devices is often limited by funding or size. Many families use toy ride-on cars for early mobility, which can be easily adapted for safety and accessibility. The modified ride-on car will be provided for 8-weeks, and families will be provided with suggested use frequencies and provided with support for implementing the device intervention with their child.
224011890|NCT04701359|DEVICE|TiN-alloy based total knee arthroplasty|TiN-alloy based TKA implanted for knee osteoarthritis.
224296441|NCT00072072|DRUG|erlotinib hydrochloride|
224296442|NCT06394674|DRUG|Furmonertinib|Drug: Furmonertinib
223546719|NCT03502915|DRUG|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
223546720|NCT03502915|OTHER|Placebo|100% oxygen via Nitronox delivery device
223546721|NCT02638467|DRUG|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
224011891|NCT04701359|DEVICE|CoCr-coating based total knee arthroplasty|CoCr-coating based TKA implanted for knee osteoarthritis.
224011892|NCT03451682|DIETARY_SUPPLEMENT|procyanidine|Natural antioxidant
224296443|NCT04542265|COMBINATION_PRODUCT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
224296444|NCT03016221|OTHER|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
224296445|NCT03016221|OTHER|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
223390985|NCT01509274|BIOLOGICAL|Saline|3 ml of saline injected once into the plantar fascia
223390986|NCT01509274|OTHER|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
224011893|NCT02666859|DEVICE|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
223390987|NCT00619723|DRUG|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
223546722|NCT02638467|PROCEDURE|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant \> 3 x 106 CD34+ cells/kg BW recipient from bone marrow or \> 3 x 108 nucleated cells/kg BW recipient from bone marrow"
223546723|NCT02638467|DRUG|Bone Marrow cells|
223546724|NCT03073863|DRUG|Atorvastatin|Analysis
223546725|NCT01504516|DRUG|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
223546726|NCT01504516|DRUG|Aricept|Aricept 10 mg Tablets
223546727|NCT05730946|DIAGNOSTIC_TEST|Interview- based questionnaire|Interview-based questionnaire by the use of an interview guide to explore and understand the Challenges faced in the past and the concerns for the future experienced by parents of CLP patients.
224011894|NCT00002003|DRUG|Mitoxantrone hydrochloride|
224011895|NCT00002003|DRUG|Etoposide|
224011896|NCT02311231|DRUG|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
224127491|NCT03442894|PROCEDURE|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
223390988|NCT00619723|DRUG|Placebo|Inactive ingredient matching the active medication in appearance.
223390989|NCT00619723|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
223390990|NCT02795247|PROCEDURE|Anterior Cruciate Ligament Reconstruction|
223546728|NCT01964378|DRUG|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
223546729|NCT01964378|DRUG|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
223546730|NCT01611740|PROCEDURE|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~* the variability of the cardiac cycle duration ;~* the variability of respiratory cycle amplitude and duration ;~* and their relationships."
223546731|NCT00384215|DRUG|insulin glargine [rDNA origin] injection|
223546732|NCT01587248|DEVICE|Harmonic|Dissection with harmonic scalpel
223546733|NCT01587248|PROCEDURE|electrocautery|Dissection in modified radical mastectomy
223546734|NCT03242226|DEVICE|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
223546735|NCT03242226|DEVICE|single vision spectacles|Wear single vision spectacle only
223546736|NCT04625400|DIAGNOSTIC_TEST|bronchoscope|Bronchoscopy in Assessment of Patients With Post-intubation Tracheal Stenosis.
223546737|NCT05710250|BEHAVIORAL|6-week MBSR program|"Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
223564142|NCT06080893|DRUG|Ferric carboxymaltose|"FCM can be administered in a short IV infusion of 15-20 minutes, allowing doses of 2 g in a single session, and furthermore, FCM is excellently tolerated and safe for patients.~FCM will be administered intravenously at preop 24th hour according to weight and preop hgb level"
223564143|NCT05807854|PROCEDURE|Arthroscopy|The surgeon reattaches the torn tendon to the bone with anchors and sutures.
223564144|NCT05807854|DEVICE|Reverse Shoulder Arthroplasty|It consists in replacing the shoulder joint with a total shoulder prosthesis (reverse design).
223564145|NCT06501092|DEVICE|Point Mini|Patient is fit with the Point Mini finger prosthetic system, which consists of 1-4 ratcheting mechanical digits and mounting brackets
223564146|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
223564147|NCT03525600|DRUG|APL-2|Complement (C3) Inhibitor
224011897|NCT02311231|DRUG|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
223390991|NCT07096245|BEHAVIORAL|Vaccine Information Video Dissemination|"The intervention is a brief, community-informed educational video (2-3 minutes) focused on seasonal flu and COVID-19 vaccination. The video was developed using human-centered design and community-based participatory methods with Indigenous community members in California. It aims to promote trust in vaccines by presenting clear, culturally relevant health information.~The video is disseminated using three behavioral delivery strategies: (1) paid advertisements on Facebook and Instagram targeting adults in California, (2) peer-to-peer sharing by participants who previously enrolled in the study and are invited to serve as seeds who share the video with their personal contacts, and (3) distribution by trusted community-based organizations (CBOs) using their existing communication networks, including WhatsApp, social media, email, and newsletters. All viewers are prompted to complete a one-question trust poll and invited to participate in an optional anonymous survey on vaccine attitud"
223390992|NCT07097454|DEVICE|Hypotension Prediction Index Monitoring|HPI monitoring is performed using the Edwards Lifesciences HemoSphere platform to provide real-time hypotension prediction based on arterial pressure waveform analysis. Interventions such as fluid bolus or vasopressor are administered per protocol when HPI ≥ 85.
223390993|NCT07097454|OTHER|Standard PACU Monitoring|Standard monitoring in the post-anesthesia care unit (PACU), including non-invasive blood pressure, heart rate, and oxygen saturation measurements. No Hypotension Prediction Index (HPI) monitoring is used. Interventions are performed according to routine institutional practices.
223390994|NCT03649048|DRUG|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
223390995|NCT03649048|DRUG|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
223390996|NCT03649048|RADIATION|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
224011898|NCT02615002|DRUG|Piromelatine|
224011899|NCT02615002|DRUG|Placebo|
224011900|NCT06352684|DEVICE|CadAI-B for Breast|CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations.
224011901|NCT01170104|DRUG|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
224011902|NCT01170104|PROCEDURE|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
224011903|NCT04738292|DRUG|Onapristone|Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
224011904|NCT04738292|DRUG|Fulvestrant|Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
224127492|NCT03442894|PROCEDURE|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
224127493|NCT05421832|DEVICE|Digital Speech Application|A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
223390997|NCT06792084|BEHAVIORAL|motivational interviewing|Motivational interviewing is a directive and client-centered approach used to elicit behavioral change by helping the client explore and resolve ambivalence. Motivational interviewing is a specific method of helping individuals understand their problems and take action for change. In this study, the motivational interview program created in line with the literature (Li et al, 2023; Miller and Rollnick, 2013; Çelik Örücü, 2020) consists of 5 sessions in total, one session per week. There are specific goals and objectives for each session.
223390998|NCT06788340|DRUG|PK-model to decide when to dose Vedolizumab and Ustekinumab|the pharmacokinetic model will include information about inflammatory parameters both in blood- and fecal samples, as well as weight, sex, previous treatments and drug concentration.
223390999|NCT06496139|BEHAVIORAL|Therapist-guided internet-delivered cognitive behavioural therapy|The intervention consists of 8 weeks of therapist-guided self-help ICBT.
223391000|NCT06438185|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.
223391001|NCT04639986|DRUG|Sacituzumab Govitecan-hziy|Sacituzumab govitecan 10 mg/kg via IV injection administered on Days 1 and 8 of a 21-day cycle. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
223391002|NCT04639986|DRUG|Eribulin Mesylate Injection|Eribulin is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
224011905|NCT01548534|DIETARY_SUPPLEMENT|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
223391003|NCT04639986|DRUG|Capecitabine Oral Product|Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
223391004|NCT04639986|DRUG|Gemcitabine Injection|Gemcitabine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
223391005|NCT04639986|DRUG|Vinorelbine injection|Vinorelbine is administered by intravenous (IV) following recommended doses and regimens as per approved package inserts.
223391006|NCT06583655|RADIATION|SLND(clinical low risk)|treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT
223391007|NCT06583655|RADIATION|SLND(clinical high risk, genomic low risk)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
224127494|NCT04813653|DRUG|cyclosporine in combination with carfilzomib and dexamethasone|patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
224127495|NCT05217693|DRUG|BB-1705|BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
223391008|NCT06583655|RADIATION|SLND alone ,clinical high risk and genomic high risk group|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
223391009|NCT06583655|RADIATION|Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)|treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
224127496|NCT01284322|DRUG|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
223391010|NCT02848001|DRUG|CC-90009|CC-90009
223391011|NCT02338648|DRUG|SUN-131 1.5% TDS|Active transdermal patch
223391012|NCT02338648|DRUG|Placebo TDS|Placebo transdermal patch for blinding
223391013|NCT01195896|DEVICE|New NPWT system|According clinical routine (Instruction for Use)
223391014|NCT05659199|DEVICE|extracorporeal shockwave|Patients will be treated with extracorporeal shockwave therapy (ESWT) with bladder lithotomy position, twice a week for 4 weeks, 3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3Hz each time. Extracorporeal shockwave (RUIDI.SWT001, Shenzhen, China) can provide a kind of physical spark wave energy, that will be delivered by the probe. The water sac probe will be moved slowly over the groin, perineum and crura of the penis.
223391015|NCT05659199|BEHAVIORAL|myofascial release|pressure was applied at 1 kg/cm2 (within the patient's tolerable range depending on the individual) to the points where patients had a VAS pain score of 4 or more during palpation. Intermittent pressure will be applied for 180-210s at the tenderness until the muscle relaxed.
223391016|NCT01410097|BEHAVIORAL|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
223391017|NCT01410097|BEHAVIORAL|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
223391018|NCT06379048|PROCEDURE|Mattress Suturing|Horizontal mattress suture in interrupted fashion
223391019|NCT06379048|PROCEDURE|Primary Suturing|Horizontal primary suture in interrupted fashion
223391020|NCT06379048|PROCEDURE|Continuous Subcutaneous Suturing|Subcutaneous suture in continuous fashion
223391021|NCT00652054|DRUG|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
223391022|NCT01668745|BIOLOGICAL|Early measles vaccine|
223546738|NCT05710250|BEHAVIORAL|6-week muscular relaxation program|"Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily)."
224011906|NCT01548534|DIETARY_SUPPLEMENT|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
224011907|NCT02948673|DIETARY_SUPPLEMENT|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
223391023|NCT00908570|DRUG|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
223391024|NCT00908570|DRUG|Placebo|Placebo cream
223391025|NCT02471729|DEVICE|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
223391026|NCT06544200|DEVICE|Polymeric Hydrogel Matrix|application of Polymeric Hydrogel Matrix along the suture line at the completion of lung resection
223391027|NCT00000914|DRUG|Indinavir sulfate|
223391028|NCT00000914|DRUG|Ritonavir|
223391029|NCT00000914|DRUG|Nelfinavir mesylate|
223391030|NCT00000914|DRUG|Efavirenz|
223391031|NCT05252299|OTHER|Rolling Fresher Group|The use of telemedicine to provide remote CSS installation instruction via audio and visual input by a Certified child passenger safety technician (CPST)
223546739|NCT06170567|OTHER|The effect of puzzles on students' course success|The effect of puzzles on students' course success
223546740|NCT02253043|DEVICE|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
223546741|NCT01796288|RADIATION|simultaneous radiotherapy|
224011908|NCT02948673|OTHER|Placebo|4 oral placebo tablets for 4 weeks
224011909|NCT03293004|DIETARY_SUPPLEMENT|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
224011910|NCT03293004|DIETARY_SUPPLEMENT|Vitamin C|Escalating dose of Vitamin C
224011911|NCT03293004|DIETARY_SUPPLEMENT|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
224011912|NCT03293004|DIETARY_SUPPLEMENT|Gummy Placebo|Gummy placebo
224011913|NCT05769712|DIAGNOSTIC_TEST|Shear wave ultrasonic imaging|Shear wave ultrasonic imaging technique was used to measure the superficial and deep shear wave velocity of supraspinatus tendon at 10mm (distal end) and 15mm (proximal end) from the attachment end of the greater tubercle of the humerus on the long axis section of supraspinatus tendon.
223391032|NCT06578299|DRUG|Inetetamab and Paclitaxel ± Pertuzumab|"Inetetamab and Paclitaxel ± Pertuzumab Inetetamab：was administered as an intravenous (IV) loading dose of 8mg/kg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 6mg/kg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously on the first day of every three weeks, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.~Pertuzumab：was administered as an intravenous (IV) loading dose of 840mg q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420mg q3w on Day 1 of subsequent cycles, until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination."
223391033|NCT02289599|DRUG|E2307|
223391034|NCT02289599|DRUG|E2307 Matching Placebo|
223546742|NCT01796288|DRUG|Erlotinib|
223546743|NCT02765048|BEHAVIORAL|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
223546744|NCT01642446|PROCEDURE|Precise hepatectomy|Precise hepatectomy
223546745|NCT01642446|OTHER|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
223546746|NCT01569815|DRUG|LCZ696|LCZ696 400 mg once daily
223546747|NCT02469220|DIETARY_SUPPLEMENT|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
223546748|NCT02469220|DIETARY_SUPPLEMENT|Standardized FODMAP|Blinded food supplements containing FODMAPs
223546749|NCT05364710|DIETARY_SUPPLEMENT|Transfer factor from colostrum ultrafiltrate|Proteins that confer immune protection, isolated from cow colostrum ultrafiltrate and used to promote immune health and surveillance.
223546750|NCT03949868|BEHAVIORAL|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
223730438|NCT05353231|BEHAVIORAL|Placebo-Control|The condition is designed as a placebo control for the Attention Feedback Awareness and Control Training (A-FACT) training condition. Participants will be instructed that they will complete a task designed to reduce their attentional bias to some thoughts. Rather than the quantity categorization task with trial-level feedback, participants only engage in the quantity categorization task. The task is identical in all other ways to the A-FACT condition. Participants will complete approximately 100 trials in total wherein randomly 1 or 2 neutral trials follow each negative trial.
224011914|NCT03097081|OTHER|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
224011915|NCT03097081|DEVICE|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
224011916|NCT02850510|BEHAVIORAL|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
224011917|NCT01556191|DRUG|Gefitinib|250 mg per day (oral)
224011918|NCT01556191|DRUG|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
224011919|NCT01556191|DRUG|Erlotinib|150 mg per day (oral)
224011920|NCT03618043|DRUG|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
224296446|NCT03016221|OTHER|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
224296447|NCT03016221|OTHER|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
224296448|NCT03016221|OTHER|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
224011921|NCT05308797|PROCEDURE|ESP block|Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
224011922|NCT05308797|PROCEDURE|CASP block|Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
224011923|NCT03122223|BIOLOGICAL|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
224011924|NCT03122223|BIOLOGICAL|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
224011925|NCT03122223|BIOLOGICAL|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
224011926|NCT03122223|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
223391035|NCT05906108|BEHAVIORAL|Self-initiated learning|A WeChat Subscription will be created for delivering the intervention. The educational materials involving introduction to internet addiction, the impact of internet addiction and strategies in coping with IA will be posted to the account at the beginning of the intervention. The materials will be prepared in different format including text and video followed by 3 to 5 multiple choice questions (MCQs), and one post for one topic. Relevant materials can be found by typing the keywords in the account or searching under the content list. Participants will be required to follow the account to study the materials at their own pace and complete the MCQs. There will be no limited access to the materials and attempts for MCQs.
224011927|NCT03950843|DRUG|CKD-825|"* Dosage Form: capsule~* Dosage: 3 types(low/medium/high dose)~* Frequency: QD(once daily) administration"
223391036|NCT05906108|BEHAVIORAL|Personalized and interactive behavioural support|The intervention group will receive 3-month personalized and interactive behavioural support via WeChat, which including regular messages and real-time conversation. The regular messages will cover the generic information about abstinence support, health warnings, benefits of reducing internet time, knowledge reinforcement, goal setting, encouragement and reminders for self-initiated online learning. The messages will be personalised according to baseline demographic characteristics and internet addiction level, and continually adapted to any change in internet behaviours change reported by subjects during the conversations. A total of 19 messages with a tapering schedule. Personalized real-time conversation via WeChat will be available based on participants' demand.
223391037|NCT05906108|BEHAVIORAL|General health information|Participants in control group will receive WeChat messages on general health information (similar frequency as the intervention group) and reminders on follow-up surveys via WeChat. Various topics will be involved in the general health information such as healthy diet, sleep management, exercise and mood management.
223391038|NCT01511042|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
223391039|NCT01511042|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
223391040|NCT01511042|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
223391041|NCT01473914|DIETARY_SUPPLEMENT|Low dose: supplemental zinc, selenium and vitamin E|"1. ZINC 25mg (AS ZINC SULFATE)~2. SELENIUM 50 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
223391042|NCT01473914|DIETARY_SUPPLEMENT|Standard renal vitamin: B and C renal vitamin|"1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)"
223391043|NCT01473914|DIETARY_SUPPLEMENT|Medium dose: supplemental zinc, selenium and vitamin E|"1. ZINC 50 mg (AS ZINC SULFATE)~2. SELENIUM 75 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
223391044|NCT00711243|DRUG|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
223391045|NCT00711243|DRUG|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
223391046|NCT00711243|DRUG|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
223391047|NCT00982787|DRUG|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
223391048|NCT04776629|DRUG|Orticumab|A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
223391049|NCT04776629|DRUG|Placebo|Placebo for orticumab, containing all components of formulation except the active ingredient
223391050|NCT03765489|DEVICE|electrical muscle stimulation|electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction
223391051|NCT03765489|PROCEDURE|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
223391052|NCT02661880|BEHAVIORAL|preferred music|listening to preferred music choices
223391053|NCT02571478|BEHAVIORAL|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
223564148|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every month
223564149|NCT03525600|OTHER|Sham Procedure|Subjects will receive a Sham procedure every other month
223564150|NCT01195376|DRUG|BEZ235|
223564151|NCT04823455|PROCEDURE|fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion|Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
223564152|NCT02117960|DIETARY_SUPPLEMENT|Omega-3|4 cap 1 g Omega-3 per day for 2 months
224011928|NCT03950843|DRUG|Placebo oral capsule|"Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration"
224011929|NCT01834872|DEVICE|Amigo|
224011930|NCT01834872|DEVICE|Manual ablation|
224011931|NCT04670289|DRUG|TenoMiR (Low Dose)|Mimic of miR29a
224011932|NCT04670289|DRUG|TenoMiR (Medium Dose)|Mimic of miR29a
224011933|NCT04670289|DRUG|TenoMiR (High Dose)|Mimic of miR29a
223391054|NCT02764892|DRUG|V81444|Single oral dose of V81444
223391055|NCT02902588|OTHER|ICG-PULSION|Intravenous administration of indocyanine green
224011934|NCT04670289|DRUG|Placebo|0.9% saline
224011935|NCT05465447|DEVICE|subjective refraction|Short-term postoperative (1-3 months) and long-term postoperative (3-5 years) subjective optometry results were measured by subjective refraction.
224011936|NCT04835350|DEVICE|Pancreas4ALL - meal announcement or full closed loop|Patient using AID Pancreas4ALL in mode meal announcment or full closed loop.
223391056|NCT02902588|DEVICE|LiMON, Pulsion Medical Systems|Application of near infrared light
224011937|NCT02920580|PROCEDURE|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
224011938|NCT02920580|PROCEDURE|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
224011939|NCT02408601|OTHER|Helioseal - F|"Helioseal -F ( Resin based sealant)~1. isolate the tooth surface~2. etch the fissure anatomy with 37% phosphoric acid for 20 seconds~3. wash the tooth surface and dry it. No salivary contamination is accepeted~4. using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~5. light cure the sealant~6. check for high points and the occlusion"
224011940|NCT02408601|OTHER|ART sealant|"Fuji IX extra strength~1. isolate the tooth surface~2. condition the fissure anatomy using a GC conditioner for 10 seconds~3. wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~4. dry the tooth surface~5. mix the GIC according to the standard powder: liquid ratio~6. place the mix onto the fissures using a plastic spatula~7. apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~8. apply pressure for 10-15 sec and withdraw the finger in a sideways motion~9. scrap out the excess material~10. check for the high points and the occlusion~11. apply petroleum jelly onto the GIC mix~12. advice patient not to eat or drink for 30 minutes."
224011941|NCT00817700|OTHER|Sleep restriction|Sleep restriction.
224127497|NCT04240665|BEHAVIORAL|Digital Memory Notebook (DMN) Application|Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
224127498|NCT02693483|DRUG|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
224127499|NCT06702501|DEVICE|PeriCut Catheter System performs minimally invasive pericardiotomy|The PeriCut Catheter System will incise the pericardium to reduce filling pressures of the heart.
224127500|NCT01361009|DRUG|pramipexole|as prescibed by the investigator
224127501|NCT02576457|BIOLOGICAL|BMS-936559|
224127502|NCT02576457|OTHER|Placebo|
223391057|NCT02902588|OTHER|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
223391058|NCT04911517|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
223391059|NCT05343780|DRUG|Heptex|Dukung Anak 200 mg + Milk thistle 100 mg
223391060|NCT05343780|OTHER|Rice bran|Placebo
223391061|NCT01164020|DIETARY_SUPPLEMENT|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
223391062|NCT01164020|OTHER|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
223391063|NCT01164020|OTHER|Resistance training|resistance training twice a week for 24 weeks
223391064|NCT01626482|OTHER|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
223391065|NCT01626482|OTHER|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
223391066|NCT01050829|DRUG|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
223391067|NCT01050829|DRUG|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
223391068|NCT05739422|PROCEDURE|Neuropilates online exercise class|Online, remotely supervised neuropilates exercise class
224011942|NCT01182883|DRUG|IMC-A12|
224011943|NCT01182883|DRUG|Temsirolimus|
224011944|NCT02935660|DEVICE|enLighten Laser|Laser tattoo removal treatment
224011945|NCT02642263|DRUG|Carbetocin|Postpartum uterotonic drug
224011946|NCT00400127|DEVICE|Silesian suspension belt|
224127503|NCT00598195|DRUG|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
224127504|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
224127505|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
224127506|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
224127507|NCT03216278|DRUG|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
223391069|NCT05739422|PROCEDURE|Online generalised exercise class|Online, remotely supervised generalised exercise class
223391070|NCT05739422|PROCEDURE|Unsupervised home exercise programme|Unsupervised, home based generalised exercise programme
223391071|NCT03558581|OTHER|Educational|
223391072|NCT05744518|OTHER|Response monitoring|Other: Response monitoring (no intervention)
223391073|NCT06091813|BEHAVIORAL|Nutrition Counseling|Dietitian-led nutrition coaching via 5 Telenutrition visits, utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process.
223391074|NCT04623619|DIETARY_SUPPLEMENT|Acetyl L-Carnitine|Administering 2 gr of Acetyl L-Carnitine orally in addition to the standard of care therapy for 14 days
223391075|NCT01144702|DRUG|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
223391076|NCT04074941|OTHER|Dietary intervention|Intervention include low sodium or usual sodium diet
223391077|NCT01402570|DIETARY_SUPPLEMENT|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
223391078|NCT03804957|OTHER|Autologous blood patch injection (ABPI)|Autologous blood patch injection (ABPI) through a coaxial needle at the site of biopsy
223391079|NCT03804957|OTHER|CT-guided core needle biopsy (CNB)|Standard 18g lung core biopsy
223391080|NCT02236260|PROCEDURE|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
223391081|NCT02236260|DRUG|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
223391082|NCT01965743|BEHAVIORAL|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
223391083|NCT04801303|DRUG|Calcitriol|Administration of Calcitrol 0.25mcg/24h for a year in Friedreich's Ataxia patients (n=20)
224011947|NCT00503100|DEVICE|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
224011948|NCT03277092|DEVICE|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
224011949|NCT03277092|PROCEDURE|Usual care|The blood drawing is performed traditionally
224011950|NCT01109927|DRUG|Insulin|Insulin treatment in accordance to glucose values
224011951|NCT00965367|DEVICE|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
224127508|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
223391084|NCT04801303|OTHER|Blood analysis for frataxin's level measurement|"1. Five blood analysis in Friedreich's Ataxia patients: before starting the treatment, and after fifteen days, 4 months, 8 months and 12 months of the treatment.~2. To validate the Frataxin's levels measurement, a blood analysis will also be done in two kind of controls for every Friedreich's Ataxia patient, only once at the beginning of the trial.~The control groups will be composed by:~* Heterozygous Ataxia's Friedreich controls (a close relative of the patient, either a heterozygous sibling or one of the parents)~* Age- and gender-matched controls (supposedly non-heterozygous)."
223391085|NCT04801303|DIAGNOSTIC_TEST|Blood analysis for hypercalcemia's control|Five blood analysis in Friedreich's Ataxia patients for monitoring the hypercalcemia risk (with measurement of Calcium, D Vitamin, renal function, albumin, protein, phosphate, sodium and potassium) Before starting the treatment, and after fifteen days, at 4 months, 8 months and 12 months of the treatment.
223391086|NCT03514459|OTHER|Systems Analysis and Improvement Approach|SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement \[CQI\] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
223564153|NCT02117960|DIETARY_SUPPLEMENT|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
224011952|NCT04012476|DRUG|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
224011953|NCT05842772|OTHER|Shared decision making intervention for patients with kidney failure when planning end-of-life care|Testing a shared decision making intervention and a patient decision aid for patients with kidney failure, their relatives, and the health professionals.
224011954|NCT02296723|DRUG|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
224011955|NCT01820585|DRUG|Placebo|Tablets
224011956|NCT01820585|DRUG|ESL 400 mg|tablets
224011957|NCT01820585|DRUG|ESL 800 mg|tablets
224011958|NCT01820585|DRUG|ESL 1200 mg|tablets
224127509|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
224127510|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
224127511|NCT03216278|DRUG|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
224127512|NCT03241563|DRUG|Sodium Deoxycholate|
223391087|NCT03798015|OTHER|mitral valve surgery|assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
223391088|NCT05360810|DEVICE|Wei Nasal Jet Tube|"comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures~airway devices which can use for gastrointestinal procedures"
223391089|NCT05360810|DEVICE|Gastro Laryngeal Tube|comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
223391090|NCT02350101|DEVICE|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
223391091|NCT02730910|OTHER|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
223391092|NCT02730910|OTHER|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
223391093|NCT06007001|DEVICE|Telemedicine|"Pilot 1a/b : the tele-rehabilitation intervention in BC or H\&N operated patients will consist of a series of exercises. The physiotherapist during teleconsultation rehabilitation program will explain to the patient how to perform the movements and regulate breathing. Practical advice on correct and incorrect habits will also be dispensed by the physiotherapist during the teleconsultation.~Pilot 2: the tele-rehabilitation intervention will consist of tele psychological support performed by a trained psychologist in each participating center It will consist of the learning of techniques for managing negative emotions, for relaxation and for implementing effective behavioural and coping strategies.~For each group, the TC will be scheduled every week for 8 weeks. The session will be available on a secure platform (Edumeet). Moreover, if they agree to, patients will also wear a smart watch to monitor physical parameters such as physical activity, sleeping and heart rate."
223391094|NCT03806114|PROCEDURE|Posterior Approach Precautions|These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
223391095|NCT03806114|PROCEDURE|Anterior Approach Precautions|These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
223546751|NCT03949868|BEHAVIORAL|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
223546752|NCT03949868|BEHAVIORAL|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
223546753|NCT02351011|BIOLOGICAL|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
223546754|NCT02351011|BIOLOGICAL|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
223546755|NCT02351011|BIOLOGICAL|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
223546756|NCT00327925|PROCEDURE|Find Cancer Associated Antibodies|
223546757|NCT01718899|BIOLOGICAL|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
223391096|NCT03806114|PROCEDURE|No Precautions|For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
223391097|NCT04618523|DRUG|Artesunate-amodiaquine|Artemisinin-based combination treatment
223391098|NCT04618523|DRUG|Artemether-lumefantrine|Artemisinin-based combination treatment
223391099|NCT02892955|DEVICE|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the MOMENTUM 3 IDE Study.
223391100|NCT05264038|DRUG|OC514 (Low dose)|Low dose level of OC514
223391101|NCT05264038|DRUG|OC514 (Mid dose)|Mid dose level of OC514
223391102|NCT05264038|DRUG|OC514 (High dose)|High dose level of OC514
223391103|NCT05264038|OTHER|Placebo|Placebo to match
223546758|NCT05468645|DRUG|[14C]Hemay005|Name: \[14C\]Hemay005 Dose: 60 mg/100 µCi Storage: store at -10℃ to -30 °C, tightly closed and protected from light.
223546759|NCT05859646|DIETARY_SUPPLEMENT|Probiotic use|Probiotics were used for 3 months and all participated patients were followed for 6 months.
223546760|NCT00900497|BIOLOGICAL|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
223546761|NCT05362292|DRUG|Tolterodine Tartrate ER|Anticholinergic
223546762|NCT05362292|DRUG|Mirabegron|Beta-3-adrenergic agonist
223546763|NCT05362292|DRUG|Placebo|matching placebo pill
223546764|NCT04010097|OTHER|chewing gum|The test involves chewing a chewing gum for 4 minutes
223546765|NCT05918978|DRUG|Efgartigimod|Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
223546766|NCT05223998|PROCEDURE|Full-thickness skin microcolumns implantation|Surgical harvest and implantation of FTSM on an open wound requiring coverage.
223546767|NCT04792190|DRUG|dapagliflozin|Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
223546768|NCT04792190|DRUG|Placebo|Subjects will take 1 blinded capsule of placebo drug dosed once daily
223546769|NCT04740151|PROCEDURE|Best PEEP|In OLV, the investigator will perform a PEEP decremental titration trial, decreasing PEEP from 16 to 4 cmH2O (steps of 2-cmH2O, lasting 1 minute). At the end of every step driving pressure (Pplat-PEEP) will be calculated, and the PEEP corresponding to the lowest driving pressure + 2cmH2O will be set.
223546770|NCT04740151|PROCEDURE|Standard PEEP|In OLV, a PEEP of 5 cm H2O will be set.
223546771|NCT06551350|OTHER|Data Collection|Collection of medical data from MICU intervention file and the medical records of patients at the destination hospital
224127513|NCT03241563|DRUG|Triamcinolone|Triamcinolone 40mg/ml
224127514|NCT04459702|DRUG|hydroxychloroquine|Treatment with the drug hydroxychloroquine
223391104|NCT03648736|OTHER|blood withdrawal|"* peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure~* central-venous during TASH"
223391105|NCT05433818|BEHAVIORAL|Group A|Skin-to-Skin Contact (SSC) contributes to mother-infant interaction and can increase breastfeeding success
223391106|NCT05433818|OTHER|Group B|education with a structured and expert opinion-based breastfeeding brochure
223391107|NCT01962103|DRUG|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
223391108|NCT01962103|DRUG|nab-paclitaxel|IV infusion
223546772|NCT04393662|DIAGNOSTIC_TEST|Measurement of Muscle strength using a dynamometer|"Muscle strength will be measured in the elbow bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). Supination tests will be performed with the forearm in neutral position, 60° pronation and 60° supination. The elbow will be in 90° flexion, and the shoulder in 45° flexion. Constant pressure is applied to lever of device for 3 to 5 seconds. Maximum torque will be recorded automatically. For each position, three repetitions of 3s (to 5s) contractions will be performed with a break of 15 (or 30s) between the repetitions. There will be an additional break of 2 minutes between measurements of the supination strength in the different positions. This parameter will be analysed regarding asymmetry between both limbs.~Isometric endurance of forearm supination will be measured in neutral forearm. Flexion tests will be carried in the same setting as for supination. Flexion tests will be performed with the elbow in 90, 45 and 0° of flexion."
223546773|NCT04393662|DIAGNOSTIC_TEST|Range of motion clinical measurement (shoulder and elbow)|The range of motion parameters (degree) of both shoulders and elbows will be documented. The circumference of the arm will be measured on the line between the medial acromion and the cubital fossa at 1/3 from the cubital fossa
223546774|NCT04393662|DIAGNOSTIC_TEST|Electromyography (EMG)|Electromyographic (EMG) data will be collected using a wireless EMG system (myon AG, Schwarzenberg, Switzerland). Surface electrodes will be placed bilaterally on biceps and triceps following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles)
223546775|NCT03345355|DIAGNOSTIC_TEST|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
223546776|NCT00659841|DRUG|Ciclesonide|200µg Ciclesonide versus placebo
223546777|NCT00659841|DRUG|Placebo|placebo
223546778|NCT05096637|OTHER|PreventiPlaque App|PreventiPlaque is an app that supports patients with atherosclerotic plaque by strengthening their adherence.
223546779|NCT05237583|BEHAVIORAL|Prehabilitation|All participants will be offered a multimodal prehabilitation program. This program will include an individualized and supervised aerobic and resistance exercise training program, nutritional optimization, and psychological support. The program will last 6 months or until liver transplantation, whichever comes first.
224011959|NCT05517187|OTHER|no intervention|Regenerative endodontic treatment induced with blood clot in root canal space as a secondary treatment for failed root canal treated incisors
224011960|NCT05517187|BIOLOGICAL|Platelet rich fibrin|Regenerative endodontic treatment with platelet rich fibrin in root canal space as a secondary treatment for failed root canal treated incisors
223391109|NCT01321749|PROCEDURE|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
223391110|NCT05994339|DRUG|Almonertinib|Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
223391111|NCT00376649|BEHAVIORAL|lifestyle changing workshop|
223391112|NCT03825939|DRUG|Intravenous Placebo|IV 0.9% sterile saline
223391113|NCT03825939|DRUG|Intravenous Tranexamic Acid|1g TXA IVPB (intravenous piggyback)
223391114|NCT05740033|PROCEDURE|Split-Thickness Skin Graft for Radial Forearm Donor Site Closure|This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.
223391115|NCT05740033|PROCEDURE|Hatchet Flap for Radial Forearm Donor Site Closure|The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
223391116|NCT03427294|OTHER|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
223391117|NCT06504277|PROCEDURE|Low Pressure Penumoperitoneum|Maintained Pneumoperitoneum with low pressure of 10 mm Hg
223391118|NCT06504277|OTHER|Standard Pressure Group (No intervention- active comparator)|Maintained Pneumoperitoneum at standard pressure of 15 mm Hg
223391119|NCT03239535|BIOLOGICAL|Mesenchymal stem cells|Intramuscular injection
223391120|NCT03239535|BIOLOGICAL|Normal saline|Intramuscular injection
223391121|NCT01606358|DRUG|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
223391122|NCT06162364|OTHER|VR|playing a video using VR
223391123|NCT06162364|OTHER|theoretical training|Training was provided through theoretical education
223391124|NCT06162364|OTHER|training with video|Training was given with two-dimensional video
223546780|NCT05121961|PROCEDURE|Sacroiliac intra-articular injection|CT guided injection of platelet-rich plasma versus steroid/anesthetic into the sacroiliac joint
223546781|NCT05004415|DRUG|AT-527 (R07496998)|Study participants will receive a single radiolabeled dose of 550 mg AT-527.
223546782|NCT01928433|DRUG|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
223546783|NCT01928433|DRUG|Finafloxacin placebo i.v. once daily|Infused over 60 mins \[i.v. pump\]) for at least 3 days.
223546784|NCT01928433|DRUG|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
223546785|NCT01928433|DRUG|Finafloxacin placebo tablets once daily|Administered as four tablets
223391125|NCT03649035|DEVICE|HTP treatment|Elegible patients will undergo HTP treatment, followed by standard of care Chemo therapy and SBRT protocol.
224011961|NCT04142229|DEVICE|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
223391126|NCT04179838|BEHAVIORAL|Sleep-Deprived|Sleep for 4 hours at home.
223391127|NCT04179838|BEHAVIORAL|Non-Sleep Deprived|Sleep for 8 hours at home.
223391128|NCT03869619|OTHER|Real-life epidemiological platform of lymphoma in France|"The REALYSA database will be described with the following characteristics:~* Number of patients included per month in total and according to subtype of lymphoma~* Number of patients in each region in total and according to subtype of lymphoma"
223391129|NCT00324818|DRUG|metronidazole and azithromycin|
223391130|NCT01667718|DRUG|Bismuth|Bismuth 220mg b.i.d for 2 weeks
223391131|NCT01667718|DRUG|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
223391132|NCT01667718|DRUG|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
223391133|NCT01667718|DRUG|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
223391134|NCT06576518|OTHER|Therapeutic exercise|An individualised incremental exercise programme was simultaneously supported by an adherence plan to assess and promote compliance.
223391135|NCT00163618|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
223546786|NCT01928433|DRUG|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
223546787|NCT01928433|DRUG|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins \[i.v. pump\]) for at least 3 days
223546788|NCT01928433|DRUG|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
224127515|NCT04459702|DRUG|Azithromycin|Treatment with the drug azithromycin
223391136|NCT03456102|DRUG|Pravastatin|"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."
224127516|NCT04459702|DRUG|Ritonavir|Treatment with the drug ritonavir
224127517|NCT04459702|DRUG|Lopinavir|Treatment with the drug lopinavir
223391137|NCT03662802|OTHER|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
223391138|NCT03161470|OTHER|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
223391139|NCT03161470|OTHER|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
223391140|NCT03161470|OTHER|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
223391141|NCT05639049|DEVICE|Enova GF3|Enova GF3, monofocal IOL
223391142|NCT05639049|DEVICE|Tecnis 1-piece ZCB00|Tecnis 1-piece ZCB00, monofocal IOL
223391143|NCT06067256|DRUG|Female Contraceptive|Effimia® exerts its action by means of a gonadotropin suppression mechanism through the estrogenic and progestin action exerted by EE and NGM. The contraceptive effect of Effimia® is based on the interaction of various factors, the most important of which consist of ovulation inhibition and endometrial modifications.
223391144|NCT04947215|DIAGNOSTIC_TEST|stress biomarkers|used to estimate the reference values of putative biomarkers of birth stress such asCTnT, CTnI, copeptin, NT-proBNP and hs-CRP in the cord blood of full term neonates
223546789|NCT01928433|DRUG|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
223546790|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
223546791|NCT00893360|BIOLOGICAL|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
223546792|NCT03093714|DRUG|FDL169|CFTR corrector
223546793|NCT03093714|DRUG|Placebo|Placebo for FDL169
223546794|NCT05535114|OTHER|Yoga-resistance exercise|Breathing exercise (5 minutes), flexibility (5 minutes), resistance exercise (20 minutes), relaxation \& meditation (10 minutes).
223546795|NCT00220506|DRUG|Provigil|
223546796|NCT01392573|DRUG|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
223546797|NCT01392573|DRUG|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
224011962|NCT04142229|OTHER|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
224011963|NCT03111459|DEVICE|Medtronic Valiant Thoracoabdominal Stent Graft System|The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
223391145|NCT05454891|DRUG|Extended bolus of insulin then standard bolus of insulin|For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
223391146|NCT05454891|DRUG|Standard bolus of insulin then extended bolus of insulin|For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
223391147|NCT06119893|DRUG|submucosal 8 mg (2 mL) dexamethasone application|The mucoperiosteal flap was applied. After operation, submucosal dexamethasone 8 mg (2 mL) was applied to the operation area as a test group.
223391148|NCT06119893|DRUG|submucosal 2 mL 0.9% isotonic sodium chloride application|The mucoperiosteal flap was applied. After operation, 2 mL 0.9% isotonic sodium chloride was applied to the operation area as a control group
223546798|NCT01058252|COMBINATION_PRODUCT|INVOCell, Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~* Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~* Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst \> 10 mm).~* Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~* On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~* Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
223546799|NCT01058252|PROCEDURE|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
223546800|NCT01058252|PROCEDURE|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~* E2 level is over 150 pg/ml/per mature follicle (\> 15 mm)~* Domminent follicle is greater than 18 mm in mean diameter~* LH Remains as Baseline, OR~* The day when Urinary LH Surge is positive"
223546801|NCT01058252|PROCEDURE|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~* Poor patient compliance~* Premature Ovulation~* Premature LH Surge~* Endometrium \< 7 mm~* Poor Follicular Development~* E2 Level \> 2,500 pg/ml"
223546802|NCT01058252|PROCEDURE|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
223546803|NCT02636647|BIOLOGICAL|Fecal transplant|
223546804|NCT00436436|DRUG|O6-benzylguanine|
223546805|NCT00436436|DRUG|temozolomide|
223546806|NCT05254756|DEVICE|Bouquet speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
223391149|NCT05362188|DRUG|Nicotinamide Topical|"Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel)."
224127518|NCT03506321|DIAGNOSTIC_TEST|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
223391150|NCT03205878|OTHER|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
223391151|NCT03205878|DEVICE|CPAP|Patients will receive CPAP according to standard care
223391152|NCT04692311|DEVICE|an intelligent client-centred task-oriented training|3 x 45min of training with i-ACT system
223391153|NCT04692311|OTHER|Semi-structured interview|Participants, patients and therapists, were invited to a semi-structured interview after training period.
223391154|NCT01290068|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
223391155|NCT01290068|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
223391156|NCT01290068|DEVICE|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
223391157|NCT05442151|DRUG|PET/CT ([F-18]FAPI-74)|PET/CT using \[18F\] FAPI-74 injection
223546807|NCT05254756|DEVICE|Traditional plastic 2-blade disposable speculum|Quantitative assessments of visualization of cervix, ease-of-use by the provider, and comfort of the patient
223546808|NCT04803474|DIAGNOSTIC_TEST|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair|Measurement of blood values, questionnaire scores and measurements of hormone levels in hair
224127519|NCT02236546|DIAGNOSTIC_TEST|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
223391158|NCT05399472|DIAGNOSTIC_TEST|Dorsiflexion lunge test|The dorsiflexion lunge test (DLT) will be used to measure ankle dorsiflexion. To perform this test, the participant stands in front of a wall holding the foot of their limb to be measured perpendicularly to it. The other foot is to be kept behind it. The participant is asked to perform a lunge (to dorsiflex the ankle and bring the knee into flexion) until the front knee touches the wall without the heel lifting off the ground. The participant steps away from the wall as much as possible as long as the knee keeps touching the wall. Measurement in centimeters is taken from the heel of the examined leg to the wall.
223391159|NCT05399472|DIAGNOSTIC_TEST|Jack Test|The Jack Test will be used to measure the first toe dorsiflexion under load. The examiner pulled the proximal phalanx of the hallux to dorsiflexion with his hand until the maximal amount of mobility was reached with the subject standing. The static arm of the goniometer was placed along the first metatarsal longitudinal axis while the free movable arm followed the proximal phalanx of the hallux axes.
223391160|NCT03610204|OTHER|Buffalo horn technique|The participants receive a 30-min massage session, twice a week for a total 6 sessions.
223391161|NCT04811872|BIOLOGICAL|Intact umbilical cord milking (I-UCM)|Umblical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.
223391162|NCT04811872|BIOLOGICAL|Cut-umbilical cord milking(C-UCM)|This technique involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM.
223391163|NCT04811872|BIOLOGICAL|Delayed Cord Clamping (DCC)|Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60 seconds before clamping the cord.
223391164|NCT01608750|DRUG|Pantoprazol|40mg/day, oral, 28 days
223391165|NCT01608750|DRUG|Folic Acid|5 mg/day, oral, 28 days
223391166|NCT04562168|DIAGNOSTIC_TEST|Autoderm® dermatology search engine (ML model) testing|GP using a smartphone camera will take an image of the skin problem and will use the Autoderm ML interface to upload the anonymized image. The obtained predicted diagnosis will be recorded in case report form.
223391167|NCT06278740|DIAGNOSTIC_TEST|Musculoskeletal Ultrasound|Upper extremity pathologies of participants with ultrasound
223391168|NCT04750395|DRUG|Haloperidol Solution|Oral transmucosal haloperidol solution 2.5mg
223391169|NCT04750395|DRUG|Olanzapine Tablets|Oral transmucosal olanzapine tablet 5.0mg
223391170|NCT02351414|DEVICE|Total Knee Arthroplasty (EVOLUTION®)|
223391171|NCT03096938|DIAGNOSTIC_TEST|methylation markers screening|Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
223391172|NCT04755114|OTHER|Turkish Music|Turkish Music;In choosing the music, patients will be asked about their favorite vocalist and music pieces before the procedure. The researcher will then download these music pieces from YouTube and create a 30-minute list and listen to patients.
223391173|NCT04755114|OTHER|comedy movie|Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. Prior to the research, attention will be paid to the selection of comedy films that do not contain violence, swearing and obscene scenes that may adversely affect patients. In the selection of comedy films, the opinions of two experts from Mimar Sinan University, Faculty of Fine Arts, Department of Cinema and Television and İnönü University will be preferred, and the films Kemal Sunal and Şener Şen, one of the actors that Turkish people know closely, laugh most and have settled into their culture, will be preferred.
223391174|NCT00513695|DRUG|sunitinib malate|Given PO
223391175|NCT00513695|DRUG|paclitaxel|Given IV
223391176|NCT00513695|DRUG|doxorubicin hydrochloride|Given IV
223391177|NCT00513695|DRUG|cyclophosphamide|Given PO
223391178|NCT00513695|BIOLOGICAL|filgrastim|Given SC
223391179|NCT00513695|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223391180|NCT00513695|OTHER|laboratory biomarker analysis|Correlative studies
223546809|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - OptiMA|"All children randomized to this arm will be treated with a RUTF, with weekly ration determined according to MUAC, weight and presence of nutritional edema. Ration will be adjusted weekly according to the change in MUAC and weight throughout the outpatient follow-up until the child achieves nutritional recovery.~RUTF dosage will 170 kcal/kg/d for the most severely wasted (MUAC \< 115 mm or edema) and reduced to 125 kcal/kg/d for children with MUAC 115-119mm and 75 kcal/kg/d for children with MUAC 120-124 mm.~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet nutritional recovery criteria, and then a monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition). Referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected)."
224127520|NCT02236546|OTHER|Molecular assays on biopsied tissue|Correlative studies
224127521|NCT02236546|DEVICE|positron emission tomography|Undergo FDG-PET/CT
224127522|NCT02236546|DEVICE|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
224127523|NCT06554314|DIETARY_SUPPLEMENT|probiotics|Eat a capsule for once, and once a day
223391181|NCT00513695|OTHER|flow cytometry|Correlative studies
223391182|NCT04562350|OTHER|XatJove Anoia Aplication|All students (age 12-16 years) from middle school and high school in the sanitary region of Anoia, province of Barcelona, will access a Platform ( ABH Health), where the users will enter specific registration data ( age, sex..etc), after every visit the users will be provided with a 6 multiple choice questionary and asked to punctuate in a scale from 1 to 10, the satisfaction of the service provided. Appart from this data, researchers will use a software to register specific Health-related words and classify them as Health-problems. While Osona students will attend face-to-face consultations as usual, apart from this data,Registrations will be reviewed later and specific search techniques and strategies will be coded. A qualitative review will be performed too.
223546810|NCT04698070|DIETARY_SUPPLEMENT|Nutritional Strategy - ComPAS|All children randomized to this arm will be treated with RUTF, with weekly ration determined according to MUAC and presence of nutritional edema. Children enrolled with MUAC \< 115 mm or edema will receive 1000 kcal/d (2 sachets/day) RUTF until MUAC has surpassed 115 mm and/or edema is resolved for 2 weeks at which time ration will be reduced to 500 kcal/d (1 sachet/day) until MUAC \> or = to 125 mm is achieved for 2 consecutive weeks. Children enrolled with MUAC 115-124 mm will receive 1 sachet/day until MUAC \> or = 125 mm is achieved for 2 consecutive weeks and clinically well. Following nutritional recovery, a study nurse will conduct monthly community-based follow-up in their villages (vital status, anthropometric measures and clinical condition) with referral to the health facility for appropriate nutritional/medical care if illness or acute malnutrition relapse detected) for the remainder of the 6 month period following inclusion.
223546811|NCT04698070|OTHER|National nutritional Strategy (Niger)|"Different protocols for SAM and MAM comprise the Niger National Nutrition Protocol:~1. SAM: Children with MUAC\<115 or WHZ\<-3 or nutritional edema, will be treated with RUTF, according to a dosage table based on weight at each visit.~2. MAM: Children aged between 6-24 months with MUAC between 115 -124 mm and WHZ\>-3 will be treated with RUSF. Children with the same anthropometry but age 24-59 m will only receive supplementation if they develop criteria for SAM during the 6 month study period. They will be monitored via monthly home visits by a study nurse.~All children will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
223546812|NCT01983592|OTHER|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
223546813|NCT01983592|OTHER|Unmedicated lactose/sucrose globule|
223546814|NCT00100737|DRUG|interleukin-2|
223546815|NCT00100737|DRUG|rituximab|
223546816|NCT00947219|DEVICE|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
223546817|NCT00947219|DEVICE|Control device|Device is used 3 times a week on non-consecutive days
223546818|NCT00006261|BIOLOGICAL|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
223546819|NCT00006261|DRUG|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
223730439|NCT01942291|DRUG|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
223730440|NCT01897740|DRUG|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
223730441|NCT01072812|DRUG|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
223730442|NCT05484973|DEVICE|AMMA Portalbe Scalp Cooling System|AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
223730443|NCT02946645|DEVICE|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
224127524|NCT02116660|DRUG|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
223391183|NCT05948150|OTHER|using a breastfeeding pillow|To make the breastfeeding pillow group use the breastfeeding pillow from the 8th hour in the postnatal period and to make evaluations at 24 and 48 hours
223391184|NCT05948150|OTHER|not using a breastfeeding pillow|The non-breastfeeding pillow group was evaluated at 24 and 48 hours without the use of a breastfeeding pillow
223391185|NCT06524050|BEHAVIORAL|standard care|standard care
223391186|NCT06574750|DRUG|CUREAⓇ (ARIBIO, Ltd., Seoul, Republic of Korea)|Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
223391187|NCT06574750|DRUG|JuvedermⓇ (Q-Med AB, Uppsala, Sweden)|Hyaluronic acid filler injection were administered into the mid-dermis of the nasolabial fold.
223391188|NCT01272050|RADIATION|radiation therapy|"RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration."
223546820|NCT00006261|DRUG|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
223546821|NCT00006261|DRUG|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
223546822|NCT00006261|DRUG|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
223546823|NCT00006261|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
224127525|NCT02116660|DRUG|Nevirapine|Nevirapine (NVP) 200 mg tablets
223391189|NCT06070519|DIAGNOSTIC_TEST|CPET and related variables evaluation|"At the baseline visit ,CPET-related variables, echocardiographic, ECG, therapy and blood chemistry data will be collected. The baseline CPET will be repeated within 2 weeks. Patients will perform 4 follow up visits at 6, 12, 18 and 24 months after the baseline visit. At every study step, it will be performed:~* Echocardiography (LVEF)~* Blood sample (Na+, MDRD, Hb)~* Maximal ramp protocol CPET (peakVO2, VE/VCO2 slope)"
223391190|NCT06439550|DRUG|Serplulimab|300mg, q3w
223391191|NCT06439550|DRUG|Trastuzumab|First dose 8mg/kg, maintenance 6mg/kg, q3w
223546824|NCT01906268|OTHER|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
223546825|NCT01906268|OTHER|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
223546826|NCT00766116|DRUG|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
224011964|NCT01827995|OTHER|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
224011965|NCT01827995|OTHER|Routine assessment|Follow up in the clinic
223391192|NCT06439550|DRUG|Oxaliplatin + Tegafur|oxaliplatin (130mg/m2, q3w) + Tegafur (40mg/m2, bid d1-d14, q3w).
223546827|NCT00766116|DRUG|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
223546828|NCT03309982|DIETARY_SUPPLEMENT|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
223546829|NCT03309982|OTHER|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
223546830|NCT00466180|BEHAVIORAL|Nevirapine from twice-a-day to once-a-day|
223546831|NCT04063917|DEVICE|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
223546832|NCT05406128|OTHER|preoperative erector spina plane block|Erector spina plane block will be applied to preoperative group patients in the preoperative period.
223546833|NCT05406128|OTHER|intraoperative erector spina plane block|In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
223546834|NCT01152801|DRUG|Everolimus (RAD001)|
223546835|NCT02752490|DRUG|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
223546836|NCT02752490|DRUG|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
223546837|NCT01771874|DRUG|MDMA|125 mg per os, single dose
223546838|NCT01771874|DRUG|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
223546839|NCT01771874|DRUG|Placebo|per os
223546840|NCT01102491|DRUG|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
223546841|NCT00539123|BEHAVIORAL|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
223391193|NCT06518460|DIAGNOSTIC_TEST|Functional Efficiency of Self-sufficiency Test|The Barthel Index has 10 items focusing on mobility, feeding, grooming, hygiene, dressing, bladder control and bowel control. It scores from 0-100 points. A higher score indicates better performance. The Action Research Arm Test is 19-item observational measure used for the assessment of UE performance in stroke recovery. Scores range from 0-57 points. A higher score indicates a better outcome.
223391194|NCT01907490|DRUG|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
223391195|NCT05634421|OTHER|E-learning|The E-learning is under development at the department of Dermatology from MUMC+.
223391196|NCT00105859|BEHAVIORAL|Education and Counseling|
223391197|NCT01524159|DIETARY_SUPPLEMENT|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
223564154|NCT01899508|PROCEDURE|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
224011966|NCT04385589|DRUG|Dapagliflozin|Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.
223391198|NCT01524159|DIETARY_SUPPLEMENT|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
223391199|NCT04544241|BEHAVIORAL|Cancer Survivorship Leadership Training for Clergy Wives and Widows|We will meet with Clergy Wives and Widows monthly for 2-3 hours over 10 months. These sessions will be delivered using innovative online format through Zoom over the ten months. During each meeting session, experienced community and academic leaders will present their expertise with relationship to cancer survivorship and caregiving. These individuals will have extensive experience in the particular area they are presenting in. In addition, allotted time will be given for discussion and group activities that can be performed virtually. To receive credit for completion of the training program, each participant must complete the training and deliver a group workshop. All clergy wives and widows will complete a demographic questionnaire, in addition to pre- and post- intervention questionnaires
223391200|NCT04751552|PROCEDURE|Erector Spinae Plane Block (for postoperative pain relief)|A ultrasound guided single bolus injection of 20 ml of levobupivacaine or placebo between the erector spinae muscle and process transversus of vertebra T5.
223391201|NCT04332900|DEVICE|Elastic hip strap|The SERF Strap consist of a thin, elastic material that is secured to the proximal aspect of the leg, wraps in a spiral fashion around the thigh, and is anchored around the pelvis. The line of action of the SERF Strap pulls the hip into abdcution and external rotation.
223391202|NCT04332900|DEVICE|Insole|Foot orthoses with semi-rigid arch support and medial elevation at the forefoot and at the rearfoot by 7° each that is made from a block of ethyl vinyl acetate with a thermo-moldable polymer (shore hardness of 45 A) and is manufactured through an automated computer numeric control machine (CNC routers).
223391203|NCT04247113|BEHAVIORAL|Parent-based prevention following bariatric surgery|PBP-B is an adapted version of Parent-Based Prevention (PBP), an innovative approach with demonstrated efficacy in targeting the familial effects of parents with eating disorders on their young children's healthy behaviors. PBP-B addresses the parental cognitions and behaviors that putatively increase the risk for maladaptive outcomes in their children.
223391204|NCT06574659|PROCEDURE|Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol|Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol
223391205|NCT06574659|PROCEDURE|The standard SBT guiding weaning group|The standard SBT guiding weaning protocol
223391206|NCT02835547|OTHER|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
223391207|NCT04656756|BEHAVIORAL|Personalized Care|A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
223391208|NCT00311948|BEHAVIORAL|Telephone counseling + interactive website = more abstinence|
223391209|NCT00311948|BEHAVIORAL|Behavioral: interactive website|
223391210|NCT02099786|OTHER|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
223391211|NCT02099786|OTHER|Standard of care|Hearing testing done in the audiology clinic after oncology referral or patient self referral
223391212|NCT00080912|RADIATION|radiation therapy|Given in a single fraction or multiple fractions
223391213|NCT01590225|DRUG|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
223391214|NCT01590225|DRUG|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 24 weeks.
223564155|NCT01899508|DEVICE|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
224011967|NCT04385589|DRUG|insulin|insulin
224011968|NCT02293213|BEHAVIORAL|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
224011969|NCT02293213|BEHAVIORAL|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
224011970|NCT02293213|BEHAVIORAL|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
224011971|NCT02293213|BEHAVIORAL|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
224011972|NCT02293213|BEHAVIORAL|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
223391215|NCT01590225|DRUG|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 24 weeks.
223564156|NCT00411827|PROCEDURE|PRK with conjunctival impression cytology before and after surgery|
224011973|NCT02293213|BEHAVIORAL|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
224011974|NCT06396364|DEVICE|Cryotherapy|Treatment group: the ankle was immobilized in a walking boot, then a third-generation cryotherapy device (Z- One®, Zamar) was applied daily for 2 hours two times a day up to the day of surgery. The walking boot was removed when the cryotherapy device was applied.
224011975|NCT02925598|DEVICE|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
224011976|NCT02925598|DEVICE|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
224011977|NCT02925598|DEVICE|ETT insertion|'ETT insertion' was done following anesthesia induction.
224127526|NCT02116660|DRUG|Lamivudine|Lamivudine (3TC) 150 mg tablets
223391216|NCT01590225|DRUG|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
223391217|NCT01590225|DRUG|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m\^2 once weekly (QW) for 48 weeks.
223391218|NCT01590225|DRUG|Ribavirin|"Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily \[BID\]) for 48 weeks."
223730444|NCT02946645|PROCEDURE|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
223730445|NCT02946645|OTHER|Placebo|No interventions.
223730446|NCT02680912|DEVICE|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
223730447|NCT02680912|DEVICE|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
223730448|NCT03097874|BEHAVIORAL|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
223730449|NCT03097874|BEHAVIORAL|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
224011978|NCT06110390|DEVICE|High flow nasal oxygen|An interface applied to the nostrils allowing fresh gas flows of up to 60 liters per minute and inspired oxygen concentrations of up to an fiO2 of 1.0
224127527|NCT02116660|DRUG|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
223391219|NCT05335486|DEVICE|RELEARN Neurofeedback|"Standard care + The RELEARN intervention.~Intervention group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines.~During standard care, intervention group participants will be subject to the RELEARN intervention, consisting of encephalography (EEG) neurofeedback of cerebral movement evoked signatures of pain, where the participants will be instructed in attempting to manipulate these signatures to reduce pain perception."
223730450|NCT06300242|BEHAVIORAL|Reminders|Reminders
223730451|NCT06300242|BEHAVIORAL|Financial Incentive|$50 financial incentive for getting vaccinated within 1-week
223730452|NCT06300242|OTHER|Placebo|No special messages or incentives
224127528|NCT02116660|DRUG|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
224127529|NCT02116660|DRUG|Lopinavir|Lopinavir (LPV) 200 mg tablets
224127530|NCT02116660|DRUG|Ritonavir|Ritonavir (r) 100 mg tablets
224127531|NCT02116660|DRUG|Atazanavir|Atazanavir (ATV) 300 mg tablets
223391220|NCT05335486|OTHER|Standard care control|"Standard Care control.~Control group participants will be seen at the orthopedic ward and receive standard care for knee osteoarthrosis, defined by Danish clinical guidelines. During standard care, the control group participants will be asked to attend eight control sessions with no RELEARN intervention with an approximate duration of 5 minutes per session. Also, participants will undergo three follow-up sessions: one month, three months, and five months post-intervention"
223391221|NCT02569125|DRUG|Everolimus|4.5 mg/m² daily
223391222|NCT03836300|BEHAVIORAL|Parent-Infant Inter(X)action Intervention (PIXI)|Psychoeducation around the diagnosed disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.
223391223|NCT01839890|DEVICE|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
223730453|NCT02069743|OTHER|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
224011979|NCT00182559|DRUG|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
224011980|NCT00182559|DRUG|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
224011981|NCT01462032|BEHAVIORAL|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
224127532|NCT02116660|DRUG|Darunavir|Darunavir (DAR) 400 mg tablets
224127533|NCT04776811|DEVICE|Continuous glucose monitoring system|Medtronic Guardian Connect with Guardian Sensor 3
224127534|NCT00411788|DRUG|Rapamycin|oral rapamycin 6 mg daily
224127535|NCT00411788|DRUG|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
224127536|NCT06370936|OTHER|Standardized diet with commercially available animal meats (comparator products)|Fully controlled standardized diet with commercially available meats from animal origin. Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
223730454|NCT01121887|BEHAVIORAL|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
223391224|NCT01839890|DEVICE|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
223391225|NCT01417156|DRUG|Nintedanib|150 mg bid
223391226|NCT01417156|DRUG|Pirfenidoneone|Existing treatment
223391227|NCT04595188|OTHER|Sulphur amino acids|"For the total sulphur amino acid requirement, there are 7 different methionine test levels (without dietary cysteine) ranging from 5 to 40 mg of methionine per kilogram body weight per day.~For the minimum methionine requirement, there are 7 different methionine test levels (with excess dietary cysteine)."
223391228|NCT00770783|DEVICE|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
223391229|NCT00770783|DEVICE|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
223391230|NCT02447211|DRUG|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
223391231|NCT02447211|OTHER|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
223391232|NCT03411031|DRUG|Elotuzumab|Elotuzumab according to dosing schedule outlined in treatment arms.
223391233|NCT03411031|DRUG|Lenalidomide|Lenalidomide according to dosing schedule outlined in treatment arms.
223391234|NCT03411031|DRUG|Dexamethasone|"Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert."
224011982|NCT01462032|BEHAVIORAL|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
224011983|NCT00294606|DRUG|Comparison of Effects of Phenylephrine and Norepinephrine|
224011984|NCT00313625|DRUG|busulfan|
224011985|NCT00313625|DRUG|melphalan|
224011986|NCT00313625|DRUG|methotrexate|
223391235|NCT03302169|PROCEDURE|Radical prostatectomy with posterior rhabdosphincter reconstruction|To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
223391236|NCT03302169|PROCEDURE|Radical prostatectomy without posterior rhabdosphincter reconstruction|Standard technique with a running suture to perform the urethrovesical anastomosis
223391237|NCT00933023|DRUG|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
223391238|NCT00933023|DRUG|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
223391239|NCT01198223|DRUG|garlic , nystatin|mouthwash
223391240|NCT00038181|DRUG|Thalidomide|
223391241|NCT05063513|BIOLOGICAL|Autologous Hematopoietic Stem Cell Transplantation|Experimental arm will undergo mobilisation with CY 4 g/m2 (in two divided doses), followed by Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body weight given in 4 daily doses) plus ATG and unmanipulated autologous graft and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
223391242|NCT05063513|DRUG|Rituximab|Control arm will receive 4 successive weekly infusions of rituximab (antiCD20) 375 mg/m2 body surface area for four weeks and maintenance by Mycophenolate Mofetil (2 g/day) starting 3 months after randomization.
223391243|NCT00818766|DRUG|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
223391244|NCT00818766|DRUG|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
223391245|NCT03525405|DRUG|napabucasin|Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
223391246|NCT03710967|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the primary motor cortex
223391247|NCT06328205|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
223546842|NCT00539123|BEHAVIORAL|abstinence-contingent buprenorphine (ACB)|Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
223546843|NCT06199765|OTHER|Needlestick Injury Prevention|this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
223546844|NCT06598072|DRUG|Mouthwash CPC+Zn+F|A mouthwash containing CPC + Zn and fluoride
223546845|NCT06598072|DRUG|Essential oils mouthwash|Essential oils mouthwash
224011987|NCT00313625|DRUG|tacrolimus|
224011988|NCT00313625|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224011989|NCT00313625|PROCEDURE|peripheral blood stem cell transplantation|
224011990|NCT02155751|BEHAVIORAL|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
223546846|NCT06598072|DEVICE|Dental floss|Dental Floss
223546847|NCT00002348|DRUG|Mitoguazone|
223546848|NCT05951647|DRUG|Chamomile extract mouthwash|5% chamomile extract mouthwash in a dose of 15 ml twice daily.
223546849|NCT05951647|DRUG|Pomegranate peel extract mouth wash|5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.
223391248|NCT06328205|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
223391249|NCT06328205|DRUG|Lidocaine Hydrochloride|When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\]. once a day. 1 ml per time.
223391250|NCT06328205|BEHAVIORAL|placebo injection|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. 1 milliliter of normal saline will be used for injection.
223391251|NCT05350657|BEHAVIORAL|Ketogenic Diet|2 week isocaloric, high protein and low carbohydrate ketogenic diet
223391252|NCT03973125|DRUG|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
223391253|NCT04496804|BEHAVIORAL|Behavioral Intervention for Physical Activity in MS (BIPAMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing physical activity in people with MS.
223391254|NCT04496804|BEHAVIORAL|Wellness for MS (WellMS)|A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing wellness in people with MS.
223546850|NCT05951647|DRUG|Combination of 5% chamomile extract and pomegranate peel extract mouthwash|Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.
223546851|NCT05951647|PROCEDURE|Scaling|Patients will be managed by scaling
223546852|NCT05951647|DRUG|Scaling and Chlorohexidine mouthwash|scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.
223546853|NCT05125146|BEHAVIORAL|e-CBTi|See arm/group description
223546854|NCT05125146|DRUG|Trazodone|See arm/group edescription
223391255|NCT05120986|OTHER|IND/GLY/MF|Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study when attending participating community pharmacies with a first prescription of IND/GLY/MF with sensor or IND/GLY/MF without sensor
223391256|NCT00810667|DRUG|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
223391257|NCT00810667|DRUG|Placebo|twice daily oral dose
223546855|NCT03289754|DEVICE|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
223546856|NCT06613880|DRUG|standard IST combined with Romiplostim N01|Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.
223546857|NCT02151786|DRUG|Lansoprazole|Lansoprazole intravenous 30 mg
223546858|NCT04814953|OTHER|questionnaires|EQ-5D-5L questionnaire questioning their overall health on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). In addition patients will have to fill in the generic 15D questioning 15 specific dimensions on 5 levels as well as the BaSQoL, which is a disease specific questionnaire for patients with KC. The Time-trade off task is the final question.
223391258|NCT01080638|DRUG|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
223546859|NCT01607125|DRUG|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
223391259|NCT05984524|BEHAVIORAL|Gamma-Music Based Intervention|Gamma or Control lights with Music-Based Intervention for 8 week period
223391260|NCT00126828|PROCEDURE|External beam radiotherapy|
223391261|NCT05884736|OTHER|Neuromonitoring|Multimodal neuromonitoring will include: Transcranial colour-coded Doppler (TCCD), Electroencephalography (EEG), and Somatosensory evoked potentials (SSEP) or brainstem auditory evoked potentials (BAEP)
223546860|NCT01607125|DRUG|Placebo|capsules, orally, once daily for 13 to 14 days
224296449|NCT03016221|OTHER|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
224296450|NCT03016221|OTHER|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
223546861|NCT02909088|DRUG|Ecopipam 50mg|
223546862|NCT02909088|DRUG|Ecopipam 100mg|
223546863|NCT03533660|BEHAVIORAL|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
223546864|NCT03533660|BEHAVIORAL|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
223564157|NCT00411827|PROCEDURE|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
224296451|NCT03016221|OTHER|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
223546865|NCT06007027|DEVICE|SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy|The laser probe is gently inserted up to the top of the vagina, and subsequently withdrawn and rotated in order to deliver a complete treatment of the vaginal wall.
223546866|NCT00297739|DRUG|Risperidone|
223546867|NCT04544735|BEHAVIORAL|Integrated Physical Therapy and Coping Skills Training|The proposed intervention will provide pelvic health physical therapy interventions including: education about vaginal moisturizers and lubricants, low back and hip assessment and instruction in accommodations (e.g., strategies for accommodating sexual position of choice), instruction in vulvar massage, instruction and facilitation of vaginal dilator use, and pelvic floor muscle training (PFMT) and exercises. Women will be given a set of vaginal dilators. Cognitive behavioral techniques that have been successfully used by physical therapists in prior intervention studies will be integrated into the PT intervention including breathing and relaxation techniques, guided imagery, systematic desensitization, cognitive restructuring techniques and coping thoughts, and problem solving
223546868|NCT06183489|DRUG|Elranatamab|Elranatamab will be administered via a subcutaneous injection (SC)
223391262|NCT01866462|OTHER|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
223391263|NCT02236962|DRUG|Placebo|
223546869|NCT00633178|BEHAVIORAL|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
224011991|NCT02155751|BEHAVIORAL|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
224011992|NCT05198895|DEVICE|Near-infrared (NIR)|NIR spectral assessment of glycated nail keratin vs glycated haemoglobin (HbA1c)
224011993|NCT02184364|DRUG|Low dose of Klimadynon®|
223391264|NCT02236962|DRUG|Ephedrine, pioglitazone|
223546870|NCT00633178|BEHAVIORAL|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
223546871|NCT06630533|OTHER|Baduanjin Exercise Group|Baduanjin exercises (Eight-Part Exercises or Eight-Part Brocades), an important part of Qigong, consist of eight postures (1-holding the hands high with palms up, 2- posing as an archer shooting, 3- holding one arm aloft, 4- looking backwards, 5- swinging the head and lowering the body, 6- moving the hands down the back and legs and touching the feet, 7- thrusting the fists and making the eyes glare, and 8- raising and lowering the heels).
223546872|NCT05570708|DRUG|MDMA, LSD, psilocybin|"* MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting"
223546873|NCT03586375|OTHER|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
223730455|NCT01121887|BEHAVIORAL|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
223730456|NCT02299609|OTHER|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
223730457|NCT00427466|DRUG|Pemetrexed|
223730458|NCT01806831|DEVICE|"Biocellulose Mask, Farhorm®"|
223730459|NCT00596570|PROCEDURE|PCI|Percutaneous coronary interventiom
223730460|NCT05519423|BEHAVIORAL|Physical Activity Incentive Program|Physical Activity Incentive (PAI) programs, which is a method used in preventive health services, are recommended by a number of public health institutions, including the World Health Organization, thanks to the universal access and high potential of health services. PAI is defined as offering verbal or written advice/guidance to encourage the individual to increase their current level of physical activity.
223730461|NCT02709785|DRUG|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
223730462|NCT02709785|DRUG|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
223391265|NCT04985292|DIETARY_SUPPLEMENT|Probiotic, Lactobacillus|10\^10 colony-forming units of a Lactobacillus strain, packaged in a capsule, once daily
223391266|NCT04985292|DIETARY_SUPPLEMENT|Placebo|Inactive substance packaged to be identical to active treatment
224011994|NCT02184364|DRUG|Medium dose of Klimadynon®|
224011995|NCT02184364|DRUG|High dose of Klimadynon®|
224011996|NCT02184364|DRUG|Oestrofeminal®|
224011997|NCT02184364|DRUG|Placebo|
224011998|NCT02544451|DRUG|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
224011999|NCT02544451|DRUG|LUM/IVA|LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
223391267|NCT00086684|DRUG|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
223391268|NCT00086684|DRUG|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
223391269|NCT00086684|DRUG|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
223391270|NCT02340403|PROCEDURE|NMR Spectroscopy|
223391271|NCT06018675|OTHER|kinesiotherapy|Group 1: Kinesiotherapy Group 2: Dry needling Group 3: lidocain injection
223391272|NCT02043795|DEVICE|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
223391273|NCT02826486|DRUG|BL-8040|BL-8040 subcutaneous (SC) injections
223391274|NCT02826486|DRUG|Pembrolizumab|Pembrolizumab will be given as a 30-minute IV infusion
223391275|NCT02826486|DRUG|Chemotherapy|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
223391276|NCT05162703|DIAGNOSTIC_TEST|AsthmaTuner|Exercise challenge test using AsthmaTuner mobile phone app and spirometer.
223391277|NCT05659732|DRUG|PEP07|PEP07 is a selective Chk1 inhibitor maleate drug which is supplied as a hard gelatin capsule. PEP07 will be provided as 20 mg and 150 mg strength capsules to be administrated orally. Patients allocated to different dose levels of PEP07 monotherapy will receive either 20 mg or 150 mg oral capsules for 2 consecutive days followed by 5 days treatment off (2-on/5-off) schedule every week, 4 weeks as a treatment cycle.
223391278|NCT04025840|OTHER|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
223391279|NCT04025840|DRUG|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
223391280|NCT04515251|DIAGNOSTIC_TEST|Ultrasound measurements|ultrasound measurement at the level of the left renal vein on a sagittal plane according to age
223391281|NCT00006207|DRUG|PRO 2000|
224012000|NCT03815682|BIOLOGICAL|Arm A: RPTR-147:1|Escalating doses of RPTR-147:1 as a monotherapy
224012001|NCT03815682|BIOLOGICAL|Arm B: RPTR-147:1 and Pembrolizumab|Escalating doses of RPTR-147:1 in combination with Pembrolizumab
224012002|NCT03815682|BIOLOGICAL|Arm C: RPTR-147:2|Escalating doses of RPTR-147:2 in patients with HPV positive tumors
223391282|NCT03686605|OTHER|Thai version of the Edmontom Symptom Assessment System (ESAS)|Screening and diagnostic questionaire for depression
223391283|NCT04132960|DRUG|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
223391284|NCT00980863|BEHAVIORAL|lifestyle intervention to increase physical activity|
224012003|NCT00085462|BIOLOGICAL|aldesleukin|
223391285|NCT04197804|OTHER|Routine tests perform|The subjects of the Tourette group and control group are subjected to routine tests performed at Tourette Center and Extrapyramidal Diseases. Both groups are initially subjected to an evaluation that aims to identify the IQ and therefore 4 tasks are presented. The 1st (with a duration of about 2 and a half minutes) and the 2nd (with a duration of about 2 minutes) related to the motor field, the 3rd (with duration of about 1 minute) and the 4th (with duration about 3 minutes) the language field. These evaluations are in practice at the Center for Tourette patients; the tasks will be administered to both groups.
223391286|NCT05706272|OTHER|Comprehensive geriatric assessment (CGA)|The intervention includes a holistic comprehensive geriatric assessment using the PASTEL assessment tool that includes medical, psychiatric, functional and social aspects. Physical tests will include function, risk of falling, hand muscle strength, Timed up and Go (TUG), chair-stand test, blood pressure, saturation and BMI. A proactive person centered care plan will be established based on identified needs and the patients own priorities. A nurse will coordinate the care in the elderly team at the intervention practice with access to rehabilitation staff such as physiotherapist and occupational therapist. Follow-ups at the primary care practices will be carried out in accordance with the study plan. To strengthen care coordination, contact will be taken with other health care providers before the follow-ups.
224012004|NCT00085462|BIOLOGICAL|filgrastim|
223391287|NCT05706272|OTHER|Care as usual|The control group will receive care as usual at the matched control primary care centers
223391288|NCT03691701|OTHER|strict blood pressure control|Home SBP target \< 120 mmHg or 90th percentile for age and height (whichever is lower)
223391289|NCT00328601|DRUG|Thioctic Acid|
223391290|NCT05820126|BIOLOGICAL|Cold-stored platelet concentrate|Patients will be transfused a unit of pooled, pathogen reduced platelets that have been stored for \>24 hours at 1-6˚C
223391291|NCT06849271|PROCEDURE|Radical Nephrectomy (RN)|"Complete remove of the kidney. In addition as part of the intervention, a procedure termed Lysis of abdominal adhesions may be performed according to patient medical condition and/or surgeon criteria."
223730463|NCT02709785|DRUG|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
223730464|NCT00237874|DRUG|Aripiprazole|
223730465|NCT03982823|PROCEDURE|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
223730466|NCT03982823|PROCEDURE|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
223730467|NCT01482039|PROCEDURE|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
224012005|NCT00085462|BIOLOGICAL|gp100-fowlpox vaccine|
224012006|NCT00085462|BIOLOGICAL|therapeutic autologous lymphocytes|
224012007|NCT00085462|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
224012008|NCT00085462|DRUG|cyclophosphamide|
224012009|NCT00085462|DRUG|fludarabine phosphate|
224012010|NCT04306406|OTHER|Raspberries|Red raspberry smoothies drink
224012011|NCT04363034|BIOLOGICAL|Convalescent Plasma|1-2 units (200-400 mL per unit, not to exceed 550 mL total) of ABO compatible, low isohemagglutinin titer, COVID-19 convalescent plasma
224012012|NCT00526500|BEHAVIORAL|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
224012013|NCT02555852|DRUG|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
224012014|NCT02555852|DRUG|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
223391292|NCT06849271|PROCEDURE|Partial nephrectomy (PN)|"Partial remove of a section in the kidney. In addition, as part of the intervention, a procedure termed Lysis of abdominal adhesions may be performed according to patient medical condition and/or surgeon criteria."
223391293|NCT06849271|PROCEDURE|Radical Prostatectomy (RP)|"Complete remove of the prostate gland. In addition as part of the intervention, two procedures termed Lysis of abdominal adhesions and/or Lymphadenectomy  (removal of regional lymph nodes) may be performed according to patient medical condition and/or surgeon criteria."
223391294|NCT05417789|DRUG|Emactuzumab|Emactuzumab administered once every 2 weeks (q2w)
223391295|NCT05417789|DRUG|Placebo|Matching placebo administered once every 2 weeks (q2w)
223546874|NCT04666974|BEHAVIORAL|iCBT|Online CBT modules will be completed weekly with content mirroring in-person CBT for their diagnosis. Homework will be submitted weekly through the OPTT platform which will be reviewed by a trained professional who will provide personalized feedback.
223546875|NCT04666974|BEHAVIORAL|In-Person CBT|Participants will be assigned to in-person CBT that will mirror the content and homework covered in the iCBT group. It will be delivered by professionals and attended weekly.
223730468|NCT01482039|PROCEDURE|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
223730469|NCT06346990|OTHER|Holy Quran Recital|Holy Quran recital for four days. Typically, the second, third, fourth- and fifth-days following CABG. The daily sessions were done at 2 PM and 8 PM for 20 minutes each
223730470|NCT05016921|DEVICE|TcMS|Transcutaneous magnetic stimulation targeting the stellate ganglion
224012015|NCT02555852|DRUG|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
224012016|NCT02555852|DRUG|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
224012017|NCT02555852|DRUG|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
224012018|NCT02555852|DRUG|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
224012019|NCT02555852|DRUG|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
224012020|NCT02555852|DRUG|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
224012021|NCT02555852|DRUG|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
224012022|NCT02555852|DRUG|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
224012023|NCT02555852|DRUG|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
224012024|NCT02555852|DRUG|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
224012025|NCT02555852|DRUG|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
224296452|NCT04337684|DRUG|Long Term Follow-Up|"Menkes disease is a form of inherited copper deficiency associated with neurodevelopmental delays and neurological problems. Copper Histidinate is being evaluated for efficacy and safety in patients with Menkes disease. The purpose of this protocol is to collect long term follow-up data.~During the study, patients and/or parent/legal guardian will be contacted by the investigator by either telephone or an in-person visit to assess long term follow-up."
224296453|NCT04718194|BEHAVIORAL|ESTEEM iCBT|The online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
223391296|NCT04205565|DRUG|Test group: L-oxiracetam Injection|L-oxiracetam injection, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
223391297|NCT04205565|DRUG|Control group: Oxiracetam Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Oxiracetam injection, 6 vials, once a day, IV.
223730471|NCT01863212|PROCEDURE|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
223730472|NCT01863212|BEHAVIORAL|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
223391298|NCT04205565|DRUG|Placebo group: Placebo Injection|Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
223546876|NCT06692894|OTHER|Observational|Blood will be collected from one cohort to identify potential blood biomarkers.
223730473|NCT01863212|OTHER|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
224012026|NCT02555852|DRUG|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
223546877|NCT00996658|DRUG|Placebo|Placebo matching linagliptin tablets once daily
223546878|NCT00996658|DRUG|Linagliptin|Linagliptin tablets once daily
223546879|NCT06719466|OTHER|low linoleic acid (LA)|diet guidance with low linoleic acid (LA) diet
223546880|NCT06717100|DRUG|Nintedanib 150 MG [Ofev]|Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
224012027|NCT02555852|DRUG|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
224012028|NCT02554227|OTHER|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
223730474|NCT02504008|DRUG|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
223730475|NCT02504008|DRUG|Placebo|Once weekly for 6 weeks
224012029|NCT01979627|PROCEDURE|transulnar approach interventional procedure|
224012030|NCT01979627|PROCEDURE|transradial approach interventional procedure|
224296454|NCT04718194|BEHAVIORAL|Self-monitoring control|Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
224012031|NCT00998790|DEVICE|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
224012032|NCT01489891|DRUG|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
224012033|NCT01489891|DRUG|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
224012034|NCT02417519|OTHER|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
224296455|NCT00564226|DRUG|SSR240600C|oral administration
224296456|NCT00564226|DRUG|tolterodine|oral administration
224296457|NCT00564226|DRUG|placebo|oral administration
224296458|NCT01108666|DRUG|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
224296459|NCT05461118|PROCEDURE|Experimental:Treatment group|Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
224296460|NCT06168318|DRUG|VH4004280 Formulation A|Oral administration of VH4004280 Formulation A in fasted or fed conditions.
224296461|NCT06168318|DRUG|VH4004280 Formulation B|Oral administration of VH4004280 Formulation B in fasted or fed conditions.
224296462|NCT06168318|DRUG|VH4004280 Formulation C|Oral administration of VH4004280 Formulation C in fasted or fed conditions.
224296463|NCT06168318|DRUG|VH4004280 Formulation D|Oral administration of VH4004280 Formulation D in fasted or fed conditions.
224296464|NCT06168318|DRUG|VH4004280 Formulation E|Oral administration of VH4004280 Formulation E in fasted or fed conditions.
224296465|NCT05228496|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
224296466|NCT05228496|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 1 cycle of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
224296467|NCT03755479|DEVICE|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
224296468|NCT01192984|BIOLOGICAL|KW-0761|Intravenously 8 times at 1-week intervals
223391299|NCT02631486|OTHER|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
223391300|NCT00934024|DRUG|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
223391301|NCT01111318|DRUG|BI 10773|2 tablets BI 10773 25 mg single dose
223391302|NCT00648778|DRUG|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
223391303|NCT00648778|DRUG|Loxitane® Capsules 25 mg|25mg, single dose fasting
223391304|NCT04443972|OTHER|PD VitalOs cement®|PD VitalOs cement®\* is a synthetic bone grafting cement designed for bone void filling and bone regeneration in dental surgery
223391305|NCT04443972|OTHER|Hydroxyapatite bone graft|a bioceramic bone substitute, providing a scaffold for bone deposition
223391306|NCT04443972|OTHER|biodegardable collagen membrane|provide efficacious barriers that were interposed between the flap and root surface.
223391307|NCT01927575|DEVICE|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
223391308|NCT01927575|DEVICE|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
223391309|NCT01927575|DEVICE|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
223391310|NCT00725491|DRUG|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
223564158|NCT01031316|OTHER|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
223564159|NCT01031316|OTHER|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
224012035|NCT02417519|OTHER|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
224012036|NCT02417519|OTHER|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
224296469|NCT01598441|DRUG|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
224296470|NCT01598441|DRUG|distilled water|1-2 ml aerosolized distilled water inhalation per session
224296471|NCT01939041|DEVICE|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
223391311|NCT00725491|DRUG|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 \<= 50 pg/ml (\<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
224012037|NCT02316951|DEVICE|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
223391312|NCT01753180|BIOLOGICAL|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
223391313|NCT01753180|DRUG|saline|Local intra-coronary administration of saline at or into the CTO
223391314|NCT02389179|DRUG|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
223391315|NCT04775160|DEVICE|SmartSafe|"The SmartSafe Ecological Momentary Intervention is contained in the MEmind smartphone application and consists of a Safety plan, an Enhanced contact via app (app-EC) intervention, and a mental toolbox. The Safety plan is a set of personalized coping strategies that the patient can use in a suicidal crisis. Our safety plan was adapted to a digital environment, including the possibility to activate pre-recorded messages, lead to websites with health resources, or put the patient in contact with the emergency services. The Enhanced contact via app (app-EC) intervention is inspired by the SIAM project and consists in messages that will be sent via the MEmind app inquiring patients about their mental well-being and informing them of the means to request preferential or urgent care. The mental toolbox contains videos relaxation techniques videos and behavioral activation and mentalization exercises."
223391316|NCT01999920|DRUG|Vilazodone|10mg to 40mg per day for 12 weeks
223391317|NCT01999920|DRUG|Placebo|One to two pills per day for 12 weeks
223391318|NCT03805386|DRUG|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
223391319|NCT03805386|DRUG|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
223391320|NCT00620386|DEVICE|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
223391321|NCT00620386|DEVICE|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
223391322|NCT01200693|DEVICE|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
223391323|NCT01200693|DEVICE|Everolimus eluting stent|Implantation of Everolimus eluting stent
223391324|NCT01200693|DEVICE|Zotarolimus eluting stent|Implantation of Zotarolimus eluting stent
223391325|NCT00991393|DEVICE|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
223391326|NCT03359850|DRUG|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
223391327|NCT01841684|DRUG|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
223391328|NCT01841684|DRUG|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
223391329|NCT04241588|DEVICE|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.
223391330|NCT04241588|OTHER|Control|A 3D printed hand with be fitted to simulate a prosthesis.
223564160|NCT01191736|BEHAVIORAL|No training, assessed within 60 mins|Subjects receive no training in resuscitation
223564161|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
224012038|NCT04662853|DIAGNOSTIC_TEST|Gut microbiota determination from feces samples.|Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
223564162|NCT01191736|BEHAVIORAL|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
224012039|NCT06113887|OTHER|psychoeducation based on acceptance and commitment therapy|Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
224012040|NCT03001076|DRUG|Bempedoic acid|bempedoic acid 180 mg tablet
224012041|NCT03001076|DRUG|Ezetimibe|ezetimibe 10 mg tablet
224012042|NCT03001076|OTHER|Placebo|matching placebo tablet
224012043|NCT03581760|OTHER|Cycling Exercise|Cycling exercise will be performed in the patients once a day.
224012044|NCT03581760|OTHER|Conventional Physiotherapy|Conventional physiotherapy will be performed in the patients twice a day.
224012045|NCT02148640|DRUG|Innovator infliximab|
224012046|NCT02148640|DRUG|Biosimilar infliximab|
224012047|NCT06200129|DIAGNOSTIC_TEST|sws grade 1|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 1.
224012048|NCT06200129|DIAGNOSTIC_TEST|sws grade 2|Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 2
223546881|NCT06715930|PROCEDURE|Interventional treatment|The procedure was performed via the traditional transfemoral arterial approach, under general anesthesia and complete heparin anticoagulation. PEDs were introduced using Marksman or Phenom-27 microcatheters (Medtronic, Irvine, USA), while coils were introduced via Echelon-10 microcatheters (Medtronic, Dublin, Ireland). An appropriate working projection was used to generate three-dimensional rotational angiography. Un-subtracted images were used to verify whether PED was completely deployed and attached to the parent artery. Wall apposition was enhanced using balloon angioplasty if post-deployment imaging indicated inadequate apposition. Overlapping devices were used when a single PED was not enough to cover the aneurysm neck and reconstruct blood flow. Neurointerventionalists with more than 15 years of experience conducted all endovascular procedures. The same dual-antiplatelet therapy was used for 6 months post-procedure, followed by aspirin monotherapy for a minimum of 12 months.
223546882|NCT06716073|PROCEDURE|Surgery|comparison of 2 surgical procedures
223546883|NCT06716944|DEVICE|Acupuncture|self-acupuncture
223546884|NCT06715657|DRUG|Morphine intrathecal|patients intrathecal anaesthesia with morphine
223546885|NCT06715657|DRUG|propofol|patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection 15 min before the end of surgery
223546886|NCT06715657|DRUG|propofol|patients will receive 0.5 mg/kg propofol diluted in 10 ml saline 0.9% IV injection just before intrathecal anaesthesia
223546887|NCT06719401|OTHER|Foot Chest Compression|Foot chest compression is an alternative cardiopulmonary resuscitation (CPR) technique where the rescuer uses one foot to perform compressions on the chest instead of their hands. The heel of the foot is placed on the lower half of the sternum, with the foot parallel to the sternum to ensure effective pressure. The opposite foot provides stability by being positioned beside the patient.
223546888|NCT06719401|OTHER|Hand Chest Compression|Hand chest compression is the conventional method of performing chest compressions during CPR. It involves the use of both hands, with one hand placed over the other on the lower half of the sternum. The rescuer positions their body directly over the patient, using the weight of their upper body to deliver compressions of 50-60 mm depth at a rate of 100-120 compressions per minute. Proper technique includes full chest recoil between compressions, maintaining a straight arm posture, and avoiding pressure on the xiphoid process to minimize injury risks. This method adheres to the 2020 AHA guidelines for high-quality CPR.
223546889|NCT06718023|BEHAVIORAL|Nordic walking|NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
223546890|NCT06718023|BEHAVIORAL|Strength training|Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
223546891|NCT06718023|BEHAVIORAL|Bungy Pump Exercises|Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, , a total of 12 weeks. Participants used professional Bungy Pump Pole.
223546892|NCT06717568|DIAGNOSTIC_TEST|no intervention|This is a diagnostic test with no intervention.
223546893|NCT06715956|OTHER|Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis|This observational study classifies patients with non-cystic fibrosis bronchiectasis into inflammatory subtypes based on sputum analysis. No active treatment or intervention is administered during this observational phase. Participants will later be considered for treatment with HSK31858 as part of an independent clinical trial.
223546894|NCT03070990|DRUG|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
223546895|NCT06716697|BEHAVIORAL|physical and mental fatigue|physical and mental fatigue as a result of exposed to exams
223546896|NCT06714890|DEVICE|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation Combined with Accommodation-related Visual Training
224012049|NCT06200129|DIAGNOSTIC_TEST|control|Group of patients without scattered white lesions in the dueodenum on endoscopy.
224012050|NCT00095420|BEHAVIORAL|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
224012051|NCT00095420|BEHAVIORAL|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
224012052|NCT00095420|BEHAVIORAL|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
224012053|NCT00095420|BEHAVIORAL|Usual training|Participants will receive the usual training offered in their local school districts.
224012054|NCT02823405|DRUG|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
224012055|NCT02823405|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
224012056|NCT04072692|OTHER|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
224012057|NCT04072692|OTHER|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
224296472|NCT01939041|DEVICE|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
223391331|NCT01629511|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
224012058|NCT04072692|OTHER|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
224296473|NCT01939041|BEHAVIORAL|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
224296474|NCT01908413|DRUG|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
223391332|NCT01629511|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
223391333|NCT01629511|DRUG|Busulfan|Given IV
223391334|NCT01629511|DRUG|Clofarabine|Given IV
223391335|NCT01629511|BIOLOGICAL|Filgrastim|Given SC
223391336|NCT01629511|DRUG|Gemcitabine|Given IV
223391337|NCT01629511|DRUG|Methotrexate|Given IV
223391338|NCT01629511|DRUG|Tacrolimus|Given PO
223391339|NCT03290378|DRUG|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
223391340|NCT03290378|OTHER|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
223730476|NCT03973840|DRUG|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
223730477|NCT06263751|OTHER|Product prescription program- NutriConnect Credit|Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F\&V shopping. The Rewards credit can be used either through the Schnucks App or in store.
223730478|NCT06263751|OTHER|Product prescription program- NutriConnect Delivery|Patient receives produce (F\&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
223730479|NCT04139187|OTHER|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
223730480|NCT01693575|DEVICE|Pupil expansion with APX 100 device|Patients with small pupils (\<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
223730481|NCT03043027|DRUG|liposomal bupivicaine|local anesthetic
223730482|NCT03043027|DRUG|Bupivacaine|local anesthetic
223546897|NCT06714890|OTHER|Visual Training|Accommodation-related Visual Training
223546898|NCT02161536|DEVICE|Motus Cleansing System|
223546899|NCT02906410|OTHER|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
223546900|NCT02906410|OTHER|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
223730483|NCT03043027|DRUG|Saline Solution|saline injection
223730484|NCT05195827|DRUG|PRM-125|Antihypertensive
223730485|NCT05643768|BEHAVIORAL|Inspiratory muscle strength training (IMST)|30 breaths/day, 5 days/week, 6 weeks
223546901|NCT00752921|DRUG|etoricoxib|120 mg
223546902|NCT00752921|DRUG|placebo|placebo
223546903|NCT03898284|DIAGNOSTIC_TEST|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
223730486|NCT01388764|DRUG|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
223730487|NCT00982592|DRUG|oxaliplatin|Given IV
223730488|NCT00982592|DRUG|leucovorin calcium|Given IV
223730489|NCT00982592|DRUG|fluorouracil|Given IV
223730490|NCT00982592|OTHER|placebo|Given PO
223730491|NCT00982592|DRUG|vismodegib|Given PO
223730492|NCT00982592|OTHER|laboratory biomarker analysis|Correlative studies
224012059|NCT04802616|DRUG|Ismigen|Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).
224012060|NCT04802616|DRUG|Placebo|Matched tablets without any active substance.
224012061|NCT00156689|DRUG|levetiracetam|
224012062|NCT06058312|OTHER|Self-questionnaire|The self-administered questionnaires to be completed at the time of inclusion will be presented to the patient on a tablet during the inclusion visit and will be completed on the same day in the Day Hospital using the Compusense software. Online self-questionnaires and sensory tests at the 9th week of treatment will also be conducted using the Compusense software in small groups at a designated location within the center.
224012063|NCT06058312|OTHER|Self-questionnaire|The MediLite questionnaire consists of nine items that assess daily consumption of fruits, vegetables, grains, meats and meat products, dairy products, alcohol, and olive oil, as well as weekly consumption of legumes and fish.
223730493|NCT03128346|PROCEDURE|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
223730494|NCT03128346|DRUG|Hydromorphone Hydrochloride|IV, Hydromorphone
223546904|NCT04999735|BEHAVIORAL|CHDR Monitoring Remotely (MORE)|CHDR MORE is a highly customizable platform which allows remote monitoring of patients and trial subjects, data ingestion, and data management. The current infrastructure includes an Android app to unobtrusively collect data from smartphone sensors, and a connection to the Withings Health online platform to collect wearable data. Data is stored on a secure server in a structured data scheme ensuring clear data management processes, forming a prerequisite for comprehensive data analysis. The Android app enables data collection from multiple smartphone sensors (e.g. location data, accelerometer and ambient light) as well as phone usage logs (e.g. app usage, calls and texts).
223546905|NCT04999735|BEHAVIORAL|Withings Steel HR|The Withings Steel HR is a commercially available smartwatch that combines various sensors to measure activity (steps, sleep, etc.) and heart rate (HR). HR is measured using a PPG (photoplethysmogram, i.e. optically obtained volumetric measurement) based on a commercially available sensor (AS7000) incorporating low-noise and high-sensitivity analogue circuitry. The manufacturer supplies the algorithm for converting the PPG signal into HR values. Data is transferred from the watch to the smartphone using the Withings Health Mate app from where it will be uploaded to the output server.
223546906|NCT04999735|BEHAVIORAL|Withings Body+ scale|Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.
224012064|NCT06058312|OTHER|Self-questionnaire|"The CITAS is a self-administered questionnaire consisting of 18 items evaluated on a five-point Likert scale and divided into three dimensions: 1) quantitative changes in taste perception (hypogeusia and ageusia), 2) qualitative changes in taste perception (heterogeusia, cacogeusia), and 3) nutrition-related problems (difficulty eating hot or fatty foods).~Using a Likert scale ranging from 1 to 5 (where 1 = no difficulty or absence of disturbance and 5 = maximum difficulty or disturbance), CITAS assesses the four dimensions of taste disturbances: taste intensity, discomfort, phantogeusia, and parageusia, as well as overall taste alterations.~For the original version by Kano and Kanda (2013), five items assessing changes in smell from the modified CITAS version by Drareni et al. 2021 will be added in this study."
224012065|NCT06058312|OTHER|Self-questionnaire|"Food neophobia will be assessed using the Food Neophobia Scale (FNS) developed by Pliner \& Hobden (1992). The FNS consists of ten statements evaluated on a 7-point agreement scale ranging from 1 = I strongly disagree to 7 = I strongly agree. Individual FNS scores are calculated as the sum of the ratings given to the ten statements after reversing the neophilic items; thus, scores theoretically range from 10 to 70, with higher scores reflecting higher levels of food neophobia."
224012066|NCT06058312|OTHER|Self-questionnaire|The quality of life related to food in cancer patients is composed of 46 items with a 4-point scale (never, almost never, almost always, always). The questionnaire is divided into different subdomains: Cooking, where one eats and conviviality, Eating and drinking, After eating.
224012067|NCT06058312|OTHER|Self-questionnaire|Individual baseline disgust sensitivity is assessed using the Disgust Sensitivity-Short Form (DS-SF) questionnaire; this questionnaire is a shortened version of the disgust scale aimed at measuring disgust of animal origin, based on contamination and revulsion (Haidt, 2004; Haidt et al., 1994; Inbar, Pizarro, and Bloom, 2009; Olatunji et al., 2007). This measure consists of 8 items divided into 2 parts. In the first part, statements were rated on a scale from 1 (not at all agree-very false about me) to 5 (completely agree-very true about me); for the second part, additional statements were rated from 1 (not at all disgusting) to 5 (extremely disgusting). The total disgust sensitivity score is obtained by summing the scores after two items have been reversed and ranges from 8 to 40.
224012068|NCT06058312|OTHER|Self-questionnaire|The subscale of reward sensitivity from the short version of reward and punishment sensitivity has been selected (17 items). Each item will be assessed on a 4-point Likert scale, ranging from 1 (completely no) to 4 (completely yes).
224012069|NCT06058312|OTHER|Self-questionnaire|"The EmoPrefMed questionnaire was developed to measure declared appreciation and emotional responses to selected Mediterranean diet (RM) products and changes in appreciation before and after chemotherapy.~The assessment of the acceptability of a series of RM foods (listed in the questionnaire appendix) will be evaluated using a nine-point hedonic scale ranging from a minimum of 1 = I don't like it at all to a maximum of 9 = I like it a lot (Peryam \& Pilgrim, 1957).~Emotions will be assessed using a check-all-that-apply (CATA) list of emotions, including 4 negative and 4 positive emotions with low, moderate, and high arousal levels (It brings me joy, It intrigues me, It relaxes me, It annoys me, It leaves me indifferent, It makes me sad, It's monotonous, It disgusts me). Patients will be asked to select all the emotions they deem appropriate to describe the food product."
224012070|NCT06058312|OTHER|Self-questionnaire|"Food-related attitudes will be measured using the HTAS (Health and Taste Attitude Scale) proposed by Roininen et al. (1999), consisting of six subscales focusing on perceived health and taste aspects of foods. The two scales selected in this study are general interest in health (eight items, measuring overall interest in a healthy diet) and the use of food as a reward (six items, measuring attitudes towards using food as a reward). Each subscale consists of an equal number of statements phrased positively and negatively (Roininen et al., 1999). All items were rated on a seven-point category scale, ranging from strongly disagree to strongly agree. As suggested by Roininen et al. (1999), negative statements were reversed and recoded for the calculation of final scores."
223730495|NCT03128346|DRUG|Aspirin|Oral Aspirin
223730496|NCT03128346|DRUG|Acetaminophen|Oral acetaminophen
223730497|NCT03128346|DRUG|Fentanyl|IV, fentanyl
223730498|NCT02404376|DRUG|Exenatide|Intravenous administration of Exenatide
224127537|NCT06370936|OTHER|Standardized diet with commercially available PBMAs (intervention products)|Fully controlled standardized diet with commercially available Plant-Based Meat Analogues (PBMAs). Fully controlled means that all food products 8-week intervention will be provided by the HNRU at Wageningen University. The standardized diet is designed to maintain body weight, and follows the average nutritional pattern of middle-aged men and women in the Netherlands, while taking individual habitual energy intake into account. The diet will have the same dietary composition for each person and energy intake will be based on the energy requirements of an individual. The diet is the same for both intervention periods, except for the origin of meat products: PBMAs versus meat of animal origin.
224127538|NCT04905381|BEHAVIORAL|Usual care|This arm receives usual care (control group)
223730499|NCT02404376|OTHER|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
223730500|NCT02404376|DRUG|Placebo|Intrevenous administration of Placebo
223546907|NCT04999735|BEHAVIORAL|Withings Blood Pressure Monitor|Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
223546908|NCT00971282|DRUG|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
224012071|NCT06058312|OTHER|Self-questionnaire|"The response to PROP (6-n-propyl-2-thiouracil) is measured using 1.5 cm diameter paper disks previously soaked in a solution of deionized water with a concentration of 3.2 mM PROP, dissolving 0.5477 g/L of PROP. Each paper disk will contain approximately 0.280 mg of PROP. Participants are asked to place the paper disk on the tip of their tongue for 20 seconds, then remove it and assess the perceived bitter intensity on a Labelled Magnitude Scale (LMS).~The LMS scale consists of a vertical line of 100 units with labels placed at no sensation, 0; barely detectable, 1.4; weak, 6; moderate, 17; strong, 34.7; very strong, 52.5; and the strongest imaginable sensation of any kind, 100. Numeric labels are not reported on the scale. Participants are instructed to think of the strongest imaginable sensation as the most intense sensation they can imagine in the realm of taste. Participants are encouraged to ask questions about the use of the scale if they need more clarification."
224012072|NCT06058312|OTHER|Self-questionnaire|The odors (Mint, Anise, Banana, Pine, Garlic, Cinnamon, Lemon) are trapped in tightly packed microcapsules (aminoplast type, diameter: 4-8 μm). Microcapsule-based ink is printed on cardboard paper (SILK-250 g; Size: 11 cm × 21 cm). Each odorant has been printed in a defined area (2 cm in diameter). The odor is released by simply rubbing the printed microcapsule reserve (scratch-and-sniff method).Patients receive a disposable single-use sample and are asked to identify the odors and evaluate on a visual analog scale the perceived intensity, perceived irritation, and appreciation of each odor.
224012073|NCT06058312|OTHER|Self-questionnaire|"Two model foods were developed to investigate responses to variations in sweetness, acidity, and freshness. The first range consists of Apple-Mint Juice, composed of four samples containing different concentrations of mint syrup (0, 15, 60, 240 g/kg). The second range is a chickpea mousse made up of four samples containing different quantities of citric acid and glucose-fructose syrup (glucose-fructose syrup: 0, 50, 100, 200 g/kg; citric acid: 8, 6, 4, 4 g/kg). Participants are asked to evaluate the samples using the Labelled Affective Magnitude Scale. Regarding the LAM scale, subjects are instructed to consider the extremes of appreciation, the best I can imagine and the worst I can imagine. After a break, they are asked to taste the samples again and rate the intensity of sweetness, acidity, apple flavor, mint flavor, and freshness on the Labeled Magnitude Scale: from 'not detectable' to 'the strongest imaginable'."
224012074|NCT03374527|OTHER|blood sample collection|Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
224012075|NCT03374527|PROCEDURE|Synovial Fluid collection|Synovial fluid is collected when prescribed in patients with psoriatic arthritis
224012076|NCT05253287|DRUG|Growth Hormone|GH therapy will be initiated at a low dose of 2U/day and titrated slowly based on IGF-1 levels) subcutaneously for 1 year.
224012077|NCT05087901|DIAGNOSTIC_TEST|Multifocal electroretinogram|A device that records electric potentials generated by the retinal photoreceptors and neural elements in a multifocal fashion
224012078|NCT04463966|DRUG|Tranexamic acid injection|1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
224012079|NCT04831918|DEVICE|Mueller cemented cups|Patients undergo total hip arthroplasty with the implant of Mueller cemented cups
224012080|NCT00229138|DRUG|EC-MPS, Tacrolimus|
224012081|NCT02505438|BEHAVIORAL|Exercise|
224127539|NCT04905381|BEHAVIORAL|LENA Star Program sessions|LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.
223564163|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
223730501|NCT00276159|DRUG|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
223730502|NCT04059679|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
223730503|NCT04059679|DRUG|Aspirin 81 mg|EC aspirin 81 mg qd
223730504|NCT00333866|DRUG|pregabalin|600mg/day
223730505|NCT00333866|DRUG|pregabalin|450mg/day
223730506|NCT00333866|DRUG|pregabalin|300mg/day
223730507|NCT00333866|DRUG|placebo|placebo
223730508|NCT02542878|DEVICE|Foam roller|A bout of 60 seconds of myofascial release with foam roller
223730509|NCT03508817|DRUG|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
223730510|NCT02533947|BEHAVIORAL|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
223730511|NCT02533947|BEHAVIORAL|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
223730512|NCT02370979|BIOLOGICAL|Blood samples|
223546909|NCT00971282|OTHER|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
223546910|NCT05246202|BEHAVIORAL|Alcohol-Anxiety Personalized Feedback Intervention 2.0|AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
223546911|NCT05246202|BEHAVIORAL|Control Personalized Feedback Intervention|C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
223546912|NCT03172754|DRUG|Nivolumab|PD-1 inhibitor
223546913|NCT03172754|DRUG|Axitinib|Tyrosine kinase inhibitor
223546914|NCT00211796|DRUG|Divalproex Sodium ER|
223546915|NCT03400358|OTHER|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
223546916|NCT01779336|DRUG|PL225B|"* Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
223546917|NCT00778076|DEVICE|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
223546918|NCT00778076|DEVICE|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
223546919|NCT01904396|DRUG|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
223546920|NCT03914430|OTHER|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
223546921|NCT03474263|BIOLOGICAL|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
223546922|NCT04426175|DEVICE|2D and 3D cutting method using a low energy Femtosecond laser LDV Z8 for LASIK flap cutting|2D and 3D cutting methods were randomly used in same subjects
223546923|NCT02155101|DRUG|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
223546924|NCT02155101|DRUG|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
223546925|NCT03690401|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
224012082|NCT01843790|DRUG|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
224127542|NCT05761275|PROCEDURE|Elective cystectomy|Adnexal cyst removal for presumed benign adnexal pathology.
224127543|NCT05761275|PROCEDURE|Elective oophorectomy|Ovarian removal for presumed benign adnexal pathology.
223546926|NCT03690401|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
223546927|NCT04564235|GENETIC|genome-wide analyses|genome-wide analyses will be done in patients and parents (father, mother)
223546928|NCT04564235|GENETIC|Search for de novo mutations in paternal sperm samples|Sperm analysis will be done in paternal samples
223546929|NCT01405404|BEHAVIORAL|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
223546930|NCT01405404|OTHER|Parent Training|12-session group on parenting skills and child behavior management
223546931|NCT02948699|DIETARY_SUPPLEMENT|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
223546932|NCT02141230|DRUG|Alli® 60 mg|Participants purchasing Alli®
223546933|NCT02944721|GENETIC|Genetical analyses|
223546934|NCT02944721|OTHER|Chronic pain identification questionnaires|
223546935|NCT02944721|OTHER|Neurophysiological and psychophysical evaluations|
224127544|NCT05761275|PROCEDURE|Elective salpingectomy|Tubal removal for presumed benign adnexal pathology.
224127545|NCT05761275|PROCEDURE|Elective tubal sterilization|Tubal obstruction as a definitive contraceptive method (tubal cauterization with or without sectioning, partial or total removal of both tubes, or obstruction with small clips/ligatures).
224127546|NCT06493825|OTHER|Aurora Mindfulness app versus sham|It would either immersive virtual reality exposure for the experimental group or non-immersive virtual reality exposure for the placebo group.
224127547|NCT05355350|DRUG|Piperacillin / Tazobactam Injection|4.5 grams QID
224127548|NCT05355350|DRUG|Meropenem|1 gram TID
224127549|NCT03893175|DRUG|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
224127550|NCT03893175|DRUG|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
224127551|NCT03893175|DRUG|Placebo|By mouth
224127552|NCT03893175|DRUG|Oxycodone|5 mg by mouth every 6 hours as needed for pain
224012083|NCT01843790|DRUG|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
224296475|NCT02613741|OTHER|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
224296476|NCT03914118|DRUG|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
224296477|NCT03914118|DRUG|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
224296478|NCT03914118|DRUG|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
223546936|NCT02944721|OTHER|Quality of life questionnaires|
223546937|NCT05018195|PROCEDURE|Excise adipose tissue|Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
223546938|NCT00001901|DRUG|Etanercept|
224012084|NCT02235389|DRUG|Alteplase (Actilyse)|
224012085|NCT02235389|DRUG|Standard therapy|
224012086|NCT02878889|DRUG|S-1|
224012087|NCT03235102|OTHER|No treatment given|Completion of a survey
224012088|NCT05419973|OTHER|Anthropometric measurement for pregnant women|Weight, length, upper arm circumference
224012089|NCT05419973|OTHER|Anthropometric measurement for infants|birth weight, length, head circumference, nutritional status
224012090|NCT05419973|OTHER|Blood sampling|3 ml of blood will be taken, 1,5 ml each to measure the complete blood count, and other 1,5 ml to measure ferritin, Fe serum, vitamin D levels, vitamin D receptors, IL-6 and IL-10.
224012091|NCT03189745|BIOLOGICAL|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
224012092|NCT00502463|DRUG|Docetaxel|75mg/m² day 1
224012093|NCT00502463|DRUG|Cisplatin|75mg/m² day 1
224012094|NCT00502463|DRUG|5-FU|750mg/m²/day day 1-5
224012095|NCT00502463|RADIATION|Radiotherapy|standard fraction up to a total dose of 70Gy/35 fractions/7weeks or accelerated regimen, up to a total dose of 72Gy/42 fractions over 6 weeks
224012096|NCT00502463|DRUG|Cetuximab|250mg/m²/week after an initial loading dose of 400mg/m²
224012097|NCT03592550|DEVICE|Ultrasound imaging|Abdominal ultrasound imaging of the liver
224012098|NCT00160602|DRUG|Certolizumab Pegol|
224012099|NCT04836689|DEVICE|nasal intermittent positive pressure ventilation (NIPPV).|"NIPPV will be administered using Leoni (Heinen\&Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).~After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.~For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate\<100 bpm), saturation\<90% and\>94% episodes (as measured in the monitor), 1-hour saturation histogram clasification."
224012100|NCT06326593|OTHER|Wii aerobic training|Nintendo Wii Fit Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character
224012101|NCT06326593|OTHER|conservative chest care|Diaphragmatic deep breathing exercises Bronchial hygiene techniques Assisted cough Stretching exercises and ROM exercises for both upper and lower limbs
224012102|NCT02022189|PROCEDURE|Renal Biopsy|
224012103|NCT04192903|DRUG|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
224012104|NCT00727701|BEHAVIORAL|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
224296479|NCT03178721|DIAGNOSTIC_TEST|blood sample|study B regulatory in blood and its correlation with atherosclerosis
223546939|NCT05487690|OTHER|3D printing guide plate|3D-printed customized guide plate will be used to guide the puncture in the spinal minimally invasive and interventional surgeries. to help to reduce intra-operative radiation.
223546940|NCT05487690|OTHER|Conventional guidance|The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
223546941|NCT00869492|DRUG|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
223546942|NCT00869492|DRUG|nadifloxacine|Nadifloxacine 1% cream twice dailly
223546943|NCT04111796|OTHER|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
223546944|NCT03962907|DRUG|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
224012105|NCT00895154|BEHAVIORAL|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
224012106|NCT00895154|BEHAVIORAL|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
224012107|NCT01993927|DRUG|Voglibose|Voglibose Tablets / Voglibose OD Tablets
223730513|NCT06408623|DRUG|chidamide combined with Sintilimab and bevacizumab|chidamide combined with Sintilimab and bevacizumab
223730514|NCT00456547|PROCEDURE|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
224012108|NCT05084469|PROCEDURE|PET-MRI in pain-free remission period|Patients will performed PET-MRI scans. A first 30 minutes acquisition will be performed at time=60min after injection. A second 75 minutes acquisition will be performed at time=150min. Each scans will contain functional dynamic \[18F\]F13640 PET acquisition, anatomical and functional MRI images acquisition and pain evaluation using a score visual analogic scale.
223730515|NCT01804374|DRUG|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
223730516|NCT01804374|DRUG|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
223730517|NCT00330564|DRUG|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
223730518|NCT02716571|OTHER|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
223730519|NCT00529854|OTHER|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
223730520|NCT01271660|DRUG|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
223730521|NCT01271660|DRUG|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
223391362|NCT02890173|DRUG|CS-3150|
223391363|NCT02890173|DRUG|Eplerenone|
223391364|NCT04617457|DRUG|nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)|preoperative chemotherapy
223391365|NCT05143060|DIETARY_SUPPLEMENT|Cereal powder|Eat or drink oral glucose (reference) the valley of fiber powder upgrade formula, perfect meals, by extraction shu cereal bars, light appearance suits (by extraction shu compound dietary fiber powder, feeding combination 1:1) and 17 extraction enzyme 6 kinds of food respectively in different periods.
223391366|NCT05143060|DIETARY_SUPPLEMENT|Pure glucose powder|Pure glucose powder
223391367|NCT04601766|DRUG|APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
223730522|NCT03296930|DRUG|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
223730523|NCT03296930|DRUG|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
223730524|NCT00068497|DRUG|gefitinib|Given orally
223730525|NCT00203125|DRUG|rasagiline mesylate|0.5 or 1 mg oral, once-daily
224012109|NCT00777088|DEVICE|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
224012110|NCT04495101|BIOLOGICAL|Prolastin|Intravenous infusion 120 mg/kg
223730526|NCT00203125|OTHER|tyramine|50 mg once daily
223730527|NCT06361485|BIOLOGICAL|Lumbar Injections with 10cc's of Wharton's Jelly Allograft|Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
223730528|NCT00005094|DRUG|celecoxib|Given orally
223730529|NCT00005094|OTHER|placebo|Given orally
223730530|NCT01660698|DIETARY_SUPPLEMENT|Maltodextrin|maltodextrin powder
223730531|NCT01660698|DIETARY_SUPPLEMENT|Probiotic|probiotic blended in maltodextrin powder
223730532|NCT01421108|BEHAVIORAL|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
223730533|NCT01421108|BEHAVIORAL|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
223730534|NCT01102504|DRUG|Placebo|Placebo
223730535|NCT01102504|DIETARY_SUPPLEMENT|Ateronon|Tomato extract containing 28 mg lycopene/ day
223730536|NCT00673465|DRUG|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
223730537|NCT00673465|DRUG|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
223730538|NCT00673465|DRUG|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
223730539|NCT03578159|OTHER|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
224012111|NCT04495101|DRUG|Standard Medical Treatment|Standard medical treatment per local policies or guidelines
223546945|NCT03962907|DRUG|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
223546946|NCT04247893|DEVICE|blood flow restriction|Occlusion training is an exercise approach whereby resistance exercise or aerobic exercise is performed whilst an occlusion cuff is applied to proximal aspect of the muscle.
223391368|NCT04601766|DRUG|APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2|Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)
223391369|NCT00942357|DRUG|Carboplatin|Given IV
223391370|NCT00942357|DRUG|Cisplatin|Given IV
223546947|NCT04247893|DEVICE|Photobiomodulation|Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.
223546948|NCT04247893|DEVICE|Placebo photobiomodulation|Placebo photobiomodulation - photobiomodulation device turned off.
223546949|NCT04266392|DRUG|[18F]-DCFPyl Ligand|To assess the performance of \[18F\]-DCFPyl PET with whole-body MRI and multiparametric pelvic/prostate MRI for PCa detection in men with recurrence as determined by biochemical PSA level or evidence on CIM. Results of tracer uptake and MRI image features on whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on CIM that usually includes bone scan (BS) and CT scan of the abdomen and pelvis, or PET imaging with F-18 Fluciclovine.In addition, in patients who undergo biopsy when performed as standard of care, we will correlate image features directly with histopathological findings on lesion biopsy to directly demonstrate that 'radiotracer and/or MRI positive' lesions contain tumor cells.
223546950|NCT05253937|DRUG|Epinephrin|The study will enroll acute myocardial infarction patients who suffered from a cardiac arrest in the cardiac catheterization laboratory during percutaneous intervention procedure. Cardiac Resuscitation was performed according to the European Resuscitation Council (ERC) Guidelines. The preferred route of epinephrine administration was through the central venous access (by internal jugular or subclavian vein). Thus, if available, it was the preferred method of medication delivery. However, in cases without central venous access, the route of epinephrine administration (peripheral intravenous or arterial intracoronary) during cardiac arrest was left to the treating physicians.
223730540|NCT05423028|PROCEDURE|Ultrasound-guided nerve hydrodissection|Peri- median nerve injection for hydrorelease and decompression
224012112|NCT05609110|DEVICE|Remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg.
224012113|NCT05609110|DEVICE|Sham remote ischemic conditioning|Remote ischemic conditioning is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg.
224012114|NCT05240079|DEVICE|Heart rate measurement with Caducy system (twice). SpO2 measurement with Caducy system (Twice).|Heart rate and SpO2 measurement with Caducy (the visage of the subject is filmed 30 seconds and 1 minute with a camera) and heart rate and SpO2 measurement with gold standard (heart rate monitor and oximeter pod linked to an acquisition station). The procedure is repeated twice.
223391371|NCT00942357|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
223391372|NCT00942357|DRUG|Paclitaxel|Given IV
223391373|NCT00942357|OTHER|Quality-of-Life Assessment|Ancillary studies
223391374|NCT00942357|RADIATION|Radiation Therapy|Undergo radiation therapy
224012115|NCT02247973|BIOLOGICAL|mesenchymal stem cells|Intravenous administration of up to 1\~2x10\^6 MSCs per kg,for 2 times,d0 and d14
224012116|NCT02247973|BIOLOGICAL|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
224012117|NCT02955732|DEVICE|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
224012118|NCT04715165|DRUG|USG-STAP with bupivacaine and dexmedetomidine|Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
224012119|NCT04715165|DRUG|IP bupivacaine and dexmedetomidine|Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
224012120|NCT03300973|PROCEDURE|sling surgery|transoburator vaginal tape ,inside out procedure under spinal anathesia
224012121|NCT04428073|BIOLOGICAL|Covax-19™|Therapeutic vaccine for SARS-CoV-2 infection
224012122|NCT03286101|DRUG|0.5% Ivermectin lotion|The intervention is composed of a single application of the 0.5% ivermectin lotion.
223391375|NCT00428701|DRUG|Esomeprazole Sodium|
223391376|NCT01397357|OTHER|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
223391377|NCT00472563|DRUG|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
223546951|NCT02151916|OTHER|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
223730541|NCT04383405|OTHER|Aquatic Training|Aquatic Training training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises follow a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e. catching a ball thrown by the therapist). Subjects performed three sessions a week for four weeks and each session lasting 45 minutes. The training was carried out by a physiotherapist who had at least 5 years of experience in aquatic neurorehabilitation.
223391378|NCT00882518|DRUG|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
224012123|NCT03286101|DRUG|Vehicle|The intervention is composed of a single application of the vehicle control.
224012124|NCT00672945|DRUG|PRX-03140|
224012125|NCT00672945|DRUG|Placebo|
224012126|NCT02850484|DRUG|Budesonide|Inhaled corticosteroid
224012127|NCT02850484|DRUG|Formoterol|Long Acting Beta Agonist (LABA)
224012128|NCT04670939|PROCEDURE|breath exercises|diaphragmatic breathing exercise that used during weaning is the respiratory physiotherapy
224012129|NCT03948165|PROCEDURE|Distal Transradial Access|The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
224012130|NCT02047331|PROCEDURE|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
224012131|NCT02047331|PROCEDURE|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
224012132|NCT04328883|DRUG|Aspirin|Oral and inhaled ASA formulations
224012133|NCT06378385|BEHAVIORAL|Childhood Early Oral Aging Syndrome index|Development and validation of a Childhood Early Oral Aging Syndrome index for the primary dentition as a diagnostic and epidemiological survey tool considering the current changes found in the pediatric population.
224012134|NCT00421954|DRUG|Ziprasidone|subjects will use ziprasidone
224012135|NCT02712710|DEVICE|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
224012136|NCT02729831|BEHAVIORAL|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
224012137|NCT02729831|BEHAVIORAL|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
224012138|NCT02729831|BEHAVIORAL|Provider Report|A short report that includes the patients' goals and treatment preferences
224012139|NCT03046654|DIAGNOSTIC_TEST|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os'.
224012140|NCT03046654|DIAGNOSTIC_TEST|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
224012141|NCT03046654|DIAGNOSTIC_TEST|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
224012142|NCT00460226|DRUG|lamotrigine|lamotrigine treatment for 12weeks
224012143|NCT03206762|DEVICE|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
224012144|NCT00004815|DRUG|growth hormone|
224012145|NCT00614965|DRUG|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
224012146|NCT00614965|DRUG|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
224012147|NCT00614965|DRUG|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
224127553|NCT06553313|DEVICE|Micro-Western Array|The subjects first took the energy measurement of the pulse sphygmograph and Ryodoraku, rested for 20 minutes, and then repeated the measurements again. In order to comply with the acupuncture treatment course was 5 weeks in the previous study, we have two blood draw point. Each subject's blood was drawn for the first time, and then for the second time in 5 weeks later. Each subject drew 10ml of blood each time. The blood samples are analyzed by Micro-Western Array (MWA) and Enzyme-linked immunosorbent assay (ELISA) to obtain the serum protein content value of healthy individuals.
224127554|NCT04420416|OTHER|Survey|The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
224127555|NCT00279552|DRUG|Recombinant human intrinsic factor|
224127556|NCT04181567|OTHER|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
224127557|NCT04181567|DRUG|agomelatine|agomelatine
223391379|NCT00882518|DRUG|Chlorpromazine|50 mg, oral, double dose
223391380|NCT05596110|BEHAVIORAL|TENS and KT|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
224012148|NCT05321459|OTHER|Neurological prognosis|"In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool."
224012149|NCT04265326|OTHER|Measurement of Quality of Life|Quality of life will be measured using Head and Neck Cancer Inventory and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
224012150|NCT00211211|DEVICE|Balloon Kyphoplasty|
224127558|NCT04181567|DRUG|Placebo|placebo
223546952|NCT02151916|OTHER|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
223546953|NCT02319460|BIOLOGICAL|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
223546954|NCT02319460|BIOLOGICAL|Plasma|
223546955|NCT00003420|PROCEDURE|computed tomography|
223546956|NCT03397524|OTHER|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
223546957|NCT04106258|DRUG|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
223546958|NCT03692403|DRUG|Quinagolide 360 µg|Vaginal ring containing quinagolide 360 µg for daily releases
223546959|NCT03692403|DRUG|Quinagolide 720 µg|Vaginal ring containing quinagolide 720 µg for daily releases
223546960|NCT03692403|DRUG|Quinagolide 1080 µg|Vaginal ring containing quinagolide 1080 µg for daily releases
223546961|NCT03692403|DRUG|Placebo|Matching placebo
223546962|NCT05783895|DIAGNOSTIC_TEST|Post screening diagnostic test|1\) anti-PF4/heparin antibody test (ELISA) and 2) in vitro platelet aggregation tests. The diagnosis of HIT is made when both tests are positive or when a platelet aggregation test is positive.
223546963|NCT06069830|DRUG|4 cycles of ESA regimen with sandwiched radiotherapy|Pegaspargase, 2500U/m2, i.m. d1; etoposide, 200mg, p.o., d2-d4; Dexamethasone, 40mg, p.o. d2-d4；
223546964|NCT06069830|DRUG|2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|Pegaspargase, 2500U/m2, IM, d1; PD-1 monoclonal antibody, 200mg, i.v. d2;
223546965|NCT06069830|DRUG|2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|PD-1 monoclonal antibody, 200mg, i.v. d1
223546966|NCT03985280|DEVICE|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
223546967|NCT03985280|DRUG|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
224012151|NCT00453791|DRUG|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
224012152|NCT00453791|DRUG|Placebo|Placebo MDI will be given to the subjects.
224127559|NCT03854643|OTHER|Pilates group|Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
224127560|NCT03854643|OTHER|Control group|These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
224127561|NCT01594632|DRUG|Jadelle|LNG containing subdermal contraceptive implant
223546968|NCT03972618|BEHAVIORAL|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
223546969|NCT03938051|OTHER|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
223546970|NCT03938051|OTHER|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
224127562|NCT01594632|DRUG|Sino-implant (II)|LNG containing subdermal contraceptive implant
223546971|NCT04310696|OTHER|Buteyko Breathing exercises|Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
223546972|NCT04310696|OTHER|Pursed lip breathing|Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
223546973|NCT02529111|DEVICE|"Echonavigator software"|
223546974|NCT01147393|DRUG|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over \~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
223546975|NCT01147393|BIOLOGICAL|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
223546976|NCT00752492|OTHER|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
223546977|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
223546978|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
223546979|NCT01444001|BIOLOGICAL|Pneumococcal Vaccine|0.5 mL, intramuscular
223546980|NCT03644810|DIAGNOSTIC_TEST|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
223546981|NCT03644810|DIAGNOSTIC_TEST|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
223546982|NCT03644810|PROCEDURE|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
223391381|NCT05596110|BEHAVIORAL|TENS and sham taping|TENS will be delivered using three E704SD TIMER TENS devices (or similar) through pairs of electrodes placed on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
223391382|NCT05596110|BEHAVIORAL|KT and sham TENS|KT (Kinesio Tex Gold) will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants. In addition, sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs.
223391383|NCT05596110|BEHAVIORAL|Sham TENS and sham taping|Sham TENS will be applied on the medial and lateral joint lines of the knee and ankle joints and the anterior and posterior joint lines of the hip joint of both legs. In addition, sham tapes will be applied to major postural muscles including the bilateral gluteus medius (i.e., crosses hip joint), quadriceps (i.e., crosses the knee joint), and gastrocnemius (i.e., crosses ankle joint) of the participants.
223391384|NCT01723800|DRUG|PI3K inhibitor BKM120|Given PO
223391385|NCT01723800|DRUG|pemetrexed disodium|Given IV
223391386|NCT01723800|DRUG|carboplatin|Given IV
223391387|NCT01723800|OTHER|laboratory biomarker analysis|Correlative studies
223391388|NCT01723800|OTHER|pharmacological study|Correlative studies
223391389|NCT01723800|PROCEDURE|quality-of-life assessment|Ancillary studies
223391390|NCT04395456|DRUG|AMY-101|C3 complement inhibitor
223391391|NCT04395456|OTHER|WFI 5% glucose|Placebo
223391392|NCT04861753|OTHER|Reiki and back massage|In the current study, at the beginning of the treatment, the researcher held his hands 2-3 cm above the patient sand adjusted the aura of the patient by making circular movements from the head to the feet. After this process of aura attunement, the researcher placed his hands directly on the patient's body. In the areas where the practitioner had placed his hands for an average of three minutes, starting from between the eyes, the researcher felt various degrees of warmth and tingling in his palms. Only the back was left exposed to prevent the patient becoming cold. The researcher took a little non-aromatic baby oil in hand and heated it, then began a 20-minute-long massage. The massage consisted of 6.5 minutes of effleurage (stroking), 3.5 minutes of petrissage (kneading), 13 minutes of effleurage and seven minutes of petrissage.
223391393|NCT02343653|BEHAVIORAL|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training."
223391394|NCT02343653|BEHAVIORAL|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
223391395|NCT02137252|DRUG|Naltrexone|
223391396|NCT02137252|DRUG|Sugar Pill|
223391397|NCT03224728|DEVICE|intraocular lens|
223391398|NCT06966492|DRUG|Stannous Fluoride Toothpaste (SnF)|stannous fluoride toothpaste
223391399|NCT00435669|DRUG|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
223391400|NCT00435669|DRUG|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
223391401|NCT05623501|DRUG|Dihydromyricetin|Dose-escalation and lysine preparation
223391402|NCT02465905|OTHER|raw milk|
223391403|NCT02465905|OTHER|Heated milk|
223391404|NCT01559077|DRUG|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
223391405|NCT01559077|DRUG|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
223391406|NCT00154661|DRUG|pentoxifylline|
223391407|NCT01971528|DEVICE|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
223391408|NCT01971528|OTHER|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
224127563|NCT02426372|BIOLOGICAL|QBECO SSI|QBECO Site Specific Immunomodulators
224127564|NCT00818324|DRUG|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
223391409|NCT03797911|COMBINATION_PRODUCT|Active resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Activated resistive capacitive monopolar radiofrequency is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
223391410|NCT03797911|COMBINATION_PRODUCT|Inactive resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Disactivated resistive capacitive monopolar radiofrequency inactived is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
223391411|NCT02813915|DEVICE|NICOM|Use of NICOM and PLR to obtain patient fluid status
223546983|NCT03457610|BEHAVIORAL|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
223546984|NCT02027727|OTHER|No Intervention|no intervention- tihs is an observational study
223546985|NCT01563900|DEVICE|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
223546986|NCT01563900|DEVICE|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
223564164|NCT01191736|BEHAVIORAL|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
224127565|NCT05903300|OTHER|Surveys and Questionnaires|The intervention consists of completing the MIPIM-P, QuickDash, and Brief Pain Inventory questionnaires.
224127566|NCT05544019|DRUG|SGR-1505|SGR-1505 will be administered orally.
224127567|NCT00636376|PROCEDURE|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
224127568|NCT00138034|PROCEDURE|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
224127569|NCT05509231|BEHAVIORAL|High-intensity exercise|Gross motor physical fitness activities to improve proprioceptive awareness, motor control, and coordination.
224127570|NCT05509231|DEVICE|Wearable glove and arm sleeve device to measure movement|Sign language and other fine motor skills activities using wearable technology.
224127571|NCT04709991|PROCEDURE|Endovascular procedure|Creation of a bone and arterial panorama using EndoNaut® software. The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.
224296480|NCT04556552|DEVICE|Non invasive VN stimulation (nVNS)|"Stimulation of vagus nerve with active device. Participants will be administered nVNS using the electroCore GammaCore-S non-invasive VNS device. The intensity of the stimulus will be adjusted by the user, to the maximum tolerable level to ensure nVNS without causing excessive pain, the burst frequency to 5 kHz, and the envelope frequency to 25 Hz.~The duration of delivery will be 2 minutes, and the beginning will coincide with initiation of acquisition of the HR-PET scan which will be 90 seconds in duration; following an additional 8 minutes, a second VNS delivery will be administered, in conjunction with which another scan will be obtained."
223391412|NCT03599817|BEHAVIORAL|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
223391413|NCT05548114|PROCEDURE|EUS-guided gastrojejunostomy|AXIOS lumen-apposing metal stent will be used to create a gastrojejunostomy under EUS guidance.
224012153|NCT05096520|PROCEDURE|radiofrequency|the radiofrequency needle will be advanced percutaneously towards the intermedius genicular nerve on the periosteum of the distal femoral shaft region until bone contact is achieved. In addition to imaging the nerve with ultrasound, sensory stimulation at 50 Hz frequency will be applied with a threshold value less than 0.6 V in order to determine its position more accurately. In order to prevent the inactivation of the motor nerves, the relevant nerve will be tested for the absence of fasciculation in the region of the lower extremity compatible with the application with the stimulation with a frequency of 2.0 V and 2 Hz. Before the activation of the Baylis brand radiofrequency generator, an injection of 1 ml of 2% lidocaine will be made, then the radiofrequency electrode will be added to the needle and the temperature level at the tip of the electrode will be increased to 80 degrees for 2 minutes, the procedure will be performed for each genicular nerve.
224012154|NCT05096520|PROCEDURE|control|The intermedius genicular nerve will be found under US guidance and the genicular nerve will be blocked by injecting 1 ml of 2% lidocaine.
224012155|NCT05096520|DRUG|2% lidocaine|2% lidocaine
224012156|NCT01141153|DRUG|Acetylsalicylic Acid + clopidogrel + acenocoumarol|"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent"
224012157|NCT01141153|DRUG|Acetylsalicylic Acid + clopidogrel|"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent."
224012158|NCT02341443|PROCEDURE|Implants|"Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
224012159|NCT03243682|PROCEDURE|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
224127572|NCT06536153|COMBINATION_PRODUCT|Amaranth grain flat bread|The recipe will be produced according to the recommended dietary allowance (RDA); based on RDA, 200 g of flat-bread (30% chickpea and 70% amaranth grain) comprised 30 mg of iron, which can satisfy 50% of RDA supposing 15-20% iron absorption (54). A prior study concluded that the acceptability was satisfactory in the community (55). Also, a study from the Hawassa University Department of Food Sciences reported that amaranth-grain flat-bread was safe for consumption for 48 hours after preparation and improved the nutritional values (56). To lower the phytate levels in the amaranth grain, home-level processing will be used. For 24 hours, amaranth grain will be soaked in water with 5 milliliters of lemon juice per 100 milliliters of water, and it will germinate for 72 hours. It will be sun-dried, roasted, and ground using a nearby electrical mill before fermented bread is made
224127573|NCT01727713|DRUG|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
224127574|NCT00313599|DRUG|lapatinib|
224127575|NCT00313599|DRUG|paclitaxel|
224127576|NCT05474508|OTHER|Diaphragmatic breathing|Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.
224127577|NCT05474508|OTHER|Aerobic exercises|Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
223564165|NCT01191736|BEHAVIORAL|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
223391414|NCT05548114|PROCEDURE|Surgical gastrojejunostomy|A surgical gastrojejunostomy will be created via laparoscopic or robotic techniques (preferred) or open technique (if these methods fail), as clinically appropriate.
223391415|NCT00347984|OTHER|Systane Lubricant eye drops|
223730542|NCT04383405|OTHER|Conventional Training|Conventional land-based therapy consists of customized exercises focused on static and dynamic postural stability improvement. The exercises included the active-assisted mobilization, the muscle stretching the postural transition, the balance and the gait training. The control approach was carried out three times a week for four weeks and each session lasted 45 minutes.
223730543|NCT00429104|DRUG|Herceptin|4 mg/kg IV Over 90 Minutes
224012160|NCT03243682|PROCEDURE|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
223391416|NCT02015611|DIETARY_SUPPLEMENT|Vitamin D|2,000 IU/ day of Vitamin D3
223546987|NCT04015011|COMBINATION_PRODUCT|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
223546988|NCT02859831|OTHER|water samples|
223546989|NCT02975804|DEVICE|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
223546990|NCT05495880|PROCEDURE|Laryngoscopy with forearm-support|forearm-supported head extension during direct laryngoscopy
223546991|NCT05495880|PROCEDURE|Laryngoscopy without forearm-support|without forearm-support for head extension during direct laryngoscopy
223546992|NCT00901225|DRUG|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
223391417|NCT02015611|DIETARY_SUPPLEMENT|Placebo|Placebo
223391418|NCT04421131|DEVICE|Pocket colposcope/Mobile phone camera|The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
223391419|NCT04421131|OTHER|mIVAA|A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
223391420|NCT06491537|BEHAVIORAL|Early Time-Restricted Eating (eTRE)|12 weeks of eTRE intervention. Study staff will provide 7 support sessions with brief behavioral support, including evidence based strategies of problem-solving, action planning, and motivational interviewing.
223391421|NCT06491537|BEHAVIORAL|Control|The control group will be instructed to maintain their average eating window for the 12-week period. Study staff will contact participants 7 times to encourage maintenance.
223730544|NCT00429104|DRUG|GM-CSF|250 mcg/m\^2 Subcutaneously
224012161|NCT02708407|PROCEDURE|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
224012162|NCT02776995|OTHER|Thermography imaging|Thermography imaging of the treated - irradiated body area.
224012163|NCT05458570|OTHER|Breast Cancer positive patients|
224012164|NCT00587626|DEVICE|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
224012165|NCT00587626|DEVICE|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
224012166|NCT02097173|DRUG|Methotrexate|
224012167|NCT00004583|DRUG|Lopinavir/Ritonavir|
223730545|NCT01829191|DEVICE|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
223730546|NCT01829191|DEVICE|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
223730547|NCT01907815|DRUG|Akt Inhibitor GSK2141795|Given PO
223730548|NCT01907815|OTHER|Laboratory Biomarker Analysis|Correlative studies
224012168|NCT00004583|DRUG|Nelfinavir mesylate|
223391422|NCT03435471|OTHER|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
223391423|NCT03435471|OTHER|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
224012169|NCT00004583|DRUG|Lamivudine|
224012170|NCT00004583|DRUG|Stavudine|
223391424|NCT01059656|DRUG|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
223391425|NCT05122169|DRUG|Povidone-Iodine|Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
223391426|NCT05122169|DRUG|Chlorhexidine|Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
223391427|NCT00189124|DRUG|Dehydroepiandrosterone (DHEA)|
224012171|NCT03117998|BIOLOGICAL|REMD-477|Administered as repeated SC doses in subjects with Type 1 Diabetes
224012172|NCT03117998|BIOLOGICAL|Placebo Comparator|Administered as a repeated SC doses in subjects with Type 1 Diabetes
223391428|NCT04937140|DIAGNOSTIC_TEST|14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients|assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
223546993|NCT02588417|DRUG|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
223546994|NCT02588417|DRUG|Levobupivacaine|levobupivacaine 2.5 mg
223546995|NCT01408277|BIOLOGICAL|Santyl|2 mm Santyl applied once daily
223546996|NCT01408277|PROCEDURE|Control|Standard Care
223546997|NCT03355248|OTHER|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
223546998|NCT05802277|DIAGNOSTIC_TEST|Hamstring muscles function assessment|Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
223546999|NCT00000792|DRUG|Hypericin|
223547000|NCT02039011|DRUG|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
223547001|NCT02039011|DRUG|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
223547002|NCT02620475|DEVICE|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
223547003|NCT05045859|BEHAVIORAL|CBCT for PTSD|CBCT for PTSD is a 15-session, manualized therapy developed by Monson and Fredman, designed to simultaneously improve PTSD symptoms and enhance relationship functioning. It assumes that PTSD exists within the couple's relationship and that partners can join together to reduce the presence of PTSD in their relationship. Sessions are organized into three phases of treatment: (1) psychoeducation about PTSD and relationships; (2) behavioral interventions to enhance relationship functioning; and (3) dyadic cognitive intervention designed to contextualize trauma memories and address trauma-relevant cognitions held by either partner that keep the PTSD and/or relationship distress alive. Out-of-session assignments are designed to assist the couple in reinforcing skills learned in the sessions.
223547004|NCT00682175|OTHER|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
223547005|NCT01861561|DRUG|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
223547006|NCT01861561|DRUG|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
223547007|NCT03942198|DRUG|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
223547008|NCT03942198|DRUG|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
223547009|NCT00034671|DRUG|Posaconazole oral suspension|
223547010|NCT02056444|DRUG|Tranexamic Acid|
223730549|NCT01907815|DRUG|Trametinib|Given PO
223730550|NCT00808977|DRUG|Dersalazine sodium|Dersalazine sodium 2400 mg daily
223391429|NCT02286258|DRUG|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
223547011|NCT05285579|BIOLOGICAL|Blood collection|Systematic extra blood sampling at inclusion, 6 weeks after inclusion and in case of progression of the cancer
223547012|NCT05285579|OTHER|Tumour samples|reuse of tumour tissue collect in usual patient care
223547013|NCT01239771|DRUG|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
223547014|NCT01239771|DRUG|Placebo|Two subjects in each cohort will be given placebo.
223547015|NCT05276128|DIETARY_SUPPLEMENT|lipids|Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
223547016|NCT03699566|OTHER|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
223391430|NCT02286258|DRUG|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
223391431|NCT05338931|DRUG|AT101(Anti-CD19 Chimeric Antigen Receptor T cell)|Anti-CD19 Chimeric Antigen Receptor T cell
223547017|NCT03699566|OTHER|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
223547018|NCT03699566|OTHER|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
223547019|NCT01349673|DRUG|Budesonide Foam|Topical
223564166|NCT01191736|BEHAVIORAL|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
223564167|NCT03619707|DRUG|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
224012173|NCT04624087|BEHAVIORAL|food-specific go/no-go computerized training|Participants will perform the computerized food specific go/no-go training a designated number of times over a four week duration (frequency varies by group). Each training session will last approximately 10 minutes and occur on different days of the week.
223391432|NCT03506256|DRUG|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
223391433|NCT06342687|PROCEDURE|High compliance with ERAS protocol|Patients were categorized into two groups based on their adherence to the ERAS protocol: group 1 with a compliance rate below 80% and group 2 with a compliance rate of 80% or above.
223391434|NCT03352674|DRUG|Insulin Glargine Ezelin|Insulin Glargine (Ezelin) once daily at individually adjusted dose
223391435|NCT03352674|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
223391436|NCT04119362|OTHER|Quality of live questionnaires|EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
223547020|NCT04378101|OTHER|Eating disorder diagnosis group|This is an observational study, no active intervention is applied. Participants are assigned to an eating disorder diagnosis group based on their lifetime history of disordered eating behaviors and symptoms.
224012174|NCT04624087|BEHAVIORAL|nonfood-specific go/no-go computerized training|Participants will perform the computerized general go/no-go training 1 time per week over a four week duration. Each training session will last approximately 10 minutes and occur on different days of the week.
224012175|NCT04846777|DEVICE|Mindfulness ecological momentary intervention|Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
224012176|NCT04846777|DEVICE|Self-monitoring placebo|Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
224012177|NCT01796379|BEHAVIORAL|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
224012178|NCT01796379|BEHAVIORAL|Moderate Training|
224012179|NCT01636323|OTHER|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
224012180|NCT03583775|OTHER|Cardiovascular Magnetic Resonance Imaging|Cardiovascular Magnetic Resonance Imaging or MRI exam from children's with congenital heart disease
224012181|NCT04295967|OTHER|formalin fixed paraffin embedded blocks|The study will be conducted using formalin fixed paraffin embedded blocks of seventy cases of urothelial carcinomas .CD31-PAS dual-staining will be performed to confirm the presence of VM.
224012182|NCT00612872|DRUG|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
224012183|NCT00704899|PROCEDURE|Physiotherapy|Structured exercise regimen
224012184|NCT00704899|DRUG|Amitryptiline|Amitryptiline 25mg once daily
224012185|NCT02290080|DRUG|Oxygen|see arm description
224012186|NCT00438672|DRUG|Placebo Injection|Injection without steroid
224012187|NCT00438672|DRUG|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
224012188|NCT01035567|PROCEDURE|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
224012189|NCT01035567|PROCEDURE|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
224012190|NCT04050657|OTHER|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
224012191|NCT04270253|PROCEDURE|Conservative therapy|Conservative therapy including aquatic exercises, land-based exercises, balneotherapy, TENS therapy
223391437|NCT04119362|OTHER|Optional translational project|Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
223391438|NCT00007631|DRUG|Tretinoin 0.1% cream or placebo|
223391439|NCT00007631|OTHER|Placebo|Patients receive placebo for same amount of time
223391440|NCT02247778|PROCEDURE|conventional plate osteosynthesis|Standard incision
223391441|NCT02247778|PROCEDURE|mini-incision-type osteosynthesis|Mini-incision
223547021|NCT04507048|OTHER|Active educational intervention|an active educational intervention will be provided in the experimental arm, consisting in the administration of a booklet (passive intervention) + an oral standardized explanation of the booklet given by a trained dermatologist for each center.
224012192|NCT04270253|PROCEDURE|Manual therapy|End-range mobilization
224012193|NCT00501280|BEHAVIORAL|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
224012194|NCT04744493|DEVICE|ExaBlate 4000|The Exablate 4000, an advanced, non-invasive technique for performing ablation of the Thalamus for treating Essential Tremor, received FDA PMA (P150038) approval for unilateral treatment of Essential Tremor in 2016.
224012195|NCT04327297|DIETARY_SUPPLEMENT|Amino acid-based formula|Amino acid based formula is formula which is used as dietary supplement instead of dairy products in cow's milk allergic infants
224012196|NCT00045773|DRUG|Sertraline|50 - 200mg, once per day for 12 weeks.
224012197|NCT04827472|DRUG|Normal saline|100ml
223547022|NCT04507048|OTHER|Passive educational intervention|"Administration of a booklet containing the explanation of 2 clinical rules for early detection of atypical melanocytic lesions: the ABCDE and the ugly duckling rules."
223730551|NCT00808977|DRUG|Mesalazine|Mesalazine 2400 mg daily
224012198|NCT04827472|DRUG|DWJ1521|Single dose
223391442|NCT00716391|OTHER|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
223391443|NCT00716391|OTHER|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
223391444|NCT01622829|PROCEDURE|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
223391445|NCT01622829|OTHER|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
223391446|NCT01622829|OTHER|usual physiotherapy|physiotherapy, treatment as usual
223391447|NCT00729937|DRUG|Cephalexin|500 mg, four times per day.
224012199|NCT04827472|DRUG|DWP14012 Tablet|Single dose, Tablet
224012200|NCT01447940|DEVICE|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
224012201|NCT00143208|DRUG|Xalacom|
223391448|NCT00729937|DRUG|Clindamycin|300 mg, four times per day.
224012202|NCT01468181|DRUG|LY2189265|
224012203|NCT01468181|DRUG|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
224012204|NCT01468181|DRUG|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
224012205|NCT01468181|DRUG|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
224012206|NCT01468181|DRUG|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
224012207|NCT01468181|DRUG|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
224012208|NCT00878826|DRUG|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
224012209|NCT04888962|OTHER|OUD|History of opioid use disorder.
224012210|NCT05353075|OTHER|Sub Occipital Muscle Inhibition|The therapist sits at the head end of the table, palms beneath the subject's head, pads of his fingertips on the posterior arch of the atlas, which will be palpated by the therapist between the external occipital protuberance and the spinous process of the axis vertebra. The therapist locates the gap between the occipital condyles and the spinous phase of the C2 vertebra with the middle and ring fingers of both hands the therapist then rests the base of the skull on his or her hands, with toward the therapist. The pressure will be held at the same level for four minutes until tissue relaxation will be achieved. The subject will be asked to keep his eyes closed during the SMI technique to prevent eye movements disturbing the Sub occipital muscle tone.
224012211|NCT05353075|OTHER|Sub Occipital Inhibition with Hold Relax Agonist Contraction|Therapist will passively flex the lower extremity with knee extended to the end range of Hip Flexion. Once the end range of motion will attain the patient will apply a 10second isometric force against the therapist manual resistance. After the isometric contraction of hamstring the patient will ask to perform a concentric contraction of opposing muscle (hip flexors) for 10 seconds. As the patient performs the concentric contraction the therapist takes up the slack into any ROM that was gained keeping limb into new stretch position for 10-15 seconds and then rest for 5 seconds. Three repetitions of this technique will be performed on each subject.
223391449|NCT00729937|OTHER|Placebo|Placebo tablet administered orally.
223391450|NCT00729937|DRUG|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
223391451|NCT04215237|DRUG|Atorvastatin 20 Mg Oral Tablet|Atorvastatin 20mg oral once a day
223547023|NCT04058015|OTHER|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
223547024|NCT04058015|OTHER|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
223547025|NCT04058015|OTHER|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose \< 200 mg/dL in the patients with Diabetes mellitus.
223547026|NCT04058015|OTHER|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose \< 200 mg/dL in patients who were absent of Diabetes mellitus.
223547027|NCT02065323|DRUG|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
223547028|NCT02065323|DRUG|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
223564168|NCT02258750|DIETARY_SUPPLEMENT|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
223564169|NCT02258750|OTHER|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
223547029|NCT04190680|BEHAVIORAL|Kokkerelli Learning Street|"The Kokkerelli Learning Street focusses on one specific food product (kale, tomato, asparagus, pepper, strawberry, blue berry, mushroom, carrot, or leek) and consists of multiple components:~1. An introduction lesson at school. Children are introduced to the product and familiarised with growing and harvesting processes and the importance of the product regarding health.~2. A visit to a grower's farm during which children are introduced to the precise planting, growing and harvesting procedures of the product. Children are allowed to enter the facilities (e.g., the greenhouse) and observe and experience the farming of the product.~3. A cooking workshop at the facilities of Kids University for Cooking BV. Children prepare a meal with help of volunteers. After preparing the meal, children help to set the table and consume their self-prepared meal.~4. An evaluation lesson at school. Children evaluate the Learning Street together with their peers and teacher."
223391452|NCT02287155|BEHAVIORAL|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
223547030|NCT03346083|DRUG|Betrixaban|Factor Xa inhibitor.
223547031|NCT02887157|DEVICE|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
223564170|NCT00932438|DEVICE|LC beads loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan
223564171|NCT00932438|DRUG|Oxaliplatin|Oxaliplatin 85 mg/sqm, IV infusion every two weeks
224127578|NCT00736710|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
223391453|NCT06121882|DEVICE|Microfragmented Adipose Tissue derived using the Lipogems® System|Intra-articular knee injection of Microfragmented Adipose Tissue (MFat) derived using the Lipogems® System.
223391454|NCT06121882|DRUG|Saline Injection|Intra-articular knee injection of saline
223391455|NCT04614753|OTHER|Dealcoholized Muscadine Wine|300 ml of Dealcoholized Muscadine Wine
223391456|NCT04614753|OTHER|Control Beverage|300ml of Sugar Water and Acid Content
223391457|NCT05333731|DRUG|Oxytocin|In the two groups, if spontaneous labor does not occur after PROM, they all receive the oxytocin for up to 24h.
223391458|NCT03939663|DRUG|misoprostol|misoprostol 2 tablets
223391459|NCT03939663|DRUG|Placebo|starch pills manufactured to mimic misoprostol 200 mg tablets
223391460|NCT00243412|DRUG|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
223391461|NCT00243412|DRUG|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
223391462|NCT00243412|DRUG|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
223391463|NCT00243412|DRUG|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
223391464|NCT00243412|DRUG|Rituximab|500 mg or 1000 mg IV\*2.
223391465|NCT03207386|BEHAVIORAL|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
223391466|NCT05227963|OTHER|soft tissue mobilization|In this group, each participants received 45-minutes long session that includes 25-minutes of soft tissue mobilization and 20-minutes of neck isometric strengthening exercises. In each session, patient was seated on chair and sustained pressure, direct oscillation, perpendicular mobilization, parallel mobilization, and friction massage was applied on the neck musculature for a minute followed by a release for 30 seconds. This protocol was repeated three times in each session. Each session was repeated four-times a week for two-weeks (a total eight sessions).
223391467|NCT05227963|OTHER|neck isometric strengthening exercises|In this group, each participant received 20-minutes long session. Each session started in seated position and participants were asked to perform flexion, extension, side bending and rotation against resistance. During flexion movement, therapist placed hand on forehead and asked patient to move the neck forward, while in extension, therapist hand was placed at back of the head and patient had to move neck in backward direction. However, in side bending and rotation- therapist hand was placed at lateral side of the head and asked patient to side bend the neck and look at shoulder in the same direction respectively. Each session was repeated four-times a week for two-weeks (a total eight sessions).
223391468|NCT05970666|DRUG|TACE with adebrelimab and bevacizumab|TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
223391469|NCT05349552|RADIATION|stereotactic body radiation therapy|The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
223391470|NCT06745063|DRUG|Empagliflozin|12 week treatment with 10mg empagliflozin daily
223391471|NCT06745063|DRUG|Placebo|12 week treatment with 10mg placebo daily
223391472|NCT06724718|OTHER|smartwatch|Patients in the smartwatch group will undergo rhythm monitoring with a smartwatch
223391473|NCT06724718|OTHER|ECG|Detected POAF episodes will be confirmed via a 12-lead ECG
223564172|NCT00932438|DRUG|Leucovorin|Leucovorin 200 mg/sqm, IV infusion every two weeks
223564173|NCT00932438|DRUG|5-Fluorouracil|5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
223564174|NCT00932438|DRUG|Bevacizumab|Bevacizumab 5 mg/kg given at the discretion of the treating physician
223564175|NCT03441867|BEHAVIORAL|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
223547032|NCT02887157|OTHER|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
223547033|NCT02887157|OTHER|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
223547034|NCT05214937|BEHAVIORAL|Intervention|During the first two weeks (baseline), participants will be asked to maintain their regular movement routine to set a baseline daily average step count. Phases I-III will involve self-regulatory strategies (e.g., action planning), address reducing/interrupting sedentary time, and step counts. Participants will be encouraged to increase their steps by 1000 steps/day from the baseline phase during each subsequent phase (i.e., 3000 steps above baseline by Phase III). Phases IV-V will be a maintenance phase through which participants will be encouraged to maintain 3000 steps per day above baseline. The sessions will be grounded within the Multi-Process Action Control Framework and address perceived capability/opportunity and instrumental/affective attitudes. The 1-on-1 sessions will focus on regulation (action \& coping planning, social support, goal setting) and reflexive processing (self-regulation, habit). The final one on one session will be a booster session to revisit previous topics.
223547035|NCT05214937|BEHAVIORAL|FitBit Only|Participants will be provided with a FitBit Inspire 2 and access to publicly available resources about active living. They will receive a FitBit orientation session with a movement specialist prior to the 12-week control period.
223547036|NCT03011749|OTHER|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
223547037|NCT02936518|PROCEDURE|Lingual frenotomy and/or maxillary labial frenectomy|
223547038|NCT05708573|DRUG|Rosuvastatin|In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
223547039|NCT05708573|DRUG|ALXN2040|In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
223547040|NCT04952662|GENETIC|Genetic variants|COL1A1 rs1800012, COL1A2 rs412777, COL5A1 rs12722, ACTN3 rs1815739, ACE rs1799752, ESR1 rs2234693, MMP3 rs679620, VDR rs2228570 and GDF5 rs143383
223547041|NCT04420832|PROCEDURE|Surgical treatment|Se above
224012212|NCT00320528|DRUG|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
224012213|NCT04828837|DEVICE|bubble PEP|Using the bubble positive expiratory pressure (Bubble PEP) for breathing training of inpatients with COPD. The training course for one day of three times. Every time needs about 20 mins. Huff and cough after the breathing training the end.
224012214|NCT05155215|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells will be administered at dose level: 100×10\^6 CAR-T cells or 200×10\^6 CAR-T cells
224012215|NCT05155215|DRUG|Cyclophosphamide|300 mg/m\^2 per day for 3 days (IV)
224012216|NCT05155215|DRUG|Fludarabine|30 mg/m\^2 per day for 3 days (IV)
223391474|NCT01673230|PROCEDURE|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
223391475|NCT06069167|OTHER|Collection of data related to bowel urgency|Data will be extracted from the patient's medical record and patients will be interviewed to collect data specific to the research
224012217|NCT04953559|DEVICE|Active cTBS|Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
224012218|NCT04953559|DEVICE|Sham cTBS|Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
224296481|NCT04556552|DRUG|Oxygen (15-O) Water|Injection of radiolabelled water. H2\[15-O\] is a radioactive material. Each patient will have eight H2\[15-O\] blood flow scans. For each O-15 water scan 20 mCi of H2\[15O\] will be injected as an intravenous bolus.
224296482|NCT04556552|DEVICE|Sham Stimulation|"Sham stimulation of vagus during opioid cue exposure. Each subject in the SHAM group will undergo the action of administering the intervention, but the device will be programmed such that the stimulation will not activate the vagus nerve."
224012219|NCT04847791|DIETARY_SUPPLEMENT|Bovine lactoferrin|Oral Administration of Bovine Lactoferrin -fixed dose 800 mg / day for 30 days
224012220|NCT04847791|DIETARY_SUPPLEMENT|Placebo administration|capsule identical with the same amount as an inert compound, starch of corn powder), according to the same pattern of use.
224012221|NCT06150170|OTHER|Proprioceptive training|Proprioceptive exercises were applied to both groups. In addition to these exercises, balance, coordination and strengthening exercises will also be applied to both groups.
224012222|NCT00002324|DRUG|Nevirapine|
224012223|NCT00002324|DRUG|Zidovudine|
224012224|NCT06220136|DEVICE|TOFscan monitoring|observation and data recording
223547042|NCT04420832|OTHER|Non-surgical treatment|See above
223547043|NCT04036201|DRUG|Bupivacaine|peribulbar block
223547044|NCT02940899|OTHER|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
223564176|NCT03441867|OTHER|Standard Medical Care|Observational - standard medical care
223564177|NCT02453165|PROCEDURE|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
223564178|NCT02453165|PROCEDURE|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
223391476|NCT06418516|DEVICE|Capsule-sponge|The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
223391477|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.
223391478|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.
223391479|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.
223391480|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.
223547045|NCT05210088|DRUG|Hypoxia, intermittent|"The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored."
223547046|NCT05210088|OTHER|Normoxia|The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
223547047|NCT03612128|OTHER|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
223730552|NCT00808977|DRUG|Placebo|Placebo matching active and experimental treatments
223730553|NCT03516591|DRUG|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
223730554|NCT05612984|COMBINATION_PRODUCT|Calcium aspirin multiple micronutrients|Women randomized to CAMMS will receive weekly blister cards containing all 3 components: 1 81 mg aspirin tablet, 1 UNIMMAP MMS, and 1 500-mg elemental calcium tablets. Blister packages will be labeled with times of day and days of week when tablets are to be taken. 4 weekly blister cards will be packaged in one unit box.
223730555|NCT05612984|DIETARY_SUPPLEMENT|Iron-folic Acid|Women randomized to IFA will receive monthly (28-day) blister cards containing containing 1 combined IFA tablet to be taken each day. 1 4-weekly blister card will be packaged in one unit box.
224012225|NCT01383564|PROCEDURE|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
224012226|NCT01383564|PROCEDURE|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
224012227|NCT00545753|DRUG|Spinosad|10 minute topical application product, following by a complete rinse off.
223730556|NCT04264637|DRUG|Azelastine hydrochloride (BAYR9258)|Single dose, metered-spray solution, 2 sprays per nostril, 205.5 mcg/spray, intranasal administration.
223730557|NCT04264637|DRUG|Placebo|Single dose of Azelastine hydrochloride-matched placebo, metered-spray solution, 2 sprays per nostril, intranasal administration.
224012228|NCT00545753|DRUG|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
224296483|NCT05545618|DIAGNOSTIC_TEST|CCTA and 18F-FDG-PET/CT|18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
223391481|NCT05256719|BIOLOGICAL|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.
223391482|NCT05256719|BIOLOGICAL|Placebo-1mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
223730558|NCT04655274|DIAGNOSTIC_TEST|The Quality of Vision questionnaire|The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
224012229|NCT00545753|DRUG|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
224012230|NCT05031715|DIETARY_SUPPLEMENT|Berberine Phytosome|2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
224012231|NCT05119062|OTHER|Usual care|Families in the control group will be provided with routine care, including regular antenatal check ups, one bed side education (within 24 hours after delivery), one group session with discharge precautions (3rd to 5th day postpartum), two home visits (first week and second week after discharge respectively), and two physical body check at hospital on the 30th and 42nd day postpartum. Contents of the bed side education, pre-discharge education and home visits focuses on health related information, such as postpartum care, infant care and breastfeeding, etc.
224296484|NCT05962502|DRUG|Cetuximab and irinotecan|chemotherapy plus targeted therapy
223391483|NCT05256719|BIOLOGICAL|Placebo-2.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
223391484|NCT05256719|BIOLOGICAL|Placebo-5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
223391485|NCT05256719|BIOLOGICAL|Placebo-7.5mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
223391486|NCT05256719|BIOLOGICAL|Placebo-10mg/kg|Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
223391487|NCT05597319|PROCEDURE|Liver resection|Liver resection, different kind of according to pathology
223391488|NCT03787134|BEHAVIORAL|working memory and attention|Behavioral tests of working memory and attention
223547048|NCT03612128|OTHER|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
223547049|NCT02468687|DRUG|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
223547050|NCT04192045|OTHER|Survey|A survey will be used at 24 hours and 30 days to assess the quality of recovery
223547051|NCT05634824|DRUG|intravenous immunoglobulin plus low dose recombinant human thrombopoietin (rhTPO)|rhTPO at an initial does of 150U/kg qd subcutaneously for 28 days and IVIg 400mg/kg qd for 5 days. The maintenance treatment consisted rhTPO 150U/kg qd.
223547052|NCT05634824|DRUG|intravenous immunoglobulin|intravenous immunoglobulin
223547053|NCT01819363|PROCEDURE|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
223391489|NCT04065360|BEHAVIORAL|Group Cognitive behavioural family intervention (CBFI)|four-week, four-session CBT-based family intervention programme
223547054|NCT04263766|OTHER|Transcranial magnetic stimulation|TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.
223547055|NCT00302172|DRUG|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
223547056|NCT06413147|DEVICE|PFO closure|Surgery of PFO closure
223547057|NCT02088099|OTHER|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
224012232|NCT05119062|OTHER|an online intergenerational co-parenting programme+usual care|The program is proposed to include five sessions, with three antenatal sessions to be offered weekly during the 34-36 weeks gestation and two postnatal sessions weekly starting from the first week after discharge from hospital. The intervention will be delivered online.The program is designed for the intergenerational co-parenting families to undertake with parents together with grandmothers. The online courses will be delivered by an online platform in the study hospital. The first session will be pushed to participants in the intervention group within 2 days (around 34 weeks gestation) after recruitment. The second and third session will be pushed around 35 and 36 weeks gestation separately. The first postnatal session will be provided around the first to second week postpartum; and second postnatal session will be provided around the third to fourth week postpartum.
224012233|NCT00349362|DRUG|Testosterone|Sustanon- 200mg intramuscular testosterone
223391490|NCT04065360|BEHAVIORAL|Usual group psychoeducation|Treatment as usual in the institution studied
223391491|NCT01082497|BEHAVIORAL|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
223391492|NCT03281876|BIOLOGICAL|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
223391493|NCT03281876|BIOLOGICAL|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
223391494|NCT01510782|DRUG|Placebo to BI 655064|intravenous infusion of escalating doses
223391495|NCT01510782|DRUG|Placebo to BI 655064|subcutaneous injection of escalating doses
223391496|NCT01510782|DRUG|BI 655064|intravenous infusion of escalating doses
223391497|NCT01510782|DRUG|BI 655064|subcutaneous injection of escalating doses
223391498|NCT05295576|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
223391499|NCT00002031|DRUG|Dinitrochlorobenzene|
223547058|NCT02088099|OTHER|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
223547059|NCT00581048|DRUG|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
223547060|NCT01891396|DEVICE|Hyaluronic Acid and TH (Cingal®)|Injection into knee
223547061|NCT01891396|DEVICE|Hyaluronic Acid (Monovisc®)|Injection into knee
223547062|NCT01891396|DEVICE|Saline|Saline placebo packaged to look identical to comparator syringes. Injection into knee.
224012234|NCT00349362|DRUG|0.9% saline|Saline intramuscular injection every two weeks
223391500|NCT02208089|PROCEDURE|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
224012235|NCT05637359|DEVICE|Tracked ultrasound measurement|"Participation in the study will not involve additional visits to the hospital or additional CT scans for the included patients. For this experiment, 2D ultrasound images are obtained using an ultrasound transducer linked to the electromagnetic navigation system, which is already in place for the navigation at the operating room. After anesthesia and in parallel to the final preparations of the patient, two percutaneous ultrasound measurements of the pelvic bone are performed and recorded. The first measurements are performed in Trendelenburg patient position and the second measurements in supine patient position. When preparations are finished, normal workflow is continued, including the standard Cone Beam CT acquisition required for the navigation and sterile draping of the patient.~The acquired ultrasound scans will be analyzed post-operatively and offline. This measurement has no impact on the (navigated) surgical procedure itself."
224012236|NCT01026506|DIETARY_SUPPLEMENT|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
223391501|NCT02208089|PROCEDURE|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
224012237|NCT06131606|BEHAVIORAL|experimental group|Patients in the experimental group were told how to use the stress ball before the procedure. The patient was then taken to the angiography unit. The stress ball was placed on the palms of the patients according to the procedure position. During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes. After the procedure, the NRS and STAI were filled out as a post-test 10 minutes after the patient was taken to the ward. The answers given by the patients were recorded by the researcher by marking them on the forms.
224012238|NCT00119457|DRUG|TTP889|
224012239|NCT01696903|PROCEDURE|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
224012240|NCT00656097|BIOLOGICAL|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
223391502|NCT02494167|BIOLOGICAL|MultiTAA-specific T cells|"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
223391503|NCT05298761|DRUG|Lignocaine|Inj lignocain and inj nalbuphine given to two groups of participants and effects of both drugs
223391504|NCT06581991|DIETARY_SUPPLEMENT|Valine oral solution (50mg/ml) and isoleucine oral solution (25mg/ml)|Subjects will take valine oral solution (50mg/ml) in place of usual powdered valine supplement for 28 days. Subjects will then take isoleucine oral solution (25mg/ml) in place of their usual powdered isoleucine supplement for 28 days.
224012241|NCT00656097|BIOLOGICAL|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
224012242|NCT00656097|BIOLOGICAL|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
224012243|NCT04041453|DRUG|Ivermectin|Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
224012244|NCT04041453|DRUG|Albendazole|Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
224012245|NCT03695653|BEHAVIORAL|Drink Tracking (MA)|Weekly drink tracking for self-monitoring and assessment
224012246|NCT03695653|BEHAVIORAL|Adaptive Tailored (TA)|Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress
224012247|NCT03695653|BEHAVIORAL|Tailored (TO)|Messages are sent more frequently and tailored to some baseline characteristics
224012248|NCT01526239|OTHER|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
224012249|NCT03957824|DIAGNOSTIC_TEST|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
224012250|NCT01334424|DRUG|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
224012251|NCT02861235|OTHER|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
224296485|NCT01215513|DRUG|Degarelix|
224296486|NCT01553279|BIOLOGICAL|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.
223547063|NCT02737319|DRUG|Rosuvastatin|40 mg of rosuvastatin before angioplasty
223547064|NCT00540592|BIOLOGICAL|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
223547065|NCT00540592|BIOLOGICAL|Fluarix|Single dose, Intramuscular injection
223547066|NCT02748252|OTHER|stroke center referral|
223547067|NCT06133556|DRUG|MCBC regimen|using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
223547068|NCT06133556|DRUG|Bu/Cy regimen|control group, the standard conditioning regimen Busulfan/Cyclophosphamide
223547069|NCT04863053|OTHER|Blood samples will be taken to assess platelet function. There is no change in treatment.|
223547070|NCT05238350|PROCEDURE|Acupressure|Acupressure was performed two days a week for four weeks with a total of eight sessions on the ST34, ST35, ST36, SP9, SP10, GB34 acupuncture points following an acupressure practice guide prepared by the researcher.
223564179|NCT00626509|DRUG|sunitinib malate|
223564180|NCT00626509|PROCEDURE|adjuvant therapy|
223564181|NCT00626509|PROCEDURE|neoadjuvant therapy|
223564182|NCT00626509|PROCEDURE|therapeutic conventional surgery|
224012252|NCT02861235|OTHER|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
224012253|NCT02861235|OTHER|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
224012254|NCT02861235|OTHER|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
223391505|NCT05329662|BIOLOGICAL|Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency|"* Patients in the two groups will receive two autologous AD-MSC administrations: the group A on day 0 and day 90 ± 7; the group B on day 180 ± 14 and day 270 ± 14.~* Dose: 1.0 x 106 cells/kg patient bodyweight.~* Route: intravenous infusion~ADSCs were collected after the third passage. On the day of transplantation, the ADSCs were harvested, washed twice with NaCl 0.9%, counted and resuspended in NaCl 0.9% in a total volume of 20 ml. Each participant received a dose of 1x10\^6 cells/kg body weight infused through the intravenous route within 30 minutes before being discharged after 24 hours"
224012255|NCT02861235|OTHER|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
224127579|NCT00736710|PROCEDURE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
223391506|NCT01431365|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
223391507|NCT01431365|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
223391508|NCT02473926|BEHAVIORAL|Physical Activity|Physical Activity Program Intervention
223391509|NCT02473926|BEHAVIORAL|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
223391510|NCT05467631|OTHER|Topical oil application|Topical Comparison
223391511|NCT00683657|DRUG|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
223391512|NCT00683657|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
223391513|NCT02757326|DRUG|Opaganib|Opaganib, \[3-(4-chlorophenyl)-adamantane-1-carboxylic acid (N-(Pyridin-4-ylmethyl)pyridine-4-carboxamide) amide, hydrochloride salt\] is an orally available inhibitor of the enzyme SK2.
223391514|NCT03552848|BIOLOGICAL|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
223391515|NCT00202930|DRUG|anti-CD20 (Rituximab)|4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22
223391516|NCT01756430|DRUG|Carvedilol SR 32mg, QD|"* Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
223391517|NCT01756430|DRUG|Carvedilol SR 64mg, QD|"* Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
224012256|NCT02861235|OTHER|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
224012257|NCT05424497|OTHER|Vignettes|Presenting vignettes with fictive cases
224012258|NCT01318395|DRUG|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
224012259|NCT01318395|DRUG|Placebo|orally once per day
224012260|NCT00002229|DRUG|Saquinavir|
224127580|NCT05977517|BEHAVIORAL|Sleep and well-being tracking|This study will track sleep, learning and wellbeing of 500 freshmen under free-living conditions for 20 weeks
224296487|NCT01553279|BIOLOGICAL|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
223391518|NCT01756430|DRUG|Carvedilol IR 25mg, QD|"* Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
223391519|NCT01756430|DRUG|Carvedilol IR 25mg, BID|"* Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks."
223391520|NCT00194779|DRUG|doxorubicin hydrochloride|Given IV
223391521|NCT00194779|DRUG|cyclophosphamide|Given PO
223391522|NCT00194779|DRUG|paclitaxel|Given IV
223391523|NCT00194779|BIOLOGICAL|filgrastim|Given SC
223391524|NCT00194779|DRUG|capecitabine|Given PO
223391525|NCT00194779|DRUG|methotrexate|Given IV
223391526|NCT00194779|DRUG|vinorelbine tartrate|Given IV
223391527|NCT00194779|PROCEDURE|needle biopsy|Correlative studies
223391528|NCT00194779|PROCEDURE|therapeutic conventional surgery|Undergo definitive breast surgery
223391529|NCT00194779|OTHER|immunohistochemistry staining method|Correlative studies
223391530|NCT00194779|BIOLOGICAL|trastuzumab|Given IV
223391531|NCT00194779|DRUG|tamoxifen citrate|Given PO
223391532|NCT00194779|DRUG|letrozole|Given PO
223391533|NCT00194779|OTHER|laboratory biomarker analysis|Correlative studies
223391534|NCT03077139|DEVICE|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
223391535|NCT00470964|PROCEDURE|Titanium Sapphire laser trabeculoplasty|
223391536|NCT02598921|RADIATION|three dimensional ultrasound|
223391537|NCT02598921|DEVICE|Office hysteroscopy|
223391538|NCT01408043|DRUG|plerixafor|Given SC
223391539|NCT01408043|BIOLOGICAL|filgrastim|Given SC
223391540|NCT01408043|DRUG|etoposide|Given IV
223391541|NCT01408043|PROCEDURE|leukapheresis|Undergo apheresis
223564183|NCT00192049|DRUG|Gemcitabine|
223564184|NCT00192049|DRUG|mitomycin C|
223564185|NCT02584543|BIOLOGICAL|HEV vaccine|
223391542|NCT02051621|DRUG|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
223391543|NCT02051621|PROCEDURE|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
223391544|NCT02051621|PROCEDURE|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
224012261|NCT05606510|OTHER|Mindful exercise|In this study, a modified mindful exercise (ME) program based on mindful standing yoga refers to a type of exercise that aims to harmonize the body and mind through the effect of mindfulness meditation and stretching-awareness to carry on the actual moment through body movement and surroundings without any judgement.
224012262|NCT05606510|OTHER|usual care|Routine medicine and nursing care; as well as hospital-recommended movements (physical stretching).
223391545|NCT02773602|DRUG|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
223547071|NCT05879731|OTHER|EEG-hd (high density electroencephalogram)|"Once in the operating room, the investigators will place a 128-channel Hd-EEG (high density electroencephalogram) saline net referenced to Cz on the patient's head. Impedances will be verified and maintained \<50 kΩ for the duration of the study. The patient will be positioned supine and all routine monitors will be installed. A 5 minutes baseline resting-state Hd-EEG with eyes closed will be performed before induction. Once under general anesthesia and intubated, a no pain period of 5 minutes will take place. During this 5-min period, resting-state Hd-EEG recording will be recorded. A standardized tetanic stimulation to the ulnar nerve of the non-dominant forearm delivered by a routine nerve stimulator (100 Hz, 70 mA) for a duration of 30 seconds will then be applied. Hd-EEG recording will take place during this 30 seconds and will continue during the 5 minutes after. Once this period will be over, the Hd-EEG net will be removed and the investigators will exit the operating room."
223547072|NCT01766037|DEVICE|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
224012263|NCT00102739|DRUG|SB497115|
224012264|NCT04259151|DEVICE|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
224012265|NCT04259151|DEVICE|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
224012266|NCT03883100|DRUG|HQP1351|40 mg tablet, taken orally once every other day
224012267|NCT00955175|RADIATION|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
224012268|NCT02688218|BEHAVIORAL|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
223547073|NCT01766037|BEHAVIORAL|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
224012269|NCT02688218|BEHAVIORAL|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
224012270|NCT05570097|DEVICE|intercostal nerves cryoanalgesia|Intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
224012271|NCT02957032|DRUG|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles."
224012272|NCT02957032|DRUG|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
223391546|NCT02773602|DRUG|Clonidine|2 μg/kg of clonidine in 1 ml saline
223547074|NCT05712265|DRUG|Miricorilant|Miricorilant 6 x 100 mg coated tablets
223547075|NCT05712265|DRUG|Fluvoxamine|Fluvoxamine 50 mg tablet
223547076|NCT01084291|BIOLOGICAL|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
224012273|NCT01420887|PROCEDURE|Continuous Passive Motion|Continuous passive motion.
224012274|NCT01420887|PROCEDURE|Physical Therapy|Physical therapy.
223391547|NCT02773602|DRUG|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
223391548|NCT05662527|DRUG|Pembrolizumab|One dosage of 4mg/kg (maximum of 400mg)
223391549|NCT00494962|DRUG|lecozotan SR|
223391550|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Fumarate|Ferrous Fumarate - 300 mg
223391551|NCT06303531|DIETARY_SUPPLEMENT|Polysaccharide Iron|Polysaccharide Iron - 150 mg
223391552|NCT06303531|DIETARY_SUPPLEMENT|Ferrous Ascorbate|Ferrous Ascorbate - 100 mg
223547077|NCT01084291|OTHER|Placebo injection|Subcutaneous injection of placebo
223547078|NCT04544644|DRUG|AK104+anlotinib|AK 104 is given by intravenous infusion and anlotinib is given by oral.
223547079|NCT04626284|PROCEDURE|Heart Transplantation|Heart Transplantation
223547080|NCT00847899|DRUG|AR9281|AR9281 taken in BID dosing regimen for 28 days
223547081|NCT00847899|DRUG|AR9281|AR9281 taken in TID dosing regimen for 28 days
223547082|NCT00847899|DRUG|Placebo|Placebo taken in BID dosing regimen for 28 days
223547083|NCT00847899|DRUG|Placebo|Placebo taken in TID dosing regimen for 28 days
224012275|NCT04839952|BEHAVIORAL|Healthy Lifestyles|12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.
224012276|NCT04839952|BEHAVIORAL|Education-Only Control|This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
224012277|NCT04174898|BIOLOGICAL|human Mesenchymal Stem Cell (MSC) infusion therapy|Subjects will be infused with 100million human MSCs
223391553|NCT02732262|DRUG|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
223391554|NCT02732262|DRUG|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
223547084|NCT02963363|OTHER|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
223547085|NCT02994485|DRUG|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
223547086|NCT05401344|DIAGNOSTIC_TEST|test strips,sponges and cold dry air test|Test strips were used to evaluated the degree of dry nose, sponges were used to obtain the nasal secretion and cold dry air test was used to making diagnosis of vasomotor rihinitis.
223547087|NCT01109615|DRUG|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
223547088|NCT01109615|DRUG|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
223547089|NCT03813875|DRUG|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0\~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
223547090|NCT03813875|OTHER|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
223547091|NCT03813875|DRUG|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
223547092|NCT03813875|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0\~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
223547093|NCT03813875|DRUG|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0\~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
223547094|NCT03813875|DRUG|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0\~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
223564186|NCT02584543|BIOLOGICAL|HBV vaccine|
223564187|NCT06126718|DRUG|BR201|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
223564188|NCT06126718|DRUG|Cosentyx（Secukinumab ）|One-dosage on D1 and review pharmacokinetic and safety until D112 after drug given
224012278|NCT00000686|DRUG|Stavudine|
224012279|NCT05600686|DRUG|Cyclophosphamide|Given IV
224012280|NCT05600686|DRUG|Doxorubicin|Given IV
224012281|NCT05600686|DRUG|Etoposide|Given IV
223391555|NCT02732262|DRUG|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
223391556|NCT01526473|BIOLOGICAL|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
223391557|NCT05101668|DEVICE|Intracranial Thrombosis Aspiration Catheter|Direct Aspiration
224012282|NCT05600686|BIOLOGICAL|Loncastuximab Tesirine|Given IV
224012283|NCT05600686|DRUG|Prednisone|Given PO
224012284|NCT05600686|BIOLOGICAL|Rituximab|Given IV
223391558|NCT00468364|DRUG|insulin glargine|
223391559|NCT00468364|DRUG|NPH insulin|
224012285|NCT05600686|DRUG|Vincristine|Given IV
224012286|NCT05069675|PROCEDURE|vitrectomy|vitrectomy with gas tamponade
224012287|NCT00675675|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
224012288|NCT00675675|BEHAVIORAL|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
224012289|NCT04600830|PROCEDURE|Dry needling|Intervention with deep dry needling on latent myofascial trigger points (MTrPs) in gastrocnemius muscle.
223391560|NCT00972595|DRUG|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
223391561|NCT00972595|DRUG|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
224012290|NCT01044225|DRUG|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
224012291|NCT01044225|DRUG|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
224012292|NCT06158932|DIETARY_SUPPLEMENT|Optify Myo Inositol and D-Chiro Inositol Plus Folate and Vitamin D supplement|This product contains Myo-Inositol, D-Chiro-Inositol, Folate and Vitamin D.
224012293|NCT02062853|OTHER|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
224012294|NCT02062853|OTHER|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
224012295|NCT02007915|DRUG|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
224012296|NCT02350985|DRUG|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
224012297|NCT02350985|DRUG|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
224012298|NCT01081132|DRUG|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
224012299|NCT01081132|OTHER|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
224012300|NCT00031876|DRUG|capecitabine|
224012301|NCT00031876|DRUG|paclitaxel|
224012302|NCT01651221|OTHER|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
224012303|NCT02297139|DRUG|Dasatinib|
224012304|NCT00021736|DRUG|EYE001 anti-VEGF aptamer|
224012305|NCT05321654|BEHAVIORAL|Education for Behavior Modification|Please see arm description for a detailed description of the intervention
224012306|NCT05321654|BEHAVIORAL|Corrective Exercise Program|Please see arm description for a detailed description of the intervention
224012307|NCT03825549|BEHAVIORAL|Individual audit feedback|Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
224012308|NCT03825549|BEHAVIORAL|Peer comparison feedback|"Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber."
224012309|NCT00964964|DRUG|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
224012310|NCT00964964|DRUG|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
224012311|NCT00964964|DRUG|placebo|Placebo injected s.c. (under the skin) four times weekly
224012312|NCT00015899|DRUG|lonafarnib|
224012313|NCT05398991|DEVICE|the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd.|the Coronary Covered Stents System contains a covered stent and a delivery system
224012314|NCT05213494|OTHER|Inulin|Inulin, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
223391562|NCT02552121|DRUG|Tisotumab vedotin (HuMax-TF-ADC)|
223391563|NCT00462150|BEHAVIORAL|home-based emotional disclosure|
223391564|NCT00462150|BEHAVIORAL|time management control condition|
223391565|NCT04428814|BIOLOGICAL|CT-P43|45mg single dose
224012315|NCT05213494|OTHER|soluble corn fiber|soluble corn fiber, a dietary fiber, will be given in a beverage daily in doses 3g, 5g, 6g, or 8g dependent on arm and age of participants.
223391566|NCT04428814|BIOLOGICAL|EU-approved Stelara|45mg single dose
223391567|NCT04428814|BIOLOGICAL|US-licensed Stelara|45mg single dose
223391568|NCT02586155|DRUG|Apabetalone|100 mg capsule
223391569|NCT02586155|DRUG|Placebo|Capsule manufactured to mimic RVX000222 100 mg capsule
223391570|NCT02586155|DRUG|Atorvastatin|High-Intensity Statin
223391571|NCT02586155|DRUG|Rosuvastatin|High-Intensity Statin
224012316|NCT02101385|DRUG|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
224012317|NCT02101385|OTHER|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
224012318|NCT05850442|DIAGNOSTIC_TEST|Questionary|Patients will be asked to fill Fibromyalgia Impact Questionary, WHO Short Quality of Life Questionary, McGill Pain Questionary and Beck Anxiety Questionary
223564189|NCT05409560|OTHER|Swimming participants in the 6-hour cold water swim|The 6-hour cold water swim was the qualifying swim for the English Channel swim during the Channel Swim Camp Dinard 2021 and participants were the swimmers registered for the 6-hour cold water swim who volunteered to participate in this study
223391572|NCT04107909|PROCEDURE|laparoscopic cholecystectomy|"Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor."
223391573|NCT02655497|BEHAVIORAL|Cognitive training|
223391574|NCT02655497|BEHAVIORAL|Psychosocial education|
223391575|NCT01391897|BEHAVIORAL|psychotherapy|"multimodal complex psychotherapy"
223391576|NCT02085447|BEHAVIORAL|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
223391577|NCT05170282|DIAGNOSTIC_TEST|Radiomic Algorithm|Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
223547095|NCT03388801|OTHER|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
223547096|NCT01735383|DRUG|Etodolac Tablets USP 500mg|500 mg tablet once a day
223547097|NCT01735383|DRUG|Etodolac Tablets USP 500 mg|500 mg tablet once a day
223547098|NCT02118454|BEHAVIORAL|Daily IVR Calls Intervention|
224012319|NCT02432196|DEVICE|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
224012320|NCT01557114|DRUG|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
224012321|NCT01557114|RADIATION|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
224012322|NCT05171478|DIAGNOSTIC_TEST|Full-field optical coherence tomography|Sample obtained during bronchoscopy will be imaged using full-field optical coherence tomography
224138553|NCT04161274|PROCEDURE|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
223391578|NCT04521127|OTHER|Kinesio Taping|Taping will be performed on sitting position with contralateral lateral flexion and flexion of the neck, using muscle technique with I strip and stretching the head at the maximum level in order to benefit from the muscle release effect. Kinesio tape was applied directly on muscle with 0% stretching.
223391579|NCT04521127|OTHER|Dry needling|The trigger point on the taut band will be held with the thumb and forefinger from below and above. In the needling technique, a 0.25 \* 25-mm with nickel handle, disposable sterile steel acupuncture needle will be used. The needle tip will be inserted perpendicularly into the subcutaneous tissue and inserted into the muscle until the trigger point in the taut band was found. The same point will be pinned 8-10 times with fast needle movements inside and out. Then the needle tip will pulled back so that it did not come out of the skin, and the bottom, top and sides of the first entered point were also pinned. This procedure was applied to all trigger points in the trapeze muscle.
223391580|NCT01500473|DRUG|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
223547099|NCT02118454|BEHAVIORAL|Weekly IVR Survey Only|
223547100|NCT06215365|BEHAVIORAL|Adult cancer survivors who have completed their heavy treatments|"The study will be presented to the patient who can refuse to participate. The digital version of the questionnaire will be handed out, if the patient does not object after a period of thinking, when he or she comes to the day hospital for his or her JUMP Day. The study will therefore take place at a single point in time, and no pre-inclusion or follow-up visits are planned as part of this protocol.~Completing the questionnaire takes about 15 to 20 minutes. All questions are designed to meet the stated objectives. No personally identifiable data is collected."
223547101|NCT05536882|DRUG|Benzoyl peroxide|See arm description
223547102|NCT05536882|DRUG|Adapalene Gel|See arm description
223547103|NCT02725450|BEHAVIORAL|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
224012323|NCT00066313|DRUG|vandetanib|
224138554|NCT02325817|DEVICE|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
224012324|NCT00066313|PROCEDURE|adjuvant therapy|
223391581|NCT05784025|DEVICE|AlterG|Experimental device reducing weight perception by inducing a no-gravity environment which facilitates the execution of rehabilitation programs
223391582|NCT03705429|DRUG|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
223547104|NCT02725450|BEHAVIORAL|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
223547105|NCT00587808|PROCEDURE|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
223547106|NCT05101733|DIAGNOSTIC_TEST|Nasal provocation|Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device
223547107|NCT05101733|DIAGNOSTIC_TEST|Skin-Prick Test|Skin-Prick-Test is administered to determine an allergy against Alternaria
223547108|NCT05101733|DIAGNOSTIC_TEST|Blood draw|For further analysis
223547109|NCT05101733|DIAGNOSTIC_TEST|Collection of nasal secretion|Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray
223547110|NCT01481350|DRUG|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
223547111|NCT04981106|OTHER|Elastic Band Exercise|"The participants were asked to do exercise 4 times a day with a minimum of 2 hours interval between the sessions. The participants were instructed to avoid elastic band exercise 1 hour before or after the meals in order to prevent a physical impairment and to adopt a moderately progressive approach in order to prevent lower extremity pain after exercise and to increase the sense of success and confidence.~Through phone calls, researchers asked the participants in intervention group if they do the elastic band exercises at home and if they had any difficulty while doing these exercises, as well as the reasons if they haven't done the exercises. When the participants in control and intervention groups returned to hospital after 4 weeks, the knee joint movement, lower extremity strength, knee joint pain, quality of life, kinesiophobia, and depression levels and physical functions of these groups were compared."
223547112|NCT06495320|OTHER|Rational drug use education|Rational Drug Use Education Program for Parents: The training program consists of 30 minutes. The training program will be delivered to parents in the form of a 30-minute training session with a powerpoint presentation, using the face-to-face education model. Interactive education methods that enable parents' participation will be used. In addition, in order to increase the permanence of education, the educational content will be given to parents in the form of an educational booklet.
223547113|NCT06322550|BEHAVIORAL|cover story|After agreeing to participate, migraine patients were randomly given the briefing information and therefore their group allocation. Patients received the cover stories via the allocated flyer with study information and also by the physician from the outpatient clinic. Fifty percent of patients (Migraine as Patients \[MP\]) received the information that they will take part in a migraine study (compared to healthy controls) and that this study would investigates migraine associated dizziness by watching a visual stimulus (roller coaster video). The protocol for the intervention was standardized and identical for all participants. The other 50% (Migraine as Healthy \[MH\]) received the information that this study was in cooperation with the University's vertigo Department and that they will take part as controls since they were healthy apart from their migraine.
223547114|NCT02673099|PROCEDURE|HDF online|Hemodialysis by the HDF online method
223547115|NCT02144571|BEHAVIORAL|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
223547116|NCT00318240|DEVICE|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
224012325|NCT05607537|DRUG|E7386 Tablet|E7386 40 mg tablet.
224012326|NCT05607537|DRUG|(14C)E7386 Capsule|(14C)E7386 40 mg capsule.
224012327|NCT05607537|DRUG|(14C)E7386|(14C)E7386 administered intravenously.
224012328|NCT01921010|DRUG|Niaspan|See Arm Description
224012329|NCT01921010|DRUG|Placebo|See Arm Description
224012330|NCT01942785|DRUG|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
224012331|NCT06374017|DRUG|Normal saline, Lidocaine, dexmetomidine|The study drug of each group will be sprayed into oropharynx, the vocal cords and tracheal tree 3 minutes after induction of anesthesia and 5 minutes before intubation.
224012332|NCT06251284|OTHER|Saline nasal spray|A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
224012333|NCT05170633|DEVICE|Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)|70 random infant will receive the packed red blood cell transfusion with the Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
223391583|NCT06124729|DRUG|Bevacizumab Combined With PD-1 Monoclonal Antibody|Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS colorectal cancer with liver metastases
223391584|NCT00378144|DRUG|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
223391585|NCT00434369|DRUG|CoFactor (ANX-510)|
223391586|NCT00739063|DRUG|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
223391587|NCT04779879|BIOLOGICAL|Sotrovimab (Gen1)|Participants will be randomized to receive an IV infusion of Sotrovimab Gen 1 material
223391588|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion or by IM injection
223547117|NCT01039324|OTHER|Reports|Primary care event reports and patient letters
223391589|NCT04779879|BIOLOGICAL|Sotrovimab (Gen2)|Participants will be randomized to receive Sotrovimab Gen2 material by IV infusion
223547118|NCT01039324|OTHER|Reports and Notices|Primary care event reports, patient letters and care manager notices
223391590|NCT02716545|DEVICE|balloon assisted enteroscopy|Patients with recurrent bleeding (\>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
223391591|NCT02461160|DRUG|TAK-915 suspension|TAK-915 oral suspension
223391592|NCT02461160|DRUG|Midazolam|Midazolam oral solution
223391593|NCT02461160|DRUG|Placebo|Placebo-matching TAK-915 suspension
223547119|NCT01039324|OTHER|Usual care|This is the study's control group
223547120|NCT00781443|DRUG|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
223547121|NCT00781443|DRUG|placebo|Repeating subcutaneous injection
223547122|NCT03576014|BIOLOGICAL|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
223547123|NCT05386342|DEVICE|TufTex Over-the-Wire Embolectomy Catheter|The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
223547124|NCT05976568|DRUG|QL1706|7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
223547125|NCT05976568|DRUG|Bevacizumab|15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
224012334|NCT06296979|DEVICE|Phrenic nerve neuromodulation|The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.
224012335|NCT06296979|PROCEDURE|common Physical therapy|the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
224012336|NCT01905150|DRUG|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, and Oxaliplatin
224012337|NCT01905150|DRUG|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
223391594|NCT02461160|DRUG|TAK-915 tablet|TAK-915 tablet
223547126|NCT05976568|DRUG|Oxaliplatin injection|85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
223547127|NCT05976568|DRUG|Capecitabine|1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
223547128|NCT05976568|DRUG|Sintilimab|200 mg administered as IV infusion on Day 1 of each 21-day cycle
223547129|NCT03443089|DRUG|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
224012338|NCT01905150|DIETARY_SUPPLEMENT|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
223391595|NCT04296591|DIAGNOSTIC_TEST|fetal heart doppler findings|Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
223391596|NCT02854527|DRUG|Digoxin|single dose
223391597|NCT02854527|DRUG|Furosemide|single dose
223391598|NCT02854527|DRUG|Metformin|single dose
223391599|NCT02854527|DRUG|Rosuvastatin|single dose
223391600|NCT02854527|DRUG|Digoxin|0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
223391601|NCT02854527|DRUG|Furosemide|1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
223391602|NCT02854527|DRUG|Metformin hydrochloride|10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
223391603|NCT02854527|DRUG|Rosuvastatin|10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
223547130|NCT03443089|DRUG|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
223547131|NCT02413996|DEVICE|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
223547132|NCT02413996|BEHAVIORAL|Functional activities|Stairs, walking
223547133|NCT02413996|OTHER|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
223547134|NCT02413996|OTHER|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
223547135|NCT04574180|OTHER|Dental Crown|Pediatric size dental crown; restore damaged tooth to its normal shape, size, and function.
223547136|NCT02653586|OTHER|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
223547137|NCT05263180|BIOLOGICAL|EMB-09|EMB-09 is a FIT-Ig® bispecific antibody against PD-L1 and OX40.
223547138|NCT00002124|DRUG|Delavirdine mesylate|
223547139|NCT00002124|DRUG|Lamivudine|
223547140|NCT00002124|DRUG|Zidovudine|
223547141|NCT03280199|OTHER|simulation types|Different types of simulation interfaces and image acquisitions
223564190|NCT04918290|DEVICE|Tegaderm Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
223564191|NCT04918290|DEVICE|Transpore Eye Tape|Eye tape to protect the eye from corneal abrasions during surgery.
223564192|NCT05425394|BEHAVIORAL|Delay first bath|Newborns delay first bath to 8 hours after birth
224012339|NCT05153720|PROCEDURE|Erector spinae plane block|Ultrasound guided erector spinae plane block
224012340|NCT05153720|PROCEDURE|Caudal block|Ultrasound guided caudal block
224012341|NCT04688320|DRUG|Recombinant nonimmunogenic staphylokinase|15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
224138555|NCT02325817|DEVICE|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
223547142|NCT03529838|OTHER|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
223391604|NCT03377374|DIETARY_SUPPLEMENT|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
223391605|NCT03377374|OTHER|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
223391606|NCT05183880|DIETARY_SUPPLEMENT|Phosphatidylcholine-lipid encapsulated vitamin C|Ingesting 1000 mg of vitamin C in phosphatidylcholine-lipid encapsulated form
223391607|NCT05183880|DIETARY_SUPPLEMENT|Crystalline vitamin C|Ingesting 1000 mg of vitamin C in crystalline form
223391608|NCT00004073|DRUG|suramin|
223547143|NCT04894539|DEVICE|DS5 electrical stimulator|TENS
223547144|NCT01457664|DRUG|Placebo|Placebo to RO4995819 once daily for 14 days
223547145|NCT01457664|DRUG|RO4995819|RO4995819 doses once daily for 14 days
223547146|NCT02374281|DRUG|Glucose sucking|
223547147|NCT02374281|DRUG|Water sucking|
223547148|NCT02374281|OTHER|No sucking|
223547149|NCT01527240|DRUG|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
223547150|NCT01527240|DRUG|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
223547151|NCT05151510|PROCEDURE|Trigger point injection with 1% lidocaine|Previously discussed in prior section.
223547152|NCT05151510|DRUG|Lidocaine patch 5%|Will place lidocaine patch onto skin overlaying point of maximal tenderness
223547153|NCT06307249|GENETIC|SNP|Diagnostics of patients' carriers or not of the risk allele(s)
223547154|NCT06307249|DRUG|Palbociclib 125mg|Palbociclib 125mg/day/os over 21 days every 28 days
223547155|NCT06307249|DRUG|Bevacizumab|10mg/kg every 21 days
223547156|NCT02490397|OTHER|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
223547157|NCT02490397|OTHER|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
224012342|NCT04688320|DRUG|Alteplase|Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
224012343|NCT05423652|DEVICE|Lung point of care ultrasound|Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
224138556|NCT00259740|DRUG|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
223391609|NCT00004073|RADIATION|radiation therapy|
223391610|NCT03169231|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
223391611|NCT03169231|OTHER|Placebo|Intravenously delivered
223547158|NCT04961281|DRUG|Dexmedetomidine|injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
223391612|NCT04253665|BEHAVIORAL|Nursing discharge teaching|Nurses will provide multimorbid seniors inpatients with teaching related to self-management to prepare them to be discharged home. The teaching delivery will be tailored to patients' activation level and priorities. The intervention begins by determining the level of activation at which patients are and identifying priorities to address related to patients' life situation. A Discharge Teaching Guide will be used by nurses to deliver the teaching and includes six domains of self-management. For each domain, nurses first report whether a priority has been identified and what intervention they have proposed to address it. Then for each domain, teaching objectives are described and differ according to the level of patient activation. These six domains of self-management are found in the patient-oriented discharge summary, which is a document for the patient that summarizes what has been addressed in discharge teaching.
223391613|NCT04248530|DEVICE|Renal denervation|DENEX catheter is a device to treat resistant hypertension which delivers high-frequency energy through the three electrodes connected to the catheter in order to cauterize sympathetic nerve bundle.
223547159|NCT04961281|DRUG|Triamcinolone|injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
223547160|NCT00221546|DRUG|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
223547161|NCT06353048|PROCEDURE|fixation of tibial plateau fractures|fixation of tibial plateau fractures by screws only versus plate and screws
223547162|NCT02647476|DIETARY_SUPPLEMENT|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
223547163|NCT02647476|DIETARY_SUPPLEMENT|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
223547164|NCT00833443|DRUG|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
223547165|NCT03111212|DRUG|Iloprost|Iloprost nebulized
223547166|NCT03111212|DRUG|control|sodium chloride 0,9% nebulized
223547167|NCT02739958|DRUG|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
223547168|NCT02739958|DRUG|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
223547169|NCT00426803|DRUG|activated recombinant human factor VII|
223547170|NCT03271164|DEVICE|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
223547171|NCT03271164|OTHER|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
223547172|NCT03810014|OTHER|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
223547173|NCT03810014|OTHER|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
223547174|NCT03810014|OTHER|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
223547175|NCT03810014|OTHER|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
223547176|NCT04483258|PROCEDURE|Sedation with sevoflurane insufflation|Induction with %8sevoflurane after adequate sedation reducing %3
223547177|NCT04483258|PROCEDURE|intravenous sedation|midazolam +ketamine + atropine
223547178|NCT06348641|OTHER|baby massage|The infant massage to be applied before the examination will be applied by a single nurse=researcher. Video recordings will be taken before and during the ROP examination and evaluations will be made by two neonatal nurses other than the researcher.
223547179|NCT01603173|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
223547180|NCT01603173|DRUG|Quetiapine Fumarate|25 mg tablet once a day
223730559|NCT05426577|DIAGNOSTIC_TEST|ELISA, LAMP, Cytokine Release Assay|"IgG1 ELISA: ELISA that employs soluble Leishmania lysate or protein antigen.Results are recorded as antibody titres, which are measured by the absorbance values of products generated using enzyme conjugated anti-human antibodies.~Cytokine release assay (CRA): In this assay whole blood is stimulated for 24 hours with leishmania antigen. Cytokine levels are then assessed in the plasma fraction using flow cytometry with the BD™ Cytometric Bead Array for Human Cytokines or standard ELISA kits for human cytokines commercialized by Sigma-Aldrich (RAB0268-IL-2, RAB0222-IFN-g, RAB0224-IL-10, RAB0476-TNF-a, RAB0119-IP-10).~LAMP test for VL: We will use the LoopampTM Leishmania Detection Kit, CE-marked and produced Eiken Chemical Co., Japan."
223730560|NCT06190639|DRUG|sintilimab|200 mg once on day 1, every 21 days
223730561|NCT03030872|DEVICE|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
224296488|NCT01553279|BIOLOGICAL|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
224296489|NCT01553279|BIOLOGICAL|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
223547181|NCT00700908|BEHAVIORAL|automated telephone intervention vs. usual care|
223547182|NCT02091635|DRUG|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
223547183|NCT02091635|DRUG|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
223547184|NCT06075875|DIETARY_SUPPLEMENT|mixed animal and vegetable proteins|"mixed animal and vegetable proteins in the standard ratio (2/3:1/3; 60%:40% respectively) present in the nutritional menu over all hospitals in the general organization of teaching hospitals and institutes GOTHI; Egypt= as a control group) and continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm)."
223547185|NCT06075875|DIETARY_SUPPLEMENT|pure vegetable proteins|pure vegetable proteins continued for at least 48hours and followed for five days. The vegetable diets will be prepared from the dietetic service of our institute;calories will be calculated for 30Kcal/Kg/day (average 2000Kcal) and proteins 1.2g/Kg/day15 (average 84gm).
223547186|NCT04422691|DIAGNOSTIC_TEST|Lung ultrasound|After verbal consent the enrolled patients' lungs are evaluated with ultrasound while in isolation. The lungs are divided into 3 fields and findings are categorized according to Soldati et al., 2020.
223547187|NCT03606486|OTHER|Biospecimen Collection|Undergo collection of tumor sample and blood draw
223547188|NCT03606486|OTHER|Laboratory Biomarker Analysis|Correlative studies
223547189|NCT03606486|DEVICE|Lavage|Undergo uterine lavage
223547190|NCT03606486|OTHER|Pap Smear|Undergo pap smear
223547191|NCT00958477|BIOLOGICAL|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
223547192|NCT03499860|DIAGNOSTIC_TEST|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
223730562|NCT03656328|DIETARY_SUPPLEMENT|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
224296490|NCT01553279|BIOLOGICAL|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
224296491|NCT01553279|BIOLOGICAL|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
224296492|NCT03819621|DEVICE|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
223391614|NCT06353763|OTHER|Immersive virtual reality learning program|The immersive virtual reality learning programme was developed by the research team and two nurse experts in chronic wounds, who designed the learning content and script and created six pressure ulcer (PU) cases. Based on the standards of the European Pressure Ulcer Advisory Panel (EPUAP), the National Pressure Ulcer Advisory Panel (NPUAP) and the National Group for the Study and Advice on Pressure Ulcers and Chronic Wounds (GNEAUPP), prevention of healthy skin (case one), management of grade I, II, III and IV PUs (cases two to five) and an infected PU (debridement intervention) were developed. For each case, there was a formative version with immediate feedback and an evaluative one. Before starting the training, the students learned how to use the virtual reality glasses, buttons and joystick by playing a game that trained different dexterity movements. The computer assembly IVR application was developed using Unity 3D and the virtual objects were designed in 3Ds Max.
223391615|NCT01944163|OTHER|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
223391616|NCT04712279|DRUG|Ivermectin 0.6mg/kg/day|Use of ivermectin 0.6m/kg/day q.d.for 05 days
223391617|NCT04712279|DRUG|Ivermectin 1.0mg/kg/day|Ivermectin 1.0mg/kg/day q.d. for 05 days
223391618|NCT04712279|DRUG|Placebo|Placebo q.d.for 05 days
223391619|NCT04712279|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg/day q.d. for 05 days
223391620|NCT00018538|DRUG|calcifidiol|
223391621|NCT01313052|BEHAVIORAL|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
223391622|NCT01313052|BEHAVIORAL|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
223391623|NCT04359147|DRUG|"Yohimbine"|Effects on neural correlates of decision-making under risk and selective attention to threat
223391624|NCT04359147|DRUG|"Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
223391625|NCT04359147|DRUG|"Yohimbine + Hydrocortisone"|Effects on neural correlates of decision-making under risk and selective attention to threat
223391626|NCT04359147|DRUG|"Placebo"|Effects on neural correlates of decision-making under risk and selective attention to threat
223391627|NCT01480245|DRUG|GSK2402968|6mg/kg/week
223391628|NCT01226927|OTHER|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
223391629|NCT02899962|DRUG|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
223391630|NCT02899962|DRUG|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
223391631|NCT06077474|OTHER|Testing the the DSM-5 UCLA Posttraumatic Stress Disorder Reaction Index Self-Report Scale for Children and Adolescents (PTSD-RI-5)|Administer the DSM-5 PTSD-RI-5 scale in 155 patients with exposed to traumatic events.
223391632|NCT02367976|DRUG|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
223547193|NCT04538599|DRUG|RD13-01 cell infusion|Universal CAR-T cells targeting CD7
224012344|NCT05423652|OTHER|PRESUNA software|PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
224012345|NCT06478342|PROCEDURE|ablation|Pulsed field ablation, MRI and TEE examinations (LA strain)
224296493|NCT04009538|OTHER|Rehabilitation program|exercise program twice a week
224296494|NCT02754908|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
223391633|NCT00003080|DRUG|endocrine-modulating drug therapy|
223391634|NCT00003080|DRUG|melphalan|
223547194|NCT01918865|DRUG|ISIS-PTP1BRx|
223547195|NCT01918865|DRUG|Placebo|
223547196|NCT01918865|DRUG|daily OAD (metformin and/or sulfonylurea)|
224012346|NCT06619067|DIETARY_SUPPLEMENT|PROBAFLOR|PROBAFLOR is a food supplement made up of 11 bacterial strains and inulin. The bacterial strains present are: Bifidobacterium lactis BLC1, Lactococcus lactis LL82, Lactobacillus plantarum 14D, Lactobacillus acidophilus LA1, Streptococcus thermophilus Z57, Bifidobacterium longum SP54, Lactobacillus rhamnosus SP1, Lactobacillus bulgaricus LB2, Bifidobacterium bifidum SP9,Lactobacillus salivarius SP2, Lactobacillus casei BGP93.
224012347|NCT06619067|OTHER|Placebo|Placebo
224296495|NCT02754908|BEHAVIORAL|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
223391635|NCT00003080|DRUG|mitoxantrone hydrochloride|
223391636|NCT00003080|DRUG|tamoxifen citrate|
223391637|NCT00003080|DRUG|thiotepa|
223391638|NCT00003080|PROCEDURE|peripheral blood stem cell transplantation|
223391639|NCT00932191|PROCEDURE|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
223391640|NCT00932191|PROCEDURE|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
223391641|NCT03000062|BEHAVIORAL|Intervention group|Please see the preceding section
223391642|NCT00842192|DRUG|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
223391643|NCT03299582|DEVICE|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
223391644|NCT03299582|DEVICE|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
223547197|NCT06089031|DIAGNOSTIC_TEST|Coronary Function Test|Coronary function test may comprise of bolus thermodilution measurements of coronary microvascular function and/or acetylcholine-derived coronary vasoreactivity tests.
223391645|NCT03872973|OTHER|Neuromuscular Training|"The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses."
224012348|NCT05620797|OTHER|Immediate loading of the implants|Patients of this group will be rehabilitated by implant-retained mandibular overdenture with immediate loading of the implants as opposed to conventional maxillary complete dentures.
224012349|NCT05620797|OTHER|Delayed loading of the implant|Patients of this group will be rehabilitated by implant retained mandibular overdenture with delayed loading of the implants (after 3 months) opposed by conventional maxillary complete dentures
224012350|NCT04917445|BEHAVIORAL|Spikes-focused bad news protocol|Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
224012351|NCT05625178|DEVICE|Transcutaneous vagus nerve stimulation|tVNS will be performed by the application of an auricular electrode placed at the cymba concha of the left ear. The auricular electrode containing the anode will be applied with a conductive gel without prior disinfection. Once the electrode fits the cymba concha comfortably, the participant will lie down or take a position that is comfortable for them. Once in position, investigators initiate tVNS for 60 minutes with a below-discomfort-threshold intensity with 25 Hz and pulse width 250 uS. The electrical parameters will be modified accordingly to keep the below-discomfort threshold during the intervention.
224012352|NCT00002745|DRUG|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
224012353|NCT03223051|OTHER|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
224012354|NCT04408053|DEVICE|Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)|6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
224012355|NCT04785105|OTHER|No intervention|No intervention
224012356|NCT06092567|PROCEDURE|Group A ( Oblique Incremental Placement Technique)|In this interventional group, a Nanohybrid composite resin Nexcomp (Meta Biomed, Korea) was placed using an oblique incremental technique with increments not exceeding 2 mm in thickness.
224296496|NCT05016687|DRUG|CUR-N399|CUR-N399 will be administered as oral capsules.
224296497|NCT05016687|DRUG|Placebo|Placebo capsules matching CUR-N399 will administered.
223391646|NCT03872973|OTHER|Strobe Glasses|Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
223391647|NCT02315131|DRUG|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
223391648|NCT02315131|DRUG|Placebo|Placebo Comparator
223391649|NCT04422600|OTHER|There is no other intervention, only clinical treatment.|The investigators will then correlate that exposure with neurodevelopmental outcomes.
223391650|NCT06461000|OTHER|Survey|online survey for participants
223391651|NCT03833687|DEVICE|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
223391652|NCT01849237|GENETIC|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10\^9/l).
223391653|NCT01849237|DRUG|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
223391654|NCT02153983|DRUG|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
223391655|NCT02153983|DRUG|Placebo capsules given|Placebo capsules given twice daily
223391656|NCT02153983|DRUG|Colchicine 0.6Mg Tab|Open-label colchicine
223391657|NCT01034020|DRUG|Nicotine|
223391658|NCT04446247|DIAGNOSTIC_TEST|Owlet Smart Sock Sensor 3rd Generation|Pulse Oximetry
223391659|NCT06261645|OTHER|Early Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
223391660|NCT06261645|OTHER|Delayed Physiotherapist selected active exercises|"Exercises to restore total rotator cuff function selected and progressed according to patients performance. Performance is assessed by the physiotherapist regarding available range of motion, comfort during as well as pain-free performance.~Education on shoulder muscles functional anatomy and on effect of pain on muscle performance"
223547198|NCT06283277|DEVICE|Obstetric Ultrasound|Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
223391661|NCT05626205|DEVICE|PARO robot|PARO is an advanced interactive robot. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties. PARO has five kinds of sensors: tactile, light, audition, temperature, and posture sensors, with which it can perceive people and its environment. PARO can learn to behave in a way that the user prefers, and to respond to its new name.
223391662|NCT03330873|DEVICE|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
223391663|NCT03330873|DEVICE|Foley catheter|Foley catheter can partly separate the sides of uterus wall.
223391664|NCT06036186|DEVICE|BaroPacing treatment|BaroPacing for the first 3 weeks (day 8 to day 28) and then crossover to standard treatment for another 3 weeks (day 29 to day 49).
223391665|NCT06036186|DEVICE|Standard treatment|Individual Standard treatment as prescribed by the Physician to each subject for the first 3 weeks (day 8 to day 28) and then crossover to BaroPacing for another 3 weeks (day 29 to day 49).
223391666|NCT05582070|OTHER|actigraphy|Actigraphy examination will be performed during 2 periods of 7 days before and after nose nasal desobstruction surgery (septoplasty, septorhinoplasty or total ethmoidectomy). Respectively 2 months before surgery (inclusion) and 4 months after surgery.
223547199|NCT03464513|DEVICE|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
223547200|NCT03774797|OTHER|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
224012357|NCT06092567|PROCEDURE|Group B (Bulk-fill Placement technique)|In this group, a composite Beautifil-Bulk Restorative (SHOFU dental) was utilized for restorative purposes using a bulk-fill technique with a thickness of 4 mm
223547201|NCT03873727|BIOLOGICAL|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
223391667|NCT02633787|BIOLOGICAL|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
223391668|NCT00550459|DRUG|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
223391669|NCT00550459|DRUG|Placebo|Placebo tablet given once daily for 21 days
223547202|NCT03873727|BIOLOGICAL|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
223547203|NCT03873727|BIOLOGICAL|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
223547204|NCT01769950|OTHER|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
223547205|NCT00610844|PROCEDURE|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
223547206|NCT03748589|DEVICE|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
223547207|NCT01671553|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
223547208|NCT00002343|DRUG|Ethambutol hydrochloride|
223547209|NCT00002343|DRUG|Rifabutin|
223547210|NCT04615624|DRUG|Furosemide|Furosemide, a loop diuretic
223547211|NCT04615624|OTHER|Placebo|Normal saline
223564193|NCT03170115|DRUG|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
224012358|NCT03916640|DRUG|ADO09 formulation|Subcutaneous injection of ADO09 formulation
224012359|NCT03916640|DRUG|Placebo|Subcutaneous injection of 0.9% NaCl
224012360|NCT03916640|DRUG|Symlin®|Subcutaneous injection of pramlintide
224012361|NCT03916640|DRUG|Humulin®|Subcutaneous injection of human insulin
223391670|NCT01742897|DRUG|TTS-fentanyl|
223391671|NCT02404805|DRUG|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
223391672|NCT02404805|DRUG|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
223391673|NCT00254592|DRUG|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
224012362|NCT03916640|DRUG|Humalog®|Subcutaneous injection of insulin lispro
224127581|NCT03683706|BEHAVIORAL|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention-Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
224127582|NCT04758273|BIOLOGICAL|medium dosage inactivated SARS-CoV-2 vaccine|medium dosage
224127583|NCT04758273|BIOLOGICAL|high dosage inactivated SARS-CoV-2 vaccine|high dosage
223391674|NCT00254592|DRUG|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
223391675|NCT00254592|DRUG|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
223391676|NCT00254592|DRUG|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
223391677|NCT00254592|DRUG|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
223391678|NCT00254592|DRUG|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
223391679|NCT00254592|DRUG|Bevacizumab|10mg/kg q 2 wks
223391680|NCT05131672|PROCEDURE|open reduction and internal fixation (ORIF)|open reduction and internal fixation with pin or screw fixation
223391681|NCT05131672|PROCEDURE|cast immobilization|immobilization in a cast without reduction
223391682|NCT05096910|PROCEDURE|Uterine Closure with monofilament or polyfilament suture materials|Postoperative 6th-month isthmocele rates
223391683|NCT00147459|BIOLOGICAL|HBV vaccine booster|
223391684|NCT00763633|DRUG|vitamin B6|high dose of vitamin B6
223564194|NCT03170115|DRUG|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
223564195|NCT00484380|PROCEDURE|Coronary scanner|multislice spiral computed tomography coronary angiography
223564196|NCT01925118|BIOLOGICAL|Irradiated donor lymphocyte infusion|
224012363|NCT04715438|BIOLOGICAL|mRNA-1273 SARS-CoV-2 vaccine from Moderna|All participants will receive two vaccinations against COVID-19 according to standard of care.
224012364|NCT02085395|DRUG|SR-T100 ® Gel|
224012365|NCT04116801|PROCEDURE|microsurgical resection|resection of cerebral metastases by microsurgery
224012366|NCT03762200|DEVICE|SURGICEL Powder|SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
223547212|NCT05401539|DEVICE|Cardboard VR|Google Cardboard is a discontinued virtual reality (VR) platform developed by Google. Named for its fold-out cardboard viewer into which a smartphone is inserted, the platform was intended as a low-cost system to encourage interest and development in VR applications. To use the platform, users run Cardboard-compatible mobile apps on their phone, place it into the back of the viewer, and view content through the lenses. The parts that make up a Cardboard viewer are a piece of cardboard cut into a precise shape, magnets or capacitive tape, a hook and loop fastener, a rubber band, and an optional near field communication tag. Smartphone is inserted in the back of the device and held in place by the selected fastening device. A Google Cardboard-compatible app splits the smartphone display image into two, one for each eye, while also applying barrel distortion to each image to counter pincushion distortion from the lenses.The result is a stereoscopic image with a wide field of view.
223547213|NCT05247684|DRUG|AK112|IV infusion
223547214|NCT05247684|DRUG|Carboplatin|IV infusion
223547215|NCT05247684|DRUG|Cisplatin|IV infusion
223547216|NCT05247684|DRUG|Paclitaxel|IV infusion
223547217|NCT05206214|PROCEDURE|Manual glide path|manual glide path will be established using manual thermal treated stainless-steel files in a watch winding maneuver. . Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
223547218|NCT05206214|PROCEDURE|Mechanical glide path|glide path will be established using rotary Ni-Ti files in a reciprocating maneuver. Coronal flaring will be performed using Gates Glidden drill #3 in a brushing motion away from dangerous zone.
223547219|NCT03384459|DEVICE|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
223547220|NCT02186483|DRUG|Metformin|Metformin,1000mg, once daily
223547221|NCT02186483|DRUG|Rosuvastatin|Rosuvastatin, 20 mg, once daily
223547222|NCT02186483|DRUG|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
223547223|NCT04763889|BEHAVIORAL|CBT|CBT for those with an allergy and anxiety
224127584|NCT04758273|BIOLOGICAL|Placebo|placebo
224127585|NCT05282264|OTHER|device|closed-loop insulin
223547224|NCT03920241|BEHAVIORAL|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
223547225|NCT03920241|BEHAVIORAL|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
223547226|NCT03920241|OTHER|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
223547227|NCT06424821|DRUG|Cadonilimab|Cadonilimab + chemotherapy
223547228|NCT00755963|DRUG|estradiol valerate|Progynova® 21; 2mg/d
223547229|NCT00755963|DRUG|micronized progesterone|Utrogestan®; 200mg/d
223547230|NCT00755963|DRUG|placebo|maltodextrin
223547231|NCT06187779|OTHER|Lower segment measurment|Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
223547232|NCT05358626|DIAGNOSTIC_TEST|SARS-CoV-2 IgG Antibody testing|IgG Antibody testing for previous exposure to SARS-CoV-2
223547233|NCT01107964|DRUG|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
223547234|NCT01107964|DRUG|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
224127586|NCT02028429|DRUG|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
224127587|NCT06840119|DRUG|IMC-R117C|IV infusion
223547235|NCT03504891|DIAGNOSTIC_TEST|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
223547236|NCT03504891|DIAGNOSTIC_TEST|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
224127588|NCT06840119|DRUG|Chemotherapy drug|IV infusion
224127589|NCT06840119|DRUG|Chemotherapy drug|oral
223547237|NCT01153204|BEHAVIORAL|Group Psychotherapy|
223547238|NCT01153204|OTHER|Group Psychotherapy plus Sildenafil citrate|
223547239|NCT01153204|DRUG|Sildenafil citrate|
223547240|NCT05860907|DRUG|Huaier Granule|10g each time, three times a day
224127590|NCT06840119|DRUG|Kinase inhibitor|oral
224127591|NCT06840119|DRUG|Antiangiogenic Agent|IV infusion
224127592|NCT06840119|DRUG|Monoclonal antibody|IV infusion
224127593|NCT02913222|OTHER|Rehabilitation|Comparison of two rehabilitation approaches
224127594|NCT05743478|BEHAVIORAL|Forging Hopeful Futures|Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.
223391685|NCT00763633|DRUG|vitamin B6|low vitamin B6
223391686|NCT00154154|BEHAVIORAL|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
223391687|NCT00154154|BEHAVIORAL|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
224012367|NCT02631577|DRUG|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
224012368|NCT02631577|DRUG|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
224012369|NCT02631577|DRUG|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
223391688|NCT02102854|DRUG|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation
223391689|NCT04184427|OTHER|Anterior Power Arm|Crimpable stainless steel hook placed on orthodontic base arch wire.
223391690|NCT01452516|DEVICE|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
223391691|NCT01452516|DEVICE|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
223391692|NCT06178627|DRUG|Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
223391693|NCT06178627|DRUG|Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.|Different amphotericin B dosage
223391694|NCT06361680|DRUG|Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets|Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
223391695|NCT01960660|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|
223391696|NCT00277329|DRUG|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
223391697|NCT06060431|OTHER|Pain Science Education|The Pain Science Education program consists of two workshops, 90 and 60 minutes in length, one week apart. The content of the workshops aims to provide students with information about the contemporary pain paradigm and to re-conceptualize pain.
223391698|NCT04951869|DRUG|Protescal gel|Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
223391699|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with Alt-RAMEC protocol.|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by Alt-RAMEC protocol.
223391700|NCT05489302|DEVICE|Maxillary skeletal expander with protraction face mask with conventional protocol|The current study was conducted on a total sample of 21 young adult orthodontic patients presented with class 3 retrognathic maxilla with or without transverse maxillary deficiency by conventional protocol
223391701|NCT00664079|OTHER|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
223391702|NCT00681421|BIOLOGICAL|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
223391703|NCT00029003|DRUG|gefitinib|Given orally
223391704|NCT00029003|OTHER|laboratory biomarker analysis|Correlative studies
223391705|NCT02908971|BEHAVIORAL|soy based formula at infancy|The intervention is only past history of soy consumption
223391706|NCT03654833|DRUG|Rucaparib|PARP inhibitor
223391707|NCT03654833|DRUG|Abemaciclib|CDK4/6 inhibitor
223391708|NCT03654833|DRUG|pembrolizumab & bemcentinib|PD1 checkpoint inhibitor, AXL inhibitor
223391709|NCT03654833|DRUG|Atezolizumab & Bevacizumab|PDL1 checkpoint inhibitor, VEGF inhibitor
224127595|NCT05743478|BEHAVIORAL|Wellness Check-ins|Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
223391710|NCT03654833|DRUG|Dostarlimab and Niraparib|IG Antibody, PARP Inhibitor
223391711|NCT05611554|BEHAVIORAL|ACT|Psychological intervention focused on (a) values clarification, (b) defusion strategies, (c) training in flexible attention to the present moment (mindfulness), and (d) committed action and psychological acceptance through metaphors and experiential exercises.
223391712|NCT01068483|DRUG|BKM120|
223391713|NCT03744247|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
223391714|NCT03744247|DRUG|PD-1 antibody|3mg/kg intravenously every 2 weeks
223391715|NCT03744247|DRUG|Placebo|Intravenously every 2 weeks
223391716|NCT05391373|BEHAVIORAL|Laughter therapy|Each session started with a 10-minute breathing exercise accompanied by relaxing music, followed by 20-minute laughing exercises. Afterwards, the session was ended with a 10-minute meditation accompanied by relaxing music.
223391717|NCT05066360|DIAGNOSTIC_TEST|serum antimullerian hormone|serum antimullerian hormone will be analyzed for all participants
223547241|NCT02794896|DRUG|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
223547242|NCT02794896|DRUG|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
223547243|NCT04887194|DRUG|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
224012370|NCT03984981|OTHER|Assessment of process required to diagnose brain death in adult patients|Assessment of process required to diagnose brain death in adult patients (demographics, clinical, laboratory, imaging, and treatment data). No questionnaires or study visits will be used.
223391718|NCT02456740|DRUG|Erenumab|Administered by subcutaneous injection once a month
224012371|NCT04902677|OTHER|Cross-sectional|No intervention
223391719|NCT02456740|DRUG|Placebo|Administered by subcutaneous injection once a month
223391720|NCT03119402|BEHAVIORAL|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
223391721|NCT03119402|DEVICE|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
223391722|NCT01026753|BEHAVIORAL|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
223391723|NCT04720105|DRUG|Duobrii®|Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) will be provided at weeks 0,2,8,16 for a total of 24 weeks.
223391724|NCT02005380|OTHER|Text-based task|Participants are required to take text-based exercise.
223391725|NCT02005380|OTHER|Graphic-based Task|Participants are required to take the graphic-based exercise.
223391726|NCT02934243|DEVICE|laryngeal mask insertion|airway management with laryngeal mask
223391727|NCT02483676|DEVICE|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
223391728|NCT02483676|BEHAVIORAL|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
223391729|NCT00308204|DRUG|Raptiva|injection
223391730|NCT04196569|DEVICE|Alcon Trifocal and Trifocal Toric Intraocular Lenses|"Panoptix Model #TFAT00 for the UV Absorbing Trifocal IOL. Torics:~TFAT30, TFAT40, TFAT50, TFAT60"
223391731|NCT01364012|DRUG|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
223391732|NCT01364012|DRUG|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
223391733|NCT01364012|DRUG|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
223391734|NCT01364012|DRUG|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
224012372|NCT05918276|DRUG|Orelabrutinib and BG|"Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8\&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle."
224012373|NCT06194487|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle (50mL) per day
224012374|NCT06194487|DIETARY_SUPPLEMENT|MAXI Collagen drink|consume 1 bottle (50mL) per day
224012375|NCT06194487|DIETARY_SUPPLEMENT|Normal fish collagen drink|consume 1 bottle (50mL) per day
224012376|NCT02417077|OTHER|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
224012377|NCT04436770|OTHER|Non-immersive virtual reality therapy|"Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used."
223391735|NCT04053621|DIETARY_SUPPLEMENT|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
223391736|NCT04053621|OTHER|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
223391737|NCT04053621|DRUG|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
223391738|NCT00371579|DRUG|rosuvastatin|
223391739|NCT04840303|BEHAVIORAL|LevelMind@JC Mental Wellness Youth Hubs|Mental Wellness Youth Hubs Intervention aims to set up a series of community-based hubs for young people to enhance cognitive abilities, personal strengths and overall mental well-being. Among the experimental group participants (hub users), they are further divided into three tiers according to their psychological distress level. Tier 1 are youths with mild psychological distress level, who will be invited to participate in some innovative and interesting youth projects and activities (e.g., board game and floral artistry). Tier 2 are youths who have moderate level of psychological distress, or at risk for mental illness. Trained social workers will offer them with specific interventions (e.g., CBT, sleep intervention) according to their needs. Tier 3 are youths with severe level of psychological distress who are at risk for mental disorders. Diagnostic and medical assessment services will be delivered by psychiatrist or clinical psychologists.
223547244|NCT04887194|DRUG|Warfarin|CYP2C9 probe substrate
223547245|NCT04887194|DRUG|Dextromethorphan|CYP2D6 probe substrate
223547246|NCT04887194|DRUG|Midazolam|CYP3A4 probe substrate
223547247|NCT04887194|DRUG|Digoxin|P-gp probe substrate
223391740|NCT03248115|DIETARY_SUPPLEMENT|Green tea and green coffee extract tablets|"1. Tablets: participants were required to take 6 green tea and 3 green coffee extract tablets daily for a period of 8 weeks. No tablets were taken during the last 4 weeks of the study. Randomly chosen tablets were analysed to quantify their polyphenol content.~2. Urine collections: Several urine collections were required during the supplementation period in order have sufficient time points to estimate the plateau of the concentration of green tea and coffee polyphenols excreted in the urine to then be able to determine their bioavailability. There was a total of five 24-hour urine collections (at week 0 -before supplementation-, 2, 4, 8, and 12 -4 weeks after finishing the supplementation period).~3. Completion of study documents: Participants were provided with urine collection sheets, polyphenol questionnaires, checklists to record polyphenol tablet intake, and detailed instructions."
223391741|NCT04748107|DIAGNOSTIC_TEST|Impendence Cardiography|ICG is a noninvasive method of determining the amount of blood flow using the Non-Invasive Cardiac System - Cardiac Surveyor (NICaS) system, which provides an assessment of the cardiovascular system, respiratory system, and fluid retention.
223391742|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 10g|10 g of pure MCT oil mixed with skim milk in a standardized breakfast
223391743|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 10g|10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
223391744|NCT02409927|DIETARY_SUPPLEMENT|Control|vehicule (skim milk) with a standardized breakfast
223391745|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 20g|20g of pure MCT oil mixed with skim milk in a standardized breakfast
223391746|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 20g|20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
223547248|NCT04887194|DRUG|Rosuvastatin|BCRP probe substrate
223547249|NCT04887194|DRUG|Nivolumab|Nivolumab is a programmed death receptor (PD-1) blocking antibody
223547250|NCT01672086|DEVICE|Stelkast Surpass Acetabular System implant|
223547251|NCT06451367|OTHER|neuromuscular programm|neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
224012378|NCT04436770|OTHER|Standard Physiotherapy|"Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used."
224012379|NCT02241590|DRUG|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
224012380|NCT02241590|DRUG|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
224012381|NCT04206657|DRUG|1mg KHK7580|Single oral dose administration of 1mg KHK7580
224012382|NCT04206657|DRUG|3mg KHK7580|Single oral dose administration of 3mg KHK7580
224012383|NCT04206657|DRUG|6mg KHK7580|Single oral dose administration of 6mg KHK7580
223391747|NCT02409927|DIETARY_SUPPLEMENT|MCT oil 30g|30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast
223391748|NCT02409927|DIETARY_SUPPLEMENT|MCT homogenate 30g|30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
223391749|NCT04871776|BEHAVIORAL|Messaging informed by construal level theory|"Messages are informed by construal level theory, which suggests that emphasizing why elicits more abstract thinking, or high-level construals, and can induce an emotional mindset, which could challenge an individual's sense of identity, autonomy, or political preferences. Conversely, emphasizing how is more cognitive and evokes concrete thinking, or low-level construals, and encourages a planning or implementation mindset, which may be better for encouraging vaccine uptake."
223391750|NCT04871776|BEHAVIORAL|Usual Care|Usual messaging sent by Mass General Brigham
223391751|NCT02641327|DEVICE|EarlySense (Passive monitoring)|Passive contact-free monitoring
223391752|NCT01296776|OTHER|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
223391753|NCT01296776|DEVICE|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
223391754|NCT00653627|BIOLOGICAL|BCG|Mycobacterium bovis Bacille Calmette-Guerin
223391755|NCT05522192|DRUG|Mitoxantrone liposome|Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
223391756|NCT05522192|DRUG|Venetoclax|Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
223547252|NCT01853462|OTHER|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
223547253|NCT01853462|OTHER|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
223547254|NCT05339399|OTHER|oxytocin augmentation|Only observation of the outcome
223547255|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
223547256|NCT00407836|BIOLOGICAL|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
223564197|NCT03849053|OTHER|Mézières Therapy for Low back pain|Spinal muscular global stretching
223564198|NCT00632047|OTHER|active surveillance|
224012384|NCT04206657|DRUG|12mg KHK7580|Single oral dose administration of 12mg KHK7580
224138557|NCT04538885|BIOLOGICAL|The pleiotropic factor derived from mesenchymal stem cells|The pleiotropic factor derived from mesenchymal stem cells was smeared on the wound with a dosage of (2.5mg/2cm2), and then the wound was covered with a foam dressing; the dressing was changed every 3 days to reach clinical healing as the end of the trial.
223564199|NCT00632047|OTHER|educational intervention|
223564200|NCT00632047|PROCEDURE|examination|
223564201|NCT00632047|PROCEDURE|long-term screening|
223564202|NCT02609841|DEVICE|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
223391757|NCT01741038|BIOLOGICAL|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
223391758|NCT01741038|PROCEDURE|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
223391759|NCT01741038|OTHER|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
223391760|NCT06020911|DRUG|Biodentine|17 primary second molars of 17 children will be capped with Biodentine
223391761|NCT06020911|DRUG|Theracal light cured|17 primary second molars of 17 children will be capped with Theracal light cured
223391762|NCT00692692|PROCEDURE|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
223391763|NCT00692692|PROCEDURE|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
223391764|NCT06470451|DRUG|Hypericin|HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
223391765|NCT06470451|DRUG|Placebo|Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
223391766|NCT06236438|DRUG|Livmoniplimab|Intravenously (IV) Infusion
223391767|NCT06236438|DRUG|Budigalimab|IV Infusion
223391768|NCT06236438|DRUG|Pembrolizumab|IV Infusion
224012385|NCT04206657|DRUG|6mg KHK7580 for 8days|multiple oral dose administration of 6mg KHK7580 for 8days
224012386|NCT00004094|DRUG|carboplatin|
224127596|NCT04751435|OTHER|Cognitive interview|Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
223391769|NCT06236438|DRUG|Pemetrexed|IV Infusion
223391770|NCT06236438|DRUG|Cisplatin|IV Infusion
223391771|NCT06236438|DRUG|Carboplatin|IV Injection
223391772|NCT06236438|DRUG|Carboplatin|IV Infusion
223547257|NCT04005495|BEHAVIORAL|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
223547258|NCT02460068|DRUG|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
223730563|NCT03656328|DIETARY_SUPPLEMENT|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
224012387|NCT00004094|DRUG|fluorouracil|
224012388|NCT00004094|DRUG|hydroxyurea|
223391773|NCT02627651|OTHER|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
223391774|NCT04935333|PROCEDURE|Collection of Leiomyoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
223391775|NCT04935333|PROCEDURE|Collection of Leiomyosarcoma samples|"Peripheral blood will be collected from the candidate patient with suspected myometrial tumours, prior to the surgery already planned form medical indication in accordance with routine clinical practice.~A sample of tumour tissue will be collected during surgery and sent to pathologists for diagnosis in accordance with the usual clinical practice. The tumour paraffin block/sections will be requested for the study only after the diagnosis."
223391776|NCT04935333|PROCEDURE|Collection of control samples|Peripheral blood will be collected during an analysis or gynaecological consultation already planned by routine clinical practice. The sample will be sent to Igenomix for molecular analysis.
223391777|NCT04031625|OTHER|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
224012389|NCT00004094|DRUG|paclitaxel|
224012390|NCT00004094|PROCEDURE|conventional surgery|
224012391|NCT00004094|RADIATION|radiation therapy|
224012392|NCT01593787|DRUG|LCZ696|100 mg, 200 mg, 400 mg tablets.
224127597|NCT04751435|BEHAVIORAL|LCAM intervention|"Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic literacy screener and adapted clinical communication materials."
224127598|NCT04751435|BEHAVIORAL|Standard of care|Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics
224127599|NCT05955170|DRUG|Tucatinib in Combination of Oral VP16 and trastuzumab|Combination of tucatinib-Oral VP16-trastuzumab
223391778|NCT06751173|OTHER|Static Core Stability exercises|"i. Plank: Press the hands and knees to the floor with the back in a neutral position and wrists aligned directly under the shoulders.~ii. Side Plank: Lie on the side with knees bent and prop the upper body up on the elbow.~iii. Shoulder Bridge: Raise the pelvis off the floor until only the head, neck, shoulders, and feet are touching the mat. Place the hands at the waist.~iv. Static Crunch: Lie on the back with feet flat on the floor and knees bent at a 90-degree angle.~v. Leg Lift: Lie straight on the floor, keep the arms at the sides, and slowly lift both legs into the air."
223391779|NCT06751173|OTHER|Mckenzie exercises|"i. Prone Extension (Positioned): Lie on the stomach with pillows placed under the chest for comfort.~ii. Prone Extension on Elbow: Keep the back and buttocks relaxed and rise up on the elbows as high as possible.~iii. Prone Press-ups: Place the hands beside the shoulders. Keep the back and buttocks relaxed, and use the arms to press up.~iv. Standing Extension: Stand with feet apart and hands on the small of the back with fingers pointing backward. Bend backward at the waist, supporting the trunk with the hands.~v. Side glide in Standing: Stand at a right angle to the wall about 2 feet away. Lean the shoulder into the wall."
223547259|NCT02460068|DRUG|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
223547260|NCT02460068|DRUG|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
224012393|NCT02428062|PROCEDURE|Hemodynamic target|"The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~1. vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~2. intravenous fluids~3. patient's positioning~4. reduction of depth of anesthesia"
224012394|NCT02428062|DRUG|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
224012395|NCT02428062|DRUG|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
224012396|NCT02428062|PROCEDURE|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
224012397|NCT02428062|PROCEDURE|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
224012398|NCT02428062|DRUG|Ephedrine|Ephedrine 5-25 mg intravenous bolus
224012399|NCT02428062|DRUG|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
223391780|NCT06751173|OTHER|Spinal Mobilization|Central-Unilateral posterio anterior and lateral glide
223547261|NCT05764252|DEVICE|BioEP|All patient's EEG will have the BioEP score conducted on it
223547262|NCT00956722|DRUG|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
223547263|NCT04311268|DEVICE|F2D armband|Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
223547264|NCT03204877|DRUG|Melatonin|Oral capsules
223547265|NCT03204877|OTHER|Placebo|Oral capsules
223547266|NCT04620616|OTHER|RELX ENDS Tobacco Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
223547267|NCT04620616|OTHER|RELX ENDS Menthol Flavor|Ad libitum use of the RELX ENDS tobacco flavor product during 8-hour and 5-minute use sessions
223547268|NCT04620616|OTHER|Subject Usual Brand ENDS|Ad libitum use of the usual brand product during 8-hour and 5-minute use sessions
223547269|NCT00839280|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
223547270|NCT00839280|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
223547271|NCT03943290|DRUG|ACE-083|Recombinant fusion protein
223547272|NCT03390517|DEVICE|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
223547273|NCT02289365|DRUG|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
223730564|NCT03707327|OTHER|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
224012400|NCT02428062|DRUG|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
224012401|NCT02428062|DRUG|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
224012402|NCT00071461|DRUG|bosentan|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
224012403|NCT00071461|DRUG|Placebo|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~* Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~* body weight \< 40 kg (90 lb): 62.5 mg b.i.d."
224012404|NCT02299089|DRUG|octreotide FluidCrystal® injection depot|
224012405|NCT04949243|BEHAVIORAL|Behavioral questionaires|Behavioral surveys and questionaires
224012406|NCT02451852|DRUG|AZD9291|AZD9291 80mg tablet once daily, open label
224012407|NCT02491476|DEVICE|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
224138558|NCT03051087|DRUG|Ganirelix acetate|
224012408|NCT06645080|OTHER|Focus group or interview participation|90 minute focus group or 60 minute interview participation
223391781|NCT04005066|DRUG|Elunate®|The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
223391782|NCT03145675|DRUG|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5+0.25 mg/kg administered intravenously.
223391783|NCT03145675|DRUG|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg administered intravenously.
223391784|NCT03145675|DRUG|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg administered intravenously.
223547274|NCT02289365|DRUG|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
223730565|NCT03707327|OTHER|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
224012409|NCT06645080|OTHER|Delphi survey participation|Participation in a modified two-round Delphi technique. Optional third round in the event of insufficient agreement in the second round.
224012410|NCT00722280|PROCEDURE|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
224012411|NCT04346459|PROCEDURE|"Tracheal intubation through Fastrach - Group A"|"Insertion of the intubating laryngeal mask Fastrach and blind tracheal intubation through the device"
224012412|NCT04346459|PROCEDURE|"Tracheal intubation through I-gel - Group B"|"Insertion of the supraglottic airway device i-gel and tracheal intubation through the device guided by a fiberoptic bronchoscope"
224012413|NCT04346459|PROCEDURE|"Tracheal intubation through Protector - Group C"|"Insertion of the laryngeal mask Protector and tracheal intubation through the device guided by a fiberoptic bronchoscope"
224012414|NCT05922501|DRUG|Isatuximab|An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
224012415|NCT05922501|DRUG|Belantamab mafodotin|An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
223391785|NCT03145675|DRUG|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg administered intravenously.
223391786|NCT02449980|PROCEDURE|Primary Surgery Group|Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
223391787|NCT02449980|PROCEDURE|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
223547275|NCT02289365|DRUG|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
223547276|NCT04430361|DRUG|Megestrol|160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
223547277|NCT04430361|DRUG|5-HT3 receptor antagonist|5-HT3 receptor antagonist 2.5mg/iv
223547278|NCT04430361|DRUG|dexamethasone|dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
223730566|NCT00587639|DEVICE|rTMS Treatment|Active rTMS treatment.
224012416|NCT05922501|DRUG|Pomalidomide|An immunomodulatory agent, capsule taken orally.
224012417|NCT05922501|DRUG|Dexamethasone|A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
224012418|NCT05748223|OTHER|Mindfulness Meditation|Mindfulness meditation has been reported to produce beneficial effects on a number of psychiatric, functional somatic, and stress-related symptoms and has therefore increasingly been incorporated into psychotherapeutic programs
224012419|NCT05642832|DEVICE|Throughflow titration phase|"Ventilation will be applied in the TF mode with TF set to 0 LPM for 10 minutes. Patients will receive assist through the NAVA line of the tri-piece (NAVA set to similar settings as Servo period, \~60-80 LPM flow). Ventilation with Throughflow will be started at a TF flow of 5 LPM, and the NAVA flow will be reduced by 5 LPM. After 10 minutes measurements will be collected. If Edi is greater than or equal to 4 µV, TF flow will be increased to 10 LPM and NAVA flow will be adjusted to keep total flow constant. Measurements will be collected again after 10 minutes. TF flow will be increased in steps of 5 LPM and measurements collected every 10 minutes until Edi is below 3 µV or TF flow reaches the total flow observed during the NAVA period.~After either the Edi target has been met or TF flow has reached the total flow, ventilation with TF will be reduced in steps of 5 LPM every 10 minutes (the reverse of the above), while NAVA flow is accordingly adjusted to keep total flow constant."
223547279|NCT04749043|DEVICE|Oculus Quest 2 Virtual Reality Device|30 min VR experience exposure for labor analgesia. VR experiences include swimming in the ocean, walking through forests, engaging in 3D puzzles, exploring virtual lands, or interacting with musical objects
223547280|NCT04749043|DRUG|Nitrous oxide|30 min exposure for labor analgesia
223547281|NCT02676947|DRUG|Tocilizumab|
223730567|NCT02103764|DRUG|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
223730568|NCT02103764|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
223730569|NCT00536406|BEHAVIORAL|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
223730570|NCT00536406|BEHAVIORAL|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
223730571|NCT02060149|DRUG|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
224012420|NCT05436990|DRUG|Pembrolizumab, Vactosertib|Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
224012421|NCT06405568|BEHAVIORAL|Physical activity intervention|Participants will receive a copy of physical activity (PA) recommendations plus a PA motivation package - namely three 20-minute online webinars (explaining PA benefits and how to get started), digitized PA materials (integrating evidence-based behaviour change tools, and a digitized logbook (to track PA).
224012422|NCT05594706|OTHER|Measurement of blood levels of 1,5-anhydroglucitol|Measurement of blood levels of 1,5-anhydroglucitol
224012423|NCT06303258|OTHER|Core Stabalization Exercises|Low Intensity Warm Up Exercises Core Stabilization Exercises Cool Down Stretching Exercises
224012424|NCT06303258|OTHER|Generalized Antenatal Exercises|Low Intensity WarmUp Exercise Aerobic Training Endurance Training Pelvic Floor Muscle Training Cool Down Stretching Exercises
224012425|NCT06605846|OTHER|otago excercises|"Otago training is helpful, and one of the most powerful interventions where the original randomized controlled trials reported improvements in functional outcomes and a 35% reduction in falls for frail, high-risk older adults (Shubert et al., 2018). In Egypt, there are little researches about Otago Exercise Program.~Exercise is well-known as an economic and key adjuvant treatment in clinical oncology that improves QOL of cancer survivors. Many studies focused on investigating the benefits of exercise interventions on preventing falls and improving physical performance of older adults. Combination of strength and functional balance exercise has been demonstrated as an effective method to improve balance performance, rather than strength training alone"
224012426|NCT06605846|OTHER|Medical ADT treatment|Medical ADT treatment according to patient age, prostatic cancer stage
224012427|NCT03430180|DRUG|Naloxone hydrochloride|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
224012428|NCT03430180|DRUG|Placebo|One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
224012429|NCT06598410|OTHER|Digital gaming|Children in this group will be allowed to play digital games 5 minutes before the procedure starts. They will continue to play the game during the procedure.
224012430|NCT06598410|OTHER|watching cartoon|Children in this group will be shown a cartoon film 5 minutes before the procedure. They will continue to play the game during the procedure.
224012431|NCT03981861|DRUG|Metformin and Spironolactone|Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
224012432|NCT06856460|DIETARY_SUPPLEMENT|powder shake with very low glycemic index|2 weeks of cereal and standard process glucose assist shake as part of breakfast. The diet for the remainder of the day will remain unchanged.
224012433|NCT06856460|DIETARY_SUPPLEMENT|Ceral Breakfast|consume of 400kcal of oat-based cereal with honey for breakfast
224012434|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.
224012435|NCT06660069|DRUG|CPC Mouthwash (Parodontax Active Gum Health Mouthwash)|Mouthwash containing 0.07% w/w CPC.
224012436|NCT06660069|DRUG|Regular Fluoride Toothpaste (Crest Cavity Protection)|Toothpaste containing 0.243% w/w sodium fluoride.
224012437|NCT06660069|DRUG|Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)|Toothpaste containing 0.454% w/w SnF2.
224012438|NCT06862401|PROCEDURE|Glass ceramic onlay preparation|The participants engaged in two practice sessions, each lasting two hours. They either started with their dominant hand followed by non-dominant hand or practiced solely with their non-dominant hand. Each participant prepared a mandibular left first molar resin typodont fixed to the table for a glass ceramic onlay restoration. Preparation was conducted extraorally.
224012439|NCT06336356|DRUG|Baxdrostat|Baxdrostat will be administered orally once daily.
224012440|NCT06336356|DRUG|Placebo|Placebo will be administered orally once daily.
224012441|NCT04613414|OTHER|Early Management|Scheduled for sleep physician appointment within 1 month of home sleep apnea test/triage
224012442|NCT06588491|BIOLOGICAL|Standard lymphodepletion regimen|Standard lymphodepletion regimen
224012443|NCT06610487|DRUG|FT1|Six dose levels will be evaluated in single-dose part, and three dose levels in multiple-dose part.
224012444|NCT06610487|DRUG|Placebo|Placebo will be administered.
224012445|NCT05618912|DEVICE|Hydrocolloid dressing|A single hydrocolloid dressing will be applied to the surgical site for 7 days following dermatologic surgery
224012446|NCT05618912|OTHER|Petrolatum jelly dressing|The patient with the control wound will be covered with petrolatum jelly during this time period, which has to be re-applied daily.
224127600|NCT05965336|OTHER|Clinical Evaluation|"A clinical evaluation occurs at the first study session. The clinical evaluation assesses walking function and mobility, lower extremity, sensation, health-related quality of life (HRQoL) and foot function.~Session 2 will be a dynamometer-based evaluation of passive ankle stiffness and 3-dimensional gait analysis to evaluate baseline biomechanics. During Session 3, real-time biofeedback conditions will be used to measure the immediate effects on walking function."
224012447|NCT06871488|DRUG|CNS Stimulant|The second treatment phase (blinded within subjects crossover) will compare one week of the optimal dose of CNS Stimulant (from the prior phase) to one week of placebo for a total of 14 days of data collection.
224012448|NCT06871488|DRUG|Placebo|Placebo is only used during the second of two treatment phases. The second treatment phase (blinded within subjects crossover) will compare one week of the optimal dose of CNS Stimulant (from the prior phase) to one week of placebo.
224012449|NCT06871488|OTHER|CNS Stimulant open label first phase|The first treatment phase will optimize CNS stimulant dose under open label conditions using any approved FDA medication for pediatric ADHD at the FDA approved doses.
224012450|NCT05967169|DEVICE|Nasal Septal Strap implantation|Correction of NSD with Nasal Septal Strap implant
224138559|NCT00190983|DRUG|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
224138560|NCT02856685|DRUG|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
224138561|NCT02287402|DRUG|AO-128|AO-128 tablet
224138562|NCT03600948|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
223391788|NCT07084025|OTHER|Perceive, Recall, Plan and Perform-Intervention protocol (PRPP-I)|"delivered over a 4-week period, in 12 sessions (45/60 min, 3 days a week for 4 weeks) for all patients according to the PRPP-I protocol. The intervention will be carried out by a PRPP-certified occupational therapist working on a Master's degree.~It will consist of :~* Implementation of training in functional cognitive strategies and meta-prompts through performance in home activities,~* Repeated measurement of performance judgment criteria ;~* Assessment of cognitive strategies~* personalized implementation of the PRPP-I cognitive strategy training protocol.~* Collection of feasibility modalities when tracking the intervention (e.g., time, transport, etc.)."
223391789|NCT03727451|COMBINATION_PRODUCT|iNO|inhaled nitric oxide
223391790|NCT05197543|DIAGNOSTIC_TEST|Biomechanical rupture risk assessment|3D computational model is created from CT angiographic images available during standard AAA diagnostic process. Vascular wall stress is assessed based on the 3D model using Finite element method to identify highly stressed parts of AAA and results are compared to populational wall strength information (gathered from previous large histological study), thus rupture risk (stress/strength ratio) of each particular AAA is estimated. Other relevant factors such as gender, blood pressure, presence of intraluminal thrombus etc. are used during the calculation as well.
223391791|NCT06522217|DEVICE|nasoalveolar molding appliance|making impression then make the conventional lab procedures for group A for the production of conventional appliances
223391792|NCT06522217|DEVICE|digital nasoalveolar molding appliance|group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
223391793|NCT07096336|DIETARY_SUPPLEMENT|vitamin D3 capsule|Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
223391794|NCT07096531|OTHER|Suit therapy|Patients will receive suit therapy.
223391795|NCT07096531|OTHER|Suit therapy + Dual-task exercises|Patients will receive suit therapy in addition to dual-task exercises.
223391796|NCT07096960|BEHAVIORAL|STrAtegies for RelaTives (START) - Brazilian version|Eight individualized, weekly, home-based sessions will be delivered by trained community general health workers (CGHW). The intervention includes coping strategies, behavior management, and communication skills. Caregivers receive printed materials and structured exercises. CGHW receive a facilitator manual.
223391797|NCT07095387|BEHAVIORAL|Making room for climate emotions in the classroom|This intervention combined creative arts workshops using drawing, photography, painting and collage to introduce a theme related to climate change and promote emotional expression. The artistic creation was followed by a philosophical inquiry group discussion on a theme related to the artistic creation to allow critical thinking and sharing perceptions.
223391798|NCT07097675|BEHAVIORAL|Art Therapy|"Art Therapy Session Plan The sessions are designed to stimulate positive feelings, satisfaction, and calmness while reducing social isolation and fostering group connections. The focus will be on pleasant experiences and positive life moments, with an emphasis on identifying current strengths and capabilities. Every session begins with a sharing activity: Name three good things that happened this morning or Name three things you are grateful for today.~Session Structure:~Mood check-in → Warm-up task → Main task → Reflection → Mood check-out."
223391799|NCT07095907|PROCEDURE|Pars plana vitrectomy with epiretinal membrane peeling and controlled macular detachment|Currently, vitrectomy with epiretinal membrane peeling is the standard procedure; however, its ability to improve visual acuity in these patients remains limited. In this context, controlled macular detachment is emerging as a surgical alternative that could optimize the anatomical and functional restoration of the retina.
223391800|NCT07097207|COMBINATION_PRODUCT|CAR-T cell|Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20-CAR.p40-T or CD19-CAR.p40-T cell infusion. The CAR-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.
223391801|NCT07095998|DIAGNOSTIC_TEST|Threshold Tracking Nerve Conduction Studies|Measurement of nerve excitability parameters, including response to sub-threshold pre-pulses and other stimuli. The DS5 0 Isolated Bipolar Constant Current Stimulator is a non-invasive, non-therapeutic device that provides controlled electrical stimuli for detailed function assessment of the superficial radial, superficial peroneal, ulnar, and sural nerves.
223391802|NCT07096128|DRUG|[177Lu]Lu-PSMA-XT|\[177Lu\]Lu-PSMA-XT is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells.
223547282|NCT03969745|BEHAVIORAL|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
223547283|NCT03969745|BEHAVIORAL|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
223547284|NCT02472587|OTHER|Questionnaire|
223547285|NCT01295307|DRUG|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
223547286|NCT06485726|DRUG|Valproic Acid 500 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
223564203|NCT02260778|BEHAVIORAL|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
224012451|NCT06718335|DRUG|Pyrotinib|Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.
224012452|NCT06718712|OTHER|Lower body resistance training|The RT protocol was performed using a unilateral knee-extension machine. To reduce potential sources of bias to exercise order, subjects alternated the starting leg for each training session.
224138563|NCT04197544|PROCEDURE|endoFAVI|EndoFAVI creation to patients that require vascular access for hemodialysis.
223730572|NCT02060149|DRUG|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
223391803|NCT07096492|OTHER|Standard Swimming Training|Warm-Up: 1500 meters. Main set: 2000-3000 meters. Post-set: 1000 meters. Cool-Down: 200-400 meters.
223391804|NCT07096492|OTHER|Plyometric Training|The plyometric training intervention will focus on developing explosive power and reaction speed through various jumping and landing exercises. Progressive overload principles will be applied, with progression achieved through increasing sets and intensity. Plyometric exercises will be performed twice a week, similar to the strength group, and will begin with 3 sets of 3 repetitions in the first week. As the body adapts to the exercises, one additional set will be added each week until the third week, which will conclude with 5 sets. In the fourth week, a deload will be incorporated with 2 sets to allow for recovery. After the deload week, intensity will increase, either by performing exercises faster or exerting maximum effort during each repetition. Upper-body exercises will include the medicine ball slam, sitting medicine ball side passes, and medicine ball chest passes, focusing on explosive upper body movements. Lower-body exercises will consist of standing long jumps, partner med
223391805|NCT07096492|OTHER|Strength Training|The strength training intervention was designed to supplement standard swim training with a structured, full-body resistance program aimed at enhancing muscular strength and swimming biomechanics through progressive overload. Participants in the strength group engaged in two sessions per week for each major muscle group. Training commenced with 3 sets of 8 repetitions per exercise during the first week, with weekly increases in training volume until the third week (5 sets), followed by a deload week (3 sets) to promote recovery. The subsequent four weeks maintained a consistent 5-set structure, with progression achieved through incremental increases in load. Each session began with lower-body exercises to prioritize large muscle group activation and maximize session efficiency. Lower-body exercises included dumbbell goblet squats, step-ups, Romanian deadlifts, TRX hamstring curls, and calf raises, while upper-body work featured push-ups, TRX rows, dumbbell rows, and dumbbell shoulder p
223391806|NCT07095673|BEHAVIORAL|HealthyWE|Following baseline assessment, 60 residents will be enrolled in HealthyWE Corps program. HealthyWE Corps includes training sessions on keeping a healthy weight, healthy diet, and mental health wellness. The content of the HealthyWE protocol was carefully designed choosing skills shown to be efficacious in keeping a healthy weight and reducing pain. Self-efficacy theory guides the intervention. Behavioral interventions for reducing and managing obesity focus on building adults' self-management skills to be implemented in their daily lives. To achieve the therapeutic effects, individuals have to execute self-management skills in their daily lives. Self-efficacy is defined as a person's belief in his/her ability to perform specific skills to reduce and manage obesity.
223391807|NCT07096375|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block|"Adductor Canal Block (ACB) in the immediate preoperative period under a high-frequency ultrasound guidance in which the adductor canal is identified beneath the sartorius muscle and 20 ml of bupivacaine 0.25% will be injected in the canal using a 22-gaugusing a 22-gauge 100-mm short-bevelled regional block needle.~IPACK Block which the patient will be placed in a supine position and knee will be placed in position of 90° flexion. A low-frequency ultrasound probe will be positioned in the popliteal crease, and a spinal needle will be inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle will be placed 1-2 cm beyond the lateral edge of the artery, and 15 ml of bupivacaine 0.25% will be injected after negative aspiration."
223391808|NCT07096375|PROCEDURE|Adductor Canal Block (ACB) + iPACK Block (sham injection)|All patients will receive Adductor Canal Block in the immediate preoperative period under a high-frequency ultrasound guidance in which the adductor canal is identified beneath the sartorius muscle and 20 ml of bupivacaine 0.25% will be injected in the canal using a 22-gauge 100-mm short-bevelled regional block needle IPACK block which the patient will be placed in a supine position and knee will be placed in position of 90° flexion. A low-frequency ultrasound probe will be positioned in the popliteal crease, and a spinal needle will be inserted from the medial aspect of the knee from anteromedial to posterolateral direction in a plane between the popliteal artery and the femur. The tip of the needle will be placed 1-2 cm beyond the lateral edge of the artery, and 15 ml of normal saline will be injected after negative aspiration.
223391809|NCT07097844|DRUG|0.8 mL/kg of 0.25% bupivacaine|0.8 mL/kg of 0.25% bupivacaine
223391810|NCT07097311|DRUG|Triheptanoin|Open-label design with doses of triheptanoin up to 1.0 gm/kg/day. The dose will be titrated from Day 1-24.
223391811|NCT07095348|OTHER|Serum Xanthine Oxidase Level Assessment|Blood samples were collected from each participant and serum was separated by centrifugation. Serum xanthine oxidase (XO) levels were measured using a Human XO ELISA Kit (Cat No. E3495Hu) according to the manufacturer's instructions. This intervention involved no therapeutic intent and was performed for observational biomarker analysis only.
223391812|NCT07096648|DEVICE|Continuous vital sign monitoring|Continuous monitoring of vital signs performed using up to three CE- and FDA approved devices measuring heart rate, respiratory rate, systolic- and diastolic blood pressure, and SpO2. Data is transmitted to a CE-approved smartphone application that generates alerts in response to deviations based on predefined thresholds for duration and severity.
223730573|NCT02060149|DRUG|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
223730574|NCT02060149|DRUG|No nebulization|No nebulization will be given to the patients.
223730575|NCT01486251|DRUG|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade \> 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
223730576|NCT02877420|OTHER|Non-Technical Skills Training Curriculum|
223730577|NCT02877420|OTHER|Conventional Simulation Training Group|
223730578|NCT04612556|DRUG|Mepolizumab 100 MG [Nucala]|subcutaneous injection once a month
224138564|NCT05432674|COMBINATION_PRODUCT|Digital Fall Prevention|Exercises delivered through a tablet and remote motivational calls
224138565|NCT01844830|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
224138566|NCT01844830|DRUG|Placebo|Inactive ingredients supplied in identical nasal sprayer
223391813|NCT07096635|DRUG|Melatonin|Patients will receive oral melatonin 10 mg (two 5 mg tablets) one hour before the operation plus intra-articular analgesia at the end of surgery.
223391814|NCT07096635|OTHER|Starch tablets|Patients will receive two oral inert starch tablets of the same shape and color one hour before the operation plus intra-articular analgesia at the end of surgery.
223391815|NCT07095881|OTHER|Zirconia-based composite customized healing abutment|using Zirconia-based composite in customized healing abutment fabrication
223391816|NCT07095881|OTHER|Conventional composite customized healing abutment.|using conventional composite in customized healing abutment fabrication
223391817|NCT07096986|DRUG|Forxiga|dapagliflozin treatment at a dose of 10 mg per os daily for 6 months
223547287|NCT06485726|DRUG|Propranolol|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
223547288|NCT00955474|DRUG|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
223547289|NCT00955474|DRUG|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
223730579|NCT02818322|DEVICE|telemedical monitoring ( T)|
223730580|NCT02818322|DEVICE|classic monitoring|
223730581|NCT01996982|DEVICE|CCS Device|Core Cooling System Device
223391818|NCT07096089|PROCEDURE|Conventional physical therapy program and Sling exercise therapy|The control group received a conventional physical therapy program in addition to sling exercise therapy (SET) for 60 minutes.
223391819|NCT07096089|PROCEDURE|Whole body vibration|The study group received the same selected conventional physical therapy program in addition to sling exercise therapy (SET) given to the control group (for 30 minutes) besides whole body vibration (WBV) (for 30 minutes).
223391820|NCT07096596|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223391821|NCT07094945|DRUG|Remimazolam|Remimazolam 0.3 mg/kg is slowly injected intravenously until loss of consciousness. Remimazolam 0.6-1.0 mg/kg·h is used for anesthesia maintenance.
223547290|NCT00955474|DRUG|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
223547291|NCT00955474|DRUG|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
223547292|NCT03678337|OTHER|observational cohort with plasma samples|plasma samples
223547293|NCT05325229|DRUG|Docetaxel for injection (Albumin-bound)|Docetaxel for injection (Albumin-bound), by intravenous infusion，75 mg/m\^2 or 100 mg/m\^2 once every 3 weeks.
223730582|NCT00791167|DRUG|Paliperidone ER|
223730583|NCT05493527|DEVICE|noninvasive high frequency oscillatory ventilation|"A time-cycled, pressure-limited, and continuous-flow neonatal ventilator (SLE6000; SLE) was used for neonates assigned to the NHFOV group. The settings were as follows:~1. a frequency of 10 Hertz ( range, 8-12 Hz);~2. an inspiratory time of 50% (1:1)~3. an oscillation amplitude of 35 centimeter of water column (cmH2O) (subsequent regulation range, 20-40 cmH2O) Oscillation amplitude would be regulated according to the level of carbon dioxide(CO2). Visible chest oscillation was not necessary because elimination of CO2 during NHFOV could also occur in the upper respiratory airway dead space~4. Mean airway pressure (MAP) of 10 cm H2O ( range, 7-15) MAP was regulated according to an open lung recruitment strategy~5. fraction of inspired oxygen (FIO2) regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
223730584|NCT05493527|DEVICE|noninvasive positive pressure ventilation|"NIPPV will be delivered by ventilator generating the targeted pressures. Infants will be on:~1. Peep ranging from 5 to 10 cmH2O,~2. Peak inspiratory pressure range 15-25 cmH2O~3. Rate range 40-50 breath/minute~4. FIO2 regulated from 0.21 to 0.40 in order to maintain saturation from 90% to 95% as determined with a pulse oximeter."
223730585|NCT02379806|DRUG|Enoxaparin|
223730586|NCT02379806|DRUG|Placebo|
224138567|NCT04247815|DRUG|ATI-450|Oral, small molecule MK2 inhibitor
223391822|NCT07094945|DRUG|Propofol|Propofol 2 mg/kg is slowly injected intravenously until loss of consciousness. Remimazolam 4-12 mg/kg·h is used for anesthesia maintenance
223391823|NCT07097077|OTHER|Effect of targeted neuromotor training in patients undergoing ACL reconstruction on the volumetric activation of cerebral cortex regions during fMRI.|The effect of targeted neuromotor training in patients undergoing ACL reconstruction on the volumetric activation of cerebral cortex regions during fMRI. Differences in brain activation will be assessed between timepoint t0 (after ACL reconstruction surgery and before the start of training) and timepoint t1 (after completion of the training).
223391824|NCT07104604|DRUG|Liposomal Irinotecan|In this study, the novel drug liposomal irinotecan was added, replacing the conventional formulation of irinotecan, and used as an intensified chemotherapy regimen (liposomal irinotecan + capecitabine) combined with immunotherapy and radiotherapy for neoadjuvant treatment of mid-lower rectal cancer.
223391825|NCT03847857|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
223730587|NCT03134027|PROCEDURE|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
223730588|NCT03134027|PROCEDURE|Tumor biopsy|Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.
224012453|NCT06727708|DEVICE|Tone Your Body BioCircuit Program|Participants in the Tone Your Body group follow a 12-week BioCircuit training programme designed to improve body composition and muscle toning. The programme consists of six total-body strength exercises and two cardio exercises in a circuit format. Each exercise is performed for 45 seconds, followed by a 40-second rest between machines. The endurance exercises are performed for 3 minutes and 35 seconds each. The eccentric phase of each strength exercise is overloaded by 20% to maximise muscle development.
223391826|NCT03847857|PROCEDURE|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
223391827|NCT05980078|OTHER|Interactive consent|They were randomized to complete an interactive consent.
224012454|NCT06727708|DEVICE|Boost Performance BioCircuit Program|Participants in the Boost Performance group follow a 12-week BioCircuit training programme designed to increase strength and endurance. The programme consists of six strength exercises and two cardio exercises, also in a circuit format. Each exercise is performed for 45 seconds, with 40 seconds rest between machines, and the endurance exercises are performed for 3 minutes and 35 seconds. The strength exercises use a viscous resistance mechanism to increase strength and endurance. Participants also undergo performance tests including the jump and reach test, one minute squats and one minute push-ups.
224012455|NCT06727630|DRUG|PRJ1-3024|PRJ1-3024 is provided as capsules and is administered orally once a day
224012456|NCT06727695|DEVICE|BioStrength Intervention|Participants in the Intervention Group will undergo BioStrength training using Technogym equipment. The intervention will last for 12 weeks, with sessions conducted 3 times per week
224012457|NCT06727695|DEVICE|Conventional training|Participants in the Active Comparator group will undergo a conventional strength training program using standard gym machines. Training sessions will occur 3 times per week for 12 weeks. The goal is to compare the outcomes of BioStrength training with traditional strength training.
224012458|NCT06728124|DRUG|GZR18|Used as specified in the protocol
224012459|NCT06728124|OTHER|Placebo|Administered the same volume as GZR18
224012460|NCT06729684|DEVICE|digital health (application and smartwatch)|The application allows users to conduct self-assessments for managing symptoms and side effects related to treatment. Based on the assessment results, it provides personalized self-management strategies. Additionally, users can access features for exercise, diet, and weight management.
224012461|NCT06727786|OTHER|Serious game training|A serious game featuring a dramatic/realistic film, pauses with questions for active learning, and practice administration of naloxone and performing CPR
224012462|NCT06007222|DRUG|Aspirin group|Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg/day the end of the study period.
224012463|NCT06007222|DRUG|Non-antithrombotic group|No antithrombotic agents will be administered after randomization until the end of the study period.
224012464|NCT06732960|BIOLOGICAL|Efsubaglutide Alfa|Efsubaglutide Alfa subcutaneous injection under 1mg, 3mg, 5mg, 7.5mg, 10mg, 15mg or 20mg dose weekly.
223391828|NCT05980078|OTHER|Standard consent|They were randomized to complete a standard written consent.
223391829|NCT04075487|OTHER|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
223391830|NCT05579782|DEVICE|NIRAF Detection Technology|"Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).~After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio \> 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.~Other Name: PTeye Device"
223730589|NCT05276544|BEHAVIORAL|Dietary intervention|Dietary intervention: Preparation and follow-up of diet program.
224012465|NCT06732960|OTHER|Placebo|Placebo subcutaneous injection weekly
224012466|NCT06743100|DIAGNOSTIC_TEST|18F-Floretyrosine|Single IV administration on Day 0, followed by a PET/CT or PET/MR diagnostic scan 20-40 minutes after the IV administration of 18F-Floretyrosine.
224012467|NCT06845826|DEVICE|Point-of-Care high-sensitivity troponin testing|To establish in a randomized interventional controlled trial whether a novel POC test-guided strategy in acute chest pain patients in the ED results in a reduced length of stay compared to the usual central laboratory testing strategy when managing patients with a suspicion of NSTEMI
224012468|NCT06898853|DRUG|0.1% Ciclosporin A eye drops|The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)
224012469|NCT06898853|DRUG|Mineral oils eye drops|This arm is the comparator arm has mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)
224012470|NCT06901024|OTHER|Tendon Gliding Exercise|Tendon gliding exercises were performed for both hands in a sequential manner, with 20 repetitions in 3 sets. The exercises started with fingers and wrist positioned in extension. Subsequent positions included the hook position, full fist position, MCP joint at 90° flexion with finger extension, and MCP and proximal interphalangeal (PIP) joints at 90° flexion positions, with a 5-second hold at each position. During the TG exercises, the hand and fingers are brought to five different positions
224138568|NCT04247815|DRUG|Placebo oral tablet|Placebo tablet manufactured to match ATI-450 in appearance
224138569|NCT04247815|DRUG|Methotrexate|7.5 mg to 25 mg weekly
224138570|NCT02170649|DRUG|BIA 2-093|
224138571|NCT03411057|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
224138572|NCT03411057|OTHER|Control|Standard of care including an educational video.
224012471|NCT06901024|OTHER|Neuromobilization Exercise|The neuromobilization exercises included median, radial and ulnar nerve mobilizations. For median nerve mobilization, the patient's wrist was placed in extension, the shoulder in 90° abduction, the forearm in supination, the elbow extended, and the head positioned in lateral flexion toward the same side. For radial nerve mobilization, the wrist was initially placed in flexion and ulnar deviation, the forearm in pronation, with the elbow extended, and the head positioned in lateral flexion toward the same side. For ulnar nerve mobilization, the wrist was positioned in extension and radial deviation, the elbow fully flexed, the forearm in pronation, the shoulder in 90°abduction, and the head in lateral flexion toward the same side. The head was then moved into lateral flexion toward the opposite side while extending the elbow. The neuromobilization protocol was performed in 4 sets of 10 repetitions, with a 5-second hold for each movement.
224012472|NCT06901024|OTHER|Robotic Assitive Exercise|The robotic glove set used in this study weighs 497 grams, powered by a battery weighing 170 grams that provides a 5 V voltage and 1 A current. Made from elastic fabric, the glove wraps around all fingers on both the dorsal and palmar sides. The palm section of the glove is hollow. The device features four Velcro straps: one at the wrist, one across the web space between the thumb and index finger, one between the second and third fingers, and one between the fourth and fifth fingers, securing the inner side of the wrist. The robotic glove facilitates passive joint movements through pneumatic air pressure. The device offers several benefits, including proprioceptive stimulation, visual input, increased functional independence, pain and edema reduction, enhanced lymphatic and blood circulation, improved coordination and hand dexterity, as well as increased grasp and compression strength.
223391831|NCT06279715|OTHER|Preimplantation Genetic Testing for Aneuploidy|PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.
223391832|NCT04697680|BEHAVIORAL|Algorithm 1|A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
223391833|NCT04697680|BEHAVIORAL|Algorithm 2|A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
223391834|NCT04697680|BEHAVIORAL|Algorithm 3|A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
223391835|NCT06411652|OTHER|Reflexology|"1. First, the patient's foot will be cleaned with cotton dipped in warm water,~2. In order not to disturb the patient, the hands will be warmed and one or two ccs of baby oil will be used to facilitate the massage.~3. Before applying the main technique, the first two minutes of each session will be spent using the relaxation technique, which involves back and forth movements with the palm of the palm on the outer edge of the foot, from the outer part of the ankle to the little toe, to relieve muscle tension and spasm.~4. Then, alternate pressure will be applied to the reflex points of the right thumb by taking the heel of one foot in the left hand."
223547294|NCT05325229|DRUG|Bevacizumab|Bevacizumab, by intravenous infusion, 15 mg/kg once every 3 weeks.
224012473|NCT06901024|OTHER|Conventional Exercises|Wrist extensor exercise, wrist radial deviation exercise, and wrist flexor exercise were perfomed using a 1-kg dumbbell. Holding the 1-kg dumbbell against gravity for 10 seconds, with the shoulder flexed at 90°, elbow extended, and forearm in pronation position. Squeezing exercise with a green soft ball (Thera-Band; diameter: 5 cm); the ball was squeezed for 10 seconds, followed by relaxing. Pushing a blue Pilates ball (Thera-Band; diameter: 20 cm) against the wall with fingers in extension position. Squeezing a black Pilates ring (Thera-Band; diameter: 38 cm) with the fingers, while the MCP joints are in extension and the wrist in a neutral position.
224012474|NCT06898411|DEVICE|Single tooth restoration with IPS e.max|Examination of single tooth restorations with IPS e.max after a wearing time of more than 15 years. Intraoral situation will be examined similar to a standard dental examination while single tooth restorations will be documneted by photos.
224012475|NCT05963100|BIOLOGICAL|TCR-like CAR-T|intravenous drip of TCR-like CAR-T with indicated doses
224012476|NCT06900049|DRUG|LE051|LE051 dose escalation : dose 1 and dose 2.
224012477|NCT06735001|PROCEDURE|FA ablation|Ablation of the FA
224012478|NCT06735001|BIOLOGICAL|Lab test|Blood collection
224012479|NCT05342090|OTHER|Structured Counselling Tool|Participants will be administered a Structured Counselling Tool that addresses the following themes: outside influences, conflicting emotions, uncertainty, sexual changes and stability, normalization, self-image
224012480|NCT06898424|BEHAVIORAL|Ketoflex 12/3 Diet|plant-based ketogenic diet combined with intermittent fasting (12/3)
224012481|NCT04807712|OTHER|non interventional study|
224012482|NCT06905860|DRUG|Platelet-rich fibrin (PRF)|"The Intervention Group consists of the intra-articular application of PRF in the knee. The applications will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. A total of 3 applications of PRF will be conducted, with intervals of 14 to 28 days between them.~10ml of PRF will be applied intra-articularly, on an outpatient basis, with patients being instructed to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated."
224138573|NCT03445754|DEVICE|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
224138574|NCT03445754|DEVICE|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
223547295|NCT05254951|DIAGNOSTIC_TEST|Tidal Volume Challenge|Tidal Volume Challenge to predict fluid responsiveness with stroke volume variation and pulse pressure variation
223547296|NCT00786305|DRUG|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
223547297|NCT00786305|DRUG|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
223564204|NCT01212679|DRUG|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
223391836|NCT06411652|OTHER|Therapeutic Touch|"1. The procedure will be explained to the woman,~2. The procedure will be performed in the patient's bed.~3. The practitioner will center by making his body, mind and emotions quiet and focused, prepare himself for the practice and remain centered throughout the intervention,~4. There will be good intentions to help the woman get treatment,~5. In order to scan the energy field, the patient's entire body will be held with the palms of the practitioner's hands facing the patient, it will be moved with a soft movement from"
223391837|NCT06580509|DRUG|Tranexamic Acid Injectable Product|Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
223547298|NCT03815630|DRUG|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
223391838|NCT06580509|OTHER|Normal Saline|Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.
223547299|NCT01737762|BIOLOGICAL|HP802-247|HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
224012483|NCT06905860|DRUG|Corticosteroid|"The procedures will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. In this group, 40ml of peripheral blood will also be collected and placed for centrifugation. During the preparation for the application, a nurse (who will not participate in the study) will have a list of the randomization and will prepare the material in an opaque syringe (blinding both the applicator and the patient).~In this group of patients, a solution of 10ml containing 40mg of Triamcinolone will be administered in the first application and 10ml of saline in the second and third applications, with intervals of 14 to 28 days between the applications. The applications will be performed on an outpatient basis, with patients being advised to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated."
224012484|NCT06907082|DRUG|Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.|Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.
224012485|NCT06907862|OTHER|Reference Treatment|≥4 servings/day of soy products categorized as non-ultra processed according to the NOVA classification system (NOVA non-Group 4): ≥2 servings/day of a Group 1 soy milk and ≥1 serving/day of another Group 1 food, such as edamame or roasted soy nuts, and ≥1 serving/day of a Group 3 food, such as tofu or tempeh) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)
224012486|NCT06907862|OTHER|Control|Usual care provided by their primary care physician and/or specialist.
224012487|NCT06907862|OTHER|Active Treatment|≥4 servings/day of soy products categorized as ultra processed according to the NOVA classification system (NOVA Group 4): ≥2 servings/day of soy milk and ≥2 servings/day of other soy-based products such as soy yogurt, soy burgers, or soy ground round) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)
223391839|NCT06242808|BEHAVIORAL|Food resource coaching|Patients will meet with a food resource coach who will explain basic coaching principles including how to respond to financial crises, how to access various food resources, and the importance of consistent utilization of food resources. After the coaching session, the food resource coach will help patients select medically tailored groceries from the free community food market inventory.
223391840|NCT06242808|OTHER|Free community food support|Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)
223391841|NCT06242808|BEHAVIORAL|Medically tailored groceries|A pantry staff member helps patients select medically tailored groceries (MTG) from the free community food market inventory by prepopulating MTG in their pantry cart.
223391842|NCT04591990|DRUG|Administration of AVP|Administration of AVP
223391843|NCT04591990|DRUG|Administration of placebo AVP|Administration of placebo AVP
223391844|NCT04591990|DRUG|Administration of placebo hydrocortisone|Administration of placebo hydrocortisone
223391845|NCT04591990|DRUG|Administration of hydrocortisone|Administration of hydrocortisone
223391846|NCT02363335|OTHER|Placebo|mixed meal
223547300|NCT01737762|BIOLOGICAL|Vehicle|
223547301|NCT02148263|DEVICE|senofilcon A|
223547302|NCT05563662|PROCEDURE|Cardiac surgery|Patients with infective endocarditis undergoing open heart surgery
223547303|NCT02594007|DEVICE|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
223547304|NCT02594007|DEVICE|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
223547305|NCT02594007|DEVICE|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
223547306|NCT02310737|PROCEDURE|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
223547307|NCT02310737|PROCEDURE|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
223547308|NCT02574039|DIETARY_SUPPLEMENT|Oat bran|66g oat bran made up in 350ml skimmed milk
223547309|NCT02574039|DIETARY_SUPPLEMENT|refined grain|refined grain product and 350ml skimmed milk
223547310|NCT03386435|PROCEDURE|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
223391847|NCT02363335|OTHER|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin together
223391848|NCT02363335|OTHER|Sitagliptin|This is already known to increase GLP-1 \&amp; GIP secretion.
223391849|NCT02363335|OTHER|Roflumilast|This is already known to increase GLP-1 \&amp; GIP secretion
223391850|NCT06109493|BEHAVIORAL|ACT|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
223391851|NCT05505565|DEVICE|Abbott Freestyle Libre 2|Subjects will be educated on use of Abbott Freestyle Libre 2 and educated on how daily activities impact glucose.
223391852|NCT05505565|OTHER|Standard physical activity and nutritional counseling for prediabetes management|Subjects will be advised on recommendations for nutrition and activity goals for preventing progression of prediabetes.
223391853|NCT04569318|DEVICE|Treatment Beam|One of the subject's eyes will be treated with the treatment beam (20mW) up to 8 times for 15 minutes.
224138575|NCT01916616|BEHAVIORAL|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
223547311|NCT06493175|DIAGNOSTIC_TEST|Application of large language model in emergency chest pain triage.|The large language model MedGuide-V5 is able to quickly extract key information from a patients description, and by analyzing these descriptions, it provides physicians with a possible initial diagnosis to help them quickly prioritize the treatment of patients.
223547312|NCT06493175|DIAGNOSTIC_TEST|According to the normal procedures to receive medical treatment|After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
223547313|NCT00625586|BIOLOGICAL|RAV12|RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
223547314|NCT00625586|DRUG|Gemcitabine|1000 mg/m2 weekly, intravenously
223547315|NCT00751712|DEVICE|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
223547316|NCT02988726|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
223547317|NCT02663427|DEVICE|serological examination and gastroscope|
223547318|NCT03536325|DRUG|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
223391854|NCT06393868|DRUG|Omeprazole 20 mg Oral Tablet|Omeprazole once daily for 90 days
223391855|NCT06393868|OTHER|Placebo|Placebo once daily for 90 days
223391856|NCT04932993|BEHAVIORAL|Writing down goals|Patient will write their health goals down before the visit.
223391857|NCT04825834|OTHER|Blood Sample Collection|Subjects enrolled in the DELFI-L101 will have blood specimens collected (\~40 mL) at enrollment.
223391858|NCT03183609|OTHER|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
223391859|NCT03183609|OTHER|Rice Flour in Protein Shake|15 Grams Rice Flour BID
224138576|NCT01918787|DEVICE|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
223391860|NCT06636175|DRUG|64Cu-LLP2A|64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
223391861|NCT06636175|DEVICE|PET/CT|The results of 64Cu-LLP2A-PET/CT will not be provided to the patient or the treating oncologist/surgeon unless, in the judgment of the principal investigator, the images demonstrate an unsuspected abnormality that may warrant further evaluation.
223391862|NCT04610736|DRUG|Temozolomide Oral Suspension|One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days
223391863|NCT05792189|OTHER|Timed Up and Go Test on subjects with ORIF of distal femur fractures|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
223547319|NCT03536325|DRUG|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
223547320|NCT03536325|DRUG|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
223547321|NCT03536325|DRUG|Placebo|Participants will receive matching placebo on Day 1.
223547322|NCT05792163|DRUG|SNP318 (A)|Capsule for oral administration
223547323|NCT05792163|DRUG|Placebo (B)|Placebo capsules matching the SNP318 capsules
223547324|NCT06235918|DRUG|Tislelizumab|Tislelizumab: 200mg,administered via Intravenous (IV) injection, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
223547325|NCT06235918|DRUG|Nab-paclitaxel|260mg/m\^2, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 2 cycles
223547326|NCT06235918|DRUG|Carboplatin|AUC 5 mg/mL/min by IV infusion once every 3 weeks,day 1 of each 21-day cycle,neoadjuvant therapy : 2 cycles
223547327|NCT04313777|BEHAVIORAL|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
224138577|NCT00041691|DRUG|hMN14 (labetuzumab)|
223391864|NCT05792189|OTHER|Koos Jr assesment on subjects with ORIF of distal femur fractures|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
224127601|NCT05965336|OTHER|Evaluation of Passive Ankle Stiffness|Participants will be seated in a dynamometer with their trunk and thigh stabilized to the dynamometer chair, ankle joint aligned with the rotational axis of the dynamometer, and foot stabilized to the foot plate. EMG activity will be recorded from lower limb muscles (gastrocnemius, soleus, tibialis anterior) during all isolated contractions. Participants will first perform three maximum voluntary isometric contractions (MVIC) while seated in a dynamometer. Participants will then perform three isokinetic dorsiflexion tasks while using electromyographic biofeedback at a prescribed level of 50% MVIC soleus activation. The slope of the linear best fit line from the ankle moment vs. angle plot will yield total ankle joint stiffness (i.e., active + passive) at a fixed activation. In three additional trials, the dynamometer will move the ankle joint through the same motion without active subject resistance and the same analytical procedures will derive passive ankle joint stiffness.
223391865|NCT05792189|OTHER|Timed Up and Go Test on subjects with DFR of distal femur fracture|Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
223391866|NCT05792189|OTHER|Koos Jr assesment on subjects with DFR of distal femur fracture|Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
223391867|NCT05530486|DEVICE|CC|Application of placebo LASER
223391868|NCT05530486|DEVICE|LG1|Application of LASER GasAs 660nm 4 J/cm².
223391869|NCT05530486|DEVICE|LG2|Application of LASER GasAs 660nm 8 J/cm².
223391870|NCT05530486|DEVICE|LG3|Application of LASER GasAs 660nm 12 J/cm².
223391871|NCT05530486|PROCEDURE|Dressing|Application of Helianthus annuus oil dressing.
223391872|NCT03741192|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
223391873|NCT04514913|RADIATION|Multidetector Computed Tomography (MDCT) Scan|This is a low-dose CT scan of the chest using no contract material.
223391874|NCT04514913|PROCEDURE|Virtual Navigation Bronchoscopy (VNB)|This is a procedure where a camera will be inserted into the lung in order to guide sample collection of bronchoalveolar lavages, bronchail brushes and endobronchial biopsies.
223391875|NCT05659563|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
223391876|NCT05659563|DRUG|Tamoxifen|Tamoxifen is a selective estrogen receptor (ER) modulator
223391877|NCT01121861|PROCEDURE|Phacoemulsification with implantation of toric IOL|
223391878|NCT01568567|DIETARY_SUPPLEMENT|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
223391879|NCT03922542|COMBINATION_PRODUCT|riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
223391880|NCT03922542|COMBINATION_PRODUCT|Riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
223391881|NCT05374317|BIOLOGICAL|Yellow Fever Vaccine|Administered subcutaneously once.
223391882|NCT00075907|DRUG|Efavirenz + 2 NRTIs|
223391883|NCT00075907|DRUG|Lopinavir/Ritonavir + 2 NRTIs|
223391884|NCT00075907|PROCEDURE|Therapeutic Drug Monitoring|
223391885|NCT03862313|DEVICE|active-rtACS treatment|For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
223391886|NCT03862313|DEVICE|sham-rtACS treatment|For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
223391887|NCT03334240|DRUG|CLS003|CLS003
223391888|NCT03334240|DRUG|Vehicle|Vehicle
223391889|NCT06392022|OTHER|watching cartoons with music|The purpose of this study was to evaluate the effect of watching musical cartoons on anxiety and vital signs in children undergoing rectal irrigation.
223547328|NCT04313777|DEVICE|Virtual therapeutic support|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.
223391890|NCT02750618|BIOLOGICAL|Burosumab|solution for subcutaneous injection
223391891|NCT00848913|OTHER|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
223391892|NCT00848913|OTHER|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
223547329|NCT04313777|BEHAVIORAL|Schultz Autogenic Training|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
223391893|NCT05908565|BEHAVIORAL|Demographic Matching|At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
223547330|NCT03301337|DIETARY_SUPPLEMENT|Meat protein absorption|Meat protein absorption when digested together with a full meal.
223547331|NCT03995095|OTHER|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
224012488|NCT06906991|BEHAVIORAL|FIBROWALK|"FIBROWALK is a structured, multicomponent therapeutic program designed specifically for patients with fibromyalgia, combining evidence-based interventions that target both physical and emotional symptoms of the condition. Unlike traditional standalone interventions (e.g., exercise-only or CBT-only), FIBROWALK integrates multiple therapeutic modalities in a holistic, group-based format to address the broad symptom profile of fibromyalgia, including chronic pain, fatigue, and impaired functionality. Sessions are delivered in groups of up to 20 participants, fostering peer support and shared learning.~Key Components of FIBROWALK:~* Therapeutic Exercise~* Pain Neuroscience Education~* Cognitive-Behavioral Therapy~* Mindfulness-Based Stress Reduction~* Psychoeducation"
224127602|NCT05965336|OTHER|Gait Biomechanics|Three-dimensional gait analysis is performed as participants walk at a self-selected speed on an instrumented treadmill. Reflective markers are attached to lower extremity segments. Elastic bands are wrapped around the thighs, calves, and pelvis to which small, thermoplastic shells containing reflective markers are attached. Additional markers are taped to the participant's shoes and on the upper back, shoulder, hip, knee, and ankle joints with adhesive skin tape. Marker data is collected using a 7-camera motion analysis system (Vicon Inc., USA). Vicon motion analysis cameras will collect the location of the retroreflective markers in Vicon Nexus software.
223547334|NCT03483792|BIOLOGICAL|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
223547335|NCT03483792|GENETIC|placental biopsy|Immediately following delivery (\<12h postpartum), placental biopsies (Collection of 4 placental fragments)
223391894|NCT05908565|BEHAVIORAL|Supervision Intensity|Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
223391895|NCT01038336|BEHAVIORAL|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
223391896|NCT01038336|BEHAVIORAL|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
223391897|NCT03077737|BEHAVIORAL|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
223391898|NCT03077737|BEHAVIORAL|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
223391899|NCT00954811|DRUG|300IU rec-LH|luteal alternate doses
223391900|NCT00954811|DRUG|progesterone 600mg|luteal support
223547336|NCT04352543|BEHAVIORAL|Active Video Game Exercise|Play during 30 minutes in the easy level
223547337|NCT04352543|BEHAVIORAL|Treadmill walking exercise|30 minutes (65 - 75% heart rate maximal)
223547338|NCT04352543|BEHAVIORAL|Sedentary Behavior|Quiet Rest: 30 minutes
223547339|NCT00906178|BEHAVIORAL|CyberSenga|Internet-based HIV prevention program
223547340|NCT01467466|DRUG|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
223547341|NCT01467466|DRUG|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
223391901|NCT01660633|DRUG|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
223391902|NCT01660633|OTHER|Autologous Transplantation|Patients who are myeloablative conditioning in multiple myeloma undergoing autologous transplantation( patients own blood-forming stem cells are collected to replace diseased bone marrow or bone marrow damaged by cancer treatment)
223391903|NCT04992806|PROCEDURE|hip arthroscopy|Use epidural anesthesia or general anesthesia. The patient lies on the orthopedic traction bed to protect the perineum and perform traction of the lower limbs on the surgical side. Under arthroscopy, check the labrum, acetabular articular surface and femoral head cartilage, and round ligament in turn. The acetabular labrum with tear degeneration was treated with labrum suture or labrum revision surgery according to the injury. Perform femoral head and neck plastic or acetabular plastic surgery, osteoid osteoma debridement, etc.
223391904|NCT01353599|DRUG|Mometasone furoate|220mcg once daily, for eight weeks
223391905|NCT02572570|DEVICE|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Bulk Fill Posterior). Procedures done using local anesthesia and following ordinary restorative techniques.
223391906|NCT02572570|DEVICE|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling restored using the materials listed (Filtek Supreme Ultra). Procedures done using local anesthesia and following ordinary restorative techniques.
223391907|NCT04797104|DRUG|lerodalcibep|300 mg Q4W
223391908|NCT02763046|DRUG|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 4 x 150 mg secukinumab s.c. every 4 weeks Delayed NSAID tapering (tapering following 4 weeks of secukinumab treatment).
223391909|NCT02763046|DRUG|Secukinumab (AIN457) 150 mg s.c.|Induction: 5 x 150 mg secukinumab s.c. weekly Maintenance: 3 x 150 mg secukinumab s.c. every 4 weeks Early NSAID tapering (tapering at the start of secukinumab treatment).
223391910|NCT02763046|DRUG|Placebo - Secukinumab (AIN457) 150 mg s.c.|Placebo for 15 weeks. From Week 16 on, 5 x 150 mg secukinumab s.c. weekly.
223391911|NCT04829968|OTHER|gingival conditions control|"Peri-implant mucositis: It was diagnosed on the basis of the following criteria:~1. Visual inspection demonstrating the following signs of inflammation in the peri-implant region: red as opposed to pink colour, swollen tissues as opposed to no swelling, and soft as opposed to firm tissue consistency.~2. Presence of profuse (line or drop) bleeding and/or suppuration on probing.~3. An increase in probing pocket depths (PPDs) compared to baseline. • Peri-implantitis: It was diagnosed on the basis of the following criteria:~1\. Visual inflammatory changes in the peri-implant soft tissues combined with bleeding on probing and/or suppuration.~2\. Increasing PPDs as compared to measurements recorded at the time of placement of supra-structures."
223391912|NCT02884050|DRUG|Topiramate|antiepilepsy drug
223391913|NCT02884050|DRUG|Placebo|non-active placebo
223391914|NCT06200194|DEVICE|MiyoSmart Spectacles|No power in the central optic zone of DIMS lens for premyopic children with normal vision. Before entering elementary school, eligible preschoolers are asked to wear the DIMS spectacles after kindergarten hours and during weekends and holidays. After entering elementary school, full-time mode wearing of DIMS spectacles is required.
223391915|NCT06200194|DRUG|0.01% atropine|daily use of non-preservative 0.01% atropine eye drop for each eye over the study period.
223391916|NCT05029154|BEHAVIORAL|High intensity interval exercise|Patients in the exercise group will perform interval training (HIIT) 3 days per week, with each session consisting of four, 4-min intervals at 85-90% peak heart rate (PHR), separated by 3 min at 50% PHR. Each training session will begin with a 10-minute warm-up at 50% of PHR and end with a 5-min cool down at 50% PHR. Patients will undergo 2 initial training sessions at the exercise physiology core lab. All exercise will consist of stationary cycling to avoid discomfort associated with abdominal surgery as well as stress to the incision and help reduce fall risk. Study investigators will check in weekly with participants and remotely track exercise data and compliance via the Fitbit app.
223391917|NCT05029154|BEHAVIORAL|Attention control|Patients in the control group (physical activity education and physical activity monitoring) will receive counseling regarding the benefits of physical activity during chemotherapy treatment. During the intervention, participants will receive a weekly phone call to discuss their physical activity and remind them to engage in physical activity. Patients will be given a goal of working up to 30 minutes of exercise daily. Subjects will be urged to increase daily step counts by 250-500 steps/day. Physical activity will be objectively assessed and made available to the participant using a Fitbit.
223391918|NCT00009204|DRUG|Citalopram [Celexa]|
223391919|NCT00009204|DRUG|Perphenazine [Trilafon]|
223391920|NCT02123004|DRUG|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
224012489|NCT06906991|BEHAVIORAL|Unified Protocol|"The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy (CBT) intervention designed to address emotional dysregulation across a range of mental health conditions. Unlike traditional disorder-specific CBT interventions (e.g., CBT for anxiety or depression), the UP targets core emotional processes common to multiple disorders, making it particularly suitable for fibromyalgia patients who often experience comorbid anxiety, depression, and emotional distress. Unlike condition-specific therapies, the UP addresses the shared emotional mechanisms underlying anxiety, depression, and chronic pain, making it well-suited for fibromyalgia patients with complex emotional and physical symptomatology. UP emphasizes increasing tolerance to emotional and physical discomfort, a critical area for fibromyalgia patients who often experience heightened emotional reactivity and pain sensitivity.~The UP is delivered individually and consists of 12 structured, manualized modules."
223547342|NCT01467466|DRUG|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
223547343|NCT01467466|DRUG|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
223564205|NCT01212679|DRUG|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
224138578|NCT05061797|DIETARY_SUPPLEMENT|Thermogenic Energy Drink - Active Study Product Formula|The Thermogenic Energy Drink is the Active Study Product (ASP). This energy drink formula combines, caffeine, guarana, Vitamins C, B3, B6, B12, Magnesium, Potassium, L-Citrulline, L-Arginine HCl, L-Glutamine, and Chlorogenic Acids from green coffee bean extract. Participants will consume an assigned amount of the beverage (355 ml), under observation. They will be monitored for the following 180 minutes with measurements of respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via Visual Analog Scale (VAS).
223391921|NCT02123004|DRUG|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
223391922|NCT01697072|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
223391923|NCT01697072|OTHER|Placebo|Placebo
223391924|NCT01697072|DRUG|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
223391925|NCT01697072|DRUG|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
223391926|NCT01697072|DRUG|Capecitabine|Capecitabine is an oral fluoropyrimidine.
223391927|NCT02943954|PROCEDURE|Angiography guided PCI|
223547344|NCT01178476|DEVICE|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
223547345|NCT06554106|OTHER|Neuromuscular Electrical Stimulation Group|All patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises. In addition to the study group, NMES will be applied to the upper trapezius muscle for 30 minutes 5 days a week for 4 weeks. Neuromuscular Electrical Stimulation (NMES) applications will be performed with a Compex 3 (Compex Medical SA, Ecublens, Switzerland) model, portable and programmable electrostimulator unit in rehabilitation mode and under the supervision of an expert physiotherapist experienced in the device and application. The NMES program will be applied with a 4-channel device with a functional stimulation capacity of 120 mA, pulse duration 400 μs and pulse frequency 150 Hz.
223547346|NCT06554106|OTHER|Control Group|Patients will be taught neck normal joint movement exercises, upper trapezius stretching exercise and posture exercises.
223547347|NCT05789498|OTHER|In vitro stimulation of Pbmc with tumor antigen nanoparticles|PBMCs were isolated from peripheral blood of cancer patients, and PBMC are co-incubated with nanoparticles loading tumor antigens for specific time in vitro to detect T cells that are related with efficacy of cancer immunotherapy. The content of such T cells are studies the correlation with the efficacy of cancer immunotherapy and patient prognosis.
223547348|NCT01681667|DRUG|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
223547349|NCT04062084|DEVICE|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
223547350|NCT00714506|BEHAVIORAL|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
223547351|NCT00714506|OTHER|Physical activity control|physical activity plus successful aging health education
223547352|NCT02402530|DRUG|Placebo|Matching placebo administered as intravenous infusion.
223547353|NCT02402530|DRUG|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
223547354|NCT01027559|DRUG|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
223730590|NCT02338284|OTHER|ultrasound of globe|"* A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~* A value \> 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
223730591|NCT00135720|DRUG|Enbrel (Etanercept)|
223730592|NCT06362811|PROCEDURE|Sacral Erector Spinae Plane Block|Ultrasound-guided bilateral injection of 1ml/kg 0.25% bupivacaine into the plane underneath the erector spinae muscles over sacral crests. The needle is inserted with in-plane technique from cranial to caudal direction over S3-4.
223730593|NCT01005420|DIETARY_SUPPLEMENT|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
224012490|NCT06907225|OTHER|None-placebo|None - observational study
224012491|NCT06907108|DEVICE|Systemic vibratory therapy|The interventions were performed on a vibratory platform with side-alternating displacement of the base (Novaplate Fitness Evolution model, DAF Produtos Hospitalares Ltda, São Paulo). The individual was positioned barefoot, with knees flexed at 130º on the base of the vibratory platform. The protocol was performed over a 6-week period with 2 weekly sessions, totaling 12 sessions. The frequency was 5-16Hz according the protocol, and the peak-to-peak displacement was 2.5, 5.0, and 7.5 mm in all sessions. During the protocol, the individuals performed static and dynamic squats, with one static and one dynamic session (interleaved). The variables were evaluated before and after the interventions.
224012492|NCT06901947|DIETARY_SUPPLEMENT|Glucose drink|Intervention group will receive maltodextrin glucose drinks 2 hours prior to the operation
223391928|NCT02943954|DEVICE|Fractional Flow Reserve (FFR)|
223391929|NCT01225198|DIETARY_SUPPLEMENT|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
223391930|NCT01225198|OTHER|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
223391931|NCT01067105|DRUG|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
223391932|NCT01591278|OTHER|Pulpotomy|Comparison of two different pulp dressing agents
223391933|NCT01591278|OTHER|Pulpotomy|Comparison of two different pulp dressing agents
223391934|NCT00593723|RADIATION|IMRT|
223391935|NCT01634048|DIETARY_SUPPLEMENT|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
223391936|NCT01268982|PROCEDURE|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
223391937|NCT02730429|DRUG|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
223391938|NCT02730429|DRUG|Letrozole|Letrozole is standard of care in both arms
223391939|NCT02302833|DRUG|Cabozantinib S-malate|Given PO
223391940|NCT02302833|OTHER|Laboratory Biomarker Analysis|Correlative studies
223547355|NCT01027559|BEHAVIORAL|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
223547356|NCT01841021|DRUG|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
223547357|NCT01971671|OTHER|no intervention.|
223547358|NCT02946177|BIOLOGICAL|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
224012493|NCT04574856|RADIATION|Dose-Intensified Radiotherapy|Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.
224012494|NCT04574856|DRUG|Temozolomide|Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)
224012495|NCT04574856|DRUG|Adjuvant temozolomide|Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
224012496|NCT06906575|BEHAVIORAL|A Comprehensive Intervention to Improve Sexual and Relationship Well-being for Cancer Patients and Their Partners|"This intervention targets three core areas:~Body Image Improvement - Supports patients in understanding and accepting physical changes resulting from cancer treatments, fostering positive attitudes toward body image and self-esteem.~Psychological Flexibility Enhancement - Utilizes ACT-based strategies to help participants acknowledge and adaptively manage difficult emotions, thoughts, and experiences related to cancer diagnosis and treatment.~Dyadic Coping Skill Training - Provides structured skill-building exercises to strengthen mutual support mechanisms, enhance effective partner communication, and promote collaborative problem-solving when facing cancer-related stressors.~The intervention consists of six weekly sessions (90-120 minutes each), delivered in a hybrid format (virtual and in-person) to maximize accessibility. Each session integrates psychoeducational presentations, facilitated discussions, guided experiential exercises."
224012497|NCT06906939|DEVICE|repetetive transcranial magnetic stimulation|rTMS treatments will be performed with the MagVenture MagPro X100 stimulator equipped with the Cool-B70 A/P for sham-controlled stimulation. The coil has two sides, one of which is shielded so that no energy is imparted to the brain when the shielded side is applied to the subject's head. Small skin electrodes are applied to the scalp under the coil that impart a small microcurrent to the scalp simulating the sensation of active treatment. The operator receives a code from the device instructing them which side of the coil to use for each subject, ensuring complete treatment blinding.
223391941|NCT02302833|OTHER|Questionnaire Administration|Ancillary studies
223391942|NCT06171243|DRUG|Lidocaine topical|"Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~1. A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~2. 10 grams will be applied every 12 hours for a period of 48 hours."
223547359|NCT02946177|OTHER|Sterile Saline|0.5 mL of sterile Saline administered im
223547360|NCT00643890|GENETIC|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10\^12 vector genomes in 35 uL.
223547361|NCT04189302|PROCEDURE|connective tissue graft harvest using KPM blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using KPM blade.
223547362|NCT04189302|PROCEDURE|connective tissue graft harvest using 15 C blade|after local anesthesia is injected, the surgical procedure is initiated with 15 C blade and the connective tissue graft is detached from epithelium and underlying periosteum. then the connective tissue is harvested with the help of 2 vertical and 1 horizontal incisions using 15C blade.
223547363|NCT01125475|DEVICE|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
223547364|NCT01144416|BIOLOGICAL|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
223547365|NCT01144416|BIOLOGICAL|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
224012498|NCT06907303|DIAGNOSTIC_TEST|EndoDx|PCR assay for Endometriosis diagnosis
224012499|NCT06906393|BEHAVIORAL|Preventive treatment|4-second Sprint Interval Training (SIT) over 8 weeks to improve cardiovascular health.
224012500|NCT06906718|DEVICE|Implantation of an intraocular lens|Successful bilateral IOL implantation into the capsular bag with at least 12 months follow-up.
224012501|NCT06094387|DIAGNOSTIC_TEST|Thrombin generation assay|Thrombin generation parameters in patients receiving central catheter insertion
224012502|NCT01022112|DRUG|TA-7284-Low|TA-7284-Low
223391943|NCT06468436|DRUG|Dexmedetomidine-Esketamine Combination|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
223391944|NCT06468436|DRUG|Dexmedetomidine|"For patients with invasive ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.05×kg\] ml/h which is increased by \[0.025×kg\] ml/h every 10 min, until the Richmond Agitation-Sedation Scale (RASS) reaches -2 to -1, maximal infusion rate reaches \[0.175×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is provided as above when considered necessary by the ICU physicians, with a target RASS score of -2 to +1.~For patients with non-invasive ventilation (including high-flow nasal oxygenation) or without assisted ventilation, nighttime sedation (20:00-06:00) is provided with an initial infusion rate of \[0.0125×kg\] ml/h which is increased by \[0.0125×kg\] ml/h every 10 min, until the RASS reaches -1, maximal infusion rate reaches \[0.05×kg\] ml/h, or adverse reactions occur. Daytime sedation (06:00-20:00) is typically not required but is provided when considered necessary by the ICU physicians, with a target RASS score of -1 to +1."
223391945|NCT06447194|DRUG|Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail|Please refer to description for interventional group.
223391946|NCT06447194|OTHER|Placebo|100mL paraspinal normal saline injection intraoperatively, once.
223391947|NCT00002881|DRUG|flutamide|
223391948|NCT00002881|DRUG|goserelin acetate|
223391949|NCT00002881|DRUG|leuprolide acetate|
223391950|NCT00002881|DRUG|suramin|
223391951|NCT00002881|DRUG|therapeutic hydrocortisone|
223391952|NCT00002881|PROCEDURE|orchiectomy|
223391953|NCT04878432|DRUG|MBG453|Solution for intravenous infusion
223391954|NCT04878432|DRUG|Azacitidine|Solution for subcutaneous injection or intravenous administration
223391955|NCT04878432|DRUG|Decitabine|Solution for intravenous administration
223391956|NCT04878432|DRUG|INQOVI (oral decitabine)|Tablet for oral administration
223391957|NCT06532292|DEVICE|Biofeedback|To facilitate PFM function, electromyography biofeedback and electrical stimulation will be employed using an intravaginal probe, tailored to individual needs.
223391958|NCT06532292|DEVICE|HIFEM|The HIFEM device (i.e. BTL EMSELLA) is FDA approved and its indications are to provide entirely non-invasive electromagnetic stimulation of pelvic floor muscle for the purpose of rehabilitation of weak pelvic muscles and restoration of neuromuscular control for the treatment of male and female urinary incontinence.
223391959|NCT06962514|OTHER|Blood flow restriction cuff|Use of blood flow restriction cuff during resistance training. The cuff pressure is set at 50% of the participant's arterial occlusion pressure.
223391960|NCT06962514|OTHER|Exercise without BFR cuff|Resistance exercise performed without blood flow restriction. Same protocol as BFR group but without cuff application.
223391961|NCT04251364|DRUG|Acetazolamide|Daily acetazolamide pill intake
223391962|NCT04251364|DRUG|Atorvastatin|Daily atorvastatin pill intake
223391963|NCT04251364|DRUG|Placebo oral tablet|Daily placebo pill intake
223391964|NCT06096662|BEHAVIORAL|Verb Network Strenghtening Treatment (VNeST)|Participants are presented with a verb (representing an activity, for example, to drive) orally and in writing. The participants are first asked to name someone who may perform a given activity (an agent/subject, for example a chauffeur), then to name an object which the named activity can pe performed with (a patient/object, for example a limousine). Several types of semantic cues and assistance are given if the participant has difficulties finding adequate nouns). This procedure is repeated for three different agents and objects related to the given verb. The participants is then asked to choose one of the three sentences participants have created and expand on it by telling where, when and why the agents are performing the activity. After this, the participants are given sentences (with several foils) including the activity as well as agents and objects/patients, and are asked to indicate whether the sentences are plausible or not.
223391965|NCT06292221|OTHER|A mobile Health (mHealth) tool called 'DepWatch'|The mobile Health (mHealth) tool 'DepWatch' developed by the study team consists of the DepWatch app that is uploaded on participant's smart phones with their consent and a Fitbit provided to the participants
223391966|NCT05017246|DRUG|Bupivacaine|-Epidural bupivacaine 0.1% 2-6ml/hr based on MAP within 10% of patient's baseline MAP
223391967|NCT05017246|DRUG|Morphine|-Preservative-free intrathecal morphine (duramorph) 150mcg injection (0.15ml or a 0.5mg/0.5ml prepared solution)
224012503|NCT01022112|DRUG|TA-7284-Low-middle|TA-7284-Low-middle
224012504|NCT01022112|DRUG|TA-7284-High-middle|TA-7284-High-middle
224012505|NCT01022112|DRUG|TA-7284-High|TA-7284-High
223391968|NCT05017246|DRUG|Lidocaine|-Lidocaine infusion 1 mg/kg ideal body weight (IBW)
223391969|NCT04208152|DRUG|anle138b|capsule containing excipient and anle138b
223391970|NCT04208152|DRUG|Placebo|matching placebo capsule containing excipient
223391971|NCT04179318|DIAGNOSTIC_TEST|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
223391972|NCT04459234|DRUG|Ketamine use in CLCC sites (indication and administration protocol)|"Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription):~1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain~2. Administration protocol: route, posology, duration, administration sequence, premedication~3. Antalgic efficacy~4. Tolerance profile~5. Quality of life, anxiety and depression evaluations"
224012506|NCT01022112|DRUG|Placebo|Placebo
224012507|NCT00978627|DRUG|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
223391973|NCT04172935|DEVICE|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
223547366|NCT01144416|DRUG|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
223547367|NCT01144416|DRUG|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
223547368|NCT03123900|BEHAVIORAL|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
223547369|NCT03123900|BEHAVIORAL|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
223547370|NCT03123900|BEHAVIORAL|Combined training|Subjects included in this group receive both types of intervention.
223547371|NCT05620056|DRUG|chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs|medication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course
223730594|NCT01005420|DIETARY_SUPPLEMENT|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
223730595|NCT01195415|DRUG|Gemcitabine Hydrochloride|Given IV
223730596|NCT01195415|OTHER|Laboratory Biomarker Analysis|Correlative studies
223730597|NCT01195415|DRUG|Vismodegib|Given PO
223730598|NCT02939898|DRUG|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
224012508|NCT00978627|DRUG|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
224012509|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
223391974|NCT02185079|BEHAVIORAL|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
223391975|NCT02185079|BEHAVIORAL|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
223730599|NCT02939898|DRUG|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
223730600|NCT05320523|DEVICE|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM.|Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM, at the same trajectory.
223730601|NCT05320523|DEVICE|GPi stimulation|Bilateral high-frequency neurostimulation of the GPi using a Vercise neurostimulation system
224012510|NCT00978627|DRUG|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
224012511|NCT01153867|BEHAVIORAL|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
224012512|NCT00014807|BEHAVIORAL|Reducing Pesticide Exposure in Minority Families|
223391976|NCT04647903|DRUG|ADAIR 10 mg IR tablets|manipulated ADAIR 3x10mg
223391977|NCT04647903|DRUG|d-amphetamine sulfate|crushed d-amphetamine sulfate 3x10mg
223391978|NCT04647903|DRUG|Placebo|placebo for oral and intranasal administration
223730602|NCT05320523|DEVICE|NBM stimulation|Bilateral low-frequency neurostimulation of the NBM using a Vercise neurostimulation system
224012513|NCT01835938|DRUG|1- Erlotinib|"* Erlotinib 50 mg tablet by mouth every day for 14 days,~* Erlotinib 100 mg tablet by mouth every day for 14 days,~* Erlotinib 150 mg tablet by mouth every day for 14 days,"
224012514|NCT01835938|DRUG|placebo|"* Placebo 50 mg tablet by mouth every day for 14 days,~* Placebo 100 mg tablet by mouth every day for 14 days,~* Placebo 150 mg tablet by mouth every day for 14 days,"
223391979|NCT00300690|DEVICE|6 mm Uni-graft® (B-Braun)|
223391980|NCT00300690|DEVICE|6 mm Gore-Tex® (WL Gore)|
223391981|NCT03877679|DRUG|Triamcinolone|Triamcenolone +napolycarboxylate
223391982|NCT03877679|DRUG|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
223391983|NCT02636478|OTHER|questionnaire for travel habits|questionnaire has been used to collect information about travelling
223391984|NCT03405025|PROCEDURE|Endoscopic ultrasound guided radiofrequency ablation|To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
223391985|NCT03405025|DEVICE|ultrasound|ultrasound
223547372|NCT00124072|DRUG|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
223730603|NCT05320523|DEVICE|Sham stimulation|Ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
223730604|NCT02155842|BEHAVIORAL|High intensity endurance exercise|
223730605|NCT02155842|BEHAVIORAL|Moderate continuous endurance exercise|
223730606|NCT00167882|DRUG|5-aminosalicylate (Pentasa, Ferring)|
223391986|NCT01553357|DRUG|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
223391987|NCT02938143|PROCEDURE|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
223391988|NCT02938143|PROCEDURE|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
223391989|NCT05943717|DEVICE|lung ultrasound and electrical cardiometry|: B-lines of lung ultrasound and the parameters of cardiometry will be measured at the mid-week HD session before starting the session by 30 min then every 30min during HD session for 180 min and then after the end of the session of HD by 30 min and then The specificity and sensitivity of both techniques will be compared to each other
223391990|NCT03018184|OTHER|MRI and Muscle Dynamometer|
223391991|NCT02736552|DRUG|S-1 for 6 months|6 months S-1 after D2 resection
223391992|NCT02736552|DRUG|S-1 for 1 year|1 year S-1 after D2 resection
223391993|NCT06134037|DRUG|Aminophylline|Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
223391994|NCT00919295|DRUG|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
223391995|NCT00919295|DRUG|placebo|placebo
223391996|NCT06187428|OTHER|PainSMART-strategy|"Be PainSMART:er is a seven minute long film developed by the research group based on modern pain science and previous qualitative studies.~The film is divided into three sections:~Section 1- Educates that MSKP is a complex protective system that does not reflect the anatomical state of the body and provides reassurance that MSKP is rarely caused by serious pathology.~Section 2- Provides advice on active MSKP coping, such as encouraging work despite some pain, in an attempt to reconceptualise the belief that a painful body part needs to be rested.~Section 3- Aims to prepare patients for a biopsychosocial physiotherapy consultation by encouraging them to reflect on the film's messages.~In addition to the film, the questions posed to the participant at the initial consultation aim to facilitate the discussion around the film and MSKP reflections. Management subsequent to the initial consultation will follow usual management."
223391997|NCT06187428|OTHER|Usual physiotherapy management|Patients randomised to the control group follow usual MSKP physiotherapy management. Specifically, patients first contact their physiotherapy department online or via telephone and are triaged by a certified physiotherapist and are booked for an initial physiotherapy consultation. After triage, study information and the consent to participate, patients in the control group receive online data collection questionnaires identical to those of the intervention group at baseline and prior to the consultation, excluding the film and the questions linked to the film. The initial consultation will take place as usual according to the preferences of the physiotherapist. The physiotherapist will pose one question at start of the consultation to acknowledge the completion of control group questionnaires. Management subsequent to the initial consultation will follow usual management.
223391998|NCT04069819|DRUG|Cilostazol 50 MG Oral Tablet|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
223391999|NCT04069819|DRUG|Escitalopram|Escitalopram 20 mg tablet once daily for 6 week
223392000|NCT04069819|DRUG|Placebo|placebo
223392001|NCT01495000|DRUG|denosumab|60mg subcutaneous injection, single dose
223730607|NCT00533845|DRUG|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
223392002|NCT01495000|DRUG|placebo|placebo subcutaneous injection, single dose
223392003|NCT04131088|OTHER|Follow up of midlines|The follow-up data to be collected will be recorded on a monitoring logbook that will follow the patient (Appendix 4). The latter will be involved in the follow-up of his data insofar as he will be able to solicit the various professionals performing care on his midline in order to aim at the exhaustiveness of the filling of the book.
223392004|NCT00684372|DRUG|leflunomide|"Screening: If BK viremia (BK PCR \>10 000 copies/ml in serum) i. Reduced immunosuppression~1. MMF / AZA withdrawal~2. CNI reduction~   1. Tacrolimus 5 ng/ml in serum~  2. Cyclosporin 100 ng/ml in serum~3. Prednisolone to maintenance level~If effective =\> continue~* Stable renal function (P-Krea)~* \>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis~* Negative PCR at \> 3 months after diagnosis~If failure =\> add leflunomide~* Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy~* \<50% reduction in PCR at 4 weeks after diagnosis~* Positive PCR at \>3 months after diagnosis~Leflunomide dosing:~ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)~1. Starting at 20 mgx1 PO daily~2. Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 \>40 ug/ml"
223392005|NCT02943837|PROCEDURE|Device: 22G FNA needle|
223392006|NCT02943837|PROCEDURE|Device: 20G FNB needle|
223392007|NCT01295749|DEVICE|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
223392008|NCT01295749|DEVICE|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
223730608|NCT00728780|DRUG|ABT-143|once
223730609|NCT00728780|DRUG|ABT-335 and rosuvastatin|once
223730610|NCT02477254|BIOLOGICAL|Vaccination|A quadrivalent HPV vaccine
223730611|NCT03078647|DEVICE|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
223392009|NCT01514461|DRUG|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
223392010|NCT01514461|DRUG|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
223392011|NCT00241670|DRUG|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
223392012|NCT03499067|DEVICE|Test lens|Contact lens
223547373|NCT00124072|DIETARY_SUPPLEMENT|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
223547374|NCT00124072|DRUG|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
223547375|NCT00124072|DRUG|Placebo|Placebo vitamin B12/folic acid tablet once daily
223547376|NCT03118336|DRUG|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
223547377|NCT05204095|DEVICE|Portable slit-lamp photography|The enrolled patients will undergo portable slit-lamp photography with and without mydriasis and receive traditional slit-lamp photography for comparison.
223547378|NCT02869672|BIOLOGICAL|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
223547379|NCT02869672|BIOLOGICAL|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
223547380|NCT03402191|DRUG|L-arginine|l-arginine for thalassemia with pulmonary hypertension
223547381|NCT03402191|DRUG|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
223547382|NCT00092820|DRUG|MK0653, ezetimibe|
223547383|NCT00092820|DRUG|Comparator: placebo|
223547384|NCT01736033|DRUG|Tamsulosin|1 tablet(0.2mg) orally q.d.
223547385|NCT01736033|DRUG|Finasteride|1 tablet(5mg) orally q.d.
223547386|NCT01736033|DRUG|Placebo|1 tablet(0.2mg) orally q.d.
223547387|NCT03040128|DRUG|Minocycline|high-dose, intravenous minocycline
223547388|NCT03040128|OTHER|normal saline infusion|
223547389|NCT04981964|PROCEDURE|Exercise training|both groups received conventional physiotherapy training program, for one hour, three sessions per week, for three successive months, based on neurodevelopmental treatment, composed of approximation of the upper and lower limbs in a regular and rhythmic manner, facilitation of righting, equilibrium and protective reactions, training of postural stability and equal weight shift especially on the affected side, stretching, strengthening exercises for upper and lower limbs and back muscles
223547390|NCT02534883|DRUG|Misoprostol|To be place vaginally
223547391|NCT02534883|DRUG|Placebo|To be placed vaginally
223547392|NCT05474456|OTHER|SNAGs|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
223730612|NCT01521455|DRUG|HCP0910|250/50, BID for 2 weeks
223392013|NCT03499067|DEVICE|Control lens|Contact lens
223392014|NCT05576090|BEHAVIORAL|Mindfulness Meditation|The mindful awareness practices (MAPS) for Sleep intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA. This intervention includes educational and behavioral content related to sleep, including the importance of regularity of sleep schedules, minimizing noise and light, and reducing caffeine use later in the day. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for questions and group discussion. Home practice is a key component of MAPs and is particularly important for addressing sleep disturbance. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes, with practice prior to bedtime, and to practice at night if they awake and cannot return to sleep.
223547393|NCT05474456|OTHER|Manipulation|Wrestlers will be treated with high velocity, low amplitude thrust. The treatment will be given for 6 weeks, 2 sessions per week.
223547394|NCT06043180|PROCEDURE|Transcatheter aortic valve implantation|Intervention on aortic valve for severe aortic stenosis
223547395|NCT03328832|DRUG|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
223547396|NCT03328832|DRUG|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
223547397|NCT03328832|DRUG|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
223547398|NCT03980392|OTHER|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
223547399|NCT00886769|DRUG|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
223547400|NCT00886769|DRUG|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
223547401|NCT03019523|DIETARY_SUPPLEMENT|Caffeine Blend|Taken orally in capsule form
223547402|NCT03019523|OTHER|Sugar Pill|Taken orally in capsule form
223547403|NCT05231759|DEVICE|L'DISQ|
223547404|NCT00198679|DRUG|Chlorhexidine|
223730613|NCT01521455|DRUG|Seretide Diskus|250/50, BID for 2 weeks
223547405|NCT00873821|DRUG|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
223730614|NCT01184625|OTHER|Physical Exercise|12 weeks of physical exercise.
223392015|NCT05576090|BEHAVIORAL|Sleep Education|The Sleep Education intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine). Each session provides didactic instruction, review of behavioral techniques, and opportunity for questions. Homework includes practicing sleep hygiene and weekly reading. Key components of the intervention include information about sleep biology, characteristics of healthy and unhealthy sleep, sleep problems, stress biology and stress reduction, self-monitoring of sleep behavior, relaxation methods for improving sleep, and weekly behavioral sleep hygiene strategies.
223392016|NCT03658044|OTHER|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
223392017|NCT03658044|OTHER|Placebo|No intervention performed. Patients are offered to read the open pages on the website
223392018|NCT01934439|DEVICE|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
223392019|NCT02754050|DEVICE|Tandem Snare|
223392020|NCT04413513|OTHER|Integrated Attention Training Program (IATP)|Integrated attention training program (IATP) is a newly developed cognitive training programs that combined relaxation technique with integrated attentional training into daily life activity.
223392021|NCT04413513|OTHER|Health Education|Health educational sessions on health concerns and physical diseases commonly found in old age
223392022|NCT04122521|DIAGNOSTIC_TEST|MRI|MRI
223392023|NCT02234908|BEHAVIORAL|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
223392024|NCT02234908|BEHAVIORAL|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
223392025|NCT00954759|PROCEDURE|Chiropractic treatment|
223392026|NCT00954759|PROCEDURE|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
223392027|NCT02548832|DRUG|Berberine|"Berberine 1500 mg, each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner."
223392028|NCT02548832|DRUG|Bezafibrate|"Bezafibrate capsule 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
223392029|NCT02548832|DRUG|Berberine plus Bezafibrate|"Berberine 1500 mg each 24 h for 90 days~1 Berberine capsule 500 mg for breakfast.~1 Berberine capsule 500 mg for lunch.~1 Berberine capsule 500 mg for dinner.~Bezafibrate 400 mg each 24 h for 90 days.~1 Bezafibrate capsule 200 mg for breakfast.~1 Bezafibrate capsule 200 mg for dinner."
223730615|NCT04282993|DEVICE|Wearable devices for identifying and measuring risk factors for ischemic stroke|Identifying and monitoring cerebrovascular risk factors using wearable devices
223392030|NCT00116506|DRUG|erlotinib|
223392031|NCT00116506|DRUG|FOLFOX|
223392032|NCT00116506|DRUG|bevacizumab|
223392033|NCT04256915|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Bright Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes. Participants will receive constant blue-green light (500 nm, 506 lux)."
223392034|NCT04256915|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia (CBT-I) + Placebo Light Therapy|"CBT-I consists of 6 weekly sessions of CBT-I (90-min, 3-6 adolescents in each group) with elements that address the behavioural, cognitive and physiological factors perpetuating insomnia, including: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.~Participants will additionally undergo daily morning light therapy by wearing Re-timers (a validated portable light emitting device) at home for 30 minutes.Participants will receive red-filtered dim light (\<50 lux)."
223392035|NCT03565900|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
223547406|NCT00873821|DRUG|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
223547407|NCT00414076|DRUG|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
223730616|NCT04282993|OTHER|Standard of care monitoring|Periodical medical examinations
223392036|NCT03565900|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
223730617|NCT01860651|BEHAVIORAL|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
223547408|NCT00049257|DRUG|carboplatin|Administered Day 1 of each cycle. AUC=6.
223547409|NCT00049257|DRUG|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
223547410|NCT03816722|DEVICE|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
223730618|NCT00002714|BIOLOGICAL|bleomycin sulfate|
223730619|NCT00002714|DRUG|Stanford V regimen|
223730620|NCT00002714|DRUG|doxorubicin hydrochloride|
223730621|NCT00002714|DRUG|etoposide|
223730622|NCT00002714|DRUG|mechlorethamine hydrochloride|
223730623|NCT00002714|DRUG|prednisone|
223392037|NCT03565900|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
223547411|NCT03816722|OTHER|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
223547412|NCT06118424|BEHAVIORAL|deepfake video|The combination of the words deep and fake is called deepfake in the literature as deep learning. Deepfakes, which have recently become more widely known as a result of the shocking images and sound recordings of many people, from politicians to famous movie stars, are generally hyperrealistic videos in which people's faces and voices are used by other faces and voices without permission and manipulated digitally. Deepfakes rely on neural networks that analyze large data samples to learn to mimic a person's facial expressions, mannerisms, voice and tone. The process involves feeding a deep learning algorithm to exchange images of two people or faces.
223547413|NCT06555341|BEHAVIORAL|Experimental: Six Thinking Hats Group|"2\. Subcutaneous insulin administration was explained with the traditional training model.~3\. The Six Thinking Hats technique and how it is used was then explained in detail to the students. Any points that were not fully understood were explained again so that the technique was thoroughly reinforced.~4\. The researchers had made hats from different coloured card. All the students wore all the hats in turn and were asked the questions related to that colour hat as stated above (semi-structured questionnaire 1-6).~5\. The responses given by the students to the questions were audio-recorded. Each interview lasted 30 mins."
223547414|NCT06555341|BEHAVIORAL|Other: Video Group|"2\. Subcutaneous insulin administration was explained with the traditional training model.~3\. Then by scanning the QR code from the nursing practice skills textbook(Aylaz \&amp; Yakıncı, 2024), the researchers provided the link for the students to watch the insulin application video.~4\. Without mentioning hat colours or the Six Thinking Hats method to this group, the questions on the semi-structured questionnaire were asked, and the interviews, each lasting 30 mins, were audio-recorded.~5\. After completing the video training, the mid-test data were collected by applying the Subcutaneous Insulin Application Skill Level Observation Form during administration of insulin to a dummy."
223547415|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 150mg at 0 Day 1, Day 8, Day 15
223547416|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 300mg at 0 Day 1, Day 8, Day 15
223547417|NCT05980065|DRUG|Placebo|Subcutaneously administrate placebo at 0 Day 1, Day 8, Day 15
223547418|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 600mg at 0 Day 1, Day 8, Day 15
223547419|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 900mg at 0 Day 1, Day 8, Day 15
223547420|NCT05980065|DRUG|C1K|Subcutaneously administrate C1K 1200mg at 0 Day 1, Day 8, Day 15
223730624|NCT00002714|DRUG|vinblastine sulfate|
224012515|NCT03123601|DEVICE|Risk sign displays|"Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:~* Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.~* Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour."
224127603|NCT05965336|OTHER|Gait Biofeedback|Audio-visual biofeedback will be provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map will represent the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target will be provided using the heat map colors of red and target line on the bar graph. For propulsion biofeedback, a visual display with a marker will represent the current propulsion (peak AGRF) and a target provided to modulate propulsion. The plantar pressure and AGRF measurements from the participant's baseline walking trials will be used to determine customized biofeedback targets.
223547421|NCT04721158|DEVICE|Continuous glucose monitor|Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
223392038|NCT00413101|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
223392039|NCT05241340|DRUG|Sasanlimab|Sasanlimab (PF-06801591) is a recombinant humanized monoclonal antibody (immunoglobulin gamma-4 with kappa light chains, IgG4 kappa) directed against programmed death 1 (PD-1). Manufactured by Pfizer, Inc.
223392040|NCT05241340|RADIATION|Stereotactic Body Radiation Therapy|This current study is designed to deliver a biologically equivalent dose of 43.2Gy using a strategy of HD hypo-fractionated radiation therapy 8Gy x 3 in combination with Sasanlimab
223547422|NCT02867228|OTHER|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
223547423|NCT00166127|DRUG|Levosimendan|
223547424|NCT03159910|BEHAVIORAL|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
223547425|NCT03159910|BEHAVIORAL|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
223547426|NCT02542059|RADIATION|68Ga-exendin PET/CT|68Ga-exendin PET/CT
223547427|NCT03440554|DIAGNOSTIC_TEST|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
223547428|NCT00224965|BEHAVIORAL|Behavior Therapy|
223547429|NCT01060254|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
223730625|NCT00002714|DRUG|vincristine sulfate|
223730626|NCT00002714|RADIATION|radiation therapy|
223730627|NCT01288469|DRUG|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
223547430|NCT01060254|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
223730628|NCT01288469|DRUG|Placebo (for alirocumab)|One SC injection in the abdomen only.
223392041|NCT05241340|PROCEDURE|Radical Cystectomy + pelvic lymph node dissection + urinary diversion|"This will include a cysto-prostatectomy in males or a radical cystectomy with anterior exenteration in females, bilateral pelvic lymph node dissection, and creation of a urinary diversion (ileal conduit, Indiana pouch or orthotopic neo-bladder). Robotic assisted or open surgery will be permitted.~Because there is currently equipoise regarding standard or extended template pelvic lymph node dissection, the limits of node dissection will not be protocol mandated. In the standard template, nodal packets will include the common iliac, external iliac, internal iliac (or hypogastric) and obturator nodes. Patients receiving an extended template will have the standard nodes with the addition of the para-aortic, para-caval, pre-sacral, and pre-sciatic node packets. The decision for urinary diversion is multifactorial involving patient factors (e.g., adequate renal function) and preference; thus, it will be made on a case-by-case basis."
223392042|NCT02719886|DEVICE|Ultrasound|Estimation of fetal weight by ultrasound
223392043|NCT01880866|DRUG|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
223392044|NCT06581510|PROCEDURE|esthetic dental crowns|Minimal Preparation of esthetic dental crown
223392045|NCT06581510|PROCEDURE|control group|Nuu smile ready-made zirconia crown with its well-known reduction
223392046|NCT01299103|DEVICE|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
223392047|NCT01689051|OTHER|human glucagon-like peptide 1 (7-36)amide|
223392048|NCT01689051|OTHER|human glucagon-like peptide 1 (9-36)amide|
223392049|NCT06378515|OTHER|Physical activity, postural changes and cognitive tasks|"1. Measuring while patients are sitting in rest for 5 minutes.~2. Supine to stand test: lying down (5 min) standing up (5 min)~3. Repeated sit stand test: sitting (10 sec) ↔ standing (10 sec), changing position every 10 seconds for 5 minutes.~4. Paced breathing in sitting position: letting patients breath 6 breaths/minute (0.1Hz) for 5 minutes.~5. Breath hold manoeuvre in sitting position: 60s normal breathing, then 32s breath hold + 88s normal breathing repeated 3 times.~6. Arithmetic stress test by giving the subject single digit addition. To give the pressure, subject needs to do as many as possible calculation within 1 minute with 1 minute break. This is repeated 3 times."
223392050|NCT02761668|PROCEDURE|ParS+Ortho 4W|Orthodontics 4 weeks post surgical
223392051|NCT02761668|PROCEDURE|ParS+Ortho 6M|Orthodontics 6 months post surgical
223547431|NCT01630317|PROCEDURE|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
223547432|NCT01630317|PROCEDURE|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
224138579|NCT05061797|DIETARY_SUPPLEMENT|Placebo|A carbonated soft drink with the same appearance, flavor and aroma as the active study product. Study participants will consume an assigned amount of the beverage (355 ml) under observation. They will then be monitored for the subsequent 180 minutes with measurements for respiration for Resting Energy Expenditure (RER) and other metabolic markers as well as satiety via a Visual Analog Scale (VAS).
223392052|NCT04810208|DRUG|Docetaxel|Docetaxel in NanoZolid formulation, for intratumoural injection
223392053|NCT03623503|OTHER|Observational study|
223392054|NCT03014154|OTHER|Training|
223392055|NCT00002578|DRUG|cytarabine|
223547433|NCT04512118|DIAGNOSTIC_TEST|PET-CT of 18F-FDG|Whole-body 18F-FDG-PET/CT was performed on a digital hybrid system (Vereos, Philips®)
223547434|NCT05171166|PROCEDURE|HAIC|Hepatic arterial infusion chemotherapy is consist of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 would be intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
223547435|NCT05171166|PROCEDURE|TACE|A standard hepatic artery catheter would be introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery would be performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply, the proportion of the liver supplied by each artery would be estimated by the arteriography. After optimal positioning of the catheter, cTACE or DEB-TACE protocol would be performed to embolize the tumor supplying artery blood flow until the stasis of the supplying artery.
223547436|NCT05171166|DRUG|FOLFOX|oxaliplatin,leucovorin, and 5-FU
223547437|NCT05171166|DRUG|cTACE or DEB-TACE|lipiodol or microspheres that mixed with EPI
223547438|NCT05171166|DRUG|Donafenib|200 mg of donafenib (consisting of two 100-mg tablets) twice daily.
223547439|NCT06324474|DRUG|Hyaluronic acid|Gengigel syringe containing 1ml of 0.8% HA
223547440|NCT06324474|BEHAVIORAL|scaling and root planning|scaling and root planning using ultrasonic scaler
223547441|NCT06290388|DRUG|23ME-01473|23Me-01473 given by intravenous infusion
223547442|NCT03929913|DEVICE|Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)|The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
224138580|NCT04092998|PROCEDURE|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
224138581|NCT04354779|DIAGNOSTIC_TEST|a specifically designed self-administered questionnaire|The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
224138582|NCT00286364|DRUG|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
223392056|NCT00002578|DRUG|gallium nitrate|
223392057|NCT00002578|DRUG|leucovorin calcium|
223392058|NCT00002578|DRUG|methotrexate|
223392059|NCT06013007|PROCEDURE|ICI-guided JINS approach|OCT- or IVUS-guided JINS approach in DES implantation (DES types including Healing-Targeted SUPREME/Infinity Sirolimus-Eluting Stent, GuReater™ Sirolimus-Eluting Stent, XIENCE Alpine Everolimus-Eluting Stent, Promus PREMIER™ Everolimus-Eluting Stent, Resolute Integrity™ Zotarolimus-Eluting Stent, Firebird 2™ Sirolimus-Eluting Stent, Firekingfisher™ Sirolimus-Eluting Stent).
223392060|NCT00256178|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
223392061|NCT00256178|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
223392062|NCT00256178|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
223392063|NCT00200863|DEVICE|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
223392064|NCT00780338|OTHER|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
223547443|NCT06016075|DEVICE|Hyperpolarised MRI|Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
223547444|NCT06016075|DEVICE|Sodium MRI|MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
223547445|NCT06016075|DEVICE|Deuterium metabolic imaging (DMI) MRI|Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
223547446|NCT02294032|DRUG|Immunosuppressive Agents|standard of care for patients post-transplant
224012516|NCT04694209|PROCEDURE|maxillary and mandibular telescopic retained overdentures supported by 4 implants|The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.
224012517|NCT04694209|PROCEDURE|maxillary and mandibular screw retained hybrid prostheses supported by 4 implants|Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
223392065|NCT01960257|DEVICE|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
223392066|NCT01960257|OTHER|SOC DOT|
223392067|NCT06404957|BEHAVIORAL|Mindfulness-based Applied|Mindfulness-Based Practices is planned to be an 8-week program of mindfulness meditation and gentle Hatha yoga taught in an online class for up to 14 participants.
223547447|NCT06351826|OTHER|ELLASI|A structured intervention for polytrauma patients
223392068|NCT06404957|BEHAVIORAL|Active Comparator: Control groups|No intervention will be made in this group.
223392069|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
223392070|NCT01709825|DIETARY_SUPPLEMENT|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
223547448|NCT06351826|OTHER|Standard|Unstructured interventions that are given in everyday practice (standard intervention)
223547449|NCT04841993|DRUG|Cannabis decoction|A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
223547450|NCT04841993|DRUG|Cannabis oil|A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
223547451|NCT04841993|DRUG|Vaporized cannabis|100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
223547452|NCT01881282|DRUG|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
223547453|NCT01881282|DRUG|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
223547454|NCT04990583|BEHAVIORAL|Face-to-Face PrEP Adherence Intervention Based on LifeSteps|This single session intervention, based on LifeSteps, will occur with a study adherence coach either in-person or remotely via HIPAA compliant videoconferencing software. The topics covered during the session will include: experience taking PrEP, risk behavior education, mental health and substance use as barriers to adherence, other barriers to adherence, formulating a dosing schedule, storing and transporting medications, and response to slips in adherence. Participants assigned to the Carium condition will also receive an introduction to the Carium app.
223730629|NCT01288469|DRUG|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
223392071|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
223392072|NCT01709825|DIETARY_SUPPLEMENT|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
223392073|NCT05553821|OTHER|Cold sand bag|A sand bag weighing 3.5-4 kg is applied to the CAG area of patients.
223392074|NCT05553821|OTHER|A sand bag|A sand bag
223392075|NCT02002221|DRUG|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
224012518|NCT03838887|DEVICE|ultrasound machine|Ultrasound machine with a vocal software
224012519|NCT02516332|DRUG|Lexapro|
224012520|NCT02516332|DRUG|Placebo|
223392076|NCT02002221|DRUG|Placebo|Matching placebo of vildagliptin 50 mg twice daily
223392077|NCT02002221|DRUG|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
223392078|NCT02002221|DRUG|Metformin|Patients continued their prescribed metformin dose, if applicable.
223392079|NCT05584384|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
224012521|NCT02516332|BEHAVIORAL|Supervised Aerobic Exercise|
223392080|NCT05584384|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
223392081|NCT01274702|OTHER|Visual Reconstitutions Therapy|
223392082|NCT01274702|OTHER|Saccadic Eye Movement Training|
223392083|NCT03982732|BIOLOGICAL|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
223392084|NCT04949217|PROCEDURE|Inlay Bristow|A modified Bristow procedure
223392085|NCT04949217|PROCEDURE|Bristow|Traditional Bristow procedure
223392086|NCT04858932|DEVICE|Continuous Glucose Monitor|a handheld reader and a wearable sensor placed on the back of the arm used to obtain glucose measurements
223392087|NCT04858932|DEVICE|Wrist Actigraphy Device|a watch like wearable sensor
223392088|NCT04858932|DEVICE|Food Weight Scale|a scale to measure food weight
223392089|NCT04858932|DEVICE|Smart Body Weight Scale|a full body composition scale that provides fat and muscle mass, water retention, bone mass, and weight trends
223392090|NCT01380561|DRUG|asimadoline|10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
223392091|NCT03963193|DRUG|Etoposide|Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
223392092|NCT03963193|DRUG|Irinotecan|Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
223392093|NCT02492373|DRUG|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
223392094|NCT02492373|DEVICE|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
223392095|NCT04464174|DRUG|Ipatasertib|Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
223392096|NCT04464174|DRUG|Capecitabine|Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
223392097|NCT04464174|DRUG|Eribulin|Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
223392098|NCT04464174|DRUG|Carboplatin|Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
223392099|NCT04464174|DRUG|Gemcitabine|Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
223392100|NCT03405831|DRUG|Ivabradine|Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
223392101|NCT03405831|DRUG|Placebo|Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
223392102|NCT05638776|DRUG|REGEND001 cell therapy|Transplantation of the cell product
223547455|NCT04990583|BEHAVIORAL|Adherence Coaching Facilitated by Carium Adherence App|The Carium app will be used to deliver medication reminders to participants, track medication adherence, engage in two-way secure messaging with participants, and connect with participants through a secure video feature. The adherence coach will use the secure messaging feature to support the participant with their adherence
223547456|NCT02977078|BEHAVIORAL|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
224012522|NCT03037931|DRUG|Ferric Carboxymaltose|Intravenous Iron
224012523|NCT03037931|DRUG|Placebo|Normal Saline Solution
224012524|NCT00605215|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
223392103|NCT05638776|DRUG|Placebo|Transplantation of Placebo
223392104|NCT03347110|DRUG|Bimekizumab|Bimekizumab at a prespecified dose.
223392105|NCT02023983|OTHER|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
223392106|NCT02023983|OTHER|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
223392107|NCT00155311|PROCEDURE|orthodontic treatment|
223392108|NCT01900769|DRUG|Blood Volume Dilution|
223392109|NCT03665740|DRUG|Resveratrol|resveratrol is an OTC supplement
223392110|NCT04455867|BEHAVIORAL|Diabetes Exercise and Healthy Lifestyle Program|The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.
223392111|NCT04455867|OTHER|Outpatient care|Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education
223392112|NCT02105467|DRUG|Grazoprevir 100mg / Elbasvir 50 mg FDC|
223392113|NCT02105467|DRUG|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
224012525|NCT00605215|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
224012526|NCT00605215|DRUG|Avonex®|Avonex® will be administered per dose and schedule specified in the arm description.
224012527|NCT01716897|DRUG|E2609|
223392114|NCT06575634|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
223392115|NCT01004354|DRUG|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
223392116|NCT06262763|DEVICE|Laser Therapy|High-intensity
223392117|NCT06262763|OTHER|Traditional exercises|Hamstring and piriformis stretch, plank exercises and bird dog exercise
223392118|NCT06262763|OTHER|Placebo laser|Not directed radiation to participant
223392119|NCT02892045|DEVICE|MMG|neuromuscular monitoring device
224012528|NCT02081443|DRUG|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
224012529|NCT02081443|DRUG|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
223392120|NCT03271801|BEHAVIORAL|child health education|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
223392121|NCT03271801|BEHAVIORAL|skills training|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
224012530|NCT00658255|DRUG|budesonide/formoterol|
224012531|NCT00658255|DRUG|formoterol|
224012532|NCT03134105|OTHER|Monthly Feedback on activity and patient-reported angina|Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
223392122|NCT00402909|DRUG|Nateglinide|
223392123|NCT00665405|RADIATION|CT scan|Thoracic CT scan
223392124|NCT03630497|DRUG|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
223392125|NCT02765997|BIOLOGICAL|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
223730630|NCT01288469|DRUG|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
224012533|NCT03134105|OTHER|End-of-Study Feedback|Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
223392126|NCT02765997|BIOLOGICAL|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen \[G-CSF\] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
223392127|NCT02901353|DEVICE|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
223392128|NCT02591277|DRUG|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
223392129|NCT05268653|BEHAVIORAL|Motivatıonal İnterviewing (Treatment Group)|Obese adolescents will be given a 6-session motivational interview.
224012534|NCT06138314|OTHER|Physical Exercise Program|The physical exercise program will consist of exercises from three different exercise modalities: aerobic training, balance exercises, and isometric exercises.
224012535|NCT06138314|OTHER|Neural Mobilization|Neural mobilization techniques for the upper and lower quadrants will be actively performed by participants.
224012536|NCT04049734|DRUG|oral losatan|50 mg of oral losartan one hour before the ERCP once
224012537|NCT04869228|DRUG|GT0918 tablets or placebo|GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
224012538|NCT02766192|DRUG|Ketamine|
224012539|NCT02766192|BEHAVIORAL|TIMBER Psychotherapy|
224012540|NCT02766192|DRUG|Placebo (normal saline)|
224012541|NCT03635528|DEVICE|Test Lens 1|EMO-114
224012542|NCT03635528|DEVICE|Test Lens 2|EMO-116
224012543|NCT03635528|DEVICE|Test Lens 3|EMO-118
224012544|NCT03635528|DEVICE|Test Lens 4|RMY-100
224012545|NCT03635528|DEVICE|Test Lens 5|Biofinity multifocal D Lens
224012546|NCT03635528|DEVICE|Control Lens 1|EMO-117
224012547|NCT03635528|DEVICE|Control Lens 2|Proclear 1 day
223392130|NCT02877901|DRUG|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
223392131|NCT02877901|DRUG|placebo|one tablet at bed time
223392132|NCT01404767|DRUG|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
223392133|NCT01404767|DRUG|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
223392134|NCT01518322|DEVICE|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
223392135|NCT01308125|PROCEDURE|PICSO|"* Baseline (hemodynamic) measurement~* Intra coronary~* Blood sampling~* LAD occlusion: for 3 min or until pain with and without PICSO~* Break recovery: the patient can recover from pain for 3 min~* CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.~* PICSO: start automatically and continued for 10 min.~* PCI/PICSO: concomitantly for the whole duration of the PCI intervention.~* 24h Follow up: additional blood samples every 6 hours (4 times)~* 30 days follow up."
223392136|NCT04242277|DEVICE|Investigational WF-OCT device|Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
223392137|NCT05132062|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention is a catheter based technique widely used to restore coronary vessel patency. It is performed by fluoroscopic guidance and it requires the use of iodinated contrast medium. The use of iodinated contrast media has been historically linked to AKI occurring within days after their administration and typically referred to as CA-AKI. Furthermore, CA-AKI has been associated with long-term impairment of kidney function, need for renal replacement therapy, and subsequent all-cause mortality.
223392138|NCT03104192|BEHAVIORAL|Develop & Refine MOWI w/o Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
223392139|NCT03104192|BEHAVIORAL|MOWI Weight Loss Maintenance|Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).
223392140|NCT03104192|BEHAVIORAL|Develop & Refine MOWI w Fitbit|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
223547457|NCT02977078|DEVICE|Inhaler casing|Monitors inhaler use
223547458|NCT02977078|DEVICE|Mobile application|Mobile application software linked to inhaler casing
223547459|NCT02891226|DRUG|Mirikizumab|
223547460|NCT02891226|DRUG|Placebo|
223547461|NCT05271942|PROCEDURE|Tilt and Tumble|The Tilt and Tumble technique is used to remove the human lens.
223547462|NCT05271942|PROCEDURE|Divide and Conquer|The Divide and Conquer technique is used to remove the human lens.
223547463|NCT00145626|DRUG|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
223547464|NCT00145626|DEVICE|Miltenyi Biotec CliniMACS|Stem cell selection device
223547465|NCT00145626|PROCEDURE|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
223547466|NCT02932826|BIOLOGICAL|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml NS
223547467|NCT02932826|DRUG|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
223547468|NCT05592301|DIAGNOSTIC_TEST|Diffusion-weighted Magnetic Resonance Imaging (DW-MRI)|The Diffusion-weighted Magnetic Resonance Imaging (DW-MRI) is used to diagnose perioperative stroke.
223547469|NCT05592301|DIAGNOSTIC_TEST|Transcranial Doppler (TCD)|Used to diagnose PFO
223547470|NCT05592301|DIAGNOSTIC_TEST|Transthoracic Echocardiogram (TTE)|Used to diagnose PFO.
223547471|NCT04883255|DRUG|10 mg Δ9-tetrahydrocannabinol (THC)|5-day course of orally-administered THC (dronabinol), 10 mg
223547472|NCT04883255|DRUG|600 mg cannabidiol (CBD)|5-day course of orally-administered CBD, 600 mg
223547473|NCT04883255|DRUG|Placebo|5-day course of orally-administered placebo
223547474|NCT01326299|OTHER|Carbohydrate placebo|dissolve in water and consume with meal
223547475|NCT01326299|OTHER|Nutritional ingredient|Dissolve in water and consume with meals
223547476|NCT01326299|OTHER|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
223547477|NCT01326299|OTHER|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
223730631|NCT01680523|PROCEDURE|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
224138583|NCT06289842|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
223547478|NCT01326299|OTHER|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
223547479|NCT06332586|BEHAVIORAL|Diversified teaching|Diversified teaching (read and jointly mark the key points of the triage diagnosis teaching manual and read the TMS online course at any time, 1 triage diagnosis seminar/quarter, interactive teaching) for triage diagnosis nurses
223547480|NCT03381287|DRUG|HTD1801 Tablets, 500 mg|500 mg/day (250 mg BID)
223547481|NCT03381287|DRUG|HTD1801 Tablets, 1000 mg|1000 mg/day (500 mg BID)
223547482|NCT03381287|DRUG|HTD1801 Tablets, 2000 mg|2000 mg/day (1000 mg BID)
223547483|NCT03381287|DRUG|Placebo to match 500 mg HTD1801|2 tablets/day (1 tablet BID)
223547484|NCT03381287|DRUG|Placebo to match 1000 mg HTD1801|4 tablets/day (2 tablet BID)
223547485|NCT03381287|DRUG|Placebo to match 2000 mg HTD1801|8 tablets/day (4 tablet BID)
223547486|NCT03261921|DRUG|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
223547487|NCT03261921|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
223547488|NCT03261921|DRUG|Bupivacaine|local anesthetic agent
223547489|NCT05809427|DEVICE|Periodontal probing|"Imaging/Scanning and recording : Ultrasonic periodontal probing per operator (10 teeth X 6 sites/teeth = 60 probing sites per operator). In addition, 2 teeth per patient will be probed with the ultrasonic probe a second time (2 teeth x 6 sites per tooth = 12 sites per patient) for intra-operator reproducibility purpose.~Manual probing per operator with the OMS probe (part of the routine of care)"
223547490|NCT06460870|OTHER|Mojzisova method|The home based regular exercises stretching and strengthning exercises twice daily along with hot pack. Manual therapy was applied in the first half of the menstrual cycle, once a month, for one hour. It includes mobilization of ribs, lumbar spine, and sacroiliac joints as well as coccygeal treatment, and internal rectal work. The patient was received 2 sessions per month for 3 months, for 45 minutes.
223547491|NCT06460870|OTHER|Stretching exercises|Stretching exercises was performed such as cobra pose, cat/cow pose and baby pose along with hotpack for 2 sessions per month for 45 min for 3 months.
223392141|NCT03104192|DIETARY_SUPPLEMENT|Develop & Refine MOWI w Fitbit/Protein|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
223392142|NCT06295172|DEVICE|Lafullen15|Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
223392143|NCT06295172|DEVICE|Lafullen|Apply a maximum of 1.0 ml for each side of the nasolabial fold using both the test device (Lafullen15) and the control device (Lafullen).
223392144|NCT01571323|DRUG|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
223392145|NCT01571323|DRUG|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
223392146|NCT01571323|DRUG|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
223392147|NCT02792517|DRUG|Erenumab|A single dose of erenumab administered in the abdomen.
223392148|NCT02792517|DRUG|Ethynil Estradiol/Norgestimate Oral Contraceptive|Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
223392149|NCT02931864|OTHER|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
223547492|NCT02398201|DRUG|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
223547493|NCT03654274|DRUG|Relugolix|Relugolix 40-mg tablet administered orally once daily
223547494|NCT03654274|DRUG|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
223547495|NCT03359369|DIAGNOSTIC_TEST|level of serum cholesterol and triglyceride|other
224012548|NCT02139293|DEVICE|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
224012549|NCT00551590|DRUG|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
224012550|NCT00551590|DRUG|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
224012551|NCT00551590|DRUG|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
224012552|NCT00551590|DRUG|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
224012553|NCT01084837|DRUG|velcade|"INDUCTIoN (Cycles 1-4)~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~* Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~* Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
224012554|NCT00834626|PROCEDURE|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
224012555|NCT04613232|DEVICE|Wearable sensor|The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
224012556|NCT04330924|OTHER|Create Real-life Experience And Teamwork In Virtual Environment (CREATIVE)|3D virtual hospital environment where participants can perform physical and social interaction and presence using avatars.
223392150|NCT02931864|OTHER|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
223392151|NCT04784091|DRUG|TP-03|TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
223392152|NCT04784091|DRUG|TP-03 Vehicle|Vehicle of TP-03 ophthalmic solution, administered twice a day
223392153|NCT03243110|DIAGNOSTIC_TEST|breathing test|Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
223392154|NCT05221541|PROCEDURE|vibration|whole-body vibration and soleus tendon vibration will be applied to participants
223392155|NCT05642871|RADIATION|DKI and APT|DKI and APT in patients with ovarian malignancy before and after treatment
223392156|NCT04712344|BIOLOGICAL|COVID-19 convalescent plasma|Infusion of a total of three units of COVID-19 convalescent plasma administered on three separate occasions during Day 1 and Day 2 in Addition to standard treatment.
223392157|NCT00793962|RADIATION|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
223392158|NCT00793962|RADIATION|conventional fractionation radiotherapy|50Gy/25/f/5w
223547496|NCT05086965|OTHER|Playing the virtual game simulation|The virtual game simulation developed by the researchers and designed by the researchers will be played on the computer for the students of the intervention group. Virtual game simulations are virtual games developed by researchers, specific to a clinical scenario, and prepared by transferring the videos taken with an action camera to the computer environment and displaying them in two dimensions.
223547497|NCT02544347|OTHER|gingival crevicular fluid|gingival crevicular fluid was collected
223547498|NCT02544347|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
223547499|NCT02276742|BEHAVIORAL|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
223547500|NCT02276742|OTHER|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
223547501|NCT05005273|DRUG|Nivolumab|Specified dose on specified days
223547502|NCT05005273|DRUG|Ipilimumab|Specified dose on specified days
223547503|NCT05005273|DRUG|BMS-986207|Specified dose on specified days
223547504|NCT05005273|OTHER|Placebo|Specified dose on specified days
223547505|NCT02612493|OTHER|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
223392159|NCT01144065|PROCEDURE|Hair sampling for the measurement of cortisol and testosterone|Hair sampling for the measurement of cortisol and testosterone
223392160|NCT00856193|DRUG|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
223547506|NCT05011175|OTHER|Survey|Participants responded to questions about their exercise habits and perceived levels of intensity as well as demographic information.
223547507|NCT04972266|DEVICE|AcumenTM Hypotension Prediction Index software|The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.
223547508|NCT01471821|DRUG|antiretroviral treatment|antiretroviral treatment
223547509|NCT05409703|BEHAVIORAL|reiki therapy|reiki therapy for nurses
223547510|NCT06376864|BEHAVIORAL|Activity Breaks|The Activity Breaks intervention is a 5-minute Activity Breaks programme that allows classroom teachers of all ages and ability levels to lead simple movement activities within their classrooms, negating the need for additional personnel or space.
223547511|NCT06619899|OTHER|PAP exercise with 0% body mass|The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass.
223547512|NCT06619899|OTHER|PAP exercise with 20% body mass|Description: The participants will perform 6 x 30m sprints. Before each sprint they will perform 2 x 4 countermovement jumps with 0% body mass
223547513|NCT06619899|OTHER|No PAP exercise|No PAP exercise will be performed. The participants will perform only 6 x 30m sprints.
223547514|NCT05750108|DEVICE|Parasym device (active, current (mA) < discomfort threshold)|Active transcutaneous Vagal Nerve Stimulation (tVNS) (Parasym device, Parasym Health, Inc, London, UK) will be performed with a clip attached to the ear at 20 hertz (Hz), 250 microseconds (ms) at a current just below discomfort threshold for 30 minutes twice a day, starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
223547515|NCT05750108|DEVICE|Parasym device (sham, current (mA) = 0)|Parasym device will be attached to the ear twice a day, turned on but current set to 0 milliamp (mA), starting on post-MI day 0. Stimulation will continue until 7 days post-MI or discharge.
223547516|NCT06116981|OTHER|High Induction Magnetic Field Therapy|High Induction Magnetic Field Therapy is a method that has no side effects, is non-invasive and easy to apply, and is used to increase circulation in tissues.
223392161|NCT00856193|DRUG|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
223392162|NCT00794690|DRUG|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
223392163|NCT01585974|OTHER|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
223392164|NCT01186068|DRUG|V-101|Cream QD
223392165|NCT01186068|OTHER|vehicle|Cream QD
223392166|NCT04936763|DEVICE|Janesse 20 (Cross-linked Hyaluronic Acid)|Janesse 20 will be administered at baseline (visit 2, day 0) and, if the Investigator will evaluate necessary, also at day 30 (visit 3). The Investigational device will be injected with retrograde technique (moving backward) with homogeneous amount on the length of each side of Labia Majora. The Janesse 20 dosage administered will be 1 ml in left labia and 1 ml in right labia for each session.
223392167|NCT01227473|BEHAVIORAL|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
223392168|NCT01227473|BEHAVIORAL|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
223392169|NCT06577961|DRUG|Vorolanib|stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD
223392170|NCT06577961|DRUG|cadonilimab|stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W
223547517|NCT06116981|OTHER|Conservative Treatment|Shoulder exercises, transcutaneous electrical nerve stimulation, stretching.
223547518|NCT06714942|DIETARY_SUPPLEMENT|Proprietary Blend of Ashwagandha|One capsule (300mg) is taken twice daily with water
223547519|NCT06714942|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha root extract|One capsule (300mg) is taken twice daily with water
223392171|NCT05115851|OTHER|Anodal tDCS cerebellar stimulation group|three-session ctDCS (2 mA, 20 min). The active (anode) and the returning (cathode) electrodes will be placed bilaterally over the cerebellum (1 -2 cm below inion of occipital bone) and the right buccinator muscle, respectively xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
223392172|NCT05115851|OTHER|Anodal tDCS cerebral (M1) stimulation group|three-session a-tDCS (2 mA, 20 min), the anode will be positioned over the lesioned M1 (C3, International 10-20 system) and the cathode would be located over the supraorbital area. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
223392173|NCT05115851|OTHER|Sham Group|three-session a-tDCS (2 mA, 20 min), Sham tDCS followed a similar protocol as Anodal tDCS cerebral (M1) stimulation and arrangement but stimulation for 30 s, after which the current was ramped-down and turned off for the rest of the treatment. xbox kinect based balance and mobility training using games from Xbox Adventure Pack for 50 mins.
223730632|NCT01680523|RADIATION|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
223730633|NCT01680523|RADIATION|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
223392174|NCT01946620|DRUG|Flutiform|
223392175|NCT01946620|DRUG|Formoterol|
223392176|NCT06445738|RADIATION|Arm A: Radiotherapy Omission|Omission of radiotherapy based on pre-surgical MRI and pathology findings at surgery.
223392177|NCT06445738|OTHER|Arm B: Standard Treatment|Ineligible for RT omission on study; includes management of MRI-detected lesions.
223392178|NCT00137150|PROCEDURE|Placement of implants|
223547520|NCT06714942|DIETARY_SUPPLEMENT|Placebo|One capsule (300mg) is taken twice daily with water
223547521|NCT06716853|GENETIC|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
223547522|NCT06716853|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks commencing at D+30
223547523|NCT06716853|DRUG|Cabozantinib|40mg QD once PD occurs as assessed at D+30 or at subsequent visits
223547524|NCT06716762|PROCEDURE|Open Surgery|Open cyst excision and Roux-en-Y hepaticojejunostomy performed through a 10 cm incision
223547525|NCT06716762|PROCEDURE|Laparoscopic Surgery|Laparoscopic cyst excision and Roux-en-Y hepaticojejunostomy performed through small incisions with a laparoscope
223547526|NCT06717620|BEHAVIORAL|Body composition before and after exams|Measurement of body composition, eating habits, physical exercise in the same group of students before and after the exams
223547527|NCT06719323|BEHAVIORAL|Family Walking Instruction with Support by Heart (Family WISH) program|Researchers will compare the 12-week Family WISH program, based on self-efficacy theory, to a comparison group receiving a family walking health education sheet to evaluate the long-term effectiveness of the Family WISH program.
224012557|NCT03934138|OTHER|Educational movie on placebo mechanisms|"Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)"
224012558|NCT03934138|OTHER|Informative movie on hand washing|Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
224012559|NCT04107987|DIETARY_SUPPLEMENT|Reglicem|Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
223392180|NCT04488341|OTHER|aerobic exercises in addition to diet recommendations|aerobic exercises time of session 40-50 min initial 10 min warm up exercises on treadmill in low intensity and active phase 20- 30 min intensity will increase until patient reach to target heart rate then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks
223392181|NCT04488341|OTHER|diet recommendations|control group will receive diet recommendations for 12 weeks
223547528|NCT06719323|BEHAVIORAL|Comparison group|a family walking health education sheet received
223730634|NCT04537507|PROCEDURE|Coronary angiography|
224012560|NCT04107987|OTHER|Placebo|Placebo
223392182|NCT01754155|RADIATION|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
223392183|NCT06966817|DRUG|control group(chlorhexidine)|The sponge swab is dipped in 0.25% chlorhexidine solution and used once for each part of the mouth, 4 times a day to provide oral care.
223392184|NCT06966817|DRUG|Experimental Group(cetylpyridinium chloride)|The mouth is cleaned by dipping a sponge swab into 0.05% cetylpyridinium chloride solution and using it once for each part of the mouth, 4 times a day.
223392185|NCT02741726|DEVICE|acupoint stimulation|Electric stimulation was given through electrode attached to acupoints
223392186|NCT02741726|DEVICE|no stimulation|patients were only attached electrodes without electric current
223392187|NCT06668168|DIETARY_SUPPLEMENT|Ketone Monoester (KE)|25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate\].
223392188|NCT06668168|BEHAVIORAL|Ketogenic diet|Ketogenic diet (\<50 g carbohydrate per day)
223392189|NCT05966506|BEHAVIORAL|Dyad-based Zoom health coaching|This will be delivered by a certified nurse coach, certified in holistic nursing who will provide 6 sessions of Zoom health coaching over 12 weeks to dyads, biweekly (weeks 1, 3, 5,7, 9 \&11) for 45 minutes
223547529|NCT06718829|OTHER|Core Stability Exercises|Patients will perform core stability exercises three times weekly for eight weeks. The exercises include abdominal hollowing, bridge, right-angle leg lifts with thigh press, seated twist, knee-to-chest with elbow flexion, prone abdominal hollowing, prone arm and leg lift, quadruped abdominal hollowing, quadruped arm or arm-leg lifts, and various plank positions: forearm plank, side plank, forearm plank with hip raise, and forearm plank with straight legs.
223547530|NCT06718829|OTHER|Sensorimotor Training Exercises|Patients will perform sensorimotor training exercises three times weekly for eight weeks, progressing through three phases: static (weeks 1-2), dynamic (weeks 3-4), and functional (weeks 5-8). Exercises, repeated 3-5 times per session with rest intervals, advance from simple to complex as patients master each level. Static exercises include standing on firm/soft surfaces and single-leg balances. Dynamic exercises add forward lunges and T-band kicks. Functional training incorporates walking on various surfaces, toe and heel skipping, squats, balance drills on wobble boards, and multidirectional rolling movements with visual and single-leg variations. This progression enhances coordination, balance, and functional stability.
223547531|NCT06718829|OTHER|Traditional physical therapy program|All patients will undergo a traditional physical therapy program consisting of stretching exercises, strengthening exercises, and scar management techniques, three times weekly for eight weeks.
223547532|NCT06717529|OTHER|Sodium hyaluronate (hyaluronic acid)|The patient will receive one 3mL Sodium Hyaluronate injection containing 75 mg of active substance in one knee joint.
223730635|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin|Augmentation of horizontal deficient anterior maxilla using the conventional protocol of cortical shell technique
223392190|NCT05966506|BEHAVIORAL|Fitbit activity monitor|"Participants will be instructed to use the Fitbit to monitor their partners' PA in addition to their own. All participants will be instructed to friend their health coach to enable real-time monitoring of PA to inform coaching zoom calls. The Fitbit will provide feedback on steps, active minutes, and calories burned. Participants will be asked to wear the device on most days and while they sleep."
223392191|NCT05966506|OTHER|Electronic newsletters|Newsletters will be sent twice monthly during months 1-3 via email or text with an online link. Newsletters will be designed to share educational PA-related information from publicly available resources. Newsletters will also contain tips for overcoming barriers to PA ,finding time to exercise, low-cost ways to be active and being active with kids.Newsletters will also contain links to brief exercise routines that participants can do in their homes and information on low cost/free exercise classes in the community, which may help to overcome perceived access barriers
223392192|NCT03994172|DRUG|Teriparatide or human parathyroid hormone (PTH) 1-34|Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
223392193|NCT03994172|DRUG|Cinacalcet|This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
223730636|NCT05311332|PROCEDURE|Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin using patient specific surgical guide then positioned with another guide|using a patient-specific surgical guide to harvest bone cortical shell from the chin and another patient-specific surgical guide to fix it in the atrophied maxillary anterior area
223730637|NCT01894165|DRUG|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
223730638|NCT01894165|DRUG|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
223392194|NCT03994172|DRUG|placebo tablet|The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
224012561|NCT02704754|DRUG|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
224012562|NCT02704754|OTHER|placebo|Pill with inactive ingredients
224012563|NCT01048554|DRUG|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
224012564|NCT01048554|DRUG|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
223392195|NCT03994172|DIETARY_SUPPLEMENT|Calcium citrate tablet|Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal \~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
223547533|NCT06717529|DRUG|Methylprednisolone Acetate Injection|The patient will receive 2mL of methylprednisolone acetate solution containing 80 mg of the medicine in other knee joint.
223547534|NCT06719388|BEHAVIORAL|combination of exercise therapy and a jaw-mobilizing device|Participants in the experimental group will receive a combination of exercise therapy and a jaw-mobilizing device. The intervention includes structured exercise therapy sessions and the use of the jaw-mobilizing device for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
223547535|NCT06719388|BEHAVIORAL|exercise therapy only|Participants in the control group will receive exercise therapy only. This intervention involves the same structured exercise therapy sessions as the experimental group for 12 weeks, beginning one week prior to radiotherapy. Follow-ups will occur at weeks 16, 24, and 36 to assess outcomes.
223547536|NCT06719310|DRUG|ACC017+FTC/TAF|ACC017+FTC/TAF
223547537|NCT06719310|DRUG|Placebo|Placebo
223547538|NCT06719193|COMBINATION_PRODUCT|Enhanced community-wide TB intervention|"Interventions in the intervention arms consist of the following key components:~1. an optimized national recommended set of interventions; such as the implementation of all types of contact investigation, targeted TB screening and diagnosis at key affected population, and optimized HIV screening and TPT for PLHIV;~2. intensive, active, and community-based HH screening and diagnosis of TB using combined TB screening (clinical and X-ray) and X-pert MTB/RIF, as indicated;~3. community-based enhanced TPT; and~4. community-based awareness creation and health education using the community social associations."
223547539|NCT06719193|COMBINATION_PRODUCT|Routine TB program activities|In the control arm, the standard of care will continue per the national guideline.
223547540|NCT06718842|BEHAVIORAL|walking free online supervised program|this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)
223547541|NCT06714903|OTHER|treatment option-sintilimab plus fruquintinib|sintilimab plus fruquintinib
223547542|NCT06714903|OTHER|treatment option-fruquintinib alone|fruquintinib alone
223547543|NCT06719206|BEHAVIORAL|Digital self-management program|The program consists of commercially available technologies, e.g. applications including behavour change techniques for reducing sedentary behavior (SB) (i.e. self-monitorization of physical activity, reminders for breaking SB/doing physical activity, and providing feedback on physical activity/breaks from SB) and a webpage containing information and tips (provided in short videos and text) regarding how to reduce SB. The participants will be receive help with setting goals for reducing time spent in sedentary/being active and help with planning for what activities to do to replace time in sedentary. Participants will then have access to the webpage and download the application to their smartphones. Follow-up meetings with the physiotherapist (digital or physical) will be conducted after 2, 8 and 12 weeks after start of intervention.
224127604|NCT05965336|OTHER|Plantar Pressure Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For plantar pressure biofeedback, a visual display of a foot with a colored heat map represents the current plantar pressure, in addition to bar graphs representing real-time movement of plantar pressure in specific areas of the foot. A target is provided using the heat map colors of red and target line on the bar graph. Participants are informed that the target is a measurement of the pressure under their foot, and their goal is to decrease pressure to achieve their target.
223547544|NCT06715176|OTHER|Clinical periodontal measurements at baseline (T0)|Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.
223547545|NCT06715176|OTHER|Saliva collection at baseline (T0)|Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.
223547546|NCT06715176|OTHER|Scaling and root planing|Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.
223547547|NCT06715176|OTHER|Clinical periodontal measurements at T1, T3, and T6.|Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
223547548|NCT06715176|OTHER|Saliva collection at T1, T3, and T6.|Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
223547549|NCT06714994|DEVICE|free spectacles|Children will receive free spectacles
224127605|NCT05965336|OTHER|Propulsion Biofeedback Gait Training|Participants will complete a 3-dimensional gait evaluation prior to training, after a 6-minute control bout without biofeedback, and following three 6-minute biofeedback training bouts (total 18-minutes). Individualized biofeedback targets will be calculated from each participant's immediate biofeedback session to best minimize plantar pressure whilst maintaining or enhancing propulsion. Audio-visual biofeedback is provided using a screen placed in front of the treadmill and a speaker. For propulsion biofeedback, a visual display with a marker represents the current propulsion (peak AGRF) and a target provided to modulate propulsion. Participants are informed that the marker is a measurement of how hard they are pushing the ground backward, and their goal is to push-off more to achieve their target.
224127606|NCT04315376|BEHAVIORAL|Exercise-Diet Intervention|The participants who performed exercise-diet intervention performed an Astrand-rhyming test before and after the exercise program intervention. Participants followed a progressive exercise-program during four months according to initial physical fitness. The main exercises consisted of improving aerobic, speed and resistance performance. During all single sessions, breathlessness and fatigue were measured using 0 to10 Borg scale. A personal trainer certified by American College of Sports Medicine (ACSM) supervised three sessions per week, the other two unsupervised training days the subjects were given the detailed training program to do in house/park. And also, this group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
224127607|NCT04315376|BEHAVIORAL|Diet Intervention|This group received a diet intervention that consisted of a 20 percentage reduction of total energy expenditure estimated by the Mifflin formula with a nutrients distribution as follows: 50% carbohydrates, 30% lipids, and 20% proteins.
224127608|NCT00001019|BIOLOGICAL|rgp120/HIV-1 SF-2|
224127609|NCT00001019|BIOLOGICAL|MTP-PE/MF59|
224127610|NCT05226819|DRUG|PPI quadruple therapy|Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
224127611|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
224127612|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
224127613|NCT00755690|BEHAVIORAL|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
224127614|NCT03272945|PROCEDURE|Linked-color imaging|Linked-color imaging colonoscopy
224127615|NCT00004993|DRUG|Parathyroid hormone (hPTH 1-34)|
224127616|NCT04891770|DRUG|Tenofovir Alafenamide|Administered as film-coated oral tablets
224127617|NCT04891770|DRUG|VIR-2218|Administered as a sub-cutaneous (SC) injection
224127618|NCT04891770|DRUG|Nivolumab|Administered intravenously
224127619|NCT04891770|DRUG|Selgantolimod|Administered as film-coated oral tablets
224127620|NCT00284778|DRUG|Alimta®|
224127621|NCT00284778|DRUG|Taxotere®|
223392196|NCT03994172|DIETARY_SUPPLEMENT|Vitamin D3|Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
223392197|NCT03674697|DEVICE|Green LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
224127622|NCT06371872|PROCEDURE|total transfixing injury to the rotator cuff|develop an appropriate prescription strategy with a view to improving patients' quality of life in the short, medium and long term in this condition
224127623|NCT06169592|PROCEDURE|Liver transplantation|Related transplantation of the right lobe of the liver
224127624|NCT06973005|DRUG|AZD2389|Oral dose on Days 5 to 13, Day 16, and Day 17. On Day 14 co-administered with a combination of midazolam and caffeine. On Day 15 co-administered with bupropion.
224127625|NCT06973005|DRUG|Midazolam|"Single oral dose on:~* Day 1 (co-administered with caffeine)~* Day 14 (co-administered with caffeine and AZD2389)"
224127626|NCT06973005|DRUG|Caffeine|"Single oral dose on:~* Day 1 (co-administered with midazolam)~* Day 14 (co-administered with midazolam and AZD2389)"
224127627|NCT06973005|DRUG|Bupropion|"Single oral dose on:~* Day 2 (alone)~* Day 15 (co-administered with AZD2389)"
224127628|NCT04725370|OTHER|NA - survey instrument|Survey instrument was administered verbally to parents of the Guatemalan cohort.
224127629|NCT04819100|DRUG|Selpercatinib|Administered orally.
224127630|NCT04819100|DRUG|Placebo|Administered orally.
223547550|NCT06714695|DRUG|Chitosan|chitosan mouthwash
224127631|NCT06036927|DRUG|TQC2731 injection|TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.
224127632|NCT06036927|DRUG|TQC2731 matching placebo|It'a a placebo injection without active substances.
224127633|NCT00551824|DRUG|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
224127634|NCT01542476|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
224127635|NCT00837512|DEVICE|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
224127636|NCT00837512|DEVICE|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
224127637|NCT06973096|DRUG|CART-EGFR-IL13Ra2 cells|autologous T cells transduced with a bicistronic lentiviral vector containing a murine scFv targeting EGFR epitope 806 and a humanized scFv targeting IL13Ra2; both scFvs are fused to the 4-1BB and CD3ζ signaling domains.
224127638|NCT06180278|OTHER|Blood tests|Participants will have blood tests done at each scheduled visit (approximately every 6 months).
224127639|NCT06180278|DRUG|Inebilizumab|Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
224127640|NCT06621979|PROCEDURE|Bypass surgery type one anastomosis gastric bypass|Adult patients who have undergone single-anastomosis gastric bypass followed by fundoplication of the excluded stomach for the treatment of disabling post-bypass gastroesophageal reflux, resistant to medical treatment and requiring surgical intervention.
224127641|NCT06131346|OTHER|Evaluation of clinical and paraclinical data.|Retrospective data collection from available medical files of patient.
224127642|NCT01113021|DEVICE|Photon stimulation by low level laser therapy|
224127643|NCT00100412|DRUG|Graded dobutamine infusions|
224127644|NCT00100412|DRUG|Graded phenylephrine injections|
224127645|NCT00100412|BEHAVIORAL|Psychosocial challenge involving socioevaluative public speaking|
224127646|NCT00235651|DRUG|Amphotericin B|
224127647|NCT03217578|OTHER|SMA Newborn Screening|
224127648|NCT02843373|DEVICE|TMS|
224127649|NCT01125176|DRUG|thalidomide|50 mg oral dosing every other day
224127650|NCT01125176|DRUG|lenalidomide|varying oral doses every other day (max 25 mg/day)
223547551|NCT06719297|OTHER|Personalized cognitive-sensorimotor VR/MR training|Thinking task integrated walking and balance training program
224127651|NCT01125176|BIOLOGICAL|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
224127652|NCT01096082|DRUG|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
224127653|NCT01096082|DRUG|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
224127654|NCT05155696|DIETARY_SUPPLEMENT|Experimental: Kefir probiotic drink (supplied by Nourish)|125ml per day of dairy based probiotic drink (Kefir) containing ≥ 50billion colony forming units (CFU), supplied in plain packaging.
224127655|NCT05155696|DIETARY_SUPPLEMENT|Placebo comparator|125ml of non-fermented dairy based placebo (UHT milk) per day, supplied in plain packaging.
224127656|NCT04576637|PROCEDURE|Neurophysiological monitoring during intubation|In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
223392198|NCT03674697|DEVICE|White LED light therapy|You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
224012565|NCT03636282|BEHAVIORAL|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
224127657|NCT04058054|DEVICE|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
224127658|NCT04058054|DEVICE|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
224127659|NCT04058054|DEVICE|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
224127660|NCT04058054|DRUG|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
224012566|NCT02596438|OTHER|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
224012567|NCT04639271|DRUG|Pyrotinib Plus And|Pyrotinib::400mg/d,qd,po
224127661|NCT04058054|DRUG|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
224127662|NCT02290054|PROCEDURE|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
224127663|NCT02290054|PROCEDURE|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
224127664|NCT02290054|PROCEDURE|Intra-venous anesthesia|
224127665|NCT01082718|DRUG|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
224127666|NCT03577093|OTHER|There is no intervention at all.|There is no intervention at all.
223392199|NCT05264025|DRUG|Fexofenadine|tablet
223392200|NCT05264025|DRUG|Placebo|tablet
223547552|NCT06719297|OTHER|Standard of Care|Standard walking and balance training
223547553|NCT06715189|DIAGNOSTIC_TEST|serum Adiponectine and Resistin|corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
224127667|NCT04599205|DRUG|Tranexamic acid|fractional co2 laser, microneedling and topical tranexamic acid gel
224127668|NCT04051021|BEHAVIORAL|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
224127669|NCT04051021|OTHER|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
224127670|NCT00450203|BIOLOGICAL|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
224127671|NCT00450203|DRUG|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
224127672|NCT00450203|DRUG|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
224127673|NCT00450203|DRUG|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
223547554|NCT06715189|DIAGNOSTIC_TEST|fibroscan|hepatic fibrosis detection in type 2 diabetes mellutis
223547555|NCT06716554|DIETARY_SUPPLEMENT|Shatavari extract|Shatavari is scientifically known as Asparagus racemosus. One capsule containing Shatavari 300mg should be taken once daily.
224127674|NCT00450203|PROCEDURE|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
224127675|NCT00450203|PROCEDURE|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
224127676|NCT00450203|PROCEDURE|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
224127677|NCT00450203|DRUG|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
224127678|NCT02426242|OTHER|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
224127679|NCT00222729|DRUG|Pemetrexed|500 mg/m2 day 1 q 21 days
223392201|NCT04025398|BEHAVIORAL|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
223392202|NCT04025398|BEHAVIORAL|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
223547556|NCT06716554|DIETARY_SUPPLEMENT|Shatavari + Ashwagandha extract|Shatavari is scientifically known as Asparagus racemosus along with Ashwagandha root extract scientifically known as Withania somnifera. One capsule containing Shatavari 300mg + Ashwagandha root extract 250mg should be taken once daily.
223547557|NCT06716554|DIETARY_SUPPLEMENT|Placebo|Placebo (starch)
223547558|NCT06717737|BEHAVIORAL|Control group： Maintaining old exercise habits|The control group will maintain their original daily habits without any intervention behaviors for them
224127680|NCT00222729|DRUG|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
224127681|NCT00515008|BEHAVIORAL|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
224127682|NCT00515008|BEHAVIORAL|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
224127683|NCT03634605|PROCEDURE|Chemical pleurodesis|
224127684|NCT03634605|DRUG|Tetracycline Topical Ointment|
224127685|NCT03634605|DRUG|Normal saline|
224296498|NCT00605865|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
223392203|NCT03627988|OTHER|Patients with invasive breast cancer will receive:|"* Mastectomy with Immediate prosthetic breast reconstruction~* Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
223547559|NCT06717737|BEHAVIORAL|Intervention group：Conducted a 6-month team training intervention|"Spanning six months, the program incorporated aerobic training, resistance training, and functional exercises essential for rescue operations. Each training session was led by certified professionals who emphasized adherence to safety protocols and provided real-time feedback.~Central to the training process was the significance of teamwork and mutual support, with sessions conducted in small groups focused on shared objectives. This framework fostered a collaborative environment that promoted peer support and motivated participants to actively engage in their fitness regimen. The group setting enabled firefighters to encourage one another and share individual progress, thereby enhancing their sense of responsibility and belonging."
224127686|NCT03634605|DRUG|Lidocaine 2% Injectable Solution|
224127687|NCT01011881|OTHER|pleural level of procalcitonin|no intervention
224127688|NCT01809561|PROCEDURE|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
224127689|NCT04266860|OTHER|Experimental - Test Results and Education|"First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case."
224127690|NCT00870272|DRUG|Misoprostol|400mcg misoprostol taken sublingually or buccally
224127691|NCT03671759|BEHAVIORAL|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
223392204|NCT04028557|OTHER|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
223392205|NCT05119257|BIOLOGICAL|Bispecific antibodies (bsAB)|BsAbs equipped with a target-specificity directed to a TAA and an effector-specificity for an activating receptor on T cells, such as CD3 or CD28, are applied intravenously in repeated cycles until disease progression or dose limiting toxicity.
223547560|NCT06715202|PROCEDURE|Patient Education Booklet|Before the surgery, a personal information form and the SF-36 Quality of Life Scale will be filled out. The educational content regarding the problems that these patients may encounter with the DJ stent after the surgery until they are discharged will be explained in sections and the patients' questions will be answered. When the patient comes to the hospital for DJ stent removal 4 weeks after discharge, the Ureteral Stent Symptom 1st Questionnaire and the SF-36 Quality of Life Scale will be filled out while the DJ stent is in place. The Ureteral Stent Symptom 2nd Questionnaire and the SF-36 Quality of Life Scale will be applied 4 weeks after the stent is removed. The education booklet will be prepared by the researchers in accordance with the recommendations of the European Association of Urology and the relevant literature.
224012568|NCT04639271|DRUG|Trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle
223547561|NCT06717724|DRUG|Periarticular Procaine Injection (PAPI)|Participants will receive periarticular 5 ml procaine injections targeting painful joints for 10 consecutive days alternating between knee- and/or hip joints
223547562|NCT06717724|OTHER|Kinesiotherapy|Kinesiotherapy
223547563|NCT06716476|DRUG|Vitamin D|Supplemental with Vitamin D 4000 IU
224012569|NCT04639271|DRUG|Abraxane|Abraxane 125mg/M2, qw iv
224012570|NCT03464799|OTHER|immunohistochemical staining|immunohistochemical staining
224012571|NCT02997943|BEHAVIORAL|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
224012572|NCT02997943|BEHAVIORAL|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
224012573|NCT02997943|BEHAVIORAL|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
224012574|NCT02997943|BEHAVIORAL|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
224012575|NCT01327859|DRUG|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
224012576|NCT01327859|DRUG|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
224012577|NCT01327859|DRUG|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
224127692|NCT03671759|BEHAVIORAL|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
224127693|NCT01798706|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
224127694|NCT01798706|DRUG|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
224127695|NCT01798706|DRUG|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
224127696|NCT02124187|DEVICE|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
224127697|NCT02124187|DEVICE|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
224127698|NCT02124187|DEVICE|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
224127699|NCT01284179|BEHAVIORAL|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
224012578|NCT02233452|DRUG|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
224012579|NCT02233452|DRUG|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
224012580|NCT02233452|DRUG|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
224012581|NCT04288609|OTHER|Intendu|Cognitive remediation using VR adaptive platform for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
224012582|NCT04288609|OTHER|Paper and Pencil cognitive remediation training|Cognitive remediation using paper and pencil tasks for response inhibition, self-initiation, cognitive flexibility, sustained attention, divided attention, working memory, planning, persistence.
224012583|NCT02535429|OTHER|massage|
224012584|NCT04397991|OTHER|Furosemide|Patients will receive nebulised furosemide solution 1 mg/kg
224012585|NCT04397991|OTHER|Placebo|Patients will receive nebulised 0.9% saline
224012586|NCT01417143|DRUG|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
224012587|NCT00657020|DRUG|Nicotine|Nicotine lozenge containing 4 mg of nicotine
224012588|NCT00657020|DRUG|Placebo|Placebo lozenge
224012589|NCT03095690|OTHER|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
224012590|NCT04725786|OTHER|thoracic echography|The research intervention corresponds to the performance of a thoracic echography to diagnose an incipient pulmonary interstitial syndrome.
224012591|NCT06148363|DEVICE|High-Definition transcranial Direct Current Stimulation (HD-tDCS)|tDCS, or Transcranial Direct Current Stimulation, is a non-invasive brain stimulation technique that involves applying a small, constant direct current through electrodes placed on the scalp to modulate neuronal activity in specific brain regions.
224012592|NCT06148363|DEVICE|sham High-Definition transcranial Direct Current Stimulation (HD-tDCS)|In the sham condition, tDCS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
224012593|NCT05297669|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
224012594|NCT05297669|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours."
224012595|NCT04782336|OTHER|Sample Collection|"Sample Collection - Adult Population:~* Two (2) Nasal AND/OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample~Sample Collection - Paediatric Population:~* Two (2) Nasal OR~* Two (2) Throat Swabs AND/OR~* One (1) Saliva Sample"
224012596|NCT05557513|DEVICE|STANDARD Q COVID-19 Ag Test|"Device Name: STANDARD Q COVID-19 Ag Test Manufactured by SD Biosensor, Inc., Korea~Purpose: To detect COVID-19 (Its manufacture specification sensitivity was at 84.97% and specificity 98.4%)"
224012597|NCT05978973|DIETARY_SUPPLEMENT|Elemental Diet|. Elemental diets contain all daily required vitamins, micronutrients and macronutrients. The ingredients are readily digestible (carbohydrates, amino acids and medium chain fatty acids) and are absorbed within the proximal small bowel. One main disadvantage of elemental diets such as Vivonex is their unpalatability3 which has limited their use.
224127700|NCT01284179|BEHAVIORAL|Educational|Educational recordings regarding FCP and FGIDs.
224127701|NCT05666011|DEVICE|M22 IPL|IPL is an attractive option in the treatment of KP as the provider can utilize cut-off filters to target both melanin for hair removal and erythema with a single device. An added benefit of IPL is the larger crystal size, allowing for efficient coverage of a larger body surface area. IPL has been utilized in the treatment of KP and KP variants, with outcomes showing reductions in both erythema and texture.
224127702|NCT03817593|OTHER|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
224127703|NCT02949765|DRUG|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
224127704|NCT02949765|DIETARY_SUPPLEMENT|Iron-rich diet|
224127705|NCT00496873|DRUG|Cytoxan|600 mg/m\^2 on Day 1 of 21-day cycle.
224127706|NCT00496873|DRUG|Nipent|4 mg/m\^2 on Day 1 of 21 Day Cycle.
224127707|NCT00496873|DRUG|Rituxan|375 mg/m\^2 on Day 1 of 21 Day Cycle.
224127708|NCT01224912|BEHAVIORAL|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
224127709|NCT04652063|OTHER|Osteopathic Manipulative Medicine|Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
224127710|NCT00942773|DRUG|Voriconazole|
224127711|NCT00096096|DRUG|mycophenolate mofetil|
223392206|NCT03825224|PROCEDURE|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
223547564|NCT06717633|DEVICE|extracorporeal shock wave therapy|The ESWT will be administered using an ESWT device (Modus ESWT Compact Model-Portable) once weekly over three consecutive weeks, resulting in a total of three sessions. A radial shockwave mode was chosen for the therapy. During each session, participants will receive 3000 pulses at an 12-Hz frequency and pneumatic pressure of 2.5 bars
223547565|NCT06717633|DEVICE|low-level laser therapy|The MLS (Multiwave Locked System) laser is a specific type of low-level laser therapy (LLLT) that combines two different wavelengths of light-typically 808 nm (near-infrared) and 905 nm (mid-infrared)-to produce therapeutic effects. These wavelengths are delivered simultaneously in a synchronized manner, which is intended to enhance the overall effectiveness of the treatment. LLLT will be conducted with the laser device (MLS Laser M6 Robotic Multiwave Lock System, Asalaser, Italy) with the use of protective goggles, and the treatment parameters were set as follows: 100% power, 3 Joules per treatment spot with 904 nm wavelength, and a treatment area of 20 cm². The LLLT will be applied to five points on the anterior part of the joint space, with each point treated for 3 minutes, totaling 15 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
223547566|NCT06717633|DEVICE|pulsed electromagnetic field therapy|For PEMF, the applicator of the device (Easy QS Magnetotherapy Portable Magnetotherapy Medical Device, Asalaser, Italy) will be positioned to target the medial and lateral aspects of the knee. The treatment parameters were defined as follows: rectangular field shape, 30 Hz frequency, 10 mT intensity, and a duration of 20 minutes. A total of 8 sessions were applied for 4 weeks, 2 days a week.
224012598|NCT05304052|BEHAVIORAL|Mindfulness Meditation classes|The mindful awareness practices (MAPS) intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes.
224012599|NCT05180188|BEHAVIORAL|Training|In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
224012600|NCT00000632|BIOLOGICAL|Env 2-3|
224012601|NCT05379036|DRUG|prescribing anapproved drug, examination|"* Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months."
224012602|NCT00003601|DRUG|fenretinide|
224127712|NCT00096096|DRUG|tacrolimus|
224127713|NCT02826044|DRUG|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
224127714|NCT03048240|DEVICE|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
223392207|NCT05481710|DIAGNOSTIC_TEST|Nociplastic Pain Criteria|All participants will be assessed with the specific nociplastic pain criteria
223392208|NCT03348618|BIOLOGICAL|IVIG|Intravenous immunoglobulin
223392209|NCT02766335|DRUG|Docetaxel|Given IV
223392210|NCT02766335|BIOLOGICAL|Durvalumab|Given IV
223392211|NCT02766335|OTHER|Laboratory Biomarker Analysis|Correlative studies
223392212|NCT00501995|DRUG|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
223547567|NCT06719154|DEVICE|Profhilo Structura|2 injections (30 days apart) of investigated medical device into superficial fat compartments of zygomatic arch and preauricular area
223547568|NCT06719154|OTHER|Sham (No Treatment)|Sham (No Treatment)
224012603|NCT00003601|DRUG|tretinoin|
224012604|NCT05366101|DRUG|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
224012605|NCT05366101|BEHAVIORAL|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
224012606|NCT03178643|DRUG|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
224127715|NCT03048240|DRUG|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
223392213|NCT04859452|DRUG|DBPR108 tablets|Drug: DBPR108, tablet, oral
223392214|NCT04859452|DRUG|Metformin hydrochloride tablets|Drug: Metformin hydrochloride, tablet, oral
223392215|NCT04859452|DRUG|Glibenclamide tablets|Drug: Glibenclamide, tablet, oral
223392216|NCT04859452|DRUG|Valsartan Capsules|Drug: Valsartan, capsule, oral
223392217|NCT04859452|DRUG|Simvastatin tablets|Drug: Simvastatin, tablet, oral
223392218|NCT02396511|BIOLOGICAL|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
223392219|NCT02396511|BIOLOGICAL|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
223547569|NCT06719115|DIETARY_SUPPLEMENT|UClear|Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
224012607|NCT03178643|DRUG|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
224012608|NCT03178643|DRUG|Dihydroartemisinin-Piperaquine (DP)|"3\) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
224012609|NCT01001338|DRUG|RDEA594|Uricosuric agent for the treatment of gout.
224012610|NCT01001338|DRUG|Placebo|Matching Placebo
224012611|NCT01001338|DRUG|Allopurinol|Allopurinol
224012612|NCT06429644|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery, also known as breast-conserving therapy or lumpectomy, is a surgical procedure used to treat breast cancer while preserving as much of the breast tissue as possible. During this procedure, the surgeon removes the cancerous tumor along with a surrounding margin of normal tissue. The goal is to remove the cancerous cells while maintaining the appearance and function of the breast as much as possible.
224012613|NCT00774930|DRUG|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
224012614|NCT00774930|DRUG|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
224012615|NCT06017843|OTHER|Camps site selection for active case finding for TB using MATCH-AI|The primary intervention in this study is the roll-out of MATCH-AI, an artificial intelligence software that models sub-district TB prevalence, to guide site selection of ACF camps. The MATCH-AI tool uses a Bayesian modelling approach to predict TB prevalence to a resolution of 10,000 population that are mapped as polygons. The model integrates data from a range of sources including historical TB facility notification data, previous ACF data as well as contextual factors such as demographics, income, population density, health indicators such as vaccination coverage and climate related variables to predict localized TB prevalence. In the intervention arm, camps will be conducted primarily in locations guided by MATCH-AI.
224012616|NCT02857569|DRUG|Ipilimumab IT|
224012617|NCT02857569|DRUG|Ipilimumab IV|
224012618|NCT02857569|DRUG|Nivolumab IV|
224012619|NCT01181323|OTHER|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
224012620|NCT01181323|BIOLOGICAL|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
224012621|NCT01181323|OTHER|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
224012622|NCT01181323|BIOLOGICAL|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
224012623|NCT05294601|OTHER|High-Intensity Interval Training|high intensity exercise with games
224012624|NCT05294601|OTHER|Medium-Intensity Interval Training|medium intensity exercise with games
224012625|NCT00766363|DRUG|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
224012626|NCT00766363|DRUG|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
224012627|NCT00766363|DRUG|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
224127716|NCT03238235|DRUG|Givinostat|suspension of Givinostat (10 mg/mL)
224127717|NCT03238235|DRUG|Placebo|suspension manufactured to mimic Givinostat
224012628|NCT00766363|DRUG|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
224012629|NCT00766363|DRUG|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
224012630|NCT00766363|DRUG|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
224012631|NCT02548598|PROCEDURE|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
224012632|NCT00167089|BEHAVIORAL|Treadmill Training|Partian body weight support treadmill training, 30 min/day \* 3 days /week
224012633|NCT02890212|DIETARY_SUPPLEMENT|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
224012634|NCT02890212|DIETARY_SUPPLEMENT|placebo|administration of placebo pills for randomized subjects
223547570|NCT06719115|OTHER|Placebo|Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
224012635|NCT03020576|DEVICE|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
224012636|NCT03020576|OTHER|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
224127718|NCT04194658|DRUG|Letrozole 2.5mg|Pretreatment letrozole 12.5 mg for 2 days prior to misoprostol.
224127719|NCT00271440|PROCEDURE|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
224127720|NCT03342612|PROCEDURE|Brain Magnetic Resonance Imaging (MRI)|
224127721|NCT02018614|OTHER|algoplus|
224127722|NCT00540969|PROCEDURE|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
224127723|NCT00540969|RADIATION|radiation therapy|Patients undergo radiotherapy for 1 week
224127724|NCT02146989|OTHER|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
224127725|NCT00177541|BEHAVIORAL|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
224127726|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
224127727|NCT01318083|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
224127728|NCT01318083|DRUG|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
224127729|NCT03868228|PROCEDURE|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
224127730|NCT05896761|DRUG|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
224127731|NCT05896761|DRUG|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
224127732|NCT01011920|DRUG|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
224127733|NCT01011920|DRUG|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
224127734|NCT01011920|DRUG|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 \& 0 every 3 weeks for a maximum of 4 cycles
224127735|NCT01011920|DRUG|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4
224127736|NCT01011920|RADIATION|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
224127737|NCT01011920|DRUG|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
223392220|NCT02905604|DEVICE|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
223392221|NCT02905604|DEVICE|dmPFC Sham iTBS|Sham iTBS
223392222|NCT06062550|DRUG|Esketamine|Different doses of esketamine in the esketamine-dexmedetomidine combination as a supplement to sufentanil for postoperative intravenous analgesia.
223392223|NCT05115695|OTHER|traditional physiotherapy approach|Traditional upper extremity strengthening and tonus regulation (weight shifting, weight bearing, active reaching in sitting exercises) exercises consisting of Neurodevelopmental Therapy (NDT-Bobath) approaches will be applied to the second group for 45 minutes, 3 days a week for 6 weeks.
223392224|NCT05115695|OTHER|muscle strengthening exercise/Proprioceptive Neuromuscular Facilitation (PNF)|Muscle strengthening with scapular and upper extremity patterns of PNF exercise approach will be applied to the first group for 6 weeks, 3 days a week, 30 minutes a day.
224012637|NCT01153321|DRUG|AZD2423|100mg Oral dose od
224012638|NCT01153321|DRUG|AZD2423 Placebo|Oral dose od
224012639|NCT05108129|PROCEDURE|M-TAPA block|"After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25% bupivacaine will be injected between the transversus abdominis muscle and the lower aspect of the costal cartilage. The same procedure will be repeated on the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
224012640|NCT05108129|PROCEDURE|OSTAP block|"The patients will receive oblique subcostal TAP block in the supine position immediately after the endotracheal intubation. The anesthesiologist of the operating room will place the ultrasound with a linear probe subcostally and from the xiphoid to the right iliac crest obliquely. Rectus abdominis muscle and underlying transversus abdominis muscle, will be identified near the costal margin. The needle will be directed to the transversus abdominis fascia. Local anesthetic solution of 25 ml 0.25% will be injected to between rectus abdominis and transversus abdominis muscles along the oblique subcostal line. The same procedure will repeated to the contralateral side.~Standard perioperative and postoperative multimodal analgesia The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, dexketoprofen, and tramadol."
224012641|NCT02751541|DRUG|Sunscreen Sport Spray (BAY987519)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
224012642|NCT02751541|OTHER|Untreated Skin|This site is patched without treatment as irradiated control.
224012643|NCT03385343|DIAGNOSTIC_TEST|VLE imaging for staging EAC|Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
224012644|NCT00002987|BIOLOGICAL|bleomycin sulfate|
224012645|NCT00002987|DRUG|cyclophosphamide|
224012646|NCT00002987|DRUG|doxorubicin hydrochloride|
224012647|NCT00002987|DRUG|etoposide|
224012648|NCT00002987|DRUG|prednisolone|
224127738|NCT01011920|OTHER|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
224127739|NCT05041192|DIETARY_SUPPLEMENT|Synaquell|7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
224127740|NCT05041192|DIETARY_SUPPLEMENT|Placebo|7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
223392225|NCT02776943|BIOLOGICAL|umbilical cord mesenchymal stem cells|
223392226|NCT02776943|DEVICE|Hyaluronic acid|
223392227|NCT01903798|DRUG|Mycophenolate mofetil|Immunosuppressive agent
223392228|NCT01903798|DRUG|Prednisolone|Corticosteroid
223392229|NCT01903798|DRUG|Rilonacept|
223392230|NCT01007669|BEHAVIORAL|Physical activity and Health check|Strength training, aerobic capacity training.
223392231|NCT01007669|BEHAVIORAL|Health check only|Health check
223392232|NCT01123057|PROCEDURE|riboflavin-induced collagen cross-linking treatment|"The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.~The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application."
223392233|NCT01123057|DEVICE|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
223392234|NCT03618017|BEHAVIORAL|CCC website|ConnectedCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
223392235|NCT03618017|BEHAVIORAL|Static care plan|"The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
223392236|NCT01223378|DRUG|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
223392237|NCT01223378|DRUG|Latanoprost|0.005% ophthalmic solution, QD 28 days
223392238|NCT04331613|BIOLOGICAL|CAStem|CAStem will be administered intravenously.
223392239|NCT05161338|DIAGNOSTIC_TEST|MICROBIOME GENETIC ANALYSIS|Vaginal samples will be taken. A floxed nylon swab will be rotated against the posterior vaginal wall, Nucleic acid extraction and genetic analisys will be performed
223392240|NCT05161338|DIAGNOSTIC_TEST|VAGINAL PH VALUE|Intravaginal Ph value meassurement.
223392241|NCT05161338|DIAGNOSTIC_TEST|SERUM PROGESTERONE LEVELS|Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.
223392242|NCT05161338|DIAGNOSTIC_TEST|SERUM OESTRADIOL LEVELS|Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
223392243|NCT03903302|DRUG|CS1-Sodium Valproate|Single and multiple dose evaluation of CS1
223392244|NCT02436161|BEHAVIORAL|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
223392245|NCT00191126|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
223392246|NCT00191126|DRUG|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
224012649|NCT00002987|DRUG|vincristine sulfate|
224012650|NCT00002987|RADIATION|radiation therapy|
224012651|NCT04461093|OTHER|Acupressure wristband and Palanosetron|"Group 1 Patients with odd numbers labelled form will be Group I patients. They will receive intravenous dexamethasone 8mg during induction. Acupressure P6 wristband is applied after induction and removed prior to emergence to maintain blinding. Intravenous ondansetron 4mg is given prior to skin closure.~Group 11 Patients with even numbers labelled form will be Group II patients who will receive intravenous palonosetron 0.075mg during induction."
223392247|NCT00191126|PROCEDURE|surgery|surgery
223392248|NCT01384110|DIETARY_SUPPLEMENT|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
223392249|NCT03739281|DIAGNOSTIC_TEST|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
223392250|NCT03739281|DIAGNOSTIC_TEST|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
223392251|NCT06042595|BEHAVIORAL|Psychotherapy|Patients treated at the inpatient psychotherapy unit of the University Hospital receive 8 to 10 weeks of multimodal psychotherapeutic treatment. Treatment consists of individual as well as group psychodynamic therapy. Additionally, patients receive an individual combination of music, art, relaxation and body-oriented group therapy. Therapeutic treatment is provided by a multiprofessional, interdisciplinary team of psychotherapists with either a medical or psychology degree, art and music therapists, specialist nurses, social workers, and physiotherapists.
223392252|NCT02392117|DRUG|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
223392253|NCT04765930|OTHER|Q-switched nd:YAG laser toning|Q-switched nd:YAG laser toning for melasma.
223392254|NCT01389050|RADIATION|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
223392255|NCT01389050|RADIATION|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
223392256|NCT04722432|DEVICE|Outside the Scope (OTS), Detachable Catheter System|Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
223392257|NCT01012895|DRUG|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
223392258|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
223392259|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
223392260|NCT01012895|DRUG|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
223392261|NCT01012895|DRUG|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
223392262|NCT01012895|DRUG|Ribavirin|"Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"
224127741|NCT02112162|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/MRI
223392263|NCT01153828|DRUG|Retapamulin|Prescription for retapamulin
223392264|NCT01153828|DRUG|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
223392265|NCT01153828|DRUG|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
223392266|NCT05140044|DEVICE|Balance Exercises - Smartphone Delivery|1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
223547571|NCT06718660|BEHAVIORAL|Tailored Educational Nursing program|The intervention is a structured educational program designed to enhance nursing competence in biomedical waste management at El-Minia University Hospital. It was developed based on evidence-based guidelines, national and international standards, and a detailed assessment of baseline knowledge and practices among the participating nurses.
223547572|NCT06715826|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.
223392267|NCT05140044|OTHER|Balance Exercises - Traditional Paper Delivery|1st week: standing balance tasks; 2nd week: standing with arm manipulation tasks; 3rd week: gait balance tasks; 4th week: gait with arm manipulation tasks.
223392268|NCT01834534|BEHAVIORAL|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
223392269|NCT03164551|DEVICE|GERI+ incubator|The embryo culture of consented participants were carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos were reviewed firstly by GERI Assess software, using bright-field imaging. Finally the embryo(s) with the highest EEVA grade are transferred were followed up until the achievement of implantation and confirmation of pregnancy.
223392270|NCT03164551|DEVICE|Conventional incubator|The embryo culture of consented participants were carried out in conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade were transferred and were followed up until the achievement of implantation and confirmation of pregnancy.
223392271|NCT01515423|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
223392272|NCT01515423|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
223547573|NCT06715826|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.
223547574|NCT06715826|DRUG|[68Ga]Ga-DOTA-H2D3|Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.
223547575|NCT06715826|DRUG|[18F]F-RESCA-RB14|Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
223547576|NCT06715215|DIAGNOSTIC_TEST|Acute phase proteins|Assessment of acute phase proteins levels in patients diagnosed with immune thrombocytopenia
223547577|NCT06715449|DRUG|Empagliflozin 10 MG|Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day in addition to their usual stroke care.
223547578|NCT06718985|OTHER|No intervention|No intervention
223547579|NCT06718153|DIAGNOSTIC_TEST|Immunohistochemistry and in situ hybridisation analysis|immunohistochemistry and in situ hybridisation analysis for several markers, including p53, beta-Catenin and albumin, but also markers considered diagnostic for HCC such as Glutamin Synthetase, Glypican-3 and HSP70, to identify a more rational diagnostic-prognostic algorithm for primary liver lesions.
223547580|NCT06718400|PROCEDURE|Sentinel Skin Flap|Willing participants who will be receiving an intestinal transplantation will receive a sentinel skin flap on their forearm from the same donor
224012652|NCT01471496|PROCEDURE|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
223392273|NCT01515423|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
223392274|NCT01515423|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
223547581|NCT06715293|DEVICE|Hemopill|Hemopill will be swallowed to detect the presence of active bleeding in the upper GI tract
223547582|NCT06715293|PROCEDURE|OGD|OGD will be performed to compare the results of the hemopill
223547583|NCT04584398|DEVICE|Respiratory muscle training with steam inhalation|
223547584|NCT00790049|DRUG|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
223547585|NCT00790049|DRUG|Placebo; oral|matching placebo
223547586|NCT06716398|OTHER|Test product|Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
223547587|NCT06716398|OTHER|Comparator product|Twice daily applications, in association of a reference medical treatment during a 3-month-associated-treatment phase, then alone during a 3-month-maintenance phase. The product is applied to the entire face.
223547588|NCT06715969|OTHER|Myofascial Release Techniques|Separate techniques will be applied to the parts of the thoracolumbal fascia that surround the erector spina, quadratus lumborum, latissimus dorsi muscles and extend in that direction to patients in the MFR group. Techniques will continue for 180 seconds, tissue shift will be carried further as relaxation is achieved. Applications Total 8 sessions will be applied twice a week by an experienced physiotherapist.
223547589|NCT06715969|OTHER|Myofascial Induction Techniques|"MIT will be applied to the lumbal region by a physiotherapist trained and experienced in fascial treatments to patients in the MIT group. Applications 2 sessions per week, a total of 8 sessions will be applied, with an average of 20-25 minutes. The application principles of this technique will be as follows.~* Induction of the lumbal interfacial triangle region (stroke application) (3 min)~* Induction of the lumbal interfacial triangle region (deep induction application) (3 min)~* Cross-hands myofascial induction (3 min)"
224127742|NCT02112162|DEVICE|positron emission tomography|Undergo FDG PET/MRI
224127743|NCT02112162|DEVICE|magnetic resonance imaging|Undergo FDG PET/MRI
224012653|NCT01994759|OTHER|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
223392275|NCT01515423|DRUG|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
223392276|NCT01515423|DRUG|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
223392277|NCT01515423|DRUG|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
224012654|NCT01994759|DRUG|Glucocorticosteroid injection|"Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections)."
224012655|NCT01994759|BEHAVIORAL|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
224012656|NCT04393753|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
224012657|NCT01177800|DRUG|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
224012658|NCT01177800|DRUG|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
224012659|NCT04472559|BEHAVIORAL|Self-acupressure|Self-acupressure
224012660|NCT06332937|PROCEDURE|postmastectomy breast reconstruction|postmastectomy immediate breast reconstruction
223392278|NCT01515423|DRUG|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
223392279|NCT01515423|DRUG|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
223392280|NCT01722708|DRUG|Clindamycin|Oral clindamycin 300 Milligrams\*2/Day for a week
223392281|NCT01722708|DRUG|Metronidazole|Oral metronidazole 500 Milligrams\*2/Day for a week
223392282|NCT03490110|BEHAVIORAL|State regulation skill training|Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total \~4.5 hours per week).
223392283|NCT03490110|OTHER|Treatment-as-usual|Participants receive clinical care as usual over a matched time period.
223392284|NCT06010953|DRUG|SS109|on-demand treatment with SS109 at the time of a new hemorrhage event
223392285|NCT01015534|DRUG|Temozolomide|
223392286|NCT01015534|RADIATION|Whole brain irradiation|
223392287|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
223392288|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
223392289|NCT01125917|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
223392290|NCT02919189|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
223392291|NCT04469595|DRUG|Iluvien 0.19 MG Drug Implant|0.19 mg Fluocinolone Acetonide Intravitreal Implant
223392292|NCT04469595|DRUG|Aflibercept|2 mg/0.05 mL Aflibercept Anti-VEGF intravitreal injection
223392293|NCT04786002|DRUG|Busulfan|The BU administration regimen was four times a day (Q6h), continuous intravenous infusion for 2 hours, 3 or 4 days in a row.
223392294|NCT05824754|OTHER|Just-In-Time-Adaptive-Intervention (JITAI)|"Behavioral: MiWaves behavioral messages~Participants will be using the MiWaves mobile app for 30 days. When a participant is assigned to receive a message, a message will be randomly selected from a pool of intervention message sets. Messages are based in motivational interviewing and include affect management and behavioral economic strategies."
223392295|NCT06557642|DRUG|Entonox|30 minute inhalation using demand valve and mouthpiece
224012661|NCT05526079|OTHER|Watchfuf waiting|Careful review of patient response with the hope of avoiding radical surgery.
224012662|NCT04399811|DIAGNOSTIC_TEST|Near-infrared Vision Photograph|The near-infrared image will be recorded (by a infrared camera connected to a laptop) for each enrolled patient
224012663|NCT06448273|DRUG|TQB3702 tablets|TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.
224012664|NCT06448273|DRUG|TQB3702 placebo|TQB3702 placebo contains no active substance.
224127744|NCT02112162|OTHER|laboratory biomarker analysis|Correlative studies
223392296|NCT06557642|DRUG|Medical Air|30 minute inhalation using demand valve and mouthpiece
223392297|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
223392298|NCT05153811|BEHAVIORAL|mHealth|Participants will engage with an application designed to gamify drinking reduction.
223392299|NCT05153811|BEHAVIORAL|Counseling|Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
223392300|NCT03926351|DIETARY_SUPPLEMENT|Omega-3 capsules|BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
224127745|NCT03189576|DIAGNOSTIC_TEST|blood draw|
224127746|NCT05990660|DEVICE|JuxtaFlow System|Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
224012665|NCT03527550|OTHER|Cognitive Control Training|Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
224012666|NCT00940732|OTHER|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
224012667|NCT00940732|OTHER|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
224012668|NCT00940732|OTHER|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
224012669|NCT04678999|BEHAVIORAL|Mind-body exercise and education|The intervention will delivered via a secure Zoom video platform.
224012670|NCT02729662|DRUG|Tolvaptan|"* Before administration of tolvaptan~  * TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~ * 24-hour urine collection・Hematology/urinalysis: Once/year~ * Physical findings: Blood pressure and medical interview at ambulatory visit~* Hospitalization for education and examination at the start of tolvaptan administration~  * 24-hour urine collection・Hematology/urinalysis・Inulin clearance~ * Physical findings: Body weight, blood pressure~ * Adverse Events~* After administration of tolvaptan~  * TKV・Liver capacity・inulin clearance: Once/year~ * 24-hour urine collection: Once/6 months~ * Hematology/urinalysis: Once/month in principle~ * Physical findings: Blood pressure and medical interview at ambulatory visit~ * Adverse Events"
224012671|NCT01912560|DRUG|CAT-2003|
224012672|NCT01912560|DRUG|Placebo|
224012673|NCT01912560|DRUG|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
224012674|NCT06279026|BIOLOGICAL|UTAA17 Injection|After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
224012675|NCT04325360|PROCEDURE|Cathodal Transcranial Direct Current Stimulation|20 minutes of cathodal stimulation at 2mA, with cathode electrode placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system), the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
224012676|NCT04325360|PROCEDURE|Sham Transcranial direct current stimulation|Participants will received 20 mins of Sham stimulation, where stimulation will happen for the first 30 seconds and in the last 30 seconds of the intervention (at 2mA), with no stimulation in the between time. The cathode electrode will be placed over the focal epileptic area (determined by EEG exam and located according to the 10-20 system),the anode electrode will be placed over the supraorbital region, contralateral to the cathode electrode.
224012677|NCT05336851|DIAGNOSTIC_TEST|Biomarker blood draw and saliva collection|Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)
224012678|NCT04896151|DIAGNOSTIC_TEST|Minnesota Multiphasic Personality Inventory -2- Restructured Form - Experimental|The MMPI-2-RF-EX is a broadband, self-report measure of personality and psychopathology was developed for research purposes in order to develop the MMPI-3 (Ben-Porath \& Tellegen, 2020), which is comprised of a subset of MMPI-2-RF-EX items.
224127747|NCT00178360|BEHAVIORAL|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~* Group singing~* Group drumming~* Music assisted relaxation~* Group song writing~* Lyric analysis~* Improvisation~* Music with art"
223392301|NCT03926351|DIETARY_SUPPLEMENT|Olive oil|Soft gelatine capsule containing 1000 mg olive oil, refined.
223392302|NCT04655547|OTHER|Dietary guidance|Dietary guidance with focus on texture and energy intake, preformed by certified dietitians.
223392303|NCT06141083|DIETARY_SUPPLEMENT|TCI188 Probiotic|take two tablets per day
223392304|NCT06141083|DIETARY_SUPPLEMENT|Placebo|take two tablets per day
223392305|NCT03680677|PROCEDURE|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
223392306|NCT03680677|OTHER|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
223392307|NCT03680677|DIAGNOSTIC_TEST|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
223392308|NCT02501928|DRUG|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
223392309|NCT02501928|DRUG|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
223392310|NCT02501928|DRUG|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
223392311|NCT02501928|DRUG|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
223392312|NCT06243276|PROCEDURE|One stage implant surgery|It is a technique in which the healing cap is connected to the implant at the stage of implant placement.
223392313|NCT06243276|PROCEDURE|Two stage implant surgery|It is a technique in which the healing cap is connected to the implant three months after the implant is placed.
223392314|NCT00428272|DRUG|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
223547590|NCT06715969|OTHER|classıcal phsyotherapy|15 sessions of mictowave diathermy (MDD), Vacuum Interference, Infraruj and Classic waist exercise program will be applied to patients in this group.
224012679|NCT04849494|OTHER|ATS-DLD-78-C and ISAAC questionnaires|Early, natal and postnatal period data were recorded from the hospital database system and patient file. The morbidities observed during the follow-up of the newborns, the duration of hospitalization, needed of oxygen, surfactant administration, positive pressure ventilation requirement, and need for mechanical ventilation support and duration were noted from patient file records. Anthropometric measurements of all patients were taken. Demographic information, socioeconomic level, mother/father education level, mother's smoking status and medical history were questioned, and physical examinations of the patients were performed. were performed for screening respiratory diseases. After the physical examination, the validated Turkish forms of ATS-DLD-78-C and ISAAC questionnaires were filled in face-to-face by the research doctor who did not know the patients' medical history
224012680|NCT01010334|OTHER|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
224012681|NCT03898037|BEHAVIORAL|weight loss intervention|weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.
224012682|NCT03898037|DRUG|metformin intervention|metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
224012683|NCT00911937|DRUG|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
224012684|NCT00911937|DRUG|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
224012685|NCT04428268|DRUG|Chloroquine Phosphate Tablets|Orally administered
224012686|NCT04284215|DRUG|Albumin paclitaxel combined with cisplatin|Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen chemotherapy can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy.
224012687|NCT01498679|DRUG|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
224127748|NCT01191294|OTHER|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
224127749|NCT02740569|OTHER|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
223392315|NCT00428272|DRUG|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
223392316|NCT00428272|DRUG|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
223392317|NCT00428272|DRUG|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
223392318|NCT05610215|PROCEDURE|hybrid ablation|simultaneous thoracoscopic epicardial and catheter endocardial ablation
223392319|NCT05610215|PROCEDURE|catheter ablation|catheter endocardial ablation
223392320|NCT05392868|DEVICE|SDF|38% silver diamine fluoride solution
223392321|NCT05392868|DEVICE|KNO3|5% potassium nitrate solution
223392322|NCT00556868|OTHER|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
223392323|NCT00858494|DRUG|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
223392324|NCT05354037|PROCEDURE|Enamel matrix derivative application for treatment of intrabony defects|EMD application will be associated to M-MIST approach in control group and flapless approach in test group.
223547591|NCT06716268|OTHER|phonation and respiratory tasks|"Participants performed various tasks to evaluate pelvic floor muscle activity and displacement. These included a maximum voluntary contraction (cutting off the flow of urine mid-stream), a pelvic floor strain (bearing down for a bowel movement), and the Valsalva maneuver to clear the Eustachian tubes. Additionally, phonation and respiratory exercises were conducted, such as producing the ah sound at different pitches, open-mouth exhalation, coughing, and semi-occluded vocal tract (SOVT) exercises using a small coffee straw, commonly used in singing warm-ups to enhance vocal efficiency. Each task lasted 3 seconds, with 1-minute rest intervals to assess their impact on pelvic floor displacement"
224012688|NCT01498679|DRUG|Placebo|Placebo administered once daily in the evening via a NDPI
224012689|NCT03398213|OTHER|Acupuncture|Acupuncture
224012690|NCT03398213|OTHER|Sham procedure|Ear stimulation with plaster
224012691|NCT02369146|DRUG|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
224012692|NCT02635568|OTHER|Cannabis Use|Observational Study
224012693|NCT02114710|DRUG|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
224012694|NCT00157560|DRUG|Chemotherapy, multiple agents|
224012695|NCT05201118|DRUG|Selinexor|Selinexor, 20 mg/tablet, is a first-in-class, oral Selective-Inhibitor-of-Nuclear-Export (SINE) compound that impedes XPO-1which is a major nuclear export protein of macromolecular cargo frequently overexpressed in MM.
224012696|NCT05201118|DRUG|CT103A|CT103A consists of autologous T lymphocytes transduced with anti-BCMA CAR lentiviral vector that containing a unique CAR structure with a fully human single-chain variable fragment (scFv).
224012697|NCT05033951|OTHER|Standard care|Both groups: standard care+ questionnaires
224127750|NCT01741194|DRUG|AC-1204|AC-1204 taken once daily, by mouth
224127751|NCT01741194|DRUG|Placebo|Placebo taken once daily, by mouth
223730639|NCT05199298|OTHER|"Mandala Activity-Based Breastfeeding Program"|Training modules for breastfeeding and Maternal -infant attachment will be implemented with pregnant women in the study group at 32-36 weeks of gestation. The training will be explained by the researchers by shooting a video. In addition, for each week, mandala drawings will be videotaped by the researcher who received mindfulness-based art therapy training and will be sent to the Whatsapp accounts of the pregnant women. t 36 weeks of gestation, the Prenatal Attachment Scale and Spielberger State Anxiety Inventories will be sent to mothers as Google forms. The mother will be called 24 hours after the birth and the situation of having a problem with breastfeeding will be determined. In the first week, in the first and second months after the birth, questionnaire forms and online questionnaires will be applied to the mothers, apart from the follow-up and counseling in the postpartum 2nd month, the posttests of the scales
223730640|NCT05316753|PROCEDURE|Cardioversion with a pulsed biphasic waveform|Cardioversion with a pulsed biphasic waveform
223730641|NCT05316753|PROCEDURE|Cardioversion with a biphasic truncated exponential waveform|Cardioversion with a biphasic truncated exponential waveform
224012698|NCT01767701|DRUG|Raltegravir|400mg twice daily for 3 months
224012699|NCT00583193|DRUG|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
224012700|NCT00626301|DRUG|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
224012701|NCT02608723|DEVICE|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
224127752|NCT04008862|BEHAVIORAL|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare -primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
224127753|NCT01348282|DRUG|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
224127754|NCT01348282|DRUG|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
223392325|NCT06979102|OTHER|Real Patient Interactive Stoma Care Management Teaching|"The real patient interactive stoma care management teaching will be carried out with ileostomy patients who have recently undergone ileostomy surgery and their caregivers in the intervention group. The 2nd month after discharge, the newly ileostomy patients and their caregivers will be asked one open-ended question to elicit their thoughts and suggestions regarding the real patient interactive stoma care management teaching. The question is: A real patient with a previous ileostomy participated in the stoma care management teaching. He demonstrated how to perform ileostomy care on himself and shared his experiences and suggestions regarding adapting to life with an ileostomy. What are your thoughts and suggestions regarding this teaching?"
223392326|NCT06979102|OTHER|Standard Stoma Care Management Teaching|The standard stoma care management teaching will be carried out with ileostomy patients who have recently had their ileostomy opened and their caregivers in the control group.
223392327|NCT03737357|DEVICE|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
223392328|NCT03737357|DEVICE|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
223392329|NCT03442556|DRUG|Carboplatin|Given IV
223392330|NCT03442556|DRUG|Docetaxel|Given IV
223392331|NCT03442556|OTHER|Laboratory Biomarker Analysis|Correlative studies
223392332|NCT03442556|DRUG|Rucaparib Camsylate|Given PO
223392333|NCT03442556|DRUG|Rucaparib|Given PO
223392334|NCT06484556|DRUG|NW-301V|TCR-T cell targeting KRAS G12V mutation
223392335|NCT06484556|DRUG|NW-301D|TCR-T cell targeting KRAS G12D mutation
223392336|NCT03427736|DRUG|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
223392337|NCT03427736|DRUG|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
223392338|NCT03427736|DRUG|Ketamine|IV Ketamine will be given per standard of care, not prescribed for this study
223392339|NCT03427736|DRUG|Oxycodone|PO Oxycodone(solution or tablet) will be given per standard of care, not prescribed for this study
223392340|NCT03427736|DRUG|Morphine|IV Morphine will be given per standard of care, not prescribed for this study
223392341|NCT04941131|DRUG|Chlorhexidine digluconate, povidone iodine|This is a mouth wash that can be used over the counter.
224012702|NCT02608723|DEVICE|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
223547592|NCT06715332|DEVICE|Colorectal ESD with SpydrBlade Flex|"The allocated intervention would be performed under sedation or monitored anaesthesia by experienced endoscopists with at least 50 case experience of colon ESD.~Colon ESD procedure would be performed as per described in the literature. After submucosal injection of solution to create a cushion, mucosal incision and submucosal dissection would be performed with the SydrBlade Flex. Submucosal plane dissection will be performed using the SpydrBlade Flex (BRF, cutting frequency 400kHz, power setting 35W). The exact resection strategy would be according to the endoscopists' preference, including different adjunctive techniques such as countertraction, tunnelling or pocket creation method. Upon completion of ESD, the resultant mucosal defect would be examined for any perforation or bleeding."
223547593|NCT06718777|OTHER|0.1% polyhexanide Care|After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.1% polyhexanide solution. Then, 2 treatments were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care and four follow-ups were performed.
223547594|NCT06718777|OTHER|0.9 % NaCl Care|After the patient was randomized for pressure ulcer care, data were recorded at the first follow-up before care and pressure ulcer care was performed with 0.9% sodium chloride. Then, 2 care sessions were performed at 48-hour intervals and PUSH scores were recorded before each care. A total of three pressure ulcer care sessions and four follow-ups were performed.
223547595|NCT06714877|OTHER|prism treatment group|wearing prism glasses
223547596|NCT06714877|PROCEDURE|botulinum toxin group|botulinum toxin injection
223547597|NCT06716892|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous MSOT imaging of muscle and subcutaneos regions.
223547598|NCT06717048|DEVICE|Repeated Low-level Red-light|In addition to single vision spectacle lenses (SVS) with power for correcting distance refraction, the subjects used the prescribed power low-intensity red light treatment instrument for the prescribed number of treatments from Monday to Friday, with a 3-minute interval of 4 hours.
223547599|NCT06717048|DEVICE|Red LED|In addition to SVS with power for correcting distance refraction, red LED will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
223547600|NCT06717945|DRUG|remimazolam besylate|Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
223547601|NCT06717945|DRUG|propofol|Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
223547602|NCT06719518|DEVICE|ViTrack device|In the operating room the ViTrack™ device will be applied the wrist. Monitoring will start in the operating room and will continue throughout the surgery. The device can be worn on either wrist. It will be connected to a power unit that will capture blood pressure data and stream the data to a secure laptop
223547603|NCT06716515|DEVICE|digital inclinometer|Digital inclinometer to assess gender difference in knee repositioning error
223547604|NCT06718478|DEVICE|SakuraBead Resorbable Microspheres|Temporary Embolization of Genicular Arteries using SakuraBead Resorbable Microspheres
223547605|NCT06719336|RADIATION|High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy|Twice-daily thoracic radiotherapy at a dose of 54 Gy in 30 fractions with IMRT and VMAT
223547606|NCT06719336|DRUG|atezolizumab or durvalumab|atezolizumab 1200 mg Q3W or durvalumab 1500 mg Q4W
223547607|NCT06716775|DEVICE|Tumor treating felds (TTF)|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.
224012703|NCT02608723|DEVICE|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
224012704|NCT01424449|RADIATION|[11C]PHNO|examine the effects of \[11C\]PHNO mass carry-over and displaceable binding
224012705|NCT01424449|DRUG|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
223547608|NCT06716775|OTHER|Best Standard of Care|Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.
223547609|NCT04685213|DEVICE|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
223547610|NCT04685213|DEVICE|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily up to two weeks or until hospital discharge, whichever came first (phase I).
224012706|NCT04940403|DEVICE|Burt|18 one-hour sessions of unimanual upper-limb tasks during robot-assisted training with the Burt.
224012707|NCT04940403|DEVICE|Burt + BurtVision|18 one-hour sessions of combination of unimanual and bimanual upper-limb tasks during robot-assisted training with the BurtVision.
224012708|NCT05152420|DRUG|VMX-C001|VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
223547611|NCT06716411|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
223547612|NCT06716047|OTHER|Oral administration|Take it directly
223547613|NCT06717087|OTHER|Acupuncture+lifestyle intervention|8 weeks Acupuncture treatment for 2-3 times/week, 30min each time and lifestyle intervention((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
224012709|NCT05152420|DRUG|Placebo|VMX-C001 matched placebo
224012710|NCT05152420|DRUG|Apixaban|FXa Inhibitor
224012711|NCT05152420|DRUG|Rivaroxaban|FXa Inhibitor
224012712|NCT05152420|DRUG|Edoxaban|FXa Inhibitor
224012713|NCT02775773|DRUG|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
224012714|NCT02775773|DRUG|Oxytocin|2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
223392342|NCT06586827|OTHER|VCU-RRTC Online Course|"Approved by ACRE as its accrediting body and has been offered virtually through the VCU RRTC for over 15 years. The course currently entails:~i. Six modules ii. Six online discussion boards iii. Assignments in each module iv. One quiz per module v. Final assignment"
223547614|NCT06717087|OTHER|Metformin+lifestyle intervention|8 weeks Metformin 500 mg three times a day with meals and lifestyle intervention ((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
223547615|NCT06716489|BEHAVIORAL|Aerobic exercise|Participants will undergo an aerobic exercise training program on a motorized treadmill at an intensity corresponding to 60-70% of their heart rate reserve (calculated by adding baseline heart rate to 60-70% of reserve heart rate). The program will last 16 weeks and will consist of three 1-hour, 10-minute sessions per week, divided into four phases: a 5-minute warm-up at an intensity below the target exercise heart rate (baseline + 30-40% of the reserve heart rate); a 50-minute main exercise session at the target exercise heart rate intensity; a 5-minute cool-down at an intensity below the target exercise heart rate; and a 10-minute relaxation and general stretching phase. This structured exercise protocol was designed to evaluate the effects of aerobic exercise on sensory perception, musculoskeletal alterations, and psychosocial factors in patients with migraine.
223547616|NCT04486690|DRUG|Ketofol (propofol to ketamine ratio 1:1)|"* Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min"
223547617|NCT04486690|DRUG|propofol|"Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min."
224012715|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
224012716|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
224012717|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
224012718|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
224012719|NCT00613665|BIOLOGICAL|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
224012720|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
224012721|NCT00613665|BIOLOGICAL|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
224012722|NCT03273361|BEHAVIORAL|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
224012723|NCT03002831|BIOLOGICAL|Cytokine-induced Killer Cells|
224012724|NCT03002831|DRUG|Tegafur-Gimeracil-Oteracil Potassium|
224012725|NCT02109315|DRUG|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
223392343|NCT06586827|OTHER|Zoom Technical Assistance Sessions (6 total)|Technical Assistance sessions will be provided to small groups of participants of 5-7 via Zoom technology. There will be one virtual TA session for each of the six modules that will last for 1 hour. The TA sessions will be provided by a trained SE expert/ mentor. The TA sessions will have instructional plans so that they are delivered consistently and will align with the associated module's content and will entail application and discussion that facilitates implementation and reflection of the material.
224012726|NCT02109315|DRUG|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
224012727|NCT02988518|BEHAVIORAL|COGMED program|"Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.~In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.~Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.~The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index."
224012728|NCT00003773|DRUG|oglufanide disodium|
223392344|NCT06983925|DRUG|GS1-144 Tablet with new preparation (T)|GS1-144 Tablet with new preparation (T)
224012729|NCT06186661|OTHER|neurophysiological exercise|The content of the treatment program consisted of neurophysiological exercises based on Bobath.
224012730|NCT06186661|OTHER|cognitive rehabilitation|Cognitive rehabilitation sessions of the experimental group included 30 minutes of remedial and functional adaptive approaches and 30 minutes of implementation of Multicontextual treatment intervention.
224012731|NCT00187564|DRUG|controlled-release oral alpha-lipoic acid|
224127755|NCT04498429|OTHER|Integrated Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
223392345|NCT06983925|DRUG|GS1-144 Tablet with present preparation (R)|A single oral dose of GS1-144 Tablet with present preparation
223392346|NCT02782663|DRUG|ABT-494|Tablet: Oral
224127756|NCT04498429|OTHER|Verbal Cueing Protocol|The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
224127757|NCT03641989|OTHER|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
224127758|NCT03641989|OTHER|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD\&C Blue No. 1.
224127759|NCT03755531|DRUG|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
224127760|NCT03755531|DRUG|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
223392347|NCT05531812|OTHER|G2R with individual coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Individual coaching at home from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; Water, Sanitation and Hygiene (WASH) practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
224012732|NCT03410368|BIOLOGICAL|NK cells|Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
223392348|NCT05531812|OTHER|G2R with group coaching|"1. Consumption support in the form of a monthly cash transfer for 12 months, totaling US$280-$320;~2. A one-time asset transfer of US$300 delivered \~7 months into the program;~3. Enrollment, training, and support to participate in a Village Savings and Loans Association (VSLA) or similar group;~4. Group coaching in a community setting from a trained coach using a structured curriculum focused on essential topics, including: child nutrition; infant and young child feeding (IYCF) best practices; WASH practices and practical solutions; preventative health care; positive parenting and life skills; gender; climate risk mitigation strategies; rights, linkages, and access to services."
223392349|NCT05276050|DEVICE|active F8-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
223392350|NCT05276050|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
223392351|NCT06983821|DRUG|Cyclophosphamide|IV Cyclophosphamide 15mg/kg/dose (age and eGFR adjusted), 2 doses 2 weeks apart
223547618|NCT01101529|DRUG|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
223547619|NCT01101529|DRUG|Placebo|Placebo will be administered instead of Emend
223547620|NCT03440866|DRUG|Administration of drugs concomitantly.|Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
223547621|NCT01085526|BIOLOGICAL|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
223547622|NCT01085526|DRUG|Alutard phl prat|
223547623|NCT00769054|DRUG|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
223547624|NCT00769054|DRUG|Isotonic NaCl|Local Infiltration with NaCl
223547625|NCT03005340|DRUG|Treatment B|Bazedoxifene 20 mg
223547626|NCT03005340|DRUG|Treatment C|Cholecalciferol granule 10 mg
223547627|NCT03005340|DRUG|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
223547628|NCT01207206|DRUG|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
224012733|NCT04357444|DRUG|1: ILT101|Subcutaneous injections, once-daily administration for 10 consecutive days.
224012734|NCT04357444|DRUG|2: Placebo Comparator|placebo in Subcutaneous route
224012735|NCT04531644|PROCEDURE|double stimulation|the patients will be treated with two consecutive ovarian stimulations in one cycle
223547629|NCT04446312|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
223547630|NCT00192543|BEHAVIORAL|diet of fish and fruit|fish and fruit in specified quantities
224012736|NCT04531644|PROCEDURE|conventional ovarian stimulation|the patients will be treated with one conventional ovarian stimulation in one cycle
224012737|NCT04539535|OTHER|General Movements Assessment on two different surfaces in infants with DS and typically infants on the same day|Different surface
224012738|NCT00106587|DEVICE|PTCA|
224012739|NCT00106587|COMBINATION_PRODUCT|paclitaxel coated balloon catheter (device with drug)|
224012740|NCT04948281|OTHER|no intervention|no intervention
224012741|NCT01844687|DRUG|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
224012742|NCT01465529|DRUG|OligoG CF-5/20|6% OligoG CF-5/20 in water
224012743|NCT01465529|DRUG|Saline|0.9% NaCl in water
224127761|NCT01868373|BIOLOGICAL|Microbiota Transplantation (FMT)|Active therapy
223392352|NCT06983821|DRUG|Standard of Care (SOC)|Participants will receive standard of care induction agent and glucocorticoid taper, at investigator discretion
223392353|NCT06983821|DRUG|Prednisone|4 weeks prednisone taper
223392354|NCT06983821|DRUG|Rituximab (R)|Rituximab infusions, dosing and schedule at clinician/investigator discretion
223547631|NCT00192543|BEHAVIORAL|fruit and fish|no drugs
223547632|NCT00192543|BEHAVIORAL|diet only|Fish and fruit
223392355|NCT05806840|BEHAVIORAL|Rapid Adaptation to Prevent Drug Use (RAPD)|RAPD will include a novel bundle of implementation strategies to support rapid responses to urgent drug use events. The strategies deployed will be based on the first step of the After Action Review: critical analysis and reflection.
223392356|NCT05806840|BEHAVIORAL|Standard Implementation|Standard implementation of the Michigan Model for Health (MMH) includes curriculum materials and as-needed technical assistance provided by a school health coordinator.
223547633|NCT00192543|BEHAVIORAL|regular diet|no change in regular diet
223547634|NCT03931187|BEHAVIORAL|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 28-30 days during IVF-ET.
223547635|NCT00655837|DRUG|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
223547636|NCT00655837|DRUG|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
223547637|NCT00655837|DRUG|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
223547638|NCT05379699|OTHER|TOR-BSST© eLearning Training|An online self-directed training program for TOR-BSST© dysphagia screeners.
224012744|NCT00933855|BEHAVIORAL|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
224012745|NCT03196154|DIAGNOSTIC_TEST|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
224012746|NCT03196154|DIAGNOSTIC_TEST|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
224127762|NCT04963712|DRUG|Zadaxin|1.6 mg subcutaneous injection, once a day in the first 2 weeks, and 1.6 mg subcutaneous injection, twice a week in the successive 22 weeks.
223392357|NCT06200831|PROCEDURE|Staged resection|Patients randomized to staged resection will be operated according to the decision made by the tumor board meeting (liver or colorectal cancer first, based on tumor burden and symptoms), but both resections have to be done within a time period of 4-12 weeks.
223392358|NCT06200831|PROCEDURE|Simultaneous resection|In cases with simultaneous surgery, the liver resection is performed prior to colon resection in order to keep a low central venous pressure during the first part of the surgical procedure and to avoid congestion of the anastomosis line owing to possible Pringle manoeuvre.
223547639|NCT05379699|OTHER|Standard TOR-BSST© Training|Standard 4-hour in-person TOR-BSST© screener training conducted by a Speech-Language Pathologist.
223547640|NCT02224170|DRUG|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
223547641|NCT02224170|DRUG|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
223547642|NCT02175186|DRUG|ALBIS|
224012747|NCT01283204|DRUG|SP|"\<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest."
224012748|NCT01283204|DRUG|FL/Tax|"\<Every q 3 weeks\>~1. Day1 : Paclitaxel 175mg/m2 IVF for 2hours~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
224012749|NCT01283204|DRUG|FL/Doc|"\<Every q 3 weeks\>~1. Day1 : Docetaxel 75mg/m2 IVF for 1hour~2. Day1 : Leucovorin 20mg/m2 IVF for 1hour~3. Day1\~3 : 5-FU 1000mg/m2 IVF for 24hours"
224012750|NCT01283204|DRUG|FOLFOX|\<Every q 2 weeks\> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1\~2 : 5-FU 1200mg/m2 IVF for 24hours
224012751|NCT00002323|DRUG|Nevirapine|
224012752|NCT00002323|DRUG|Zidovudine|
224127763|NCT00000579|PROCEDURE|Low Tidal Volume Ventilation|
224127764|NCT00000579|PROCEDURE|Positive End-Expiratory Pressure|
224127765|NCT00000579|DRUG|Lysofylline|
223547643|NCT02175186|DRUG|Placebo|
223547644|NCT02685826|DRUG|Durvalumab|single use vials administered via intravenous infusion
223547645|NCT02685826|DRUG|Lenalidomide|capsules for oral administration
223547646|NCT02685826|DRUG|Dexamethasone|tablets for oral administration
223547647|NCT03154476|DRUG|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
223547648|NCT03154476|DRUG|Placebo|Placebo capsules matching study drug
223547649|NCT04734158|OTHER|corneal imaging|corneal imaging using AS-OCT
223547650|NCT06091358|DEVICE|PrO2|"The intervention arm will receive a handheld PrO2 device and will participate in two unsupervised sessions and one supervised via Microsoft teams sessions per week.~Participants will complete 3 sessions per week, for 4 weeks. Each session will include 6 x 6 inspirations at 80% of MIP. MIP will be measured on the supervised session day each week."
223547651|NCT00200967|DRUG|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
223547652|NCT00200967|DRUG|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
223547653|NCT02751944|DIETARY_SUPPLEMENT|NEM|Dietary supplement for the support of joint health.
224127766|NCT00000579|DRUG|Methylprednisolone|
224127767|NCT00000579|DRUG|Ketoconazole|
224127768|NCT00000579|PROCEDURE|Fluid Management|
224127769|NCT00000579|PROCEDURE|Pulmonary Artery Catheter|
224127770|NCT02811133|DRUG|Inositol|Subjects will receive inositol
224012753|NCT00669370|DRUG|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
224012754|NCT04539782|OTHER|Physiotherapy intervention|Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
223392359|NCT03577782|BIOLOGICAL|Entyvio (Vedolizumab)|"1. Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~2. Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
223392360|NCT06247410|DRUG|Rotigotine 8Mg/24Hrs Patch|Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
223392361|NCT04097340|DEVICE|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
223392362|NCT04097340|DEVICE|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
223392363|NCT03106428|DRUG|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
223392364|NCT06568224|DRUG|Mesalazine|oral mesalazine 1g qid
223392365|NCT06340997|DEVICE|Transesophageal echocardiography|"* D.Echocardiography(Transthoracic and transesophageal):~* 2D echocardiography (to detect LA function, severity of MS and Wilkins score).~The following conventional parameters were measured :~* left atrial volume index (LAVi), and left ventricular ejection fraction (LVEF) by modified biplane Simpson's rule , left atrial emptying fraction calculated as (LAVi max-LAVi min)/LAVi max × 100 ,\]degree of concomitant mitral regurgitation. The maximum and minimum LAA areas were measured by planimetry. LAA area change (%) was calculated using the following formula: LAA area change = \[(maximal LAA area-minimal LAA area)/maximal LAA area\] × 100.~* Transesophageal echocardiogram (TEE) (to detect LAA function) .~* LAA flow velocity patterns by pulsed-wave Doppler~* Early diastolic emptying velocity~* Late diastolic emptying velocity or LAA contraction flow~* LAA filling velocity~* Systolic reflection waves~* Two-Dimensional- LAA fractional area change (LAAAC%)"
223392366|NCT00838526|DRUG|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
223392367|NCT00838526|DRUG|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
223392368|NCT02810925|PROCEDURE|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
223392369|NCT02810925|PROCEDURE|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
223392370|NCT02810925|DIETARY_SUPPLEMENT|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
223392371|NCT02810925|DIETARY_SUPPLEMENT|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
223392372|NCT01306266|DRUG|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
223392373|NCT01306266|DRUG|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
223392374|NCT02287181|DRUG|Remifentanil|short acting opiate
223392375|NCT02287181|DRUG|Propofol|hypnotic drug
223392376|NCT02287181|OTHER|Bispectral index|electroencephalograph
223392377|NCT00972790|PROCEDURE|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
223392378|NCT03455088|BEHAVIORAL|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
224012755|NCT00640081|BIOLOGICAL|cetuximab|
223392379|NCT03455088|DRUG|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
223392380|NCT00520897|DRUG|Raltegravir (MK0518)|400mg BID; 48 weeks
223392381|NCT00520897|DRUG|Placebo|400mg QD
223392382|NCT00520897|PROCEDURE|Leukopheresis|pack of cells as per protocol
223392383|NCT00520897|PROCEDURE|Sigmoid Biopsy|gut samples as per protocol
223392384|NCT06577207|OTHER|Initial investigations for all cases|Initial investigations for all cases: 1. Pulse oximetry. 2. Complete blood count. 3. Electrolytes. 4. Kidney function test. 5. Random blood glucose 6. Other investigations ordered for certain cases according to clinical manifestation \& previous findings \> Lines of treatment will be recorded
223392385|NCT05643872|DRUG|PTX-022|QTORIN rapamycin 3.9% anhydrous gel
223392386|NCT05698433|OTHER|No intervention|No intervention
223392387|NCT00348829|PROCEDURE|mitral valve repair|surgical mitral valve repair
224012756|NCT00640081|DRUG|capecitabine|
223392388|NCT02680951|DRUG|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
223547654|NCT02751944|DIETARY_SUPPLEMENT|Placebo|Placebo
224012757|NCT00640081|DRUG|fluorouracil|
224012758|NCT00640081|DRUG|leucovorin calcium|
224012759|NCT00640081|DRUG|oxaliplatin|
224012760|NCT00640081|OTHER|immunohistochemistry staining method|
224012761|NCT00640081|OTHER|laboratory biomarker analysis|
224012762|NCT06445829|DRUG|Magnesium sulfate|adding 300mg magnesium sulfate into cocktail injection
224012763|NCT05567354|DRUG|PF614|PF614 100 mg capsules
224012764|NCT05567354|DRUG|Oxycodone|Oxycodone HCl IR 40mg
223392389|NCT02680951|DRUG|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
223392390|NCT02680951|DRUG|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
223547655|NCT01950728|DEVICE|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
224012765|NCT05567354|OTHER|Placebo|placebo powder
224012766|NCT05626790|OTHER|Exercise|All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.
223392391|NCT02680951|DRUG|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: \[weight (Kg) x dose (per m2)\] divided by 30"
223547656|NCT01950728|DEVICE|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
223547657|NCT01950728|DEVICE|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
223547658|NCT04892706|DRUG|IDP-126 Gel|Gel applied to face once daily in the evening.
223547659|NCT04892706|DRUG|IDP-126 Vehicle Gel|Gel applied to face once daily in the evening.
223547660|NCT04892706|DRUG|Epiduo® Forte Gel|Gel applied to face once daily in the evening.
223547661|NCT00936663|DRUG|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
223547662|NCT00936663|DRUG|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
223547663|NCT01444430|DRUG|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
223547664|NCT01444430|DRUG|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
223547665|NCT03273686|PROCEDURE|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
223547666|NCT04991493|DRUG|Tramadol hydrochloride|"pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured."
223547667|NCT04991493|OTHER|Normal Saline|"pre-tramadol group: Normal Saline will be injected intravenously when the incision was washed and sutured.~post-tramadol group: Normal Saline will be injected intravenously 15 minutes before anesthesia."
223547668|NCT05989568|BEHAVIORAL|BASIS-T|BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
223547669|NCT05989568|BEHAVIORAL|Attention Control (ACC)|Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
223730642|NCT03477877|BEHAVIORAL|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
223730643|NCT03477877|BEHAVIORAL|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
224012767|NCT05626790|OTHER|PNF Stretching|"In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~1. Biceps: Flex-Add-ER repositioned half pattern~2. Brachioradialis: Flex-Abd-ER repositioned half pattern~3. Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches."
224127771|NCT03702205|DIETARY_SUPPLEMENT|Betaine supplementation|Group taking oral betaine supplementation
223392392|NCT02680951|DRUG|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~* 30 mg for patients age 1 - 1.99~* 50 mg for patients age 2 - 2.99~* 70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
224012768|NCT05626790|OTHER|Prolonged Stretching|"In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~1. In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~2. In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched."
224012769|NCT04245228|BEHAVIORAL|Wellness Coach|Trained in motivational interviewing who will call the patient weekly for 12 sessions for an approximately 30-minute intervention
224012770|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"Placebo-controlled crossover design:~* Dietary Supplement: Antrodia Cinnamomea Products~* Dietary Supplement: Placebo"
224012771|NCT06633003|DIETARY_SUPPLEMENT|Antrodia cinnamomea Products|"A arm :~Stage I :~• Dietary Supplement: Antrodia Cinnamomea Products~Stage II:~• Dietary Supplement: Placebo~B arm :~Stage I :~• Dietary Supplement: Placebo~Stage II:~• Dietary Supplement: Antrodia Cinnamomea Products"
224012772|NCT01994967|DRUG|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
224012773|NCT01994967|DRUG|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
224012774|NCT03865927|OTHER|Placebo Oral Tablet|see Arm/Group description
224012775|NCT03865927|DRUG|GKT137831|GKT137831 is a NOX enzyme inhibitor
224012776|NCT00941967|DRUG|gemcitabine hydrochloride|Given IV
224012777|NCT00941967|DRUG|oxaliplatin|Given IV
224012778|NCT00941967|DRUG|sorafenib tosylate|Given orally.
224012779|NCT04379505|DEVICE|Ring gantry kV-CBCT combined with linear accelerator (Halcyon)|-Varian Medical Systems is the manufacturer
224012780|NCT04379505|RADIATION|Quad shot radiation|Treatment of each cycle should ideally take place on two consecutive days. Allowing for holidays, weekends, and other scheduling issues or unexpected delays, treatment may be completed within five calendar days.
224012781|NCT05854095|DEVICE|Pivot Bridge|transcatheter for short-term treat Functional Tricuspid regurgitation
224012782|NCT04798859|OTHER|Family centered in-home rehabilitation|Goal-oriented individualized intervention targeting brain injury related areas noted as challenging by the child and family
224012783|NCT04798859|OTHER|Control|Usual follow-up in the municipality
224012784|NCT00650884|DEVICE|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
224012785|NCT05672420|BIOLOGICAL|umbilical cord derived mesenchymal stem cells|umbilical cord derived mesenchymal stem cells, intravenous infusion
224012786|NCT04719546|OTHER|Observation of related perinatal factors|Data described in Primary outcome measures will be collected in both groups
224012787|NCT04480138|DRUG|Pegylated Interferon-α2b|1 mcg/kg on day 1 and day 8 after safety evaluations.
224127772|NCT03702205|DIETARY_SUPPLEMENT|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
224127773|NCT06175611|DEVICE|COVID-19/Flu A/Flu B/RSV Test Kit|"The performance characteristics of EDAN's Test Kit will be evaluated in a prospective, non-randomized, observational, post-market, multicenter, comparison clinical performance study using anterior nasal and oropharyngeal swabs from subjects suspected of respiratory infection.~Samples will be obtained fresh, collected prospectively and will be tested with the study device COVID- 19/Flu A/Flu B/RSV Test Kit. The results will be compared against a reference, CE marked, in-vitro diagnostic device, used in the standard of care.~This clinical performance study has been designed to minimize any possible, discomfort, or other foreseeable risks to the participants."
223392393|NCT02412917|DRUG|FV-100|antiviral nucleoside analog
224012788|NCT04480138|OTHER|Standard of Care|Standard of care as per local authority
224012789|NCT05659498|BEHAVIORAL|Cardiac Rehabilitation Program|The standard cardiac rehabilitation program consists of the following: a (1) consultation with a kinesiologist to assess level of fitness and to prepare an individually customized exercise plan, (2) consultation with a dietitian to guide the participant with healthy nutrition choices, (3) on site supervised and/or virtual exercise sessions with gradual elaboration of a home program, (4) weekly educational capsules and monthly workshops related to cardiac health, and, (5) if deemed necessary by the treating team, consultation with a psychologist, an occupational therapist, a physiotherapist, or a social worker.
224012790|NCT01145209|DRUG|Fludarabine Phosphate|Given IV
224012791|NCT01145209|BIOLOGICAL|Ofatumumab|Given IV
224012792|NCT01145209|DRUG|Cyclophosphamide|Given IV
224127774|NCT02028338|COMBINATION_PRODUCT|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
224127775|NCT02028338|COMBINATION_PRODUCT|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
224127776|NCT00047281|DRUG|celecoxib|
224127777|NCT00047281|DRUG|cyclophosphamide|
224127778|NCT00047281|DRUG|etoposide|
224127779|NCT00047281|DRUG|thalidomide|
223392394|NCT02412917|DRUG|valacyclovir|antiviral nucleoside analog
223392395|NCT06328465|DIAGNOSTIC_TEST|Diffusion whole body MRI|Diffusion whole body MRI protocol, consisting of sagittal T1-weighted and T2-weighted sequences on the whole spine, axial T1 weighted, T2-weighted and diffusion-weighted images from head to mid-thigh, performed on a 1.5 T scanner.
224012793|NCT00407108|PROCEDURE|Vitrectomy|
224012794|NCT05271370|DRUG|PRO 140 350|Pro140 SC injection 350 mg
224012795|NCT05271370|DRUG|PRO 140 525|525 mg
224012796|NCT05271370|DRUG|PRO 140 700|700 mg
224012797|NCT00124683|DRUG|Bupropion|
224012798|NCT00124683|DRUG|nicotine transdermal patch|
224012799|NCT05890859|DIAGNOSTIC_TEST|DXA scan|The patients will undergo 5 DXA scans fro pre- to post treatment
224012800|NCT05890859|BEHAVIORAL|Physical testing|The patients will undergo tests for maximal muscle strength and functional performance before and after treatment
224012801|NCT04550338|DRUG|Tranexamic acid|Oral administration of blinded medications
224012802|NCT04550338|DRUG|Placebo|Oral administration of blinded medications
224012803|NCT05031000|DIAGNOSTIC_TEST|blood glucose measurement: POCT|measurement of blood glucose concentration using 5 different POCT glucometer
224012804|NCT05031000|DIAGNOSTIC_TEST|blood glucose measurement: reference|measurement of blood glucose concentration using 2 different laboratory analyzer
224012805|NCT04694261|BEHAVIORAL|SM-ART|Intervention is a group based training delivered by midwives on SM-ART module. These training will consist of 6 sessions, one per week for 90 to 120 minutes each.
223392396|NCT06390709|OTHER|Lab Collection Only|2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.
224012806|NCT06069310|DRUG|Mepolizumab 100 MG|Monthly administartion of mepolizumab 100mg
224012807|NCT02550353|PROCEDURE|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
224012808|NCT02550353|PROCEDURE|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
224012809|NCT06339853|DEVICE|WELT-IP with wearable devices (Apple/galaxy watch. Oura ring)|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot. By using WELT-IP simultaneously with wearing an Apple Watch/Galaxy Watch and Oura Ring, sleep and environmental data can be collected.
224012810|NCT04331678|BEHAVIORAL|Comparator App|"Participants will download and agree to use the study app at least once per week during the 3-month intervention period.~The app allows participants to invite a network of friends and family to provide emotional and logistical support during their treatment."
224012811|NCT03100877|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
223392397|NCT01320293|DRUG|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
223392398|NCT03051477|DRUG|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
223392399|NCT01160328|DRUG|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
223392400|NCT01160328|DRUG|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
223392401|NCT03376334|OTHER|Mental Motor Imagery|
223392402|NCT02541968|BEHAVIORAL|Cognitive-behavioral therapy (face-to-face)|
223392403|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy|With therapist support
223392404|NCT02541968|BEHAVIORAL|Internet-based Cognitive-behavioral therapy without therapist support|
223392405|NCT01026246|DRUG|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
223392406|NCT01026246|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
223392407|NCT05944146|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
223392408|NCT05944146|DRUG|Dobutamine|infusion dobutamine
223392409|NCT04343131|BEHAVIORAL|Dietary intervention|Crossover dietary manipulation using three different types of diet for 7 days each
224012812|NCT03100877|DRUG|Cyclophosphamide|Given IV
224012813|NCT03100877|BIOLOGICAL|Filgrastim|Given SC or IV
224012814|NCT03100877|OTHER|Laboratory Biomarker Analysis|Correlative studies
224012815|NCT03100877|DRUG|Lenalidomide|Given PO
224012816|NCT03100877|PROCEDURE|pheresis|Undergo apheresis
224012817|NCT03100877|DRUG|Melphalan|Given IV
224012818|NCT03100877|BIOLOGICAL|Palifermin|Given IV
224012819|NCT03100877|RADIATION|Total Marrow Irradiation|Undergo TMI
224012820|NCT03446326|DEVICE|Pacing|Assess the non-invasively determined stroke volume and cardiac output response at different paced heart rates in patients with a cardiac pacemaker or implanted defibrillator with preserved ejection fractions (LVEF≥50%)
224012821|NCT03804489|OTHER|Decision aids|Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.
224012822|NCT00703209|PROCEDURE|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
223547670|NCT03994016|BEHAVIORAL|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
223547671|NCT05040698|DRUG|Fostamatinib|Open label Fostamatinib
223547672|NCT05910567|DIAGNOSTIC_TEST|Focused Assessment with Sonography for Trauma (FAST) Examination|A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.
223547673|NCT05910567|OTHER|No Intervention: Standard of Care - Without the FAST Examination|Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
223547674|NCT01144624|DRUG|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
223547675|NCT01144624|DRUG|Placebo|Intravenous infusion of a saline solution
223547676|NCT01224327|BIOLOGICAL|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
223547677|NCT01224327|DRUG|Conserved therapy|Oral or intravenous administration
223547678|NCT00643942|OTHER|No intervention required|
223547679|NCT05812339|DEVICE|Gastric Alimetry System|Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
223547680|NCT03300206|DEVICE|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
223547681|NCT06717204|DRUG|Vericiguat Oral Tablet [Verquvo]|Vericiguat in addition to conventional treatment
223547682|NCT06717204|DRUG|Prescription Drugs|Conventional treatment only
224012823|NCT03859245|BEHAVIORAL|Photobiomodulation|Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.
223564206|NCT04339998|DIAGNOSTIC_TEST|Point-of-Care Ultrasonography (POCUS)|"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:~Pulmonary POCUS Evaluation:~1. B lines: absent (\< 3 lines), present (\> 3 lines), fused~2. Consolidation: yes or no~   a. Bilateral: yes or no~3. Pleural Effusion: yes or no~4. Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities~Cardiac POCUS Evaluation:~1. Parasternal long axis~2. Parasternal short axis~   1. Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed~  2. EPSS (E-point septal separation): normal (\<10 mm), abnormal (\>10 mm)~  3. Left ventricular (LV) mass approximation by septal thickness~  4. Left Ventricular Chamber Size by internal diameter at diastole"
223564207|NCT03927482|BEHAVIORAL|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
223564208|NCT03927482|BEHAVIORAL|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
223564209|NCT05248997|DRUG|rimegepant 75 mg ODT|One dose of rimegepant 75 mg ODT
223564210|NCT05248997|DRUG|Matching placebo|One dose of matching placebo
223564211|NCT06150365|BIOLOGICAL|KSX01-TCRT cell therapy|Patient autologous T cell therapy
223730644|NCT03477877|BEHAVIORAL|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
223730645|NCT03477877|OTHER|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
223730646|NCT03477877|BEHAVIORAL|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
223730647|NCT00563381|DRUG|Tiotropium bromide|18 mcg/daily
223730648|NCT00563381|DRUG|Salmeterol|100 mcg/daily
223730649|NCT00563381|DRUG|Placebo Salmeterol|Placebo identical to Salmeterol device
223730650|NCT00563381|DRUG|Placebo Tiotropium|Placebo identical to Tiotropium device
224012824|NCT03859245|BEHAVIORAL|Ketogenic diet|Experimental group will follow a clinically prescribed ketogenic diet.
223730651|NCT00569478|OTHER|rehabilitation|Nursing consultations and physical training
223730652|NCT00110149|BIOLOGICAL|rituximab|
223730653|NCT00110149|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223564212|NCT01396824|OTHER|No intervention|No intervention
223564213|NCT05783063|DEVICE|Active iTBS|Mag-TD
223564214|NCT05783063|DEVICE|Sham iTBS|Mag-TD
224012825|NCT00635427|BIOLOGICAL|VPRIV®|Intravenous infusion, every other week (EOW)
224012826|NCT03307005|DRUG|Zolpidem Tartrate|Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
223392410|NCT01823367|BEHAVIORAL|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
223392411|NCT02561325|DRUG|Sodium Bicarbonate and Sodium chloride|
223392412|NCT02475928|DIETARY_SUPPLEMENT|zinc gluconate|Zinc supplementation plus nutritional education
223392413|NCT02475928|DIETARY_SUPPLEMENT|Placebo|
223392414|NCT02475928|BEHAVIORAL|Nutritional education|
223392415|NCT02907060|DEVICE|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
223392416|NCT02907060|DRUG|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
223392417|NCT01555216|DRUG|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
223392418|NCT01555216|DRUG|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
223392419|NCT02312414|DRUG|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
223547683|NCT06321445|OTHER|providing ASA score|ASA scoring, or the American Society of Anesthesiologists (ASA) Physical Status Classification System, is a framework used by anesthesiologists to assess the preoperative physical fitness of a patient before surgery. It categorizes patients into six classes based on their overall health status, ranging from ASA I (a healthy patient) to ASA VI (a declared brain-dead patient whose organs are being removed for donor purposes). The ASA score helps in predicting perioperative risks and assists healthcare professionals in making informed decisions about anesthesia management and the need for special precautions during and after surgery.
223547684|NCT01491061|DRUG|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
223547685|NCT01491061|DRUG|Placebo|os, two doses 12 hours apart prior to PCI
224012827|NCT03307005|DRUG|Placebo oral capsule|Placebo capsule one per night taken for 7 nights
223547686|NCT00008411|DRUG|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
223547687|NCT00008411|DRUG|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
223547688|NCT01239277|OTHER|protein|20g protein
224012828|NCT00298259|PROCEDURE|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
224012829|NCT06228391|DRUG|IV ketamine|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg for 40 minutes twice a week for 3 weeks.
224127780|NCT03654547|DRUG|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
223392420|NCT01553955|PROCEDURE|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
223392421|NCT00425321|DRUG|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
223547689|NCT01239277|OTHER|protein and carbohydrate|20g protein and 20g carbohydrate
223547690|NCT01239277|OTHER|protein and leucine|20g protein, 2.5g leucine
223547691|NCT03572231|DRUG|mirabegron|oral
223392422|NCT00425321|DRUG|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
223392423|NCT00425321|DRUG|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
223392424|NCT00425321|DRUG|Placebo|Placebo once daily for up to 12 weeks
223392425|NCT00931411|OTHER|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
223392426|NCT00931411|OTHER|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
223392427|NCT02280200|DEVICE|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
223547692|NCT03572231|DEVICE|solifenacin|oral
223547693|NCT03572231|DRUG|darifenacin|oral
223547694|NCT03572231|DRUG|imidafenacin|oral
223547695|NCT03572231|DRUG|tolterodine|oral
223547696|NCT03572231|DRUG|oxybutynin|oral
223547697|NCT03572231|DRUG|trospium|oral
223547698|NCT03572231|DRUG|fesoterodine|oral
224012830|NCT06228391|DRUG|Midazolam|Subjects will receive a single infusion of midazolam at 0.045mg/kg for 40 minutes twice a week for 3 weeks.
224012831|NCT04654026|DRUG|Aspirin/Clopidogrel|No intervention, only observational studies
224012832|NCT04972305|OTHER|Exercise and ergonomics|12 week exercise and fit bike
224012833|NCT04972305|OTHER|Ergonomics|Fit bike
224012834|NCT00562055|DRUG|Atomoxetine|
224012835|NCT00562055|DRUG|PNU-165442G; [S,S]-reboxetine|
224012836|NCT06283368|PROCEDURE|Thyroidectomy, Bilaterally Total|Thyroidectomy, Bilaterally Total
224012837|NCT06283368|PROCEDURE|Thyroidectomy, Unilaterally Total|Thyroidectomy, Unilaterally Total
224012838|NCT06283368|PROCEDURE|Thyroidectomy, Complementary|Thyroidectomy, Complementary
224012839|NCT06283368|PROCEDURE|Thyroidectomy, Near Total|Thyroidectomy, Near Total
224012840|NCT02213341|PROCEDURE|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
224012841|NCT02213341|PROCEDURE|Blood draw|
223392428|NCT05754268|PROCEDURE|Chinese version of the surgical risk assessment system|There is no need to interfere with the patient. Investigators can observe the outcome after using the system for evaluation.
223392429|NCT00811967|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
223392430|NCT00811967|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
223392431|NCT06601465|DRUG|Vericiguat|Tablet - 2.5 mg, 5 mg, 10 mg
223392432|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 1
224012842|NCT02054611|OTHER|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
224012843|NCT02054611|OTHER|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
223392433|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 2
223392434|NCT06841445|DRUG|HRS9531 Tablet|HRS9531 Tablet dose 3
223392435|NCT06841445|DRUG|HRS9531 Tablet placebo|HRS9531 Tablet placebo
223392436|NCT05273151|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
223392437|NCT03483012|DRUG|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
223392438|NCT03483012|PROCEDURE|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
223547699|NCT03572231|DEVICE|propiverine|oral
224012844|NCT00366002|DRUG|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
224012845|NCT06086600|OTHER|Instrument Assisted Soft Tissue Mobilization|"give gentle strokes from proximal to distal to check for trigger point or taut band. After knowing the exact location, give gentle strokes with minimal pressure in all directions by keeping the instrument in 30 to 60 degree angle. Application time will be between 40- 120 seconds.~Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles)"
224012846|NCT06086600|OTHER|Dynamic oscillatory stretch technique|"Passively dorsiflexe the ankle to a point of the first stretch sensation. The next component to DOS, 2- second, passive stretch with slow oscillations at end range was applied. This procedure is repeated 10 times in each set with total of 3 sets .Therefore,10reps x2 second hold oscillation x 3 sets are given.Conventional treatment will include~* Hot pack for 10-15 min (calf muscles)~* Stretching exercises of gastro-soleus (10reps x 2Sets).~* Post session : Cold pack for 5 minutes (calf muscles"
224012847|NCT02111187|DRUG|LDE225|Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
224012848|NCT02644291|DRUG|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
224012849|NCT04144101|DRUG|Etoricoxib|Etoricoxib 60 mg QD Oral
224012850|NCT04144101|DRUG|Aceclofenac|Aceclofenac 100 mg BID Oral
224012851|NCT05469750|DRUG|Dalpiciclib+ letrozole +capecitabine|Continue medication to disease progression
224012852|NCT00014651|DRUG|vapreotide|
224012853|NCT00014651|PROCEDURE|conventional surgery|
224012854|NCT01721460|DRUG|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
224012855|NCT04580082|BEHAVIORAL|Mindfulness lessons|14 lessons on mindfulness, each lasting approximately 20 minutes.
224012856|NCT06414707|DRUG|Vonoprazan, Amoxicillin and Levofloxacin|Group (1) included 160 patients received Vonoprazan 20 mg oral once daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
224012857|NCT06414707|DRUG|Pantoprazole 40mg, Amoxicillin and Levofloxacin|Group (2) included 160 patients received Pantoprazole 40 mg oral twice daily + Levofloxacin 500 mg oral once daily + Amoxicillin 1 gm oral twice daily for 14 days.
224012858|NCT01254240|DEVICE|UVA / UVB phototherapy|UVA / UVB phototherapy
224012859|NCT01254240|DEVICE|UVB phototherapy|UVB phototherapy
224012860|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 100 days
224012861|NCT00294515|DRUG|Valganciclovir|900 mg orally daily for up to 200 days
224012862|NCT02706899|DRUG|vadastuximab talirine|Intravenous (IV) push every 4 weeks
224012863|NCT02706899|DRUG|Azacitidine|75 mg/m\^2 given intravenously or subcutaneously for 7 days every 4 weeks
224012864|NCT02706899|DRUG|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
224012865|NCT00324675|DRUG|Rosiglitazone|4 mg tablets, bid, 12 months
224127781|NCT05813210|DIAGNOSTIC_TEST|Exercise in combination with biomarkers and pharmacological stress CMR test|A bicycle ergometry combined with pharmacoligical stress test is performed. High sensitive Troponin is taken before and after the stress test.
224127782|NCT00843310|DRUG|Lenalidomide (Revlimid)|
224127783|NCT00843310|DRUG|Melphalan|
224127784|NCT00843310|DRUG|Dexamethasone|
223392439|NCT06609408|OTHER|Nature and Game Based Activities|Individuals in experimental group will participate nature and game activities such as terrarium making, planting flowers, making puzzles in intervention.
223392440|NCT02063568|DRUG|Oxytocin|
223547700|NCT05097560|DEVICE|high flow nasal cannula|HFNC provides humidified, heated, oxygen-enriched air at constant concentration with a flow up to 60L/min through a nasal cannula. It washouts the anatomical dead space and decreases the work of breathing.
223547701|NCT05097560|DEVICE|Venturi mask|VM is commonly used by COPD patients during exercise training.
224012866|NCT00324675|DRUG|Placebo|2 tablets per day
224012867|NCT04550533|OTHER|Therapeutic Adherence|To measure adherence to treatment in oncohematological patients in treatment with oral anti-cancer drugs
224296499|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
223392441|NCT06209099|PROCEDURE|Nonoperative Management (NOM)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Nonoperative Management (NOM)
223392442|NCT06209099|PROCEDURE|Local Excision (LE)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Local Excision (LE)
223547702|NCT02248441|OTHER|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
223547703|NCT06046183|BEHAVIORAL|Process group|The medical student process group serves as a space for students to gain increased self-awareness through guided exploration of the psychodynamic processes.
223547704|NCT05641584|OTHER|retrospective data review study|Patient information will be scanned retrospectively from the computer environment and patient cards. No intervention will be made to the patients.
223547705|NCT05084079|DRUG|CSII with formula-based initial insulin regimen|Initial total daily insulin dose(TDD) for CSII was calculated with a formula :（estimate TDD-1(eTDD-1) = 0.35× body weight (kg) + 2.05× FPG (mmol/L) + 4.24×triglyceride(mmol/L) + 0.55× waist circumference (cm) - 49.1）, 42% of which was assigned as total basal dose and 58% as total premeal dose, with the pre-meal doses divided into 30:35:35 for breakfast, lunch and dinner.
223392443|NCT06209099|PROCEDURE|Total Mesorectal Excision (TME)|Drug: Oxaliplatin (OXA) Drug: Capecitabine (CAPE) Radiation: intensity modulated radiotherapy (IMRT) Behavioral: DRE-Endoscopy-MRI-CEA Procedure: Total Mesorectal Excision (TME)
223392444|NCT00794768|DRUG|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
223392445|NCT00794768|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
223730654|NCT04682015|OTHER|WeChat platform group|Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.
223730655|NCT03923855|DEVICE|BTL-899|BTL-899 therapy
223730656|NCT02793141|OTHER|No intervention|No intervention will be administered
224012868|NCT05703997|DIETARY_SUPPLEMENT|Cyclic, 5-day calorie restriction|Cyclic, 5-day, calorie-restricted (about 600 Kcal on day 1; about 300 Kcal on days 2 to 5), plant-based, low-protein, low-carbohydrate diet.
224012869|NCT05703997|DRUG|Atezolizumab|Atezolizumab 1200 mg administered intravenously.
224012870|NCT00133510|BIOLOGICAL|Trivalent Subviron Influenza vaccine (Fluzone)|
224012871|NCT06270706|DRUG|PLN-101095|PLN-101095
223392446|NCT00673699|PROCEDURE|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
223392447|NCT05061589|PROCEDURE|permanent colostomy|An operation that creates an opening for the colon through the abdomen
223392448|NCT06455813|DRUG|Bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
223547706|NCT05084079|DRUG|CSII with weight-based initial insulin regimen|TDD for CSII was started with 0.5 IU/kg, 50% of which was assigned as total basal dose and 50% as total premeal dose, and the total pre-meal dose was divided equally before each meal.
223730657|NCT02452398|DEVICE|Treatment group|The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.
223730658|NCT02452398|OTHER|No intervention|Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
223730659|NCT00499876|DRUG|mefloquine|250mg weekly PO for 6 months
223730660|NCT00499876|OTHER|placebo|1 tablet weekly PO for 6 months
223730661|NCT02301494|DRUG|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
224012872|NCT06270706|DRUG|Pembrolizumab|Pembrolizumab
224012873|NCT04224207|BIOLOGICAL|Wharton's jelly derived mesenchymal stem cell|The mesenchymal cells that were used in this study were isolated from Wharton's jelly of the umbilical cord that was collected allogenicly from a single donor with the mother's consent. All cell preparation and cultivation procedures were conducted in a current Good Manufacturing Practice (cGMP) accredited laboratory (Onkim Stem Cell Technologies, Turkey).Cells were solubilized from cryopreservation before being made ready for injection. Average cell viability for each treatment was over 90.0% and each patient received cell numbers between 2-6x106 in a 1.5 ml saline solution .
224012874|NCT00240799|DRUG|acetaminophen extended release|
224012875|NCT00240799|DRUG|placebo|
224012876|NCT01565278|DRUG|Soybean oil (Standard treatment)|1\. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
224012877|NCT01565278|DRUG|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
224012878|NCT05794308|BEHAVIORAL|Non-Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot does not, or only minimally, provide relational behavioral cues. Participants will view their progress of daily step counts.
224012879|NCT05794308|BEHAVIORAL|Relational Chatbot Physical Activity Intervention|Mobile app-based intervention. Participants will engage in a daily chat with a physical activity promotion chatbot. The chatbot provides relational behavioral cues. Participants will view their progress of daily step counts.
224012880|NCT03863873|PROCEDURE|Platelet-Rich Plasma Injection Group|Platelet-Rich Plasma Injection Group
224012881|NCT04573348|DIAGNOSTIC_TEST|Savicell's ImmunoBiopsy™|ImmunoBiopsy and ELISA
224012882|NCT03090139|DRUG|Anti-TNF Therapy|Anti-TNF therapy.
223547707|NCT03920462|DEVICE|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
223392449|NCT06455813|DRUG|Macrogol 3350 and electrolytes|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
223392450|NCT06455813|DRUG|A combination of macrogol 3350 and electrolytes and bisacodyl|The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents
223392451|NCT05422001|DRUG|low dose ketamine|"Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml"
223392452|NCT05422001|DRUG|Placebo (saline)|Isotonic Saline
223392453|NCT06044142|DRUG|Curcumin|Curcumin and low laser therapy will be used on patients undergoing chemotherapy
223392454|NCT06044142|DEVICE|Laser|Low level laser therapy
223392455|NCT00318890|DRUG|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
223392456|NCT00318890|DRUG|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
223392457|NCT00318890|PROCEDURE|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
223392458|NCT00318890|DRUG|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
223547708|NCT04619238|DIAGNOSTIC_TEST|King's Health Questionnaire|patients fulfilled questionnaire
223730662|NCT02301494|DRUG|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
223547709|NCT04619238|DIAGNOSTIC_TEST|the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form|patients fulfilled ICIQ-SF questionnaire
223547710|NCT02797301|OTHER|synthetic test|The children performed the synthetic test with no time restriction.
223547711|NCT02797301|OTHER|computerised test|The children performed the computerised test with no time restriction.
223730663|NCT00002245|DRUG|Abacavir sulfate|
223547712|NCT01297608|DRUG|caoted suppository|coated suppository with active drug
223547713|NCT01297608|DRUG|coated suppository|coated suppository with placebo
223730664|NCT00002245|DRUG|Amprenavir|
223547714|NCT05875727|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|One dose of 20vPnC will be administered intramuscularly.
223547715|NCT03451513|BEHAVIORAL|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
223547716|NCT03451513|BEHAVIORAL|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
223547717|NCT05871424|DRUG|buprenorphine patch group|5 mcg/h buprenorphine patch will be applied preoperatively
224127785|NCT04617613|DRUG|Omeprazole, Amoxicillin, Metronidazole and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
223392459|NCT04809532|PROCEDURE|Transverse abdominis plane (TAP) block|Ultrasound guide bilateral TAP block at end of cesarean section
223547718|NCT05871424|DRUG|placebo group|simple dressing tape only will be applied
223547719|NCT01386489|BIOLOGICAL|VRC-HIVDNA016-00-VP|
223547720|NCT01386489|BIOLOGICAL|VRC-HIVADV014-00-VP|
223392460|NCT04809532|DRUG|Bupivacain|20ml 0.25% bupvicaine
223392461|NCT04809532|DRUG|Tramadol|intravenous tramadol
223730665|NCT00002245|DRUG|Lamivudine|
223392462|NCT04417621|DRUG|LXH254|LXH254 will be supplied as tablet for oral use.
223392463|NCT04417621|DRUG|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
223392464|NCT04417621|DRUG|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
223392465|NCT04417621|DRUG|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
223392466|NCT06994754|DEVICE|clear aligners|aligners made with 1mm thickness sheet and covering the whole palate
223392467|NCT06995391|BEHAVIORAL|Contemporary Guideline-Adherence|Participants randomized to Contemporary Guideline-Adherence will receive weekly app and text-based messaging encouraging them not to exceed guideline-directed amounts of alcohol, as well as messaging explaining that abstinence is acceptable and may be the best way to avoid AF and that, if a participant decides to consume alcohol, a Mediterranean drinking pattern may be the most healthy.
223392468|NCT06995391|BEHAVIORAL|Alcohol Abstinence|Participants randomized to Alcohol Abstinence will receive weekly app and text-based messaging encouraging avoiding all alcohol consumption.
223392469|NCT03390803|OTHER|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
223392470|NCT06538415|OTHER|Pulse Diet|Participants will consume cooked pulse (112 calories -lentils, red kidney beans, black beans, and pinto beans) during 14 weeks.
223392471|NCT06538415|OTHER|Control Rice Diet|Participants will consume cooked rice (112 calories) during 14 weeks.
224012883|NCT04138264|OTHER|Preoperative opioid counseling|preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
224012884|NCT04206202|DEVICE|3D-Printed Patient-Specific Intramedullary Guide|The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.
223392472|NCT04782076|DRUG|Dabigatran|Administered orally.
223392473|NCT04782076|DRUG|Selpercatinib|Administered orally.
223392474|NCT02574598|DRUG|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
223392475|NCT02574598|DRUG|Docetaxel|Use on both arms as standard of care.
223392476|NCT05323708|BIOLOGICAL|Bmab 1000|60mg/ml Prefilled syringe single dose
223392477|NCT05323708|BIOLOGICAL|Prolia®|60mg/ml Prefilled syringe single dose
223392478|NCT00462917|BEHAVIORAL|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
223392479|NCT00462917|BEHAVIORAL|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
223392480|NCT00462917|BEHAVIORAL|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
223392481|NCT00462917|BEHAVIORAL|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
223392482|NCT03466450|DRUG|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
223547721|NCT05773807|OTHER|Bispectral index|In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
223547722|NCT05773807|OTHER|Observer's assessment alert Sedation|In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
223547723|NCT05773807|PROCEDURE|Gastroscopy|Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
224012885|NCT03678428|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
224012886|NCT03678428|DRUG|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
223392483|NCT03466450|DRUG|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
223392484|NCT04910100|DRUG|Nebivolol Ophthalmic Suspension 1 Percent|1 drop instilled into each eye twice daily
223392485|NCT04910100|DRUG|Nebivolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
223392486|NCT04910100|DRUG|Timolol Ophthalmic Suspension 0.5 Percent|1 drop instilled into each eye twice daily
223392487|NCT04910100|DRUG|Timolol Ophthalmic Solution 0.5 Percent|1 drop instilled into each eye twice daily
223392488|NCT02179762|BEHAVIORAL|moderate exercise intervention|Perform moderate exercise therapy
223392489|NCT02179762|BEHAVIORAL|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
223547724|NCT05773807|DRUG|Propofol|Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
223547725|NCT00145210|DRUG|Nebivolol and Atenolol|
224012887|NCT03678428|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
224012888|NCT03678428|DRUG|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
223392490|NCT02179762|OTHER|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
223392491|NCT02179762|OTHER|laboratory biomarker analysis|Correlative studies
223392492|NCT02179762|BEHAVIORAL|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
224012889|NCT03678428|DRUG|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
224012890|NCT03678428|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
224012891|NCT00440440|DRUG|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
224127786|NCT04617613|DRUG|Omeprazole, Amoxicillin and Clarithromycin|The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
224296500|NCT02503020|DIETARY_SUPPLEMENT|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
223392493|NCT02179762|BEHAVIORAL|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
223392494|NCT02179762|BEHAVIORAL|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
223392495|NCT02179762|BEHAVIORAL|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
223392496|NCT05401981|OTHER|Story checklist|The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
223392497|NCT06018467|DRUG|Dasatinib 100 Mg Oral Tablet|"Dasatinib tablets in blister packs of 10 tablets, from either: Sandoz, STADA Nordic, Zentiva or Bristol-Myers Squibb"
223392498|NCT06018467|DIETARY_SUPPLEMENT|Quercetin 1.250 mg (oral)|five 200mg Quercetin Phytosome capsules, from Thorne
223392499|NCT06018467|DIETARY_SUPPLEMENT|Nicotinamide Riboside 1g (oral)|four 250mg Nicotinamide Riboside Capsules, from Elysium Health
223392500|NCT06997848|PROCEDURE|colonic stent|colonic stent deployment
223547726|NCT04178525|DEVICE|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
223547727|NCT04178525|DEVICE|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
223547728|NCT00349011|PROCEDURE|Personalized risk assessment|
223547729|NCT00349011|PROCEDURE|genetic counseling intervention|
223547730|NCT05984758|DIAGNOSTIC_TEST|AS-OCT imaging|Image acquisition with the Optovue RTVue OCT and the Heidelberg Spectralis OCT2 machines
223547731|NCT05984758|DIAGNOSTIC_TEST|Slit lamp examination|SLE of anterior chamber
223547732|NCT01530178|DRUG|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
223547733|NCT01530178|DRUG|Placebo Oral Tablet|
223547734|NCT05977816|DEVICE|Negative Pressure Wound Therapy|Application of a negative wound pressure therapy dressing to the wound post laparotomy
223547735|NCT05977816|OTHER|Standard wound dressing|Application of a standard wound dressing to the wound post laparotomy
223547736|NCT00276406|DRUG|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
223547737|NCT00276406|DRUG|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
223547738|NCT04713410|DRUG|Prednisolone|Regimen will be to administer prednisolone as a single dose of 60 mg/m2 once daily for 6 weeks, then 40 mg/m2 on alternate day.
224012892|NCT00440440|DRUG|placebo|placebo gel apply daily
223547739|NCT03033680|DRUG|[F-18]PBR06|PET radiopharmaceutical
223547740|NCT05965076|PROCEDURE|Glycine Perio Flow|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss and glycine perio-flow.
223547741|NCT05965076|BEHAVIORAL|Angled Toothbrush|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and an angled toothbrush.
223547742|NCT05965076|PROCEDURE|Standard Professional Oral Hygiene|Professional plaque and tartar removal by means of titanium curettes, bridge and implant floss.
223547743|NCT05965076|BEHAVIORAL|Standard Domiciliary Oral Hygiene|Patients will be educated and motivated in domiciliary oral hygien by means of bridge and implant floss and a standard toothbrush.
224012893|NCT05176041|OTHER|Naser Al-Husban|observation
224012894|NCT04542889|DIAGNOSTIC_TEST|Absolute coronary flow and resistance measurements|Thermodilution-based measurements of absolute coronary resistances using the FFR pressure guide (PressureWire® Certus® from St Jude Medical Abbott) and the Rayflow® microcatheter (Hexacath, Paris, France).
224012895|NCT04542889|DIAGNOSTIC_TEST|IMR measurement|IMR measurement by thermodilution using the St Jude pressure guide.
224012896|NCT00236600|DRUG|topiramate|
224012897|NCT01967589|DRUG|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
224012898|NCT01967589|DRUG|placebo|Once-daily doses for oral administration
224012899|NCT02848287|DRUG|normal saline|1\*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
224012900|NCT02848287|DRUG|ropivacaine|1\*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
223392501|NCT02051556|BEHAVIORAL|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
223392502|NCT02051556|BEHAVIORAL|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
223392503|NCT02051556|BEHAVIORAL|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
223392504|NCT07005726|BIOLOGICAL|BCG Vaccine|The WHO-prequalified BCG-Japan or BCG-Denmark
223392505|NCT05712395|BEHAVIORAL|Exercise|Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
223392506|NCT05426369|BIOLOGICAL|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein|Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)
223547744|NCT06513741|BEHAVIORAL|Mentoring Workshop|"Faculty mentoring workshop with the title Faculty Mentoring; building stronger by digging deeper was designed as a two-day workshop of three hours each for the faculty members of the two institutions at separate times"
223547745|NCT01470131|DRUG|Masitinib|Masitinib 6 mg/kg/day
224012901|NCT00918892|GENETIC|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
224012902|NCT00918892|OTHER|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
224012903|NCT00918892|OTHER|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
224012904|NCT03280589|OTHER|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex \[6\]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
224012905|NCT03280589|OTHER|Sitting Quietly|Participant breaths in their natural way with out instruction
224012906|NCT03280589|OTHER|Deep breathing|Participant is required to pay attention to each breath
224012907|NCT02910050|DRUG|Bicalutamide|50mg once a day orally
224012908|NCT02910050|DRUG|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
224012909|NCT04559763|DEVICE|Non-Invasive Controlled Hypoxia|Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
224012910|NCT04559763|OTHER|Introduction of Motion conditions: tapping or rubbing|Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
224012911|NCT02483026|DIETARY_SUPPLEMENT|Multi vitamin|Multi vitamin
224012912|NCT02483026|DIETARY_SUPPLEMENT|vitamin D|Vitamin D
224012913|NCT00935727|OTHER|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
224127787|NCT03380117|BEHAVIORAL|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
223392507|NCT06072859|OTHER|Humidified Forest Oils|60mls Limonene in 200mls water humidified with a diffuser.
223392508|NCT06072859|OTHER|Forest oils and audio-visual forest exposure|60mls Limonene in 200mls water humidified with a diffuser and audiovisual Forest sights and sounds on Surface Pro tablet.
223547746|NCT01470131|DRUG|Placebo|Matching placebo
223547747|NCT01470131|DRUG|Bortezomib|Standard therapy (cycles of bortezomib)
223547748|NCT01470131|DRUG|Dexamethasone|Standard therapy (cycles of dexamethasone)
223547749|NCT04213469|BIOLOGICAL|PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells|Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
223547750|NCT01819207|OTHER|blood test by thromboelastography|
223392509|NCT07010276|DEVICE|DBS Arm|Patients in the DBS treatment arm will undergo surgical DBS implantation.
223392510|NCT07010276|DEVICE|VNS arm|Patients in the VNS treatment arm will undergo surgical VNS implantation.
223547751|NCT00192920|BEHAVIORAL|Transfusion practice|
223547752|NCT01798901|DRUG|HDAC inhibitor AR-42|Given PO
224012914|NCT04642716|OTHER|Saliva collection of patients and salivary free amino acids analysis|
224127788|NCT04165343|RADIATION|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
224127789|NCT04165343|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
223392511|NCT06756035|DRUG|CT-95|Weekly IV dosing
223392512|NCT01949662|DRUG|Lorazepam|3 mg by vein one time only.
223392513|NCT01949662|DRUG|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
223547753|NCT01798901|DRUG|decitabine|Given IV
223547754|NCT01798901|OTHER|laboratory biomarker analysis|Correlative studies
223547755|NCT01798901|OTHER|pharmacological study|Correlative studies
223547756|NCT05667883|DRUG|glucocorticoid + cytoxan|The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
223547757|NCT06345261|DRUG|DiphenhydrAMINE 50 Mg/mL Injectable Solution|injection of Diphenhydramine 50 Mg/mL
223547758|NCT06345261|DRUG|Saline|injection of saline
223547759|NCT00816491|DEVICE|conventional white light colonoscopy|conventional white light colonoscopy
223547760|NCT00816491|DEVICE|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
223547761|NCT03120663|DRUG|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
224012915|NCT04714749|PROCEDURE|Endovenous treatment|Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
224012916|NCT04714749|DEVICE|Cyanoacrylate glue|Treatment of great saphenous vein (its tributaries and possible incompetent perforators feeding the ulcer) by endovascular cyanoacrylate glue
224012917|NCT04305717|DEVICE|ReDS-guided strategy|A discharge scheme based on specific target value given by the device
224138584|NCT03734952|RADIATION|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
224138585|NCT03734952|DRUG|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
224012918|NCT03182361|DEVICE|Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants|Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
224012919|NCT02008851|BIOLOGICAL|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
224138586|NCT03734952|PROCEDURE|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
223392514|NCT01949662|DRUG|Haloperidol decanoate|8 mg/day by vein.
223392515|NCT01949662|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
223392516|NCT04891510|DEVICE|REVOLVE Advanced Adipose System|The REVOLVE system is an all-in-one fat processing device that harvests, filters, actively washes, and removes strands from lipoaspirate and allows for reinjection without any additional manipulation (REVOLVE 2020).
223392517|NCT04891510|DEVICE|LipoGrafter|The LipoGrafter system is designed to be a start-to-finish closed system with minimal processing of the lipoaspirate, minimizing the risk of contamination and fat cell damage (LipoGrafter 2020).
223392518|NCT04891510|PROCEDURE|Viality|The Viality system uses the AuraClens solution that acts as a surfactant to bring impurities like blood, free oil, and cellular debris into solution, where they can be flushed out through suction.
223547762|NCT04850924|OTHER|evaluation psychological trauma|9 classes of symptoms to be evaluated
223547763|NCT00154817|PROCEDURE|radiotherapy|
223547764|NCT01903772|OTHER|Inspiratory Muscle Training|
223547765|NCT05103553|OTHER|Outpatient Clinic|Follow-up in outpatient clinic
223547766|NCT00125814|DRUG|Interferon alfa-2b|
223547767|NCT00125814|PROCEDURE|Structured treatment interruptions|
223547768|NCT01747343|BEHAVIORAL|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
223392519|NCT07017569|BEHAVIORAL|Mobile health application|"This group will receive the mHELP mobile and watch application with full functionality which provides weekly self-assessment and self-reported events PLUS self-management functionality. The self- management functionality includes additional on-demand features (see the attached list of features). These include~* a breath functionality that provides a times breathing exercise similar to the one provided by the Apple iWatch; users can see changes in their heart rate during the breathing exercise and will see a summary of heart rate changes~* a calendar features that allows students to upload their class schedule and see different activities such as self-assessments~* a journaling feature that allows participants to write a journal~* a task list to take note of major tasks and add them to calendar~* a set of relaxation media including videos and audios that participants can use on demand"
223392520|NCT07017634|DEVICE|Novosis Putty|Single Level TLIF surgery with Novosis Putty
224012920|NCT02755051|BEHAVIORAL|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~1. Sleep education~2. Sleep scheduling, limit setting, and stimulus control~3. Teaching relaxation strategies and other adaptive coping skills~4. Parenting strategies (differential attention, rewards, consequences)~5. Identification of maladaptive \& adaptive cognitions~6. Problem solving \& communication skills~7. Sleep restriction; bright light to change circadian rhythms~8. Review gains and plan for long-term maintenance"
224012921|NCT04512794|DEVICE|AcQMap High Resolution Imaging and Mapping System|Evaluate the safety and effectiveness of the AcQMap System in mapping atrial arrhythmias when a specific procedure work flow is followed.
223392521|NCT07017634|OTHER|Standard of Care|Single Level TLIF surgery with standard of care bone graft
223392522|NCT07017777|BIOLOGICAL|PCV13i|3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
223392523|NCT07017777|BIOLOGICAL|Prevnar 13|3 doses: 2 months (Dose 1) months (Dose 2), 12-15 months (Booster dose)
224012922|NCT02802189|OTHER|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles"
224012923|NCT02802189|OTHER|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~* Upper border of the trapezius muscle~* sternocleidomastoid~* levator scapulae muscle~* splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~* Ischemic compression~* Muscle energy technique~* Strain-counterstrain technique"
224012924|NCT06218862|DRUG|Sivelestat sodium|Sivelestat sodium was administered through a 24-hour continuous intravenous infusion at a rate of 0.2 mg/kg/h, for at least 72 hours and a maximum duration of 14 days.
223392524|NCT05609981|OTHER|Clinical medication review focused on deprescribing|"A pharmacist-led intervention consisting of a clinical medication review with the focus on deprescribing in older patients using multidose drug dispensing (MDD) systems.~Pharmacist are trained in deprescribing and a developed toolbox to support the intervention is provided"
223392525|NCT07017244|DIETARY_SUPPLEMENT|Verum|1st cycle - 30 days continuous use Cycle 2 - 30-day washout
223392526|NCT07017244|DIETARY_SUPPLEMENT|Active comparator|1st cycle - 30 days continuous use Cycle 2 - 30-day washout
223547769|NCT05336734|BEHAVIORAL|Psychotherapy|see group description
223547770|NCT05077540|DRUG|oxytocin|20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)
223547771|NCT05077540|DRUG|misoprostol|800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)
223547772|NCT04245449|BEHAVIORAL|TEAACH|"TEAACH e-learning: 3-months of online educational modules include neuroscience education (based on an effective pain educational model37) to improve patient self-efficacy, and strategy-training38 to improve patients' problem-solving abilities for at-home arm use. The course is live on the MUSC MoodleCE platform.~TEAACH in-clinic therapy: 24 in-clinic sessions; 3 times/week for 4 weeks (month 1), 2 times/week for 4 weeks (month 2) and 1 time/week for 4 weeks (month 3) with 200 movement repetitions per session. In our RCTs, this therapy dose required \~1.0-1.5 hours/session. A critical element of TEAACH is the focus on linking in-clinic therapy to out-of-clinic real world paretic arm use via MoodleCE Learning Activities."
223547773|NCT04346186|DIAGNOSTIC_TEST|IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
223547774|NCT04346186|DIAGNOSTIC_TEST|Elisa-test for IgM and IgG to SARS-CoV-2|Elisa-test for IgM and IgG to SARS-CoV-2
223547775|NCT00164840|DRUG|Esomeprazole|
223547776|NCT03811392|PROCEDURE|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
223547777|NCT03811392|PROCEDURE|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
223547778|NCT03812341|OTHER|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
223547779|NCT00669825|DRUG|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
224012925|NCT06218862|DRUG|Control|Not use Sivelestat sodium
224012926|NCT00464867|BIOLOGICAL|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
224012927|NCT00735475|BIOLOGICAL|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
224012928|NCT00735475|BIOLOGICAL|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
223547780|NCT00669825|DRUG|Placebo|Placebo to be administered via intragastric tube
223547781|NCT01487174|DRUG|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
224012929|NCT03814148|DRUG|LENINGRADO 5 association|1 coated sustained-release tablet, oral, once a day.
224012930|NCT03814148|DRUG|Natrilix® SR|1 coated sustained-release tablet, oral, once a day.
224012931|NCT03814148|OTHER|Natrilix SR Placebo|1 coated sustained-release tablet, oral, once a day.
224012932|NCT03814148|OTHER|Leningrado 5 association Placebo|1 coated sustained-release tablet, oral, once a day.
224012933|NCT04405349|BIOLOGICAL|VB10.16|Vaccination
224012934|NCT04405349|BIOLOGICAL|Atezolizumab|Intravenously infusion
224012935|NCT04535310|DEVICE|Precision1® Daily Disposable Contact Lens|Soft, spherical contact lens used to correct distance vision.
224012936|NCT01769651|OTHER|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
224012937|NCT00526838|DRUG|XL228|1-hour IV infusion
224012938|NCT04258202|OTHER|Alveolar recruitment maneuver|The two methods for performing an alveolar recruitment maneuver. Alveolar recruitment maneuvers consisted of a stepwise increase in tidal volume to a plateau pressure of 30 cm H2O versus a stepwise increase in PEEP H2O to a plateau pressure of 30 cm H2O.
224012939|NCT05746364|BEHAVIORAL|Brief CAT-Informed Intervention for Young People experiencing Difficulties with Eating|The therapy draws upon the principles of Cognitive Analytic Therapy (CAT), focussing on collaboratively identifying relational patterns (relationships with self and others) that young people experience difficulties with. The young person will be invited to attend 5 weekly sessions, each lasting 30-50 minutes. It will be delivered within a seven-week window (allowing for cancellations/missed sessions). Researchers will follow the RIDE manual treatment guide, which was developed by Clinical Psychologists, CAT accredited therapists and researchers.
224012940|NCT03626987|DIAGNOSTIC_TEST|mass spectrometry (MALDI-TOF)|The determination of the protein composition of the bacterial spectrum
224012941|NCT04192019|DRUG|Micro-glucagon|Administration of 80 µg (micro-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
224012942|NCT04192019|DRUG|Mini-glucagon|Administration of 150 µg (mini-dose) subcutaneous Dasiglucagon 5 min before the start of exercise
224012943|NCT06095687|BEHAVIORAL|Mindfulness Meditation|Five, 20-minute audio-recorded training sessions of mindfulness of breath and body meditation, practiced over consecutive days, delivered remotely via Qualtrics.
224012944|NCT06095687|BEHAVIORAL|Clinical Hypnosis|Five, 20-minute audio-recorded training sessions of clinical hypnosis with suggestions targeting pain management, practiced over consecutive days, delivered remotely via Qualtrics.
224012945|NCT05661422|DEVICE|RESP™ Biosensor|The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.
223547782|NCT01487174|DRUG|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
223547783|NCT06028152|OTHER|"End-of-life conversation game called Hello"|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace"
223547784|NCT02482662|PROCEDURE|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
223547785|NCT00395473|DRUG|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
223547786|NCT00057564|DRUG|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
223547787|NCT00057564|DRUG|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
223547788|NCT01537315|DRUG|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
223547789|NCT01537315|OTHER|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
223547790|NCT03323853|BEHAVIORAL|Computerized Assessment and Referral System (CARS) Self-Assessment Screener|Subjects will take the CARS-SA Screener.
223547791|NCT03323853|BEHAVIORAL|CARS-SA Summary Results|Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
223547792|NCT02197572|DRUG|Sapanisertib|Sapanisertib capsules.
223547793|NCT02769429|DEVICE|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
223547794|NCT02769429|DEVICE|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
223547795|NCT05433701|RADIATION|Stereotactic Body Radiotherapy|"* Verify the setup position and respiration of patients as in the simulation CT image.~* To precisely align the tumor prior to each treatment, cone-beam CT and gated fluoroscopy using the On-board Imager mounted on the linear accelerator are performed.~* The Real-time Position Management system is used to monitor the accuracy of breathing phase during treatment."
223547796|NCT05433701|PROCEDURE|Radiofrequency Ablation|\- RFA are performed under local anesthesia or monitored anesthesia care with either a 15-gause or 17-gause internally cooled electrode, depending on the size of the tumor.
223547797|NCT01460810|OTHER|1000CsK Silicon Oil Tamponade|Details covered in arm description
223547798|NCT00337831|PROCEDURE|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
223547799|NCT02204423|PROCEDURE|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
223564215|NCT05747209|OTHER|Observation of Exercise Program Adherence|Observation of a monitored group exercise regimen utilizing standard of care high-load resistance training and functional exercises with compound movements under close supervision and with the goal of improving functional mobility, body composition, and strength after cancer treatment to study adherence and attendance to the exercise program.
223392527|NCT07017322|DEVICE|Alpha-Stim AID|Subjects will receive non-invasive cranial electrotherapy stimulation (CES) treatment in 20-minute group sessions taking place immediately prior to breakfast, lunch, and dinner. This study uses the Alpha-Stim AID® CES device which will be set to the highest amplitude that is tolerated by the participant (with a minimum of 200 microampere (µA) and a maximum of 500 µA stimulation) at 0.5 hertz for a duration of 20 minutes per session, 3 sessions per day, for 3 separate days of stimulation (180 minutes of stimulation total).
224012946|NCT01390077|DRUG|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
224012947|NCT01917539|DEVICE|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
223392528|NCT07017231|OTHER|histamine dihydrochloride|A small drop of histamine dihydrochloride (1%, in saline) will be applied to two previously determined areas followed by a prick through the drop.
223392529|NCT07017231|OTHER|Cowhage|Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
223392530|NCT07017907|DEVICE|Heart rate-based AI software for detecting thyrotoxicosis|A software-based investigational medical device that uses artificial intelligence to detect the thyrotoxic state in patients with hyperthyroidism. The device analyzes resting heart rate data collected from wearable devices along with thyroid function test results (free T4 and TSH). The device is not FDA-approved and will be used solely for observational performance evaluation without influencing clinical care.
223392531|NCT04748822|OTHER|questionnaires|The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
223547800|NCT05370274|PROCEDURE|Strength training intervention|The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb (the wrist extensors and the elbow and shoulder flexors). In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Training will start at 50% of 1RM and progress by 10% each week to reach 80% of 1RM by week 4. The same gradation of intensity will be applied to the grip muscles. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
223547801|NCT05370274|PROCEDURE|Cranial nerve non-invasive neuromodulation (CN-NINM)|During each strength training session, the CN-NINM will be applied, with the help of a portable stimulator comprising a network of 18 electrodes, directly on the tongue of the participants for 20 minutes. The participants will hold the CN-NINM in place by pressing their tongue upwards. The CN-NINM will generate high-frequency pulses (50 μsec to 150 Hz), and the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink.
223547802|NCT04570306|DRUG|Belimumab|The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
223547803|NCT04356300|BIOLOGICAL|Exosome of MSC|Exosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
223547804|NCT05382741|DRUG|Durvalumab Injection for intravenous use 500 mg vial solution for infusion|MEDI4736
223547805|NCT05382741|DRUG|Regorafenib 30 mg capsules|BAY73-4506
223547806|NCT01607762|DRUG|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
223547807|NCT01607762|DRUG|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
223547808|NCT01607762|DRUG|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
223547809|NCT01607762|DRUG|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
223547810|NCT01607762|DRUG|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
223547811|NCT00594607|DEVICE|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
223547812|NCT00594607|DEVICE|Fx8 (Fresenius)|Polysulphone dialysis membrane
223730666|NCT03970161|DEVICE|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
224012948|NCT01917539|DEVICE|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
224012949|NCT03095131|DEVICE|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
224012950|NCT02442336|BEHAVIORAL|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
223392532|NCT07016906|OTHER|MRI|Knee MRI at different degrees of flexion
223392533|NCT07017153|OTHER|Questionnaire B|Questionnaire regarding patient decision aid: How Do I Control My Blood Pressure? Lifestyle Options and Choices of Medicines.
223392534|NCT07017153|OTHER|Questionnaire A|Questionnaire regarding patient decision aid: Hypertension - How to Prevent Cardiovascular Diseases
223392535|NCT07018310|OTHER|blood sampling|Additional blood sampling as part of routine care
223547813|NCT01047917|BEHAVIORAL|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
223392536|NCT07016763|DIETARY_SUPPLEMENT|Oral fatty acid|Intervention therapy (treatment group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) and oral supplementation of FAs (550 mg/tablet), vitamin B6 (0.21 mg/tablet), perilla frutescens (20 mg/tablet) and liquorice (200/mg/tablet) (2 tablets a day with meals)
223392537|NCT07016763|DRUG|Mometasone Furoate Nasal Spray (MFNS)|Standard therapy (control group) daily treated for 90 consecutive days by INCs (mometasone furoate; 1 puff in each nostril, twice a day) only
223392538|NCT07032402|BEHAVIORAL|Education and Counseling|Mothers who consent will have the ABÖS-M App installed on their smartphones and will create a personal login. Researchers will provide brief training on how to use the app. The intervention consists of four educational modules designed with individualized and gamified content. Mothers are expected to complete all modules within two weeks. The app monitors their progress and provides automated feedback based on their performance, encouraging mothers to review topics if needed. Weekly WhatsApp reminders will be sent to promote app engagement, and researchers will track login frequency and usage time. Mothers who fail to complete the modules within the specified timeframe will be excluded from the study. Participants will also be asked to fill out a daily care diary throughout the intervention period.
223392539|NCT07032402|OTHER|Standard Care|"After obtaining written and verbal consent, the ABÖS-M App will be installed on their smartphones, and researchers will provide face-to-face instructions on its basic use. Mothers in the control group will receive routine newborn care education provided by clinical nurses, which includes non-standardized safe sleep information typically given before hospital discharge. No structured or individualized training will be provided by the researchers during the study period. For one month, control group participants will have limited access to certain app features, including the About Us section, care diary, and assessment tools. Mothers will be asked to complete the care diary daily, and researchers will send regular reminders."
223547814|NCT02807220|DRUG|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
223392540|NCT03810040|DEVICE|140 microns denuding pipette|the degranulated needle size was 140 microns
223392541|NCT03810040|DEVICE|150 microns denuding pipette|the degranulated needle size was 150 microns
223547815|NCT02228044|BEHAVIORAL|Prevention program|
223547816|NCT03801928|DRUG|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
223547817|NCT04847440|DRUG|ATI-2173|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
224012951|NCT01472549|DRUG|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
223547818|NCT04847440|DRUG|Viread|Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
223547819|NCT04847440|DRUG|AB-729|AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
224012952|NCT01472549|DRUG|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
223547820|NCT05130684|DRUG|Nivolumab|adding nivolumab to conventional neoadjuvant CRT
223547821|NCT02520492|DEVICE|noninvasive method of ICP measurements (Elios)|
223730667|NCT01435954|DRUG|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
224012953|NCT04995939|PROCEDURE|Laboratory parameters and Scoring systems|Neutrophil/ Lymphocite ratio, albumin level and scoring systems has been evaluated.
224012954|NCT05869578|PROCEDURE|Anesthesia Intervention|Patients exposed to any anesthesia intervention will be assessed to whether the exposure to anesthesia confers a risk for perioperative outcomes
223730668|NCT01435954|DRUG|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
223730669|NCT03559465|PROCEDURE|skin biopsy|"A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy."
224012955|NCT01302860|DRUG|ACZ885|
223392542|NCT00002897|DRUG|cisplatin|
224012956|NCT00844532|DEVICE|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
224012957|NCT00601159|DRUG|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
224138587|NCT03734952|RADIATION|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
224138588|NCT01453998|BIOLOGICAL|Infanrix hexa|Single dose, licensed formulation, intramuscular into right thigh
224138589|NCT01453998|BIOLOGICAL|Prevenar 13|Single co-administered dose, intramuscular into left thigh
224138590|NCT01453998|BIOLOGICAL|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
224138591|NCT03296293|OTHER|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
224138592|NCT03296293|OTHER|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
224138593|NCT03296293|OTHER|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
223392543|NCT00002897|DRUG|fluorouracil|
223392544|NCT00002897|PROCEDURE|conventional surgery|
223392545|NCT02668575|BEHAVIORAL|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
223392546|NCT06581380|DRUG|JK-1201I|JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
224012958|NCT03573687|DIETARY_SUPPLEMENT|Micellar Casein Protein|The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
224012959|NCT03573687|OTHER|Resistance Exercise Training|Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
224127790|NCT04165343|DIAGNOSTIC_TEST|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
224127791|NCT04165343|DIAGNOSTIC_TEST|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
223392547|NCT06581380|DRUG|Topotecan|Topotecan will be administered per drug label.
223392548|NCT00316290|BEHAVIORAL|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
223392549|NCT00316290|BEHAVIORAL|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
223392550|NCT00266279|DRUG|Oxaliplatin, Capecitabine|"Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21"
223392551|NCT03434522|DEVICE|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
223392552|NCT04785547|DRUG|Blinatumomab|15 mcg/m2/day for 28 days
223392553|NCT01869933|DRUG|OC-10X|
223392554|NCT00477880|BIOLOGICAL|Cetuximab|
223392555|NCT02350465|BEHAVIORAL|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
223392556|NCT02350465|BEHAVIORAL|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
223392557|NCT04135937|DRUG|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
223392558|NCT04135937|DRUG|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
224012960|NCT03111511|DRUG|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
223392559|NCT04135937|BEHAVIORAL|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
223392560|NCT04135937|DRUG|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
223392561|NCT04135937|BEHAVIORAL|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
223392562|NCT06757647|DRUG|Acalabrutinib|Given PO
224012961|NCT03111511|DRUG|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
224012962|NCT03111511|DRUG|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
224012963|NCT04736901|DRUG|Enoxaparin|0.5 mg/kg every 12 hours
224012964|NCT04736901|DRUG|Enoxaparin|40 mg/day
224012965|NCT04736901|DRUG|Rivaroxaban|10 mg once daily
224012966|NCT04736901|DRUG|Rivaroxaban|20 mg once daily
224012967|NCT04736901|DRUG|Apixaban|2.5 mg twice daily
224012968|NCT04736901|DRUG|Apixaban|5 mg twice daily
224012969|NCT04621513|DEVICE|laser acupuncture (RJ laser S/N 1813458)|use a low-level-laser acupuncture on acupoint
224012970|NCT04621513|DRUG|western medicine|Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD
224127792|NCT04224740|DRUG|Pembrolizumab|Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)
223392563|NCT06757647|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223392564|NCT06757647|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223392565|NCT06757647|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223392566|NCT06757647|PROCEDURE|Computed Tomography|Undergo CT
223392567|NCT06757647|PROCEDURE|Magnetic Resonance Imaging of the Heart|Undergo CMR
223392568|NCT03097627|DRUG|ICG Intervention|The intervention to be administered is the drug indocyanine green.
223392569|NCT03097627|DEVICE|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
223392570|NCT03577080|OTHER|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
223392571|NCT00821743|DEVICE|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
223392572|NCT01573585|BEHAVIORAL|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
223392573|NCT01573585|BEHAVIORAL|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
223392574|NCT04873947|DEVICE|Pulse Oximeter|The investigational device will be placed on the finger of the left or right hand per the instructions for use. Simultaneous data collection will be set up for the system under test and control oximeter.
223392575|NCT06750107|BEHAVIORAL|Safe South Africa|"The Safe South Africa intervention is a gender- and developmentally-tailored, designed to reduce actual or intended HIV risk behaviors, actual or intended IPV perpetration frequency, and endorsement of IPV supportive attitudes. This intervention comprises 2-hour sessions, held once a week for a total of two weeks. The intervention also includes take-home activities to deepen behavioral engagement with received sessions and to prime the pump for up-coming sessions. Part 2 involves behavioral practice, including bystander intervention techniques."
223392576|NCT01043692|OTHER|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
223392577|NCT01333592|DRUG|KAD-1229|
223392578|NCT00886080|PROCEDURE|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
223392579|NCT03870815|PROCEDURE|CABG|Patients who undergoing CABG
223392580|NCT03870815|PROCEDURE|PCI|Patients who undergoing PCI with DES
223392581|NCT00949637|BEHAVIORAL|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
224012971|NCT04259944|DRUG|CAPOX|"DAY 1~* OXA 130 mg/m2 administered as intravenous infusion over 2 hours in 250 mL dextrose 5%~* CAPE 1000 mg/m2 administrated per os twice daily~DAY 2-14~• CAPE 1000 mg/m2 os twice daily~Cycle length is 3 weeks comprising 2 hours of oxaliplatin infusion every 21 days, 14 days of oral capecitabine and 7 days of resting."
224012972|NCT04259944|DRUG|Capecitabine|"DAY 1-14~• CAPE 1250 mg/m2 os twice daily~Cycle length is 3 weeks comprising 14 days of oral capecitabine and 7 days of resting."
223392582|NCT00949637|BEHAVIORAL|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
223392583|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase I|Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
223392584|NCT03411161|DRUG|Paclitaxel|Paclitaxel (IV) at 80 mg/m²/week
223392585|NCT03411161|DRUG|Combination therapy (S81694 + paclitaxel) phase II|S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
223392586|NCT05702333|DRUG|Epinephrine Norepinephrine Dobutamine Dopamine Levosimendan|Vasoactive-inotropic drugs were administered according to clinical decision of the doctor in charge.
223730670|NCT03559465|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
223730671|NCT00168727|DRUG|ibritumomab tiuxetan (Zevalin®)|
224012973|NCT04259944|DRUG|FOLFIRI|"Day 1:~* IRI, 180 mg/m2 administered as iv infusion over 30-90 minutes in 250 mL dextrose 5%, concurrently (via a Y-connector) with~* LV, 400 mg/m2 administered as an iv infusion over 2 hours, in 250 mL dextrose 5%, followed by~* 5-FU, 400 mg/m2 administered as a bolus injection (iv push administered by hand) and then at 2400 mg/m2 administered as a iv infusion over 46 hours.~Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest."
224012974|NCT00003827|DRUG|amifostine trihydrate|
224012975|NCT00003827|DRUG|cytarabine|
224012976|NCT00003827|DRUG|topotecan hydrochloride|
224012977|NCT03222388|OTHER|Questionnaire - IIEF 5/15|International Index of Erectile Function
224127793|NCT04224740|DRUG|Standard of care therapy|Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
224127794|NCT00363012|BIOLOGICAL|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
224127795|NCT00363012|OTHER|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
224127796|NCT00363012|OTHER|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
224127797|NCT00363012|PROCEDURE|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
223392587|NCT04114682|OTHER|Multi parametric MRI scan|There will be no intervention to the standard of care these patients receive. However, consented participants will be asked to make two study visits where a multiparametric MRI scan will be performed - these visits will be defined as visit 2 and visit 3. An optional echocardiogram may be included at Visit 2.
223547822|NCT06004258|OTHER|Painless Vaccination|"Structural adaptation of the vaccination areas and cozy decoration (colorful room, mobiles to hang on the ceiling) Nursing uniforms decorated with children's pictures Introduction of toys, stuffed animals, stamps and reward stickers, drawings and crayons, soothing music in the background~Antalgic measures by age ranges:~0-6M (FLACC scale) Breastfeed for two minutes if infant is breastfeeding Glucose 33% or 50% or if rotavirus vaccination, on mother's pacifier or gloved finger (non-nutritive sucking) Comfort between vaccinations 6-15M (FLACC scale) Position infant sitting on guardian's lap facing forward Distraction techniques: stuffed animals, toys, audiovisual devices 3-6Y (Wong-Baker scale) Involve child, explain Child sits on tutor's lap facing forward Distraction techniques: audiovisual devices, drawings 6-14Y (VAS scale)Always seated. Distraction method: audio-visual devices, breathing"
223547823|NCT04094324|BEHAVIORAL|Questionnaires|4 questionnaires will be answered via iPads
223547824|NCT02180204|DRUG|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
223547825|NCT02180204|DRUG|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
223547826|NCT00118274|BIOLOGICAL|incomplete Freund's adjuvant|Given intradermally and subcutaneously
223547827|NCT00118274|BIOLOGICAL|melanoma helper peptide vaccine|Given intradermally and subcutaneously
223547828|NCT00118274|BIOLOGICAL|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
223547829|NCT00118274|BIOLOGICAL|tetanus toxoid helper peptide|Given intradermally and subcutaneously
223730672|NCT03888547|OTHER|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
223730673|NCT05594914|DRUG|AK104|AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
223730674|NCT05489809|PROCEDURE|Endotracheal extubation with suctioning|General anestheisa is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying suctioning.
223392588|NCT00856492|BIOLOGICAL|bevacizumab|Given IV
223392589|NCT00856492|BIOLOGICAL|pegfilgrastim|Given subcutaneously
223547830|NCT00118274|DRUG|cyclophosphamide|Given IV
223547831|NCT00855777|DRUG|etoricoxib|etoricoxib 120 mg/day for 3 days
223547832|NCT00855777|DRUG|ibuprofen|ibuprofen 1,800 mg/day for 3 days
223547833|NCT02014506|DRUG|Fludarabine|40mg/M2 once daily IV on days -7 to -2
223547834|NCT02014506|DRUG|Cyclophosphamide|50 mg/kg IV on day -3 and -2
223547835|NCT02014506|BIOLOGICAL|anti-thymocyte globulin|
223730675|NCT05489809|PROCEDURE|Endotracheal extubation with positive pressure|General anesthesia is maintained with an endotracheal tube. At the end of anesthesia, the endotracheal tube is removed by applying positive pressure.
223730676|NCT03349749|DEVICE|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
223730677|NCT02046109|PROCEDURE|Repair|
223730678|NCT02046109|PROCEDURE|Replace|
223730679|NCT02548247|DIETARY_SUPPLEMENT|Orafti® Inulin|Dietary fiber
223730680|NCT02548247|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223730681|NCT01116154|DRUG|lenalidomide|Given orally
223730682|NCT01116154|DRUG|vorinostat|Given orally
223392590|NCT00856492|DRUG|cyclophosphamide|Given IV
223392591|NCT00856492|DRUG|doxorubicin hydrochloride|Given IV
223392592|NCT00856492|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223392593|NCT00818350|DRUG|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
223392594|NCT04069273|DRUG|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
223392595|NCT04069273|DRUG|Ramucirumab|Ramucirumab 10 mg/kg IV
223392596|NCT04069273|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV
223392597|NCT03852953|OTHER|Under- or overdiagnosed cancer|Diagnosed with a cancer that was visible on prior mammograms
223392598|NCT03852953|OTHER|Screening|Invited or attended BreastScreen Norway
223547836|NCT02014506|BIOLOGICAL|filgrastim|Beginning on day 4 and continuing until blood counts recover
223547837|NCT02014506|RADIATION|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 \& -4 (severe aplastic anemia)
223547838|NCT02014506|PROCEDURE|TCRαβ-depleted hematopoietic cell transplantation|
223547839|NCT02014506|DEVICE|CliniMACS|Immunogenetic depletion of TCRαβ cells
223547840|NCT00584818|DRUG|PB127 for Injectable Suspension|"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
223547841|NCT00864175|DRUG|INCB007839|100 mg BID
223547842|NCT00864175|DRUG|INCB007839|200 mg BID
223547843|NCT00864175|DRUG|INCB007839|300 mg BID
223547844|NCT00864175|DRUG|INCB007839|300 mg BID
223392599|NCT06024408|DRUG|ALN-PNP|Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
223392600|NCT06024408|DRUG|Placebo|Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
223392601|NCT07073586|PROCEDURE|Lymphovenous Anastomosis|Microsurgical creation of multiple lymphatic-venous connections in the most affected limb under general anaesthesia.
223392602|NCT07073586|OTHER|Complete Decongestive Therapy|Complete Decongestive Therapy, comprising bandaging, skin care and exercise, followed by compression garments.
223392603|NCT04239755|DRUG|Doxycycline 100 MG Oral Tablet|doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 day
223392604|NCT04239755|OTHER|placebo|placebo in addition to the standard treatment.
223392605|NCT05012618|DRUG|LUNA18|LUNA18 Capsule
223392606|NCT05012618|DRUG|Cetuximab|Cetuximab as a IV infusion
223392607|NCT06814756|BIOLOGICAL|phage therapy|Single anti-Morganella morganii bacteriophage drug product
223392608|NCT02290444|DRUG|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
223392609|NCT05797974|OTHER|MyChart enabled virtual weight loss coach|MyChart-enabled virtual coach utilized to aid in preoperative weight loss.
223392610|NCT05797974|OTHER|Standard preoperative weight loss tools|Participants will utilize current standard preoperative weight loss tools.
223392611|NCT07086105|DRUG|Adze1.C|Conditionally replicative oncolytic adenovirus expressing CD40L, administered by intratumoural injection in dose escalation cohorts.
223392612|NCT01380600|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10\^6 pfu/kg, 1x10\^7 pfu/kg, 3x10\^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
223392613|NCT06903728|DEVICE|continous glucose monitoring|Pregnant women with type 2 diabetes are given a sensor \< week 14 of their pregnancy and will use it until 4-6 post partum. They will receive training in how to use the sensor, and support when needed.
223392614|NCT07087080|OTHER|Blood sampling|Single blood sampling (16 ml) after study inclusion before undergoing the PET-CT scan
223392615|NCT07088705|DEVICE|SML 577 nm|"A 577 nm yellow and 810 nm red lasers will be used for stimulation. The panmacular stimulation is planned, with the laser covering the entire central retina between the vascular arches, including the foveal region according to the study protocol.~Patient preparation will include obtaining informed consent, local anesthesia of the conjunctival sac with 0.05% proxymetacaine drops to reduce discomfort, and the administration of 0.1% tropicamide to dilate the pupil and increase access to the retina during laser stimulation. Next, a Volk macular contact lens (Volk Optical, Mentor, OH, USA) will be placed on the cornea using a viscoelastic agent. A modern 577 nm yellow laser (Supra Scan 577, Quantel Medical, Cedex, France) will be used for stimulation. The panmacular stimulation is planned, with the laser covering the entire central retinal area between the vascular arches, including the foveal region."
223392616|NCT07088705|DEVICE|SML 810 nm|Preparation for SML using an 810 nm red laser will involve informed consent, local anesthesia of the conjunctival sac with 0.05% proxymetacaine drops to reduce discomfort during the procedure, and the administration of 0.1% tropicamide to dilate the pupil and increase access to the retina during laser stimulation. A Volk macular contact lens (Volk Optical, Mentor, OH, USA) will then be placed on the cornea using a viscoelastic agent. Central retinal stimulation will be performed using an 810 nm SML. The panmacular stimulation protocol will be used, with the laser covering the entire central retinal area between the vascular arcs, including the foveal region. During one session, approximately 1500-2000 confluent local applications of 200 μm diameter will be performed using 1.4 W of power with a duration of 0.15 seconds and a 5% duty cycle.
223392617|NCT07088705|OTHER|Sham SML|It is worth emphasizing that the experiment was designed as a factorial study design with the patient blinded. To this end, patient preparation, laser treatment duration, and auditory and visual sensations during the sham procedure will be the same as those experienced with a truly lasered eye. Consequently, fellow eye of an each RP eye that undergone the SML stimulation in either arm 1 or 2 will be included in the sham group (60 eyes).
223547845|NCT00864175|DRUG|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
223547846|NCT00864175|DRUG|Docetaxel|
223547847|NCT01503684|OTHER|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
223547848|NCT00564733|DRUG|carboplatin|Given IV
223547849|NCT00564733|DRUG|docetaxel|Given IV
223547850|NCT00564733|DRUG|gemcitabine hydrochloride|Given IV
223547851|NCT00564733|DRUG|paclitaxel|Given IV
223547852|NCT00564733|PROCEDURE|computed tomography|Undergo FDG PET/CT
223547853|NCT00564733|PROCEDURE|positron emission tomography|Undergo FDG PET/CT
223547854|NCT00564733|RADIATION|fludeoxyglucose F 18|Given IV
223547855|NCT00564733|OTHER|imaging biomarker analysis|Correlative studies
223547856|NCT01014767|DRUG|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 \& 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
223547857|NCT01014767|DRUG|Cisplatin|Cycles 1 \& 2: 70 mg/m²/d IV over 6 hours on day 4
223547858|NCT01014767|DRUG|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m\^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 \& 5: 1 g/m\^2 IV over 1 hour on day 2 and 3"
223547859|NCT01014767|DRUG|Dactinomycin|Cycles 1 \& 2: 45 µg/kg/day (max. 2 mg), IV on day 1
223547860|NCT01014767|DRUG|Doxorubicin|Cycles 1 \& 2: 25 mg/m²/day IV over 12 hrs on days 1-3
223547861|NCT01014767|DRUG|Etoposide|"Standard Arm (1), Cycles 1 \& 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
223547862|NCT01014767|DRUG|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 \& 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
223547863|NCT01014767|DRUG|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
223547864|NCT01014767|DRUG|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
223392618|NCT07091513|PROCEDURE|group ESP|. In the ESP group, a high frequency linear transducer (HFL50XP, SonoSite Inc., Bothell, WA, USA ) was located vertically approximately 3 cm lateral to the projection point with identification of the spinous process, lamina, transverse process, and the erector spinae muscle. The skin and subcutaneous tissues were infiltrated using 5 mL of 1% Lidocaine Hydrochloride. A 22-G peripheral nerve block needle (50 mm) (SonoTAP, Pajunk, Geisingen, Germany) was inserted in-plane from caudal to cranial between the fascia of the erector spinae muscle and the transverse process under the ultrasound guidance. After hydro-localization using 1 ml of with normal saline, this plane was opened. The same 20 mL mixture of LA was injected after negative aspiration of blood.
223392619|NCT05170503|DRUG|Sintilimab|Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles
224012978|NCT05421507|RADIATION|Radioactive Iodine-125 Seeds Implantation|Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.
224012979|NCT03182218|DRUG|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
224012980|NCT00484822|DRUG|Bemiparina Sodica|3.500 UI/día.
223392620|NCT07097649|DEVICE|Textured lateral wedge insole|Participants in the experimental group will wear custom-designed textured lateral wedge insoles made from EVA material. These insoles incorporate lateral wedging to offload the medial knee compartment and a textured surface to enhance plantar sensory input. Participants will use the insoles during daily activities for a period of 8 weeks, with no additional intervention or exercise protocol.
223392621|NCT07097649|DEVICE|Use of lateral wedge flat insole|Participants in this arm will use a customized lateral wedge flat insole with the same lateral inclination as the experimental insole but without any textured surface. This design allows for controlling the mechanical effect of the wedge while eliminating additional sensory stimulation.
223392622|NCT07096284|DIAGNOSTIC_TEST|PvCO2-PaCO2/CaO2-CvO2 ratio|"Patients diagnosed with septic shock will undergo serial measurements of arterial and venous blood gas analyses, arterial lactate levels, and calculation of the Pv-aCO₂/Ca-vO₂ ratio at predefined time points: H0 (baseline), H2, H6, H12, and H24.~Calculation Formulas:~1. Arterial Oxygen Content (CaO₂):CaO2 = SaO2 × Hb × 1,34 + PaO2 × 0,0031~2. Venous Oxygen Content (CvO₂):CvO2 = SvO2 × Hb × 1,34 + PvO2 × 0,0031~3. Pv-aCO₂/Ca-vO₂ Ratio: P(v-a) CO2/C(a-v)O2=(PcvCO2-PaCO2)/(CaO2 -CcvO2)."
223392623|NCT07096882|BIOLOGICAL|SDT-M001 injection|Cascade primed immune cells(CAPRI); SDT-M001 injection is administered at three dose levels:1.5e9 cells, 3e9 cells,6e9 cells. The cells will be reinfused in 3 divided doses, administered every other day, and the total process will take 5 days.
223392624|NCT07096778|DRUG|Inobrodib|40 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.
223392625|NCT07096778|DRUG|Pomalidomide|4 mg orally once daily on Day 1 to 21 of each 28-day cycle
223392626|NCT07096778|DRUG|Dexamethasone|40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle
223392627|NCT07095530|PROCEDURE|titanium membrane|surgical treatment for horizontal ridge augmentation by titanium mesh and PVDF membrane
223392628|NCT07097389|DIETARY_SUPPLEMENT|Cellobiose|Cellobiose powder (Savanna Ingredients GmbH), 5 g per day and 10 g per day, mixed into \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
223392629|NCT07097389|DIETARY_SUPPLEMENT|Oligofructose P95|Oligofructose (Orafti® P95, Beneo GmbH), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
223392630|NCT07097389|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin powder (Special Ingredients Limited), 5 g per day and 10 g per day, dissolved in \~200 mL water and taken orally with breakfast for the first 7 days and the rest of the 21 days.
223392631|NCT07097714|PROCEDURE|Piezocision with ribose cross-linked collagen matrix (Ossix® Volumax)|A full-thickness mucoperiosteal flap will be elevated to expose the alveolar bone. Vertical corticotomy grooves (piezocision) will be created in strategic locations to accelerate orthodontic tooth movement. The Ossix® Volumax collagen matrix will be trimmed and applied directly onto the decorticated bone surface to support bone regeneration and soft tissue augmentation.
223392632|NCT07097714|PROCEDURE|control|A minimally invasive full thickness flap will be raised to expose the alveolar bone. Vertical corticotomy grooves will be performed in strategic locations to accelerate orthodontic tooth movement. The Deepitelized Free Gingival Graft (DFGG) will be placed and secured over the areas of decortication to promote soft tissue healing and augmentation.
223730683|NCT01116154|OTHER|laboratory biomarker analysis|Correlative studies
223730684|NCT02546557|PROCEDURE|Coronary Artery Bypass Graft surgery|
223730685|NCT01529879|DEVICE|New Abutment Connection implant|New abutment connection implant
223730686|NCT01529879|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
223730687|NCT02532933|DEVICE|DePuy Synthes Attune PS RP|
224012981|NCT00484822|DRUG|Heparina Cálcica|10.000 UI/día.
224012982|NCT04247763|OTHER|Saturated Fat Meal|
224012983|NCT04247763|OTHER|Oleic Sunflower Oil Meal|
224012984|NCT00318071|DEVICE|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
224138594|NCT04849819|DRUG|Corticosteroids, immunosuppressors, biological agents|We do not prescribe new medications to patients but only observe their adverse effects on the eye.
223547865|NCT01014767|DRUG|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
223547866|NCT01014767|DRUG|Vincristine|"Standard Arm (1), Cycles 1 \& 2 : 1.5 mg/m\^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 \& 2: 1.5 mg/m\^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
223547867|NCT02641756|OTHER|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
223547868|NCT02142335|DRUG|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
223547869|NCT01579058|DRUG|bisoprolol|bisoprolol 5mg qd for 4 years
223547870|NCT01579058|DRUG|placebo|placebo for 4 years
223547871|NCT02590276|BEHAVIORAL|characterization|
223547872|NCT00276939|BEHAVIORAL|Low-fat, low-Glycemic Index, vegan diet|
223730688|NCT01669733|OTHER|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
223730689|NCT01669733|OTHER|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
223730690|NCT04885686|DEVICE|Endomethasone N RCS|Root canal sealer
223730691|NCT04885686|DEVICE|Endomethasone SP RCS|Root canal sealer
223730692|NCT01891695|RADIATION|39.6 Gy radiation|
223730693|NCT00806754|DRUG|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
223730694|NCT00806754|DRUG|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
223730695|NCT01800864|OTHER|obesity|
223730696|NCT05874856|DIAGNOSTIC_TEST|Heart rate variability, blood pressure and pulse wave velocity|Resting HRV in supine and standing position, blood pressure and pulse wave velocity in supine position at first and last week of inpatient treatment
224012985|NCT02744911|DEVICE|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
223392633|NCT07097103|BEHAVIORAL|Mediterranean Diet Intervention|Participants will follow a personalized diet plan over 24 weeks, based on the guidelines of the Mediterranean diet and defined according to their needs and the state of the disease; no food category will be excluded a priori. Individualized nutritional counseling and support materials (weekly meal plans, sample recipes, portion guides) will be provided by a qualified nutritionist. Adherence to the Mediterranean diet will be monitored periodically. Participants will maintain their usual diet during a pre-baseline period of at least 4 weeks, then switch to the Mediterranean plan under the supervision of a nutritionist.
223392634|NCT07097103|BEHAVIORAL|Intensive Physical Activity Intervention|Participants will perform exercise, over 24 weeks, according to WHO recommendations for adults, including those aged ≥ 64 years, to achieve at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-100 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of moderate and vigorous activity during the week. The WHO 2020 also recommend moderate-intensity or greater muscle-strengthening exercises involving alla major muscle groups for 2 or more days per week. Adherence will be monitored during in-person sessions and through wearable devices for activity tracking.
223392635|NCT07097103|OTHER|Control|Participants will continue their usual medical management for early Parkinson's disease according to current clinical guidelines, without any additional dietary or exercise interventions provided by the study, and will be monitored through standard follow-up visits but will not receive any study-specific dietary or physical activity programs.
223392636|NCT07090005|DEVICE|EndoZip System|The EndoZip System is a single-use automated suturing device, designed to create multiple internal gastric segmentations in the stomach using an endoscopic approach.
223547873|NCT06331039|OTHER|PFMT|PFM exercises were done. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
223547874|NCT06331039|OTHER|PFMT+Otago|It were done by combining Otago exercises and PFM exercises. Each session were 45 minutes, 2 days a week on a group basis with the physiotherapist, and 1 day a week as a home program, for 12 weeks.
223547875|NCT02406521|DRUG|Pazopanib|
223547876|NCT02406521|DRUG|Sorafenib|
223547877|NCT02406521|DRUG|Radium-223|
223547878|NCT04365426|DEVICE|Mechanical stimulus|Electrical dynamometer to measure mechanical pressure
224012986|NCT02744911|BEHAVIORAL|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
224012987|NCT02744911|BEHAVIORAL|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
223547879|NCT04365426|PROCEDURE|Thermal (cold) stimulus|Water cold bath
223547880|NCT04365426|OTHER|Oral contraceptive (OC)|Oral contraceptive (OC)
223547881|NCT04365426|OTHER|No oral contraceptive (No OC)|No oral contraceptive (No OC)
223547882|NCT01360814|PROCEDURE|quality-of-life assessment|Ancillary studies
223547883|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive multidisciplinary structured intervention
223547884|NCT01360814|OTHER|questionnaire administration|Ancillary studies
223547885|NCT01360814|OTHER|counseling intervention|Receive multidisciplinary structured intervention
223730697|NCT05874856|DIAGNOSTIC_TEST|Assessment of cognitive function, balance, strength and cardiorespiratory fitness|"THINC-it test for cognitive function; One-leg Standing test for balance assessment; 10-time chair rise test and hand grip test for strength assessment; Åstrand-Ryhming Test for cardiorespiratory fitness.~All assessments will be performed at first and last week of inpatient treatment."
223730698|NCT05874856|BEHAVIORAL|Monitoring of physical activity and sleep|GENEActiv accelerometer will be worn on the wrist daily during 8-week inpatient treatment.
224012988|NCT05805228|OTHER|Sexual Counseling|Pregnancy and postpartum period-specific sexual counseling was given to pregnant women and their spouses.
223392637|NCT07090005|DEVICE|OverStitch Endoscopic Suturing System (ESG)|The OverStitch ESG is suturing device, designed to create manual suturing in the stomach using an endoscopic approach.
223392638|NCT07097571|PROCEDURE|Glenohumeral Joint Injection and Suprascapular Nerve Block|An intra-articular injection into the glenohumeral joint will be performed using 4 cc of normal saline and 1 cc of betamethasone. Additionally, a suprascapular nerve block will be administered with 5 cc of lidocaine(%2).
223392639|NCT07095335|OTHER|education intervention A-CHARM|Didactic education plus virtual simulation regarding discrimination in the hospital setting
224012989|NCT01080716|BIOLOGICAL|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
224012990|NCT01080716|BIOLOGICAL|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
224012991|NCT01080716|BIOLOGICAL|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
223392640|NCT07095179|BEHAVIORAL|Eupnea|Participants will breathe normally.
223392641|NCT07095179|BEHAVIORAL|Intermittent inspiratory muscle training (IIMT)|Intermittent inspiratory muscle training (IIMT) will be conducted throughout the trial
223392642|NCT07097012|BIOLOGICAL|Tdap Vaccine Administration|The Tdap vaccine will be administered according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
223547886|NCT01360814|BEHAVIORAL|exercise intervention|Receive multidisciplinary structured intervention
223547887|NCT01360814|OTHER|educational intervention|Receive multidisciplinary structured intervention
223547888|NCT01360814|BEHAVIORAL|telephone-based intervention|Receive standard care
223547889|NCT01360814|PROCEDURE|standard follow-up care|Receive standard care
223547890|NCT01484496|BIOLOGICAL|Placebo|Placebo
223547891|NCT01484496|BIOLOGICAL|Belimumab 200 mg SC|Belimumab 200 mg SC
223547892|NCT01484496|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
223547893|NCT01890096|RADIATION|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
223547894|NCT01890096|RADIATION|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
223730699|NCT05874856|BEHAVIORAL|Monitoring of self-rated exhaustion, mood and tension|Using the customized PsyMate app.
224012992|NCT01080716|BIOLOGICAL|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
224012993|NCT01056718|DRUG|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
224012994|NCT03812302|DIAGNOSTIC_TEST|68-Ga HA-DOTATATE PET/CT|See arm description.
224012995|NCT01466101|DRUG|Placebo administration|Administration of placebo
223547895|NCT01645735|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
223547896|NCT01645735|DRUG|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
224012996|NCT01466101|DRUG|Pregabalin administration|Administration of pregabalin
224012997|NCT04600492|DRUG|Riociguat Oral Tablet|Take any dose of Riociguat from 0.5mg to 2.5mg, or placebo
224012998|NCT02293564|DRUG|gevokizumab|Solution for subcutaneous injection
224012999|NCT04976504|DEVICE|Oxygen reserve index|This is an observational study of the routine clinical practice with no specific additional interventions required. The investigators enrolled the ASA physical status I to III patients scheduled for elective surgery with planned arterial catheter placement before induction. ORi and standard monitors were placed. The patients were preoxygenated and received anesthesia induction as routine clinical practice. Intubation was done by video-laryngoscope. The endotracheal tube was not connected to the breathing circuit to avoid apneic oxygenation. Ventilation was resumed when SpO2 fell to 90%. ORi and SpO2 were recorded every ten seconds.
224013000|NCT05086276|DRUG|FX-322|Active Comparator
224013001|NCT05086276|DRUG|Placebo|Placebo
224013002|NCT06571565|COMBINATION_PRODUCT|conservative treatment|Conservative treatment will be applied to the back-neck region in both groups. In this treatment, 20 min hotpack, 10 min ultrasound agent (frequency 0.5-3.5MHz), 20 min Transcutaneous Electrical Nerve Stimulation (TENS) agent (Conventional TENS; Frequency 60-80 Hz, current passage time 50-100 microseconds) will be given.
224013003|NCT06018727|DRUG|Hydrocortisone|Hydrocortisone 20 mg capsule will be administered orally.
224013004|NCT06018727|DIETARY_SUPPLEMENT|Yohimbine|Yohimbine 20 mg capsule will be administered orally.
224013005|NCT06018727|DRUG|Placebo|Two placebos will be administered orally.
224013006|NCT00287690|DRUG|Genistein|Drink taken once daily
224013007|NCT00287690|DRUG|Placebo|Drink taken once daily
224127798|NCT00363012|OTHER|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
224127799|NCT03408496|OTHER|Myofascial release|Manual therapy
224127800|NCT03408496|OTHER|Muscle stretching|Muscle stretching
224127801|NCT03408496|OTHER|Control|Medical appointment
223392643|NCT07097012|BIOLOGICAL|RSV Vaccine|The RSVpreF vaccine will be administered according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
223392644|NCT07097012|OTHER|Saline (as a placebo)|Normal saline (0.5mL) will be administered as a placebo according to the Product Monograph. Participants will be asked to look away during vaccine administration to maintain blinding.
223392645|NCT07097246|OTHER||We do not intervene with the subjects; we only observe their body composition data.
223392646|NCT07097181|BEHAVIORAL|web-based sensory awareness training|"The girl in the intervention group of the study 4 weeks to inform students, raise awareness and provide sensory education. Sensory awareness training will be provided throughout. Presentations to inform during training will be done, then Graded Sensory Discrimination, Graded Motor Imagery (DMI) and a home exercise program, as well as a body awareness training program.~protocol will be applied."
223392647|NCT07095686|DRUG|nL-CHCHD-001|Personalized antisense oligonucleotide
223547897|NCT05342324|DIAGNOSTIC_TEST|Optical coherence tomography angiography|To evaluate the vessel density in choriocapillary vascular networks, using optical coherence tomography angiography
223547898|NCT02111915|BEHAVIORAL|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
223547899|NCT02111915|OTHER|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
223547900|NCT00344175|DRUG|pitavastatin|
223547901|NCT00344175|DRUG|simvastatin|
223547902|NCT03371199|DRUG|Sodium chloride|Sodium chloride tablets, 250 mg
223547903|NCT03371199|DRUG|Placebo Oral Tablet|Starch tablets
223547904|NCT05356988|BEHAVIORAL|Physical activity experiment|The Physical Activity (PA) group will have access for one year to the PA website to help increase aerobic and strength training activities.
223547905|NCT05356988|BEHAVIORAL|Balance and flexibility control|The static Balance and Flexibility (BF) website will include infographics, videos, and articles for participants to view at their leisure around stretching and balance exercises.
223547906|NCT00573391|DRUG|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
223547907|NCT00573391|DRUG|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
223547908|NCT03961243|BIOLOGICAL|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
224013008|NCT04018573|BEHAVIORAL|PATHS Sexual Communication Toolkit|The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
223547909|NCT04826783|DEVICE|Lasers|The laser tip was applied as vertical and horizontal scan along the subgingival implant . The procedure was carried out on day zero, seven and 14.
224127802|NCT03714113|DIAGNOSTIC_TEST|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
224127803|NCT02796924|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
224127804|NCT04099316|DEVICE|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
223392648|NCT07095426|DIETARY_SUPPLEMENT|inulin|6g inulin from chicory root per day for one week and 12g inulin per day for eight weeks dissolved into cool or room temperature liquid
223392649|NCT03065192|DRUG|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
223392650|NCT00955617|OTHER|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
223392651|NCT07097740|DEVICE|Polymer Prosthetic Heart Valve|Surgical implantation of polymer prosthetic valve.
223392652|NCT07095816|DRUG|Acetaminophen|A prospective randomized controlled trial was conducted involving pediatric patients with solid tumors. Participants who met the inclusion criteria were randomly assigned using a computer-generated random number table. The APAP group was administered acetaminophen orally at a dose of 10 mg/kg body weight 2 hours before the surgical procedure.
223392653|NCT07095816|DRUG|Sterilized water|The placebo group was administered 10 mg/kg of sterile water orally two hours before the surgical procedure.
223392654|NCT07096869|DRUG|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|IV infusion, 260 mg/m\^2
223392655|NCT07096869|DRUG|Abraxane®|IV infusion, 260 mg/m\^2
223392656|NCT07097116|OTHER|Hiking Bench Exercise Program|The training is performed 2 times per week over 8 weeks. It includes 4 progressive phases using a hiking bench, simulating hiking posture exercises targeting endurance, trunk control, and leg strength.
223547910|NCT04570878|PROCEDURE|SC TAP|Bilateral subcostal transverse abdominis plane block will be performed using 0.25% ropivacaine (0.5mL/kg for each side, MAX 20mL for each side) under ultrasound-guidance at the end of surgery.
223547911|NCT04570878|PROCEDURE|Control|No regional block is provided at the end of surgery.
223547912|NCT06107543|DRUG|Nebulized Lidocaine|Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
223547913|NCT06107543|DRUG|Iv Lidocaine|Intravenous %2 lidocaine was administered before induction of anesthesia.
223392657|NCT07097116|OTHER|Structured Land-Based Exercise Program|This protocol adds aerobic warm-up, dynamic stretching, foundational strength (glutes, core), and cool-down flexibility work. Exercises are adapted to sailing-specific demands and performed 2 times per week alongside hiking bench work.
223392658|NCT07097038|DRUG|Oliceridine|Intraoperative analgesia should be administered with Oliceridine
223392659|NCT07097038|DRUG|Oxycodone|Oxycodone is used for intraoperative analgesia
223392660|NCT07095712|DRUG|nL-TARD-001|Personalized antisense oligonucleotide
223392661|NCT07096323|PROCEDURE|Nanofat only|"Fat was collected from either the lower abdomen or lateral upper thigh. A blunt-tipped infiltration cannula (Luer Lock Mercedes Gold Liposuction Cannula 4mm x 30 cm, Pakistan) was used for injection of Klein solution for tumescent anesthesia. Liposuction cannula was then used, connected to a 50 ml syringe mounted with a stopper to generate negative pressure for liposuction. The lipoaspirate was washed to obtain pure adipose tissue, and mechanical emulsification was achieved by transferring the fat through progressively smaller sieves (2.2 mm, 1.5 mm, 1.2 mm) between two 10 ml syringes connected with Luer-Lock connectors, with at least 30 passages each. The emulsion was not filtered and is referred to as Nanofat 2.0."
223392662|NCT07096323|PROCEDURE|Nanofat mixed with PRP|Nanofat is prepared the same way as arm 1. PRP was prepared as follows: Ten milliliters of venous autologous whole blood were collected with tri-sodium citrate as an anticoagulant, then centrifuged at 112g (1000 rpm) for 10 minutes. The plasma was transferred to new tubes without tri-sodium citrate and centrifuged again at 448g (2000 rpm) for 10 minutes to separate the platelet pellet and platelet-poor plasma (PPP). PRP was kept for mixing it with nanofat while PPP was discarded
223392663|NCT07096934|OTHER|Standard of Care (SOC)|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded.
223392664|NCT07096934|BIOLOGICAL|SoC + Low dose CYWC628|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. Low dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
223392665|NCT07096934|BIOLOGICAL|SoC + High dose CYWC628|The participant's DFU will be sharply debrided (as needed), dressed with SoC and offloaded. High dose CYWC628 applied once weekly to diabetic foot ulcer (DFU) for up to 12 weeks
223392666|NCT03816475|RADIATION|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
223392667|NCT07097233|PROCEDURE|Virtual Reality Haptic Simulator|Students will use a virtual reality haptic simulator as an adjunct educational tool before treating real patients in the clinical setting.
223392668|NCT07097233|PROCEDURE|Mobile app|Students will use a mobile app as an adjunct educational tool before treating real patients in the clinical setting.
223392669|NCT07097233|PROCEDURE|Control|Students will directly treat real patients without using virtual reality haptic simulator or mobile app.
223392670|NCT07096505|BEHAVIORAL|Early time restricted eating with calorie restriction|Participants followed a diet with 25% energy restriction and an 8-hour eating window from 08:00 to 16:00. Dietary compliance was monitored by dietitian through food consumption records.
223392671|NCT07096505|BEHAVIORAL|Delayed Time Restricted Eating with calorie restriction|Participants followed a diet with 25% energy restriction and an 8-hour eating window from 12:00 to 20:00. Dietary compliance was monitored by dietitian through food consumption records.
223392672|NCT07096505|BEHAVIORAL|Control group with calorie restriction|Participants followed a diet with 25% energy restriction and a usual eating window from 08:00 to 20:00. Dietary compliance was monitored by dietitian through food consumption records.
224013009|NCT04018573|BEHAVIORAL|Parent Support Film|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance."
224013010|NCT04648722|PROCEDURE|Hemithyroidectomy|We investigated patients who received a hemithyroidectomy at the Department of General Surgery, Division of Endocrine Surgery and a follow-up visit (3-12 months post-surgery) at the thyroid outpatient clinic of the Department of Endocrinology and Metabolism, Medical University of Vienna between 1994 and 2018.
224013011|NCT06380673|OTHER|Implementation of cow's milk in decreasingly heated forms|Implementation of cow's milk in decreasingly heated forms in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
224013012|NCT06380673|OTHER|Implementation of heated cow's milk|Implementation of heated cow's milk in cow's milk allergic subjects, tolerant to heated cow's milk, to assess the influence on tolerance induction.
224013013|NCT06380673|OTHER|No intervention|Healthy subjects undergo no intervention.
223392673|NCT07097051|OTHER|real tACS|Those who randomized into real tACS arm will receive ten-session of individually tailored tACS targeting peak alpha power for 20-minutes
223392674|NCT07097051|OTHER|sham tACS|Those who randomized into sham tACS arm will receive ten-session of active sham tACS intervention for 20-minutes
223392675|NCT03476616|DRUG|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
223547914|NCT01179308|OTHER|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
223547915|NCT01179308|OTHER|Balanced general anesthesia and postoperative opioids|General anesthesia alone
223547916|NCT03247582|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
223392676|NCT03476616|DRUG|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM \<130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added \[indapamide (D) 1.25 mg od\]. All groups at both arms will be evaluated at 24 wks by ABPM.
223392677|NCT06915038|DIAGNOSTIC_TEST|NavDx|NavDx is a clinically validated blood test to detect circulating tumor HPV DNA (ctHPVDNA). In this study, ctHPVDNA results, in conjuction with specimen analysis, will be used to assign post-surgical adjuvant treatment.
223392678|NCT06915038|RADIATION|Adjuvant Radiation 30 Gray|If undetectable postoperative ctHPVDNA levels and five or more positive nodes, or confirmed extranodal extension (ENE) (greater than 2 mm) deintensified radiation treatment of 30 gray.
223392679|NCT06915038|RADIATION|Adjuvant Radiation 40 Gray|If detectable postoperative ctHPVDNA, then reimage to evaluate for potentially operable disease, followed by appropriate surgery as indicated. If surgery is performed, repeat ctHPVDNA levels will be checked, and if then negative, subject will be placed in observation if N0 or N1 disease, and 30 Gy of radiation if N2 disease on final pathologic staging. If repeat ctHPVDNA level is positive, or shows no obvious operable disease, then subject will undergo 40 Gy of radiation.
223547917|NCT03369665|DRUG|Mavenclad®|Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
223547918|NCT05959317|OTHER|Pilates Exercises|Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
223547919|NCT05959317|OTHER|Neural dynamic mobilization|Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
223547920|NCT02553928|DRUG|Memantine (once daily)|
223547921|NCT02553928|DRUG|Memantine (twice daily)|
223547922|NCT01316458|DRUG|STI571 (Glivec®)|
223730700|NCT03610022|DRUG|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
223730701|NCT01650233|BEHAVIORAL|Mindfulness-based stress reduction|
223730702|NCT01953055|RADIATION|Stereotactic ablative radiotherapy|
224013014|NCT00488332|PROCEDURE|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
224013015|NCT00488332|PROCEDURE|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
224013016|NCT00488332|BEHAVIORAL|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
224013017|NCT05963373|DIAGNOSTIC_TEST|Urine analysis|Diagnostic test
224013018|NCT02497248|PROCEDURE|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
224013019|NCT04933773|OTHER|Movement artifact - knocking|60 seconds motion artifact simulation - knocking with sensors
224013020|NCT04933773|OTHER|Movement artifact - tremor|60 seconds motion artifact simulation - tremor with sensors
224013021|NCT04933773|OTHER|Artifact - ambient light|60 seconds artifact simulation - ambient light using sensor opening
224013022|NCT04933773|OTHER|Artifact - low perfusion|60 seconds artifact simulation - reduced perfusion using a cuff
223730703|NCT01927510|BEHAVIORAL|Early mobilisation|
223730704|NCT00492037|DRUG|YM087 oral|
223730705|NCT02475746|DRUG|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
224013023|NCT04933773|OTHER|SpO2 measurement|Two SpO2 measuring devices are active simultaneously on one hand during measurement.
224013024|NCT05591885|DIETARY_SUPPLEMENT|Study product group (Nutrilite Memory Builder)|During study intervention, subjects are required to take the randomly assigned study product following the instructions.Take one tablet twice daily with meals.
224013025|NCT05591885|DIETARY_SUPPLEMENT|Placebo group|During study intervention, subjects are required to take the randomly assigned placebo following the instructions.Take one tablet twice daily with meals.
224013026|NCT01018147|PROCEDURE|4-dimensional computed tomography|Undergo 4-D CT imaging
224013027|NCT06306339|DRUG|Burfiralimab|Humanized monoclonal antibody.
224013028|NCT06306339|DRUG|SOC (Standard of care)|"The following medications listed are allowed to be administered during the course of the clinical study.~1. biologic disease-modifying antirheumatic drug (bDMARD)~2. conventional synthetic disease-modifying antirheumatic drug (csDMARD)"
224013029|NCT06306339|DRUG|Placebo|The placebo for Burfiralimab (hzVSF-v13)
224013030|NCT04289831|PROCEDURE|Preoperative Biliary Drainage (PBD)|Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines
223392680|NCT05993273|PROCEDURE|Epidural|The epidural catheter is placed while the patient is awake, before the induction of general anesthesia. The intervertebral spaces used for catheter insertion are alternatively T4-T5, T5-6 or T6-T7. After locating the epidural space through the technique of the loss of resistance, a catheter is introduced for about 5 cm and left in place for the administration of drugs into the epidural space. Once the correct functioning of the epidural catheter has been verified with a negative test for cerebrospinal fluid aspiration and a negative bolus test for the onset of signs and symptoms from intrathecal infusion, the catheter is used intraoperatively for administration of local anesthetics in refracted boluses (Lidocaine and Ropivacaine ) at anesthetic dosage and postoperatively for continuous infusion of Ropivacaine 0.15% at 5 mL/h.
223392681|NCT05993273|PROCEDURE|ESP block|Erector spinae plane (ESP) block is performed after induction of general anesthesia, with the patient in a lateral decubitus position. With the aid of the ultrasound guide with linear probe, the transverse process of T5 ipsilateral to the site of the operation is identified. With the in-plane technique, the lower fascia of the ESP muscle is hydrodissected through the administration of Ropivacaine 0.5% 3 mg/Kg lean body weight. Subsequently, a catheter is introduced and left in place for continuous postoperative infusion of Ropivacaine 0.2% at 12 mL/h.
223392682|NCT05993273|PROCEDURE|Cryoanalgesia|Cryoanalgesia is performed after the induction of general anesthesia, single lung ventilation and after performing the first thoracoscopic surgical access. A cryoanesthesia device with a dedicated atraumatic angled-tip cryoprobe is inserted through the thoracoscopic access. The active tip of the probe is positioned in contact with the intercostal nerves from T3 to T8 and kept resting for 4 ½ minutes on each nerve at a temperature of -70°C, under direct thoracoscopic vision, generating an interruption of the sensory functions.
223564216|NCT04262882|BEHAVIORAL|Multilevel Family Planning Intervention|"The intervention is comprised of community dialogues, or facilitated discussions, aimed to reshape community norms around gender roles, equity, and family size, and critically analyze the social and community influences of family-wealth and poverty with the overall goal of reconstructing individual attitudes and group norms on paths to/definitions of a successful family inclusive of family planning. Dialogues are enhanced to address knowledge, motivation, self-efficacy, and relationship dynamics, tailored to men and women. Sessions include both gender segregated and integrated groups with couples in the community."
224013031|NCT04289831|PROCEDURE|Surgery|The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy
224013032|NCT00138567|DRUG|vildagliptin|
224013033|NCT02819830|BEHAVIORAL|Exercise Intervention|Combined strength and aerobic exercise
224013034|NCT02037464|DIETARY_SUPPLEMENT|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
224013035|NCT00538200|DIETARY_SUPPLEMENT|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
224013036|NCT00538200|OTHER|Dietary Advice|Standard dietary advice
224013037|NCT00710359|DIETARY_SUPPLEMENT|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
224013038|NCT02270515|OTHER|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
224013039|NCT01174290|DRUG|Haloperidol decanoate|"IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
224013040|NCT01174290|DRUG|Placebo|"D5W 0.2mL IV q6h~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
224013041|NCT01850277|DRUG|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
224013042|NCT01850277|PROCEDURE|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
224013043|NCT01850277|DRUG|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% \>95%
224138595|NCT05137730|DRUG|rhPTH(1-84)|Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
224127805|NCT04099316|DEVICE|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
223392683|NCT05546021|PROCEDURE|NOL monitor|"NOL technology uses a multiparameter-based sensor platform, and advanced algorithm, to continuous monitor Autonomic Nervous System (ANS) functions. NOL reflects a patient's nociceptive state and analgesic effect, helping to optimize the administration of systemic and/or regional analgesics and avoiding overdose or underuse of these drugs.~The nociception level is a multiparameter monitor that combines information from the finger photoplethysmogram amplitude, skin conductance, skin conductance fluctuation, heart rate, heart rate variability, and their time derivatives into one index ranging from 0 (absence of noxious stimulation) to 100 (severe noxious stimulation). The nociception level is a composite score derived from a set of physiologic variables (i.e., peripheral effectors of the autonomous nervous system): heart rate, heart rate variability, the amplitude of the photoplethysmogram, skin conductance, skin conductance variability, and the time derivatives of these variables."
223392684|NCT06076733|DEVICE|high definition-transcranial alternating current stimulation|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
223392685|NCT06076733|DEVICE|sham transcranial alternating current stimulation|Sham tACS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
223392686|NCT06222931|DEVICE|Triplanar vibrating platform|Mechanical vibration emitted by triplanar vibrating platforms
223392687|NCT06222931|DEVICE|Side-alternating vibrating platform|Mechanical vibration emitted by side-alternating vibrating platforms
223392688|NCT06222931|OTHER|Sham vibration|Simulated vibration
223392689|NCT01532401|OTHER|sodium chloride|sodium chloride 500mg
223392690|NCT01532401|OTHER|Methylcellulose crystalline|Methylcellulose 37 ml
224013044|NCT01850277|PROCEDURE|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
224013045|NCT04065945|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
224013046|NCT05156684|DRUG|Placebo|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
224013047|NCT05156684|DRUG|Pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two trental tablets daily
224013048|NCT05156684|DRUG|zinc|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
224127806|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
224127807|NCT01257217|DEVICE|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
224127808|NCT01257217|DEVICE|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
224127809|NCT01257217|DEVICE|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
224127810|NCT00467909|BEHAVIORAL|micronutrients|
223392691|NCT00003405|BIOLOGICAL|recombinant interferon alfa|
223392692|NCT00003405|DRUG|amifostine trihydrate|
223392693|NCT00003405|DRUG|bromodeoxyuridine|
223392694|NCT00003405|DRUG|cytarabine|
223392695|NCT00003405|DRUG|idarubicin|
223392696|NCT00003405|DRUG|idoxuridine|
223392697|NCT00003405|DRUG|isotretinoin|
223392698|NCT00003405|DRUG|mitoxantrone hydrochloride|
223392699|NCT06774521|OTHER|control|There is no intervention
223392700|NCT06774521|OTHER|reformer|"Reformer exercises:~Foodwork Swan Short Spin Long Stretch Keen Stretch Hug Tree Bridge Pulling Straps Short Box Abdominal Hundred Twist Star"
223392701|NCT06774521|OTHER|mat|"Mat exercises:~Neck exercises Trunk stabilization exercises Shoulder exercises Posture exercises"
223392702|NCT06948136|DRUG|Delta-9-THC Low Dose|Active Delta-9-THC administered intravenously over 20 minutes.
223392703|NCT06948136|DRUG|Placebo|Small amount of sterile ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
223392704|NCT06948136|DRUG|Delta-9-THC Medium Dose|Active Delta-9-THC administered intravenously over 20 minutes
223730706|NCT02475746|DRUG|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
223392705|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
223392706|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
223392707|NCT01110590|DRUG|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
223392708|NCT01110590|DRUG|Placebo|Placebo
223730707|NCT03586180|BEHAVIORAL|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
223392709|NCT06756503|DIAGNOSTIC_TEST|fecal elastase|To investigate exocrine pancreatic insufficiency (EPI), all patients will be asked to provide a stool sample for fecal elastase (Fel-1) analysis. Participants will be instructed to collect their stool sample in a sterile, disposable plastic container and submit it to the Gastroenterology Chemistry Laboratory (Litwin Laboratory) for processing and analysis. Based on previously published reports, samples will be refrigerated at 4-8 °C for no more than 48 hours. The concentration of Fel-1 in all samples will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (ScheBo-Pancreatic Elastase 1™, Giessen, Germany), with fecal elastase extracted and analyzed according to the manufacturer's instructions.
223392710|NCT06756503|DIAGNOSTIC_TEST|Serum cytokines|Cytokines will be quantified using the Bio-Plex Pro™ Human Cytokine 27-plex commercial kit (Bio-Rad Laboratories, USA) following the kit instructions.
223547923|NCT03926910|DIAGNOSTIC_TEST|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~* Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~* Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~* Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~* Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~* Then, if the ΔPP is \>10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
223547924|NCT00976638|OTHER|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
223547925|NCT00976638|OTHER|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
223547926|NCT04463537|PROCEDURE|Body Temperature Measurements|"measurements were carried out on the patients in the study firstly by not changing the position of the auricle. The duration was measured by stop watch and the results were recorded in the data form. The levels of patients' discomfort were evaluated by the Visual Comparison Scale.~The measurement was then repeated after a minute, this time by changing the position of the auricle. The duration was measured for this position and the results were recorded in the data form."
223547927|NCT00377897|PROCEDURE|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
223547928|NCT03925103|PROCEDURE|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
223547929|NCT03925103|PROCEDURE|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
223547930|NCT03569878|BEHAVIORAL|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
223730708|NCT03550456|OTHER|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
223730709|NCT03550456|OTHER|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
223730710|NCT03550456|OTHER|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
223730711|NCT06321315|BEHAVIORAL|Case-based instruction|"Case-based instruction will be applied to the students in the intervention group. Student Information Form, Critical Thinking Motivation Scale, Academic Motivation Scale and Knowledge Assessment Form will be . All students will receive classical in-class theoretical education about such as hemorrhages, hyperemesis gravidarum, oligohydramnios and urinary system diseases. In the intervention group, after the theoretical teaching of each subject within the scope of the Risky Pregnancy and Care course, cases prepared on the basis of the subject taught to the students will be applied. Student Information Form (13th and 14th questions), Critical Thinking Motivation Scale, Academic Motivation Scale, Knowledge Assessment Form and Visual Comparison Scale will be applied to all students as post-test data after case-based teaching of four topics."
223730712|NCT01533025|PROCEDURE|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
223392715|NCT05718024|DRUG|Dexmedetomidine-esketamine|Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
223547931|NCT03569878|BEHAVIORAL|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
223547932|NCT03194308|BEHAVIORAL|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
223547933|NCT04065698|DRUG|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
223547934|NCT05858476|OTHER|21-Day Detox and Green Drink supplement|"Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement."
223547935|NCT00004049|DRUG|apomine|
223547936|NCT06015360|PROCEDURE|Fat Graft|Fat grafting
223547937|NCT05849350|DIETARY_SUPPLEMENT|Whey protein|Intake of whey protein
223547938|NCT05849350|DIETARY_SUPPLEMENT|Maltodextrin|Intake of maltodextrin
223547939|NCT04098653|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
223547940|NCT04098653|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
223547941|NCT04098653|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
223547942|NCT02872870|BEHAVIORAL|auditory lexical decision task|
223547943|NCT02872870|DEVICE|electroencephalogram|
223392716|NCT05718024|DRUG|Propofol-remifentanil|Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
223392717|NCT06235086|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
223392718|NCT06235086|DRUG|Dulaglutide|Dulaglutide, SC, once a week
224127811|NCT03173820|GENETIC|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
223392719|NCT05242393|OTHER|No intervention is planned|No intervention is planned
223392720|NCT06074016|DRUG|Zolmitriptan intranasal.|Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
223392721|NCT06074016|DRUG|Zolmitriptan oral.|Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
223392722|NCT05319132|OTHER|Adult subjects with ROSAH syndrome|The main objective is to evaluate the ex vivo inhibitory potential of DF-003 on alpha-1 kinase activity.
223392723|NCT04021043|DRUG|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Given IV
223392724|NCT04021043|BIOLOGICAL|Ipilimumab|Given IV
223392725|NCT04021043|BIOLOGICAL|Nivolumab|Given IV
223392726|NCT04021043|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223392727|NCT05390086|OTHER|Standard of care|The study is being implemented among children who are seeking care at collaborating hospitals for signs and symptoms suggestive of TDD. All children will be treated by the hospital physicians following the usual hospital procedures. The study will not interfere in any with the administration of required treatments and interventions.
223392728|NCT03058159|OTHER|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
223392729|NCT04151134|DIAGNOSTIC_TEST|Step serial sectioning histological processing|Step serial sectioning histological processing
223392730|NCT05979688|BEHAVIORAL|yogic breathing exercise|A typical session will begin with the yoga instructor demonstrating a breathing exercise technique. The participants will learn and practice each technique.
223392731|NCT03285412|DRUG|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
223392732|NCT03285412|OTHER|Endocrine therapy|Hormone therapy
223392733|NCT05971940|DRUG|Orforglipron|Administered orally.
223392734|NCT05971940|DRUG|Placebo|Administered orally
223392735|NCT06034080|OTHER|Changes to the electronic health record (EHR)|"EHR changes will include minor changes to prescription fields to make it easier for clinicians to order wait and see antibiotics to be filled only if the child worsens or does not improve rather than antibiotics to take immediately."
223392736|NCT06034080|OTHER|Individualized audit and feedback reporting for clinicians|Automated audit and feedback reports detailing participating clinicians' antibiotic prescribing habits for AOM both individually and in comparison to their peers will be shared with clinicians on a quarterly basis throughout the intervention period.
223392737|NCT06034080|OTHER|Clinician education sessions|Virtual education sessions will be held for clinicians to learn more about national guidelines for antibiotic prescribing for AOM, etc. The sessions will be recorded and distributed to clinicians who were unable to attend. Attendance of these sessions will apply toward continuing medical education credits for participants.
224013049|NCT05156684|DRUG|zinc + pentoxifylline|Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
224013050|NCT03517033|DRUG|Torrent's Nebivolol Tablets|
224013051|NCT03517033|DRUG|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
224013052|NCT04261426|DRUG|Intravenous Immunoglobulin|IVIG 0.5g/kg/d for 5 days
224013053|NCT04261426|OTHER|Standard care|Standard care
224013054|NCT06077253|PROCEDURE|Iridotomy|Peripheral iridotomy (size \>200µm)
224127812|NCT03173820|GENETIC|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
223392738|NCT06034080|OTHER|Use of a shared decision-making (SDM) aide|A previously validated SDM aide for AOM will be used by clinicians during visits with children with AOM. The aide will be available online and in paper form.
223392739|NCT06034080|OTHER|Shared decision-making (SDM) education|Clinicians will receive education on SDM and how to use the aid via virtual, recorded sessions.
223392740|NCT05230862|DIETARY_SUPPLEMENT|Ladder Supplement|Caffeine 200mg L-Theanine 200mg L-Citrulline 6g Creatine 5g Beta-Alanine 1.6g Phosphatidylserine 100mg
223392741|NCT05230862|DIETARY_SUPPLEMENT|Placebo|Placebo
223547944|NCT01352208|DRUG|ASP9521|oral
223547945|NCT02933879|DRUG|NVXT topical|topical treatment
224127813|NCT02421328|DEVICE|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
223547946|NCT02933879|DRUG|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
223392742|NCT04566900|BEHAVIORAL|Neurofeedback|Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.
223392743|NCT04566900|OTHER|Placebo|Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.
223392744|NCT06144450|OTHER|Web-Based Monitoring Program|"The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module."
223547947|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
223547948|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
223547949|NCT01530529|DRUG|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
223547950|NCT01530529|DRUG|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
224013055|NCT02996331|OTHER|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
224013056|NCT02996331|OTHER|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
224013057|NCT02996331|OTHER|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
224013058|NCT02305836|PROCEDURE|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
224013059|NCT02305836|DRUG|donepezil|cholinesterase inhibitors (ChE-Is)
224013060|NCT04869293|DEVICE|Hypnosis 3D virtual reality headset|3D experience to journey through a natural and therapeutic environment. Immersion is amplified by the realism of 3D environment, a soothing sound atmosphere and specific medical hypnosis.
224013061|NCT00294918|DRUG|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
224013062|NCT00475397|DRUG|Duloxetine|
224013063|NCT00475397|DRUG|Placebo|
224013064|NCT06290674|OTHER|Extracorporeal Shockwave therapy|2000 shots, 120mJ pulse energy setting, 3 bar pressure, and 15 Hz for 15 minute per session.
224013065|NCT06290674|OTHER|Balanced low-calorie diet|1500 k/cal for 6 weeks
224013066|NCT01996189|DEVICE|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
223547951|NCT04859348|OTHER|routine physical therapy|G- A 36 participants received only routine treatment for GDM which includes insulin therapy and diet control guided by gynecologist and routine physical therapy which includes walk for 1 hr with proper warm up and cool down periods, three times in a week from 20-24 weeks of gestation to till delivery.
223547952|NCT04859348|OTHER|routine physical therapy and antenatal exercises|G- B 36 participants receive routine therapy (insulin therapy and diet control) and Aerobic and strengthening Exercises for 3 days a week, for 2 weeks 6 sessions under the supervision of physiotherapist and remaining was performed at home. Exercise was started from 15 min and reach to 30 mins gradually.10-15-minute warm-up, cool-down period was included by using ACOG Guideline. Aerobic exercise includes a brisk walk and strengthening exercise were performed with hold for 5 seconds and 10 repetitions. Exercise should stop if they experience any signs of dizziness, dyspnea, amniotic fluid leaking or vaginal bleeding. Confidentiality and blindness ensure by random allocation.
223547953|NCT02882191|DRUG|LevoCept|placement of LevoCept IUD
223547954|NCT02031003|DIETARY_SUPPLEMENT|Infant formula|Infant formula
223547955|NCT00220155|DRUG|Gemcitabine|
224013067|NCT01996189|DEVICE|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
223392745|NCT05229770|DIETARY_SUPPLEMENT|Fruit smoothie|Participants randomised to the intervention arm will receive a 250 ml fruit smoothie as diet supplement for 20 weeks in addition to the regular OAT clinic follow-up. The fruit smoothies will be marketed products including combinations of the following fruits: apple, pineapple, mango, bananas, orange, blueberries, passion fruit, coconut, lime, and blackcurrant. The participants will receive a mixture of different smoothie types with the option of removing alternatives based on preferences. Fruit smoothie products will come in plastic bottles and will be delivered directly to the participants on a weekly basis. Each participant will receive a total of seven smoothie bottles per week with an oral agreement with each participant to consume one of these per day. Delivery of fruit smoothie will generally be given in parallel with delivery of OAT medication.
223392746|NCT05627193|OTHER|Teleclinic|Instead of visiting surgeon after travelling from far flung areas for a post surgery follow up appointment, the follow up visit will be done using telephone.
223392747|NCT05627193|OTHER|Physical Clinic|Patients will have to travel to come physically to hospital to meet the operating surgeon.
223392748|NCT03266640|DRUG|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
223392749|NCT04571749|BEHAVIORAL|Customized handoff|A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
223392750|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223392751|NCT01893307|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMPT
223392752|NCT01893307|OTHER|Laboratory Biomarker Analysis|Correlative studies
223392753|NCT01893307|RADIATION|Photon Beam Radiation Therapy|Undergo IMRT
223392754|NCT01893307|RADIATION|Proton Beam Radiation Therapy|Undergo IMPT
223547956|NCT05921591|DRUG|IRL201104|Lyophilised powder for reconstitution for IV dosing
224013068|NCT00994084|BEHAVIORAL|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
224013069|NCT00994084|BEHAVIORAL|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
224013070|NCT01719354|OTHER|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
224013071|NCT01719354|OTHER|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
224013072|NCT00173654|PROCEDURE|blood drawing|
223392755|NCT01893307|OTHER|Quality-of-Life Assessment|Ancillary studies
223392756|NCT06241729|OTHER|Algorithms to predict the probability of a primary refractory state|Follow-up of a cohort of patients with diffuse large-cell B lymphoma from 2024 using algorithms to predict the probability of a primary refractory state
223392757|NCT05721261|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.
223392758|NCT05721261|DEVICE|Sham Temporary Peripheral Nerve Stimulation System|Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
223392759|NCT05303662|DIAGNOSTIC_TEST|Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs|Pooled throat/nose sample and a rectal sample is taken prior to the ERCP
223392760|NCT05303662|DIAGNOSTIC_TEST|MDRO-testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted. Then cultured for presence of MDRO's
223392761|NCT05303662|DIAGNOSTIC_TEST|Microbiome through rectal swab|An rectal swab is collected for microbiome purposes
223392762|NCT05303662|DIAGNOSTIC_TEST|Microbiome testing duodenal aspirate|Duodenal aspirate is collected from the duodenum, diluted and undiluted for microbiome analysis
223392763|NCT06002711|DIAGNOSTIC_TEST|MR scanning; Clinical data collection|Multi-dimensional spatial heterogeneity analysis of MRI
223547957|NCT05921591|DRUG|Placebo|Matching placebo for IRL201104
223547958|NCT05820841|DRUG|R-miniCHOP + Acalabrutinib|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5)~* Acalabrutinib 100 mg p.o. twice daily starting from D1 of first R-miniCHOP cycle continuously to D21 of cycle 8.~Cycles repeated every 3 weeks"
223547959|NCT05820841|DRUG|R-miniCHOP|"* Rituximab i.v.: 375 mg/m2 (D0)~* Cyclophosphamide i.v.: 400 mg/m² (D1)~* Doxorubicin i.v.: 25 mg/m² (D1)~* Vincristine i.v.: 1 mg (D1)~* Prednisolone p.o.: 40 mg/m² (D1 to D5).~Cycles repeated every 3 weeks"
223547960|NCT00534768|PROCEDURE|active debridement|debridement on 1st, 3-5th and 7th postoperative days
223547961|NCT00534768|PROCEDURE|control group|Postoperative debridement on 7th postoperative day
223547962|NCT05711160|DIAGNOSTIC_TEST|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
223547963|NCT05711160|DIAGNOSTIC_TEST|CBCT images|All patients have been undergoing CBCT scans for both jaws
223547964|NCT05711160|DIAGNOSTIC_TEST|IOS images|The patient's teeth have been dried with air syringe and scanned with the Intraoral scanner
223547965|NCT03409081|DRUG|gilteritinib|oral
223547966|NCT00804895|DRUG|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
224013073|NCT05089253|OTHER|Dry Needling|"The subject will be in the supine position and receive dry needling. The first point will be at the medial femoral condyle of the knee joint line in vastus medialis muscles. The second point will be at the lateral femoral condyle of the knee joint line in vastus lateralis muscles. The third point will be above the base of the patella in the rectus femoris muscle. The fourth point will be 2cm above the third point in rectus femoris muscles. These four points were the most common places of trigger point at quadriceps muscles. Dry needling is affected on A-delta fibers. Therefore when superficial dry needling with a noxious stimulation leads to stimulation on A-delta fibers, the excitation remains almost 72 hours and gradually decreases.~The standard 9- point dry needling technique will be applied for 20 minutes per session 3 times a week for 4 weeks."
223730713|NCT04944953|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
223547967|NCT00804895|DRUG|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
223547968|NCT00804895|DRUG|Verapamil|standard prophylactic treatment
223392764|NCT05724043|DEVICE|SmartJournal|SmartJournal is a tablet application with three modules: Module 1 offers a system for simple check-box registration of daily oral hygiene routines. This module also includes an open text field where the caregiver can give a brief description of strategies used if the patient shows resistant behaviors. Module 2 offers a system for monitoring the patient's oral health through monthly check-ups. This module is an image-based, interactive learning- and assessment tool. Upon completion of the monthly oral health assessment health personnel receive a summary report with suggestions for tailored preventive and/or curative measures to be initiated. Module 3 offers an easily accessible knowledge base which includes information on geriatric oral health, standard equipment and procedures for daily oral hygiene routines for patients with various care needs. It also includes scientifically documented strategies that may be used to approach patients with dementia refusing oral care assistance.
223392765|NCT04042753|DRUG|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
223547969|NCT01206140|OTHER|Laboratory Biomarker Analysis|Correlative studies
223392766|NCT04042753|DRUG|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
223392767|NCT04042753|DRUG|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
223392768|NCT05775913|DEVICE|Tubal Selective Delivery System (TSDS)|A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
223392769|NCT05996419|OTHER|DSB-I|Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they identified prior to start.
223392770|NCT05030038|BIOLOGICAL|Fecal swab collection|Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
223392771|NCT05030038|BIOLOGICAL|Blood samples|Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.
223392772|NCT06443164|BEHAVIORAL|Empowered Relief|Pain Management Course that has been used to treat pain in patients with different pain conditions.
223392773|NCT06443164|OTHER|Standard of Care|Gender Affirming surgery without any attention to pain conditions prior to surgery.
223547970|NCT01206140|DRUG|Selumetinib|Given PO
223547971|NCT01206140|DRUG|Temsirolimus|Given IV
223547972|NCT05388604|DEVICE|RF device|The entire defined treatment area will then be treated by delivering adjacent pulses with minimal overlap of 10% or less. Parameters may be adjusted throughout the treatment in order to increase subject comfort.
223547973|NCT05388604|DEVICE|Microneedling device|"Test spots may be performed prior to the first treatment. Test spots may be performed prior to the first treatment. It will follow a similar procedure to treatment but only in an inconspicuous place, such as behind the ear, in an area no larger than 2in x 2in.~The tip will be placed in contact with the skin, and parameters may be adjusted throughout the treatment and will determined by the Clinician."
224013074|NCT05089253|OTHER|Kinesio tapping|"The subject will be in the supine position and receive Kinesio taping. The Kinesio tape application with no tension one Y strip with a length of 20 cm, an anchor of 2 cm.~The Kinesio tape will be applied to the participants in supine with the knee in 90 flexions. Two Y-shaped tapes are applied above and below the patella. The tape will be removed after 48 hours after application. The Kinesio tape will be applied 3 times a week for 4 weeks."
224013075|NCT06306547|OTHER|no interventions were involved|no interventions were involved
224013076|NCT00927030|DRUG|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
224013077|NCT00927030|DRUG|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
224127814|NCT02421328|DEVICE|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
223392774|NCT05277714|OTHER|Sham|The sham protocol will last 15 minutes per session, and during each session, the participants will receive the same instruction but will be shown a random signal, the goal being that the control strategy that the participant tries to implement is not correlated with the visual feedback provided by the gauge.
223547974|NCT03586024|DRUG|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
223547975|NCT05111197|RADIATION|SRT|"Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface)."
223547976|NCT05111197|DRUG|Immunotherapy|Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
223730714|NCT04944953|DRUG|Botulinum toxin type A injection [HG-102]|Single administration, Day 0, 20 units
223730715|NCT01622790|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
223392775|NCT05277714|OTHER|NF|"The neurofeedback protocol will be the same during the 8 sessions constituting the protocol and taking place over a period of 4 weeks (2 neurofeedback sessions per week, the first and the last one in an MRI context). It will last 15 minutes per session, and during each session, the patient will have to increase the brain activity of her dlPFC using a visual gauge representing the activity level of her own dlPFC. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
223392776|NCT06102590|OTHER|Individualized red blood cell transfusion strategy|Prescription of RCBT is restricted to patients who present Hb ≤ 9.0 g/dL and O2ER ≥ 30%.
223392777|NCT06102590|OTHER|European guidelines red blood cell transfusion strategy|RBCT according to ESICM guidelines
223392778|NCT06197802|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
223392779|NCT06197802|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
223392780|NCT06633900|DRUG|IM naltrexone|The study drug is an intramuscular injection of naltrexone (380mg), administered every 4 weeks via an injection in the ventrogluteal region.
223392781|NCT06633900|BEHAVIORAL|Usual Care|Participants assigned to usual care will receive a harm reduction bundle in clinic. It will include the following components: 1) intranasal naloxone 4mg x 2, 2) participant choice of safer consumption kits based on substances and route used (specific materials for inhaled use vs. injecting, based on common use practices in the region), 3) fentanyl test kits with 2 lateral flow assays per package along with instructions to minimize false positive results, and 4) information about universal overdose precautions (behavioral modifications to optimize safety like using in the presence of others, use a test dose of new substances, etc.)
223730716|NCT01622790|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
223730717|NCT01622790|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
224013078|NCT05873764|DRUG|200 mg RV521/78 µCi [ 14C]-RV521.|200 mg RV521/78 µCi \[ 14C\]-RV521
224013079|NCT03482830|PROCEDURE|Major emergency gastrointestinal surgery|"* Open, laparoscopic, or laparoscopically-assisted procedures~* Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction"
224013080|NCT02478710|DRUG|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
224013081|NCT02478710|DRUG|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
224013082|NCT06292962|DEVICE|non-invasive transcutaneous vagal nerve stimulation (tVNS)|The device is used stimulate the vagus nerve
224013083|NCT06292962|DEVICE|Sham device|Sham device that does not stimulate the vagus nerve
224013084|NCT02880891|PROCEDURE|prothetic procedure|splinted crown
224013085|NCT03941951|BEHAVIORAL|Non-impositive Program for Optimizing the Use of Antimicrobials|Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
223392782|NCT00070564|BIOLOGICAL|pegfilgrastim|Given IV
223392783|NCT00070564|DRUG|AC regimen|Given IV
223392784|NCT00070564|DRUG|cyclophosphamide|Given IV
223392785|NCT00070564|DRUG|doxorubicin hydrochloride|Given IV
223392786|NCT00070564|DRUG|paclitaxel|Given IV
223392787|NCT05437965|OTHER|Treatment made by experienced clinicians|Treatment made by experienced clinicians
223392788|NCT04812912|DIAGNOSTIC_TEST|Hormone biomarker analysis|For female patients, hormone biomarker analysis will be performed to measure: anti-Mullerian hormone (AMH), estradiol and FSH in the blood. In male patients, hormone biomarkers of testicular function and spermatogenesis will be monitored: testosterone, inhibin B, steroid hormone binding globulin (SHBG) and FSH. Sperm analysis will also be performed in male patients to monitor changes in sperm count.
223392789|NCT04812912|BEHAVIORAL|QoL Questionnaires|All participants will respond to protocol questionnaires, which will include both validated questionnaires as well as non-validated ones. This design will allow for basic demographic, psychosocial and sexual-health-related data to be obtained.
224013086|NCT03741452|OTHER|transversalis fascia plane block|patient controlled analgesia devices with tramadol
224013087|NCT00130624|PROCEDURE|Multidisciplinary intervention: primary or secondary care|
224013088|NCT01237587|DRUG|Duloxetine|Administered orally
224013089|NCT01237587|DRUG|Placebo|Administered orally
224013090|NCT03309462|DEVICE|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
223730718|NCT00001723|DRUG|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
223730719|NCT00001723|DRUG|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
224013091|NCT05307211|PROCEDURE|Cervical Interlaminar Epidural Steroid Injection|Fluoroscopy-guided cervical interlaminar epidural steroid injection will be administered to patients with chronic neck pain due to cervical disc herniation. The injection area is cleaned 3 times with an antiseptic solution and covered with a sterile cloth. Local anesthesia with 2 ccs 3% prilocaine will be applied to the skin and subcutaneous tissues in the area of interest. Under fluoroscopy guidance, the needle is advanced into the C7-T1 intervertebral disc level. With the help of the loss of resistance technique, it is understood that the needle is in the epidural space, and second control is provided by administering contrast material. After the confirmation of needle place is done, a mixture of 12 mg dexamethasone, 1 cc 2% lidocaine, 1 cc saline is injected. The patient is taken to the restroom after the procedure and followed up for any complications.
224127815|NCT01044173|DEVICE|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
223392790|NCT04740736|PROCEDURE|Saline Infusion|Patient with hypovolemia on day 1 will be randomized to a saline or sham infusion prior to the Day 2 exercise test.
223392791|NCT05284721|BEHAVIORAL|Family Peer Navigator for Early Psychosis|The Family Peer Navigator model is theoretical underpinning by the Social-Ecological Model and the Social Cognitive Theory, that incorporates a mixture of evidence- and research-based strategies, to include three key components: 1) Introduction and Assessment; 2) Individual Psychoeducation; 3) Six Brief Check-In
223392792|NCT05284721|BEHAVIORAL|Care Coordination|active control, treatment as usual including services provided by the coordinated specialty care program for first-episode psychosis.
224013092|NCT05307211|OTHER|Neck Stabilization Exercises|The physiotherapist will design an exercise protocol for neck stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
224013093|NCT05307211|OTHER|Neck and Scapular Stabilization Exercises|The physiotherapist will design an exercise protocol for neck and scapular stabilization. Each exercise will be applied three days a week throughout a 4-week program, accompanied by a physiotherapist, and will begin with 7 to 10 repetitions at first, increasing to 10 to 15 repetitions in the following weeks, taking into account the patient's condition. After the physiotherapist-assisted exercises are completed, the protocol will continue as home-based exercises until the assessments are completed.
224013094|NCT05017103|BIOLOGICAL|Sintilimab|Given IV
223392793|NCT05113316|BEHAVIORAL|Messy Memories App|"The Messy Memories mobile app is an intervention targeting stress-related problems based on practices with proven effectiveness, to overcome barriers and provide access to evidence-informed intervention strategies aimed to improve mental health in frontline healthcare workers.~The app allows the user to self-administer exposure therapy techniques outside of the traditional psychotherapy context. The Messy Memories app was initially released in a written form for self-help, but with widespread use of smartphones, a mobile application has the potential to further reduce barriers and increase access to care among frontline healthcare workers. The current study proposes to examine this newly developed application for usability and feasibility in a small sample of frontline healthcare workers (Phase I) and then test efficacy of the application in a larger-scale RCT (Phase II) where the application will be compared to a TAU condition."
223392794|NCT03159897|DRUG|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
223392795|NCT03159897|DRUG|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
223392796|NCT03159897|DRUG|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
223392797|NCT03159897|DRUG|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
223392798|NCT03883997|OTHER|No intervention|Cross-sectional
223392799|NCT01114802|BEHAVIORAL|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
223392800|NCT01114802|BEHAVIORAL|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
223392801|NCT01247584|GENETIC|DNA analysis|
223392802|NCT01247584|GENETIC|mutation analysis|
223392803|NCT01247584|GENETIC|polymerase chain reaction|
223392804|NCT01247584|OTHER|laboratory biomarker analysis|
223392805|NCT02581579|DIETARY_SUPPLEMENT|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
223392806|NCT02581579|OTHER|Placebo|Placebo, 1 capsule per day during 14
223392807|NCT02696668|OTHER|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
223392808|NCT02696668|OTHER|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~1. Limits of stability training with eyes open / eyes closed~2. Self induced movement strategies with eyes open / eyes closed~3. Gaze stability exercises in sitting / standing / walking~4. Sensory integration~5. Habituation exercises"
223392809|NCT06102174|DRUG|Placebo|Placebo
223392810|NCT06102174|DRUG|Active|Sisunatovir
224013095|NCT02135354|DRUG|Azithromycin|"* From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
223392811|NCT05598320|DRUG|TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
223392812|NCT05598320|DRUG|Placebo for TransCon CNP|Once-weekly subcutaneous injection of 100 µg/kg placebo for TransCon CNP
223392813|NCT05687448|DRUG|Apixaban 5 MG Oral Tablet|Patients treated with apixaban 5 mg twice daily (BID)
223392814|NCT05687448|DRUG|Aspirin 75 to 100mg once a day|Patients treated with Aspirin 75 to 100mg once a day
223392815|NCT06149845|PROCEDURE|Full Pulpotomy|Pulpotomy is a more conservative pulp treatment option where only the coronal pulp is removed and a medicament placement over the remnant radicular pulp after haemostasis is achieved.
223392816|NCT05201287|OTHER|VIA Disc NP|VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
223547977|NCT03138551|BEHAVIORAL|Mealtime PREP (Promoting Routines of Exploration and Play)|
223547978|NCT02688192|BEHAVIORAL|Exercise Intervention|Participate in fitness program
223547979|NCT02688192|BEHAVIORAL|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
224013096|NCT02135354|DRUG|Placebo|"* From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
224013097|NCT02216045|DRUG|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
224013098|NCT02216045|DRUG|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
224013099|NCT05194332|DEVICE|LIFUP sonication to the amygdala|LIFUP sonication to amygdala will be performed.
224013100|NCT04114864|BEHAVIORAL|Psycho-educational sessions|"Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks."
224013101|NCT03053154|OTHER|Sagittal pelvic tilt assessment|Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
224013102|NCT03636425|OTHER|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
224013103|NCT03693885|OTHER|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
224013104|NCT00465075|DRUG|Bazedoxifene/conjugated estrogens combination|
224013105|NCT01520220|DRUG|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
224013106|NCT00293514|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|
224013107|NCT00740987|DEVICE|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
224013108|NCT03699826|DEVICE|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
224013109|NCT05601271|DRUG|Allopurinol|Allopurinol 100 to 300 mg a day for 3 months
224013110|NCT00672334|DRUG|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
224013111|NCT00672334|DRUG|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
224013112|NCT01630694|PROCEDURE|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
223392817|NCT05631717|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (1 × 10 \^6 cells / kg body weight, suspended in 30ml saline), intravenous drip once.
223392818|NCT05631717|DRUG|Interleukin-2|IL-2 (1×10\^6IU) will be injected subcutaneously every other day for 2 weeks (7 times), with an interval of 2 weeks. 4 weeks is a cycle, and three cycles were continuously treated for 12 weeks.
223392819|NCT04928612|DRUG|CBP-1018|CBP-1018 for injection, IV infusion
223392820|NCT00931528|DRUG|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
223392821|NCT00931528|OTHER|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
223392822|NCT02897102|BEHAVIORAL|Training|Training program based on abacus and other activities
223392823|NCT02897102|OTHER|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
223392824|NCT00386451|DEVICE|Catheter locking systems|
223392825|NCT05771181|DRUG|Vitamin E|Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.
223392826|NCT05771181|DRUG|Fruquintinib|Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
223392827|NCT05771181|DRUG|Tislelizumab|Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
223392828|NCT05494502|PROCEDURE|Erector spinae plane block|Prior to general anesthesia, ultrasound guided erector spinae plane block (ESPB; performed with 0.5% ropivacaine 35 ml with dexmedetomidine 1 microgram/kg) is performed at T2 level (15 ml) and T4 level (20 ml).
223392829|NCT05494502|PROCEDURE|Control group|General anesthesia alone.
224013113|NCT01630694|PROCEDURE|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
224013114|NCT01630694|PROCEDURE|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
224013115|NCT01630694|PROCEDURE|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
224013116|NCT01630694|PROCEDURE|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
224013117|NCT01630694|PROCEDURE|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
224013118|NCT06502431|OTHER|phase contrast sequences|patients will benefit from phase contrast sequences complementary to the morphological MRI performed as part of the patient management.
223392830|NCT05953766|DRUG|Ropivacaine injection|Presacral nerve block using 20mL of local ropivacaine 5.0mg/ml
223392831|NCT05953766|DRUG|Normal saline injection|Sham block using 20 mL of normal saline (0.9% sodium chloride)
223392832|NCT04964206|PROCEDURE|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed according to the routine practice of each study center.
223392833|NCT04964206|PROCEDURE|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
223392834|NCT00613808|DRUG|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
223392835|NCT05821231|COMBINATION_PRODUCT|SBRT + MEDI5752|"SBRT (5 fractions of 10 Gy every two or three days) will be delivered to one lung metastasis (12 days maximum) in combination with MEDI5752\* administered intravenously.~The first dose of MEDI5752 will be administered on the day of the last SBRT fraction, then every 3 weeks for up to a maximum of 12 months.~\* Dosing 500 mg or 750 mg, according to the recommended dose determined during the dose exploration phase"
223392836|NCT04861714|DEVICE|Regeneten|Augmentation of standard subscapularis repair with regeneten patch
223392837|NCT04861714|PROCEDURE|Standard repair|Standard subscapularis repair
224013119|NCT00667147|DRUG|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
224013120|NCT00667147|DRUG|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
223392838|NCT06284382|OTHER|High score at Childhood Trauma Questionnaire.|"In the presence of early trauma arm, 15 participants are recruited based on a high Childhood Trauma Questionnaire total score."
223392839|NCT06284382|OTHER|Low score at Childhood Trauma Questionnaire.|"In the absence of early trauma arm, 15 participants are recruited based on a low Childhood Trauma Questionnaire total score."
223392840|NCT00505830|OTHER|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
223392841|NCT00137501|DRUG|Nifedipine|"Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks."
223392842|NCT00961857|DRUG|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
223392843|NCT00961857|DRUG|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
223392844|NCT00961857|DRUG|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
223392845|NCT00961857|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
224013121|NCT01118013|BIOLOGICAL|anti-thymocyte globulin|
224013122|NCT01118013|BIOLOGICAL|donor lymphocytes|
224013123|NCT01118013|BIOLOGICAL|filgrastim|
224013124|NCT01118013|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224013125|NCT01118013|DRUG|busulfan|
224013126|NCT01118013|DRUG|fludarabine phosphate|
224013127|NCT01118013|DRUG|methotrexate|
224013128|NCT01118013|DRUG|mycophenolate mofetil|
224013129|NCT01118013|DRUG|tacrolimus|
223392846|NCT00961857|DRUG|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
223392847|NCT00961857|DRUG|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
223392848|NCT04823325|PROCEDURE|Orthognathic Surgery|The duration for presurgical orthodontic treatment was; 7,7 ± 1,7 months.
223392849|NCT03759548|OTHER|Assessment of nutritional status|Observational study. Assessment of nutritional status.
223392850|NCT04781426|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg|PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily
223392851|NCT05457504|BEHAVIORAL|Remote blood pressure monitoring|Participants assigned to this arm will participate in the experimental intervention
224013130|NCT01118013|OTHER|reduced-intensity transplant conditioning procedure|
224013131|NCT01118013|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224013132|NCT01118013|PROCEDURE|peripheral blood stem cell transplantation|
224013133|NCT03814551|BEHAVIORAL|Signage|Placement of signage discouraging consumption of beverages with added sugar
224013134|NCT01747551|DRUG|Oxaliplatin|
224013135|NCT01747551|DRUG|Leucovorin|
224013136|NCT01747551|DRUG|Fluorouracil|
224013137|NCT01747551|DRUG|Ziv-aflibercept|
224013138|NCT01382277|DRUG|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
224013139|NCT01142115|DEVICE|Intermittent catheter CP063CC|intermittent catheterisation
223392852|NCT05457504|BEHAVIORAL|Usual Care|Participants assigned to this arm will participate in a placebo intervention
223392853|NCT04566666|DRUG|Placebo|Placebo of SCD-044 product
223392854|NCT04566666|DRUG|SCD-044_Dose 1|SCD-044 tablets in Dose 1.
223392855|NCT04566666|DRUG|SCD-044_Dose 2|SCD-044 tablets in Dose 2
223392856|NCT04566666|DRUG|SCD-044_Dose 3|SCD-044 in Dose 3
223392857|NCT00749905|OTHER|low fiber diet|Low fiber diet for 5 days prior to colon capsule
223392858|NCT00749905|OTHER|regular diet|Regular diet until 1 day before colon capsule
223392859|NCT04337398|BEHAVIORAL|Exercise training for 12 weeks (wearables)|Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.
223392860|NCT04337398|BEHAVIORAL|Exercise training for 12 weeks (wearables and exergames)|Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
223392861|NCT01290549|DRUG|Polatuzumab Vedotin|Participants will receive escalating intravenous dose of polatuzumab vedotin.
223392862|NCT01290549|DRUG|Rituximab|Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.
223392863|NCT02416063|DRUG|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia"
223392864|NCT02416063|DRUG|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia"
223392865|NCT02416063|DRUG|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia"
223392866|NCT02930499|DEVICE|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
223392867|NCT02930499|DEVICE|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
223392868|NCT05294978|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Data of macular optical coherence tomography (OCT)
223392869|NCT02839538|PROCEDURE|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
223392870|NCT02839538|PROCEDURE|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
223392871|NCT01557504|DRUG|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).
223392872|NCT01557504|DRUG|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
224013140|NCT01142115|DEVICE|SpeediCath|intermittent catheterisation
224013141|NCT05953168|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression
224013142|NCT04556487|OTHER|evaluation|we will evaluate the home environment of the children asking by parents
224013143|NCT00633880|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
224013144|NCT00633880|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
224013145|NCT03208036|DEVICE|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
224013146|NCT03208036|DEVICE|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
224013147|NCT03208036|BEHAVIORAL|Cognitive Remediation|Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
223392873|NCT01557504|DRUG|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
223392874|NCT01557504|DRUG|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
223392875|NCT05368818|OTHER|Secukinumab|Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
223392876|NCT03458585|OTHER|Self-administered questionnaire|Self-administered questionnaire
223392877|NCT02571491|DRUG|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
223392878|NCT02571491|OTHER|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
223392879|NCT02571491|DRUG|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
223392880|NCT02571491|DRUG|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
223392881|NCT02810626|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
223392882|NCT01897428|DRUG|Test-Bepotastine salicylate 9.64 mg|
223392883|NCT01897428|DRUG|Reference-bepotastine besilate 10 mg|
223392884|NCT06194968|DRUG|Urokinase|administered intravenously
223392885|NCT06194968|DRUG|Alteplase|administered intravenously
223392886|NCT02058069|DEVICE|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
223392887|NCT00731835|PROCEDURE|Endovascular Revascularization|"* angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~* stent placement~* atherectomy"
223392888|NCT05933018|DIAGNOSTIC_TEST|liver elastography|the imaging of the liver will perform in the fasting state, in the morning hours by one specialist, dedicated to this procedure,
223392889|NCT03866213|DIAGNOSTIC_TEST|BiliSpec|BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
223392890|NCT03359993|PROCEDURE|Premedication of intubation|The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
223392891|NCT00987532|BEHAVIORAL|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
223392892|NCT00987532|BEHAVIORAL|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
223392893|NCT05356871|OTHER|VO2max validity and reliability assesment|Reliability assessment of VO2max determination with three repeated measures for two methods.
223392894|NCT00397462|DEVICE|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
223392895|NCT02676882|DIETARY_SUPPLEMENT|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
223392896|NCT01371604|DRUG|IDX184|IDX184 50 mg tablet administered orally
223392897|NCT01371604|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
223392898|NCT01371604|DRUG|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
223392899|NCT01371604|DRUG|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
223392900|NCT03773523|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
223392901|NCT01288807|DRUG|Milnacipram|Titration to 200mg PO daily
223392902|NCT00958828|DEVICE|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
223392903|NCT00958828|DEVICE|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
223392904|NCT02913911|OTHER|feedback|Sit to stand training with external feedback
223392905|NCT01164293|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
223392906|NCT05628597|DEVICE|Fos Biomedical patch product|Participants will apply a Fos Biomedical patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
224013148|NCT03208036|BEHAVIORAL|Bridging Group|Participants complete 45 minutes of activities and discussion to practice engaging cognitive skills through performance of everyday activities and to learn strategies to use cognitive abilities most effectively. Curriculum generated from Action-based Cognitive Remediation and Compensatory Cognitive Training intervention manuals.
224013149|NCT03406078|BIOLOGICAL|Tezepelumab|Tezepelumab subcutaneous injection
223392907|NCT05628597|DEVICE|Fos Biomedical patch product:placebo|Participants will apply a placebo patch system (consisting of 2 single-use patches) on a daily basis for 12 weeks.
224013150|NCT03406078|OTHER|Placebo|Placebo subcutaneous injection
223392908|NCT04977011|OTHER|relaxing music|30 minutes relaxing music for continuity 3 days since admission
223392909|NCT04298398|BEHAVIORAL|Mindfulness Based-Cognitive Therapy (MBCT)|MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
224013151|NCT02149953|DIETARY_SUPPLEMENT|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
224013152|NCT02720120|DRUG|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
224013153|NCT02720120|DRUG|Placebo|Participants will receive single IV infusion of placebo.
224013154|NCT03849677|OTHER|Endothelial function and inflammation|Analysis of endothelial function, oxidative stress
224013155|NCT00599443|BIOLOGICAL|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
223392910|NCT04298398|BEHAVIORAL|Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)|EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice \& Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott \& Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
223392911|NCT04298398|OTHER|Treatment as usual (no intervention)|Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
223392912|NCT01942577|DEVICE|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
223392913|NCT00183547|BEHAVIORAL|"Living in Harmony depression prevention program"|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
223392914|NCT00183547|BEHAVIORAL|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
223392915|NCT02687451|DRUG|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
223392916|NCT02687451|DRUG|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
223392917|NCT02321111|DRUG|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
223392918|NCT02321111|DRUG|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
223392919|NCT02265094|OTHER|Electroencephalography|EEG recordings during memory tests
223392920|NCT02265094|BEHAVIORAL|Neuropsychological assessment|patterns of eye gaze during cognitive tests
223392921|NCT00149682|BEHAVIORAL|6-month educational program|
223392922|NCT00149682|BEHAVIORAL|6-month standard care program|
223392923|NCT03760692|DEVICE|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
223547980|NCT02688192|DEVICE|Monitoring Device|Wear an electronic accelerometer
224013156|NCT00599443|BIOLOGICAL|Placebo Comparator|0.5 mL im, single dose
224013157|NCT04512131|PROCEDURE|dialysis mode|intermittent hemodialysis or continuous renal replacement therapy
224013158|NCT03321877|DRUG|Change to dose of patient's regular medication|Dose reduction of the drug each patient was already taking
224013159|NCT02906189|RADIATION|MRI|
224013160|NCT02091206|DRUG|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
224013161|NCT02091206|DRUG|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
224013162|NCT02091206|DRUG|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
224013163|NCT02091206|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
224013164|NCT00759005|DRUG|propranolol and cortisol|
224013165|NCT00700778|BIOLOGICAL|recombinant human chorionic gonadotropin|
224013166|NCT00700778|GENETIC|microarray analysis|
224013167|NCT00700778|OTHER|immunohistochemistry staining method|
223392924|NCT03760692|DEVICE|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
223392925|NCT01396668|DRUG|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
223392926|NCT04304989|OTHER|mHealth program|mobile health applications
223547981|NCT02688192|OTHER|Quality-of-Life Assessment|Ancillary studies
224013168|NCT00700778|OTHER|laboratory biomarker analysis|
224127816|NCT03694574|BEHAVIORAL|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don't think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It's very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, \& Hoffmann, 2011)"
223392927|NCT04304989|OTHER|usual care|usual care
223392928|NCT00927589|DRUG|carboplatin|Intravenous repeating dose
223392929|NCT00927589|DRUG|docetaxel|Intravenous repeating dose
223392930|NCT00927589|DRUG|trastuzumab|Intravenous repeating dose
223392931|NCT01799629|DRUG|Glycerin suppositories|
223730720|NCT03100032|BIOLOGICAL|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
224013169|NCT00700778|PROCEDURE|needle biopsy|
223547982|NCT03896854|BIOLOGICAL|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19 cells/kg).
223547983|NCT00075764|DRUG|anastrozole|Given orally
223730721|NCT03100032|PROCEDURE|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
224013170|NCT06172153|OTHER|No interventions|No intervention
223392932|NCT02478944|DEVICE|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
223392933|NCT01125189|DRUG|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
223547984|NCT00075764|DRUG|fulvestrant|Given intramuscularly
223730722|NCT00927784|BIOLOGICAL|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
223730723|NCT00927784|DRUG|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
224013171|NCT03378453|DEVICE|PET-scan18F-AV-45|The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr
224013172|NCT03378453|DEVICE|PET-scan18F-AV-45|PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
224013173|NCT00544986|DRUG|Anastrozole|
224013174|NCT02527863|DRUG|Tolvaptan|60 mg Tolvaptan pr day for 1 day
224013175|NCT02527863|DRUG|Placebo|1 tablet Unikalk pr day for 1 day
224013176|NCT03440060|DIAGNOSTIC_TEST|procalcitonin|procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
223392934|NCT01125189|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
223392935|NCT01125189|DRUG|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
223392936|NCT01125189|DRUG|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
223392937|NCT01125189|DRUG|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
223392938|NCT04135092|BIOLOGICAL|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
223392939|NCT04135092|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223392940|NCT04135092|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
223392941|NCT04135092|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
223392942|NCT04135092|DRUG|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
223392943|NCT04062669|BIOLOGICAL|Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) low dose formulation, administered intramuscularlyat Days 1 and 61.
223392944|NCT04062669|BIOLOGICAL|Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 1 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly at Day 1.
223392945|NCT04062669|BIOLOGICAL|Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lower dose (Lrd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lower dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
223547985|NCT04965298|DRUG|Lansoprazole|Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
223547986|NCT04965298|OTHER|Matched placebo|Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
223547987|NCT05922228|OTHER|neural flossing with proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week contract relax technique of proprioceptive neuromuscular facilitation for 5 minutes, 10 repetitions ×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 10 minutes
223547988|NCT05922228|OTHER|Neural flossing without proprioceptive neuromuscular facilitation|neural flossing technique for 5minutes, 10 repetitions×1 set, 3 days/week total of 15 sessions were given as 3 sessions/week up to 5 weeks, each session consisting of 5 minutes
223547989|NCT01119196|OTHER|Icodextrin dialysate|use of alternate SOC dialysate
223730724|NCT00352144|DRUG|Eszopiclone|Eszopiclone 3 mg
223730725|NCT00352144|DRUG|Placebo|Placebo tablet
223730726|NCT02170051|BEHAVIORAL|CBSST-CCT|
223730727|NCT02170051|BEHAVIORAL|Goal focused supportive contact|
223392946|NCT04062669|BIOLOGICAL|Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the Lowest dose (Ltd-) RG SAM (CNE) group will receive 2 doses of RG SAM (CNE) lowest dose formulation, administered intramuscularly, according to a 0, 2-month schedule (i.e. at Days 1 and 61)
223392947|NCT04062669|DRUG|Saline Placebo|Subjects in the Saline Placebo group will receive 2 doses of saline Placebo, administered intramuscularly Day 1 and 61.
223392948|NCT04062669|BIOLOGICAL|RabAvert|Subjects in the RabAvert Group will receive 2 doses of RabAvert vaccine, administered intramuscularly, at Days 1 and 61.
223392949|NCT05669404|BEHAVIORAL|Salt Restriction Group (SRG)|Patients assigned to the SRG continued to consume their usual diet, but they had to restrict their sodium intake to 2,000 mg/ day. They were given a detailed booklet containing information about table salt, foods rich in sodium, and practical ways to decrease salt consumption. During each 45-min individual session, they received intensive counselling and training to increase adherence to salt restriction. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
223392950|NCT05669404|BEHAVIORAL|DASH Diet combined with salt restriction Group (DDG)|Patients assigned to the DDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the DASH diet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the DASH diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
223392951|NCT05669404|BEHAVIORAL|Mediterranean Diet combined with salt restriction Group (MDG)|Patients assigned to the MDG received a more extensive booklet, which which in addition to the information regarding salt restriction, contained detailed information about the MedDiet, and practical advice about how to start and stay on the assigned dietary pattern. In addition to the booklet, each patient received an individualized eating plan with six sample daily menus, incorporating the goals of the MedDiet diet. During the 45-min individual sessions, patients were intensively counselled and trained to increase adherence to salt restriction and the assigned dietary pattern. Also, they were instructed to keep their body weight stable and not to change their physical activity level over the next 3 months.
223547990|NCT02010593|DRUG|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-\[\[4-\[(2,4,6-trimethylphenyl)amino\]-2- pyrimidinyl\]amino\]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR
223547991|NCT02010593|DRUG|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
223547992|NCT05504187|DRUG|KP104|KP104 will be administered.
223547993|NCT00088270|DRUG|OSI-7904L|
223730728|NCT02353598|DRUG|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
223730729|NCT02353598|DRUG|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
224013177|NCT05412251|RADIATION|health promotion program|Multi-domain intervention 120 minutes cognitive training, 120 \~180 minutes physical exercise per weeks, and 60 minutes diet nutrition education per month
224013178|NCT05404724|DRUG|itraconazole、 SHR0302 tablets|Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
224013179|NCT04482959|DRUG|Carbetocin|(1-deamino-1-monocarba-(0-2-methyltyrosine)-oxytocin) is a long-acting synthetic agonist analogue of the human oxytocin
224013180|NCT04482959|DRUG|Sodium chloride 0.9%|Physiological solution will be used as placebo
224013181|NCT02835118|DRUG|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
224013182|NCT02835118|DRUG|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
224013183|NCT01865175|DRUG|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
224013184|NCT01865175|DRUG|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
224013185|NCT03851718|DEVICE|Acupuncture Procedure|Each session will run about 30\~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
224127817|NCT03694574|BEHAVIORAL|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don't come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it's more difficult at the beginning. (Szasz et al., 2011)"
223392952|NCT05927012|DRUG|KER-047|Oral tablet, daily (or every other day) administration
223392953|NCT05832268|OTHER|Obstetric Anal Sphincter Injury|We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
223392954|NCT00920868|DRUG|dasatinib|dasatinib at 50 mg PO BID)
223392955|NCT00920868|DRUG|bevacizumab|7.5 mg/kg IV day 1
223392956|NCT00920868|DRUG|Oxaliplatin|130 mg/m2 IV day 1
223392957|NCT00920868|DRUG|Capecitabine|850 mg/m2 PO BID on days 1-14
223547994|NCT00088270|DRUG|5-Fluorouracil/Leucovorin|
223392958|NCT03559972|OTHER|on-label facial injection|Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
223392959|NCT03942757|OTHER|bilirubin serum level determination|bilirubin serum level before and after phototherapy treatment will be measured
223392960|NCT03942757|OTHER|Phototherapy|Preterm infant \< 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
223392961|NCT02501122|OTHER|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
223392962|NCT00707239|DRUG|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
223392963|NCT00707239|DRUG|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
223392964|NCT00707239|DRUG|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus \[MRSA\]).
223392965|NCT04711538|DEVICE|MRI|imaging inner ear and petrous bone of the candidate by MRI and CT
223392966|NCT01157793|DRUG|r-hGH|r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
223392967|NCT01157793|DRUG|r-hGH|Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
223392968|NCT04478383|PROCEDURE|a new transosseous suture technique|a new technique using the spur base on the insertional site to drill the suture tunnel to repair Achilles sleeve avulsion.
223392969|NCT03655171|DIAGNOSTIC_TEST|Video-based quantitative methods|The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
223392970|NCT02088177|DRUG|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
223392971|NCT00596531|DRUG|Acamprosate|Oral administration, 666 mg, tid, for 4 months
223392972|NCT00596531|DRUG|Placebo|Oral administration of 2 pills, tid, for 4 months
223392973|NCT06205862|PROCEDURE|fecal microbiota transplantation|We will use fecal suspensions and capsules prepared from the feces of healthy donors for fecal microbiota transplantation. Participants are required to complete one colonoscopy and infuse 150ml of fecal suspension into the terminal ileum under endoscopy, performing the first fecal microbiota transplantation (FMT) on day 0. Subsequently, for 2 days continuously (day 1-2), the participants will undergo microbiota transplantation in the form of oral capsules, taking 40 FMT capsules within one day (20 capsules bid). Subsequently, participants will receive a maintenance treatment with oral FMT capsules (20 capsules bid) at 3, 6, and 9 months (approximately every 75 to 90 days). Participants will undergo their first follow-up colonoscopy between 6 to 12 months(the high-risk adenoma group will receive colonoscopy at 6 months, and the low-risk adenoma group will receive colonoscopy at 12 months).
223392974|NCT06206304|OTHER|Root canal therapy|Traditional root canal therapy was performed with rubber-dam isolation.
223392975|NCT05733429|OTHER|eye cervical re-education|patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
223392976|NCT05733429|OTHER|motor imagery therapy|the patients will receive motor imagery therapy for four weeks; the first week will receive kinesthetic imagery, the second week will receive visual imagery, the third week will receive action observation exercises with motor imagery and the fourth week will receive motor control exercises in front of a mirror.
223547995|NCT03497468|OTHER|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
223547996|NCT03497468|OTHER|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
223547997|NCT01773967|DRUG|LGG|LGG 10\^10 cfu PO BID X 5 days
223547998|NCT01773967|DRUG|micro-crystalline cellulose|1 capsule PO bid x 5 days
223547999|NCT02623777|DIETARY_SUPPLEMENT|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
223548000|NCT02623777|DIETARY_SUPPLEMENT|Short chain fatty acids|Short chain fatty acids administered
223548001|NCT04311970|DEVICE|EsoCheck|All patients with known diagnosis of EoE will be administered the EsoCheck device prior to standard of care endoscopy
223548002|NCT05760027|OTHER|Plyometric exercise|The group of athletes will perform plyometric stability exercises and their usual exercise for 30 days.
223548003|NCT05760027|OTHER|Regular exercise|The group of athletes will perform their usual exercise for 30 days.
223548004|NCT01135459|DRUG|CEP-33457|CEP-33457 will be administered per dose and schedule specified in the arm description.
223548005|NCT01135459|DRUG|Placebo|Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
223548006|NCT01640015|OTHER|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
223392977|NCT05733429|OTHER|conventional physical therapy|the patients will receive conventional physical therapy programs in the form of hot packs, therapeutic massage, cervical isometric strengthening exercises, and scapular stabilization exercises.
223392978|NCT03801135|DRUG|Fibrinogen concentrate|Haemocomplettan will be infused after plasma exchange procedure
223392979|NCT03801135|OTHER|Fresh Frozen Plasma|Fresh frozen plasma will be part of replacement fluid
223392980|NCT01976026|DEVICE|Flow Diversion|
223392981|NCT01976026|DEVICE|Best Standard Therapy|
223392982|NCT01228201|BEHAVIORAL|Moderate continuous training|Three training sessions per week in a total of 12 weeks
223548007|NCT01703052|DRUG|CHF 6001 SD or placebo|Dry Powder Inhaler
223548008|NCT01703052|DRUG|CHF 6001 MD or placebo|Dry Powder Inhaler
224013186|NCT03851718|BEHAVIORAL|Power pumping|It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
224013187|NCT02893007|OTHER|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
224127818|NCT03694574|BEHAVIORAL|control|No instruction
224127819|NCT01647594|BEHAVIORAL|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
224127820|NCT01647594|BEHAVIORAL|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
224127821|NCT03756974|DRUG|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
224127822|NCT03756974|DRUG|Placebo|Placebo of BX-1, oral solution
224127823|NCT01842620|DRUG|Metformin|Oral antidiabetic agent
224127824|NCT01158495|PROCEDURE|Intubation with a cuffed ET Tube|
223392983|NCT01228201|BEHAVIORAL|Aerobic interval training|Three training sessions per week in a total of 12 weeks
223392984|NCT02651701|PROCEDURE|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
223392985|NCT04435912|DRUG|Hydrocortisone 200mg IV|single dose pre-treatment given IV given at the time when the patient is attached to the cardiopulmonary bypass machine
223392986|NCT01352572|DRUG|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
223392987|NCT01352572|DRUG|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
223548009|NCT04177615|PROCEDURE|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
223548010|NCT05351840|DRUG|LivaloV|Treatment A, Tablet, Oral, QD for 7 Days
223548011|NCT05351840|DRUG|A|Treatment B, Tablet, Oral, QD for 10 Days
223548012|NCT05351840|DRUG|LivaloVA|Treatment C, Tablet, Oral, QD for 7 Days
223548013|NCT02994082|BEHAVIORAL|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
223548014|NCT02994082|BEHAVIORAL|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
224127825|NCT01158495|PROCEDURE|CT scan Radiation|
224127826|NCT01414816|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
224127827|NCT00993603|BEHAVIORAL|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
224127828|NCT04883385|OTHER|medical data collection|collection of medical data from patients' medical records
223392988|NCT01778530|DRUG|TRC105|Intravenous infusion.
223392989|NCT05194826|PROCEDURE|Test|immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
223392990|NCT05194826|PROCEDURE|Control|immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
223392991|NCT03472014|BIOLOGICAL|IMVAMUNE®|IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
223392992|NCT05587010|DEVICE|AFO|ankle foot orthosis
223392993|NCT05587010|DEVICE|lycra sock|custom fitted lycra sock
223392994|NCT05587010|DEVICE|OrthPed splint|novel compression splint
223392995|NCT00535210|BEHAVIORAL|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
223548015|NCT02994082|BEHAVIORAL|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
223392996|NCT00535210|BEHAVIORAL|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
224013188|NCT02193126|OTHER|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
224013189|NCT03767829|DRUG|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
224013190|NCT03767829|DRUG|Placebo|Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
224013191|NCT03767829|DRUG|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
224013192|NCT06274229|OTHER|Air pollution and noise reducing installations|A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.
224013193|NCT05630729|OTHER|My Kidney Guru|My Kidney Guru is a program that will offer pediatric patients with CKD developmentally appropriate, interactive, and engaging instruction and practice opportunities to build knowledge and skills to manage CKD.
224013194|NCT04278196|OTHER|AI-Box|AI-box is a system fixed adjacent to magnet controlled capsule endoscopy. Patients who accept the check of magnet controlled capsule endoscopywill be enrolled .
223392997|NCT00004310|DRUG|Clomipramine|
223392998|NCT04952181|DEVICE|optical biometry|optical biometry is a fast, noncontact method it uses the method of partial coherence interferometry (PCI) to measure the axial length (AXL), based on reflection of the interference signal of the retinal pigment epithelium.
223392999|NCT04952181|DEVICE|ultrasonic biometry|ultrasonic biometry is contact method depends on ultrasonic transducer producing thin sound beam travelling through different media of the eye when it faces interface of substance dissimilar from that it is travelling through part is reflecting and the other travel through the different substance
223393000|NCT04696224|DRUG|Tranexamic acid|The surgical technique consists in patient in supina position with previous reduction with lower limb traction (on a traction table or manual) associated or not with the use of percutaneous reduction clamps. Longitudinal lateral incision of 3-5 cm proximal to the greater trochanter, approximately 5 cm long, will be performed. After the skin and subcutaneous incision, the fascia lata will be incised in the same direction, with exposure of the gluteal muscles and the proximal femur. The awl will be introduced at the tip of the greater trochanter and then, at the same location, an intramedullary guidewire, towards the proximal shaft, crossing the fracture. A 3 cm incision to the thigh and inferior to the initial incision with template to introduce the screw in the center of the femoral head. Then, a 2cm incision will be made at the distal end of the nail, and a hole in the femur for the distal lock in dynamic nail hole with a 4.5mm drill where a cortical screw will be inserted.
223393001|NCT04696224|OTHER|Saline solution|30 patients who will not receive the TXA, but will receive a 100ml intravenous saline solution 0,9% after anesthetic induction and before incising the skin (such as group 1) and a compress soaked in saline solution as used in group 2
223393002|NCT05417841|DRUG|Insulin Degludec and Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp BID in T2DM
223393003|NCT05417841|DRUG|Insulin Aspart Injection|To evaluate the efficacy and safety of the IDegAsp QD plus IAsp BID in T2DM
223393004|NCT01894919|BIOLOGICAL|Bexsero® vaccine (1 dose at study month zero)|
223393005|NCT01894919|BIOLOGICAL|Bexsero® vaccine (2 doses 1 month apart)|
223393006|NCT02862236|DRUG|Hypericum perforatum extract|250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
223393007|NCT04882813|DRUG|Dapagliflozin|Dapagliflozin dispensing claim is used as the exposure group.
223393008|NCT04882813|DRUG|Sitagliptin|Sitagliptin dispensing claim is used as the reference group.
223393009|NCT04127279|BIOLOGICAL|Cream|"The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.~The placebo cream is devoid of the essential oils"
223393010|NCT05638464|DEVICE|multisite HD-tDCS EMG-driven robot hand|Multisite HD-tDCS will individual stimulation montages with robot hand training will be applied on chronic stroke survivors. In the multisite HD-tDCS group, 5-8 sintered Ag/AgCl ring electrodes will be placed based on the neuroimaging and computation modelling. The location of the electrodes will be identified by the individual brain activity in the primary motor cortex derived from tasked-based fMRI. The Finite Element Model (FEM) will be used to simulate the electric field distribution on individual brain. Optimization of stimulation montages will be based on the derived activation pattern of the brain. After 20-minute multisite HD-tDCS, EMG-driven robot hand training will be conducted.
223548016|NCT02994082|BEHAVIORAL|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
223548017|NCT02994082|DRUG|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
224013195|NCT02627404|OTHER|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
224013196|NCT02627404|DEVICE|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
224013197|NCT05843825|PROCEDURE|Surgical placement of dental implants|Three dental implants were placed (one anterior in midline area and two posterior at first molar area).
224127829|NCT02739594|DRUG|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
223393011|NCT05638464|DEVICE|Sham HD-tDCS EMG-driven robot hand|"Sham stimulation with robot hand training will be applied on chronic stroke survivors.~After the sham stimulation, EMG-driven robot hand training will be conducted."
223393012|NCT01433471|DRUG|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
223393013|NCT03711188|DRUG|Nivolumab|Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
223548018|NCT02994082|DRUG|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
223548019|NCT02994082|DRUG|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
223548020|NCT02994082|DRUG|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
223548021|NCT02994082|DRUG|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
223548022|NCT02994082|DRUG|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
223548023|NCT02994082|DRUG|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
223548024|NCT02994082|BEHAVIORAL|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
223548025|NCT02994082|BEHAVIORAL|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
223393014|NCT03711188|DRUG|Ipilimumab|Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
223393015|NCT03711188|DRUG|IMM-101|A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
223548026|NCT05912595|DEVICE|EXOPULSE Mollii Suit Stimulation|"We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of tissue oxygenation and frequent MS symptoms following a single session of active versus sham Exopulse Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. After this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of Exopulse Mollii suit employed for one month (3 sessions per week) on tissue oxygenation and MS related symptoms."
223548027|NCT06436014|OTHER|Providing VR experience|Participants undergoing VR intervention will experience a VR program of their choice based on personal preferences. Among these programs are videos offering natural visual experiences. For instance, participants can opt for videos featuring seaside views, forest tours, or lake landscapes.
223548028|NCT06368843|DRUG|Gargle with ketamine|The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
223548029|NCT02226588|DRUG|Misoprostol|
223548030|NCT06156878|COMBINATION_PRODUCT|Anti-EGFR and PD-1 inhibitor arm|Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.
223548031|NCT03472820|OTHER|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
224013198|NCT05843825|DEVICE|Overdenture supported by locator attachment system|"Implants were loaded after three months by using locator attachments.~Control group:Iocator attachments picked up using block out spacer.~Study group:Iocator attachments picked up without using block out spacer"
224013199|NCT03230877|DEVICE|Toffee full face mask with 'Improved Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.
223548032|NCT03472820|OTHER|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
223548033|NCT03472820|OTHER|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
224013200|NCT03230877|DEVICE|Toffee full face mask with 'Normal Seal'|Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
224013201|NCT00157313|BEHAVIORAL|Integrated treatment, family involvement|
224013202|NCT00157313|BEHAVIORAL|Social skills training|
224013203|NCT04801277|PROCEDURE|Electroacupuncture on acupoints vs sham points|Randomized double blinded clinical trial
224013204|NCT00546026|OTHER|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
224013205|NCT04825561|DRUG|AD-208|PO, Once daily(QD), 24weeks
224013206|NCT04825561|DRUG|AD-2081|PO, Once daily(QD), 24weeks
224013207|NCT04825561|DRUG|placebo of AD-208|PO, Once daily(QD), 24weeks
224013208|NCT04825561|DRUG|placebo of AD-2081|PO, Once daily(QD), 24weeks
223548034|NCT03472820|OTHER|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
224127830|NCT02739594|DRUG|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
223393016|NCT00663793|DRUG|Acyline|300 mcg/kg
223548035|NCT03472820|OTHER|PhytoGanix (tropical fruit flavor)|Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
224013209|NCT03661762|DEVICE|CAVA|prototype device for monitoring dizziness
224127831|NCT03318640|BEHAVIORAL|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
224013210|NCT03732404|DRUG|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
223393017|NCT00663793|DRUG|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
223393018|NCT00663793|DRUG|Finasteride|1 mg PO once daily \[day -2 to day 12) 14 days total
223393019|NCT00001042|BIOLOGICAL|Aluminum hydroxide|
223393020|NCT00001042|BIOLOGICAL|Lipid A, Monophosphoryl|
223393021|NCT00001042|BIOLOGICAL|Lipid A, Liposome-encapsulated monophosphoryl|
223393022|NCT00001042|BIOLOGICAL|Syntex adjuvant formulation|
223393023|NCT00001042|BIOLOGICAL|MF59|
223393024|NCT00001042|BIOLOGICAL|Threonyl Muramyl Dipeptide|
223393025|NCT00001042|BIOLOGICAL|rgp120/HIV-1 SF-2|
223393026|NCT00001042|BIOLOGICAL|MTP-PE/MF59|
223393027|NCT00000876|DRUG|CD4-IgG2|
223393028|NCT01739465|PROCEDURE|Self expanding metallic stent (SEMS)|Self expanding metallic stent
223393029|NCT01739465|PROCEDURE|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
223393030|NCT01739465|PROCEDURE|Photodynamic therapy (PDT)|Photodynamic therapy
223393031|NCT04812444|DEVICE|Zylox Peripheral Venous Stent|Self-expanding stent implantation during the index procedure.
223393032|NCT04812444|DEVICE|Zilver Vena Venous Stent|Self-expanding stent implantation during the index procedure.
223393033|NCT00483444|BEHAVIORAL|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
223393034|NCT02042508|OTHER|strengthening|
223393035|NCT02042508|OTHER|hybrid training programme|
223393036|NCT03501823|OTHER|Photoacoustic tomography|A non-invasive, safe modality that relies on light and sound to generate images.
223393037|NCT00659308|PROCEDURE|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
223393038|NCT00659308|PROCEDURE|anterior stromal puncture|the other group is submitted to anterior stromal puncture
224013211|NCT03732404|DRUG|Placebo|The control group will receive plain water with the same volume and timing of treatment.
223393039|NCT04871360|DIETARY_SUPPLEMENT|L-Citrulline supplement|The intervention will consist of oral supplementation of six grams of pure l-citrulline for eight weeks.
223393040|NCT04871360|DIETARY_SUPPLEMENT|Carboxymethyl cellulose supplement|The intervention will consist of oral carboxymethyl cellulose supplementation as a placebo.
223393041|NCT03830489|DRUG|polyethylene glycol|The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
223393042|NCT03830489|DRUG|polyethylene glycol plus ascorbic acid|The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
223393043|NCT01400477|DRUG|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
223393044|NCT01400477|OTHER|Placebo|Placebo Comparator
223393045|NCT03743051|DRUG|Anamorelin Hydrochloride|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
223393046|NCT03743051|DRUG|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
223393047|NCT00383318|PROCEDURE|Gene mutation sample|
223393048|NCT02768818|DIETARY_SUPPLEMENT|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
223393049|NCT02768818|DIETARY_SUPPLEMENT|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
223393050|NCT02720718|DEVICE|Stratafix|
223393051|NCT02720718|DEVICE|Vicryl|
223393052|NCT01422200|BIOLOGICAL|2011-2012 seasonal flu vaccine Subcutaneous|
223393053|NCT01422200|BIOLOGICAL|2011-2012 seasonal flu vaccine Intramuscular|
223393054|NCT00711087|DRUG|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
223393055|NCT00711087|OTHER|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
223393056|NCT00494637|DRUG|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
223393057|NCT00811733|BIOLOGICAL|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
223393058|NCT00316511|DRUG|Aroplatin|
223393059|NCT00793871|DRUG|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
223393060|NCT01874028|DRUG|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
223393061|NCT03426111|DEVICE|Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)|This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
223393062|NCT03426111|BEHAVIORAL|Lifestyle modification|Hypocaloric diet and moderate physical exercise
223393063|NCT05947383|DRUG|Psilocybin|Psilocybin 25 mg oral capsule
223393064|NCT05947383|DRUG|Placebo|Niacin 100 mg oral capsule
223393065|NCT04465669|DEVICE|Orsiro stents|"Percutaneous coronary intervention with implantation of either:~a Orsiro® biolimus a9 eluting coronary stent"
224013212|NCT00350103|DRUG|SPM 929|"* Pharmaceutical form: Immediate release film-coated tablets~* Concentration: 50mg/ 100mg~* Route of administration: Oral use"
224013213|NCT00350103|DRUG|Placebo|"* Pharmaceutical form: Immediate release film-coated tablets~* Route of administration: Oral use"
224013214|NCT02862522|OTHER|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
224013215|NCT01879553|BIOLOGICAL|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
224013216|NCT03408977|OTHER|probe meal|The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
224013217|NCT04188275|DIAGNOSTIC_TEST|Periodic ARV7 and miRNA evaluation|Determination of AR-V7 splice variants on circulating tumor cells and evaluation of circulating levels of miRNA by blood sample collection during PSA assessment at different time points along the treatment course (initiation, 8-weeks assessment, progression).
224013218|NCT02995642|DRUG|18F-FPPRGD2|One single intravenous injection.
224013219|NCT02995642|DEVICE|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
224013220|NCT02995642|PROCEDURE|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
224013221|NCT02995642|DEVICE|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
224013222|NCT01161875|DEVICE|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:~* facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation~* helmet use with non-invasive pressure support ventilation mode to define adequate settings~* helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
224013223|NCT02657044|PROCEDURE|EMR|
224013224|NCT02657044|PROCEDURE|ESD|
224013225|NCT02046629|DRUG|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
224013226|NCT02046629|DRUG|cholestyramine|Pharmaceutical form:power Route of administration: oral
224013227|NCT02712905|DRUG|INCB059872|"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth."
224013228|NCT02712905|DRUG|all-trans retinoic acid (ATRA)|
224013229|NCT02712905|DRUG|azacitidine|
224013230|NCT02712905|DRUG|nivolumab|
224013231|NCT03391817|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation administered in gastroscopy
224013232|NCT01099475|PROCEDURE|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
224013233|NCT01099475|PROCEDURE|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
224013234|NCT02815943|PROCEDURE|biliopancreatic diversion with duodenal switch|
224013235|NCT02815943|PROCEDURE|sleeve gastrectomy|
224013236|NCT02815943|OTHER|liquid meal|will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
224013237|NCT02815943|RADIATION|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
224013238|NCT02815943|OTHER|[7,7,8,8-2H]-palmitate|i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.
224013239|NCT02815943|DEVICE|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
223393066|NCT04465669|DEVICE|Resolute Integrity® stents|"Percutaneous coronary intervention with implantation of either:~a Resolute Integrity® zotarolimus eluting coronary stent"
223548036|NCT03472820|OTHER|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
223548037|NCT02089009|OTHER|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
224013240|NCT03591653|DRUG|LXI-15028|The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.
224013241|NCT03591653|DRUG|Placebo|Placebo
224013242|NCT04593043|DRUG|Warfarin|Warfarin dispensing claim is used as the reference
224013243|NCT04593043|DRUG|Dabigatran|Dabigatran dispensing claim is used as the exposure
224013244|NCT01624103|PROCEDURE|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
224013245|NCT01624103|PROCEDURE|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
224013246|NCT01227200|DRUG|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
224013247|NCT00899873|GENETIC|cytogenetic analysis|
224013248|NCT00899873|OTHER|flow cytometry|
224013249|NCT00899873|OTHER|fluorescence activated cell sorting|
224013250|NCT00899873|OTHER|immunoenzyme technique|
224127832|NCT00041717|DRUG|Fampridine-SR|25mg bid (twice daily)
224127833|NCT00041717|OTHER|Placebo|Placebo
224127834|NCT03774693|OTHER|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
223548038|NCT02089009|OTHER|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
223548039|NCT02089009|OTHER|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
224127835|NCT03774693|PROCEDURE|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
224127836|NCT01350037|DRUG|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
223393067|NCT02500589|BEHAVIORAL|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
223548040|NCT01324960|DRUG|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
223548041|NCT01324960|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
223548042|NCT04073511|DRUG|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
223548043|NCT04073511|DRUG|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
223548044|NCT04073511|DRUG|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
223548045|NCT03805854|DEVICE|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
223548046|NCT03805854|DEVICE|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
223730730|NCT02353598|DRUG|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
224013251|NCT00899873|OTHER|laboratory biomarker analysis|
224013252|NCT04664400|BEHAVIORAL|Symbolic conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) through symbolic conditioning (no actual heat stimuli, only pictures of thermometers)
224127837|NCT01350037|DRUG|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
224127838|NCT03734107|BEHAVIORAL|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
224127839|NCT00527111|DRUG|Cetuximab|
224127840|NCT00527111|DRUG|5-fluorouracil|
223548047|NCT03805854|DEVICE|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
223548048|NCT03805854|DEVICE|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
223730731|NCT02353598|DRUG|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
224013253|NCT04664400|BEHAVIORAL|Conditioning|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from experience (with actual heat stimuli).
224013254|NCT04664400|BEHAVIORAL|Instructions|Participants will learn associations between cues and thermal stimuli with varying temperatures (low vs. high) from verbal instructions.
224013255|NCT04664400|BEHAVIORAL|Counterfactual|Thermal stimuli will be either the better outcome or the worse outcome out of two possible outcomes.
224013256|NCT02794922|DRUG|Neurovit Forte|
224013257|NCT02794922|DRUG|Corn Starch|
224127841|NCT00527111|RADIATION|Pelvic irradiation|
224127842|NCT05025072|DRUG|Hydroxycarbamide dispersible tablets|Hydroxycarbamide dispersible tablets (20 x 50 mg)
224127843|NCT05025072|DRUG|Hydroxycarbamide film-coated tablet|Hydroxycarbamide film-coated tablet (1000 mg)
224127844|NCT02998437|DRUG|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
224013258|NCT01472458|BEHAVIORAL|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
224013259|NCT02801032|DRUG|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
224013260|NCT02801032|DRUG|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
224013261|NCT01307683|BEHAVIORAL|Mindful Moms|"8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session"
223393068|NCT02500589|OTHER|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
223393069|NCT03665220|OTHER|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
223393070|NCT03665220|OTHER|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
223393071|NCT03665220|OTHER|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
223393072|NCT01984320|PROCEDURE|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
223393073|NCT03901794|DEVICE|Non-invasive hemodynamic monitor|MAP, HR, CO, SVI, from Non-invasive hemodynamic monitor
223393074|NCT04191525|DIETARY_SUPPLEMENT|BPL-1 Probiotic capsules|BPL-1 Probiotic 1 capsule/day
223393075|NCT04191525|DIETARY_SUPPLEMENT|Placebo|Placebo masked with the same presentation as the experimental product 1 capsule/day
223393076|NCT01270438|DRUG|FOLFOX regimen|Given IV
223393077|NCT01270438|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223393078|NCT01270438|BIOLOGICAL|bevacizumab|Given IV
223393079|NCT01270438|DRUG|oxaliplatin|Given IV
223393080|NCT01270438|DRUG|leucovorin calcium|Given IV
223393081|NCT01270438|DRUG|fluorouracil|Given IV
223393082|NCT04647084|DRUG|Lidocaine 2% Injectable Solution|An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.
223393083|NCT04647084|DEVICE|Buzzy|The Buzzy vibrating ice pack will be placed on the subject's arm with an elastic band around it, and it will remain there as the arm is cleaned and prepped and the IV inserted. The Buzzy device will be removed once the IV is inserted.
223548049|NCT03805854|DEVICE|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
223730732|NCT04912947|DIETARY_SUPPLEMENT|Immusystem|Dietary supplement containing: Piceid, Glycine, Glutamine, Acetylcysteine, Zinc and Vitamin B6
223730733|NCT04912947|OTHER|Placebo|Maltodextrin placebo capsule
224013262|NCT05196490|DEVICE|Micro-CT|Micro computed tomography (micro-CT) is an imaging method in which cross-sectional images are obtained and these images are transferred to the computer through specific software, processed and stored.
224013263|NCT05196490|DEVICE|CAD/CAM|CAD/CAM (computer aided design-computer aided manufacturing) is a production method that is frequently used in many areas of technology. These systems are composed of a data acquisition unit, software for designing virtual restoration, and a computerized milling device.
224013264|NCT04870229|DRUG|Carnosine|
224013265|NCT04870229|DRUG|Placebo|Placebo
224013266|NCT04768855|DRUG|LY3540378|Administered IV or SC.
224013267|NCT04768855|DRUG|Placebo|Administered IV or SC.
224013268|NCT04768855|DRUG|LY3540378|Administered SC.
224013269|NCT06294405|DEVICE|Intraocular lens Implantation|Intraocular lenses are implanted during cataract surgery to replace the human crystalline lens.
224013270|NCT04225689|OTHER|CD-TREAT diet|Dietary intervention
224013271|NCT02923791|BIOLOGICAL|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
224013272|NCT02923791|BIOLOGICAL|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
224013273|NCT06486792|DRUG|Apixaban|Patients who have had an ischemic stroke will receive either an anticoagulant or aspirin according to their randomization arm.
224127845|NCT02998437|DRUG|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
223548050|NCT03805854|DEVICE|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
223393084|NCT06080269|DEVICE|technology based intervention along with conventional therapy|Technology based intervention are training session given to the participants through devices which has software installed to train cognitive functions for patients with cognitive deficit.
223548051|NCT03653806|OTHER|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
223548052|NCT05957458|DEVICE|Airdoc device of red light for Myopia|This light is Narrow-Band, Long-Wavelength Lighting with three different illumination (400lux, 800lux, 1200lux) or irridiance (1.2mW, 0.6mW, 0.37mW) respectively. And the wavelength is 650nm. It allows biocular therapy.
223730734|NCT03580694|DRUG|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
224013274|NCT06486792|DRUG|Aspirin|Aspirin is used as the standard of care
224013275|NCT01856452|DEVICE|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
224013276|NCT01856452|DEVICE|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
223393085|NCT06080269|OTHER|conventional therapy alone|Participants in the control group will receive only conventional therapy
223393086|NCT00573690|DRUG|carboplatin|Given IV
223393087|NCT00573690|DRUG|cisplatin|Given IV
223393088|NCT00573690|DRUG|etoposide|Given IV
223393089|NCT00573690|DRUG|pemetrexed disodium|Given IV
223393090|NCT00573690|DRUG|sorafenib tosylate|Given orally
223548053|NCT01413711|DRUG|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
223548054|NCT00022295|DRUG|idronoxil|
223548055|NCT05257421|DEVICE|shockwave machine|shockwave therapy. 2000 impulses will be applied, 1000 on the TrPs and 1000 surrounding it, with Energy level up to 2,5 bars and frequency of 10Hz
223548056|NCT05257421|OTHER|leg and back exercises|"the exercise program will include 5 exercises that focuses on the back and lower limbs. These exercises are:~* Bridge~* Plank~* Squat~* Push-ups~* Back extension Each exercise will be done for 3-5 sets."
223548057|NCT05257421|COMBINATION_PRODUCT|shockwave and exercises|both types of interventions will be applied for the patient
223548058|NCT03183752|DRUG|Metformin|500 mg metformin three times daily
223548059|NCT03183752|DRUG|Placebo|500 mg placebo three times daily
223548060|NCT04583124|OTHER|ATENTO-B|Patients will perform therapeutic exercise and vagal activation techniques before medical treatment and will follow the usual care after medical treatment.
223548061|NCT04583124|OTHER|ATENTO-T|Patients will perform therapeutic exercise and vagal activation techniques throughout medical treatment and will follow the usual care after medical treatment.
223548062|NCT01166789|DRUG|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
223548063|NCT01166789|DRUG|Placebo|2 capsules daily, taken in morning and evening
223548064|NCT06093958|DIAGNOSTIC_TEST|Manual loading of the chest wall|The chest wall will be loaded by either compression of the abdominal wall, compression of the lumbar spine, or compression of the sternum.
223548065|NCT00725946|DRUG|Iodine-124|
223730735|NCT03580694|DRUG|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
223730736|NCT03037411|DEVICE|Peripheral stenting|stent implantation during the index procedure
223393091|NCT03412136|DIETARY_SUPPLEMENT|Control|Participants were given 5 minutes to ingest the non-caloric beverage which contained 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water and sweetened with 0.2g sucralose (Tate \& Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.
223393092|NCT03412136|DIETARY_SUPPLEMENT|Glucose|Participants were given 5 minutes to ingest the beverage which contained either 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight and was flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
223548066|NCT00725946|RADIATION|PET/CT with Iodine-124|
223548067|NCT01696799|DRUG|Econazole Nitrate|
223548068|NCT01696799|DRUG|placebo|
223548069|NCT01194219|DRUG|Apremilast|
223730737|NCT01032642|DEVICE|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
224013277|NCT05197283|OTHER|Glucose as reference food|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested two times, in different visits, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224013278|NCT05197283|OTHER|White bread|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from white bread, along with 300ml water, tested two times, in different visits, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224013279|NCT05197283|OTHER|Regular spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from regular spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223548070|NCT01194219|DRUG|Placebo|Identical matching placebo
223393093|NCT03412136|DIETARY_SUPPLEMENT|Protein|Participants were given 5 minutes to ingest the beverage which contained 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) per kg of bodyweight and flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
223393094|NCT02446041|OTHER|Non-Interventional Study|Non-Interventional Study
223393095|NCT02738918|DRUG|Nulojix (Belatacept)|Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
223393096|NCT02600936|DEVICE|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
223393097|NCT00997841|PROCEDURE|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
223393098|NCT05680519|OTHER|theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
223393099|NCT05680519|OTHER|Control group|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice.
223393100|NCT04316338|DEVICE|Intermittent theta-burst stimulation (iTBS)|Non-invasive brain stimulation technique
223393101|NCT04683861|PROCEDURE|Spinal cord stimulation|Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
223393102|NCT04319471|DRUG|Capecitabine/S-1|Drug: Capecitabine/S-1
223393103|NCT04319471|DRUG|Chemotherapy|Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle
223393104|NCT04319471|RADIATION|Head and neck radiotherapy|IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma；
223393105|NCT04319471|OTHER|Local Consolidative Therapy|radiotherapy，surgery or interventional therapy for all metastatic sites.
223393106|NCT00639756|DRUG|Allopurinol|Allopurinol 300 mg
223393107|NCT00639756|DRUG|Placebo|Placebo given for 2 weeks
223393108|NCT05606640|DIAGNOSTIC_TEST|Biopsychological pain assessment|At baseline (T0) patients underwent the somatosensory pain assessment, joint structure and function assessment and filled in all questionnaires. During one month after baseline (T1) patients wore an activity tracker and filled in the Illness Perceptions Questionnaire and the International Physical Activity questionnaire. During one year after the baseline assessment (T2) patients filled in every month The Brief Pain Inventory, Illness Perceptions Questionnaire and the EQ-5D-5L quality of life questionnaire.
223393109|NCT00192582|BEHAVIORAL|Motivational Interview with care plan and education|
223548071|NCT01194219|DRUG|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
223548072|NCT00292045|BIOLOGICAL|NY-ESO-1 protein/CpG 7909|Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
224013280|NCT05197283|OTHER|Whole wheat spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from whole wheat spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
223393110|NCT01936844|DRUG|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
223393111|NCT01936844|DRUG|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
223393112|NCT01936844|DRUG|Placebo|Placebo twice daily for days 1, 2, and 3
223393113|NCT01936844|DRUG|Placebo|Placebo daily for days 4-14
223393114|NCT01656460|RADIATION|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy"
223393115|NCT01656460|RADIATION|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
223393116|NCT01656460|RADIATION|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
223393117|NCT01656460|RADIATION|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
223548073|NCT00758940|DEVICE|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
223548074|NCT06302803|BEHAVIORAL|Intermittent fasting plus time-restricted eating|Participants in the mTRE group will be instructed to eat during a window of 8 h (8 am to 4 pm) 5 days and fast (approximately 500-600 kcal per day) 2 days per week.
223548075|NCT06302803|BEHAVIORAL|Calorie restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on eating time.
223548076|NCT04474197|DRUG|VX-864|Tablets for oral administration.
223548077|NCT04474197|DRUG|Placebo|Placebo matched to VX-864 for oral administration.
223730738|NCT02643082|DRUG|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
224127846|NCT02998437|DRUG|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
223393118|NCT01113892|DEVICE|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
223393119|NCT04760080|OTHER|pre-treatment data|"We will evaluate in all patients pre-treatment data :~* Melanoma staging at treatment initiation~* Melanoma characteristics at initial diagnosis~* Number and location of metastasis~* Performans status~* Demographic information"
223393120|NCT04760080|OTHER|during study treatment|"We will evaluate in all patients during study treatment :~* Rate of adverse events~* Type of adverse events~* Radiological response to treatment by CTscans that are routinely performed every three months."
223393121|NCT03693131|DRUG|Icosapent (MND-2119)|Icosapent (MND-2119) capsules.
224013281|NCT05197283|OTHER|High fibre - low carbohydrates spaghetti|Fourteen healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from high fibre - low carbohydrate spaghetti No 7, along with 300ml water, tested once, within 10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224127847|NCT02915367|BEHAVIORAL|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
223393122|NCT03693131|DRUG|Icosapent (EPADEL CAPSULES 300)|Icosapent (EPADEL CAPSULES 300) capsules.
223393123|NCT00707148|DRUG|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
223393124|NCT00707148|BIOLOGICAL|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
223393125|NCT02385773|DIETARY_SUPPLEMENT|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
223393126|NCT02385773|DIETARY_SUPPLEMENT|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
223393127|NCT04425057|OTHER|Interval training|
223393128|NCT06477198|OTHER|QLB|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the convex probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the quadratus lumborum muscle, the needle will be punctured and 5 ml of saline will be injected into the posterior border of the quadratus lumborum muscle between QLM and latissimus dorsi muscle.. After the block location is confirmed, 30 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (60 ml totally).
223393129|NCT06477198|OTHER|ESPB|ESP block will be performed. Convex probe will be placed longitudinally 4 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle, 2 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for the block in each side (total 60 mL).
223393130|NCT06477198|OTHER|Postoperative analgesia management|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
223393131|NCT03359616|PROCEDURE|Transanally curable surgical resection|Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
223393132|NCT03359616|PROCEDURE|Laparoscopic total mesorectal excision|Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
223393133|NCT01376999|DRUG|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
223393134|NCT01607515|OTHER|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
223393135|NCT02569801|DRUG|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
223393136|NCT02569801|DRUG|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
223393137|NCT00428246|DRUG|paricalcitol|1 mcg or 2 mcg for 4 weeks.
223393138|NCT00428246|DRUG|Placebo|Placebo
223393139|NCT00762255|DRUG|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
223393140|NCT00762255|DRUG|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
223393141|NCT00762255|DRUG|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
223393142|NCT02200055|DEVICE|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
223548078|NCT05231850|DRUG|Tislelizumab|All eligible patients receive received 200 mg Tislelizumab intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
223548079|NCT05655533|DIAGNOSTIC_TEST|Magnetic resonance Imaging scanners of sacroiliac joints.|"Patients will undergo MR imaging examinations with a closed 1.5-Tesla Magnetic resonance Imaging scanners of sacroiliac joints.~The patients will be imaged in the supine position using a body phased-array coil.~Evaluate the added value of DWI in detection of acute sacroiliitis and whether ADC values can be helpful in detection and differentiation of active stage, so determine whether supplementation of DWI with quantitative ADC mapping to the routine MR examination is of great value as non-invasive tool or not"
223730739|NCT02643082|DRUG|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
223393143|NCT03468517|OTHER|Bathe method:|BATHE technique, on the other hand, is one of the short therapeutic consultation techniques that strengthen the doctor-patient relationship. BATHE stands for the initials of the questions that include the titles for Background, Affect, Trouble, Handling and Empathy. It allows evaluating the physiological stress of the patients quickly. BATHE method necessitates an empathetic expression that includes the view of the patient in addition to asking the key questions by the doctor doing the interview
223393144|NCT01114035|GENETIC|blood samples and skin biopsies|to detect mutations
223393145|NCT01114035|GENETIC|Skin biopsies|to detect mutations
223730740|NCT01867021|BIOLOGICAL|Fluvirin(TIVf)|
224013282|NCT01860378|OTHER|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
224013283|NCT01860378|OTHER|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
224013284|NCT00733187|DRUG|ABT-869|0.25 mg/kg
223393146|NCT01614496|OTHER|Algorithm for insulin administration|
223393147|NCT03822091|DRUG|Terlipressin|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1. 1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~2. A dose of 20gram/day to 60gram/day in the following days."
223393148|NCT03822091|DRUG|Terlipressin and Noradrenaline|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~* the creatinine values decrease by \<12.5%~* MAP increase of \<10 mmHg~* urine output of \<200 ml in 4 hours."
223548080|NCT04281420|DRUG|ATG-019|ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
223730741|NCT01867021|BIOLOGICAL|Agriflu (TIV)|
223548081|NCT04281420|COMBINATION_PRODUCT|ATG-019 + Niacin ER|ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
223548082|NCT04396548|DRUG|Midodrine Oral Product|Patients will receive oral 10 mg tablet of midodrine with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine.
223548083|NCT04396548|DRUG|Inert tablet containing sugar (placebo)|: Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
223548084|NCT02499913|BEHAVIORAL|breath alcohol monitoring|Daily breath alcohol monitoring
223548085|NCT02499913|BEHAVIORAL|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
223548086|NCT04234347|PROCEDURE|Intravenous access method|Comparing long and short axis approach to USGPIV access.
223548087|NCT02334020|OTHER|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
223730742|NCT02239757|PROCEDURE|Left radial approach|Primary PCI performed through left radial approach.
224013285|NCT03014479|DRUG|Trelagliptin|Trelagliptin 100 mg or 50 mg
223564217|NCT04262882|BEHAVIORAL|Time and attention matched control|"This intervention serves as the attention-matched control. The format and delivery will mirror that of the Family Health = Family Wealth intervention (i.e., number, timing, and duration of sessions). The focus of the intervention is on community sanitation and at-home hygiene (hand-washing, food preparation) following an intervention manual that was developed for community groups in Uganda."
223564218|NCT02566187|DRUG|Fimasartan/Atorvastatin Combination Tablet|
223564219|NCT02566187|DRUG|Fimasartan|
223564220|NCT02566187|DRUG|Atorvastatin|
223564221|NCT00014443|DRUG|thalidomide|
223564222|NCT00014443|DRUG|topotecan hydrochloride|
223564223|NCT04645316|DRUG|Sevoflurane|In the sevoflurane group (n = 25), after the induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, the Sevoflurane concentration will be adjusted between 1-2%, the BIS value will be 40-60, and it will be inhaled with an air / O2 mixture to be FiO2: 0.4.
223564224|NCT04645316|DRUG|Desflurane|In the desflurane group (n = 25), after induction of anesthesia with 2 mg / kg propofol and 1 µg / kg remifentanyl, rocuronium 0.6 mg / kg will be given for intubation. In this group, Desflurane concentration will be adjusted between 6-8%, BIS value will be 40-60 and it will be inhaled with a mixture of air / O2 mixture to be FiO2: 0.4.
223564225|NCT04645316|DRUG|Propofol|In the propofol-remifentanyl group (n = 25), rocuronium 0.6 mg / kg will be administered for intubation after 2 mg / kg propofol and 1 µg / kg remifentanil. Maintenance of anesthesia will be adjusted to be between 10 mg / kg / h for the first 10 minutes, 8 mg / kg / h for the following 10 minutes, and then by 6 mg / kg / h propofol infusion, with the BIS value between 40-60. Patients in this group will be inhaled with a mixture of air / O2 to be FiO2: 0.4. Inhalation anesthetics will not be used in this group.
223564226|NCT01301066|DRUG|Pitavastatin|Pitavastatin 4 mg QD
223564227|NCT01301066|DRUG|Pravastatin|Pravastatin 40 mg QD
223564228|NCT06036706|RADIATION|Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning|Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
223564229|NCT06036706|RADIATION|Hypo-fractionated stereotactic brain irradiation|Patients receiving hypo-fractionated stereotactic brain irradiation
223564230|NCT06036706|RADIATION|Normo-fractionated proton therapy brain irradiation|Patients receiving normo-fractionated proton therapy brain irradiation
223393149|NCT01700062|DIETARY_SUPPLEMENT|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
223393150|NCT02528877|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
223393151|NCT02528877|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoeitic stem cell transplant
223393152|NCT02528877|DRUG|Fludarabine Phosphate|Given IV
223393153|NCT02528877|OTHER|Laboratory Biomarker Analysis|Correlative studies
223393154|NCT02528877|DRUG|Melphalan|Given IV
223393155|NCT02528877|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo hematopoietic stem cell transplant
223393156|NCT02528877|OTHER|Pharmacological Study|Correlative studies
223393157|NCT02528877|DRUG|Ruxolitinib Phosphate|Given PO
223393158|NCT02528877|DRUG|Sirolimus|Given PO
223393159|NCT02528877|DRUG|Tacrolimus|Given IV or PO
223393160|NCT03863535|DRUG|Conbercept|Participants were randomized (1:1) to receive IVC+PRP or PRP monotherapy. Patients in IVC+PRP group with diabetic macular edema (DME) received 3 monthly IVC injections along with standard PRP within 1 week after the first injection. Those without DME received 1 lVC injection and standard PRP within 1 week after the injection . Re-treatments in both groups were at the investigators'discretion.
223393161|NCT03863535|PROCEDURE|Panretinal coagulation|The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.
223393162|NCT01871623|PROCEDURE|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
223393163|NCT01871623|PROCEDURE|One-piece Le Fort I Osteotomy|conventional approach
223393164|NCT03442751|DRUG|Test Article A|Riboflavin Ophthalmic Solution A
223393165|NCT03442751|DRUG|Test Article B|Riboflavin Ophthalmic Solution B
223393166|NCT03442751|DRUG|Placebo|Placebo Vehicle of Test Article
223393167|NCT03442751|DEVICE|KXL medical device system|Mock UVA light source
224013286|NCT03014479|DRUG|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
223393168|NCT03442751|DEVICE|KXL medical device system|Cross-linking UVA light source
223393169|NCT04997252|DRUG|Apalutamide|apalutamide as neoadjuvant therapy
223393170|NCT00498394|BEHAVIORAL|Clinical diet trial|
223393171|NCT04311866|DEVICE|Synthetic pants|The use of synthetic materials is preferred (glass fiber), resistance, durability and low weight makes them optimal. To give some extra strenght to the cast, fiber strips are placed anterior and posterior at the level of the groin, this can facilitate the transportation of the patient avoiding the use of a bar.
223393172|NCT04311866|DEVICE|Spica cast|The use of the spica cast is a standard practice for the management of the femoral shaft fractures, however its use, under some circumstances has been related to a wrong management of the cast, auto-retrieval, patient discomfort, and a difficult situation trying to maintain personal hygiene for the patient.
223393173|NCT05421819|DIETARY_SUPPLEMENT|Calcium and vitamin D supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 plus flavonoids once per day.
223393174|NCT05421819|DIETARY_SUPPLEMENT|Calcium, vitamin D and prebiotic supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
223393175|NCT05421819|DIETARY_SUPPLEMENT|Calcium, vitamin D and flavonoid supplement|One hundred fifty postmenopausal women with osteopenia will be randomly and blindly allocated to receive in of the 3 different dietary supplements once per day. Patients of group A will receive orally 600 mg calcium and 2400 IU vitamin D3, group B will receive the same dose of calcium and vitamin D3 plus prebiotics once per day and group C will receive the same dose of calcium, vitamin D3 and flavonoids once per day.
223393176|NCT04291287|DRUG|Antithrombotic Agent|"Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)"
223393177|NCT05516680|DEVICE|electro-acupuncture|Acupoints consist of Neiguan (PC6, bilateral), Shuigou (GV26), Sanyinjiao (SP6, affected side), Yintang (EX-HN3), Shangxing (GV23), Baihui (GV20), and Sishencong (EX-HN1). Disposable stainless-steel needles (0.25mm× 40 mm）will be used. After skin disinfection, the acupuncturists will twist and thrust the needle handles to achieve the sensation of achiness, heaviness, and numbness (known as de qi) at all acupoints. Following needle manipulations, electroacupuncture instruments(SDZ-V) will be used to attached the needle handles at EX-HN3, GV23, GV20 and EX-HN1 with a dilatational wave of 5 \~ 10 Hz and a current intensity of 1 \~ 3 mA depending on the patient's tolerance. The needles will be removed after 30 minutes except for GV26 without needle retention. Participants will receive 12-20 electroacupuncture sessions over four weeks at a frequency of 3-5 times per week.
223730743|NCT02239757|PROCEDURE|Right radial approach|Primary PCI performed through right radial approach.
224013287|NCT04520503|DRUG|Propofol|The dose of propofol required for loss of consciousness and the total induction dose of propofol will be recorded for every patients.
224013288|NCT04520503|DEVICE|EEG monitoring|The processed EEG spectrogram and indices, such as patient status index, 95% spectral edge frequency, and suppression ratio, will be obtained from Sedline monitoring device. The raw pre-induction EEG will be extracted from Sedline at the end of induction and it will be analyzed by an external software to calculate the mean frequency, frequency band power and its distribution.
224127848|NCT01930799|BEHAVIORAL|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
223393178|NCT05516680|DEVICE|MRI-navigated rTMS|MRI:All MRI scans were taken to acquire high-resolution T1-weighted anatomical images on the 3T MRI Scanner. Electromyography(EMG):Surface EMG was used to record MEPs from the abductor pollicis brevis for determining RMT of the non-lesioned motor cortex.A single TMS pulse was delivered to the location to identify the RMT,defined as the minimum intensity capable of evoking at least 5 MEPs of \>50 μV in 10 consecutive trials.MRI-navigated rTMS:Using BrainSight system,left DLPFC targeting was individualized by reconstructing MRI data into a 3-dimensional brain image for neuro-navigation. Left DLPFC localization was central middle frontal gyrus,between superior frontal sulcus and middle frontal sulcus based on T1-weighted anatomical images.Focal rTMS was administered using a Magstim Rapid 2 connected to Y125-round coil that was identical.rTMS was applied at 110% RMT to the left DLPFC.At each session,3000 pulses were applied at 10 Hz with a total of 12-20 rTMS sessions over a 4-week period.
223548088|NCT00521209|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
223548089|NCT00521209|OTHER|Stand procedures, no intervention|
223548090|NCT00888914|DRUG|RT001|RT001
223548091|NCT00888914|DRUG|RT001|RT001
223548092|NCT00888914|DRUG|RT001|RT001
223548093|NCT00888914|DRUG|RT001|RT001
224013289|NCT03457051|PROCEDURE|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint. The device that will be used is: Stryker TKA Triathlon system implant Cruciate retaining radius femur design. This device has been approved for use by Health Canada.
224013290|NCT03457051|PROCEDURE|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced. The device that will be used is: Stryker PKR implant cemented and fixed bearing design. This device has been approved for use by Health Canada.
224013291|NCT04705701|PROCEDURE|Hemodialysis|Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
224013292|NCT04793789|OTHER|monofocal toric lens|not applicable as patients are already implanted with the monofocal toric lens
224013293|NCT04201340|DEVICE|DRI OCT Triton with SS-OCT Angio software|The Topcon DRI OCT Triton with SS-OCT Angio software is an OCT with a fundus camera used for diagnostic purposes
224013294|NCT04201340|DEVICE|Cirrus HD-OCT 5000|The Zeiss Cirrus HD-OCT 5000 is an OCT used for diagnostic purposes
224013295|NCT04201340|DEVICE|TRC-50DX|The TRC-50DX retinal camera images the fundus used for diagnostic purposes
224013296|NCT04668404|DIAGNOSTIC_TEST|Sonoclot|Sonoclot machine
224013297|NCT01781078|RADIATION|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
224013298|NCT01781078|DEVICE|ImageReady System implant|Pacemaker and lead(s) implant
224013299|NCT01986452|DEVICE|CPAP therapy|
224013300|NCT01986452|OTHER|Support|
224013301|NCT03588559|DIAGNOSTIC_TEST|Blood Pressure Measurement|Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
224013302|NCT00652470|PROCEDURE|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
224013303|NCT00652470|PROCEDURE|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
224013304|NCT05299593|DRUG|tafluprost/timolol|"One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day."
224127849|NCT04353622|DEVICE|Exoskeleton robot for upper extremity|"Robot-assisted Treatment Program:~* 10 minutes elbow flexion/extension~* 10 minutes forearm supination/pronation~* 10 minutes wrist flexion/extension~* 10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)"
223548094|NCT00888914|OTHER|Vehicle Comparator|Vehicle Comparator
223548095|NCT04388007|OTHER|Thoracic spinal manipulation|High velocity, low amplitude force manipulation
224013305|NCT04831151|DRUG|Yasmin|Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone
224013306|NCT04831151|DRUG|Diane-35|Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate
224127850|NCT04353622|OTHER|Conventional physiotherapy|Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
223548096|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
224127851|NCT00972400|GENETIC|protein analysis|
224127852|NCT00972400|OTHER|laboratory biomarker analysis|
224127853|NCT00972400|OTHER|mass spectrometry|
224127854|NCT00972400|OTHER|questionnaire administration|
224127855|NCT00972400|PROCEDURE|assessment of therapy complications|
224127856|NCT00972400|PROCEDURE|cognitive assessment|
224127857|NCT00972400|PROCEDURE|quality-of-life assessment|
224127858|NCT04357353|BIOLOGICAL|Platelet rich plasma|PRP will be used in the experimental arm.
224127859|NCT04357353|OTHER|Placebo Sham Injection|sham injection
223548097|NCT00938613|DRUG|Placebo|nasal spray, one spray per nostril at time 0
223548098|NCT00938613|DRUG|Budesonide|nasal spray, one spray per nostril at time 0
223548099|NCT04340388|DRUG|Dolutegravir 50 MG|15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
224013307|NCT05523843|OTHER|Tulsa Life Chart (TLC)|The TLC is a self-administered, interactive assessment of patient history. Participants are asked to provide information from birth to their current age in developmental epochs (i.e., ages 0 to 5; 6 to 10; 11 to 14; 15 to 18; 19 to 25; 26 to 35; and so on in 10-year increments). Participants are first asked to rate their average mood during the epoch. They are then asked about locations lived, schools attended, people they were close to, hobbies, medical conditions, medications, hospitalizations, direct and indirect substance use exposure, mental health symptoms, mental health treatment, and important life events. The information is then displayed in an interactive, graphic of the individual's life that is reviewable by the patient and the healthcare providers enrolled in the study that the patient consents to having access.
223393179|NCT02596204|OTHER|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
223393180|NCT02596204|DEVICE|FitBit|All subjects will wear a FitBit activity monitor.
223393181|NCT02896634|BIOLOGICAL|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
223393182|NCT05183139|DRUG|Ixazomib|Ixazomib capsules
223548100|NCT04340388|DRUG|Antiretroviral/Anti HIV|15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
223548101|NCT06361966|DEVICE|3d printed prosthetic socket|3d printed prosthetic socket produced through multi-jet fusion (MJF)
223548102|NCT02445729|OTHER|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
223548103|NCT02445729|OTHER|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
223548104|NCT01037998|DRUG|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
224127860|NCT00722553|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
224127861|NCT00722553|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
224127862|NCT00722553|DIETARY_SUPPLEMENT|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
223393183|NCT05183139|DRUG|Pomalidomide|Pomalidomide capsules
223393184|NCT05183139|DRUG|Lenalidomide|Lenalidomide capsules
223393185|NCT05183139|DRUG|Dexamethasone|Dexamethasone tablets
223393186|NCT03651154|PROCEDURE|Hypovolemic Phlebotomy|Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
223393187|NCT06058572|DRUG|Rifaximin 200Mg Tab|Drug rifaximin 200 mg tablet form orally twice daily (with or without food) from day-8 of transplant to day + 60 of transplant
223393188|NCT06058572|PROCEDURE|allogenic hematopoietic stem cell transplantation|Control arm will undergo allogenic hematopoietic stem cell transplantation as standard of care
223393189|NCT06402110|OTHER|Femoral Triangle Block|Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.
223393190|NCT06402110|OTHER|Adductor Canal Block|Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.
223393191|NCT02923778|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223548105|NCT00222755|BEHAVIORAL|Disease Management|Self-management, care management, guidelines
223548106|NCT05050292|OTHER|Personalized cognitive stimulation|"Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser.~Performance feedback will be shown after each activity."
223548107|NCT05050292|OTHER|Sham cognitive stimulation|"Non-therapeutic online games based on artistic and creative tasks. Activities will match in duration to those of the experimental intervention.~Performance feedback will be shown after each game."
223548108|NCT00056173|DRUG|GTI-2040|
223564231|NCT06036706|OTHER|Cognitive assessment by a trained neuropsychologis|Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
223564232|NCT00002389|DRUG|Abacavir sulfate|
223564233|NCT00002389|DRUG|Lamivudine|
223564234|NCT00002389|DRUG|Zidovudine|
223548109|NCT02831127|OTHER|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
223548110|NCT02831127|OTHER|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
223393192|NCT02923778|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223393193|NCT02923778|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223393194|NCT02923778|RADIATION|Radiation Therapy|Undergo radiation therapy
223393195|NCT02923778|BIOLOGICAL|Talimogene Laherparepvec|Given IT or via intralesional injection
223393196|NCT04009278|OTHER|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
223548111|NCT06287242|OTHER|spinal manipulation|High velocity, low amplitude (HVLA) manipulation of the cervical or thoracic spine
223730744|NCT04770350|DEVICE|Focused Ultrasound|The DWL Doppler ultrasound device enables visual and auditory waveform confirmation of the middle cerebral artery, and optical tracking technology (e.g., AntNeuro Visor2™ system) may be used in tandem with the Brainsonix ultrasound device to track a patient's brain in virtual space as well as their physical location, thereby ensuring accurate placement.
223730745|NCT00881712|RADIATION|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
223730746|NCT00881712|RADIATION|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
224013308|NCT05599659|BEHAVIORAL|Palliative care|"It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team.~The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans.~The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant."
224013309|NCT01805752|OTHER|Task-shifting to lower-cadre providers at PMTCT sites|
224013310|NCT01805752|OTHER|POC CD4+ cell count testing|
224013311|NCT01805752|OTHER|integrated mother-infant care|
224013312|NCT01805752|OTHER|Prominent role for influential family members (male partners) in collaboration with CHWs|
224013313|NCT01394978|OTHER|Control|Standard surgical techniques including staples and sutures.
224127863|NCT05609747|PROCEDURE|Nonsurgical root canal therapy|After administration of LA and rubber dam isolation, acess cavity will be prepared using carbide burs in high speed hand piece with copious irrigation. Working length will be determined using root ZX apex locator and will be verified radiographically. Canal preparation will be done with protaper rotary instruments in which Sx to S2 will be used to shape the canals and F1 and F2 will be used to finish until the apex. 5ml of 5.25% NaOCl will be used as irrigant after each instrument. After instrumentation , the canals will be irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals will be dried with absorbent paper points, filled with calcium hydroxide paste and access cavity will be restored with IRM. Patients will be recalled after 1 week.At the next appointment, after paste removal, copious irrigation with 5.25% NaOCl will be done and canals will be dried with paper points. Canals will be obturated with Gutta-Percha and ZOE based sealer.
223730747|NCT00881712|RADIATION|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
223730748|NCT03859349|DIAGNOSTIC_TEST|Selective Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
223730749|NCT03859349|DIAGNOSTIC_TEST|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
223393197|NCT05968261|PROCEDURE|Real time 'near remote' guidance of regional blocks|Trainees who are to perform regional blocks will do so under expert guidance via tele-mentoring. This will be done using a novel technology consisting of a wirelessly linked iPad which will display the ultrasound image to the block operator/trainee. This image will be concurrently visualized by an expert mentor through their smartphone, who will then provide feedback/guidance in real-time to the operator/trainee.
223393198|NCT06399185|DRUG|Normal saline|20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
223548112|NCT01871545|DEVICE|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
223548113|NCT00698438|DEVICE|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
223548114|NCT00698438|PROCEDURE|Trabeculectomy|standard trabeculectomy
223548115|NCT00001040|DRUG|Saquinavir|
223548116|NCT00001040|DRUG|Zidovudine|
223548117|NCT00001040|DRUG|Zalcitabine|
224013314|NCT01394978|DEVICE|ProGEL Pleural Air Leak Sealant with standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
223548118|NCT01506557|DIETARY_SUPPLEMENT|cholecalciferol|dose 800 IU/day for 6 month
223548119|NCT01506557|DIETARY_SUPPLEMENT|placebo|oil capsules
223548120|NCT03110718|DEVICE|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
223548121|NCT00060671|DRUG|rituximab|
223548122|NCT00060671|DRUG|Pixantrone (BBR 2778)|
223548123|NCT00202696|DRUG|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
223548124|NCT00202696|OTHER|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
223548125|NCT03930589|PROCEDURE|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
223548126|NCT03930589|OTHER|Standard of care|Standard of care
224013315|NCT01394978|DEVICE|ProGEL Pleural Air Leak Sealant without standard surgical closure|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG). Standard closure means, for example, suturing or stapling of visible air leaks incurred during resection of lung parenchyma.
224013316|NCT04787887|DRUG|Abcertin|60IU/kg Single Intravenous Administration
224013317|NCT04787887|DRUG|EU-sourced Cerezyme|60IU/kg Single Intravenous Administration
224127864|NCT01706445|OTHER|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
224127865|NCT00952289|DRUG|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
223548127|NCT04532515|DEVICE|Seal-G Surgical Sealant|"Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
223548128|NCT04532515|DEVICE|Seal-G MIST System|"Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis"
223548129|NCT01567033|BEHAVIORAL|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
223548130|NCT04828135|DRUG|Hyperpolarized 129Xenon gas|Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
223548131|NCT02058979|DRUG|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
223548132|NCT02058979|DRUG|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
224013318|NCT00018278|DRUG|Aricept|
224013319|NCT00018278|DRUG|Exelon|
224013320|NCT00018278|DRUG|Nicoderm Patch|
224127866|NCT00952289|DRUG|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
223548133|NCT03694951|BEHAVIORAL|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
223548134|NCT02118948|BEHAVIORAL|Abuse-focused intervention|
223548135|NCT02118948|BEHAVIORAL|Sexual behavior-focused intervention|
223564235|NCT01891617|OTHER|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
223730750|NCT01397474|OTHER|PPTFM|Peripheral Perfusion Targeted Fluid Management
224013321|NCT00649636|DRUG|Fluoxetine Capsules 40 mg|40mg, single dose fasting
224013322|NCT00649636|DRUG|Prozac Pulvules 40 mg|40mg, single dose fasting
223548136|NCT00598507|DRUG|ZK-EPO|Participants were treated with 16 mg/m\^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
223393199|NCT06399185|DRUG|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
223393200|NCT06399185|DRUG|Esketamine|Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
223393201|NCT06399185|DRUG|Combined dexmedetomidine-esketamine|Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
223393202|NCT02603887|OTHER|Laboratory Biomarker Analysis|Correlative studies
223393203|NCT02603887|BIOLOGICAL|Pembrolizumab|Given IV
223548137|NCT00300378|DRUG|desvenlafaxine 50 mg|
223548138|NCT00300378|DRUG|desvenlafaxine 100 mg|
223548139|NCT00719992|PROCEDURE|coronary angiography|effect of level of HS-CRP
223548140|NCT00934583|BEHAVIORAL|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
223548141|NCT04834726|BEHAVIORAL|Opt-In (Call-Back)|Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.
223730751|NCT01966900|BIOLOGICAL|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
223730752|NCT04510012|OTHER|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.|Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
223730753|NCT03138278|OTHER|Telephone support on demand|Dedicated phone number for help and advice for caregivers
224013323|NCT00003489|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
224013324|NCT00000739|DRUG|Dapsone|
224013325|NCT02019667|DRUG|SGS-742|
224013326|NCT02019667|DRUG|Placebo|
224013327|NCT02577822|DEVICE|Taperloc standard length stem|
224013328|NCT02577822|DEVICE|Taperloc short length stem|
224013329|NCT03763890|DEVICE|Post-end-Expiratory pressure|Titrate the PEEP from 24 cmH2O to 6 cmH2O, 2 cmH2O/step and record EIT, trans-pulmonary pressure, hemodynamic parameter and Blood-gas analysis.
224127867|NCT03091062|DEVICE|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
224013330|NCT02286986|DRUG|Cannabidiol|
224013331|NCT00128089|BEHAVIORAL|Dietary treatment|
224013332|NCT06404801|BEHAVIORAL|Stance Control|Instead of stability coming from a locked knee joint, the brace is able to lock and unlock at just the right time while walking
224013333|NCT01410968|DRUG|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
224013334|NCT00287807|BEHAVIORAL|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
224127868|NCT03091062|DEVICE|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
224138596|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
223393204|NCT05334641|OTHER|Listening Music|The patients in the experimental group were listened to music.
223393205|NCT05334641|OTHER|Not Listening Music|The control group was not listened to music.
223393206|NCT03935698|OTHER|Physiotherapy|
223393207|NCT04539002|BEHAVIORAL|Aerobic exercise|Aerobic exercise performed on a stationary ergometer for 30 minutes, thrice weekly, with graded supervision. Participants will participate in the intervention over 24 weeks.
223393208|NCT04539002|BEHAVIORAL|Education Group Control|A monthly, hour-long, class over various MS topics and symptoms, led by a trained facilitator.
223393209|NCT02051348|BIOLOGICAL|Pylopass|Pylopass
223393210|NCT02051348|BIOLOGICAL|Placebo|Placebo
223393211|NCT05611983|BEHAVIORAL|sensory relearning|feasibility of early sensory relearning
223393212|NCT02877225|DRUG|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
223393213|NCT02877225|DRUG|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
223393214|NCT04390919|OTHER|elevated monocyte count|The monocyte count at admission was higher than 0.445×10\*9 cells/L
223393215|NCT05236114|OTHER|Observation|No intervention
223393216|NCT06519357|DRUG|Lamivudine 300 MG|Participants receive 300 mg of Lamivudine daily for 24 weeks
223548142|NCT04834726|BEHAVIORAL|Opt-in (In-Bound)|Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.
223548143|NCT04834726|BEHAVIORAL|Standard Message|The message describes that the patient is eligible for the COVID vaccine.
223393217|NCT06547086|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
223548144|NCT04834726|BEHAVIORAL|Clinician Endorsement|The message will describe an endorsement from the provider to get the vaccination.
223393218|NCT06163040|DRUG|Elotuzumab in combination with pomalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
223393219|NCT06163040|DRUG|Elotuzumab in combination with lenalidomide and dexamethasone|Participants who received elotuzumab in combination with pomalidomide and dexamethasone for RRMM and had ≥2 prior lines of therapy (including lenalidomide and a proteasome inhibitor)
223393220|NCT05017025|DRUG|Aurora A Kinase Inhibitor LY3295668|Given PO
223393221|NCT05017025|DRUG|Osimertinib|Given PO
223393222|NCT05330182|DRUG|LMN-201|"LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism"
223393223|NCT05330182|DRUG|Placebo|Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
223548145|NCT04834726|BEHAVIORAL|Scarcity|The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.
223548146|NCT04834726|BEHAVIORAL|Opt-Out Framing|This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.
223548147|NCT04834726|BEHAVIORAL|Phone Call|The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.
223548148|NCT02176629|OTHER|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
223730754|NCT03823001|DIAGNOSTIC_TEST|virtual biopsy (VB) monitoring protocol|"1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
223730755|NCT00296881|DEVICE|PERIOWAVE|
224127869|NCT04356144|DIAGNOSTIC_TEST|Thrombin Generation Assay (TGA)|"TGA via a fluorimetric module. Coagulation cascade is activated upon addition of different concentrations of tissue factor and phospholipids. The fluorogenic substrate Z-Gly-Gly-Arg-AMC (ZGGR-AMC) is cleaved by formed thrombin over time. By plotting the changes in fluorescence as a function of time (cnt/min), it depicts the Thrombin Generation Curve (thrombin generated - plotted against time). The area under the thrombin curve is defined as the endogenous thrombin potential (ETP)."
223393224|NCT05326230|DEVICE|Paradise™ (PRDS-001) Renal Denervation Ultrasound System|Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
223393225|NCT05326230|DEVICE|Renal Angiogram|Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
223393226|NCT00356226|DRUG|clonidine|
223548149|NCT02176629|OTHER|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
223548150|NCT02328521|DRUG|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
223548151|NCT02328521|DRUG|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
223548152|NCT06443333|OTHER|Data collection and follow-up observation|At the time of enrollment, the patient's biological samples are collected to obtain genetic information. Following enrollment, trained investigators carry out a 2-year follow-up observation through face-to-face, telephone call or online visits. During the follow-up, basic clinical information, laboratory tests, imaging examinations, neurophysiology, clinical classification, medication use, and scale assessments are collected.
223548153|NCT06443333|OTHER|Data collection|Collect demographic and genetic information from healthy volunteers upon enrollment.
223548154|NCT00283543|DRUG|Gliadel Wafer|
223393227|NCT00681343|DRUG|Thymoglobulin|Induction
223548155|NCT00283543|DRUG|Temozolomide|
223548156|NCT00283543|PROCEDURE|Limited field radiation|
223548157|NCT03487016|DRUG|Gemcitabine|Arm A
223548158|NCT03487016|DRUG|Nab-paclitaxel|Arm A
223548159|NCT03487016|DRUG|5-FU|Arm B Arm C
223548160|NCT03487016|DRUG|Irinotecan Liposomal Injection|Arm B Arm C
223730756|NCT00824239|PROCEDURE|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
223730757|NCT00824239|PROCEDURE|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
223393228|NCT00681343|DRUG|Campath-1H|Induction
223393229|NCT00681343|DRUG|Daclizumab|Induction
223548161|NCT03487016|DRUG|Oxaliplatin|Arm C
223548162|NCT04143581|DRUG|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
223548163|NCT02663336|OTHER|Comparison ABPM with OBPM|No interventions
223548164|NCT00514930|DEVICE|Hexablate|
223548165|NCT04734262|DRUG|Sitravatinib|Sitravatinib QD PO Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
223548166|NCT04734262|DRUG|Tislelizumab|Tislelizumab Q3W IV Tislelizumab is a programmed death receptor-1 (PD-1) blocking antibody
223548167|NCT04734262|DRUG|Nab-paclitaxel|Nab-paclitaxel D1, D8 Q3W IV Nab-paclitaxel is a chemotherapy drug which combines the chemotherapy drug paclitaxel with albumin
223548168|NCT03161210|OTHER|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
223548169|NCT03161210|OTHER|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
223548170|NCT03161210|OTHER|Saline|Saline is a control group
223393230|NCT03438838|PROCEDURE|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
223393231|NCT03438838|PROCEDURE|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
224127870|NCT04356144|DIAGNOSTIC_TEST|Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)|Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
223393232|NCT00850811|DRUG|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
223393233|NCT05716126|DRUG|[14C]Iruplinalkib (WX-0593)|Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
223393234|NCT04421599|OTHER|The Necessity of Aspiration|"The patients who met the inclusion criteria and agreed to participate in the study were assigned to the Experimental Group A who were administered IM injection during which aspiration lasted for 5-10 seconds, to the Control Group who were administered IM injection during which aspiration lasted for 1-2 seconds, and to the Experimental Group B who were not administered IM injection according to the stratified block randomization list. The same Intramuscular Injection Application Protocol was applied while all the injections were administered."
223393235|NCT03197623|DRUG|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
223393236|NCT03197623|DRUG|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
223393237|NCT03757819|DEVICE|tDCS|Brain Stimulation
223393238|NCT03757819|DEVICE|SHAM|Placebo device
223393239|NCT01110018|DRUG|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
223393240|NCT01110018|DRUG|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
223393241|NCT05059613|OTHER|probiotics|one times a day during the whole treatment
223393242|NCT02174003|DEVICE|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
223393243|NCT06429722|DRUG|NMRA-335140 80 mg|Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.
223393244|NCT06429722|DRUG|Placebo|Placebo will be administered orally
223393245|NCT06855225|DRUG|Tremelimumab|Tremelimumab is administered at 300mg intravenously once at Cycle 1.
223393246|NCT06855225|DRUG|Durvalumab|Durvalumab is administered at 1500mg intravenously every 3 weeks for Cycles 1-8, then every 4 weeks for Cycles 9+.
223393247|NCT06855225|DRUG|Gemcitabine|Gemcitabine is administered at 1000mg/m\^2 intravenously on Day 1 and Day 8 of Cycles 1-8 only.
223393248|NCT06855225|DRUG|Cisplatin|Cisplatin is administered at 25mg/m\^2 intravenously on Day 1 and Day 8 of Cycles 1-8 only.
223393249|NCT04993131|PROCEDURE|Liver transplant|Liver transplant.
223393250|NCT06655805|DEVICE|Non-invasive ventilation, Invasive mechanical ventilation, high-flow nasal oxygen|No intervention is intended by the nature of this observational study.
223393251|NCT02902523|DRUG|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
223393252|NCT02902523|DRUG|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
223393253|NCT05836207|BEHAVIORAL|Abstinence-focused Contingency Management (CM) - stand alone|Outpatient abstinence-focused contingency management (CM) as stand-alone treatment (12 weeks). Monetary incentives (vouchers) are provided for cannabis abstinence, based on twice-weekly rapid test urinalysis and an escalating reward scheme with bonuses. Urine samples are collected at the treatment centre during 15-minute sessions by a trained CM-practitioner. For each cannabis-negative urine, patients receive a monetary voucher starting at €5 and escalating to max. €35 after eight consecutive weeks of cannabis abstinence, with an additional €10 bonus after two consecutive cannabis-negative urines. The voucher-value is reset to €5 after a cannabis-positive urine test. Total earnings can be max. €675 for 12 weeks of consecutive cannabis abstinence (average: €8 p/day). Youths sign an agreement stating that vouchers must be spent on recovery-oriented goals.
223548171|NCT00363142|DRUG|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
223548172|NCT00363142|DRUG|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
223548173|NCT03396302|OTHER|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
223548174|NCT00208065|DRUG|almotriptan or pseudoephedrine|
223548175|NCT02137447|DEVICE|Negative Pressure treatment|
223548176|NCT01757301|OTHER|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
223548177|NCT01757301|OTHER|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
223548178|NCT06341361|DIAGNOSTIC_TEST|OCT-based machine learning FFR|OCT-based machine learning FFR and wire-based FFR
223548179|NCT04254146|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
223548180|NCT03467256|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
224013335|NCT05375032|OTHER|Cycling combined with cognitive tasks|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM). The cognitive task will be a PowerPoint presentation structured in a way that is consistent with the phases of the cycling program. The passive phases (6 minutes of warm-up and 4 minutes of passive cycling back to cool down), images of the nearby environment will be played. For the active phase (20 minutes of assisted active cycling) the PowerPoint presentation will be structured with tasks related to: orientation, memory, calculation, language, similarities.
224013336|NCT05375032|OTHER|Cycling|A 30-minute session of Forced Cycling aerobic exercise performed with lower limbs and free active cycling performed with upper limbs combined with cognitive stimuli. An intelligent cycle ergometer (Motomed Viva 2 Parkinson) will be used, at a reserve heart rate of 55-70% (Borg scale 12-14) during the active part. The forced cycling program will consist of a 6-minute passive warm-up part (40-60 RPM), a 20-minute active part (90 RPM), and a 4-minute passive cool down (40 RPM).
224013337|NCT05038163|OTHER|Nutrition Facts|The nutritional information label for each beverage is enlarged.
224013338|NCT05038163|OTHER|Text Warning|The health risks of sugary beverages are communicated to subjects using words/text and simple images.
224013339|NCT05038163|OTHER|Graphic Warning|The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
224013340|NCT06642896|DEVICE|pupillometer|describe the feasibility of pupillometry measurements in sedated but non-cerebrosed children in intensive care and the operating room
224013341|NCT06642896|DEVICE|pupillometer|Pupillometry measurements at 5 and 25 minutes for children treated with osmotherapy, followed by measurements twice a day during hospitalization in the intensive care unit
224013342|NCT06006780|DEVICE|Porcine acellular dermal matrix|Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage
224013343|NCT06006780|OTHER|Coronally advanced flap (CAF)|Coronally advanced flap for root coverage
224013344|NCT00981136|PROCEDURE|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
224013345|NCT00981136|PROCEDURE|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
224013346|NCT02409524|BIOLOGICAL|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
224013347|NCT02409524|BIOLOGICAL|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
224013348|NCT02409524|BIOLOGICAL|CRCL|Autologous tumor-derived chaperone protein mixture
224013349|NCT05572593|GENETIC|Pharmacogenomics (PGx) genetic testing|A buccal swab to collect cells from the inside the cheek
224013350|NCT01511341|BEHAVIORAL|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
224013351|NCT00427570|BIOLOGICAL|BCG vaccine|
224013352|NCT00427570|BIOLOGICAL|biological therapy|
224013353|NCT00427570|DRUG|fluorouracil|
224013354|NCT00427570|DRUG|semustine|
224013355|NCT00427570|DRUG|vincristine sulfate|
224013356|NCT00045227|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|
224013357|NCT00045227|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|
224013358|NCT00045227|BIOLOGICAL|recombinant vaccinia-B7.1 vaccine|
224013359|NCT00045227|BIOLOGICAL|sargramostim|
224013360|NCT00045227|DRUG|docetaxel|
224013361|NCT05524753|BEHAVIORAL|AquOTic|group-based aquatic occupational therapy sessions with 1:1 support
224013362|NCT03063801|OTHER|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
223393254|NCT05836207|BEHAVIORAL|Standard Outpatient Cognitive Behavioural Therapy (CBT)|"CBT is the usual care first line treatment for CUD in youth, in the Netherlands. CBT for CUD is focused on learning cognitive, emotional, motivational and behavioral skills to reduce or cease cannabis use, and generally consists of 12 once-weekly 60-minute sessions and 'homework' exercise assignments, provided by a psychologist.~Youths receive 12 weeks of outpatient usual care CBT consisting of once-weekly 60-minute sessions according to the standard CBT youth protocol by a trained psychologist. CBT-youths receive the same cannabis urine-testing procedures as CM-youths, but test results will not be disclosed to treatment staff or patient, and no rewards will be given for cannabis abstinence."
223393255|NCT03851237|DRUG|64Cu-DOTA-ECLIi|-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
223393256|NCT03851237|DEVICE|PET/CT|-Standard of care
223393257|NCT06594926|DRUG|Testosterone Enanthate|Testosterone enanthate is a depot formulation used in Australia typically for androgen replacement in people with confirmed testosterone deficiency.
223393258|NCT03401463|OTHER|traning seminar|There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.
223393259|NCT06252571|COMBINATION_PRODUCT|- Melatonin - Active light ttherapy|1 tablet per day, in the evening + morning light therapy over 6 weeks
223393260|NCT06252571|COMBINATION_PRODUCT|- Placebo drug - Placebo light therapy|1 tablet per day in the evening + morning placebo light therapy
223393261|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
223548181|NCT03467256|DRUG|Fludarabine|given IV
223548182|NCT03467256|DRUG|Cyclophosphamide|given IV
223548183|NCT03467256|DRUG|Tocilizumab|given IV
223548184|NCT03467256|DRUG|Cytarabine|given IV
223548185|NCT03467256|DRUG|Etoposide|given IV
223548186|NCT03467256|DRUG|Dexamethasone|given IV
223548187|NCT01266226|DEVICE|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
223393262|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
223548188|NCT01266226|DEVICE|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
223548189|NCT05511506|OTHER|aqueous humor collection|Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
223548190|NCT00730353|DRUG|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
224013363|NCT00330265|DEVICE|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
224013364|NCT00330265|OTHER|Conventional Wound Therapy|Normal Saline Dressings
224013365|NCT00432666|DRUG|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
224013366|NCT00432666|DRUG|Placebo|Placebo
224013367|NCT02247557|DRUG|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
224013368|NCT02247557|DRUG|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
224013369|NCT02247557|DRUG|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
224013370|NCT02130921|BEHAVIORAL|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
224013371|NCT02345187|DIETARY_SUPPLEMENT|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
224013372|NCT02345187|DIETARY_SUPPLEMENT|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
224013373|NCT00004404|DRUG|clotrimazole|
224013374|NCT00004404|DRUG|hydroxyurea|
224013375|NCT02439047|PROCEDURE|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~\- Adipose tissue samples : will be collected during surgery for breast reconstruction"
224013376|NCT06374173|DRUG|TGI-6 Injection|TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.
224013377|NCT00565851|BIOLOGICAL|Bevacizumab|Given IV
223548191|NCT00730353|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
224013378|NCT00565851|DRUG|Carboplatin|Given IV
224013379|NCT00565851|DRUG|Docetaxel|Given IV
224013380|NCT00565851|DRUG|Gemcitabine Hydrochloride|Given IV
224013381|NCT00565851|OTHER|Laboratory Biomarker Analysis|Correlative studies
224013382|NCT00565851|DRUG|Paclitaxel|Given IV
224013383|NCT00565851|OTHER|Quality-of-Life Assessment|Ancillary studies
224013384|NCT05183776|DEVICE|Fractional administration device|The novel fractional administration device enable the administration of the microspheres in fractions determined by the user. For this study, 5 fractions of 20% will be administered and validated using MRI.
224013385|NCT00150423|DRUG|Pregabalin|
224013386|NCT02214056|OTHER|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
224013387|NCT02214056|PROCEDURE|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
224127871|NCT03241758|DIAGNOSTIC_TEST|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
224127872|NCT02142192|DRUG|natalizumab|Administered as specified in the treatment arm
224127873|NCT00469196|PROCEDURE|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
223393263|NCT00691717|DRUG|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
223393264|NCT00691717|OTHER|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
223393265|NCT04061239|DRUG|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
223393266|NCT04061239|DRUG|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
223548192|NCT02750046|PROCEDURE|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
223548193|NCT00794846|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
223548194|NCT00794846|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
223393267|NCT04061239|DRUG|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
223393268|NCT04061239|DRUG|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
223393269|NCT04563936|DRUG|LY01005 3.6 mg|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
223393270|NCT04563936|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
223393271|NCT02757755|BIOLOGICAL|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
223393272|NCT02757755|BIOLOGICAL|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
223393273|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
223548195|NCT04754971|OTHER|psycho-education program|Psychoeducation Practice 1 day per week, 60-90 min. sessions will take 8 weeks. At the end of the training, the final test will be applied to the experimental and control group. 3rd and 6th month follow-up measurements are planned to be carried out intermittently at the end of the month.
223393274|NCT02757755|BIOLOGICAL|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
223393275|NCT01963741|DRUG|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
223548196|NCT02263872|DRUG|Minocycline|Minocycline 200mg perday
223548197|NCT02691416|DRUG|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
224013388|NCT06209333|OTHER|Standard Patient Education|Standard Patient Education will take approximately 20 minutes. Within the scope of standard patient education, some recommendations will be made to the patient to lose weight, drink sufficient water, avoid consuming caffeinated foods and beverages, acidic/carbonated or alcoholic beverages, spicy/acidic foods, and quit smoking. Patients will be evaluated on the day they receive standard patient training (before receiving this training) and 10 weeks after the training.
224013389|NCT06209333|OTHER|bladder training|Interval urination in bladder training in bladder training will be determined according to the bladder diaries filled in by the patients. If the patient is able to do it, bladder education will be improved by increasing the interval urination in bladder training. A total of 5 sessions of bladder training will be applied to patients, the first session of which will be face-to-face. Within the scope of Bladder Training, the patient will be given information about bladder, pelvic floor, incontinence and relaxation techniques. The patient will be asked to fill out a 3-day bladder diary before starting bladder training, and an appropriate progressive timed voiding program will be drawn according to the bladder diaries, and the patient will be given a training brochure to implement this program.
224013390|NCT06209333|OTHER|pelvic floor exercise|This training will take between 45 and 60 minutes.Within the scope of exercise training, patients will be taught 3 types of contractions: maximal (fast), slow and submaximal contractions. The patient will be asked to continue the maximum and submaximal contraction for 1-2 seconds, and to continue the Deceleration contraction for 3-10 seconds. These contractions will be performed in different positions such as supine, lying on the side, sitting, crawling, squatting and standing, specifically for the pelvic floor November muscle strength of the patient. These exercises will be performed every day and each type of contraction (maximal, slow and submaximal contraction) will be performed 8-12 repetitions, 3 sets per day. Progress will be achieved with follow-ups.
224013391|NCT02588105|DRUG|AZD0156|All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
224013392|NCT02588105|DRUG|Olaparib|Module 1 combination with olaparib
224013393|NCT02588105|DRUG|irinotecan|Module 2 combination with irinotecan/FOLFIRI
224013394|NCT02588105|DRUG|Fluorouracil|Module 2 combination with irinotecan/FOLFIRI
223393276|NCT01963741|DRUG|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was \<30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
223548198|NCT02691416|DRUG|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
223548199|NCT05496985|DIAGNOSTIC_TEST|Simplified Evaluation of CONsciousness Disorders (SECONDs)|All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
223548200|NCT04970173|OTHER|use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy|Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
223548201|NCT06125184|DRUG|Vasopressor test|Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
223548202|NCT01724229|DRUG|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
224013395|NCT02588105|DRUG|Folinic Acid|Module 2 combination with irinotecan/FOLFIRI
224013396|NCT00976872|DRUG|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
224013397|NCT00976872|DRUG|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
223393277|NCT02680236|OTHER|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
223393278|NCT02689583|BIOLOGICAL|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin \> Clarithromycin \> Levofloxacin \>Tetracycline \> Furazolidone \> Metronidazole.
223393279|NCT02689583|GENETIC|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
223393280|NCT02689583|DIETARY_SUPPLEMENT|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
223393281|NCT03839420|DEVICE|CZM IOL|implantation of CZM IOL
223393282|NCT03839420|DEVICE|Competitor IOL|implantation of Competitor IOL
223548203|NCT03595735|DEVICE|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
223548204|NCT01525823|DRUG|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
223548205|NCT01525823|DRUG|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
223548206|NCT05429580|DRUG|Tranexamic acid|given intravenous tranexamic acid
223548207|NCT05429580|OTHER|5% Dextrose|given placebo.
223548208|NCT00393991|DRUG|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
223548209|NCT00393991|DRUG|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
223548210|NCT00393991|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
223548211|NCT00393991|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
224013398|NCT04674787|OTHER|Peripheral nerve stimulation provocation study|Study which measures stimulation thresholds in volunteers induced by low frequency electromagnetic gradients used in MRI scanners.
224013399|NCT00563888|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
224013400|NCT02500810|DRUG|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
224013401|NCT00950222|DRUG|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
224013402|NCT00544375|DEVICE|Optical measurement|Optical measurement neonatal tissues
224013403|NCT02799264|DRUG|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
223548212|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
223548213|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
223548214|NCT03924804|DRUG|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
223548215|NCT03842774|DIETARY_SUPPLEMENT|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
224013404|NCT05405439|DRUG|TQB3823 tablets|TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
224013405|NCT05405439|DRUG|Abiraterone acetate tablets|Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
224013406|NCT05405439|DRUG|prednisone acetate tablets|Prednisone acetate tablet is a kind of glucocorticoids
224013407|NCT05103787|PROCEDURE|deep parasternal intercostal plane block|Twenty milliliters of 0.25% bupivacaine will be placed bilaterally in the fascial plane between internal intercostal muscle and transversus thoracis muscle at intercostal space 4 or 5, lateral from sternum, with ultrasound guidance using high-frequency linear transducer.
224013408|NCT05103787|PROCEDURE|control|Skin puncture with needle will be performed on the same location as the treatment group without administration of local anesthetics.
224013409|NCT04101552|PROCEDURE|socket shield technique with xenophobic graft particulate and without the use of graft|the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
224013410|NCT00283088|PROCEDURE|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
223548216|NCT03842774|DIETARY_SUPPLEMENT|Placebo|Placebo supplement will be given to the test group.
223548217|NCT03480984|OTHER|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
223548218|NCT03480984|OTHER|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
224013411|NCT00283088|DRUG|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
224013412|NCT02199743|DRUG|Lurasidone|Compare to haloperidol and perphenazine
224013413|NCT02199743|DRUG|Haloperidol|Compare to lurasidone
224013414|NCT02199743|DRUG|Perphenazine|Compare to lurasidone
224013415|NCT02237443|DRUG|Rocuronium|Administration of a NMBD
224013416|NCT02237443|DRUG|Vecuronium Bromide|Administration of a NMBD
224013417|NCT02237443|DRUG|Succinylcholine|Administration of a NMBD
224013418|NCT05838144|DEVICE|Acapella device|Group A. Will use Acapella device.
224013419|NCT05838144|OTHER|Only routine chest physical therapy program|Group B. Will take medications and perform routine chest physical therapy program.
224013420|NCT02628639|DEVICE|high-density electroencephalography|
223393283|NCT02630576|DEVICE|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
223393284|NCT00470470|DRUG|imatinib mesylate|Given orally
223393285|NCT00470470|OTHER|laboratory biomarker analysis|Correlative studies
223393286|NCT01117896|OTHER|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
223393287|NCT01117896|OTHER|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
223393288|NCT01152073|DIETARY_SUPPLEMENT|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
223393289|NCT01152073|DIETARY_SUPPLEMENT|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
223548219|NCT05687227|BEHAVIORAL|Online education and counseling|Online education and counseling regarding gynecological examination
223548220|NCT02165943|DEVICE|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
223548221|NCT00375466|DRUG|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
224013421|NCT04312334|OTHER|Control|Soap: Non-antimicrobial bar soap will be used as a reference product for four of the the experiments. Hand-cleaning with SuperTowel will be the reference produce for two of the experiments.
224013422|NCT04312334|OTHER|Treatment|The Supertowel is a durable fabric with a permanent anti-microbial treatment. The treated fabric must be dipped in water and then rubbed against the hands so that pathogens will be transferred to the fabric where they will be killed.
224013423|NCT02113345|BEHAVIORAL|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
224013424|NCT03274167|DRUG|Gabapentin 300mg|
223393290|NCT01152073|DIETARY_SUPPLEMENT|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
223393291|NCT02336945|DEVICE|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
223393292|NCT00221455|BEHAVIORAL|Patient diabetic self-management using the diabetic patient portal tools|
223393293|NCT00221455|BEHAVIORAL|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
223393294|NCT03110237|OTHER|Control Balance Training (BT) class|Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.
223548222|NCT00375466|DRUG|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
223548223|NCT00439101|DRUG|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
223548224|NCT00439101|OTHER|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
223548225|NCT04858607|DIAGNOSTIC_TEST|Blood sample|Serology, immune status, T cell immunity, and T cell aging.
224013425|NCT03274167|DRUG|Placebo oral capsule|
224013426|NCT00743301|OTHER|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
224013427|NCT02158052|DRUG|Tacrolimus|Tacrolimus starting on Day -1
224013428|NCT02158052|DRUG|Equine Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
224013429|NCT02158052|PROCEDURE|Kidney transplant from a related donor|On Day 0 the renal transplant is performed according to standard surgical techniques.
224013430|NCT02158052|DRUG|Bone marrow transplant from a related donor|Donor bone marrow (\> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
224013431|NCT02158052|RADIATION|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
224013432|NCT04310384|DEVICE|ShuttleScope|Alternative intervention
224013433|NCT04310384|DEVICE|MacIntosh Laryngoscope|Gold Standart
224127874|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 1|Patients will undergo imaging on a modern CT scanner with spectral imaging capabilities. A dose neutral spectral acquisition mode will routinely be used. Contrast material protocol and scan ranges are similar among all three arms.
223393295|NCT03110237|OTHER|Fallproof Balance Training (BT) class|There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
223548226|NCT04858607|DIAGNOSTIC_TEST|Saliva sample|Antibody tests
223730758|NCT01987297|DRUG|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
223730759|NCT01987297|DRUG|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
224013434|NCT06246266|PROCEDURE|Helfer Skin Tap Technique group|During intramuscular vaccine administration, the muscle will be tapped with the palmar surface of the fingers of the other hand that is not used, with light rhythmic movements, counting for 1-15 seconds. Then, when the muscle is entered with the injection, it will continue to be hit with light rhythmic movements for 1-3 seconds. Thus, the muscle will relax and the fibers around the muscle will be stimulated. Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
224013435|NCT06246266|PROCEDURE|ShotBlocker Technique group|"The protruding but not sharp surface on the ShotBlocker tool will be placed on the baby's skin before intramuscular vaccine administration.~Injection will be applied to the middle part of this vehicle, which has a 'U' appearance. This tool, which does not cause any harm to the skin surface, will provide stimulation to the muscle fibers according to the Gate Control Theory related to pain."
224013436|NCT05016518|DRUG|Arm I (Propofol group)|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
224013437|NCT05016518|DRUG|Arm II (Remimazolam group)|Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
224013438|NCT05470049|DRUG|SHR8554 Injection and SHR0410 Injection|Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose
224013439|NCT05470049|DRUG|SHR8554 Injection and SHR0410 Injection|Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose
224013440|NCT05470049|DRUG|SHR8554 Injection and Placebo for SHR0410 Injection|Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
224013441|NCT00555724|DRUG|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
224013442|NCT03258684|DRUG|Hydrocortisone, Vitamin C, and Thiamine|Intervention
224013443|NCT03258684|OTHER|Normal saline|Placebo
224013444|NCT04984434|DRUG|F182112|Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
224013445|NCT05144126|OTHER|CT radioraphic assessment|CT radioraphic assessment
224013446|NCT05616520|DEVICE|drug-coated balloon|The intervention relates to a drug-coated balloon catheter includes a balloon and cover the drug-coated balloon surface.
224013447|NCT00155974|BIOLOGICAL|Community-based vaccine outreach intervention|
224013448|NCT05163782|DEVICE|New ankle foot orthosis with anterior support|New ankle foot orthosis with anterior support developed by Turbomed
224013449|NCT05163782|DEVICE|Ankle foot orthosis with anterior support|Ankle foot orthosis with anterior support from Turbomed
224013450|NCT05163782|DEVICE|Ankle foot orthosis from competitor 1|Ankle foot orthosis with posterior support from competitor 1
224013451|NCT05163782|DEVICE|Ankle foot orthosis from competitor 2|Ankle foot orthosis with posterior support from competitor 2
224013452|NCT02368028|OTHER|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
223548227|NCT03271216|DEVICE|No intervention|no intervention
223548228|NCT04877678|DRUG|Bepotastine|10 mg Bepotastine, twice a day
223548229|NCT04877678|DRUG|Placebo|Identical looking placebo, twice a day
223548230|NCT05002348|DEVICE|Laser acupoint stimulation(Laser pen)|Select 5-7 acupuncture points according to physical fitness. Each acupoint is performed once a day. The acupuncture point stimulation process takes about 3-5 minutes. The patient wears goggles and observes the patient's vital signs (blood pressure, heartbeat and blood oxygen) with a physiological monitor. , If the patient has any discomfort, the procedure will be stopped for a maximum of 10 days.
224013453|NCT00003424|DRUG|tamoxifen citrate|
224013454|NCT06422468|DEVICE|FibriCheck recordings|PPG, ACC, GYR, ECG and sound measurements
224013455|NCT04541784|OTHER|WOMAN-PRO III|"Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app WOMAN-PRO III."
224013456|NCT04541784|OTHER|Three counselling sessions with gynaecology-oncology nurses|Standardized care, three counselling sessions with a gynaecology-oncology nurse.
224013457|NCT03289429|DRUG|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
224013458|NCT03289429|DRUG|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
224013459|NCT03289429|OTHER|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
224013460|NCT03289429|OTHER|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
224013461|NCT05900362|DEVICE|VitalCare Platform|All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
223393296|NCT03458611|BEHAVIORAL|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent \& Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
223393297|NCT03458611|BEHAVIORAL|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
223393298|NCT01101113|DRUG|cinacalcet|cinacalcet 25mg qd or 50 mg qd
223393299|NCT01101113|DRUG|control|vit D + P binder
223393300|NCT00749450|DRUG|capecitabine|Given orally
223393301|NCT00749450|DRUG|fluorouracil|Given IV
223393302|NCT00749450|DRUG|oxaliplatin|Given IV
223393303|NCT00578201|DRUG|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
223393304|NCT00793455|BEHAVIORAL|Educational outreach|Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
223393305|NCT01809353|DRUG|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
223393306|NCT01809353|OTHER|Placebo|Single matching intravenous dose
223393307|NCT04355078|OTHER|Neuromuscular Training|Muscular and neural training by complex exercises
223393308|NCT04355078|OTHER|Strength Training|Strength Training
223393309|NCT02566772|DRUG|TAS3681|TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
223393310|NCT01785082|DRUG|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
223393311|NCT06497907|DIETARY_SUPPLEMENT|polymeric formula|Patients with growth faltering received nutritional rehabilitation with polymeric formula and were reassessed after 12 weeks by anthropometric measurements
223393312|NCT06497907|DIETARY_SUPPLEMENT|peptide based formula|patients who were defined as non responders and underwent upper gastrointestinal endoscopy and diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula
223548231|NCT04113889|DRUG|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
223548232|NCT04113889|DRUG|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
223548233|NCT01830348|DRUG|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
223548234|NCT01830348|DRUG|placebo vehicle gel|
223548235|NCT02358408|DEVICE|Blood glucose monitoring systems for self-testing|
223548236|NCT02321605|BEHAVIORAL|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero \& Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
223548237|NCT02321605|BEHAVIORAL|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
223548238|NCT05655975|PROCEDURE|upper gi endoscopy|In all patients undergoing RYGB gastric bypass, an upper gastrointestinal endoscopy will be performed at the 1st postoperative year to measure the diameter of the gastrojejunostomy anastomosis.
223548239|NCT00622921|BEHAVIORAL|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
223548240|NCT06014307|BEHAVIORAL|Diet order: PBMA, Animal|Participants will follow the PBMA, and Animal diets (in this order) for 4-6 weeks each.
224013462|NCT03750045|DIAGNOSTIC_TEST|Jamar|The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
223548241|NCT06014307|BEHAVIORAL|Diet order: Animal, PBMA|Participants will follow the Animal, and PBMA diets (in this order) for 4-6 weeks each.
223548242|NCT01949129|DRUG|VP16|60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
223548243|NCT01949129|RADIATION|TBI|2 x 2Gy/day , 3 days (total 12Gy)
223548244|NCT01949129|DRUG|Thiotepa|2x5 mg/kg BW, 1 day
223548245|NCT01949129|DRUG|Treosulfan|14g/m² BS, 3 days
223393313|NCT01268462|OTHER|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
223393314|NCT01268462|OTHER|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
223548246|NCT01949129|DRUG|Fludarabine|30 mg/m² BS, 5 days
223548247|NCT01949129|DRUG|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
223548248|NCT01949129|DRUG|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
223548249|NCT01949129|DRUG|Cyclophosphamide|as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
224013463|NCT03750045|DIAGNOSTIC_TEST|Wooden box|The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
224013464|NCT03750045|OTHER|Virtual environment|The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
224013465|NCT05919862|PROCEDURE|Robot system|Prosthetically guided Implant placement utilising robotic surgery based on a digital plan
224013466|NCT05919862|PROCEDURE|Freehand surgery|Freehand implant placement by experienced surgeon.
224013467|NCT04633798|PROCEDURE|IPL/Lipiflow|To treat patients with MGD using intense pulsed light combined with lipiflow
224013468|NCT04633798|PROCEDURE|IPL/MGX|To treat patients with MGD using intense pulsed light combined with meibomian gland massage
224013469|NCT02648490|DRUG|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
223548250|NCT01949129|DRUG|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
223548251|NCT04480229|BEHAVIORAL|Telenursing and Counseling|After the first face-to-face training, counseling on the phone was conducted every week for four cycles of chemotherapy treatment. In total, six counseling sessions and four face-to-face training sessions were conducted for each patient.
223548252|NCT00132301|DRUG|Docetaxel|Chemotherapy agent
223548253|NCT00132301|DRUG|Prednisone|steroid in combination with chemotherapy agent
223548254|NCT03388541|DRUG|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
224013470|NCT02648490|DRUG|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
224013471|NCT02648490|DRUG|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
224013472|NCT02648490|DRUG|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
224013473|NCT02648490|DRUG|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
223548255|NCT03388541|DRUG|Placebo|A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
223548256|NCT00921388|OTHER|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
223548257|NCT00921388|BEHAVIORAL|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
224127875|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 2|Patients will undergo imaging on a modern 128 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
223548258|NCT06405165|OTHER|student success|The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
223548259|NCT01288157|DRUG|Golimumab|Single dose of 100 mg subcutaneously
223548260|NCT01288157|DRUG|Golimumab|Single dose of 50 mg subcutaneously
223548261|NCT02012218|DRUG|ADT|
223548262|NCT02012218|DRUG|Brexpiprazole|
223548263|NCT01043718|BEHAVIORAL|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
224127876|NCT04989192|DIAGNOSTIC_TEST|Scan at CT scanner 3|Patients will undergo imaging on a modern 20 slice CT-scanner without spectral imaging capabilities. A standard acquisition protocol will be used. Contrast material protocol and scan ranges are similar among all three arms.
224127877|NCT05513703|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
224127878|NCT02932475|DRUG|Metformin|1000 mg twice a day
224127879|NCT02932475|DRUG|Placebo|Delivered to match active drug
223393315|NCT01268462|OTHER|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
223393316|NCT01268462|OTHER|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
223393317|NCT06996886|DRUG|AZD5004|Participants will be receiving three different formulations (F1, F3, and F4) as single dose of AZD5004 orally in fasted and fed state.
223393318|NCT03345680|OTHER|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
223393319|NCT03104517|BIOLOGICAL|AMDC-USR (iltamiocel)|Autologous Muscle Derived Cells for Urinary Sphincter Repair (generic name: iltamiocel)
223393320|NCT03104517|OTHER|Placebo|Placebo control is the vehicle solution used for the study product.
223393321|NCT06863311|DRUG|XL092|100 mg orally
223393322|NCT06863311|DRUG|Nivolumab|480 mg intravenously.
223548264|NCT01043718|BEHAVIORAL|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
223548265|NCT04590053|BIOLOGICAL|Allocetra-OTS|Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
224013474|NCT02142140|BEHAVIORAL|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
223393323|NCT06671873|DRUG|100 µCi [14C] HMPL-306|D1: 250 mg/100 µCi \[14C\] HMPL-306 Single dose
223393324|NCT00477737|DRUG|Sevoflurane|
223548266|NCT03186625|DRUG|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
223548267|NCT03186625|DRUG|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
223730760|NCT05315128|DRUG|Methotrexate|A randomized comparative effectiveness clinical trial
224013475|NCT02142140|BEHAVIORAL|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
224013476|NCT02142140|BEHAVIORAL|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
224013477|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
223393325|NCT00477737|DRUG|propofol|
223393326|NCT06856629|OTHER|Eccentric blood-flow restriction training|Eccentric blood-flow restriction training
223548268|NCT02193997|OTHER|Fiber|
223548269|NCT02193997|OTHER|Fiber|
223548270|NCT02193997|OTHER|Placebo|
223548271|NCT02171143|DRUG|ASP2409|intravenous (IV)
224127880|NCT04559152|DIETARY_SUPPLEMENT|Zinc Supplementation Group|Enrolled subjects received zinc capsule 20mg daily in the morning after meal for 12 weeks
223548272|NCT02171143|DRUG|Placebo|intravenous (IV)
223548273|NCT01830985|DRUG|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
223730761|NCT02505867|DEVICE|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
223730762|NCT00306618|DRUG|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
223730763|NCT01862874|BIOLOGICAL|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
223548274|NCT02880228|DRUG|Dexamethasone|Given PO
223730764|NCT01862874|BIOLOGICAL|Placebo|Formulated with AAHS adjuvant
223730765|NCT02097004|BIOLOGICAL|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
223730766|NCT02097004|BIOLOGICAL|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
223393327|NCT06856629|OTHER|Eccentric free-flow training|Eccentric free-flow training
223393328|NCT06688461|OTHER|Experimental group: Exercise training|HIIT program, 3 times per week for 12 weeks
223393329|NCT07018349|DRUG|2.5% Oral minoxidil|AGA patients will be randomly allocated in both groups using the envelopes method to reduce the biasness. For 3-months, patients in Group-A will get 2.5mg of minoxidil once daily, while those in Group-B will receive 1mg of minoxidil once daily orally. After starting therapy, patients will be asked to come back for evaluations 3 months later. Safety, satisfaction, and the effects of the treatment will be reported. Final outcomes will be evaluated at 3 months post treatment.
223548275|NCT02880228|OTHER|Laboratory Biomarker Analysis|Correlative studies
223548276|NCT02880228|DRUG|Lenalidomide|Given PO
223548277|NCT02880228|BIOLOGICAL|Pembrolizumab|Given IV
223548278|NCT03506412|DRUG|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
223548279|NCT00738569|DRUG|Raltegravir|Raltegravir 400 mg PO BID for 12 months
223548280|NCT03406403|DEVICE|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
224013478|NCT02142140|DRUG|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
223548281|NCT03406403|DRUG|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
224013479|NCT04490967|COMBINATION_PRODUCT|Silymarin|Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
223548282|NCT03406403|OTHER|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
224013480|NCT04490967|PROCEDURE|Salicylic acid|Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
224013481|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
224013482|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
224013483|NCT00969709|DRUG|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
224013484|NCT00969709|DRUG|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
224013485|NCT03639831|DIETARY_SUPPLEMENT|Proprietary, standardized botanical extract|2 capsules/ day providing the proprietary botanical extract as unique active ingredient
224013486|NCT03639831|DIETARY_SUPPLEMENT|Placebo (maltodextrin)|2 capsules/ day providing no active component
223548283|NCT01265017|DRUG|Estradiol, medroxyprogesterone, hydrocortisone, GH|"* Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,"
223548284|NCT01265017|DRUG|Matching placebo|matching placebo
223548285|NCT00836771|DIETARY_SUPPLEMENT|Infant Formula|
223548286|NCT01143909|OTHER|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
223548287|NCT02593058|BEHAVIORAL|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
224013487|NCT01140698|OTHER|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
224013488|NCT02907307|DEVICE|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
224013489|NCT02907307|DEVICE|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
224013490|NCT02907307|DRUG|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
224013491|NCT00061984|BIOLOGICAL|pegfilgrastim|
224013492|NCT00061984|DRUG|doxorubicin hydrochloride|
224127881|NCT04559152|DIETARY_SUPPLEMENT|Placebo Group|Enrolled subjects received placebo tablet, which was inserted into capsule of the same shape and color as zinc capsule, daily in the morning after meal for 12 weeks
224127882|NCT00367497|DRUG|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
223393330|NCT07018349|DRUG|1% Oral Minoxidil|Group-B will receive 1mg of minoxidil once daily orally
223393331|NCT07018141|OTHER|Bioactive Sealant with Etching: Participants in this group received a fluoride-releasing bioactive pit and fissure sealant (BeautiSealant, Shofu) applied after etching the tooth surface with 37% phosp|This group received BeautiSealant (a bioactive giomer-based sealant) applied after etching the enamel surface with 37% phosphoric acid for 15 seconds. The etching process creates micro-retentive patterns in the enamel to enhance micromechanical bonding, potentially improving the sealant's retention and wear resistance while also benefiting from the bioactive material's fluoride release and enamel remineralization properties.
224013493|NCT00061984|DRUG|ifosfamide|
224013494|NCT00061984|PROCEDURE|multimodality therapy|
224013495|NCT05389085|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM), Photoacoustic imaging (PAI) and tape-strippng of RNA and lipids|In vivo RCM will be used to diagnose pigmented tumours at a cellular level and provide information on skin microarchitecture. MSOT detects skin chromophores as melanin, hemoglobin, water, collagen, and lipids, which will be included in analysis of diagnostic accuracies. MSOT will also be used to measure tumour thickness; delineate tumour borders and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. RNA and lipid profiles from tape stripping results will be compared to imaging and histopathology diagnosis.
224013496|NCT03695237|DRUG|Leuprolide Acetate (LA)|Administered intramuscularly as an injection
224013497|NCT02482168|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody
224127883|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
224127884|NCT01323257|DRUG|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
224127885|NCT01323257|DRUG|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
224127886|NCT01323257|DRUG|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
224127887|NCT01323257|DRUG|TMC435|50 mg capsule once daily for 7 days (Trt F)
224127888|NCT01323257|DRUG|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
224127889|NCT01290081|OTHER|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
224127890|NCT02538588|DEVICE|Nebulizer 1|
224127891|NCT02538588|DEVICE|Nebulizer 2|
224127892|NCT00473161|DEVICE|surface EMG biofeedback|
224127893|NCT01506778|DEVICE|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
224127894|NCT01921257|DRUG|Cat-PAD|
223393332|NCT07018141|OTHER|Bioactive Sealant without Etching: In this group, the same bioactive sealant (BeautiSealant, Shofu) was applied directly without acid etching. This simplified technique evaluates the sealant's effecti|In this group, BeautiSealant was applied directly to the tooth surface without prior etching. The goal was to simplify the procedure by eliminating the etching step, relying instead on the sealant's chemical bonding and bioactive properties (such as fluoride release and S-PRG technology) to maintain retention and resist wear, while reducing the risk of enamel alteration and improving clinical efficiency.
223393333|NCT07018141|OTHER|Conventional Resin-Based Sealant with Etching (Control): This group received a conventional resin-based sealant (Fisseal, Promedica) following standard acid etching. This technique represents the trad|This group served as the control and received Fisseal (a conventional resin-based sealant) applied following standard etching with 37% phosphoric acid. This method is considered the gold standard for fissure sealing, offering strong micromechanical adhesion and proven wear resistance, making it a reliable benchmark for evaluating the performance of newer bioactive materials.
223393334|NCT07017413|PROCEDURE|Transosseous Maxillary Sinus Lift using Osseodensification|A surgical procedure utilizing the Versah® osseodensification technique for transcrestal sinus floor elevation. The approach involves the use of specialized Densah® burs to prepare the osteotomy and elevate the sinus membrane through a transosseous (crestal) access, avoiding the lateral window technique. No grafting materials will be used in this procedure.
224127895|NCT01921257|DRUG|Placebo|
224127896|NCT05307822|OTHER|Non-combusted cigarette variant 42001401|Menthol flavor variant of a non-combusted cigarette (42001401)
224127897|NCT05307822|OTHER|Non-combusted cigarette variant 42001399|Menthol flavor variant of a non-combusted cigarette (42001399)
223393335|NCT07017465|OTHER|Water melon (sugar baby)|Participants will consume a portion of watermelon Type A containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
223393336|NCT07017465|OTHER|watermelon (Charleston gray)|Participants will consume a portion of watermelon Type B containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
224013498|NCT01149109|DRUG|Temozolomide and lomustine|
224013499|NCT01149109|DRUG|Temozolomide|
224013500|NCT02807662|BEHAVIORAL|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
224013501|NCT05732051|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy
224127898|NCT05307822|OTHER|Non-combusted cigarette variant 40007386|Menthol flavor variant of a non-combusted cigarette (40007386)
224127899|NCT05307822|OTHER|Non-combusted cigarette variant 42001402|Non-Menthol flavor variant of a non-combusted cigarette (42001402)
224127900|NCT03462446|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
224127901|NCT03462446|DRUG|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
224127902|NCT04008589|DEVICE|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
224127903|NCT04008589|DEVICE|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
224127904|NCT01996735|DRUG|Ticagrelor 180 mg single dose|
224127905|NCT01996735|DRUG|Placebo|
224127906|NCT03568149|PROCEDURE|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
224138597|NCT03495453|DEVICE|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
224138598|NCT02017613|DRUG|RP6530|Escalating doses starting at 25 mg BID
223393337|NCT07017465|OTHER|watermelon (Crimson sweet)|Participants will consume a portion of watermelon Type C containing 50 grams of available carbohydrate to evaluate its glycemic index and glycemic load.
223393338|NCT07018557|DRUG|Eszopiclone 3 mg|Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).
224127907|NCT03568149|PROCEDURE|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~* Ovarian vein diameter \<4mm~* Slow ovarian blood flow (\<3cm/sec)~* Retrograde blood flow~* Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~* Standard 2D study, to measure vessels diameter~* Vascular doppler study, to evaluate flow direction and blood speed~* 3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
223393339|NCT07018557|DRUG|Placebo|Placebo pills identical to the active comparator.
223393340|NCT07017764|OTHER|Core stability exercises|Core stability exercises will be performed for 8 weeks, 3 times per week, 30 minutes per session. The program includes bed, wedge, and Swiss ball exercises. Bed exercises involve bridges, curl-ups, bird dog, and side bridges. Wedge exercises include curl-ups in various arm positions. Ball exercises involve bridges, curl-ups, bird dog, and push-ups. Each position is held for 7 seconds with 10 seconds of rest, repeated 10 times per set, for 2 sets per session with 60 seconds rest between sets.
223393341|NCT07017764|OTHER|Theraband resisted exercises|TheraBand resisted exercises will be performed for 8 weeks, 3 times per week, 30 minutes per session. Each session includes a 5-minute warm-up (stretching and joint mobilization), 30 minutes of resistance training for lower limbs (ankle, knee, hip), and a 5-minute cool-down with deep breathing and self-massage. Exercises include ankle flexion/extension, knee flexion/extension, and hip flexion/extension, abduction/adduction using elastic bands. Movements are done alternately on both sides, 10 reps each, 3 sets per session, with 1-2 min rest between sets. Yellow bands are used in weeks 1-4; green bands in weeks 5-8.
223393342|NCT07017764|OTHER|Traditional physical therapy program|All patients will receive a traditional physical therapy program consisting of ambulation training, stretching exercises for lower limb muscles, and range of motion exercises.
223393343|NCT07017725|DRUG|CID-103|Strength:20 mg/mL. Route of administration: IV infusion. Treatment duration: QW for 6 weeks, then at the same dose Q2W up to Week 12. If treatment continues after Week 12, dosing will occur monthly for up to a maximum treatment duration of six months.
223393344|NCT07018063|DRUG|nab-paclitaxel|Nab-paclitaxel is administered as an intravenous (IV) infusion at a dose of 125 mg/m² on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
223393345|NCT07018063|DRUG|oxaliplatin|Oxaliplatin is administered as an intravenous (IV) infusion at a dose of 85 mg/m² on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
223393346|NCT07018063|DRUG|S-1|"S-1 is administered orally twice daily (BID) on days 2 to 15 of each 3-week cycle, for a total of 3 cycles. The dose is based on body surface area (BSA) as follows:~BSA \< 1.25 m²: 40 mg BID (total 80 mg/day); BSA 1.25-1.5 m²: 50 mg BID (total 100 mg/day); BSA \> 1.5 m²: 60 mg BID (total 120 mg/day)"
223393347|NCT07018063|DRUG|sintilimab|Sintilimab is administered as an intravenous (IV) infusion at a fixed dose of 200 mg on day 1 of each 3-week cycle, for a total of 3 cycles in the neoadjuvant (preoperative) setting.
223393348|NCT07018063|PROCEDURE|D2 Gastrectomy|Curative-intent D2 radical gastrectomy is performed 3 to 6 weeks after completion of neoadjuvant therapy. The procedure includes either proximal, distal or total gastrectomy depending on tumor location, with en bloc resection of the stomach and systematic D2 lymphadenectomy according to Japanese Gastric Cancer Association (JGCA) guidelines. D2 lymph node dissection involves removal of both perigastric (N1) and second-tier (N2) lymph nodes.
223393349|NCT01870089|DEVICE|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
223393350|NCT05975073|DRUG|AMG 193|Administered PO
223393351|NCT05975073|DRUG|IDE397|Administered PO
223564236|NCT05040165|DEVICE|Iceform liner and sleeve|Subjects will be asked to use the investigational device as their primary prosthesis for up to 6 months. TPE material durability evaluated through monthly online questionnaires.
223564237|NCT02507466|BEHAVIORAL|exercise|Variable conditions of stepping practice
224013502|NCT05732051|DIETARY_SUPPLEMENT|Placebo|Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
224013503|NCT00543712|DRUG|PRO95780|Intravenous repeating dose
224013504|NCT04068766|DEVICE|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
224013505|NCT04068766|DRUG|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
224013506|NCT04068766|DRUG|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
224013507|NCT04095481|DEVICE|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
224013508|NCT00452426|DEVICE|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
224013509|NCT00452426|OTHER|benzodiazepines and opioid sedation|per site's current standard of care
224127908|NCT03154723|DRUG|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
224138599|NCT00032838|DRUG|Yohimbine|
224138600|NCT00307242|DRUG|Adefovir Dipivoxil|
224138601|NCT02994095|BEHAVIORAL|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
224138602|NCT02356146|DRUG|Tacrolimus C12|
223393352|NCT07034820|DIETARY_SUPPLEMENT|Nimsai Herbal|Oral Nimsai Herbal is a novel botanical formulation, administered as one 600 mg capsule per day for a duration of 10 consecutive days. It is specifically designed to target the underlying venous congestion hypothesized by the War-Drill Model, aiming to promote hemorrhoid regression and symptom resolution.
224013510|NCT03086525|OTHER|Diagnosis/Prognosis|The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
223393353|NCT07034820|DIETARY_SUPPLEMENT|Placebo|This intervention consisted of an oral placebo, formulated to be identical in appearance, taste, and packaging to Nimsai Herbal. It was administered as one capsule per day for 10 consecutive days to ensure blinding and serve as a control for comparison.
223393354|NCT06708338|PROCEDURE|Needle bevel orientation for arteriovenous fistula puncture|"For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm.~Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups:~* Bevel-up group~* Bevel-down group"
223393355|NCT06705816|OTHER|None interventional|This is an observational study
223393356|NCT05845983|DIETARY_SUPPLEMENT|Lactobacillus acidophilus|Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2\*10\^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
223393357|NCT05845983|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
223393358|NCT01001754|DRUG|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
223393359|NCT01001754|DRUG|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
223393360|NCT01001754|DRUG|Ribavirin|Daily oral administration (400-600 mg BID)
223393361|NCT07042334|BEHAVIORAL|Serious game for transition readiness|The serious game is an interactive narrative fiction game in which players guide a character through a hospital setting, making choices that simulate real-life healthcare scenarios. The game is designed to improve skills such as communication with healthcare providers, understanding medical information, and managing appointments and medications. No drugs or medical devices are used in this intervention.
223393362|NCT07045818|BEHAVIORAL|Emotional provocation task involving multisensory aversive stimuli|To elicit hemodynamic responses in the dorsolateral prefrontal cortex (DLPFC) and activate the sympathetic nervous system, we used a standardized multisensory aversive stimulation protocol comprising: (i) Visual stimuli: 72 high-arousal images from the GAPED database (moral violations, legal violations, fear-related) shown in 12 blocks (6 images/block, 5 s each) with 20 s baseline and 30 s stimulation; (ii) Auditory stimuli: each block paired with 30 s of calibrated 90 dB(A) high-frequency narrowband white noise (4 kHz center frequency), shown to increase heart rate; (iii) Cold-pain stimuli: during each block, participants placed both hands on 0 °C ice-filled bottles for pain-induced sympathetic activation. This tri-modal task reliably provokes DLPFC engagement and autonomic responses.
223393363|NCT06731270|BIOLOGICAL|Atezolizumab|Given atezolizumab
223393364|NCT06731270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223393365|NCT06731270|BIOLOGICAL|Cemiplimab|Given cemiplimab
223393366|NCT06731270|PROCEDURE|Computed Tomography|Undergo CT
223393367|NCT06731270|DRUG|Diclofenac Potassium|Given PO
223393368|NCT06731270|OTHER|Electronic Health Record Review|Ancillary studies
223393369|NCT06731270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223393370|NCT06731270|BIOLOGICAL|Nivolumab|Given nivolumab
223393371|NCT06731270|BIOLOGICAL|Pembrolizumab|Given pembrolizumab
223393372|NCT06731270|PROCEDURE|Positron Emission Tomography|Undergo PET
223393373|NCT06718439|PROCEDURE|Restrictive Transfusion|Red blood cell transfusion when the participant's hemoglobin level is measured below 70 g/L or to maintain a hemoglobin target range of 70-80 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
223393374|NCT06718439|PROCEDURE|Liberal transfusion|Red blood cell transfusion when the participant's hemoglobin level is measured below 90 g/L or to maintain a hemoglobin target range of 90-100 g/L. This strategy will be adhered to during surgery and up to 6 hours in the post-operative anesthesia care unit.
224013511|NCT04752982|BEHAVIORAL|c-SIGHT intervention|The c-SIGHT active intervention involves grasping, lifting and balancing wooden rods using the unaffected hand. C-SIGHT uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
224013512|NCT04752982|BEHAVIORAL|c-SIGHT attentional control|The c-SIGHT attentional control exercises involves grasping and lifting wooden rods from one end using the unaffected hand. Identical to the intervention group, the c-SIGHT attentional control version uses a training mat, three wooden rods of different lengths, a laptop (to run the computer program) and a small motion tracking sensor which records the user's session length and trials completed. The participant's existing television is used to present the program (connected to the laptop).
223393375|NCT06924853|OTHER|Platelet lysate|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist into 8 yellow top tubes and 1 purple top tube and processed into 5cc PL of which 4cc will be used for treatment and the remaining 1cc will be frozen and used for QC. A lavender top blood tube will be collected and used for quantitative CBC analysis (Beckman Coulter DxH 500 Series). Patient will lie on table prone with a pillow under their abdomen to flatten their L-spine, sterilely prepped and draped. Provider to put patient in conscious sedation to maintain study blinding. The physician will then use a 25-gauge needle under intermittent x-ray visualization to access the TF space. The physician will inject the TF space with x-ray contrast (0.5mL of OMNIPAQUE) to confirm epidural flow. Once flow is confirmed, the physician will inject 4mL of the PL, and 0.5mL of 0.5% ropivacaine into the epidural space at each level of interest. A 0.22 micron filter will be used.
223393376|NCT06924853|OTHER|Saline control|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist into 8 yellow top tubes and 1 purple top tube and processed into 5cc PL of which 4cc will be used for treatment and the remaining 1cc will be frozen and used for QC. A lavender top blood tube will be collected and used for quantitative CBC analysis; same as active treatment to maintain blinding. Patient will lie on table prone with a pillow under their abdomen to flatten their L-spine, sterilely prepped and draped. Provider to put patient in conscious sedation to maintain study blinding. The physician will then use a 25-gauge needle under intermittent x-ray visualization to access the TF space. The physician will inject the TF space with x-ray contrast (0.5mL of OMNIPAQUE) to confirm epidural flow. (6) Once flow is confirmed, the physician will inject 4mL of sterile saline (0.9%), and 0.5mL of 0.5% ropivacaine into the epidural space at each level of interest.
223393377|NCT06889350|DRUG|HD-P023|Single dose administration of HD-P023
224013513|NCT03224923|DRUG|Ticagrelor 60mg|twice daily
223393378|NCT06889350|DRUG|Teneligliptin|Single does administration of Teneligliptin and Empagliflozin High
223393379|NCT06889350|DRUG|Empagliflozin High|Single does administration of Teneligliptin and Empagliflozin High
223393380|NCT07045116|DEVICE|Electronic anesthesia|The child will receive electronic anesthesia to the right side of the upper jaw; the pain and anxiety level will be assessed.
223393381|NCT07045116|DEVICE|Conventional anesthesia|The child will receive conventional anesthesia to the maxillary left side
223393382|NCT04229667|OTHER|Improved Community Health Volunteer (CHV) program|"Multi-modal intervention targeting intensive household monitoring of high-needs patients using monthly visits to measure blood pressure and blood sugar, adherence to treatments and compliance with clinics visits, and motivational interviewing to facilitate behavior change and psychosocial support."
223393383|NCT06741345|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles for oral administration
223393384|NCT03245112|DRUG|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
223393385|NCT01872286|DEVICE|AKE-1|
223393386|NCT01872286|DEVICE|Pillcam SB2|
223393387|NCT05372965|OTHER|experimental-periodontitis-mirna-223-gingival tissue-saliva samples|Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
223393388|NCT05372965|OTHER|control-clinical healthy mirna-223-gingival tissue-saliva samples|Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
223393389|NCT01799044|DEVICE|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
223393390|NCT03653884|DIAGNOSTIC_TEST|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
223548288|NCT02593058|BEHAVIORAL|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
223730767|NCT02097004|DRUG|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
223730768|NCT04847947|DRUG|Cholecalciferol|Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks
224013514|NCT03224923|DRUG|Clopidogrel 75mg|once daily
223548289|NCT03475342|DRUG|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
223548290|NCT03475342|OTHER|Placebo|Ampoules and packaging for both arms will be identical in appearance.
223548291|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
223548292|NCT00115193|DRUG|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
223548293|NCT00584532|DRUG|Placebo|10 Placebo Capsules taken orally every day.
223730769|NCT04847947|DRUG|Placebo|Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
223730770|NCT02873000|BEHAVIORAL|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
223730771|NCT00922181|DEVICE|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
224013515|NCT03224923|DRUG|Aspirin 81 mg|once daily
224013516|NCT03890718|PROCEDURE|Photorefractive keratectomy in mile keratoconus|Topo-guided photorefractive keratectomy will be performed using an excimer laser (Allegretto Wave Topolyzer, Alcon, Inc.) with a 6 mm optical area and a transition area of 2 mm in all eyes. At that point, the partial topography-guided photorefractive keratectomy laser treatment will be finished. The arrangement will be to treat 70% of the cylindrical and spherical part to not surpass 50μm of stromal expulsion. The estimation of 50μm as the most extreme removal depth recommended by Kanellopoulos in Athens protocol will be chosen
223393391|NCT02845700|BEHAVIORAL|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
223393392|NCT02845700|BEHAVIORAL|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
223393393|NCT03068039|OTHER|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
223393394|NCT03068039|OTHER|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
223393395|NCT01022697|OTHER|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
223393396|NCT05641844|DEVICE|RD2 Ver.02|Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
223393397|NCT05641844|OTHER|Saline|Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
223393398|NCT02452476|DRUG|CHF5633|Rescue treatment (if needed)
224013517|NCT00418626|DRUG|Nilotinib|
224013518|NCT00233870|DRUG|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
223393399|NCT02452476|DRUG|Poractant alfa|Rescue treatment (if needed)
223393400|NCT04874831|DRUG|domatinostat in combination with avelumab|domatinostat tablets and avelumab infusion
223393401|NCT03552380|DRUG|Entinostat|RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
223393402|NCT03552380|DRUG|Nivolumab|Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 28 day cycles.
223393403|NCT03552380|DRUG|Ipilimumab|Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
223393404|NCT01801904|DRUG|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
223393405|NCT00168779|DRUG|telmisartan 80 mg / hydrochlorothiazide 25 mg|
223393406|NCT00168779|DRUG|valsartan 160 mg / hydrochlorothiazide 25 mg|
223393407|NCT00168779|DRUG|placebo|
223393408|NCT01231776|OTHER|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
223393409|NCT04200027|PROCEDURE|total mesorectal excision|Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
223393410|NCT00150280|DRUG|celecoxib and ibuprofen SR|
223393411|NCT02072980|DEVICE|Delefilcon A contact lenses|Silicone hydrogel contact lenses
223393412|NCT06498843|OTHER|administration of an isotonic seawater solution (9g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis, and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
223393413|NCT06498843|OTHER|administration of a hypertonic seawater solution (21g/L) in the nose|"1. pump spray group : people with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis and other upper respiratory infections/conditions).~2. sprays per nostril, at least 2 times a day up to 6 times a day. For 7 days"
223393414|NCT04319354|DIAGNOSTIC_TEST|Analysis of cfDNA|Analysis of cfDNA through liquid biopsy
223393415|NCT07057167|OTHER|Diagnostic Laparoscopy videos|"Diagnostic laparoscopy videos will be collected and stored on internal hard drives.~Pseudo-anonymized laparoscopic videos will be annotated by expert clinicians. Artificial intelligence (AI)-based solutions will be developed, trained, and validated."
223393416|NCT06338579|OTHER|Questionnaire|"A questionnaire is distributed and self-administered 4 weeks before the start of an embarked mission on a surface ship at the Toulon naval base, during an embarked mission of at least 4 weeks.~The questionnaire consists of 2 parts:~* A section on socio-demographic characteristics~* A section on self-medication practices during this deployment"
223393417|NCT01848600|BEHAVIORAL|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
223393418|NCT01757275|DRUG|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
223393419|NCT01757275|DRUG|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
223393420|NCT01757275|DRUG|Esomeprazole Mg|40 mg tablet once daily for 27 days
223393421|NCT02139137|OTHER|Computerized Cognitive Training - active|Cognitive training using working memory span task
223393422|NCT02139137|OTHER|Computerized cognitive training - sham|Sham training condition
224013519|NCT05432726|OTHER|calculating CARG score|"Before the initiation of chemotherapy, study participants will complete the GA questions included in the CARG toxicity score.~Total risk score will be calculated ranging from 0 (lowest toxicity risk) to 19 (highest toxicity risk), incorporates measures of functional status such as fall history, hearing problems, physical capabilities, performance status as well as objective measures including age, gender, height, weight, cancer type, type and dose of chemotherapy, hemoglobin, and creatinine clearance.~CARG score will be stratified as low (score 0-5), intermediate (score 6-9) and high risk (score 10-19).~Chemotherapy-related toxicities will be assessed and graded as per the NCI-CTCAE, version 5.0.~Hospitalizations due to AEs during first-line chemotherapy will be collected.~Subsequent changes in chemotherapy dosage, treatment delays, and treatment discontinuation due to adverse effects as well as mortality rate after treatment will also be monitored."
224138603|NCT03685370|PROCEDURE|LOS|placement of epidural catheters with LOS technique
224138604|NCT03685370|PROCEDURE|X-ray placement|placement of epidural catheters with x-ray guide
224138605|NCT02863939|DEVICE|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
223393423|NCT00233233|BEHAVIORAL|Standardized Asthma Education Program|
223393424|NCT04665986|DRUG|Navelbine|Navelbine 25mg/m2 on day 1 and 8, every 3 weeks
223393425|NCT04665986|DRUG|Docetaxel|Docetaxel 90mg/m2 on day 1, every 3 weeks
223393426|NCT00795652|BEHAVIORAL|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
223548294|NCT00584532|DRUG|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
223548295|NCT00746525|OTHER|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
223548296|NCT00746525|OTHER|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
223548297|NCT00746525|OTHER|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
223548298|NCT02102243|DRUG|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
223548299|NCT02102243|DRUG|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
223548300|NCT02102243|DRUG|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
223548301|NCT02102243|PROCEDURE|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
223548302|NCT02102243|PROCEDURE|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
223548303|NCT02102243|PROCEDURE|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
223548304|NCT02102243|PROCEDURE|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
223730772|NCT00922181|DEVICE|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
224013520|NCT04123574|DRUG|Talabostat Mesylate|"BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day."
224013521|NCT06145477|BEHAVIORAL|Chicago Parent Program - individualized for families (CPPi)|CPPi is a 8-12 session individual- based parenting skills program
223393427|NCT01488773|DRUG|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
223393428|NCT01488773|DRUG|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
223393429|NCT02601014|BIOLOGICAL|Ipilimumab|Given 1 mg/kg IV
223393430|NCT02601014|BIOLOGICAL|Nivolumab|Given 3 mg/kg IV
223393431|NCT02601014|DRUG|Enzalutamide|given orally per standard of care
223548305|NCT05035459|DIAGNOSTIC_TEST|lung ultrasound|drug adjustment based on lung ultrasound results
223548306|NCT05035459|DIAGNOSTIC_TEST|Lung ultrasound|drug adjustment independent on lung ultrasound results
223548307|NCT02579434|DRUG|Midazolam I.V.|Midazolam I.V. 1mg/ml
223548308|NCT05263570|DRUG|Standard Therapy|Standard Therapy, including TCbHP, THP, EC-THP, AC-THP
223548309|NCT04831437|RADIATION|Hypofractionated EBRT|EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
223730773|NCT03478267|DIAGNOSTIC_TEST|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
224013522|NCT01405326|BIOLOGICAL|adalimumab|40mg sc. every two weeks for six months
224138606|NCT02863939|OTHER|exercise|
224138607|NCT04556370|DRUG|Normal saline|Normal saline infusion simultaneous with subarachnoid block
223548310|NCT04831437|RADIATION|Standard EBRT|EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
224013523|NCT06198205|OTHER|Fundamental motor skills|This will receive fundamental motor skills(FMS) program include 12 basic motor skills(running,hopping,galloping,leaping,jumping,sliding,strinking,dribbling,catching overhand throwing and underhand rolling)
223393432|NCT01168427|DEVICE|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
223393433|NCT02624180|DRUG|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
223393434|NCT02624180|DRUG|Placebo|A substance containing no medication
223393435|NCT03190031|OTHER|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
223393436|NCT03190031|OTHER|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
224013524|NCT06198205|OTHER|Regular after school program|This group will receive regular afterschool programs unstructured child's free play which include sliding, hide and seek, sea-saw, and running along with reading, drawing. Each intervention session lasted 60 minutes. The study will be conducted in the duration of 8 weeks with 3 sessions per week (total 24 sessions) will be given to the students.
224013525|NCT00214578|DRUG|Seroquel (quetiapine)|
224013526|NCT02770456|DIETARY_SUPPLEMENT|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
224013527|NCT02770456|DIETARY_SUPPLEMENT|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
224013528|NCT02770456|DIETARY_SUPPLEMENT|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
224013529|NCT01342341|DRUG|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
224013530|NCT01444833|DRUG|Candesartan|32 mg per day duration 6 months
224013531|NCT02474485|DEVICE|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
224013532|NCT02474485|DEVICE|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
224013533|NCT02474485|PROCEDURE|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
224013534|NCT02474485|PROCEDURE|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
224013535|NCT02474485|OTHER|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
223548311|NCT02746328|DRUG|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
224013536|NCT02837224|DEVICE|The Situate Detection System|The Situate Detection System for locating surgical sponges
224013537|NCT01635205|PROCEDURE|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
224013538|NCT01635205|PROCEDURE|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
223393437|NCT06632964|BIOLOGICAL|Recombinant oncolytic adenovirus injection solution of VT-101|Active ingredient: VT-101 recombinant oncolytic adenovirus Specifications: 2×10\^10 IFU/ml, 0.5ml/ capsule Method of administration: intravesical perfusion
223393438|NCT02771977|OTHER|Drug-specific alert|A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
223393439|NCT03358927|BEHAVIORAL|Immediate Fast-Track Care|Eligible for fast-track care at enrollment
223393440|NCT03358927|BEHAVIORAL|Deferred Fast-Track Care|Eligible for fast-track care after 6 months on ART
223393441|NCT03987789|OTHER|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
223393442|NCT03987789|OTHER|Low PEEP|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
223548312|NCT05407207|DEVICE|Tennant Biomodulator ®|Tennant Biomodulator ® (Avazzia, Inc., Texas, USA)(FDA Classification: 882.5890 Neurology, Biofeedback device) is FDA-cleared for symptomatic relief and management of chronic pain. The device is simply activated using device buttons and does not need to be adjusted or monitored once therapy begins, making it easy for the purpose of therapy under unsupervised conditions or for use in busy HD clinics. The device will be used with FDA-cleared TENS electrodes that will be connected to the device via wires, providing an electrically conductive interface between the device and the subject's skin.
223548313|NCT04987827|OTHER|No intervention|No intervention
223564238|NCT00868140|DRUG|pioglitazone|pioglitazone 45 mg
223564239|NCT00868140|DRUG|Placebo|placebo daily
223564240|NCT04047433|GENETIC|screening for single nucleotide polymorphism|samples from both arms will be tested for a set of single nucleotide polymorphism
223564241|NCT04047433|GENETIC|whole exome sequencing|samples from arm #1 (women with external anal sphincter) will be tested for identifying specific genetic mutation
223564242|NCT05453500|DRUG|Cyclophosphamide|Given IV
223564243|NCT05453500|DRUG|Doxorubicin|Given IV
223564244|NCT05453500|DRUG|Etoposide|Given IV
223564245|NCT05453500|DRUG|Prednisone|Given PO
223564246|NCT05453500|BIOLOGICAL|Rituximab|Given IV
223564247|NCT05453500|BIOLOGICAL|Tafasitamab|Given IV
223564248|NCT05453500|DRUG|Vincristine|Given IV
223564249|NCT05453500|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223564250|NCT05453500|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223564251|NCT05453500|PROCEDURE|Computed Tomography|Undergo CT scan
223564252|NCT05453500|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223564253|NCT05453500|PROCEDURE|Biospecimen Collection|Undergo blood sample and cerebrospinal fluid collection
224013539|NCT03975777|OTHER|LO|Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at \~73% of peak aerobic work rate interspersed with 1 min recovery periods)
224013540|NCT03975777|OTHER|HI|Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at \~100% of peak aerobic work rate interspersed with 1 min recovery periods)
223393443|NCT06165276|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Protein Conjugate Vaccine (TetraMen-T).|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
223393444|NCT06165276|BIOLOGICAL|Meningococcal Group C-CRM197 Conjugate Vaccine|Pharmaceutical form:suspension for injection-Route of administration:Intramuscular (IM)
223393445|NCT05978401|DRUG|GLS-012+GLS-010|Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
223393446|NCT05978401|DRUG|GLS-012+GLS-010|Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
223393447|NCT05978401|DRUG|GLS-012+GLS-010+pemetrexed+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
223393448|NCT05978401|DRUG|GLS-012+GLS-010+paclitaxel+carboplatin|GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with paclitaxel and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
223393449|NCT04252027|OTHER|Sample collection|Plasma and urine sample collection
223393450|NCT00882752|PROCEDURE|molecular analysis|bowel disease
223393451|NCT04705792|PROCEDURE|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
223393452|NCT03926429|OTHER|Standardised data collection|The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
223393453|NCT02477644|DRUG|Olaparib|Tablets, per os, 300 mg twice daily;
223393454|NCT02477644|DRUG|Placebo|Tablets, per os, 300 mg twice daily.
223393455|NCT03177525|BEHAVIORAL|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
223393456|NCT03177525|BEHAVIORAL|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
223393457|NCT04207658|BEHAVIORAL|Valsalva's Style Pushing|The second stage of labour is defined as the time passed after the cervical dilatation reaches 10cm. The expulsion stage is the time between the sight of baby's head in the vulva and the end of labour. the participants are given information about the study after self introduction of each gravid is done for completing baseline obstetric data forms by midwives. Also, blood samples for pre and postpartum haemoglobin level changes are collected. The perineal area is examined for postpartum tears through pad checks. Vital findings (respiration, pulse and TA) are evaluated prior to their transfer to the delivery room. Just after the birth, mothers are tested for pH, pO2, pCO2 and lactate levels in blood while the newborns are tested for pH, pO2 (mmHg) and pCO2 levels through umbilical artery along with 1st min and 5 min APGAR analysis. The visual scale is utilized for determination of first 24-hour fatigue and they are recorded in follow-up forms.
223393458|NCT01872312|DEVICE|treatment with valves (The Spiration® IBV Valve System)|treat BPF
223393459|NCT02620995|DRUG|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
223393460|NCT02620995|OTHER|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
223393461|NCT04537884|DRUG|UBX1325|Investigational drug intravitreal injection
223393462|NCT06464484|DIETARY_SUPPLEMENT|Probiotics (Lactobacillus rhamnosus GG (ATCC 53103)|Already mentioned in arm/group descriptions
223393463|NCT01941615|DRUG|faldaprevir|oral doses for 10 days (period B)
223393464|NCT01941615|DRUG|Microgynon®|oral doses for 23 days (period A+B)
223393465|NCT01941615|DRUG|BI 207127|oral doses for 10 days (period B)
223393466|NCT02769507|DEVICE|DC Stimulator PLUS (NeuroConn)|
223393467|NCT01987778|OTHER|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
223393468|NCT02654054|DRUG|Elagolix|Film-coated tablets
223393469|NCT02654054|DRUG|Placebo for Estradiol/Norethindrone Acetate|Placebo capsules
223393470|NCT02654054|DRUG|Estradiol/Norethindrone Acetate|Commercially-available E2/NETA tablets were over-encapsulated to maintain study blinding.
223393471|NCT02654054|DRUG|Placebo for Elagolix|Film-coated placebo tablets
223393472|NCT06118476|BEHAVIORAL|3D animation|Education with 3D animation videos
223393473|NCT00420420|DRUG|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
223393474|NCT00420420|DRUG|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
223393475|NCT00273182|DEVICE|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
223393476|NCT00273182|DEVICE|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
223393477|NCT02364765|DRUG|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
223393478|NCT04821076|OTHER|Diet intervention - caloric restriction|Energy restriction is set to 25 kcal / kg fat-free mass
223393479|NCT04821076|OTHER|Exercise intervention|Exercise will consist of supervised resistance training, interval training and moderate intensity cycling
223393480|NCT04821076|OTHER|Diet intervention - Energy balance|Energy balance is set to 50 kcal / kg fat-free mass
223393481|NCT03289091|BEHAVIORAL|water-based continuous aerobic training|Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
223393482|NCT03289091|BEHAVIORAL|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
223393483|NCT02626091|PROCEDURE|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation."
223393484|NCT05475314|DIETARY_SUPPLEMENT|ReFerm(R)|Enemas of approx 250 mL twice daily
223393485|NCT06885619|OTHER|Diagnostic Test: echocardiography and blood collection|Blood samples were collected from all patients at the time of myocardial infarction (MI) diagnosis. For those with acute ST-elevation myocardial infarction, blood samples were taken on the day of diagnosis(T0), as well as two days (T1), one week (T2) and one month (T3) after percutaneous coronary intervention (PCI). Echocardiography was performed at the time of STEMI diagnosis, and then again at one week, one month, and six months post-onset.
223393486|NCT03641469|DEVICE|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
223393487|NCT07096700|OTHER|VR and walking brace-based gait rehabilitation|The study implements the use of VR and wearable sensors to enhance gait analysis in clinical practice. Participants will take part in two outpatient sessions (T1 and T2) involving the use of VR and wearable sensors, during which they will be asked to complete standardized gait tests and questionnaires. These two sessions will be separated by a one-week home phase (Th), during which participants will wear the walking brace in their daily activities and their gait and physiological data will be recorded by wearable sensors. A final session (T3), conducted without VR, will be scheduled two months later to assess the long-term retention of the intervention effects.
223393488|NCT07097480|PROCEDURE|Blood samples collection|Blood samples of 40 ml will be taken.
223548314|NCT04872569|BEHAVIORAL|Decision-making tool|"Participants will be directed to use the decision tool for 3 months using it at their own pace.~The tool covers topics relevant to women with disabilities in considering or planning a pregnancy and reflects core elements of decision making tools based on the Ottawa Framework for Decision Support."
223548315|NCT05593705|OTHER|observation|photograph for maxillary labial frenum and measurements with a periodontal probe
223548316|NCT04042454|OTHER|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
224013541|NCT03053687|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
224013542|NCT03053687|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
224013543|NCT03769662|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
224013544|NCT01789567|DEVICE|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
224013545|NCT04764643|DRUG|N-acetylcysteine solution|use N-acetylcysteine solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
224013546|NCT04764643|DRUG|sodium thiosulfate solution|use sodium thiosulfate solution to alleviate esophageal irritation caused by Lugol's chromoendoscopy
224138608|NCT04556370|DRUG|Norepinephrine|Different infusion dose of norepinephrine simultaneous with subarachnoid block
224138609|NCT05425485|BEHAVIORAL|Multi-component intervention|Web-based strategy with processes, materials, and patient and doctor education formats.
224138610|NCT02471001|BIOLOGICAL|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
223393489|NCT07097480|PROCEDURE|Saliva samples collection|Saliva samples will be collected
223393490|NCT07095374|OTHER|Rapid palatal expansion|Patients undergone orthopedic treatment with rapid palatal expander
223393491|NCT07097727|DRUG|acetyl cysteine 600 mg|patients received acetyl cysteine 600 mg/ 12h IV in addition to antibiotics
223393492|NCT07097727|DRUG|antibiotics and saline.|patients received only antibiotics and saline
224013547|NCT05916339|DRUG|Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication|"Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid~Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)"
224013548|NCT05916339|DRUG|Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.|"If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue.~Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex"
224013549|NCT00903604|DRUG|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
224013550|NCT00903604|DRUG|Placebo|Three 10-minutes infusions of isotonic saline solution
224013551|NCT02121951|PROCEDURE|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
224013552|NCT02121951|PROCEDURE|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
224013553|NCT02121951|DRUG|MAC|Incremental doses are given to the targed sedation and analgesia
223548317|NCT04042454|OTHER|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics for a period of 8-14 weeks (dependent on infants age at baseline). The intervention last's until the infant's age of 17 weeks.
223548318|NCT05940389|DEVICE|Naso Alveolar Mold|The NAM appliance is constructed according to the Grayson technique \[8\] with the nasal stent added from the start. The adhesive paste is used to hold the alveolar plate in place and labial taping is used. Patients are followed each 2 to 3 weeks for the appliance to be relined and selectively ground to modify the pressure as needed.
224013554|NCT00016601|DRUG|Indinavir sulfate|
224013555|NCT00016601|DRUG|Ritonavir|
224013556|NCT00016601|DRUG|Nelfinavir mesylate|
224013557|NCT00016601|DRUG|Efavirenz|
224013558|NCT00016601|DRUG|Nevirapine|
224013559|NCT00016601|DRUG|Medroxyprogesterone acetate|
224013560|NCT01029951|PROCEDURE|manipulation|
224013561|NCT01029951|PROCEDURE|Mobilisation|
224013562|NCT01029951|DEVICE|Activator instrument|
224138611|NCT05068193|DRUG|BR2008-1 (R)|After fasting at least 10 hours, two tablets of BR2008-1 will be administered orally with 150mL of water around 8 a.m.
223548319|NCT05940389|DEVICE|Taping with nasal elevator:|For the lip approximation, Airoplast tape is used which is water resistant transparent and coated with hypoallergic adhesive on one side. The nasal elevator is 3D printed from the design inspired by the Dynacleft nasal elevator. Patients will be followed each 2 to 3 weeks for any modifications or adjustments.
223548320|NCT06028698|OTHER|Inducing positive emotion music|listening to music could induce emotion response, this study is going to investigate inducing positive emotion music countering mental fatigue.
223548321|NCT00496431|DRUG|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
224013563|NCT02914275|BIOLOGICAL|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
224013564|NCT02914275|BIOLOGICAL|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
224013565|NCT05268445|PROCEDURE|Chemical and Mechanical Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis|Angioplasty for Refractory Intracranial Arterial Vasospastic Stenosis
224013566|NCT00091169|DIETARY_SUPPLEMENT|levocarnitine|Given orally
224013567|NCT00091169|OTHER|placebo|Given orally
224013568|NCT00872989|DRUG|docetaxel|Given IV
224013569|NCT00872989|DRUG|vandetanib|Given orally
224013570|NCT03191500|DEVICE|steerable catheter|peripheral vascular disease
224138612|NCT05068193|DRUG|BR2008 (T)|After fasting at least 10 hours, one tablet of BR2008 will be administered orally with 150mL of water around 8 a.m.
224013571|NCT06301425|OTHER|Intervention group|"Patients in interventional group could choose one of the following treatment protocols and then receive allo-HSCT if they were CR after the second consolidation:~1. . Venetoclax plus azacitidine: azacitidine 75mg/m2/d d1-7; venetoclax 400mg/d, d1-21;~2. . Venetoclax plus CAG: venetoclax 400mg qd d1-14; aclacinomycin 20mg qd d1-4; cytarabine 10mg/m2 q12h subcutaneous injection d1-14; G-CSF 300μg qd d1-14;~3. . Venetoclax plus IA: venetoclax 400mg qd d1-4; idarubicin 10mg qd d1-4; cytarabine 500mg qd d1-4;~4. . Venetoclax plus AA: venetoclax 400mg qd d1-7; aclacinomycin 20mg qd d1-7; cytarabine 100mg/m2 qd d1-7."
224013572|NCT06301425|OTHER|Control group|Receive allo-HSCT directly without the second consolidation chemotherapy.
224013573|NCT03074890|DEVICE|Application Protocol|Application lMassive Transfusion Protocol
224138613|NCT03886831|DRUG|PRT543|PRT543 will be administered orally
223393493|NCT00868530|BIOLOGICAL|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
223393494|NCT03311204|DEVICE|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
223393495|NCT03311204|OTHER|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
223730774|NCT06406985|BEHAVIORAL|Weight-loss through dietary and lifestyle changes|Weight-loss participants will complete one online, self-paced education session each week for 12 weeks. Education sessions focus on topics such as self-monitoring weight, meal routines, and dietary habits with an emphasis on protein and fiber intake. During these 12 weeks, participants will receive weekly messages from nutrition coaches as well as a monthly nutrition coaching call. After the first 12 weeks, participants will enter a follow-up period where nutrition coaching messaging will occur as needed and with the opportunity to still participate in a monthly nutrition coaching call. Participants are asked to weigh daily on a provided WiFi scale that automatically uploads their weight data to a website for researchers and coaches to monitor. Participants will also submit food records and self-reported weight and hip circumferences.
224013574|NCT00661479|DRUG|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
223393496|NCT03309501|DRUG|Tong-Luo-Qu-Tong Plaster|for 14 days as two period of treatment, daily 1 time.
223393497|NCT03309501|DRUG|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two period of treatment, daily 1 time
223393498|NCT07110948|PROCEDURE|Tongue tie release|surgical release of tongue tie
223393499|NCT07113457|OTHER|Acute Intermittent Hypoxia (AIH)|This intervention involves breathing lowered levels of oxygen (similar to those experienced on a tall mountain) for 60 seconds at a time. This is immediately followed by 60 seconds of breathing normal room air. These bouts are repeated approximately 15 times. For the intervention, the participant is fitted with a non-rebreathing mask which supplies the two different air levels
223393500|NCT07113366|DRUG|FAE cream|Ficus awkeotsang Makino extract (FAE)
223393501|NCT07113366|DRUG|Placebo|Placebo
223393502|NCT07111572|DIAGNOSTIC_TEST|fecal calprotectin|patients will accpet test of FC combine FIT
224013575|NCT00661479|DRUG|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
224013576|NCT00661479|DRUG|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
224013577|NCT00661479|OTHER|Sham (no implant)|Sham in the fellow eye on Day 1.
224013578|NCT06083779|GENETIC|low-depth whole-genome sequencing technology|the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
224013579|NCT02784054|DRUG|Carboplatin|
224013580|NCT02784054|DRUG|Etoposide|
224013581|NCT02784054|DRUG|Cyclophosphamide|
224013582|NCT02784054|DRUG|Bleomycin|
224013583|NCT02784054|DRUG|Thiotepa|
224013584|NCT02784054|DRUG|Melphalan|
224013585|NCT02784054|RADIATION|Reduced dose radiotherapy|
224013586|NCT03955796|DEVICE|Hydrophobic IOL|RayOne Hydrophobic Aspheric, hydrophobic IOL
224013587|NCT03955796|DEVICE|Non-hydrophobic IOL|RayOne Aspheric, non-hydrophobic IOL
224013588|NCT01877772|PROCEDURE|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
224013589|NCT01877772|PROCEDURE|Control|The control group will undergo standard rotator cuff repair.
224013590|NCT05130047|DRUG|Aldafermin|1 mg solution
224013591|NCT05130047|DRUG|Placebo|Aldafermin placebo solution
224013592|NCT00508703|RADIATION|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
224013593|NCT00508703|PROCEDURE|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
224013594|NCT01015339|DRUG|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
224013595|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
224013596|NCT01015339|DRUG|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
224013597|NCT01015339|DRUG|cisplatin|80mg/m2, day 1 of every 3 weeks
224013598|NCT03208777|GENETIC|taking blood samples|taking blood samples and measure telomeric abnormalities
224013599|NCT02259647|DRUG|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
224013600|NCT02259647|DRUG|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
224013601|NCT01302067|DRUG|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
224013602|NCT01302067|DRUG|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
224013603|NCT01302067|DRUG|Placebo|Oral, 1 tablet per day, 12 weeks duration
224013604|NCT04864288|DEVICE|Shear Wave Elastography|is a quantitative method in which the probe generates acoustic impulses through the tissue to create molecular vibration. These vibrations create shear waves so that elasticity might be calculated, because it is proportional to the speed of the waves
224013605|NCT05342506|DRUG|Toripalimab + ScTIL|Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
224013606|NCT02738203|DRUG|Vaginal 2% Lidocaine|Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
224013607|NCT02738203|DRUG|Surgical Lubricant Jelly|Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
224013608|NCT05022160|DRUG|pudendal nerve block|All patients in the study group will receive bilateral pudendal nerve block at the end of surgery, with help of landmark technique, using 0.5% bupivacaine
224138614|NCT03647436|OTHER|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
223548322|NCT00742170|DEVICE|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
224013609|NCT04675190|PROCEDURE|Major abdominal Surgery|Any surgery performed under general or regional anesthesia and procedures involving abdominal cavity is considered major abdominal surgery and those who have undergone any major abdominal surgery before 6 months from the date of ultrasound findings confirming the presence or absence of gall stone will be considered exposed.
224013610|NCT05939973|DEVICE|g-Cath EZ Delivery Catheter with Snowshoe Suture Anchors|The intent is to evaluate the safety and preliminary efficacy of a new Snowshoe suture placement pattern, POSE2.0 (sutures placed in the mid + distal body without fundus), with a moderate intensity diet and exercise program.
224127909|NCT05881551|DEVICE|eEgg|In the eEgg-Arm, patients are given the eEgg immediately before the intervention to familiarize themselves with this method. Here, the patient is asked to press the device with maximum force for five seconds, which would correspond to an NRS value of 10, and to press the eEgg only with half force, which corresponds to an NRS value of 5. Following the instruction, the current pain score present is recorded and documented using the NRS and the eEgg. The same procedure takes place at the end of the 24h observation interval when the eEgg is returned. Within the 24h interval, pain assessment is performed hourly using the NRS (during the day) and the eEgg (preferably at hourly intervals throughout the day). If necessary, additional measurements can be taken with the eEgg.
224127910|NCT05881551|OTHER|NRS|Patients record their pain on the numeric rating scale (NRS) within the 24-hour interval. An interval from 0 to 10 is given (0 = no pain, 10 = most pain imaginable).
224127911|NCT00363805|DIETARY_SUPPLEMENT|green tea|Given orally
224127912|NCT00363805|DRUG|Polyphenon E|Given orally
224127913|NCT00363805|OTHER|placebo|Given orally
224127914|NCT02241746|OTHER|no intervention|
224127915|NCT02231255|DRUG|Sifrol®|
224127916|NCT01805232|DRUG|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
223393503|NCT07111260|DEVICE|pHA130 Hemoadsorption + High-Flux Hemodialysis|A combination blood-purification procedure in which a pHA130 hemoperfusion cartridge is connected in series with a high-flux hemodialyzer. Blood first passes through the HP cartridge to adsorb protein-bound uremic toxins and is then dialyzed. In the 4-hour arm the HP cartridge remains online for the entire 4-hour session; in the 2-hour arm the cartridge is removed after 2 hours and dialysis continues alone for the remaining 2 hours. Blood-flow rates are 250-350 mL/min (4-hour arm) or 200-250 mL/min (2-hour arm).
223393504|NCT07112534|OTHER|Static stretching|Static stretching: 3 sets of 1 minute and 30 seconds of rest between sets
224013611|NCT00266227|DRUG|placebo|Intravenous repeating dose
223393505|NCT07112534|OTHER|Foam rolling|Foam rolling: 3 sets of 1 minute and 30 seconds of rest between sets
223393506|NCT07113522|DRUG|MT-501|MT-501 Tablets
223548323|NCT05961683|DEVICE|NIV plus software|interventions received by infants studied after placing them on ventilator using NIV plus software
224013612|NCT00266227|DRUG|rituximab|Intravenous repeating dose
224127917|NCT01805232|DRUG|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
223393507|NCT07111325|BIOLOGICAL|iEV|induced pluripotent stem cell-derived extracellular vesicles
223393508|NCT07111325|BIOLOGICAL|PRP|PRP injection
223393509|NCT07111325|OTHER|immobilization|immobilization
223393510|NCT07113535|OTHER|RAM cannula|RAM cannula as an interface for non invasive ventilation in preterm newborns
223393511|NCT07113535|OTHER|Short binasal prong|Short binasal prong as an interface for non invasive ventilation in preterm newborns
223548324|NCT04067791|DIETARY_SUPPLEMENT|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
223548325|NCT04067791|DIETARY_SUPPLEMENT|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
223548326|NCT00480740|DRUG|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
223548327|NCT03153891|OTHER|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
224013613|NCT00266227|DRUG|methotrexate|Oral or parenteral repeating dose
224013614|NCT00266227|DRUG|folate|Intravenous repeating dose
224013615|NCT03241927|BIOLOGICAL|Pembrolizumab|Day 1 of each 3 week cycle
224013616|NCT05887154|DEVICE|Microwave ablation|microwave ablation
224013617|NCT03559231|PROCEDURE|dFTRD|Duodenal Full-Thickness Resection
224013618|NCT03559231|PROCEDURE|EMR|Endoscopic Mucosal Resection
224013619|NCT03927339|DIAGNOSTIC_TEST|pre and post excercise group|"Treadmill Training Protocol~Each eligible participant in the patients group was then prospectively assigned to undergo exercise session of full-body-free weight treadmill training. Once the participants were prepped, they performed stretching for 5 min and slow walking for 3 min as a warm-up exercise before starting the training. Stretch was carried out similarly to all the subjects to quadriceps femoris and the hamstring. In the warm-up time period , it was enforced for 3 min at the speed of1 km/h. Then patients began the walking trials and walked at 1 to 1.34 m/s on an electric car treadmill (JACO fitness: JACO-212C)."
224127918|NCT01685632|PROCEDURE|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
223730775|NCT01995032|DRUG|750 mg metformin and 7.5 g L-citrulline daily p.o.|
224013620|NCT01593332|DRUG|Rituximab|two 500 mg rituximab infusions 2 weeks apart
224013621|NCT01593332|DRUG|Rituximab|500mg,two times with two weeks interval
224013622|NCT00417261|DRUG|ATF936|
223393512|NCT07111910|DEVICE|Virtual Reality Infection Control Training|This study evaluates a VR training program designed specifically to improve infection control skills among healthcare workers during the Hajj pilgrimage, one of the world's largest mass gatherings. Unlike traditional training, this VR intervention offers immersive, realistic simulations tailored to the unique cultural and environmental challenges of Hajj. It focuses on practical skill-building and clinical readiness in crowded, high-risk settings. Using a rigorous randomized controlled trial design, the study aims to show that VR training is more effective than conventional methods, potentially setting a new standard for infection control education in mass gathering healthcare.
223393513|NCT07111195|DEVICE|The ONCOhabitats software for MRI-based habitat segmentation|"ONCOhabitats is an MRI-based software platform designed to segment IDH-wildtype glioblastomas into four biologically distinct habitats (HAT, LAT, IPE, and VPE) based on vascular heterogeneity.~In this study, the software is applied preoperatively to generate imaging biomarkers that guide surgical sampling and are assessed for their ability to predict overall survival and stratify patients accordingly.~The intervention includes advanced perfusion imaging processing using the HTS methodology, non-invasive tumor characterization, and integration with molecular and histopathological data."
223393514|NCT07111611|PROCEDURE|Non-Traumatic Nasopharyngeal Suction Procedure|A modified suctioning technique that avoids deep catheter insertion and minimizes mucosal contact. Sterile saline (0.9%) is instilled into one nostril, and secretions are aspirated using external suction via the opposite nostril or mouth. This approach is designed to reduce pain and physiological stress compared to standard suction methods in preterm infants undergoing non-invasive ventilation.
224013623|NCT00417261|DRUG|AXT914|
224013624|NCT03866499|DRUG|BPI-7711|180 mg, oral, QD
224013625|NCT03866499|DRUG|Gefitinib|250 mg, oral, QD
223393515|NCT07113171|DEVICE|Conventional Direct Laryngoscope|The Macintosh laryngoscope blade was used for intubation. The technique involved neck extension to create a direct line of sight to the vocal cords for successful tracheal tube placement.
223393516|NCT07113171|DEVICE|Video Laryngoscope|The video laryngoscope allowed visualization of the glottis on a monitor without the need for cervical extension, facilitating intubation in anticipated difficult airway cases.
223393517|NCT07112209|COMBINATION_PRODUCT|Rezvilutamide combined with docetaxel|"Intervention Description:~Drug:Rivarestatine Description: 240mg, po, qd Drug:Docetaxel Description:75mg/m2，ivgtt q3w Drug:Prednisone Description:5mg,po,bid"
223393518|NCT07112859|PROCEDURE|Complete Pulpotomy with Biodentine|"Administration of local anesthesia followed by rubber dam isolation.~Removal of coronal pulp tissue to perform a complete pulpotomy.~Hemostasis achieved with saline-soaked cotton pellet.~Placement of Biodentine as the pulp-capping agent on the radicular pulp.~Temporary restoration placed immediately after Biodentine placement.~Permanent composite restoration placed after 1 week.~Follow-up visits at 7 days, 1 month, and 3 months for clinical and radiographic evaluation."
223393519|NCT07113392|DRUG|Suraxavir Marboxil|Suraxavir Marboxil will be administered as oral suspension: 40 mg (if weight ≥ 32 kg), or 20 mg (if weight \<32 kg).
223393520|NCT07113392|DRUG|Oseltamivir|Oseltamivir will be administered as oral granules: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≤ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
223393521|NCT07113444|OTHER|Tai Chi|Yang style of Tai Chi (24 form)
223393522|NCT07113444|OTHER|Moderate-Intensity Combined Exercise (MICE)|start from warm up (5 minute )repetitions in circuit in the exercises bent row with elastic band, bodyweight squats, adapted push-ups (on the wall or on the counter), deadlifts with an elastic band, presses with an elastic band and an abdominal band on the floor or adapted on the chair and cool down in the end
223393523|NCT07113444|OTHER|Control ( No Exercise )|The CON session will last 60 minutes and will be conducted only sitting. Participants will be told not to sleep and will not be allowed to use reading materials or any electrical gadgets during the CON session.
223548328|NCT03153891|OTHER|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
223548329|NCT05110781|BIOLOGICAL|Atezolizumab|Given IV
223548330|NCT05110781|RADIATION|Radiation Therapy|Undergo radiation therapy
223548331|NCT05110781|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223548332|NCT05778994|DEVICE|INTORUS|Exercise protocol with intorus
223548333|NCT02382991|DEVICE|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
223548334|NCT02382991|DEVICE|NMPK-3C60|1 month with NMPK - 3 months with 3C60
223548335|NCT03667313|COMBINATION_PRODUCT|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
223548336|NCT03667313|COMBINATION_PRODUCT|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
223548337|NCT01626781|DEVICE|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
223548338|NCT01626781|OTHER|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
223548339|NCT02148068|PROCEDURE|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
223548340|NCT00386620|BEHAVIORAL|Questionnaire|45 minute survey about health, pain and relationships
223548341|NCT00386620|BEHAVIORAL|Interview|Feedback on use of handheld computer electronic diaries (ED).
223548342|NCT04665804|DIETARY_SUPPLEMENT|Creatine Supplementation|Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
223548343|NCT04665804|DIETARY_SUPPLEMENT|Glucosamine and Chondroitin sulfate supplementation|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
223564254|NCT04746924|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous injection.
224013626|NCT03866499|DRUG|Placebo Tablet|250 mg gefitinib placebo tablet, QD
224013627|NCT03866499|DRUG|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
223548344|NCT04665804|OTHER|Supervised Exercise training|"Lower Extremity Resistance Exercise Training Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
223548345|NCT04665804|OTHER|Home Exercise Program|"2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension"
224013628|NCT02295553|DRUG|Ketamine|
224013629|NCT02295553|DRUG|Propofol|
224013630|NCT01869387|DEVICE|Non-invasive ventilation|
224013631|NCT02279628|DRUG|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
224013632|NCT02279628|DRUG|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
224013633|NCT01493011|DEVICE|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
224013634|NCT05184023|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
224013635|NCT05184023|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions.
224013636|NCT03284047|DRUG|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
224013637|NCT02940405|DRUG|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
223548346|NCT04665804|PROCEDURE|Electrotherapy + Heating|Interferential Current therapy (2P), in combination with heating pad for 20 minutes
223548347|NCT04665804|PROCEDURE|Joint Mobilization|Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization
223548348|NCT05211089|OTHER|Optical Coherence Tomography imaging of choroid|A single expert retinal specialists used a Topcon DRI-1 SS-OCT to do the Choroidal Thickness measurements. A 12, 9-mm radial line scan procedure was performed. Each radial line was automatically scanned 32 times in the same spot, followed by the creation of 12 high-resolution average B-scan images. Each scan was double-checked to confirm that it was centred on the fovea. Only scans of good quality were included. The perpendicular distance between the outer border of the RPE and the junction of the choroid and sclera was used to calculate CT. It was calculated automatically using the mapping software incorporated into the device and displayed as a colourful topographic map with nine subfields defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) style grid.
223730776|NCT01995032|DRUG|Placebo|
224013638|NCT02940405|DRUG|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
224013639|NCT05589168|BEHAVIORAL|Triage nurse|Triage nurse joins 911 call
224013640|NCT05589168|BEHAVIORAL|No triage nurse|Triage nurse does not join 911 call (business as usual)
224013641|NCT00153881|DRUG|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
224013642|NCT02194673|OTHER|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
224013643|NCT02194673|OTHER|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
224013644|NCT02194673|OTHER|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
224013645|NCT03725085|DRUG|Mucinex™ extended-release (SE)|2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
224013646|NCT03471351|DRUG|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
224013647|NCT03471351|BIOLOGICAL|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
224013648|NCT06399133|OTHER|Warm water intake|Nurses assessed the patients' gag and swallow reflexes in the SG. Patients who experienced nausea after reflex assessment were considered to have positive reflexes and were administered warm water. Packaged water was boiled in a kettle and poured into 200 mL disposable cups. After cooling the water to 38-40°C using a thermometer, patients were instructed to drink it within 3 min.
224013649|NCT06399133|OTHER|High-fiber diet|After initiating oral intake, the patients collaborated with a dietitian to incorporate high-fiber foods containing 30 g of fiber daily into their meal menus.
224013650|NCT06399133|OTHER|Abdominal massage|Patients in the SG received abdominal massages twice a day, in the morning from 08:00 to 09:00 and in the evening from 19:00 to 20:00, for 15 min per session, starting one day postoperatively.
224013651|NCT04775771|BEHAVIORAL|Animal Assisted Practice|The children, who were planned to be hospitalized for at least three days and were randomized to the experimental and control groups, were asked by the researcher using the face-to-face interview technique, and the questions in the patient information form were filled in on the form. Then, pre-test data were recorded by determining their anxiety levels with the State Anxiety Scale for Children, levels of fear with the Child Fear Scale, emotional and psychological well-being with the Stirling Children's Emotional and Psychological Well-being Scale. Unlike the other scales, the anxiety levels were assessed twice with one-hour intervals on the first day with the Children's State Anxiety Scale. On the third day, the anxiety levels were evaluated twice with one-hour intervals on the first day using the State Anxiety Scale for Children. The second group, the children in the control group, had the same procedure except for the intervention; but no intervention was made.
224013652|NCT01900197|DRUG|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
223393524|NCT07111949|OTHER|SSC Group 1 (Operation room)|"Salivary cortisol sampling from mothers, pain assessment (VAS), and measurement of physiological findings will be done at the following 3 measurement times. (1)Before transfer to the operating room (OR) (2)1 hour (h) after admission to the post-op room (PR) (3)at least 1 h after admission to the maternity ward (MW) The stress levels of the newborns will be assessed using the Neonatal Stress Scale at the following 4 measurement times, the heart rate and O2 saturation will be measured and recorded.~1. At least 5 min after the initiation of SSC in the OR~2. During the Hep-B vaccination in the PR~3. At least 30 min after SSC after admission to the MW~4. At least 24 h after birth in the MW, at least 30 min after SSC. The success of the newborn sucking will be assessed using the LATCH at the following 3 measurement times.~(1) At least 5 min after the initiation of SSC in the OR (2)At least 1 h after admission to the MW, during SSC (3)At least 24 h after birth in the MW during SSC."
224013653|NCT06417528|PROCEDURE|Chronic Post Surgery Pain (CPSP)|"The outcome variable is the presence of CPSP assessed 3 months after surgery and defined as an average pain intensity of at least 3 on the NRS scale (11-point one-dimensional pain scale) in the last three days, and pain localized to the surgical field (or in the lesion area) projected into the innervation territory of a nerve located in this area or referred to a dermatome.~Separate prediction models will be developed using data derived from surveys conducted at the relevant time points for the development of the risk index."
224013654|NCT00090129|DRUG|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
223393525|NCT07111949|OTHER|SSC Group 2 (Post-operation room)|"SC sampling from mothers, pain assessment (VAS), and measurement of physiological findings will be done at the following 3 measurement times. (1)Before transfer to the OR (2)1 hour (h) after admission to the PR (3)At least 1 h after admission to the MW.~The stress levels of newborns will be assessed using the Neonatal Stress Scale at the following 4 measurement times, and heart rate and oxygen saturation will be measured and recorded.~(1)At least 5 min after birth under radiant heater in the baby care room (BCR) (2)At least 10 min after being taken to the BCR during Hep-B vaccination under radiant heater (3)At least 5 min after being admitted to the maternity ward after SSC (4)5 min after being held in the mother's arms Newborn sucking success will be assessed using LATCH at the following 3 measurement times.~(1)At least 5 min after starting SSC in the post-op care unit (2)During SSC after being admitted to the MW (3)At least 24 h after being held in the mother's arms in the MW."
223393526|NCT07111585|OTHER|Personalized health coaching program|"Clinical: Pre-discharge education on HF management (e.g., symptoms, treatment, diet, medication, lifestyle) is provided with a booklet and website link. A digital scale is given. After discharge, 12-week phone coaching monitors medication adherence, weight, and sodium intake.~Functional: Patients are referred to cardiac rehab for tailored exercise plans. Education on home exercise and oxygen monitoring is provided, with QR-linked videos. Coaching supports exercise adherence.~Psycho-cognitive: Emotional support is based on the PERMA model. Patients with severe issues are referred to psychiatry. Post-discharge, coaching includes psychiatric appointment support and use of the 100-Day Diary for self-care and gratitude journaling.~Social: Nurses foster trust and social reintegration. Referrals to community services are made as needed. Weekly calls ensure service connection and address unmet needs via social workers."
223393527|NCT07111585|OTHER|standard care|Participants in the control group will receive standard care, including guideline-directed medical therapy, based on the latest clinical guidelines currently provided to patients with HF at the hospital, as well as HF education. HF education will be provided using a booklet that includes information on HF (definition, causes, symptoms, diagnosis, treatment, medications, and self-management), an exercise poster, a symptom log, a symptom checklist, fall prevention tips, and a dietary guide. Additionally, nutritionist consultations on HF-related diets, cardiac rehabilitation exercises, and financial support available through the social work department, if necessary, will be provided.
223393528|NCT07112352|COMBINATION_PRODUCT|Smart devices with Personalised data feedback and habit coaching|Smart devices (smartwatch and sleep mat) with a bespoke 'Healthy Habits' application with three healthy habit coaching and data feedback modules, focused on active minutes, steps and sedentary time, viewable on a tablet.
223393529|NCT07112352|DEVICE|Smart devices with data feedback|"Smart devices (smartwatch and sleep mat) with a standard off-the-shelf data feedback application (WithingsTM App) providing generalised data feedback from the participant's smartwatch and sleep mat, viewable on a tablet for 6 months."
223393530|NCT07112352|OTHER|Control|Standard care where they will be signposted to National Health Service (NHS) guidance on Healthy Ageing for older adults.
223548349|NCT04940468|OTHER|Diet Intervention|The dietary fiber intake target will be 19 g/d for ages 9-18 and females age 19 and older and 23g/d for males age 19 and older.
223548350|NCT01890265|DRUG|Pamrevlumab|Solution for infusion
223548351|NCT01890265|DRUG|Placebo|Solution for infusion
223548352|NCT01890265|DRUG|Sub-Study: Pirfenidone|Pirfenidone concomitant therapy will not be provided by the Sponsor.
223548353|NCT01890265|DRUG|Sub-Study: Nintedanib|Nintedanib concomitant therapy will not be provided by the Sponsor.
224127919|NCT01685632|PROCEDURE|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
224127920|NCT05320770|PROCEDURE|US guided TMJ intra articular injection|therapeutic TMJ intra articulatr injection of blood under sonography guidance to reduce joint hyper mobility
224127921|NCT02353637|DIETARY_SUPPLEMENT|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
224127922|NCT03870711|DRUG|lidocaine spray|10% lidocaine spray 4 puffs
223548354|NCT02288000|DRUG|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
223393531|NCT07111338|DRUG|Telitacicept 160mg|Telitacicept (RC18) is a recombinant TACI-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby inhibiting B-cell differentiation and plasma-cell survival. In this study, it is supplied as a sterile, preservative-free, lyophilized powder (160 mg/vial) that is reconstituted with 1 mL water for injection and administered subcutaneously into the abdomen or thigh at a fixed dose of 160 mg once weekly for 24 weeks. Each injection is performed by trained study personnel, and pre-filled backup syringes are available to ensure exact dosing. No dose escalation or tapering is planned; dose reductions or temporary discontinuation are allowed only for predefined safety criteria.
223548355|NCT02288000|DRUG|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
223548356|NCT04644510|DEVICE|Lung ultrasonography|Standardized eight-point Lung ultrasonography
223548357|NCT01445613|DEVICE|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
223548358|NCT00245453|DRUG|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
223548359|NCT00245453|DRUG|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
223548360|NCT00245453|DRUG|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
223730777|NCT04542772|OTHER|Mirror Therapy|Participants will receive the standard-of-care; multidisciplinary rehabilitation intervention based on their needs and tolerance, and will receive an additional 30 min of Mirror Therapy education. During Mirror Therapy education, the patients will be educated or shown how to perform MT and the patients will complete the recommended exercises on their own for 30 minutes/day for 5 days a week/ for 4 weeks. Standard Mirror Therapy Protocol will be followed.
224127923|NCT03870711|DRUG|Placebo|Sterile water 4 puffs
224127924|NCT00760227|OTHER|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
223393532|NCT06918574|OTHER|Breastfeeding Education with Breastfeeding Roadmap|"Information about the Breastfeeding Roadmap prepared by the researchers will be explained to the mothers in the intervention group and hung in poster rooms."
223393533|NCT06917963|DRUG|Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM)|This intervention consists of intensified intravenous omeprazole therapy specifically designed to reduce high-output ileostomy after surgery. It includes an initial loading dose of 80 mg omeprazole administered intravenously on the day before surgery (or on the day of surgery in emergency cases), followed by a continuous treatment of 40 mg intravenously twice daily (at 6:00 AM and 6:00 PM) during hospitalization and after discharge to complete 10 day therapy, distinguishing it from standard once-daily omeprazole dosing protocols typically used for gastrointestinal ulcer prophylaxis.
223393534|NCT06917963|DRUG|Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).|The control group will receive standard intravenous omeprazole therapy as per routine clinical practice for gastrointestinal prophylaxis. Participants will receive a single daily dose of 40 mg omeprazole intravenously administered at 6:00 AM during hospitalization. This standard dosing regimen serves as the comparator for assessing the efficacy of the intensified dosing regimen used in the experimental group.
223393535|NCT06216899|OTHER|Whole-food based smoothie|The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
223393536|NCT06216899|OTHER|Formula|Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
223548361|NCT05918016|DIAGNOSTIC_TEST|Routine cranial ultrasounds|we will use the routine cranial ultrasounds
223548362|NCT02931409|PROCEDURE|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
223548363|NCT02931409|PROCEDURE|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
223548364|NCT04193904|DRUG|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
223548365|NCT04193904|RADIATION|Hypofractionated Preoperative Radiation|Radiation will be delivered as 30Gy/10 fractions over two weeks.
223548366|NCT01918891|BEHAVIORAL|Nurse Practitioner Only|
223548367|NCT01918891|BEHAVIORAL|Nurse Practitioner + Health Coach|
223548368|NCT03029039|OTHER|Blood samples|Blood samples will be collected at inclusion.
223548369|NCT00945373|DRUG|calcium dobesilate|2.5% gel
223730778|NCT04542772|OTHER|Regular Rehabilitation|Participants will receive the standard-of-care, multidisciplinary rehabilitation intervention based on their needs and tolerance.
224127925|NCT00760227|OTHER|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
223548370|NCT00945373|PROCEDURE|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
223548371|NCT05396339|DRUG|IAE0972|IAE0972 is an investigational product
223548372|NCT00432068|DRUG|Octreotide pamoate|
223548373|NCT00770627|DIETARY_SUPPLEMENT|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
223730779|NCT06069284|OTHER|No intervention|No intervention
223730780|NCT01904591|DIETARY_SUPPLEMENT|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
223730781|NCT01904591|DIETARY_SUPPLEMENT|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
223393537|NCT04745221|OTHER|autologous fecal bacteria|autologous fecal bacteria transplantation
223393538|NCT05442801|DRUG|Cyclopentolate|Well known eye drop used for cycloplegic refraction among children.
223393539|NCT05442801|DRUG|Tropicamide|Well known eye drop used for cycloplegic refraction among children.
223393540|NCT07112768|DIAGNOSTIC_TEST|Serum levels of LH, FSH, testosterone, prolactin, and ferritin|Measurement of both hormonal and biochemical markers in Jordanian PCOs females, including Serum levels of LH, FSH, testosterone, prolactin, and ferritin)
223393541|NCT07112469|BEHAVIORAL|Health promotion communication|"1. Students (Research subjects):~   * All students: Students perform plays during flag-raising ceremonies for all grades. These plays emphasize the importance of increasing physical activity for better health.~  * Selected students from Phase 1: Students selected in Phase 1 are guided to play games that help them identify healthy behaviors. They also receive flyers with messages about the benefits of physical activity.~2. Parents:~   Parents receive flyers with messages about the benefits of physical activity.~3. Schools:~Research team advises school principals and discusses ways to adjust factors that affect students' physical activity time. These factors are assessed based on cross-sectional study results, literature reviews, and the evaluation of the current situation at each school."
223393542|NCT07112469|BEHAVIORAL|Guidance and practice in developing physical activity plans|"The intervention is exclusively implemented for students who participated in the Phase 1 survey. These students are being guided to create weekly physical activity plans by keeping a journal. They are also encouraged to self-monitor their progress. A Facebook page has been created to launch the Active Moments with Family challenge and provide regular health-related updates. Teachers are sharing this page with parents to promote participation in the challenge and enhance their health knowledge."
223393543|NCT06463028|DRUG|Sapanisertib|Oral
223393544|NCT06463028|DRUG|Serabelisib|Oral
223393545|NCT06463028|DRUG|Paclitaxel|Infusion
223548374|NCT03027518|OTHER|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
223548375|NCT03376139|DRUG|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
224013655|NCT00090129|DRUG|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
224013656|NCT00002332|DRUG|Thymopentin|
224013657|NCT04698642|DRUG|CBL-514|Both sides of the abdominal region will receive CBL-514.
224013658|NCT00423943|DRUG|modafinil|200 milligrams daily dose
224013659|NCT00423943|DRUG|Placebos|capsule containing placebo
224013660|NCT04898439|OTHER|greening of the school environment|The school will be greened and biodiversity will be increased. This will be done on the playground and area around the school. Special needs corners for playing, relaxing or gardening will be installed.
224013661|NCT05443646|DRUG|HLX10|"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"
224127926|NCT00760227|OTHER|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
223393546|NCT06932484|PROCEDURE|parameters|during surgery hemodynamic will be optimized based on percentage variation of different variables
223393547|NCT04823897|DRUG|CCI-001|"Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase."
223393548|NCT05517330|BIOLOGICAL|Tislelizumab|200mg IV Q3W
223393549|NCT05517330|DRUG|Afatinib|30mg PO QD
223548376|NCT03376139|DRUG|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
223548377|NCT05346744|OTHER|Chairside CAD/CAM ceramic materials for dental restoration|"6 crowns made from 6 chairside ceramic materials were milled by CEREC MCXL-EF mode for mandibular first molar of each participant.~The six materials are as follows:~ZIR: InCoris TZI (Dentsply Sirona, York, PA)， CD: Celtra Duo (Dentsply Sirona, York, PA), EMA: e.max CAD (ivoclar, Vivadent AG), LC: LiCi (UPCERA, China), ENA: Vita Enamic (Vita Zahnfabrik, Bad Sackingen, Germany) RC: RunCi (UPCERA, China)"
223564255|NCT04746924|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous injection.
223564256|NCT04746924|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous injection.
223564257|NCT04746924|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution.
223564258|NCT05239143|BIOLOGICAL|P-MUC1C-ALLO1 CAR-T cells|P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.
223564259|NCT05239143|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
223564260|NCT06974929|DRUG|HRS-6209 Capsules|Oral HRS-6209 capsules.
223564261|NCT06974929|DRUG|Letrozole Tablets|Oral Letrozole tablets.
224013662|NCT05443646|RADIATION|hypofractionated radiotherapy|45Gy/3Gy/3week
224013663|NCT05443646|RADIATION|Prophylactic Cranial Irradiation (PCI)|25Gy/2.5Gy/2week
224013664|NCT04369482|DEVICE|Alcon Clareon|Implantation of an intraocular lens Alcon Clareon
224013665|NCT04369482|DEVICE|Hoya Vivinex|Implantation of an intraocular lens Hoya Vivinex
224127927|NCT00843297|DEVICE|Coolgard|invasive Cooling via femoral ICY-catheter
224127928|NCT00843297|DEVICE|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
223393550|NCT06950983|BEHAVIORAL|AYA-NAV|Support for AYA and vocational navigation sessions from clinical team
223393551|NCT06949436|PROCEDURE|GK SRS|Under local anaesthesia, a Leksell stereotactic head frame is fixed to the patient's head to allow for complete cranial immobilization during treatment. The retrogasserian (i.e., mid-cisternal) target will be utilized at a single 4 mm isocenter, and 40 Gy will be administered to the 50% isodose line while limiting the brainstem to 12 Gy.
223730782|NCT04853511|DEVICE|OCT-FLIM (optical coherence tomography-fluorescence life time)|comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
224013666|NCT04032587|BEHAVIORAL|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
224013667|NCT04032587|BEHAVIORAL|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
224013668|NCT05216497|DRUG|Ingavirin®, 90 mg capsules|90-180 mg/day for 7 days on top of standard therapy
223393552|NCT00858273|DIETARY_SUPPLEMENT|Antioxidant supplement|1 capsule daily with dinner
223393553|NCT00858273|OTHER|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
224013669|NCT05216497|DRUG|Placebo|1-2 capsules for 7 days on top of standard therapy
224013670|NCT04464954|DEVICE|Auricular semi-permanent (ASP gold) needles|ASP semi-permanent Battlefield Acupuncture needles are semi-permanent needles that will remain in subject ears for 2-8 days and will be allowed to fall out on their own
224013671|NCT04464954|DEVICE|Intradermal (long) needles using J-type No. 2 (.18)x 15mm|Intradermal (long) needles will remain in subject ears for 15-30 minutes and will be removed by a member of the study staff.
224013672|NCT04464954|DEVICE|Pyonex needles (Seirin Yellow 0.2 x 0.6mm)|Pyonex needles will remain in subject ears for 2-21 days and allowed to fall out on their own.
224013673|NCT03042897|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo DASH diet
224013674|NCT03042897|BEHAVIORAL|Exercise Intervention|Undergo in aerobic exercise
223393554|NCT00858273|DRUG|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
223393555|NCT02257502|DRUG|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
223393556|NCT04199104|DRUG|Lenvatinib|Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
223393557|NCT04199104|BIOLOGICAL|Pembrolizumab|Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
223393558|NCT04199104|DRUG|Placebo|Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
223393559|NCT03414502|DRUG|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg daily.
223393560|NCT03414502|DRUG|Abatacept|Starting dose may be adjusted as needed at investigator's discretion.
223393561|NCT03414502|DRUG|Adalimumab|Starting dose may be adjusted as needed at investigator's discretion.
223393562|NCT03414502|DRUG|Azathioprine|Starting dose may be adjusted as needed at investigator's discretion.
223393563|NCT03414502|DRUG|Baricitinib|Starting dose may be adjusted as needed at investigator's discretion.
223393564|NCT03414502|DRUG|Certolizumab|Starting dose may be adjusted as needed at investigator's discretion.
223393565|NCT03414502|DRUG|Etanercept|Starting dose may be adjusted as needed at investigator's discretion.
223393566|NCT03414502|DRUG|Golimumab|Starting dose may be adjusted as needed at investigator's discretion.
223393567|NCT03414502|DRUG|Hydroxychloroquine|Starting dose may be adjusted as needed at investigator's discretion.
223393568|NCT03414502|DRUG|Infliximab|Starting dose may be adjusted as needed at investigator's discretion.
223393569|NCT03414502|DRUG|Leflunomide|Starting dose may be adjusted as needed at investigator's discretion.
223393570|NCT03414502|DRUG|Minocycline|Starting dose may be adjusted as needed at investigator's discretion.
223393571|NCT03414502|DRUG|Rituximab|Starting dose may be adjusted as needed at investigator's discretion.
223393572|NCT03414502|DRUG|Sarilumab|Starting dose may be adjusted as needed at investigator's discretion.
223393573|NCT03414502|DRUG|Sulfasalazine|Starting dose may be adjusted as needed at investigator's discretion.
223393574|NCT03414502|DRUG|Tofacitinib|Starting dose may be adjusted as needed at investigator's discretion.
223393575|NCT05120193|DEVICE|Mapping and Ablation|Minimally invasive catheter mapping and ablation procedure
223730783|NCT02949102|DIETARY_SUPPLEMENT|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
223730784|NCT02949102|DIETARY_SUPPLEMENT|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
223730785|NCT01150864|DEVICE|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
223730786|NCT02260921|DEVICE|iovera°|
223730787|NCT02260921|DEVICE|Sham Comparator|
224013675|NCT03042897|OTHER|Laboratory Biomarker Analysis|Correlative studies
224013676|NCT03042897|OTHER|Quality-of-Life Assessment|Ancillary studies
224013677|NCT05611008|DEVICE|CDSS|A Clinical Decision Support System (CDSS) that calculates older patients' personalized fall risk and provides the GP with advice on how to adjust the patient's medication in order to lower the fall risk.
223548378|NCT04896801|RADIATION|MR-guided RT|The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
223393576|NCT06404112|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
223393577|NCT06404112|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
223393578|NCT06404112|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
223393579|NCT06404112|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
223730788|NCT00707824|DRUG|nalbuphine|nalbuphine 5 mg epidural
224013678|NCT05611008|DEVICE|Patient Portal|A patient portal that provides general information on falls and fall risk to the older patients and helps the patient to prepare for the consultation by filling out a Question Prompt List (QPL). The QPL is a list of possibly relevant questions and topics from which the patient can select those that are important to him/her. These will already be sent to the GP before the consultation takes place.
224013679|NCT04447664|DEVICE|Inclouded telespirometry system|Components of the system: Portable digital ultrasonic spirometer (Uscom SpiroSonic MOBILE), android mobile application, clinical web cloud application
224013680|NCT02273817|DRUG|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
224013681|NCT05273697|PROCEDURE|Underwater Cold Snare Polypectomy|"The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~1. Complete suction of air from the intestinal tract~2. Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~3. Complete immersion of the lesion in water~4. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~5. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
224127929|NCT00843297|OTHER|Conventional treatment|Intensive care-treatment without cooling
223393580|NCT03325062|BEHAVIORAL|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
223393581|NCT03325062|BEHAVIORAL|Experimental: MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
223393582|NCT04797000|DRUG|Eltrombopag|Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
223393583|NCT04797000|DRUG|Placebo|Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
223393584|NCT05110144|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
223393585|NCT05110144|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
223393586|NCT05110144|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
223393587|NCT05110144|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
223393588|NCT05110144|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
223393589|NCT05110144|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
223393590|NCT06543212|OTHER|physiotherapy exercises|physiotherapy exercises to improve eye alignment and eye control post strabismus surgery
223548379|NCT00631280|BEHAVIORAL|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
223564262|NCT05819541|DRUG|Montelukast Oral Granules|Oral montelukast granules, USP powder, or crushed tablets at weight-based doses between 2 mg/kg and 3 mg/kg to a maximum of 180 mg.
223564263|NCT05819541|DRUG|Albuterol|Inhaled albuterol by metered-dose inhaler (MDI) or nebulizer
223564264|NCT05819541|DRUG|Corticosteroid|Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)
223564265|NCT02187887|BEHAVIORAL|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
223564266|NCT06046859|DRUG|Fluoxetine|Subjects will be randomized to take Fluoxetine (10mg by mouth per day for first 14 days then 20 mg by mouth for 9 months). The randomized drug will be prescribed by the study team on the day of randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy at the 2 week, 3 month, and 6 month follow-up visits
223564267|NCT06046859|DRUG|Placebo|When a patient is enrolled, the inpatient research pharmacy will dispense the appropriately randomized medication in a visually similar, over-encapsulated form as Fluoxetine
223393591|NCT06184061|COMBINATION_PRODUCT|Herbal Supplement|Herbal supplement will be the mixture of strawberry, black mulberry, blueberry, raspberry, ginseng, ashwagandha, honey, water
223393592|NCT02543788|PROCEDURE|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
224013682|NCT05273697|PROCEDURE|Conventional Cold Snare Polypectomy|"The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~1. If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~2. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~3. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible"
224013683|NCT02943486|OTHER|dac-MSCs|Cell-free therapy
224013684|NCT02943486|OTHER|MSCs|Cell-based therapy
224013685|NCT02943486|DRUG|Fitostimoline|Triticum vulgare
224013686|NCT00987246|DRUG|Placebo Gel|Topical
224013687|NCT00987246|DRUG|LAS41005|Topical
224013688|NCT00987246|DRUG|LAS106521|Topical
224013689|NCT01329692|BEHAVIORAL|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, \& 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
224013690|NCT05102604|OTHER|Avocado|Subjects will eat one avocado in addition to their usual diet
224013691|NCT05102604|OTHER|Habitual diet|Subjects will eat their usual diet
224013692|NCT02383056|DEVICE|Omnilux|Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
224013693|NCT02383056|DEVICE|Omnilux Sham|Sham light instead of phototherapy from the same light device
223393593|NCT06009107|BIOLOGICAL|HY004|A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.
223393594|NCT06009107|DRUG|Cyclophosphamide|Administered intravenously.
223393595|NCT06009107|DRUG|Fludarabine Phosphate|Administered intravenously.
223393598|NCT06581965|OTHER|Short duration prophylaxis|"Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group)."
223393599|NCT06581965|OTHER|Higher intensity and longer duration prophylaxis|"The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min)."
223393600|NCT06581965|OTHER|Control|4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
223548380|NCT00631280|BEHAVIORAL|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
223730789|NCT00707824|DRUG|nalbuphine|nalbuphine 10 mg epidural
224013694|NCT04214600|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|"Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills"
224013695|NCT02590705|DRUG|Lidocaine|surface anesthesia with lidocaine
223548381|NCT05788601|DRUG|Dapiglutide|GLP-1/GLP-2 receptor agonism
223548382|NCT05788601|DRUG|Placebo|Placebo
223548383|NCT04095052|DIETARY_SUPPLEMENT|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
224013696|NCT04479345|OTHER|Questionnaire|Online questionnaire
224013697|NCT00435591|DRUG|Conivaptan|ampoule or premix bag
224013698|NCT00435591|DRUG|placebo|ampoule or premix bag
224013699|NCT00210470|BIOLOGICAL|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.
224013700|NCT00210470|DRUG|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
224013701|NCT00210470|DRUG|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
224013702|NCT00210470|DRUG|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
224013703|NCT00210470|DRUG|Omeprazole|21 days of 20 mg. orally
223548384|NCT04095052|DIETARY_SUPPLEMENT|Placebo|Microcrystalline Cellulose capsule
223393601|NCT02562235|DRUG|Riociguat (Adempas, BAY63-2521)|For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
223393602|NCT02695251|OTHER|low AGE meal|Patients will receive a low AGE (eggs) meal
223548385|NCT02725905|BEHAVIORAL|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
223548386|NCT02725905|BEHAVIORAL|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
223548387|NCT04821934|OTHER|TR|"TR is a specific remote tele rehabilitation program on exercise activity managed by the physiotherapist (PT) at home, this is the experimental group. PT will explain the rehabilitation program at hospital discharge by the use of a brochure and videos. TR will include an early exercise re-conditioning program \[aerobic exercise at the free body (with or without tools), cyclette and walking with a pedometer\] comprising 20 sessions of 60 minutes/day, 6 out of 7 days to be performed at home, for one month after discharge. The sessions will be self-managed by the patients 4 times a week and an expert PT will remotely supervise 2 times a week through a dedicated platform. The program will be progressively incremental and divided into 4 different levels of intensity (0- 3).~In addition to this specific rehabilitation program, the patients will be followed by a nurse tutor once a day for two weeks and once a week for a further two weeks in a program of Telesurveillance."
223548388|NCT04821934|OTHER|TSu|"The patients of this group will perform a usual Telesurveillance and will be considered as control group.~All patients, at discharge from the hospital, will be provided with a finger pulse oximeter and a dedicated application (app) on their personal smartphone and will be advised on free physical activity to be performed at home. The nurse will check through scheduled calls (once a day for two weeks and once a week for a further two weeks) the patient's health condition, vital parameters and drugs administration. Patients will be able to contact the nurse at each time, in case of specific need, out of the scheduled call, 7/7 days.~A follow up by phone will be planned by nurse tutor at 2 months from the end of the study."
223548389|NCT00648258|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
223548390|NCT00648258|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
223548391|NCT00003935|DRUG|etoposide|
223548392|NCT00003935|DRUG|vincristine sulfate|
223548393|NCT00003935|RADIATION|radiation therapy|
223548394|NCT00137059|DRUG|acetaminophen sustained-release|
223548395|NCT04635202|BEHAVIORAL|exercise training on elliptical device|This group (n=30) will receive aerobic training on an elliptical trainer for 16 weeks (3 sessions per week). The session will start with 5 minutes warming up at 50 % of maximal heart rate (MHR), 20-minute continuous ET at 70% of MHR, 12 minutes (4×3) intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervals, and finally 5-minute cool-down period at 50% of MHR
223548396|NCT04635202|BEHAVIORAL|group B (control group)|this group will receive general advises on maintaining physical activities for 16 weeks without any additional supervised training
223548397|NCT00572598|DRUG|4- [F-18] fluoropaclitaxel|4- \[F-18\] fluoropaclitaxel, \<84 micrograms, \<10 mCi, IV followed by PET/CT imaging
223548398|NCT04176393|DRUG|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
223548399|NCT00860626|DRUG|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
223548400|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (\>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
223730790|NCT00707824|OTHER|NSS|NSS
223730791|NCT01490229|DRUG|Ezetimibe|os, 10 mg, once daily, 1 year
223730792|NCT01490229|DRUG|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
223730793|NCT02319889|RADIATION|Stereotactic Body Radiotherapy|Undergo SBRT
224127930|NCT00364845|DRUG|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
224127931|NCT00364845|DRUG|Placebo|Prefilled syringe placebo, to match active arm
224127932|NCT06520176|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
223393603|NCT02695251|OTHER|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
223393604|NCT05097287|DRUG|Dupilumab|solution for injection subcutaneous
223393605|NCT05097287|DRUG|Placebo|solution for injection subcutaneous
224127933|NCT06520176|DRUG|Cytarabine|Day 1\~Day 2: 200g/m\^2, q12h
224127934|NCT06520176|DRUG|Pegfilgrastim|Day 6: 6mg
224127935|NCT06520176|DRUG|Cyclophosphamide|Day 1\~Day 2: 1～2g/m\^2
224127936|NCT06520176|DRUG|G-CSF|Subcutaneous injection at dose 5ug/kg, from day 6 until the end of mobilization.
223548401|NCT00860626|DRUG|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
223548402|NCT04466384|DEVICE|BIS|Subjects will be sequentially assigned to the propofol or propofol and remifentanil group. The purpose is to capture the BIS value in association with these anesthetics.
224127937|NCT06520176|DRUG|G-CSF|Starting from the 9th day, if the white blood cell count is less than 20,000/μL, administer G-CSF at a dose of 5μg/kg by subcutaneous injection until the collection is completed.
223393606|NCT06807970|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|Patients in intervention group will have GLP-1RA semaglutide for 48 weeks and then stops for one month before and after TKR following the latest anesthesia guideline for GLP-1RA. Followed by TKR They will continue semaglutide for 48 weeks during the post-operative follow-up period. This is decided based on balancing treatment effect of semaglutide, waiting time for TKR, and TKR follow-up requirement. In Hong Kong, waiting time for TKR would be \~4 years and so a period of 12 months treatment of semaglutide is reasonable. And in the STEP 6 trial, weight loss at week 52 (-12%) is similar to that in study end at week 68(-13·2%), and STEP5 trial showed maintaining semaglutide to week 104 could maintain weight loss of similar degree as in week 52. And the consensus of assessing TKR Patient-Reported Outcome Measures (PROMs) is one year follow up.
223393607|NCT06807970|OTHER|Control (Standard treatment)|If patients are randomized to the control group, they will receive routine follow-up with general advice on diet and physical activity but will not receive semaglutide, and will not be offered a specific management program for their weight. This is in line with current practice.
223393608|NCT03030378|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
223393609|NCT03030378|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223393610|NCT03030378|PROCEDURE|Computed Tomography|Undergo a CT scan
223393611|NCT03030378|BIOLOGICAL|Edodekin alfa|Given SC
223393612|NCT03030378|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
223393613|NCT03030378|BIOLOGICAL|Pembrolizumab|Given IV
223393614|NCT03030378|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223393615|NCT02874040|PROCEDURE|Endoresection|Endoresection of the tumor scar
223393616|NCT02874040|PROCEDURE|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
223548403|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior frontal gyrus (IFG)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
223548404|NCT04650438|DEVICE|Transcranial Magnetic Stimulation (TMS) over the left inferior parietal lobule (IPL)|MagPro X100, with MagPro software version 7.1; connected to a figure-of-eight coil (MC-B70) or a circular coil (MC-125). The device is CE marked and bears an ISO 13485 certificate complying with good manufacturing practice. Continuous theta burst stimulation protocol will be applied.
224013704|NCT05351359|BEHAVIORAL|mHealth|A mHealth-enabled just-in-time adaptive intervention that is based on the HealthReact system developed by the participating centre at the Faculty of Science of the University of Hradec Kralove. The HealthReact system consists of a server-side application that is connected to the Fitbit server. As such, the system allows for just-in-time text messages triggered by pre-defined context as recorded by the Fitbit wearable monitor. For example, a prompt to take a break from sedentary behaviour can be triggered after 30 sedentary minutes, a suggestion to increase walking cadence can be triggered when continuous, but slow walking is detected, or a motivational message with a specific goal to take more steps to reach their usual daily step count can be triggered when the total daily steps are too low. The mHealth component will be delivered for the entire duration of the study (i.e., 12 months).
224013705|NCT05351359|BEHAVIORAL|phone counselling|Regular monthly phone calls by trained counsellors support participants in their effort to increase physical activity and reduce sedentary behaviours. The counsellors will use various behaviour change techniques, such as goal-setting, feedback, action planning, etc. The phone counselling will be provided during the first six months, i.e. 6 phone calls will be delivered.
224013706|NCT05351359|BEHAVIORAL|Fitbit tracker|Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
224013707|NCT05351359|BEHAVIORAL|brief advice|A brief advice will be provided by the general practitioner at the start of the study.
224127938|NCT03894527|BEHAVIORAL|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (\~70% VO2peak). Time will vary based upon individual fitness levels to burn \~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
224127939|NCT03894527|BEHAVIORAL|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
224127940|NCT00267280|DRUG|torcetrapib/atorvastatin|
223548405|NCT05598905|DRUG|Pregabalin 150mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
223548406|NCT05598905|DRUG|Oxycodone 10mg|one 10mg tablet
223548407|NCT05598905|DRUG|Lacosamide 150 mg|one capsule of 150mg 90 minutes after 10mg of oxycodone
223548408|NCT05496361|DEVICE|Tianyi Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
223730794|NCT02319889|DRUG|Carboplatin|Given IV
223730795|NCT02319889|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
224127941|NCT00267280|DRUG|simvastatin|
224127942|NCT01529476|DRUG|Levofloxacin|levofloxacin 500 mg,QD,7\~10 days
224127943|NCT01529476|DRUG|Nemonoxacin|Nemonoxacin 500mg,QD,7\~10 days
223393617|NCT06956664|OTHER|Conventional Physiotherapy|Standard physical-agent package delivered three times weekly for 6 weeks: 20 min moist hot-pack (≈70 °C hydrocollator packs); 5 min continuous therapeutic ultrasound (1 MHz, 1 W cm-²); 20 min biphasic TENS (100 Hz, 100 µs). Initiated 2 weeks after the caudal epidural steroid injection (CESI).
224013708|NCT05438017|DEVICE|Dreem 3 System vs PSG|Dreem 3 System to be worn by each participant while undergoing in-lab sleep study with PSG.
223393618|NCT06956664|BEHAVIORAL|Aerobic Exercise Programme|Supervised treadmill walking three times weekly for 6 weeks: 5 min warm-up at \~40 % HR\<sub\>max\</sub\>; 10-25 min load at 55-80 % HR\<sub\>max\</sub\> (5 % weekly progression); 5 min cool-down. Heart-rate telemetry and Borg CR-10 used to titrate intensity. Starts 2 weeks post-CESI.
223393619|NCT06956664|BEHAVIORAL|Core-Stabilization Exercise Programme|Phased lumbopelvic motor-control regimen three times weekly for 6 weeks: Phase I isolated transversus abdominis/multifidus activation with pressure biofeedback; Phase II functional co-contraction with limb movements in quadruped, sitting, standing; Phase III dynamic tasks on Swiss-ball/BOSU with resistance. Progression requires pain ≤ 3/10 VAS and flawless technique. Begins 2 weeks post-CESI.
223393620|NCT05445830|PROCEDURE|High-Intensity-Interval-Exercise|Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
223548409|NCT05496361|DEVICE|Solitaire FR Revascularization Device|Revascularization Device using the Mechanical thrombectomy technique for recanalization of an occlusion large vessel in the brain
223548410|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
223548411|NCT03666988|DRUG|GSK3368715|GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
223548412|NCT01014806|BIOLOGICAL|Influenza VLP Vaccine|Single dose; 0.5mL
223548413|NCT01014806|BIOLOGICAL|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
223548414|NCT00876252|BIOLOGICAL|IC43|
223548415|NCT00876252|DRUG|Placebo|NaCl
224013709|NCT02501798|DRUG|Methylphenidate|Drug: Methylphenidate
224013710|NCT02501798|DRUG|Placebo|Drug: Placebo
224013711|NCT02571595|BEHAVIORAL|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
223548416|NCT02881775|DEVICE|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
223548417|NCT02881775|DEVICE|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
223548418|NCT00451061|DRUG|Alfuzosin|
223548419|NCT00451061|DRUG|Tamsulosin|
223548420|NCT04902430|PROCEDURE|Power chain and Crimpable hook for En-Masse Retraction|"Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 212 g per side) extending between the crimpable hooks and the miniscrew"
223548421|NCT04902430|PROCEDURE|T- Loop|Closing retraction T-loops will be fabricated using 0.017 x 0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine
223548422|NCT01166347|DEVICE|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
223548423|NCT01166347|DEVICE|Control LVAD|Any FDA-approved LVAD for destination therapy.
223548424|NCT00560300|DRUG|1 alpha D2|Vitamin D sterol
223548425|NCT00560300|DRUG|1,25 dihydroxy vitamin D3|Active vitamin D sterol
223548426|NCT00560300|DRUG|Sevelamer HCl|Phosphate binder
223548427|NCT00560300|DRUG|Calcium Carbonate|Phosphate binder
223548428|NCT05325203|BIOLOGICAL|Ongericimab|Administered by subcutaneous injection
223548429|NCT05325203|DRUG|Placebo|Administered by subcutaneous injection
223548430|NCT05925348|DIAGNOSTIC_TEST|Patients with cardiopulmonary bypass|"Due to the observational design of the study, no study-specific interventions are performed.~Blood samples are measured to analyze blood-levels of endotoxin"
223548431|NCT03566472|DIAGNOSTIC_TEST|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
223548432|NCT01654939|DRUG|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
223730796|NCT03957304|DRUG|Dexmedetomidine|Intranasal dexmedetomidine
223730797|NCT05812612|DRUG|ursodeoxycholic acid|To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
223730798|NCT00256893|DRUG|ropinirole|
224013712|NCT03245151|DRUG|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
224013713|NCT03245151|DRUG|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
224013714|NCT04079751|PROCEDURE|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
224013715|NCT04079751|PROCEDURE|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
224013716|NCT02611336|DRUG|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 3 months
224013717|NCT06308003|PROCEDURE|Anterior hip arthroplasty|Anterior hip arthroplasty
224013718|NCT02245737|DRUG|Lanabecestat|Administered orally
224013719|NCT02245737|DRUG|Placebo|Administered orally
224013720|NCT00936741|DRUG|mifepristone|Mifepristone 300 mg to 1200 mg once daily
224013721|NCT06062290|DEVICE|Electromyography (EMG)|Measurement of the compound muscle action potential for the assessment of neuromuscular function
224013722|NCT06062290|DEVICE|Kinemyography (KMG)|Measurement of the muscle velocity for the assessment of neuromuscular function
224127944|NCT02422927|DIETARY_SUPPLEMENT|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
224127945|NCT02422927|OTHER|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
224127946|NCT02422927|OTHER|Placebo|placebo
223393621|NCT05445830|PROCEDURE|Moderate-Intensity-Continuous-Exercise|Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
223393622|NCT05445830|PROCEDURE|Strength training|Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
223393623|NCT05445830|PROCEDURE|Baseline assessment|Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
223393624|NCT05445830|PROCEDURE|1 year follow-up|Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
223393625|NCT04291612|OTHER|Physical exam|Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.
223393626|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken twice a day for 24 weeks
223393627|NCT06467435|DRUG|Kamuvudine-9|96 mg tablets taken once
223393628|NCT06377020|BEHAVIORAL|PACT2|Behavioral lifestyle intervention
223393629|NCT06167291|RADIATION|Arm 1- Ipsilateral|Given by I-RT
223393630|NCT03968900|BEHAVIORAL|Sleep restriction condition|On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition (4 hours, TIB \[Time in Bed\]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
223393631|NCT03968900|BEHAVIORAL|Sleep extension condition|sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, (TIB); 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham Highlands Hospital sleep unit at 7:00 p.m. and do an initial CO breathe test and fill out study questionnaires and a timeline follow-back procedure Participants will monitored for smoking withdrawal. Every 2 hours, participants to fill out various questionnaires. Participants will repeat the same conditions as the first night. After a two-week washout, participants will be crossed over to the alternate sleep extension/restriction condition.
223393632|NCT05317728|DEVICE|BAL-FAIOL IOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
223393633|NCT05317728|DEVICE|Monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
223393634|NCT05317728|PROCEDURE|Cataract surgery|Phacoemulsification with a clear cornea incision
224127947|NCT04997889|COMBINATION_PRODUCT|Artificial salivary containing cumin and ginger extract|The artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the artificial salivary containing cumin and ginger extract will be stopped for 7-10 days. After that, the artificial salivary containing cumin and ginger extract will be used 2 g/time (3 times/day) into the mouth for 3 days.
224127948|NCT04997889|OTHER|Commercial artificial salivary|The commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 6 days. Then, the commercial artificial salivary will be stopped for 7-10 days. After that, the commercial artificial salivary will be used 2 g/time (3 times/day) into the mouth for 3 days.
224127949|NCT02624401|DRUG|Dexmedetomidine|Intravenous infusion
223393635|NCT06799650|DRUG|Gammora®|Gammora® SC + Tenofovir/3TC + darunavir+ritonavir
223393636|NCT06369012|DRUG|Mefenamic acid 500 mg|To compare the effectiveness of mefenamic acid versus tranexamic acid in the management of abnormal uterine bleeding.
223393637|NCT06544525|OTHER|Physical therapy|The intervention will be physical therapy standard of care.
223393638|NCT03696654|PROCEDURE|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
224127950|NCT02624401|DRUG|Propofol|Intravenous infusion
224127951|NCT02624401|DRUG|S-ketamine|Intravenous infusion
223393639|NCT05411991|DIAGNOSTIC_TEST|UNa measurement after intravenous loop diuretic bolus|Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.
223548433|NCT02822053|PROCEDURE|US-guided laser ablation for refractory neoplasms|
223548434|NCT05807373|PROCEDURE|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice)
223548435|NCT01634217|BIOLOGICAL|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
223393640|NCT05411991|DRUG|Intravenous acetazolamide 500 mg OD|Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (\>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.
223548436|NCT05522283|DIAGNOSTIC_TEST|Stool and blood CMV PCR|Quantitative stool CMV-PCR (CMV R-gene® kit, limit of detection 450 copies/ml, Biomerieux, France) and quantitative serum CMV-PCR (Cobas® CMV, limit of detection 150 copies/ml, Roche, USA) were collected within seven days of colonoscopy.
223393641|NCT05411991|DRUG|Intravenous bumetanide TID|An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
223393642|NCT05411991|DRUG|Oral chlorthalidone OD|In case of hypernatremia (\>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
223393643|NCT05411991|DRUG|Intravenous canrenoate 200 mg OD|At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), intravenous canrenoate 200 mg OD is provided. Canrenoate is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L or if serum potassium levels are \>5.5 mmol/L. If canrenoate is administered, oral mineralocorticoid receptor drugs are temporarily withhold until switch to oral diuretic treatment.
223393644|NCT05411991|OTHER|Maintenance infusion|A maintenance infusion with 500 mL dextrose 5% and 3 g MgSO4 is started at an infusion rate of 20 mL/h upon the moment of first protocol-specified administration of intravenous diuretics and continued until switch to oral diuretic therapy. 40 mmol KCl is added if serum potassium levels are \<4 mmol/L. In case of hypotonic hyponatremia with serum sodium concentration \<130 mmol/L, dextrose 5% will not be provided and MgSO4 will be administered in 50 mL of normal saline (NaCl 0.9%).
223393645|NCT05411991|DRUG|Oral potassium supplements|If serum potassium levels are \<3.5 mmol/L at any time during the administration of intravenous diuretics, oral potassium supplements are provided as needed to keep serum potassium levels \>4 mmol/L
223393646|NCT05411991|OTHER|Intravenous hypertonic saline|In case of hypotonic hyponatremia with serum sodium concentration \<125 mmol/L, a bolus of 150 mL hypertonic saline 3% is administered and repeated OD if necessary, until sodium levels are ≥135 mmol/L.
223548437|NCT05088044|OTHER|training porogram|training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration
223548438|NCT05000307|DIAGNOSTIC_TEST|Blood sample|Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
223548439|NCT03558646|OTHER|There is no intervention planned (observational)|There is no intervention planned (observational)
223548440|NCT03541499|BIOLOGICAL|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10\^7 colony forming units (CFU) or 10\^9 CFU.
224013723|NCT04064593|DIAGNOSTIC_TEST|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
224013724|NCT06106932|DRUG|Leuprolide Acetate|Leuprolide acetate was administered 3 months before laparoscopy in women of group A.
224013725|NCT04268290|COMBINATION_PRODUCT|Single incision plus one port laparoscopic surgery|SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.
224013726|NCT06631950|OTHER|Educational intervention|The educational intervention group will be provided with information that should allow them to correctly answer questions on fecundity knowledge and fecundity risks factors. The fecundity information will be provided through a short animated educational video (3 minutes) that will be sent out digitally. The control group is not receiving such information.
224013727|NCT06274372|DEVICE|flow controlled ventilation|effects of flow controlled ventilation
223548441|NCT03541499|OTHER|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
223548442|NCT03554018|DRUG|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
223548443|NCT03554018|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
223548444|NCT03554018|BEHAVIORAL|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health\_Info/Back\_Pain/default.asp)
223548445|NCT03554018|DRUG|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
224013728|NCT06274372|DEVICE|volume controlled ventilation|effects of volume controlled ventilation
224013729|NCT00875498|PROCEDURE|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
224013730|NCT00875498|PROCEDURE|sham iTBS|iTBS placebo (placebo coil)
224013731|NCT04620304|BIOLOGICAL|UB-421 SC(dB4C7C22-6 mAb)|The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
224013732|NCT02830360|DRUG|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
223548446|NCT04103476|COMBINATION_PRODUCT|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
223393647|NCT05411991|OTHER|Switch to oral diuretic therapy|"Upon complete resolution of clinical signs of fluid overload with UNa \<80 mmol/L, intravenous diuretics are switched to an oral schedule including:~* Loop diuretics with dose \& frequency at the discretion of the treating physician~* Chlorthalidone 50 mg if added for diuretic resistance at any time during the intravenous diuretic phase~* Spironolactone 25 mg or another equivalent mineralocorticoid receptor antagonist"
223548447|NCT04103476|OTHER|Placebo|Placebo
223548448|NCT05698303|DRUG|Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)|CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
223548449|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
223548450|NCT06340230|DRUG|SHR-A1811 Injection + Adebrelimab Injection|Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
223548451|NCT06340230|DRUG|SHR-A1811 Injection|Drug: SHR-A1811 Injection
223548452|NCT01224886|BEHAVIORAL|Physical activity|Supervised exercise intervention
223548453|NCT02894398|DRUG|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
223548454|NCT02894398|DRUG|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
223548455|NCT02894398|DRUG|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
224013733|NCT02830360|PROCEDURE|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
223393648|NCT05411991|OTHER|Usual AHF care|It is recommended to administer an intravenous loop diuretic dose at least BID (or through continuous infusion), with the aim of achieving a urine output 3-5 L per day until the patient is considered in an optimal volume status as is recommended by current guidelines.
224013734|NCT05444218|PROCEDURE|Open flap debridement|After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
224127952|NCT02624401|DRUG|Sevoflurane|Inhalation
224127953|NCT02624401|DRUG|Placebo|Intravenous infusion of saline (Ringer's Acetate)
223548456|NCT02894398|DRUG|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
223548457|NCT02894398|DRUG|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
223548458|NCT03961802|OTHER|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
223548459|NCT01402869|DRUG|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
223548460|NCT01402869|DRUG|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
223548461|NCT01154452|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223548462|NCT01154452|OTHER|Laboratory Biomarker Analysis|Correlative studies
223548463|NCT01154452|OTHER|Pharmacological Study|Correlative studies
223548464|NCT01154452|DRUG|Vismodegib|Given PO
223548465|NCT05949918|BEHAVIORAL|Stage-matched interventions|"The study intervention will be designed based on each Stage of Change of the Transtheoretical Model of Change in that participants in each Stage of Change will receive the intervention that matches the Stage of Change they would be in.~A 12-week interval would be considered between administering the intervention and posttest 1 and the same interval would be used between posttest 1 and posttest 2."
223548466|NCT04892719|DIAGNOSTIC_TEST|Fluoroscopic chest imaging with 4Dx technology software analysis|4DxV utilizes a novel software algorithm to analyze data from cinefluoroscopy images to calculate regional ventilation and pulmonary function changes. Cinefluorography uses a fluorescent screen with X-rays to make real-time moving images the lung described below. This is the same x-ray fluoroscopy that is used in clinical imaging and the fluoroscopic imaging time is approximately 1 minute leading to an effective radiation dose of 2 mSv (200 mRem). This is significantly lower that the radiation exposure from a standard chest CT. Fluoroscopy images are acquired at each of five views for approximately enough time to capture at least one complete, continuous breath. The subject is required to remain in the same position for each of the five fluoroscopy imaging sequences. These images will be analyzed by the novel 4Dx technology to provide the 4Dx lung function analysis report.
223730799|NCT01650623|BEHAVIORAL|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
223548467|NCT04073901|OTHER|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
223548468|NCT02835703|PROCEDURE|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
223548469|NCT06396702|OTHER|EASE-SOT|EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys) using electronic patient reported outcome measures (ePROMs). The intervention duration is 8 weeks. Based on individual preference, EASE-psy may be administered in person or virtually via Microsoft Teams. Based on individual preference, participants may receive ePROMs either on tablets or to their personal electronic devices via email, while at the hospital ward and in clinics, ensuring easy access and administration of these tools.
223548470|NCT01904929|OTHER|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
223548471|NCT00572104|OTHER|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
223548472|NCT00572104|OTHER|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
223548473|NCT03455894|DEVICE|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
223730800|NCT01650623|BEHAVIORAL|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
224127954|NCT04160468|DRUG|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
224127955|NCT04160468|DRUG|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
223730801|NCT02281461|DEVICE|Male circumcision using a non-surgical device|Male Circumcision
223730802|NCT04061915|BEHAVIORAL|Infographic Intervention|The intervention consists of participants viewing an HIV self-testing infographic.
224013735|NCT05444218|OTHER|Er: YAG irradiation|An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
223730803|NCT04061915|BEHAVIORAL|Paper-based HIV self-testing information|The control arm will read paper-based HIV self-testing instructions.
223730804|NCT06434844|PROCEDURE|Auricular acupunctures|After disinfection of the external ear with 75% alcohol wipes, 018x 13 filiform needles (Mocm International Limited) will be used to perform the auricular acupunctures at the relaxation point, tranquilizer point and master cerebral point at the left and right external ears.
223730805|NCT06434844|PROCEDURE|Sham acupunctures|The auricular acupoints of finger, shoulder and tonsil will be targeted instead. These points are also located at the external ear and comparable to those in the intervention group. The external ear will be disinfected with 75% alcohol wipes. Auricular acupunctures with 018x 13 filiform needles (Mocm International Limited) will be carried out at the finger point, shoulder point and tonsil point of the left and right external ears.
224013736|NCT05444218|DRUG|Metronidazole|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
224013737|NCT05444218|DRUG|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
224013738|NCT05444218|DRUG|Placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
224013739|NCT05689203|DRUG|QLS1128|dose 1
224013740|NCT05689203|DRUG|QLS1128|dose 2
224127956|NCT01187901|DRUG|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
223548474|NCT04524221|DRUG|PTG-100|PTG-100, 600mg taken twice daily in capsule form for 42 days
223548475|NCT04524221|DRUG|Placebo|Placebo taken twice daily in capsule form for 42 days
223548476|NCT02847169|DEVICE|filcon IV1 toric lens|toric contact lens
223548477|NCT02847169|DEVICE|ocufilcon D toric lens|toric contact lens
223730806|NCT04855097|DIAGNOSTIC_TEST|BVA-100|The BVA-100 is a medical device that calculates human blood volume using the method of tracer dilution. The device utilizes a tracer of human serum albumin tagged with iodine-131 to measure injected intravascularly and a series of timed blood draws. The amount of tracer in each blood draw is used to calculate the unknown blood volume. Data inputs come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and tracer transudation rate are reported, with statistics showing the quality of the results.
224013741|NCT05689203|DRUG|Placebo|Placebo
224013742|NCT00442273|DRUG|Umbilical cord serum eyedrops|
224013743|NCT00442273|DRUG|Autologous serum eyedrops|
224013744|NCT03250923|DRUG|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
224127957|NCT01187901|DRUG|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
223548478|NCT01837680|DRUG|Insulin|
223548479|NCT00788060|DRUG|Everolimus (RAD001)|5mg per day, continuously
223548480|NCT00788060|DRUG|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
223548481|NCT03128983|DEVICE|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
223548482|NCT01412125|OTHER|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
223548483|NCT01412125|OTHER|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
223548484|NCT02990715|DEVICE|C-Scan System|"1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure"
223393649|NCT03598426|DRUG|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
223393650|NCT05613985|OTHER|Usual Care alone|"Usual Care is defined as the following procedures to apply to the foot ulcer, carried out in the order in which they are listed:~Sharp debridement (the debridement will be performed only if non-vital tissue is present), Mild washing of the whole ulcer with physiological solution, Treatment with topical antiseptic containing Iodopovidone, Covering with iodopovidone impregnated gauze while the ulcer is clinically infected (PEDIS ≥ 2) \[If, during the study, PEDIS is \< 2, the ulcer will be covered with nonadherent paraffin gauze\].~Treatment 2 times a week (4 treatment weeks, 8 treatments)."
223548485|NCT02075086|DRUG|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
223548486|NCT06709079|DRUG|Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)|Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
223548487|NCT06718764|DEVICE|Neurosteer's single-channel EEG monitoring device|"Neurosteer device will be attached to participants forehead and readings will be collected for the duration of their NSICU stay.~Neurosteer auditory stimulation will be done 3-4 times a day to coincide with RASS and 1-2 times a day to coincide with CAM-ICU. The research team will correlate collected hourly RASS and CAM-ICU assessments with Neurosteer derived signals and parameters."
223548488|NCT06713031|PROCEDURE|cannulated compression screws + iliac bone graft|"Using cannulated compression screws + iliac bone graft technique to treat old femoral neck fractures"
223548489|NCT06713031|PROCEDURE|DCS + medial support plate + iliac bone graft|"Using DCS + medial support plate + iliac bone graft technique to treat old femoral neck fractures"
223548490|NCT03672214|PROCEDURE|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
223548491|NCT03672214|PROCEDURE|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
223548492|NCT00775255|DRUG|clarithromycin 250 mg/5 mL powder for oral suspension|
223548493|NCT02348190|OTHER|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
223548494|NCT01852643|PROCEDURE|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
223548495|NCT01852643|PROCEDURE|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
223548496|NCT03874767|BEHAVIORAL|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
223548497|NCT03199833|DEVICE|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
223730807|NCT04111484|OTHER|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
223730808|NCT04111484|OTHER|Saline|Placebo
224013745|NCT02593721|PROCEDURE|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
224127958|NCT01187901|DRUG|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
224127959|NCT01187901|DRUG|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
223393651|NCT05613985|DEVICE|System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care|"System VULNOFAST® plus / VULNOLIGHT®: VULNOFAST® plus sterile solution, in combination with a red light source VULNOLIGHT®. VULNOFAST® plus and VULNOLIGHT® will be used in accordance with their Instructions for Use (IFU) and User Manual.~Treatments 2 times a week (4 treatment weeks, 8 treatments of Usual Care and 8 treatments of system VULNOFAST® plus / VULNOLIGHT®)."
223393652|NCT00947362|OTHER|Electro-thermo-coagulation|
223393653|NCT00947362|DRUG|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
223393654|NCT00947362|DRUG|saline|physiological saline
223393655|NCT06526949|BEHAVIORAL|Reiki|Reiki application was performed by a responsible researcher who has a Level 3 (Reiki Master) certificate. To prevent contamination between patients and to provide a suitable environment during the intervention, a curtain-screen system was used in the intensive care unit, and patients were fitted with earplugs to provide a quiet environment during the procedure. During the treatment (total time 30 minutes) the Reiki practitioner gently placed his/her hands on or above the patient's head and eyes, upper body from neck to pelvic area, arms and legs (standard Reiki hand positions). The application was limited and performed once due to the rapid changes in intubation time, intensive care unit stay and hemodynamic stability.
224127960|NCT01912768|DEVICE|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
224127961|NCT01912768|DEVICE|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
223393656|NCT06526949|OTHER|(Sham Reiki)|n the placebo (sham Reiki) group, treatments were performed by sham practitioners (not involved in the study) who had no experience with energy work and did not believe in energy therapy. In order to ensure blinding during the sham application, the patients were given the same hand movements as the experimental group for the same duration. In order not to distract the patients during the application, the area was separated with a curtain and screen system and earplugs were used. The sham practitioner gently placed his hands on or above the patient's head and eyes, upper body from the neck to the pelvic area, arms and legs for 30 minutes. The application was simulated in a manner similar to standard Reiki hand positions.
223393657|NCT03886584|OTHER|Monitoring source test|Internal- and external-monitoring correct responses and inversions
223393658|NCT05731128|DRUG|Dupilumab|injection solution subcutaneous
223393659|NCT05731128|DRUG|Placebo|injection solution subcutaneous
223393660|NCT04827862|DRUG|Pembrolizumab|pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy
223393661|NCT05918861|DRUG|Dalcetrapib|Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
223393662|NCT05918861|DRUG|Placebo|matching placebo tablets
223393663|NCT04515875|BEHAVIORAL|Daily Engagement Meaningful Activity (DEMA)|This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.
223393664|NCT04515875|BEHAVIORAL|Information Support (IS)|This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
223393665|NCT05925023|DRUG|Sirolimus|Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
223393666|NCT05956340|BEHAVIORAL|Research interview|Research interview to capture speech data with high quality cardioid headset microphone
223393667|NCT06346132|DEVICE|Virtual reality application|In this group, virtual reality will be added to usual care
223393668|NCT03175302|BEHAVIORAL|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
223393669|NCT05954559|DRUG|Elucirem (Gadopiclenol)|Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.
224127962|NCT01912768|DEVICE|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
224127963|NCT03765801|DRUG|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
224127964|NCT03765801|DRUG|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
223548498|NCT03199833|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Arm Cycle ergometer with or without FES~* Neuro Muscular Electrical Stimulation~* Upper limb exercises using augmented or virtual reality environment~* Occupational therapy exercises~* Constraint induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training~* Mirror therapy~* Writing training~* Chemodenervation Therapy"
223548499|NCT02668341|OTHER|non-interventional|non-interventional survey study
223548500|NCT04698239|DEVICE|LASER MILESMAN 445 NM|Laser application
223548501|NCT02610972|DEVICE|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
223393670|NCT05689736|BEHAVIORAL|Motivational Enhancement|"Motivational Enhancements (ME) will include three features:~1. Personalized change plan. Parents will describe their intervention goals, motivation for participation, steps they are willing to take to meet those goals, as well as potential barriers to engagement and strategies to try to overcome such barriers. We will display the change plan to remind parents of their personalized responses. ME will also integrate participants' change plan responses into intervention content.~2. Assessment feedback. We will provide norm-referenced feedback for each selected parenting measure after the week 1 assessment. For simplicity, feedback will graphically categorize the parent or child in 3 categories per outcome: red (≥90th %ile), yellow (70-89th %ile), and green (\<70th %ile).~3. Modified, personalized SMS text nudges. Parents will receive 2 weekly personalized SMS messages based on their change plan responses."
223548502|NCT05095298|DRUG|Vaccine, COVID19|It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
223548503|NCT04317144|BEHAVIORAL|Web-based follow-up programme.|Participants who are randomized to the intervention-group will have access to web-based follow-up for one year. The programme includes short films of equipment used in intensive care e.g. ventilator, suction-device. Continous renal replacement therapy , central vein catheter among other things. About 15 short films with icu-staff talking and show how the equipment works and alarm sounds. The intervention also includes lectures about how the ICU works and what problems a critically ill patient can suffer from post-icu. There is a built-in conversation tool in the programme that can be used both by the participant and the staff who works with the follow-up programme. Questionnaires is sent out 2,6 and 12 month post-icu. The questions include PTSD, Depression, QoL and physical activity. At the end of the study, participants are sent a questionnaire asking for their experience using the web-based follow up programme.
223548504|NCT04317144|BEHAVIORAL|No follow-up|"Participants randomized to no follow-up receive e-questionnaires 2, 6 and 12 months post-ICU care. The questions are the same as in web-based follow-up intervention group and include PTSD, Depression, QoL and physical activity."
223548505|NCT03919565|DRUG|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
223548506|NCT03919565|DRUG|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
223548507|NCT03919565|DRUG|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
223548508|NCT02108886|DRUG|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
223548509|NCT02108886|DRUG|Placebo|empty capsule filled with sugar
223548510|NCT02108886|OTHER|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
223548511|NCT01539447|DRUG|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
223548512|NCT01539447|DRUG|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
224127965|NCT03505567|DEVICE|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
223548513|NCT01235663|BEHAVIORAL|advisory support|regular advisory support to the prolong breast-feeding period
224013746|NCT02593721|DRUG|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
224013747|NCT00171041|DRUG|valsartan|
224013748|NCT00229437|DRUG|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
224013749|NCT00229437|DRUG|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
224127966|NCT03505567|DEVICE|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
223548514|NCT00894777|OTHER|Clinical record review|
223548515|NCT06012630|DIAGNOSTIC_TEST|Ultarsound|Median nerve evaluation of participants with ultrasound
223548516|NCT04593368|OTHER|FMT|oral dosing of fecal microbiome from allogeneic donor, 0.5-2 g/kg of recipients weight
224013750|NCT00229437|DRUG|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
224013751|NCT00229437|DRUG|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
224127967|NCT02884817|DRUG|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
223548517|NCT02587832|DEVICE|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
224127968|NCT02884817|OTHER|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
224127969|NCT02884817|OTHER|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
224127970|NCT03948659|PROCEDURE|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
224127971|NCT00849979|BEHAVIORAL|Questionnaire|Day 1 MDASI-GI Questionnaire
224013752|NCT04410640|OTHER|survey|Members chosen for this study group are general surgery residents. A quintet with stations composed of normal pancreaticobiliary anatomy, common bile duct tumor, stony cholecystitis, pancreatic head cancer and cholelithiasis was assembled for the study. Each station contained CT, 3D-STL images and 1:1 solid models of cases. Each imaging method associated with the scenarios of the quintet is observed by the residents of the study. An explanatory assessment measure is being used as data collection method where the perception of each imaging method is being evaluated based on their effectiveness in problem identification as well as their efficiency in diverse diagnosis and pre-surgery organization. Participants' perception of residency training was evaluated with a multi-entry survey. The focus of the survey, which was applied by our team was by domains, self determined decision-making, diverse diagnosis, academic scholarship, and scientific appraisal.
223393671|NCT05689736|BEHAVIORAL|Simplification|We will follow recommendations of research on improving the readability of patient-directed text (e.g., fewer, shorter, less complex words, minimizing colons, semicolons, and decimal points). We will employ the Dale-Chall Readability (DCRI) score, which was developed for health education materials and, compared to other readability metrics, has higher correlations with comprehension. The target DCR score is 7 (8th grade reading level). We will avoid lower DCR scores because moderate levels of complexity enhance, attention, absorption, satisfaction, and ultimately engagement.
223393672|NCT05689736|BEHAVIORAL|Gamification|"Gamification will include four features:~1. Game-like graphical environment (e.g., avatars to represent the participant).~2. Digital rewards. Parents will receive points and badges for completing intervention activities.~3. Leaderboard. A leaderboard will be used to activate competitive motives and social referencing. The leaderboard will display the points/badges of the participant relative to 4 other actual or simulated anonymized parents who are at a similar point in the intervention; their number of points and badges will be determined by those of the participant.~4. Modified, personalized SMS text nudges. SMS text nudges will alternate between Core content (e.g., reminder to complete a module) and reminders about game features such as badges and standings."
224013753|NCT06226675|PROCEDURE|PENG Block|To apply local anesthetic under psoas tendon
224013754|NCT06226675|PROCEDURE|LFCN block|to apply local anesthetic around lateral femoral cutaneous nerve
223393673|NCT05689736|BEHAVIORAL|Low Engagement Nudges|SMS text nudges will be sent to participants who have fallen behind in completing specific intervention tasks within a given time window; e.g., failing to log-in to the next module by a predetermined date, timed to program enrollment or in a prespecified number of days since completing the previous module.
223393674|NCT05689736|BEHAVIORAL|Essentials for Parenting Toddlers and Pre-schoolers (EFP)|"All parents will receive the Core intervention content, including text, demonstrations (videos and vignettes), and interactive activities (e.g., skill-building), and comprising five modules: Communicating with Your Child; (2) Giving Directions; (3) Creating Structure; (4) Using Discipline and Consequences; and (5) Using Time-out. The Core intervention will be augmented with more prescriptive behavioral skills practice exercises and SMS text nudges to remind participants to complete intervention modules.~All conditions will be housed on Westat servers accessible through any device that can use the Internet, including computers, tablets, and smartphones. Westat has extensive technical capacities for web programming/hosting."
223393675|NCT06484790|DRUG|NW-301V|TCR-T T cell targeting KRAS G12V mutation
223393676|NCT06484790|DRUG|NW-301D|TCR-T T cell targeting KRAS G12D mutation
223393677|NCT05096273|BEHAVIORAL|ReACT|ReACT is a novel cognitive behavioral treatment and is a PNES intervention that targets sense of control and catastrophic symptom expectations
223393678|NCT05655546|OTHER|Access to Cue Health COVID-19 Remote testing and treatment for COVID-19|Participants will receive at home COVID-19 test for themselves and others in their household.
223393679|NCT06072612|BIOLOGICAL|SV-BR-1-GM|SV-BR-1-GM is an experimental, allogeneic, whole cell breast tumor cell line stably transfected with the CSF2 gene (encoding GM-CSF) to secrete GM-CSF in vivo to consequently augment dendritic cell activity
223393680|NCT06072612|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent with indications for treatment of malignant diseases including breast cancer. Cyclophosphamide (Cytoxan) 300 mg/m2 I.V., single dose, will be given to patients assigned to the SV-BR-1-GM. Cyclophosphamide will be administered 2-3 days prior to SV-BR-1-GM inoculations.
223548518|NCT02587832|DEVICE|NCPAP|Bubble CPAP System.
224013755|NCT00509691|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
224013756|NCT00509691|GENETIC|polymerase chain reaction|
224013757|NCT00509691|OTHER|diagnostic laboratory biomarker analysis|
224013758|NCT00509691|OTHER|flow cytometry|
224013759|NCT00509691|OTHER|immunologic technique|
224127972|NCT00849979|OTHER|Interview|Open-ended, audiotaped interviews
224127973|NCT06100471|OTHER|Observational study|Observational study in different tissues in identifing new genetic markers related to endometriosis disease
224127974|NCT03758378|OTHER|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
224127975|NCT03611933|OTHER|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
224127976|NCT00040833|PROCEDURE|complementary or alternative medicine procedure|
224127977|NCT00040833|PROCEDURE|pain therapy|
223548519|NCT02560220|BIOLOGICAL|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
224013760|NCT03299998|PROCEDURE|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
224013761|NCT03299998|PROCEDURE|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
224013762|NCT01534377|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
224127978|NCT00470353|DIETARY_SUPPLEMENT|calcium carbonate|
224127979|NCT00470353|DIETARY_SUPPLEMENT|cholecalciferol|
224127980|NCT00470353|OTHER|immunohistochemistry staining method|
223393681|NCT06072612|DRUG|Interferon infiltration of the inoculation site|Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
223393682|NCT06072612|DRUG|Retifanlimab|Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
223393683|NCT06072612|DRUG|Treatment of Physician's Choice|Patients in the TPC arm of the study will be treated with one or a combination of the following: carboplatin, taxanes, capecitabine, gemcitabine, vinorelbine or eribulin in accordance with the investigators and institutional standard of care. For HER2+ patients, a HER2-targeted agent of the physician's choice can be part of TPC.
223393684|NCT06092892|PROCEDURE|Breast Surgery (BCS or mastectomy) with TAD/SNB|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
223393685|NCT06092892|RADIATION|Adjuvant Radiation Therapy|Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
223393686|NCT03983512|DEVICE|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
223393687|NCT06162468|PROCEDURE|Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel|EUS-PCA using gemcitabine and paclitaxel
223393688|NCT03685448|DRUG|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
223393689|NCT05334381|BEHAVIORAL|Adapted-STAT ED|Patient navigator assigned to provide culturally informed motivational interviews, brief case management, psychoeducation and telephone contacts
223393690|NCT05334381|BEHAVIORAL|Standard Enhanced Treatment|Follow up phone calls following discharge from the emergency department to confirm mental health treatment referral recommendations
223393691|NCT04496479|BIOLOGICAL|LYG-LIV0001|Allogenic hepatocytes suspended in a buffered cell preservation solution with increasing number of lymph nodes being transplanted for the dose escalation. Subjects will also receive immune suppression, including tacrolimus capsules to follow the dose prescribed by the investigator as well as a short course of prednisone.
223393692|NCT06270589|BEHAVIORAL|MF-HIIT|A single bout of 20-min MF-HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s mindful intervals), and finally a 2-min cool-down.
223393693|NCT06270589|BEHAVIORAL|MF-only|A single bout of 20-min intervention mindfulness intervention that includes 5 x 90s mindful intervals separated by sitting rest
223548520|NCT03280368|OTHER|Bloodtest|
223548521|NCT03280368|OTHER|Questionnaires|
224127981|NCT00470353|OTHER|laboratory biomarker analysis|
224127982|NCT00470353|OTHER|pharmacological study|
223393694|NCT06270589|BEHAVIORAL|HIIT-only|A single bout of 20-min HIIT protocol delivered through a motor-driven treadmill. The protocol will start with a 1.5-min warm-up, then a 16.5-min main exercise (6 x 90s exercise intervals separated by 5 x 90s rest intervals), and finally a 2-min cool-down.
223548522|NCT01107639|BIOLOGICAL|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
223548523|NCT01107639|DRUG|cisplatin|"* Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5"
223548524|NCT01107639|DRUG|docetaxel|"* Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5"
223548525|NCT01107639|PROCEDURE|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
223730809|NCT05173402|DEVICE|dentoalveolar compensation method|orthopedic treatment was performed using the dentoalveolar compensation method with permanent apparatus with a palatal expanding screw
223730810|NCT05173402|DEVICE|face mask|orthopedic treatment was performed using a face mask.
224127983|NCT00470353|PROCEDURE|biopsy|
224127984|NCT04898426|OTHER|Enhanced bowel preparation instruction|Automated delivery of SMS, pre-recorded phone call, and link to an information website.
224127985|NCT01401816|OTHER|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
224013763|NCT01534377|BEHAVIORAL|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
224013764|NCT04107168|DRUG|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
224013765|NCT04107168|DRUG|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
224013766|NCT04107168|DRUG|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
223393695|NCT06270589|BEHAVIORAL|Sitting rest|Participants will sit in a comfortable chair, placed on the treadmill, while watching a HIIT video without mindfulness instructions for 20 minutes.
223393696|NCT05678647|DRUG|Sucrosomial Iron|20 capsules of Sucrosomial Iron 30 mg is given after blood donation
223393697|NCT05678647|DRUG|Iron Sulfate|20 tablets of oral iron sulphate (Duroferon®) 100 mg is given after blood donation
223393698|NCT05584826|DRUG|MDMA|On 2 separate treatment visits, participants will receive dosing of 100 mg MDMA HCl (\~84 mg MDMA) + 40 mg MDMA HCl (\~34 mg MDMA) supplement unless tolerability issues arise from the first dose or the participant declines
223393699|NCT04168125|DEVICE|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
223393700|NCT04168125|DEVICE|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
223393701|NCT06504134|DIAGNOSTIC_TEST|the Novel Esophageal Cell Collection Device|Using the novel cell collection device and the deep learning method to collect and classify esophogeal cell to identify if the participants are GERD patients
223393702|NCT01977105|BEHAVIORAL|Grow Together peer group|"Participants in this intervention will:~* Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.~* Complete an intervention video activity approximately weekly:~  * 1\. View educational videos addressing topics related to healthy infant growth~ * 2\. Create photos/videos modeling healthy behaviors and post them to the group~ * 3\. Provide and receive feedback on posts~ * 4\. Be encouraged to share information with key caregivers of their child~* Attend group party soon after enrollment, to meet peers and group leader in person.~* Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.~* Have basic program information provided to pediatrician to enhance conversation during office visits."
223393703|NCT01491568|DEVICE|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
223393704|NCT05231811|OTHER|massage|Pregnant women by the researcher; Foot massage consisting of classical massage techniques will be applied in a room in the clinic reserved for this application. During the massage; A pillow will be placed under the patient's leg and a disposable cover will be placed on the pillow. During the massage, pregnant women will be massaged with baby oil or vaseline cream. The soles of the pregnant women will be rubbed by the practitioner's fingers. The practitioner will make circular movements by applying pressure to the sole of the pregnant woman's feet with her thumb, and will apply pressure to the foot with up and down movements, using the joint protrusions on the upper surface of the hand that she has made into a fist. The heel and ankle will be squeezed between the thumb and forefinger of the researcher and kneaded and the massage will be terminated. During the application, the researcher who performs the massage will pay attention to the precautions applied in the hospital.
223393705|NCT04446169|DIAGNOSTIC_TEST|SARS-CoV 2 RNA PCR Urine|Search for SARS-CoV 2 RNA in urine through PCR
223730811|NCT00019578|PROCEDURE|Sterotactic radiosurgery|
224013767|NCT04107168|DRUG|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
224013768|NCT04107168|DRUG|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
224013769|NCT04107168|DRUG|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
224013770|NCT04107168|DRUG|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
224013771|NCT00688883|DRUG|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
224013772|NCT00670839|BIOLOGICAL|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
224013773|NCT00670839|BIOLOGICAL|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
224013774|NCT02905955|DEVICE|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
224013775|NCT02241005|OTHER|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
224013776|NCT02241005|OTHER|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
224127986|NCT03243513|OTHER|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
224127987|NCT03929588|DEVICE|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
223393706|NCT04446169|DIAGNOSTIC_TEST|SARS-CoV 2 RNA PCR Semen|Search for SARS-CoV 2 RNA in Semen through PCR
223393707|NCT04446169|DIAGNOSTIC_TEST|Semen Qualitative Analysis|Search for Semen Alterations in patients with past SARS-CoV 2 infection
223393708|NCT04446169|DIAGNOSTIC_TEST|IIEF-5 questionnaire|IIEF-5 assessment in patients with past SARS-CoV 2 infection
223393709|NCT04446169|DIAGNOSTIC_TEST|Male Sexual Health Questionnaire (MSHQ)|Male Sexual Health Questionnaire (MSHQ) assessment in patients with past SARS-CoV 2 infection
223393710|NCT04446169|DIAGNOSTIC_TEST|IPSS questionnaire|IPSS assessment in patients with past SARS-CoV 2 infection
223393711|NCT04446169|DIAGNOSTIC_TEST|SECRET questionnaire|SECRET questionnaire assessment in patients with past SARS-CoV 2 infection
223393712|NCT04446169|DIAGNOSTIC_TEST|Interleukin assessment in semen|Assessment of Interleukin presence and quantitative analysis in semen, to study if a previous inflammation/infection due to SARS-CoV 2 in testis was present
224127988|NCT03929588|DEVICE|Phoropter|Manual refraction and ETDRS chart
224013777|NCT05920460|BEHAVIORAL|Cognitive Behavioral Therapy Program|"Brief description of the Cognitive Behavioral Therapy program is given below:~* Session 1: Mutual understanding and rapprochement~* Session 2: Sleep hygiene education~* Session 3: Psychoeducation about stimulus control strategies; monitoring sleep environments, and identification of behavioral habits at bedtime, dysfunctional beliefs, and attitudes about sleep.~* Session 4: Training on relaxation techniques~* Session 5: Psycho education about depression~* Session 6: Cognitive restructuring~* Session 7: The terminating session"
224013778|NCT02366468|DRUG|ranibizumab 0.5 mg|intravitreal injection
224013779|NCT02622776|OTHER|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
224013780|NCT00873431|BIOLOGICAL|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
223393713|NCT03320343|OTHER|MRI|3D morphological MRI and diffusion tensor imaging
223393714|NCT01168232|DRUG|Ixabepilone|Given IV
223548526|NCT01107639|PROCEDURE|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
223548527|NCT05360251|DEVICE|PDL(595nm)|One subject was treated with pulsed dye laser (Vbeam platinum, 595 nm, Candela Corporation): energy dosages of 9-11 J/cm2, pulse durations of 10/20 ms, and spot size of 7 mm.
224013781|NCT04553289|OTHER|exercising into pain|the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale
224013782|NCT04553289|OTHER|exercising with no/slight pain|the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
224127989|NCT03929588|DEVICE|Autorefractor|Automated refraction
224127990|NCT04355156|DRUG|Axitinib|"* All patients randomised to this arm will receive 3mg BD, and increased at 2 weeks to 5mg BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)~* At 8 weeks, after tumour CT RECIST assessments, responders will continue monotherapy. In non-responders, those with disease progression, monotherapy can be continued if patient chooses to continue and if tolerated"
224127991|NCT04355156|DRUG|Placebo|"* All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)"
224127992|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Behavioral Counseling|
223548528|NCT05360251|DEVICE|IPL(DPL)|One subject was treated with IPL(delicate Pulsed Light, Dye-VL, Alma Lasers Corporation): energy dosages of 8.4-10.6 J/cm2, pulse durations of 10/12 ms, and spot size of 10×30 mm.
223393715|NCT01168232|OTHER|Laboratory Biomarker Analysis|Correlative studies
223548529|NCT05360251|DEVICE|IPL(M22 590)|One subject was treated with IPL(M22 590, 590-1200nm, Lumenis Limited): energy dosages of 15-18 J/cm2, pulse durations of 3-4 ms, pulse delay of 30-40 ms, and spot size of 15×35 mm.
223548530|NCT05360251|DEVICE|IPL(M22 vascular)|One subject was treated with IPL(M22 vascular, 530-650nm and 900-1200nm, Lumenis Limited): energy dosages of 9-17 J/cm2, pulse durations of 4-6 ms, pulse delay of 20-40 ms, and spot size of 15×35 mm.
223548531|NCT05923697|BEHAVIORAL|AF-EMDR|"Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol."
224013783|NCT01552603|DEVICE|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
223393716|NCT02064998|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
224013784|NCT03882541|OTHER|Music therapy|To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.
224127993|NCT01745393|BEHAVIORAL|Clinic Quality Improvement + Attention Control|
224127994|NCT03757481|OTHER|no intervention|SF-36 questionnaire , PembQoL, Villalta score ,PembQoL
224127995|NCT03591146|DRUG|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
224127996|NCT03591146|DRUG|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
223393717|NCT02064998|BEHAVIORAL|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
223393718|NCT02064998|BEHAVIORAL|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
223393719|NCT06575803|OTHER|clinical measurements and evaluation|clinical performance of single restorations fabricated for the patients from pressed and repressed ceramics
223393720|NCT02059512|PROCEDURE|Group 1|Coronary artery bypass grafting with intramyocardial administration of autologous bone marrow mononuclear cells 0.2 ml - 10 injection in the zone of blood supply LAD.
223393721|NCT02059512|PROCEDURE|Group 0|Coronary artery bypass grafting with intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD.
224127997|NCT00236639|DRUG|topiramate|
223548532|NCT04405440|BEHAVIORAL|Behavioral avoidance task|Behavioral task able to measure avoidance actions, US-expectancy, and reward-related indexes in different learning times
223548533|NCT06525480|PROCEDURE|Percutaneous pulmonary thrombectomy|Pulmonary thrombus extraction
223548534|NCT06846086|DRUG|Melatonin 10 MG|Melatonin
223548535|NCT06846086|DRUG|Placebo|placebo
223548536|NCT04245306|OTHER|computerized test for pragmatic inferences|Computerized tests
223548537|NCT05028348|DRUG|Selinexor|Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
223548538|NCT05028348|DRUG|Elotuzumab|Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.
223548539|NCT05028348|DRUG|Pomalidomide|Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
223548540|NCT05028348|DRUG|Dexamethasone Oral|Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
223548541|NCT03245242|OTHER|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
223548542|NCT03245242|OTHER|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
223548543|NCT05306665|BEHAVIORAL|ACT intervention|One day in person workshop + telephone booster
224013785|NCT03882541|DRUG|Sedation with midazolam|To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music
224013786|NCT04285203|OTHER|Educational Video Intervention|Educational videos
224013787|NCT04293692|BIOLOGICAL|UC-MSCs|0.5\*10E6 UC-MSCs /kg body weight suspended in 100mL saline containing 1% human albumin intravenously at Day1, Day3, Day5, Day7
224013788|NCT04293692|OTHER|Placebo|100mL saline containing 1% human albumin intravenously at Day 1, Day 3, Day 5, Day 7
224013789|NCT00002459|RADIATION|radiation therapy|
224013790|NCT05295420|PROCEDURE|platelet rich plasma|Injection of Platelet Rich Plasma in the female conditions that suffer from SUI
224013791|NCT03711344|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
224013792|NCT02699723|DRUG|Arsenic Trioxide|Given PO
224013793|NCT02699723|DRUG|Itraconazole|Given PO
223548544|NCT05222412|DRUG|Iptacopan|Patients receive Iptacopan
223548545|NCT06284460|DRUG|ASTX029|Given by PO
223548546|NCT06284460|DRUG|ASTX727|Given by PO
223548547|NCT06262048|DRUG|Tamsulosin Hydrochloride|2 days pre-op, day of surgery, 2 days post-op
223548548|NCT06262048|OTHER|Placebo|2 days pre-op, day of surgery, 2 days post-op
224013794|NCT02699723|OTHER|Laboratory Biomarker Analysis|Correlative studies
224013795|NCT01587027|DRUG|Aminophylline|Aminophylline dosage form-tablet dosage-500mg
224013796|NCT01587027|DRUG|Methazolamide|Methazolamide dosage form-tablet dosage-250mg
223548549|NCT03610854|DEVICE|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
223548550|NCT05318300|DIETARY_SUPPLEMENT|tested formula with fiber|formula containing fibers
223548551|NCT05318300|DIETARY_SUPPLEMENT|Control|formula without fiber
223548552|NCT05354492|OTHER|Program to Support Well-Being after Adversity|You will be asked to meet on Zoom weekly for 6 weeks with our trained program facilitators along with the other 6-10 members of the intervention group. Meetings will last approximately 75-90 minutes each, and will involve a variety of discussions and activities related to navigating the changes you may face after experiencing a difficult life event. These sessions will be audio-recorded for research purposes and to ensure that facilitators are doing a good job delivering the program.
223548553|NCT05327660|COMBINATION_PRODUCT|Quitline Treatment as Usual (TAU)|Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content).
224013797|NCT01587027|DRUG|Aminophylline and Methazolamide|Aminophylline 500mg orally and Methazolamide 250mg orally
223548554|NCT05327660|COMBINATION_PRODUCT|Remote Carbon Monoxide (CO) Monitoring|Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor.
223548555|NCT05327660|COMBINATION_PRODUCT|Incentivized Remote CO Monitoring|Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor.
223548556|NCT05176340|OTHER|Specific Thematic Nursing Care Action Modules (STNC-AM)|"The STNC-AM platform that investigators present here is an educational program that integrates education and coaching.~The nurse coaching component was based on the STNC-AM platform. This online platform can guide nurses' health education for the comprehensive care of stroke patients. Nurses can use an iPad and enter the STNC-AM platform website, where they can directly access the Care Action Module."
223730812|NCT00751751|DRUG|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
224013798|NCT04744545|BEHAVIORAL|Meru Health Program|12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
224013799|NCT04744545|DIETARY_SUPPLEMENT|Curcumin|1500mg/day curcumin plus black pepper to aid absorption
224013800|NCT01164644|DRUG|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
224013801|NCT01164644|DRUG|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
223393722|NCT02059512|PROCEDURE|Group 2|Coronary artery bypass grafting with intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells intramyocardial administration 0.2 ml - 10 injection in the zone of blood supply LAD.
223393723|NCT03605121|PROCEDURE|cardiac surgery|The relationship between body mass index or waist circumference and clinical outcome in patients undergoing cardiac surgery will be assessed
223548557|NCT01177085|BEHAVIORAL|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
223548558|NCT04599491|DEVICE|Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module'|Study patients randomized into the 'Sidestream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with sidestream etCO2 monitoring using the 'Respironics LoFlo Sidestream CO2 Module'.
224013802|NCT04083677|DEVICE|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
224013803|NCT03051789|DEVICE|Menstrual Cup|Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect \~30 ml of menstrual blood when inserted into the vaginal canal
224013804|NCT03051789|OTHER|Cash transfer|A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
224013805|NCT03051789|OTHER|Cups and Cash|Combination of both interventions, using the same interventions and implementation methods.
224013806|NCT01004055|DEVICE|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
224013807|NCT01004055|DRUG|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
223548559|NCT04599491|DEVICE|Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'|Study patients randomized into the 'Mainstream capnography' arm will receive postoperative ventilation on the ICU with INTELLiVENT-ASV with mainstream etCO2 monitoring using the 'Respironics Capnostat 5 Mainstream CO2 sensor'.
223548560|NCT01986894|DRUG|Placebo|Single oral dose of Placebo
223548561|NCT01986894|DRUG|Pomalidomide|Single oral dose of 4 mg pomalidomide
223548562|NCT01986894|DRUG|Pomalidomide|Single oral dose of 20 mg pomalidomide
223548563|NCT01986894|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
223548564|NCT02297815|DRUG|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
223548565|NCT02297815|DRUG|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
224013808|NCT01004055|DRUG|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
224013809|NCT05710159|DEVICE|iBLAD Application to monitor symptoms and quality of life by the use of pateint-reported outcomes|Development and implementation of a national multimodality application for patients with bladder cancer that builds upon knowledge from the iBLAD study.
224013810|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
224013811|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
224013812|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
224013813|NCT00504998|GENETIC|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
224013814|NCT00504998|GENETIC|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
224013815|NCT04547868|OTHER|Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
223548566|NCT01356862|DRUG|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
223393724|NCT04576507|DRUG|Active Cannabis|2.98% THC:4.91% CBD cannabis.
223393725|NCT04576507|DRUG|Placebo Cannabis|\<0.01% THC:CBD cannabis.
223393726|NCT06155656|OTHER|Pea protein concentrate|Ingestion of a soup containing 25 g of protein from pea protein concentrate
223393727|NCT06155656|OTHER|Pea protein isolate|Ingestion of a soup containing 25 g of protein from pea protein isolate
223393728|NCT06155656|OTHER|Pea protein extrudate|Ingestion of a soup containing 25 g of protein from pea protein extrudate
223393729|NCT06155656|OTHER|Whey protein|Ingestion of a soup containing 25 g of protein from whey protein
223393730|NCT06637358|BEHAVIORAL|Extended Scheduled Gradual Reduction (SGR)|The extended SGR program will allow participants additional time to reduce smokeless tobacco use until they reach zero. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
223548567|NCT01356862|DRUG|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
223548568|NCT01422941|DEVICE|CAVU Attune Device|The CAVU Attune device is used with LAGB.
223548569|NCT04013269|DEVICE|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
223548570|NCT00662831|DRUG|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
223548571|NCT00662831|DRUG|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
223548572|NCT02678962|DEVICE|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
223548573|NCT02678962|DEVICE|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
223548574|NCT02678962|DEVICE|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
223548575|NCT02678962|DEVICE|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
223548576|NCT02678962|DEVICE|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
223548577|NCT02678962|DEVICE|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
223548578|NCT05274412|OTHER|hypotension prediction index(HPI)|Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
223548579|NCT05274412|OTHER|ordinary goal-directed hemodynamic therapy|Keep pulse pressure variation \>12%; keep cardiac index \>2L/min/cm\^2; keep mean arterial pressure \> 65mmHg.
223548580|NCT02449811|DRUG|Perindopril|
223548581|NCT02449811|DRUG|Olmesartan|
223548582|NCT02449811|DRUG|Amlodipine|
223548583|NCT02449811|DRUG|Hydrochlorothiazide|
224127998|NCT04737031|OTHER|Clinician Nudge|"Investigators will use the Best Practice Alert functionality within the EMR as the conduit to the point of decision-making. Epic currently fires a BPA for each new patient presenting to ACC within the Medical Assistant check-in and vital sign workflow, requiring that medical assistants assess tobacco use status within the past 30 days and satisfy the alert with one of three possible answers. Upon opening the Epic Order tab at a patient's next visit after the screening encounter, clinicians will receive the implementation strategy, placed directly over the order interface. The clinician will be required to acknowledge or opt-out when presented with the order. Opting-out will require clinicians to acknowledge a reason for opt-out using a checklist or free text."
223548584|NCT00600106|DRUG|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
223548585|NCT00600106|DRUG|Placebo|1 mg placebo
223548586|NCT02678403|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
223548587|NCT02678403|DEVICE|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
223548588|NCT00252512|BEHAVIORAL|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
223548589|NCT00252512|OTHER|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
223548590|NCT03965104|BEHAVIORAL|Hypertension Canada Professional Certification Program: HC-PCP|The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
223548591|NCT03631771|DRUG|Iohexol|Iohexol administered intravascularly
223393731|NCT06637358|BEHAVIORAL|Quit Coach|Weekly check-ins and support will be given to this group via the quit coach interactions. The intent of this program is to reduce the number of times participants use smokeless tobacco down to zero. Participants will also receive text-based support messages.
223548592|NCT03631771|DRUG|Iodixanol|Iodixanol administered intravascularly
223548593|NCT03631771|DRUG|Iopromide|Iopromide administered intravascularly
223548594|NCT03631771|DRUG|Ioversol|Ioversol administered intravascularly
223548595|NCT04098887|RADIATION|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV\_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV\_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV\_2000 and PTV\_6670, respectively).
223548596|NCT00137488|DEVICE|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
223548597|NCT02322580|DRUG|etanercept|
223548598|NCT01734798|RADIATION|Radiation|
223548599|NCT01734798|DRUG|gemcitabine and cisplatin|
223548600|NCT01734798|OTHER|Radiotherapy and Drug|
223548601|NCT00115271|DRUG|Nutritional supplements|
223548602|NCT06549504|DRUG|AG2202T|AG2202T Single-dose
223548603|NCT06549504|DRUG|AG2202R|AG2202R Single-dose
223548604|NCT04496908|PROCEDURE|amniotomy|Artificially rupturing membranes
223548605|NCT04496908|DEVICE|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.
223393732|NCT04470518|OTHER|diagnostic algorithm|"Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).~The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache \& Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor))."
223393733|NCT03848715|BIOLOGICAL|Endotoxin|Endotoxin
223548606|NCT04496908|DRUG|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
223548607|NCT04644588|DIAGNOSTIC_TEST|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.|Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
223548608|NCT05291546|DRUG|REGN9035|Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
223548609|NCT05291546|DRUG|REGN5381|Part B: Selected doses administered by IV infusion on day 1.
223548610|NCT05291546|OTHER|Placebo|Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
223548611|NCT01780844|DRUG|ASKP1240|intravenous infusion
224013816|NCT04547868|OTHER|Decaffeinated Coffee|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of decaffeinated coffee will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
223393734|NCT03848715|BIOLOGICAL|Placebo|Placebo
223393735|NCT05310747|BEHAVIORAL|Artwork present|A virtual museum exhibit with a curated selection of artworks
224013817|NCT04547868|OTHER|Warm water|Once the surgical team deems it appropriate to begin a clear liquid diet (in the post-operative period), approximately one cup of warm water will be provided to the patient three times daily. Additives such as cream, milk, sweetener and sugar, will be permitted. The intervention(s) will continue until a change is required as per the treating team or until hospital discharge. Patients will be asked to avoid any additional caffeine intake, such as tea, for the duration of the trial. If a patient receives an NG tube or is placed NPO by the treating team, the intervention will be halted and restarted once a clear liquid diet is restarted. All other aspects of the patients' care will be at the discretion of the treating team as per their standard practices.
224013819|NCT04096053|OTHER|TEACHH|See arm/group description.
224013820|NCT02708264|DEVICE|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
224013821|NCT04797650|DRUG|CTP-543 matching placebo|Administered as tablets.
224013822|NCT04797650|DRUG|CTP-543|Administered as tablets.
224013823|NCT00446043|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
224013824|NCT01800552|PROCEDURE|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
224013825|NCT01008319|DRUG|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
223393736|NCT05310747|BEHAVIORAL|Artwork absent|The same virtual museum exhibit space as the 'Artwork present' condition but with all of the artworks removed from the walls
223393737|NCT05310747|BEHAVIORAL|Social connection high|Participants will identify a person from their life that makes them feel socially connected and then write (1) about that person and (2) an experience they had with that person that made them feel socially connected.
223548612|NCT01780844|DRUG|Tacrolimus|intravenous or oral
223548613|NCT01780844|DRUG|Mycophenolate Mofetil (MMF)|intravenous or oral
223548614|NCT01780844|DRUG|Basiliximab|intravenous
223548615|NCT01780844|DRUG|Methylprednisone|Intravenous
223548616|NCT01780844|DRUG|Prednisone|Oral
223548617|NCT00600275|DRUG|BGT226|
223548618|NCT06179810|OTHER|Baduanjin exercise|Baduanjin exercise
223548619|NCT02078050|OTHER|Phrenic nerves magnetic stimulations|
223548620|NCT01061723|DRUG|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223548621|NCT01061723|DRUG|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
223548622|NCT01811069|PROCEDURE|Head up|30˚ reverse trendelenburg body position
223548623|NCT02795624|PROCEDURE|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
223548624|NCT02795624|PROCEDURE|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
223393738|NCT05310747|BEHAVIORAL|Social connection low|Participants will identify a person from their life that makes them feel socially disconnected and then write (1) about that person and (2) an experience they had with that person that made them feel socially disconnected.
224013826|NCT01008319|DRUG|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
223393739|NCT06282029|BEHAVIORAL|Group Therapy|Acceptance and Commitment Therapy based group therapy
223393740|NCT06459284|OTHER|retrospective data analysis|Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling
223393741|NCT06166576|PROCEDURE|Ablative radioembolization|The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
223393742|NCT03249831|DRUG|Cyclophosphamide|Orally daily
223393743|NCT03249831|DRUG|Pentostatin|Intravenous
223393744|NCT03249831|DRUG|Rabbit anti-thymocyte globulin|Intravenous
223393745|NCT03249831|DRUG|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
223393746|NCT03249831|DRUG|Mycophenolate mofetil|IV or oral
223393747|NCT03249831|BIOLOGICAL|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
223393748|NCT06836440|DEVICE|Free Prescription Glasses|Participants can choose from a variety of frames, and the research team will customize the glasses according to their pupillary distance and prescription. Once the glasses are ready, they will be provided to the participants following standard usage instructions. In case of loss or damage, participants should report it to the project team and will be provided with replacement glasses as needed. Each year, participants in the intervention group will undergo an eye exam to assess changes in vision, and their glasses prescription will be updated if necessary.
223393749|NCT04982640|BEHAVIORAL|Iyengar yoga|60 minute group-classes of Iyengar yoga delivered twice weekly for 12 weeks
223393750|NCT04982640|BEHAVIORAL|Standard Exercise|60 minutes, twice weekly for 12 weeks, group-based walking program
223393751|NCT04982640|BEHAVIORAL|Nutrition Counseling|One, 30-minute session with registered dietitian
223393752|NCT03510858|OTHER|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
223393753|NCT03510858|OTHER|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
223393754|NCT04969133|DRUG|Levobupivacaine Hydrochloride 2.5 MG/ML|To compare TAP block versus local infiltration of the trocar wounds with levobupivacaine 2.5 mg/ml for post operative pain relief after laparoscopic appendicectomy in children
223393755|NCT05453578|OTHER|Placebo|0.9 percent sodium chloride
223548625|NCT02795624|PROCEDURE|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
224013827|NCT03271567|DIAGNOSTIC_TEST|Nanodisk-MS assay|Nanodisk-MS assay is a recently reported novel assay for quantitative detection of various MTB antigen peptides, using nanotechnology and mass spectrometry that showed remarkable sensitivity and specificity in diagnosing active pulmonary and extrapulmonary TB. This assay detected MTB-specific antigens, CFP-10 and ESAT-6, in patients' serum samples.
224013828|NCT02018939|OTHER|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
224013829|NCT03787927|DRUG|Autologous Platelet Transfusion (room-temperature-stored)|The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
224013830|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 5 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
224013831|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 10 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
223393756|NCT05453578|BIOLOGICAL|WRAIR-PAM-CF1|Bacteriophage combination composed of the following phages: PaWRA01Phi11, PaWRA01Phi39, PaWRA02Phi83, and PaWRA02Phi87.
223393757|NCT05167565|OTHER|MRI/DTI|High resolution MRI scans will be acquired from each infant at three time points (\~3, 6, and 12 months), while they are naturally asleep to measure the progressive myelination of the major brain fiber tracks, grey matter maturation, and to create generative models for source reconstruction of EEG sensor data.
223393758|NCT05167565|OTHER|EEG|EEG will be used to record infant brain activity during reaching and grasping actions to analyze beta activity
223393759|NCT05167565|OTHER|Eye Tracking|Infants will be presented with the experimental stimuli, which will consist of images of adults displaying different facial expressions and non-social images (e.g. a cross, a geometric pattern). This procedure is based on commonly used eye tracking paradigms designed to assess attention biases in infancy. Infant eye movement and position will be measured during stimuli presentation.
223393760|NCT05167565|OTHER|Ages and Stages Questionnaire (ASQ)|"The parents will be asked to complete the ASQ questionnaire (Developmental questionnaire).~ASQ-3 has 5 aspects: Communication, Gross motor, Fine motor, Problem solving and Personal-Social Each aspect has 6 questions, if the answer is Yes, score = 10, Sometimes = 5 and Not yet = 0. ASQ-3 average = average score of 5 aspects."
223393761|NCT05167565|OTHER|Infant Behavior Questionnaire Revised (IBQ-R)|"The parents will be asked to complete the IBQ-R questionnaire (Developmental questionnaire).~The 191-item instrument provides scores on 14 temperament scales which in turn cluster into 3 overarching factors: Positive Affectivity/Surgency, Negative Emotionality, and Orienting/Regulatory Capacity. Items are rated on a 7-point scale."
223548626|NCT03935789|BEHAVIORAL|BLAST|12-week self-guided intervention using a web-based platform
223548627|NCT01631201|DRUG|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
223548628|NCT01631201|DRUG|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
223548629|NCT02152475|DRUG|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
223548630|NCT02152475|DEVICE|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
223548631|NCT05197933|PROCEDURE|Laparoscopic resection|Laparoscopic resection for GIST at unfavorable anatomic site of stomach will be conducted
223548632|NCT05508542|BEHAVIORAL|Progressive relaxation exercises|Personal information form, Pittsburgh Sleep Quality Index (PUKI), Prenatal Anxiety Screening Scale and Pregnancy Stress Rating Scale will be applied to the pregnant women at the first interview. Afterwards, the researcher will first give training on progressive relaxation exercises to the patient in the patient's room. Afterwards, the Relaxation Exercises CD will be played and the exercises will be performed with the patient along with the CD. A relaxation exercise program will be installed on the patients' phones via the Whatsapp application. It is planned that the trainings will be applied to the patients one-to-one and will last an average of 40-45 minutes for each patient.
223548633|NCT04345029|DIETARY_SUPPLEMENT|Dietary supplement consumption|"The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days."
223393762|NCT05167565|OTHER|Beck Depression Inventory (BDI)|"The parents will be asked to complete the BDI questionnaire (Mental health questionnaire).~Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression."
223393763|NCT05167565|OTHER|The Brief Fear of Negative Evaluation Scale (BFNE)|"The parents will be asked to complete the BFNE questionnaire (Mental health questionnaire).~The BFNE measures anxiety associated with perceived negative evaluation. This scale is composed of 12 items describing fearful or worrying cognition. Scores from for each item are added up to obtain the total score."
223393764|NCT05167565|OTHER|Edinburgh Postnatal Depression Scale|"The parents will be asked to complete the Edinburgh Postnatal Depression Scale (Mental health questionnaire).~This is a set of 10 screening questions that can indicate whether a parent has symptoms that are common in women with depression and anxiety during pregnancy and in the year following the birth of a child. The total score is calculated by adding the numbers selected for each of the 10 items. If the parent's score is 10 points or above, they should speak to a health professional about those symptoms."
223393765|NCT05012098|DRUG|Bintrafusp alfa/M7824|Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
223393766|NCT05012098|DRUG|Ibuprofen|400 mg or comparable non-steroidal anti-inflammatory drugs (NSAIDs) dose up to 2 hours before and 8 hours after the start of each dose for prophylaxis of flu-like symptoms.
223393767|NCT05012098|DIAGNOSTIC_TEST|PET scan|Screening
223393768|NCT05012098|DIAGNOSTIC_TEST|CT scan|Screening
223393769|NCT05012098|PROCEDURE|Tumor tissue biopsy|Baseline, and subsequent weeks as stipulated in the study calendar.
223393770|NCT05012098|DIAGNOSTIC_TEST|Brain MRI|Baseline
223393771|NCT05012098|DIAGNOSTIC_TEST|Dotate scan|Baseline
223393772|NCT05012098|DIAGNOSTIC_TEST|PET FDG scan|Baseline
223393773|NCT05012098|DIAGNOSTIC_TEST|Nuclear bone scan|Baseline
223393774|NCT05012098|DIAGNOSTIC_TEST|EKG|Baseline
223393775|NCT05209620|DRUG|ICP-022|"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."
223548634|NCT03839849|PROCEDURE|: i-PRF|The description of this intervention has been already given before
224013832|NCT03787927|DRUG|Autologous Platelet Transfusion (cold-stored 15 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
223393776|NCT05209620|DRUG|Pemetrexed|Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).
223393777|NCT04496674|DRUG|CC-1 and Toczilizumab|Adminsitration of CC-1 and Toczilizumab
223393778|NCT04104438|DRUG|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
223548635|NCT03839849|PROCEDURE|saline|The description of this intervention has been already given before
223548636|NCT03777254|BIOLOGICAL|RC28-E|RC28-E intravitreous injection 50ul
223393779|NCT05980767|DEVICE|Temporary Peripheral Nerve Stimulation System|Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation.
224013833|NCT03787927|DRUG|Aspirin|Aspirin (325mg) will be administered the day before every transfusion.
223393780|NCT02344121|RADIATION|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
223393781|NCT03974113|DRUG|Fitusiran|Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous
223393782|NCT04971096|DIETARY_SUPPLEMENT|PS23 live|PS23 belongs to Lactobacillus paracasei group.Probiotic capsules contain 30 billion CFU (colony forming units) of PS23
224013834|NCT03787927|DRUG|Clopidogrel|Clopidogrel (600mg) will be administered the day before every transfusion.
224013835|NCT00944398|DIETARY_SUPPLEMENT|Zinc fortified food|Daily consumption
224013836|NCT00944398|DIETARY_SUPPLEMENT|Zinc supplement|Liquid supplement containing zinc sulfate
224013837|NCT00944398|OTHER|Placebo supplement|Liquid placebo supplement
224013838|NCT00944398|DIETARY_SUPPLEMENT|Non-fortified food|Non-fortified complementary food.
224013839|NCT04950829|DEVICE|Conventional brackets|These brackets are used in a conventional way, where the orthodontist used to apply elastic parts to engage the arch to the slot of the brackets.
224013840|NCT04950829|DEVICE|Self-ligating brackets|These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.
224013841|NCT04950829|PROCEDURE|Self-Ligating Brackets with flapless corticotomy|"These brackets do not need to use elastic parts to engage the arch to the brackets. The orthodontist can use sliding caps to open and close the slots of these brackets.~Flapless corticotomy will be performed in order to stimulate acceleration in tooth movement during the orthodontic treatment in this group only."
224013842|NCT05925361|PROCEDURE|Laparoscopic pedicled single flap peritoneum vaginoplasty|After the perineal part of the operation, in which the vaginal cavity will be dissected, a laparoscopy will be started. During laparoscopy, a single flap peritoneum will be harvested. The flap will be checked for adequate blood supply. The flap will be brought down to the (neo) vaginal cavity and sutured around a dilatator cylinder wise.
224013843|NCT05436197|BEHAVIORAL|PLAYshop Program|The intervention includes: 1. Educational Training - the 60 min virtual/hybrid workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be provided with physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
224013844|NCT01423032|DRUG|bendamustine|100 mg/m² iv, day 1+2, q4w
224013845|NCT01423032|DRUG|Fludarabine|25 mg/m² iv, days 1-5, q4w
224013846|NCT00465920|BEHAVIORAL|modified cognitive behavioural therapy (mCBT)|
224013847|NCT04100876|GENETIC|Global DNA methylation will be quantified in the DNA samples by colorimetry|Global DNA methylation will be quantified in the DNA samples by colorimetry
224013848|NCT01473004|DEVICE|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
223548637|NCT03171519|BEHAVIORAL|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
223548638|NCT03171519|BEHAVIORAL|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
224127999|NCT04737031|OTHER|Patient Nudge|Patients will receive a message sent through myPennMedicine following establishment of their smoking status (at the screening encounter). In all cases, the message will include information specific to the upcoming appointment with the oncology clinician.
223548639|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
223548640|NCT01285570|DRUG|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
224013849|NCT06338930|OTHER|Remote monitoring|The intervention group will enroll in the remote monitoring programme. In the standard of care patients visit the outpatient clinic every six months. Patients in the control group will remain in the six-monthly follow-up programma, whereas patients in the intervention group will only visit the outpatient clinic two-yearly. The latter group will be monitored remotely via questionnaires, calprotectin analysis (using CalproSmart) and blood analyses. An IBD nurse will evaluate all incomming data and undertake action if necessary.
224013850|NCT00703937|DRUG|Ferric Carboxymaltose (FCM)|
224013851|NCT00703937|DRUG|Standard Medical Care (SMC) for the treatment of IDA|
224013852|NCT03084341|PROCEDURE|Neuromuscular Electrical Elongation|Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
224013853|NCT03084341|PROCEDURE|Proprioceptive Neuromuscular Facilitation|Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
223393783|NCT04971096|DIETARY_SUPPLEMENT|PS23 heat-treated|The PS23 heat-treated probiotic capsule contain 30 billion of PS23 cells.
223393784|NCT04971096|DIETARY_SUPPLEMENT|Placebo|The placebo capsule contains microcrystalline cellulose.
223393785|NCT06793696|OTHER|Nurse prompt|Nurse prompt to complete COWS
223393786|NCT06793696|OTHER|Provider prompt|Provider prompt to use EMBED CDS
223393787|NCT06793696|OTHER|Patient facing materials|Patient materials provided at discharge from ED
223393788|NCT06793696|OTHER|EMBED|Original EMBED CDS
223393789|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg orally once a day
223393790|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg\*2 orally once a day
223548641|NCT01285570|DRUG|5% dextrose in water|Placebo
223548642|NCT00692614|DRUG|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
224013854|NCT03789448|OTHER|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
224013855|NCT03862001|BEHAVIORAL|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
224013856|NCT04661800|OTHER|Sniffin's stick test|The sniffin's stick test is a three-part test consisting of smelling odor pens: 1) determining a detection threshold, 2) discriminating ability, 3) ability to identify odors. It lasts about 30 minutes, is achievable in the room.
224013857|NCT00370305|DRUG|rosiglitazone|89 mg BID for 8 weeks, orally
224013858|NCT04365023|DRUG|platinum chemotherapy|First line platinum chemotherapy
224013859|NCT04484103|OTHER|Assessment of the diagnostic performance of the PI-RADS score (as a stand-alone) and of the RPCRC for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in 251 patients.|"The following features will be retrieved from the CRFs of the patients included in the MRI-FIRST trial: age, DRE findings, PSA level, prostate volume, maximal PI-RADS score; the history of biopsy will be set to a default value of none since all patients included in the MRI-FIRST trial were biopsy naïve.~Then, the RPCRC will be used to calculate two different risks: the risk of detectable prostate cancer and of significant prostate cancer (ISUP ≥2) at subsequent biopsy.~The PI-RADS score (as a stand-alone) and the risks predicted by the RPCC will be compared to the results of the prostate biopsy performed during the MRI-FIRST trial.~Throughout the study, the version 2 of the PI-RADS score will be used."
224013860|NCT00964093|DEVICE|Silver Alginate|(Algidex ™)
224013861|NCT04220697|OTHER|electroencephalography (EEG)|recording of resting state EEG using 64 surface electrodes
224013862|NCT04220697|OTHER|questionnaires|Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
224013863|NCT04220697|OTHER|high frequency electrical stimulation of the forearm skin (HFS)|HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
224013864|NCT04220697|OTHER|cutaneous mechanical pinprick stimulation|Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
224013865|NCT06524206|BEHAVIORAL|The Awareness, Courage and Love Intervention|Derived from Functional Analytic Psychotherapy (FAP), the Awareness, Courage, and Love (ACL) Intervention brings the FAP principles to a broader population. In the ACL model, awareness is defined as engaging in mindful awareness of one's self (feelings, needs, values), other individuals, and the context in which interactions are taking place. Courage is defined as engaging in authentic, vulnerable self-disclosures (e.g. struggles, appreciation), and asking for what one wants and needs. Love is defined as providing empathically accurate responsiveness, including provision of safety, validation, and giving the other person what they have asked for when possible.
224013866|NCT04772898|BEHAVIORAL|Hippotherapy|The hippotherapy involves occupational therapy while being on a horse.
224013867|NCT03041051|BIOLOGICAL|PCV13|
224013868|NCT03041051|BIOLOGICAL|PPV23|
224013869|NCT02651857|DEVICE|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
224013870|NCT02651857|DEVICE|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
223393791|NCT06796868|DRUG|GW117 Tablets|GW117 Tablets 20mg\*3 orally once a day
223393792|NCT06796868|DRUG|Placebo|placebo orally once a day
223564268|NCT05666778|DEVICE|Menstrual Cup|Menstrual cups are inserted vaginally to collect menstrual flow, with some designed especially for use during intercourse, which will be used in this study. Medical devices registered with the U.S. FDA, a reusable silicon cup can last up to 10 years, is cost-effective, and has reduced environmental impact.
223564269|NCT03268954|DRUG|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
223564270|NCT03268954|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
223564271|NCT03352466|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
224013871|NCT00336089|BEHAVIORAL|exercise intervention|
224013872|NCT00336089|OTHER|educational intervention|
224013873|NCT00336089|PROCEDURE|complementary or alternative medicine procedure|
224013874|NCT00336089|PROCEDURE|fatigue assessment and management|
224128000|NCT06505057|OTHER|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation|Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation
224128001|NCT02572830|BEHAVIORAL|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
223393793|NCT04635189|DRUG|Daratumumab|Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks
223393794|NCT04635189|DRUG|Lenalidomide|Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle
223393795|NCT04635189|DRUG|Dexamethasone|Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
223393796|NCT06645327|OTHER|a change in operating room table position, which will mimic an IV fluid bolus|"Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained"
223393797|NCT03722680|DRUG|Riluzole|Riluzole during chemotherapy (oxaliplatin)
223393798|NCT03722680|DRUG|Placebo Oral Tablet|placebo
223393799|NCT06271564|DRUG|Magnetite ZnO Composite Nanoparticles|Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
223393800|NCT06271564|DRUG|Topical Placebo Gel|Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
223393801|NCT06558409|BEHAVIORAL|" Safer Still  Interactive Intervention"|An interactive intervention will be developed to help promote safe storage of firearms during the critical period immediately following high-risk care transitions.
223393802|NCT06558409|OTHER|Enhanced Usual Care (EUC):|Families randomly assigned to the control condition will receive a psychological placebo that will feature an education only website developed by NCH's web design team. This website will cover warning signs for suicide, the leading methods of suicide - so that both conditions have content that features information about firearms - and locating professional help. The control website will NOT feature these three behavioral economic strategies--namely (a) multiple suggested alternatives for means restriction, (b) requests to justify inaction regarding means restriction, and (c) normative feedback about means restriction.
223393803|NCT05653518|DEVICE|Tandem t:slim X2 with Control-IQ Technology|FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM
223393804|NCT05653518|DEVICE|Sensor augmented pump (SAP) therapy|Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
223393805|NCT05086419|OTHER|Sub-symptom threshold aerobic exercise|For the first three weeks, participants will be offered guided sub-symptom threshold aerobic exercise on a treadmill or exercise bike once a week. The remaining 2-4 sub-symptom threshold aerobic exercise workouts per. week will be on their own. Location and mode of exercise (treadmill, walking, jogging, exercise bike / bicycle, swimming, or elliptical machine) will be individually adapted to the patients experience, preferences and opportunities. The intensity of the sub-symptom threshold aerobic exercise will always be monitored using a heart rate monitor and/or ratings of perceived exertion (Borg RPE). If there still is a need for closer follow-up after the first three weeks, a physiotherapist in primary health care service will be involved under supervision from a physiotherapist (research fellow) in the project.
223393806|NCT06773910|DRUG|BMS-986489|BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.
223393807|NCT06773910|DRUG|Durvalumab|Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
223393808|NCT01490086|DRUG|RP5063|daily
223548643|NCT04120844|BEHAVIORAL|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
224013875|NCT00336089|PROCEDURE|management of therapy complications|
223564272|NCT03352466|BIOLOGICAL|BioThrax|Commercially available anthrax vaccine
223564273|NCT03352466|OTHER|Placebo|Normal saline
223564274|NCT02202915|BEHAVIORAL|Behavioral Checklist|
223730813|NCT00751751|DRUG|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
224013876|NCT00336089|PROCEDURE|pain therapy|
224013877|NCT00336089|PROCEDURE|quality-of-life assessment|
224013878|NCT03368339|DRUG|PR013 (0.045%)|PR013 topical Ophthalmic Drops (0.045%)
224013879|NCT03368339|DRUG|PR013 (0.06%)|PR013 topical Ophthalmic Drops (0.06%)
224013880|NCT03368339|DRUG|Vehicle|Vehicle
224013881|NCT00279643|PROCEDURE|Laser Hair Removal|
223393809|NCT01490086|DRUG|placebo|daily
223393810|NCT01490086|DRUG|aripiprazole|daily
223393811|NCT06018285|BEHAVIORAL|Stepped Approach to Reducing Risk of Suicide in Primary Care|Intervention consists of implementation of clinical pathway for youth suicide risk
223393812|NCT06614725|BIOLOGICAL|RSVPreF3 OA investigational vaccine|1 dose of RSVPreF3 OA investigational vaccine administered intramuscularly on Day 1 to participants in OA-RSV and Adults-AIR-RSV groups.
223393813|NCT06614725|COMBINATION_PRODUCT|Placebo|1 dose of placebo (saline solution) administered intramuscularly on Day 1 to participants in OA-Placebo and Adults-AIR-Placebo groups.
223564275|NCT03255967|BEHAVIORAL|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to person with dementia (PWD)-informal caregiver dyads through HHC
223564276|NCT03255967|BEHAVIORAL|Standard of Care|Subjects receive care through usual home healthcare assignment process.
223564277|NCT03628482|PROCEDURE|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
223564278|NCT03628482|PROCEDURE|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
224013882|NCT02436590|DEVICE|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
224013883|NCT02470910|DEVICE|Magnetic Resonance Imaging|
224013884|NCT04401852|DRUG|MgSo4|a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
224013885|NCT04401852|DRUG|Isotonic saline|equal volume of isotonic 0.9% saline over 15-20 minutes
224013886|NCT02530164|DEVICE|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
224013887|NCT02389582|DRUG|Dabigatran|Use for 5 days
224013888|NCT02389582|DRUG|Enoxaparin|Use for 5 days
224013889|NCT02516020|DRUG|Global|Embryos are cultured in single step culture from day 1 to day 5
224013890|NCT02516020|DRUG|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
224013891|NCT02947087|DRUG|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
223548644|NCT04120844|BEHAVIORAL|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
223548645|NCT02706418|PROCEDURE|Clinical Massage Therapy|
223548646|NCT01067118|DRUG|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
223548647|NCT01067118|DRUG|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
223548648|NCT00615225|PROCEDURE|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
223548649|NCT06084000|DEVICE|Drug-coated balloon (Bingo© [Paclitaxel-coated Balloon], Yinyi Ltd., China)|"* Patients treated with DCB will receive dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) for 1-3 months, followed by long-term single antiplatelet therapy (SAPT, aspirin or P2Y12 inhibitor).~* Patients with bailout stenting will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration in Drug-eluting stent Arm), and then followed by long-term SAPT."
223548650|NCT06084000|DEVICE|Drug-eluting stent|"* Patients treated with DES will generally receive DAPT for 6 months unless deemed as with high ischemic and/or bleeding risks (see special consideration below), and then followed by long-term SAPT.~* Special consideration:~  1. Patients will take additional assessment (both DAPT score and PRECISE-DAPT score) to determine their personalized duration of DAPT.~ 2. The duration of DAPT is extended to 12 months for patients diagnosed as acute coronary syndrome within 12 months.~ 3. If anticoagulation is indicated, patient will receive a short-term triple antithrombotic therapy (generally 1 to 4 weeks), followed by a variable length of dual antithrombotic therapy (oral anticoagulation (OAC) plus a single antiplatelet agent, preferably clopidogrel) and subsequent long-term OAC mono-therapy. The duration of dual antithrombotic therapy is determined by bleeding risks (HAS-BLED score) according to current guidelines."
223548651|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate venous blood sampling
223548652|NCT01020461|DEVICE|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
224013892|NCT02947087|DRUG|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
224013893|NCT01075828|DRUG|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
223548653|NCT01971684|DRUG|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
223548654|NCT01065675|OTHER|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
223548655|NCT01087983|DRUG|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
223548656|NCT01087983|DRUG|Sirolimus|Starting oral dose 1 mg daily.
223548657|NCT01087983|DRUG|Metformin|Starting oral dose 1000 mg daily.
223548658|NCT00854789|BIOLOGICAL|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
223548659|NCT02840253|DEVICE|NIRS|
223548660|NCT06221410|OTHER|Alternative teaching method: Funny Scenario-Based Education|"A humorous scenario is written and performed by students as part of this alternative educational intervention. The engaging approach facilitates both a deeper understanding of complex medical terminology and adds a sense of humor and fun to the learning process.~Approximately 5 to 10 students will participate in each small group. A group size will be determined based on the voluntary interest and willingness of the students. These dynamic teams will provide students with opportunities to collaborate, enhance peer interaction, and cultivate soft skills such as communication and teamwork, all while having fun together."
223548661|NCT06221410|OTHER|Alternative teaching method: Mind-mapping Education|As part of an alternative educational intervention, Mind-mapping Education encourages students to visually map out information, creating a graphic representation of their ideas and knowledge. Using such mind maps, students can see the connections and hierarchies in the information they are learning because they have a central idea with branches that denote related concepts, facts, and details.
223548662|NCT03153501|DIAGNOSTIC_TEST|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
223548663|NCT03783962|BEHAVIORAL|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
224013894|NCT05109182|DEVICE|Innersight3D|Innersight3D generates a virtual interactive 3D model of the CT scan.
224013895|NCT01057329|DRUG|Atomoxetine|mg according to body weight
224013896|NCT01057329|DRUG|Duloxetine|30 mg / die
224013897|NCT01057329|DRUG|Olanzapine|5mg 1 wwek and 10 mg from second week
224013898|NCT01057329|DRUG|Aripiprazole|5 mg from week 1, 10 mg from week 2
224128002|NCT02572830|BEHAVIORAL|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
223393814|NCT06005649|BIOLOGICAL|HY004|"Autologous 2nd generation bispecific CAR-T cells targeting both CD22 and CD19, single infusion intravenously.~Start Dose level: 2.00 x 10\^6/kg CAR+T-cells"
223393815|NCT05899985|COMBINATION_PRODUCT|FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System|"FerroTrace will be injected peri-tumorally during the surgeons staging endoscopy, with an MRI conducted 12h to 28 days after injection. The MRI will be blinded to the clinical team and will assess the location of the primary draining lymph nodes (sentinel lymph nodes or SLNs).~Patients will proceed to standard of care neoadjuvant therapy and/or surgery. During surgery, indocyanine green (ICG) will be used to identify draining lymph nodes. Following surgery, pathologists will use FerroMag to identify SLNs which will undergo standard H\&E assessment, and if negative ultras-staging (fine serial slice and immunochemistry)."
223393816|NCT05825404|DEVICE|Smart Ambient Bright Light (SABL)|The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
223393817|NCT05825404|OTHER|Control|Usual light.
223548664|NCT03783962|BEHAVIORAL|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
223393818|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
223393819|NCT06243666|OTHER|No intervention|No intervention was implemented.
223393820|NCT06243666|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
223548665|NCT03458325|COMBINATION_PRODUCT|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
224013899|NCT05014711|DRUG|Remifentanil|Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
224013900|NCT05014711|DRUG|Fentanyl|Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
224013901|NCT01736800|DRUG|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
223393821|NCT00533481|DRUG|MK0557|
223393822|NCT01876771|DRUG|[177]Lu-DOTA-TATE|Peptide receptor radionuclide therapy (PPRT)
223393823|NCT06406439|DEVICE|Smart Insulin Pen|During the 12-week, for basal insulin, the treatment group will input and inject the dosage using the DIA:CONN P8, using only the insulin injection and injection recording functions, same as the blind CGM period. For bolus insulin, when the carbohydrate counting is entered or the type of meal is selected into the DIA:CONN P8 application, the insulin dosage is automatically calculated and set using the entered information and other indicators. Subjects inject the insulin at that calculated dosage using the DIA:CONN P8.
223393824|NCT06406439|DEVICE|Injection of bolus insulin via conventional therapy using insulin pen|During the 12-week, the control group will use DIA:CONN P8 to manually input and inject the dosage of both basal and bolus insulin, only using the insulin injection and injection recording functions, same as the blind CGM period.
223548666|NCT05761288|BEHAVIORAL|Intraoperative microbreaks and exercises|"Intraoperative microbreaks and exercises will include standardized breaks lasting approximately 1.5-2 minutes. During these breaks, surgeons will perform a set of targeted stretches or exercises while remaining sterile. Intervention exercises include: chest and shoulder opener elbows in pockets, chin tuck, neck rotation, squat with truncal rotation (chair pose with prayer), and forward bend."
223730814|NCT04446546|PROCEDURE|Vascular access by pass using a cold stored venous allograft|Creation or surgical repair of a vascular access for hemodialysis using a cold venous allograft
223730815|NCT00070174|DRUG|asparaginase|
224013902|NCT01736800|DRUG|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
224013903|NCT04357600|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell|All research samples will be treated by Intravenous injection of allogeneic mesenchymal stem cells and hemodynamic observation will be done for 24 hours after treated. Periodic post-treatment observation will be done on 1st month, 3rd month, and 6th month after therapy. The Independent variable in this research is Child-Pugh B Cirrhosis caused by Hepatitis B, while the dependent variable is the degree of liver function damage consisting of an examination of liver function, Child-Pugh score, and MELD score.
224013904|NCT06226324|OTHER|neuropsychological test|The subjects were evaluated for memory, cognition, mood and sleep
224013905|NCT06048679|DEVICE|Endovascular pulmonary artery flow-limiting covered stent implantation|selective reduction of flow in the pulmonary arteries affected by anomalous pulmonary venous drainage using a modified flow-limiting covered stent
224013906|NCT05514041|DRUG|Varenicline solution|OC-01 nasal spray 0.03 mg
224013907|NCT05514041|DRUG|Placebo nasal spray (OC-01 Vehicle Nasal Spray)|Placebo nasal spray (OC-01 Vehicle Nasal Spray)
223393825|NCT06367231|OTHER|VibrantMinds|We are exploring the potential of computer games to reveal insights into the cognitive abilities of older adults. We developed the VibrantMinds (https://vibrant-minds.org/vibrantminds2/start) platform, featuring five games: Whack-a-Mole, Bejeweled, Mahjong Solitaire, Word Search, and Memory Game. Our evaluation focused on the usability of these games, their appeal to users, and their effectiveness in enhancing cognitive functions. The next phase of our study aims to determine whether these games can offer meaningful data on the cognitive skills of older adults.
223393826|NCT05825638|OTHER|Continuous training session|Continuous training consists of a 5 minute warm up, 5 minute cool down and 20 minutes of moderate intensity work. The workload is set at 60% of the patient's maximum power
223393827|NCT05825638|OTHER|Interval training session|Interval training consists of a 5-minute warm-up, a 5-minute cool-down and 20 minutes of alternating 60 seconds of high-intensity work (100% of the maximum power recorded in the incremental test that was carried out when the patient was admitted to the pulmonary rehabilitation department) and 60 seconds of unloaded pedalling or rest.
223393828|NCT05940181|BIOLOGICAL|XH001+ sintilimab|During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).
223393829|NCT02157935|DRUG|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
224013908|NCT00105001|DRUG|Fludarabine Phosphate|Given IV
223393830|NCT02157935|DRUG|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
223393831|NCT02157935|OTHER|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
223393832|NCT02157935|OTHER|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
223393833|NCT05831085|PROCEDURE|State-of-the-Art Percutaneous Coronary Intervention|supported by intracoronary imaging (e.g., intravascular ultrasound \[IVUS\] or optical coherence tomography \[OCT\]), intracoronary physiology (e.g., fractional flow reserve \[FFR\] or instantaneous wave-free ratio \[iFR\]), contemporary metallic drug-eluting stents (DES), guideline-directed optimal medical therapy \[GDMT\] with advanced cardiovascular and anti-diabetic medications \[e.g., a sodium-glucose cotransporter \[SGLT\]-2 inhibitors\]) in patients with type 2 diabetes and three-vessel coronary artery disease (CAD) (not involving left main)
223393834|NCT05831085|PROCEDURE|standard CABG|Coronary-Artery Bypass Grafting
223393835|NCT01406379|PROCEDURE|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
223393836|NCT01406379|PROCEDURE|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
223393837|NCT02619084|PROCEDURE|STN DBS|Bilateral STN DBS
223393838|NCT00572936|DRUG|Latanoprost|prostaglandin
223393839|NCT00572936|DRUG|Dorzolamide|carbonic anhydrase inhibitor
224013909|NCT00105001|RADIATION|Total-Body Irradiation|Undergo total-body irradiation
224013910|NCT00105001|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
223393840|NCT00572936|DRUG|Timolol|beta blocker
223393841|NCT04572503|PROCEDURE|Barbed Suture Modified Anterior Palatoplasty|Barbed Suture Modified Anterior Palatoplasty using single resorbable polydioxanone barbed bidirectional size 0 monofilament suture
223393842|NCT04527718|DRUG|Placebo|placebo as a single SC injection on Day 1;
223393843|NCT04527718|DRUG|611|611 as a single SC injection on Day 1;
223393844|NCT02739789|DEVICE|tDCS|tDCS
223393845|NCT02739789|DEVICE|Sham tDCS|Sham tDCS
224013911|NCT00105001|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
224013912|NCT00105001|DRUG|Tacrolimus|Given IV or PO
224128003|NCT02021526|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
223393846|NCT00001271|DRUG|IgG-RFB4-SMPT-dgA|
223393847|NCT01103180|DRUG|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
223393848|NCT01867918|PROCEDURE|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
223393849|NCT01867918|DRUG|Standard Chemotherapy|
223393850|NCT03659214|BEHAVIORAL|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
223393851|NCT06515119|BEHAVIORAL|Resources-Oriented Salutogenic (ROS) intervention|Participants in intervention group will receive an online ROS course via Zoom meeting, post daily salutogenic recordings and comments on Facebook. A closed Facebook group will be created to deliver resources booklet, zoom meeting links, as well as encourage participants share their daily salutogenic recording, give comments and thumps-up by group members.
223393852|NCT01804179|OTHER|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
223393853|NCT01804179|OTHER|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
223393854|NCT01804179|OTHER|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
223393855|NCT01804179|OTHER|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
224013913|NCT00105001|DRUG|Mycophenolate Mofetil|Given PO
224013914|NCT00105001|DRUG|Sirolimus|Given PO
224013915|NCT00253084|DRUG|IPX054 200 mg|IPX054 containing 50 mg carbidopa and 200 mg levodopa
224013916|NCT00253084|DRUG|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
224013917|NCT00253084|DRUG|IPX054 Placebo|Placebo to match IPX054 200 mg
224013918|NCT00253084|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
224013919|NCT05560438|DEVICE|Tyromotion Amadeo and Armeo Senso|Robot assisted rehabilitation for arm- and hand function with Tyromotion Amadeo and Armeo Senso
224013920|NCT02143752|BEHAVIORAL|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
224013921|NCT02143752|BEHAVIORAL|Quit Line|see arm
224013922|NCT03475277|DRUG|Ketamine|Acute administration
224128004|NCT04953650|BEHAVIORAL|Intermittent fasting|The intervention group is required to perform intermittent fasting for two days. The intermittent fasting method for this group will mimic the Sunnah Muslim fasting; they are allowed to consume food and calorie water without restriction in between dusk and dawn. During the five ad libitum days, they are allowed to have a variety of foods and drinks. Subjects will be informed about healthy food choices; choosing low-fat meat and dairy options, increasing fruit and vegetable intake.
224128005|NCT04953650|OTHER|No intervention|The control group will receive education training at the baseline as well, regarding blood pressure and nutrition. They will have usual exercise prior to the intervention. Furthermore, the group will have equal health education through health promotion leaflets which have been issued by the ministry of health.
223393856|NCT01804179|OTHER|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
223393857|NCT01727752|PROCEDURE|Decompression|
223393858|NCT02201537|DEVICE|renal echography|"Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
223548667|NCT04199065|OTHER|Good Practice Guidelines implementation|Implementation of Good Practice Guidelines on the framework of the Best Practice Spotlight Organization in Spain (CCEC® / BPSO®), that allows a standardized methodology for providing care and registering indicators.
223548668|NCT04614012|OTHER|treated with hyperimmune plasma|administration of hyperimmune plasma at day 1 and based on clinical response on day 3 and 5
223548669|NCT03339310|DEVICE|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
223548670|NCT02584062|PROCEDURE|no-touch fluid-air exchange|
224013923|NCT01579279|DRUG|ABT-652 6 mg|6 mg capsules
223548671|NCT02584062|PROCEDURE|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
224013924|NCT01579279|DRUG|ABT-652 12 mg|12 mg capsules
224013925|NCT01579279|DRUG|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
224128006|NCT00240630|DRUG|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
224128007|NCT00240630|DRUG|placebo|placebo to match
224128008|NCT01924910|DIETARY_SUPPLEMENT|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
224128009|NCT01924910|DIETARY_SUPPLEMENT|Placebo|
224128010|NCT01613014|DRUG|ABT-436|Target dose - 400mg BID
224128011|NCT01613014|DRUG|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
223548672|NCT01142076|DRUG|Xinju Xiaogao Prescription|treatment group
223548673|NCT01142076|DRUG|placebo|Therapeutic dose of 10%
224013926|NCT01579279|DRUG|Placebo|Placebo capsules
224013927|NCT01579279|DRUG|Duloxetine|Duloxetine capsules
224013928|NCT00272675|DRUG|Chlorhexidine gluconate (drug) vs placebo|
224013929|NCT03323073|OTHER|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
224013930|NCT02355054|DRUG|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
224128012|NCT01218412|BEHAVIORAL|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
223393859|NCT00696215|DRUG|placebo|Placebo 1 mg once a day
223393860|NCT00696215|DRUG|rasagiline|1mg
223393861|NCT05729737|DIAGNOSTIC_TEST|Contrast-enhanced ultrasound(CEUS)|CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in pancreatic tumors, it is safe and widely used in liver and pancreatic disease.
223393862|NCT04468685|DRUG|Ondansetron|Interperitoneal administration in the gall bladder bed
223393863|NCT04468685|DRUG|Normal saline|Interperitoneal administration in the gall bladder bed
223393864|NCT01722578|DRUG|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
223393865|NCT01722578|DRUG|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
223393866|NCT01570478|DRUG|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
223548674|NCT02956746|BIOLOGICAL|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
223548675|NCT02956746|BIOLOGICAL|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
223548676|NCT02956746|BIOLOGICAL|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
223730816|NCT00070174|DRUG|busulfan|
223730817|NCT00070174|DRUG|cyclophosphamide|
223730818|NCT00070174|DRUG|cyclosporine|
224013931|NCT02230098|OTHER|Remote Ischemic Conditioning|
224013932|NCT05839392|BIOLOGICAL|Biological characterization of AML with MECOM or atypical 3q26 rearrangements|Peripheral blood and bone marrow withdrawal
224013933|NCT05377437|OTHER|Natural Language Processing|Natural Language Processing: classification and regression tasks.
224128013|NCT06376214|DRUG|Dratumumab / Hyaluronidase Injection [Darzalex Faspro]|Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.
224128014|NCT06376214|DRUG|Pomalidomide 4 MG|Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.
224128015|NCT06376214|PROCEDURE|autologous stem cell transplantation (ASCT)|"The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~."
223393867|NCT01570478|DRUG|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
223393868|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
224013934|NCT05734352|OTHER|Questionnaire|Completion of the patient reported experience measurements (PREMs) questionnaire
224013935|NCT02877329|BEHAVIORAL|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
224013936|NCT02630602|DIETARY_SUPPLEMENT|Functional goat cheese|60 g per day during 12 weeks
224013937|NCT02630602|DIETARY_SUPPLEMENT|Control cheese|60 g per day during 12 weeks
224128016|NCT01117688|PROCEDURE|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
223393869|NCT06165887|OTHER|No intervention|This is an observational study, no intervention will be implemented.
223393870|NCT05396898|DRUG|LCP-tacrolimus|Prophylaxis of transplant rejection in liver and kidney allograft recipients
223393871|NCT05396898|DRUG|twice-daily tacrolimus|Prophylaxis of transplant rejection in liver, kidney or heart allograft recipients
223393872|NCT04581993|DIETARY_SUPPLEMENT|Super Cereal - wheat soya blend with sugar|Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.
223393873|NCT04581993|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement-medium quantity (LNS-MQ)|Children will receive LNS during 6-23 months of age.
223393874|NCT04581993|BEHAVIORAL|Social and behavior change communication (SBCC)|SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.
223393875|NCT05855200|BIOLOGICAL|Dostarlimab|Dostarlimab will be administered.
223393876|NCT05855200|DRUG|CAPEOX|CAPEOX will be administered.
223393877|NCT05855200|DRUG|FOLFOX|FOLFOX will be administered.
223393878|NCT03098212|OTHER|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
223393879|NCT05941312|PROCEDURE|autologous products|After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
223393880|NCT01008358|BIOLOGICAL|CP 675,206|
224013938|NCT04580342|DRUG|oral Ivabradine|Ivabradine group will receive ivabradine 5mg PO in the evening and 1 hour before anesthetic induction
224013939|NCT04580342|DRUG|oral Propranolol|propranolol group will receive propranolol 10 mg PO in the evening and 1 hour before anesthetic induction.
224013940|NCT05909852|DRUG|ABP 501-HCF|Participants will receive a single-dose SC injection of ABP 501-HCF.
224013941|NCT05909852|DRUG|ABP 501-LCF|Participants will receive a single-dose SC injection of ABP 501-LCF
224013942|NCT01983254|BEHAVIORAL|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
224128017|NCT00462020|DRUG|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
224128018|NCT00462020|DRUG|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
223393881|NCT05925465|PROCEDURE|Maxillary and mandibular nerve block|receive bilateral combined maxillary and mandibular nerve block
223393882|NCT05925465|OTHER|Control|not receive any nerve block
223393883|NCT05965375|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
223393884|NCT06487793|BEHAVIORAL|Enhanced Insomnia Coach|The intervention combines the Insomnia Coach app with additional brief alcohol intervention to facilitate behavior change for both drinking behavior and insomnia symptoms. Insomnia Coach contains multiple components of CBT-I (e.g., stimulus control, cognitive restructuring, relaxation training, sleep hygiene/psychoeducation, monitoring of sleep via journals). The brief alcohol intervention content added to the CBT-I app is based on CBT skills for moderate drinking, delivered in a motivational enhancement style, and has demonstrated efficacy among young adults and veterans (e.g., correcting perceived norms, use of protective behavioral strategies, challenging expectancies).
223393885|NCT06487793|BEHAVIORAL|Sleep hygiene comparator|Content is based on sleep hygiene practices, but without additional CBT-I content featured in the experimental condition. There is also not brief alcohol intervention content in the control condition.
223393886|NCT03321682|OTHER|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
223393887|NCT03321682|OTHER|Strength Training|Exercises carried out using weights and involving the main muscle groups.
223393888|NCT05229094|DEVICE|Eva Nexus|Eva Nexus vitrectomy device
223393889|NCT02561429|PROCEDURE|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
223393890|NCT00000929|DRUG|Nonoxynol-9|
223730819|NCT00070174|DRUG|cytarabine|
224013943|NCT01983254|OTHER|education program|web-based, ICU-specific education program
224013944|NCT06169683|DEVICE|Lyric4|Lyric4 Hearing instrument use
224013945|NCT06502912|OTHER|no intervention|no intervention
224013946|NCT03211754|DIETARY_SUPPLEMENT|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
224013947|NCT04337892|DEVICE|Standard of Care4|The current standard of care for surgical planning for the participating investigator surgeon is to use Zeiss Veracity Surgical, so this same method will be used for the surgery actually performed on participating patients.
224013948|NCT01954966|DRUG|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
224013949|NCT01954966|DRUG|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
223393891|NCT04621344|DIAGNOSTIC_TEST|Guided bronchoscopy and/or endosonography|Endoscopic procedures aimed at sampling of intrathoracic lymph nodes or pulmonary lesions
223393892|NCT01207180|OTHER|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
223393893|NCT01207180|OTHER|Satisfaction survey|Patients will be given a satisfaction survey.
223548677|NCT02956746|BIOLOGICAL|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
223393894|NCT01207180|OTHER|Control group --- no intervention|Control group
223393895|NCT02378129|DRUG|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
223393896|NCT02378129|DRUG|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
223393897|NCT02493660|DEVICE|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
223548678|NCT02327585|BEHAVIORAL|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
223548679|NCT02039765|DRUG|Brimonidine tartrate|
224013950|NCT04591431|DRUG|Erlotinib|TT arm
224013951|NCT04591431|DRUG|Trastuzumab|TT arm
223393898|NCT02493660|PROCEDURE|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
223393899|NCT01687894|DRUG|Vasopressins|Vasopressins propofol vasopressins sevoflurane
223393900|NCT01687894|DRUG|Placebo|Placebo propofol \& placebo sevoflurane
223393901|NCT01687894|DRUG|propofol|vasopressin propofol \& placebo propofol
223393902|NCT01687894|DRUG|sevoflurane|vasopressins sevoflurane placebo sevoflurane
223393903|NCT03073876|DRUG|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
223393904|NCT03073876|DRUG|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
223393905|NCT01980030|DRUG|Romiplostim|
223393906|NCT05074368|BIOLOGICAL|ChAdOx1-nCov-19 (Astra-Zeneca)|vaccine inoculation and mixed inoculation
223393907|NCT05074368|BIOLOGICAL|SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine|vaccine inoculation and mixed inoculation
223548680|NCT00820989|BIOLOGICAL|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (\~5 minutes)
223548681|NCT03663309|DIAGNOSTIC_TEST|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~* Bring 4-day food diary (attached)~* Fill symptoms and complaints questionnaire (attached)~* Provide 24 h diet recall in case a food diary absents~* Fill Biagi score questionnaire (attached)~* Perform blood test of TTG~* Provide stool and urine samples"
223548682|NCT01634230|DRUG|OCR-002|daily dose: 10 g infused over 24 hours
223548683|NCT02100254|BEHAVIORAL|behavioral intervention|View personal narrative informational video
223548684|NCT02100254|BEHAVIORAL|behavioral intervention|View fact-based informational video
223393908|NCT01847404|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
223393909|NCT01847404|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
223393910|NCT01847404|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
223393911|NCT01847404|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
223393912|NCT05147935|BEHAVIORAL|Palliative Care Consultation|In person or telehealth clinic visit with palliative care physician or nurse practitioner
223548685|NCT00460655|DRUG|GSK1358820|botulinum toxin type A
223548686|NCT00460655|DRUG|Placebo|Placebo
223548687|NCT04265248|DEVICE|Virtual Reality Headset|The subjects will wear the Virtual Reality Headset with a mobile phone inserted into it with the applications Full Dive VR and VR Ocean Aquarium 3D.
223548688|NCT04265248|BEHAVIORAL|Exercise|The subjects will perform evidence-based exercises for the neck.
223548689|NCT00454740|DRUG|solifenacin succinate|Oral
224013952|NCT04591431|DRUG|Trastuzumab emtansine|TT arm
224013953|NCT04591431|DRUG|Pertuzumab|TT arm
224013954|NCT04591431|DRUG|Lapatinib|TT arm
223393913|NCT01521650|DIETARY_SUPPLEMENT|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
223393914|NCT04552795|DRUG|3TC|12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.
223393915|NCT04435834|DRUG|Propofol or Sevoflurane|Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
223393916|NCT05718934|DRUG|Neostigmine and glycopyrrolate|See arm descriptions
224013955|NCT04591431|DRUG|Everolimus|TT arm
224013956|NCT04591431|DRUG|Vemurafenib|TT arm
224013957|NCT04591431|DRUG|Cobimetinib|TT arm
223393917|NCT05718934|DRUG|Sugammadex|See arm descriptions
224013958|NCT04591431|DRUG|Alectinib|TT arm
224013959|NCT04591431|DRUG|Brigatinib|TT arm
224013960|NCT04591431|DRUG|Palbociclib|TT arm
224013961|NCT04591431|DRUG|Ponatinib|TT arm
224013962|NCT04591431|DRUG|Vismogedib|TT arm
224013963|NCT04591431|DRUG|Itacitinib|TT arm
224013964|NCT04591431|DRUG|Ipatasertib|TT arm
224013965|NCT04591431|DRUG|Entrectinib|TT arm
224013966|NCT04591431|DRUG|Atezolizumab|TT arm
224013967|NCT04591431|DRUG|Nivolumab|TT arm
224013968|NCT04591431|DRUG|Ipilimumab|TT arm
224013969|NCT04591431|DRUG|Pemigatinib|TT arm
224013970|NCT04591431|DRUG|Oncology Drugs|Standard of Care Arm
223393918|NCT05731518|DRUG|SC0245|SC0245 Quaque Die(QD) administered with a 3-day on and 4-day off schedule in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
223393919|NCT05731518|DRUG|Irinotecan|Irinotecan 80mg/m\^2 via IV administered for every 4 weeks (fixed dosing) in Day 1 Day8 and Day 15 of each cycle. One cycle is consisted of 28 days.
223393920|NCT01200446|DIETARY_SUPPLEMENT|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
223393921|NCT01200446|DIETARY_SUPPLEMENT|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
223393922|NCT06203613|RADIATION|[18F]F-H3RESCA-3A12及[68Ga]Ga-NOTA-3A12|The dose of \[18F\]RCCB6 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 MCi\]/kg, and the method of administration was intravenous push, with a single visualization administered once.
223393923|NCT04610905|BEHAVIORAL|Reducing sedentary behaviour|This group needs to download an app on their computer and their smartphone. This app will give a notification every 30 minutes to walk during 2 minutes during working hours. The participants will receive a diary to write down whether they stand up.
223393924|NCT04610905|BEHAVIORAL|Increase physical activity|This group will be asked to be more physically active. They need to be active during 150min/week. It can include walking, to ride a bike, jogging, tennis, football,... Additionnaly they need to be active in periods of at least 10 minutes. The participants will receive a diary to write down which activity they did and also for how long.
223393925|NCT04904211|OTHER|Home-based chemotherapy|To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
223393926|NCT00348127|DEVICE|Neurovision|
223393927|NCT02138877|PROCEDURE|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
223393928|NCT02138877|PROCEDURE|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
223393929|NCT04699929|DRUG|YH001|YH001 will be administered intravenously over 60minutes every three weeks (Q3W) for up to 1 years .
223393930|NCT05158673|DIETARY_SUPPLEMENT|Placebo of Cocoa flavonoids|Dietary supplement: The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks
223393931|NCT05158673|DIETARY_SUPPLEMENT|Cocoa flavonoids|Dietary supplement: Two 500 mg capsules of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours (one in the morning and one at night) for 12 weeks
223393932|NCT05116501|DIAGNOSTIC_TEST|Whole-exome sequencing|Whole Exome Sequencing (WES), as a comprehensive genetic test, will be used to identify changes in a patient's DNA that are causative or related to patient's low VWF levels.
223393933|NCT02480517|DEVICE|Ultrasound|
223393934|NCT02480517|DEVICE|Sham Ultrasound|
223393935|NCT00935116|DRUG|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
223393936|NCT02392481|PROCEDURE|Biofluid sampling|
223393937|NCT01480323|DRUG|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
223393938|NCT01480323|DRUG|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
223393939|NCT04365010|DRUG|Sodium Bicarbonate Ringer's Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
223393940|NCT04365010|DRUG|0.9% Sodium Chloride Injection|For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
223393941|NCT00268450|BIOLOGICAL|bevacizumab|"Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles"
223393942|NCT00268450|DRUG|cisplatin|Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
223393943|NCT00268450|DRUG|gemcitabine hydrochloride|Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
223393944|NCT00268450|DRUG|paclitaxel|After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
224013971|NCT04591431|DRUG|Pralsetinib|TT arm
224013972|NCT04591431|DRUG|Selpercatinib|TT arm
224013973|NCT04591431|DRUG|Talazoparib|TT arm
224013974|NCT04591431|DRUG|Tepotinib|TT arm
224013975|NCT04591431|DRUG|Alpelisib|TT arm
224013976|NCT01939665|DEVICE|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
224013977|NCT00434213|DRUG|Daytrana|Methylphenidate Transdermal System (MTS)
224013978|NCT04322838|DIAGNOSTIC_TEST|MeDALL questionnaire for allergic diseases|Questionnaire about allergic symptoms and disease
224128019|NCT04715230|BIOLOGICAL|IXT-m200|IXT-m200 binds METH with high selectivity and affinity. The product contains a murine METH-binding variable region and the constant domains of a human immunoglobulin G (IgG) 2κ. This antibody isotype was chosen because of the lower risk of immune response compared to an IgG1 or IgG3. IXT-m200 targets METH, does not rely on binding to any endogenous target for its action, and has been well-tolerated in previous clinical studies.
224013979|NCT04322838|DIAGNOSTIC_TEST|Registration of allergic symptoms|Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
224013980|NCT04322838|DIAGNOSTIC_TEST|Skin Prick Test|Diagnostic skin test for sensitization to allergens
224013981|NCT04322838|DIAGNOSTIC_TEST|Specific IgE in serum|Diagnostic test for sensitization to allergens in serum
223548690|NCT00330304|DRUG|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
223393945|NCT00268450|PROCEDURE|cysectomy|
223393946|NCT03690050|PROCEDURE|Diode 577 nm subthreshold micropulse laser|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist
223393947|NCT03690050|PROCEDURE|Standard threshold laser (532 nm laser)|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
223393948|NCT01410214|DRUG|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
223393949|NCT01410214|DRUG|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
223393950|NCT01068639|BEHAVIORAL|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
223548691|NCT00330304|DRUG|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
223548692|NCT00330304|DRUG|isoniazid|Isoniazid, 10mg/kg daily for study period
224013982|NCT04322838|DIAGNOSTIC_TEST|Nasal provocation test|Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
223393951|NCT02380339|BEHAVIORAL|Psych-Educational session and virtual reality|Psych-Educational session and virtual reality
223548693|NCT00330304|OTHER|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
223393952|NCT02380339|BEHAVIORAL|Psych-Educational and BF sessions|Psych-Educational and BF sessions
223393953|NCT05370625|DIETARY_SUPPLEMENT|Totum-854|To compare Totum-854 with Placebo on blood pressure
223548694|NCT03749928|DEVICE|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
223548695|NCT03749928|DEVICE|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
223548696|NCT05253742|OTHER|No intervention - the investigators are evaluating a new image acquisition method on an MRI scanner|The investigators will evaluate the performance of a modified MRI acquisition method against an existing method in fetal imaging in volunteers
223548697|NCT02536144|PROCEDURE|magnetic-controlled capsule endoscopy system|"1. A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~2. The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~3. While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~4. The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
223548698|NCT02536144|PROCEDURE|Colonoscopy|"1. Bowel preparation should be well done before the examination.~2. A tube with illumination and camera system would insert into colon from anus.~3. From the pictures captured by the camera ,the doctor would see the mucous of the colon."
223548699|NCT06133855|RADIATION|Pulsed electromagnetic field|The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.
223548700|NCT06133855|OTHER|traditional physical therapy program|"A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles."
224013983|NCT04322838|DIAGNOSTIC_TEST|Basophil Activation Test|Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
224013984|NCT04641377|OTHER|Multicomponent exercise intervention plus health education|The multicomponent training will be performed twice a week, on pre-established and non-consecutive days. The sessions will be held by video call (approximately 60 min) in small groups (maximum three participants) and will be taught by students of the Physical Education course, previously trained to carry out the intervention. The order of the multicomponent training will be: joint mobilization, aerobic stimulus, balance exercise, strength exercises and stretching of the main muscles used during the training session. Health education will also be carried out on one of the two days. The conversation on the topic of the week will take place during stretching.
224013985|NCT04641377|OTHER|Health Education|Once a week, participants in the health education group will be sent a message with a material with various topics related to the management of breast cancer diagnosis and physical activity. In addition, two days after this material is sent, members of ABRACE: Telehealth will have a conversation with the participants of this group, at a google meet of approximately 30 minutes, about the theme sent by message. The themes will be: depression, pain, fatigue, body image, symptoms in the arm and breast, vasomotor symptoms, neuropathy, arthralgia, sexual dysfunction, quality of life, physical activity and eating habits.
224013986|NCT02610907|OTHER|Buffer|The sleeve contains phosphate buffered saline buffer
223548701|NCT00585988|DEVICE|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
223548702|NCT00585988|DEVICE|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
223548703|NCT03723798|DRUG|SA001 Low dose|3 tablets b.i.d for 12 weeks
223548704|NCT03723798|DRUG|SA001 Mid dose|3 tablets b.i.d for 12 weeks
223548705|NCT03723798|DRUG|SA001 High dose|3 tablets b.i.d for 12 weeks
223548706|NCT03723798|DRUG|Placebo|3 tablets b.i.d for 12 weeks
223548707|NCT02366676|DRUG|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month)
223730820|NCT00070174|DRUG|daunorubicin hydrochloride|
223730821|NCT00070174|DRUG|etoposide|
223730822|NCT00070174|DRUG|gemtuzumab ozogamicin|
223730823|NCT00070174|DRUG|methotrexate|
223730824|NCT00070174|DRUG|mitoxantrone hydrochloride|
223393954|NCT05370625|DIETARY_SUPPLEMENT|Placebo|Five capsules per day to consume orally in two intakes
223393955|NCT02780258|DEVICE|Restylane Silk|
223393956|NCT02476019|DRUG|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
223393957|NCT02476019|DRUG|Placebo|Placebo administered subcutaneously
223393958|NCT02502149|BIOLOGICAL|rFVIIIFc|As per arm description
223393959|NCT05464979|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.
223393960|NCT05464979|DRUG|midazolam, fentanyl|Midazolam at 0.1mg/kg BW, fentanyl at 1ug/kg BW, rocuronium bromide at 0.6mg/kg BW was given intravenously for induction intubation; After the intubation was completed, sufentanil at 0.1 μg/kg/h was administered for analgesia, and remazolam tosylate at an initial dose of 0.075 mg/kg/h was administered for sedation, and the dose of remazolam tosylate was adjusted according to the RASS score.
223548708|NCT01527422|DRUG|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
223548709|NCT01542463|DRUG|insulin detemir|Prescribed at the discretion of the physician
223548710|NCT03351868|GENETIC|Gene-modified autologous stem cells|Infusion for 5x10\^6\~1x10\^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
223548711|NCT04406103|BEHAVIORAL|Sleepwell|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
223548712|NCT04406103|BEHAVIORAL|Empower|Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
223548713|NCT03618667|DRUG|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
224013987|NCT02610907|OTHER|Own output|The sleeve contains the subject own ileal effluent
224128020|NCT04715230|DRUG|Lorazepam|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting.
224128021|NCT04715230|DRUG|Haloperidol|Haloperidol is commonly used to treat agitation due to psychosis.
224128022|NCT05630404|DRUG|Surgical ESPB|"In group IE, transverse processes will be palpated before sewing the surgical incision by the surgery team. The local anesthetic solution will be administered after the needle contacts the transverse process and its location is confirmed by negative aspiration. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 5 mL of solution will be injected the proper injection site. Local anesthetic solution will be injected at 4 levels along the surgical incision line. A dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
223393961|NCT00005575|DRUG|Imipramine|
223393962|NCT00005575|BEHAVIORAL|Cognitive-behavior therapy|
223393963|NCT02766270|DRUG|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
223393964|NCT02766270|RADIATION|Radiotherapy|
223393965|NCT01644656|DEVICE|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
223730825|NCT00070174|PROCEDURE|allogeneic bone marrow transplantation|
224013988|NCT02610907|OTHER|simulated output|The sleeve contains simulated output
224013989|NCT06039631|PROCEDURE|Surgery|In the surgical group, patients will undergo curative surgery for laryngeal/hypopharyngeal cancer along with cervical lymph node dissection. Organ preservation surgery is recommended.
223393966|NCT04333160|DRUG|JTA-004|Patients will undergo a single intra-articular injection of JTA-004 into the knee joint
223393967|NCT04333160|DEVICE|Hylan G-F 20|Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint
223393968|NCT04333160|OTHER|placebo|Patients will undergo a single intra-articular injection of placebo into the knee joint
223393969|NCT02968576|DRUG|TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]|
223393970|NCT02968576|DEVICE|Proteus Sensor System|
223393971|NCT03855774|GENETIC|Polymorphisms|Classification of sleep disorders using 22 genetic polymorphisms
223393972|NCT02545582|DEVICE|VITARIA System|Implantable vagus nerve stimulator
223393973|NCT05755880|PROCEDURE|Intrathecal dexamethason|After general anesthesia intrathecal dexamthasone will be added
223393974|NCT02222922|DRUG|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
223393975|NCT02222922|DRUG|fluconazole|combination drug used for drug-drug interaction sub-study
223393976|NCT02222922|DRUG|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
223393977|NCT02222922|DRUG|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
223548714|NCT04712123|OTHER|relapse due to S. aureus|to find out if it is the same S. aureus in both infections
223548715|NCT02869165|DRUG|Conjugated equine estrogen topical cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
223548716|NCT02869165|DRUG|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
223548717|NCT05147753|DRUG|Moxonidine|0.6 mg moxonidine daily
223548718|NCT05706207|DRUG|HB0030 injection|0.03 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548719|NCT05706207|DRUG|HB0030 injection|0.3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548720|NCT05706207|DRUG|HB0030 injection|1 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548721|NCT05706207|DRUG|HB0030 injection|3 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548722|NCT05706207|DRUG|HB0030 injection|10 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548723|NCT05706207|DRUG|HB0030 injection|20 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
224013990|NCT06039631|RADIATION|Radiation|"In the surgical group, depending on postoperative pathology results, adjuvant radiotherapy or concurrent radiochemotherapy may be administered as deemed necessary. If postoperative pathology indicates extracapsular invasion of lymph nodes or positive surgical margins, concurrent radiochemotherapy based on cisplatin is recommended.~In the concurrent radiochemotherapy group, patients will undergo target delineation based on the scope before induction chemotherapy. Radiotherapy will be administered at a total dose of 70 Gy over 35 fractions, and concurrent chemotherapy will involve weekly administration of cisplatin at a dosage of 30 mg/m²."
224013991|NCT06039631|DRUG|Toripalimab|In the both groups, starting three weeks after the completion of radiotherapy, patients will receive adjuvant immunotherapy using a specific protocol of toripalimab at a dose of 240 mg every 3 weeks for a total of 8 cycles.
224013992|NCT00697697|DRUG|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
224013993|NCT00697697|DRUG|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
223393978|NCT01254643|BIOLOGICAL|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
223393979|NCT03010228|BIOLOGICAL|VLA15 with Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
223548724|NCT05706207|DRUG|HB0030 injection|30 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548725|NCT05706207|DRUG|HB0030 injection|40 mg/kg intravenously, every 3 weeks, till tumor progress or intolerance
223548726|NCT00465608|DRUG|propranolol|propranolol by mouth (per os)
223548727|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor|Arm A
223548728|NCT01998061|DRUG|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
223548729|NCT01009905|DRUG|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
223548730|NCT05116397|OTHER|Inspired gas|Inspired gas content
223548731|NCT00792090|OTHER|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
223548732|NCT00792090|OTHER|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
223548733|NCT03154255|BEHAVIORAL|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
223548734|NCT04105686|OTHER|Control Infant Formula|Ready to feed infant formula, feed ad libitum
224013994|NCT02034370|DEVICE|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
224013995|NCT02034370|DEVICE|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
224013996|NCT06191497|PROCEDURE|non surgical periodontal therapy|NSPT based on Guided biofilm therapy principle (EMS Dental, Switzerland)
224013997|NCT06191497|DRUG|Chlorhexidine mouthwash|0.12% chlorhexidine based mouthwash used twice a day for 15 days after therapy
224013998|NCT03743285|DEVICE|AID System|AID system
224013999|NCT03743285|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
223548735|NCT04105686|OTHER|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
223548736|NCT05406739|OTHER|Test Meals|"For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute \[60 kcal\]; 2 slices of bread \[120 kcal\] with 30 g strawberry jam \[75 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water.~After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute \[120 kcal\]; 4 slices of bread \[240 kcal\] with 60 g strawberry jam \[150 kcal\]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water."
223548737|NCT04122989|OTHER|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
223548738|NCT05810909|DIETARY_SUPPLEMENT|amorphous calcium carbonate/ Placebo|The dosage was 1000 mg calcium carbonate (400mg calcium element) per day, and placebo (calcium carbonate change to excipient)
223548739|NCT03966209|DRUG|JS001(PD-1 inhibitor)|240mg I.V. Q3W
223548740|NCT01160393|DEVICE|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
224014000|NCT05464797|PROCEDURE|Pulp therapy|partial or complete removal of inflamed pulp tissue
224014001|NCT05464797|DIAGNOSTIC_TEST|Cytokines level in pulpal blood.|Measuring the concentration of IL-8 and MMP-9 in the dental pulp during inflammation.
224014002|NCT04208945|DRUG|Colistin|500000 units of inhaled colistin three times daily for 10 days
223393980|NCT03010228|BIOLOGICAL|VLA15 without Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
223393981|NCT01598961|OTHER|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
224014003|NCT04988867|DRUG|Trofinetide|Trofinetide solution of 10-30 mL based on subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
224014004|NCT06337604|DRUG|TNP-2092 capsules|TNP-2092 capsules 300 mg twice daily(BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
224014005|NCT06337604|DRUG|TNP-2092 capsules placebo|TNP-2092 Capsules Placebo 300 mg BID : Taken with 240 mL of warm water 30 minutes (± 5 minutes) after breakfast and dinner, with a 12-hour interval between the two doses. Such administration will last 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
224014006|NCT06337604|DRUG|Rabeprazole sodium enteric-coated tablets|Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days. The last administration will be on the morning of Day 15. There will be a total of 29 doses.
224014007|NCT03454841|DRUG|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
224014008|NCT03454841|DRUG|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
224014009|NCT02435121|DRUG|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
224014010|NCT02951689|DIETARY_SUPPLEMENT|Probiotic|
224014011|NCT02951689|DIETARY_SUPPLEMENT|Placebo|
224014012|NCT00063427|DRUG|MAC-321|
224014013|NCT02407158|DEVICE|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
224014014|NCT02442089|BEHAVIORAL|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
224014015|NCT01503385|DRUG|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
224014016|NCT00912262|DRUG|Capsaicin Topical Liquid|
224014017|NCT01854138|DEVICE|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
224014018|NCT01432184|PROCEDURE|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
224014019|NCT01699503|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
224014020|NCT01990729|DIETARY_SUPPLEMENT|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
224128023|NCT05630404|DRUG|US guided ESPB|"US guided ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle 2 ml saline will be enjected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block in each side (total 40 mL).~Tenoxicam 20 mg and a dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia."
224014021|NCT02478268|DRUG|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
224014022|NCT02478268|DEVICE|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
223393982|NCT01598961|OTHER|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
223393983|NCT01598961|OTHER|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
224014023|NCT02828540|DRUG|HT047 High-dose group|HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
224014024|NCT02828540|DRUG|HT047 Low-dose group|HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
224014025|NCT02828540|DRUG|Placebo|placebo having the same appearance as HT047 Tab. 250mg
224014026|NCT00741364|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
223393984|NCT06160609|DRUG|Belantamab Mafodotin|Belantamab Mafodotin will be administered.
223393985|NCT06160609|DRUG|GSK3174998|GSK3174998 will be administered.
223393986|NCT03485144|BIOLOGICAL|TV003|Live attenuated virus vaccine-TetraVax-DV
223393987|NCT03485144|BIOLOGICAL|Placebo for TV003|Placebo
223548741|NCT01724216|DEVICE|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
223548742|NCT02770066|DEVICE|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~* Antiplatelet therapy (usually standard)~* Cholesterol-lowering drugs (usually standard)~* Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~* Smoking cessation, diet and physical activity (usually standard)"
223548743|NCT00175916|DRUG|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
223548744|NCT04808791|DRUG|Irinotecan|"Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor."
223548745|NCT04808791|DRUG|Oxaliplatin|"Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent."
223548746|NCT04808791|DRUG|TAS 102 (Trifluridine/Tipiracil)|"Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor"
223548747|NCT06553586|OTHER|Data collection|"Data of the proposed study will be collected from two main sites, namely they:~1. All emergency departments of health service outlets received the concerned victims of RTAs in Riyadh Region throughout the last five years (2019-2023). The records and documents of these hospitals will be reviewed and the researcher will determine and pick up the victims of RTAs only and record them in a relevant form designed to fit with the proposed study.~2. The General Administration of Traffic in Riyadh Region."
223548748|NCT03650413|DRUG|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
223548749|NCT02463084|OTHER|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
224014027|NCT04278222|DRUG|Anlotinib Plus Toripalimab|Anlotinib 12mg oral administration daily d1-d14, q3w; Toripalimab 240mg iv drop d1, q3w
224014028|NCT00951002|PROCEDURE|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
223548750|NCT02463084|OTHER|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
223548751|NCT01817842|BEHAVIORAL|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
223548752|NCT01817842|BEHAVIORAL|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
223548753|NCT01817842|BEHAVIORAL|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
224014029|NCT04096833|OTHER|Virtual Reality Group|Participants are from 3 to 14 years old who attend a pediatric primarey health care of the Fuensanta Health Center (Valencia) for immunization by vaccine.
223548754|NCT00648921|DRUG|Olanzapine Tablets 5 mg|5mg, single dose fasting
223548755|NCT00648921|DRUG|Zyprexa® Tablets 5 mg|5mg, single dose fasting
224014030|NCT03420170|OTHER|Graded Exercise Integrated Education|"Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~1. 3 mins. exercise and 2 mins. rest~2. Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)"
224014031|NCT03420170|OTHER|Conventional Physical Therapy|Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
224014032|NCT00345527|BEHAVIORAL|Emotion and Behaviour Regulation Treatment (EBRT)|
224014033|NCT00345527|BEHAVIORAL|Cognitive Behavioural Therapy|
224014034|NCT04488627|DIAGNOSTIC_TEST|Conventional transthoracic echocardiographic examination at the intensive care unit.|Conventional transthoracic echocardiographic examination at the intensive care unit targeted to inferior caval vein examination from different views.
224014035|NCT00831753|BIOLOGICAL|DTaP IPV HB PRP~T vaccine|0.5 mL, Intramuscular
224014036|NCT00831753|BIOLOGICAL|DTaP-HB-IPV and Haemophilus influenzae type b|0.5 mL, Intramuscular
224014037|NCT05243238|DIETARY_SUPPLEMENT|dietary supplement flavonoids|patients were allocated to receive either hesperidin, diosmin, or combination of both and the fourth group was assigned as a control group without intervention
223548756|NCT02821065|DEVICE|Remote Patient Monitoring|
223730826|NCT02325375|PROCEDURE|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
223730827|NCT03906838|DRUG|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
224014038|NCT02015455|OTHER|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
224014039|NCT02415517|BEHAVIORAL|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken \& Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
224014040|NCT02415517|BEHAVIORAL|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
224014041|NCT05108545|DRUG|Amphotericin B liposomes|Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
224014042|NCT00146120|DRUG|Idarubicin|
224014043|NCT00146120|DRUG|Cytosin-Arabinosid|
224014044|NCT00146120|DRUG|Etoposide|
224014045|NCT00146120|DRUG|All-trans Retinoid acid|
224014046|NCT02393027|DRUG|[18F] LBT-999 PET|
224014047|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Single dose
224014048|NCT04221399|DRUG|DWP16001|Tablets, Oral, Once daily, Multiple dose
224014049|NCT03138772|OTHER|This is an observational study, no intervention used.|No intervention is being used in this study.
224014050|NCT06410768|BEHAVIORAL|multistage shared decision-making program|The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.
224014051|NCT05918237|OTHER|Arctiva|A colloidal oatmeal cream designed to stimulate healing and repair of damaged tissue naturally, working with the body instead of against it.
224014052|NCT04921787|OTHER|Low Intensity|Training and education only, a low-intensity strategy inclusive of an HBOT manual, one-time live training on how to use the HBOT manual, and 7 video conference presentations.
224014053|NCT04921787|OTHER|High Intensity|Practice facilitation, a high-intensity strategy inclusive of low-intensity training, plus practice facilitation that is based in part on a program planning model. This study is a hybrid implementation effectiveness design, testing an implementation strategy while observing and gathering information on the clinical intervention's impact on relevant outcomes.
224014054|NCT02029872|DRUG|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
224014055|NCT02029872|DRUG|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
224128024|NCT05261672|DRUG|Midazolam/ bupivaciane|20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.
224128025|NCT05261672|DRUG|Bupivacain|20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
224014056|NCT02029872|DRUG|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
224014057|NCT03932669|DRUG|Nilotinib|150-300mg daily dose of nilotinib
224014058|NCT02719587|PROCEDURE|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
224014059|NCT02719587|PROCEDURE|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
224014060|NCT02719587|PROCEDURE|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
224014061|NCT00005645|DRUG|ILX-295501|
224014062|NCT02234648|DIETARY_SUPPLEMENT|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
224014063|NCT02234648|OTHER|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
224014064|NCT03412747|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
224014065|NCT03412747|DRUG|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
224014066|NCT03412747|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
224014067|NCT02081417|BEHAVIORAL|Seeking Safety|SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
224014068|NCT03469531|DRUG|Nimotuzumab|Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
223393988|NCT03998267|DEVICE|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
223393989|NCT03998267|OTHER|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
223393990|NCT02783924|DRUG|Cholecalciferol|Vitamin D preparation
223393991|NCT02783924|DRUG|Placebo|placebo
223393992|NCT03721120|DIAGNOSTIC_TEST|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~* regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~* regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~* for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
224014069|NCT03469531|DRUG|Cisplatin|Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
224014070|NCT03469531|RADIATION|external-beam radiation|Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
224014071|NCT03469531|RADIATION|brachytherapy|high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
224014072|NCT00525382|DRUG|levocetirizine dihydrochloride|
224014073|NCT01170559|DEVICE|Implantable Loop Recorder|
224014074|NCT02856854|DRUG|EMB-001|EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)
224014075|NCT02856854|DRUG|Placebo|EMB-001 matched placebo
224014076|NCT02856854|DRUG|Cocaine IV|Cocaine administered at doses of 20 and 40mg
224014077|NCT02856854|DRUG|Saline IV|Cocaine matched placebo
223393993|NCT02090088|DRUG|Not applicable- observational study|
223393994|NCT02265393|DRUG|OTO-104|
223393995|NCT02265393|DRUG|Placebo|
223393996|NCT03207776|OTHER|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
223393997|NCT03207776|OTHER|COPD Clinical Pathway|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
223393998|NCT02570620|DEVICE|Ultrasonography of the cervix|
223393999|NCT00316732|PROCEDURE|IPSS Questionnaire|
223394000|NCT00316732|PROCEDURE|EQ-5D Questionnaire|
223394001|NCT03525704|DEVICE|Saline Solution Enriched|Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution
223548757|NCT05050968|OTHER|Physical activity|Between V1 and V2 (i.e. 12 weeks), the APAG (Adapted Physical Activity Group) will participate at a physical training program, 3 sessions of 1h30 per week consisting of endurance activities (60-75% of VO2 peak) and muscle strengthening while the CG will not perform any controlled physical training program. Then, between V2 and V3, no APA (Adapted Physical Activity) program will be offered to both groups.
223548758|NCT04381416|DEVICE|SEAD treatment|up to two 30-min endometrial ablation sessions using the IUB SEAD™ device, in a hospital outpatient clinic
223548759|NCT00548626|PROCEDURE|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
224014078|NCT06086366|OTHER|[11C]DTBZ PET scan|One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
224014079|NCT06086366|OTHER|[18F]SDM8 PET scan|One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
224014080|NCT06086366|OTHER|MRI scan|One MRI scan
224014081|NCT01096485|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
224014082|NCT01096485|DRUG|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
224014083|NCT01426867|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
224014084|NCT01426867|DRUG|Brinzolamide ophthalmic suspension, 1%|
224014085|NCT01426867|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
224014086|NCT01812551|DRUG|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
224014087|NCT01812551|DRUG|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
223394002|NCT03525704|DEVICE|Saline Rinse Solution|sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
223394003|NCT05280392|OTHER|Self-administered questionnaires|4 self-questionnaires given to EHVA T02 participants: at inclusion (Q1, week 0), at the beginning of the ATI period (Q2, week 18), at the end of the ATI period (Q3, date depending on the participant) and at the end of the follow-up period of the clinical trial (Q4, week 54 at the latest)
223394004|NCT05280392|OTHER|Semi-directive individual interviews|With EHVA T02 participants (n=10 to 15): at the end of the follow-up period of the clinical trial.
223394005|NCT05280392|OTHER|Semi-directive individual interviews|With patients who refused to participate to EHVA T02 or patients not included because of negative screening results (n=10 to 15): within 21 days after the refusal or the results of the screening
223394006|NCT00116779|DRUG|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
223394007|NCT01690117|BEHAVIORAL|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer's Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
223548760|NCT00548626|PROCEDURE|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
223548761|NCT01005641|DRUG|exemestane|25 mg daily
223548762|NCT01005641|DRUG|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
223548763|NCT03697005|OTHER|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
224014088|NCT01683656|DRUG|niacin/laropiprant|
224014089|NCT01683656|DRUG|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
224014090|NCT01263665|DEVICE|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
224014091|NCT00636311|DRUG|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
223394008|NCT05368324|BEHAVIORAL|CogFun-RV|CogFun-RV intervention combines training in daily living skills, organization, task planning, time organization, emotional regulation, self-esteem and mindfulness in children and the parents. It consists of 12 sessions, each lasting 75 minutes. Parents will participate in the parental guidance and psychoeducation program with one of the two therapists assigned to the child. As it is a program of a simultaneous nature, excessive impact on the daily life of families is avoided. All sessions will be carried out individually.
223394009|NCT01087918|DEVICE|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
223394010|NCT01087918|OTHER|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
223394011|NCT01037218|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
223394012|NCT01037218|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
223394013|NCT01502319|BEHAVIORAL|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
223394014|NCT00150735|DRUG|LEVETIRACETAM|
223394015|NCT04412356|PROCEDURE|Tracheotomy|Surgical procedure to secure airway
223394016|NCT01475799|DEVICE|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
223394017|NCT03035591|DRUG|ODM-207|
223394018|NCT04249960|BEHAVIORAL|Managed transition|Young people, their family and clinicians will receive transition guidelines and will be asked to follow them as much as possible.
223394019|NCT04879992|DRUG|Esomeprazole|Proton pump inhibitor
223548764|NCT03697005|OTHER|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
223548765|NCT06147128|PROCEDURE|Emergency scenario in a simulated setting where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model|Performance of emergency scenario where open conversion is necessary due to vessel injury during robotic surgery on a dry lab model with Da Vinci robotic system
223548766|NCT04097275|OTHER|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
223548767|NCT04097275|OTHER|Withdraw of blood|"Blood will be collected in:~* 1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~* 1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~* 1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
223548768|NCT03654040|BIOLOGICAL|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
223548769|NCT03654040|PROCEDURE|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
223548770|NCT03654040|DRUG|cyclophosphamide|40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.
223548771|NCT03654040|DRUG|mesna|"Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX."
223564279|NCT00778258|BIOLOGICAL|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
223564280|NCT00778258|BIOLOGICAL|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
224014092|NCT00636311|DRUG|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
224014093|NCT00086333|DRUG|SGN-15, Docetaxel|
224014094|NCT03191773|COMBINATION_PRODUCT|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
224014095|NCT01667211|DRUG|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
224014096|NCT03254446|DRUG|TRC150094|TRC150094 Tablet 45 mg
224014097|NCT03254446|DRUG|Placebo|Matching Placebo Tablet
224014098|NCT00381615|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
224014099|NCT00381615|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
223394020|NCT04879992|DRUG|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
223394021|NCT04879992|DRUG|Tetracycline,Metronidazole|Antibiotics for H. pylori eradication
223394022|NCT04879992|DRUG|amoxicillin rifabutin|Antibiotics for H. pylori eradication
223394023|NCT05709418|BEHAVIORAL|Intensiv support for first graders in Norway|Intervention targeting early numeracy skills that are known to be important for mathematical development, focusing on counting skills, counting strategies, number knowledge, word problem solving and basic understanding of addition and subtraction
223394024|NCT00554385|DRUG|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
223394025|NCT01268553|DRUG|Treprostinil|Transition to inhaled treprostinil
223394026|NCT03711097|DRUG|Vanish XT Dental Varnish|Varnish will be applied to the front surface of the intervention upper central and lateral incisors
223394027|NCT02264769|DRUG|Carbetocin|
223394028|NCT01059838|BEHAVIORAL|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
223394029|NCT02961595|BIOLOGICAL|Oral Polio Vaccine (OPV)|Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
223394030|NCT03295838|BEHAVIORAL|Mentalization-based treatment|See Arm description
223394031|NCT02593695|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
223394032|NCT02593695|OTHER|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
223394033|NCT00576719|BEHAVIORAL|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
223394034|NCT00576719|BEHAVIORAL|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
223394035|NCT00576719|OTHER|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
223394036|NCT01651117|BEHAVIORAL|Peer Mentoring|Patients will receive peer mentoring.
223548772|NCT03654040|DRUG|everolimus|EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
223548773|NCT06280768|DRUG|SHR-2004 injection|dose 1 or dose 2 or dose 3 or dose 4 or dose 5 or dose 6
223548774|NCT01489709|DRUG|Vesicare|oral
223548775|NCT04983693|BEHAVIORAL|Dementia-friendly Worship Service|Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
223548776|NCT00000763|DRUG|TNP-470|
223394037|NCT02386319|DRUG|Melatonin|Gelatin capsules
223548777|NCT00596557|DRUG|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
223548778|NCT01963182|DRUG|Irinotecan|
223548779|NCT02802293|DEVICE|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
224128026|NCT05540470|DRUG|PART|"Chloroquine (150mgs tablets) weight-adjusted dosage ; An 8-aminoquinoline drug~1. Primaquine (PQ) (15 mg tablets): weight-adjusted dosage. Rationale: this short-course posology has been chosen to facilitate the adherence to treatment for asymptomatic individuals participating to the Module A.~   Primaquine will be administered to all participants to Module A during the induction phase of the intervention.~2. OR tafenoquine (TQ) (150 mg tablets): 2 tablets as a single dose (orally), (Rationale: the posology chosen corresponds to that used in phase III trials for the radical cure of P. vivax and the therapeutic recommendation in Brazil). Tafenoquine will only be administered during the full implementation phase to participants who do not meet exclusion criteria."
223394038|NCT02386319|DRUG|Placebo|Placebo capsules
223394039|NCT02714218|BIOLOGICAL|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
223394040|NCT02714218|BIOLOGICAL|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
223394041|NCT02714218|BIOLOGICAL|Nivolumab 1 mg/kg IV|
223394042|NCT02714218|BIOLOGICAL|Ipilimumab 3 mg/kg IV|
223394043|NCT02714218|BIOLOGICAL|Nivolumab 6 mg/kg IV|A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to \~ 480mg.
223394044|NCT01342471|BEHAVIORAL|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
223548780|NCT02802293|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
223564281|NCT00193791|OTHER|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
224014100|NCT00381615|BIOLOGICAL|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
224014101|NCT00381615|BIOLOGICAL|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
223394045|NCT01342471|BEHAVIORAL|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
223394046|NCT03295071|OTHER|Patient-reported outcomes (PROs)|Patient-reported outcomes (PROs)
223394047|NCT04086056|OTHER|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
223394048|NCT04670328|DIAGNOSTIC_TEST|not required|Diagnostic tests( hematological parameters) were assessed.
223394049|NCT01242293|OTHER|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
223548781|NCT03174626|BEHAVIORAL|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
223394050|NCT01242293|OTHER|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
223394051|NCT01242293|OTHER|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
223394052|NCT01910493|BEHAVIORAL|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
223394053|NCT02534051|OTHER|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth \& well-being, counselling about birth risks, and discussion of breastfeeding.
223394054|NCT05234801|DEVICE|DARCO™ Headed Cannulated Screw|The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.
223394055|NCT05234801|DEVICE|ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System|A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.
223394056|NCT05234801|DEVICE|ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module|A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
223394057|NCT05714592|OTHER|Blood sample|The referring haematologist will suggest that the patient participate in the study during the consultation. In these patients, the investigators will perform OGM on the cytogenetic sample
223548782|NCT03174626|OTHER|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
223394058|NCT01774760|DRUG|18F-EF5|
223548783|NCT02621476|BEHAVIORAL|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
224014102|NCT00381615|BIOLOGICAL|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
224014103|NCT00381615|BIOLOGICAL|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
223548784|NCT02621476|BEHAVIORAL|Usual care|Usual care
223548785|NCT06554561|DRUG|Pomalidomide|3-5mg d1-d14 for 4-6 cycles, every 21 days as induction/consolidation chemotherapy, Then 3-5mg d1-d14 for 12 cycles, every 28 days as maintenance treatment.
223548786|NCT06554561|DRUG|Rituximab|375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 4-6 cycles will be prescribed.
223548787|NCT06554561|DRUG|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 4-6 cycles will be prescribed.
223548788|NCT05498935|OTHER|CPB time|Cardiopulmonary bypass time
223394059|NCT01774760|PROCEDURE|Pretreatment PET/CT-scan (performed two times)|
223548789|NCT05562206|DEVICE|CGMIS (Continuous Glucose Monitoring Infusion Set)|An integrated combination CGM/insulin infusion system
223548790|NCT01884324|OTHER|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
223548791|NCT01472354|BEHAVIORAL|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
223548792|NCT03535311|PROCEDURE|Measurement of sternal-notch to umbilicus distance|"* The sternal notch to upper border of umbilicus length measurement in centimetres.~* The length of the umbilical stump in centimetres.~* The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~* The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
223548793|NCT03151122|BEHAVIORAL|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
224014104|NCT00381615|BIOLOGICAL|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
224014105|NCT05551312|OTHER|Virtual Essential Newborn Care (vENC) training|Essential Newborn Care Mobile Virtual Reality Simulation
224014106|NCT03990493|BIOLOGICAL|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV (1 injection)
223394060|NCT01730989|DIETARY_SUPPLEMENT|Estromineral Serena Plus|
223394061|NCT01730989|DIETARY_SUPPLEMENT|Estromineral|
223394062|NCT05582889|BEHAVIORAL|Fitbit Intervention|Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
223394063|NCT01268631|DRUG|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
223548794|NCT03151122|PROCEDURE|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
223548795|NCT04795115|OTHER|Auditory rhythmical cueing|Auditory rhythmical cueing intervention targeting balance and gait for 30 minutes x5 per week for 3 weeks.
223548796|NCT06367660|DRUG|Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine|In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
224014107|NCT03990493|BIOLOGICAL|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)|IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
224014108|NCT02031692|DRUG|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
224014109|NCT05137015|OTHER|Injury prevention program|"The execution of the program takes 10-15 minutes. The program will be performed in the training sessions, after the usual warm-up.~The program is based on scientific evidence that has previously shown good efficacy on injury prevention in football. The exercise categories address 7 aspects:~1. Balance~2. Core stability~3. Hamstring eccentrics~4. Glute activation~5. Plyometrics~6. Running~7. Games The games are included with the aim to increase the attractiveness of the program.~Each category contains 2 exercises and the coach is free to decide which one to choose in every training session. All exercises are organized in five or six levels with increasing difficulty (physically and cognitively)."
224014110|NCT05071196|OTHER|Facilitated Vegan Diet|Vegan boxed meal kits
224014111|NCT05071196|OTHER|Omnivorous Diet|Non-vegan boxed meal kits
224014112|NCT03606434|OTHER|Hypoxic exposure|30 minutes of intermittent hypoxia
224014113|NCT01627977|OTHER|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
224014114|NCT06072508|BIOLOGICAL|Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.
224014115|NCT02335710|DEVICE|Journey II BCS TKA|
224014116|NCT01801735|DRUG|Meloxicam Test Capsules|
224014117|NCT01435616|DRUG|Glargine|
224014118|NCT01435616|DRUG|LY2605541|
224014119|NCT01528345|DRUG|Dovitinib|Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
224014120|NCT01528345|DRUG|Fulvestrant|Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
224014121|NCT01528345|DRUG|Dovitinib Placebo|Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
223394064|NCT01268631|DRUG|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
223394065|NCT01681446|DRUG|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
223394066|NCT05603169|OTHER|High intensity resistance Exercise Training|The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks
223548797|NCT01202201|OTHER|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
223548798|NCT04165551|BIOLOGICAL|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
223548799|NCT04165551|BIOLOGICAL|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
223548800|NCT01997593|DRUG|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
223548801|NCT02775630|PROCEDURE|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
223394067|NCT05603169|OTHER|High intensity aerobic Exercise Training|The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
224014122|NCT05938140|DRUG|Nirmatrelvir/ritonavir|Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
224014123|NCT02601976|DRUG|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
224014124|NCT02601976|DRUG|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
224014125|NCT04717245|DRUG|Promestriene Vaginal|Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
224014126|NCT04717245|OTHER|Fractional CO2 LASER|"LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.~Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1"
224014127|NCT04717245|OTHER|Microablative Fractional radiofrequency|"Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.~The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.~All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third."
224014128|NCT01569672|BEHAVIORAL|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
224014129|NCT01569672|BEHAVIORAL|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
224014130|NCT01119872|OTHER|Positive End-expiratory Pressure (PEEP)|"All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment."
224014131|NCT01151410|DRUG|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
224128027|NCT05540470|DRUG|Malakit|"delivery of a sturdy, lightweight, waterproof plastic involucre that contains:~* 1 laminated sheet with illustrated instruction~* 1 complete anti-malarial treatment targeting P. falciparum, but also effective in acute forms of P. vivax with association with artemisinin derivatives~  * A blister of 24 tablets of Artemether 20 mg + lumefantrine 120 mg of generic medication~ * Two 15 mg tablets of primaquine, to be given as a single dose (145)~* 1 symptomatic treatment (analgesic, antipyretic): a blister pack of 10 paracetamol 500 mg tablets~* 3 Malaria rapid diagnostic tests (RDTs) in individual packs and with easy-to-use retractable lancets. Three tests will be included, taking into account the possibility of having one or two negative or invalid tests before returning to a distribution site for further supplies."
224128028|NCT05540470|OTHER|CROSS-SECTIONAL PRE- AND POST-INTERVENTION SURVEYS|Surveys will include the collection of a detailed questionnaire on recent malaria and mobility history, a clinical examination, and a venous blood sample
223394068|NCT02420925|PROCEDURE|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
223394069|NCT01199939|DRUG|Etravirine|400mg once daily orally for 48 weeks
223394070|NCT01199939|DRUG|Ritonavir|100mg once daily orally for 48 weeks
223394071|NCT01199939|DRUG|Darunavir|800mg once daily orally for 48 weeks
223394072|NCT06327139|DEVICE|Conventional 5 point closed face immobilisation mask.|The conventional closed face mask is a standard of care immobilization device for head and neck cancer patients which covers and immobilizes the entire anterior portion of the patients head, neck and shoulders using a semi rigid thermoplastic material.
223394073|NCT06327139|DEVICE|5 point open face immobilization mask|The 5 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face or chest. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the level of their clavicle.
223394074|NCT06327139|DEVICE|3 point open face immobilization mask|The 3 point open face mask is a type of immobilization device for head and neck cancer patients which does not cover the patients face. The device uses a semi rigid thermoplastic material and covers from the superior aspect of the patients head to the below the patients chin. The three point mask does not cover the patients shoulders and does not extend inferiorly to the level of the clavicle.
223394075|NCT03494712|DRUG|S 95010|Single administration of S 95010 in healthy volunteers
223394076|NCT03494712|OTHER|Placebo|Single administration of placebo in healthy volunteers
223394077|NCT01962610|OTHER|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
223548802|NCT00524888|PROCEDURE|suturing laceration|suturing simple lacerations of the hand
223548803|NCT00524888|PROCEDURE|bioadhesive|using bioadhesive on simple lacerations of the hand
223394078|NCT05303610|OTHER|Observational|This is a cross sectional study. The aim of the study is to evaluate the myofascial chain lines in addition to the general evaluation parameters in patients with patellofemoral pain syndrome (PFPS) and to determine whether deviations from normal in the myofascial structure have an effect on the development of PFPS.
223548804|NCT04921852|PROCEDURE|costoclavicular brachial plexus block|A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.
223548805|NCT04921852|PROCEDURE|lateral sagittal infraclavicular block|A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
223548806|NCT03043690|DIETARY_SUPPLEMENT|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
223548807|NCT03043690|OTHER|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
224014132|NCT01151410|DRUG|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
224014133|NCT00200629|PROCEDURE|Adenosine SPECT myocardial perfusion imaging|
224014134|NCT00200629|PROCEDURE|Combined adenosine / exercise SPECT myocardial perfusion imaging|
224014135|NCT01763801|DEVICE|P-Max|tip placement in correspondence to the P-Max on the ECG
224014136|NCT01763801|DEVICE|P-Submax|tip placement in correspondence to the P-Submax on the ECG
224014137|NCT01350739|PROCEDURE|intraumbilical incision|vertical, intraumbilical incision
224014138|NCT01350739|PROCEDURE|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
224014139|NCT02534506|DRUG|Urelumab|
224014140|NCT02534506|DRUG|Nivolumab|
224014141|NCT01253070|PROCEDURE|Biopsy|Undergo biopsy
224014142|NCT01253070|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
224014143|NCT01253070|DRUG|Cytarabine|Given IV
223394079|NCT04868695|PROCEDURE|1) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3|1\) Fronto-Sphenoethmoidektomie 2) Draf 2b 3) Draf 3
223548808|NCT03178825|DEVICE|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
223548809|NCT00122876|PROCEDURE|Photodynamic therapy|
223548810|NCT00122876|DRUG|Talaporfin Sodium|
223548811|NCT06312163|DEVICE|The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.|The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
223548812|NCT02678754|OTHER|No intervention required, purely observational|
223548813|NCT04163653|DIAGNOSTIC_TEST|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
224014144|NCT01253070|DRUG|Daunorubicin Hydrochloride|Given IV
224014145|NCT01253070|OTHER|Laboratory Biomarker Analysis|Correlative studies
224014146|NCT01253070|OTHER|Quality-of-Life Assessment|Ancillary studies
224014147|NCT01253070|OTHER|Questionnaire Administration|Ancillary studies
224014148|NCT01253070|DRUG|Sorafenib Tosylate|Given PO
224014149|NCT02544477|DEVICE|High-flow Nasal Cannula Oxygen (HFNCO)|
224014150|NCT02544477|DEVICE|Conventional oxygen treatment|
224014151|NCT01580254|DRUG|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
224014152|NCT01580254|DRUG|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
224014153|NCT01580254|DRUG|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
224014154|NCT03767140|PROCEDURE|acupuncture|The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
224014155|NCT06104553|DRUG|SHR-A1912; R-Chemo|SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)
224014156|NCT06104553|DRUG|SHR-A1912; R-Chemo|SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
224014157|NCT02767336|DEVICE|Blood Glucose Monitoring System.|In vitro diagnostic medical device
224014158|NCT00847080|DRUG|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
224014159|NCT00847080|DRUG|Placebo|Placebo 1 tablet per day per 2 weeks
224014160|NCT05902949|PROCEDURE|Streching Group|The Streching group will perform a conventional stretching exercise.
224014161|NCT05902949|PROCEDURE|Heel group|The heel pad group will be applied a plantar support during the months of the study.
224014162|NCT02078908|DRUG|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
224014163|NCT02078908|DRUG|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
224014164|NCT02078908|DRUG|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
224014165|NCT02078908|DRUG|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
224014166|NCT02352168|DRUG|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
224014167|NCT02352168|DRUG|Placebo|1 putt/nostril,b.i.d
223394080|NCT06261424|PROCEDURE|IMPACT - rehabIlitation prograM for sPAstiC aTaxias|The rehabilitation program will last 12 weeks and consists of three training sessions of 60 minutes per week (2 sessions in a therapy room and 1 session in an adapted pool with multiple levels of water) for a total of 36 sessions. Participants will be divided into 7 subgroups of 6 participants and each sub-group will be supervised by one physiotherapist (PT) and one physiotherapy technologist for safety considerations. It will focus on these three domains: 1) postural control; balance, trunk-limbs and multi-joints control and coordination and 3) functional mobility. Each domain contains a standardized list of exercises with different difficulty levels and specific times allocation. All exercises will be executed by the participants at each session at the appropriate difficulty level. The initial level of difficulty for each exercise will be determined by the PT based on individual results of the pre-intervention assessment and on individual performance, fatigue level and safety.
223394081|NCT05379413|DRUG|Botulinum toxin type A|Botulinum neurotoxin (BoNT) Type A injection with either OnaBoNT-A, AboBoNT-A, IncoBoNT-A
223394082|NCT04291313|DIETARY_SUPPLEMENT|Vitamin D3 (90µg)|The intervention is a higher dose of vitamin D than what is currently recommended to Danish pregnant women
223394083|NCT04291313|DIETARY_SUPPLEMENT|Vitamin D3 (10µg)|This intervention serves as a control as they get the current recommended vitamin D dose
223394084|NCT03164018|DRUG|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
223394085|NCT05951803|BEHAVIORAL|Brief Behavioral Intervention in Insomnia|Weekly intervention of 4 sessions where behavior therapy techniques are administered, such as stimulus control, sleep hygiene, sleep restriction and progressive muscle relaxation. Each session lasts 60 minutes.
223548814|NCT04163653|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
224014168|NCT01030406|DRUG|40/0mg taken first|8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
224014169|NCT01030406|DRUG|80/0mg taken first|8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
224128029|NCT05540470|OTHER|QUALITATIVE STUDY|Systematic mapping of stakeholders in the pre-intervention period Semi-structured interviews and focus groups. Observational techniques Participatory approach. Participatory design of a community-based adverse event surveillance system
224128030|NCT00277316|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
223394086|NCT00372684|GENETIC|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
223394087|NCT00372684|GENETIC|with uncomplicated malaria|with uncomplicated malaria
223394088|NCT03984864|OTHER|Exercise therapy|3-4 items from a list of 10 general exercises - intended for treatment of low back pain
223394089|NCT01255488|BEHAVIORAL|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
223394090|NCT03521388|BEHAVIORAL|Take care of your mood (CUIDA TU ANIMO in Spanish)|The adolescents will be registered in the Website www.cuidatuanimo.org
223394091|NCT03521388|OTHER|Control|The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
223394092|NCT01823861|BEHAVIORAL|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
223394093|NCT03726697|OTHER|Tahneek|A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
223564282|NCT05470842|DEVICE|Continuous glucose monitoring (Dexcom G6)|"All participants will be issued with the Dexcom G6 device. The trial team will buy the readers or smartphones and sensors and provide the participants with all the necessary equipment. Participants will be shown how to wear the Dexcom G6 device, which they will be asked to wear for up to 10 days (=the lifespan of one sensor).~There will be no change in the standard care of the participants' diabetes management, during the study period."
223564283|NCT06655363|OTHER|Anatomical description|Anatomical description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
223564284|NCT06655363|OTHER|Radiological (MRI) description|Radiological (MRI) description of cervical ligament, calcaneo fibular ligament, interosseus talo-calcaneal ligament, talo-fibular ligament.
223564285|NCT05076409|DRUG|BI 425809|Period 1 and period 2
223564286|NCT05076409|DRUG|fluconazole|Period 2
223564287|NCT06980272|DRUG|SSGJ-707|Subjects receive SSGJ-707 intravenously.
223564288|NCT06980272|DRUG|Pembrolizumab|Subjects receive Pembrolizumab intravenously.
223564289|NCT01926041|DRUG|Varenicline for tobacco smoking cessation|The 16-week varenicline course conforms to real-practice government regulations in Taiwan.
224014170|NCT01030406|DRUG|40/240mg taken first|8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
224014171|NCT01030406|DRUG|80/480mg taken first|8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
224014172|NCT01030406|DRUG|0/0mg taken first|Placebo All arms taken with a 48 hour washout between doses
224128031|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
224128032|NCT00604058|BIOLOGICAL|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
224128033|NCT04913714|BEHAVIORAL|3-month radio intervention on infant vaccination|Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
224128034|NCT01152164|BEHAVIORAL|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
224128035|NCT06998147|OTHER|correlation and regression analyses|to evaluate the association interplay among balance, functional mobility, cognitive function, psychological well-being, and community participation in addition to identify the anticipated contributing factors that function as predictors of MS features.
223394094|NCT01803698|BEHAVIORAL|Training in the use of IOM charts|
224014173|NCT02573194|DIETARY_SUPPLEMENT|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
224014174|NCT04263753|PROCEDURE|Bladder conservative surgery in placenta accretta|"After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~\* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~\* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20"
224014175|NCT04164342|OTHER|surveys|Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
224014176|NCT05972928|DRUG|Sitagliptin 100mg|Sitagliptin at a dose of 100 mg every 24 hours for 3 months
224014177|NCT00760474|DRUG|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
224014178|NCT00760474|DRUG|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
224014179|NCT02622529|OTHER|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
224014180|NCT04662177|DRUG|Dexmedetomidine|The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
224014181|NCT06462703|DEVICE|Tablet-based neurorehabilitation with myReha|The myReha therapy software provides cognitive therapy in the domains attention, executive functions, perception, language, speech, arithmetics, and memory. It automatically creates weekly plans that are individually tailored to a patient's abilities and provides real-time feedback when completing tasks. Intelligent algorithms ensure that the exercises always remain at the optimum level of difficulty.
223394095|NCT03700983|DIETARY_SUPPLEMENT|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
223394096|NCT03196583|DEVICE|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
223394097|NCT03238651|DRUG|TAK-659|TAK-659 Tablets.
223394098|NCT02493153|PROCEDURE|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
223394099|NCT04780893|DEVICE|Modius Sleep|The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
223394100|NCT03142477|OTHER|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
223394101|NCT03142477|OTHER|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
223394102|NCT03142477|OTHER|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
223394103|NCT06351891|DRUG|14-day bismuth quadruple regimen containing cefuroxime and tetracycline|14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.
223394104|NCT06351891|DRUG|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin|14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
223394105|NCT05580874|OTHER|Massage|The babies in the massage group were given a massage once a day.
223394106|NCT05580874|OTHER|Swaddling|Control group
223394107|NCT04842331|DRUG|RESP301 (a nitric oxide generating solution)|Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.
223394108|NCT04842331|DRUG|Standard of Care (SOC)|Participants will receive institutional SOC for the treatment.
223394109|NCT02479620|DRUG|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
223394110|NCT03497741|DIAGNOSTIC_TEST|procalcitonin measurement|For each patient were blood cultures were taken, a procalcitonin level was determined
223564290|NCT01926041|BEHAVIORAL|Individualized counseling about both smoking cessation and weight control techniques|The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.
223564291|NCT05547399|DRUG|Zanubrutinib|Administered orally as a tablet or capsule
224014182|NCT04237870|DEVICE|Active cTBS|Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.
224014183|NCT04237870|DEVICE|Sham|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
224014184|NCT02919930|DEVICE|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
224128036|NCT03453151|DRUG|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
224128037|NCT00958308|OTHER|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
223394111|NCT05861518|BEHAVIORAL|Hypnosis|In the hypnosis group, patients were given hypnosis sessions of approximately 30 minutes each, in groups of three, once a week. In this way, session standardization was achieved. Arm catalepsy was suggested in all patients. The first session was used as hypnosis induction, progressive muscular relaxation and introduction to hypnosis. In the second session, in addition to the first session, self-hypnosis training was given. The second session was applied as the same 3rd session. In these patients, in addition to analgesia suggestions, the feeling of worthlessness was especially studied with the recommendation of a psychiatrist.
224128038|NCT00958308|OTHER|Placebo|Placebo is devoid of microorganisms.
223394112|NCT03875508|DRUG|Risankizumab|Risankizumab to be injected subcutaneously (SC)
223394113|NCT03875508|DEVICE|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
223394114|NCT03048708|PROCEDURE|Bariatric surgery|patients who had received treatment with bariatric surgery for medical reasons
223394115|NCT06000150|DIAGNOSTIC_TEST|Corneal topography|AS-OCT,PENTACAM
223394116|NCT03198442|PROCEDURE|F-18 FDG breast PET scan|
223394117|NCT05418842|OTHER|Prehabilitation|In addition to usual care, the prehabilitation group will exercise 3 times a week, starting immediately after diagnosis and throughout the pre-treatment period. Each exercise session will encompass 5-min warm-up and 45-min conditioning exercises. Aerobic training will be performed using low-volume high intensity interval training (HIIT). The HIIT duration is 16-20 minutes and it will be performed with 8-10 intervals of high intensity (1 minute) and 8-10 intervals of low intensity (1 minute). High intensity intervals will be set to an external load that represents 85-90% of estimated VO2Peak. In addition, patients will do resistance training at moderate intensity. Patients will complete 2 sets of 12 repetitions of 5 upper and lower body exercises.
223394118|NCT04229693|OTHER|no intervention|no intervention, only observational.
223394119|NCT06205771|OTHER|H2S content|H2S content
223394120|NCT00401648|DRUG|Brivaracetam|
223394121|NCT02720328|BIOLOGICAL|Blood samples for DOAC measurement|
223394122|NCT00725868|OTHER|Data private hospitals, angioplasty, sampling of blood|"* Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~* coronary angioplasty~* Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
223394123|NCT02066844|DRUG|Celestone|2cc
223394124|NCT02066844|DRUG|Lidocaine|5cc
223394125|NCT04336280|OTHER|Symptom questionnaire|Arabic version of the International Prostate Symptom Score: Known and validated questionnaire to quantify and qualify the severity of symptoms of the lower urinary tract
223394126|NCT04336280|DIAGNOSTIC_TEST|Urodynamics|Urodynamics: the standard diagnostic tool, it includes invasive recording of the pressure that is produced when the bladder muscle contracts via pressure sensors introduced in the urinary bladder through special types of urethral catheters.
223394127|NCT03036826|DRUG|Piperacillin/tazobactam|antiinfective therapy with Piperacillin/Tazobactam within routine care
223394128|NCT03036826|DRUG|Meropenem|antiinfective therapy with Meropenem within routine care
223394129|NCT00073203|DRUG|R228060|
223394130|NCT00073203|DRUG|Placebo and Paroxetine|
223394131|NCT02869243|DRUG|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
223394132|NCT03101956|PROCEDURE|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
223564292|NCT06601218|DRUG|Oral cannabis low THC|4 months daily dosing with oral cannabis low THC
223564293|NCT06601218|DRUG|Placebo Comparator|4 months of daily dosing with oral placebo
223564294|NCT06601218|DRUG|Oral cannabis high THC|4 months of daily dosing with oral cannabis with high THC
223564295|NCT06601218|DRUG|Oral cannabis THC/CBD|4 months of daily dosing with oral cannabis with THC and CBD
223564296|NCT06593184|DEVICE|Trans-spinal magnetic stimulation|Trans-spinal magnetic stimulation activates afferent spinal roots and increases cortical excitability.
223564297|NCT06593184|DEVICE|Sham Comparator|Sham trans-spinal magnetic stimulation involves masking, where the sound of stimulation persists even though no magnetic pulses are delivered
223394133|NCT03101956|PROCEDURE|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
223394134|NCT05773105|DRUG|Cadonilimab+regorafenib|cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
223548815|NCT04755998|OTHER|Use of virtual reality glasses during vaccination applications in children|"To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~\- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student."
223548816|NCT00310375|DRUG|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
224014185|NCT02919930|DEVICE|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
224014186|NCT00165100|PROCEDURE|Dynamic Area Telethermometry (DAT)|
224014187|NCT04670718|DEVICE|Optical Coherence Tomography Probe|Use of OCT probe for examination of gastrointestinal tract
224014188|NCT02204501|DRUG|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~* On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~* On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
223394135|NCT02996409|DRUG|HVIGI|High Volume Image-Guided Injection with a saline/lidocain solution
223394136|NCT02996409|DRUG|LVIGI|Placebo control with injection of a saline/lidocain solution (low volume)
223394137|NCT02996409|OTHER|Progressive exercise program|A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
223394138|NCT02542007|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
223394139|NCT02542007|DEVICE|sirolimus-eluting stent system|
223394140|NCT05300815|OTHER|Delphi Questionaire|"This study involves the use of questionnaires across 3 rounds as follows:~The objectives of round 1 are to collect participant demographic information and generate a list of adverse events. Round 1 will be open for 3 weeks with email reminders being provided at weeks 1 and 2.~The objectives of round 2 will be to share a list of adverse events generated from round 1 (with the addition of adverse events identified in literature if not generated in round 1) and allow participants to rate from 1-4 how important each item is for inclusion on informed consent. As per round 1, the round 2 questionnaire will remain active for 3 weeks with email reminders sent at weeks 1 and 2.~The objective of round 3 is to further gain consensus on adverse events from the results of round 2 where agreement was not reached. Round 3 remains active for 3 weeks with email reminders sent at weeks 1 and 2."
223394141|NCT00518271|DRUG|Rapamune® (Sirolimus)|
223394142|NCT00518271|DRUG|Tacrolimus|
223394143|NCT00518271|DRUG|Corticosteroids|Perioperative
223548817|NCT02186782|DRUG|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
223548818|NCT02186782|DRUG|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
223548819|NCT06554600|DRUG|Zanubrutinib|160mg bid PO（d0-d20）
223548820|NCT06554600|DRUG|Polatuzumab Vedotin|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
224014189|NCT02204501|DRUG|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
224014190|NCT02204501|DRUG|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
224014191|NCT04887064|DRUG|Sotorasib|Sotorasib will be administered as an oral tablet.
224014192|NCT05834205|OTHER|Plyometric Training|"Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1\&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3\&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5\&6"
224014193|NCT05834205|OTHER|Drills|Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
224014194|NCT02079480|DRUG|BMS-986090|
224014195|NCT02079480|DRUG|Placebo matching with BMS-986090|
224014196|NCT02079480|DRUG|Keyhole limpet hemocyanin|
224014197|NCT03419832|OTHER|NEAT Form|The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
224014198|NCT03419832|OTHER|Standard Form|The regular IRB approved version.
224014199|NCT00000998|DRUG|Trimetrexate glucuronate|
224014200|NCT00000998|DRUG|Leucovorin calcium|
223394144|NCT03154983|DRUG|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
223394145|NCT02954484|DRUG|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
223394146|NCT02954484|DRUG|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
223394147|NCT02954484|DRUG|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
223394148|NCT02954484|DRUG|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
223394149|NCT02954484|DRUG|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
223394150|NCT02954484|DRUG|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
223394151|NCT01424007|BEHAVIORAL|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
223394152|NCT03973606|OTHER|Heath literacy assessment in Arab women in East Jerusalem|A 4-sessions intervention to increase the participant's self-efficacy when interacting with their physician and increase their cardiovascular health knowledge.
223394153|NCT04220515|BIOLOGICAL|Inactivated Poliomyelitis Vaccine Made From Sabin Strain|Type I D antigen 30DU;Type II D antigen 32DU;Type III D antigen 45 DU
223394154|NCT04731805|BEHAVIORAL|Moving On After Breast Cancer|Patient education intervention that is evidence-based, physical therapy, patient \& family centered through the use of face to face instruction, a booklet, and therapeutic exercise DVD. The education materials are designed to deliver information on short term, long term, and late physical and functional effects of breast cancer treatment and given to breast cancer survivors before beginning cancer treatment. The education materials are designed to be used before, during, and after breast cancer treatment.
223394155|NCT00015964|DRUG|ZD1839|
223394156|NCT00240721|DRUG|topiramate|
223394157|NCT06550856|PROCEDURE|SUTURE-CLOSURE OMENTOPEXY IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired using full thickness suture closure using 3/0 vicryl suture then omental patch laied over the sutures.
224014201|NCT02217501|DRUG|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
224014202|NCT02217501|DRUG|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
224014203|NCT03656952|DRUG|PF-06700841|a single oral dose of 200 mg PF-06700841
224014204|NCT03656952|DRUG|Placebo|Placebo matching PF-06700841
224014205|NCT03656952|DRUG|moxifloxacin|a single oral dose of 400 mg moxifloxacin
224128039|NCT05931523|BEHAVIORAL|Stress First Aid|The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
224128040|NCT01468909|OTHER|Laboratory Biomarker Analysis|Correlative studies
223394158|NCT06550856|PROCEDURE|OMENTOPEXY ALONE IN REPAIR OF PERFORATED PEPTIC ULCER|Patients presented with perforated peptic ulcer will be repaired by using omental patch without any attempt for primary closure of perforation.
223394159|NCT00637845|DRUG|Esomeprazole Magnesium|40mg once daily
223548821|NCT06554600|DRUG|Bendamustine|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
223394160|NCT00637845|DRUG|Lansoprazole|30mg twice daily
223394161|NCT05410249|DIAGNOSTIC_TEST|Serum IL10 By ELISA|measurement Of IL10 by ELISA
223548822|NCT06554600|DRUG|Rituximab|Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
223548823|NCT01905189|PROCEDURE|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
223548824|NCT01719848|OTHER|Measurements of parameters related with physical examinations for difficult airway prediction|
223548825|NCT03032211|DEVICE|Alfapump|Implant Alfapump® System
223548826|NCT03526094|OTHER|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
223548827|NCT03526094|OTHER|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
224014206|NCT02654951|OTHER|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
224014207|NCT02654951|OTHER|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
224014208|NCT03653325|DEVICE|ORI measurement|Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
224014209|NCT03653325|DEVICE|oxygen saturation measurement|Oxygen (FiO2) will be titrated according to oxygen saturation
224128041|NCT01468909|DRUG|Paclitaxel|Given IV
224128042|NCT01468909|DRUG|Pazopanib Hydrochloride|Given PO
224128043|NCT01468909|OTHER|Placebo|Given PO
224128044|NCT03828084|DRUG|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
223394162|NCT05410249|DIAGNOSTIC_TEST|SNP -3279 A/C of FOXP3|Genotyping of -6054 del/ATT will be performed using the real-time polymerase chain reaction.
223394163|NCT05410249|DIAGNOSTIC_TEST|SNP-924 A/G Of FOXP3|Genotyping of -924 A/G polymorphisms was performed using the real-time polymerase chain reaction.
223394164|NCT06076993|BEHAVIORAL|BodyKind programme|"BodyKind is a four-session, teacher-led, school-based programme for adolescents aged 15-17 years. This programme was developed by a team of international experts in body image and incorporates empirically supported principles of cognitive dissonance (which involves publicly criticising body ideals) and self-compassion (which involves reappraising self-critical evaluations). BodyKind also contains a social activism component that aims to tackle appearance biases, discrimination and racism and promote greater inclusivity and compassion for others.~Programme Outline Lesson 1. Appearance Bias Lesson 2. Self-compassion \& social media Lesson 3. Compassion for others Lesson 4. Becoming agents of change Learning Objectives~* To cultivate skills in awareness, mindfulness, non-judgement, reflection, conscientiousness, compassion~* To decrease levels of body dissatisfaction and self-criticism~* To improve levels of self-compassion, positive body image, psychological wellbeing"
223394165|NCT06409845|DRUG|Eptinezumab 100 or 300 mg ev|Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
223394166|NCT02140151|DRUG|Ranibizumab 0.5mg|
223394167|NCT00520377|DRUG|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
223394168|NCT00520377|DEVICE|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
223394169|NCT03652051|DRUG|AZR-MD-001 Low Dose|AZR-MD-001 is an ophthalmic ointment
223394170|NCT03652051|DRUG|AZR-MD-001 Mid Dose|AZR-MD-001 is an ophthalmic ointment
223548828|NCT03526094|OTHER|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
223548829|NCT03526094|OTHER|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
223730828|NCT04119492|BEHAVIORAL|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
224014210|NCT04636736|DIAGNOSTIC_TEST|HIV drug resistance testing|HIV drug resistance testing in people newly diagnosed in HIV in Poland
223394171|NCT03652051|DRUG|AZR-MD-001 High Dose|AZR-MD-001 is an ophthalmic ointment
223394172|NCT03652051|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
223394173|NCT00004008|DRUG|bryostatin 1|
223394174|NCT04956744|BIOLOGICAL|IMS001|IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC).
223394175|NCT00124189|DRUG|GRN163L|Weekly intravenous infusion
223548830|NCT03526094|OTHER|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
223548831|NCT03526094|OTHER|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
223548832|NCT03526094|OTHER|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
224128045|NCT01264250|DRUG|AZD2927|Single dose of AZD2927
223394176|NCT02545569|DEVICE|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
223394177|NCT04377204|DRUG|marcaine bupivacaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
223394178|NCT04377204|DRUG|Lidocaine|This drug is already FDA approved and used for the indication as a local anesthetic. The study herein would like to examine the pain outcomes of enrolled patients who will either have lidocaine alone OR lidocaine+bupivacaine combination locally prior to rhinoplasty surgery.
223548833|NCT03526094|OTHER|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
223548834|NCT03526094|OTHER|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
223548835|NCT03526094|OTHER|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
223548836|NCT01387750|OTHER|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
223730829|NCT05710536|OTHER|Formulation X|This formulation containing stem cell secretome and liquorice root extract
224014211|NCT00337259|DRUG|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
223394179|NCT03778346|BIOLOGICAL|CAR-T therapy in Relapsed/Refractory multiple myeloma|Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
223394180|NCT05224739|PROCEDURE|Minimally Invasive Liver Resection|laparoscopic and robotic liver resections
224014212|NCT04580927|BEHAVIORAL|Breastfeeding self-efficacy (BSE)|Self-efficacy is determined by factors such as prior experience, vicarious learning, persuasion of others and physiological state, which in turn impact on one's behaviours and actions. One's sense of self-efficacy is modifiable, and can be readily targeted for intervention. An increasingly studied key determinant of breastfeeding outcomes is breastfeeding confidence, also referred to as breastfeeding self-efficacy (BSE). The investigators will use a nurse-administered validated BSE intervention tool.
224128046|NCT01264250|DRUG|Placebo|Single dose of placebo
224014213|NCT01844960|PROCEDURE|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
224014214|NCT01844960|PROCEDURE|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
224014215|NCT04997980|DRUG|Amiodarone Injection|
223394181|NCT05545722|BEHAVIORAL|life coaching group with diabetes|Each patient was interviewed once a week. Coaching interviews were conducted one-on-one and in accordance with coaching principles.
223394182|NCT02549781|OTHER|Go-Nogo test|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
223394183|NCT03238664|PROCEDURE|Biopsy|Undergo biopsy of bladder tumor
223394184|NCT03238664|DEVICE|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
223394185|NCT03238664|OTHER|Laboratory Biomarker Analysis|Correlative studies
223394186|NCT03238664|PROCEDURE|Radical Cystectomy|Undergo RARC
223394187|NCT03238664|DEVICE|Ultrasonography|Undergo CEUS
223394188|NCT00155064|DRUG|captopril, Losartan (drug)|
223394189|NCT04310202|OTHER|Abbreviated Profile of Hearing Aid Benefit (APHAB)|An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.
223394190|NCT04310202|OTHER|Glasgow Benefit Inventory (GBI)|An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.
223394191|NCT04310202|OTHER|Additional follow-up visits after surgery|There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
223394192|NCT04259164|DRUG|QVM149|Anti-inflammatory effect of Glycopyrronium added to Mometasone / Indacaterol
223394193|NCT04259164|DRUG|QMF149|Mometasone / Indacaterol
223394194|NCT02550561|DEVICE|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
223394195|NCT03507361|OTHER|HRV-BASED MUSIC|Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
223394196|NCT04526028|DRUG|Fulvestrant Injectable Product|Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
223394197|NCT04526028|DRUG|Palbociclib|Palbociclib is in the form of oral capsules, which are divided into three specifications: 75 mg, 100 mg and 125 mg. The recommended dose is 125 mg once daily for 21 days, followed by 7 days (3/1 dosage regimen), 28 Day is a treatment cycle.
223548837|NCT01387750|OTHER|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
223548838|NCT03513913|PROCEDURE|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
223548839|NCT03045588|OTHER|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
223548840|NCT04796558|OTHER|AVAS Classification|Validation of AVAS classification
223548841|NCT02516397|DIETARY_SUPPLEMENT|Omnia|12weeks of treatment
224014216|NCT05362500|DRUG|Glycolic Acid 70%|Group A: contain 27 patients which had been treated every 2 weeks for 12 weeks with 70% glycolic acid to assess chemical peeling and cold water was used for washing
224014217|NCT05362500|DRUG|Tranexamic acid injection|Group B: contain 27 patients treated with an intradermal injection of 0.05 mL of tranexamic acid solution in normal saline (4 mg/mL) into the melasma lesion at 1 cm distance using a sterile insulin syringe, weekly for 12 weeks
223548842|NCT02516397|DIETARY_SUPPLEMENT|Placebo|12weeks of treatment
223548843|NCT00579969|DRUG|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
223548844|NCT00579969|DRUG|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
223548845|NCT03117114|DEVICE|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
224014218|NCT02866630|BIOLOGICAL|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
224014219|NCT02800018|OTHER|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
224014220|NCT03104946|DIAGNOSTIC_TEST|Mental Development Index;Auditory Brainstem Response;okineticnystagmus|mental development index(MDI）\<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
224128047|NCT02368340|OTHER|Pulmonary function test|Pulmonary function testing performed
224128048|NCT02368340|OTHER|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
223394198|NCT01307865|DRUG|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
224128049|NCT02368340|OTHER|Sample collection|Blood and urine sample collections
224128050|NCT05594680|DRUG|Cilostazol|Cilostazol 50 MG
224128051|NCT05594680|DRUG|Methotrexate|Methotrexate (MTX) is the first-line therapy for treatment of RA patients. MTX suppresses proliferation of synovial fibroblasts, modulates cytokine synthesis and superoxide anion production, and inhibits neutrophil chemotaxis.
223394199|NCT02742662|DEVICE|Wearable technology, smartscale|
223394200|NCT02742662|BEHAVIORAL|Smartphone applications|
223394201|NCT02742662|BEHAVIORAL|Standard Weight Management Visits|
223394202|NCT00989482|BEHAVIORAL|Computer kiosk Education|computerized patient education; guidelines for physicians
223394203|NCT04082026|BEHAVIORAL|Early Adolescent Skills for Emotions EASE)|"EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~* Identify their feelings and body reactions~* Practice breathing exercises~* Get active: Make a plan to positively change their actions~* Manage their problems"
223394204|NCT02394600|DRUG|Grastek®|one tablet daily for four months
223394205|NCT02394600|DRUG|Placebo|one tablet daily for four months
223394206|NCT00333320|PROCEDURE|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
223394207|NCT00333320|PROCEDURE|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
223394208|NCT05220982|BEHAVIORAL|Conversation Training Therapy|Training clear speech in conversation with new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
223394209|NCT05220982|BEHAVIORAL|Global Voice Prevention and Therapy Model|Training of four new voices (i.e., resonant voice in connected speech, falsetto for quiet talking, oral twang for talking over noise, and belt for healthy yelling) defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with new vs other or old voice at each step. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
223394210|NCT05220982|BEHAVIORAL|Modified Conversation Training Therapy|Training clear speech in conversation with no use of new vs old voice. Training will occur over four weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
223394211|NCT05220982|BEHAVIORAL|Modified Global Voice Prevention and Therapy Model|Training of a new resonant voice in connected speech defined and trained by the anatomy and physiology of the system (i.e., Estill Voice Training's Figures). Training occurs in a bottom-up speech hierarchy with no use of new vs old voice. Additional methods are used in asynchronous telepractice to support the new voices during week 1 (e.g., vocal hygiene and education). Training will occur over three weekly synchronous telepractice sessions. Each session lasts 45-60 minutes. The ecological momentary intervention (EMI) platform (app, server, web portal) will reflect the goals of the intervention. Participants will use the EMI platform to practice voice targets three times a day.
223548846|NCT03117114|OTHER|Standard polypectomy|Absence of an EVD, standard polypectomy
223548847|NCT04211285|DIAGNOSTIC_TEST|e-GAB|android application for comprehensive geriatric assessment
223548848|NCT04211285|DIAGNOSTIC_TEST|standard physician performed CGA|CGA by an experienced geriatrician blinded to the result of e-GAB
223548849|NCT00004846|DRUG|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
223548850|NCT01127932|BEHAVIORAL|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
223548851|NCT01127932|BEHAVIORAL|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
223548852|NCT02209935|OTHER|Early Rehabilitation Protocol|
223548853|NCT02209935|OTHER|Usual care|
223548854|NCT00807183|OTHER|woodstove|installation of new EPA-certified woodstove
223548855|NCT00807183|OTHER|inactive air filter|air filter units without filter in place
223548856|NCT00807183|OTHER|Active air filter|air filter units correctly operating
223548857|NCT01458301|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
223548858|NCT01458301|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
223548859|NCT01458301|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
223548860|NCT01458301|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
223548861|NCT01458301|DRUG|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
223730830|NCT00118365|OTHER|placebo|Given orally
223730831|NCT00118365|DRUG|eflornithine|Given orally
224128052|NCT05594680|DRUG|Placebo|Placebo
224128053|NCT02227329|DRUG|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
224128054|NCT02227329|DRUG|Heparin Lock|3 mL of 100 U/ml heparin
224128055|NCT02227329|DRUG|Normal Saline|
223394212|NCT01686373|DEVICE|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
223394213|NCT01686373|DEVICE|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
223394214|NCT04280692|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites
223548862|NCT04679961|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group.
223548863|NCT02589197|DEVICE|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
223548864|NCT02589197|DEVICE|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
223548865|NCT04388215|DRUG|CKD-828|orally, 1 tablet once a day for 8 weeks
223548866|NCT04388215|DRUG|CKD-828(placebo)|orally, 1 tablet once a day for 8 weeks
223548867|NCT04388215|DRUG|D326|orally, 1 tablet once a day for 8 weeks
223548868|NCT04388215|DRUG|D326(placebo)|orally, 1 tablet once a day for 8 weeks
223548869|NCT04388215|DRUG|D337|orally, 1 tablet once a day for 8 weeks
223548870|NCT04388215|DRUG|D337(placebo)|orally, 1 tablet once a day for 8 weeks
224014221|NCT04817943|OTHER|Non applicable|When the patient enters the operating room, oxygen saturation, blood pressure, and electrocardiogram are monitored, and general anesthesia is induced using 1-2 mg/kg of 1% propofol. 0.8 mg/kg of rocuronium, a neuromuscular blocker, is injected intravenously, and a human endotracheal tube is intubated. A thermometer is attached to the inside of the double-layered endotracheal tube cuff, which measures the temperature in the trachea. After the endotracheal intubation is performed, the esophageal thermometer is inserted, and from this point, the temperature measured by the esophageal thermometer and the thermometer of the endotracheal tube are recorded. The temperature immediately after insertion of the esophageal thermometer is set as Tbaseline, and the temperature of the esophagus and trachea, the temperature of the operating room, and the temperature of breathing circuit with heated wire humidifier are recorded every 5 minutes from thereafter until the end of the operation.
223548871|NCT04388215|DRUG|D013|orally, 1 tablet once a day for 8 weeks
223548872|NCT04388215|DRUG|D013(placebo)|orally, 1 tablet once a day for 8 weeks
223394215|NCT04280692|DRUG|Sulfadoxine-Pyrimethamine|Sub-curative 500mg/25mg single dose regimen
223394216|NCT04280692|DRUG|Piperaquine|Sub-curative 480mg single dose regimen
223548873|NCT05461599|DEVICE|SparkRx Mobile App|The SparkRx app will be fully self-guided and completed by participants at home. It is designed to be completed over 5 weeks but users may progress through the app at their own pace. The app progresses linearly, i.e., a task must be completed before a participant can progress to the next task. Content for a given week is not expected to take more than 60 minutes to complete.
223548874|NCT01802099|OTHER|Enteral nutrition|
223548875|NCT01802099|OTHER|Parenteral nutrition|
223548876|NCT00131352|DEVICE|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
223548877|NCT00131352|OTHER|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
223548878|NCT04762082|DRUG|Tadalafil 10 MG|comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
223548879|NCT03366363|OTHER|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
223548880|NCT03369015|DRUG|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
223548881|NCT03369015|DRUG|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
223548882|NCT03369015|DRUG|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
223548883|NCT03110211|PROCEDURE|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
223548884|NCT03110211|PROCEDURE|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
223548885|NCT04858542|BEHAVIORAL|Educational Vocal Health Modules|We have developed four educational health modules (total duration of approximately 30 minutes). First, these modules explain how masks impact communication and voice, then they describe health strategies to improve communication and voice, and finally, they give real-life examples of how the strategies can be implemented into the work setting.
223548886|NCT03782623|DIAGNOSTIC_TEST|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
223394217|NCT04280692|DRUG|Artemether lumefantrine|Three day curative regimen 20mg/120mg
223394218|NCT04280692|DRUG|Primaquine|Single low dose regimen 0.25 mg base/kg
223394219|NCT03831009|PROCEDURE|Open reduction internal fixation (ORIF)|Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
223394220|NCT03831009|OTHER|Conservative treatment|Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
223548887|NCT05671523|PROCEDURE|Dry needling|Firstly the skin is cleaned with a piece of cotton immersed in alcohol. Then sterilized disposable thin, stainless steel needles (25 × 0.30 mm) will be inserted into the skin over the nodule in A1 pulley anatomic location. The duration of needling will be 1 minute. The needle will be inserted deeply at 45° to the level of metacarpophalangeal level to the nodule. The needle may be inserted into the tendon. This is confirmed by needle movement when the patient ﬂexes and extends the distal phalanx. The needle is withdrawn slowly until this motion ceases, and the needle tip is in the A1 pulley. This will be repeated 2 times per week for 5 weeks.
223564298|NCT00362271|DRUG|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
223730832|NCT00118365|DRUG|sulindac|Given orally
223730833|NCT00118365|OTHER|laboratory biomarker analysis|Correlative studies
223548888|NCT05671523|OTHER|conventional treatment|"Finger splint is designed to stabilize and immobilize a small finger joint. A wide, flat band offers comfortable pressure distribution and control. Contoured finger splint with a comfortable, close fit. The patient will use the splint at night. Can easily be adjusted to accommodate swollen digits. Suitable for a number of finger conditions.~Therapeutic ultrasound is often used by physiotherapists to reduce pain, increase circulation and increase mobility of soft tissues. Additionally, the application of ultrasound can be helpful in the reduction of inflammation, reducing pain and the healing."
223548889|NCT03230318|DRUG|derazantinib|Derazantinib was administered orally at 300 mg once daily
223548890|NCT01053533|DRUG|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction\& supportive therapy and antivirus therapy when necessary
223548891|NCT01053533|DRUG|western therapy|supportive therapy and antivirus therapy when necessary
223394221|NCT00656656|DRUG|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
223394222|NCT01315392|PROCEDURE|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
223394223|NCT01315392|PROCEDURE|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
223394224|NCT03527069|DRUG|Cipros 10 association|oral, once a day.
223548892|NCT02253082|DRUG|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
224014222|NCT04011943|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
223394225|NCT03527069|DRUG|Crestor 10 mg|oral, once a day.
223394226|NCT04629040|OTHER|Lateral wedge insole|Lateral wedge insole for knee osteoarthritis patient
223394227|NCT04629040|OTHER|Ordinary insole|Ordinary insole
223394228|NCT06976723|DEVICE|Nerivio|Remote electrical neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
223394229|NCT02294214|DEVICE|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
223394230|NCT02294214|DEVICE|Active ingredient|Transfluthrin (Active ingredient)
223394231|NCT02294214|DEVICE|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
223394232|NCT07017270|DRUG|Semaglutide Pen|Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.
223548893|NCT02253082|BIOLOGICAL|Fresh frozen plasma|Standard FFP from the Blood Bank
224014223|NCT00057031|DRUG|DN-101 (calcitriol)|
224014224|NCT02461043|DRUG|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
224014225|NCT02461043|RADIATION|radiation|radiation
224014226|NCT01619397|DEVICE|Test condom with new Xanthan gum condom coating|
224014227|NCT02627092|OTHER|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
224014228|NCT03935802|RADIATION|radiation|
224014229|NCT03063333|OTHER|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
224014230|NCT03063333|OTHER|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
224014231|NCT01503593|DEVICE|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
224014232|NCT05121246|DRUG|MB05 (Proposed palivizumab biosimilar)|Single IM dose of 3 mg/kg
224014233|NCT05121246|DRUG|EU-Synagis®|Single IM dose of 3 mg/kg
223394233|NCT07017582|DIETARY_SUPPLEMENT|Soidum Bicarbonate|Supplementation with 0.03 g/kg of sodium bicarbonate
223394234|NCT07017582|DIETARY_SUPPLEMENT|Placebo|0.03 g·kg-1 body mass sodium chloride
223548894|NCT02705482|BIOLOGICAL|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
223548895|NCT02705482|BIOLOGICAL|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
223548896|NCT02705482|BIOLOGICAL|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
223548897|NCT00209144|DRUG|Intensive insulin therapy|
223730834|NCT03241342|DRUG|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
224014234|NCT05121246|DRUG|US-Synagis®|Single IM dose of 3 mg/kg
224014235|NCT04154059|OTHER|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
224014236|NCT03397875|PROCEDURE|Zinc oxide based sealer|After root canal treatment obturation will be done using zinc oxide eugenol based sealer.
224014237|NCT03397875|PROCEDURE|Epoxy resin based sealer|After root canal treatment obturation will be done using epoxy resin based sealer.
224014238|NCT03397875|PROCEDURE|Bioactive silicone based sealer|
224014239|NCT06610656|OTHER|Pacifier and White Noise Therapy|Infants will receive both pacifier and white noise therapy to enhance sleep quality and reduce restlessness
223394235|NCT07018804|PROCEDURE|Bronchoscopic brushing|The collected samples are digested with tissue collagenase for the culture of airway basal cells (BCs).
223394236|NCT07018804|GENETIC|Single - cell cloning|After primary BCs are expanded in the P1 passage, single-cell cloning libraries are established by planting them into 384-well cell culture plates in a single-cell per well format using a flow chamber cell sorter. Ten samples are selected from the expandable clones for the identification of differentiation and proliferation capabilities, while the remaining clones are cryopreserved.
223394237|NCT07018804|GENETIC|Cell function identification|For single-cell samples of each patient, in vitro expansion culture is performed to observe the morphology of cells at each passage and calculate the clonogenic rate. Immunofluorescence technique is used to detect the expression of the cell proliferation marker Ki67, and the proliferation capacity is evaluated by combining with the CCK8 assay. Cells at passages P3-P5 are seeded on the permeable membrane of cell culture inserts at a density of \\(10\^6\\) cells/cm², and after 21 days of culture, the differentiated structures are collected. The expression of ciliated cell marker Ace-Tubulin and goblet cell marker MUC5AC is detected to assess the differentiation capacity. Meanwhile, cells are injected subcutaneously into NSG mice at \\(10\^6\\) cells/injection site for in vivo differentiation for 28 days, and the differentiated structures are collected for pathological analysis.
223394238|NCT07018804|GENETIC|Identification of local microenvironmental changes|The air-liquid interface (ALI) differentiation culture medium is collected, and cell debris is removed by high-speed centrifugation. The supernatant is then collected to extract proteins. Target proteins are purified via immunoprecipitation or affinity chromatography, followed by desalting and concentration for mass spectrometry analysis to detect inflammatory cytokines and extracellular matrix (ECM). Real-time PCR and Western blot techniques are used to measure the expression levels of epithelial markers, mesenchymal markers, and ECM in cells across all groups, thereby evaluating changes in the local microenvironment around small airways.
223394239|NCT07018804|GENETIC|Gene editing|After plasmid construction, based on gene function, the CRISPR-Cas9-sgRNA (all-in-one) plasmid is transiently transfected into expanded single-cell strains via Nucleofection to knockout the target gene, or the CRISPR-dCas9 fusion-sgRNA plasmid is transiently transfected to activate or inhibit the target gene. After 3-5 days of culture, viable cells are sorted by FACS, and single cells are seeded into 96-well plates for two additional passages of expansion. Samples are collected for Sanger sequencing to screen successfully constructed cell lines.
223394240|NCT07018804|PROCEDURE|Prevention of ferret airway basal cell transplantation|Before surgery, basal cells (BCs) of recipient ferrets are collected by bronchoscopic brushing, followed by in vitro culture and identification. Prior to the onset of BOS, the cells are injected into recipient ferrets via bronchoscopy. Outcomes including ferret survival rate, body weight, CT imaging, and lung tissue pathology are collected to evaluate the preventive effect of BCs on BOS.
223548898|NCT05828615|OTHER|Group A|"Close your eyes and exhale through your left nostril fully and slowly, once you have exhaled completely, release your right nostril and place your ring finger on the left nostril.~Breathe in deeply and slowly from the right side. Make sure your breath is smooth and continuous. Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
223548899|NCT05828615|OTHER|Group B|"The position of the woman should be relaxed and comfortable e.g., crock lying, sitting, standing position. Place one hand on chest and other on stomach and close eyes to relax and focus on breathing. Slowly breathe in through nose with your closed mouth.Breathe out through your nose and try to use as small effort as possible and make your breaths slow, relaxed and smooth.~Aerobics exercises (Walking): 3-5 days per week at moderate intensity, of approximately 30 minutes.~Start slowly and gradually increase your walking pace over 3 minutes until the activity feels moderate (slightly increased breathing, but should still be able to talk.~Walk at a moderate pace for about 10 minutes the first then gradually increase time with RPE(8-9)."
223564299|NCT06605651|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages (PP1493 and PP1815) intra-articular injection with 0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
224014240|NCT06610656|OTHER|pacifier therapy|Infants will receive pacifier therapy to enhance sleep quality and reduce restlessness
224014241|NCT03414541|DRUG|DS102|DS102
224014242|NCT03414541|OTHER|Placebo|Placebo
224014243|NCT02697994|OTHER|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
224014244|NCT02697994|OTHER|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
224014245|NCT00775463|DRUG|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
224014246|NCT00775463|DRUG|placebo|
224014247|NCT00346671|OTHER|Rest|30 min supine rest
224014248|NCT00346671|OTHER|Sham|30 min session with Sham practitioner
224014249|NCT00346671|OTHER|Reiki|30 min session with Reiki practitioner
224014250|NCT02173847|PROCEDURE|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
224014251|NCT02173847|DEVICE|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
224014252|NCT02173847|DEVICE|Diode laser|Low power, near infrared diode laser for welding the surgical wound
224128056|NCT01590680|RADIATION|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
224128057|NCT05924776|BIOLOGICAL|Plasmodium immunotherapy|Inoculation 1-5 × 10\^6 Plasmodium vivax once
224128058|NCT01301560|RADIATION|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
224128059|NCT01301560|RADIATION|Observation|No local treatment
224128060|NCT05929144|OTHER|MRI sequences testing|Testing different MRI sequences in order to optimize them
224128061|NCT00161980|DRUG|Fibrin Sealant VH S/D|
224128062|NCT00161980|PROCEDURE|Surgical intervention alone without Fibrin Sealant VH S/D application|
224128063|NCT04889534|PROCEDURE|Analgesia|Patients will be observed during postoperative period,
223548900|NCT02440139|DEVICE|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
223548901|NCT05930847|DEVICE|Digital Game Application|The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
223548902|NCT05930847|DRUG|Use of medication for asthma|The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
223548903|NCT01378650|DRUG|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
224014253|NCT02140281|DRUG|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
224014254|NCT02140281|DRUG|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
224014255|NCT01495832|OTHER|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
224014256|NCT01495832|OTHER|Control Group|The control group will consume comparator foods for 12 weeks.
224014257|NCT05146180|DEVICE|Parametric positron emission computed tomography|Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
224014258|NCT06019741|DRUG|Rivaroxaban and aspirin 80|rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
224014259|NCT06019741|DRUG|Aspirin 80|aspirin 80 mg orally post coronary bypass surgery
224014260|NCT04601701|DRUG|Bevacizumab Ophthalmic and Intravitreal Dexamethasone.|Pro re nata patients with CRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
224014261|NCT04601701|DRUG|Bevacizumab Ophthalmic.|Pro re nata patients with CRVO will receive Bevacizumab. And then depending on their clinical status of CRVO, Bevacizumab will be injected.
224014262|NCT04772482|DIAGNOSTIC_TEST|Sensitivity Patch Testing|Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
224014263|NCT04725474|BIOLOGICAL|visugromab (CTL-002)|monoclonal antibody
224014264|NCT00305240|PROCEDURE|T Wave Alternans Test|
224014265|NCT02110719|DRUG|Celebrex|
224014266|NCT02110719|DRUG|Gabapentin|
224014267|NCT02110719|DRUG|IV acetaminophen|
224014268|NCT02110719|DRUG|oral acetaminophen|
224014269|NCT02110719|DRUG|oral ibuprofen|
224014270|NCT02110719|DRUG|percocet|
224014271|NCT02110719|DRUG|vicodin|
224128064|NCT01511419|BIOLOGICAL|LAIV H7N3|2 doses of vaccine
224128065|NCT01511419|BIOLOGICAL|placebo|2 doses of placebo
224128066|NCT07006584|OTHER|Experimental|Group B participated in the same workshops and additionally completed functional gait training using the SSM Fisior® program. The intervention period lasted 12 weeks for both groups, with 2 additional weeks allocated for baseline and post-intervention assessments (T1 and T2).
224014272|NCT02110719|DRUG|Oxycodone|
224014273|NCT02110719|DRUG|dilaudid|
224014274|NCT02110719|DRUG|Dexamethasone|
224014275|NCT02110719|DRUG|zofran|
224014276|NCT00839904|BEHAVIORAL|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
224014277|NCT00919347|OTHER|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~1. RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~2. LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~3. SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~* Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa \< 0.1 bpm2.~* Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa \< 0.5 bpm2 or 0.1 \< RFa \< 0.5 bpm2.~* Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
224014278|NCT01550445|DRUG|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
224014279|NCT01238900|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
224014280|NCT00006230|DRUG|rubitecan|
224014281|NCT06248099|DRUG|Nebivolol-Test product|Test-Product: Nebivolol tablets 5 mg Manufactured by: Hetero Labs Limited, India
224014282|NCT06248099|DRUG|Nebivolol-Reference product|Reference-product: Nebilet tablets 5 mg Manufactured by: BERLIN CHEMIE AG, Germany
224014283|NCT00682747|DRUG|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
224128067|NCT07006584|OTHER|Active Comparator #1|Group A attended only the physical activity workshops offered by Centro Integral del Adulto Mayor (CIAM), consisting of one weekly class each of gymnastics, dance, swimming, and Tai Chi, held on different days of the week.
224128068|NCT02708043|OTHER|Flexible-Laryngeal Mask Airway|
224014284|NCT02253901|DRUG|BILR 355 BS|
224014285|NCT02253901|DRUG|Ritonavir|
224014286|NCT02253901|DRUG|TRUVADA|
224014287|NCT04338087|OTHER|Questionnaire and personal interviews.|Questionnaire and personal interviews.
224014288|NCT04021550|DEVICE|Continuous Positive Airway Pressure CPAP|All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
224014289|NCT04021550|DRUG|Telmisartan 80mg|Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
224014290|NCT04021550|DIETARY_SUPPLEMENT|Alpha-Lipoic Acid 600mg|Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
224014291|NCT04021550|OTHER|Microcrystalline Cellulose|Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
224128069|NCT04478682|OTHER|Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application|Breastfeeding support provided to mothers through WhatsApp messaging application will be maintained for the first 6 months after birth. In the first 1 month, standard information sharing will be made through whatsApp. Also, for the first 6 months, solutions generating shares will be made according to the problems and questions of the mother regarding breastfeeding.
224128070|NCT06116435|BEHAVIORAL|Prevent T2|The PreventT2 curriculum is based on the original 2002 Diabetes Prevention Prevention (DPP) trial and follow-up studies. It promotes modest weight loss (5-7%) and increased physical activity through a lifestyle change program and also reflects new literature on self-efficacy, physical activity, and diet. There are 16 modules that will be delivered over 6 months. Participants will receive a calorie goal and be asked to count calories in order to reduce their caloric intake.
223394241|NCT07018804|PROCEDURE|Transplantation treatment of ferret airway basal cells|Stable cell lines with target gene knockdown are established in ferret basal cells (BCs). After ferrets develop bronchiolitis obliterans syndrome (BOS), the constructed cell lines are transplanted into recipient ferrets to validate the therapeutic effect of gene-corrected BCs on the disease.
223394242|NCT07018284|PROCEDURE|AH Plus (Dentsply Sirona, Charlotte, NC, USA)|Root canal obturation using AH Plus (Dentsply Sirona, Charlotte, NC, USA), a resin-based sealer with low solubility and shrinkage. Used in combination with gutta-percha for root canal filling
223394243|NCT07018284|PROCEDURE|NeoSealer Flo|Root canal obturation using NeoSealer Flo (Avalon Biomed, Houston, TX, USA), a premixed bioceramic sealer based on calcium silicate. Used in combination with gutta-percha to enhance apical healing and biocompatibility.
223394244|NCT07018284|PROCEDURE|Continuous Wave Condensation|A warm vertical compaction technique using heat-softened gutta-percha to obturate the canal in three dimensions. Considered the gold standard for achieving dense and homogenous root canal fillings.
224014292|NCT02790944|GENETIC|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
224014293|NCT04822974|OTHER|blood collection|longitudinally collection of blood samples for each patient included.
224014294|NCT03856489|OTHER|Richards-Campbell Sleeping Questionnaire (RCSQ)|This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
224014295|NCT02970331|DRUG|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
224014296|NCT00737971|DRUG|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
224128071|NCT06116435|BEHAVIORAL|Move group-based classes|The Move physical activity support program group-based classes are based on Self-Determination Theory and encourage improvements in autonomous motivation for physical activity. These group-based classes are integrated within the Prevent T2 program curricula.
223394245|NCT07018284|PROCEDURE|Single Cone Technique|A cold hydraulic condensation technique using a single gutta-percha cone matched to the last rotary file, combined with a high-flow sealer. Designed for simplified obturation with minimal operator variability
223394246|NCT00946738|OTHER|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
223394247|NCT00946738|OTHER|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
223394248|NCT02033031|DRUG|Lucentis intravitreal injection|Lucentis intravitreal injection
224014297|NCT00737971|DRUG|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
224014298|NCT00737971|DRUG|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
224128072|NCT06116435|BEHAVIORAL|Fitness Membership|Participants will receive 6 months of the Peloton fitness membership. This includes access to livestream and on-demand fitness classes including walking, strength training, yoga, meditation, stretching, etc.
224128073|NCT06116435|BEHAVIORAL|Mental Imagery|Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
224128074|NCT06116435|BEHAVIORAL|Move 1:1 Support|Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
223394249|NCT02033031|DRUG|Avastin intravitreal injection|Avastin intravitreal injection
223394250|NCT02068612|BEHAVIORAL|Moderate Intensity Continuous Training+Interval Training|
223394251|NCT02068612|BEHAVIORAL|Low Intensity Continuous Training|
224014299|NCT00669994|DRUG|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
224014300|NCT05331677|PROCEDURE|correction of deformities around the knee with external fixator|minimally invasive surgery
224014301|NCT03701529|DRUG|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
224014302|NCT03701529|DRUG|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
224128075|NCT01805700|OTHER|Caffeine enhanced energy drink|Comparison of different energy drinks
224128076|NCT01805700|OTHER|Glucose drink|Glucose drink (containing 84mg glucose alone)
224128077|NCT03047993|DRUG|Azacitidine|Given IV or SC
223730835|NCT03241342|DRUG|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
224014303|NCT04168333|BIOLOGICAL|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
224014304|NCT04168333|BIOLOGICAL|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
224014305|NCT00995969|DRUG|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
224014306|NCT00995969|DRUG|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
224014307|NCT02888704|DRUG|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
224014308|NCT04708210|DRUG|IBI319|Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
224014309|NCT02838927|OTHER|No intervention|No intervention
223394252|NCT04052620|DRUG|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
223394253|NCT04052620|DRUG|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
224014310|NCT01415362|DEVICE|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
224014311|NCT03867032|BEHAVIORAL|Auditory training|Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
224014312|NCT00406159|DEVICE|Hyperbaric Oxygen Therapy|
224014313|NCT03497416|OTHER|No intervention|No intervention
224014314|NCT02856477|BIOLOGICAL|urine analysis|a sample of urine is collected during 8 hours.
224014315|NCT00322543|DEVICE|Corio™ Pimecrolimus-eluting stent|
224014316|NCT00184665|DRUG|insulin detemir|
224014317|NCT00184665|DRUG|insulin NPH|
224014318|NCT00184665|DRUG|insulin aspart|
224014319|NCT05898347|OTHER|Active surveillance|"Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised."
224128078|NCT03047993|DRUG|Glutaminase Inhibitor CB-839|Given PO
224128079|NCT06692946|BEHAVIORAL|Cooperative Parent-Mediated therapy|Parent-mediated therapy is an intervention where parents are trained to use therapeutic techniques to support their child's development and manage symptoms, often used for conditions like autism spectrum disorder (ASD).
224128080|NCT06692946|BEHAVIORAL|Treatement as Usual|"Cognitive Behavioral Therapy (CBT) is a structured, short-term psychological treatment that focuses on identifying and changing negative thought patterns and behaviors. It aims to help individuals develop healthier ways of thinking and coping with challenges by addressing both cognitive (thought) and behavioral components.~Parent training is an educational intervention where parents learn strategies and techniques to effectively manage their child's behavior and support their development, often used to address challenges associated with conditions like autism or ADHD."
223730836|NCT01267812|DRUG|bortezomib|Given SC or IV
224014320|NCT01165853|OTHER|Glucose|25% dose at 8-week intervention assigned to subjects.
224014321|NCT01165853|OTHER|Fructose|25% dose at 8-week intervention assigned to subjects.
224014322|NCT03836716|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
224014323|NCT03347097|DRUG|TIL|
223394254|NCT04052620|OTHER|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
223730837|NCT01267812|BIOLOGICAL|rituximab|Given IV
223730838|NCT01267812|OTHER|laboratory biomarker analysis|Correlative studies
223730839|NCT01267812|OTHER|immunohistochemistry staining method|Correlative studies
223730840|NCT01267812|GENETIC|RNA analysis|Correlative studies
223730841|NCT01267812|GENETIC|gene expression analysis|Correlative studies
223730842|NCT01267812|GENETIC|DNA analysis|Correlative studies
223730843|NCT01267812|OTHER|pharmacological study|Correlative studies
223730844|NCT01267812|OTHER|pharmacogenomic studies|Correlative studies
224014324|NCT03347097|DRUG|PD1-TIL|
224014325|NCT01102010|BIOLOGICAL|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
224014326|NCT06417567|DRUG|NEPA|NEPA in Preventing Postoperative Nausea and Vomiting after General Anesthesia Gastrointestinal Cancer Surgery
224014327|NCT05486962|BEHAVIORAL|Remote Patient Monitoring|Patients undergoing elective abdominal surgery will be asked to use a wearable activity tracker, vivosmart®HR by Garmin, pre and post-operatively to help remotely monitor health metrics. Data collected through the Garmin device will be reviewed to assess compliance and improvement in activity. Aggregate data will be analyzed to assess feasibility and effectiveness of this device in improving patient recovery.
223548904|NCT01378650|DRUG|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
223548905|NCT00211172|BEHAVIORAL|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
223394255|NCT02201784|DRUG|Levobupivacaine|Comparison of Equipotent doses
223394256|NCT02201784|DRUG|Ropivacaine|Comparison of equipotent doses
223394257|NCT02494661|BEHAVIORAL|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
223394258|NCT02494661|BEHAVIORAL|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
223394259|NCT03161977|OTHER|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
223394260|NCT02841982|PROCEDURE|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
223394261|NCT02841982|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
223394262|NCT02841982|DEVICE|PAJUNK StimuLong|
223548906|NCT02509936|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
223548907|NCT02509936|DIETARY_SUPPLEMENT|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
223548908|NCT02967549|DEVICE|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
223548909|NCT02967549|DEVICE|PAV|PAV delivered by the Stephanie ventilator (Stephan)
223548910|NCT01692496|DRUG|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
223730845|NCT01267812|OTHER|Questionnaire Administration|
223548911|NCT00770562|DRUG|rituximab|
223730846|NCT05833295|PROCEDURE|Downhill walking|Change in the H/M ratio after a downhill walk.
223548912|NCT00770562|DRUG|Dexamethasone|
223548913|NCT01816776|DEVICE|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
223548914|NCT01816776|DEVICE|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
223548915|NCT03493672|DIAGNOSTIC_TEST|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
223548916|NCT01643408|DRUG|asparaginase Erwinia chrysanthemi|
223730847|NCT05833295|PROCEDURE|Walking on flat ground|Change in the H/M ratio after a Walking on flat ground
223730848|NCT01719523|DRUG|EPI-743|
223730849|NCT00849810|DRUG|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
223730850|NCT00849810|DRUG|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
224014328|NCT00481624|DRUG|Epoetin Alfa plus Iron|"1. One (1) injection of Procrit®, by needle, inserted just under the skin;~2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan."
223730851|NCT03234764|OTHER|Immunotherapy|
223394263|NCT02841982|DRUG|single dose ropivacaine|"* 0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~* given immediately after the correct position of the tip of the needle has been verified."
223394264|NCT02841982|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5\~2mg, lock time: 10min, 1h limitation: 6\~8mg
223394265|NCT00059592|DRUG|Valacyclovir|
223394266|NCT00165763|DRUG|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
223394267|NCT03078686|PROCEDURE|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
223394268|NCT03078686|PROCEDURE|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
223394269|NCT03078686|PROCEDURE|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
223394270|NCT03078686|PROCEDURE|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
223394271|NCT03078686|PROCEDURE|cSVF in Normal Saline IV|cSVF + NS for IV Placement
223394272|NCT03442439|BEHAVIORAL|Nutrition and Play Intervention|Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
223394273|NCT03442439|BEHAVIORAL|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
223394274|NCT05668702|OTHER|crossover design|The researcher took venous blood sample in a tube from each patient and according to the list of order determined via randomization scheme formed on the computer, the patients' glucose levels were measured by taking a capillary blood sample from the side of the middle fingertip and palm of the dominant hand with the glucometer. Before the study, the patient's pain assessment at the end of each measurement was carried out by a nurse who was trained by the researcher about the use of Visual Analog Scale.
223394275|NCT01729949|DIETARY_SUPPLEMENT|Active Treatment Beverage|Strawberry and Blackcurrent extract
223394276|NCT01729949|DIETARY_SUPPLEMENT|Placebo Treatment Beverage|without active components
223394277|NCT02431364|DRUG|Verdinexor|Participants received verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
223394278|NCT02431364|OTHER|Placebo|Participants received placebo matched to verdinexor; Dosage form: coated, immediate release Tablet; Route of administration: oral
223394279|NCT02715011|DRUG|JNJ-63709178|Participants will receive JNJ-63709178 in Part 1 and Part 2.
223394280|NCT00916383|DRUG|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
223394281|NCT00916383|DRUG|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
223394282|NCT00258960|DRUG|Liposomal Doxorubicin|
223394283|NCT00258960|DRUG|Cyclophosphamide|
223394284|NCT00258960|DRUG|Trastuzumab|
223394285|NCT03878927|DRUG|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
223394286|NCT03878927|DRUG|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
223394287|NCT06551480|DEVICE|Biometry|Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
223394288|NCT03419689|PROCEDURE|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
223394289|NCT03419689|PROCEDURE|Blood sample collection|"Blood samples will be taken:~* At the time of first diagnosis~* About 1 week after starting any treatment~* At each radiological response assessment~* At each subsequent relapse or disease progression"
223394290|NCT03419689|PROCEDURE|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~* At the time of diagnosis or progression~* Any surgical procedures for management of tumour related medical conditions~* At each subsequent relapse or disease progression"
223394291|NCT03419689|PROCEDURE|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
223394292|NCT05066880|OTHER|Exercise training|Exercise training for 8 weeks
223394293|NCT03561129|OTHER|Embryo transfer|all the fresh embryo transfers, performed between January 1997 and December 2016 at Humanitas Fertility Center after IVF-ICSI cycles, divided per operator
223394294|NCT03355612|DRUG|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
223394295|NCT03355612|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
223394296|NCT04771559|OTHER|COVID-19 antibody test|5 cc blood sample from each participant will be taken 4 weeks after the second dose of the COVID-19 vaccine . After blood samples are centrifuged at 2500 rpm for 10 minutes, the separated serum will be backed up in two different ependorphs and stored at -80 or -20 degrees. The samples will be delivered to the working center in a manner suitable for cold chain transport. COVID-19 antibody test will be performed on the blood samples
223394297|NCT01112059|DRUG|Doxycycline|100 mg twice a day for 8 days
223394298|NCT01112059|OTHER|placebo|placebo
223394299|NCT04778475|OTHER|Intensive therapy|PT services twice a day for 3-5 days and then daily for the remainder of hospital stay
224014329|NCT01534689|DEVICE|Erchonia FX-405™ Laser|The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
224014330|NCT05565027|DEVICE|Dynamic digital radiography|The use of advanced dynamic X-ray photography and acquisition technology can obtain high-definition dynamic lung images of patients throughout the respiratory cycle for analysis.
224014331|NCT05565027|DEVICE|Pneumotachograph|The pneumotachograph monitors the flow rate, and the lung volume is calculated by integrating.
223548917|NCT04934696|DRUG|BMS-986166|Specified dose on specified days
223548918|NCT04934696|DRUG|Oral contraceptive|Specified dose on specified days
224128081|NCT06693622|BEHAVIORAL|Patient survey|To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.
223394300|NCT04778475|OTHER|Standard of care therapy|PT services 3-5 times a week for 15 to 30 minutes
223394301|NCT04132687|PROCEDURE|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
223548919|NCT03915444|DRUG|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
223548920|NCT03190499|OTHER|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
224014332|NCT03384160|DIAGNOSTIC_TEST|Group 1 -Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
224014333|NCT03384160|DIAGNOSTIC_TEST|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
223394302|NCT03636178|PROCEDURE|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
223394303|NCT03636178|PROCEDURE|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
223394304|NCT01444261|DIETARY_SUPPLEMENT|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
223394305|NCT01444261|OTHER|control|No dietary supplements
224014334|NCT05335551|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC Liver testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC Liver results will be utilized in conjunction with standard of care assessments to determine patient management in the study arm.
224014335|NCT01767571|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
224014336|NCT01767571|DRUG|Cephalexin 250mg/5ml|Test product 10 ml
224014337|NCT05059743|DRUG|[14C]-Larotinib|Patients will receive single dose of orally \[14C\]-Larotinib on Day 1.
224014338|NCT04266600|PROCEDURE|Extensive mesentery resection|Surgeons will perform a high ligation of the ileocolic pedicle, between the superior mesenteric artery and the bifurcation of the ileal and right colic branches, and to fully mobilize the mesentery off of the retroperitoneum prior to bowel transection and anastomosis
224014339|NCT04361851|DRUG|Pembrolizumab|Experimental
224014340|NCT03251391|OTHER|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
224014341|NCT03251391|OTHER|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
224014342|NCT02842762|DEVICE|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
224014343|NCT02842762|PROCEDURE|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
224014344|NCT02842762|DEVICE|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
224128082|NCT06696001|BEHAVIORAL|Psychoeducation|For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.
224128083|NCT06696001|BEHAVIORAL|Behavioral Activation|Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.
224128084|NCT06375811|DRUG|Elagolix 200 MG|Elagolix tablet
224128085|NCT06375811|OTHER|Placebo or SOC IVF|Sugar pill manufactured to mimic Elagolix 200mg
224128086|NCT06696365|DEVICE|TMS|The intermittent theta burst (iTBS) will be delivered using the MagVenture MagPro X100 stimulator equipped with a Cool B-70 A/P (combined active \& sham) figure of eight coil. MagVenture MagPro X100 is available commercially and has been FDA approved to treat major depressive disorder and obsessive-compulsive disorder.
224128087|NCT07026734|PROCEDURE|Deep brain stimulation surgery - GPi|Deep brain stimulation (DBS) surgery will be performed as normal clinical care. People with PD who are approved for GPi DBS will be enrolled in the study prior to their surgery.
223394306|NCT01922505|DRUG|PPI triple therapy|
223394307|NCT05462197|BEHAVIORAL|Qigong Wuqinxi|Wuqinxi is an exercise method developed by the ancient Chinese physician Hua Tuo by combining the ancient guide, breathing, and imitating the shapes of five animals, such as tiger, deer, bear, ape, and bird, combined with the zang-fu and meridian theory of traditional Chinese medicine. There have been studies in the past proven that this exercise can achieve health-promoting effects
223394308|NCT03774355|DRUG|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
223394309|NCT03774355|DRUG|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
223730852|NCT04333784|OTHER|Exercise training|Exercise with blood flow restriction (with a pneumatic cuff).
224014345|NCT02842762|DEVICE|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
224014346|NCT03909529|DRUG|Digoxin 250 MCG Oral Tablet|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
224014347|NCT03909529|DRUG|Spironolactone 25 mg/ 5 mL S/F Suspension|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
224014348|NCT01141556|DRUG|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
223394310|NCT04115215|BEHAVIORAL|Physical exercise (PE)|This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Participants will receive a leaflet with instructions to perform five strength-based exercises and instructors will recommend participants to perform the exercises and walk at least 15 minutes daily.
223394311|NCT04115215|DEVICE|Transcranial current stimulation (tCS)|This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 1,5 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols.
223394312|NCT04115215|OTHER|Control|Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
223394313|NCT02039193|BEHAVIORAL|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, \& Brown, 1992; Borkovec \& Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
223394314|NCT06328933|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223394315|NCT06328933|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224128088|NCT07026734|PROCEDURE|Deep Brain Stimulation Surgery - STN|Deep brain stimulation (DBS) surgery will be performed as normal clinical care. People with PD who are approved for STN DBS will be enrolled in the study prior to their surgery.
223394316|NCT06328933|BEHAVIORAL|comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223394317|NCT06460805|DIETARY_SUPPLEMENT|Partial enteral nutrition|70% caloric intake from enteral nutrition formula and 30% caloric intake from a limited range of solid foods
223394318|NCT05919277|DIAGNOSTIC_TEST|Dengue Immunoglobulin G antibodies performed with ELISA|All participants who agree to participate by signing an informed consent form will undergo a finger prick for the determination of Immunoglobulin G antibodies measured by ELISA. In a subgroup of persons who test positive, they will be invited to have blood drawn for neutralization determination in order to study serotypes and the presence of other flaviviruses.
223394319|NCT03700762|DIAGNOSTIC_TEST|ultrasound gray-scale ratio|RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
223394320|NCT03716362|DEVICE|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
223394321|NCT00026065|BEHAVIORAL|Biofeedback|
223548921|NCT05740631|DRUG|Ocaliva|Assignment of treatment obeticholic acid will be started (randomized) after the study visit and administered orally in a single-blind fashion for 21 days.
223548922|NCT05740631|DRUG|Placebo|Assignment of treatment placebo will be started (randomized) after the study visit and placebo will be administered orally in a single-blind fashion for 21 days.
223548923|NCT02439307|DRUG|Rifaximin|1200 mg of rifaximin for 2 weeks.
223548924|NCT02439307|DRUG|Placebo|Placebo for 2 weeks
224014349|NCT02587988|DRUG|HCP1302|
224014350|NCT02587988|DRUG|HGP0904|
224014351|NCT02587988|DRUG|Placebo (for HCP1302)|
224014352|NCT02587988|DRUG|Placebo (for HGP0904)|
224014353|NCT01242826|DRUG|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
224014354|NCT01631227|DRUG|Eprosartan|Eprosartan 450 mg
223730853|NCT03903705|DRUG|Fruquintinib in Combination with Sintilimab|"Fruquintinib plus Sintilimab:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off +Sintilimab 200mg Q4W, intravenous dosing~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2weeks on/1 weeks off + Sintilimab 200mg Q3W, intravenous dosing~Cohort E: Fruquintinib 3 mg QD, continuous, oral dosing, + Sintilimab 200mg Q3W, intravenous dosing~Fruquintinib monotherapy arm:~Fruquintinib 5 mg QD, oral dosing, 3 weeks on/1 weeks off~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
223730854|NCT02050776|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
223394322|NCT05988580|OTHER|Pasta dish with resistant starch|Pasta dish with 20-22% of resistant starch
223394323|NCT05988580|OTHER|Original version of pasta dish|Original pasta dish, not reinforced with resistant starch
223394324|NCT02214992|DRUG|Telmisartan/Ramipril|Fixed dose combination tablet
223394325|NCT02214992|DRUG|Telmisartan|
223394326|NCT02214992|DRUG|Ramipril capsule|
223394327|NCT02214992|DRUG|Ramipril tablet|
223394328|NCT00556244|PROCEDURE|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
223394329|NCT02371434|BIOLOGICAL|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 10\^6, 1 x 10\^6, and 2.5-3 x 10\^6 cells/kg body weight in cohorts of three patients each.
223394330|NCT05387187|DRUG|Pu Yang Wan Wu Tang plus Pentoxifylline|Pu Yang Wan Wu Tang 5g TID Pentoxifylline 100mg TID
223394331|NCT05387187|DRUG|Pentoxifylline|Pentoxifylline 100mg TID
223394332|NCT00033397|PROCEDURE|biopsy|
223394333|NCT00033397|PROCEDURE|magnetic resonance imaging|
223394334|NCT00033397|PROCEDURE|radiomammography|
223394335|NCT00033397|PROCEDURE|ultrasound imaging|
223394336|NCT00033397|RADIATION|gadopentetate dimeglumine|
223394337|NCT00033397|DRUG|chemotherapy|
223394338|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 180mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
223394339|NCT05582798|DRUG|Alpha 1-Proteinase Inhibitor 120mg/kg|alpha1-proteinase inhibitor (human) intravenous infusion
223394340|NCT05582798|DRUG|Sodium chloride|Sodium chloride 09.% intravenous infusion
223394341|NCT03075020|OTHER|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
223394342|NCT03075020|OTHER|AIR|Room air will be administered as placebo
223394343|NCT05579457|OTHER|Short Physical Performance Battery|The SPPB was applied to determine the physical performance levels of the elderly. This test is a valid and reliable test that measures the performance of the lower extremities and can be applied for elderly. The SPPB included three sections: getting up from a chair, standing balance, and walking speed. At the end of these tests, the scores of the three sections were calculated and higher scores were evaluated as reflecting higher levels of physical performance
223394344|NCT01907230|DRUG|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
223394345|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
223394346|NCT01508884|DRUG|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
223394347|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
223394348|NCT01508884|DRUG|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
223394349|NCT01508884|BIOLOGICAL|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
223394350|NCT01508884|DRUG|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
223394351|NCT04877847|DEVICE|Low-frequency therapeutic ultrasound (LOTUS)|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on per normal operating instructions.
223394352|NCT04877847|DEVICE|LOTUS System with Ultrasound Disabled|Participants will wear low-frequency therapeutic ultrasound system for procedure. Device will be turned on and set to Control Setting.
223394353|NCT04166201|PROCEDURE|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
223394354|NCT01254773|DRUG|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
223394355|NCT03247569|DRUG|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
223394356|NCT05961696|DRUG|Mosunetuzumab|Subcutaneous (SQ or Sub-Q) injection under the skin
223394357|NCT00356382|DRUG|Lactobacillus (L.) casei|
223394358|NCT05670808|DRUG|Epinephrine injection|Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
223394359|NCT03818113|OTHER|cardioplegia with HTK-Bretschneider cardioplegic solution|cardioplegia with HTK-Bretschneider cardioplegic solution
223394360|NCT03818113|OTHER|cardioplegia with St. Thomas cardioplegic solution|cardioplegia with St. Thomas cardioplegic solution
223394361|NCT07079813|DEVICE|EasyStars™ High Density Mapping Catheter|All patients underwent treatment for complex arrhythmias using EasyStars™ High Density Mapping Catheter.
224014355|NCT01631227|DRUG|Eprosartan Mesylate|Eprosartan mesylate 600 mg
224014356|NCT01631227|DRUG|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
223394362|NCT02235454|DEVICE|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
223394363|NCT03323398|BIOLOGICAL|mRNA-2416|mRNA encoding human OX40L
223394364|NCT03323398|BIOLOGICAL|Durvalumab|PD-L1 inhibitor
223394365|NCT07095127|DRUG|NVG-2089|Study Treatment
223394366|NCT07097857|OTHER|SFDI|SFDI imaging is performed on both treated and untreated limb.
223394367|NCT07096765|DRUG|Group O|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
223394368|NCT07096765|DRUG|Group T|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
223394369|NCT07096765|DRUG|Group C|"Ultrasound guided External Oblique And Rectus Abdominis Plane (EXORA) Block block (0.3 ml/kg ,~%0.25 bupivacaine) will be performed Drug: Tramadol 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; Patient-controlled analgesia settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg."
223394370|NCT07097402|BEHAVIORAL|Self-compassion intervention (Self-Compassion for Healthcare Communities course)|An online 6-week mindful self-compassion course with weekly sessions.
223394371|NCT07097155|OTHER|Daily Avocado Consumption|Participants follow their usual diet and consume one avocado per day for 4 months
223394372|NCT07090317|DRUG|Iparomlimab and Tuvonralimab|The administration regimen of Iparomlimab and Tuvonralimab is: the recommended dose of Iparomlimab and Tuvonralimab is 5mg/kg, intravenous infusion, with a treatment cycle of 21 days. The subjects will continue to receive treatment with Iparomlimab and Tuvonralimab until the termination criteria are met.
223394373|NCT07094503|BEHAVIORAL|Wysa Digital Chatbot Program|Wysa is a digital rules-based chatbot program platform offering cognitive-behavioral therapy-based guided self-help modules, including five modules for eating and body image developed by our team. Participants in this arm will engage with the digital chatbot program daily for three months to complete all five modules.
223394374|NCT07096141|BEHAVIORAL|DBT-informed Group Psychotherapy for Emotion Regulation|An 8-session Dialectical Behaviour Therapy informed emotion regulation psychotherapy group.
224014357|NCT01631227|DRUG|Placebo Eprosartan|Placebo Eprosartan
224014358|NCT01090479|DRUG|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
224014359|NCT05332353|DRUG|Bacillus Calmette-Guerin|Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
223394375|NCT07096817|BEHAVIORAL|Highly intensive individualized balance therapy|"In the form of a camp with total therapy hours of 40 hours with a central theme of Circus, children will receive individualized (1 therapist per child) intensive therapy. The intervention is functional, and divided in six activity categories: jumping, sitting balance, walking and running, circus, individual goals and group activities with focus on social interaction. Each category should: 1. partially or fully cover the multisystemic balance framework of Horak, with the overall program covering the entire framework, 2. be fun and focusing on collaboration rather than competition."
223394376|NCT07096050|OTHER|HyaleXo|Treatment of HyaleXo 3 times
223394377|NCT07095244|DIETARY_SUPPLEMENT|Iron Supplement|FeraMAX Pd powder 15: NPN 80109337 FeraMAX Pd Therapeutic 150 capsules: NPN 80075623 (for an adolescent that can swallow capsules)
223394378|NCT07095244|DIETARY_SUPPLEMENT|Comprehensive Nutrition Management|Standard nutrition care will depend on the results of the nutrition assessment, as well as underlying conditions, and will be performed regardless of iron supplementation. The intervention will be at the discretion of the dietician but may include; diet education, recommendations for vitamin and mineral supplements, optimization of tube feeds (if the child is tube fed), high protein or high energy diet education if the child is underweight, dddition of oral nutrition supplements (i.e., Pediasure or Ensure) to promote weight gain in orally fed children, discussion surrounding enteral feeding (for children who are orally fed, but severely malnourished and cannot meet their nutritional needs by mouth).
223548925|NCT03743545|OTHER|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
223548926|NCT05523830|OTHER|No Intervention|No intervention
223548927|NCT04886102|OTHER|An additional 5 mL venous blood tube taken from patients during their routine medical check-up at the hospital|Research protocol involving the human person (Category 3 - Non-interventional research\_ not related to a health product) Serology, molecular biology, phylogenetic and phylodynamic analyzes of hepatitis B and D
224014360|NCT03193359|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
224014361|NCT00768079|OTHER|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
223548928|NCT02413944|PROCEDURE|ACTH stimulation test|ACTH stimulation test
223564300|NCT06605651|DRUG|0.9% NaCl solution|Three intra-articular injections during and/or following DAIR procedure
223564301|NCT06658652|DRUG|Enlicitide decanoate|Oral tablet
224014362|NCT00768079|BIOLOGICAL|Benralizumab|A single dose of benralizumab (MEDI-563) 0.3 or 1 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
224014363|NCT00666601|DRUG|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
224014364|NCT00666601|DRUG|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
224014365|NCT03460691|PROCEDURE|Bariatric surgery|Bariatric surgery will done to the patients who were morbid obesity
224014366|NCT01097707|DRUG|LY500307|Administered orally, daily for 24 weeks
224014367|NCT01097707|DRUG|Placebo|Administered orally, daily for 24 weeks
223394379|NCT07097610|OTHER|Mosaic Puzzle Intervention|This study aims to investigate the effect of mosaic puzzle application on nomophobia in adolescents. The data for the study will be collected over a 5-week period. The experimental group children will be asked to play mosaic puzzle games for 1 hour, 2 days a week for 5 weeks at a time deemed appropriate by the school under the supervision of the researcher. The control group children will not be given any application; they will only be observed, and a final test will be administered at the end of the 5 weeks. The study is planned as a single-center study, and a total of 30 children aged 12-14 with a nomophobia scale score of 60 or higher who meet the inclusion criteria will be included in the study.
223394380|NCT07095062|DEVICE|HD-EEG recordings, combined with cognitive and motor assessment|Participants will undergo high-density EEG (HD-EEG) recordings under two conditions: at rest and while performing an upper limb motor task. The data obtained will be used to reconstruct source cortical activity and derive patterns of functional connectivity, using advanced neurophysiological analysis techniques, including the Avalanche Transition Matrix (ATM). In addition, patients will complete a neuropsychological assessment and participate in an intensive multidisciplinary rehabilitation program lasting 3 to 4 weeks, depending on age. The intervention aims to assess changes in the functional organization of the brain before and after treatment, as well as one year later, in order to explore potential biomarkers of disease progression.
223548929|NCT03377816|BEHAVIORAL|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
223548930|NCT03377816|BEHAVIORAL|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
223548931|NCT02003976|PROCEDURE|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
223548932|NCT02003976|OTHER|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
223548933|NCT03666520|OTHER|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
223548934|NCT05371834|DEVICE|Microwave Treatment (Swift System)|"Localized microwave energy applied to the wart lesion. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).~For common warts (usually hands, elbow, knees): Treatment starts at 6W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeated on the same wart as is tolerable (3-5 repetitions).~For plantar warts: Treatment starts at 8W and applied locally for a 2 second burst and the dose and duration is adjusted (up or down) as is tolerable for the subject. Treatment is repeat on the same wart as is tolerable (3-5 repetitions).~Less power for a longer time will result in a more gradual temperature rise. Higher power for a shorter time will result in a more immediate temperature rise."
223548935|NCT05371834|DEVICE|Cryotherapy|Local application of Cryotherapy. Treatment is in 4-week intervals (minimum of 2 treatments, maximum of 4 treatments).
224014368|NCT00343447|BIOLOGICAL|autologous tumor cell vaccine|
224014369|NCT00343447|BIOLOGICAL|rituximab|
224128089|NCT04681573|DIAGNOSTIC_TEST|blood tests|"Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day."
223548936|NCT04295837|OTHER|ABLE|Home-based occupational therapy compensatory programme addressing activities of daily living
224128090|NCT02959710|DRUG|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
223548937|NCT04295837|OTHER|Usual Care|Standard occupational therapy
224014370|NCT00343447|DRUG|cyclophosphamide|
224014371|NCT01015547|DRUG|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
224014372|NCT01015547|DRUG|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
224014373|NCT01015547|DRUG|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
224128091|NCT02959710|DRUG|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
224128092|NCT02959710|DRUG|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
224128093|NCT06699966|DRUG|Celecoxib|The dose of celecoxib will be at the maximum recommended FDA approved dose (400mg daily). Participants will take two 200mg tablets of celecoxib daily with a meal for 8 weeks.
224128094|NCT06699966|DRUG|Minocycline|Dosing of minocycline will gradually increase from 50 mg per day during Week 1, increase to 50 mg b.i.d. during Week 2, and finally reach 100 mg b.i.d. during Weeks 3-8.
224128095|NCT06693440|DRUG|PD-1 Inhibitors|Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
223394381|NCT07095322|BEHAVIORAL|Strength Education Session|Strength education session given at the first 4 weeks of intervention to educate women on muscle-strengthening exercises
223394382|NCT07095322|BEHAVIORAL|Gym Membership|12 weeks gym membership to allow participant to go to the gym on their own
223548938|NCT04482972|PROCEDURE|DCB|Angioplasty with DCB is an angioplasty technique which allows drug delivery to the coronary artery without stent implantation.
223548939|NCT04482972|PROCEDURE|DES|Angioplasty with DES is an angioplasty technique which permits drug delivery to the coronary artery and permanent implantation of a stent.
224014374|NCT05573867|OTHER|Physical activity on prescription|"All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke."
224014375|NCT02704793|OTHER|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
224014376|NCT02704793|OTHER|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
224014377|NCT05847959|DRUG|Traditional Chinese medicine prescription：XinKang-I|XK-I will be used in intervention group (20 grams of radix astragalus, 20 grams of radix codonopsis, 10 grams of stir-fried semen lepidii, 8 grams of sweet apricot kernel, 10 grams of cassia twig, 15 grams of poria cocos, 10 grams of atractylodes, 5 grams of honey-roasted licorice, 15 grams of radix et rhizoma salviae miltiorrhizae, 10 grams of chuanxiong rhizoma, 5 grams of tangerine peel).Patients will take XK-I once a day, divided into morning and evening administration. The treatment lasted for 8 weeks.
224014378|NCT00566878|BIOLOGICAL|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
224014379|NCT04223739|DRUG|Landiolol|"Landiolol infusion with incremental doses (range from 2,5µg/kg/min to 80 µg/kg/min) with go of heart rate \< 90 bpm. Doses are modified every 10 minutes if necessary.~Once heart rate goal is obtained, switch to an oral dose of Bisoprolol."
224014380|NCT04223739|DRUG|Amiodarone|Amiodarone loading dose of 5-7 mg/kg in 1 hour followed by an infusion of 1 g/day until conversion to sinus rhythm. Once sinus rhythm is obtained, switch to an oral dose of 200mg/day
224014381|NCT00116883|DRUG|GW685698X aqueous nasal spray|
223394383|NCT07095322|BEHAVIORAL|Group Exercise Session|Optional exercise sessions from week 4 to week 12 of the intervention if the participants want to join
223548940|NCT01057693|DRUG|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
223548941|NCT01057693|DRUG|Placebo|Placebo is supplied as capsules and given 3 times daily.
223548942|NCT01570517|DEVICE|IASD System|Implantation of the DC Devices Inc. IASD System
224014382|NCT00152932|DRUG|Dorzolamide 2% drops|
224014383|NCT00152932|DEVICE|HRF and CLBF|
224014384|NCT02876159|BIOLOGICAL|2016-2017 Influenza Vaccine|Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
224014385|NCT05347043|OTHER|Montreal cognitive assessment|Montreal cognitive assessment and standardized neuropsychological evaluation (Test of Attentional Performance of Zimmermann and Fimm ; Wechsler Adult Intelligence Scale 4th version digit span ; Wechsler memory scale III, spatial span ; Wisconsin Card Scoring Test, GREFEX version ; Wechsler Adult Intelligence Scale 4th version block design ; Six elements test GREFEX version; free and cued selective reminding test, 16 items, B version ; Behavioral Rating Inventory of Executive Function ; Modified Fatigue Impact Scale)
224128096|NCT06692491|DRUG|Albumin-Bound Paclitaxel|Albumin-Bound Paclitaxel 260mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with albumin-bound paclitaxel if PDOs show the highest response to this drug under the guidance of MTB.
223394384|NCT07095322|BEHAVIORAL|Training Log|To record the exercise done for 24 weeks duration. Consist of date, day, exercise, set, repetitions, load, RPE
223394385|NCT07095322|BEHAVIORAL|Support group|For reminders and support for the participant for the first 12 weeks of intervention
223394386|NCT07095088|OTHER|Mind-body therapy|In addition to the 1-week birth preparation training at the Kayseri City Education and Research Hospital Pregnancy School, the intervention group received Mindfulness-Based Parenting and Birth Preparation Training. This training aimed to teach participants how to monitor their thoughts and emotional states, how to deepen their sensory awareness of their bodies, how to be more careful about how their minds work, and how to deepen their sensory self-awareness, so that they would be more sensitive during the birth and parenting processes. A total of 9 separate sessions were implemented. Mindfulness-Based Parenting and Birth Preparation Training was held once a week for 9 weeks, with the duration of each session varying according to the parents' compliance and needs in the program, and each session lasted an average of 150 minutes.
223548943|NCT02147210|OTHER|biological analysis|
223548944|NCT03169868|DIAGNOSTIC_TEST|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
223548945|NCT03200431|OTHER|New adhesive strip|This is a newly developed strip.
223548946|NCT05503979|DRUG|Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]|1 tab every 24 hrs for 12 weeks
223548947|NCT02289196|DRUG|Vx-006: 0,5mg|
224014386|NCT00201227|OTHER|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
224014387|NCT01530451|DRUG|Desmopressin|120mg OD
224014388|NCT01530451|DRUG|Placebo|one tab OD
224014389|NCT05032989|PROCEDURE|Extraction of mandibular 3rd molar via Cowhorn forcep technique|Cowhorn forceps technique used to extract the tooth results in less post operative pain and swelling also it makes the extraction easier.
224014390|NCT05032989|PROCEDURE|Extraction of mandibular 3rd molar via conventional technique|Conventional method of extraction uses dental elevator and forceps resulting in post operative pain and swellig.
223548948|NCT02289196|DRUG|Vx-006: 1mg|
223548949|NCT02289196|DRUG|Vx-006: 5mg|
223548950|NCT02289196|DRUG|Vx-006: 10mg|
223394387|NCT07095478|DRUG|Artesunate|Patients with HPV positive CIN2/3 will receive 3 cycles of oral artesunate 200mg OD prior to standard of care therapeutic LLETZ. Each 21 day treatment cycle will comprise oral artesunate 200mg OD for 14 days followed by a 7 day treatment break.
223394388|NCT07097623|OTHER|respond to 3 rounds of online Delphi surveys|In the first round, the responses of the participants will be collected, coded, and categorised into several themes/factors anonymously. In the second round, the participants will obtain the controlled feedback of all other participants and rate the level of agreement of the factors using a 5-point Likert scale ('strongly agree', 'agree', 'neither agree or disagree', 'disagree', and 'strongly disagree'; or 'essential', 'important', 'don't know/depends', 'unimportant', and 'should not be considered'). In the third round, the participants will rank the importance of the factors. In each round, the participants will be expected to complete the survey within one month.
223394389|NCT07097623|OTHER|attend an individual semi-structured interview|The individual semi-structured interview will be audio-recorded, last for 45 minutes at maximum, and carried out by a trained and independent research assistant in a meeting room of PolyU or a room affiliated with the respective acute wards of the participating hospitals.
223394390|NCT07097467|OTHER|Buteyko Breathing Technique|The buteyko breathing technique is a breath holding technique mostly used in Asthma patients
223394391|NCT06926894|DRUG|Rapidly generated virus specific T (R-MVST) cells|"Group A dose escalation schedule:~* Cohort (-1A): 0.25x10\^6 R-MVST TNC/kg~* Cohort (1A): 0.5x10\^6 R-MVST TNC/kg~* Cohort (2A): 1x10\^6 R-MVST TNC/kg~Groups B \& C dose escalation schedule:~* Cohort (-1B) + (-1C): 1x10\^6 R-MVST TNC/kg~* Cohort (1B) + (1C): 2x10\^6 R-MVST TNC/kg~* Cohort (2B) + (2C): 4x10\^6 R-MVST TNC/kg"
223394392|NCT07095491|OTHER|Experimental|A structured hybrid training program based on self-care and self-efficacy will be implemented for the intervention group. The training will be conducted in two sessions, one day per week, over a total of two weeks.
223394393|NCT07095491|OTHER|Control|The control group will not receive any different intervention and will continue the process with routine nursing care (standard treatment).
223394394|NCT07096726|DEVICE|Five-point ultrasound|In-person study visits will be done on initial evaluation and then at least every 48 hours, during which serial five-point ultrasound will be performed to assess venous congestion. Each visit will not be at strict intervals; a reasonable time window is every 48 hours +/- 12 hours. Ultrasound may be performed more frequently if clinically indicated. During these visits or between them, ultrasound of the heart may additionally be performed. Each visit will last between 10 and 60 minutes.
223394395|NCT07096726|OTHER|Standard of care|Standard of care will most likely include radiographic investigations (chest X-ray, chest CT), laboratory evaluation (complete blood counts, metabolic panel, B-type natriuretic peptide, high-sensitivity troponin, electrolytes, renal function, urine testing), volume status, and cardiopulmonary physical exam.
223394396|NCT04433182|DRUG|Copanlisib|"Induction phase: 6 cycles of Copa-RB every 28 days according to the following schedule~* Copanlisib (Copa): 60 mg/day i.v. on days 1,8,15~* Rituximab (R): 375 mg/sqm i.v. day 1\*~* Bendamustine (B): 90 mg/sqm i.v. days 1-2\*~note: during cycle 1 rituximab can be administered on day 2: in this case bendamustine will be administered on days 2-3; in the case of a frail patient or a patient with high tumor burden copanlisib could be administered on day 1, rituximab on day 2 and bendamustine on days 3-4, at physician discretion.~Maintenance phase: patients who reach at least SD after induction will receive a maintenance with copanlisib in monotherapy according to the following schedule:~• Copanlisib: 60 mg/day i.v. on days 1 and 15 in 28-day cycles for 1 year"
223394397|NCT02841501|GENETIC|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
223548951|NCT00237666|DRUG|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
223548952|NCT04169529|DEVICE|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
223548953|NCT00533728|DRUG|Soluble beta-glucan (SBG)|
223548954|NCT01564823|DRUG|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
223548955|NCT01564823|DRUG|Metronidazole|Metronidazole 250 mg/8h 3 months
223548956|NCT01564823|DRUG|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
223548957|NCT01564823|DRUG|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
224014391|NCT04568694|PROCEDURE|Delayed Lung Transplantation|Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
224014392|NCT04568694|PROCEDURE|Conventional Lung Transplantation|Reference Therapy
224014393|NCT01560468|DRUG|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
223548958|NCT01017042|DRUG|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
224014394|NCT01833845|DRUG|Ribavirin|weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
224014395|NCT01833845|DRUG|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
224014396|NCT02207569|DEVICE|CoreValve Evolut R TAVR system|
224014397|NCT04470232|OTHER|Self-assessment questionnaires|"120 patients with coxofemoral pathologies will pass the SUSHI-score and the HOOS-12 score questionnaires.~The HAGOS (Hip and Groin Score) questionnaire will be also passed by the subject, for the convergent validity."
224014398|NCT02796625|OTHER|Painful Stimuli|warm or painful heat administration
224014399|NCT01236534|DRUG|Lubiprostone|24 mcg twice daily for 21 days.
224014400|NCT01236534|DRUG|Placebo|matching placebo twice daily for 21 days.
224014401|NCT01611805|DRUG|GSK1605786|Opaque Swedish orange body and cap.
224014402|NCT01611805|DRUG|GSK1605786 Placebo|Opaque Swedish orange body and cap.
224014403|NCT02235831|DEVICE|Nelfilcon A MF contact lenses (DACP MF)|Multifocal contact lenses in Low, Medium, High Add
223394398|NCT07111286|OTHER|Assessment|"Before and after the programme :~* Self-questionnaires: assessment of pain (visual analogue scale), functional disability (Oswestry), kinesiophobia (Tampa scale of Kinesiophobia), mood (Hospital Anxiety Depression Scale), quality of life (SF12), level of physical activity (Simple Physical Activity Questionnaire), and level of motor imagery (Kinesthesic and Visual Imagery Questionnaire-10)~* Functional tests: Sorensen test, Shirado test, Time Up and Go test (TUG), 6-minute walk test, 200-metre fast walk test, measurement of maximum isometric strength of back extensors/flexors, 3D analysis of locomotion, posture and trunk flexion.~* Evaluation of excitability and inhibition mechanisms within the primary motor cortex at rest and during motor imagery using single and double pulse TMS. Excitability between the brain and the erector spinae muscles and inhibition of the primary motor cortex will be measured at rest and during imagery of back flexion and extension movements"
223394399|NCT07111286|OTHER|Motor imagery task sessions|3 sessions of 30 minutes per week
223394400|NCT07111286|OTHER|Cognitive task sessions|3 sessions of 30 minutes per week
223394401|NCT07111286|OTHER|Assessment of satisfaction and tolerance|During the final assessment, which will take place after the programme. Satisfaction and tolerance will be assessed using a visual analogue scale.
223394402|NCT06282965|DRUG|Angiotensin (1-7)|The drug will be dissolved in 0.9% USP/NF grade sterile for injection saline (NaCl) and prepared in a concentration that aligns with the participant's weight.
223394403|NCT06282965|DRUG|Sterile saline|Sterile solution of 0.9% NaCl in water.
223394404|NCT07110987|PROCEDURE|Phototherapy|Triple continuous phototherapy per AAP Guudelines
223394405|NCT07110987|DRUG|ursodeoxycholic acid (UDCA)|10mg/kg/day orally divided in two doses (URSORASHA) . Given with feeds untill the bilirubin level drop down to limits that don't need therapy due to AAP guidelines.
223394406|NCT04214535|DEVICE|Tritanium C Anterior Cervical Cage|50 subjects undergoing anterior cervical discectomy and fusion surgery using the Tritanium C Anterior Cage for one or two-levels
223394407|NCT04124497|DRUG|Daratumumab|"* Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1."
223394408|NCT04124497|DRUG|Pomalidomide|4 mg once daily on days 1-21
223394409|NCT04124497|DRUG|Dexamethasone|Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
223394410|NCT06377930|DRUG|RAP-219|RAP-219 oral tablet
223394411|NCT06014086|DRUG|PH-762|PH-762 is a potent RNAi molecule targeting PD-1.
223394412|NCT06375564|DRUG|177Lu-AB-3PRGD2 radioligand therapy|Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
223394413|NCT04874207|DRUG|Regorafenib|Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
223394414|NCT03800407|OTHER|Observational study|Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
223394415|NCT04791839|DRUG|Zimberelimab|Zimberelimab will be supplied by Arcus Biosciences.
223394416|NCT04791839|DRUG|Domvanalimab|Domvanalimab will be supplied by Arcus Biosciences.
223394417|NCT04791839|DRUG|Etrumadenant|Etrumadenant will be supplied by Arcus Biosciences.
223394418|NCT05589181|DRUG|High Dose Buprenorphine|32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
223394419|NCT05589181|DRUG|Standard Buprenorphine Dose|12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
223394420|NCT04259788|OTHER|AHEI diet|Main intervention is the consumption of an AHEI diet for 12 weeks.
223394421|NCT02361528|DRUG|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
223394422|NCT02361528|DRUG|Placebo|placebo subcutaneously, for 5 days
224014404|NCT02235831|DEVICE|Nelfilcon A single vision contact lenses (DACP)|
223394423|NCT05708768|OTHER|Receiving physician manned rapid response car services|All patients receiving services from the physician manned rapid response car will be included
223394424|NCT04748510|PROCEDURE|Functionally Aligned Total Knee Arthroplasty|Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
223394425|NCT04748510|PROCEDURE|Mechanically Aligned Total Knee Arthroplasty|Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
223394426|NCT01376752|PROCEDURE|Maximal cytoreductive surgery|Maximal cytoreductive surgery
223394427|NCT01376752|DRUG|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
223394428|NCT06207942|DEVICE|Feed back controlled temperature device|If core temperature exceeds 37.7 degrees celsius a feedback controlled-device will be used at set to 37.5 degrees celsius
224014405|NCT04592042|BEHAVIORAL|Feel-Good- Group|Eight sessions of group intervention focussing on information on emotion regulation, training of emotion regulation techniques and mindfulness.
223394429|NCT06207942|OTHER|High MAP|A mean arterial blood pressure (MAP) of \>85mmHg will be used. Vasopressors will be titrated to this target during 36 hours
223394430|NCT06207942|OTHER|Deep sedation|Deep sedation for at least 36 hours
223394431|NCT06207942|OTHER|Fever control without a device|Management of fever in the intensive care unit without a device
223394432|NCT06207942|OTHER|Low MAP|A mean arterial blood pressure (MAP) of \>65mmHG will be used. Vasopressors will be titrated to this target during 36 hours
223394433|NCT06207942|OTHER|Minimal sedation|A strategy of minimal sedation in the intensive care unit, used only as needed to facilitate transport, imaging and invasive procedures
223394434|NCT02218463|DRUG|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
223394435|NCT02218463|DRUG|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
223394436|NCT05730257|PROCEDURE|Robot-Assisted Kidney Transplantation|Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
223394437|NCT05730257|PROCEDURE|Open Kidney Transplantation|Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
223394438|NCT06067230|BIOLOGICAL|mRNA-1345|Sterile liquid for injection
223394439|NCT02133560|BEHAVIORAL|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
223394440|NCT02133560|BEHAVIORAL|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
223394441|NCT02133560|BEHAVIORAL|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
223394442|NCT06167434|DEVICE|Future Cardia™ Insertable Cardiac Monitoring (ICM) System|The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.
223394443|NCT05062239|DRUG|Discontinuance of treatment with statins 7 to 14 days prior to surgery until 30 days postoperative|Discontinuance of prior statin therapy
223394444|NCT05062239|DRUG|No-intervention.|Continuance of prior statin therapy
223394445|NCT05757700|BIOLOGICAL|19(T2)28z1xx TRAC T cell|"Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6"
223394446|NCT05678218|PROCEDURE|Endoscopic Ultrasound registration|Registration of all findings during Endoscopic Ultrasound
223394447|NCT03076008|OTHER|Observational|No intervention
223394448|NCT05681481|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
223394449|NCT05681481|DRUG|Prednisone|Oral Prednisone
223394450|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Active|The patients will be treated with cTBS and usual medical treatment after endovascular treatment
223394451|NCT06639360|DEVICE|Transcranial Magnetic Stimulation Sham|The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
223394452|NCT05878730|DIAGNOSTIC_TEST|urine collection|"* Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~* at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~* Measure of 6-SMT will be made by a validated radio-immunology assay"
223394453|NCT05878730|DIAGNOSTIC_TEST|Level of Proteins|"* blood sample at V2 (2x3.5mL citrate tubes)~* measured by ELISA"
223394454|NCT05878730|DIAGNOSTIC_TEST|Level of mRNA and miRNA|"* blood sample at V2 (2x2.5mL PAX-gene tube)~* measured by quantitative RT-PCR"
224014406|NCT06301984|DEVICE|Insight GS|"The Andromeda Insight Growing System (Insight GS) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth.~The Andromeda Insight Growing System consists of blades, clamps and pedicle screws used to form a distinct spinal construct in growing children. The implanted blade is used to brace the spine during growth and minimize the progression of scoliosis. The components are implanted from a posterior approach and are made from Titanium alloy (Ti6AL-4V-ELI), and High Density Polyethylene (HDPE)."
224014407|NCT00447811|DRUG|MOA-728|
224128097|NCT06692491|DRUG|Epirubicin|Epirubicin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with epirubicin if PDOs show the highest response to this drug under the guidance of MTB.
224128098|NCT06692491|DRUG|Gemcitabine|Gemcitabine 1000mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with gemcitabine if PDOs show the highest response to this drug under the guidance of MTB.
223394455|NCT05878730|DIAGNOSTIC_TEST|Level of plasmatic and intraerythrocytic lithium|"* blood sample at V2 (mmol/L)~* 4mL EDTA tube"
223394456|NCT05293366|DIAGNOSTIC_TEST|Assessments of endocrinological phenotypes of LO-COCO patients|Assessment of:thyroid-stimulating hormone(TSH),free triiodothyronine (FT3), free thyroxine (FT4),calcitonin,antibodies against thyroglobulin (AbTG) and against thyroperoxidase (AbTPO),adrenocorticotropic hormone (ACTH),cortisol, luteinizing hormone (LH),follicle-stimulating hormone(FSH),Testosterone,17-beta estradiol,sex hormone binding globulin (SHBG),progesterone, prolactin (PRL), growth hormone (GH), insulin growth factor-1 (IGF-1), dehydroepiandrosterone sulphate (DHEAS),delta 4-androstenedione,aldosterone,renin,glycemia, insulinemia, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, HbA1c, vitamin D, adiponectin, irisin, IL-6.Thyroid and ovarian ultrasounds, pituitary and adrenal MRI will be performed as well. Body composition will be assessed with bioimpedance analysis and DXA scans.Female sexual dysfunctions will be evaluated with Female Sexual Function Index (FSFI), Sexual Inhibition and Sexual Excitation Scale (SIS/SES),Body Uneasiness Test (BUT).
223394457|NCT05293366|DIAGNOSTIC_TEST|Assessment of muscular phenotypes of LO-COCO patients|Questions will be collected regarding the tolerance to physical activity and modifications after diagnosis of Covid. Muscular strength will be assessed by means of tests (Medical Research Council Scale) and dynamometers. Balance will be assessed with a Romberg test, tolerance to stress will be assessed by means of cyclometer.
223394458|NCT05293366|DIAGNOSTIC_TEST|Assessment of neuropsychiatric phenotypes of LO-COCO patients|Validated questionnaires will be collected to investigate depression (Beck Depression Inventory-II, BDI-II), apathy (Apathy Evaluation Scale, AES), anxiety (Test Anxiety Inventory, TAI), attention and cognitive functions (Montreal Cognitive Assessment and Quick Mild Cognitive Impairment). Fatigue will be assessed by Fatigue Rating Scale (FRS) and Fatigue Severity Scale (FSS). Muscle power will be assessed by six-minute walking test and sit and stand up test. The presence of myopathy will be evaluated by mean electrophysiological study.
224014408|NCT02015182|OTHER|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).~Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
224128099|NCT06692491|DRUG|Vinorelbine|Vinorelbine 25-30mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with vinorelbine if PDOs show the highest response to this drug under the guidance of MTB.
223394459|NCT05293366|PROCEDURE|Muscle biopsy|Muscle biopsy will be performed upon need.
223394460|NCT05293366|DIAGNOSTIC_TEST|Assessment of pulmonary phenotypes of LO-COCO patients|Modified Medical Research council questionnaire will be administered for evaluating of the dyspnoea level. Complete respiratory status assessment, including global spirometry, CO lung diffusion capacity and arterial gases analysis will be run. HRCT - high resolution CT scan of the chest - will be performed in selected cases to rule out the eventual sequelae of SARS-Cov2 related pneumonia.
223394461|NCT05293366|DIAGNOSTIC_TEST|Assessment of cardiological phenotypes of LO-COCO patients|Cardiological assessment will be run upon data collected from: Short Form-36 Health Survey (SF36), echocardiogram at rest and during stress tests, six-minute walking test, N-terminal fragment brain natriuretic peptides (NT-proBNP)
223394462|NCT05293366|DIAGNOSTIC_TEST|Assessment of vascular phenotypes of LO-COCO patients|The assessment of the potential post-thrombotic vascular damage will comprise the investigation of prevalence of previously unknown deep venous thrombosis by ultrasonography.
223394463|NCT05293366|DIAGNOSTIC_TEST|Assessment of dermatological phenotypes of LO-COCO patients|Dermatology evaluation will account on: thrichoscopy, dermoscopy, onychoscopy and capillaroscopy, confocal microscopy, skin ultrasonography
223394464|NCT05293366|PROCEDURE|Tissue biopsy|Tissue biopsy will be performed upon need.
223394465|NCT05975333|BEHAVIORAL|Writing|Participants will be asked to write about their experiences with cancer, guided by several specific open-ended writing prompts to spark ideas.
223394466|NCT05975333|BEHAVIORAL|Interview|Following completion of the writing exercise, participants will reflect on their experiences with the writing intervention in a semi-structured private interview with a member of the research team.
223394467|NCT06700512|DEVICE|Hearing Aid Signia Pure C&G 7IX|Receiver in Canal (RIC) hearing aid, M Receiver
223394468|NCT06700512|DEVICE|Own Hearing Aid|subjects' own hearing aids, any brand, any model
223394469|NCT06434909|DRUG|Cytalux™ (pafolacianine) for fluorescent imaging|"Cytalux™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye for real-time cancer margin status.~This is used in conjunction with appropriate imaging system."
223394470|NCT06434909|PROCEDURE|Image Guided Surgery|prostatectomy using appropriate imaging system
223394471|NCT04859296|DRUG|Placebo|Vaporized placebo
223394472|NCT04859296|DRUG|Low CBG|Vaporized CBG (5 mg)
223394473|NCT04859296|DRUG|High CBG|Vaporized CBG (15 mg)
223394474|NCT04859296|DRUG|Low THC|Vaporized THC (5 mg)
223394475|NCT04859296|DRUG|High THC|Vaporized THC (15 mg)
223548959|NCT04345900|DRUG|Plinabulin|a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
223548960|NCT04345900|DRUG|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
223548961|NCT04157153|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
223548962|NCT00162591|DRUG|remifentanyl|
223548963|NCT01672879|BIOLOGICAL|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
223548964|NCT01672879|BIOLOGICAL|SIM|Intravenous infusion over 30 minutes every 2 weeks
223548965|NCT00305903|DRUG|Rivastigmine, memantine|
223394476|NCT06025721|BEHAVIORAL|Cardiovascular Risk Homeless Support|There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve cardiovascular health behaviors. The coach will encourage a focus on smoking\>medication\>sleep\>physical activity\>healthy eating to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief cardiovascular health education as needed in participants' preferred format (handout, video, audio, etc.).
223394477|NCT06228053|DRUG|SX-682|Specified dose twice daily
223394478|NCT06228053|DRUG|Enzalutamide|Specified dose once daily
223394479|NCT05226507|DRUG|NXP800|NXP800 is an anti-neoplastic, oral small molecule.
223394480|NCT05895747|DRUG|Low Dose 5-hydroxytryptophan|5-hydroxytryptophan 100mg PO BID
223394481|NCT05895747|DRUG|High Dose 5-hydroxytryptophan|5-hydroxytryptophan 200mg PO BID
223394482|NCT05895747|DRUG|Low Dose Creatine Monohydrate|Creatine monohydrate 5g PO qday
223394483|NCT05895747|DRUG|High Dose Creatine Monohydrate|Creatine monohydrate 10g PO qday
223394484|NCT05895747|DRUG|Placebo|Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
223394485|NCT06271850|OTHER|Ergonomics breastfeeding training|The ergonomics training includes the most ergonomically appropriate methods to breastfeed and ergonomic guidelines, including how to cuddle and breastfeed the baby correctly.
223394486|NCT06271850|OTHER|Pilates exercises|Pilates exercises, 3 times per week, for 8 weeks, in the form of neck extensor stretching, neck extensor and rotation stretching, pectoral muscle stretching, strengthening of deep neck flexors and scapular retractor, and core strengthening exercises ( pelvic bridging, plank, cat and camel, curl up, single leg abdominal press and double leg abdominal press).
223394487|NCT04510090|DRUG|EP547|EP547
223394488|NCT04510090|DRUG|Placebo|Placebo
223394489|NCT04755335|DIAGNOSTIC_TEST|Ultrasound|In this project, The investigators will use Alpinion ECUBE-12R (Alpinion, Bothell, WA) US platform. This state-of-the-art research US machine provides beam formed as well as Plane-Wave imaging options that allow high frame rate imaging. The investigators have characterized the acoustic output of this system for safe human studies and obtained the IRB approval for human studies. It should be noted that our technique is not limited to the Alpinion system; the investigators can also use other US systems, such as Verasonics, Vantage, (Redmond, WA). This technique can be adapted to other modern US machines in the future.
223394490|NCT06181656|BIOLOGICAL|Pneumonia vaccine|Given by SC
223394491|NCT05728151|DRUG|Articaine and Epinephrine Only Product|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
223394492|NCT05728151|DRUG|levobupivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
223394493|NCT05728151|DRUG|mepivacaine|comparison between its effect with the other two local anesthetic drugs in peribulbar block on oculocardiac reflex intraoperatively and in peribulbar block on postoperative pain in pediatrics undergoing squint surgeries with general anesthesia
223394494|NCT05736666|BEHAVIORAL|Treadmill-based perturbation training|The intervention consists of disturbances delivered on a treadmill that simulates tripping over an obstacle or being perturbed to the side. These disturbances require a compensatory step to respond. Through this task-specific training, participants should learn to control their trunk motion in a way that will cause them to avoid a trip or fall to the side.
223394495|NCT05736666|BEHAVIORAL|Education Control|Fall prevention educational material
223394496|NCT06183944|OTHER|Hierarchical clustering methods|Hierarchical clustering methods will be used to form homogeneous groups of patients based on their data at diagnosis: presence or absence of symptoms, clinical and biological data, and presence or absence of favouring factors. Patient evolution at 6 months can fall into categories: stable, aggravation or progress, which are determined by events such as recurrence, hemorrhage, functional sequelae or death.
223394497|NCT06172517|OTHER|Orthosis intervention|Clinical feasibility trial with one group using a custom-made foot orthotics prescribed by podiatrists (foot impression, polypropylene orthotics and covering at podiatrists' discretion).
223394498|NCT03938883|DEVICE|Ocular Bandage Gel (OBG)|A modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
223394499|NCT03938883|DEVICE|Bandage Contact Lens (BCL)|A bandage contact lens protects an injured or diseased cornea from the mechanical rubbing of the blinking eyelids, therefore allowing it to heal. It is a normal (usually soft, but not always) contact lens has no power. It is not intended to improve your vision.
223394500|NCT06396871|DIAGNOSTIC_TEST|Oral glucose tolerance test|75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min
223394501|NCT06396871|DIAGNOSTIC_TEST|Liver Ultrasound|A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.
223394502|NCT06396871|DIAGNOSTIC_TEST|Fibroscan of the Liver|FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).
223394503|NCT06396871|DIAGNOSTIC_TEST|Magentic Resonance Imaging (MRI) of the liver|The exact calculation of liver fat with proton density fat fraction will take place with MRI.
223394504|NCT01240681|PROCEDURE|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
223394505|NCT04434339|PROCEDURE|erector spinae block|A volume of 20 ml for each side of erector spinae plane with 0.25% plain bupivacaine
223394506|NCT04434339|PROCEDURE|transversus abdominis block|A volume of 20 ml for each side of transversus abdominis plane with 0.25% plain bupivacaine
223394507|NCT01749826|DRUG|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
223394508|NCT03261778|DEVICE|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
224014409|NCT03450512|OTHER|prospective study on digestive affections in an homogeneous cohort of hematological patients|"Systematic realization during the induction and/or every consolidation of a CTscan with injection, at the same time as the thoracic CTscan (to research an invasive fungal bronchopulmonary infection), in front of a febrile neutropenia with persistent fever after 5 days of antibiotics and presence of digestive signs.~Statement of the information characterizing the digestive affection: clinical symptoms, microbiological, characteristic, realized additional explorations, infectious complications and specific therapeutics.~The abdominal scanner will be repeated in case of suspicion of complication or clinical worsening. In case of EC, the abdominal scanner will be realized before beginning the next cycle of AML treatment to evaluate digestive remission. Finally, a CT scan, will be performed when digestive disease, digestive neoplasia or digestive symptoms are noted at AML diagnosis."
224128100|NCT06692491|DRUG|Cisplatin|Cisplatin 90mg/m2,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with cisplatin if PDOs show the highest response to this drug under the guidance of MTB.
224128101|NCT06692491|DRUG|Irinotecan|Irinotecan 125mg/m2,D1,D8,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with irinotecan if PDOs show the highest response to this drug under the guidance of MTB.
224128102|NCT06692491|DRUG|Fluorouracil|Fluorouracil 600mg/m2,D1-5,q3w Patients with advanced rare tumours who failed to standard treatment will be administrated with fluorouracil if PDOs show the highest response to this drug under the guidance of MTB.
223394509|NCT00240448|DRUG|telmisartan 80 mg/hydrochlorothiazide 25 mg|
223394510|NCT00240448|DRUG|valsartan 160 mg/hydrochlorothiazide 25 mg|
223394511|NCT00240448|DRUG|placebo|
223394512|NCT01805518|DIETARY_SUPPLEMENT|Scelectium Tortuosum|"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."
223394513|NCT03699618|DRUG|Anti-VEGF|Standard of care treatment with anti-VEGF only
224014410|NCT03234985|BIOLOGICAL|Biological analyses|Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
224014411|NCT01963923|BEHAVIORAL|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
224014412|NCT04855838|DEVICE|Oral neuromuscular training|The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
224014413|NCT04637178|BEHAVIORAL|Resistance training|Resistance training sessions twice a week for ten weeks
223394514|NCT03699618|OTHER|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
223394515|NCT03727919|BEHAVIORAL|Exoskeleton-assisted gait training|In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
223394516|NCT05501418|BIOLOGICAL|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be IV infusion with 12 months of follow up after treatment.
223394517|NCT05501418|BIOLOGICAL|Controlled normal saline|Normal saline will be IV infusion with 12 months of follow up after treatment.
223394518|NCT04904497|BEHAVIORAL|Early Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: trained family members and health staff about the intervention process"
224014414|NCT04637178|BEHAVIORAL|Endurance training (habitual)|Endurance training for ten weeks (habitual routines)
224014415|NCT04603638|DRUG|Magnesium|40 mg/kg(peroperative), 40 mg/kg (postoperative 12 h)
224014416|NCT04603638|DRUG|Isotonic|100 ml
224014417|NCT03699085|BEHAVIORAL|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
224128103|NCT06692491|DRUG|Nivolumab|Nivolumab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with nivolumab under the guidance of MTB.
224128104|NCT06692491|DRUG|Pembrolizumab|Pembrolizumab 200mg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with pembrolizumab under the guidance of MTB.
223394519|NCT03424005|DRUG|Capecitabine|Capecitabine will be administered 1250 mg/m\^2 orally twice daily on Days 1-14, of each 21 day cycle.
223394520|NCT03424005|DRUG|Atezolizumab|"For Atezolizumab (Atezo) + SGN-LIV1A, Atezo + Sacituzumab Govitecan, or Atezo + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.~For Atezo + Nab-Paclitaxel, Atezo + Selicrelumab + Bevacizumab, Atezo + Ipatasertib, or Atezo + Nab-Paclitaxel + Tocilizumab: atezolizumab will be administered IV, 840 mg on Days 1 and 15, of each 28-day cycle."
223394521|NCT03424005|DRUG|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle.
223394522|NCT03424005|DRUG|SGN-LIV1A|SGN-LIV1A will be administered IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle.
223394523|NCT03424005|DRUG|Bevacizumab|Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
223394524|NCT03424005|DRUG|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle.~Or~Eribulin will be administered by IV, 1.4 mg/m\^2 on days 1 and 8 of each 21 day cycle."
223394525|NCT03424005|DRUG|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
223394526|NCT03424005|DRUG|Tocilizumab|Tocilizumab will be administered IV, 8 mg/kg infusion on Day 1 of each 28 day cycle.
223730855|NCT05451368|OTHER|Coronary artery calcification lesions|Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
223730856|NCT02279173|DRUG|Romiplostim|Romiplostim subcutaneous weekly injection
224014418|NCT02789046|PROCEDURE|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
224014419|NCT03751579|PROCEDURE|coelioscopic surgery|observational study based on the computation of respiratory quotient in patient cohort treated by routine coelioscopic surgery
224014420|NCT00875654|GENETIC|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke
224014421|NCT03248154|DEVICE|Procellera|burn dressing
224014422|NCT03407664|OTHER|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
224014423|NCT01170793|BEHAVIORAL|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
224014424|NCT05383508|OTHER|CA35|Nicotine concentration: 3.5 % e-liquid flavor: Tobacco
224014425|NCT05383508|OTHER|CM35|Nicotine concentration: 3.5 % e-liquid flavor: Menthol
224014426|NCT05383508|OTHER|Cig|Subjects' preferred brand of commercially available, regular or mentholated cigarettes
224014427|NCT04865341|BEHAVIORAL|IMB|Intervention content will be focused on the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
224014428|NCT04865341|BEHAVIORAL|Information-Only Control|Intervention content will be focused on the information construct of the Information-Motivation-Behavioral Skills (IMB) model. We plan to incorporate previously developed content as much as possible and will include professionally produced videos about HIV testing and PrEP and other resources. We believe our approach of guiding YMSM through intervention modules based on theory will help improve content retention/use and ultimately influence constructs posited to result in behavior change. We foresee using multiple forms of attention-matched material, media, and programming to engage (and retain engagement) of YMSM throughout the brief single-session intervention (45-60 minutes).
223394527|NCT03424005|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered by IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.
223394528|NCT03424005|DRUG|Sacituzumab Govitecan|Sacituzumab govitecan will be administered by IV, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.
223394529|NCT03424005|DRUG|Abemaciclib|Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each cycle (cycle=28 days).
223394530|NCT03424005|DRUG|Fulvestrant|Fulvestrant IM injection at a dose of 500 mg will be administered on Days 1 and 15 of Cycle 1, and then on Day 1 of each cycle thereafter (cycle=28 days).
223394531|NCT03424005|DRUG|Ribociclib (dose #1)|Ribociclib tablets will be administered by mouth once daily.
223394532|NCT03424005|DRUG|Inavolisib (dose #2)|Inavolisib tablets will be administered by mouth once daily.
223394533|NCT03424005|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan will be administered at a dose of 5.4 mg/kg by IV infusion on Day 1 of each 21-day cycle.
223394534|NCT03424005|DRUG|Ribociclib (dose #2)|Ribociclib tablets will be administered by mouth once daily.
223394535|NCT03424005|DRUG|Letrozole|Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each cycle (cycle = 28 days).
223730857|NCT01899690|DRUG|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
224014429|NCT02103205|DIETARY_SUPPLEMENT|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
223394536|NCT03424005|DRUG|Inavolisib (dose #1)|Inavolisib tablets will be administered by mouth once daily.
223394537|NCT03424005|DRUG|Inavolisib|Inavolisib tablets will be administered by mouth once daily.
223394538|NCT05085834|DRUG|Zinc Gluconate|Two 45 mg capsules once daily
223394539|NCT05085834|DRUG|Placebo|Two placebo capsules once daily
223394540|NCT05815628|DIAGNOSTIC_TEST|DISQVER|NGS based infection diagnosis
223394541|NCT05842967|BIOLOGICAL|RSVpreF|120-µg
224014430|NCT02103205|DIETARY_SUPPLEMENT|Formula with low iron concentration (2mg/L) without lactoferrin|
224014431|NCT02103205|DIETARY_SUPPLEMENT|Formula with normal iron concentration (8 mg/L) without lactoferrin|
223394542|NCT05842967|OTHER|Placebo|Placebo
223548966|NCT00276055|DRUG|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
223548967|NCT04193449|DIAGNOSTIC_TEST|colonoscopy|colonoscopy procedure
223548968|NCT04148066|DIAGNOSTIC_TEST|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
223548969|NCT03823586|DIAGNOSTIC_TEST|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
223548970|NCT02838043|DIETARY_SUPPLEMENT|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
223394543|NCT05988996|BEHAVIORAL|Participant guided peer support gathering|This prospective observational cohort study will be assessing parental stress, anxiety, and sense of belonging before and after participant attendance at the culturally concordant peer group session.
223394544|NCT05974176|BEHAVIORAL|Trauma Focused CBT (TF-CBT)|TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
223394545|NCT05974176|BEHAVIORAL|Trauma Systems therapy (TST)|Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
223394546|NCT06462989|OTHER|ECHONEXT|ECHONEXT Artificial intelligence algorithm
223394547|NCT04482348|OTHER|Explanation|Explanation provided to patients for more pain than expected
223394548|NCT03831230|GENETIC|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
223548971|NCT01476540|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
223548972|NCT02370992|RADIATION|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
223548973|NCT04224233|OTHER|Home-based physical activity programme|iLiFE is a 12-week individualised programme, adapted to the participants' needs and preferences. This programme will be conducted in participants' home and include everyday tasks to train endurance, balance, flexibility and strength. The intervention incudes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt activities to everyday tasks, increase frequency and/or intensity, monitor progress, clarify doubts, motivate higher daily energy expenditure and manage expectations. Phone-calls aim to clarify doubts and to monitor patients' motivation/evolution, following a motivational interview. At the start of the program, the physiotherapist will be present at all sessions, but these face-to-face visits will decrease over time. Patients will also receive a personalised manual (iLiFE manual) with activities to do in their everyday tasks.
223548974|NCT04224233|OTHER|Usual care|Participants will receive a leaflet with exercises and PA recommendations.
223548975|NCT03278795|PROCEDURE|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
223730858|NCT06401395|DEVICE|DIGIPARK MONITOR|remote monitoring application (containing a questionnaire to assess the patient's symptoms, adapted from the clinical examination using the MDS-UPDRS scale). This questionnaire will be completed weekly for 12 months via the DIGIPARK MONITOR application by the patient or caregiver.
223730859|NCT02090660|OTHER|ICG Localization with Spy thoracoscope localization|
223730860|NCT02240160|DRUG|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
223394549|NCT04715581|DIETARY_SUPPLEMENT|Preoperative nutritional optimization|"1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery."
223394550|NCT04715581|BEHAVIORAL|Preoperative exercise training|"1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery."
223730861|NCT00188149|DRUG|Combined chemotherapy (ABVD, BACOPP-D)|
223730862|NCT00188149|PROCEDURE|Radiation therapy|
223394551|NCT04715581|BEHAVIORAL|Postoperative exercise training|"1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge."
223394552|NCT03370263|DRUG|Benlysta|Benlysta will be administered intravenously or subcutaneously.
223394553|NCT04940000|OTHER|Patient managed at the IUCT-O and by a private speech therapist (near the patient's home).|"Each patient included will have a video-assisted remote speech therapy consultation with a private speech therapist (near the patient's home) and the expert speech therapist of IUCT-O center.~At the end of this video consultation, the patient and the private speech therapist will be asked to complete a satisfaction questionnaire."
223730863|NCT05001386|BIOLOGICAL|Blood collection for the evaluation of the anti-drugs sensitivity|The M.D investigators and the medical team identify the patients ( index cases and healthy volunteers) in a medical appointment. They inform them, collect the non-opposition right and the blood samples: 5 mL heparin tube and 5 mL dry tube for each person , one time.
223730864|NCT05947370|DRUG|Berberine Chloride|Traditional Chinese medicine
224014432|NCT03629379|DRUG|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
224014433|NCT03629379|DRUG|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
224014434|NCT01419470|DRUG|dapoxetine|"1. multiple dosing~2. 12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
224014435|NCT04100278|BEHAVIORAL|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
224014436|NCT06442007|BEHAVIORAL|Behavioral Activation - single session intervention (BA-SSI)|Single session intervention
224014437|NCT06442007|BEHAVIORAL|4-session Mindset intervention|This is comprised of 4 sessions.
224014438|NCT05912101|PROCEDURE|Pericapsular Nerve Group Block|A convex USG Probe (1-5 mHz) is placed transversely on the SIAS (Spina Iliaca Anterior Superior). The probe is then rotated 45 degrees and aligned with the pubic ramus. In this position, the iliopubic eminence, ilipsoas muscle-tendon, femoral artery and pectineus muscle are observed. A 100 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial to the musculofascial plane with the psoas tendon in front and the pubic ramus behind and the injection is performed.
223394554|NCT06277310|OTHER|3 Wishes Project|palliative care initiative in which clinicians elicits and implements small acts of kindness for dying patients and their families
223394555|NCT00751699|DRUG|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
223394556|NCT00751699|DRUG|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
223394557|NCT00751699|DRUG|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
223394558|NCT05286229|DRUG|Etentamig|Intravenous (IV) Infusion
223394559|NCT01051310|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve
223394560|NCT03869320|DRUG|ACT-1004-1239|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
223394561|NCT03869320|OTHER|Placebo|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
223394562|NCT03869320|DRUG|ACT-1004-1239 (Food-effect subpart)|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
223394563|NCT03869320|OTHER|Placebo (Food-effect subpart)|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
223394564|NCT01823328|DRUG|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
223394565|NCT01823328|DRUG|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
223394566|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
223394567|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
223394568|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
223394569|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
223394570|NCT00505713|GENETIC|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
223730865|NCT05947370|DRUG|Placebo|Placebo control
223394571|NCT06092814|DEVICE|Active transcranial alternating current stimulation (tACS)|Transcranial Alternating Current Stimulation (tACS) is a device that applies a low-intensity electrical current to the brain through electrodes on the scalp.
223394572|NCT05796219|RADIATION|Low dose mammogram|Low dose mammogram
223730866|NCT06391164|DRUG|XC243 25 mg|Patients will receive the Investigated Product (IP) once in the morning at least 30 minutes before eating for 7-10 days
223394573|NCT04030442|DRUG|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
223394574|NCT04030442|OTHER|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
223548976|NCT03278795|PROCEDURE|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
223548977|NCT03951766|BEHAVIORAL|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
223548978|NCT02553187|DRUG|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
223548979|NCT04198883|COMBINATION_PRODUCT|Protheracytes|Intramyocardiac (LV) injection of stem cells with a dedicated catheter
223548980|NCT00318929|DRUG|Divalproex Sodium Extended-Release Tablets|Once a day dosing
223394575|NCT01543438|OTHER|Video Prescription (additional education)|receives video prescriptions
223548981|NCT04061109|DRUG|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
223548982|NCT00352859|DRUG|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
223548983|NCT00352859|DRUG|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
224014439|NCT05912101|PROCEDURE|Suprainguinal Fascia Compartment Block|A linear USG probe (7-13 mHz) is placed parasagittal to obtain an image of the SIAS. The probe is then shifted medially to identify the fascia iliaca, iliac muscle, internal oblique muscle and deep circumflex iliac artery. A 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is advanced in-plane from caudal to cephalic and injected between the fascia iliaca and iliac muscle.
224014440|NCT05912101|PROCEDURE|3-1 Block|A linear USG probe (7-13 mHz) is placed at the level of the femoral fold and the femoral vein-arterial-nerve is visualized. The femoral nerve is located below the fascia iliaca. At this point, a 50 mm 21G block needle (Stimuplex A®:B. Braun Melsungen AG, Japan) is inserted in-plane from lateral to medial and injected lateral to the femoral nerve. After injection, pressure is applied distal to the needle entry site to spread the local anesthetic proximally in the nerve sheath.
224014441|NCT04702698|DRUG|Peposertib|Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.
224014442|NCT04702698|DRUG|Peposertib|Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
224014443|NCT05019404|PROCEDURE|Functional anterior temporal lobectomy (FATL)|Patients are placed in the supine position with the head contralaterally rotated 30°. The 3D model of incision and bone flap is printed prior to surgery by the slicer software based on the MRI data. Slightly curve incision with the length of about 6 cm in the temporal region is marked according to the 3D model. Temporal craniotomy via small bone window with the diameter of about 3 cm is performed. From the temporal pole along T1 about 5 cm posteriorly, temporal horn is opened by dissecting the middle temporal gyrus. The head of temporal horn is exposed. The amygdala is resected. Then, the parahippocampal gyrus and hippocampus are en bloc resected. The lateral temporal lobotomy is easy due to large view following the removal of mesial structures. The lateral posterior temporal lobotomy is no more than 5 cm from the temporal pole.
223394576|NCT00745862|BEHAVIORAL|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
223394577|NCT03176303|DEVICE|SpinalStim|PEMF osteogenesis stimulator
223730867|NCT06391164|DRUG|XC243 50 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
224014444|NCT05019404|PROCEDURE|Anterior temporal lobectomy (ATL)|Patients are placed in the supine position with the head contralaterally rotated 30°. Large frontotemporal craniotomy is performed. Question mark-shaped incision with the length of 20- 25 cm in the frontotemporal region is marked. The size of the bone flap is approximately 5×7 cm for the exposure of lateral temporal lobe. ATL consists of en bloc resection of the anterior 5 cm of lateral temporal lobe, followed by the removal of mesial structures including the amygdala, parahippocampal gyrus, and hippocampus.
224014445|NCT06256237|DRUG|JS004|Specified dose on specified days.
224014446|NCT06256237|DRUG|Toripalimab|Specified dose on specified days.
224014447|NCT06256237|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
224014448|NCT06256237|DRUG|Etoposide|Specified dose on specified days.
224014449|NCT06256237|DRUG|Platinum|Specified dose on specified days.
224014450|NCT05979415|DRUG|Apomorphine Cartridge|Staccato Cartridge
223394578|NCT04276961|OTHER|Acupuncture|Acupuncture will be given for a total of 12 session over 4 weeks. Acupuncture at acupoints Tianshu (ST25), Shangjuxu (ST37), Zusanli (ST36), and Neiguan (PC6) bilaterally will be given.
223548984|NCT01288625|DRUG|Amifostine|500 mg sc, qod, 3 times per week
223730868|NCT06391164|DRUG|XC243 75 mg|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
223394579|NCT02178657|DRUG|Autologous bone marrow mononuclear cell intra-arterial injection|
223394580|NCT01692041|DRUG|ivy leaves dry extract|5 ml twice daily po
223394581|NCT01692041|DRUG|Placebo|5 ml per os twice daily
223394582|NCT00751920|PROCEDURE|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
223394583|NCT06576180|DRUG|Carboplatin（ neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223394584|NCT06576180|DRUG|Paclitaxel （neoadjuvant）|Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223394585|NCT06576180|DRUG|Anti-PD-1 Drugs|Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223394586|NCT06576180|PROCEDURE|Surgical resection|Standard of care
223548985|NCT01288625|RADIATION|Amifostine|500mg rinsing wash, qod, 3 times per week
223548986|NCT06319209|OTHER|Preoperative resolved COVID-19|We observed postoperative outcomes only in patients who had or did not have COVID-19 before surgery, without any additional intervention.
223548987|NCT05595343|PROCEDURE|Laparoscopic distal pancreatectomy|Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
223548988|NCT03819257|DIAGNOSTIC_TEST|Endoanal ultrasound|For the assessment of the internal and external anal sphincter integrity. To evaluate fistulas/perianal abscess and seton placement.
223548989|NCT03819257|DIAGNOSTIC_TEST|High-resolution anorectal manometry|"1. rest - basal anal pressures at rest over 60 s~2. squeeze - anal pressure during voluntary effort; long squeeze - anal pressure during sustained voluntary effort~3. cough - anorectal pressure changes during cough~4. push - anorectal pressure changes during simulated defecation~5. rectoanal inhibitory reflex - reflex anal response to rectal distension~6. rectal sensation - assessment of rectal sensitivity to distension."
224296501|NCT05410366|OTHER|Safe harbor clinical practice guideline|A safe harbor is a special type of clinical practice guideline which, under existing federal law, may serve as the legal standard of care, not just evidence of the standard of care. If a patient with a safe harbor condition satisfies all safe harbor inclusion criteria and does not meet any exclusion criteria, no imaging is required, and the patient may be discharged with specific instructions. If a patient is excluded from the safe harbor, then imaging decisions are per customary practice. The safe harbor clinical practice guidelines are provided to treating ED physicians, but they are not obligated to use them. The safe harbor pathways do not limit the diagnostic and therapeutic approach patients and physicians undertake during a clinical encounter. They have the liberty in this decision to proceed jointly down a clinical pathway most appropriate to the individual clinical circumstance.
223548990|NCT03819257|DIAGNOSTIC_TEST|Balloon expulsion test|A non-latex balloon will be inserted in the rectum after applying lubricating gel. This balloon is then filled with 50ml of warm water. The patient is ask to sit on a commode and to try to expel the device in privacy, while the time is being recorded. The test ends when the patient expelled the balloon or when 3 minutes are reach.
223548991|NCT05842525|DRUG|intensive treatment|Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）
223730869|NCT06391164|DRUG|Placebo|Patients will receive the IP once in the morning at least 30 minutes before eating for 7-10 days
223730870|NCT00003204|DRUG|cyclophosphamide|Given IV
223730871|NCT00003204|DRUG|fludarabine phosphate|Given IV
223730872|NCT00003204|DRUG|vincristine sulfate|Given IV
223730873|NCT00003204|DRUG|prednisone|Given PO
223730874|NCT00003204|BIOLOGICAL|rituximab|Given IV
223394587|NCT00000594|DRUG|cholestyramine|
223394588|NCT06230926|OTHER|Validity, Reliability and Adaptation|The Hoehn \& Yahr Scale (HDS) and the Unified Parkinson's Disease Rating Scale (UPDRS) will be used for the clinical evaluation and disease staging of the individuals included in the study. In addition to the PDQoL-7 questionnaire, the 'Short Form-36' and 'Parkinson's Disease Questionnaire-39' questionnaires will be administered to patients to assess concurrent validity. Since at least 5-10 times the number of items in the questionnaire (7 items) must include at least 5-10 times the number of participants in order to perform factor analysis, a pretest of the questionnaire will be applied to individuals with PD with at least 35-70 participants. To determine the test-retest reliability, the PDQoL7 questionnaire will be administered again to the same patients after 2 weeks.
223394589|NCT01269216|DRUG|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
224296502|NCT00616044|PROCEDURE|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
224296503|NCT00616044|PROCEDURE|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
223394590|NCT01269216|DRUG|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
223394591|NCT06648395|BEHAVIORAL|CBT Text Messages|CBT text messages will be sent 3 times per week for 4 weeks
223394592|NCT06648395|BEHAVIORAL|Supportive Messages|Supportive text messages will be sent 3 times per week for 4 weeks
223394593|NCT01024504|DRUG|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
223394594|NCT01024504|DRUG|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
223394595|NCT01024504|DRUG|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
223394596|NCT02194283|DRUG|Ambroxol - in single rising doses|
223394597|NCT02194283|DRUG|Placebo|
223548992|NCT05842525|DRUG|Maintenance treatment|Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
223730875|NCT00003204|OTHER|laboratory biomarker analysis|Correlative studies
223730876|NCT00002222|DRUG|Valganciclovir|
223730877|NCT00280462|DRUG|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
223730878|NCT00280462|DRUG|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
223730879|NCT00280462|DRUG|Placebo|Placebo
223394598|NCT01237171|RADIATION|Cesium-131 Brachytherapy Seed|85 Gray Dose
224014451|NCT05138744|OTHER|Behavioral activation using virtual reality|The investigators will encourage behavioral activation (increase in the number and time of conducted activities) situating the person in motivating situations using virtual reality
224014452|NCT00089921|DRUG|SCIO-469|60 mg capsule three times daily for 12 weeks
224014453|NCT00089921|DRUG|SCIO-469|30 mg capsule three times daily for 12 weeks
224014454|NCT00089921|DRUG|Placebo|2 capsules three times daily and one tablet daily
224014455|NCT00089921|DRUG|SCIO-469|100 mg tablet once daily for 12 weeks
223394599|NCT05532111|DRUG|Rituximab combined with tacrolimus induction + rituximab maintenance|RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.
223394600|NCT05532111|DRUG|Rituximab combined with tacrolimus induction + tacrolimus maintenance|RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).
223394601|NCT05532111|DRUG|Glucocorticoid combined with cyclophosphamide induction + maintenance|PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
223394602|NCT05348772|DRUG|AmnioPul-02|Mesenchymal stem / stromal cells, MSC
223394603|NCT06577142|OTHER|Burn 2 Learn|"The 'Burn 2 Learn' group encompassed the following components and implementations. A brief introductory seminar will be conducted with the principle, school event coordinator, school sports teacher and students from grade 8 to 10. The aim of this seminar is to provide a better understanding of the rationale and presenting evidence of the beneficial effects of high intensity interval training on overall wellbeing of students. The sessions will be conducted thrice a week for 10 to 15 minutes by the research team members for a period of 10 weeks. The sessions will consist of high intensity interval training activities such as lunges, jumping jacks, boxing, dancing and sports activities. The intervals ranging between 8-16, 30 second work out followed by 30 seconds rest, maintaining a 1:1 work rest ratio.~51 participants will be in the experimental group A giving them Burn 2 Learn exercise protocol along with the normal sports training plan for ten weeks."
223394604|NCT06577142|OTHER|Control Group|51 participants will be in control group B and will perform their routine school physical activities, sports games or any exercise routines.
224014456|NCT02360033|BEHAVIORAL|Systemic Therapy for Social Anxiety Disorder|
224014457|NCT02360033|BEHAVIORAL|Cognitive Behavioral Therapy for Social Anxiety Disorder|
224014458|NCT00020735|DRUG|toremifene|
224014459|NCT00020735|PROCEDURE|conventional surgery|
224014460|NCT00020735|PROCEDURE|neoadjuvant therapy|
224014461|NCT02880267|DEVICE|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
224014462|NCT01167764|DRUG|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
224014463|NCT03188913|DIAGNOSTIC_TEST|Coagulation tests|The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether
224296504|NCT00616044|PROCEDURE|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
223394605|NCT05737524|OTHER|Telerehabilitation (VAST 2)|The telehealth platform will be available by a web secure link accessible on a home computer or loaded on user friendly tablets that are customized for the patient's impairments. Telerehabilitation services will include 2 out of 3 disciplines: Occupational Therapy, Speech Therapy, Physical Therapy. All therapy interventions will be delivered by licensed therapists and will be based on patients' specific impairments and goals. Therapy intervention will be provided 3x/wk. for each of 2 disciplines. The intervention will be going on for 4 weeks which will total to 24 sessions. Self-management support with trained health coach will be integrated into 1 therapy session each week. An additional individual 30 minute session will occur with the health coach each week.
224014464|NCT05928351|OTHER|Pain Neuroscience Education|"The experimental group will follow a PNE protocol based on previous procedure for 6 weeks in addition to the standard physiotherapy program (SPP) in postoperative period.~Each PNE session will take 45-60 min. PNE will be conducted in line with international guidelines and covered the neurophysiology of pain, transition from acute to chronic pain, and the nervous system ability to modulate the pain experience."
224014465|NCT05928351|OTHER|Standard Physiotherapy Program (SPP)|The control group will follow a SPP. The 45-minute-long treatment sessions will be held 5 days per week. The treatment program will be organized in 3 periods as 0-2 weeks, 3-4 weeks and 5-6 weeks. The overall treatment program will include scar massage, patellar mobilization, coldpack, ankle pump, quadriceps and hamstring strengthening, hip range of motion, hip strengthening exercises, squat, ascending and descending stairs, walking training. All exercises will be 10 repetitions x 2 sets.
223548993|NCT02613195|DRUG|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
224014466|NCT02396329|DRUG|Chlorhexidine|
224014467|NCT02396329|DRUG|Povidone-Iodine|
224014468|NCT04560010|DRUG|Tranexamic Acid Injection (TXA)|Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later
224014469|NCT01871805|DRUG|Alectinib|Participants will receive alectinib as described in the arm descriptions.
224014470|NCT01737424|DRUG|LC28-0126|LC28-0126
224014471|NCT01737424|DRUG|Placebo|Placebo
224296505|NCT05000086|DRUG|99Tc methylene diphosphonate|22mg qd，Once a day for 7 consecutive days
223394606|NCT02547428|DRUG|CTN SR|CTN SR tablets, daily, Orally.
223394607|NCT02547428|DRUG|Matching placebo|Matching-placebo tablets daily, orally.
223394608|NCT05138588|DEVICE|rTMS|For each subject, a verum condition and a control condition will be programmed. We will use the QPS-5 method (4 pulses, Inter-Stimulation Interval; ISI: 5 seconds).
223394609|NCT04399616|OTHER|Risk Map|The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
223394610|NCT01479465|BIOLOGICAL|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
224014472|NCT01563159|OTHER|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
224014473|NCT02854969|BEHAVIORAL|Device: Anapphylaxis|
224014474|NCT00727779|BEHAVIORAL|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
224014475|NCT02720302|BEHAVIORAL|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
224014476|NCT02720302|BEHAVIORAL|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
224014477|NCT01405833|DRUG|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
224014478|NCT01405833|DRUG|Placebo|Single dose IV matched placebo
224014479|NCT03121248|RADIATION|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
224014480|NCT03121248|RADIATION|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
224014481|NCT03121248|RADIATION|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
224014482|NCT03121248|RADIATION|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
223394611|NCT01479465|DRUG|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
223394612|NCT01479465|DRUG|Leucovorin|l-Leucovorin 200 mg/m\^2 or dl-leucovorin 400 mg/m\^2 administered via intravenous infusion over 2 hours
223394613|NCT01479465|DRUG|Irinotecan|Irinotecan 180 mg/m\^2 administered via intravenous infusion over 90 minutes
223394614|NCT01479465|DRUG|Fluorouracil|Fluorouracil 400 mg/m\^2 administered via intravenous bolus and 2400 mg/m\^2 via intravenous infusion over 46 hours
224014483|NCT03121248|RADIATION|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
224014484|NCT03121248|RADIATION|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
224014485|NCT03121248|RADIATION|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
224014486|NCT03121248|RADIATION|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
224014487|NCT03097484|DRUG|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
224014488|NCT01157676|PROCEDURE|Open radical cystectomy|Standard of care removal of urinary bladder.
223548994|NCT05350540|OTHER|ICG dye|Patients assigned to the intervention group will undergo surgery guided by tissue perfusion as directed by the ICG imaging
224014489|NCT01157676|PROCEDURE|Robotic assisted radical cystectomy|Standard of care removal of urinary bladder using DaVinci robot.
224014490|NCT01157676|DEVICE|DaVinci robot|DaVinci robotic surgical system.
224014491|NCT05197725|DEVICE|Face mask|Individuals in intervention communities will be given surgical or KF94 face masks.
224014492|NCT05197725|BEHAVIORAL|Face mask awareness|Intervention individuals will be told about the importance of wearing face masks that cover the nose, mouth, and chin. Mask by mask promoters and community and religious leaders will encourage mask wearing.
224014493|NCT05197725|BEHAVIORAL|Face mask promotion through community values or individual information|"In intervention communities randomized to mask promotion through community values, promotional discussions and media will focus on encouraging groups of people to wear masks as a reflection of their values.~In intervention communities randomized to mask promotion through individual information, promotional discussions and media will target individuals and focus on the instrumental value of wearing masks (preventing the inhalation of viral particles)"
224014494|NCT02437071|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
224014495|NCT02437071|RADIATION|Radiotherapy|
223394615|NCT02807038|PROCEDURE|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
223394616|NCT00944931|DEVICE|DC Brain Polarization|
223394617|NCT04820465|OTHER|Non available due to cross-sectional study design|Non available since this study (survey) has a cross-sectional design
223394618|NCT01791673|DEVICE|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
223394619|NCT03043326|DRUG|Tenofovir Disoproxil Fumarate and Emtricitabine|This is an observational study. Pre-exposure Prophylaxis with TDF/3TC will be distributed to all participants elegible to receive PrEP.
223394620|NCT02162251|DRUG|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
223394621|NCT01011751|DRUG|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
223394622|NCT01011751|DRUG|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
223394623|NCT01011751|DRUG|Venlafaxine|Venlafaxine capsule.
223394624|NCT01011751|DRUG|Leuprorelin|Leuprorelin injection.
223394625|NCT01011751|DRUG|Flutamide|Flutamide tablet
223394626|NCT01011751|DRUG|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
223394627|NCT06309160|BEHAVIORAL|COMPASS Across Settings (CAST)|CAST will begin with an initial joint session with the student, caregiver, special education teacher, and pre-employment transition specialist that allows for discussion on the student's postsecondary goals, preferences, frustrations, challenges, and strengths related to social skills, adaptive/self-management, communication, problem behaviors, learning skills, and sensory sensitivities and preferences. This discussion will pinpoint critical social, communication, and work behavior/learning goals related to postsecondary goals and inform the intervention plans that are generated for each goal. Following this initial consultation, there will be four additional 1-hour sessions that incorporate evidence-based coaching, provided by the investigators, including performance feedback monitoring and instructional support. Each session is standardized and allows for assessment of student progress and intervention modification/self-reflection on the implementation of the intervention plans.
223394628|NCT00464958|DRUG|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
223394629|NCT06576414|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|the first hour of ACT intervention followed by 1 hour of back exercise class, which led by a trained ACT counsellor and a trained exercise trainer
223394630|NCT06576414|BEHAVIORAL|back exercise|1 hour of back exercise class led by a trained exercise trainer
224014496|NCT02437071|PROCEDURE|Radiofrequency ablation|
224014497|NCT03268525|DRUG|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
223394631|NCT06576414|BEHAVIORAL|back care education|1 hour long interactive lesson to participants about LBP-related pathology, disability, psychology, and pain management skills.
223394632|NCT04158258|DRUG|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
223394633|NCT04158258|DRUG|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
223394634|NCT04158258|DRUG|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
223394635|NCT04158258|DRUG|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
223394636|NCT04158258|DRUG|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
223394637|NCT04158258|DRUG|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
223394638|NCT01173523|DRUG|STA-9090|
223394639|NCT05648773|BEHAVIORAL|Messaging|Booster reminder message
223394640|NCT05648773|BEHAVIORAL|Financial Incentive|Financial Incentive for getting boosted within 2-weeks of the message
223394641|NCT05648773|OTHER|Placebo|Treatment as usual; no additional message and no incentive.
223394642|NCT01056783|DRUG|OC000459|OC000459 100mg, twice daily, tablet
223394643|NCT01056783|DRUG|Placebo|Placebo tablets to match OC000459 tablets, twice daily
223394644|NCT05362916|DRUG|Letermovir|Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.
223394645|NCT01957514|OTHER|Cytology Specimen Collection Procedure|Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
223394646|NCT01957514|OTHER|Laboratory Biomarker Analysis|Correlative studies
223394647|NCT01957514|OTHER|Quality-of-Life Assessment|Ancillary studies
223394648|NCT01957514|OTHER|Questionnaire Administration|Ancillary studies
223394649|NCT06192589|DRUG|Cannabidiol|Cannabidiol (Epidiolex) will be administered orally 2.5 mg/kg twice daily (5 mg/kg/day) for 28 days in Part 1 and for 9 days (morphine cohort) or 12 days (citalopram cohort) in Part 2.
223394650|NCT06192589|DRUG|Placebo|Placebo will be administered orally twice daily for 28 days in Part 1
223394651|NCT06192589|DRUG|Citalopram|Citalopram (Celexa) will be administered once at 20 mg on days 1 and 13.
223394652|NCT06192589|DRUG|Morphine|Morphine will be administered once at 15 mg on days 1, 4, and 11.
223394653|NCT02717507|DRUG|Carvedilol|Given PO
223394654|NCT02717507|OTHER|Laboratory Biomarker Analysis|Correlative studies
223394655|NCT02717507|OTHER|Pharmacogenomic Study|Correlative studies
223394656|NCT02717507|OTHER|Pharmacological Study|Correlative studies
223394657|NCT02717507|OTHER|Placebo Administration|Given PO
223394658|NCT02717507|OTHER|Quality-of-Life Assessment|Ancillary studies
223394659|NCT02717507|OTHER|Questionnaire Administration|Ancillary studies
223394660|NCT06332807|GENETIC|NGGT002|adeno-associated viral vector with human phenylalanine hydroxylase gene
223394661|NCT05309278|BEHAVIORAL|Physical training|Older adults assigned to this group will undergo two weekly sessions of remote and supervised physical training at home for 1 hour on non-consecutive days. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
223394662|NCT05309278|BEHAVIORAL|Cognitive training|These participants will also perform a weekly remote and supervised cognitive training session with neurobic exercises for 1 hour. In addition to the supervised cognitive training session, participants will also be prescribed asynchronous neurobic exercises to be performed on the remaining days of the week (without supervision). The intervention will last for 12 weeks, and all asynchronous neurobic exercises will be recorded in the following synchronous sessions by the supervisor. All synchronous meetings will be held on Google Meet, and supervisors will undergo training to standardize their procedures
224014498|NCT03268525|DRUG|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
224014499|NCT00555594|DRUG|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
224014500|NCT06415565|OTHER|conventional physiotherapy|Methods applied as conventional physiotherapy methods are: hotpack, Transcutaneous electrical nerve stimulation and ultrasound.
224128105|NCT06692491|DRUG|Durvalumab|Durvalumab 10mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with durvalumab under the guidance of MTB.
223394663|NCT04627792|BEHAVIORAL|IUSECAMH Parent Intervention (Waitlist)|We will use a switching replication design in which fifty guardians will be randomly assigned using a lottery to receive the intervention and fifty will be assigned to a group who will receive the intervention at a later time point
223394664|NCT05552820|DEVICE|Verum Electroacupuncture|Acupoints: Cuanzhu (BL2), Taiyang (EX-HN5), Sibai (ST1), Sizhukong (TE23), Baihui (GV20), Fengchi (GB20), Hegu (LI4), Zusanli (ST36), Guangming (GB23), Sanyinjiao (SP6), and Taichong (LR3). All acupoints will be taken bilaterally, except Baihui (GV20). The subject is placed in the supine position with eyes close. After routine sterilization, the sterile polyethylene cylindrical needle pad will be adhered to the acupoints. Then, the sterile acupuncture needles (0.25 mm×0.40 mm, Hwato brand, China.) will be inserted into the skin through the needle pad. Twirling and lifting-thrusting manipulations will be performed on the acupoints until Deqi is reported by the subject. Two pairs of electrodes will be connected at the needle handles on BL2 and EX-HN5 with a 2 Hz, continuous-wave electro-stimulation provided by the electroacupuncture apparatus (SDZ-Ⅲ type, Hwato brand, China). The pulse amplitude is about 1-2 mA.
223394665|NCT05552820|DEVICE|Sham Electroacupuncture|Sham acupoints: SA1(1 cm above BL2), SA2 (1 cm above SJ23)，SA3 (1 cm above EX-HN5), SA4 (1 cm lateral to ST2), SA5 (the midpoint of the line between GV20 and right EX-HN1), SA6 (the midpoint of the line between GB20 and SJ16), SA7 (1 cm lateral to LI4), SA8 (the midpoint of the line between ST36 and GB34), SA9 (the midpoint of the line between GB37 and BL58), SA10 (1 cm backward to SP6), SA11 (the midpoint of the line between LR3 and SP4). After routine sterilization, placebo needles will be used (Streitberger, Asia-med GmbH). The tingling sensation produced when the Streitberger needle is fixed on the skin causes the subject to believe that the needle is piercing the skin, simulating a skin puncture. The electric stimulator is applied to bilateral SA1 and SA3 with no current output. The exterior appearance, indicator light, prompt tone of the sham device, and stimulation parameters are all indistinguishable from the normal one.
223394666|NCT01439802|DEVICE|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
223394667|NCT01315431|DRUG|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
223394668|NCT02690831|OTHER|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
223394669|NCT02690831|OTHER|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
223394670|NCT02690831|DEVICE|Powerbreathe|
223394671|NCT01866826|DRUG|Rifaximin|subject will receive three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily)
223394672|NCT01866826|OTHER|Placebo|subject will receive three capsules of placebo by mouth twice daily.
223394673|NCT04384094|DEVICE|Esthesiometer measurement|Measuring the corneal sensitivity using rebound technology.
223394674|NCT04513392|PROCEDURE|Laser treatment|A flexible laser fiber will be utilized via a channelled laryngoscope to ablate the benign laryngeal lesions as per standard of care.
223394675|NCT05181046|DEVICE|Nanodropper adaptor|The Nanodropper adaptor is a sterile medical device that reduces the size of administered eyedrops by coupling to the original bottle.
223394676|NCT05181046|OTHER|Original eyedrop bottle/No Nanodropper|The original eyedrop bottle dispenses standard eyedrops.
223394677|NCT00709995|DRUG|Enzastaurin|Administered orally
223394678|NCT00709995|DRUG|Sunitinib|Administered orally
223394679|NCT00709995|DRUG|Placebo|Administered orally
223394680|NCT05624918|DRUG|Nab paclitaxel|125 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
224128106|NCT06692491|DRUG|Atezolizumab|Atezolizumab 1200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with atezolizumab under the guidance of MTB.
223394681|NCT05624918|DRUG|Gemcitabine|1000 mg/m\^2 IV over 30 minutes or per site standard on days 1, 8, and 15 of a 28 day cycle
223394682|NCT05624918|DEVICE|NovoTTF-200T(P)|Worn \> 18 hr /day starting C1D1 until completion of cycle 3
223394683|NCT05627843|DIETARY_SUPPLEMENT|Curcumin capsules 1 gm|Dietary supplement
223394684|NCT05627843|DIETARY_SUPPLEMENT|Placebo capsule|placebo corn starch
223394685|NCT02347059|DRUG|L-dopa|Antiparkinsonian medication
223394686|NCT02347059|DRUG|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
223394687|NCT05832632|BEHAVIORAL|Headspace Basics Program|30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
223394688|NCT05832632|BEHAVIORAL|Headspace Breathing Exercises|30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
223548995|NCT02701309|DEVICE|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
223548996|NCT01541865|DEVICE|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
224128107|NCT06692491|DRUG|Sintilimab|Sintilimab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with sintilimab under the guidance of MTB.
224128108|NCT06692491|DRUG|Tislelizumab|Tislelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with tislelizumab under the guidance of MTB.
224128109|NCT06692491|DRUG|Camrelizumab|Camrelizumab 200mg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with camrelizumab under the guidance of MTB.
224128110|NCT06692491|DRUG|Toripalimab|Toripalimab 240kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with toripalimab under the guidance of MTB.
223730880|NCT01477606|DRUG|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
223730881|NCT01477606|DRUG|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
224128111|NCT06692491|DRUG|Serplulimab|Serplulimab 3mg/kg,q2w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with serplulimab under the guidance of MTB.
224128112|NCT06692491|DRUG|Adebrelimab|Adebrelimab 20mg/kg,q3w Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with adebrelimab under the guidance of MTB.
224128113|NCT06692491|DRUG|Envafolimab|Envafolimab 150mg,qw Patients with advanced rare tumours who failed to standard treatment carrying no targeted alterations will be administrated with envafolimab under the guidance of MTB.
224128114|NCT06692491|DRUG|Osimertinib|Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.
224128115|NCT06692491|DRUG|Alectinib|Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.
224128116|NCT06692491|DRUG|Vemurafenib|Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.
224128117|NCT06692491|DRUG|Pamiparib|Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.
224128118|NCT06692491|DRUG|Pyrotinib|Pyrotinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib under the guidance of MTB.
224128119|NCT06692491|DRUG|Imatinib|Imatinib 400mg, qd Patients with advanced rare tumours who failed to standard treatment carrying CKIT mutation will be administrated with imatinib under the guidance of MTB.
224128120|NCT06692491|DRUG|Palbociclib|Palbociclib 125mg, 21/7 dosing schedule Patients with advanced rare tumours who failed to standard treatment following HR(+)/HER-2(-) will be administrated with palbociclib under the guidance of MTB.
224128121|NCT06692491|DRUG|Savolitinib|Savolitinib 300mg, qd Patients with advanced rare tumours who failed to standard treatment carrying C-MET mutation will be administrated with savolitinib under the guidance of MTB.
224128122|NCT06692491|DRUG|Entrectinib|Entrectinib 600mg, qd Patients with advanced rare tumours who failed to standard treatment carrying ROS-1 fusion or NTRK fusion will be administrated with entrectinib under the guidance of MTB.
223394689|NCT05832632|BEHAVIORAL|Headspace Stress Program|20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
223730882|NCT01477606|DRUG|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
224014501|NCT06415565|OTHER|thoracic mobilization methods|Methods applied as conventional physiotherapy methods: hotpack, Transcutaneous electrical nerve stimulation and ultrasound applications will be applied. Also within the scope of thoracic mobilization: thoracic region extension stretching in the kneeling position, thoracic flexion in the crawling position, halo exercise, thoracic rotation exercises in the crawling position, thoracic rotation in the side lying position. , quadruped extension and rotation exercises will be applied. Patients will be informed that these exercises can also be done as home exercises and they will be asked to practice for 8 weeks.
224014502|NCT02021097|DRUG|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
224128123|NCT06692491|DRUG|Other|"Patients with advanced rare tumours who failed to standard treatment in RWS ICF Group will be administrated with empirical chemotherapy(e.g., Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine, Vinorelbine, Cisplatin, Irinotecan, Fluorouracil), immunological(e.g., Nivolumab, Pembrolizumab, Durvalumab, Atezolizumab, Sintilimab, Tislelizumab, Camrelizumab, Toripalimab, Serplulimab,Adebrelimab,Envafolimab) or targeted drugsl(e.g., Osimertinib, Alectinib, Vemurafenib, Vemurafenib, Pyrotinib, Imatinib, Palbociclib, Savolitinib, Entrectinib)treatments."
224128124|NCT06692712|GENETIC|MELPIDA|Gene Therapy agent
223394690|NCT05832632|BEHAVIORAL|Active Control (Audiobook)|30-day smartphone-based Audiobook book consisting of 10 minutes per day.
223394691|NCT06453499|OTHER|Physical therapy|ultrasound for 5 minutes,Tens and hot packs for 20 minutes, back exercise
223394692|NCT05045287|RADIATION|hypofractionated radiotherapy|Undergo hypofractionated RT，obeserve reconstruction failure，cosmetic result and recurrence rate
223730883|NCT05885789|PROCEDURE|Intubation in Bed-Up-Head-Elevated (BUHE) position|Comparing laryngoscopic view in paediatric patients during sniffing position and BUHE position
223730884|NCT06793748|COMBINATION_PRODUCT|PEP-TISSEEL|Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
223730885|NCT06793748|DRUG|TISSEEL Fibrin Sealant KIT|Fibrin Sealant (TISSEEL® VH SD Kit)
224128125|NCT06692933|DRUG|Cannabidiol in the form of hemp|Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel
223394693|NCT02386137|DEVICE|Contrast-enhancement ultrasound with Sonovue|
224128126|NCT06692933|DRUG|Clopidogrel|75 mg oral clopidogrel
223394694|NCT05108974|DRUG|Choline Bitartrate|Powdered drink mix for daily consumption
223394695|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
223394696|NCT02083068|BIOLOGICAL|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
223394697|NCT02083068|BIOLOGICAL|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
223394698|NCT00994812|DRUG|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
223394699|NCT03145415|PROCEDURE|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
223394700|NCT03145415|PROCEDURE|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
223394701|NCT02489188|PROCEDURE|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
223394702|NCT02489188|OTHER|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
223394703|NCT02489188|PROCEDURE|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
223394704|NCT02710721|OTHER|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
223394705|NCT02710721|OTHER|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
223394706|NCT05894707|DRUG|SCT650C|Recombinant anti-IL-17A antibody
223394707|NCT01662778|DRUG|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
223394708|NCT01662778|DRUG|6 microns at 50mg|STAG generated monodisperse 6 micron particles
223394709|NCT01662778|DRUG|Placebo Comparator|No drug just solvent
223394710|NCT01662778|DRUG|MDI FP|
223394711|NCT05592171|PROCEDURE|Microwave ablation + Occlusafe + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
224128127|NCT06693583|DEVICE|Virtual Reality Headsets|Virtual reality (VR) headsets are used as a form of distraction technique widely throughout healthcare. Women will be assisted to apply the VR prior to their colposcopy examination beginning. They will be shown an immersive video of walking through a forest that reminds them to breath deeply. The aim is that this will relax them during the colposcopy examination.
223394712|NCT05592171|PROCEDURE|Microwave ablation + Occlusafe|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~After positioning and inflating the Occlusafe® balloon in the artery that connects to the HCC nodule, the blood flow tends to go preferentially to the HCC nodule compared to the healthy liver. The increase in the water content in the tumor area, after using the Occlusafe® balloon microcatheter, could increase the ability of microwave ablation to cover larger volumes in a shorter time."
223394713|NCT05592171|PROCEDURE|Microwave ablation + DEB-TACE|"Microwave ablation (MW) is based on the production of heating by friction given by the oscillation of water molecules.~The delivery of drug-releasing microspheres (DEB-TACE) at the same time as microwave ablation, could promote the arrest of tumor growth."
223394714|NCT01061593|DIETARY_SUPPLEMENT|Immunoxel|1 lozenge once per day
223394715|NCT01061593|OTHER|Placebo|1 lozenge once per day
224296506|NCT05352165|DRUG|standard long-term therapy|The standard whole-course neoadjuvant therapy group was treated with neoadjuvant simultaneous radiotherapy and chemotherapy (Total Neoadjuvant Therapy, TNT) based on guidelines and clinical experience.
224296507|NCT05352165|DRUG|FOLFOX and standard long-term radiotherapy|FOLFOX and standard long-term radiotherapy based on organoids drug sensitivity
223394716|NCT00742209|DRUG|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
223394717|NCT00742209|DRUG|Placebo|Placebo-control
223394718|NCT03524651|DRUG|Ferrous Sulfate|Blisters of 10 capsules containing 150 mg of ferrous sulfate.
223394719|NCT03524651|DRUG|Fe-ASP|Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
223394720|NCT03524651|DRUG|Ferrous Sulfate|Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
223394721|NCT03524651|DRUG|Fe-ASP|Blisters of 10 capsules containing inactive ingredients of Microfer.
223394722|NCT02562066|DRUG|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
223394723|NCT02562066|DRUG|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
223394724|NCT03679689|DIETARY_SUPPLEMENT|artificially sweetened beverages|artificially sweetened beverages restriction
223394725|NCT01736592|DRUG|Long term follow up in all patients who received SAR422459 in previous study TDU13583|Blood draw for the laboratory assessment
223394726|NCT01551771|DRUG|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
224014503|NCT02021097|DRUG|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
224014504|NCT05462301|OTHER||Neonatal bedside echocardiography was performed by a trained neonatologist or sonographer
224296508|NCT05352165|DRUG|FOLFIRI and standard long-term radiotherapy|FOLFIRI and standard long-term radiotherapy based on organoids drug sensitivity
224296509|NCT05352165|DRUG|5-FU and standard long-term radiotherapy|5-FU and standard long-term radiotherapy based on organoids drug sensitivity
224296510|NCT05352165|DRUG|5-FU and pembrolizumab and standard long-term radiotherapy|5-FU and pembrolizumab and standard long-term radiotherapy based on organoids drug sensitivity
224296511|NCT05352165|DRUG|Other individualized treatments|Other individualized treatments based on organoids drug sensitivity
223394727|NCT01551771|DRUG|GW824575 matched-placebo|Placebo
223394728|NCT02287792|PROCEDURE|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
223394729|NCT00595621|DEVICE|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
223394730|NCT04305743|DRUG|OnabotulinumtoxinA 100 UNT|Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
223394731|NCT00087815|DRUG|dexamethasone|
223394732|NCT00087815|DRUG|hyperbaric oxygen|
223394733|NCT00087815|PROCEDURE|cognitive assessment|
223394734|NCT00087815|PROCEDURE|magnetic resonance imaging|
223394735|NCT00087815|PROCEDURE|positron emission tomography|
223394736|NCT00087815|PROCEDURE|quality-of-life assessment|
223394737|NCT00324987|BIOLOGICAL|Bevacizumab|Given IV
223394738|NCT00324987|DRUG|Imatinib Mesylate|Given PO
223394739|NCT00324987|OTHER|Laboratory Biomarker Analysis|Correlative studies
223394740|NCT00324987|OTHER|Pharmacological Study|Correlative studies
223394741|NCT04551456|BIOLOGICAL|Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS|Randomised, Double-blind, Placebo-controlled, Intravenous Infusion HumanWharton' Jelly-derived Mesenchymal Stem Cells in Patients With Coronary Artery Disease
223394742|NCT03295292|BIOLOGICAL|Stem cells|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
223394743|NCT03295292|OTHER|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
223394744|NCT04982289|DRUG|ALXN1830|Administered as an SC infusion.
223394745|NCT04982289|OTHER|Placebo|Administered as an SC infusion.
223394746|NCT03413462|DRUG|HS-25|HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
223394747|NCT03413462|DRUG|Placebo of HS-25|Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
223394748|NCT02976857|BIOLOGICAL|C-CAR-011|lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
223394749|NCT03253614|DIAGNOSTIC_TEST|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
223394750|NCT03253614|DIAGNOSTIC_TEST|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
223394751|NCT03253614|DIAGNOSTIC_TEST|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
223394752|NCT03817125|DRUG|Placebo for antibiotic|Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
223394753|NCT03817125|DRUG|Vancomycin pretreatment|Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
223394754|NCT03817125|DRUG|Nivolumab|Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
223394755|NCT03817125|DRUG|Matching Placebo for SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
223394756|NCT03817125|DRUG|SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
223394757|NCT03095664|BEHAVIORAL|Intervention group|A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
223394758|NCT00942084|DRUG|Acyclovir|"Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
223394759|NCT00479999|DRUG|VRC-HIVADV027-00-VP|
223394760|NCT00479999|DRUG|VRC-HIVADV038-00-VP|
223394761|NCT00247715|DRUG|algeldrate/magnesium oxide|
223394762|NCT00247715|DRUG|ranitidine|
223394763|NCT00247715|DRUG|pantoprazole|
223394764|NCT04348552|OTHER|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related|Primary care professionals reports of potential patient safety incidents, non-COVID-19 related
223394765|NCT00940628|BEHAVIORAL|Diet and Exercise|mildly hypocaloric diet and physical exercise
223394766|NCT00940628|DRUG|orlistat [Xenical]|120mg po tid
223394767|NCT04885309|PROCEDURE|Nerve Stimulator-guided Obturator Nerve Block|Following the confirmation of spinal anesthesia level in the patients in the ONB group while in the lithotomy position, ONB was applied unilaterally or bilaterally, depending on the tumor position. A needle with a nerve stimulator was advanced vertically 2 cm below and 2 cm from the pubic tubercle. The needle is inserted through the skin and into the lower ramus of the pubic bone. When contraction was observed in the adductor muscle groups and the aspiration was negative, 10 mL 0.25% levobupivacaine at 0.3-0.5 mA was administered. The operation was started 10 minutes after the injection. TURBT operations were performed with a 30 degree optic and a 26 F bipolar resectoscope. All spinal anesthesia and ONB procedures were performed by the same anesthesia team. All TURBT operations were performed by the same surgeon.
223394768|NCT00234637|DRUG|Rivastigmine, memantine|
223394769|NCT04842071|DIAGNOSTIC_TEST|18F-sodium fluoride|Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.
223394770|NCT00199420|DRUG|Istradefylline (KW-6002)|
223394771|NCT03182231|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
223394772|NCT02246751|DEVICE|Targeted Training for trunk control|Orthotics Research and Locomotor Research Unit (ORLAU) standers will be custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
223394773|NCT01276340|DEVICE|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
223394774|NCT03979391|DIAGNOSTIC_TEST|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
223394775|NCT01772589|PROCEDURE|New saw blade|
223394776|NCT01772589|PROCEDURE|Reprocessed saw blade|
223394777|NCT06187129|DEVICE|nerve ultrasound|nerve ultrasound
223394778|NCT01797874|DRUG|Pazopanib|Experimental
223394779|NCT01797874|DRUG|Placebo|placebo arm
223394780|NCT04369391|DRUG|SEP363856 150 mg|SEP363856 tablet 150 mg
223394781|NCT04369391|DRUG|Placebo|Placebo tablet
223394782|NCT04369391|DRUG|moxifloxacin 400 mg|moxifloxacin tablet 400 mg
223548997|NCT05715658|DRUG|Dabigatran etexilate capsule|Adult healthy subjects and elderly healthy subjects only take one 110 mg dabigatran etexilate capsule (low-dose specification in the instruction manual) orally. Elderly patients with atrial fibrillation take dabigatran etexilate according to routine medical treatment.
223548998|NCT01313910|DIETARY_SUPPLEMENT|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
223548999|NCT04830943|DRUG|Cerebrolysin|Cerebrolysin will be prescribed in a dose of 5 ml ampoule once daily through intramuscular injection (1ml contains 215.2 mg cerebrolysin) for five times per week, for a total of 40 treatments (for 8 weeks), after which the cycle was individually repeated according to the response of the patient to therapy for a maximum of 24 weeks
223549000|NCT00004891|DRUG|chemotherapy|
223549001|NCT00004891|PROCEDURE|computed tomography|
223549002|NCT00004891|PROCEDURE|conventional surgery|
223549003|NCT00004891|PROCEDURE|neoadjuvant therapy|
223549004|NCT00004891|PROCEDURE|positron emission tomography|
223549005|NCT00004891|PROCEDURE|radionuclide imaging|
223549006|NCT00004891|RADIATION|fludeoxyglucose F 18|
223549007|NCT00004891|RADIATION|radiation therapy|
223549008|NCT03806530|DRUG|Gabapentin|100 mg capsule
223549009|NCT03806530|DRUG|Ropinirole|0.50 mg capsule
223549010|NCT03806530|DRUG|Placebo Gabapentin|Placebo capsule
223549011|NCT03806530|DRUG|Placebo Ropinirole|Placebo capsule
223394783|NCT03359148|DEVICE|Disposable ventilator system|
223394784|NCT03359148|DEVICE|Conventional reused ventilator system|
223549012|NCT00903422|DRUG|eltrombopag olamine|thrombopoietin receptor agonist
223730886|NCT06793748|COMBINATION_PRODUCT|PEP-TISSEEL|Purified Exosome Product (PEP™) and Fibrin Sealant (TISSEEL® VH SD Kit) (Biologic) (PEP-TISSEEL)
223730887|NCT06793748|DRUG|TISSEEL Fibrin Sealant KIT|Fibrin Sealant (TISSEEL® VH SD Kit)
224296512|NCT03676517|RADIATION|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
224296513|NCT00400361|DRUG|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
223394785|NCT06377774|OTHER|No intervention in this study|No intervention in this study
223394786|NCT00517504|DRUG|Methylphenidate|"* 1-week single blind placebo lead-in phase.~* step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
223394787|NCT03981172|BEHAVIORAL|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
223394788|NCT01487967|OTHER|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
223394789|NCT06359990|BEHAVIORAL|BrotherlyACT|BrotherlyACT is a digital intervention to prevent youth violence and substance use among trauma-exposed young Black males, ages 125-24. This intervention combines life skills coaching, safety planning tools, and an AI-driven chatbot to reduce the risk and effects of violence and early substance use.
223394790|NCT06359990|OTHER|BrotherlyACT Waitlist Control Group (WCG)|During the waiting period, participants in the control group do not receive the BrotherlyACT intervention but may continue with their usual activities or interventions.
223394791|NCT01974622|DRUG|Visudyne|Half fluence verteporfin
223394792|NCT04807010|PROCEDURE|Prostate Artery Embolization|Prostate artery embolization reduces symptoms from benign prostatic hyperplasia by delivering embolic materials to the prostate through the prostatic arteries.
223394793|NCT04807010|PROCEDURE|Sham Prostate Artery Embolization|Angiogram without embolization initially. At 6 months patients will be allowed to crossover to prostate artery embolization.
223394794|NCT01451450|DRUG|QGE031|QGE031 liquid for subcutaneous injection.
223549013|NCT00903422|OTHER|Placebo|Placebo tablets with no active pharmaceutical ingredient
223394795|NCT01451450|DRUG|Placebo|Placebo liquid for subcutaneous injection.
223394796|NCT03280810|OTHER|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
224014505|NCT03231631|BEHAVIORAL|Education plan and adherence to exercise|"* Send text messages with motivational sense at any time of the day, every 3 or 4 days.~* They will be given the option of performing directed exercise at the cardiac rehabilitation center.~* It will be recorded in an Excel table every time that text is sent to the patient.~* At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
224014506|NCT02293304|OTHER|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
224014507|NCT02293304|OTHER|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
224128128|NCT06693193|DEVICE|Immersive Virtual Reality|Individuals will participate in three VR sessions using Oculus headsets, experiencing virtual environments featuring realistic natural stimuli or custom settings tailored to their preferences and valued activities. Each environment allows for the adjustment of auditory elements (such as animal sounds, rustling wind, or specific music), visual elements (such as people, objects, or animals), and the time of day and weather conditions. The operator will use a user-friendly smartphone app to customize the environment, making real-time adjustments to settings and content. Throughout the VR experience, the operator can monitor the participant's visual focus in real-time.
224296514|NCT03955471|DRUG|Niraparib|Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
223394797|NCT05898724|PROCEDURE|Blank group|include six orthodontic patients, which have a surgical procedure to install two orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed orthodontic titanium miniscrews.
223394798|NCT05898724|PROCEDURE|Silver hydroxyapatite|include six orthodontic patients, which have a surgical procedure to install two silver hydroxyapatite nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed silver hydroxyapatite nano-coated orthodontic titanium miniscrews.
223394799|NCT05898724|PROCEDURE|Zinc oxide|include six orthodontic patients, which have a surgical procedure to install two zinc oxide nano-coated orthodontic titanium miniscrews in the two lateral parts of the maxilla of each patient, so this group will include 12 installed zinc oxide nano-coated orthodontic titanium miniscrews.
223394800|NCT00656422|DRUG|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
223394801|NCT00656422|DRUG|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
223394802|NCT01151124|BIOLOGICAL|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
223394803|NCT06431724|OTHER|Patient Survey|A simple data intake collection from the patients regarding their medical history that will allow the researchers to assess if recommended guidelines were followed.
223394804|NCT06431724|OTHER|Provider Survey|A survey will be used to evaluate providers' practices, knowledge and adherence to guidelines, and decision making related to current practice for cervical screening in women \>65.
223394805|NCT01998919|DRUG|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
223394806|NCT01998919|DRUG|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
223394807|NCT01998919|DRUG|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
223394808|NCT01998919|DRUG|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
223394809|NCT01998919|DRUG|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
223394810|NCT00853008|DRUG|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
223394811|NCT00853008|DRUG|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
223394812|NCT00853008|DRUG|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
223394813|NCT00853008|DRUG|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
223394814|NCT00853008|DRUG|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
223394815|NCT00853008|DRUG|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
223394816|NCT00853008|DRUG|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
223394817|NCT00853008|DRUG|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
223394818|NCT00853008|DRUG|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
223394819|NCT00853008|DRUG|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
223394820|NCT00853008|DRUG|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
223394821|NCT00853008|DRUG|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
223394822|NCT01358435|BIOLOGICAL|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
223394823|NCT01358435|BIOLOGICAL|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
223549014|NCT03534505|OTHER|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
223549015|NCT03534505|OTHER|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
223549016|NCT05836558|PROCEDURE|mitral valve repair in right minithoracotomy|reparative surgery of the mitral valve accessing heart via an incision in the right 3rd or 4th intercostal space.
224014508|NCT00468104|DRUG|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
223394824|NCT02084862|DEVICE|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
223394825|NCT02084862|DEVICE|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
223549017|NCT03286192|BEHAVIORAL|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
223549018|NCT00048945|DRUG|PEGASYS|
224014509|NCT00468104|DRUG|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
224014510|NCT01351831|OTHER|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
224014511|NCT01351831|OTHER|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
224014512|NCT03518827|OTHER|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
224014513|NCT05164029|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
224014514|NCT01681173|DIETARY_SUPPLEMENT|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
224014515|NCT01681173|DIETARY_SUPPLEMENT|Placebo|200ml Placebo, BID, over 24 months
223394826|NCT04504968|OTHER|Multimodal intervention|"1. Optimal control: HbA1c between 7.6-8.5% (60-69 mmol/mol) and Blood Pressure\<150/90 mmHg~2. The physical exercise program that will be used will be the Vivifrail program (Erasmus + UE). Vivifrail includes: Strength for arms and legs, balance and gait, flexibility and resistance. The duration will be 16 weeks. (3 weeks to explain the program in the Trial site and the rest of weeks, it will be carried out at home).~3. Nutritional and educational program to increase diabetes knowledge, develop practical self-care skills for diabetes and increase the likelihood of improving glycemic control safely. The intervention aims to minimize the risk of hypoglycemia, ensure optimal nutritional status and help to maintain functional status. Seven separate sessions of 45 minutes each one twice a week for a period of 3-4 weeks in small groups. They will be moderated by a physician or diabetes educator and focused on behavioral changes and key points."
223394827|NCT04504968|OTHER|Usual care group|The level of usual health care that a patient with diabetes receives from their local national health system
223394828|NCT02675036|PROCEDURE|Tooth extraction|
223549019|NCT04787731|DRUG|Bupivacaine Local Anesthetic|Long lasting local anesthetic administered to be compared to Lidocaine for quality of life outcomes in dental patients undergoing endodontic treatment
223549020|NCT00295646|DRUG|tamoxifen|20 mg/d
223549021|NCT00295646|DRUG|anastrozole|1 mg/d
223549022|NCT00295646|DRUG|zoledronic acid|4 mg q6m
223549023|NCT00295646|OTHER|goserelin|3.6 mg goserelin subcutaneously every 28 days
224014516|NCT02615080|DRUG|CRD007|
224014517|NCT02615080|DRUG|Placebo|
224014518|NCT04292184|DRUG|Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%|The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.
224014519|NCT02646007|BIOLOGICAL|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
224014520|NCT02518737|OTHER|Meal Test|
224014521|NCT02510209|BEHAVIORAL|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
224014522|NCT01710891|PROCEDURE|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
224014523|NCT01710891|PROCEDURE|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
224128129|NCT06692634|OTHER|mechanical ventilation setting|VT reduction, EIP setting, RR reduction, and a new EIP programing.
224128130|NCT06692062|RADIATION|Hypofractionated Radiation Therapy|R0 resection: 45-50Gy/20-25f R1 resection: 54-56Gy/25-28f R2 resection: 60-70Gy/30-35f
224296515|NCT03955471|DRUG|Dostarlimab|TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
224296516|NCT00055133|DRUG|Micellar Paclitaxel for Injection|
223394829|NCT00776841|DRUG|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
223549024|NCT02626156|DEVICE|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
223549025|NCT02626156|DEVICE|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
223549026|NCT02517255|DEVICE|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
223549027|NCT06182098|OTHER|1/2 maintenance fluids|Patients will receive 1/2 maintenance normal saline (with a maximum of 50 mL/hr), over one hour.
223549028|NCT06182098|DRUG|Ketorolac|0.5mg/kg, with a maximum of 30mg
223549029|NCT06182098|DRUG|Diphenhydramine|0.5mg/kg, with a maximum of 25mg
223549030|NCT06182098|DRUG|Prochlorperazine|0.15mg/kg, with a maximum of 10mg
223549031|NCT06182098|OTHER|bolus|20mL/kg normal saline bolus, with a maximum of 1L, given over one hour
223549032|NCT00161915|DRUG|Fibrin Sealant|
224014524|NCT03922646|BEHAVIORAL|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
224014525|NCT03922646|BEHAVIORAL|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
224014526|NCT02518321|DEVICE|Technology-Assisted Toileting|
224014527|NCT02428361|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
224014528|NCT05675787|DRUG|Medroxyprogesterone acetate + Atorvastatin|MPA (at a dosage of 250-500 mg/day,) + Atorvastatin (at a dosage of 20 mg/day), by mouth,
224014529|NCT04696380|DRUG|Nicotine|Participants will sample high vs low nicotine.
224128131|NCT07023783|BEHAVIORAL|Transdiagnostic Sleep Health Intervention (TSHI)|"A transdiagnostic sleep health intervention (TSHI) will be delivered across six weekly 50-minute one-on-one sessions with a sleep expert via a HIPAA-compliant videoconference link. The six weekly TSHI sessions are outlined as:~Week 1: Consists of discussing sleep physiology and discussing appropriate bed and wake up times.~Week 2: Consists of discussing how to set/importance of setting, a bedtime routine Week 3: Consists of discussing how to improve daytime function through energy management for daily and weekly tasks.~Week 4: Consists of discussing the sleep beliefs the participant holds and possible corrections of any unhelpful sleep beliefs.~Week 5: Consists of educating participants on sleep hygiene and how it is influenced by environmental, social, and physical factors.~Week 6: Consists of discussing sleep behavior changes observed during the TSHI and collaborating with the participant on plans to maintain their new sleep pattern."
224296517|NCT05320601|DEVICE|Repetitive Peripheral Magnetic Stimulation|Repetitive Peripheral Magnetic Stimulation at trigger point of upper trapezius muscle
224296518|NCT05320601|PROCEDURE|Dry needling|Dry needling at trigger point of upper trapezius muscle
223394830|NCT00776841|DRUG|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
223394831|NCT00776841|DRUG|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
223394832|NCT01302743|DRUG|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
223549033|NCT03271320|OTHER|appearance scales|appearance scales : AVS; ASWAP; DAS 59
223549034|NCT02569463|DRUG|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
223394833|NCT01302743|DIETARY_SUPPLEMENT|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
223549035|NCT02628041|RADIATION|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
224014530|NCT04696380|DEVICE|JUUL e-cigarette|Participants will sample preferred vs non-preferred JUUL flavors.
224014531|NCT02261597|BEHAVIORAL|Cold Pressor Test|Repeated immersion of hand in ice-cold water
224296519|NCT03012672|DRUG|Cladribine|Given IV
224296520|NCT03012672|DRUG|Cytarabine|Given IV
224296521|NCT03012672|BIOLOGICAL|Granulocyte Colony-Stimulating Factor|Given SC
223394834|NCT01302743|DIETARY_SUPPLEMENT|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
224296522|NCT03012672|DRUG|Mitoxantrone Hydrochloride|Given IV
223394835|NCT03024502|DRUG|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
223394836|NCT03024502|DRUG|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
223394837|NCT03024502|DRUG|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
223394838|NCT05762250|OTHER|Auricular Acupuncture|Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
223394839|NCT00837837|DRUG|Chlorpheniramine|
223394840|NCT00004115|RADIATION|yttrium Y 90 monoclonal antibody HMFG1|
223394841|NCT03492515|DRUG|recombinant human thrombopoietin|If platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count \<30×10\^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10\^9/L and 50×10\^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
223394842|NCT03492515|DRUG|Platelet Concentrate|according to the their conditions, use if necessary
223394843|NCT00593515|BEHAVIORAL|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
223394844|NCT00593515|BEHAVIORAL|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
223394845|NCT01676207|PROCEDURE|Coronary Angiography with collateral flow measurements|"* Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion."
223549036|NCT02628041|RADIATION|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
224014532|NCT02534454|BEHAVIORAL|Active Retraining|
223394846|NCT01676207|PROCEDURE|Coronary Angiography with collateral flow measurements|"* Diagnostic coronary angiography and LV angiography~* Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~* Right and left IMA CFI during a 1-minute ostial vessel occlusion~* Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~* IMA angiography (left and right) during distal IMA and coronary occlusion."
223394847|NCT00897715|DRUG|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
223394848|NCT00897715|DRUG|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
223394849|NCT06391307|OTHER|Crystallized phenol|Crystallized phenol + Exosome + Stem Cell
223394850|NCT06391307|BIOLOGICAL|Crystallized phenol + Exosome|Crystallized phenol + Exosome will be applied to wound area.
223394851|NCT06391307|BIOLOGICAL|Crystallized phenol + Stem Cell|Crystallized phenol + Stem cell will be applied to wound area.
223394852|NCT06391307|BIOLOGICAL|Crystallized phenol + Exosome + Stem Cell|Crystallized phenol + Exosome + Stem Cell will be applied to wound area.
224014533|NCT02534454|BEHAVIORAL|Sham Retraining|
224014534|NCT02534454|DEVICE|Active transcranial direct current stimulation (TDCS)|
224014535|NCT02534454|DEVICE|Sham transcranial direct current stimulation (TDCS)|
224014536|NCT02534454|DRUG|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
224014537|NCT04206930|OTHER|Art Therapy|1 session of 2 hours per week in a closed group for 10 weeks
224014538|NCT04483505|DRUG|Combination, Rogaratinib + palbociclib + fulvestrant|"Patients will receive rogaratinib, palbociclib and fulvestrant in cycles of 28 days.~Escalation Dose will follow a classic 3+3 schedule.The planned dose-levels are as follows:~* Level 1: Rogaratinib 400 mg PO BID + standard fulvestrant 500 mg every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 3 patients).~* Level 2: Rogaratinib 600 mg PO BID + fulvestrant 500 mg IM every 2nd weeks until the start of the 2nd cycle, becoming every 4 weeks + palbociclib 100 mg PO per day until day 22 followed by a 7-day rest, escalable to 125 mg per day in cycle 2 (N = 6 patients).~Treatment will continue until disease progression."
224014539|NCT05366790|BEHAVIORAL|CEASE and CEASE-A|CEASE (for parents) and CEASE-A (for adolescents) are evidence-based tobacco and vaping cessation interventions delivered in pediatric practices.
224014540|NCT05923671|DIAGNOSTIC_TEST|Histological analysis|Histological staining of gingival biopsies with haematoxylin-eosin.
224014541|NCT05923671|DIAGNOSTIC_TEST|Immunohistochemical analysis|Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
224014542|NCT03686631|BEHAVIORAL|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
224014543|NCT05915650|BEHAVIORAL|Pain Neuroscience Education|Carry out pain neuroscience education intervention for TKA patients
224014544|NCT05915650|BEHAVIORAL|Routine Education|Carry out routine education intervention for TKA patients
224014545|NCT06572098|OTHER|Complex decongestive therapy|Complex decongestive therapy consists of 4 phases. It will be performed by a lymphedema physiotherapist trained in Complex Decongestive Physiotherapy. Complex decongestive therapy consists of manual lymph drainage, skin care, multilayer bandaging and therapeutic exercises.
224014546|NCT05635942|DRUG|optimized quadruple therapy|Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
224014547|NCT05635942|DRUG|standard quadruple therapy|Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
224014548|NCT02947269|DRUG|Prucalopride|Prucalopride 2mg capsule
224014549|NCT02947269|DRUG|Placebo Oral Capsule|Placebo capsule
224014550|NCT05501977|PROCEDURE|thoracotomy|thoracic surgery for pulmonary diseases
224014551|NCT03152097|DIETARY_SUPPLEMENT|Commercially available Diindolylmethane|Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
223394853|NCT04790903|DRUG|Venetoclax|Participants will self-administer Venetoclax, as described in the Arm Descriptions.
223394854|NCT04790903|DRUG|Polatuzumab Vedotin|Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
223394855|NCT04790903|DRUG|Rituximab|Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
223394856|NCT04790903|DRUG|Cyclophosphamide|Participants will receive Cyclophosphamide at a dose of 750 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
223394857|NCT04790903|DRUG|Doxorubicin|Participants will receive Doxorubicin at a dose of 50 mg/m\^2 by IV infusion or bolus on Day 1 of Cycles 1-6.
223394858|NCT04790903|DRUG|Prednisone|Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
223394859|NCT00422916|BEHAVIORAL|behavioral intervention|
223394860|NCT02009553|OTHER|Information sheet|
223394861|NCT02009553|OTHER|No information sheet|
223394862|NCT01219816|DRUG|Epratuzumab|Combination of chemotherapy + Epratuzumab
223394863|NCT01219816|DRUG|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
223394864|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ lower dose (10\^8 TU) at weeks 0, 8 and 16.
223394865|NCT01428596|BIOLOGICAL|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
223394866|NCT01428596|BIOLOGICAL|HIVAX|Vaccine 1.0 ml SQ higher dose (10\^9 TU) at weeks 0, 8 and 16.
223394867|NCT00063934|BIOLOGICAL|oblimersen sodium|Given IV
223394868|NCT00063934|DRUG|doxorubicin hydrochloride|Given IV
224014552|NCT03152097|OTHER|Placebo|A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
223394869|NCT00063934|DRUG|docetaxel|Given IV
223394870|NCT00063934|BIOLOGICAL|filgrastim|Given SC
223394871|NCT00063934|BIOLOGICAL|pegfilgrastim|Given SC
224014553|NCT04860297|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
224014554|NCT01464840|DRUG|Azithromycin|500 mg intravenous infused over 1 hour
224014555|NCT00421031|DRUG|DVS-233 SR|
224014556|NCT05667103|DEVICE|Embotrap stent retriever|Embotrap has a novel design of an open outer cage for clot capture and a closed inner channel for clot stabilization, with great thrombus fixation and anti-escape ability, to improve the successful recanalization rate and good prognosis of patients.
224014557|NCT05667103|DEVICE|Solitaire FR, Trevo stent retriever without inner channel|Other stent retriever without inner channel, such as Solitaire FR, Trevo, and other stent retrievers approved by FDA or NMPA.
224014558|NCT00944515|DRUG|placebo|placebo tablet or syrup 3 days/week
224014559|NCT00944515|DRUG|azithromycin|azithromycin 3 days/week
224014560|NCT00396019|DRUG|PEG-Intron|
224128132|NCT03492463|DRUG|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
223394872|NCT00063934|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223394873|NCT00063934|OTHER|pharmacological study|Optional correlative studies
223394874|NCT00063934|OTHER|laboratory biomarker analysis|Optional correlative studies
223394875|NCT04341363|DEVICE|Tattoo machine|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
223394876|NCT05348460|DIETARY_SUPPLEMENT|Ketone ester drink (DeltaG®, 500 mg/kg body weight)|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
223394877|NCT05348460|DIETARY_SUPPLEMENT|Taste-matched, isovolumic placebo drink|In a double blind fashion, subjects will receive a ketone ester drink ór a taste-matched, isovolumic placebo drink and will then perform the 31P MRS exercise protocol. After 1-2 weeks, subjects will cross-over and repeat the 31P MRS exercise protocol, this time receiving the other treatment.
223394878|NCT04181294|BEHAVIORAL|Family meetings using time limited trials as default ICU communication and care planning approach|Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
224014561|NCT05012553|OTHER|education of self and peer assesment|Stoma care skill achievement is expected to be higher in the group that received self- and peer-assessment training compared to the group that did not receive training.
224014562|NCT04811131|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
224014563|NCT04811131|DRUG|ARQ-252 Vehicle cream|ARQ-252 Vehicle cream
224014564|NCT04811131|DEVICE|NB-UVB phototherapy active treatment|NB-UVB phototherapy active treatment
224014565|NCT04811131|DEVICE|NB-UVB phototherapy sham treatment|NB-UVB phototherapy sham treatment
224014566|NCT05705843|DRUG|Intraosseous Vancomycin Injection|• IO vancomycin is administered via an intraosseous cannulation device (Arrow EZ-IO; Teleflex, Morrisville, NC) in the OR after sterile prep and draping has occurred prior to skin incision (500mg in 150mL NS).
224014567|NCT05705843|DRUG|Intravenous Vancomycin|IV Vancomycin will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg generally 1000-1750mg in 500mL NS).
224014568|NCT02910284|BIOLOGICAL|Observational|
224296523|NCT03012672|OTHER|Quality-of-Life Assessment|Ancillary studies
223394879|NCT04181294|BEHAVIORAL|Usual practice|Baseline practice of ICU communication and care planning
223394880|NCT05219760|DEVICE|LIVIA|"The study aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial.~Both programs are composed of 10 weekly sessions proposing educational material, questionnaires and exercises. They are based on current scientific theories of grief but present their content differently. Compared to LIVIA 1, LIVIA 2.0 is less based on academic readings and participants can choose more freely which topics and exercises they want to do. LIVIA 2.0 also offers a system of reminder messages to maximize adherence as well as more elaborate automated guidance."
223549037|NCT05046873|DRUG|Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
223549038|NCT05046873|DRUG|semaglutide 1.34 mg/mL (placebo)|Participants will receive a subcutaneus (s.c) co-formulation injection of 0.5 mg semaglutide and 5 mg NNC0480-0389 together with a subcutaneus injection (s.c) of semaglutide(placebo)on two separate dosing visits separated by at least 8 weeks.
223549039|NCT05046873|DRUG|Semaglutide 1.34 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
223549040|NCT05046873|DRUG|NNC0480-0389 A 10 mg/mL|The participants will be receive a subcutaneus (s.c) injection of 0.5 mg semaglutide and 5 mg NNC0480 0389 on two separate doing visits separated by at least 8 weeks.
224014569|NCT02536820|BEHAVIORAL|psychoneuroimmune therapy|
224014570|NCT02536820|DRUG|Conventional treatment|Actual diabetes treatment in each participant
224014571|NCT04986839|DRUG|Paracetamol injection|Intravenous Paracetamol
224014572|NCT04986839|DRUG|Ibuprofen injection|Intravenous Ibuprofen
223394881|NCT05068180|DRUG|low-dose neuroleptanalgesia|Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
223394882|NCT05068180|DRUG|Placebo|The same volume of normal saline is to be administrated intravenously 30 minutes before the end of the procedure.
223549041|NCT02001324|OTHER|Web-based data collection|
223549042|NCT02001324|OTHER|Paper-based data collection|
224014573|NCT02703064|DIETARY_SUPPLEMENT|Furocyst|Furocyst caps BD
224014574|NCT03914638|DRUG|Salbutamol 4Mg Tablet|Salbutamol 4 mg, three times daily
224014575|NCT03914638|DRUG|Placebo oral capsule|Placebo, three times daily
224014576|NCT02782312|DRUG|ICS+LABA|Seretide is inhaled for one year
224014577|NCT02782312|OTHER|routine therapy|routine therapy for one year
224014578|NCT03236038|DIAGNOSTIC_TEST|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
224014579|NCT02647775|PROCEDURE|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
224014580|NCT02647775|PROCEDURE|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
224014581|NCT01923090|DRUG|Finasteride|Finasteride 5mg once daily for 3 weeks
224014582|NCT01923090|DRUG|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
223394883|NCT02863094|DEVICE|transcranial magnetic stimulation|
223394884|NCT00210769|DRUG|paliperidone ER Oros|
223394885|NCT02257346|DRUG|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
223549043|NCT05976152|DRUG|dl-3-butylphthalide|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
224014583|NCT02631824|PROCEDURE|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
224014584|NCT02631824|DEVICE|TFNA|Trochanteric Femoral Nail Advance
224014585|NCT02631824|DEVICE|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
224014586|NCT03888157|DRUG|Liraglutide|Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
224014587|NCT00044798|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
224014588|NCT00044798|DRUG|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
224014589|NCT00044798|PROCEDURE|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
223394886|NCT02257346|DRUG|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
223394887|NCT00774501|PROCEDURE|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
223394888|NCT00840749|RADIATION|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
223394889|NCT00840749|PROCEDURE|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
223394890|NCT02757001|OTHER|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
223394891|NCT01434095|PROCEDURE|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
223549044|NCT05976152|DRUG|dl-3-butylphthalide placebo|"First stage： Routine stroke treatment: hypoglycemic, antihypertensive, antiplatelet, anticoagulant and other conventional cerebrovascular disease treatment drugs.~Placebo group: routine stroke treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group: routine stroke treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Second stage： 14d washout period after first stage. Routine PSCI treatment: 5-10 mg Donepezil, qd. Placebo group: Routine PSCI treatment + oral Butylphthalide Placebo Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks.~Butylphthalide group:~Routine PSCI treatment + oral Butylphthalide Soft Capsules, 2 capsules/time, tid, an empty stomach for 24 weeks."
223549045|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy with AI|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. The Eleos Health platform provides real-time data that optimizes this therapy and helps the provider tailor the intervention to the specific client.
223394892|NCT01683435|OTHER|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
223394893|NCT03481673|BEHAVIORAL|COPE for Asthma|The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
223394894|NCT01080482|DRUG|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
223730888|NCT02228551|OTHER|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
223730889|NCT04537767|DRUG|Esmolol|The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
223730890|NCT04537767|DRUG|Placebo|Placebo
223730891|NCT04234581|DIETARY_SUPPLEMENT|Lysulin|Participants will be randomly allocated for 3 months to LysulinTM (1,110 mg TID, i.e. 3.3 g/day) or matching placebo.
223730892|NCT04762797|OTHER|Non|This is a retrospective study, without intervention.
223730893|NCT04876625|DEVICE|myTAP oral appliance plus mouth shield|myTAP anti-snoring oral appliance worn with mouth shield for all 8-weeks; the mouth shield is a comfort accessory that fits over the oral appliance itself and extends into the oral vestibule.
223730894|NCT04876625|DEVICE|myTAP oral appliance alone for first 4 weeks|myTAP anti-snoring oral appliance worn alone for first 4 weeks followed by wearing it for 4 weeks with the mouth shield
223730895|NCT04682067|BEHAVIORAL|Contingency Management|Escalating financial incentives contingent upon biochemical evidence of abstinence
223730896|NCT04682067|BEHAVIORAL|Usual Care smoking cessation|Usual care smoking cessation support
224014590|NCT00003453|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223730897|NCT02990091|DRUG|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
223394895|NCT02125682|DRUG|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
223394896|NCT02125682|DRUG|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
223394897|NCT04232865|DEVICE|Biop System|"Stage 1 - Training:~Up to 320 women in whom a complete procedure with the Biop System will be performed. Biopsies will be taken solely based on colposcopy examination. Enrolled participants will include at least 80 participants Histopathology identified with a high-grade lesion and at least 80 participants Histopathology identified as normal or with a low-grade lesion.~Stage 2 - Validation:~Up to 330 HIV negative women in whom a complete procedure with the Biop System will be performed.~Validation stage will also include up to 165 HIV positive participants. All participants will be enrolled in up to 3 sites in South Africa."
223394898|NCT01436513|DRUG|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
223394899|NCT01436513|DRUG|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
223394900|NCT01436513|DRUG|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
223394901|NCT01436513|DRUG|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
223394902|NCT02637882|OTHER|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
223394903|NCT02637882|OTHER|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
223394904|NCT02637882|OTHER|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
223394905|NCT03775616|OTHER|Educational Intervention|Receive financial navigation program intervention
223394906|NCT03775616|OTHER|Questionnaire Administration|Ancillary studies
223394907|NCT03775616|OTHER|Quality-of-Life Assessment|Ancillary studies
223394908|NCT03266653|DRUG|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
223394909|NCT04747158|BIOLOGICAL|Convalescent plasma|COVID-19 convalescent plasma at admission, after confirmation of eligibility, 200 ml on day 1 and 2
223394910|NCT01960413|DRUG|Montelukast added to Hydroxyurea|
223394911|NCT01960413|DRUG|Placebo added to Hydroxyurea|
223394912|NCT03486808|DEVICE|IFG stimulation|stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
224014591|NCT06251362|PROCEDURE|Sleep restriction|Participants will experience a night of acute sleep restriction. During this night, they will sleep 3 hours less than usual.
224014592|NCT01594775|DRUG|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
224014593|NCT01594775|DRUG|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
224014594|NCT02843061|DRUG|Rituximab|
224014595|NCT02843061|BIOLOGICAL|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
224014596|NCT02751268|DRUG|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
224014597|NCT02751268|DRUG|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
224014598|NCT02072785|DRUG|Vincristine Sulfate Liposome|
224014599|NCT02072785|DRUG|Vincristine Sulfate|
224014600|NCT03955523|OTHER|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation \>5% VO2peak for at least 3 minutes of exercise.
224128133|NCT03492463|OTHER|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
223394913|NCT03486808|DEVICE|DLPFC stimulation|stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
223394914|NCT03486808|DEVICE|Sham stimulation|sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
223394915|NCT03859596|PROCEDURE|MGB/OAGB|BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
223394916|NCT03995485|DRUG|KW-136 capsule|KW-136 60 mg was provided in a single capsule of 60 mg.
223394917|NCT03995485|DRUG|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
223394918|NCT06123091|OTHER|Questionnaires with patient reported outcome measures|Questionnaires to gain insight of the prevalence of extracutaneous manifestations and the impact of the disease on the quality of life.
223394919|NCT00776035|PROCEDURE|PET (Positron Emission Tomography)|This is a diagnostic scan that requires the injection of radioactive tracer compounds intravenously using an IV placed in the arm.
223394920|NCT00776035|PROCEDURE|Echocardiogram|An echocardiogram is an ultrasound of the heart. Participants received a complete 2D- and Doppler echocardiographic examination on the day of the PET scan.
223394921|NCT00776035|RADIATION|^15O-water|This is a radioactive tracer used to study blood flow in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
223394922|NCT00776035|RADIATION|1-^11C-palmitate|This is a radioactive tracer used to study fatty acid usage in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
224014601|NCT03955523|DIETARY_SUPPLEMENT|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
224014602|NCT02223676|PROCEDURE|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
224296524|NCT03012672|OTHER|Questionnaire Administration|Ancillary studies
224014603|NCT05251194|DEVICE|video laryngoscope at thyroid surgical position|After induction of anesthesia and muscle relaxation, the patient will be positioned with a standard pillow to exposure neck for thyroid surgery (thyroid surgical position). Then, tracheal intubation will be performed with a McGrath video laryngoscope. During laryngoscopy with the McGrath video laryngoscope, the intubation practitioner will record the modified Cormack-Lehane grade and the percentage of glottic opening (POGO) score when it is assumed that a direct laryngoscope is used and when using the video laryngoscope, respectively.
224014604|NCT00148070|DRUG|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
224014605|NCT00148070|PROCEDURE|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
223394923|NCT00776035|RADIATION|1-^11C-glucose|This is a radioactive tracer used to study glucose usage in the heart during the PET scan. It was administered intravenously at a dose of 20 Mci..
224014606|NCT03664934|OTHER|Exercises|Neck-specific exercises for chronic whiplash associated disorders
224014607|NCT02129270|DRUG|Lidocaine HCl 2% .|comparison of different dosages of drug
224014608|NCT02129270|DRUG|Lidocaine HCl 1%|comparison of different dosages of drug
224014609|NCT06280040|DIAGNOSTIC_TEST|Clinical examination and multimodal ocular imaging|Imaging consists of sonography, fundus photography, oximeter, optical coherence tomography angiography, and Microperimetry.
223394924|NCT00791778|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
223394925|NCT00791778|DRUG|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
223394926|NCT04677777|BIOLOGICAL|PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)|PP-007 is PEGylated carboxyhemoglobin. Eligible patients will receive two doses of PP-007 (at least 24 hours apart) to evaluate extended drug exposure along with MT and/or IVT (individually or together) as SOC to evaluate safety in AIS patients.
223394927|NCT03306745|DIETARY_SUPPLEMENT|Profertil female|"For micronutrient ingredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate."
223394928|NCT03306745|DIETARY_SUPPLEMENT|Folic acid 400 mg|Folic acid 400 mg
224014610|NCT03100487|DEVICE|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
224014611|NCT00564694|PROCEDURE|psychosocial assessment and care|
224014612|NCT00564694|PROCEDURE|quality-of-life assessment|
224014613|NCT00133406|DRUG|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
224014614|NCT00133406|DRUG|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
224014615|NCT00133406|DRUG|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
224014616|NCT00133406|DRUG|zinc|40 mg twice weekly for 12 months
224014617|NCT04417738|DEVICE|unilateral transcranial photobiomodulation, near infrared mode|The investigators are applying a supra luminous LED at 810 nm and 250 mW/cm2 to the forehead of the participant at F3 and F4.
223394929|NCT02435693|OTHER|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
223394930|NCT02435693|OTHER|Without PHARMACEUTICAL CARE programe|
223394931|NCT03102346|OTHER|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
223394932|NCT00450099|DRUG|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
223394933|NCT04508257|DIETARY_SUPPLEMENT|Oral feeding of Investigational Formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
224014618|NCT04417738|DEVICE|Sham treatment|The sham treatment is identical to the active treatment except that the sham treatment has a piece of aluminum foil covering the led so that the participant will experience warmth but receive no photons.
224014619|NCT06003140|DEVICE|Celsi Warmer|A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
224014620|NCT04323176|OTHER|Village Model implementation|Participate in the Village Model using a website
224014621|NCT02528526|DRUG|OXY111A|OXY111A intravenous infusion
224014622|NCT03014076|DRUG|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
224014623|NCT03014076|DRUG|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
224014624|NCT00473148|PROCEDURE|BNP-guided weaning|BNP-guided weaning
224014625|NCT00473148|PROCEDURE|Standard physician-directed weaning|Standard physician-directed weaning
224014626|NCT05918718|DRUG|Letrozole|assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
224014627|NCT05918718|DRUG|methotrexate|methotrexate
224128134|NCT03492463|OTHER|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
224128135|NCT03492463|OTHER|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
223394934|NCT04508257|DIETARY_SUPPLEMENT|Oral feeding of Control formula (Stage 1&2)|Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
223394935|NCT04508257|DIETARY_SUPPLEMENT|Breast feeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
223394936|NCT03335475|BEHAVIORAL|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
224014628|NCT03698903|BEHAVIORAL|Take a STAND 4 Health|The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
224014629|NCT00371683|DRUG|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
223394937|NCT03335475|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
223394938|NCT03971136|DIAGNOSTIC_TEST|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
223394939|NCT01285362|DRUG|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
223394940|NCT01285362|DRUG|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
224014630|NCT00371683|DRUG|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
224014631|NCT01010659|DEVICE|Lacrimal Tube|Lacrimal Tube
224014632|NCT05103371|BEHAVIORAL|"Experiment: Millie prevention program, adolescents and active parents"|"Prevention program: Millie, with the participation of adolescents and parents"
224014633|NCT05103371|BEHAVIORAL|"Experiment: Millie prevention program, adolescents only"|"Prevention program: Millie, with the participation of adolescents only, no parental involvement in the program"
224014634|NCT04563208|DRUG|Placebo|Placebo administered on Days 1-5
224014635|NCT04563208|DRUG|DuACT|Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
224014636|NCT03181789|BIOLOGICAL|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
224014637|NCT03181789|BIOLOGICAL|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
224128136|NCT05549063|OTHER|Mobility and Stability Exercise|Mobility and stability exercises
223394941|NCT05921903|BIOLOGICAL|RSVPreF3 OA Investigational Vaccine|0.5 mililiter dose was administered intramuscularly as 1 dose to RSV\_IC\_1 and RSV\_HA groups, and 2 doses to RSV\_IC\_2 group.
223394942|NCT04684147|BIOLOGICAL|single dose of CNCT19|Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide
223394943|NCT06089408|OTHER|Best Practice|Use a regular blanket
223394944|NCT06089408|OTHER|Supportive Care|Use a weighted blanket
223394945|NCT06089408|OTHER|Survey Administration|Ancillary studies
223394946|NCT06188520|DRUG|AZD8421|CDK2 inhibitor
223394947|NCT06188520|DRUG|Camizestrant|SERD
224014638|NCT03181789|BIOLOGICAL|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
224014639|NCT03181789|BIOLOGICAL|Placebo|Administered bilaterally using the TDS-IM EP device
224014640|NCT03181789|DEVICE|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
224014641|NCT05885087|DEVICE|Foley or balloon catheter|Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
224014642|NCT02624791|DEVICE|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
224014643|NCT02624791|DEVICE|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
224014644|NCT02624791|OTHER|No contact lenses|simulated driving tests
224014645|NCT04012801|DIAGNOSTIC_TEST|C13 breath test|C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.
223394948|NCT06188520|DRUG|Ribociclib|CDK4/6 inhibitor
223394949|NCT06188520|DRUG|Palbociclib|CDK4/6 inhibitor
223394950|NCT06188520|DRUG|Abemaciclib|CDK4/6 inhibitor
224014646|NCT00700492|DRUG|progesterone|vaginal capsules 3X200mg daily
224014647|NCT01131182|DRUG|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
224014648|NCT01131182|DRUG|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
224014649|NCT01131182|DRUG|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
224128137|NCT05549063|OTHER|Stretching Exercise|Balance and reaching exercise
224128138|NCT06876220|BEHAVIORAL|Mindfulness-based Cognitive Therapy for Life (MBCT-L)|MBCT-L is an 8-week group intervention where participants are guided to practice mindfulness and cognitive exercise. The course covers themes such as anchoring, acceptance, and decentering. The course will be provided by mindfulness teachers who have completed the training offered by Oxford Mindfulness Foundation (OMF). Throughout the eight weeks, the course guides the participants through various themes such as anchoring, acceptance, and decentering. The sessions involve guided mindfulness practices, reflection, discussion, inquiry, and weekly home practice. The language of instruction is Cantonese.
224014650|NCT02423148|DRUG|Indocyanine green (ICG)|
224014651|NCT02423148|DEVICE|FluoSCOPE|
224014652|NCT04831541|DRUG|68Ga-PSMA-11|Each subject receive a single intravenous injection of 68Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
224014653|NCT03343327|DRUG|Chronocort®|Single dose of 20mg Chronocort® administered in one treatment period
224014654|NCT03343327|DRUG|Cortef®|Single dose of 20mg Cortef® administered in one treatment period
224014655|NCT05110352|DIAGNOSTIC_TEST|Polysomnography|A polysmnography is planned for every patients in order to evaluate the Apnea-Hypopnea Index (AHI).
223394951|NCT06621953|DEVICE|BFR|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to either 80% or 40% of limb occlusion pressure during lower limb strengthening exercises, as determined by Phase One (2318/MODREC/24a). These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum in Week 1, 25% in Week 2 and 30% in Week 3.
223394952|NCT06621953|OTHER|control group|Standard residential rehabilitation consists of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
223394953|NCT05873816|DEVICE|ProtEmbo - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the ProtEmbo cerebral embolic protection device.
223394954|NCT05873816|DEVICE|Sentinel - Cerebral Embolic Protection|Subjects will undergo TAVR following placement of the Sentinel cerebral embolic protection device.
223394955|NCT05685472|BIOLOGICAL|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
223394956|NCT02409316|DRUG|[18F]FES|\[18F\]FES PET/CT scan
224014656|NCT05110352|DIAGNOSTIC_TEST|Pharyngeal ph-metry Restech|Pharyngeal ph-metry Restech over 24 hours (night and day)
224014657|NCT05110352|PROCEDURE|Peptest|Saliva sample to look for an association between pharyngolaryngeal reflux and obstructive sleep apnea syndrome
224014658|NCT05110352|BEHAVIORAL|Questionnaire RSS-12|Questionnaire with 12 items about quality of life. Score between 0 and 5.
224014659|NCT05110352|PROCEDURE|Reflux Sign Assessment|RSA score about anatomy and morphology of the mouth
224014660|NCT04339530|OTHER|Normal weight and overweight adults|Association between vitamin D levels and insulin resistance
224014661|NCT00662818|DRUG|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
224014662|NCT00662818|DRUG|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
224014663|NCT00662818|DRUG|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
223730898|NCT02990091|DIETARY_SUPPLEMENT|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
223730899|NCT00847054|DRUG|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
223394959|NCT06427538|OTHER|Saline Flush|sterile saline 20 mL flushed into their catheter by trained nurses or study team members every 6 ± 2 hours
223730900|NCT03140644|OTHER|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
224014664|NCT00662818|DRUG|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
224014665|NCT06387628|DRUG|LM-108|LM-108, 10mg/kg, d1, q6w
224014666|NCT06387628|DRUG|Toripalimab|Toripalimab, 240 mg, d1, q3w
224014667|NCT06387628|DRUG|Eribulin|Eribulin 1.4 mg/m2, d1, 8 , q3w
224014668|NCT06387628|DRUG|Nab paclitaxel|Nab paclitaxel 125 mg/m2, d1, 8 , q3w
224014669|NCT02055391|BEHAVIORAL|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
224014670|NCT02055391|BEHAVIORAL|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
224014671|NCT00659178|DRUG|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
224014672|NCT02338973|DRUG|Interferon gamma-1b|
224014673|NCT02884310|DRUG|Remifentanil adapted to SPI|
224014674|NCT02884310|DRUG|Remifentanil fixed|
224014675|NCT06204952|DRUG|Joins®(Clematidis Radix,Trichosanthes Root,Prunella Spike Extract)|In patients with facet joint syndrome, Joins® (Clematidis Radix, Trichosanthes Root, Prunella Spike Extract) is administered at a dosage of 1 tablet three times a day for 12 weeks.
224014676|NCT06204952|DRUG|Placebo|In patients with facet joint syndrome, placebo drug is administered at a dosage of 1 tablet three times a day for 12 weeks.
224014677|NCT02327351|OTHER|Biological: TCR alfa beta T cell depletion|
224014678|NCT04802798|DIETARY_SUPPLEMENT|Fibre 1|Food derived fibre presented as a white powder
224014679|NCT04802798|DIETARY_SUPPLEMENT|Fibre 2|Food derived fibre presented as a white powder
224014680|NCT04802798|DIETARY_SUPPLEMENT|Placebo|Simple sugar, presented as a white powder
224014681|NCT03619304|DIETARY_SUPPLEMENT|coffee|coffee beverage
224014682|NCT00723541|PROCEDURE|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
224014683|NCT00574613|DRUG|P144|Cream 0,3 ml once a day (3 months)
224014684|NCT00574613|DRUG|placebo|Cream 0,3 ml once a day (3 months)
224014685|NCT05737368|RADIATION|fractionated radiotherapy|fractionated radiotherapy (500cGy \*5F, 600cGy\*5F, 350cGy\*10F, according to the tumor volume)
224014686|NCT05737368|DRUG|cadonilimab|Cardunizumab (10mg/kg, Q3W, d1)
224128139|NCT04946916|DIAGNOSTIC_TEST|blood sample taken|Comparaison of Neurofilament light chain serum concentration between the arms
224128140|NCT06691906|DRUG|Enlicitide decanoate|Oral tablet
223730901|NCT03787251|DRUG|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
224014687|NCT01026532|BIOLOGICAL|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
224014688|NCT00749034|BIOLOGICAL|VPM1002|live vaccine
224014689|NCT00749034|BIOLOGICAL|BCG|commercially available live vaccine BCG
224014690|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
224014691|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
224014692|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
224014693|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
224014694|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
224014695|NCT00439803|BIOLOGICAL|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
224014696|NCT00439803|BIOLOGICAL|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
224014697|NCT00439803|BIOLOGICAL|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
224014698|NCT02586571|BEHAVIORAL|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
224014699|NCT03780075|DRUG|1.11GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
224014700|NCT03780075|DRUG|2.00 GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 2.00 GBq (54 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
224014701|NCT03780075|DRUG|3.70GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
224014702|NCT00688558|DRUG|JTT-705 600 mg and simvastatin 40 mg|"* JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~* Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
224014703|NCT00688558|DRUG|Placebo and simvastatin 40 mg|"* Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~* Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
224014704|NCT03922516|DIAGNOSTIC_TEST|ULDCT|Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
224014705|NCT04490200|DEVICE|VESTA respirator|The protocol will be composed by the use of the VESTA respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
223394960|NCT04160624|PROCEDURE|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
223394961|NCT06432803|OTHER|PET-Scan analysis|Investigate and determine the clinical value of different cortex/striatal metabolic ratio patterns in each antibody-specific subtype of autoimmune encephalitis
223394962|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
223394963|NCT06513481|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
223394964|NCT03143790|PROCEDURE|Extracorporeal Shockwave Terapy|Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
223394965|NCT00423878|DRUG|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
223394966|NCT00423878|DRUG|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
223394967|NCT00423878|DRUG|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
223394968|NCT00423878|DRUG|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
223394969|NCT05317312|DRUG|MR-107A-02|MR-107A-02 oral tablet
223394970|NCT05317312|DRUG|Placebo|Placebo oral tablet
223394971|NCT05758870|PROCEDURE|surgical stabilization of low rib fratures|surgical stabiliazation of rib fractures by internal fixation
223394972|NCT05758870|OTHER|converstive treatment of low rib fratures|chest wall fixation band
223394973|NCT00235755|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
223394974|NCT00235755|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
223394975|NCT00235755|DRUG|Placebo|Oral tablet.
223394976|NCT04128930|DEVICE|PAP titration at home|Fixed CPAP or APAP titration at home
224014706|NCT04490200|DEVICE|Conventional N95 respirator|The protocol will be composed by the use of the N95 respirator for 21 days (approximately 8 consecutive shifts lasting 6 to 12 hours, followed by approximately 36 hours of rest). Each participant will receive a total of approximately 8 respirators, with instructions for a maximum usage time of 6 hours. Therefore, participants will receive 1 respirator to be used in each shift of 6 hours, and 2 respirators in shifts of 12 hours. All participants will receive a booklet with guidelines and training in the use and proper handling of the respirator. All respirators will be sterilized and packaged in the laboratory, to ensure that they are not contaminated before use by the participants. The intervention will not change the participants' routine, considering that they already follow instructions for the use of protective personal equipment (PPE) and the proposed intervention will follow all local regulations and guidelines for the use and conservation of PPE and semi facial respirators.
223394977|NCT01494675|OTHER|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.~The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
223394978|NCT04982861|DRUG|Cefixime Trihydrate 100 mg/5 mL Dry Syrup|Participants received a single dose of 5 mL of cefixime dry syrup with 240 mL of water
223394979|NCT04982861|DRUG|Suprax 100 MG in 5 mL Oral Suspension|Participants received a single dose of 5 mL of Suprax with 240 mL of water
223394980|NCT04271228|DEVICE|DreaMed Advisor Pro|Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
223394981|NCT01105897|PROCEDURE|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
223394982|NCT02700217|PROCEDURE|Bupivacaine and Diamorphine|
223394983|NCT02700217|PROCEDURE|Remifentanil, Propofol and Cistracurium|
223394984|NCT02700217|PROCEDURE|Bupivacaine and Rectus Sheath injection|
223394985|NCT01459133|DRUG|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
223394986|NCT02588898|DEVICE|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
223394987|NCT02314026|DEVICE|Suspected NASH BreathID test with 13C-Octanoate|Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
223394988|NCT02314026|DEVICE|Suspected NASH Breath test with 13C Methacetin|Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
223394989|NCT02056223|DRUG|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
223394990|NCT02056223|DRUG|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
223394991|NCT03974867|DRUG|Prednisone 5Mg Tab|"Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;"
223394992|NCT03974867|DRUG|Methylprednisolone 40 mg|"Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;"
223549046|NCT05745103|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders.
223394993|NCT01332344|DRUG|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
223394994|NCT01332344|DRUG|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
223394995|NCT06976307|BEHAVIORAL|High Carbohydrate Diet|Participants randomized to this group will participate in a group-based weight behavioral management program and consume a high carbohydrate (HC) diet. Because this protocol uses a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine HC diet with time-restricted eating (TRE) or HC diet with additional exercise counseling and support.
223394996|NCT06976307|BEHAVIORAL|Reduced Carbohydrate Diet|Participants randomized to this group will participate in a group-based behavioral weight management program and consume a reduced carbohydrate (RC) diet. Because this is a sequential, multiple assignment, randomized trial (SMART) design, response will be assessed at week 4. Responders will continue with their 1st stage assignment for the remainder of the study. Non-responders will be randomized to 2nd stage intervention of either combine RC diet with time-restricted eating (TRE) or RC diet with additional exercise counseling and support.
223394997|NCT05586100|DRUG|Toripalimab+cetuximab|"Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy."
223394998|NCT01075789|DRUG|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
223549047|NCT05296551|OTHER|Motor Task|A visuomotor task is presented where an individual must match their knee to an ellipse that moves up and down on a screen, resulting in a marching-in-place motion at a specified frequency.
223394999|NCT01075789|DRUG|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
224014707|NCT03988920|DRUG|Tenapanor|NHE3 Inhibitor
224014708|NCT03988920|DRUG|Sevelamer Carbonate|Phosphate binder
224014709|NCT05286320|DRUG|Lenvatinib/Pembrolizumab plus SBRT combinations|Five-fraction SBRT (week 4-week 5) to PVTT and connected HCC tumor in 2 weeks Lenvatinib 12/8 mg/day for 96 weeks (no lenvatinib from 7 day before SBRT to 7 days after SBRT) Pembrolizumab 200 mg q 3 week x 32 cycles
224014710|NCT01386073|DRUG|FreshKote|Three times a day for three months
224014711|NCT01386073|DRUG|Systane|three times a day for three months
224014712|NCT06298929|PROCEDURE|medial rectus fenestration|Fenestration technique involves making two splitting incisions by blunt dissection parallel to the muscle fibers on the superior and inferior borders of the muscle, leaving 1 mm of muscle fibers on each edge. The rectangular wide central part is excised from the insertion and between the two splitting incisions to a point back 5-8 mm depending on the angle of the esotropia.
224014713|NCT06298929|PROCEDURE|medial rectus recession|recession is one of the gold standard weakening procedures that involves disinsertion of the muscle and re-suturing to the sclera at a more posterior location to decrease its contractile power.
223395000|NCT04257214|BEHAVIORAL|Psychosocial treatment|Participants randomly assigned to one of four psychosocial treatment conditions including cognitive behavioral therapy and a certified recovery specialist.
223395001|NCT03329339|PROCEDURE|1 L PEG with ascorbic acid with prepackaged, low residue diet|Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
223395002|NCT02354729|OTHER|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
223395003|NCT02573961|DEVICE|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
223395004|NCT02573961|BEHAVIORAL|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
223395005|NCT02573961|BEHAVIORAL|low caloric diet|Tailored balanced low caloric diet
223395006|NCT05590611|OTHER|Dietary Intervention with Brown Bread|The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
223395007|NCT05590611|OTHER|Dietary Intervention with Sourdough Bread|The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.
223395008|NCT00138008|DRUG|endocrine therapy|Drug: endocrine therapy
223395009|NCT00138008|PROCEDURE|radiotherapy|Procedure/Surgery: radiotherapy
223395010|NCT04507295|DEVICE|cerebral oximetry ( INVOS 5100 )|"in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~1. Increase FIO2 up to 100%~2. Increase PEEP up to 5 cmH2O~3. Decrease insufflation pressure"
223395011|NCT05699941|DEVICE|Ectoin® Inhalation Solution|Ectoin Inhalation Solution (Class-IIa Medical Device Directive (MDD) legacy medical device) is an isotonic, aqueous solution containing Ectoin 1.3 % and sea salt 0.6%. It is used for moistening the lung epithelium by the Ectoin hydro complex and supports the barrier function of the lung epithelium. The inhalation solution can be administered with jet, mesh, and ultrasound nebulizers.
223549048|NCT05296551|OTHER|Cognitive-motor dual-task|"While performing the Motor Task intervention, letters of different colors and orientation randomly appear one at a time on the screen. During the Cognitive-motor dual-task, individuals are instructed to count the number of times that either 1 (simple cognitive task), or 2 (complex cognitive task) characters appear on the screen during the motor task."
223549049|NCT02455102|OTHER|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
223549050|NCT03672812|DRUG|Liraglutide|liraglutide 3mg 6/6 hours
223549051|NCT00442533|DRUG|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
223549052|NCT00062491|DRUG|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
224014714|NCT01146782|DEVICE|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
224014715|NCT02211885|DRUG|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
223549053|NCT00276068|DRUG|topical lidocaine + oral desipramine, and/or placebo|
224014716|NCT03390647|DRUG|E6130|Oral dose
224014717|NCT03390647|DRUG|Placebo|E6130-matched placebo
224014718|NCT00008073|DRUG|doxorubicin hydrochloride|
224014719|NCT00008073|DRUG|octreotide acetate|
224014720|NCT02685345|DRUG|DS-8500a 25 mg|
224014721|NCT02685345|DRUG|DS-8500a 75 mg|
224014722|NCT02685345|DRUG|placebo|
224014723|NCT03384901|PROCEDURE|vitrectomy|Pars plana vitrectomy and ILM (internal limiting membrane) peeling
224014724|NCT02729285|DRUG|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
224014725|NCT02729285|DRUG|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
224014726|NCT02729285|PROCEDURE|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
223395012|NCT05123313|BEHAVIORAL|Deprescribing intervention|"The intervention is comprised of a minimum of three consultations with a general practitioner (GP), where adjustment of the patient's medication is made according to the patient's preference, goals and needs~Consultation 1: Patient and GP discuss how the patient feels about their medical treatment, and the GP provides the patient with written material for the patient to prepare prior to the next consultation.~Consultation 2: A clinical pharmacist have beforehand examined the patient's medication list and provided suggestions to the GP on which drugs can be deprescribed. The patient and GP discuss the patient's preferences and initiate deprescribing initiatives aligned with the patient's priorities.~Consultation 3: Patient and GP follow up on the changes initiated and initiate new deprescribing initiatives if such can be identified. If needed, subsequent consultations (Consultation X) are planned until the patient and GP consider the patient's medical treatment optimal."
223395013|NCT01532934|BEHAVIORAL|motivational enhancement therapy|Four 45-minute MET sessions
223395014|NCT01532934|OTHER|standard care|
223395015|NCT06439251|COMBINATION_PRODUCT|Group 1|The treatment included TENS therapy, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques. Participants in Group A also received Phonophoresis as an experimental technique.
223395016|NCT06439251|COMBINATION_PRODUCT|Group 2|The treatment included routine physiotherapy with TENS, hot pack application, stretching exercises, isometric strengthening, straight leg raises with traction, and tibial gliding techniques.
223395017|NCT05608681|DRUG|EP-104GI|Extended-release fluticasone propionate \[FP\] for injectable suspension for gastrointestinal administration, Powder suspended in vehicle
223395018|NCT05608681|OTHER|Matching vehicle control|A sterile liquid containing sterile water and excipients necessary to prepare a uniform suspension of the powder.
223395019|NCT06984302|OTHER|proactive therapy|drugs and fluids will be given based on the hypotension prediction index
223395020|NCT05821075|DRUG|Prednisolone|prednisolone 60mg tablet once daily for 5 days then tapering dose
223395021|NCT05821075|DRUG|Cerebrolysin|intramuscular Cerebrolysin 10 mg daily for 3 weeks
223395022|NCT06596759|BEHAVIORAL|Diaphragmatic Breathing|REDCap will be used to administer the Mayo Bloating Questionnaire (MBQ) and collect self-reported compliance to diaphragmatic breathing (DB) exercises over a 4 week follow up period. After completion of the MBQ, the patient will be taught DB techniques by an individual physical therapist face to face over a 30-minute session. The patient will be instructed to complete 5-10 minutes of diaphragmatic breathing twice a day for a period of 4 weeks. Patients will receive a telephone call and electronic health record portal message to check progress and answer any questions. At the end of the 4-week follow up period, patients will repeat the MBQ and self-report their adherence to daily diaphragmatic breathing. The questionnaire will include prompts investigating perceived side effects and attitudes towards therapy, willingness to perform DB therapy, likelihood to attempt self-guided DB in the future, and if the participant would recommend the therapy to a friend.
223395023|NCT06603883|BIOLOGICAL|Fecal microbiota transplantation (FMT) by nasal jejunal tube|FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
223395024|NCT06670222|DRUG|Arsenic Trioxide (ATO)|"Study treatment: oral Arsenic 5d/7 for 21 days over a 28-day cycle, three doses tested (0.10 mg/kg, 0.15 mg/kg and 0.20 mg/kg).~Dose escalation cohort to determine the dose limiting toxicity according to a BOIN (Bayesian optimal interval) scheme, 9 patients will be treated at each dose.~An expansion cohort at the selected dose will be conducted with 6 patients.~Tolerability will be assessed after one treatment cycle. Response will be assessed after 3 cycles of treatment. Responders may continue study treatment until progression or limiting toxicity. Limiting toxicity is defined as any grade III/IV extra-hematological toxicity or grade IV hematological toxicity lasting more than 25 days."
224014727|NCT03392285|DEVICE|Internal fixation or hip arthroplasty|Patients treated according to the routine at the orthopedic department with screw fixation of an undisplayed femoral neck fracture or hip arthroplasty for a displaced femoral neck fracture.
224014728|NCT01912677|DRUG|Nifedipine|
223395025|NCT06613074|DEVICE|Ali Pay intelligent navigation applet|"The intelligent navigation applet comprises of three function modules:~1. Stroke knowledge public education: information regarding prevention and emergency treatment of stroke would be push to users\&#39; mobile phones regularly;~2. Stroke recognition: questionaires, voice interaction, and facial recognition are employed to identify patients with AIS and large vessel occlusion;~3. Hospital recommendation: this module combines real-time traffic and average in-hopital delay of each stroke center nearby, recommending the stroke center in which patients are mostly likely to receive reperfusion therapy"
223395026|NCT04988919|DIETARY_SUPPLEMENT|4D|multi-ingredient supplement mixed with 24 ounces of water
223395027|NCT04988919|DIETARY_SUPPLEMENT|placebo|taste-matched placebo mixed with 24 ounces of water
223395028|NCT02154867|BIOLOGICAL|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
223395029|NCT02154867|OTHER|Placebo fecal transplant|Fecal transplantation with own feces
223549054|NCT02487147|OTHER|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
223549055|NCT02487147|OTHER|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
223549056|NCT03150290|OTHER|Indirect Calorimetry.|REE measurement
223549057|NCT03150290|DEVICE|18-FDG-PET|18-FDG-PET
224014729|NCT01912677|DRUG|Labetalol|
223549058|NCT02466035|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
224014730|NCT01912677|DRUG|Methyldopa|
224014731|NCT02930031|DIETARY_SUPPLEMENT|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
224014732|NCT02930031|DIETARY_SUPPLEMENT|Placebo|500 mL orally, daily for eight days following exercise
224014733|NCT00956059|DRUG|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4\~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6\~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
223549059|NCT05645796|OTHER|Adopted contrast media amount by using different approaches|Using different contrast media approaches recommended by literature to explore the impact on the contrast enhancement in chest CT
223395030|NCT05385653|BEHAVIORAL|"experimentation of the virtual reality RevBED"|"ReVBED is a VR-based exposure scenario for CBT for the induction of food craving in patients with bulimia nervosa and binge eating disorder.~The use of ReVBED requires no VR experience and only generic and commonly used virtual reality tools (a computer with VR software, a wireless virtual reality headset, two controllers and headphones), all with a CE mark, allowing its users to move in and interact with a specially designed virtual environment.~This exhibit scenario takes place in a VR environment built to represent a standard apartment consisting of four exhibit rooms (a bedroom, a teenager's bedroom, a living room and a kitchen) in which the ReVBED user moves sequentially through the scenario. In each room, specific cues of craving are displayed. These cues are not only visual, but also audio, emotional and socio-environmental. A central hall connects the other rooms and serves as a safe place for debriefing, where measures such as craving are assessed."
223395031|NCT04327544|BEHAVIORAL|Frailty Intervention|In overall, participants will attend one session of frailty talk, 22 sessions of low to moderate intensity of multi-components exercise course and 6 session of nutrition education interventions. Both nutritional education and exercise intervention will be conducted concurrently for a 12-week (3-month) of intervention period. Noted that every session will be held in PPR flats' facility area or hall around 60 minutes that will be conducted by the dietitian or nutritionist and physiotherapist from the research team.
224014734|NCT00956059|DRUG|prednisone|In the initial 16\~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
223395032|NCT05719935|DEVICE|KinematX total wrist arthroplasty system|The KinematX total wrist implant is a joint metal/polymer semi-constrained cemented prosthesis that utilizes an articulation that mimics the midcarpal joint instead of the radiocarpal joint.
223395033|NCT01867528|PROCEDURE|Laparoscopic adhesiolysis|
223395034|NCT01867528|PROCEDURE|Open adhesiolysis|
223395035|NCT05711420|BEHAVIORAL|Gamification method group|Gamification method group
224014735|NCT00677716|DRUG|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
224014736|NCT03358251|DEVICE|Pocket-X Gel|Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.
224014737|NCT03358251|PROCEDURE|Scaling and root planing|Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
224014738|NCT02220231|PROCEDURE|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
224014739|NCT05029232|DIAGNOSTIC_TEST|MLPA for duchenne|MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up
224014740|NCT01487447|OTHER|Customized sound|treatment with customized sound therapy
224014741|NCT01487447|OTHER|Regular Masker|treatment with white noise
224014742|NCT01533480|DRUG|Zirgan|0.15% ganciclovir gel(Zirgan)
223395036|NCT05711420|BEHAVIORAL|Flipped learning group|Flipped learning group
223395037|NCT06676878|DEVICE|Incremental exercise|A graded exercise test will be performed on a treadmill. After 3 minutes of standing on the treadmill, participants will walk at a speed of 4 km/h for the first 3 minutes, then the speed will be increased to 8 km/h. After this point, the treadmill speed will be increased by 2 km/h every 3 minutes until voluntary exhaustion.
223395038|NCT07013422|OTHER|Psychoeducational support|Study Intervention: psychoeducational sessions, 5 sessions were given to the participants allocated to the intervention arm (60-90 minutes each) covering health education, stress management, coping strategies, and communication with children
224128141|NCT06692816|OTHER|Rehabilitation|As a therapeutic exercise program, it was planned to apply joint range of motion, walking, balance, coordination, cycling, isometric and isotonic strengthening exercises by a trained physiotherapist with at least 5 years of experience and that the patients would do these exercises three times a day, in 3 sets, with 10 repetitions.
224128142|NCT06112314|DRUG|Brenetafusp|Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.
224128143|NCT06112314|DRUG|Nivolumab|Concentrate for solution for infusion at a unit dose of 10 mg/mL.
223549060|NCT02860234|DRUG|Oxaliplatin|
223549061|NCT02860234|DRUG|Capecitabine|
223549062|NCT02860234|RADIATION|intensity modulated radiotherapy|
223549063|NCT02860234|PROCEDURE|DRE-Endoscopy-MRI-CEA|
223549064|NCT02860234|PROCEDURE|Nonoperative Management|
223549065|NCT02860234|PROCEDURE|Local Excision|
223549066|NCT02860234|PROCEDURE|Total Mesorectal Excision|
223549067|NCT02860234|BEHAVIORAL|Quality of Life Questionnaires|
223549068|NCT02445105|BEHAVIORAL|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
223549069|NCT02445105|BEHAVIORAL|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
223549070|NCT02919891|OTHER|Questionnaire|Questionnaires
224014743|NCT01533480|DRUG|genteal gel|0.3% Hypromellose gel
224014744|NCT02341131|BEHAVIORAL|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
224014745|NCT02341131|BEHAVIORAL|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
224014746|NCT02318173|DEVICE|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
224014747|NCT03806101|DRUG|PF-04965842|200 mg dose of PF-04965842 once daily (QD) for 3 days
224014748|NCT03806101|DRUG|Rosuvastatin|Single 10 mg dose of rosuvastatin
224014749|NCT00719147|PROCEDURE|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
224014750|NCT00719147|OTHER|Functional Status and Symptom Questionnaire|Questionnaire
223395039|NCT07015463|OTHER|Multi-component intervention in health literacy|Multi-component intervention aiming at increasing the health literacy of patients suffering from hypertension, in achieving the target blood pressure goal three months after the start of the intervention in poorly controlled hypertensive patients
224014751|NCT04080921|COMBINATION_PRODUCT|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
224014752|NCT00447889|DRUG|gadoteric acid|
223395040|NCT07017790|OTHER|Amino-acid PET|Patients received 18-fluoroDopa then a PET exam
223395041|NCT07017439|DRUG|Beta-3 agonists (Mirabegron/Myrbetriq)|Patients in this arm will receive the medication in pill form following their procedure
223395042|NCT07017439|OTHER|Placebo group post rezum|Patients in this arm will receive the placebo pill following their procedure.
223395043|NCT06624410|OTHER|Educational Intervention|"Pre-operative anxiety levels will be assessed with the mYPAS-SF6-12 (below). Subjects will be observed for behaviors and then given a score out of possible 5 across 5 domains that corresponds with demonstrated behaviors, specified in the figure below. The 5 domains include Activity, Vocalization, Emotional Expressivity, State of Arousal, and Use of Parent. Note that the Vocalization domain differs in that It's possible scores range from 1-7. Pilot data collection will involve mYPAS scoring in isolation to demonstrate existing anxiety burden at Doernbecher Children's Hospital."
223549071|NCT04326218|OTHER|Blood sample|"Serum samples will be sent for centralised analyses in Nice.~On these samples, different analysis will be performed :~* anti-PLA2R1 and anti-THSD7A antibodies~* anti-PLA2R1 and anti-THSD7A epitopes~* HLA typing"
223549072|NCT03345303|DRUG|Bortezomib|Bortezomib Injectable Solution
223549073|NCT02903693|OTHER|cross sectional|
223549074|NCT02339805|OTHER|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
223549075|NCT02339805|DEVICE|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
224014753|NCT02799901|BIOLOGICAL|Nivolumab|Injection of nivolumab
224014754|NCT02799901|RADIATION|hypofractionned radiotherapy|radiation
224014755|NCT02656329|DRUG|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
224014756|NCT02656329|DEVICE|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
223549076|NCT01232127|DRUG|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
223549077|NCT01232127|DRUG|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
223549078|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
223549079|NCT01232127|DRUG|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
223549080|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
224014757|NCT02656329|DRUG|Thyroid blocking|Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
224014758|NCT02656329|DRUG|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
224014759|NCT02656329|DEVICE|Implantable Cardioverter Defibrillator|All participants allocated to the SoC (control) group underwent ICD implantation.
224014760|NCT01139580|DRUG|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
224014761|NCT01139580|DRUG|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
224014762|NCT05654142|BEHAVIORAL|Base intervention|12 Group Lifestyle Balance videos and digital motivational messages
224014763|NCT05654142|BEHAVIORAL|Augmented Intervention|12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
224014764|NCT05067153|DRUG|Fragmin 5000 UNT in 0.2 ML Prefilled Syringe|30 days postoperative prophylactic treatment.
224014765|NCT01164904|DRUG|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
224014766|NCT02546622|BIOLOGICAL|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
224014767|NCT02546622|BIOLOGICAL|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
224014768|NCT05774132|PROCEDURE|ultrasound guided Subgluteal sciatic nerve block|Patients will be positioned in lateral decubitus and the ultrasound scanning for the sciatic nerve in the subgluteal region will be started between the two bony landmarks (greater trochanter and ischial tuberosity ) using high frequency linear probe then approached via 5 cm block needle under ultrasound guidance after which bupivacaine 0.25% (0.3 ml/kg) will be administered in increments .
223730902|NCT03787251|DRUG|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
223730903|NCT02999945|DIETARY_SUPPLEMENT|SGA-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
223730904|NCT02999945|DIETARY_SUPPLEMENT|IUGR-enhanced nutrients|Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
223730905|NCT02999945|OTHER|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
223730906|NCT02999945|OTHER|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
223730907|NCT00005622|DRUG|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
224014769|NCT05774132|PROCEDURE|ultrasound guided Caudal block|Patients will be positioned in lateral decubitus and their sacral hiatus will be palpated under the scanning of the ultrasound using high frequency linear probe then approached via 5 cm block needle that pierce the sacrococcygeal ligament then will be advanced to caudal canal under ultrasound guidance after which bupivacaine 0.25% (1 ml/kg) will be administered in increments.
224014770|NCT02784249|PROCEDURE|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
224014771|NCT02784249|DEVICE|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
223395044|NCT06443788|DIAGNOSTIC_TEST|transperineal ultrasound|"The following measurement will be recorded:~1. Amniotic fluid pooling assessment will be performed in sagittal and transverse planes. ,~   * Images will be evaluated for appearance of accumulated hypoechogenic fluid around cervix. Whenever collection is spotted, three largest dimensions of fluid will be measured (length, width, depth).~  * Fluid accumulations around the cervix that are clearly demarcated from surrounding tissues will be considered positive.~2. Cervical length: it will be measured between the internal os point to the external os point below. Cervical dilatation will be measured in a transverse plane from inner to inner.~3. Presence of fetal part prolapse and/or cord prolapse"
223395045|NCT02291237|DRUG|Eleclazine|Tablet (s) administered orally once daily
223395046|NCT02291237|DRUG|Placebo|Placebo to match eleclazine administered orally once daily
223395047|NCT05430646|DEVICE|Covered metal ureteral stents|The CMUS is a fully covered, self-expanding, large caliber metal stent. The stent is made of super-elastic nickel-titanium alloy, which maintain lumen patency via providing long-term direct wall support.
223395048|NCT05430646|DEVICE|Tandem DJ stents|Tandem DJ stents represents for two stents side-by-side, which improves the urine flow by better withstanding the compressive tumoral forces and allowing urine to flow between the stents.
223395049|NCT03903432|OTHER|MRI|candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
223395050|NCT01149863|DRUG|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
223395051|NCT01851044|PROCEDURE|Platelet Rich Plasma|
223395052|NCT01851044|PROCEDURE|Whole Blood Injection|
223395053|NCT01851044|PROCEDURE|Saline Injection|
223395054|NCT06732921|DEVICE|Alertwatch - Recovery Control Tower|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
223395055|NCT02112851|OTHER|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
223395056|NCT01306305|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~* 15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
223395057|NCT06301542|DEVICE|Functional electrical stimulation|The FES system will be placed on the plantar flexors, dorsiflexion, and quadriceps muscles and be paired with the machine learning directed inertial measurement units.
223549081|NCT01232127|DRUG|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
223549082|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
224014772|NCT02784249|PROCEDURE|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
224014773|NCT04713449|OTHER|Empowered Survivor Online|Informational online intervention for head and neck cancer survivors
223549083|NCT01232127|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
223549084|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
223549085|NCT01232127|DRUG|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
223730908|NCT00005622|RADIATION|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
223730909|NCT04673331|OTHER|exercise capacity|3minute step test and 1minute sit to stand test used assessment of exercise capacity.
223730910|NCT00402766|DRUG|Cisplatin|Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
223730911|NCT00402766|DRUG|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
224014774|NCT04713449|OTHER|Springboard Beyond Cancer|Informational online intervention for all cancer survivors
224014775|NCT04713449|OTHER|Survey Administration|Survey measures administered at BL, two and 6 months post-baseline
223395058|NCT06745128|DRUG|Tirzepatide|Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 32-week period. Following the instructions of the FDA-approved prescribing label, participants or a licensed study clinician will administer the tirzepatide injection subcutaneously in either the abdomen, thigh, or upper arm once weekly for 32 weeks total. Following the instructions of the FDA-approved prescribing label, the dosing schedule will include a 4-week titration at a starting dosage of 2.5mg/week. After four weeks, dosage will be increased in 2.5mg increments. The recommended maintenance dosages per prescribing label are 5mg/week, 10mg/week, or 15mg/week injected subcutaneously. Maximum dosage (up to 15mg/week) will be optimized for each individual. We will use commercially available tirzepatide, primarily dispensed as ZEPBOUND® for this study, but in the event of medication shortage or other pharmacy-related issue, MOUNJARO® may be dispensed as an alternative.
223395059|NCT03326193|DRUG|Niraparib|Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
223549086|NCT05196750|OTHER|Behavioural questionnaires and assessments on mother and child|Questionnaires include, but not limited to, State Trait Anxiety Inventory, Beck Depression Inventory, LYNDON Maternal Health and Well Being, Facial Imitation Task, Deferred Imitation, Habituation, Relational Binding, Behavioural Observation, Mirror Self Recognition, Standardized Assessment and Experimental Task, Snack and Sticker Delay, Implicit Attitude Test
223549087|NCT00714662|DEVICE|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
223549088|NCT03563482|DIAGNOSTIC_TEST|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
223549089|NCT03680196|DRUG|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
223549090|NCT05466552|PROCEDURE|PCI procedure|During the PCI procedure, use of ECMO/Impella 5.0 is allowed hemodynamic instability (bail- out).
223549091|NCT06426875|DIAGNOSTIC_TEST|Isometric Exercises|Isometric External Rotation (Perform isometric external rotation exercises with a resistance band to strengthen the rotator cuff.) Hold each contraction for 10-15 seconds. Isometric Internal Rotation (Hold each contraction for 10-15 seconds) Isometric Abduction (Supraspinatus). ( each contraction for 10 -15 sec) 10 repetition 3 sets Isometric Adduction (Subscapularis) Overhead Isometric Holds (Hold each contraction for 15-20 seconds) Isometric Shoulder External Rotation Against Resistance: (Hold each contraction for 15-20 seconds) Isometric Shoulder Press (Hold each contraction for 15-20 seconds) 15 to 20 repetitions 4 sets Total duration of 30 to 35 minute session three sessions per week total four weeks of intervention, reading will be taken on baseline and after 2nd week and 4th week
223549092|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Screening-2002|Nutritional Risk Screening-2002
223549093|NCT05417672|DIAGNOSTIC_TEST|Nutritional Risk Index|Nutritional Risk Index
223549094|NCT05417672|DIAGNOSTIC_TEST|Mini Nutritional Assessment|Mini Nutritional Assessment
223549095|NCT05417672|DIAGNOSTIC_TEST|Glasgow Prognostic Score|Glasgow Prognostic Score
223549096|NCT05417672|DIAGNOSTIC_TEST|Prognostic Nutritional Index|Prognostic Nutritional Index
223549097|NCT05417672|DIAGNOSTIC_TEST|Anthropometric measurements|middle arm circumference
223549098|NCT05417672|DEVICE|Handgrip strength test|Handgrip strength test
223730912|NCT00402766|DRUG|Pemetrexed|Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes
223730913|NCT00402766|DRUG|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
223549099|NCT01091038|OTHER|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
223549100|NCT01091038|OTHER|Routine Care|Routine Care
223549101|NCT05358743|OTHER|Probiotic group|Participants will use the probiotic product once daily (1 tablet/day) for 8 weeks
223549102|NCT05358743|OTHER|Placebo group|Patients will chew placebo products (blueberry tablets) once daily (1 tablet/day) for 8 weeks.
223730914|NCT00994292|DRUG|YM150|oral
223730915|NCT00994292|DRUG|Placebo|oral
223549103|NCT02596139|OTHER|No Interventions|
223549104|NCT03879616|BEHAVIORAL|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
223730916|NCT03598192|PROCEDURE|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
223730917|NCT03598192|PROCEDURE|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
223730918|NCT03598192|DRUG|Ropivacaine|Ropivacaine has been treated the both group
223730919|NCT03598192|DRUG|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
223730920|NCT04137003|OTHER|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
224014776|NCT04739943|BEHAVIORAL|Mobile Monitoring|Participants use a smartphone app for self monitoring of respiratory symptoms
223395060|NCT03326193|BIOLOGICAL|Bevacizumab|Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
223395061|NCT07052864|DRUG|Dexamethasone|8 mg of Intravenous Dexamethasone in 100 ml Normal saline given 1 hour before anesthesia induction
223730921|NCT04137003|OTHER|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
224014777|NCT05540067|BEHAVIORAL|Acceptance-Based Behavior Therapy (ABBT)|In the first session, the interventionist will introduce the concept of acceptance and its possible benefits in the context of life values and participant-identified challenges related to the COVID-19 pandemic, mental health, and social support. Interventionists will help participants identify potential challenges to acceptance. At the second session, participants will practice acceptance-based coping skills and a social support behavioral plan will be developed. These discussions will help the participant clarify how best to align their values with decisions on how to manage their mental health and social support in the context of the COVID-19 pandemic.
223395062|NCT07052864|DRUG|Placebo|100ml of Normal saline administration 1 hour before anesthesia induction
223395063|NCT06736223|DRUG|ITF2357|ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose
223395064|NCT04691427|DEVICE|Virtual Eye Rotation Vision Exercises (VERVE)|A video game designed with elements of vision therapy will be delivered to participants utilizing consumer-available virtual reality headsets (VIVE Pro Eye).
223395065|NCT00978874|RADIATION|fludeoxyglucose F 18|
223395066|NCT00978874|RADIATION|fluorine F 18 EF5|
223395067|NCT04420494|OTHER|Umbilical Cord Blood|The diagnosis is definitely immune cytopenia (IRC), including autoimmune hemolytic anemia (AIHA, Hgb \<100g / L, acquired pure red aplastic anemia (PRCA, Hgb \<100g / L, EVANS syndrome , Hgb \<100g / L and / or platelet count \<30 × 109 / L, or blood cell reduction secondary to immune diseases (the same as the treatment indications, or neutrophils \<0.5 × 109 / L), at least after hormone therapy Patients who are ineffective (did not reach PR after 4 weeks of hormone therapy) or who have not achieved PR after 3-5 mg / kg / d of cyclosporine. These patients would be treated with umbilical cord blood.
223730922|NCT03527095|DRUG|FDL169|CFTR corrector
224014778|NCT05540067|OTHER|Treatment-as-Usual (TAU)|TAU includes brief mental health screening, consultation with providers, and referrals to psychotherapy and/or psychiatric medication.
224014779|NCT01135303|DEVICE|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
224014780|NCT00911768|DIETARY_SUPPLEMENT|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
224014781|NCT00911768|DIETARY_SUPPLEMENT|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor"
224014782|NCT02734953|DRUG|Nitric Oxide|Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
224014783|NCT02729883|OTHER|Quality-of-Life Assessment|Ancillary studies
224014784|NCT02729883|OTHER|Questionnaire Administration|Complete interviews
224014785|NCT02729883|PROCEDURE|Supportive Care|Receive patient navigation via the Take the Fight strategists
224014786|NCT04630288|DRUG|Clopidogrel|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
224014787|NCT04630288|DRUG|Ticagrelor|Describe the safety of Ticagrelor vs Clopidogrel use, in patients with ACS in terms of major bleeding between 30 days and one year after the index ACS event. An ITT approach and IPCW method to adjust for change of initial treatment will be used for the analysis.
224014788|NCT00258557|DRUG|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
223730923|NCT00300586|DRUG|observation|observation, second line chemotherapy if progression
224014789|NCT00258557|DRUG|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
224014790|NCT00866970|BIOLOGICAL|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
224014791|NCT00866970|BIOLOGICAL|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
224014792|NCT00866970|BIOLOGICAL|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
224014793|NCT00866970|BIOLOGICAL|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
224014794|NCT06090006|OTHER|Screening package|Y-Check is a novel intervention delivering a health check-up and where indicated will provide on-the-spot care and referral for common conditions on two occasions in adolescence (in young adolescents (10-14 year-olds) - soon after the onset of puberty - and again in older adolescents (15-19 year-olds) - when many adolescents become, or are soon to become, sexually active). It will also provide health promotion information and materials to support positive behaviours and healthy lifestyles during adolescence and beyond. Adolescents will only be screened for conditions that have an accurate, low-cost, acceptable screening test and a locally accessible, effective intervention. The conditions selected for screening will be chosen to reflect the local epidemiological contexts (e.g. screening for malaria will only take place in high malaria endemic areas).
224128144|NCT06112314|DRUG|Nivolumab + Relatlimab|Concentrate for solution for infusion at a unit dose of 16 mg/mL.
224128145|NCT00484250|DRUG|metronidazole,doxycycline|
223395068|NCT05771389|DIAGNOSTIC_TEST|serum raftlin-1 protein levels|Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
223395069|NCT02886780|BEHAVIORAL|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
223395070|NCT02886780|BEHAVIORAL|Self-help|
223395071|NCT03302676|DIETARY_SUPPLEMENT|Chewing gum|
223395072|NCT01932866|OTHER|diabetic risk score|
223395073|NCT01688557|DEVICE|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
223395074|NCT01688557|DEVICE|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
223395075|NCT02272257|BEHAVIORAL|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
223395076|NCT02272257|BEHAVIORAL|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
223395077|NCT00703872|DRUG|Oral HDV-Interferon + ribavarin|Naive pateints
223395078|NCT00703872|DRUG|Injectable HDV-Interferon + ribavarin|Nonresponders
223395079|NCT01122186|BEHAVIORAL|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
223730924|NCT00300586|DRUG|gemcitabine|1250 mg/m² D1, D8 q21 days
223730925|NCT00300586|DRUG|erlotinib|150 mg daily
223730926|NCT06369194|PROCEDURE|Colorectal Surgery|Postoperative Audit
224014795|NCT06090006|DIAGNOSTIC_TEST|Psychosocial and mental health disorder screening|HEEADSSS stands for Home, Education/Employment, Eating, Activities, Drugs, Sexuality, Suicide/Depression, and Safety (Klein et al., 2014) and Patients´ Health Questionnaire - Adolescent (PHQ-A), Generalised Anxiety Disorder (GAD-9) and counselling and referral where indicated
224014796|NCT06090006|DIAGNOSTIC_TEST|Alcohol, tobacco and substance use screening|World Health Organization (WHO) ASSIST-Y tool (Humeniuk, 2016) and referral where indicated
224014797|NCT06090006|BEHAVIORAL|Diet and physical activity screening|HEEADSSS (Klein et al., 2014) and counselling and advice
224014798|NCT06090006|DIAGNOSTIC_TEST|Underweight and overweight screening|MUAC (Middle Upper Arm Circumference), BMI (Body Mass Index) followed by Counselling and advice +/- referral where indicated
224014799|NCT06090006|DIAGNOSTIC_TEST|Anemia|Hemocue. Iron and folic-acid supplementation (3 months supply) if anaemic. If severely anaemic (\<8g/dl) refer to health facility.
224014800|NCT06090006|BEHAVIORAL|Oral health screening|Questions on oral health and visual inspection followed by advice, gift of toothpaste and toothbrush, fluoride varnish application +/- Silver Diamine Fluoride application +/- referral
224014801|NCT06090006|BEHAVIORAL|Circumcision screening|Question on circumcision status. Visual inspection. Referral for Voluntary Medical Male Circumcision) where uncircumcised (males only)
224014802|NCT06090006|BEHAVIORAL|Risky behaviours|Question (s) on sexual activity and other risky behaviours, followed by Risk reduction counselling, Provision of condoms, Provision of modern contraceptives (emergency contraception, depot injections, oral contraceptive pill) (females only) PreExposure Prophylaxis (PrEP) (females only)
224014803|NCT06090006|DIAGNOSTIC_TEST|HIV testing|HIV oral mucosal self-test +/- confirmatory blood-based rapid diagnostic test followed by Counselling + referral to treatment where indicated
224014804|NCT06090006|DIAGNOSTIC_TEST|STI (CT, NG, TV) testing|Chlamydia Trachomatic (CT) /Neisseria Gonorrhea (NG) test on urine sample, Trichomoniasis Vaginalis (TV) test and treatment where indicated
224014805|NCT06090006|BEHAVIORAL|Immunization screening|Question on Human Papilloma Virus (HPV) immunisation history. Review of vaccination card. Followed by referral to immunization
224014806|NCT06090006|DIAGNOSTIC_TEST|Visual impairment screening|Peek Acuity or Snellen Tumbling-E and Refer to specialist if indicated
224014807|NCT06090006|DIAGNOSTIC_TEST|Hearing screening|"HearScreen smartphone app +/- HearTest plus Inspection for presence of wax and wax removal.~Refer to specialist if indicated"
224014808|NCT06090006|DIAGNOSTIC_TEST|Physical impairment screening|Questions on physical impairment. Jump or squat test Functional reach test Referral to specialist if indicated
223549105|NCT02720523|DRUG|Placebo|Tablet; Oral
223549106|NCT02720523|DRUG|Upadacitinib|Tablet; Oral
223549107|NCT04118543|OTHER|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
224014809|NCT06090006|DIAGNOSTIC_TEST|Uncontrolled epilepsy screening|Questions on experience of convulsions followed by referral to specialist if indicated
224014810|NCT06090006|DIAGNOSTIC_TEST|Pre-hypertension screening|Blood pressure measured using digital sphygmomanometer followed by counselling and advice if indicated
224014811|NCT03857997|BIOLOGICAL|Patient blood sampling|sequencing by WGS and RNA-seq
224014812|NCT03857997|BIOLOGICAL|Parents blood sampling|sequencing by WGS
224014813|NCT00467350|DRUG|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
224014814|NCT00467350|DRUG|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
224014815|NCT01666964|OTHER|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
224014816|NCT03192657|DRUG|Basiliximab|The first administration should be within 8 weeks after disease onset.
224014817|NCT03192657|DRUG|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
224014818|NCT03192657|DRUG|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
224014819|NCT00534898|DRUG|Bexarotene|
223395080|NCT01122186|BEHAVIORAL|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
223395081|NCT02713412|OTHER|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
223395082|NCT02713412|OTHER|Water|300ml water
223395083|NCT03933566|PROCEDURE|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
223395084|NCT03933566|PROCEDURE|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
223395085|NCT06035978|DRUG|Nebivolol|Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
223395086|NCT06035978|DRUG|Valsartan and Sacubitril|Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
223395087|NCT06035978|DRUG|Carvedilol|Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
223395088|NCT06035978|DRUG|Bisoprolol|Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
223549108|NCT04118543|OTHER|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
223549109|NCT02340169|DRUG|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
223395089|NCT06035978|DRUG|Metoprolol|Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
223395090|NCT06035978|DRUG|Spironolactone|Verospiron (Spironolactone) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
223395091|NCT03237338|PROCEDURE|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
223395092|NCT03237338|PROCEDURE|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
223549110|NCT02947633|DRUG|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
223730927|NCT00840554|OTHER|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
224014820|NCT00534898|DRUG|Fenretinide|
224014821|NCT00534898|DRUG|Placebo|
224014822|NCT00329810|DRUG|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
224014823|NCT00453193|DRUG|Pentostatin|4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks
224014824|NCT00453193|DRUG|Alemtuzumab|30 mg IV three times weekly
223395093|NCT03088761|DEVICE|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
223395094|NCT00699998|DRUG|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
223395095|NCT00699998|DRUG|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
223395096|NCT00699998|DRUG|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
223395097|NCT01406574|DRUG|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
223395098|NCT01406574|DRUG|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
223395099|NCT03093701|DRUG|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
224014825|NCT01357291|BEHAVIORAL|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
224014826|NCT01357291|BEHAVIORAL|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
224014827|NCT04136743|DEVICE|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
224014828|NCT04136743|DRUG|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
224014829|NCT01422642|DEVICE|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
224014830|NCT01422642|DEVICE|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
224014831|NCT01312636|DRUG|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
223395100|NCT06833437|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|Patients in the 68Ga-Pentixafor PET/CT group will first undergo 68Ga-Pentixafor PET/CT, followed by adrenal venous sampling (AVS). The subsequent treatment will be guided based on the diagnostic results.
223395101|NCT06833437|DIAGNOSTIC_TEST|AVS|Patients in the adrenal venous sampling (AVS) group will first undergo adrenal venous sampling (AVS), followed by 68Ga-Pentixafor PET/CT. The subsequent treatment will be guided based on the diagnostic results.
223395102|NCT00367302|DRUG|buprenorphine|maintenance
223395103|NCT00367302|DRUG|methadone|maintenance
223395104|NCT01833650|DIETARY_SUPPLEMENT|thymus honey mouthwash|
223395105|NCT03548727|DIAGNOSTIC_TEST|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
223395106|NCT00473590|DRUG|Bevacizumab|15 mg/kg administered by intravenous infusion
223395107|NCT00473590|DRUG|Bortezomib|1.3 mg/m\^2 administered by intravenous bolus injection
223395108|NCT00473590|DRUG|placebo|Intravenous repeating dose
223395109|NCT03781687|PROCEDURE|Bilateral ESP Block|Bilateral ESP Block will be performed at T8
223395110|NCT03781687|PROCEDURE|Unilateral ESP Block|Unilateral ESP Block will be performed at T8 (right side)
223395111|NCT03781687|DEVICE|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
223395112|NCT06499675|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy / bariatric surgery
223395113|NCT06499675|PROCEDURE|Liver Biopsy|intraoperative liver biopsy
223395114|NCT00395161|DRUG|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
223395115|NCT00395161|DRUG|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants \< or equal to one year of age, and 20 mg/day elemental zinc for patients \> 1 year of age)
223395116|NCT00395161|DIETARY_SUPPLEMENT|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
223395117|NCT00395161|DRUG|Selenium|one enteral dose daily of selenium (40 μg for infants \< 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children \> 13 years)
223395118|NCT00395161|OTHER|saline|equivalent volume of intravenous saline
223395119|NCT00395161|OTHER|sterile water|equivalent volume of sterile water
223395120|NCT00395161|OTHER|selenium|equivalent volume of sterile water
223395121|NCT00395161|DIETARY_SUPPLEMENT|whey-protein|one enteral dose daily of whey-protein
223395122|NCT04791137|BEHAVIORAL|Imagery cognitive bias modification|The imagery cognitive bias modification intervention is derived from that developed via experimental psychopathology research (e.g. Holmes et al., 2009) and adapted for clinical applications in the context of depression (e.g. Blackwell \& Holmes, 2010; Blackwell et al., 2015). The intervention is a series of training sessions in which participants listen to training scenarios consisting of descriptions of everyday situations, structured so that they start ambiguously but always end positively. Participants are instructed to imagine themselves in the situations described as the scenarios unfold. It is hypothesised that via repeatedly practising imagining positive resolutions for ambiguous situations in the training sessions, a bias is trained to automatically imagine positive resolutions for ambiguous situations encountered in daily life.
223395123|NCT02920671|OTHER|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
223395124|NCT02920671|OTHER|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
223395125|NCT02920671|OTHER|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
223395126|NCT02920671|OTHER|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
223395127|NCT05107947|OTHER|Biocentric light|Light that changes in intensity and spectral distribution during the day to mimick daylight. High in intensity and high circadian stimulus during daytime and low intensity and low circadian stimulus during late afternoon and night.
223395128|NCT03062709|BEHAVIORAL|Breathe Easy Coalition written materials|written materials about secondhand and thirdhand environmental smoke exposure in children
223395129|NCT03062709|BEHAVIORAL|Maine Tobacco Helpline|referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
224014832|NCT01887886|DRUG|erlotinib|150 mg orally daily
223395130|NCT03062709|DIAGNOSTIC_TEST|Urine cotinine testing|the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
223395131|NCT01756183|DRUG|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
223395132|NCT02647697|DRUG|Radiprodil oral|"* Active Substance: Radiprodil~* Pharmaceutical Form: dry granules for oral suspension~* Concentration: 30 mg~* Route of Administration: oral use"
223395133|NCT00795327|DEVICE|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
223395134|NCT04505527|BEHAVIORAL|Lateral stepping|Subjects will step laterally, changing direction every 10 m, thus alternating lead and lag limbs.
223395135|NCT04505527|BEHAVIORAL|Forward walking|Subjects will have a typical forward walking
223395136|NCT00297076|DRUG|GW873140|
223395137|NCT00199394|DRUG|Istradefylline (KW-6002)|
223395138|NCT01656980|DRUG|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
223395139|NCT01656980|PROCEDURE|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
223395140|NCT02486874|DEVICE|PoreSkin|a human acellular dermal matrix
223395141|NCT01107691|OTHER|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
224014833|NCT01887886|DRUG|onartuzumab|15 mg/kg IV every 3 weeks
224014834|NCT01887886|DRUG|placebo|IV every 3 weeks
224014835|NCT00478387|BIOLOGICAL|The current season's trivalent killed influenza vaccine|
224128146|NCT04867655|OTHER|Orange Juice|Approximately 500 ml of orange juice will be consumed and then blood and urine samples will be collected for 24 hours
223549111|NCT02947633|DRUG|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
223549112|NCT04980625|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.
223549113|NCT04980625|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.
223549114|NCT01229007|BIOLOGICAL|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
223549115|NCT01018017|DRUG|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
223549116|NCT01018017|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
223549117|NCT03179852|BEHAVIORAL|nutrition education|nutrition education
223549118|NCT00164658|BEHAVIORAL|Familial risk assessment and personalized prevention messages|
223549119|NCT01479751|DRUG|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
223549120|NCT01479751|DRUG|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
223549121|NCT01479751|DRUG|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
223549122|NCT06138353|DRUG|Shuxuening injection or placebo|Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
223549123|NCT06110949|DEVICE|Triaxial accelerometry|A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).
223549124|NCT03674970|DRUG|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
223549125|NCT02403063|DRUG|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
223549126|NCT02403063|DRUG|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
223549127|NCT02403063|DRUG|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
223549128|NCT02277574|BIOLOGICAL|AMP-110|2, 5, or 10 mg/kg
223730928|NCT00840554|OTHER|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
224014836|NCT00557180|DRUG|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
223549129|NCT02277574|OTHER|Placebo|Placebo
223549130|NCT01469936|DIETARY_SUPPLEMENT|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
223549131|NCT01469936|DIETARY_SUPPLEMENT|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day"
223549132|NCT01158820|DRUG|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
223549133|NCT01158820|DRUG|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
223549134|NCT01158820|DRUG|Midazolam load|2 mg bolus prior to bronchoscopy
223549135|NCT01158820|DRUG|Fentanyl load|50 µg bolus prior to bronchoscopy
223549136|NCT01158820|DRUG|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
223549137|NCT01158820|DRUG|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
223549138|NCT01158820|DRUG|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
223549139|NCT01158820|DRUG|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
223549140|NCT01158820|DRUG|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
224014837|NCT00557180|DRUG|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
224014838|NCT00557180|DRUG|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
224014839|NCT04184843|OTHER|iWalk Toolkit|"Intervention period: 5 months~Intervention:~1. A toolkit consisting of 3 components: an educational guide, a smartphone app, and an educational video.~2. Access to a clinical expert by email or phone"
224014840|NCT02158351|PROCEDURE|liver and white adipose tissue biopsies|
223395142|NCT04718831|DIETARY_SUPPLEMENT|Spirulina|Spirulina, as demonstrated in previous researches in vitro and in animals, can regulate immunity, enhance anti-virus activity, lower inflammation response and slower tumor progression. Liver function and liver fibrosis is improved by Spirulina as well. In our recent clinical trial, hepatitis B patients that received anti-virus medicine orally and was supplemented with Spirulina FEM-102 showed lower qHBsAg, reflecting the clearance of cccDNA. It might be related to immune modulation against HBV, which is induced by Spirulina.
223395143|NCT00896974|OTHER|Laboratory Biomarker Analysis|Correlative studies
223395144|NCT00896974|OTHER|Pharmacological Study|Correlative studies
223395145|NCT00896974|DRUG|Retinoid 9cUAB30|Given orally
223395146|NCT01835041|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
223395147|NCT01835041|DRUG|oxaliplatin|Given IV
223549141|NCT06438198|OTHER|Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg|A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio \> 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
223549142|NCT04650295|OTHER|Household Remedy|If the participant experiences a muscle cramp one tablespoon (one sip) of the household product will be taken. The treatment phase of the study will be for 28 days.
223549143|NCT04650295|OTHER|Tap water|If the participant experiences a muscle cramp one tablespoon (one sip) of tap water will be taken. The treatment phase of the study will be for 28 days.
223549144|NCT04335071|DRUG|Tocilizumab (TCZ)|Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) Actemra® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
224014841|NCT02842151|PROCEDURE|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
223395148|NCT01835041|DRUG|leucovorin calcium|Given IV
223549145|NCT04335071|DRUG|Placebo|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
224014842|NCT02842151|DEVICE|ACRYSOF® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
224014843|NCT02842151|DEVICE|Topcon® KR-1W Wave-Front Analyzer|Wavefront and topography system used to obtain autorefraction data
223549146|NCT03343561|BEHAVIORAL|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
223549147|NCT04545879|DIETARY_SUPPLEMENT|Raw garlic juice containing allicin|Fresh garlic juice containing around 48mg allicin for 7 days
224014844|NCT00591851|DRUG|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|AC \[Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)\] Followed By Paclitaxel (P)
223549148|NCT00858351|BEHAVIORAL|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
223549149|NCT00858351|BEHAVIORAL|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
224014845|NCT05863728|PROCEDURE|Piezosurgery assisted group|apicectomy will be done using the Piezosurgery device
224014846|NCT05863728|PROCEDURE|Trephine Bur assisted group|apicectomy will be done using the trephine burs
224014847|NCT04571450|BEHAVIORAL|Reintervention|This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
224014848|NCT05218070|DRUG|EgyVax Vaccine Candidate|EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant
224014849|NCT05218070|DRUG|Placebo|0.5ml Saline (0.9%)
224014850|NCT02739555|DEVICE|Thermal destruction with radiofrequency or laser|
224014851|NCT02739555|DRUG|Acide Zoledronique|
224014852|NCT05381415|OTHER|Inhalation of bronchodilation therapy at FRC|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from FRC (functional residual capacity, in a random order, with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
224128147|NCT04867655|OTHER|Orange juice with either 6g or 3 g of β-Glucan|Approximately 500 ml of orange juice mixed with either 6g or 3 g of β-Glucan will be consumed and then blood and urine samples will be collected for 24 hours
224128148|NCT07036952|DRUG|Omega 3 fatty acids|1gm tab twice daily.
224128149|NCT07036952|DRUG|Omega -3 fatty acids|1gm tablet twice daily.
224128150|NCT06880939|DIETARY_SUPPLEMENT|Krill Oil Functional Food|Take 2g of krill oil orally daily, with each krill oil capsule containing 1g, by consuming one capsule within 30 minutes after breakfast and one capsule within 30 minutes after dinner. The supplementation period begins on the day of the first bladder instillation treatment and continues until the day of the last bladder instillation treatment.
223395149|NCT01835041|DRUG|irinotecan hydrochloride|Given IV
223395150|NCT01835041|DRUG|fluorouracil|Given IV
223395151|NCT01835041|OTHER|laboratory biomarker analysis|Correlative studies
224014853|NCT05381415|OTHER|Inhalation of bronchodilation therapy at RV|"the patient will be asked to inhale the bronchodilator (salbutamol pMDI, 400 µg) with a spacer from VR , with the assistance of an operator. The spacer will be connected to a Fleish flowmeter placed in series with the pMDI device.~The valve included in the spacer will guarantee that only the air inhaled by the patient will pass through the flowmeter, reducing the risk of contamination. In both cases a low inspiratory flux and a period of apnea after inhalation of 10 seconds will be used. Before and after the administration it will be asked to the patient to execute a spirometry, a plethysmography, a lung diffusion test, and the NEP technique. These will allow the characterization of the bronchodilator effect in terms of static and dynamic volumes, heterogeneity of ventilation distribution and volume of closure, expiration flux-limitation."
224014854|NCT05734898|BIOLOGICAL|NKG2D CAR-NK|Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
224014855|NCT04433546|DRUG|Pemziviptadil (PB1046)|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
223395152|NCT03367819|DRUG|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223395153|NCT03367819|DRUG|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
223395154|NCT05256186|OTHER|Basketball Pre-injury Attack program|The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
223395155|NCT04805112|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits to distribute to their sexual partners for partner testing or couple testing. Phone interviews will be conducted with the participants to assess whether they provided a HIV self-test to their partner, if the test was used, how it was used (partner testing or couple testing), if the partner disclosed his results, the partner's reaction to the results, and if the partner went for confirmatory testing
223395156|NCT00835302|PROCEDURE|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
223395157|NCT02833987|DRUG|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
223395158|NCT02833987|DRUG|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
223395159|NCT02833987|DRUG|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
223395160|NCT02833987|DRUG|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
223395161|NCT00102752|DRUG|Glufosfamide|
223395162|NCT00102752|DRUG|Gemcitabine|
223395163|NCT00584454|BIOLOGICAL|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
223395164|NCT02176954|DEVICE|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
223395165|NCT02176954|DEVICE|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
223395166|NCT02176954|DEVICE|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
223395167|NCT01926431|OTHER|Exercise|
223395168|NCT01926431|OTHER|Rest|
223395169|NCT01390025|BIOLOGICAL|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
223395170|NCT01390025|BIOLOGICAL|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
223395171|NCT03457181|OTHER|music|effect of music on anxiety scores
223395172|NCT03457181|OTHER|operating room noise|effect of operating room noise on anxiety scores
223549150|NCT05920174|DEVICE|NEO|Subjects will be implanted with the NEO device.
223549151|NCT06207552|GENETIC|BBM-F101 injection|The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.
223549152|NCT01706731|BEHAVIORAL|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
223549153|NCT01706731|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
223549154|NCT05812963|DIAGNOSTIC_TEST|IVUS-guided PCI group|In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
223549155|NCT05812963|DIAGNOSTIC_TEST|FFR-guided PCI group|In FFR-guided PCI group, FFR measurement for non-IRA stenosis (\>50% visual estimation) will be performed by continuous infusion of adenosine (140\~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR ≤0.80 will be targeted for PCI. In case of non-IRA stenosis \>90%, we will judge FFR value of ≤0.80.
223549156|NCT00286650|PROCEDURE|3rd molar teeth extraction|
224014856|NCT04433546|DRUG|Low Dose (10 mg) Control|Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
224014857|NCT01398995|OTHER|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
224014858|NCT02758067|DRUG|brexpiprazole|2- 4 mg/day, tablets, oral, 28-weeks
223395173|NCT05260294|PROCEDURE|Epidural space identification with cervical epidural steroid injection employing CST and LORT.|Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
223395174|NCT04400162|BEHAVIORAL|Usability of the CCT|Evaluation of the usability of the provided training.
223395175|NCT04400162|BEHAVIORAL|Changes in regards to the depressive disorder|Evaluation of depressive symptoms and whether they change in regards to the provided training.
223395176|NCT00051948|DRUG|TLK286|
223395177|NCT05870384|BEHAVIORAL|Group Interpersonal Psychotherapy|Ten sessions of IPT-G, which focuses on the common problem area of patient relatives, will be applied.
223395178|NCT04504994|BEHAVIORAL|inclusion condition|cyberball game: ex- versus over-inclusion condition
223395179|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
223395180|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
223395181|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
223395182|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
223395183|NCT00982657|DRUG|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
223395184|NCT00982657|DRUG|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
223395185|NCT00676702|DIETARY_SUPPLEMENT|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
223395186|NCT00676702|DRUG|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
223395187|NCT05589077|BEHAVIORAL|Education on Female Athlete Nutritional Concerns|Visual and audio information presented within the Qualtrics system will cover topics on the Female Athlete Triad, Relative Energy Deficiency in Sport, and eating disorders.
223549157|NCT03586960|DEVICE|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
223549158|NCT05881707|DRUG|CKD-828, D064, D702|QD, PO
224014859|NCT02758067|DRUG|risperidone|4-6 mg/day, tablets, oral, 28-weeks
224014860|NCT03598010|DEVICE|Actitan-F (7dd)|1 sack every 4 hours, maximum 4 sacks/day for 7 days.
224014861|NCT03598010|DEVICE|Actitan-F (28dd)|1 sack every 4 hours, maximum 4 sacks/day for 28 days.
224014862|NCT05573880|DEVICE|Galileo Med35|whole-body vibration training on the platform
224014863|NCT03654521|DIAGNOSTIC_TEST|Fetal interventricular septum thickness|Two-dimensional ultrasound fetal cardiac imaging test
224014864|NCT00387946|DRUG|SSR591813L (dianicline)|
224014865|NCT01974401|DEVICE|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
224014866|NCT04834544|COMBINATION_PRODUCT|DCVAC/OvCa|An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines
224014867|NCT04834544|COMBINATION_PRODUCT|Placebo|Placebo
224014868|NCT04107298|DEVICE|SUNDANCE™ Drug Coated Balloon|Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
224014869|NCT00259402|DRUG|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
224014870|NCT04247334|DEVICE|Transcranial direct current stimulation|20 minutes of 2 milliamp transcranial direct current stimulation
224014871|NCT03318224|OTHER|none (observational study)|only assessments via questionnaires, no interventions
224014872|NCT00577967|DRUG|Gabapentin|
224014873|NCT03802461|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Feces from healthy donor
224014874|NCT02355990|PROCEDURE|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
224014875|NCT04360343|DRUG|Film-coated tablet|uncoated tablet
224014876|NCT02559895|DRUG|ALD403|
224014877|NCT02559895|DRUG|Placebo|
224014878|NCT04693195|DRUG|BLU-5937|Oral administration of BLU-5937 tablets
224014879|NCT04693195|DRUG|Placebo|Oral administration of matching placebo for BLU-5937 tablets
224014880|NCT02158988|PROCEDURE|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
223395188|NCT00725920|DRUG|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
223395189|NCT00725920|DRUG|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
223395190|NCT02000791|OTHER|Comparison of fibreoptic view|
223549159|NCT01740687|DEVICE|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
223549160|NCT01740687|PROCEDURE|NovaSure|Nova Sure Endometrial Ablation
224014881|NCT06268067|DEVICE|PET/CT|F-18 FDG PET/CT studies
224014882|NCT05808777|OTHER|Phone interview|A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
224014883|NCT00588653|DEVICE|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
224014884|NCT03666572|OTHER|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
223549161|NCT03321071|BEHAVIORAL|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
223730929|NCT04719507|PROCEDURE|erector spinae block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 3 cm laterally to obtain the appropriate visualization. Under aseptic precautions, the needle is inserted and advanced perpendicular to the skin in all planes to contact the transverse process of the vertebra at a variable depth of 2-4 cm from the skin depending on the build of the individual. At this point, the needle tip lies between the erector spinae muscle and transverse process. After negative aspiration, 20 ml of 0.25% bupivacaine is administered in cephalad and caudal directions.
223395191|NCT04558073|BEHAVIORAL|Body Project (BP)|"The BP intervention offers discussions and exercises to make participants realize the cost of pursuing social ideals valuing thinness. This produces cognitive dissonance, a cognitive discomfort due to a contradiction between speech and beliefs, which motivates to modify one's beliefs. The curriculum includes discussions on techniques of the advertising industry and the unique ideal of beauty promoted worldwide, as well as on the costs of pursuing the thin-ideal. Participants are also challenged to try behaviours they avoid because their appearance bother them. Societal activism actions are also discussed."
223395192|NCT04558073|BEHAVIORAL|Healthy Weight Program (HW)|The HW intervention allows participants to make personalized changes in their diet and physical activity each week gradually, to aim for a health-ideal rather than a thin-ideal. The intervention is based on small changes, based on behavioural change techniques. Advice is given on what types of changes introduce to promote health, and how to implement changes sustainably. Difficulties are discussed in the group with a problem-solving approach. The last session introduces a long-term view of lifestyle change.
223395193|NCT01959633|DRUG|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
223395194|NCT01959633|DRUG|Peg-interferon|"In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only~In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD."
223395195|NCT01959633|DRUG|Cobimetinib|Cobimetinib 60 mg o.d. (21 days on followed by 7 days off)
223395196|NCT03511027|DEVICE|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
223395197|NCT03511027|OTHER|SME only|At discharge, participants will be provided with self-medication education.
223395198|NCT04825392|DRUG|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
223395199|NCT06468592|PROCEDURE|Tilted insertion of implants|Using osteotomes, implants are inserted and tilted from 30° to 45° into the palatal direction from the maxillary sinus.
223549162|NCT03321071|BEHAVIORAL|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
223730930|NCT04719507|PROCEDURE|thoracic paravertebral block|ultrasound probe is placed parallel to the vertebral spine at T4 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle is inserted cranial to caudal direction using in-plane approach . After confirming the displacement of pleura with 0.5-1 ml of local anesthetic (LA), 20 ml of 0.25% bupivacaine is administered for the block.
223730931|NCT04719507|DRUG|Pethidine Only Product in Parenteral Dose Form|pethidine (1 mg/kg ) once
223730932|NCT01866501|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
224014885|NCT03666572|OTHER|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]
224014886|NCT03666572|OTHER|Placebo (Lactose)|Placebo (Lactose)
224014887|NCT01852253|PROCEDURE|2% chlorhexidine|
224014888|NCT01852253|PROCEDURE|0.12% chlorhexidine|
224014889|NCT04824690|DEVICE|Virtual reality|Immersive virtual reality tour of the operating theatre before surgery and distraction methods both using VR headset
224014890|NCT05484362|OTHER|D-Glucose beverage as reference food|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
223395200|NCT06468592|PROCEDURE|Straight insertion of implants|The implants are inserted in an axial direction into the maxillary sinus according to Summers' traditional technique.
223395201|NCT03234543|PROCEDURE|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
223395202|NCT03234543|PROCEDURE|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
223395203|NCT03207984|PROCEDURE|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
223395204|NCT05373108|DRUG|Macitentan|Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
223395205|NCT05579028|DIETARY_SUPPLEMENT|Nutridrink ONS 200 ml|Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
223395206|NCT03854760|BEHAVIORAL|anesthesiologist with limited experiment|Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
223549163|NCT05452252|DIAGNOSTIC_TEST|functional mandibular evaluation|Active mandibular movements including depression, protrusion, and left-right deviation, facial anthropometry was measured on facial shape on photograph, and phenotype and asymmetry
223549164|NCT04217018|DIAGNOSTIC_TEST|Prediction of molecular pathology|Prediction of 1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations or molecular subgroups by leveraging AI
223549165|NCT02588157|DEVICE|Macintosh|Direct laryngoscopy
223549166|NCT02588157|DEVICE|Glidescope|Glidescope videolaryngoscope
223549167|NCT02588157|DEVICE|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
223549168|NCT05125744|DIAGNOSTIC_TEST|Assisted Ventilation|patients will be invasively ventilated in assisted mode. In all enrolled patients ventilated in assisted mode. Diaphragmatic activity will be evaluated through ultrasound (primary end point) and electrical activity of the diaphragm (optional) at stepwise decreasing of PEEP level. Also, the activity of remaining respiratory muscles will be assessed through sonography at the same levels of PEEP (secondary end point).
223549169|NCT01226303|DRUG|ATRA|see the protocol
223549170|NCT01226303|DRUG|ATRA + IDA|see the protocol
223730933|NCT01866501|DEVICE|EZ-IO|
223730934|NCT00157950|BIOLOGICAL|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
223730935|NCT00157950|BIOLOGICAL|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
223730936|NCT00842686|DRUG|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
224014891|NCT05484362|OTHER|15mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
223395207|NCT01185327|BEHAVIORAL|Breastfeeding|Breastfeeding
223395208|NCT03058627|PROCEDURE|PCI|FFR guided PCI
223395209|NCT05138861|DRUG|TP-03 (Lotilaner Ophthalmic Solution), 0.25%|A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
223395210|NCT01522209|PROCEDURE|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
223549171|NCT02171689|DRUG|[14C]- BIBW 2992 MA2|
223549172|NCT00827814|DRUG|Dutasteride|Dutasteride 0.5 mg od.
223549173|NCT02529683|DRUG|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
223549174|NCT03914989|OTHER|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
223549175|NCT02006186|BEHAVIORAL|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
223549176|NCT00196209|PROCEDURE|catheter ablation|catheter ablation to treat persistent atrial fibrillation
223549177|NCT00196209|PROCEDURE|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
223549178|NCT03420144|DRUG|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
223549179|NCT03420144|DRUG|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
223549180|NCT01103856|BEHAVIORAL|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
223730937|NCT03408756|DRUG|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
223730938|NCT00939328|BIOLOGICAL|rituximab|
223730939|NCT00939328|DRUG|bendamustine hydrochloride|
223730940|NCT04486781|DRUG|Pembrolizumab + sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
223730941|NCT05390957|BEHAVIORAL|Acceptance Based Behavioural Therapy - Revised|The study intervention is a revised, updated version of a previously studied eight-module (8-week) online, acceptance-based behavioural therapy (ABBT) for chronic pain that was tailored specifically to a military, RCMP, and veteran population. The online treatment material is administered via the WebCAPSI Therapy program.
223730942|NCT00735592|OTHER|Observational|Retrospective data obtained from electronic files
223730943|NCT04867850|OTHER|Usual Care|Individual clinicians will receive an automated weekly email detailing a weekly roster of their upcoming repeat-patient visits (Index Visit) with patients at high risk of 6-month mortality as determined by a validated machine learning prognostic algorithm. Clinicians will receive a HIPAA compliant text message on the morning of the appointment reminding them to consider a serious illness conversation with patients on the list.
223395211|NCT01522209|DEVICE|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
223549181|NCT01103856|BEHAVIORAL|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
223549182|NCT03744338|OTHER|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
223549183|NCT02615119|DRUG|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
223549184|NCT02615119|DRUG|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
223549185|NCT04514731|DRUG|Magnesium sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of isotonic saline over 15 minutes after spinal anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/hour) until the end of surgery.
223730944|NCT04867850|OTHER|Clinician Nudge|Clinicians will receive the usual care weekly email and text message described above under Usual Care. In addition, embedded in the weekly email, clinicians will receive performance feedback information detailing their documented SICs relative to those documented by peers.
223395212|NCT01522209|RADIATION|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
223395213|NCT01522209|RADIATION|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
223395214|NCT06132061|OTHER|universal prevention|Health education related to depression to strengthen the participants' self-care skills to reduce sub-health risk factors.
223395215|NCT06132061|OTHER|selective prevention|Psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) aimed at risk factors to prevent more severe depressive symptoms.
223395216|NCT06132061|OTHER|targeted prevention|Therapeutic psychosocial interventions (including but not limited to cognitive behavioral therapy, acceptance commitment therapy, mindfulness training) to reduce patients' depressive symptoms.
223549186|NCT04514731|DRUG|Isotonic Saline|Isotonic saline group receives the same volume of isotonic saline, administered according to the same methods as in the magnesium group.
223549187|NCT04871828|DRUG|Leukotriene Receptor Antagonist|Zafirlukast
223549188|NCT04871828|OTHER|Placebo|Placebo
223549189|NCT02062515|DRUG|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
223730945|NCT04867850|OTHER|Patient Nudge|Ahead of the Index Visit, high risk patients as identified by the prognostic algorithm will receive a nudge via personal text message and email consisting of a normalizing message prompting patients with a personalized link to a short electronic questionnaire on SIC topics.
223730946|NCT00714454|OTHER|APS Topical Lotion|
223730947|NCT00714454|OTHER|Placebo|
223395217|NCT06132061|OTHER|Waiting treatment.|Waiting treatment.
223549190|NCT01484145|DRUG|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
224014892|NCT05484362|OTHER|30mg of Crocus Sativus as beverage|Eleven healthy subjects (male: 6, female: 5) after 10-14h fast, consumed 50 g D-glucose, three times, in different weeks along with 250 mL water; and 50 g D-glucose containing 15 mg and 30 mg of Crocus Sativus tested once, in different weeks along with 250 mL water. Fingertip capillary blood glucose samples were taken at 0, 15, 30, 45, 60, 90 and 120 min postmeal. The first glucose sample was taken exactly 15 min after the beginning of the consumption of the tested beverage.
224014893|NCT05366036|OTHER|No Intervention|This is a non-interventional study.
223549191|NCT02060786|DRUG|generic clopidogrel (Plavitor® )|
223549192|NCT02060786|DRUG|original clopidogrel (Plavix® )|
224014894|NCT01216800|PROCEDURE|adjuvant therapy|
224014895|NCT01216800|PROCEDURE|assessment of therapy complications|
224014896|NCT01216800|PROCEDURE|quality-of-life assessment|
223395218|NCT07056920|PROCEDURE|Zirconia shell technique|Customized Zirconia membrane will be printed as a porous shell and will be used as a non resorbable membrane for horizontal ridge augmentation of deficient posterior mandibular region.
223395219|NCT06839170|OTHER|FM-IRDs assisted|A Foundation Model for Assisting the precision Diagnosis of Inherited Retinal Diseases: FM-IRDs
223395220|NCT06839170|OTHER|without FM-IRDs|without FM-IRDs
223549193|NCT02462031|DRUG|KD101|200mg, 400mg, 800mg, 1400mg
223549194|NCT02462031|DRUG|placebo|200mg, 400mg, 800mg
223549195|NCT04368377|DRUG|Tirofiban Injection|Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
224014897|NCT01216800|RADIATION|3-dimensional conformal radiation therapy|
224014898|NCT01216800|RADIATION|intensity-modulated radiation therapy|
224014899|NCT01929629|DRUG|Part A|Single ascending doses
224014900|NCT01929629|DRUG|Part B|Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
224014901|NCT02700347|DRUG|Pyrazinamide|
223549196|NCT04368377|DRUG|Clopidogrel|Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
223549197|NCT04368377|DRUG|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
224014902|NCT02700347|DRUG|Allopurinol|
223395221|NCT01458665|PROCEDURE|Conventional arthroscopic rotator cuff repair|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
223395222|NCT01458665|PROCEDURE|Arthroscopic rotator cuff repair with PRP|"* Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound."
223395223|NCT00695344|DRUG|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
223549198|NCT04368377|DRUG|Fondaparinux|Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
223549199|NCT05445258|DEVICE|InnoCath AB® hyper-compliant balloon catheter|endovascular treatment of lesions in the superficial femoral artery (SFA) and/or popliteal artery pars I/II without further luminal widening, and/or for short-term interruption of blood flow with the InnoCath AB® hyper-compliant balloon cathe-ters (100 or 200 mm length)
223549200|NCT00711152|OTHER|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
223549201|NCT00711152|OTHER|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
223549202|NCT01970644|RADIATION|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
223549203|NCT06400628|BEHAVIORAL|Self-management education|The base line data will be taken and used as control, while the final result will be utilized as the case
223730948|NCT00386776|OTHER|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
223730949|NCT02552563|BEHAVIORAL|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
223730950|NCT01500629|DEVICE|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
223730951|NCT01500629|DEVICE|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
223395224|NCT00695344|DRUG|azathioprine or mycophenolate mofetil|2 times per day during 2 years
223395225|NCT03754010|PROCEDURE|Scaling and root planning|Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
223395226|NCT03754010|DRUG|Hyaluronic acid gel (HA) and SRP|In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.
223395227|NCT03754010|DRUG|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.
223395228|NCT03754010|DRUG|HA mouthrinse+gel and SRP|In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
223395229|NCT01257269|OTHER|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
223549204|NCT04770688|DRUG|Osimertinib|Osimertinib, 80mg, QD, p.o.
223549205|NCT04770688|DRUG|Anlotinib|"(Phase Ib) Anlotinib, from 8mg to10mg to 12mg, QD, p.o. from day 1 to 14 of a 21-day cycle.~(Phase IIa)Anlotinib, given at RP2D dose QD, p.o. from day 1 to 14 of a 21-day cycle."
223549206|NCT00326001|DEVICE|Gold tip catheter|Radiofrquency ablation using gold tip catheter
223549207|NCT00326001|DEVICE|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
223549208|NCT03626064|BEHAVIORAL|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
223549209|NCT03626064|DRUG|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
223549210|NCT00965289|DRUG|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
223549211|NCT03015155|PROCEDURE|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
223549212|NCT01840813|DRUG|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
223549213|NCT01840813|DRUG|Normal saline|It is a placebo group
223549214|NCT00550186|OTHER|placebo|
223549215|NCT00550186|DRUG|Ringers Lactate|
223549216|NCT00550186|DRUG|HaemoHES 6%|
223395230|NCT03717155|DRUG|Avelumab|Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
223395231|NCT03717155|DRUG|Cetuximab|Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
223395232|NCT03717155|DRUG|Gemcitabine|Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
223395233|NCT03717155|DRUG|Cisplatin|Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
223549217|NCT02489149|OTHER|Multi-sector interventions|"* Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~* For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~* For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~* Helping families to have more knowledge about your citizen rights."
223395234|NCT03717155|DRUG|Carboplatin|In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
223549218|NCT02489149|OTHER|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
224014903|NCT03049553|DEVICE|Cobas HPV-DNA test|"Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other"
223395235|NCT01710787|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
223395236|NCT01710787|DRUG|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
223395237|NCT01710787|DRUG|Placebo|3 unilateral intranasal sprays per dose
223395238|NCT01298232|OTHER|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
223395239|NCT03081832|DRUG|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
223395240|NCT03081832|OTHER|Control|Not treated.
223395241|NCT06328621|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223395242|NCT06328621|PROCEDURE|Computed Tomography|Undergo low-dose CT
223395243|NCT06328621|OTHER|Electronic Health Record Review|Review of medical records
223395244|NCT06328621|OTHER|Survey Administration|Complete survey
223395245|NCT02519374|DRUG|Placebo (including Maltodextrin)|
223395246|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 1
223395247|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 2
223395248|NCT02519374|DRUG|PROMITOR® (including Maltodextrin)|Investigational product dose 3
223395249|NCT03989882|OTHER|Wheat germ energy ball|wheat germ mixed other ingredients to make an energy ball
223395250|NCT03989882|OTHER|Control|corresponding control without wheat germ
223549219|NCT01310010|DRUG|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
223549220|NCT05697653|BEHAVIORAL|Skin-to-Skin contact.|Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
223549221|NCT01543919|DRUG|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
223549222|NCT01543919|DRUG|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
223549223|NCT01543919|DRUG|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
223549224|NCT01543919|DRUG|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
223549225|NCT01543919|DRUG|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
223549226|NCT01543919|DRUG|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
223730952|NCT05704608|OTHER|Aerobic training|Exercises on a treadmill at different speeds and inclination were performed.
223730953|NCT00588848|DEVICE|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
224014904|NCT01998100|BEHAVIORAL|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
224014905|NCT01998100|BEHAVIORAL|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
224014906|NCT02323178|DRUG|eltrombopag|initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
224014907|NCT01453543|OTHER|deep transverse friction massage|For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
224014908|NCT01307657|OTHER|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
224014909|NCT03688451|DRUG|Rituximab|Intrathecal administration over 3-5 minutes
224014910|NCT00262145|DRUG|tea extracts|
224014911|NCT06397326|BEHAVIORAL|Return to work coordinator + PRATICAdr 2.0|The Return to work coordinator (RTW-C) uses PRATICAdr. 2.0 (web application).
224014912|NCT06397326|BEHAVIORAL|Return to work coordinator only|The Return to work coordinator (RTW-C) intervenes on employees on sick leave as usual
224014913|NCT00035191|DRUG|galantamine|
224014914|NCT02819557|DRUG|Ataluren|White to off-white powder for oral suspension.
223395251|NCT06212531|PROCEDURE|Medical male circumcision using standard surgical technique.|Medical male circumcision using the WHO standard technique followed by examination of wound healing and behavioral risk assessment.
223395252|NCT01987440|DRUG|lubricating gel|
223395253|NCT00006186|PROCEDURE|Autologous fresh whole blood|
223395254|NCT02445716|DRUG|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
223395255|NCT02445716|DRUG|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
223395256|NCT00073164|DRUG|Divalproex Sodium Extended-Release Tablets|
223395257|NCT00073164|DRUG|Olanzapine|
223395258|NCT00073164|DRUG|Risperidone|
223395259|NCT02508623|DRUG|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
223395260|NCT02508623|DRUG|Placebo|Placebo 1 tablet BID for 60 days
223395261|NCT04904250|DEVICE|Emboshield|a distall occlusion Emboshield NAV6 will be used as the embolism protection device during CAS
223395262|NCT04904250|DEVICE|Spider|a distal SpiderFX will be used as the embolism protection device during CAS
223395263|NCT01388959|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
223395264|NCT03645473|DEVICE|Monarch Airway Clearance System|HFCWO Airway Clearance Device
223395265|NCT03082534|DRUG|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
223395266|NCT07090278|DRUG|ulinastatin|Ulinastatin for the treatment of sepsis patients during ICU stay
223395267|NCT07090629|OTHER|Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring|Epicardial adipose tissue measurement
223395268|NCT07095192|OTHER|Preimplementation of HCV Point of care testing|Exploring the pre-implementation of HCV Point of care antibody and RNA tests
223395269|NCT07096219|PROCEDURE|Catheter Ablation|A minimally invasive procedure that delivers energy through catheters to destroy abnormal cardiac tissue causing arrhythmias.
223395270|NCT07096219|DIAGNOSTIC_TEST|ultrasonic cardiography (UCG)|Trans-thoracic echocardiography (TTE) is performed in the resting position. Trans-esophageal echocardiography (TEE) is performed under surfa
224014915|NCT00531453|DRUG|bortezomib, dexamethasone, and thalidomide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime)."
223395271|NCT07096856|DEVICE|Robotic assisted cholecystectomy|Robotic assisted cholecystectomy
224014916|NCT00531453|DRUG|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles."
223395272|NCT07096115|DRUG|Taiglididine|The first patient receives an intravenous injection of 1 mg taiglididine for anesthesia induction, followed by 1-2 mg/kg propofol. When the patient's bispectral index (BIS) drops below 60, eyelash reflex disappears, and MOAA/S score is 0, intravenous rocuronium 0.6 mg/kg is given, and a laryngeal mask is inserted by a senior anesthesiologist using a unified method 1 min later. From the second patient onward, the taiglididine dose is dynamically adjusted based on the previous patient's response to laryngeal mask insertion using BCD-UDM: if the previous patient shows a positive insertion response (positive response or MOAA/S ≥2 within 2 min after induction), the next patient's dose increases by 0.1 mg; if negative, a random number (1-95) generated by computer determines the dose: doses remain unchanged when the number is 6-95 (89% probability) and decrease by 0.1 mg when the number is 1-5 (11% probability). A collaborator not involved in result evaluation provides a sealed envelope with
223395273|NCT07097831|DRUG|HRS-1301 Tablets|HRS-1301 tablets.
223395274|NCT07097831|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin calcium tablets.
223549227|NCT03780751|BEHAVIORAL|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
224014917|NCT02457988|DEVICE|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
224014918|NCT05252104|DIAGNOSTIC_TEST|CORE-TOS diagnostic tool|Collection of clinical findings from clinical examination, subdivided into 5 sub-categories. Positivity in 4 or 5 of these subcategories is considered diagnostic for thoracic outlet syndrome (TOS).
223395275|NCT06817330|OTHER|Intervention group, listening to recorded music|Participants in the group receiving music will be offered a tablet with several pre-created playlists. When the patient has made a selection, they will listen to music via headphones for 30 minutes before each ECT treatment session. The headphones will be removed and the music stopped after the 30 minutes. After active ECT treatment, the headphones will be put back on the patient and the music played for another 12 minutes while the patient is recovering and moved to the recovery room. If patients protest against the music and/or headphones, the researcher will ask them to put the headphones back on. If the patient still protests after asking to put the headphones back on, this will be written down by the researcher, with the amount of time without the (control) intervention noted. No coercion will be used during the whole study process.
223549228|NCT03780751|BEHAVIORAL|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
223549229|NCT05112848|BIOLOGICAL|NVX-CoV2373|"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."
223549230|NCT05047133|DRUG|Tranexamic acid|TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
223549231|NCT01196897|DEVICE|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
223549232|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using bupivacaine: xylocaine|Patients will have the cotton swab soaked in the LA medication introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml of the medication injected via a syringe connected to a 20 G catheter into their nostrils bilaterally.
223549233|NCT05854537|PROCEDURE|Sphenopalatine ganglion block using normal saline|Patients will have the cotton swab soaked in normal saline introduced into their nostrils along the superior edge of the middle concha to the posterior wall of the nasopharynx to receive approximately 0.5ml of the medication, and then they will have 1.5 ml normal saline injected via a syringe connected to a 20G catheter into their nostrils bilaterally.
223549234|NCT03814135|DRUG|Hipnos 3|1 tablet, oral, once a day.
223549235|NCT03814135|DRUG|Hipnos 5|1 tablet, oral, once a day.
223549236|NCT03814135|OTHER|Hipnos 5 Placebo|1 tablet, oral, once a day.
223549237|NCT03814135|OTHER|Hipnos 3 Placebo|1 tablet, oral, once a day.
223549238|NCT01038505|DRUG|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
223549239|NCT06511687|BIOLOGICAL|Nirsevimab|Nirsevimab will be administered in a single dose at birth for newborn cohort and at the beginning of the campaign for the other cohorts under study
224014919|NCT00490230|DRUG|WR 279396|
223395276|NCT06817330|OTHER|Control group, headphones with no music|The control group will wear headphones without music for the same duration as the music group (30 minutes before ECT and 12 minutes after ECT) to reduce bias and achieve a similar level of background-noise dampening.
223395277|NCT01236716|DRUG|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
223395278|NCT01236716|DRUG|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
223549240|NCT00104728|DRUG|ZD1839|
223549241|NCT00190333|DRUG|escitalopram|escitalopram
223549242|NCT01963767|DRUG|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
223549243|NCT01963767|DIETARY_SUPPLEMENT|Placebo|
223549244|NCT04451200|DRUG|Busulfan Injection|injections doses will be personalized by PK at days -7 and -4
223549245|NCT04277624|DRUG|fezolinetant - test formulation|Administered orally
224014920|NCT03748992|DRUG|gNO|"This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.~Participants will be treated for 3 weeks (5 days per week), Monday through Friday, and followed monthly for 3 months.~The treatment period includes a physical exam, vital signs, blood tests, echocardiogram, spirometry test, sputum sample, questionnaires, and the inhalation gas treatment. During the inhalation gas treatment, participants will wear a face mask (similar to an oxygen mask) and will be given nitric oxide gas through the participants nose for three treatments with fifty minutes each time. They will then be followed up monthly during the Follow-up period with tests that include a physical exam and questionnaires."
224014921|NCT01681888|DEVICE|Sanger EMG Biofeedback Device|
224014922|NCT04224337|DRUG|Durvalumab + doxorubicin + ifosfamide|Durvalumab: 1500mg via IV infusion on day 1 Q3W for 4 cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W for up to a maximum 12 months Doxorubicin 20mg/m2 via IV infusion on day 1 to day 3 Q3W (up to 4 cycles) Ifosfamide: 1.5g/m2 (with mesna) via IV infusion on day 2 to day 4 Q3W (up to 4cycles)
224014923|NCT03480308|DRUG|Fentanyl|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
223549246|NCT04277624|DRUG|fezolinetant - reference formulation|Administered orally
223395279|NCT06933355|DRUG|JARDIANCE 25mg|"The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients.~4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2.~4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2."
223395280|NCT06933355|DRUG|Placebo|The intervention will be SGLT2i compared with placebo. The trial include a total of 8 non-diabetic kidney transplant recipients. 4 patients will randomly be assigned to start in the active arm, and treated with a single dose SGLT2i at intervention day 1 and a single dose placebo at intervention day 2. 4 patients will randomly be assigned to start in the non-active arm, each participant will be treated with a single dose placebo at intervention day 1 and a single dose SGLT2i at intervention day 2.
223395281|NCT05797870|COMBINATION_PRODUCT|Selective Internal Radiation Therapy with 188Re-SSS lipiodol|"The treatment with 188Re-SSS lipiodol SIRT requires two steps during the patient's hospitalization: the pre-treatment simulation step and the treatment step itself.~Pre-therapeutic simulation is performed during the screening phase, before definite patient inclusion, and is composed of two procedures: a diagnostic liver angiography and a liver perfusion scintigraphy (MAA scan and SPECT/CT).~The therapeutic stage is also composed of two procedures a therapeutic liver angiography with 188Re-SSS lipiodol and a 188Re-SSS lipiodol SPECT/CT."
223395282|NCT05180825|DRUG|Trametinib|Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each.
223395283|NCT05180825|DRUG|Vinblastine|weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each
223395284|NCT06465316|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223395285|NCT06465316|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223395286|NCT06465316|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223395287|NCT06465316|PROCEDURE|Computed Tomography|Undergo PET/CT
223395288|NCT06465316|DRUG|Iberdomide|Given PO
223395289|NCT06465316|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
223395290|NCT06465316|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
223395291|NCT06465316|DRUG|Teclistamab|Given SC
223395292|NCT02546986|DRUG|CC-486|CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
223395293|NCT02546986|DRUG|Pembrolizumab|Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
223395294|NCT02546986|DRUG|Placebo|Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
223395295|NCT05016960|BEHAVIORAL|Sleep-SMART|Sleep-SMART is a telehealth delivered treatment for insomnia that follows the standard 6 session 50-minute Cognitive Behavioral Therapy for Insomnia (CBT-I) format. Sleep-SMART delivers CBT-I treatment along with training in select cognitive strategies from CogSMART to enhance intervention learning and adherence.
223395296|NCT03719105|DRUG|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
223395297|NCT03719105|DRUG|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395298|NCT03719105|DRUG|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395299|NCT03719105|DRUG|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395300|NCT03719105|DRUG|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395301|NCT03719105|DRUG|calaspargase pegol|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395302|NCT03719105|DRUG|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395303|NCT03719105|DRUG|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395304|NCT03719105|DRUG|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223395305|NCT03719105|DRUG|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
223549247|NCT03960684|DEVICE|Levita Magnetic Surgical System|Levita Magnetic Surgical System
223549248|NCT02524249|DRUG|Caffeine|
223549249|NCT02524249|DRUG|Placebo (dextrose)|
224014924|NCT03480308|DRUG|Dexamethasone|Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
223395306|NCT05120934|DRUG|Amitriptyline 25 MG|25 mg orally for 4 weeks
223395307|NCT05120934|DRUG|Amitriptyline 50 MG|50 mg orally for 4 weeks
223395308|NCT05120934|DRUG|Duloxetine 30 MG|30mg orally for 4 weeks
223395309|NCT05120934|DRUG|Duloxetine 60 MG|60mg orally for 4 weeks
223395310|NCT05120934|DRUG|Placebo 30 MG|30mg tablet with no active study ingredient for 4 weeks
223395311|NCT05120934|DRUG|Placebo 60 MG|60mg tablet with no active study ingredient for 4 weeks
223395312|NCT05743036|DRUG|ZN-c3|ZN-c3 tablet by mouth, in combination with encorafenib
223395313|NCT05743036|DRUG|Encorafenib|Encorafenib capsule by mouth, in combination with ZN-c3
223395314|NCT05743036|DRUG|Cetuximab|Infusion
223395315|NCT04796961|OTHER|Implementation Intervention|The implementation intervention involves training, coaching, expert consultation, organizational strategy meetings.
223395316|NCT06494111|DRUG|Pravastatin|Given by PO
223395317|NCT06494111|DRUG|Pentoxifylline|Given by PO
223395318|NCT06494111|DRUG|Tocopherol|Given by PO
223395319|NCT04640987|BIOLOGICAL|Allogeneic Stem Cell Transplant|The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
223549250|NCT03015285|BEHAVIORAL|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
223730954|NCT00588848|DEVICE|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
223730955|NCT01499667|DRUG|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
223395320|NCT04640987|DEVICE|CliniMACS Prodigy System|Device used for production of T-allo10 cells.
223395321|NCT04640987|DRUG|T-allo10 cells addback|T-allo10 cells are made by manipulating the participant's stem cell donor's white blood cells (CD4+ T cells) in the presence of their (participant's) CD14+ monocytes.
223395322|NCT06041958|DEVICE|Extracorporeal shock wave therapy|2 times/week for 12 weeks
223395323|NCT06041958|DEVICE|Pulse electromagnetic field therapy|2 times/week for 12 weeks
223395324|NCT06041958|OTHER|Rehabilitation|2 times/week for 12 weeks
223730956|NCT01499667|DRUG|Placebo|Matching placebo in capsules for oral administration once daily.
223395326|NCT05738187|PROCEDURE|local cryotherapy treatment|cryotherapy
223395327|NCT05136820|DEVICE|Atrial Flow Regulator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
223395328|NCT05136820|DEVICE|Sham Comparator|Subjects will be randomized 1:1:1 where subjects will either receive the 6mm AFR device, 8mm AFR device or Sham procedure.
223395329|NCT05308758|OTHER|Game-based High-Intensity Interval Training|There will be two training sessions each week. In each training session, there will be four sets of training programs separated by 3 minutes of passive recovery in accordance with a previous study.Each set of activities will last for around 5 minutes; therefore, the total duration of each training session will be approximately 30 minutes. A small group size (4-6 children per group) will be adopted to facilitate individual supervision and adaption of the exercise program.
223395330|NCT05308758|OTHER|GameSAE|Similar to GameHIIT, the intervention will comprise 8 weeks of structured aerobic exercise sessions, lasting one hour on average in each session and up to twice per week. Six to eight stations of multidimensional exercises will be set up for each session. Adopting the train-the-trainer (TTT) model, training will be provided by front-line healthcare providers or trained helpers. Children will be instructed to finish the exercises in all stations one after another in a predetermined order.
223395331|NCT06090890|DRUG|Colchicine|Add 0.5mg QD orally and start using it within 48 hours after intervention.
223395332|NCT06090890|DRUG|Prednisone|0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.
223395333|NCT06090890|DRUG|Aspirin|Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.
223395334|NCT06090890|DRUG|P2Y12 Receptor Antagonist|Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.
223395335|NCT06090890|DRUG|Lipid-lowering drug|Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
223395336|NCT03700125|PROCEDURE|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
223395337|NCT06172088|OTHER|Fasting|Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
223395338|NCT06384417|BEHAVIORAL|Hello for Cancer game|"To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~The questions used in Hello for Cancer were modified from the original Hello game based on the results of phase 1 of testing this game in cancer populations. The modifications made to the game will be assessed for acceptability during this study."
223395339|NCT06384417|OTHER|Table Topics game|To play Table Topics, players are provided a deck of cards that have a variety of general conversation starter questions. The group takes turns selecting a card and reading it to the group for the group to answer. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
223395340|NCT05609253|DRUG|Itraconazole in capsule form|Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
223395341|NCT05609253|DRUG|Itraconazole in solution form|Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
223395342|NCT03623646|DRUG|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
223395343|NCT03623646|DRUG|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
223395344|NCT05965518|BEHAVIORAL|High-Intensity Interval Training|Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.
223395345|NCT05965518|BEHAVIORAL|Continuous Moderate Exercise|Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
223395346|NCT04064138|PROCEDURE|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
223549251|NCT06619821|BEHAVIORAL|Emotiaonl skill enhancement|This intervention combines online material with practical, emotion-focused activities. Participants will receive training on emotional awareness and emotion regulation strategies, along with completing weekly writing assignments. These assignments focus on recent negative events and the emotions associated with them, encouraging emotional expression and processing.
224014925|NCT03480308|DRUG|Bupivacaine|Bupivacaine
223395347|NCT04064138|PROCEDURE|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
223395348|NCT04064138|OTHER|General anesthesia|General anesthesia
223395349|NCT02513160|DRUG|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
223395350|NCT02513160|DRUG|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug."
224014926|NCT02593266|BEHAVIORAL|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~* Module 1: Depression and family~* Module 2: Psychoeducation about depression~* Module 3:The child's perspective on their parent's depression~* Module 4: Skills development~* Module 5: Preparation for the family session~* Module 6: Family session~* Module 7: Revision and future planning~* Follow-up"
224014927|NCT03814096|DIAGNOSTIC_TEST|Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)|Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
224014928|NCT03417895|DRUG|SHR-1210|A humanized anti-PD-1 monoclonal antibody
224014929|NCT03417895|DRUG|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
224014930|NCT06212882|DIAGNOSTIC_TEST|Lower concentration and lower volume contrast agent group|CT images using lower concentration and lower volume contrast material
224014931|NCT04865133|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224014932|NCT04865133|OTHER|Electronic Health Record Review|Medical record reviewed
224014933|NCT04972565|BEHAVIORAL|Usual Care plus Inspiratory Muscle Training (IMT)|Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
224014934|NCT05003609|OTHER|Early Rehabilitation|The intervention involves a progression of rehabilitation exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 mins) at each session. The intervention will be administered 5 days per week (weekdays) while the patient remains in ICU, censored at 28 days after randomisation.
224014935|NCT06348082|BEHAVIORAL|Mindfulness-based therapy for insomnia (MBTI)|MBTI will be administered in 6 weekly sessions. Session 1 consists of introductions and an overview. Subsequent sessions consist of mindfulness concepts/practice and behavioral strategies for sleep. Each session will begin with guided formal meditation followed by discussion. Mindfulness practice (at home) expectations are 30-45 minutes of meditation/day at least 5 days during the period of the intervention, followed by 20 minutes/day until the final follow-up assessment (at 12 weeks). Mindfulness concepts: Overview of Mindfulness, Mindfulness of the Body, Obstacles to Mindfulness, Working with Difficult Emotions, Cultivating Positive Emotions, Working with Difficult Thoughts, Mindful Interactions.
223395351|NCT02513160|DRUG|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
223395352|NCT02513160|DRUG|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
223395353|NCT02513160|DRUG|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
223395354|NCT00070031|DRUG|edotecarin|
223395355|NCT05696301|DEVICE|Winback® on|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is activated."
223549252|NCT06619821|BEHAVIORAL|PCE promotion|The intervention requires parents to complete a weekly parent-child interaction task designed to foster positive childhood experiences. Parents will engage in structured activities with their children and document the interactions. Each week, they are expected to upload a report.
223549253|NCT06619821|BEHAVIORAL|Psychoeducation|Psychoeducation includes sessions for both parents and adolescents, covering key topics such as stress, emotional distress, and mental disorders. The content provides foundational knowledge to help participants understand and manage these challenges.
223549254|NCT06709287|OTHER|clear aligners|The investigators measured pain and chewing performance at 8 time points during the first 6 months.
223549255|NCT06709287|OTHER|orthodontic metal bracket|Conventional metal bracket.
224014936|NCT06420661|BEHAVIORAL|SPACE for T1D|school-partnered collaborative care model
224014937|NCT06420661|BEHAVIORAL|Enhanced usual care|routine diabetes care with optional monthly insulin dose adjustment
224014938|NCT06457789|DRUG|[18F]F-AraG PET imaging|Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.
224014939|NCT06457789|DRUG|[89Zr]Zr-Df-Crefmirlimab PET imaging|Patients will receive a static whole-body PET scan following a \[89Zr\]Zr-Df-Crefmirlimab injection.
223395356|NCT05696301|DEVICE|Winback® off|"For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is not activated."
223395357|NCT05696301|BEHAVIORAL|self-massage of the scar|The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.
223395358|NCT05236205|PROCEDURE|Caries removal with a lowspeed drill|"1. Initial periapical and interproximal radiographs;~2. Prophylaxis with toothbrush and fluoride toothpaste;~3. Relative isolation with lip bumper, cotton roll, and aspirator;~4. Microbiological sampling with ear curette for standardization of volume of carious tissue;~5. Removal of carious dentin with carbide burs and manual instruments;~6. Additional microbiological sampling;~7. Clinical inspection of texture of remaining dentin with an exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months."
223395359|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~5. Second microbiological sample of remaining dentin with curette;~6. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~7. Restoration with glass ionomer cement;~8. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
223395360|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement;~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
223395361|NCT05236205|PROCEDURE|Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)|"1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment."
224014940|NCT05858528|DIAGNOSTIC_TEST|PEST screening questionnaire|PEST questionnaire to screen for PsA performed every 6 months
223395362|NCT01279317|DIETARY_SUPPLEMENT|placebo co-ingestion|25 ml water co-ingested with a glucose-containing beverage
223395363|NCT01279317|DIETARY_SUPPLEMENT|vinegar co-ingestion|25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
223549256|NCT00954161|OTHER|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
223549257|NCT00954161|OTHER|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
223549258|NCT06716723|PROCEDURE|Nephrectomy|Receipt of a laparoscopic nephrectomy for kidney donation
223549259|NCT06715566|BEHAVIORAL|ActForStroke|ActForStroke is a combination of 10 sessions high-intensity gait training and subsequent with up 7 coaching sessions until 1 year after stroke.
223549260|NCT06715566|BEHAVIORAL|Standard care|Usual rehabilitation services
224014941|NCT04524377|PROCEDURE|Deep Brain Stimulation|"Deep brain stimulation involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses. Or the electrical impulses can affect certain cells and chemicals within the brain.~The amount of stimulation in deep brain stimulation is controlled by a pacemaker-like device placed under the skin in the upper chest. A wire that travels under the skin connects this device to the electrodes in the brain."
224014942|NCT05759481|DRUG|Propofol|Propofol is administered starting at surgery induction and ending at skin closure
224014943|NCT05759481|OTHER|Placebo|Placebo is administered starting at surgery induction and ending at skin closure
224014944|NCT05204355|DIAGNOSTIC_TEST|MRI|Patients will be imaged using MRI
224014945|NCT05204355|DRUG|Hyperpolarized Xe129|Hyperpolarized Xe129 will be used to image the lungs of a subset of participants.
224128151|NCT06880939|DIETARY_SUPPLEMENT|Olive Oil|Instead of taking krill oil orally, use placebo capsules that are visually similar, with the contents being olive oil, each capsule containing 1g. Take one capsule within 30 minutes after breakfast and one capsule within 30 minutes after dinner. The duration of intake begins on the day of the first bladder instillation treatment and continues until the day of the last bladder instillation treatment.
224128152|NCT07031089|OTHER|Non-interventional study (RIPH category 3)|The study aims to describe and evaluate an existing care pathway, implemented within the framework of current clinical practice, without modifying the modalities of care or adding specific interventions. No additional procedures are imposed on participants, apart from data collection for evaluation purposes and telephone interviews.
223395364|NCT05902884|DEVICE|MSOT Acuity Echo|Imaging of muscles applying Multi-spectral optoacoustic tomography (MSOT)
223730957|NCT02902965|DRUG|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
223395366|NCT06167499|OTHER|Diabetes Therapeutic Education conducted by nurses|"Individual consultations with the therapeutic education IDE, who will help the patient to achieve the therapeutic objectives set before the medical consultation.~Once the objectives have been set, the IDE will set up individual workshops and subsequently assess the patient's learning and its impact on his or her care. These workshops can include equipment demonstrations and practical exercises, explanations of treatment adaptation protocols, and dietary or sexual advice."
223395367|NCT04938310|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy
223395368|NCT04938310|DEVICE|support garment|A custom made support garment
223395369|NCT02841618|OTHER|High Linoleic Acid Healthy Cookies|
223395370|NCT02841618|OTHER|High Oleic Acid Healthy Cookies|
223395384|NCT06452355|DEVICE|KOKO Device|The intrauterine drain is extended into the uterus, where low pressure vacuum is applied to the uterus through the fabric intrauterine drain. The KOKO™ device utilizes this vacuum to remove excess blood and compress the uterus reducing further blood loss.
224014946|NCT05204355|DIAGNOSTIC_TEST|HRCT|High Resolution Computer Tomography
224014947|NCT05367271|DRUG|Botulinum Toxin A|20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
224014948|NCT05367271|DRUG|Dexamethasone|1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
223395385|NCT03581500|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223395386|NCT03581500|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223395387|NCT03700138|DRUG|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
223395388|NCT03700138|DRUG|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
223395389|NCT05682066|DEVICE|Innovalve MR system|Innovalve MR system
223395390|NCT03428958|DRUG|NUC-3373 + leucovorin|NUC-3373 + leucovorin
223395391|NCT03428958|DRUG|NUC-3373|NUC-3373
223395392|NCT03428958|DRUG|NUFOX|NUC-3373 + oxaliplatin
223395393|NCT03428958|DRUG|NUFOX + VEGF pathway inhibitor|NUC-3373 + oxaliplatin + bevacizumab
223395394|NCT03428958|DRUG|NUFOX + EGFR inhibitor|NUC-3373 + oxaliplatin + cetuximab/panitumumab
223395395|NCT03428958|DRUG|NUFIRI|NUC-3373 + irinotecan
224014949|NCT04834635|PROCEDURE|FundoRingOAGB|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
223395396|NCT03428958|DRUG|NUFIRI + VEGF pathway inhibitor|NUC-3373 + irinotecan + bevacizumab
223395397|NCT03428958|DRUG|NUFIRI + EGFR inhibitor|NUC-3373 + irinotecan + cetuximab/panitumumab
223395398|NCT03428958|DRUG|NUC-3373 + bevacizumab|NUC-3373 + bevacizumab
223395399|NCT03874117|OTHER|Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis|Twice weekly hemodialysis for 4 weeks, then thrice weekly hemodialysis for 4 weeks.
223395400|NCT03874117|OTHER|Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis|Thrice weekly hemodialysis for 4 weeks, then twice weekly hemodialysis for 4 weeks.
223395401|NCT05683145|BEHAVIORAL|Computerized Cognitive Behavioral Therapy for Insomnia|This is a computerized version of cognitive behavioral therapy for insomnia that is augmented by support from a licensed mental health professional. The intervention consists of 6 modules designed to provide education regarding sleep and insomnia, establish behavioral modifications to reduce insomnia symptoms, and monitor progress. Participants will be able to complete these intervention at their own pace, which will take between 6-9 weeks.
223395402|NCT05745480|OTHER|Opioid Misuse Screening with an Addiction Consult Service|Opioid Misuse Screening with an addiction consult service for brief intervention/motivational interviewing (MI), medication assisted treatment (MAT), or referral to substance use treatment as an outpatient.
223395403|NCT02971501|BIOLOGICAL|Bevacizumab|Given IV
223395404|NCT02971501|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224014950|NCT04834635|PROCEDURE|OAGB|laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
224014951|NCT06545500|DRUG|Glycopyrrolate (85 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
224014952|NCT06545500|DRUG|Glycopyrrolate (42.5 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
224014953|NCT06545500|DRUG|Glycopyrrolate (14 μg)|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
224014954|NCT06545500|DRUG|Placebo|Administered by a standard jet nebulizer, twice daily for 7 consecutive days
224014955|NCT05618106|OTHER|Low FODMAP DIET = Diet with Low polyol, FOS and GOS|Low Polyol diet
224128153|NCT04355091|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage forms, rather than using acupuncture needles.
223395405|NCT02971501|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223395406|NCT02971501|PROCEDURE|Computed Tomography|Undergo CT scan
223395407|NCT02971501|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223395408|NCT02971501|DRUG|Osimertinib|Given PO
223549261|NCT06718062|DRUG|Aliskiren|Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20138002. The primary objective is to evaluate the non-inferiority of Aliskiren in lowering serum uric acid levels, and its effects on blood pressure and kidney function.
223730958|NCT02902965|DRUG|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
223730959|NCT02902965|DRUG|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter."
223730960|NCT02673489|DRUG|DCV|
223730961|NCT02673489|DRUG|SOF|
223730962|NCT02673489|DRUG|RBV|
223730963|NCT00293254|DRUG|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
223730964|NCT00293254|DRUG|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
223730965|NCT00066950|DRUG|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
223730966|NCT00066950|DEVICE|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
223730967|NCT02335489|DEVICE|Implantation with the commercially available Axium neurostimulator|
223730968|NCT05111158|DIAGNOSTIC_TEST|mfERG|mfERG was performed by RETI Scan (Roland consulting company) and software 6.16.3.10 according to the protocol of the International Society for Clinical Electrophysiology of Vision (ISCEV)
223730969|NCT05070117|BEHAVIORAL|Exercise training|Study participants perform resistance/strength exercises 2-3 times per week for one hour, for one year.
223730970|NCT04413409|PROCEDURE|Metastasectomy for the metastatic sites|patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy
223730971|NCT02680743|OTHER|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
223730972|NCT05618964|OTHER|Deep Neck Flexors & Extensors exercises|"Deep neck flexor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck flexor muscle in supine Craniocervical flexion in supine~Deep Neck Extensor exercises (2 set of 10 repetitions) that includes:~Contraction of deep neck extensors in quadruped position Segmented extension movement with the head bent down onto their chest in a horizontal direction,"
223730973|NCT00503308|PROCEDURE|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
223730974|NCT00369993|DRUG|fluticasone propionate/salmeterol|
223730975|NCT01411696|DRUG|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
223730976|NCT02233309|OTHER|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
223730977|NCT01601249|PROCEDURE|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
223730978|NCT04960150|DEVICE|Press tack needle|"Press tack needle acupuncture using Seirin Pyonex sized 0.20x1.2mm"
223730979|NCT04960150|DEVICE|Plesterin|Plesterin
223730980|NCT05651633|DRUG|lidocaine hydrochloride 5mg/g|1-2 drops up to six times daily for a maximum of 7 days
223730981|NCT01509833|DRUG|rFSH|Administration of rFSH for ovarian stimulation.
223730982|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
223730983|NCT01509833|DRUG|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
223730984|NCT04502953|PROCEDURE|Vertical plication|Vertical plication of the rectovaginal septum was done
223730985|NCT04502953|PROCEDURE|Horizontal plication|Horizontal plication of the rectovaginal septum was done
223730986|NCT01151644|BIOLOGICAL|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
223730987|NCT00232817|DRUG|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
223395409|NCT05316116|DRUG|Siltuximab|Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).
223395410|NCT05660109|DRUG|TPM502|TPM502 contains 3 peptides each consisting of two overlapping T cell epitopes that encompass the major gluten epitopes for HLA-DQ2.5
223395411|NCT05660109|OTHER|Placebo|Placebo
223395412|NCT06217159|DIETARY_SUPPLEMENT|Poikilocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.
223730988|NCT05738161|DRUG|Magrolimab|Magrolimab in combination with cytotoxic chemotherapy in advanced urothelial carcinoma
223730989|NCT05738161|DRUG|Cisplatin|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
223730990|NCT05738161|DRUG|Gemcitabine|Standard first line platinum-based chemotherapy in advanced urothelial carcinoma
223730991|NCT05527145|PROCEDURE|Minimally invasive surgery|Surgery with decompression. Central decompression of the stenotic segment with undercutting of the lateral recesses.
223395413|NCT06217159|DIETARY_SUPPLEMENT|Normocapnia|Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
223395414|NCT05507671|BIOLOGICAL|BCG (Bacillus Calmette-Guérin) vaccine|Application of BCG vaccine (0.1 ml intradermal) in the right arm deltoid insertion
223395415|NCT05507671|OTHER|Placebo|Application of BCG solvent (0.1 ml intradermal) in the right arm deltoid insertion
223395416|NCT02904577|OTHER|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
224014956|NCT01361191|DRUG|R-MEGACHOP|"* If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~* If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
224014957|NCT00435175|DRUG|estradiol|
224128154|NCT07039942|DEVICE|Omnipod 5|"The Omnipod 5 Automated Insulin Delivery System (Omnipod 5 System) is a tubeless insulin pump with a mono-hormonal insulin delivery system designed to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in people aged 2 years and older who require insulin.~The Omnipod 5 System is intended to function as an automated insulin delivery system when used with compatible Continuous Glucose Monitoring (CGM) systems."
224128155|NCT06704178|DIETARY_SUPPLEMENT|NuBest Tall Growth Protein Powder|NuBest Tall Growth Protein Powder includes a proprietary blend of vitamins, minerals, and probiotics designed to enhance children's health outcomes.
223395417|NCT05258773|DRUG|SENS-401 (R-Azasetron Besylate)|Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
223395418|NCT05534269|BIOLOGICAL|autologous muscle precursor cells|Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
223395419|NCT04814693|DEVICE|EndoRotor® System (Interscope, Inc., Northbridge, MA USA),|The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.
223395420|NCT04814693|PROCEDURE|Conventional endoscopic devices (according to standards of care)|Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.
223395421|NCT05721937|DRUG|Abrocitinib|taken by mouth
223395422|NCT05277922|DRUG|C21|C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
223395423|NCT05277922|DRUG|Sodium Nitroprusside|Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control
223395424|NCT03018288|DRUG|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30-minute intravenous (IV) infusion (prior to radiation therapy (RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with heat shock protein peptide complex -96 (HSPPC 96) or placebo vaccine if any is available.
223395425|NCT03018288|BIOLOGICAL|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
223395426|NCT03018288|DRUG|Temozolomide|Temozolomide (TMZ) will be administered on day 1 of radiation therapy (before radiation therapy (RT) treatment) and continue throughout RT at the dose of 75 mg/m\^2. Post RT: The starting TMZ dose will be 150 mg/m\^2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m\^2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
223549262|NCT06718062|DRUG|Losartan|Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20143030. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.
223549263|NCT06718894|OTHER|Biologic fluid sampling|The only interventions in addition to standard clinical practice will be blood sampling, the collection of morning spot urine and the collection of the discarded effluent of the plasmapheresis procedure (when performed according to clinical indication).
223549264|NCT05913544|OTHER|SINTYA|10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session
223549265|NCT06716918|DRUG|Corticosteroid Injection|Participants who have received antenatal corticosteroids (betamethasone or dexamethasone) prior to cesarean section as part of their prenatal care.
223549266|NCT06716996|DEVICE|repeated transcranial magnetic stimulation|20 sessions of repeated transcranial magnetic stimulation
223549267|NCT06716996|DEVICE|sham treatment|20 sessions of sham treatment
223549268|NCT06714825|BIOLOGICAL|HS235|Up to 4 Single and 3 Multiple Ascending Doses
223549269|NCT06714825|DRUG|Placebo|Subcutaneous Injection
223549270|NCT03687775|OTHER|Stability assessment|Qualitative and quantitative stability assessment
224128156|NCT06704178|DIETARY_SUPPLEMENT|Placebo Powder|The placebo powder is designed to mimic the appearance and taste of the NuBest Tall Growth Protein Powder but does not contain the active ingredients.
223549271|NCT03941483|DRUG|ASP1128|Intravenous Infusion
223549272|NCT03941483|DRUG|Placebo|Intravenous Infusion
223395427|NCT03018288|OTHER|Placebo|One week post radiation therapy (RT), participants will receive weekly x 4 a dose of heat shock protein peptide complex -96 (HSPPC 96) 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of Temozolomide (TMZ). HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Participants who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if participants are doing well, they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
223395428|NCT03018288|PROCEDURE|Surgery|Tissue for vaccine production and neo-epitope monitoring.
223395429|NCT06961708|DRUG|Oral Fosmanogepix|Oral Tablet
223549273|NCT01211392|OTHER|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
223549274|NCT01252589|OTHER|HRQOL questionnaire|
223549275|NCT02835144|OTHER|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
223549276|NCT02835144|OTHER|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
223549277|NCT00014729|DRUG|isotretinoin|
224014958|NCT05121558|OTHER|Yoga|Participants will have instructional yoga classes twice each week over the course of 8 weeks. Each yoga class will be 60 minutes, and it will be taught by an experienced yoga instructor. Participants will be provided with a home-based guided program for days classes are not held. Participants in the yoga group will also have the option to participate in a recorded final check-in session after they have completed their 16 yoga classes. The discussion facilitator will follow the Semi-Structured Interview Guide to further understand participants' experiences in the yoga group.
223395430|NCT06961708|DRUG|IV Fosmanogepix|IV infusion
223395431|NCT06961708|DRUG|IV placebo|Matching IV placebo
223395432|NCT06961708|DRUG|oral placebo|Matching oral placebo
223395433|NCT03593473|DRUG|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
223395434|NCT03593473|DRUG|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
223395435|NCT06031194|OTHER|Non-Interventional Study|Non-interventional study
223395436|NCT04867954|OTHER|Ensure Plus®|In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
223395437|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
223549278|NCT04624100|PROCEDURE|Hernia repair|Primary or mesh repair of primary ventral or incisional hernia
223549279|NCT00570843|DRUG|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
223549280|NCT00570843|DRUG|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
223549281|NCT00928343|DRUG|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
223549282|NCT00928343|DRUG|Placebo|Matching subcutaneous or oral placebo
223549283|NCT01082081|DRUG|Paracetamol 1000 mg|Paracetamol 1000 mg
223549284|NCT01082081|DRUG|Paracetamol 500 mg|Paracetamol 500 mg
223549285|NCT01082081|DRUG|Placebo|Placebo
223549286|NCT02345733|OTHER|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
223549287|NCT02345733|DRUG|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
223549288|NCT03714438|DRUG|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
223549289|NCT03714438|DIETARY_SUPPLEMENT|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
223549290|NCT00537537|DRUG|Telbivudine|
223549291|NCT01980199|DRUG|Fexinidazole|"600 mg tablets given orally, after the main daily meal~* at the daily dose of 1800 mg (3 tablets) once a day for 4 days~* continued by 1200mg (2 tablets)once a day for 6 days"
223549292|NCT04152954|DEVICE|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
223549293|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
223549294|NCT00932035|DRUG|isosulfan blue based lymphatic mapping|
223549295|NCT00932035|PROCEDURE|axillary lymph node dissection|Undergo standard axillary lymph node dissection
223549296|NCT00932035|PROCEDURE|quality-of-life assessment|Ancillary studies
224014959|NCT05121558|OTHER|Education control|Participants will have educational sessions over 8 weeks. The sessions will be on the causes and impact of Chemotherapy-Induced Peripheral Neuropathy (CIPN), how yoga may help with CIPN, and how different therapies may help with CIPN. To encourage participation and adherence, patients in the EC group will receive sixteen free yoga sessions after completing the study. Patients in the EC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
224014960|NCT05121558|OTHER|Usual care|Participants in the usual care control group will complete the same assessments as the other two arms. To encourage participation and adherence, patients in the UC group will receive sixteen free yoga sessions after completing the study. Patients in the UC group will be asked to not go for their own yoga classes locally until their participation in the study is completed.
223395438|NCT04867954|OTHER|Clinical validation MRI|"Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 1/2 or 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 or 1/2 dose of GBCA will be administered, if required."
223395439|NCT04867954|OTHER|Pre-clinical validation contrast enhanced MRI + fasting|Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
223395440|NCT04519216|BEHAVIORAL|Telesimulation|Telesimulation educational intervention
223395441|NCT05785494|OTHER|Narstaende.se|Web-site with supportive information, videos and chat forum targeting family caregivers of patients with life-threatening illness.
223395442|NCT05582460|DIAGNOSTIC_TEST|Reporter Gene Assay|Transcription factor reporter gene assay using luciferase
223395443|NCT05582460|DIAGNOSTIC_TEST|Flow Cytometry|Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.
223730992|NCT05527145|PROCEDURE|Percutaneous Spacer|percutaneous image guided outpatient procedure that enables interspinous spacer insertion and fusion
223730993|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
223730994|NCT00799487|DRUG|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
223395450|NCT05873777|DIAGNOSTIC_TEST|18F-FDG PET/CT, 68Ga-FAPI-LM3 PET/CT|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-LM3, and undergo PET/CT imaging within the specified time. A part of participants will undergo additional 68Ga-FAPI-46 PET/CT for comparison.
223395451|NCT01127256|DRUG|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
223395452|NCT01127256|DRUG|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
223395453|NCT05252325|DEVICE|hyaluronic acid plus lidocaine|local injection for correction of nasolabials fold
223395454|NCT05252325|DEVICE|hyaluronic acid without lidocaine|local injection for correction of nasolabial folds
223395455|NCT01415518|DRUG|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
223395456|NCT01415518|DRUG|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
223395457|NCT01415518|DRUG|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
223395458|NCT05531123|DRUG|Tislelizumab|Tislelizumab 200 mg I.V. Q3W on the day 1
223395459|NCT05531123|DRUG|gemcitabine and cisplatin|Cisplatin 70mg/m2 I.V. Q3W on the day 1, dose fractionation is allowed ;Gemcitabine 1000mg/m2 I.V. Q3W on the day 1 and day 8
223395460|NCT05531123|RADIATION|Modified hypofractionation|"* Whole bladder 44Gy / 16fractionation (If N1: Whole bladder + Pelvic nodes 44Gy / 16fractionation) (Positive lymph nodes can be dosed to the maximum tolerable dose)~* Tumor boost 11Gy / 4fractionation~* Radiosensitizing chemotherapy: DDP 75-80 mg/m2 weekly Q3W"
223395461|NCT00679211|DRUG|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
223395462|NCT01473823|DIETARY_SUPPLEMENT|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
223395463|NCT01922037|DRUG|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
223395464|NCT04295083|BEHAVIORAL|clay based group study|"Clay based group work sessions were applied to the experimental group for 60-90 minutes once a week for 6 weeks. The sessions are composed of structured or semi-structured activities prepared for the purpose of the literature by the researcher for the purposes such as acquiring new solutions and life skills to reduce loneliness and hopelessness of individuals aged 65 and over, and sharing their feelings, thoughts, and memories with other individuals. Clay Study Activity Booklet . Four expert opinions were obtained for the booklet created. Methods such as narration, sharing experiences, group practice, question-answer, learning by doing, imagining were used in the activity program. The physical, psychological, social and mental characteristics of the elderly were taken into consideration in the selection of these methods."
223395465|NCT05890924|OTHER|WAST questionnaire|"WAST questionnaire, designed and validated as a screening tool for violence against women and intimate partner violence.~(ref: Brown JB, Lent B, Brett PJ, Sas G, Pederson LL. Development of the Woman Abuse Screening Tool for use in family practice. Fam Med. 1996 Jun;28(6):422-8.)"
223395466|NCT03944668|BEHAVIORAL|Exercise|36 sessions of comprehensive cardiac rehabilitation over 12 weeks
223395467|NCT01730053|DRUG|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
223395468|NCT01730053|DRUG|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
223395469|NCT01730053|DRUG|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
223395470|NCT01730053|DRUG|Placebo|Placebo for alirocumab and ezetimibe.
223549297|NCT00932035|OTHER|Questionnaire administration|Ancillary studies
223549298|NCT00670930|DRUG|omalizumab at a dose of 0.016mg/kg/IU/mL|
223549299|NCT00670930|DRUG|Placebo|
223549300|NCT04949945|BEHAVIORAL|Self Help Culturally Cognitive Behavioral Therapy|Experimental group (CHF patients)will be screened on PHQ9 questionnaire for depression after receiving guided self help culturally adapted cognitive therapy they will be reassessed for their depression,improvement in functional disability ,improvement in classification of NYHA,reduction in hospital admission as compare to control group.
223549301|NCT01464749|BEHAVIORAL|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
223395471|NCT01042353|PROCEDURE|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
223395472|NCT01042353|PROCEDURE|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
223395473|NCT05460013|DIETARY_SUPPLEMENT|Traditional Control|Placebo control is a compounded made-up shake that is traditionally used by the Haematology ward to supplement patients receiving HSCT. The control provides an equivalent of 500kcals and 20.6g protein, 3.4g fiber per day. The participants will be randomly assigned to consume the control twice daily for the duration of 7 days prior to the admission to the day of discharge.
223549302|NCT01464749|BEHAVIORAL|usual care|no specific rehabilitation
223549303|NCT04592471|DEVICE|kneeMID500-STRONG700|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) per device type (2 device types: Knee MID 500 and Knee STRONG 700) totalling 60 patients will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
223549304|NCT04584047|PROCEDURE|Cell-based non-invasive prenatal testing|Blood sampling.
224014961|NCT04723966|DIETARY_SUPPLEMENT|TPN|Total parenteral nutrition
223395474|NCT05460013|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|The product to be studied is a standard polymeric formula. It is intended to provide 500cals, 18.4g protein, and 5g fiber per day. The fiber contained is mostly presented in the form of soluble fiber (inulin, fructo-oligosaccharide). The participants will be randomly assigned to consume the intervention twice a day for the duration of 7 days prior to the admission to the day of discharge.
223395475|NCT00004789|DRUG|heme arginate|
223395476|NCT00004789|DRUG|tin mesoporphyrin|
223395477|NCT02549404|DRUG|KHK7580|Oral administration
223730995|NCT03864211|PROCEDURE|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to five target lesions.
224014962|NCT04352998|DIETARY_SUPPLEMENT|One dose pre-workout condition|one dose of a multi-ingredient pre-workout supplement
223549305|NCT03199677|DRUG|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
223549306|NCT01274234|DEVICE|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
223549307|NCT00187304|DEVICE|Aortic valve replacement|
223549308|NCT05874505|DRUG|Adalimumab|Adalimumab 80 mg at Day 0 then 40 mg subcutaneous at week 1, 3, 5, 7, 9, 11, 13 and 15
223549309|NCT05874505|DRUG|Tocilizumab|Tocilizumab 162 mg subcutaneous each week for 15 weeks
223730996|NCT03864211|DRUG|Toripalimab|"Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation."
223730997|NCT04481750|DRUG|MT-1186|Solution or suspension
223730998|NCT04481750|DRUG|MT-1186-matching placebo|Solution or suspension
223730999|NCT06147310|PROCEDURE|Study Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Alveolar ridge preservation with blood platelet concentrate: heat-treated albumin (Alb-PRF) and advanced platelet-rich fibrin. The experimental site will be filled with A-PRF plugs/membranes until level flushed with the level of bone. An additional Alb-PRF membrane will be tucked and inserted below the buccal and oral flap. Surgical flaps will not be raised. Soft tissue will be tunnelled and undermined for insertion of the Alb-PRF membrane. The extraction site and membranes will be stabilized by cross-mattress sutures and allowed for secondary intention healing.
224014963|NCT04352998|DIETARY_SUPPLEMENT|Two dose pre-workout condition|two doses of a multi-ingredient pre-workout supplement
224014964|NCT04352998|DIETARY_SUPPLEMENT|Placebo condition|one dose of a placebo
224014965|NCT04252274|DRUG|Darunavir and Cobicistat|Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
224014966|NCT04083820|DRUG|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
224014967|NCT04245943|BEHAVIORAL|Exercise training|18 weeks supervised strength and aerobic exercise training.
224014968|NCT02272673|DIETARY_SUPPLEMENT|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
224014969|NCT00684619|DRUG|Nelarabine|1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
224014970|NCT02125045|DIETARY_SUPPLEMENT|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
224014971|NCT02125045|DIETARY_SUPPLEMENT|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
224014972|NCT02056990|OTHER|Advice|
224128157|NCT06720922|PROCEDURE|Resonance-guided Laser Interstitial Thermal Therapy (MRgLITT)|MRgLITT employs laser energy delivered through a stereotactically placed laser applicator to precisely ablate the epileptogenic tissue.
224128158|NCT06720922|PROCEDURE|Open Surgery|Traditional Open Surgery
224128159|NCT00187707|DRUG|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
224128160|NCT00229372|BEHAVIORAL|Prolonged Exposure (PE) therapy|
223731000|NCT06147310|PROCEDURE|Control Group|The tooth will be extracted automatically, tooth sectioning will be performed if necessary for multi-rooted teeth to minimize trauma. Cross mattress suture will be applied and site allowed to heal naturally.
223731001|NCT02197507|DEVICE|Digitized sensor|Measure of grip strength of the dominant hand
223731002|NCT03867929|OTHER|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
224014973|NCT04605289|DRUG|lemongrass essential oil gel|"The lemongrass oil gel will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
224014974|NCT04605289|DRUG|Placebo|"The placebo will be administered by means of a syringe with a bent, blunt-end needle. The needle will be carefully inserted into the periodontal pocket and the gel will be applied in the test sites in a gentle probing manner, attempting to fill the full extent of the pocket. The gel will be applied up to the gingival margin and the excess gel will be removed with sterile gauze.~Periodontal dressing will be applied after the delivery of the drug, and they will be also asked not to eat for thirty minutes.~After placement of the gel in situ, patients will be instructed to follow strict oral hygiene protocol and not chew hard or sticky foods at the gel placement sites for rest of the week."
224014975|NCT04605289|PROCEDURE|Scaling and root planing|Conventional mechanical treatment by ultra-sonic scalers
224128161|NCT02674607|DIETARY_SUPPLEMENT|Spirulina|
224128162|NCT03238092|DRUG|Testosterone|testosterone gel daily during the late luteal phase.
224128163|NCT03238092|DRUG|Estradiol|oral estradiol during the late luteal phase.
223731003|NCT04316754|OTHER|music|"During angiography, the Intervention-1 group will listen to the music that the child wants to listen to. The Intervention-2 group will listen to the Arts of Fugue by Bach. No music will be played to the control group."
223731004|NCT00384995|DRUG|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
223731005|NCT00384995|DRUG|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
223731006|NCT02579850|DRUG|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
223395478|NCT01470248|DRUG|Arsenic Trioxide|Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
223395479|NCT05502939|BEHAVIORAL|Music Program|"The cohort of students entering the program at the Colburn school in Los Angeles will be a part of a traditional strings curriculum. Students will join the program on a full scholarship and will be provided all materials necessary for instruction, including an instrument. Students will attend Colburn twice a week in a group setting and will receive private instruction once a week.~The program will last 2, 15-week semesters (fall, spring) for 2-years. There will be 2 groups of 10 students. Students will undergo group instruction for 1 hour, 2 times a week and private instruction for 45 minutes, once a week."
223395480|NCT05502939|BEHAVIORAL|After School Enrichment Program|The afterschool program will be led by instructors and will include visual arts, theater, and general cultural studies. Students attend the program 3 days per week in the afternoon for 1 hour long lessons. Students will take part in an end of the year celebration to share their work with family and community members.
223395481|NCT06426342|BEHAVIORAL|metaverse-based blended online intervention|A new metaverse-based blended online intervention was developed using an online program and coaching via metaverse to prevent depression among Generation MZ Employees in South Korea.
223395482|NCT06617208|DEVICE|Neuropixel probe recording|Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.
223395483|NCT06356571|DRUG|Isatuximab SC-OBDS|Pharmaceutical form:Solution for SC-OBDS administration-Route of administration:SC-OBDS
223395484|NCT06356571|DRUG|Montelukast|Pharmaceutical form:As per local commercial product-Route of administration:Oral
223731007|NCT02579850|DRUG|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
223731008|NCT02579850|PROCEDURE|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
223731009|NCT02579850|OTHER|COPD assessment test|COPD assessment test (CAT) at visit 1
223731010|NCT02579850|PROCEDURE|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
223731011|NCT02579850|OTHER|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
223731012|NCT02579850|OTHER|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
223731013|NCT03263442|DRUG|Thiamine|200 mg IV three times daily for seven days
223731014|NCT03263442|DRUG|Normal saline|Normal saline IV three times daily for seven days
223731015|NCT02890706|DEVICE|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
223731016|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
223731017|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237 mL
223731018|NCT01464385|OTHER|Nutritional Beverage|Nutritional Beverage Oral 237mL
223731019|NCT01550380|DRUG|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
223731020|NCT03917108|DEVICE|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
223731021|NCT03917108|DEVICE|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
223731022|NCT02045706|OTHER|Community Health Worker Trainings|
223731023|NCT02178631|BEHAVIORAL|Deprexis|Online self-help
223549310|NCT03368781|DEVICE|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
223395485|NCT06356571|DRUG|Dexamethasone|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
223549311|NCT05962281|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation which involves the use of low intensity currents propagated via the scalp, is widely implemented as both a fundamental and clinical neuroscientific tool. Over the last decades, tDCS showed significant therapeutic promise, as numerous studies revealed that it can result in improved attention and executive functions in patients with neurological disorders, through modification of neuronal excitability.
223549312|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
223549313|NCT04750343|BIOLOGICAL|GBP510 (RBD 10μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 10μg/dose) on Days 0 and 28.
223549314|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
223549315|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
223549316|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose) - Stage 1|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
223549317|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution) - Stage 1|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
223549318|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 10μg/dose) - Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 10μg/dose) on Days 0 and 28.
223549319|NCT04750343|BIOLOGICAL|GBP510 adjuvanted with AS03 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 adjuvanted with AS03 (RBD 25μg/dose) on Days 0 and 28.
223549320|NCT04750343|BIOLOGICAL|GBP510 (RBD 25μg/dose)- Stage 2|Participants will receive intramuscular (IM) injections of GBP510 (RBD 25μg/dose) on Days 0 and 28.
223549321|NCT04750343|OTHER|Normal saline (0.9% sodium chloride solution)- Stage 2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
223549322|NCT06552845|DIAGNOSTIC_TEST|LGE-MRI Scan|Participants will receive LGE-MRI scan before catheter ablation and 3 months after catheter ablation
223549323|NCT05304442|DRUG|Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]|Single Dose of IV Iron
223549324|NCT05304442|DRUG|Ferrous Sulfate 65 mg elemental iron (325 mg tablets)|Once daily by mouth for 42 days
223549325|NCT03431454|PROCEDURE|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
223549326|NCT03431454|PROCEDURE|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
223731024|NCT02178631|OTHER|CAU|Care as usual
223395486|NCT06356571|DRUG|Acetaminophen|Pharmaceutical form:As per local commercial product-Route of administration:Oral or IV
223395487|NCT06356571|DRUG|Diphenhydramine|Pharmaceutical form:As per local commercial product-Route of administration:Oral (as premedication) or IV/oral equivalent (for management of infusion reaction)
223395488|NCT06356571|DRUG|Methylprednisolone|Pharmaceutical form:As per local commercial product-Route of administration:IV
223395489|NCT06356571|DRUG|Carfilzomib|Pharmaceutical form:As per local commercial product-Route of administration:IV
223395490|NCT01741311|BEHAVIORAL|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
223395491|NCT01741311|BEHAVIORAL|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
223395492|NCT05708235|DRUG|Giredestrant|Giredestrant is a highly potent, non-steroidal, oral selective ER antagonist and degrader (SERD)
223395493|NCT05708235|DRUG|Abemaciclib|Abemaciclib is an orally administered CDK4/6 inhibitor
223549327|NCT03431454|PROCEDURE|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
223549328|NCT01949766|DRUG|Glycerol phenylbutyrate|
223549329|NCT03493451|DRUG|Tislelizumab|Administered intravenously
223549330|NCT05262777|DEVICE|GP0112|Injectable gel
223549331|NCT05262777|DEVICE|Restylane Lyft Lidocaine|Injectable gel
223549332|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
223549333|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
223549334|NCT01238991|BIOLOGICAL|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
223549335|NCT06293534|DIAGNOSTIC_TEST|TSH,T3,T4|Diagnosis of the psychiatric disorders among study group will be assessed and recorded and history of Electroconvulsive therapy (ECT) also will be recorded , physical examination for signs that suggests actual thyroid disease such as unexplained bradycardia or tachycardia, hypothermia , goiter or non palpable thyroid among study group will be assessed
223549336|NCT06095934|OTHER|neo-antigen vaccine|anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy
223549337|NCT03370419|BEHAVIORAL|Treatment|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
223549338|NCT03370419|BEHAVIORAL|Usual care|Usual care
223549339|NCT01746355|PROCEDURE|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
223549340|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
223549341|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
223731025|NCT01725438|OTHER|sample blood|
223731026|NCT03785665|DEVICE|MDI|Capsule MD1 (Motility dummy 1)
223395494|NCT05708235|DRUG|Inavolisib|Inavolisib is a potent, selective inhibitor of the Class I phosphatidylinositol 3-kinase α (PI3K-alpha isoform (p110-alpha)
224014976|NCT03280147|DRUG|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
223395495|NCT04577014|DRUG|Retifanlimab|"Phase I:~Dose Level 1 - 375 mg (flat dose) Dose Level 0 - 210 mg (flat dose) Dose Level -1 - 375 mg (flat dose) Dose Level -2 - 375 mg (flat dose)~Phase II: 375 mg (flat dose)"
223395496|NCT04577014|DRUG|Gemcitabine|"Phase I:~Dose Level 1 - 900 mg/m2 Dose Level 0 - 900 mg/m2 Dose Level -1 - 750 mg/m2 Dose Level -2 - 675 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab ) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
223395497|NCT04577014|DRUG|Docetaxel|"Phase I:~Dose Level 1 - 75 mg/m2 Dose Level 0 - 75 mg/m2 Dose Level -1 - 60 mg/m2 Dose Level -2 - 50 mg/m2~The dose level with ≤ 1 DLT seen per patients will be declared the RP2D.~Phase II: Participants will be treated with the RP2D of gemcitabine/docetaxel (when administered in combination with Retifanlimab) for cycle 1, with Retifanlimab added on cycle 2 day 1 at a flat dose of 375mg. Gemcitabine/docetaxel will continue for 5 additional cycles (total of 6 cycles),"
223395498|NCT05838690|OTHER|Personalized Intubation Safety (PINS) Bundle|The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
223549342|NCT01091714|DIETARY_SUPPLEMENT|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
223549343|NCT03272386|OTHER|Observational study|Completing a questionnaire
223549344|NCT05915195|OTHER|Postural and Kinesthetic Awarness|Firstly, patient performed therapeutic activities/exercise to achieve balance in sitting position using chair with arm rest and with planted feet then progressed to sitting on chair without arm rest with proper feet placement. Once the patient achieved balance in sitting on chair then shifted to sitting on the stool and later standing in parallel bar that leads to balance training in independent standing.
224014977|NCT03280147|DRUG|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
224014978|NCT05674487|DEVICE|Trans-cervical balloon|Induction of labor by cervical ripening with trans-cervical balloon (Foley catheter).
224014979|NCT05674487|DRUG|Misoprostol|Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
223395499|NCT02243605|DRUG|Cabozantinib S-malate|Given PO
223395500|NCT02243605|OTHER|Laboratory Biomarker Analysis|Correlative studies
223395501|NCT05047926|BEHAVIORAL|Behavioral Counseling|Undergo behavioral counseling
223395502|NCT05047926|DIETARY_SUPPLEMENT|Nutritional Supplement Drink|Given Boost or Ensure
223395503|NCT05047926|OTHER|Physical Activity|Complete physical activity assignments
223395504|NCT05047926|OTHER|Survey Administration|Complete surveys
223395505|NCT05047926|PROCEDURE|Computed Tomography|Undergo CT scans
223395506|NCT05047926|PROCEDURE|Biospecimen Collection|Undergo blood collection
223395507|NCT05047926|BEHAVIORAL|Health Education|Complete Resilient Living program
223549345|NCT05915195|OTHER|Routine Physical Therapy|Range of motion exercises (Active assisted), stretching exercises, strengthening and positioning.
223549346|NCT05236179|OTHER|Integrative therapies|Integrative therapy methods used at the Filderklinik, such as music therapy, therapeutic painting, therapeutic sculptural forming, speech therapy, eurythmy therapy, rhythmical massage, external applications, coloured light therapy
223731027|NCT03520231|DRUG|Denosumab|RANK Ligand Inhibitor
223395508|NCT05047926|OTHER|Medical Device Usage and Evaluation|Wear a FitBit
223395509|NCT06266182|BEHAVIORAL|Acceptance and Commitment Therapy|ACT intervention will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive a web-based intervention consisting of educational and practical tasks/activities. Participants will learn to recognize moments of choice (actions that lead towards values or away from them) and to use attention flexibly to free themselves from the power of thoughts, to open up and accept emotions, and to be able to determine what is important and take action in line with values. All of the tasks will be available in written form and audio. The ACT intervention is built from standard ACT exercises.
223395510|NCT06266182|BEHAVIORAL|Education|Education will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive information about post-transplant prescriptions along with exercises to support the implementation. Participants will learn about nutrition, personal hygiene, preventing infections, coping with fatigue, resuming activity, rest and sleep, engaging in social interactions, and sexual health. The content is prepared based on available guides for HCT recipients.
223731028|NCT03520231|OTHER|Denosumab Placebo|Placebo
223395511|NCT03587402|OTHER|Transcutaneous perineal stimulation|Surface stimulation
223731029|NCT03520231|DRUG|Gemcitabine|Antineoplastic Agent
223731030|NCT03520231|DRUG|Carboplatin|Antineoplastic Agent
223731031|NCT03520231|DRUG|Cisplatin|Antineoplastic Agent
224014980|NCT06643039|BIOLOGICAL|Nasopharyngeal swab|Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.
224128164|NCT02687594|DRUG|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
224128165|NCT04634240|PROCEDURE|Percutaneous Coronary Intervention (PCI)|PCI of all qualifying lesions.
223395512|NCT03587402|OTHER|Anal stimulation|Intra-cavitary stimulation
223395513|NCT05673980|DRUG|Vitamin D2|Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
223395514|NCT05673980|OTHER|placebo|This group will not do any intervention
223395515|NCT00632268|DRUG|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
223395516|NCT00663936|DRUG|T-817MA|224 mg T-817 MA once daily
223395517|NCT00663936|DRUG|Placebo|Placebo once daily
223395518|NCT05304130|BIOLOGICAL|Otilimab|Otilimab will be administered via pre-filled syringe.
223549347|NCT04050787|PROCEDURE|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
224014981|NCT06643039|OTHER|Questionnaire|questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
224014982|NCT00867308|DRUG|Lenalidomide 50 mg|
224014983|NCT00867308|DRUG|Lenalidomide 15 mg|
224014984|NCT00604825|DRUG|Other: Placebo|
224014985|NCT00604825|DRUG|GSK232802|
224014986|NCT00604825|DRUG|PREMARIN|
223395519|NCT06492135|DRUG|survodutide|survodutide
223395520|NCT06356714|DRUG|Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens|"Nocardia Rubra Cell Wall Skeleton 200 mcg-400 mcg, 0.3 ml diluted in water for injection or lidocaine, was injected subcutaneously every 2 or 3 weeks.~Efficacy was evaluated every 2 cycles according to RECIST 1.1 criteria. Patients are enrolled and given this study regimen of drugs on top of their prior second- or third-line regimen until disease progression or intolerable toxicities occur; or the patient requests to be discharged."
223395521|NCT01034202|DRUG|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
223395522|NCT01034202|DRUG|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
223395523|NCT01034202|DRUG|placebo|Placebo comparator
223395524|NCT01034202|DRUG|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
223395525|NCT01034202|DRUG|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
223395526|NCT04553731|BEHAVIORAL|empowerment program with mHealth|empowerment program with mHealth
223395527|NCT04606212|DRUG|Losartan|administration of losartan (50 mg) (oral)
223395528|NCT04606212|DRUG|Placebo Oral Tablet|administration of placebo (oral)
223395529|NCT02019472|BIOLOGICAL|adalimumab 40 mg|SC injections
223395530|NCT02019472|BIOLOGICAL|sirukumab 100 mg|SC injections
223395531|NCT02019472|BIOLOGICAL|sirukumab 50 mg|SC injections
223395532|NCT02019472|DRUG|Placebo|SC injections
223395533|NCT01441024|DRUG|DAS181|20 mg per day of DAS181-FO3 for 5 days
223395534|NCT01441024|OTHER|Placebo|20 mg per day of Lactose for 5 days
223731032|NCT03520231|DIETARY_SUPPLEMENT|Calcium|Calcium Supplement
223731033|NCT03520231|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D Supplement
224014987|NCT05853380|DEVICE|Informed Vital Core App|All subjects assigned to a single arm, pulse rate measurement will be collected, calculated, and displayed on the web based application. A conventional ECG device will also be used to collect and display the heart rate at the same time. If additional consent is obtained subjects may provide blood pressure and SpO2 measurements for the web based application.
224014988|NCT02604875|OTHER|observation|blood sampling during 24 hours
224014989|NCT02549105|DRUG|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
224014990|NCT02549105|DRUG|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
224014991|NCT06509815|DEVICE|MIRA|The study device is a Multi-Sensory Stimulation Device named MIRA, which uses commercially available hardware and builds off the SOLUNA software created by Studio Elsewhere. The device produces audio and visual stimuli of immersive experiences. Participants in the intervention group will either have periodic or scheduled intervention sessions. The study team member will roll the MIRA device into the patient participant's room before the session and roll it out after. The intervention requires the participant to be in bed. The study team member will set up the device and start the intervention session which can last between 15-60 minutes. During the session, data will be collected by the study team member.
224014992|NCT00695032|DRUG|cisplatin|
224014993|NCT00695032|DRUG|ifosfamide|
224128166|NCT07083167|OTHER|No Interventions.|No interventions.
224128167|NCT07083570|BEHAVIORAL|Active scapular repositioning|The examiner will first passively position the participant's scapula in a neutral position on the posterior chest wall. The participant will then be instructed to actively maintain that position.
224128168|NCT07083570|PROCEDURE|Passive scapular repositioning|The examiner will passively position and hold the participant's scapula in a neutral position.
224128169|NCT07083570|PROCEDURE|Sham scapular repositioning|The examiner will perform gentle shoulder girdle movements that do not alter scapular positioning.
224128170|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 1.~Subject will receive placebo at dose level 1."
224128171|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 2.~Subject will receive placebo at dose level 2."
224128172|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 3.~Subject will receive placebo at dose level 3."
224128173|NCT07083362|DRUG|HRS-8829;Placebo|"Subject will receive HRS-8829 at dose level 4.~Subject will receive placebo at dose level 4."
223395535|NCT02813655|DRUG|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
223395536|NCT02813655|DRUG|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
223395537|NCT05418881|DEVICE|Mobile Tracking Device (one spot)|Patients will be fitted with 4 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, FitBit Sense®, Withings ScanWatch®).
223395538|NCT05418881|DEVICE|Mobile Tracking Device + Activity Sensor (longitudinal)|Patients will be fitted with 1 of 3 different tracking devices (Garmin Fenix 6 Pro®, Apple Watch 7®, Withings ScanWatch®). The type of tracking device will be randomized. Additionally an Activity Tracker and one-channel ECG (Movesense®) will be worn by the patients.
223395539|NCT00172172|DRUG|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
223395540|NCT00172172|DRUG|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
223395541|NCT00172172|DRUG|placebo|Placebo injected subcutaneously and 700 mg calcium orally
223395542|NCT04469075|DRUG|Clindamycin Phosphate|phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
223395543|NCT04469075|DRUG|Triamcinolone Acetonide|triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
223395544|NCT04680026|DRUG|HBI-3000|Small molecule, multi-ion channel blocker
223395545|NCT04680026|DRUG|Placebo|Normal saline
223395546|NCT03364725|DRUG|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
223395547|NCT05688566|DEVICE|pinnacle trainer|The pinnacle trainer (S776MA, SportsArt, Taiwan) was used in this study.
223395548|NCT06578546|DRUG|Venetoclax|100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.
223395549|NCT06578546|DRUG|Azacitidine|75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.
223395550|NCT06578546|DRUG|Orebatinib|20mg qod, d4-d21, oral, every 28 days for a treatment cycle.
223731034|NCT03899142|BIOLOGICAL|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
223731035|NCT01431833|DRUG|TR-701 FA|Oral single dose 200 mg
223731036|NCT00301574|DRUG|galantamine|
224014994|NCT00695032|OTHER|laboratory biomarker analysis|
224014995|NCT05772273|DRUG|Azacitidine|Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7.
223395551|NCT05023447|BEHAVIORAL|BRIDGE Intervention|Intensive clinical assessment; \>16 sessions of Cognitive Analytic Therapy (CAT); Development of a shared formulation
223395552|NCT05023447|BEHAVIORAL|Service as Usual|Likely to range from social services, mental-health services, forensic services to no intervention
223731037|NCT01463878|DIETARY_SUPPLEMENT|Glycerna|Diabetes specific formula
223731038|NCT01463878|DIETARY_SUPPLEMENT|Jevity - Control Diet|Control Diet
223395553|NCT00200447|DRUG|carbidopa/l-dopa|
223395554|NCT00200447|DRUG|carbidopa/l-dopa/entacapone|
223731039|NCT02461108|BEHAVIORAL|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
223395555|NCT00200447|DRUG|Stalevo|
223395556|NCT00200447|PROCEDURE|[123I]-IBZM imaging|
223395557|NCT03014583|DEVICE|Precision Spectra™ system|Neurostimulation procedures
223395558|NCT00726856|DRUG|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
223731040|NCT02461108|BEHAVIORAL|Tax|Frame the price difference as a 10% tax on less nutritious food items.
223395559|NCT01449656|DEVICE|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
223395560|NCT01449656|DEVICE|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
223395561|NCT02806908|DRUG|JZP-110|
223395562|NCT02806908|DRUG|Placebo|
223395563|NCT04404543|DRUG|SYHA1807|Escalation Cohort Administration: Orally
223395564|NCT04404543|DRUG|SYHA1807|Dose Expansion Cohort Administration: Orally
223395565|NCT05319925|OTHER|Patient reported outcome measure|Newly developed patient-reported instrument to measure financial effects of a cancer diagnosis and therapy of cancer patients in Germany
223395566|NCT04886583|DEVICE|Gabi Baby Band|Every enrolled patient must wear the Gaby Baby Band on the left arm in the aim to perform data analytics after the test has been performed
223731041|NCT02461108|BEHAVIORAL|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
223731042|NCT01262950|OTHER|portable motion detector|
223731043|NCT00052208|DRUG|gefitinib|Given PO
223731044|NCT00052208|RADIATION|radiation therapy|Undergo radiation therapy
223731045|NCT00052208|OTHER|laboratory biomarker analysis|Correlative studies
224014996|NCT05772273|BIOLOGICAL|Donor lymphocyte infusion|The 4 DLI doses (dose range: ±10%) of sib-matched donor HSCT patients were 1×10\^6/kg, 5×10\^6/kg, 1×10\^7/kg, 5×10\^7/kg; The 4 DLI doses (dose range: ±10%) of haploidentical or unrelated donor HSCT patients were 1×10\^5/kg, 5×10\^5/kg, 1×10\^6/kg, 5×10\^6/kg.
224014997|NCT05772273|DRUG|Camrelizumab|Camrelizumab 200mg Q2W for sib-matched donor HSCT patients, 100mg Q2W for haploidentical or unrelated donor HSCT patients.
224014998|NCT05708807|OTHER|Observational - all|All stroke patients are included.
223395567|NCT04931030|OTHER|Dietary advice|Subjects are provided dietary advice by the dietitians as part of the research team/ investigators
223395568|NCT06152562|DIAGNOSTIC_TEST|VerifyNow antiplatelet therapy response test|VerifyNow testing after minimum of 2 hours and at latest 24 hours after the first four dosis of ASA
223395569|NCT04651855|DRUG|Mesenchymal stem cells isolated from Wharton's jelly|Intrathecal administration of mesenchymal stem cells
223549348|NCT04050787|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
223549349|NCT00711048|DRUG|AZD1386|oral, single dose
223549350|NCT00711048|DRUG|Placebo|Oral solution, single dose
223549351|NCT06260631|DEVICE|high-intensity laser acupuncture and Exercise therapy program|"The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
223549352|NCT06260631|OTHER|Sham laser acupuncture|"Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises."
223549353|NCT05999630|DRUG|Artificial Tears Methylcellulose|Participants will self-administer the artificial tears according to the schedule.
223549354|NCT05740527|DEVICE|Noninvasive electrical stimulation of genital nerves|A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
223549355|NCT03722420|DRUG|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
223549356|NCT03722420|DRUG|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
223549357|NCT02709512|DRUG|ADI-PEG 20 plus Pem Platinum|Investigational Drug in combination approved standard of care treatment for this indication
224014999|NCT03691480|PROCEDURE|simple exsufflation|simple exsufflation
224015000|NCT03691480|PROCEDURE|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
223395570|NCT00381082|DRUG|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
223395571|NCT00381082|DRUG|Banlice Mousse Aerosol (Pfizer, Australia)|
223395572|NCT00381082|DRUG|3) KP24 Medicated Foam (Nelson Laboratories)|
223395573|NCT04445272|DRUG|Tocilizumab|Treatment with Tocilizumab
224015001|NCT04906252|DIAGNOSTIC_TEST|Echocardiography|Patients presenting in cardiac arrest will undergo echocardiography as is the standard of care at their institution
224015002|NCT04906252|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|Patients presenting in cardiac arrest will undergo an electrocardiogram (ECG) as is the standard of care at their institution
224015003|NCT04502732|OTHER|NSSM and GEBT|The time to half gastric emptying (T1/2) will be assessed via Gastric Emptying Breath Tests (GEBT) and Nuclear Scintigraphy of a Solid Meal (NSSM) at baseline, 2 months, and 6 months. This data will be collected from seven adult subjects, with obesity, who have recently received Endoscopic Bariatric and Metabolic Therapy.
224015004|NCT00452023|DRUG|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
224015005|NCT06180031|DRUG|Pericapsular nerve group block using bupivicaine and magnesium sulphate|This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus
223395574|NCT04961385|BIOLOGICAL|Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine|Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
223549358|NCT02709512|OTHER|Placebo plus Pem Platinum|Placebo in combination approved standard of care treatment for this indication
224015006|NCT03387137|BIOLOGICAL|RSV 6120/∆NS2/1030s|Delivered as nose drops
224015007|NCT03387137|BIOLOGICAL|Placebo|Delivered as nose drops
223395575|NCT01760304|DRUG|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
223731046|NCT01558830|DRUG|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
224015008|NCT05574517|PROCEDURE|Without reverse insertion of a ureteral catheter|Traditional tubeless percutaneous nephrolithotomy usually need retrograde ureteral catheter insertion. Our intervention is that the tubeless percutaneous nephrolithotomy is executed without reverse insertion of a ureteral catheter.
224015009|NCT05248906|DIAGNOSTIC_TEST|Giant cell arteritis|Ultrasound 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Temporal artery biopsy
224128174|NCT07079163|DEVICE|Obturator block|A manually fabricated obturator using a preoperative maxillary cast, retained with clasps and wire. Delivered immediately after maxillectomy.
223395576|NCT01760304|DRUG|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
223395577|NCT04429503|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
223395578|NCT04429503|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
224128175|NCT07079163|DEVICE|Obturator block|A digitally designed obturator based on fused CBCT and intraoral scan data. Fabricated in resin using 3D-printing, and retained with 3D-printed clasps and palatal screws. Delivered immediately post-maxillectomy
224128176|NCT07079163|DEVICE|Obturator block|A digitally designed and 3D-printed obturator fabricated in metal, using CBCT and intraoral scan data. Retention is provided by metal clasps and palatal screws. Delivered during or immediately after surgery.
224015010|NCT05578274|RADIATION|SBRT + LDRT|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions.~LDRT is planned to irradiate EQD2 (α/β=10) 6 Gy to lesions, considering the scattered dose caused by SBRT.~If there are non-irradiated lesions, they are defined as internal control, and the total dose is limited to 0.5 Gy or less.~CTV allows up to 5 mm margin for GTV, and 3-10mm for PTV margin from CTV. It is planned that the iso-dose line corresponding to the prescribed dose contains at least 90% of PTV and 95% of GTV."
224015011|NCT05578274|RADIATION|SBRT alone|"SBRT is performed according to the protocol of each institution. However, the total fraction of SBRT is fixed to 3, and the treatment interval is maintained for 1-2 days.~The scattered dose should not exceed EQD2 (α/β=10) 2 Gy for non-irradiated lesions."
224015012|NCT02979405|DRUG|Phenylephrine|prophylactic infusion of phenylephrine 40 mcg/min
224015013|NCT04153838|OTHER|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
224015014|NCT03831386|PROCEDURE|Vacuum-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.
224015015|NCT03831386|PROCEDURE|Gravity-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
224015016|NCT05444894|GENETIC|EDIT-301|Administered by intravenous infusion after myeloablative conditioning with busulfan.
224015017|NCT06611332|OTHER|Electroacupuncture|The main acupoints selected for the electroacupuncture group are bilateral BL23, bilateral BL25, bilateral GB30, bilateral LR11, bilateral LR8, GV4, GV3, and the affected BL40, and the secondary acupoints selected are bilateral BL54, the affected side BL57 and the affected side BL60.The treatment will be administered once every other day for 30 minutes each time, lasting for 8 consecutive weeks, totaling 24 sessions.
224015018|NCT06611332|OTHER|Sham electroacupuncture|In the sham electroacupuncture group, the acupoints will be at a position 2 cm lateral to the correct acupoints horizontally. The dosage and treatment course are the same as those in the electroacupuncture group.
224128177|NCT07074314|OTHER|Laughter yoga|"Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes."
224128178|NCT00488618|DRUG|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
223395579|NCT06094699|OTHER|Sleep friendly order set|"Every evening, the following orders (which comprise the sleep-friendly order set) will be input into the EMR:~Hold vital signs and neurological checks overnight Retime applicable medications outside of the nighttime window of 10pm-6am Retime daily lab draws outside of the nighttime window of 10pm-6am Order melatonin if no clinical contraindications Discontinue finger stick glucose measurements for patients with a stable blood glucose values Change DVT prophylaxis to enoxaparin for all clinically eligible patients"
223395580|NCT06094699|OTHER|Patient sleep menu|Patients will be given a menu of non-pharmacological options that support sleep by improving comfort and reducing anxiety.
223395581|NCT06161194|OTHER|Supervised group exercise therapy|Participants will participate in a 90 minutes supervised group exercise therapy program 2 times a week for 8 consecutive weeks.
223395582|NCT05516108|BEHAVIORAL|Mindfulness|The mindfulness intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific meditation techniques through didactic explanation and guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention on the intended target, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts build on the skills trained in each lesson, encouraging participants to practice brief moments of mindful awareness, mindfulness while doing daily tasks, or formal meditation.
223395583|NCT05516108|BEHAVIORAL|Coping|The coping intervention includes 14 daily 20-minute audio lessons plus brief daily practice prompts. Lessons train specific coping techniques through didactic explanation and guided practice. Lessons train coping skills (reflection, reappraisal, and problem solving) without encouraging focus on or acceptance of present experience (i.e., mindfulness skills). Participants are instructed to: (1) reflect and let their minds drift, (2) reframe or reappraise past and anticipated events, and (3) analyze and solve personal problems. Practice prompts build on the skills trained in each lesson, encouraging participants to take brief reflection breaks or to practice reappraisal or problem-solving skills.
223395584|NCT05413343|DRUG|Ceftazidime-avibactam|Patients with severe sepsis and treatment with CAZ-AVI will be enrolled. Blood samples at 0 hour, 2 hours, 4 hours, 6 hours, and 8 hours after the first time and the steady state concentration(more than 4 times drug administration) of drug administration will be collected to detect plasma drug concentrations of CAZ-AVI
223395585|NCT04150939|PROCEDURE|Core Biopsy|Undergo core biospy
223395586|NCT04150939|PROCEDURE|Cryosurgery|Undergo cryoablation
223395587|NCT04150939|DRUG|Immunotherapeutic Agent|Receive standard of care immunotherapy
223395588|NCT06853184|DRUG|Artesunate|Low Dose Artesunate: 2.4 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices High Dose Artesunate: 4.8 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices
223731047|NCT01558830|DRUG|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
223549359|NCT04115514|DRUG|Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.|"Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway."
223549360|NCT04115514|OTHER|Non-intervention|Standard of Care (SOC)
223549361|NCT03609502|BEHAVIORAL|behavioral training|the participants will be trained to perceive a non-native speech contrast
223549362|NCT05497739|DRUG|Intraperitoneal chemotherapy|5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
223549363|NCT05497739|DRUG|Adjuvant systemic chemotherapy|Oxaliplatin 85 mg/m\^2 on Day 1; S-1 depends on Body Surface Area (BSA), 40 mg Bid, Days 1-10 (BSA \< 1.25 m\^2), 50 mg Bid, Days 1-10 (BSA 1.25-1.50 m\^2), 60 mg Bid, Days 1-10 (BSA \> 1.50 m\^2).
223549364|NCT05567445|DIAGNOSTIC_TEST|Echocardiography, CBC, Liver function, kideny function|Echocardiography, AST, ALT, UREA,CREAT. , CBC,may blood cultures.
223549365|NCT05415553|PROCEDURE|IOBT|Surgery of inferior oblique muscle belly transposition for treatment of primary position hypertropia with inferior oblique overaction
223549366|NCT05415553|PROCEDURE|IO-Rec|Surgery of inferior oblique muscle recession for treatment of primary position hypertropia with inferior oblique overaction
223549367|NCT00348478|BEHAVIORAL|water and health education program to improve hygiene|
223549368|NCT00240812|DRUG|ibuprofen; pseudoephedrine HCl|
223549369|NCT03902015|DEVICE|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
223549370|NCT02499627|DRUG|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
223549371|NCT02499627|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
223549372|NCT05153603|DRUG|Olaparib mono-maintenance therapy|Olaparib mono-maintenance therapy in patients with newly diagnosed, histologically confirmed, advanced (FIGO stage III-IV) ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer is defined as drug exposure. At least one dose of olaparib tablets monotherapy as maintenance therapy will be required.
223549373|NCT01184703|OTHER|Low GI food|Comparison of carbohydrates in diabetic patients
223549374|NCT01434901|DRUG|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
223549375|NCT01434901|DRUG|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
223549376|NCT01434901|DRUG|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
223549377|NCT01434901|DRUG|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
223549378|NCT05400850|OTHER|YOGA|Five different YOGA Asana's will made randomly
223549379|NCT05124028|DRUG|Orelabrutinib|50mg po qd 6 weeks
223549380|NCT04737356|BEHAVIORAL|Cognitive behavior therapy|Internet-based CBT intervention based on CBT theory as well as self-determination therapy for low self-esteem among adolescents.
223549381|NCT04322409|DEVICE|Neuromuscular Electrical Stimulation|"5 sessions that consist of NMES over the peroneus longus muscle. This consists of a biphasic current with a phase duration of 240us delivered in a frequency of 75 pules per second, with a ramp-up time of 2-seconds, followed by a 50-s rest period (no stimulation). Each cycle will consist of 10 seconds of on time, and 50 seconds off, with 10 cycles being performed each session."
223549382|NCT04322409|DEVICE|Transcutaneous Electrical Nerve Stimulation|5 sessions that consist of 11-minutes of TENS over the skin of the peroneus longus. This consists of a biphasic current will be continuously applied at 100 pulses per second, with a phase duration of 100us for 10 minutes. The intensity will be turned up until the point the subjects feel the current (sensory threshold)
223549383|NCT01895400|DRUG|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
224015019|NCT06611878|BEHAVIORAL|Music training - intensive|Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered twice a week for 5 months.
224128179|NCT00488618|DRUG|Placebo|Dose-matched placebo oral administration, once per day.
224128180|NCT07083661|BEHAVIORAL|Mindfulness-based intervention on parent empowerment in reducing children's screen time (MORE)|Participants will receive a 6-week MORE group training by integration of mindfulness-based component into a modified Hands-on Parent Empowerment-20 (HOPE-20) programme.
223549384|NCT01895400|DRUG|Placebo|Take placebo drug 1T bid po medication for 8 weeks
223549385|NCT01384565|DRUG|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
223549386|NCT01384565|DRUG|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
223395589|NCT06853184|DRUG|Ganciclovir (GCV)|Standard Treatment Ganciclovir: GCV or VGCV and SOC per local institutional practices
223395590|NCT06852807|DRUG|18F-MFBG|Patients with neuroblastoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
223395591|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
223395592|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
223549387|NCT05254990|DRUG|Reparixin|Reparixin 600 mg tablets, administered orally at the dose of 1200 mg TID (2 tablets TID) as add-on therapy to standard of care up to 21 days. IMP can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that reparixin is taken with food. However, if the patient is unable to eat, the study drug may still be administered without concomitant food ingestion.
223549388|NCT05254990|OTHER|Placebo|"Administered orally three times a day (TID) as add-on therapy to standard of care up to 21 days.~Placebo can be taken with a glass of water (about 250 mL) and a light meal or snack, as it is preferable that placebo is taken with food. However, if the patient is unable to eat, the placebo may still be administered without concomitant food ingestion."
223549389|NCT05464238|OTHER|Exercise rehabilitation|The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.
223549390|NCT05464238|OTHER|Standard treatment|Standard treatment during study duration
223549391|NCT04015817|OTHER|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
223549392|NCT03293355|BEHAVIORAL|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
223549393|NCT00284414|PROCEDURE|Ultrasonography or MRI|
223549394|NCT05881486|DRUG|Ondansetron 8mg|8 mg Ondansetron+100 ml normal saline
223549395|NCT05881486|DRUG|Fosaprepitant 150 mg|150 mg fosaprepitant +100 ml normal saline
223731048|NCT01738763|DIETARY_SUPPLEMENT|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
223395593|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, intravenous injection for 60 to 90 minutes. Every 2 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
223549396|NCT05148936|OTHER|COVID-19 Testing Home-based (Aim 1)|Implementation of Antigen and PCR testing at participant homes
223549397|NCT05148936|OTHER|COVID-19 Testing Mobile (Aim 1)|Implementation of Antigen and PCR testing at mobile test sites
223549398|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 1 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - active outreach
223731049|NCT02436889|DRUG|Mirabegron|
223731050|NCT02436889|DRUG|Tolterodine Tartrate|
224128181|NCT07083687|DRUG|Lorlatinib 100 mg|After enrollment, patients will receive 100 mg of lorlatinib orally once daily until disease progression, unacceptable toxicity, or withdraw study .
223549399|NCT05148936|OTHER|COVID-19 Testing Mobile Approach 2 (Aim 2)|Implementation of Antigen and PCR testing at mobile test sites - baseline outreach
224128182|NCT07082361|DIAGNOSTIC_TEST|conventional clinical criteria of weaning from mechanical ventilation|Patients will be weaned after fulfilling the conventional clinical criteria of weaning from mechanical ventilation by using spontaneous breathing trials
224128183|NCT07082361|DIAGNOSTIC_TEST|conventional clinical criteria and ultrasonic criteria for weaning|Patients will be weaned using the conventional clinical criteria and ultrasonic criteria for weaning.
223549400|NCT04401150|DRUG|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
223549401|NCT04401150|DRUG|Control|Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
223731051|NCT02843932|OTHER|functional brain MRI|functional imagery during motor-perception tasks
223731052|NCT01806324|DRUG|HL040XC|single dose
223731053|NCT01806324|DRUG|Losartan + Atorvastatin|Single dose
223731054|NCT04913025|DRUG|Nivolumab|60-minute IV infusion, as a flat dose of 480mg
223731055|NCT04913025|DRUG|Pembrolizumab|60-minute IV infusion, as a flat dose of 400mg
223731056|NCT00479661|DRUG|Dexmedetomidine|Continuous infusion
223731057|NCT00479661|DRUG|Propofol|Continuous infusion
223731058|NCT05066373|DRUG|EDP1815 capsule A|EDP1815 capsule A is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
223395594|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg,q3w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, intravenous injection for 60 to 90 minutes. Every 3 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
223549402|NCT01420224|OTHER|Commercial airline flight|Normal scheduled passenger flight
223549403|NCT06253455|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
224015020|NCT06611878|BEHAVIORAL|Music training - minimal|Music training entails learning novel songs the participant chooses from a list. Songs are similar in complexity and length (number of words, high frequency words, harmony, musical complexity, length of verses and chorus). Offering a variety of songs allows to examine memory performance regardless of the specific song chosen. Sessions last 30 to 40 minutes, conducted based on a manual (1. mood observation; 2. warm-up; 3. teaching the chorus, observed liking of song; 4. singing entire chorus; 5. singing chorus in context, 6. session closure with favourite song; 7. final mood observation; session rating), and are video-recorded. External evaluators audit the sessions video recordings to determine adherence to the manual. Sessions are offered once a month for 5 months.
224015021|NCT06611878|OTHER|Treatment as Usual (TAU)|Medications, behavioural interventions and other treatments that participants may receive outside the study during the period of participation.
224015022|NCT05202210|BIOLOGICAL|blood and urine sampling|extra sample of blood and urine will be collected
224015023|NCT06675825|DEVICE|BougieCap|The BougieCap is attached to the tip of the endoscope, offers direct visual and tactile control and the endoscope acts as a carrier of the radial and longitudinal force vectors for the dilation.
224015024|NCT06675825|DEVICE|Savary-Bougie (A) or balloon dilation (B)|"A: In the Savary- Bougie treatment, dilators of different sizes are advanced to dilate the stenosis. The same procedure is then repeated with the next larger dilator, with the position of the dilator being checked radiologically each time.~B: In the case of balloon dilation, a balloon is inserted and inflated at the level of the stenosis. Depending on the age of the child and possibly also the etiology of the stenosis, different balloons sizes are applied, which are then maintained inflated for about one until three minutes and the respective pressure. This procedure could take place under endoscopic or radiological control."
224128184|NCT07082413|OTHER|Nutritional Intervention|This study will follow a randomized controlled trial design aimed at evaluating the impact of nutritional intervention on personal satisfaction and perceived quality of life. The protocol includes two assessment points: a baseline measurement at the start of the intervention (Day 0) and a second measurement after a follow-up period (Day 90), allowing for the analysis of with-in-subject changes associated with the intervention.
223395595|NCT05345522|BIOLOGICAL|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q3w|Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, intravenous injection for 60 to 90 minutes. Every 3 weeks is a cycle, the first day of each cycle is administered, a total of ≥ 4 cycles.
223395596|NCT04618731|DIAGNOSTIC_TEST|caries prevalence def ,DMF|the examination will carried out on dental chair using diagnostic set
223395597|NCT03197441|OTHER|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
223395598|NCT03650699|DEVICE|Electropalatography Biofeedback Training|The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
223395599|NCT05637216|DRUG|Losartan 25 milligram capsule|Losartan 25 milligram oral capsule
223395600|NCT05637216|DRUG|Placebo|Placebo 25 milligram oral capsule
223395601|NCT02207205|DRUG|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
223395602|NCT02862015|OTHER|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
223395603|NCT02862015|DRUG|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
223395604|NCT01138787|DIETARY_SUPPLEMENT|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
223395605|NCT01138787|DIETARY_SUPPLEMENT|Placebo spread|Single dose (30 gr) of regular light margarine
223395606|NCT01138787|DIETARY_SUPPLEMENT|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
223395607|NCT05051735|DRUG|Paracetamol|Paracetamol 500 mg
223395608|NCT05051735|DRUG|Placebo|Placebo
223395609|NCT02003209|DRUG|Aromatase Inhibition Therapy|Given at the investigator's discretion
223395610|NCT02003209|DRUG|Carboplatin|Given IV
223549404|NCT00795444|DRUG|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
223549405|NCT01897727|DRUG|Spironolactone|
223549406|NCT01897727|DRUG|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
223395611|NCT02003209|OTHER|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
223395612|NCT02003209|DRUG|Docetaxel|Given IV
223395613|NCT02003209|DRUG|Goserelin Acetate|Given SC
223549407|NCT01391689|DIETARY_SUPPLEMENT|diindolylmethane|Given PO
223549408|NCT01391689|DIETARY_SUPPLEMENT|placebo|Given PO
223549409|NCT02424500|DEVICE|d-Nav|Insulin dosage is adjusted as required
223549410|NCT02424500|DEVICE|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
223549411|NCT05211674|OTHER|quantified analysis of postural control during activities of daily living|functional tests that reproduce tasks of daily living (timed up and go test with and without dual cognitive task, modified Glittre ADL test)
223549412|NCT06474000|BEHAVIORAL|Oxytocin induction group|"Participants in the oxytocin induction group filled out the Information Form at the time of application to the delivery room. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
223549413|NCT06474000|BEHAVIORAL|Control group|"Participants in the control group filled in the Information Form when they applied to the birth centre. Routine care was performed. ALPS-Neo was filled before, during and at 5 minutes after the drying of the newborn within 1-40 minutes after birth. ALPS-Neo was filled before, during and 5 minutes after the first injection. ALPS-Neo was filled before, during and 5 minutes after the blood glucose measurement procedure."
223549414|NCT00395070|BIOLOGICAL|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
223549415|NCT00395070|DRUG|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
223549416|NCT00395070|DRUG|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
223549417|NCT04776616|DEVICE|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day
223549418|NCT04776616|DEVICE|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day
223549419|NCT00212875|DRUG|epoetin alfa|
223549420|NCT00078806|DRUG|Etanercept|Administered by subcutaneous injection twice a week
223549421|NCT00078806|DRUG|Placebo|Administered by subcutaneous injection twice a week
223549422|NCT02200757|DRUG|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
224128185|NCT07083258|DEVICE|Progressive Inspiratory Muscle Training (IMT)|The intervention involves the application of inspiratory muscle training using the POWERbreathe Plus device. Training will be conducted at an initial intensity of 50% of the individual's MIP and will be increased weekly by 10%, reaching 80% by week four. Sessions will take place 5 days per week and consist of 2 sets of 30 repetitions per day, with 2-minute rest intervals between sets. This training aims to improve inspiratory muscle strength and endurance, as well as core stability, respiratory function, dynamic balance, and trunk isokinetic strength.
223549423|NCT02200757|DRUG|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
223549424|NCT01734785|DRUG|Linagliptin|tablet
223549425|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
223549426|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
223549427|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination
223549428|NCT01734785|DRUG|Empagliflozin placebo + Linagliptin placebo|Matching Empagliflozin + Linagliptin low dose
223549429|NCT01734785|DRUG|Empagliflozin + Linagliptin|Fixed dose combination.
223549430|NCT01212887|BIOLOGICAL|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
223549431|NCT01212887|BIOLOGICAL|aldesleukin|
223549432|NCT01212887|DRUG|cyclophosphamide|
223549433|NCT01212887|DRUG|fludarabine phosphate|
223549434|NCT01212887|OTHER|laboratory biomarker analysis|
223549435|NCT01212887|OTHER|pharmacological study|
223549436|NCT00566982|DRUG|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
223549437|NCT00566982|DRUG|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
223549438|NCT04994028|OTHER|Conventional treatment|Behavioral and life style modification and dyspnea prevention education i.e. Sitting: Sit upright with back against chair, feet wide apart, leaning forward with arms on bedside table or on knees. Standing: Lean back against wall with feet slightly apart with head and shoulder relaxed. In Bed: Elevate head of the bed, support and elevate arms with pillow. Stairs: Lean forward with on banister when climbing stairs.
223549439|NCT04994028|OTHER|conventional treatment with volume Spirometry and deep breathing|Group B or interventional group was received conventional treatment along with volume Spirometry and deep breathing exercise, total 5 breaths with 3sec inhalational breath hold for each breath at one session per day for volume Spirometry and for deep breathing exercise 10 times with breath hold 2sec at every session for 5 minutes 3 times per week for total duration of two weeks.
223549440|NCT05754398|BEHAVIORAL|six independent and interconnected educational training sessions|"Each of the six components will be offered each month for six consecutive months. Each session will last approximately 30 to 40 minutes.~All the six sessions will be delivered through a face-to-face approach."
223549441|NCT02476032|DEVICE|Prof applied oxalate|Crest Sensi-Stop strips (Procter \& Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
223549442|NCT02476032|DEVICE|Self applied oxalate|Subjects will apply the strips (Procter \& Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
223549443|NCT02476032|DEVICE|Prof applied placebo|Crest Sensi-Stop strips (Procter \& Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
223549444|NCT04875468|OTHER|TheraCem self-adhesive resin cement|MDP, calcium and fluoride releasing cement for dental zirconia crowns
223549445|NCT04875468|OTHER|Multilink adhesive resin cement|(non MDP, non-calcium and fluoride releasing cement)
223549446|NCT03127917|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline capsules given at 6 g/day
223395614|NCT02003209|OTHER|Laboratory Biomarker Analysis|Correlative studies
223395615|NCT02003209|BIOLOGICAL|Pertuzumab|Given IV
223395616|NCT02003209|OTHER|Quality-of-Life Assessment|Ancillary studies
223395617|NCT02003209|PROCEDURE|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
223395618|NCT02003209|BIOLOGICAL|Trastuzumab|Given IV
223395619|NCT02003209|RADIATION|Whole Breast Irradiation|Undergo whole breast irradiation
223395620|NCT05839314|DRUG|Huaier granule|Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.
223395621|NCT05839314|DRUG|Renin-angiotensin-aldosterone system inhibitors (RASI)|"Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening."
223395622|NCT05839314|DRUG|Ciclosporin soft capsules|"The initial dose of Ciclosporin soft capsules is an oral dose of 3.5mg/kg/d, divided into two equal doses, given every 12 hours. Assess the plasma concentration of CsA (valley value) every 2 weeks in the first 8 weeks. If the plasma concentration of CsA reaches 100-150ug/L, continue to maintain the dose. If the plasma concentration of CsA is below the target concentration, increase the dose of CsA. If the plasma concentration of CsA is higher than the upper limit of the target concentration, appropriate dose reduction. A single dose adjustment is 25mg/d. After increasing/decreasing the dose, CsA concentration is remeasured at intervals of 2 weeks ±3 days until the target concentration is reached.~CsA at target concentration followed by 24 weeks of treatment, then the dosage shall be adjusted according to efficacy."
223395623|NCT06145841|DIAGNOSTIC_TEST|Pathogen metagenomic next-generation sequencing|In diagnosing patients with AIDS combined with severe pneumonia and/or sepsis, use pathogen metagenomics technology to detect peripheral blood specimens
223395624|NCT00638508|DRUG|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
223395625|NCT00638508|DRUG|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
223395626|NCT06269458|BEHAVIORAL|Baby Massage|In the baby massage application, mothers were trained on baby massage and the massage applied by the mother to her baby was observed once. The baby massage video prepared by the researchers was shared with mothers. Mothers were informed about the importan
223395627|NCT06269458|BEHAVIORAL|Monther-Baby Yoga|"Mothers were asked to choose the most suitable time of day for themselves and the baby, to ensure that the baby was fed at least 45 minutes before yoga, and to practice yoga in a calm and dimly lit environment, listening to music or white noise of their choice. One yoga session lasted approximately 20 minutes. Mothers and their babies did mother-baby yoga three times a week for four weeks. Mothers were informed about the importance of having the same treatment room for each treatment. All mothers were called once a week by a researcher to provide counseling and follow-up of the process.~At the end of four weeks, measurement tools were applied to all mothers and the groups were changed, massage was applied to the yoga group, and yoga intervention was applied to the massage group, as in the beginning of the research. At the end of four weeks, all mothers were evaluated for mother-infant attachment and the infant's sleep diary."
223395628|NCT05911334|BEHAVIORAL|ROADE Program|Outpatient Behavioral Intervention for Eating Disorder
223549447|NCT03127917|OTHER|Placebo|Maltodextrin capsules given as placebo
223549448|NCT01748188|PROCEDURE|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
223549449|NCT01748188|PROCEDURE|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
223549450|NCT01748188|PROCEDURE|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
223549451|NCT01748188|PROCEDURE|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
223731059|NCT05066373|DRUG|EDP1815 capsule B|EDP1815 capsule B is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The capsule is radio-labeled with approximately 4 MBq 99mTc-DTPA
223549452|NCT01748188|PROCEDURE|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
223549453|NCT02061072|OTHER|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
223549454|NCT00141648|DRUG|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
223549455|NCT00141648|RADIATION|Radiotherapy|Total 45 Gy in 25 fractions
223731060|NCT05066373|DRUG|EDP1815 tablet|EDP1815 tablet is an orally administered, pharmaceutical preparation of a single strain of Prevotella histicola. The tablet is radio-labeled with approximately 4 MBq 99mTc-DTPA
223731061|NCT01879501|BEHAVIORAL|Low Vision Self-Management Program|The program has been describe above.
223731062|NCT06413342|DRUG|Sintilimab|Patients should receive their first dose of sintilimab within 42 days after completing the final radiotherapy session and continue treatment until disease progression, occurrence of intolerable toxicity, loss to follow-up, death, or as determined by the investigator, whichever comes first. The maximum duration of sintilimab treatment is 12 months (from the initiation of therapy). No other anti-tumor therapies are permitted during the treatment period.
223731063|NCT01084174|DRUG|Peanut powder|Delivered orally
223731064|NCT01084174|DRUG|Peanut extract|Delivered sublingually
223731065|NCT01084174|DRUG|Placebo extract|Delivered sublingually
223731066|NCT01084174|DRUG|Placebo powder|Delivered orally
224128186|NCT07083258|OTHER|Placebo Training|The placebo group will perform identical training sessions using the same device but with a constant minimal resistance set at 15% of the initial MIP, insufficient to induce a physiological training effect. This intervention is designed to control for placebo response. Assessment protocols will be identical to those in the experimental group.
223395629|NCT05972902|DRUG|Dydrogesterone|Dydrogesterone molecular structure and pharmacologic effects are closely related to endogenous progesterone
223549456|NCT05672641|OTHER|Inertial training|Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
223549457|NCT05672641|OTHER|Body building training|Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
223549458|NCT02468531|OTHER|oxygen|50% oxygen inhalation
223549459|NCT02468531|DRUG|Xenon|50% Xenon inhalation
223549460|NCT01308814|DRUG|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
223549461|NCT01308814|DRUG|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
223549462|NCT04982341|PROCEDURE|prone position|patients are returned from prone to supine position while receiving oxygenation through HFNC
223731067|NCT03412487|PROCEDURE|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
223731068|NCT03582072|BEHAVIORAL|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.\*
223731069|NCT00273442|DRUG|timolol maleate|
223731070|NCT00273442|DRUG|dorzolamide/timolol maleate fixed combination|
223395630|NCT05972902|DRUG|Cetrorelix acetate|GnRH antagonist
223395631|NCT05972902|DRUG|Triptorelin|GnRH agonist
223395632|NCT03606616|PROCEDURE|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
223395633|NCT00739713|DIETARY_SUPPLEMENT|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
223395634|NCT00739713|DIETARY_SUPPLEMENT|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
223395635|NCT01030419|BEHAVIORAL|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
223395636|NCT01030419|BEHAVIORAL|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
223549463|NCT06464705|DEVICE|PEMF treatment|Pulsed electromagnetic field (PEMF) therapy is an emerging modality for the treatment of musculoskeletal disorders. Time-varying magnetic pulses are generated by passing an electrical current through a coil. PEMF has been shown to be effective in vitro and in vivo studies for tissue repair and accelerating muscle regeneration. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
223731071|NCT01034462|DRUG|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
223731072|NCT01034462|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
223731073|NCT05039242|OTHER|Conventional Physical Therapy)|"Participants will receive a Hand exercise program including 8 different movements according to Flat 20 (flexion, extension, radial deviation of the fingers, dorsal flexion, palmar flexion, ulnar deviation of the fingers, and opposition and abduction of thumbs.~Repetitions include 5 times during each session, as given in the study. Balanced resistive hand exercise with use of physio hand ball squeezes including finger abduction and adduction exercises with MCP extended and gross grip.~Each contraction to be held for 3-5 seconds with a 20-second rest between contractions. Five repetitions of each resistive exercise will be done."
223395637|NCT02486237|OTHER|None, observational study|None, it is an observational study
223395638|NCT00370552|DRUG|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m\^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
223395639|NCT00370552|DRUG|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m\^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
223395640|NCT00370552|DRUG|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m\^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
223395641|NCT04092309|DRUG|ACE inhibitor, Sacubitril-Valsartan|Search for Protective effect after chemotherapy and bone marrow transplantation
223395642|NCT00017693|BIOLOGICAL|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
223395643|NCT00017693|BIOLOGICAL|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
223395644|NCT04789993|OTHER|No intervention.|There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient.
223395645|NCT00003744|DRUG|gemcitabine|
223395646|NCT01152372|PROCEDURE|Insulin, glucose and staple isotopes|
224015025|NCT04491396|BEHAVIORAL|Gentle Yoga and Yogic Breathing|"Gentle Yoga (GY) postures can be done while seated on a chair (sometimes called Chair Yoga) and have been shown to benefit people with symptoms associated with cancer.12 However, Yoga is under-studied in the area of scleroderma. While most traditional Yoga postures can be practiced by anyone, people with scleroderma often have limited physical movement and can be prone to injury. Gentle Yoga postures are physically much easier to do than traditional Yoga and, thus, may be more accessible for SSc patients with musculoskeletal and other impairments. Gentle Yoga postures that are done while seated on a chair also combine easily with YB, but little is known about the specific benefits of the GY+YB combination (GYYB). Further study is needed to determine whether GYYB may be an effective strategy for improving QoL in SSc patients. The Yoga intervention to be used in this study specifically involves GY done while seated in combination with YB."
224015026|NCT06729580|BEHAVIORAL|Behavioural Activation|10-week standardized behavioural activation program.
224015027|NCT06727838|DRUG|HRS-7535 tablets|HRS-7535 tablets.
224015028|NCT06727838|DRUG|Metformin Hydrochloride Extended-release Tablets|Metformin Hydrochloride Extended-release Tablets.
224015029|NCT06727838|DRUG|Metformin Hydrochloride Tablets|Metformin Hydrochloride Tablets.
224015030|NCT04954404|DEVICE|transcatheter mitral valve repair/transcatheter mitral valve replacement|transcatheter mitral valve repair/transcatheter mitral valve replacement
224015031|NCT03647488|DRUG|Capmatinib|Capmatinib 400 mg (tablets) orally taken twice daily
224015032|NCT03647488|DRUG|Spartalizumab|Spartalizumab 400 mg via intravenous infusion once every 28 days
223395647|NCT00495807|BEHAVIORAL|No Words|Without any words was given during pain management
223395648|NCT00495807|BEHAVIORAL|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
223549464|NCT06464705|DEVICE|Placebo treatment|In this study the placebo group uses the same PEMF machine, but it does not generate any electrical current that have treatment effect. As the active PEMF device does not produce heat or cause any sensation to the tissue, participants are blinded to the treatment. In each treatment, you need to put the reconstructed limb into the machine for 10 minutes.
223395649|NCT00495807|BEHAVIORAL|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
223395650|NCT00495807|BEHAVIORAL|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
223395651|NCT00962897|PROCEDURE|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
223395652|NCT00962897|PROCEDURE|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
223395653|NCT03500198|DEVICE|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
223395654|NCT03500198|DEVICE|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL|Intraocular lens replaces the natural lens removed during cataract surgery.
223395655|NCT00531167|DRUG|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
223395656|NCT00326391|DRUG|methylphenidate hydrochloride extended-release tablets|
223549465|NCT02013778|DRUG|HCQ|
223549466|NCT03172078|PROCEDURE|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
223549467|NCT00422643|DRUG|Sodium hyaluronate (hyaluronic acid)|
223549468|NCT02525484|DRUG|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
223395657|NCT06424548|DRUG|Administration of Sarpogrelate|Aspirin 100mg plus Sarpogrelate 100mg
223395658|NCT06424548|DRUG|Traditional administration of Clopidogrel|Aspirin 100mg plus Clopidogrel 75mg
223395659|NCT05845801|OTHER|Register|Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.
223549469|NCT06388096|DIAGNOSTIC_TEST|Pattern Electroretinogram|Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
223549470|NCT01135888|DEVICE|Skin cooling devices|Cooling vest and cooling bandana
223549471|NCT04102709|DEVICE|Health Tag|Health Monitoring Device
224128187|NCT07084324|BEHAVIORAL|Unstuck and On Target|Children will receive the Unstuck and On Target (Unstuck) curriculum, a manualized cognitive-behavioral intervention that teaches executive functioning (EF) skills such as flexibility, emotional regulation, and goal-setting. Caregivers will attend concurrent Spanish-language sessions focused on understanding EF challenges and learning strategies to support their child's skills at home. Weekly home practice sheets in Spanish summarize each session and provide practical tips and activities. The program is designed to be neurodiversity-affirming and accessible to Spanish-speaking families.
224128188|NCT06390982|RADIATION|Radiotherapy|45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.
223395660|NCT03827265|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
223395661|NCT02904772|DRUG|alipogene tiparvovec|A dose of 1x10(\*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
223549472|NCT03889340|DEVICE|IQool|Subjects will undergo hypothermia therapy with the IQool system
223549473|NCT00293813|DRUG|Alendronate|Alendronate 70 mg PO QW
223549474|NCT00293813|DRUG|Denosumab|denosumab 60 mg SC q 6 mos
224015033|NCT03647488|DRUG|Docetaxel|Docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
224015034|NCT03694275|DRUG|Soticlestat|TAK-935 tablets
224015035|NCT01274845|OTHER|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
224015036|NCT05331092|OTHER|Cryotherapy|20 minutes of cryotherapy on the dominant ankle with ice bags
224015037|NCT05077085|DRUG|Bezlotoxumab|single intravenous infusion of bezlotoxumab 10 mg/kg
224015038|NCT05077085|PROCEDURE|Fecal Microbiota Transplantation (FMT)|single infusion of 198 cc fecal suspension (derived from 60g donor feces) via duodenal tube or coloscopy
224015039|NCT05077085|DRUG|Vancomycin oral|14 days vancomycin oral 125mg QID (250mg QID when 125mg not available)
223395662|NCT02904772|DRUG|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
223395663|NCT02904772|DRUG|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
223395664|NCT02904772|DRUG|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
223549475|NCT00293813|DRUG|Placebo|Placebo for alendronate and placebo for denosumab
223549476|NCT05415423|BEHAVIORAL|Developing an objective measure of experienced pain|"At the beginning of each study, participants are randomly allocated into one of two groups.~Within each group all participants are exposed to the same painful stimulus. One group experiences a painful stimulus of higher intensity compared to that of the other group. The painful stimuli are physically identical for every subject within the same group and within the standard of previous pain research.~Participants are then asked to evaluate the painful stimulus they just received according to a self-reported scale (NRS, VAS, gLMS, NRS-MB). Participants are also asked to decide multiple times whether they prefer a larger amount of money and experience the same or more painful stimulus they received before or a smaller amount of money and no (or a less) painful stimulus. The smaller amount of money is progressively increased across choices until it matches the larger amount, similar to multiple price-list methods (MPL) which are standard in economics."
223549477|NCT06277947|PROCEDURE|China Hyperthermic Intraperitoneal Chemotherapy(C-HIPEC)|The C-HIPEC would be performed at bedside in the general ward within 24 hours after surgery. The HIPEC treatment instruments are BR-TRG-II system, which can control the temperature stably to 43℃±0.1℃.
224015040|NCT02498431|PROCEDURE|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
224015041|NCT02498431|PROCEDURE|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
224015042|NCT02498431|DEVICE|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
224015043|NCT02666469|OTHER|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
224015044|NCT02666469|OTHER|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
224015045|NCT02666469|DEVICE|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
224128189|NCT06390982|DRUG|Tislelizumab|200 mg IV on Day 1 of each 21-day cycle.
224128190|NCT06390982|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice daily (bid) on Day 1 to 14 of each 21-day cycle in CAPOX regimen
224128191|NCT06390982|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1 of each 21-day cycle in CAPOX regimen
224128192|NCT06390982|DRUG|Capecitabine|825 mg/m2 orally twice daily (bid) 5 days/week during radiotherapy.
224128193|NCT01468727|DIETARY_SUPPLEMENT|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
224128194|NCT01468727|DIETARY_SUPPLEMENT|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
224128195|NCT03257163|DRUG|Capecitabine|Given PO
224128196|NCT03257163|OTHER|Laboratory Biomarker Analysis|Correlative studies
224128197|NCT03257163|BIOLOGICAL|Pembrolizumab|Given IV
224128198|NCT03257163|RADIATION|Radiation Therapy|Undergo radiation therapy
224128199|NCT07162701|DIAGNOSTIC_TEST|Bioimpedance analysis|Patients' body composition will be assessed using bioimpedance analysis (Akern)
223395665|NCT02165449|DRUG|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
223549478|NCT05207644|DRUG|30 mg letrozole followed by 800 mcg misoprostol|30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
223549479|NCT01299337|DRUG|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
223549480|NCT01087658|DRUG|Glutamine|Per os
223549481|NCT01087658|DRUG|Calcium and Magnesium|Intravenous
223549482|NCT02853396|OTHER|Cognitive Behaviour Therapy|
223549483|NCT02853396|OTHER|Psychoeducation|
224015046|NCT01319630|DEVICE|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
224015047|NCT01319630|DEVICE|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
224015048|NCT02417402|OTHER|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
224015049|NCT02417402|OTHER|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
224015050|NCT02772419|DRUG|benralizumab|SC administration
224015051|NCT02772419|DRUG|benralizumab|SC administration
224015052|NCT02772419|DRUG|Placebo|SC administration
224015053|NCT03963531|OTHER|chemotherapy, surgery, radiotherapy, interventional radiology.|
224015054|NCT00136539|DRUG|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
224015055|NCT00136539|DRUG|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
224015056|NCT00136539|DRUG|Adriamycin|Given every three weeks for 12 weeks after surgery.
224015057|NCT00136539|DRUG|Cytoxan|Given every three weeks for 12 weeks after surgery.
224015058|NCT03541174|DRUG|Aprocitentan 12.5 mg|Tablet, oral use
224015059|NCT03541174|DRUG|Aprocitentan 25 mg|Tablet, oral use
224128200|NCT06389383|OTHER|Nasal Swab|"* Nasal swab once a week for the duration of the stay in intensive care unit/intensive care (procedure already carried out routinely to detect nasal staphylococcus once a week).~* Nasal swab every 14 days when the newborn is hospitalized in routine care/kangaroo unit/hospitalization at home"
224128201|NCT06062823|DRUG|Afatinib 40 MG|Afatinib 40mg administered orally daily.
223549484|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
223549485|NCT02507661|DRUG|no-preservation of alveolar ridge - 2 months|
223549486|NCT02507661|DRUG|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
223549487|NCT02507661|DRUG|no-preservation of alveolar ridge - 4 months|
223549488|NCT02507661|PROCEDURE|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
223549489|NCT02507661|DRUG|no-preservation of alveolar ridge - 9 months|
223549490|NCT00788931|DRUG|IV LBH589|
223549491|NCT00788931|DRUG|Oral LBH589|
223549492|NCT00788931|DRUG|trastuzumab|
223549493|NCT00788931|DRUG|paclitaxel|
223549494|NCT01278238|DRUG|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
223549495|NCT01278238|DEVICE|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
224015060|NCT03541174|DRUG|Placebo|Matching placebo tablet
224015061|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
224015062|NCT00000145|DIETARY_SUPPLEMENT|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
224015063|NCT00000145|DIETARY_SUPPLEMENT|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
224015064|NCT00472160|PROCEDURE|Non Invasive Ventilation|Non Invasive Ventilation
224015065|NCT04928430|DRUG|XAV-19|150 mg of XAV-19 single IV perfusion
223731074|NCT05039242|OTHER|Kinesiotaping with I shaped application|Participants will receive Kinesiotape, by using I application technique from proximal to distal on dorsum of hand and forearm with less than 50% stretch of the subjects on both hands, once a week for a total time period of 4 weeks with 4 KT applications in total (19). Kinesiotape will be worn by the subjects for 3 days. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs.
224015066|NCT04928430|DRUG|Placebo|Single IV infusion
224015067|NCT02775825|OTHER|survey|
224015068|NCT05559008|DRUG|Azacitidine Injection|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
223395666|NCT01126242|DEVICE|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
223395667|NCT01126242|DEVICE|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
223395668|NCT01126242|DEVICE|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
223395669|NCT00755742|OTHER|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
223395670|NCT01167478|DIETARY_SUPPLEMENT|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
223395671|NCT01167478|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
223395672|NCT01983267|DRUG|cannabis|use of cannabis oil or cigarets
223395673|NCT03252405|DEVICE|mask ventilation|before intravenous induction, mask application is made. then intravenous cannulation and induction
223395674|NCT03252405|DEVICE|intravenous cannulation|induction is applied by using intravenous cannulation
223395675|NCT04347720|DRUG|Indomethacin|Intravenous formulation
223395676|NCT04347720|DRUG|Ibuprofen|Intravenous and oral formulations
223395677|NCT04347720|DRUG|Acetaminophen|Intravenous and oral formulations
223395678|NCT04544774|DRUG|AIT|AIT for airborn allergens (SCIT/SLIT)
223395679|NCT04544774|DIAGNOSTIC_TEST|NAPT|NAPT test with airborn allergens ( HDM, Threes, Grasses)
223395680|NCT04262648|DIETARY_SUPPLEMENT|Lactobacillus Reuteri|Lactobacillus Reuteri NCIMB 30351
223395681|NCT04262648|DIETARY_SUPPLEMENT|Placebo|Sunflower oil
223549496|NCT01278238|OTHER|Placebo|Neither phenylephrine nor lower limb bandaging
223549497|NCT02744495|DRUG|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
223549498|NCT02744495|DRUG|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
223549499|NCT00113672|BEHAVIORAL|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
224015069|NCT05559008|DRUG|Dasatinib|Azacitidine Injection，SC and Dasatinib PO will be administered in T1 subtypes
224015070|NCT05559008|DRUG|Linperlisib|Azacitidine Injection，SC and Linperlisib PO will be administered in T2 subtypes
224015071|NCT05559008|DRUG|Tucidinostat|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
224015072|NCT05559008|DRUG|SHR2554|Tucidinostat PO and SHR2554 PO will be administered in T3.1 subtypes
224015073|NCT05559008|DRUG|Camrelizumab|Camrelizumab and Apatinib will be administered in T3.2 subtypes
224015074|NCT05559008|DRUG|Apatinib|Camrelizumab and Apatinib will be administered in T3.2 subtypes
224015075|NCT02002650|DRUG|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
224015076|NCT02002650|DRUG|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
224015077|NCT01978522|OTHER|Randomisation of questionnaire receipt.|"1. The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~2. Self-completion questionnaire handed to participants immediately after completing the CAPI."
224015078|NCT02217332|DRUG|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
224015079|NCT04719325|OTHER|Herbert screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion and application of Herbert screw
223395682|NCT04650217|DRUG|Carbidopa/levodopa|"L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose."
223395683|NCT04650217|DRUG|Placebo|Carbidopa/levodopa matched placebo
223549500|NCT00113672|BEHAVIORAL|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
223549501|NCT00113672|BEHAVIORAL|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
223549502|NCT00113672|BEHAVIORAL|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
223549503|NCT02364804|DRUG|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
223549504|NCT04034719|OTHER|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
223549505|NCT04034719|OTHER|usual practice|Parents will be carried their newborn as their usual practice.
223549506|NCT04103151|DEVICE|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
223731075|NCT05039242|OTHER|Kinesiotaping with Fan-shaped Application|"Participants will receive exercise interventions as group A along with that the Kinesiotape will be applied, by using fan cut application technique on MCP joints involving extensor tendons of fingers on dorsal surface of both hands of subjects, once a week for a total time period of 4 weeks with 4 KT applications in total.~Kinesiotape will be worn by the subjects for 3 days. Less than 50% stretch with space correction technique. basic hand exercises will accompny it. Weekly assessments will be completed for pain, ROM, joint stiffness, grip strength and ADLs."
223731076|NCT06217289|OTHER|Observation|Observation and knowledgement on behavior of healthcare professional workers during hpreparation of oral solid pharmaceutical drug
223731077|NCT05609045|BIOLOGICAL|Lyophilized COVID-19 mRNA Vaccine|RH109 is a mRNA-based vaccine encoding the N-Terminal Domain (NTD) - Receptor Binding Domain (RBD) derived from Spike (S) protein of SARS-CoV-2 Omicron variant.
223731078|NCT05609045|DRUG|Sodium chloride|0.9% sodium chloride
224015080|NCT04719325|OTHER|Lag screw|Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion. Application of either lag screw according to Champy's osteosynthesis lines.
223731079|NCT05346159|DIAGNOSTIC_TEST|the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS|"Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior"
223731080|NCT02678845|OTHER|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
223731081|NCT02562430|DRUG|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
223731082|NCT02562430|DRUG|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
223731083|NCT01404390|DRUG|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
223731084|NCT01404390|DRUG|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
223731085|NCT04688307|BEHAVIORAL|Motivational interviewing|Motivational interviewing for smoking reduction and adherence to diet and physical activity for obtaining ideal body weight
223731086|NCT03327298|PROCEDURE|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
224015081|NCT00330486|DRUG|Acamprosate|
224015082|NCT05560334|DRUG|Pemigatinib Pill|13.5mg, po, 2 weeks on/1 week off, Q3W
224015083|NCT03437681|BEHAVIORAL|Insufficient sleep|Four days of insufficient sleep
224015084|NCT02706613|BEHAVIORAL|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
224015085|NCT02706613|BEHAVIORAL|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
223395684|NCT04650217|BEHAVIORAL|Exercise training|Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
223549507|NCT04774588|OTHER|VSI streamer and Microsoft Hololens 2 classed as a Class III device by Health Canada.|1.1 Description of VSI streamer device and software The VSI Streamer is a box that can be connected to ultrasound, endoscope, microscope, laparoscope and other devices via HDMI connection. The view of the imaging devices, which is conventionally displayed on a monitor, is transmitted wirelessly and in real time to the Mixed Reality HoloLens 2 (Microsoft Inc.) and appears as a virtual monitor that can be flexibly moved and positioned in space. Since this is Mixed Reality, the real environment remains visible. If required, several virtual monitors can be streamed into the Mixed Reality glasses at the same time
223549508|NCT02144402|OTHER|infant formula with DHASCO|
223549509|NCT02144402|OTHER|infant formula with DHASCO-B|
223549510|NCT04317443|PROCEDURE|Super-mini percutaneous nephrolithotomy (SMP)|SMP will be performed under general anesthesia in prone/supine position. Renal puncture will be performed under ultrasound/fluoroscopy guidance based on the preference of the participating surgeon. Tracts will be dilated to 14 Fr. Stone fragmentation will be performed with holmium laser and fragments will be extracted with the active suction system. For the exit strategy, placement of a nephrostomy tube or JJ stent will be decided by the participating surgeon.
223549511|NCT04317443|PROCEDURE|Extracorporeal Shock Wave Lithotripsy (ESWL)|ESWL will be performed under sedation/analgesia, shock wave lithotripsy parameters will be determined based on the device and the settings of local center. For patients requiring multiple sessions, maximum 3 (or more) sessions will be allowed. Ureteral stenting prior to ESWL will be performed based on the decision of the participating center.
223549512|NCT01391169|OTHER|seromuscular flap enforcement|seromuscular flap enforcement
223549513|NCT05203211|PROCEDURE|Testicular sperm extraction (TESE)|During the procedure, the testis is exposed through a small incision and one or more biopsies are taken blindly. A vertical incision is made in the median raphe, skin, dartos and tunica vaginalis to expose tunica albuginea. The tunica albuginea is incised for about 4 mm at upper pole near the head of epididymis.
223549514|NCT02985918|DEVICE|High-intensity NPPV|In the high-intensity NPPV group, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O, typically ranging from 20 to 30 cmH2O (or a tolerated maximum), to obtain a VT 10-15 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of arterial blood gases (ABGs; up to 30 cmH2O) to achieve normocapnia (if possible), or to maximally decrease PaCO2 toward normocapnia if normocapnia can not be achieved. If PaCO2 decreases to less than 35 mmHg, IPAP will be decreased to achieve normocapnia.
223549515|NCT02985918|DEVICE|Low-intensity NPPV|In the low-intensity NPPV group, as well as during the 6-hour trial of low-intensity NPPV, IPAP is initially adjusted in increments/decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT 6-10 mL/kg PBW and a respiratory rate \<25 breaths/min. Subsequent adjustments to IPAP are based on the results of ABGs (up to 20 cmH2O) to achieve a pH of ≥7.35 and to reduce PaCO2 to a level deemed appropriate by the attending physician.
223731087|NCT04914104|BEHAVIORAL|Mindfulness Training - Headspace App|The intervention group will receive free access to the mobile app Headspace and directed to access the app three times a week for at least 15 minutes.
223731088|NCT03441854|DEVICE|HFNC group|Application of HFNC oxygen delivery after extubation.
224015086|NCT02407990|BIOLOGICAL|BGB-A317|In the dose escalation part, the dose levels were escalated following a modified 3+3 dose escalation scheme. In the scheduled exploration part, participants were assigned to doses and dose schedules. In the fixed dose exploration part, participants were assigned to dose group(s) not to exceed the maximum tolerated dose. In the dose expansion part, participants were assigned to different groups based on their tumor type.
223731089|NCT01484873|DRUG|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
223731090|NCT06131242|OTHER|It is an observational study|It is an observational study
223731091|NCT04918550|OTHER|no drug and device|there is no intervention
223731092|NCT06131307|PROCEDURE|Education|Paternalistic leadership training will be given to clinical manager nurses.
223731093|NCT03416257|OTHER|No intervention|
224015087|NCT02407990|BIOLOGICAL|BGB-A317|Participants were assigned to different groups based on their tumor types
224015088|NCT01608763|BEHAVIORAL|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
224015089|NCT00606125|DRUG|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
223731094|NCT00608231|DRUG|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
223731095|NCT00608231|DRUG|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
224015090|NCT00000500|DRUG|aspirin|
224015091|NCT00000500|DRUG|carotene|
224015092|NCT04782401|OTHER|Ultrasound guided genicular nerve block + exercise treatment|This method was used to inject a total of 6 mL of lidocaine plus 40 mg of triamcinolone (TA) at 3 separate target sites: the superior lateral, superior medial, and inferior medial genicular nerves plus exercise treatment
224015093|NCT04782401|DEVICE|Physical therapy + exercise treatment|Ten sessions of hotpack as a surface warmer, TENS as a analgezic current, ultrasound therapy as a deep warmer and exercise treatment.
223395685|NCT04650217|BEHAVIORAL|Control|Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
223395686|NCT05111327|OTHER|Structured guideline|Students in the intervention group will receive more learning materials before study. The structured guideline will be used to facilitate students' learning in simulation by the facilitator.
223395687|NCT03388151|DRUG|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
223549516|NCT04615234|DEVICE|Pharmacogenomics test (PGx)|"The clinicians of the TGTG group patients receive the PGx test report within 48 hours and all the participants start the new treatment within 72 hours. According with both Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines, the PGx report places the most ADs widespread in Italy, into three recommended categories: 1) use as directed (labelled as Green), 2) use with caution (labelled as Yellow), 3) use with extreme caution (labelled as Red)"
223549517|NCT00286624|BIOLOGICAL|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
223549518|NCT00286624|DRUG|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
223549519|NCT00286624|DRUG|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
223549520|NCT00286624|DRUG|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
223549521|NCT04719221|DRUG|Evolocumab|The maximum dose of combined cholesterol therapy (Statin + Ezetimibe) is prescribed for 2 months, and a cholesterol test is performed in an outpatient clinic to ensure that LDL-Cholesterol \<70mg/dL is met. Patients who do not meet the criteria are randomized to maintain current treatment or receive additional Evolocumab according to randomization.
223549522|NCT04719221|DEVICE|NIRS IVUS|near-infrared spectroscopy
223549523|NCT01179984|DEVICE|Bard® LifeStent® Vascular Stent System|Stent Implantation
223549524|NCT02414516|DRUG|OBP-801|OBP-801 will be administered IV
223549525|NCT01465386|DRUG|bortezomib|Given SC
223549526|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 15 opioid tablets for post-operative pain
223549527|NCT04278703|DRUG|Oxycodone|Patients will be given a prescription for 25 opioid tablets for post-operative pain
223731096|NCT02564042|DRUG|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
223549528|NCT04278703|DRUG|oxycodone|Patients will be given a prescription for 35 opioid tablets for post-operative pain
223549529|NCT05741892|DEVICE|Fracture reposition with 3D printed patient specific repositions guides|Comminuted tibial- or/and femur shaft fractures will be treated using 3D printed patient-specific repositions guides.
223549530|NCT02945124|OTHER|K tape|Applying K tape to children to the lower limb muscles during motor activities.
223549531|NCT05409469|PROCEDURE|surgery|surgery on patients with aortic dissection
223549532|NCT03284983|OTHER|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
223549533|NCT02661204|DEVICE|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
223549534|NCT00703742|DRUG|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
223549535|NCT00370266|DRUG|Triamcinolone|
223731097|NCT02564042|DRUG|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
223731098|NCT02564042|DRUG|Vehicle cream|White to off-white vehicle cream base to be applied topically
223395688|NCT03388151|DRUG|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
223549536|NCT03943576|DRUG|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
223549537|NCT03943576|DEVICE|HA|Hya Joint Plus synovial fluid supplement 3mL
223549538|NCT05350215|DRUG|Placebo oral capsule|Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep
223549539|NCT05350215|DRUG|Atomoxetine Oral Capsule [Strattera]|Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
223549540|NCT00473889|DRUG|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
223549541|NCT00473889|DRUG|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
223549542|NCT00473889|DRUG|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
223549543|NCT00473889|DRUG|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
223549544|NCT00868829|DEVICE|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
223731099|NCT03502226|BEHAVIORAL|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
223731100|NCT06120556|DRUG|GLP-1 receptor agonist|Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
223731101|NCT01549392|DEVICE|DECT|DECT at tumor progression and 3 months later
223731102|NCT01549392|DEVICE|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
223731103|NCT04723550|DEVICE|Hospital telemedicine management system|Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.
223731104|NCT04723550|OTHER|Usual care|Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
223395689|NCT01088477|OTHER|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
224015094|NCT04037267|PROCEDURE|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
223395690|NCT05204992|PROCEDURE|ultrasound guided hydrodissection|Injection of steroids, saline and bupivicaine ultrasound guided
223395691|NCT02883972|OTHER|Intervention letter|Behavioural-insight informed letter template
223395692|NCT02883972|OTHER|Control letter|Invitation letter used by local area last year (updated as required)
223395693|NCT02883972|OTHER|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
223395694|NCT04333316|PROCEDURE|large head|implantation of large head total hip
223395695|NCT04333316|PROCEDURE|dual mobility cup|implantation of dual mobility total hip
223395696|NCT00857155|OTHER|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
223395697|NCT00839358|DRUG|albumin|albumine 40 g every 15 days
223395698|NCT00839358|DRUG|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
223395699|NCT00839358|DRUG|Placebo|saline solution
223395700|NCT02070250|BEHAVIORAL|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
223395701|NCT04897854|DRUG|Folfirinox|In both arms the intervention will be FOLRINIOX or nab paclitaxel in combination with gemcitabine per investigator's choice
223395702|NCT02035111|DRUG|Tianshu capsule|
223395703|NCT02035111|DRUG|Sugar pill|
223395704|NCT05635591|BIOLOGICAL|Autologous monocyte - derived DCs pulsed with EBV antigen|Patients will receive approximately （5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
223395705|NCT02496182|DRUG|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
223395706|NCT02496182|DRUG|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
223395707|NCT02496182|DRUG|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
223395708|NCT05264662|DRUG|Adacel (Tdap)|Administer Adacel to hiv infected and hiv uninfected pregnant mothers
224015095|NCT03147404|DRUG|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
224015096|NCT03484845|DRUG|Lactoferrin and ferrous fumarate|"* Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
223395709|NCT03975894|BIOLOGICAL|Serial prophylactic exchange blood transfusion (SPEBT).|"Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% \<30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion."
224015097|NCT03723616|BEHAVIORAL|Control|Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.
223395710|NCT01644240|DRUG|TD-8954|Intravenous infusion
223395711|NCT01644240|DRUG|Placebo - saline|Intravenous infusion
223395712|NCT03036657|DEVICE|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
223395713|NCT03036657|DEVICE|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
223395714|NCT04413019|OTHER|Clinical follow up|"Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection."
223395715|NCT04540991|PROCEDURE|implant placement|The implants are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
223731105|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
223395716|NCT04540991|PROCEDURE|gingiva former placement|Gingiva former are placed in accordance with each implant system manufacturer's instructions and the treatment were performed according to the patient's standards and indications. Surgical procedures of oppeninf implant cower and gingiva former placement on all patients are performed by the same operator with the same surgical approach, protocol and instrumentation.
223395717|NCT04540991|DIAGNOSTIC_TEST|Collecting gingival epithelial cellsusing the swab technique|Samples of gingival epithelial cells are collected from each participant's implementation site using the swab technique at three different time points: a control swab is taken just before the placement of the dental implant (T0); the second swab is taken 90 days after implantation meaning immediately before placement of the gingiva former (T1); and the third swab is taken 21 days after placement of the gingiva former (T2).
223395718|NCT01381965|PROCEDURE|Vitreous surgery for macular hole|Vitreous surgery for macular hole
223395719|NCT01963104|PROCEDURE|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395720|NCT01963104|PROCEDURE|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223731106|NCT03103386|DIETARY_SUPPLEMENT|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
223731107|NCT01356966|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
223731108|NCT01356966|DRUG|Placebo|2 placebo pills PO BID for12 weeks
223731109|NCT01356966|DIETARY_SUPPLEMENT|Folate|Folate 1 mg daily for 12 weeks
223731110|NCT00213083|DRUG|Carraguard (PC-515)|
223731111|NCT04219332|DRUG|Subserosa injection of indocyanine green|After preoperative exploration, the indocyanine green powder (Dandong Yichuang Pharmaceutical Co) is dissolved in 0.5 mg/ml of sterile water and the prepared solution (1.5 ml for each point) is injected along the subserosal of the stomach at 6 specific points along the lesser and greater curvature of the stomach.
223731112|NCT04219332|DRUG|submucosal injection of indocyanine green|One day before surgery, 1.25 mg/ml indocyanine green (Dandong Yichuang Pharmaceutical Co) was prepared in sterile water and 0.5 ml of the solution was injected into the submucosal layer at 4 quadrants around the primary tumor, amounting to 2.5 mg of indocyanine green.
223731113|NCT01179945|OTHER|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.~Each solution will be consumed over 5 minutes."
223731114|NCT01179945|OTHER|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.~Each solution will be consumed over 5 minutes."
223731115|NCT01219920|DRUG|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
223731116|NCT01219920|DRUG|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
223731117|NCT02743806|DRUG|Vedolizumab|Vedolizumab IV infusion
223731118|NCT01550796|BEHAVIORAL|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
223731119|NCT05383300|DRUG|Oxytocin nasal spray|Intranasal spray containing 40 IU of oxytocin
223731120|NCT05383300|OTHER|Placebo spray|Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin
223731121|NCT05692765|BEHAVIORAL|smartphone application to enhance fruit and vegetables intake among adolescents|"This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups."
223731122|NCT03589443|DRUG|Multiplexed heptapeptides|Heptapeptides QRH and KSP
223731123|NCT01887574|OTHER|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
223731124|NCT04750720|OTHER|Sampling by venipuncture (and eventually by nasopharyngeal swab)|"Biological samples :~* Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test~* PBMC (peripheral blood mononuclear cells)~* Nasopharyngeal samples (not mandatory)~Associated data :~* Demographic data~* Description of clinical manifestations related to SARS-CoV-2 infection~* Notion of hospitalization/ambulatory follow-up~Blood Fractioning~* Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)~* Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells"
223731125|NCT00849381|BIOLOGICAL|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
224015098|NCT03723616|BEHAVIORAL|Text Only|Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
223395721|NCT01963104|PROCEDURE|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395722|NCT01963104|PROCEDURE|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395723|NCT01963104|PROCEDURE|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395724|NCT01963104|PROCEDURE|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395725|NCT01963104|PROCEDURE|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395726|NCT01963104|PROCEDURE|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223549545|NCT04499027|DIAGNOSTIC_TEST|Lung ultrasound scan|"12 hours postoperatively using a convex ultrasound probe LUS will be performed by an experienced radiologist according to standardized protocols. For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines will be identified. Each one will be divided into upper and lower halves, making a sum of 6 different quadrants for each side: anterior superior, anterior inferior, lateral superior, lateral inferior, posterior superior, posterior inferior.~For each quadrant a score will be assigned based on B lines which are defined as comet like artifacts indicating subpleural interstitial edema as follows:~(0) normal aeration: A lines with lung sliding or fewer than two isolated B lines; (1) moderate loss of lung aeration: well-defined, multiple B lines ; (2) severe loss of lung aeration: multiple coalescent B lines; and (3) complete loss of lung aeration or lung consolidation."
223549546|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 3 months|Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
224015099|NCT03723616|BEHAVIORAL|Text + Graphic|This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
224015100|NCT01745731|OTHER|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
224015101|NCT02792673|OTHER|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
224015102|NCT02792673|OTHER|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
224015103|NCT02792673|OTHER|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
224015104|NCT02792673|DEVICE|Labotect embryo transfer catheter|
224015105|NCT01546636|OTHER|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
224015106|NCT01546636|OTHER|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
224015107|NCT02107183|DEVICE|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
224015108|NCT02107183|DEVICE|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
224015109|NCT05415943|DEVICE|Diagnostic microprobe (inPROBE) medical device|Introduction of the inPROBE microprobe (two simultaneous punctures) into the breast as a procedure prior to surgical resection of tumors with known HER2 receptor status.
224015110|NCT04865198|DIAGNOSTIC_TEST|Neurl1 gene expression|This observational case control study. The gene expression was examined.
224015111|NCT04865198|DIAGNOSTIC_TEST|RGS14 gene expression|This observational case control study. The gene expression was examined.
224015112|NCT01458431|DRUG|Levobupivacaine|continuous levobupivacaine subfascial infusion
224015113|NCT01458431|DRUG|NaCl|continuous NaCl subfascial infusion
223549547|NCT05870969|BEHAVIORAL|Liver cancer surveillance every 6 months|Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
223395727|NCT01963104|PROCEDURE|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
223395728|NCT01963104|PROCEDURE|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care."
223395729|NCT03560401|DEVICE|Knight-Taylor [chairback] brace|Knight-Taylor \[chairback\] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
223395730|NCT02850146|DRUG|18F-AV-1451|
223395731|NCT05863884|BEHAVIORAL|Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake|CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
223395732|NCT06053346|BEHAVIORAL|Pay For Performance (PFP)|Wraparound mental health, psychosocial, and addiction treatment services provided by contractor under an schedule of rewards or penalties that was agreed to with Santa Clara County.
223395733|NCT06053346|BEHAVIORAL|Usual Care (UC)|Outpatient and inpatient mental health and psychosocial services delivered by Santa Clara County services and systems.
223395734|NCT00677664|DRUG|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
223395735|NCT00677664|DRUG|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
223395736|NCT03458442|OTHER|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
223395737|NCT03458442|OTHER|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
223395738|NCT01621334|BEHAVIORAL|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
223395739|NCT01621334|BEHAVIORAL|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
223395740|NCT02094274|DRUG|LAS40468|
223395741|NCT02094274|DRUG|Salmeterol/fluticasone propionate|
223395742|NCT02094274|DRUG|Placebo|
223395743|NCT04735510|DRUG|cyclosporine ophthalmic emulsion 0.05%|All subjects will receive restasis
223549548|NCT05870969|BEHAVIORAL|Liver cancer surveillance annually|Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
223549549|NCT04058899|DRUG|Dexmedetomidine|sedative and might be analgesic drug
223549550|NCT04058899|DRUG|Nalbuphine|agonist antagonist narcotic
223549551|NCT04058899|DEVICE|infusion pump|infusion pump for titration of fluid containing drug infusion
223549552|NCT04683406|DRUG|ZSP1273 600 mg|3 X 200-mg tablet taken orally
223549553|NCT04683406|DRUG|Placebo to Oseltamivir|Placebo capsules matching oseltamivir2 X 75-mg
223549554|NCT04683406|DRUG|Oseltamivir(oral)|2 X 75-mg tablet taken orally
223549555|NCT04683406|DRUG|Placebo to ZSP1273|Placebo capsules matching ZSP1273 600 mg
223549556|NCT03577834|DIETARY_SUPPLEMENT|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
223549557|NCT03577834|DIETARY_SUPPLEMENT|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
223549558|NCT01108328|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
223549559|NCT00426868|OTHER|Direct injection of ADRCs into the Left Ventricle|Dose escalation
223549560|NCT00426868|OTHER|Direct injection of placebo into the Left Ventricle|
223549561|NCT02432781|DIETARY_SUPPLEMENT|Carbohydrate-rich drink|
223549562|NCT02432781|DIETARY_SUPPLEMENT|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
223549563|NCT05703724|DEVICE|AI algorithm for the detection of glaucoma|The investigational device that will be used during this study is an AI algorithm embedded into an API for the detection of glaucoma developed by MONA.health
223549564|NCT00833469|DRUG|Escitalopram|Once daily by mouth
223549565|NCT05042401|DRUG|SHR-1703|SHR-1703 low dose
223549566|NCT05042401|DRUG|placebo|placebo low dose
223549567|NCT05042401|DRUG|SHR-1703|SHR-1703 high dose
223395744|NCT01836471|DRUG|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
223549568|NCT05042401|DRUG|placebo|placebo high dose
223549569|NCT02438033|DEVICE|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
223549570|NCT03592771|BEHAVIORAL|THRIVE App|Participants in the THRIVE App group receive a weekly text message to prompt them to log into the THRIVE app to answer questions about their AET adherence and related adverse symptoms. The app can be accessed through any web-enabled device or Internet browser. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
223549571|NCT03592771|BEHAVIORAL|Tailored Feedback Messages|Participants receive weekly tailored feedback messages and/or images based on their baseline survey responses and use of the app during the 6-month intervention phase. Some tailored feedback includes links to symptom-specific educational materials and coping strategies for participants who report low-severity symptoms. Message categories are tailored to participant's responses to the app and baseline survey.
223549572|NCT02671006|OTHER|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
223549573|NCT03275090|DRUG|Smoflipid ®|
223549574|NCT06096090|DRUG|Interleukin-2|Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells
223395745|NCT01836471|DRUG|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
223395746|NCT01836471|DRUG|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
223549575|NCT06096090|DRUG|Placebo|Placebo administration
223549576|NCT02872597|DRUG|Ipratropium|
223549577|NCT02872597|DRUG|0.9% Sodium Chloride|
223549578|NCT02872597|DRUG|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
223549579|NCT02872597|DRUG|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
223549580|NCT03466398|BEHAVIORAL|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
223549581|NCT00042016|DRUG|decitabine (5-aza-2'deoxycytidine)|
223549582|NCT02044952|DRUG|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
223549583|NCT03073083|PROCEDURE|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
223549584|NCT03073083|PROCEDURE|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
223549585|NCT03073083|PROCEDURE|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
223549586|NCT04960748|BEHAVIORAL|WOMEN FIGHTING TO STOP CERVICAL CANCER|The group intervention draws on theories of social diffusion, cognitive consistency, and social influence, and our own recently developed and tested group intervention that mobilized people living with HIV in Uganda to successfully act as change agents for HIV prevention within their social networks. The intervention actively targets internalized stigma, disclosure decision making, healthy living, and advocacy communication skills. The ultimate goal of the program is to encourage female social network members to get screened for cervical cancer.
223549587|NCT04463940|OTHER|No intervention|No intervention
223549588|NCT05617989|OTHER|lung ultrasound|non-invasive ventilation and diuretic
223549589|NCT02402803|OTHER|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
223549590|NCT03399864|BEHAVIORAL|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
223549591|NCT03399864|OTHER|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
223549592|NCT05797051|DIAGNOSTIC_TEST|Microscopic hyperspectral imaging system|Microscopic hyperspectral imaging system
223549593|NCT05128864|PROCEDURE|High Tibial Osteotomy|Surgery procedure - High Tibial Osteotomy
223549594|NCT02227030|DRUG|BIIB 722 CL solution|
223549595|NCT02227030|DRUG|BIIB 722 CL tablet|
223549596|NCT02227030|DRUG|Placebo solution|
223549597|NCT02227030|DRUG|Placebo tablet|
224015114|NCT05452174|DRUG|Mirtazapine|Mirtazapine, sold under the brand name Remeron, is an atypical antidepressant, and as such is used primarily to treat depression.
224015115|NCT01313247|DRUG|paracetamol|1000 mg 4 times daily
224015116|NCT01313247|DRUG|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
223395747|NCT01836471|DRUG|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
223549598|NCT06339086|DRUG|Semaglutide Injection|"The subject will receive either a dose of semaglutide subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
223549599|NCT06339086|DRUG|Semaglutide Injection(Ozempic®)|"The subject will receive either a dose of Ozempic® subcutaneously once weekly. The initial dose of semaglutide is 0.25mg per week and will be increased to 0.5mg after 4 weeks. After 4 weeks of 0.5mg administration, the dose will be increased to 1mg and continued at a stable does of 1mg for 24 weeks.~Treatment duration 32 weeks."
223549600|NCT06339086|DRUG|Metformin|"Metformin ≥ 1500mg/day (or maximum tolerated dose ≥ 1000mg/day) and ≤2000mg/day.~Treatment duration 32 weeks."
223549601|NCT03644498|OTHER|Non-Interventional|Non-Interventional
223549602|NCT04633135|DEVICE|Philips stove|Philips Smokeless stove HD4012LS
223549603|NCT04633135|DEVICE|Gyapa stove|Wood stove made in Ghana
223549604|NCT05242835|PROCEDURE|Standard duodenal switch|Standard duodenal switch as second stage surgery after a sleeve gastrectomy (100cm common channel and 150cm alimentary limb)
223549605|NCT05242835|PROCEDURE|Single-anastomosis duodenal switch|Single-anastomosis duodeno-ileal anastomosis as second stage surgery after a sleeve gastrectomy (250cm common channel)
223549606|NCT03804242|BEHAVIORAL|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
223549607|NCT01101893|DRUG|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
223549608|NCT01101893|DRUG|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
223549609|NCT01101893|DRUG|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
223549610|NCT04830215|DRUG|Brexpiprazole|Oral brexpiprazole tablets as adjunctive therapy to ADT
223549611|NCT04226625|DRUG|Propofol|Intravenous administration
223549612|NCT04226625|DRUG|Desflurane|Volatile administration
223549613|NCT02212366|DEVICE|Active TDCS|Active Stimulation
223549614|NCT02212366|DEVICE|Sham TDCS|Sham Stimulation
223549615|NCT02075424|OTHER|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
223549616|NCT00306839|PROCEDURE|standardized Lichtenstein technique|
223549617|NCT04263116|PROCEDURE|Balloon Assisted Maturation|Angioplasty was performed under direct vision with or without the use of a guidewire using a 1 mm larger balloon than the size of the vein. BAM is performed over the whole length of the vein sparing the spatulated end of the vein
223549618|NCT03398941|DRUG|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
223549619|NCT02236572|DRUG|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~* Anastrozole 1 mg~* Letrozole 2.5 mg~* Exemestane 25 mg"
223549620|NCT02443337|DRUG|LY3023414|Administered orally
223549621|NCT02443337|DRUG|Necitumumab|Administered IV
223549622|NCT00579553|DRUG|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
223549623|NCT00579553|DRUG|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
223549624|NCT02435459|PROCEDURE|No lining|No lining material placed under amalgam dental restorations
223395748|NCT00128882|DRUG|Anti-D|Subcutaneous injection
223549625|NCT02435459|PROCEDURE|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
223395749|NCT00774163|BIOLOGICAL|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
223395750|NCT00774163|OTHER|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
223549626|NCT02435459|PROCEDURE|RMGI cement|placement of lining material under amalgam dental restorations
223549627|NCT02435459|PROCEDURE|Resin Bonding Agent|placement of lining material under amalgam dental restorations
223549628|NCT00659386|DRUG|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
223549629|NCT04453358|DEVICE|InCourage-Connect|This intervention will provide patients with clearly stated treatment goals and provide them with interactive feedback based on usage date to help support airway clearance therapy adherence.
223395751|NCT01580124|PROCEDURE|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
223549630|NCT04453358|DEVICE|InCourage|This intervention will provide standard of care airway clearance therapy with no interactive feedback on treatment goals and usage.
223395752|NCT01580124|PROCEDURE|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
223549631|NCT00635349|DRUG|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
223395753|NCT02307942|PROCEDURE|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
223549632|NCT00635349|DRUG|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
223549633|NCT00635349|DRUG|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam \[7.5 mg or 15 mg once daily\] or aceclofenac \[100 mg twice daily\]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
223549634|NCT00203736|DRUG|Sulfadoxine-pyrimethamine|
223549635|NCT00203736|DRUG|Artesunate plus sulfadoxine-pyrimethamine|
223549636|NCT02011230|OTHER|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
223549637|NCT04779450|OTHER|Kinesiotherapy protocol|The kinesiotherapy protocol is an exercise-based treatment designed to gain upper limb range of motion and muscle strengthening.
223549638|NCT04779450|OTHER|Usual orientations|Usual orientations for post-breast cancer women, such as skin care, return to activities, upper limb functionality, self-care, lymphedema, and physical activity practice.
223549639|NCT01059045|PROCEDURE|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
223549640|NCT01059045|OTHER|Control|No intervention
223549641|NCT01206634|PROCEDURE|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
223549642|NCT01206634|BEHAVIORAL|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
223549643|NCT00253513|DRUG|fludarabine|30 mg/m2, IV for 5 days
223549644|NCT00253513|DRUG|treosulfan|12 or 14 g/m2, IV for 5 days
223549645|NCT00253513|PROCEDURE|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
223549646|NCT04129983|COMBINATION_PRODUCT|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
223549647|NCT01389453|PROCEDURE|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
223549648|NCT00164008|DRUG|zoledronic acid vs pamidronate|
224015117|NCT01823692|OTHER|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
224015118|NCT02879474|BEHAVIORAL|Melanoma scale questionnair|
224015119|NCT04236505|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) group based intervention|4 week ACT psychological intervention group based on Flaxman and McIntosh's ACT in the work place group format
224015120|NCT04236505|BEHAVIORAL|Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention|4 week Mindfulness based stress reduction (MBSR) informed brief mindfulness skills group intervention
224015121|NCT04236505|BEHAVIORAL|Wait list Control group|this group are placed on a wait list for group treatment whilst the other experimental groups run. This group are offered the MBSR based mindfulness skills once the follow up data has been collected from the other two experimental groups
224015122|NCT02853838|OTHER|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
224015123|NCT02853838|OTHER|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
224015124|NCT02853838|OTHER|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
224015125|NCT00852540|DRUG|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
224015126|NCT00852540|DRUG|Linezolid|Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
223395754|NCT02445261|RADIATION|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
223549649|NCT03532698|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
223549650|NCT03532698|DRUG|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
223549651|NCT04169464|DRUG|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
223549652|NCT00127881|DRUG|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
223549653|NCT04771689|DRUG|Buprenorphine/Naloxone|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.
223549654|NCT06393777|DIETARY_SUPPLEMENT|honey|analgesic effect of honey
223549655|NCT03775317|PROCEDURE|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
223549656|NCT03775317|PROCEDURE|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
223549657|NCT03107728|DEVICE|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
223549658|NCT03107728|DEVICE|Conventional orthotic brace|Participants will use the standard of care orthosis
223549659|NCT03888378|DRUG|0.3% Topical Minocycline Ointment|0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
223549660|NCT03888378|DRUG|1% Topical Minocycline Ointment|1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction
223549661|NCT03888378|OTHER|Topical Vehicle Ointment|Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction
223549662|NCT00049322|BIOLOGICAL|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
224015127|NCT01119105|DRUG|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
224015128|NCT01119105|DRUG|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
223549663|NCT05663008|PROCEDURE|128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)|128 electrode EEG and 8 bipolar EMG or HD-EMG will be noninvasively recorded from electrodes placed in a montage over the scalp and arm muscles while the participant is resting or performing tasks designed to engage specific cortical networks of interest (cognitive, behavioural, motor and sensory)
224015129|NCT01119105|DRUG|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
224128202|NCT06352372|DEVICE|noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)|The proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills.
223549664|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
223549665|NCT00693069|DRUG|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
223549666|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
223549667|NCT00693069|DRUG|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
223549668|NCT00453869|OTHER|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
223549669|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
224015130|NCT00421044|DRUG|Patupilone/EPO906|
224015131|NCT05384405|DEVICE|Active iTBS|MagPro X100
223395755|NCT05973188|DRUG|Warfarin|Anticoagulant
223395756|NCT05973188|DRUG|Rivaroxaban 20 MG Oral Tablet|Anticoagulant
223395757|NCT05973188|DRUG|Apixaban 5mg or 2.5mg oral tablet|Anticoagulant
223549670|NCT00383669|DIETARY_SUPPLEMENT|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
223549671|NCT02552095|DEVICE|Triathlon PKR|
223549672|NCT04051749|PROCEDURE|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
223549673|NCT04847570|OTHER|Music session|Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
224015132|NCT05384405|DEVICE|Sham iTBS|MagPro X100
224015133|NCT00824356|DRUG|GSK1004723 (200mg)|Intranasal antihistamine.
223395758|NCT02285361|DRUG|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
223395759|NCT02285361|DRUG|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
223395760|NCT02285361|DRUG|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
224015134|NCT00824356|OTHER|Placebo|Equivalent to GSK1004723 in presentation etc.
224015135|NCT00824356|DRUG|GSK1004723 (1000mg)|Intranasal antihistamine.
224015136|NCT01039623|BIOLOGICAL|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
224015137|NCT00460200|GENETIC|polymorphism analysis|
224015138|NCT00460200|OTHER|laboratory biomarker analysis|
224015139|NCT00460200|OTHER|physiologic testing|
224015140|NCT00460200|OTHER|questionnaire administration|
224015141|NCT00460200|PROCEDURE|conventional surgery|
223395761|NCT02462590|DRUG|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
223395762|NCT02462590|DRUG|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
223395763|NCT05306002|COMBINATION_PRODUCT|Antioxidant therapy|Antioxidant therapy based in the following dietary components: Zinc, Selenium, Magnesium, carotenoids, indole-3-carbinol, curcumin, epigalactocatechin, caffeine, resveratrol, lycopene, genistein, phytoestrogens
223395764|NCT03124368|DRUG|Danicopan|Participants received study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period).
223395765|NCT02892669|OTHER|non interventional study|non interventional study
223395766|NCT05529927|DRUG|Sustained-release Dexamphetamine|"During the first week, patients will be individually titrated to the target dose of 90 mg/day, if tolerated. From the second week onwards, patients are prescribed 3 tablets (30 mg) per day, if tolerated. Titration can be slower but should be finished at the end of week 4. After 4 weeks dosages can no longer be increased, and only be reduced.~Patients will visit the treatment centre 2 times per week to take their study medication under supervision of the treatment staff and to receive take-home medication for the days in between study visits.~After 24 weeks patients will be randomized to either (double-blind) continuation or discontinuation (placebo) of SR-Dexamphetamine treatment to assess the consequences of discontinuation, during a 6 weeks period."
223395767|NCT05529927|DRUG|Placebo|"Dispensed under the same conditions and with similar frequency as the investigational product (see above).~After 24 weeks study medication will be discontinued in the placebo group."
223395768|NCT01109212|DRUG|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
223395769|NCT01109212|DRUG|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
223549674|NCT06273566|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the AdT-Physio, Brief Cope and GSES questionnaires in random order.
223549675|NCT03072043|DRUG|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
223549676|NCT03072043|DRUG|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m\^2.
223549677|NCT03475446|DEVICE|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
223549678|NCT03475446|DEVICE|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
223395770|NCT06323681|DRUG|Peginterferon α-2b based treatment group|Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.
224128203|NCT06827704|BEHAVIORAL|Enhanced physical activity monitor which is Fitbit watch with mobile App|Participants will receive an enhanced physical activity monitor treatment for 6 months which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor (Fitbit watch). Edit
224128204|NCT06827704|BEHAVIORAL|Bollywood-style group dance|Participants will participate in 60-minute, moderate-intensity Bollywood-style culturally tailored group dance virtual sessions, 2x/week for 6 months
224128205|NCT06827704|BEHAVIORAL|PAMDance|Participants will receive an enhanced physical activity monitor treatment for 6 months which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor (Fitbit watch). In addition, Participants will participate in 60-minute, moderate-intensity Bollywood-style culturally tailored group dance virtual sessions, 2x/week for 6 months
224296525|NCT05925673|OTHER|Mirror Therapy|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
223395771|NCT06323681|DRUG|NAs monotherapy group|First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.
223395772|NCT01622218|BEHAVIORAL|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
223395773|NCT00505219|BIOLOGICAL|Ixmyelocel-T|Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
223549679|NCT03475446|DEVICE|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
224015142|NCT00460200|PROCEDURE|fatigue assessment and management|
223395774|NCT00505219|OTHER|Standard of Care Only|Core decompression of the femoral head to remove necrotic tissue
223395775|NCT00165464|DRUG|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
223549680|NCT03475446|DEVICE|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
223549681|NCT03475446|DEVICE|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
223549682|NCT03475446|DEVICE|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
223549683|NCT03475446|DEVICE|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
223549684|NCT03475446|DEVICE|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
224015143|NCT00460200|PROCEDURE|psychosocial assessment and care|
224015144|NCT02926599|BEHAVIORAL|Personal Optimization Training|
223395776|NCT00165464|DRUG|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
223549685|NCT03475446|DEVICE|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
223395777|NCT00165464|DRUG|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
223395778|NCT02224651|DRUG|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
224015145|NCT01593345|OTHER|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
223395779|NCT02224651|DRUG|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
224128206|NCT05786599|DRUG|methadone|"The treatment arm will take methadone 2 mg PO q8h and a placebo called placeboD PO qdaily. PlaceboD and duloxetine will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
224128207|NCT05786599|DRUG|duloxetine|"The control arm will receive duloxetine 30 mg PO qdaily, and a placebo called placeboM PO q8h. PlaceboM and methadone will be placed in capsules to be virtually indistinguishable.~Participants will be followed (televisit or in-person) by assessors every week; this will take approximately 15 minutes. This includes review of questionnaire(s), adverse events (and any potential management), and recommendations on dose titration. To maintain blinding and ensure standardization across assessors, titration protocols will be provided. If pain is not controlled, the assessors will instruct the participant to increase their methadone/placeboM drug by 1 capsule PO q8h and their duloxetine/placeboD drug to 2 capsules PO qdaily (the study maximum). If there are poorly tolerated adverse events the dose will be reduced to the previously tolerated dose, and then the following week they may attempt to titrate up again per the above protocol."
223395780|NCT02224651|DRUG|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
223395781|NCT02224651|DRUG|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
223395782|NCT04754932|OTHER|Cognitive Stimulation Therapy|Group-based therapy for people living with mild to moderate stage dementia, delivered by two trained facilitators.
223395783|NCT00234975|DRUG|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
223549686|NCT01466205|DRUG|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
223549687|NCT01466205|DRUG|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
223549688|NCT01340664|DRUG|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
224128208|NCT05898750|DIETARY_SUPPLEMENT|MorDom|oral powder in tea bags contains 4gm twice daily (equal concentration of each drugs)
223395784|NCT05835440|OTHER|no intervention|interviews
223395785|NCT00490750|PROCEDURE|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
223395786|NCT00490750|PROCEDURE|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
223395787|NCT01498796|DRUG|Ketorolac|
223395788|NCT01498796|DRUG|Normal Saline|
223395789|NCT01185678|DRUG|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
223395790|NCT05743829|PROCEDURE|Tissue excision as part of routine clinical care|Tissue excision
223395791|NCT00381862|DRUG|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
223549689|NCT01340664|DRUG|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
223549690|NCT01340664|DRUG|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
223549691|NCT01340664|DRUG|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
223549692|NCT02452385|DRUG|CM082 tablet|CM082 tablets taken orally
223549693|NCT00415870|BEHAVIORAL|Printed Material|Printed Material
223549694|NCT00415870|BEHAVIORAL|Weekly Weighing|Weekly Weighing
223549695|NCT00415870|BEHAVIORAL|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
223549696|NCT00415870|DEVICE|Text Message|Text Message
223549697|NCT00415870|BEHAVIORAL|Diet Goals via Cell Phone|Diet Goals via Cell Phone
223395792|NCT00381862|DRUG|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
223395793|NCT00381862|DRUG|fluorouracil|as per institutional standard of care
223395794|NCT00381862|DRUG|irinotecan hydrochloride|as per institutional standard of care
223395795|NCT00381862|DRUG|leucovorin calcium|as per institutional standard of care
223395796|NCT00381862|DRUG|oxaliplatin|as per institutional standard of care
223395797|NCT00381862|DRUG|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
223395798|NCT00381862|PROCEDURE|quality-of-life assessment|baseline
223395799|NCT05855135|DEVICE|OPTIMIZER® Integra CCM-D System (Treatment Arm)|"The CCM-D System is an implantable cardiac device system that combines cardiac contractility modulation and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a Cardiac Contractility Modulation - Defibrillator. All 300 subjects will be implanted with the CCM-D System and followed for a period of at least two years."
223395800|NCT02095548|DRUG|SM04690, 0.03mg/2mL|
223395801|NCT02095548|DRUG|SM04690, 0.07mg/2mL|
223395802|NCT02095548|DRUG|SM04690, 0.23mg/2mL|
224015146|NCT01593345|OTHER|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
224015147|NCT00852033|BEHAVIORAL|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
224015148|NCT00852033|BEHAVIORAL|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
223395803|NCT02095548|DRUG|Placebo|
223395804|NCT02173691|DRUG|Tiotropium inhalation powder capsules|
223395805|NCT02173691|DRUG|Salmeterol inhalation aerosol|
223395806|NCT02173691|DRUG|Placebo inhalation aerosol|
223395807|NCT02173691|DRUG|Placebo inhalation powder capsules|
223395808|NCT02773901|DEVICE|HS-1000|
223395809|NCT01182012|BEHAVIORAL|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
223549698|NCT00415870|BEHAVIORAL|Food Monitoring|Food Monitoring
223549699|NCT03994211|DRUG|pamiparib 60 mg|Single dose of 60 mg pamiparib orally on Days 1 and 10
223549700|NCT03994211|DRUG|pamiparib 20 mg|Single dose of 20 mg pamiparib orally on days 1 and 7
223395810|NCT00598741|OTHER|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
223395811|NCT00292734|DRUG|Zolpidem|
223395812|NCT05176821|DRUG|esomeprazole plus amoxicillin|amoxicillin 750mg QID + esomeprazole 20mg QID for 14 days
223549701|NCT03994211|DRUG|itraconazole|200 mg itraconazole once a day al Day 3 to day 8
223395813|NCT05176821|DRUG|amoxicillin, furazolidone, bismuth potassium citrate , esomeprazole|amoxicillin 1000mg BID + furazolidone 100mg BID + bismuth potassium citrate 600mg BID + esomeprazole 20mg BID for 14 days
223395814|NCT05576142|DIAGNOSTIC_TEST|Oral examination|Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.
223395815|NCT06578377|OTHER|descriptive study|It is a descriptive study
223395816|NCT05037201|BEHAVIORAL|Text message|The intervention arm will receive a text message stating that the vaccine is reserved for them on a specific date. They will have the ability to reschedule to a different day, opt-out of this text messaging intervention, or if previously vaccinated they can upload documentation to the Ascension website.
223395817|NCT03776357|DEVICE|VERA clinic|A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
223395818|NCT01664663|RADIATION|Standard radiochemotherapy to 68 Gy|
223395819|NCT01664663|RADIATION|Dose escalated radiochemotherapy up to 84 Gy|
223395820|NCT03055455|DIAGNOSTIC_TEST|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
223395821|NCT05651321|OTHER|Samples materials of basic taste stimuli and enteral nutrition preparations|Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
223395822|NCT01750775|DRUG|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
223395823|NCT01750775|DRUG|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
223395824|NCT00004656|PROCEDURE|Metabolic assessment with body composition evaluation|
223549702|NCT03994211|DRUG|rifampin|600 mg rifampin once a day from days 3 to 11
223549703|NCT03994211|DRUG|pamiparib|60 mg pamiparib orally twice a day in 28-day cycles
223549704|NCT02015949|DRUG|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
223395825|NCT05509907|OTHER|Pedi@ctivity Analysis and Tracking Mobile Applications and Web Platform|"Pedi@ctivity Analysis Mobile Application and than Pedi@ctivity Analysis and Tracking Web Platform synchronized with the Pedi@ctivity Tracking Mobile Application, will be developed. The collected data will be analyzed with statistical methods and models using artificial intelligence algorithms will be created. According to the evaluations, physical activity and exercise videos and programs will be prepared and uploaded to web platform. Programs will include stretching, strengthening, balance, aerobic, calisthenic exercises and aerobic dance. The exercise and physical activity program will also be synchronized with the Pedi@ctivity Tracking Mobile Application and the smart watch. Pedi@ctivity Mobile Applications will provide health parameters from the smart watch, suggestions suitable for the exercise and physical activity program, and motivational feedback. Each adolescent will be included in a 3-month program. After the 3-month all evaluations at the beginning will be repeated."
223395826|NCT06575478|DRUG|Fuling Yunhua Granules|Fuling Yunhua Granules
223549705|NCT02015949|DRUG|Placebo|Twice daily placebo tablet for two weeks
224015149|NCT00852033|BEHAVIORAL|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
224015150|NCT00852033|OTHER|Assessment only|No intervention, assessment only.
224015151|NCT03756987|DRUG|Ropivacaine Injection|Ropivacaine will be injected in the erector spinae plane
224015152|NCT03756987|DRUG|Normal saline|Normal saline will be injected in the erector spinae plane.
223395827|NCT06575478|DRUG|Fuling Yunhua Granules matched placebo|Fuling Yunhua Granules placebo
223395828|NCT06575478|DRUG|Dihuang Baoyuan Granules|Dihuang Baoyuan Granules
223395829|NCT06575478|DRUG|Dihuang Baoyuan Granules matched placebo|Dihuang Baoyuan Granules placebo
223395830|NCT06574685|DIETARY_SUPPLEMENT|Twinkle Eyez Supplementation|The intervention supplement consisted of marigold extract, zeaxanthin, elderberry extract, bilberry extract, lycopene extract, multivitamin, silicon dioxide, inulin, and dextrose monohydrate, all in powder form and packaged in individual sachets (Twinkle Eyez™; Xmegami, Selangor, Malaysia). Each sachet contained 4.6 mg of lutein and zeaxanthin and 15.4 mg of elderberry extract.
223395831|NCT06574685|DIETARY_SUPPLEMENT|Placebo|The placebo supplement was identical in composition but excluded the active ingredients.
223395832|NCT04189978|DIAGNOSTIC_TEST|Clinical evaluation|The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.
223395833|NCT01367678|DEVICE|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
223395834|NCT01367678|DEVICE|i-Gel extraglottic airway device|Directly measured mucosal pressures
223395835|NCT06578611|COMBINATION_PRODUCT|Enhanced recovery after surgery|Recommended pre-, intra-, and post-operative care interventions in the enhanced recovery after surgery.
223395836|NCT02599285|DEVICE|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
223395837|NCT02599285|DEVICE|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
223395838|NCT05754892|OTHER|Blood sample|For patients with ACC : blood (30ml) sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : blood (30ml) sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
223395839|NCT05754892|OTHER|Urine sample|For patients with ACC : urine sampling before surgery and every 3 months during 3 years after surgery for biobanking For patients with MPP : urine sampling before surgery and every 6 to 12 months for MPP during 3 years after surgery for biobanking
223395840|NCT05754892|OTHER|Tumor sample|For patients with ACC and patients with MPP : tumor sample during surgery
223395841|NCT06411158|OTHER|Interventionist-guided training|Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
223549706|NCT02146053|DIETARY_SUPPLEMENT|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
223549707|NCT02146053|DIETARY_SUPPLEMENT|Placebo|placebo capsules: methyl cellulose
223549708|NCT00583674|DRUG|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549709|NCT00583674|DRUG|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549710|NCT00583674|DRUG|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
224015153|NCT00531739|OTHER|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
224015154|NCT01694173|OTHER|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
224015155|NCT01694173|OTHER|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
224015156|NCT01694173|OTHER|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
224015157|NCT01694173|OTHER|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
224015158|NCT00618618|DRUG|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
224015159|NCT00618618|DRUG|Placebo|
224015160|NCT04974242|OTHER|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
224015161|NCT05631470|DIAGNOSTIC_TEST|MR screening|This study is to compare the results of MR-FFR with pressure-wired-based FFR measurement.
224015162|NCT02197403|DRUG|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion
223395842|NCT06411158|DEVICE|Home pelvic floor exercises guided by the leva® device|Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
223395843|NCT06411158|OTHER|Education|Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
223395844|NCT02179892|DRUG|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
224015163|NCT02197403|DRUG|Propofol|25\~75mcg/kg/min continuous infusion
224128209|NCT00244894|PROCEDURE|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
223395845|NCT02179892|DRUG|Bupivacaine and Dexamethasone Injection|As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
223395846|NCT02179892|DRUG|IV Acetaminophen|Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
223395847|NCT02179892|DRUG|Oral Acetaminophen|Oral acetaminophen 650 mg every 6 hours.
223395848|NCT04055701|OTHER|assesment of thymus volume|assesment of thymus volume
224015164|NCT02929329|DRUG|Omecamtiv Mecarbil|Omecamtiv mecarbil tablets for oral administration
224015165|NCT02929329|DRUG|Placebo|Matching placebo tablets
224015166|NCT02929329|DRUG|Standard of Care|Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
223395849|NCT06295874|OTHER|Effect of aromatherapy massage on vital signs, pain, anxiety and comfort level|The study applied a mixture of lavender, thyme and eucalyptus oil (5 drops of lavender oil, 4 drops of thyme oil, 3 drops of eucalyptus oil and 20 ml of almond oil in 20 ml) to patients who were monitored in intensive care on high-flow and oxygen, for three days. It was conducted as a randomized controlled single-blind study to evaluate the effects of aromatherapy massage applied twice a day for a total of 30 minutes on some physiological parameters, pain, anxiety and comfort levels.
223395850|NCT05480072|DRUG|Palmitoylethanolamide|Palmitoyethanolamide (PEA) s a dietary supplement with anti-inflammatory and analgesic properties. Subjects will receive PEA (Levagen+) 600 capsules mg twice daily (BID) orally from Day 1 to Day 21
223395851|NCT05480072|OTHER|Placebo|Participants will receive placebo matched to 600 mg PEA (Levagen+) capsules BID orally from Day 1 to Day 21
223395852|NCT04024969|DIAGNOSTIC_TEST|T2* MRI|Research T2\* weighted MRI sequence
223395853|NCT04024969|DIAGNOSTIC_TEST|Lumbar puncture to test for presence of unmatched oligoclonal bands|Current clinical standard practice
223395854|NCT04903639|DIAGNOSTIC_TEST|sleep study|The polysomnography consists of electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), electromyogram (EMG), pulse oximetry, thoracic and abdominal straps, body posture sensor, nasal thermistor and nasal cannula to assess respiratory flow and pressure and bipolar channel limb movements (tibialis anterior). Electrodes and sensors were attached to patients by sleep physiologist. Data collection was obtained following signal perception by preprocessed computer (DOMINO Software, ver. 2.6.0; SOMNO Medics GmbH).
223395855|NCT05938647|OTHER|Risk factor: group 3|Severe dengue, no shock. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes.
223395856|NCT05938647|OTHER|Risk factor: group 4|Dengue shock syndrome. No diagnostic or therapeutic intervention; the characteristics of participants will be analyzed by demographics, severity, laboratory results, fluids accumulation, and outcomes
223395857|NCT05089513|PROCEDURE|Robotic surgery|Robotoc surgery (Da Vinci) in both donor and recipient
223395858|NCT05976321|DRUG|TAK-279|TAK-279 capsules.
224015167|NCT01531010|DEVICE|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
224015168|NCT02371213|OTHER|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
224015169|NCT04960189|PROCEDURE|Acupuncture|Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
224015170|NCT01183234|DRUG|SPD544|two 30mg capsules, single oral dose
224015171|NCT01183234|DRUG|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
224015172|NCT04735328|BEHAVIORAL|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
224015173|NCT04735328|BEHAVIORAL|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post Traumatic Stress Symptoms (PTSD).
224015174|NCT04735328|BEHAVIORAL|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
224128210|NCT00244894|PROCEDURE|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
223395859|NCT05644054|DRUG|THC|Patients will be administered a one-time dosage of 0.2 mg/kg THC oil (AXIBAN, T10/C2, manufactured by Panaxia Pharmaceuticals, Lod, Israel)
223395860|NCT05644054|DRUG|Placebo|Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
224015175|NCT04401501|OTHER|Manual Therapy and Exercises|Combination of physiotherapy (manual therapy) techniques and exercises for cervicogenic headache
223395861|NCT06578832|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH, buffering capacity
223395862|NCT06578832|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities
223395863|NCT06578832|DIAGNOSTIC_TEST|biochemical tests|urea, calcium, potassium, phosphorus
223395864|NCT06578832|DIAGNOSTIC_TEST|Oral Health Habits|Tooth brushing frequency Dental floss usage Annual dentist visits
223549711|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
224015176|NCT04401501|OTHER|Exercise|Exercises for cervicogenic headache
224015177|NCT00704379|DRUG|Placebo|an inactive substance
224015178|NCT00704379|DRUG|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
224015179|NCT03787082|DRUG|Nitrates|1,000 mg/11.18 mmol, oral
224015180|NCT03787082|DRUG|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
224015181|NCT03787082|DRUG|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
224015182|NCT03250234|OTHER|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
224015183|NCT03250234|OTHER|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
224015184|NCT01819259|DRUG|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
224015185|NCT01819259|DRUG|Placebo|
224015186|NCT00962403|BEHAVIORAL|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
224015187|NCT03925545|DEVICE|FluidVision AIOL|Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
223395865|NCT06578832|DIAGNOSTIC_TEST|Oral Findings|"DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries.~DDE Index: Developmental Defects of Enamel index. BAKH Index: Basic Anatomic Keratinization Hierarchy, typically used in specific studies.~DI (Debris Index): Assesses oral hygiene based on the amount of debris on the teeth.~CI (Calculus Index): Measures the amount of calculus (tartar) on the teeth. OHI-S (Simplified Oral Hygiene Index): Assesses oral hygiene based on the presence of debris and calculus.~MGI (Modified Gingival Index): Assesses the severity of gingivitis based on inflammation."
223395866|NCT06578832|DIAGNOSTIC_TEST|Quality of Life Assessment|KINDLR Scale: Used to assess disease-related quality of life from both the child's and the parent's perspectives.
223549712|NCT00583674|DRUG|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549713|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549714|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549715|NCT00583674|DRUG|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549716|NCT00583674|DRUG|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
223549717|NCT01140867|DRUG|zonisamide|zonisamide 100 mg tablet
224015188|NCT03925545|DEVICE|AcrySof IQ monofocal IOL|Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject
224015189|NCT03925545|PROCEDURE|Cataract surgery|Standard cataract extraction with phacoemulsification
224015190|NCT04301531|OTHER|Mass testing using RDTs|To determined the prevalence of asymptomatic malaria parasitaemia. In arm 1 all participants will be tested six times over the study period while in arm 2 the participants will be only be tested at baseline and evaluation.
224015191|NCT04301531|DRUG|Treatment for all cases confirmed positive malaria cases with ACTs|During each mass testing, all confirmed positive cases are treated in both arms.
223395867|NCT05071209|DRUG|Elimusertib|Given PO
223395868|NCT00232297|DRUG|SSR149744C|
223549718|NCT03235921|DRUG|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
223549719|NCT03235921|OTHER|placebo|no drug given to the control group
223549720|NCT00633087|DRUG|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
224015192|NCT04301531|OTHER|Determination of Hb|Hb of all children in the subgroup study are measured using a haemocure photometer.
223549721|NCT02997865|BEHAVIORAL|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
223549722|NCT01146184|DEVICE|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
223549723|NCT02977364|DRUG|HS-10241|
223549724|NCT04013776|DIETARY_SUPPLEMENT|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
223549725|NCT05730868|PROCEDURE|myofascial release|Soft tissue release will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
223549726|NCT05730868|PROCEDURE|muscle energy technique|Muscle energy Technique will be performed on the trapezius, sub occipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
223549727|NCT05730868|PROCEDURE|MFR & MET|combination of myofascial release and muscle energy technique will be performed on the trapezius, suboccipital and sternocleidomastoid muscles. The visual analog scale will be used to check pain intensity. Algometer will be used to check the pain pressure threshold and tissue hardness. neck disability index will be used to check neck disability
223549728|NCT05730868|PROCEDURE|conventional therapy|traditional physical therapy devices are used to relieve pain and spam. this will include a hot pack, ultrasound, and TENS (Transcutaneous electrical nerve stimulation)
223549729|NCT01926444|DRUG|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
224015193|NCT04301531|OTHER|Household survey|Determine the prevalence of febrile illnesses among children in the subgroup study
224015194|NCT04301531|OTHER|Community-base management of malaria|Between interventions, participant who become febrile are tested and treated if confirmed positive for malaria by CHWs
224128211|NCT00244894|PROCEDURE|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
224128212|NCT00244894|PROCEDURE|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
223395869|NCT05944913|DEVICE|Prevena|PREVENA™ is a CE-marked class IIa medical device. The PREVENA™ Incision Management System is also intended to manage the environment of closed surgical incisions and surround intact skin in patients at risk for developing post-operative complications, such as infection, by maintaining a closed environment via the application of a negative pressure wound therapy system to the incision.
223395870|NCT05308134|OTHER|Standard fortification|Standard fortification assumes that the nutrient content of human milk is constant and involves use of a standard fixed dose of multi-nutrient fortifier and as appropriate nutrient modulars.
223395871|NCT05308134|OTHER|Target fortification|Target fortification involves use of a multi-nutrient fortifier as well as weekly analysis of energy and macronutrients of human milk and subsequent addition of fat and protein modulars if needed.
223395872|NCT05308134|OTHER|BUN adjustable fortification|BUN (blood urea nitrogen) adjustable fortification involves use of a multi-nutrient fortifier as well as weekly BUN tests and subsequent addition of a protein modular according to a prescribed algorithm.
223395873|NCT02755103|BEHAVIORAL|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
223395874|NCT03142139|BIOLOGICAL|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~* timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~* delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
223395875|NCT03142139|BIOLOGICAL|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~* timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~* delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
224015195|NCT03276325|DRUG|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
224015196|NCT03276325|DRUG|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
224015197|NCT02937454|DRUG|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
224015198|NCT02937454|OTHER|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
224015199|NCT02703051|DRUG|GMI-1271|
224015200|NCT02703051|DRUG|Filgrastim|
224015201|NCT02703051|DRUG|Placebo Injection|
224015202|NCT02703051|DRUG|Placebo Infusion|
224015203|NCT01940224|DRUG|Pregabalin|Preoperative administration of pregabalin 300mg
224015204|NCT01940224|DRUG|Placebo|Preoperative administration of placebo
224128213|NCT00244894|PROCEDURE|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
224128214|NCT04046406|DEVICE|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
224128215|NCT04637945|DIETARY_SUPPLEMENT|ACRB|Product will be consumed once daily, preferably with breakfast.
224128216|NCT04637945|OTHER|Placebo|Product will be consumed once daily, preferably with breakfast.
224128217|NCT00478725|DRUG|GW786034, oral|oral, 800 mg
224128218|NCT00478725|DRUG|GW786034, IV|IV, 5 mg
224128219|NCT00478725|DRUG|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
223549730|NCT00742131|DRUG|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.
223549731|NCT00841243|DIETARY_SUPPLEMENT|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
223549732|NCT03579693|DIETARY_SUPPLEMENT|CoQ10|CoQ10 tablet
223549733|NCT03579693|DIETARY_SUPPLEMENT|Nicotinamide riboside|NR tablet
223549734|NCT03579693|DIETARY_SUPPLEMENT|Placebo|Sugar pill designed to mimic coQ10 and NR
223549735|NCT04972188|DRUG|ZYIL1 Capsule|NLRP3 inflammasome inhibitor
223549736|NCT01119144|DEVICE|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
223549737|NCT01119144|DEVICE|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
223549738|NCT02441101|DEVICE|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
223395876|NCT03142139|BIOLOGICAL|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
223395877|NCT05955937|OTHER|Enhanced HF Clinical Care (Core-HF)|All clinical care providers involved in HF care at participating RRHs will be trained in a HF service bundle including a care protocol (treatment algorithm based on global guidelines), self-care training for patients and providers, and medication stock management to ensure supply of HF medications to patients in need.
223395878|NCT05955937|OTHER|Digital health intervention (Medly Uganda) plus enhanced HF clinical care (Core-HF)|A patient-facing mobile health application designed to improve self-care will be provided to the study participant, which will operate on all mobile devices. This will be introduced after the Core-HF intervention has been delivered.
223395879|NCT01833481|RADIATION|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
223549739|NCT02441101|DEVICE|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
223549740|NCT04868305|PROCEDURE|Intramedullary nail|"Intertan nail (Smith \& Nephew)\* or Gamma 3 nail (Stryker)\*~\* All of the above-mentioned products are subjects to change into an equivalent product"
223549741|NCT04868305|PROCEDURE|Hip arthroplasty|"Total hip arthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~* Cup: Cemented Avantage dual mobility cup (Zimmer Biomet)\*~Hemiarthroplasty:~* Cemented: Lubinus (Link)\*, Exeter (Stryker)\*~* Uncemented: Restoration Modular (Stryker)\*~  * All of the above-mentioned products are subjects to change into an equivalent product"
224015205|NCT01940224|DRUG|Morphine|Postoperative administration of morphine via PCA pump for 48h
224015206|NCT03268447|DIETARY_SUPPLEMENT|Lactobacillus plantarum P8|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
224128220|NCT01760993|DRUG|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
223549742|NCT05918965|DEVICE|transcutaneous electrical vagal neurostimulation|daily for 12 weeks
223549743|NCT05365789|DEVICE|Blocked Nose Baby nasal spray|One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
223549744|NCT05365789|OTHER|Standard of care|Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
223549745|NCT00933439|DRUG|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
223549746|NCT05393999|BIOLOGICAL|BMS-986414|Broadly neutralising antibodies BMS-986414
223549747|NCT05393999|BIOLOGICAL|BMS-986413|Broadly neutralising antibodies BMS-986413
223549748|NCT00043745|DIETARY_SUPPLEMENT|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
223549749|NCT00043745|DIETARY_SUPPLEMENT|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
223549750|NCT01736267|DEVICE|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
223549751|NCT02408172|DRUG|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
223549752|NCT02408172|DRUG|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
223549753|NCT00403013|PROCEDURE|Positioning and anesthesia|Positioning during axillary plexus block
224015207|NCT03268447|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
224015208|NCT04152304|OTHER|Sinex program (neuromuscular training program)|The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
224015209|NCT00560560|BIOLOGICAL|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
224296526|NCT05925673|OTHER|Neuromuscular Stimulation (NMES)|Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
223395880|NCT03578432|DRUG|Everolimus|Given PO
223395881|NCT03578432|OTHER|Laboratory Biomarker Analysis|Correlative studies
224128221|NCT05053997|BEHAVIORAL|NAVIGATE|Patients' symptoms are systematically monitored by use of bi-weekly patient reported outcomes and nurse navigators will initiate appropriate actions in terms of medical treatment or guidance of self-management strategies. Nurse navigators will motivate and support patients in health behavior changes and in selfmanaging their treatment and symptoms, and, if relevant, refer to existing rehabilitation services at the hospital or at the local rehabilitation center. Physiotherapists will supervise a training program aimed at improving patients' physical function and thus potentially surgery and overall treatment adherence and outcomes.
224128222|NCT00000255|DRUG|Nitrous oxide|
223395882|NCT03578432|OTHER|Survey Administration|Ancillary studies
223395883|NCT03574285|DRUG|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
223395884|NCT03574285|DRUG|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
223395885|NCT04736849|DEVICE|Percutaneous epidural and dorsal root stimulation|"Abbott percutaneous trial lead for dorsal root ganglion neurostimulation (Model MN10350)~Abbott percutaneous trial lead for epidural neurostimulation (Model 3086)~Abbott clinician programmer for epidural and dorsal root ganglion neurostimulation (Model 3874)~Ripple Neuromed Nomad Neurostimulation System"
223395886|NCT02090348|DRUG|dimethyl fumarate|Administered as specified in the treatment arm
223395887|NCT04795648|DEVICE|Transfluthrin|Passive emanator with formulated transfluthrin
223395888|NCT04795648|DEVICE|Placebo|Passive emanator with formulated inert ingredients
223395889|NCT06539507|DRUG|BCX17725|BCX17725 for injection
223395890|NCT06539507|DRUG|Placebo|Placebo for injection
223395891|NCT00658723|DRUG|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
223395892|NCT00658723|DEVICE|SURGICEL™|Absorbable hemostat
223395893|NCT02411656|OTHER|Laboratory Biomarker Analysis|Correlative studies
223395894|NCT02411656|BIOLOGICAL|Pembrolizumab|Given IV
223395895|NCT06546449|DRUG|LH-001|LH-001 will be administered oral
223395896|NCT06546449|DRUG|Placebo|Placebo will be administered oral
223395897|NCT06481709|DRUG|RLF-OD032|100 mg/mL oral suspension
223395898|NCT06481709|DRUG|Kuvan|100 mg powder for oral solution
223395899|NCT02017158|OTHER|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
223395900|NCT06576232|DEVICE|Median LCS|End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
223395901|NCT03314792|DRUG|Tapentadol|"* Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~* Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
223395902|NCT03314792|DRUG|Oxycodone|"* OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~* OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
223395903|NCT06968104|DEVICE|transcutaneous vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (taVNS) delivered using the CE-certified tVNS® device (tVNS Technologies GmbH). Stimulation parameters include a pulse width of 250-500 μs, frequency of 10-25 Hz, and an individually titrated intensity (typically up to 5 mA). The device operates with a 20-50% duty cycle and is used at home.
223395904|NCT06968104|DEVICE|transcutaneous vagus nerve stimulation|Sham stimulation using the same CE-certified tVNS® device. Electrode placement is on the earlobe, which lacks vagus nerve innervation. Stimulation parameters (pulse width, frequency, intensity, duty cycle) mirror those of the active condition, with intensity adjusted to perceptual threshold to mimic the sensation of real stimulation and preserve blinding.
223395905|NCT02874625|PROCEDURE|Dental restoration|Teeth with caries will be restored
223549754|NCT01999686|DRUG|DLBS3233|
223549755|NCT01999686|DRUG|Metformin XR|
223395906|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - including VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including virtual reality, online (videos, animations, articles), and print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
223549756|NCT01999686|DRUG|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
223549757|NCT01999686|DRUG|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
223549758|NCT02528942|RADIATION|Radiation therapy|Radiation therapy will be given to study patients.
224128223|NCT03573128|BEHAVIORAL|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
224128224|NCT03573128|OTHER|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
224128225|NCT04395352|DEVICE|Endocuff Vision (ECV)|Detachable disposable (single-use) device that fits over the distal colonoscope end.
224128226|NCT00681967|DRUG|Gefitinib|250 mg; oral
224128227|NCT00681967|DRUG|Gefitinib|250mg; oral
223395907|NCT05383911|BEHAVIORAL|SCD Shared Decision-Making Toolkit for AYAs - without VR|The SCD Shared Decision-Making Toolkit for AYAs (SDMT-AYA) targets multi-level barriers to uptake of disease-modifying therapies by providing technology-enhanced tools for: 1) clinicians (i.e., training in motivational interviewing, values elicitation, and cultural humility); 2) AYAs and caregivers (i.e., user-centered multimedia decision aids, including online videos, animations, and articles as well as print materials); and 3) implementation (e.g., clinic audit and feedback strategies).
223395908|NCT06966622|PROCEDURE|3D visualization system with coaxial illumination|operation through 3D visualization system with coaxial illumination
223395909|NCT06966622|PROCEDURE|microscope with standard illumination|operation through microscope with standard illumination
223549759|NCT00110786|BIOLOGICAL|Ragweed MATAMPL|
223549760|NCT04603469|OTHER|Non invasive blood pressure|measurement of blood pressure during induction of general anesthesia
223549761|NCT00881530|DRUG|BI 10773|BI 10773 high dose once daily
223549762|NCT00881530|DRUG|Metformin|open label comparator
223549763|NCT00881530|DRUG|BI 10773|BI 10773 low dose once daily
223549764|NCT00881530|DRUG|Sitagliptin|open label comparator
223549765|NCT05934110|DRUG|EMP16-120/40|"EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID)."
223549766|NCT05934110|DRUG|MR orlistat 120 mg|"MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID)."
223549767|NCT05934110|DRUG|Conventional orlistat 120 mg,|"Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID)."
223549768|NCT05934110|DRUG|EMP16-60/20|"Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)"
223395910|NCT06576531|OTHER|Therapeutic exercise|A stepped training intervention designed ad hoc based on a combination of aerobic and strength exercises.
223395911|NCT05702931|DRUG|Semaglutide 14 MG [Rybelsus]|At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
223395912|NCT05702931|DRUG|Placebo|Saline
223549769|NCT05934110|DRUG|Placebo|"Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)"
223549770|NCT06041022|OTHER|Exposure factors|Including demographical data, laboratory features and liver histological indicators.
223549771|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
223549772|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
223549773|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56
223549774|NCT01509846|BIOLOGICAL|Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
223549775|NCT01509846|BIOLOGICAL|Placebo: 1-3 doses|Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
223549776|NCT01687881|OTHER|Chiropractic|Chiropractic Spinal Manipulative Therapy
223395913|NCT02651662|DRUG|cemiplimab|Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.
223549777|NCT01687881|OTHER|Sham Chiropractic|Sham manipulation
223395914|NCT02651662|DRUG|odronextamab|Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
223395915|NCT06546254|DRUG|Lidocaine 1% Injectable Solution|10 cc 1% lidocaine paracervical injection
223395916|NCT06546254|OTHER|Capped needle|Tapping the cervicovaginal junction with a capped needle
223395917|NCT05584735|BIOLOGICAL|Influenza vaccine|Observe effects of flu vaccine on microbiome
223395918|NCT05584735|BIOLOGICAL|COVID-19 vaccine|Observe effects of COVID-19 vaccine on microbiome
223395919|NCT06441994|DRUG|PSW-1025|PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
223549778|NCT02194946|DRUG|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
223549779|NCT02194946|DRUG|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
223549780|NCT05833412|DIAGNOSTIC_TEST|Septicyte Rapid ®|SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).
224128228|NCT03695640|DRUG|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
224128229|NCT03695640|PROCEDURE|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
224128230|NCT00091143|BIOLOGICAL|gp100 antigen|
223549781|NCT05833412|DIAGNOSTIC_TEST|FilmArray® blood culture identification (BCID2®)|After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
223549782|NCT03836846|BEHAVIORAL|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
223549783|NCT03836846|BEHAVIORAL|Treatment as usual|TAU as per standard of care
223549784|NCT04017780|DEVICE|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
223549785|NCT04017780|DEVICE|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
223549786|NCT04017780|DEVICE|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
223549787|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)|Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
223549788|NCT05508178|BIOLOGICAL|Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)|Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
223549789|NCT05508178|DRUG|Placebo|Norovirus vaccine (rNV-2v) vehicle without antigen
223549790|NCT06227312|DEVICE|LADY 1 Pro, New Life Balance|whole-body vibration training on the platform
223549791|NCT06227312|OTHER|exercises|calf raises and modified drop jumps
223549792|NCT01743612|PROCEDURE|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
223549793|NCT01743612|PROCEDURE|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
223549794|NCT00373646|DRUG|Thalidomide, Pharmion|200 mg p.o. daily
223549795|NCT01552512|DIETARY_SUPPLEMENT|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
223549796|NCT01552512|OTHER|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
223549797|NCT02250131|PROCEDURE|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
223549798|NCT03686930|DRUG|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
223549799|NCT03686930|DRUG|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
223549800|NCT03686930|DRUG|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
223549801|NCT03686930|DRUG|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
223395920|NCT01471483|BEHAVIORAL|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
223549802|NCT01899131|DEVICE|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
224128231|NCT00091143|BIOLOGICAL|incomplete Freund's adjuvant|
224128232|NCT00091143|BIOLOGICAL|keyhole limpet hemocyanin|
224128233|NCT00091143|DRUG|fludarabine phosphate|
224128234|NCT00091143|PROCEDURE|peripheral blood stem cell transplantation|
223395921|NCT01471483|OTHER|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
223395922|NCT05704166|DRUG|Pirfenidone/Placebo|Patients were given drugs orally one week before radiotherapy, 200mg/ time, 3 times a day in the first week; 300mg/ time 3 times daily for the second week and 400mg/ time 3 times daily for the third to eighth week. Take it after a meal.
223395923|NCT04099966|DRUG|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
223395924|NCT03305848|DRUG|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.
223549803|NCT03565822|OTHER|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
223549804|NCT04901806|DRUG|PBI-200|PBI-200 will be administered orally over continuous 28-day cycles
223549805|NCT05557994|OTHER|Method|treatment of mature teeth with apical periodontitis
223549806|NCT05729555|DRUG|Compound ibuprofen polyrelease tablets|Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage：Once a day, one tablet at a time
223731126|NCT05175690|DIAGNOSTIC_TEST|Diagnostic Software as Medical Device|"AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols."
224015210|NCT02381600|DRUG|Vitamin D|"Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
224015211|NCT00140985|DRUG|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
224015212|NCT00140985|DRUG|Comparator: amlodipine / Duration of Treatment: 20 weeks|
224015213|NCT02869516|OTHER|Clinical data collection|
224015214|NCT03870347|DIAGNOSTIC_TEST|Endoscopic ultrasound|Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
224015215|NCT02731183|PROCEDURE|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
224015216|NCT05442996|DRUG|HLX35|The dose of HLX35 is set at 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. It is administered intravenously every 2 weeks on day 1 of each cycle.
224015217|NCT05442996|DRUG|HLX10|The dose of HLX10 is fixed at 200 mg. It is administered intravenously once every 2 weeks on day 1 of each cycle.
223395925|NCT03648229|PROCEDURE|Selective laser trabeculoplasty (SLT)|Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
223395926|NCT03648229|DRUG|Latanoprost ophthalmic solution|Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
223395927|NCT03648229|DRUG|Timolol ophthalmic solution|Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
224015218|NCT02539147|BIOLOGICAL|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
223395928|NCT00631592|DRUG|GSK1349572|
223395929|NCT00489866|DRUG|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
223395930|NCT00489866|DRUG|Placebo|Same as active drug.
223549807|NCT05729555|DRUG|reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)|"Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20℃ -25℃ manufacturer: JOHNSON \& JOHNSON CONSUMER INC. Usage and dosage：Once a day, two tablets at a time~Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20℃ -25℃, shading manufacturer: JOHNSON \& JOHNSON CONSUMER INC Usage and dosage：Once a day, two tablets at a time"
223549808|NCT04556357|DRUG|Phenylephrine|A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
223549809|NCT04556357|DRUG|Norepinephrine|A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
223549810|NCT01637584|DRUG|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
223549811|NCT01637584|DRUG|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
223549812|NCT02967419|OTHER|No Intervention|
223549813|NCT00097929|DRUG|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
223549814|NCT00148031|DRUG|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
223549815|NCT00148031|BEHAVIORAL|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
223395931|NCT06488586|DRUG|Low dose IV Ketamine vs. IN Esketamine|For IV ketamine treatment, ketamine is administered at 0.5mg/kg over 40 minutes. For IN esketamine treatment, esketamine is administered as a nasal spray, two sprays per nostril (56mg total) for the first treatment and three sprays per nostril (84mg) for the rest of the acute series. All treatments are administered at the academic center under the supervision of a mental health care professional. Patients are asked to come fasting at least two hours prior to treatment and to remain resting in the treatment room throughout the dosing session. Throughout each dosing session, blood pressure, oxygen levels, and onset, duration and severity of common side effects are recorded by nursing staff and/or physicians. Patients are discharged after a minimum of 30 minutes post administration, provided that the vital signs return to baseline and that the patient is calm, alert, and oriented.
223395932|NCT05745818|DRUG|Colchicine Pill|oral pills
223549816|NCT00148031|BEHAVIORAL|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
223549817|NCT00148031|BEHAVIORAL|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
223549818|NCT02843438|OTHER|Fluorescein angiography|
223549819|NCT02843438|OTHER|Dilated fundus examination|
223549820|NCT02843438|BIOLOGICAL|Toxoplasmosis serology|
223731127|NCT02393833|PROCEDURE|Blood samples collection|"Blood samples to be collected at the following time points:~1. Baseline, (after the completion of induction chemotherapy and, if randomized to CM maintenance, before start of CM maintenance.)~2. Months 12, 18 and 36 after start of induction chemotherapy~3. At time of confirmatory evidence of progression"
223731128|NCT02220582|OTHER|MRI|Magnetic Resonance Imaging
223731129|NCT04751825|BEHAVIORAL|I-EAET|See information in arm description.
224015219|NCT06081504|OTHER|Wii fit exercises program|Wii fit exercises for balance training and lower limb strengthening for 30 minutes. In addition to warming up and cooling down, 10 minutes each in the form of a range of motion exercises and stretching.
224015220|NCT06081504|OTHER|Pilates exercises program|Selected pilates exercises for balance training and lower limb strengthening: Articulating bridge, Spine stretch, Single leg stretch, Double leg stretch, Criss-cross, One leg kick, Side kick, Hip twist, and Standing footwork for 30 minutes, 10 repetitions each. In addition to the warming up and the cooling down exercises before and after the pilates exercises, 10 minutes each in the form of a range of motion exercises and stretching, and deep friction massage for scar management.
224015221|NCT06081504|OTHER|Standard physical therapy program|All patients will receive the standard physical therapy program consisting of 45 minutes per session of a supervised and individualized exercise program for three sessions per week for eight weeks which will include: Stretching exercises for lower limb muscles, each stretch will be maintained for 45 seconds, 3 repetitions, strengthening exercises for lower limb muscles starting from 50 to 60% of 1 repetition maximum and the intensity will be increased gradually until 80 to 85 % through the treatments weeks.
224015222|NCT00975767|DRUG|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
224015223|NCT00975767|DRUG|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
224015224|NCT02163564|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
224015225|NCT00037830|DRUG|GM1 ganglioside|100 mg twice per day by subcutaneous injection
223395933|NCT00864630|BEHAVIORAL|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
223549821|NCT02843438|DRUG|Anti-toxoplasmosis treatment|
223549822|NCT02843438|DRUG|Anti-inflammatory treatments|
223549823|NCT02843438|OTHER|Puncture in anterior chamber|
223549824|NCT00517010|DRUG|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
223731130|NCT01830660|DRUG|Hetrombopag Olamine Tablets|
223731131|NCT01830660|DRUG|placebo|
223731132|NCT04922203|OTHER|in Situ Simulation|2 sessions of in situ simulation with 4 crisis scenarios and debriefing focused on non technical skills
224015226|NCT00037830|DRUG|Placebo|Twice per day subcutaneous injection, equal volume as active drug
224015227|NCT01778257|DIETARY_SUPPLEMENT|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
224015228|NCT01778257|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Mate extracts.
224015229|NCT05377775|DEVICE|Iliac Stenting|Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
224015230|NCT03114800|DEVICE|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
224015231|NCT04875559|OTHER|Standardised multimodal pain treatment regimen|"Preoperatively:~* Paracetamol 1000 mg p.o.~* Celecoxib 400 mg p.o.~* Dexamethasone 12 mg p.o.~Perioperatively:~* Ondansetron 4 mg IV~* Bupivacaine 2.5 mg/mL, 20 mL LIA~* Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~* Paracetamol 1000 mg p.o. every 6h PRN~* Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~* Oxycodone 5 mg IV or 10 mg p.o. PRN~* Ondansetron 4 mg IV or p.o. PRN"
224015232|NCT04545229|OTHER|VR-based Pain Alleviation Tool (VR-PAT)|Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
224015233|NCT04325243|DRUG|Sildenafil 50 mg|50 mg oral Sildenafil tablet
224015234|NCT04325243|DRUG|Placebo oral tablet|placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
224015235|NCT02855697|DRUG|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
224015236|NCT02855697|DRUG|Cediranib|20mg dose of cediranib was selected for this study
223549825|NCT00399607|PROCEDURE|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
223549826|NCT00399607|PROCEDURE|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
223395934|NCT06190808|DIAGNOSTIC_TEST|Dexcom G7 Continuous Glucose Monitor|Continuous glucose monitor
223395935|NCT05365451|DRUG|MetFORMIN Oral Solution|liquid
223395936|NCT05365451|DRUG|Cimetidine 400 MG|tablet
223549827|NCT00399607|PROCEDURE|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
223549828|NCT00399607|PROCEDURE|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.
223549829|NCT00399607|PROCEDURE|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
223731133|NCT05481645|DRUG|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
224015237|NCT02855697|DRUG|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
224015238|NCT03292432|BEHAVIORAL|TERA Intervention (TERA)|"A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with VSee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior)."
223395937|NCT05365451|DRUG|Furosemide Oral Liquid Product|oral solution
223395938|NCT05365451|DRUG|Probenecid 500 MG|tablet
223395939|NCT06503588|OTHER|Guidelines promoting surgical abstention|Guidelines promoting surgical abstention
223395940|NCT06651372|BIOLOGICAL|The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons|Serological tests detecting IgM and IgG
223395941|NCT04985435|DRUG|Filgotinib|200 mg tablet once daily or 100 mg once daily
223395942|NCT04985435|DRUG|Anti-Tumor Necrosis Factor Alpha Drug (Product)|Adalimumab subcutaneous injections 40 mg once every two weeks Etanercept subcutaneous injections 50 mg weekly
223395943|NCT04985435|BEHAVIORAL|50 patients will have a Free Choice between Filgotinib and anti TNF|50 patients will be given the opportunity to choose between either TNFi (etanercept 50 mg SC once a week or adalimumab 40 mg SC once every two weeks) or filgotinib, an oral JAKi, 200 mg once a day while another group of 50 patients will be randomized to the same treatment arms.
223731134|NCT05481645|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
223731135|NCT05481645|DRUG|Carboplatin Injection|Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
223731136|NCT05481645|DRUG|Paclitaxel Injection|Paclitaxel is a diterpene alkaloid with anticancer activity
223731137|NCT05481645|DRUG|Doxorubicin Hydrochloride Injection|Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
223731138|NCT05481645|DRUG|Gemcitabine Hydrochloride Injection|Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
223731139|NCT05481645|DRUG|Docetaxel injection|Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
223731140|NCT04497077|DIETARY_SUPPLEMENT|tart cherry|Either tart cherry juice or freeze dried powdered tart cherry in capsule was given
223395944|NCT05366010|DEVICE|Oscillation and Lung Expansion (OLE) therapy|Respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
223395945|NCT05125809|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
223395946|NCT05125809|OTHER|Placebo|A 5% dextrose/glucose solution administered QM via IV infusion
223731141|NCT04497077|DIETARY_SUPPLEMENT|placebo|either cornstarch capsule or kool-aid
223731142|NCT02310464|DRUG|OBI-833/OBI-821|
223395947|NCT00671112|DRUG|Bortezomib|"Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line."
223395948|NCT00671112|DRUG|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
223395949|NCT00716599|DEVICE|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
223395950|NCT03691519|DRUG|Omega-3 treatment|"Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day)."
223395951|NCT03691519|DIETARY_SUPPLEMENT|Placebo|"The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day)."
223395952|NCT04468425|DRUG|Tofacitinib Citrate|Period 1: Xelijanz® 5 mg tablet (tofacitinib citrate) for single oral dosing. Period 2: Tofacitinib Citrate Topical Gel 3.2% for repeat topical dosing BID for 14 days.
223395953|NCT00586703|DEVICE|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
223395954|NCT01422213|DRUG|Placebo|capsules; daily; orally
223395955|NCT01422213|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
223395956|NCT01422213|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
223395957|NCT01860365|OTHER|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
223395958|NCT01860365|OTHER|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
223395959|NCT01155856|OTHER|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
223395960|NCT05271175|DEVICE|Active intermittent theta burst stimulation|An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil.
223395961|NCT05271175|DEVICE|Sham intermittent theta burst stimulation|"An accelerated iTBS (aiTBS) treatment (4 sessions with 30 minutes break between them) was administered daily for a 5-day period over the left DLPFC using the MagVenture Cool-B65 Active/Placebo (A/P) coil. The MagVenture Cool-B65 Active/Placebo (A/P) coil is designed to support true double blinded clinical trials as it can produce active and placebo stimulation by flipping the coil and can mimic tapping sensation during placebo condition During the sham condition, the coil produced the same sound as the real active condition but did not deliver any stimulation on the side of the participant's skull."
223731143|NCT02234375|DRUG|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
223731144|NCT04357392|DRUG|Prednisone|Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
224015239|NCT03292432|BEHAVIORAL|Standard of Care (SOC)|Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
224015240|NCT05364892|OTHER|Blood samples (80 mL)|Blood samples (80 mL) at inclusion, once a year for 5 years, and if relapse or change of treatment
224015241|NCT05364892|OTHER|Fecal samples|Fecal samples at inclusion
224015242|NCT05364892|OTHER|Urinary sample (20-40 mL)|Urinary samples at inclusion, once a year for 5 years, and if relapse or change of treatment
224015243|NCT05364892|OTHER|Questionnaires|Questionnaires at inclusion, once a year for 5 years, and if relapse or change of treatment
224015244|NCT00146627|DRUG|Eflornithine|
224015245|NCT00146627|DRUG|Nifurtimox|
224015246|NCT05271552|DRUG|BXCL501|Sublingual Film
224015247|NCT05271552|DRUG|Matching Placebo|Sublingual Placebo Film
224015248|NCT02289573|DEVICE|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
223395962|NCT00991887|RADIATION|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
223395963|NCT06130566|DRUG|Amlitelimab|Injection solution SC injection
223395964|NCT06130566|DRUG|Placebo|Injection solution SC injection
223395965|NCT07023588|DRUG|Venetoclax|Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.
224015249|NCT02698085|OTHER|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
224015250|NCT02698085|OTHER|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
224015251|NCT02483000|BIOLOGICAL|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
224015252|NCT02483000|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
224015253|NCT02483000|DRUG|Carmustine|Given IV
224015254|NCT02483000|DRUG|Clearing Agent|Given IV
224015255|NCT02483000|DRUG|Cytarabine|Given IV
224015256|NCT02483000|DRUG|Etoposide|Given IV
224015257|NCT02483000|RADIATION|Indium In 111-DOTA-Biotin|Given IV
224015258|NCT02483000|OTHER|Laboratory Biomarker Analysis|Correlative studies
224015259|NCT02483000|DRUG|Melphalan|Given IV
224015260|NCT02483000|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
224015261|NCT02483000|OTHER|Pharmacological Study|Correlative studies
223395966|NCT06872450|OTHER|informational intervention|informational intervention
223395967|NCT02070705|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
223395968|NCT02070705|DRUG|Ferumoxytol|Given IV
224015262|NCT02483000|RADIATION|Yttrium Y 90-DOTA-Biotin|Given IV
224015263|NCT06540534|PROCEDURE|Dexamethasone|In the adjuvan group (dexamethasone)group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of dexamethasone(8mg).
224015264|NCT06540534|PROCEDURE|kontrol group|In the control group, a total of 25 ml of local anesthetic mixture will be applied, consisting of 23 ml of 0.5% bupivacaine and 2 ml of 0.9% saline.
224015265|NCT00497185|BEHAVIORAL|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
224015266|NCT01076426|DRUG|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
224015267|NCT01076426|DIETARY_SUPPLEMENT|Oligosaccharide|oligosaccharide one pack per day
224015268|NCT02502903|DRUG|BIV009|
224015269|NCT02502903|OTHER|Placebo|
224015270|NCT01915472|DRUG|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
224015271|NCT01014143|DRUG|Fluoride|Half mouth toothbrushing twice a day for four days.
224015272|NCT01014143|DRUG|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
224015273|NCT01014143|DRUG|Fluoride, triclosan|Half mouth Brushing twice daily
224015274|NCT03902925|PROCEDURE|Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision
224015275|NCT03902925|PROCEDURE|Peribulbar injection|Peribulbar injection of 4-6 ml of ropivacaine 10%
224015276|NCT06172387|DRUG|intra-arterial infusion albumin|The experimental group would inject 20% human blood albumin solution into the responsible blood vessel supply area by catheter artery at a dose of 0.6g/kg. The infusion time is 20-30 minutes. All participant will receive mechanical thrombectomy and a standard clinical therapy.
224015277|NCT06172387|OTHER|mechanical thrombectomy and a standard clinical therapy|mechanical thrombectomy and a standard clinical therapy
224015278|NCT02405403|DRUG|[18F]DPA-714 PET|\[18F\]DPA-714 Positron Emission Tomography
224015279|NCT00665158|BEHAVIORAL|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
224015280|NCT00665158|BEHAVIORAL|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
223395976|NCT03640338|DEVICE|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
223395977|NCT06880419|DRUG|Recombinant Humanized Anti-CD25 Monoclonal Antibody Injection|"Model-predicted patients at high risk (HR): Recombinant humanized anti-CD25 monoclonal antibody: 50 mg/day when the post-transplant model predicts high risk in the second week post-prediction and 25 mg/day in the fourth and sixth weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.~Model-predicted patients at moderate risk (MR): Recombinant anti-CD25 humanized monoclonal antibody: 25 mg/day when the model predicts intermediate risk post-transplantation and at the 2nd, 4th, and 6th weeks post-prediction. Administered in combination with conventional aGVHD prevention regimen.~Model-predicted patients at low-risk (LR): A conventional aGVHD prevention regimen only was used."
223549830|NCT04383028|PROCEDURE|MELD algorithm use to aid in the planning of SEEG electrode trajectories|"During the routine SEEG planning meetings, the planning of SEEG trajectories, including the number and location of electrodes, will follow the usual clinical pathway and be planned according to the expertise of the attending neurosurgeon, neurophysiologist and neurologist at the multidisciplinary team meeting. Once the trajectories have been planned, anonymised scans for each patient (linked to them via a unique study ID) will be run through the MELD classifier and the top 3 MELD identified lesion clusters will be considered for further implantation.~These top 3 MELD classifier identified clusters will then be merged with the existing clinical plan to assess if each of the clusters are already being sampled by an SEEG electrode. If there is already an electrode in each lesion, no adjustments will be made. If there are clusters that are not being recorded from, and it is technically possible, extra electrodes (up to 3) will be added to record from these additional locations."
223549831|NCT04532840|DEVICE|cryotherapy (Gymna Cryoflow ICE-CT)|Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
223549832|NCT04532840|OTHER|Exercising, Positioning and splinting, Pressure Therapy and Massage|Exercising, Positioning and splinting, Pressure Therapy and Massage
223549833|NCT00897780|BEHAVIORAL|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
223549834|NCT02501148|DEVICE|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
223549835|NCT03147378|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
223549836|NCT03298698|DRUG|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
223549837|NCT03298698|DRUG|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
223549838|NCT03823105|DEVICE|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelerometric data
223549839|NCT05841719|OTHER|Screening test|Capillary blood sampling by finger-prick devices and second confirmatory venous sampling when needed.
223549840|NCT03215628|DIAGNOSTIC_TEST|TCEUS|Intravenous sulphur hexafluoride microbubbles
223549841|NCT00178971|DRUG|adjunctive treatment with buspirone|buspirone 15-30 mg qd
223549842|NCT00178971|DRUG|placebo|placebo
223549843|NCT04149171|DRUG|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
223549844|NCT04149171|DRUG|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
223549845|NCT04619667|DEVICE|High Flow Nasal Cannula (HFNC)|HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
223549846|NCT04619667|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet"
223549847|NCT04465604|OTHER|Wearing surgical face mask sprayed with hypertonic saline|The inner surface of a standard surgical face mask will sprayed by 10 to 15 ml of HTS (6% w/v Saline solution prepared by adding 6 gram NaCl to 100 ml of water if not commercially available) and allowed to air dry. The participant will wear the face mask for 20-30 minutes every 6 hours until discharge, intubation for mechanical ventilation or death. A new HTS sprayed mask will be worn by the participant every 24 hours. The data items will be collected on daily basis
224015281|NCT05613374|DEVICE|The C-Mill virtual reality treadmill|The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.
224015282|NCT05613374|OTHER|Conventional Physical Therapy Program|"The Conventional Physical Therapy Program include the following:~* Postural reactions exercises. (using balance board, balance beam, and manual balance perturbations)~* Indoor open environment gait training exercises (over ground gait training exercises.). (using obstacles,cones , stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)"
223395978|NCT07112456|DRUG|Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare|\*\*Intervention Description:\*\* Nebulized ketamine is administered as a single dose of 0.5 mg/kg of ketamine hydrochloride diluted in 0.9% normal saline to a total volume of 5ml. The solution is delivered via a standard jet nebulizer over approximately 15-20minutes. This intervention is given once at the time of enrollment in the emergency department, in addition to standard asthma care. The ketamine used is in injectable solution form (typically 50 mg/mL concentration), drawn and diluted immediately prior to nebulization. Participants are monitored continuously for 60 minutes after administration to assess changes in peak expiratory flow rate (PEFR), symptom relief, and adverse events. The goal is to evaluate the bronchodilatory effect and safety of nebulized ketamine in adults with moderate to severe asthma exacerbation who present to the emergency department.
223549848|NCT03549494|DIETARY_SUPPLEMENT|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
224015283|NCT06271460|OTHER|Traditional physiotherapy|All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.
224015284|NCT03224754|BEHAVIORAL|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
223395979|NCT07112456|DRUG|Placebo nebulization (5 mL normal saline) plus standard asthma care|\*\*Intervention Description (Control Group):\*\* Participants in the control group will receive a single nebulized dose of 5 mL of 0.9% normal saline, delivered using a standard jet nebulizer over approximately 10-15 minutes. This placebo intervention is administered once at the time of enrollment in the emergency department, after standard asthma care. Standard care includes repeated doses of nebulized salbutamol and ipratropium, systemic corticosteroids (oral or intravenous), and supplemental oxygen as needed. The placebo solution is identical in appearance and volume to the active ketamine solution used in the intervention group to maintain blinding. All participants will be monitored for 60 minutes after nebulization to assess changes in peak expiratory flow rate (PEFR), symptom relief using a visual analog scale (VAS), and the occurrence of any adverse events.
223395980|NCT07111377|BEHAVIORAL|Brief Cognitive Behavioral Therapy|Participants received an 8-session culturally adapted Brief Cognitive Behavioral Therapy intervention targeting suicidal ideation, psychological distress, and financial stress. Therapy included crisis stabilization, cognitive restructuring of maladaptive thoughts related to economic hardship, behavioral activation, problem-solving skills for financial and psychosocial stressors, and emotion-regulation training. It concluded with relapse prevention planning and connection to supportive community resources. Sessions were delivered weekly, either individually (60 minutes) or in groups (90 minutes), based on participant preference.
223395981|NCT02988960|DRUG|ABBV-927|Intravenous
223395982|NCT02988960|DRUG|ABBV-927|Intratumoral
223395983|NCT02988960|DRUG|ABBV-181|Intravenous
223395984|NCT03274193|BEHAVIORAL|Yoga training program|The hatha yoga program will be led by an experienced yoga instructor. Each 60 minutes session will consist of 10 minutes of breathing exercises (pranayama), 40 minutes of yoga pose practice (asana), and 10 minutes of supine meditation/relaxation (savasana). Yoga props, such as blocks and belts, will be used in accordance to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably. The yoga poses are chosen for providing a restorative session and based on their purported relationship to restorative effects. Participants will be instructed to maintain their concentration and breath control at all times during the yoga session.
223395985|NCT00002100|DRUG|Curdlan sulfate|
223395986|NCT02843984|DRUG|Lactoferrin|
223395987|NCT03856801|OTHER|Exercise|Whole-body vibration training in hypoxia and normoxia condition
223395988|NCT04455165|PROCEDURE|Aortic valve replacement|Aortic valve replacement with or without associated cardiac surgery (coronary bypass, mitral valve surgery,...)
223549849|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
223549850|NCT00429871|DRUG|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
223549851|NCT00429871|DRUG|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
223549852|NCT00429871|DRUG|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
223549853|NCT02969915|BEHAVIORAL|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
223549854|NCT02969915|BEHAVIORAL|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
223549855|NCT01789359|OTHER|Blueberry Juice|Dietary intervention
224015285|NCT06084091|DEVICE|Myocardial spectrometric measurement|Myocardial spectrometric measurement during open-heart Surgery
224015286|NCT00662935|PROCEDURE|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
224015287|NCT03234101|BEHAVIORAL|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1\) Healthy body weight (Minimum: BMI \<30kg/m2 or WC of \<88 in females or \<92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits \& vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation \>12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (\>6 hours)"
223549856|NCT02626936|OTHER|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
223549857|NCT02626936|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
223549858|NCT02626936|DRUG|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
223549859|NCT02626936|DEVICE|Dexcom G4 Platinum glucose sensor|
223549860|NCT02626936|DEVICE|Accu Chek Combo insulin pump|
223549861|NCT00124969|DRUG|Amlodipine|10mg
223549862|NCT00124969|DRUG|Placebo|10mg
224015288|NCT00168623|DRUG|Vitamin A|
224128235|NCT04615702|DIAGNOSTIC_TEST|serum lipase or amylase|"Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits) is helpful in diagnosis~Acute pancreatitis is diagnosed when two of three criteria are present including:~1. Clinically (abdominal pain consistent with acute pancreatitis),~2. Laboratory ( elevated serum lipase or amylase at least 3 times above the normal limits)~3. Imaging criteria of acute pancreatitis"
224128236|NCT04615702|DEVICE|ultrasound|helpful in diagnosis of acute pancreatitis and its etiology (Gallstones)
224128237|NCT04615702|DEVICE|CT|helpful in diagnosis of acute pancreatitis and its etiology . assist in detection of type and severity of acute pancreatitis
223395989|NCT06717776|BEHAVIORAL|Compensation Based Problem Solving Therapy|"Compensation-Based Problem Solving Therapy (CB-PST) is a therapeutic approach based on the occupational adaptation model. It entails the implementation of compensatory strategies with the objective of enhancing the performance of both extremities in daily life activities. The therapy encompasses the implementation of problem-solving training.~The occupational problem is defined.~The development of compensation-focused strategies is based on the personal factors and occupational environment identified as relevant to the problematic occupation, as determined according to the principles of the occupational adaptation model.~Once a compensatory strategy has been selected, the next step is to apply it and evaluate its efficacy, with the expectation that an adaptive response will be observed, and that the resulting adaptation will be reflected in improved occupational performance, as guided by the occupational adaptation model."
223549863|NCT03353662|OTHER|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
223549864|NCT03353662|OTHER|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
223549865|NCT03353662|OTHER|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
223549866|NCT03353662|OTHER|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
223549867|NCT03353662|OTHER|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
223549868|NCT03353662|OTHER|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
223549869|NCT02622295|BEHAVIORAL|Single-session electrically induced exercise|A single session of electrically induced exercise to the quadriceps and hamstring muscle groups of people with paralysis.
223549870|NCT02622295|BEHAVIORAL|Electrically-induced exercise training|Multiple sessions of electrically induced exercise to the quadriceps and hamstring muscle groups for up to 3 years in people with paralysis.
223549871|NCT01393899|DRUG|Placebo|oral tablets twice daily
224015289|NCT02164123|OTHER|Spinal mobilization|Experimental group
224015290|NCT02164123|OTHER|Spinal Mobilization II|Active comparator group
224015291|NCT02164123|OTHER|Placebo|Placebo group
224015292|NCT00495586|DRUG|Placebo|One pill to be taken every eight hours for 8 days
224015293|NCT00495586|DRUG|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
224015294|NCT02641600|DEVICE|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
224015295|NCT02641600|DEVICE|Placebo stockings|Placebo stocking with pressure applied to the legs
224015296|NCT01955889|BEHAVIORAL|Mobile Health Technology|
224015297|NCT01955889|BEHAVIORAL|Stretching & Strengthening Exercises|
224015298|NCT01955889|BEHAVIORAL|Walking with Pedometer|
223395990|NCT06717776|BEHAVIORAL|standard rehabilitation|The standard rehabilitation program is provided to all individuals in the inpatient service on an equal basis. The program allows individuals to utilize the physiotherapy and occupational therapy units on a weekly basis, with access available on weekdays. These units are staffed by physiotherapists and occupational therapists. All individuals included in the study received the same service from the same therapists at the same times in a homogeneous manner. All individuals received physiotherapy, electrotherapy, and hydrotherapy as part of this service. In the physiotherapy unit, the first intervention was 25 minutes of electrotherapy for the upper extremity. This was followed by 40 minutes of physiotherapy exercises, conducted with the assistance of a physiotherapist. The final component of the physiotherapy unit programme was 15 minutes of hydrotherapy. In the occupational therapy unit, a standard 40-minute occupa
223395991|NCT01007305|PROCEDURE|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
223395992|NCT01007305|PROCEDURE|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
223395993|NCT03806673|DRUG|marcaine|epidural block
223395994|NCT05416840|DRUG|Clonidine controlled-release patch|"Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
223395995|NCT05416840|DRUG|Amlodipine|"Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6)."
223395996|NCT03564457|OTHER|No interventions will take place (observational)|No interventions will take place (observational)
223395997|NCT03334929|DEVICE|Virtual Reality headset|The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
223395998|NCT00263822|DRUG|erlotinib hydrochloride|
223395999|NCT04190992|OTHER|E-based & personalized breast reconstruction surgery decision aid|This decision aid contains information regarding surgical options, including breast reconstruction and mastectomy, such as the advantages and disadvantages, the complication probabilities of each option, a value clarification exercise for the patient's self-evaluation, and a summary of the participant's decision-making process.
223396000|NCT04190992|OTHER|Usual care|A pamphlet introduce the introduction of types of surgery
223396001|NCT05190939|DIAGNOSTIC_TEST|water as bladder distending media|water will be used for bladder dissension during cystoscopy
223396002|NCT05190939|DIAGNOSTIC_TEST|intravenous dye|intravenous dye using methylene blue or fluorescein will be used for visual aid of ureteral jets during cystoscopy
223549872|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
224015299|NCT01795573|BIOLOGICAL|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
224015300|NCT02952807|DRUG|Misoprostol|vaginal Misoprostol Plus Foley Catheter
224015301|NCT02952807|DEVICE|Foley Catheter|
224015302|NCT03487354|DRUG|Misoprostol|Misoprostol
223396003|NCT05190939|DIAGNOSTIC_TEST|No intervention|Saline only, no dye
223549873|NCT01393899|DRUG|CP-690,550|oral tablets twice daily
223549874|NCT02503085|DRUG|Nurofen for Children®|
223549875|NCT02503085|DRUG|Algifor Dolo Junior®|
223549876|NCT00100958|DRUG|indole-3-carbinol|
223549877|NCT05767788|OTHER|Movement with Mobilization (MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
223549878|NCT05767788|OTHER|Sham Movement with Mobilization (Sham MWM)|"Painful active functional knee movement is identified. The most comfortable passive medial, lateral, medial rotatory, lateral rotatory, postero-anterior, and antero-posterior light-touch glide, is applied to the knee of the patient.~Three sets of 10 repetitions are applied. Corresponding home MWM exercise is taught. The treatment is conducted for 12 sessions over 6 weeks."
223549879|NCT00175760|PROCEDURE|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
223549880|NCT03330678|DIETARY_SUPPLEMENT|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
223549881|NCT03017339|OTHER|Functional Exercise|
223549882|NCT03017339|RADIATION|Low Level Laser Therapy|
224015303|NCT02301260|BEHAVIORAL|Speed of Processing Training (SPT)|
224015304|NCT02301260|BEHAVIORAL|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
224015305|NCT04814641|BIOLOGICAL|hypophosphatemia occurrence in infants with severe bronchiolitis admitted in a pediatric intensive care unit|Serum phosphorus level \< 1.55 mmol/L at any time between admission and the 5th day.
224015306|NCT04451174|DRUG|Prednisone|Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
224015307|NCT02038543|DRUG|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
223731145|NCT05901675|OTHER|Lifestyle Management Program|The program utilizes registered dietitians, exercise physiologists and psychologists and is designed to induce larger initial weight losses than traditional lifestyle change programs. The early part of the program provides a highly structured dietary intervention, which consists primarily of meal replacements provided to the participant as part of the program (shakes and nutrition bars). Gradually, as the program progresses, there is a shift towards a primarily food-based meal plan that leads to more moderate and sustainable weight loss. Throughout the program, participants attend weekly individual appointments that rotate among the clinical specialties (dietary and behavioral). The emphasis on lifestyle change means the goal is to help the participant learn to make healthy behavior changes that can be sustained long after completion of the program, thus enabling maintenance of a healthier weight.
223731146|NCT05901675|OTHER|Post-stroke Optimization of Walking using Explosive Resistance|POWER training will take place over a 12-week period (3 sessions/week) with exercises including leg press, calf raises, and jump training, all performed at high concentric velocity, as well as trials of fast walking and functional movements.
224015308|NCT00827866|OTHER|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
224015309|NCT00827866|OTHER|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
224015310|NCT00158860|DRUG|Valaciclovir|1g once daily
224015311|NCT00158860|DRUG|Placebo|placebo
224015312|NCT02216305|PROCEDURE|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorrhoidal base with absorbable suture
224015313|NCT02216305|PROCEDURE|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorrhoid. Other procedures will not be associated.
224015314|NCT02117947|BEHAVIORAL|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
223396004|NCT02737774|DRUG|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
223396005|NCT02737774|DRUG|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
223396006|NCT00285064|PROCEDURE|CT|
223396007|NCT03793608|DRUG|Dupilumab|Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
223396008|NCT03752814|DEVICE|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
223396009|NCT01891864|DRUG|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
223396010|NCT01891864|DRUG|Enbrel|Enbrel is used as reference product to GP2015.
223396011|NCT04480684|DIAGNOSTIC_TEST|Three-dimensional Endoanal Ultrasound|"Three-dimensional endoanal ultrasound is the gold standard diagnostic tool in the assessment of obstetric anal sphincter injury. The anorectal transducer is inserted directly into the anal canal which allows assessment of the anal sphincter complex.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
223396012|NCT04480684|DIAGNOSTIC_TEST|Transperineal Ultrasound(multiplanar)|"If endoanal ultrasound is declined or not tolerated, the anal sphincter will also be assessed using three-/four-dimensional (3D/4D) transperineal ultrasound with the probe placed externally on the area of the fourchette.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed."
223396013|NCT04480684|DIAGNOSTIC_TEST|The MolecuLight i:X: Bacterial autofluorescence camera|"The bacterial load of the perineal wound will be measured every week using the MolecuLight i:X. This is a system, which uses fluorescent illumination to capture and document the presence of bacteria.~Patients will be assessed at weekly intervals with until the wound infection has resolved and the wound has clinically healed.~These findings will be supported by microbiological analysis of the wound fluid with swab culture and sensitivity."
223396014|NCT04480684|DEVICE|Silhouette® 3D camera: Three-dimensional wound measuring camera|For wound that have superficially dehisced, the wound surface area, depth, volume and healing progress will be precisely measured using the Silhouette® 3D camera. This is a system that uses 3D laser technology to track wound healing progression.
223396015|NCT05491902|DIAGNOSTIC_TEST|[C11] Leucine PET scan|Each participant will receive an i.v. bolus of the PET radioligand, \[11C\]-Leucine (\<100 μg), for each scan. \[11C\]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (\<100 μg) with no adverse effects.
223396016|NCT05491902|DIAGNOSTIC_TEST|[18F] Flutemetamol PET scan|Each participant will receive an i.v. bolus of the PET radioligand, \[18F\]-Flutemetamol (\< 10 μg), for each scan.
223396017|NCT05491902|DIAGNOSTIC_TEST|MRI scan|Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.
223396018|NCT03793764|PROCEDURE|TAP block|USG guided TAP block
223396019|NCT03793764|PROCEDURE|QL block|USG guided QL block
223396020|NCT03906799|DRUG|OMT-28|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
223396021|NCT03906799|DRUG|Placebo|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
223396022|NCT00000947|DRUG|Azithromycin|
224015315|NCT02117947|BEHAVIORAL|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
223396023|NCT03782168|OTHER|There is no other intervention, only clinical treatment.|The purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with PA. The sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in PA.
223396024|NCT05361863|DEVICE|Orthodontic brackets|Interventions involving orthodontic brackets of different slot sizes
223396025|NCT02698163|DEVICE|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
223396026|NCT02698163|DEVICE|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
223396027|NCT00772863|DRUG|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
223396028|NCT00452764|BEHAVIORAL|Withdrawal of medication|
223396029|NCT01312376|BIOLOGICAL|OC-DC vaccine|All subjects will receive a dose of 5-10 million cells of OC-DC intradermally
223396030|NCT01312376|DRUG|Bevacizumab|Patients will start receiving Bevacizumab at 15 mg/kg starting Day 30 and every 4 weeks thereafter until end of study.
223396031|NCT01312376|DRUG|cyclophosphamide 300 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous cyclophosphamide for 300 mg/m2/d for 3 days.
223396032|NCT01312376|DRUG|fludarabine 30 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous fludarabine 30 mg/m2/d for 3 days
223396033|NCT01312376|DRUG|ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells|All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109 (10-15 billion) T-cells with escalating doses in cohort 2 and 3.
223396034|NCT02689765|DIETARY_SUPPLEMENT|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
223396035|NCT02689765|DIETARY_SUPPLEMENT|Placebo|Placebo capsules is identically packaged.
223396036|NCT01313065|DRUG|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
223549883|NCT03017339|RADIATION|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
224015316|NCT00563485|DRUG|Doxazosin GITS (Cardura XL)|
223396037|NCT02892331|BEHAVIORAL|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
223396038|NCT02892331|BEHAVIORAL|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
223396039|NCT01116167|DRUG|Letrozole -Berberine|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine~1.5g daily for 6 month."
223396040|NCT01116167|DRUG|Letrozole|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine Placebo~5 tablet tds for 6 months"
223396041|NCT01116167|DRUG|Berberine|"Berberine~1.5g daily for 6 month.~Letrozole placebo~1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6."
223396042|NCT01480869|DRUG|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
223396043|NCT01480869|DRUG|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~* 100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level \< 10 ng/mL~* 100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level \< 20 ng/mL~* 100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level \< 30 ng/mL"
223396044|NCT01950455|DRUG|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
223396045|NCT05163483|DRUG|Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab|"Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years"
223396046|NCT00610428|DRUG|Staccato Placebo|Inhaled Staccato Placebo
223549884|NCT02409641|DRUG|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
223549885|NCT06421480|OTHER|Detecting Risky Behaviors and Providing a Safe Environment in Patients Receiving Inpatient Treatment in a Psychiatric Clinic Using Machine Learning Model|Using machine learning, the computer will be trained to detect suicide and violent behavior. Cameras will be placed in patient rooms. These cameras will transfer the image to the computer. The computer will process these images and detect suicidal and violent behavior early. A warning will appear on the computer screen
224015317|NCT00563485|DRUG|Terazosin (Hytrin)|
224015318|NCT04646538|OTHER|Regenerative Endodontics Procedures (REPs)|REPs was done for 10 mature maxillary necrotic teeth with periapical lesions. Instrumentation was done using Protaper Next system till size X3. Irrigation with 1.5 % NaOCl was done in the first visit. in the second visit, bleeding was induced in the canal by irritating the periapical area followed by the application of Biodentine as cervical plug then completion of the coronal restoration.
224128238|NCT04615702|DIAGNOSTIC_TEST|Liver enzymes (Bilirubin, alanine transferase (ALT), aspartate aminotransferase, (AST) and alkaline phosphatase). Calcium. Triglycerides.|help in diagnosis of the etiology of acute pancreatitis elevated Bilirubin, ALT, AST and alkaline phosphatase suggest biliary pancreatitis
223396047|NCT00610428|DRUG|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
223396048|NCT00610428|DRUG|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
223549886|NCT05748301|OTHER|AI Clinician|N/A - Study is observational study testing the feasibility of running the AI Clinician in real time.
223549887|NCT04372550|OTHER|Exercise|Resistance and aerobic exercise in addition to standard of care rehabilitation
223549888|NCT04372550|OTHER|Standard of Care|Standard of care rehabilitation
223549889|NCT04432922|OTHER|Hospitalized Patients for COVID-19 Infection|Face to face semi-directed interviews about perceptions, representations and experiences of septic isolation, including nine opened-questions.
223549890|NCT01555996|BEHAVIORAL|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
223549891|NCT01555996|BEHAVIORAL|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
223731147|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for cough|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have neurogenic cough for which superior laryngeal nerve block is recommended will undergo this procedure under ultrasound guidance. Patients without neurogenic cough will also be recruited for ultrasound assessment to establish landmarks and normal variation. Patients will be assessed for their comfort with undergoing the procedure and clinicians will be surveyed on the ease and benefit of performing the procedure under ultrasound guidance.
223396049|NCT00752128|DEVICE|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
223396050|NCT01317628|BEHAVIORAL|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
223731148|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for vocal fold atrophy or vocal fold paresis/paralysis|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have vocal fold atrophy or vocal fold paresis/paralysis for whom injection laryngoplasty is recommended will undergo laryngeal ultrasound prior to the procedure to assess baseline anatomy as well as following the procedure (both immediately following the procedure as well as at follow-up visits) in order to assess the amount of injectate.
223396051|NCT04456140|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223549892|NCT01145963|OTHER|Control pasta|control pasta
223549893|NCT01145963|OTHER|Experimental pasta B|experimental pasta
223549894|NCT01145963|OTHER|Experimental pasta C|experimental pasta
223549895|NCT03964168|DRUG|Biologic Agent|Patients who discontinued a bioloic agent
223549896|NCT00995436|DEVICE|Extraoral anchorage|Extra oral anchorage
223549897|NCT00995436|DEVICE|Miniscrews|Intraoral skeletal anchorage using mini screws
223731149|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphagia|Patients with and without swallowing complaints will be enrolled to assess their tongue, suprahyoid and infrahyoid musculature, including muscle identification, bulk and function.
224015319|NCT06434454|BEHAVIORAL|EFT Group:Emotional Free Technıcal|The young individuals in the intervention group will be informed about the study, including its purpose and methodology, and their consent will be obtained. Emotional Freedom Techniques (EFT) will be applied to groups of 20 individuals to improve sleep quality, and all scales will be administered beforehand. EFT will be applied twice, with a 15-day interval between sessions, and the same scale questionnaires will be administered again after the second EFT session. Subsequently, the analysis will be conducted.
224015320|NCT05333770|DEVICE|High-frequency repetitive transcranial magnetic stimulation|TMS is an investigational device that provides a way to test the function of a specific part of the brain that is devoted to moving my affected upper limbs by directing a low electrical current to that part of the brain through the scalp.
223396052|NCT04456140|OTHER|Genetic Counseling|Watch pre-test genetic counseling video
223396053|NCT04456140|OTHER|Genetic Testing|Undergo genetic testing
223396054|NCT04456140|OTHER|Survey Administration|Ancillary studies
223396055|NCT00349973|DRUG|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
223396056|NCT00349973|OTHER|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
223396057|NCT06579209|DIETARY_SUPPLEMENT|Nicotinamide adenine dinucleotide|Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo
223549898|NCT00995436|DEVICE|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
223549899|NCT02021890|BEHAVIORAL|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
223396058|NCT03348540|BEHAVIORAL|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
223549900|NCT02021890|BEHAVIORAL|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
223549901|NCT01744067|DRUG|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
223549902|NCT01744067|DRUG|Placebo|Placebo capsules 3 times a day (oral administration)
223549903|NCT06482775|DRUG|dexmedetomidine|The dosing and administration will be implemented according to an algorithm based on pain scoring results
223549904|NCT01415297|DRUG|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
223549905|NCT02592278|DRUG|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
223549906|NCT02592278|DRUG|Control Group|Twice a day brush with fluoride toothpaste.
224015321|NCT02372656|DRUG|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
223396059|NCT03348540|BEHAVIORAL|Comparison Task|Neutral- neutral stimuli prior to response task
223396060|NCT06147882|BEHAVIORAL|The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.|The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.
223396061|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
223396062|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
223396063|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
223549907|NCT01656005|DRUG|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
223549908|NCT01656005|DRUG|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
223549909|NCT01656005|DRUG|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
223549910|NCT01656005|DRUG|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
223549911|NCT01656005|DRUG|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
223549912|NCT04373148|OTHER|There is no intervention|There is no intervention
223549913|NCT00050557|BEHAVIORAL|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
224015322|NCT02372656|DRUG|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
224015323|NCT02372656|DRUG|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
223396064|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
223396065|NCT01161069|DRUG|PF-03049423|PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
223396066|NCT01161069|DRUG|Placebo|Placebo in oral solution, given once daily for 14 days
223396067|NCT03509064|OTHER|Collection sheet|Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
223549914|NCT00050557|BEHAVIORAL|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
223549915|NCT03789123|DRUG|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
223549916|NCT05561647|OTHER|No Intervention|This is non-interventional study.
223396068|NCT02286713|BEHAVIORAL|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
223549917|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
223549918|NCT00700193|BIOLOGICAL|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
223549919|NCT02321228|PROCEDURE|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
224015324|NCT01029652|DRUG|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
224015325|NCT01029652|DRUG|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
223396069|NCT02286713|BEHAVIORAL|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
223396070|NCT02286713|BEHAVIORAL|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
223549920|NCT02321228|PROCEDURE|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
223549921|NCT03034707|DIETARY_SUPPLEMENT|biotin|
223549922|NCT04787003|DRUG|oncolytic virus (OVV-01) injection|intratumoral injection of OVV-01 with or without immune checkpoint inhibitors
223549923|NCT06160596|GENETIC|Long term survival multimodal analysis|"* To describe global signatures (Digital histology, Radiomic, Genomic, Transcriptomic, Proteomic, (Epigenomic) and clinical signature) that are associated with a patient's unexpected survival compared to standard patients across three cohorts of solid tumors with unmet medical needs.~* To describe global signatures in the overall population (pan-cohort).~* To describe clinical, digital pathology, radiomic, genomic, transcriptomic, proteomic and epigenomic signatures associated with patients' unexpected survival compared to standard patients for each cohort and in all cohorts (pan-cohort)"
223549924|NCT05573698|DRUG|DT-216|DT-216 will be administered by intravenous (IV) injection
223396071|NCT00425243|DRUG|zolpidem-MR (SL800750)|
223396072|NCT05993364|DEVICE|Free Aspire with Expiratory Flow Accelerator (EFA) technology|Treatment sessions during which the EFA technology is used. Depending on the patient's clinical conditions, an oxygen additional support can be provided, while using the device. If present, during the sessions the tracheal cannula must be cuffed. Tracheal cannula aspiration must be provided when necessary. Sessions take place three times a day and take 20 minutes each time, from Monday to Saturday.
223396073|NCT05993364|DEVICE|In-Exufflator Machine|Sessions using the In-Exufflator machine to improve the cough function, when the oxygen saturation decreases and the bronchial secretions increases.
223396074|NCT05993364|OTHER|Traditional respiratory treatment|"Standard rehabilitative treatment to improve the secretions management, that includes:~* A change of the patient posture every three hours;~* Airways humidification depending on the secretions features;~* Aspiration in the tracheal cannula whenever necessary."
223396075|NCT05993364|OTHER|Traditional swallowing treatment|"Traditional rehabilitative treatment carried out by the speech and language pathologist in order to:~* Obtain decannulation (when a tracheal cannula is applied) following the Bargellesi Protocol steps;~* Improve oral structures strength and motility;~* Improve oral and perioral sensitivity with thermal or gustative or tactile stimulations;~* Improve the swallowing function with food trials of different consistencies, volume and temperature;~* Improve swallow efficacy and safety through the prescription of compensatory postures;"
223396076|NCT02510443|DEVICE|ESS305 (Essure, BAY1454032)|Bilateral insert placement
223396077|NCT04314037|DRUG|Cesol (Test)|Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.
223549925|NCT05573698|DRUG|Placebo|Matching Placebo will be administered by intravenous (IV) injection
223549926|NCT06159283|DRUG|Immunoglobulins|Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
223549927|NCT05945498|BIOLOGICAL|TB/Flu-05E vaccine|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis
223549928|NCT05945498|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of placebo buffer solution
223549929|NCT04115124|BEHAVIORAL|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
223396078|NCT04314037|DRUG|Biltricide (Reference)|Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
223396079|NCT06151873|DIAGNOSTIC_TEST|Adapted sport|control group sample, healthy subjects without musculoskeletal, neurological or vestibular alterations can participate.
223549930|NCT00953953|DEVICE|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
223549931|NCT00392977|DIETARY_SUPPLEMENT|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
223549932|NCT05827289|DEVICE|Cancer Patients Better Life Experience (CAPABLE)|The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
224015326|NCT01029652|DRUG|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
223396080|NCT06151873|DIAGNOSTIC_TEST|Adapted sport|Subjects with cerebral palsy/acquired brain damage belonging to the Spanish National Soccer Team with cerebral palsy and acquired brain damage may participate as an experimental group.
223396081|NCT02490631|DRUG|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
223396082|NCT06034106|BEHAVIORAL|Pomegranate (Punica granatum) peel compress|Pomegranate (Punica granatum) peel compress was applied 3 days a week for 3 weeks by turning the powder into porridge check.
223396083|NCT06034106|BEHAVIORAL|Hot compress|Hot compress was applied 3 days a week for 3 weeks.
223396084|NCT05982470|DRUG|Estradiol Gel|Estradiol gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
223549933|NCT01849315|BEHAVIORAL|AKIDS II|Physically active intervention
223549934|NCT03399942|PROCEDURE|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
223549935|NCT05266846|DRUG|Pembrolizumab injection|Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
224015327|NCT01029652|DRUG|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
223396085|NCT05982470|DRUG|Estradiol Placebo Gel|Estradiol placebo gel 2.5 g (containing 17β estradiol 1.5mg) once daily (percutaneous application) for 12 months
223549936|NCT01530646|BEHAVIORAL|Weight loss|-750kcal/d
223549937|NCT01530646|DIETARY_SUPPLEMENT|Soy|2 x 25g/d SPC
223549938|NCT01530646|DIETARY_SUPPLEMENT|Whey|2 x 25g/d WPI
223731150|NCT06579989|DIAGNOSTIC_TEST|Ultrasound for dysphonia|Adult patients who are seen at the Sean Parker Institute for the Voice and are determined to have muscle tension dysphonia will undergo ultrasonography during their visit with laryngology or speech language pathology.
223731151|NCT05746754|RADIATION|CSI|30 Gy in 10 fractions to CNS
223396086|NCT05982470|DRUG|Progesterone Soft Capsule|Progesterone soft capsules 100mg once daily (oral) for 12 months
224015328|NCT01436851|BIOLOGICAL|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
224015329|NCT00558337|DRUG|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
224015330|NCT04553250|PROCEDURE|Doubled-stapled colorectal anastomosis|Anastomosis performed between the colon an the rectal stump, using a double-stapled technique.
223396087|NCT05982470|DRUG|Progesterone Placebo Soft Capsule|Progesterone placebo soft capsules 100mg once daily (oral) for 12 months
223396088|NCT03832686|OTHER|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
223396089|NCT01370447|DRUG|EPI-743|EPI-743 (oral solution \[100 mg/mL\] or liquid-filled capsules \[100 mg or 200 mg\]) will be administered per dose and schedule specified in the arm.
224015331|NCT05525884|OTHER|non-invasive method, Fibroscan|Liver Ultrasound and transient elastography (FibroScan®)
224015332|NCT06327750|DEVICE|Hemodialysis (DNa = PNa)|High-flux hemodialysis with an expected zero diffusive sodium balance (DNa = PNa)
224015333|NCT06327750|DEVICE|Hemodialysis (DNa<PNa)|High-flux hemodialysis with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L)
224015334|NCT06327750|DEVICE|Hemodialysis after isolated ultrafiltration (DNa=PNa)|High-flux hemodialysis after isolated ultrafiltration with an expected zero diffusive sodium balance (DNa=PNa)
224015335|NCT06327750|DEVICE|High volume hemodiafiltration (DNa=PNa)|High volume hemodiafiltration with an expected zero diffusive sodium balance (DNa=PNa) Convection volume: ≥23L/session
224015336|NCT06327750|DEVICE|High volume hemodiafiltration (DNa<PNa)|High volume hemodiafiltration with expected diffusive sodium efflux (DNa\<PNa, difference: 3 mmol/L) Convection volume: ≥23L/session
224015337|NCT06301282|BEHAVIORAL|assessment during the transition between OFF-levodopa (i.e. withdrawal of levodopa phase) and ON-levodopa (i.e. effect of Levodopa phase)states|Electroencephalographic measurements are taken during both motor and non-motor assessments while the transition between the OFF-levodopa and ON-levodopa states occurs
224015338|NCT02095951|DRUG|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
224015339|NCT03618823|DRUG|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
224015340|NCT03618823|DRUG|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
224015341|NCT03618823|DRUG|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
224015342|NCT02631512|DEVICE|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
224015343|NCT02631512|DEVICE|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
224015344|NCT03918369|PROCEDURE|Laparoscopic right hemicolectomy with intracorporeal anastomosis.|Intracorporeal anastomosis group The laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis. In this procedure, intracorporeal division of the mesoileum and transverse colon is performed, as shown in the animation. The ileum and transverse colon are divided with the Endopath® Echelon Flex ™ 60 stapler. The specimen is inserted in a plastic bag. Side-to-side isoperistaltic mechanical anastomosis is performed using the same endostapler. A running suture is performed of the mechanical suture orifice, with another reinforcing suture with Monocryl ™ (poliglecaprone 25) or with STRATAFIX ™ Spiral Knotless barbed suture. The specimen is extracted through a Pfannestiel minilaparotomy (3.5-4 cm) Wound Protector
224015345|NCT03918369|PROCEDURE|Laparoscopic right hemicolectomy with extracorporeal anastomosis.|Laparoscopic right hemicolectomy with extracorporeal anastomosis with the technical features of each center
224015346|NCT02503033|DRUG|HMPL-523|Oral administration, once daily
224015347|NCT02001298|DRUG|remifentanil|
224015348|NCT02001298|DRUG|nitroprusside|
223396090|NCT07079930|DRUG|Psilocybin and D-Serine|"A single administration of the drug, with dosage divided as follows:~Cohort 1: 15 mg of Psilocybin and 5 gr of D-Serine Cohort 2: 25 mg of Psilocybin and 7 gr of D-Serine"
223396091|NCT07079930|DIAGNOSTIC_TEST|Physical Examination|The physical examination will include diagnosis and documentation of any significant clinical abnormalities or diseases. It will be performed during the baseline rating visit (preparation phase).
223396092|NCT07079930|DIAGNOSTIC_TEST|Vital signs|"Vital sign measurements (blood pressure, pulse, and oxygen saturation) will be taken at screening, preparation, baseline rating, administration day, day 2, day 28, and day 84.~Vital signs will be assessed at the following time points on the administration day and on day 2: pre-administration, and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours post-administration."
223396093|NCT07079930|DIAGNOSTIC_TEST|ECG test|A 12-lead ECG will be performed to rule out underlying cardiac abnormalities. An ECG will be conducted for each patient during the screening and Day 2 visits.
223396094|NCT07079930|DIAGNOSTIC_TEST|Comprehensive Blood Panel|"A comprehensive blood panel will be performed to assess kidney and liver function, electrolyte balance, and glucose levels.~It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84."
224015349|NCT04638920|OTHER|No intervention|No intervention
224015350|NCT03392545|COMBINATION_PRODUCT|Combined immune adjuvants and radiation|24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
224015351|NCT00964886|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
224015352|NCT00964886|DRUG|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
223396095|NCT07079930|DIAGNOSTIC_TEST|Complete Blood Count|"Complete Blood Count will be performed to check for hematological abnormalities.~It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84."
223396096|NCT07079930|DIAGNOSTIC_TEST|Urinalysis|Urinalysis will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84.
223396097|NCT07079930|DIAGNOSTIC_TEST|Urine Toxicology Screen|Urine Toxicology Screen will be performed to rule out illicit drug use. It will be conducted during the Screening visit, and on Day 2, Day 28, and Day 84.
223396098|NCT07079930|DIAGNOSTIC_TEST|A pregnancy Urine test|A urine pregnancy test will be performed for women of childbearing potential only. It will be conducted during the screening and baseline rating visits. If the urine test is positive, a serum β-hCG test will be performed for confirmation.
223396099|NCT07079930|DIAGNOSTIC_TEST|Electroencephalogram|EEG will be performed during the baseline rating scale and Day 7 visits to evaluate brain activity
223396100|NCT07079930|DIAGNOSTIC_TEST|Plasma Amino Acid Levels|The following blood test parameters - D-Serine, L-Serine, and Glycine - will be assessed during the Screening and Day 28 visits.
223396101|NCT07079930|DIAGNOSTIC_TEST|Plasma Inflammation Markers|The following blood test parameters - Tumor Necrosis Factor Alpha (TNF-α), Interleukin-6 (IL-6), and C-Reactive Protein (CRP) - will be assessed during the Screening and Day 28 visits.
223396102|NCT07079930|DIAGNOSTIC_TEST|Plasma Brain-Derived Neurotrophic Facto|Plasma BDNF (Brain-Derived Neurotrophic Factor) levels will be measured during the screening and Day 28 visits.
223396103|NCT07079930|OTHER|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (MINI) will be administered during the screening visit to rule out any current or past major psychiatric disorders.
223396104|NCT07079930|OTHER|Family Psychiatric History Assessment|The Family Psychiatric History Assessment (FPHA) will be administered during the screening visit to help rule out any current or past major psychiatric disorders.
223396105|NCT07079930|OTHER|Beck Depression Inventory|The Beck Depression Inventory (BDI) will be administered at the following visits: screening, baseline, day 7, day 28, and day 84. It will be used to assess baseline mood and to rule out depressive symptoms.
223396106|NCT07079930|OTHER|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory (STAI) will be administered at the following visits: screening, baseline, day 7, day 28, and day 84. It will be used to screen for anxiety disorders.
223396107|NCT07079930|BEHAVIORAL|Profile of Mood States|"The Profile of Mood States (POMS) will be administered to assess baseline mood and emotional state.~It will be administered at the following visits: screening, baseline, administration day, day 2, day 7, day 28, and day 84.~On the administration day and on day 2, it will be administered at the following time points: pre-administration, and 8 and 20 hours post-administration."
223396108|NCT07079930|BEHAVIORAL|Subjective Units of Distress Scale|"Subjective Units of Distress Scale (SUDS) will be administered to assess anxiety and stress levels.~It will be administered at the following visits: screening, baseline, administration day, day 2, day 7, day 28, and day 84.~On the administration day and on day 2, it will be administered at the following time points: pre-administration, and 8 and 20 hours post-administration."
223396109|NCT07079930|OTHER|Five-Dimensional Altered States of Consciousness questionnaire|"The Five-Dimensional Altered States of Consciousness questionnaire (5D-ASC) will be used to assess the acute subjective psychedelic experience. It will be administered after the acute effects have subsided - at 6.0 hours post-administration on the administration day, and again on day 2 - to evaluate five key experiential dimensions: visual restructuralization, oceanic boundlessness, reduction of vigilance, anxious ego dissolution, and auditory alterations. Each item will be rated using a Visual Analogue Scale (VAS) ranging from NO, not more than usually (0 mm) to YES, much more than usually (100 mm)."
223396110|NCT07079930|BEHAVIORAL|Integration|The integration process is conducted to support participants in processing and incorporating their therapeutic experience into daily life, with the aim of enhancing emotional insight and psychological well-being. Integration will take place at the following visits: 8.0 hours post-treatment on the administration day, day 2, day 7, day 28, and day 84.
223396111|NCT07079631|BIOLOGICAL|BNT314|Intravenous (IV) infusion
223396112|NCT07079631|DRUG|BNT327|IV infusion
223396113|NCT07079631|DRUG|SoC chemotherapy treatment 1|IV infusion / IV bolus
223396114|NCT07079631|DRUG|SoC chemotherapy treatment 2|IV infusion / IV bolus / oral
223396115|NCT07079631|DRUG|Bevacizumab|IV infusion
223549939|NCT05312840|DRUG|Cisplatin / Carboplatin，Gemcitabine，Cindilimab|1\. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
224015353|NCT00964886|BEHAVIORAL|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
223549940|NCT00087087|DRUG|pemetrexed disodium|
224015354|NCT00964886|DRUG|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
224015355|NCT00964886|DRUG|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
224015356|NCT02758847|DEVICE|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
224128239|NCT04615702|DEVICE|EUS /Secretin-stimulated magnetic resonance cholangiopancreatography (MRCP)|helpful in idiopathic acute pancreatitis diagnosis
224015357|NCT02758847|DEVICE|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
224015358|NCT05071820|OTHER|Health U mobile application|Health U mobile application delivers daily microlearning modules and the health coach interactions within the Health U application
224015359|NCT05071820|OTHER|National Diabetes Prevention Program|CDC recognized National DPP that follows a set curriculum with modules delivered over 12 months
224015360|NCT06203366|PROCEDURE|Vojta therapy|Vojta therapy is an old treatment method which was discovered by Professor Vaclav Vojta, a neurologist and pediatrician. It has been used to treat children with impair motor function in Thailand since 2011. Vojta therapy encourage the movement of children via positioning and stimulate the specified zone.
224015361|NCT02449369|DRUG|Preop acetaminophen IV|
224015362|NCT02449369|DRUG|Preop orphenadrine IV|
224015363|NCT02449369|DRUG|Postop oral oxycodone & acetaminophen|
224015364|NCT02449369|DRUG|Postop hydromorphone IV|
224015365|NCT02449369|DRUG|Postop oral orphenadrine|
223396116|NCT07082608|DEVICE|Endoscopic Sleeve Gastropathy|"Weight loss through diet, exercise, and behavioural changes positively impacts sleep quality. Reduction in body weight can alleviate OSA symptoms and improve overall sleep architecture1,2,3 Surgical weight loss procedures play a crucial role in managing obesity-related health issues, including OSA.4 Endobariatric procedures, including Endoscopic Sleeve Gastroplasty (ESG), have gained attention as a weight loss solution with the potential for improving obesity-related health issues.~ESG involves suturing the stomach to reduce its size, limiting food intake. Unlike traditional bariatric surgeries, ESG doesn't require incisions. ESG has shown promise in achieving clinically significant weight loss, up to 20% of TBWL. By reducing stomach capacity, it promotes satiety and calorie restriction. ESG is generally safe, with fewer complications compared to more invasive procedures"
223396117|NCT07082608|OTHER|Lifestyle Modification alone|Participants will follow a structured program involving a low-calorie diet (typically 1200-1500 kcal/day), regular physical activity (150 minutes of moderate-intensity exercise per week), and behavioural therapy sessions.
223396118|NCT07112807|OTHER|Strengthening Exercises|Strengthening exercises targeting the middle and lower trapezius and serratus anterior muscles will be performed. The program will progress by increasing the number of exercises and the amount of resistance.
223396119|NCT07112807|OTHER|ShoulderSphere Exercises and Resistive Exercises|In addition to strengthening exercises, exercises will be performed using the ShoulderSphere in the frontal, sagittal and transverse planes with the shoulders in 90° flexion and the elbows in extension.
223396120|NCT07112807|OTHER|Bodyblade Exercises and Resistive Exercises|In addition to strengthening exercises, 15 minutes of exercises using the Bodyblade will be performed. Individuals will perform oscillation exercises in the frontal, sagittal, and transverse planes while holding the Bodyblade bar firmly with their shoulders in 90° flexion and elbows in extension.
223549941|NCT05982912|DIAGNOSTIC_TEST|breath sampling|We collect a breath sample of exhaled air and analyse the VOC profile in this sample
223549942|NCT02131662|DRUG|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
223731152|NCT01538420|DRUG|GLPG0492|Oral solution
223549943|NCT02131662|DRUG|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
223549944|NCT02131662|DRUG|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
223549945|NCT02131662|DRUG|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
223549946|NCT02131662|DRUG|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
223731153|NCT01538420|DRUG|Placebo|Placebo oral solution
223731154|NCT02289898|DRUG|Demcizumab|administered intravenously
223731155|NCT02289898|DRUG|Abraxane®|administered intravenously
223731156|NCT02289898|DRUG|gemcitabine|administered intravenously
223731157|NCT02289898|DRUG|Placebo|
223731158|NCT03634449|DEVICE|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
224015366|NCT02449369|DRUG|Postop oral oxycodone|
224015367|NCT02449369|DRUG|Postop acetaminophen IV|
224015368|NCT02449369|DRUG|Postop orphenadrine IV|
224015369|NCT00523640|DRUG|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
224015370|NCT05184712|DRUG|Ivonescimab (SMT112 or AK112) Injection|Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles. Afterward, Ivonescimab (SMT112 or AK112) Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
224015371|NCT05184712|DRUG|Placebo Injection|Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
224015372|NCT03139669|DEVICE|Viba collection brush|HPV home collection kit using the viba collection brush to collect cervical cells for HPV DNA testing.
224015373|NCT00366080|DRUG|GSK189254|
224015374|NCT05305612|OTHER|early anticoagulation|Anticoagulation prior to transseptal puncture
224015375|NCT05305612|OTHER|late anticoagulation|Anticoagulation after transseptal puncture
224296527|NCT05925673|OTHER|Mirror Therapy + NMES|Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
223396121|NCT01804790|DRUG|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.
223396122|NCT01804790|RADIATION|Radiotherapy 50 Gy|5 radiations per week of 2 Gy for 5 weeks
223396123|NCT01804790|DRUG|Capecitabine|1600 mg/m² (800 mg/m² twice daily) for 5 weeks
223396124|NCT01804790|PROCEDURE|TME surgery|
223396125|NCT01804790|DRUG|mFolfox6 or capecitabine|oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
223396126|NCT07085273|DRUG|Irinotecan Liposomal|FOLFIRINOX + Karelizumab Irinotecan liposomal: 60 mg/m2, IV infusion, d1; 5-FU: 400 mg/m2, IV infusion, d1, followed by 1200 mg/m2/d x 2 days of continuous IV infusion (total 2400 mg/m2, 46-48h infusion); Calcium folinate: 400 mg/m2, IV infusion, d1; Oxaliplatin: 85 mg/m2, IV infusion, d1; Karelizumab: 200 mg, IV infusion, d1; Repeat every 2 weeks.
223549947|NCT04565912|DRUG|Sage extract mouthwash|Patients will be exposed to sage extract mouthwash and will be instructed to use 10 ml of sage extract mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month.
223396127|NCT07076329|DIETARY_SUPPLEMENT|Ambrosia bar|"The experimental intervention involves the AMBROSIA bar alongside healthy dietary counseling.~The AMBROSIA bar is a novel chocolate bar designed for older Heart Failure (HF) and Atrial Fibrillation (AF) patients to prevent undernutrition. Its distinguishing features are:~* Unique Composition: It contains a unique and specific blend of probiotic strains and a cocktail of micro/macronutrients.~* Patented Probiotic Efficacy: The SYNBIO® blend is patented (RM2004A000166, EP1743042) for its exceptional intestinal mucosal adhesion, ensuring effective colonization and persistence.~* Optimal Delivery Matrix: The chocolate bar serves as a palatable and effective vehicle for probiotic delivery, confirmed to maintain probiotic viability.~* Targeted Nutritional Strategy: The bar aims to modulate gut microbiota and address undernutrition, inflammation, and cachexia in the target."
224015376|NCT05301491|OTHER|Dance Therapy Group|"Dance therapy group patients are going to be treated 3 days a week for 8 weeks. Patients who started treatment are going to be randomly divided into groups that includes four individuals, due to COVID-19 pandemic preventions.~Dance therapy is going to be applied with individualized choreographies specially prepared for the patients, taking the expert opinion of the dance therapist. Choreographies of different dance genres (step/aerobic dance, zumba, salsa, bachata, oriental etc.) are going to be used in the program. Sessions are going to be with the practitioner in a bright, clean, empty and noiseless room in front of a full-length wall mirror. The practitioner is going to participate to dance therapy throughout the sessions, allowing patients to imitate movements. Session duration is going to be 40 minutes. Patients will be given a one-minute rest period during music transitions."
224015377|NCT05301491|OTHER|Exercise Group|"The patients in the control group is going to perform conventional low back exercises. The program of the patients will start with stretching and warming exercises, and will continue with strengthening exercises.~Exercises planed for control group;~1. Unilateral hip-knee flexion (self-assisted exercise)~2. Bilateral hip-knee flexion (self-assisted exercise)~3. Straight leg lifting with the aid of a sheet/rigid band~4. Posterior pelvic tilt~5. Bridge building exercise~6. Cat-camel exercise~7. Half shuttle in sagittal plane~8. Right and left rotational shuttle~9. Trunk hyperextension in prone position~10. Rotational exercise with hip-knee flexed in supine position Patients are going to do exercises with ten repetitions. As the sessions progressed, the number of repetitions will be increased."
223396128|NCT07079449|PROCEDURE|Dry Needling|Dry needling applied to bilateral active trigger points in the masseter and temporalis muscles once per week for three weeks.
223396129|NCT07079449|PROCEDURE|Lidocaine Hydrochloride|Lidocaine (20 mg/mL) injected into each active trigger point in the masseter and temporalis muscles once per week for three weeks.
223549948|NCT04565912|DRUG|Chlorohexidine based mouthwash|Patients will be exposed to Chlorohexidine based mouthwash , and will be instructed to use 10 ml of 0.12% chlorohexidine based mouthwash 2 times per day for 1 minute, such a regimen will be continued for one month
223549949|NCT01618240|OTHER|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
223549950|NCT01618240|OTHER|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
223549951|NCT02360852|DRUG|A4250|A4250 once daily
223549952|NCT01708044|DRUG|Pramlintide acetate|
223549953|NCT01708044|OTHER|Placebo|Placebo Comparator
223549954|NCT03137953|PROCEDURE|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
223549955|NCT03137953|DIAGNOSTIC_TEST|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
224015378|NCT05301491|OTHER|Pyhsiotherapy Modalities|20 minutes hotpack, 3-5 minutes ultrasound and 20 minutes conventional type Transcutaneous Electrical Nerve Stimulation (TENS) are going to be applied to lumbar region of all patients in prone position.
224015379|NCT04367259|PROCEDURE|TMJ Arthrocentesis|Temporomandibular joint arthrocentesis
224015380|NCT05192148|OTHER|Patients|On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
224015381|NCT05084859|DRUG|SM08502|SM08502 to be administered orally.
223549956|NCT00809926|DRUG|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
223549957|NCT00809926|DRUG|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
223396130|NCT07079449|PROCEDURE|Mepivacaine Hydrochloride|Mepivacaine (30 mg/mL) injected into each active trigger point in the masseter and temporalis muscles once per week for three weeks.
223396131|NCT07087184|BEHAVIORAL|Whole Milk-Skim Milk|If randomized to the whole milk-skim milk treatment sequence, participants will be instructed to restrict their liquid milk consumption to only whole milk for the first 2 months and to only skim milk for the last 2 months of the enrollment period. Participants will receive weekly app and text-based message reminders of their randomization assignments.
223396132|NCT07087184|BEHAVIORAL|Skim Milk-Whole Milk|If randomized to the skim milk-whole milk treatment sequence, participants will be instructed to restrict their liquid milk consumption to only skim milk for the first 2 months and to only whole milk for the last 2 months of the enrollment period. Participants will receive weekly app and text-based message reminders of their randomization assignments.
223396133|NCT06866574|BIOLOGICAL|Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli)|Participants received 3 doses of 9-valent HPV vaccine according to a 0, 1, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle of the upper arm)
223549958|NCT00130039|DRUG|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
223549959|NCT00130039|DRUG|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
224015382|NCT05084859|DRUG|Abiraterone|Abiraterone to be administered orally.
224015383|NCT05084859|DRUG|Prednisone|Prednisone to be administered orally.
224015384|NCT05084859|DRUG|Docetaxel|Docetaxel to be administered intravenously.
224015385|NCT05084859|DRUG|FOLFIRI Protocol|FOLFIRI Protocol to be administered intravenously.
224015386|NCT05084859|DRUG|Panitumumab|Panitumumab to be administered intravenously.
224015387|NCT03775434|DRUG|Experimental: B244|B244 suspension in 30ml/bottle
224015388|NCT01859988|DRUG|Dupilumab|
224015389|NCT01859988|DRUG|Placebo|
224015390|NCT02842177|PROCEDURE|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
224015391|NCT02842177|PROCEDURE|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
224015392|NCT02842177|RADIATION|Transvaginal ultrasound|
224015393|NCT02842177|DEVICE|Cu-IUD|
224015394|NCT00712140|BIOLOGICAL|trastuzumab|Given IV
224015395|NCT00712140|DRUG|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
224015396|NCT04040790|DEVICE|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
224015397|NCT04040790|DEVICE|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
224015398|NCT04040790|DEVICE|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
224015399|NCT04040790|DRUG|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
224015400|NCT03693326|DRUG|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
224015401|NCT02065687|DRUG|Carboplatin|Given IV
224015402|NCT02065687|OTHER|Laboratory Biomarker Analysis|Correlative studies
224015403|NCT02065687|DRUG|Metformin Hydrochloride|Given PO
224015404|NCT02065687|DRUG|Paclitaxel|Given IV
224015405|NCT02065687|OTHER|Placebo Administration|Given PO
224015406|NCT02065687|OTHER|Quality-of-Life Assessment|Ancillary studies
224015407|NCT02065687|OTHER|Questionnaire Administration|Ancillary studies
224015408|NCT01569477|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
224015409|NCT01569477|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
224015410|NCT01854398|DEVICE|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
224015411|NCT01854398|DEVICE|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
224015412|NCT01903824|DRUG|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
224015413|NCT01903824|DRUG|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
224015414|NCT01903824|DRUG|modafinil|modafinil 200 mg tablet, over-encapsulated
224015415|NCT01903824|DRUG|Placebo|Placebos formulated to match each active drug
224015416|NCT01665131|DEVICE|Cameron Health S-ICD SQ-RX|
224015417|NCT00706290|BEHAVIORAL|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
224015418|NCT03228628|DRUG|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
224015419|NCT03228628|OTHER|Placebo|inhale medical air (22% O2 - 78% N2)
223549960|NCT02530476|DRUG|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
224015420|NCT04138108|OTHER|Psychoeducation|The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
224015421|NCT03758859|OTHER|sodium hyaluronate eyedrops|sodium hyaluronate eyedrops administered - route ocular -topical
223396134|NCT06866574|BIOLOGICAL|Aluminum Adjuvant|Participants received 3 doses of Aluminum Adjuvant according to a 0, 1, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle the upper arm).
223396135|NCT06782360|DEVICE|Active Neurostimulation|The stimulation frequency, pulse width, and amplitude will be varied in order to determine the optimal stimulation conditions for elongating the period of peak subject performance during the experimental tasks. Amplitude, pulse width, and frequency meet or exceed International Electrotechnical Commission (IEC) 60601-2-10:2016 requirements. The amplitude range specified is selectable for either channel with any frequency and pulse width combination. We will test an amplitude range of 0 mA - 5.0 mA. We will test a frequency range of 1 Hz - 150 Hz. We will test a pulse width range of 50 μs - 750 μs. The study coordinator should apply neurostimulation when the reported cognitive state metric corresponding to the performance task reaches different thresholds. These thresholds will be determined before execution of the study and will be chosen to maximize the likelihood of discovering an optimal trigger for neurostimulation based on reported cognitive state.
223396136|NCT06782360|DEVICE|Sham Stimulation|Modulation of stimulation frequency and amplitudes outside of the known physiological effective ranges during intervention periods.
223396137|NCT06178016|OTHER|Bystander Intervention Program for Dating Violence|"The Bystander Intervention Program for Dating Violence includes the following topics: Dating violence and its types (Session 1), risk factors and consequences of dating violence (Session 2), bystander intervention in dating violence and barriers to intervention (Session 3), bystander intervention strategies for dating violence (Session 4), self-care for bystanders witnessing dating violence (Session 5).~Each session is planned to last 60-90 minutes. Materials will be used in the Bystander Intervention Program for Dating Violence are PPT (PowerPoint Presentations) slides, videos, interactive scenarios, and group discussions. The Bystander Intervention Program for Dating Violence is planned to be applied face-to-face in 4 groups (12, 10, and 10 people) at scheduled times in a quiet room suitable for the group."
223396138|NCT07089667|BEHAVIORAL|virtual reality exergame|virtual reality exergame using Nintendo RingFit
223396139|NCT07089667|BEHAVIORAL|Conventional|Conventional-based aerobic exercise using video aerobic exercise of the Ministry of Health (KEMENKES) protocol
223396140|NCT04052217|DEVICE|Penile Ring|Penile Ring at base of penis
223396141|NCT06902233|DEVICE|High-definition transcranial infraslow grey noise stimulation|HD-tIGNS will be administered three times a week (30 minutes/ session) for a total of 4 weeks (i.e., 12 sessions in total) using a 32-channel transcranial current stimulator. The HD-tIGNS will be used to alter the functional connectivity strength between the three cortical networks \[namely the salience network (SN), the default mode network (DMN) and the somatomotor network (SMN)\] in the infraslow frequency spectrum (0.1 Hz). A total of fifteen circular Ag/AgCl electrodes \[eleven stimulation electrodes (C1, C2, C3, C4, F7, F8, FC3, FT7, FPz, Fz, and O2) and four electrodes with zero current (FC1, FC2, FC4, and FCz)\] will be placed on a neoprene head cap following the International 10-10 EEG system. The optimal montages has been created using the Stimweaver optimization software by the Neuroelectrics company, to specifically decrease the functional connectivity i.e., phase synchronization of the brain regions of the SN with the SMN and the DMN.
223396142|NCT06902233|DEVICE|Sham Comparator|The Actisham protocol (with FC2 as the itchy electrode) created by the Neuroelectrics will be used for the sham stimulation group. Similar to the active treatment group, the actisham will be administered three times a week (30 minutes/ session) for a total of 4 weeks (i.e., 12 sessions in total) using a 32-channel transcranial current stimulator.Similar to active group, a total of fifteen circular Ag/AgCl electrodes will be placed on a neoprene head cap following the International 10-10 EEG system to appropriately blind the participant. The electrodes would comprise of four stimulation electrodes (FC1, FC2, FC4, and FCz) and eleven electrodes (C1, C2, C3, C4, F7, F8, FC3, FT7, FPz, Fz, and O2) with zero current.
223396143|NCT06906874|DRUG|Activated Charcoal|oral activated charcoal capsules
223396144|NCT06906874|DRUG|Phosphate Binders|calcium-based or non-calcium based (sevelamer) binders
223396145|NCT07092046|DRUG|Sevoflurane (Volatile Anesthetic)|An inhalational anesthetic agent will be used for the maintenance of anesthesia, administered at a concentration of 2-3% in a gas mixture consisting of 40% oxygen and air.
223396146|NCT07092046|DRUG|Propofol 1%|An intravenous hypnotic agent will be used for anesthesia induction at a dose of 2-3 mg/kg.
223396147|NCT07092046|DRUG|Remifentanil 2 MG|A short-acting opioid will be administered intravenously for maintenance of anesthesia at a dose of 0.02-0.2 micrograms per kilogram per minute (μg/kg/min).
223396148|NCT07092046|DRUG|Rocuronium 50 mg/5 ml|A neuromuscular blocking agent will be administered intravenously at a dose of 0.6-1.2 mg/kg for induction, and 0.15 mg/kg for maintenance of muscle relaxation during surgery.
223549961|NCT02530476|DRUG|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
223549962|NCT01465438|DRUG|Adalimumab|Adalimumab 40 mg every other week
223549963|NCT01503346|DRUG|DaHuang GanTsao Tang|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
223396149|NCT07092046|DRUG|Lidocaine %2 ampoule|This agent will be administered intravenously at a dose of 1-1.5 mg/kg prior to anesthesia induction to reduce injection pain and facilitate smooth induction.
223396150|NCT07092046|DRUG|Ephedrine Hydrochloride 0,05 mg/ml ampoule|This agent will be administered intravenously at a dose of 0.1 mg/kg to treat intraoperative hypotension that does not respond to fluid replacement or adjustment of anesthetic depth.
223396151|NCT07092046|DRUG|Sugammadex 200 MG in 2 ML Injection|Sugammadex will be administered intravenously at a dose of 2 mg/kg or 4 mg/kg, depending on the degree of neuromuscular blockade.
223396152|NCT07092046|DRUG|Fentanyl (IV)|Fentanyl will be administered intravenously as part of the anesthesia induction regimen, at a dose ranging from 1 to 2 micrograms per kilogram (µg/kg).
223396153|NCT07092046|DRUG|Atropine Sulphate 0.5mg/ml ampoule|In cases of intraoperative bradycardia, defined as a heart rate (HR) below 45 beats per minute (bpm), 0.5 mg of the agent will be administered intravenously.
223396154|NCT07092046|PROCEDURE|Peripheral Intravenous Cannulation|All participants received peripheral intravenous cannulation using 18-20 G IV cannulas placed on the dorsum of the hand before anesthesia induction.
223396155|NCT07092046|PROCEDURE|Mechanical Ventilation|Following endotracheal intubation, mechanical ventilation will be initiated using volume-controlled settings, with a tidal volume (TV) of 6-8 mL/kg, respiratory rate (RR) of 12 breaths per minute, and fraction of inspired oxygen (FiO₂) set at 50%. Ventilator parameters will be adjusted to maintain end-tidal carbon dioxide (ETCO₂) between 30 and 36 mmHg.
223396156|NCT07092046|PROCEDURE|Peripheral Intravenous Cannulation|All participants will undergo peripheral intravenous cannulation with 18-20 gauge (G) IV (intravenous) cannulas placed on the dorsum of the hand prior to anesthesia induction.
223396157|NCT07092046|DRUG|Crystalloid solutions|Participants will receive calculated maintenance fluid therapy with crystalloids administered via intravenous infusion, both prior to and throughout the surgical procedure.
223396158|NCT07092046|PROCEDURE|Endotracheal Intubation|Following induction of anesthesia and establishment of neuromuscular blockade, endotracheal intubation will be performed using a standard technique in all participants.
223396159|NCT07092046|PROCEDURE|American Society of Anesthesiologists (ASA) Standard Monitors|Routine monitoring in accordance with American Society of Anesthesiologists (ASA) guidelines, including noninvasive blood pressure, electrocardiogram (ECG, D2 lead), end-tidal carbon dioxide (ETCO₂), and peripheral oxygen saturation (SpO₂), will be performed in all patients starting from the preoperative period and continuing throughout the surgery.
223549964|NCT00808522|DRUG|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
223549965|NCT00343564|DRUG|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
223549966|NCT00343564|DRUG|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
223549967|NCT06554249|PROCEDURE|Vulsellum group|"The patients are asked to empty the bladder before IUD insertion. The vulsellum is applied on the cervix, sounding of the uterus is done and the IUD is inserted according to the standard technique of IUD insertion.~Pain intensity is assessed after the procedure using a visual analogue scale."
223549968|NCT06554249|PROCEDURE|Ultrasound group|"During the two hour period before IUD insertion, the patients are asked to drink about one liter of water and to avoid micturition.~Abdominal ultrasound is used to obtain a sagittal view of the uterus and the IUD is introduced into the uterine cavity under ultrasound guidance.~The vulsellum and uterine sound are not used during IUD insertion. Pain intensity is assessed after the procedure using a visual analogue scale.."
223549969|NCT05875844|DIAGNOSTIC_TEST|Wrist Splint|Wrist Splint to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
223549970|NCT05875844|DIAGNOSTIC_TEST|Occupational Therapy|Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
223549971|NCT00502580|BEHAVIORAL|Interview|Interview taking about 10 minutes to complete.
223549972|NCT04169204|DIAGNOSTIC_TEST|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
223549973|NCT00901238|PROCEDURE|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
223731159|NCT03634449|DEVICE|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
224015422|NCT04767243|PROCEDURE|open flap debridement and filled with A-PRF ( Advanced platelet rich fibrin)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
224015423|NCT04767243|PROCEDURE|open flap debridement and filled with Bioactive glass (Perioglas®)|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
224015424|NCT04767243|DRUG|open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF|After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
224015425|NCT00778960|BEHAVIORAL|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
223396160|NCT07092046|PROCEDURE|Minimal-Flow Anesthesia|In the minimal-flow anesthesia group, after induction and once a minimum alveolar concentration (MAC) of 1 is achieved, the fresh gas flow will be reduced to 0.5 L/min with a mixture of 45% oxygen (O₂) and 55% air, and maintained throughout the surgical procedure. At the end of surgery, the flow will be increased to 3 L/min to facilitate emergence. Disposable anesthesia circuits, bacterial filters, and face masks will be used for each patient, and carbon dioxide (CO₂) absorbers will be replaced daily.
223396161|NCT07092046|PROCEDURE|Normal-Flow Anesthesia|In the normal-flow anesthesia group, after induction and once a minimum alveolar concentration (MAC) of 1 is achieved, the fresh gas flow will be adjusted to 2 L/min and maintained during the surgical procedure. For emergence, the flow will be increased to 3 L/min. Disposable anesthesia circuits will be used, and daily maintenance protocols, including replacement of carbon dioxide (CO₂) absorbers, will be applied in the same manner as in the minimal-flow group.
223396162|NCT07092046|DIAGNOSTIC_TEST|Anesthesia Circuit Sampling|Sterile swab samples will be collected from both the inspiratory and expiratory limbs of the anesthesia circuit-once prior to circuit connection and again immediately after disconnection at the end of the surgical procedure. All samples will be processed for microbial culture and species-level identification.
223396163|NCT07092046|PROCEDURE|Body Temperature Monitoring|In addition to routine monitoring-including electrocardiogram (ECG), non-invasive blood pressure, peripheral oxygen saturation (SpO₂), and end-tidal carbon dioxide (ETCO₂)-body temperature will be continuously monitored in both study groups throughout the surgical procedure using appropriate thermal sensors. Temperature measurements will be recorded at 5-minute intervals and used to assess the impact of different fresh gas flow rates on intraoperative thermoregulation.
223549974|NCT06154148|PROCEDURE|Sustained Diagonal Flexion positioning|This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
224015426|NCT00778960|BEHAVIORAL|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
224015427|NCT00778960|BEHAVIORAL|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
224015428|NCT00778960|BEHAVIORAL|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
224015429|NCT01234051|DRUG|Docetaxel, Oxaliplatin|"1\. Treatment Schedule~1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.~1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days."
224015430|NCT03699553|BEHAVIORAL|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
224015431|NCT03699553|BEHAVIORAL|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
224015432|NCT03827083|OTHER|cerebral pulse oximetry|Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia
224015433|NCT02006251|DEVICE|Real-time Instrumentation|To prepare the acetabulum and place the implants on the day of surgery, surgeons will receive either parts necessary to create the real-time with a surrogate model of the acetabular surface or standard surgical alignment instruments provided by the manufacturer of the implant. For the experimental group, the surgeon will be provided with 3 parts necessary to create the real-time instrument: (1) a patient-specific surrogate bone model with a built-in guide pin trajectory which was planned in the 3D planning software, (2) a non-specific plastic arm available in different sizes, and (3) bone cement. The real-time instrument is created to position a peripheral guide wire on the acetabular rim to serve as a visual aid for reaming and impacting the acetabular shell using standard reaming tools supplied by the manufacturer. Once the acetabular shell is placed, the procedure is performed in the same manner for both groups, using the standard manufacturer instruments.
224015434|NCT02006251|PROCEDURE|Standard Total Hip Arthroplasty|Total hip arthroplasty performed according to standard of care
224015435|NCT04491552|DIAGNOSTIC_TEST|Patients monitored with TruGraf and TRAC testing|This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
224015436|NCT03028753|DEVICE|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
224015437|NCT03028753|PROCEDURE|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
223396164|NCT07092046|DIAGNOSTIC_TEST|Nasopharyngeal Swab Collection|A sterile nasopharyngeal swab (Dry SWAB) will be collected from each patient upon arrival in the operating room, prior to anesthesia induction. Each sample will be labeled with the patient's identification number, date, time, and collection site, and will be transferred in appropriate transport medium to the microbiology laboratory for culture and microbiological analysis.
223549975|NCT06154148|PROCEDURE|Traditional prone position|The infant is placed vertically between the mother's breasts firmly attached to the chest and below their clothes.
223549976|NCT05007548|DRUG|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
223396165|NCT07092046|DIAGNOSTIC_TEST|Microbiological Culture and Identification|All collected swab samples-including both nasopharyngeal and anesthesia circuit specimens-will be cultured using the serial dilution method on 5% sheep blood agar within 15 minutes of arrival at the microbiology laboratory. Cultures will be incubated at 35-37°C for 48 hours. Colony growth will be evaluated by a clinical microbiologist, and microorganisms will be identified to the species level using an automated MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) system.
223396166|NCT07088211|DRUG|Sacituzumab Tirumotecan and Toripalimab|The dosing regimen for the combination of Sacituzumab Tirumotecan and Toripalimab is as follows: the recommended dose of Sacituzumab Tirumotecan is 5mg/kg, administered intravenously every 2 weeks, and Toripalimab is administered intravenously (without prophylactic medication), with a fixed dose of 240mg, and 3mg/kg is used for subjects with baseline body weight\<50kg. Each infusion lasts for 30 minutes (not less than 20 minutes, not more than 60 minutes), administered once every 2 weeks. The subjects will continue to receive combination therapy with Sacituzumab Tirumotecan and Toripalimab until the termination criteria are met.
223396167|NCT07096791|DRUG|KH607 tablet|oral，once daily for 14 days
223396168|NCT07096791|DRUG|placebo|oral，once daily for 14 days
223396169|NCT07095036|OTHER|Spinal cord stimulation (SCS)|After implantation of SCS trial leads - which is standard of care for evaluating whether SCS improves chronic pain - patients will visit clinic before the trial leads are explanted. During these visits, stimulation will be turned off and the leads will be disconnected from the clinical external pulse generator and reconnected to an external research stimulator. Patients will be seated in a chair and will interface with a touch-screen display where they will participate in a psychophysical task (a two-alternative forced-choice task). More specifically, the task will involve selecting between two options on a screen while spinal stimulation is delivered through the leads. As the patients perform the tasks, audio or video recordings will be made for future research analysis, education, or scientific communication. The research stimulator will also collect epidural signals through the stimulation leads.
223396170|NCT07095699|DEVICE|EndoSCell System|EndoSCell Scaner (ES) is a new type of intraoperative cell-level fluorescence-guided imaging technology that can be used for direct and rapid intraoperative tissue cell interpretation. This technology uses a handheld cell microscope system to magnify local tissue by about 1280 times, and can perform rapid real-time scanning and imaging of in vivo or excised ex vivo tissue.
223396171|NCT07095413|DIAGNOSTIC_TEST|Wesper Lab Home Sleep Apnea Test|Subjects will wear the Wesper Lab home sleep apnea tests, which includes 2 wireless sensors and a pulse oximeter.
223396172|NCT07096414|DIETARY_SUPPLEMENT|Vitamin D3|Administration of vitamin D3 capsule 50,000 IU/week for 8 weeks
223396173|NCT05479435|BEHAVIORAL|Blue Prescription Exercise Program|"After the evaluation, participants will receive feedback and physical activity training, along with an explanation of the benefits of exercise, provided in the form of a brochure. They will then be enrolled in the Blue Prescription program, which includes weekly follow-ups for 12 weeks and a re-evaluation at the end of the 12th week. Motivation and support will be offered in accordance with the Blue Prescription philosophy, addressing home exercise programs, physical activity selection, and overcoming obstacles. Participants will be encouraged to determine the most suitable program for themselves and maintain an activity diary.~Throughout the study, participants will have the opportunity to communicate with the physiotherapist via various methods such as phone, SMS, or email."
223396174|NCT05479435|BEHAVIORAL|Video Based Home Exercise Program|After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.
223396175|NCT05479435|BEHAVIORAL|Supervised Group Exercise Program|DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Participants will engage in exercises with a physiotherapist three days a week for 12 weeks, and the effectiveness of the program will be re-evaluated at the end of the 12th week.
223396176|NCT07096557|DRUG|Coenzyme Q10|Coenzyme Q10 100 mg capsule once daily for 3 months
223396177|NCT07094958|BIOLOGICAL|stromal vascular fraction (SVF)|Autologous stromal vascular fraction (SVF) isolated from adipose tissue was injected intradermally into one side of the face to evaluate its efficacy in treating atrophic acne scars. SVF was freshly prepared on the same day of injection using enzymatic digestion and centrifugation.
223396178|NCT07094958|OTHER|Normal Saline (NS)|Normal saline (NS) was injected intradermally into the contralateral side of the face and served as a placebo comparator to SVF in this split-face study on atrophic acne scars.
223549977|NCT03139461|OTHER|PT-REFER Capacity-building Toolkit|"1. Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~2. Support from Change Agent~3. Technical Assistance Calls"
223549978|NCT06237634|OTHER|splint and exercise and advices|A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.
223549979|NCT06237634|OTHER|Triamsinolon Asetonid ozone|40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.
223549980|NCT06237634|OTHER|ozone|In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
223731160|NCT04788888|DEVICE|Navitor Transcatheter Aortic Valve and FlexNav Delivery System|"For traditional application, the Navitor valve is indicated for transcatheter delivery in patients with symptomatic severe native aortic stenosis who are intermediate or low surgical risk.~For the valve-in-valve application, the Navitor valve is indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve.~Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Navitor valve and FlexNav Delivery system"
224015438|NCT03028753|PROCEDURE|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
224015439|NCT06218654|DIAGNOSTIC_TEST|biomarkers|"Serum tests for specific cardiac troponin (cTPI), neuron-specific enolase (NSE), natriuretic peptides (NT-ProBNP), S100 protein (S100B), Soluble Suppressor of Tumorigenesis-2 (sST2), and soluble urokinase plasminogen activator receptor (suPAR) tests will be performed, as well as urinary tests for epinephrine and norepinephrine. On these samples, conducted according to clinical practice, additional measurements will also be taken for glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase (UCH-L1) as specific study biomarkers on blood samples.~All samples will be collected within 24 hours of admission to the Emergency Department (T0) and after 72 hours (T1). A sample at day 7 (T2) will be taken."
224015440|NCT01973244|DRUG|somapacitan|"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
224015441|NCT01973244|DRUG|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
224015442|NCT06179784|BEHAVIORAL|Cognitive Behaviour Therapy including third-wave|All treatment modules are based on evaluated treatment manuals and contain methods from Cognitive Behaviour Therapy including methods from the third wave like Acceptance and Commitment Therapy or Mindful Selfcompassion.
224015443|NCT04679480|DRUG|Cemiplimab Injection [Libtayo]|"Investigational product: a combination of an anti-PD1 antibody (Cemiplimab) and a HHI (Sonidegib).~Cemiplimab will be supplied as a liquid in a sterile, single-use 10 ml vial. Each vial will contain a volume of 7ml at a concentration of 50mg/ml. Cemiplimab will be prepared for infusion (as described in SmPC (Fachinformation Swissmedic) Libtayo, see Appendix) at the trial site and administered as a flat 350mg dose in 100ml NaCl 0.9% as an IV infusion over approximately 30 minutes (±10 minutes) in an outpatient setting. Each patient's dose will be administered as a flat 350mg dose in every 3 weeks, starting from week 2 of the trial.~The Hedgehog Inhibitor used for the trial will be Sonidegib. Sonidegib is a white 200mg capsule, orally administered once daily. Sonidegib will be administered in a 2 week cycle every 4 weeks (pulsed therapy: 2 weeks on, 2 weeks off), starting from week 0 of the trial."
224015444|NCT02723526|OTHER|Blood drawing|
224015445|NCT06294054|COMBINATION_PRODUCT|neoadjuvant chemotherapy with cisplatine|Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
224296528|NCT04566341|DEVICE|OCT - TCE|Participants will be asked to swallow the TCE. They may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE is past the pharynx. We will advance the TCE until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
224296529|NCT03805100|BIOLOGICAL|Ranibizumab|Intravitreal injection
224296530|NCT03254030|OTHER|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
223396179|NCT06911684|COMBINATION_PRODUCT|lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|"Group A patients received two cycles of QL1706, regorafenib, and CAPOX induction therapy, followed by sequential short-course radiotherapy, and then continued with four cycles of QL1706, regorafenib, and CAPOX consolidation therapy.~lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase.~Regorafenib:80 mg, oral (PO), once daily (qd), Days 1-14, every 3 weeks (q3w) during the neoadjuvant treatment phase.~CAPOX: Oxaliplatin( 130 mg/m², IV over 2 hours, Day 1, every 3 weeks (q3w))+ Capecitabine( 1000 mg/m², PO, twice daily (bid), Days 1-14, every 3 weeks (q3w)).~Short-course radiotherapy:The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose."
223396180|NCT06911684|COMBINATION_PRODUCT|lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy|"Group B patients received short-course radiotherapy followed by six cycles of QL1706, regorafenib, and CAPOX consolidation therapy.~lparomlimab and Tuvonralimab Injection(QL1706): 5 mg/kg, intravenous (IV), on Day 1, every 3 weeks (q3w) during the neoadjuvant treatment phase. Regorafenib:80 mg, oral (PO), once daily (qd), Days 1-14, every 3 weeks (q3w) during the neoadjuvant treatment phase. CAPOX: Oxaliplatin( 130 mg/m², IV over 2 hours, Day 1, every 3 weeks (q3w))+ Capecitabine( 1000 mg/m², PO, twice daily (bid), Days 1-14, every 3 weeks (q3w)). Short-course radiotherapy:The total dosage was 25Gy consisted of 5 fractions of 5 Gy to clinical target volume without a boost dose."
223396181|NCT07097415|DEVICE|Continuous blood glucose monitoring assisted blood glucose management|(1) individualized health education sessions conducted by endocrinology healthcare providers covering CGM concepts, usage methods, advantages, risks, and precautions, along with hands-on device demonstration and provision of written materials and user manuals; (2) development of an integrated CGM data management platform that connects with community healthcare information systems for real-time data transmission, storage, and analysis; (3) establishment of standardized CGM response protocols for healthcare providers, including glucose target setting, dietary and exercise recommendations, personalized medication adjustments based on glucose fluctuations, and management procedures for hypoglycemic and hyperglycemic alerts; and (4) mobile application setup and data transmission configuration for patients.
223396182|NCT07095517|DRUG|Tirzepatide|Study drug injected subcutaneously once a week
223396183|NCT07097350|DEVICE|computer-aided detection alone|colonoscopy with computer-aided detection
223396184|NCT07097350|DEVICE|transparent cap-assisted colonoscopy combined with computer-aided detection|transparent cap-assisted colonoscopy combined with computer-aided detection
223396185|NCT07096479|DRUG|Telpegfilgrastim Injection|Within 48 ± 12 hours after the end of each chemotherapy cycle, a single subcutaneous injection of a fixed dose of 2mg of Telpegfilgrastim is administered. Use once per chemotherapy cycle and enroll in 1-4 cycles based on the patient's actual condition.
223549981|NCT04945525|OTHER|Care Continuity Program|The Care Continuity Program is an online patient self-assessment tool used by prescribers of opioids to better identify patient risk factors and opioid therapy benefit. This tool is completed by the patient, outside of the office, using an internet enabled device and follows a compliance driven protocol developed by analyzing case law against physicians in mis-prescribing opioid cases. Results, in the form of a date and time stamped legal report, are instantly transmitted to the prescriber's electronic health records, mitigating the prescriber's civil and criminal risk. A brief of findings is displayed within the software through a dashboard and on the summary page of the report. Prescribers may use the summary page to help them identify the appropriateness of initiating opioid therapy and/or continuing opioid therapy.
224015446|NCT04161625|BEHAVIORAL|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis\&Svettis)"
224015447|NCT02942992|BEHAVIORAL|Resistance exercise|resistance exercise
224015448|NCT00468559|DRUG|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
224015449|NCT00468559|DRUG|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
224015450|NCT00468559|DRUG|Double Blind Placebo|Double Blind Placebo
224015451|NCT06488989|DEVICE|left bundle branch area pacing|Cardiac resynchronization therapy obtained by conduction system pacing
224015452|NCT04294927|PROCEDURE|Risk-reducing salpingectomy with delayed oophorectomy|"* BRCA1: RRS at age 25-40 and RRO at a maximum age of 45 (advised between 35 and 45).~* BRCA2: RRS at age 25-45 and RRO at a maximum age of 50 (advised between age 40 and 50).~* BRIP1, RAD51C, RAD51D: RRS at age 25-50 and RRO at a maximum age of 55 (advised between 45 and 55)"
224015453|NCT04294927|PROCEDURE|Risk-reducing salpingo-oophorectomy|"* BRCA1 at a maximum age of 40 (advised between age 35 and 40)~* BRCA2 at a maximum age of 45 (advised between age 40 and 45)~* BRIP1, RAD51C, RAD51D: at a maximum age of 50 (advised between 45 and 50)"
224015454|NCT04602221|DRUG|Lamotrigine|Tablet
224015455|NCT04602221|DRUG|BI 409306|Film-coated tablet
224015456|NCT04602221|DRUG|Placebo|Tablet, Film-coated tablet
224015457|NCT04602221|DRUG|BI 425809|Film-coated tablet
224015458|NCT00029133|PROCEDURE|mild intraoperative hypothermia (33 degrees Celsius)|
224015459|NCT00936546|DRUG|Rituximab|Mabthera, Rituximab 1000 mg I.V.
223396186|NCT07095166|BEHAVIORAL|Meal Location|The location at which the child will eat the experimental meal - home or lab
223396187|NCT07097142|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223396188|NCT07097142|DRUG|Cisplatin|Given IV
223396189|NCT07097142|DRUG|Gemcitabine|Given IV
223396190|NCT07097142|DRUG|Mitomycin|Given IV
223396191|NCT07097142|DRUG|Fluorouracil|Given IV
223396192|NCT07097142|PROCEDURE|Computed Tomography|Undergo CT scan
224015460|NCT04684407|PROCEDURE|ROOT CANAL TREATMENT|TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT
224015461|NCT04973904|DRUG|Toripalimab|IV infusion
224015462|NCT04973904|DRUG|Paclitaxel|IV infusion
224015463|NCT04973904|DRUG|Cisplatin|IV infusion
224015464|NCT04973904|DRUG|Bevacizumab|IV infusion
224015465|NCT05406076|BEHAVIORAL|oral motor therapy|Rigorous Chinese language oral motor therapy, including treatment of oral perceptual disorders and treatment of oral motor disorders. The treatment follows three basic principles: a combination of basic training and specific treatment; a combination of self-help and assisted treatment; and a combination of exercises, cues, and stimulation techniques. 30-40 min/session, 1 session/day, 5 sessions/week.
223396193|NCT07097142|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223396194|NCT07097142|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223396195|NCT07097142|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and urine sample collection
223396196|NCT07097142|OTHER|Survey Administration|Ancillary studies
223396197|NCT07096570|BEHAVIORAL|Selected Multisensory Training (SMST)|A 12-week supervised exercise program involving two 40-minute sessions weekly. The program includes proprioceptive challenges on progressively firmer surfaces, vestibular activation with gait drills and head movements, and visual tracking tasks. Intensity progresses every three weeks by increasing surface instability, adding handheld weights, and reducing visual input (eyes open to eyes closed). The intervention aims to improve neuromuscular activation, balance, and sensory integration in older women with diabetic peripheral neuropathy.
223396198|NCT07095309|DRUG|Artesunate|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
224015466|NCT05406076|BEHAVIORAL|ABA|The mainstream ASD intervention approach with evidence-based support is currently recognized worldwide. Treatment follows the operational core principles of ABA, which are to establish learning goals based on the child's ability level, design teaching situations and select reinforcers for them, change the child's behavior problems with operational constraints, and to eliminate or improve problem behaviors through appropriate interventions to shape new adaptive behaviors. The training time is at least 20 hours per week.
224015467|NCT01089738|DRUG|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
224015468|NCT01089738|DRUG|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
224015469|NCT01089738|DRUG|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
224015470|NCT01089738|DRUG|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
224015471|NCT02231801|BEHAVIORAL|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
224015472|NCT04554043|DRUG|SHR7280|treatment
223396199|NCT07095309|DRUG|Artesunate matching Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
223396200|NCT04941092|OTHER|no intervention|no intervention, retrospective comparison
223396201|NCT07097220|DRUG|General Anesthesia (GA) group|In the General Anesthesia (GA) group (n = 59), patients received combined intravenous-inhalation general anesthesia. Anesthesia induction was performed using propofol and remifentanil, followed by maintenance with sevoflurane to ensure adequate anesthetic depth and hemodynamic stability throughout the procedure.
223549982|NCT05715060|PROCEDURE|Median sternotomy closure (sternal closure)|Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
223731161|NCT04959344|BIOLOGICAL|Kleb4V target dose|Two doses of the non-adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
224015473|NCT04554043|DRUG|Placebo oral tablet|blank control
223549983|NCT01296503|DRUG|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
223549984|NCT01296503|DRUG|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
223549985|NCT00295789|DRUG|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
223549986|NCT00295789|DRUG|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
224296531|NCT00289757|BIOLOGICAL|Havrix™|2 doses at 6 months interval
223396202|NCT07097220|DRUG|General-Epidural Anesthesia (GEA) group|In the General-Epidural Anesthesia (GEA) group (n = 47), patients received the same general anesthesia protocol as the GA group, in addition to epidural anesthesia. An epidural catheter was placed preoperatively at the T7-T9 vertebral level using a midline approach under strict aseptic conditions. Following successful catheterization and confirmation of proper placement, a continuous intraoperative infusion of 0.25% ropivacaine was administered via the epidural route to provide segmental analgesia and reduce intraoperative opioid requirements.
223396203|NCT07097441|DRUG|Placebo drug ( normal saline )|At the end of surgery patients will be given placebo ( normal saline ) instead of neostigmine ( reversal agent of atracurium ) , to observe Heart rate, blood pressure , respiratory rate and oxygen saturation on extubation and post operative airway reflexes and residual paralysis
223396204|NCT07097441|DRUG|neostigmine (reversal agent)|At the end of surgery patients will be given neostigmine ( reversal agenr ) , to observe Heart rate, blood pressure , respiratory rate and oxygen saturation on extubation and post operative airway reflexes and residual paralysis
223396205|NCT07103343|BEHAVIORAL|MOVI-OLE intervention|"In the MOVI-OLE! classrooms, traditional desks and chairs will be replaced by three dynamic learning zones:~A) Dynamic seating: an area with traditional wheeled desks combined with dynamic seats such as fitballs, stools, pedal desks, etc.; B) Standing desks: an area with manually adjustable high desks to allow standing work. Students will also have stools with small backrests and footrests for when they need to sit; C) Vertical boards: vertical boards (vinyl, paper, chalkboard paint, etc.) installed on walls for standing work.~To facilitate use and adapt to classroom routines, teachers will decide how to distribute students among the different zones, with the requirement that all students spend at least 20 minutes per school day in zone B.~In addition to the workstations, teachers will receive training and didactic support materials focused on student-centered methodologies and the use of open learning spaces."
223549987|NCT05004844|DIAGNOSTIC_TEST|Viscoelastic assays and aggregometry tests|Viscoelastic assays and aggregometry tests performed with ROTEM will allow us to characterize the clot forming abilities and platelet functions of our patients. ROTEM is used routinely for aiding clinicians in choosing the appropriate blood products for patients ROTEM requires samples of whole blood in an amount that does not entail additional burden or risk for patients. In our study, viscoelastic assays and aggregometry will be performed upon arrival, and 24-,48-,72-hours post-admission.
223549988|NCT04294355|DEVICE|Artificial intelligence-Assisted colonoscopy|Artificial intelligence-Assisted colonoscopy for detection of colonic polyp
223549989|NCT04294355|PROCEDURE|Conventional colonoscopy|Conventional colonoscopy
223549990|NCT00100802|OTHER|Laboratory Biomarker Analysis|Correlative studies
223549991|NCT00100802|DRUG|Lomustine|Given PO
223549992|NCT00100802|RADIATION|Radiation Therapy|Undergo radiation therapy
223549993|NCT00100802|DRUG|Temozolomide|Given PO
223549994|NCT01541488|DRUG|BI 1021958|tablet
223549995|NCT01541488|DRUG|BI 1021958|drinking solution / tablet
223731162|NCT04959344|BIOLOGICAL|Kleb4V target dose + AS03|Two doses of the adjuvanted Kleb4V target dose will be administered intramuscularly 2 months apart
224296532|NCT06306235|OTHER|Questionnaire|Part A: 30 patients will be interviewed. Part B: 300 patients will complete written questionnaire on tablet.
223549996|NCT01541488|DRUG|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
223549997|NCT06093399|DEVICE|System ON|The DBS system will be turned on, and the individual's stutter will be assessed.
223549998|NCT06093399|DEVICE|System OFF|The DBS system will be turned off, and the individual's stutter will be assessed.
223549999|NCT00611390|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
223731163|NCT04959344|BIOLOGICAL|Kleb4V low dose|Two doses of the non-adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
223731164|NCT04959344|BIOLOGICAL|Kleb4V low dose + AS03|Two doses of the adjuvanted Kleb4V low dose will be administered intramuscularly 2 months apart
223731165|NCT04959344|BIOLOGICAL|Placebo|Two doses of the Placebo will be administered intramuscularly 2 months apart
224015474|NCT03538301|DRUG|ND-L02-s0201 (Low Dose)|Intravenous administration every 2 weeks
224015475|NCT03538301|DRUG|ND-L02-s0201 (High Dose)|Intravenous administration every 2 weeks
224015476|NCT03538301|OTHER|Other: Placebo|Saline
224015477|NCT03795129|BEHAVIORAL|SleepLife Application w/FitBit|"Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application."
224015478|NCT03795129|BEHAVIORAL|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
224296533|NCT00712426|DRUG|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
224296534|NCT00712426|DRUG|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
224296535|NCT04749472|OTHER|Sling|Participants wore six different shoulder slings in a randomized order.
223396206|NCT05296148|DEVICE|Transcatheter Tricuspid Valve Implantation|Implantation of a tricuspid coaptation valve through a transcatheter approach.
223396207|NCT07111741|DEVICE|Total contact cast|Arm with 51 patients was given total contact cast for offloading DFU
223396208|NCT07111741|DEVICE|Posterior slab cast|Arm with 48 patients were given posterior slab cast for offloading DFU
223396209|NCT07112300|PROCEDURE|cervical nerve radiofrequency|Pulsed radiofrequency treatment is applied to the cervical 5-6-7 nerve roots defined under ultrasound guidance in the intertubercular or interscalene space by approaching the cervical 5-6-7 nerve roots with an inplane technique via a cannula electrode.
223396210|NCT07107646|BEHAVIORAL|vision training system, VTS|Participants in this group will receive individualized visual perceptual learning using the Vision Training System (VTS). The training involves blurred Gabor stimuli presented via a computer-based application. Each participant will complete approximately 20 training sessions over 3 months, with each session lasting 15 to 30 minutes, conducted twice per week. The program is designed to enhance uncorrected visual acuity, contrast sensitivity, and other visual functions by engaging neural mechanisms related to perceptual learning. Training progression is adaptive based on individual performance. The VTS software was developed in collaboration with Bar Ilan University.
223550000|NCT00611390|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
223550001|NCT02712996|DRUG|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
223550002|NCT02712996|DRUG|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
223550003|NCT01562886|DRUG|Rilpivirine|Rilpivirine 26mg
224015479|NCT03685851|PROCEDURE|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
224015480|NCT03745261|DRUG|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
224015481|NCT03745261|DRUG|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
224015482|NCT03745261|DRUG|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
224015483|NCT03745261|DRUG|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
224015484|NCT03745261|DRUG|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
224015485|NCT04898491|OTHER|Pain assessment using a behavioral scale|"The pain of the subjects will be evaluated by two independent observers and with a blind result between them, coinciding with the application of two painful procedures used in routine practice: suction of tracheal secretions and the pressure in the nail bed by means of a pressure algometer. In addition, a painless procedure will also be performed to establish an element of control with the procedures painful. This will consist of the application of gentle friction with a cloth gauze, on a part of healthy skin tissue of the patient. The measurement will be performed twice for each patient and procedure depending on the level of sedation, so that the first measurement will be performed with a deeper sedation level and the second with a change in sedation level to moderate-mild.~In turn, the pain assessment will be carried out in three moments: first or baseline measurement, during the application of the painless and 15 minutes after finishing the procedures."
223396211|NCT07111104|DRUG|Immunotherapy|"The immunotherapy intervention consists of treatment with immune checkpoint inhibitors, specifically Nivolumab (OPDIVO), Atezolizumab (TECENTRIQ), Pembrolizumab (KEYTRUDA).~These drugs are monoclonal antibodies that block PD-1 or PD-L1 pathways, aiming to enhance the immune system's ability to recognize and destroy cancer cells. The treatment is administered intravenously according to standard dosing schedules."
223550004|NCT01165125|DRUG|FF / GW642444|200mcg/25mcg Novel DPI
223550005|NCT01165125|DRUG|ketoconazole|400mcg overencapsulated tablets
223550006|NCT01165125|DRUG|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
223550007|NCT04815200|DEVICE|Copper Nickel titanium arch wire|Patient will receive 0.014 round Copper Nickel titanium CuNiTi archwire and will be ligated using a ligature wire.
223550008|NCT06160323|PROCEDURE|EUS-guided coeliac ganglion neurolysis / celiac plexus neurolysis|"The EUS scope was first inserted into the stomach, and the coeliac trunk was visualized by scanning from the lesser curve of the gastric body. After visualization, the scope was rotated clockwise, enabling visualization and identification of the left adrenal gland. The coeliac ganglia are often seen to the left of the coeliac artery, between the aorta and the left adrenal gland, at the level between the coeliac artery and the left adrenal artery. They are also visualized cephalad to the coeliac artery in some cases. Hypoechoic nodular structures linked by hypoechoic threads residing in the periphery of this region were defined as the coeliac ganglia . A 19G or 22G needle was used for puncture of the CGN. After confirming the lack of backflow of blood with aspiration, a mixture of 5ml of 0.25-0.5% bupivacaine and 5ml absolute alcohol was injected.~For cases in which celiac ganglia could not be visualized, EUS-guided coeliac plexus neurolysis (CPN) will be performed."
223550009|NCT02778984|DEVICE|QuadraLite masks|The intervention is identical in the two group
223550010|NCT02778984|OTHER|standard mask|
223550011|NCT02151656|DRUG|F17464|
223550012|NCT02151656|DRUG|Placebo|
223731166|NCT05870020|OTHER|Questionnaire (DBS-QoLs)|"The DBS-QoLs questionnaire will be sent to the patients for answer:~The questonnaire will be sent at :~* the inclusion~* 15 days after the inclusion~* 1 year after the inclusion"
223731167|NCT03252301|DEVICE|PMD 200|finger sensor which estimate objectively the pain level
223731168|NCT00298220|BEHAVIORAL|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
223396212|NCT07111104|RADIATION|Radiotherapy|The radiotherapy intervention involves targeted delivery of ionizing radiation to metastatic lesions. Radiotherapy may be given either concurrently with immunotherapy or sequentially afterward, depending on the patient's treatment plan. The purpose is to achieve local tumor control and potentially enhance the systemic immune response through immunogenic cell death. Different radiation techniques and dose regimens may be employed based on lesion size, location, and clinical considerations.
224128240|NCT04615702|DRUG|Ringer lactate|"The initial infusion rate for mild cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload.~The initial infusion rate for both severe cases :~* For patients without dehydration is (130-150mL/h).~* In case of dehydration/ shock: (150-600mL/h) with close monitoring of patients with comorbidities such as cardiac problems or renal failure to avoid volume overload d. The target~* A mean arterial pressure of 65mmHg or more,~* Urine output of 0.5mL/kg per hour or more When these parameters achieved, the infusion rate decreased to the level that maintain these parameters."
224128241|NCT04615702|COMBINATION_PRODUCT|NSAID / paracetamol +/- opiates+/- epidural analgesia|"Pain control (Modified World Health organization (WHO) analgesia ladder) Step1: NSAID / paracetamol Paracetamol 1gm IV infusion /8h + Diclofenac sodium 75mg /12h.~Step 2: Opiates +/- NSAID/ paracetamol Pethidine 25 mg IV/4h~Step 3: Interventional treatment (epidural analgesia) +/- opiates +/- NSAID/ paracetamol In case of severe pain not responding to the above analgesia"
224128242|NCT04615702|COMBINATION_PRODUCT|Quinolones + Metronidazole /Carbapenems ± Metronidazole|"* Mild attack: no antibiotic prophylaxis administered.~* Severe attack:~* Timing: Antibiotic prophylaxis administered to cases presented early within 72 hrs of disease onset.~* Duration: Not more than 2 weeks~* Antibiotics given:~  * Quinolones + Metronidazole ( the 1st choice in ward) Ciprofloxacin 400mg IV /12 h + metronidazole 500mg IV/8h~ * Carbapenems ± Metronidazole (the 1st choice in ICU patients and in case of sensitivity to quinolones) Imipenem .5gm IV/6h + metronidazole 500mg IV/8h~    b. Therapeutic (in cases with pancreatic or extrapancreatic infections)~ * In case of pancreatic infection, Carbapenems ± metronidazole were given."
223396213|NCT07112625|OTHER|education and coaching|education associated to coaching
223396214|NCT07112625|OTHER|education|education without coaching
223396215|NCT07111156|OTHER|Topical Cream containing 0.1% Pinorox®|"Mode of Usage: Apply a coin size (approximately 1g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
223396216|NCT07111156|OTHER|Topical Cream containing 1% Pinorox®|"Mode of Usage: Apply a coin sized (approximately 1 g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
223396217|NCT07111156|OTHER|Placebo (Base Cream)|"Mode of Usage: Apply a coin sized (approximately 1 g) amount of the test treatment to the face and gently massage it until fully absorbed.~Frequency: Apply the treatment twice daily Route of administration: Topical Dosage Form: Semisolid (Cream) Storage Condition: Store at room temperature 15°C to 30°C, away from sunlight."
223396218|NCT07111793|OTHER|Extended phenotyping|Extended phenotyping (analysis performed at Nantes University Hospital, MANDATORY DELIVERY WITHIN 24 HOURS) = 1 EDTA 3 mL tube for patients included in Nantes.
223396219|NCT07111793|OTHER|Blood sample for WES|Blood sample for WES : 1 x 3 mL EDTA tube (if not included in DIABACT IV biocollection)
223396220|NCT07111793|OTHER|Blood sample for PBMC freezing|Blood sample for PBMC freezing integrated into the biocollection: 1 EDTA tube = 3 mL
223396221|NCT07111793|OTHER|POPC score evaluation|Assessment of POPC score (Pediatric Overall Performance Category)
223550013|NCT05964179|BEHAVIORAL|time extended feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
223731169|NCT00298220|BEHAVIORAL|Dissemination guideline and patient information letters|
224015486|NCT01511094|PROCEDURE|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
224015487|NCT01445600|DRUG|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
224015488|NCT05960253|PROCEDURE|Pericapsular Nerve Group Block|1st group to be applied PENG block
224015489|NCT05960253|PROCEDURE|Lumber Erector Spinae Plane Block|2nd group to be applied Lumber ESP block
224015490|NCT01685723|BEHAVIORAL|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
223396222|NCT07111793|OTHER|Questionnaire completion|"Questionnaires completed by parents or children:~* SDQ~* PedSQL4.0"
223550014|NCT05964179|BEHAVIORAL|time restricted feeding|Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
223550015|NCT03390725|BEHAVIORAL|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
223731170|NCT00298220|BEHAVIORAL|Tailored educational training|for GP(T)s
224015491|NCT01685723|BEHAVIORAL|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
224015492|NCT03598959|DRUG|tofacitinib|orally 10 mg daily
224015493|NCT03598959|DRUG|chidamide|orally 20 mg twice weekly
224015494|NCT04540887|DEVICE|Pulsed Electromagnetic Field (PEMF) Therapy|PEMF therapy will be self-administered by all trial participants using the B. Body, B. Pad, and Control Unit. Participants will administer this therapy twice a day (morning and evening) for 8-minute sessions over a four week period.
224128243|NCT04615702|DIETARY_SUPPLEMENT|Fresubin 2Kcal fiber drink|"Severe cases Timing: Within at least 48 hrs of admission provided that there are no intestinal complications.~Route: Nasogastric tube Nutrients: Polymeric feeding formula~* Nutrient: Fresubin 2Kcal fiber drink 200ml (2Kcal/ml)~* Total caloric requirements ꞊ body weight (kg) X 30Kcal/day Pattern : Continuous infusion~* The nutrition started with small amount and increased gradually over 16hrs~* Infusion rate ꞊ Total caloric requirements / 16hrs"
223396223|NCT07113223|DEVICE|Willem™ platform ECG assessment|AI-assisted ECG analysis via the Willem™ platform
224015495|NCT04220762|DRUG|WIN-1001X|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
224015496|NCT04220762|DRUG|Placebo|"This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated."
224015497|NCT02186249|DRUG|Nivolumab|
224015498|NCT02186249|DRUG|Ipilimumab|
224015499|NCT02733055|OTHER|posturographic evaluation|subjects will undergo CDP testing using one of the ext\_mCTSIB tests without (baseline) and with oculomotor task
224015500|NCT00515853|BEHAVIORAL|Biofeedback|Biofeedback sessions or biofeedback exercises
224015501|NCT05255887|OTHER|Informing Patients With Video|24-48 hours before the surgery, the patients will be shown an informative video about the intensive care environment in a separate room through a one-on-one interview. (The content of the training to be done with the video is stated in the appendix) In the study, no attempt will be made to the control group patients other than the routine practice of the institution before the surgery. In the study, the day of discharge from the intensive care unit will be counted as the first day, and on the second day, the 'Intensive Care Experience Scale' will be applied to the patients in both the experimental and control groups by face-to-face interview method.
224128244|NCT04615702|DEVICE|nasogastric tube|in case of ileus or vomiting
223396224|NCT06581107|PROCEDURE|CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation|During the procedure, the participants first undergo a CT scan. The radiologist plans the trajectories based on the registered preoperative CECT (contrast-enhanced computed tomography) and intraoperative CT. All participants then undergo navigation, localization, and establishment of cryoprobe trajectories using the interventional master-slave system. On the day of the procedure, the number of needle adjustments, number of cryoprobes used, puncture time, ablation time, and procedure time are recorded. The performance of the research device is evaluated by the radiologists. Postoperative complications of the participants are recorded 7±1 days postoperatively/on the day of discharge based on the postoperative CT scan (whichever comes first).
223396225|NCT06361927|DRUG|SSGJ-707|bispecific antibody
223396226|NCT06940063|PROCEDURE|Active music-based intervention|Musical experience includes playing an instrument, singing, or songwriting.
223396227|NCT06936436|OTHER|Implanon (Etonogestrel)|implanon is a long acting ,reversible contraceptive implants used to prevent pregnancy
223396228|NCT02107924|PROCEDURE|APPI of TKR-Stimulan|
223396229|NCT06459102|OTHER|Motor Learning|In addition to the conventional physiotherapy program .... per week for 4 weeks Sessions of motor learning exercise will be performed. For the exercise, the participant will sit in a chair with back support, in front of a table, with arms on the table. The participant will wear a glove with an IMU sensor on the upper surface and a pressure sensor on the palm, and a cylinder will be placed in the palm. The participant will be asked to bring the wrist into extension and then back into flexion while grasping the cylinder with maximum force. The participant will be asked to maintain maximum strength during the entire movement. The participant will be given visual feedback on muscle strength and range of motion of the wrist on the monitor in front of them throughout the movement. The same protocol will be applied by keeping the size of the cylinder in the participant's palm the same and changing the weight.
223550016|NCT00741065|PROCEDURE|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
223550017|NCT00644826|BEHAVIORAL|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
223550018|NCT04454060|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
223550019|NCT06286332|OTHER|Music Therapy|30 minutes of self-selected music playback every day.
223550020|NCT03623438|BEHAVIORAL|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
223550021|NCT03623438|BEHAVIORAL|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
223550022|NCT02434211|OTHER|Questionnaire and focus group|
223550023|NCT02065349|DRUG|ASP8477|oral
223731171|NCT00298220|BEHAVIORAL|Tailored outreach based facilitator support|in the practices of the GPTs
223731172|NCT00298220|BEHAVIORAL|Facilitation of co-operation with local addiction services|
223550024|NCT02065349|DRUG|Placebo|oral
224015502|NCT00278837|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
223550025|NCT03333694|DRUG|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
224015503|NCT01262027|DRUG|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
224015504|NCT03856385|BEHAVIORAL|Mindful Walking|Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
224015505|NCT03609892|DRUG|Berberine|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，esomeprazole 20 mg BID, ,and Bismuth 100 mg 2 capsules BID.
224015506|NCT03609892|DRUG|Amoxicillin|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Amoxicillin 500 mg 2 capsules BID plus berberine 100 mg 3 tablets TID, esomeprazole 20mg 1tablet BID, and bismuth 100 mg 2 capsules BID
224015507|NCT03609892|DRUG|Esomeprazole|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Esomeprazole 20mg 1 tablet BID plus berberine 100 mg 3 tablets TID,amoxicillin 500 mg 2 capsules BID, and bismuth 100 mg 2 capsules BID
224015508|NCT03609892|DRUG|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
224015509|NCT03609892|DRUG|Tetracycline|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
224015510|NCT03609892|DRUG|Furazolidone|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus Tetracycline 250mg 2 capsulesTID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
224015511|NCT03609892|DRUG|Esomeprazole|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of esomeprazole 20 mg 1 tablets BID plus Tetracycline 250mg 2 capsules TID, furazolidone 100mg 1 tablets BID， and bismuth 100 mg 2 capsules BID
224015512|NCT03609892|DRUG|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of bismuth 100 mg 2 capsules BID plus Tetracycline 250mg 2 capsules TID ，furazolidone 100mg 1 tablets BID and esomeprazole 20 mg 1 tablets BID
224015513|NCT04554017|OTHER|Education/Training|It consisted of a brief overview of hypertension, risk factors, complications and much emphasis placed on the preventive measures (what they include and why it is necessary to practice them).
224015514|NCT02469272|DRUG|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
224015515|NCT05010239|OTHER|30-minute Mindfulness-Based Supportive Therapy|The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.
224015516|NCT05010239|OTHER|30-minute supportive listening|Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
224015517|NCT04435210|DRUG|Hydralazine|Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.
224015518|NCT04435210|DRUG|Nifedipine|Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
224015519|NCT05564260|BEHAVIORAL|Kaleidescope|watching kaleidescope
224015520|NCT05564260|BEHAVIORAL|Virtual Reality|wearing virtual reality glasses
224015521|NCT03638167|BIOLOGICAL|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
224015522|NCT00476866|DEVICE|intermittent positive-pressure breathing (IPPB)|
223550026|NCT03333694|DRUG|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
223550027|NCT03100266|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamonosus GG
223550028|NCT03100266|OTHER|Inactive capsules|Placebo
223550029|NCT02607410|DRUG|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
223731173|NCT00298220|BEHAVIORAL|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
224015523|NCT03782675|DEVICE|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
224015524|NCT03782675|DEVICE|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
224015525|NCT00589121|DRUG|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
224015526|NCT00589121|RADIATION|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
224015527|NCT00589121|PROCEDURE|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
224015528|NCT01315691|DRUG|Liposomal amikacin for inhalation|"* Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
223396230|NCT06459102|OTHER|Control|The control group will receive a conventional physiotherapy program for 4 weeks, 5 days a week. Eccentric training for the extensor carpi radialis brevis (ECRB) muscle, the most affected wrist extensor tendon, and static stretching exercises for the ECRB muscle will be given. For eccentric training, the weight that the patients can lift in 10 maximal repetitions will be calculated and they will be asked to work with this weight. The best stretching position for the ECRB tendon is extension of the elbow joint, pronation of the forearm and flexion of the wrist with ulnar deviation. Each participant will be taught to perform each exercise for 10 repetitions and 10 seconds. Patients will perform these exercises in a sitting position. In the control group, daily exercises will be performed under the supervision of a physiotherapist
223396231|NCT03859921|DRUG|Dydrogesterone|Progesterone
223396232|NCT03859921|DRUG|Placebo|Placebo with appearance similar to Dydrogesterone
223731174|NCT00298220|BEHAVIORAL|Reminder-card for GP's desk|
223731175|NCT00298220|BEHAVIORAL|Personal feedback to patients|Patients receive advise based on their premeasurement answers
224015529|NCT01315691|DRUG|Placebo for liposomal amikacin for inhalation|"* Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days."
224015530|NCT02661919|DEVICE|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
223396237|NCT05556798|DRUG|Belantamab Mafodotin|Belantamab mafodotin will be administered via IV infusion in an outpatient setting on Day 1 of Cycles 1-3. Treatment with belantamab mafodotin will be given at an initial dose of 1.0 mg/kg. The study will have a 3+3 dose escalation design for belantamab mafodotin. Belantamab mafodotin dose levels are 1.0 mg/kg, 1.4 mg/kg, and 1.9 mg/kg
223396238|NCT05556798|DRUG|Nirogacestat|1:1 randomization between nirogacestat 100mg BID or 100 mg QD during the 4 day run-in period. Treatment with nirogacestat will be 100mg BID continuously during each cycle for all subjects.
223396239|NCT05556798|DRUG|Pomalidomide|After the 4-day run-in period, all patients will receive nirogacestat in combination with belantamab, mafodotin and pomalidomide. Pomalidomide was added for day 1-14 for cycle 1-3 and day 1-14 and day 21-35 for C4+.
223396240|NCT06846203|OTHER|Core stabilization Exercise Group|"This group will be subjected to following core stabilization exercises:~1: Sit-up-1, 2: Sit-up-2, 3: Back extention-1, 4: Back extention-2 , 5: Front plank, 6: Back bridge , 7: Quadruped , 8:Side bridge A combination of activities will be administered and alterations will be made every session.~Session will be held 3 times per week for 8 consecutive weeks."
223396241|NCT06846203|OTHER|Neuromuscular Fascilitation Exercise Group|"This group will be subjected to neuromuscular facilitation exercises :~Week 1: McGill curl up, Week 2: Bird dog stretch, Week 3: Side bridge or mermaid side bridge with bent knees, Week 4: Single leg stretching, Week 5: Shoulder bridge Week 6: Tai chi Warrior stance, Week 7 \& 8: Cat - cow - downward facing dog, Hip circumduction, hamstring stretching, starting position Session will be held 3 times per week for 8 consecutive weeks"
223396242|NCT05289193|DIAGNOSTIC_TEST|PET Scan|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
223396243|NCT05289193|DRUG|Nivolumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
223396244|NCT05289193|DRUG|Ipilimumab|"Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg."
223396245|NCT05289193|PROCEDURE|Surgical Resection of Melanoma|"Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma."
223396246|NCT05986630|DEVICE|TEOSYAL® TPVM|"Injection of TEOSYAL® TPVM at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
223396247|NCT05986630|DEVICE|COMPARATOR|"Injection of a COMPARATOR at Baseline~Optional Touch-up treatment at 4 weeks if needed to achieve optimal correction as judged by the PI."
223396248|NCT06049134|BIOLOGICAL|PCV20|Given by Injection into the muscle
223396249|NCT02325973|DEVICE|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
223396250|NCT06570759|PROCEDURE|Early intervention for OMI|Early PCI for OMI (+) STEMI (-) patients
223396251|NCT06570759|PROCEDURE|Standard early intervention for STEMI|Early PCI for OMI (+) and STEMI (+) patients
223550030|NCT02607410|DRUG|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
223550031|NCT01521598|DRUG|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
223550032|NCT01521598|DRUG|Placebo|This is the placebo. Patients will be randomized the placebo.
223550033|NCT05340530|DRUG|The injectable TQD3606|TQD3606 is a fixed-dose combination of meropenem and avibatam.
223550034|NCT05340530|DRUG|meropenem|Meropenem is a carbapenem antibiotic
223550035|NCT05340530|DRUG|Avibactam Sodium|Avibactam is beta-lactamase inhibitor.
223550036|NCT05340530|DRUG|Placebo|It is a placebo.
224128245|NCT04615702|PROCEDURE|retroperitoneal necrosectomy|"* General anesthesia , Supine position with 30 degree tilt towards the right side~* A left subcostal 5 cm incision is performed one finger below the left costal margin over the midaxillary line and the muscles were divided sequentially~* Then, aspiration is done from the possible collection.~* After confirmation that it was the site of the collection, the fibrotic thick wall was opened by a scissor, as the collection is opened, pus drained spontaneously.~* At first, a wide suction was introduced in the cavity and the friable loose necrotic tissue was aspirated. Then, a circuit of flushing saline was created in the residual cavity by injection of saline through the previously placed PCD followed by aspiration of the saline and detached loose necrotic tissue fragments by the wide suction tube~* After completion of the procedure, large bore surgical drain was placed into the collection. The fascia was closed over the drains. The skin closed by interrupted sutures"
224128246|NCT04615702|PROCEDURE|open necrosectomy|"Open necrosectomy was done after failure of the minimally invasive techniques. The procedure was done under general anesthesia under the coverage of Tienam (.5gm/6h IV) following the results of culture and sensitivity of the percutaneous drain effluent Surgical exploration of the peritoneal cavity was done through midline exploratory incision, there were 2 large pus collections extending from the Rt. and Lt. Lumber regions deep down into the pelvis, the intervening septa were divided and the pus was aspirated by a wide suction drain.~The lesser sac was opened and necrosectomy was done The previously placed PCD repositioned in the site of necrosectomy as a port for continuous irrigation while a wide tube drain was placed in the lesser sac for drainage. Another 2 tube drains were placed in the pelvis."
224128247|NCT04615702|PROCEDURE|Endoscopic transmural cystogastrostomy|"for pancreatic pseudocyst Antibiotic prophylaxis with Ciprofloxacin 400mg IV /12 hour was administered before the procedure and continued for 5 days after the procedure At first the cyst morphology was evaluated by EUS and color Doppler ultrasound is used to identify nearby vessels The puncture was performed using a 19-gauge needle, which was introduced into the pseudocyst via a therapeutic linear array echoendoscope. Then, a 0.035-inch guidewire was introduced through the needle and coiled within the pseudocyst under fluoroscopic guidance.~The needle was removed and a 10F cystotome was advanced over the guidewire and the tract was dilated by the cystotome, after dilatation, a 10F double-pigtail stent was placed and a sample of the aspirate is sent for chemical and microbiological analysis"
224128248|NCT04615702|PROCEDURE|open cystogastrostomy|"for pancreatic pseudocyst general anesthesia, 1 gm of cefotax was given IV at the induction of anaesthesia, supine position over the operating table A transverse supraumbilical incision was performed. A 5 cm horizontal anterior gastrotomy was performed (Image 23a). Hemostasis of the submucosal vessels was performed before the incision of the gastric mucosa.~First, the cyst was punctured followed by an incision of 5 cm at the posterior gastric wall. Aspiration of the cyst content was done for chemical and microbiological analysis The wall of the pseudocyst is hemmed to the gastric wall with continuous sutures made of a vicryl 2/0 alongside the entire circumference of the orifice Nasogastric tube was placed in the stomach. The procedure was completed by suturing the anterior gastrotomy with a vicryl 2/0 continous sutures in 2 layers A tube drain was inserted at the pelvis with closure of the abdominal wound in a standard way."
223396252|NCT06570759|PROCEDURE|Standard delayed intervention for NSTEMI|Medical stabilization and then PCI for OMI (-) and STEMI (-) patients
223396253|NCT05888779|OTHER|Beverage One (Milk)|Participant will consume beverage one (milk) and complete novel cognitive assessment questionnaire on paper.
223396254|NCT05888779|OTHER|Beverage Two (Juice)|Participant will consume beverage two (fruit drink) and complete novel cognitive assessment questionnaire on paper.
223396255|NCT06420349|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223396256|NCT06420349|PROCEDURE|Computed Tomography|Undergo CT
223396257|NCT06420349|BIOLOGICAL|Heat Shock Factor 1 Pathway Inhibitor NXP800|Given PO
223396258|NCT06420349|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223396259|NCT06420349|PROCEDURE|Positron Emission Tomography|Undergo PET
223396260|NCT06420349|PROCEDURE|Ultrasound-Guided Biopsy|Undergo ultrasound-guided tumor biopsy
223396261|NCT02068508|DRUG|Pioglitazone|Pioglitazone Tablets
223396262|NCT03242850|BEHAVIORAL|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
223396263|NCT05110417|DRUG|Pyridostigmine Bromide 60 Milligrams (mg)|One tablet will be provided to patients during the second visit.
223550037|NCT02709720|DRUG|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
223550038|NCT02709720|DRUG|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
223550039|NCT02709720|DRUG|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
223550040|NCT02709720|DRUG|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
223550041|NCT02709720|RADIATION|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
223550042|NCT03478670|GENETIC|Strimvelis|"Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273."
223550043|NCT00718536|DRUG|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
223550044|NCT04093960|DIETARY_SUPPLEMENT|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
223550045|NCT02132572|DEVICE|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
223550046|NCT03215381|DRUG|[11C]AZD1390|\[11C\]AZD1390
223550047|NCT04679038|BIOLOGICAL|SHR-1701|Intravenous (IV) on Day 1 of each cycle
223550048|NCT04679038|DRUG|Famitinib|Famitinib, po, qd
223550049|NCT02308267|OTHER|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
223550050|NCT02308267|OTHER|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
223550051|NCT02308267|PROCEDURE|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
224128249|NCT04615702|PROCEDURE|percutaneous catheter drainage (PCD) for infected necrosis|"PCD~* The percutaneous drainage catheter placed through peritoneal approach under US guidance, the drain size was 12 F.~* After placement of the percutaneous catheter, aspirate was sent for microbiological assessment~* The PCD was flushed with 50 ml saline, three times daily to keep the drain open and improve lavage of the collection"
223550052|NCT04522934|BEHAVIORAL|Pain Neuroscience Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of pain neuroscience education. The latter was focused on the influence of psychosocial factors in the experience of pain, differences between acute and chronic pain and central-peripheral awareness.
224128250|NCT04615702|PROCEDURE|Endoscopic ultrasound (EUS) guided aspiration for infected necrosis|endoscopic approach it was done to one patient in the form of EUS guided aspiration of pus in a case with infected necrosis followed by percutaneous US guided aspiration of the residual
223550053|NCT04522934|BEHAVIORAL|Biomedical Education|Patients received 24 sessions, in an 8-week period, of multimodal physiotherapy (therapeutic heat, manual therapy and exercises) along with four sessions of biomedical education. The latter was focused on the anatomy and pathomechanics of the shoulder.
223550054|NCT02824692|DEVICE|heart lungs and abdomen ultrasound|
223550055|NCT00945568|DRUG|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
223731176|NCT05908513|DRUG|N-acetylcysteine|Will be used as capsule form, 600mg per day if the patient can tolerate it. If not, we may decrease the dosage.
224128251|NCT01536002|DRUG|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
224128252|NCT05210205|DIETARY_SUPPLEMENT|EAA|EAA-enhanced protein snack bars
224128253|NCT05210205|DIETARY_SUPPLEMENT|Energy Dense|Energy dense snack bars (same calories in a smaller volume of food)
223396264|NCT06247956|DRUG|SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Oxaliplatin: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
223396265|NCT06247956|DRUG|Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|Adebrelimab: Specified dose on specified days. Oxaliplatin Injection: Specified dose on specified days. Capecitabine Tablets: Specified dose on specified days. Paclitaxel Injection: Specified dose on specified days. Cisplatin Injection: Specified dose on specified days.
223396266|NCT06330025|OTHER|Children between 2 and 8 years, without medical treatments or pathologies impacting food intake and his parents|The group comprises 102 children aged between 2 and 8 years, hospitalized for at least 48 hours and their parents. The children's pathologies and medical treatments should not influence their food intake.
223396267|NCT03874923|OTHER|Fluid challenge|After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
223731177|NCT05908513|DRUG|Placebo|Similar chemical structure of NAC but without function
224128254|NCT05210205|DIETARY_SUPPLEMENT|Control|Low energy dense snack bars (same calories in a greater volume of food)
223550056|NCT03519724|DRUG|Sugammadex|Reversal of deep NMB
223550057|NCT03519724|DRUG|Neostigmine|Reversal of moderate NMB
223550058|NCT00238082|DRUG|HFA-134A Beclomethasone DIpropionate (QVAR)|
223550059|NCT00175565|DRUG|inhaled fluticasone 500 mcg b.i.d.|
223550060|NCT03826459|PROCEDURE|Non-Locking Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& non-locking technique. The second layer cannot be of a locking technique.
223550061|NCT03826459|PROCEDURE|Locked Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running \& locking technique. The second layer can be locking or non-locking.
223550062|NCT01515579|DRUG|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
224128255|NCT00111475|DRUG|Romiplostim|Administered by subcutaneous injection
224128256|NCT00111475|DRUG|Placebo|Administered by subcutaneous injection
224128257|NCT03303092|DRUG|TEV-48125|TEV-48125 will be subcutaneously administered once monthly for 3 months.
224128258|NCT03303092|DRUG|TEV-48125 or placebo|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
224128259|NCT03303092|DRUG|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
224128260|NCT02863367|DRUG|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
224128261|NCT02863367|DRUG|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
224128262|NCT00050986|DRUG|Temozolomide|Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
224128263|NCT00050986|DRUG|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
223396270|NCT05765643|OTHER|Nurse parental support in symptom management using a mobile health App|Parents in this group will receive a mobile App that includes health assessment, monitoring, health education and nurse support using phone calls over a 3-month period
223396271|NCT01442480|DIETARY_SUPPLEMENT|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
223396272|NCT01442480|DIETARY_SUPPLEMENT|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
223396273|NCT04136171|DRUG|Eplontersen|Eplontersen by subcutaneous injection
223396274|NCT04136171|DRUG|Placebo|Eplontersen-matching placebo by subcutaneous injection
223396275|NCT04892472|DEVICE|NovoTTF-200T|All patients enrolled in this group will receive TTFields treatment, delivered for at an average of least 18 hours a day using NovoTTF-200T concomitant with pembrolizumab, a standard immunotherapy agent, which is delivered intravenously.
223550063|NCT01515579|DRUG|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
223550064|NCT04202666|DEVICE|convex skin barrier|Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)
223550065|NCT02505022|DRUG|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
224015531|NCT06417580|OTHER|Placebo Treatment|Desensitizing protocol with none active ingredient to evaluate the control of cervical dentin hypersensitivity
224015532|NCT06417580|OTHER|Nitrate Potassium Treatment|Desensitizing protocol with potassium nitrate gel to analyze and compare with other groups the effects of controlling cervical dentin hypersensitivity
224015533|NCT06417580|OTHER|Pregabalin Treatment|Desensitizing protocol with experimental 10% pregabalin gel to evaluate the control of cervical dentin hypersensitivity
224015534|NCT05789368|DIETARY_SUPPLEMENT|Placebo sachet|consume 1 sachet per day
224015535|NCT05789368|DIETARY_SUPPLEMENT|VeCollal sachet|consume 1 sachet per day
224015536|NCT05789368|DIETARY_SUPPLEMENT|Collagen sachet|consume 1 sachet per day
224128264|NCT01170117|DRUG|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
223396276|NCT04892472|DRUG|Pembrolizumab (MK-3475) 200 mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
223396277|NCT04833335|OTHER|MRI perfusion sequence|Quantitative analysis
223396278|NCT06258148|DRUG|TG103|TG103 injection, 7.5mg, 15 mg, SC, once a week
223396279|NCT06258148|DRUG|Placebo|Placebo, SC, once a week
223396280|NCT05857488|DEVICE|Transnasal introduction tube|Imaging of the GI tract using the transnasal introduction tube and system. Optional gut microbiome sample collection using the microbiome brush and/or intestinal potential difference measurement using the intestinal potential difference probe.
223550066|NCT02505022|BEHAVIORAL|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
223550067|NCT01469481|DRUG|PF-04991532|a single oral dose of \[14C\]PF-04991532 (450 mg/100 uCi suspension)
223550068|NCT04824664|OTHER|survey|survey among surgeon
223550069|NCT00265486|DRUG|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
223550070|NCT04666142|OTHER|Comparison of the personal characteristics of the experimental and control groups|General characteristics of the individuals in the experimental and control groups were compared.
223550071|NCT04666142|OTHER|Light applied experimental group, control group treated with standard intensive care lighting|"According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control"
223396281|NCT04932863|BIOLOGICAL|BNT162b2 mRNA Covid-19 Vaccine|Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
223550072|NCT03804892|DIAGNOSTIC_TEST|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
223550073|NCT03804892|DIAGNOSTIC_TEST|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
223550074|NCT03804892|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
223550075|NCT03804892|OTHER|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
223550076|NCT03804892|OTHER|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
224015537|NCT00847808|DRUG|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
224015538|NCT03893669|BIOLOGICAL|NBP607|1 dose, 0.5ml, Intramuscular (IM) injection
224015539|NCT03893669|BIOLOGICAL|Agrippal|1 dose, 0.5ml, Intramuscular (IM) injection
224015540|NCT04204603|DRUG|CKD-506|Tablets for oral administration
224015541|NCT04204603|DRUG|Placebo|Tablets for oral administration
224015542|NCT03404453|DIAGNOSTIC_TEST|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
224015543|NCT01134536|DRUG|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight \<20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight \>=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
224015544|NCT00007449|DRUG|DPC 083|
224015545|NCT04708730|DEVICE|Delipid Extracorporeal Lipoprotein filter from Plasma|As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
224015546|NCT03924765|DEVICE|Powered hip exoskeleton|The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
224128265|NCT01170117|DRUG|Placebo|Control Group will receive placebo pill
223550077|NCT03265145|DRUG|Stiolto Respimat|Duration - 12 months
223396282|NCT03851406|DEVICE|5% Hypertonic Saline|Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.
224015547|NCT05410431|OTHER|clinical and radiologic manifestations of rare presentations of Dermoid cyst|
223396283|NCT03851406|OTHER|No treatment|No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
223396284|NCT04013802|BIOLOGICAL|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
223550078|NCT03265145|DRUG|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
224015548|NCT05702814|OTHER|No Intervention|As this is an observational study, no intervention will be administered.
224015549|NCT04336787|OTHER|Survey|A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.
224015550|NCT02824081|BIOLOGICAL|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
223396285|NCT04521764|BIOLOGICAL|Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein|Given IT
223396286|NCT04521764|PROCEDURE|Computed Tomography|Undergo CT scan
223396287|NCT04521764|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223396288|NCT04521764|PROCEDURE|Biopsy|Undergo tumor biopsy
223396289|NCT04521764|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223396290|NCT06583577|DEVICE|3D Ostomy simulator|The ostomy simulator is 3D printed model created in collaboration with Earl E. Bakken Medical Devices Center at the University of Minnesota. The anatomically accurate model is created by analyzing de-identified segmental imaging after bowel diversion surgeries. The Stratasys J750 Polyjet 3D Printer is utilized to create the simulator using usual synthetic material.
223396291|NCT05346276|DIAGNOSTIC_TEST|68Ga-DOTA-hLAG-3 PET/CT|Each participant receives a single intravenous injection of 68Ga-DOTA-hLAG-3, and undergo PET/CT imaging within the specified time.
223396292|NCT02177461|DRUG|Telmisartan|
223550079|NCT03265145|DRUG|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
224015551|NCT03821753|OTHER|Case|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
224015552|NCT03821753|OTHER|Control|"* OCT~* OCT-Angiography,~* Retinophotography~* Neuropsychological tests"
224015553|NCT04059172|DRUG|Ibuprofen 200 mg and acetaminphen 650 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
223396293|NCT02177461|DRUG|Enalapril|
223396294|NCT02177461|DRUG|Clonidine|
223396295|NCT00375986|PROCEDURE|Manual placental removal at Cesarean delivery|
223550080|NCT03265145|DRUG|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
223550081|NCT02070328|OTHER|Registry|
223550082|NCT00328718|DRUG|montelukast (5mg QD)|
223550083|NCT00328718|DRUG|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
223550084|NCT00331877|PROCEDURE|family conference with bereavement information leaflet|
223550085|NCT05863403|DIAGNOSTIC_TEST|Neuromuscular Training|Neuromuscular Training on Balance and Fall in Geriatric Population With Fall Risk
223550086|NCT05863403|DIAGNOSTIC_TEST|Traditional Exercise|Traditional Exercise on Balance and Fall in Geriatric Population With Fall Risk
224015554|NCT04059172|DRUG|Ibuprofen 200 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
223396296|NCT00375986|PROCEDURE|Spontaneous placental removal at Cesarean delivery|
223396297|NCT03224312|OTHER|no intervention|no intervention
223396298|NCT03472300|OTHER|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
223396299|NCT02800460|PROCEDURE|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
223396300|NCT03511105|DRUG|GSK2798745|GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
223396301|NCT03511105|DRUG|Placebo|Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
223396302|NCT03511105|DRUG|Lipoplysaccharide from Escherichia Coli|LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
223396303|NCT03511105|DRUG|Saline|Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
223396304|NCT03945305|DEVICE|Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning.|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mmHg.
223396305|NCT03945305|OTHER|Previous antihypertensive treatment|Patients are only treated with previous antihypertensive treatment.
223396306|NCT04540809|OTHER|Assessment of strength, proprioception, skill and coordination of the hand|Disease Activity Score 28 was used to determine the disease activity of patients with PsA. Grip strength was measured with the help of Baseline Digital Hand Dynamometer®. Pinch strength was measured with Baseline Hydraulic Pinch Gauge®. Wrist proprioception was assessed by measuring the joint position sensation using a goniometer by actively repeating the target angle predetermined by the researcher (30 ° for flexion and extension, 15 ° for ulnar deviation, 10 ° for radial deviation. Finger skills were assessed using a mobile application called Ball Tap©. The application included the fastest contact of the participants to the balls coming from different parts of the screen for 30 seconds. Two hand coordination and skills were evaluated using the Purdue Pegboard test. The Michigan Hand Outcomes Questionnaire was used for functional evaluation of the hand, and the Health Assessment Questionnaire was used to assess the general functional condition and health-related quality of life.
223396307|NCT02810457|DRUG|FKB238 (bevacizumab)|
223396308|NCT02810457|DRUG|Avastin (bevacizumab)|
223550087|NCT03751826|OTHER|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
223396309|NCT02810457|DRUG|Paclitaxel|
223396310|NCT02810457|DRUG|Carboplatin|
223396311|NCT03215680|OTHER|Climate|Hot and temperate climate
223396312|NCT02943980|DEVICE|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
223550088|NCT03751826|OTHER|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
224015555|NCT04059172|DRUG|Placebo oral tablet|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
223396313|NCT02943980|DEVICE|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
223396314|NCT01566188|DIETARY_SUPPLEMENT|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
223396315|NCT01566188|DIETARY_SUPPLEMENT|Placebo|6 months of supplementation with placebo
223396316|NCT04173507|DRUG|Avelumab|Given IV
223396317|NCT04173507|DRUG|Talazoparib|Given PO
223396318|NCT04173507|DRUG|Talazoparib Tosylate|Given PO
224128266|NCT06459622|DIAGNOSTIC_TEST|Serum IL_25 and eosinophils in nasal polyp tisuee|Serum IL-25 and eosinophils in nasal polyps tisuer obtained and measured to identify the sensitivity of nasal polyps to corticosteroids
224128267|NCT01392989|DRUG|CIK cells|Standard of care
224128268|NCT01392989|DRUG|Cyclosporine|5 mg/kg, po
223396319|NCT02950415|BEHAVIORAL|virtual|Parent is present via an internet pad (iPad)
223396320|NCT02950415|BEHAVIORAL|coaching|Parent learns what to say verbally to soothe child
223396321|NCT02950415|BEHAVIORAL|physical|Parent is present in the operating room
223396322|NCT02950415|BEHAVIORAL|no coaching|Parent does not learn what to say verbally to soothe child
223396323|NCT00497068|BEHAVIORAL|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
223396324|NCT00497068|BEHAVIORAL|non-contingent|Participants receive vouchers regardless of tobacco use status
223396325|NCT00497068|BEHAVIORAL|control|this group receives no vouchers
223396326|NCT02215655|BEHAVIORAL|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
223396327|NCT05486039|BEHAVIORAL|Changing behaviour|Changing the lying position and mattress system
223396328|NCT03861390|DRUG|60 mg Prednisone|Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
224015556|NCT02391753|DEVICE|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
223396329|NCT03861390|DRUG|Placebo|Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
223396330|NCT02818452|OTHER|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
223550089|NCT03751826|OTHER|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
223550090|NCT03739151|BEHAVIORAL|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
223550091|NCT02971371|DEVICE|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
223550092|NCT02656394|DRUG|GL101|Topical Gel
223550093|NCT02656394|DRUG|Placebo|Placebo topical gel
223550094|NCT04204850|DRUG|Cabozantinib|Cabozantinib is a multi-tyrosine kinase inhibitor with activity against VEGFR 1,2,3, MET and AXL, as well as RET, KIT, ant FLT-3.
223550095|NCT00126152|BEHAVIORAL|Exercise, education and medical management|
223550096|NCT03520309|PROCEDURE|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
223550097|NCT03666338|OTHER|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
223550098|NCT01723969|GENETIC|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
223731178|NCT00246727|DRUG|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
224015557|NCT04595565|DRUG|Capecitabine|2000 mg/m² day 1-14 q21 day cycle for eight cycles
224015558|NCT04595565|DRUG|Carboplatin|AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles
224015559|NCT04595565|DRUG|Cisplatin|25mg/m3 weekly or 75 mg/m3 q3w
223396331|NCT02818452|OTHER|Oatmeal|
223396332|NCT02818452|OTHER|Hot cereal|
224015560|NCT04595565|DRUG|Sacituzumab govitecan|10 mg/kg body weight on days 1, 8 q3w
224015561|NCT03642626|DRUG|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
224015562|NCT03642626|DRUG|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
224015563|NCT03642626|DRUG|Fludarabine 30mg/m2 4 doses|30 mg/m2 IV daily for 4 doses
224015564|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 2 doses|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
224015565|NCT03642626|DRUG|Fludarabine 30mg/m2 3 doses|30 mg/m2 IV daily for 3 doses
224015566|NCT03642626|DRUG|Cyclophosphamide 500 mg/m2; 3 doses|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
224015567|NCT03642626|DRUG|Fludarabine 25mg/m2 3 days|25 mg/m2 i.v. daily for 3 days
224015568|NCT03642626|DRUG|Cyclophosphamide 250 mg/m2; 3 days|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
224015569|NCT03642626|DRUG|Tecartus|TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
224015570|NCT03642626|DRUG|Abecma, Intravenous Suspension|Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
224015571|NCT03642626|DRUG|Cyclophosphamide 900 mg/m2; 1 day|Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
224015572|NCT03642626|DRUG|Breyanzi Injectable Product|Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
223396333|NCT01217112|DRUG|GWP42003|100 mg capsules, PO, BD, 91 days
223396334|NCT01217112|DRUG|GWP42003|5 mg capsules, PO, BD, 91 days
223396335|NCT01217112|DRUG|GWP42004|5 mg capsules, PO, BD, 91 days
223396336|NCT01217112|DRUG|Placebo|0 mg capsules, QDS, PO, 91 days
223396337|NCT03192488|DRUG|Cetirizine|Cetirizine tablet 10 mg
223396338|NCT03192488|DRUG|Placebo oral capsule|Gelatin placebo
223396339|NCT03192488|OTHER|Hypoxia|Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft
223550099|NCT06006871|BEHAVIORAL|The Secret Trail of Moon (MOON): Cognitive training with Serious Video Game|Patients are pharmacologically stable and receive a cognitive intervention with our videogame twice a week in the hospital (10 sessions) and twice a week in their home with a computer video game (other 10 sessions).
223550100|NCT06006871|DRUG|Usual treatment for ADHD|All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
223550101|NCT06452732|OTHER|MFC for the determination of leukemia stem cell|MFC for the determination of leukemia stem cell
223550102|NCT06617286|BIOLOGICAL|CD30 CAR T-cell|After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.
223550103|NCT02043145|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
223550104|NCT03565341|DEVICE|PiQo4|PiQo4 Laser System for treatment of Melasma
223550105|NCT04894019|DEVICE|Continuous invasive blood pressure monitoring|Continuous invasive blood pressure monitoring using an arterial catheter
223550106|NCT04894019|DEVICE|Intermittent non-invasive blood pressure monitoring|Intermittent non-invasive blood pressure monitoring using upper-arm cuff oscillometry
223550107|NCT05593315|OTHER|Mindfulness and Buteyko techniques|Joint implementation of a general relaxation program and a respiratory rehabilitation program in patients with poorly controlled asthma.
223550108|NCT05883202|DEVICE|Connect®|Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
223550109|NCT05883202|DEVICE|Multi-unit|Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
224015573|NCT05929209|DIAGNOSTIC_TEST|Assessment of disease biomarkers|Assessment of serum, histological and radiological biomarkers
223396340|NCT01401361|DEVICE|Treatment Arm|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
223396341|NCT03669211|DIAGNOSTIC_TEST|Cardiac stress test|In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
223396342|NCT01637428|DEVICE|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
223396343|NCT00389311|DRUG|Normosol-R|
223396344|NCT00389311|DRUG|Nonoxynol-9|
223396345|NCT00389311|PROCEDURE|Gastrointestinal instrumentation|
223396346|NCT00867529|BIOLOGICAL|rituximab|Given IV
223396347|NCT00867529|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
223550110|NCT05859139|OTHER|DA Scaling Strategies|For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
223550111|NCT05694663|DEVICE|Vivistim|After one month of prehabiliatory training, the patient will then undergo surgical placement of the implantable VNS device (Vivistim System) consisting of an implantable neurostimulator and an implantable lead and electrode per standard of care. The device comes with a controller and software system which allows for control of the stimulation settings during the rehabilitation phase. The PMA number for this device is 210007 and the date of FDA notice of approval occurred on August 27, 2021.
223550112|NCT06718114|PROCEDURE|immediate urinary catheter removal|Immediate urinary catheter removal indicates that the urinary catheter will be removed immediately after surgery.
224015574|NCT06145438|DRUG|Dienogest|Drug is administered orally at the same time every day
224015575|NCT06145438|DRUG|Depo Medroxyprogesterone acetate|Drug is injected intramuscularly on the buttock
224015576|NCT06145438|DRUG|Leuprolide (as Leuprolide Acetate)|Drug is injected intramuscularly on the buttock
224015577|NCT06145438|DRUG|Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)|Drug is administered orally at the same time every day
224015578|NCT06576258|DIAGNOSTIC_TEST|cobas eplex multiplex PCR|Positive blood culture samples from the intervention group are subjected to cobas eplex multiplex PCR in addition to the SOC culture methods.
223550113|NCT06718114|PROCEDURE|early removal of urinary catheter|The urinary catheter will be kept after surgery and be removed within 48 hours after surgery.
223731179|NCT00207207|PROCEDURE|Alternate site blood glucose testing|
223731180|NCT05533281|DRUG|tropisetron|One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
224015579|NCT06538311|DEVICE|Active rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
224015580|NCT06538311|DEVICE|Sham rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
223396348|NCT00867529|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
223396349|NCT00867529|OTHER|pharmacological study|Correlative studies
223396350|NCT00867529|OTHER|laboratory biomarker analysis|Correlative studies
223396351|NCT02213172|DIETARY_SUPPLEMENT|Bifidobacterium longum R0175|
223396352|NCT02213172|DIETARY_SUPPLEMENT|Lactobacillus paracasei HA-196|
223396353|NCT02213172|OTHER|Placebo|
223396354|NCT01660750|DRUG|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
223396355|NCT01660750|DRUG|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
223396356|NCT01660750|DRUG|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
223396357|NCT04310670|OTHER|Psychotherapy|The patient will be treated according to Lacanian psychoanalytic ethics, which allows to adequately respond to the patient's request for healing but who at the same time does not ignore the progress of scientific research in the neurological field
224015581|NCT04988555|DRUG|Enzomenib|DSP-5336 orally
223396358|NCT04310670|BEHAVIORAL|Physiotherapy|Physiotherapy treatment will be articulated through the use of techniques designed to qualify the functionality of the subject divided by symptom: weakness, dystonic attitudes of the limbs, walking disorders, tremor.
223396359|NCT04310670|OTHER|Non-Invasive Brain Stimulation (NIBS)|"Diversified transcranial electrical maneuver protocols with an on-line or off-line approach may be applied for therapeutic purposes. This will include: transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), random noise stimulation (tRNS)."
223396360|NCT04903015|DIAGNOSTIC_TEST|MRI|"The following sequences of the MRI will be acquired during the inclusion visit:~* 3D T1 gradient echo (GRE): anatomy; registration; cerebral, white matter, and grey matter volumetry; and cortical thickness;~* multiecho 3D T2 GRE: quantitative susceptibility mapping (QSM), iron overload quantification;~* continuous arterial spin labeling (ASL) 3D: cerebral perfusion;~* resting-state fMRI: functional connectivity;~* 64-direction DTI (b=1000 and 2500): alterations in white matter and its microstructure, anatomic connectivity;~* monovoxel spectroscopy of the mesencephalus with short echo time (TE)."
223396361|NCT00198718|DRUG|Vitamin A (retinyl palmitate)|
223396362|NCT00841386|DRUG|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
223396363|NCT00841386|DRUG|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
223550114|NCT06718881|OTHER|simulation application in a virtual reality environment|In the project, theoretical lessons were given on preeclampsia, postpartum care, and condom counseling, each in a separate week. After each theoretical lesson, an application was made in the laboratory on the subject explained in the same week. The applications were made in the form of a simulation application in a virtual reality environment for the students in the experimental group.
223731181|NCT05533281|DRUG|metoclopramide|One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
223731182|NCT05533281|DRUG|dexamethasone|One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
224015582|NCT04988555|DRUG|azoles|Posaconazole, Voriconazole, or Fluconazole
224015583|NCT04988555|DRUG|Venetoclax|Venetoclax orally
224015584|NCT04988555|DRUG|Gilteritinib|Gilteritinib orally
224015585|NCT04988555|DRUG|Azacitidine (AZA)|Azacitidine orally
224015586|NCT05734638|BEHAVIORAL|MIM-DASH|Randomized participants will receive the MIM DASH, MIM or DASH intervention in eight weekly, 1-hour group sessions via telehealth (video and telephone access). Participants will receive session materials such as PowerPoint presentations so they can follow along by phone or videoconferencing. After completion of the eight weekly sessions, the participants will receive one follow-up call every other week for 8 weeks. The 3- and 6-month data will be collected as listed in the study AIMs. A manual of operations will detail all procedures related to the protocol, including participant recruitment, data collection, database usage, and database management.
224015587|NCT05734638|BEHAVIORAL|MIM Only|"The MIM-only intervention group will receive the MIM education only in eight weekly sessions of 30 minutes each. To maintain equipoise among the intervention groups, this group will also have 30 minutes of social time to interact with the trainer and peers. To avoid cross contamination, the interventionist will not also deliver the intervention to the MIM DASH group. Each participant will have access to the digital meditations with mindfulness practice recordings as well as a weekly diary to document study activities. Participants will be instructed to perform mindfulness meditations at least five times a week and record the time in their diary. After completion of the eight weekly sessions, these participants will receive six coaching calls (two per month for 3 months) focused on mindfulness practice."
224015588|NCT05734638|BEHAVIORAL|DASH Only|"The DASH-only group will receive the DASH education only in eight weekly sessions of 30 minutes each. This group will also have 30 minutes of social time to interact with the trainer and peers, will receive their education from a different interventionist (also a registered dietician) and receive two coaching calls per month for 3 months, in this case focused on healthy eating DASH principles."
223396364|NCT01288677|DRUG|TMC649128|Escalated doses
223731183|NCT05533281|OTHER|normal saline|Equal dose of normal saline was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
224015589|NCT05394753|BEHAVIORAL|Unified Protocol for mood disorders|The group-based UP is structured and manualized and consists of 9 1.5 hours weekly sessions (90-min, 18 participants in each group). The group-based UP is a course consisting of components of psycho-education about mood disorders, cognitive and behavioural skills, and relapse prevention and is adapted for the non-clinical population in the current study. The UP will be led and delivered by trained therapists.
224015590|NCT00391859|PROCEDURE|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
224015591|NCT02880345|DRUG|PEMBROLIZUMAB|
224015592|NCT02880345|RADIATION|hypofractionated radiation|
224015593|NCT05638698|BIOLOGICAL|TG01 Vaccine|used to assess molecular disease control rate when combined with other interventional methods.
224015594|NCT05638698|DRUG|QS-21|used to assess molecular disease control rate when combined with other interventional methods.
224015595|NCT05638698|DRUG|Balstilimab|used to assess molecular disease control rate when combined with other interventional methods.
224015596|NCT00153270|DRUG|Sodium Valproate|
224015597|NCT04844814|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|Anakinra 100 mg/d subcutaneous injection
224015598|NCT04844814|DRUG|Prednisone|Prednisone 30 mg/d
224015599|NCT04844814|DRUG|Placebo of Prednisone|Placebo of Prednisone
224015600|NCT04844814|DRUG|Placebo of Anakinra|Placebo of Anakinra
224015601|NCT06412354|DEVICE|EasyCross™ first-in human|"At T0 the patient will undergo the TAVR procedure including the investigational procedure with the VIVHEART EasyCross™ catheter.~The interventional cardiologist will introduce the VIVHEART EasyCross™ catheter through the femoral artery with a percutaneous access according to the clinical practice through a vascular introducer on an already positioned guidewire. An operator in the procedure room will start a chronometer at this point to measure the investigational device crossing procedure duration.~The VIVHEART EasyCross™ catheter will be progressed into the aorta and up to the aortic valve.~At that time the external part of the VIVHEART EasyCross™ catheter will be opened to allow the self-centering of the catheter on the aortic valve. The guidewire will be introduced and once having crossed the valve the VIVHEART EasyCross™ catheter will be retracted by the physician and removed from the patient's body."
224015602|NCT05695586|BEHAVIORAL|Mindful Self-Compassion (MSC) training|8-week Mindful Self-Compassion (MSC) intervention protocol, developed by Germer and Neff (2013, 2019). After the training, participants will enter a 12-month phase of regular MSC-based supervised practice.
224015603|NCT05695586|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) training|8-week Mindfulness Based Stress Reduction (MBSR) intervention protocol, as developed by Stahl \& Goldstein (2010). After the training, participants will enter a 12-month phase of regular MBSR-based supervised practice.
224015604|NCT04039971|PROCEDURE|ACL Reconstruction|Surgical techniques
224015605|NCT05465200|PROCEDURE|Structured treatment of cardiogenic shock patients|"Creation of hub\&spoke structure which covers all Lower Silesian Voivodeship (Poland) for treatment of cardiogenic shock patients. Based on shared protocol patients are reported to hub by spoke and decision is made as for patient transfer or further treatment in the spoke facility. If decision on transfer is made, patient is further treated according to hub on site shock team protocol"
224015606|NCT04548544|BEHAVIORAL|Training for Awareness, Resilience, and Action (TARA)|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
224015607|NCT04367285|OTHER|Sensor-based Training|Sensor-based Training consists of twelve sessions of upper limb training with PABLO®-Tyromotion. For each session the training consists in interactive-games based on virtual reality which allowed a task-oriented approach and a neurocognitive feedback. The exercises require precision tasks and one-dimensional and bidimensional reaction, allowing to train the attention, the strength control and movement control, the coordination and the movement precision. The interactive-games were chosen from those proposed by the Tyromotion PABLO® System.
224015608|NCT04367285|OTHER|Upper limb motor training|Upper limb motor training, without robotic support. Subjects performed specific exercises aimed to recovery global upper limb functions, to control hand grasp and to improve hand's fine movements.
224015609|NCT06478511|PROCEDURE|Classic Immediate implant|The teeth will be extracted gently using periotomes to preserve facial and lingual bone plates. All walls of the socket will be inspected and checked for the presence of fenestration or dehiscence defects in bone. The length and width of extracted roots will be measured to determine the length and diameter of implants placed. The osteotomy sites will be prepared and the drills will be used in proper sequence according to manufacturer's instructions, with maximum use of bone apical to the extraction sockets. The drills will extend 3 to 5 mm beyond the apex of the socket to ensure primary stability after placement, taking care of the anatomical boundaries. The implants will be placed.
224015610|NCT06478511|PROCEDURE|Immediate implant combined with subepithelial connective tissue graft|Connective tissue graft was harvested from palate using trap door technique utilizing a horizontal incision 3-4 mm away from the gingival margin with two vertical incisions on the either end of the first incision, the door is then undermined and opened using a sharp dissection, the underlying connective tissue is then harvested using a periosteal elevator, and the door was then sutured using 4 0 silk sutures Finally, the connective tissue graft was immediately placed into the recipient site after a tunneling procedure and sutured with 6-0 nonresorbable monofilament sutures.
224015611|NCT06478511|PROCEDURE|Immediate dental implant placement using socket shield technique|The crown of the involved tooth will be removed and the root will be then sectioned in a mesiodistal direction along its long axis as far apical as was possible using a long shank fissure bur. Preserving the facial root section unmanipulated and attached to the tooth socket. Periotomes will be then inserted between the palatal root removed gentelly.The remaining root section will be then reduced coronally to 1 mm above the alveolar crest.The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants and the root section will be checked for immobility with a sharp probe. With the preparation steps complete, the tooth root hereafter will be known as the socket-shield. An osteotomy will be then sequentially prepared and internal conical connection implant was inserted palatal to the shield with the implant 2 mm below the facial crest.
224015612|NCT05785923|DIAGNOSTIC_TEST|Point-of-Care Echocardiogram|Four view ultrasound of the heart performed at the bedside by trained emergency medicine physicians.
224015613|NCT01758900|DEVICE|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
224015614|NCT01758900|DEVICE|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
224015615|NCT03122691|DRUG|cannabis|Cannabis will be self-administered by study participants
223396365|NCT02332226|BEHAVIORAL|Representational approach|Representational approach to patient education
223396366|NCT00304798|BEHAVIORAL|Hospital admission|
224015616|NCT01707745|PROCEDURE|Intravitreal Bevacizumab|
224015617|NCT01831479|DRUG|Rosuvastatin|Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
224015618|NCT01831479|DRUG|Olmesartan|Single administration of olmesartan 40mg tablet QD for 7 consecutive days
224015619|NCT01831479|DRUG|Rosuvastatin and olmesartan|Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
224015620|NCT00086255|DRUG|Tiagabine|
224015621|NCT01892540|DIAGNOSTIC_TEST|positron emission tomography/computed tomography|Undergo PET/CT
224015622|NCT01892540|DIAGNOSTIC_TEST|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
224015623|NCT01892540|DEVICE|Position Device|
224015624|NCT02538952|DEVICE|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
224015625|NCT02538952|OTHER|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
224015626|NCT06149325|PROCEDURE|Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 45 minutes
223396367|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
223396368|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
223396369|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
223396370|NCT00660257|BIOLOGICAL|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
223396371|NCT04528667|DRUG|STI-5656|STI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
223396372|NCT04528667|DRUG|Placebo|Placebo capsules
223396373|NCT00118339|DRUG|chemoprotection|
223550115|NCT06714760|PROCEDURE|Reconstruction following parcellar resections of the mandibular gingival region|"In our surgical approach, we have used periosteum, galea, or pericranium flaps for reconstruction of bone and tissue defects in the cervicofacial region, with excellent results. To treat mandibular osteoradionecrosis, we harvested periosteum flaps from the radius, demonstrating efficacy in bone regeneration. For minor defects, such as those of the nose, we used flaps from the medial femoral condyle, despite the complexity of harvesting.~The cranial region, particularly the temporo-parietal area, offered excellent vascularization, allowing the use of revascularized flaps for reconstruction of the oral mucosa after removal of carcinomas. These flaps have also been effective in the treatment of pharyngeal fistulas, proving to be a functionally reliable solution for oral cavity and cervicofacial defects."
223550116|NCT06715839|DRUG|[68Ga]Ga-DOTA-H2D3|Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.
224015627|NCT06149325|PROCEDURE|Sham Repetitive somatosensory stimulation (RSS)|Tactile stimuli on the index finger of the intact hand, for a duration of 4 minutes spread over 45 minutes in 6 blocks of 40 seconds
224015628|NCT04083105|DRUG|Nitrous Oxide|Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
224015629|NCT04083105|DRUG|Midazolam|Intranasal midazolam will be given after nitrous oxide administration.
224015630|NCT02846272|PROCEDURE|Observation|Observation of MRI changes in subjects
224015631|NCT04893577|DRUG|EDTA|Patients will treat their cold sore with EDTA eye drops based upon their randomization.
224015632|NCT04893577|DRUG|Abreva|Patients will treat their cold sore with Abreva based upon their randomization
224015633|NCT05822830|DRUG|Tirzepatide|Administered SC
224015634|NCT05822830|DRUG|Semaglutide|Administered SC
223396374|NCT00118339|PROCEDURE|complementary or alternative medicine procedure|
223396375|NCT00118339|PROCEDURE|management of therapy complications|
223396376|NCT02512302|DRUG|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
223396377|NCT02512302|DRUG|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
223396378|NCT02512302|DRUG|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
223396379|NCT02512302|DRUG|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
223396380|NCT02512302|DRUG|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
223396381|NCT04144413|DRUG|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
223396382|NCT04144413|DRUG|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
223396383|NCT04144413|OTHER|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
224015635|NCT06804616|DRUG|20% benzocaine Gel|Participants in this group received 20% Benzocaine Gel applied to the injection site for 5 minutes prior to local anesthesia administration. The gel acts as a topical anesthetic to numb the area and reduce pain perception during the injection procedure.
224015636|NCT06804616|DEVICE|Powered Toothbrush|Participants in this group received vibration stimulation using a powered toothbrush applied to the injection site for 1 minute before the local anesthesia injection. The vibration works on the principle of gate control theory, aiming to disrupt pain signals and reduce discomfort during the injection procedure.
224015637|NCT05937893|OTHER|Keto-ester followed by Magnetic Resonance Spectroscopic Imaging (MRSI) scans|Following baseline scans, the participant will orally consume the keto-ester, for subsequent scans which will include repeated BHB MRSI acquisitions to dynamically measure BHB labeling in the brain, followed by a final GABA MRSI acquisition.
224015638|NCT01370590|DRUG|Atorvastatin|20 mg tablet administered orally once daily
224128269|NCT01392989|DRUG|Mycophenolate Mofetil|15 mg/kg, oral
224015639|NCT01370590|DRUG|Ezetimibe|10 mg tablet administered orally once daily
224015640|NCT01370590|DRUG|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
224015641|NCT01370590|DRUG|Placebo to atorvastatin|Administered orally once daily
224015642|NCT01370590|DRUG|Placebo to ezetimibe|Administered orally once daily
224015643|NCT01370590|DRUG|Placebo to ezetimibe/atorvastatin|Administered orally once daily
224015644|NCT03140839|BEHAVIORAL|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
224015645|NCT03140839|BEHAVIORAL|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
224015646|NCT03140839|OTHER|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
224015647|NCT01739439|DRUG|gemcitabine hydrochloride|Given IV
224015648|NCT01739439|RADIATION|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
223550117|NCT06715839|DRUG|[18F]F-RESCA-RB14|Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.
223550118|NCT06715839|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
223550119|NCT06715839|DRUG|[18F]F-RESCA-T4|Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
223550120|NCT06715839|DRUG|[68Ga]Ga-NOTA-G5|Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.
223550121|NCT06715839|DRUG|[18F]F-RESCA-G5|Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.
223550122|NCT06715839|DRUG|[68Ga]Ga-NOTA-WWH347|Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.
223550123|NCT06715839|DRUG|[18F]F-RESCA-WWH347|Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.
223550124|NCT06715839|DRUG|[68Ga]Ga-NOTA-RND20|Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.
223550125|NCT06715839|DRUG|[18F]F-RESCA-RND20|Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
223550126|NCT06717464|DRUG|Capecitabine|1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)
223550127|NCT06717464|DRUG|Toripalimab|240mg intravenous injection, q3w, for 54 weeks (18 cycles)
224015649|NCT01739439|RADIATION|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
224015650|NCT01739439|RADIATION|radiosurgery|Undergo radiosurgery boost
223550128|NCT06719167|BEHAVIORAL|Psychoterapy|During 11 weeks admission the programme will include group sessions using different modalities (psychoeducation videos, live psychoeducation groups, expressive arts therapy, equine facilitated therapy, mindfulness and discussion groups) all using TIST methodology. Parallell individual therapy with therapist (psychologist or psychiatrist) and milieu therapist. All therapists will be trained minimum in TIST level 1 and recieve supervision from an expert TIST therapist.
223550129|NCT06715410|DEVICE|CO2|To collect CO2 data
223550130|NCT06713278|OTHER|masseter muscle thickness measurement|masseter muscle thickness measurement with ultrasonography
223550131|NCT06713278|OTHER|scales|headache impact scale (HIT-6) Short SF-36 fibromyalgia total score widespread pain index symptom severity scale fibromyalgia impact questionnaire (FIQ)
223550132|NCT01586689|BEHAVIORAL|Oxford House|community-based recovery home for participants recovering from substance dependency
223550133|NCT01586689|BEHAVIORAL|Safe Haven|professionally-staffed treatment facility
223550134|NCT01586689|BEHAVIORAL|Usual aftercare|control group - participants may or may not seek treatment on their own
224015651|NCT01739439|PROCEDURE|diffusion-weighted magnetic resonance imaging|Correlative studies
224015652|NCT04910451|OTHER|No Intervention|
224015653|NCT05172050|DRUG|Raloxifene|Raloxifene was administered as 60 mg hard gelatine capsule(s) once a day. Starting from day 2 of treatment: one single capsule (plus one of placebo to guarantee the blinding) containing 60 mg raloxifene was administered in Group 1, and 2 capsules 60 mg each for a total of 120 mg in Group 2.
224015654|NCT05172050|OTHER|Placebo|Placebo was administered orally once a day as 2 capsules (for maintaining the blinding design)
224015655|NCT00352638|OTHER|counseling intervention|
224015656|NCT00352638|OTHER|educational intervention|
224015657|NCT00352638|OTHER|study of socioeconomic and demographic variables|
224015658|NCT04676061|DRUG|Norethindrone acetate (NTA)|norethindrone acetate, 5 mg tablet, orally, once daily for 7 consecutive days, every 4 weeks
224015659|NCT04676061|DRUG|Placebo|Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
224015660|NCT03974477|DEVICE|SALT CONTROL H equipment to control and monitor salt during cooking process|Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
224015661|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
224128270|NCT01392989|DRUG|Thymoglobulin|7.5 mg/kg, IV
224128271|NCT01392989|RADIATION|Total Lymphoid Irradiation (TLI)|
224015662|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
224015663|NCT00490152|BEHAVIORAL|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
224015664|NCT00933790|DRUG|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
224015665|NCT02576119|DRUG|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
224015666|NCT02576119|DRUG|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
223396384|NCT03426306|DIAGNOSTIC_TEST|4DCT-Ventilation|4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
223396385|NCT00827008|DRUG|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
223396386|NCT06270381|OTHER|EMPOWER|The EMPOWER intervention (Enhancing and Mobilizing the POtential for Wellness and Emotional Resilience) is a cognitive-behavioral and acceptance-based intervention divided into six modules.In the current application, this intervention is conducted in 6 in-presence or online 50-minute sessions and 2 booster sessions 2 and 4 weeks after the final intervention. It is a manualized treatment in which each session has a specific goal: 1st) Welcome, initial assessment and adherence to the intervention; 2nd) Psychoeducation and transmission of resources for stabilization; 3rd) Psychoeducation on Trauma, Grief and Cognitive-Behavioral Model; 4th)Promoting Experiential Acceptance; 5th) Imagined dialogue; 6th) Coping Training; and two final boosting sessions. In every session, the impact of the previous consultation and evolution is evaluated. This intervention was developed by Lichtenthal et al., 2022.
223396387|NCT06270381|OTHER|Treatment as usual (TAU)|The treatment as usual (TAU) consists of supportive psychotherapy based on a non-structured and integrative method that focuses on the development of more adaptive coping strategies, understanding and working on the patient's internal models of self, others, and the world. The TAU will be considered during the same period as the EMPOWER intervention.
223550135|NCT04283188|BEHAVIORAL|Dialectical behavioral therapy|Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
224015667|NCT04419129|DEVICE|Oxford UKA|knee arthroplasty
224015668|NCT04419129|DEVICE|Vanguard TKA|knee arthroplasty
224015669|NCT03106168|PROCEDURE|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
224015670|NCT00963053|DRUG|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
224015671|NCT02271438|DRUG|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.
224015672|NCT02271438|DRUG|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
224015673|NCT02271438|DRUG|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
223396388|NCT01969149|DRUG|Exenatide|
223550136|NCT00529672|PROCEDURE|crossectomy and short stripping|under spinal or complete anaesthesia
223550137|NCT00529672|PROCEDURE|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein\>
223550138|NCT00529672|PROCEDURE|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
223731184|NCT05833191|DEVICE|Auricular vagus stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
224015674|NCT02271438|DRUG|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
223396389|NCT01969149|DRUG|Insulin|
224015675|NCT01719705|DRUG|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
224015676|NCT01719705|DRUG|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
224015677|NCT01719705|DRUG|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
224015678|NCT06239389|DRUG|Thalidomide 100mg|Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.
224015679|NCT06239389|DRUG|Hydroxyurea|Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
223396390|NCT04126980|BEHAVIORAL|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
223396391|NCT00438581|DRUG|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
224015680|NCT06084923|OTHER|Observation|Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
224015681|NCT00380224|DRUG|bifeprunox, olanzapine|
224015682|NCT06012422|OTHER|evaluation group|Elderly individuals will be evaluated once, by face-to-face interview method.
224015683|NCT06487429|DRUG|Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab|"Short range radiotherapy, PCTV (clinical planned target area) DT 25Gy/5F, once a day, for a total of 5 days, continuous irradiation, and IMRT (intensity modulated radiation therapy) technology; After a week of rest, radiotherapy and chemotherapy combined with immunotherapy will be performed~* Disitamab Vedotin: 2.5 mg/kg, intravenous infusion, d1, Q3W;~* Sintilimab: 200mg, iv;~* S-1: 40 mg/dose, oral, bid, d1-14; Q3W Whether to undergo adjuvant therapy after surgery is determined by the researcher"
224015684|NCT04229264|DRUG|Apixaban|Oral Apixaban 2.5 mg twice daily for one year
224015685|NCT04229264|DRUG|ASA|Acetil Salicilic Acid 100mg once daily for one year
224015686|NCT04229264|DRUG|Clopidogrel 75mg|Clopidogrel 75mg once daily for 3 months
224015687|NCT02726100|BEHAVIORAL|SMARTHealth Diabetes|SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
224015688|NCT00353288|BIOLOGICAL|MeMuRu-OKA (study vacc)|
224015689|NCT00353288|BIOLOGICAL|MMR, Varicella vacc (control)|
224015690|NCT00539435|PROCEDURE|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
224015691|NCT00349934|BIOLOGICAL|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
223550139|NCT04416243|BEHAVIORAL|Recumbent Stepping, High-Intensity Interval Training|"The intervention will involve 12 weeks of supervised, progressive (i.e., intensity increases after midpoint testing based on reassessment of aerobic fitness) HIIT sessions two to three times per week. HIIT exercise sessions will be manualized and led by exercise leaders. Secondary outcomes testing will occur at baseline (week 0), midpoint (following week 6 of training), and post-intervention (following week 12 of training).~The individual HIIT sessions will involve 10 cycles of 60s intervals at the wattage associated with 90% VO2peak followed by 60s of active recovery intervals at 15 watts, totaling 20 min in length. All exercise sessions will begin and end with a 5-minute warm-up and cool-down, respectively. Required power output for each interval of the exercise session will be individualized and completely automated. VO2peak from baseline and midpoint testing will be used to determine exercise intensity for weeks 1-6 and weeks 7-12, respectively."
223550140|NCT04824014|DIAGNOSTIC_TEST|4FMFES-PET|Intravenous 4FMFES injection, followed with PET imaging
224015692|NCT03313375|OTHER|Continuous Exercise|Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
223396392|NCT01434160|DRUG|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
223396393|NCT02764762|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
223396394|NCT02764762|DRUG|Adalimumab|Adalimumab injection for subcutaneous use.
223396395|NCT02764762|DRUG|Methotrexate|Methotrexate oral tablets.
223550141|NCT00054743|PROCEDURE|Blood draw|
223550142|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification and Targeted memory reactivation during REM sleep|Emerging evidence shows that REM sleep is crucial for processing emotional memories and consolidating implicit memories. By using targeted memory reactivation (TMR), a known method where sound S1 and sound S2 are associated with a waking experience(i.e.negative emotional words is associated with alcohol-related cues and positive emotional words is associated with healthy lifestyle cues) and strengthened during REM sleep, the investigators aim to augment the control of craving levels in patients with Alcohol Use Disorder.
223396396|NCT01002989|DEVICE|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
223396397|NCT01002989|DEVICE|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
224015693|NCT03313375|OTHER|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
223396398|NCT06147999|DEVICE|Biophotonizer - a Biophoton Generator|A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.
223396399|NCT03182504|DRUG|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
223396400|NCT03182504|DRUG|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
223396401|NCT03742661|DEVICE|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
223396402|NCT06575855|OTHER|IASTM|Group A received IASTM by using Graston Tool
223396403|NCT06575855|OTHER|METS|Group B received METs
223550143|NCT06457113|BEHAVIORAL|Emotional Attention Bias Modification|These patients will receive the treatment of emotional attention bias modification (EABM) without association with the sound S1 and sound S2.
224015694|NCT06123039|DIAGNOSTIC_TEST|Tidal Volume Challenge|The tidal volume challenge is a fluid response test that consists of increasing the tidal volume from 6 ml/kg to 8 ml/kg for 1 minute and evaluating PPV. If PPV increases by more than 2%, it is considered positive, otherwise it will be negative.
224015695|NCT06123039|PROCEDURE|Recruitment maneuver obtaining individualised PEEP|The alveolar recruitment maneuver is a well-studied procedure to open the lung during invasive mechanical ventilation, allowing us to achieve the best PEEP for that lung, which is individualised PEEP.
224015696|NCT05180500|DRUG|Q-Griffithsin|Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.
224015697|NCT05180500|DRUG|Placebo|A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
224015698|NCT04720248|DRUG|Metamizole|Patients will receive metamizole intraoperatively and throughout 48h postoperatively.
224015699|NCT06575790|BEHAVIORAL|Simple Meal Bolusing|Participants will enter pre-determined numbers for small, medium, or large carbohydrate meals rather than using precise carbohydrate counting
224015700|NCT06575790|BEHAVIORAL|Carbohydrate counting|Participants will be instructed to enter accurate carbohydrate counts to the best of their ability for all meals and snacks
224015701|NCT06572449|DRUG|KarXT|Specified dose on specified days
224015702|NCT01028313|DRUG|LBH589|20 mg PO three times weekly
224015703|NCT01028313|DRUG|Methylprednisolone|1 mg/kg/day PO continuously
224015704|NCT00440921|DRUG|Single donor Allogenous Fibrin Sealant|
224015705|NCT06076395|DEVICE|LMA (Laryngeal Mask Airway)|Pressure controlled versus Volume controlled ventilation using LMA
224015706|NCT04617275|DRUG|PF-06882961|PF-68882961 will be provided as tablets twice a day (BID)
224015707|NCT04617275|OTHER|Placebo|Placebo comparator will be provided as tablets twice daily for 12 weeks
224015708|NCT02822105|BIOLOGICAL|the H3N2 M2SR monovalent influenza vaccine|The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
224015709|NCT02822105|OTHER|Placebo|saline
224015710|NCT00002851|PROCEDURE|adjuvant therapy|
224015711|NCT00002851|RADIATION|low-LET electron therapy|
224015712|NCT00002851|RADIATION|low-LET photon therapy|
223396404|NCT01892501|PROCEDURE|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
223396405|NCT01892501|DEVICE|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
223396406|NCT05685147|GENETIC|Non-invasive Preimplantation genetic testing for aneuploidy status|In the intervention group, comprehensive chromosome screening using NGS will be performed according to the recommendations of the company in all SCM samples. Sequence of replacement shall be altered by the NiPGT result after morpholgy.
223550144|NCT00475553|OTHER|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
223550145|NCT00475553|OTHER|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
224015713|NCT05177887|DEVICE|Traumacel PULVIS, Traumacel ENDO Applicator|Haemostatic plant polysaccharide powder made of the oxidized cellulose with flexible applicator (38 cm).
224015714|NCT00231803|OTHER|Combined CKD and CVD Prevention|Perindopril, Lisinopril, Captopril, Candesartan, Losartan, Amlodipine, Verapamil, Chlorthalidone
224128272|NCT03716817|DEVICE|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
224128273|NCT02417870|BIOLOGICAL|aldesleukin|
223550146|NCT06521385|DEVICE|Makani Science Respiratory Monitoring System|Subjects monitored by the Makani Science Respiratory Monitoring System
224015715|NCT00231803|OTHER|Cardiovascular Disease prevention|Atorvastatin, Rosuvastatin, Simvastatin, Aspirin, Clopidogrel
224015716|NCT00231803|OTHER|Treatment of Chronic Kidney Disease complications|Calcitriol, Calcium carbonate, Erythropoietin, Sodium bicarbonate
224015717|NCT00231803|OTHER|Usual care|No prescribed intervention, just those that the patient's own family physician thought indicated
224015718|NCT01853202|BEHAVIORAL|Supervised aerobic exercise training|
224015719|NCT05586802|DRUG|Anastrozole|This will be an experimental treatment for 26 weeks in Group 1 Arm A and Arm B as well for Group 2 Arm D
224015720|NCT05586802|DRUG|Semaglutide|This will be an experimental treatment for 26 weeks in Group 2 Arm E
224128274|NCT00833248|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
224128275|NCT00833248|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
224128276|NCT00833248|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
224015721|NCT05586802|DRUG|human chorionic gonadotropin|This will be an experimental treatment for 26 weeks in addition to anastrozole in Group 1 - Arm B
224015722|NCT05586802|DRUG|Testosterone gel|This will be an active comparator for 26 weeks in Group 2 - Arm C
224015723|NCT00067262|DRUG|Divalproex Sodium Extended-Release Tablets|
224128277|NCT05075148|OTHER|radiology|Interventional radiology for aneurysmal bone cyst ( percutaneous alcoholization, vascualr embolisation)
224128278|NCT05366972|DEVICE|Ultrasonographic measurements|"Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles"
224128279|NCT06177795|BEHAVIORAL|Post-visit patient text messaging|Patients will be sent text message reminders 4 days and 14 days after their primary care visit. The message delivered 4-days post-visit will remind the patient that a screening mammogram was recently ordered by their doctor, that appointments have been reserved for them, and to pre-commit to scheduling. The message delivered at 14-days post-visit will remind the patient of their recent screening mammogram order and encourage them to schedule their appointment, if one has not already been scheduled.
223396407|NCT03552068|DRUG|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
223396408|NCT03552068|DRUG|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
223396409|NCT04070001|DRUG|400 Mg Ibuprofen|1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
223396410|NCT04070001|DEVICE|laser application|A single irradiation of laser after elastomeric separator placement
223396411|NCT04070001|OTHER|placebo tablets|Placebo lactose tablets 1-hour before elastomeric separator placement
223396412|NCT05923801|DEVICE|switch to BT electrode position|use of different electrode positions of ECT device
223550147|NCT01248988|OTHER|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
223550148|NCT05414448|DEVICE|ENDOCUFF|ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.
223550149|NCT00143494|PROCEDURE|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
223550150|NCT04400916|DRUG|Tranexamic acid|A single drop administered topically
223550151|NCT04400916|OTHER|Balanced Salt Solution|A single drop administered topically
224015724|NCT03337659|OTHER|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
224015725|NCT04101188|OTHER|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
224015726|NCT04101188|OTHER|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
224128280|NCT06177795|BEHAVIORAL|Default pended order|A default pended order for a mammogram will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.
223396413|NCT05923801|DEVICE|continue with RUL electrode position|use of different electrode positions of ECT device
223396414|NCT05149625|DEVICE|Dexcom G6|continuous glucose monitoring device
223396415|NCT02790567|OTHER|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
223396416|NCT02790567|OTHER|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
223396417|NCT02790567|OTHER|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
223550152|NCT04109807|OTHER|Ozone|ozone exposure
224015727|NCT04101188|OTHER|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
223550153|NCT04109807|OTHER|FA|Filtered air exposure
223550154|NCT01120470|DRUG|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
223550155|NCT01120470|DRUG|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
223550156|NCT05340868|DRUG|Semaglutide Pill|Oral semaglutide treatment
223550157|NCT00084708|DIETARY_SUPPLEMENT|calcitriol|
223550158|NCT00084708|DRUG|dexamethasone|
223550159|NCT00084708|DRUG|gefitinib|
224015728|NCT05604001|DEVICE|hysteroscopic ablation of submucous uterine fibroid using diode laser|patients with symptomatic submucosal fibroids (heavy menstrual bleeding) were elected for hysteroscopy and laser ablation of the myoma
224015729|NCT02437253|DRUG|Adalimumab|Subjects will be treated with adalimumab (20 mg \[weight 15-\<30 kg\] or 40 mg \[weight ≥30 kg\] administered subcutaneously \[subQ\] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
224015730|NCT02437253|OTHER|Placebo|Saline placebo
224015731|NCT06273982|BEHAVIORAL|STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)|STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.
224128281|NCT06177795|BEHAVIORAL|High risk bidirectional post-visit text messaging|High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component after their visit. This intervention will query the patient about common questions or concerns about breast cancer screening. The bi-directional text messaging intervention will provide additional educational materials based on patient response as well as information about resources to help navigate to screening.
224128282|NCT03545698|OTHER|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
223396418|NCT02790567|OTHER|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
223550160|NCT05388383|DEVICE|Ti-robot|Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
223550161|NCT02315807|DEVICE|transcranial direct current stimulation|
223550162|NCT00802997|DEVICE|Sinergy|radiofrequency denervation
223550163|NCT00802997|DEVICE|Placebo sham|sham procedure
223731185|NCT05833191|DEVICE|Tibial Nerve Stimulation|When the nervus tibialis approaches the medial malleolus, it approaches the surface. In this study, bilateral transcutaneous electrical nerve stimulation (TENS) electrodes will be placed under the medial malleolus approximately at the point where the tibialis nerve contacts the surface.
224015732|NCT06273982|BEHAVIORAL|ARC (assisted referral to community care)|ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.
224015733|NCT05535218|DRUG|Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi|"Neoadjuvant treatment: 7,5mg/kg sacituzumab-govitecan IV, on days 1, 8, of each 21 day cycle; Pembrolizumab will be administered in combination with sacituzumab-govitecan on day 1, every 21 days, at the standard dose of 200 mg intravenously. A total of 4 cycles is planned before surgery.~After surgery patients will receive additional 13 cycles of pembrolizumab at the standard dose, every 3 weeks, accounting for a total of 17 cycles of perioperative pembrolizumab (neoadjuvant + adjuvant)."
224015734|NCT05482334|DRUG|Sargramostim for Injection|Recombinant human GM-CSF
224015735|NCT05482334|DRUG|Saline Placebo|Bacteriostatic Saline
224128283|NCT00472472|DEVICE|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
224128284|NCT02006667|DRUG|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
224128285|NCT02006667|DRUG|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
224128286|NCT02006667|DRUG|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
223396419|NCT05979103|BEHAVIORAL|Listening to Reggae Music and told the stereotype|Participants in this group will be told about he stereotype of reggae in making people more calm. They will listen to reggae music over the 4 weeks. Each day, we will send them a playlist to listen to.
223396420|NCT05979103|BEHAVIORAL|Listening to Preferred Music|Participants in this group will NOT be told the stereotype for the audio they are listening to. They will listen to preferred music over the 4 weeks. Each day, we will remind them to listen to preferred music.
223550164|NCT06421506|PROCEDURE|Less invasive surfactant administration during high flow nasal cannula treatment|Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
224015736|NCT03171779|OTHER|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
224015737|NCT05259592|BEHAVIORAL|Psychotherapy|Modular Patient Centred CBT (MPC) for CPTSD (Folke, Friis, Thomsen \& Roitmann, 2020) is a psychotherapy treatment manual consisting of up to 32 individual therapy sessions broken down by five treatment modules (each consisting of six sessions) that directly address the symptoms of CPTSD: 1) Affect dysregulation, 2) Disturbed relationships, 3) Negative self-concept, 4) PTSD symptoms, and 5) Insomnia and trauma-related nightmares.
223550165|NCT02617407|DRUG|Livionex® Dental Gel|Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
223550166|NCT02617407|DRUG|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
223550167|NCT02617407|DEVICE|Kolibree Toothbrush|Electric Toothbrush
223731186|NCT06119360|PROCEDURE|Face-to-face approach|A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
223731187|NCT06119360|PROCEDURE|Conventional approach|Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
224128287|NCT02037802|DEVICE|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
224128288|NCT02037802|DRUG|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
224128289|NCT02037802|DRUG|Propofol|fentanyl propofol atracurium besylate
224128290|NCT02037802|DRUG|Bupivacaine|
224128291|NCT02037802|DRUG|Fentanyl|
224128292|NCT00000513|BEHAVIORAL|diet, reducing|
224128293|NCT00000513|BEHAVIORAL|diet, sodium-restricted|
224128294|NCT00000513|DRUG|chlorthalidone|
224128295|NCT00000513|DRUG|atenolol|
224128296|NCT02939937|DRUG|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
224128297|NCT02939937|DRUG|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
224128298|NCT05603702|DRUG|Lacosamide|Study Visit 1: Baseline study assessments will be made and questionnaires completed in person, on day 0. Drug treatment days will then occur on days 1-7. Study Visit 2: Following completion of the 7-day drug treatment period, participants will have a face-to-face clinic visit on day 8 (with a 3 day grace period), where similar assessments and questionnaires will again be completed. Participants will return all unused drug at this visit, for disposal and to monitor compliance. A follow-up phone visit will occur on day 21 (with a 3 day window) to assess for adverse events and medication changes
223731188|NCT05241106|DRUG|HYML-122|each treatment cycle is comprised of 28-day consecutive dosing of HYML-122. Upon completion of each cycle, patients may continue to receive oral HYML-122 tablets if they are benefit from the treatment and the toxicity is tolerable.
224015738|NCT06082947|DEVICE|CliniMACS®|CliniMACS® αβT cell/CD19+B cell depletion device for Children and Young Adults with Hematologic Malignancies undergoing alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
224015739|NCT04381897|DRUG|N-acetyl cysteine|Oral solution for N-acetyl cysteine is prepared in syringes and provided to the participants along with instructions on how to administer them.
224015740|NCT04381897|OTHER|Placebo|NAC Placebo-matching solution is prepared in syringes and provided to the participants along with instructions on how to administer them.
224015741|NCT06423690|DEVICE|EAS1 System|tumor ablation system in IRE method
224128299|NCT04446793|DRUG|Onvansertib|15 mg/m\^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
224128300|NCT04446793|BIOLOGICAL|Bevacizumab|5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
224128301|NCT04446793|DRUG|FOLFIRI|FOLFIRI (180 mg/m\^2 irinotecan, 400 mg/m\^2 leucovorin, 400 mg/m\^2 bolus 5-fluorouracil \[5-FU\], and 2400 mg/m\^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.
224128302|NCT01826422|DIETARY_SUPPLEMENT|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
224128303|NCT01826422|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
224128304|NCT02467803|OTHER|Scapula mobilization|
224128305|NCT02467803|OTHER|Shoulder ROM exercises|
224128306|NCT06467643|PROCEDURE|non-instrumented root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were irrigated with room temperature 5.25% sodium hypochlorite which was activated ultrasonically for 30 seconds and then intra-canal heated using a heat carrier to a temperature fixed at 150 degree celsius. Three consecutive cycles of PAU and intra-canal heating of sodium hypochlorite were performed. After the first and the last cycle, root canals were irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) and kept in the canal for 60 seconds and then flushed out with 5 mL of saline. Root canals of this group were kept un-instrumented.
223396421|NCT05615818|DRUG|Futibatinib|Dose 20 mg once a day (QD)
223396422|NCT05615818|DRUG|Ivosidenib|Dose 500 mg QD
223396423|NCT05615818|DRUG|Zanidatamab|Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W
224015742|NCT06649929|BEHAVIORAL|Couples-based treatment- Patient|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
224015743|NCT06649929|BEHAVIORAL|Couples-based treatment- Partner|couples will attend 3-telehealth based sessions to provide eduction, increase self-efficacy and teach skils based in principles of brief behavioral therapy for insomnia
224015744|NCT06649929|OTHER|Information control- Patient|Information only plus treatment as usual
224015745|NCT06649929|OTHER|Information control- Partner|Information only plus treatment as usual
224015746|NCT03959826|BEHAVIORAL|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
224015747|NCT03959826|BEHAVIORAL|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
224015748|NCT03152058|DRUG|Certolizumab Pegol|"Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
224015749|NCT05859451|DEVICE|Tobacco Heating System (THS)|Participant who are not willing to quit cigarette smoking during the study duration will switch from cigarettes to using THS
224015750|NCT05859451|OTHER|Smoking abstinence|Participant who are willing to quit cigarette smoking and will not use any electronic nicotine delivery system during the study duration
223396424|NCT05615818|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)
223396425|NCT05615818|DRUG|Neratinib|Dose: 240 mg QD (combination with trastuzumab)
223396426|NCT05615818|DRUG|Encorafenib|Dose: 450 mg QD (Combination with binimetinib)
223396427|NCT05615818|DRUG|Binimetinib|Dose: 45 mg twice a day (BID) (Combination with encorafenib)
223396428|NCT05615818|DRUG|Niraparib|Dose: 200 mg QD or 300 mg QD
223396429|NCT05615818|DRUG|Cisplatin|Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
223396430|NCT05615818|DRUG|Gemcitabine|Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)
223396431|NCT06642181|DRUG|Guanfacine pharmacotherapy|It is a pharmacotherapy
223396432|NCT06642181|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement (MORE)|It is a mindfulness intervention
223396433|NCT00789048|OTHER|radiograph|One radiograph with the patient lying on his contralateral side
223396434|NCT05382273|BEHAVIORAL|T-Break Guide|"The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~* The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~* The second week focuses on the emotional experience (e.g., anxiety, boredom).~* The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy."
223396435|NCT01468714|DRUG|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
223396436|NCT05862623|DRUG|AER-01|AER-01 solution for inhalation delivered via nebulizer
223396437|NCT05862623|DRUG|Placebo|Placebo for solution for inhalation delivered via nebulizer
223396438|NCT03979625|OTHER|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
223396439|NCT01366417|DRUG|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
223396440|NCT01366417|DRUG|70% isopropyl alcohol|Curity Alcohol Prep Pads
223396441|NCT06266325|OTHER|There is no intervention. Exposures are predictor variables of mortality.|Predictor variables of mortality will be in following categories: sociodemographic, clinical (comorbidities, treatment), caregiver-specific, functional, nutritional, cognitive, psychological/behavioural, home care, healthcare utilization, and assessment-specific information.
223396442|NCT06313541|RADIATION|SBRT or LDRT|Radiotherapy: (1) Low dose radiotherapy (LDRT) : a dose of 2 Gy/1 Fx was given to all visible lesions in the whole body within 1 week before the first course of PD-1/PD-L1 inhibitor combined with chemotherapy (different parts of the lesion could be irradiated separately, but it was required to be completed within 1 week); (2) SBRT: patients received first-line immunotherapy combined with chemotherapy, and their response was evaluated every 6 weeks. Individualized SBRT was planned based on the treatment responses.
223396443|NCT06313541|DRUG|PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy|The control group received standard PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy as first-line treatment, and the experimental group received extra treatment response adapted hybrid radiotherapy.
223396444|NCT03604224|DRUG|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
223550168|NCT04357730|DRUG|Alteplase 50 MG [Activase]|Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (\>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
223550169|NCT04357730|DRUG|Alteplase 50 MG [Activase]|wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
223550170|NCT03706742|BEHAVIORAL|Mailed outreach|The investigators will randomize all baby boomer patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
223550171|NCT01335893|DRUG|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
223550172|NCT06106061|DEVICE|Decompression + FFX®|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression associated with the use of FFX® implant
223550173|NCT06106061|PROCEDURE|Decompression alone|Surgical treatment of degenerative lumbar spinal stenosis by spinal decompression alone
223550174|NCT04524715|DEVICE|Non-invasive red LLLT treatment to chest of patient.|Expose patient to LLLT light while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
223550175|NCT04524715|DEVICE|Sham Device Treatment|Expose patient to sham device while lying on their back, elevated at an angle of approximately 45 degrees from horizontal. Position light over the patient's chest at a 33-degree bias to their right and left sides for 20 minutes each side respectively.
224015751|NCT06640634|DEVICE|active in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
224015752|NCT06640634|DEVICE|sham in therapeutic tDCS (Th-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in therapeutic tDCS (Th-tDCS) in patients diagnosed with PDPH. In the sham tDCS groups, the duration and electrodes application were the same of active in therapeutic tDCS (Th-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
223396445|NCT03627975|PROCEDURE|Conservative treatment|"1. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~2. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~3. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
223396446|NCT01068860|DRUG|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
223396447|NCT01068860|DRUG|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
223396448|NCT00400374|DRUG|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
223396449|NCT00400374|DRUG|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
223396450|NCT01441648|OTHER|contact lens wear|tinted contact lens wear
223396451|NCT01928264|BEHAVIORAL|Physical activity|
223396452|NCT01156779|DRUG|SR-exenatide|Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
223396453|NCT01483703|DEVICE|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
223396454|NCT01321879|DRUG|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
223396455|NCT01956578|OTHER|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
223396456|NCT02695446|DRUG|Minocycline|Oral extended release minocycline
223396457|NCT03176069|OTHER|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
223396458|NCT03176069|OTHER|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~* Kinesiotherapy~* Manual therapy~* Electrotherapy (electric electrostimulation, ultrasound)~* Behavioral therapy"
223396459|NCT00513240|DRUG|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
223396460|NCT00513240|DRUG|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
223396461|NCT02647710|BEHAVIORAL|PHAT Life Intervention|HIV Prevention behavioral health intervention
223396462|NCT02647710|BEHAVIORAL|Health Promotion Control|Behavioral health intervention control
223396463|NCT05263908|DRUG|nirmatrelvir / ritonavir|The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.
223396464|NCT00469430|DRUG|cefotaxim and metronidazol|iv administration for at least 24 h
223396465|NCT05973539|OTHER|Diet|Eucaloric diet enriched in either carbohydrates or fat (both contributing to 65% total energy intake)
223396466|NCT00316238|DRUG|olanzapine-RAIM|
223396467|NCT00316238|DRUG|placebo|
223396468|NCT00279435|DRUG|visilizumab|
223396469|NCT04962295|OTHER|No intervention|No intervention
223396470|NCT06520618|DRUG|Qing Re He Ji|Oral administration of Qing Re He Ji
223396471|NCT06520618|DRUG|Shuanghuanglian Oral Liquid|Oral administration of Shuanghuanglian Oral Liquid
223396472|NCT01921608|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
223396473|NCT05564156|BEHAVIORAL|Intervention groups|The drugs used by the participants within 24-48 hours after hospitalization were recorded. In the case of new prescribing, the recommendations made by the investigators to the physician are recorded in intervention group. The medication reconciliation report will be evaluated before the discharge of the participants and possible omissions discussed with the physician in charge. A detailed medication review will be accomplished by the investigators during the hospitalization of the participants.
223396474|NCT04588701|PROCEDURE|surgical procedures commonly done for anal fistula|Surgical procedures performed, including fistulotomy; fistulotomy with sphincter repair; seton; advancement flap; fistula plug;
223396475|NCT01641640|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
223396476|NCT01641640|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223396477|NCT01641640|DRUG|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
223396478|NCT02340429|DEVICE|DE500 Digital Video Otoscope|
223396479|NCT01545648|DRUG|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
223396480|NCT03076892|DEVICE|Aktilite® Galderma|preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
223396481|NCT03076892|DEVICE|PHOS ISTOS PDT|preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
223396482|NCT02308969|DRUG|LSD|100ug per os, single dose
223396483|NCT02308969|DRUG|Placebo|Capsules containing mannitol looking identical to LSD
223396484|NCT06360172|BEHAVIORAL|Motivational Interviewing|Motivational interviewing, or MI, is a collaborative, person-centered counseling technique to uncover and enhance a person\&#39;s motivation for behavior change
223550176|NCT02552745|DRUG|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
223550177|NCT00283803|DRUG|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
223550178|NCT00283803|DRUG|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
223550179|NCT00283803|DRUG|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
224015753|NCT06640634|DEVICE|active in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|"Active in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. The stimulations were delivered using a battery-driven direct current stimulator (HDCstim-DC stimulator, Newronika S.r.l. Milano - Italy). The current was administered through a pair of saline-soaked surface electrodes. The anode, measuring 3x3 cm, was placed over the primary motor cortex (M1) in the dominant hemisphere. This location was identified using the International 10-20 EEG system for C3 (left M1) or C4 (right M1). The cathode, measuring 6x4 cm, was positioned over the contralateral supraorbital region, immediately below the Fp position.~In the active a-tDCS groups, each session consisted of 20 minutes stimulation with a 2 mA intensity for 3 consecutive days."
224015754|NCT06640634|DEVICE|sham in preventive tDCS (Pr-tDCS): anodal transcranial Direct Current Stimulation (a-tDCS)|Sham in preventive tDCS (Pr-tDCS) in patients who have undergone a lumbar puncture for diagnostic purposes. In the sham tDCS groups, the duration and electrodes application were the same of active in preventive tDCS (Pr-tDCS), but the current was stopped 30 s thereafter. The subject felt the initial itching sensation, but no changes in cortical excitability are produced
224015755|NCT00133809|DRUG|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
224015756|NCT05145140|DRUG|Standardized Western Medicine Treatment|Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
224128307|NCT06467643|PROCEDURE|conventional root canal treatment with passive ultrasonic activation of heated sodium hypochlorite|Root canals were convetionally prepared using Reciproc Blue rotary files according to the manufacturer's instructions. Once the instrumentation was done, the canal was irrigated with 5 mL of 17% ethylenediaminetetraacetic acid (EDTA) kept for 60 seconds and then flushed with 5 mL of saline. NaOCl was placed in the canal and PUA followed by intracanal heating was performed three times as described for group 1 (IHAN).
224296536|NCT03569150|OTHER|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
223396485|NCT03785522|DRUG|Insulin degludec|Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
223396486|NCT02598635|DRUG|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels \<20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
223396487|NCT02598635|DRUG|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
223396488|NCT00180843|DRUG|salbutamol + ipratropium bromide nebules|
223550180|NCT03173976|DRUG|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
223550181|NCT01127607|DRUG|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
223550182|NCT05315115|OTHER|Sham intervention|The participant's head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust.
223731189|NCT01828281|DEVICE|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
224015757|NCT05145140|DRUG|Tangningtongluo tablet and cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.There are two dosage forms: tablet and cream.
224015758|NCT05145140|DRUG|Tangningtongluo tablet|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
224015759|NCT05145140|DRUG|Tangningtongluo cream|Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
224015760|NCT00766545|DRUG|cilostazol|oral tablet 100 mg, twice daily, over 1 year
224015761|NCT00766545|DRUG|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
224015762|NCT00002888|DRUG|cisplatin|
224015763|NCT00002888|DRUG|fluorouracil|
224015764|NCT00002888|DRUG|paclitaxel|
224015765|NCT04927884|BIOLOGICAL|N-803|"Dose: 15 μg/kg subcutaneously (SC)~Frequency: administered on Day 8 of each cycle (every 3 weeks)"
224015766|NCT04927884|BIOLOGICAL|PD-L1 t-haNK|"Dose: \~2 × 10\^9 cells intravenously (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
224128308|NCT04813848|PROCEDURE|Application of varnish fluoride desensitizing agent on buccal surfaces of exposed dentin|"Varnish fluoride is a single dose transparent varnish with 5 % sodium fluoride (22.600 ppm fluoride) and 5 % calcium fluoride.~The application was performed according to the manufacturer's instructions. The varnish was applied on a clean and dry surface, then after 10-20 seconds to allow the fluoride varnish to be absorbed, was then dried with air."
224128309|NCT04813848|PROCEDURE|Application of bonding agent desensitizing agent on buccal surfaces of exposed dentin|Bonding agent is a single dose dual curing universal adhesive and its application was performed according to the manufacturer's instruction for cases with hypersensitive tooth necks. The bonding was applied without etching, on a clean and dry surface. After 10 s any excess material was removed and then light cured for 30 s.
224128310|NCT04348487|OTHER|Modified cephalica venous access|This modified technique prioritized the safety in TIVAPS by using several modified landmarks and techniques. The catheter was inserted through cephalic vein in deltopectoral groove regio and implanted the port in the anteromedial of thorax. Generally, the percutaneous and Seldinger technique was used to ensure safety and minimal tissue disruption. To connect the trimmed catheter to port pocket, the author anchored a special trocar from anteromedial of thorax to the deltopectoral groove for guidance.
224128311|NCT00266019|BEHAVIORAL|Weight Management (diet, exercise, and behavior modification)|
224128312|NCT04549597|DRUG|Tenapanor|Use of tenapanor
224015767|NCT04927884|DRUG|Sacituzumab Govitecan-Hziy|"Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)"
224128313|NCT05913960|DEVICE|sham stimulation|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
224015768|NCT04927884|DRUG|Cyclophosphamide|"Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)"
224015769|NCT00706953|DRUG|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
224015770|NCT01511705|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
224015771|NCT01511705|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
224015772|NCT06500676|DRUG|GFH375|GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
224015773|NCT02713061|DRUG|TAK-850|TAK-850 injection
224015774|NCT04260178|OTHER|An Education-Based Intervention Program and handbook (EBIP, hospital and home)|A handbook was developed in line with the literature and input from two specialist physicians. The handbook consisted of 4 sections that concerned improving breathing exercises, drug compliance, nutrition and illness self-care behavior.
224015775|NCT04260178|OTHER|PFT, BMI, BDI, SCMP-G|pulmonary function test(PFT), the Baseline Dyspnea Index(BDI), body mass index(BMI) and the Self Care Management Process in Chronic Illness(SCMP-G) scale
224015776|NCT04441853|OTHER|YouTube video|Tutoral session on using YouTube personal stories on older people
224015777|NCT04441853|OTHER|Control|Tutorial session with same content without Youtube video
224015778|NCT05101824|RADIATION|SABR|Two fractionation regimes are available (37.5 Gy in 3 fractions and 30.0 Gy in 3 fractions)
224015779|NCT06071897|DRUG|monoclonal antibodies GD2|"Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy"
223396489|NCT00180843|DRUG|nebulized saline|
223396490|NCT01839708|BEHAVIORAL|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
223396491|NCT04777942|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
223396492|NCT04777942|PROCEDURE|Surgery alone|hepatic resection remove the liver tumors
223396493|NCT03540888|OTHER|Deep transverse Friction Massage|The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
223396494|NCT03540888|OTHER|Dynamic stretching intervention|Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
223731190|NCT04337749|DRUG|Chorhexidine scrub|Chorhexidine scrub was given to patients for 2 weeks
223731191|NCT04337749|DEVICE|ZnO-NPs socks|ZnO-NPs socks were given to patients for 2 weeks
224015780|NCT02549456|PROCEDURE|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
224015781|NCT02549456|PROCEDURE|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
224015782|NCT06727747|OTHER|Cervical traction|Cervical traction procedure was performed using Saunders device. During the procedure, the patient lies in installed in a supine position with 20 degrees of cervical flexion and the physiotherapist gradually increases (5 minutes) the load to the defined kilograms which is maintained for 10 minutes then progressively decreases (5 minutes) the load to zero kilograms. The procedure is performed twice with a rest interval of 5 minutes.
223396495|NCT03540888|OTHER|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
224015783|NCT06727747|OTHER|Rehabilitation|The rehabilitation program compiled cervical spine mobilization, stretching of neck muscles and isometric strengthening exercises. Passive stretching of neck muscles groups was carried-out in a seated position with 3 repetition of 30 seconds each. Isometric strengthening exercises of neck extensors were performed in a seated position, against the resistance of the physiotherapist hand for 3 repetitions of 10 seconds each
224015784|NCT05361564|DRUG|Brigatinib|After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
224015785|NCT02031549|OTHER|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
223396496|NCT01279824|BEHAVIORAL|swallowing therapy|Standardized behavioral swallowing intervention
224015786|NCT02317432|BEHAVIORAL|Comparison of a combined CBT + exercise intervention and enhanced usual care|
224015787|NCT00967031|DRUG|capecitabine|
224015788|NCT00967031|DRUG|lapatinib ditosylate|
224015789|NCT00967031|OTHER|circulating tumor cell analysis|
224015790|NCT00967031|OTHER|laboratory biomarker analysis|
223396497|NCT03849924|BEHAVIORAL|Self-affirmation|Self-affirmation implementation intentions in the form of a questionnaire.
223396498|NCT05496205|DRUG|iN1011-N17|"This study will be conducted in approximately 104 healthy subjects in up to 13 sequential dose cohorts. Thirteen cohorts will consist of up to 8 subjects, including 2 subjects receiving placebo and 6 subjects receiving iN1011-N17.~Each subsequent cohort will continue to be randomized and dosed until maximum exposure is attained or a stopping criterion has been reached."
223396499|NCT05496205|DRUG|Placebo|Matching Placebo for each formulations
223396500|NCT00890383|DRUG|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
223396501|NCT03941808|DRUG|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
223396502|NCT03941808|DRUG|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
223396503|NCT01930162|DRUG|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
223396504|NCT04078594|OTHER|sepsis e-alert|At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
223396505|NCT04534530|OTHER|Systematic screening for ischemic heart disease in type 2 diabetic patients|Systematic screening for ischemic heart disease in type 2 diabetic patients at very high cardiovascular risk, without known coronary heart disease.
223396506|NCT03808649|DRUG|1500ml of 2.5% mannitol|1500ml of 2.5% mannitol was used in experimental group
223396507|NCT03808649|DRUG|different volume of 2.5% mannitol|different volume of 2.5% mannitol based on BMI was used in active comparator group
223396508|NCT06080035|OTHER|Topical Cetyl Tranexamate Mesylate|Topical product will be applied onto clean skin morning and night.
223396509|NCT06189664|DIAGNOSTIC_TEST|Frozen section|Frozen section analysis
223396510|NCT02836002|DRUG|Sulfadoxine-pyrimethamine (low dose)|\- subcurative regimen (500mg/25mg)
223396511|NCT02836002|DRUG|Piperaquine (low dose)|\- subcurative regimen (480 mg)
223396512|NCT02836002|DRUG|Sulfadoxine-pyrimethamine (high dose)|\- curative regimen (1000mg/50mg)
224015791|NCT06658574|DRUG|Acetaminophen|Arm 1: Once cleared for oral intake - acetaminophen tablets 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days\&#39; dispensed as unit-dose tablets Arm 2: Once cleared for oral intake - acetaminophen liquid (160 mg/5 mL) 650 mg PO every 6 hours PRN - mild pain (1 - 3) to a maximum of 4 grams daily for 3 days; 650 mg = 20.3 mL, dispensed as a unit-dose cup
224015792|NCT05165888|BEHAVIORAL|Communication and Bias Mitigation Training|Training to improve communication skills and reduce the effect of racial bias on clinician communication behavior
224015793|NCT05165888|BEHAVIORAL|Communication skills training|Training to improve communication skills between physicians and caregivers.
224015794|NCT06825416|DRUG|SHR-2004 injection|SHR-2004 injection in low dose.
223396513|NCT02836002|DRUG|Piperaquine (high dose)|\- curative regimen (960 mg)
223396514|NCT02836002|BIOLOGICAL|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
223550183|NCT05315115|OTHER|Chiropractic Care|A registered chiropractor will assess the entire spine, and both sacroiliac joints will be assessed for vertebral subluxation by a registered chiropractor. The clinical indicators that will be used to assess the function of the spine before spinal adjustment intervention include assessing for joint tenderness to palpation manually palpating for a restricted intersegmental range of motion, assessing for palpable asymmetric intervertebral muscle tension, and any abnormal or blocked joint play and end-feel of the joints.
224015795|NCT06825416|DRUG|SHR-2004 injection|SHR-2004 injection in high dose.
224015796|NCT06825416|DRUG|Enoxaparin sodium injection|Enoxaparin sodium injection.
223396515|NCT02836002|DRUG|Atovaquone-proguanil|\- curative regimen: 1000/400 mg, for 3 days
223396516|NCT04302415|DRUG|There is no other intervention, only clinical treatment.|There is no other intervention, only clinical treatment.
223731192|NCT04337749|COMBINATION_PRODUCT|Combination of chorhexidine scrub and ZnO-NPs socks|Combination of chorhexidine scrub and ZnO-NPs socks were given to patients for 2 weeks
224015797|NCT06825416|DRUG|Enoxaparin sodium injection placebo|Enoxaparin sodium injection placebo.
224015798|NCT06825416|DRUG|SHR-2004 placebo|SHR-2004 placebo in low dose.
224015799|NCT06825416|DRUG|SHR-2004 placebo|SHR-2004 placebo in high dose.
224015800|NCT06056804|DRUG|capecitabine|825-1000mg/m2,po,bid
224015801|NCT06056804|DRUG|tislelizumab|200mg,iv.gtt,q3w
224015802|NCT06056804|DRUG|thymalfasin|4.8mg,sc,biw
224015803|NCT06056804|RADIATION|long-term radiotherapy|50 Gy/25 f, 2 Gy/day
223550184|NCT05315115|OTHER|Physical therapy intervention|The standardized treatment protocol will be provided according to the guidelines, which will include various modalities and treatment approaches, including stretching exercises; massage; strengthening exercises of weak muscles, weight-bearing, balance (static and dynamic) and gait training; electrical stimulation; treadmill use; and endurance training for the improvement of gait, motor function, strength and functional mobility in Spinal Cord Injuries children, where Conventional Therapy will be provided according to the respective needs of the individual patient.
223550185|NCT05730556|DEVICE|Nerivio ®|Non-invasive wearable, remote electrical neuromodulation (REN) device controlled by a smartphone application worn on an armband on the upper arm.
223550186|NCT05730556|DEVICE|Sham|Electrical stimulation to mimic study treatment intervention
223550187|NCT03640325|BEHAVIORAL|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
223550188|NCT05368259|DEVICE|AGBS|The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.
223550189|NCT06097533|DRUG|Cannabisextrakt Avextra 10/10 Lösung|medical cannabinoids
223550190|NCT05906472|OTHER|Feeds continued|Enteral feeds are continued up until time of surgery
223550191|NCT05906472|OTHER|Feeds held|Enteral feeds are stopped 6 or more hours before surgery
224015804|NCT02248181|DRUG|Pramipexole|
224015805|NCT06607757|DRUG|Capivasertib|find arm A description
224015806|NCT06607757|DRUG|Fulvestrant injection|find arm B description
224015807|NCT06608147|OTHER|Sampling|sternal bone marrow aspiration
224015808|NCT05593445|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
223396517|NCT04785378|DEVICE|Medical mask|Participants will carry out field tests one day wearing a medical mask and the other day without a mask.
223396518|NCT04785378|OTHER|Field tests|Participants will perform 6 MWT and ISWT tests to determine their exercise capacity, and a 30-second sit and stand test to determine lower extremity endurance.
223396519|NCT02083744|BEHAVIORAL|PsychoEducational Support|
223396520|NCT02083744|BEHAVIORAL|Usual Care|Standard Heart Failure Care
223396521|NCT05352620|OTHER|Implant assisted maxillary overdenture|For each patient, an implant assisted maxillary overdenture will be fabricated using a minimally invasive flapless surgical technique with OT-Equator and Smart Box attachment
223396522|NCT00160303|DRUG|Prolotherapy|
223396523|NCT00160303|DRUG|Local Corticosteroid Therapy|
223396524|NCT02110082|BIOLOGICAL|Urelumab|
223396525|NCT02110082|BIOLOGICAL|Cetuximab|
223396526|NCT01051960|DRUG|Ambrisentan|Ambrisentan 5mg or 10mg once daily
223396527|NCT01474174|BIOLOGICAL|trivalent influenza vaccine|Given IM
223396528|NCT01474174|OTHER|laboratory biomarker analysis|Correlative studies
223396529|NCT02635594|DIETARY_SUPPLEMENT|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
223396530|NCT02635594|OTHER|Placebo|1000mg cellulose + 475mg L-tartaric acid
223396531|NCT00754130|DRUG|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
223396532|NCT00754130|DRUG|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
223396533|NCT00661557|BIOLOGICAL|Meningococcal vaccine GSK134612 (Nimenrix)|one dose, as intramuscular injection
223396534|NCT02300064|OTHER|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
223396535|NCT02300064|OTHER|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
223396536|NCT02300064|OTHER|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
223550192|NCT03721783|PROCEDURE|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
223550193|NCT03880045|DRUG|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
223550194|NCT03880045|DRUG|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
223550195|NCT03880045|OTHER|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
223550196|NCT03168165|OTHER|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
223550197|NCT02572297|OTHER|video-EEG|Registration of seizures during video-EEG
223550198|NCT04888026|DEVICE|Quantitative sensory testing|"The following QSTs are conducted:~The pressure pain threshold on the tibialis anterior~The Cold-pressor test~Repeat of the pressure pain threshold to assess conditioned pain modulation"
223550199|NCT03046927|DRUG|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
223550200|NCT03046927|OTHER|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
223550201|NCT00282633|DEVICE|Dermabond|
223550202|NCT02052661|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
224015809|NCT05593445|DRUG|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
224015810|NCT06598436|OTHER|Digital Health Coaching (Patient-Level Intervention)|The patient-level intervention combines the role of digital health navigator and chronic disease health coach to facilitate access to devices and broadband, offer digital skills training, and provide chronic disease health coaching focused on telehealth modalities.
223396537|NCT02300064|OTHER|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
223731193|NCT04337749|DEVICE|Placebo socks|Placebo socks were given to patients for 2 weeks
223396538|NCT06068062|OTHER|modification of OSCE using TBL format|Modification of Team-based learning format and implementing OSCE using that modified format to teach clinical skills to medical students.To teach clinical skills this structure of TBL was modified and with use of OSCE following strategy was planned as intervention. First of all, the students were provided with the resource material regarding the skills to be taught. Then a formative OSCE session was organized where students were divided into groups each with 5 students. They were rotated in two OSCE stations. First each student one by one was supposed to perform the task that was clearly documented and was evaluated by peers and facilitator. Immediate feedback from peers and facilitators was given to each student. Students were also instructed to discuss among themselves and designate roles also to make a plan and act like team in performing task on OSCE station 2.
223396539|NCT02564601|BEHAVIORAL|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
224015811|NCT06598436|OTHER|Practice Facilitation (Clinic-Level Intervention)|The clinic-level intervention includes primary care clinic support through practice facilitation that empowers team members to address racial/ethnic disparities in telehealth use through consistent review of telehealth equity data and input from clinic-specific Patient Advisory Councils (PACs).
224015812|NCT06610591|PROCEDURE|Achilles Lengthening Surgery|The procedure is undertaken under general anaesthetic and involves horizontal hemi-section of the Achilles tendon via small 'stab' incisions at three levels to effect a lengthening of the tendon. The patient is then placed in a walking cast for four weeks thereafter. This surgery is usual care for most children with symptomatic ITW with plantarflexion contractures who have failed non-operative management.
224015813|NCT00231452|DRUG|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
224015814|NCT01577459|DRUG|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
224015815|NCT01577459|OTHER|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
224015816|NCT05595252|BIOLOGICAL|cervical biopsy|cervical biopsy made during and after pregancy
224015817|NCT04807582|OTHER|[18F]FPIA PET/MRI|18F-fluoropivalate tracer injection followed by PET/MRI scan
224015818|NCT04631692|BEHAVIORAL|Health literacy intervention|"We will translate and adapt an intervention developed by Ferreira et al. to address health literacy and improve CRC screening. This intervention combined a 2-hour health literacy training targeting primary care physicians (which also included information about CRC screening) and a patient level intervention that consisted of a brochure and video.~In order to promote generalizability, large-scale diffusion, dissemination and sustained use beyond the funded-research period, we will use blended learning to develop a 2-hour e-learning health literacy training in French and a one-hour booster session.~The patient-facing intervention (video + brochure) will follow key plain language and health literacy principles to translate evidence-based information in content that all patients can understand. Existing materials developed in France will be used and adapted as relevant."
224015819|NCT05559476|BIOLOGICAL|RSVPreF3 OA investigational vaccine|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.
224015820|NCT05559476|BIOLOGICAL|FLU HD vaccine|FLU HD vaccine administered intramuscularly in the deltoid region of the dominant arm (Co-Ad Group) or the non-dominant arm (Control Group).
224015821|NCT06403709|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
224015822|NCT05157269|DRUG|Nitazoxanide|Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days
223396540|NCT02564601|BEHAVIORAL|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
223396541|NCT03904251|DRUG|Gemtuzumab Ozogamicin|Given IV
223396542|NCT03904251|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223396543|NCT02584101|BEHAVIORAL|ACT|ACT therapy administered in 3 sessions over a 4 week period
223396544|NCT02584101|BEHAVIORAL|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
223731194|NCT05749445|DRUG|Nirmatrelvir-Ritonavir|Nirmatrelvir-Ritonavir
224015823|NCT05157269|DRUG|Placebo|Two matching placebo tablets administered orally twice daily for 5 days
224015824|NCT05157269|DIETARY_SUPPLEMENT|Vitamin Super-B Complex|Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
223396545|NCT04556682|DEVICE|Rotational atherectomy|Device used for severely calcified coronary lesion preparation before stent implantation.
223396546|NCT04556682|DEVICE|Intravascular lithotripsy|Device used for severely calcified coronary lesion preparation before stent implantation.
223396547|NCT06453668|BIOLOGICAL|TCD601|Investigational Product
223396548|NCT03696212|DRUG|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
223731195|NCT01761110|BEHAVIORAL|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
223731196|NCT01901497|DEVICE|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
223731197|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 13|HBM9161 680 mg qw by q2w from week 13
223731198|NCT05015127|DRUG|Placebo|Placebo
223396549|NCT00606112|DRUG|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
223396550|NCT06121323|OTHER|Sodium lactate infusion|Dosage of sodium-lactate: 0.5 mol/L; 3 mL/kg/time; maximal 300 mL/hour.
223396551|NCT06121323|OTHER|Sodium lactate ingestion|Oral dose is equal to the i.v. dose.
223396552|NCT06507410|DRUG|Propofol|Continuous propofol infusion will be given with syringe pump for maintenance, with the initial rate set at 25-75 mic/kg/min IV during the first 10-15 min. To avoid administering sedatives at rates greater than clinically necessary, infusion rates will be gradually titrated to 25-50 mic/kg/min and regulated with the clinical response, with an onset of peak drug action expected to occur within 2 min.
223396553|NCT06507410|DRUG|Propofol combined with clonidine|Patients will receive 2 μg/kg of clonidine for injection intravenously 30 min before induction of sedation, administered over 10 min.
223550203|NCT04290247|DIAGNOSTIC_TEST|Ultrasound|Ultrasound imaging for fracture diagnosis before conventional X-ray
223550204|NCT01133756|DRUG|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
223550205|NCT01133756|DRUG|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
223550206|NCT01133756|DRUG|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
223550207|NCT05502926|DIAGNOSTIC_TEST|lung ultrasound score|peroperative and postoperative 12 point trans-thoracic lung ultrasound
224015825|NCT03070327|BIOLOGICAL|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10\^6, 3x10\^6, and 1x10\^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10\^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
224015826|NCT03070327|DRUG|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
224015827|NCT03070327|DRUG|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
224015828|NCT05242419|DRUG|Sodium Chloride Injection|0.9% Sodium Chloride Injection
224015829|NCT05242419|DRUG|Huperzine A Injection|Huperzine A Injection
224015830|NCT06611046|OTHER|organ donor|"Observational study with sample collection of serum, liver tissue and perfusate fluid from liver donors. No specific interventions were done to the donors as part of the study. The samples were analyzed for specific microNA expression by RT-qPCR.~\*Control group: only serum samples were collected from this group."
224015831|NCT06609980|DRUG|autologous fecal matter transplant|Autologous fecal matter transplant will be used to re-seed the child's gut with his or her own personalized microbiome composition which was preserved prior to antibiotics use.
224015832|NCT03005353|DRUG|Cumin seed extract|patients will receive the drug in suppository form
224015833|NCT03005353|DRUG|clotrimazole|patients will receive the drug in suppository form
223396554|NCT05720741|BEHAVIORAL|Project THINK|Project THINK is a 30-minute self-guided digital intervention designed to teach children and adolescents how to change the way that they think. Specifically, Project THINK is based on the principles of cognitive restructuring, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project THINK uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for assessing the presence of unhelpful thoughts and replacing them with more helpful ones. Although never formally tested in a randomized trial, Project Think has been used by hundreds of students, and feedback has been very positive.
223550208|NCT01116999|PROCEDURE|light guided tracheal intubation|Tracheal intubation light guided technique.
223550209|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
223550210|NCT01566149|DRUG|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
223550211|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
223550212|NCT00663806|BEHAVIORAL|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
223550213|NCT02234713|BEHAVIORAL|Motivational Interview|
224015834|NCT02305654|PROCEDURE|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
224015835|NCT02305654|DRUG|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
224015836|NCT02305654|DRUG|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
224015837|NCT02305654|DRUG|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
224015838|NCT02305654|RADIATION|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
224296537|NCT03081234|DRUG|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
223550214|NCT02234713|OTHER|Video Attention Control|
223550215|NCT02904850|BIOLOGICAL|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
223550216|NCT04008641|OTHER|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
223550217|NCT00479505|DRUG|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
223550218|NCT00479505|DRUG|Placebo|Placebo
223550219|NCT01848977|DEVICE|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
223550220|NCT01848977|DEVICE|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
223550221|NCT03601442|BIOLOGICAL|CTL019|CTL019
223396555|NCT05720741|BEHAVIORAL|Project SHARE|Intervention delivered in a web browser that focuses on encouraging feelings disclosure to trusted others using facts about the brain, testimonials from peers, and writing exercises (also referred to as Sharing Feelings Intervention; Schleider et al., 2021).
223396556|NCT06121817|OTHER|Food/meal intervention|2 types of exotic fruits, durian and banana, are the study test meals. Both isocaloric test meals are performed at breakfast. All subjects are required to consume the entire meal within 10 minutes.
223396557|NCT03068234|DRUG|Pirfenidone|A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
223396558|NCT03068234|DRUG|Placebo oral capsule|Placebo for pirfenidone capsule
223396559|NCT03068234|DRUG|Steroids|Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
223396560|NCT00958958|OTHER|multifaceted strategy|"There are multifaceted Interventions Including~1. Distribution of educational materials: distribution of published or printed recommendations for clinical care.~2. Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~3. Reminders~4. Practical training"
223396561|NCT05183841|DRUG|Bronchodilator (Ipratropium and Fenoterol)|8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
223550222|NCT03276728|DRUG|AMG 986 IV|AMG 986 solution for infusion
223550223|NCT03276728|DRUG|AMG 986 PO|AMG 986 tablets for oral (PO) administration
223550224|NCT03276728|DRUG|Placebo PO|Matching placebo tablets for oral administration
223550225|NCT03276728|DRUG|Placebo IV|Matching placebo solution for infusion
223550226|NCT00023933|DRUG|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
223550227|NCT03302689|DRUG|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
223550228|NCT03302689|DRUG|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
223550229|NCT02295228|OTHER|No intervention|There are no interventions. This is an observational trial.
223550230|NCT02565693|DRUG|Apixaban|
223550231|NCT02565693|DRUG|Aspirin|
223550232|NCT02565693|DRUG|Carbasalate calcium|
223550233|NCT02565693|DRUG|Clopidogrel|
223731199|NCT05015127|DRUG|HBM9161 680 mg qw by q2w from week 7|HBM9161 680 mg qw by q2w from week 7
224015839|NCT02305654|PROCEDURE|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
224015840|NCT06485986|OTHER|DBS on/off|DBS will be turned on and off for experimental periods to compare the effect of DBS on behaviour.
224015841|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT alone that are not treated with CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit and at 12-18 months, or earlier if they develop symptoms. While 12-18 months is the preferred window for repeat imaging, if imaging during this time frame is not achievable, the patient may return anytime throughout the remainder of the study.
223396562|NCT05183841|OTHER|Placebo|8 puffs of placebo via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
224015842|NCT05838547|DRUG|64Cu-25%-CANF-Comb|Patients treated with OMT and CEA will receive an intravenous injection of 4-6 mCi of 64Cu-25%-CANF-Comb radiotracer for PET/MR imaging at the initial imaging visit.
223396563|NCT02945241|DRUG|Vancomycin|Intravenous
223550234|NCT02565693|DRUG|Dipyridamole|
223550235|NCT02565693|OTHER|No antithrombotic treatment|
223550236|NCT03069742|OTHER|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
223550237|NCT03069742|OTHER|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
223550238|NCT04447235|DRUG|Placebo|Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
223550239|NCT04447235|DRUG|Ivermectin|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
223550240|NCT04447235|DRUG|Losartan|Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
223550241|NCT00069875|DRUG|Gemcitabine|
223550242|NCT00069875|DRUG|LY293111|
223550243|NCT00069875|DRUG|cisplatin|
223550244|NCT04858815|BEHAVIORAL|yogic breathing|participation in yogic breathing
223550245|NCT06010784|BEHAVIORAL|Family support|"* Family tip sheets sent via mobile text at the start of the program and then every 3 weeks, to a total of 6 mobile text messages~* Weeks 1-4 (4 weeks):~  i. Welcome package mailed in the first week of the program ii. Weekly: one 10-lbs box of produce iii. Recipes accompanying each box (sample recipe card attached to submission) iv. Bi-Weekly: Grocery store gift cards (2x USD 20, to a total of USD 40)~* Weeks 5-19 (total of 10 weeks over the 19-week study timeline):~  i. An optional online form (goal sheet) is sent to the parent/caregiver every other week (total 5) with questions about trying new FV items to be submitted in the next 7 days. As an incentive, a USD 10 gift card is sent to those who complete it (a potential total of USD 50).~ii. Week 11: an extra USD 20 gift card in the week after a school holiday to re-engage participants due to the school-year break."
223731200|NCT05015127|DRUG|Placebo|Placebo qw by HBM9161 680mg qw from week 12
223550246|NCT06010784|BEHAVIORAL|BGCAA's after-school program with CATCH curriculum|"1. The whole BGCAA's after-school program runs for 3h, Mon-Fri for the school year across all sites where the organization offers the program. All children enrolled are expected to attend a minimum of 2x/week.~2. In the BGCAA's after-school program, children participate in active recreational time (approx. 60 min, offered 1x/week at a minimum) which is a mixture of free play, structured physical activity games, and/or sports activities (including soccer, football, and basketball).~3. Uniquely to sites participating in the study, BGCAA's staff will deliver selected CATCH (Coordinated Approach to Child Health) curriculum components in blocks of 45-60 min, 2x/week, as part of the after-school program. The curriculum will focus on healthy eating education and physical activity designed for elementary school-aged children. More information on CATCH at https://catch.org/ (accessed 8/11/2023)"
224015843|NCT04489134|DRUG|Treatment A|Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
223396564|NCT02945241|OTHER|Cystatin C dosing algorithm|Expressed in milliliters per minute
223396565|NCT02945241|OTHER|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
223396566|NCT03113864|DIETARY_SUPPLEMENT|Placebo|Daily supplementation for 9 months
224015844|NCT04489134|DRUG|Treatment B|Administration of a 2 mg dose of LCP-tacro (Envarsus®)
224015845|NCT04489134|DRUG|Treament C|Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
223396567|NCT03113864|DIETARY_SUPPLEMENT|Lutein|Daily Supplementation for 9 months
224015846|NCT04489134|DRUG|Treatment D|Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
224015847|NCT04489134|BIOLOGICAL|Pharmacocinetik|Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.
224015848|NCT04489134|GENETIC|Genetic|A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.
224015849|NCT04489134|OTHER|Selection visit:|"During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal."
224015850|NCT04891562|OTHER|interlimb coordination of the lower limbs and synchronization|4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)
224015851|NCT00727311|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
224015852|NCT00727311|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
224015853|NCT06688422|DEVICE|incentive spirometry|The study will have one intervention group of patients using incentive spirometry in addition to standard of care treatment, including chemo/radiation and immunotherapy maintenance. Patients will use the incentive spirometer 10 times (10 breaths) every hour they are awake. Patients will be asked to start using the incentive spirometer as soon as they are enrolled in the study. Patients will be asked to continue to use incentive spirometry daily, including the duration of chemoradiation and up to three months post-treatment.
224015854|NCT06619951|DRUG|VC004 and Itraconazole|A single dose of VC004 was administered in the period 1. and a single dose of VC004 and Itraconazole coadministration in the period 2.
224015855|NCT06619951|DRUG|VC004 and rifampicin|A single dose of VC004 was administered in the period 1. and a single dose of VC004 and rifampicin coadministration in the period 2.
224015856|NCT06685848|DEVICE|Hemanext ONE system|Hypoxic red blood cells
224015857|NCT06685848|DEVICE|Conventional RBCs|Conventional manufactured Red blood cells
224015858|NCT04877353|DEVICE|NIV|NIV applied for approximately 30 to 45 min at 2- to 4-h intervals for 48 h following surgery
224015859|NCT06716658|DRUG|JAK1 Inhibitor|Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
224015860|NCT06715618|OTHER|FMS test|Each participant will perform two FMS™, one at the beginning of the competitive season and one at the end of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
223396568|NCT02256618|OTHER|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
223396569|NCT01057706|OTHER|chiropractic|spinal manipulation and mobilization
223396570|NCT01057706|BEHAVIORAL|exercise|strengthening, stretching, balance
223396571|NCT01967862|PROCEDURE|computed tomography|Undergo CT
223396572|NCT01967862|PROCEDURE|bone scan|Undergo bone scan
223396573|NCT01967862|PROCEDURE|3-Tesla magnetic resonance imaging|Undergo axial MRI
223396574|NCT01967862|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
223396575|NCT01967862|RADIATION|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
223396576|NCT01967862|PROCEDURE|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
223396577|NCT01967862|PROCEDURE|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
223396578|NCT01967862|OTHER|laboratory biomarker analysis|Correlative studies
223396579|NCT02069015|BEHAVIORAL|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
223396580|NCT06280911|OTHER|Date Fruit group|Consumption of Date Fruit
223396581|NCT06280911|OTHER|Nipple group|Nipple Stimulation
223396582|NCT01082328|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
223396583|NCT00031590|DRUG|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
223396584|NCT00031590|DRUG|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
223396585|NCT00031590|DRUG|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
223396586|NCT00031590|DRUG|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
223396587|NCT00031590|DRUG|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
223396588|NCT00031590|RADIATION|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
223396589|NCT05302401|BEHAVIORAL|intrapartum uninterrupted midwife support|Prenatal women will be trained about the birth process and psychological and physical support will be provided to women during childbirth. Among these supports, healthy women will be exercised during the labor action, given positions that facilitate childbirth, their hands will be held when they need them, their oral intake will not be restricted, and warm showers will be applied according to their wishes. (These applications can be increased.)
223396590|NCT01650480|OTHER|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
223396591|NCT02154568|DRUG|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
223396592|NCT05506046|BEHAVIORAL|Reduced nicotine message exposure|Participants will be shown two messages about harms of reduced nicotine cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that reduced nicotine cigarettes will still have the rest of the harmful chemicals and cause diseases as the regular cigarettes, but they would make it easier to quit.
223396593|NCT05506046|BEHAVIORAL|Modified risk message exposure|Participants will be shown two messages about electronic cigarettes as an alternative to regular cigarettes. The two messages will be drawn from a pool of five messages. The messages will communicate that electronic cigarettes are less likely than regular cigarettes to cause severe diseases such as lung cancer.
223396594|NCT05506046|BEHAVIORAL|Combined message exposure (reduced nicotine + modified risk)|Participants will be shown two messages, one from the reduced nicotine message set and one modified risk message set.
223396595|NCT05506046|BEHAVIORAL|Control message exposure|Participants will be shown two messages about drinking bottled water. These will be selected from a pool of five message. The messages display specific water products and describe hydration as a healthy activity.
223396596|NCT05587322|DRUG|BLI5100|Orally via tablet
223396597|NCT05587322|DRUG|Placebo|Orally via tablet
223396598|NCT05046912|BEHAVIORAL|Yoga|8 weeks of online weekly yoga or chair yoga class
223396599|NCT05046912|BEHAVIORAL|Mindfulness|8 weeks of online weekly mindfulness class
223396600|NCT04212325|PROCEDURE|Group C (Continuous sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
223396601|NCT04212325|PROCEDURE|Group S (sciatic nerve block)|Patients randomized to this group will receive a sciatic nerve block at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After single injection sciatic nerve block, outcome measures will be assessed.
223396602|NCT00766012|DRUG|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
223396603|NCT00766012|DRUG|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
223396604|NCT01780012|BEHAVIORAL|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
224015861|NCT06723197|DRUG|vonoprazan+amoxicillin|Drug combinations for dual regimens：vonoprazan+amoxicillin
224015862|NCT06723197|OTHER|Duration of eradication regimen: 7-day|Duration of eradication regimen: 7-day
224015863|NCT06723197|DRUG|vonoprazan+amoxicillin+tetracycline+bismuth|Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth
224015864|NCT06723197|OTHER|Duration of eradication regimen: 10-day|Duration of eradication regimen: 10-day
223396605|NCT00683722|DRUG|Prochymal™|IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
223396606|NCT00683722|DRUG|Placebo|IV infusion of excipient of Prochymal™.
223396607|NCT00299325|DRUG|Rimonabant|Tablet, oral administration
223396608|NCT00299325|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
223396609|NCT00299325|OTHER|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
223396610|NCT00519857|DRUG|Tibolone|1.25 mg p.o, once daily for 3 years
224015865|NCT06723197|OTHER|Duration of eradication regimen: 14-day|Duration of eradication regimen: 14-day
224296538|NCT03081234|DRUG|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
224296539|NCT03081234|DRUG|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
224296540|NCT00506649|OTHER|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
223396611|NCT00519857|DRUG|Placebo|Tablet p.o, once daily for 3 years
223396612|NCT01714830|DEVICE|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
223396613|NCT01714830|DEVICE|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
223396614|NCT03666130|PROCEDURE|endoscopic septoplasty|endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
223396615|NCT04248114|DIAGNOSTIC_TEST|Ultrasound of the Neck|Anatomical measurements were performed on participants during an ultrasound exam
223396616|NCT05882019|DEVICE|Breast Exam with Bexa|Breast exam with Bexa uses pressure elastography to produce a map of the breast tissue's elasticity.
223396617|NCT00485719|DRUG|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
224015866|NCT06887751|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"The self-guided Online version of Acceptance and Commitment Therapy (iACTforDGBI) intervention will include 8 weekly sessions of around 20 minutes each, and will comprise ACT-consistent informative texts, audio exercises, and videos.~The intervention is expected to have the following overall structure: Session 1: Introduction to the intervention and promotion of creative hopelessness, Awareness of bodily sensations, Values clarification Session 2: Committed action, Acceptance, Cognitive defusion Session 3: Self as context, Conclusions Session 4-8: personalised content (in-depth material and tasks based on individual difficulties assessed with diary)"
224015867|NCT06887751|OTHER|Psychoeducation|"Participants in the active control group will be asked to complete 8 weekly 20-minute sessions of an online course for education on DGBIs. This course will be delivered through a similar platform than the one delivering the online ACT for DGBI intervention, via the same website. The intervention platform will have similar designs and structure, and will be developed by the same web development company.~The content of the education course will be based on the IBS school intervention (e.g., Ringström et al., 2009), in particular its online version (Lindfors et al., 2021), developed by members of the current research team. This education intervention was based on the biopsychosocial model of DGBI and was originally developed and tested as a face-to-face group intervention with six 2-h sessions held weekly. IBS school generally aims at increasing disease knowledge in people with IBS and covers a wide spectrum of issues related to IBS, such as disease pathophysiological me"
223396618|NCT01026519|DRUG|REGN88|Single dose of REGN88 and 43 day follow up.
224015868|NCT06728033|OTHER|supra-inguinal fascia iliaca compartment block|Supra-inguinal fascia iliaca compartment block with 40 ml of 0.25% ropivacaine
224015869|NCT06728033|DRUG|Tramadol|intravenous tramadol at a dose of 2 mg/kg
224015870|NCT06728865|DRUG|The treatment regimen is Furmonertinib combined with Bevacizumab.|The treatment regimen is Furmonertinib combined with Bevacizumab.
224015871|NCT06729671|DIETARY_SUPPLEMENT|Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule|Bifidobacterium longum APC1472 capsule
224015872|NCT06729671|DIETARY_SUPPLEMENT|maltodextrin|maltodextrin
224015873|NCT06729151|DRUG|Onabotulinum toxin A|Cystoscopic injection of Onabotulinum toxin A per standard clinic protocol.
224015874|NCT06729151|BEHAVIORAL|Conservative management (dietary and behavioral)|Dietary and behavioral modifications consistent with recommendations from the American Urogynecological Society
224015875|NCT05798793|DRUG|Camrelizumab plus TP|The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
224015876|NCT05798793|DRUG|TP|The participants will receive docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
223396619|NCT01026519|OTHER|Placebo|Placebo to match REGN88 administration
223396620|NCT00516841|DRUG|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
223396621|NCT00907543|OTHER|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
223396622|NCT00907543|OTHER|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
223396623|NCT03144908|OTHER|Standard Operating Procedures|Observational on Standard Operating Procedures
223396624|NCT01282684|DRUG|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
223396625|NCT01282684|DRUG|Placebo|Matching placebo for PLX5622.
223396626|NCT01120808|PROCEDURE|Paper tape|Paper tape assigned to each participant's randomly selected foot.
223396627|NCT00706459|DEVICE|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
223396628|NCT03051100|DRUG|Bempedoic acid 180mg|bempedoic acid 180 mg
223396629|NCT03051100|DRUG|Ezetimibe 10mg|ezetimibe 10 mg
223396630|NCT03051100|DRUG|Atorvastatin 20mg|atorvastatin 20 mg
223396631|NCT03051100|OTHER|Placebo|placebo
224015877|NCT06729515|DEVICE|PCA|Immediately post-surgery, patients in the PCA group received a programmed PCA infusion (YG-B-3; Jiangsu Yaguang Medical Device Co., Ltd., China) containing either ketorolac (180 mg) or sufentanil (200 µg) in 100 mL, delivered as a 2 mL/h basal infusion with 0.5 mL boluses; lockout interval: 15 min.
224015878|NCT06729515|DEVICE|CEA|Following epidural catheter placement in the operating room, the CEA group received an initial bolus of 2% lidocaine (3 mL). Once sensory blockade was confirmed, continuous epidural infusion of 0.1% ropivacaine (8 mL/h) commenced.
224015879|NCT06729515|DEVICE|RISS|RISS blocks were performed at the T4-T10 level under ultrasound guidance (EPIQ5 with L12-4 linear 7.5 MHz transducer; Philips Healthcare, Best, Netherlands). A 19-gauge, 40-cm catheter was advanced 3-5 cm beyond the needle tip into the subserratus plane, its position confirmed by injecting 5 mL of 0.2% ropivacaine. A further 15 mL of 0.2% ropivacaine was then administered. The catheter was connected to a PCA pump programmed to deliver a 7 mL/h basal infusion with 2 mL boluses; lockout interval: 30 min.
223396632|NCT06292845|DRUG|Topical application of a fluorescent imaging agent|"The fluorescent imaging agent will be topically applied only onto the resection planes of the freshly resected tumor specimen.~During incubation and after each washing steps, visible light and fluorescent overlay images will be acquired using a fluorescence sensitive camera system."
223396633|NCT00874575|DIETARY_SUPPLEMENT|Placebo|
224015880|NCT06729749|OTHER|Bioptron Pro 1 Class II|Bioptron Pro 1 Class II: Made by Bioptron AG, Wollerau, Switzerland, a device with a floor stand emits a polarized light lamp. The device has an ergonomic table stand that can be combined with a functional floor stand, allowing flexible use in domestic and professional environments. easily adjustable height and head inclination and the ability to rotate the device head up to 360 allow a convenient usage of nearly any position. Treatments can easily be timed by a control panel down to 30 seconds, an integrated distance rod ensures the recommended distance from the skin surface It will be used for the treatment procedures for all participants in group B only with the following parameters, Wavelengths ranging from 480-3400 nm, Degree of polarization \>95% (590 - 1550 nm), Specific power density Av. 40 mW/cm2 Light energy per minute av.2.4 J/cm2, Light Intensity per min. 10.000 lux, Weight without stand 3.4 kg and Weight with stand7.8 kg ,Energy consumption in sleep mode0.5
224015881|NCT06729749|OTHER|Vitamin D|All participants in both groups will take this supplements daily for 3 months
224015882|NCT06729086|DRUG|sedation using propofol|The different complications studied will be for example respiratory, neurologic and cardiac based on several clinical and biological parameters.
224015883|NCT06729086|DRUG|sedation using sevoflurane|The differents complications studied will be for example respiratory, neurologic and cardiac based on severl clinical and biological parameters.
224015884|NCT04207177|DRUG|Mycophenolate Mofetil 500 mg Tab|Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
224015885|NCT04207177|DRUG|Tacrolimus capsule|Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
224015886|NCT06900894|BIOLOGICAL|Platelet-Rich Fibrin (PRF)|PRF was prepared using a centrifugation protocol and applied to the extraction socket.
224015887|NCT06900894|DEVICE|Kinesio Taping|Kinesio Tape was applied postoperatively to the masseter and submandibular region.
224015888|NCT06900894|OTHER|Standard Postoperative Care|Patients in the control group received standard postoperative care.
224015889|NCT01551459|DRUG|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
224015890|NCT01551459|DRUG|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
224015891|NCT02818959|DEVICE|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
224015892|NCT05939856|OTHER|Lymph node dissection before bladder resection|Lymph node dissection before bladder resection
224015893|NCT05939856|OTHER|Lymph node dissection after bladder resection|Lymph node dissection after bladder resection
224015894|NCT06906068|DIETARY_SUPPLEMENT|Three strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®|A probiotic beverage (98 g) at dose of 50.10\^9 CFU, taken once daily for 14 weeks.
224015895|NCT06906068|OTHER|Placebo|Non fermented beverage (98 g) with no probiotic strains, taken once daily for 14 weeks.
223396634|NCT00874575|DIETARY_SUPPLEMENT|Vitamin D|
223396635|NCT00874575|DIETARY_SUPPLEMENT|Beta-hydroxy-Beta-methylbutyrate|
223396636|NCT00874575|DRUG|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
224015896|NCT06906146|DEVICE|CRET therapy|Capacitive Resistive Electric Transfer (CRET) therapy is a treatment modality that applies high-frequency electrical currents to stimulate tissue regeneration, enhance blood circulation, and reduce muscle pain. It operates through two modes: the capacitive mode, which targets superficial tissues such as skin and muscle, and the resistive mode, which penetrates deeper structures like tendons, ligaments, and joints. This technique is widely used in rehabilitation, sports physiotherapy, and pain management to accelerate muscle recovery and optimize neuromuscular function.
224015897|NCT06906146|DEVICE|Sham CRET Therapy|Same as CRET therapy but in a aham form.
224015898|NCT06905912|DEVICE|Biomedics55 Premier contact lenses, and Altius Tinted Contact Lenses|Biomedics55 Premier contact lenses, and Altius Tinted Contact Lenses
224015899|NCT06906952|PROCEDURE|robotic natural orifice specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Then the rectal stump was incised and disinfected with iodophor, the protective sleeve was placed into the abdominal cavity through the assistant hole. An assistant delivered oval forceps into the pelvic cavity through the anus and used oval forceps to grip one end of the protective sleeve. Then slowly pulled out the protective sleeve. Eventually, one end of the protective sleeve was placed inside the abdominal cavity and the other outside the anus, completely covering the rectal stump and the perianal area. Tumor was pulled out of the rectal stump, then the colon was then disconnected at 10 cm above the tumor. The anvil was placed into the stump of the sigmoid colon and disinfected with iodophor, and then the anvil was delivered into the abdominal cavity. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon.
223396637|NCT04636775|DIAGNOSTIC_TEST|Microbiome|Nasal and buccal swabs, and stool sample, as well as the extracted DNAs
223396638|NCT04746287|DRUG|CKD-510 single dose|Investigational drug
223396639|NCT04746287|DRUG|CKD-510 food effect|Investigational drug
223396640|NCT04746287|DRUG|CKD-510 multiple dose|Investigational drug
223550247|NCT03501992|BEHAVIORAL|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
223396641|NCT04746287|DRUG|Placebo|Matching placebo
223396642|NCT05408299|BIOLOGICAL|Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)|Vaccination
223550248|NCT03501992|BEHAVIORAL|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
223550249|NCT03501992|BEHAVIORAL|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff-nurses, medical secretaries, receptionists, and clinical assistants-regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
223550250|NCT03501992|BEHAVIORAL|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
223550251|NCT03941873|DRUG|Sitravatinib|Administered orally as a capsule
223550252|NCT03941873|DRUG|Tislelizumab|Administered intravenously
224015900|NCT06906952|PROCEDURE|robotic transabdominal specimen extraction surgery|After the rectum and its mesorectum were dissociated, the rectum was transected at 2 cm below the tumor by using a linear stapler. Take a 6cm incision through the rectus abdominis muscle in the lower left abdomen and place an incision protective cover. Cut off the intestinal tube 10cm from the upper edge of the tumor and place a stapler base. The rectal stump was sutured with purse-string suture. Place a circular stapler through the anus for end-to-end anastomosis of the rectum and sigmoid colon. After completion of digestive tract reconstruction. The pelvic and abdominal cavities were washed repeatedly with normal saline until there were no blood remained. Close the abdominal cavity layer by layer.
224015901|NCT04198753|DIAGNOSTIC_TEST|Skin tape stripping|Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
224015902|NCT04198753|DEVICE|Skin barrier assessment|A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
224015903|NCT04198753|DIAGNOSTIC_TEST|Blood draw|Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
224015904|NCT06905899|OTHER|audiobook app|audio book listening
224015905|NCT06906653|BEHAVIORAL|Augmented Initial Type 2 Diabetes Care|"The intervention will include 4 components: 1) Making primary care providers (PCPs) aware that the patient has been selected to receive Augmented Initial Type 2 Diabetes (T2D) Care, 2) encouraging early care manager outreach to establish care, ensure prescribing of appropriate medications, and support medication adherence, 3) a one-on-one virtual health educator visit to reinforce self-management education and ensure set-up of remote glucose monitoring or continuous glucose monitoring (if eligible), and 4) a one-on-one virtual nutrition visit to provide individualized counseling."
224015906|NCT06906159|DIETARY_SUPPLEMENT|Cricket protein|Muffins made with cricket-derived protein from house crickets (Acheta domesticus )
224015907|NCT06906159|DIETARY_SUPPLEMENT|Whey protein|Muffins made with whey protein
224128314|NCT05913960|DEVICE|accelerated intermittent theta burst stimulation|"Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
224128315|NCT05913960|DEVICE|high frequency stimulation|"Participants in the active stimulation group will receive the high frequnency stimulation to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.~Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system."
224015908|NCT06905977|DEVICE|pentacam|we will follow up on cases of thick cornea with high back elevation
224128316|NCT03140930|DIETARY_SUPPLEMENT|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
223550253|NCT04876404|DIAGNOSTIC_TEST|PET/MR Imaging|The hybrid PET/MR scanner can provide information on brain activity during various motor and cognitive tasks.
223550254|NCT05832606|OTHER|Food box containing 30 different plants|Food boxes during first 12 weeks of therapy. Clinical follow-up until end of immunotherapy.
223550255|NCT02092636|OTHER|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
224015909|NCT06906666|OTHER|Athletes sample|Elite athletes in whom the risk of injury will be calculated and the influence of confounding factors will be assessed through a personal interview.
224015910|NCT06906445|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
224015911|NCT06906445|OTHER|Anti-Inflammatory Diet|The modified diet plan will be given to each study participant
224015912|NCT06906445|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
224015913|NCT06906445|OTHER|Sham Diet|Dietary counselling alone
224015914|NCT06906445|OTHER|Advanced Therapy|Advanced therapy as standard dose and schedule
224015915|NCT06907394|OTHER|Osteopathic Manipulations|Osteopathic Manipulations (a. Myofascial release technique: Direct scar release+ Indirect scar release 'Fascial unwinding'; b. Grand Maneuver; Visceral manipulations of uterus
224128317|NCT03140930|DIETARY_SUPPLEMENT|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
224128318|NCT03140930|DIETARY_SUPPLEMENT|Placebo duodenal|Duodenal infusion of placebo (tap water)
223396643|NCT05071599|DEVICE|Twin Arch Brackets|Twin Arch Brackets characterized by double horizontal slots which make it capable to accept two arch wire at the same time which in turn can achieve a better control over orthodontic tooth movement
223396644|NCT01160692|DIETARY_SUPPLEMENT|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
223396645|NCT01160692|OTHER|Placebo|Daily oral intake of matching placebo tablets for 3 months
223731201|NCT03295578|OTHER|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
224015916|NCT06907394|OTHER|Control Group|Paracetamol tablets
224015917|NCT06907264|DEVICE|Wearable ECG Garment for Continuous Atrial Fibrillation Screening and Stroke Risk Assessment|This intervention utilizes a wearable ECG garment, a non-invasive, textile-based device for continuous 24-hour ECG monitoring. The garment features embedded electrodes to capture heart rate, rhythm, HRV parameters (e.g., SDNN, RMSSD, LF/HF), and P-wave indices (e.g., P-wave duration, PtfV1), enabling comprehensive assessment of atrial fibrillation (AF) and stroke risk. The device is lightweight, comfortable, and supports wireless data transmission to the cloud for real-time analysis. The study incorporates machine learning algorithms to identify AF patterns and explore stroke risk predictors, targeting individuals aged 40+ at high stroke risk. It also evaluates device acceptability and usability, aiming to improve AF detection rates, enable early intervention, and reduce stroke risk.
224015918|NCT00484107|DRUG|Conjugated Estrogen Cream (Premarin®)|
224015919|NCT06524765|OTHER|Living conditions|There are many patients with multi-resistant bacterial infections in intensive care units (ICU), making it possible for a great deal of these pathogens to exist in the ICU environment. The exposure factors in this study were ICU environment or daily living environment.
224015920|NCT03236987|DRUG|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
224015921|NCT03236987|DRUG|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
224015922|NCT03236987|DRUG|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
224015923|NCT03236987|DRUG|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
224015924|NCT03992846|DRUG|75 mg linzagolix tablet|For oral administration once daily
224015925|NCT03992846|DRUG|200 mg linzagolix tablet|For oral administration once daily
224015926|NCT03992846|DRUG|Add-back capsule (E2 1 mg / NETA 0.5 mg)|For oral administration once daily
224015927|NCT03992846|DRUG|Placebo tablet to match 75 mg linzagolix tablet|For oral administration once daily
224015928|NCT03992846|DRUG|Placebo tablet to match 200 mg linzagolix tablet|For oral administration once daily
224015929|NCT03992846|DRUG|Placebo capsule to match Add-back capsule|For oral administration once daily
224015930|NCT02708654|BEHAVIORAL|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
224015931|NCT02708654|BEHAVIORAL|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
224015932|NCT02708654|BEHAVIORAL|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
224015933|NCT02708654|BEHAVIORAL|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
224015934|NCT05353946|DEVICE|Percutaneous coronary intervention (PCI)|Optimal stent expansion by IVUS-guided PCI.
224015935|NCT05444569|DRUG|LY3537021|Administered SC.
224015936|NCT05444569|DRUG|Liraglutide|Administered SC.
224015937|NCT05444569|DRUG|Placebo|Administered SC.
224015938|NCT02956785|DRUG|10 mg Dinoprostone; CTS, UK|
224015939|NCT02956785|DRUG|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
224015940|NCT02956785|DRUG|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
224015941|NCT04714931|DIAGNOSTIC_TEST|Sentinel lymph node detection|Tracer (Indocyanine green or blue dye) will be injected into the IP and utero-ovarian ligaments, after opening of the pelvic and paraaortic retroperitoneal spaces, sentinel lymph nodes which can be identified with the tracer involvement will be removed. Then, systematic lymphadenectomy will be performed according to the routine practice.
224128319|NCT03140930|DIETARY_SUPPLEMENT|Placebo ileal|Ileal infusion of placebo (tap water)
224128320|NCT01569425|OTHER|Dietary intervention|High Calorie breakfast and high calorie dinner
224128321|NCT01173796|PROCEDURE|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
223396646|NCT04967820|OTHER|resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak
223731202|NCT03295578|OTHER|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
223731203|NCT03295578|DEVICE|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
223731204|NCT01260285|DRUG|Vardenafil|10 mg PO once
223396647|NCT06012344|OTHER|post facilitation stretch|PFS Post-Facilitation Stretch Participants in this arm received the intervention of post-facilitation stretch technique. Post-facilitation stretch involves the application of manual stretching techniques to the targeted muscles after a facilitation phase, which aims to enhance muscle extensibility. The participants underwent a standardized post-facilitation stretch protocol focusing on the hamstring muscles.
223396648|NCT06012344|OTHER|post isometric relaxation|Participants in this arm of the study received the intervention of post-isometric relaxation technique. Post-isometric relaxation involves the application of isometric contraction followed by a relaxation phase to promote muscle lengthening and improve flexibility. The participants underwent a standardized post-isometric relaxation protocol targeting the hamstring muscles.
223396649|NCT06012344|OTHER|hamstring nordic lower|Participants in this arm received the intervention of hamstring Nordic lower exercise. The hamstring Nordic lower exercise is a challenging eccentric exercise that specifically targets the hamstring muscles. Participants performed the exercise under supervision and followed a standardized protocol for the number of repetitions, sets, and rest intervals.
223396650|NCT05986604|BEHAVIORAL|Memory Support Intervention|The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. The memory support strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
223396651|NCT05986604|BEHAVIORAL|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|TranS-C aims to provide one protocol to treat a range of sleep and circadian problems because sleep and circadian problems are often not so neatly categorized and because the existing research provides few guidelines to treat more complex patients.
223396652|NCT03105908|BEHAVIORAL|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
223396653|NCT03105908|BEHAVIORAL|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
223396654|NCT05370950|DRUG|SHR-1209|SHR-1209，single subcutaneous injection of 450mg
223396655|NCT02059135|BIOLOGICAL|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
223396656|NCT02059135|OTHER|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
223396657|NCT03115437|OTHER|Hard cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by hard cushioning.
223396658|NCT03115437|OTHER|Soft cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by soft cushioning.
223731205|NCT03886233|DRUG|Corticosteroid Series|immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
223731206|NCT03146715|OTHER|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
224015942|NCT01924728|DEVICE|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
224015943|NCT01924728|DEVICE|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
224015944|NCT03542370|OTHER|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
224015945|NCT03618121|DEVICE|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
224128322|NCT01173796|PROCEDURE|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
224128323|NCT03159377|DEVICE|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
223731207|NCT03070782|DRUG|ISIS 681257|ISIS 681257 solution for SC injection.
223731208|NCT03070782|DRUG|Placebo|Sterile normal saline (0.9% NaCl)
223731209|NCT01083576|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
223731210|NCT01083576|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
224128324|NCT06297850|DEVICE|Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)|A CGM device placed on the posterior aspect of the upper arm in which a sensor placed in the skin registers glucose values. Via Bluetooth, these readings are sent to a receiver near the patient every 5 minutes. The CGM system can alert when deviating glucose levels, but will for this observational study be blinding to patients and clinical staff. Thus, the patients' diabetic care will rely on standard practice.
224128325|NCT05329987|OTHER|Rehabilitation|Intervention focused on balance, gait and postural transfers rehabilitation. 20 session of 90 minutes (60 minutes of physiotherapy and 30 minutes of occupational therapy), 2 times a week, for 10 weeks.
224128326|NCT05632458|DEVICE|Thrombectomy|Thrombectomy using double stent retriever vs thrombectomy using single stent retriever.
224296541|NCT04766736|PROCEDURE|Quantification of netrin-1 signals by antibody-based approaches|Samples have been obtained upon curative surgery without any other therapy administered and subsequently characterized by pathologists after FFPE inclusion.
223396659|NCT00779935|BIOLOGICAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
223396660|NCT01169064|DEVICE|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
224015946|NCT03618121|DEVICE|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax \& Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
224015947|NCT03618121|BEHAVIORAL|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
224015948|NCT03618121|BEHAVIORAL|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
224015949|NCT01574391|DEVICE|Epidrum|Epidrum is used
224015950|NCT04183309|OTHER|Measure the transpulmonary pressure in pediatric patients|Esophageal pressure will be measured by an esophageal ballon to assess transpulmonary pressure during laparoscopy surgery. Lung collapse will detected when transpulmonary pressure became negative and using lung ultrasound images. Lung ultrasound examinations will be performed at different times-points: after anesthesia induction, 10 minutes after pneumoperitoneum insufflation, and at the end of surgery. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery.
224015951|NCT04058366|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
223396661|NCT01169064|DEVICE|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
223396662|NCT04900259|BEHAVIORAL|COVID-19 pandemic|Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
224015952|NCT04058366|DRUG|IVA|Tablet for oral administration.
224015953|NCT02466750|BIOLOGICAL|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
224015954|NCT05971459|BEHAVIORAL|Improvised Active Music Therapy|During the music improvisation process, the accredited music therapist will carefully listen to the participant's initial musical expression, including tempo, rhythmic structure, dynamics, and beat. The accredited music therapist will then join, reflecting or confirming aspects of the participant's musical expression using standard music therapy improvisation techniques such as mirroring, matching, dialoguing, and containing on their electronic instrument. By comparing the participant's and therapist's musical responses over the sessions, it will be possible to identify note frequency, velocity of movement, synchronization, and acquisition of rhythmic complexity.
224015955|NCT00817973|DIETARY_SUPPLEMENT|Casein|
224015956|NCT00817973|DIETARY_SUPPLEMENT|Whey|
224015957|NCT00817973|DIETARY_SUPPLEMENT|Cod|
224015958|NCT00817973|DIETARY_SUPPLEMENT|Gluten|
224015959|NCT00734383|DRUG|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
224128327|NCT05847244|DRUG|Metformin|The intervention will consist in giving metformin starting with 500 mg once daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner)
223396663|NCT04287660|DRUG|clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells|"* clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function."
223396664|NCT01454323|OTHER|Bone marrow mononuclear cells|Intracoronary infusion of autologous bone marrow-derived mononuclear cells
223396665|NCT06968026|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|The eligible participants will undergo an intensity sweep consisting of six stimulation trains over the right dorsolateral prefrontal cortex (DLPFC), with stimulation intensities ranging from 100% to 150% of the individual resting motor threshold (RMT), increasing in 10% increments. Each train will last 60 seconds, comprising 40 seconds of active rTMS at 1 Hz and a 20-second intertrain interval (ITI). Synchronous electrocardiogram (ECG) data will be continuously recorded throughout the entire procedure.
223396666|NCT06968286|PROCEDURE|SRP|participants with periodontitis treated with scaling and root planning
223396667|NCT06968286|PROCEDURE|SRP+Injectable platelet rich fibrin|The iPRF will be prepared by the same operator according to the protocol developed by Miron and Choukron in 2017. It involves collecting 10 mL of intravenous blood from the participant using venipuncture of the antecubital vein under sterile conditions. The collected blood is transferred to a plain sterile test tube without anticoagulant and immediately subjected to centrifugation at 70-g force at 700 rpm for 3 minutes. After centrifugation, the blood separates into two parts: the bottom layer consists of a red blood cell compartment, and the top layer is platelet-rich fibrin plasma, which is still in liquid consistency. The top platelet-rich fibrin layer is aspirated into a 2-mL syringe and locally delivered in to the periodontal pocket
223550256|NCT02092636|OTHER|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
223731211|NCT04237441|OTHER|number of participants with surgical complications|observation before and after multidisplinary team conference (MDT) was implemented
224128328|NCT03832920|OTHER|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
224128329|NCT03664284|PROCEDURE|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
224015960|NCT00734383|DRUG|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
224015961|NCT06236659|DIETARY_SUPPLEMENT|Consumption of three different doses of hydrolyzed collagen (HC) with resistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
224015962|NCT06236659|DIETARY_SUPPLEMENT|Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each intervention lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All interventions were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of dietary supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
224015963|NCT05079451|DRUG|3BNC117-LS|3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
224015964|NCT05079451|DRUG|10-1074-LS|10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
224015965|NCT02751411|DEVICE|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
224015966|NCT02751411|DRUG|Macrogol 4000|Stool softener
224015967|NCT05596058|OTHER|dual task protocol: active exercises with concomitant cognitive training in executive functions|"The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises."
224015968|NCT05596058|OTHER|active exercise|Physical activity and motor task only
224015969|NCT05596058|OTHER|cognitive task only|cognitive exercise in executive functions
224015970|NCT00534144|DRUG|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
224015971|NCT00534144|DRUG|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
224015972|NCT05834439|OTHER|flower printing activities for the elderly|Experimental group
224015973|NCT05834439|OTHER|Routine activities in nursing home|Control group
224015974|NCT06014840|OTHER|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD|Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
224015975|NCT04929405|BEHAVIORAL|ADAPT|ADAPT, is multi-modal to promote a targeted approach to individual parental bereavement experiences and is not time or geographically limited. ADAPT is based on the theoretical foundations of the Adaptive Leadership (AL) framework. Our interdisciplinary team developed a web-based, multi-modal intervention, labeled ADAPT, that incorporates varied self-management strategies including: A: Asking for assistance (option to connect with child's healthcare team); DA: Developing Adaptive ability (self-management tools: e.g. stress reduction, legacy building); P: Accessing Pertinent online resources (grief support networks/websites); and T: Tracking one's health (self-administered surveys for grief, sleep, anxiety, and depression). Parents can download ADAPT on any digital device (phones/computers) using a Quick Response (QR) bar code or weblink.
224015976|NCT03505034|DRUG|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1\*10\^6 cells/kg, once a month for 4 months
224015977|NCT04476368|OTHER|weekly yoga classes|Weekly 90 min pregnancy-adapted yoga classes lead by certified yoga instructors.
224015978|NCT04476368|OTHER|walk|20-30 min easy walking
224015979|NCT02747641|PROCEDURE|Pixel CO2 Laser System|
224015980|NCT03284801|OTHER|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
224015981|NCT03056027|DIAGNOSTIC_TEST|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
224015982|NCT00607347|OTHER|Glucose|Oral Glucose Tolerance Test
224128330|NCT02561416|BEHAVIORAL|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
224296542|NCT00709839|DRUG|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
224296543|NCT00709839|DRUG|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
224015983|NCT00641901|BEHAVIORAL|counseling|"The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires."
224015984|NCT01074918|DRUG|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
224015985|NCT01074918|DRUG|Potassium Chloride|Potassium Chloride
224015986|NCT00734097|DRUG|Esomeprazole 40 mg|Once a day
224128331|NCT02561416|BEHAVIORAL|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
224015987|NCT00734097|PROCEDURE|Physical Exam|every visit
224015988|NCT00734097|OTHER|Quality of Life Questionnaires|every visit
224015989|NCT00734097|PROCEDURE|pregnancy test, if applicable|as needed
224015990|NCT05478850|PROCEDURE|radiotherapy under anesthesia|Body temperature change will be investigated before the procedure and during recovery in Radiotherapy patients who need anesthesia due to childhood malignancies.
224015991|NCT01946763|BEHAVIORAL|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
224015992|NCT01946763|BEHAVIORAL|pre operative education|
224015993|NCT02512367|OTHER|Dental care education program|Dental care education program
224015994|NCT02512367|OTHER|Surveillance|Surveillance
224015995|NCT00098332|DRUG|forodesine hydrochloride|
223396668|NCT06968286|PROCEDURE|SRP+ciprofloxacine loaded iPRF|"The concentration of the ciprofloxacin drug to be loaded in iPRF will be decided based on the study of Murugan et al., 2024. According to their study, 1 mg/mL of the drug concentration will be found to be biocompatible with maximum efficacy and showed a sustained release of 59% of the loaded drug at the end of the 14-day observation. 1 mg of the drug will be weighed and mixed with 100 μL of deionized water and shaken for 30 seconds to make the drug completely soluble, which will be done just before the blood collection from the participants. Then, 900 μL of the obtained i-PRF will be dispensed in a vial containing a 1-mg/100 μL solution of ciprofloxacin and shaken gently for 10 seconds to obtain a homogenous mix with a final concentration of 1 mg/mL.~This mixture will further immediately loaded in a 1-mL insulin syringe and injected into the periodontal pocket until it filled the pocket"
223396669|NCT04584801|DEVICE|Structured Light Plethysmography|"Development Phase (Original Part A): Participants will have two 5-minute SLP measurements (Pre and Post bronchodilator).~Participants will also undergo standard of care spirometry assessment"
223396670|NCT03548818|DRUG|Interferon Gamma-1B|Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.
223396671|NCT03939702|DRUG|BMS-986177|An orally administered anticoagulant to prevent and treat thromboembolic events
223396672|NCT06320340|OTHER|Exercise|the patients were performed following five exercises for 20 minutes of treatment session two days a week for the 8 weeks.: (1) the swan-dive vol. I, (2) the swan-dive vol II., (3) breast stroke preparation vol. I, (4) breast stroke preparation vol. II, and (5) swimming vol. II. All the exercises were repeated for the 10 times in a session. Before the exercises, patients were taught and instructed about the five key elements (lateral expansion, centralization, positioning the chest, the shoulder girdle, and the head) of clinical pilates that they should pay attention to while performing the exercises. In addition, verbal and tactile feedbacks were given to patients during all the treatment sessions to maintain the good posture and to perform exercises properly.
224015996|NCT02540928|DRUG|AMG 319 hydrate|
224015997|NCT02540928|DRUG|Placebo|
224015998|NCT06135428|OTHER|Education Group|"Training content was prepared in three stages according to the resilience model in midwives. The training will be in the form of 45-minute presentations and sharings, and individual studies will be carried out in the form of homework according to people's methods of coping with stress. These homework assignments may occasionally include more or less individual meetings depending on the person's coping situation. However, at least 3 meetings will be held. Training and interviews will be conducted by researchers. For this, at least one of the researchers will receive training including personal awareness and motivational interviews."
224015999|NCT01553773|DRUG|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
224016000|NCT01553773|DRUG|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
224016001|NCT06408480|DIAGNOSTIC_TEST|Neonatologist-performed lung ultrasound|lung ultrasound conducted in min 5, 15, 30, 60 min after birth in late preterm and term infants
224016002|NCT02609347|OTHER|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
224016003|NCT02609347|OTHER|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
224016004|NCT03566446|BIOLOGICAL|CALRLong36 peptide|200 ug CALRLong36 peptide in water mixed with 500ul montanide
224128332|NCT02561416|DRUG|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
224128333|NCT03568539|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks.
224296544|NCT03011736|OTHER|Laboratory Biomarker Analysis|Correlative studies
224016005|NCT05198011|PROCEDURE|3D customized Titanium Mesh (Study)|approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.
224016006|NCT05198011|PROCEDURE|Conventional ridge augmentation (Control)|the conventional technique of ridge augmentation using Titanium Mesh
224016007|NCT01764685|DRUG|Topiramate|Max therapeutic dose of 150mg/day
224016008|NCT01764685|BEHAVIORAL|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
223396673|NCT06320340|OTHER|Electrotherapy|Two channels of four-channelled Compex SP Fit-3 (MediCompex SA in Geneva, Switzerland) was used to apply NMES (120 mA, 400 μs, 150 Hz) on lower trapezius and serratus anterior muscles for 20 minutes during exercise.
223396674|NCT03516695|DEVICE|TheraSphere®|Intra-arterial Yttrium-90 glass microspheres
224016009|NCT01764685|DRUG|Placebo|Placebo
224016010|NCT06015828|DIETARY_SUPPLEMENT|bovine lactoferrin|Neonates will receive a daily dose of 150 mg/kg body weight per day (up to a maximum of 300 mg/day) of bovine lactoferrin and will be prepared for administration by addition by syringe of sterile water (4 mL) orally or through gavage feeding, once the infant's enteral feed volume is more than 12 mL/kg per day until 36 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer.
224016011|NCT04619979|PROCEDURE|patients undergoing gynecological surgery under general anesthesia|patients undergoing gynecological surgery under general anesthesia
224016012|NCT03013153|PROCEDURE|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
224128334|NCT05526170|DEVICE|Devices for long-term monitoring of objective and subjective parameters of the body|Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
224296545|NCT03011736|PROCEDURE|Parathyroidectomy|Undergo parathyroidectomy
223396675|NCT03837054|BIOLOGICAL|Blood collection and Micronuclei assay on binucleate lymphocytes in culture|"The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures."
223396676|NCT05511870|DRUG|Etripamil Nasal Spray 70mg|Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223396677|NCT05511870|DRUG|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
223396678|NCT01047384|PROCEDURE|acupuncture-moxibustion therapy|
223396679|NCT01047384|PROCEDURE|Regular therapy|
223396680|NCT00789854|DRUG|Quetiapine XR|300 mg once daily (od)
223396681|NCT00789854|DRUG|Lithium carbonate|900 mg once daily (od)
223396682|NCT00789854|DRUG|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
223396683|NCT06476990|BEHAVIORAL|Healthy food box|All participants received 12 weekly deliveries of food containing approximately $8 worth of shelf-stable food items purchased from a local food bank (beans, canned vegetables and no-sugar added fruit, shelf-stable dairy products, canned tuna, and whole grains) and $25 of fresh produce (5-7 items including leafy greens, peppers, potatoes, broccoli, carrots, zucchini, cauliflower, celery, cabbage, asparagus, apples, or strawberries). When seasonably available, fresh vegetables and fruit were sourced from local farmers via a local food hub. In addition to food, participants in the Food + CHW group also received 7 weekly virtual sessions with a CHW (four 90-minute ZOOM counseling sessions and three 30 to 60-minute check-in phone calls). CHW sessions included diabetes-appropriate cooking and nutrition education and personalized benefit enrollment and linkage to existing food access resources (for example SNAP, Double up Food Bucks, and Kansas Senior Farmers Market Vouchers).
224016013|NCT03013153|PROCEDURE|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
224128335|NCT05480787|DRUG|Remimazolam 0.1mg/kg/h|Remimazolam Tosilate for Injection(36mg)
223396684|NCT03972904|DIETARY_SUPPLEMENT|Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
224016014|NCT01750203|OTHER|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
224016015|NCT02233543|DRUG|QVA149|Delivered once daily via single-dose dry powder inhaler
224016016|NCT02233543|DRUG|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
224016017|NCT00447655|BEHAVIORAL|Self-management and peer support|
224016018|NCT01446757|PROCEDURE|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
224016019|NCT01446757|PROCEDURE|control group|No intervention
224016020|NCT00347607|BEHAVIORAL|community surveillance and re-treatment|
224016021|NCT00561366|DRUG|Placebo|Placebo t.i.d.
224016022|NCT00561366|DRUG|Arimoclomol|capsule, 400 mg t.i.d.
224016023|NCT05233332|DRUG|HL-085|12mg BID HL-085
224016024|NCT05233332|DRUG|Vemurafenib|720mg BID Vemurafenib
224016025|NCT02984202|DEVICE|auditory midbrain implant (AMI)|
224016026|NCT00603304|DRUG|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
224016027|NCT00603304|DRUG|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
224016028|NCT00603304|DRUG|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
224016029|NCT00603304|DRUG|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
224016030|NCT00603304|DRUG|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
224016031|NCT00603304|DRUG|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
224016032|NCT05077644|DEVICE|Stella (TM) Mobile Application|Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
224016033|NCT06034418|DEVICE|Pulse radiofrequency treatment|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, pulse radiofrequency will be applied to each nerve in 2 cycles of 120 seconds for the patients in this group. The pulse radiofrequency current will be 20 milliseconds wide and 45 volts in size. The tip temperature shall not be more than 42℃.
224016034|NCT06034418|DRUG|Nerve block with 1 cc betamethasone and 1 cc 1% lidocaine|In the procedures to be performed under fluoroscopy, vascular structures will be detected primarily by ultrasonography for safety purposes. A standard RF device will be used for the process. A 22-gauge and 10 cm straight radiofrequency cannula with 1 cm active tip will be used. For each nerve, sensory stimulation will be performed at 50 Hz and the patient will be expected to feel numbness and tingling with a maximum 0.7 V. Motor stimulation will be at 2 Hz and no muscle contraction up to 2 V is expected. Following the appropriate cannula placement, patients will be injected with 1 cc betamethasone and 1 cc 1% lidocaine for each nerve. A total of 2 cc volume will be injected for each nerve.
224016035|NCT06471777|PROCEDURE|Fluid removal|Fluid removal during kidney replacement therapy
224128336|NCT05480787|DRUG|Remimazolam 0.3mg/kg/h|Remimazolam Tosilate for Injection(36mg)
224128337|NCT05480787|DRUG|Remimazolam 0.5mg/kg/h|Remimazolam Tosilate for Injection(36mg)
224016036|NCT00616902|DRUG|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
224016037|NCT00616902|DRUG|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
224016038|NCT01483547|DEVICE|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
224128338|NCT00000748|DRUG|Sulfamethoxazole-Trimethoprim|
224128339|NCT02909673|BEHAVIORAL|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
224128340|NCT02666092|OTHER|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
224128341|NCT02666092|BIOLOGICAL|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
224296546|NCT05174117|COMBINATION_PRODUCT|single irradiation|46-48h irradiation after photosensitizer injection: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2
223396685|NCT03972904|DIETARY_SUPPLEMENT|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
223396686|NCT00167011|PROCEDURE|CT|
223396687|NCT05578261|DEVICE|intermittent theta burst stimulation|stimulatory protocol
223396688|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
223396689|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
223396690|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
223396691|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
223396692|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
223396693|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus half dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.
223396694|NCT06560151|BIOLOGICAL|3.75 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
223396695|NCT06560151|BIOLOGICAL|7.5 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
223396696|NCT06560151|BIOLOGICAL|15 µg H5N8 antigen plus MF59|Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.
223396697|NCT06560151|BIOLOGICAL|3.75 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
223396698|NCT06560151|BIOLOGICAL|7.5 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
224016039|NCT05851703|OTHER|Manual therapy application|"In lower cervical lateral flexion problems, pushing technique will be applied with instrument support from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, instrument-assisted pushing technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present."
224016040|NCT05851703|OTHER|Proprioceptive Neuromuscular Facilitation|With the rhythmic initiation technique, it is to teach the movement to the person, to improve the feeling of movement, coordination and to help relaxation. With rhythmic initiation, we want the patient's initial passive and then active participation to understand the movement, the direction and rhythm of the movement. After people actively participate, they can use active joint movement.
224016041|NCT03573583|BEHAVIORAL|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
224016042|NCT03573583|BEHAVIORAL|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
223396699|NCT06560151|BIOLOGICAL|15 µg H5N1 antigen plus full dose AS03A|Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
223396700|NCT05067556|BEHAVIORAL|Acceptance and Commitment Therapy for chronic pain (ACT-CP)|Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.
223396701|NCT06585176|OTHER|No intervention|This concerns a natural history study. No interventions will be used.
223396702|NCT00923013|DRUG|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour intravenous (i.v.) infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the principal investigator (PI).
223396703|NCT00923013|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenous (i.v.) infusion every week x8, begin day 1 in half of randomized patients and in all hairy cell leukemia variant (HCLv) patients, and then again in all patients at least 6 months later when hairy cell leukemia (HCL) is detected by blood fluorescence-activated cell sorting (FACS).
223396704|NCT00923013|PROCEDURE|BMbx|Baseline and week 5.
223396705|NCT00923013|DIAGNOSTIC_TEST|MRI|Baseline and week 5.
223396706|NCT00923013|DIAGNOSTIC_TEST|EKG|Baseline and week 5.
223396707|NCT00923013|DIAGNOSTIC_TEST|Echocardiogram|Baseline.
223396708|NCT00923013|DIAGNOSTIC_TEST|Abdominal/splenic ultrasound|Baseline and week 5.
223396709|NCT00923013|PROCEDURE|Stress test|Baseline.
223396710|NCT06524739|BIOLOGICAL|IgPro20|IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration
223396711|NCT06524739|BIOLOGICAL|Placebo|2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
223396712|NCT06585254|DEVICE|Transcutaneous vagus nerve stimulator|A device attached to the tragus of the ear which when activated stimulates an ascending branch of the vagus nerve
223396713|NCT04512378|BEHAVIORAL|Behavioural Experiments for Intolerance of Uncertainty|Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
223396714|NCT05768854|DRUG|Bisphosphonate|Administered per investigator discretion via intravenous (IV) infusion
223396715|NCT05768854|BIOLOGICAL|Setrusumab|A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
223550257|NCT02092636|OTHER|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
223550258|NCT05168371|BEHAVIORAL|Cognitive-Behavioural Therapy - Online (CBT-O)|"Face-to-face CBT was adapted for web-based self-directed therapy. CBT-O was found to be feasible and usable (Stephenson et al., 2021; Zippan et al., 2020).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to CBT; 2) The cognitive model and thought records; 3) Unhelpful thinking patterns; 4) Cognitive restructuring; 5) Behavioral experiments; 6) Self-touch and sensate focus; 7) Sensate focus with your partner; and 8) Maintaining (and extending) your gains."
223550259|NCT05168371|BEHAVIORAL|Mindfulness-Based Therapy - Online (MBT-O)|"The content of MBT-O was adapted from an efficacious face-to-face mindfulness intervention for women with Sexual Interest/Arousal Disorder (Brotto et al., 2021; Paterson et al., 2017). MBT-O was found to be feasible and usable (Brotto et al., under review).~Each of the eight modules has between-module activities to complete. The eight modules are: 1) Psychoeducation, introduction to mindfulness; 2) Increasing awareness of physical sensations in the body; 3) Exploring movement and body image; 4) Awareness of sexual thoughts and beliefs; 5) Working with aversion, self-touch; 6) Exploring sexual sensations, knowing limits; 7) Integrating the partner into mindful touching; and 8) Maintaining (and extending) your gains."
223550260|NCT04505644|DRUG|lidocaine patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
223550261|NCT04505644|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
223550262|NCT04505644|DRUG|IV saline infusion +Sham patch|received i.v. saline infusion +Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
223550263|NCT01575236|DEVICE|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
223550264|NCT01575236|DEVICE|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
223550265|NCT02033681|PROCEDURE|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
223550266|NCT02033681|PROCEDURE|Saline Solution|Saline solution is injected into the tissue as a placebo control.
223550267|NCT02905838|DEVICE|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
223550268|NCT02905838|DEVICE|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
223550269|NCT02415244|PROCEDURE|TEE|Spinal cord segments will be imaged using the TEE
223396716|NCT05122052|OTHER|Psychological session|Just before the oncology visit, each patient is invited to undergo a psychological session of 20-30 minutes. During the session with a psycho-oncologist the following tasks are addressed: 1) favor emotional expression identifying the most difficult issues to promote mechanisms of elaboration of living experiences; 2) offer a containment of intense emotions; 3) assess awareness of diagnosis and prognosis; 4) favor expression of fears of treatment expectancy; 5) favor expression of difficulties on the inability to cope with prior commitments after the disease; 6) assess family and friend network; 7) improve the patient medic communication and relationship. At the end of the session, the distress thermometer and ESAS-r scale are compiled together with the demographic characteristics. All outstanding issues that are relevant to the therapeutic plan are then discussed between the psychotherapist and the medic before the oncology visit together with delivery of the DT and ESASr scale result.
223550270|NCT04008303|PROCEDURE|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
223550271|NCT05824663|DRUG|HBM1020|Intravenous (IV) Administrations on Days 1 of each 21-day treatment cycle.
223550272|NCT00816010|BEHAVIORAL|telephone contact|for lifestyle and compliance counseling
223550273|NCT05891015|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)|Mindfulness Intervention for Emotional Distress (MIED) program provide standard audio instructions for mindfulness exercises, introduce the nature and law of anxiety, depression and other emotions, the source of anxiety, depression and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
224016043|NCT04682444|DRUG|Enisamium Iodide|Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
224016044|NCT04682444|DRUG|Placebo|Patients ingested placebo tablets after meal without chewing in the dose 0.5 g (2 tablets), 3 times a day, for 7 days.
224016045|NCT04004936|OTHER|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
223396717|NCT06620562|DRUG|Naltrexone/Bupropion|Patient randomized in the Neltrexone/Bupropion group will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release 8mg/90mg, up to 2 tabs twice a day (32mg/360mg) adjusted according to tolerance and side-effects to improve long-term use. Duration of therapy will be 24 months.
223396718|NCT06620562|DRUG|Placebo|Patient randomized in the placebo group will be started one month after surgery on a progressive numbers of matched placebo tablets up to 2 tabs twice a day. Duration of therapy will be 24 months.
223396719|NCT06975267|BEHAVIORAL|Norwegian version of Second Step Early Learning|"The interventions is a 28 weeks program divided into five themes. The themes are 1. Skills that promotes learning, 2. Empathy, 3. Managing emotions, 4. Friendship skills and problem solving, and 5. Transitioning to school.~The intervention consists of daily activities. The guidebook is a central part of the program and provides the kindergarten teachers with practical tools and activities to implement the program in everyday settings. The guidebook includes:~28 weekly themes: Each week introduces a new theme with related activities and discussion topics.~Brain-building games: Activities designed to strengthen children's cognitive skills and self-regulation.~Songs and music: Songs that reinforce the learning of social skills. Parent connections: Information sheets and activities to involve parents in their children's social-emotional development.~Puppet theatre: The use of hand puppets Dog and Snail to illustrate and discuss feelings and social situations."
223550274|NCT02565875|BEHAVIORAL|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
223550275|NCT02565875|BEHAVIORAL|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
223550276|NCT02565875|OTHER|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
223550277|NCT00418600|DRUG|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
223550278|NCT00418600|DRUG|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
223550279|NCT00418600|DRUG|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
223550280|NCT02866162|GENETIC|High-throughput exome sequencing|
223550281|NCT02982772|OTHER|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
223731212|NCT03343808|PROCEDURE|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
224016046|NCT04004936|OTHER|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
224016047|NCT00619333|DRUG|follitropin and lutropin|follitropin and lutropin
224016048|NCT01859273|BEHAVIORAL|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
224016049|NCT01800084|DEVICE|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
224016050|NCT03805347|DRUG|Helminthostachys zeylanica(L.)Hook|Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
224016051|NCT03805347|DRUG|Starch|Starch in capsule, 1gm/time, 3 times daily
224016052|NCT01295762|OTHER|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
224016053|NCT05612152|OTHER|Referral to Quitline|An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
223550282|NCT02982772|OTHER|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
223550283|NCT01720875|DRUG|Vorinostat Velcade Dexamethasone|
223550284|NCT01234480|DEVICE|BD SurePath Plus Pap test|BD SurePath Plus Pap test
223550285|NCT01234480|DEVICE|BD SurePath Pap test|BD SurePath Plus Pap test
223731213|NCT03527966|BIOLOGICAL|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
223731214|NCT03527966|BIOLOGICAL|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
224016054|NCT05612152|OTHER|Choose2Quit|An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
224016055|NCT00808054|DRUG|EMLA|0.5g topical EMLA
224016056|NCT03797261|DRUG|Venetoclax|tablet, oral
224016057|NCT03797261|DRUG|AMG 176|solution, intravenous
224128342|NCT03439748|BEHAVIORAL|Positive Affect Treatment|Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
223396720|NCT06975267|BEHAVIORAL|Free play|"Control kindergartens will have additional designated playtime consisting of free play for 28 weeks. The checklist for play conditions is defined as when: Time is set aside in the daily kindergarten routine where (1) it is clearly announced or signaled to the children that it is now free play, (2) it is an absence of requirements for sedentary sitting (unless it is part of the children's play), (3) it is not a situation where children are required to follow instructions (unless it is part of the children's play or general rules in the kindergarten (?)), (4) it is an absence of a pronounced learning outcome or goal with the activities available for the children (beyond what is defined by the children themselves), (5) the children can start and finish activities themselves, and choose what they want to participate in, and (6) adults can join in the game/initiate, but on the children's terms, and the children can choose to leave this game whenever they want."
223396721|NCT04333017|DEVICE|Percutaneous radiofrequency ablation of parietal endometriosis|Treatment is carried out under local anaesthesia after surgical asepsis, in interventional radiology room. Radiofrequency needles are inserted percutaneously under ultrasound guidance. Number of needles depends on the size of lesion (1 or 2 or 3 needles). In case of proximity between lesion and peritoneum, artificial ascites can be performed. Treatment is carried out in accordance with device's instructions for use (thyroid nodules treatment algorithm), with a gradual increase in power every 5 minutes, without exceeding the maximum authorised power (depending on number and length of needles). State of coagulation is monitored under visual ultrasound control of ablation area (diffusion of Co bubbles), until a decrease in effective power is obtained. Several ablation zones are performed on the same nodule with overlapping of the different impacts. An ice pack is applied to the treated area. An analgesic PO treatment of step 1 and/or 2 is prescribed for 5 days.
223396722|NCT02484716|DRUG|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
223396723|NCT02484716|DRUG|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
223396724|NCT03933904|DRUG|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
223396725|NCT06485622|PROCEDURE|open bypass group|After heparinization, the target artery is clamped above and below the anastomosis. The target artery is dissected along the anterior wall, calcium portions or mural thrombus are removed. Graft (autologous or prosthetic graft) is cut obliquely and anastomosis suturing starts with distal angle. Next stage is tunnel creating for graft conduction.
223396726|NCT06485622|PROCEDURE|bare metal stent group|Bare metal stent implantation during the index procedure.
223396727|NCT06485622|PROCEDURE|plain old balloon angioplasty group|Only plain old balloon was used during the index procedure.
223396728|NCT06485622|PROCEDURE|drug-coated balloon group|Drug-coated balloon was used during the index procedure.
223396729|NCT06485622|PROCEDURE|directional atherectomy group|Directional atherectomy (with or without drug-coated balloon) during the index procedure.
223396730|NCT06485622|PROCEDURE|hybrid repair group|Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery. Arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological). Endovascular revascularization followed.
223396731|NCT05458440|OTHER|Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors|The investigators aim to demonstrate that it is possible to implement a biobank of leucocytes from convalescent donors that could be used as raw material to generate anti-SARS COV-2 viral specific T cells. The protocol will be explained during hospitalisation for each donor. If they agree, they will be included before they leave hospital. Few weeks later, if they have no exclusion criteria, they will consult in the hemapheresis department of the Nancy University hospital. After medical exams, a whole blood bag and blood samples will be taken with the aim to establish a bank of cryopreserved human leucocytes as a raw material for the generation of a T-Lymphocyte immunotherapy.
223396732|NCT06460285|BEHAVIORAL|EmRes|There will be six, one hour, treatment sessions across nine weeks of emotional resolution therapy, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a licensed therapist.
223396733|NCT06460285|BEHAVIORAL|Mindfulness|There will be six, one hour, treatment sessions across nine weeks of a mindfulness intervention program, a post treatment assessment, and a follow up assessment three months later. The sessions will occur over zoom with a trained member of the study staff.
223396734|NCT05694260|DRUG|Bempedoic acid|Once daily oral dosing with oral tablets.
223396735|NCT04453436|DRUG|Tenofovir Disoproxil|Genotipic resistance test
223396736|NCT05385549|DRUG|Imatinib Mesylate|Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)
223396737|NCT02224157|DRUG|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
223396738|NCT02224157|DRUG|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
223396739|NCT01639157|DRUG|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
224016058|NCT05189873|DRUG|Long GnRH agonist + HRT|Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
223396740|NCT01639157|DRUG|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
223396741|NCT00002346|DRUG|Adefovir dipivoxil|
224016059|NCT05189873|DRUG|HRT|In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
224016060|NCT00667771|DRUG|Naltrexone|
224016061|NCT06419478|OTHER|postoperative symptoms|Observational study, focusing solely on symptom surveys of patients.
224016062|NCT06335602|DEVICE|LASER acupuncture|Low level LASER therapy
224016063|NCT03361280|DRUG|Beta blocker|Beta blockers are administered as described in arms.
224016064|NCT02708329|PROCEDURE|T-provisional stenting|Standard endovascular T-provisional stenting technique
224016065|NCT02708329|PROCEDURE|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
224016066|NCT02708329|PROCEDURE|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
224016067|NCT02062593|PROCEDURE|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
224016068|NCT04666402|OTHER|Blood tests for Single Nucleotide Polymorphisms|This extra test would be performed on participants assessed in the specialist liver clinic. This test would require an extra 5ml of blood to be taken at the time of routine blood tests for clinical purposes.
224016069|NCT04666402|DIAGNOSTIC_TEST|Faecal microbiome analysis|This test will be undertaken for all participants who give consent and are assessed through the new liver care pathway, in the community liver assessment clinic. All participants will be given the equipment to take a stool sample at the time of presentation at the community liver assessment clinic and asked to return the sample to the clinic. The sample will be processed to remove genetic material so the microbiome can be identified.
224016070|NCT04666402|DIAGNOSTIC_TEST|Serum for diagnostic biomarkers|Blood samples will be taken alongside blood taken for clinical assessment. In total, an extra 5ml of blood. These samples will be used to explore novel blood biomarkers using ELISA and mass-spectroscopy techniques in the University of Manchester.
224016071|NCT03531385|DIAGNOSTIC_TEST|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
224016072|NCT03531385|DIAGNOSTIC_TEST|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
224016073|NCT03531385|OTHER|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
224016074|NCT03531385|OTHER|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
224016075|NCT01869582|DEVICE|Fetoscope, Fetal heart rate|
224296547|NCT05174117|COMBINATION_PRODUCT|Double irradiation|46-48h, 72h after photosensitizer injection, divided into two irradiation times: power density: 200mW·cm-2, irradiation time: 900s, volume density: 180 J·cm-2;Power density: 200mW·cm-2, irradiation time: 300s, volume density: 60 J·cm-2.
224296548|NCT02483832|BEHAVIORAL|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
223396742|NCT06582472|PROCEDURE|Ophthalmological examination including imaging assessments|Ophthalmological examination including imaging assessments (SD-OCT, Spectral Domain Optical Coherence Tomography, a procedure to study and quantify possible retinal neurodegeneration and OCT-A, Optical coherence tomography angiography, a procedure to study and quantify possible retinal vascular abnormalities)
223396743|NCT06582472|PROCEDURE|confocal analysis of cornea|Confocal analysis of cornea: a procedure to study and quantify possible corneal nerve degeneration as a marker of involvement of diabetic neuropathy
223396744|NCT06582472|PROCEDURE|Dynamic Vessel Analyzer (DVA)|Dynamic Vessel Analyzer (DVA), a device that measures the response of retinal arteries and veins to a standardized stimulus (flickering light) allowing direct quantification of the inflammatory status of the retinal vasculature
223396745|NCT06582472|PROCEDURE|tear sampling collection|Collect and analyze tear samples to identify biomarkers in tears and at the endothelium of the ocular surface through impression conjunctival cytology and the quantitative/qualitative analysis of pro-inflammatory cytokines
223396746|NCT06582472|PROCEDURE|blood sampling collection|collection and analysis of blood samples to identify diabetic retinopathy biomarkers and early abnormalities of the vascular retinal system.
224016076|NCT01869582|DEVICE|Upright Resuscitator, Resuscitation|
224016077|NCT01869582|DEVICE|Doppler, Fetal heart rate|
224016078|NCT01869582|DEVICE|Standard Resuscitator, Resuscitation|
224016079|NCT04343872|BEHAVIORAL|Receive lifestyle modification alone|Participants will receive a 12-month lifestyle intervention program (telehealth + peer coach). The intervention comprises of the Center for Disease Control and Prevention (CDC)-adapted DPP Prevent Type 2 (PreventT2) lifestyle intervention program consisting of 26 classes delivered by trained health educators via telehealth. Additionally, the peer coach provides ongoing support over 12-months with tapered calls mirroring ongoing classes. Participants are randomized at the practice level. Two clinics will be randomized to receive the lifestyle intervention program alone.
223396747|NCT05867615|DRUG|[177Lu]Lu-PSMA I&T|177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
223550286|NCT01234480|PROCEDURE|colposcopy with biopsy/ECC|Colposcopy with biopsy/ECC for subjects with 1)BD SurePath Pap NILM, but HPV positive, or 2) BD SurePath Plus Pap test result of ASC-US or higher 3)BD SurePath Pap ASC-US or higher
223396748|NCT05906628|DRUG|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
223396749|NCT05906628|DRUG|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
223396750|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
223396751|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
223396752|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
223550287|NCT01234480|DEVICE|HPV DNA test|digene HC2 HPV DNA test
223550288|NCT00924677|PROCEDURE|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
223550289|NCT00924677|PROCEDURE|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
223550290|NCT02974140|DEVICE|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
223550291|NCT02974140|PROCEDURE|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
223550292|NCT02429804|PROCEDURE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
223550293|NCT02429804|DRUG|Fludeoxyglucose F-18|Given IV
223550294|NCT02429804|DRUG|Fluorine F 18 Sodium Fluoride|Given IV
224016080|NCT04343872|BEHAVIORAL|Metformin therapy|The two other clinics will be randomized to receive the lifestyle intervention program (described above) with METFORMIN therapy recommendations. Participants are randomized at the practice level. The primary care provider at the clinic will prescribe metformin and participants would be encouraged to take it if the primary care provider consider prescribing.
224016081|NCT04033185|OTHER|virtual reality, robot assisted gait training|study group: 15 sessions virtual reality, robot assisted gait training
224016082|NCT04033185|OTHER|conventional treatment|study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
224128343|NCT03439748|BEHAVIORAL|Negative Affect Treatment|Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
223550295|NCT02429804|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
224016083|NCT01850446|DRUG|Ergoferon|Safety and Efficacy
223550296|NCT02429804|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI
224016084|NCT01850446|DRUG|Oseltamivir|Safety and Efficacy
224128344|NCT01532323|OTHER|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
224128345|NCT05131451|DIAGNOSTIC_TEST|Point of Care Autonomous AI diabetic retinopathy exam|Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.
224128346|NCT00429065|DRUG|Rituximab|
223550297|NCT04189796|DIETARY_SUPPLEMENT|Cheese|Daily oral intake of cheese
223550298|NCT03051880|DRUG|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
223550299|NCT03051880|DRUG|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
223550300|NCT00617084|DEVICE|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
223550301|NCT00617084|DEVICE|Abbott Xience V|Abbott Xience V
223550302|NCT00040781|DRUG|gefitinib|Given orally
224128347|NCT04149899|DRUG|WB007 0.05%|WB007 Ophthalmic Solution 0.05%
224128348|NCT04149899|DRUG|WB007 0.15%|WB007 Ophthalmic Solution 0.15%
224128349|NCT04149899|DRUG|WB007 0.4%|WB007 Ophthalmic Solution 0.4%
224128350|NCT04149899|DRUG|Timolol 0.5%|Timolol Maleate 0.5% Ophthalmic Solution
224128351|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
223396753|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
223396754|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
223396755|NCT04578535|DRUG|HYQVIA|Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
223396756|NCT01191034|DRUG|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
223550303|NCT00040781|OTHER|pharmacological study|Correlative studies
223550304|NCT00040781|OTHER|laboratory biomarker analysis|Correlative studies
223550305|NCT06431672|OTHER|interpersonal group psychotherapy|Interpersonal psychotherapy (IPT) was developed by Stuart and O'Hara (1995). It addresses four domains of conflict. The intervention is an eight-session P-IPTG, which consisted of four sessions in pregnancy and four in postpartum.
223550306|NCT06263907|PROCEDURE|Stellate gangalion block|The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
223550307|NCT01253083|BEHAVIORAL|mobility training with dynamic body weight support|
223550308|NCT02522429|DEVICE|Low Intensity Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
223550309|NCT02956252|PROCEDURE|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
223550310|NCT02956252|PROCEDURE|General anesthesia|General anesthesia was used in patients who underwent LC
223396757|NCT05901974|DRUG|Venetoclax|Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-28);
223396758|NCT05901974|DRUG|azactidine|azacitidine 75 mg/m2 subcutaneously once daily on days 1-7
223396759|NCT00461942|DRUG|Green Tea Polyphenols (EGCG/ECG)|
223396760|NCT02926066|DRUG|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
223396761|NCT03135717|DIETARY_SUPPLEMENT|Nutritional care|"* Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry~* Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation~* Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)~* Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
223396762|NCT00416611|BEHAVIORAL|Implementation of guidelines|
223550311|NCT00936637|OTHER|Extensively hydrolyzed infant formula|
223550312|NCT01000298|DRUG|Placebo|liquid placebo medication given twice per day for 7 days
223550313|NCT01000298|DRUG|Amoxicillin|liquid amoxicillin given twice per day for 7 days
223550314|NCT01000298|DRUG|Cefdinir|liquid cefdinir given twice per day for 7 days
223550315|NCT02580032|OTHER|No treatment given|No treatment given.
223550316|NCT03987139|OTHER|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
223550317|NCT03987139|OTHER|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
223550318|NCT03987139|OTHER|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
223550319|NCT03937388|OTHER|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
223550320|NCT05538949|DRUG|EB-203|"* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1.~* Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8."
223550321|NCT05538949|DRUG|Placebo|Placebo 1Drop, QD / Day1, BID / Day5\~Day8.
223550322|NCT03440463|BEHAVIORAL|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
223550323|NCT03440463|BEHAVIORAL|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
223550324|NCT03440463|BEHAVIORAL|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
224016085|NCT01378780|BEHAVIORAL|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
223396763|NCT03487471|DIAGNOSTIC_TEST|Real-time elastography|Breast ultrasound with real-time elastography
223396764|NCT03487471|DIAGNOSTIC_TEST|Shear wave elastography|Breast ultrasound with shear wave elastography
223396765|NCT00399061|DRUG|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
223396766|NCT06581354|PROCEDURE|PROVISIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
223396767|NCT04459936|OTHER|URICORI|Treatment for cardiovascular risk factors according to national guideline administered at the department of Rheumatology
223396768|NCT04459936|OTHER|CONTROL|Treatment for cardiovascular risk factors according to national guideline administered at the General Practitioner
223396769|NCT01060072|DRUG|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
223396770|NCT01060072|DRUG|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
224016086|NCT01378780|BEHAVIORAL|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
224016087|NCT01347801|DRUG|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
224016088|NCT01347801|DRUG|Placebo (Saline)|Normal saline (NaCl 0,9%)
224016089|NCT01347801|DRUG|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
224016090|NCT01347801|OTHER|OGTT|Oral glucose tolerance test with 75 g glucose
224016091|NCT01347801|OTHER|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
224016092|NCT01085266|DRUG|Dimebon (latrepirdine)|
224016093|NCT05060978|BEHAVIORAL|Watch your Weight During the Holidays Program|Participants in this group will have two video call individual sessions and one video call group session. This intervention will include self-monitoring strategies (self-weighing, diet monitoring and physical activity), and nutrition counseling and education. In addition, participants in this group will receive a weighing scale to achieve self-monitoring of body weight from the beginning of the study intervention until the end of the 52-weeks follow-up.
224016094|NCT05060978|OTHER|Relative 5:2 Fasting|Participants in this group will will have two video call individual sessions and one video call group session. This intervention will receive eating recommendations to follow a 5:2 intermittent fasting. They will be given low-calorie menus of 550 kcal and 660 kcal, for women and men respectively, which the participants in this group will apply on fasting days. The fasting will be held twice a week and on the remaining five days, the participants will not have any type of caloric restriction (it will be ad libitum). They will only have the general recommendation to adhere to a healthy dietary pattern.
224016095|NCT05060978|OTHER|Control Group|Participants in this group will receive online information and a PDF file brochure during an individual video call session at the beginning of the 8-week period. This information will be about leading a healthy eating based on the norm for health promotion and education for healthy eating in Mexico (NOM-043-SSA2-2012).
224016096|NCT06153225|DIETARY_SUPPLEMENT|Protein products|In total 4 protein products will be tested containing a single or mixture of plant and dairy protein sources in a randomized order
224016097|NCT01451125|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
224016098|NCT03820674|OTHER|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
224016099|NCT03820674|OTHER|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
224016100|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Single dose of theobromine
223396771|NCT01693016|DEVICE|non-invasive measurement of Hb|
224016101|NCT01544829|DIETARY_SUPPLEMENT|Theobromine|Multiple doses of theobromine
224016102|NCT01544829|DIETARY_SUPPLEMENT|Placebo|Placebo capsules
224016103|NCT00759915|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
223396772|NCT01693016|PROCEDURE|taking blood samples|
223396773|NCT00837148|DRUG|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
223396774|NCT03733769|PROCEDURE|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
223396775|NCT00447174|BEHAVIORAL|Dyadic treatment for parental bereavement|
223396776|NCT01291355|OTHER|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
223550325|NCT03899025|RADIATION|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
223550326|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
223550327|NCT03691337|DRUG|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
223550328|NCT03691337|DRUG|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
223550329|NCT06156657|OTHER|subcostal TAP block|Comparison between subcostal TAP block and opioids for postoperative pain after laparscopic sleeve gastrectomy
223550330|NCT02841683|BEHAVIORAL|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
224016104|NCT00759915|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
224016105|NCT03546322|OTHER|Registry|Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
224016106|NCT02272296|DEVICE|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
224016107|NCT02272296|DEVICE|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
224016108|NCT04452565|DRUG|Drug: NA-831|NA-831 is a neuroprotective drug, available at 30 mg capsule
224016109|NCT04452565|COMBINATION_PRODUCT|NA-831 and Atazanavir|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet"
224016110|NCT04452565|COMBINATION_PRODUCT|NA-831and Dexamethasone|"Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg"
224016111|NCT04452565|COMBINATION_PRODUCT|Atazanavir and Dexamethasone|Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
224016112|NCT01886612|DEVICE|Duo-STIM neuromuscular electrical stimulator|
224016113|NCT01886612|DEVICE|AV Impulse System Model 6000|
224016114|NCT04843553|DRUG|Oral Nicotinamide|
224016115|NCT03730480|DEVICE|Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes|Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
224016116|NCT01227577|DRUG|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
224016117|NCT04330885|OTHER|Supervised abdominal exercises and stationary biking|Explain pain to the patients in order to minimize fear of movement
224016118|NCT03138928|DEVICE|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
223550331|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Enhanced Parent Involvement|
223550332|NCT01139411|BEHAVIORAL|Behavioral Weight Control with Minimal Parent Involvement|
223550333|NCT04343430|PROCEDURE|Clinical examination centered on congestion|Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
223550334|NCT04343430|PROCEDURE|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography|Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
223550335|NCT04343430|PROCEDURE|Biological: Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed before discharge from hospital
224016119|NCT00633724|BIOLOGICAL|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
223396777|NCT03526068|DEVICE|SafeZoneUVC|SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
223550336|NCT04343430|PROCEDURE|Telephone interview|Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
223550337|NCT04343430|BEHAVIORAL|Kansas City Cardiomyopathy Questionnaire (KCCQ)|Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
223550338|NCT01521923|BIOLOGICAL|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
223550339|NCT01521923|BIOLOGICAL|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
223550340|NCT05895877|DRUG|Goofice®|Once daily before breakfast.
223396778|NCT05374655|OTHER|Preoperative blood glucose control|Patients included in this group, under the guidance of endocrinologists, develop hypoglycemic strategies for patients, follow up and guide patients to take medication, review HbA1c levels after 6 weeks, perform surgical treatment if they meet preoperative HbA1c\<7.5%, continue hypoglycemic therapy if still above standards, and administer drugs according to the corresponding type of heart disease during this period.
223396779|NCT01509339|DRUG|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
223396780|NCT01416636|DRUG|Treprostinil sodium|
223396781|NCT01193777|DRUG|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
223550341|NCT05895877|DRUG|Goofice® Placebo|Once daily before breakfast.
223550342|NCT03174405|DRUG|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
223550343|NCT01175876|DEVICE|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
223550344|NCT01175876|PROCEDURE|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
223550345|NCT02841007|DEVICE|geko neuromuscular electrostimulation device|
223550346|NCT01283776|DRUG|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
223550347|NCT01236066|OTHER|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children \<5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
223550348|NCT01807169|PROCEDURE|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
224016120|NCT03597074|DIAGNOSTIC_TEST|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
224016121|NCT02480153|BIOLOGICAL|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
224016122|NCT02480153|BIOLOGICAL|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
224016123|NCT03898401|COMBINATION_PRODUCT|Platelet rich plasma|After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.
224016124|NCT05272956|PROCEDURE|enteral feeding with pushed syringe by the parents|enteral feeding pushed by parents with a syringe
224016125|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
224128352|NCT00782418|DRUG|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
223396782|NCT01193777|DRUG|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
223396783|NCT00818077|OTHER|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
223550349|NCT01692288|BEHAVIORAL|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
223550350|NCT00812396|DRUG|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
223550351|NCT00812396|DRUG|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
223550352|NCT00812396|DRUG|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
223550353|NCT01325051|DRUG|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
224016126|NCT01159587|DRUG|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
224016127|NCT05251467|OTHER|Focus group|Focus group to confirm PROM conceptual framework
224016128|NCT05251467|OTHER|Patient interview (n = approximately 10)|Patient interviews to refine possible questions for the PROM
224016129|NCT05251467|OTHER|Questionnaire (n = 180)|Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
224016130|NCT05251467|DEVICE|Testing of the pilot PROM in a smartphone app (n = 150)|Daily testing of the pilot PROM in a smartphone app for 2 weeks
224128353|NCT00782418|DRUG|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
224128354|NCT04393584|DRUG|Irinotecan|d1 Irinotecan 180mg/m² every two weeks
224128355|NCT04393584|DRUG|5-FU|d1-2 5-FU 2450 mg/m² every two weeks
224128356|NCT04393584|DRUG|Leucovorin|d1 Leucovorin 200 mg/m² every two weeks
223396784|NCT04553159|BIOLOGICAL|Autologous adipose derived stem cells|Once consented, tumescent liposuction will be performed and 100-300ml of lipoaspirate will be collected. The harvested lipoaspirate will be processed aseptically in theatre through centrifugation at 1200g, then the sediment will be washed with Phosphate buffered saline and then incubated at 37 degrees celsius in 0.075% Collagenase type 1a for 1 hour. This will then be washed in an equal volume of 10% Fetal Bovine Serum then filtered through a 100 micrometer cell strainer. Red cells lysed using the Red cell lysis buffer will be performed followed by washing in Phosphate buffered Saline and centrifugation and the stromal vascular fraction cell pellet collected and diluted into 5ml normal saline solution for immediate infiltration. cell counts and viability using Trypan blue will be perfomed prior to the infiltration
223396785|NCT03126773|DRUG|BAY86-4891|Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
224016131|NCT05566977|OTHER|autologous adoptive T regulatory cell transfer.|Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
224128357|NCT04393584|DRUG|Oxaliplatin|d1 Oxaliplatin 85 mg/m² every two weeks
224128358|NCT04393584|DRUG|Docetaxel|d1 Docetaxel 50mg/m2 every two weeks
223396786|NCT03453775|DEVICE|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
223396787|NCT03453775|DEVICE|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
223396788|NCT02301169|BEHAVIORAL|Heat pain stimuli A|
223396789|NCT02301169|BEHAVIORAL|Video A|
223396790|NCT02301169|DRUG|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
223396791|NCT02301169|BEHAVIORAL|Heat pain stimuli B|
223396792|NCT02301169|BEHAVIORAL|Video B|
223396793|NCT02301169|DRUG|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
223396794|NCT02162056|DEVICE|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
223396795|NCT03839628|OTHER|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
223396796|NCT00380874|DRUG|Pregabalin|150- 600 mg/day (double blind in divided doses)
223396797|NCT00380874|DRUG|Placebo|Placebo
223396798|NCT04159389|OTHER|Mental visualization|Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
223396799|NCT02912702|DRUG|Pegaspargase|2000U/m2 day5
223396800|NCT02912702|DRUG|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
224128359|NCT06347276|DEVICE|PFO occluder; ASD occluder|Transcatheter closure of atrial septal defect (ASD) and patent foramen ovale (PFO) All cases will be examined with DW-MRI preoperatively, and DW-MRI will be repeated 24 hours and 4 weeks after the transcatheter closure procedure.
224128360|NCT05978830|DEVICE|Transcranial ultrasound stimulation|In each active/sham-ultrasound stimulation experiment, subjects first underwent two baseline motor evoked potential (MEP) tests, with an interval of 15 minutes between the two baseline tests. After 15 minutes of true/pseudo-transcranial ultrasound stimulation, subjects immediately underwent a MEP test, and then 15 minutes later, subjects underwent another MEP test. The MEP was tested again 15 minutes later.
224128361|NCT03927248|DRUG|Nivolumab|See description in Arms/Groups section
223396801|NCT02912702|DRUG|etoposide|100 mg/m2 was administered once on the first day of every week
223396802|NCT02912702|DRUG|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
223396803|NCT02912702|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
223396804|NCT02912702|DRUG|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
223396805|NCT04959721|COMBINATION_PRODUCT|Injection with triamcinolone acetonide, bupivacaine, and normal saline|"Triamcinolone acetonide is a synthetic corticosteroid medication used intra-articularly to treat various joint conditions. Bupivacaine is a medication used to decrease feeling in a specific area. In nerve blocks, it is injected around a nerve that supplies the area, or into the spinal canal's epidural space. Saline is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.~The procedure will be performed with the patient in a prone position under a C-arm fluoroscopy scanner, with the thorax rests on 2 pillows, flexing the neck maximally, and the head turns 60-90° away from the side of injection. The C-arm tube will be angled cephalad, until it was at a tangent to the cervical facet joint space. A 26-gauge, 90 mm spinal needle will be inserted parallel to the C-arm beam. To confirm intra-articular placement of the needle tip, an arthrogram of the cervical facet joint will be performed by injecting 0.3 mL of contrast."
223396806|NCT03699332|DRUG|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
223396807|NCT03699332|RADIATION|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
223396808|NCT03699332|PROCEDURE|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
223396809|NCT03816423|OTHER|video|Participants randomized to the intervention group, will wacth a pre-appointment video, followed by a routine prenatal care visit.
223396810|NCT00218023|DRUG|Modafinil|The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
223550354|NCT04328545|DEVICE|Anodal tDCS on DLPFC|Participants will receive anodal tDCS on the left DLPFC for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
223731215|NCT05792371|PROCEDURE|induced membrane technique|Masquelet technique, also called an induced membrane technique (IMT), was first introduced to treat critical size bone defect up to 25 cm in 1986 by Pr. Alain Charles Masquelet et al. IMT is a two-stage surgical operation that recently provides a more popular option for the treatment of critical size bone defect as well as fracture nonunion. Basically, first stage of IMT comprises the implantation of a polymethylmethacrylate (PMMA) cement spacer loaded with antibiotics into defect site. During 6 to 8 weeks, this spacer induces the formation and maturation of a thin layer called induced membrane surrounding it via a foreign body immune response. In stage II, the spacer is carefully removed while keeping induced membrane at the fracture site, autologous bone graft is then performed to provoke bone healing.
223396811|NCT00218023|DRUG|Levodopa/Carbidopa|Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.
223396812|NCT00218023|DRUG|Naltrexone HCl|Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
223396813|NCT00218023|DRUG|Placebo|Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
223550355|NCT04328545|DEVICE|Anodal tDCS on M1|Participants will receive anodal tDCS on the left M1 for 30 min duration, cathode will be placed over the right supra orbital area. The electrodes are 25cm², The stimulation current is 2 milliamperes (2mA).
223550356|NCT04328545|DEVICE|Sham tDCS|Participants will receive sham tDCS. The anode will be placed on the left DLPFC and the cathode on the over the right supra orbital area. The electrodes are 25cm², There will be a ram up and down of 30 seconds each, after the ramp up the current will be turned off.
223550357|NCT03150550|BEHAVIORAL|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
223550358|NCT03150550|BEHAVIORAL|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
223550359|NCT03197610|PROCEDURE|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
223550360|NCT02318017|DRUG|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
223550361|NCT02318017|DRUG|Placebo|
223550362|NCT02003443|BEHAVIORAL|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
223550363|NCT06000592|DEVICE|Digitimer|transcutaneous spinal cord stimulation for blood pressure control following spinal cord injury.
223550364|NCT00219596|DRUG|Xalacom|
223550365|NCT00219596|DRUG|unfixed Latanoprost and Timolol|
223550366|NCT04452123|PROCEDURE|Laparoscopic argon plasma treatment of endometrioma|Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
223550367|NCT04452123|PROCEDURE|Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary|Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.
223550368|NCT01416740|PROCEDURE|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
223550369|NCT01416740|DRUG|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
223550370|NCT01279044|BEHAVIORAL|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications-beliefs, thoughts, and attitudes-that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
223550371|NCT01279044|BEHAVIORAL|Standard HIV testing with information only|Standard HIV testing with information only
223731216|NCT05792371|PROCEDURE|Bone graft (Stage II of IMT)|Bone graft is only performed in this group to provoke bone healing, as same as demonstrated in the stage II of IMT.
223731217|NCT02683889|DRUG|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
224128362|NCT02324842|DRUG|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
223550372|NCT01582009|DRUG|panobinostat|Given orally
223550373|NCT01582009|DRUG|everolimus|Given orally
223550374|NCT01582009|OTHER|laboratory biomarker analysis|Correlative studies
223550375|NCT01582009|OTHER|pharmacological study|Correlative studies
223550376|NCT01582009|OTHER|liquid chromatography|Correlative studies
223550377|NCT01582009|OTHER|mass spectrometry|Correlative studies
223550378|NCT01582009|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223731218|NCT05516706|OTHER|Dynamic stretching|Participants in this group performed a 10 minutes warm-up followed by 15 minutes of dynamic stretching exercises which included arm cross-over, scapular scaption, upper body twist walking lunges, cat and cow pose, and rotator cuff movements.
224128363|NCT02324842|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
224128364|NCT03537339|OTHER|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
224128365|NCT02805556|DRUG|BMS-663068|Single oral dose of BMS-663068
223396814|NCT00218023|BEHAVIORAL|Motivational Interviewing (MI)|The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
223396815|NCT00218023|BEHAVIORAL|Contingency management (CM)|Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
223396816|NCT00218023|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
224016132|NCT05513924|DRUG|Latanoprost 0.005% Ophthalmic Solution|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~The LT solution will be applied immediately to vitiligo patch one drop (contains 1.5 μg of LT) for every 2.5 cm.~This procedure will be repeated every two weeks for six months."
224016133|NCT05513924|DRUG|5Fluorouracil|"The affected area cleaned with betadine surgical solution followed by alcohol 70%.~Local anesthetic, pridocaine cream, applied on the treated area under occlusion for 30 min before the procedure.~Using automated microneedling device (Dr Pen Derma Pen Ultima A6®) , which has a disposable head that personalized for each patient and sterilized after each session.~The derma pen will penetrate the skin with variable depths ranging from 0.25 to 0.5 mm (not more than the depth of the epidermis). It will pass vertically over the vitiligo area in a circular pattern until pinpoint bleeding appears.~Topical application of 5-fluorouracil 5% solution will be rubbed over the affected area for about 2 minutes. Occlusive dressing for hours.~This procedure will be repeated every two weeks for six months."
224016134|NCT02323451|DEVICE|Medical Chitosan|intra-articular injection
223396817|NCT03389503|PROCEDURE|Radial approach|Approach site for coronary angiography and coronary intervention
223396818|NCT00474084|DEVICE|Intravascular Coronary Stent|
223396819|NCT01707290|DRUG|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
223396820|NCT01105364|DRUG|antiangiogenesis therapy|
223396821|NCT01105364|DRUG|stabilized sulphur hexafluoride microbubble-based contrast agent|
223396822|NCT01105364|OTHER|imaging biomarker analysis|
223396823|NCT01105364|OTHER|pharmacological study|
223396824|NCT01105364|PROCEDURE|computed tomography|
223396825|NCT01105364|PROCEDURE|magnetic resonance imaging|
223396826|NCT01198470|DEVICE|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
223550379|NCT01582009|OTHER|immunohistochemistry staining method|Correlative studies
223550380|NCT05415969|OTHER|CKD-aP|Identification of CKD-aP prevalence and severity among patients on dialysis.
223731219|NCT05516706|OTHER|Plyometric push up|Participants in this group performed 10 minutes of warm-up followed by 15 minutes of plyometric push training which included one-arm push-ups and depth push up
224016135|NCT02323451|DRUG|Sodium Hyaluronate Injection|intra-articular injection
224016136|NCT01435330|DRUG|BVS857|
224016137|NCT01435330|DRUG|Placebo|
224016138|NCT00446628|BEHAVIORAL|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
223396827|NCT03360383|PROCEDURE|percutaneous vertebroplasty|Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.
223550381|NCT01558284|DRUG|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
223396828|NCT03360383|PROCEDURE|conservative treatment|complete on bed with prevention of complications
223550382|NCT01558284|DRUG|Placebo|Placebo
223550383|NCT03320837|DIETARY_SUPPLEMENT|Infant formula|Breast milk substitute containing synbiotics
223550384|NCT03320837|OTHER|Breast milk|Breast milk
223550385|NCT03051295|OTHER|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
223550386|NCT02805465|DEVICE|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
223396829|NCT00578045|PROCEDURE|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
223396830|NCT02500095|OTHER|Fasting|72 hours of fasting
223396831|NCT02500095|DRUG|Saline|Concomitant saline during fasting
223396832|NCT02500095|DRUG|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
223396833|NCT02452606|DRUG|Stalevo®|"* Sleep disorders in Parkinson's disease~* Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~* If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
223550387|NCT02805465|DEVICE|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
223550388|NCT04783311|BIOLOGICAL|EuCorVac-19|Two intramuscular doses (0.5mL per dose) at 3-week interval
223550389|NCT04783311|OTHER|Normal Saline|Two intramuscular doses (0.5mL per dose) at 3-week interval
223550390|NCT03369366|DEVICE|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
223396834|NCT04924387|PROCEDURE|Exercise|All patients will start learning how to activate the abdominal muscles in the first training session. The exercise progression will be adapted according to the capacity of each patient, considering their pain levels. The exercises will be made in 1 to 3 series of among 8 and 15 repetitions and the isometric contractions for 5 to 10 seconds. The rests between series will be of 30 seconds, and between exercises of 2-3 minutes.
223550391|NCT03369366|DEVICE|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
223550392|NCT02877576|PROCEDURE|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
223396835|NCT02670226|OTHER|Samples|Blood samples, muscle biopsy
223550393|NCT02877576|BEHAVIORAL|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
223550394|NCT02877576|BEHAVIORAL|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
223550395|NCT03056235|DEVICE|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
223550396|NCT03056235|DEVICE|Saline|Saline control
223550397|NCT00119197|BIOLOGICAL|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
223550398|NCT00119197|BIOLOGICAL|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
223550399|NCT00510445|DRUG|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
223550400|NCT01665911|DRUG|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
223550401|NCT01665911|DRUG|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
223731220|NCT06103357|OTHER|blood sample collection|Before and after angioplasty, blood samples upstream and downstream of the coronary lesion will be taken, arterial sampling at the aortic root level will be performed, and peripheral venous blood will be collected.
224016139|NCT04314804|COMBINATION_PRODUCT|PPP001|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
224016140|NCT04314804|COMBINATION_PRODUCT|Placebo|1 pellet smoked up to 3 times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
223396836|NCT04944043|DRUG|TQ05105 Tablet|TQ05105 tablet is a Janus Kinase (JAK) inhibitor, which can inhibit the abnormal activation of JAK 2-V617F mutation, thereby inhibiting the sustained abnormal activation of JAK / STAT pathway.
223550402|NCT01665911|DRUG|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
223550403|NCT01665911|DRUG|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
223550404|NCT01665911|OTHER|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
223550405|NCT04973995|BEHAVIORAL|several physical examinations|By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
223731221|NCT02558257|BEHAVIORAL|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
223731222|NCT01430156|DRUG|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
223731223|NCT01430156|DRUG|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
224016141|NCT00897312|BIOLOGICAL|infliximab|
224016142|NCT00897312|BIOLOGICAL|pegylated interferon alfa|
224016143|NCT00897312|BIOLOGICAL|ticilimumab|
224016144|NCT00897312|DRUG|ribavirin|
224016145|NCT00897312|OTHER|high performance liquid chromatography|
223731224|NCT05245747|DEVICE|Vitls Tego Device|The Tégo VSS Sensor is a battery-operated adhesive patch with integrated sensors and wireless transceiver which is worn on the upper body and records heart rate (HR), respiration rate, blood oxygen levels (SpO2), and body temperature. The Tégo VSS Sensor continuously gathers multiparameter physiological data from the person being monitored and then transmits the encrypted data via bi-directional communication to a third-party connectivity relay.
224016146|NCT00897312|OTHER|laboratory biomarker analysis|
224016147|NCT00512317|DRUG|ganaxolone|liquid suspension dosed tid
224016148|NCT04729413|BEHAVIORAL|Couples Counseling|Psychoeducational counseling on relationships and maternal and child health in the context of HIV.
223396837|NCT03710408|OTHER|Intravenous hydration|"Participants assigned to the intravenous hydration arm will receive their hydration therapy through an intravenous access. This access will be achieved by inserting a BD VenflonTM Pro Safety - 22G in a vein in the dorsal side of the hand or further up the forearm. If the participants is suspected of becoming delirious and at risk of removing the cannula from the hand/forearm, it may be inserted at the dorsal side of the foot. The clinical staff judge this risk and decide site of placement.~Furthermore, a sham subcutaneous access device BD Saf-T-Intima™ Integrated Safety Catheter System will be placed on the abdomen without piercing the skin."
223396838|NCT03710408|OTHER|Subcutaneous hydration|"Participants assigned to the subcutaneous hydration arm will receive their hydration therapy through a subcutaneous access. This access will be achieved by placing a BD Saf-T-Intima™ Integrated Safety Catheter System on the abdomen or, alternatively if the participants is suspected of becoming delirious and at risk of removing the needle, it will be placed on the back at the scapular region.~Furthermore, a sham IV access device BD VenflonTM Pro Safety - 22G will be placed on the dorsal side of the hand without piercing the skin."
223396839|NCT05375357|PROCEDURE|Application of L-PRF on the donor area|After implant uncovering procedure with apically positioned flap, the donor area is covered with a layer of L-PRF
223550406|NCT04778891|OTHER|Comprehensive Medication Management services|Comprehensive Medication Management services (CMM services) is an evidence-based and patient-centred service which involves an assessment of patient's medications to determine that each medication is appropriate, effective for the medical condition being treated, safe for the patient in the presence of other medications and co-morbidities, and that the patient is able and willing to take the medications as intended. As all patient care providers need a structured, rational thought process for sound clinical decision retrieval, the Pharmacotherapy Workup was developed and adopted as a systematic problem-solving process. This process represents the cognitive work taking place in the mind of the practitioner, and is used to identify, resolve, and prevent drug therapy problems (DTP), establish therapy goals, select interventions and evaluate outcomes.
223550407|NCT01671709|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
223396840|NCT05375357|PROCEDURE|Secondary intention healing of the donor area|After implant uncovering procedure with apically positioned flap, the donor area is left to heal by secondary intention
223396841|NCT01477346|OTHER|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
223550408|NCT02081508|BEHAVIORAL|Interference onset|Temporal duration of interference onset.
224016149|NCT04729413|OTHER|Enhanced Standard of Care|Enhanced standard of care with education on pregnancy and postpartum health, similar to what is presented to women at routine antenatal and postpartum care.
224016150|NCT02619149|DRUG|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
224128366|NCT02805556|DRUG|BMS-626529|Single intravenous dose of \[13C\]BMS 626529
224128367|NCT00433732|DRUG|sumatriptan|
224128368|NCT00433732|DRUG|naproxen sodium|
224128369|NCT05808998|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy using TomoTherapy
224128370|NCT04767256|DRUG|Dexamethasone and dexmedetomidine|General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
223731225|NCT05846906|DRUG|Sildenafil Citrate|oral sildenafil (Respatio® 20mg )
223731226|NCT05846906|DRUG|Clomiphene Citrate 50mg|used for ovionulation induct
223731227|NCT05520931|OTHER|Questionnaire and register-based data assessment|Primary data will be collected via a generic questionnaire from the two groups. Secondary data will consist of register-based socio-economic data and medical charts data collected from the Danish Health Data Authority and Denmark' Statistics.
224016151|NCT02619149|DRUG|Saline solution|Saline iv as placebo control
224016152|NCT01639495|DEVICE|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
224016153|NCT05174455|DRUG|Niraparib Tosylate Monohydrate|Given PO
224016154|NCT05149911|BEHAVIORAL|Life Coaching|Sessions with a professional life coach.
224016155|NCT01717690|DRUG|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
224016156|NCT05351684|DRUG|Dolutegravir 50 MG|already included in arm/group descriptions.
224016157|NCT01775475|DRUG|cyclophosphamide|Given IV
224016158|NCT01775475|DRUG|doxorubicin hydrochloride|Given IV
224016159|NCT01775475|DRUG|vincristine sulfate|Given IV
224016160|NCT01775475|DRUG|prednisone|Given PO
224016161|NCT01775475|DRUG|lomustine|Given PO
224016162|NCT01775475|DRUG|etoposide|Given PO
224128371|NCT04767256|DRUG|Dexmedetomidine|Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
224128372|NCT04767256|OTHER|Ultrasound-guided lumbar erector spinae plane block|The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
224016163|NCT01775475|DRUG|cyclophosphamide|Given PO
224016164|NCT01775475|DRUG|procarbazine hydrochloride|Given PO
223396842|NCT01477346|OTHER|Standard care|Continuing standard General Practitioner led care.
223396843|NCT02949973|DRUG|voclosporin|
223396844|NCT00063726|DRUG|bortezomib|
223550409|NCT00789152|DRUG|desloratadine|desloratadine 5 mg daily x 8 days
223550410|NCT00789152|DRUG|levocetirizine|levocetirizine 5 mg daily x 8 days
223550411|NCT00735553|DRUG|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
223550412|NCT00735553|DRUG|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
223550413|NCT00735553|DRUG|Placebo|Two placebo capsules orally daily for up to four months
224016165|NCT01775475|OTHER|laboratory biomarker analysis|Correlative studies
224016166|NCT00416832|DRUG|cyclophosphamide|
224016167|NCT00416832|DRUG|dacarbazine|
224016168|NCT00416832|DRUG|doxorubicin hydrochloride|
224016169|NCT00416832|DRUG|etoposide|
224016170|NCT00416832|DRUG|prednisone|
224016171|NCT00416832|DRUG|procarbazine hydrochloride|
224016172|NCT00416832|DRUG|vincristine sulfate|
224016173|NCT00416832|RADIATION|radiation therapy|
224016174|NCT00159133|DRUG|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
224016175|NCT01893125|DRUG|CNV2197944|
224016176|NCT01893125|DRUG|Placebo|
223396845|NCT02847949|BIOLOGICAL|IGN002|IGN002 is a monoclonal antibody fusion protein
223396846|NCT06525350|DRUG|Glumetinib tablets|An ATP competitive, highly selective MET receptor tyrosine kinase inhibitor
223396847|NCT06525350|DRUG|HB1801 (docetaxel, albumin-bound）|An improved new formulations of docetaxel
223396848|NCT06525350|DRUG|Docetaxel|A chemotherapy drug
223396849|NCT01861743|OTHER|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
223396850|NCT01861743|OTHER|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
223396851|NCT05526677|DEVICE|x-guide dynamic navigation system|One implant placement is assisted with x-guide dynamic navigation system. The other implant placement is assisted with static surgical guide
223396852|NCT04851977|BIOLOGICAL|Respiratory Syncytial Vaccine|BARS13 low dose (one dose of 10 μg rRSV-G protein/10 μg CsA by IM injection to the deltoid region of one arm, and one dose of placebo \[saline/mannitol\] by IM injection to the deltoid region of the other arm, given sequentially).
223396853|NCT04851977|BIOLOGICAL|Respiratory Syncytial Vaccine|BARS13 high dose (IM injection of 10 μg rRSV-G protein/10 μg CsA administered to the deltoid region of each arm \[one injection of 10 μg rRSV-G protein/10 μg CsA per arm\], given sequentially). The high dose is twice the strength of the low dose.
223550414|NCT01692106|PROCEDURE|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
223550415|NCT00090961|OTHER|educational intervention|
223550416|NCT00090961|OTHER|supervised exercise program|
223550417|NCT01173107|DRUG|colchicine|colchicine 1T tid
223550418|NCT02480413|OTHER|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
223550419|NCT06391580|DEVICE|Poly-L-lactin Acid (PLLA) Based Facial Injectable|Poly-L-lactin Acid (PLLA) Based Facial Injectable
223550420|NCT02056028|PROCEDURE|Hepatic resection|
223550421|NCT04227275|BIOLOGICAL|CART-PSMA-TGFβRDN|Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
224016177|NCT05384353|OTHER|[18F]-SynVesT-1|PET radioligand binding to synaptic vesicle protein 2A as a proxy for synaptic density
224016178|NCT03650517|PROCEDURE|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
224016179|NCT03650517|PROCEDURE|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
224016180|NCT03650517|PROCEDURE|Robotic Surgery|Procedure is performed using robotic instruments
224016181|NCT03650517|PROCEDURE|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
224016182|NCT01738425|DRUG|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
224016183|NCT01738425|DRUG|GIC-1001 matching placebo|"Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]"
224016184|NCT02844426|DRUG|bifid triple viable capsule and pectin|
224016185|NCT02844426|DRUG|maltodextrin|
224016186|NCT00420433|PROCEDURE|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
224016187|NCT00420433|PROCEDURE|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
224016188|NCT00420433|PROCEDURE|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
224016189|NCT05788393|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine group will receive continuous intraoperative dexmedetomidine IV infusion \[1ug/kg dexmedetomidine over 15 min as a loading dose and 0.5ug/kg/h for maintenance\].The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
224016190|NCT05788393|DRUG|Lidocaine IV|lidocaine group will receive continuous intraoperative lidocaine IV infusion \[1.5 mg/kg lidocaine over 15 min as a loading dose and 1.5 mg/kg/h for maintenance\]. The continuous intraoperative IV infusion of study drug will be stopped 10 min before the end the surgical procedure.
224016191|NCT05674331|PROCEDURE|Extraction site development technique|The technique is described by Molnar et al. in 2019. The aim is to reconstruct the buccal bony wall with a xenogenic membrane with a slow absorption rate properties. This technique aims to stabilizate and enlarge the blood clot .
224016192|NCT05674331|DEVICE|autogenous tooth bone graft|ATB was invented by Kim et al. in 2011. The extracted tooth is grinded and goes throw a sterilization procedure by the manufacturer's recommendation. The graft material can be used immediately for ARP.
224016193|NCT05674331|PROCEDURE|Socket seal technique|After tooth removal neither graft nor any membrane material is inserted to the extraction socket. A soft tissue pounch is harvested from the hard palate and it is fixed above the extraction socket with single interrupted sutures.
224016194|NCT05406830|DEVICE|verum acupuncture|The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
224016195|NCT05406830|BEHAVIORAL|health education|According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.
224016196|NCT05406830|DEVICE|sham acupuncture|We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
224016197|NCT01813929|DRUG|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
224016198|NCT01813929|DRUG|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
224016199|NCT04644562|OTHER|Erector Spinae plane block|Ultrasound-guided lumbar Erector Spinae plane block in patients undergoing Lower Limb vascular Surgery
224016200|NCT05999097|DIETARY_SUPPLEMENT|Short Chain Fructooligosaccharides|The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.
224016201|NCT05999097|DIETARY_SUPPLEMENT|Placebo Group|This group will receive 12 g of corn starch as a control group.
224016202|NCT01299870|DRUG|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
224016203|NCT01299870|DRUG|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
223396854|NCT04851977|BIOLOGICAL|Placebo|Placebo (IM injection of saline/mannitol administered to the deltoid region of each arm \[one injection per arm\], given sequentially).
223396855|NCT00144820|DRUG|Injection of Hyaluronan or Saline|
223396856|NCT02857816|DEVICE|NURO System PTNM Therapy|
223396857|NCT05669625|BIOLOGICAL|Investigational live attenuated varicella vaccine|0.5 ml/vial
223396858|NCT05669625|BIOLOGICAL|Placebo of live attenuated varicella vaccine|0.5 ml/vial
223396859|NCT06345859|BEHAVIORAL|Heart rate variability biofeedback|This is a Phase 2 parallel intervention design with random assignment. We will randomly assign participants to one of two biofeedback conditions. Both conditions involve completing breathing exercises at home, 30 minutes per day for 10 days, while receiving continuous feedback about parasympathetic activity from the computer.
223396860|NCT05286736|DIAGNOSTIC_TEST|Neuroimaging|This project will use neuroimaging (7T MRI: structural, diffusion and rest-state functional MRI) and non-invasive brain stimulation (TMS: PAS. SAI) techniques to quantify structural and functional changes in brain function.
223396861|NCT05286736|DIAGNOSTIC_TEST|Quantitative assessments|Quantitative assessments of motor function (gait, gait initiation, reactive balance, bradykinesia, repetitive alternating movements, rigidity, stop-signal reaction time), and neuropsychological function
223396862|NCT06194838|DEVICE|Ossur Power Knee|Newest version of the commercially-available powered knee developed by Ossur.
223396863|NCT06194838|DEVICE|Reboocon Intuy Knee|Commercially-available powered knee developed by Reboocon.
223396864|NCT05507125|BEHAVIORAL|Mental health|Early life exposure to abuse and development of hidradenitis suppurativa
223396865|NCT06267469|DEVICE|Thermoplastic orthosis|The use of the author's orthosis is aimed at correcting the anatomical alignment of the MP (metacarpophalangeal) joints, IP (interphalangeal) by properly tensioning the central extensor band and the lateral bands of the thumb's extensor apparatus. It should significantly increase the mobility of the hand in connection with improving hand grip and reducing pain.
224016204|NCT00239343|DRUG|gefitinib|
224016205|NCT01470313|DRUG|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
224016206|NCT01470313|DRUG|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
224016207|NCT01556477|DRUG|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
224016208|NCT01556477|DRUG|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
224016209|NCT06164080|OTHER|participants receiving Corticosteroid|Pregnant women using antenatal corticosteroids for any reason before 34 weeks
224016210|NCT00007345|DRUG|Romidepsin|
224016211|NCT04217733|DRUG|pentoxyifylline|Pentoxyifylline two times daily for 3 months
224016212|NCT04217733|DRUG|Mebeverine|Mebeverine 3 times for 3 months
224016213|NCT04217733|DRUG|ethosuximide|ethosuximide 3 times for 3 months
224016214|NCT05166187|OTHER|Best Practice Advisory|Patients in this arm will have a Best Practice Advisory displayed in the Electronic Medical Record (EMR) as part of the discharge order workflow.
224016215|NCT04433585|DRUG|LY3471851|Administered SC
224016216|NCT04433585|DRUG|Placebo|Administered SC
224016217|NCT02436785|OTHER|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
224016218|NCT02436785|OTHER|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
224016219|NCT02800577|DEVICE|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
224016220|NCT04095741|DIAGNOSTIC_TEST|Questionnaires|Filling in questionnaires of general functioning and symptomes of anorexia nervosa and autism spectrum disorders will demanded to children and their parents. The children all have a history of anorexia nervosa.
224016221|NCT03975738|OTHER|To be part of a blog|To be part of a blog - to respond to questions and free to comment on other participants comments
224016222|NCT05977504|OTHER|Multi-Psychological Empowerment Courses|9 times online course and 3-days workshop for 6 months of psychological Empowerment Courses.
224016223|NCT00988520|DRUG|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
224016224|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
224016225|NCT00988520|DRUG|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
223396866|NCT06813703|DEVICE|Using an electrical stimulation device to relieve pain during colonoscopy|In the electrical stimulation group, the device's current intensity will be adjusted to the maximum tolerance below the participant's pain threshold, while in the control group, the current intensity will be set to the minimum.
223396867|NCT06587893|OTHER|echography|performance of ultrasound of the scapular regions to identify and measure the suprascapular notch in our group of healthy adult volunteers.
223396868|NCT06655207|DEVICE|Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding|Oli is a non-invasive wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding, including postpartum haemorrhage.
223396869|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon
223396870|NCT06657833|DEVICE|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent|Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
223396871|NCT00931086|DRUG|belimumab|IV 10mg/kg q28days
224016226|NCT00988520|DRUG|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
224016227|NCT00988520|DRUG|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
224016228|NCT02074553|DRUG|Ro542-4802/F03 (Reference)|Participants will receive Ro542-4802/F03 (containing 50% SLS) 600 mg capsules orally on Day 1.
224016229|NCT02074553|DRUG|Ro542-4802/F07 (Test)|Participants will receive Ro542-4802/F07 (containing 25% SLS) 600 mg capsules orally on Day 1.
224016230|NCT02074553|DRUG|Ro542-4802/F08 (Test)|Participants will receive Ro542-4802/F08 (containing 3% SLS) 600 mg capsules orally on Day 1.
224016231|NCT02074553|DRUG|Ro542-4802/F14 (Test)|Participants will receive Ro542-4802/F14 (containing 12.5% SLS) 600 mg capsules orally on Day 1.
224016232|NCT04661956|PROCEDURE|Transbronchial cryobiopsy/Transbronchial lung biopsy (forcep)|Transbronchial lung biopsy by cryoprobe or by forcep
224016233|NCT04278040|DRUG|Melphalan|Inhalations with low doses of Melphalan for 5 consequent days
224016234|NCT01633918|BEHAVIORAL|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
224016235|NCT01633918|BEHAVIORAL|Usual health education|Usual health education lessons
224016236|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
224016237|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
224016238|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
224016239|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
224016240|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
224016241|NCT00367887|DRUG|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
224016242|NCT00367887|DRUG|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
224016243|NCT00367887|DRUG|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
224016244|NCT00118833|DRUG|Hypericum perforatum (St. John's wort)|
224016245|NCT01658150|DRUG|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
224016246|NCT03325920|DEVICE|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
224016247|NCT04123834|PROCEDURE|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
224016248|NCT04123834|PROCEDURE|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
224016249|NCT04123834|DEVICE|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
224016250|NCT05787028|DRUG|AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Take one AD16 tablet in the morning
224016251|NCT05787028|DRUG|AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg|Participants will take a placebo pill matching AD16 once in the morning
224016252|NCT05172141|BIOLOGICAL|IBI314(low dose)|intravenously, once, on Day 1
224016253|NCT05172141|BIOLOGICAL|IBI314(high dose)|intravenously, once, on Day 1
224016254|NCT05172141|BIOLOGICAL|IBI314(medium dose)|intravenously, once, on Day 1
224016255|NCT05172141|OTHER|Placebo|intravenously, once, on Day 1
224016256|NCT02898844|BEHAVIORAL|Mixed Diet Condition|One roommate dieted and the other ate normally.
224016257|NCT02898844|BEHAVIORAL|Both Diet Condition|Both roommates dieted.
224016258|NCT02057120|PROCEDURE|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
224016259|NCT02057120|DEVICE|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
224016260|NCT02342743|DEVICE|CEFALY|
224016261|NCT00321113|DRUG|tacrolimus|immunosuppression
224016262|NCT00321113|DRUG|mycophenolate mofetil|oral
223550422|NCT04227275|DRUG|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
223550423|NCT04227275|DRUG|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
224016263|NCT00321113|DRUG|steroids|oral
224016264|NCT02486133|DRUG|Prezista|once daily
224016265|NCT02486133|DRUG|Norvir|once daily
224016266|NCT02486133|DRUG|Tivicay|once daily
223550424|NCT04227275|DRUG|Anakinra|In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
224016267|NCT02486133|DRUG|Truvada|once daily
223550425|NCT02039167|DEVICE|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
223550426|NCT03101189|DRUG|ACT-541468|Capsule
223550427|NCT03101189|DRUG|placebo|Matching placebo capsule
223550428|NCT06282237|OTHER|survey|Quality of life survey and motor performace survey
224016268|NCT02486133|DRUG|Kivexa|once daily
224016269|NCT02486133|DRUG|Descovy|once daily
224016270|NCT04875676|BIOLOGICAL|VXA-G1.1-NN|Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant
224016271|NCT04187989|BEHAVIORAL|Social Media Intervention|Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.
224016272|NCT04593316|OTHER|Saliva collection|A saliva sample will be collected before physical exercise.
224016273|NCT04593316|BEHAVIORAL|Questionnaires|The participant will fill in questionnaires relative to his heath status and psychological and motivational resource questionnaires before physical exercise.
224016274|NCT04593316|OTHER|Ingestible core temperature capsule intake|The participant will ingest a capsule before physical exercise in order to continuously monitor core temperature during physical exercise.
224016275|NCT04593316|OTHER|Physical exercise|The participant will perform a walk/run test.
224016276|NCT04593316|OTHER|Heart rate monitoring|Heart rate will be monitored during physical exercise thanks to a chest belt.
224016277|NCT04593316|OTHER|Core temperature monitoring|Heart rate will be monitored during physical exercise thanks to an ingestible core temperature capsule.
224016278|NCT06445426|DEVICE|Cystometry|The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure. The investigational device is inserted into a 12F single-use hydrophilic catheter. After correct positioning is verified by ultrasound and x-ray, the investigational device is released from the insertion catheter. The insertion catheter is then carefully removed, securing the correct positioning of the investigational device inside the bladder. The investigational device is connected to a data logger. In the conventional device, the intravesical pressure is recorded using a water perfused 3F catheter with a 3 ml/hour perfusion rate. The 3F catheter is hooked on an 8F catheter to facilitate introduction into the bladder. The catheters used for pressure transmission are connected to external transducers and a computer with software processing the recording
224016279|NCT03305354|BEHAVIORAL|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
224016280|NCT03305354|BEHAVIORAL|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
224016281|NCT03646656|BEHAVIORAL|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
224016282|NCT03602066|DRUG|Chlorine Dioxide Sterilization|Given via oral rinse
224016283|NCT03602066|OTHER|Laboratory Biomarker Analysis|Correlative studies
224016284|NCT03602066|OTHER|Placebo|Given via oral rinse
224016285|NCT00092495|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
224016286|NCT01793311|OTHER|decaffeinated coffee|contains caffeine 0.5-2 mg
224016287|NCT01793311|OTHER|regular dose coffee|contains 91.8 mg of caffeine
224016288|NCT01793311|OTHER|high dose coffee|contains 144 mg of caffeine
224016289|NCT02454179|DRUG|pembrolizumab|
224016290|NCT02454179|DRUG|Acalabrutinib|
223396872|NCT03447639|DRUG|Povidone-iodine irrigation|Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
223396873|NCT04251247|DIAGNOSTIC_TEST|D-dimer/fibrinogen ratio|The ratio of D-dimer (ng/ml) to fibrinogen (mg/dl)
223396874|NCT06824974|BEHAVIORAL|Time-restricted eating plus healthy diet|Subjects will restrict calorie consumption to 8-10 hours during the day plus will follow a healthy plant-based diet.
223396875|NCT06858319|DRUG|zigakibart|solution for subcutaneous injection
223396876|NCT06858761|PROCEDURE|Robot-assisted surgical strategy|Primary or revision bariatric surgery (for complications or side effects of a previous surgery), using a robotic approach. The robot used will be the Da Vinci X or Xi model (depending on the center) from the company Intuitive Surgical.
223396877|NCT06858761|PROCEDURE|Conventional laparoscopic surgical strategy|Primary or revision bariatric surgery (for complications or side effects of a previous surgery), using a conventional laparoscopic approach
223396878|NCT06858761|OTHER|Visual analog scale|All patients will have pain evaluation with visual analog scale
223396879|NCT06858761|OTHER|EQ-5D-5L questionnaire|All patients will have quality of life assessment with EQ-5D-5L questionnaire
223396880|NCT06858761|OTHER|Impact of Weight on Quality of Life (IWQOL) questionnaire|All patients will have Quality of life assessment with IWQOL questionnaire
224016291|NCT04012138|DRUG|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
224016292|NCT04012138|DRUG|Insulin Aspart|"Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
224016293|NCT03130803|BEHAVIORAL|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
224016294|NCT02859532|RADIATION|elastography SWIRE|
223396881|NCT01147068|BIOLOGICAL|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
223396882|NCT03746132|DEVICE|EPIFLO|EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
223396883|NCT03181633|DRUG|ACH-0144471|ACH-0144471 will be administered to all participants enrolled in the study.
223396884|NCT02702830|OTHER|Cardiopulmonary Exercise Testing|Undergo CPET
223396885|NCT02702830|DEVICE|Magnetic Resonance Imaging|Undergo MRI
223396886|NCT06596434|DRUG|Drug: 4-Aminopyridine|Active study drug
224016295|NCT03182725|DRUG|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
224016296|NCT03182725|DRUG|Placebo|A substance that has no therapeutic effect and will act as a control.
224016297|NCT02558686|OTHER|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
223396887|NCT06596434|OTHER|Placebo|Placebo comparator
223396888|NCT06989853|DRUG|Placebo|The effects of placebo will be determined.
223396889|NCT06989853|DRUG|Methamphetamine|Placebo and methamphetamine will be administered intravenously during experimental sessions.
224016298|NCT02558686|OTHER|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
224016299|NCT02558686|OTHER|Placebo|Individuals will not perform any action after the application of trigger point dry needling
224016300|NCT00938470|DRUG|capecitabine|Given PO
223396890|NCT06989645|DRUG|SYN321|Intra-articular
223396891|NCT06989645|DRUG|Placebo|Intra-articular
223396892|NCT06668883|PROCEDURE|Sputum collection for molecular analysis|Sputum collection to be used with syndromic multiplex PCR testing
223396893|NCT06668883|DEVICE|Breath and cough collection for molecular analysis|Breath and cough collection with two proprietary devices to be used with syndromic multiplex PCR testing
223396894|NCT06995651|DRUG|Dorzagliatin|Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.
223396895|NCT06995651|DRUG|Placebo|Randomized, double-blind, cross-over study of Dorzagliatin 75 mg orally twice daily for 7 days compared to matched-placebo orally twice daily for 7 days.
223396896|NCT02755285|DEVICE|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
223396897|NCT00665782|OTHER|laboratory biomarker analysis|
223396898|NCT00665782|OTHER|questionnaire administration|
223396899|NCT00665782|OTHER|study of socioeconomic and demographic variables|
223396900|NCT00665782|PROCEDURE|assessment of therapy complications|
223396901|NCT00665782|PROCEDURE|psychosocial assessment and care|
223396902|NCT00665782|PROCEDURE|therapeutic conventional surgery|
223550429|NCT02419378|DRUG|Alemtuzumab|
224016301|NCT00938470|DRUG|docetaxel|Given IV
224016302|NCT00938470|DRUG|fluorouracil|Given IV
224016303|NCT00938470|DRUG|oxaliplatin|Given IV
223396903|NCT01597778|BIOLOGICAL|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
224016304|NCT00938470|RADIATION|radiation therapy|Undergo radiation therapy
224016305|NCT00938470|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223396904|NCT01597778|BIOLOGICAL|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
223396905|NCT06581978|PROCEDURE|Whole-Body Vibration Intervention|Whole-Body Vibration Intervention
223396906|NCT06581978|PROCEDURE|Exercise Intervention Group|Traditional Chinese medical exercises training
223396907|NCT00422604|DRUG|salmeterol|
223396908|NCT00422604|DRUG|tiotropium|
223396909|NCT00422604|DRUG|GSK233705|
223396910|NCT00004883|BIOLOGICAL|trastuzumab|Given IV
223396911|NCT00004883|OTHER|laboratory biomarker analysis|Correlative studies
223396912|NCT01417793|BEHAVIORAL|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
223396913|NCT01838369|DRUG|BI-505|
223396914|NCT03211676|DEVICE|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
223396915|NCT03211676|DEVICE|Elisio-21H|hemodialysis with Elisio-21H dialyzer
223396916|NCT06615921|OTHER|No Intervention|This is a non-interventional study.
224016306|NCT02808637|OTHER|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
223396917|NCT01210560|DRUG|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
224016307|NCT02808637|OTHER|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
224016308|NCT02808637|OTHER|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
224016309|NCT02808637|OTHER|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
224016310|NCT01412463|DEVICE|stent placement|"* pre-dilation of the study lesion is mandatory~* stent placement with 1 Protégé Everflex+ stent~* only 1 stent is allowed within the study protocol~* post-dilation may be performed but is not mandatory"
224016311|NCT04851925|OTHER|MR Fingerprinting|Specific Magnetic Resonance Imaging protocol
224016312|NCT04171323|BEHAVIORAL|Cognitive Training|Participants will be completing a total of 40 computerized sessions.
223396918|NCT01210560|DRUG|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
223396919|NCT01210560|DRUG|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
223396920|NCT01210560|DRUG|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
223396921|NCT01210560|DRUG|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
223396922|NCT04837196|DRUG|ASP7517|Intravenous (IV)
223396923|NCT04837196|DRUG|Pembrolizumab|Intravenous (IV)
223396924|NCT06691425|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT (5 x 8 Gy)
223396925|NCT06691425|DRUG|Chemotherapy|Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
223396926|NCT07112495|OTHER|pregnant women with|pregnant women with
224016313|NCT04171323|BEHAVIORAL|Computerized Cognitive Stimulation|Participants will be completing a total of 40 computerized cognitive stimulation sessions.
224016314|NCT00267839|BEHAVIORAL|physical exercise, wellness|
223396927|NCT07113015|DRUG|propranolol|40 mg orally twice daily, titrated up to a maximum of 80 mg/day.
223396928|NCT07113015|DRUG|Amantadine|100 mg orally twice daily, titrated up to a maximum of 200 mg/day.
223396929|NCT07113314|DIETARY_SUPPLEMENT|Lactoferrin Bovine|In addition to standard treatment, a gold-soluble formulation of bovine lactoferrin or bLF (Mosiac®) at the standard dose of 200 mg/day, in single administration, from the start of chemo/radiotherapy treatment and throughout the risk period.
223550430|NCT04073862|OTHER|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
223550431|NCT01304615|BEHAVIORAL|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
223550432|NCT01304615|BEHAVIORAL|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
223550433|NCT01304615|BEHAVIORAL|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
223550434|NCT05242341|BEHAVIORAL|application(APP) teaching|Teaching the use of the APP
223550435|NCT03005236|DRUG|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
223550436|NCT03005236|DRUG|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
223396930|NCT07037498|DIETARY_SUPPLEMENT|Moringa Oleifera|Participants receive MRJ capsules containing 490 mg of Moringa oleifera leaf extract and 10 mg of royal jelly, taken orally twice per week for 12 months. The capsules are plant-based, produced using locally sourced ingredients, and are part of a food-based supplementation strategy developed as an alternative to iron-folic acid tablets. The intervention is combined with standardized nutrition education via TikTok videos. Adherence is monitored weekly through teacher log sheets and WhatsApp documentation. and Participants receive iron-folic acid (IFA) tablets containing 60 mg of elemental iron and 400 µg of folic acid, taken orally once per week for 12 months in accordance with Indonesia's national supplementation guidelines for adolescent girls. This control intervention is combined with the same standardized nutrition education via TikTok videos. Compliance is tracked weekly through teacher-supervised control sheets and WhatsApp photo submissions.
223550437|NCT01403779|RADIATION|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
224016315|NCT00767416|BIOLOGICAL|MEDI-559|Cohort 1 (5 to \<24 months): N=80 MEDI-559 at 10\^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10\^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
223396931|NCT05813886|OTHER|biodex balance system|The balance tests of the patients were performed 2 to24 WEEKS after their recovery from the disease, which was confirmed by the evaluations of the Covid-19 staff and negative polymerase chain reaction test.
224016316|NCT00767416|OTHER|Placebo|Cohort 1 (5 to \< 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
223396932|NCT06722651|DEVICE|Netrod™ six-electrode radiofrequency renal denervation system|"Netrod™ renal denervation (RDN) system, which is indicated for the treatment of uncontrolled hypertension. It consists of the following two components:~* Netrod™ Six-Electrode Basket Radiofrequency Renal Denervation Catheter and~* Netrod™ Renal Denervation Radiofrequency Generator The catheter's electrodes deploy into a self-adaptive basket structure, optimizing contact with the vessel wall for effective ablation."
223396933|NCT06722651|DEVICE|Sham Procedure|Patients will be remained on the catheterization table for at least 20 min prior to sheath removal.
223396934|NCT03271684|OTHER|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
223396935|NCT03271684|OTHER|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
223396936|NCT01522456|DRUG|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
223396937|NCT01522456|DRUG|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
223396938|NCT04910594|DRUG|recombinant human erythropoietin|To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
223396939|NCT02975947|DEVICE|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher \& Paykel's HUMIGARD system (Fisher \& Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
223396940|NCT02975947|DEVICE|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
223550438|NCT03741907|PROCEDURE|FAUCS|extraperitoneal cesarean with a paramedian left section
223550439|NCT03741907|PROCEDURE|MLC|Gold standard
223550440|NCT06510803|DRUG|The case intervention is the sevoflurane concentrations with the Drager Apollo workstation|The increases in the sevoflurane concentrations during induction of anesthesia with the Drager Apollo compared with the GE Ohmeda workstations
224016317|NCT05105451|OTHER|Collecting clinical data, EGG，arterial blood gas data and venous blood sample|Collecting clinical data(before induction of anesthesia and first day after surgery), EGG（first day after surgery），arterial blood gas data(before induction of anesthesia and first day after surgery) and venous blood sample （before induction of anesthesia and first day, third day and 7th day after surgery）
224016318|NCT04952454|PROCEDURE|External Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via skin incision.
224016319|NCT04952454|PROCEDURE|Endonasal Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via endonasal route.
224016320|NCT04952454|PROCEDURE|Transcanalicular Dacryocystorhinostomy|The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via transcanalicular route.
224016321|NCT02853253|DIETARY_SUPPLEMENT|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
223396941|NCT03859544|OTHER|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
223396942|NCT00298727|BEHAVIORAL|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
223396943|NCT00298727|BEHAVIORAL|ePBL|Online Problem-Based Course
223396944|NCT01406587|DRUG|PP4001|50 mg, 1 dose every 12 hours x 4 doses
223396945|NCT01406587|DRUG|PP4001|100 mg, 1 dose every 12 hours x 4 doses
223396946|NCT01406587|DRUG|PP4001|200 mg, 1 dose every 12 hours x 4 doses
223396947|NCT01406587|DRUG|Placebo|Placebo, 1 dose every 12 hours x 4 doses
223396948|NCT04306211|DEVICE|SuperNO2VA|SUPERNO2VA is nasal PAP device for oxygen delivery
223550441|NCT02097628|PROCEDURE|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
223550442|NCT02097628|PROCEDURE|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
224016322|NCT02853253|DIETARY_SUPPLEMENT|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
224016323|NCT00409266|DEVICE|Computer assisted navigation|
223396949|NCT06353347|DRUG|HTD1801|HTD1801 1000 mg administered orally BID as four capsules
224016324|NCT04962932|BEHAVIORAL|Internet-deliviered exposure-based CBT|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
224016325|NCT04962932|BEHAVIORAL|Internet-delivered stress management treatment|The intervention last for 10 weeks and include: Internet-SMT include life-style advice (e.g., exercise, sleep advice), relaxation and problem-solving skills to reduce stress. Patients are offered regular online contact with a psychologist with the same frequency and intensity as in the CBT arm.
224016326|NCT01739842|DIETARY_SUPPLEMENT|Kudzu extract|
224016327|NCT02265627|DRUG|BIIL 284 BS|
224016328|NCT00431080|DRUG|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
224128373|NCT04767256|OTHER|PCIA|Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
224128374|NCT03374514|DRUG|Dexamethasone|instilation of the solution in the middle ear
223396950|NCT06353347|DRUG|Placebo|Matching placebo administered orally BID as four capsules
223396951|NCT03048227|DEVICE|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
223396952|NCT03681249|DRUG|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
223396953|NCT03681249|DRUG|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
223396954|NCT05593809|RADIATION|SPECT with pentavalent 99mTc DMSA|"A dose of 555-740 MBq 99mTc (V) DMSA is injected into a peripheral vein. Delayed brain SPECT/CT images will be obtained at 2-3 h after injection. Imaging will be performed on a hybrid dual head SPECT/CT machine (Symbia T, Siemens, Erlangen, Germany) fitted with a low energy high-resolution collimator, using 15% energy window set at 140 keV.~SPECT images are acquired in a noncircular 360° arc for a total of 64 frames, 25-s/frame, using a 128 × 128 matrix size. Following SPECT acquisition, low-dose CT is acquired for anatomical localization and attenuation correction. The used CT parameters are: tube voltage 130 kV, tube current 80 mA, and slice thickness 1 mm. Images will be reconstructed using manufacturer's iterative protocol (four iterations, four subsets, and Gaussian filter 8 mm). The reconstructed images will be reviewed on a viewing workstation running OsiriX MD version 6.5.2 (Pixmeo, Bernex, Switzerland)."
223396955|NCT00114660|DRUG|Cocoa butter application|
223396956|NCT05655130|DRUG|Dexamethasone|Intraoperative 10 mg IV Dose
223550443|NCT01097096|BIOLOGICAL|CAD106|150μg and 450μg doses were reconstituted and administered via intramuscular injection
223550444|NCT01097096|BIOLOGICAL|Placebo|Identical placebo to CAD106 administered via intramuscular injection
223550445|NCT01097096|BIOLOGICAL|Alum|An adjuvant (additive to increase potency ) of low, middle or high doses which was mixed with reconstituted active CAD106
223550446|NCT01097096|BIOLOGICAL|MF59|An adjuvant (additive to increase potency) of low, middle and high doses which was mixed with reconstituted active CAD106
223550447|NCT02562846|OTHER|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
223550448|NCT04359862|DRUG|Sevoflurane|25 patients sedated with Sevoflurane via inhalation, starting with 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
224128375|NCT03374514|DRUG|Sterile isotonic saline solution|Sterile isotonic saline solution
224128376|NCT04705727|DRUG|Budesonide Formoterol Drug Combination|This combination will be used to treat the asthma exacerbation, patients will take one inhalation of budesonide/formoterol Turbuhaler® 100/6 μg every 5 minutes (Maximum 12 inhalations).
224128377|NCT04705727|DRUG|nebulisation of terbutaline|Patients will receive 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered.
224128378|NCT01325480|DEVICE|Cardiac Pacing|
223396957|NCT05655130|DRUG|Methylprednisolone|"The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)"
223550449|NCT04359862|DRUG|Propofol|25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)
223550450|NCT05985798|DRUG|Sin-Bev-TACE|Sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) are administered at 3-7 days after the first TACE. The study treatment of sintilimab and bevacizumab will last up to 24 months. TACE can be repeated on demand.
223550451|NCT05985798|DRUG|Len-TACE|Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started at 3-7 days after the first TACE. TACE will be repeated on demand.
223550452|NCT01540786|PROCEDURE|High resolution urodynamic assessment|
223550453|NCT01540786|PROCEDURE|Conventional urodynamic assessment|
223550454|NCT03703232|DEVICE|Investigational prosthetic foot|Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
223550455|NCT01377909|DRUG|statin|daily statin orally for 48 weeks
223550456|NCT00271908|BEHAVIORAL|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
224016329|NCT00431080|DRUG|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
224016330|NCT00431080|DRUG|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
224016331|NCT00431080|DRUG|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
224016332|NCT00431080|DRUG|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
224016333|NCT00431080|DRUG|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
224016334|NCT03455621|PROCEDURE|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
224016335|NCT00252837|DRUG|Tesaglitazar|
224128379|NCT01472172|DEVICE|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
224128380|NCT02750800|BIOLOGICAL|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
223396958|NCT05655130|OTHER|Standard of Care|standard of care surgery
223396959|NCT01597310|DRUG|Warfarin|single doses at specified time periods
223396960|NCT01597310|DRUG|Dexpramipexole|multiple doses
223396961|NCT03290963|DRUG|Lithium|Lithium will be dosed in units (LI level \> or = 0.4 milliequivalents (mEq)/L)
223396962|NCT03290963|DRUG|Placebo|Placebo tablets, dosed in units
223550457|NCT03268889|DRUG|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
223550458|NCT00886860|DRUG|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
223550459|NCT00886860|DRUG|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
223550460|NCT03133494|OTHER|ABG analysis|ABG analysis was performed and compared between two groups
223550461|NCT00618735|DRUG|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
223550462|NCT00618735|DRUG|BIIB021|Twice daily dosing
224016336|NCT00252837|BEHAVIORAL|Dietary and Lifestyle counseling|
224016337|NCT02510898|BEHAVIORAL|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
224016338|NCT03433508|BIOLOGICAL|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
223396963|NCT03290963|DRUG|Ketamine|All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.
224016339|NCT03433508|OTHER|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
224016340|NCT05837715|DEVICE|Chattanooga Stabilizer pressure biofeedback|"Stabilization exercises, which form the basis of spinal stabilization training, increase the strength and endurance of the postural and stabilizer muscles by using the basic principles of motor learning, and improve balance control in stable and unstable positions.~In addition, stabilization exercises include kinesthetic training and functional training.~Spinal stabilization training is very important for proper control of extremity movements.~It is also an important factor in the formation of proper spinal posture and the neutral position required for the spine.~In cervical region problems, cervical stabilization exercises that activate the deep neck flexors (longus colli and longus capitis) can be applied.~Cervical stabilization training improves the cervical proprioception sense as well as strength and endurance, thereby reducing joint position sense error."
224128381|NCT02750800|BEHAVIORAL|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
224128382|NCT02191787|DRUG|Seresis®|
224016341|NCT05837715|DEVICE|VibraSens - Focal Vibration Therapy (TechnoConcept - France)|"Vibration applications have also started to be used for treatment purposes. Therapeutic vibration produces minor changes in skeletal muscle length. Vibrations elicit a response called the tonic vibration reflex, which includes activation of muscle spindles, neural signals by Ia afferents, and activation of muscle fibers via large α-motor neurons. The tonic vibration reflex can also cause an increase in activation of motor units through activation of muscle spindles and polysynaptic pathways. It is well known that the input of the proprioceptive pathways (Ia, IIa and possibly IIb) plays an important role in the production of isometric contractions. The increase in isometric strength after application of vibration with extensive sensory stimulation may be the result of more efficient use of the positive proprioceptive feedback loop. It can be predicted that the increased muscle strength after vibration application is due to neural adaptation."
224016342|NCT05837715|OTHER|Telerehabilitation|Telerehabilitation is a method that aims to provide rehabilitation to patients/clinicians by reducing obstacles such as distance, time and cost by using information and communication technologies. Telerehabilitation enables patients who cannot access rehabilitation due to geographic, economic or physical disabilities to benefit from rehabilitation services. The COVID-19 pandemic has highlighted the importance of telerehabilitation practices. In order to minimize the risk of transmission in the COVID-19 pandemic, the physical activity levels of individuals have decreased and their access to rehabilitation services has been restricted by the restriction of social life.
224016343|NCT00363909|DRUG|citalopram hydrobromide|
224016344|NCT00363909|OTHER|placebo|
224016345|NCT00377494|BIOLOGICAL|MVA-CSO Vaccine|
224016346|NCT00377494|BIOLOGICAL|PfCSP DNA (VCL-2510) Vaccine|
224016347|NCT03840915|DRUG|Cisplatin|Cisplatin was administered intravenously at a dose of 75 milligrams per meter square (mg/m\^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
224016348|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
223396964|NCT03971786|BEHAVIORAL|Quality of life|Assessment of quality of life through measuring scales
223396965|NCT00981487|DRUG|Ondansetron|24 mg one time
223396966|NCT00981487|DRUG|Ondansetron|24 mg, on time in the am
224016349|NCT03840915|DRUG|Pemetrexed|Pemetrexed was administered intravenously at a dose of 500 mg/ m\^2 over 10 minutes every 21 days.
224016350|NCT03840915|DRUG|Nab-paclitaxel|Nab-paclitaxel was administered intravenously at as dose of 100 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
223396967|NCT01889147|BIOLOGICAL|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
224016351|NCT03840915|DRUG|Gemcitabine|Gemcitabine was administered intravenously at a dose of 1250 mg/m\^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
224016352|NCT03840915|DRUG|Docetaxel|Docetaxel was administered intravenously at a dose of 75 mg/m\^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
224016353|NCT03840915|DRUG|M7824|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
224016354|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
224016355|NCT03840915|DRUG|Carboplatin|Carboplatin was administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
224016356|NCT03840915|DRUG|Bintrafusp alfa|M7824 was administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
224016357|NCT03840915|DRUG|Paclitaxel|Paclitaxel was administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).
224016358|NCT06074965|DEVICE|Medtronic Extended Infusion Set|Each subject will be given 2 types of infusion sets to wear and change sets per label use (3 days for Medtronic Quick-set™ and 7 days for Medtronic Extended).
224016359|NCT01431222|DEVICE|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
224016360|NCT00309959|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
224016361|NCT00309959|OTHER|Laboratory Biomarker Analysis|Correlative studies
223396968|NCT01889147|BIOLOGICAL|Placebo|
223396969|NCT04395482|OTHER|Lung CT scan analysis in COVID-19 patients|This research project will evaluate the morphological characteristics of the lung by CT scan analysis in COVID-19 patients which will be identified as specific patterns using artificial intelligence technology and their impact on outcome.
223396970|NCT05756582|DIAGNOSTIC_TEST|Prevalence of Latent Tuberculosis Infection|The prevalence of Latent Tuberculosis Infection \[LTBI\] is defined as 1) tuberculin conversion after a documented negative-baseline tuberculin skin test (TST), 2) positive result of the QuantiFERON-TB Gold (QFT) test performed \[higher response than the cut-off value of 0.35 IU / ml of INF-γ was detected in at least one test tube (TB1 or TB2)\], 3) chest imaging excluding pleural and/or pulmonary lesions suggestive of active tuberculosis and 4) final medical evaluation done by a Specialist in Infectious Diseases which excluded active disease. All four criteria must be met.
223550463|NCT04535973|DIAGNOSTIC_TEST|unstimulated saliva sample for hormone analysis|hormone levels will be determined in frozen samples of unstimulated saliva
223550464|NCT04535973|OTHER|quality of life questionnaire|all participants will fill out self-perceived quality of life questionnaire
223550465|NCT01174979|DRUG|Caroverin|treatment with eardrops 2 times for 48 hours
224128383|NCT02191787|DRUG|Placebo|
224128384|NCT04281745|BIOLOGICAL|CORETOX Inj|Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.
223396971|NCT01364376|DRUG|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
223396972|NCT01565889|DRUG|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
223396973|NCT01565889|DRUG|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
223550466|NCT02941770|BEHAVIORAL|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
223550467|NCT02941770|OTHER|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
223550468|NCT03238703|DRUG|Anastrozole|Given PO
223550469|NCT03238703|DRUG|Exemestane|Given PO
223396974|NCT01565889|DRUG|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
223396975|NCT01565889|DRUG|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
223396976|NCT01565889|DRUG|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
223396977|NCT01565889|DRUG|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
223396978|NCT01565889|DRUG|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
223396979|NCT01565889|DRUG|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
223396980|NCT01565889|DRUG|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
223396981|NCT01565889|DRUG|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
223731228|NCT02848157|DRUG|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
223731229|NCT02848157|DRUG|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
223731230|NCT02848157|DRUG|Ropivacaine|
223731231|NCT03752359|DIETARY_SUPPLEMENT|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
224016362|NCT04535024|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
224016363|NCT04535024|DRUG|Sintilimab|Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
224016364|NCT05325801|BIOLOGICAL|BMCA and GPRC5D dual target CAR-T cells(OriC321)|Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321
223396982|NCT01565889|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223396983|NCT04800640|OTHER|Experimental: Electroanalgesia|The sample will consist of 66 individuals, of both men and women, where they will be randomly included in two groups: Intervention group composed of 33 patients who will effectively receive the treatment through electroanalgesia via TENS;
223396984|NCT04967573|DRUG|Rivaroxaban|Rivaroxaban 20 mg or 10 mg for 3 months
223396985|NCT05123430|PROCEDURE|Monitoring of the pressure of the middle left atrium|During the MitraClip surgery, additional catheter is installed in order to monitoring the ppressure of the middle left atrium
223396986|NCT02723344|DIETARY_SUPPLEMENT|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
223396987|NCT02723344|OTHER|Sunflower and medium chain triglyceride oils|Placebo
223396988|NCT00524940|BIOLOGICAL|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
224016365|NCT00600678|DIETARY_SUPPLEMENT|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
224016366|NCT00821574|DRUG|Fluvastatin|Fluvastatin: daily 80 mg, oral
224016367|NCT00821574|DRUG|Valsartan|Valsartan: daily 160 mg, oral
224016368|NCT00821574|DRUG|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
224016369|NCT01119599|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
224016370|NCT01119599|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
224016371|NCT01119599|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224128385|NCT03298412|DRUG|Blinatumomab|Blinatumomab is administered as a continuous IV infusion.
223396989|NCT03473184|DRUG|Diacerein 1% ointment|Diacerein 1% ointment and vehicle ointment were applied on Day 1 at two randomly assigned skin sites on each side of the lower thoracic area of the back according to a randomization scheme. One side of the back was irradiated on Day 2, including an untreated irradiated control site, and the other side was to remain non-irradiated.
223396990|NCT01326845|DRUG|Deferasirox|
223396991|NCT02060305|DRUG|Bevacizumab intra-articular injection|Bevacizumab, 20\~40mg, intra-articular injection every 28 days for 4 times
223396992|NCT05667376|OTHER|Local drug delivery|Local application of curcumin gel into the periodontal pocket
223396993|NCT05667376|DRUG|curcumin gel|curcumin gel
223396994|NCT03564392|BEHAVIORAL|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
223396995|NCT01410903|DEVICE|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
223396996|NCT02964247|DRUG|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
223396997|NCT02964247|DRUG|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
223396998|NCT04851847|DEVICE|Guided Tissue Regeneration (GTR)|Use of resorbable collagen membrane to treat periodontal intrabony defects.
223396999|NCT06239727|DRUG|PD-1 blocking antibody|"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1."
223397000|NCT06239727|DRUG|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
223397001|NCT06239727|DRUG|Cisplatin (80 mg/m2)|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
223397002|NCT06239727|RADIATION|Reduced-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F."
223397003|NCT06239727|RADIATION|Conventional-dose Intensity-modulated radiotherapy|"1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F."
223397004|NCT06239727|DRUG|Cisplatin (100 mg/m2)|Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
223397005|NCT06239727|DRUG|Capecitabine|Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
224016372|NCT01119599|OTHER|Laboratory Biomarker Analysis|Correlative studies
224016373|NCT01119599|OTHER|Pharmacological Study|Correlative studies
223550470|NCT03238703|OTHER|Laboratory Biomarker Analysis|Correlative studies
223550471|NCT03238703|DRUG|Letrozole|Given PO
223550472|NCT03238703|OTHER|Quality-of-Life Assessment|Ancillary studies
223550473|NCT03238703|OTHER|Questionnaire Administration|Ancillary studies
223550474|NCT03238703|DRUG|Tamoxifen Citrate|Given PO
224016374|NCT01119599|DRUG|Temozolomide|Given PO
224016375|NCT01119599|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224016376|NCT01283477|DEVICE|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
224016377|NCT01283477|DEVICE|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE \& LEFT IN PLACE FOR 30 MINUTES
224016378|NCT00406055|DEVICE|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
224016379|NCT06020053|PROCEDURE|saline irrigation at various temperatures (4°C, 25°C)|cold serum application
224016380|NCT00884494|DRUG|Ghrelin infusion to assess effects on insulin sensitivity|
224128386|NCT04360616|DIAGNOSTIC_TEST|imaging|perform US and mammography examination
224128387|NCT05960019|DIETARY_SUPPLEMENT|Fermented milk product|This is a type of cultured bovine milk, that is prepared through mesophilic fermentation of milk, that is widely available in Kenya. Participants will be expected to consume 250ml of the mala each day for breakfast.
224128388|NCT05960019|DIETARY_SUPPLEMENT|Fermented cereal based product|This is a fermented cereal-based porridge prepared from a mix of ground millet and sorghum that is mixed with water into a gruel which is fermented into a non-alcoholic beverage or meal depending on desired thickness. Participants will be expected to consume 250ml of the porridge each day for breakfast.
224016381|NCT04212520|OTHER|No intervention|No intervention
223550475|NCT03238703|DRUG|Toremifene Citrate|Given PO
223550476|NCT04381052|DRUG|Clazakizumab|Dose is 25mg intravenously over 30 minutes.
223550477|NCT04381052|OTHER|Placebo|Intravenously administered over 30 minutes.
223550478|NCT01440114|DRUG|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
223731232|NCT03752359|DIETARY_SUPPLEMENT|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
224016382|NCT04009915|PROCEDURE|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.
224016383|NCT04009915|PROCEDURE|Open surgery|Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
224016384|NCT01600820|OTHER|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
224016385|NCT01600820|OTHER|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
224016386|NCT01600820|OTHER|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
224016387|NCT05778669|OTHER|Monitoring of medical, health and psychosocial conditions|"Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system."
224016388|NCT01264822|DRUG|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
224016389|NCT04417296|DIAGNOSTIC_TEST|antepartum computerised cardiotocography analysis|A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
224016390|NCT02313376|BIOLOGICAL|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
224016391|NCT06327581|DRUG|Lactic Acid|patients will be treated with MN combined with lactic acid solution 1%. Lactic acid solution 88% concentration PH (6.84), diluted with distilled water to have a final concentration of 1%
224016392|NCT06327581|DRUG|vit D|patients will be treated with MN combined with topical application of vitamin D3 (an aqueous preparation of cholecalciferol (2.5 mg/ ml), The maximum total amount of vitamin D3 injected into a patient in every session will be 2.5 mg (1 ml)
224016393|NCT06327581|DRUG|Triamcinolone Acetonide|patients will be treated with MN combined with triamcinolone acetonide injectable suspension (Epirelefan®, 40mg/ ml, Eipico, Egypt) (10 mg/ml) will be used in a dose of 0.1 ml/cm2 area
224016394|NCT06327581|DRUG|Saline|patients will be treated with MN combined with normal saline 0.9%
224016395|NCT03167372|OTHER|Litebook® Advantage|Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
224016396|NCT03167372|OTHER|Fitbit Flex2 TM|Standard system activity and sleep tracker
223397006|NCT01057680|DIETARY_SUPPLEMENT|creatine monohydrate|Powder, 0.1 g per day, 12 months
223397007|NCT01057680|DIETARY_SUPPLEMENT|sugar placebo|powder, 0.1 g/day, 12 months
223397008|NCT00748592|DRUG|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
223397009|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
223397010|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
223397011|NCT00748592|DRUG|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
223397012|NCT03918629|BIOLOGICAL|Clostridium difficile|Toxoid-based Clostridium difficile vaccine
223397013|NCT03918629|BIOLOGICAL|Placebo|Normal saline solution (0.9% sodium chloride)
223397014|NCT05215444|DIAGNOSTIC_TEST|some prognostic factors|cortisol level, renin, troponin I, MDA ,catalase, super oxide dismutase, liver functions, kidney functions, arterial blood gases, sodium level, potassium level. white blood cells count
223397015|NCT01615367|OTHER|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
223397016|NCT01615367|DRUG|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
223550479|NCT01440114|DRUG|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
223550480|NCT02859285|OTHER|Placebo vulvar cream|
223550481|NCT02859285|OTHER|Estradiol vulvar cream|
224016397|NCT02056353|DEVICE|LOGIC-Insulin algorithm|
224016398|NCT02056353|DEVICE|Paper protocol|
224016399|NCT00171808|DRUG|Letrozole|
223550482|NCT04434430|DRUG|Gabapentin|Oral Gabapentin 600 mg
223550483|NCT04434430|OTHER|Placebo|Oral NaCl 500 mg
223550484|NCT02357537|BEHAVIORAL|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
224128389|NCT05960019|BEHAVIORAL|Behavioural modification counselling|Standard of care shall comprise behavioural (lifestyle) modification counselling delivered monthly. This shall consist of provision of counselling on lifestyle modification in an effort to help the patients prevent progression of the pre-diabetes and provide help with any emerging complications of the disease. Counselling on lifestyle modification shall comprise provision of standard dietary and exercise advice for pre-diabetics by a study doctor.
223550485|NCT01143961|DEVICE|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
223550486|NCT01794507|DRUG|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
223550487|NCT01794507|DRUG|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
223550488|NCT01794507|DRUG|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
224016400|NCT00113100|DRUG|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
224016401|NCT04897750|COMBINATION_PRODUCT|CT001|Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
224016402|NCT03534401|BEHAVIORAL|ARCHES Kenya|ARCHES: Contraceptive counselors in intervention clinics will receiving training to ) provide counseling and education regarding risk of partner detection of contraceptive methods, and women's and girls' strategies to use contraceptive methods to minimize partner detection risk integrated into standard contraceptive counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) offer palm-sized educational materials on RC and IPV, as well as IPV services to all clients.
224016403|NCT00626132|DIETARY_SUPPLEMENT|Eucommia|two capsules three times a day orally for 2 weeks
224016404|NCT02134418|BEHAVIORAL|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
224016405|NCT04571359|OTHER|Oxalate to creatinine ratio|Comparsion between 24 hours urine oxalate and spot urine oxalate to creatinine ratio
224016406|NCT00875927|OTHER|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
224016407|NCT00875927|OTHER|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
224016408|NCT00875927|OTHER|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
224016409|NCT00875927|OTHER|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
224016410|NCT00875927|OTHER|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
224016411|NCT05104281|DRUG|osimertinib oral and bevazizumab intravenously|osimertinib 80mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days.
224016412|NCT03037853|OTHER|Healthy volunteers|MRI scanner
224016413|NCT05466409|OTHER|Visualization of the hyoid bone|Visualization of the hyoid bone using POCUS of upper airway (probe positioning: transverse plane). Hyoid bone visualization will be assessed as a binary outcome (yes/no).
224016414|NCT05466409|OTHER|Visualization of vocal cords|Visualization of the vocal cords through the cricoid cartilage using POCUS of upper airway (probe positioning: transverse plane). Vocal cords visualization will be assessed as a binary outcome (yes/no).
224016415|NCT05466409|OTHER|Localization of thyrohyoid membrane|Localization of thyrohyoid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Thyrohyoid membrane visualization will be assessed as a binary outcome (yes/no).
224016416|NCT05466409|OTHER|Visualization of epiglottis and pre-epiglottic space|Visualization of epiglottis and pre-epiglottic space using POCUS of upper airway (probe positioning: midsagittal plane). Epiglottis and pre-epiglottic space visualization will be assessed as a binary outcome (yes/no).
224016417|NCT05466409|OTHER|Visualization of cricothyroid membrane|Visualization of cricothyroid membrane using POCUS of upper airway (probe positioning: midsagittal plane). Cricothyroid membrane visualization will be assessed as a binary outcome (yes/no).
223550489|NCT03697161|DRUG|OV101 (gaboxadol)|OV101 (gaboxadol)
223550490|NCT06095869|OTHER|progressive relaxation exercise|Breastfeeding mothers in the progressive relaxation exercise group were applied gradual relaxation exercise before going to bed 3 days a week and for 4 weeks, under the supervision of the researcher, accompanied by a training CD prepared by the Turkish Psychologists Association.
224016418|NCT05466409|OTHER|Visualization of thyroid gland|Visualization of thyroid gland using POCUS of upper airway (probe positioning: transverse plane). Thyroid gland visualization will be assessed as a binary outcome (yes/no).
224016419|NCT05466409|OTHER|Hyoid bone to skin distance|Measurement of hyoid bone to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
224016420|NCT05466409|OTHER|Anterior commissure to skin distance|Measurement of anterior commissure to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
224016421|NCT05466409|OTHER|Epiglottis to skin distance|Measurement of epiglottis to skin distance (mm) using POCUS of upper airway (probe positioning: midsagittal plane).
224016422|NCT05466409|OTHER|Thyroid isthmus to skin distance|Measurement of thyroid isthmus to skin distance (mm) using POCUS of upper airway (probe positioning: transverse plane).
223397017|NCT00475267|DEVICE|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
223397018|NCT04748484|DEVICE|KCC Active or inactive|Depending of the randomization, the KCC will be active or inactive, and will provide heat when active, but the patient won't know if the medical device is active or not. The battery charge indicator will work the same whether the device is operating or not.
223397019|NCT04935541|DRUG|Dexmedetomidine infusion|After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
224016423|NCT00335647|DRUG|fluphenazine hydrochloride|
223397020|NCT04935541|DRUG|Remifentanil infusion|After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
223397021|NCT03288064|DIETARY_SUPPLEMENT|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
223397022|NCT03288064|DIETARY_SUPPLEMENT|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
223397023|NCT03288064|DIETARY_SUPPLEMENT|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
223397024|NCT00607321|DEVICE|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
223397025|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally|Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
223397026|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
223397027|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)|Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
223397028|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days|Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.
223397029|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.
223397030|NCT05976100|DRUG|NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)|Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
223397031|NCT01709500|DRUG|LMT (atorvastatin, simvastatin, or rosuvastatin)|
223397032|NCT01709500|DRUG|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
223397033|NCT01709500|DRUG|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
224016424|NCT06463561|DEVICE|Continuous positive airway pressure|Treatment will start with an empirical pressure of 8 cmH2O and, within a maximum of 3 weeks, the pressure will be adjusted by means of automatic titration, establishing the pressure corresponding to the 95th percentile.
224016425|NCT06463561|OTHER|Hygienic-dietary recommendations and daily physical activity promotion|Hygienic-dietary recommendations on sleep and intervention for the promotion of daily physical activity, establishing walking as a goal 10,000 steps per day. To do this, they will be provided with a pedometer and asked to fill out a form with the steps walked each day. At each visit, the distance walked will be reviewed and the goal set will be reiterated.
224128390|NCT05295368|OTHER|Multicomponent intervention|Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
224128391|NCT05596903|OTHER|EMDR 2.0 group protocol|EMDR 2.0 group protocol
223397034|NCT02571699|OTHER|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
223397035|NCT02749500|OTHER|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
223397036|NCT02749500|DEVICE|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
223397037|NCT00197171|BIOLOGICAL|Combined Hepatitis A and B vaccine|
223397038|NCT04015973|DIETARY_SUPPLEMENT|High energy diet|An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
224016426|NCT00316628|BIOLOGICAL|influenza vaccine|
224016427|NCT00833768|DRUG|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
224016428|NCT00833768|DRUG|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
223397039|NCT04105673|OTHER|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
223397040|NCT02826629|DEVICE|Manual dexterity|Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
223397041|NCT02826629|DEVICE|Oculomotor movements|Oculomotor movements during behavioral task will be recorded using a video-oculography device
224128392|NCT05596903|OTHER|Mhgap stress module|Mhgap stress module
224128393|NCT04379219|DRUG|Methotrexate|giving methotrexate at least 1 w week before surgery
223397042|NCT02826629|DEVICE|TMS coupled to EMG recording|The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
223397043|NCT02826629|OTHER|Psychopathological evaluations|
224016429|NCT01004848|BEHAVIORAL|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
224016430|NCT00099827|BEHAVIORAL|Education|Individuals will receive information about depression
224016431|NCT03959410|DIAGNOSTIC_TEST|Cervical biopsy|in office Cervical biopsy
223397044|NCT02826629|OTHER|Neuropsychological evaluations|
224016432|NCT03724773|DEVICE|Long-Arm Cast|A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.
224016433|NCT03724773|DEVICE|Sugar-Tong Splint|A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
224016434|NCT00470340|DRUG|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
224016435|NCT04708353|DRUG|placebo capsule (vitamin c)|the patient will receive one placebo capsule (vitamin c) once one hour before the operation
224016436|NCT04708353|DRUG|Group pregabalin 150|the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
224016437|NCT04708353|DRUG|Group pregabalin 300|the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
224016438|NCT05052177|DEVICE|Edge to edge repair in systemic tricuspid valve regurgitation|Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.
224016439|NCT01071343|DEVICE|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
224016440|NCT04531826|OTHER|5-strand hamstring graft preparation|Five-strand hamstring graft preparation
224016441|NCT04723238|DRUG|Duloxetine 60mg Test Drug Enteric Coated Granules|Investigational Medicinal Product
224016442|NCT04723238|DRUG|Duloxetine 60mg Reference Product Enteric Coated Granules|Cymbalta (Eli Lilly)
224016443|NCT04185129|DRUG|Foster|a randomized study for comparison asthma patients using Foster or Relvar. The primary end point is lung function improvement evaluation
224016444|NCT04587752|BEHAVIORAL|CBT for Weight Bullying|Cognitive-behavioral therapy for weight-related bullying delivered by audio/video telehealth.
224016445|NCT01621568|DRUG|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
224016446|NCT01621568|DRUG|Sunitinib|50mg/day for 2 weeks daily, by mouth with 1 week off (3 week cycle)
224016447|NCT03130881|DRUG|PLB1003|PLB1003 is a capsule and is administered orally.
224016448|NCT01662375|OTHER|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
224016449|NCT05687357|DRUG|Tislelizumab|IV infusion
224128394|NCT02542917|DEVICE|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
224016450|NCT05687357|DRUG|S-1|Oral tablets
224016451|NCT05687357|DRUG|Oxaliplatin|IV infusion
224016452|NCT05687357|DRUG|Nab paclitaxel|IV infusion
224016453|NCT05687357|RADIATION|Radiation|TOMO/VMAT
224016454|NCT05399914|OTHER|S-NIPPV|Synchronized noninvasive positive pressure ventilation during the first 10 minutes after birth.
224016455|NCT00201890|PROCEDURE|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
224016456|NCT01051830|OTHER|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
224016457|NCT01379378|DEVICE|Artificial urinary sphincter|Standard of care
224016458|NCT01379378|DEVICE|InVance Sling|Standard of care
224016459|NCT01379378|DEVICE|AdVance Sling|Standard of care
224016460|NCT01379378|DEVICE|Virtue Sling|Standard of care
224016461|NCT01379378|DRUG|Contigen|2.5-10 cc
224016462|NCT05057780|OTHER|Communication Skills Curriculum|Our novel intervention adapted curricula around effective skills used to navigate common communication challenges in clinical practice. These skills were selected after determining patterns from multiple communication sessions delivered to over 6,000 healthcare providers. Our main goal was to enhance communication with patients by helping residents gain confidence and competence using these under-utilized communication skills, regardless of the communication challenge. Over the course of three, 1-hour long sessions on communication in the 2017-2018 academic year, internal medicine residents learned three of these highly effective and often under-utilized skills; reflective listening, responding to emotion and reframing, respectively.
224016463|NCT02334423|BIOLOGICAL|Botulinum toxin, Type A|Botulinum toxin, Type A
224016464|NCT02334423|OTHER|0.9% sterile, unpreserved saline|Placebo
224128395|NCT02874404|DRUG|Ibrutinib|Given PO
224128396|NCT02874404|OTHER|Laboratory Biomarker Analysis|Correlative markers
224128397|NCT02874404|DRUG|PI3K-delta Inhibitor TGR-1202|Given PO
224128398|NCT04687605|PROCEDURE|Temporary hypercapnia|Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
223397045|NCT03631589|BIOLOGICAL|MSCs|mesenchymal stem cells therapy
223397046|NCT04127773|DEVICE|oro gastric tube|According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.
223397047|NCT00128440|DRUG|BEA 2180 BR|
223397048|NCT00128440|DRUG|tiotropium|
223397049|NCT00270244|BEHAVIORAL|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions-one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
224128399|NCT05631548|DEVICE|iTBS to dmPFC|TMS will be delivered with a MagVenture Mag Pro R30 with the Cool-B70 A/P coil with active liquid cooling and active/sham sides. Approximately 25% of the nasion-inion distance, or Talairah coordinates X 0 Y+60 Z+60 will be measured.The first session will begin with the acquisition of the resting motor threshold (rMT; lowest stimulus intensity that elicits a visible twitch on 50% of the trials) on the contralateral hand. iTBS (triplet 50 Hz bursts, repeated at 5 Hz, 2 sec on and 8 sec off; 600 pulses per session) will be delivered at 110% of the rMT and will last about 3 minutes. Each participant will receive 2 sessions with a 15-20 minute interval between sessions.
223731233|NCT02657382|BEHAVIORAL|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
223731234|NCT02657382|OTHER|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
223731235|NCT00805623|DIETARY_SUPPLEMENT|sucrose|1 cc of sucrose 33.5% with or without pacifier
224128400|NCT05631548|DEVICE|Sham iTBS|Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 2 sessions with a 15-20 min interval between sessions.
223731236|NCT04079829|OTHER|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
224016465|NCT01635777|DRUG|Miltefosine|2.5 mg/kg/day for 12 weeks
224128401|NCT01592409|DRUG|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
223397050|NCT00270244|BEHAVIORAL|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
223397051|NCT06509802|BEHAVIORAL|Web-based Single-session Intervention of Mindset on Intelligence, Failure, and Emotion (We-SMILE)|This study will be a two-arm randomised controlled trial to examine the efficacy of the We-SMILE for pre-practicum social work and/or counselling students by comparing to the We-SMILE intervention group and the no-intervention training-as-usual group.
223397052|NCT02142790|DRUG|paclitaxel liposome injection|
224016466|NCT01635777|DRUG|Miltefosine|2.5 mg/kg/day for 8 weeks
224016467|NCT05845034|PROCEDURE|PVI + SPEs ablation|electrophysiology substrate mapping is the critical difference between both groups.
224016468|NCT05845034|PROCEDURE|PVI ablation|electrophysiology substrate mapping is the critical difference between both groups.
224016469|NCT03232853|OTHER|Elearning|Elearning
224016470|NCT02930226|BIOLOGICAL|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
224016471|NCT02930226|BIOLOGICAL|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
224016472|NCT00042718|DRUG|levofloxacin, azithromycin, amoxicillin/clavulanate|
224016473|NCT01846377|BEHAVIORAL|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
224016474|NCT04211662|BEHAVIORAL|Tailored Multidimensional Intervention. the tailored intervention will be implemented through 6 months using a multidimensional approach (skill building, psychoeducation and peer support).|Skill-building can be defined as training the family caregivers the following skills (1) hands-on training in such skills as positioning, transferring and mobility techniques and assistance with activities of daily living; (2) coping strategies and stress management (3) communicating with healthcare professionals. Psycho-education is teaching and provision the family caregivers the knowledge and information regarding stroke (stroke definition, types of stroke, risk factors, prevention of recurrent stroke, medication management, stroke complications and measures for prevention and management of these complications). Besides, family caregivers will be taught and given the knowledge and information regarding managing stroke survivors' emotions and behaviors. Peer support can be defined as engaging the family caregivers of stroke survivors in interactions with their peers for support and exchanging advices and experiences.
224016475|NCT05502549|DRUG|CB03-154|CB03-154 tablet once daily.
224016476|NCT05502549|DRUG|Placebo|Placebo tablet once daily.
224016477|NCT00652327|DRUG|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
223397053|NCT06265454|DRUG|low dose atropine eye drops|Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
223397054|NCT06265454|DRUG|Placebo|placebo
223397055|NCT06213077|DIETARY_SUPPLEMENT|Nitric Oxide|Naturally produced and found in many different kinds of cells and organ systems, NO is an integral molecule in regulating blood pressure and maintaining a healthy cardiovascular system. NO produced or generated in the vasculature then diffuses into the underlying smooth muscle causing these muscles to relax. This results in vasodilation, causing a reduction in systemic blood pressure and an increase in blood flow and oxygen delivery to specific vascular beds.
223397056|NCT06213077|DRUG|Tadalafil|Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).
223397057|NCT06213077|OTHER|Placebo|Nitric Oxide Placebo Compound
223397058|NCT03143283|BEHAVIORAL|Safety Study Lethal Means Counseling|Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
223397059|NCT04245254|DIETARY_SUPPLEMENT|Collagen Protien Powder|Collegen Protein Powser
223397060|NCT06079372|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
223397061|NCT06079372|DRUG|asfotase alfa|Asfotase alfa will be administered via SC injection.
224016478|NCT00652327|DRUG|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
224016479|NCT00848731|DRUG|nitric oxide|nitric oxide gas is delivered by facemask
223397062|NCT01756027|DEVICE|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
223397063|NCT01756027|DEVICE|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
223397064|NCT02044380|DRUG|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
223397065|NCT00740636|DRUG|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
224016480|NCT01076647|DRUG|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
224016481|NCT01076647|DRUG|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
224016482|NCT02765802|DRUG|Peginterferon Lambda-1A|
224016483|NCT02582112|OTHER|Active Comparator: Warming group|Placebo Comparator: Control group
224016484|NCT00920075|DRUG|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
224016485|NCT04677634|DIETARY_SUPPLEMENT|ISOThrive Prebiotic Nectar|The test material is ISOThrive. It is an approximately 90% pure maltosyl-isomalto-oligosacchride (MIMO) prebiotic syrup produced by bacterial fermentation/bio-conversion of sucrose and maltose. It is taken 1g daily.
224128402|NCT01592409|DRUG|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
224128403|NCT04544436|DRUG|Ocrelizumab|The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).
224128404|NCT04544436|DRUG|Ocrelizumab|Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
223397066|NCT00740636|DRUG|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
224016486|NCT04538001|DEVICE|Balloon implantation|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and balloon implantation.
223397067|NCT02125500|DRUG|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
223397068|NCT04787471|COMBINATION_PRODUCT|30 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
223397069|NCT04787471|COMBINATION_PRODUCT|10 minute photoactivation of riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes
223397070|NCT07078136|DIAGNOSTIC_TEST|Multimodal AI Model|Patients' endoscopic images, EUS images, and clinical data will be analyzed by a multimodal AI model for lesion classification and GIST risk stratification.
223397071|NCT07078136|DIAGNOSTIC_TEST|Expert Endoscopist Assessment|Endoscopic ultrasound images will be interpreted by experienced endoscopists for comparison with the AI model.
223397072|NCT05204927|DRUG|177Lu-PSMA-I&T|Radioligand therapy
223397073|NCT05204927|DRUG|Abiraterone with Prednisone or Enzalutamide|Hormone Therapy
223397074|NCT05160532|DRUG|Placebo|5ml of normal saline (NS)
223397075|NCT05160532|DRUG|Dextrose prolotherapy (DPT)|25% dextrose, mixing 2.5ml of sterile water and 2.5ml of 50% dextrose.
223397076|NCT07094243|BEHAVIORAL|Motivational Psychotherapy|A structured short-term intervention based on motivational psychotherapy, delivered in individual sessions over 8 weeks to improve adolescent depression and academic self-concept.
223397077|NCT07096180|DRUG|Chemotherapy drug|Participants in the standard care group receive conventional chemotherapy for breast cancer according to clinical guidelines. Treatment includes 8 cycles of chemotherapy administered every 3 weeks. No Traditional Chinese Medicine (TCM) is provided in this group.
223550491|NCT06095869|OTHER|relaxation background music|In the relaxation background music group, breastfeeding mothers were listened to relaxation background music on the Progressive Relaxation Exercise CD before going to bed 3 days a week and for 4 weeks.
224016487|NCT04538001|PROCEDURE|Rotator cuff repair|Subjects will undergo arthroscopic surgical intervention of debridement, long head of biceps tenotomy if deemed necessary with or without acromioplasty, and partial repair
224016488|NCT03210922|DEVICE|Miami cervical collar|Collar group is put on the Miami cervical collar.
224016489|NCT01599494|DRUG|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
224016490|NCT01599494|DRUG|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
224016491|NCT01599494|DRUG|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
224016492|NCT01599494|DRUG|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
224016493|NCT01599494|DRUG|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
223397078|NCT07096180|OTHER|Integrative Treatment (Chemotherapy + TCM)|Participants in the integrative care group receive conventional chemotherapy combined with Traditional Chinese Medicine (TCM) treatment. Herbal formulas are prescribed by licensed TCM physicians based on syndrome differentiation and are aimed at strengthening vital qi and harmonizing stomach function. Treatment is conducted under Taiwan's National Health Insurance coverage.
223731237|NCT00569699|DRUG|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25 m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
224016494|NCT02133209|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
224016495|NCT02133209|BEHAVIORAL|Stress Management for Headaches|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
224016496|NCT00254618|DRUG|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
224016497|NCT00254618|DRUG|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
224016498|NCT00254618|DRUG|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
224016499|NCT02926898|DRUG|ZX008 (Fenfluramine Hydrochloride)|"ZX008 0.5 mg/kg/day (maximum 20 mg/day). ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL.~\*Note: The 0.5 mg/kg/day dose of ZX008 fenfluramine hydrochloride in this study is equivalent to 0.4 mg/kg/day (maximum 17 mg/day) dose of fenfluramine base."
223397079|NCT07097636|OTHER|Video education|A video demonstrating the steps of the urodynamic procedure was shown, and afterward, participants' questions were answered by an experienced nurse who performed the procedure.
223397080|NCT07097636|OTHER|No intervention|Children scheduled to undergo urodynamic testing for any reason received the procedure without any prior video-based education being provided to their parents
223397081|NCT06438575|DIAGNOSTIC_TEST|Xpert® Xpress MVP test|The Xpert® Xpress MVP is an FDA-cleared point-of-care test for vaginitis diagnosis
224016500|NCT02926898|DRUG|Matching Placebo|Matching Placebo
224016501|NCT06397300|PROCEDURE|bilateral Ultrasound guided erector spinae plane (ESP) block|To perform ESP block in the lateral position bilaterally ,the skin will be disinfected with 70% alchol bilaterally and a linear transducer is placed in a longitudinal parasagittal orientation and erector spinae muscle, trapezius muscle, rhomboid major muscle (rhomboid major muscle is absent below T6 level) and transverse process are visualized and local anesthetic is injected (0.25% bupivacaine 20 ml in each side) in the area between transverse process and erector spinae muscle at T10 level.
224016502|NCT06397300|PROCEDURE|quadratus lumborum block|In the lateral decubitus position. Right block will be performed; the patient will then repositioned for the left block. An ultrasound device with a convex probe (5-8 MHz) will be placed in the mid-axillary line just above the iliac crest. Then, scan dorsally to keep the transverse orientation until seeing the aponeurosis of the transverses abdominus muscle and by following this aponeurosis, QL muscle will be visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle. A spinal needle (20G) will be inserted in-plane from the anterior to posterior direction, and the tip of the needle will be advanced anterior to the QL muscle. The target site for injection is the plane between the quadratus lumborum and psoas major muscles. This will be followed by injection of 0.25% bupivacaine 20 ml in each side.
224128405|NCT04544436|DRUG|Antihistamine|Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
224128406|NCT04544436|DRUG|Methylprednisolone|Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
223397082|NCT06438575|DIAGNOSTIC_TEST|Usual Care|Usual methods used by the healthcare provider for vaginitis diagnosis
223731238|NCT02622542|DEVICE|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
223731239|NCT02622542|OTHER|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
224016503|NCT06397300|PROCEDURE|lumbar epidural|"under strict aseptic precautions, lumbar epidural was performed for patients in Group III using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces was chosen for the injection.~The epidural space identified by the loss of resistance technique. The catheter was advanced 4 cm cephalad. When the aspiration test results for blood and cerebrospinal fluid were negative, a test dose of (3 mL) 2% lidocaine with 1: 200,000 adrenaline was given after the placement of the epidural catheter.~Then this will be followed by injection of 0.25% bupivacaine 15 ml as a single injection after induction of general anesthesia."
223397083|NCT03362372|BEHAVIORAL|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~1. Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~2. Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~3. Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
223397084|NCT07089771|PROCEDURE|Virtual Chromoendoscopy|"High-Definition Virtual Chromoendoscopy (HD-VCE):~Surveillance colonoscopy using high-definition virtual chromoendoscopy enhances mucosal visualization through advanced imaging filters integrated into the colonoscope. This dye-free technique improves detection of dysplasia by increasing contrast and highlighting subtle mucosal patterns during withdrawal. HD-VCE reduces procedure time and eliminates risks related to dye application, offering a practical alternative to dye-based methods. Its efficacy in IBD surveillance requires further validation."
223397085|NCT07089771|PROCEDURE|Dye-Based Chromoendoscopy|"High-Definition Dye-Based Chromoendoscopy (HD-DCE):~Surveillance colonoscopy using high-definition dye-based chromoendoscopy involves segmental application of indigo carmine dye via a spray catheter. The dye enhances mucosal surface patterns, aiding dysplasia detection. HD-DCE is currently considered a gold standard in IBD surveillance due to superior dysplasia detection rates."
223397086|NCT07112066|DIAGNOSTIC_TEST|FAPI tracer|18F-FAPI-74 PET/CT, cardiac MRI, echocardiography and blood sample for BMP5 serum concetration is performed at baseline and 12-month follow-up.
223397087|NCT07113288|DEVICE|Inspire® UAS System|Participants will be implanted with a commercially available Inspire® UAS System. In addition, participants will receive a patient remote which is used to initiate therapy each night.
223397088|NCT07111247|DRUG|Gonadotropin Releasing Hormone Antagonists Relugolix|Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.
223397089|NCT00741507|BEHAVIORAL|Alcohol drinking|Never drinking of alcohol
223397090|NCT00741507|BEHAVIORAL|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
223397091|NCT00741507|BEHAVIORAL|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
223397092|NCT00741507|BEHAVIORAL|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
223397093|NCT00741507|BEHAVIORAL|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
223397094|NCT06932094|DRUG|QLS5132|antibody drug conjugate (ADC).
223397095|NCT06933459|DRUG|Test Drug|AJU-C714
223397096|NCT06933459|DRUG|Reference Drug|C714R
223397097|NCT03072420|OTHER|Compression of the fingertip under MRI.|Compression of the fingertip by a static loading on the phalanx distal of the index of the subjects; Then also a shear stress in the transverse direction of the finger. The data provided by the MRI images will be geometric information such as the thickness of the skin and its possible variation as a function of the area of the finger, the total thickness of soft tissues in compression as a function of the variation in l The angle between the axis of the phalanx and the plane of contact; Mechanical type information relating to the displacements and reaction forces, to the internal deformations of the different areas of the finger.
223397098|NCT05372614|PROCEDURE|Biopsy Procedure|Undergo biopsy
223397099|NCT05372614|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223397100|NCT05372614|PROCEDURE|Computed Tomography|Undergo CT scan
223397101|NCT05372614|PROCEDURE|Echocardiography Test|Undergo echocardiography
223731240|NCT02526472|PROCEDURE|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
224016504|NCT03481543|PROCEDURE|In-line nebulization through NIV mask|In-line nebulization will be given through NIV circuit.
224016505|NCT03481543|PROCEDURE|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
223397102|NCT05372614|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223397103|NCT05372614|DRUG|Neratinib Maleate|Given PO
223397104|NCT05372614|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223397105|NCT01744444|DRUG|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
223397106|NCT01744444|DRUG|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
223397107|NCT05063981|DRUG|Mepolizumab|Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
223397108|NCT03737695|PROCEDURE|Biospecimen Collection|Undergo biospecimen collection
223397109|NCT03737695|OTHER|Medical Chart Review|Undergo clinical information collection
223397110|NCT05916313|DRUG|BI 764532|BI 764532
223397111|NCT05224102|DRUG|Faricimab|Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
223397112|NCT06792175|DIAGNOSTIC_TEST|Solicue Machine Learning Models|"A comprehensive machine-learning tool aimed at providing probability estimates for several compatible disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), Bipolar Affective Disorder (BPAD), Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia Spectrum Disorders (SSD). By offering a multi-diagnostic assessment based on speech analysis, Solicue aims to assist clinicians in navigating this complexity and potentially identifying conditions that might otherwise be overlooked in initial assessments.~Solicue leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features."
223397113|NCT06792175|DIAGNOSTIC_TEST|Mercuria Machine Learning Models|"Mercuria is designed to stratify the risk of bipolar disorder in individuals presenting with depressive symptoms. This is a critical clinical need, as misdiagnosis of bipolar disorder as unipolar depression is common and can lead to inappropriate treatment, potentially worsening outcomes. By analyzing speech patterns characteristic of bipolar disorder, Mercuria aims to provide an additional tool for clinicians to differentiate between these conditions more accurately, guiding appropriate treatment decisions.~Mercuria leverages machine learning to analyze a wide range of clinically relevant speech features, including linguistic content, prosodic elements (such as pitch, rhythm, and intonation), and other paralinguistic features."
223397114|NCT05065047|DRUG|Belantamab mafodotin|Given by IV
223550492|NCT06095869|OTHER|control group|Mothers in this group received routine care practices in the clinic. No intervention was made to the mothers in the control group, only data collection tools were applied.
223397115|NCT05399498|DRUG|Psilocybin|Psilocybin 25mg capsule
223397116|NCT04198350|PROCEDURE|Islet implantation|Transplantation of allogeneic pancreatic human islets will be performed into the anterior chamber of a single eye with the poorest visual acuity (see inclusion/exclusion criteria below). Up to 40 000 IEQ of islets in a maximum volume of 350µl will be transplanted.
223397117|NCT05753748|PROCEDURE|Endoscopic Eradication Therapy|Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
223397118|NCT06345495|DRUG|Ruxolitinib|Given by PO
223397119|NCT06345495|PROCEDURE|Allogeneic Stem Cell Transplantation|Given by Transplant
223397120|NCT06345495|DRUG|Levetiracetam|Given by PO
223397121|NCT06345495|DRUG|Eltrombopag|Given by PO
223397122|NCT06345495|DRUG|Busulfan|Given by IV
223397123|NCT06345495|DRUG|Romiplostim|Given by IV
223397124|NCT06345495|DRUG|Fludarabine phosphate|Given by IV
223397125|NCT06345495|DRUG|Cyclophosphamide|Given by IV
223397126|NCT06345495|DRUG|Mesna|Given by IV
223731241|NCT02526472|PROCEDURE|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
224016506|NCT06533358|DRUG|MT1002 Injection|MT1002 is infused once only, once for 4h. MT1002 is for subjects with acute coronary syndrome undergoing PCI
224016507|NCT06292468|OTHER|Traditional physical therapy|This group received 30 minutes of muscle stretching (quadriceps, gastrocnemius, hamstrings, tibialis), bilateral ankle strengthening, gait training and foot care guidelines, 3 times a week for a duration of six weeks.
224016508|NCT06292468|OTHER|Plantar cutaneous sensory stimulation|This group received 45 minutes of plantar cutaneous sensory stimulation, TENS, muscle stretching (quadriceps, gastrocnemius, hamstrings, tibialis), bilateral ankle strengthening, gait training, and foot care guidelines, 3 times a week for a duration of six weeks.
224016509|NCT04984538|OTHER|Pharmacogenomic Testing|Cheek swab as a part of routine care
224016510|NCT02752698|PROCEDURE|Micro Hand S robotic surgery|20-70 patients undergo Micro Hand S robotic surgeries
224128407|NCT02310802|DRUG|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
224128408|NCT02310802|DRUG|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
223397127|NCT06345495|DRUG|Tacrolimus|Given by IV or PO
223397128|NCT05199077|DRUG|GM-XANTHO|a topical applied ointment
223731242|NCT04996888|DEVICE|AI based preoperative automatic reminder system|the patients in the experimental group will be sent a message and a phone call by AI system on the day before colonoscopy, which will emphasize the importance of bowel preparation, the directions for use and side effects of purgatives, the proper food type, and the start time. The system is an non-invasive AI system.
223550493|NCT06294262|BIOLOGICAL|TETRALITE|Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
224016511|NCT02752698|PROCEDURE|laparoscopic surgery|20-70 patients undergo laparoscopic surgeries
224016512|NCT02752698|PROCEDURE|da Vinci robotic surgery|20-70 patients undergo da Vinci robotic surgeries
223731243|NCT02424747|OTHER|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
223397131|NCT05862103|OTHER|Treatment Strategies|AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
224128409|NCT02310802|DRUG|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
224128410|NCT02310802|DRUG|Placebo|Placebo dispersible tablets for single oral administration
224128411|NCT06677307|DRUG|KRRO-110|KRRO-110 drug product, IV
223550494|NCT01056406|BEHAVIORAL|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
223550495|NCT02350075|PROCEDURE|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
223550496|NCT02350075|DEVICE|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
224128412|NCT03875326|DEVICE|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
223550497|NCT02104791|DRUG|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
224128413|NCT03875326|DEVICE|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
224128414|NCT03875326|DEVICE|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
224128415|NCT03875326|DEVICE|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
224128416|NCT05805423|PROCEDURE|bilateral superficial cervical plexus blocks and local wound infiltration|10mL bupivacaine at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
224128417|NCT05805423|PROCEDURE|placebo injection and local wound infiltration|10mL normal saline at Erb's point bilaterally and 10mL 0.25% Bupicacaine at incision
224128418|NCT04860661|DRUG|Esketamine|After delivery, the parturient was given a loading dose of esketamine, and then a small dose of esketamine was added into PCIA analgesia pump
224128419|NCT04860661|DRUG|Normal saline|10 ml normal saline
223731244|NCT03966001|OTHER|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
223731245|NCT03966001|OTHER|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
223731246|NCT04653805|OTHER|Current clinical practice in primary care of patients with type 2 diabetes mellitus|
223550498|NCT05435131|DIAGNOSTIC_TEST|GCF obtaining|GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
223731247|NCT02746874|PROCEDURE|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
223731248|NCT02746874|PROCEDURE|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
223731249|NCT00499018|DRUG|Rituximab|375 mg/m2 day 1
224128420|NCT03172221|DIAGNOSTIC_TEST|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
224128421|NCT00718757|DRUG|Dexamethasone|5 doses given on Days 6-10
224128422|NCT00718757|DRUG|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
224128423|NCT00718757|DRUG|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg"
224128424|NCT05618340|DEVICE|Pulsed electric field ablation device;Cardiac Pulsed Electric Field Ablation Catheter|"Routinely placing a coronary sinus electrode catheter, puncturing the interatrial septum, placing one sheath into the left atrium, confirming that the catheter is well in place, and setting the treatment time of the pulse ablation system in advance.~Pulmonary vein-by-pulmonary vein ablation using a circular pulse catheter, waiting for the end of the pulse ablation phase and immediate effect confirmation."
224128425|NCT06214455|OTHER|Low sugar diet and 10-12 hour eating window|Low sugar diet and 10-12 hour eating window for four weeks
224128426|NCT06214455|OTHER|Low sugar diet, 8 hour eating window and fasting|Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.
224128427|NCT05888792|OTHER|Variant of Defocus Incorporated Spectacle lens (DG2)|DG2 is a variant of Defocus Incorporated Spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously
224128428|NCT05397886|DRUG|Remimazolam Besylate|Remimazolam Besylate is used as intervention drug for general anesthesia, which followed by flumazenil administration at the end of anesthesia, to be compared to propofol total intravenous anesthesia during radiofrequency catheter ablation of atrial fibrillation.
224128429|NCT05397886|DRUG|Flumazenil|Flumazenil is used as additional intervention drug to facilitate emergence from general anesthesia in the Remimazolam with Flumazenil group.
224128430|NCT05397886|DRUG|Propofol|Propofol is used as active comparator drug for general anesthesia until the end of anesthesia, to be compared to remimazolam besylate during radiofrequency catheter ablation of atrial fibrillation.
224128431|NCT02957058|PROCEDURE|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
224128432|NCT00216099|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
223550499|NCT05435131|DIAGNOSTIC_TEST|Saliva Obtaining|Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
223550500|NCT05435131|DIAGNOSTIC_TEST|Serum obtaining|Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
223550501|NCT06380725|DEVICE|Transcranial alternating current stimulation(real stimulation)|Real tACS is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of weak current to the brain by means of electrodes placed in the skull.
223550502|NCT06380725|DEVICE|Transcranial alternating current stimulation(sham stimulation)|Transcranial alternating current stimulation (sham-stimulation) is an emerging noninvasive neuro-regulation technique that applies a specific frequency of stimulation and a specific intensity of a weak current to the brain by means of electrodes placed in the skull. The subjects felt the same as the real stimulus when receiving the sham-stimulus treatment, but the sham-stimulus did not have the current stimulation.
223550503|NCT02343601|DEVICE|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
223550504|NCT01463163|DRUG|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
223397144|NCT05858996|BEHAVIORAL|Pain-CPG-EIT|"Following randomization champions and stakeholder team members from the communities will be identified. The investigators will recommend the following individuals to be members of the stakeholder team: a nurse in a leadership position (e.g., director of nursing); the designated champion(s); nursing home administrator; physician/medical director, nurse practitioner and/or physician assistant; unit nurse; nursing assistant; activity staff; social worker; pharmacist; and rehabilitation therapists.~Following the first stakeholder team meeting, treatment communities will be provided with a research nurse facilitator to work 8 hours weekly during months one and two and then for four hours weekly starting in month three for a total of 12 months to provide the four components of the PAIN-CPG-EIT."
223550505|NCT01463163|DRUG|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
223731250|NCT00499018|DRUG|Ciclofosfamide|1200 mg/m2 day 1
223731251|NCT00499018|DRUG|Doxorubicina|70 mg/m2 day 1
223731252|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
223731253|NCT00499018|DRUG|Prednisone|100 mg day g 1-5
224016513|NCT03477773|OTHER|High-intensity exergaming|Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (\~70% HRmax). Periods of exercise were performed at an intensity \>85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.
224016514|NCT02570087|PROCEDURE|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
224016515|NCT00564889|DRUG|cyclophosphamide|300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
224016516|NCT00564889|DRUG|dexamethasone|40 mg weekly taken orally
224016517|NCT00564889|DRUG|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
224016518|NCT03627273|DIAGNOSTIC_TEST|6 minutes walking test with walker|to walk during 6 minutes with walker
224016519|NCT03627273|DIAGNOSTIC_TEST|6 minutes walking test|to walk during 6 minutes with walker
224016520|NCT04373824|DRUG|Ivermectin|Ivermectin 200 to 400 mcg per kg body weight
224016521|NCT00398268|PROCEDURE|Kirschner-wire fixation|
224016522|NCT03500159|DRUG|AQX-1125 200 mg|Synthetic SHIP1 activator
224016523|NCT03500159|DRUG|Placebo|Appearance and weight matched tablets without the active product ingredient
224128433|NCT00216099|DIETARY_SUPPLEMENT|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
224128434|NCT00216099|DIETARY_SUPPLEMENT|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
223550506|NCT02929160|PROCEDURE|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
223550507|NCT02929160|PROCEDURE|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
223731254|NCT00499018|DRUG|Pegfilgrastim|6 mg day +1
223731255|NCT00499018|DRUG|Mitoxantrone|8 mg/m2/days 1-3
223731256|NCT00499018|DRUG|ARA-C|2000 mg/m2/12h day 1 - 3
223731257|NCT00499018|DRUG|Lenograstim|5 μg/Kg/days +2
223731258|NCT00499018|DRUG|BCNU|300 mg/m2 day -7
223731259|NCT00499018|DRUG|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
223731260|NCT00499018|DRUG|VP-16|100 mg/m2/12h days -6,-5,-4,-3
223731261|NCT00499018|PROCEDURE|ASCT|PBSC Reinfusion
223731262|NCT00499018|DRUG|Ciclofosfamide|750 mg/m2 day 1
223731263|NCT00499018|DRUG|Doxorubicina|50 mg/m2 day 1
223731264|NCT00499018|DRUG|Vincristina|1,4 mg/m2 (max 2 mg) day 1
223731265|NCT00022620|DRUG|paclitaxel|
223731266|NCT05049876|OTHER|urine sample taken during consultations|urine sample taken during consultations
224016524|NCT01710644|DRUG|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
224016525|NCT01710644|DRUG|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
224016526|NCT03535597|DEVICE|Quikclot Radial (QC) Pad|The QC pad will be applied over the radial artery access site covered with either a Coban™ bandage, a Tegaderm™ dressing, or a TR Band after TRA.
224016527|NCT00603252|BIOLOGICAL|Twinrix|
224016528|NCT00603252|BIOLOGICAL|Engerix-B|
224016529|NCT00603252|BIOLOGICAL|Havrix|
224016530|NCT00603252|BIOLOGICAL|HBVAXPRO|
224016531|NCT00603252|BIOLOGICAL|Vaqta|
224016532|NCT03942185|DRUG|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
224016533|NCT03942185|DRUG|Oral Chinese Herbal Medicine according with syndrome differentiation therapy|Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
224016534|NCT03942185|DRUG|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
224016535|NCT00653666|OTHER|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is \< 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
224016536|NCT01011387|PROCEDURE|NPWT System|Dressing change 3 times per week
224016537|NCT01011387|DEVICE|NPWT system|3 dressing changes/week for maximum 4 weeks.
224016538|NCT02708914|BIOLOGICAL|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
224016539|NCT02708914|BIOLOGICAL|Eprex|Eprex® is chosen as the comparator.
224016540|NCT02518789|DRUG|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
223731267|NCT03388060|PROCEDURE|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
224016541|NCT02518789|DRUG|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
224016542|NCT02518789|DRUG|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
224016543|NCT02518789|DRUG|Etomidate|"After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate."
224016544|NCT02518789|DRUG|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg
224016545|NCT02518789|DRUG|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg
224016546|NCT01097382|DRUG|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
224016547|NCT06414187|DEVICE|Intra-Aortic Balloon Pump|Patients who are randomized to the IABP-arm will be supported with IABP according to local, clinical guidelines (including algorithms for anticoagulation, verification of correct positioning and weaning strategies). The IABP console and disposables should be used according to the instructions for use, including the use of an appropriate-sized IABP balloon alligned with patient length and height.
224016548|NCT01182467|RADIATION|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
224016549|NCT04557943|DRUG|Prolotherapy|"Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th."
224016550|NCT04557943|DRUG|Sodium Hyaluronate|Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
224016551|NCT02794753|BEHAVIORAL|Working memory training|
224016552|NCT02794753|BEHAVIORAL|Game|
224016553|NCT03655821|DRUG|Pemetrexed|Dosing is either based on BSA or renal function
224016554|NCT00000731|DRUG|Zidovudine|
223397145|NCT05858996|OTHER|Pain-CPG-Education Only|The Pain-CPG-Education only group will be provided with the same education as used in Component II of the Pain-CPG-EIT intervention. The education will be provided based on the preferences of the community (this may be face-to-face; online; or via handouts).
223397146|NCT02298959|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223397147|NCT02298959|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223397148|NCT02298959|PROCEDURE|Computed Tomography|Undergo CT scan
224016555|NCT00000731|DRUG|Acetaminophen|
224016556|NCT00806572|DRUG|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
224016557|NCT00065377|DRUG|Glucosamine Hydrochloride|
224016558|NCT01178554|BEHAVIORAL|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
224016559|NCT01178554|BEHAVIORAL|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
224016560|NCT01178554|BEHAVIORAL|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita \& Weisz, 2004)
224016561|NCT02202382|DRUG|Korean Red Ginseng, Varicocelectomy|
224016562|NCT02202382|DRUG|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
224016563|NCT02202382|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
223397149|NCT02298959|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
223397150|NCT02298959|BIOLOGICAL|Pembrolizumab|Given IV
223397151|NCT02298959|BIOLOGICAL|Ziv-Aflibercept|Given IV
223397152|NCT03375307|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223397153|NCT03375307|PROCEDURE|Biospecimen Collection|Undergo blood collection
223397154|NCT03375307|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223397155|NCT03375307|PROCEDURE|Bone Scan|Undergo bone scan
223397156|NCT03375307|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223397157|NCT03375307|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223397158|NCT03375307|DRUG|Olaparib|Given PO
223397159|NCT03375307|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223397160|NCT05838768|DRUG|HRO761|Tablet
223397161|NCT05838768|BIOLOGICAL|pembrolizumab|Concentrate for solution for infusion
223397162|NCT05838768|DRUG|irinotecan|Concentrate for solution for infusion
223397163|NCT06452225|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block.
223397164|NCT06452225|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound guided transversus abdominis plane block.
223397165|NCT01136902|DIETARY_SUPPLEMENT|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
223731268|NCT03388060|PROCEDURE|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
223731269|NCT03388060|PROCEDURE|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
223731270|NCT03179995|DRUG|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
224016564|NCT02617849|DRUG|Pembrolizumab|200 mg IV every 3 weeks
224016565|NCT02617849|DRUG|Carboplatin|AUC=6, every 3 weeks x 4
224016566|NCT02617849|DRUG|Paclitaxel|175 mg/m2, every 3 weeks x 4
223397166|NCT02844543|DEVICE|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
223397167|NCT02844543|OTHER|SCAT-3|The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
223731271|NCT03179995|OTHER|Placebo|Normal saline will be administered in the same fashion as Octreotide
223731272|NCT03198533|DEVICE|Triathlon PA|Implantation of Knee Prosthesis
223731273|NCT03198533|DEVICE|Triathlon Pressfit|Implantation of Knee Prosthesis
224016567|NCT05598671|PROCEDURE|PCNL without reverse insertion of a ureteral catheter|The ureteral catheter was not retrograde inserted during PCNL
224016568|NCT01513980|PROCEDURE|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
224016569|NCT01513980|PROCEDURE|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
224016570|NCT06485362|DIAGNOSTIC_TEST|Termography|Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).
224016571|NCT01854723|DRUG|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
224016572|NCT01854723|DRUG|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
224016573|NCT00573495|BIOLOGICAL|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
224016574|NCT01574196|OTHER|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
224016575|NCT02998580|DEVICE|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
224128435|NCT05495074|OTHER|ATP III dietary intervention|The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.
224128436|NCT02544971|BEHAVIORAL|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
223397168|NCT02844543|DEVICE|Desktop Eye-Tracker|Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
223397169|NCT05147415|OTHER|Placebo|Inactive comparator
223397170|NCT05147415|DRUG|Tesomet|Fixed-dose combination
223397171|NCT05045443|DRUG|Curcumin|Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement
223397172|NCT05045443|DIETARY_SUPPLEMENT|Standard of Care|As per institution protocol for Standard of nutritional Care
223397173|NCT01921868|DRUG|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
223731274|NCT00022633|DRUG|gemcitabine hydrochloride|
223731275|NCT00022633|DRUG|paclitaxel|
223731276|NCT02248610|OTHER|Non-interventional study|
224016576|NCT02998580|DEVICE|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
224016577|NCT01980927|PROCEDURE|NUCCA atlas correction|"A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine."
224016578|NCT00765453|OTHER|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
224016579|NCT00765453|OTHER|Placebo infusion|Placebo infusion
224016580|NCT00610740|DRUG|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
224016581|NCT00610740|PROCEDURE|therapeutic conventional surgery|hysterectomy
224016582|NCT06550089|DRUG|Oxytocin|Oxytocin is a synthetic molecule used to reduce the likelihood of postpartum hemorrhage.
224016583|NCT02665338|DEVICE|Transcranial Magnetic Stimulation|
224016584|NCT00942760|DEVICE|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
224016585|NCT03007043|OTHER|blood sample|
224016586|NCT03580005|DRUG|methylphenidate HCl ERCT|methylphenidate HCl ERCT
224016587|NCT03580005|DRUG|Placebo|Placebo to Match Quillichew ERCT
224016588|NCT06486207|COMBINATION_PRODUCT|Gong's mobilization|increases the range of motion for shoulder medial rotation by allowing shoulder medial rotation with the humeral head in a normal position against the glenoid cavity of the scapula
224128437|NCT02544971|OTHER|Control|Treatment as usual
224128438|NCT05932511|DRUG|30% ascorbic acid in DMSO|see above
223550508|NCT05068505|BEHAVIORAL|Community health worker delivered multicomponent intervention|"The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters"
223397174|NCT03220204|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
223550509|NCT03780530|PROCEDURE|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
223550510|NCT03780530|PROCEDURE|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
223550511|NCT03780530|PROCEDURE|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
223550512|NCT03726658|DRUG|AGN-241751|AGN-241751 is supplied in tablet form
223550513|NCT03726658|DRUG|Placebo|Placebo is supplied in tablet form
223397175|NCT03220204|BEHAVIORAL|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
223397176|NCT03241862|DEVICE|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
223550514|NCT03376711|BEHAVIORAL|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers \& peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
223550515|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
223550516|NCT01318135|DRUG|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
223550517|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
223550518|NCT01318135|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
223550519|NCT00090779|DRUG|Emtricitabine/ tenofovir disoproxil fumarate|once daily
223550520|NCT00090779|DRUG|Lopinavir/Ritonavir|twice daily
223550521|NCT05483699|OTHER|Squeezing a ball|The children in the squeezing soft ball group were given the ball before the procedure. They were told to squeeze and loosen the ball with the hand that was not used for the procedure while intravenous cannula was being inserted.
223550522|NCT05483699|OTHER|Blowing bubbles|The children in the blowing bubble group were shown the bubble blower before intravenous cannulation and they were told how bubbles were formed and how they would blow. During intravenous cannulation, the child blew the blower
223550523|NCT05483699|OTHER|Kaleidoscope|Children in the Kaleidoscope group were given the kaleidoscope before intravenous cannulation and they were shown how to use it. The children were told to look at the kaleidoscope during the procedure until the procedure ended
223550524|NCT04679623|COMBINATION_PRODUCT|Midazolam|Midazolam Injection, 10mg
224016589|NCT06486207|OTHER|Kendall Exercise|The Kendall exercise methods were as follows: Strengthening the deep cervical flexors, lying flat on the back with the chin down and then lifting the head and holding this position for 2-8 seconds to strengthen deep cervical flexors
223397177|NCT01924832|DRUG|dimethyl fumarate|tablet
223397178|NCT02246140|OTHER|Cerebral MRI and MRA|
223397179|NCT04071210|DIETARY_SUPPLEMENT|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
223397180|NCT04071210|DIETARY_SUPPLEMENT|Placebo tablet|Placebo tablet twice a day for 12 weeks
223397181|NCT01028547|DRUG|dexamethasone|single Bolus dose of dexamethasone 8mg
223397182|NCT01028547|OTHER|normal saline|2 ml 0.9% saline
223397183|NCT03588754|DRUG|Propranolol|Propranolol Extended Release (160mg/day).
223397184|NCT03588754|DRUG|Placebo|Placebo pill administered orally.
223550525|NCT04679623|DRUG|Seizalam|Seizalam, 10 mg
223550526|NCT00002509|BIOLOGICAL|filgrastim|
223550527|NCT00002509|DRUG|carboplatin|
223550528|NCT00002509|DRUG|cyclophosphamide|
223550529|NCT00002509|DRUG|etoposide|
223550530|NCT00002509|DRUG|mesna|
223550531|NCT00002509|PROCEDURE|autologous bone marrow transplantation|
223550532|NCT00002509|PROCEDURE|peripheral blood stem cell transplantation|
223550533|NCT01156025|DRUG|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
224016590|NCT05682703|DIAGNOSTIC_TEST|Proteomics technology and liquid biopsy|using proteomics technology and liquid biopsy to investigate the changes of plasma and urine metabolites by collecting residual blood and urine from routine diagnosis and treatment or physical examination
223550534|NCT01156025|DRUG|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
223550535|NCT05832515|DRUG|Fludarabine Phosphate for Injection|Intravenous injection of fludarabine phosphate at a dose of 30 mg/m2 from day -5 to day -2 of immunoablative conditioning regimen.
223550536|NCT02179424|BEHAVIORAL|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
223550537|NCT02179424|BEHAVIORAL|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
223550538|NCT02179424|BEHAVIORAL|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
223550539|NCT02179424|BEHAVIORAL|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
224016591|NCT03539887|DRUG|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
224016592|NCT03539887|DRUG|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
224016593|NCT00998998|BEHAVIORAL|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
224016594|NCT00998998|BEHAVIORAL|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
224016595|NCT00998998|DIETARY_SUPPLEMENT|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
224016596|NCT01755208|PROCEDURE|light-scattering spectroscopy|Undergo light-scattering spectroscopy
224016597|NCT04355247|DRUG|MethylPREDNISolone 80 Mg/mL Injectable Suspension|"* Patients will be admitted to a regular room in the hospital (not ICU)~* They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.~* Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital."
224016598|NCT05570773|OTHER|peer support program|Peer support: It has been suggested that peer support provides an alternative way for students to learn and makes a positive contribution to both academic and psychosocial aspects of higher education (Hogan, Fox, Barratt-See 2017). Peer academic support involves academic encouragement (support for lowering exam-related stress and motivation for lessons) and solving students' academic problems (answering questions about lessons, sharing study habits, studying together, answering questions about assignments)
224016599|NCT01239459|DRUG|Teriflunomide HMR1726|"Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition"
224128439|NCT02902172|DRUG|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
224128440|NCT02902172|DRUG|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
224128441|NCT03277950|OTHER|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
223397185|NCT03312387|OTHER|Exercise|Aerobic exercise performed 3/d per week during intervention
223397186|NCT03312387|DIETARY_SUPPLEMENT|Essential Amino Acids|Mixture of 10g of essential amino acids ingested throughout intervention
223397187|NCT03312387|DIETARY_SUPPLEMENT|Placebo|10g of maltodextrin ingested throughout intervention
223397188|NCT00728260|BIOLOGICAL|None administered in this study|N/A in this study
223397189|NCT02220556|PROCEDURE|Blood sampling|
223397190|NCT05414500|DRUG|Mogamulizumab|Administered IV
223397191|NCT05414500|DRUG|Brentuximab vedotin|Administered IV
223397192|NCT04710576|DRUG|Axatilimab|Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
223397193|NCT05726981|PROCEDURE|Fine needle aspiration biopsy (FNAB)|"Thyroid FNAB is a minimally invasive procedure performed routinely by an experienced sonographer.~It is a safe and brief procedure, performed with a 27G or 25G (very fine) needle (3 needles, i.e. 1 needle per pass)"
223397194|NCT04581824|DRUG|Dostarlimab|Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
223397195|NCT04581824|DRUG|Pembrolizumab|Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
223397196|NCT04581824|DRUG|Chemotherapy|"Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision."
223550540|NCT02179424|BEHAVIORAL|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
224016600|NCT01239459|DRUG|Cholestyramine|"Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55"
224128442|NCT03277950|OTHER|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
224128443|NCT03277950|OTHER|Healthy|Healthy do not play game
223397197|NCT01188525|DRUG|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
224016601|NCT05447091|BEHAVIORAL|LOH game- high dose|Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
224016602|NCT05447091|BEHAVIORAL|LOH game- low dose|Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.
224016603|NCT05447091|BEHAVIORAL|LOH sham game|Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
224016604|NCT02793388|DRUG|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
224016605|NCT02793388|DRUG|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
224128444|NCT01412645|DIETARY_SUPPLEMENT|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
224128445|NCT00947570|BEHAVIORAL|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
224128446|NCT01434472|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
224128447|NCT01434472|DRUG|Cyclosporine|Given PO
224128448|NCT01434472|DRUG|Fludarabine Phosphate|Given IV
224128449|NCT01434472|RADIATION|Indium In-111 Ibritumomab Tiuxetan|Given IV
224128450|NCT01434472|DRUG|Mycophenolate Mofetil|Given PO
223397198|NCT04796909|BEHAVIORAL|Occupational Performance coaching|The OPC intervention comprises three components: (1) connect - building parents' trust in the coach by using verbal and nonverbal strategies; (2) structure - building parents' competence by adopting a problem-solving framework of setting goals, exploring options, planning action, carrying out plans, checking performance, and generalizing; and (3) share - building parents' autonomy by reciprocally exchanging information between the coach and parents with an emphasis on eliciting parents existing knowledge. During the exploration of the options for a particular goal, collaborative performance analysis is used. The coach follows the four steps to (a) identify parents' perception of what currently happens, (b) identify what they would like to happen, (c) explore barriers and bridges to the desired performance, and (d) identify their needs for taking actions to achieve goals. Parents are guided to find strategies to facilitate their child's performance to support goal achievement.
223397199|NCT04796909|BEHAVIORAL|Parent consultation|The parent consultation consists of the use of the toolbox to provide parents with available environmental resources and strategies to enhance community participation of their child with developmental disability, followed by the understanding of current situation and the identification of problems encountered by parents. Direct informing approach will be used to instruct parents about the availability of environmental resources close to their living areas and what they can plan to do by using possible supportive strategies. In addition, information about child disability and/or developmental milestone may be provided if needed.
223397200|NCT06153836|PROCEDURE|Neurotization Procedure|Undergo placement of nerve graft
223397201|NCT06153836|OTHER|Questionnaire Administration|Ancillary studies
223397202|NCT06153836|PROCEDURE|Subcutaneous Mastectomy|Undergo standard of care NSM
223397203|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))|"Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
223397204|NCT05249959|DRUG|Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)|"Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks"
223397205|NCT06117150|DEVICE|Drug-eluting Coronary Spur Stent System|All subjects enrolled will be treated with the Drug-eluting Coronary Spur Stent System.
223397206|NCT03879135|BIOLOGICAL|rVWF|Recombinant von Willebrand factor
223397207|NCT03879135|BIOLOGICAL|rFVIII|Recombinant Factor VIII
224016606|NCT01856777|DEVICE|Semi-quantitative panel test|
224016607|NCT01856777|DEVICE|High sensitivity urine pregnancy test|
224016608|NCT04208282|DEVICE|7 day infusion set|7 days survival of the sets
224016609|NCT02811952|OTHER|without intervention|without intervention
224128451|NCT01434472|OTHER|Pharmacological Study|Correlative studies
224128452|NCT01434472|BIOLOGICAL|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
224128453|NCT01434472|RADIATION|Total-Body Irradiation|Undergo TBI
224128454|NCT01434472|RADIATION|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
224128455|NCT01434472|DRUG|Fludarabine|Given IV
224128456|NCT01240044|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
223397208|NCT04162847|DEVICE|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
223397209|NCT06557733|PROCEDURE|Biopsy Procedure|Undergo biopsy
223397210|NCT06557733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223397211|NCT06557733|DRUG|EP2/EP4 Antagonist TPST-1495|Given PO
223397212|NCT06557733|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
223397213|NCT06557733|PROCEDURE|Gastrointestinal Endoscopy|Undergo GI endoscopy
223397214|NCT06557733|OTHER|Questionnaire Administration|Ancillary studies
223397215|NCT05653687|DEVICE|Intraoperative fluoroscopy|Fluoroscopy is a medical procedure that makes a real-time video of the movements inside a part of the body by passing x-rays through the body over a period of time.
223397216|NCT06581874|OTHER|Clinical assessment by emergency psychiatrist|After a clinical assessment by the emergency department psychiatrist which does not lead to hospitalization, the patient will be given a psychiatric interview and sent home.
223397217|NCT06581874|OTHER|Psychiatric consultation booked through Med@Psy platform|The patient will be seen within 48 hours after the consultation with his or her general practitioner by a psychiatrist taking part in the study.
223397218|NCT06375083|BEHAVIORAL|Cognitive Behavioral Therapy|The computerized Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) course is comprised of 12 online sessions and is augmented by use of a companion workbook. The computerized Cognitive Behavioral Therapy for Depression (cCBT-D) course is comprised of 12 online sessions.
223397219|NCT05252949|DIETARY_SUPPLEMENT|Oleoylethanolamide (OEA)|Oleoylethanolamide (OEA) is a naturally occurring ethanolamide that acts as a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, thereby modulating lipid profiles.
223397220|NCT05252949|DIETARY_SUPPLEMENT|Placebo|Visually matching placebo capsules will contain the same inactive ingredients present in the manufactured OEA capsules, with the exception of any OEA compound.
223397221|NCT06513728|OTHER|MPACT Intervention|MPACT has 4 components: accredited training about patient centered, trauma informed methadone treatment, staff education about trauma symptoms with navigation to self screening and treatment or stress management, clinic self assessment tools for trauma informed, patient centered care, and reflective supervision for counselors, case managers and peer staff.
223397222|NCT05512143|DEVICE|Transcranial magnetic stimulation|Participants will undergo a standard course of TMS treatment (30 sessions/6 weeks).
223397223|NCT05493904|PROCEDURE|OCT-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using OCT.~OCT Reference site: Most normal looking segment, No Lipidic plaque. Operator can decide 1 of 2 methods for stent sizing.~1. By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane \[EEL\] can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm (Ex\> mean external elastic membrane reference diameter 3.35mm, 3.25mm stent diameter will be chosen).~2. By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm (Ex\> mean distal reference lumen diameter 2.55mm, 2.75mm stent diameter will be chosen)."
223397224|NCT05493904|PROCEDURE|Angiography-guided PCI|"For patients randomly allocated to this arm, PCI for complex lesions will be performed using angiography only.~The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 30% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended."
223397225|NCT05493904|DEVICE|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
223397226|NCT06522607|DEVICE|rapid palatal expander|Clinical evaluation of the patients who will be treated with rapid palatal expander for about 6 month.
223731277|NCT03116607|OTHER|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
223550541|NCT02179424|BEHAVIORAL|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
223397234|NCT06293183|OTHER|Mobile app|Participants in the intervention group will be expected to watch the training video in the mobile application installed on their phones or tablets and then regularly enter all the food and liquid amounts they consume during the day into this application. In the mobile application data entry area, visuals that will be included in the application showing the amount and types of foods consumed by the participants during the day (1 soup bowl, 1 vegetable dish plate, 1 meat dish plate, 1 water glass, 1 tea glass, tablespoon, dessert spoon, teaspoon, ladle). etc.) will choose through. The mobile application will calculate the total amount of liquid consumed by the participants in 24 hours, and will give a yellow warning when the amount of liquid consumed is 2-2.5 liters, an orange warning when it is 2.5-3 liters, and a red warning when it is 3 liters and above. This will contribute to reducing the amount of fluid intake of participants between two dialysis sessions.
223397235|NCT00813150|DRUG|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
223397236|NCT00813150|DRUG|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
223397237|NCT00813150|DRUG|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
223550542|NCT00296465|DRUG|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
223550543|NCT00296465|DRUG|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
223550544|NCT00296465|DRUG|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
223550545|NCT00296465|DRUG|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
223550546|NCT01842672|DRUG|Clofarabine|Dose Escalation of Clofarabine
223550547|NCT01842672|DRUG|Mitoxantrone|
223550548|NCT01775553|DRUG|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
223550549|NCT03240861|OTHER|18F-FHBG|Given IV
224016610|NCT03438877|PROCEDURE|Intensive dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
224016611|NCT03438877|PROCEDURE|Regular dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
224016612|NCT06540625|DEVICE|the use of CP device application on human subjects.|"Trained providers will be asked to apply CP at 10N of force to the marked location using the cricoid applicator for one minute. Data relating to applied force across the whole one minute will be measured continuously and will be captured and stored. The CP device will have a microdisc port for internal memory and then the wifi on the board will transfer the information to a cloud server for backup and storage for redundancy.~A threshold of 10 ± 2 N applied force will be set to define successful CP attempts. Participants must remain in this range for 95% of the trial time after the first five seconds have passed.~At any point during the CP application, if the volunteer experiences pain, they can request that the pressure be stopped. However, we do not expect any pain with 10N, except for minor discomfort."
224016613|NCT04108143|DEVICE|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
224128457|NCT01240044|PROCEDURE|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
224128458|NCT04659226|GENETIC|Blood sampling for microRNA testing|Blood samples will be collected and analyzed for the microRNA profile by means of microfluidic cards
223550550|NCT03240861|BIOLOGICAL|Aldesleukin|Given SC
223550551|NCT03240861|DRUG|Busulfan|Given IV
223550552|NCT03240861|BIOLOGICAL|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
223550553|NCT03240861|PROCEDURE|Computed Tomography|Undergo PET/CT
223550554|NCT03240861|BIOLOGICAL|Filgrastim|Given SC
223550555|NCT03240861|DRUG|Fludarabine|Given IV
223550556|NCT03240861|PROCEDURE|Leukapheresis|Undergo leukapheresis
223550557|NCT03240861|DRUG|Plerixafor|Given SC
223550558|NCT03240861|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224016614|NCT06429007|DRUG|Metformin|"Metformin will be initiated at 25% of the target dose (4 mg/kg administered twice daily, total daily dose 8 mg/kg) for three weeks. In the absence of adverse effects, metformin dose will be escalated to 50% of the target dose (8 mg/kg administered twice daily for a total daily dose of 16mg/kg) for remaining 3 weeks to minimize potential gastrointestinal upset at higher doses. Parents will be documenting adverse events and performing glucometer checks twice a day for 3 days post dose escalation.~Parents will then receive a 6-week supply of metformin at the target dose (16 mg/kg administered twice daily, total daily dose 32 mg/kg). Adverse events will be documented and glucometer checks will be performed twice a day for 3 days following dose escalation."
224016615|NCT04662034|DEVICE|CMIC|The C-MIC System consists of three implantable parts: a transvenous and an epicardial lead which are both connected to an implanted power source, and an external programing device. The patch lead is placed over the free wall of the left ventricle and fixated with sutures. When lead placement is achieved, the leads are then tunneled subcutaneously to the infraclavicular region and connected to the power source.
224016616|NCT04662034|DRUG|Standard of Care (SOC)|Patients receive optimal SOC based defined in pertinent guideline and at the discretion of the investigator
224016617|NCT05591989|DEVICE|NEUROMARK System|The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
224016618|NCT05215665|DRUG|GEMOX Regimen|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
224016619|NCT05215665|DRUG|Lenvatinib|8/12mg PO QD continuously
223397238|NCT00100607|DRUG|AAE581|
224016620|NCT05215665|DRUG|Toripalimab|240mg IV d1 Q3W
224016621|NCT05652647|DRUG|Oral [14C]PF-07081532|A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.
224016622|NCT05652647|DRUG|Oral PF-07081532 and IV [14C]PF-07081532|In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
224016623|NCT03848676|DIAGNOSTIC_TEST|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
224016624|NCT04743791|DRUG|Dupilumab|Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
224016625|NCT04743791|OTHER|Placebo|Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
224128459|NCT05362643|OTHER|Acupuncture|Manual acupuncture on acupoint Tai Xi(KI3), bilateral;Sanyinjiao (SP6), bilateral; Zusanli (ST36), bilateral; Shenmen (HT7) unilateral, in the arm without arteriovenous fistula;Guan Yuan (CV4), unilateral, attempt to achieve De qi sensation. After generating needling sensation, needles were manipulated for one minute, every ten minutes during needle retention (20 minutes), using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
224128460|NCT05362643|OTHER|Sham Acupuncture|Manual acupuncture performed as superficial needling (5mm depth) on non-acupuncture points without an attempt to achieve De qi sensation and without stimulation, lasting 20 minutes, using Sterilized stainless steel needle (0,25x25mm; Tewa, asia-med GmbH).
224128461|NCT01409031|DRUG|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
224128462|NCT01409031|OTHER|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
223397239|NCT05354388|PROCEDURE|Resection surgery of gastrointestinal stromal tumor|oral administration of Ripretinib 150 mg QD. Resection of gastrointestinal stromal tumors was performed in patients who achieved PR or SD
223397240|NCT06682741|OTHER|Exercise|supervised exercise training; twice a week for 12 months
223397241|NCT05423093|BEHAVIORAL|Single-Session Virtual Group Psychoeducational Session about Postpartum Depression|Session contents include (1) Introduction to clinic staff, contacts, and resources (2) A video-recorded testimonial of a patient with a history of perinatal depression followed by a group discussion about/reflection on the video; (3) Review of prevalence and signs of PPD; (4) Discussion of clinic PPD screening procedures and rationale for screening; (5) Discussion of self-care and mood monitoring; (6) Discussion of relevant local resources, including information about availability of primary care resources for parents (including uninsured parents) and information about resources addressing social needs.
223397242|NCT06417099|DRUG|Dihydroartemisinin|dihydroartemisinin 40mg tid po for 90 consecutive days
223397243|NCT04440189|DEVICE|GID SVF-2 Device System|The GID SVF-2 Device System is used for harvesting, filtering, separating and concentrating autologous stromal vascular fraction from adipose tissue.
223397244|NCT03837626|DRUG|Placebo - Cap|6 months of 1 pill a day
223397245|NCT03837626|DRUG|Amiloride Pill|Max dose of 5 mg a day for 6 months
223397246|NCT04585984|DIETARY_SUPPLEMENT|Experimental - Probiotic|Patients in the experimental group will take one compound (pill) a day for 21 days, containing a 50% combination of two probiotics: Lactobacillus rhamnosus and Bifidobacterium longum, at a dose of 10\^9 cfu/day. The carrier of lyophilized probiotics is maltodextrin and the mixture is encapsulated in hypromellose capsules.
223397247|NCT04585984|DIETARY_SUPPLEMENT|Placebo|Patients in the control group will take one unit of placebo a day for 21 days.
223397248|NCT06410196|BEHAVIORAL|Mood modulation|Autobiographical memory recall designed to modulate mood and affective state by reminiscing about personal life events
223397249|NCT05120635|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
223550559|NCT03632460|DRUG|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
223550560|NCT01632852|BIOLOGICAL|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
224128463|NCT05092737|PROCEDURE|Prone positioning|Prone position during invasive mechanical ventilation
224128464|NCT01892033|BEHAVIORAL|Aerobic Exercise|12 weeks of brisk walking
224128465|NCT04652336|PROCEDURE|laparoscopic sleeve gastrectomy|Comparator arm - will receive standard laparoscopic sleeve gastrectomy
224016626|NCT05982795|OTHER|Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge|"A CultureSwab MaxV(+) (BD, Franklin Lakes, NJ) will be placed under endoscopic visualization to the middle meatus through a sterile sheath (red rubber urinary catheter) and gently rotated 5 full turns or until the tip is saturated with mucus (no more than 20 seconds).~Under direct visualization, a sterile Leukosorb sponge (Leukosorb; Pall Scientific, Port Washington, NY) will be placed in the middle meatus. A piece of Leukosorb filter paper will additionally be placed in the olfactory cleft. The sponge and paper will be left for 5 minutes and will then be removed under direct visualization and collected for analysis."
224016627|NCT05982795|OTHER|Olfactory Function Testing|"Olfactory function will be tested using the Sniffin' Sticks extended test kit (MediSense, NL) using the established threshold, discrimination, and identification (TDI) scoring system. Odors will be delivered using felt-tip pens (Sniffin' Sticks, MediSense, NL). The pen cap will be removed from the pen for approximately 3 seconds, and the pen's tip will be brought in front of the subject's nose and carefully moved from left to right nostril. Threshold testing will be obtained by asking the subject to identify the pen containing the odor from two pens containing only solvent. This will be conducted starting with the lowest concentration of odor and moving stepwise until patient is no longer able to identify the odor from the solvent.~Subjects may also be asked to complete the University of Pennsylvania Smell Identification Test (UPSIT). The UPSIT can be self-administered and uses microencapsulated odorants which are released by scratching standardized odor-impregnated test booklets."
224016628|NCT05982795|OTHER|Survey Completion|"Participants will be asked to complete the validated Cystic Fibrosis Questionnaire-Revised (CFQ-R) survey. This survey evaluates Cystic Fibrosis-specific and general quality of life metrics.~Participants will also be asked to complete the validated Sino-nasal Outcome Test-22 (SNOT-22) which is the most commonly used survey for evaluating outcomes in patients with chronic rhinosinusitis.~Participants will also be asked to complete the validated Sinus Control Test (SCT) - a 4-question questionnaire that assesses disease control in chronic rhinosinusitis.~Participants will be asked to complete the questionnaire of olfactory disorders (QOD). This is a 25-question validated survey used to assess the impact of olfactory dysfunction on patients with sinonasal disease."
224016629|NCT05465083|DEVICE|Lungpacer AeroPace Protect System|AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
224016630|NCT05253794|DRUG|Colchicine 0.6 mg|oral tablet daily for 6 months
224128466|NCT04652336|PROCEDURE|ligamentum teres cardiopexy with sleeve gastrectomy|experimental arm - Ligamentum teres will be divided from umbilicus to up to umbilical fissure. The ligament will then be wrapped around lower esophagus and sutured.
224128467|NCT05667155|BIOLOGICAL|CB dualCAR-NK19/70|Lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19/CD70 CAR and IL15
224128468|NCT02576964|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
224128469|NCT02576964|DRUG|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
224128470|NCT01773135|OTHER|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery \& preterm delivery) and investigators compare between these 2 groups by level of hormone."
223397250|NCT05639946|DRUG|brivaracetam|Drug dosage will be individually titrated for each participant with a goal of 100mg BID according to the following dose escalation protocol that we use clinically: 50mg BID for 2 weeks, followed by 50mg TID for 2 weeks, followed by 100mg BID for 48 days as tolerated. Participants will be allowed to reduce the dose of brivaracetam if they experience unacceptable side effects defined as increased somnolence according to routine clinical practice with other drugs in this class used for pain.
223397251|NCT05639946|DRUG|Placebo|Participants will receive placebo drug
223397252|NCT05302583|OTHER|Aromatherapy Inhaler|Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
223397253|NCT06303804|BEHAVIORAL|Educational videos|Participants will be delivered a link to complete demographic information and the initial assessment. Upon completing the (initial) pre-test knowledge assessment, participants will be sent links to the three educational videos staggered across 7 days. Educational videos will determine gaps in knowledge related to opioid use and overdose based on questionnaire responses. Upon the completion of the 7 days, participants will be sent a link to the (final) post-test knowledge assessment to complete.
223397254|NCT01683318|PROCEDURE|Thermal Pulsation therapy|
223397255|NCT02832687|DRUG|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
223397256|NCT02832687|DRUG|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
223397257|NCT02408835|DEVICE|PICO™|Negative pressure wound therapy device for closed surgical wounds.
223397258|NCT02154451|DEVICE|Infrared Imaging Device- ALIAS|Infrared Camera
223397259|NCT04380935|BIOLOGICAL|Convalescent plasma|Convalescent plasma of recovered COVID-19 patients (donor)
223550561|NCT04715841|OTHER|gait assessment|gait assessment were done using 3DMA system
223550562|NCT00988052|DRUG|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
223397260|NCT04380935|DRUG|Standard of care|"According to national or hospital guidelines COVID-19 Management Protocol"
224016631|NCT05253794|DRUG|Placebo|oral tablet daily for 6 months
224016632|NCT05326815|DIAGNOSTIC_TEST|N-Telopeptide, Bone Marker|"This is a prospective specimen collection cohort study to evaluate the correlation between serum and urine values of the bone marker of interest (N-Telopeptide), and their association with baseline DEXA scan measures and fracture risk within 6 months.~Study samples will be obtained longitudinally. One collection of both serum and urine collection will be obtained. The urine will be collected as second void of day and at the same time the blood collection is drawn."
224016633|NCT03562975|DRUG|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
224016634|NCT05709600|DIETARY_SUPPLEMENT|Fasting mimicking diet|"Intermittent fasting with human fasting mimicking diet (Prolon®) will be performed for five days prior to living kidney donation in the donor. Prolon® a plant-based diet designed to attain fasting-like effects while provide providing both macro- and micronutrient. Each participant will obtain Prolon® diet during the first visit and the diet will stored at the participant's home at room temperature. Additionally, the participant will receive a food plan for the exact consumption of the diet. Regular phone with a predefined standardized questionnaire will be used to determine each participant's well-being, as well as his or her dietary adherence. Furthermore, the participants will be asked to write down each consumed food items they are consuming in diet-book, which is handed to them during the first visit.~The participants are only allowed to consume water, coffee or tea without sugar simultaneously to the Prolon® diet."
224128471|NCT06124547|DRUG|Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet (Test or reference)
224128472|NCT03270696|DRUG|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
223397261|NCT01735825|DEVICE|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
223397262|NCT01735825|DEVICE|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
223397263|NCT01735825|DEVICE|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
224128473|NCT05034484|DRUG|ALPN-303|Multiple dose levels will be evaluated.
223397264|NCT01092234|OTHER|Traditional ward|provision of care in a traditional unit/ward.
224128474|NCT05034484|DRUG|Placebo|Placebo will be administered
224128475|NCT00019500|DRUG|raloxifene|
223397265|NCT01092234|OTHER|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
223397266|NCT02606916|RADIATION|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
223397267|NCT02606916|DRUG|DDP|DDP(25 mg/m2.qw) for six weeks.
223397268|NCT02606916|DRUG|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
223397269|NCT00111605|BIOLOGICAL|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
223397270|NCT00111605|BIOLOGICAL|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
223397271|NCT00111605|BIOLOGICAL|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
223731278|NCT05373329|DEVICE|Sanvello (app)|Sanvello is a commercially available mobile app designed to teach users strategies to manage their stress, anxiety, and depression. Users can choose which tools they want to use. The strategies are digital implementations of existing practices in psychology such as thought records, mindfulness meditation \& relaxation exercises, and behavioral activation.
224128476|NCT00019500|PROCEDURE|evaluation of cancer risk factors|
224128477|NCT02555644|DRUG|Prexasertib|Administered IV
224128478|NCT02555644|DRUG|Cisplatin|Administered IV
224128479|NCT02555644|DRUG|Cetuximab|Administered IV
224128480|NCT02555644|RADIATION|Intensity Modulated Radiation Therapy|
224128481|NCT03241472|DRUG|Letrozole|oral tablets 5 mg
224128482|NCT03241472|DRUG|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
223397272|NCT00111605|BIOLOGICAL|Sodium chloride injection (0.9%)|"All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.~Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273."
223397273|NCT00976001|OTHER|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
223397274|NCT00976001|OTHER|As the general practitioner wants to do|
223397275|NCT01113437|DRUG|Omalizumab|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
224128483|NCT02515864|DRUG|FYU-981|
224128484|NCT02515864|DRUG|Placebo|
224128485|NCT02515864|DRUG|Moxifloxacin|
224128486|NCT02515864|DRUG|Moxifloxacin Placebo|
224128487|NCT01123122|OTHER|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
223397276|NCT01113437|DRUG|Placebo|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
223397277|NCT04775082|DRUG|Liraglutide|"The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.~The dose will increase each week over 4 or 5 weeks until the final dose is reached."
223397278|NCT04775082|DRUG|Placebo|The study medicine must be injected in a skin fold in the stomach, thigh or upper arm once daily.
223397279|NCT05492136|PROCEDURE|Additional margin coagulation|After performing the hepatectomy the selected device should be applied onto the surgical margin following the protocol 3-4 s/cm2 of liver transection surface at maximum power output in order to perform an additional margin coagulation
223397280|NCT05249868|OTHER|Exposure SARS-CoV-2 Infection|"The exposure variable is confirmed SARS-CoV-2 infection with diagnosis after 11 May 2020.~Positive confirmatory test on nucleic acid amplification (rRT-PCR) or having had symptoms for \<5 days is positive on a PRAg test."
223397281|NCT04733079|OTHER|Cleanweb electronic messaging ePro|Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached
223397282|NCT04733079|OTHER|Usual follow-up|Adaptation and follow-up of ULT according to referring physician's habits
223397283|NCT06255223|RADIATION|High-dose Radiotherapy (HDRT)|SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).
223397284|NCT06255223|RADIATION|Low-dose Radiotherapy (LDRT)|Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.
223397285|NCT06255223|DRUG|Anti-PD-1 monoclonal antibody|At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
223397286|NCT03448042|DRUG|Runimotamab|Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
223397287|NCT03448042|DRUG|Trastuzumab|Trastuzumab will be administered via IV infusion
224016635|NCT05709600|DIETARY_SUPPLEMENT|Ketogenic diet|"Isocaloric, ketogenic diet will be performed for seven days prior to living kidney donation in the donor.~The ketogenic diet is based on the KetoCal 4:1 formula diet (Nutricia Milupa GmbH, Erlangen, Germany). Main fat sources are plant oils including palm oil and sunflower oils. The formula diet is provided as a powder that has to be mixed with water before use. To avoid a shortage in protein uptake supplement formula diets K-AM and Fortimel® (both Nutricia Milupa GmbH, Erlangen, Germany) will be used additionally. Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan by the dietetics at the University Hospital of Cologne to ensure standardized food consumption"
224016636|NCT05709600|DIETARY_SUPPLEMENT|Dietary restriction of sulfur containing amino acids|"Isocaloric, dietary restriction of sulfur containing amino acids will be performed for seven days prior to living kidney donation in the donor.~A dietary restriction of sulfur containing amino acids without restriction in protein uptake will be achieved by following the X Met X Cys Maxamaid formula diet (Nutricia Milupa GmbH, Erlangen, Germany). The formula diet is provided as a powder that has to be mixed with water before use. A minimum of methionine and cysteine uptake (10% of the common uptake per day) will be achieved by consuming individuial calculated amounts of the Fortimel® formula diet (Nutricia Milupa GmbH, Erlangen, Germany). To avoid a restriction in fat and energy uptake additionally the Calogen and Duocal formula diets (both Nutricia Milupa GmbH, Erlangen, Germany) will be used. A salt ingestion of 5g/day, which is common for western diets, is aimed at. The participants will receive a daily food plan to ensure standardized food consumption."
224016637|NCT05709600|DIETARY_SUPPLEMENT|Control Group ( healthy, low-fat, moderate protein and high carbohydrate diet)|Participants in the control group will be instructed to adhere to a healthy, low-fat, moderate protein and high carbohydrate diet as described in current nutritional recommendations. The control diet will be based on the formula diet Fortimel® (Nutricia Milupa GmbH, Erlangen, Germany). Salt uptake will be standardized employing either broths or salt tablets to not interfere with the steady-state salt and water homeostasis. A salt ingestion of 5g/day, which is common for western diets, is aimed at.
224016638|NCT02539745|OTHER|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
224016639|NCT02539745|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
224016640|NCT00351312|DEVICE|special socks|
224016641|NCT05490342|DIAGNOSTIC_TEST|Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.|Blood test to value the antibody response to vaccination
224128488|NCT06330662|PROCEDURE|Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only|The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
223397288|NCT03448042|DRUG|Tocilizumab|Participants will receive IV tocilizumab if needed
223397289|NCT03664232|DRUG|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally twice daily for 12 weeks.
223397290|NCT03664232|DRUG|Placebo|Participants will receive a matching placebo orally twice daily for 12 weeks.
223397291|NCT03904173|DIAGNOSTIC_TEST|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
223397292|NCT05687123|PROCEDURE|Biospecimen Collection|Undergo a blood sample collection
223397293|NCT05687123|PROCEDURE|Computed Tomography|Undergo a CT scan
223397294|NCT05687123|DRUG|Lutetium Lu 177 Dotatate|Given IV
223397295|NCT05687123|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224016642|NCT04055532|OTHER|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
224016643|NCT06498011|OTHER|Home Graded Repetitive Arm Supplementary Program (GRASP)|The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.
224016644|NCT06498011|OTHER|integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)|The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
224016645|NCT01296789|OTHER|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
224016646|NCT01296789|OTHER|Usual Care|Usual Care
223397296|NCT05687123|PROCEDURE|Positron Emission Tomography|Undergo a SSR PET/CT scan
223397297|NCT05687123|DRUG|Sunitinib Malate|Given PO
223397298|NCT05187390|PROCEDURE|VATS application|The chronic pain findings of the patients who underwent VATS will be questioned at the postoperative 1st and 3rd months.
223397299|NCT02485093|DEVICE|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
223397300|NCT02485093|DEVICE|VIP|Ventricular pacing must be less than 10%.
223397301|NCT01733550|DEVICE|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
223397302|NCT01733550|DEVICE|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
223397303|NCT01733550|DEVICE|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
223397304|NCT00012792|BEHAVIORAL|Exercise Training|
223397305|NCT05083026|DIAGNOSTIC_TEST|COVID-19 neutralizing antibody|"This study enrolled persons already who received COVID-19 vaccination under government policy.~1. We collect 5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination~2. isolate serum and store in -80 degree deep freezer~3. measure neutralizing Antibody"
223397306|NCT04107324|PROCEDURE|ARAPS|In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
223397307|NCT04107324|PROCEDURE|PVE|Portal vein embolisation
223397308|NCT02597764|BEHAVIORAL|Diaphragmatic Breathing|
223397309|NCT02597764|BEHAVIORAL|Standard Urotherapy|
223397310|NCT03238521|PROCEDURE|Spinal osteosynthesis with classical pedicle finder|Posterior thoracic and lumbar osteosynthesis with classical pedicle finder
223397311|NCT03238521|PROCEDURE|Spinal osteosynthesis with pedicle finder with impedancemetry|Posterior thoracic and lumbar osteosynthesis with pedicle finder with impedancemetry
223397312|NCT04364893|OTHER|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors|Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors
223397313|NCT00210028|DRUG|Tamoxifen|
223397314|NCT00210028|DRUG|Zarnestra|
223397315|NCT04057729|DRUG|IMP4297|10mg/capsule.
223397316|NCT04506034|DRUG|lidocaine patches|for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
223397317|NCT04506034|DRUG|IV lidocaine|received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
223397318|NCT04506034|DRUG|IV saline infusion|received i.v. saline infusion.
223397319|NCT03707210|BEHAVIORAL|VR training program|Use VR software to make a training education program.
223731279|NCT00487747|DRUG|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
223397320|NCT02267681|DRUG|Fentanyl|Intravenous fentanyl for sedation/analgesia
223397321|NCT02267681|DRUG|Alfentanil|Intravenous alfentanyl for sedation/analgesia
223397322|NCT02267681|DRUG|Propofol|Intravenous propofol for sedation
223397323|NCT04740450|DEVICE|Kinesio taping|skin colored Kinesio-Tex Gold tape, 50 mm \_ 5 m (Kinesio Holding Corp, Albuquerque, NM) tapped in technique described by Gozluklu et al in 2020
223397324|NCT04740450|DEVICE|Wound Tape|skin colored wound tape tapped in technique described by Gozluklu et al in 2020
223397325|NCT06140524|DRUG|Linvoseltamab|Administered per the protocol
223397326|NCT03334435|DRUG|Baricitinib|Administered orally
223397327|NCT03334435|DRUG|Placebo|Administered orally
223397328|NCT03922321|DRUG|RVT-1401|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
223397329|NCT02249975|DEVICE|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~* Device malfunctions~* Adverse events~* Patient Pain~* Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
223397330|NCT02832232|OTHER|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
223397331|NCT02832232|OTHER|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
223397332|NCT02832232|OTHER|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
223397333|NCT01387659|PROCEDURE|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
223397334|NCT03632499|OTHER|rehabilitation|rehabilitation
223397335|NCT00525681|DRUG|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
223397336|NCT00525681|DRUG|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
223397337|NCT02828293|OTHER|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
223397338|NCT03275493|BIOLOGICAL|CD19 CAR-T cells|Express a Second Generation 4-1BB: CD19 CAR-T cells
223397339|NCT03275493|BIOLOGICAL|CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology
223397340|NCT02508337|DRUG|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
223397341|NCT02508337|DRUG|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
223397342|NCT04966871|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
223397343|NCT04966871|BIOLOGICAL|PfSPZ Challenge (7G8) for CHMI|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
223550563|NCT01523743|DEVICE|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
223550564|NCT01523743|DEVICE|Standard care|The coated intermittent catheter normally used by subject
223550565|NCT04594135|DRUG|anti-CD5 CAR T cells|anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells
223550566|NCT06204588|PROCEDURE|control group: SFA only|Single flap approach
223550567|NCT06204588|PROCEDURE|Test group 1: VCMX + Low level LASER therapy + Single flap approach|using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
223550568|NCT06204588|PROCEDURE|Test group 2: Low level LASER therapy + Single flap approach|Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).
224016647|NCT04133051|DRUG|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
224016648|NCT04133051|DRUG|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
224016649|NCT02545933|DRUG|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
224016650|NCT02545933|DRUG|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
224016651|NCT02545933|DRUG|Aspirin|Aspirin will be administered at the dose of 81mg once daily
224128489|NCT03420131|DIAGNOSTIC_TEST|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
224128490|NCT00074841|DRUG|Azithromycin/Chloroquine|
224128491|NCT00074841|DRUG|Sulfadoxine-Pyrimethamine/Chloroquine|
224128492|NCT05357352|OTHER|NAFLD/NASH|the characteristics of patients with advanced fibrosis in a community-based referral center.
223397344|NCT04966871|OTHER|Normal Saline|normal saline placebo control
223550569|NCT05033886|DRUG|fezolinetant|oral
223550570|NCT05033886|DRUG|placebo|oral
223397345|NCT00618111|DRUG|Granisetron|
223397346|NCT01022840|DRUG|S-Ketamine|drug
223397347|NCT01022840|OTHER|Placebo Comparison|saline control
223397348|NCT05221944|OTHER|Patients had a history of antithrombotic therapy|Patients with antithrombotic drugs were identified and grouped and their medical records were reviewed.
223397349|NCT05221944|OTHER|Patients had no history of antithrombotic therapy|Patients had no history of antithrombotic therapy
223550571|NCT06107374|DRUG|[18F]F-AraG|Two PET scans
223550572|NCT02569476|DRUG|Zanubrutinib|
223550573|NCT02569476|DRUG|Obinutuzumab|
224016652|NCT02545933|DRUG|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
224128493|NCT00995345|DRUG|KRP-104|Tablet
224128494|NCT00995345|DRUG|Placebo|Tablet
223397350|NCT01961050|BEHAVIORAL|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
224016653|NCT05571345|DRUG|PF614|PF614 capsules (50 mg or 100 mg)
224016654|NCT05571345|DRUG|Oxycodone Hydrochloride 40 mg|Oral 20 mg tablets (two each)
224128495|NCT02555566|PROCEDURE|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
224128496|NCT02555566|PROCEDURE|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
224128497|NCT03634358|PROCEDURE|Bipolar scissors|
224128498|NCT03634358|PROCEDURE|classic scalpel|
224128499|NCT01860534|BEHAVIORAL|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
224128500|NCT04125797|OTHER|Application of adhesive|Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
224128501|NCT05477342|BEHAVIORAL|Board Game|The BG group that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player) GP1- GP 2- GP 3- GP 4.
223397351|NCT01961050|OTHER|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
223397352|NCT04067050|DEVICE|comfilcon A asphere|Contact Lens
223397353|NCT04067050|DEVICE|Spectacles|Habitual spectacles
223397354|NCT01446341|PROCEDURE|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
223397355|NCT01446341|PROCEDURE|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
223397356|NCT05294679|DRUG|Propofol|All patients completed pre-anaesthesia assessment, signed informed consent, and completed vital signs on the day before surgery, with values as baseline vital signs. On the day of surgery, after routine preparation before colonoscopy (fasting for at least 6h and water restriction for at least 2h before surgery), venous access was established in the left hand. 0.5μg/kg fentanyl was administered intravenously after oxygen inhalation through a nasal catheter (4-6 L/min). About 3 minutes after fentanyl administration, sedation induction was performed with ciprofol or propofol immediately.
223397357|NCT05294679|DRUG|Ciprofol|Ciprofol
223397358|NCT03379337|DIAGNOSTIC_TEST|Dental imaging|The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
223397359|NCT01588288|PROCEDURE|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
223397360|NCT00659711|DRUG|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
223397361|NCT00659711|DRUG|Placebo|will be placed on a placebo for 12 weeks.
223397362|NCT03160378|BEHAVIORAL|Organizational skills training|10 sessions of parent and child training in a group format.
223550574|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture|Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.
223550575|NCT06646172|PROCEDURE|Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride|Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
224016655|NCT05571345|DRUG|Placebo|Placebo to match PF614 capsules will be provided by the sponsor.
224016656|NCT05488145|OTHER|Best Practice|Receive standard of care
224016657|NCT05488145|OTHER|Internet-Based Intervention|Receive application intervention
224016658|NCT05488145|OTHER|Questionnaire Administration|PROMIS medication adherence questionnaire is a well-defined self-report measure of medication-taking habits used to objectively assess adherence to medication and therapy. At the end of the study period, we will perform data analysis.
224016659|NCT05488145|OTHER|Survey Administration|Improvement in patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.
224128502|NCT05477342|BEHAVIORAL|Tobacco Cesseation Education|The TCE group were divided three group that E1 (Precontemplation) -E2 (Contemplation)-E3 (Preparation) according to the thinking stages scale.
224128503|NCT05477342|BEHAVIORAL|Combined İntervention|"The CI group was divided into five groups for play that will play the game were divided into four groups with five or six participants in each group. (GP (Game Player)GP 5- GP 6- GP 7- GP 8- GP 9).~The CI group was divided into three groups for education that E4 (Precontemplation) -E5 (Contemplation)-E6 (Preparation) according to the thinking stages scale."
223397363|NCT03160378|OTHER|Treatment as usual|Treatment as usual in the outpatient clinic
223397364|NCT02677753|RADIATION|Fluoroscopy|
223397365|NCT01062425|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
223397366|NCT01062425|DRUG|Cediranib Maleate|Given PO
223550576|NCT00002322|DRUG|Atevirdine mesylate|
223550577|NCT00002322|DRUG|Zidovudine|
223397367|NCT01062425|RADIATION|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
223397368|NCT01062425|OTHER|Laboratory Biomarker Analysis|Correlative studies
223397369|NCT01062425|OTHER|Placebo Administration|Given PO
224016660|NCT05118828|BEHAVIORAL|Guided internet-based cognitive behavioural therapy|AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.
224016661|NCT05118828|BEHAVIORAL|Treatment as usual in Prompt Mental Health Care (TAU-PMHC)|TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
224016662|NCT06374108|BEHAVIORAL|Progressive resistance training|The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
224016663|NCT04517214|DRUG|Toripalimab|PD-1 inhibitor
224016664|NCT04517214|RADIATION|IMRT to the nasopharynx and neck|IMRT to the nasopharynx and neck
224016665|NCT04517214|DRUG|Gemcitabine and Cisplatin Chemotherapy|Systemic chemotherapy
224016666|NCT04517214|DRUG|Adjuvant chemotherapy with Capecitabine|Adjuvant chemotherapy after radiation
224016667|NCT06081153|DRUG|Evolocumab|See arm description.
224016668|NCT06081153|DRUG|Placebo|See arm description.
224016669|NCT06089850|OTHER|Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.|"Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant"
224016670|NCT00835900|DRUG|varenicline|variable dosing schedule
224016671|NCT00835900|DRUG|placebo|placebo
224016672|NCT02817802|DEVICE|Magmaris|PCI (Magmaris)
224016673|NCT05520372|COMBINATION_PRODUCT|Autologous immune enhancement therapy (AIET) for cancer patients|Autologous NK cell and CD8 T cell therapy for cancer patients
224016674|NCT04631900|BEHAVIORAL|Christianity approach as framework for spiritual intervention|Intervention includes use of Bible verses, prayer, hymns singing, sharing and caring for others (mutual support) within the group. Through these activities, participants have opportunities to re-build and further develop their connectedness to themselves, to others, to their living, their environment, and to larger meaning and purpose.
224016675|NCT03397043|OTHER|Protein intake (dose)|Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
224016676|NCT00935818|DRUG|Varenicline|varenicline - 1 mg bid for 12 weeks
224016677|NCT00935818|DRUG|placebo|placebo for 12 weeks
224016678|NCT00935818|DRUG|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
224016679|NCT02437201|BEHAVIORAL|Liberty Program|
224016680|NCT05624151|DRUG|Dexmedetomidine +Bupivacaine|infraorbital nerve block by dexmedetomidine plus bupivacaine
224016681|NCT05624151|DRUG|Magnesium Sulfate + Bupivacaine|infraorbital nerve block by magnesium sulphate plus bupivacaine
224016682|NCT05624151|DRUG|Bupivacaine|infraorbital nerve block by bupivacaine only
224016683|NCT03373942|OTHER|Choroidal thickness measurements with SD-OCT device|
224016684|NCT00732589|DRUG|1% xylocaine|10 cc. of 1%xylocaine, once a week
224016685|NCT00732589|OTHER|ultrasound|ultrasound at shoulder area about 10 mins.
223397370|NCT01062425|DRUG|Temozolomide|Given PO
223397371|NCT00498043|DRUG|R-CHOP14 induction regimen|R-CHOP14 induction regimen
223397372|NCT00498043|DRUG|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
223397373|NCT00151879|DRUG|SPM 927|
223397374|NCT02933164|DEVICE|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
223397375|NCT03390608|DRUG|Endocrine therapy|Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
223397376|NCT03390608|RADIATION|Radiotherapy|Radiotherapy versus no radiotherapy.
224016686|NCT02527824|DRUG|Oxaliplatin, Irinotecan, S-1|"Treatment will be delivered every 2 weeks~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day1-7"
224016687|NCT05390021|COMBINATION_PRODUCT|PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent|The research study procedures include a screening for eligibility and a single study visit. PET/MRI in one study visit of approximately four hours.
224016688|NCT00979134|DRUG|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
224016689|NCT00979134|DRUG|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
224016690|NCT00979134|DRUG|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
224016691|NCT00000747|DRUG|Nevirapine|
224016692|NCT05060640|PROCEDURE|Detection of anal HSIL in a routine colonoscopy.|Detection of anal HSIL in a routine colonoscopy by using acetic acid and NBI/BLI.
224016693|NCT06533085|PROCEDURE|Adductor canal block by surgeon|"Three groups were evaluated in the study. All three groups underwent intraoperative PCI.~Group 1 (Adductor canal block by surgeon) Group 2 (Adductor canal block by anesthesiology specialist ) Group 3 (Control group)"
223397377|NCT03390608|DRUG|Herceptin|Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
223397378|NCT03390608|DRUG|Chemotherapy|Chemotherapy versus no chemotherapy.
223397379|NCT03390608|PROCEDURE|Type of breast cancer surgery|Type of surgery (partial mastectomy, mastectomy, other).
223550578|NCT01929200|DRUG|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
223550579|NCT01929200|DRUG|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
223550580|NCT04782349|OTHER|mulligan mobilization with low level laser therapy and traditional physical therapy exercises|"for mulligan mobilization: for improving the limited range of motion of shoulder joint, the therapist will apply posterolateral mobilization for the shoulder joint. Three sets of painless glides of 10 repetitions will be applied with a rest interval of 30 s between each set.~For low level laser application: Laser specifications is as follows: 850 nm wave length and pulsed application with 8 W applied for 20 minutes. laser will be applied over painful points of the shoulder.~For traditional physical therapy exercises: the patients will receive the following exercise program: self stretching exercises for shoulder joint, pully exercises, back climbing exercises, finger ladder exercises, circumduction exercises and pendulum exercises"
223550581|NCT04782349|OTHER|low level laser therapy and traditional physical therapy exercises|patients in this group will receive low level laser and traditional physical exercises as described before for group (A)
224128504|NCT01504854|DRUG|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
223550582|NCT04782349|OTHER|physical therapy exercises|The patients will receive traditional physical therapy exercises only as described before for group (A)
224128505|NCT01504854|DRUG|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
223397380|NCT03390608|OTHER|Age at diagnosis|Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).
223550583|NCT02569346|DRUG|Triumeq|Single-dose Triumeq as a whole tablet
223550584|NCT02569346|DRUG|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
223397381|NCT03390608|OTHER|Screen detected tumor|Screening detected tumor (yes, no).
223731280|NCT04774198|DIAGNOSTIC_TEST|blood sample|Blood samples are collected within 24 hours before the surgical procedure, on postoperative day two and seven. Samples collected are as following: TruCulture, flow cytometry, markers of systemic inflammation (Plasma level of pro- and anti-inflammatory molecules assed by Olink inflammation panel, leucocytes, differential count, hemoglobin, thrombocytes and CRP)
223731281|NCT01454947|BEHAVIORAL|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
223731282|NCT01454947|BEHAVIORAL|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
223731283|NCT01454947|BEHAVIORAL|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
223731284|NCT05492331|OTHER|Music Therapy|Patient preferred artist or music genre to be playing from an iPad
223731285|NCT06064474|BEHAVIORAL|High ventilation breathwork with retention (HVBR)|Intervention
223731286|NCT06064474|BEHAVIORAL|Placebo HVBR|Placebo
224016694|NCT06600776|DRUG|Ultra Rapid Lispro (URLi)|"Dosage Form:~Subcutaneous insulin infusion~Dosage:~Based on individual carbohydrate counting, adjusted using the MiniMed 780G hybrid closed-loop system.~Frequency:~Administered at mealtime (premeal) during one phase and immediately after meals (postmeal) during the other phase.~Duration:~Each intervention phase lasts up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~Both interventions (mealtime and postmeal dosing) are applied to the single arm of the study."
224016695|NCT06600776|DEVICE|Insulin pump with continuous glucose monitoring (CGM)|"The insulin pump with continuous glucose monitoring (CGM) system is used by patients with Type 1 Diabetes Mellitus (T1DM) as part of their regular treatment regimen. This system combines an insulin pump with real-time glucose monitoring, adjusting basal insulin delivery every 5 minutes based on continuous glucose data. In this study, participants are already using the system before the trial begins. The research does not examine the effect of the CGM itself but rather focuses on the timing of insulin bolus delivery (mealtime vs. postmeal) using their existing treatment system.~Frequency:~The system delivers basal insulin continuously and requires the patient to manually deliver bolus doses at mealtime (premeal) or postmeal, depending on the study phase.~Duration:~The device is used continuously throughout the entire study period, with each intervention phase (premeal vs. postmeal dosing) lasting up to 4 weeks.~Arm or Group/Intervention Cross-Reference:~This device will be us"
224016696|NCT05917470|DRUG|ONCT-534|ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
223397382|NCT03390608|OTHER|Menopausal status at diagnosis|Menopausal status (premenopausal, postmenopausal).
223397383|NCT03390608|OTHER|Tumor size|Tumor size (≤5 mm, 6-≤10 mm).
223397384|NCT03390608|OTHER|Estrogen receptor (ER) status|ER-status (positive, negative).
223397385|NCT03390608|OTHER|Tumor grade|Tumor grade (1, 2, 3).
223397386|NCT03390608|OTHER|HER2-status|HER2-status (positive, negative).
223397387|NCT03390608|OTHER|Intrinsic subgroups of breast cancer|Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
223397388|NCT03390608|OTHER|Nodal status|N-status (N0, N1).
223397389|NCT02342678|BEHAVIORAL|Yoga Therapy|
223550585|NCT02569346|DRUG|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
223550586|NCT04301323|DRUG|BHVI1 eye drops|Including 35 children enrolled to receive BHVI1 eye-drops once nightly
223550587|NCT04301323|DRUG|BHVI2 eye drops|Including 35 children enrolled to receive BHVI2 eye-drops once nightly
223550588|NCT04301323|DRUG|BHVI3 eye drops|Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
224128506|NCT05927727|DIAGNOSTIC_TEST|Ultrasound and biyopsy|Each participant has undergone to ultrasound and biopsy procedure if they have suspicious lymph node in axillar region
224128507|NCT03973684|DEVICE|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
224128508|NCT03973684|OTHER|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
224128509|NCT02444819|DRUG|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
223397390|NCT02342678|BEHAVIORAL|Physical Conditioning|
223397391|NCT02015728|DEVICE|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
223397392|NCT02015728|DRUG|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
223397393|NCT02015728|DRUG|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
223397394|NCT02015728|DRUG|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
223397395|NCT02015728|DRUG|Everolimus|Everolimus is an mTOR pathway inhibitor.
223397396|NCT02015728|DRUG|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
223397397|NCT02015728|DRUG|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
223397398|NCT02436928|BIOLOGICAL|AT-501 High Dose vaccine|Comparison of each dose of vaccine
223397399|NCT02436928|BIOLOGICAL|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
223731287|NCT01517269|BEHAVIORAL|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
223731288|NCT01517269|BEHAVIORAL|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
224016697|NCT04302974|PROCEDURE|Different structures and processes of primary care management strategies|Different structures and processes of primary care management strategies includes: Multi-morbidity, continuity-of-care, different service delivery models and management strategies (i.e. investigation frequency and specific drug regimens)
224128510|NCT01934894|DRUG|cabazitaxel|
223397400|NCT02436928|BIOLOGICAL|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
223397401|NCT02436928|BIOLOGICAL|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
223397402|NCT05726201|DIAGNOSTIC_TEST|ultrasound|Point-Of-Care Ultrasound (POCUS) As an Early Screening Tool for Diagnosing Skull Fractures In Children With Mild Closed Head Injuries
223397403|NCT05628610|DRUG|Tislelizumab|200mg d1, Q3W
223397404|NCT05628610|RADIATION|Radiation|Radiotherapy dose: 5,000 c G y / 30f
224128511|NCT01934894|DRUG|lapatinib|
224128512|NCT00786136|DRUG|rosuvastatin|rosuvastatin
224128513|NCT04406051|PROCEDURE|norepinephrine infusion and colloid preloading (NOR-COL)|in parturients allocated to the NOR-COL group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 5 mL/kg of colloid infusion prior to the initiation of spinal anesthesia
224128514|NCT04406051|PROCEDURE|norepinephrine infusion and crystalloid co-loading (NOR-CRYST)|in parturients allocated to the NOR-CRYST group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated. This group will also receive 10 mL/kg of crystalloid infusion simultaneously with the initiation of spinal anesthesia
224128515|NCT02857114|OTHER|massage|
223397405|NCT05628610|DRUG|Paclitaxel|Paclitaxel: 150mg / m2 ,d1, q3w
223397406|NCT05628610|DRUG|Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs|cisplatin, carboplatin, naidaplatin and other platinum drugs
223397407|NCT01742312|RADIATION|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
223397408|NCT01742312|PROCEDURE|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
223397409|NCT01742312|OTHER|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
223397410|NCT02383017|DIETARY_SUPPLEMENT|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
223397411|NCT02383017|DIETARY_SUPPLEMENT|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
223397412|NCT03334513|DRUG|Bevacizumab|intravitreal injection of bevacizumab
223397413|NCT03334513|DRUG|Ranibizumab|intravitreal injection of ranibizumab
223731289|NCT02969512|OTHER|HIPPER|Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes.
223731290|NCT02969512|OTHER|OASIS Online Educational Webinars|2-hour online educational large group sessions
223731291|NCT04343963|DRUG|Pyridostigmine Bromide|One 60mg tablet P.O. once per day for 14 days
223731292|NCT04343963|DRUG|Placebo|One tablet P.O. once per day for 14 days
223397414|NCT02029118|DRUG|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
223550589|NCT02042287|DEVICE|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
223550590|NCT02042287|DRUG|Metronidazole|Oral antibiotic
223550591|NCT04907630|BEHAVIORAL|Antenatal Education|educational intervention
223397415|NCT02029118|DEVICE|acupoint|select acupoint according to traditional Chinese medicine
223550592|NCT06393803|DRUG|2mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
223731293|NCT05127889|DRUG|curodont|"* To limit undesirable oral ingestion, the appropriate dose for the patient will be determined with the help of the dosing guide.~* The varnish will be mixed with the brush to avoid separation of the material during storage~* However, to guarantee the best results suction will be used during application of the varnish.~* A thin uniform layer of the varnish will be applied on the lesion surface by using the supplied brush~* The applicator brush won't be moved through accumulated saliva to prevent premature setting on the bristles.~* After application the patient will be instructed to close his mouth, avoid rinsing, eating soft diet and avoid hot drinks for 4 hrs."
224016698|NCT04302974|PROCEDURE|Multi-disciplinary Risk Factor Assessment and Management Programmes for diabetes (RAMP-DM)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for diabetes (RAMP-DM), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All DM patients are eligible to enrol into the DM RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
224016699|NCT04302974|PROCEDURE|Multi-disciplinary Risk Factor Assessment and Management Programmes for hypertension (RAMP-HT)|Under the Multi-disciplinary Risk Factor Assessment and Management Programmes (RAMP) for hypertension (RAMP-HT), multi-disciplinary teams of health care professionals (doctors, nurses, dietitians, pharmacists, opticians etc) were established at designated GOPCs. All HT patients are eligible to enrol into the HT RAMP programmes. Each patient in the RAMP receives a comprehensive risk factor and complication screening to determine his/her overall cardiovascular risk and presence of modifiable risk factors, and according to their risk level and need, the patient may receive additional interventions such as additional counselling by the nurse or additional consultations with a senior doctor.
224016700|NCT04302974|PROCEDURE|Patient Support Call Centre (PSCC)|RAMP Patients can also be referred to the Patient Empowerment Programme(PEP) - a structured self-care education programme delivered by non-governmental organisations(NGOs). If the DM control is suboptimal but the patient is unable to attend the PEP, they may be referred to the Patient Support Call Centre(PSCC) service. PSCC provides individualized telephone counselling by trained nurses. PSCC empowers high-risk DM patients to engage in self-care behaviours by providing regular protocol-led telephone support to advise and reinforce healthy behaviours. Targeted self-care behaviours include self-monitoring, medication management, balanced diet, exercise, risk factor reduction, problem solving and healthy coping. Enrolled patients receive weekly to bi-weekly calls in the first 3 months and additional calls as required for a maximum of 9 months. Subsequent follow-up calls are undertaken to assess self-care behaviours related to the selected goals and to develop a care plan with the patient.
223397416|NCT02029118|DRUG|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
223397417|NCT02004418|RADIATION|11C-Choline|
223397418|NCT02333942|DEVICE|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
223397419|NCT04981418|DEVICE|customised pelvic support shorts|"These apply targeted compressive forces to the pelvic girdle through selective precisely positioned reinforced lycra panels that aim to stabilize and align body segments to improve function and reduce unwanted movements. The construction material (Nylon and Elastane) is durable and breathable, and its mechanical properties enable it to provide dynamic stability and support (rather than the rigid support provided by off-the-shelf belts) during movement/functional activities. This aims to optimise comfort and movement to increase wear compliance, which is crucial as any benefits gained rely upon this."
223397420|NCT04981418|OTHER|Exercise|Women will be provided with up to a maximum of 4 exercises from a pre-defined list of exercises. Suggested dosages are referred to in the protocol. The exercise programme contains a range of exercise focused around the pelvic girdle and hips (including movement control and strengthening
223550593|NCT06393803|DRUG|5mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
223550594|NCT06393803|DRUG|10mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
223550595|NCT06393803|DRUG|20mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
223550596|NCT06393803|DRUG|30mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose or multiple doses.
223550597|NCT06393803|DRUG|40mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
223550598|NCT06393803|DRUG|50mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
223550599|NCT06393803|DRUG|60mg KH607 tablets|Subject receive KH607 tablets or placebo orally single dose.
223550600|NCT02494154|DEVICE|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
223550601|NCT02494154|DEVICE|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
223550602|NCT00222144|DRUG|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
223550603|NCT03210857|OTHER|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
223550604|NCT03782064|DRUG|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
223550605|NCT03782064|BIOLOGICAL|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
223550606|NCT02597530|DEVICE|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
223550607|NCT00825695|DIETARY_SUPPLEMENT|cocoa|two servings of cocoa daily for one month
223550608|NCT01410929|PROCEDURE|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
223550609|NCT06059677|DRUG|Active smoked cannabis|Assessment of active cannabis smoking and driving impairment
223731294|NCT05747729|DRUG|Surufatinib and Serplulimab|"Surufatinib: Safety lead-in : Oral, QD, starting dose 250 mg, adjusted according to DLT. Dose expansion: administration according to the dose determined in the safety lead-in phase.~Serplulimab: 300 mg intravenous infusion on day 1, repeated every 3 weeks."
224016701|NCT04781257|DIAGNOSTIC_TEST|New test candidates|"The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period:~CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect~Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial"
224016702|NCT01149577|DRUG|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
224016703|NCT04854824|DRUG|Recommended treatment schedule|Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle oxygen therapy
224016704|NCT04854824|DRUG|Control treatment schedule|Treatment regimens different from the recommended one according to family physician personal practice
224016705|NCT06663592|OTHER|Conventional treatment|hot pack, stretching of the neck muscles, cervical isometrics exercise
224016706|NCT06663592|OTHER|Tensioner Neuro Dynamic Mobilization|Median nerve tensioner neural mobilization with addition to conventional treatment
224016707|NCT06663592|OTHER|Slider Neuro Dynamic Mobilization|Median nerve neural sliding mobilization with addition to conventional treatment
224016708|NCT01533597|DRUG|Solifenacin|Solifenacin (5mg, qd, oral)
224016709|NCT01533597|DRUG|Solifenacin plus Tamsulosin|Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
224016710|NCT03507751|DRUG|Meropenem|1.0 gram of meropenem given intravenously every 8 hours
224016711|NCT03507751|DEVICE|CRRT|Continuous renal replacement therapy for three days
224016712|NCT06607354|OTHER|Grass fed lamb|This study investigated the impact of consuming grass finished lamb on total blood plasma and blood plasma phospholipids (PL) FA and on cardiovascular risk factors, including heart rate, blood pressure (BP), HDL-cholesterol, LDL-cholesterol, and TAG cholesterol, in humans.
224128516|NCT02426593|DEVICE|IMED-4|Non-invasive novel lung hydration status sensor.
224128517|NCT02500238|OTHER|Saliva sample|All participants will provide a saliva sample.
224128518|NCT02500238|OTHER|Urine Sample|All participants will provide a urine sample.
223550610|NCT06059677|DRUG|Placebo smoked cannabis|Assessment of placebo cannabis smoking and driving impairment
224016713|NCT06604520|DRUG|Vortioxetine|Individuals with bvFTD and mood symptoms will receive approximately 12 weeks of treatment with vortioxetine
224128519|NCT02500238|OTHER|Toe nail clippings|All participants will provide toe nail clippings.
224128520|NCT02500238|OTHER|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
224128521|NCT02507193|PROCEDURE|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
223550611|NCT03589287|BIOLOGICAL|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
223731295|NCT05037734|DEVICE|Persona Partial Knee System|Unicompartmental Knee Replacement
224016714|NCT01831570|OTHER|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
224128522|NCT02507193|PROCEDURE|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
224128523|NCT05668312|OTHER|Tele-prehabilitation|Preoperative tele-rehabilitation using a virtual reality system.
224128524|NCT05668312|OTHER|Standard prehabilitation|Preoperative home-based rehabilitation delivered with a printed booklet for the Con-O subjects and no intervention for the Con-Y subjects.
224128525|NCT04151355|DRUG|Atorvastatin 20mg|atorvastatin (20 mg once daily)
224128526|NCT00694954|DEVICE|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
224128527|NCT00694954|OTHER|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
224128528|NCT06400316|DIETARY_SUPPLEMENT|Amino Acid Supplement|The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
224128529|NCT05038748|OTHER|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders \& Schizophrenia (K-SADS) for DSM-5
224128530|NCT05038748|OTHER|ASD diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
224128531|NCT05931744|DRUG|Budesonide|after application of topical vasoconstrictor packs into both nasal cavities, using 1 cc 28 gauge needle sterile syringe, one pack of budesonide ampule 0.5 mg/2ml was injected into visible polyps on both cavities 1 ml in each cavity weekly for 5 consecutive weeks
224016715|NCT06610877|DEVICE|Focused Ultrasound Neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction). Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
224016716|NCT06610877|DEVICE|Focused ultrasound neuromodulation|Each ultrasound stimulation protocol will last for 60 seconds, consisting of 4 pulse trains of 5 seconds duration separated by 10 second intervals without stimulation. Across successive stimulation protocols (up to 25/patient) investigators will systematically vary pulse repetition frequency, duty cycle, and acoustic intensity to determine how these parameters contribute to the behavioral effect (transient tremor reduction) in each patient. Parameters will be shuffled to control for group-level carry over effects and will include sham (unfocused or off-target stimulation) conditions to control for non-specific auditory confounds.
224016717|NCT05599555|BIOLOGICAL|mRNA BNT162b2 vaccine|mRNA vaccine Comirnaty (BNT162b2 mRNA, BioNTech/Fosun-Pharma, Mainz, Germany/Shanghai, China)
224016718|NCT05599555|BIOLOGICAL|CoronaVac vaccine|Inactivated CoronaVac vaccine (Sinovac Life Sciences, Beijing, China)
224128532|NCT05931744|DRUG|Prednisone|patients given oral prednisone 1 mg/ kg with max. dose 70 mg/d divided into two doses for 3 days then tapered gradually for two weeks
224128533|NCT05931744|DRUG|Saline|saline intrapolyp injection
224128534|NCT05415150|DRUG|Thrombolytic Agent|Subjects may receive one or more of the treatment options
224128535|NCT06313177|PROCEDURE|syndesmosis fixation with screws|syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
224128536|NCT00736866|DRUG|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
224128537|NCT00736866|DRUG|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
224128538|NCT06365515|DRUG|Levodopa administration|To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
224128539|NCT06365515|DRUG|Placebo administration|Placebo tablets will be administered as the placebo-controlled condition.
224128540|NCT04356417|OTHER|- Synthetic anti-malarial drugs|Prevalent users will be those with at least one dispensing of AMD or ARBs/ACEi's from 01/01/2019 to 01/01/2020. Exposed users will be those among prevalent users who still received AMD or ARBs/ACEi's on 31/12/2019. The inclusion period will be from 01/01/2019 to 01/01/2020. The study end date will be 30/06/2020. For each treatment AMD or ARB/ACRi's, the persistence of treatment will be defined as the length of time from initiation to discontinuation. Initiation will be the date of the first reimbursement of AMD or ARB/ACRi's during the inclusion period. We will define the discontinuation of treatment as a period of more than 90 days without fulfilment of a prescription for the same treatment after the period covered by the previous prescription i.e 30 days. Exposure to a combination of drugs will be defined as a period shorter than 30 days between the prescription of two different systemic drugs and the fulfilment of another prescription for both drugs in the following 90 days.
224128541|NCT02652312|DRUG|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
224128542|NCT02652312|DRUG|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
224128543|NCT02652312|PROCEDURE|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
224128544|NCT02652312|PROCEDURE|fentanyl|1.5 μg/kg intraoperative
224128545|NCT02652312|PROCEDURE|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
224128546|NCT02652312|PROCEDURE|Atracurium|0.5 mg/kg IV for endotracheal intubation
224128547|NCT02652312|PROCEDURE|diclofenac sodium|1 mg/kg for postoperative analgesia
224128548|NCT02652312|PROCEDURE|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
224128549|NCT01091987|BEHAVIORAL|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
224128550|NCT05663736|DRUG|Gemigliptin|DPP-4 inhibitor
224128551|NCT05663736|DRUG|Glimepiride|Glimepiride
224128552|NCT03670069|DRUG|Itacitinib|Given PO
224128553|NCT03670069|OTHER|Laboratory Biomarker Analysis|Correlative studies
224128554|NCT00809458|DRUG|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
224128555|NCT03248947|DRUG|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
223731296|NCT03453710|PROCEDURE|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
224016719|NCT06611189|OTHER|surgery|In order to preserve kidney from warm ischemia during graft implantation, on the back table, graft were prepared for implantation with standard techniques. The kidney was introduced into the bag which was filled with a small amount of ice and preservation fluid (Figure 1). After inplacement of the graft, a small hole was made near the hilum and the renal artery and vein were passed through the hole. A Kocher clamp was used to maintain the fluid and ice in place and as a handle. Also, a Hartman Mosquito Clamp was used to mark urether-side, and to maintain orientation.
224016720|NCT06611189|OTHER|Ray-Tech sponge technique|On the back table, graft were prepared for implantation with standard techniques. A Raytech sponge is soaked in ice-cold preservative solution, and wrapped around the kidney and held with a clamp (Figure 2). Position and oriantation of the graft was done by direct vision of urether.
224016721|NCT06611202|OTHER|Exercise|"A multidisciplinary six-minute walking group intervention-spearheaded by physiotherapists, occupational therapists, and psychologists-in enhancing physical activity, mobility, cognitive function, and functional independence among patients with dementia.~Physiotherapy Component: A six-minute walking group will be conducted twice a week for 8 weeks, targeting improvements in mobility, endurance, and balance. Occupational Therapy Intervention: Occupational therapists will integrate functional tasks (Games and throwing of balls to court, bean bag target game to enhance exercise relevance to daily activities. A psychologist will provide mental health support during the sessions, utilising techniques like time focus reminiscence therapy to engage patients and reduce anxiety."
224016722|NCT06611202|DRUG|Clonazepam|Medication on our dementia wards are being review during ward round and when needs arise. The medication management in drugs will be fully documented and accounted for in the course of the study.
224016723|NCT02791178|PROCEDURE|Optical coherence tomography (OCT)|Special camera to study part of your heart that was affected
223397421|NCT04981418|OTHER|advice|standardised advice on management of pelvic girdle pain, through a discussion centred around 'Guidance for Mothers-to-be and New Mothers: Pregnancy-related Pelvic Girdle Pain' booklet (https://pogp.csp.org.uk/system/files/pogp-pgppat\_3.pdf). This publicly available, specialist physiotherapy approved, standardised leaflet, provides information reflective of current best practice. The participant can use this as an ongoing resource.
223397422|NCT01795963|BEHAVIORAL|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
224016724|NCT02791178|PROCEDURE|Index of microcirculatory resistance (IMR)|Special wire to study part of your heart that was affected
224016725|NCT02791178|OTHER|Cardiac MRI|Special scanner if the heart to assess the damage of your heart
224128556|NCT03248947|OTHER|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
224128557|NCT06301841|OTHER|experimental|"At day 3, clinicians have to consider all the early microbiological results (including the respiratory broad-panel mPCR (Biofire FilmArray Pneumonia plus Panel de Biomérieux) and procalcitonin, and subsequently to apply an algorithm of early antibiotics discontinuation or de-escalation.~Discontinuation is encouraged in case of no bacteria documentation and a procalcitonin \< 1 ng/L; discontinuation is even encouraged if a viral documentation is concurrently obtained. In case of no bacteria documentation and a procalcitonin \> 1 nd/L, antibiotic continuation is encouraged for additional two days.~In case of bacteria documentation, antibiotic continuation is encouraged, but with narrowing the spectrum as much as possible. The duration of antibiotics is based on a procalcitonin algorithm: procalcitonin \< 0.1 nd/l: discontinuation; 0.1 ng/l \< procalcitonin \< 0.25 ng/l: additional 1 day; procalcitonin \> 0.25 ng/l: additional 2 days."
224128558|NCT01100307|DRUG|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
224128559|NCT01100307|OTHER|sham injection|sham injection every 6 weeks
224128560|NCT05135130|DRUG|ON101 Cream|Not applicable in this retrospective study
223550612|NCT04651465|BEHAVIORAL|Tuning in to Kids|A parenting program that includes 6 group supervisions of parents, where emotion coaching and promotion of kids emotional competence are main focus.
223550613|NCT00604552|DEVICE|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
223550614|NCT02446769|DEVICE|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
223550615|NCT03202212|PROCEDURE|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
223550616|NCT03202212|PROCEDURE|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
223550617|NCT06085235|BEHAVIORAL|exercise|cycling exercise for 15min, with 5min warm up
223550618|NCT02564588|DRUG|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
223550619|NCT02564588|DRUG|Placebo|Placebo once daily
223397423|NCT01795963|BEHAVIORAL|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz \& Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite \& Fincham, 2007; Braithwaite \& Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
223550620|NCT05402215|BEHAVIORAL|The flipped classroom model was used to teach students' clinical practice skills.|Videos for clinical applications have been prepared by researchers. These prepared videos were shared with the students in the experimental group one week before the lesson day of each application for preliminary study and the students were asked to work on these videos. On the day of the lesson, group work, question-answer and discussion activities were held with the students in the classroom environment. At the end of the lesson, the students were asked to do the applications on the simulation models of the application and the checklists were filled.
223397424|NCT04505670|DRUG|Donepezil|donepezil orally 5mg
223397425|NCT04505670|DRUG|Placebo oral tablet|Placebo
223550621|NCT05402215|BEHAVIORAL|control group|To the students in the control group, the application was explained by the researcher (instructor conducting the course) using presentation and demonstration methods. Each application was made on different days. The prepared checklists were filled by the other researcher.
223550622|NCT05833009|DEVICE|Acupuncture|All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
223550623|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The clinical symptoms will be evaluated before and after MT intervention.
223550624|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The acoustic features will be evaluated before and after MT intervention.
223731297|NCT03453710|PROCEDURE|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
223731298|NCT04287491|OTHER|Oculus Go Virtual Reality System|The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.
224016726|NCT05587790|BEHAVIORAL|Weight Management Intervention|Participants attend virtual dietary education sessions and over time create a diet plan that satisfies their individual needs. Participants aim to lose 1-2 pounds weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and anthropometric measures of waist and hip circumference, and body composition.
223731299|NCT05244330|OTHER||
223731300|NCT01053416|PROCEDURE|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
224016727|NCT06402240|BEHAVIORAL|Dialectical Behavior Therapy|Dialectical behavior therapy (DBT) in its fully adherent form is a comprehensive intervention involving individual, group, and phone coaching sessions that addresses complex psychological conditions including suicidality, personality disorders, and post-traumatic stress disorder. Evidence for briefer formats incorporating the group skills training format have been successful for many types of conditions, which includes alcohol and substance use disorders. DBT skills training (DBT-ST) involves structured lessons for learning skills in 5 areas: mindfulness, emotion regulation, distress tolerance, interpersonal effectiveness, and addiction. The current intervention is an internet-delivered version of DBT-ST which aims to teach people the same 5 areas of skills in an online environment with a chatbot and interactive format.
224016728|NCT06728956|OTHER|READY for MS UK digital programme|Online self-directed programme supported by HCPs
224016729|NCT06729320|BIOLOGICAL|Umbilical cord blood mononuclear cells|Intravenous infusion of UCB-MNCs (3×10\^8/ time, once a week, four times in total)
224016730|NCT06729320|COMBINATION_PRODUCT|Conventional hematopoietic recovery therapy|Including but not limited to G-CSF, TPO, TPO receptor agonists, transfusions of red blood cells, platelets, etc.
223397426|NCT04505670|DRUG|Topical Zinc Oxide|Topical Zinc Oxide 20%
223397427|NCT01109693|DRUG|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
223397428|NCT01109693|DRUG|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
223731301|NCT03907358|PROCEDURE|phacoemulsification|
223731302|NCT02994212|DIETARY_SUPPLEMENT|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
223397429|NCT06461806|DIETARY_SUPPLEMENT|Protein supplement - Plant protein|Pea/lupine protein powder mix
223397430|NCT06461806|DIETARY_SUPPLEMENT|Protein supplement - Animal protein|Whey protein powder
223397431|NCT05848193|OTHER|MyHeadHealth online application|MyHeadHealth is an online application to be accessed through the patients smartphone. The goal of MyHeadHealth is to improve treatment compliance by providing patients with free and convenient access to resources and activities that align with their treatment plan
223397432|NCT05848193|OTHER|Standard of Care|Patients will receive Standard of Care from our concussion clinic as necessary as per the consultation with the physician
223397433|NCT03458078|DRUG|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
223397434|NCT03458078|DRUG|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
224016731|NCT06728150|RADIATION|computerized tomography|The patients will have 3 monthly CT scans of the brain for 2 years and 6 monthly CT scans for 2 years for total of 4 years.
224016732|NCT06728618|DRUG|Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel|"Neoadjuvant treatment: the participants will receive Tislelizumab 200 mg, Cisplatin 75 mg/m2, Nab-paclitaxel 260 mg/m2 (each 3-week cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles.~Adjuvant treatment: the participants will receive Tislelizumab 200 mg (each 3-week cycle, a total of 8 cycle) and Cetuximab (250 mg/m2, each 2-week, a total of 12 cycle) for a total of half a year."
224016733|NCT06727994|OTHER|Providing Genital Hygiene training|"After the informed consent of all participants in the study is obtained, pre-test data, Self-Care Power Scale and Genital Hygiene Behavior Scale will be collected face-to-face.~Genital Hygiene training will be given. Reminder training will be given 15 days, 1 month and 2 months after the training, and 1 month after the reminder training, the Self-Care Power Scale and Genital Hygiene Behavior Scale will be re-administered to women as a final test."
224016734|NCT06728670|BEHAVIORAL|Tranexamic acid Intravenous Infusion|A slow intravenous infusion of 1g TXA was administered at a rate of about 1ml/min.
224016735|NCT06728670|BEHAVIORAL|TXA intramuscular injection|5ml intramuscular injections of TXA with twice, each injection time no more than 30 seconds, the injection site was selected as triangle
223397435|NCT03458078|DRUG|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
223397436|NCT05405751|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
223397437|NCT03084653|OTHER|Survey|Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
223397438|NCT00498147|OTHER|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
223731303|NCT05083962|BEHAVIORAL|Healthy Lifestyle Program|An intensive behavior change curriculum designed to help create and sustain healthy habits
223731304|NCT02649998|DRUG|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
224016736|NCT06729476|DEVICE|Uroshield vibrator device|UROSHIELDTM is a small device that generates low-energy surface acoustic waves, which transmit energy to the endotracheal tube through a thin cable attached to the tube. Laboratory studies using catheterized urinary tract models have shown a significant reduction in microbial colonization and reduced development of antimicrobial resistance in UROSHIELDTM device treated individuals.
224016737|NCT06729034|DRUG|Apixaban (Eliquis)|5 mg twice daily
224016738|NCT06729034|DRUG|Placebo|placebo twice daily
224016739|NCT06728306|BEHAVIORAL|Immersive Virtual Reality-Based Relaxation|"Participants experienced a 20-minute immersive relaxation session using the virtual reality headset and the Nature Treks application, while seated comfortably. Participants were instructed to select the natural environment they found most relaxing from options such as Blue Ocean, Orange Sunset, Violet Down, White Winter, and Green Meadows, and spent 20 minutes immersed in their chosen virtual environment."
224016740|NCT06728306|BEHAVIORAL|Non-immersive VR-Based Exergaming|"Participants engaged in a 20-minute calisthenic exercise session guided by the Kinect Adventures game on the Xbox Kinect 360 system. The exercise session consisted of playing two rounds each of the game segments 20,000 Leaks, Reflex Ridge, and River Rush, each lasting approximately 3 minutes"
224016741|NCT06728306|BEHAVIORAL|Jacobson's Relaxation|Participants underwent 20 minutes of progressive relaxation training as developed by Dr. Jacobson. The training involves a series of deep diaphragmatic breaths followed by the systematic tensing and relaxing of 16 major muscle groups throughout the body. Participants were guided through the exercise by an approximately 20-minute audio recording prepared by a psychologist and available online
224016742|NCT06729359|DIAGNOSTIC_TEST|Ultrasonography of the abdomen and pelvis|ultrasonography of the abdomen and pelvis using a 3.5mhz abdominal probe
224016743|NCT06867718|DRUG|RGT001-075|RGT001-075 is a small molecule GLP-1 agonist
224016744|NCT06867718|DRUG|Placebo Comparator|Placebo comparator
224016745|NCT06897605|DRUG|Dapagliflozin (DAPA)|Dapagliflizin 10 mg tablets once daily for 12 weeks
224016746|NCT06897605|DRUG|Erythropoiesis Stimulating Agent|Erythropoiesis stimulating agent (ESA) therapy
224016747|NCT06774001|PROCEDURE|Appendicectomy|Both open and minimally invasive (laparoscopic and robotic) interventions are eligible for inclusion. Laparoscopic and robotic converted to open cases are also eligible.
224016748|NCT06896981|DRUG|Metformin with Semaglutide|One arm: Metformin 500 mg bd, Other arm: Metformin 500 mg bd + Semaglutide 0.5 mg once weekly
224016749|NCT02390700|BIOLOGICAL|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
224016750|NCT03227406|BEHAVIORAL|Sleep deprivation|Subjects are kept awake all night.
224016751|NCT03227406|BEHAVIORAL|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
224016752|NCT02691533|DRUG|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
224016753|NCT02691533|DRUG|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
224016754|NCT02691533|DRUG|No Lipid Emulsion/Placebo|
224016755|NCT06907472|DRUG|Protocol-based treatment|"PROTOCOL:~Step 1: Metformin 500 mg daily Step 2: Metformin 1000 mg daily Step 3: Metformin 1000 mg twice daily Step 4: Metformin 1000 mg twice daily + glibenclamide 5 mg daily Step 5: Metformin 1000 mg twice daily + glibenclamide 5 mg twice daily"
224016756|NCT06907459|OTHER|upper Track of Deep Front Facial Line realese|The MFR techniques were applied to the designated regions, with soft, steady pressure lasting 90 to 120 seconds postural correction exercises The upper track of deep front facial line release procedures were applied. Hyoid mobilization; Larynx mobilization; Sternal oscillations; and Barral's Transversus Thoracis mobilization. The thoracic inlet releasing ; intrathoracic fascia elongation; scalene releasing and diaphragm relaxation
224016757|NCT06907459|OTHER|Myofascial Release With IASTM|The instrument is designed to mobilize soft tissues. Facilitation approaches were employed to break apart adhesions. Emollient Gel/Lubrication Gel (Hawk Grips product) was also used to lubricate the skin and allow the instrument to move more easily. The tool has two sides: one for therapy and the other for holding plus postural correction exercises
224016758|NCT06907459|OTHER|supervised corrective exercises|The exercise program included cervical stabilization exercises performed in 3 sets of 10 repetitions with a 10-second maintenance, scapular stabilization exercises plus stretching of cervical muscles.
224128561|NCT06367790|OTHER|Experimental group|"The athletes included in the experimental group will undergo an intervention using a plyometric exercise protocol, 2 days a week, and dry needling of the gastrocnemius muscles will be applied in a weekly session.~To perform the dry needling intervention, 0.3x50mm disposable steel needles will be used, applying the quick in-and-out technique. To do this, first of all, the intervention area will be cleaned with alcohol and sterile gloves will be used to perform the manoeuvre in complete safety. The active or latent trigger point is then located within the taut band by inserting the needle deeper and deeper, and then moving the needle up and down in search of a local contraction response. A maximum of 8 insertions or up to the athlete's tolerance limit will be applied."
224128562|NCT06367790|OTHER|Control group|The athletes included in the control group will perform an intervention using a plyometric exercise protocol, 2 days a week, under the same conditions as the experimental group.
224128563|NCT06802146|DRUG|Inqovi|Combination of a nucleoside metabolic inhibitor and cytidine deaminase inhibitor, 10mg DEC / 100mg CED tablet, taken orally per protocol.
224128564|NCT02196649|DEVICE|Endoscopic Clip|
224128565|NCT00500786|BIOLOGICAL|CYT006-AngQb|
224128566|NCT05122650|DRUG|JZP385|JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
224128567|NCT05122650|OTHER|Placebo|Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
224128568|NCT06622694|BIOLOGICAL|RD13-02|"Before cell infusion (Day 0), subjects will undergo a lymphodepleting chemotherapy based on the Fludarabine + Cyclophosphamide (FC regimen). Prior to the lymphodepleting chemotherapy, subjects must undergo an assessment, and only those meeting the criteria will be eligible for the lymphodepleting chemotherapy. The CAR T infusion should be performed at least 48 hours after the completion of the lymphodepleting chemotherapy. The infusion will be administered intravenously as a single dose. It should be completed within 30 minutes, with continuous cardiac monitoring during the infusion to observe heart rate (HR), blood pressure (BP), respiratory rate (R), and peripheral oxygen saturation (SpO2) for up to 2 hours post-infusion."
224128569|NCT04026412|BIOLOGICAL|nivolumab|Specified dose on specified days
224128570|NCT04026412|BIOLOGICAL|ipilimumab|Specified dose on specified days
224128571|NCT04026412|BIOLOGICAL|durvalumab|Specified dose on specified days
224128572|NCT04372576|DIAGNOSTIC_TEST|Assessment of ventilator-associated pneumonia criteria|Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.
224128573|NCT05107206|DEVICE|Mechanical Thrombectomy using the Envi™-SR Thrombectomy device|Clot removal using the Envi™-SR Thrombectomy device
224128574|NCT05107206|DEVICE|Mechanical Thrombectomy using the Solitaire or Trevo Revascularization Device|Clot removal using the Solitaire or Trevo Revascularization Device
224128575|NCT03340181|OTHER|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
224128576|NCT06060275|DIAGNOSTIC_TEST|serum sample and nerve conduction study and cerebrospinal fluid study|serum sample and cerebrospinal fluid study to detect Neurofilament light chain Nerve conduction study
224128577|NCT06406777|DIAGNOSTIC_TEST|Spirometry|Spirometry measures lung function, specifically the amount and/or speed of air that can be inhaled and exhaled.
224128578|NCT06406777|DIAGNOSTIC_TEST|Contrast Lung Computed Tomography (CT) Scan|CT scan of the lungs using contrast
223397439|NCT00648791|DRUG|Finasteride Tablets 5 mg|5mg, single dose fasting
223397440|NCT00648791|DRUG|Proscar Tablets 5 mg|5mg, single dose fasting
223397441|NCT04056260|PROCEDURE|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
223397442|NCT01615458|BEHAVIORAL|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
223397443|NCT02843321|BIOLOGICAL|T-cell infusion, influenza vaccination|Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
223397444|NCT00317343|DRUG|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
223397445|NCT00460603|DRUG|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
223731305|NCT02649998|DRUG|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
223397446|NCT00460603|DRUG|AG-013726|AG-013726 5 mg bid every 2 weeks
223397447|NCT00460603|DRUG|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
223397448|NCT04711993|OTHER|Aerobic exercise|"Patients will do aerobic exercise three days a week for 40 minutes during 8 weeks. Aerobic exercise protocol will consist of warm up, loading and cooling periods. . Exercise prescription will be prepared in line with the recommendations of The American College of Sports Medicine."
223397449|NCT04711993|OTHER|Stretchin exercise|Patients will do stretching exercise three days a week for 40 minutes during 8 weeks. Stretching exercises will start with active warm-up activities. Static stretching method will be used.
223397450|NCT00289848|DRUG|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
224016759|NCT06906328|BEHAVIORAL|Cognitive remediation program, with the PRESCO® software|"The program runs for 12 weeks, with two sessions per week, one with a neuropsychologist. In the first 4 weeks, the patient will have weekly sessions at the center and complete the other session at home using the app provided for the study. For the next 8 weeks, sessions with the neuropsychologist will be every other week, with the other session at home. The neuropsychologist will track progress through the software history and follow up by phone if needed.~The proposed program will be based on a software solution for cognitive rehabilitation, developed and validated for the treatment of attention and memory disorders and neurodegenerative, neurotraumatic and neuropsychiatric pathologies (PRESCO® software, marketed by HappyNeuron)."
224016760|NCT06906328|BEHAVIORAL|Control program, with the AUDITICO® software|"Control program, with the same functional characteristics but without the targeted cognitive functions.~For the control program (comparator), we will use a software solution from the same company, but dedicated to stimulating and training auditory functions (AUDITICO® software). The advantage of this solution is that, like PRESCO®, it offers training exercises that are not aimed at re-educating cognitive functions. These include, for example, sound identification and discrimination activities. This tool can also be used by anyone, and is accessible for follow-up by the practitioner. It also offers levels of increasing difficulty, making it stimulating for users."
224016761|NCT06907277|DRUG|Dexmedetomidine|Dexmedetomidine (DXM) loading dose of 0.6 µg/kg followed by DXM infusion given at a rate of 0.4 ml/kg/h and was provided as 0.15 µg/kg/h for 24-h PO.
224016762|NCT06907277|DRUG|Fentanyl|A bolus of fentanyl 5 µg/kg followed by an intraoperative (IO) fentanyl infusion of 3-5 µg/kg/h that was continued as PO analgesia for 24 hours in a dose of 0.3 µg/kg/h.
224016763|NCT06907277|DRUG|Lidocain|Lidocaine (LID) loading dose (1 mg/kg) followed by a continuous infusion till 24 h PO as 1.5 mg/kg/h.
224016764|NCT03754114|OTHER|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
224128579|NCT06406777|DIAGNOSTIC_TEST|Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan|MRI will be taken while subject is lying on their back breathing 100% oxygen.
224128580|NCT06406777|DRUG|129Xe MRI scans|MRI will be taken while subject is lying on their back breathing room oxygen and taking a breath of 129Xe and holding it for a few seconds.
223397451|NCT00289848|DRUG|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
223397452|NCT05867030|DRUG|lenalidomide|lenalidomide is administered orally
223397453|NCT05867030|DRUG|rituximab|rituximab is administered intravenously
223397454|NCT05867030|DRUG|parsaclisib|parsaclisib is administered orally
223397455|NCT00278057|DRUG|dialysisis with and without glucose in the dialysis|
223397456|NCT02129231|DRUG|calcined magnesia|We ensured the patient took the drug at night before meals
223397457|NCT02129231|DRUG|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
223397458|NCT02129231|DRUG|Rosuvastatin|We ensured the patient took the drug at night before meals
223397459|NCT00894972|OTHER|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
223397460|NCT00860795|BIOLOGICAL|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
223397461|NCT00860795|DRUG|placebo|placebo 25 ml daily in 2 divided doses for 10 days
223397462|NCT05265286|DRUG|FRSW117|"Subjects of high dose group are being received four doses(50 IU/kg,once a week or every 7 days) of FRSW117.~Subjects of low dose group (40 IU/kg,once a week or every 7 days)are being received four doses of FRSW117."
223397463|NCT01121614|DEVICE|LOTUS|Device used to seal blood vessel
223397464|NCT01121614|DEVICE|Ethicon Harmonic Scalpel|
223550625|NCT05879809|DEVICE|"The mini apps named SOUL GYM on the Wechat"|Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals. The neuroimaging features will be evaluated before and after MT intervention.
223550626|NCT00243139|DEVICE|Mandibular advancement device (activator)|
223731306|NCT01624389|DRUG|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
223397465|NCT01121614|DEVICE|LigaSure bipolar vessel sealing device|
223397466|NCT05650112|BIOLOGICAL|FB-001|FB-001 is formulated as a powder in capsule intended for oral administration
223397467|NCT05650112|BIOLOGICAL|Placebo|In order to maintain study blinding, matching placebo in identical packaging is manufactured using an inactive powder in capsule
223397468|NCT01316081|DIETARY_SUPPLEMENT|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
223397469|NCT05799638|OTHER|Guideline-Directed Medication Treatment (GDMT)|GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose
223397470|NCT03871543|DEVICE|AquaComfort Plus|Test Lens 1
223397471|NCT03871543|DEVICE|Acuvue Oasys 1-Day|Test Lens 2
223731307|NCT01414283|DRUG|PSMA ADC|PSMA ADC administered IV
223397472|NCT00194441|OTHER|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
223397473|NCT01570790|DRUG|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
223397474|NCT01570790|DRUG|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
223397475|NCT01570790|DRUG|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
223731308|NCT00459784|PROCEDURE|Dementia Training Program|
223731309|NCT06636045|OTHER|Not applicable- observational study|No intervention. Observational study.
223731310|NCT04034381|OTHER|No intervention (descriptive survey only)|No intervention
223731311|NCT03402386|DRUG|MT-6548|Oral tablet
223731312|NCT02756689|OTHER|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
223731313|NCT02756689|OTHER|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
224016765|NCT03754114|OTHER|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
224016766|NCT03449251|DRUG|Apelin|Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
224016767|NCT03449251|DRUG|Relaxin|Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
224016768|NCT03449251|DRUG|Normal saline|Vehicle
224016769|NCT03449251|DIAGNOSTIC_TEST|Verapamil|NO independent challenge agent
224016770|NCT03449251|DIAGNOSTIC_TEST|LN Monomethyl arginine|Basal NO synthase inhibitor
224016771|NCT06017934|BEHAVIORAL|Volunteer-led physical activity|Participants will be assessed by the therapy team who will prescribe tailored activity and then liaise with the mobility volunteers, who will deliver the intervention. Participants who can mobilise independently will be encouraged to perform walking exercises, progressing their walking distance over set markers in the hospital (e.g., to the end of the bed and back; to the doorway and back; to the toilet and back). Participants who require assistance in mobility will perform bed (e.g., hip abduction, static quads), or chair exercises (e.g., ankle pumps, knee extension, arm raise), and will be progressed to performing walking exercises when their physical function improves. Volunteers will check with nursing staff that participants are safe to exercise before each activity session. Participants will receive the mobility sessions twice daily, starting upon recruitment and continuing until the day of discharge from hospital.
223397476|NCT04294407|OTHER|No intervention|no intervention in this study
223397477|NCT05273528|BIOLOGICAL|Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine|The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
223397478|NCT02383979|DEVICE|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
223397479|NCT02383979|DEVICE|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
223397480|NCT00454337|DRUG|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
223397481|NCT00454337|DRUG|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
223397482|NCT02028897|OTHER|Conventional embryo culture|
223397483|NCT02028897|OTHER|Enclosed embryo culture|
223397484|NCT03920124|OTHER|Step and walk-based high intensity interval exercise|"Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of \~30 min daily or \~150 min weekly)."
223397485|NCT02127151|DRUG|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
223397486|NCT01313897|DRUG|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
223397487|NCT03618693|PROCEDURE|Spinal anesthesia|Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
223731314|NCT00804830|DRUG|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
223731315|NCT05546645|OTHER|Questionnaire|Hypersecretion questionnaire
223731316|NCT02237950|DRUG|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
223731317|NCT02237950|DRUG|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
223397488|NCT03618693|DEVICE|TAP Block|TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
223731318|NCT02237950|DRUG|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
223731319|NCT01294293|DRUG|TLR8 Agonist VTX-2337|Given SC
224296549|NCT03474432|DEVICE|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
224016772|NCT05767060|DRUG|BAT7104 injection|According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.
224016773|NCT04381650|DRUG|TAK-981|TAK-981 IV infusion.
224016774|NCT04381650|DRUG|Pembrolizumab|Pembrolizumab IV infusion.
224016775|NCT05125705|BIOLOGICAL|Platelet rich plasma injection|The PRP is prepared by RegenLab's RegenKit-THT, in accordance with operating instructions supplied with the kit. The device allows automated blood collection (8 mL) and blood component separation in closed circuit. After centrifugation at room temperature for 9 minutes at centrifugal force of 1500g, the RegenTHT tube is then inverted several times before re-suspension, allowing 4mL of PRP to be obtained for each tube. 2.5mL will be injected into patients
224128581|NCT05514366|PROCEDURE|Modifying EIP under a tOLA before pneumoperitoneum|"Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)"
224296550|NCT02586142|DRUG|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
224296551|NCT02586142|OTHER|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
224296552|NCT00959361|BEHAVIORAL|pharmaceutical care|consultation with the pharmacists and usual care
223397489|NCT03618693|OTHER|Standard|Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
223397490|NCT04223336|BEHAVIORAL|Brief physical activity and diet intervention|The intervention is an integrated care pathway that provides a computerized prompts for practitioners in the STOP program via their online portal. For a participant who is in the intervention group, the online portal will screen the participant for their physical activity and fruit/vegetable consumption and provide the practitioner (who is seeing this participant for their visit) with computerized alerts for physical activity and fruits/vegetable consumption. Specifically, the portal will prompt practitioners to provide a brief intervention for these two behaviours using risk communication and will also suggest brief intervention language designed based on the Elicit-Provide-Elicit framework. The portal will also have available a self-monitoring resource for physical activity and fruits/vegetable consumption and will prompt practitioners to provide this self-monitoring resource to the participant during their visit.
223397491|NCT03627117|DRUG|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
223397492|NCT03627117|DRUG|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
223397493|NCT01837901|DEVICE|Transcorneal electrostimulation|
223397494|NCT05961046|DEVICE|Vivity IOL|Vivity IOL
223397495|NCT02865304|DRUG|endostar|
223397496|NCT02814604|OTHER|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
223397497|NCT01229995|DEVICE|dental implants - zirconia abutmetns - prefabricated abutments|
224296553|NCT03291353|DRUG|pembrolizumab|200 mg IV given every three weeks
224296554|NCT01233648|OTHER|rate control via CRT-D and AVN ablation|rate control
224296555|NCT01233648|OTHER|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
223397498|NCT00004919|DRUG|cisplatin|Given IV
223397499|NCT00004919|DRUG|irinotecan hydrochloride|Given IV
223397500|NCT00004919|DRUG|amifostine trihydrate|Given IV
223397501|NCT00004919|OTHER|pharmacological study|Correlative studies
223397502|NCT00179907|PROCEDURE|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors \< 20 mm, 21-25 mm and 26-40 mm respectively
223397503|NCT00695461|DIETARY_SUPPLEMENT|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
224296556|NCT01825889|DRUG|Evacetrapib|
224296557|NCT03972449|BEHAVIORAL|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
224296558|NCT03972449|BEHAVIORAL|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
224296559|NCT00044109|DEVICE|Magnets|
224016776|NCT05125705|OTHER|Saline injection|Saline injection
224016777|NCT00593294|BEHAVIORAL|Physical exercise|45 minutes each day for three times/week for 6 months
224016778|NCT00593294|DRUG|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
224016779|NCT00593294|DIETARY_SUPPLEMENT|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
224016780|NCT03605173|DIAGNOSTIC_TEST|free vitamin d test|using the patient's blood serum ELISA test for free vitamin d can be performed
224016781|NCT03605173|DIAGNOSTIC_TEST|total vitamin d|routinely measured from serum
224296560|NCT04524052|DRUG|DWRX2003|Intramuscularly injection at pre-defined injection sites
224128582|NCT05514366|PROCEDURE|Modifying EIP under a tOLA with pneumoperitoneum|"Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) \< 97% is detected."
224128583|NCT05514366|PROCEDURE|Atelectasis test|It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs \> 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is \>10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
224128584|NCT00003648|GENETIC|DNA stability analysis|
224296561|NCT04524052|DRUG|Placebo|Intramuscularly injection at pre-defined injection sites
223731320|NCT01294293|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223731321|NCT01294293|OTHER|Pharmacological Study|Correlative studies
223731322|NCT01294293|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223731323|NCT01294293|DRUG|Paclitaxel|Given IV
223731324|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
224016782|NCT02946190|BIOLOGICAL|Pertagen® aP + Td-pur®|see arm/group descriptions
224016783|NCT02946190|BIOLOGICAL|Boostrix® dTpa|see arm/group descriptions
224016784|NCT04694430|PROCEDURE|Blood sample|2 ml venous blood was collected and separated into serum.
224016785|NCT04694430|OTHER|Data collection|"1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool."
224016786|NCT04694430|PROCEDURE|Throat swab|"Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time."
224016787|NCT02637973|DRUG|Empagliflozin|25 mg once daily
224128585|NCT00003648|GENETIC|gene rearrangement analysis|
224128586|NCT01429987|DRUG|plecanatide|Subjects receive experimental study drug for 12 weeks.
224128587|NCT01429987|OTHER|Placebo|Subjects receive experimental study drug for 12 weeks.
224128588|NCT04136561|DEVICE|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
224016788|NCT02637973|DRUG|Placebo|once daily
224016789|NCT01304238|DRUG|lepirudin|lepirudin
224016790|NCT01304238|DRUG|danaparoid|danaparoid
224016791|NCT01304238|DRUG|argatroban|argatroban
224016792|NCT01304238|DRUG|fondaparinux|fondaparinux
224128589|NCT04826224|BIOLOGICAL|Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.|Bone marrow aspirate concentrate contains a median nucleated cell count of 121,700/uL, and platelets of 384,000/uL. This leads to a cellular dose of approximately 400 million cells.
224296562|NCT00793780|DRUG|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
224016793|NCT02112032|DRUG|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
224016794|NCT02112032|DRUG|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
224016795|NCT05610202|DRUG|TQB3702 tablets|TQB3702 tablets are selective BTK inhibitors.
224016796|NCT00477360|DEVICE|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
224016797|NCT06372873|OTHER|re-evaluate by two senior radiologists in our medical center|The allocated images obtained from the contributing hospitals will be re-evaluated by two senior radiologists in our clinical center
224128590|NCT01373567|DRUG|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
224296563|NCT00793780|OTHER|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
224296564|NCT01857960|BEHAVIORAL|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
224296565|NCT02858492|DRUG|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
223397504|NCT00695461|DIETARY_SUPPLEMENT|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
223397505|NCT05021393|OTHER|Clinical Pharmacist Intervention|Medication review, patient education, counseling, and corresponding written recommendation will be performed by clinical pharmacists for all randomized patients.
223397506|NCT04237376|DRUG|Tenofovir Alafenamide 25 MG|Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
223397507|NCT04237376|DRUG|Tenofovir Disoproxil Fumarate 300 MG Oral Tablet|Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.
223397508|NCT00086229|DRUG|Glucosamine|
223397509|NCT00086229|DRUG|Chondroitin|
223397510|NCT03495557|PROCEDURE|Control|Fascial closure with simple polydioxanone suture 2/0 stitches
223397511|NCT03495557|DEVICE|Experimental|Onlay polypropylene mesh placement (MN mesh)
223397512|NCT03775525|DRUG|GZ17-6.02|Super enhancer Inhibition
223397513|NCT03775525|DRUG|Capecitabine|antimetabolite
224128591|NCT00572806|DRUG|insulin aspart|
224128592|NCT02630082|PROCEDURE|Circumcision|
224128593|NCT02630082|PROCEDURE|Flexible sigmoidoscopy|
224128594|NCT00548080|DRUG|MK0991, caspofungin acetate / Duration of Treatment:|
224016798|NCT00201786|DRUG|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
224016799|NCT02511912|PROCEDURE|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
224016800|NCT03029351|DRUG|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
224016801|NCT03029351|DRUG|Placebo|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
224016802|NCT04027192|DRUG|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
224016803|NCT04027192|DRUG|BAY2328065 tablet|50 mg tablet, orally
224016804|NCT04027192|DRUG|Placebo LSF|Matching Placebo LSF, orally
224016805|NCT04027192|DRUG|Placebo tablet|Matching Placebo tablet, orally
224016806|NCT04027192|DRUG|Midazolam|1 mg per day, orally
224016807|NCT06334484|DEVICE|Advanced hybrid closed loop systems|Collect data from advanced hybrid closed loop users
224016808|NCT01345773|PROCEDURE|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
224016809|NCT05420376|PROCEDURE|Split Mesh|TEP repair of inguinal hernias using either split or whole mesh
224016810|NCT01572103|DIETARY_SUPPLEMENT|Coffee|Administration of 4 cups of coffee per day for 1 month
224016811|NCT01572103|DIETARY_SUPPLEMENT|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
224016812|NCT00491569|DRUG|Sarcosine and D-serine|
224016813|NCT03062579|DRUG|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
224296566|NCT02858492|DRUG|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
224296567|NCT01211704|DRUG|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
224296568|NCT01211704|DRUG|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
224016814|NCT01034176|DRUG|levofloxacin|500 mg tablet, daily, 30 days
224016815|NCT01034176|DRUG|placebo|no dose, tablet, daily, 30 days
224016816|NCT00715962|BEHAVIORAL|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
224016817|NCT00715962|OTHER|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
224016818|NCT00715962|OTHER|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
224128595|NCT04360187|DRUG|Crisaborole Ointment|Crisaborole ointment 2%
224128596|NCT04360187|DRUG|Crisaborole Placebo Vehicle|Placebo for crisaborole ointment
224128597|NCT00205725|DRUG|Ziprasidone, Olanzapine|
224128598|NCT05201586|OTHER|Conditional Cash Transfer|CCTs will be given to participants in the form of a pre-loaded debit card.
223397514|NCT06349525|DEVICE|telescopic overdenture|Maxillary implant supported telescopic overdenture
223397515|NCT06349525|DEVICE|Locator overdenture|Maxillary implant supported locator overdenture
224128599|NCT05201586|OTHER|Semi-structured interviews|Research team will conduct semi-structured interviews exploring how social determinants of health and social needs impact health. Participants will be asked to set a health goal. 6 months after the initial interview, the team will interview the patients again and evaluate whether that health goal was achieved.
224128600|NCT01249183|BIOLOGICAL|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
224128601|NCT01249183|BIOLOGICAL|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
224128602|NCT03951961|DRUG|Midostaurin|50mg Midostaurin bid for 12 months
224128603|NCT05106660|PROCEDURE|Ambulatory Laparoscopic Sleeve Gastrectomy|Same-day discharge
223397516|NCT04969679|DRUG|E. coli Nissle 1917 (Mutaflor®)|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
224016819|NCT04362384|DRUG|Vitamin E ovules|Endoanal vitamin E ovules will be prescribed
224016820|NCT04362384|DRUG|Prednisolone ointment|Endoanal Prednisolone ointment will be prescribed
224128604|NCT05106660|PROCEDURE|Conventional Laparoscopic Sleeve Gastrectomy|Next-day discharge
224128605|NCT04592276|DIETARY_SUPPLEMENT|PS128|Participants took two capsules with PS128 after dinner for 30 days.
224128606|NCT04592276|DIETARY_SUPPLEMENT|placebo|Participants took two capsules without PS128 after dinner for 30 days.
224128607|NCT00256867|DRUG|GSK523338|
224128608|NCT06316258|BEHAVIORAL|Compassion focused therapy group|6 session compassion focused therapy group for adults with ABI
223397517|NCT04969679|DRUG|Placebo|Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)
224016821|NCT02567747|OTHER|Data collection|Data will be collected retrospectively for cases identified through RIPS\*/ DANE\*\* from 2008 until 2014 and through PAI\*\*\* from 2009 until 2014. \*Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. \*\*Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. \*\*\*Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
224016822|NCT00006342|GENETIC|chromosomal translocation analysis|
224016823|NCT00006342|GENETIC|gene rearrangement analysis|
224016824|NCT00006342|GENETIC|mutation analysis|
224016825|NCT02207348|DRUG|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
224016826|NCT05029180|OTHER|Termination of resuscitation|Do estimate the approaches used worldwide when terminating resuscitative efforts
224016827|NCT02080312|DRUG|Magnevist (gadopentetate dimeglumine)|
224016828|NCT04257591|OTHER|hamstring strengthening|A progressive and individualized hamstring strengthening protocol
224016829|NCT06101849|BEHAVIORAL|I-Can-Manage-Pain after cancer (Pain Management Program)|6-week online interprofessional cancer pain management program (I-Can-Manage-Pain after cancer) for survivors of breast cancer. The program will cover the topics of understanding cancer pain, exercises to manage pain and psychological strategies to cope with pain
224016830|NCT00107120|DRUG|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
224016831|NCT00107120|DRUG|Placebo|Placebo once daily for up to 8 weeks
224128609|NCT05344079|DEVICE|18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey)|Patients in this group were entered the epidural space from the midline using the loss of resistance method with an 18-Gauge Touhy (Egemen®, Combifix Standard Spinal Epidural Combined Set, İzmir, Turkey) needle from the L4-L5 or L5-S1 vertebral space. After the free cerebrospinal fluid flow is observed by passing the spinal needle through the epidural needle, spinal anaesthesia was maintained with 10-15 mg hyperbaric bupivacaine (Bustesin®, 0.5% Spinal Heavy Vem Pharmaceuticals, Turkey). After the epidural catheter was fixed in such a way that it remained 5 cm in the epidural space, the adapter was inserted and fixed. Whether the catheter is in place or not was checked by 2 mL (40 mg) Lidocaine (Aritmal®, 2% 100 mg/5 mL amp., Biosel, Turkey) + 1/2000000 adrenaline test dose.
224296569|NCT05837572|OTHER|Standardized meal|"Assessment of the validity of the ES-LFPQ: Each participant will complete the ES-LFPQ in before (fasted state) and after a standardized meal (fed state).~Evaluation of the reproducibility of the ES-LFPQ: With at least one week of difference between tests, each participant will repeat the same protocol performed in the previous visit and under the same conditions."
223397518|NCT03534687|BEHAVIORAL|Aerobic Exercise|12-week supervised aerobic exercise
223550627|NCT03072472|DEVICE|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
224016832|NCT00294853|PROCEDURE|MDCT calcium score|
224016833|NCT06258460|OTHER|psychotherapy training program intervention|The intervention group will receive a two-day multimodal-based intensive educational intervention of CBT with 8 weeks follow-up (supervision based online teaching).
224016834|NCT06258460|OTHER|the wail-list control intervention|The wail-list control group will receive a message encouraging them to complete all questionnaires from baseline to the last follow-up at 8 weeks.
224296570|NCT02737982|PROCEDURE|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
223397519|NCT01253629|DRUG|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
223397520|NCT01253629|DRUG|Placebo|Placebo medication identical in appearance to active medication was provided
223397521|NCT00395629|DRUG|Deferasirox (ICL670)|
223397522|NCT06127342|BEHAVIORAL|Moderate Intensity Exercise|Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 5 minutes, then slowly cycle on a stationary bike for 30 minutes, then cycle on the stationary bike at a slow speed for 5 minutes.
224016835|NCT02068209|DRUG|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
224016836|NCT02068209|DRUG|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
224016837|NCT05228041|DRUG|Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)
224016838|NCT06064175|DRUG|Ibuprofen 400 mg|Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
224016839|NCT06064175|DRUG|Ibuprofen 800 mg|Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
224016840|NCT03620370|DRUG|Normobaric oxygen therapy|In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
224016841|NCT05997368|OTHER|Survey1|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
224296571|NCT00044421|DRUG|Ruboxistaurin mesylate|
224016842|NCT05997368|OTHER|Survey2|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
224016843|NCT05997368|OTHER|Survey3|As a research, it was planned to be a quantitative research. Data collection will be conducted through online and face-to-face surveys. Scales and forms to be found and used in the research: The Pain Beliefs Questionnaire-PBQ, Numerical Rating Scale (NRS-11) and The Central Of Pain Scale-COPS. By handing out the paper format to the participants and uploading it to the Google Forms system online, it can be downloaded from mail, social media or mobile phone applications such as message, Mail, etc. They will be asked to participate in the study by accessing
224016844|NCT02377115|OTHER|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
224016845|NCT02774031|DEVICE|Aisys with Et control|
224016846|NCT02774031|DEVICE|Aisys conventional|
224016847|NCT02774031|DEVICE|Flow-i with ACG|
224016848|NCT02774031|DEVICE|Flow-i conventional|
224016849|NCT01706887|OTHER|Diet Amiloride|only arm of the trial
224016850|NCT00005829|DRUG|gemcitabine hydrochloride|
224016851|NCT03173677|DIETARY_SUPPLEMENT|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
224016852|NCT03173677|DIETARY_SUPPLEMENT|Glucose intake|300 calories of glucose
224016853|NCT03173677|DIETARY_SUPPLEMENT|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
224016854|NCT01635920|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
224128610|NCT05344079|DEVICE|20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump|spinal anesthesia was maintained with 10-15 mg of hyperbaric bupivacaine (Bustesin 0.5% Spinal Heavy; Vem Pharmaceutical Industry and Trade Ltd.) after free cerebrospinal fluid flow was observed by entering the subarachnoid space with a 22 G spinal needle (Egemen Quincke Sharpened Spinal Anesthesia Needle; İzmir) from the L4-L5 or L5-S1 vertebral space. At the end of the operation, a 20-gauge infiltrative analgesia catheter connected to an ON-Q elastomeric pump that provides 5 mL/hour infusion prepared with 60 mL of 0.9% NaCl + 60 mL of 0.5% Bupivacaine (Marcaine 0.5%; AstraZeneca Industry and Trade Ltd.) was placed on the fascia by the surgeon in such a way that all the holes of the catheter were under the skin and parallel to the incision line. Pain pump and the catheter was withdrawn at the end of the postoperative 24th hour.
224128611|NCT01913210|DIETARY_SUPPLEMENT|Ginseng|
224128612|NCT04583566|GENETIC|COVID-19 Diagnostic and Assessment Tests|Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
224128613|NCT01958736|OTHER|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
224128614|NCT01958736|OTHER|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
224128615|NCT03223220|DRUG|Ketamine|IV infusion
224128616|NCT03223220|OTHER|Normal Saline|IV infusion
224128617|NCT03223220|DRUG|Midazolam injection|Injection
224128618|NCT03742336|DRUG|PF-04965842|Single oral 200 mg dose of PF-04965842
224128619|NCT03742336|DRUG|Dabigatran|Single 75 mg dose of dabigatran
224128620|NCT00505700|DRUG|velcade|
224128621|NCT00505700|DRUG|Idarubicin|
224128622|NCT00505700|DRUG|Cytarabine|
224016855|NCT01635920|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
224016856|NCT05080816|DIETARY_SUPPLEMENT|Parenteral nutrition (PN)|Overnight infusion of parenteral nutrition. Supplied as all-in-one-bag format. Infusion rate of 0.2 g N/kg/day.
224016857|NCT05080816|DIETARY_SUPPLEMENT|Enteral nutrition|Oral nutrition drink. 2 \* 200 ml on the night before operation. 1\* 200 ml on the morning of operation day.
224016858|NCT05080816|OTHER|Control|Overnight infusion of crystalloid fluid (Ringer acetate) infused at the same rate (ml/kg) as intervention PN
224016859|NCT04616703|RADIATION|CT imaging|CT of abdomen
224016860|NCT02838433|OTHER|biological samples|blood and tissue samples
224016861|NCT02907164|BEHAVIORAL|Email invitation|Receive emails encouraging them to sign up
224016862|NCT02907164|BEHAVIORAL|Social norm|Receive information about how many people have signed up
224016863|NCT02907164|BEHAVIORAL|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
224016864|NCT02907164|BEHAVIORAL|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
224016865|NCT04568460|OTHER|Intervention Group Sessions|Participants will undergo a multi-session group intervention over the course of six months.
224016866|NCT04647045|DIETARY_SUPPLEMENT|Cultured milk drink|Each bottle contains 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01. In each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose.
224016867|NCT02709915|OTHER|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
224016868|NCT02709915|OTHER|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
224128623|NCT05355090|DIETARY_SUPPLEMENT|PP|Protein Pacing three times per day
224016869|NCT01600521|DRUG|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
224016870|NCT00194987|DRUG|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
224016871|NCT00194987|DRUG|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
224016872|NCT01487408|DRUG|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
224128624|NCT01675219|PROCEDURE|white light TUR-BT|traditional transurethral bladder tumor resection
223397523|NCT06127342|BEHAVIORAL|Low Intensity Exercise|Participants will wear a heartrate monitor and cycle on a stationary bike at a slow speed for 40 minutes.
223397524|NCT02805153|DRUG|PEG-rhG-CSF|
223397525|NCT02805153|DRUG|rhG-CSF|
223397526|NCT02309320|BIOLOGICAL|ALX-0171|
224016873|NCT01664598|DRUG|Tocilizumab|8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
224016874|NCT03085030|DRUG|Antioxidant Formula|Antioxidant tablet will be taken by the patients
224016875|NCT03085030|DRUG|Placebo|The placebo will be taken by the patients
224016876|NCT01950026|PROCEDURE|cryotherapy application|"* Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
224016877|NCT00686725|DRUG|Temozolomide|
224016878|NCT00686725|RADIATION|Radiotherapy|
224016879|NCT04581889|OTHER|Diagnostic test|Presence of antibodies in saliva
223397527|NCT02309320|OTHER|Placebo|
223397528|NCT01293916|OTHER|Spica casting|single versus double leg spica casting
223397529|NCT02570308|DRUG|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
223397530|NCT00128635|RADIATION|iodine I 131 monoclonal antibody TNT-1/B|
223397531|NCT00941135|OTHER|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
223397532|NCT00105118|DEVICE|Magstim Super Rapid Magnetic Stimulator|
223397533|NCT02780037|BEHAVIORAL|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
223397534|NCT02780037|BEHAVIORAL|Regulatory frame: promotion|Exercise program presented as promoting improvement.
223397535|NCT02780037|BEHAVIORAL|Regulatory frame: not implied|Exercise program presented without implied consequences.
223397536|NCT02271334|DRUG|A006 DPI|Single dose 110 mcg, 1 inhalation
223397537|NCT02271334|DRUG|A006 DPI|Single dose 220 mcg, 1 inhalation
224016880|NCT02924974|DRUG|Morphine|mixed with bupivacaine
224016881|NCT02924974|DRUG|Lidocaine|sham procedure (s.c. lidocaïne)
224128625|NCT01675219|PROCEDURE|blue light TUR-BT|photodynamic transurethral bladder tumor resection
224128626|NCT01675219|DRUG|optimized MMC|six weekly optimized mitomycin-C instillations
224128627|NCT01675219|DRUG|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
224128628|NCT05818293|DEVICE|radiofrquency device|• The radiofrequency system has been used for treatment of subcutaneous fat layers.
224128629|NCT04339075|OTHER|Questionnaires|Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
224128630|NCT03088293|DRUG|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
224128631|NCT03088293|DRUG|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
223397538|NCT02271334|DRUG|Proventil® MDI|Single dose 90 mcg, 1 inhalation
223397539|NCT02271334|DRUG|Proventil® MDI|Single dose 90 mcg, 2 inhalations
223397540|NCT03121846|DRUG|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
223397541|NCT04242498|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
223397542|NCT04242498|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
223550628|NCT03103646|DRUG|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
224128632|NCT04307147|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.
224128633|NCT04307147|DRUG|Vinorelbine|Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
224128634|NCT00189007|DRUG|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
224128635|NCT00189007|DRUG|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
224128636|NCT02851680|BIOLOGICAL|blood samples|
224128637|NCT06864754|OTHER|WashU DIEP Flap Video|Video uses visual cues and graphics to help explain complex procedures in a simplified, comprehensible fashion to patients.
224128638|NCT05029596|DRUG|Normal Saline Group|A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.
224016882|NCT06385405|DEVICE|Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment|The target site for alpha frequency Transcranial Magnetic Stimulation (αTMS) was identified based on alterations in alpha band spectral connectivity, which were measured using four frontal electroencephalography (EEG) channels (F1, F3, F5, FC3) subsequent to 10Hz transcranial magnetic stimulation (TMS). Alpha band spectral connectivity refers to the degree of similarity between the spectral waveforms of the alpha band across channels. The alpha frequency stimulation rate was defined as the highest spectral peak within the alpha band ranging from 7 to 13 Hz of the target channel. Each treatment cycle consisted of 20 daily sessions over a 4-week span, and stimulation was administered for 2 seconds every minute for a total duration of 20 minutes at 80% of the individual's motor threshold.
224128639|NCT05029596|DRUG|Heparin Group|All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.
224016883|NCT06385405|DEVICE|10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC)|Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4 weeks (20 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. The strongest evidence supports high-frequency treatment over the left dorsolateral prefrontal cortex (DLPFC). The common stimulation frequency is 10Hz. It is usually applied for a duration of 4 weeks, 5 days a week.
224016884|NCT04697771|OTHER|Fine Motor Skills Training|The fine motor skills training program was planned for the areas of difficulty that children with ADHD experience in the fine motor area as stated in the literature (Lavasani \& Stagnitti, 2011). The fine motor goals were organized for 8 weeks, each week including a different fine motor area and practicing handwriting. For each fine motor goal, 3 different activities were identified that did not require materials or could be practiced with materials that could be easily found in each child's home. For example, for the fine motor strengthening goal, three different activities were planned for the same purpose with tools such as play dough, nails, and staples (Case-Smith \& O'Brien, 2013). The activities determined each week were repeated three days a week in the same way and applied to all children. Within the 40-minute session, each activity was performed for 10 minutes under the guidance of an expert occupational therapist.
224016885|NCT00712309|DEVICE|Lifestent|Stent for endovascular treatment of popliteal artery lesions
224016886|NCT00712309|DEVICE|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
224128640|NCT06181396|DRUG|Oxytocin|Native oxytocin analog
224128641|NCT00683358|BIOLOGICAL|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A\*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
224128642|NCT00364546|DRUG|CG 5503;tapentadol|
223397543|NCT06133387|DEVICE|Endoscopic submucosal dissection using the ELS System|All subjects will undergo endoscopic submucosal dissection, with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.
223397544|NCT00432926|BEHAVIORAL|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
223397545|NCT00432926|BEHAVIORAL|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
224128643|NCT02993224|DRUG|Deferasirox dispersable tablet (DT)|"Deferasirox DT was provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The strengths provided in an individual country could differ and reflected the strengths available commercially in each country.~For iron chelation naive participants, the starting dose on Baseline Day 1 was 20 mg/kg/day in TDT and 10 mg/kg/day in NTDT.~For iron chelation (deferoxamine and/or deferiprone) pre-treated participants, the starting dose was equivalent to the dose of deferoxamine received (for participants pre-treated with deferoxamine) and based on their serum ferritin levels (for participants pre-treated with deferiprone).~Participants took deferasirox DT once daily for 24 weeks (core phase). The required number of deferasirox DT tablets were to be dispersed with gentle stirring in a glass of water."
224128644|NCT02993224|DRUG|Deferasirox film coated tablet (FCT)|"Deferasirox FCT was provided as 90 mg, 180 mg, 360 mg film coated tablets for oral use. The FCT starting dose on Week 25 was 14 mg/kg/day in TDT and 7 mg/kg/day in NTDT.~Participants took deferasirox FCT once daily for 24 weeks during the core phase and up to 48 weeks during the extension phase. For patients with difficulties in swallowing deferasirox FCT, it was allowed to crush the film-coated tablets and administer the study drug by sprinkling the full dose on soft food (like yogurt or apple puree)."
224128645|NCT05122663|BEHAVIORAL|Vestibular Rehabilitation|Vestibular Rehabilitation refers to the specific interventions that physical therapists provide to patients with dizziness and vertigo symptoms. These interventions can involve repositioning maneuvers, habituation exercises, gaze stabilization, and/or balance training exercises, depending on the specific etiology of dizziness and vertigo per an established clinical protocol utilizing a patient's history and exam findings. Physical therapists instruct patients in how to perform these exercises at home and provide instructions and referral for patients to follow-up with an outpatient physical therapist for further care.
224128646|NCT05122663|OTHER|Usual Care|Usual Care refers to any combination of diagnostic testing, medications, and patient education or counseling provided by a patient's treating ED physician.
223397546|NCT00432926|BEHAVIORAL|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
223397547|NCT04146441|COMBINATION_PRODUCT|SonoVue|1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
223397548|NCT04146441|DRUG|Chemotherapy|FOLFIRINOX Regime according to Norwegian national guidelines
223550629|NCT03103646|DRUG|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
224128647|NCT01834924|OTHER|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
224128648|NCT04286412|BIOLOGICAL|Nonacog alfa|Nonacog alfa is indicated in India for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
224016887|NCT06414837|DRUG|HR091506 tablets + placebo of febuxostat tablets|HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd, from Week 1 to 36.
224016888|NCT06414837|DRUG|febuxostat tablets + placebo of HR091506 tablets|febuxostat tablets 20mg/ 40mg/ 60mg/80mg qd + placebo of HR091506 tablets 20mg/ 40mg/ 60mg/80mg qd . from Week 1 to 36.
224016889|NCT03356626|DEVICE|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
224128649|NCT01270581|OTHER|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
224128650|NCT01270581|OTHER|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
224128651|NCT06463769|BEHAVIORAL|8 week predominantly plant-based New Nordic LPF-diet program|An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.
223397549|NCT00765102|DRUG|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m\^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
223397550|NCT00765102|DRUG|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m\^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m\^2.
223397551|NCT03197389|DRUG|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
223397552|NCT02940756|DRUG|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
223397553|NCT02940756|DRUG|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days."
223397554|NCT02940756|DRUG|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
224016890|NCT03356626|DEVICE|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
224128652|NCT06463769|BEHAVIORAL|maintenance of the predominantly plant-based New Nordic LPF-diet|Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.
224128653|NCT01032512|DIETARY_SUPPLEMENT|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
224128654|NCT01032512|DIETARY_SUPPLEMENT|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
224128655|NCT05331612|BEHAVIORAL|Blended intervention condition|Participants receive the online protocol treatment and face-to-face sessions during 13 weeks.
223397555|NCT06471049|PROCEDURE|Benign Hysterectomy|removal of the uterus
223397556|NCT00602251|DRUG|Terbinafine|
223397557|NCT01325363|DEVICE|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
223397558|NCT00053716|DRUG|Liprostin [liposomal Prostaglandin E1]|
223397559|NCT05636696|BEHAVIORAL|Samen Minder Moe (Dutch intervention name)|'Samen Minder Moe' is a mindfulness-based cognitive behavioral therapy for cancer-related fatigue directed at couples.
224016891|NCT03356626|DEVICE|Thunderbeat|to use Thunderbeat when performing gastrectomy
224016892|NCT03760731|BEHAVIORAL|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
224016893|NCT03760731|BEHAVIORAL|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
224128656|NCT02003651|DIETARY_SUPPLEMENT|Quick Defense|Echinacea product from Gaia Herbs.
223397560|NCT05715411|OTHER|Placebo with light therapy glasses|Placebo
223397561|NCT05715411|OTHER|light therapy with light therapy glasses|light therapy
223397562|NCT02054429|DRUG|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
223397563|NCT04129125|DEVICE|Zoom Reperfusion System|Thrombectomy
224016894|NCT04821687|DRUG|Ongentys 50mg|Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
224016895|NCT04821687|DRUG|Madopar Tab. 125 or Perkin Tab. 25-100mg|Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
224016896|NCT00070824|PROCEDURE|acupuncture|
224016897|NCT01505218|DRUG|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:"
224016898|NCT01505218|DRUG|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
224128657|NCT02003651|DIETARY_SUPPLEMENT|Placebo|Placebo
224128658|NCT02686697|DRUG|L-Carnosine|
224128659|NCT02686697|DRUG|Placebo|
224128660|NCT02686697|BEHAVIORAL|Cognitive Training|Cognitive Training for 2 weeks
224128661|NCT04353960|DIAGNOSTIC_TEST|electrocardiograph|electrocardiograph monitor during strabismus surgery
224128662|NCT02322320|DRUG|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
224128663|NCT01766830|DEVICE|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
224128664|NCT01766830|DEVICE|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
224128665|NCT01766830|DEVICE|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
223397565|NCT02547012|DRUG|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
223397566|NCT02547012|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
223397567|NCT02816632|OTHER|mRI|Neural bases of feedbacks' influence on decision making processes
223397568|NCT02816632|OTHER|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
223550630|NCT03103646|DRUG|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
223731325|NCT00371423|DEVICE|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
223731326|NCT00415103|DRUG|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
224016899|NCT06312228|OTHER|Helfer Skin Tap|Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.
224016900|NCT06312228|OTHER|Buzzy|The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
224016901|NCT02982395|DRUG|Nanoxel®M|Intravesical
224016902|NCT02982395|DRUG|Mitomycin-C|Intravesical
224128666|NCT01766830|DEVICE|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
224296572|NCT00432302|DRUG|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
224296573|NCT03365167|RADIATION|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
224296574|NCT03365167|RADIATION|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
223397569|NCT06809543|DEVICE|Polynucleotides (Tropho Tend)|"Tropho Tend is administered by injecting the solution at level of muscular-tendineal (MJT) or osteo-tendineal junctions (OTJ) using a fine-gauge needle (usually 25-30G).~Before injecting the product, the target area will be disinfected with alcohol or another antiseptic, with the antiseptic removed with physiologic sterile solution.~Total number of treatments will consist in 3 Tropho Tend administrations: at T0 - basal visit;~* T1 - after 2 weeks;~* T3 - after 4 weeks."
223397570|NCT06809543|PROCEDURE|Rehabilitation physiotherapy|Rehabilitation physiotherapy (standard of care)
223397571|NCT03314636|DRUG|Carfilzomib|See in arm description
223397572|NCT03314636|DRUG|Lenalidomide|See in arm description
223397573|NCT03314636|DEVICE|PET-CT|See in arm description
223397574|NCT03314636|DRUG|Dexamethasone|See in arm description
224016903|NCT05564780|DRUG|RASI and/or a single pill combination based RASI|The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
224016904|NCT02982460|OTHER|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
224016905|NCT02982460|OTHER|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
224016906|NCT04413487|OTHER|Extra echocardiogram|Subjects will receive an extra echocardiogram after 2 cycles of chemotherapy
224016907|NCT02630693|DRUG|Palbociclib 100mg|100mg PO daily
224016908|NCT02630693|DRUG|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
224016909|NCT02630693|DRUG|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
224016910|NCT05396469|DIAGNOSTIC_TEST|National guideline treatment|All discovered diseases will recieve national guideline treatment and follow up
224016911|NCT01175447|DRUG|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
224016912|NCT02004470|PROCEDURE|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
224016913|NCT04844645|OTHER|mini program|To design, construct, and test the mini program in patients managing cancer pain
224016914|NCT04844645|OTHER|conventional pharmaceutical care|conventional pharmaceutical care
224016915|NCT01639560|DRUG|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
224016916|NCT01639560|DRUG|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
224128667|NCT01766830|DEVICE|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
224128668|NCT01766830|DEVICE|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
223397575|NCT06973356|DRUG|Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.|Description: A single intravenous infusion of anti-CD19/BCMA CAR gene vector injection(dose-escalating infusion of 1.0-4.0 x10\^6 TU/kg）.
223397576|NCT06126055|DEVICE|Band Ligation|Placing bands in distal esophagus
223397577|NCT01261728|DRUG|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
223397578|NCT06194448|DRUG|Osimertinib|80 mg daily (or 40 mg daily for dose reduction)
223397579|NCT06194448|DRUG|Cisplatin or Carboplatin; Pemetrexed or Paclitaxel|Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles
223397580|NCT06194448|DRUG|Radiation|"Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%"
224016917|NCT01160289|DRUG|LY2452473|Administered orally, once daily for 12 weeks
224016918|NCT01160289|DRUG|tadalafil|Administered orally, once daily for 12 weeks
224016919|NCT01160289|DRUG|placebo (tadalafil)|Administered orally, once daily for 12 weeks
224016920|NCT01160289|DRUG|placebo (LY2452473)|Administered orally, once daily for 12 weeks
224016921|NCT03026192|DEVICE|near infrared spectroscopy|Near infrared spectroscopy will be placed on infants both with and without hsPDA
224016922|NCT03759314|OTHER|Observation|to use a simple screening tool to find out the risk of falling, the nutritional status and the level of cognitive functioning activity
224016923|NCT05696587|OTHER|Multimodal rehabilitation|"The multimodal rehabilitation program included comprehensive therapy 5 times a week during the 4 weeks between assessments. The therapy consists of:~* Individual physical therapy focused on improving range of motion and alleviating pain in the affected limb;~* Mechanical desensitization;~* Transcutaneous electric nerve stimulation (TENS) electrotherapy;~* Aquatherapy (arm or leg whirlpool bath of the affected extremity);~* Graded Motor Imagery, including the Recognise™ app and mirror therapy;~* Psychoeducation on relaxation and coping with chronic pain."
224016924|NCT01467882|DRUG|Triptorelin|Powder and solution for solution for injection
224016925|NCT03712059|DIAGNOSTIC_TEST|FIT test and colonoscopy|All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.
224016926|NCT03712059|DIAGNOSTIC_TEST|Polypectomy and biopsy|All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with \< 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.
224128669|NCT01766830|DEVICE|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
224016927|NCT03712059|DIAGNOSTIC_TEST|Classification|Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
224016928|NCT01156792|DRUG|FP 100|FP 100mcg BID
224016929|NCT01156792|DRUG|GSK2190915 100|GSK2190915 100mg QD (AM)
224016930|NCT01156792|DRUG|GSK2190915 300|GSK2190915 300mg QD (AM)
224016931|NCT01156792|DRUG|montelukast|montelukast 10mg QD (PM)
224016932|NCT01156792|DRUG|placebo|placebo BID
224016933|NCT01156792|DRUG|FP/SAL 100/50|FP/SAL 100/50mcg BID
224016934|NCT02487732|DRUG|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
224016935|NCT02487732|DRUG|Prasugrel|Prasugrel 10mg once daily for 5 weeks
224128670|NCT01766830|DEVICE|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
224128671|NCT01766830|DEVICE|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
224016936|NCT01474434|DRUG|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
224128672|NCT01766830|DEVICE|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
224128673|NCT04575857|DRUG|Atorvastatin|Participants in the intervention arm will receive a pill packet with atorvastatin (40mg) x 18 months.
224128674|NCT04575857|DRUG|Placebo|Participants in the control arm will receive a pill packet with placebo x 18 months.
224128675|NCT03342391|OTHER|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
223397581|NCT06052813|DRUG|BN104 monotherapy|Phase I(adults): Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
223397582|NCT06052813|DRUG|BN104 monotherapy|Phase I(adolescent): Will be administered orally twice daily (approximately every 12 hours)
224128676|NCT01727635|OTHER|body-mind-spirit group therapy|8-session therapy
224128677|NCT04212338|OTHER|Before intravitreal injection music intervention|The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.
224128678|NCT04212338|OTHER|during intravitreal injection music intervention|The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
224128679|NCT03136185|DRUG|Bomedemstat|Oral (capsule) administration according to dose allocation.
224128680|NCT00466999|DRUG|misoprostol|single dose of 400 mcg misoprostol administered sublingually
224128681|NCT00466999|PROCEDURE|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
223397583|NCT06052813|DRUG|BN104 monotherapy - rp2d|receiving oral BN104 treatment at a dose of 600 mg BID (300 mg BID when co-administered with strong CYP3A4 inhibitors)
223397584|NCT05986149|BEHAVIORAL|Conversation about arts and culture|intergenerational conversation about arts and culture between older adults and international students who native language is not English.
224016937|NCT01474434|DRUG|Placebo|matching placebo tablets
224016938|NCT03312283|DRUG|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
224016939|NCT03312283|DRUG|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
224016940|NCT00057629|BEHAVIORAL|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
224016941|NCT00057629|BEHAVIORAL|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
224016942|NCT00057629|BEHAVIORAL|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
224016943|NCT03711331|OTHER|FilmArray® Pneumonia panel plus|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
224016944|NCT03711331|OTHER|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
224016945|NCT01045343|OTHER|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
224296575|NCT00010192|BIOLOGICAL|rituximab|Given IV
224296576|NCT00010192|BIOLOGICAL|aldesleukin|Given SC
224296577|NCT00010192|OTHER|laboratory biomarker analysis|Correlative studies
224296578|NCT00010192|OTHER|pharmacological study|Correlative studies
224016946|NCT01045343|OTHER|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
224016947|NCT02871531|PROCEDURE|Pneumatic retinopexy|
224016948|NCT02871531|PROCEDURE|Vitrectomy|
224016949|NCT04859569|DRUG|LY01011|subcutaneously (SC) once every 4 weeks (Q4W)
224016950|NCT04859569|DRUG|Xgeva®|subcutaneously (SC) once every 4 weeks (Q4W)
224016951|NCT00901706|OTHER|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
224016952|NCT00901706|OTHER|APS usual care|APS usual care consists of social, medical, and legal assistance.
224016953|NCT03403218|BEHAVIORAL|Case group|assessment of quality on posture, transfers and displacement
224016954|NCT04719624|DEVICE|Adaptos®-Si [0.5-1 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
224016955|NCT04719624|DEVICE|Adaptos®-Si [1-2 mm] (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
224016956|NCT04719624|DEVICE|Geistlich Bio-Oss (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
224016957|NCT04719624|PROCEDURE|Tooth extraction without bone graft material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth and the socket is filled only by clot. Subject will be followed at 2 weeks, 5 months, and 10 months for healing.
224016958|NCT04719624|DEVICE|Adaptos® (bone grafting surgery)|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of one of the four randomized, synthetic bone graft substitutes with a gelatin sponge (Spongostan Dental). Following 5 months of healing a dental implant will be placed. The subjects will then be followed for another 5 months for healing. Follow-up visits will be at 2 weeks, 5 months, and 10 months.
224128682|NCT02007785|BEHAVIORAL|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
224128683|NCT03972592|DRUG|Topical 0.1% Sirolimus|The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
224128684|NCT03972592|DRUG|Topical Vehicle|The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
224128685|NCT01920620|BEHAVIORAL|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
223550631|NCT00703963|DEVICE|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
224016959|NCT04579822|BIOLOGICAL|influenza vaccine|quadrivalent influenza vaccination in the flu seasons
224016960|NCT03753659|DRUG|Pembrolizumab|IV infusion
224016961|NCT03753659|PROCEDURE|Radio Frequency Ablation (RFA)|Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
224016962|NCT03753659|PROCEDURE|Microwave Ablation (MWA)|Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
224016963|NCT03753659|RADIATION|Brachytherapy|Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
224016964|NCT03753659|DRUG|Transarterial Chemoembolisation (TACE)|According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
224128686|NCT01920620|BEHAVIORAL|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
224128687|NCT04242017|DRUG|Triptoreline|Comparison of the duration of ADT (Triptoreline)
224128688|NCT03055104|OTHER|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
224296579|NCT04404946|OTHER|phenylephrine infusion|in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
223397585|NCT02962648|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion."
224016965|NCT00993668|OTHER|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
223731327|NCT00415103|DRUG|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
223731328|NCT00415103|DRUG|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
224016966|NCT00993668|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
224016967|NCT00999674|OTHER|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
224016968|NCT00208780|DRUG|Tetrahydrobiopterin|
224016969|NCT00208780|DRUG|Tetrahydrobiopterin|
224128689|NCT00125658|OTHER|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
224128690|NCT00125658|OTHER|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
224296580|NCT04404946|OTHER|norepinephrine infusion|in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
223397586|NCT05708248|DRUG|pentoxifylline|400 mg pentoxifylline tablets twice daily with meals for 6 months
223397587|NCT06223672|OTHER|Walnuts|56g of walnuts consumed each day for 7 days
223731329|NCT05805982|BEHAVIORAL|Educational Video|Pre-recorded educational video including hereditary cancer information, genetic cancer testing candidates, types of testing, type of results, benefits and risks, recommendations according to results, inheritance and common questions.
223731330|NCT05805982|BEHAVIORAL|In person genetic cancer counseling|"Includes:~Family history of cancer (3-generation family tree) Personal Cancer Risk Assessment Education on inheritance and expression of disease Types of tests Preparation on possible outcomes according to results Obtaining consent for test Opportunity to solve doubts"
224128691|NCT04148924|OTHER|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~* HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~* BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~* Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
224296581|NCT04404946|OTHER|placebo infusion|in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
224296582|NCT05916261|BIOLOGICAL|Personalized neoantigen tumor vaccine|neoantigen tumor vaccine with or without Pembrolizumab In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with Pembrolizumab
223397588|NCT06223672|OTHER|Simply White Diary-free chocolate bar|68g of the white chocolate style-bar each day for 7 days
223397589|NCT04831021|PROCEDURE|Dialysis without physical exercise|Hemodialysis control condition
223397590|NCT04831021|PROCEDURE|Dialysis with pre-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will be performed 60 minutes before connection to hemodialysis.
223397591|NCT04831021|PROCEDURE|Dialysis with per-dialytic physical exercise|Patients will pedal for 30 minutes using a ergometer directly attached to the dialysis bed. The exercise will start 30 minutes after the start of dialysis.
223731331|NCT04969549|OTHER|Theta burst stimulation|It consists of 20 sessions of iTBS over the dlPFC.
223731332|NCT05447637|DIAGNOSTIC_TEST|Invitae multi-cancer gene panel|Invitae's multi-cancer panel tests for 84 genes associated with hereditary cancer risk.
223731333|NCT01485770|DRUG|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
223731334|NCT01485770|DRUG|Placebo|Placebo to match ADX-N05 once a day for 2 consecutive weeks
224016970|NCT06196632|DRUG|Peginterferon-α; Nucleoside analogs|Patients with chronic hepatitis B were treated with the combination of peginterferon-α and nucleoside analogs
224016971|NCT04894760|DIAGNOSTIC_TEST|Rapid Antigen Test (PanBio Ag test)|Rapid Antigen Test (PanBio Ag test)
224016972|NCT04955444|OTHER|Quality improvement bundle|The quality improvement bundle consists of (1) patient education, (2) provider education, and (3) EHR enhancements including order sets and best practice alerts.
224016973|NCT06526013|OTHER|Cholesterol self-measurement|Patients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
224016974|NCT02351518|OTHER|No intervention|There will be no interventions in this study
224016975|NCT02136160|BEHAVIORAL|attitude change, behavioral change|
224016976|NCT02136160|BEHAVIORAL|prevention program|
224128692|NCT04148924|OTHER|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~* socio-demographic characteristics : sex, age, type and stage of cancer, performans status~* ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
224128693|NCT00833235|OTHER|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
224016977|NCT03606668|DEVICE|HTC Vive Virtual Reality (VR) system|VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
224016978|NCT00160043|DRUG|SH T00268C|1250 mg experimental drug od
224016979|NCT00160043|DRUG|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
224016980|NCT01452321|PROCEDURE|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
224016981|NCT00952120|DEVICE|GSUC|Gauze-based wall suction negative pressure wound therapy
224016982|NCT00952120|DEVICE|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
224128694|NCT02876055|DRUG|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
224128695|NCT02876055|DRUG|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
224128696|NCT02876055|DRUG|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
224128697|NCT05128253|OTHER|High fat meal in a subset of patients with NAFL or NASH|In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
224128698|NCT01239186|OTHER|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
224016983|NCT01639781|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
224128699|NCT04065477|BEHAVIORAL|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
224128700|NCT02669550|DEVICE|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
224128701|NCT02669550|DEVICE|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
224128702|NCT02280967|BEHAVIORAL|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
224128703|NCT02476981|DRUG|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
224128704|NCT02476981|DRUG|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
224128705|NCT02476981|DRUG|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
224128706|NCT02476981|DRUG|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
224016984|NCT01639781|DIETARY_SUPPLEMENT|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
224016985|NCT06261580|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, and FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
224016986|NCT06261580|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
224016987|NCT03710031|OTHER|PNS Tracking|Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota \[(GM) richness and diversity\] and diet (macronutrients: carbohydrates, fats and proteins).
224128707|NCT02476981|DRUG|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
224128708|NCT06553274|PROCEDURE|Individualized nutrition intervention|"After the patients were enrolled, they were given nutritional assessment by full-time clinical nutritionist and designed individualized nutritional management program, which included: Nutritional Assessment once a week for 4 weeks after Transplantation + 30 days, and nutritional assessment once a week for 4 weeks after Transplantation + 60 days, nutritional assessment every 2 weeks for 8 weeks; nutritional assessment every 4 weeks for 1 year after Transplantation + 120 days after transplantation; nutritional assessment during hospitalization in the ward and after discharge from the hospital, they were followed up in the nutrition counseling clinic or by telephone. The total energy intake was 25-35 kcal/kg/d and the protein intake was 1.2-1.5 g/kg/d. According to theFive-step nutritional treatment principle, individual nutritional prescriptions were designed by clinical nutritionists."
224128709|NCT02715960|DRUG|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
224128710|NCT05437224|DRUG|Ambrisentan|eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
223397592|NCT05866835|OTHER|Manufacture of custom-made IOP|"Manufacture of custom-made unimaxillary and modified unimaxillary intra-oral protection (IOP) with vertical dimensions of 4 mm and 6 mm. 3D modeling of a IOP based on:~* digital recording of the maxillary and mandibular dental arches~* mandibular wedging performed with an inter-arch piece~* digital recording of the inter-arch position"
223397593|NCT05866835|OTHER|Ventilation tests|"Realization of a ventilation test (VO2max) to determine the Maximum Aerobic Speed (MAS).~Measurement of ventilatory parameters without IOP and with each IOP :~* At rest, standing still.~* During a 4 minute run on a treadmill at 50% of MAS.~* During a 4-minute run on a treadmill, at a speed corresponding to 70% of MAS"
223397594|NCT05866835|OTHER|Evaluation of comfort level:|Collection from participants (self-questionnaire)
223397595|NCT06676917|DRUG|Datopotamab deruxtecan|Trophoblast cell surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) consisting of a humanized anti-TROP2 monoclonal antibody (MAAP-9001a), a GGFG tetra-peptide linker, and a Topo I inhibitor (MAAA-1181a, derived from exatecan). Upon binding to TROP2 on the cell surface, Dato-DXd internalizes into the cells and releases MAAA-1181a in the cytoplasm which inhibits cell replication and promotes cell apoptosis.
224016988|NCT02238353|DRUG|azelastine + fluticasone|
224016989|NCT02238353|DRUG|Placebo|
224016990|NCT01770106|DRUG|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
224016991|NCT01770106|DRUG|Alendronate|Alendronate 70mg once weekly
224016992|NCT00730457|BIOLOGICAL|VAX125|Single intramuscular dose
224016993|NCT00080132|DRUG|implitapide|
224016994|NCT01944813|BEHAVIORAL|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
224016995|NCT04641494|DIETARY_SUPPLEMENT|Conjugated linoleic acid|CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
224016996|NCT04641494|DIETARY_SUPPLEMENT|High oleic acid safflower oil capsules|
224128711|NCT01443455|BEHAVIORAL|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
224296583|NCT02130583|BEHAVIORAL|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
224296584|NCT02130583|BEHAVIORAL|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
224016997|NCT03422523|DRUG|Atezolizumab|Intravenous drip
223397596|NCT04555317|COMBINATION_PRODUCT|Musculoskeletal health package|3 month prehabilitation exercise program during radiotherapy with assessment of BMD at baseline with appropriate management according to fracture risk assessment (with either (a) lifestyle advice, (b) calcium and vitamin D (c) calcium, vitamin D and bisphosphonate (alendronate))
223397597|NCT04383327|BEHAVIORAL|ParentCorps-Professional Development (PD)|Multi-component school-based intervention that promotes early childhood mental health and development. Teachers (pre-primary to 4th grade) will participate in a 3-day ParentCorps-PD training during the school term. They will also receive 8 sessions (8 hours) of face-to-face group-based coaching during after the training. Coaching sessions are to help teachers apply EBI strategies in their classrooms, engage families, and develop competencies.
223397598|NCT04383327|BEHAVIORAL|T-Wellness|A brief teacher stress management psychoeducation package, adapted from EBIs including one-day workshop for common stress management and stress management, and three follow-up group support sessions (3 additional monthly 1-hr wellness sessions for teachers as a group that were integrated into the 3 of the 8 PD coaching sessions. A total 3 hours of coaching were included.
223397599|NCT06919536|OTHER|No intervention (observational study)|There is no intervention, this is a observational study,
223550632|NCT00703963|OTHER|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
224016998|NCT03422523|DRUG|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
224016999|NCT03422523|DRUG|Gemcitabine 1000 mg|intravenous drip
224017000|NCT03422523|DRUG|Oxaliplatin 100 MG|intravenous drip
224017001|NCT02541123|OTHER|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
224017002|NCT02677454|DEVICE|Flash Glucose Monitor|
224017003|NCT04227964|DEVICE|Enamel matrix derivative, bone replacement graft, barrier membrane|
224017004|NCT04227964|PROCEDURE|Tooth extraction and replacement|
224017005|NCT04943367|DEVICE|TEAS|Transcutaneous electrical acupuncture stimulation
224017006|NCT01444573|DEVICE|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
224017007|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
224017008|NCT01293305|DRUG|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
224017009|NCT00002448|DRUG|Ritonavir|
224017010|NCT00002448|DRUG|Efavirenz|
224017011|NCT00002448|DRUG|Saquinavir|
224017012|NCT02426346|BEHAVIORAL|Behavioral weight control|Prescription of diet \& physical activity and behavioral strategies for weight control
224017013|NCT02426346|BEHAVIORAL|Group-based physical activity|Teens exercise for 60 minutes with their group
224017014|NCT02426346|BEHAVIORAL|Group-based incentives|Adolescents earn reinforcements within group
224017015|NCT02426346|BEHAVIORAL|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
224017016|NCT03660800|DRUG|CTAP101 Capsules|Calcifediol Extended-Release Capsules
224017017|NCT01942265|DRUG|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
224017018|NCT01942265|DRUG|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
224017019|NCT01942265|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
224017020|NCT02057523|DRUG|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
224017021|NCT03098420|DRUG|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
224128712|NCT01443455|BEHAVIORAL|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
224128713|NCT01443455|BEHAVIORAL|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~\--------------------------------------------------------------------------------"
224128714|NCT02608437|DRUG|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
224128715|NCT02608437|DRUG|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
224128716|NCT03705962|DRUG|Tobramycin|
224128717|NCT03705962|OTHER|Placebo: normal saline|
223397600|NCT07005817|BEHAVIORAL|Experimental Health Communication|"Participants view a brief psychoeducational video about the value of connecting in-person with others and receive guided instructions for creating if-then behavioral plans for increasing moments of high-quality social connection. Over the next four weeks, they view messages on a simulated social media platform to encourage in-person, connections with strangers and acquaintances on a platform called Invibe. The Invibe feed will also have approximately 15 background posts each day from users' about their lives, including food, fitness, pets, and travel, common on social media platforms.~During the 4-week Invibe phase, after participants complete each Day Report, they will view the Invibe simulated social media feed. Participant exposure to each target message will be both passive, via that day's feed, and forced, via inclusion on the Day Report. Participants will see 12 social media messages during this 4-week phase, shown in random order within the first 3 daily posts."
223550633|NCT04295811|DEVICE|EsoGuard (lab assay)|EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)
223550634|NCT04295811|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.
224017022|NCT03098420|DRUG|4mg Dexamethasone|1 mL (4mg) of dexamethasone
224017023|NCT03098420|DRUG|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
224017024|NCT03098420|DRUG|Morphine|
224017025|NCT03098420|DRUG|Bupivacaine Hydrochloride|
224017026|NCT03098420|DRUG|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
224017027|NCT03098420|DRUG|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
224017028|NCT05253677|DEVICE|CT-guided PCI|CT-guided PCI with standardized pre-procedural planning and online guidance.
224017029|NCT05253677|DEVICE|IVUS-guided PCI|use of IVUS during PCI procedure (standard of care)
224017030|NCT04355910|BEHAVIORAL|Calorie restriction|"Participants randomized to IFD were asked to restrict energy and carbohydrate on two non-consecutive days each week (75% energy restriction) and to consume a plant foods-based diet that met their estimated energy requirements for the remaining 5 d of the week.~The CCR group was prescribed a daily plant foods-based diet that was relatively low in fat with moderate energy-restriction (25% energy restriction).~The plant foods-based diet included adequate fruit and vegetable, nuts and seeds, whole-grain cereals, olive oil, fish and seafood, a moderate consumption of dairy products, poultry, eggs, and lean red meat."
224017031|NCT02835833|DRUG|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
224128718|NCT01438567|DRUG|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
224017032|NCT02835833|DRUG|Bevacizumab|Bevacizumab will be given at 15 mg/kg
224017033|NCT05621603|BEHAVIORAL|Training|"The proposed intervention for the school workforce draws on a mental health integrated disaster preparedness model, emphasizing peer support, developed and used successfully by our team working with communities experiencing multiple disasters.~The 3 hour training is comprised of 4 modules - Module 1: Emergency Preparedness Module 2: Psychological Preparedness Module 3: Peer Support Module 4: Shared Leadership and Feedback Session"
224128719|NCT01438567|DRUG|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
224017034|NCT06378489|DRUG|Etonogestrel implant|The etonogestrel implant will be inserted on the inner side of the non-dominant upper arm of the patient. Three months after insertion, a repeat transvaginal ultrasound will be performed to document endmetrial thickness and an endometrial biopsy will also be done using the Pipelle to document the histology of the endometrium. If the biopsy showed regression of the hyperplasia, the implant will be left in place for a minimum of 12 months until 3 years. If the repeat biopsy showed non-resolution of the hyperplasia, the patient will be referred to a gynecologic oncologist for further management
224128720|NCT01227538|OTHER|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
224128721|NCT00965705|BEHAVIORAL|Therapy|Individual Therapy and Group Therapy
224017035|NCT00454389|DEVICE|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
224017036|NCT00454389|DRUG|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
224017037|NCT01319214|DRUG|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
223731335|NCT02151253|DRUG|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
224017038|NCT01498159|BEHAVIORAL|Pharmacist disease/medication management|
224017039|NCT01498159|BEHAVIORAL|Pharmacist-patient encounters|
224017040|NCT01498159|BEHAVIORAL|Pharmacist medication intensification and adherence support|
224017041|NCT01498159|BEHAVIORAL|Pharmacist communication with primary care physicians|
224017042|NCT01498159|BEHAVIORAL|Pharmacist documentation in electronic medical record|
224017043|NCT01498159|BEHAVIORAL|Health promoter-patient encounters in-person or by phone|
224017044|NCT01498159|BEHAVIORAL|Health promoter medication and lifestyle support|
224017045|NCT01498159|BEHAVIORAL|Health promoter communication with pharmacists|
224017046|NCT04316351|DRUG|Toripalimab + Pemetrexed + Anlotinib|"Toripalimab 240 mg iv d1 + anlotinib 12mg po d1-d14 + pemetrexed 500mg / m2 d1 Q3W for 4 cycles, followed by Toripalimab 240mg iv d1 + anlotinib 12mg po d1 + pemetrexed 500mg / m2 d1 Q3W for another 31 cycles (up to a total of 35 cycles).~If there is no disease progression, patients will receive anlotinib po 12mg d1-d14 + pemetrexed 500mg / m2 d1, Q3W for maintenance therapy until PD per RECIST v1.1 or loss of clinical benefit."
224128722|NCT00122005|BIOLOGICAL|GM-CSF gene transduced allogeneic vaccine GVAX|
224017047|NCT00670345|DRUG|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
224017048|NCT00670345|DRUG|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
224128723|NCT01926054|DRUG|Acthar gel|
224128724|NCT00488033|PROCEDURE|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
224128725|NCT01423617|DIETARY_SUPPLEMENT|Zenoctil|3 tablets 2 times daily
224017049|NCT04565847|DRUG|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
224128726|NCT01423617|OTHER|Placebo|3 tablets 2 times daily
224128727|NCT06430047|DRUG|EsoDuo® Tablet|QD, PO
224128728|NCT01515306|BIOLOGICAL|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
224128729|NCT01515306|DRUG|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
224017050|NCT04565847|DRUG|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
224017051|NCT00407576|DRUG|[11C]MeS-IMPY|
224017052|NCT00653445|DRUG|Rosuvastatin|40mg
224017053|NCT00653445|DRUG|Ezetimibe|10mg
224017054|NCT02292927|BEHAVIORAL|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
224017055|NCT03262324|OTHER|VAS-FA Turkish version|Self-reported outcome questionnaires
224128730|NCT04567966|PROCEDURE|Split-block technique|Horizontal ridge augmentation using the split-block technique where a cortical bone plate harvested from the external oblique ridge was split in half and fixed at a distance from the atrophied ridge. Then autogenous bone chips were packed in the gap between the plate and the ridge.
224128731|NCT04567966|PROCEDURE|Cortico-cancellous block graft|Horizontal ridge augmentation using a cortico-cancellous block harvested from the chin of the mandible.
224128732|NCT06417931|BEHAVIORAL|Patient education and counselling|The pharmacist intervention was aimed at identifying and addressing barriers to treatment adherence through tailored strategies
224128733|NCT00086957|BIOLOGICAL|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
224128734|NCT00086957|DRUG|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
224017056|NCT02898415|PROCEDURE|Liver transplantation|
224017057|NCT00568802|DRUG|Hydroxyurea|
224017058|NCT00568802|DRUG|Placebo to match hydroxyurea|
224017059|NCT02851927|PROCEDURE|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
224017060|NCT02851927|PROCEDURE|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
224128735|NCT00086957|DRUG|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
223397601|NCT07005817|BEHAVIORAL|Simulated Social Media Platform Only|To rule out placebo and nonspecific effects, the Keep Social RCT engenders positive expectations in all participants by promoting the use of Invibe as a beta social media platform to build and maintain social ties, a framing that mirrors information-as-usual for wellness through social media connections. Those in the Placebo Control condition receive no further health communication (view no psychoeducational video) and encounter all background content on Invibe (all target messages excluded) with control posts that feature unrelated content.
224017061|NCT01277900|PROCEDURE|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
224017062|NCT01039792|DRUG|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
224017063|NCT01039792|DIETARY_SUPPLEMENT|Placebo|placebo
224017064|NCT03394729|DRUG|Propolis tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
224017065|NCT03394729|DRUG|Xilytol tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
224017066|NCT05296018|OTHER|Mandala coloring page|Mandala program will be applied three days a week (30 minutes) for 8 weeks.
224017067|NCT05823831|DIAGNOSTIC_TEST|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire|Brief Infant-Toddler Social and Emotional Assessment (BITSEA) questionnaire was used to assess children's social-emotional development.
224017068|NCT05823831|DIAGNOSTIC_TEST|Brief Infant Sleep Questionnaire (BISQ) questionnaire|A brief Infant Sleep Questionnaire (BISQ) was used to assess children's sleep.
224017069|NCT05823831|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire|A Multidimensional Scale of Perceived Social Support (MSPSS) questionnaire was used to evaluate maternal social support.
224017070|NCT05823831|DIAGNOSTIC_TEST|Brief Symptom Inventory (BSI) questionnaire|A brief Symptom Inventory (BSI) questionnaire was used to evaluate psychological distress.
224017071|NCT04280341|BIOLOGICAL|RC48-ADC in combinaton with JS001|"The study has 2 parts which include dose escalation phase and dose extension phase.~Dose escalation will use a 3+3 design and will enroll cohorts of 3-6 patients with HER2-Positive Advanced Malignant Solid Tumors sequentially at escalating doses of 2.0mg/kg and 2.5mg/kg to RC48-ADC and JS001 is fixed dose of 3.0mg/mg"
224017072|NCT03117322|BIOLOGICAL|agave inulin|Duration: four weeks Dosage: powder 4 g/d
224017073|NCT03117322|BIOLOGICAL|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
223397602|NCT07006636|OTHER|Watermelon Juice + liquid meal test at baseline|WMJ will be purchased from a commercially available brand. The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
223397603|NCT07006636|OTHER|Sweetened placebo beverage +liquid meal test at baseline|The placebo beverage made of water and sugar will match the sugar content provided in 355 ml of WMJ (approximately 10-20 g). The liquid meal test will be in the form of the Boost nutritional drink (8 fl.oz., vanilla flavor), which is commercially available.
223397604|NCT06141655|DRUG|Influenza vaccine|Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
223397605|NCT05421221|DEVICE|Sniffin' sticks Duftquartett|"4-odor training set over 12 weeks with Sniffin' sticks Duftquartett"
223397606|NCT06616636|DRUG|Azacitidine|Given by IV
223397607|NCT06616636|DRUG|Rezatapopt|Given orally with food
224017074|NCT03117322|OTHER|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
224017075|NCT03117322|OTHER|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
224017076|NCT04067648|DRUG|Sufentanil Injection|three doses of sufentanil was intravenously given during anesthesia induction
224017077|NCT01476098|DRUG|Placebo|SB-705498 placebo
224017078|NCT01476098|DRUG|SB-705498|400 or 600mg oral SB-705498
224017079|NCT00950586|DRUG|GSK1043702|Oral dose in liquid or tablet formulation
224128736|NCT02460926|PROCEDURE|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
224128737|NCT02626104|DIETARY_SUPPLEMENT|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
224128738|NCT02626104|DIETARY_SUPPLEMENT|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
223397608|NCT02816372|OTHER|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
223397609|NCT04671940|OTHER|DNA Analysis|Molecular analysis includes DNA analysis on the blood/saliva and on the cancer specimens from the biopsies \& subsequent resections
223550635|NCT00645840|DRUG|Anakinra|Patients will receive daily anakinra therapy for 28 days
223550636|NCT00402324|DRUG|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
223550637|NCT00402324|DRUG|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
224017080|NCT00950586|DRUG|Dextromethorphan|30mg Oral dose
224017081|NCT00950586|DRUG|Placebo|To match GSK1034702
224128739|NCT02837692|DRUG|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
224128740|NCT02837692|DRUG|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
224128741|NCT02837692|DRUG|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
224128742|NCT02837692|DRUG|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
224128743|NCT00634244|DRUG|alvocidib|Given IV
224128744|NCT00634244|DRUG|mitoxantrone hydrochloride|Given IV
224128745|NCT00634244|DRUG|carboplatin|Given IV
224128746|NCT00634244|DRUG|cytarabine|Given IV
223397610|NCT07011446|DEVICE|Safer Seat Usability Trial|"Participants will be asked to transfer onto/off of the vehicle seat using their normal method of transfer and then to trial transferring onto/off of a vehicle seat with the Safer Seat 1 one or more times with study personnel. Demographic data will be recorded for all participants to include age, sex, and type of mobility disability. Transfers will be observed by the research personnel and success in transfers will be recorded according to the Physical Mobility Scale.~Usefulness and usability of the Safer Seat transfer experience will be reported by participants via Technology Acceptance Model Surveys; and participants will engage in a brief semi structured interview that will be audio recorded and transcribed via Microsoft Teams."
224017082|NCT01466933|BEHAVIORAL|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
224017083|NCT01466933|BEHAVIORAL|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
224017084|NCT00725933|DRUG|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
224017085|NCT01656733|DRUG|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
224017086|NCT01656733|DRUG|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
224128747|NCT00634244|DRUG|sirolimus|Given PO
224128748|NCT00634244|DRUG|etoposide|Given IV
224128749|NCT00634244|DRUG|topotecan hydrochloride|Given IV
223397611|NCT04029623|OTHER|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
223550638|NCT00402324|DRUG|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
223550639|NCT02625220|DEVICE|Prototype toric lens senofilcon A|Investigational prototype
224017087|NCT05300347|DIAGNOSTIC_TEST|adenosine deaminase enzyme deficiency test|adenosine deaminase enzyme deficiency
224017088|NCT02684448|PROCEDURE|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
224017089|NCT05786430|DRUG|Lazertinib/Pemetrexed/Carboplatin|Combination of lazertinib 240 mg (80 mg, 3 tablets) and pemed-S + carboplatin. Once a day lazertinib 240 mg pemed-S: 500mg/m2 q3w carboplatin: AUC5 q3w (only administered up to 4 cycles)
224017090|NCT05721404|DRUG|Icodextrin Peritoneal Dialysis Solution|Icodextrin (Extraneal) for long night dwell
224017091|NCT05721404|DRUG|Hypertonic Dextrose solution|Hypertonic Dextrose solution for long night dwell
224017092|NCT04660591|DEVICE|femoral stem in hip arthroplasty|using lateral approach to the hip we will compare the effect of femoral stem length on the oncological and functional outcomes in patients with proximal femoral metastasis.hip arthroplasty is a surgical procedure that involves changing the head of the femur (the ball) with or without replacing the articular surface of the acetabulum (the socket ).and replacing it with metal head based on a stem covered with cement to fix it to the bone of the femur.
224017093|NCT02825173|DEVICE|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
224017094|NCT04361682|PROCEDURE|Surgical Drain Management|
224017095|NCT00580645|DRUG|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
224017096|NCT00580645|DRUG|placebo|placebo
224017097|NCT03117231|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
224128750|NCT04158908|BEHAVIORAL|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~1. Principles of introducing prognosis in the setting of worsened scan results~2. Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~3. Addressing informational needs and psychological reactions~4. Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
224128751|NCT00908206|DRUG|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
224128752|NCT02915406|DEVICE|CliniMACs|
224128753|NCT01850784|DIETARY_SUPPLEMENT|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
224128754|NCT01850784|DIETARY_SUPPLEMENT|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
224128755|NCT01784406|BEHAVIORAL|Autonomy supportive counselling|
224017098|NCT03117231|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
224017099|NCT03180177|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m\^2, 43°C, 90min.
224017100|NCT03180177|PROCEDURE|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
224017101|NCT03180177|DRUG|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
224017102|NCT03180177|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
224017103|NCT02218294|DRUG|BCX4161|
224017104|NCT04738227|RADIATION|Low-Level Laser Therapy|Low level laser will be applied and post laser results will be seen to assess any improvements.
224017105|NCT04326595|PROCEDURE|surgical and medical evacuation|surgical evacuation:the dilation of the cervix and surgical evacuation of the uterus (potentially including the fetus, placenta and other tissue) medical evacuation: induction of abortion by the use of ecbolics
224017106|NCT03773315|DIETARY_SUPPLEMENT|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
224128756|NCT02166021|BIOLOGICAL|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
224128757|NCT04019093|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
223550640|NCT04449107|BEHAVIORAL|Android based mobile phone application|An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
224017107|NCT03773315|DIETARY_SUPPLEMENT|Placebo|Starch placebo 500 mg/day for 12 weeks
224017108|NCT00682890|DRUG|placebo|placebo birth control pill daily
224017109|NCT00682890|DRUG|metformin|2000 mg per day for 3 months daily birth control pill
224017110|NCT03545503|DRUG|Etomidate|Etomidate will be administered as the sedative for RSI on even days
224017111|NCT03545503|DRUG|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
224017112|NCT02139761|DRUG|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
224017113|NCT02139761|DRUG|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
224017114|NCT06154109|DRUG|Xiaopi granules|Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
224017115|NCT06154109|DRUG|Xiaopi decoction|Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
224128758|NCT04019093|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
224128759|NCT04937582|DIAGNOSTIC_TEST|Cognitive assessment|Complete cognitive and psychological assessment
224017116|NCT06154109|DRUG|Placebo|The placebo does not contain any active pharmaceutical ingredients .
224017117|NCT03786523|BEHAVIORAL|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
224128760|NCT04937582|DIAGNOSTIC_TEST|Imaging|"Brain MRI~Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)"
224128761|NCT04937582|DIAGNOSTIC_TEST|Routine care|"Electroencephalogram (EEG)~Optional: polysomnography, lumbar puncture"
224128762|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary
224128763|NCT04937582|OTHER|Psychiatric evaluation|Psychiatric consultation if necessary (before the end of their participation in the study)
224128764|NCT03361319|DRUG|Vargatef|small molecule triple kinase inhibitor
223550641|NCT03619434|PROCEDURE|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
223550642|NCT03619434|PROCEDURE|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
223550643|NCT01843166|DRUG|Premarin vaginal cream|2g at bedtime twice weekly
223550644|NCT01843166|DRUG|Placebo cream|2g at bedtime twice weekly
223550645|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 milliliter (mL), Intramuscular (IM)
223550646|NCT03205358|BIOLOGICAL|Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine|0.5 mL, IM
223397612|NCT04029623|OTHER|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
224128765|NCT03361319|DRUG|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
224128766|NCT03361319|OTHER|placebo|Placebo in place of Ninedanib
224128767|NCT01769079|DRUG|Nitrate|Two arms: placebo and nitrate
224128768|NCT01769079|DRUG|Placebo|
224128769|NCT01864759|BIOLOGICAL|ICOVIR-5|
224128770|NCT04369430|DRUG|AKST4290|Oral AKST4290
224128771|NCT04369430|DRUG|Placebo|Oral Placebo
224128772|NCT04279379|DRUG|Sintilimab|200mg d1,ivdrip, repeated every 3 weeks
224128773|NCT04279379|DRUG|Decitabine|10mg d1-5, ivdrip,repeated every 3 weeks
223397613|NCT06207318|BEHAVIORAL|Acceptance and commitment therapy|The intervention will be based on Acceptance and Commitment Therapy (ACT). ACT is an empirically-based therapeutic approach that focuses on psychological flexibility, acceptance, and the reduction of experiential avoidance. It encourages individuals to change their relating to thoughts and experiences and act in accordance with their values.
223397614|NCT06103292|DIAGNOSTIC_TEST|ionized calcium levels|measuring calcium level in trauma patients
223550647|NCT05795673|OTHER|Peer support program (intervention phase)|"Implementation and Evaluation:~Intervention of mentor to provide peer support targeting psychosocial skills, coping and quality of life of adolescents with cystic fibrosis during the pediatric-adult transition The evaluation of the feasibility of the peer support program consists of assessing the effectiveness of its implementation in terms of its effect on the target audience, its acceptability to participants, and its implementation.~The mentor and the mentee will be in contact once a month for a minimum of 3 months and a maximum of 6 months by telephone.~The mentor will know the themes that the teenager would like to address in the context of peer support.~The mentee will complete the various questionnaires provided in the protocol to answer the primary and secondary endpoints."
223550648|NCT00521729|PROCEDURE|Exposure to Cold Temperature|
224128774|NCT02435277|DRUG|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
224128775|NCT02435277|DRUG|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
224128776|NCT02435277|DRUG|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
224128777|NCT02435277|DRUG|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
224128778|NCT01187108|DRUG|N-acetylcysteine|NAC 600 mg oral once daily
224128779|NCT01187108|DRUG|Acetazolamide|Acetazolamide 250 mg oral once daily
224128780|NCT01187108|DRUG|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
224128781|NCT02204241|DRUG|Carfilzomib|
223397615|NCT02236039|PROCEDURE|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
223397616|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles); Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
223550649|NCT04875494|BEHAVIORAL|Counseling/support group therapy|6 weeks of counseling group therapy; 2 sessions of 30 min each week, with a psychologist and two former victims
224128782|NCT02204241|DRUG|Cyclophosphamide|
224128783|NCT02204241|DRUG|Dexamethasone|
224128784|NCT00008138|DRUG|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
224128785|NCT00008138|DRUG|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
224128786|NCT00008138|PROCEDURE|debulking surgery|exploratory laparotomy, interval cytoreduction (to \< 1 cm residual)
224128787|NCT02704221|BEHAVIORAL|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
224128788|NCT02704221|BEHAVIORAL|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
224128789|NCT02704221|BEHAVIORAL|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
224128790|NCT06503861|BEHAVIORAL|Food Is Medicine intervention|The intervention provides regular meal kits as well as cooking and nutritional education.
224128791|NCT04935060|BEHAVIORAL|A guide to inform the process of delivering the outcomes of a dementia assessment|The guide provides information that informs the approach taken to assessing people for dementia. It aims to guide clinicians. patients and their companions to think about how the diagnostic process is carried out, taking into account patient preferences, particularly around how they would like diagnostic decisions to be communicated to them.
224128792|NCT04935060|BEHAVIORAL|Usual Care|Clinicians conduct the dementia assessment as per standard protocols
224128793|NCT01763476|PROCEDURE|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
224128794|NCT01763476|PROCEDURE|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
223550650|NCT04875494|BEHAVIORAL|Physical Exercise|6 weeks of physical exercise training; 2 sessions of 30 min each week, with an instructor
223550651|NCT02508545|OTHER|perceived egocentric distance (PED) measurements|
223550652|NCT02508545|OTHER|Parabolic flight|
223550653|NCT06192472|PROCEDURE|Chemical sclerotherapy|Sclerosant will be retained within the vein
224017118|NCT03786523|BEHAVIORAL|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
224017119|NCT05347368|OTHER|Control group (conventional therapy)|Physical therapy will be performed using physical agent modality that include hot pack (15 min), and therapeutic exercises (5 repetition per set, 2 sets each session) therapeutic exercises include spinal extension exercise, prone hip extension exercise, posterior pelvic tilt, cat-camel exercise
224017120|NCT05347368|OTHER|Primal Reflex release Technique|The SI/Lumbar release Iliopsoas release Piriformis release Hamstring release Gastrocnemius release
224017121|NCT03170999|OTHER|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
224017122|NCT03170999|OTHER|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
224017123|NCT03170999|OTHER|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
224017124|NCT03028220|DEVICE|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
224017125|NCT03028220|DEVICE|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
224017126|NCT02224690|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
224017127|NCT02224690|DRUG|Placebo|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
224017128|NCT00141219|DRUG|pregabalin|150-600mg/day, BID
224017129|NCT00141219|DRUG|Placebo|Placebo
224017130|NCT05949294|DRUG|ARO-SOD1 Injection|single doses of ARO-SOD1 Injection by IT infusion
224017131|NCT05325580|DRUG|Magnesium sulfate|"magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum"
224017132|NCT00297596|DRUG|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
224017133|NCT00297596|DRUG|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
224017134|NCT02244021|DRUG|BRENTUXIMAB VEDOTIN|"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."
224017135|NCT05179382|OTHER|Control protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position.
224128795|NCT03114982|BIOLOGICAL|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
223550654|NCT06192472|DRUG|1% Sodium Tetradecyl Sulphate|1% Sodium Tetradecyl Sulphate
223550655|NCT06192472|DRUG|3% Sodium Tetradecyl Sulphate|3% Sodium Tetradecyl Sulphate
223550656|NCT06192472|DRUG|0.5% Polidocanol|0.5% Polidocanol
223550657|NCT06192472|DRUG|3% Polidcanol|3% Polidcanol
223550658|NCT02235792|DEVICE|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
223550659|NCT04599803|DEVICE|Verily Sleep Apnea (VSA) Program/App|The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.
224128796|NCT03114982|BIOLOGICAL|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
224128797|NCT01251172|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
224128798|NCT01251172|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
224128799|NCT01251172|PROCEDURE|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
224128800|NCT01251172|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
224128801|NCT01251172|OTHER|Laboratory Biomarker Analysis|Correlative studies
224128802|NCT01251172|DRUG|Melphalan|Given IV
224128803|NCT04543474|OTHER|Low Lactose Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
223550660|NCT04293224|OTHER|DGA Mediterranean diet pattern, energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations.
224017136|NCT05179382|OTHER|Hydration protocol|I.10 minutes of initial rest in the supine position; II. 90 minutes of treadmill aerobic exercise at an intensity of 60% of the vo2 peak; IV. 60 minutes of passive recovery in the supine position. V. Water ingestion distributed in 10 equal portions, administered at regular intervals of 15 minutes from the 15th minute of exercise until the end of the recovery period.
224017137|NCT02580643|BIOLOGICAL|APS|intra-articular injection
224017138|NCT06265064|DIAGNOSTIC_TEST|STOP-Bang score >= 3 with factors predicting difficult intubation|patients with STOP-Bang score \>= 3 with Mallampati score ≥ 3 or neck circumference \>42 cm or mentothyroid distance \<6 cm
224017139|NCT02314845|OTHER|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
224017140|NCT02314845|OTHER|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
224128804|NCT04543474|OTHER|Low FODMAP Diet|First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.
224017141|NCT00645866|DRUG|capecitabine|
224128805|NCT04319562|PROCEDURE|needle-embedding therapy|"First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan)."
224128806|NCT04319562|DEVICE|shame needle-embedding therapy|The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
224128807|NCT02539082|DEVICE|Regenseal|Regenseal, collagen, injection in the defect area
224128808|NCT02539082|DRUG|normal saline|placebo, normal saline, injection in the defect area
224017142|NCT00645866|DRUG|docetaxel|
224017143|NCT00645866|DRUG|epirubicin hydrochloride|
224017144|NCT00645866|OTHER|laboratory biomarker analysis|
224017145|NCT00645866|OTHER|pharmacogenomic studies|
224017146|NCT00645866|PROCEDURE|biopsy|
224128809|NCT04284982|BEHAVIORAL|16-week supervised heavy resistance training program with weekly undulating periodization|Participants trained a whole-body program consisting of squat, bench press, deadlift and pendlay row two times per week for 16 weeks
224128810|NCT04158713|DRUG|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
224128811|NCT00654511|DRUG|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
224128812|NCT00654511|DRUG|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
224128813|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
223550661|NCT04293224|OTHER|DGA Mediterranean diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the DGA Mediterranean diet pattern will be based on the Table A7-1 of the 2015 Dietary Guidelines for Americans which outlines daily nutritional goals for age-sex groups based on Dietary Reference Intakes (DRI) and dietary guidelines recommendations
224017147|NCT00645866|PROCEDURE|neoadjuvant therapy|
224017148|NCT00645866|PROCEDURE|therapeutic surgical procedure|
224017149|NCT02730637|OTHER|Early nephrologist consultation|
224017150|NCT02274532|DEVICE|SoftHand|Biomechanical, ADL, and functional testing.
224017151|NCT00002768|BIOLOGICAL|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
224017152|NCT00002768|DRUG|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
224017153|NCT00002768|DRUG|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
224017154|NCT00002768|DRUG|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
224017155|NCT00002768|DRUG|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
224017156|NCT00002768|PROCEDURE|peripheral blood stem cell transplantation|Infusion on Day 0
224017157|NCT02317133|BIOLOGICAL|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
224017158|NCT02317133|BIOLOGICAL|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
224017159|NCT00802698|DEVICE|Transcorneal electric stimulation|central artery occlusion
224017160|NCT00802698|DEVICE|Transcorneal stimulation|new waveform
224128814|NCT00654511|DRUG|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
223397617|NCT05058404|DRUG|Immunochemotherapy regimen: Rituximab-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of Rituximab-bendamustine Q28 (28-days cycles);~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-bendamustine Q28 + 2 cycles Q28 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
224017161|NCT00802698|DEVICE|transcorneal electric stimulation|Novel waveform central artery occlusion
224017162|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
223397618|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of R-CHOP Q21 + 2 cycles Q21 of rituximab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis planned by the study."
224017163|NCT00729079|BEHAVIORAL|DPP|"1. The primary outcome measure is weight loss with a goal of 7% of initial weight.~2. Secondary outcomes are adherence to behavior changes:~   1. Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~  2. Fat intake less than 25% and saturated fat less than 10%~  3. Fiber intake of at least 25 grams per day~  4. Fasting blood sugar \< 100 mg/dL~  5. Absence of tobacco use"
224017164|NCT00122460|DRUG|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
224017165|NCT00122460|DRUG|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
224128815|NCT01720615|DRUG|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
224128816|NCT01720615|DRUG|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
224128817|NCT01554540|DRUG|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
223550662|NCT04293224|OTHER|TAD diet pattern, negative energy balance|Foods and beverages will be provided for participants for eight weeks. During the controlled feeding portion of the study the be based on evidence collected from What We Eat in America (WWEIA) data. Based on this data the participants will be provided a diet that reflects American dietary trends.
224017166|NCT00950794|DRUG|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
224128818|NCT05228444|BEHAVIORAL|CircadianCare|enhancing circadian rhythmicity through an assessment of the patient's specific circadian features/needs and an ad hoc, personalized light-dark, meal and activity schedule to cover the whole of the inpatient stay.
223550663|NCT01518725|DIETARY_SUPPLEMENT|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
223550664|NCT01518725|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
223550665|NCT00890435|OTHER|questionnaire administration|
223550666|NCT00890435|PROCEDURE|psychosocial assessment and care|
224017167|NCT00950794|DRUG|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
224017168|NCT02595073|DRUG|DSXS|Active treatment
224017169|NCT02595073|DRUG|Placebo|Placebo treatment
224017170|NCT02962960|DRUG|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
224017171|NCT02962960|DRUG|Placebo|subcutaneous administration every two weeks from week 0 to week 50
224128819|NCT05369117|BEHAVIORAL|indocyanine green labeled fluorescent laparoscopy|indocyanine green fluorescence labeling was performed under gastroscope before surgery and internal jugular vein puncture was performed routinely for better fluid replenishment after surgery
224017172|NCT01478529|DRUG|mirabegron OCAS|oral administration
223397619|NCT05058404|DRUG|Immunochemotherapy regimen: R-CHOP (Arm B)|"Arm B (Experimental arm):~4 cycles of R-CHOP Q21 (21-days cycles); R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging: induction therapy shall be completed based on the response achieved and on the treatment chosen:~* if in CR: patients will receive no more chemotherapy but will complete induction with the MoAb only, in this case: 4 cycles of rituximab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of R-CHOP Q21+ 2 cycles Q21of rituximab~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion: these patients will be included in the analysis."
223550667|NCT01116388|OTHER|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
224128820|NCT01984034|BEHAVIORAL|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
224128821|NCT01984034|OTHER|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
223550668|NCT01116388|OTHER|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
224017173|NCT01478529|DRUG|mirabegron|iv administration
224128822|NCT00368134|DRUG|Vildagliptin|
223731336|NCT02151253|DRUG|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
224128823|NCT01370096|DRUG|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
224128824|NCT01370096|DRUG|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
223550669|NCT02484443|BIOLOGICAL|Dinutuximab|Given IV
224128825|NCT00937768|DRUG|Goserelin Acetate|Given SC
224128826|NCT00937768|OTHER|Laboratory Biomarker Analysis|Correlative studies
223731337|NCT06437860|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
223731338|NCT06437860|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
223550670|NCT02484443|OTHER|Laboratory Biomarker Analysis|Correlative studies
224017174|NCT00568035|DRUG|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
224017175|NCT05252650|BEHAVIORAL|pain|postoperative pain
224017176|NCT00681330|BIOLOGICAL|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
224017177|NCT05849948|BEHAVIORAL|choronobiological nutrition|Providing infant nutrition in accordance with crinobiological nutrition
224017178|NCT01164124|DIETARY_SUPPLEMENT|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter \& Gamble.Inc)
224017179|NCT01164124|OTHER|Placebo|routine feedings
224128827|NCT00937768|DRUG|Leuprolide Acetate|Given IM
224128828|NCT00937768|OTHER|Quality-of-Life Assessment|Ancillary studies
224128829|NCT00306917|DEVICE|non-coated femoral hip stem|total hip replacement
224128830|NCT00306917|DEVICE|coated femoral hip stem|total hip replacement
224128831|NCT06691100|BEHAVIORAL|Aerobic Exercise|30-minute exercise bout in a cycle ergometer at 60 to 70% of the Heart Rate Reserve (HRR) and corresponding power (watts).
224128832|NCT06688032|OTHER|Jarlsberg cheese|Jarlsberg cheese contains Propionebacterium freudenreichii (PF) producing the K2-vitamer MK-9(4H) and DHNA in addition to the K2-vitamers found in Norvegia cheese
224017180|NCT01605019|DEVICE|CoSeal|3 - 8mls of Coseal
224017181|NCT01605019|DEVICE|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
224128833|NCT06688032|OTHER|Norvegia|Cheese with different content of K2 vitamers
224128834|NCT06691308|COMBINATION_PRODUCT|WL276 CAR-T cells|This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses
224128835|NCT07017023|DRUG|Losartan with BA|7-day losartan (Cozaar, 50mg; oral tablet) with 7-day BA
224017182|NCT04629573|PROCEDURE|Lumber Epidural|Epidural procedure was performed by attending anesthesiologists who had completed at least 50 epidural procedures during their training. Patient was placed in the sitting position, the skin over the lumbar area was cleaned and a sterile technique was observed throughout the procedure. Skin and subcutaneous tissue were infiltrated with 1% lidocaine 2 mL at the intended site of epidural placement (L2-3 or L3-4 interspace). The lumbar epidural space was then located, using a midline approach with an 18 gauge Tuohy epidural needle via a loss of resistance technique with 2 mL of saline, 20 gauge epidural catheter was placed in each patient. We deliver an initial bolus of 20 ml bupivacaine 0.5% plus 100 mcg Fentanyl, followed by continuous infusion of bupivacaine 0.5% plus 1mcg/ml Fentanyl (3-5 ml/hr.).
224017183|NCT04629573|PROCEDURE|General anesthesia|Anesthesia was initiated with IV fentanyl 1 µg/kg, propofol 2 mg/kg and cisatracurium 0.15 mg/kg to facilitate endotracheal intubation. After tracheal intubation, anesthesia was maintained with sevoflurane in O2 and air (FiO2 of 0.5), cisatracurium 1µg/kg/min and fentanyl 0.5 µg/ kg /h were infused. Volume-Controlled ventilation was performed in all patients. Cisatracurium and fentanyl infusion was stopped at the end of surgery, neuromuscular blockade was reversed, and the patient was extubated and send to post-anesthesia care unit.
224017184|NCT01908192|DRUG|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
224017185|NCT01908192|DRUG|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
224017186|NCT01451827|DRUG|Tolvaptan MR|50/80 mg capsules
224017187|NCT01451827|DRUG|Tolvaptan IR|60/30 mg capsules
224017188|NCT01451827|DRUG|Placebo|tablet
224017189|NCT00379028|DRUG|Budesonide/Formoterol Turbuhaler|
224017190|NCT00379028|DRUG|Salmeterol/Fluticasone Diskus|
224017191|NCT05786105|OTHER|Bone Marrow samples collection|Bone Marrow samples collection - one ethylenediaminetetraacetic acid (EDTA) tube - for Optical Genome Mapping
224128836|NCT07017023|OTHER|Placebo with BA|7-day placebo (oral; microcellulose in identical capsules) with 7-day BA
224128837|NCT07017595|BEHAVIORAL|Visual-acoustic biofeedback: experimental|Visual-acoustic biofeedback treatment incorporates elements of traditional voice training, including auditory models, verbal descriptions of articulator placement, and cues for repetitive motor practice using images and diagrams of the vocal tract as visual aids. Our experimental software will provide several options for visualizing the fundamental frequency of the voice (for targets involving vocal pitch) and for visualizing vocal tract resonances. Custom targets for pitch and resonance will be created for each participant based on their baseline voice characteristics and personal voice goals. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments influence the proximity of their output to the target.
223397620|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm A)|"Arm A (Standard arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-bendamustine Q28 (28-days cycles);~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in Stable Disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
223550671|NCT02484443|OTHER|Pharmacological Study|Correlative studies
224017192|NCT04051736|BIOLOGICAL|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
224017193|NCT01960777|PROCEDURE|Onstep|
224017194|NCT01960777|PROCEDURE|Laparoscopic repair|
224017195|NCT01795482|DEVICE|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
224128838|NCT05729217|OTHER|SBQ-LC survey|Symptom burden questionnaires of Long COVID
224128839|NCT07020273|BEHAVIORAL|ELEVATE|ELEVATE uses implementation strategies to support clinicians (support clinicians by revising professional roles to enable point of care tobacco treatment with a team are approach and support clinicians by providing clinical decision support tools).
224128840|NCT07020273|BEHAVIORAL|ELEVATE-S|ELEVATE-S uses implementation strategies to support clinicians (support clinicians by revising professional roles to enable point of care tobacco treatment with a team are approach and support clinicians by providing clinical decision support tools) and implementation strategies to support patients with chronic care model-informed self-management support (patient centered flexible goals and patient-generated health data).
224128841|NCT05030285|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention includes 6 sessions via video-conferencing that has been tailored for people living with cognitive impairment. The sessions incorporate the use of psychoeducation and relaxation videos to improve home-based practise for long-term outcomes.
223550672|NCT02484443|BIOLOGICAL|Sargramostim|Given SC
223550673|NCT04677543|DRUG|ALIS|Inhalation via nebulization over approximately 6 to 15 minutes.
224128842|NCT02678780|DRUG|Lenvatinib|
224128843|NCT02034357|OTHER|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
223550674|NCT04677543|DRUG|Azithromycin|Oral tablet
223550675|NCT04677543|DRUG|Ethambutol|Oral tablet
223550676|NCT04677543|DRUG|ELC|Inhalation via nebulization over approximately 6 to 15 minutes.
223550677|NCT02870062|OTHER|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
224128844|NCT02034357|OTHER|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
224128845|NCT06693713|OTHER|Mental Health Youth Series|The Mental Health Youth Series is an eight-week program for youth ages 11-15 that uses games, short films, discussion questions, and exercises to engage with mental health and faith topics. The intervention package includes a facilitation guide and a guide for parents and caregivers. The program is intended to be conducted by an experienced facilitator, although there is no specific training provided for facilitators outside of the facilitation guide.
223397621|NCT05058404|DRUG|Immunochemotherapy regimen: G-bendamustine (Arm B)|"Arm B (Experimental arm):~4 cycles of G-bendamustine Q28 (28-days cycles); G-Bendamustine = Obinutuzumab and Bendamustine~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case 2 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-bendamustine Q28;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
223550678|NCT02870062|OTHER|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
224128846|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection of nanoparticles in rectum, 28 mg Fe (7 mg Fe/mL)
224128847|NCT06693375|DEVICE|Rectal Magnetomotoric ultrasound (MMUS)|MMUS examination of lymphnodes in rectum
224017196|NCT02424734|DRUG|Ceftaroline Fosamil|Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
224017197|NCT02424734|DRUG|Ampicillin|Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
224128848|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 56 mg Fe (3,5 mg Fe/mL)
223550679|NCT03074201|PROCEDURE|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
223550680|NCT03074201|DEVICE|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
223550681|NCT05287776|DEVICE|Narrow band UVB|Narrow band UVB emitting UVB at wavelength 311nm
223550682|NCT03987711|DRUG|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
223550683|NCT03987711|DRUG|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
223550684|NCT03987711|OTHER|No oral anticoagulation|No oral anticoagulation
224017198|NCT02424734|DRUG|Aminoglycoside|Optional, will be given as per local standard of care.
224017199|NCT01240473|DRUG|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
224017200|NCT01642251|DRUG|Cisplatin|Given IV
224017201|NCT01642251|DRUG|Etoposide|Given IV
224017202|NCT01642251|DRUG|Veliparib|Given PO
224017203|NCT01642251|DRUG|Placebo|placebo of Veliparib
224017204|NCT01578200|DRUG|Lanthanum Carbonate|
224017205|NCT01578200|DRUG|Calcium Carbonate|
224017206|NCT04054700|DEVICE|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
224017207|NCT04054700|DEVICE|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
224017208|NCT00752557|DRUG|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
224017209|NCT00752557|DRUG|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
224017210|NCT00752557|DRUG|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
224017211|NCT02881905|DEVICE|ball attachment|it is attachment part that connects the overdenture to the implant
224017212|NCT02881905|DEVICE|cm loc attachment|It is a new attachment made of peek material
224017213|NCT06226740|OTHER|Single Visit Non Surgical Root Canal Treatment Protocol|The current study aimed to compare the effects of different obturation techniques on postoperative pain level and radiographic healing in non-surgical endodontic treatment applied in a single visit in teeth with single root canal and apical periodontitis.
224017214|NCT05083000|DRUG|Topotecan|Topotecan hydrochloride is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitor activity. It is a well-established chemotherapeutic agent used for cancer treatment.
224017215|NCT05571371|OTHER|Measuring inflammatory serum biomarkers|Measuring inflammatory serum biomarkers
224017216|NCT06093776|DEVICE|ioveraº system|the use of surgical procedure that produces lesions in peripheral nervous tissue through application of extreme cold
224017217|NCT02262091|DIETARY_SUPPLEMENT|Food fibers|
224017218|NCT02262091|DIETARY_SUPPLEMENT|Maltodextrin|
224017219|NCT02262091|BIOLOGICAL|Influenza vaccine (incl. criterion)|
224017220|NCT04441060|OTHER|Distress intervention (CBT & Mindfulness-based program)|Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT \& Mindfulness-based program.
224017221|NCT02166294|OTHER|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
224017222|NCT02166294|PROCEDURE|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
224128849|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum : 56 mg Fe (14 mg Fe/mL)
224128850|NCT06693375|DRUG|Iron oxide nanoparticles|Submucosal injection in rectum 112 mg Fe (14 mg Fe/mL)
224128851|NCT06692751|BIOLOGICAL|Blood sampling|2 tubes of 5 mL
224128852|NCT06692751|PROCEDURE|Ophthalmological examination|"angiographic optical coherence tomography (OCT-A) on both eyes after pupil dilation.~An optional 20-30 minute WLR may be offered following OCT-A."
223397622|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease (SD) at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
223550685|NCT03343678|DRUG|Venetoclax|Venetoclax given alone and then in combination with BI 836826
223550686|NCT03343678|DRUG|BI 836826|Venetoclax given in combination with BI 836826
223550687|NCT06343272|DIETARY_SUPPLEMENT|EAA supplementation|"The experimental group will receive the mixture (Amino-Ther® PRO, Professional Dietetics, Milan) composed of (in mg): L-leucine 1200, l L-isine 900, L-threonine 700, L-isoleucine 600, L-valine 600, L-cystine 150, L histidine 150, L-phenylalanine 100, L-methionine 50, L-tryptophan 50, vitamin B6 0.85, vitamin B1 0.70, citric acid 409, acidomalic 102.5, succinic acid 102.5.~1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days There are: proteins 0.00 g, carbohydrates 2.1 g, fats 0.00 g"
224128853|NCT06692751|OTHER|angina severity questionnaire|at inclusion, 3 months and 1 year Estimated filling time: 2 minutes
223550688|NCT06343272|OTHER|Isocaloric placebo|The control group will take 25g of maltodextrins daily with the same methods as the treated group: 1 sachet dissolved in 150 ml of water at 10.00 am +1 sachet at 4.00 pm daily for 60 days
223550689|NCT03799952|BEHAVIORAL|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
224128854|NCT06168864|DIAGNOSTIC_TEST|Artificial intelligence models for segmentation and characterization of prostate cancer|rtificial intelligence algorithms for the automatic segmentation of prostate cancer lesions on medical images.
224128855|NCT02472548|BIOLOGICAL|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
224128856|NCT02472548|BIOLOGICAL|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
224128857|NCT02472548|OTHER|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
224128858|NCT01427569|DRUG|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
224128859|NCT01427569|OTHER|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
224128860|NCT02532595|PROCEDURE|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
223731339|NCT02485574|PROCEDURE|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in right side of disc space and anterior bridging cages augmented with auto bone in left side of disc space in transforaminal lumbar interbody arthrodesis.
224128861|NCT02532595|PROCEDURE|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
224128862|NCT06925672|OTHER|Questionnaire|"This is an anonymous questionnaire; based upon previous similar studies.~The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs:~A. Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics.~B. Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy.~C. Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy.~This questionnaire will be presented in its Arabic version."
224128863|NCT07046793|DIAGNOSTIC_TEST|POCUS|Ultrasound screening of the distal forearm.
223550690|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
223550691|NCT00749788|DRUG|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
223731340|NCT02029950|DRUG|Cytarabine|Given IV
224128864|NCT06889025|OTHER|Experimental: tASC/CBTp: gamma band electric stimulation for 20 minutes at the beginning of the CBTp session|For the transcranial stimulation we will use the tES device from NeuroMyst,. The gamma pulses are delivered to a study participant via stimulating electrodes positioned at participant's head according to the required technique. The tACS will be applied the first 20 minutes from the classic CBTp session for the experimental group.
224128865|NCT06889025|OTHER|Sham Comparator|For the Sham group the investigators will use the same tES device from NeuroMyst. The Sham stimulation will be applied only for a few seconds in Sham group. The CBTp will follow the same protocol for both arms.
223550692|NCT00749788|DRUG|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
223550693|NCT03343340|OTHER|Early CRRT|Continous Renal Replacement Therapy
223550694|NCT03343340|OTHER|Late CRRT|Continous Renal Replacement Therapy
224128866|NCT06734702|DRUG|Neoadjuvant therapy|The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks.
224128867|NCT06734702|RADIATION|Hypo-RT and concurrent chemotherapy|Definitive dose of hypofractionated thoracic radiotherapy with concurrent chemotherapy
223550695|NCT03343340|OTHER|Standard Medical Therapy|Standard Medical Therapy
223550696|NCT01145781|PROCEDURE|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
224128868|NCT06734702|RADIATION|CFRT and concurrent chemotherapy|Definitive dose of conventionally fractionated thoracic radiotherapy with concurrent chemotherapy
224128869|NCT06734702|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
224128870|NCT06891781|DEVICE|Deep Brain Stimulation|AlphaDBS System
224128871|NCT04604106|DIAGNOSTIC_TEST|Eyetracker|Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
224128872|NCT04604106|DIAGNOSTIC_TEST|Ages & Stages questionnaire|The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
224128873|NCT04604106|DIAGNOSTIC_TEST|Bayley Scale of Infant Development|The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
224128874|NCT05431140|DEVICE|CloudCare|Only eligible subjects to whom CloudCare is introduced as part of their new standard care will be enrolled. Participants will not be subjected to extra procedures on top of their standard of care, except that they will be asked to fill out short questionnaires about their treatment satisfaction and the emotional burden caused by diabetes, which are not standard in the participating study locations.
223550697|NCT04312139|DIAGNOSTIC_TEST|Echocardiography|Baseline and prospective follow-up echocardiography
224017223|NCT05064683|OTHER|white noise|Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
224017224|NCT05849831|DIAGNOSTIC_TEST|Ultrasound measurement of Optic nerve sheath diameter|Ocular ultrasonography will be performed by single skilled examiner with patients placed in supine position with closed eyes. A layer of ultrasound gel will be applied over the closed upper eyelid and the liner high frequency probe 7 - 12 MHz of SonoSite M-Turbo ultrasound machine is placed on temporal area of eyelid with the hand holding it resting on forehead of patient. ONSD is measured 3mm behind the globe in the transverse plane perpendicular to the optic nerve. For each eye one measurement will be made and the reported ONSD corresponds to the mean of the two values obtained for each patient. An average ONSD greater than 5 mm is considered abnormal and elevated intracranial pressure should be suspected. all enrolled subjects will be eligible for ONSD measurements, SOFA score calculation, as well as GCS assessment on daily basis for up to 10 consecutive days, until ICU discharge or death.
224017225|NCT03594201|OTHER|semen pretreatment|semen pretreatment
224128875|NCT04105556|OTHER|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
224128876|NCT01327040|OTHER|light exposure|12-hour light exposure of approximately 200 lux
224128877|NCT04980846|OTHER|Driving under the influence of alcohol with a driving simulator|"Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected."
224128878|NCT06759194|PROCEDURE|Holmium Laser Enucleation of the Prostate|Enucleation of the prostate gland using holmium laser energy
224128879|NCT06759194|PROCEDURE|Bipolar Enucleation of the Prostate|Enucleation of the prostate gland using bipolar energy
224128880|NCT00544128|DRUG|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
224128881|NCT00544128|DRUG|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
224128882|NCT05800444|DRUG|BAY3283142|Oral administration as tablet.
223550698|NCT04312139|DIAGNOSTIC_TEST|Computerized Tomography Aortic Valve Calcium Score|Baseline and prospective follow-up CT calcium score of aortic valve
223731341|NCT02029950|DRUG|Daunorubicin Hydrochloride|Given IV
223731342|NCT02029950|DRUG|Etoposide|Given IV
224017226|NCT03983603|DIETARY_SUPPLEMENT|Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)|Soft chews containing 0.5g plant stanols delivered as plant stanol esters
224017227|NCT03983603|DIETARY_SUPPLEMENT|Placebo soft chew|Soft chew that does not contain plant stanols
224128883|NCT05800444|OTHER|Placebo|Oral administration as tablet.
224128884|NCT00521092|DRUG|sunitinib malate|Given orally
224128885|NCT00521092|PROCEDURE|laboratory biomarker analysis|Correlative study
224128886|NCT00521092|PROCEDURE|pharmacological study|Correlative study
224128887|NCT05468944|PROCEDURE|Transanal specimen extraction robotic surgery|Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
224128888|NCT05468944|PROCEDURE|Transabdominal specimen extraction robotic surgery|Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
223550699|NCT04312139|OTHER|Untargeted LC/MS and LC-MS/MS|Serum samples untargeted proteomics and metabolomics
223550700|NCT04312139|OTHER|Targeted LC/MS and LC-MS/MS|Serum samples targeted proteomics and metabolomics
223550701|NCT04312139|DIAGNOSTIC_TEST|multiplex ELISA|Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
223550702|NCT02149355|OTHER|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
223397623|NCT05058404|DRUG|Immunochemotherapy regimen: G-CHOP (Arm B)|"4 cycles of G-CHOP Q21 (21-days cycles) G-CHOP = Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 2 cycles of G-CHOP Q21 + 2 cycles Q21 of obinutuzumab;~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the EOI shall be considered for salvage therapy at clinician discretion."
224017228|NCT06171581|OTHER|stress ball|In the study, the experimental group was given a round, compressible ball for stress ball application and it was planned to squeeze this ball in their hands as often as they wanted during anaesthesia and endometrial biopsy application. The endometrial biopsy procedure is a procedure that usually takes between 8-10 minutes. The results will be evaluated considering these average times. As it is foreseen that individuals may experience the most intense anxiety and stress during anaesthesia and biopsy, it was preferred to cover this time period.
224017229|NCT06171581|OTHER|control|In the study, the no intervention group ( control group) will receive no intervention and blood pressure and stress measurements will be made with routine care and nursing interventions.
224017230|NCT05766085|DIAGNOSTIC_TEST|Dexamethasone suppression test|Determination of cortisol levels at 9.00 am after taking 1 mg of dexamethasone the previous evening at 11.00 pm (1mg DST)
224017231|NCT06275139|OTHER|Integrated Assessment of Cervicocerebral Vessels|Integrated assessment of cervicocerebral vessels shall be performed, including transcranial color-coded doppler, cerebral perfusion with multislice CT, and cognitive function assessment.
224017232|NCT06520254|OTHER|Massage therapy|"A 30-minute massage session will be applied in the following structures:~* Flexor hallucis longus muscle,~* Flexor digitorum longus muscle,~* Tibialis posterior muscle,~* Semitendinosus muscle,~* Semimembranosus muscle,~* Gluteus maximus muscle,~* Longissimus muscle,~* Levator costarum muscles 1-5 During the massage session basic Swedish massage techniques were used."
224017233|NCT05515380|OTHER|8-stage model based exercise program|The experimental group would follow exercises related to 8 phases of tennis serve, which would be based on 8-stage model. The participants would follow this program for three days per week for 12 weeks.
224017234|NCT05515380|OTHER|Conventional exercise program|The control group would follow conventional exercise program advised by coaches. The participants of this group would also follow this program for three days per week for 12 weeks.
224017235|NCT00470366|BIOLOGICAL|pegfilgrastim|
224017236|NCT00470366|DRUG|cisplatin|
224017237|NCT00470366|DRUG|ifosfamide|
224017238|NCT00470366|DRUG|paclitaxel|
224017239|NCT01984073|DRUG|ER Niacin Oral Fat Challenge|Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
224017240|NCT01984073|DRUG|IR Niacin Oral Fat Challenge|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
224017241|NCT01984073|OTHER|Placebo Oral Fat Challenge|Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
224017242|NCT03639467|DRUG|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
224017243|NCT04491565|OTHER|educational video|an interactive educational video was viewed by participants in the intervention arm.
224017244|NCT04100577|OTHER|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
223397624|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm A)|"Arm A (Standard arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~Patients will undergo an early restaging after cycle 4: those with at least a stable disease will complete the induction treatment with 4 cycles of G-CVP Q21;~Both Arms:~Whichever the regimen, in responding patients (Complete Remission CR, Partial Remission PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 Monoclonal Antibody (MoAb) used for induction.~Patients in both arms with progressive disease at any time and patients in stable disease SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
223550703|NCT03730714|DRUG|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
223550704|NCT03730714|DRUG|"Local Anesthetic, Epinephrine, Morphine and Surgicel"|Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
223550705|NCT03730714|DRUG|"Normal Saline"|normal saline 0.9% to soak the surgicel according to the planned technique
223731343|NCT02029950|DRUG|Idarubicin Hydrochloride|Given IV
223731344|NCT02029950|OTHER|Laboratory Biomarker Analysis|Correlative studies
223550706|NCT06351423|BEHAVIORAL|Forest Bathing (FB)|"The forest bathing (FB) intervention will be comprised of four 2-hour sessions held in a country park on four consecutive weekends during the daytime. The FB sessions will cover 1-2 kilometers per forest visit. Participants will convene at the country park entrance. An FB guide will provide a briefing and commence the forest trip. Following 20 minutes for participants to slow down and share their experiences, they will be invited to mindfully center themselves using their five senses for another 20 minutes. Subsequently, the participants will be afforded 20 minutes to wander along a designated forest path, followed by another 20 minutes during which they will be encouraged to stroll in a designated area to help foster a deep connection with the forest.~Participants will have a 20-minute interval between each activity to share their experiences. A tea ceremony will be held at the end of each FB session."
224017245|NCT00602563|BEHAVIORAL|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
224017246|NCT00602563|BEHAVIORAL|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)
224017247|NCT00602563|BEHAVIORAL|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
224017248|NCT00602563|BEHAVIORAL|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
224017249|NCT06193304|DRUG|Eliglustat|Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion
224017250|NCT02996474|DRUG|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
224128889|NCT06897826|OTHER|Proprioceptive neuromuscular facilitation|The reason for choosing the proprioceptive neuromuscular facilitation technique is that it increases the hip flexion angle more than static stretching. Participants first lay down on the stretcher in a supine position. Then, the participant's lower extremity was lifted straight until the physiotherapist felt resistance. After reaching this position, the participant was asked to try to extend his lower extremity straight with half of his strength. After 10 seconds, the participant was given time to relax and after the participant relaxed, the lower extremity was brought to the new range of motion. This process was applied 3 times.
224128890|NCT06897462|DIETARY_SUPPLEMENT|SRW Ndo1|The investigational product (IP) is a health supplement for glycaemic control. Each capsule contains 80 mg of dahlia4® (Dahlia pinnata extract), 80 mg of Eriomin® (Citrus limon extract), and 100 mg of Mulberry leaf extract (with 5% 1-deoxynojirimycin).
224128891|NCT06898619|BEHAVIORAL|Crisis Management Training for Third-Year Nursing Students|"Crisis management is essential for nurses, who often work on the front lines during emergencies. This training program for third-year nursing students equips them with the skills and knowledge required to handle crises effectively. The program includes nine stages: raising awareness, assessing baseline knowledge, reinforcing foundational concepts, introducing advanced techniques, practicing through simulations, reflecting on learning, providing feedback, summarizing key points, and enhancing learning with additional resources.~Participants explore critical topics such as disaster response, triage, communication strategies, and teamwork. Simulated scenarios help develop practical skills like decision-making and prioritization under pressure. Feedback and reflective discussions reinforce learning, while additional resources encourage ongoing professional growth.~By bridging theoretical knowledge with practical application, the training prepares nursing students to respond confidently t"
224128892|NCT06899347|PROCEDURE|Total Thyroidectomy + Central Compartment Neck Dissection|"Thyroidectomy will be performed with the patient in the supine position with the neck hyperextended. A 3 to 6 cm transverse cervicotomy, two fingers above the sternal notch, will be performed, and the midline will be opened. After the inferior laryngeal nerve and parathyroids are visualized, the thyroidectomy will be achieved.~When performed, pCCND will aim at removing the nodes of Level VI, which has been reported to contain the thyroid gland and the adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the brachiocephalic artery, and laterally on each side by the carotid sheaths"
224128893|NCT07082556|OTHER|US-guided PNM|Stimulation will be applied for 15 minutes at 4 Hz, using a 250 ms pulse duration.
224128894|NCT07082309|DIETARY_SUPPLEMENT|Ketone Monoester (KE) and whey protein beverage|Ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg)
223550707|NCT06351423|BEHAVIORAL|MIND diet|The participants will undertake four three-month nutrition programmes consisting of four nutrition counselling sessions in an activity room at each participating community centre. All intervention sessions will be conducted by a registered nutritionist. In the nutrition sessions, the participants will learn to modify their diet to meet the MIND diet guidelines. The MIND diet promotes 10 healthy food groups and limits five unhealthy food groups (Morris et al., 2015a; Arjmand et al., 2022). As a reference, a 7-day sample menu will be provided which meets the required number of servings per day.
224017251|NCT02996474|DRUG|Decitabine|Will be administered at a dose of 20 mg/m\^2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
224017252|NCT04493502|DRUG|Placebo|Administered IV
224017253|NCT04493502|DRUG|LY3041658|Administered IV
224017254|NCT04277182|BIOLOGICAL|burn wound dressing|"1. st. group: It will be considered as a control group and rats will not be treated.~2. nd. group: Vehicle group, Propolis vehicle will be applied topically to rats for 21 days.~3. rd group: Silver Sulfadiazine group, 1% Silver Sulfadiazine will be applied topically to rats for 21 days.~4. th. group: Nitrafurozon group, 0.2% Nitrafurozon will be applied topically for 21 days.~5. th. group: 10% Propolis group, 10% Propolis will be applied topically for 21 days.~6. th. group: 15% Propolis group, 15% Propolis will be applied topically for 21 days."
223397625|NCT05058404|DRUG|Immunochemotherapy regimen: G-CVP (Arm B)|"Arm B (Experimental arm):~4 cycles of G-CVP Q21 (21-days cycles) G-CVP = Obinutuzumab, Cyclophosphamide, Vincristine, Prednisone.~After cycle 4 patients will undergo an early restaging. Induction therapy shall be completed based on the response achieved and on the treatment chosen as below specified:~* if in CR: patients will receive no more chemotherapy but will complete induction with the Monoclonal Antibody (MoAb) only, in this case: 4 cycles of obinutuzumab;~* if less than CR (PR, SD): the immunochemotherapy program will be completed as outlined for Arm A: 4 cycles of G-CVP Q21~Both Arms: in responding patients (CR, PR) at the end of induction a standard maintenance will follows (1 dose every 8 weeks for 2 years) with the same anti-CD20 MoAb used for induction.~Patients in both arms with progressive disease at any time and patients in SD at the End Of Induction (EOI) shall be considered for salvage therapy at clinician discretion."
223397626|NCT07018180|DEVICE|Use of COVER patchs for continuous glucose monitoring sensor|"The intervention consists of wearing a patch over the continuous glucose monitoring (CGM) sensor typically used by the participant.~The COVER patch is compatible with a wide range of CGM devices on the market, including Freestyle 2 or 3, Dexcom G6/One or G7/One+, and Guardian Sensor 4 or Simplera.~At each sensor change, the participant is required to apply a new COVER PATCH over the CGM sensor. This is done throughout the entire duration of their participation in the study, which lasts for 4 months."
224017255|NCT02379104|DEVICE|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
223397627|NCT05303194|BEHAVIORAL|Patient Priorities Care (PPC) Approach|First, identify patient priorities, and second align care received with those priorities.
223397628|NCT05303194|BEHAVIORAL|Adapted PPC|First, identify patient priorities, and second align care received with those priorities.
223550708|NCT03563755|OTHER|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
223550709|NCT05100771|OTHER|Pediatric brain MRI|Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)
224017256|NCT00377923|DRUG|Progesterone|
224017257|NCT00540046|DEVICE|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
224017258|NCT01269515|DRUG|Etoricoxib|90 mg QD
224017259|NCT02108990|DRUG|Acetaminophen|
224017260|NCT05310851|OTHER|PIOMI and non-nutritive sucking|"PIOMI group; The first three minutes of the five minutes include massages aimed at strengthening the cheeks, lips, gums and tongue; the last two minutes consist of non-feeding suction application.~Infants in the Non-nutritive sucking group will receive pacifier 3 minutes before 1 hour any feeding time and, 2 minutes before 10 minutes."
224017261|NCT04971278|BEHAVIORAL|Supportive care program|Community Health Workers, a home visiting doctor service, a supportive care nurse, and behavioral health specialist engage the population to address a range of biopsychosocial needs with end goal in increasing support in the community and engaging palliative and hospice care when appropriate to prevent hospital readmissions, shorten length of stay, reduce hospital utilization, and decrease overall patient cost with a focus on hospital spend.
224128895|NCT07082309|DIETARY_SUPPLEMENT|Control|Placebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).
224128896|NCT06765707|BEHAVIORAL|Pharmacist delivered symptom monitoring and management|Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.
224128897|NCT07067801|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|Study of the Standard of care versus Placebo
224128898|NCT07067801|DRUG|Placebo|Control
224128899|NCT06809166|DRUG|Contrave|"CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic. Dose recommendation for CONTRAVE® is tablet based, with each tablet containing 8mg of naltrexone and 90mg of bupropion. The maximum recommended daily dose is two tablets, administered orally, twice daily (32mg/360mg), taken once in the morning and once in the evening. Tablets and dispensing schedule will be done under the oversight of The Royal pharmacy (i.e., they will instruct the participants on the dosing schedule).~Medication adherence and side effects will be reported daily using our online data capture system (REDCap) (approximately 1min) starting on the evening of the first dose of administration. If adverse events are significantly concerning, there is a mechanism in place for dealing with such events."
223397629|NCT06303141|OTHER|Closed Chain exercises|"Open eyes and closed eyes across arm (3 sets x 60 sec) Lateral step down (3 sets x 6-12 reps) Semi-Squat Exercise (3sets x 6-12 reps) Thera-band isometric (3 sets x 10 -15sec each)"
223550710|NCT04726930|PROCEDURE|Intercostal nerve blocks|Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.
223550711|NCT04726930|PROCEDURE|Paravertebral block|Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
223550712|NCT02176200|DRUG|Berodual® Respimat®, low inspiratory flow rate|
223550713|NCT02176200|DRUG|Berodual® Respimat®, medium inspiratory flow rate|
223550714|NCT02176200|DRUG|Berodual® Respimat®, high inspiratory flow rate|
224017262|NCT02598024|BEHAVIORAL|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
224296585|NCT03838861|BEHAVIORAL|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
224296586|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + Regenfast + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland) mixed with polynucleotide and hyaluronic acid-based gel (Regenfast®). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
224296587|NCT06633211|PROCEDURE|Alveolar ridge preservation using DBBM + collagen matrix|Post extraction sites be filled up to the level of the highest point of the alveolar bone crest using particulate DBBM xenograft (Bio-Oss, Geistlich Pharma AG, Wolhusen, Switzerland). The alveolus will be sealed with a porcine collagen membrane (Mucograft Seal, Geistlich Pharma AG, Wolhusen, Switzerland) and secured with 4-6 simple interrupted sutures (Resolon 6-0, Resorba Medical GmbH, Nuremberg, Germany).
224296588|NCT04113824|PROCEDURE|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
224296589|NCT04113824|PROCEDURE|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
224296590|NCT02045992|DIETARY_SUPPLEMENT|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
223397630|NCT06303141|OTHER|Neuromuscular Training|"Neuromuscular Training Exercise:~* Single Leg Raise (3 sec x 30sec each)~* Ankle eversion/inversion (3 sets x 25 reps)~* Double Hopping in place then out of place (3 sets 30 sec)~* Reach with feet (3 sets x 30-60 sec each)~* Reach with hands (3 sets x 30-60 sec each)~* Wobble board Exercise (3sets x 30-60sec each"
223550715|NCT02176200|DRUG|Berodual® HFA-MDI, low inspiratory flow rate|
224017263|NCT02598024|BEHAVIORAL|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
224128900|NCT06809166|DRUG|Placebo|"Placebo intervention will follow the exact same protocol in terms of tablet numbers as the CONTRAVE intervention.~Generic Placebo pills will be packaged by The Royal Pharmacy into blister packs identical to Contrave."
224128901|NCT06809166|BEHAVIORAL|Diet Program|All participants will receive an individualized dietary intervention with appropriate energy restriction from registered dietitians at Dr. Shiau's LEAF weight management clinic (called the 4-week BUDS program, which is offered to clients with obesity at the LEAF clinic). The program involves weekly touch points with a registered dietitian, and meal planning/coaching and integrates a partial meal replacement with a commercial shake.
224296591|NCT03783273|DIETARY_SUPPLEMENT|Vitamin D3|Single dose vitamin D3
223397631|NCT06303141|OTHER|Mobilization with Movement|"Joint mobilization with movement (by Mulligan) refers to manual therapy techniques that are used to modulate pain and treat joint dysfunctions that limit the range of motion (ROM).~(3 sets x 6 oscillation/glide each)"
223550716|NCT02176200|DRUG|Berodual® HFA-MDI, medium inspiratory flow rate|
224017264|NCT02891837|DRUG|L-citrulline|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~* Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
224017265|NCT02891837|OTHER|Placebo|"* Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~* Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~* Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~* 9 mg/kg/hr continuous infusion for up to 48 hours."
224017266|NCT00493298|DRUG|Tysabri|According to the local prescribing information
224017267|NCT04184739|OTHER|My Braces App|An App designed to support patients undertaking orthodontic treatment.
224128902|NCT07076966|DEVICE|3D device|Use 3D machine to generate the 3D image
223397632|NCT00491868|DRUG|R744|100μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
223550717|NCT02176200|DRUG|Berodual® HFA-MDI, high inspiratory flow rate|
223550718|NCT00442377|PROCEDURE|exposure to malaria sporozoites|
223550719|NCT02704949|RADIATION|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
224128903|NCT07082478|DEVICE|in-ear device measuring blood flow|"A small in-ear wearable device will be placed to monitor the blood flow to the head. The investigators will make sure it fits comfortably and show the participant how to use it properly.~Dexcom G6 Pro: This continuous glucose monitor (CGM) will be placed under the skin of the abdomen to monitor sensor sugar levels.~These sensors will be placed during visit one and will be worn together for 10 days. A followup visit (visit 2) will occur remotely at 4-6 days later. A final visit will occur after 10 days when the device will be removed."
224128904|NCT07082569|OTHER|Volume Control Ventilation|Standard mode of mechanical ventilation delivering a preset tidal volume. Commonly used in ICU patients requiring controlled ventilation.
224128905|NCT07082569|OTHER|Pressure Control Ventilation|Pressure-targeted ventilation mode that delivers breaths at a fixed pressure. Commonly used in critically ill patients.
224128906|NCT07082569|OTHER|Pressure-Regulated Volume Control (PRVC)|Hybrid ventilation mode that automatically adjusts inspiratory pressure to achieve a preset tidal volume.
224128907|NCT07083882|BIOLOGICAL|freezedried autologous encapsulated fecal microbiota transplantation|The freezedried autologous encapsulated microbiota transplantation increases the exposure of the small intestine to the microbiota residing in the colon. Prior evidence was found that this has strong immunomodulatory effects leading to potential preservation of beta cell function in type 1 diabetes.
224128908|NCT07083882|OTHER|placebo matching capsule without microbial content|this is the matching placebo capsule that looks from the outside identical to the actual treatment but does not contain the fecal microbiota.
224128909|NCT07082517|OTHER|Percentage analysis|Analysis the percentage of the population with risk factors that may lead to a PAD.
224128910|NCT07084584|DRUG|GB3226|GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles
224128911|NCT07083141|OTHER|Peer Mentoring Program|A 13-week peer mentoring program in which trained third-year midwifery students supported first-year students through regular meetings aimed at enhancing academic adaptation, confidence, and professional understanding.
224128912|NCT07083323|DRUG|HY05350 for injection|HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
224128913|NCT07083323|DRUG|HY05350 for injection|HY05350 should be administered intravenously at recommended dose, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.
224128914|NCT07084623|DRUG|Pre-procedure lignocaine spray (PPL)|Administration of 2 mL of 4% lignocaine spray in the oropharynx before the fiberoptic bronchoscopy procedure, followed by additional 2% lignocaine spray according to body weight (3 mg/kg)
224128915|NCT07084623|DRUG|Lignocaine Spray (Spray-as-you-go)|Administration of 2% lignocaine spray via oral scope insertion during the fiberoptic bronchoscopy procedure, according to body weight (3 mg/kg), with standard procedural sedation with midazolam and initial 2 mL of 4% lignocaine spray in the oropharynx for gag reflex suppression
224128916|NCT07083908|DEVICE|THD® Anopress (Sensyprobe) first|Anorectal manometry with THD® Anopress (Sensyprobe) first then with High Resolution Anorectal Manometry (Laborie)
223397633|NCT00491868|DRUG|R744|150μg/4week for 8 weeks, then 50\~250μg/4week for 16 weeks
223397634|NCT00491868|DRUG|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
223397635|NCT00491868|DRUG|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750\~9000IU(i.v.)/1\~3week for 16 weeks
223397636|NCT00491868|DRUG|R744 placebo|0 μg/4week for 24 weeks
223397637|NCT00491868|DRUG|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1\~3 times/week for 16 weeks
224128917|NCT07083908|DEVICE|High Resolution Anorectal Manometry first|Anorectal manometry with High Resolution Anorectal Manometry (Laborie) first followed by THD® Anopress (Sensyprobe)
224128918|NCT07082712|OTHER|Thyroid profile|Thyroid profile in patients with acute coronary syndrome within 24 hour from admission
224128919|NCT07082621|DRUG|N-acetylcysteine (NAC) spray|N-acetylcysteine (NAC) mucoadhesive nanoparticles in the form of spray 3 times daily for 6 weeks
224128920|NCT07082621|DRUG|Conventional treatment|"topical anesthetics agents (BBC \[Benzocaine, Benzydamine, and Cetalkonium chloride\] oral spray - oracure gel), topical antifungal agents (Miconaz oral gel)\*, sodium bicarbonate mouth wash (Alkamsir sachets), ice chip,s and anti-inflammatory mouth wash.~(Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology \[MASCC/ISSO\] guidelines) 3 times daily for 6 weeks."
224128921|NCT07082192|DRUG|Test drug CB03-154 5mg group|One CB03-154 tablet (5mg/tablet) once daily.
224128922|NCT07082192|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
224128923|NCT07082192|DRUG|Test drug CB03-154 15mg group|Three CB03-154 tablets (5mg/tablet) once daily.
224128924|NCT07082192|DRUG|Placebo Group|Three Placebo tablets once daily.
224128925|NCT07083102|OTHER|Experimental|"* Eligible participants will be randomly assigned to one of the following groups using a computer-generated sequence with allocation concealment via sealed opaque envelopes:~  * Group A: Control group~ * Group B: Full-coverage PFM crowns~ * Group C: Full-coverage Zirconia crowns~* Baseline gingival samples will be collected with the help of sterile swab from the target tooth region prior to prosthesis placement and at the follow-up visits i.e. 1, and 3 months; both for experimental groups and control group.~* Microbial analysis will be conducted through culture techniques to quantify CFUs and identify species.~* Alongside, the same sample from sterile swabs will be smeared by fixating it on a microscopic slide and then Candida albicans will be stained by Periodic Acid Schiff technique, and the bacterial species using Gram staining."
224128926|NCT07083986|PROCEDURE|Carotid Artery Stent Placement|Carotid Artery Stent Placement was performed according to the standard technique.
224128927|NCT07083986|PROCEDURE|carotid endarterectomy|Carotid endarterectomy with stenting was performed according to the standard technique. For the purpose of the greatest comparability in the volume of anesthesia, it was decided to use regional anesthesia in all cases, including adequate dynamic observation of neurological status.
224296592|NCT03783273|COMBINATION_PRODUCT|Whey protein-complex|Whey protein complex-bound vitamin D3
224296593|NCT03783273|OTHER|Water|500 mL water
224296594|NCT03783273|OTHER|Milk|500 mL milk
224296595|NCT03783273|OTHER|Juice|500 mL juice
224017268|NCT03037073|DRUG|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
224128928|NCT07083674|BEHAVIORAL|Multi-level communication intervention|The intervention will target multiple levels (provider, unit, hospital) and will respond to identified modifiable communication challenges. Aim 2 intervention mapping will finalize the specific intervention; we anticipate it will involve training and education of staff members and new unit protocols for communication.
224017269|NCT03037073|DRUG|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
224128929|NCT07084116|DRUG|Tretinoin 0.1% cream|Tretinoin 0.1% cream formulation.
224128930|NCT07084116|DRUG|Bland cream (non-drug)|Bland cream formulation.
224128931|NCT07083466|DIAGNOSTIC_TEST|complete blood count|blood test
224296596|NCT05649241|DRUG|Nicotine patch|Nicotine replacement therapy patch
224296597|NCT05649241|DRUG|Nicotine gum|Nicotine replacement therapy gum
223397638|NCT07027072|DRUG|KDS2010|KDS2010 will be administered orally once daily, two tablets per day, for 24 weeks. Dosage will be either 60 mg or 120 mg depending on the assigned group.
223397639|NCT07027072|DRUG|Placebo|Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, two tablets per day, for 24 weeks.
224017270|NCT04662099|BIOLOGICAL|Conditioning chemotherapy followed by CAR T cell infusion|Conditioning chemotherapy: Cyclophosphamide 250 mg/m\^2 and fludarabine 30 mg/m\^2 IV infusion on days -5, -4, and -3 CAR T cells infusion: 0.75x10\^6-3.0X10\^6 CAR+ T cells per kg of recipient bodyweight. if DLTs don't occur at the dose of 3.0X10\^6 CAR+ T cells per kg, the investigators will discuss whether to try higher dose.
224017271|NCT01588431|DRUG|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
224017272|NCT04881981|RADIATION|SCART radiation therapy|We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
223397640|NCT01289678|DRUG|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
224017273|NCT02632526|DRUG|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
224017274|NCT02632526|DRUG|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
224017275|NCT02632526|DRUG|AZD5718 placebo oral suspension|Single and multiple doses
224017276|NCT02632526|DRUG|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
224017277|NCT06470061|DRUG|Resveratrol, Quercetin, and Curcumin (RQC)|"2000 mg Curcumin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~334 mg Resveratrol/day, taken twice daily for 24 months (galactomannan formulation, capsule form)~60 mg Quercetin/day, taken twice daily for 24 months (galactomannan formulation, capsule form)"
224128932|NCT07083466|DIAGNOSTIC_TEST|serum albumin|blood test
223397641|NCT06137235|OTHER|cows milk infant formula and follow-on formula with bioactive ingredients|infant formula and follow-on formula with bioactive ingredients
223397642|NCT06137235|OTHER|standard cows milk infant formula and follow-on formula|standard cows milk infant formula and follow-on formula
223397643|NCT06878170|BIOLOGICAL|RBM-001|To evaluate the safety and tolerability of the RBM-001 vaccination in healthy adults.
223550720|NCT02704949|RADIATION|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
223550721|NCT00843258|DEVICE|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
223550722|NCT01294137|DEVICE|ventilatory polygraphy|
223731345|NCT02029950|OTHER|Pharmacological Study|Correlative studies
223731346|NCT02029950|DRUG|Pomalidomide|Given PO
224128933|NCT07084636|OTHER|Video Laryngeal Mask|Video laryngeal mask will be used in this group
224128934|NCT07084636|OTHER|Endotracheal intubation|Endotracheal intubation will be performed in this group.
224128935|NCT07083622|DIETARY_SUPPLEMENT|Vitamin C|The patients received vitamin C supplementation
224128936|NCT07083622|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
224128937|NCT07083128|DEVICE|Parasternal intercostal thickening|Temporal change in parasternal intercostal thickening fraction at initiation and 30 minutes of spontaneous breathing trial
224128938|NCT07082907|OTHER|intervention group|Before using the nebulizer, children were given 2 fish in a bowl accompanied by their parents. The child patient was in the fowler/semifowler position, the movements of the fish were monitored during the nebulization period, and the fish was fed by the child during this process (Communication was provided for at least 5 minutes.)
224128939|NCT07074704|DEVICE|Hi-tACS|Sham tACS intervention (0 mA) Twice a day, 40 min each time, for 10 days tACS intervention (15 mA) Twice a day, 40 minutes each time, for 10 days
224128940|NCT07074704|DEVICE|Sham Comparison|Sham tACS intervention (0 mA) Twice a day, 40 min each time, for 10 days tACS intervention (15 mA) Twice a day, 40 minutes each time, for 10 days
224128941|NCT07083921|DEVICE|plantar pressure|Healthy individuals carry loads with their dominant and non-dominant hands.
224296598|NCT05649241|BEHAVIORAL|Medication Therapy Management|Medication therapy management delivered by pharmacist - 1 in-person coaching session, and 5 follow-up telephonic coaching sessions.
224296599|NCT02452541|OTHER|Prognostic tests|"* Brain CT-Scan on day 1, 3 and 7~* Brain MRI on day 7~* SomatoSensory Evoked Potentials on day 7~* Electroencephalogram on day 7~* Serum biomarkers on day 1, 3 and 7~* Daily clinical exams"
224296600|NCT01097941|BIOLOGICAL|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
224017278|NCT06470061|DRUG|Curcumin|2000 mg Curcumin/day, taken twice daily for 7 days preceding each study visit (baseline and months 3, 6, 12, 18, and 24 for a total of 42 non-consecutive days over 24 months.
224017279|NCT04498338|OTHER|Neural mobilization combined with conventional physical therapy program|Neural mobilization of sciatic nerve combined with TENs and exercise program applied 3 times/week for successive 6 weeks.
224017280|NCT04498338|OTHER|Conventional physical therapy program|TENs and exercise program applied 3 times/week for successive 6 weeks.
224017281|NCT06315504|OTHER|Observation|Observation
224017282|NCT03500601|OTHER|Nut components|nut components consumed daily for a period of 28 days
224128942|NCT07083037|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE; DBT + Parenting)|The BRIDGE intervention includes 12 weeks of 20-60-minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use).
224128943|NCT07083973|BEHAVIORAL|Prone position|"Patients were ventilated based on the ARDS-Net recommendations . Patients were kept in a supine position. The process of lung ventilation and perfusion assessment was as follows:~1. PEEP was determined by the attending doctor and was kept the same during the supine and prone period.~2. 3D-EIT was used to monitor the ventilation and perfusion of ARDS patients at three timepoints: T1: supine position, T2: prone position at 30min, T3: prone position over 10 hours."
224296601|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
224296602|NCT01097941|BIOLOGICAL|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
224296603|NCT00937378|DRUG|SER120|Nasal Spray, once a day
223397644|NCT07036081|DIETARY_SUPPLEMENT|Wilbo's Blends+|"A new feeding plan will be developed by the study dietitians. Participants will be transitioned from their current enteral feeding plan to incorporate Wilbo's Blends+. In this new plan Wilbo's Blends+ can provide up to 100% but not lower than 30% of their total daily calorie requirements depending on participant's individual clinical needs, as assessed by the study dietitian.~All participants will be on at least 30% Wilbo's Blends+ for at least 7 days.~If required clinically there is the option to transition participants onto Wilbo's Blends+ over 1-6 days, for children who are deemed particularly sensitive to change in their feeding plan.~Participants or their families/carers will complete an electronic workbook consisting of:~* GI tolerance records for 7 days whilst receiving Wilbo's Blends+~* Compliance records for 7 days whilst receiving Wilbo's Blends+~* Ease of use and palatability questionnaire at the end of the study intervention (after last administration of Wilbo's Blends+"
223397645|NCT07038473|PROCEDURE|Investigational Procedure|"It consists of prospective blood sample collection from children, adolescents and first-degree relatives of T1D probands.~Study without any Investigational Medicinal Product (IMP) administration."
223397646|NCT02996656|DRUG|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
223397647|NCT02996656|DRUG|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
223397648|NCT01132729|DRUG|Valacyclovir Hydrochloride|1000 mg caplet
223397649|NCT07040319|DRUG|Glecaprevir/pibrentasvir|100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg
223397650|NCT06705829|BIOLOGICAL|Prothrombin|"Comparison of prothrombin time results obtained with the different thromboplastins reagent for subgroup (extrinsic pathway factor and for those with hepatocellular insufficiency) by a regression line and a Bland-Altman representation.~Comparison of extrinsic pathway factor assays obtained with the different thromboplastins reagent for each subgroup by a regression line and a Bland-Altman representation.~Evaluation and determination of the sensitivity of the prothrombin time according to the activity rate obtained for each factor (for each reagent)."
223397651|NCT06724549|DRUG|BN104|This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
223550723|NCT05597540|DRUG|Short antibiotic treatment|7 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
223550724|NCT05597540|DRUG|Usual antibiotic treatment|14 day-duration antibiotic treatment. The choice of antibiotic treatment is left to the medical team in charge of the patient.
223550725|NCT02595866|DRUG|Antiretroviral Therapy|Given PO
223550726|NCT02595866|PROCEDURE|Biopsy|Undergo biopsy
223550727|NCT02595866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224017283|NCT03500601|OTHER|Placebo|Placebo consumed daily for a period of 28 days
224017284|NCT01976117|DEVICE|enose|
224017285|NCT01986673|DRUG|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
224017286|NCT01986673|DRUG|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
224017287|NCT01060579|DRUG|AR-12286 0.5% ophthalmic solution|q.d. PM
224017288|NCT01060579|DRUG|AR-12286 0.25% Ophthalmic solution|q.d. PM
224017289|NCT01060579|DRUG|Latanoprost ophthalmic solution|q.d. PM
224017290|NCT02816944|PROCEDURE|EUS-guided laser ablation for refractory neoplasms|
224017291|NCT04659941|BIOLOGICAL|BCG vaccine|Using aseptic methods, 1 mL of Sterile Water for Injection, is added to one vial of vaccine. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Drop the immunizing dose of 0.1 mL of BCG VACCINE from the syringe and needle onto the cleansed surface of the skin.
224017292|NCT04659941|BIOLOGICAL|0.9% sodium chloride (NaCl) saline solution|A 0.1 ml of 0.9% NaCl saline solution applied intradermally in the lower insertion of the deltoid muscle of the right arm will be used as placebo, except contraindications or impossibilities.
224017293|NCT04318847|DRUG|Ondansetron 4 MG|Administration of ondansetron 4 mg or 8 mg according to weight
224017294|NCT02120742|BEHAVIORAL|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
224296604|NCT00937378|DRUG|Placebo|Nasal Spray
223397652|NCT07042529|PROCEDURE|OptEx-TAVI|"During TAVI with either self-expanding or balloon-expandable TAVs:~* Pre-dilatation: systematic pre-dilatation with an optimally-sized balloon.~* Post-dilatation: systematic TAV post-dilatation with an optimally-sized balloon.~Optimally-sized balloon:~1. The recommended balloon size used for pre- and post-dilatation is the perimeter-derived mean diameter of the native aortic annulus minus 1 mm and should never exceed the perimeter-derived mean diameter of the native aortic annulus. A smaller-sized balloon should be considered in case of severe left ventricular outflow tract calcium and/or severely calcified leaflets in combination with a shallow sinus of Valsalva.~2. In case of post-dilatation of the Evolut TAV (Medtronic, USA), the instructions for use (IFU) for post-dilatation of the Evolut valve should be respected.~3. Also, a balloon-expandable TAV has to be post-dilated with an optimally-sized balloon in case of randomization to the OptEx-TAVI arm."
224128944|NCT07083375|DRUG|QL1706 , bevacizumab, etoposide , cisplatin or carboplatin|Participants will receive QL1706 (5 mg/kg, IV, day 1), bevacizumab (7.5 mg/kg, IV, day 1), etoposide (100 mg/m², IV, days 1-3), plus either cisplatin (75 mg/m² split over days 1-2, IV) or carboplatin (AUC=5, IV, day 1) every 21 days for 4-6 cycles. Dose adjustments may be made based on clinical judgment. Patients who do not experience disease progression or intolerable toxicity will proceed to maintenance therapy with QL1706 (5 mg/kg, IV, day 1) and bevacizumab (7.5 mg/kg, IV, day 1) every 21 days, continued until disease progression, unacceptable toxicity, consent withdrawal, investigator decision, loss to follow-up, death, or other protocol-defined criteria. All participants will receive dual-agent maintenance therapy.
224128945|NCT06929897|PROCEDURE|Pulmonary Vein Isolation|"1. Pulmonary vein isolation (PVI) is performed as the primary procedure.~2. After PVI, direct current (DC) cardioversion is performed to restore normal sinus rhythm. If the patient converts to sinus rhythm, they are randomly assigned to either the PVI-only group or the additional left atrial posterior wall ablation group.~3. Patients who fail to convert to sinus rhythm after DC cardioversion are excluded from randomization."
224128946|NCT06929897|PROCEDURE|Additional Left Atrial Posterior Wall Ablation|"1. Additional left atrial posterior wall ablation is performed.~2. Complete electrical isolation of the entire left atrial posterior wall is confirmed (posterior box lesion isolation must be achieved).~3. Post-procedural rhythm monitoring follows the study protocol."
224128947|NCT06929897|PROCEDURE|Non-PV trigger test|"1. If atrial fibrillation triggers are identified with isoproterenol infusion, additional focal ablation is performed.~2. Post-procedural rhythm monitoring follows the study protocol."
224128948|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), active condition|Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
224128949|NCT06140940|PROCEDURE|High-definition transcranial direct current (HD-tDCS), sham condition|"Participants will receive a session of sham HD-tDCS, which will be delivered following the same procedures as active HD-tDCS but the intensity of the current will be set at 4mA during the 30 first seconds at the beginning of the 15-min period of the stimulation, and equal to 0 mA for the reminding period of stimulation to simulate the tingling sensation often experienced by individuals during active stimulation.~The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task)."
224128950|NCT07082205|BIOLOGICAL|Antimalarial monoclonal antibodies|L9LS Antimalarial monoclonal antibodies (mMAbs)
224017295|NCT02751320|DRUG|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
224017296|NCT02751320|DRUG|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
224128951|NCT07082205|DRUG|Dihydroartemisinin - Piperaquine (DP)|Post-Discharge Malaria Chemoprevention
223550728|NCT02595866|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223550729|NCT02595866|BIOLOGICAL|Pembrolizumab|Given IV
223550730|NCT02595866|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223550731|NCT03439644|OTHER|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
223550732|NCT01074476|DIETARY_SUPPLEMENT|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
224017297|NCT02751320|DRUG|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
224017298|NCT02751320|OTHER|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
224017299|NCT02751320|DRUG|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
224017300|NCT02751320|DRUG|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
224017301|NCT01021215|DRUG|Zileuton|1200 mg twice daily given orally (PO) for 6 days
224128952|NCT07082205|BIOLOGICAL|Placebo mMAB|Placebo anti malarial monoclonal antibody (placebo mMAB) which is Normal saline
224128953|NCT07082205|DRUG|Placebo PDMC|Placebo PDMC course which comprises placebo DP oral tablets
224128954|NCT03042013|DRUG|ASP8273|Oral
224128955|NCT07083388|DRUG|Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg|Orally administered once per day
224128956|NCT07083388|DRUG|Dapagliflozin 10 mg|Orally administered once per day
224128957|NCT07083388|DRUG|Pioglitazone 30 mg|Orally administered once per day
224128958|NCT07083388|DRUG|Metformin HCl 1000 mg|Orally administered once per day
224128959|NCT04315649|OTHER|3D movie viewing|3D movie viewing
224128960|NCT07082933|OTHER|Standard medical treatment|Standard medical treatment
224128961|NCT06825884|BIOLOGICAL|Extracellular micro vesicles (EV)|Extracellular micro vesicles (EV) as direct perilesional injection into the diabetic chronic foot ulcers (DFU) which have not healed after using standard of care.
224128962|NCT07083180|OTHER|Recreative activity|Patients practice a leisure activity before surgery (20 minutes)
224128963|NCT07083180|OTHER|Medical Hypnosis by virtual reality|Patients benefit from a medical hypnosis session using virtual reality (20 minutes)
224128964|NCT07083934|DEVICE|Peripheral nerve stimulator|Peripheral nerve stimulator along with ultrasound
224017302|NCT01021215|DRUG|Celecoxib|200 mg twice daily given orally for 6 days
224017303|NCT01021215|OTHER|laboratory biomarker analysis|Correlative studies
224128965|NCT07083934|DEVICE|No peripheral nerve stimulator|No peripheral nerve stimulator with ultrasound. Only ultrasound will be used
224128966|NCT07084259|DRUG|PCSK9 inhibitor|Single dose of subcutaneous administration of PCSK9 inhibitors (evolocumab) after PCI in patients with coronary artery disease and elevated post-PCI lipid core burden (maxLCBI4mm ≥ 200).
224128967|NCT07084259|DRUG|Standard Lipid-Lowering Therapy|Lipid-lowering therapy with high-intensity or maximally tolerated statins with or without ezetimibe, as per current clinical guidelines, excluding the use of PCSK9 inhibitors.
224128968|NCT07082881|OTHER|Colostrum|The treatment group will undergo the following treatment protocol within the initial 48-72 h: Investigators will select storage bags with the closest lactation time to the current time while wearing sterile gloves for the entire procedure. Next, using two 1-mL sterile syringes, investigators will draw 0.1 mL of colostrum from each bag and tightly cap the needle hubs to ensure hygiene and safety. Each syringe will be labeled with the hospitalization number, the infant's name, and the date of the mother's colostrum expression. The bags will be then left to sit at room temperature for 5 min to reach an appropriate temperature for oropharyngeal administration of the colostrum. Subsequently, the tip and cap of the first syringe will be removed, and the colostrum will be slowly injected along the right oral mucosa of the participants, lasting at least 20 s. After injection, a sterile cotton swab will be used to gently wipe the right buccal mucosa for at least 10 s.
224128969|NCT07082881|OTHER|Normal Saline|For the control group, normal saline will be used instead of colostrum. The rest of the procedure will be the same as that for the treatment group.
224128970|NCT07082296|BEHAVIORAL|iCBT-Academia|iCBT-Academia is a brief, self-guided, internet-based cognitive behavioral therapy (iCBT) program specifically tailored to address the real-life challenges faced by the university and research community. It consists of four modules, each designed to be completed over a week.
224128971|NCT07082348|BEHAVIORAL|Herbs and Spices Nutrition Education Program|Participants will attend two group visits at the UNLV Nutrition Center (weeks 0 and 3 of the 6-week intervention), where trained RDs will deliver the HSNP, covering the principles and health benefits of the Dietary Guidelines for Americans (DGA), recommended food group intake, and practical, budget-friendly strategies for incorporating herbs and spices into the diet. Sessions will include education, supporting materials, and a sensory evaluation of 20 foods (spanning fruits, vegetables, grains, dairy, and proteins) prepared with various herbs and spices, rated using a 9-point hedonic scale to identify preferred flavor profiles and promote long-term DGA adherence through enhanced taste and acceptability.
224128972|NCT07083557|OTHER|Endothelial cell collection|Participants may opt to have testing performed including blood sampling, urine sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS, having adipose (fat) or muscle biopsies, or non-invasive endothelial function testing to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
224128973|NCT07083544|BEHAVIORAL|Written Sleep Hygiene Strategies (W-SHS)|Participants assigned to the W-SHS group received a printed handout containing general sleep hygiene strategies. These strategies were designed to improve sleep quality and included recommendations on maintaining a consistent sleep-wake schedule, minimizing light exposure before bedtime, avoiding screens and heavy meals in the evening, optimizing the sleep environment (e.g., room temperature, noise), and managing nap timing. Participants were instructed to apply these strategies consistently for 10 consecutive days. No individual guidance was provided.
224128974|NCT07083544|BEHAVIORAL|Verbal Sleep Hygiene Strategies (V-SHS)|Participants in the V-SHS group received the same general sleep hygiene strategies as the W-SHS group, but delivered through a one-on-one verbal education session. A trained researcher in sleep and sport science conducted a 40-minute session with each athlete, explaining each strategy and offering personalized clarifications and suggestions. Participants were then instructed to implement these strategies over a 10-day period.
223397653|NCT07042529|PROCEDURE|SoC-TAVI|During TAVI with either self-expanding or balloon-expandable TAVs: Pre-dilatation: optional, as per operator preference and post-dilatation: optional, as per operator preference. Operators are only encouraged to post-dilate the implanted TAV in case of ≥ moderate paravalvular regurgitation or a suboptimal transvalvular gradient. The balloon size used for pre- or post-dilatation is left at the operator's discretion.
224128975|NCT07083401|DRUG|Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg|Orally administered once per day
223397654|NCT00450593|GENETIC|gene expression analysis|
224128976|NCT07083401|DRUG|Dapagliflozin 10 mg|Orally administered once per day
224128977|NCT07083401|DRUG|Pioglitazone 30 mg|Orally administered once per day
224128978|NCT07083401|DRUG|Metformin HCl 1000 mg|Orally administered once per day
224128979|NCT07083089|OTHER|Thorough Hearing assessment|Otoscopy Tympanometry Tonal audiometry (air and bone conduction) Vocal audiometry (in silence and in noise) Distorsion Products of OtoAcoustic Emissions (DPOAE) Middle Ear Muscle Reflex (MEMR) Auditory Brainstem Response (ABR) Electrocochleography (EcochG)
223397655|NCT00450593|GENETIC|microarray analysis|
223397656|NCT00450593|GENETIC|molecular genetic technique|
223397657|NCT00450593|GENETIC|mutation analysis|
224017304|NCT01994655|OTHER|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
224017305|NCT01994655|OTHER|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
223397658|NCT00450593|OTHER|laboratory biomarker analysis|
223397659|NCT00450593|PROCEDURE|mutation carrier screening|
223397660|NCT00450593|PROCEDURE|study of high risk factors|
223550733|NCT01074476|OTHER|Placebo|Placebo tablets, twice per day for 3 months
224017306|NCT04110639|DEVICE|Intracranial pressure (ICP) monitor|The investigators' hypothesis is that by utilizing an intracranial pressure (ICP) monitor to detect the presence or absence of waveforms in the femoral head, investigators could reliably assess the perfusion levels within the femoral head and possibly reduce the incidence of osteonecrosis.
224017307|NCT04110639|OTHER|Standard of Care|10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
224017308|NCT02549196|DRUG|Donepezil|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
223397661|NCT07044323|BEHAVIORAL|Active Virtual Reality Treatment|The self-administered active VR treatment will consist of 8 twice-weekly sessions, each approximately 1 hour in duration, during which subjects will participate in a variety of Virtual Reality active games that require leg movements while receiving high-quality visual feedback of the missing lower leg.
224017309|NCT02549196|DRUG|Solifenacin|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
224017310|NCT04867928|DRUG|Venetoclax+azacitidine|subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
224017311|NCT03860701|PROCEDURE|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
224017312|NCT06375447|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for insomnia.
224017313|NCT03096704|DIAGNOSTIC_TEST|vitamine d dosage|dosage of vitamine D in slow transit time constipation
224017314|NCT02679027|OTHER|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
224017315|NCT02679027|OTHER|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
223397662|NCT05247125|COMBINATION_PRODUCT|Blue light exposure + Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed. Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
223397663|NCT05247125|DRUG|Melatonin treatment|3 mg Melatonin pill will be given 1 hour before going to bed.
223397664|NCT05247125|DEVICE|Blue light exposure|Blue light exposure will be performed during 30-minute sessions with the use of the lamps (Lumie/Vitamin L) in the morning.
223397665|NCT05247125|COMBINATION_PRODUCT|Placebo|Placebo light exposure will be performed by using lamp turned off; and placebo pill will be given in the evening
223397666|NCT07047183|DRUG|VEN (Venetoclax)|Enrolled patients will receive: Venetoclax: 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Days 3-14. Azacitidine: 75 mg/m² on Days 1-7. Cycle duration: 28 days Total cycles: 1 to 2 cycles
223397667|NCT05369754|BIOLOGICAL|YBSW015 injection|Prepared YBSW015 injection is intravenously injected by an infusion pump or gravity infusion with intravenous infusion of 250 mL for 60 min±10 min.
224017316|NCT00410943|DRUG|OROS Hydromorphone HCI SR (slow release)|
223397668|NCT04952961|BEHAVIORAL|Training in Vulval Self-Examination|Face-to-face training in vulval self-examination Supplemented with use of aids ( hand mirror, mobile phone with selfie-stick), patient information leaflet, reminders to self-examine
223550734|NCT00811291|DIETARY_SUPPLEMENT|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
223550735|NCT00811291|DIETARY_SUPPLEMENT|calcium|according to protocol
223550736|NCT00000553|DRUG|simvastatin|
223550737|NCT00000553|DRUG|niacin|
224017317|NCT04579289|OTHER|questionnaire|"A questionnaire was e-mailed to all identified institutions, with 3 reminders in one month. It included 39 questions concerning :~* morbidity and mortality linked with COVID-19~* structural features of the facility (location, architecture, residents characteristics)~* human resources~* crisis management (visits and circulation restrictions, personal protective equipment)"
224017318|NCT03896412|OTHER|Detecton of circulating tumor DNA|7 blood samples to design a molecular probe
224017319|NCT01244854|BEHAVIORAL|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
224128980|NCT05185882|OTHER|Single leg squat|Single leg squat exercise in different circumstances
224128981|NCT07082426|DEVICE|Balloon expandable TAVI|Prospective, single-arm, multi-center early experience study.
223397669|NCT04030299|DEVICE|Over-the-counter fitting|In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
223397670|NCT06725030|DEVICE|Symani Surgical System|The Symani Surgical System (Symani) is designed for open microsurgery procedures, featuring articulated and interchangeable instruments.
223397671|NCT06715592|DRUG|Bleomicina|Colposcopically guided ECT following intralesional administration / intravenous Bleomycin or intralesional Cisplatin according to ESOPE recommendations. Reassessment after 30 days by colposcopy and conization with acquisition of histological examination.
223550738|NCT00000553|DRUG|antioxidants|
223550739|NCT04153695|OTHER|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
223550740|NCT02520388|DRUG|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
223397672|NCT07049536|OTHER|Assessment Group|Allogeneic Stem Cell Transplant recipients will be evaluated with a supervisor physiotherapist for 2 days between the time they are admitted to the stem cell transplantation unit.
223550741|NCT02520388|DRUG|Placebo|
223550742|NCT04839250|PROCEDURE|heads-up method|3D surgical video system, which includes Alcon NGENUITY 3D visualization system (Alcon, Fort Worth, TX) and Leica M822 and M844 microscopes (Leica Microsystems, Wetzlar, Germany),can be used to perform head-up phacoemulsification combined with intraocular lens implantation surgery.
223550743|NCT01480726|PROCEDURE|Surgery|
223550744|NCT06220877|PROCEDURE|Buccal Pad of Fat|surgical procedure
223550745|NCT06220877|PROCEDURE|A-PRF|blood sample
223550746|NCT06220877|PROCEDURE|fibrin glue|procedure
223550747|NCT06220877|PROCEDURE|oxidized cellulose|procedure
224017320|NCT06211881|DRUG|Chi-GVM|"Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle."
224017321|NCT03505541|BIOLOGICAL|Adiponectin and TNFa|Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
224017322|NCT00283127|PROCEDURE|Home sampling (urine test) for uro-genital C.trachomatis.|
224017323|NCT03994289|BEHAVIORAL|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
224017324|NCT03994289|BEHAVIORAL|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
224017325|NCT01010191|OTHER|Sugar pill|
224017326|NCT04496492|DRUG|Tocotrienol|Tocotrienol 200 mg orally twice a day
224017327|NCT00185965|DRUG|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
224017328|NCT03954392|BEHAVIORAL|Cognitive behavior therapy with social cognitive training (CBT+SCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, the investigators will teach the teen explicitly about theory of mind and social perspective taking during each session and we will use examples from their own life to help them learn the skills.
224017329|NCT03954392|BEHAVIORAL|CBT-only|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. The investigators will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents.
224017330|NCT01103362|DRUG|flibanserin|all patients will receive open-label flibanserin 100mg
224017331|NCT02093091|PROCEDURE|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
223397673|NCT07049536|OTHER|Control Group|Adult healthy group with similar sociodemographic characteristics to the evaluation group.
223397674|NCT03765983|DRUG|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
223397675|NCT03765983|DRUG|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
223397676|NCT00218595|BEHAVIORAL|DBT|Dialectical behavior therapy plus opiate replacement medication.
223550748|NCT01176617|DEVICE|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
224017332|NCT02093091|PROCEDURE|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
224017333|NCT00254631|DRUG|Oxycodone hydrochloride|
224017334|NCT04132531|PROCEDURE|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
224017335|NCT04611321|DRUG|IBI318|IBI318 will be given fixed dose via intravenous (IV) infusion on Day 1 of each 14-day cycle until disease progression or loss of clinical benefit.
224017336|NCT02533531|DEVICE|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
224128982|NCT06930404|OTHER|facial scans, videos and heart rate variability measurements|Ignite app to collect data (videos, photos and heart rate variability)
224128983|NCT00992446|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
223397677|NCT00218595|BEHAVIORAL|I/GDC|Individual and group drug counseling plus opiate replacement medication.
223397678|NCT05771077|DRUG|Poly(Amidoamine) dendrimer|to evaluate the Remineralizing effect of Poly Amido Amine Dendrimer, Nanohydroxy apatite \& Their Combination on demineralized enamel \& Their Clinical Efficacy on White Spot lesion
223397679|NCT06743009|OTHER|N-lactoyl-phenylalanine|Intravenous infusion of N-lactoyl-phenylalanine (Lac-Phe)
223397680|NCT06743009|OTHER|NaCl|0.9% isotonic NaCl infusion
223397681|NCT06893965|DIAGNOSTIC_TEST|Intra ocular pressure Measure|Measurement of IOP before injection (T0), just after the injection (T1) then 15 (T15), 30 (T30) and 45 (T45) minutes after the injection. Measurement are done with Perkins Tonometer
223397682|NCT03719027|DIAGNOSTIC_TEST|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
223397683|NCT03482973|DRUG|Bupivacaine Group|20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
223550749|NCT03305952|BEHAVIORAL|CBCT|
224128984|NCT00992446|DRUG|Bortezomib|Given IV
224128985|NCT00992446|DRUG|Carmustine|Given IV
224128986|NCT00992446|DRUG|Cytarabine|Given IV
224128987|NCT00992446|DRUG|Etoposide|Given IV
223550750|NCT03305952|OTHER|TAU|
223397684|NCT03482973|OTHER|Placebo|20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
224017337|NCT00648154|DRUG|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
224017338|NCT00648154|DRUG|Femara® Tablets 2.5 mg|2.5mg, single dose fed
224017339|NCT01423721|DRUG|Bromihexine hydrochloride syrup|syrup
224017340|NCT01423721|DRUG|Bromihexine hydrochloride granules|granules
224017341|NCT02002793|OTHER|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
224017342|NCT02002793|OTHER|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
224017343|NCT02195154|DRUG|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
224017344|NCT02567773|DRUG|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
224017345|NCT02567773|DRUG|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
224017346|NCT02567773|DRUG|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
223397685|NCT05008874|OTHER|Natural History Observation|Data collection on progression of disease
223397686|NCT01553669|BEHAVIORAL|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
223397687|NCT02452437|DRUG|Oxycodone|Controlled release oxycodone 40 mg twice daily
223397688|NCT03196336|OTHER|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
223397689|NCT03626038|DEVICE|A.L.P.S. Proximal Humerus Plating System|Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
223397690|NCT07061899|DIAGNOSTIC_TEST|Anal swap for Chlamydia and Gonorrhoea|"If inflammation is observed on endoscopy up to 35 cm from the anal opening, a swab will be taken during the procedure to test for Chlamydia and Gonorrhoea using standard PCR techniques. If the swab is not taken during the endoscopy, it will be collected during a follow-up outpatient visit. The tests will be analysed immediately at the Department of Microbiology, Aarhus University Hospital.~If positve, the patient will be offered treatment at the department of Venerological diseases."
223397691|NCT01943383|GENETIC|iPSC|Single blood draw for the production of induced pluripotent stem cells.
223397692|NCT01930682|DRUG|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
223397693|NCT01930682|PROCEDURE|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
223397694|NCT01930682|PROCEDURE|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
223550751|NCT04809493|PROCEDURE|Conventional dialysis treatment|Conventional dialysis treatment
223550752|NCT04809493|PROCEDURE|Isonatremic dialysis treatment|Isonatremic dialysis treatment
224017347|NCT02032979|BEHAVIORAL|Psychiatric test|
224017348|NCT02047903|DRUG|Afatinib|50, 40, 30 or 20 mg
223397695|NCT01268527|DRUG|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
223397696|NCT01268527|DRUG|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
223397697|NCT01268527|DRUG|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
223397698|NCT01268527|DRUG|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
223397699|NCT01268527|DRUG|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
223397700|NCT01268527|DRUG|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
223397701|NCT01268527|OTHER|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
223550753|NCT03035864|DRUG|rhNGF|Eye Drop 20 μg/mL
223550754|NCT03035864|OTHER|Vehicle|Vehicle Eye Drop
223550755|NCT01223339|DRUG|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
223550756|NCT01223339|DRUG|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
224017349|NCT00376831|DRUG|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
224017350|NCT00376831|DRUG|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
224017351|NCT03496831|DRUG|Biologic Agents|
223397702|NCT01268527|OTHER|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
224017352|NCT02588300|PROCEDURE|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
224017353|NCT01014533|DRUG|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
224017354|NCT01014533|DRUG|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
224017355|NCT05769647|DEVICE|Virtual Reality Glasses|3 minutes after the individual starts watching the video, the IV catheter insertion attempt will be performed while continuing to watch the video.
224017356|NCT05769647|DEVICE|Stress Ball|Patients will be given a ball and instructed to tighten and loosen with their free hand during IVC placement. The patient will continue to squeeze the ball throughout the IV catheter insertion attempt.
224017357|NCT03901482|DRUG|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
224017358|NCT03901482|DRUG|Placebos|Placebo for STS101
224017359|NCT00296400|DRUG|Rosuvastatin|
224017360|NCT00296400|DRUG|Atorvastatin|
224017361|NCT02810574|BEHAVIORAL|Cognitive training|
224017362|NCT02810574|DEVICE|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
224017363|NCT02810574|DEVICE|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
224017364|NCT00559611|PROCEDURE|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
224017365|NCT00559611|PROCEDURE|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
224017366|NCT00057174|DRUG|Disease management of gastroesophageal reflux disease|
224017367|NCT00543374|DRUG|Placebo|Placebo
224017368|NCT00543374|DRUG|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
224017369|NCT01140711|PROCEDURE|fMRI imaging following visual stimulation of food and non-food images|"fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 \* w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape."
224017370|NCT00669682|OTHER|Congestive heart failure|Spontaneous occurrence of fluid overload.
224017371|NCT01321320|OTHER|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
224017372|NCT02097082|DEVICE|STANZA Drug-eluting resorbable Scaffold|
224017373|NCT06439459|PROCEDURE|Stromal vascular fraction transplantation|"Stromal vascular fraction was extracted from subcutaneous fat harvested from either the abdomen or the posterior inner thigh region. The SVF cell-pellet was washed and was adjusted to 2×10\^6 cells/mL. The skin was marked with methylene blue and a total of 0.5ml (around 1×10\^6 cells) were transplanted intradermally at the center of each 2cm×2cm squares.~The expander was inflated two times a week using constant pressure inflation method, where the intracapsular pressure was monitored using a pressure meter and the inflation was halted when the pressure reached 100 mmHg. This procedure was repeated until adequate skin area was achieved for subsequent facial restoration surgery."
224128988|NCT00992446|DRUG|Melphalan|Given IV
224128989|NCT00992446|DRUG|Rituximab|Given IV
223397703|NCT01268527|OTHER|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
223397704|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
223397705|NCT01268527|OTHER|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
224017374|NCT04291222|DEVICE|Iron biocorrodable coronary scaffold system|Implantation of Iron biocorrodable coronary scaffold system
224017375|NCT04881604|DEVICE|Adjustable Compression Wrap|"Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
224128990|NCT00992446|DRUG|Vorinostat|Given PO
224128991|NCT04562064|DEVICE|corneal tomography scans|corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
224128992|NCT02222012|DEVICE|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
224296605|NCT06444945|DEVICE|Heating pad|Heating pad will be used for heating purpose.
224296606|NCT06444945|DEVICE|Transcutaneous electrical nerve stimulation(TENS)|TENS is used for symptomatic pain relief
223397706|NCT01268527|OTHER|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
223397707|NCT01268527|DRUG|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
224017376|NCT04881604|DEVICE|Compression Sleeve|"Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily."
224017377|NCT00412061|DRUG|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
224017378|NCT00412061|DRUG|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
224017379|NCT00412061|DRUG|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
224017380|NCT01739491|DRUG|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
224017381|NCT00578461|DRUG|Ara C|3000 mg/m\^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
224017382|NCT00578461|DRUG|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
224017383|NCT00578461|DRUG|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
224017384|NCT00578461|RADIATION|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
224017385|NCT00410982|DRUG|Busulfan|Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous
224017386|NCT00410982|DRUG|Gemcitabine|Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.
224017387|NCT00410982|DRUG|Melphalan|Day -3 and Day -2 = 60 mg/m\^2 Intravenous.
224017388|NCT00410982|OTHER|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
224017389|NCT00410982|DRUG|Rituximab for Patients with B-Cell Malignancies|375 mg/m\^2 Intravenous on Days 1 and 8.
224128993|NCT02222012|DEVICE|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
224128994|NCT06829381|PROCEDURE|Tailored BPL length|Total bowel length measure and BPL will be 40% of total bowel length ensuring at least 250 cm common channel
223550757|NCT01223339|DRUG|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
223550758|NCT01223339|DRUG|Placebo|Placebo tablets administered once daily in the fed state for 7 days
224017390|NCT00410982|DRUG|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
224017391|NCT02307461|DRUG|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
224017392|NCT02307461|DRUG|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
224128995|NCT06829381|PROCEDURE|Control - BPL 180 cm|Total bowel length measure and BPL will be180 cm
223397708|NCT00870844|DRUG|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
223397709|NCT00870844|DRUG|Placebo|Vials with solution for IV infusion
223397710|NCT01530464|DRUG|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
223397711|NCT01530464|DRUG|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
223397712|NCT01530464|DRUG|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
223550759|NCT05822037|BIOLOGICAL|CT0594CP|Cell injection
223550760|NCT00310336|DRUG|S-adenosyl-L-methionine|
223550761|NCT00310336|DRUG|betaine|
223550762|NCT00310336|DRUG|pegylated interferon alpha2b|
223550763|NCT00310336|DRUG|ribavirin|
224017393|NCT02307461|DRUG|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
224017394|NCT03451617|DEVICE|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
224017395|NCT03451617|DEVICE|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
224017396|NCT00221026|DRUG|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
224017397|NCT00221026|PROCEDURE|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
224017398|NCT00289497|DEVICE|TempTouch®|
224017399|NCT01942590|DRUG|Clenbuterol|
224017400|NCT01942590|DRUG|Placebo|
224017401|NCT04157374|OTHER|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
224017402|NCT04157374|OTHER|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
224128996|NCT07083492|DIAGNOSTIC_TEST|non-invasive measurement of zink protoporphyrin|validation of non-invasive measurement of zink protoporphyrin
224017403|NCT02647216|BEHAVIORAL|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
224017404|NCT02647216|BEHAVIORAL|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
224017405|NCT05332145|BEHAVIORAL|MAP to Health|In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
224017406|NCT05101031|DEVICE|Starling SV|The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.
224017407|NCT00111215|DRUG|Tranexamic Acid|
224128997|NCT07082751|BEHAVIORAL|Lifestyle Guidance|Lifestyle Guidance
224128998|NCT02931695|OTHER|evaluation of QT interval duration|ECG to evaluation of QT interval duration
224128999|NCT02931695|OTHER|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
223397713|NCT04579354|OTHER|virtual reality tour|Patients will be guided via VR on their way through the hospital to the operating theater
223397714|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Treatment Team|The trained professionals (the Digital Navigators) support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs).
223397715|NCT06575582|BEHAVIORAL|Support from Digital Navigators to Patients|The trained professionals (the Digital Navigators) accompany and support the selected patients to find a suitable app for them and integrate it into their treatment.
223397716|NCT06575582|BEHAVIORAL|Training for Digital Navigators|The training takes place in the six study centers and is preferably aimed at medical assistants.
223397717|NCT00437567|DIETARY_SUPPLEMENT|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
223550764|NCT04732923|OTHER|Assigned intervention - procedure|"This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires"
224017408|NCT00111215|DRUG|Desmopressin Acetate|
224129000|NCT06916754|BEHAVIORAL|Combined Behavioral Intervention|The intervention includes 12 weekly sessions integrating Motivational Interviewing, Cognitive Behavioral Therapy, and relapse prevention strategies. Techniques include enhancing motivation to change, identifying cognitive distortions, managing high-risk situations, and developing alternative coping strategies.
223397718|NCT00437567|OTHER|Placebo|Similar quantity of sterile water to be added to milk
224017409|NCT00312923|DRUG|Policosanol|20 mg of policosanol in capsular form daily
224017410|NCT00312923|DIETARY_SUPPLEMENT|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
224017411|NCT04307420|PROCEDURE|Sonic Fill Restoration|Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.
224129001|NCT06916754|BEHAVIORAL|Ericksonian Hypnotherapy|This therapy includes 12 weekly sessions involving individualized trance induction, indirect suggestion, therapeutic metaphor, and ego-strengthening techniques. The sessions follow Ericksonian principles and are delivered by certified hypnotherapists.
224296607|NCT06444945|PROCEDURE|Mulligan mobilization with movement (MWM)|It provides short term pain relief and to restore pain-free, functional movements by achieving full range at the joint
224296608|NCT06444945|PROCEDURE|Kaltenborn joint mobilization|The purpose of joint mobilization is to restore normal, painless joint function. In restricted joints, this involves the restoration of joint play to normalize the roll-gliding that is essential to active movement.
224296609|NCT06444945|PROCEDURE|Resistance Training exercise|Resistance training increases muscle strength by making your muscles work against a weight or force.
223397719|NCT00908544|OTHER|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
223397720|NCT00908544|OTHER|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
223397721|NCT04192643|DRUG|Tranexamic Acid 100 MG/ML|1 GR TRANEXAMİC ACİD İN 100 ML SALİNE SOLUTİON GİVEN İN 15 MİNUTES
223397722|NCT04192643|DRUG|Placebos|100 ML SALİNE SOLUTİON
223397723|NCT01593397|DRUG|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
223397724|NCT02162277|DEVICE|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
223550765|NCT02375373|OTHER|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
224017412|NCT04307420|PROCEDURE|Composite Resin Restoration|Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
224017413|NCT02880384|OTHER|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
224017414|NCT06327932|PROCEDURE|TURBT|Transurethral Resection of Bladder Tumors
224017415|NCT06327932|PROCEDURE|HIVEC|Hyperthermic Intravesical Chemotherapy with Gemcitabine (3g/150ml NS) at 45 °C for 60 minutes. Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
224017416|NCT06327932|PROCEDURE|Intravesical Chemotherapy|Intravesical Chemotherapy with Gemcitabine (3g/150ml NS). Induction perfusion was required to start within 4 weeks, once a week (±5 days) for 6 to 8 times. After the last induction infusion, maintenance infusion was performed, once every month (±2 weeks) for 1 year from the first induction infusion.
224017417|NCT06327932|DRUG|Gemcitabine|Gemcitabine (3g/150ml NS).
224017418|NCT01022060|DIETARY_SUPPLEMENT|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
224017419|NCT01022060|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
224017420|NCT01422421|OTHER|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
224017421|NCT01422421|OTHER|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
224017422|NCT02433340|DRUG|ABT-122|
224129002|NCT06922552|PROCEDURE|Giomer pit and fissure sealant with etching applied on Permanent Molars Affected by MIH|"* Cleaning with a bristle brush and a non-fluoridated paste will be operated by a slow speed handpiece and absolute isolation (using rubber dam and Young's bow).~* Phosphoric acid etch will be applied to the occlusal fissures for 30 seconds. Teeth will be washed using air-water spray for 30 seconds then drying using air for 15 seconds. Proper etching will be confirmed by a dull frosty-white appearance of the enamel An adequate amount of primer will be dispensed on the enamel surface of the pit and fissure using a brush then will be left undisturbed for 5sec. Gentle air blow for 3 sec and then dryness with stronger stream of air until a thin and uniform bonding layer is obtained.~* The giomer sealant (BeautiSealant, Shofu, Kyoto, Japan) will be applied into the occlusal fissures applied Using the syringe needle tip and a brush into the pits and fissures. Stirring the sealant with the syringe-tip during or after placement will help eliminate any possible bubbles and enhance the flow."
224129003|NCT06922552|PROCEDURE|Resin based sealant applied on Permanent Molars Affected by MIH|"Cleaning with a bristle brush and a non-fluoridated paste will be operated by a slow speed handpiece and absolute isolation (using rubber dam and Young's bow).~* Phosphoric acid etch will be applied to the occlusal fissures for 30 seconds. Teeth will be washed using air-water spray for 30 seconds then drying using air for 15 seconds. Proper etching will be confirmed by a dull frosty-white appearance of the enamel~* The resin sealant (UltraSeal XT™ hydro™) will be applied Using the syringe needle tip and a brush into the pits and fissures. Stirring the sealant with the syringe-tip during or after placement will help eliminate any possible bubbles and enhance the flow into the pit and fissures. Photo - curing for the sealant will be done for 20 seconds using LED light curing unit. The tip of the light will be held as close as possible to the sealant, without actually touching the sealant.~the surfaces will be checked with an explorer to ensure that no voids were present."
224129004|NCT06923501|DEVICE|Tools for Coping with Cancer Calm Health mobile app program|"Participants will be asked to use a 13-session self-management program Tools for Coping with Cancer within the Calm Health mobile app."
224129005|NCT06923241|BEHAVIORAL|menu labelling type|Participants will be given a restaurant's menu with calorie information or a menu with calorie information and NS labelling.
224129006|NCT06924879|OTHER|Mindfulness-Based Pregnancy Stress Reduction Program|Mindfulness-Based Pregnancy Stress Reduction Program Training Content Session 1 Introduction to the program Course preparation Orientation process Session 2 Introduction to Mindfulness practices Session 3 Focusing on the moment Session 4 Coping with thoughts Connecting with pregnant women's bodies Becoming aware of their thoughts, feelings and bodily senses Session 5 Releasing emotions and thoughts Session 6 Awareness Session 7 Keeping distance from thoughts Session 8 Accepting Awareness
224017423|NCT00386139|DRUG|Aliskiren/HCTZ|
224017424|NCT00622258|DRUG|Everolmus|
224017425|NCT04428372|DRUG|Mannitol|Hypertonic mannitol infusion
224017426|NCT04428372|DRUG|0.9% saline|Normal saline 'placebo' arm
224017427|NCT04182945|OTHER|Data collection for algorithm development|50% of the research prototypes (4 pieces) will be mounted to the patient on left side of the body (sub clavicula, lateral ribcage, upper arm and wrist), after being admitted to the ICU and having signed the informed consent. As soon as a patient gets fever, the other 50% of the research prototypes (4 pieces) will be applied on the right side of the body (sub clavicula, lateral ribcage, upper arm and wrist). Data will be collected unobtrusively (no diagnosis will be made) and used for fever detection algorithm development.
224017428|NCT02291081|OTHER|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination~* Anamnesis with the participants~* File recherche,Physical examination~* Documentation of the cardiovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Exercise Montreal Cognitive Assessment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
224017429|NCT03971630|OTHER|Telemedicine|Patients will be followed up using the MyVENT System and APP
224017430|NCT05285930|COMBINATION_PRODUCT|Bee venom phonophoresis|phonophoresis with Bee Venom gel in form of a noncontact low-frequency pulsed ultrasound delivered through Bee Venom gel as a topical treatment at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care. The performance of the ultrasound applicator was tested regularly before and after each patient exposure; each test included all relevant acoustic field parameters (pressure amplitude, frequency) and uniformity of the field distribution. This type of test of the acoustic output of the applicators was important to eliminate the possibility of any malfunctioning of the devices.
224129007|NCT06926374|PROCEDURE|Robotic surgery using the Sentire Surgical System|Robotic surgery using the Sentire Surgical System
224129008|NCT06929767|OTHER|biomarker-guided decision making|-recommendations for antibiotic and steroid Rx provided to study physician based on bio-marker (serum CRP, blood eosinophils, sputum colour) results.
224129009|NCT06929767|OTHER|GOLD recommendations|Recommendations provided to study physician for Rx of antibiotics and steroids based on current GOLD recommendations
224129010|NCT04881851|DIETARY_SUPPLEMENT|Inositol + alpha lipoic acid|Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
224129011|NCT04881851|DIETARY_SUPPLEMENT|Inositol|Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
224017431|NCT05285930|DEVICE|low intensity ultrasound|a noncontact low-frequency pulsed ultrasound delivered through plain gel only at a distance of between 5 and 15 mm from the ulcer wound bed, and time was 10 minutes for each session in addition to conservative treatment of medical ulcer care.
224017432|NCT00611429|BEHAVIORAL|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
224017433|NCT00611429|BEHAVIORAL|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
224017434|NCT01618604|PROCEDURE|Quantitative Sensory Testing|following the standardized protocol of DFNS
224017435|NCT01618604|PROCEDURE|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
224129012|NCT04881851|DIETARY_SUPPLEMENT|Folic acid (placebo comparator)|Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
224129013|NCT05809011|DRUG|Dexamethasone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
224129014|NCT05809011|DRUG|Prednisone|After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
224129015|NCT06930859|DRUG|Ribociclib|CDK4/6 inhibitor
224129016|NCT06930859|DRUG|Letrozole|Aromatase inhibitor
224129017|NCT06930859|DRUG|Anastrozole|Aromatase inhibitor
223397725|NCT04600947|DRUG|LP002|10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.
223550766|NCT02311036|OTHER|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
224129018|NCT06939140|PROCEDURE|Bipolar prostatectomy|Endoscopic transurethral bipolar enucleation or reaction of the prostate
224129019|NCT06939062|PROCEDURE|Bipolar enucleation of the prostate (BipolEP)|Endoscopic transurethral enucleation of the prostate using bipolar energy
224129020|NCT06939062|PROCEDURE|Bipolar transurethral resection of the prostate (B-TURP)|Endoscopic transurethral resection of the prostate using bipolar energy
224129021|NCT04321694|DRUG|KHK2455|
223397726|NCT01156545|DRUG|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
223397727|NCT01156545|DRUG|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
223397728|NCT00226577|DRUG|Gemcitabine|Gemcitabine (GemzarR) 1500 mg/m2
223397729|NCT00226577|DRUG|Pemetrexed|Pemetrexed (AlimtaR) 500 mg/m2
223397730|NCT00226577|PROCEDURE|Surgery|When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
223397731|NCT01189162|DEVICE|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
223550767|NCT06496308|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
223550768|NCT06496308|DRUG|Bendamustine|Bendamustine IV will be administered as per the schedule specified in the respective arm.
223550769|NCT06496308|DRUG|Rituximab|Rituximab IV will be administered as per the schedule specified in the respective arm.
223550770|NCT06496308|DRUG|Venetoclax|Venetoclax PO will be administered as per the schedule specified in the respective arm.
223550771|NCT00343499|DRUG|valsartan|
224017436|NCT01618604|PROCEDURE|Repetition of four QST parameters|"* warm detection threshold (WDT)~* cold detection threshold (CDT)~* mechanical detection threshold (MDT)~* mechanical pain threshold (MPT)"
224017437|NCT02325427|DEVICE|tDCS|tDCS could deliver either real or sham stimulation.
224017438|NCT00350116|DRUG|topical vitamin B12|
224017439|NCT03368638|OTHER|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
224017440|NCT03589508|BEHAVIORAL|In-person sessions: ABCP_P|6 weekly sessions of alcohol prevention conducted in person.
224129022|NCT06951672|DEVICE|This study will evaluate the safety and functionality of the AMEND™ Trans-Septal System for annuloplasty as a therapy for mitral regurgitation.|The ability to deploy the annuloplasty ring in a percutaneous fashion affords an improved safety profile for surgical candidates, as well as surgical style solution for those patients that are at elevated risk for surgery due to comorbidities and advanced age. This early feasibility study allows treatment of higher risk surgical candidates with a surgical- level annuloplasty repair therapy by the AMEND™ Implant.
224129023|NCT05170659|DRUG|Relatlimab|
224129024|NCT02503176|DRUG|KCT-0809 ophthalmic solution|
224129025|NCT03744546|DRUG|ABBV-8E12|Solution for infusion
224129026|NCT07082452|DRUG|Venetoclax|Venetoclax 400 mg orally once Daily
224017441|NCT03589508|BEHAVIORAL|Video conference sessions: ABCP_T|6 weekly sessions of alcohol prevention conducted by video conference.
224017442|NCT02501915|DEVICE|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
224017443|NCT06132243|DRUG|Jaktinib Hydrochloride Tablets|Orally, one tablet at a time
224017444|NCT02810548|PROCEDURE|OFD alone|Periodontal surgical cleaning procedure
224129027|NCT07082452|DRUG|Azacitidine|75 mg/m2 Subcutaneous (SC) or intravenous (IV) Daily with a continuous 7-day scheme or on a 5-on/2-off \[weekend\]/2-on schedule (5-0-2) in 28-day cycle
224017445|NCT02810548|DRUG|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
224017446|NCT02810548|DRUG|Nanohydroxyapatite|Synthetic bone graft
224017447|NCT02516475|DIETARY_SUPPLEMENT|zinc sulfate|1 zinc sulfate capsule for 15 weeks
224017448|NCT02516475|OTHER|corn starch|1 corn starch capsule for 15 weeks
224017449|NCT01178385|BEHAVIORAL|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
224017450|NCT01178385|BEHAVIORAL|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
224017451|NCT00058760|BEHAVIORAL|NIA intervention (after school health promotion didactic program)|
224017452|NCT06253091|PROCEDURE|robit-assist extraperitoneal laparoscopic radical cystectomy|robit-assist laparoscopic radical cystectomy was performed extraperitoneal
224017453|NCT03802084|DRUG|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~* 1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
224017454|NCT01786733|BEHAVIORAL|Behavioral Activation|
224017455|NCT01786733|BEHAVIORAL|Supportive Therapy|
224017456|NCT00297687|BIOLOGICAL|MnB rLP2086|
224129028|NCT07082634|PROCEDURE|Socket shield concept and immediate implant placement|"Tooth Sectioning: The tooth will be sectioned mesiodistally using a fissure bur, preserving the buccal segment.~Palatal fragment extraction: carefully after sectioning the tooth , the palatal fragment is luxated and extracted with the most important factor is taking care of the buccal part not to become loose , the extraction is done using a periotome to be minimally invasive and to preserve the bone from major damage.~Shield Preparation: The buccal fragment is reduced to bone level using a round bur, a beveled edge is created using a diamond football bur, and the shield is thinned to maintain structural integrity.~Implant Site Preparation: Sequential osteotomy performed under copious irrigation, ensuring primary stability.~Implant Placement: A Megagen implant is inserted"
224129029|NCT07082400|PROCEDURE|right heart catheter|measurement of hemodynamics of pulmonary circulation in patients diagnosed with heart failure with preserved ejection fraction
224129030|NCT06085924|DRUG|SoC|COVID-19 treatment as per government guidance
224129031|NCT06085924|OTHER|Disease description|No intervention
224129032|NCT03906344|DRUG|INCB052793|
224129033|NCT03675737|BIOLOGICAL|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
223550772|NCT00367562|DRUG|ENALAPRIL VALSARTAN METHYLPREDNISONE|
224129034|NCT03675737|DRUG|Cisplatin|Administered as an IV infusion on Day 1 Q3W
224129035|NCT03675737|DRUG|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
224129036|NCT03675737|DRUG|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
224129037|NCT03675737|DRUG|capecitabine|Administered orally BID on Days 1 to 14 Q3W
224129038|NCT03675737|DRUG|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
223550773|NCT04042597|DRUG|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
223550774|NCT04685980|PROCEDURE|spinal anaesthesia with local anaesthetic and intrathecal morphine|Patients undergoing cesarean delivery and received spinal anaesthesia with local anaesthetic and intrathecal morphine
223550775|NCT03569787|DIAGNOSTIC_TEST|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
224017457|NCT06341348|OTHER|Case management|Case Management (CM) is multi-component interventions, that comprised the provision of health education and professional advice, referring the client to another health care team, discussing a daily life plan, making reservations, and follow-up by telephone. All interventions were delivered by a nursing case manager who had over 5 years of nursing experience and received more than 20 hours of CM training.
224017458|NCT03868072|DRUG|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
224017459|NCT03868072|DRUG|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
224017460|NCT05132192|PROCEDURE|living donor liver transplantation|Living donor liver transplantation
224017461|NCT05132192|PROCEDURE|Thrombectomy or interposition graft|Portal flow restoration due to PVT in any manner
224017462|NCT03774485|DEVICE|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
224017463|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
224017464|NCT00857272|DRUG|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
224129039|NCT05841680|BEHAVIORAL|SSI Module|Single Session Intervention (SSI) module for youth with anxiety disorders and their parents. The SSI module will include psychoeducation on the cognitive behavioral conceptualization of anxiety, introduction to self-regulation strategies to manage physiological manifestations of anxiety, and cognitive restructuring of anxiogenic thoughts. The SSI module will also involve parents and present strategies on how parents can support their children in managing anxious feelings and thoughts.
224129040|NCT06337812|DIETARY_SUPPLEMENT|Potato Starch|"Participants will consume 10 grams (1/2 a packet) of Bob's Red Mill Potato Starch twice a day for the first 7 days and then increase to 20 grams (full packet) of potato starch for approximately 3 weeks. Potato starch can be mixed into cold food or beverage for consumption.~In addition, participants will have evaluations and provide blood and stool samples during the study."
224129041|NCT05487417|DRUG|Minocycline|Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
224129042|NCT05380388|BIOLOGICAL|Malaria Vaccine|blood stage Plasmodium vivax malaria vaccine
224129043|NCT05380388|BIOLOGICAL|HBV vaccine|HBV Vaccine
223731347|NCT05091099|DRUG|Alendronate|On time Zoledronate: Zoledronate would be given (one dose for one year) after the completiong of denosumab on time Alendronate and Zoledronate: Alendronate would be given one month before the the completiong of denosumab and the following 3 months (Total four months). After the completion of Alendronate, Zoledronate would be given (one dose).
224017465|NCT05639660|OTHER|non-interventional|The treatment guideline recommends the 3+Q2m regimen for Aflibercept, but this study is an observational study, no intervention is made in the subjects' treatment regimen. There is no prescribed visit plan. According to the decision of the doctor and the patient according to the treatment plan, the patient needs to come to the clinic within the prescribed time window (3, 6, and 12 months) to facilitate the recording of data.
224017466|NCT02876276|PROCEDURE|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
224017467|NCT02039453|DRUG|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (\>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
224017468|NCT02039453|DRUG|pethidine dose|pethidine dose 50mg, IV bolus (25mg if \< 50kg or \>70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
224017469|NCT00485901|DRUG|Olanzapine Hydrochloride|
224017470|NCT00485901|DRUG|Haloperidol|
224017471|NCT06112561|DEVICE|CO/CI/SVR|fluctuations of CO/CI/SVR regarding data from radial or femoral arterial cannula, and the therapeutic intervention that it demands these values.
224017472|NCT02238665|DEVICE|Endomicroscopy|
224017473|NCT04650308|DIAGNOSTIC_TEST|Neuropeptide Y examination|This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit
224017474|NCT02395874|PROCEDURE|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
224017475|NCT01688830|DRUG|Dabigatran|
224017476|NCT01688830|DRUG|BI 655075|
224017477|NCT01688830|DRUG|Placebo|
224017478|NCT04822597|DRUG|Lidocaine patch|Lidocaine is a local anesthetic.
224129044|NCT05383235|OTHER|ROUTINE CARE|1\. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient
224296610|NCT05199168|PROCEDURE|intraoperative nerve monitoring|Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
224017479|NCT04822597|DEVICE|Buzzy(R)|Buzzy provides non-invasive pain relief by vibrating and cooling the skin which distracts from pain sensations.
224017480|NCT04822597|OTHER|Ice pack|Ice cools the skin and can provide some numbing for pain.
223731348|NCT00255047|BIOLOGICAL|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
223731349|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
223731350|NCT00255047|BIOLOGICAL|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
223731351|NCT00255047|BIOLOGICAL|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
223731352|NCT04358848|DEVICE|X-PLO2R|Portable Oxygen Concentrator (POC)
224017481|NCT01285609|DRUG|Ipilimumab|
224017482|NCT01285609|DRUG|Placebo|
224017483|NCT01285609|DRUG|Paclitaxel|
224017484|NCT01285609|DRUG|Carboplatin|
224017485|NCT05880615|OTHER|collection of datas|"collection of datas:~* Post-operative occurrence (within the first 48 hours after extubation) of post-operative delirium via the CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) scale result~* Post-operative hypoxemia defined as a PaO2/FiO2 ratio \< 300 in the first 48 hours after extubation~* reflex ileus defined as the absence of gas and/or matter in the first 48 hours after extubation,~* total morphine consumption in the first 48 hours after surgery~* pain at 24 hours and 48 hours after surgery~* post-operative nausea and vomiting, major complications (neurological, respiratory, cardiac, infectious)~* mortality 30 days after surgery"
224017486|NCT03283072|DEVICE|Intervention 1|15 bouts of 2mins:1min hypoxia:hyperoxia
224017487|NCT03283072|DEVICE|Intervention 2|15 bouts of 1mins:1min hypoxia:hyperoxia
224017488|NCT03283072|DEVICE|Intervention 3|8 bouts of 2mins:1min hypoxia:hyperoxia
224017489|NCT03283072|DEVICE|Intervention 4 (sham)|15 bouts of 1min:1min normoxia
224017490|NCT00209716|DRUG|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
224017491|NCT00209716|DRUG|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1\~5 of each 28 day cycle.
223731353|NCT03417453|DEVICE|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
224129045|NCT05383235|DEVICE|Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task|"2\. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing."
224129046|NCT01667068|OTHER|Comprehensive non invasive cardiovascular examination|"* Anamnesis with the participian~* File recherche,Physical examination~* Documentation of the carciovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Measuring of the arterial media thickness~* Exercise Montreal Cognitive Assesment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics"
223397732|NCT04731727|DRUG|Riboflavin|Corneal cross linking achieved by combination of Riboflavin and ultraviolet light
223397733|NCT01003873|BIOLOGICAL|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
223397734|NCT01003873|PROCEDURE|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
223397735|NCT01003873|BIOLOGICAL|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
223397736|NCT01003873|BEHAVIORAL|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
223397737|NCT01003873|BEHAVIORAL|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
223397738|NCT01003873|BEHAVIORAL|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
224017492|NCT00209716|DRUG|Briplatin|15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle.
224017493|NCT03797677|DEVICE|MN 4000|Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
224017494|NCT06181565|OTHER|Datas of Medistim machine|Datas will be collected by Medistim machine before and after pericardial closure: Flow through the grafts, Resistance on grafts, Pulsatility of the grafts, Systolic and diastolic curves before and after pericardial closure
224017495|NCT00015041|DRUG|Buprenorphine|
224017496|NCT04563286|OTHER|questionnaire on life quality|Two sets of 30 PROMs questions will be created. The v-ATTR and wt-ATTR questionnaires will be critically evaluated by the whole panel, taking into account observations and feedback from patients. The 2 scores will be administered to consecutive patients evaluated at dedicated ambulatory clinics of the 4 Institutions. To confirm score reliability and responsiveness, 2 distinct patient cohorts will be recruited. The reliability cohort will be assembled to demonstrate the instrument's test-retest reliability. A second cohort of patients (responsiveness cohort) will be assembled to demonstrate the instrument's responsiveness to changes in clinical status. Patients experiencing a heart failure hospitalization within 6 months will enter the responsiveness cohort at the time of hospital admission.
224017497|NCT03219515|DRUG|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
224017498|NCT03219515|DRUG|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
224017499|NCT02279225|RADIATION|Group Phototherapy|
224017500|NCT02279225|RADIATION|Phototherapy + Physical activity|
224017501|NCT02279225|OTHER|Physical activity|
224017502|NCT02279225|OTHER|Placebo|
224017503|NCT06074029|DRUG|Immune Checkpoint Inhibitors|Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab
224017504|NCT00100581|DRUG|Efavirenz|
224017505|NCT00100581|DRUG|Lamivudine|
223397739|NCT04118491|DEVICE|hyperbaric oxygen and sham hyperbaric oxygen|see arm descriptions
223397740|NCT04113473|OTHER|Yoga Therapy|"An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes."
223397741|NCT03678246|PROCEDURE|Ramped position|LSFOI glottis view
223397742|NCT03678246|PROCEDURE|Supine position|LSFOI glottis view
223731354|NCT03417453|DEVICE|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
223731355|NCT03092531|BEHAVIORAL|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
223731356|NCT04731168|DEVICE|Mandibular advancement device|Patients will have a mandibular advancement device during the first postoperative night
223731357|NCT02395900|DIETARY_SUPPLEMENT|Flaxseed|
223731358|NCT02395900|OTHER|control|
224017506|NCT00100581|DRUG|Lopinavir/ritonavir|
224017507|NCT00100581|DRUG|Pegylated interferon alfa-2a|
224017508|NCT00100581|DRUG|Ribavirin|
224017509|NCT00100581|DRUG|Tenofovir disoproxil fumarate|
224129047|NCT03754933|BIOLOGICAL|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
224129048|NCT03754933|DRUG|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used for treatment of patients with chronic lymphocytic leukemia.
224129049|NCT00213928|DRUG|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
224129050|NCT02964286|DEVICE|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
224129051|NCT02522832|OTHER|Titre 1|Virus infection
224129052|NCT02522832|OTHER|Titre 2|Virus infection
224129053|NCT02522832|OTHER|Titre 3|Virus infection
224129054|NCT06234618|OTHER|visual deprivation|A group of patients walking with eyes open and walking with visual deprivation.
224129055|NCT00683475|BIOLOGICAL|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
224129056|NCT00683475|DRUG|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.
224129057|NCT00683475|DRUG|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
223397743|NCT03202082|BEHAVIORAL|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
223397744|NCT01772329|OTHER|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
223397745|NCT01772329|OTHER|Routine Care|Routine Care. No Cognitive Therapy Intervention
223397746|NCT04143373|PROCEDURE|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
223397747|NCT03403673|OTHER|Frailty assessment tools|There is evidence to suggest that patients who are frail have a higher risk of developing complications after major surgery. Our aim is to ask you simple questions about your physical ability to perform daily life activities, assess your general health condition and ask you to do simple tasks such as drawing a clock or walking for a short distance to assess your speed of walking. Our main aim is to identify a tool that will assist us to identify patients who are at risk of frailty
223731359|NCT06114355|PROCEDURE|EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)
223731360|NCT05982275|GENETIC|CARTemis-1|A dose escalation design will be applied in successive patient cohorts until identification of Dose Limiting Toxicity (maximum dose: 6x10\^6 CAR-T/kg divided over 2 days).
223731361|NCT06250231|OTHER|No intervention|No intervention
224129058|NCT00683475|BIOLOGICAL|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
224129059|NCT01524172|BEHAVIORAL|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
224129060|NCT01524172|BEHAVIORAL|Standard Mental Health Treatment|Trauma and evidence informed therapy
224129061|NCT03611517|BEHAVIORAL|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
224129062|NCT02922634|OTHER|Mini Cog|short cognitive screen, short Frailty screen
223397748|NCT03655730|OTHER|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
223397749|NCT03655730|OTHER|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
223397750|NCT02047474|DRUG|oxaliplatin|Given IV
223397751|NCT02047474|DRUG|leucovorin calcium|Given IV
223397752|NCT02047474|DRUG|irinotecan hydrochloride|Given IV
223397753|NCT02047474|DRUG|fluorouracil|Given IV
223397754|NCT02047474|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223397755|NCT02047474|OTHER|laboratory biomarker analysis|Correlative studies
223731362|NCT04831203|DIETARY_SUPPLEMENT|An egg-protein hydrolysate (NWT-03)|As described in the experimental arm
223731363|NCT04831203|DIETARY_SUPPLEMENT|Placebo|As described in the Control arm
224129063|NCT04485091|COMBINATION_PRODUCT|20% TCM and PBM|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.
224129064|NCT04485091|OTHER|20% TCM and PBM placebo|The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
224129065|NCT02723604|DEVICE|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
224129066|NCT00696462|DEVICE|forced-air warming|forced-air warming device
224129067|NCT03191669|OTHER|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
224129068|NCT03397927|DEVICE|orthosis|
224017510|NCT02552368|DEVICE|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
224017511|NCT01957449|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
224129069|NCT03978182|DEVICE|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
224129070|NCT01258530|DRUG|over-encapsulated oseltamivir|75 mg once
223550776|NCT02019615|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
223550777|NCT02020434|DRUG|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
223550778|NCT00033423|BIOLOGICAL|rituximab|
223550779|NCT00033423|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223550780|NCT00577707|DRUG|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
223550781|NCT00577707|DRUG|Pemetrexed|pemetrexed 500 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
224017512|NCT01957449|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
223550782|NCT00577707|DRUG|Cisplatin|cisplatin 75 mg/m\^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
224017513|NCT00414245|DRUG|metformin|
224129071|NCT01258530|DRUG|oseltamivir|75 mg once
224129072|NCT02130479|BEHAVIORAL|Contingency Management-Family Engagement|
224129073|NCT02130479|BEHAVIORAL|Treatment as Usual|
224129074|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
224129075|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
224129076|NCT00518921|DRUG|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
224129077|NCT00518921|DRUG|Placebo|Placebo, double dummy
224129078|NCT05611099|DEVICE|Dreem 3 System vs WatchPAT One|Dreem 3 System and WatchPAT One will be worn simultaneously during 3 nights by each study participant, in order to compare the TST automatically outputted by both devices.
224129079|NCT05611099|OTHER|Usability Questionnaire|After having undergone the 3 nights of measurement, an end of Study Questionnaire will be performed on a separate day to obtain Usability feedback from participants who have undergone simultaneous recordings with the Dreem 3 + WatchPAT devices.
224129080|NCT02753036|DRUG|Chemotherapy|standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
223550783|NCT00577707|PROCEDURE|Resection|
224017514|NCT05302349|OTHER|Core Exercise Group|"Core Exercise Group Procedure:~Weeks 1-4 (Five days a week)~1. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * Active pelvic floor exercise (supine position)~  * Bridge exercise (supine position)~  * Back Extension and Ball Back Extension exercises (prone position)~  * Abdominal and Oblique Crunch exercises (supin position)~  * Leg lift exercise (prone position)~  * Plank and Side Plank exercise~  * Superman exercise~Weeks 5-8 (Three days a week)~1. Stretching exercises and strengthening exercises for low back pain.~2. Core stabilization exercise :~   * The same exercises as for Weeks 1-4 will perform."
224129081|NCT00762372|DRUG|desflurane|volatile liquid for inhalation
224129082|NCT00762372|DRUG|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
224129083|NCT00762372|DRUG|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
224129084|NCT01682499|DRUG|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
224129085|NCT04815551|DRUG|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
224129086|NCT04815551|DRUG|Placebo|Placebo is sterile liquid for IV infusion.
224129087|NCT03364335|DRUG|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
224129088|NCT03364335|DRUG|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
224129089|NCT03364335|DRUG|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
224129090|NCT03364335|DRUG|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
224129091|NCT03364335|DRUG|Placebo|Placebo
224129092|NCT05297656|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization with graston tecnique and Home exercises programe
224129093|NCT05297656|OTHER|Sham Instrument Assisted Soft Tissue Mobilization|Instrument Assisted Soft Tissue Mobilization to be applied superficially so it is not like a real graston tecnique and Home exercises programe
224017515|NCT05302349|OTHER|Routine Therapy Group|"Routine Therapy Group Procedure:~Weeks 1-4 (Five days a week)~1\. Hotpack ultrasound, conventional TENS, stretching exercises and strengthening exercises for low back pain.~Weeks 5-8 (Three days a week)~1.Stretching exercises and strengthening exercises for low back pain."
224017516|NCT01645293|GENETIC|Genetically modified T cells # 1138|
224017517|NCT01543529|DRUG|RO4917838|Single dose of RO4917838
224017518|NCT01543529|DRUG|Placebo to RO4917838|Single dose of placebo to RO4917838
224129094|NCT05297656|OTHER|Home exercises programe|Only Home exercises programe
224129095|NCT03987919|DRUG|Tirzepatide|Administered SC
224129096|NCT03987919|DRUG|Semaglutide|Administered SC
224129097|NCT00866892|PROCEDURE|Irrigation|irrigation
224017519|NCT01543529|OTHER|Alcohol|Standard alcoholic drink
224017520|NCT00002570|DRUG|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
224017521|NCT00002570|DRUG|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
224017522|NCT01453426|DRUG|BG00012 Dose 1|
224017523|NCT01453426|DRUG|BG00012 Dose 2|
224017524|NCT04842370|DRUG|PHI-101|PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
224017525|NCT02894567|DEVICE|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
224017526|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-probiotic-combination|Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
224129098|NCT00866892|PROCEDURE|No irrigation|no irrigation
224017527|NCT03585413|DIETARY_SUPPLEMENT|Micronutrient-placebo-combination|micronutrient (capsule)-placebo (powder)-supplement
224017528|NCT00094042|DRUG|Iron Supplement, 120mg|
224017529|NCT03664362|BEHAVIORAL|The BSHAPE Intervention|The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
224017530|NCT02531945|DEVICE|Use of Biomod device|
224017531|NCT03616977|DRUG|LY900014 U-200|Administered SC
224017532|NCT03616977|DRUG|LY900014 U-100|Administered SC
224017533|NCT06049576|PROCEDURE|Biospecimen Collection|Undergo blood and stool sample collection
224017534|NCT06049576|PROCEDURE|Bone Scan|Undergo bone scan
224017535|NCT06049576|PROCEDURE|Computed Tomography|Undergo CT
224017536|NCT06049576|BIOLOGICAL|Ipilimumab|Given IV
224017537|NCT06049576|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224017538|NCT06049576|DRUG|Myrciaria dubia Prebiotic Supplement|Given PO
224017539|NCT06049576|BIOLOGICAL|Nivolumab|Given IV
224017540|NCT02774967|PROCEDURE|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
224017541|NCT05299697|DRUG|TG103 15 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.
224129099|NCT02222389|BEHAVIORAL|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
224129100|NCT02222389|BEHAVIORAL|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
224129101|NCT02222389|BEHAVIORAL|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
224129102|NCT02222389|BEHAVIORAL|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
224129103|NCT05766228|OTHER|Web-Based Intercultural Midwifery Training|The training program is a program where students can log in via the internet using the password given to them by a smartphone or computer. The web base is compatible with mobile phones and is suitable for use at any time of the day. The trainings were prepared and explained by the researchers on the web page in the form of a video presentation with the theory-based didactic classroom technique using a Power Point presentation. The training program covered six weeks and consisted of two sessions of 30 minutes each week. In the first five weeks, general information on the development of intercultural midwifery and the main components of cultural competence models are explained. In the last week, training was completed with case presentations in the form of two sessions.
224129104|NCT01445106|DRUG|Nelfinavir|
224017542|NCT05299697|DRUG|TG103 22.5 mg|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg, 15 mg to 22.5 mg.
224129105|NCT01445106|DRUG|Nelfinavir Mesylate|
224129106|NCT03726619|BEHAVIORAL|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
224296611|NCT03111914|DIAGNOSTIC_TEST|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
224296612|NCT04425538|DRUG|Infliximab|Either infliximab or infliximab-abda will be used at the discretion of the investigator
224296613|NCT01428050|DRUG|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
224296614|NCT01428050|DRUG|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
224296615|NCT02718508|BEHAVIORAL|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
224296616|NCT00926224|DEVICE|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
223731364|NCT05283668|BIOLOGICAL|i-PRF|"* Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~* The treatment was depigmentation by laser thin injection by I-PRF Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
223731365|NCT05283668|PROCEDURE|Diode Laser|"Local anesthesia was achieved using field block technique.~* A soft tissue diode surgical laser unit was used in a contact method using a flexible fiber optic hand piece with initiated tip.~* Laser irradiation parameters were adjusted as follows: Wavelength \[940 ± 10 nm\], irradiation mode \[contact continuous wave\], Power \[2 W\] and 300 μm fiber tip diameter (Jokar et al., 2019).~Post-operative instructions Instruct the patients to avoid tooth brushing on the day of surgical treatment to prevent mechanical trauma and allow re-epithelialization."
224017543|NCT05299697|DRUG|Placebo|Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
224017544|NCT00060762|BEHAVIORAL|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
224017545|NCT00060762|BEHAVIORAL|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
224017546|NCT00060762|BEHAVIORAL|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
224017547|NCT04268927|DRUG|GnRH ant/letrozole|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
224017548|NCT04268927|DRUG|GnRH ant|"Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
224017549|NCT04072068|DRUG|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
224017550|NCT03499145|DEVICE|Ophthalmology diagnostic system.|An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
224017551|NCT02923492|BEHAVIORAL|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
224017552|NCT01173497|DRUG|INIPARIB + irinotecan|21 day cycle
224017553|NCT03638973|PROCEDURE|Biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
224129107|NCT03726619|BEHAVIORAL|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
224129108|NCT02440295|PROCEDURE|Lower Extremity Amputation|
224296617|NCT05311748|DIAGNOSTIC_TEST|Ultrasound and doppler|Penile echocolour doppler ultrasound
223550784|NCT03363191|DRUG|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
224129109|NCT02440295|DEVICE|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
224129110|NCT02440295|DRUG|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
224129111|NCT04753138|DEVICE|TotalFill Bioceramic Sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
224129112|NCT04753138|DEVICE|AH+ Sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
223550785|NCT03363191|DRUG|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
223550786|NCT03363191|DRUG|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
224017554|NCT02167737|BEHAVIORAL|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
224017555|NCT02167737|BEHAVIORAL|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
224017556|NCT00925132|DRUG|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
224017557|NCT06654102|OTHER|Deep UVA Irradiation|A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 1 and 2 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
224017558|NCT06654102|OTHER|Deep UVA+HEV Blue Light Irradiation|A timed series of 6 UV doses will be administered to subsites 2 to 7 within Test Site 3 and 4 using an accurately calibrated solar simulator by varying the irradiation intensity for each subsite and keeping the duration of irradiation constant for all subsites. The duration of irradiation for each test site will be 30 minutes.
224017559|NCT00427310|DRUG|fluorouracil|
224017560|NCT00427310|OTHER|Observation|
224017561|NCT00427310|DRUG|sodium heparin|
224017562|NCT06745934|BEHAVIORAL|Healthy Minds Program|Participants in this arm engage with the Healthy Minds Program app/
224017563|NCT01732159|OTHER|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
224129113|NCT02211183|PROCEDURE|Best Repair of torn Rotator Cuff|
224129114|NCT02211183|DEVICE|InSpace™ system|
224129115|NCT01194804|DRUG|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
224129116|NCT06078787|DRUG|Olaparib 150 MG|Olaparib should be dosed 2 x 150 mg tablets (300 BID)
224129117|NCT05871021|RADIATION|Dose escalation of radiation dose beyond the therapeutic standard|Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab
224129118|NCT02883777|BEHAVIORAL|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
224129119|NCT02883777|BEHAVIORAL|Conventional Diet|Conventional diet over 1 year after transplantation.
223550787|NCT01078194|DEVICE|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
223550788|NCT00331656|DEVICE|Non-invasive positive pressure mask ventilators|
223550789|NCT00331656|DEVICE|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
223550790|NCT06552832|OTHER|CAVEAT|Brief manualized parent-child psychotherapy
223550791|NCT02452216|DRUG|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
223550792|NCT02452216|OTHER|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
223550793|NCT02452216|PROCEDURE|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
223550794|NCT03299244|DRUG|Etelcalcetide|Administered intravenously three times per week.
223550795|NCT03299244|DRUG|Cinacalcet|Cinacalcet administered orally once a day.
223550796|NCT01777464|BIOLOGICAL|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
224129120|NCT01225757|DEVICE|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
224017564|NCT06906016|BIOLOGICAL|Collection of blood samples for the study of HBV biomarkers|The intervention involves the additional and minimal collection of two blood samples during routine care procedures (9mL in a dry tube and 9mL in a Paxgene tube). These samples are specifically collected for research purposes and will be stored in the laboratory at the Henri Mondor Biobank Platform under the responsibility of Pr Bijan Ghaleh-Marzban for 15 years. The samples will be preserved under strict conditions and may be used for future analyses related to the pathology of HBV infection or other scientific advancements, with the patient's informed consent.
224017565|NCT06907420|DEVICE|Visual stimulation|40 Hz visual stimulation will be delivered at the same time of day over 5 consecutive days. Participants will lay down while wearing the customized sleep mask with inbuilt red LEDs flickering at 40 Hz linked to a microcontroller. Participants will be asked to keep their eyes closed and encouraged to fall asleep for the full stimulation duration of 60 minutes.
224017566|NCT06907433|OTHER|Kinesiotaping|The lymphatic correction technique described by Kase for use in sacroiliac sprains or inflammations was used in KT of the dysfunctional sacroiliac joint. While the patient is standing with the spine in a neutral position, the base part of the fan-shaped cut Kinesio tape will be attached approximately 2-3 inches (approximately 5-8 cm) above the dysfunctional sacroiliac joint. Then, the patient is asked to lean forward and rotate in the opposite direction to the dysfunctional side. The tail parts of the fan-shaped tape are passed downward and inward at a 45-degree angle over the sacroiliac joint and attached to the superior edge of the gluteus maximus. The base of another kinesio tape was attached approximately 2-3 inches (approximately 5-8 cm) below the dysfunctional sacroiliac joint, the tails of the fan-shaped tape were passed upward and inward at a 45-degree angle over the sacroiliac joint and attached approximately to the upper edge of the PSIS.
223397756|NCT01436240|BEHAVIORAL|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
223397757|NCT04680169|DEVICE|Bronchoscopic intubation through AuraGain LMA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
224129121|NCT04706169|DEVICE|Surface Electromyography|SEMG was used to measure the amplitude and onset of five shoulder muscle electrical signal, performing glenohumeral abduction. In this movement, the middle deltoid muscle was selected because it is a main motor. The infraspinatus muscle represented the rotator cuff muscle group. The middle deltoid muscle was selected as the representative of shoulder abduction because it is a main motor in this movement. The trapezius muscle and the serratus anterior muscle were chosen as representative established of the ascending scapular rotator muscles.
224129122|NCT01303380|DRUG|Canakinumab|
224129123|NCT03621943|PROCEDURE|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
224129124|NCT03621943|PROCEDURE|Early Cord Clamping|The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
223397758|NCT04680169|DEVICE|Bronchoscopic intubation through I-gel SGA|Comparing two different SGAs as conduit for bronchoscopic tracheal intubation
223397759|NCT00999986|DRUG|cyclophosphamide|50 mg oral per day for 7 days
223397760|NCT03888469|DEVICE|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
223397761|NCT03888469|DEVICE|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
223397762|NCT04993001|OTHER|Open lung extubation|Before starting emergence from anesthesia, the patient will be transferred to their hospital bed or stretcher and seated at 30 degrees. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be maintained at the same level or increased to 50% (minimum FiO2) with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilation mode will be changed to pressure support. The level of pressure support will be modified by the anesthesiologist to generate the same volumes as with controlled ventilation. The PEEP will be maintained at the same level. The minimum respiratory rate will be reduced by 4 min-1. The inspiratory flow for triggering will be 2 L.min-1.
223397763|NCT04993001|OTHER|Conventional extubation|Before starting emergence from anesthesia, the patient will be transferred to his hospital bed or stretcher and kept in the supine position. Secretions from the patients' oropharynx will be suctioned. To prevent the patient from coughing, the anesthetic gas or intravenous agent will be stopped after the transfer and suction procedure are completed. The FiO2 will be increased to 100% with a fresh gas flow rate greater than or equal to 10 L.min-1. The ventilator will be stopped with the APL valve open to atmosphere. The patient will be manually ventilated with the reservoir bag until spontaneous ventilation resumes. Then, the patient may be manually assisted if the treating anesthesiologist deems it necessary.
224129125|NCT05321095|DIAGNOSTIC_TEST|Albuminuria test|During participation, subjects are asked to collect one or more urine samples for albuminuria determination.
223397764|NCT04947592|DRUG|Fluconazole 150 mg|fluconazole 150 MG once daily for 14 days
223397765|NCT04845867|DEVICE|ISAR-M THYRO|A diagnostic device for early detection of haemorrhage following thyroid surgery
223397766|NCT00452244|DRUG|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
223397767|NCT00452244|DRUG|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
223550797|NCT01777464|BIOLOGICAL|sham|sham solution
223550798|NCT03973554|OTHER|pearl powder|natural product, support bone and joint health
223550799|NCT03973554|DRUG|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
223550800|NCT00431444|DRUG|Raloxifene|
223550801|NCT00431444|DRUG|Zoledronic acid|
223550802|NCT00431444|DRUG|Placebo oral pills|
223550803|NCT00431444|DRUG|Placebo intravenous (i.v.) infusion|
223550804|NCT04431843|DIETARY_SUPPLEMENT|Spirulina maxima extract|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
223397768|NCT05623423|OTHER|(Admira Fusion, Voco GmbH, Germany)|cavity margins will be extended to the proximal area, incisal edge, facial and lingual surfaces All enamel margins will be beveled at a 45° angle to the external cavosurface.(approximately 0.5-2.0 mm) An impression for the upper anterior teeth will be taken to produce a silicon palatal index The proximal margins of the restorations will be achieved using the Unica anterior matrix teeth will be etched using 37% phosphoric acid gel for 30 s then rinsed with air water for 20 s A single coat of universal bond cured using and LED light curing unit for 10 s Using the chosen enamel shade of the ORMOCER Resin Composite a thin layer (0.5-1 mm) Unica matrix will used to produce the proximal margins of the restorations Contouring, finishing and polishing of the restoration will be done Dental floss and finishing strips will be used Rubber dam will then be removed and occlusion will be checked using an articulating paper
224017567|NCT06907433|OTHER|Rigid taping|The technique specified in the study by Allah et al. was taken as a reference for RT of the dysfunctional sacroiliac joint. Patients were placed in a lateral position on their healthy side, with the affected side uppermost, hip flexed to 45 degrees, and the femur in a neutral position. The rigid tape was attached to the anterior superior iliac spine of the upper hip and pulled tight, and attached linearly to the posterior superior iliac spine. Another piece was attached between the same points, but in a curved shape with the opening facing downward.
224017568|NCT06907433|OTHER|Exercise|Patients in all 3 groups were shown an exercise program by a physiotherapist that included lumbopelvic stabilization, flexibility and strengthening exercises for the low back and hip, and were asked to apply the exercise program for 15 days by providing visual material showing the exercises.
224017569|NCT06905847|DRUG|HSK39004 in healthy|1.5-12mg
224017570|NCT06905847|DRUG|HSK39004|Placebo
224017571|NCT06905847|DRUG|HSK39004 in COPD|1.5-6mg
224017572|NCT06907498|DRUG|Paromomycin|Paromomycin 500mg X3 / day
224017573|NCT05563467|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
224017574|NCT06056544|BEHAVIORAL|Client Centered Care Coordination|During the initial C4 sessions, participants will be offered PrEP. For participants who initiate PrEP, C4 staff will provide an individualized PrEP initiation plan. During subsequent C4 sessions, C4 staff will review the prevention plan and goals with participants and use autonomy supportive counseling to address the barriers that are identified by participants that impact their motivation to use PrEP and adhere to PrEP through referrals to support services (e.g, PrEP access programs, addiction medicine services, housing, and job resources). In addition, the C4 staff will ensure any medical issues related to PrEP adherence are addressed by the site medical providers.
224017575|NCT04636177|BEHAVIORAL|Pain Rehabilitation Virtual Reality (PRVR)|Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
224129126|NCT05321095|DIAGNOSTIC_TEST|HbA1c test|During the screening visit, HbA1c will be measured with a point-of-care test (Affinion HbA1c, Abbott).
223397769|NCT05623423|OTHER|Methacrylate Based Composite|The exact same steps as in the intervention will be done but using the chosen shades of Methacrylate Based Composite Resin. (Ceram.X Spectra ST, Dentsply Sirona, UK)
223397770|NCT02135523|RADIATION|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
223397771|NCT05533619|DRUG|Proton pump inhibitor|Inpatients using proton pump inhibitor
223397772|NCT03539302|DRUG|Flecainide Acetate|Oral inhalation form using a nebulizer
224129127|NCT05321095|DIAGNOSTIC_TEST|Creatinine test|During the screening visit, creatinine will be measured with a point-of-care test (i-STAT Alinity handheld analyser, Abbott).
224129128|NCT00376987|DIETARY_SUPPLEMENT|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
224129129|NCT04093817|DEVICE|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
224129130|NCT05057546|DRUG|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
224129131|NCT05975775|PROCEDURE|Laparoscopic radical prostatectomy|Prostate cancer may require laparoscopic radical prostatectomy, a surgical procedure performed under general anaesthetic.
223397773|NCT01585090|OTHER|doing strengthening exercises of pelvic floor muscles|
223397774|NCT03784638|PROCEDURE|lingually-based triangle flap design|A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
223550805|NCT04431843|DIETARY_SUPPLEMENT|Placebo|once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
223550806|NCT03593486|DEVICE|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
223550807|NCT03593486|DEVICE|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
223550808|NCT05303506|DIAGNOSTIC_TEST|serum ferritin and AST|observiational study
223550809|NCT03803670|DIAGNOSTIC_TEST|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
223550810|NCT05494463|DEVICE|Miller blade|After laryngoscopy with Macintosh blade patient will be evaluated in laryngoscopy with Miller blade
223550811|NCT03679949|DRUG|Oxycodone|Oxycodone, 2.5 mg
224129132|NCT04987983|OTHER|Experimental SLP-R|SLP-R will be given to the infant during bottle-feeding.
224129133|NCT04987983|OTHER|Experimental SLP-L|SLP-L will be given to the infant during bottle-feeding.
224129134|NCT02783794|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
224129135|NCT02783794|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
223397775|NCT03784638|OTHER|buccally based triangular flap design|A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
223397776|NCT06582238|OTHER|Dentists in Clinical Practice|Experience in managing Dentine Hypersensitivity
223397777|NCT02585908|BIOLOGICAL|CIK|CIK cells will be used against tumor cells.
223397778|NCT02585908|BIOLOGICAL|γδ T|γδ T cells will be used against tumor cells.
223397779|NCT02585908|BIOLOGICAL|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
223397780|NCT01506505|DRUG|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
223397781|NCT05802628|DRUG|Cetylpyridinium Chloride Buccal Tablets|Subjects administrated single dose of Cetylpyridinium Chloride Buccal Tablet
223397782|NCT06357897|DRUG|Local PEG4000|PEG-Chula is developed from PEG 4000 used at King Chulalongkorn Memorial Hospital with added sweetener and flavours. Children will be given PEG-Chula at a dose of 0.5 - 1 g/kg/day.
223397783|NCT06357897|DRUG|Commercial PEG4000|For commercial PEG, We use Forlax as the control group. Children will be given Forlax at a dose of 0.5 - 1 g/kg/day.
223550812|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 1:0)|Cannabis with high THC concentration and negligible CBD concentrations
223550813|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 0:1)|Cannabis with high CBD concentration and negligible THC concentrations
224017576|NCT05565352|DRUG|Ketamine Hydrochloride|Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist has been used for general anesthesia since the 1970s, however, reports and trials by the end of the twentieth century and onward using subanesthetic doses suggested robust and rapid antidepressant and anti-suicidal effects. Ketamine is available as a 50/50 racemic mixture of enantiomers (S)-ketamine and (R)-ketamine.Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
224017577|NCT04538443|OTHER|functional capacity|impact of hemodialysis on functional capacity in children with CKD
223550814|NCT03679949|DRUG|Cannabis (THC:CBD = ~ 1:1)|Cannabis with equivalent CBD and THC concentrations
223731366|NCT05545696|DEVICE|AI on algorithm|The mandibles of the participants were scanned with ''AI on'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
224017578|NCT04538443|OTHER|muscle strength|impact of hemodialysis on muscle strength in children with CKD
224017579|NCT04538443|OTHER|Quality of life of children|impact of hemodialysis on Quality of life in children with CKD
224017580|NCT04538443|OTHER|Quality of life of families|impact of hemodialysis on Quality of life of families of children with CKD
224017581|NCT00763737|PROCEDURE|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
224017582|NCT00589238|DRUG|carboplatin|
223550815|NCT03679949|DRUG|Placebo|Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
223550816|NCT01603043|DRUG|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
223550817|NCT01603043|DRUG|Sham injection|Mock injection administered as an empty hub without needle
224017583|NCT00589238|DRUG|cyclophosphamide|
224017584|NCT00589238|DRUG|doxorubicin hydrochloride|
224017585|NCT00589238|DRUG|paclitaxel|
224017586|NCT02502799|BEHAVIORAL|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
224017587|NCT02502799|BEHAVIORAL|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
224017588|NCT02502799|DRUG|Methylphenidate|Adolescents will receive methylphenidate.
224017589|NCT01710332|DRUG|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
224017590|NCT02166125|PROCEDURE|Endosuturing|Endoscopic suturing
223397784|NCT01927120|DRUG|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
223397785|NCT01927120|DRUG|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
223397786|NCT01927120|DRUG|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
223397787|NCT02298127|OTHER|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
223397788|NCT00107627|OTHER|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
223397789|NCT00107627|OTHER|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
223397790|NCT00107627|OTHER|Skin staples;|Skin staples;
223397791|NCT04127227|DRUG|sintilimab,pegaspargase,gemcitabine,oxaliplatin|"All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimens their first-line therapy.~Patients with CR or PR will receive sintilimab maintenance therapy"
223550818|NCT00000333|DRUG|Benztropine|
223550819|NCT02747147|DEVICE|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
223550820|NCT01628068|DEVICE|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
224129136|NCT05658185|BEHAVIORAL|MIDITRA|"The psychological treatment protocol will be implemented over 10 group sessions of face-to-face psychological treatment with patients. The treatment sessions will have the following objectives and themes:~* Adjustment to the disease:~* Self-esteem/self-concept:~* Coping with fear:~* Emotional self-regulation:~* Social area and enjoyment:~* Decision making and problem solving:~* Communication and listening skills:"
224017591|NCT04555538|DIAGNOSTIC_TEST|Cardiac MRI|These are routinely performed for many cardiac conditions, including atrial arrhythmias. The adverse effects are small but include claustrophobia and metallic objects. Therefore all patients will be counselled prior to the scans by an experienced MRI practitioner and standard measures will be taken to avoid distress during the scan. Furthermore, patients will be screened using routine clinical protocols in order to avoid any harm due to interaction of the MRI scanner with metallic objects.
224296618|NCT04795830|COMBINATION_PRODUCT|Bioceramic root repair material as pulp dressing in pulpotomy in primary molars|BC RRM-F, a novel premixed bioceramic-based putty, can be used as a pulp dressing to promote pulp healing and repair with an added convenience for the pediatric patient. The aim of the present study is to evaluate the efficacy of a bioceramic root repair material as pulp dressing in pulpotomy in primary molars. The success of this material as pulpotomy dressing in primary molars will be evaluated clinically and radiographically in comparison to mineral trioxide aggregate pulpotomy. Both materials will be compared in terms of ease of handling, time to perform procedure and convenience of application. Each material's success will be evaluated by comparing its performance with or without the added peripheral seal of a stainless steel crown.
224296619|NCT04795830|COMBINATION_PRODUCT|Mineral Trioxide Aggregate as pulp dressing in primary molars (MTA)|MTA's sealing ability, biocompatibility, ability to stimulate hard tissue formation and its regenerative ability when used in contact with pulp tissues has made MTA pulpotomy the new gold standard as opposed to formocresol pulpotomy in treating the amputated pulp stumps of primary molars.
223550821|NCT03160456|DEVICE|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
224017592|NCT05871567|PROCEDURE|colorectal resection|potential resective surgery
224017593|NCT03312452|DEVICE|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
224017594|NCT03312452|DEVICE|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
224017595|NCT01621737|DRUG|Oxytocin|42 IU BID for six weeks
224017596|NCT01621737|DRUG|Oxytocin|84 IU BID for six weeks
224129137|NCT01406847|OTHER|Spinal Manipulation|High velocity low amplitude joint-biased intervention
224129138|NCT01406847|OTHER|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
224296620|NCT04030065|DRUG|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
224296621|NCT02119286|DRUG|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
224296622|NCT02119286|DRUG|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
224296623|NCT02119286|DRUG|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
224296624|NCT02119286|DRUG|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
223550822|NCT03160456|DEVICE|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
224017597|NCT01621737|DRUG|Placebo|Vehicle placebo
224017598|NCT06074276|OTHER|Food: whole almonds|60 grams or (\~2 oz) will be consumed 5 times per week.
224017599|NCT06074276|OTHER|Food: non-nut snack|Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth
224017600|NCT03910686|COMBINATION_PRODUCT|Transcranial magnetic stimulation and cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
224296625|NCT04259463|PROCEDURE|Third molars extraction|Third molars extractions with concious sedation or general anesthesia
223550823|NCT05101811|DRUG|Vitamin D Levels measurement using chemiluminescent assay|Measurement of serum vitamin D levels
223550824|NCT05101811|DEVICE|Vitamin D level assessment|Using lIAISON DEVICE
223550825|NCT00360178|DRUG|Valsartan plus Hydrochlorothiazide|
224017601|NCT00618527|DRUG|mycophenolate mofetil (Cellcept)|1 gram po, bid
224017602|NCT00618527|DRUG|human interferon beta 1a (Rebif)|44mcg sq injection every other day
224017603|NCT00564460|DRUG|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
224017604|NCT00564460|DRUG|Placebo|Placebo once daily for 8 weeks
224017605|NCT01092741|DRUG|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
224017606|NCT04165876|DEVICE|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
224129139|NCT01406847|OTHER|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
224129140|NCT00748553|DRUG|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
224129141|NCT00748553|DRUG|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
224296626|NCT03512132|BIOLOGICAL|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
224296627|NCT03512132|BIOLOGICAL|Urine sample|Urine sample on an empty stomach
224017607|NCT04165876|DEVICE|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
224017608|NCT04165876|DEVICE|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
224017609|NCT04165876|DEVICE|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
224129142|NCT01852097|BEHAVIORAL|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~1. Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~2. Give feedback to individuals on their questionnaire responses.~3. Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~4. Provide advice on overcoming practical barriers.~5. Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~6. Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
224129143|NCT00315705|DRUG|clofarabine|Clofarabine 20-40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
224129144|NCT00315705|DRUG|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
224129145|NCT00315705|DRUG|Cyclophosphamide|Cyclophosphamide 340-440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
224129146|NCT01021605|DEVICE|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
224129147|NCT03761043|BEHAVIORAL|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
224129148|NCT01642524|BIOLOGICAL|hypertonic saline mixed Dextran|single dose administered intravenously
224129149|NCT01642524|BIOLOGICAL|Saline solution|placebo - saline solution
224129150|NCT05099146|BEHAVIORAL|pictures|pictures with brushing technique demonstrated technique for proper brushing
224129151|NCT05099146|BEHAVIORAL|video|video of brushing technique demonstrated technique for proper brushing
224129152|NCT05099146|BEHAVIORAL|control|oral hygiene instructions provided
224129153|NCT00262418|DRUG|Administration of ivermectin or permethrin|
224129154|NCT00355212|PROCEDURE|percutaneous ablation of hepatocellular carcinoma|
224129155|NCT03233412|PROCEDURE|Control|Exertion of the cervix transformation zone
224129156|NCT03233412|DRUG|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
224129157|NCT05304910|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm description.
223550826|NCT00360178|DRUG|Candesartan plus Hydrochlorothiazide|
223550827|NCT00360178|DRUG|Amlodipine|
224129158|NCT05304910|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
224129159|NCT00948818|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
223550828|NCT03265444|BIOLOGICAL|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
223550829|NCT01763333|DRUG|BI 1026706 Placebo|Placebo to BI 1026706
223550830|NCT01763333|DRUG|BI 1026706|different dose formulations
223731367|NCT05545696|DEVICE|AI off algorithm|The mandibles of the participants were scanned with ''AI off'' scanning in line with the recommended scanning protocol. All scans were performed by the same operator.
223731368|NCT02188251|DIETARY_SUPPLEMENT|Activamp|
223731369|NCT02188251|OTHER|Placebo|
223731370|NCT00296478|DRUG|Endometrin|Endometrin 100mg BID x 10weeks
224129160|NCT00948818|DRUG|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
224129161|NCT01919918|DRUG|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
223731371|NCT00296478|DRUG|Endometrin|Endometrin 100mg TID x 10weeks
223731372|NCT00296478|DRUG|Crinone|Crinone QD x 10weeks
224017610|NCT05087979|DEVICE|Stable airway management (SAM) device|SAM is positioning device that will maintain patient's head, neck, and therefore their airway in the correct position during their procedure.
224017611|NCT02632162|OTHER|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
224129162|NCT01716533|PROCEDURE|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
224129163|NCT01716533|OTHER|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
224129164|NCT05591599|DIAGNOSTIC_TEST|calponin 2|serum calponin 2 level
224129165|NCT03355937|PROCEDURE|Sperm Chip|Sperm selection using by conventional or with sperm chip
224017612|NCT05446233|DRUG|[14C] Antaitavir Hasophate|100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate
224129166|NCT02474524|BEHAVIORAL|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
224017613|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
224017614|NCT02915302|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative|0.5-mL, Intramuscular (2016-2017 formulation)
224017615|NCT05037877|DIETARY_SUPPLEMENT|HUM supplement|HUM supplement - 1 capsule per day
224129167|NCT02474524|BEHAVIORAL|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
224129168|NCT06552611|COMBINATION_PRODUCT|Transcutaneous electrical spinal cord stimulation + therapy|A two-channel transcutaneous spinal cord stimulator (SCONE, SpineX, Inc.) will deliver non-invasive electrical stimulation during hand therapy sessions. For each session, two self-adhesive hydrogel electrodes will be positioned along the midline of the C3-C4 and C6-C7 spinous processes over the skin as cathodes to stimulate the cervical spinal cord at two vertebral levels. An additional pair of electrodes will be symmetrically positioned over either the iliac crests or shoulders, functioning as anodes. The electrical current employed for the transcutaneous spinal cord stimulation is biphasic, featuring a 1-millisecond pulse width, a base frequency of 30 Hz, and an overlapping frequency of 10 kHz. Stimulation intensity will range from 0 to 120 milliamperes (mA), with incremental increases of 5 mA until reaching the level that facilitates voluntary movement. The stimulation amplitude will be fine-tuned for each specific activity based on the therapist's observation.
224129169|NCT06552611|OTHER|Occupational Therapy|The hand therapy program is comprised of intensive, progressive, functional task practice following a standardized protocol. The protocol consists of repetitive activities of gross upper limb movement, isolated finger movements, bimanual task performance, simple and complex pinch, and grip performance. Several activities with various difficulty levels are designated for each category, and the participant will perform 1-2 activities within each category in each training session. Activities are chosen according to the participant's ability, interests, and needs and are modified as function progresses over time.
224129170|NCT02529241|DRUG|Group 1:LCB01-0371|"1. Period:LCB01-0371 Tablet 400 mg~2. Period: LCB01-0371 Tablet 400 mg"
224129171|NCT02529241|DRUG|Group 2:LCB01-0371|"1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg"
224129172|NCT02765178|OTHER|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
224129173|NCT02765178|OTHER|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
224129174|NCT02765178|OTHER|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
223397792|NCT01614873|DEVICE|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
223397793|NCT03493191|DRUG|0.5μg/kg SHR0410|a single dose of 0.5μg/kg SHR0410
223397794|NCT03493191|DRUG|1μg/kg SHR0410|a single dose of 2μg/kg SHR0410
223397795|NCT03493191|DRUG|2μg/kg SHR0410|a single dose of 2μg/kg SHR0410
223397796|NCT03493191|DRUG|5μg/kg SHR0410|a single dose of 5μg/kg SHR0410
223397797|NCT03493191|DRUG|10μg/kg SHR0410|a single dose of 10μg/kg SHR0410
223731373|NCT01135199|DRUG|pomalidomide (CC-4047|
223731374|NCT01250834|DRUG|Atorvastatin|Administered orally.
224017616|NCT05037877|DIETARY_SUPPLEMENT|Placebo|Placebo supplement - 1 capsule per day
224017617|NCT00110110|BIOLOGICAL|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
224017618|NCT00110110|DRUG|Carboplatin|Given at 28 mg/kg/dose.
224017619|NCT00110110|DRUG|Cyclosporine|Given at 33 mg/kg/dose
224017620|NCT00110110|DRUG|Etoposide|Given at 12 mg/kg/dose
224017621|NCT00110110|DRUG|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
224017622|NCT00110110|PROCEDURE|cryosurgery|Local application of extreme cold to destroy residual tumor.
224129175|NCT02765178|OTHER|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
224129176|NCT02765178|OTHER|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
224129177|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
224129178|NCT01407497|BIOLOGICAL|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
224129179|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
224129180|NCT01407497|BIOLOGICAL|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
224129181|NCT03408951|OTHER|Recording|The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
224129182|NCT01809418|DEVICE|keePAP|
223397798|NCT03493191|DRUG|20μg/kg SHR0410|a single dose of 20μg/kg SHR0410
223397799|NCT00392691|DRUG|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients \> 80kg) for imaging.
223397800|NCT00392691|DRUG|rituximab|250 mg/m2
223397801|NCT00392691|DRUG|melphalan|"* Dose level 1: 100 mg/m2~* Dose level 2: 140 mg/m2~* Dose level 3: 170 mg/m2~* Dose level 4: 200 mg/m2"
223397802|NCT00392691|DRUG|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
223397803|NCT00392691|PROCEDURE|autologous hematopoietic stem cell harvesting and transplantation|"Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.~Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils \> 0.5x109/l for at least 2 consecutive days."
223397804|NCT00127114|DRUG|Amantadine|
223397805|NCT00127114|DRUG|Placebo|
223397806|NCT05579964|DRUG|Dexmedetomidine Hcl 100 Mcg/mL Inj|Priming dose of 0.5 mcg/kg in a 5 ml syringe mixed in priming fluid and 0.25 mcg/kg/hour DEX infusion diluted in 0.9% NaCl 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
223397807|NCT05579964|DRUG|Placebo|Priming dose of NaCl 0.9% in a 5 ml syringe mixed in priming fluid and NaCl 0.9% 20 ml in a 20 ml syringe administered to the CPB reservoir with an infusion rate of 10 ml/hour
223397808|NCT05810532|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water
223397809|NCT05810532|OTHER|1 hour of fasting time|Oral intake is not allowed for 4 hours before sedation, while water is allowed to intake before 1 hour of sedation
223397810|NCT02686307|PROCEDURE|ICD Implant|Implantation of an implantable cardioverter/defibrillator
223397811|NCT02433132|OTHER|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
223397812|NCT01796678|DRUG|Arginine|
223397813|NCT01796678|DRUG|Placebo|Saline or Sugar pill was given as placebo
223397814|NCT00944060|OTHER|lifestyle intervention|
223397815|NCT04430062|PROCEDURE|Surgical procedures performed under general anesthesia|Surgical procedures performed under general anesthesia in patients with perioperative SARS-CoV-2 infection
223397816|NCT02107131|DRUG|Intravitreal ranibizumab 0.3mg|
223397817|NCT02696291|DRUG|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
223731375|NCT01250834|BIOLOGICAL|LY2189265|Administered subcutaneously.
224017623|NCT00110110|PROCEDURE|laser therapy|Local and precise application of laser beams to destroy residual tumor.
224017624|NCT04970030|PROCEDURE|ML lithotripsy|we will proceed under fluoroscopic vision with TTS mechanical lithotripter (Trapezoid, RX Wireguided Retrieval Basket, Boston Scientific) with mechanical fragmentation of the stone and subsequent complete cleaning of the biliary tract using the fluoroscopic technique.
224129183|NCT03242083|OTHER|quality of life questionnaire|quality of life questionnaire
224129184|NCT00745368|DRUG|Raltegravir|400 mg tablets twice daily during duration of trial
224129185|NCT00003444|BIOLOGICAL|recombinant interferon alfa|
224129186|NCT00003444|RADIATION|radiation therapy|
224129187|NCT00862316|DEVICE|Oxford Unicompartmental Knee|Knee Arthroplasty
224129188|NCT05811767|OTHER|Health Examination|The study is a cross-sectional study and therefore there is no intervention. The study consist only of tests, questionnaires and a blood test. See the elements under outcomes measures.
224129189|NCT01290445|DRUG|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
224129190|NCT01290445|BEHAVIORAL|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
224129191|NCT01290445|OTHER|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
224129192|NCT04521348|DRUG|multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody|Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
224129193|NCT05626517|DIAGNOSTIC_TEST|Ocular Imaging|The retinal photography will be acquired from macula-centre and an optic-disc centre for both left and right eye after their cardiac assessment. Patient will be required to focus at a target inside the machine for approximately 5 to 10 seconds, with a flash followed at the end when eye image is captured. Based on patients' eye conditions, additional or less images may be taken. This allows a snapshot of both retinal and coronary vessels at a single point in time, no mydriatic drops will be used. Participants will be given the option to undergo mydriatic photographs of the retina at SNEC/SERI depending on participant eye condition. For mydriatic photograph, images will be obtained after pupil dilation and graded for presence and severity of diabetic retinopathy according to the modified ETDRS system and other retinal abnormalities by trained graders.
224017625|NCT04970030|PROCEDURE|EHL lithotripsy|after administration of IV antibiotic therapy, we will proceed to cholangioscopy with SpyGlass ™ DS (Boston Scientific Corporation, USA), treatment of difficult biliary lithiasis with electrohydraulic lithotripsy with Autolith probe (Northgate Technologies Inc USA) and subsequent complete cleaning of the biliary tract using the fluoroscopic technique
224017626|NCT05074927|DIAGNOSTIC_TEST|diaphragm ultrasonography|For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation
224017627|NCT04290936|DRUG|Vemlidy® (Tenofovir Alafenamide; TAF)|Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
224129194|NCT05626517|OTHER|Questionnaires|3 to 4 questionnaires will be administered (i.e. EQ5D, International Index of Erectile Function, Pittsburgh Sleep Quality Index, General Questionnaire) to investigate the correlation between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and outcomes.Only male patients who are literate in English language will be invited to complete the International Index of Erectile Function (IIEF) questionnaire. Participants have the option to not complete the whole IIEF questionnaire or some of the questions if they are not comfortable with answering those questions.
224129195|NCT05480293|DRUG|Ranibizumab|ranibizumab，0.5mg,IVT
224129196|NCT05480293|DRUG|SCT510A|SCT510A，1.25mg,IVT
224129197|NCT02054143|PROCEDURE|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
224129198|NCT02054143|DRUG|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
224129199|NCT03446651|DRUG|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
224129200|NCT03446651|OTHER|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
223397818|NCT02696291|DRUG|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
223397819|NCT02696291|DRUG|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
223397820|NCT02696291|DRUG|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
223397821|NCT02696291|DRUG|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
223397822|NCT02696291|DRUG|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
223397823|NCT06358768|OTHER|teamwork job improvement overall|increase of teamwork capacities and skills improvement
223397824|NCT06358768|OTHER|teamwork job improvement in actor scenario vs mannequin scenario|increase of teamwork capacities and skills improvement. Comparison within different roles and different scenario learning
223397825|NCT02312167|DEVICE|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
223397826|NCT00218712|BEHAVIORAL|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
223397827|NCT00218712|BEHAVIORAL|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
223397828|NCT06871254|OTHER|Therapeutic Intermittent Hypoxia (TIH) + Exercise Training (ET)|TIH in combination with upper limb and respiratory ET. The intervention is predominantly home-based and will be delivered three times per week for six weeks.
223397829|NCT02773147|DRUG|Cyanocobalamin|
223397830|NCT02773147|DRUG|Folate|
223397831|NCT02773147|DRUG|Pyridoxine|
223397832|NCT04707573|DRUG|Vadadustat|oral capsules
223397833|NCT03123744|DRUG|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
223397834|NCT00180531|DEVICE|Renewal TR2|
223397835|NCT05227391|PROCEDURE|Oral Letrozole|Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.
223397836|NCT05227391|PROCEDURE|Oral estradiol valerate|Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.
224017628|NCT04290936|DRUG|Placebo|Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
224017629|NCT00625248|DRUG|Antithrombotics|With or without or discontinuted use of Antithrombotics
224017630|NCT00040677|DRUG|Low Dose ICA-17043|Low dose arm
224017631|NCT00040677|DRUG|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
224129201|NCT05553678|DRUG|Midazolam|Midazolam (0.03 mg/kg/30 min) will administered during UIA clipping through microscope.
224129202|NCT05553678|DRUG|Normal saline|Normal saline (0.03 mg/ml/30 min) will administered during UIA clipping through microscope.
224129203|NCT06164145|OTHER|Usual care|The training program used in this study is the stroke rehabilitation program focusing on health education for stroke and a routine exercise program based on the National Strategic Plan for Stroke Rehabilitation in Myanmar.
224017632|NCT00040677|DRUG|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
224017633|NCT03508037|OTHER|Neuromodulation electroencephalographic signals and functional electrical stimulation based|First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
224017634|NCT04088487|BEHAVIORAL|New in Town-Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs-mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
224017635|NCT03527173|BIOLOGICAL|S.sonnei vaccine|Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).
224017636|NCT03527173|DRUG|Placebo|Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
224017637|NCT03527173|BIOLOGICAL|S. sonnei 53G challenge strain|Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
224017638|NCT05601947|OTHER|Structured Proprioception and Closed Kinetic Chain Exercises Group|In this group, an exercise program consisting of 3 stages, ranging from simple to difficult and including closed kinetic chain exercises and proprioceptive exercises, will be applied.
224017639|NCT05601947|OTHER|Wii Based Balance Training Program Group|"In addition to electrotherapy and conventional exercise program, wii-based balance training program will be applied 5 days a week for 3 weeks. Balance Surf, which includes lateral weight transfer, Balance Adventure, which includes versatile balance exercises, and balance bowling for static and dynamic postural control will be implemented in the Fizyosoft Balance System. Each game will be practiced under the supervision of a physiotherapist for a total of 3 minutes, respectively, Balance surf, Balance adventure, Balance surf, Balance bowling and Balance surf, for a total of 15 minutes."
224017640|NCT01481220|DRUG|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
224017641|NCT00001267|DRUG|zidovudine|
224017642|NCT00001267|DRUG|2',3'-dideoxyinosine|
224129204|NCT01766570|OTHER|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
224129205|NCT01766570|OTHER|Placebo|
224129206|NCT05634096|DIAGNOSTIC_TEST|Oximetry|Children underwent oximetry simultaneously with video-polygraphy or video-polysomnography in routine clinical practice. The data are retrospectively collected from the patient's recording.
224129207|NCT00332514|BEHAVIORAL|telephone call by a pharmacist|
224129208|NCT04586114|DRUG|Corticosteroids and Derivatives|Any systemic corticosteroid treatment administrated during ICU stay
224129209|NCT04400409|OTHER|Intervention A - Vascular Care + site 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
224129210|NCT04400409|OTHER|Intervention B - Standard Care + site 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the site staff will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
223397837|NCT05255731|RADIATION|Low frequency laser activated photobiomodulation|"Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal."
223397838|NCT05255731|OTHER|Low frequency laser photobiomodulation inactive|The same protocol as the activated group
224129211|NCT04400409|OTHER|Intervention A - Vascular Care + CPC EQuIP 6MWT administration|Implementation of multiple strategies related to improving lipid management, starting with a referral to the vascular care team. The subject will undergo a visit with a vascular care team, including a Vascular Medicine specialist who will obtain a patient history and prescribe a lipid lowering therapy regimen. The subject will also meet with a pharmacist to answer questions related to access to medications, drug side effects, and potential interactions with the subject's other medications. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
224129212|NCT04400409|OTHER|Intervention B - Standard Care + CPC EQuIP 6MWT administration|Consists of provision of the treating provider with a copy of the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol. Subjects will return at 6 and 12 months for lab draws and endpoint event assessments but will not meet with vascular care team. Additionally, the CPC EQuIP team will conduct and guide the subjects through 6MWTs at protocol-dictated time points.
224017643|NCT02148549|DRUG|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
224017644|NCT00798915|DRUG|Placebo|Intravenous infusion of 1% human albumin in normal saline
224017645|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
224017646|NCT00798915|DRUG|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
224017647|NCT00798915|DRUG|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
224017648|NCT02134977|DRUG|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
224017649|NCT00672893|OTHER|Vibration Response Imaging|12 seconds of recording lung sounds
224017650|NCT04097301|DRUG|MLM-CAR44.1 T-cells at day 0 Single intravenous infusion|Lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3.
224017651|NCT04975477|PROCEDURE|Esophagogasrtoduodendoscopy and liver stiffness|Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.
224017652|NCT04975477|PROCEDURE|hepatic venous pressure gradient|A method was used to evaluate portal pressure.
224017653|NCT02198079|BIOLOGICAL|Sputum|
224017654|NCT02010008|BEHAVIORAL|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
224017655|NCT03383120|DEVICE|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
224017656|NCT03383120|PROCEDURE|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
224017657|NCT01773291|OTHER|acupuncture|acupuncture on GV26 and 12 Well points
224017658|NCT01773291|OTHER|laser acupuncture|laser acupuncture on GV26 and 12 Well points
224017659|NCT01773291|OTHER|control|sham laser acupuncture
224017660|NCT02522351|OTHER|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
224017661|NCT02522351|OTHER|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
224017662|NCT02522351|OTHER|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
224017663|NCT02522351|OTHER|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
224017664|NCT02522351|OTHER|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
224017665|NCT02522351|OTHER|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
224017666|NCT05986747|BEHAVIORAL|Video-based CBT guided self-help Interventions|"Seven modules were developed from the corresponding modules of self help. Each video was of 3-5 minutes duration. Each week 2-3 videos will be sent to participants through secure WhatsApp connection. Participants received daily reminders in the form of short pre-recorded audio messages through whatsapp.~Trained RAs will provide guidance as well as technical assistance during the intervention period. They will call participants once a week for 15 minutes. This call will include, feedback from previous session, explanation of current week and discussion on home work assignments."
224017667|NCT04004247|DEVICE|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
224017668|NCT05160792|DEVICE|Pressure monitoring system under compression bandages on index leg|Adding a Graducheck device under the compression bandages on the index leg and comparing to other leg, which has compression but without the device.
224129213|NCT00918086|DIETARY_SUPPLEMENT|Vitamin D pill|Oral tablet taken for 16 weeks
224129214|NCT00918086|DIETARY_SUPPLEMENT|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
224129215|NCT05917626|BEHAVIORAL|Digital SPA|A psychological digital intervention for chronic pain in adolescents, based on evidence-based cognitive-behavioral and Acceptance and Commitment Therapy techniques. The intervention will be co-created with patients in a previous phase of the study, so the exact number or format of sessions and content has not been determined yet.
223397839|NCT05460767|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
224017669|NCT06460584|OTHER|Pursed Lip Breathing|In each set, 10 times will be included. Reading will be taken from 1st POD and comparison will be done on each 4rth POD. Ask the patient to sit in a comfortable position and relax. Then, instruct the patient to take deep breath 12 through nose for two counts, and keep mouth closed. Inhale for 2 seconds. Now, ask the patient to purse the lips as if the patient was going to gently flicker the flame of candle. Now the patient will breathe out gently while counting for 4 seconds.
224129216|NCT06168071|DEVICE|taVNS|Recently, implantable VNS received FDA approval for augmenting motor recovery from ischemic stroke-induced hemiplegia when used during standard physical and occupational therapy sessions. VNS is FDA-approved for epilepsy therapy in children and is used for generalized refractory epilepsy. VNS may be achieved through an implantable stimulator on the left vagus nerve in the carotid sheath, or transcutaneously through the auricular branch of the vagus nerve (taVNS). All participants will be fitted with the device by attaching adhesive contacts to the left ear. Stimulation sessions will occur once for 30 minutes. The investigators will obtain baseline measure, tolerability questionnaires, vital signs, and EEG data.
224017670|NCT06460584|OTHER|Incentive Spirometer|For the use of flow based IS, the Patient will be sited in a comfortable Position (Semi-Recumbent Position Of 45 Degrees), With a Pillow under the knees or Semi-Fowler Position on bed, and then asked to perform this technique with the same order to ensure that she / he understands the process. The patient will be instructed to inhale with a slow continuous and deep breathing, and hold for a period of not less than 5 seconds and exhale passively. And is instructed to hold the spirometry upright to perform slowly inhalation, thus lifting the ball. At the end of the evaluation of respiratory measures for patients with lung function, and then compare the results with the previous results. IS will be recommended to be performed by patient every 10 breaths hourly and 5 times per day.
224017671|NCT00827320|DRUG|Levetiracetam|1000 mg tablet
224017672|NCT03821441|BIOLOGICAL|bOPV(Candy)|"A single dose of 1 pill orally of bOPV to subjects aged 48 months who recieved bOPV (candy) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available ,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
224017673|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who recieved bOPV (liquid) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
224017674|NCT03821441|BIOLOGICAL|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who received tOPV (liquid) produced by Beijing Tiantan Biological Products Co., Ltd. in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
224017675|NCT03068533|OTHER|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
224017676|NCT03068533|OTHER|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
224129217|NCT00882726|DRUG|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
224129218|NCT00882726|DRUG|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
224129219|NCT00882726|DRUG|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
224129220|NCT00882726|DRUG|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
224129221|NCT05142332|OTHER|Covid-19 vaccine education materials|videos and flyers containing Covid-19 vaccine educational information
224129222|NCT01935687|DEVICE|Using of instrumented wheel|Using of instrumented wheel
224129223|NCT01935687|DEVICE|Using of ergometer roller|Using of ergometer roller
223397840|NCT05718414|DEVICE|Ultrasound via artifical intelligence|"The peripheral nerve and plan block regions (adductor canal, axillary brachial plexus, PECS, popliteal, rectus sheath, ESP, femoral, and superficial cervical plexus regions) and related anatomical landmarks are practised by 3 anesthesiology residents who were in the training program of regional anesthesia and qualified to perform ultrasound guided techniques . Then, scans of 8 block types for all 40 volunteers; when the scan success gauge on the AI software was 100% at the time the images were saved. Using this procedure, 960 ultrasound images were acquired in both raw and AI-processed forms for expert assessment ."
223397841|NCT06059287|DRUG|Henagliflozin|Henagliflozin 10mg qd po
223397842|NCT06059287|DRUG|Metformin|Metformin 1000mg bid po
224017677|NCT00203476|DRUG|Niacin|
224017678|NCT00203476|DRUG|Colestipol|
224017679|NCT00203476|DRUG|Ezetimibe|
224129224|NCT05277870|DEVICE|Nanodropper adaptor|Patients will use their standard prescription for open-angle glaucoma or ocular hypertension with a Nanodropper attachment on the medication bottle.
224129225|NCT05277870|DEVICE|control|Patients will use their prescribed IOP-lowering medication using standard eyedropper on the medication bottle.
224129226|NCT03535038|DIAGNOSTIC_TEST|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
224129227|NCT03535038|DIAGNOSTIC_TEST|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
224129228|NCT03226223|DRUG|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
224129229|NCT01963299|DRUG|5 ml Ropivacaine 10% + physiological saline|
224129230|NCT01963299|DRUG|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
224129231|NCT03317275|DEVICE|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
224129232|NCT03317275|PROCEDURE|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
224129233|NCT03317275|OTHER|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
223397843|NCT06452017|OTHER|Telerehabilitation exercise program|5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.
223397844|NCT06452017|OTHER|Routine medical care|The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
223397845|NCT06582576|DIAGNOSTIC_TEST|Effect of different gastric electrical stimulator stimulation paragdimes on brain, heart, and stomach.|Measuring EEG, ECG, and ultrasound in both groups during different stimulation intensities provided by the previously implanted gastric electrical stimulator.
223550831|NCT01527877|DRUG|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
224017680|NCT02054988|OTHER|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]) was measured at baseline and after 10-days of coffee intake."
224017681|NCT02054988|OTHER|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
224017682|NCT04628819|DIETARY_SUPPLEMENT|Babybiane Imedia or placebo|Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
224017683|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
224017684|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
224017685|NCT01190514|DRUG|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
224017686|NCT01190514|DRUG|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
224017687|NCT04685057|DIETARY_SUPPLEMENT|Placebo|Intervention with a daily dose of placebo for 6 months
224017688|NCT04685057|DIETARY_SUPPLEMENT|Probiotic|Intervention with a daily dose of probiotic for 6 months
224129234|NCT02233400|DRUG|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
224129235|NCT02961712|BIOLOGICAL|NK cells|single intravenous injection of NK cells (0.9\~1\*10\^9)
224129236|NCT02961712|BIOLOGICAL|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
224129237|NCT01264094|DRUG|Clevudine|clevudine 30 mg qd
224129238|NCT06371014|DRUG|Ondansetron oral membrane|A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
223397846|NCT04773340|BEHAVIORAL|Dialectical Behavior Therapy|Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
223397847|NCT00246194|DRUG|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
223397848|NCT04527133|DRUG|Aprotinin|Intravenous or inhalation
224017689|NCT04685057|DIETARY_SUPPLEMENT|Follow-up probiotic|Intervention with a daily dose of probiotic for 6 months
224017690|NCT00892931|DRUG|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
224017691|NCT02839759|OTHER|TELLYHealth|Educational videos and questions.
224017692|NCT06384638|BIOLOGICAL|topical application of coconut oil|topical application of coconut oil
224017693|NCT06384638|OTHER|scaling and debridement|scaling and debridement
224017694|NCT04487912|DRUG|Tilmanocept|Combined peri-areolar and peri-tumoral injection of 99m-Tc Tilmanocept
224017695|NCT04487912|DRUG|Nanocolloid|Combined peri-areolar and peri-tumoral injection of 99m-Tc Nanocolloid
224017696|NCT02088307|DIETARY_SUPPLEMENT|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
224017697|NCT04390022|DRUG|Ivermectin|Single dose of STROMECTOL® tablets at 400mcg/kg
224017698|NCT04390022|DRUG|Placebo|Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
224017699|NCT03241225|BEHAVIORAL|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
224017700|NCT03241225|BEHAVIORAL|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
224017701|NCT06093854|RADIATION|Intraoperative radiotherapy (IORT)|Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)
224129239|NCT05012852|DEVICE|VagiVitalAC|In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
224129240|NCT02464397|DEVICE|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
224129241|NCT00003353|BIOLOGICAL|filgrastim|
224017702|NCT06093854|RADIATION|Stereotactic body radiotherapy (SBRT)|postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)
224017703|NCT01013454|DRUG|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload \[drug amount loaded in each patch\]) will be applied to the upper back over a single 24 hour period
224017704|NCT01281150|DRUG|Carboplatin|Given IV
224017705|NCT01281150|OTHER|Laboratory Biomarker Analysis|Correlative studies
224129242|NCT00003353|DRUG|melphalan|
224129243|NCT00003353|PROCEDURE|bone marrow ablation with stem cell support|
224129244|NCT00003353|PROCEDURE|peripheral blood stem cell transplantation|
224129245|NCT04585295|DIETARY_SUPPLEMENT|Betaine|50 mg/kg Betaine consumed twice daily for 7 days.
224129246|NCT04585295|DIETARY_SUPPLEMENT|BCAA Big 6|1 level scoop (\~18 g) of NOW Foods BCAA Big 6, consumed once per day for 7 days.
224129247|NCT04585295|DIETARY_SUPPLEMENT|Placebo|50 mg/kg Placebo consumed twice daily for 7 days.
224129248|NCT05856825|PROCEDURE|Robot-assisted radical cystectomy|Robot-assisted radical cystectomy
224129249|NCT01495338|DRUG|AC-170 0.17%|1 drop in one eye at one timepoint
224129250|NCT01495338|DRUG|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
224129251|NCT01495338|DRUG|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
224129252|NCT01495338|DRUG|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
224129253|NCT01894477|PROCEDURE|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
224129254|NCT01894477|DRUG|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
224129255|NCT01894477|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
224129256|NCT01894477|RADIATION|Total-Body Irradiation|Undergo TBI
223397849|NCT06789523|BEHAVIORAL|Friendship Bench|"The Friendship Bench model comprises 6 weekly, individual sessions with trained peer workers in addition to the usual care. Peer workers will help participants identify problems, outline potential solutions, and implement selected solutions.~The adaptation of Friendship Bench for Vietnamese methadone patients made revisions, such as removing the 'Belief in supernatural powers' section, replacing the Shona Symptom Questionnaire with DASS-21, and adding meth use. But this adaptation removed women-focused content on pregnancy and postpartum depression that we plan to include."
223397850|NCT06789523|BEHAVIORAL|Usual psychiatric care|Usual care includes monthly check-ups by peer workers, referral to hospital-based psychiatric services or other available mental health services if needed. This usual care might surpass standard psychiatric care in other provinces given that peer workers in Haiphong have been well trained on case management skills.
223397851|NCT06792955|DRUG|HRS9531 injection|Multi-dose pen of HRS9531 injection solution.
223397852|NCT06792955|DRUG|HRS9531 injection|Single-dose pen of HRS9531 injection solution.
224129257|NCT01894477|DRUG|Treosulfan|Intravenously administered Treosulfan
223397853|NCT06655493|OTHER|No treatment given|Participants will continue their normal care and will not get any treatment as part of this study.
224129258|NCT01894477|OTHER|Laboratory Biomarker Analysis|Correlative Studies
224129259|NCT05471245|DEVICE|Magic Touch SCB by Concept Medical Inc.|PCI with drug-coated balloon
224129260|NCT05387252|DIETARY_SUPPLEMENT|Mulberry juice|Mulberry is a common macrophanerophyte that can be found in fields or farms. Mulberry fruits contain a large amount of anthocyanins and a relatively small amount of pro-anthocyanins. The plant is easy to grow and the fruit price is low compared with other types of plants producing anthocyanins, and thus a reliable source for anthocyanin supplements. Current laboratory evidence has shown that specific anthocyanins can reduce inflammation status, and potentially thrombosis. One of the enzymes inhibited by specific anthocyanins is cyclooxygenase which catalyzes the synthesis of prostanoids, including thromboxane and prostaglandins. Moreover, a critical study has shown that cyanidin 3-O-glucoside, the main anthocyanin in mulberry fruit, is an allosteric regulator of interleukin-17A.
224129261|NCT03102944|DIAGNOSTIC_TEST|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
223731376|NCT04671225|BEHAVIORAL|Groups Psychoeducation|Manual-structured group psychoeducation with 8 sessions of 90 minutes over the course of 8 weeks (at one session per week). The manual is centred on behavioural principles from social education and self-regulation philosophies. All groups will have 6-8 participants and two health professionals to conduct the sessions; a psychiatric nurse and either a psychologist or a psychiatric resident. Patients will be offered to invite their relatives for 2-3 psychoeducation-days for relatives.
224017706|NCT01281150|DRUG|Paclitaxel|Given IV
224017707|NCT01281150|OTHER|Pharmacological Study|Correlative studies
224017708|NCT01281150|DRUG|Veliparib|Given PO
224017709|NCT04420715|OTHER|Training on coronary angiography using 3D coronary artery simulator|Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
224129262|NCT06116877|PROCEDURE|implant supported overdenture|mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
224129263|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
224129264|NCT00960128|DRUG|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
224129265|NCT05961189|DRUG|Azithromycin|Standard of care, 5 days of drug per manufacturer's instructions.
224129266|NCT01874652|DEVICE|Light Weight Breast Implants|Light Weight Breast Implants
224129267|NCT02730845|DRUG|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
224129268|NCT02730845|DRUG|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
224129269|NCT05691075|PROCEDURE|Arthrodesis of the metatarsophalangeal joint|Isolated surgery of the first ray of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach
224129270|NCT04851678|OTHER|None - observational study|None - observational study
224129271|NCT01936285|DRUG|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
223397854|NCT07078175|PROCEDURE|Xingnao Kaiqiao Acupuncture|"Acupuncture procedure developed by Prof. Shi Xuemin. Key acupoints include DU26, PC6, SP6, LI4, and GV20, applied with rapid and penetrating stimulation.~Arm(s): Xingnao Kaiqiao Acupuncture"
224017710|NCT03290209|PROCEDURE|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
224017711|NCT03290209|PROCEDURE|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
224017712|NCT03720054|BEHAVIORAL|MapTrek|Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
224017713|NCT03720054|BEHAVIORAL|Fitbit|Fitbit Only
224017714|NCT00414037|DRUG|Eszopiclone|
224017715|NCT00414037|DRUG|Placebo|Placebo-treatment
224017716|NCT00947739|DRUG|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
224017717|NCT02055196|BIOLOGICAL|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
224017718|NCT02055196|DRUG|irinotecan hydrochloride|Given IV
224017719|NCT02055196|OTHER|laboratory biomarker analysis|Correlative studies
224017720|NCT04574752|DIAGNOSTIC_TEST|next generation sequencing|diagnostic performance of molecular and culture techniques in S. aureus screening using paired nasal and groin swabs, to determine, if any, discrepancy between the diagnostic techniques on S. aureus detection in orthopaedic patients
224017721|NCT02618915|GENETIC|DTX101|solution for IV infusion
224017722|NCT00610103|DRUG|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
224017723|NCT02032277|DRUG|Cyclophosphamide|Cyclophosphamide
224017724|NCT02032277|DRUG|Placebo|Placebo for Carboplatin
224017725|NCT02032277|DRUG|Doxorubicin|Doxorubicin
224017726|NCT02032277|DRUG|Paclitaxel|Paclitaxel
224017727|NCT02032277|DRUG|Carboplatin|Carboplatin
224129272|NCT01936285|DRUG|Placebo|
224129273|NCT03609528|DEVICE|CamPROBE|To be completed
224129274|NCT01999855|OTHER|Phoniatric tests|
224129275|NCT04447989|DRUG|Sildenafil|Sildenafil citrate injection or powder for suspension
224129276|NCT04447989|DRUG|Placebo|dextrose 5%
224017728|NCT02032277|DRUG|Veliparib|Veliparib
224017729|NCT02032277|DRUG|Placebo|Placebo for Veliparib
224017730|NCT01864057|DRUG|thiamine hydrochloride 100 mg|
224017731|NCT05316415|OTHER|Acemaşiran Music Group|Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
224017732|NCT00559858|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|
224017733|NCT00559858|OTHER|placebo|
224017734|NCT00559858|PROCEDURE|quality-of-life assessment|
224129277|NCT05714098|BEHAVIORAL|Gerofit Exercise Program|The tele-Gerofit exercise intervention has training focused on meeting the physical activity guidelines and incorporating cardiovascular, strength, and balance training. Sessions will also include a mindfulness component, warm up, cool-down, and safety checks. Exercises are personalized to each person's functional status. Intensity of exercises will be determined by participants providing a rating of perceived exertion (RPE) on a scale of 0 (easy) to 10 (very hard) throughout the session. Initial exercise sessions will start at low-intensity and will gradually increase the duration and intensity to allow each person to reach recommended exercise levels at their own pace. Exercises are done virtually via Zoom. Each cohort will have 5-8 participants. The exercise program will be optimized after each cohort with modifications based on participant and exercise expert feedback.
223397855|NCT07078175|PROCEDURE|Electroacupuncture|Routine electroacupuncture using standard acupoints for hemiplegic upper limb rehabilitation, including LI15, LI11, SJ5, and LI4, with low-frequency electrical stimulation.
223397856|NCT06736158|GENETIC|Genetic testing for inherited bleeding disorders|Gene panel for bleeding: This analysis will look at a list of genes known to be associated with rare coagulation, platelet, connective tissue, and bleeding disorders. There are currently 318 genes on the panel however this list may be updated throughout the study. Genes of study include those on the the International Society of Thrombosis and Haemostasis (ISTH) TIER-1 (the first group of genes are the diagnostic-grade) and TIER-2 gene list, as well as additional genes identified in published research.
223397857|NCT07081438|BEHAVIORAL|icbt|12-Week Therapist-Based iCBT for OCD (Adapted Version of OCD Net: https://therapistguide.webcbt.se/index.html)
223397858|NCT07081100|DIETARY_SUPPLEMENT|Probiotic group|Participants took a freeze-dried probiotic powder every day, half an hour after a meal.
223397860|NCT06861231|DEVICE|Transcraneal Direct Current Stimulation (tDCS)- Active|The stimulation will use a neoprene cap with carbon rubber electrodes and sponges soaked in saline solution (5x5 cm). The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC), and the cathode over the right supraorbital area (rSO). Constant current intensity of 2mA and a stimulation time of 20 minutes per day for 12 days will be applied, with an initial and final ramp of 30 seconds.
223397861|NCT06861231|DEVICE|Transcranial Direct Current Stimulation (tDCS)- Sham|Participants assigned to the sham tDCS group will also receive 12 home-based sessions of 20 minutes each. However, to mimic the sensation of active stimulation without delivering therapeutic current, the stimulator will only apply current during the initial and final 30-second ramp periods. The device will remain on for 20 minutes, but no current will be applied after the first ramp, simulating an active procedure without physiological effect.
224129278|NCT02605421|DRUG|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
224129279|NCT02605421|DRUG|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
224017735|NCT04937803|DEVICE|Drug-coated balloon|Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.
224017736|NCT04937803|DEVICE|Zotarolimus-Eluting Coronary Stent|Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
224017737|NCT01617304|OTHER|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
224017738|NCT02708719|PROCEDURE|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
224017739|NCT05025202|OTHER|Isometric exercise training|A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
224017740|NCT03167931|OTHER|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
224017741|NCT03167931|OTHER|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
224017742|NCT00001407|DRUG|Interferon Gamma|
224017743|NCT05412849|RADIATION|Radiotherapy|Radiotherapy site, time perspective and dose
224017744|NCT04834206|DRUG|Docetaxel, nedaplatin, fluorouracil|Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
224017745|NCT04834206|RADIATION|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
224017746|NCT04834206|DRUG|Nedaplatin|Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
224017747|NCT05344482|OTHER|Secukinumab|Included all the patients treated with secukinumab
224017748|NCT04716491|DEVICE|Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.|When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
224017749|NCT03023228|BEHAVIORAL|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
224129280|NCT02605421|DRUG|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
224129281|NCT02605421|DRUG|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
223397862|NCT06861231|BEHAVIORAL|Cognitive Training (CT)|All participants will complete 12 home-based cognitive training sessions, each lasting 50 minutes. The training will include structured tasks focused on executive function and memory, such as categorization, problem-solving, autobiographical recall, planning, and schedule analysis. Instructions will be provided at the start of each session, and participants will work independently or with caregiver support.
223397863|NCT07096713|DRUG|Intervention 1: Brolucizumab|Intravitreal injection of Brolucizumab (6 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.
223397864|NCT07096713|DRUG|Intervention 2: Aflibercept|Intravitreal injection of Aflibercept (2 mg/0.05 mL) for the treatment of center-involving diabetic macular edema.
223731377|NCT04671225|BEHAVIORAL|Waiting-list|Participants in the control group will be assigned to a waiting list and receive group-psychoeducation after the active intervention groups.
223731378|NCT00000854|DRUG|Nandrolone decanoate|
223731379|NCT02678260|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
224017750|NCT00273767|DRUG|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
224017751|NCT00273767|DRUG|placebo|60ml of NaCl IV slow
224017752|NCT06071260|DRUG|0.01% atropine eye drop|One drop of 0.01% atropine will be administered to both eyes before bedtime. Baseline parameters were measured before and after atropine application.
224017753|NCT02833532|DEVICE|Volus/Powerfill|Maximum: 22ml
224129282|NCT02605421|DRUG|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
224129283|NCT02605421|BIOLOGICAL|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
224129284|NCT02605421|BIOLOGICAL|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC \> 2000/μL for 3 consecutive days.
224129285|NCT01014637|DRUG|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
224129286|NCT01014637|DRUG|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
224017754|NCT05534256|BEHAVIORAL|Sit Less Program|The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
224017755|NCT04956172|DEVICE|NeuroCatch Platform 2|To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
224017756|NCT01465204|BEHAVIORAL|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
224017757|NCT01465204|BEHAVIORAL|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
224129287|NCT02267863|DRUG|APTO-253|APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
224129288|NCT00978861|DRUG|Hydrogen Peroxide|Whitening product syringe type
224129289|NCT03419767|DRUG|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
224129290|NCT03419767|OTHER|blank|Patients under carotid revascularization surgery without taking melatonin
224129291|NCT00048594|DRUG|aprepitant|
224129292|NCT00048594|DRUG|Comparator: placebo (unspecified)|
224129293|NCT06391073|BEHAVIORAL|Self-Measured Blood Pressure Monitoring|Prompted SMBP with tailored feedback
224129294|NCT06391073|BEHAVIORAL|Physician appointment and transportation scheduling|Physician appointment and transportation scheduling or none dependent on current BP control
224129295|NCT05024123|DIETARY_SUPPLEMENT|Placebo|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
223397865|NCT07097519|OTHER|Immersive Virtual Reality (IVR)|This intervention involves the use of a high-end immersive virtual reality (IVR) application through the Oculus Quest 2 headset. Nurses participate in a rhythm-based exergame, Beat Saber, for at least 10 minutes per session, during 8-16 clinical shifts over an 8-week period. The game engages users in physical movement to music, requiring whole-body coordination and providing visual, auditory, and haptic feedback. The intervention aims to reduce stress and anxiety and enhance job performance among ICU nurses by providing an immersive, engaging, and therapeutic experience within the clinical environment.
223397866|NCT07096999|OTHER|Non-Interventional Study|Non-interventional study
223397867|NCT07097688|BIOLOGICAL|Sodium Hexametaphosphate (SHMP) Inorganic polyphosphates (poly[P]) are linear polymers of orthophosphate (Pi) residues linked by energy-rich phosphoranhydride bonds, Ithas multiple physiological funct|The study will be with two parallel arms (1:1 allocation ratio). The sample size per group will be calculated according to the following equation for binary outcomes; N = (Zα/2 + Zβ) 2 ×p1(1 - p1) + p2(1 - p2)/δ 2 so the minimal sample size for an equal size clinical trial is 27teeth in each group. We will recruit 30 teeth in each group for possible attrition
223397868|NCT04563715|DIAGNOSTIC_TEST|HIV counseling and testing|Receive HIV testing risk assessment and advice about risk reduction and future testing.
224129296|NCT05024123|DIETARY_SUPPLEMENT|AstraGin|"Before each study day, the participants were subjected to a reduced nitrate content diet (avoid foods such as dark chocolate, beets, garlic, nuts and seeds, bacon, ham, and hot dogs,, day-1) for 24h. All subjects took a 50 mg placebo (maltodextrin) capsule at 9 p.m. and began fasting for 12 hours, except for a small amount of water in the night before the experiment. On each study day, all subjects collected their first blood sample at 9 a.m. from the median cubital vein using the indwelling catheter method. After the first blood collection, all subjects took 50 mg placebo and 5 g of L-arginine with 250 mL water.~Additional blood samples were collected at 0, 15, 30, 45, 60, 90, 120, 150, and 180 min for analysis of the plasma concentration of amino acids, total nitrite, nitrate, and asymmetric dimethylarginine (ADMA) content.~All subjects collected their urine during 0 \~ 180 min to measure 1) nitrate and 2) cGMP content."
224129297|NCT06165484|PROCEDURE|laparoscopy and hysteroscopy|laparoscopy and hysteroscopy for patient with failed IVF
224129298|NCT00000741|DRUG|Methylprednisolone|
224129299|NCT02990637|DIETARY_SUPPLEMENT|OLECOL|Olive leaf extract
224129300|NCT02990637|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224129301|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
224129302|NCT01165723|BIOLOGICAL|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
224129303|NCT01980121|DEVICE|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
224129304|NCT05804409|DIAGNOSTIC_TEST|FECAL ELASTASE|screening for pancreatic exocrine insufficiency in MAFLD patients
224129305|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
224129306|NCT04171037|PROCEDURE|Oxygen Therapy|Receive oxygen via non-rebreather
223397869|NCT04563715|BEHAVIORAL|Network intervention|Key individuals are trained to provide advice about regular testing and risk reduction.
224017758|NCT04847726|DIAGNOSTIC_TEST|contrast enhanced ultrasound|contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
224017759|NCT04847726|DIAGNOSTIC_TEST|Dynamic CT|Participants underwent dynamic CT for hepatic lesion
224017760|NCT04847726|DIAGNOSTIC_TEST|Liver MRI|Participants underwent liver MRI for hepatic lesion
223397870|NCT07095569|DEVICE|(Shoulder individual nerves TRF (thermal radio frequency): Patients will receive shoulder individual nerves Thermal RF.|Shoulder individual nerves thermal RF technique: The patient will be put in the sitting position, monitored with electrocardiography, pulse oximetry, and non-invasive blood pressure. after disinfection A high-frequency linear transducer (10-15 Hz) will be placed parallel and cephalad to the spine of the scapula. The probe will be moved from cephalad to caudad until the trapezius and supraspinatus muscles were identified. The suprascapular nerve will be identified as a hyperechogenic structure in the suprascapular fossa deep to the superior transverse scapular ligament. A 10 cm radiofrequency needle, with a 10 mm active tip, will be inserted in plane with the ultrasound beam and advanced to reach the proximity to the nerve. A nerve stimulator was used as an additional nerve-finding modality.
223397871|NCT07095569|DRUG|conservative treatment|Patients will receive conservative treatment Acetaminophen (paracetamol 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.
223397872|NCT07104721|DRUG|YTS109 cell|Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3×10⁶ STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.
223397873|NCT07100249|DRUG|HDM2012|HDM2012 will be administered via IV infusion.
224017761|NCT04508231|OTHER|Gender-affirming hormone therapy|Gender-affirming hormone therapy according to the recommendations of the Endocrine Society
224017762|NCT00728715|DRUG|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
224017763|NCT00728715|DRUG|High dose of budesonide|1600 mcg/d of budesonide
223397874|NCT05043480|DEVICE|PEMF|Participants will receive pulsed electromagnetic fields (PEMF) exposure to alternate lower limbs weekly for 16 weeks. Participants will place alternate lower limb into the PEMF machine. Each lower limb will be exposed to 1.5mT magnetic field exposure for 10 mins once a week (total 10 min each week) for 16 weeks.
223397875|NCT02562573|DRUG|PBI4050|
224017764|NCT00728715|DRUG|A|medium dose of budesonide-formoterol
224017765|NCT00728715|DRUG|B|High Dose Inhaled Budesonide
224017766|NCT04762654|OTHER|Modified Child Dental Anxiety Scale (MCDASf)|The MCDASf is self-reported dental anxiety measure effective among children aged 5-12 years.11 The scale has eight questions about 'going to the dentist generally,' 'having teeth examined,' 'teeth being scraped and polished,' 'injections in the gum,' 'fillings,' 'having a tooth taken out,' 'being put to sleep for treatment,' and 'having a mixture of gas and air that will help you feel comfortable for treatment but will not make you sleep.' The scores of each question ranged from 1 'relaxed' to 5 'very worried.' The scores are also represented by cartoon faces varied according to emotions and anxiety levels. The total scores can range from 8 to 40.
224129307|NCT04171037|OTHER|Questionnaire Administration|Ancillary studies
224129308|NCT04171037|DEVICE|Optiflow THRIVE|Oxygen Administration
224129309|NCT04209777|DRUG|Probiotic Blend Chewable Tablet|Lactobacillus-reuteri probiotics were used as an experimental drug.
223397876|NCT03304301|BEHAVIORAL|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
223397877|NCT07112248|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223397878|NCT07112248|DIETARY_SUPPLEMENT|inulin|Inulin is a kind of soluble dietary fiber.
223397879|NCT07110766|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
223397880|NCT07110766|DRUG|Placebo|Administered orally placebo
223397881|NCT07111312|DIETARY_SUPPLEMENT|Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.|Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
223397882|NCT07111312|OTHER|Placebo control|Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
223550832|NCT01663311|DEVICE|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
224017767|NCT02650245|DIETARY_SUPPLEMENT|EAS Myoplex Protein Drink + 10gm lactulose|
224129310|NCT04209777|DRUG|Antibiotics|Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
224129311|NCT00132821|DRUG|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
224129312|NCT00132821|DRUG|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
224129313|NCT00132821|DRUG|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
224129314|NCT00132821|DRUG|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
224129315|NCT01413984|BEHAVIORAL|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
224129316|NCT00490763|BEHAVIORAL|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
224129317|NCT04462718|OTHER|Radiofrecuency|EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.
224129318|NCT04462718|OTHER|Therapeutic Exercise|CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
224129319|NCT05966493|DRUG|lufepirsen high dose|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
224129320|NCT05966493|DRUG|Vehicle|Matching vehicle without lufepirsen.
224129321|NCT05966493|DRUG|lufepirsen low dose|Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
224129322|NCT02918487|DRUG|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
224129323|NCT02918487|DRUG|Placebo|Inactive compound that is similar looking as the intervention
224129324|NCT02918188|DRUG|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
224129325|NCT03212131|DRUG|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
223397883|NCT07112963|DRUG|Fluoride Varnish|"Application of fluoride varnish to proximal surfaces of primary molars following standard clinical protocols to promote remineralization and arrest early carious lesions.~Application of resin infiltrant material to proximal non-cavitated carious lesions in primary molars, performed according to manufacturer instructions to arrest lesion progression.~Sequential application of resin infiltration followed by fluoride varnish on proximal surfaces of primary molars to maximize caries arrest and remineralization effects."
224017768|NCT04254302|OTHER|WECARE web platform|The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
224129326|NCT00916123|DRUG|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
224129327|NCT00916123|DRUG|Prednisone|10 mg per day starting on cycle 1, day 1
224129328|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
224129329|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
224017769|NCT03457207|PROCEDURE|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
224129330|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
224129331|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
224129332|NCT00916123|DRUG|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
224129333|NCT05583435|BEHAVIORAL|One-on-one professional coaching|One-on-one professional coaching
224129334|NCT05583435|BEHAVIORAL|Small-group professional coaching|Small-group professional coaching
223731380|NCT05599607|DIETARY_SUPPLEMENT|Probiotic mixture|Mixture of strains of lactobacillus and bifidobacteria
223397884|NCT07113418|DIAGNOSTIC_TEST|ELISA|Enzyme-Linked Immunosorbent Assay. It's a lab technique used to detect and measure specific proteins like antibodies or antigens in a biological sample using enzyme-linked antibodies. When a substrate is added, the enzyme causes a color change, which makes it easy to measure the result accurately.
223397885|NCT07111000|PROCEDURE|Epley Maneuver|The patient's head is turned 45 degrees towards the side that caused the most nystagmus or reproduced their initial symptoms. The patient is then laid down with their head hanging over the edge of the bed. After that, the head will be rotated 90 degrees in the opposite direction, with the head remaining in a dependent position. The patient is then asked to roll onto their side with their head facing downward. They are then brought back to a sitting position and the head is moved forward 45 degrees. Each position is held until the vertigo and/or nystagmus subsides or for at least 30 seconds
223731381|NCT05599607|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224017770|NCT02358382|DRUG|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
223731382|NCT03479606|BEHAVIORAL|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
224017771|NCT04969887|DRUG|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
224017772|NCT04969887|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
224017773|NCT04362605|PROCEDURE|Endoscopic Negative Pressure Therapy|"In patients with suspected insufficiency of the esophagojejunostomy first an index endoscopy under general anesthesia with endotracheal intubation was indicated. Standard gastroscopes with outer diameter of 9.8mm were used with carbon dioxide insufflation.~Definition of a anastomotic leak were endoscopic or radiological dehiscences at the esophagojejunostomy with extravasation of fluids and gas. In cases of insufficiencies start of endoluminal ENPT were indicated.~Decision criteria for placement of OPD or OFD were the defect size, radiological findings and clinical situation of the patient. A CT scan in patients with suspected EJAL was done in all cases.~For endoluminal ENPT, the open-pore drainage system is placed within the lumen of the digestive tract at the entrance to the cavity."
224017774|NCT05694754|DEVICE|Theta Burst Transcranial Magnetic Stimulation|Magventure MagPro R30 stimulation Device, MCF-B70 stimulation Coill
224017775|NCT05335720|DRUG|rhEGF|EASYEF® spray 50 mcg, sprayed twice a day for 14 days.
224017776|NCT05615090|PROCEDURE|Arm I (Prepectoral),|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
224017777|NCT05615090|PROCEDURE|Arm II (Subpectoral)|The intervention will be delivered through a smartphone app. The app provides users with ED symptom self-monitoring, psycho-education and relapse prevention in an evidence-based CBT-E.
224017778|NCT00233805|DEVICE|Sirolimus coated Bx Velocity™|drug-eluting stent
224017779|NCT00233805|DEVICE|Bare metal Bx Velocity™|bare-metal stent
224017780|NCT04482686|DRUG|Ivermectin|Treatment days 1, 4, and 8
224017781|NCT04482686|DRUG|Doxycycline Hcl|10 day treatment
224017782|NCT04482686|DIETARY_SUPPLEMENT|Zinc|10 Day treatment
224017783|NCT04482686|DIETARY_SUPPLEMENT|Vitamin D3|10 day treatment
224017784|NCT04482686|DIETARY_SUPPLEMENT|Vitamin C|10 day treatment
224017785|NCT04162340|BIOLOGICAL|CD4 CAR T cells|CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
223731383|NCT05125978|DRUG|Canadá|Canadá association 1 tablet twice a day
223731384|NCT05125978|OTHER|Canadá placebo|Placebo of Canadá association 1 tablet twice a day
223731385|NCT05125978|DRUG|Dipyrone|Dipyrone 1 tablet twice a day
224017786|NCT02839954|BIOLOGICAL|anti-MUC1 CAR-pNK cells|
224017787|NCT03011502|OTHER|Biological samples collection of blood and feces|
224017788|NCT03168789|BEHAVIORAL|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
224017789|NCT03168789|BEHAVIORAL|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
224017790|NCT01344512|DRUG|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
224017791|NCT01344512|DRUG|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
224017792|NCT01344512|DRUG|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
224129335|NCT00864422|BEHAVIORAL|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
224129336|NCT00864422|BEHAVIORAL|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
224129337|NCT05275621|DEVICE|Virtual Reality|"A Virtual Reality game is provided through a headset. Subjects play in a virtual environment. Positioning of the headset occurs before starting the procedure and is maintained throughout the procedure. The headset used will be Oculus Rift 2 by Facebook Tech. ltd.. The software is designed specifically for the purpose by Softcare Studios. The game played is called Drums."
223731386|NCT05125978|OTHER|Dipyrone placebo|Placebo of dipyrone 1 tablet twice a day
223731387|NCT05125978|DRUG|Tramadol hydrochloride|Tramadol 1 coated tablet twice a day
223731388|NCT05125978|OTHER|Tramadol hydrochloride placebo|Placebo of tramadol 1 coated tablet twice a day
224017793|NCT04511182|BEHAVIORAL|Exercise-based cardiac rehabilitation|"Exercise program is based on aerobic exercise and supplemented by strength training following the principle of gradual improvement. The type of exercise, such as walking, jogging, cycling, and the intensity of exercise which is recommended to use a cardiotach or pedometer to detect, are both defined by the results of CPET, such as METs value. Participators must be prepared for about 5-10 minutes to warm up and recover before and after exercise. 30-50 minutes a day, 5 days a week, with a total exercise time of not less than 150 minutes per week. It can be carried out in different stages according to the physical condition. After 1-3 months, the exercise prescription will be re-adjusted according to the results of reexamination.~All patients will undergo Cardiopulmonary Exercise Test, SF-36, echocardiography and laboratory examination prior to initiation of the trial, and which will be checked again after 3 months, and 6 months."
224017794|NCT03592901|DRUG|brachial plexus anesthesia|Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
224017795|NCT01970631|BEHAVIORAL|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
224017796|NCT01970631|OTHER|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
224129338|NCT05275621|PROCEDURE|PICC positioning|A PICC is inserted under ultrasound guidance through a modified Seldinger technique in a deep vein of the upper arm. The skin is infiltrated with 0.5-1ml 2% lidocaine before dilation of the skin. Tip guidance and positioning is achieved through intracavitary ECG.
224129339|NCT02565771|OTHER|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
224129340|NCT01800006|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
224129341|NCT02776410|BEHAVIORAL|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
224129342|NCT04736706|BIOLOGICAL|Pembrolizumab|Pembrolizumab 400 mg administered Q6W via IV infusion
224129343|NCT04736706|DRUG|Belzutifan|Belzutifan 120 mg administered QD via oral tablet
224129344|NCT04736706|BIOLOGICAL|Pembrolizumab/Quavonlimab|Pembrolizumab/quavonlimab is a co-formulated product composed of pembrolizumab 400 mg in combination with quavonlimab 25 mg, administered Q6W via IV infusion
224129345|NCT04736706|DRUG|Lenvatinib|Lenvatinib 20 mg administered QD via oral capsule
224129346|NCT01928108|BEHAVIORAL|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
224129347|NCT01928108|BEHAVIORAL|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
224129348|NCT06426199|DRUG|Chitosan-Hyaluronate Gel Mixture|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Chitosan-Hyaluronate Gel Mixture into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
224129349|NCT06426199|DRUG|Hyaluronic Acid|The operation will be under GA. TMJ arthroscopy will performed by the same TMJ arthroscopy surgeon. Lysis and lavage will be performed in the upper joint space in all cases based on the triangulation technique with an inferolateral approach. The arthroscopic procedure will include lysis of adhesions, lavage, manipulation, and debridement of the upper joint space. A 1.9-mm arthroscope with a video monitoring and recording system and a 2.2-mm protective cannula sheath will be used for TMJ arthroscopy. Ringer's lactate will be used as irrigation fluid. Both groups will receive the same arthroscopic treatments. The injection of 2 ml of Hyaluronic acid into affected joints will be performed. Needles will be removed after the injection sites and covered its sites with gauze dressing.
224129350|NCT01945424|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
224129351|NCT03021291|DEVICE|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
224129352|NCT02731118|DIETARY_SUPPLEMENT|Salovum|AF-enriched egg yolk
224129353|NCT02731118|DIETARY_SUPPLEMENT|Placebo|egg yolk
224129354|NCT05178992|BEHAVIORAL|Socially Assistive Robot Activity|Participants will attend two weekly sessions with robot activities. Each session will last 30 minutes. Participants will attend robot sessions for 8 weeks.
224129355|NCT03363828|DRUG|Estrofem|Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
224129356|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
224129357|NCT01473251|DRUG|Avastin|1.25 mg monthly for 4 months
224129358|NCT01473251|DRUG|Lucentis|0.5 mg monthly for 4 months
224129359|NCT05342584|DRUG|Venetoclax Oral Tablet|Given PO
224129360|NCT05342584|DRUG|Daunorubicin|Given IV
224129361|NCT05342584|DRUG|Cytarabine|Given IV
224129362|NCT04336397|DIAGNOSTIC_TEST|multi-target stool DNA test|Cluster randomized trial of high and medium intensity outreach with MT-sDNA compared with usual care
224129363|NCT05138185|DEVICE|Exoskeleton assisted gait on a treadmill|Subjects were instructed to walk on a treadmill at a constant speed during trials of 5 minutes. All subjects carried out four trials: (1) NoExo: subjects only wore the sensors to acquire their basal motion; (2) Free: subjects wore the exoskeleton although the actuator was mechanically decoupled, so it enabled the free movement of the knee; (3) Echo: the device provided gait assistance following the Echo-control strategy; and (4) Pattern: the device provided gait assistance following the Pattern strategy. During trials, patients wore a safety harness that did not support any weight. Previously to the execution of the trials, the gait velocity was self-selected by the subjects to a comfortable level. Subjects rested between trials for five minutes. Healthy subjects also performed a previous trial under variable gait speed. They walked over the treadmill as in the NoExo condition, although the gait speed randomly varies from 1km/h to 3km/h in 0.2km/h steps for 15 seconds at least.
224017797|NCT01970345|DRUG|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
224017798|NCT01970345|DRUG|Placebo/saline|Placebo
224129364|NCT01507584|DEVICE|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
224129365|NCT04017533|PROCEDURE|GMK Sphere TKR|Se earlier
224129366|NCT03398746|PROCEDURE|LOOP Technique|Placement of subcutaneous loop drain
224129367|NCT03398746|PROCEDURE|Standard incision and drainage|Incise and drain with placement of packing
224129369|NCT06221722|DIAGNOSTIC_TEST|BOLD-fMRI|Blood-Oxygen-Level Dependent Functional Magnetic Resonance Imaging
224129370|NCT06221722|DRUG|Regular treatment of functional constipation|at least 3 months of continuous regular treatment. This treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.
224129371|NCT06221722|DRUG|fluoxetine|Fluoxetine oral treatment for 4 weeks.
224129372|NCT04216927|DRUG|Nitric Oxide|gNO will be entrained at 20 ppm into the oxygenator of the CPB circuit
224129373|NCT04216927|DRUG|Oxygen|Oxygen alone will be entrained for placebo arm
223397886|NCT07111000|PROCEDURE|Sham maneuver|This control maneuver will involve coordinated movements of the hands and legs, while excluding any head movement. Patients will be at first in a sitting position with both feet on the ground and both hands placed on the thighs and then they will be asked to lift both hands off the thighs, keeping the arms extended. They will then be asked to return to their initial upright sitting position. Patients will then raise their right foot off the ground while keeping the left one planted on the ground. It will be an alternating movement between lifting the right and left feet while maintaining a smooth and well- controlled rhythm for 90 seconds.
223397887|NCT07110831|DRUG|Fluoxetine|Participants in the intervention arm will receive oral fluoxetine capsules starting with 20mg daily for 12 weeks. The dose of the fluoxetine may be adjusted during follow-up by titrating the dose against the participants' response..
223397888|NCT07110831|BEHAVIORAL|Cognitive-behavioral therapy|Participants with HAM-D score of between 8 and 13 (mild depression) will receive sessions of Cognitive Behavioural Therapy (CBT) as per standard routine care. Participants in the intervention arm will also receive sessions of CBT as per standard routine care.
223397889|NCT07113158|DRUG|Aspirin + Acid folic|Aspirin 100 mg/day and Acid Folic 5 mg/day + gold standard treatment
223397890|NCT07113158|DRUG|Placebo Aspirin + Placebo Acid folic|The Placebo Aspirin 100 mg/j + Placebo folic acid 5 mg/j + reference treatment
223397891|NCT07110935|DRUG|intravenous iron|intravenous iron dextran
224129374|NCT05972759|OTHER|Forced and voluntary exercise|Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and complete a single bout of both FE and VE. The 150-minute experimental session will be completed in the OFF antiparkinsonian and Off-DBS state.
224129375|NCT04491786|DRUG|Gabapentin|Gabapentin plus nefopam
224129376|NCT03673748|DRUG|Mesenchymal stem cells (MSC)|Endovenous injection of MSV in saline solution
224129377|NCT03673748|DRUG|Placebo|Endovenous injection of saline solution without cells
223397892|NCT07110935|DRUG|oral iron|oral iron(ferrous Sulphate)
223397893|NCT07105514|DIETARY_SUPPLEMENT|Indole-3-propionic acid (IPA)|Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Active capsules are taken orally and contain 250 mg of IPA each.
223550833|NCT01663311|DEVICE|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
224017799|NCT00536302|DIETARY_SUPPLEMENT|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
224017800|NCT00536302|DIETARY_SUPPLEMENT|Placebo|Matching placebo solution per day by mouth for 48 weeks.
224017801|NCT00714545|RADIATION|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
224017802|NCT00413998|PROCEDURE|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
224017803|NCT00413998|PROCEDURE|CABG|Patients will undergo coronary artery bypass grafting alone.
224017804|NCT02277041|DRUG|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
224017805|NCT02277041|DRUG|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
224017806|NCT00759018|BIOLOGICAL|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10\^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
224017807|NCT00400348|DRUG|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
224017808|NCT00005951|DRUG|irinotecan hydrochloride|
224017809|NCT00005951|DRUG|temozolomide|
224129378|NCT06224829|PROCEDURE|Pain Inducing Massage|60 seconds of direct pressure to the neck resulting in 5/10 pain . This will be repeated four times for a total of 240 seconds
224017810|NCT02617303|PROCEDURE|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
224017811|NCT02617303|PROCEDURE|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
224017812|NCT03346161|OTHER|"Usual care American Society of Plastic Surgeons booklet Breast Reconstruction"|-Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
224017813|NCT03346161|OTHER|Decision tool|-Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
224129379|NCT06224829|PROCEDURE|Pain Free Massage|60 seconds of direct pressure to the neck resulting in 0/10 pain . This will be repeated four times for a total of 240 seconds
224129380|NCT06224829|PROCEDURE|Cold Water Bath|Participants will place their hand in a cold water bath maintained at 6 to 8 degrees Celsius for 60 seconds. This will be repeated four times for a total of 240 seconds.
224129381|NCT04689386|OTHER|"Group I (GE-I) - Stimulation of reflex rolling from the Vojta method"|"This manoeuvre does not require the newborn to be moved, but only a slight rotation of the head towards the side from which the stimulus is delivered. The starting position for performing the first phase of reflex rolling is the asymmetric supine position, with the limbs freely lying on the resting surface.~A digital pressure will exert on the chest area, where the mammillary line crosses the insertion of the diaphragm, either at the level of the 6th rib, or between the 5th and the 6th, or between the 6th and the 7th. A one minute stimulus will be performed on each side. The intervention will be repeated twice a day, ensuring that the period between one intervention and another is at least two hours."
223397894|NCT07105514|DIETARY_SUPPLEMENT|Placebo|Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Placebo capsules are taken orally and contain maltodextrin.
224129382|NCT04689386|OTHER|Group II (GE-II) - expiratory flow increase technique|The technique adapted to the premature infant will be performed. This maneuver consists of slowly applying light pressure to the infant's chest with one hand, obliquely, starting from the end of the inspiratory plateau until the end of expiration, which is prolonged. The hand should be placed between the sternal notch and the xiphoid process of the newborn's sternum. The therapist's other hand is placed on the last ribs (without applying pressure) as a bridge, of which the columns are the thumb and forefinger (or middle finger). Therefore, contact with the infant's abdomen is avoided and the expansion of the lower rib is limited, allowing a better displacement of the diaphragm and avoiding an increase in intra-abdominal pressure. The maneuver will be repeated three times, respecting the infant's responses and their physiological constants. The intervention will be repeated twice a day, trying to ensure that the period between one intervention and another is at least 2 hours.
224129383|NCT05324826|DEVICE|Butterfly Network handheld ultrasound|Patients would be examined with a handheld US machine which would allow for dynamic imaging chairside and could easily be integrated into both hospital-based and private clinical practices. This would allow the patient to benefit from realtime imaging and a faster preliminary diagnosis with virtually no additional risks.
224129384|NCT03977285|PROCEDURE|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
224129385|NCT03794141|BEHAVIORAL|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
224129386|NCT03794141|BEHAVIORAL|life style advise|all test persons were given information on healthy diet and life style
224129387|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
224138615|NCT01180114|BEHAVIORAL|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
223397895|NCT07113301|PROCEDURE|incisional or core-needle biopsy for tumor diagnosis|incisional or core-needle biopsy for tumor diagnosis
223397896|NCT07111715|DEVICE|Small bowel Video Capsule Endoscopy (VCE) using an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC),|Small bowel Video Capsule Endoscopy (VCE) will be performed using the an Capsule System equipped with a Deep Neural Network based system called SmartScan (SC), which is able to automatically select suspected lesions thus creating a very short video constituted only by selected images.
223397897|NCT07112144|BIOLOGICAL|DTacP|Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml；Injection；
224017814|NCT03346161|OTHER|Usual Care Group - Outcome Measures|"* Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort."
224017815|NCT03346161|OTHER|Decision Group - Outcome Measures|"* Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~* Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~* Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~* Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~* Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit)."
224017816|NCT03346161|OTHER|Demographic and Background Questions|"* Asks 15 questions~* Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision"
224017817|NCT00433940|DRUG|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
224017818|NCT01246557|DRUG|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
224017819|NCT01246557|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
224017820|NCT00551265|DRUG|Cyclophosphamide|Given IV
224017821|NCT00551265|PROCEDURE|Laboratory Biomarker Analysis|Correlative studies
224017822|NCT00551265|BIOLOGICAL|Oregovomab|Given IV
224138616|NCT01180114|OTHER|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
224138617|NCT06157047|PROCEDURE|Crestal Bone Expansion obtained with the Magnetic Mallet®|A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
224138618|NCT03723005|DEVICE|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
224138619|NCT03723005|DEVICE|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
224138620|NCT04627012|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224138621|NCT04627012|DRUG|Opdivo|3mg/mg intravenously every 3 weeks
224138622|NCT04627012|DRUG|Camrelizumab|200mg intravenously every 3 weeks
224138623|NCT04627012|DRUG|Keytruda|200mg intravenously every 3 weeks
224138624|NCT04627012|DRUG|Toripalimab|240mg intravenously every 3 weeks
224138625|NCT04627012|DRUG|Sintilimab|200mg intravenously every 3 weeks
224138626|NCT04627012|DRUG|Tislelizumab|200mg intravenously every 3 weeks
224138627|NCT05723315|DRUG|recombinant human B-type natriuretic peptide|The recombinant human B-type natriuretic peptide produces physiological effects by imitating endogenous B-type natriuretic peptide
224138628|NCT02881983|OTHER|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
224138629|NCT02978209|DEVICE|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
224138630|NCT00163072|DRUG|transdermal Megace|oral vs transdermal levels
224138631|NCT02276521|BIOLOGICAL|Cervarix®|All groups will received one dose of Cervarix® vaccine
224138632|NCT05790473|DIAGNOSTIC_TEST|Artificial Intelligence|Development of AI algorithm for early detection of fetal brain anomalies in the first trimester of pregnancy
224138633|NCT04448093|PROCEDURE|dental treatment|Dental treatment of adequacy of oral environment and assessment of quality of life and self-esteem through questionnaires comparing a group that received treatment with another that did not.
224138634|NCT01940510|DRUG|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
224138635|NCT01940510|DRUG|rifampin|Multiple doses Days 8-16 and Days 17-20
224138636|NCT05397483|BEHAVIORAL|Legal Education plus Trauma-informed Therapy (LETiT)|Group-1: Experimental (n=75 participants) will receive the LETiT which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
224138637|NCT05397483|BEHAVIORAL|Intervention As Usual (IAU)|Group-2: Controlled (n=75 participants) will receive the IAU which consists of a total of 12-group integrated sessions lasting approximately 60-90 minutes per session every week with 20-25 persons per sub-group.
224138638|NCT04468334|DEVICE|LARIAT + PVI|LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
224129388|NCT06233318|PROCEDURE|Pecto-intercostal Fascial Block with normal saline|The US probe will be placed at sagittal plane, 2 cm lateral to the midline of the sternum to identify the second to the fifth costal cartilage from the ribs. Consequently, the US probe will be positioned in the space between the fourth and fifth costal cartilages at the sternum. After identifying the fascial planes of the chest wall, the pectoralis major muscle (PMM), the external intercostal muscle (EIM), the costal cartilage, the pleura, and the lungs. A sterile 22G blunt Stimuplex, 50 mm needle (B. Braun, Bethlehem, Pa) will be advanced and placed under the PMM and above the EIM. Following negative aspiration, PN solution with investigational product according to group randomization/allocation will be injected at each side in 5 mL aliquots ensuring appropriate spread of the PN solution. The separation of the fascial plane and the spread of the drug will be observed on the ultrasound image in real time.
224129389|NCT02568917|PROCEDURE|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
224017823|NCT06101043|PROCEDURE|Pectoral nerve block|An ultrasound probe was placed obliquely over the second and third ribs below the lateral one-third of the clavicle. After identification of the anatomical structures, the needle was advanced along a superior-medial-to-inferior-lateral passage to the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL ropivacaine (0.375% w/v) was injected at the level of the third rib. The anesthetic spread around the axilla, and the needle was withdrawn to the point in the plane between the pectoralis major and minor muscles. A second injection of 20 mL ropivacaine (0.375% w/v) was then delivered (PECS II).
224296628|NCT00998478|OTHER|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
224296629|NCT06180265|DIAGNOSTIC_TEST|presepsin, procalciton, endotoxin|measurement of presepsin, procalciton, endotoxin plasmatic levels
224017824|NCT01413776|DIETARY_SUPPLEMENT|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
224017825|NCT05643352|PROCEDURE|Barbed reposition pharyngoplasty|Barbed reposition pharyngoplasty was performed in all patients
224017826|NCT04680338|DIAGNOSTIC_TEST|CMR stress perfusion imaging|CMR stress perfusion imaging with feedback of clinically actionable findings to general practitioner and participant
224017827|NCT01678105|DRUG|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
224017828|NCT05680623|DIAGNOSTIC_TEST|PPAP diagnosis|"Serum amylase (total or the pancreatic isoform) and/or lipase activity will be systematically measured at least on postoperative days 1 and 2.~A CT with pancreas protocol iv contrast infusion will be performed in the postoperative course when clinically required, facing patients' clinical worsening, suspicious of abdominal complications."
224017829|NCT05324397|DEVICE|NEUROMARK System|The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
224017830|NCT01814852|DEVICE|Shockwave system|
223397898|NCT07112144|BIOLOGICAL|DTaP|Vaccinate 1 dose at 2 months, 4 months, 6 months, 18-24 months and 6 years of age respectively, with each injection dose being 0.5 ml.Injection
223397899|NCT07112144|BIOLOGICAL|DTacP-IPV/Hib|Administer 1 dose at 2 months, 4 months, 6 months and 18 months of age respectively, with each injection dose being 0.5 ml.Injection
223397900|NCT07111832|DRUG|SHR-A1811 for Injection|SHR-A1811 for injection.
223397901|NCT07111832|DRUG|SHR-1316 Injection|SHR-1316 injection.
223397902|NCT07111832|DRUG|Toripalimab Injection|Toripalimab injection.
223397903|NCT07111832|DRUG|Paclitaxel for Injection|Paclitaxel for injection.
223397904|NCT07103369|DRUG|SM17 for injection|SM17 monoclonal antibody for intravenous infusion use
223397905|NCT07103369|OTHER|SM17 placebo for injection|placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein
224017831|NCT01814852|DEVICE|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
224017832|NCT05389917|PROCEDURE|Pancreaticoduodenectomy|"In Pre Operative phase~64 Slice MD CT scan will be taken in all patients undergoing PD in pre op period 3D reconstruction of Peripancreatic vascular system using MDCT images Measure longitudinal distance between Root of Left renal vein, origin of IPDA Measure distance between origin of SMA , MCA and the IPDA~In Intraoperative period~Distance will be measured using standard disposable ruler from Root of Left renal vein to IPDA after Transection of Pancreas followed by specimen removal and to measure the distance between MCA, SMA and IPDA using standard disposable ruler ."
224017833|NCT06118203|DRUG|Semaglutide|Semaglutide in addition to standard of care
224017834|NCT03927573|DRUG|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
224017835|NCT03266705|DRUG|tafamidis|bioequivalence study
223397906|NCT07112586|DRUG|Plasma derived exosomes|Exosomes derived from patients' plasma, centrifuged at high speeds multiple times
223397907|NCT07109453|OTHER|18 Test Products along with positive and negative control|1\. Deep Hydration Gel 2. Anti-Wrinkle Gel 3. Anti-Aging Gel 4. Under Eye Cream 5. Brightening Cream 6. Moisturizing Cream 7. Anti-Acne Serum 8. Face Toner 9. Anti-Aging Toner 10. Clear Glow Toner 11. Super Anti-Aging Serum 12. Sun Screen SPF50 13. Anti-Pigmentation Serum 14. Super Cleansing Cream 15. Root Revive Hair Serum 16. Root Nourishment Hair Oil 17. Anti-Acne Face Wash 18. Ever Glow Face Wash 0.04 gm/ml of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
223550834|NCT06269510|BEHAVIORAL|ENGAGE-ALD Application (APP)|"Participants randomized to this will complete the app at the time of enrollment.~If in-person, will complete the app on a research laptop or iPad. The ENGAGE-ALD app consists of two modules developed based on preliminary data: 1) a misconception correction module and 2) a treatment matching module designed to match patients to participant's preferred form of alcohol treatment based on preferences for 19 different dimensions of alcohol treatment. The intervention will consist of administering a single session of the ENGAGE-ALD app."
223550835|NCT06269510|BEHAVIORAL|Treatment Facilitation bundle|Participants will complete a survey. The module includes motivational interviewing-informed content tailored to address and assist in overcoming barriers. After taking the survey, participants will receive a virtual coaching session (either via phone or online virtual platform). Sessions will focus on identifying participant goals with respect to alcohol use and liver health, providing education on risks of alcohol use to liver health and risks of relapse, reviewing participants individually identified barriers to alcohol treatment, exploring benefits of and these barriers to alcohol treatment, and performing collaborative goal-setting, among other topics.
223550836|NCT06269510|BEHAVIORAL|Enhanced Usual Care|This group will receive standard hepatology care, and an educational pamphlet defining alcohol treatment resources available within Michigan Medicine and giving information on how participants can access these resources. This information will be given directly to participants that enroll in person or e-mailed to participants or sent via postal mail for those that enroll remotely.
223550837|NCT05895097|DEVICE|Left bundle branch pacemaker|Left bundle branch pacing (LBBP) will be the pacing technique. In brief, after localizing the His bundle area the LBBP lead will be positioned approximately 1-1.5 cm distal to the His bundle position in the right ventricular septum. Before screwing the lead deep into the interventricular septum, the suitable position will be confirmed by fluoroscopic signs and adequate paced QSR morphology. Final lead position will be confirmed according to ECG parameters. Given that the pacing parameters with LBBP are typically low and stable, backup RV lead will not be mandatory.
224017836|NCT04643522|OTHER|Clinical assessment|Comparison of semen analysis results and sex-related hormone levels between the dependent groups which were defined as before COVID-19 and after COVID-19 (the data of the same patient group were compared as before and after the diagnosis of COVID-19).
223397908|NCT07113379|BIOLOGICAL|Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain.|Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
223397909|NCT07105254|DRUG|Roflumilast topical 0.3% foam|Roflumilast 0.3% topical foam
223397910|NCT07111169|DEVICE|intermittent theta burst stimulation (iTBS) intervention|iTBS protocol: Intervention with an 80-120% resting threshold was used. In the active group, the left dlPFC was selected as the stimulation site and a stimulation protocol with iTBS parameters was given. This was a neuro-modulation protocol of excitatory sequences, with theta burst stimulation at 50 Hz, repeated at 5 Hz, stimulation for 2 s with an interval of 8 s, for a total of 1,800 pulses, with a treatment time of about 20 min/session, two sessions per day, with a15-30 min rest between sessions, and five consecutive days of treatment per week, with a rest of 2 days, and two weeks of treatment.
223397911|NCT07111143|OTHER|nursing intervention|medication only
223397912|NCT07110753|BEHAVIORAL|combined lifestyle intervention focusing on various lifestyle components, delivered by a lifestyle coach and oncology nurse|The combined lifestyle intervention focuses on various lifestyle components, including nutrition, physical activity, sleep, stress and sense of purpose, and is structured around the process of behaviour change. It is delivered by a lifestyle coach in collaboration with an oncology nurse.
223550838|NCT05895097|DEVICE|Conventional pacing|Right ventricular pacing in patients with LVEF ≥ 40% and cardiac resynchronization therapy in patients with LVEF \< 40 %
223550839|NCT01605357|DRUG|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
224017837|NCT04601870|OTHER|No Financial Incentive|No monetary incentive to participate in quit planning and quit counseling with a tobacco cessation specialist.
224017838|NCT04601870|OTHER|Financial Incentive (100 dollars)|Financial incentive (100 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
224017839|NCT04601870|OTHER|Financial Incentive (50 dollars)|Financial incentive (50 dollars) to participate in quit planning and quit counseling with a tobacco cessation specialist.
224017840|NCT01879059|BEHAVIORAL|Exercise|short period of inactivity (5 days) followed by a return to physical activity (1 day)
224017841|NCT03472248|BEHAVIORAL|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
224129390|NCT02568917|PROCEDURE|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
223397913|NCT07110753|BEHAVIORAL|short online lifestyle intervention by lifestyle coach and educational materials after 6 months|The control group receives 4 online group sessions from a lifestyle coach and all educational materials after 6 months of intervention
224129391|NCT04145830|DEVICE|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
224129392|NCT02348411|DEVICE|ExAblate|
224017842|NCT03461536|BEHAVIORAL|Ultrasound-first Clinical Decision Support tool|"Intervention: The intervention is the CDS tool, which consists of 4 components:~1. Four questions which assess the appropriateness of ultrasound for this patient~2. A link to the evidence~3. Buttons to remove CT scan and order ultrasound~4. If the CT scan order is kept, reasons why ultrasonography is not appropriate The CDS tool will be placed or integrated into EPIC, at the point of order entry. The tool will be triggered by an order for CT scan for kidney stone.~Appropriateness criteria for ultrasound:~1. Adults aged \>18 and \< 76~2. Non-obese (men \< 285lbs, women \< 250lbs)~3. Low risk of Stone Emergency (Obstructing stone and any of the following: urosepsis, renal deterioration, post kidney transplant, solitary kidney, intractable symptoms)~4. Low risk of clinically significant alternative diagnosis (e.g. appendicitis, cholecystitis, AAA, ovarian torsion) If all responses are affirmative, then the subject should receive US, and US order is provided."
224017843|NCT03932812|BEHAVIORAL|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
224017844|NCT02016859|OTHER|Immature Platelet Fraction|
224017845|NCT03161600|BEHAVIORAL|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
224017846|NCT02822859|DEVICE|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
224017847|NCT02822859|DEVICE|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
224017848|NCT02822859|DEVICE|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
224017849|NCT06352476|BEHAVIORAL|Sleep Hygiene Training|The effect of sleep hygiene education in a pre-test quasi-experimental study.
224017850|NCT04193436|DRUG|PF-06835919 25 mg|PF-06835919 in 25 mg oral tablet will be administered on Day 1
224017851|NCT02878577|DEVICE|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
224017852|NCT06078865|DEVICE|FX Artificial Shoulder Prosthesis|Humelock II Anatomic Shoulder System, Humelock II Reversible Shoulder System, Humelock Reverse Shoulder System, Humeris Shoulder System,Easytech Anatomical Shoulder System, PRCT II Fracture Plate, V-135
224017853|NCT02585232|BEHAVIORAL|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
224017854|NCT02585232|BEHAVIORAL|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
224017855|NCT03781999|DIETARY_SUPPLEMENT|Actiful|supplement containing 500 mg orange extract and 200 mg pomegranate actives
224017856|NCT03781999|OTHER|Placebo|Maltodextrin
224017857|NCT03215810|PROCEDURE|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
224017858|NCT03215810|DRUG|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
223397914|NCT07111845|BEHAVIORAL|Medical Consultation|Participants will be randomly assigned to receive medical consultation about urinary stone disease from one of five sources: a real urologist (in-person) or one of four AI chatbots (ChatGPT, Gemini, Perplexity, or Microsoft Copilot). Each participant will be instructed to ask all their questions related to urinary stone disease and continue the consultation until they feel adequately informed. The consultation format (human vs. AI) will depend on group assignment. After the session, participants will complete a validated satisfaction questionnaire (CSQ-8) to assess their experience.
223397915|NCT04240626|DRUG|Neurontin|600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours
224017859|NCT03215810|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
224017860|NCT03215810|DRUG|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
223550840|NCT01605357|DRUG|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
223550841|NCT04576910|BIOLOGICAL|vaccinated with Sabin IPV|the 4th dose of polio vaccination
223550842|NCT04576910|BIOLOGICAL|vaccinated with bOPV|the 4th dose of polio vaccination
224129393|NCT06397924|DIETARY_SUPPLEMENT|Chitin Fiber|Dietary fiber isolated from an edible insect (chitin)
224129394|NCT06397924|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224129395|NCT01385423|DRUG|Preparative Regimen|Fludarabine 25 mg/m\^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (\*if \< 4 months from prior transplant, omit day -4 dose)
224129396|NCT01385423|BIOLOGICAL|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
224296630|NCT01271751|DRUG|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
224017861|NCT03215810|OTHER|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
224296631|NCT01271751|DRUG|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
224017862|NCT03215810|DRUG|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
224017863|NCT02630888|DRUG|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
224017864|NCT02630888|DRUG|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
224017865|NCT00064610|DRUG|VELCADE TM (bortezomib) for Injection|
224017866|NCT02313233|DIETARY_SUPPLEMENT|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
224017867|NCT02313233|DIETARY_SUPPLEMENT|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
224017868|NCT03445923|OTHER|Time lapse monitoring (KID Score)|The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
224017869|NCT03018054|DRUG|E6007|once daily administration
224017870|NCT03018054|DRUG|Placebo|once daily administration
224129397|NCT05540899|RADIATION|Hypofractionated Postoperative Radiotherapy|Hypofractionated Postoperative Radiation Therapy
224129398|NCT01401010|DRUG|Doripenem|500 mg every 8 hours
223397916|NCT04240626|DRUG|Dilaudid Injectable Product|.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours
223397917|NCT04240626|DRUG|Marcaine Injectable Product|0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.
224129399|NCT01401010|DRUG|doripenem|1000 mg every 8 hours
224129400|NCT06600048|DRUG|Hyperbaric prilocaine|Patients will receive 1.5 ml (30 mg) 0.5% hyperbaric prilocaine.
223397918|NCT04240626|DRUG|Oxycodone Hydrochloride|1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control
223397919|NCT04240626|DRUG|Hycet 7.5Mg-325Mg/15Ml Solution|Dosage: 10-15ml q4h prn for pain control
223397920|NCT04240626|DRUG|Zofran Injection|4 mg IV for nausea control while inpatient, prn
223397921|NCT04240626|DRUG|Scopolamine patch|Topical application patch for nausea control, used with/without Ativan.
223397922|NCT04240626|DRUG|Ativan|0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control
223397923|NCT04240626|DRUG|Flexeril Oral Product|5 mg orally q8h prn for muscle spasms.
223397924|NCT04240626|DRUG|Tylenol Suspension|1000 mg q6h PRN for pain control.
223397929|NCT06925932|BEHAVIORAL|Dietary advice - Sweet taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are sweet but have no or low amounts of free sugars, e.g., sweet no- or low-free sugar foods, fruit, and no- or low-calorie sweeteners.
223397930|NCT06925932|BEHAVIORAL|Dietary advice - Taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are non-sweet but are full of tasty flavours, e.g., non-sweet foods and drinks with nuts, herbs or spices.
224129401|NCT06600048|DRUG|Hyperbaric bupivacaine|Patients will receive 1.5 ml (7.5 mg) 0.5% hyperbaric bupivacaine.
224129402|NCT06579833|RADIATION|Histotripsy|Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.
224129403|NCT05954377|OTHER|Quarterly remote motivational interviews|Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
224129404|NCT06983028|DRUG|Atacicept|Atacicept 150 mg SC QW via pre-filled syringe
224129405|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
224017871|NCT01859286|OTHER|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
224017872|NCT05345808|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide formulated with chondroitin sulfate and sodium hyaluronate
224017873|NCT01965353|DRUG|Panobinostat|\- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
224017874|NCT01965353|DRUG|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
224129406|NCT00430313|PROCEDURE|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
224129407|NCT03966105|DIAGNOSTIC_TEST|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
224129408|NCT04144452|OTHER|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
224129409|NCT04144452|OTHER|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
224129410|NCT06603662|DRUG|Prednisone|Subjects assigned to the Intervention A group will receive oral prednisone 50 mg once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours for 5 days.
223550843|NCT01202240|DRUG|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
223550844|NCT02274220|DIETARY_SUPPLEMENT|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
223550845|NCT02274220|DIETARY_SUPPLEMENT|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
223550846|NCT01148901|DRUG|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
224017875|NCT01965353|DRUG|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
224017876|NCT01965353|DRUG|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
224017877|NCT02318953|DEVICE|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
224129411|NCT06603662|DRUG|Dexamethasone|Subjects assigned to the Intervention B group will receive a single oral dose of dexamethasone 10 mg, plus standard ibuprofen 600 mg every 8 hours for 5 days.
224129412|NCT06603662|DRUG|Placebo|Subjects assigned to the Control group will receive oral placebo once a day for 5 days, plus standard ibuprofen 600 mg every 8 hours.
224129413|NCT05414617|DEVICE|Intra-articular single injection|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injection will be performed at Day 1."
224129414|NCT05414617|DEVICE|Intra-articular three injections|"Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.~The injections will be performed at Days 1, 8 and 15."
224296632|NCT02704780|DRUG|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
224296633|NCT01066091|OTHER|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
224296634|NCT01066091|OTHER|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
224017878|NCT02318953|OTHER|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
224296635|NCT01066091|OTHER|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
223397931|NCT06925932|BEHAVIORAL|Dietary advice - No taste|Asked to reduce their free sugar intakes to \< 5%TEI and replace sweet foods and drinks that are high in free sugars with foods and drinks that are non-sweet and have no strong flavours, e.g., non-sweet plain foods and drinks.
224017879|NCT04130763|BIOLOGICAL|FMT capsule|FMT capsules administration starts in the first week of enrollment. Capsules are taken for three consecutive days in the first week. From week 2, anti-PD-1 therapy will be administrated in combination with the maintenance dose of FMT treatment once every two weeks for up to 6 times.
224017880|NCT00809744|DRUG|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
224129415|NCT01054677|BEHAVIORAL|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
224129416|NCT06378073|DIAGNOSTIC_TEST|Incentive Spirometer|"Specificity and sensitivity: Incentive spirometry is a specific type of spirometry that aims to encourage people to breathe deeply intentionally but does not provide a measurement or inform management of chronic lung diseases. Less than 5 repetitions per day (sensitivity 93%, specificity 77%) and less than 2 balls per repetition (sensitivity 93%, specificity 77%) were predictive of postoperative pulmonary complications. (1) Validity and reliability: Incentive spirometry can be used as a simple mean to follow lung function, especially VC, in the postoperative period in spontaneously breathing patients. Incentive spirometry is noninvasive and can be performed repeatedly at the bedside in the intensive care setting. (2)~Interpretation:~There are only three numeric values that are required to interpret spirometry:~* Forced Vital Capacity (FVC)~* Forced Expiratory Volume (FEV1)~* FEV1/FVC ratio."
224129417|NCT06378073|DIAGNOSTIC_TEST|Numeric Pain Rating Scale|"Sensitivity: The area under the receiver operator characteristic curve for the NRS as a test for pain that interferes with functioning was 0.76, indicating fair accuracy. A pain screening NRS score of 1 was 69% sensitive for pain that interferes with functioning. (4) he diagnostic value of different NRS cut-off values for administering analgesics is determined by an ROC curve. Sensitivity of NRS \> 3 for 'unbearable' pain in older patients was 72% with a specificity of 97·2%. With a cut-off point NRS \> 4, sensitivity increased to 83%, while specificity was 96·7%. (5) Validity and reliability: The numerical rating scale is a reliable and valid tool for pain assessment in patients with musculoskeletal impairments. (3)~Measurement (circle): Categorical /Numerical /Both:~Numerical:~The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. no pain) to '10' representing the other pain extreme (e.g. pain as bad as you can imagine or worst pain imaginable)"
224129418|NCT05121077|OTHER|Training|2 types of training intervention will be applied in terminal heart failure patients supported with a left ventricular assist device.
224017881|NCT00830089|DRUG|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
224129419|NCT02654106|RADIATION|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
224129420|NCT02654106|DRUG|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
224129421|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
224129422|NCT01401426|PROCEDURE|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
224129423|NCT05020938|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
223397932|NCT06932107|DRUG|Aprepitant Injection|Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
223397933|NCT06932107|DRUG|Aprepitant Injection Placebo|Before anesthesia induction, 4.4ml was given by a single intravenous injection, which was completed within 30 seconds
223731389|NCT06494839|PROCEDURE|Bipolar electrocautery tonsillectomy technique|The BED tonsillectomy procedures were done under general anesthesia, and the patient's position was the same as in the other method. The bipolar machine was adjusted to 30 watts, and a mucosal incision was cauterized with a single straight or stepped bipolar forceps. After carefully cauterizing the tissue, the palatine tonsil was located and removed from the superior to the inferior pole. Most of the identifiable vessels supplying the tonsil were cauterized before being separated from the tonsil. Point coagulation was used to maintain hemostasis. By using point coagulation, hemostasis was maintained. To avoid bias stemming from competence, consultants performed all of these tonsillectomies.
224017882|NCT04976244|PROCEDURE|Intravitreal injection|Intravitreal injection to the regimen pro re nata
224017883|NCT01073787|DRUG|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
224017884|NCT03078777|DRUG|Fexofenadine|Fexofenadine will be administered to patients.
224017885|NCT00810433|PROCEDURE|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
224129424|NCT03135028|DRUG|Entospletinib|400 mg (2 × 200 mg tablets) orally twice daily
224129425|NCT03135028|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
224138639|NCT03247413|DRUG|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
224138640|NCT03247413|DRUG|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
223397934|NCT05696444|DEVICE|RAS Prostatectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system.
223397935|NCT05696444|DEVICE|RAS Cystectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for cystectomy will have the RAS surgery using the Medtronic Hugo RAS system.
223397936|NCT05696444|DEVICE|RAS Nephrectomy|Subjects indicated for Robotic Assisted Surgery (RAS) for nephrectomy (Radical/Partial) will have the RAS surgery using the Medtronic Hugo RAS system.
223397937|NCT05673577|DRUG|Camrelizumab+cetuximab+chemotherapy|"Camrelizumab: 200mg vgtt q3w, 3 weeks as a cycle; Cetuximab first dose 400mg/m2, vgtt, following by 250 mg/m2 after first dose, qw, 3 weeks as a cycle; albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles; cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles;~Then, in maintenance therapy, Camrelizumab: 200mg vgtt q2w; Cetuximab 500mg/m2, vgtt q2w until intolerable toxicity or disease progression"
223397938|NCT01609790|BIOLOGICAL|Bevacizumab|Given IV
223397939|NCT01609790|OTHER|Laboratory Biomarker Analysis|Correlative studies
223397940|NCT01609790|OTHER|Pharmacological Study|Correlative studies
223397941|NCT01609790|OTHER|Placebo Administration|Given IV
223397942|NCT01609790|BIOLOGICAL|Trebananib|Given IV
223397943|NCT06940973|GENETIC|Parental samples|"On fertilization, following the conventional ICSI/IVF procedure, samples from cumulus cells (obtained during the routine oocyte denudation process) and surplus sperm cells present in seminal plasma will be retrieved. These samples will be stored frozen at -20°C until they are sent to Igenomix. There, they will be used to perform the genetic analysis required to achieve the study's objectives, provided the patient consents to participate. If the patient ultimately chooses not to participate, these samples will be destroyed.~Parents may be asked to provide a saliva sample for the same purpose in cases where obtaining the samples during fertilization was not possible or if the collected samples were unsuitable for processing in the laboratory. The saliva sample may be collected at the clinic during one of the scheduled visits for reproductive treatment or, alternatively, by the parents at home using a kit provided by the clinic."
223550847|NCT05226832|PROCEDURE|40mg Triamcinolone Injections in the Bladder|Patients will undergo a standard of care cystoscopy with non-standard of care solumedrol injections in the clinic. Subjects will have lidocaine jelly instilled into their bladder for 5 minutes prior to injection cystoscopy. Injections will be performed using a 17fr flexible cystoscope in the outpatient setting. There will be 10 intravesical Injections of 1cc of 40mg solumedrol diluted to 10cc with injectable normal saline. The needle will penetrate the bladder at a depth of 2-3mm using a Laborie endoscopic single use needle, about the length of a pencil tip. The patient may experience discomfort with cystoscopy and injections. Any procedure complications will be noted based on the Clavien-Dindo Classification Index, discussed in the safety section. This is estimated to take 30 minutes.
223550848|NCT04768205|DEVICE|Kinesio tape|The Kinesio tex tape is a medical tape that had been certified and patented.
223550849|NCT03548896|PROCEDURE|Post extraction socket|\*\*Dental implant will be placed 3 months after tooth extraction
223550850|NCT06495892|DRUG|Diuretic therapy|Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
223550851|NCT06097078|DEVICE|Eso-SPONGE®|minimally invasive treatment and prevention of anastomotic leakages and perforations in the upper gastrointestinal tract (upper GIT)
223550852|NCT06522477|OTHER|Virtual reality gait training|Individuals will walk on a treadmill with overhead harness system in place while viewing 1st-person perspective walking videos on a television placed immediately in front of the treadmill.
223550853|NCT02054039|DEVICE|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
223550854|NCT02054039|DEVICE|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
223550855|NCT05715138|PROCEDURE|GPi-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 1.5mm) will be inserted into the posteroventral part of bilateral GPi nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
224017886|NCT05347251|OTHER|Cervicothoracic mobility program|"Participants in this group will receive mobilization at a cervical and thoracic level along with conventional physical therapy protocol like Hot packs and exercise therapy.~At the cervical, PA glides (central) and transverse glides will be given for mobilization.~At thoracic, PA glides (central) and transverse glides will be given for mobilization.~Exercise therapy includes stretching and strengthening both cervical and thoracic muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck~stretching exercises (flexors, extensors, side benders~and rotators) will perform as well. Similarly, at the thoracic~level, strengthening and stretching of thoracic muscle will be performed"
224017887|NCT05347251|OTHER|Conventional Treatment|"It will be the control group. The participants who will be allocated in this group receive the only conventional physical therapy protocol (Hot pack and exercise therapy). Exercise therapy includes stretching and strengthening of neck and upper back muscles. At the cervical level, neck isometric (flexion, extension, side bending) will be given to patients to enhance strengthening, and neck stretching exercises (flexors,~extensors, side benders, and rotators) will perform~as well. Similarly at the thoracic level, strengthening and stretching of thoracic muscle will be performed."
224017888|NCT01180205|DRUG|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
224017889|NCT01180205|DRUG|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
224017890|NCT01180205|DRUG|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
224017891|NCT01180205|DRUG|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
224017892|NCT00219102|DRUG|aliskiren|
224017893|NCT02441231|DRUG|Visbiome|Visbiome probiotic
224017894|NCT02441231|OTHER|Placebo|Placebo
224017895|NCT02774239|DRUG|Human normal immunoglobulin G (IgG)|"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."
224017896|NCT05365360|DEVICE|LaserCap SD|LaserCap SD
224017897|NCT05365360|DEVICE|Sham LaserCap|Sham LaserCap
224017898|NCT05365360|DEVICE|LaserCap HD+|LaserCap HD+
223397944|NCT06940973|DIAGNOSTIC_TEST|PGT-A|On day 3 of development, assisted hatching will be performed to facilitate biopsy at the blastocyst stage. Each embryo will be biopsied in the laboratory using conventional trophectoderm (TE) biopsy techniques on day +5, +6, or +7 of development, depending on when they reach the appropriate blastocyst stage. After biopsy, blastocyst will be vitrified following the clinical routine protocol and store until the genetic results are available. The biopsy samples will be placed in a PCR tube labeled with its corresponding study-specific code and stored in a cold rack at 4°C before being transferred to a freezer at -20°C. Finally, the samples will be sent to the Igenomix for preimplantation genetic testing for aneuploidy.
223397945|NCT06940973|GENETIC|TE rebiopsies and spent blastocyst media collection|"After obtaining the PGT-A results, any embryo not genetically confirmed as euploid and without ploidy abnormalities will be thawed, washed, and cultured for rebiopsy. A complementary analysis using next-generation sequencing (NGS) techniques will be performed to confirm the diagnosis and determine the origin of the abnormalities. For this additional analysis, in addition to the new biopsies, the individual culture medium of each embryo will be aspirated after an incubation period of 8 to 24 hours. The collected medium will be placed in PCR tubes and stored in a freezer at -20°C before being sent to the laboratory.~Regardless the result of these complementary analysis, no rebiopsied blastocyst will be considered for clinical purposes."
223397946|NCT06941233|BEHAVIORAL|Our Peers - Empowerment and Navigational Support - Community Living (OP-ENS - CL)|Op-ENS - CL is a 12-month, remote delivered peer navigator intervention. Participants will meet with a trained peer navigator who mentors nad supports them through a manualized process of collaborative conversations, barrier identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
223550856|NCT05715138|PROCEDURE|STN-DBS|An elaborate target/trajectory planning and a precise image fusion of MRI and stereotactic CT scanning are performed before surgery. After microelectrode recording, two sets of quadripolar DBS leads (contact interval is 0.5mm) will be inserted into the dorsolateral part of bilateral STN nuclei separately. Subsequently, an implantable pulse generator will be connected via extension wires and implanted at the left/right subclavicular area subcutaneously.
223550857|NCT05715138|DEVICE|GPi-DBS devices|"1. DBS electrode: 3387 (Medtronic, Minneapolis, MN, USA) or L302 (PINS Medical, Beijing, China) or 1210(SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
224017899|NCT01290653|OTHER|Dry needling|Deep dry needling until achieving twitch response of the muscle
224017900|NCT01290653|OTHER|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
224017901|NCT01290653|OTHER|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
224017902|NCT04595318|DRUG|Standard clinical care first, followed by standard clinical care and varenicline|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
224017903|NCT04595318|DRUG|Standard clinical care and varenicline first, followed by standard clinical care|Standard clinical care includes substance use disorder treatment program-based individual behavioral counseling at least once a month using motivational and cognitive behavioral strategies. Varenicline therapy includes a one month's supply of the medication in standard doses: 0.5 mg for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 21 days.
224017904|NCT02907515|DEVICE|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
224017905|NCT02907515|DEVICE|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
224017906|NCT00054054|DRUG|cisplatin|
224017907|NCT00054054|DRUG|docetaxel|
224017908|NCT00054054|DRUG|fluorouracil|
224017909|NCT00054054|RADIATION|radiation therapy|
224017910|NCT04762121|PROCEDURE|Peripheral IV|Insertion of peripheral intravenous catheter
224017911|NCT02183844|BEHAVIORAL|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
224017912|NCT01354561|PROCEDURE|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
224017913|NCT06476613|OTHER|Permissive Hypotension|Patients will be randomized in 1:1 fashion to either a) Permissive Hypotension (MAP target \> 60mmHg) or b) Usual Care. The duration of the intervention will extend until the patient no longer needs vasopressors to maintain prespecified MAP.
224017914|NCT02412410|BEHAVIORAL|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
224017915|NCT04617561|DRUG|Ursodeoxycholic acid|Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
224017916|NCT04617561|DRUG|Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)|Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
224017917|NCT02479321|OTHER|GDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
224138641|NCT03428841|PROCEDURE|Audiometry|
224138642|NCT02892838|DEVICE|mobile bearing knee system for total knee arthroplasty|
223397947|NCT06940011|DIETARY_SUPPLEMENT|Endocalyx Pro|4 capsules once daily OR 2 capsules twice daily
223397948|NCT06940011|OTHER|Placebo|4 capsules once daily OR 2 capsules twice daily
224129426|NCT03135028|DRUG|Cytarabine|"100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle"
223397949|NCT06940128|PROCEDURE|Direct Ischemic Conditioning A|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.
223397950|NCT06940128|PROCEDURE|Direct Ischemic Conditioning B|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.
223397951|NCT06940128|PROCEDURE|Direct Ischemic Conditioning C|Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.
223397952|NCT06940999|OTHER|Traditional physical therapy|Application of laser three times per week in addition to applying deep friction massage, stretching exercises along with the uses of pressure garment.
223397953|NCT06945107|DRUG|Picankibart|"The participants in picankibart treatment group will receive picankibart 200mg SC at Weeks 0, 4, 8, 20 and 32.~The participants in IL-17 mAb continued treatment group will receive picankibart 200mg SC at Weeks 16, 20, 24 and 36."
223397954|NCT06945107|DRUG|Secukinumab|The participants in IL-17 mAb continued treatment group who have received secukinumab before enrollment, will receive secukinumab 300mg SC at Weeks 0, 4, 8 and 12.
223397955|NCT06945107|DRUG|Placebo|"The participants in picankibart treatment group will receive placebo SC at Weeks 12, 16, 24 and 36.~The participants in IL-17 mAb continued treatment group will receive placebo SC at Week 32."
223397956|NCT06945107|DRUG|Ixekizumab|The participants in IL-17 mAb continued treatment group who have received ixekizumab before enrollment, will receive ixekizumab 80mg SC at Weeks 0, 4, 8 and 12.
223397957|NCT06795035|DIAGNOSTIC_TEST|Continuous Saline Thermodilution|Continuous saline thermodilution for determination of microvascular resistance reserve (MRR) is a novel operator-independent method to assess coronary microvascular function. CST has been studied in the setting of angina with nonobstructive coronary arteries (ANOCA), but not in the setting of acute MI. In contrast, bolus thermodilution, used to determine the index of microcirculatory resistance (IMR), has been shown in the setting of STEMI to predict extent of myocardial injury and long-term clinical outcomes (e.g., heart failure, mortality, nonfatal MI, and ischemic stroke). In contrast to bolus thermodilution techniques, CST does not require the use of active medications (e.g., papaverine or adenosine) -- only a small volume of normal saline.
224017918|NCT02479321|DEVICE|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
224017919|NCT02084173|BEHAVIORAL|MET + CRA|
224017920|NCT04083573|OTHER|application of medical augmented reality glasses|Endoscopic images from medical monitor and medical augmented reality glasses will be collected and reviewed. Outcomes from both series of images will be compared
224017921|NCT04374851|DEVICE|Polaris miniRITE BTE|The Polaris device is programmed with computer software to match the Hearing loss of the participant.
224017922|NCT04374851|DEVICE|Viron miniRiTE BTE|The Viron Hearing device is programmed with computer software to match the Hearing loss of the participant.
224017923|NCT01927926|DIETARY_SUPPLEMENT|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
224017924|NCT01927926|DIETARY_SUPPLEMENT|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
224017925|NCT06243861|BEHAVIORAL|Mother-child bond|assessing whether the mother-child bond is degraded in the UK, in comparison with that of mothers in post-natal care
224129427|NCT00748540|DEVICE|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
223397958|NCT03212235|RADIATION|Hypofractionated radiation therapy|Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
223397959|NCT06941298|BEHAVIORAL|Neuroimaging Investigation|Participants will undergo fMRI neuroimaging at two timepoints, at the start of the study and at the 1 year follow up. The fMRI is one hour in duration. During the fMRI, participants will complete two tasks investigating diverse aspects of reward circuitry activity. After this is completed, participants will be followed up for another year clinically.
223397960|NCT04388852|BIOLOGICAL|Ipilimumab|Given IV
223397961|NCT04388852|DRUG|Valemetostat|Given PO
223397962|NCT03886025|OTHER|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
223397963|NCT03886025|BEHAVIORAL|Cognitive training|Iowa Gambling Task will be used for cognitive training
223397964|NCT03886025|OTHER|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
223397965|NCT06946641|DRUG|QLS12010|QLS12010 oral capsule(s)
224017926|NCT02679573|DRUG|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
224017927|NCT02679573|DRUG|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
224017928|NCT02679573|DRUG|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
224129428|NCT03803761|DRUG|Copanlisib|Given IV
224129429|NCT03803761|DRUG|Fulvestrant|Given IM
224138643|NCT02892838|DEVICE|fixed bearing total knee prosthesis|
224138644|NCT01392053|OTHER|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
224138645|NCT04694105|DRUG|Dexmedetomidine injection|perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline
224017929|NCT03390218|BEHAVIORAL|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
224017930|NCT03390218|BEHAVIORAL|Treatment as usual|Individual and group therapy, generic in nature
224017931|NCT00004204|DRUG|temozolomide|
224017932|NCT01344954|DRUG|TB-402|Administered intravenously over 10 minutes
224017933|NCT01344954|DRUG|Rivaroxaban|Administered orally as a capsule once a day for 35 days
224129430|NCT00720239|OTHER|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
224129431|NCT04747808|DRUG|LL-BMT1|Drug-printed contact lens in both eyes
224129432|NCT02464787|DIETARY_SUPPLEMENT|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
224129433|NCT03765346|DRUG|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
224129434|NCT03765346|DRUG|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
223550858|NCT05715138|DEVICE|STN-DBS devices|"1. DBS electrode: 3389 (Medtronic, Minneapolis, MN, USA) or L301 (PINS Medical, Beijing, China) or 1200 (SceneRay, Suzhou, China);~2. Extension wire: 37086 (Medtronic, Minneapolis, MN, USA) or E202 (PINS Medical, Beijing, China) or 1340/SR1341 (SceneRay, Suzhou, China);~3. Implantable pulse generator: ACTIVA PC/RC (Medtronic, Minneapolis, MN, USA) or G102/G102R (PINS Medical, Beijing, China) or 1180/SR1101 (SceneRay, Suzhou, China)."
224129435|NCT03765346|DRUG|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
224129436|NCT03765346|DRUG|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
224017934|NCT01344954|DRUG|TB-402|Administered intravenously over 10 minutes
224129437|NCT02824380|DRUG|DA-4001 H|5% minoxidil / high dose of finasteride
224129438|NCT02824380|DRUG|DA-4001 L|5% minoxidil / low dose of finasteride
224129439|NCT01791868|DRUG|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
224129440|NCT01791868|DRUG|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
224129441|NCT04757935|BEHAVIORAL|Yoga|Yoga for 30 minutes three times weekly for 8 weeks in addition to three, 1-hour in-studio yoga sessions.
224129442|NCT03604471|DRUG|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
224129443|NCT05715541|OTHER|"mobile applications with the name Set My INR"|"The relevant software company assisted in developing the phone application. The language of the application created with the name Set My INR is Turkish. The application provided an opportunity for patients to share and communicate with their physician after having the INR value measured in a health institution near their place of residence before coming to the hospital"
224129444|NCT02532634|DRUG|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
224129445|NCT02532634|DRUG|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
224129446|NCT00308425|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
224017935|NCT01046773|DRUG|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
224017936|NCT01046773|DRUG|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
224017937|NCT03996343|DEVICE|Endotracheal intubation|COMPLETE
224017938|NCT03996343|DEVICE|Laryngeal mask airway|COMPLETE
224017939|NCT03801122|DRUG|Tranexamic acid|Administration of tranexamic acid, with 3 injections/8 hours.
224129447|NCT00530322|PROCEDURE|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
224129448|NCT05960344|PROCEDURE|Spirometry|Supervised v unsupervised spirometry
224129449|NCT04208867|BEHAVIORAL|QI Collaborative|Facilities that participated in a QI collaborative to improve PCC for MH services
223550859|NCT00642707|DRUG|PRO 140 (humanized monoclonal antibody to CCR5)|
224017940|NCT00212420|PROCEDURE|parenteral nutrition; enteral nutrition|
224017941|NCT01214265|DEVICE|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
224017942|NCT04156854|DIAGNOSTIC_TEST|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
224017943|NCT05636423|OTHER|Survey|Online survey via a questionnaire composed of 28 questions.
224017944|NCT01143779|DRUG|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
224017945|NCT05619029|RADIATION|X-ray|Chest radiographs
224017946|NCT00836420|PROCEDURE|no intervention|the value of the clinical use of microdialysis monitoring of the brain
224017947|NCT03561831|DRUG|Propofol|propofol based anesthesia
224017948|NCT03561831|DRUG|Sevoflurane|sevoflurane based anesthesia
224017949|NCT01506609|DRUG|Placebo|
224017950|NCT01506609|DRUG|Veliparib|
224017951|NCT01506609|DRUG|Carboplatin|
224017952|NCT01506609|DRUG|Temozolomide|
224017953|NCT01506609|DRUG|Paclitaxel|
224138646|NCT04694105|DRUG|Dexamethasone|perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)
224138647|NCT04694105|DRUG|saline|perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
223397966|NCT06946641|DRUG|Placebo|Matching placebo oral capsule(s)
223397967|NCT03376724|OTHER|Functional Exercise Protocol|Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.
223397968|NCT03376724|OTHER|Minimal|Analgesic use when necessary and a single back scholl class
223397969|NCT03427242|DRUG|Apatinib|oral apatinib 750mg qd
223397970|NCT03460002|BIOLOGICAL|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
223397971|NCT03460002|BIOLOGICAL|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
223397972|NCT00518700|OTHER|new MPS|
223397973|NCT00518700|OTHER|RepleniSH|
223397974|NCT00980694|DIETARY_SUPPLEMENT|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
223397975|NCT04941820|OTHER|clinical pharmacist intervention|clinical pharmacist intervention
223550860|NCT00642707|DRUG|Placebo Comparator|
223550861|NCT05795270|OTHER|Treatment|Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
223550862|NCT01016132|DEVICE|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
223550863|NCT06213207|OTHER|Simulator based training to manage asphyxia and essential newborn care using neonatalie|The intervention, HBB training package will be used which was applied to train the hospitals staff in Nepal (Chaulagain et al., 2021) and Laerdal Global Health (Laerdal Global Health, 2021) to enhance the competencies on the resuscitation to newborn using NeoNatalie. Health workers will receive 5 days simulation training by expert pediatrician and pediatric nurse who have prior working experience in Neonatal Intensive Care Unit (NICU) or Special Neonatal Care Unit. After the training, mentoring and coaching will be provided experienced newborn coach/trainer on a monthly basis for six months.
223550864|NCT04160312|DIETARY_SUPPLEMENT|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
223550865|NCT04160312|DIETARY_SUPPLEMENT|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
223550866|NCT04303429|DRUG|FOLFOX/XELOX/Capecitabine|Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
223550867|NCT02227810|OTHER|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
224017954|NCT05253820|PROCEDURE|distal radial approach|coronary diagnosis and intervention via distal vs conventional radial approach
224017955|NCT05253820|PROCEDURE|conventional radial access|conventional radial access
224017956|NCT05128461|OTHER|Exercise|M-CIMT-based telerehabilitation will be implemented.
224017957|NCT05128461|OTHER|Home program|Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
224017958|NCT02389920|DRUG|Nilotinib|
224017959|NCT01777451|OTHER|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
224017960|NCT05413109|RADIATION|Coronary CT angiography|"A coronary CT angiography will be used to study the relationship between the PA and the LMCA and 4 radiological patterns will be considered:~1. Normal: minimum distance between the two vessels\> 1 mm;~2. Proximity: distance between the two vessels ≤1 mm without displacement or stenosis of the LMCA;~3. Dislocation: dislocation of the LMCA by the main branch of the PA with a take-off angle \<60 ° (the take-off angle is defined by the angle formed by the perpendicular to the aortic valve ring and the longitudinal axis of the LMCA);~4. Compression: stenosis of the LMCA ≥50% due to extrinsic compression by the PA."
224017961|NCT05319301|DIETARY_SUPPLEMENT|Melatonin|A single dose of melatonin (1.9 mg)
224017962|NCT02276183|DIETARY_SUPPLEMENT|Nutrition intervention, test formula|
224017963|NCT02276183|BEHAVIORAL|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
224017964|NCT04418570|BEHAVIORAL|cognitive remediation|
224017965|NCT04418570|OTHER|attendance to an Early Intervention Service for Psychosis|
224017966|NCT00002996|DRUG|flecainide acetate|
224017967|NCT00090077|DRUG|GW695634|
224017968|NCT02192125|DEVICE|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:~1. patient station (PS), which is installed in the home environment of the patient:~   Includes:~   Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~2. Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~   Includes:~   Laptop MySQL- database~3. station networking (NS), which allows a combination of a several of HS. database"
223397976|NCT06950957|DEVICE|Video Laryngeal Mask Airway (VLMA)|A second-generation supraglottic airway device with an integrated video camera, used for airway management in adult patients undergoing elective septoplasty. The device allows real-time visualization of the glottic inlet to identify blood infiltration or anatomical challenges. Prior to removal, a fiberoptic bronchoscope will be introduced through the device's lumen to assess the distal trachea for blood contamination. Parameters such as airway insertion time, ventilation mechanics, hemodynamic data, analgesic requirements, and postoperative recovery scores (e.g., Aldrete score, sore throat incidence) will be recorded and analyzed.
224129450|NCT01668563|PROCEDURE|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
224129451|NCT01668563|PROCEDURE|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
224129452|NCT04436224|DRUG|Hydromorphone|Intravenous analgesia using hydromorphone in ICU patients with non-mechanical ventilation(NS 40ML+ hydromorphone 10mg ，IV-Pump)
224129453|NCT04436224|DRUG|Fentanyl|Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
224129454|NCT04436224|DRUG|Butorphanol|Intravenous analgesia using butorphanol in ICU patients with non-mechanical ventilation(NS 40ML+ butorphanol 10mg，IV-Pump)
223397977|NCT06950957|DEVICE|Endotracheal Tube (ETT)|A standard cuffed endotracheal tube inserted using direct laryngoscopy, employed for airway management during elective septoplasty. At the end of surgery, a fiberoptic bronchoscope will be passed through the ETT to evaluate the distal trachea for blood contamination. Airway insertion time, ventilation parameters, intraoperative hemodynamics, analgesic use, and postoperative outcomes (including sore throat and recovery scores) will be documented and compared with the VLMA group to assess differences in airway safety and clinical performance.
223397978|NCT05671588|PROCEDURE|Controlled combined exercise group|Patients will undergo protocol-defined combined aerobic-resistant therapy on a cycling ergometer and multifunctional fitness device
223397979|NCT05671588|PROCEDURE|Conventional rehabilitation|Patients will undergo conventional rehabilitation.
224129455|NCT01814800|BIOLOGICAL|RI-002|Immune Globulin Intravenous (IGIV)
224129456|NCT02030145|PROCEDURE|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
223397980|NCT06955520|DRUG|Vonoprazan|a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.
223397981|NCT06955520|DRUG|Esomeprazole 40mg|It is a proton pump inhibitor which reduces the excessive acid secretion in the stomach and it heals grade B esophagitis (\>5mm ulcer between two mucosal folds in esophagus)
223397982|NCT06949228|DRUG|tenecteplase|Patients treated with standard of care mechanical thrombectomy (MT) that achieved mTICI 2b or higher revascularization. Patients will be randomized into one of two arms: IA TNK or control.
223397983|NCT06954493|DRUG|Ibrexafungerp|Ibrexafungerp Oral Tablet
223397984|NCT06951581|DIETARY_SUPPLEMENT|Short Chain Fatty Acid|Participants in this arm will receive an oral formulation of short-chain fatty acids (SCFAs) daily for 12 weeks. SCFAs are administered as a dietary supplement to investigate their potential impact on the systemic and urinary metabolome in kidney transplant recipients.
223397985|NCT06951581|DIETARY_SUPPLEMENT|Placebo Capsule(s)|Oral capsules with sacharosa (200 mg) matching SCFA appearance, administered once a day.
223397986|NCT07112001|BEHAVIORAL|PositiveLinks with Counseling|A community health worker delivered, specialized counseling intervention through video call on the PositiveLinks app
223397987|NCT07112001|BEHAVIORAL|Standard of Care (SOC)|This intervention includes the use of the unmodified PositiveLinks app and the standard of care for addressing anxiety and depression in the HIV clinic
223397988|NCT05776953|DRUG|Ketorolac|IV Ketorolac for pain
223397989|NCT04760990|OTHER|data collection|clinical data collection regarding COVID-19 suggestive symptoms or confirmed SARS-CoV-2-infections (medical events), recorded comorbidities (concomitant diseases relevant to MS and COVID-19) and recorded vaccinations (other treatments). This information is systematically collected during the routine clinical visits of the patient within the SMSC every 6-12 months.
223397990|NCT04760990|OTHER|analysis of blood samples|analysis of archived serum samples collected every 6-12 months within the SMSC for measurement of anti-SARS-CoV-2 antibodies in pre-pandemic reference samples and prospectively determine the anti-SARS-CoV-2-serostatus during the study period.
223397991|NCT03796988|DEVICE|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
223397992|NCT06068101|DIAGNOSTIC_TEST|Secreening test for primary aldosteronism and Confirmatory Testing|Serum aldosterone and plasma direct renin concentrations were measured by a chemiluminescent immunoassay. A positive PA screening was defined by aldosterone \> or = 10 ng/dL and aldosterone to renin ratio \> or = 2 ng/dL/uUI/mL
223397993|NCT03570827|DRUG|Androgen Suppression|Given androgen suppression therapy
223397994|NCT03570827|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223397995|NCT03570827|OTHER|Quality-of-Life Assessment|Ancillary studies
223397996|NCT03570827|OTHER|Questionnaire Administration|Ancillary studies
223397997|NCT03758417|BIOLOGICAL|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
223397998|NCT05768906|OTHER|observational|Observation of disagreements and even real legal conflicts on life-sustaining therapies limitation decisions between relatives and physicians
223397999|NCT06956157|DRUG|N-Acetylcysteine Tablets|In addition to participants' existing medication regimens, NAC will be added.
223398000|NCT06956157|DRUG|Placebo Oral Tablet|Placebo oral tablets are identical in appearance (size, shape, color), packaging, taste, and administration schedule to the N-Acetylcysteine tablets to maintain blinding. The tablets contain inert excipients and no active pharmacological ingredients.
224017969|NCT03704246|DRUG|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
223398001|NCT06954714|PROCEDURE|Drug-eluting stent implantation|"IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.~In DES group, latest second-generation DES will be used in accordance with standard practice guideline."
223550868|NCT02227810|OTHER|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
223550869|NCT02227810|OTHER|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
224017970|NCT04612959|OTHER|Psychosexual care|The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
224017971|NCT01873066|DEVICE|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
224017972|NCT01873066|DEVICE|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
224017973|NCT05839015|BEHAVIORAL|mHealth Intervention Based on Self-Compassion|Self-compassion techniques aim at developing compassionate skills for emotion regulation, such as self-kindness, recognition of common humanity, and mindfulness.
224017974|NCT02850120|PROCEDURE|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
224017975|NCT02850120|PROCEDURE|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
224017976|NCT02850120|PROCEDURE|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
224017977|NCT05352568|BEHAVIORAL|Cognitive Training|Computer-Based Cognitive Training from BrainHQ (Posit Science)
224017978|NCT00003025|BIOLOGICAL|vitespen|
224017979|NCT01502631|DRUG|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
224017980|NCT01502631|DRUG|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
224017981|NCT00313001|DRUG|biphasic insulin aspart|
224017982|NCT00313001|DRUG|exenatide|
224017983|NCT05078320|BEHAVIORAL|Exposure and response prevention (ERP)|"The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP).~Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns."
224017984|NCT05309915|DRUG|STP707|STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
224017985|NCT01798121|BIOLOGICAL|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
224017986|NCT01798121|BIOLOGICAL|Reference standard|Response of reference standard material compared to Aplisol@.
224017987|NCT04923074|OTHER|diffusion tensor imaging(DTI) evaluation|DTI is a new kind of MRI technique to evaluate peripheral neuropathy
224017988|NCT06109025|COMBINATION_PRODUCT|FESIA GRASP|The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.
224017989|NCT06109025|COMBINATION_PRODUCT|VIRTUAL REHAB|VirtualRehab is a therapeutic physical rehabilitation tool that uses virtual reality to provide therapy for patients with neurological or musculoskeletal disorders; providing a wide range of activities designed to improve mobility, coordination and strength.
224017990|NCT06109025|COMBINATION_PRODUCT|GLOBUS ELITE|is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
224017991|NCT01115296|DIETARY_SUPPLEMENT|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
224129457|NCT02030145|PROCEDURE|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
223550870|NCT01451749|DRUG|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
223550871|NCT01451749|DRUG|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
224017992|NCT01115296|OTHER|Placebo|Placebo
224017993|NCT01293487|BIOLOGICAL|RN564|Intravenous, single dose with experimental dose
224017994|NCT04643288|PROCEDURE|open flap debridement|open flap debridement for managing two and three walls intrabony periodontal defects
224129458|NCT04436822|DEVICE|Continuous Glucose Monitoring|CGM and frequent sample testing
224129459|NCT01333982|OTHER|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
224129460|NCT01333982|OTHER|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
224129461|NCT05807334|OTHER|DASH eating plan with eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to eat 2 whole eggs per day to supplement the DASH eating pattern.
224129462|NCT05807334|OTHER|DASH eating plan without eggs|Participants will receive guidance to follow a DASH dietary pattern tailored to their caloric requirements and their personal and cultural food preferences, along with sample meal plans and other supplemental educational materials to help them adopt and maintain the dietary pattern during this study. During this 8-week phase, they will also be instructed to exclude eggs from their diet on a daily basis.
224129463|NCT01470573|PROCEDURE|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
224129464|NCT02249286|BEHAVIORAL|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
224129465|NCT02249286|OTHER|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
224129466|NCT01188382|PROCEDURE|CSF dynamic investigation|
224129467|NCT01689207|DRUG|Avibactam (AVI)|PART A: AVI IV infusion
224017995|NCT04643288|PROCEDURE|n-HA bone graft|Nanocrystalline Hydroxyapatite bone graft substitute for managing two and three walls intrabony periodontal defects
224017996|NCT03936582|BEHAVIORAL|Treatment|information already included in arm/group descriptions
224129468|NCT01689207|DRUG|Aztreonam (ATM)|PART A: ATM IV infusion
224129469|NCT01689207|DRUG|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
224129470|NCT01689207|DRUG|Placebo|PART A, PART B, PART C: matching placebo IV infusions
224129471|NCT03744780|BEHAVIORAL|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
223550872|NCT03905915|DEVICE|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
223550873|NCT04691037|DIAGNOSTIC_TEST|CCTA|All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.
224129472|NCT05959772|RADIATION|Photobiomodulation|"Light-Aid equipment from Bright Photomedicine-Brasil will be used, with an 850 nm Arsenide, Gallium and Aluminum (AsGaAl) LED. Exposure time between 4 and 9 minutes; radiant exposure of approximately 41mW/cm2; with 8 clusters in each session. Two tapes containing four clusters each will be arranged, and each cluster contains 25 led's adding up to a total of one hundred (100) led's arranged in each on the tape"
224129473|NCT03566693|DEVICE|Dexcom G6 CGM System|continuous glucose monitor
224129474|NCT03566693|DEVICE|Blood glucose meter|Blue-tooth enabled blood glucose meter
224129475|NCT05130333|OTHER|No intervention|No intervention
223550874|NCT03063606|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
224129476|NCT00004013|BIOLOGICAL|trastuzumab|
224129477|NCT00004013|DRUG|paclitaxel|
224129478|NCT00335946|DEVICE|HANS non-needle acupuncture|
224129479|NCT00335946|PROCEDURE|Stimulation of two acupuncture points bi-lateral|
224129480|NCT03943758|DIETARY_SUPPLEMENT|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given 6 packs (60g/pack) pre-packaged formula LRD and asked to use the formula according to individual needs prior to colonoscopy.
223550875|NCT03063606|DRUG|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
224129481|NCT03943758|DIETARY_SUPPLEMENT|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
224129482|NCT04640324|DRUG|Nutraceutical therapy|Oral administration of 303mg of silybin-phospholipid complex, 10mg of vitamin D, and 15mg of vitamin E, twice a day for six months
224129483|NCT02244723|OTHER|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
224129484|NCT01150955|DIETARY_SUPPLEMENT|Resveratrol|500 mg three times a day for five weeks.
224129485|NCT01150955|OTHER|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
224129486|NCT00294008|DRUG|Risperdal Consta|flexible dosage for 24 months
224129487|NCT02844023|BEHAVIORAL|Clinical evaluation|With questionnaire.
224129488|NCT02844023|OTHER|Paraclinical evaluation|Symptom inflammatory, biomarkers.
224129489|NCT02844023|DEVICE|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
224129490|NCT02844023|OTHER|Ophthalmologic examination|
224017997|NCT00174512|DRUG|GTN|
224017998|NCT00174512|DRUG|Moxifloxacin|
224017999|NCT01975974|DEVICE|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
224129491|NCT02844023|BIOLOGICAL|Dosage of biomarkers|Control patients.
224129492|NCT02954003|DEVICE|Endo Bypass System|Subject is implanted with the device for up to 3 years.
224129493|NCT03076047|DEVICE|end-tidal CO2 (ETCO2) monitoring|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2, Capnostream, and Massimo
224129494|NCT00149604|DRUG|conjugated estrogens|
224129495|NCT00149604|DRUG|Raloxifene|
224129496|NCT00149604|BEHAVIORAL|exercise plus mild caloric restriction for weight loss|
223398002|NCT06954714|PROCEDURE|Drug-coated balloon angioplasty|"IVUS (OPTICROSS, Boston Scientific, USA) will be recommended to select proper size of predilatation balloon (semi- or non-compliant balloon), DCB, or DES. Optimal lesion preparation is defined as satisfying all of the followings: 1) a fully inflated balloon of the correct size for the vessel (balloon with vessel ratio \>0.90); 2) ≤35% residual stenosis; 3) TIMI (Thrombolysis In Myocardial Infarction) flow grade 3; and 4) the absence of a flow-limiting coronary artery dissection.15 After successful lesion preparation, patients will receive either DCB or DES according to randomly allocated groups.~In DCB group, commercially available DCB (Agent, Boston Scientific, USA) will be used. DCB angioplasty will be recommended as follows to fully optimized procedural results. First, DCB size should be 1:1 ratio with reference vessel size. Second, delivery time of DCB should be within 30 seconds. Third, total inflation time of DCB will be recommended from 30 to 60 seconds."
223398003|NCT05207865|DRUG|Rimegepant|rimegepant ODT 75mg daily
223550876|NCT05481983|OTHER|Walk exercise|The control group will be recommended to walk 5 days a week, 30-45 minutes (min.) (at least 150 minutes of physical activity per week), as recommended by ACOG for pregnant women. Exercise intensity will be given as 4-6 units for moderate-intensity exercise according to the Modified Perceived Difficulty Level (RPE).
223550877|NCT05481983|OTHER|One-on-one clinical exercise training|One-on-one clinical exercise training will be given by a specialist physiotherapist who has received special training in antenatal exercise. The program is designed to be 2 days a week for 8 weeks.
224129497|NCT05056467|PROCEDURE|Induction of Labor|Induction of Labor at 39 weeks of gestation
223550878|NCT05532228|PROCEDURE|Adenotonsillectomy|adenotonsillectomy by cold dissection
224018000|NCT04705636|DEVICE|"Connected device named Leo from Ludocare society"|"Connected device named Leo from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device."
224018001|NCT00395460|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
224129498|NCT02499003|DRUG|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
224129499|NCT06291103|DRUG|Conversion to Belatacep|CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
223550879|NCT04704713|DRUG|Afamelanotide|
223550880|NCT04704713|DRUG|Placebo|
223550881|NCT04944615|PROCEDURE|The guidewire successfully passed the CTO lesion|"The successful passage of the guide wire through the CTO lesion was defined as: the guide wire successfully passed through the CTO lesion and reached the distal true lumen as confirmed by angiography.~Aspirin load dose (300 mg), clopidogrel load dose (300 mg), or ticagrelor load dose (180 mg) is recommended for all subjects prior to stent implantation and is recommended to be taken at least 6 hours prior to surgery."
223550882|NCT03079531|DRUG|Secukinumab|Secukinumab 300 mg administered subcutaneously.
223550883|NCT01941927|DRUG|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
224018002|NCT00395460|DRUG|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
224018003|NCT04709315|DRUG|dexemedetomidine and rocuronium|In the DR group, patients received pretreatment with Dex 1 µg / kg in 10 ml 0.9% saline over 10 minutes and rocuronium 0.6 mg/kg was the intubating muscle relaxant
224018004|NCT04709315|DRUG|0.9% saline and succinyl choline 1mg/ kg|0.9% saline over 10 minutes, and succinyl choline 1mg/ kg
224018005|NCT04984733|DRUG|Temozolomide|"Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths."
224018006|NCT04984733|DRUG|Temozolomide 50mg/m2/day|Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
224129500|NCT06291103|DRUG|Standard of care treatment (SOC regimen) with Tacrolimus|Tacrolimus will be continued until kidney graft survival with objective of whole blood through levels between 6 and 8 ng/mL
224296636|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-coated balloon|"SeQuent Please (BBraun) + tailored antithrombotic regimen:~1. Stable patients without OAC: perioperative SAPT (preferably) or perioperative DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative SAPT (preferably) or perioperative DAPT and lifelong OAC~3. ACS patients without OAC: 1-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 1-month SAPT and lifelong OAC"
224018007|NCT04984733|DRUG|Temozolomide 3 month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
224018008|NCT04984733|DRUG|Temozolomide 24month|Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
224018009|NCT04399590|OTHER|Interficial Intelligence|Interficial Intelligence
224018010|NCT01679574|DRUG|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
224018011|NCT01679574|DRUG|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
224018012|NCT01679574|DRUG|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
224018013|NCT01124409|RADIATION|EPID Verification|Set up error verification and correction by EPID
224018014|NCT01124409|RADIATION|CBCT verification|Setup error verification and correction by CBCT
224018015|NCT00580346|DEVICE|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
224018016|NCT05715866|DEVICE|non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
224296637|NCT04814212|DEVICE|Percutaneous coronary intervention using drug-eluting stent|"Biofreedom (Biosensors), Synergy (Boston Scientific), Ultimaster Tansei (Terumo) and Integrity Onyx (Medtronic), Xience Pro S (Abbott) or Promus Elite (Boston Scientific) or any other DES can also be used provided that it has a CE mark for 1-month DAPT, combined with tailored antithrombotic regimen:~1. Stable patients without OAC: 1-month DAPT followed by lifelong SAPT~2. Stable patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and life-long OAC~3. ACS patients without OAC: 3-month DAPT followed by lifelong SAPT~4. ACS patients with OAC: perioperative DAPT followed by 6 months SAPT (ADP receptor blocker) and lifelong OAC"
224296638|NCT03310411|DRUG|Lasmiditan|Administered orally
224296639|NCT03310411|DRUG|Sumatriptan|Administered orally
223398004|NCT02813291|DEVICE|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~\- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
223398005|NCT02813291|DEVICE|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~\- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
223550884|NCT01941927|DRUG|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
223550885|NCT01198574|DIETARY_SUPPLEMENT|Iron group|Ferrous fumarate, 60 mg, weekly dose
224296640|NCT03310411|DRUG|Placebo for Lasmiditan|Administered orally
223398006|NCT03861117|PROCEDURE|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
223550886|NCT01198574|DIETARY_SUPPLEMENT|Vitamin A group|Retinol, weekly dose, 15,000 IU
223550887|NCT01198574|DIETARY_SUPPLEMENT|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
223550888|NCT01198574|DIETARY_SUPPLEMENT|Placebo group|folic acid only as placebo group
223550889|NCT00648648|DRUG|adavosertib|adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
224018017|NCT05715866|PROCEDURE|therapeutic exercise|patients receive adapted therapeutic exercise
223550890|NCT00648648|DRUG|gemcitabine|Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
223550891|NCT00648648|DRUG|cisplatin|Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
223550892|NCT00648648|DRUG|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
223550893|NCT02288299|DEVICE|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
223550894|NCT01010451|PROCEDURE|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
224018018|NCT05715866|BEHAVIORAL|sleep hygiene measures|caregivers receive a brochure with sleep hygiene measures
224018019|NCT04841356|PROCEDURE|Immediate Compression Garment|"Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study."
224018020|NCT02489123|DRUG|Enzalutamide|Given PO
224018021|NCT02489123|OTHER|Laboratory Biomarker Analysis|Correlative studies
224018022|NCT04452396|DEVICE|use of continuous glucose monitoring|Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
224018023|NCT02974439|DRUG|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
224018024|NCT02974439|DRUG|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
224018025|NCT04299438|DRUG|Propranolol Hydrochloride|2mg/mL vials
223398007|NCT03861117|PROCEDURE|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
223550895|NCT01010451|PROCEDURE|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
224018026|NCT04299438|OTHER|Saline|0.9% saline in vials matching the vials of the active drug
224018027|NCT04771611|DRUG|Fisetin|\~20mg/kg /day oral for four days (days 0,1 and days 8,9)
224018028|NCT04771611|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient . Oral for four days (days 0,1 and days 8,9)
224018029|NCT02395029|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
224018030|NCT04223830|DEVICE|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care endoscopic retrograde cholangiopancreatography (ERCP) or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
224018031|NCT00862719|DRUG|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
223398008|NCT06705205|OTHER|SAS video|The intervention is a short, animated storytelling video, with soundtrack, aimed at reducing addiction stigma.
224018032|NCT05885243|DEVICE|ESWT|will be given once a week, total 5 sessions ofESWT+ home exercises program
224129501|NCT04901065|DRUG|Xylocaine|The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle
223398009|NCT01611844|DEVICE|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
223398010|NCT01611844|DEVICE|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~* 1 intradermal injection of Tuberculin (5UI)~* 1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
223398011|NCT06335017|DIETARY_SUPPLEMENT|Induction of labor|In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
223398012|NCT06004661|DRUG|AAA617|Administered intravenously once every cycles (1 cycle = 6 weeks)
223398013|NCT06004661|DRUG|68Ga-PSMA-11|Single intravenous dose of approximately 150 MBq
223398014|NCT06957249|DRUG|Optic White 5%HP ActivShine Toothpaste|0.76% MFP toothpaste
223398015|NCT06957249|DRUG|Crest3DWhite Advanced Radiant Mint Toothpaste|0.243% NaF toothpaste
223398016|NCT05618834|BEHAVIORAL|Promoting Positive Care Interactions (PPCI)|"The PPCI consists of four steps: (1) stakeholder engagement in developing facility specific goals; (2) environment and policy assessments; (3) flexible staff education; and (4) ongoing mentorship, motivation, and support (in-person visits and text messages) for staff to optimize care interactions.~A research nurse facilitator (RNF), a registered nurse (RN) with prior experience in long-term care will work with an identified internal champion monthly to implement the four steps of PPCI. The PPCI intervention comprehensively focuses on intrapersonal, interpersonal, organizational, and environmental/policy factors to bring together evidence and key stakeholders to optimize daily care interactions in assisted living."
223398017|NCT05618834|BEHAVIORAL|PPCI-Staff Education Only (EO)|The EO will include a 30-45 min in-service session and monthly f/u visits for booster education. The education content and process will be the same as outlined in Step 3 of the PPCI for treatment sites.
223398018|NCT06524544|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223398019|NCT06524544|PROCEDURE|Computed Tomography|Undergo CT
223398020|NCT06524544|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398021|NCT06524544|BIOLOGICAL|Pembrolizumab|Given IV
223398022|NCT06524544|OTHER|Questionnaire Administration|Ancillary studies
223398023|NCT06524544|BIOLOGICAL|Sacituzumab Govitecan|Given IV
223398024|NCT06336044|DEVICE|Karisma|Intradermal injection
223398025|NCT03286387|OTHER|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
223398026|NCT06222853|BIOLOGICAL|anti-CD19-CAR-T cells|Three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×10\^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
224018033|NCT05885243|DEVICE|customized insoles|Will be given customized insoles+ home exercise program. Insoles will be used for 12 weeks.
224018034|NCT05885243|COMBINATION_PRODUCT|combined ESWT and custtomized insoles|Will be given once a week, total 5 sessions of ESWT+ home exercise program. Also, simultaneous insoles will be provided. Insoles will be used for 12 weeks.
224018035|NCT04654845|PROCEDURE|Pulpotomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Wait until confirmation of absence of bleeding from the conducts. Placement of polytetrafluroethylene in pulp chamber. Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
223398030|NCT01882660|DRUG|Decitabine|
223398031|NCT00899301|OTHER|biologic sample preservation procedure|Tissue, urine and blood collection.
223398032|NCT05022667|DEVICE|PTeye|The surgeon will first take 5 baseline NIRAF measurements on the thyroid gland (or neck muscle, if thyroid is absent) using the disposable sterile fiber probe that is connected to the PTeye console, as per device functionality requirements.
223398033|NCT06962852|GENETIC|BI 3720931|BI 3720931
223550896|NCT02953561|DRUG|Avelumab|Given IV
223550897|NCT02953561|DRUG|Azacitidine|Given SC or IV
223550898|NCT02953561|OTHER|Laboratory Biomarker Analysis|Correlative studies
223550899|NCT00899418|GENETIC|gene expression analysis|
223550900|NCT00899418|GENETIC|polymerase chain reaction|
224129502|NCT04901065|DRUG|Placebo|The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
224129503|NCT02667990|OTHER|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
224129504|NCT02667990|OTHER|standard stiletto|standard stiletto without insole
224129505|NCT02667990|OTHER|comfy trainer|comfy trainer
224296641|NCT03310411|DRUG|Placebo for Sumatriptan|Administered orally
223550901|NCT00899418|GENETIC|polymorphism analysis|
223550902|NCT00899418|OTHER|immunohistochemistry staining method|
223398034|NCT06962488|BEHAVIORAL|Regular Care|Educational brochures and lifestyle guidance on blood pressure control, medication adherence, physical activity, and healthy diet, provided at baseline only. No additional counseling or genetic risk disclosure will occur during the 12-month intervention period.
224018036|NCT04654845|PROCEDURE|Pulpectomy|"Access to pulp chamber. Removal of the pulp chamber tissue. Use of Sodium Hypochlorite (5.25% NaCl) during the whole procedure and in the amount considered appropriate by each operator.~Establishment of working length by means of Electronic Apex Locator and a number 8 K file.~Access to all conducts with a number 10 K file. Rotary instrumentation with one reciprocating system up to working length and up to an apical diameter of 25.~Placement of polytetrafluroethylene in pulp chamber. No intermediate medication will be filled into the conducts.~Placement of temporary filling. Reduction of the occlusal surface of the tooth until there is no contact with the articulating paper from 200μ."
224018037|NCT00324116|DRUG|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
224018038|NCT05786703|DIAGNOSTIC_TEST|Biochemical, weight measurements, Blood pressure and blood sugar level|At first visit short interview using the STEPwise approach of the STEPS surveillance tool for NCDs from the WHO will be conducted. On subsequent visits, hypertension and blood sugar level and cholesterol levels will be measured and adherence to medication will be assessed. The patient's registry will be developed following recommendation from the HEARTS technical package of World Health Organization (WHO) with some modification if needed.
224018039|NCT01806623|DRUG|Fluconazole|Single oral dose of 150mg Fluconazole
224018040|NCT00751361|DEVICE|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
224129506|NCT02142179|BEHAVIORAL|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
223398035|NCT06962488|BEHAVIORAL|SBP PRS Dissemination|Participants receive individualized SBP PRS reports and structured genomic counseling sessions delivered by trained genetic counselors. Counseling addresses key constructs of the Health Belief Model, including perceived susceptibility, severity, and benefits of behavior change, with an emphasis on lifestyle modification and medication adherence.
223398036|NCT06961747|DRUG|Zilucoplan|Dose formulation: Solution for injection. Route of administration: Subcutaneous injection.
223398037|NCT06257108|OTHER|Class II Cavity Restorations|The study involved a split-mouth design in which Ultradent PQ1 Bond (standard bond) and Ultradent Peak Universal Bond (chlorhexidine-containing bond) were used as the bonding agents, and Tetric N Ceram Bulk Fill composite was used as the restorative material for the restoration of primary molars with class II cavity.
223398038|NCT01817517|DEVICE|Medtronic Activa Deep Brain Stimulation System|
223398039|NCT03907254|OTHER|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
223398040|NCT05912010|DIAGNOSTIC_TEST|NP/OP swab|NP/OP (nasopharyngeal/oropharyngeal) swabs will be collected from all cases at enrollment for respiratory pathogen multiplex PCR or pneumococcus culture.
223398041|NCT06644924|COMBINATION_PRODUCT|Intervention: AS MDI|Drug Treatment: (Albuterol Sulfate metered dose inhaler \[AS MDI\] - PT007) Randomized participants will receive a single-dose (2 inhalations)
223398042|NCT06644924|COMBINATION_PRODUCT|Intervention: Ventolin Evohaler|Drug: Treatment (Ventolin Evohaler) Randomized participants will receive a single-dose (2 inhalations)
223398043|NCT06644924|COMBINATION_PRODUCT|Intervention: Placebo matching AS MDI|Drug: Treatment (Placebo MDI) Randomized participants will receive a single-dose (2 inhalations to match AS MDI)
223398044|NCT04441307|BEHAVIORAL|Healthy Foundations|Healthy Foundations combines elements of a community-based parent education program with additional information about infant and child development, good parenting practices, parent health behavior, and couple support.
223398045|NCT04441307|BEHAVIORAL|Family Foundations|A modified version of Family Foundations, an evidence-based preventive intervention for couples during the transition to parenthood, will be implemented to address several aspects of parent and family adjustment, including parent health behavior, particularly alcohol use, and couple relationship dynamics, to promote a healthy parenting environment.
223398046|NCT03262259|BEHAVIORAL|GSDG multi-component intervention|Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
223398047|NCT04090398|PROCEDURE|Biospecimen Collection|Correlative studies
223398048|NCT04090398|PROCEDURE|Bone Scan|Undergo bone scan
223398049|NCT04090398|PROCEDURE|Computed Tomography|Undergo CT scan
224018041|NCT00457652|DRUG|Rosuvastatin|7 day treatment rosuvastatin 20mg
224018042|NCT00153153|DRUG|polyethyleneglycol3350|
224296642|NCT01418963|DRUG|RO5285119|single and multiple ascending oral doses
224296643|NCT01418963|DRUG|placebo|single and multiple oral doses
224296644|NCT00619112|DRUG|temozolomide|single arm study
224296645|NCT00276822|OTHER|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
223398050|NCT04090398|OTHER|Electronic Health Record Review|Ancillary studies
223398051|NCT04090398|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223550903|NCT00781638|DEVICE|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
223398052|NCT04090398|DRUG|Paclitaxel|Given IV
223398053|NCT04090398|RADIATION|Radium Ra 223 Dichloride|Given IV
224129507|NCT02800564|BEHAVIORAL|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
224129508|NCT02800564|BEHAVIORAL|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
224018043|NCT05468892|DRUG|Trifluridine Tipiracil|"Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest"
224018044|NCT05468892|DRUG|Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]|Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
224018045|NCT03635723|DEVICE|Activity monitor|Technology allowing measurement of physical activity
224129509|NCT03649100|PROCEDURE|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
224129510|NCT04719338|DIAGNOSTIC_TEST|presence of HCV RNA in peripheral blood mononuclear cells (PBMCs) .|samples of peripheral blood from each patient into EDTA tube will be collected and tested for HCV RNA in peripheral blood mononuclear cells (PBMCs) .
224018046|NCT00568412|DEVICE|Zarzenda|Topical cream, applied twice daily for three weeks
224018047|NCT00568412|DRUG|Elidel|1% cream, applied topically twice daily for three weeks
224018048|NCT05690724|DIETARY_SUPPLEMENT|Mitocholine™ or Placebo|Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.
224018049|NCT01266681|DRUG|amiodarone|"Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
224018050|NCT01266681|DRUG|Dronedarone|"Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
224018051|NCT05417022|DEVICE|Diamondback 360TM orbital atherectomy system|Use of the Diamondback 360TM orbital atherectomy system in the preparation of calcified coronary lesions before implantation of a coronary endoprothesis
224018052|NCT01737827|DRUG|INC280|INC280 was administered orally on a continuous twice a day (BID) dosing schedule, from Day 1 until Day 21 of each 21-day cycle. INC280 was initially supplied as hard gelatin capsules and subsequently also as film-coated tablets.
224018053|NCT04411160|DRUG|Vitamin C|4 gram of vitamin c slowly intravenous once daily for 4 days duration.
224018054|NCT04411160|DRUG|Nitric Oxide|nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose
224018055|NCT04411160|DEVICE|ventilators|All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90%
224129511|NCT03816306|DRUG|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
224129512|NCT02912806|PROCEDURE|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
224129513|NCT03855137|DRUG|Atogepant 30 mg|Tablets containing 30 mg atogepant
224129514|NCT03855137|DRUG|Atogepant 60 mg|Tablets containing 60 mg atogepant
224129515|NCT03855137|DRUG|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
224129516|NCT01105416|BEHAVIORAL|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
224129517|NCT01105416|BEHAVIORAL|ESC|Enhanced standard care
224129518|NCT02406547|DEVICE|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
224129519|NCT02406547|DEVICE|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
224129520|NCT02335216|DEVICE|Implantation with the commercially available Axium neurostimulator|
224129521|NCT03880240|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
224129522|NCT03880240|OTHER|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
224129523|NCT01672996|DRUG|Ioforminol 160 mgI/mL|Given as s single administration to the subject
224129524|NCT01672996|DRUG|Ioforminol 200 mgI/mL|Given as a single administration to the subject
224129525|NCT01672996|DRUG|Iopamidol 300 mgI/mL|Given as a single administration to the subject
224129526|NCT00406952|PROCEDURE|electronic diary|
224018056|NCT02521987|PROCEDURE|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
224018057|NCT02521987|PROCEDURE|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
224129527|NCT00406952|DRUG|Sertraline|
224129528|NCT00406952|DRUG|Placebo|
224129529|NCT00406952|PROCEDURE|voice acoustics|
224018058|NCT04454775|DIAGNOSTIC_TEST|coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.|
224018059|NCT00680446|DRUG|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
224018060|NCT01964924|DRUG|Akt Inhibitor GSK2141795|Given PO
224018061|NCT01964924|OTHER|Laboratory Biomarker Analysis|Correlative studies
224296646|NCT01300910|DEVICE|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
224296647|NCT01300910|PROCEDURE|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
224296648|NCT00794755|DIETARY_SUPPLEMENT|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
224018062|NCT01964924|DRUG|Trametinib|Given PO
224018063|NCT06142266|OTHER|Exercise rehabilitation program|This program will consist of twice-weekly supervised exercise sessions, including aerobic training and resistance exercises targeting the lower limbs for 12-week
224018064|NCT04572308|BIOLOGICAL|CD7 CAR-T|"Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;"
224018065|NCT00922753|OTHER|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
224018066|NCT00922753|OTHER|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
224018067|NCT00922753|OTHER|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
224018068|NCT03003455|PROCEDURE|Nasotracheal intubation over a bougie|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
223398054|NCT04090398|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
223398055|NCT05618028|DRUG|ABBV-525|Oral; Tablet
223398056|NCT06497699|DRUG|Dexycu|single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
223398057|NCT06061913|BEHAVIORAL|Breast Pump suction pattern|Mothers who have reached secretory activation and are pumping \<350 mLs/day will be randomized to one of three breast pump suction patterns.
223398058|NCT04214067|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223398059|NCT04214067|RADIATION|Brachytherapy|Undergo vaginal brachytherapy
223398060|NCT04214067|PROCEDURE|Computed Tomography|Undergo CT
223398061|NCT04214067|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223398062|NCT04214067|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224018069|NCT03003455|PROCEDURE|Conventional Nasotracheal Intubation|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
223398063|NCT04214067|BIOLOGICAL|Pembrolizumab|Given IV
223398064|NCT04214067|OTHER|Quality-of-Life Assessment|Ancillary studies
223398065|NCT04214067|OTHER|Questionnaire Administration|Ancillary studies
223398066|NCT04214067|PROCEDURE|X-Ray Imaging|Undergo x-rays
224018070|NCT03524053|OTHER|Exercise induced bronchoconstriction|Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
224129530|NCT05177952|OTHER|Blood Flow Restriction|Resistance training with BFR
224129531|NCT05177952|OTHER|Standard of Care|Resistance Training with no BFR
224129532|NCT06552559|DRUG|Selinexor|Combination chemotherapy
224129533|NCT01341431|DRUG|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
224129534|NCT01915004|OTHER|Educational Intervention|Bladder Training Video
224129535|NCT03679663|DEVICE|Ultrasound|Use of ultrasound to identify pre-puncture site
224129536|NCT05913934|BEHAVIORAL|Gait analysis|Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
224129537|NCT02635737|DEVICE|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
224129538|NCT06409078|DEVICE|repeated transcranial magnetic stimulation treatment group|Patients with irritable bowel syndrome received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 1 week.
224129539|NCT06409078|DRUG|Western medicine group|Patients with irritable bowel syndrome were given pivotal ammonium bromide tablets orally at 50 mg three times daily for seven days in the Western medicine group.
224129540|NCT02730507|DEVICE|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
224129541|NCT02730507|DEVICE|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
224129542|NCT00704509|DRUG|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
224018071|NCT03524053|OTHER|Inhibited EIB|Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
224018072|NCT01153958|DRUG|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
224129543|NCT00704509|DRUG|Placebo|Encapsulated tablets, orally, 12 weeks
224129544|NCT00704509|DRUG|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
223398067|NCT05242848|BEHAVIORAL|Exercise intervention|The intervention is a supervised group-based exercise intervention for 16 weeks, including two outdoor sessions per week. The workout consists of two parts, endurance and a strength training segment. Every workout follows the same structure and lasts approximately 45 minutes. The exercise starts with roughly 15 minutes of endurance warm-up. After the warm-up follows the interval with eight repetitions of 30 seconds uphill, and the participants can freely choose between walking or running. The desired intensity of the intervals is \>13 on Borg-score 20. The session will end with four specific exercises focusing on strength training of large muscle groups, including mm. pectoralis major, rectus abdominis, quadriceps femoris, gluteus maximus and latissimus dorsi. The strength training program follows the same structure as the intervals. Clinical staff, research staff, and people with user experience will supervise the exercise sessions.
224018073|NCT01153958|DRUG|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
224129545|NCT00300300|PROCEDURE|Computer-assisted surgery|no description
224129546|NCT00347854|OTHER|Systane Free lubricant eye drops|
224129547|NCT00347854|OTHER|Visine Tears Lubricant Eye Drops|
224129548|NCT00347854|OTHER|Refresh Liquigel Lubricant Eye Drops|
223398068|NCT04645589|DRUG|Myfortic|There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
223398069|NCT02084810|DRUG|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
224129549|NCT00347854|OTHER|Refresh Plus Lubricant Eye Drops|
224129550|NCT02065622|DRUG|Adalimumab|
224129551|NCT02065622|OTHER|Placebo|
223398070|NCT02084810|DRUG|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
223398071|NCT00134680|DRUG|Letrozole|Letrozole tablets 2.5 mg by mouth daily
223398072|NCT00134680|DRUG|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
224018074|NCT01127152|PROCEDURE|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
224018075|NCT02670759|DRUG|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
224018076|NCT02670759|DRUG|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
224018077|NCT02299180|BEHAVIORAL|ACP|
224129552|NCT05866471|DRUG|Psilocybin|The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of botanically-derived psilocybin.
224129553|NCT05866471|DEVICE|Transcutaneous auricular Vagus Nerve Stimulation (taVNS)|For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
224129554|NCT05866471|BEHAVIORAL|Psychosocial Support Alone|Participants assigned to Psychosocial Support Alone will not receive taVNS following psilocybin dosing.
224129555|NCT05866471|OTHER|Sham taVNS|For both the active and sham taVNS procedure, participants will be provided with, and trained on, taVNS devices that apply gentle stimulation to the left ear via either electrodes or an earpiece that fits over the left ear.
224129556|NCT02117167|DRUG|AZD2014|Target: m-TOR
224129557|NCT02117167|DRUG|AZD4547|Target: FGFR
224129558|NCT02117167|DRUG|AZD5363|Target: AKT
224129559|NCT02117167|DRUG|AZD8931|Target: HER2, EGFR
224129560|NCT02117167|DRUG|Selumetinib|Target: MEK
224129561|NCT02117167|DRUG|Vandetanib|Target : VEGF, EGFR
224129562|NCT02117167|DRUG|Standard maintenance for squamous NSCLC|
224129563|NCT02117167|DRUG|Pemetrexed|Standard maintenance for non squamous NSCLC
224129564|NCT02117167|DRUG|Durvalumab|Target: PD-L1
224129565|NCT02117167|DRUG|savolitinib|target : MET
224129566|NCT02117167|DRUG|Olaparib|target : PARP
224129567|NCT03769935|DRUG|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
224129568|NCT04349306|DRUG|RASBURICASE SR29142|Pharmaceutical form:solution for infusion Route of administration: intravenous
224129569|NCT02307721|DRUG|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
224129570|NCT02307721|DRUG|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
224129571|NCT02307721|DRUG|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
223398073|NCT01332669|PROCEDURE|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
224018078|NCT01780181|DRUG|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
224018079|NCT01780181|DRUG|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
224018080|NCT00473005|DRUG|Capecitabine|825 mg/m2 bid, Oral
224018081|NCT00473005|DRUG|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
224018082|NCT01034605|DIETARY_SUPPLEMENT|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
224129572|NCT02307721|DEVICE|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
224129573|NCT01787643|OTHER|Height-Adjustable Desk Intallation in Office|
224129574|NCT06519552|GENETIC|JWK008 Single intravenous infusion administration|"Six participants with MPS I will be enrolled in the study. The participantss will be divided into two different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^12vg/kg, and the high dose is 2.0×10\^13vg/kg. Only one intravenous infusion of JWK008 will be administered to each participant."
224129575|NCT03265509|DIETARY_SUPPLEMENT|glutamine supplementation|30 g/day glutamine supplementation for three months
224129576|NCT03265509|DIETARY_SUPPLEMENT|fantomalt supplementation|30 g/day fantomalt supplementation for three months
224129577|NCT05833893|DRUG|XPO1 inhibitor|COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
224129578|NCT00129805|DRUG|MCI-9042|
224129579|NCT00129805|DRUG|Aspirin|
224129580|NCT01272297|DEVICE|LI-ESWT|Low intensity shock wave treatment - 12 sessions
223398074|NCT04596774|PROCEDURE|Traditional Approach|Patients received intraoperative 10 mL/kg/h IV izolen infusion. Opioids and PONV prophylaxis were applied when required.
223398075|NCT04596774|PROCEDURE|Enhanced Recovery After Surgery (ERAS) Approach|Patients did not preoperatively smoke for 48 hours, drank clear liquids until the last 2 hours and received 6 mL/kg/h IV izolen infusion intraoperatively. In these; gastric aspiration was applied before extubation, PONV prophylaxis was supported routinely, and patient controlled analgesia was added to the routine analgesia plan for the first postoperative 48 hours.
223398076|NCT01236508|RADIATION|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
223398077|NCT00295581|DRUG|PpPfs25/ISA51 & ScPvs25/ISA51|
224018083|NCT02090036|DRUG|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
224018084|NCT02090036|DRUG|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
224018085|NCT05842239|DEVICE|Hyperbaric oxygen therapy|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
224018086|NCT06180018|OTHER|interrupted sutures|Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
224018087|NCT03302078|DRUG|BI 1015550|Fed state
224129581|NCT03342482|OTHER|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
224129582|NCT01687413|RADIATION|Intensity-modulated radiation therapy (IMRT)|
224129583|NCT01687413|DRUG|Cisplatin|
224129584|NCT05818527|DEVICE|Acceledent vibrating device|used to accelerated the movement of teeth during orthodontic treatment
224129585|NCT04115696|DEVICE|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
223398078|NCT00637312|DEVICE|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
224018088|NCT03302078|DRUG|BI 1015550|Fasted state
224018089|NCT02971761|DRUG|Enobosarm|Given PO
224129586|NCT02276235|DEVICE|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
223398079|NCT00637312|DEVICE|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
223398080|NCT05267379|DIAGNOSTIC_TEST|Take blood samples|Blood samples are used to check for polymorphisms in NSAID metabolization genes and to determine the diclofenac levels.
223731390|NCT06494839|PROCEDURE|Cold steel dissection technique|The cold steel blunt dissection tonsillectomy was carried out under general anesthesia while the patient was in the Rose position and had an endotracheal intubation. The tonsil was retracted medially with a tonsil holding forceps, and in the upper pole, the mucosal incision was made. To protect the tonsillar pillars, a delicate dissection was performed, and the suction tip was used to stop the hemorrhage. The tonsillar fossa was packed with swabs. The other palatine tonsil was then similarly removed. Hemostasis was secured by silk ligation and bipolar electrocautery.
223731391|NCT01957553|DEVICE|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
223731392|NCT01957553|DEVICE|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
224018090|NCT02971761|OTHER|Laboratory Biomarker Analysis|Correlative studies
224018091|NCT02971761|BIOLOGICAL|Pembrolizumab|Given IV
224018092|NCT00876681|PROCEDURE|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
224018093|NCT02854787|DRUG|Phenylephrine|A bolus of 100 mcg
224018094|NCT02854787|DRUG|Norepinephrine|A bolus of 0,2 mcg/kg
224018095|NCT03971903|BEHAVIORAL|Attention bias modification|The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
224018096|NCT02133118|DRUG|individual SUs, insulin, pioglitazone|
224018097|NCT01034163|DRUG|Panobinostat|
224018098|NCT01034163|DRUG|Placebo|Placebo
224018099|NCT05382143|DRUG|Atosiban|Pilot study
224018100|NCT03281655|DRUG|Visnadine, prenylflavonoids and bovine colostrum|15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
224018101|NCT01462123|OTHER|endoscopic assessment of colonic polyps|
224018102|NCT03677765|PROCEDURE|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
224018103|NCT05412797|BEHAVIORAL|Cycling/Using a DeskCycle|The intervention was conducted in two phases. In phase 1, the intervention group were given the DeskCycles to use for 8 weeks. In phase, the control group from phase 1 were given the DeskCycles to use. Intervention group from phase 1 became controls in phase 2
224018104|NCT05412797|BEHAVIORAL|Regular activities|The active comparator performed normal daily activities
224018105|NCT06507995|DRUG|thoracic interlaminar epidural injection|. Injections were administered under sedation and sterile conditions, with all patients positioned prone and monitored. A single physician performed all injections using an 18 gauge Tuohy needle, employing the loss of resistance technique and confirming the epidural space placement with 5 mL of nonionic contrast.
224018106|NCT00492102|DRUG|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing \>1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
223398081|NCT05270577|OTHER|Prehabilitation|prehabilitation
224018107|NCT01757444|DEVICE|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
224018108|NCT01757444|DEVICE|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
223398082|NCT05270577|OTHER|Standard care|No intervention
223398083|NCT06578208|OTHER|Spinal Manipulation|The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction (Fagundes Loss et al., 2020).
223731393|NCT04304391|PROCEDURE|Resective Gingival Surgery|Gingivectomy and gingivoplasty:Resective gingival surgical procedured
223731394|NCT03600610|DEVICE|gadolinium-enhanced cardiac MRI|cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
223731395|NCT05416320|DRUG|Calcipotriol|Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
224018109|NCT04328116|DEVICE|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use)
224018110|NCT01876459|OTHER|MRI|
224018111|NCT01876459|PROCEDURE|lumbar puncture|
224018112|NCT01876459|BEHAVIORAL|neuropsychological tests|
224018113|NCT03950050|DRUG|Ambroxol|"Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
224018114|NCT03515343|DIAGNOSTIC_TEST|Screening colonoscopy according to resect-and-discard strategy|This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
224018115|NCT03891693|DEVICE|Passeo-18 Lux and SUPERA® stent|Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
224018116|NCT01566253|DRUG|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
223398084|NCT00612274|DRUG|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
223398085|NCT00612274|DRUG|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
223398086|NCT00612274|DRUG|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
223550904|NCT01791621|OTHER|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
223550905|NCT04587882|BEHAVIORAL|Telehealth|Participants will receive weekly activity summaries and tailored notifications about their activity and goal setting behaviors.
223550906|NCT04587882|BEHAVIORAL|Control|Participants will get usual care and wear a smartwatch.
223550907|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
223550908|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
223550909|NCT03159975|DRUG|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
223550910|NCT04212078|DRUG|Levofloxacin Ophthalmic|0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
223731396|NCT05416320|DRUG|Subject's already prescribed drug|Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
223731397|NCT04544254|PROCEDURE|Bilateral transversus thoracis muscle plane block|The block will be performed in between intercostal space 4 and 5, lateral from sternum, with ultrasound guided. Twenty milliliters bupivacaine 0.5% 1mg/body weight will be injected between internal intercostal muscle and transversus thoracis muscle on both sides.
224018117|NCT01566253|DRUG|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
224018118|NCT03026751|PROCEDURE|Bone Marrow Aspirate|Bone marrow aspirate
224018119|NCT02086604|DRUG|Brentuximab vedotin|
224018120|NCT02086604|DRUG|Lenalidomide|
224018121|NCT01857128|DEVICE|Drawtex dressing|
224018122|NCT01857128|DEVICE|Negative Pressure Wound Therapy|
224018123|NCT04673253|OTHER|Passive leg Raise|The intervention will be performed immediately after spinal anesthesia, and passive leg raise will be performed using two standard pillows placed under the heel so that the leg is approximately 30 cm above the horizontal plane of the table. The passive leg raising position will continue until the cord is clamped.
224018124|NCT04673253|OTHER|control|The controlled group was positioned in the normal supine position.
224018125|NCT04315259|DEVICE|Diode laser|irrigation activated by diode laser versus soft tissue laser application therapy
224018126|NCT02884895|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
224018127|NCT02884895|DEVICE|Direct Laryngoscopy|Direct Laryngoscopy
224018128|NCT00989534|BEHAVIORAL|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
224018129|NCT00989534|BEHAVIORAL|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
224018130|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
224018131|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
224018132|NCT00116753|DRUG|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
224018133|NCT00223873|PROCEDURE|Penile Vibratory Stimulation|
224018134|NCT02849717|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
224018135|NCT00528645|DRUG|saracatinib|Given orally
224018136|NCT00313131|DRUG|tinidazole+fluconazole vs metronidazole+clotrimazole|
224018137|NCT02641860|BIOLOGICAL|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
224018138|NCT01460173|OTHER|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
224018139|NCT02627170|DEVICE|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
224018140|NCT02627729|DEVICE|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
224018141|NCT02627729|DEVICE|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
224018142|NCT01058031|BEHAVIORAL|MBSR|Mindfulness Based Stress Reduction
224018143|NCT04600154|DRUG|MS-20|Specific fraction from fermented soy milk
224018144|NCT04600154|OTHER|Placebo|Fermented soy milk without active component
223398087|NCT05679947|OTHER|Mobilization protocol|The mobilization protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the day of discharge. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 hours after surgery. Implement mobilization protocol three times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every two hours. Level 2: Range of motion (PROM) should occur at least three times a day. Level 3: The head of bed (HOB) \>30 degrees. Duration goal: 5-15 minutes. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 minutes. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 minutes. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 minutes. Progress to level 6. Level 6: Patient is able to ambulate at least three times a day.
224018145|NCT04431700|OTHER|Anti-inflammatory diet|Anti-inflammatory diet with increased vegetables, fruit, plant polyphenols, lean proteins, foods rich in omega-3s and unsaturated fats as well as decreased in processed refined foods.
223398088|NCT04406181|BEHAVIORAL|HADS|Hospital Anxiety and Depression Scale
223731398|NCT04544254|PROCEDURE|Control|A needle will be place in the similar area to the transversus thoracis muscle plane block, but no drugs will be injected to the area
224018146|NCT04431700|OTHER|Regular diet|Focus on food journal and recording all food intake.
224018147|NCT01445301|DRUG|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
223398089|NCT04406181|BEHAVIORAL|a survey|made up specifically for issues concerning the medical/psychological/access aspects during the COVID-19 outbreak
223550911|NCT04212078|DRUG|Cefuroxime|The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
223731399|NCT02988505|OTHER|Standard care|
223731400|NCT03009435|OTHER|prophylactic manual rotation|
223731401|NCT01981291|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
223731402|NCT01981291|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
223731403|NCT01981291|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
223731404|NCT01981291|PROCEDURE|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
223731405|NCT01981291|DRUG|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
223731406|NCT02829281|DRUG|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
223731407|NCT02829281|DRUG|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
223731408|NCT02829281|DRUG|Saline|Joint injection of Saline
223731409|NCT01904682|DRUG|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
223731410|NCT01333059|DRUG|Midazolam|
223731411|NCT01333059|DRUG|Normal saline|
223731412|NCT01333059|DRUG|Fentanyl|
224018148|NCT01445301|DRUG|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
224018149|NCT02614417|OTHER|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
223550912|NCT00556439|DRUG|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
223550913|NCT00556439|DRUG|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
223731413|NCT05576493|PROCEDURE|phaco+MP-TSCPC|The procedure starts with performing the cyclophotocoagulation using the Micropulse P3 device (IQ 810 Laser Systems; Iridex, Mountain View, CA, USA) at 2500 mW with a duration of 90 seconds in each hemisphere at a 31.3% duty cycle under local anesthesia and then performing phacoemulsification and IOL implantation.
223731414|NCT05576493|PROCEDURE|phaco+TSCPC|The procedure starts with performing the cyclophotocoagulation using the IRIDEX's G probe device (IRIDEX Corp. Mountain View, CA, USA) at 1500 to2000 mW with a duration of 1500 ms applying about 15 shots in one hemisphere only under local anesthesia and then performing phacoemulsification and IOL implantation.
223731415|NCT05576493|PROCEDURE|phaco+endocyclophotocoagulation|phacoemulsification will be done and endocyclophotocoagulation will be done after cataract extraction
223731416|NCT05576493|PROCEDURE|phaco GSL|phacoemulsification will be done and then the angle is visualized by direct goniolens then the synechia are dissected by cohesive viscoelastic.
223731417|NCT02697175|DEVICE|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
224018150|NCT05372952|DEVICE|Dynetic-35 Peripheral Balloon-Expandable Stent System|Stenotic iliac lesions will be treated with the Dynetic 35 stent via a radial access
224129587|NCT02276235|DEVICE|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
223550914|NCT04328896|OTHER|CGM-Tele-monitoring|"Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis"
223550915|NCT00496977|PROCEDURE|annual CT screening|
223731418|NCT02697175|OTHER|No Live Video-Colposcopy|The TV will be shut off during colposcopy
223731419|NCT06137716|DEVICE|Training with a Robotic Hand Exoskeleton|The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
223731420|NCT04990154|BEHAVIORAL|a 12-week intradialytic exercise|a 12-week intradialytic exercise (supine lower-limb ergometer, 30 minutes/session, 3 sessions/week)
223731421|NCT03566823|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
223731422|NCT03566823|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
224018151|NCT02141451|DRUG|Rituximab|Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
224018152|NCT02141451|DRUG|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
224018153|NCT04223817|DEVICE|7.0 T RMI|Single 7.0 Tesla MRI of both hands in the same time
224018154|NCT03755375|DEVICE|TENS|transcutaneous electrostimulation to improve the pain.
224018155|NCT03755375|BEHAVIORAL|Postural exercises|breathing exercises in the lay-down position, hip anteversion and retroversion in the sitting position, and anteversion, retroversion, and lateral movement in the stand-up position
224018156|NCT03755375|DEVICE|Biofeedback|pelvic floor muscle coordination and relaxation exercises using intravaginal probes
224018157|NCT03755375|BEHAVIORAL|Manual therapy|myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas
224018158|NCT05644860|COMBINATION_PRODUCT|Nanohybrid Compisite Group (Filtek Z250)|Orthodontic brackets shall be bonded with Nano hybrid composite
224018159|NCT05644860|COMBINATION_PRODUCT|Conventional Composite Group (Transbond XT)|Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
224018160|NCT02407301|OTHER|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
224018161|NCT02407301|OTHER|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
224018162|NCT02407301|OTHER|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
224018163|NCT02407301|OTHER|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
224018164|NCT02407301|OTHER|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
224018165|NCT05239637|OTHER|Heparin stopped before ECMO decannulation|Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.
224018166|NCT05239637|OTHER|Heparin reduced after ECMO decannulation|Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
224018167|NCT03575988|OTHER|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
224018168|NCT01147276|DRUG|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
224018169|NCT02150343|DRUG|HDM-SPIRE|1 dose every 4 weeks
224018170|NCT02150343|DRUG|Placebo|1 dose every 4 weeks
224018171|NCT05192668|OTHER|Quiet time care|This study is a non-self before and after control study. The data of VLBWIs in the control group is collected in the early stage, and the quiet time intervention is carried out in the later period, and the data of VLBWIs in the intervention group is collected
224018172|NCT02187627|DRUG|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\].
224018173|NCT02187627|DRUG|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6931643 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[11C\]RO6931643 will be 370-740 MBq (10-20 mCi).
224129588|NCT04408859|DRUG|Neoadjuvant Chemotherapy|The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
224129589|NCT03122028|DEVICE|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
224129590|NCT03081286|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
223398090|NCT02772211|DRUG|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
223398091|NCT02772211|DRUG|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
223550916|NCT02100423|DRUG|curcumin|Given PO
224018174|NCT02187627|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[18F\]RO6958948 injected will be \</=10 mcg, injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of \[18F\] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
223398092|NCT02772211|DRUG|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
223398093|NCT03368092|DRUG|Dornase Alfa Inhalant Solution [Pulmozyme]|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
223398094|NCT03368092|DRUG|Placebos|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
223398095|NCT05904834|OTHER|Flexibility training|Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
223398096|NCT03033368|DRUG|Rilpivirine|Rilpivirine 25 mg tablet
223398097|NCT02735681|PROCEDURE|meibomian gland probing|Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
223398098|NCT02735681|PROCEDURE|Left eye Meibomian Gland Probing Control Group|There will be no probing in the left eye. This will be used as a control for the right eye.
224018175|NCT04572113|DEVICE|Cervical collar|Data will be recorded while patients are not wearing or wearing one of two cervical collars
224018176|NCT03946579|OTHER|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
224018177|NCT05660343|DRUG|Ozonized Olive Oil Solutions|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, 100 ml bottle.
224018178|NCT05660343|DEVICE|Low Level Laser LLL Therapy|(0.03PPM ozone + 6-6.5 PH olive oil, viscosity at 25°C 55mPas, relative density gr/ml (20°C) 0.98 pycnometer, Ozonated olive oil, 100 ml bottle, and 810 nm diode laser, 3.4 j/cm2 energy density, 0.5w power, CHEESE DEN7A/DEN4A 810, 2 min for each side
224018179|NCT02729753|DEVICE|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
224018180|NCT02729753|DEVICE|CryoBalloon™ Swipe Ablation System|Tissue Ablation using CryoBalloon™ Swipe Ablation System
224018181|NCT00036023|DRUG|darbepoetin alfa|
224018182|NCT05941728|OTHER|Avocado|The intervention treatment will contain avocado
224018183|NCT05941728|OTHER|Oil + Fiber|The active comparator will contain a snack with oils and fibers that mimic an avocado
224018184|NCT05941728|OTHER|Average American Diet|The sham comparator will contain foods/beverages that mimic a standard American Diet
224018185|NCT05420844|OTHER|Kintsugi voice journaling application|Participants will use the Kintsugi voice journaling phone application for three months.
224018186|NCT04127708|BIOLOGICAL|acupuncture|acupuncture group and control group
224018187|NCT01090427|DRUG|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
224018188|NCT01090427|DRUG|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
224018189|NCT01090427|OTHER|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
223398099|NCT06626477|DEVICE|Intra nasal mechanical stimulation treatment (INMEST)|The treatment is performed with the Walther System manufactured by Abilion Medical Systems AB.
224018190|NCT01200589|BIOLOGICAL|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
223550917|NCT02100423|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
223550918|NCT02100423|OTHER|laboratory biomarker analysis|Correlative studies
223550919|NCT02100423|OTHER|pharmacological study|Correlative studies
223550920|NCT00315510|DRUG|Rosuvastatin|
223550921|NCT02298309|OTHER|Test-and-Treat TB|
223550922|NCT06059807|DEVICE|maxillary expansion|Maxillary Expansion Using Hyrax and Hybrid Hyrax Appliances
224018191|NCT01200589|BIOLOGICAL|Rituximab|sourced locally from commercial stock
224018192|NCT01200589|BIOLOGICAL|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
224018193|NCT01200589|BIOLOGICAL|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
224018194|NCT04235179|RADIATION|SABR|SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
223398100|NCT06626477|DEVICE|Sham (No Treatment)|A modified Walther System not delivering active treatment manufactured by Abilion Medical Systems AB.
224018195|NCT04232059|DEVICE|cerebral oximetry|evaluation of the changes of cerebral oxygen saturation during hyperventilation and normo-ventilation (using near-infrared spectroscopy) in pediatrics undergoing posterior fossa tumor resection.
224018196|NCT05045508|DRUG|OC-01 (varenicline 0.6mg/ml) nasal spray|OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.
224018197|NCT05045508|DRUG|Placebo (vehicle) Nasal Spray|Placebo (vehicle) nasal spray \[control\]
223398101|NCT05159375|DIETARY_SUPPLEMENT|Elio|Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract
223398102|NCT05159375|OTHER|SMCC|Placebo comparator
223398103|NCT02024607|DRUG|BBI608|
223731423|NCT00528333|DRUG|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
224018198|NCT02000193|DRUG|fulvestrant|"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE."
224018199|NCT01025401|DEVICE|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
224018200|NCT00439231|DRUG|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
224018201|NCT01660581|BIOLOGICAL|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
224018202|NCT01660581|BIOLOGICAL|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
224018203|NCT03566654|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
224018204|NCT03566654|DEVICE|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
224129591|NCT03081286|PROCEDURE|Fat graft|The harvested lipoaspirate is injected at the site of pain.
223398104|NCT02024607|DRUG|Fluorouracil|
224018205|NCT03566654|DEVICE|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
224018206|NCT00837798|DEVICE|CRM Device|Pacemaker, ICD, or CRT device
224018207|NCT00287066|DRUG|Inhaled Human Insulin|
223398105|NCT02024607|DRUG|Oxaliplatin|
223731424|NCT00528333|DRUG|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
223731425|NCT00528333|DRUG|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
223731426|NCT03109574|DEVICE|BioFlo DuraMax Chronic Hemodialysis Catheter|
224018208|NCT00287066|DRUG|Regular Human Insulin|
224018209|NCT04602273|DRUG|Azacitidine Injection [Vidaza]|
224129592|NCT03081286|PROCEDURE|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
223398106|NCT02024607|DRUG|Leucovorin|
223398107|NCT02024607|DRUG|Irinotecan|
223398108|NCT02024607|DRUG|Bevacizumab|
223398109|NCT02024607|DRUG|Capecitabine|
223398110|NCT02024607|DRUG|Regorafenib|
223398111|NCT06759753|DRUG|Aleeto|According to the groups, patients would be treated with Aleeto via intravenous injection, and the specific dosage of Aleeto will depend on the grouping.
223398112|NCT06759753|DRUG|Placebo|Placebo with the same dosage form, odor and color as Aleeto was administered in the same way and course of treatment.
223398113|NCT05803551|DRUG|Ketamine Hydrochloride|Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
223398114|NCT05803551|DRUG|Placebo|Intravenous 0.9% saline infusions for three consecutive days.
223398115|NCT04514692|DRUG|GCSF|Granulocyte Colony Stimulating Factor (GCSF)
223550923|NCT05135572|DIAGNOSTIC_TEST|Fibromiyalgia and foot pain|Sensory and motor conduction studies will be performed in the lower extremities. Nerve conduction studies will be performed by another physician unaware of the patient's diagnosisFunctional status will be evaluated by using the Turkish version of the Fibromyalgia Impact Questionnaire (FIQ).Neuropathic Pain will be evalutaed by using the Turkish version of the Neuropathic Pain Questionnaire.
223550924|NCT04220580|OTHER|Blood samples|3 blood samples, two for RNA and one for metabolites are taken 5 minutes before a Cold Pressor Test and again 1 hour after the Cold Pressor Test.
223550925|NCT05363722|DRUG|IBI310（0.5mg/kg）|IBI310 0.5mg/kg IV d1 Q6W
223731427|NCT03109574|DEVICE|Standard of Care Catheter|
224129593|NCT02317406|DRUG|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
224129594|NCT02317406|DRUG|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
224129595|NCT04072354|DRUG|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
224129596|NCT04072354|DRUG|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
224129597|NCT04072354|DRUG|Placebo|Placebo tablet dosed once daily
224129598|NCT05165576|BEHAVIORAL|Child-centered communication|The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
224129599|NCT02920684|OTHER|Passive legs mobilisation|A physiotherapist performs a passive leg movement
223398116|NCT06581224|OTHER|Primary Hospital Provider Team|The PHP team aims to enhance continuity during hospital readmissions with a consistent cohort of seven hospital medicine physicians and two advanced practice providers (APPs). To improve care transitions, the team will have an integrated case manager who will continue following PHP patients during subsequent hospitalizations. Physicians will follow a standard seven-day service schedule, with the two APPs alternating five-to-seven-day periods. Daily huddles between physicians and APPs will further promote continuity. During the index admission, the PHP team will create a care plan in consultation with the patient to improve standardization of inpatient care and transition to outpatient settings. Communication will be a core tenet of the team, with scheduled monthly team meetings of physicians, APPs, case manager, dyad partner, and representatives from nursing and therapy services to revise individualized care plans for PHP patients and brainstorm solutions for complex challenges.
223398117|NCT03811964|OTHER|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
223398118|NCT06066580|DRUG|Sevasemten|Sevasemten is administered orally once per day
223398119|NCT03112408|BEHAVIORAL|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
223398120|NCT03112408|BEHAVIORAL|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
223731428|NCT04429737|DIETARY_SUPPLEMENT|clam protein capsules|The prediabetes patients in this arm will receive Clam protein capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
224129600|NCT02920684|OTHER|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
224129601|NCT02920684|OTHER|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
224129602|NCT02920684|OTHER|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
224129603|NCT00495664|DEVICE|Titan stent and Taxus-Liberte stent|
224129604|NCT02946710|BIOLOGICAL|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
224129605|NCT01444495|RADIATION|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
224129606|NCT01444495|PROCEDURE|Surgery|Total mesorectal excision of rectal cancer
224129607|NCT05104099|DRUG|Metvixia Topical Cream|"Metvixia is applied with a spatula, in a thick layer, to clinically visible lesions and all over the vulva. After applying the cream, the area will be covered with a bandage which should remain in place for 3 hours. After 3 hours of application, the bandage and the cream will be carefully removed. The application area will be cleaned and then immediately exposed to a continuous spectrum of light at a wavelength of 405 nm by a xenon lamp.~The most fluorescent areas will be identified. Then in white light, the practitioner will perform at least two biopsies under non-topical local anesthesia in the area of application of Metvixia®: one in the fluorescent area and one in the non-fluorescent area.~If there is no fluorescent labeling, two samples will be taken from two different non-fluorescent areas. In the event that all the zone is fluorescent , two samples will be taken from two different fluorescent zones."
224129608|NCT04973228|DRUG|Roflumilast Foam|Roflumilast 0.3% foam for topical application
224129609|NCT04973228|DRUG|Vehicle Foam|Vehicle foam for topical application
223398121|NCT03112408|BEHAVIORAL|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
223398122|NCT03112408|BEHAVIORAL|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
223398123|NCT05364931|DRUG|Cotadutide|Cotadutide administered subcutaneously once daily
223398124|NCT05364931|DRUG|Placebo|Placebo administered subcutaneously once daily
223398125|NCT02833961|DEVICE|Magnetic resonance imaging|
224018210|NCT03541031|DIETARY_SUPPLEMENT|Micronutrient & Fish oil|Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).
224018211|NCT03541031|DIETARY_SUPPLEMENT|Olive oil & Safflower oil|Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
224018212|NCT01587391|DRUG|Placebo to BI 163538 XX|1 single dose per subject as oral solution
224018213|NCT01587391|DRUG|BI 163538 XX|1 single dose per subject as oral solution
224129610|NCT04237207|DEVICE|Naída Cochlear Implant Q90 sound processor (Naida CI Q90) & software|Control cochlear implant sound processor
224129611|NCT04237207|DEVICE|301-M062 sound processor & software|New cochlear implant sound processor
224129612|NCT06421246|BEHAVIORAL|Staff-facing screen|Activity will be monitored before and after the introduction of a staff-facing screen
224129613|NCT06681623|DRUG|Ublituximab|Drug: ublituximab
224129614|NCT06684535|DRUG|Dexmedetomidine|Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.
224129615|NCT06684535|DRUG|Saline|Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.
224129616|NCT06684431|BIOLOGICAL|N-pVAX1|Crimean Congo Hemorrhagic Fever Vaccine
224018214|NCT01605916|DRUG|AZD6244|Tablet Oral bid
224018215|NCT05012501|DIAGNOSTIC_TEST|test NETs markers|NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), tissue factor, endotoxin, factor X, TAT complex, and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits.
224018216|NCT02073747|DRUG|Normal Saline|One hour inhaled normal saline
224018217|NCT02073747|DRUG|Albuterol|One hour inhaled ten milligrams of albuterol
224018218|NCT03744104|BIOLOGICAL|Quadrivalent influenza vaccine|0.5 mL, intramuscular, one dose
224018219|NCT03744104|BIOLOGICAL|Trivalent influenza vaccine A|0.5 mL, intramuscular, one dose
223398126|NCT06800144|BEHAVIORAL|Heart rate synchronized motor imagery music therapy|Participants included in this group will listen a metronome sound in a rhythm synchronized with their heart rate.
223398127|NCT06800144|BEHAVIORAL|Heart rate synchronized music therapy|Participants included in this group will listen to soothing/relaxing music without lyrics in a rhythm synchronized with their heart rate.
223398128|NCT05551000|OTHER|Experimental, comparator and control|"To quantify the effect of a training intervention for elderlies on improved range of motion, dynamic balance, gait speed, gait coordination, everyday movements and strength compared to a training group from the Norwegian elderly concept Stærk og Stødig and a control group."
223398129|NCT04550494|PROCEDURE|Biopsy Procedure|Undergo biopsy
223398130|NCT04550494|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224018220|NCT03744104|BIOLOGICAL|Trivalent influenza vaccine B|0.5 mL, intramuscular, one dose
223398131|NCT04550494|PROCEDURE|Computed Tomography|Undergo CT scan
223398132|NCT04550494|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398133|NCT04550494|DRUG|Talazoparib|Given PO
223398134|NCT06408545|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy methods were focused on promoting Values clarification, Acceptance, Cognitive defusion, Committed action and Flexible attention to the present moment, and included methods such as the Garden Metaphor, Funeral exercise or Mindfulness training.
223398135|NCT06325566|DRUG|Rexlemestrocel-L + HA mixture|Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
224018221|NCT03481192|BEHAVIORAL|Two visits for evaluation|"Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition."
223398136|NCT06325566|DRUG|Saline|Saline solution injection adjacent to the index disc.
223398137|NCT03593525|OTHER|SPARK|see above
224018222|NCT04270201|OTHER|Saliva collection|Saliva collection
224018223|NCT02878902|OTHER|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
224018224|NCT02689518|DRUG|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
224018225|NCT05361525|PROCEDURE|modified saldhana's technique|tummy tuck with anatomic definition using liposuction
224018226|NCT05361525|PROCEDURE|Traditional abdominoplasty|uses the traditional technique of abdominoplasty with liposuction with v-shaped dissection till the coastal margin
224018227|NCT01853774|BEHAVIORAL|Tailored navigation|
224129617|NCT06684626|DRUG|Sodium Hyaluronate|Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
224129618|NCT06684626|DRUG|Levofloxacin 500mg|Treatment typically involves fluoroquinolones alone, such as levofloxacin.
224129619|NCT07013890|DRUG|FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium|"FICOXPEA® is a phytoterapic compound made of:~* phycocyanin (spirulina platensis extract) 250 mg~* palmitoylethanolamide 200 mg~* L-selenometionine 11 mg"
223398143|NCT04543253|OTHER|MUSE biofeedback|biofeedback through a headband
223398144|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
223550926|NCT05363722|DRUG|IBI310（0.3mg/kg）|IBI310 0.3mg/kg IV d1 Q6W
223550927|NCT05363722|DRUG|sintilimab|sintilimab 200 mg IV d1 Q3W
223550928|NCT05363722|DRUG|bevacizumab|bevacizumab 15 mg/kg IV d1，Q3W
223550929|NCT01704508|DRUG|Artemether-lumefantrine|
223550930|NCT01704508|DRUG|Dihydroartemisinin-piperaquine|
223550931|NCT04690218|DIAGNOSTIC_TEST|Hospital anxiety and depression scale|Self assessment scale suitable for hospital community as well as public community. Applying the scale does not require any psychopathologic training.
223550932|NCT04690218|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|Self assessment scale for public community. Applying the scale does not require any specially trained personnel.
223550933|NCT04690218|BEHAVIORAL|Nutritional Status Questionnaire|It consists of 26 items, questioning the frequency and amount of certain nutritional elements (ones known to worsen and benefit mastalgia) consumed by the individual.
223398145|NCT04097236|OTHER|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
223398146|NCT04673149|BIOLOGICAL|GLS-5310|GLS-5310 DNA plasmid vaccine
223398147|NCT04673149|BIOLOGICAL|Placebo|Placebo
223398148|NCT06489834|OTHER|Group Drumming|Weekly group drumming for 8 weeks
223398149|NCT04396873|DRUG|11C-MC1|Injected IV followed by PET scanning
223398150|NCT04396873|DRUG|11C-PS13|Injected IV followed by PET scanning
223398151|NCT04396873|DRUG|18f-florbetaben|Injected IV followed by PET scanning
223398152|NCT05537233|DRUG|Semaglutide|Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
223550934|NCT03785353|BEHAVIORAL|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
224018228|NCT06276907|BIOLOGICAL|Plasma Exchange|On day 1 Response assessment will be done to assess the need for a second session from day 3-7 and subsequently every week till day 28. A minimum of 3 sessions would be considered in the first seven days. The duration of each session would be 3-4 hours. Patients with partial response (not meeting criteria for a complete response after 3 sessions) would be considered for additional sessions as decided by the treating physician until desired complete response, adverse effects, liver transplant, death, or clinical futility. The complete response will be defined as a sustained reduction in bilirubin and international normalized ratio without any clinical worsening requiring discontinuation of therapy. Failure of therapy would be defined as the development of adverse effects, new onset sepsis, or organ failure. In such patients, further sessions would be deferred. Blood access was established with a double-lumen catheter inserted into the patient's femoral or jugular vein.
224018229|NCT06276907|OTHER|Standard Medical Treatment|Patients randomized to SMT Group will be given standard medical therapy (SMT) only included as per requirement.
224018230|NCT02772406|DEVICE|Linked Color Imaging|
224129620|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
224129621|NCT01637051|DEVICE|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
223550935|NCT04062981|DRUG|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
223550936|NCT04369456|OTHER|blood sample|a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
223550937|NCT02454530|BIOLOGICAL|Nivestim®|
223550938|NCT00325130|BIOLOGICAL|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
223550939|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
223731429|NCT04429737|DIETARY_SUPPLEMENT|Clam peptide plus Chlorella capsules|The prediabetes patients in this arm will receive Clam peptide plus Chlorella capsules with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
224018231|NCT02772406|DEVICE|white light imaging|
224018232|NCT03002753|BEHAVIORAL|detached mindfulness|Please see detailed study description.
224018233|NCT03002753|BEHAVIORAL|cognitive restructuring|Please see detailed study description.
224018234|NCT05354180|OTHER|navicular mobilization|Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week
224018235|NCT05354180|OTHER|rigid tapping|"A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
224018236|NCT05354180|OTHER|Navicular Mobilization and Rigid Taping|"Plantar glide combined with rotation of navicular bone against the talus The glide will be given in 20 repetitions of 3 sets, for 5 days a week.~A non-elastic zinc oxide sports tape will be applied to patients. Patient will be advised to protect the tape from getting wet.~Tape will be changed on every 3rd day (48 hours) on Wednesday and Friday."
224018237|NCT02704468|OTHER|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
223398153|NCT05537233|DRUG|Placebo|Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
223398154|NCT03662776|BEHAVIORAL|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
223550940|NCT00325130|BIOLOGICAL|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
223550941|NCT00325130|BIOLOGICAL|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
223398155|NCT03662776|BEHAVIORAL|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
223398156|NCT02160015|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223398157|NCT02160015|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223398158|NCT02160015|PROCEDURE|Computed Tomography|Undergo CT
224018238|NCT00939666|PROCEDURE|Wait&see or TEM with intensive follow-up|Wait\&see or TEM with intensive follow-up
224018239|NCT03800615|PROCEDURE|Cut the sling|Cut the mid-urethral sling for stress urinary incontinence
224018240|NCT02911415|PROCEDURE|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
224018241|NCT00349674|DRUG|Azathioprine: 2 mg/kg/day|
224018242|NCT00349674|DRUG|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
224018243|NCT06425874|PROCEDURE|Breast-conserving surgery|Breast-conserving surgery
224018244|NCT06425874|PROCEDURE|Mastectomy|Mastectomy without reconstruction
224018245|NCT06425874|PROCEDURE|Mastectomy with reconstruction|Any type of reconstruction(include implant and autologous)
224018246|NCT01526031|PROCEDURE|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
224018247|NCT01526031|PROCEDURE|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
224018248|NCT01526031|PROCEDURE|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~* 1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~* 2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~* 3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~* 4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
224018249|NCT01526031|PROCEDURE|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~* transcutaneous electrical nerve stimulation (TENS) for 15 minutes~* transcutaneous infrared thermotherapy (TDP) for 15 minutes~* manual physical therapy for 15 minutes~* simple home exercise program"
224018250|NCT00882154|DRUG|Cefdinir 300 mg Capsule (Sandoz, Austria)|
224018251|NCT00882154|DRUG|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
223398159|NCT02160015|PROCEDURE|Electrocardiogram|Undergo ECG
223398160|NCT02160015|DRUG|Ibrutinib|Given PO
223398161|NCT02160015|DRUG|Lenalidomide|Given PO
223398162|NCT02160015|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398163|NCT02160015|BIOLOGICAL|Rituximab|Given IV
223398164|NCT04164082|PROCEDURE|Biopsy Procedure|Undergo bladder biopsy
223398165|NCT04164082|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223398166|NCT04164082|PROCEDURE|Computed Tomography|Undergo CT
223398167|NCT04164082|PROCEDURE|Cystoscopy|Undergo cystoscopy
223398168|NCT04164082|DRUG|Gemcitabine Hydrochloride|Given intravesically
223398169|NCT04164082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398170|NCT04164082|BIOLOGICAL|Pembrolizumab|Given IV
224018252|NCT01892826|DRUG|hCG|5000IU
223398171|NCT04164082|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
223398172|NCT06645860|PROCEDURE|SDF+KI+LED Light 20s|After the silver diamine fluoride (SDF) and potassiım iodide (KI) application, 20-second LED light will be applied to the cavity.
223398173|NCT06645860|PROCEDURE|SDF+KI|Silver diamine fluoride (SDF) and potassium iodide(KI) will be applied.
223398174|NCT06346119|OTHER|this arm will received relaxing touch (hands, feet, head) during 30 minutes twice a day|Patients who will be included in this arm will receive massage twice a day of the head (10 minutes), feet (10 minutes) and hands (10 minutes)
223398175|NCT01955499|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223398176|NCT01955499|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224018253|NCT05094505|OTHER|Exercise in normoxia|Exercise at sea level, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
224018254|NCT05094505|OTHER|Control diet|Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
224018255|NCT05094505|OTHER|Exercise in hypoxia|Exercise at 3000m altitude, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
224129622|NCT04883580|DEVICE|Navigation and Positioning System for Orthopedic Surgeries|"Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation"
224129623|NCT03394170|OTHER|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
223398177|NCT01955499|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223398178|NCT01955499|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
224018256|NCT05094505|OTHER|Low carbohydrate diet|Low carbohydrate diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 40% of energy from fat, 20% from protein and 40% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
223398179|NCT01955499|DRUG|Ibrutinib|Given PO
223398180|NCT01955499|DRUG|Lenalidomide|Given PO
223398181|NCT01955499|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398182|NCT01955499|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224018257|NCT00201994|DRUG|Tolvaptan|
224018258|NCT06485453|DRUG|Botox 200 UNT Injection|Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
224018259|NCT00225966|DEVICE|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
224018260|NCT04708925|OTHER|conservative versus plasmapharesis therapy|conservative versus plasmapharesis therapy
224018261|NCT03265938|DEVICE|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
224018262|NCT05636956|OTHER|Education and Counseling Program|Researches created an education and counseling program. In this context, patients receive an one hour education. Education program consist of face-to-face informing and teach-back method. At the end of the face-to-face informing, researchers give a comicbook about instructions of living with CIEDs as a written material. After discharge, researches follow-up patients with phone calls. In the context of phone calls researches continue to informing patients, remind related instructions for that time and answer questions of patients. Patients are allowed to reach reserarches any time if they have any concern or question. This program lasts for six months.
224018263|NCT03871842|DEVICE|active tDCS|Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
224018264|NCT03871842|DEVICE|sham tDCS|The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
224018265|NCT02679508|DRUG|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
224018266|NCT02679508|DRUG|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
224018267|NCT01285271|DRUG|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
224018268|NCT01285271|DRUG|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
224018269|NCT03143166|DRUG|Dabigatran Etexilate|Tablet, film coated
224018270|NCT03143166|DRUG|Rabeprazol sodium|Tablet
224018271|NCT01906970|DEVICE|ClampArt|
223398183|NCT05904171|BEHAVIORAL|Tangotherapy|"Learning and practicing a series of moves - both individual and with a partner - taken from Argentine Tango, according to the Riabilitango (R) approach. The training is aimed at improving both physical (e.g., balance, change of direction, coordination, endurance) and cognitive (i.e., learning, divided attention, inhibition, planning) domains, in a pleasant, enjoyable, and inclusive environment.~This group-based training will take place twice a week (1h each session), for 6 weeks."
223398184|NCT05904171|BEHAVIORAL|Physical activity|Walking and stretching in group twice a week (1h each session), for 6 weeks.
223398185|NCT05636748|DIAGNOSTIC_TEST|18F-GP1 PET/CT|Patient will receive 1 18F-GP1 PET/CT
224018272|NCT00002197|DRUG|Abacavir sulfate|
224018273|NCT04360486|BIOLOGICAL|Anti-Sars-CoV-2 Convalescent Plasma|Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma
223398186|NCT05636748|DIAGNOSTIC_TEST|Agitated Contrast Echocardiogram|Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.
223398187|NCT05636748|DIAGNOSTIC_TEST|MRI Head|Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.
223398188|NCT05636748|DIAGNOSTIC_TEST|ECG Monitoring|All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.
223398189|NCT06345443|DIETARY_SUPPLEMENT|Nicotinamide Riboside Malate|Active supplement.
223398190|NCT06345443|OTHER|Placebo|Placebo
223398191|NCT04214626|DRUG|Rituximab|"Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles)."
223398192|NCT04214626|DRUG|Lenalidomide|Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223550942|NCT00325130|BIOLOGICAL|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
223550943|NCT04124094|DRUG|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
224129624|NCT04357379|BEHAVIORAL|IQOS|Participants will try an IQOS product and then take home the IQOS to sample for one week.
224018274|NCT04341467|DRUG|Amisulpride|The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
223398193|NCT04214626|DRUG|Cyclophosphamide|Induction Chemotherapy: 750mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223398194|NCT04214626|DRUG|Epirubicin|Induction Chemotherapy: 70mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223398195|NCT04214626|DRUG|Vincristine|Induction Chemotherapy: 1.4mg/m2 (Max: 2mg), Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223398196|NCT04214626|DRUG|Prednisone|Induction Chemotherapy: 100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
223398197|NCT04214626|DRUG|Methotrexate|Induction Chemotherapy: 1g/m2, Intravenous administration on day 3 of each 3-week cycle from 2 to 5 cycles for patients with high recurrence risk of the central nervous system.
223398198|NCT05019716|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223398199|NCT05019716|PROCEDURE|Biopsy Procedure|Undergo biopsy
223398200|NCT05019716|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223398201|NCT05019716|PROCEDURE|Chest Radiography|Undergo chest x-ray
224018275|NCT04341467|DRUG|Olanzapine|The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
224018276|NCT01702272|DEVICE|Procleix Dengue Virus Assay|in vitro diagnostic assay
224018277|NCT05249491|DIAGNOSTIC_TEST|Microbiological evaluation of dental plaques with children with or without black tooth stain|Evaluation of the etiological factors of black tooth stain according to the questionnaire
224018278|NCT06058754|BEHAVIORAL|The ADAPT Program|The ADAPT Program is a structured and individualized 10-week group-based program, in which two occupational therapists teach groups of people, the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT Program 3.0 includes 2 individual two-hour sessions (sessions 1 and 10) conducted in the clients homes and eight two-hour group-based sessions (sessions 2-9). Moreover, two booster sessions (sessions 11 and 12) are delivered to support sustainable gains after termination of the 10-week ADAPT Program 3.0
224018279|NCT06058754|BEHAVIORAL|UOT|UOT is delivered by one occupational therapist. Sessions are individualised and focused on improving ADL ability e.g. by practicing the performance of ADL task or adjusting home environments. UOT typically includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement in collaboration with the individual client
224018280|NCT04013087|DIETARY_SUPPLEMENT|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
224018281|NCT04013087|DIETARY_SUPPLEMENT|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
224018282|NCT04013087|DIETARY_SUPPLEMENT|Breast feeding|Breast feeding of human milk for 16 weeks
224018283|NCT06262074|OTHER|Structured Exercise Program|30 minutes of structured exercise programs
224018284|NCT06262074|OTHER|Non structured exercise program|Non structured exercises
224018285|NCT02104297|DRUG|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
224018286|NCT02104297|DRUG|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
224018287|NCT02104297|DRUG|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
224018288|NCT04013568|OTHER|Exercise|"First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students~Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes"
224018289|NCT04879953|DRUG|PIPAC with systemic chemotherapy|PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.
224018290|NCT04879953|DRUG|Systemic chemotherapy alone|Intravenous chemotherapy
224018291|NCT06248970|BEHAVIORAL|Rehabilitation therapy|"Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers."
224018292|NCT06248970|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
224129625|NCT01574313|PROCEDURE|stellate ganglion block|stellate ganglion block
224129626|NCT01574313|DRUG|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
224129627|NCT01574313|DRUG|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
224129628|NCT01574313|DRUG|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
224129629|NCT00319852|BIOLOGICAL|DTaP-IPV combined vaccine|0.5 mL, IM
224129630|NCT00319852|BIOLOGICAL|DTaP vaccine|0.5 mL, IM
224129631|NCT02318914|DRUG|gevokizumab|
224129632|NCT06108427|OTHER|Renin measurements|Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
224129633|NCT02100748|DRUG|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
224129634|NCT02100748|DRUG|Morphine|Morphine 4 mg will be administered every 4 hours
224129635|NCT02100748|DRUG|Placebo|Placebo will be administered every 4 hours
224018293|NCT06248970|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
224018294|NCT04395872|BEHAVIORAL|Psychiatric counseling|Patients who are admitted to the COVID-19 care unit of the Catholic University of Daegu Hospital are subject to consultation with the psychiatrist. By retrospectively reviewing the medical records of the request and the results of the subjects, We collected Socio-demographic information, medical severity (oxygen saturation, chest x-ray readings, medication being administered), clinical psychological scale (PHQ-9, GAD-7, PC-PTSD-5, AIS, P4, SF-36, SCL-90-R) This study evaluates whether there is a difference in psychological scale according to differences in socio-demographic status and medical severity, and compares psychological psychological measures before and after referral to mental health medicine to evaluate the effectiveness of psychiatric counseling.
224018295|NCT00223717|DRUG|Clonidine|0.1-0.2mg po. Single dose.
224018296|NCT00223717|DRUG|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
224018297|NCT00223717|DRUG|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
224129636|NCT06687174|DRUG|MY008211A tablets|MY008211A BID
224129637|NCT06687174|DRUG|MY008211A tablets matched placebo|Matching placebo to MY008211A taken twice a day.
224129638|NCT06686914|DRUG|Cannabidiol (CBD) Oil 300mg|Cannabidiol (CBD) Oil 300mg, 1 dose
224129639|NCT06686914|DRUG|Cannabidiol (CBD) Oil 150mg|Cannabidiol (CBD) Oil 150mg, 1 dose
224129640|NCT06686914|DRUG|Placebo Oil|Placebo Oil, 1 dose
224018298|NCT00223717|DRUG|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
224018299|NCT00223717|DRUG|Sildenafil|25- 100 mg po. Single dose.
224129641|NCT06874595|OTHER|Cycling exercise at 65% of HRR for 20 minutes followed by HD-tDCS (exercise + HD-tDCS)|Subject will complete a Cycling exercise at 65% of HRR for 20 minutes and then a High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
224129642|NCT06874595|OTHER|Cycling exercise at 65% of HRR exercise followed by sham HD-tDCS (exercise + sham tDCS)|Subject will complete a Cycling exercise at 65% of HRR for 20 minutes and then a sham High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
224129643|NCT06874595|OTHER|No exercise followed by HD-tDCS (no exercise + HD-tDCS).|No exercise but a High-definition transcranial direct current stimulation (HD-tDCS) is a non-invasive brain stimulation technique that uses small electrodes to deliver weak electric currents to the scale. Transcranial direct current stimulation (tDCS) uses weak direct currents of the order of 0.5 mA to 4 mA to modulate cortical activity by exciting or suppressing underlying neurons.
224296649|NCT00794755|DIETARY_SUPPLEMENT|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
224296650|NCT03044717|OTHER|Nutrition survey|Survey will be done prior to the initiation of the education
224296651|NCT03044717|OTHER|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
223398202|NCT05019716|DRUG|Cisplatin|Given IV
223398203|NCT05019716|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
224129644|NCT06874595|OTHER|State Anxiety Inventory|"A widely used psychological assessment tool designed to measure both state and trait anxiety. 40 self-report items rated on a 4-point Likert scale (1 = Almost Never to 4 = Almost Always). Higher scores indicate higher levels of anxiety. Scores are compared to normative data to determine if they fall within the range of typical or clinical anxiety."
224129645|NCT06874595|OTHER|Visual Analog Scale for Anxiety|"The Visual Analogue Scale for Anxiety (VASA) is a 100-millimeter line that helps people measure how anxious they feel. The scale has a mark on the left end that indicates not at all anxious and a mark on the right end that indicates very anxious."
224129646|NCT05998616|BEHAVIORAL|Exercise Training Program|The intervention group will be encouraged to complete aerobic and resistance training exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment for monitoring walking and complete resistance training will be provided to the intervention group. The exercise training prescription involves 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and resistance training consisting of 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands.
224296652|NCT03044717|OTHER|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
224296653|NCT01440036|PROCEDURE|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
224296654|NCT04006483|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
223398204|NCT05019716|DRUG|Etoposide|Given IV
223398205|NCT05019716|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
224018300|NCT00223717|DRUG|Nifedipine|10-30 mg po. Single dose.
224018301|NCT00223717|DRUG|Hydralazine|10-50 mg po. Single dose
224018302|NCT00223717|DRUG|Hydrochlorothiazide|12.5-100 mg po. Single dose.
224018303|NCT00223717|DRUG|Placebo|Po or patch. Single dose.
224018304|NCT00223717|DRUG|Bosentan|62.5 -125 mg po. Single dose.
224018305|NCT00223717|DRUG|Diltiazem|30-60 mg po. Single dose.
223398206|NCT05019716|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398207|NCT05019716|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223398208|NCT06022016|GENETIC|For each person (index case or related) included in this study:|"* an health questionnaire will be completed in order to gather information on the participant's medical history and lifestyle.~* a saliva sample will be taken (if applicable) so that a genetic analysis can be performed."
223398209|NCT00932412|DRUG|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
224018306|NCT00223717|DRUG|Eplerenone|50-100 mg po. Single dose.
224018307|NCT00223717|DRUG|guanfacine|1-3 mg po. Single dose.
224018308|NCT00223717|DIETARY_SUPPLEMENT|L-arginine|6-17 g po. Single dose
224018309|NCT00223717|DRUG|captopril|25-50 mg PO. Single dose.
224018310|NCT00223717|DRUG|carbidopa|25-200 mg PO. Single dose.
223398210|NCT00932412|DRUG|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
223398211|NCT01875601|BIOLOGICAL|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
223398212|NCT01875601|BIOLOGICAL|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
223398213|NCT05879978|DRUG|Obrixtamig|Obrixtamig
223398214|NCT05879978|DRUG|Ezabenlimab|Ezabenlimab
223398215|NCT05541653|OTHER|Financial Well-being Interventions|Tax preparation; access to public benefits; financial counseling and microgrants
223398216|NCT05541653|OTHER|Place-based Interventions|Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
223398217|NCT05725681|OTHER|High protein ramen|Participants will be served one portion of high-protein instant ramen noodles \[CHEF WOO Roasted Chicken Flavor Ramen Cup Noodles, Borealis Foods; 71 g\]
223398218|NCT05725681|OTHER|Standard ramen|Participants will be served one portion of standard instant ramen noodles \[RAMEN EXPRESS Chicken Flavor Ramen Cup Noodle Chef Woo, Borealis Foods; 71 g\]
223398219|NCT06202443|OTHER|Early PT|Physical therapy delivered within the first three months after surgery.
223398220|NCT06202443|OTHER|Delayed PT|Physical therapy delivered greater than 3 months after surgery.
224018311|NCT00223717|DRUG|losartan|25-200 mg PO. Single dose.
224018312|NCT00223717|DRUG|metoprolol tartrate|25-100 mg PO. Single dose.
224018313|NCT00223717|DRUG|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
224018314|NCT00223717|DRUG|prazosin hydrochloride|0.5-1 mg PO. Single dose.
224018315|NCT00223717|DRUG|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
224018316|NCT00223717|OTHER|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
224018317|NCT00223717|DRUG|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
224129647|NCT05998616|BEHAVIORAL|Flexibility Program|The control group will be encouraged to complete stretching and range of motion exercises three times a week, and either at home, in the community (e.g., park, shopping mall), or any suitable environment of the participant's choice. Exercise equipment (yoga mat) for monitoring walking and complete flexibility training will be provided to the control group. The flexibility training prescription involves stretches from the Stretching for People with MS: An Illustrated Manual from the National MS Society.
224129648|NCT05650450|DEVICE|DES+DCB|Hybrid approach is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES for a de novo long (\>38 mm) lesion (located in the larger, more proximal part of the vessel -reference vessel diameter -RVD \>2.75 mm-) and DCB inflation for a concomitant and contiguous de novo small vessel disease (distally located with RVD ≤2.75 mm ≥ 2.0 mm)
223550944|NCT04124094|DRUG|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
224018318|NCT00223717|OTHER|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
224018319|NCT01815762|OTHER|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
224018320|NCT01725789|DRUG|Ferinject®|"Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight \<50Kg .~Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight \<50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value \<15ng/mL and Hb\<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)"
224018321|NCT01725789|DRUG|normal saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
224018322|NCT03683823|BEHAVIORAL|Attention guidance|Explicitly guiding attention towards faces during public speaking exposures
224018323|NCT03683823|BEHAVIORAL|Control intervention|Public speaking exposures
224018324|NCT00365677|DEVICE|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
224018325|NCT00365677|DEVICE|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
224129649|NCT00808327|DRUG|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
224129650|NCT00808327|DRUG|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
224296655|NCT04006483|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
223398221|NCT06005623|DEVICE|SENS Motion + Motivational Feedback|"To weeks prior to surgery and in a 12-week period following discharge after TKA/UKA patients will be equipped with a discrete patch and built-in accelerometer (SENS Motion, Denmark, Copenhagen) attached on the thigh of the leg not undergoing surgery.~Following discharge after TKA/UKA patients randomized to the intervention-group will receive the app (SENS motion). On their provided app, patients will be able to choose between two tabs. Tab 1 will allow patients to view predefined goals, all of which are locations in a self-selected city. The sensor will measure the physical activity and daily rhythm of the patient, and accelerometer counts will be converted into daily steps, which will be visible to the patients. In Tab 2, patients will be able to see graphical representations of their daily activity as well as their history during the period in which they have worn the accelerometer. The graphical representations include: Daily steps, physical active minutes, and type of activity."
223398222|NCT06400147|BEHAVIORAL|Strategy Training|This intervention will use an adapted form of strategy training for people with neglect.
223398223|NCT06400147|BEHAVIORAL|Attention Control|This intervention will use a reflective listening protocol.
223398224|NCT06348238|BEHAVIORAL|Self-Affirmation|Self-affirmation theory contends that integrity of one's self-concept (self integrity) is essential for navigating daily stressors. When individuals encounter information or contexts that pose a threat to one's self-integrity, we can adopt maladaptive coping strategies to alleviate the discomfort. One strategy for strengthening self-integrity is engage in an explicit process of reinforcing sources of self-worth - self-affirmation. Self affirmation interventions have participants engage in an exercise writing about core personal values (a writing induction). In a writing induction, participants review a list of values and are instructed to choose up to two that are important to them. Participants are then asked to write a few sentences about why their chosen values are important to them and identify times in which these values have helped them navigate challenges.
223550945|NCT04124094|OTHER|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
223550946|NCT00055926|DRUG|CP-724,714|
224018326|NCT03456427|DEVICE|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) \& Mediolateral Oblique (MLO).
224018327|NCT03456427|DEVICE|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
224018328|NCT06452498|DRUG|Metformin Hydrochloride|Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.
224018329|NCT06452498|DRUG|Placebo|Capsule filled with cellulose.
224018330|NCT02813876|OTHER|Enhanced recovery protocol|
224018331|NCT01323972|BIOLOGICAL|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
224018332|NCT03804970|BEHAVIORAL|cash rewards for the fellow up|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
224018333|NCT03804970|BEHAVIORAL|Showing retinal photos to participants|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
224018334|NCT03804970|BEHAVIORAL|SMS reminders for participants and their family|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
224018335|NCT03804970|BEHAVIORAL|Watching brief video and basic explanation for disease|This basic explanation will be offered by professional doctors or nurses.
224018336|NCT03804970|BEHAVIORAL|Having the Diabetic Club|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
224018337|NCT04129827|OTHER|Clinical, self-reported psychological and biomechanical assessments|"1. medical check up~   * active and passive Range Of Motion (ROM)~  * anterior drawer test~  * knee's alignment~  * modified cincinnati rating system questionnaire (mCRSQ)~  * tegner lysholm knee scoring scale (TLKS)~  * Tegner Activity Level Score (TALS)~2. self-reported psychological questionnaires~   * Tampa Scale of Kinesiophobia (TSK)~  * ACL Return to Sport after Injury (ACL-RSI) score~3. biomechanical tests~   * Stability test: to balance on one/two legs on a free to move disc for 30s~  * Jump test: i) a maximize jump with both legs; ii) a maximize jump with only one leg; three consecutive jumps; iv) jump coordination path where the patient had to perform a forward-backward-forward jump and a sideway jump on one leg~  * Coordination test: a square hurdle was used for the quick test, where the patient had to step in and out with both feet for a total of 15-rep as quickly as possible~  * fatigue test: to rise and sit from a chair for 30-rep as quickly and safely as possible"
224129651|NCT06634381|BEHAVIORAL|CRF Visual Aid|After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
224129652|NCT07029334|OTHER|Social Prescribing|"The SP intervention consists of a series of intervention components delivered across the SP pathways:~Intervention components~GP:~1. Social prescribing from physician to patient~   Link Worker:~2. Initial phone contact~3. Clarification and follow-up consultations~4. Personalized matching with local services and activities~5. Care coordination~6. Introductory visits to local services and activities~7. Accompanied (if needed)~8. Follow-up conversations~9. Concluding conversations~10. Group-based courses~    GP / Link Worker:~11. Re-prescribing (where appropriate)~Each intervention component is described in detail in the TIDieR checklist"
224129653|NCT07023757|PROCEDURE|Socket preservation|After tooth extraction, the extraction socket will be filled with a collagen plug in one group or a platelet-rich fibrin plug in the other.
224296656|NCT04006483|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
224129654|NCT06692829|PROCEDURE|robotic rehabilitation|In addition to conventional therapy, the robotic therapy group was planned to receive robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 45 minutes, accompanied by a physiotherapist trained in robotic rehabilitation and with at least 5 years of experience. A total of 20 treatment sessions will be applied 2 days a week.
224129655|NCT06692829|PROCEDURE|conventional rehabilitation|It was planned for the conventional therapy group to receive an exercise program consisting of 45 minutes of active, passive range of motion exercises and strengthening exercises, accompanied by a physiotherapist with at least 5 years of experience in stroke rehabilitation. A total of 20 treatment sessions will be applied 2 days a week.
224129656|NCT06693102|BEHAVIORAL|Digital intervention targeting cancer-related cognitive impairments|The intervention is developed using a person-centered approach and includes key components such as psychoeducation, cognitive training, compensatory strategy training, and cognitive restructuring exercises. Participants receive weekly remote support from a therapist and are encouraged to complete the program within a six-week period.
224129657|NCT06693102|BEHAVIORAL|Crossword and sudoku taks|Participants receive crossword and sudoku tasks. They are encourraged to solve such tasks for a minimum of 15 minutes daily for six weeks.
224129658|NCT06693778|OTHER|electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI|eCDS tool for risk stratification of pediatric mTBI patients
224129659|NCT01344811|PROCEDURE|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
224129660|NCT01344811|OTHER|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
224129661|NCT00444223|PROCEDURE|fluorine F 18 FEQA + positron emission tomography|
224129662|NCT06052735|OTHER|Correlation research|The relationship among pain perception, temporomandibular disorder severity and spine health
224129663|NCT06693401|OTHER|Intervention group: PD rehabilitation complemented with Occupational Therapy programme|"In intervention group both Physiotherapy and Occupational Therapy programmes were implemented.~Occupational Therapy programme consisted in trainning the amplitude of the movements involved in the realization of each letter of the alphabet separately and through fine motor exercises. Specifically the tasks consisted of performing:~1. 2 types of handwriting exercises, namely for tracing the upper and lower-case letters of the alphabet guided by dotted lines and writing a sentence with and without spatial boundaries, in Portuguese language (to be performed for about 45 minutes, three times a week) and;~2. 4 groups of fine motor tasks exercises, namely for hand manipulation (2 exercises), finger isolation (3 exercises), finger flexion and extension (2 exercises) and coordination (1 exercise). All exercises were performed 10 times, in triplicate, for each hand on a regular basis of 2-3 times per week."
224129664|NCT06693401|OTHER|Control Group: conventional physiotherapy programme|In this group only the conventional physiotherapy programme was implemented. This programme has the purpose of improving balance and reducing the risk of falls, enhancing mobility and motor function, managing muscle stiffness and rigidity, addressing gait abnormalities, and providing education and support. In this regard, participants were guided and supervised in each physiotherapy session by a Parkinson's disease healthcare specialist.
224129665|NCT05838833|DRUG|INV-001|Patient will be assigned to one of three arms.
224129666|NCT06687161|DEVICE|Transcranial Magnetic Stimulation (TMS) therapy|Each treatment consists of 600 TMS pulses (\~3 minutes) applied to the L-DLPFC
224129667|NCT06687161|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I)|9-week fully-automated, Internet-delivered CBT-I program: SHUTi OASIS (Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness)
224129668|NCT06517953|DRUG|Icotinib|An orally first-generation EGFR inhibitior.
224129669|NCT06517953|DRUG|Befotertinib|An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.
224129670|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
224018338|NCT04007250|DEVICE|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~* FENIX™ System Implant~* FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
224018339|NCT06127823|BEHAVIORAL|Dietary treatment|Dietary counselling
224018340|NCT01159210|BIOLOGICAL|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
224018341|NCT04664803|DRUG|Cefecin Tab.|
224018342|NCT04664803|DRUG|Omnicef Cap.|
224018343|NCT00480129|BEHAVIORAL|Probiotic or placebo yogurt consumed daily|
224018344|NCT00480129|DEVICE|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
224018345|NCT00480129|PROCEDURE|Blood sample|
223398225|NCT06049849|DEVICE|Biophoton Energizing Brain and Whole Body|The patient is to be energized within a strong biophoton field which is constantly generated by active biophoton generators.
224018346|NCT00480129|PROCEDURE|Nasal lavage|
224018347|NCT01116102|DRUG|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
224018348|NCT04687280|OTHER|non interventional|non interventional, study on data
224018349|NCT03906422|DEVICE|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
224018350|NCT03906422|DEVICE|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
224018351|NCT03906422|DEVICE|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
224018352|NCT05000931|DEVICE|Osia 2 System|Osia 2 System in a pediatric population aged 5 - 11 years by quantifying the type, frequency and severity of adverse events.
224018353|NCT04168528|DRUG|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
224018354|NCT00901654|BIOLOGICAL|ACE527 vaccine|"First cohort: Two doses, each of 3x10\^9 cfu of each strain (9x10\^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10\^10 cfu of each strain (9x10\^10 cfu total per dose) administered on Days 0 and Day 21"
224018355|NCT00901654|BIOLOGICAL|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
224018356|NCT06458413|DRUG|Utidelone Capsule Plus Capecitabine|"Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle ."
224018357|NCT03141905|OTHER|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
224129671|NCT03408847|COMBINATION_PRODUCT|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
224129672|NCT06715709|DRUG|Dexamethasone IV|Patients will receive dexamethasone administered intraoperatively at the time of anesthesia. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus.
224138648|NCT03831308|DIAGNOSTIC_TEST|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
223398226|NCT03568656|DRUG|CCS1477|Capsules, oral
223398227|NCT03568656|DRUG|Abiraterone acetate|Abiraterone acetate 500mg tablets plus prednisone/prednisolone
223398228|NCT03568656|DRUG|Enzalutamide|Enzalutamide 40mg capsules/tablets
223398229|NCT03568656|DRUG|Darolutamide|300mg tablets
223398230|NCT03568656|DRUG|Olaparib|150mg tablets
224018358|NCT03141905|OTHER|Usual Care|Standard clinical care
224018359|NCT01002300|DRUG|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
223398231|NCT03568656|DRUG|Atezolizumab|840mg/14ml concentrate for solution for infusion vials
223398232|NCT03103087|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
223398233|NCT03103087|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
223398234|NCT03103087|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
224018360|NCT05987202|OTHER|DA closure in a population of premature infants|Evaluate the incidence of DA closure in a population of premature infants treated with BTM per os for bronchopulmonary dysplasia
224018361|NCT04638634|BIOLOGICAL|CSL760|An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin
224018362|NCT06247059|DEVICE|Box Fan|Classrooms assigned to this arm will be equipped with 2 - 8 box fans each with a single minimum efficiency reporting value-14 (MERV-14) filter sufficient to increase effective air changes per hour to 12 based on the clean air delivery rate measured in cubic feet per minute of the box fan + filter \* 60 divided by the room volume.
224018363|NCT06247059|DEVICE|UV Germicidal Irradiation Lamp Unit|Classrooms assigned to this arm will be equipped with one or two 222nm wavelength light ultraviolet germicidal irradiation lamp units (number of units per classroom based on room volume).
224018364|NCT06247059|DEVICE|Combined: Box Fan and UV Germicidal Irradiation Lamp Units|Classrooms assigned to this arm will be equipped with both box fans and UV germicidal irradiation lamp units.
224018365|NCT06609629|PROCEDURE|Selective lung recruitment|A bronchial blocker with a lumen is inserted in one inferior pulmonary lobe using a fibroscope. The baloon of the blocker is expended to isolate the lobe. A second ventilator is used to apply a pressure of 45cmH2o through the lumen of the blocker. The recruiting pressure is maintained 30 to 60 second. After the procedure, the blocker is removed and the procedure is repeated in the controlateral inferior lobe.
224018366|NCT06610331|PROCEDURE|FREE GİNGİVAL GRAFT|Free Gingival Graft removal from the palate donor area for the treatment of gingival recession
224018367|NCT06610331|DEVICE|polyvinylpyrrolidone sodium hyaluronate gel|Patients are told to gargle with a mouthwash containing polyvinyl pyrrolidone sodium hyaluronate twice a day for 2 weeks. 15 ml (1 tablespoon) of mouthwash containing polyvinyl pyrrolidone sodium hyaluronate is poured into a glass and approximately 40 ml (3 tablespoons) of water is added and mixed well, then it is shaken for at least 1 minute, making contact with the entire mouth.
224018368|NCT06863324|DIAGNOSTIC_TEST|Radiation induced Lymphocyte Apoptosis diagnostic test|Diagnostic test for estimation of individual radiosensitivity, based on blood test, whose clinical value has been demonstrated in predicting complications in patients irradiated for breast or prostate cancer. These tests are based on the rate of radiation-induced lymphocyte apoptosis, known as the RILA (Radiation Induced Lymphocyte Apoptosis) score
224129673|NCT06715709|DRUG|Dexamethasone IV+Oral|Patients will receive dexamethasone administered intraoperatively and on the morning of the first postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
224129674|NCT06715709|DRUG|Dexamethasone IV+Oral 2 Day|Patients will receive dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
223398235|NCT03103087|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
223398236|NCT04316546|DRUG|MK-7075 (miransertib)|MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
223398237|NCT03505801|DEVICE|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
223550947|NCT04923334|BEHAVIORAL|Brief Pain Teleconsult|The Brief Pain Teleconsult intervention includes 2 sessions provided by a licensed physical therapist over about 1 week. The sessions focus on pain education from a biopsychosocial perspective that is designed to address negative pain appraisals and catastrophizing thoughts, providing advice to be active and engage in exercise and physical activity, and reassurance that activity is beneficial and safe.
223550948|NCT04923334|BEHAVIORAL|Telehealth Physical Therapy|The Telehealth Physical Therapy intervention involves weekly telehealth sessions provided over 10 weeks. Telehealth Physical Therapy is provided by a licensed physical therapist. Key components of the intervention include reinforcing biopsychosocial education messages and developing an exercise and physical activity program using cognitive behavioral principles such as goal setting and positive reinforcement. Pain coping strategies including mindful breathing and progressive relaxation techniques will be included.
224018369|NCT06885970|DRUG|Cytisinicline administration|Participants will receive in the smoki
224129675|NCT04207567|BEHAVIORAL|Bodyweight exercises (push-ups, angled-rows, bodyweight squats) on weekdays|Participants will be instructed to perform one set each of push-ups, angled-rows, and bodyweight squats every weekday. They will be given the equipment and training necessary to properly perform the exercises. They will also be trained in the Tiny Habits® Method and receive digital coaching.
224129676|NCT00406640|DRUG|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
224129677|NCT00406640|DRUG|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
223398238|NCT05437705|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication. The MagPro X100\* magnetic stimulator and Cool-B65 Butterfly Coil are FDA-approved for rTMS treatments of depression.
223731430|NCT04429737|DIETARY_SUPPLEMENT|Placebo|The prediabetes patients in this arm will receive Placebo with a dose for 2g/d (500mg/capsule, 2 capsules/time, 2 times/day at day and night ) for 6 months ( Blood draw every 3 months) . After taking tested substance 6 months, the prediabetes patients will be continuous tracked for 3 years and be blood drawed every 6 months.
223398239|NCT05828082|PROCEDURE|Biopsy Procedure|Undergo biopsy
223398240|NCT05828082|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223398241|NCT05828082|PROCEDURE|Computed Tomography|Undergo CT
223398242|NCT05828082|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398243|NCT05828082|PROCEDURE|Positron Emission Tomography|Undergo PET/MRI or PET/CT
223398244|NCT05828082|DRUG|Tuvusertib|Given PO
223398245|NCT05828082|PROCEDURE|Ultrasound Imaging|Undergo U/S
223550949|NCT02949050|BIOLOGICAL|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
223550950|NCT02949050|BIOLOGICAL|SCIT|Treatment group consists of patients who completed \> 1 year of SCIT while control group patients did not undergo SCIT
223731431|NCT02733367|DRUG|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
224018370|NCT00377091|DRUG|Fondaparinux|
224018371|NCT00812331|DRUG|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
224018372|NCT01506453|DRUG|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
224018373|NCT01506453|DRUG|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
224018374|NCT02560311|OTHER|observation|
224018375|NCT02866500|BEHAVIORAL|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
224018376|NCT05786989|DRUG|selinexor|Given PO
224018377|NCT01809496|BEHAVIORAL|Informational Counseling|
224018378|NCT01809496|BEHAVIORAL|Patient Centered Counseling|
224129678|NCT05475262|DEVICE|Active white noise|Active white noise of 57 dB - 60 dB from 10 pm to 6 am
224129679|NCT05475262|DEVICE|Inactive white noise|Sham comparator - white noise machine played at lower decibel level not expected to impact sound level changes
224129680|NCT05507944|DIAGNOSTIC_TEST|FeNO measurement|Diurnal measurements before work and at 3 hours after work start.
224018379|NCT05346133|BEHAVIORAL|Suicide Prevention Intervention for Adolescents|Suicide Safety Planning Intervention (SPI). SPI is a very brief intervention (20-45 minutes) that provides patients with specific strategies to use to decrease the risk of suicidal behavior. SPI begins with psychoeducation about suicide risk, then the clinician and patient collaboratively create a stepwise plan that includes a simple list of individually tailored, concrete coping mechanisms to be enacted during or leading up to a crisis. The steps of the safety plan include: 1) recognizing warning signs of a crisis; 2) employing internal coping strategies; 3) using social contacts and settings to distract from suicidal thoughts; 4) seeking help from family members or close friends; 5) contacting healthcare or emergency services; and 6) reducing access to means. SPI providers work with caregivers to help them monitor warning signs of suicide risk, encourage the use of the safety plan by their adolescent, and reduce access to lethal means in the home.
224129681|NCT05741593|OTHER|Analysis of the verbatim from the transcription of the recorded interviews.|recorded semi-structured interviews between the patients and the pharmacist
224129682|NCT06726018|BEHAVIORAL|Conditioned Pain Modulation (CPM)|Participants will receive a testing stimulus of pressure applied per ascending intensity at the web space of the foot until the pain reaches 40 out of 100, then discontinued. After testing the stimulus, participants will then receive a conditioning stimulus by immersing the non-dominant hand into the water-cooled by refrigeration unit with a temperature of 6 degree Celsius (males) or 8 degree Celsius (females) for 60 seconds. Subjects will be asked to rate the cold pain during the four 60-second trials. Participants completely removed their hand from the cold pressor for 30 seconds following each of the four 60-second immersions, during which time the testing stimulus will be re-applied per the sequential paradigm to the web space of the foot. Participants complete four 60-second periods of immersion.
224018380|NCT04199897|DIETARY_SUPPLEMENT|Succrose rinsing|Sucrose rinsing 7-8 times a day for 14 days
224018381|NCT04199897|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic lozenges 2 times a day for 35 days
224018382|NCT04199897|OTHER|xylitol rinsing|Xylitol rinsing 7-8 times a day for 14 days
224018383|NCT04199897|OTHER|Placebo tablets|Placebo lozenges 2 times a day for 35 days
224018384|NCT02301715|DRUG|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
224018385|NCT02301715|DRUG|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
224018386|NCT05803031|DRUG|Melaleuca Alternifolia Oil|"Tea tree oil 5% gel (Sigma Aldrich® Steinheim, Germany) for local sub gingival application was prepared by the Department of Pharmaceutics, Faculty of Pharmacy.~The gelling agent; Carbopol 940 (1% w/v) was first soaked in distilled water for 2 h then TTO dissolved in an appropriate amount of propylene glycol was added to the Carbopol dispersion. Methyl paraben 0.2% w/v dissolved in preheated water was used as a preservative. The gel mixture was then magnetically stirred for 30 min. Finally, pH was adjusted using 1 N NaOH added dropwise with gentle stirring with a spatula until the desired pH value (6.5-7) was reached. The gel was sterilized by autoclaving at 110 °C for 20 min."
224018387|NCT05803031|PROCEDURE|Non-surgical periodontal debridement|Scaling and root surface debridement
224129683|NCT07046403|DEVICE|High Purity Type-I Collagen-based Skin Substitute and SOC|The SOC in this study is wound care covering with High Purity Type-I Collagen-based Skin Substitute applied weekly or as needed followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
224129684|NCT07046403|DEVICE|Dehydrated Human Amnion / Chorion Membrane and SOC|The SOC in this study is wound care covering with Dehydrated Human Amnion/Chorion Membrane followed by a padded 3-layer dressing comprised of first layer - non-adherent and porous paraffin gauze (Cuticel), second layer - absorbent 4x4 gauze pads \& third layer - soft roll and compressive wrap (Crepe Bandage)
224138649|NCT04394455|BEHAVIORAL|Brief cognitive behavioral therapy|9 structured psychotherapy sessions, weekly, 60-90 minutes duration. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
223398246|NCT03504397|DRUG|zolbetuximab|Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.
223398247|NCT03504397|DRUG|placebo|Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
223398248|NCT03504397|DRUG|oxaliplatin|Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.
223398249|NCT03504397|DRUG|folinic acid|Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
223398250|NCT03504397|DRUG|fluorouracil|Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
223398251|NCT03431714|DRUG|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
224129685|NCT06724172|BEHAVIORAL|Self-Management|We will universally offer social needs supports (grocery, physical activity, transportation support) widely in use in clinical settings. Patients may elect to receive all, some, or none of the supports. The patient-directed, structured self-management intervention will be provided through mobile health technology (mHealth) and/or mailings, according to patient preference. Participants will receive health information to support health education and behavior change.
224129686|NCT06724172|BEHAVIORAL|Community-Based|As is currently in use broadly by community health workers, participants will complete a detailed social needs assessment and active assistance with referrals to evidence-based home visiting programs; maternal child health services to promote social support and resource access; and services to improve social determinants of health including active enrollment assistance for WIC, SNAP, healthcare and insurance, legal support, housing, job training, mental health and others. Community health workers will deliver group and individual physical activity support and assistance with behavioral goal setting.
224129687|NCT04166045|DEVICE|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
224129688|NCT04166045|DEVICE|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
224129689|NCT06926192|COMBINATION_PRODUCT|Surgery combined with secukinumab|Surgery combined with secukinumab
224018388|NCT02610166|BEHAVIORAL|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
224018389|NCT02610166|OTHER|Usual Care|Children in usual care group receive standard medical care.
224129690|NCT06728566|DEVICE|Inmersive virtual reality|"In addition to conventional training, IVR training aims to provide a detailed preview of the tasks and procedures required in the standard training with selected virtual scenarios:~Scenario 1: Inspection and Use of Personal Protective Equipment (PPE):~In this scenario, the worker will inspect the equipment to ensure it is in good condition and properly used: Harness, Helmet, Lanyards, Carabiners, Lifelines, Energy Absorbers~Scenario 2: Working on an Elevated Metal Structure:~Structure Ascent: Ascent Method: Use specific ascent systems, ensuring you are always connected to an anchor point.~Positioning on the Structure: Secure Anchorage: Once the working position is reached, secure the anchor to a fixed and reliable point.~Structure Descent: Unanchoring and Reanchoring: Unanchor and re-anchor at secure points as you descend.~Additional Safety Measures: Weather Conditions, signage and delimitation:~Scenario 3: Rescue at Heights: Accessing the Person in Danger, rescue Techniques."
224129691|NCT06728566|OTHER|Conventional training|"The working at heights training provided by the National Learning Service (SENA) in Colombia includes key steps to ensure safety and proper equipment use:~* Harness Use: Inspect for damage, wear it like a vest, and ensure correct orientation. Adjust shoulder and leg straps for comfort and secure the chest strap.~* Final Check: Verify D-rings are correctly positioned, and all buckles are securely fastened.~* Helmet: Inspect for damage and adjust for a secure fit.~* Lanyards: Select in good condition, connect properly, keep tension, and avoid overloading.~* Carabiners: Use certified carabiners with functioning locks, connected to proper points.~* Lifelines and Energy Absorbers: Install and tension lifelines properly; check energy absorbers before use.~* Climbing/Descending: Maintain three contact points and secure tools to avoid accidents."
224138650|NCT04394455|BEHAVIORAL|Crisis intervention therapy|3 structured sessions of crisis intervention. One session each week for three weeks. Provided by one therapist and one co-therapist. Provided through telepsychiatry.
224138651|NCT05688501|OTHER|descriptiv group|no intervention
223398252|NCT00413699|DRUG|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
223398253|NCT00413699|DRUG|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
223398254|NCT06386055|BEHAVIORAL|Active exercise|The intervention group will be provided with training courses for 3 months.
223731432|NCT05298280|DEVICE|Pendulum appliance|In the PG, all patients received a pendulum appliance as described by Angelieri et al. The Nance button was anchored to the first and second premolars with removable wires. The 0.032-inch TMA wires were activated 45 degrees to produce a force of 200-250g per side. On average, intraoral reactivation of the distalizing springs was performed twice during the procedure. When a super Class I molar relationship was obtained, pendulum was replaced by a Nance holding arch. The average treatment duration was 8 months followed by bracket conventional therapy.
223731433|NCT05298280|DEVICE|clear aligners|The standardized orthodontic intervention was represented by the maxillary molar distalization protocol proposed by Align Technology: it was planned in order to obtain a sequential distalization on the upper arch, and the staging was set at 0.25 mm per aligner. During sequential distalization aligners are set up to distalize one tooth at a time. The attachments were engineered by Align Technology to achieve predictable tooth movements. Each couple of aligners was worn for 7 days.
224018390|NCT01206036|DRUG|Docetaxel|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
223398255|NCT05524389|RADIATION|Vaginal brachytherapy|"High-dose rate vaginal brachytherapy (VBT) was delivered with a vaginal cylinder.For VBT administered alone, the dose is recommended: 3 fractions of 7 Gy or 5 fractions of 6 Gy or 6 fractions of 5 Gy.~For VBT administered after completion of EBRT: 2-3 fractions of 4-6 Gy."
224018391|NCT01206036|DRUG|Temsirolimus|DL 1: Docetaxel 60mg/m\^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m\^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m\^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
224018392|NCT04323631|DRUG|Hydroxychloroquine|Oral
224018393|NCT04323631|OTHER|The control group will not receive hydroxychloroquine|The control group will not receive hydroxychloroquine
224018394|NCT03706313|DRUG|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
223731434|NCT05395520|OTHER|Retrospective chart review|Retrospective chart review to be conducted at Methodist Charlton Medical Center (MCMC) in Dallas, TX. Adult patients who received vancomycin while inpatient at MCMC with at least one corresponding vancomycin trough level taken at steady state will be included. All vancomycin orders by providers are entered as pharmacy to dose; thus dosing and routine monitoring is conducted by pharmacists.
223398256|NCT05524389|RADIATION|Pelvic external beam radiotherapy|EBRT was delivered to the pelvic area using a total dose of 45-50.4Gy in 25-28 fractions over 5-6 weeks with the intensity-modulated radiotherapy (IMRT) technique, three-dimensional conformal radiotherapy (3D-CRT) modality
223398257|NCT05524389|OTHER|Observation|No radiotherapy is administrated, but active follow-up and quality of life questionnaires is needed after surgery.
223398258|NCT05524389|DRUG|Chemotherapy|Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.
223398259|NCT04629495|DRUG|Rapamycin|RAPA will be administered orally 1mg daily
223731435|NCT06489652|DRUG|89Zr-Oxine-RY_SW01 Cell Injection|Biodistribution and metabolic kinetic characterization of zirconium-labeled cells in vivo for the treatment of systemic sclerosis by intravenous infusion of 89Zr-Oxine-RY\_SW01 cells injection
224129692|NCT06777654|OTHER|Robotic therapy (RT)|The Bi-Manu-Track (BMT) robot will be provided as the robotic practice. The BMT can be switched from the bilateral practice modules involving bilateral upper limbs to the unilateral module involving the affected upper limb. According to the group assignment, participants will practice the unilateral or bilateral module of BMT training.
223731436|NCT01839773|DRUG|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
223731437|NCT01839773|DRUG|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
223731438|NCT01348347|DRUG|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
223731439|NCT01348347|DRUG|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
223731440|NCT01348347|DRUG|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
224129693|NCT06777654|OTHER|Mirror therapy (MT)|The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.
223398260|NCT04629495|OTHER|Placebo|Placebo will be administered orally once daily
223398261|NCT03644641|PROCEDURE|Desflurane Group|General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).
223398262|NCT03644641|PROCEDURE|Propofol Group|General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).
223398263|NCT04992078|DEVICE|NAVIO/CORI Surgical System|Unicompartmental knee replacement with robotic assistance
223398264|NCT04992078|PROCEDURE|Non-robotic conventional instrumentation|Unicompartmental knee replacement with non-robotic conventional instrumentation
223398265|NCT00075816|BIOLOGICAL|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
223398266|NCT00075816|BIOLOGICAL|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
223398267|NCT02767557|DRUG|Tocilizumab|Intravenous infusion
224129694|NCT06777654|OTHER|Dose-matched control intervention|Participants in the control group will receive therapist-mediated rehabilitation per session.
224129695|NCT04614545|DRUG|Phentermine 37.5 Mg|Patients will receive 37.5 mg of phentermine daily for a 12 week duration
224129696|NCT04614545|BEHAVIORAL|Dietary program|Patients will be able to select either the Mediterranean diet or the Ketogenic diet and will work with a dietician
223398268|NCT02767557|DRUG|Gemcitabine|Intravenous infusion
223398269|NCT02767557|DRUG|nab-Paclitaxel|Intravenous infusion,
223398270|NCT05678322|DRUG|18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent|Under development for the diagnosis of prostate cancer by Blue Earth Diagnostics. rhPSMA-7.3 (18F) will be administered intravenously as a single-dose injection. The molecular structure of the drug substance comprises a prostate-specific membrane antigen (PSMA) binding motif, a peptide spacer, an 18F-radiolabeled silicon fluoride acceptor moiety and a gallium chelator complex.
223398271|NCT05678322|DEVICE|PET MRI Imaging|rhPSMA-7.3 (18F) PET MRI imaging will be conducted once at baseline and a second time within one year of the initial scan.
224129697|NCT04614545|BEHAVIORAL|Exercise program|Patients will be provided with a personalized exercise program
224129698|NCT01454401|DEVICE|LeucoPatch treatment|weekly
224138652|NCT00091026|BIOLOGICAL|cetuximab|Given IV
223398272|NCT05823285|DRUG|QLS31903|0.01μg/kg-2.16 μg/kg QLS31903 for injection
223398273|NCT03903289|PROCEDURE|Automated red cell exchange|Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.
223398274|NCT03903289|PROCEDURE|Manual red cell exchange|Active Comparator: Manual red cell exchange
223398275|NCT03903289|PROCEDURE|Simple red cell transfusion|Active Comparator: Simple red cell transfusion
223398276|NCT00161226|DEVICE|Levonorgestrel intrauterine system|
223398277|NCT00026988|DRUG|Creatine|
223398278|NCT06513078|OTHER|Static cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 10 minutes.
223731441|NCT03418298|BEHAVIORAL|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
223731442|NCT03402685|DEVICE|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
223731443|NCT00278083|DRUG|Study drug administration|
223731444|NCT00278083|PROCEDURE|Tuberculin intradermal skin test|
224138653|NCT00091026|DRUG|gemcitabine hydrochloride|Given IV
224138654|NCT00091026|BIOLOGICAL|bevacizumab|Given IV
224138655|NCT00091026|DRUG|erlotinib hydrochloride|Given orally
223398279|NCT06513078|OTHER|Static sham cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 10 minutes. A pin hole in the cup allowed pressure to slowly leak out during the treatment.
223398280|NCT06513078|OTHER|Dynamic cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 5 minutes, then did ankle exercises for 3 minutes, and lastly lay prone on the table for the last 3 minutes.
223398281|NCT06513078|OTHER|Dynamic sham cupping|4 cups were placed on the gastrocnemius, negative pressure was applied and participants lay prone on a table for 5 minutes, then did ankle exercises for 3 minutes, and lastly lay prone on the table for the last 3 minutes. A pin hole in the cup allowed pressure to slowly leak out during the treatment.
223398282|NCT01989585|PROCEDURE|Biopsy Procedure|Undergo biopsy
223398283|NCT01989585|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223398284|NCT01989585|PROCEDURE|Computed Tomography|Undergo CT
223398285|NCT01989585|DRUG|Dabrafenib|Given PO
224129699|NCT05167500|DRUG|Lorlatinib|"No treatment will be administered to the patient as an active treatment of this study. Only retrospective data about the patients treated in the compassion use program of Lorlatinib will be collected. The information below is related to Lorlatinib, target drug for the collection of data.~Lorviqua 25 mg film-coated tablets.The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Dosing interruption or dose reduction may be required based on individual safety and tolerability.Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily."
224129700|NCT07053670|DRUG|CAR T cells|chimeric antigen receptor T cells
223398286|NCT01989585|PROCEDURE|Echocardiography Test|Undergo echocardiography
223731445|NCT00278083|PROCEDURE|Lung function test for FEV1|
223731446|NCT00278083|PROCEDURE|Asthma symptom scores diary|
223731447|NCT00278083|PROCEDURE|Quality of life diary|
224018395|NCT03706313|PROCEDURE|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
224018396|NCT03706313|DRUG|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
224018397|NCT04789278|OTHER|Notification|Notification of coronary calcium to the patient and their clinician
224129701|NCT07054060|PROCEDURE|carotid endarterectomy|Carotid endarterectomy is a surgical procedure used to reduce the risk of stroke due to carotid artery stenosis. During an endarterectomy, the surgeon opens the artery and removes the plaque.
224129702|NCT07054060|PROCEDURE|Carotid artery stenting|Carotid artery stenting is an endovascular procedure in which a stent is deployed in the lumen of the carotid artery to treat narrowing of the carotid artery and reduce the risk of stroke.
224129703|NCT07060300|OTHER|Agree to Pharmacogenetic Testing|Caregivers agree to receive pharmacogenetic testing for their child.
224129704|NCT04748783|OTHER|Water|Subject participants will rinse mouth one time for 60 seconds with 10 mL of sterile water.
224129705|NCT04748783|OTHER|Peroxyl|Subject participants will rinse mouth one time for 60 seconds with 10 mL Peroxyl (1.5% w/v hydrogen peroxide) rinse
224129706|NCT04748783|DRUG|Periogard|Subject participants will rinse mouth one time for 60 seconds with 10 mL Periogard (0.12% Chlorhexidine Gluconate) rinse.
224129707|NCT04748783|OTHER|Colgate Total Zero|Subject participants will rinse mouth one time with Colgate Total Zero Fresh Breath (0.075% Cetylpyridinium Chloride) 20ml for 30 seconds
224129708|NCT05612672|OTHER|GeoHAI|A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
224129709|NCT06899243|DIETARY_SUPPLEMENT|CL22205|200 mg, Route : Oral, One capsule a day after breakfast for 360 days
224129710|NCT06899243|OTHER|Placebo|Route : Oral, One capsule a day after breakfast for 360 days
224129711|NCT06894017|DRUG|Ozurdex (dexamethasone)|Intravitreal dexamethasone implant (Ozurdex) given according to the recommendations by the manufacturer.
224138656|NCT01896388|DRUG|Ifenprodil Tartrate|
224138657|NCT01896388|DRUG|Placebo|
223398287|NCT01989585|OTHER|Laboratory Biomarker Analysis|Correlative studies
223398288|NCT01989585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398289|NCT01989585|PROCEDURE|Multigated Acquisition Scan|Undergo multigated acquisition scan
223398290|NCT01989585|BIOLOGICAL|Navitoclax|Given PO
223398291|NCT01989585|OTHER|Pharmacological Study|Correlative studies
223398292|NCT01989585|DRUG|Trametinib|Given PO
223398293|NCT06048744|PROCEDURE|external oblique intercostal block|U S guided external oblique intercostal block after induction.
223398294|NCT06048744|PROCEDURE|Erector Spine block|US guided erector spine block after induction
223398295|NCT06106581|BIOLOGICAL|VLA1553 full dose|Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate
223398296|NCT06106581|BIOLOGICAL|VLA1553 half dose|Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate
223398297|NCT06106581|BIOLOGICAL|Control|Nimenrix
223398298|NCT00451373|DEVICE|CVVH and SLED|
223398299|NCT00451373|DRUG|Vancomycin|
223731448|NCT00278083|PROCEDURE|Breath nitric oxide|
223731449|NCT00278083|PROCEDURE|Breath condensate|
223731450|NCT00278083|PROCEDURE|Sputum induction|
223731451|NCT00278083|PROCEDURE|Blood sampling|
224018398|NCT01851954|DRUG|Clarithromycin|IV clarithromycin infusion
224018399|NCT02455154|DRUG|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
224018400|NCT02455154|DRUG|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
224018401|NCT02455154|DRUG|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
224018402|NCT00612469|DRUG|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
224018403|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
224018404|NCT00612469|DRUG|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
224018405|NCT00612469|DRUG|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
224018406|NCT05468346|DRUG|[14C]-HEC585|Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
224129712|NCT07063589|OTHER|Mobile application|Cannabis use patterns and their resulting subjective experiences, along with social and health-related correlates will be collected in real time using a mobile application specifically designed for this study by a local custom software development company (Osedea, Montreal).
224129713|NCT07063316|DRUG|SGLT2 inhibitor|SGLT2 inhibitor
224129714|NCT07062588|DRUG|AGA2115|Subcutaneous injection
224129715|NCT07062588|OTHER|Placebo|Subcutaneous injection
224129716|NCT06898190|BEHAVIORAL|Learning Early Infant Feeding Cues (LEIFc)|Coaching sessions using SS-OO-PP-RR are conducted at infant age of 2 and 3 months. This occurs during an infant feeding session between mother and infant with the interventionists offering coaching specific to responsive feeding during the session. At the conclusion of the visit, the interventionists and mother develop specific strategies to practices prior to the next visit. At the following visit, a discussion of reflection and review occurs prior to the infant feeding session to identify what is going well and what still needs work.
224129717|NCT06898684|BEHAVIORAL|Exercise|Moderate-high intensity exercise, with three sessions per week during 12 weeks. Includes both aerobic and resistance training and will also include exercises that strengthen coordination and balance.
224129718|NCT06899321|OTHER|Cosmetic product M68|Cosmetic skin brightening product to be applied to defined test site
224129719|NCT06899321|OTHER|Cosmetic product Z15|Cosmetic skin brightening product to be applied to defined test site
224129720|NCT06899321|OTHER|Cosmetic product R52|Cosmetic skin brightening product to be applied to defined test site
224129721|NCT06899321|OTHER|Cosmetic product J61|Cosmetic skin brightening product to be applied to defined test site
224129722|NCT06899321|OTHER|Cosmetic product U36|Cosmetic skin brightening product to be applied to defined test site
223731452|NCT00278083|PROCEDURE|Urinalysis|
224129723|NCT06897956|OTHER|Oral health educational program|Oral health educational program about oral hygiene, prevention of dental caries and techniques of tooth brushing
224129724|NCT06898879|BEHAVIORAL|Collaborative Decision Skills Training|An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.
224129725|NCT06898879|BEHAVIORAL|Leveling Up|An ten-session group intervention that focuses on psychoeducation, befriending, and Veteran to Veteran support. Each session is 60 minutes long.
224129726|NCT07063030|GENETIC|LX107 Injection|Subjects will receive subretinal injection of LX107 on Day 0.
224129727|NCT06769646|OTHER|No tretament given|No treatment given
224129728|NCT07067749|DIAGNOSTIC_TEST|multiparametric magnetic resonance imaging (mpMRI) of the bladder|"This study will investigate the role of bladder mpMRI as a tool to expedite treatment in patients with muscle invasive bladder cancer.~mpMRIs will be investigated as a possible replacement of standard TURBt, a planned surgical procedure for cancer local staging.~mpMRis will be reported according to the Vesical Imaging - Reporting and Data System Stanrdars (VI-RADS) to provide a score indicating probability of muscle invasion."
224129729|NCT07067749|PROCEDURE|Transurethral resection of bladder tumour (TURBt)|This is a planned endoscopic surgical procedure consisting in resection of the bladder tumour through a electrified loop manouvred with an endoscope. In muscle invasive bladder cancer, this procedure allows histological confirmation of presence of detrusor muscle invasion.
224129730|NCT07067749|GENETIC|Circulating tumour DNA levels assessment|"Blood samples will be collected from each enrolled patient at pre-planned time points:~1. Cystoscopy, both arms~2. mpMRI (experimental arm) or TURBt (control arm)~3. Definite cancer treatment, both arms~ctDNA levels will be measured on the collected blood samples."
224129731|NCT02362711|DRUG|NPC-16 Standard Dosing Regimen Group|
224018407|NCT06432608|DIETARY_SUPPLEMENT|fermented milk, Yakult|Study subjects will be provided with a product based on fermented milk, Yakult (80mL) daily for four weeks in order to know the effects of clinical manifestation of functional constipation and short-fatty acids in the Mexican population
224018408|NCT06168097|PROCEDURE|100 women undergoing surgery (laparoscopy / laparotomy) with presumed diagnosis of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
224018409|NCT06168097|PROCEDURE|women with intraoperative and / or histopathology findings suggestive of endometriosis|"1. We Will take Both blood and tissue samples used to study them.~2. We Will take approximately 3 ml of blood which will be used from the blood sample collected for routine preoperative tests (Surgical profile) before their planned surgery.~3. Small tissue samples will be taken from the tissue which is surgically excised as a part of treatment.~4. It will include tissue from inner lining of uterus (endometrium) in all participants and from excised endometriosis tissue in patients with endometriosis."
224018410|NCT04324203|OTHER|Three-dimensional Virtual Reality and Horticultural Therapy|VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
224129732|NCT02362711|DRUG|NPC-16 Continuous Dosing Regimen Group|
224018411|NCT05921825|DIAGNOSTIC_TEST|Red cell distribution width|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
224018412|NCT05921825|DIAGNOSTIC_TEST|lactate albumin ratio measurement|Blood will be drawn from the peripheral vein, arterial or a central catheter. This procedure will be done at diagnosis, 3 ,7, 14 and 21 days of sepsis
224018413|NCT06208319|OTHER|data collection|data collection from the patient's medical record. The data will be that of routine care, with no procedures added by the research.
224018414|NCT00055601|DRUG|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
224129733|NCT02362711|DRUG|Placebo Group|
224129734|NCT02725073|PROCEDURE|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter \[MAJ-1419; Olympus America, Center Valley, Pa., USA\]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research \& Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
224018415|NCT00055601|DRUG|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
224018416|NCT00055601|DRUG|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
224018417|NCT00055601|RADIATION|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
224018418|NCT00055601|DRUG|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
223398300|NCT00451373|DRUG|Daptomycin|
223398301|NCT00451373|DEVICE|FX60, AV600 (dialyzer)|
223398302|NCT03004274|OTHER|Running sutures|
223398303|NCT03004274|OTHER|Interrupted sutures|
223398304|NCT04115319|DRUG|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
223398305|NCT04115319|DRUG|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
223731453|NCT05034770|OTHER|major ozone autohemotherapy|This treatment is based on treating 100 ml of the pa- tient's blood with 100 ml of O3 followed by reinfusion in the donor, in a fast procedure. Each patient received 10 sessions of autohemotherapy with O3 twice a week.
223731454|NCT03580317|OTHER|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
224018419|NCT00055601|PROCEDURE|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
224018420|NCT03532087|DRUG|Denosumab 120 mg|Denosumab 120 mg every 3 weeks.
224018421|NCT03532087|DRUG|Denosumab 60 mg|Denosumab 60 mg every 6 months.
224018422|NCT03272581|OTHER|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
223398306|NCT00474890|DRUG|cetericine and pseudoephedrine|
224129735|NCT04604249|DIAGNOSTIC_TEST|SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France)|Presence of specific SARS-CoV-2 antibodies (IgM or IgG).
224129736|NCT05911009|DRUG|BC 007 or matching placebo|Participants will be treated with two infusions of BC 007 or placebo two weeks apart, according to a double-blind design
223398307|NCT01864993|DIETARY_SUPPLEMENT|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
223398308|NCT01864993|DIETARY_SUPPLEMENT|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
223398309|NCT02653963|DRUG|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
223398310|NCT00804310|DRUG|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
223398311|NCT00804310|DRUG|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
223398312|NCT04289441|DIETARY_SUPPLEMENT|Bifiasthm|Subjects will be instructed to take an active or placebo sachet twice daily for eight weeks, and subsequent intake of one dose daily for a further eight weeks.
223398313|NCT04289441|DIETARY_SUPPLEMENT|Placebo|Placebo
223398314|NCT05549843|OTHER|Manual therapy|Each session will last approximately 50-60 minutes, with 1 physiotherapy session per week over a period of 3 weeks. Each session is made up of 10 steps, of which 9 correspond to manual interventions commonly used in the field of manual therapy.
224018423|NCT04536987|DEVICE|HEXORR|The subject receives robotic assistance from the HEXORR robot during finger and thumb movements. Several different video games are used to provide feedback of performance and motivate the training. The assistance level is adjusted automatically in some games and manually in other games to enable a target success rate of 67% when playing the games.
224018424|NCT00117845|BIOLOGICAL|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
224129737|NCT06814340|DEVICE|ECMO + near apneic ventilation|"Near apneic ventilation will be use during the first 3 days of ECMO. Patients will be ventilated in BIPAP/APRV or pressure-controlled ventilation. PEEP will be set to maintain the same mean airway pressure obtained during the standardized ventilation period pre-randomization to prevent lung derecruitment (PEEP ≥15cmH2O). If BIPAP/APRV is used, an RR of 2-4/min will be set with high pressure set at 30cmH20 for 3 sec. If pressure-controlled ventilation is selected, a respiratory rate of two sigh breaths/min with 30 cmH2O plateau pressure will be applied. Each sigh breath will be of three seconds duration.~Neuromuscular blockade and sedation could be used at the discretion of the attending physician. After 3 days on ECMO, apneic ventilation could be pursued (at the physician's discretion). If not, ultra-protective lung ventilation will be applied (i.e standard of care). Prone positioning on ECMO will be left to the physicians' discretion."
224129738|NCT06814340|DEVICE|ECMO + ultra-protective lung ventilation|"Ultra-protective lung ventilation will be used up to the ECMO weaning. This group will receive ultra-protective lung ventilation with BIPAP/APRV or VCV mode setting a PEEP \>10 cmH2O, ΔP 14-15 cmH2O, RR 15-20/min, Vt 3-4ml/kg and lowest FiO2 to maintain SpO2\>92%.~The use of prone positioning during ECMO will be left at the physician's discretion."
224129739|NCT07070674|DRUG|AC-003|AC-003 capsules will be administered orally.
224018425|NCT04112329|BEHAVIORAL|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
223398315|NCT00323375|DRUG|AQ-13|A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).
223398316|NCT00323375|DRUG|Chloroquine (CQ) Treatment|A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
223398317|NCT00961675|DRUG|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4 gtt BID (twice a day)
223550951|NCT02947802|OTHER|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
223550952|NCT02947802|OTHER|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
224018426|NCT05834426|DIAGNOSTIC_TEST|Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)|For metabolomic analysis, different portions of the blood (plasma and lymphocytes) will be subjected to metabolite extraction by the extraction method defined by Glasgow Polyomics. With protein precipitation, 200 microliters (uL) of the fluid with the metabolites is transferred to a new microtube and must be maintained at -80 °C until the time of metabolomic analysis.
224018427|NCT05020288|DRUG|Orelabrutinib|Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
224018428|NCT04452968|BEHAVIORAL|intermittent fasting|Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.
224018429|NCT04452968|BEHAVIORAL|Caloric restriction|Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
224129740|NCT06898203|DEVICE|SkinScan3D|A handheld, simple, low-cost, and user-friendly technology that combines liquid lens technology and artificial intelligence (AI).
224138658|NCT03855748|OTHER|Healthy group|"Subjects undergo the following activities:~1. Walking~2. Jogging (8-11 km/h)~3. Maximal 5 meters sprint acceleration~4. Single leg drop jump from 35 cm height~5. Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~6. Maximal change of direction at 45, 135, 180 degrees~7. Single-leg cross-country skiing exercise"
224138659|NCT05262582|PROCEDURE|Sigle port RATS|The incision is performed in the 5-6th intercostal space under the breast folds without violating the mammalian tissue. This port is used for the camera and both arms simultaneously.
224138660|NCT05262582|PROCEDURE|Two ports RATS|The incision is performed in the 4th intercostal space along anterior axillary fossa, for the camera and left arm. The other incision is subxiphoid longitudinal incision about 4cm for the right arm.
223398318|NCT00961675|DRUG|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID (twice a day)
223550953|NCT00647244|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
223550954|NCT00647244|DRUG|Abacavir|Abacavir 300 mg oral tablet twice daily
223550955|NCT01130909|DRUG|AZD6765|75 mg
223550956|NCT01130909|DRUG|AZD6765|150 mg
223550957|NCT01130909|DRUG|Ketamine|0.5 mg/kg
223550958|NCT01130909|DRUG|Placebo|125 mL sterile NaCl 0.9%
223550959|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1g phosphorus/d\]
223550960|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[0,5 g calcium\]
223550961|NCT02095392|DIETARY_SUPPLEMENT|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate \[1 g phosphorus/d\] and calcium \[1 g calcium\]
223550962|NCT02095392|DIETARY_SUPPLEMENT|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
223550963|NCT03238274|DEVICE|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
223550964|NCT05698394|DRUG|Esketamine|0.2 mg/kg S-ketamine in 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth
223550965|NCT05698394|DRUG|Placebo|20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
223550966|NCT01633255|DRUG|18F-Fluciclatide|
223550967|NCT06614036|DRUG|Remimazolam|Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
224018430|NCT00474877|DEVICE|Static resting splints|
224018431|NCT02851641|PROCEDURE|"pushed mono-canaliculonasal intubation"|
224018432|NCT04369859|BEHAVIORAL|Examine the impact of COVID-19 during pregnancy|clinical data collection
224018433|NCT01789645|OTHER|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
224018434|NCT01789645|PROCEDURE|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
224129741|NCT07070063|DEVICE|Virtual Reality Therapy|Eight sessions of virtual reality therapy will be administered over a two-week period (four sessions per week, each lasting 20 minutes). The intervention will be delivered using the VRTierOne device (Stolgraf®), which employs a head-mounted display to create a fully immersive environment. Through the integration of visual, auditory, and kinesthetic stimuli, the therapy provides a multi-sensory experience that can have calming and mood-enhancing effects, as well as support psychological engagement and motivation in the rehabilitation process. The virtual environment-designed as a therapeutic garden-is rich in symbols and metaphors derived from Ericksonian psychotherapy. The central element of this environment is the Garden of Revival, a metaphor for the patient's health. Once vibrant and full of life, the garden is now neglected and requires care and effort to be restored. Throughout the therapeutic process, the patient is guided by a symbolic narrative reflecting their individual
224129742|NCT07070063|DEVICE|Pelvic Floor Muscle Electrostimulation with EMG Biofeedback|Eight sessions of pelvic floor muscle electrostimulation combined with EMG biofeedback will be provided over a two-week period (four sessions per week). The intervention will be delivered using a specialized EMG-Biofeedback electrostimulation device equipped with a screen for real-time signal visualization. Vaginal electrodes will be used to ensure precise stimulation and accurate detection of pelvic floor muscle activity. During each 30-minute session, patients will receive symmetrical biphasic rectangular electrical impulses at a frequency of 50 Hz, with a 5-second stimulation phase followed by a 10-second rest period. The intensity of the stimulation will be individually adjusted to ensure both safety and comfort. The integrated biofeedback system will allow participants to observe their muscle activation patterns on the screen, enhancing their awareness and control of pelvic floor function and supporting the learning of correct activation during voluntary contractions.
224129743|NCT06854627|PROCEDURE|Daily prone position sessions|Prone position sessions will be extended at least 16 hours, but no longer than 24 hours. Prone sessions will be repeated if PaO2/FiO2 ratio decreases to \< 150 after returning to supine position within the first 7 days after randomization. The extension of repeated prone sessions will follow the same criteria.
224129744|NCT06854627|PROCEDURE|Prolonged prone position sessions|Prone position sessions will be extended at least 48 hours AND until PaO2/FiO2 ratio is ≥ 200, but no longer than 120 hours. Prone sessions will be repeated if PaO2/FiO2 ratio decreases to \< 150 after returning to supine position within the first 7 days after randomization. The extension of repeated prone sessions will follow the same criteria.
224138661|NCT02118857|OTHER|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
224138662|NCT01921946|DRUG|Fimasartan|
224138663|NCT01921946|DRUG|Rosuvastatin|
224018435|NCT03644953|DRUG|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
224018436|NCT04746053|OTHER|Pelvic ultrasound|Pelvic or vaginal ultrasound
223550968|NCT06614036|DRUG|Midazolam|Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
223550969|NCT06295900|OTHER|Intervention 1 Group|20 patients were included in this group and aromatherapy was applied once a day, for a total of 30 minutes, for three days, with a mixture of lavender, medicinal chamomile, and neroli oil (2 drops of lavender oil, 4 drops of medicinal chamomile, 6 drops of neroli oil in 20 ml of sweet almond oil). Massage is planned.
224018437|NCT04746053|BIOLOGICAL|blood sample|blood sample (5ml)
224018438|NCT00910689|DRUG|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
224018439|NCT00910689|DRUG|Placebo control|Placebo
223550970|NCT06295900|OTHER|Intervention 2 Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
223550971|NCT06295900|OTHER|Placebo Control Group|It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
223550972|NCT03469622|DEVICE|EndoRings|EndoRings-assisted colonoscopy
223550973|NCT03469622|DEVICE|Standard colonoscopy|Standard colonoscopy without any additional devices
223550974|NCT01163305|DRUG|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
224129745|NCT06864949|DEVICE|AMCOP appliance|"The device measure will be determined with OrthoCad program on digital models, taking the distance between the vestibular cusps of the upper first molars, at the level of the most prominent point. AMCOPs are preformed devices and there are five different measures based on transverse diameter: 1 (45mm), 2 (50mm), 3 (55mm), 4 (60mm), 5 (65mm).~Requiring expansion, we will choose an higher AMCOP measure than the transverse distance measured on the digital models at T0.~The clinical indications for use of the AMCOP device will be as follow:~* in the first week, wear the appliance during the night and for 30 minutes during the day~* from the second week onward, wear the appliance for one hour during the day and throughout the night During this time, every month we will visit patients and we will expand the device by soaking it in hot water at about 70 °C for 30 s and then in cold water to stabilize it in its new shape."
223550975|NCT04625530|DRUG|ferric carboxymaltose|Ferric carboxymaltose 20 mg/kg (with a maximum dose of 1000 mg ferric carboxymaltose in a single Infusion) (Ferinject® 1000 mg/20ml, Vifor (International) AG, St. Gallen, Switzerland) will be diluted in 250 ml of 0.9% m/V sodium chloride solution and administered over 15 minutes intravenously between day -27 and day -7. The colour of ferric carboxymaltose is dark brown. A single Ferinject administration should not exceed 20 mg iron/kg body weight.
224129746|NCT05617014|RADIATION|Neuraceq|Amyloid PET imaging with Florbetaben (Neuraceq) injection
224129747|NCT05617014|RADIATION|Amyvid|Amyloid PET imaging with Amyvid (Florbetapir) injection
223398319|NCT04111289|DRUG|-Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)|"* After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
223398320|NCT03751033|DEVICE|BSS|Intraoperative aberrometry measurements for BSS will be performed.
223398321|NCT03751033|DEVICE|DiscoVisc|Intraoperative aberrometry measurements for DiscoVisc will be performed.
224018440|NCT00910689|BEHAVIORAL|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
224129748|NCT05617014|RADIATION|Tauvid|Tau PET imaging with Tauvid (Flortaucipir) injection
224129749|NCT05617014|RADIATION|MK-6240|Tau PET imaging with MK-6240 injection
224129750|NCT05617014|RADIATION|NAV4694|Amyloid PET imaging with NAV4694 injection
224129751|NCT05617014|RADIATION|PI-2620|Tau PET imaging with PI-2620 injection
224129752|NCT07074964|OTHER|Autonomic nervous system intervention|Manual therapy applied to structures adjacent to the vagus nerve along its pathway. Head: CV4 tecnique and Jugular foramen tecnique; Neck: stretching and mobilization of the superficial and deep layers; Thorax: Longitudinal and transverse translations of the mediastinum; Diaphragm tecniques, Abdomen: Stretching of the gastro-phrenic ligament with lowering of the stomach and general treatment of the small intestine and the mesentery. Stretching, compression and traction movements will be carried out on these structures.
224129753|NCT07074964|OTHER|Slight finger pressure|The hands will be placed on areas similar to those in the intervention group, with the fingertips in contact with the skin of the area. A slight finger pressure will be applied, which would not have the same effect as the proposed techniques, since those techniques require a greater intensity of manipulation of the described tissues and structures.
224129754|NCT07075380|BEHAVIORAL|online questionnaire|Online questionnaire assessing physical activity level, completed twice at a 6-month interval.
224129755|NCT05563298|DEVICE|Neuro RX Gamma device|The Neuro RX Gamma device is a portable, wearable, low level light therapy (LLLT) delivery device. The Vielight Neuro RX Gamma delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
223550976|NCT04625530|DRUG|tranexamic acid|Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively. The colour of the medicament is transparent.
224129756|NCT05563298|DEVICE|Sham Neuro RX Gamma device|The Sham device is indistinguishable from the active device. The sham device will not deliver light for the 20 minutes session duration.
223398322|NCT04689191|BIOLOGICAL|Experimental Group A and C meningococcal polysaccharide vaccine|One dose of Experimental Group A and C meningococcal polysaccharide vaccine
223398323|NCT04689191|BIOLOGICAL|Control Group A and C meningococcal polysaccharide vaccine|One dose of Control Group A and C meningococcal polysaccharide vaccine
223398324|NCT01239810|DRUG|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
223550977|NCT04625530|DRUG|ferric carboxymaltose and tranexamic acid|Ferric carboxymaltose (Ferinject® 1000 mg/20 ml) will be administered between day -27 and day -7 and tranexamic acid (Tranexam OrPha 1000 mg/10 ml) 15-30 minutes prior to surgery followed by infusion of tranexamic acid through syringe pump (1 mg/kg/h) till 4 h postoperatively.
224129757|NCT07078747|BEHAVIORAL|To compare the effectiveness of video- and model-based training methods in improving Leopold maneuver skills among midwifery students.|"This study involves two educational interventions aimed at improving Leopold maneuver skills among midwifery students. Both intervention groups receive a standardized 2-hour theoretical lecture about the purpose, application, and clinical relevance of the Leopold maneuvers.~In the Video-Based Training Group, students watch an instructional video developed by the research team that visually demonstrates each step of the maneuver.~In the Model-Based Training Group, students perform the maneuvers on anatomical models under the supervision of an instructor.~These interventions are conducted in separate sessions to prevent cross-group contamination."
223550978|NCT02521974|BIOLOGICAL|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
223398325|NCT05736757|DRUG|Tissue Plasminogen Activator|Injection of 50 ug tissue plasminogen activator into the suprachoroidal cavity or subretinal space to assist in bleeding liquefaction
224018441|NCT00910689|DRUG|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
224018442|NCT05259254|OTHER|Mobile Application|the mobile application will be consist of 4 modules which are: video observed therapy, health education, reminder system, and feedback.
224018443|NCT05259254|OTHER|Direct Observed Therapy|it is a specific strategy that require identification, training, and supervision by various parties such as healthcare worker, community volunteer, or family members to directly monitor the ingestion of anti-TB medication. DOT was aimed to improve medication adherence by active monitoring and documenting the consumption of each dose taken. Conducting DOT is not only limited to directly observe the treatment, but also can assess medication side effects as well as to document the visit and information regarding medications (e.g., frequency and timing of taking medication).
223398326|NCT06370637|OTHER|Barrier Cream|Patients in the control arm will be treated with a 15% zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.
224129758|NCT00500045|DRUG|nicotinic acid|niacin 1500 mg po qd
224129759|NCT04941378|DRUG|OTL38|One time infusion of OTL38
224129760|NCT04941378|DEVICE|intraoperative imaging camera system|intraoperative imaging camera system
224129761|NCT07083700|BEHAVIORAL|Frame Access|FRAME™ provides a collaborative care platform that connects patients with evidence-based resources, education and support from a dedicated care team throughout their reproductive health care journey. More specifically, for patients exploring fertility treatment. Frame supplements the patient experience by providing patients with direct contact to board-certified fertility coaches and resources that can be accessed between appointments in a web-based application. Regular use of Frame's platform may help patients make lifestyle changes that can improve their fertility outcomes as well as boost their emotional health throughout the treatment process and reduce feelings of overwhelm and loneliness which can lead to patients dropping out of care.
224129762|NCT07084727|OTHER|Arterial stiffness|"Non-invasive test. A blood pressure cuff and tonometer (a type of pen placed on the neck) are used to measure the speed at which a pressure wave propagates from one place to another.~Every time the heart contracts, a pressure wave is generated that propagates from the heart to the blood vessels at a certain speed. The stiffer the blood vessels, the faster the wave propagates."
224129763|NCT07084727|OTHER|Flow-meditad dilatation|"This study measures the capacity with which blood vessels expand when we briefly cut off blood flow. The endothelium, the inner layer of blood vessels, regulates this expansion. By ultrasound, we measure the difference in diameter of the elbow artery. To cut off the blood flow, we clamp the forearm with a blood pressure cuff for 5 minutes.~When the blood pressure cuff is released, it triggers increased blood flow in the arm, causing the blood vessels to expand. We record this expansion using the above techniques."
224129764|NCT07084727|OTHER|Dynamic retinal vessel analyzer|Eye imaging measures the capacity with which your blood vessels in the retina can expand in response to a flicker light stimulation.
224129765|NCT07083531|OTHER|Healthy volunteers without SCT|Participants will donate blood for serum bone turnover markers, complete blood count, calcium, phosphorus, albumin, parathyroid hormone, and hemoglobin electrophoresis. Participants will undergo a bone density evaluation and muscle mass measurement via dual-energy x-ray absorptiometry (DEXA) scanning. Participants will fill out dietary calcium intake and pain burden questionnaires. Participants will fill out a survey for frailty assessment, undergo 6-minute walk gait velocity and short physical performance battery (SPPB).
224138664|NCT01943422|DRUG|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
223398327|NCT06370637|OTHER|Dermategrity Everyday Barrier Cream|Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.
223398328|NCT04231825|DEVICE|Transcranial alternating current stimulation|Transcranial alternating current stimulation across the prefrontal cortex using electrodes F3 and F4.
223398329|NCT02646995|DIETARY_SUPPLEMENT|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
223398330|NCT02646995|DIETARY_SUPPLEMENT|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
223550979|NCT05250921|PROCEDURE|Corticision|Corticision will be performed to enhance teeth alignment.
224018444|NCT00507195|DRUG|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
224138665|NCT01943422|DRUG|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
224138666|NCT04472364|DEVICE|HemoPill Acute ®|Capsule positive: Endoscopy endoscopy will be performed within 12 hours. Capsule negative: Endoscopy will be performed after 48 to 96 hours.
224138667|NCT04428684|DRUG|Pepti 3.6 mg|Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
224138668|NCT04802980|DRUG|HB002.1T|HB002.1T is a vascular endothelial growth factor receptor decoy
224138669|NCT04802980|DRUG|Oxaliplatin|Oxaliplatin is an anti-tumor drug
224138670|NCT04802980|DRUG|Capecitabine|Capecitabine is an anti-tumor drug
224138671|NCT04802980|DRUG|Paclitaxel|Paclitaxel is an anti-tumor drug
224138672|NCT04802980|DRUG|Gemcitabine|Gemcitabine is an anti-tumor drug
224138673|NCT04802980|DRUG|Cisplatin|Cisplatin is an anti-tumor drug
223550980|NCT05250921|DEVICE|Conventional fixed appliance|No surgical intervention is going to be applied to the patients in this group.
224129766|NCT07083531|OTHER|Healthy volunteers with SCT|Participants will donate blood for serum bone turnover markers, complete blood count, calcium, phosphorus, albumin, parathyroid hormone, and hemoglobin electrophoresis. Participants will undergo a bone density evaluation and muscle mass measurement via dual-energy x-ray absorptiometry (DEXA) scanning. Participants will fill out dietary calcium intake and pain burden questionnaires. Participants will fill out a survey for frailty assessment, undergo 6-minute walk gait velocity and short physical performance battery (SPPB).
223398331|NCT05958043|DEVICE|3D- printed Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
223550981|NCT06716541|PROCEDURE|ERCP implantation of a biodegradable stent|Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a biodegradable stent to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
223550982|NCT06716541|PROCEDURE|ERCP implantation of plastic stents|Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a plastic stent or multiple stents to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
223550983|NCT06714968|OTHER|Digital|After the pre-test application is completed, the students in the experimental group will be allowed to install the designed game application on their phones. After the installation process, students will be allowed to play the game for 2 weeks. After 2 weeks from the date of downloading the game, access to the game will be automatically blocked. After completing the application steps, when the student thinks that he/she is ready to apply the post-test, he/she will be able to perform the post-test application. In the post-test application, there will be no repeated return of the student to the questions or multiple answer submission. Two weeks after the application is completed, the knowledge test will be applied to the students again in order to objectively evaluate the learning. In this process, students will be prevented from accessing the application.
223731455|NCT03580317|OTHER|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
224018445|NCT04852367|DEVICE|Focused Ultrasound|Focused ultrasound targetting the tumour at subablative powers, to facilitate drug release
224018446|NCT04852367|DRUG|Doxorubicin|Doxorubicin infusion
224018447|NCT04852367|DRUG|ThermoDox|ThermoDox infusion
224018448|NCT01849159|BIOLOGICAL|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
224018449|NCT01849159|OTHER|Reference therapy: 400 mL of 0.9% NaCl solution|
224018450|NCT02727062|DEVICE|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels."
224018451|NCT02727062|DEVICE|Accelerometer|Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
224018452|NCT00119210|DRUG|Bupropion SR|
224018453|NCT00119210|OTHER|placebo|
224018454|NCT04734093|DIAGNOSTIC_TEST|Evaluation of sonographic signs of gouty arthritis|the EULAR scanning protocol for the knee and 1st MTP will be considered \[2\]. Further, scanning of the double contour sign over the femur condyles anteriorly and posteriorly in sagittal planes will be assessed. Examination of erosions, tophus, double contour, effusion, and echogenic foci will be recorded.
224018455|NCT06000137|DRUG|Dezocine|dezocine for patient-controlled analgesia
224018456|NCT06000137|DRUG|Sufentanil injection|sufentanil for patient-controlled analgesia
224018457|NCT06000137|DRUG|Flurbiprofen|Flurbiprofen for patient-controlled analgesia
224018458|NCT06000137|DRUG|Granisetron Injection|granisetron has antiemetic function.
224018459|NCT02892786|OTHER|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
224129767|NCT07082114|DRUG|HDM1002 100 mg|HDM1002 tablets, 100 mg once daily, 52 weeks
224129768|NCT07082114|DRUG|HDM1002 200 mg|HDM1002 tablets, 200 mg once daily, 52 weeks
224129769|NCT07082114|DRUG|HDM1002 400 mg|HDM1002 tablets, 400 mg once daily, 52 weeks
224018460|NCT01832285|DRUG|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
224018461|NCT00339456|DRUG|HAART|
224018462|NCT05715918|BIOLOGICAL|Vaccine for intramuscular injection|Volunteers ( Group 1 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
224018463|NCT05715918|OTHER|Placebo comparator (without active ingredient) for intramuscular injection|Volunteers ( Group 2 - 150) will receive the vaccine twice spaced 21 days apart, intramuscularly, at a dose of 0.5 ml
224129770|NCT07082114|DRUG|Dapagliflozin (DAPA)|dapagliflozin 10mg will be provided
224138674|NCT04802980|DRUG|Carboplatin|Carboplatin is an anti-tumor drug
224138675|NCT04176055|DRUG|Haloperidol|haloperidol intervention
223398332|NCT05958043|DEVICE|CAD/CAM-milled Full-arch Implant-supported Provisionals Restorations|"The full-arch provisional restorations will be placed on dental implants that should be positioned to allow for the fabrication of a prosthesis that spans at least 12 units (from the right first molar to the left first molar, accepting distal extensions). Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments will be put at the torque the manufacturer recommends (30-35 Ncm typically), according to the appropriate gingival height.~At visit three, the full-arch provisional will be screwed in using the manufacturer's specified torque (15 Ncm typically). For 12 to 15 weeks (about three months), the patient will be in the preliminary phase, during which time data will be gathered. Once the stipulated time has elapsed, the definitive prosthesis in monolithic zirconia prosthesis will be placed."
223398333|NCT05682456|DIETARY_SUPPLEMENT|High-fat shake|The high-fat shake consisted of 53% (w/v) fresh cream, 3% (w/v) sugar and 44% (w/v) water
223398334|NCT05682456|DIETARY_SUPPLEMENT|Reference shake|The reference shake consisted of 43% (w/v) full cream milk, 48% (w/v) full cream yoghurt, 4% (w/v) lemonade, 4% (w/v) fantomalt (Nutricia B.V., the Netherlands) and 1% (w/v) wheat fiber
223398335|NCT03444181|BEHAVIORAL|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
223731456|NCT03580317|OTHER|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
224018464|NCT01135407|OTHER|Recording during computerized tests|"Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions."
224018465|NCT01135407|OTHER|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
224018466|NCT01135407|OTHER|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
224018467|NCT05480579|BIOLOGICAL|placebo|Dose4 placebo of single IV injection
224018468|NCT05480579|BIOLOGICAL|IBI311|Dose2 IBI311 of single IV injection
224018469|NCT05480579|BIOLOGICAL|IBI311|Dose4 IBI311 of single IV injection
224018470|NCT05480579|BIOLOGICAL|placebo|Dose3 placebo of single IV injection
224018471|NCT05480579|BIOLOGICAL|placebo|Dose1 placebo of single IV injection
224018472|NCT05480579|BIOLOGICAL|IBI311|Dose1 IBI311 of single IV injection
224018473|NCT05480579|BIOLOGICAL|IBI311|Dose 3 IBI311 of single IV injection
224018474|NCT05480579|BIOLOGICAL|placebo|Dose2 placebo of single IV injection
224018475|NCT00698945|DRUG|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
224018476|NCT00698945|DRUG|Alphagan|Alphagan: two drops a day for 28 days
224018477|NCT03372707|DIAGNOSTIC_TEST|Cuff Leak Test|The Respiratory Therapist (RT) will perform the CLT on all enrolled patients. The patients will first be switched to volume assist-control (V-AC) with a respiratory rate of 10 breaths/min (to allow patient assist), constant flow of 60 l/min, and tidal volume set to match the average tidal volume currently being delivered during supportive ventilation. The RT will document the average exhaled volume over 3-5 breaths after switching to V-AC. The test will be performed by deflating the ETT balloon cuff with a 10 cc syringe, and: a) auscultation with a stethoscope to identify audible air leak around the ETT, and b) measuring the difference between the average exhaled volume prior to cuff deflation and the average exhaled volume over 3-5 breaths after cuff deflation.
224129771|NCT07084701|DEVICE|Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD)|Participants will be randomly assigned to either an intervention group receiving NSCLD or a control group receiving a sham-intervention treatment. Cognitive function will be assessed using standardized tests before and after the intervention.
224018478|NCT03207009|GENETIC|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
224129772|NCT07084701|DEVICE|sham-intervention treatment|Participants will be randomly assigned to either an intervention group receiving NSCLD or a control group receiving a sham-intervention treatment. Cognitive function will be assessed using standardized tests before and after the intervention.
224138676|NCT05102708|OTHER|Prognostic factors of severe COVID-19|prognostic factors: patients´ epidemiological characteristics (such as age, sex), comorbidities, length of hospitalization, critical care admission, treatments received, laboratory results, vital signs.
223398336|NCT03444181|BEHAVIORAL|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
223398337|NCT03558802|OTHER|questionnaire|questionnaire
223398338|NCT00191581|DRUG|Humalog Mix 50|
223398339|NCT00191581|DRUG|Human Insulin Mix 50:50|
224018479|NCT04558879|BEHAVIORAL|CT|12 weeks of exercise Cardiovascular Training
223398340|NCT01820143|DRUG|Ilaprazole|
224018480|NCT04558879|BEHAVIORAL|RT|12 weeks of exercise Resistance Training
223398341|NCT01820143|DRUG|Esomeprazole|
223398342|NCT01563042|DRUG|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
223398343|NCT01563042|DRUG|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
224018481|NCT05548140|DEVICE|Novel Motorized Spiral Enteroscopy|This study involves performance of spiral enteroscopy in one arm and single balloon enteroscopy in the other arm in patients who satisfy inclusion criteria
224018482|NCT04751266|PROCEDURE|minimally invasive repair of pectus excavatum|substernal insertion of a metal bar
224018483|NCT04026880|DRUG|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
224018484|NCT04026880|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
224018485|NCT03429231|DIETARY_SUPPLEMENT|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
224018486|NCT00001396|DEVICE|Paragon Pacemaker|
224018487|NCT00607685|DRUG|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
224018488|NCT00607685|DRUG|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
224018489|NCT02863497|BEHAVIORAL|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
224018490|NCT03251781|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
224018491|NCT04837898|DIETARY_SUPPLEMENT|Haskapa|Haskapa Ltd, Oxford, UK
224018492|NCT04837898|DIETARY_SUPPLEMENT|Placebo|isocaloric to the haskap powder
224018493|NCT03468231|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
224018494|NCT03468231|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
224018495|NCT03468231|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
224018496|NCT02924428|DEVICE|Venus Versa|
224018497|NCT00183001|DRUG|Vitamin K|
224018498|NCT06054282|BEHAVIORAL|"Ready for Tonsillectomy educational mobile application"|"The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions."
224018499|NCT02687893|BEHAVIORAL|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
224129773|NCT07082179|DRUG|Iparomlimab and Tuvonralimab combined with paclitaxel polymer micelles and Platinum (cisplatin/carboplatin)|"Induction therapy regimen：Iparomlimab and Tuvonralimab 5 mg/kg, every 3 weeks (q3w), administered via intravenous infusion. Paclitaxel polymer micelles in combination with platinum: In cycle 1, paclitaxel polymer micelles 230 mg/m² administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min. In cycle 2, if the patient's nadir neutrophil count is ≥1.0×10⁹/L and the nadir platelet count is ≥80×10⁹/L after cycle 1, and no grade II-IV non-hematologic toxicities have occurred, then paclitaxel polymer micelles 300 mg/m² will be administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min.~The local treatment regimen is either surgery or standard radiotherapy. The consolidation therapy regimen consists of Iparomlimab and Tuvonralimab for 1 year , with the decision to combine with chemotherapy left to the discretion of the treating physician on an individual basis."
224129774|NCT07082985|OTHER|Placebo (Placebo trial)|The Placebo capsule supplement was taken for 14 days (4 capsules per day)
223731457|NCT03580317|OTHER|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
223550984|NCT06717828|BEHAVIORAL|Tai Chi Exercise|Tai Chi is a moderate-intensity exercise suitable for middle-aged and elderly individuals. Participants will engage in the practice five times a week (three sessions will be in-person teaching, and two will be online), with each session lasting 60 minutes, continuing until the end of a six-month follow-up. Before the intervention begins, participants will receive a manual or instructional video on Tai Chi to understand its principles, practice techniques, and safety precautions. Each class will start with a warm-up and include a review of Tai Chi principles and movements, breathing techniques, and relaxation methods. Participants will document their Tai Chi practice over 24 weeks by submitting exercise weekly logs, while researchers will monitor their exercise progress weekly via phone using standardized forms to assess frequency, completion status, adverse events, and adherence.
223550985|NCT06717828|BEHAVIORAL|Regular Exercise|The intervention for middle-aged and elderly individuals includes a combination of common activities: 15 minutes of walking, 15 minutes of body coordination activities (including limb movements and balance training), 15 minutes of muscle stretching, and 15 minutes of relaxation. Each exercise session lasts for 60 minutes, conducted five days a week. The heart rate during exercise will be adjusted based on monthly fitness assessments, and the daily activity level will be evaluated through logs and fitness trackers.
223731458|NCT01840709|BEHAVIORAL|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
224018500|NCT02687893|BEHAVIORAL|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (\~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
224018501|NCT06271629|DIAGNOSTIC_TEST|Insomnia severity index|"The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties."
224018502|NCT02680002|BIOLOGICAL|7.5 mcg H5N1 (stored as monobulk)|
224018503|NCT02680002|BIOLOGICAL|15 mcg H5N1 (stored as monobulk)|
224018504|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored as monobulk)|
224018505|NCT02680002|BIOLOGICAL|90 mcg H5N1 (stored in vials)|
224018506|NCT02680002|OTHER|MF59|
224018507|NCT02680002|OTHER|MF59 (stored as monobulk)|
224018508|NCT04200885|DRUG|Dexketoprofen Trometamol|Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
224018509|NCT04200885|DRUG|Dexamethasone 21-Phosphate|Injections were administered in the immediate preoperative period as a single shot.
224018510|NCT04200885|DEVICE|Therapeutic Elastic Bandage|The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
224018511|NCT04889547|DRUG|Dexamethasone|Intraoperative intravenous dexamethasone
224018512|NCT04889547|OTHER|No dexamethasone|No intraoperative intravenous dexamethasone
224018513|NCT02442154|PROCEDURE|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
224018514|NCT04499820|DIETARY_SUPPLEMENT|Nutrof|DHA docosahexaenoic acid Omega 3s may be of interest in cases of retinopathies.
224018515|NCT04499820|DIETARY_SUPPLEMENT|Meralut|vitamin A, natural flavonoids, lutein and zeaxanthin
224018516|NCT03173573|DRUG|FDL176|CFTR modulator
224018517|NCT03173573|DRUG|Placebo|Placebo for FDL176
224018518|NCT04259645|DRUG|Drug: Bupivacaine 0.375% 20 mL|20 mL 0.375% Bupivacaine
224018519|NCT04259645|DRUG|Drug: Bupivacaine 0.375% diluted to 0.1875%|Each block of 0.375% Bupivacaine x 20 ml mixed (diluted) with Normal Saline Solution 20 mL (total 40 mL)
224296657|NCT03983083|BEHAVIORAL|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
223731459|NCT05657678|DRUG|Vitamin D3 - 750 000 IU|a single administration of 750,000 IU of vitamin D3
224018520|NCT06016673|PROCEDURE|Transcranial Magnetic Stimulation (TMS)|Participants will receive intermittent theta burst stimulation (iTBS) to two brain areas, the right dorsolateral prefrontal cortex (rDLPFC) and the vertex.
224018521|NCT03790319|BEHAVIORAL|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
224018522|NCT03790319|BEHAVIORAL|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
224018523|NCT02856828|DEVICE|DIE|digital image enhancement
224018524|NCT00284687|DRUG|Artesunate|PO Artesunate
224018525|NCT03187691|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
224018526|NCT02977585|DEVICE|10 cmH2O peep|positive end expiratory pressure
224296658|NCT01860911|DRUG|Insulin|
224296659|NCT01860911|DRUG|NG-monomethyl-L-arginine|
224296660|NCT02936011|DEVICE|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
224129775|NCT07082985|OTHER|Maca (Maca trial)|The Maca capsule supplement was taken for 14 days, with a daily dosage of 1600 mg of Maca (equivalent to 4 capsules per day, each containing 400 mg of Maca).
224129776|NCT07083739|DRUG|TQB3473 Tablets|TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.
224129777|NCT07077187|DIAGNOSTIC_TEST|computerized dynamic posturography|Patients in each arm will have computerized dynamic posturography performed at baseline prior to taking first tablet as well as at 4 weeks and 8 weeks. In the adjuvant therapy arm, subjects will be evaluated on rasagiline but in a functional OFF state for their other Parkinson disease medications.
224129778|NCT07077187|DRUG|Rasagiline 1 mg capsule|Rasagiline 1 mg oral tablet daily will be administered to study participants.
224129779|NCT07077187|DRUG|Placebo|Placebo 1 mg oral tablet daily will be administered to study participants.
223398344|NCT02445248|BIOLOGICAL|Tisagenlecleucel|The target dose of CTL019 transduced cells for adult patients consisted of a single infusion of 5 x 10\^8 viable CTL019 transduced cells, which was administered via intravenous infusion. The acceptable dose range was 1 - 5x10\^8 viable CTL019 transduced cells.
223398345|NCT02445248|DRUG|Lymphodepleting chemotherapy|Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle was planned. The use of any additional bridging therapy prior to the recommended lymphodepleting chemotherapy was at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy was started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The lymphodepleting regimen was: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) and cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).
224018527|NCT04312893|OTHER|Acupuncture (Press Tack Needle)|Press Tack Needle (PYONEX made by Seirin Corporation). The needles appear identical to the press tack placebo with the only different is the needle itself which was removed in the placebo needles.
224018528|NCT04312893|OTHER|press tack placebo|press tack placebo (made by Seirin Corporation), which looks identical to press tack needles but, with no needle element.
224018529|NCT00504660|DRUG|Capecitabine|Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
224129780|NCT07083856|BEHAVIORAL|Reiki|Reiki
224129781|NCT07083856|BEHAVIORAL|Self-Acupressure|Self-Acupressure
224018530|NCT00504660|DRUG|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
224018531|NCT00504660|DRUG|Temozolomide|Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.
224018532|NCT00504660|DRUG|Lomustine|Arms 2,3 = 100 mg/m\^2 PO on Day 4.
224129782|NCT07084311|DRUG|nL-ATN1-002|Personalized antisense oligonucleotide
224129783|NCT07084207|DEVICE|Symani® Surgical System|"Robotic-assisted surgery consists of participants who undergo nerve coaptation with the Symani Surgical System, according to the Instruction for Use (IFU). In order for the surgery to be considered a robotic assisted surgery, the participants must be randomized to the RAS group which will include:~* Participants where all nerve coaptations were performed entirely with Symani.~* Participants who underwent a hybrid procedure, where a coaptation was commenced using Symani but a switch to manual suturing occurred during the procedure"
224129784|NCT07084207|PROCEDURE|Manual Surgery|"Manual surgery consists of participants who undergo nerve coaptation through manual techniques by a surgeon using handheld instruments without robotic assistance. In order for the surgery to be considered a manual surgery, the participants must be randomized to the MS group which will include:~* Participants where all nerve coaptations were performed entirely manually.~* Participants who underwent a hybrid procedure, where a coaptation was commenced using manual suturing but a switch to Symani occurred during the procedure."
224129785|NCT07082023|PROCEDURE|V-NOTES Mesh-Free Sacrocolpopexy|Mesh-free sacrocolpopexy performed via vaginal natural orifice transluminal endoscopic surgery (V-NOTES).
224129786|NCT07082023|PROCEDURE|Laparoscopic Mesh-Free Sacrocolpopexy|Mesh-free sacrocolpopexy performed via conventional laparoscopy.
223398346|NCT01554670|PROCEDURE|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
224018533|NCT00504660|DRUG|6-Thioguanine|Arms 1,2,3 = 80 mg/m\^2 PO Every 6 Hours on Day 1-3.
224018534|NCT01662726|DRUG|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
224018535|NCT03701815|BEHAVIORAL|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
224129787|NCT07083505|DRUG|HB1801|HB1801 \[administered according to the clinical trial protocol\]
224129788|NCT07083505|DRUG|Taxotere®|Taxotere® 75 mg/ m\^2 \[administered according to the clinical trial protocol\]\]
224129789|NCT07082153|DEVICE|the coronary sinus balloon pump|The coronary sinus balloon pump comprises a coronary sinus balloon pump catheter system and a coronary sinus balloon pump therapeutic device. This product is indicated for the treatment of ST-segment elevation myocardial infarction (STEMI) with or without coronary microvascular dysfunction (CMD), by intermittently occluding coronary sinus blood flow during percutaneous coronary intervention (PCI) procedures to reduce myocardial infarction size.
224129790|NCT06930222|DIAGNOSTIC_TEST|blood sampling|blood samples obtained for 3 different days, limited to 5cc
224138677|NCT02242994|DEVICE|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
224138678|NCT02242994|DEVICE|Experimental App|Participant receives experimental app to test speed and error rate of communication.
224138679|NCT06226506|DRUG|Test (T) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.
224129791|NCT06926179|DRUG|neoadjuvant immunotherapy|"Patients in the cohort received neoadjuvant immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors, as part of routine clinical care. The specific regimens included monotherapy or combination with chemotherapy. The agents used may include nivolumab, camrelizumab, sintilimab, atezolizumab, or others.~This is a retrospective observational study. All interventions (neoadjuvant immunotherapy ± chemotherapy, surgery, or other treatments) were determined by treating physicians as part of standard care. The study aims to evaluate perioperative and survival outcomes across different treatment paths in real-world clinical settings."
224129792|NCT06929546|DIAGNOSTIC_TEST|Anti-phospholipid antibodies|Serum samples will be obtained for determination of IgG and IgM isotypes of 4 anti-phospholipid antibodies including anti-cardiolipin (aCL), anti-phosphatidylserine (aPS), anti-phosphatidic acid (aPA) and anti-phosphatidylcholine (aPC) with in-house ELISAs.
224129793|NCT07082140|OTHER|Social media based education|"Participants in the intervention group will be required to follow the Instagram account created specifically for the training. The Instagram account will be made private to prevent women in the control group from accessing Instagram posts. The training provided via Instagram will last 2 weeks, including the process of sharing all posts and videos. After the completion of the training, the Healthy Lifestyle Behaviors Scale and the Preconceptional Knowledge and Attitude Scale will be applied as a post-test."
224129794|NCT06930469|BEHAVIORAL|structured team model with shared decision-making|Structured team model based on shared decision-making model: ① Maternal Critical Care Review: Pre-hospital (prenatal checkup): Obstetricians and nurses conduct regular prenatal checkups for mothers, identify high-risk mothers, and set up high-risk maternal health records. Referral: Critically ill pregnant women establish a green channel for timely referral to the obstetrics department or ICU, and contact the relevant personnel of the structured management team. Assessment: The multidisciplinary team conducts a comprehensive assessment of the extent of the maternal condition, vital signs, and laboratory test results. Identification: Identify the main causes of critical maternal illness and potential risks, such as hemorrhage, infection, and organ failure. Rescue plan: according to the assessment results, formulate a personalized rescue plan and clarify the responsibilities and tasks of each department. Monitoring: real-time monitoring of maternal vital signs and changes in condition, a
224129795|NCT06930469|BEHAVIORAL|conventional multidisciplinary resuscitation care|"The observation group implemented a structured team model based on a shared decision-making model, which operated as follows:~(1) Constructing a structured management team: multidisciplinary medical and nursing staff, including obstetricians, ICU doctors, obstetric nurses, ICU nurses, head nurses, anesthesiologists, ultrasonographers, and family members of the patient's main companions, are divided into small teams according to their functions, and each small team has a team leader who is responsible for the coordination of the overall situation and the rapid coordination of information. Obstetricians and ICU doctors are responsible for life support, obstetric evaluation, condition monitoring and development of resuscitation plan for critically ill mothers. Anesthesiologists are responsible for anesthesia management, pain control and intraoperative resuscitation support. The nurse manager coordinates the nursing team to ensure the standardization of rescue care. Obstetrician and ICU nu"
224129796|NCT06930950|OTHER|Cashew nut oral immunotherapy|Cashew nut oral immunotherapy (OIT) where the aim is desensitizing individuals with cashew nut allergies. The approach involves the gradual administration of increasing doses of cashew nut protein. The goal of OIT is to increase the threshold of tolerance to cashew nuts, thereby reducing the risk of severe allergic reactions upon accidental exposure
224018536|NCT03029312|DEVICE|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
224018537|NCT05974215|DEVICE|assessment of change in bone height by cone beam computed tomography|bone height was measured at 1 ,30 ,90 days after denture insertion
224129797|NCT06929364|DIETARY_SUPPLEMENT|Omni Biotic Stress|Multistrain probiotic formulation (Omni Biotic Stress), 1 sachet daily for 8 weeks
224129798|NCT06929364|OTHER|Placebo|Inert powder identical in appearance and taste to probiotic, 1 sachet daily for 8 weeks
224018538|NCT01248780|DRUG|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
224129799|NCT07082660|DEVICE|High-Frequency Capacitive-Resistive Diathermic Current Therapy (TECAR)|20 minutes per session, 3 times per week for 4 weeks
224129800|NCT07082660|BEHAVIORAL|Lumbal Stabilization Exercise Program|3 sessions per week for 4 weeks, each session includes core stabilization and lumbar control exercises (12 sessions total).
224129801|NCT06930612|BIOLOGICAL|CM512|Administered subcutaneous injection
224129802|NCT06930612|DRUG|Placebo|Administered subcutaneous injection
224138680|NCT06226506|DRUG|Reference (R) Aprepitant injection|Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.
223398347|NCT04320225|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
224018539|NCT01248780|DRUG|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
223398348|NCT04968535|DEVICE|StimaWELL|mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
223398349|NCT02596971|DRUG|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
223731460|NCT05657678|DRUG|Vitamin D3 - 500 000 IU|a single administration of 500,000 IU of vitamin D3
224018540|NCT01248780|DRUG|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
224018541|NCT06050187|PROCEDURE|implant casts fabrication|four implant casts fabricated
224018542|NCT03540953|DRUG|Endoscopic injection of Mitomycin C|administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
224018543|NCT00003555|DRUG|amifostine trihydrate|
224129803|NCT07082491|BEHAVIORAL|Mindfulness-based stress reduction|The intervention consists of 8 in-person sessions over a period of 8 weeks, with each session lasting about three hours, once per week, with an intensive full-day practice session lasting 7 hours. The instructors provide audio recordings at each session to be used as daily practice. The MBSR program is an introductory pathway to mindfulness practices that works through the systematic and continuous cultivation of specific mental states that foster a different relationship with stress.
224129804|NCT07084194|OTHER|Chitosan Nanoparticles Irrigant|using Chitosan Nanoparticles irrigant as a final irrigation solution.
224129805|NCT07084194|OTHER|aloe vera nanoparticles irrigant|using Aloe Vera Nanoparticles irrigant as a final irrigation solution.
224018544|NCT00003555|DRUG|paclitaxel|
224018545|NCT00383136|DRUG|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
224018546|NCT00383136|DRUG|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
224018547|NCT03200600|DRUG|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
224018548|NCT03200600|DRUG|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
224018549|NCT03200600|DRUG|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
224018550|NCT03200600|DRUG|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
224018551|NCT02091648|BEHAVIORAL|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
224018552|NCT02091648|BEHAVIORAL|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
224018553|NCT00445900|DRUG|cyclophosphamide|
224129806|NCT07084194|DEVICE|Diode Laser Activation|activation of nanoparticles irrigants using diode laser
224129807|NCT07084194|DEVICE|ultrasonic activator|activation of nanoparticles irrigants using ultrasonic activator
224129808|NCT07076251|OTHER|Family Box program|Boxes will include approximately five pounds of dry ingredients (e.g., whole grains, legumes, flour), which translates into about 40 servings of food for a family of four per month. Each ingredient box will include culturally relevant recipes and, six times out of the twelve boxes, include a culturally relevant book for the family's child/children.
224018554|NCT00445900|DRUG|prednisone|
224018555|NCT00445900|DRUG|thalidomide|
224018556|NCT00445900|OTHER|immunohistochemistry staining method|
224018557|NCT00445900|OTHER|laboratory biomarker analysis|
224129809|NCT07082062|DIETARY_SUPPLEMENT|GLP-1 formula Group|Participants in the intervention group will consume a single dose of GLP-1 formula drink (50 mL) on the study day. The formula includes Bifidobacterium breve (probiotic), ClpB formula (prebiotic), and Rocket Apple extract. The ClpB formula consists of kombucha, soy peptide powder, L-arabinose and erythritol.
224129810|NCT03752853|BEHAVIORAL|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
224129811|NCT07083193|DRUG|AC-101|AC-101 tablets will be administered orally.
223398350|NCT02596971|DRUG|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
223398351|NCT02596971|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
223398352|NCT02596971|DRUG|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
224018558|NCT00445900|PROCEDURE|biopsy|
224018559|NCT00534573|DRUG|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
224018560|NCT02001610|DIETARY_SUPPLEMENT|Acidophilus pearls|"* Acidophilus pearls are encapsulated using patented process~* Subjects take one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
224018561|NCT02001610|DIETARY_SUPPLEMENT|Hard shell gelatin capsules|"* Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~* Subjects consume one capsule (containing at least 1 x 10\^9 colony forming units) every morning for 12 days"
224018562|NCT01652599|DRUG|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
224018563|NCT02887807|DRUG|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
224018564|NCT02887807|DRUG|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
224018565|NCT04862871|BEHAVIORAL|Physical Activity - Pediatric Pain Rehabilitation Center|While admitted to the Pediatric Pain Rehabilitation Center program, patients receive 1-3 hours of individual and group physical therapy 5 times per week and completed a 30-60 minute home exercise program 9 times per week. The median length of stay for the program is 5 weeks. The amount of aerobic exercise prescribed is individualized to each patient and ranged from 10-20 minutes per session. The duration of aerobic exercise prescribed progressed by 5-10 min weekly until the child reached 20-30 minutes. Patients are instructed to reach a moderate to vigorous intensity of exercise (defined at 5-7/10 rate of perceived exertion). The mode of exercise varied dependent on patient ability and interest. Typical modes of exercise included: walking, running, stationary biking, swimming, sports (i.e., soccer, dance), and online aerobic workouts. Patients were prescribed an individualized 30-60 minute discharge home program using the same structure upon completing the program.
224018566|NCT02562495|DEVICE|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
224018567|NCT02774161|OTHER|Ultrasound Tomography|Undergo B-mode ultrasound imaging
224018568|NCT03064035|DRUG|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
224018569|NCT05022225|OTHER|None. This is a qualitative interview study.|There is no intervention in this study. This is a qualitative research study where participants will take part in focus group discussions.
224018570|NCT00517907|DRUG|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
224129812|NCT07084753|DRUG|Levobupivacaine|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
224129813|NCT07084753|DRUG|Dexamethasone contained in the solution for thoracic paravertebral block|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
223398353|NCT02596971|DRUG|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
223398354|NCT02596971|DRUG|Prednisone|Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m\^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
223398355|NCT02596971|DRUG|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
223398356|NCT02596971|DRUG|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.
223398357|NCT03190993|OTHER|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
224129814|NCT07084753|DRUG|Adrenaline|Used in thoracic paravertebral block: 10 ml of 0.33% levobupivacaine, combined with 1.33 mg of dexamethasone and 40 mcg of adrenaline, is injected at each level (six levels, at the Th5, Th7, and Th9 levels bilaterally; a total of 200 mg of levobupivacaine, 8 mg of dexamethasone and 240 mcg of adrenaline).
224129815|NCT07084753|DRUG|Dexmedetomidin|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
224129816|NCT07084753|DRUG|ketamine|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
224129817|NCT07084753|DRUG|Lidocain|A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total volume of 40 ml. Anesthesia is commenced with the infusion from syringe 1 over a 10-minute period at a rate of 15 ml/hour. The anesthetic mixture was maintained at a rate of 5-10 ml per hour.
224129818|NCT07084753|DRUG|Sufentanil|Following three-minute preoxygenation, sufentanil (5 to 15 micrograms), propofol (1 to 2 mg/kg ideal body weight), and rocuronium (0.8 to 1 mg/kg ideal body weight) are administered intravenously during induction of anesthesia. Anesthesia is sustained with sevoflurane maintained at 0.6-1.3 MAC. Sufentanil is added at the assessment of the anesthesiologist in the operating room.
223731461|NCT06211348|DEVICE|Genomic Sequencing|Individuals who request prenatal diagnostic testing with standard chromosomal microarray will be offered genomic sequencing (GS) as an option to assess for additional disease risk.
224018571|NCT03103763|DRUG|Warfarin|Patients on warfarin for atrial fibrillation
224129819|NCT07084753|PROCEDURE|Opioid free anesthesia based on thoracic paravertebral block|Patients scheduled for laparoscopic sleeve gastrectomy will be anesthetized without the use of opioids, with general anesthesia and pain blockade using a thoracic paravertebral block
224129820|NCT07084753|PROCEDURE|Opioid based Anesthesia|Patients scheduled for laparoscopic sleeve gastrectomy will be anesthetized with opioids and general anesthesia
224129821|NCT07084753|PROCEDURE|Opioid free anesthesia, Opioid free anesthesia based on intravenous dexmedetomidine, ketamine and lidocainedexmedetomidine, ketamine and lidocaine|Patients who are scheduled for laparoscopic gastrectomy will be anesthetized without the use of opioids and under general anesthesia, with analgesia by intravenous administration of dexmedetomidine, ketamine and lidocaine.
224129822|NCT07084753|DEVICE|Ultrasound guided thoracic paravertebral block|"Patients are positioned prone, with the identification of the 1st rib achieved using a convex XX Hz ultrasound probe. The left and right transverse processes of the 5th, 7th, and 9th thoracic vertebrae are marked accordingly. TPVB is executed in a paramedian sagittal oblique scan utilizing an in-plane needle insertion approach at the Th5, Th7, and Th9 levels bilaterally. An insulated echogenic needle, sized between 10-15 cm and 22-20 G, is employed. The skin and subcutaneous tissue at each level are infiltrated with 1.5 ml of 1% lidocaine.~Ultrasound guidance combined with nerve stimulation (dual monitoring) is utilized at each corresponding paravertebral space. Verification of the paravertebral space is established through visualization of pleural displacement, as observed via the ultrasound probe following the injection of 1 ml of 5% glucose, as well as via a motor response at a current intensity of 0.3-0.5 mA."
224018572|NCT00650351|DRUG|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
224018573|NCT00650351|DRUG|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
224018574|NCT04826861|BEHAVIORAL|SLIM intervention|Core components: 1) goal setting, 2) motivational interviewing, 3) feedback, 4) health technology
224129823|NCT07084753|DEVICE|Nerve stimulator for peripheral nerve blocks|During the application of the thoracic paravertebral block, verification of the distance of the insulated echogenic needle tip from the thoracic spinal nerve is monitored using via a motor response at a current intensity of 0.3-0.5 mA.
224129824|NCT07084753|DRUG|Metoclopramide 10mg|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg) and metoclopramide (10 mg) intraoperatively
224129825|NCT07084753|DRUG|Ondasetron 4mg|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intraoperatively.
224129826|NCT07084753|DRUG|Thiethylperazine|To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg) and thiethylperazine (6.5 mg) intravenously.
224129827|NCT07084753|DRUG|Dexamethasone, 8 mg intravenously|To prevent postoperative nausea and vomiting (PONV), patients receive intraoperatively dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intravenously.
224138681|NCT02001116|OTHER|Quality Improvement intervention|"1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
223398358|NCT03190993|OTHER|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
223398359|NCT00001298|DRUG|carboxypeptidase-G2|
223398360|NCT02779920|PROCEDURE|per oral pylorotomy|The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
223398361|NCT01899482|OTHER|Manual Lymphatic Drainage|
224018575|NCT04900987|DEVICE|Steri-strips|Pneumatic TR band compression with use of steri-strips
223398362|NCT01899482|BEHAVIORAL|Education|Behavioral education.
223731462|NCT03760783|OTHER|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
224018576|NCT05760053|DRUG|EP/EC+PD-1|Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
224018577|NCT00465556|BEHAVIORAL|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
224018578|NCT00465556|BEHAVIORAL|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
224018579|NCT02998736|DRUG|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
223731463|NCT00552916|DEVICE|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
223731464|NCT00552916|DEVICE|Compex Motion Stimulator|'False' FES
223731465|NCT00748033|DEVICE|Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12|The subjects were first catheterized with this reference catheter.
223731466|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 5 seconds|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds
224018580|NCT02998736|BIOLOGICAL|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
224018581|NCT02272088|BEHAVIORAL|physical activity-moderate|cross -over of moderate and intense physical activity
224018582|NCT02272088|BEHAVIORAL|Intense physical activity|cross -over of moderate and intense physical activity
224018583|NCT04119258|BEHAVIORAL|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
224018584|NCT04147117|DEVICE|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
224018585|NCT00434005|DRUG|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
224018586|NCT00434005|DRUG|Placebo|matched appearance to acetylcysteine and ascorbate intervention
224018587|NCT06242860|DEVICE|ELM|Treatment of dry eye with ELM device
224018588|NCT04207151|BEHAVIORAL|SNAPS intervention|"The intervention is multi-level yet, targets the weakest chains in the link of PrEP initiation at safety-net hospitals designed for scalability, sustainability, and implementability across a wide range of settings. It consists of Surveillance by STI testing, Navigation by unannounced patient navigators to the Sexual Health Clinic (SHC), Accelerated follow-up with providers with PrEP expertise, Point-of-care PrEP counseling and laboratory testing, and Seamless, consistent, longitudinal, comprehensive care (SNAPS). SNAPS will selectively target those care settings where PrEP prescribing is particularly rare or absent (eg, OB/GYN). Study team will utilize a quasi- experimental design to compare rates of PrEP uptake overall, PrEP initiation in disproportionately-impacted groups, and PrEP retention pre-versus post-initiation of SNAPS, controlling for secular trends."
224018589|NCT04020627|OTHER|BiPAP Group|"BIPAP~\- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
224018590|NCT04020627|OTHER|CPAP Group|"CPAP~\- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
224018591|NCT04279392|DRUG|Zoledronic Acid 5 mg/Bag 100 ml Inj|Zoledronic acid infusion
224018592|NCT04279392|DRUG|Placebos|Saline infusion
224018593|NCT02961543|OTHER|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
224018594|NCT02961543|OTHER|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
224018595|NCT06043583|PROCEDURE|Intrauterine device|The vagina is visually inspected to check the size and position of the uterus. The speculum is inserted into the vagina. The IUD is placed inside the uterus and then the strings are cut.
224018596|NCT06043583|PROCEDURE|Uterine artery embolization|The right common femoral artery is punctured under ultrasound guidance and a 5F vascular sheath is inserted into the Rt common femoral artery. A 5F catheter was inserted into the internal iliac artery, and a 2.0F microcatheter is advanced into the uterine artery. Embolization is performed using polyvinyl alcohol (PVA). One third (20 mL) of a 60-mL mixture comprising 150-250-µm PVA particles was injected at the beginning of embolization into each uterine artery, followed by injection of at least two thirds (40 mL) to all (60 mL) of a mixture comprising 250-355- µm PVA particles and finally completion with 355-500- µm PVA particles. Embolization was performed until complete cessation of blood flow in the ascending uterine artery for 10 heart beats.
224018597|NCT01488877|DRUG|PF-03882845|3 mg tablet once daily
224018598|NCT01488877|DRUG|PF-03882845|up to 10 mg tablet once daily
224018599|NCT01488877|DRUG|PF-03882845|up to 30 mg once daily
224018600|NCT01488877|DRUG|Spironolactone|spironolactone 25 mg once daily
224018601|NCT01488877|OTHER|placebo|placebo once daily
224018602|NCT04860076|DRUG|Pembrolizumab|Standard of care
224018603|NCT04294953|DRUG|Duloxetine|Each Patient will receive oral Duloxetine capsule 60mg at the night before operation(12hrs before surgery), the 2nd dose 60 mg Duloxetine capsule 1hr before operation and 3rd dose 60mg capsule after 24hrs postoperative
224129828|NCT07083219|BEHAVIORAL|Aerobic High Intensity Interval Training|"HIIT Protocol (Individualization of Exercise Program): Peak power will be calculated with Graded Exercise Test (GXT), with 90% of peak power used as the target range for the intervention.~Total Training Time: 35 minutes.~Warm-Up Phase:~1. Duration: 10 minutes~2. Intensity: 40-50% of peak power~HIIT Work and Rest Cycles:~Each session includes 20 minutes of intervals with the following pattern:~Work: 1 minute at 90% of peak power Rest: 3 minutes at 40% of peak power Repeat for five cycles. 5 minute cool down at 40% of peak power~Monitoring:~VO₂ and heart rate will be continuously measured.~Lactate levels will be measured at the following points:~1. Before the warm-up~2. After completing the warm-up (1st-minute intervention)~3. During the second minute of each rest period"
224018604|NCT04294953|DRUG|Placebo oral tablet|Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
224018605|NCT01035073|DRUG|Duloxetine|30-60 mg daily for 8 weeks
224018606|NCT03318042|OTHER|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
223398363|NCT02029066|DRUG|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm\^2 once for 24 hours.
224296661|NCT03802253|BEHAVIORAL|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later, Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
223398364|NCT00595920|BIOLOGICAL|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
223398365|NCT00351468|DRUG|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
224018607|NCT03318042|OTHER|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
224018608|NCT02342431|DEVICE|Forced air warming compressible|Warming with a compressible forced air mattress
224129829|NCT07083804|DIAGNOSTIC_TEST|Gastric biopsies|"After obtaining informed consent, patients receive routine endoscopic procedures with an additional biopsy taken for research purposes.~Invasive screening method used in routine care."
224129830|NCT07083804|DIAGNOSTIC_TEST|Stool sampling|"Stool samples are taken and sent within 10 days of the endoscopy. Self-collected stool samples are analyzed using antigen testing and molecular techniques to detect H. pylori and associated resistance mutations.~Experimental diagnosis."
224129831|NCT07082218|BEHAVIORAL|Sleep Intervention|The investigators will randomly assign participants (adolescents with concussion) to a personalized sleep schedule and sleep health recommendation, based on a meeting with an administrator after enrollment and randomization. They will undergo testing prior to the intervention, after the intervention (2 weeks after the initial visit, intervention length=2 weeks), and 6 weeks after intervention completion.
224129832|NCT07083518|DEVICE|Anodal transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, direct current applied directly to the head through scalp electrodes.
224129833|NCT07083518|DEVICE|Sham transcranial direct current stimulation|Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
224129834|NCT05032053|DRUG|Antithrombotic drugs|The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
224129835|NCT06920719|DRUG|YHP2406|Test drug: YHP2406, Comparator: YHR2501
224129836|NCT06920719|DRUG|YHR2501|Test drug: YHP2406, Comparator: YHR2501
223398366|NCT05594992|DRUG|JR-141|IV infusion, 2.0 mg/kg/week
223398367|NCT03088072|DRUG|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl \>50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow \<5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
223398368|NCT03088072|DEVICE|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
224129837|NCT05104671|OTHER|scapular stabilization exercises.|"General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:"
224129838|NCT05104671|OTHER|Thoracic manipulation.|• Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
224296662|NCT03802253|BEHAVIORAL|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
224296663|NCT04601298|OTHER||
224296664|NCT01529398|OTHER|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
223398369|NCT03088072|DRUG|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
223731467|NCT00748033|DEVICE|LoFric POBE Hydro-Kit II, 24 hours|An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
224018609|NCT02342431|DEVICE|Forced air non-compressible|Warming with a non-compressible forced air mattress
224018610|NCT01693705|PROCEDURE|Tracheostomy|
224018611|NCT04955340|DRUG|[14C]-resminostat|1 single dose of 400 mg \[14C\]-resminostat
224018612|NCT00602940|PROCEDURE|Acupuncture|12 treatments over 8 weeks
224018613|NCT00602940|PROCEDURE|Sham Acupuncture|12 treatments over 8 weeks
224018614|NCT05145153|PROCEDURE|Thoracic surgery application|The chronic pain findings of the patients who underwent thoracic surgery will be questioned at the postoperative 3rd and 6th months.
224018615|NCT00955253|DRUG|Guanfacine|2mg oral guanfacine (encapsulated)
224018616|NCT00955253|DRUG|Placebo|placebo
223398370|NCT03088072|DRUG|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
223398371|NCT00508014|OTHER|Usual Care|Usual Care with primary care provider during time period
223398372|NCT00508014|BEHAVIORAL|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
223398373|NCT04457908|DIAGNOSTIC_TEST|intelligent assessment|intelligent neurological function assessment
223398374|NCT04740710|BEHAVIORAL|Breathing and Attention Training|A guided audio recording will instruct participants to alter their breathing and pay attention in specific ways.
223398375|NCT03588910|DRUG|Acetaminophen|50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
223398376|NCT03588910|DRUG|Ibuprofen 600 mg|25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
223398377|NCT03588910|DRUG|Oxycodone|The number of tablets of oxycodone prescribed is the only difference between the two arms.
223398378|NCT00611923|DRUG|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
223398379|NCT00611923|DRUG|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
223398380|NCT05260567|BEHAVIORAL|Exercise and Lifestyle Change|"Patients will undergo to weekly phone call/videoconference for 12 weeks and discuss the behaviour change.~They also will undergo to home-based exercise training will be performed twice a week for 12 weeks via Zoom (up to 5 patients per session). Each session will be comprised of warm-up (10 min), the main part (15 to 20 min), and cooldown (5 to 10 min). The training aims to develop resistance, aerobic and functional capacity such as getting up, walking, pulling, pushing, throwing, transferring body weight or external loads. In addition, patients will be encouraged to increase their physical activity. Patients will be provided with a Fitbit device to monitor their step count and will be recommended to increase their previous week's average step count by 10%."
223398381|NCT00838903|BIOLOGICAL|albiglutide|albiglutide
223398382|NCT00838903|DRUG|sitagliptin|sitagliptin
224018617|NCT05212805|BEHAVIORAL|Aerobic exercise|Interventions will be delivered through twenty supervised 40-minutes aerobic sessions (3 times a week). Patients will be trained on a bicycle ergometer (5-minute warm-up, 30 minute of intense training, 5-minute cool-down). Warm-up will be performed at the 30% of the maximal heart rate, while training will be performed at the 50-70% of the maximal heart rate as recommended by the general guidelines for aerobic exercise training specific for MS. Actual heart rate will be constantly monitored by a wearable heart rate monitor.
224018618|NCT05212805|BEHAVIORAL|Task-oriented upper-limb training|The training will consist in twenty 1-hour sessions (3 times a week) of exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, including unimanual and bimanual task-oriented exercises.
224018619|NCT05212805|BEHAVIORAL|Sport events participation|A subgroup of participants will also be involved in events promoting sports activity including both aerobic and task-oriented exercises (e.g., water sports such as sailing, windsurfing, canoeing) in order to evaluate their potential role to increase adherence to training, participation and quality of life.
224018620|NCT02957851|DRUG|Medical Air|
224018621|NCT02957851|DRUG|EMONO|
224129839|NCT05104671|OTHER|Myofascial release.|The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
224129840|NCT06930690|DRUG|Dexamethasone Sodium Phosphate Injection|One time dose of dexamethasone sodium phosphate given intravenously at the time of surgery
224129841|NCT04940936|BEHAVIORAL|A Patient Decision Aid|The Patient Decision Aid informs about the pros and cons of each option
224129842|NCT06930547|OTHER|Experimental|"In this study, the experimental group will undergo a smoking cessation training program consisting of eight sessions over four weeks, conducted twice a week. Each session is planned to last approximately 40-45 minutes.~During the program, before each session, the previous session will be reviewed to reinforce learning and establish continuity between sessions. Feedback will be collected to ensure engagement and comprehension. At the end of each session, a summary of the session's agenda will be provided.~Before each session, both the experimental and control groups will be evaluated using a smoking cessation status form to assess their progress. Additionally, follow-up assessments will be conducted one month and three months after the program to test the retention of the training's effectiveness."
224129843|NCT06930911|BIOLOGICAL|Antibiotic therapy|Evaluating antibiotic exposure in premature infants before 35 weeks in a tertiary care neonatal unit
224129844|NCT06929637|DRUG|Infusion Therapy|Infusion of amino acids once daily - dose 1g/kg, maximum 100 g daily for 3 consecutive days starting D1 after kidney transplantation procedure
224129845|NCT06929637|DRUG|Saline solution infusion|Infusion of saline solution a s standard rehydration therapy after kidney transplantation
224129846|NCT06929793|DIETARY_SUPPLEMENT|Multiple Micronutrients|"1. Multiple micronutrient~2. Calcium Carbonat 766 mg~3. Vitamin D3 5000 IU~4. DHA 300 mg"
223398383|NCT00838903|DRUG|glimepiride|Glimepiride
223398384|NCT00838903|DRUG|metformin|Metformin
223398385|NCT00838903|BIOLOGICAL|placebo albiglutide|placebo to match albiglutide
223398386|NCT00838903|DRUG|placebo sitagliptin|placebo to match sitagliptin
223398387|NCT00838903|DRUG|placebo glimepiride|placebo to match glimepiride
224018622|NCT04209959|DRUG|nifekalant|Nifekalant was randomly given intravenously as a loading dose of 0.3 mg/kg, 0.4 mg/kg, or 0.5 mg/kg for five minutes without the continuous infusion for all study population, while blood pressure, surface electrocardiograms (ECG), intracardiac electrograms were monitored for half an hour. While nifekalant was given intravenously, QT interval, QTc interval and RR interval were recorded at 0, 1, 3, 5, 10, 15, 20 and 30minutes, respectively, because drug action almost disappeared within 30minutes since a single dose of intravenous nifekalant injection. These doses of nifekalant were determined based on the results of the previous study and the medicine operation instruction. Once AF continued after administration or Torsade de points was observed, external electrical cardioversion was given immediately.
224018623|NCT00030498|DRUG|erlotinib hydrochloride|Given orally
224018624|NCT00030498|OTHER|laboratory biomarker analysis|Correlative studies
224129847|NCT06929793|DRUG|Standard Antenatal Vitamin|Standard Antenatal Vitamin given in Community Health Centers
224129848|NCT06929078|OTHER|Protective lung ventilation methods with different positive end-expiratory pressure during Laparoscopic Surgeries|Protective lung ventilation methods with positive end-expiratory pressure help in prevention of atelectasis and improvement of intraoperative ventilator parameters e.g low driving pressure and improved dynamic compliance resulting in better oxygenation of lungs ere will be three groups in this study. Individualized positive end-expiratory pressure with recruitment maneuver and fixed positive end-expiratory pressure will be interventional groups. They will be compared with conventional ventilation group in which no additional positive end-expiratory pressure will be applied. The effects on respiratory parameters and oxygenation of patients will be compared for each group. This study will determine which method of positive end-expiratory pressure is superior and how it differs from conventional ventilation for prevention of atelectasis induced by pneumoperitonium and improvement of respiratory mechanical parameters and oxygenation in Mechanical ventilation during laparoscopic surgeries.
224129849|NCT06930807|OTHER|Adaptive postoperative management based on minimal residual disease|participants will not receive postoperative treatment if (neoadjuvant therapy efficacy reaches pCR and) MRD results keep negative.
224129850|NCT06930378|PROCEDURE|Nerve Suture|"Sensory nerve coaptations will be performed~1. either by suturing the donor to the recipient nerve immediately (1 coaptation)~2. or by interposing an autograft originating from the zone of the flap to be discarded (2 coaptations). The anterior cutaneous branch (ACB) of the 3rd or 4th intercostal nerve (ICN) will be connected to the sensory branch of the 10th, 11th or 12th ICN of the flap."
224138682|NCT03523221|DRUG|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
224138683|NCT03838068|BIOLOGICAL|Biodentine|Biodentine is considered a calcium silicate cement
224296665|NCT01529398|OTHER|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
223398388|NCT06040515|DRUG|Probiotic Formula|Capsule with 25 billion live strains of Escherichia coli Nissle 1917
223398389|NCT02734966|DRUG|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
223398390|NCT02734966|DRUG|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
223398391|NCT02734966|DRUG|Tiopronin Injection|Tiopronin Injection 200mg OD
223398392|NCT04565145|DRUG|Kava Dietary Supplement|Participants will be given three 75mg kava capsules per day for one week
224018625|NCT04109105|OTHER|NHS-PEG coated collagen patch|Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
224018626|NCT04277351|DEVICE|Transcranial alternating current stimulation|Focal transcranial stimulation over auditory cortex by means of 5 electrodes delivering an electric current (max. 2mA). In addition to active stimulation, also a placebo (sham) stimulation is employed as a control condition. All subjects included in the study receive all tACS stimulation conditions.
224018627|NCT03057990|DRUG|Pyrimethamine|Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
223398393|NCT04565145|DRUG|Placebo|Participants will be given three placebo capsules per day for one week
223398394|NCT04122963|PROCEDURE|High power CLOSE-guided PVI ablation|CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)
224018628|NCT01567904|DRUG|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
224138684|NCT03838068|BIOLOGICAL|mineral trioxide aggregate|calcium based silicate cement
224138685|NCT03838068|PROCEDURE|cervical pulpotomy|coronal pulp tissue was removed till the orifice
224138686|NCT03838068|DRUG|Local Anesthetics Procaine|40 mg/0.01 mg/ml contains sodium metabisulfite and sodium and articaine as an active substance
223398395|NCT04122963|PROCEDURE|Standard CLOSE-guided PVI ablation|Standard AF ablation according to the CLOSE-protocol
223398396|NCT05661539|DEVICE|Transvaginal Ultrasonography|The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.
223550986|NCT06717828|BEHAVIORAL|Control|All participants will be advised not to change their existing lifestyle habits and will only receive health education related to fatty liver throughout the intervention. The educational methods will include large group sessions, individual education, and telephone follow-ups, conducted every two months. Additionally, dietary and exercise assessments will be carried out during the intervention, with dietary intake recorded using a three-day food diary to track daily calorie consumption.
224018629|NCT00537953|DRUG|Miltefosine , meglumine antimoniate|
224138687|NCT03240393|DRUG|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and \< 6 cMET mutations
224018630|NCT04101318|DEVICE|Non-Conformité Européene marked product|New Baseplate is not named at this point
224018631|NCT04101318|DEVICE|Conformité Européene marked competitor products|The Conformité Européene marked competitor products are considered Standard of Care or products considered to be part of Standard of Care in coming years.
224018632|NCT01128816|DEVICE|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
224018633|NCT00702351|DRUG|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
224018634|NCT00217308|DRUG|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
224018635|NCT00558259|DRUG|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
224018636|NCT00558259|DRUG|matching placebo twice daily (BID)|Matching placebo BID
224018637|NCT03170895|DRUG|Sorafenib|Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
224018638|NCT03170895|DRUG|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
224018639|NCT06181487|OTHER|High Intensity Functional Training|12 weeks of high-intensity functional training, 3 times/week. Each class lasts 60 minutes, including warm-up, physical training, and cool down.
224018640|NCT00148512|DRUG|1. Tesofensine (NS 2330)|
224018641|NCT02443090|DRUG|fispemifene|
224018642|NCT02443090|OTHER|Placebo|
224018643|NCT02969239|DRUG|Norepinephrine|bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
224018644|NCT02969239|DRUG|Phenylephrine|bolus administered phenylephrine 100mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
224018645|NCT01244178|DRUG|Insulin|Intravenous Hyperinsulinemic therapy
224018646|NCT01244178|DRUG|Insulin|Standard Intravenous Insulin Therapy
224129851|NCT06929611|OTHER|Combined continous caudal epidural with general anaesthesia|"A 17- or 18-gauge Tuohy-type needle will be inserted in the midline into the caudal canal. An initial dose of 20 ml of 0.25% bupivacaine will be injected in the caudal canal in order to perform sensory block and spare motor power. Then a dose of 10 ml 0.25% bupivacaine will be injected through the epidural catheter every 1-hour intra operatively and at 0-hour and 1-hour post operative then the catheter will be removed 1 hour post operative.~-The following factors will be assessed:~1. Intra operative heart rate and blood pressure.~2. Post operative pain assessment according to numeric pain scale score.~3. Time to rescue analgesia (intravenous analgesia administered after surgery).Patients with numeric pain scale score ≥ 3 at any point of time, will receive intravenous morphine 5mg.~4. Estimated blood loss and surgeon satisfaction of surgical field.~5. Total intra operative and post operative analgesia.~6. Common complications."
224129852|NCT05366413|OTHER|Early Referral|Directing a patient for a pain specialist consult earlier than standardly occurs.
223550987|NCT06718959|DEVICE|the test product (Jet Floss EX)|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add used the test product (Jet Floss EX) twice a day. Subjects used the test product (standard sprinkler, water twice) to flush all gingival margins and adjacent spaces with 440ml of water, start with water pressure gear 1 for the first time and continued with this gear after reaching the highest level that can be asapted. If felt uncomfortable, eligible subjects can adjust it to a suitable gear. The specific installation and usage of the teeth punch refer to the product instruction.
223550988|NCT06718959|OTHER|the control product (interdental brush)|subjects continued to use distributed manual toothbrush and toothpaste every morning and evening, and add auxiliary product (interdental brush) twice a day.
224018647|NCT04289051|DEVICE|HYDRAL Oral Rinse|Application 4 times a day for two weeks
224018648|NCT04289051|DEVICE|BIOTENE® Oral Rinse|Application 4 times a day for two weeks
224018649|NCT04289051|DEVICE|Placebo Oral Rinse|Application 4 times a day for two weeks
224018650|NCT01901341|DRUG|CB-5945|
224018651|NCT01901341|DRUG|Placebo|
224129853|NCT05366413|OTHER|Pain Management Strategies|Specialized plan with procedures to ease pain
224138688|NCT01711684|DRUG|Diphenylcyclopropenone (DPCP)|Topical application of study drug
224018652|NCT05927662|PROCEDURE|lumbar discectomy|mini-open discectomy
224018653|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"* 3 pulses at 50Hz repeated each 200 ms for 2 seconds~* 80% MT~* 20 days treatment"
224018654|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
224018655|NCT01315587|DEVICE|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
224018656|NCT01806103|BEHAVIORAL|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
224018657|NCT00864201|DRUG|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
224018658|NCT02093559|BEHAVIORAL|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
224018659|NCT02977637|PROCEDURE|Feraheme MRI/MRA|
224018660|NCT01152632|OTHER|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
224018661|NCT02944591|DEVICE|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
224018662|NCT02787889|OTHER|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)\] on net protein synthesis over 8 weeks.
224018663|NCT02787889|OTHER|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
224018664|NCT01630746|DRUG|TAK-438|
224018665|NCT01630746|DRUG|TAK-438|
224018666|NCT01182701|BEHAVIORAL|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
224018667|NCT03450187|DRUG|TP-271|multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
224129854|NCT05511753|DEVICE|electroacupuncture|Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
224129855|NCT06940388|DRUG|Tislelizumab|During ChemoImmunotherapy: Patients in the investigational arm will receive 8 cycles of tislelizumab 150 mg IV on Day 1, followed by mFOLFOX6 (Q2W).
224129856|NCT06940388|DRUG|Total neoadjuvant therapy (TNT)|Patients will be treated with 6 weeks of capecitabine-based CRT followed 4 weeks later by 16 weeks of chemotherapy with mFOLFOX6, Q2W.
224129857|NCT06937775|OTHER|Periodontal measurements (plaque index, gingival index and probing pocket depth scores )|Plaque index (PI), gingival index (GI) and probed pocket depth (PPD) scores will be recorded at T0, T1, T2 and T3 assessment periods to evaluate the periodontal status and oral care effectiveness of the participants. PPD is the distance between the gingival margin and the sulcus base. Measurements will be made at 6 different sites (mesio-vestibular, vestibular, disto-vestibular, mesio-oral, oral, disto-oral) of each tooth using a Williams periodontal probe (Hu Friedy, Chicago, Illinois, USA). During the measurements, care will be taken to position the probe as parallel as possible to the long axis of the tooth and not to apply excessive force.
224129858|NCT06937775|OTHER|Biochemical Sample Supply (Collection of serum and saliva samples)|"Serum and saliva samples will obtained from all individuals included in the study at T0, T1, T2 and T3 for biochemical analyses.~For standardisation purposes, blood samples will be collected from the antecubital fossa with the patients in a sitting position. After resting for 30 minutes (min) at room temperature, the samples will be centrifuged (4ºC at 3000 rpm for 5 min) and serum samples will be obtained. The samples will be transferred into eppendorf tubes and stored in the freezer (-80ºC) until the study day.~Sampling will be performed early in the morning. Participants will be warned not to consume anything other than water for the last 12 hours and not to brush their teeth that morning. Individuals will be left with their mouths open for 5 min to allow saliva to accumulate at the floor of the mouth. Unstimulated saliva samples accumulated at the floor of the mouth will be collected and transferred to eppendorf tubes."
224129859|NCT06937775|PROCEDURE|Rapid maxillary expansion with Hyrax appliance|Rapid maxillary expansion (RME) is the most commonly preferred treatment of skeletal jaw stenosis in the transversal direction. Bilateral anchorage is the process of increasing the transversal dimension of the midpalatal suture (sutura palatina media) by applying strong tensile forces in the lateral direction to the dentoalveolar structures of the teeth and/or palatal bone. The primary goal of treatment is to provide orthopedic movement through sutural separation.
224129860|NCT06954025|DRUG|High-intensity inpatient MDMA-assisted psychotherapy|"Drug: 3,4-methylenedioxymethamphetamine (MDMA) Session 1: 80 mg MDMA HCl followed by a supplemental dose of 40 mg Session 2: 120 mg MDMA HCl followed by a supplemental dose of 60 mg~Psychotherapy: manualized psychotherapy"
224129861|NCT06531031|DIAGNOSTIC_TEST|InfectID-BSI (Bloodstream Infection) qPCR Assay|"InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent.~InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours."
224129862|NCT05617898|BEHAVIORAL|Motivational Interviewing|Three motivational interviewing sessions will target sensitivity to social reward, including subjective evaluation of social interaction, socially rewarding stimuli, and events (e.g., interactions with others, feedback from others).
224129863|NCT05617898|BEHAVIORAL|Nutrition Didactic Training|The Nutrition didactic training will ask participants to discuss pros and cons of healthy eating habits and how to improve their current eating habits.
224129864|NCT04042571|DEVICE|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
224138689|NCT02017236|DRUG|Volitinib|600mg Volitinib ,single dose,oral
223550989|NCT01643057|DEVICE|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
223550990|NCT02949024|DRUG|IVT Aflibercept|IVT aflibercept \[2 mg (50 µL)\]
223550991|NCT02949024|DRUG|SC CLS-TA|\[4 mg (100 µL)\]
223550992|NCT05031143|DRUG|Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease|Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
223550993|NCT04210661|OTHER|prediction software with spell checker|test with prediction software with spell checker
224138690|NCT04880538|PROCEDURE|Endoscopic procedure|Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
224138691|NCT01755494|DRUG|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
224138692|NCT01755494|DRUG|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
224138693|NCT01755494|DRUG|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
224138694|NCT01755494|DRUG|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
223398397|NCT04293939|DIAGNOSTIC_TEST|Functional Magnetic Risonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. MRI Protocol: T1 weighted image structural, T2 weighted image structural, fMRI task. Task fMRI: experiment will be implemented using the block design is as follow: 1.Rest (control condition): no touch; 2.Soft touch (stimulus condition): gentle strokes on infant's right leg (\~15 cm area) with a soft brush at a velocity of \~5 cm/s Stimulus blocks will last for \~15s, allowing the blood-oxygen-level-dependen (BOLD) signal to reach the steady state. Control blocks duration will be randomized (10-18s) to avoid foresee activation phenomena. Condition will be administered multiple times (\~10 times). Two run will be administered. The stimulus will be administered using a soft brush. A regular audio signal will help the operator to keep a constant stroke velocity. Audio commands will also be used to direct the operator. Infant must be asleep (natural sleep) during the fMRI acquisition.
223398398|NCT01535417|DRUG|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
223398399|NCT01535417|DRUG|Celebrex|
223398400|NCT00002234|DRUG|Efavirenz|
223398401|NCT00002234|DRUG|Adefovir dipivoxil|
223398402|NCT00002234|DRUG|Lamivudine|
223398403|NCT00002234|DRUG|Didanosine|
223398404|NCT00516022|DRUG|Mistletoe extract|The drug will be administered 3 times a week at home.
223398405|NCT04632186|DEVICE|EXOPULSE Mollii suit|"All sessions start with rated perceived pain with the NRS and the ShoulderQ questionnaire and assessed body function with the Fugl-Meyer UE scale, Ashworth scale and the Neuroflexor, before the start of the intervention.~Session 1. Stimulation with TENS according to best clinical practice. Session 2. Stimulation with the Mollii suit according to current best experienced practice with selective stimulation directed to the shoulder region Session 3. Stimulation using the full body Mollii suit according to current best experienced practice.~Outcome of each session is assessed with a pain drawing, the NRS (during and after treatment) and the Fugl-Meyer UE, Ashworth scale and the Neuroflexor (after treatment)."
223398406|NCT01447550|DRUG|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
223550994|NCT03527511|OTHER|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
223550995|NCT02662426|DRUG|Lingdancao granules|4 packs per time (3g/pack), three times per day
224018668|NCT02966301|DRUG|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
224018669|NCT06155448|OTHER|Perennial Malaria Chemoprevention effect|Assessing the effectiveness and feasibility of Perennial malaria chemoprevention delivery through EPI platform.
224018670|NCT02579499|DRUG|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
223398407|NCT01850238|BIOLOGICAL|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
224018671|NCT02579499|DRUG|targeted LDL-C goal statin|"1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
224018672|NCT00169052|BEHAVIORAL|Health Care Management and Supported Rehabilitation|
224138695|NCT01755494|DRUG|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
224138696|NCT01674244|BEHAVIORAL|Integrative Exercise|
224138697|NCT01674244|BEHAVIORAL|Monitor Only Waitlist|
223398408|NCT01850238|OTHER|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
223398409|NCT04976010|OTHER|No intervention|There will be no intervention in the separate goups, as this is an observational study
223398410|NCT03726970|RADIATION|CBCT radiation|CBCT scanning
223398411|NCT00683618|DRUG|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
223398412|NCT00683618|DRUG|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
223398413|NCT04570670|DRUG|monomethyl fumarate 190 mg|
223398414|NCT04570670|DRUG|dimethyl fumarate 240 mg|
223398415|NCT02746718|OTHER|Blood sample|A blood sample for CPK dosage and pompe disease test
223550996|NCT02662426|DRUG|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
223550997|NCT02662426|DRUG|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
223550998|NCT02662426|DRUG|analogous Lingdancao granules|4 packs per time, three times per day
223550999|NCT05954949|PROCEDURE|Adenomas detection rate with the different observation methods|Films performed in white light high definition, NBI and indigo-carmine dye, will be compared blindly to detecte number of adenomas with the different observation methods
223551000|NCT01202890|DRUG|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
223551001|NCT01202890|DRUG|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
224129865|NCT06195501|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing (FEES) ; Transesophageal Ecocardiography (TEE)|"Flexible Endoscopic Evaluation of Swallowing (FEES):~FEES is performed for analysis of swallowing ability according to the same methodology as in the initial trial: one day before a TEE and max. 4 hours after TEE. Before the FEES anticongestive nose drops are applied and the nostrils are anaesthetized by applying a lidocaine gel via cotton sticks. During the FEES examination the participants sit upright and are asked to swallow various consistencies: FEES is aborted in case of aspiration of any of the consistencies during the examination.~Transesophageal Ecocardiography (TEE):~For the TEE anesthesia is applied via intravenous injection of propofol or a combined anesthesia, through intravenous application of propofol and local anesthesia, using lidocaine spray. All patients undergoing a TEE are sober before and at least two to four hours after TEE."
224129866|NCT00755846|DRUG|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
224296666|NCT01529398|OTHER|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
223398416|NCT06536361|OTHER|Virtual Reality-Based Learning Tool|The intervention involves the use of a virtual reality-based learning tool to teach thorax and lung physical examination skills. The tool uses Oculus Meta Quest 3 VR headset to provide immersive simulation experiences. The VR tool includes high-quality graphics and interactive scenarios to facilitate skill development.
223551002|NCT04695353|PROCEDURE|Telemedicine: Virtual visits (videoconferences, texts)|Patients will receive clinical care by using telemedicine (virtual visits)
224018673|NCT02749435|OTHER|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
224018674|NCT02156128|BEHAVIORAL|Cogmed working memory training|
224018675|NCT02156128|BEHAVIORAL|Control group|
224018676|NCT02479048|DIETARY_SUPPLEMENT|Test meal 1|High fat meal (HF) with ½ avocado (\~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
224018677|NCT02479048|DIETARY_SUPPLEMENT|Test meal 2|High fat meal (HF) with 1 avocado (\~136g) matched for energy but not macronutrient content or type.
224018678|NCT02479048|DIETARY_SUPPLEMENT|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
224018679|NCT06284720|DEVICE|Gamma tACS (40 Hz) over the precuneus|5 sessions of gamma tACS (40 Hz) over the precuneus
224018680|NCT06284720|DEVICE|Sham tACS over the precuneus|5 sessions of sham tACS over the precuneus
224018681|NCT00832637|DRUG|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
224018682|NCT00832637|DRUG|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
223551003|NCT00095472|DRUG|L-NMMA|
224018683|NCT00832637|DRUG|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
224018684|NCT03782077|PROCEDURE|Deflation of pneumatic tourniquet|Deflation of pneumatic tourniquet
224018685|NCT03809559|DEVICE|MRCP+|Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
224018686|NCT00370331|DRUG|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
224129867|NCT00755846|DRUG|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
223551004|NCT00095472|DRUG|Sodium Nitrite|
224129868|NCT00755846|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
224296667|NCT03778398|OTHER|Neurologic music therapy|Customized piano training
223398417|NCT06536361|OTHER|Traditional Small Group Training|The intervention involves traditional small group training conducted in the Nursing Principles Skills Laboratory. This training includes hands-on practice with physical examination techniques using simulation mannequins and feedback from instructors. The approach is designed to provide practical experience without the use of virtual reality technology.
223551005|NCT03159468|BEHAVIORAL|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
223551006|NCT03159468|BEHAVIORAL|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
223551007|NCT03159468|OTHER|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
224018687|NCT00370331|DRUG|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
224018688|NCT00003493|DRUG|dexamethasone|
224018689|NCT00003493|DRUG|pegylated liposomal doxorubicin hydrochloride|
224018690|NCT00003493|DRUG|vincristine sulfate|
224018691|NCT06277544|PROCEDURE|lateral ankle ligament repair or reconstruction|repair or reconstruction procedure for lateral ankle ligament
224018692|NCT01874431|DRUG|Finerenone (BAY94-8862)|
223398418|NCT02062060|DRUG|Abametapir Lotion 0.74% w/w|
223551008|NCT02377414|DRUG|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
223551009|NCT02377414|DRUG|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
223551010|NCT00076089|DRUG|Roflumilast|
223551011|NCT05701839|PROCEDURE|face mask ventilation|In participants with face mask ventilation, oxygen inhaled through face mask at a flow rate of 5 L/min.
223551012|NCT05701839|PROCEDURE|nasopharyngeal tube ventilation|In participants with nasopharyngeal tube ventilation, oxygen inhaled through face mask before induction and through nasopharyngeal tube after consciousness disappear at a flow rate of 5 L/min.
223551013|NCT05701839|DEVICE|oxygen saturation monitoring|In participants with oxygen saturation monitoring, assist ventilation through face mask will be performed when oxygen saturation drops to 95%, it lasts for another 10 seconds when oxygen saturation restores to 100%.
224018693|NCT01874431|DRUG|Placebo|
224018694|NCT01072760|PROCEDURE|K wire|Mallet finger treatment
224018695|NCT03507465|DRUG|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
224018696|NCT03507465|DRUG|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
224018697|NCT01528176|DRUG|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
224018698|NCT05741359|DRUG|CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection|CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
224018699|NCT03061071|DEVICE|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
224018700|NCT03061071|DEVICE|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
224129869|NCT00755846|DRUG|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
224129870|NCT00755846|DRUG|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
224129871|NCT00755846|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
224129872|NCT06283784|OTHER|Yovis Capsules|Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
224129873|NCT06283784|OTHER|Placebo|Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
224129874|NCT04783532|BEHAVIORAL|Telehealth Mindfulness Program|Enrolled participants will participate in an individual (one-on-one) Telehealth-delivered (online with audio and video) mindfulness intervention with a trained mindfulness therapist. The intervention is adapted from mindfulness-based cognitive therapy and includes eight sessions lasting 75 minutes each (except the first session which lasts 90 minutes) over a 3-month period.
223398419|NCT02062060|DRUG|Vehicle Lotion|
223398420|NCT03557619|DRUG|Venetoclax|tablet; oral
223398421|NCT03557619|DRUG|ethinyl estradiol/levonorgestrel|tablet; oral
223398422|NCT05770141|PROCEDURE|laser hemorrhoidoplasty|A skin incision of 3 mm was made about 1 to 1.5 cm of distance from the anal verge at the base of each hemorrhoidal node. The probe was driven through the incision in the submucosal tissue until reaching the area underneath the distal rectal mucosa. Then, ten to twelve effective pulses (adjusted to respective node dimensions) were fired. Half of them were fired in the submucosal tissue, the others in the intra-nodal compartment determining the shrinkage of the hemorrhoidal piles. The anal wounds were left open. At the end of the procedure an anal tampon was positioned.
223398423|NCT05770141|PROCEDURE|open surgical hemorrhoidectomy|The anodermal wedge was incised, eventually removing external fibrosis and/or skin tags when present. Upward dissection started at this level with en-bloc excision of mucosal and submucosal layers from the underlying internal anal sphincter up to the anorectal ring. A compressive haemostatic sponge was left in place for 12-24 hours.
223398424|NCT05331131|DRUG|Ketamine Topical|Ketamine hydrochloride in mouthwash form
223551014|NCT05701839|DEVICE|oxygen reserve index monitoring|In participants with oxygen reserve index monitoring, assist ventilation through face mask will be performed when oxygen reserve index drops to 0.1, it lasts for another 10 seconds when oxygen reserve index restores to 0.1.
223551015|NCT02524145|OTHER|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
224018701|NCT05515003|OTHER|Individualized patient education|"In the intervention group, patients will undergo a single, personalized education session led by the researcher, lasting 30 to 60 minutes. Identified knowledge gaps will be addressed through focused education, followed by interactive question-and-answer sessions covering fatigue, diarrhea/constipation, abdominal pain, mental health, nutrition, exercise, and sleep.~Follow-up calls will be conducted in the 1st, 2nd, and 3rd weeks post-education to monitor patient progress. Each call will assess general health status, symptom severity, and changes in bowel habits. Patients will be encouraged to review educational materials and ask questions, with appointment reminders provided during the 3rd week. These calls will each last approximately 10-15 minutes.~One month later, follow-up interviews will evaluate the education's impact using updated data collection tools, ensuring a thorough assessment of its effect on patient outcomes."
224018702|NCT01376427|DRUG|Dexamethasone|Dexamethasone
224018703|NCT01376427|DRUG|Methotrexate|Methotrexate
224018704|NCT01376427|DRUG|Vincristine|Vincristine
224129875|NCT03835000|PROCEDURE|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
224129876|NCT00775502|DRUG|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
224129877|NCT05386654|DEVICE|imPulse™ Tor System|Self-directed blood pressure data capture
224129878|NCT03830814|PROCEDURE|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
224129879|NCT05160558|DRUG|BIIB132|Administered as specified in the treatment arm
224129880|NCT05160558|DRUG|BIIB132-Matching Placebo|Administered as specified in the treatment arm
223398425|NCT04405492|DEVICE|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Evaluated point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Clinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different clinical samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
223398426|NCT04405492|DEVICE|Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|"After inclusion, demographic and medical data will be collected. Point-of-care devices will be tested immediately. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken (D0). A follow-up at D15, M1, M3, M6, M9 will be done. At each visit, participants will be asked information about their health status and their contacts with COVID-19 patients. Blood samples (capillary and venous), salivary sample and nasopharyngeal swab will be taken. Point-of-care devices will be tested during the visit.~Cinical samples will be stored in a dedicated biobank. Other SARS-CoV-2 diagnostic tests will be evaluated in the laboratory on the different samples retrieved from the biobank.~For all antigenic, molecular and serological tests evaluated, the reference method will be real-time RT-PCR as well as the result of medical imaging carried out as part of patient care."
223398427|NCT04405492|DEVICE|Capillary and salivary sampling|Two rapid tests (NG Biotech) allowing anti-SRAS-CoV-2 antibodies detection from a fingerpick blood sample and antigen detection from a salivary sample will be provided in 3 pharmacies of Ile de France. The inclusion of lay persons will be carried out in pharmacies by investigators of the recruiting centers (Bacteriology and Virology departments). After inclusion, one of the tests will be given to the participant for self-testing. After performing the test, the participant will complete a questionnaire to give a feedback on the test usability and the result obtained.
223731468|NCT02104713|BIOLOGICAL|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~1. Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~2. Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~3. Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~4. Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
224018705|NCT00768794|DIETARY_SUPPLEMENT|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
224018706|NCT00768794|DIETARY_SUPPLEMENT|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
224018707|NCT01981473|OTHER|no intervention|
224018708|NCT01981473|OTHER|no intervention|
224018709|NCT01981473|OTHER|no intervention|
224018710|NCT04374344|OTHER|Qualitative analysis of PPG, single-lead ECG, and 12-lead ECG measurements|Participants are instructed to qualitatively analyse PPG, single-lead ECG, and 12-lead ECG heart rhythm traces.
224018711|NCT01336803|DRUG|Feraheme|5 mg/kg by intravenous (IV) administration
224018712|NCT01336803|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
224018713|NCT00809601|DEVICE|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
224018714|NCT05251662|DRUG|Sintilimab|200mg IV d1 Q3W
224018715|NCT05251662|DRUG|IBI305|7.5mg/kg IV d1 Q3W
224129881|NCT00133900|PROCEDURE|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
224129882|NCT03924141|BEHAVIORAL|Training in de-escalation|Will receive one hour of de-escalation training
224129883|NCT05747131|BEHAVIORAL|Emotion Detectives In-Out|Emotion Detectives In-Out is a blended cognitive-behavioral intervention for children with emotional disorders aged between 7 to 12 years and their parents. It contains group sessions, online self-guided sessions and videoconference sessions. The groups will consist of about 5 to 7 children. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists with specific training in the program. The online sessions were developed by the research team and are completely self-guided. These sessions last approximately 45 minutes. Parents will be asked to participate in 2 face-to-face sessions, 4 videoconference sessions and 10 self-guided online sessions. It is a transdiagnostic and emotion-focused manualized cognitive-behavioral therapy designed to help children reduce the intensity and frequency of strong and aversive emotional experiences and to help parents reduce parental emotional behaviors.
224129884|NCT05747131|BEHAVIORAL|Coping Cat|Coping Cat is a cognitive behavioral therapy for children with anxiety aged between 7 to 13 years. Coping Cat consists of 16 weekly group sessions with the children (5 to 7 children per group) and 2 sessions with the parents. Face-to-face sessions have an expected duration of 90 minutes and will be implemented by clinical psychologists.
224129885|NCT00310570|DEVICE|Circumferential thermoplastic thimble splint|
224129886|NCT00310570|DEVICE|"dorsal aluminium foam Mexican Hat splint"|
224129887|NCT00310570|DEVICE|stack splint (control)|
224129888|NCT00352755|PROCEDURE|Surgical debulking with peritonectomy|
224129889|NCT00352755|DRUG|Intraperitoneal 5FU|
224018716|NCT05251662|DRUG|GEMOX|Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W
224018717|NCT03235960|DEVICE|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
224018718|NCT05423626|DEVICE|technologies of robotic mechanotherapy with FES|"Technologies of robotic mechanotherapy with FES (ExoAtlet I):~Simulator is designed for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* exoskeletal robotic device for moving the patient and forming a walking pattern~* a device for functional electrical stimulation (FES) of peripheral nerves controlling the muscles of the rehabilitated limb."
224018719|NCT05423626|DEVICE|biofeedback virtual reality technologies|"Brief information biofeedback virtual reality technologies:~ReviVR Multisensory Passive Rehabilitation Simulator is intended for rehabilitation in case of motor deficiency of the lower extremities and recovery of walking caused by stroke and other diseases and injuries of the central nervous system.~The main components of the simulator are:~* hardware and software complex, including a monitor and a personal computer;~* virtual reality helmet;~* sandals with air chambers."
224018720|NCT00452062|DRUG|Dexamethasone|
224018721|NCT03354091|DEVICE|FitBit Flex 2|Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
224129890|NCT00352755|DRUG|FOLFOX|
224129891|NCT05293652|OTHER|Iontophoresis|Hydrocortisone iontophoresis
224129892|NCT05293652|OTHER|Phonophoresis|Hydrocortisone Phonophoresis
224129893|NCT05293652|OTHER|traditional PT program|Ultrasound and deep friction massage
224129894|NCT04597281|OTHER|Lifestyle intervention|The intervention group, will receive education on Mediterranean lifestyle (Mediterranean diet and physical activity promotion), combined with the provision of extra-virgin olive oil and fish, in order to be consumed at least 3 times per week. Physical activity sessions with a physical activity monitor will also be offered for free to the children (2 sessions of 60 minutes of moderate-vigorous physical activity, per week)
224129895|NCT01278017|DRUG|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
223398428|NCT06574074|BEHAVIORAL|Gain-Life (Give informAtIoN to transform Life)|The Gain Life intervention comprises four components: (i) information about depression, (ii) awareness of available services, (iii) stigma reduction through dispelling myths and facts about depression, and (iv) a life transformation story. The first module aims to raise awareness about depression, with a particular focus on its causes, manifestations, and the potential negative consequences of untreated depression. The second component includes the types of services offered, costs, distance to service providers, and operating hours. The third component address stigma and misconceptions surrounding depression by addressing the root causes of stigma, dispelling myths, and providing accurate information about depression. The final module of the Gain Life intervention features recovery stories of individuals who have overcome depression. This module includes two 8-minute video stories of individuals who successfully recovered from depression.
223398429|NCT00760916|DRUG|UT-15C 1 mg|UT-15C 1 mg
223398430|NCT00760916|DRUG|UT-15C 0.25 mg|UT-15C 0.25 mg
223398431|NCT00760916|DRUG|UT-15C 5 mg|UT-15C 5 mg
223731469|NCT03038958|DRUG|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
223731470|NCT03038958|DRUG|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
224018722|NCT00514891|BIOLOGICAL|Vitamin A|The effect of vitamin A given with different vaccines will be studied
224018723|NCT04540393|BIOLOGICAL|AZD1222|Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) \> 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
224018724|NCT05901662|OTHER|Competence training program|A 3-hour weekly course training session in four consecutive weeks and provided services to community-dwelling older adults for two months.
224018725|NCT05901662|OTHER|Control|This group provided their routine services at senior activity centers.
224018726|NCT00220467|BEHAVIORAL|Aerobic exercise|
224129896|NCT04366752|OTHER|venous ultrasound|Venous ultrasound will be performed on patients once a week, every week from the day of admission in ICU until the day of patient discharge
224129897|NCT04366752|OTHER|blood sample|blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in ICU until the day of patient discharge
224129898|NCT01928121|OTHER|Care provided by AF expert program|
224129899|NCT04252612|DRUG|Pramlintide|SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
224129900|NCT00128700|DRUG|temozolomide|
224129901|NCT00128700|DRUG|vatalanib|
224018727|NCT04223427|PROCEDURE|Directional and single ring STN-DBS on gait|"Surgery for STN-DBS and STN-LFP recordings during gait initiation (M1): 15 days~* Surgery for STN-DBS electrodes implantation~  * Placement of stimulation electrodes according to the usual procedure, including a MRI with contrast product~ * Intraoperative electrophysiological recordings~ * Intraoperative clinical evaluation~ * Intraoperative identification of the electrodes and final position with X-Ray~ * Post-operative 3D helical TDM without iode injection~* STN-LFP recordings during gait initiation performed 3 to 5 days after surgery~* Placement of the neurostimulator (5 days after surgery)~* Acute testing of STN-DBS for first parameters setting programming~Follow-up of the patient with outpatient visits as usually performed in PD patients operated for STN-DBS with progressive adaptation of parameters settings using single-ring stimulation.~Directional and single ring STN-DBS on gait (M7)"
224129902|NCT00128700|PROCEDURE|adjuvant therapy|
224129903|NCT00128700|RADIATION|radiation therapy|
224129904|NCT06163443|DIETARY_SUPPLEMENT|Vitamin B|MTHFR, MTR, and MTRR polymorphysm based L-methylfolate (1 mg), P5P (pyridoxal-5-phosphate, 50 mg), and Methylcobalamin (500 mcg) prescription
224129905|NCT06163443|DIETARY_SUPPLEMENT|Placebo|MTHFR, MTR, and MTRR polymorphysm based placebo prescription
224129906|NCT01797510|BEHAVIORAL|Web Based Health Coaching|
224129907|NCT02429258|DRUG|Farxiga|Farxiga 10mg/day
224129908|NCT02429258|DRUG|Placebo|Placebo
224129909|NCT02429258|DRUG|Metformin|Metformin background therapy \>/= 1500mg/day
224129910|NCT02429258|DRUG|Insulin|Insulin \>/= 30 units
224129911|NCT06394518|DRUG|TNP-2092 for injection|The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)
223398432|NCT00760916|DRUG|Placebo|Placebo
224129912|NCT06394518|DRUG|placebo|The placebo for TNP-2092 active drug
224129913|NCT04825119|DRUG|Nusinersen|Patients with SMA who will be treated with nusinersen will be included.
224129914|NCT03440255|DEVICE|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
224018728|NCT01147601|DRUG|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
224129915|NCT02723266|BEHAVIORAL|STOPPING-GDM|Educational counseling and skills building Intervention
224129916|NCT02397694|DRUG|BIC|75 mg tablet administered orally once daily
224129917|NCT02397694|DRUG|F/TAF|200/25 mg FDC tablet administered orally once daily
224129918|NCT02397694|DRUG|DTG|50 mg tablet administered orally once daily
224129919|NCT02397694|DRUG|BIC Placebo|Tablet administered orally once daily
224129920|NCT02397694|DRUG|DTG Placebo|Tablet administered orally once daily
224129921|NCT02397694|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
224129922|NCT04274166|DRUG|secukinumab 150 mg (2 injections per dose|secukinumab 150 mg (2 injections per dose
224129923|NCT04478149|DEVICE|SafelyYou|technology to detect and prevent falls
223398433|NCT04751643|OTHER|Therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|"Therapeutic plasma exchange (TPE) ; 3 sessions in 3 consecutive days (Day 1 to Day 3) in intensive care unit in addition to usual treatments.~Plasma removed is replaced by thawed fresh frozen plasma. Plasma blood volume exchanged : 1.2 Apheresis type: centrifugation"
224018729|NCT01147601|DRUG|Control (placebo) group|Control (placebo) group
224018730|NCT01711723|DRUG|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
224018731|NCT01827618|DRUG|Rapamycin|
224018732|NCT02335528|BEHAVIORAL|SimCoach|
224018733|NCT05900687|BEHAVIORAL|Use of mHealth Question Prompt List app|mHealth Question Prompt List app that facilitates in asking questions with a physician during a consultation specific to GERD
224018734|NCT00545051|DRUG|Placebo|po monthly for 12 months
224018735|NCT00545051|DRUG|ibandronate|150mg po monthly for 12 months
224129924|NCT04478149|OTHER|Control|technology present but not activated
224129925|NCT00887146|DRUG|concomitant temozolomide (TMZ)|75 mg/m\^2, orally daily
223398434|NCT04751643|OTHER|Usual treatments in intensive care unit according to the current state of knowledge|Usual treatments of patients in intensive care unit with hyperinflammatory condition due to Covid-19 infection consist in supporting respiratory function, oxygen supplementation, non invasive ventilation, invasive ventilation, antibiotic, vasopressive support and corticosteroids (in absence of bacterial secondary infection)
223551016|NCT02524145|DRUG|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
223551017|NCT02524145|DRUG|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
224018736|NCT03404687|RADIATION|ultrasound|for assessment of adnexal masses size and pattern
224018737|NCT03404687|DIAGNOSTIC_TEST|cancer antigen 125 level|for prediction of malignancy
224018738|NCT03404687|RADIATION|Doppler|for detection of blood flow
224129926|NCT00887146|RADIATION|radiotherapy|
224129927|NCT00887146|DRUG|procarbazine|Days 8-21: 60 mg/m\^2 orally
224129928|NCT00887146|DRUG|adjuvant temozolomide (TMZ)|150 or 200 mg/m\^2 orally
224129929|NCT00887146|DRUG|CCNU|Day 1: 110 mg/m\^2 orally
224129930|NCT00887146|DRUG|vincristine|Days 8 and 29: 1.4 mg/m\^2 IV
224129931|NCT06019936|DRUG|MT2004 Capsule|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
224129932|NCT06019936|DRUG|MT2004 Capsule Placebo|The stratified randomization method will be used in this study. In treatment period, the participants will orally receive the MT2004 Capsule Placebo (BID) for 12 weeks with the dose level of 25mg. The adjustment of the dose level will base on the decesion of Independent Data Monitoring Board (IDMC). The highest dose will not exceed the 50mg BID.
224129933|NCT00078559|DRUG|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
224129934|NCT00078559|DRUG|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
224129935|NCT00078559|DRUG|Tacrolimus|2mg orally twice daily, on days 1-60
224129936|NCT00078559|PROCEDURE|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
224129937|NCT00078559|DRUG|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
224129938|NCT00078559|DRUG|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
224129939|NCT00078559|DRUG|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
224018739|NCT01241175|DRUG|Magnesium Sulfate|
224129940|NCT00078559|DRUG|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
224129941|NCT00078559|DRUG|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
224129942|NCT00078559|DRUG|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
224129943|NCT00078559|DRUG|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
224129944|NCT00078559|DRUG|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
224129945|NCT00078559|DRUG|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
224129946|NCT04765436|BIOLOGICAL|PTX-COVID19-B|Sterile solution for injection
224129947|NCT04765436|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224129948|NCT06239506|OTHER|no intervention|no intervention
224129949|NCT03617133|RADIATION|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of \~20% IB, \~50% IIB, \~20% IIIB and \~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
224129950|NCT03617133|RADIATION|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
224129951|NCT03617133|RADIATION|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
224129952|NCT03617133|RADIATION|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by \~50%.
224129953|NCT03617133|RADIATION|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
224138698|NCT01025817|DRUG|Everolimus and tacrolimus|"Everolimus:~* Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~* Dose: 1.5 mg per day~* Frequency: 0.75 mg twice daily~Tacrolimus:~* Dose adjusted to maintain specific blood levels"
223551018|NCT02524145|DRUG|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
223551019|NCT03631004|DRUG|Olanzapine|olanzapine 10 mg is given before surgery
224018740|NCT01241175|DRUG|normal saline|
224018741|NCT05963139|DRUG|Bupivacaine|US guided IPACK block will be performed with 10/15/20 ml %0,25 bupivacaine and adductor block will be performed with 15 ml %0,25 bupivacaine.
224018742|NCT05963139|DRUG|Morphine Sulfate|In this group,adductor block will be performed with 15 ml %0,25 bupivacaine using a 22 gauge 10 mm block needle and patients will be postoperatively administered patient controlled analgesia with morphine.
224018743|NCT01888900|DRUG|DUAL|Asunaprevir and Daclatsvir
224018744|NCT01888900|DRUG|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
224018745|NCT05686538|OTHER|iDLI|TCRab/CD19 depleted DLI 14 days after allogeneic stem cell transplantation. Targeted cell doses: \>10e7 NK cells/kg and \>10e6 TCRgd cells/kg
224018746|NCT01237275|DRUG|SSRI treated group|characterize in arm of a study (SSRI treated group)
224018747|NCT01123876|DRUG|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
224129954|NCT03617133|RADIATION|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
224018748|NCT05467189|DRUG|Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)|As part of routine treatment.
224018749|NCT04645667|DRUG|Tacrolimus|Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.
224018750|NCT00990977|BEHAVIORAL|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
224018751|NCT02234687|DRUG|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
224018752|NCT02234687|DRUG|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
224018753|NCT02234687|DRUG|Placebo|Placebo, one dose, one time
224018754|NCT03271021|DRUG|FMX101|FMX101, 4% minocycline foam
224018755|NCT03271021|DRUG|Vehicle Foam|Vehicle Foam
224018756|NCT04331145|DRUG|Ticagrelor 60mg|"Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months."
224018757|NCT02903264|OTHER|Gestational diabetes mellitus|
224018758|NCT01548378|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
224018759|NCT01548378|GENETIC|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
224018760|NCT01548378|GENETIC|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
223731471|NCT01474057|BEHAVIORAL|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
224018761|NCT01548378|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
224018762|NCT02192879|DEVICE|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
224018763|NCT02192879|DEVICE|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
224018764|NCT02192879|DRUG|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
223731472|NCT01474057|OTHER|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
224018765|NCT05117164|OTHER|enteral feeding as per predefined protocol|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
224018766|NCT03034538|DRUG|Zonegran|100mg
224018767|NCT03034538|DRUG|Zonegran|200mg
224296668|NCT02833545|DEVICE|Ozone gas|Injection of ozone gas intra articularly
224129955|NCT03617133|RADIATION|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or \>2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
224129956|NCT03617133|DRUG|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
224129957|NCT03617133|OTHER|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of \<=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (\>80%) will adhere to the \<=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
224129958|NCT01694420|DRUG|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
224018768|NCT00154765|DEVICE|sling suspension exercises|
224018769|NCT01847469|BEHAVIORAL|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
224018770|NCT01847469|DRUG|Zonisamide|
224018771|NCT01847469|DRUG|Placebo|
224018772|NCT04303767|DRUG|Casein phosphopeptide amorphous calcium phosphate|varnish containing calcium and phospate ions which act as a source for tooth remineralization
224018773|NCT04303767|PROCEDURE|Atraumatic restorative treatment|excavation of dental caries and restoring with light cured Glass Ionomer Restoration
224018774|NCT04318067|DRUG|Melatonin 3 mg|Melatonin 3 mg is given ones a day - at bedtimes for 6 month
224018775|NCT01478139|PROCEDURE|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
224018776|NCT01478139|PROCEDURE|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
224018777|NCT03912246|BIOLOGICAL|biological samples|collection of blood, urine, saliva, stool, skin and mouth swabs, tears
224129959|NCT04202718|DIAGNOSTIC_TEST|VitalPatch Device|The VitalPatch® is an IRB (791130) and FDA approved wearable device that allows for the constant monitoring of biometric measurements and may have utility in the health management of individuals at high-risk for poor health outcomes and in the detection or prevention of adverse events within settings where more traditional telemetry monitoring devices are not currently in use.
224129960|NCT03136133|DIETARY_SUPPLEMENT|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
224129961|NCT04859335|RADIATION|gammaknife radiosurgery|Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.
224129962|NCT03808038|OTHER|None- Observational Study|None- Observational Study
224129963|NCT05454202|DEVICE|ANI|Pain measurement during care procedures in palliative care
224018778|NCT03912246|PROCEDURE|lumbar puncture|collection of cerebrospinal fluid
224018779|NCT00287495|DRUG|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
224018780|NCT00180323|DEVICE|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
224018781|NCT01739816|BEHAVIORAL|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
224018782|NCT02734927|OTHER|realization of computerized exercises|
224018783|NCT02717403|BEHAVIORAL|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
224018784|NCT02717403|BEHAVIORAL|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
223551020|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with mechanical debridement|Non-surgical treatment of peri-implantitis with mechanical debridement .
224018785|NCT02717403|BEHAVIORAL|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
224018786|NCT02717403|BEHAVIORAL|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
224018787|NCT02257567|DRUG|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
224018788|NCT02257567|DRUG|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
224018789|NCT02257567|DRUG|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
224129964|NCT01689402|DEVICE|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
223551021|NCT05683405|PROCEDURE|Non-surgical treatment of peri-implantitis with air polishing|Non-surgical treatment of peri-implantitis with air polishing
224018790|NCT02257567|DRUG|Rituximab|Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
224018791|NCT02257567|DRUG|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
224018792|NCT02350777|PROCEDURE|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10\^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
224018793|NCT02350777|DEVICE|CliniMACS Cell Selection System|
224018794|NCT02115516|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
224018795|NCT02115516|BIOLOGICAL|0.9% Sodium Chloride (Placebo)|
224018796|NCT03018951|OTHER|Tool Development meeting|Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
224018797|NCT03018951|OTHER|Pilot Test 1 assessment session|Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.
224018798|NCT03018951|OTHER|Pilot Test 2 assessment session|Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
224018799|NCT04460274|OTHER|Model Building|Model building
224018800|NCT04460274|OTHER|Model validation|Model validation
224018801|NCT04016467|OTHER|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
224129965|NCT05996172|BEHAVIORAL|CAMS Single Session Consultation|CAMS is a clinical intervention designed to modify how clinicians engage, assess and plan treatment with suicidal patients. The foundational brief intervention that all participants will receive includes 1 90-minute session of CAMS assessment and planning interview with follow-up care navigation. CAMS is based around a model of STB which states that youth become suicidal in response to overwhelming pain, and treatment identifies and targets the drivers of suicide as the primary focus of assessment and intervention.
224129966|NCT05996172|BEHAVIORAL|Driver Focused Skills Training|The CAMS approach focuses on therapeutic assessment, collaborative identification and treatment of the patient-defined STB drivers (i.e., the problems that make suicide compelling to the patient) and utilizes problem-focused treatment sessions to address the drivers in order to reduce the wish to die. In the SOARS brief intervention model, specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality.
224138699|NCT01025817|DRUG|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
224138700|NCT01769261|OTHER|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
223551022|NCT03994887|DEVICE|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
223551023|NCT03424993|OTHER|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
223551024|NCT03424993|OTHER|Control|Participants will consume their routine habitual dietary sodium intake \> 3400mg per day with regular pre determined check in phone calls from a registered dietician.
223551025|NCT05798546|BIOLOGICAL|Neo-T|Patients will recive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
223551026|NCT05798546|DRUG|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
223551027|NCT05798546|DRUG|Fludarabine|Fludarabine 25 mg/m2/day iv on day-5 and day-4 for two days.
223551028|NCT05798546|DRUG|Interleukin-2|500,000IU/m2 SC,after each cell infusion,IL-2 will start within 24 hours and every 8-12 hours for up to 6 doses.
224129967|NCT05996172|BEHAVIORAL|Caregiver Skills Training|Caregivers will receive 3, 30-minute modules across 3 sessions that provide explicit coaching in several skills adapted from evidence-based treatments for youth suicidality including DBT and CBT.48,49 Module content will include 1) psychoeducation on suicidality and the escalation cycle and creation of a communication plan related to responding to youth suicidality (i.e., Crisis Escalation and Communication Plan); 2) positive communication and relationship building strategies including reflective listening, validation, and how to implement regular teen-directed one-on-one time; and 3) setting up behavioral expectations, house rules, and using positive reinforcement based contingency management in the home (i.e., targeted praise, using rewards to promote more effective behaviors). All modules will include didactic skill building, role-play of skill use with the therapist, and a check-in with the youth and youth therapist to collaboratively problem-solve barriers to use of skills.
223398435|NCT06648681|DRUG|Lemborexant 5 mg|"The intervention is the oral administration of a study drug containing lemborexant 5 mg daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge or until the first diagnosis of delirium, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, as defined by a Richards Campbell Sleep Score \<50 within 1 hour, another insomnia medication may be administered on participant request and clinician judgement.~If participants develop delirium, the study drug will be discontinued."
223398436|NCT06648681|DRUG|Control (placebo) group|"The control group will receive an oral placebo tablet daily between 2000h and 0000h for the first 7 days following when initiation criteria is met or until their hospital discharge, whichever occurs first.~Initiation criteria:~I. The participant has been extubated for at least 2 hours II. all other sedative medications have been discontinued for \>1 hour III. the participant has a Richmond Agitation and Sedation Scale (RASS) score of \>-1 or a Pasero Opioid-induced Sedation Scale (POSS) score \<3.~If satisfactory sleep is not achieved with the 5 mg dose of the study drug, as defined by a Richards Campbell Sleep Score \<50 within 1 hour, another insomnia medication may be administered on participant request and clinician judgement.~If participants develop delirium, the study drug will be discontinued."
223398437|NCT02129166|DRUG|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
223398438|NCT02129166|DRUG|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
223398439|NCT03924726|PROCEDURE|Micro-osteoperforation (MOP)|Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
223398440|NCT05998187|DRUG|intra-rectal botulinum toxin injections|Patients with fecal incontinence who have failed conservative treatments and are candidates for intra-rectal botulinum toxin injections.
223731473|NCT04433650|DEVICE|Pictorial support in person-centred care for children (PicPecc)|"Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments."
223731474|NCT04391127|DRUG|Hydroxychloroquine|Hydroxychloroquine: 400 mg PO every 12 hours for one day. Subsequently 200 mg every 12 hours per 4 more days.
224018802|NCT04016467|OTHER|Sham thoracic treatment|Hand placement on thorax without thrust.
224018803|NCT06032936|DRUG|BBP-398|BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
224129968|NCT05996172|BEHAVIORAL|Lethal Means Safety|The CAMS Therapeutic Assessment incorporates low levels of lethal means restriction (see above). Experimental Intervention Component 4 will provide a high level of lethal means restriction that includes the evaluation of the need for a lock box, the provision of a lock box if needed, structured process for evaluating home safety in each room of the house, specific directives to accomplish, follow up with the clinician, and problem-solving barriers to lethal means safety over two, 30-minute modules delivered across 2 sessions.
224129969|NCT05784337|DEVICE|Mi-thos® Transcatheter Mitral Valve Replacement System|Transcatheter Mitral Valve Replacement
224129970|NCT01796262|DIETARY_SUPPLEMENT|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
224129971|NCT01796262|DIETARY_SUPPLEMENT|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
224129972|NCT02168933|DEVICE|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
224129973|NCT02168933|DEVICE|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
224129974|NCT01483898|BIOLOGICAL|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
223398441|NCT00002772|BIOLOGICAL|filgrastim|
223398442|NCT00002772|DRUG|carboplatin|
223398443|NCT00002772|DRUG|carmustine|
223398444|NCT00002772|DRUG|cisplatin|
223398445|NCT00002772|DRUG|cyclophosphamide|
223398446|NCT00002772|DRUG|doxorubicin hydrochloride|
223398447|NCT00002772|DRUG|paclitaxel|
223398448|NCT00002772|DRUG|tamoxifen citrate|
223398449|NCT00002772|DRUG|thiotepa|
223398450|NCT00002772|PROCEDURE|autologous bone marrow transplantation|
223398451|NCT00002772|PROCEDURE|peripheral blood stem cell transplantation|
224018804|NCT06032936|DRUG|osimertinib|Osimertinib is a mutant-selective, third-generation EGFR inhibitor that targets both EGFR-activating mutations (e.g., exon 19 deletion and L858R) and EGFR-dependent on-target resistance mutation toward the 1st generation EGFR inhibitor (i.e., T790M). It is currently a first-line therapy for EGFR-mutant (EGFRmut) NSCLC, with average progression-free survival of approximately 19 months in previously untreated subjects.
224018805|NCT00944073|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
224018806|NCT02275975|DRUG|K-877|
224018807|NCT02275975|DRUG|Fluconazole|
224018808|NCT00504608|DRUG|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
224018809|NCT02712086|OTHER|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
224129975|NCT01483898|OTHER|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
223398452|NCT00002772|RADIATION|radiation therapy|
223398453|NCT05138705|BIOLOGICAL|Quadrivalent Influenza Virus Split Vaccine|0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
224018810|NCT03814031|OTHER|NO internvention|NO internvention
224018811|NCT01632982|BEHAVIORAL|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
224129976|NCT05632029|DEVICE|active laser|32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
223398454|NCT05795543|PROCEDURE|Subtalar Arthrodesis by Screws|Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern
223398455|NCT02594033|DRUG|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
223398456|NCT06188078|OTHER|Control|Babies in the control group will be fed only breast milk or formula, and a urine bag will be inserted after 25 minutes and they will be expected to urinate. The success of the transaction and the processing time will be recorded.
223551029|NCT00753727|DRUG|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
223551030|NCT00753727|RADIATION|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
223551031|NCT00371202|PROCEDURE|keratoplasty|
223551032|NCT01435473|PROCEDURE|Cardiac Surgery|
223731475|NCT04391127|DRUG|Ivermectin|Ivermectin 12 mg PO every 24 hours for one day (in case of weight less than 80 kg) or 18 mg PO every 24 hours for one day (in case of weight over 80 kg) Subsequently this group will take two tablets of placebo 12 hrs after ivermectin ingestion and then one tablet of placebo each 12 hrs per 4 more days.
223731476|NCT04391127|DRUG|Placebo|Two tablets of placebo PO every 12 hours for one day. Subsequently one tablet of placebo every 12 hours per 4 more days.
224129977|NCT05632029|DEVICE|sham laser|32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
224129978|NCT03121833|DRUG|Endostar|Recombinant Human Endostatin Injection
224129979|NCT03121833|DRUG|Placebo|500ml 0.9% sodium chloride
224129980|NCT03121833|DRUG|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
223731477|NCT01649661|BEHAVIORAL|questionnaire|
224018812|NCT01632982|BEHAVIORAL|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
224018813|NCT01632982|BEHAVIORAL|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
224018814|NCT05688345|DRUG|Remimazolam|The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
224018815|NCT05688345|DRUG|Propofol|Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
224129981|NCT04689594|COMBINATION_PRODUCT|CLS2702C/CLS2702D|"CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month; transplantation and assessment period, 6 months \[24 weeks\]); follow-up period, 6 months \[24 weeks\]) Other Names: •Human (autologous) oral mucosal cell sheet~•Transplantation device"
224138701|NCT01769261|OTHER|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
224018816|NCT05688345|DRUG|Dexmedetomidine|The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
224129982|NCT05915494|OTHER|intermittent pneumatic compression, physiotherapy, and walking|intermittent pneumatic compression group (n = 20 inhalation injury children). in this children group, intermittent pneumatic compression will be used to resist diaphragm muscle during 10-set-training session which will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). In other inhalation group, n =20, traditional physical therapy program will be handled only). Also, free walking for 30 minutes daily will be performed by children.
224129983|NCT05915494|OTHER|physiotherapy and walking|in this children group, n = 20, for 12 weeks, traditional physical therapy program (chest physical therapy, flexibility exercises, range of motion exercises) will be handled. Also, free walking for 30 minutes daily will be performed by children.
224129984|NCT01554839|BEHAVIORAL|"Family of Heroes"|One hour online educational tool
224129985|NCT01554839|BEHAVIORAL|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
224129986|NCT04977154|OTHER|Primary prevention|The primary prevention that the trainers put in place for the hockey players
224129987|NCT00554463|DRUG|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
224129988|NCT00554463|DRUG|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
224129989|NCT00554463|DRUG|Etoposide|Concurrent: 120 mg/m\^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m\^2, IV on days 43-45 and days 65-66.
223398457|NCT06188078|OTHER|The bladder stimulation technique|"Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. A urine bag will be inserted 25 minutes after the feeding.~The newborn will be held under the armpit by the nurse, male infants will be held with their legs hanging down, and female infants will be held in the hip flexion position.~Newborns with spontaneous voiding during the period from the beginning of the investigation procedure to positioning the newborn will be excluded from the study.~The bladder stimulation technique will be repeated sequentially for 3 minutes until voiding begins.The success of the transaction and the processing time will be recorded."
223398458|NCT06188078|OTHER|Bath|Newborns will be fed formula or pumped breast milk, depending on the baby's age and weight. Babies will be bathed under running water 20 minutes after feeding.The bathing process will take 4 minutes in total. After bath, a urine bag will be inserted at the 25th minute of feeding. The success of the transaction and the processing time will be recorded.
223551033|NCT03714984|OTHER|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
224018817|NCT03141723|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
224129990|NCT00554463|DRUG|Cisplatin|Concurrent: 60 mg/m\^2, IV on days 1 and 22. Adjuvant: 60 mg/m\^2, IV on days 43 and 64.
224129991|NCT00554463|RADIATION|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
223551034|NCT03714984|OTHER|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
223551035|NCT02552173|RADIATION|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
223551036|NCT04200794|BEHAVIORAL|musical instrumental training|Learning to play a string instrument in a group setting (school class)
224129992|NCT03863067|PROCEDURE|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
223551037|NCT04200794|BEHAVIORAL|sensitization to music|sensitization to music via listening, theory, moderate practice on small percussive instruments and choir singing in a group setting (school class)
223551038|NCT01465867|DIETARY_SUPPLEMENT|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
223551039|NCT01465867|OTHER|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
223551040|NCT01465867|OTHER|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~\+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
223551041|NCT01465867|OTHER|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~\+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
223551042|NCT00626782|DRUG|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
224018818|NCT03141723|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
224129993|NCT01480479|DRUG|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
224129994|NCT01480479|DRUG|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
224129995|NCT01480479|DRUG|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
224138702|NCT01769261|OTHER|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
224296669|NCT02833545|DRUG|Steroid injection|Injection of steroids (diprospan) intra articularly
224129996|NCT06194175|PROCEDURE|Bariatric surgery|"Participants whose application for bariatric surgery was accepted, regardless of the type of surgical intervention (e.g., sleeve gastrectomy, Roux-en-Y Gastric Bypass).~This longitudinal study includes five measurement times: before surgery and then, 6 months, one year, one and a half years and two years after surgery. At each measurement time, participants are asked to respond to a set of online questionnaires. Responses are anonymous."
224129997|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] with preservative|solution for intramuscular injection, 0.5 ml
224129998|NCT05152017|BIOLOGICAL|Flu-M Quadro [inactivated split influenza vaccine] without preservative|solution for intramuscular injection, 0.5 ml
224129999|NCT05152017|BIOLOGICAL|Placebo|solution for intramuscular injection, 0.5 ml
224018819|NCT03141723|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
224018820|NCT03141723|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost \[3 cents per bag\]
224018821|NCT04006054|DRUG|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
224018822|NCT04006054|DRUG|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
224018823|NCT01288521|DRUG|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
224018824|NCT01288521|DRUG|Tacrolimus alone, Then Tacrolimus + Ketoconazole|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
224018825|NCT01065844|DRUG|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
224018826|NCT06421610|DRUG|PITAC|Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor effect, respectively. Based on the available data and experience from 11 PITAC procedures at OPC, PITAC with cisplatin, oxaliplatin and doxorubicin for intrapleural administration is expected to be well tolerated with a minimal of nausea, subcutaneous emphysema and transient chest pains.
224130000|NCT05015166|BEHAVIORAL|Experimental: Internet delivered self-help program with therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises which a therapist gives feedback on.
224130001|NCT05015166|BEHAVIORAL|Internet delivered self-help program without therapist support|During 8 weeks of treatment participants are taught how emotional conflicts may underlie and perpetuate symptoms of social anxiety. They are also taught how to observe their own anxiety and emotional avoidance (i.e. defenses) and how to gradually approach previously warded off feelings. The final part of the program contains material on how one may express previously warded off emotions to improve important relationships. The treatment program consists of text, videos and a series of experiential exercises.
224130002|NCT00425711|DRUG|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
224130003|NCT05079867|DEVICE|Cochlear implantation|Electrode surgically implanted in patient's cochlea to improve hearing
224130004|NCT00728312|DRUG|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
223398459|NCT05994872|PROCEDURE|Reverse drilling technique|A standard hamstring autograft procedure was performed using reverse drilling technique to prepare bone tunnel.
223398460|NCT05994872|PROCEDURE|Traditional extraction drilling|A standard hamstring autograft procedure was performed using traditional extraction drilling to prepare bone tunnel.
224130005|NCT00728312|DRUG|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
224130006|NCT05484180|OTHER|training and counseling supported guided imagery application|After the preparation process, as a nursing attempt to the individuals in the experimental group; Training and consultancy supported guided imagery based on the health promotion model will be implemented. This initiative; It will take a total of 12 weeks, including 6 weeks of training program and 6 weeks of counseling program and guided imagery.
224130007|NCT05958758|DRUG|Psilocybin-assisted therapy within a community of practice model (group administered)|The community of practice is 10 weeks long, meeting virtually for 2 hours each week, in a structured process, run through the Roots to Thrive treatment program. The psilocybin-assited therapy sessions occur midway through the 10-week program.
224130008|NCT05066035|DRUG|Neostigmine|"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."
224296670|NCT04029311|DEVICE|Nuance Pro|Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
224296671|NCT04029311|DEVICE|autoPAP|autoPAP
224296672|NCT04029311|DEVICE|TAP PAP|TAP PAP
224296673|NCT01352130|DRUG|Ondansetron|Intravenous Ondansetron 8 mgs
224296674|NCT01352130|DRUG|Granisetron|Intravenous Granisetron 1 mgs
224296675|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|As a experimental vaccine for 6 months to 5 years old.
223398461|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) at 60 Hz|Bilateral subthalamic nucleus deep brain stimulation at 60 Hz
223398462|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) at 130 Hz|Bilateral subthalamic nucleus deep brain stimulation at 130 Hz
223398463|NCT02549859|DEVICE|Deep Brain Stimulation (DBS) Off (Sham)|Deep Brain Stimulation (DBS) Off (Sham)
223551043|NCT00626782|DRUG|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
224296676|NCT06314685|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 6-11 months and 12-23 months.
223731478|NCT03551054|BEHAVIORAL|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
223731479|NCT03551054|BEHAVIORAL|Health Education|
223731480|NCT02769455|OTHER|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
223731481|NCT02769455|OTHER|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
223731482|NCT01958320|OTHER|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
224296677|NCT06314685|BIOLOGICAL|Group ACYW135 Meningococcal Polysaccharide Vaccine|As a control vaccine for ages 2-5 years.
224018827|NCT03106597|DRUG|Manidipine 20mg|"After a 1\~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
224018828|NCT03106597|DRUG|Amlodipine 10mg|"After a 1\~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
224018829|NCT02819154|BEHAVIORAL|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :~* Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.~* Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)~* ADL: Assessment of independence in activities of daily life"
224018830|NCT02440009|DRUG|Itraconazole|Oral itraconazole 200 mg BD for 6 months
224296678|NCT00452517|PROCEDURE|Percutaneous Coronary Intervention|
224296679|NCT03623386|OTHER|PD neurofeedback|PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
224296680|NCT03623386|OTHER|PD control|PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
224296681|NCT05502692|BEHAVIORAL|CHARACTERISE|Cohort 1 Cohort 2
224296682|NCT03282630|PROCEDURE|Sphenopalatine ganglion acupuncture|"* active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~* sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
223398464|NCT06574581|BIOLOGICAL|ADSC01|The initial 3 subjects will receive low-dose AD-MSC (1x10E6 cells/kg) infusion therapy only once; if no adverse events after 4 weeks, the next 4-7 subjects will receive medium-dose AD-MSC (1x10E6 cells/kg) infusion therapy twice; if no adverse events after 4 weeks of the last infusion, the next 8-10 subjects will receive high-dose AD-MSC (1x10E6 cells/kg) infusion therapy three times.
223731483|NCT01958320|OTHER|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
223731484|NCT01958320|DRUG|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
223731485|NCT00722033|DRUG|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
223731486|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base and eugenol gum product|PARTICIPANTS WILL USE A EUGENOL BASED product PRIOR TO TOOTHBRUSHING
223731487|NCT06366568|DRUG|fluoride toothpaste containing 1450 ppm of MFP in a PCC base|toothbrushing 2x a day for 2 minutes each time
223731488|NCT00004860|DRUG|leucovorin calcium|
223398465|NCT01399775|PROCEDURE|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
223398466|NCT01399775|PROCEDURE|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
224130009|NCT05066035|DRUG|Sugammadex|The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.
223398467|NCT05080075|BIOLOGICAL|Platelet Rich Plasma Injection|Research participants own blood will be used to prepare the platelet rich plasma injectate, which will be injected into the affected knee using ultrasound guidance.
223398468|NCT03444428|OTHER|Non Invasive Ventilation|Assessments for those participants who are being set up onto NIV
224018831|NCT02440009|DRUG|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
224018832|NCT04985968|DRUG|Cobitolimod 250 mg|Rectal administration
224018833|NCT04985968|DRUG|Cobitolimod 500 mg|Rectal administration
224018834|NCT04985968|DRUG|Placebo|Rectal administration
224018835|NCT01863576|DIETARY_SUPPLEMENT|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
224018836|NCT01863576|DIETARY_SUPPLEMENT|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
224018837|NCT03614637|OTHER|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
224018838|NCT01580423|DRUG|aprepitant|125 mg capsule
224018839|NCT01580423|DRUG|placebo|capsule identical to aprepitant
224018840|NCT02013518|BEHAVIORAL|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
224018841|NCT05827432|DEVICE|Field-cycling imaging (FCI)|FCI scan
224018842|NCT00732225|DEVICE|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
224018843|NCT00732225|DEVICE|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
224018844|NCT00732225|DEVICE|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
224018845|NCT00732225|DEVICE|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
224018846|NCT00732225|DEVICE|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
223398469|NCT03444428|OTHER|Without Non Invasive Ventilation|Assessments for those participants who are not being set up onto NIV
223398470|NCT03070236|OTHER|Survey|Select questions will be ask in the survey
224018847|NCT01775280|RADIATION|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
224018848|NCT03830749|DRUG|Eltrombopag|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
224018849|NCT05663879|DRUG|ID120040002|Drug: ID120040002
224018850|NCT05663879|DRUG|Compound-X|Drug: Compound-X
224018851|NCT05663879|DRUG|Placebo comparator|Placebo comparator
223398471|NCT01710865|OTHER|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
223398472|NCT01710865|OTHER|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
224018852|NCT04913454|OTHER|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training|40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
224018853|NCT04913454|OTHER|Cognitive training|Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)
223398473|NCT02962583|OTHER|Weight loss|
223398474|NCT02962583|DRUG|Probiotic Formula|
223398475|NCT02962583|DRUG|Placebos|
223398476|NCT03173898|PROCEDURE|PDL anesthesia versus local infiltration|Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
223398477|NCT06338488|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
223398478|NCT06338488|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
223398479|NCT05035407|DRUG|IL-2 (Aldesleukin)|dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period beginning within 24 hours of cell infusion and continuing for up to four days (maximum 12 doses).
224018854|NCT01501760|DRUG|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
224018855|NCT01501760|DRUG|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
224018856|NCT00950274|DRUG|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
224130010|NCT02670915|DRUG|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
224130011|NCT02670915|DRUG|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
224130012|NCT02670915|DRUG|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
224130013|NCT01225367|DEVICE|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
224130014|NCT02022072|DEVICE|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
224296683|NCT02903992|RADIATION|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
223398480|NCT05035407|DRUG|Cyclophosphamide|30 mg/kg IV infusion over 1 hour (+ 10 min) Once daily x 2 doses (Days -6 and -5)
223398481|NCT05035407|BIOLOGICAL|KK-LC-1 TCR|1 x 108 transduced KK-LC-1 TCR T cells
223398482|NCT05035407|DRUG|Fludarabine|25 mg/m2 IV infusion over 30 minutes (+ 10 min) To be administered following completion of cyclophosphamide. Once daily x 5 doses (Days -6, -5, -4, -3, -2)
224018857|NCT00950274|DRUG|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
223398483|NCT05816239|PROCEDURE|Dual Energy CT|Patient will receive Dual Energy CT
223398484|NCT06265051|DRUG|Tirofiban|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
223398485|NCT06265051|DRUG|Saline placebo|After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.
223398486|NCT02820857|DRUG|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
223398487|NCT02820857|DRUG|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
224018858|NCT03213860|OTHER|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
224018859|NCT00164931|DRUG|Intravenous omeprazole infusion|
223398488|NCT05753618|DRUG|Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
223398489|NCT05753618|DRUG|Omission of Granulocyte Colony-Stimulating Factor (G-CSF)|Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
223398490|NCT06315205|DRUG|Letrozole LEBE 75 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 75 mg
223398491|NCT06315205|DRUG|Letrozole LEBE 150 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 150 mg
223398492|NCT06315205|DRUG|Letrozole LEBE 225 mg|14 oral doses of Femara 2.5 mg/daily + 28-days (at least) washout period + single IM injection of Letrozole LEBE 225mg
223398493|NCT01034878|DRUG|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
223398494|NCT00271193|BEHAVIORAL|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
223731489|NCT00004860|DRUG|tegafur-uracil|
224130015|NCT02573376|BEHAVIORAL|Directly Observed Therapy|
224130016|NCT02573376|BEHAVIORAL|Wirelessly Observed Therapy|
224130017|NCT01235169|DEVICE|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
224130018|NCT02807064|DRUG|Bifidobacteria|0.5 ml per os all days for 2 months
223398496|NCT03346096|DRUG|Thiotepa|fixed dose 5mg/kg on days -7-6
223398497|NCT02399137|DRUG|MM-141|
223398498|NCT02399137|DRUG|Placebo|
223398499|NCT02399137|DRUG|Gemcitabine|
223398500|NCT02399137|DRUG|Nab-Paclitaxel|
223398501|NCT01668615|DRUG|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
223398502|NCT03503604|BIOLOGICAL|hPV19 mAb|Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks
223398503|NCT03503604|BIOLOGICAL|hPV19 mAb|Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
223398504|NCT03503604|DRUG|5-Fluorouracil|400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
223398505|NCT03503604|DRUG|Oxaliplatin|IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
223398506|NCT03503604|DRUG|Leucovorin|IV infusion, 400 mg/m2 every 2 weeks
223398507|NCT03503604|DRUG|Paclitaxel|IV infusion, 175 mg/m2 every 3 weeks
223398508|NCT03503604|DRUG|Carboplatin|IV infusion, AUC=6 every 3 weeks
224018860|NCT00164931|PROCEDURE|Scheduled second endoscopy|
224130019|NCT02807064|DRUG|placebo|0,5 ml per os all days for 2 months
224130020|NCT03945032|OTHER|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
224130021|NCT02077985|BEHAVIORAL|Sensory Adapted Dental Environment|See study arm description.
224130022|NCT02963896|DRUG|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
224130023|NCT03725202|DRUG|Upadacitinib|Administered orally once a day
224296684|NCT05080426|BEHAVIORAL|Family Supportive Supervisor Training 2.0|FSST 2.0 is a workplace intervention package designed to increase supervisors' family and leave supportive behaviors and leave supportive behaviors. The package includes Workplace Assessment tool, 2 45-60 minute online training modules (family-supportive supervisor training and supervisors' leave supportive behavior training), a webinar, behavior training, and individualized feedback reports.
224296685|NCT03376230|OTHER|Collect of blood, urines, and intestinal biopsies|
224296686|NCT01327144|DRUG|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
223398509|NCT03503604|DRUG|Gemcitabine|IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
224018861|NCT02238574|PROCEDURE|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
224130024|NCT03725202|DRUG|Corticosteroid (CS)|At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD. The initial dose of prednisone or prednisolone was at the discretion of the investigator, based on disease severity and comorbid medical conditions, at a minimum of 20 mg QD at Baseline. At Baseline, if a participant was on a dose other than 20, 30, 40, 50, or 60 mg QD, the dose was rounded up or down, as clinically indicated per investigator discretion, to the nearest of these doses. Prednisone or prednisolone was tapered according to a predefined schedule over a 26- or 52-week period. Open-label prednisone or prednisolone was provided until the dose was tapered to 20 mg/day. Subsequently, blinded prednisone or prednisolone was provided for the remaining blinded taper regimen through Week 52.
224130025|NCT03725202|OTHER|Placebo|Administered orally once a day
223398510|NCT03503604|DRUG|Carboplatin|IV infusion, AUC=4 every 3 weeks
224018862|NCT02238574|OTHER|follow up|Intensified outpatient follow up (16 visits in 5 years)
224018863|NCT04618328|DRUG|all trans retinoic acid|ATRA is given concomitantly at a daily dose of 10 mg twice daily orally for 12 weeks
224018864|NCT05660239|OTHER|Community Intervention|To evaluate the impact of a community intervention in reducing epilepsy stigma in adolescents.
224018865|NCT02084056|DRUG|Linagliptin|Linagliptin
224018866|NCT02084056|DRUG|Metformin|Metformin
224018867|NCT02084056|DRUG|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
224018868|NCT01215201|PROCEDURE|Scaling and Root Planing|Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
224018869|NCT01215201|PROCEDURE|Diode Laser + Scaling and Root Planing|First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
224018870|NCT06532786|OTHER|Fractal Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, synchronizing each repetition with fractal external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
224018871|NCT06532786|OTHER|Isochronous Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) single in leg extension machine, synchronizing each repetition with isochronus external cues presented by a visual metronome. The rest between sets will be set at 2 minutes of rest between sets.
224018872|NCT06532786|OTHER|Self Paced|The intervention consists in a metronome-paced strength training session performed 3 times per week (with 48h of rest between sessions), during 4 weeks. Each session consists in 4 sets of 15 repetitions at 65% of the one-repetition maximal (1RM) in single leg extension machine, at their own self pace (with no metronome). The rest between sets will be set at 2 minutes of rest between sets.
224018873|NCT03695458|DEVICE|Phototherapy|The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
224018874|NCT01340677|DRUG|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
224018875|NCT01340677|DRUG|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
224018876|NCT01340677|DRUG|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
223731490|NCT01124136|DEVICE|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
223731491|NCT01124136|DRUG|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
224018877|NCT03299972|DIETARY_SUPPLEMENT|Whey Protein|25 g whey protein supplementation twice daily (breakfast and lunch)
223398511|NCT03503604|DRUG|Irinotecan|IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
223398512|NCT04278781|DRUG|AG-120|AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
224018878|NCT03299972|DIETARY_SUPPLEMENT|Control|23.75 g maltodextrin twice daily (breakfast and lunch)
224018879|NCT03299972|OTHER|Resistance Exercise|60 minutes of resistance exercise twice a week
223398513|NCT00690911|DRUG|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
224018880|NCT03819998|DIAGNOSTIC_TEST|measurement of Fetuin-A level in serum|Fetuin A level will be measured in blood of the PCOS women
224018881|NCT01865968|BIOLOGICAL|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
224018882|NCT01865968|BIOLOGICAL|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
224018883|NCT04159623|DEVICE|Belk Device|Knee exoskeleton with electrostimulation
224130026|NCT02557386|DRUG|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
224130027|NCT02557386|DRUG|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
224130028|NCT02557386|DRUG|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
223398514|NCT02353286|DEVICE|Endoscopic insertion of biodegradable biliary stent|Endoscopic insertion of biodegradable biliary stent
223398515|NCT06417190|DRUG|Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)|Single-arm, open-label
224130029|NCT02557386|DRUG|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
224018884|NCT04159623|OTHER|Standard Rehabilitative treatment|Use the standard rehabilitative treatment
224018885|NCT05792358|PROCEDURE|wet cupping therapy|wet cupping therapy will be applied to participants in this arm for three sessions once a month
224130030|NCT02557386|DRUG|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
224130031|NCT02557386|DRUG|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
224130032|NCT03130023|DEVICE|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
224130033|NCT03871140|OTHER|diagnosis|therre is no intervention diagnosis or treatment for patients
224130034|NCT01060735|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
224130035|NCT01247220|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
224018886|NCT03710668|RADIATION|MRI if indicated|MRI brain if indicated
224018887|NCT00350480|DRUG|Provera|
224018888|NCT00350480|DRUG|Combination Birth Control pills|
224018889|NCT06238518|PROCEDURE|Intravascular Lithotripsy|The size of the IVL balloon catheter is selected in a 1:1 ratio to the distal reference vessel diameter. The balloon catheter is then inflated to 4 atm, and 10 impulses are delivered. Subsequently, the balloon is inflated to 8 atm and then deflated to re-establish blood flow. Up to 100 impulses can be delivered, and the balloon can be repositioned within the lesion. In cases involving multiple lesions with different reference vessel diameters, various sizes of IVL balloons may be employed. If the IVL balloon catheter is unable to pass through the lesion, pre-dilatation can be performed using a smaller diameter noncompliant balloon or rotational atherectomy.
224018890|NCT06238518|PROCEDURE|Conventional lesion preparation strategy|Conventional lesion preparation strategy includes the use of Compliant, noncompliant, cutting, or scoring balloons, Excimer laser coronary atherectomy, or Rotational atherectomy at the discretion of the operator.
224130036|NCT01247220|PROCEDURE|Peripheral Laser|Angiography-directed peripheral laser
224130037|NCT06133647|PROCEDURE|managing Male Breast Cancer Patients at Methodist Health System|To determine the number of MBC cases as well as the demographics, characteristics, and outcomes of MBC patients at Methodist Health System (MHS).
224130038|NCT01328249|DRUG|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
224130039|NCT03226080|DRUG|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
224130040|NCT03226080|DRUG|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
224130041|NCT03226080|DRUG|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
224018891|NCT00190749|DRUG|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
224130042|NCT06054022|DEVICE|high flow nasal cannula|high flow nasal cannula provides heated and humidified gas to the airways via nasal prongs at a prescribed accurate fraction of inspired oxygen (FiO2) ranging from 0.21 to 1.0 and with a higher flow rate of up to 60 litres per minute
224130043|NCT06054022|DEVICE|nasoprong oxyen 2Litres per minute|nasoprong @L/min will deliver approximately a FiO2 of 0.3. subsequently, if incremental O2 is needed, patient will be provided with ventimask 40% and so forth
224130044|NCT01215734|BIOLOGICAL|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
224130045|NCT01215734|BIOLOGICAL|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
224018892|NCT00190749|DRUG|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
224018893|NCT02865837|OTHER|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
224018894|NCT04085185|DRUG|IBI110|Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
224130046|NCT02294409|BEHAVIORAL|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
224296687|NCT01327144|DRUG|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
224296688|NCT02636426|DRUG|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
224296689|NCT00002639|DRUG|chemotherapy|
224296690|NCT00002639|DRUG|suramin|
224296691|NCT01749917|OTHER|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
224296692|NCT01749917|OTHER|Control intervention|Active upper limb range of movement exercises for 15 minutes.
224296693|NCT05483595|DRUG|Chinese herbal medicine FYTF-919|Oral liquid 10ml
223398516|NCT02636218|DRUG|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
224130047|NCT02294409|BEHAVIORAL|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
224130048|NCT05476185|BEHAVIORAL|READY4Life Programming - classroom instruction|The intervention group receives 16 hours of classroom instruction.
224130049|NCT00623454|BEHAVIORAL|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
224130050|NCT03273205|DEVICE|Anodal tDCS|This group gets a real stimulation
223398517|NCT02636218|DRUG|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
223398518|NCT03505970|DIETARY_SUPPLEMENT|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
224018895|NCT04085185|DRUG|IBI110|IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
224018896|NCT04085185|DRUG|IBI110+ Sintilimab|"IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
224018897|NCT04085185|DRUG|IBI110+ Sintilimab|"IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
224018898|NCT01154010|DEVICE|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
224018899|NCT01154010|DEVICE|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
224018900|NCT00178100|BEHAVIORAL|Interpersonal Psychotherapy|
224018901|NCT00178100|DRUG|paroxetine|
224018902|NCT03743454|OTHER|No intervention|No intervention will be applied.
224018903|NCT04486326|DRUG|Crofelemer|Crofelemer
224018904|NCT04486326|DRUG|Placebo|placebo
224018905|NCT00125073|BEHAVIORAL|Postoperative nutritional counseling|
224018906|NCT00423631|BEHAVIORAL|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
224018907|NCT00423631|BEHAVIORAL|Standard Care|Standard care delivered by the primary care provider.
224018908|NCT04805229|OTHER|Retrospective analysis of opioid use after surgery|Retrospective analysis of opioid use after one of the following surgical procedure categories: laparoscopic cholecystectomy, laparoscopic appendectomy, minor hernia repair (including laparoscopic or open inguinal, femoral, umbilical, and epigastric hernia repair), open and laparoscopic ventral/incisional hernia repair, laparoscopic colectomy, open colectomy, vaginal hysterectomy, laparoscopic hysterectomy, and open abdominal hysterectomy.
224018909|NCT01425424|OTHER|Vitamin D supplementation|Vitamin D
224018910|NCT00320827|DRUG|CS-1008 (humanized anti-DR5 antibody)|
224018911|NCT00000473|BEHAVIORAL|dietary supplements|
224130051|NCT03273205|DEVICE|Sham tDCS|This group gets a sham stimulation
224296694|NCT05347381|DRUG|Selinexol and Dexamethasone|"Selinesol 20mg/tablet 60mg po qw first week, second week, biw third week, namely d1, d8, d15, d18.~Dexamethasone 0.75mg/tablet 1.5mg po bid d1-21;"
223398519|NCT03505970|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
223398520|NCT02790164|DRUG|Esmeron|Neuromuscular Blockade
223398521|NCT02790164|DRUG|Saline|Normal Saline
223398522|NCT01075438|BIOLOGICAL|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
223398523|NCT01075438|BIOLOGICAL|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
224018912|NCT00000473|DRUG|fatty acids, omega-3|
223398524|NCT00685217|PROCEDURE|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
223398525|NCT00685217|PROCEDURE|TVT (Gynecare)|Sling procedure for stress urinary incontinence
224018913|NCT00000473|BEHAVIORAL|diet, fat-restricted|
224018914|NCT02175251|PROCEDURE|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
224018915|NCT02175251|PROCEDURE|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
224018916|NCT02175251|PROCEDURE|Sham Comparator|10 session in 5 days with sham-controlled
224018917|NCT03095001|DRUG|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
224018918|NCT03095001|DRUG|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
224018919|NCT03095001|DRUG|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
224018920|NCT04664543|OTHER|Free diet|To follow the regular dietary habits with no restriction nor modification.
224018921|NCT04664543|OTHER|Three days low residue diet|To follow the three days before colonoscopy a diet with low content in fiber or residues.
224296695|NCT03768518|DIAGNOSTIC_TEST|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
224018922|NCT03814187|DRUG|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
224130052|NCT06254105|OTHER|HANDY programme|The manualised HANDY program includes descriptions of procedures related to the GP's evaluation of the client's need for referral to occupational therapy, procedures for referral from the GP to community-based occupational therapy, the group-based occupational therapy programme, and recommendations related to collaboration and communication between GP and occupational therapist.
224130053|NCT02551198|DRUG|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)\[PM 7-9, the day before colonoscopy\] + PEG-Asc(500mLx2 times q30min)\[AM 5-7, the day of colonoscopy\]"
224130054|NCT02551198|DRUG|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)\[PM 7-9, the day before colonoscopy\] + OSS(1b/177mL)\[AM 5-7, the day of colonoscopy\]
224130055|NCT05094921|OTHER|Aquatic Halliwick method|The Halliwick Concept is a detailed swimming programme based on the scientific principles of body mechanics and the properties of water intended to educate individuals with special needs to be water safe and to move independently in the water as much as possible (Lambeck \& Stanat 2001a).The programme consists of 10 specific progressive stages that are achieved without the use of floatation devices (Lambeck \& Stanat 2001b).
224130056|NCT05094921|PROCEDURE|Conventional physical therapy|Conventional selected exercise program for 60 minutes ,3 session per week for 3 successive months aiming to improve the motor functions of the children in form of: (1) Neuro-developmental technique, (2) Back and abdominal exercises to improve postural control and correct spinal deformities (3) improving postural responses, (4) Flexibility exercises of the soft tissue (5) Strengthening exercise (particularly knee extensors, hip abductors and the ankle dorsi-flexors muscles and (6) Improving standing, weight transfer and shift and finally facilitation of normal walking pattern .
224130057|NCT05130164|RADIATION|CBCT|Cone beam computed tomographic images selected for age estimation
224130058|NCT02260908|DRUG|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
224130059|NCT02260908|OTHER|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
224130060|NCT04913961|OTHER|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study
224130061|NCT04913961|OTHER|western medicine conventional therapy|The control group will get the western medicine conventional therapy with some additional tests for the study.
224130062|NCT01346371|DRUG|Refresh Tears 0.5% Lubricant Eye Drops|
224130063|NCT01346371|DRUG|Bepreve 1.5% Ophthalmic Solution|
224018923|NCT01326754|DRUG|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
224296696|NCT01445210|PROCEDURE|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
224296697|NCT01445210|PROCEDURE|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
224296698|NCT00105300|DRUG|Adalimumab|
224296699|NCT01996943|DRUG|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
224296700|NCT01996943|DRUG|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
223551044|NCT00100256|DRUG|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
223551045|NCT02183493|DRUG|BI 1356|
223551046|NCT00042952|DRUG|imatinib mesylate|Given orally
223551047|NCT00042952|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
223551048|NCT00042952|OTHER|laboratory biomarker analysis|Correlative studies
223551049|NCT02329977|OTHER|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
223551050|NCT00001033|DRUG|Ethambutol hydrochloride|
223551051|NCT00001033|DRUG|Isoniazid|
223551052|NCT00001033|DRUG|Pyrazinamide|
223551053|NCT00001033|DRUG|Pyridoxine hydrochloride|
224018924|NCT01326754|DRUG|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
224018925|NCT01326754|DRUG|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
224018926|NCT03231501|DRUG|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
224018927|NCT04236115|DRUG|Articaine 4%|Articaine 4% is dental local anaesthetic agent
224018928|NCT04236115|DRUG|Prilocain 3%|prilocaine is dental local anaesthetic agent
224130064|NCT00130806|DRUG|MK0478 (muraglitazar)|
224130065|NCT00130806|DRUG|Comparator: placebo|
224130066|NCT03056495|DRUG|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
224130067|NCT03710941|DRUG|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
224130068|NCT03710941|DRUG|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
224130069|NCT02701803|DEVICE|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
224296701|NCT06211608|DIAGNOSTIC_TEST|Two-dimensional and three-dimensional ultrasound of the female reproductive organ|Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer
224296702|NCT00719771|DEVICE|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
224296703|NCT04044911|BEHAVIORAL|Task model (CogWatch)|
224296704|NCT01468805|PROCEDURE|Cockroach mitigation/extermination|
224296705|NCT02438852|OTHER|Placebo|Given IV
224296706|NCT02438852|OTHER|Questionnaire Administration|Ancillary studies
224296707|NCT02438852|DRUG|Ropivacaine Hydrochloride|Given IV
224296708|NCT00863395|PROCEDURE|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
224130070|NCT05900193|DIETARY_SUPPLEMENT|TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test|Participants drank a glucose beverage for an oral glucose tolerance test along or with admixture with the TAS1R2/3 agonist sucralose or the TAS1R2/3 antagonist lactisole.
224130071|NCT05948371|OTHER|High Intensity interval Training|"High Intensity interval Training~* Frequency: 3-5 day per week~* Intensity: 60 to 80% of HRR. If atrial fibrillation present use RPE of 11-14 on a 6-20 scale.~* Time: total 30 mint time.6 mint exercise with high intensity and 2 mints of low intensity for active recovery until 30 mints complete.~Type: walking and static cycling. Walking~* Frequency 3 -5 days per week Intensity : use RPE of 11-14.~* Time:30 mint total. 6 mint walk with high intensity and 2 mint walk with low intensity until 30mints completed."
224296709|NCT05056883|DRUG|K-237 0.3-0.4mg/kg (once daily)|Ivermectin 3mg tablet
223398526|NCT05169190|PROCEDURE|Stellate Ganglion Block|After procedure informed consent, the procedure will be done using an ultrasound guided technique with a high frequency (6 to 13 MHz) linear transducer and confirmation of placement by fluoroscopy at sites who do this in clinical practice. The subject will be prepped and draped and placed in supine position in a suite with continuous vital sign monitoring and advanced cardiac life support equipment and IV placement. Local anesthesia with 1% buffered lidocaine will be achieved. After visualization of Chassaignac's tubercle of C6 is identified along with the carotid artery, internal jugular vein and longus colli and capitus muscles, a 25-gauge echo-enhanced needle will be inserted to inject anesthetic over 2 minutes anterior to the prevertebral fascia at the ventral aspect of the longus colli muscle, medial to Chassaignac's tubercle. The needle will be withdrawn and the subject will be monitored for a minimum of 30 minutes.
223398527|NCT05169190|PROCEDURE|Sham Stellate Ganglion Block|"The Sham protocol is identical to the SGB protocol except After needle tip confirmation and negative aspiration, normal saline (0.9%) + contrast (unlabeled to keep treater blinded) will be slowly injected over 2 minutes while closely monitoring the subject."
223398528|NCT01163201|BIOLOGICAL|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10\^6/kg, 10 x 10\^6/kg, 30 x 10\^6/kg, 100 x 10\^6/kg and 300 x 10\^6/kg)
224018929|NCT04236115|DRUG|Adrenalin|adrenaline is a vasoconstrictor
224018930|NCT04236115|DRUG|Felypressin|Felypressin is a vasoconstrictor
224018931|NCT03228602|OTHER|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
224018932|NCT01405365|DRUG|Metronidazole|Metronidazole 400mg TID for 10 days
224018933|NCT01405365|DRUG|Placebo|Placebo pill TID for 10 days
224018934|NCT01405365|PROCEDURE|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
224018935|NCT03060668|OTHER|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
224018936|NCT03060668|OTHER|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
224018937|NCT02673073|OTHER|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
224130072|NCT05948371|OTHER|Continuous Aerobic training|"Continuous Aerobic training~* Frequency : 3-5 days per week.~* Intensity:40-70% of HHR.~* Time : initial 5-10 then 10-15 until 30mints without rest interval~* Type : walking and static cycling."
224130073|NCT00982241|DIETARY_SUPPLEMENT|water|drinking water / normal dietary fluids for oral intake
224130074|NCT02330549|DRUG|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
223551054|NCT00001033|DRUG|Levofloxacin|
223551055|NCT00001033|DRUG|Rifampin|
224130075|NCT02330549|DRUG|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
224130076|NCT01393171|DEVICE|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
224130077|NCT01393171|PROCEDURE|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
224130078|NCT01393171|PROCEDURE|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
224130079|NCT02696915|DRUG|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
224130080|NCT02696915|DRUG|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
224130081|NCT02696915|DEVICE|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
224130082|NCT02696915|DRUG|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
224130083|NCT02456545|OTHER|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
224296710|NCT05056883|DRUG|Placebo 0.3-0.4mg/kg (once daily)|Placebo 3mg tablet
224296711|NCT04271735|DIETARY_SUPPLEMENT|Niagen|Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
224018938|NCT02673073|OTHER|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
224296712|NCT04271735|OTHER|Placebo|Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
224296713|NCT05417035|DRUG|Nebido|To evaluate if traditional treatment induces puberty similary to newer treatment
223551056|NCT06219967|DRUG|Activated Charcoal|Activated charcoal alone
224018939|NCT01714531|BEHAVIORAL|Telephone-Based Goal Management Training|
223398529|NCT01163201|BIOLOGICAL|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10\^6 cells/kg, 6 x 10\^6 cells/kg, 9 x 10\^6 cells/kg, 12 x 10\^6 cells/kg, and 15 x 10\^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
224130084|NCT02456545|OTHER|depressive syndrome|in- and outpatients with depressive syndrome
224130085|NCT02456545|OTHER|ADHD|in- and outpatients with ADHD
224130086|NCT02295735|DEVICE|Mepilex® Border Sacrum and Mepilex® Border Heel|
224130087|NCT05590741|BEHAVIORAL|Emotion Regulation Therapy via Telehealth|The initial stage of treatment focuses on psychoeducation about anxiety/depression, the impact that these cognitions/behaviors/emotions have on recent situations, and self-monitoring of worry/anxiety/depression. The sessions focus on the development of skills that help understand and regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining session focuses on terminating therapy, relapse prevention, and future goals. An Internet-based online platform will be used to promote engagement with and increase accessibility to between-session skills practice and treatment-related activities (e.g., self-monitoring, session summaries, worksheets).
224130088|NCT01490749|DRUG|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
224130089|NCT01490749|DRUG|XELOX|Patients will receive two cycles of XELOX.
224130090|NCT01490749|DRUG|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
224130091|NCT01490749|RADIATION|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
224130092|NCT01794819|DEVICE|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
224130093|NCT02052843|BEHAVIORAL|Steps to Success|
224130094|NCT02052843|BEHAVIORAL|Traditional Healthy Families|
224130095|NCT00495495|DEVICE|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
224130096|NCT00495495|DEVICE|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
224130097|NCT00239187|DRUG|E1 and G1|
223398530|NCT01163201|DRUG|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m\^2 over 1 hour
223398531|NCT01163201|DRUG|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
223551057|NCT06219967|DRUG|Activated Charcoal|Activated charcoal mixed with cola
223551058|NCT03491813|DEVICE|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
223551059|NCT03927547|DEVICE|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
223398532|NCT01163201|RADIATION|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
223398533|NCT01163201|BIOLOGICAL|Umbilical cord blood transplantation|Infusion given on day 0
223551060|NCT01732705|BEHAVIORAL|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
223551061|NCT03000556|DRUG|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
223398534|NCT00224367|BEHAVIORAL|time to first ambulation|
223398535|NCT01607450|DRUG|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
223398536|NCT01607450|DRUG|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
223398537|NCT01607450|DRUG|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
223551062|NCT02014259|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
223551063|NCT04438759|DEVICE|Oncomfort, commercially available Virtual Reality headset|Virtual Reality headset, consisting of headphones with smartphone glasses - see oncomfort.com/en, CE approval conform 93/42/EEC and 2007/47/EEC
223551064|NCT00868972|PROCEDURE|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
223551065|NCT00868972|DEVICE|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
224018940|NCT01714531|BEHAVIORAL|Telephone-Based Attention-Control|
224018941|NCT01598623|DRUG|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
224018942|NCT01598623|BEHAVIORAL|Social Skills Training|three times a week for three weeks.
224018943|NCT01598623|BEHAVIORAL|Placebo + Non Specific Counselling|
224018944|NCT00825825|DRUG|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
224018945|NCT00825825|DRUG|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
224018946|NCT00825825|DRUG|Placebo|Two weeks of placebo taken orally.
224018947|NCT02697292|DRUG|Intravenous Immunoglobulin|GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.
224018948|NCT02697292|DRUG|Placebos|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks \[week 3 and 5\] for 2 infusions.
223398538|NCT01607450|DRUG|Saline|Normal saline placebo infusion for 12 hours prior to PET study
223398539|NCT02308150|DEVICE|transcatheter aortic valve replacement|
223398540|NCT05293704|DRUG|Mizoribine|Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight \& gt At 50 kg, the dosage was 100 mg each time.
223398541|NCT04261946|OTHER|Quality of life survey|Unilateral patulous eustachian tube surgically treated were interviewed about our life's quality by a survey
224018949|NCT02697292|DRUG|Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
224018950|NCT02395146|PROCEDURE|Monitoring|intraoperative EBSLN monitoring
224130098|NCT06554834|PROCEDURE|CV4 + RR|Participants in this group will undergo three 30-minute sessions of osteopathic therapy. The intervention will involve a combination of the Fourth Ventricle Compression (CV4) technique and the Rib Raising (RR) technique. These sessions will be administered once per week over three consecutive weeks. The CV4 technique involves gentle compression of the occiput to influence cranial rhythmic impulses, while the RR technique involves mobilization of the rib cage to impact autonomic nervous system function.
223398542|NCT05807295|OTHER|Relaxation Program|The relaxation program will include progressive muscle relaxation exercises and videos for relaxation. Videos will be sent to caregivers' social media accounts. Initial applications will be implemented with caregivers. The relaxation program is planned to last 6 weeks. The program is planned to last 8 weeks in total, with pre-test and post-test applications.
223398543|NCT03003962|DRUG|Durvalumab (MEDI4736)|Anti-PD-L1 monoclonal Antibody monotherapy
223398544|NCT03003962|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
223398545|NCT03003962|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
223551066|NCT05924581|OTHER|Clinical assessment of spinal stiffness|"The clinical stiffness tests will be applied twice to the same patient by the same operator to verify intra-operator variability and twice by two operators at the same time to verify inter-operator variability.~The verification of diagnostic accuracy with respect to the radiographic reference standard will be carried out retrospectively by using the data already available and systematically collected in electronic format during medical visits and physiotherapy sessions."
224130099|NCT06554834|PROCEDURE|CV4|Participants in this group will receive three 30-minute sessions focusing solely on the Fourth Ventricle Compression (CV4) technique. The sessions will be conducted once per week for three consecutive weeks. The CV4 technique involves applying gentle pressure to the occiput with the goal of affecting cranial rhythmic impulses and promoting autonomic nervous system balance.
224130100|NCT06554834|DEVICE|sham ultrasound transducer|Participants in the placebo group will undergo three 30-minute sessions of a sham procedure using an ultrasound transducer. The transducer will be applied in a manner that mimics a therapeutic intervention, but without delivering any actual therapeutic effect. These sessions will also be conducted once per week for three consecutive weeks.
224130101|NCT06554834|DEVICE|Ultrasound Transducer Sham Procedure|Participants in the placebo group will undergo three 30-minute sessions using an ultrasound transducer as part of a sham procedure. The transducer will be applied to the body in a manner that mimics a therapeutic intervention, but it will not deliver any actual therapeutic effect. This procedure is designed to simulate the experience of receiving treatment without providing the physiological benefits associated with active ultrasound therapy. The sessions will be conducted once per week over three consecutive weeks.
223398546|NCT03003962|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
223398547|NCT03003962|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
224018951|NCT04041531|OTHER|blood sampling|venous blood sampling for oxygen affinity in-vitro test
223398548|NCT03003962|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
223398549|NCT02242812|DRUG|Telmisartan|
223398550|NCT02242812|DRUG|Metoprolol succinate|
223398551|NCT02242812|DRUG|Placebo|
223398552|NCT03103438|BIOLOGICAL|BCD-089|
223398553|NCT04261803|BIOLOGICAL|salivary sample|spit of saliva in a tube
223398554|NCT04261803|BIOLOGICAL|blood test|2millilitter blood test
223398555|NCT02521883|DEVICE|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
223398556|NCT02521883|DEVICE|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
223398557|NCT03802825|BEHAVIORAL|Diabetes Self-Management Training|The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contact with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
223398558|NCT03802825|OTHER|Standard Patient Navigation|Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
223398559|NCT01699009|OTHER|Plant based diet|
223398560|NCT01699009|OTHER|an unrestricted diet|
223398561|NCT00407134|PROCEDURE|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
223398562|NCT02926443|OTHER|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
223398563|NCT02926443|OTHER|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
224018952|NCT02328339|OTHER|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
224018953|NCT02328339|OTHER|Placebo|Placebo matched to tea with respect to taste and appearance
223398564|NCT05875402|DRUG|Chimeric antigen receptor T cell preparation targeting GCC|Chimeric antigen receptor T cell preparation targeting GCC
224018954|NCT03402815|DRUG|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
224018955|NCT00163397|DRUG|Ciclesonide|
224130102|NCT06554834|DEVICE|EEG/HRV/RSA (Electroencephalography, Heart Rate Variability, Respiratory Sinus Arrhythmia) Monitoring using Infiniti System|Participants in this study will undergo monitoring of Heart Rate Variability (HRV), and Respiratory Sinus Arrhythmia (RSA) using the Infiniti 8 measuring device. This system includes a ProComp Infiniti encoder, which is a versatile and advanced tool for capturing physiological signals, and the Biograph Infiniti software, which, along with the Physiology Suit, allows for detailed analysis and monitoring of autonomic nervous system function.
224130103|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
224130104|NCT01511835|DIETARY_SUPPLEMENT|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
224130105|NCT01511835|DRUG|Folic Acid|Folic Acid 400mcg; 1 cp/die
223398565|NCT04383561|OTHER|Non-surgical periodontal treatment|Scaling and root planing (SRP), in four clinical visits
223551067|NCT00439595|DEVICE|Hemocue 210 meter|Diagnostic device
223551068|NCT00439595|DEVICE|Copack HBCS|
224130106|NCT03061370|PROCEDURE|Esophagectomy or Gastrectomy|Surgical resection
224130107|NCT02536170|DRUG|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
223398566|NCT04383561|OTHER|Oral hygiene instructions|Oral hygiene instructions includes brushing with the modified Bass technique, interdental cleaning with dental floss and interdental brushes.
224296714|NCT00515541|DRUG|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
224296715|NCT05133791|DRUG|Annexin A5|Annexin A5 coupled to IRDye800CW as a potential treatment for RVO
223398567|NCT01468337|DRUG|Interferon gamma-1b|"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."
223398568|NCT00850057|BIOLOGICAL|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
223398569|NCT00000468|DRUG|tissue plasminogen activator|
223551069|NCT05070455|BIOLOGICAL|Asceniv™|Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
223551070|NCT03940846|DIAGNOSTIC_TEST|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
223551071|NCT00485563|BIOLOGICAL|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
224018956|NCT04160520|DRUG|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
224018957|NCT04160520|DRUG|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
224130108|NCT02536170|DRUG|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
224296716|NCT04353765|DRUG|Cabozantinib monotherapy|Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
224296717|NCT04353765|DRUG|All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC|As per authorized FDA label in advanced RCC
223398570|NCT00861640|DRUG|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
223398571|NCT00861640|DRUG|Oral Rabeprazole|Oral Rabeprazole 1 bid
223398572|NCT02162134|OTHER|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
223398573|NCT02162134|OTHER|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
224130109|NCT02536170|OTHER|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
224296718|NCT01463735|DIETARY_SUPPLEMENT|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
223398574|NCT02162134|DRUG|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
223398575|NCT02162134|DRUG|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
223398576|NCT02162134|DRUG|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
223398577|NCT02162134|DRUG|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
224018958|NCT04160520|DRUG|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
224018959|NCT04555031|DEVICE|kalifilcon A lenses|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
224018960|NCT04555031|DEVICE|Dalies Total 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
224130110|NCT01670656|DRUG|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
224130111|NCT01670656|DRUG|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
224130112|NCT01670656|DRUG|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
224130113|NCT01670656|DRUG|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
224130114|NCT04923919|DRUG|Anti-CLL1 CART cells|In this study, patients with acute myeloid leukemia were treated with autologous anti-CLL1 CAR T cells by a single, intravenous infusion.Blood and bone marrow were collected before and 12 months after infusion to detect the number and activity of CAR T cells, and to evaluate the efficacy of CAR T cells.
224130115|NCT00789958|DRUG|capecitabine|"Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
224130116|NCT00789958|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
223398578|NCT02162134|DRUG|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
224130117|NCT00789958|RADIATION|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
224130118|NCT00789958|RADIATION|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
224130119|NCT03331666|DRUG|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
223551072|NCT00485563|BIOLOGICAL|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
223398579|NCT02162134|DRUG|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
224018961|NCT04555031|DEVICE|Precision 1|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
224130120|NCT01063816|DRUG|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
224296719|NCT00746018|DEVICE|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
224296720|NCT06456736|OTHER|None, non-interventional study|Not applicable, non-interventional study
224018962|NCT04555031|DEVICE|Biotrue ONEday|Participant will wear the lens for each timepoint of 5, 10 and 15 minutes. A new lens will be inserted for each timepoint.
224018963|NCT00645307|DRUG|Extended Release OROS® Paliperidone|
224018964|NCT01398722|OTHER|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
224018965|NCT01398722|OTHER|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
224018966|NCT00804089|PROCEDURE|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
224018967|NCT00804089|PROCEDURE|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
224018968|NCT00804089|PROCEDURE|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
223398580|NCT02162134|DRUG|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
223398581|NCT02162134|DRUG|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
224018969|NCT02617680|DRUG|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
224018970|NCT02617680|DRUG|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
224130121|NCT01063816|DRUG|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
223398582|NCT01675934|PROCEDURE|Retroflexion with the adult colonoscope.|
223398583|NCT01675934|PROCEDURE|Retroflexion with the pediatric colonoscope.|
223398584|NCT02034734|DRUG|ASP3652|oral
223398585|NCT05339373|DRUG|Aceclofenac film-coated tablet 100 mg|Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
223551073|NCT00485563|DRUG|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
224018971|NCT02311868|DIETARY_SUPPLEMENT|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
223398586|NCT05339373|DRUG|Airtal® film-coated tablet 100 mg|"Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac."
224018972|NCT02311868|DIETARY_SUPPLEMENT|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
224018973|NCT01920854|DRUG|soluble ferric pyrophosphate|
224018974|NCT01920854|DRUG|Placebo|
224018975|NCT00000823|DRUG|Zidovudine|
224018976|NCT00000823|DRUG|Didanosine|
224018977|NCT00456677|DRUG|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
224018978|NCT00456677|DRUG|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
224018979|NCT02978573|DEVICE|Cartiva|Cartiva Synthetic Cartilage Implant
224018980|NCT05727969|DRUG|Dexmedetomidine|Dexmedetomidine at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
224018981|NCT05727969|DRUG|Lactated Ringer|Lactated ringer solution at a a rate of 0.5 μg/kg/hour will be infused with induction of anesthesia.
224018982|NCT05727969|PROCEDURE|Hypospadias|Children who will undergone hypospadias surgery
224018983|NCT05727969|DEVICE|Surgical pleth index|The SPI value will be measured using Datex-Ohmeda (GE Healthcare,Madison,WI 53707-7550 USA) monitoring system.
224018984|NCT04059003|DRUG|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
224018985|NCT00201747|DRUG|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
224018986|NCT00201747|DRUG|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
224018987|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
223398587|NCT03662087|COMBINATION_PRODUCT|HMA+DLI|HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
223398588|NCT03662087|BIOLOGICAL|DLI|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
223398589|NCT03908996|BEHAVIORAL|Profile by Sanford weight management plan|The purpose of this study is to observe weight changes in patients who completed endometrial cancer treatment, are clinically overweight, and who participate in the Profile by Sanford weight management program. An exploratory purpose is to examine the bacterial content of the patient's gut by examining stool specimens before starting the Profile by Sanford weight management program and after 6 months of participation in the Profile by Sanford weight management program.
223398590|NCT03428152|PROCEDURE|superior hypogastric block|superior hypogastric blockade during surgery
223398591|NCT00486746|BEHAVIORAL|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
223398592|NCT00486746|BEHAVIORAL|General information on healthy lifestyle habits|A single session
224018988|NCT00757783|DRUG|ritonavir|100 mg capsule or tablet once daily for 48 weeks
224018989|NCT00757783|DRUG|darunavir|800 mg tablet once daily for 48 weeks
224018990|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
224018991|NCT00757783|DRUG|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
224018992|NCT00757783|DRUG|atazanavir|300 mg capsule once daily for 48 weeks
224018993|NCT02293915|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
224018994|NCT02293915|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
224018995|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
224018996|NCT00666393|DRUG|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
224018997|NCT01303731|DRUG|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
224018998|NCT01303731|DRUG|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
224018999|NCT04680754|OTHER|head-neck stretching exercises|Neck stretching exercises which include basic movements of the neck are simple and effective exercises. Stretching exercises provide neuromuscular coordination and flexibility in patients by reducing pain and muscle weakness (Nakamura, Kodama, and Mukaino 2014). For this reason, neck stretching exercises should be performed in early postoperative period and a nurse should teach the patient the head-neck stretching exercises and ensure the patient's comfort after thyroidectomy.
224019000|NCT04806217|OTHER|Theory of Mind|Patients will be submitted to different neuropsychological tests used in routine and the non-verbal false belief task through in the Theory of Mind
224019001|NCT03433248|DRUG|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
224019002|NCT03433248|DRUG|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
224019003|NCT03433248|DRUG|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
224019004|NCT04044274|DEVICE|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
224019005|NCT04044274|DEVICE|Suction Cup|Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
224019006|NCT03032393|OTHER|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
224130122|NCT01063816|DRUG|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
224130123|NCT03510611|DRUG|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
223398593|NCT05002634|DIETARY_SUPPLEMENT|undenatured collagen type II (UCII) supplement|The undenatured collagen type II (UCII) supplement 40 mg will be taken once daily for 2 months.
224019007|NCT03032393|OTHER|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
224019008|NCT04320706|DRUG|Oral Oxytocin|Administration of oxytocin (24 international units) orally
223398594|NCT05377463|BEHAVIORAL|Peer support to promote uptake and persistence of medication assisted treatment (MAT)|Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.
224019009|NCT04320706|DRUG|Oral Placebo|Administration of placebo orally
224019010|NCT02881580|OTHER|No intervention : descriptive study|
224019011|NCT04937712|OTHER|RT-PCR SARS-COV2 in urine|proteinuria/renal phosphate leak/uricosuria/glycosuria/ aminoaciduria)
224019012|NCT03035968|OTHER|Vojta therapy|
224019013|NCT03035968|OTHER|conventional physiotherapy|
224019014|NCT04143074|BEHAVIORAL|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
224019015|NCT06531161|DRUG|Suxiao Jiuxin Pill|Suxiao Jiuxin Pill is a traditional Chinese medicine compound composed of Ligusticum Wallichii and Borneo Camphorwood, and its clinical safety has been confirmed. Traditional Chinese medicine theory believes that Suxiao Jiuxin Pill has the effects of promoting qi and blood circulation, removing blood stasis and relieving pain, which may help alleviate symptoms of AMS.
224019016|NCT06531161|DRUG|Placebo|Placebo is made of less than 10% of the amount of Suxiao Jiuxin Pill, with similar dosage, odor, and taste.
224130124|NCT01062620|DRUG|AXL1717|Phase I study with increasing dosage and treatment duration
224130125|NCT03285074|OTHER|No intervention|No intervention
224130126|NCT02024191|DIETARY_SUPPLEMENT|Glutamine|
224130127|NCT03583372|DRUG|Vibegron|single daily dose 75 mg
224130128|NCT03583372|DRUG|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
224130129|NCT03583372|DRUG|Tolterodine Tartrate ER|single daily dose of 4 mg
224130130|NCT01151046|DRUG|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
223551074|NCT00485563|DRUG|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
223551075|NCT00485563|DRUG|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
224019017|NCT00861523|DRUG|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
224019018|NCT02621671|BEHAVIORAL|Cognitive interview|
224019019|NCT02621671|OTHER|Survey|
224019020|NCT00496951|DEVICE|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
224019021|NCT01540864|DRUG|HPP404|Administered orally once daily for 26 weeks
224019022|NCT01540864|DRUG|Placebo|Administered orally once daily for 26 weeks
224019023|NCT02651597|OTHER|Oatmeal|
224019024|NCT05728320|DEVICE|Glucose monitoring with flash glucose monitor|All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.
224019025|NCT05316623|DEVICE|TENS|TENS (strong and comfortable intensity) applied during exercises in a telerehabilitation setting.
224019026|NCT03993951|DEVICE|ICT System|Update the Information and Communications Technology System in Family Service Agencies
224019027|NCT00051259|DRUG|Extended-Release Bupropion Hydrochloride|
224019028|NCT05189392|DEVICE|PICO|after hip arthroplasty application of visible opsite plaster on the surgical wound
224130131|NCT01151046|DRUG|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
224130132|NCT01151046|DRUG|Exemestane|Exemestane (25 mg) administered orally once per day
224130133|NCT02685891|OTHER|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
224130134|NCT02685891|OTHER|sham condition|in the sham condition, no tones will be played
224130135|NCT05078099|DEVICE|CureSight|Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
224130136|NCT03270553|DRUG|plazomicin|single intravenous dose
224130137|NCT03270553|DRUG|metformin|single oral dose
224130138|NCT02935699|DRUG|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
223551076|NCT01282385|DRUG|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
223551077|NCT01282385|DRUG|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
224296721|NCT04964518|DRUG|APG 2575 ramp up arm|APG2575 ramp up + Azacitidine
224019029|NCT02008877|DRUG|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
224019030|NCT02008877|DRUG|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
224130139|NCT02935699|DRUG|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
224130140|NCT05439460|DRUG|Phenylephrine|5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
224019031|NCT01992952|DRUG|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
224019032|NCT01992952|DRUG|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
224130141|NCT05439460|DRUG|Epinephrine|5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
224019033|NCT01992952|DRUG|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
224019034|NCT01740141|PROCEDURE|Plexus brachialis block|
224019035|NCT01049217|DRUG|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
224019036|NCT01049217|DRUG|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
224019037|NCT05922254|OTHER|Active cycle of breathing technique|The ACBT technique consists of three different breathing techniques: breathing control, thoracic expansion exercises and forced expiration technique. 1. Breathing Control 2. Thoracic Expansion Exercises: 3. Forced Expiration Technique:
224019038|NCT05922254|OTHER|Autogenic drainage|Huffing or blowing the nose helped to get rid of any secretions in the upper airways. The therapist was placed close enough to hear the subject's breathing while sitting to the side and slightly behind the patient. Both the physiotherapist's hand and the subject's hands were put on the subject's abdomen to feel the activity of the abdominal muscles. The patient inhaled slowly through the nose while using their diaphragm and holding their breath for two to three seconds to allow collateral ventilation to bring air behind their secretions. Exhalation was done through the mouth. The palm of the therapist placed on the upper chest felt the vibration of the mucous. Their positions were disclosed by the vibrations' frequency.
224019039|NCT02769403|DEVICE|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
224019040|NCT02769403|OTHER|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
224019041|NCT02769403|OTHER|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
224019042|NCT02769403|OTHER|Sick Days|Sick days during the 12 week study period will be collected
224019043|NCT02769403|OTHER|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) \& Physician Assistants \[advance practice clinicians\], and nurses) and will be linked to the consented research participant.
224019044|NCT01100827|OTHER|EGFR mutation status in patients|
224019045|NCT00856037|DRUG|Doxorubicin Hydrochloride|Given IV
224019046|NCT00856037|OTHER|Laboratory Biomarker Analysis|Correlative studies
224019047|NCT00856037|OTHER|Quality-of-Life Assessment|Ancillary studies
224019048|NCT00856037|DRUG|Topotecan Hydrochloride|Given PO
224130142|NCT05439460|DRUG|Arginine Vasopressin|5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
224130143|NCT05277688|DRUG|adjuvant concurrent chemoradiotherapy|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
224019049|NCT04463316|DIAGNOSTIC_TEST|Retrospective file studies|No intevention, retrospective file study: medical history, laboratory values, additional tests, physical and psychological complaints.
224130144|NCT05277688|RADIATION|radiotherapy|Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy.
224130145|NCT04317352|PROCEDURE|MVR|Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
224019051|NCT04422444|DIAGNOSTIC_TEST|Questionnaires|Participants will answer questionnaires in three areas: physical/functional, emotional status and cognitive status
224019052|NCT00834327|DRUG|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
224019053|NCT01038622|DRUG|L-arginine|5-day L-arginine treatment
224019054|NCT01038622|DRUG|placebo|5-day placebo treatment
223551078|NCT01251718|DRUG|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
223551079|NCT03773666|DRUG|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
224130146|NCT05837052|PROCEDURE|serplulimab plus chemotherapy as conversion treatment|Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.
224019055|NCT02412371|DRUG|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
224019056|NCT02412371|DRUG|Placebo for Veliparib|Capsule for oral administration
224130147|NCT05836519|OTHER|Survey Navicular Drop test, International Physical Activity Questionnaire (IPAQ) Short Form, 6-minute walk test, Foot Function Index (AFI), SF-36 quality of life questionnaire, Modified borg scale|Pulse oximetry will be used to measure the oxyhemoglobin value of the participants, and a sphygmomanometer will be used for blood pressure and heart rate measurements.
224296722|NCT03292536|DRUG|Merestinib|"\*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen\*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
224296723|NCT02040779|DRUG|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
224019057|NCT02412371|DRUG|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week (concurrent CRT) / cycle (consolidation)
224019058|NCT02412371|DRUG|Veliparib|Capsule for oral administration
224019059|NCT02412371|RADIATION|Radiotherapy|Radiation treatment with total dose of 60 - 63 Gy administered on Days 1 to 5 of each week for 7 weeks
224019060|NCT05134077|PROCEDURE|CT scan with contrast|CT scan with contrast is necessary to determine the position of renal cysts, their location, and size (determine volume of atrophic parenchyma will be calculated).
224019061|NCT05134077|RADIATION|Nephroscintigraphy|Nephroscintigraphy is necessary to determine the renal function
224019062|NCT03383822|DRUG|Intranasal insulin|Humalog lispro 40 IU intranasally
224019063|NCT03383822|DRUG|Intranasal placebo|Diluent intranasally
224019064|NCT05568732|PROCEDURE|Root coverage procedure will be done with VCMX|Scaling and root planing will be performed and after resolution of gingival inflammation, root coverage procedure will be done with VCMX using minimally invasive access technique.
224019065|NCT05568732|PROCEDURE|Root coverage procedure will be done with CTG|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
224019066|NCT00040027|DRUG|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
224019067|NCT00040027|DRUG|placebo + PEGinterferon alfa-2a|
224019068|NCT05096585|BEHAVIORAL|Delayed bedtime sleep restriction|bedtime 2 hr later than their normal bedtime
224019069|NCT05096585|BEHAVIORAL|Early wake sleep restriction|wake time 2 hr earlier than their normal wake time
224019070|NCT05470192|OTHER|Qigong exercise training|"Before and after the qigong exercises, 10-minute exercises will be done to stretch the large muscle groups for warm-up-cooling purposes.~The entire Baduanjin exercise consists of 8 postures:~preparation position~1. Raising arms with palms up,~2. Shooting arrows left and right like an archer in a semi-crouching position~3. Keeping one arm up~4. Looking back with trunk rotations in a semi-crouching position~5. Nodding the head and lowering the body to relieve stress,~6. Fisting and staring~7. Touching feet with hands touching back and legs~8. Raising and lowering heels"
224019071|NCT00682773|OTHER|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
224296724|NCT02040779|DRUG|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
224296725|NCT02040779|DRUG|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
224296726|NCT02132637|DRUG|Insulin Peglispro|Administered SQ
223551080|NCT03773666|DRUG|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
223551081|NCT00230776|DRUG|pregabalin|
224019072|NCT01270074|DRUG|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
224019073|NCT01270074|DRUG|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
224019074|NCT02217124|OTHER|dried apples|120 calories
224019075|NCT02217124|OTHER|muffin|120 calories
224019076|NCT01935973|OTHER|Laboratory Biomarker Analysis|Correlative studies
223551082|NCT00230776|DRUG|placebo|
224019077|NCT01935973|DRUG|Trametinib|Given PO
224019078|NCT01935973|DRUG|Uprosertib|Given PO
224019079|NCT02495792|DEVICE|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
224019080|NCT06444230|OTHER|Routine Physical therapy with Neurodevelopmental technique|participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks
224296727|NCT02132637|DRUG|Insulin Glargine|Administered SQ
224130148|NCT02025491|DRUG|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
224130149|NCT00272636|PROCEDURE|Radiofrequency catheter ablation|
224130150|NCT00272636|DRUG|Amiodarone and cardioversion|
224019081|NCT06444230|OTHER|Routine Physical therapy|participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo
224130151|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
224130152|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
224130153|NCT00967733|DIETARY_SUPPLEMENT|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
224130154|NCT00967733|DIETARY_SUPPLEMENT|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
224130155|NCT03585699|DIAGNOSTIC_TEST|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
224019082|NCT00000167|PROCEDURE|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
224130156|NCT03585699|DIAGNOSTIC_TEST|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
224130157|NCT06070740|DRUG|Durvalumab and Chemotherapy(oxaliplatin and capecitabine)|"Combination therapy includes:~Durvalumab: intravenous infusion with a fixed dose of 1500 mg on day 1, repeated every 3 weeks ± 3 days; Chemotherapy: Oxaliplatin 130mg/m2 intravenous infusion on day 1, capecitabine 1000mg/m2, orally, twice a day, from day 1 to day 14; repeated every 3 weeks ± 3 days;~After 6 cycles of combination therapy, maintain with durvalumab 1500 mg every 4 weeks ± 3 days for 2 years. Terminate the trial if confirmed disease progression, initiation of other anti-tumor therapy, unacceptable toxicity, withdrawal of informed consent or other reasons considered by the investigators."
224130158|NCT03145194|DRUG|Ticagrelor|2 x 90mg Ticagrelor tablets
224130159|NCT03145194|OTHER|Placebo|2 x matching placebo tablets
224296728|NCT05557032|PROCEDURE|cardiopulmonary resuscitation|pulse checks during cardiopulmonary resuscitation
224019083|NCT03796702|PROCEDURE|Deileostomy|Deileostomy
224019084|NCT01375088|DRUG|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
224296729|NCT00605761|DRUG|SB656933|50 mg treatment
223398595|NCT05377463|BEHAVIORAL|Behavioral Activation Treatment (BAT) to reduce depression|Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.
223398596|NCT05377463|BEHAVIORAL|No Intervention Components|Participants not assigned to components 1 and 2
224019085|NCT01449136|OTHER|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
224019086|NCT04654975|PROCEDURE|Esophagectomy for esophageal cancer|Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)
224019087|NCT04351568|OTHER|quesionnair|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality
224019088|NCT06502223|PROCEDURE|Pain Perception in Patients Undergoing Lumbar Disc Herniation Surgery|Analyze tryptophan metabolites (picolinic acid, 3- Hydroxykynurenine, anthranilic acid, kynurenine, quinolinic acid, kynurenic acid, xanthurenic acid). Concurrent VAS pain assessments were conducted, and correlations between tryptophan metabolites and VAS were evaluated.
224019089|NCT02053792|BIOLOGICAL|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
224019090|NCT05800418|DRUG|Ramucirumab Injection|Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
224019091|NCT05800418|DRUG|Ramucirumab Injection [Cyramza]|Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.
224130160|NCT03170583|DEVICE|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
224130161|NCT05597059|DIAGNOSTIC_TEST|Machine Learning Prediction|Machine Learning Prediction
224130162|NCT00357526|DRUG|OCPs|
224130163|NCT00357526|DEVICE|vaginal ring|
224130164|NCT05565976|DRUG|Dapagliflozin 10mg Tab|10mg PO q24h for 12 months
224130165|NCT05565976|DRUG|Statins (Cardiovascular Agents)|Atorvastatin 20mg PO q24h or Pravastatin 20mg PO q24h or Rosuvastatin 10mg PO q24h
224130166|NCT05565976|DRUG|Platelet Antiaggregant|Clopidogrel 75mg PO q24h or Acetylsalicylic acid 100mg PO q24h
224130167|NCT05565976|DRUG|Antidiabetic|Previously established medical treatment for type 2 diabetes will be maintained.
223398597|NCT04186793|BEHAVIORAL|Guided Grocery Shopping (GGS)|"The GGS group will be scheduled for 4 weekly sessions to co-shop with the study Registered Dietitian (RD) or clinical research coordinator (CRC). The primary shopper for the household will be required to attend all 4 sessions. The study participant will be required to attend at least 1 session and other family/household members will be encouraged to attend. The weekly sessions will take place at the family's primary grocery store. During each session, the RD will facilitate selection of low free sugar foods and guide the primary shopper on menu planning for a low free sugar diet. In the 4th session, the primary shopper will be asked to shop independently while being observed by the RD/CRC. Prior to checking out, the RD/CRC will approve and/or correct their shopping choices.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
224130168|NCT06556082|OTHER|Training|"Proprioceptive Neuromuscular Facilitation(PNF) based upper extremity strengthening exercises to increase upper extremity muscle strength will be applied to the participants in the training group 3 days a week for 8 weeks. PNF-based upper extremity strengthening exercises will be performed with an elastic resistive band using bilateral symmetrical PNF patterns of Flexion-Adduction-External Rotation-Extension-Abduction-Internal Rotation, Flexion-Abduction-External Rotation-Extension-Adduction-Internal Rotation on two different diagonals while individuals are in a sitting position in a supported chair. Core Stabilization Training will be continued for 8 weeks by increasing the difficulty and intensity of the exercises with limb movements and floor modifications after the amputee football players are taught how to find their neutral spine and how to maintain the position."
224130169|NCT06556082|OTHER|Control Group|The control group will be trained with isotonic strengthening exercises of upper extremity muscles with free weights and core stabilization training 3 days a week for 8 weeks. Isotonic exercises involve muscle contraction with movement, where the muscle length changes while maintaining constant tension. Free weights such as dumbells will be used in the implementation of the exercises. 1 Repetition Maximum (1RM) method will be used to determine the progression of the exercises.
224130170|NCT00312884|DEVICE|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
224130171|NCT01818050|OTHER|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
224019092|NCT00391131|DRUG|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
224019093|NCT00124293|DRUG|activated recombinant human factor VII|
224019094|NCT02813629|DEVICE|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
224019095|NCT01028027|DRUG|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
224019096|NCT01028027|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
224019097|NCT00701532|DRUG|Modafinil and PET (brain imaging)|duration 90 days
224130172|NCT04474899|DRUG|Moxonidine 0.4 MG|Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
224296730|NCT00605761|DRUG|SB656933|150 mg treatment
224296731|NCT05530187|DEVICE|Electronic Patient-reported Outcomes-based Model of Care|Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
223398598|NCT04186793|OTHER|Diet Provision Group|"This intervention will be applied to each family and will target foods and beverages that contain free sugars added to food by consumer, cook, or manufacturer, but preserve the family's other food group choices. During the 4 week long intervention, families will be able to choose meals from a list of foods similar to their usual diet. Groceries for each week will be delivered to the family. Each child will be provided with a lunch bag and instructed to bring lunch to school to maintain the study diet.~Families will have the opportunity to choose from a list of pre-prepared evening meals that are similar to what they consumed before study initiation but without free sugars. The families will be instructed to not eat any food outside of the assigned diet.~During the follow-up period, all participants will receive diet counseling/support calls from the dietitian and/or research team at Months 2, 4, and 6, following intervention completion."
224019098|NCT00701532|DRUG|placebo|duration 90 days
224019099|NCT01666938|OTHER|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
224019100|NCT01666938|OTHER|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
224019101|NCT02170818|OTHER|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
224019102|NCT02170818|OTHER|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
224296732|NCT06385561|DRUG|Tramadol|Tramadol is administered orally twice daily in a dosage of 100 mg (daily total of 200 mg)
224296733|NCT06385561|DRUG|Placebo|Placebo is administered orally twice daily.
224296734|NCT01030653|DRUG|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
224296735|NCT01030653|DRUG|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
223398599|NCT03173118|PROCEDURE|Endoscopic ultrasound elastography|Endoscopic ultrasound elastography performed on both groups of patients as per routine
224019103|NCT05955131|OTHER|Nutritional acute postprandial intervention: Control bread|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of control bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination
224019104|NCT05955131|OTHER|Nutritional acute postprandial intervention: bread suppelmented with Chilean beans|Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of supplemented bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination.
224019105|NCT05955131|OTHER|Nutritional acute postprandial intervention: Control glucose|Volunteers will arrive at fasting and capillary blood samples will be obtained before (0 min) and after the intake an amount of control glucose containing 50g of this monosscharide (10 min of intake), capillary slood will be also obtained at 15, 30, 60, 90 and 120 postprandial for glycemia determination.
224019106|NCT04062487|DEVICE|Mixed Reality technology|combine image with real body
224019107|NCT01027182|DRUG|Raltegravir|One 400mg tablet on day 1.
224019108|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
224019109|NCT01614431|DRUG|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
224019110|NCT03732599|PROCEDURE|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
224019111|NCT03732599|PROCEDURE|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
224019112|NCT03629639|DRUG|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
224019113|NCT04048421|PROCEDURE|hvNOTES radical colectomy|With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
223731492|NCT06346496|OTHER|Douyin Xinqing AI dialog bot|"Douyin Xinqing is an AI dialog bot. Users can start chatting with the Douyin companion bot by clicking on the Direct Message on the homepage of their accounts on Douyin app.~After a user sends any message to the Douyin companion bot, it first asks the user about his or her mood and guides him or her to start chatting around his or her emotions. According to the situation described by the user, the companion bot expresses empathy, asks questions to guide the user to talk, and provides suggestions at the appropriate time. Users can also record their emotions every day and look back regularly to observe changes in their inner feelings. In addition, the Douyin companion bot can also identify crisis situations such as suicide and severe mental illness and, if necessary, guide users to call the hotline to obtain professional psychological assistance."
224019114|NCT02336295|OTHER|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
224130173|NCT04474899|DRUG|Amlodipine 5mg|Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
224130174|NCT05801809|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
224296736|NCT00922272|DRUG|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
224296737|NCT00922272|DRUG|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
224296738|NCT04910516|BEHAVIORAL|Emotional Freedom Techniques (EFT)|It combines cognitive therapy, acceptance and stability therapy, and acupuncture point stimulation, and is based on manual stimulation of acupuncture points specific to Shiatsu or other acupressure massage fo
224296739|NCT02084602|DRUG|Artesunate|Orally administration of artesunate 4mg/Kg by three days
224296740|NCT02084602|DRUG|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
223398600|NCT06362746|DRUG|Non-immunogenic recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
223398601|NCT06362746|DRUG|Placebo|15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
224296741|NCT00929890|BEHAVIORAL|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
224296742|NCT00929890|BEHAVIORAL|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
224296743|NCT03609723|PROCEDURE|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
224019115|NCT02374892|BEHAVIORAL|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
223551083|NCT06155006|DIAGNOSTIC_TEST|rapid diagnostic test HCV Ab Plus Rapid test|The sample will be taken by trained personnel by capillary puncture of the thumb region of the fingers of the right hand, after asepsis and antisepsis, the rapid diagnostic test HCV Ab Plus Rapid test with INVIMA registration 2018RD-0002353-R1 will be used with operational characteristics that allow its performance at the point of care obtaining a result in 15 to 20 minutes. This rapid test for antibodies against HCV may be replaced by another test with similar operational characteristics (sensitivity and specificity).
223551084|NCT03551834|OTHER|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
223551085|NCT03551834|OTHER|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
224019116|NCT04213950|OTHER|Rabies PEP quality improvement bundle|The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
224019117|NCT05174936|BEHAVIORAL|PLWH intervention|The intervention curriculum will consist of five interactive training sessions (2 hours each) with four specific areas of resilience-building: individual assets (self-esteem, emotion regulation, positive future orientation), coping with infection/illness (medical adherence, stress reduction, healthy lifestyle, self-care), relationship building (family relationship, provider-patient relationship), and social support (identifying and seeking social support at various socioecological levels).
224019118|NCT05174936|BEHAVIORAL|Family member intervention|The intervention will consist of five sessions of group activities (2 hours each), with each session addressing one or more of the following areas: 1) HIV and ART knowledge; 2) support to strengthen the capacity of PLWH and their family members to adapt to living with HIV; 3) relationship building (family relationships, intimate relationships); 4) emotional and behavioral support for PLWH's adherence to care and treatment, including tailored coping or support strategies to address unique needs of some participants who may be more prone to HIV stigma (e.g., MSM and their family members); and 5) self-care.
224019119|NCT05174936|BEHAVIORAL|Healthcare provider intervention|The HCP intervention will adapt Popular Opinion Leaders (POL) principles by teaching participants skills for initiating/disseminating stigma reduction messages/practices to colleagues in the workplace. The HCP intervention will consist of four 1.5-hour sessions addressing the following topics: 1) universal HIV precautions and occupational safety (e.g., correctly knowing and practicing universal precautions and decreasing fear of PLWH); 2) intersecting stigma against PLWH (e.g., manifestations of intersecting stigma in clinical settings); 3) provider-patient relationship (e.g., reducing stigmatizing attitudes and behaviors toward PLWH, respecting patients' rights for privacy related to care and disclosure); 4) improving quality of patient care (e.g., increasing skills and comfort in working with PLWH); 5) building a supportive medical environment for better care of PLWH; and 6) skills and confidence in delivering stigma reduction messages to coworkers.
224019120|NCT00120211|RADIATION|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
224019121|NCT00120211|RADIATION|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
224019122|NCT03643393|PROCEDURE|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
224019123|NCT03149549|DRUG|CX-2009|CX-2009 Monotherapy
224019124|NCT02396628|DRUG|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
224019125|NCT02396628|DRUG|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
224130175|NCT05148585|OTHER|physiotherapy|Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.
224130176|NCT05148585|OTHER|activity-based therapy|patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
224130177|NCT00150670|DRUG|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
224130178|NCT00150670|DRUG|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
224296744|NCT05672823|PROCEDURE|Transcatheter Aortic Valve Implantation (TAVI)|Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
223551086|NCT04116177|DEVICE|Deep brain stimulation|Stimulation using VerciseTM system
223551087|NCT01663766|DRUG|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
223731493|NCT06346496|OTHER|Douyin Xinqing AI dialog bot for delayed intervention|Only the users in the waiting group had the task of waiting for the first four weeks, and they completed the three questionnaires at exactly the same point in time as those in the intervention group. Only after the first four weeks of intervention did the waiting group begin to receive the 28-day conversational intervention, and no additional questionnaires were interspersed in between.
224019126|NCT05977036|DEVICE|DiviTum® TKa assay|Will be utilized for determination of serum enzymatic activity of TK1 according to the manufacturer's instructions
224130179|NCT02919124|DEVICE|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
224130180|NCT06082752|PROCEDURE|Massage session|Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).
224130181|NCT02780765|DEVICE|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
224019127|NCT05977036|DRUG|CDK4/6 + Endocrine therapy|FDA-approved endocrine therapy plus CDK4/6 inhibitor. Ribociclib is the preferred CDK4/6 inhibitor. In the event this drug cannot be obtained due to insurance authorization or if there are specific side effect profile concerns from the treating physician, an alternative CDK4/6 inhibitor is allowed.
224019128|NCT00784940|DRUG|Anastrozole|1mg, orally, once daily
224019129|NCT00784940|DRUG|Tamoxifen|20mg, orally, once daily
224019130|NCT03799835|DRUG|BCG|Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
224019131|NCT03799835|DRUG|Atezolizumab|IV perfusion
224019132|NCT02909764|OTHER|Low Sodium Group|Breakfast Cereal
224019133|NCT02686827|DRUG|Paricalcitol|Vitamin D3 analogue
224130182|NCT02780765|DEVICE|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
224130183|NCT06195826|PROCEDURE|Gravity infusion|hysteroscopic myomectomy with the gravity infusion method
224130184|NCT06195826|PROCEDURE|Pump infusion|hysteroscopic myomectomy with the pump infusion method
224130185|NCT04899713|OTHER|Survival survey|To assess the effect of adding ZOMETA® to neoadjuvant chemotherapy on event-free survival.
224130186|NCT01006720|DRUG|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
224130187|NCT01006720|DRUG|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
224019134|NCT02686827|DRUG|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
224019135|NCT03183726|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention."
224019136|NCT04706559|DRUG|Probiotic sachet containing mixture of four strains i.e.Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii|Interventional group: Children with AD meeting eligibility criteria receiving probiotics and conventional treatment (topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients).
224019137|NCT04706559|DRUG|Conventional treatment|topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
224130188|NCT01006720|DRUG|Saline|Saline 0.9% (Saline)
224130189|NCT02916030|DIETARY_SUPPLEMENT|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
224130190|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
224130191|NCT05078580|DRUG|Iptacopan|Single oral dose of iptacopan 200 mg oral capsules
224130192|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
224130193|NCT05078580|DRUG|Iptacopan|Single oral dose of Iptacopan 200 mg oral capsules
224130194|NCT02945566|PROCEDURE|Standard TME surgery|Total mesorectal excision
224130195|NCT02945566|DRUG|Long course concurrent chemoradiation with capecitabine and radiotherapy|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
224130196|NCT02945566|RADIATION|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
224130197|NCT04868006|PROCEDURE|End-range Maitland mobilization + proprioception training|End-range Maitland mobilization performed in end position of internal rotation of the shoulder accompanied with 8--week long proprioception training
224130198|NCT04868006|PROCEDURE|Non end-range Maitland mobilization + proprioception training|Non end-range Maitland mobilization performed in loose position of the shoulder accompanied with 8--week long proprioception training
224130199|NCT04868006|PROCEDURE|Sham manual therapy technique + proprioception training|Placebo performed in loose position of the shoulder accompanied with 8--week long proprioception training
224130200|NCT00869765|DRUG|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
224130201|NCT00869765|DEVICE|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
224130202|NCT05306158|OTHER|CC+ECIG Condition|Participants will push CC- and ECIG-related pictures.
224130203|NCT05306158|OTHER|CC Condition|Participants will push CC-related images and push and pull ECIG-related pictures equally often.
224130204|NCT05306158|OTHER|Sham Condition|Participants will pull and push CC- and ECIG-related pictures equally often.
224130205|NCT03460067|RADIATION|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
224130206|NCT02052778|DRUG|Futibatinib|oral once daily dosing, 21-day cycle
224296745|NCT02384135|OTHER|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
223398602|NCT03396653|BEHAVIORAL|Peer-delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
223398603|NCT03396653|BEHAVIORAL|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
223551088|NCT04934839|DIAGNOSTIC_TEST|Test of standing balance (Equitest System). Test of walking in tied and split conditions on a force-sensorized split-belt treadmill.|"Tests of standing balance will be performed using the EquiTest System posturographic platform. Individuals will be requested to perform three tasks within the EquiTest battery: Sensory Organization test, Motor Control test backward/forward, Adaptation Test upward/downward.~Gait analysis will be performed on a force sensorized split-belt treadmill. Participants will walk at increasing velocities from 0.2 m/s to the highest sustainable velocity in tied-belt condition. Velocity will be increased by 0.1 m/s every 20 consecutive strides.~During gait analysis in the split-belt condition, participants will walk for 30 seconds with both belts at 0.4 m/s. Then, the velocity of the belt under the prosthetic limb will be increased to 1.2 m/s. After 6 minutes, the velocity of the faster belt will be restored at 0.4 m/s for 6 more minutes. Different combinations of velocities could be tested based on the patients' characteristics, maintaining a ratio of 3:1 between the velocities of the 2 belts."
223731494|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
224019138|NCT06610812|BEHAVIORAL|KETOGENIC MEDITERRANEAN diet|"each patient in group A was instructed briefly about the nature of the treatment regimen to gain the patient's confidence and cooperation. the patient will receive ketogenic Mediterranean diet with aerobic training program. The diet will contain approximately 9300 kJ accordingly, 37% as total fat, 18% as monounsaturated and 9% as saturated, and 33 g of fiber per day for 3 months with moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.~This procedure performed by using the components of ketogenic Mediterranean diet:~* Protein source: fatty fish, seafood, poultry, and eggs.~* Fats and oils: olive oil, avocado oil, and MCT oil (medium-chain triglycerides oil).~* Low carb vegetables: leafy greens, cruciferous vegetables, and other low carb veggies.~* Low carb fruits: avocados, olives, and tomato.~* Flavourings: paprika, cumin, cinnamon, coriander, anise, lemon or lime juice , mint , parsley and garlic ."
224019139|NCT06610812|BEHAVIORAL|hypo-caloric diet:|"Group (b) received low caloric balanced diet regimen with aerobic exercise for 3 months in the form of moderate aerobic exercises in the form of walking for 30 to 45 minutes a day, 3 times per week for 3 months. This group received a diet of 1800 calories or lower accordingly including a combination of two or more of the following in each meal: Non starchy vegetable: spinach, broccoli, cauliflower, peppers, mushrooms, tomatoes, etc.~Fruits: berries, apples bears, citrus fruits, melon, grapes bananas, etc. Starchy vegetables: potatoes peas, sweet potatoes etc. Fish and shellfish: salmon, clams, Trouts, oysters, etc. Eggs: whole eggs are more nutrient dense than white eggs. Poultry and meat: chicken turkey, beef, lamb, etc. Whole grains: oats, brown rice, farro etc. Legumes: chickpeas, kidney beans, lentils etc. Healthy fats: avocados, olive oil, unsweetened coconut, avocado oil. Dairy products: full-fat or reduced fat plain yogurt kefir and full-fat cheese."
224019140|NCT06610812|BEHAVIORAL|moderate aerobic exercises|moderate aerobic exercises in the form of walking from 30 to 45 minutes a day, 3 times per week for 3 months.
224019141|NCT06728501|BEHAVIORAL|Diabetes education|Patients receive 5 hours of diabetes education
224019142|NCT06729736|PROCEDURE|ERAS protocol|"The ERAS protocol includes:~* Pre-admission education, counselling and nutritional support~* Pre-induction oral analgesics~* Minimal fasting and carbohydrate loading~* Omission of nasogastric intubation~* Intra-operative abdominal nerve block~* Early mobilization~* Early oral nutrition and minimal IV fluids~* Multimodal opioid sparing analgesia~* Postoperative nausea and vomiting prophylaxis~* Early removal of urinary catheters"
224019143|NCT06906198|DRUG|VVN461 Ophthalmic Solution 1.0%|VVN461, 1.0%
224019144|NCT06906198|DRUG|VVN461 Ophthalmic Solution 0.5%|VVN461, 0.5%
224019145|NCT06906198|DRUG|VVN461 Ophthalmic Solution 0.25%|VVN461, 0.25%
224019146|NCT06906198|DRUG|VVN461 Ophthalmic Solution Placebo|Vehicle
224130207|NCT05811676|DRUG|Tranexamic acid|Intravenous administration of 10 mL (1 g of tranexamic acid), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
223398604|NCT02620293|DEVICE|Eczema Repair Emollient|An Emollient
224130208|NCT05811676|OTHER|0.9% sodium chloride|Intravenous administration of 10 mL placebo(0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
224130209|NCT04168593|PROCEDURE|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
224130210|NCT06422494|DRUG|hyperinsulinaemic hypoglycaemic clamp|Insulin will be infused at a continuous rate of 60 mU∙m-2 ∙min-1 and glucose 20% will be infused at a variable rate, aiming for stable plasma glucose levels of 5.0 mmol/L. The infusion rate of glucose will be adjusted by plasma glucose levels, measured at 5-minute intervals. After 30 minutes of stable euglycaemia, plasma glucose levels will be allowed to drop gradually to 2.8 mmol/L and will be maintained at this level for 60 minutes. Then, insulin infusion and adrenergic blockade infusions will be stopped. Glucose infusion will be increased and then tapered until stable euglycaemia plasma levels are reached.
223398605|NCT01293695|BEHAVIORAL|Hypnosis|Hypnosis relaxation in five weekly sessions
223398606|NCT01293695|OTHER|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
223398607|NCT00468819|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
224019147|NCT06907706|BEHAVIORAL|Physical Activity/Physical Functioning|"The physical activity portion of the program sessions focuses on teaching cognitive and behavioral skills to increase physical activity, including goalsetting, self-monitoring, overcoming barriers to physical activity, enlisting social support, and how to handle high risk situations that may result in relapses to a sedentary lifestyle. The health educator teaches participants about various forms of moderate intensity activity and has them practice brief bouts of activity of various types to ensure that they are doing the activities safely and correctly. Each week participants receive a handout to provide information about the behavioral skill taught that week. The program also provides activity trackers (week 1) and resistance bands (week 5). The pedometer assists participants in self-monitoring their activity, and the resistance bands provide a form of home-based exercise that participants can do even with limited space."
224019148|NCT06907706|BEHAVIORAL|Quality of Life|The survivorship portion of the program features a guided discussion on a different topic each session. The goals of the discussion are to present information about the topic, answer participants' questions about the topic, encourage participants to share solutions and ideas relevant to the topic with each other, and provide information on community resources participants can access if they require additional help. The health educator makes a brief presentation about the topic, answers questions, and then asks a series of 2-3 open-ended questions to facilitate discussion about the topic. At the end of the session, the health educator navigates participants who need additional information or service related to the topic to resources in the community.
224019149|NCT06329700|PROCEDURE|Hepatectomy|Surgical removal of a part of the liver
224019150|NCT06275308|OTHER|Ventilation manipulation|Effects of ventilation manipulation to achieve desired levels of end tidal carbon dioxide
224019151|NCT05404581|DEVICE|neuromodulation|"During the inpatient phase of the study, insular mapping will be performed with electrical stimulation to implanted SEEG electrodes in order to optimize the region for trial stimulation.~Subjects who respond favorably to trial stimulation in the hospital, will progress to the outpatient clinical trial phase where a DBS system will be implanted. All subjects will be blindly randomized to 3 months of stimulation and 3 months of sham stimulation."
224019152|NCT05176483|DRUG|Zanzalintinib|Zanzalintinib orally once daily (qd)
224019153|NCT05176483|DRUG|Nivolumab|360 mg IV infusion once every 3 weeks (q3w)
224019154|NCT05176483|DRUG|Ipilimumab|1 mg/kg IV infusion once every 3 weeks (q3w) for maximum of four doses
224019155|NCT05176483|DRUG|Nivolumab|3 mg/kg IV infusion once every 3 weeks (q3w) for first four doses, and then 480 mg IV infusion once every 4 weeks (q4w)
224019156|NCT05176483|DRUG|Nivolumab|480 mg IV infusion once every 4 weeks (q4w)
224019157|NCT05176483|DRUG|Nivolumab + Relatlimab|IV administration of nivolumab + relatlimab
224019158|NCT05992350|OTHER|Garmin physical activity tracker|The Garmin physical activity tracker is worn like a watch on the user. The tracker assesses several physical states, indicates when the body is at optimal time for activity or when the body needs to rest. The tracker also monitors stress levels and prompts relaxation when appropriate. The tracker sets goals with participants based on previously completed activity. The tracker alerts participants after a period of inactivity, encourages regular movement throughout the day, and decreases the amount of time spent sedentary.
224019159|NCT01783847|DRUG|Recombinant human erythropoietin (EPO)|4000 units per vial
224019160|NCT01783847|OTHER|Observation|Just observation
224019161|NCT01783847|DRUG|Methyl prednisolone|250 mg every 6 hours for 3 days.
224019162|NCT05615493|DEVICE|radial extracorporeal shock wave therapy|Radial extracorporeal shock wave therapy (r ESWT) will be applied by Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with a focusing depth of 4cm.The intensity will be 0.10 mJ to 0.3mJ/mm2 (2.5 bar), with frequency 4 Hz every week for one month .No anesthetic or analgesic drugs will be administered to patients during the therapy session
224019163|NCT05615493|DEVICE|sham radial extracorporeal shock wave therapy|Dornier AR2 machine (Dornier MedTech GmbH, Wessling, Germany) used under ultrasound guidance, at musculotendinous junction of medial and lateral head of the gastrocnemius for spastic calf (gastrocnemius muscle and the soleus) muscles . 1.500 pulses will be applied by an R20 probe with intensity of 0.10 mJ to 0.3mJ/mm2 (2.5 bar), \& frequency 4 Hz every week for one month without operating the machine .
223398608|NCT06891794|COMBINATION_PRODUCT|Menstrual disc with EMLA cream|Eutectic mixture of local anesthetics (EMLA) cream self-administered using a menstrual disc
223398609|NCT06891794|COMBINATION_PRODUCT|Cervical cap with EMLA cream|Eutectic mixture of local anesthetics (EMLA) cream self-administered using a menstrual disc
223398611|NCT07051798|OTHER|It is a qualitative type of study that will be conducted through face-to-face interviews.|It is a qualitative type of study that will be conducted through face-to-face interviews.
223398612|NCT06836141|DIAGNOSTIC_TEST|MRI|MRI during hospitalization and at 12 months post sICH
223398613|NCT06836141|DIAGNOSTIC_TEST|Blood Draw|Will occur during hospitalization and at 3, 6 and 12 months post sICH
223398614|NCT06836141|DIAGNOSTIC_TEST|Cognitive Test|Cognitive testing will occur during hospitalization and at 3, 6 and 12 months post sICH
223398615|NCT03666273|DRUG|Bapotulimab (BAY1905254)|Intravenous administration of escalating doses of Bapotulimab
223398616|NCT03666273|DRUG|Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)|Intravenous administration of Bapotulimab of fixed dose (expansion), and of a fixed dose of pembrolizumab
223398617|NCT04433754|OTHER|biochemical analysis|cRP, d-dimer levels and lymphocyte counts will be compared
223398618|NCT01005147|DRUG|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
223398619|NCT01005147|OTHER|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
223398620|NCT05333705|BIOLOGICAL|infusion of natural killer cells|Umbilical cord blood or donated peripheral blood of healthy donors were collected and NK cells were sorted and cultured. NK cell production will be infused after chemotherapy
223551089|NCT02023580|BEHAVIORAL|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility."
223551090|NCT03720626|DRUG|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
223551091|NCT00500357|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
223551092|NCT00003730|DRUG|fluorouracil|
224130211|NCT06422494|DRUG|Propranolol Hydrochloride 1 MG/ML|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
223731495|NCT03033381|DEVICE|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
223731496|NCT02668133|DIETARY_SUPPLEMENT|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
223731497|NCT02668133|DIETARY_SUPPLEMENT|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration \~500 FTU/20 g SQ-LNS) added during manufacturing
224019164|NCT01007643|OTHER|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
224019165|NCT01007643|OTHER|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
224019166|NCT02877238|DRUG|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
224130212|NCT06422494|DRUG|Phentolamine|When euglycaemic level of 5.0mmol/L is achieved we will start the adrenergic blockade which will continue throughout euglycaemia and hypoglycaemia. The participants will be administered a bolus of phentolamine of 70µg/kg followed by a dose of 7.0µg/kg/min continuous infusion and a bolus of propranolol of 14µg/kg followed by a dose of 1.4µg/kg/min.
224130213|NCT06159868|OTHER|Structured physiotherapy and rehabilitation|Comprehensive baseline assessment of function and nutrition using indirect calorimetry to identify nutritional requirements, to create and individualised plan for followed by daily targeted mobility retraining, exercise and nutrition.
224130214|NCT06159868|OTHER|Standard care|Standard ward based care provided by usual care teams
224130215|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
223551093|NCT00003730|DRUG|vinorelbine tartrate|
223551094|NCT03136224|DEVICE|Thermocautery|
223551095|NCT03136224|DEVICE|Plastic Clamping|
223551096|NCT03136224|DEVICE|Surgical Circumcision|
223551097|NCT00161616|DRUG|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
223551098|NCT01722526|DRUG|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
223731498|NCT02668133|DIETARY_SUPPLEMENT|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
223731499|NCT02668133|DIETARY_SUPPLEMENT|1 mg isotopically enriched 68Zn|administered intravenously
223731500|NCT05855850|DEVICE|Brainsway H4-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H4-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
223731501|NCT05855850|DEVICE|Brainsway H7-Coil Deep TMS System|Participants assigned to this arm will complete a 4-week course of 5 dTMS sessions per week (using the Brainsway H7-coil), for a total of 20 stimulation sessions. We will follow the standard Health Canada and FDA-approved protocol for depression: 18 Hz and 55 trains, for a total of 1980 pulses.
224019167|NCT02877238|DRUG|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
224130216|NCT01326052|PROCEDURE|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
224130217|NCT03533725|OTHER|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
224130218|NCT06350227|COMBINATION_PRODUCT|the absorbable hemostat and suture|The hemostasis method of the experimental group is to use both the absorbable hemostat and suture.
223551099|NCT00239993|DRUG|glatiramer acetate|
223551100|NCT00239993|PROCEDURE|Warm compress prior to injection of glatiramer acetate|
223551101|NCT00854724|DRUG|Puerarin, Placebo|400 mg, three times a day for 7 days
223551102|NCT00528502|DRUG|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
223551103|NCT00528502|DRUG|Saline|Saline is misted into the air that you breathe during the surgery.
223551104|NCT05714449|DEVICE|eye patch|standard amblyopia treatment
223551105|NCT05714449|DEVICE|After-image and MIT trainer|Common clinical training for foveation
223551106|NCT04897230|BEHAVIORAL|Hatha Yoga|The yoga poses were chosen for providing a restorative session based on their purported relationship to restorative effects to best promote cardiac autonomic recovery from mental stress.
224019168|NCT02480257|BEHAVIORAL|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
224019169|NCT02049164|DRUG|AR08|
223398621|NCT06859645|BEHAVIORAL|Motor imagey training|In addition to the prescribed exercise training, participants in the intervention group will follow a pre-designed motor imagery program for eight weeks, practicing daily. This program will include pre-recorded exercise videos specifically targeting the lumbar region, along with synchronized audio recordings providing detailed explanations of the exercises.
223398622|NCT06859645|BEHAVIORAL|Exercise training|All participants will receive telerehabilitation-based exercise training under the supervision of a physiotherapist for eight weeks. The exercise program will be delivered via videoconferencing as part of a telerehabilitation-based approach. The exercises, conducted under the physiotherapist's supervision, will consist of flexibility and stabilization exercises targeting the lumbar region and will last approximately 25 minutes per session.
224130219|NCT06350227|COMBINATION_PRODUCT|electrocoagulation and suture|The active comparator group is to use electrocoagulation and suture simultaneously to stop bleeding.
224130220|NCT06350227|OTHER|suture|The placebo comparator is to use suture alone for hemostasis.
224130221|NCT04451655|DRUG|Continuous insulin infusion|This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
224130222|NCT04004624|DEVICE|Ablation|Cardiac Ablation
224019170|NCT02049164|DRUG|Placebo|
224019171|NCT04595383|DEVICE|ti.care|Electronic platform for doctor-patient communication
224019172|NCT01377597|DRUG|ranibizumab|
224019173|NCT05448612|OTHER|Active Release Technique and muscle energy technique|74 participants divided into two groups and 37 in each group.
223551107|NCT04897230|BEHAVIORAL|Video Watching|The video was about the history of the Earth which encompasses the development of the planet Earth from its formation to the present day.
223551108|NCT04207411|DRUG|Bupivacaine|Injection of anesthetics blocks once a week during 4 weeks.
224130223|NCT02131948|DRUG|Intranasal insulin|Intranasal spray
223398623|NCT06877546|DEVICE|Lumoral treatment|"Lumoral® Treatment devices are handed over to study participants on the first visit. The treatment is performed first at the clinic under supervision by the researchers. Treatment is then repeated at home twice a week for 12 weeks.~The treatment is started by dissolving one 7 mg Lumorinse® oral tablet in 30 ml amount of pure water. The tablet dissolves in water in one minute, after which the mouthwash is poured into the mouth and swished for 60 seconds. The indocyanine green in the mouthwash adheres to the plaque surface in the teeth and gum line. The mouthwash is then spat out and the mouthpiece of the Lumoral® Treatment device is inserted into the mouth and a light is activated. After 10 minutes, the device turns itself off, after which the mouthpiece is removed from the mouth. Normal oral hygiene routines will then be performed."
224130224|NCT02131948|DRUG|Intranasal placebo|Intranasal spray
224296746|NCT03717714|DIETARY_SUPPLEMENT|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
224296747|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
224296748|NCT03717714|DIETARY_SUPPLEMENT|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
223398624|NCT00651274|DRUG|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
223551109|NCT04207411|DRUG|Lidocaine|Injection of anesthetics blocks once a week during 4 weeks.
223551110|NCT02141633|PROCEDURE|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
223551111|NCT02141633|PROCEDURE|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
223551112|NCT02141633|DRUG|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
224019174|NCT02675868|DRUG|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
224019175|NCT02675868|DRUG|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
224019176|NCT02675868|DRUG|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
224019177|NCT02675868|DRUG|Placebo|NaCl 0.9% infusion
224019178|NCT04121494|BIOLOGICAL|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
224019179|NCT04121494|BIOLOGICAL|ChadOx1 85A - IM|Intramuscular administration
224019180|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
224019181|NCT00153062|DRUG|Aggrenox|25mg aspirin, 200 mg dipyridamole
224019182|NCT00153062|DRUG|Clopidogrel placebo|placebo
224019183|NCT00153062|DRUG|Clopidogrel placebo|placebo
224296749|NCT02588950|DRUG|U-500R|
223398625|NCT00651274|DRUG|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
223398626|NCT04616612|BEHAVIORAL|SystemCHANGE (TM)|Participants randomized to the refined SystemCHANGE™ intervention will receive 7 personalized sessions with a nurse-interventionist (session 1 virtual face-to-face, sessions 2-7 via phone) and weekly feedback MMS message reports delivered to mobile phones.
224019184|NCT00153062|DRUG|Micardis|80 mg micardis
223398627|NCT04616612|OTHER|Attention Control|Participants randomized to attention control will receive nurse-led kidney disease self-care education based on materials developed by The National Institute of Diabetes and Digestive and Kidney Diseases and The National Kidney Foundation. Similar to the intervention, participants will receive one virtual visit from the nurse-interventionist and 6 phone calls (weeks 2, 3, 4, 5, 6 and 7) and weekly educational MMS messages delivered by mobile phone.
223398628|NCT00830973|OTHER|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
223398629|NCT00830973|OTHER|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
223398630|NCT03204682|DEVICE|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
223398631|NCT02912182|DRUG|Betamethasone|Betamethasone intravenous
223398632|NCT02912182|DRUG|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
223398633|NCT02912182|DRUG|Prednisolone|Oral tablets
223398634|NCT04376931|DRUG|Intravenous Solution|Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
223398635|NCT06737653|DEVICE|Gel containing postbiotics, lactoferrin, aloe barbadensis leaf juice powder and sodium hyaluronate|The gel will be applied until the wound is filled with the gel, which will be left undisturbed for 5 min.
223398636|NCT06737653|DEVICE|Placebo gel|The gel will be applied until the wound is filled with the gel, which will be left undisturbed for 5 min.
223398637|NCT02690038|DRUG|Intravenous immunoglobulin (IVIG)|"Baseline Ig \< 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
223398638|NCT02690038|DRUG|Normal Saline|"Baseline Ig \< 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig \> or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
223398639|NCT03203200|BEHAVIORAL|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
224019185|NCT00153062|DRUG|Micardis|80 mg micardis
224019186|NCT00153062|DRUG|Aggrenox placebo|placebo
223551113|NCT02141633|DRUG|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
223551114|NCT02426567|OTHER|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
223551115|NCT02426567|OTHER|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
223551116|NCT03792438|DIAGNOSTIC_TEST|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
224019187|NCT00153062|DRUG|Aggrenox placebo|placebo
224019188|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
224019189|NCT00153062|DRUG|Clopidogrel|75 mg clopidogrel
223398640|NCT06891612|BEHAVIORAL|Cognitive Assessments|Cognitive Assessments
223398641|NCT06891612|DEVICE|Eye-tracking|measurement of the points of gaze
223398642|NCT06891612|DEVICE|Electroencephalography (EEG)|Electrophysiological monitoring method to record electrical activity of the brain
223398643|NCT06891612|DEVICE|Electrocardiography (ECG)|measurement of the electrical activity of the heart
223398644|NCT05451628|DEVICE|Default CI fitting|Programming of cochlear implant speech processor according to standard clinical care
223398645|NCT05451628|DEVICE|Anatomy-based CI fitting|Programming of cochlear implant speech processor with anatomy-based fitting
223398646|NCT05134311|DEVICE|PIUR tUS Imaging System|PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging.
223398647|NCT06741553|DRUG|Lecanemab 10 mg/kg|Lecanemab was administered 10mg/kg every two weeks.
223398648|NCT02988128|DEVICE|Treatment for intracranial aneurysms|Embolization of aneurysms
223398649|NCT02988128|DEVICE|Treatment for Acute Ischemic Stroke|Revascularization of an intracranial blood vessel
223398650|NCT03481582|DRUG|Nitroglycerin|(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.
223551117|NCT00565149|BEHAVIORAL|PROOF|dietary overfeeding with high, low or normal protein content
223551118|NCT03625778|DRUG|MEDI0382|MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
223551119|NCT03625778|DRUG|Placebo|Placebo will be administered subcutaneously daily according to the Placebo cohorts.
223551120|NCT00263042|DRUG|Rimonabant|Tablet, oral administration
224019190|NCT00153062|DRUG|Micardis placebo|placebo
224019191|NCT00153062|DRUG|Micardis placebo|placebo
224019192|NCT00679393|PROCEDURE|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
224019193|NCT00679393|PROCEDURE|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
224019194|NCT06063785|DIAGNOSTIC_TEST|Acoustic Radiation Forced Impulse Imaging|Measurement of Liver stiffness
224019195|NCT06063785|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography|Measurement of optoacoustic spectra in liver and gastrointestinal tract
224019196|NCT00530907|DRUG|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
224019197|NCT00530907|DRUG|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
224296750|NCT01830634|BEHAVIORAL|Theraband with strengthening and stretching exercise|"Using the theraband for strengthening and stretching the upper and lower extremity muscles.~All exercises were performed by using a Theraband in the following movements: shoulder elevating and abducting, horizontal and oblique direction, plantar flexion, dorsi-flexion, inversion and eversion of ankle, knee extension and hip abduction. The stretching exercises were focused on the hamstring muscle and heel cord. Each movement was held for 5 seconds. The participants were instructed to perform 5-10 repetitions of each movements twice per day."
224019198|NCT05596838|PROCEDURE|Intracorneal rings placement|Intracorneal rings placement in keratoconus using laser
224019199|NCT02396043|DRUG|induction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
224019200|NCT02396043|DRUG|induction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59
224019201|NCT02396043|DRUG|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
224019202|NCT02396043|DRUG|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
224019203|NCT02396043|DRUG|reinduction phase1|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
224019204|NCT02396043|DRUG|reinduction phase2|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
224019205|NCT02396043|DRUG|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
224019206|NCT04461483|DRUG|TAK-935|TAK-935 Tablets
224019207|NCT04461483|DRUG|Placebo|TAK-935 placebo-matching tablets
224019208|NCT04690842|DIAGNOSTIC_TEST|PTH measurements post-thyroidectomy (at 5 and 60 min post thyroid removal)|We implement an algorithm employing PTH levels post-thyroidectomy to stratify patients according to their postsurgical risk for hypoparathyroidism, and to distinctively manage them in the immediate postsurgical period. High risk patients are quickly supplemented with Calcium iv and activated 25OH vitamin D. Low risk patients are clinically controlled and calcium level were checked at 24 and 48 hs post thyroidectomy.
224019209|NCT01095107|DIETARY_SUPPLEMENT|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
224019210|NCT01095107|DIETARY_SUPPLEMENT|Increased fat intake|increased fat intake : Intake \> 50 grams of fat per day between meals and snacks
224019211|NCT00275262|DRUG|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
224019212|NCT00275262|DRUG|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
224019213|NCT00690040|DEVICE|Foley catheter|Single balloon catheter
224019214|NCT00690040|DEVICE|Atad catheter|Double balloon catheter
224019215|NCT04721028|DEVICE|Human body component analyzer|The body composition analyzer is a kind of instrument that can measure the body composition health index. It is composed of professional tester, professional consulting management software, color printer A/B machine and so on.
224019216|NCT05186194|DRUG|Vitamin D, Calcium|Vitamin D, calcium are available in tablets. During the 8 weeks of training, subjects were asked to take supplement tablets per day after dinner.
224019217|NCT05186194|DRUG|Placebo|Placebo
224019218|NCT02110147|DRUG|uridine triacetate|
224019219|NCT04787497|DIETARY_SUPPLEMENT|High Phenolic Extra Virgin Olive Oil|Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
224019220|NCT02429674|BEHAVIORAL|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
224019221|NCT03059225|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
224019222|NCT03059225|DEVICE|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
224296751|NCT01374139|DRUG|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
223551121|NCT00263042|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
224019223|NCT02035592|OTHER|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
224296752|NCT01374139|DRUG|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
224296753|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 10 through 27 (Part 1)
224296754|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 2)
224296755|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 5 through 15 (Part 3)
223551122|NCT04091932|DRUG|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
223398651|NCT03481582|DEVICE|Three dimensional power doppler|Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
223398652|NCT02922127|DRUG|Ulipristal Acetate|Daily use of Ulipristal Acetate
223398653|NCT02922127|DRUG|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
223398654|NCT03817827|OTHER|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
224019224|NCT02035592|OTHER|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
224019225|NCT02035592|OTHER|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
224019226|NCT01747525|DEVICE|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
224019227|NCT02390830|OTHER|Falls Prevention|
224019228|NCT02390830|OTHER|Reduction of limitations at body function and activity levels|
224019229|NCT00831285|DIETARY_SUPPLEMENT|food product|food product given at one of six visits
224019230|NCT02707731|PROCEDURE|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
224019231|NCT04483076|DRUG|Chemotherapy drug|The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.
224019232|NCT04483076|PROCEDURE|Gastrectomy|Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
224019233|NCT04483076|PROCEDURE|Laparoscopic exploration|Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
224019234|NCT02340767|DEVICE|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
223398655|NCT03817827|DIETARY_SUPPLEMENT|Diet supplementary|Diet supplementary with soy product
223551123|NCT00491036|DEVICE|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
223551124|NCT00568373|DEVICE|Enterra Gastric Pacemaker|Gastric Pacemaker
223551125|NCT00234663|DRUG|PTC124|
223551126|NCT00106119|DRUG|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
223551127|NCT01626586|BEHAVIORAL|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
223551128|NCT02414607|BIOLOGICAL|Elderberry Juice|
223551129|NCT02414607|OTHER|Placebo|
223551130|NCT04676087|PROCEDURE|Extracorporeal Photopheresis|Undergo ECP
223551131|NCT04676087|BIOLOGICAL|Mogamulizumab|Given IV
223551132|NCT04676087|OTHER|Quality-of-Life Assessment|Ancillary studies
223551133|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 1|Single dose of 15mg AK120 or placebo is administered subcutaneously to healthy subjects
223551134|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 2|Single dose of 50mg AK120 or placebo is administered subcutaneously to healthy subjects
223731502|NCT02801240|OTHER|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
223731503|NCT00678054|DRUG|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
224019235|NCT02340767|DEVICE|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
224019236|NCT01589237|DRUG|LCQ908|
224019237|NCT04448509|OTHER|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell collection for tumor immunotherapy study of UCAR-T cells
224019238|NCT03437343|PROCEDURE|Hip arthroplasty|
224019239|NCT02594163|DRUG|Brentuximab Vedotin|
224019240|NCT02594163|DRUG|Rituximab|
224019241|NCT02594163|DRUG|Bendamustine|
224019242|NCT03732313|PROCEDURE|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
224019243|NCT03732313|PROCEDURE|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
224019244|NCT02794168|DRUG|VAS203|Treatment
224019245|NCT02794168|DRUG|Saline|Placebo
224019246|NCT00448409|BIOLOGICAL|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
224019247|NCT00448409|DRUG|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
224019248|NCT04497142|DRUG|Perampanel|Tablet taken orally 1x daily.
224019249|NCT04497142|DRUG|Standard of Care|Predetermined standard of care drug and dosing
224019250|NCT00221182|GENETIC|Autologous peripheral blood CD34 positive cell therapy|
223398656|NCT07057999|BEHAVIORAL|MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay)|The MIND diet consists of 15 components. While the first 10 of the components are considered healthy for the brain, the last 5 are considered unhealthy. The MIND diet portion and consumption frequency recommendations are as follows; olive oil consumption ≥ 48 g/day; oil seeds and nuts ≥ 5 servings/week; green leafy vegetables ≥1 serving/day; cooked vegetables ≥1 serving/day; whole grains ≥3 servings/day; legumes 3 servings/week; red fruits such as blueberries and strawberries ≥2 servings/week; poultry ≥2 servings/week; fish and seafood ≥1 serving week; red wine 1 glass/day; red meat ≤4 servings/week; butter ≤10 g/day; bakery products \<5 servings/week; fast food \<1 serving/week. Patients assigned to this group will be given a diet program based on isocaloric, MIND diet principles, which they will be asked to follow for 12 weeks.
223551135|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 3|Single dose of 150mg AK120 or placebo is administered subcutaneously to healthy subjects
224019251|NCT00289432|BEHAVIORAL|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
224019252|NCT00289432|OTHER|Support group|Standard Hospital follow-up support group
224019253|NCT00036959|DRUG|ABT-751|
224019254|NCT01680484|DIETARY_SUPPLEMENT|Bitter chocolate|
224019255|NCT01680484|DIETARY_SUPPLEMENT|Orange juice|
224019256|NCT02576301|DRUG|Phase 1 - OXi4503|Determination of MTD of OXi4503
224019257|NCT02576301|DRUG|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
224019258|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
224019259|NCT02576301|DRUG|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
224019260|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
224019261|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
224019262|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
224019263|NCT00691405|DRUG|Placebo|Placebo inhalation solution BID
224019264|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
224019265|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
224019266|NCT00691405|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
224019267|NCT00691405|DRUG|Placebo|Placebo inhalation solution QD
224019268|NCT00909337|DRUG|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
224019269|NCT01703650|DRUG|iopromide|"1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤."
224019270|NCT01703650|PROCEDURE|CT|"1. Perfusion CT will be performed by using a 320 channel MDCT~2. Patients are requested for fasting for at least 8 hours before CT scan.~3. Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~4. Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~5. During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~6. ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
224019271|NCT00071747|DRUG|lamotrigine|
224019272|NCT00238524|DRUG|SPM 927|
224019273|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
224019274|NCT00558194|BEHAVIORAL|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
223551136|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 4|Single dose of 300mg AK120 or placebo is administered subcutaneously to healthy subjects
223551137|NCT04256174|DRUG|AK120 or placebo- Part 1- Cohort 5|Single dose of 600mg AK120 or placebo is administered subcutaneously to healthy subjects
223551138|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 1|Multiple low doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
223551139|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 2|Multiple medium doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
224019275|NCT03339700|DRUG|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
224019276|NCT03339700|DRUG|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
224019277|NCT03339700|DRUG|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
224019278|NCT03339700|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
224019279|NCT03715582|DRUG|trimetazidine|Pills of masking drug - trimetazidine
224019280|NCT03715582|DRUG|Placebo Oral Tablet|Pills of masking drug - placebo
224019281|NCT01290029|DRUG|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
224019282|NCT02844725|DRUG|VVZ-149 injections|Colorless, transparent liquid in water for injection
224019283|NCT02844725|DRUG|Placebo|water for injection
224019284|NCT04364243|OTHER|Digitally supported home exercises|The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
224019285|NCT02745262|OTHER|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
224019286|NCT05555407|DIAGNOSTIC_TEST|Scintigraphic gastric emptying scan|Nuclear medicine scan that provides an assessment of gastric motility
224296756|NCT04498741|DRUG|Tacrolimus|Subjects will receive tacrolimus once daily on Day 1 and Day 24
223398657|NCT07057999|BEHAVIORAL|Traditional healthy nutrition program specific to Turkey|There are no prohibited foods in the traditional Türkiye-specific nutrition recommendations included in the TÜBER 2022 report, but there are foods that are recommended to be restricted or increased. According to the healthy nutrition program, 3 portions/day from the milk and dairy products (milk, yogurt, kefir, cheese) group; 2.5-3 portions/day from the meat, chicken, fish, eggs, legumes, oilseeds and nuts group; 2.5-4 portions/day from the vegetable group; 2-3 portions/day from the fruit group; 3-7 portions/day from the bread and cereal group; 3-4 portions/day from the fat group and finally, simple sugar consumption is recommended as a maximum of 10% of total energy. An isocaloric diet will be prepared according to the body composition and eating habits of the patients and they will be asked to follow it for 12 weeks.
223398658|NCT05446779|DIAGNOSTIC_TEST|Adrenal aldosterone synthase (CYP11B2) staining|Immunoshistochemical diagnosis of primary aldosteronism
223398659|NCT05446779|DIAGNOSTIC_TEST|Adrenal cortisol synthase (CYP11B1) staining|Immunoshistochemical diagnosis of adrenal hypercortisolism
223398660|NCT05446779|DIAGNOSTIC_TEST|Histopathological analysis|Diagnosis of any endocrine neoplasia other than primary aldosteronism or adrenal hypercortisolism
223398661|NCT00577603|PROCEDURE|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
224130225|NCT05744115|DRUG|Ga-68-PSMA-11|Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
224296757|NCT04498741|DRUG|Dabigatran|Subjects will receive dabigatran once daily on Day 1 and Day 13
224296758|NCT04498741|DRUG|Rosuvastatin|Subjects will receive rosuvastatin once daily on Day 1 and Day 13
223398662|NCT00577603|OTHER|no intervention|
223398663|NCT01595347|DRUG|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
223398664|NCT01595347|OTHER|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
223398665|NCT06424197|OTHER|Racial group-targeted messages|Colorectal cancer screening messages targeted towards participants racial group.
223398666|NCT06424197|OTHER|Explicit Commitment|Indicate explicit commitment to return at home screening kit.
223398667|NCT06762873|DIAGNOSTIC_TEST|Drug Induced Sleep Endoscopy with PNS|Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.
223398668|NCT01184430|DEVICE|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
224019287|NCT05555407|DEVICE|Wireless patch system (WPS)|Wireless wearable patches applied to the abdomen after 3 small areas of the abdomen that connect to a recording device for a total of 6 days and subjects will track mealtimes, bowel movements, and sleep using an iPhone app.
224019288|NCT04025346|OTHER|Capsimax|1 capsule to be taken before breakfast.
224019289|NCT04025346|OTHER|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
223398669|NCT04740918|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
223398670|NCT04740918|DRUG|Atezolizumab|Atezolizumab 1200 mg IV infusion
223398671|NCT04740918|OTHER|Placebo|Placebo matched to atezolizumab
223398672|NCT06007235|DEVICE|CACIPLIQ20|CACIPLIQ20 contains RGTA heparan sulphate mimetics
223398673|NCT06007235|DRUG|Placebo|Saline solution in identical spray bottles
223398674|NCT01414673|DRUG|HCG|5000 IU
223398675|NCT00333294|DRUG|Gefitinib|
223398676|NCT00333294|PROCEDURE|Radiation therapy|
223398677|NCT00333294|DRUG|Cisplatin|
223398678|NCT00333294|DRUG|Vinorelbine|
223398679|NCT06275438|OTHER|The delivery being performed via cesarean section surgery rather than natural childbirth|At Kars Harakani State Hospital and Kafkas University, 16 placentas were collected, with 8 obtained from induced deliveries and 8 from spontaneous deliveries, between 09:00-21:00. Nulliparity and multiparity were not distinguished among the expectant mothers. Placentas were obtained hours before delivery from mothers admitted to the gynecology service, whose eligibility was determined based on exclusion criteria, after obtaining signed informed consent forms, with assurances given that no interventional procedures would be performed on the mother or the baby. The method of cesarean section (spinal or general anesthesia) in the case group was recorded, ensuring that the anesthetic agents used contained the same active ingredients. Placentas from births involving different anesthetic drugs were not included in the study, aiming to standardize the procedure.
224130226|NCT02222454|DEVICE|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
224130227|NCT06242067|DRUG|Trifluridine/tipiracil|patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
224130228|NCT01196624|DEVICE|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
224296759|NCT04498741|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Days 3 through 16 (Part 4)
224296760|NCT04498741|DRUG|Midazolam|Subjects will receive midazolam once daily on Day 1 and Day 16
224296761|NCT03065595|DIETARY_SUPPLEMENT|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
224296762|NCT03065595|OTHER|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
224296763|NCT03648034|PROCEDURE|ropivacaine|To perform scalp nerve blocks with ropivacaine
224296764|NCT03648034|PROCEDURE|saline|To perform scalp nerve blocks with saline
223551140|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 3|Multiple high doses of AK120 or placebo are administered subcutaneously as a weekly dose for a total of four doses to subjects with moderate-to-severe atopic dermatitis
224296765|NCT01417819|OTHER|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
224296766|NCT05828121|BEHAVIORAL|POINT1|Receiving treatment
223551141|NCT04256174|DRUG|AK120 or placebo- Part 2- Cohort 4|Multiple high doses of AK120 or placebo are administered subcutaneously as a bi-weekly dose for a total of three doses to subjects with moderate-to-severe atopic dermatitis.
223551142|NCT04709003|DIAGNOSTIC_TEST|Serologic test|A blood test to check antibodies type and amount
224296767|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Analerg|
224296768|NCT01684137|DIETARY_SUPPLEMENT|Joalis Bambi Bronchi|
223551143|NCT04709003|DIAGNOSTIC_TEST|Respiratory swabs|PCR test to Covid-19
223551144|NCT02018029|OTHER|cardiac resynchronisation therapy|
223551145|NCT02468440|OTHER|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
223551146|NCT02998684|DEVICE|Active Transcranial Direct Current Stimulation|
223551147|NCT02998684|DEVICE|Sham Transcranial Direct Current Stimulation|
223551148|NCT02998684|BEHAVIORAL|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
223731504|NCT04106921|OTHER|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
223731505|NCT00338702|PROCEDURE|Autologous Platelet Gel|
223731506|NCT03760120|DEVICE|PEP-MASK|
224019290|NCT03849950|OTHER|SMARTCare|"1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~2. An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~3. An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~4. Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare."
224019291|NCT03849950|OTHER|Control|1\. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
224019292|NCT04271631|OTHER|Mobile Application-Based Diabetes Education|Additional education was given using application, subjects were asked to open the application at least once a day
224296769|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
223551149|NCT04739111|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)|In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
224019293|NCT04271631|OTHER|Health Coaching|Health coaching was given as face to face with a coach
224019294|NCT00189488|DRUG|Palifermin|Administered as an intravenous (IV) bolus.
224019295|NCT00189488|DRUG|Placebo|Administered as an intravenous (IV) bolus.
224019296|NCT00189488|OTHER|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~* Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~* TBI/VP-16~* Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie \> 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~* Busulfan (Bu)/Cy~* Bu/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])~* Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses \[Mel dose \> 140 mg/m\^2\])"
224019297|NCT00189488|PROCEDURE|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
224019298|NCT00189488|DRUG|Methotrexate|
224019299|NCT02176213|DRUG|Pomalidomide|4 mg PO x 21 days
224019300|NCT02176213|DRUG|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
224019301|NCT02176213|DRUG|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
224019302|NCT05223777|DEVICE|KINCISE|The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
224019303|NCT05223777|DEVICE|Traditional Handheld Mallet|The handheld mallet traditionally used in total hip arthroplasty.
224296770|NCT01684137|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
224296771|NCT04912115|DRUG|Ketamine|Ketamine is an FDA-approved N-methyl-D-aspartate (NMDA) receptor-modulating drug pharmacologically classified as an NMDA receptor antagonist (also noted to be a weak opioid receptor agonist).
224296772|NCT04912115|DRUG|Midazolam|Midazolam is a benzodiazepine used for anesthesia, procedural sedation, trouble sleeping, and severe agitation.
223551150|NCT03805061|OTHER|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
224130229|NCT01196624|DEVICE|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
224130230|NCT06254352|DIAGNOSTIC_TEST|scoring system|Clinical Risk Scores in Prediction of Outcome of Acute Upper Gastrointestinal Bleeding in Non Cirrhotic Patients.
224130231|NCT01870024|DRUG|Clonazepam|clonazepam 0,015 mg/kg
224296773|NCT04803188|DIAGNOSTIC_TEST|Magnetic Resonance|"Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy."
223551151|NCT03805061|DEVICE|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
223551152|NCT00358033|BEHAVIORAL|Counseling|
223731507|NCT06228547|OTHER|Questionnaire|Standardized questionnaire specifically made for the study. The interview lasts approximately 15 minutes. The form gathers baseline characteristics of the patients such as socio-demographic information, symptoms, lifestyle factors and gynecological history. The questionnaire focuses also on the manner in which the diagnosis was revealed to the patient and their experience of this disclosure. Lastly, the questionnaire includes items issued from French practice guidelines concerning etiological investigations, fertility assessment, osteoporotic and cardiovascular complications, HRT use, and residual symptoms
224019304|NCT02145234|DRUG|BMS-986089|
224019305|NCT02145234|DRUG|Placebo matching with BMS-986089|
224019306|NCT00006373|DRUG|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
224019307|NCT00006373|DRUG|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
224019308|NCT00006373|DRUG|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
224019309|NCT00006373|PROCEDURE|autologous bone marrow transplantation|
224019310|NCT00006373|DRUG|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
224019311|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
224019312|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
224019313|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
224019314|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
224019315|NCT00850603|BIOLOGICAL|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
224019316|NCT00484289|DRUG|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
224019317|NCT05696431|OTHER|Universal adhesives application|The adhesive will be used according to their manufacturer's instructions. Selective etching for enamel will be applied for 15 seconds, followed by rinsing and gentle air drying. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
224130232|NCT01870024|DRUG|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
224130233|NCT01870024|DRUG|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
224130234|NCT01870024|DRUG|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
224130235|NCT06163456|OTHER|Acute submaximal exercise|30 min of treadmill running at 70% of the participants maximal oxygen consumption
224130236|NCT00069420|BEHAVIORAL|Cognitive Motivational Behavior Therapy|
224130237|NCT01752582|DEVICE|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
224130238|NCT01752582|DEVICE|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
224130239|NCT05066828|OTHER|two pieces obturator|patient received two pieces obturator connecting by magnet attachment
224296774|NCT02264093|DRUG|Propranolol|
224296775|NCT02264093|DRUG|Talsaclidine|
224296776|NCT05638841|OTHER|After radiofrequency ablation of atrial fibrillation|This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.
224296777|NCT00886041|PROCEDURE|laparoscopy|subjected to laparoscopy
224296778|NCT00886041|OTHER|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
224296779|NCT03911921|DRUG|RSYRT decoction|Compound granules of traditional Chinese medicine
224296780|NCT03911921|DRUG|Astragalus membranaceus|One herb
224296781|NCT02035839|DEVICE|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
224296782|NCT02035839|DEVICE|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
223551153|NCT00358033|BEHAVIORAL|Interactive Education|
224130240|NCT01980706|DRUG|Baclofen|Baclofen is a GABA-B agonist
224130241|NCT01980706|DRUG|Placebo|Pill containing no pharmacologically active substance.
224296783|NCT02035839|DEVICE|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
224019318|NCT05696431|OTHER|universal adhesive with bioactive properties|The adhesive will be used according to their manufacturer's instructions. Enamel and dentin will be cleaned using clean and boost for 10 seconds, rinsed and gently dried. Then, the adhesive will be applied to enamel and dentin and light cured using a light-curing unit for 20 seconds. The composite material will be incrementally applied, and each increment will be light cured for 20 seconds. The restoration will be finished and polished using finishing and polishing instruments.
224019319|NCT05696431|OTHER|Fluoride-releasing universal adhesive|Fluoride-releasing universal adhesive
224019320|NCT04758689|COMBINATION_PRODUCT|Laser, exercise, and methotrexate|Laser therapy at acupuncture points, aerobic exercise, and methotrexate
224019321|NCT04758689|COMBINATION_PRODUCT|Exercise, and methotrexate|Aerobic exercise, and methotrexate
224019322|NCT04326517|PROCEDURE|Nephrectomy|Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
224019323|NCT00987454|DRUG|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
224019324|NCT00987454|DRUG|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
224019325|NCT04330131|BEHAVIORAL|3Ts - Newborn|A video shared with parents/caregivers during a universal screening in hospital mother-baby units. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
224130242|NCT06295016|OTHER|High-intensity intensive training|"Participants will conduct a 3-weeks of 130% progressive high-intensity intensive training (increasing by 10% each week).~Week 1: Increase training to 110% of participants' regular training volume. Week 2: Increase training to 120% of participants' regular training volume. Week 3: Increase training to 130% of participants' regular training volume."
224130243|NCT06295016|OTHER|Taper|"Participants will conduct a 1-week taper phase by gradually reducing to 55% of their regular training volume.~Day 1: Decrease current training volume by 20%. Day 2: Decrease current training volume by 15%. Day 3: Decrease current training volume by 10%. Day 4: Decrease current training volume by 10%. Day 5: Decrease current training volume by 10%. Day 6: Decrease current training volume by 5%. Day 7: Decrease current training volume by 5%."
224130244|NCT04753814|DIAGNOSTIC_TEST|Diagostic tests|Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, etiology and history of HF, co-morbidities, results of selected laboratory tests, selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study and distance in 6MWT and subjective assessment of quality of life according to the KCCQ questionnaire.
224130245|NCT01515995|DRUG|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
224130246|NCT03972644|PROCEDURE|Aortic valve replacement|Open heart surgery or transcatheter surgery
224019326|NCT04330131|BEHAVIORAL|3Ts - Well Baby|Four videos shared during well child immunization visits at 1-, 2-, 4-, and 6-months in pediatrician offices. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
224019327|NCT04330131|BEHAVIORAL|3Ts - Let's Talk!|A series of eight group classes involving education, feedback, and goal setting for parents/caregivers of children age one through three, delivered in a community-based organization. This intervention shares the importance of early talk and interaction with a child to support their early brain development as well as strategies for parents to do so.
224019328|NCT05402696|PROCEDURE|Endoscopic tissue resection|Endoscopic resection techniques for removal of large polyps
224130247|NCT02481726|RADIATION|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
224296784|NCT04233086|OTHER|No intervention, observational only|No intervention, observational only
224296785|NCT04252222|DEVICE|Videolaryngoscopy with VL3|Tracheal Intubation aided by VL3 Videolaryngoscope
224296786|NCT03114696|DIETARY_SUPPLEMENT|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
224296787|NCT03114696|DIETARY_SUPPLEMENT|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
224296788|NCT03678324|OTHER|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
224296789|NCT02316249|DRUG|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
224296790|NCT02316249|OTHER|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
224296791|NCT01297374|BEHAVIORAL|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
224296792|NCT00054041|BIOLOGICAL|HspE7|Given subcutaneously
224296793|NCT00054041|PROCEDURE|therapeutic conventional surgery|Undergo large loop excision
224296794|NCT00054041|OTHER|laboratory biomarker analysis|Correlative studies
223398680|NCT04784611|BEHAVIORAL|Our Peers - Empowerment and Navigational Support (OP-ENS) Peer Health Navigator Intervention|Disability peer health navigator mentored and manualized process of barriers identification, asset mapping, goal setting, and action planning along with on-going social support and information sharing.
223398681|NCT00254709|DRUG|Sirolimus|
223398682|NCT02524847|DRUG|Methoxsalen|Sterile solution used in conjunction with photopheresis procedure.
224019329|NCT02349425|DRUG|Gefapixant|Gefapixant 7.5 and 50mg tablets administered orally
224019330|NCT02349425|DRUG|Placebo (for gefapixant)|Placebo to gefapixant 7.5 and 50mg tablets administered orally
224019331|NCT05617482|OTHER|General anesthesia|All patients undergoing ceaserian section under general anesthesia
224019332|NCT05617482|OTHER|Ilioinguinal, iliohypogastric nerve blocks|In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.
224019333|NCT05617482|OTHER|TAP block|In TAP block group, the probe will be placed perpendicular to the mid-axillary line between the iliac crest and the subcostal margin and the three abdominal muscle layers will be identified, and the transverses abdominis plane will be located between the internal oblique and the transverse abdominis muscle. The TAP will be approached through in-plane technique using a 23-gauge Quincke spinal needle attached to a 20 ml syringe of 0.25% bupivacaine will be injected and the drug spread in the plane will be observed.
224130248|NCT03314220|BEHAVIORAL|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
224130249|NCT05249088|OTHER|Protocolised reduction of non-resuscitation fluids|"* Maintenance fluids are discontinued in participants with positive cumulative fluid balance who are not dehydrated~* Intravenous fluid and enteral water are given as needed to correct electrolyte disturbances~* Enteral nutrition with energy density of at least 2 kcal/ml is administered according to local practice~* Starting 72 hours after inclusion, glucose at a concentration of at least 20% and a maximal dose of 1g/kg/day may be used as nutrition if enteral feeding is not tolerated. Glucose at this dose or lower may be started earlier in patients with insulin dependent diabetes if enteral feeding is not tolerated and local protocol mandates this~* Parenteral nutrition is administered according to local protocol~* Intravenous medications are concentrated according to a predefined protocol~* Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids such that total dose of fluids covers the daily need of water (about 1ml/kg/h)"
224296795|NCT01936519|DRUG|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
224296796|NCT01936519|DRUG|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
224296797|NCT05689593|OTHER|Low-intensity ESWT Group|ESWT; With the MODUS ESWT system, the patient's shoulder will be in 80° passive abduction, the elbow will be in 90° flexion, and the forearm will be applied to 2 separate parts of the shoulder. The first application will be applied from front to back in the anterior shoulder joint and the upper limit of the treatment will be approximately 1 finger lateral to the coracoid process, the second application will be applied from the lateral scapula to the posterior shoulder joint (0.06 mJ/mm2, 1500 impulses, 1.5 bar).( Modus ESWT® RadialShockwaveTherapy)
224296798|NCT05689593|OTHER|Low-intensity laser Group|The laser will be made parallel to the joint line with the patient's arm, the arm will be in internal rotation at the posterior of the shoulder and the arm will be in external rotation at the anterior of the shoulder. The wavelength of 850 nm will be applied for 5 minutes in total 30 Joules.
224296799|NCT05689593|OTHER|Conventional Control Group|Exercises will be started with passive ROM exercises and passive stretching exercises for the flexor, abductor, internal and external rotator muscle groups until the level of pain tolerance in the supine position. In the second week, the program will be continued with active ROM and stretching exercises. In the third week, isometric strengthening exercises for flexor, abductor, internal and external rotator muscle groups will be given along with stretching exercises. Exercises will be performed 5 days a week, 60 minutes a day, accompanied by a physiotherapist.
224296800|NCT03924011|DEVICE|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
224296801|NCT03924011|DEVICE|Sham laser|Sham laser sessions will be applied 2x/week after RT.
224296802|NCT00652028|DRUG|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
224296803|NCT06165666|OTHER|Approach by functional objectives|The therapeutic approach that will be administered to the EG will be based on the training of specific tasks aimed at functional objectives. Each session will begin with activities to activate the muscles of the trunk, pelvis and lower limbs, to modify atypical movement patterns and prepare the muscles for a more effective contraction. Subsequently, activity training will be carried out in a functional and meaningful context, aimed at specific and significant functional objectives for the participant and previously agreed upon with them.
224296804|NCT06165666|OTHER|Treatment protocol|The therapeutic approach of the participants assigned to the CG will be aimed at maintaining joint ranges and transfer work, passive mobilization of the paretic lower and upper limb, maintenance of sitting posture with/without assistance, transfer from sitting to standing, from standing to sitting. and coordination work. Subsequently, initiation of walking with a support product and/or help, if possible.
224296805|NCT01031966|BIOLOGICAL|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
224296806|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
224296807|NCT01031966|DRUG|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
223398683|NCT02524847|PROCEDURE|Extracorporeal Photopheresis (ECP)|
223398684|NCT04352101|DRUG|Bupropion XL|Participants will take 150 milligrams per day (mg/d) of bupropion XL for two weeks, then the dose will be increased to 300mg/d, as tolerated, for the remaining 6 weeks of the study.
224019334|NCT05617482|OTHER|Quadratus lumborum block|For the QLB, the transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
224019335|NCT04369716|OTHER|Whole oranges|Navel oranges (227 g total)
224019336|NCT04369716|OTHER|Whole Apples|Red Delicious apple with skin (230 g)
224019337|NCT04369716|OTHER|Orange juice + orange pomace|Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]
224019338|NCT04369716|OTHER|Apple juice + apple pomace|Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]
224019339|NCT04369716|OTHER|Orange juice|Orange Juice (250 g)
224019340|NCT04369716|OTHER|Apple juice|Apple Juice (235 g)
224019341|NCT05641181|DRUG|CRB4101|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
224019342|NCT05641181|DRUG|Placebo|"After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo."
224019343|NCT05568238|PROCEDURE|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM)|Vacuum Assisted Wound Closure and Permanent On-lay Mesh-mediated fascial traction (VAWCPOM) in patients with open abdomen.
224019344|NCT00053560|DRUG|Prasterone (GL701)|
224019345|NCT05339217|DRUG|Telitacicept|160mg Telitacicept was subcutaneously injected to patients with systemic lupus erythematosus at the outer side of upper arm every week for 24 weeks.
224019346|NCT05339217|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
224019347|NCT04914299|BEHAVIORAL|"App-based positive intelligence intervention"|"A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care"
224019348|NCT04914299|BEHAVIORAL|Standard of care|Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
224019349|NCT05453123|BEHAVIORAL|telerehabilitation|examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
224019350|NCT00775320|PROCEDURE|FLT-PET scan|Imaging test
224019351|NCT00286260|DRUG|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
224019352|NCT02594761|BIOLOGICAL|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
223398685|NCT04352101|DRUG|Escitalopram|Participants will take 10mg/d of escitalopram for two weeks, then the dose will be increased to 20mg/d, as tolerated, for the remaining 6 weeks of the study.
223398686|NCT03499444|DRUG|Rucaparib|Rucaparib will be administered twice daily
223398687|NCT06058819|DIAGNOSTIC_TEST|Newborns suspected of Infections|This study will include NICU newborns of at least 7 days of life with suggestive signs of neonatal sepsis. The results will be extrapolated to this same population.
223398688|NCT02166567|PROCEDURE|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
223398689|NCT02166567|PROCEDURE|Swim-up|Semen processing will be carried out with the conventional swim-up method.
223398690|NCT06410482|PROCEDURE|US guided caudal block|"After placing the patient in the left lateral position (hips and knees flexed) following monitoring and induction of anaesthesia, the field will be sterilized with 70% alcohol in 2% chlorhexidine.~Initial scanning in the transverse plane allows for visualization of the midline and identification of the sacrococcygeal ligament between the 2 sacral cornua. The 2 cornua resemble the 2 eyes of a frog and thus are collectively called the frog-eye sign. The US probe is then rotated 90 degrees to acquire a longitudinal view. The needle is then advanced at a 20-degree angle with needle tip and length visualization Once the needle is confirmed to be in the caudal space on the screen, carefully aspirate to confirm absence of CSF or blood.~A slow injection of the local anaesthetic can then be performed, dose of (0.2 mL/kg 0.25% bupivacaine and 1 μg/kg of dexmedetomidine"
223551154|NCT00358033|BEHAVIORAL|Group Support|
224019353|NCT02594761|BIOLOGICAL|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
224019354|NCT02594761|BIOLOGICAL|Herceptin US|Intravenous Infusion, 440 mg/vial
224019355|NCT04200976|BEHAVIORAL|Tele-CABA|"Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions."
224019356|NCT04200976|BEHAVIORAL|Usual Care|Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
224019357|NCT04552977|DRUG|fluzoparil|a PARP1 inhibitor
223398691|NCT06410482|PROCEDURE|Dorsal penile nerve block|"after general anesthesia induction. With the patient in the supine position. After skin sterilization the US linear probe will be transversely placed on the root of the penis. After placing the penis in gentle traction, a50 mm block needle will be inserted from the lateral part of the penis root towards the dorsal section of the penis with the in-plane technique, It will be advanced through Dartos fascia until resistance to the needle disappeared.~Once the superficial sheath will be passed, the tip of the needle will be advanced into Buck's fascia and then positioned between Buck's fascia and tunica albuginea, lateral to the dorsal artery. After making sure there will be no blood with negative aspiration, half of the total 0.2 mL/kg dose of 0.25% bupivacaine will be administered while observing its distribution with US. The same procedure will be then repeated on the other side of the penis."
223398692|NCT01573182|BIOLOGICAL|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
223398693|NCT00782054|OTHER|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
223398694|NCT00782054|OTHER|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
224019358|NCT04552977|DRUG|temozolomide|an alkylating chemotherapeutic agent
224019359|NCT04258501|OTHER|Mulberry fruit|
224019360|NCT04258501|OTHER|Mulberry leaf|
224019361|NCT04258501|OTHER|White bean|
224019362|NCT04258501|OTHER|Apple|
224019363|NCT04258501|OTHER|Elderberry|
224019364|NCT04258501|OTHER|Turmeric|
224019365|NCT04258501|OTHER|Rice porridge|
224019366|NCT00697333|PROCEDURE|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
224130250|NCT05249088|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~* Maintenance fluids (crystalloids and/or glucose and/or enteral water) are given at a dose of 1 ml/kg/h unless local protocol states otherwise~* Glucose is used at maximal concentration of 10% unless local protocol states otherwise.~* Medications are concentrated according to local protocol"
224130251|NCT00005986|DRUG|busulfan|
224130252|NCT00005986|DRUG|cyclophosphamide|
224130253|NCT00005986|DRUG|filgrastim|
223398695|NCT04016454|PROCEDURE|Intervention|There will be one complete handover
223551155|NCT00358033|PROCEDURE|Pharmacologic case management|Provided by clinical pharmacists
223551156|NCT02248766|DEVICE|somofilcon A|somofilcon A lens
223551157|NCT02668705|OTHER|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
223551158|NCT03047811|OTHER|TCR - T cell therapy|Low dose group: 1 x 10 \^8 /kg T cell total reinfusion. High dose groups: 10 x 10 \^ 8 / kgT cell total reinfusion.
223551159|NCT03075852|DEVICE|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
224019367|NCT05479201|DIAGNOSTIC_TEST|Home based sleep test|Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
224019368|NCT02423928|BIOLOGICAL|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
224130254|NCT00005986|DRUG|recombinant interferon alfa|
224130255|NCT00005986|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223551160|NCT03504293|PROCEDURE|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
223551161|NCT02267291|OTHER|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
223551162|NCT04054206|DRUG|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
224019369|NCT02423928|DRUG|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
224019370|NCT02423928|DRUG|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
224019371|NCT04719884|PROCEDURE|Perioperative fluid optimisation|"In case of stroke volume variation (SVV) \>10% and SI and CI \>10% below the starting value, fluid challenge was performed with approximately 2 ml/kg of colloid over maximum of 5 minutes. The response was monitored.~If there was a fall in SVV and an increase in SI of \>10% and the SVV still \>10%, the second fluid challenge was performed.~If there was still a reduction in SVV after the second fluid challenge, but an increase in nSI \<10% and decrease in systemic vascular resistance (SVR), no additional fluids were given. Vasoactive drugs were used instead."
224019372|NCT03116737|DRUG|Benzocaine Otic Solution|
224019373|NCT03116737|DRUG|Placebo|
224130256|NCT00005986|PROCEDURE|peripheral blood stem cell transplantation|
224130257|NCT00005986|PROCEDURE|radiation therapy|
224296808|NCT05043623|DEVICE|Rhinoswab Junior|Rhinoswab Junior is a single use self-administered nasal swab intended to collect clinical specimens from the patient's nasal passages
224019374|NCT04839874|OTHER|No intervention|Semi-structured qualitative interviews
224019375|NCT03382379|DEVICE|Active transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.
224019376|NCT03382379|DEVICE|Sham transcranial Direct Current Stimulation (tDCS)|Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
224296809|NCT05043623|DEVICE|Combined nose and throat swab|Combined nose and throat swab (standard of care)
224130258|NCT03902743|OTHER|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
224130259|NCT03379610|DIAGNOSTIC_TEST|Nasopharngeal brush|"1. Baseline nasopharngeal brush before treatment~2. Post-treatment reassessment of residual NPC"
224130260|NCT03925818|DRUG|Bismuth Subcitrate Potassium|Pylera capsules
224019377|NCT01189084|BIOLOGICAL|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
224130261|NCT03925818|DIETARY_SUPPLEMENT|Gastrus|Gastrus 1 tablet
224130262|NCT05682820|DIAGNOSTIC_TEST|Measurements on knee MRI performed during routine clinical practice|Patients after knee injury are often advised to undergo knee MRI for diagnosis. Measurements on knee MRI performed during routine clinical practice will be made.
224130263|NCT03404596|DRUG|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
223398696|NCT02692859|BIOLOGICAL|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
224019378|NCT02789254|BIOLOGICAL|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² BSA\* day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² BSA day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-18: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2~Cohort 5:~Patient 19-21: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 44.5 mg/m² BSA day 2~Cohort 6:~Patient 22-24 and 25-31: FLYSYN 0.5 mg/m² BSA day 1, FLYSYN 14.5 mg/m² BSA day 2, FLYSYN 15 mg/m² BSA day 15, FLYSYN 15 mg/m² BSA day 29~\* The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
224019379|NCT02343874|OTHER|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
224019380|NCT05866068|DRUG|Clomiphene|Clomiphene citrate 100mg daily during IVF stimulation
224019381|NCT02830945|BEHAVIORAL|Motivational Interviewing Intervention Arm|
224019382|NCT02830945|OTHER|Control Brochure Arm|
224019383|NCT02009254|OTHER|Dietary treatment|
224019384|NCT05015907|DRUG|Ropivacaine|The nerve involved in the operation of Hickman catheter, chemoport, and Perm cath is the supraclavicular nerve. Therefore, it is judged that if only this nerve is selectively blocked, pain control can be effectively performed with a small amount of local anesthetic, and relatively few side effects occur.
224019385|NCT05015907|OTHER|Control (without intervention)|No intervention
224019386|NCT00316160|DRUG|Bupropion Hydrochloride Extended-release|
224130264|NCT03404596|BEHAVIORAL|Counseling|Brief counseling sessions, 10-15 minutes each.
224130265|NCT03404596|BEHAVIORAL|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
224130266|NCT03404596|OTHER|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
224130267|NCT00001261|DRUG|Gamma Globulin|
223398697|NCT03952182|OTHER|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
224019387|NCT00316160|DRUG|Extended-release Venlafaxine|
224019388|NCT02824666|DRUG|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
224019389|NCT02824666|RADIATION|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].
224019390|NCT04784260|OTHER|Microbiome analysis|Evaluate the bacterial composition in sperm from the different groups
224019391|NCT04171453|DRUG|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
224019392|NCT02726685|OTHER|respiratory training.|breathing exercise.
224130268|NCT05591898|BEHAVIORAL|Progressive relaxation exercises|Training booklet and CD as a guide on the implementation of Progressive Relaxation Exercises prepared by the Turkish Psychological Association; muscle relaxation exercises, rhythmic breathing and music recital. In the first 10 minutes of this three-part CD, the definition and purpose of deep relaxation and the practices to be considered during exercise are explained. In the second part of 30 minutes; relaxation exercises are explained with the sound of the stream and verbal instructions. The third part, consisting of 30 minutes; it contains only relaxation music without instructions.
224130269|NCT04899791|OTHER|Wheat bread enriched with hydroxytyrosol|Wheat bread enriched with hydroxytyrosol
224130270|NCT04899791|OTHER|Wheat bread|Wheat bread
224130271|NCT01094730|DEVICE|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
224130272|NCT01094730|DEVICE|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
224019393|NCT02726685|OTHER|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
224019394|NCT05369273|OTHER|intra-articular injection|intra-articular injection
224019395|NCT05369273|RADIATION|RMI SCANS|AT 1 MONTHS BEFORE THE INTERVENTION
224019396|NCT05369273|OTHER|RMI SCANS|AT 1MONTH AFTER THE INTERVENTION
224019397|NCT05369273|OTHER|RMI SCAN|AT 6 MONTHS AFTER THE INTERVENTION
224019398|NCT01877837|DRUG|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + \[(0.4) x (ABW - IBW)\]~b) Medications~i.) Alemtuzumab I. Hb S% must be \< or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued \>48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
224019399|NCT01877837|DRUG|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
224019400|NCT01877837|DRUG|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. \*Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
224019401|NCT01877837|PROCEDURE|Stem Cells|Infusion of Hematopoietic Stem Cells
224019402|NCT01135537|BIOLOGICAL|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
224019403|NCT00002521|DRUG|cisplatin|
224019404|NCT00002521|DRUG|cyclophosphamide|
224019405|NCT00002521|DRUG|etoposide|
224019406|NCT00002521|PROCEDURE|autologous bone marrow transplantation|
224019407|NCT00002521|PROCEDURE|bone marrow ablation with stem cell support|
224019408|NCT00002521|PROCEDURE|peripheral blood stem cell transplantation|
224019409|NCT00002521|PROCEDURE|syngeneic bone marrow transplantation|
224019410|NCT00002521|RADIATION|radiation therapy|
224019411|NCT01786473|DRUG|Testogel 1%|
224019412|NCT01786473|DRUG|Placebo|
224019413|NCT02683005|DRUG|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
224130273|NCT03102320|DRUG|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
223398698|NCT03952182|OTHER|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
223398699|NCT00842673|DRUG|ST101|30 mg; administered once/day
223731508|NCT01590238|BIOLOGICAL|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
223731509|NCT03735433|DRUG|162mg aspirin dose|2 pills of 81mg aspirin
223398700|NCT00842673|DRUG|ST101|90 mg; administered once/day
224019414|NCT03341767|DRUG|Clofazimine|50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
224019415|NCT03341767|DRUG|Placebo|Oil-wax in gelatin capsule
224019416|NCT04953325|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection
224019417|NCT04953325|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F
224019418|NCT04953325|BIOLOGICAL|Inactivated Hepatitis A Vaccine|500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
224019419|NCT02860780|DRUG|prexasertib|Administered IV
224019420|NCT02860780|DRUG|ralimetinib|Administered orally
224019421|NCT02761876|BEHAVIORAL|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
224019422|NCT02761876|BEHAVIORAL|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
224019423|NCT02761876|BEHAVIORAL|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
224019424|NCT04327076|DEVICE|Using robot system of endotracheal intubation and airway cleaning|"1. Using the control screen to control the machine, the device first extends the intubation guide rail to the mouth of the patient's oropharyngeal ventilation tube, first sends the magnetic guide strip into the epigarynx, and at the same time, extends the magnetic anchoring unit to the patient's neck. The external magnetic anchoring unit can sense and attract the magnet on the magnetic guide strip. At this point, the machine can send the guide strip into the respiratory tract.~2. Then, the control machine sends the tracheal intubation into the airway along the guide strip, and completes the balloon inflation to complete the endotracheal intubation operation.~3. During or after the operation, when the sputum suction operation is needed, the parameters of the sputum suction machine are set on the operation screen to start the sputum suction operation, and the suction robot completes the sputum suction operation automatically."
224019425|NCT01893931|BEHAVIORAL|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
224019426|NCT01893931|BEHAVIORAL|Placebo Comparator|
224019427|NCT00645801|DRUG|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
224019428|NCT00645801|DRUG|Placebo|Amitiza Placebo
224130274|NCT03102320|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
224130275|NCT03102320|DRUG|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
224019429|NCT00716508|PROCEDURE|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
224019430|NCT00716508|PROCEDURE|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
223398701|NCT00842673|DRUG|ST101|180 mg; administered once/day
223398702|NCT00842673|DRUG|Placebo|placebo to match ST101 tablets
223551163|NCT04015570|BIOLOGICAL|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
223551164|NCT04015570|OTHER|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
223551165|NCT03528655|OTHER|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
223551166|NCT02140970|DRUG|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
223551167|NCT02140970|DRUG|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
224019431|NCT03237637|DRUG|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
224019432|NCT03237637|DRUG|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
224019433|NCT04660604|DEVICE|Graston Technique®|Graston technique, one of the soft tissue mobilization techniques, has also been found to be effective method that affects muscle strength, performance and endurance through activation of muscle and nervous systems.
224019434|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
224019435|NCT00705679|DRUG|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
224019436|NCT00705679|DRUG|Tenofovir disoproxil fumarate|300 mg tablet
224019437|NCT00705679|DRUG|Tenofovir disoproxil fumarate placebo|placebo tablet
224019438|NCT00705679|DRUG|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
224130276|NCT04345926|DRUG|Propofol|Stepped propofol concentration after 20 min of LOS
224130277|NCT04345926|DEVICE|Electroencephalogram recording|Acquisition of EEG activity
224130278|NCT00570752|OTHER|Placebo|
223398703|NCT02794727|DEVICE|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
223398704|NCT02794727|DEVICE|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
223398705|NCT05744167|BEHAVIORAL|BFRT|Following a warm-up of 10 min, subjects in the experimental group will undergo BFRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). BFRT will be at 40% of 1 repetition maximum (1RM); The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
223398706|NCT05744167|BEHAVIORAL|MDRT|Following a warm-up of 10 min, subjects in the experimental group will undergo MDRT for two times per week, consisting of lower extremity exercises (leg press, knee extension, knee flexion). The exercise will be at 80% of 1RM concentric-only or 120% of 1RM eccentric-only in a 3:1 ratio. The volume % (V% = number of repetitions x number of sets x number of exercises x % 1 repetition max) = 57.6%. Progression during the 12 week program will be attained by a 1RM test every 4 weeks.
223551168|NCT02440204|PROCEDURE|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
223551169|NCT02440204|DRUG|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
224019439|NCT00705679|DRUG|Tenofovir placebo|placebo gel
224019440|NCT03129880|BEHAVIORAL|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
224019441|NCT03129880|BEHAVIORAL|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
224019442|NCT00872677|BEHAVIORAL|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
224019443|NCT00872677|OTHER|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
224019444|NCT00819962|DRUG|Bupivacaine|Local anesthetic
224019445|NCT00819962|OTHER|TAP|
224130279|NCT00570752|DRUG|BMS-582949|
224130280|NCT00570752|DRUG|Atorvastatin|
224130281|NCT00570752|DRUG|Statin|
224130282|NCT02021448|OTHER|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
224130283|NCT05047159|DEVICE|rTMS|"Stimulation will be performed for 20 working days once a day (4 weeks). Extend course to 30 sessions (6 weeks) in responders who have not achieved symptom remission.~Frequency: 10Hz; Intensity: 110% RMT; Coil-type: F8; Sessions-pulse: 3000; Site: the left dorsolateral prefrontal cortex."
224019446|NCT04017039|OTHER|Targeted Sleep Intervention|
224019447|NCT00444899|BEHAVIORAL|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
224019448|NCT00444899|OTHER|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
224019449|NCT04628351|BEHAVIORAL|Bladder Training|"Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques."
224019450|NCT04217629|DRUG|SY-005|This single-dose group will be initiated in healthy subjects at a 0.75mg dose that is the maximum recommended starting dose(MRSD). Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are2.5mg, 5mg, 10mg, 15mg, 20mg successively. The dose of multiple-doses groups are depending on the results of single-dose groups.
224019451|NCT03818685|DRUG|Nivolumab|Radiotherapy will be maintained in each Arm.
224130284|NCT05047159|DEVICE|light therapy|Active 10,000-lux fluorescent white light box for 30 min/d in the early morning for 6 weeks.
224019452|NCT03818685|DRUG|Ipilimumab|Radiotherapy will be maintained in each Arm.
224019453|NCT03818685|DRUG|Capecitabine|Radiotherapy will be maintained in each Arm.
224019454|NCT05938374|DRUG|Fluzoparib|One week before RT onset, during radiotherapy and 5 weeks post-RT, patients also take oral Fluzoparib (100mg, BID, five days per week).
224130285|NCT05047159|DEVICE|ECT|The electrode placements are bifrontal (BF); the electrical intensity is 1.5 to 2.0 times the seizure threshold (ST); 3 times per week.
224130286|NCT05047159|DEVICE|MST|A coil placement at the vertex (i.e., Cz in 10-20 electroencephalogram \[EEG\] system) with a frequency of stimulation of 100 Hz, pulse width of 0.2 to 0.4 ms, and stimulation duration of 10 seconds; 2 times per week.
224130287|NCT05047159|DRUG|drug therapy|There is no restriction on the choice of therapeutic drugs.
224130288|NCT04496440|OTHER|Contracture Correction Therapy|Non-drug and non-surgical treatment of contracted knee capsules
224130289|NCT01563640|OTHER|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
224130290|NCT01563640|OTHER|washing|normal washing of school uniforms, without permethrin insecticide impregnation
224019455|NCT05938374|RADIATION|Preoperative moderately fractionated radiotherapay|Patients will receive preoperative moderately fractionated radiotherapy (RT)(43.5Gy/15fr).
224019456|NCT04360317|DRUG|Combination of SH003 and Docetaxel|Combination of SH003 and Docetaxel
224019457|NCT05969743|DRUG|Letermovir|Patients meeting the inclusion criteria will receive letermovir 480 mg per day. Patients receiving concomitant cyclosporine will receive 240 mg of letermovir. Letermovir will be given during 14 weeks or until prednisone dose is reduced below 0.2 mg / kg / day, whichever comes earlier.
224019458|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
224019459|NCT03273556|DEVICE|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
224019460|NCT00947557|DRUG|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
224019461|NCT00947557|DRUG|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
224019462|NCT05624320|DRUG|AGN-190584|miotic for treatment of presbyopia
224019463|NCT01657955|DRUG|Bendamustine Hydrochloride Injection|
224019464|NCT01657955|DRUG|Chlorambucil|
224019465|NCT00533741|DRUG|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
224019466|NCT00533741|DRUG|Placebo|Saline for injection.
224130291|NCT00364494|PROCEDURE|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht\<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht\>25% bleed or not
224130292|NCT01842308|PROCEDURE|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
224130293|NCT01842308|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
224130294|NCT01842308|DRUG|Carfilzomib|Given IV
224130295|NCT01842308|OTHER|Laboratory Biomarker Analysis|Correlative studies
224130296|NCT01842308|DRUG|Melphalan|Given IV
224130297|NCT03237988|DRUG|CPI-444 Capsules|100mg Capsule
224130298|NCT03237988|DRUG|CPI-444 Tablets|100mg Tablets
224130299|NCT01971489|DRUG|Buparlisib|Given PO
224130300|NCT01971489|DRUG|Cisplatin|Given IV
224130301|NCT01971489|DRUG|Gemcitabine Hydrochloride|Given IV
224130302|NCT01971489|OTHER|Laboratory Biomarker Analysis|Correlative studies
224130303|NCT01971489|OTHER|Pharmacological Study|Correlative studies
224130304|NCT01971489|OTHER|Questionnaire Administration|Ancillary studies
224130305|NCT05945901|DRUG|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
224130306|NCT05945901|DRUG|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab|HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)
224130307|NCT04774042|DIETARY_SUPPLEMENT|Infloran probiotic|Infloran
224130308|NCT04774042|DIETARY_SUPPLEMENT|HAC probiotic|HAc probiotic
224130309|NCT04774042|DIETARY_SUPPLEMENT|Infloran placebo|Infloran placebo
224019467|NCT00533741|BIOLOGICAL|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
224019468|NCT01954381|DEVICE|transthoracic echocardiographic|
224019469|NCT01954381|DEVICE|Doppler ultrasound.|
224130310|NCT04774042|DIETARY_SUPPLEMENT|HAC placebo|HAC placebo
224296810|NCT05043623|DEVICE|Saliva swab|Saliva swab
223398707|NCT05148091|BIOLOGICAL|SCTV01C|A Recombinant Trimeric S Protein Vaccine against SARS-CoV-2 Alpha and Beta Variants
224130311|NCT03665350|DRUG|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
224130312|NCT04121429|OTHER|Observation|No intervention will be performed
223398708|NCT05148091|OTHER|Adjuvant|SCT-VA02B is the adjuvant of SCTV01C VACCINE applied as one of the control in the trial
223551170|NCT02440204|DRUG|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
224019470|NCT01954381|BIOLOGICAL|blood samples|
223398709|NCT05148091|OTHER|Saline|Saline is used as the other control in the trial
223398710|NCT05484492|BIOLOGICAL|demineralized and mineralized combination putty bone allograft|Subjects in this group will receive an intrasocket demineralized and mineralized combination putty bone allograft following tooth extraction
223398711|NCT05484492|BIOLOGICAL|calcium phosphosilicate putty alloplast graft|Subjects in this group will receive an intrasocket synthetic resorbable calcium phosphosilicate putty alloplast graft following tooth extraction
224296811|NCT05043623|DIAGNOSTIC_TEST|Abbott Panbio™ COVID-19 antigen self-test kit|COVID-19 antigen self-test kit for the screening of active COVID-19 infection. It is a single-use, in vitro, visually read rapid immunoassay that uses a human nasal swab specimen for the qualitative detection of nucleocapsid protein SARS-CoV-2 antigen. It is intended to be used manually by untrained lay users (self testing) in a private setting.
223551171|NCT01545297|DRUG|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
223551172|NCT01545297|DRUG|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
224296812|NCT03826498|BIOLOGICAL|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
223398712|NCT02205463|DRUG|KD019|
223551173|NCT01545297|DRUG|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
223551174|NCT03851627|DRUG|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
223551175|NCT03851627|DRUG|Placebo|Placebo Arm
224019471|NCT01094860|DRUG|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
224019472|NCT05409833|DIAGNOSTIC_TEST|Synovial biopsy and Cardiac scintigraphy with [99mTc]Tc-DPD|Congo red and Immunohistochemical analysis and/or Mass spectrometry analysis
224019473|NCT04014725|DEVICE|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
224019474|NCT00118755|DRUG|capecitabine|850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
224019475|NCT00118755|DRUG|Oxaliplatin|130 mg/m\^2 IV on Day 1 of each 3-week cycle
224019476|NCT00118755|DRUG|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
224019477|NCT00118755|DRUG|capecitabine|1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
224019478|NCT00118755|DRUG|Oxaliplatin|85 mg/m\^2 IV on Day 1 of each 2-week cycle
223551176|NCT00000407|BEHAVIORAL|Vocational counseling intervention|
223551177|NCT00000407|BEHAVIORAL|Reading materials for control participants|
223551178|NCT00000407|BEHAVIORAL|Standard of care|No education or behavioral intervention
223551179|NCT06231407|BEHAVIORAL|Recovery Oriented CBTp Medication Management|The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
223551180|NCT06231407|BEHAVIORAL|Treatment as Usual|Residents will conduct medication management appointments as normally conducted
224019479|NCT00118755|DRUG|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
224019480|NCT01203280|OTHER|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
224130313|NCT02352792|RADIATION|radiochemotherapy with 70 Gy|
224130314|NCT02352792|RADIATION|radiochemotherapy with 77 Gy|
224130315|NCT06483516|PROCEDURE|Open repair|Open repair via median laparotomy or lumbotomy
224130316|NCT06483516|PROCEDURE|Endovascular repair|EVAR if AAA simple F-BEVAR if Complex AAA
224130317|NCT05271422|DEVICE|Real Pulse Electrical Stimulation (NuEyne 01)|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
224130318|NCT05271422|DEVICE|Sham Pulse Electrical Stimulation|Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
224296813|NCT03826498|OTHER|Standard therapy|The standard therapy can include drugs, special psychology training etc.
224296814|NCT03716076|DRUG|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
224296815|NCT01385306|DEVICE|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
224296816|NCT03832699|DRUG|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
224019481|NCT00260663|PROCEDURE|Group hearing aid fittings|
224130319|NCT05848830|DIETARY_SUPPLEMENT|Mult-ingredient supplement|A mult-ingredient supplement containing Protein, both whey and casein, Creatine, Vitamin D, and Calcium. As well as antioxidants and other dietary supplements including Vitamin E, CoQ10, Alpha Lipoic Acid, L-Arginine, Beet Root Extract, Green Coffee Bean Extract, Green Tea Extract, Black Tea Extract, Curcumin, and Forskolin
224130320|NCT05848830|DIETARY_SUPPLEMENT|Placebo|The placebo sachet will contain micro-crystalline cellulose (inactive compound) and will be identical in look and taste to the active supplement.
224019482|NCT00260663|PROCEDURE|Group hearing aid follow-up|
224019483|NCT03867058|BEHAVIORAL|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
224019484|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 1|15g plant polar lipids from plant source 1. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
224019485|NCT06148974|DIETARY_SUPPLEMENT|Polar lipid 2|15g plant polar lipids from plant source 2. The lipid supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
224019486|NCT06148974|DIETARY_SUPPLEMENT|Non-polar lipids|15g non-polar plant lipids from plant source 1. The lipids supplement is consumed spread on a commercial white wheat flour bread as a source of available carbohydrates (50 g).
224130321|NCT05848830|BEHAVIORAL|Concurrent exercise training|All participants will undergo 16-weeks of exercise training, containing 3 days/week of resistance training and 2days/ week of aerobic training.
224130322|NCT00403312|BEHAVIORAL|Smoking Cessation Behavioral Program|
224130323|NCT00403312|DRUG|Nicotine Patch|
224130324|NCT00403312|BEHAVIORAL|Physical Activity|
224130325|NCT02836535|BEHAVIORAL|qualitative interviews|
223398713|NCT03992521|GENETIC|Nucleosome positioning|Stratification of patients based on nucleosome positioning from plasma DNA.
223398714|NCT01288079|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
223398715|NCT01288079|DRUG|Duloxetine|Capsule, oral, once daily
224019487|NCT06148974|OTHER|No lipids|A commercial white wheat flour bread as a source of available carbohydrates (50 g), without added lipids.
224019488|NCT04124081|DRUG|Hydronidone capsules& Entecavir capsules|take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
224019489|NCT03237351|DEVICE|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
224019490|NCT05747053|DIAGNOSTIC_TEST|AlloSure|AlloSure blood-draw at Post-operation day one and four, as well as one month, 2 months, 3, 9, 12, 15,18 and 24 months operation.
224019491|NCT05747053|DIAGNOSTIC_TEST|PAXGene|1 PAXgene tube will be collected with every biopsy performed and sent with the AlloSure test for the second 100 patients (patients 101-200). 21 gene markers will be sequenced by collecting 3 ml of blood.
224130326|NCT03585322|DRUG|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
224130327|NCT00987623|DEVICE|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
224130328|NCT00987623|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
224130329|NCT02437448|OTHER|No intervention|
223398716|NCT01288079|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
223398717|NCT02279966|DRUG|Vortioxetine 10 mg|
224019492|NCT00629434|OTHER|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
224019493|NCT00629434|OTHER|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
224130330|NCT05019040|DRUG|PA1010|TDF as control
224130331|NCT01140854|PROCEDURE|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
224130332|NCT01140854|OTHER|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
224130333|NCT03314558|OTHER|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
224130334|NCT06579196|DRUG|Trabedersen|Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).
223398718|NCT02279966|DRUG|Paroxetine 20 mg|
223398719|NCT02279966|DRUG|Placebo|
223398720|NCT00815464|DEVICE|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
223398721|NCT05981690|BEHAVIORAL|Therapist guided, parent-led CBT for preadolescent children with OCD|This treatment was adapted from an existing evidence based therapist guided parent-led CBT intervention for preadolescent children with anxiety difficulties. It consists of 6 to 8 treatment individual treatment sessions where parents learn CBT techniques to apply at home with their child
223398722|NCT03696290|DRUG|Aztreonam lysine|Nebulised aztreonam lysine 75mg
223398723|NCT03696290|OTHER|Placebo|Nebulised lactose monohydrate 5mg
223398724|NCT01132833|OTHER|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
223398725|NCT01132833|OTHER|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
224130335|NCT06579196|DRUG|Pembrolizumab|Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.
224130336|NCT01201070|DRUG|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
224130337|NCT03284242|DRUG|Treg|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
224130338|NCT04056455|DRUG|Mobocertinib|Mobocertinib capsule.
224130339|NCT05621824|DEVICE|Endoscopic ultrasound|Use endoscopic ultrasound to examine the pancreatic lesions.
224130340|NCT05621824|PROCEDURE|EUS-Fine needle aspiration|If solid mass of pancreas was found during EUS, EUS-FNA shall be conducted for diagnosis.
224130341|NCT00422838|PROCEDURE|fine-needle aspiration biopsy|aspiration of intrahepatic cells
224019494|NCT06110325|OTHER|Cawthorne and Cooksey exercise program|Participants in this group will receive an exercise program based on Cawthorne and Cooksey exercises. The intervention will last for 4 weeks, taking place three times a week, with the first session conducted in person and the remaining two assisted via video from their homes.
224130342|NCT02191241|DRUG|Red Vine Leaf Extract|
224130343|NCT01055808|DRUG|Insulins|Individual dose and frequency and duration as determined by the treating physician
224130344|NCT04392102|DRUG|ZL-2306(Niraparib）|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
224130345|NCT01172587|OTHER|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
224130346|NCT01005537|BIOLOGICAL|aldesleukin|Given IV and orally
224130347|NCT01005537|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
224130348|NCT01005537|DRUG|cyclophosphamide|Given IV
224130349|NCT03521687|DRUG|Apremilast|30 mg BID
224130350|NCT05344144|OTHER|Emotional Freedom Technique|EFT was applied to pregnant women with a history of prenatal loss twice, one week apart, by the researcher. Between the two treatments, they were given personalized homework (on waking up in the morning and before going to sleep at night) for self-administration.
224130351|NCT05344144|OTHER|Music|Music practice was applied to the pregnant women with a history of prenatal loss twice, one week apart, by the researcher. For one week after the first application, the music application was applied by the pregnant woman once a day/for 30 minutes, and the researcher was reminded by phone message.
224130352|NCT02951390|OTHER|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
224130353|NCT05606679|GENETIC|Analysis combinations of maternal KIR and HLA-C genotypes|Analysis of combinations of maternal KIR and HLA-C genotypes of the egg donor and fetus (based on the genotypes of the donor and male partner), as well as different HLA-F SNP genotypes of the recipients
224130354|NCT01151579|DRUG|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
224130355|NCT01151579|DRUG|Albuterol|Nebulized albuterol 2.5mg
224130356|NCT02458690|BEHAVIORAL|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
224130357|NCT02458690|BEHAVIORAL|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
224296817|NCT03832699|DRUG|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
224296818|NCT05645770|COMBINATION_PRODUCT|ECG, computerized task|ECG for cardiac waves computerized task for prospective memory
224296819|NCT03854786|DIETARY_SUPPLEMENT|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
224296820|NCT03854786|DIETARY_SUPPLEMENT|Pacebo|Methyl Crystalline Cellulose
224296821|NCT06305130|OTHER|No intervention|No intervention
224296822|NCT02192008|BIOLOGICAL|Salmonella Typhi|
224296823|NCT02192008|BIOLOGICAL|Salmonella Paratyphi|
224019495|NCT06110325|OTHER|Control|Control group will receive counseling focused on fall prevention and promotion of an active, healthy lifestyle through informational leaflets.
224019496|NCT00002151|DRUG|Celgosivir hydrochloride|
224130358|NCT02458690|DRUG|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. To optimize eIMPACT for CVD risk reduction, we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These medications are FDA approved for the treatment of depression and are the safest from a cardiovascular perspective.
224130359|NCT02458690|OTHER|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their Eskenazi Health primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
224130360|NCT02364167|DRUG|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
224130361|NCT02364167|DEVICE|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
224130362|NCT02364167|OTHER|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
224296824|NCT02564081|OTHER|Static Stretching lower limb|
224296825|NCT02564081|OTHER|Static stretching Cervical|
224296826|NCT03331237|PROCEDURE|scalene block|scalene block using 5ml of ropivacaine
224130363|NCT00437333|DRUG|Metformin cloridrate|
224130364|NCT00979446|BEHAVIORAL|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
224296827|NCT03331237|PROCEDURE|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
224130365|NCT00979446|BEHAVIORAL|Self-directed|Received study materials but no phone coaching
224019497|NCT03642951|DEVICE|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
224019498|NCT03642951|DEVICE|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
224019499|NCT00292162|PROCEDURE|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
224019500|NCT00292162|DRUG|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
224019501|NCT00292162|DRUG|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
224019502|NCT00292162|DRUG|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
224019503|NCT00701233|DRUG|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
224019504|NCT00701233|DRUG|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
224019505|NCT00553423|DRUG|Lactulose|Lactulose 30 ml q6h for 48 hrs
224019506|NCT00553423|DRUG|Placebo|Placebo 30 ml q6hrly for 48 hrs
224019507|NCT02118558|DEVICE|Negative Pressure Wound Therapy (NPWT)|
224019508|NCT02118558|DRUG|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
224019509|NCT01143038|BIOLOGICAL|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
224019510|NCT03344653|DEVICE|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
224019511|NCT03344653|DEVICE|Biosensors BioFreedom BA9 Drug Coated Coronary Stent|Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
224130366|NCT01276457|DRUG|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
224130367|NCT01276457|DRUG|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
224130368|NCT01276457|DRUG|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
224296828|NCT00872885|DRUG|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
224296829|NCT00872885|DRUG|Morphine|60 mg
224019512|NCT01197833|DRUG|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
224019513|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
224130369|NCT01333839|OTHER|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
224130370|NCT03134508|OTHER|treated by antiTNFα|pregnant IBD women treated by antiTNFα
224130371|NCT03134508|OTHER|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
224019514|NCT01197833|DRUG|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
224019515|NCT00562133|DRUG|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
224019516|NCT00562133|DRUG|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
224019517|NCT02178670|BIOLOGICAL|CSC-DC|
224019518|NCT03881488|DRUG|CTX-471|IV infusion every 2 weeks
224019519|NCT03881488|DRUG|Pembrolizumab (KEYTRUDA®)|IV infusion every 6 weeks
224019520|NCT00892073|DRUG|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
224296830|NCT00872885|DRUG|Placebo|single dosage
224296831|NCT01722565|PROCEDURE|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
224296832|NCT01047930|BEHAVIORAL|Exercise|"Each 3-day experimental period will include one of the following conditions:~1. Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~2. Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~3. No exercise - subject will watch television or read and they will be required to remain sedentary."
224019521|NCT00892073|DRUG|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
224130372|NCT01985633|BIOLOGICAL|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
223398726|NCT01132833|OTHER|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
224019522|NCT01346475|DRUG|valacyclovir|1000 mg orally three times daily for 5 weeks
224019523|NCT01346475|DRUG|Valacyclovir|500 mg orally once daily for 5 weeks
224019524|NCT00582868|DEVICE|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
224130373|NCT01985633|BIOLOGICAL|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
224130374|NCT02200471|DEVICE|VeinViewer|
224130375|NCT05519371|DRUG|Remimazolam|"During induction of anesthesia, the rimazolam group was given rimazolam pumped at a rate of 12 mg/kg/h~During the maintenance phase of anesthesia, the rimazolam group was given 1.0-2.0 mg/kg/h of rimazolam continuously pumped."
224296833|NCT04190030|BEHAVIORAL|mindfulness training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
224296834|NCT04190030|BEHAVIORAL|cognitive reappraisal training|Participants will listen to 20-minute lessons each day for 14 days plus complete brief (3 to 10 minute) exercises daily via their personal smartphone. Each course will involve mental exercises to reduce stress in daily life, along with direct instruction from the course leader to help in learning and applying the stress reduction techniques.
224296835|NCT00750646|DEVICE|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
224296836|NCT04111848|DRUG|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
223398727|NCT01036854|DRUG|EUR-1025|orally, 24 mg, daily for 6 days
223551181|NCT01266889|DEVICE|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
223551182|NCT03080571|BIOLOGICAL|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
223551183|NCT03080571|OTHER|standard care|
223551184|NCT01825330|DEVICE|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
224019525|NCT00582868|OTHER|CSF|analysis of CSF for cleaved tau protein
224019526|NCT00582868|OTHER|Whole blood|Analysis of whole blood for cleaved-tau protein
224019527|NCT05813639|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
224019528|NCT05813639|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|The procedure is based on positive lumbar Z- joint testing followed by medial branch neurotomy
224130376|NCT05519371|DRUG|Propofol|During induction of anesthesia, propofol 2mg/kg was given, and during the maintenance phase of anesthesia, propofol 6-8mg/kg/h was given as a continuous pump.
224130377|NCT01040208|DRUG|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
224130378|NCT01040208|DRUG|flibanserin 100 mg qhs|100mg qhs
224130379|NCT01040208|DRUG|placebo 2 tablets qhs|50 mg placebo
223398728|NCT01036854|DRUG|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
223398729|NCT01036854|DRUG|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
223398730|NCT01036854|DRUG|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
223398731|NCT00499005|DRUG|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
223398732|NCT00499005|DRUG|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
223551185|NCT01825330|DEVICE|sham|
223551186|NCT03634111|PROCEDURE|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
223551187|NCT03634111|DRUG|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
224019529|NCT05813639|PROCEDURE|Endoscopic denervation of fazet joint|The procedure is based on positive lumbar Z- joint testing followed by decapsulation of the facet joint through an endoscopic approach
224130380|NCT04877314|OTHER|Intermittent fasting|30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
224130381|NCT02991937|DRUG|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
224130382|NCT02991937|PROCEDURE|Surgical Treatment|Appendectomy
224130383|NCT01924052|DRUG|CGRP|Calcitonin-gene-related-peptide (CGRP)
224130384|NCT00643591|OTHER|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
224130385|NCT04809389|BIOLOGICAL|DelNS1-nCoV-RBD LAIV|Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
224130386|NCT04809389|BIOLOGICAL|Matching placebo|0.9% NaCl solution
224130387|NCT04550611|OTHER|Mini-pool Intravenous Immunoglobulin (MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
224130388|NCT04550611|OTHER|plasma exchange|plasma exchange (plasmapheresis ) in a regimen of removing of 1.3 plasma volumes in each cycle for total of five cycle for five consecutive days within four weeks of onset of symptoms.
224130389|NCT03524105|BEHAVIORAL|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
224130390|NCT03524105|BEHAVIORAL|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
224130391|NCT02582021|PROCEDURE|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
224130392|NCT02582021|PROCEDURE|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
224130393|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
224019530|NCT04674696|OTHER|Approach|Patients will receive 2 CAPOX cycles, followed by short-course radiotherapy and 4 CAPOX cycles.
224019531|NCT01572376|PROCEDURE|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
224019532|NCT03629327|DRUG|ASA 81mg|Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
224130394|NCT02582021|PROCEDURE|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
224130395|NCT02582021|PROCEDURE|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
224296837|NCT04111848|DRUG|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
224296838|NCT04929938|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This is a combination of cognitive-behavioural techniques oriented to improve the emotional regulation. The Unified Protocol is comprised of 8 modules and it is applied following The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders Manual (Barlow, 2017).
224296839|NCT01112813|DRUG|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
224296840|NCT02148861|DRUG|Insulin icodec|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
224296841|NCT02148861|DRUG|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
224296842|NCT02148861|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
223398733|NCT02806882|DRUG|Ceftaroline fosamil|600mg IV infusion
223398734|NCT02205073|DRUG|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
223398735|NCT02205073|DRUG|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
223398736|NCT02205073|DRUG|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
223398737|NCT04492982|BEHAVIORAL|Yoga|1 hour of group format, guided yoga practice
223398738|NCT04492982|BEHAVIORAL|Distress Tolerance|1 hour didactic group format, to develop distress tolerance skills
223398739|NCT04808674|BEHAVIORAL|Cognitive remediation program|Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer
223398740|NCT02603289|DEVICE|Invisalign|
223551188|NCT03634111|DRUG|Ropivacaine|Ropivacaine 0.25% 20 ml each side
224019533|NCT03629327|OTHER|Control Group|Participants will be randomized to take nothing on a daily basis for a duration of 6 months
224019534|NCT03629327|DRUG|ASA 325mg|Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
224019535|NCT03870217|BEHAVIORAL|Site selection|Turning off electrodes on the electrode array based on imaging and psychophysical measures
224019536|NCT04722939|DIAGNOSTIC_TEST|Cerebral oxygenation|Cerebral oxygenation will be monitored with the FORESIGHT Elite cerebral oximeter during the first 72h of critical illness, and during subsequent hemodialysis sessions
224019537|NCT02704663|PROCEDURE|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
224019538|NCT02704663|PROCEDURE|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
224019539|NCT06155227|OTHER|aerobic exercise combined with blood flow restriction|aerobic exercise combined with blood flow restriction for 18 sessions
224019540|NCT06155227|OTHER|aerobic exercise|aerobic exercise for 18 sessions
224130396|NCT02582021|PROCEDURE|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
224130397|NCT02582021|PROCEDURE|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
224130398|NCT02953392|DEVICE|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
224130399|NCT02953392|DEVICE|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
224019541|NCT03017534|PROCEDURE|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
224019542|NCT04019223|DIAGNOSTIC_TEST|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
224019543|NCT04019223|DIAGNOSTIC_TEST|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
224019544|NCT01171807|DRUG|Dex 21-P|At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.
224019545|NCT01171807|DRUG|Placebo|Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
224019546|NCT00136942|DRUG|Atorvastatin|
224019547|NCT06236555|DIAGNOSTIC_TEST|8-iso Prostaglandin F2α and Adenosine Deaminase|We took gingival crevicular fluid samples from patients who applied to our clinic and evaluated the -iso Prostaglandin F2α and Adenosine Deaminase levels in the samples.
224019548|NCT03689959|PROCEDURE|Eight plate hemiepiphysiodesis|Patient is positioned in a classic supine position. Under fluoroscopic guidance and tourniquet hemostasis, the distal femoral physis is identified. Two 3-cm incisions are made, one on either side of the patella, centred at the level of the physis. The capsule and synovium are opened to visualize the sulcus and place the plates just outside the articular portion of the joint surface, medially and laterally. Care is taken not to damage the periosteum and a needle is inserted into the physis. The 8-plate, which has a central hole, is slipped over the needle and screws inserted. After wound closure, a soft dressing is used, and the patient is allowed to ambulate as tolerated.
224019549|NCT00355459|DRUG|Tetracycline: Doxycycline analog|
224130400|NCT02953392|DEVICE|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
224130401|NCT02953392|DEVICE|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
224130402|NCT02042495|DRUG|Metformin|
223551189|NCT04490525|DEVICE|Telerehabilitation|Blood pressure (iHealth Neo/BP5s), weight (iHealth Lina), step counters(Fitbit Inspire \& Charge 3), sleep sensor (Emfit QS), and tablet (iPad Air 2).
224019550|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 3|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves
224019551|NCT06479642|PROCEDURE|Genicular nerve pulse radiofrequency ablation 4|Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves.
224019552|NCT04391634|OTHER|volume guarantee|volume guarantee assist-control mechanical ventilation
224019553|NCT04391634|OTHER|pressure-controlled|pressure-controlled assist-control mechanical ventilation
223551190|NCT05493878|DIAGNOSTIC_TEST|mRNA expression|Tumor educated platelets ITGA2b and SELP mRNA by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
224130403|NCT04100798|PROCEDURE|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
224130404|NCT04100798|PROCEDURE|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
224130405|NCT00063583|DRUG|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
224130406|NCT05256875|OTHER|chemical adherence test, medication adherence questionnaire, pharmacy refill rate|Urine/blood samples will be collected from participants, also they will be asked to complete a medication adherence questionnaire, medication records will also be examined to determine the pharmacy refill rate.
224296843|NCT05404074|DRUG|Cobitolimod 500mg|Rectal administration
224019554|NCT02415452|PROCEDURE|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
224019555|NCT04229875|OTHER|CAG Bipolar|See description of CAG Bipolar
224019556|NCT05356299|OTHER|Magnetictape bandage application|The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
223398741|NCT03687320|DEVICE|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
224019557|NCT02093000|DRUG|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
224019558|NCT02874924|DRUG|Rapamycin|treatment
224019559|NCT02874924|DRUG|Placebo|control
224019560|NCT02874924|DRUG|Rapamycin|No placebo control in this substudy group
224019561|NCT04609306|OTHER|H2O2 application to incision|A lap sponge soaked in 3% H2O2 will be applied to the incision and allowed to sit for 3 minutes.
224019562|NCT04950504|DRUG|CNP-201|CNP-201 is comprised of purified peanut extract (PPE) drug substance dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particles at a target concentration of \~5 μg of PPE per mg of PLGA.
224019563|NCT04950504|DRUG|Placebo|CNP-201 Placebo
224019564|NCT03306459|DIAGNOSTIC_TEST|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
224019565|NCT00234767|DEVICE|Pulmonary Artery Catheter|
224019566|NCT00234767|BEHAVIORAL|Protocolized Fluid Management|
224019567|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
224019568|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
224019569|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
224019570|NCT01385878|PROCEDURE|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
224019571|NCT00920049|BEHAVIORAL|Persuasion|
224019572|NCT02728869|BIOLOGICAL|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1\[8\]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
224296844|NCT03798665|DRUG|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
224296845|NCT00115557|OTHER|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
223398742|NCT03687320|DEVICE|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
223398743|NCT06275373|DRUG|Teprotumumab Injection [Tepezza]|IGF1 monoclonal antibody
223398744|NCT03170544|DRUG|MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
223398745|NCT03170544|DRUG|MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
223398746|NCT03170544|DRUG|MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
224019573|NCT02728869|BIOLOGICAL|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
224019574|NCT02728869|BIOLOGICAL|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7\[5\]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A\[8\]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
224019575|NCT02771080|PROCEDURE|Cardiac surgery|
224019576|NCT00459615|DRUG|Artesunate for Injection|
224019577|NCT02029846|DRUG|Standard Treatment|traditional drugs only
224019578|NCT02029846|DRUG|Incretin-Based Treatment|incretin-based drugs
224019579|NCT02561754|DIETARY_SUPPLEMENT|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
224019580|NCT02561754|DIETARY_SUPPLEMENT|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
224019581|NCT02561754|BEHAVIORAL|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
224019582|NCT02561754|BEHAVIORAL|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
224019583|NCT02561754|OTHER|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
224019584|NCT02389608|DEVICE|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
224019585|NCT02389608|DEVICE|Functional electrical stimulation (FES)|
224019586|NCT02389608|DEVICE|Sham stimulation|
224296846|NCT00115557|OTHER|Practice intervention 2|Performance feedback only.
224296847|NCT05384717|OTHER|Fidget Device|Fidget spinner, stress ball, pop-it, or fidget cube
224296848|NCT05384717|OTHER|Control group|No intervention
223731510|NCT05624203|DEVICE|Extracorporeal cardiac shock wave therapy(ECSW)|Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
223731511|NCT03060629|BIOLOGICAL|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10\^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
223731512|NCT03060629|BIOLOGICAL|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
223731513|NCT03060629|BIOLOGICAL|Placebo|Participants will receive matching placebo.
223731514|NCT01405742|DRUG|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
223731515|NCT05371691|DEVICE|Myofunctional appliance|Myifunctional appliance will be used for growing patients who have Cl.II div.1 malocclusion, two types of appliances are involved myobrace and twin=block appliance
223731516|NCT02503735|DRUG|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
223731517|NCT00996645|OTHER|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
223731518|NCT02160574|DRUG|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
223731519|NCT02160574|DRUG|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
223731520|NCT02160574|DRUG|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
223731521|NCT02160574|OTHER|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
223731522|NCT00118001|BEHAVIORAL|Worry exposure|
223731523|NCT00118001|BEHAVIORAL|Applied relaxation|
223731524|NCT03491371|DRUG|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
223731525|NCT04372901|PROCEDURE|Digitally constructed frameworks before implant placement|Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
223731526|NCT04372901|PROCEDURE|Digitally constructed frameworks after implant placement|Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
223731527|NCT01003912|BIOLOGICAL|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
223731528|NCT02261155|PROCEDURE|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
224019587|NCT04219579|DRUG|Antithrombin III, continuous infusion|Antithrombin-III is administered continuously
223398747|NCT03170544|DRUG|MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
223398748|NCT03170544|DRUG|MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
223398749|NCT03170544|DRUG|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
223731529|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
223731530|NCT00838890|DRUG|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
223731531|NCT00314912|DRUG|Tramiprosate (3APS)|
223731532|NCT06348602|DRUG|Cyclosporine ophthalmic solution 0.1%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
223731533|NCT06348602|DRUG|Tacrolimus ophthalmic ointment 0.03%|Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
223731534|NCT03672747|DEVICE|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
223731535|NCT04236830|DRUG|Silver diamine fluoride/ potassium iodide|Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.
223731536|NCT04236830|DRUG|Silver diamine fluoride|Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.
223731537|NCT04236830|DRUG|Resin modified glass ionomer cement|Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
223731538|NCT06382792|PROCEDURE|proximal humeral resection for tumor and allograft prosthetic composite reconstruction|allograft prosthetic composite
224019588|NCT04219579|DRUG|Antithrombin III, Intermittent infusion|Antithrombin-III is administered intermittently
224019589|NCT00677001|DRUG|R306465|
224019590|NCT06476756|OTHER|ACTIVE CYCLE OF BREATHING TECHNIQUE|Group A: combine effects of ACBT and Buteyko techniques will be performed first 3days of cardiac rehab phase 1.
224019591|NCT06476756|OTHER|Buteyko techniques|Group B: effect of buteyko techniques will be performed first three days of cardiac rehab phase 1.
223398750|NCT03170544|DRUG|Lispro 1.2 nmol/kg|Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting \~12 hours after MK-1092 administration.
223551191|NCT01947283|BEHAVIORAL|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
223551192|NCT01947283|BEHAVIORAL|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
223731539|NCT04973826|DRUG|Aztreonam-Avibactam|500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
223731540|NCT00627120|DRUG|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
223731541|NCT01335984|PROCEDURE|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
223731542|NCT01335984|PROCEDURE|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring \& Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
223731543|NCT01335984|OTHER|control group|"\- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
223731544|NCT00824512|DRUG|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
223731545|NCT00824512|DRUG|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
223731546|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
224019592|NCT00642772|OTHER|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
223398751|NCT03170544|DRUG|Placebo to glargine|Placebo to glargine, SC, as a single dose
223398752|NCT03170544|DRUG|Placebo to MK-1092|Placebo to MK-1092, SC, as a single dose
223551193|NCT02491047|DEVICE|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
223551194|NCT02491047|OTHER|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
223551195|NCT05524636|DEVICE|Exercise with peripheral magnetic stimulation of the abdominal wall muscles|8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
223551196|NCT05524636|OTHER|Exercise of the abdominal wall muscles|8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
223551197|NCT03918382|OTHER|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
223551198|NCT05811754|OTHER|Data collection|"This study will be conducted using data provided by U.S. Data Partners in the FDA's Sentinel System.~Three Data Partners will participate in this study: CVS Health Clinical Trial Services (CTS), HealthCore, Inc., and Optum."
223551199|NCT04909840|OTHER|Instructions oral hygiene with toothbrush plus dental floss|Instructions of oral hygiene with toothbrush plus dental floss
223731547|NCT01782495|DRUG|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
223731548|NCT01782495|DRUG|ribavirin|tablet
223731549|NCT00229060|DRUG|doripenem|
223731550|NCT03428360|DRUG|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category|The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
223731551|NCT00470639|DEVICE|Transcranial Magnetic Stimulation|
223551200|NCT04909840|OTHER|Instructions oral hygiene with toothbrush only|Instructions only with toothbrush
223731552|NCT01782144|OTHER|NutriSystem portion-controlled pre-packaged meals|
224019593|NCT04073459|BIOLOGICAL|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
224019594|NCT04073459|BIOLOGICAL|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
224019595|NCT03023761|DEVICE|low level laser|low level laser irradiation
224019596|NCT03023761|DEVICE|laser sham|laser without irradiation
224019597|NCT00200993|BEHAVIORAL|physical activity|
223398753|NCT03170544|OTHER|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
223398754|NCT03170544|BIOLOGICAL|Insulin|Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
223398755|NCT02387840|DEVICE|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
223398756|NCT02387840|DEVICE|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
223398757|NCT03745079|OTHER|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
223398758|NCT03745079|OTHER|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
223398759|NCT03745079|OTHER|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
223398760|NCT04273308|DEVICE|whole-body vibration training|The experimental group participated in a 12-week whole-body vibration training that was conducted 3 times per week, with 5-min continuous vibration at 12-Hz frequency and 3-mm amplitude each time. The control group were provided home DVDs on resistance exercise and manuals for preventing frailty
223398761|NCT06528379|BEHAVIORAL|Physical Activity|"The exercise programme is a 6-month progressive tailored-based exercise regime comprising~* aerobic exercises (40-60%)~* resistance exercises (20-40%)~* balance with resistance exercises (20%) .~This is peformed 3 times weekly, it is tailored to each individual but delivered in a small group-based manner. Two sessions are supervised by physiotherapist /exercise scientist and one session is unsupervised, home-based."
223398762|NCT03280238|DIAGNOSTIC_TEST|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
223398763|NCT02535403|BEHAVIORAL|ICBT|
223398764|NCT00753038|BIOLOGICAL|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
223398765|NCT00753038|DRUG|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
223398766|NCT00753038|DRUG|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
223398767|NCT00043303|DRUG|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
223398768|NCT02164045|DRUG|BMS-663068|BMS-663068
223398769|NCT03479398|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
223398770|NCT01755533|OTHER|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
223398771|NCT01755533|OTHER|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
223398772|NCT01689883|DEVICE|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
223398773|NCT01354405|DRUG|Lanreotide|120 mg every 28 days intramuscular
223398774|NCT02735902|DRUG|Vitamin K antagonist or direct oral anticoagulant treatment|"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"
223551201|NCT05202899|DRUG|sugammadex|The use of sugammadex
224019598|NCT00903006|DRUG|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
224019599|NCT00903006|DRUG|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
224019600|NCT00903006|DRUG|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
224019601|NCT04137159|OTHER|Functional Electrical Stimulation rowing exercise|Full-body aerobic exercise
224019602|NCT04275089|DEVICE|Reia Vaginal Pessary|Reia Vaginal Pessary
224019603|NCT02469389|BEHAVIORAL|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
224019604|NCT02469389|BEHAVIORAL|Health & Wellness (H&W)|"Health \& Wellness (H\&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session)."
224019605|NCT00596479|DRUG|Filgrastim (rG-CSF)|
224019606|NCT02443974|DEVICE|Brace (Fisiotensor®)|
224019607|NCT02443974|DEVICE|Sleeve (Fisiotensor®)|
224019608|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Reference product 20 ml
224019609|NCT01767532|DRUG|Cephalexin 125 mg/5ml|Test product 20 ml
224019610|NCT05074485|DRUG|anakinra|intravenous injection of 100 milligrams anakinra
224019611|NCT05074485|DRUG|Placebo|intravenous injection of 1 milliliter normal saline
224019612|NCT05074485|OTHER|Nociceptive pain challenge|The experimental, standardized, nociceptive pain challenge will induce a moderate level of sustained pain. The pain challenge involves a masseteric injection in the left or right jaw muscle of normal saline (0.15 ml bolus of 0.9% normal saline) over a 15 second period followed by continuous infusion via a closed loop infusion system for 20 minutes.
224019613|NCT03038438|DEVICE|Abre venous self-expanding stent system|venous stent
224019614|NCT00819520|DRUG|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
224019615|NCT00819520|DRUG|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
224019616|NCT00079989|DRUG|tigecycline|
223398775|NCT02735902|DRUG|Aspirin|"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
224019617|NCT02179099|DEVICE|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
224019618|NCT01847300|BEHAVIORAL|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
223398776|NCT03402295|DRUG|Bortezomib, cyclophosphamide, thalidomide, dexamethasone|Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
223398777|NCT02627690|OTHER|islet transplanted|islet transplantation
223398778|NCT02627690|OTHER|non islet transplanted|no islet transplantation (for a non nephrologic reason)
223398779|NCT03477006|BIOLOGICAL|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
223398780|NCT02251483|OTHER|Serum-derived bovine immunoglobulin protein isolate (SBI)|
223398781|NCT02251483|OTHER|Placebo|
223398782|NCT06797505|DRUG|PEG-rhGH with new preparation (T)|A single subcutaneous injection of PEG-rhGH with new preparation
223398783|NCT06797505|DRUG|PEG-rhGH with present preparation (T)|A single subcutaneous injection of PEG-rhGH with present preparation
223398784|NCT05579431|DRUG|VX-634|Suspension for oral administration.
223398785|NCT05579431|DRUG|Placebo|Suspension for oral administration.
223398786|NCT02174627|DRUG|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
223398787|NCT02174627|DRUG|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
223398788|NCT04542473|DRUG|Pancreatic Enzyme|CREON micro 5000
223398789|NCT04542473|DRUG|Ursodeoxycholic acid|Ursodiol C24H40O4 suspension
223398790|NCT04542473|OTHER|Pancreatic Enzyme placebo|Microcrystalline Cellulose,Macrogel 4000, Iron Oxide Yellow, Iron Oxide Red, Activated Charcoal.
223551202|NCT04186325|PROCEDURE|DIAPHRAGMATIC exercising|inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
223731553|NCT02235012|DRUG|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
223398791|NCT04542473|OTHER|Ursodeoxycholic acid placebo|Sodium Citrate Dihydrate, Aspartame, Carboxymethylcellulose Sodium, Citric Acid Monohydrate, Dispersible Cellulose, Glycerol, Polysorbate-80, Saccharin Sodium,Sodium Benzoate, Sodium Methylparaben, Sodium Propylparaben
223398792|NCT05050565|BEHAVIORAL|Experiences of stigma and psychological flexibility in chronic pain participants|Chronic pain participants will answer questionnaires at two points in time, two weeks apart. These questionnaires ask about stigma and psychological flexibility, as well as depression, catastrophizing, pain interference, and social adjustment. The data collected is only observational and does not include any intervention.
223398793|NCT06564818|DRUG|CYB003|CYB003 is a Deuterated Psilocin Analog.
223398794|NCT06564818|BEHAVIORAL|Psychological Support|Manualized psychological support performed by facilitators
223398795|NCT06564818|DRUG|Placebo|Placebo
223398796|NCT03667040|BEHAVIORAL|JOOL app|Participants will use the JOOL app for 30 days
223398797|NCT04564092|DRUG|DaTSCAN™ Ioflupane (123I) Injection|Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
223398798|NCT02026050|PROCEDURE|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
223731554|NCT02235012|DRUG|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
224019619|NCT05788211|OTHER|standard of care|retrospective study: standard of care
224019620|NCT05729971|PROCEDURE|nasogastric tube|The intervention consists in removing or not the nasogastric tube at the end of the surgery.
224019621|NCT00900744|DRUG|Tamoxifen|20 mg daily
223398799|NCT02026050|PROCEDURE|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
223398800|NCT02026050|PROCEDURE|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
223398801|NCT00512681|DRUG|Irinotecan, Oxaliplatin, TS-1|"* S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~* Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~* Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
223398802|NCT00071110|PROCEDURE|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
223398803|NCT00071110|PROCEDURE|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
224019622|NCT04703738|PROCEDURE|Soft tissue flap + Connective Tissue Graft|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and graft without compression. The harvest graft donor area will be the palate in the bicuspid region on the same side as the control soft tissue augmentation therapy. The CTG will be harvested using full thickness incisions that include the periosteum and will be closed using suture and coating the incision line with a tissue adhesive. No covering stents or packs should be employed. The CTG will be sling sutured in place and the flap secured using a double sling suturing technique.
224019623|NCT04703738|DEVICE|Soft tissue flap + Geistlich Fibro-Gide®|The treatment site is accessed using a full thickness flap extending at least 1 full tooth mesial and distal, vertical releasing incisions may be used to obtain flap release for full coverage of the treatment site and matrix without compression. Geistlich Fibro-Gide® is cut to shape to the treatment site and placed dry into the site. The flap is secured using a double sling suturing technique.
224019624|NCT02206594|PROCEDURE|Descemetorhexis|
224019625|NCT01948726|RADIATION|Hypofractionation with simultaneous integrated boost|
224019626|NCT01360710|DRUG|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
224019627|NCT01360710|DRUG|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
224019628|NCT03864822|DEVICE|High-Definition Transcranial Direct Current Stimulation|Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
224019629|NCT02674815|OTHER|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
224019630|NCT04304521|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver is used to reopen or prevent collapsed lung under mechanical ventilation so as to decrease respiratory complications. LRM induces a transient increase in intra-thoracic pressure and decreases in venous return, leading to a decrease in left ventricular end-diastolic area and stroke volume.
224019631|NCT04961658|BIOLOGICAL|GEM00220|Cryopreserved allogeneic, enhanced MSCs administered as a single intravenous infusion
224019632|NCT06124781|PROCEDURE|Blood sample|A blood sample (48 ml) will be collected from each patient before performing the ROAT tests. This sample will be used to perform in vitro lymphocyte proliferation test, and cytokine measurements.
224019633|NCT06124781|PROCEDURE|Skin biopsies|2 skin biopsies will be performed at the inclusion: one from positive/doubtful patch test reaction and one from control patch test. In case of positive ROAT test, 2 additional biopsies will be collected: one from positive ROAT test reaction and one from control area. Molecular analysis will be performed.
224019634|NCT06124781|PROCEDURE|ROAT test|ROAT test (repeated open application test) is a use test used to establish the clinical relevance of patch tests. Patients will be exposed to 3 solutions of increasing concentration containing the culprit allergen (nickel, limonene hydroperoxide or linalool hydroperoxide), as well as a solution containing the vehicle alone (control solution), 2 times a day for up to 21 days, in the absence of a reaction.
224296849|NCT06219993|PROCEDURE|robot-assisted modified Kasai portoenterostomy|"1. A 1.0 cm incision was made around the umblilicus for the camera port. 1.Firstly, the Exploring hepatic subcapsular spider-like telangiectasis (HSST) sign at the surface of the liver, and indocyanine green (ICG) cholangiography were observed to confirm the BA diagnosis.~2. dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With electric scissors help, the fibrous plate was horizontally cut from the middle of the portal plate and transected from to the left and to the right sides which was the Glissonian systems enter the liver parenchyma until see the bile outflow by verified by ICG. The opening of microbile ducts and abundant bile outflow were clearly visible under 10× camera of Da Vinci robot."
224019635|NCT03896204|BEHAVIORAL|telephone-suppoted joint protection technique|After joint protection technics training, patients will be followed up with telephone support for 1 month.
224019636|NCT03896204|BEHAVIORAL|joint protection technique training|Training will be given to individuals about joint protection technique
224019637|NCT01096823|BEHAVIORAL|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
224019638|NCT00327496|BIOLOGICAL|DC vaccine|
224019639|NCT04789772|DEVICE|Laser acupuncture|The interventional group receive laser acupuncture applied on acupoints of PC6 (Neiguan), HT7 (Shenmen), LI4 (Hegu), ST36 (Zusanli), SP6 (Sanyinjiao), and LR3 (Taichong).
224019640|NCT00577473|DRUG|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
223398804|NCT05344495|DRUG|hyalase group|bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
223398805|NCT05344495|DRUG|midazolam group|2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
224019641|NCT00577473|DRUG|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
224019642|NCT05564728|OTHER|Conversational Agent/Chatbot App|Well Feet is developed based on adaptive learning frameworks to deliver diabetes foot care education through a conversational agent. The learning path for each participant will be customised based on their responses to pre-module quizzes.
224019643|NCT04312217|BEHAVIORAL|Medical clowning|Medical clowning
224019644|NCT05780320|OTHER|Prophylactic amiodarone and posterior pericardiotomy|"Patients after the implementation of the protocol receive postoperative prophylactic amiodarone and a posterior pericardiotomy.~The amiodarone regimen consists of amiodarone 1mg/min x 10 hours (600 mg total) via central line upon arrival to the intensive care unit followed by 400 mg PO BID on postoperative days 1 and 2 followed by 200 mg PO BID on postoperative days 3 and 4 or until discharge, whichever occurs first.~The posterior pericardiotomy occurs during the cardiac procedure."
224019645|NCT02884908|DRUG|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
224019646|NCT02884908|OTHER|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
224019647|NCT01240226|DRUG|GDC-0941|Oral repeating dose
224130407|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
224130408|NCT00465855|COMBINATION_PRODUCT|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
224130409|NCT05442463|DRUG|Captopril Tablets|Captorpril challenge to each participant
224130410|NCT05442463|DRUG|Iohexol|Iohexol infusion to evaluate measured GFR
224019648|NCT01240226|DRUG|GDC-0941|Oral repeating dose
223398806|NCT03165812|PROCEDURE|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
224019649|NCT01240226|DRUG|ketoconazole|Oral repeating dose
224019650|NCT02450799|DEVICE|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
224019651|NCT02450799|DEVICE|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
224130411|NCT03506698|OTHER|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
224130412|NCT05125536|OTHER|Music therapy|rutin
224130413|NCT02958397|BIOLOGICAL|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
224130414|NCT06108869|OTHER|ABT Online Programme|"When the study begins, participants meet each week on Microsoft teams for a 6 week period. Each session will last approximately 1 hour. There will be a maximum of six other participants and two facilitators present at each session. Each session will consist of:~* A short ABT practice~* An educational component related to the development of our ABT practice~* A group discussion on the week's topic and how it relates to you and your diagnosis"
224130415|NCT06108869|OTHER|Delayed Control group|Participants will still meet as a group for first two weeks, before beginning with the ABT practice.
224130416|NCT00658372|DRUG|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
224130417|NCT00658372|DRUG|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
224130418|NCT00658372|DRUG|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
224130419|NCT00658372|DRUG|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
223398807|NCT03165812|PROCEDURE|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
223551203|NCT03571750|BEHAVIORAL|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
224019652|NCT02450799|DEVICE|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
224019653|NCT03468738|OTHER|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
224019654|NCT05024227|BEHAVIORAL|Experimental: nursing education interventions (including e-health platform assistance)|Nursing education intervention: Researchers use teaching, consultation and other methods to give individual cases planned learning to meet individual needs, providing 1. What is an environmental hormone-plasticizer; 2. Common types of environmental hormones (such as plasticizers) and Uses 3. Environmental hormones-sources of plasticizers 4. Environmental hormones-plasticizers harm to the human body 5. How to avoid the common environmental hormones-plasticizers and other related health education in life, and use the electronic platform to assist nursing education conduct.
224019655|NCT03390374|DRUG|Nystatin Oral|Nystatin oral suspension
224019656|NCT05114239|DRUG|Timolol 0.25% Ophthalmic Solution|Applied to treatment side prior to standard wound care
224019657|NCT05114239|OTHER|Standard Wound Care|Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
224130420|NCT04308512|DEVICE|Care4AD system|Eligible subjects will be randomized to intervention, IG, and control groups, CG, with ratio of 1:1 and will be assessed at baseline and six months. All reminders will be activated in the intervention group and de-activated in the control group. Essential ADL tasks will be preprogrammed by our care coordination expert for the IG. Patients and their caregivers in the IG will be also able to schedule additional tasks.
224130421|NCT00003662|BIOLOGICAL|anti-thymocyte globulin|
224130422|NCT00003662|DRUG|busulfan|
224130423|NCT00003662|DRUG|cyclophosphamide|
223398808|NCT04507464|BEHAVIORAL|Ecological Momentary Intervention|Participants will wear a Fitbit that has been programmed to deliver a notification (a buzz) when activity has ceased for more than 10 minutes. They will receive suggestions on their Illumivu mEMA smartphone app on how to replace sitting time with PA such as standing up 5 times or taking 20 steps, or even performing a short (20 seconds) preferred dance routine. Fitbit data will be captured in real-time via the iCardia platform. Participants will receive reminders from their smartphones to enter real-time feedback on activity options selected and how successful they were in adopting the option. These data will allow tracking of underlying preferences for behaviors and to tailor the program accordingly.
223551204|NCT03571750|BEHAVIORAL|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
224019658|NCT01485081|DEVICE|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
224019659|NCT02684851|DRUG|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
224019660|NCT02684851|DRUG|Placebo|Placebo
224019661|NCT04896112|DRUG|LNK01002|LNK01002 will be administrated orally.
224019662|NCT05050994|PROCEDURE|Microwave ablation|Children with symptomatic secondary splenomegaly will receive partial microwave ablation of spleen (up to 40-50% of total volume)
224019663|NCT03326453|DEVICE|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
224019664|NCT05023083|OTHER|Functional Status Questionnaire Urdu version|The FSQ instrument translated into Urdu consists of only 34 items, main sections addressed physical function in the activities of daily living, psychological function, role function, social function and variety of performance measures.(8) Scores range from a 0 - 4, 1 - 4, and 1 - 6 scale per question depending on section. It increases reliability and patients ease and comfort. Total score range from 0 to 100 higher score represents the more severe condition.
224019665|NCT05023083|OTHER|Original Functional Status Questionnaire|FSQ was developed to allow the comprehensive and efficient assessment of physical, psychosocial, social, and role functioning in ambulatory patients. It is a self-administered survey that takes approximately 15 min to complete. The results can be scored to produce a one-page report for clinicians to use in their practices. The responses to items within a scale are averaged and transformed to a scale with a potential range of 0 to 100.Higher score represents the more severe condition.
224019666|NCT00419133|BIOLOGICAL|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
224019667|NCT00419133|BIOLOGICAL|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
224019668|NCT05506657|OTHER|State Counselor-Coordinated Services|"A counselor affiliated with the New Jersey State Division of Vocational Rehabilitation Services coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
224130424|NCT00003662|DRUG|cyclosporine|
224130425|NCT00003662|DRUG|melphalan|
224130426|NCT00003662|DRUG|methylprednisolone|
224130427|NCT00003662|PROCEDURE|umbilical cord blood transplantation|
224130428|NCT00003662|RADIATION|radiation therapy|
224130429|NCT04006743|BEHAVIORAL|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
224296850|NCT06219993|PROCEDURE|traditional open Kasai portoenterostomy|Dissecting forceps and electric scissors were applied to dissociate the atresia bile ducts and lymph nodes in portal hepatis. Exposed the hepatic artery and portal vein. All portal vein tributaries that drain into the fibrous cone were coagulated by bipolar coagulation to expose the portal plate for resection. With scissors help, the fibrous cone of the hilar region was transected from left to right (the level of transection depends on adequate bile outflow).
224296851|NCT02400671|BEHAVIORAL|SMS messaging|
223398809|NCT00200564|DRUG|ketamine|
223398810|NCT03447587|OTHER|Electroacupuncture|Each subject will be treated with predefined acupoints including bilateral Ear-Shenmen, Touwei (ST8), Sishencong (EX-HN1), and unilateral Yintang (EXHN3) and Baihui (GV20) on the head (total 8 needles). Subject's current symptoms will be ascertained using a Traditional Chinese Medicine symptom checklist and eight additional acupoints will therefore be selected and needled based on their clinical judgements. The acupuncture treatment will consistent of two sessions per week (30 minutes) for 4 consecutive weeks.
223398811|NCT03447587|OTHER|Sham acupuncture|Subjects will be treated at 1 cm posteriorly and laterally adjacent to the same acupoints as the traditional acupuncture group using validated non-invasive sham needles. Subjects will also be assessed with Traditional Chinese Medicine checklist. The acupuncturist, setting, treatment frequency, and duration of the treatment course will be the same as in the traditional acupuncture group.
223398812|NCT03213808|OTHER|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
224130430|NCT04006743|BEHAVIORAL|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
224130431|NCT04006743|BEHAVIORAL|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
223551205|NCT03782259|DRUG|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
223551206|NCT03782259|OTHER|Placebo|Placebo
224019669|NCT05506657|OTHER|Center Facilitator-Coordinated Services|"A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers."
224019670|NCT04080908|DRUG|Ferumoxytol injection|Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
224130432|NCT04006743|BEHAVIORAL|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
224130433|NCT04006743|BEHAVIORAL|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
224130434|NCT02065869|BIOLOGICAL|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
224130435|NCT02065869|DRUG|Rimiducid|0.4mg/kg administered IV to treat GVHD
224130436|NCT02830841|DEVICE|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
224130437|NCT02830841|DEVICE|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
223551207|NCT01679938|BEHAVIORAL|primary obesity prevention|"1. Training of child care providers.~2. Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~3. Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~4. Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
224019671|NCT02103244|DRUG|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
224019672|NCT00232544|DEVICE|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
224130438|NCT04755296|DEVICE|Low level laser therapy|Low level laser therapy was applied immediately before each aerobic exercise training session by using a multidiode cluster (with four diode spots; Polaris2, manufactured by Astar ABR, Poland) )on 12 sites on the lower limb (6 on quadriceps ( 2 centrally on rectus femoris and vastus intermedius,2 laterally on vastus lateralis, and two medially on vastus medialis), 4 on hamstrings and 2 on gastrocnemius) with the following parameters: 808 nm, continous output, 200 mW each diode (total of 800 mW) power output, 24 J energy on each site (6 J for each spot) , 40 seconds at each site (8 minutes of total treatment time in lower limb) and 288 J total energy delivered per lower limb, 48 irradiation points per lower limb ,3 sessions weekly for 12 weeks.
224019673|NCT00232544|OTHER|TLC-Control|A TLC system for providing general health education
224019674|NCT03142126|DEVICE|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
224019675|NCT04742127|DIAGNOSTIC_TEST|Single surgical debridement|To describe the clinical factors associated with failure of a single surgical debridement in patients with septic arthritis of the native hip.
224130439|NCT04755296|OTHER|Aerobic exercises|Aerobic exercise program consisted of walking on the treadmill at a rate of 3 sessions/week for 12 weeks, with each session lasting for 40 minutes in the form of warming up for 5 minutes at intensity of \<50% of the previously determined VO2max of each participant, 30 minutes of treadmill exercises at intensity of (70-85%) of the previously determined VO2max of each participant then 5 minutes cooling down at intensity of\<50% of the previously determined VO2max of each participant.
224130440|NCT04755296|OTHER|Traditional physical therapy program|Patients were received traditional physical therapy program in the form of (stretching and strengthening exercises for all affected areas, diaphragmatic breathing exercises and activities of daily living).
223398813|NCT01473264|DRUG|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
224019676|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
224019677|NCT03562143|DIETARY_SUPPLEMENT|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
224019678|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum + bifidobacterium lactis|Synbiotic Supplement: Contains 5 grams of prebiotic fiber (Sunfiber®) and 8 billion active probiotics (Bifidobacterium lactis).
224019679|NCT06021171|DIETARY_SUPPLEMENT|Partially hydrolyzed guar gum|5 g Partially hydrolyzed guar gum
224019680|NCT06021171|DIETARY_SUPPLEMENT|Maltodextrin|5 g Maltodextrin
224019681|NCT02862834|GENETIC|High-throughput exome sequencing|
224019682|NCT03129139|DRUG|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
224019683|NCT02364843|DIETARY_SUPPLEMENT|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
224019684|NCT00366808|PROCEDURE|LASIK surgery|
224019685|NCT00518492|PROCEDURE|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
224019686|NCT02619981|PROCEDURE|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
224019687|NCT02619981|DRUG|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
224130441|NCT03020901|DRUG|Teicoplanin for Injection|Use Teicoplanin for Injection
224130442|NCT05916833|OTHER|hypopressive breathing|Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.
224130443|NCT05916833|OTHER|noble technique|Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
224130444|NCT03184909|DRUG|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
224130445|NCT03184909|DRUG|Placebo|Placebo capsules of look alike inert substance for control
224130446|NCT00592397|OTHER|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
224130447|NCT03463616|RADIATION|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
224130448|NCT03463616|RADIATION|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
224130449|NCT03807739|DRUG|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
224130450|NCT03807739|DRUG|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
224130451|NCT03807739|DRUG|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
223398814|NCT01473264|DRUG|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
224019688|NCT00513513|DRUG|TMC114 (darunavir) / ritonavir|
224019689|NCT03294148|OTHER|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
224019690|NCT03294148|BEHAVIORAL|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
224019691|NCT01869127|DEVICE|Shoes|A unisex canvas slip-on with a sturdy sole.
224019692|NCT01424904|DIETARY_SUPPLEMENT|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
224019693|NCT06454994|DEVICE|Eyebrow lift|Upper face lifting
224019694|NCT06454994|DEVICE|Jaw lift|Mid-face and low-face lifting
224130452|NCT04720508|DIAGNOSTIC_TEST|blood sample collection.|venipuncture procedure
224130453|NCT05009823|DIETARY_SUPPLEMENT|Standard F75|F-75 contains 75 kcal and 0.9 g protein per 100 ml.
224130454|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 With CMV|Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
224130455|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 Without CMV|Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
224130456|NCT05009823|DIETARY_SUPPLEMENT|F100|100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
224019695|NCT04032054|DEVICE|mono-axial and poly-axial screws|types of pedicular screws for thoracolumbar fractures fixation
224019696|NCT05712473|DIAGNOSTIC_TEST|PYLARIFY|PYLARIFY PET
224019697|NCT00986973|DRUG|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
224019698|NCT02575001|BEHAVIORAL|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~1. Child Attachment Interview (CAI)~2. General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~3. Parenting Stress Index with the 19-item Life Stress Scale (PSI)~4. Achenbach System of Empirically Based Assessment (CBCL, YSR)~5. Holmes and Rahe Social readjustment rating scale~6. Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~7. Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
224019699|NCT02575001|GENETIC|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
224019700|NCT02575001|PROCEDURE|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
224019701|NCT02575001|PROCEDURE|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
224130457|NCT05009823|DIETARY_SUPPLEMENT|Standard F75 + RUTF|Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
224130458|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 with CMV + RUTF|Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
224130459|NCT05009823|DIETARY_SUPPLEMENT|Alternative F75 without CMV + RUTF|Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
224130460|NCT02938065|PROCEDURE|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
224130461|NCT02938065|OTHER|2% milk|16 participants will drink 10 ounces of 2% milk
224130462|NCT02938065|OTHER|apple juice|16 participants will drink 10 ounces of apple juice
224130463|NCT02938065|OTHER|ensure clear|16 participants will drink 10 ounces of ensure clear
224130464|NCT02347241|OTHER|Educational intervention|Educational Debriefings and High frequency training and team reflection
224130465|NCT05522335|BIOLOGICAL|BBV154(Intranasal) & covaxin|Intervention Covaxin
224130466|NCT01186146|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
224296852|NCT05550883|OTHER|Aerobic exercise|The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
223398815|NCT01473264|DRUG|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
223398816|NCT01759602|DRUG|C1-esterase inhibitor (Cinryze)|
223398817|NCT03896698|DEVICE|Transcranial Ultrasound Stimulation|TUS activate the brain cells
223398818|NCT00856882|DIETARY_SUPPLEMENT|soy protein|
223398819|NCT00856882|DIETARY_SUPPLEMENT|isoflavones|
224019702|NCT00174343|DRUG|exemestane (Aromasin®)|
224019703|NCT03854773|OTHER|Erector spinae plane block (Group ESPB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
224130467|NCT01186146|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
224130468|NCT01515176|DRUG|Dinaciclib|Given IV
223398820|NCT00856882|DIETARY_SUPPLEMENT|milk protein|
223398821|NCT03257540|DEVICE|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
224130469|NCT01515176|OTHER|Laboratory Biomarker Analysis|Correlative studies
223398822|NCT05761314|DIAGNOSTIC_TEST|Molecular characterization of solid tumor in RASopathies|NGS analysis on tumor sample
224130470|NCT01515176|BIOLOGICAL|Ofatumumab|Given IV
224130471|NCT01515176|OTHER|Pharmacological Study|Correlative studies
224130472|NCT03442335|DIAGNOSTIC_TEST|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
224130473|NCT03442335|DIAGNOSTIC_TEST|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
224130474|NCT00362063|DRUG|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
224130475|NCT03727321|COMBINATION_PRODUCT|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
224130476|NCT03727321|DIETARY_SUPPLEMENT|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
224130477|NCT03727321|DIETARY_SUPPLEMENT|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
223398823|NCT02350023|DRUG|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
223398824|NCT02350023|DRUG|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
223398825|NCT06751238|BIOLOGICAL|Secukinumab|Intravenous secukinumab
224019704|NCT03854773|OTHER|Thoracal paravertebral block (Group TPVB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
224019705|NCT03854773|OTHER|Control group (group C)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
224019706|NCT03776227|DRUG|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
224019707|NCT00296673|DEVICE|Rehabilitation device|
224019708|NCT06520800|BEHAVIORAL|Treatment and handling obesity-related comorbidities in adolescents through exercise|Tailor-made, one-to-one, physical exercise program
224019709|NCT01940185|DEVICE|LINX device|
224019710|NCT03446820|OTHER|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
224019711|NCT05010837|OTHER|Kinesio taping with abdominal exercises|"Experimental group was given kinesio taping along with abdominal exercises. Kinesio taping was applied in I-band technique. the first band is applied on rectus abdominis from origin to insertion starting from pubic symphysis till the xiphoid process. the second band is applied bilaterally on the left and right side external oblique muscles.~Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed along with kinesio taping."
223398826|NCT03845660|BEHAVIORAL|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
223398827|NCT01452880|DRUG|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
224019712|NCT05010837|OTHER|Abdominal exercises|"Abdominal exercises consist of 2-3 sets of 8 to 12 repetitions of head lift with bracing, head lift with pelvic tilt, pelvic clock, bridging, knee rolling and deep breathing exercises for 1 to 4 weeks.~From 5 to 8 weeks Same abdominal exercises with 5 sets and 15 to 20 repetitions were performed."
224019713|NCT00577837|DRUG|risedronate|tablet, 5 mg risedronate daily for 6 months
224019714|NCT00577837|DRUG|risedronate|tablet, 100 mg risedronate monthly for 6 months
224019715|NCT00577837|DRUG|risedronate|tablet, 150 mg risedronate monthly for 6 months
224019716|NCT00577837|DRUG|experimental|tablet, 200 mg risedronate monthly for 6 months
224130478|NCT02371759|DRUG|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
224130479|NCT02371759|DRUG|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
224296853|NCT05550883|DRUG|Fibromyalgia Agents|tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
224296854|NCT01748331|OTHER|Fluid restriction|Patients will be randomized to strict fluid restriction \< 1 L/day versus moderate fluid restriction \< 2.5 L/day
223398828|NCT01452880|DRUG|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
223398829|NCT01025882|DRUG|gemcitabine hydrochloride|Given IV
223398830|NCT01025882|RADIATION|stereotactic body radiation therapy|Given as a single fraction
223398831|NCT02259010|DRUG|Alisertib|Alisertib tablets
223398832|NCT02259010|DRUG|Itraconazole|Itraconazole oral solution
223398833|NCT01138202|DRUG|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
223398834|NCT07091669|DRUG|Tamsulosin (0.4 mg/j)|Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain)
224130480|NCT02371759|DRUG|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
224130481|NCT02371759|DRUG|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
224130482|NCT00454064|BEHAVIORAL|cognitive-behavioral treatment|
224130483|NCT00296959|DRUG|topiramate (drug)|
224130484|NCT01896037|DIETARY_SUPPLEMENT|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
224296855|NCT03234894|DEVICE|SiteSeal Endovascular|to evaluate the safety of the SiteSeal™ Endovascular Adjunctive Compression Device across a broad array of patients undergoing interventional endovascular procedures.
224130485|NCT04601142|DRUG|Methylprednisolone|methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ
224130486|NCT02586636|DRUG|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
224296856|NCT02796131|DRUG|RDX5791|
224296857|NCT02796131|DRUG|Placebo|Placebo
224019717|NCT05550701|OTHER|lymph node yield|We recorded the number of lymph nodes dissected during surgery in patients with colorectal cancer
224019718|NCT06143969|PROCEDURE|ultrasound-assisted, catheter-directed thrombolysis|After 10 hours of alteplase infusion and EKOSTM ultrasound, the therapy is stopped, the EKOSTM catheter is removed, and the puncture site (internal jugular vein or femoral vein) has to be compressed.
224130487|NCT02586636|DRUG|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
224019719|NCT05002829|OTHER|Restricted Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be restricted to none or up to 24 hours of post-operative antibiotics.
224019720|NCT05002829|OTHER|Liberal Duration of SOC Antibiotic Use|Standard of Care Antibiotic use will be permitted for 24 hours or up to 4 days of post-operative antibiotics.
224019721|NCT00371228|PROCEDURE|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
224019722|NCT04931082|DIETARY_SUPPLEMENT|Probiotics|Capsule
224019723|NCT04931082|DIETARY_SUPPLEMENT|Placebo|Capsule
224019724|NCT04569643|DIAGNOSTIC_TEST|Actigraphy|Participants will undergo overnight leg actigraphy at baseline. Leg movements will be recorded bilaterally by actigraphic method with two ankle-worn recorders.
224019725|NCT04569643|DIAGNOSTIC_TEST|Cardiorespiratory monitoring|All participants will be scanned for presence of sleep-related breathing disorders with a portable monitoring device at baseline. The compact screening device will be attached to the patient's wrist during the night sleep.
224019726|NCT04569643|DIAGNOSTIC_TEST|Neuroimaging|All subjects will undergo brain MRI scanning at baseline and in 1-year follow-up. The imaging protocol will include axial T1, T2, T2\*, FLAIR and diffusion-weighted imaging scans that will be made on a 3-Tesla scanner.
224019727|NCT04569643|OTHER|Assessment of cognitive function|Assessment will take place at weeks 0 (baseline) and 52 (1 year follow-up). The neuropsychological protocol will be consist of Montreal Cognitive Assessment (MoCA), 12-word Verbal Memory Test, Benton Visual Retention Test, Frontal Assessment Battery, Trail Making Test (parts A and B), phonetic (as a part of the MoCA) and semantic verbal fluency assessment, Symbol Digit Modalities Test.
224130488|NCT02586636|DRUG|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
223398835|NCT07091669|DRUG|Tamsulosin (0.4 mg/j)|Omnic Ocas®, Tamsulosin hydrochloride 0.4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands
224019728|NCT04569643|OTHER|Sleep quality and mood questionnaires|Self-reporting scales and questionnaires will be used at baseline to assess sleep quality, daytime functioning and mood. The protocol includes the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale, the Geriatric Depression Scale.
224019729|NCT01337583|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
224019730|NCT01337583|OTHER|Placebo|Vaginal Ring containing no drug substance
224019731|NCT01337583|DRUG|Dapivirine|
224019732|NCT06202586|PROCEDURE|low FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
224019733|NCT06202586|PROCEDURE|high FiO2|FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
224019734|NCT03299868|DEVICE|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
224019735|NCT01465347|DRUG|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
224019736|NCT02413333|DEVICE|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
224130489|NCT05464446|DEVICE|Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices|Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
223398836|NCT07097129|PROCEDURE|Mask Ventilation|Mask ventilation with mechanical ventilator set to pressure controlled ventilation, 15 cmH20 peak pressure, 10 respiratory rates per minute
223398837|NCT07094919|DEVICE|Corheart 6 left ventricular assist system|Corheart 6 left ventricular assist system provides circulatory support for patients with advanced left heart failure.
223398838|NCT06926205|DRUG|Mosunetuzumab (IV)|6 cycle of Mosunetuzumab+CHOP and then 11 cycles more of mosunetuzumab on mnotherapy
224130490|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 200 mL tap water via nasogastric tube|
224019737|NCT02413333|DEVICE|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
224019738|NCT02413333|DEVICE|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
224019739|NCT03664089|BEHAVIORAL|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
224019740|NCT03664089|BEHAVIORAL|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
224019741|NCT02374684|DRUG|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
224019742|NCT02374684|DRUG|Placebo|Placebo to match with experimental groups
223398839|NCT01047254|DRUG|Elontril|flexible dose of Bupropion 150-300 mg
224019743|NCT04767139|BEHAVIORAL|counseling for family planning|all mothers presented to infant immunization units of the selected health centers will be counseled for family planning service and referred to the family planning unit if they decided to use.
224019744|NCT04772820|BEHAVIORAL|Telephone-based coaching|A telephone-based brief behavioral activation coaching program that will involve 10 sessions over 4 months. Sessions will focus on helping people to identify meaningful activities that they can safely do to decrease loneliness, increase physical activity and improve nutrition.
224019745|NCT01590082|DRUG|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
224019746|NCT01590082|DRUG|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
224019747|NCT01590082|DRUG|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
224019748|NCT00363870|BIOLOGICAL|Fluarix vaccine|
224019749|NCT00950326|PROCEDURE|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
224130491|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
224130492|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
224130493|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
223398840|NCT01047254|DRUG|placebo|
223398841|NCT00346983|DRUG|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
224130494|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
224019750|NCT00950326|PROCEDURE|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
224019751|NCT00950326|PROCEDURE|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
224019752|NCT00250939|BIOLOGICAL|Myozyme|20 mg/kg qow
224019753|NCT02414932|DRUG|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
224019754|NCT02414932|DRUG|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
224019755|NCT00561132|DIETARY_SUPPLEMENT|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
224130495|NCT02255812|DIETARY_SUPPLEMENT|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
224130496|NCT00501566|DRUG|satavaptan (SR121463B)|
224130497|NCT00011765|DRUG|Fluoxetine|
224130498|NCT04676750|BEHAVIORAL|Mindfulness-Based Stress Reduction|yoga, meditation and psycho education
224130499|NCT01831973|DRUG|Lipotecan|
224130500|NCT03190720|DEVICE|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
224296858|NCT03949244|DRUG|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
223398842|NCT00346983|DRUG|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
223398843|NCT07095790|DRUG|Tirofiban+Oral Dual Antiplatelet Therapy|Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 47.5 hours; sequential Oral Dual Antiplatelet Therapy (Aspirin 100mg qd; Clopidogrel 75mg qd)
223398844|NCT07095790|DRUG|Oral Dual Antiplatelet Therapy|Aspirin 100mg qd; Clopidogrel 75mg qd (after first dose of 300mg)
223398845|NCT07095946|DEVICE|Electronic Syringe Intraligament Technique|Use of an electronic syringe device to deliver local anesthesia using the periodontal ligament (PDL) technique in pediatric dental patients
223398846|NCT07095946|DEVICE|Electronic syringe IANB Technique|Use of an electronic syringe device to deliver local anesthesia via the Inferior Alveolar Nerve Block Technique in pediatric dental patients
223398847|NCT06643637|DRUG|Psilocybin|Capsule containing active ingredient, psilocybin
223398848|NCT06643637|DRUG|Placebo|Capsule with no active ingredients
223398849|NCT07101900|DIAGNOSTIC_TEST|68Ga-NYM096 PET/CT|Participants will be administered a single, intravenous bolus of 68Ga-NYM096 The recommended administered activity of 68Ga-NYM096 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator. The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NYM096 administration.
223398850|NCT03578367|DRUG|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily.
224019756|NCT00561132|OTHER|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (\<50 mg) twice daily for a period of 4 weeks
224019757|NCT01239485|DRUG|Irinotecan|"Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, \& 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~\*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4."
224019758|NCT00797251|PROCEDURE|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
224019759|NCT05429905|BIOLOGICAL|Phase I|"* Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~* Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~* Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D."
224019760|NCT05429905|BIOLOGICAL|Phase II|RP2D will be determined in Phase I
224019761|NCT00398554|DRUG|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
224019762|NCT00398554|DRUG|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
224019763|NCT00398554|DRUG|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
224019764|NCT00398554|DRUG|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
224019765|NCT00398554|DRUG|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
224019766|NCT00398554|DRUG|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
224019767|NCT00398554|RADIATION|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
224019768|NCT02434497|DRUG|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
223398851|NCT03578367|DRUG|Imatinib|Imatinib 400 mg taken orally once daily
223398852|NCT03578367|DRUG|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
223398853|NCT01267019|BEHAVIORAL|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
224019769|NCT00294177|DEVICE|atomic force microscopy|
224019770|NCT00294177|DEVICE|dual polarisation interferometry|
224019771|NCT02020759|DEVICE|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
224019772|NCT01210664|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10\^8 cells. The second cohort will receive 0.4 x10\^8 cells. The third cohort will receive 3.2 x10\^8 cells. The fourth cohort will receive 26 x10\^8 cells.
224019773|NCT05134831|DIAGNOSTIC_TEST|Rhinomanometry|"At Day 0, before the hyaluronic acid injection, the patient's nasal breathing is assessed by 4-phase rhinomanometry (bilaterally: right nostril AND left nostril).~At Month 1, the patient's nasal breathing is re-assessed by 4-phase rhinomanometry, in the same conditions as Day 0."
224019774|NCT02958631|DRUG|Fimasartan|
224019775|NCT02958631|DRUG|Losartan|
224019776|NCT00621361|DRUG|AZD2171|Oral
224019777|NCT00621361|DRUG|Etoposide|Intravenous
224019778|NCT00621361|DRUG|Cisplatin|Intravenous
224019779|NCT02657512|DRUG|rivaroxaban|rivaroxaban 40 mg/day (1 day)
224019780|NCT02657512|DRUG|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
224019781|NCT05959954|DIAGNOSTIC_TEST|Quantitative Sensory Testing (QST)|Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
224019782|NCT02632422|OTHER|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
224019783|NCT02632422|OTHER|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily room air (dSHAM).
224019784|NCT02632422|OTHER|Walking|"Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.~Walking practice will incorporate 5 walking-related tasks:~1. walking balance (e.g., walking with turns)~2. skilled walking tasks (e.g., negotiating obstacles)~3. walking with secondary task (e.g., walking and talking)~4. endurance~5. speed"
223398854|NCT01267019|BEHAVIORAL|social cognitive training|30 sessions of social cognitive training without in vivo exercises
223398855|NCT01267019|BEHAVIORAL|non-social skills training|30 sessions of skills training that has no specific social content
223398856|NCT02729025|DRUG|Evolocumab|Administered subcutaneously once a month using an autoinjector/pen.
224019785|NCT01853644|DRUG|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
224019786|NCT02407392|DRUG|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
224130501|NCT05304182|DEVICE|EYESTAR 900|The EYESTAR 900 is a device developed by Haag-Streit which utilises 3D OCT for quantitative measurements of the geometry of the entire eye, including ocular biometry and corneal topography. It is the most recent in a series of successful biometry devices by Haag-Streit (HS Pachymeter, Lenstar LS 900, LS 900 T-cone and LS 900 APS) and also allows for advanced corneal tomography examinations.
224019787|NCT02407392|PROCEDURE|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
224019788|NCT00541021|DRUG|gemcitabine hydrochloride|
224130502|NCT05304182|DEVICE|LENSTAR LS 900|"The LENSTAR LS 900 is a non-contact device for measurement of biometrical parameters of the eye, aimed to assist the calculation of intraocular lenses (IOLs) prior to intraocular lens implantation. The most common application is in preparation of cataract surgery.~This device uses OLCR (optical low-coherence reflectometry), an interferometric method to measure intraocular axial distances. Furthermore, it uses digital photography of the anterior section of the eye to measure pupil size and location, as well as the white-to-white distance of the eye. The same photographic unit, in conjunction with a specific illumination pattern, is used to measure the corneal curvature - this measurement is known as 'keratometry', or, more specifically, 'automated keratometry'."
224130503|NCT01403740|DRUG|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
224130504|NCT02329522|DEVICE|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
224130505|NCT02329522|DEVICE|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
224130506|NCT00430625|BIOLOGICAL|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
224130507|NCT05616767|OTHER|Training on self-screening and HPV vaccination administration|Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
224130508|NCT05300867|OTHER|Neurorehabilitation|Neurorehabilitation with soft exsoskeleton robotic 3-week-long
224130509|NCT05300867|OTHER|Physiotherapy|Physiotherapy 3-week-long
224130510|NCT03587558|DRUG|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
224130511|NCT03587558|DRUG|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
224130512|NCT04288804|DEVICE|Smartphone microphone sensor|The volunteer will record themselves sustaining the short a vowel sound for 10 seconds.
224019789|NCT00541021|DRUG|sorafenib tosylate|
224019790|NCT00156637|BEHAVIORAL|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
224019791|NCT00156637|BEHAVIORAL|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
224019792|NCT00156637|BEHAVIORAL|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
224019793|NCT02891408|DRUG|Firsocostat|Capsule(s) administered orally on Day 1
224130513|NCT04288804|DEVICE|Smartphone accelerometer sensor|The volunteer's smartphone's accelerometer will record accelerometer data (positions on the x, y, and z axes) while the volunteer maintains 4 positions, each for 10 seconds.
224130514|NCT02284958|BEHAVIORAL|Standard|Back care advice
224130515|NCT02284958|BEHAVIORAL|Walking|Back care advice, individualized 12 week pedometer-driven walking program
224019794|NCT02891408|DRUG|Fenofibrate|Tablet administered orally on Day 1
224019795|NCT05857982|DRUG|Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab|Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.
224019796|NCT04265820|DEVICE|unilateral implantation of IOL|unilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
223398857|NCT02729025|DRUG|Placebo|Administered subcutaneously once a month using an autoinjector/pen.
223398858|NCT07111923|OTHER|Balance Assesment|The study design was a single-group repeated measures design. Nineteen individuals meeting the inclusion criteria were included. The assessments were conducted individually in a quiet environment, isolated from other athletes and external factors. Athletes were instructed to refrain from intense exercise and training, avoid caffeine consumption, and attend the assessment in sportswear within the last 24 hours. Upon arrival for the assessments, athletes were seated to rest while demographic information was collected. Each test was explained verbally and visually, and participants were allowed to perform a trial. A crossover design method was used in the study, with the order of tests (hands on hips or hands free) determined randomly. Retest measurements were conducted 24 hours after the initial test at the same time of day. The tests performed are described below.
224019797|NCT04265820|DEVICE|bilateral implantation of IOL|bilateral phacoemulsification and implantation of IOL.IOL may be monofocal,bifocal ,or trifocal，according to the patients preference and the eyes condition.
224130516|NCT03649958|DEVICE|HIRREM-SOP or Cereset|HIRREM-SOP for ten 90 minute sessions
224019798|NCT00619203|DRUG|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
224019799|NCT00619203|DRUG|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
224019800|NCT00619203|DRUG|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
224130517|NCT03649958|DEVICE|Cereset 2x|Cereset 2x for five 90 minute sessions
224130518|NCT03375112|PROCEDURE|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
223398859|NCT07111026|BEHAVIORAL|Sisters of Heart|"The intervention consists of ten weekly, 60-75-minute in-person peer support group sessions led by trained community health workers/promotoras (CHWs/Ps), with 6-10 participants per group. Sessions will be semi-structured, covering AHA Life's Essential 8 (LE8), stress management, and individualized topics based on participant priorities and social needs identified through surveys or group discussions. Each session includes stress management, core educational content, and time for addressing participant-driven issues. CHWs/Ps will also provide individualized support outside the sessions through direct community resource navigation, including phone or in-person warm handoffs to needed services."
224130519|NCT03375112|DRUG|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
224130520|NCT03375112|DRUG|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
224130521|NCT03605810|OTHER|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
224130522|NCT03136081|DIAGNOSTIC_TEST|Candidiasis infection occurence|Candidiasis infection occurence
224130523|NCT04296500|OTHER|Decision tree modeling|"A decision tree analysis was employed to explore the process of decision-making on types of pattern based on the existence or nonexistence of a symptom. At the end of tree presented is the proportion of patients who are categorised into each pattern.~In this study, the classification was performed by applying the classification and regression tree (CART) algorithm using Scikit-learn package of Python, which performs a division using the Gini coefficient or the decrement of dispersion. The Gini coefficient is one of the tools for measuring entropy or diversity in each node and it measures the decrement by comparing the information entropy before and after separation. To avoid overfitting, the maximum number of leaf nodes was limited to four and the pruning method which complied with the principle of minimum description length was applied."
224130524|NCT00243230|DRUG|Vicriviroc 30 mg|Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period).
223398860|NCT07111026|BEHAVIORAL|Basic intervention|The Basic intervention will include assessment of AHA LE8, provision to participants of results of 1) their baseline AHA LE8 assessments, including lab results, 2) written/online information with pertinent AHA LE8 health education content, 3) stress management educational materials, and 4) written information about the Ellenton Migrant Farm Worker Clinic and a community resource list
224019801|NCT00619203|DRUG|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
224019802|NCT00619203|DRUG|Placebo|2 placebos, one po, one suppository
224019803|NCT00619203|DRUG|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
224019804|NCT00619203|DRUG|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
224130525|NCT00243230|DRUG|Vicriviroc 20 mg|Two tablets of vicriviroc 10 mg once daily for 48 weeks.
224130526|NCT00243230|DRUG|Placebo|Three tablets of placebo once daily for 48 weeks.
224130527|NCT00243230|DRUG|Placebo|Two tablets of placebo once daily for 48 weeks.
224296859|NCT03949244|DRUG|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
224296860|NCT03949244|DRUG|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
224296861|NCT03949244|DIAGNOSTIC_TEST|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
224296862|NCT04957420|DRUG|Neupro|Rotigotine Patches
224019805|NCT04621318|DRUG|Denosumab|60 mg, single-dose
224019806|NCT05517837|DRUG|BMS-986421|Specified dose on specified days
224019807|NCT05517837|OTHER|Placebo|Specified dose on specified days
224019808|NCT01054170|DRUG|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
224019809|NCT01054170|DRUG|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
224019810|NCT05101967|PROCEDURE|Dynamic Cervical Implant|Cervical discectomy through anterior approach with replacement of disc by dynamic implant
224019811|NCT05101967|PROCEDURE|Anterior Cervical Discectomt and Fusion|Cervical discectomy through anterior approach with putting of cervical cage.
224019812|NCT02534298|OTHER|functional magnetic resonance imaging|functional magnetic resonance imaging
224019813|NCT00757341|DRUG|SKI-606|
224019814|NCT00709852|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
224019815|NCT00709852|DRUG|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
224019816|NCT02951767|DRUG|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
224019817|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
224019818|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
224130528|NCT00243230|DRUG|Background ART Regimen|"An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually boosted with concomitant ritonavir."
224130529|NCT01544777|DEVICE|Study IOL|Aspheric IOL for correction of aphakia
223398861|NCT07113431|DIETARY_SUPPLEMENT|IBD-AID diet combined with Kate Farms Peptide 1.5|Combining standardized-IBD diet developed by the University of Minnesota (IBD-AID) with commercially available pea protein plant-based enteral nutrition formula (Kate Farms Peptide 1.5)
223398862|NCT07113431|OTHER|IBD-AID diet|Standardized IBD diet developed by the University of Massachusetts Medical School (IBD-AID)
223398863|NCT07113119|OTHER|Exercise intervention|Patients that will be randomly assigned in the group A will be invited to attent 1-year exercise sessions, with frequency 3 sessions per week. The program included 30 minutes of Pilates exercises, strengthening, balance and flexibility exercises, which are performed with rubber bands, mobility sticks and balls.
224019819|NCT06079541|DRUG|JMKX003142 will be administered orally|oral once
224130530|NCT01544777|DEVICE|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
224130531|NCT01544777|DEVICE|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
224019820|NCT06079541|DRUG|Placebo in Cohorts 1 to 7|oral once
224019821|NCT06079541|DRUG|Placebo in 3 Cohorts|oral once
224019822|NCT04545684|BEHAVIORAL|Motor imagery|The person will have to imagine different scenarios of manual gripping
224019823|NCT04545684|BEHAVIORAL|Placebo intervention|The placebo group will imagine a place without the presence of humans.
224019824|NCT01442779|DRUG|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
224019825|NCT05629754|DIAGNOSTIC_TEST|MRI, radiological assessment|MRI and radiological assessment of the involved knee
224130532|NCT04933305|PROCEDURE|Roux-en-Y Gastric Bypass|Laparoscopic surgical procedure
224130533|NCT05746351|DRUG|Dexmedetomidine|a group will receive epidural Bupivacaine with Dexmedetomidine in normal labor
224130534|NCT05746351|DRUG|fentanyl|a group will receive epidural Bupivacaine with fentanyl in normal labor
224019826|NCT06407596|DEVICE|high intensity laser|3 times per week, for 9 sessions
224019827|NCT06407596|DEVICE|tens+us|5 times per week, total 15 sessions for 3 weeks
224019828|NCT05040984|DRUG|Solifenacin Oral Tablet|Solifenacin 1 tablet per day
224019829|NCT05040984|DRUG|Mirabegron 25mg|Mirabegron 1 tablet per day
224019830|NCT01081054|OTHER|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
224019831|NCT00329511|DRUG|methyldopa vs. clonidine|Comparison of compliance
224019832|NCT00329511|DRUG|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
224019833|NCT03436251|DEVICE|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
224130535|NCT05746351|DRUG|Nalbuphine|a group will receive epidural Bupivacaine with Nalbuphine in normal labor
224130536|NCT04015947|DEVICE|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
224130537|NCT03956953|DRUG|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
224130538|NCT03956953|OTHER|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
224130539|NCT04188340|BEHAVIORAL|Su-Man formula massage oil|bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
224296863|NCT04646486|BEHAVIORAL|Video debriefing|Obstetric teams will review their own performance on video in a debriefing session to improve future performance.
223398864|NCT07111819|BEHAVIORAL|Self-sampling acceptance|Cervical self-sampling devices will be distributed among the study participants followed by survey on the devices acceptance
223398865|NCT07111676|BEHAVIORAL|The Solution-focused Intervention for Mental health (SIM)|SIM is a manual-based program delivered to upper secondary school students in mentor groups by a specially trained teacher. It consists of group-based, solution-focused coaching set within a normative frame of mental well-being. By co-creating perceptions and meaning through language and dialogue, focusing on resources for approaching a preferred future, students increase their solution-building capability, thereby acquiring skills to become agents in their own life, more aware of and prone to invest in mental health. For a detailed description, see Söderqvist et al. https://doi.org/10.1016/j.ssmmh.2025.100493.
223398866|NCT07112716|PROCEDURE|Empirical superior vena cava isolation|Empirical superior vena cava isolation with radiofrequency ablation
223398867|NCT07112716|PROCEDURE|Ablation without empirical superior vena cava isolation|No ablation or ablation of other arrhythmic foci wuthout empirical superior vena cava isolation
224019834|NCT03436251|DEVICE|LEEP or cold knife|For patients with HPV+ / CIN-2
224019835|NCT03436251|DEVICE|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
224019836|NCT01719419|DRUG|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
224019837|NCT01719419|DRUG|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
224130540|NCT02774226|DRUG|Tetrahydrobiopterin (BH4)|12 week intervention
224130541|NCT02774226|DIETARY_SUPPLEMENT|Antioxidant Cocktail|12 week intervention
224130542|NCT02634879|BEHAVIORAL|Incentive Change|
224130543|NCT05302739|OTHER|Facial cooling|30 s of water mist sprayed onto the face during breaks in a simulated fencing competition
224130544|NCT02159963|OTHER|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
223398868|NCT07112235|BIOLOGICAL|Rhinovirus-A16|Nasal inoculation with a dose equivalent to 100 TCID50 of rhinovirus-A16 inoculum will be administered to all participants in the study
223398869|NCT07111767|DIETARY_SUPPLEMENT|Low-Cost Post-Bariatric Diet|"Low-Cost Post-Bariatric Diet (Experimental):~Based on the American Society for Metabolic and Bariatric Surgery (ASMBS) guidelines.~Uses affordable, locally available foods (e.g., eggs, lentils, local dairy products) to meet protein and micronutrient needs.~Designed to be cost-effective and accessible for patients from low-income or rural areas."
223398870|NCT07111767|DIETARY_SUPPLEMENT|Standard High-cost Post-Bariatric Diet|"Standard Post-Bariatric Diet (Active Comparator):~The conventional high-cost diet currently followed at the study hospital. Includes imported or expensive protein supplements such as whey protein and cottage cheese, along with nutritional products not easily accessible in rural or low-resource settings."
223398871|NCT07113262|DRUG|IBI311|Teprotumumab N01 injection (code name IBI311)
223398872|NCT07113262|DRUG|Placebo|Placebo
224130545|NCT02159963|OTHER|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
223398873|NCT07112729|OTHER|Active SMS Invitation|Participants in this group will receive a text message inviting them to participate in the free FOBT program. The SMS message will include a brief explanation of the program, instructions on how to obtain a screening kit, and a contact number for inquiries. A reminder SMS message will be sent one week after the initial message.
223398874|NCT07112950|DEVICE|Press Needle Acupuncture and standart therapy|The patient will have a press needle applied, which will be removed on the seventh day.
224019838|NCT01048671|DRUG|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
224130546|NCT02159963|OTHER|Optional training|8 weeks of optional home based, unsupervised training.
223398875|NCT07112092|BEHAVIORAL|Tell-Show-Do|Standard behavioral management technique where the dental procedure is explained to the child, demonstrated, and then performed.
224130547|NCT02159963|OTHER|Control|8 weeks of control period. Participants are doing daily living.
223398876|NCT07112092|BEHAVIORAL|Music Therapy|Participants listen to calming music during the dental extraction procedure to reduce anxiety and pain perception.
223398877|NCT07112092|BEHAVIORAL|Therapeutic Play Therapy|Use of structured play activities designed to reduce dental anxiety and improve cooperation during tooth extraction.
223398878|NCT07110779|BEHAVIORAL|Telenursing consultation|Telenursing consultations, which will be carried out via telephone calls, video calls, or messaging platforms, will be held between one, three, and five months after the first consultation. The North American Nursing Diagnosis Association (NANDA-I), the Nursing Outcomes Classification (NOC), and the Nursing Interventions Classification (NIC) taxonomies will be used to structure these consultations.
223398879|NCT07111221|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt performed prior to liver transplantation in patients with increased risk of intraoperative blood loss
223398880|NCT07111221|DRUG|Non-selective beta-blockers|Non-selective beta-blockers for lowering portal hypertension
223398881|NCT07110961|PROCEDURE|A suggested immobilization test (SIT)|The Suggested Immobilization Test (SIT) is a provocative test. RLS symptoms (urge to move the leg and leg paresthesia) are primarily observed during wakefulness, especially at rest, in the evening, and/or during the night. During the test, the patient remains in a bed (or a reclining chair), at a 45° angle with legs outstretched. Originally, the SIT only quantified leg motor activity. Since 2002, it also includes the assessment of leg discomfort, which is estimated by the patient every 5 min, on a 100-mm horizontal visual analogue scale. Leg movements are quantified using surface electromyography (EMG) from bilateral anterior tibialis muscles. Using these pathological thresholds, the clinical RLS/WED diagnosis is correctly predicted in 88% of subjects with a sensitivity of 82% and a specificity of 100%.
223398882|NCT07111897|PROCEDURE|percutaneous cannulated screw fixation|fixation of calcaneal fractures by cannulated screws inserted percutaneously
223398883|NCT07111897|PROCEDURE|Plate fixation|Fixation of calcaneal fracture by plate.
223398884|NCT07112287|DEVICE|MyeloGen Gene Panel|The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.
224130548|NCT04310163|OTHER|Natural history|Parent interview and video capture
224130549|NCT03072017|BEHAVIORAL|MBAT|Breathing-based intervention
224130550|NCT03003143|DRUG|Vigabatrin 500 MG|
224130551|NCT03572270|DIAGNOSTIC_TEST|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
224130552|NCT03572270|DIAGNOSTIC_TEST|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
224130553|NCT00333268|DRUG|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
224130554|NCT00333268|DRUG|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
224130555|NCT03695991|PROCEDURE|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
223398885|NCT07113275|RADIATION|Short-course radiotherapy|Eligible subjects will receive short-course radiotherapy (SCRT). One week after the end of treatment, subjects continued to receive neoadjuvant chemotherapy.
223398886|NCT07113275|RADIATION|Long-course radiotherapy|Long-course radiotherapy (LCRT, 50.4 Gy administered in 28 fractions) will be delivered concurrently with oral capecitabine.
224019839|NCT01048671|DRUG|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
224019840|NCT05249829|BIOLOGICAL|mRNA-1273.529|Sterile liquid for injection
224019841|NCT05249829|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
224019842|NCT05249829|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
224019843|NCT02703090|DRUG|Remifentanil|
224019844|NCT02703090|DRUG|Normal saline|
224019845|NCT03650309|DEVICE|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
224019846|NCT02171416|DRUG|Rilonacept|
224019847|NCT02171416|DRUG|Placebo|
224019848|NCT05033431|DRUG|Brazikumab|Participants will receive IV or SC injection of brazikumab as per the group they are assigned.
224019849|NCT00291850|DRUG|Paclitaxel, Cisplatin, Pegfilgrastim|
223398887|NCT07113275|DRUG|Capecitabine|1000mg/m2, bid, po, d1-14,q3w
223398888|NCT07113275|DRUG|Oxaliplatin|130mg/m2, ivgtt, d1,q3w
223398889|NCT07113275|DRUG|Camrelizumab|200mg, ivgtt, q3w
223398890|NCT07113275|PROCEDURE|TME surgery|The surgery was performed 1 week after the end of neoadjuvant therapy.
223398891|NCT07111754|BEHAVIORAL|Behavioural Message|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed. This can be delivered to participants via a QR code, or a warning message on the packet."
223398892|NCT07111754|BEHAVIORAL|Behavioural message + positive framing|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed and information about AMR, framed in a positive manner. This can be delivered to participants via a QR code, or a warning message on the packet."
223398893|NCT07111754|BEHAVIORAL|Behavioural message + negative framing|"Participants are presented with an image of an antibiotic packet, that contains information about the behaviour take antibiotics exactly as prescribed and information about AMR, framed in a negative manner. This can be delivered to participants via a QR code, or a warning message on the packet."
223398894|NCT07112508|BEHAVIORAL|PRISM dashboard is a data report|The PRISM dashboard captures a clinicians activity relative to their peers. It provides social norms feedback on an array of clinical interventions that an FCP makes.
224019850|NCT03160508|PROCEDURE|Fracture fixation with the TFNA|Fracture fixation with the TFNA
224019851|NCT02047864|DIETARY_SUPPLEMENT|Creatine monohydrate|
224130556|NCT01137331|DRUG|K301|Liquid- applied once daily prior to bed
224130557|NCT01137331|DRUG|Placebo|Liquid- applied once daily prior to bed
224130558|NCT04673526|PROCEDURE|Laparoscopic intersphincteric resection|Laparoscopic intersphincteric resection for ultra low rectal cancer in elderly patients
224130559|NCT04673526|PROCEDURE|Laparoscopic abdomino-perineal procedures|Abdominoperineal resection + colostomy in left iliac fossa or perineum
224296864|NCT03687658|BEHAVIORAL|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
224296865|NCT01409590|BEHAVIORAL|Exercise program|Homogenous exercise program in local fitness centers
224296866|NCT01409590|BEHAVIORAL|Diet|Weigh loss diet program prescribed by a professional nutritionist
224296867|NCT04666415|OTHER|Osteopathic treatment|Targeted osteopathic protocol for AN : 5 sessions of osteopathic treatment that are spaced around one week between 2 sessions. Soft specific palpatory techniques on the diaphragm, digestive system and cervical region will be realized during the session of 25 minutes.
223398895|NCT07112508|OTHER|THe usual care intervention is a first contact physiotherapy service.|usual care
223398896|NCT06921382|BEHAVIORAL|Peer counseling|Participants in the intervention condition will be matched with Spanish-speaking peer counselors who will visit mothers at home regularly (weekly at the beginning of the study, monthly at the end of the study).
223398897|NCT06921382|BEHAVIORAL|Additional funds|In Month 1, mothers can choose to receive a $150 gift card or an electric breast pump. In Months 2-5, if infants are signed up for the WIC exclusive breastfeeding package, infants will receive $100 and mothers will receive $50. If infants are signed up for the WIC partial breastfeeding package, infants will receive $50 and mothers will receive $30.
224019852|NCT00513604|BIOLOGICAL|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
224019853|NCT00513604|BIOLOGICAL|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0
224019854|NCT00513604|DRUG|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
224019855|NCT00513604|DRUG|Fludarabine phosphate|Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1
224019856|NCT00513604|RADIATION|Total body irradiation|600 cGy
224019857|NCT04260880|OTHER|periodontal status in mild depression patients|Assessment of periodontal status in mild depression patients
223398898|NCT07111273|DIAGNOSTIC_TEST|FC and FIT TEST at WEEK0 2 4|FC and FIT TEST at WEEK0 2 4
224019858|NCT04260880|OTHER|periodontal status in moderate depression patients|Assessment of periodontal status in moderate depression patients
224019859|NCT04260880|OTHER|periodontal status in systemically healthy patients|Assessment of periodontal status in systemically healthy patients
224019860|NCT05529147|DRUG|Antihypertensive Agents|Study participants receive antihypertensive drug treatment as part of regular care to induce systolic BP (SBP) reductions ≥10 mmHg within 6-8 weeks, while reaching a treatment target of ≤140 mmHg, and while preserving diastolic BP ≥70 mmHg.
224019861|NCT04555980|DEVICE|Warming patch|The warming patch can increase the temp of injection site, result in a blood vessels to dilate, which may have some contribute to decreasing injection pain.
224019862|NCT04555980|DEVICE|Cotton patch|The Cotton patch will cover the injection site as placebo. It dose not have the function of heating comparing to Warming patch.
224019863|NCT04059653|DEVICE|Electrical stimulation|Electrical stimulation device
224019864|NCT04059653|OTHER|Treatment as usual|GP treatment as usual
224130560|NCT01680094|DRUG|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
224296868|NCT01429051|DRUG|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
224296869|NCT01429051|DRUG|Placebo|Matching intranasal placebo spray
224296870|NCT00626717|PROCEDURE|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
223398899|NCT07110727|BEHAVIORAL|Two days, role play, adult interactive capacity building sessions of healthcare workers on PTSD screening and management. Pre/posttest and change in practice in screening will be used for evaluation|"Intervention~1\. Capacity Building of Healthcare workers on PTSD Management For training, the three purposefully selected health facilities selected for the study were written on small pieces of paper. The papers were twisted and thrown on a table. Then, a child was asked to pick up any paper. The one picked was the intervention health facility (Buea Regional Hospital). Healthcare workers at the BRH who provide care to RTI survivors at risk of PTSD 1 month after RTI from our health units of interest in the BRH, will be selected for training (mostly unit heads and front-line staff in trauma/injury will be trained) in two role-play, adult training, interactive sessions on the screening of PTSD using the DSM-5 tool and on timely management of RTI patients with regard to PTSD, linkage to care to psychotherapists, and referrals. Pre/post knowledge evaluation on the use of the DSM-5 tool and management of PTSD will be done, and results compared."
224019865|NCT01335087|OTHER|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
223398900|NCT07112196|DRUG|Visugromab (CTL-002)|IV infusion
223398901|NCT07112196|DRUG|Placebo|IV infusion
223551208|NCT00986791|OTHER|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
223551209|NCT03451487|DRUG|Panadol®|Acetaminophen 500mg Tablet
223551210|NCT03451487|DRUG|SafeTynadol®|Acetaminophen 500mg Tablet
223551211|NCT04077424|BIOLOGICAL|Fluzone-High Dose Quadrivalent|Seasonal influenza vaccination with FDA approved vaccines for this age group.
223551212|NCT04077424|BIOLOGICAL|Fluad|Adjuvanted (MF59) inactivated influenza vaccine
223731555|NCT03992742|BEHAVIORAL|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
224019866|NCT01335087|DEVICE|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
224019867|NCT00196976|BIOLOGICAL|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
224019868|NCT00196976|BIOLOGICAL|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
224019869|NCT00196976|BIOLOGICAL|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
224019870|NCT00196976|BIOLOGICAL|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
224019871|NCT00196976|BIOLOGICAL|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
224296871|NCT00626717|PROCEDURE|Sham treatment|Fluorescein eye drops. Exposure with blue light
224296872|NCT00204958|DRUG|nutritional supplement|
224296873|NCT00204958|DRUG|glutamine popsicle|
224296874|NCT00940836|DRUG|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
224296875|NCT00940836|DRUG|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
224296876|NCT00940836|DRUG|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
224296877|NCT04426279|OTHER|questionnaire assesment|15-minute face-to-face questionnaire
224019872|NCT02105922|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
224019873|NCT02105922|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
224019874|NCT02105922|PROCEDURE|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
224296878|NCT02719106|DEVICE|Ultimaster stent|
224296879|NCT02908737|DEVICE|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
224296880|NCT05001711|DEVICE|Aria CV Acute PH System|The Aria CV Acute PH System is indicated for evaluation of hemodynamic responses (e.g. pulmonary arterial compliance, cardiac output, and effective arterial elastance) to an intravascular Balloon catheter temporarily placed in the pulmonary artery in symptomatic adult patients with WHO Group 2 or WHO Group 3 pulmonary hypertension and right ventricular dysfunction.
224296881|NCT00003144|DRUG|amifostine trihydrate|
224019875|NCT04565379|DRUG|NuSepin® 0.1 mg|NuSepin® 0.1 mg
224019876|NCT04565379|DRUG|NuSepin® 0.2 mg|NuSepin® 0.2 mg
224130561|NCT06419868|BEHAVIORAL|"Universal preventive intervention for depression and anxiety for university students"|"This is a self-applied online intervention with six modules. It should be implemented over a period of 4 to 8 weeks. It includes emotion regulation, mindfulness exercises, coping strategies, problem-solving strategies, psychoeducation of anxiety and depression, and the development of healthy behaviors, explained through the following theoretical components: mindfulness and cognitive behavioral therapy.~Participants will be guided through the program in a structured manner. They will start by accessing the CANVAS online platform, where they will find the content of the sessions in video, audio, and text formats. They will then be directed to practice exercises at home, with audiovisual material to guide them. It's crucial that participants complete the six sessions sequentially, as each session is designed to build upon the previous one, ensuring a comprehensive learning experience and effective learning."
224130562|NCT02029404|PROCEDURE|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
224130563|NCT02029404|PROCEDURE|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be \> 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
224019877|NCT04565379|DRUG|Placebo|Normal Saline
224019878|NCT02791074|OTHER|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
224019879|NCT02791074|OTHER|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
224296882|NCT00003144|DRUG|cisplatin|
224296883|NCT00003144|DRUG|gemcitabine hydrochloride|
224296884|NCT03983174|PROCEDURE|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
224296885|NCT03983174|PROCEDURE|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
224296886|NCT01254474|DEVICE|Cardiac chambers mapping with MAP 4|
224296887|NCT00085774|DRUG|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
224296888|NCT00085774|DRUG|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
223398902|NCT06933342|BEHAVIORAL|Habituation to dental examination|"The habituation will be performed by dental hygenists working in the public dental service in Rogaland or Vestland counties. The dental hygenists have completed a 2-day educational course consisting of both theoretical and practical information specifically adressing dental examination of children with autism spectrum disorder. The habituation will be done at the dental office.~The intervention consists of five structured habituation sessions with the trained dental hygienist where the different elements of a clinical dental examination will be introduced stepwise in a controlled manner. Parents/guardians will also receive a toolbox with visual aids and a dental examination mirror with instructions for use during home preparations prior to the habituation sessions."
223398903|NCT06933342|BEHAVIORAL|Preparations at home|"Participants in the augmented control group will receive a toolbox with visual aids and a dental examination mirror. The parents/guardians of these participants will receive written information on how to use these tools at home to prepare for a clinical dental examination."
223398904|NCT06853353|OTHER|Heart Failure Specialist Nurses consultations|Heart Failure Specialist Nurses consultations
223398905|NCT06002009|RADIATION|MRI|MRI of shoulder
223398906|NCT06002009|OTHER|Nerve conduction study|Nerve conduction study
223551213|NCT04077424|BIOLOGICAL|Flublock|Recombinant hemagglutinin vaccine
224019880|NCT02791074|OTHER|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
224019881|NCT00060424|DRUG|Cyclosporine|Given PO
224019882|NCT00060424|DRUG|Fludarabine Phosphate|Given IV
224019883|NCT00060424|PROCEDURE|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
224019884|NCT00060424|OTHER|Laboratory Biomarker Analysis|Correlative studies
224019885|NCT00060424|DRUG|Mycophenolate Mofetil|Given PO
224019886|NCT00060424|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
224019887|NCT00060424|RADIATION|Total-Body Irradiation|Undergo TBI
224019888|NCT00038974|DRUG|peginterferon alfa-2a|
224019889|NCT00038974|DRUG|Ribavirin|
224019890|NCT04212273|DIAGNOSTIC_TEST|Diagnostic Sonazoid-CEUS and EOB-MRI|Undergo Sonazoid-CEUS and EOB-MRI
224296889|NCT00085774|DRUG|placebo aerosol by HFA|placebo HFA
224296890|NCT03390348|DEVICE|LENA Recorder|Use of the LENA recorder to document crying and fussing
224296891|NCT02319395|GENETIC|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
224296892|NCT03667014|DRUG|Dupilumab|Dupilumab treatment
224296893|NCT04188314|DRUG|Desflurane|The intervention group will receive desflurane for maintenance of anaesthesia, and the quality of recovery score will be compared post-operatively with the control group who received isoflurane.
224296894|NCT04188314|DRUG|Isoflurane|The control group will receive Isoflurane for maintenance of anesthesia. The quality of recovery score will be compared post-operatively with patients in the intervention group who received desflurane.
224130564|NCT03975868|OTHER|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
224130565|NCT02081339|DRUG|ranibizumab, aflibercept, pegaptanib, verteporphin|
223398907|NCT06508710|DRUG|Ketamine|Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
224130566|NCT01064453|DRUG|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
223398908|NCT06508710|DRUG|Placebo|Patients randomized in this group will receive an intravenous placebo in addition to venlafaxine for one week (on Days 1, 4 and 7)
223398909|NCT06953934|DRUG|ABBV-932|Oral Capsule
223398910|NCT06142565|DEVICE|Nose plug|Participants will complete olfactory training with scented nose plugs.
223398911|NCT06142565|OTHER|Regular olfactory training|Participants will complete olfactory training with regular odors found in their home.
223398912|NCT05930106|OTHER|Intraoperative fluid ratio|This ratio is calculated by dividing the sum of procedure subcutaneous infiltration and intravenous fluid by the total aspirate volume during surgery
223398913|NCT05930106|DEVICE|Carotid Artery Doppler Peak Velocity Variation|Patients will be given a fluid maintenance rate of 1.5 ml/kg/h. To determine fluid responsiveness, the carotid artery peak velocity variation (ΔVPeak-CA) will be measured before, during, and after the procedure. If the ΔVPeak-CA goes above 15%, the patient will receive a fluid bolus of lactated ringer solution at a rate of 4-6 ml/kg over 10-15 minutes, and the team will re-measure fluid responsiveness 10 minutes after each ΔVPeaK-CA.
223398914|NCT03008642|OTHER|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
223398915|NCT05770349|PROCEDURE|coronary artery bypass grafting|Coronary artery bypass grafting
223398916|NCT04442971|BEHAVIORAL|Music Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
223398917|NCT04442971|BEHAVIORAL|Alternative Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
224019891|NCT06140654|DIAGNOSTIC_TEST|Clinical oral examination|Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
224019892|NCT06140654|DIAGNOSTIC_TEST|Food behavior|"Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons."
224019893|NCT04860167|DRUG|Propofol|Injection propofol was given to keep the BIS value 60-80 during the ERCP procedure
224019894|NCT04860167|DRUG|Diclofenac Sodium and Lignocaine 10 % spray|Injection Diclofenac sodium was given in the preoperative area 30 minutes before the procedure and four squirts of 10% lignocaine were given 5 minutes prior to the start of the procedure
224019895|NCT02388854|GENETIC|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
224019896|NCT01535560|DRUG|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
224019897|NCT01535560|DRUG|AL-60371 Vehicle|Inactive ingredients used as placebo
224019898|NCT02914977|DRUG|Daunorubicin|"* Agent: Daunorubicin~* Dose: 6.75 mg/m2/day~* Route: IV~* Schedule: Days 1-5~* Duration: One cycle"
224019899|NCT00678184|DRUG|Atorvastatin|80 mg atorvastatin on two following days each
224019900|NCT03334136|DRUG|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
223398918|NCT04442971|BEHAVIORAL|No Auditory Stimulation|Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
224019901|NCT03334136|DRUG|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
224019902|NCT02009761|DRUG|BI 655064|subcutaneous injection
224019903|NCT05983224|DIETARY_SUPPLEMENT|Quercetin|The intervention group will receive two 500 mg quercetin tablets daily, after breakfast and lunch, for twelve weeks.
224019904|NCT05983224|OTHER|Placebo|The control group will receive two placebo daily, after breakfast and lunch, for twelve weeks.
224130567|NCT00540553|DRUG|placebo|
224130568|NCT00540553|DRUG|GSK971086|
224130569|NCT04044391|DIAGNOSTIC_TEST|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
224130570|NCT02072317|DRUG|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
224130571|NCT02072317|DRUG|taxol|taxol 135 mg/m2, every three weeks for a cycle
224130572|NCT01516164|DEVICE|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
224130573|NCT04301882|DRUG|interferon combined with ribavirin (PR) antiviral therapy|Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
224130574|NCT04301882|DRUG|direct antiviral drugs (DAAs)|Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
224019905|NCT06183957|OTHER|hydrotherapy group|When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
224019906|NCT02740374|DEVICE|ROTEM|ROTEM coagulation assessment and guided transfusion management.
224019907|NCT02740374|OTHER|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
224019908|NCT03241303|DRUG|Acarbose|Glucobay tablets on experimental day.
224019909|NCT03241303|DRUG|Placebo Oral Tablet|Placebo tablets on experimental day.
224130575|NCT04042610|BEHAVIORAL|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
224130576|NCT03828006|DIETARY_SUPPLEMENT|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
223398919|NCT03717311|OTHER|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
223398920|NCT05060939|DIAGNOSTIC_TEST|COVID-19 vaccinated people|Patients with at least one dose of COVID-19 vaccine tested for SARS-CoV-2 infection with RT-PCR on respiratory specimen. RT-PCR, serological testing and viral sequencing will be applied on patient's samples
224019910|NCT03241303|DRUG|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
224019911|NCT03241303|DRUG|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
224130577|NCT03828006|OTHER|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
224130578|NCT03169010|OTHER|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
224130579|NCT03169010|GENETIC|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
224130580|NCT00538876|DRUG|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
223398921|NCT05688514|DEVICE|Innovalve MR system|Innovalve MR system
223398922|NCT02862275|DRUG|Atezolizumab|Given IV
224019912|NCT05830045|DRUG|QLP2117|Specified dose on specified days
224019913|NCT02842827|DRUG|bomedemstat|oral administration
224019914|NCT02842827|DRUG|tretinoin|oral administration
224130581|NCT02058927|DRUG|Measles vaccine|measles revaccination administered at 12 months from start of ART
224130582|NCT05118386|DRUG|RSM01|"Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM"
223398923|NCT02862275|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223398924|NCT02862275|PROCEDURE|Biospecimen Collection|Undergo blood specimen collection
223398925|NCT02862275|PROCEDURE|Computed Tomography|Undergo CT scan
223398926|NCT02862275|OTHER|Laboratory Biomarker Analysis|Correlative studies
224019915|NCT03367650|DIETARY_SUPPLEMENT|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
224019916|NCT04987086|DIAGNOSTIC_TEST|PSMA PET|PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
224019917|NCT04039477|DRUG|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks
224019918|NCT01045395|DIETARY_SUPPLEMENT|Corn starch|90mg/d
224019919|NCT01045395|DIETARY_SUPPLEMENT|Unique Marine Algae Concentrate (UMAC)|90mg/d
224019920|NCT01045395|DIETARY_SUPPLEMENT|Golden brown algae|90mg/d
224019921|NCT04280068|BEHAVIORAL|Clinician Guide (CG)|An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
224019922|NCT04280068|BEHAVIORAL|Clinician Guide plus HealthCall|HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
223398927|NCT02862275|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398928|NCT06293456|OTHER|Dignity Therapy|A trained research staff member will conduct the DT interview virtually. The interview will occur or by phone only if the participant lacks access to technology for videoconferencing. The interviewer asks a series of open-ended questions that encourages patients to talk about their lives and what matters most to them.
223398929|NCT02369718|OTHER|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
223551214|NCT00603941|DRUG|CS-7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.30, or 0.50 mg BID. At Phase 2, CS-7017 will be administered at the recommended phase 2 dose (RP2D).
224019923|NCT02686047|DEVICE|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
224019924|NCT02686047|DEVICE|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
224130583|NCT05118386|OTHER|Placebo|"Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM"
224130584|NCT04261634|PROCEDURE|Concentrated Growth Factor Membrane|Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
223398930|NCT02369718|OTHER|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR\*2 coding strategies\*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
223398931|NCT03927833|DEVICE|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
223398932|NCT05906602|DEVICE|Real Ischemic Conditioning|10-minute cycles of blood flow restriction (5 minutes) followed by blood flow release (5 minutes), repeated 5 times for a total of 50 minutes.
223398933|NCT05906602|DEVICE|Sham Ischemic Conditioning|Sham ischemic conditioning will mirror ischemic conditioning procedures, differing solely in cuff pressure during blood flow restriction to replicate to replicate perceived tightness without arterial blood flow restriction.
223398934|NCT04242446|DRUG|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
224019925|NCT02757391|BIOLOGICAL|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
224019926|NCT02757391|BIOLOGICAL|Aldesleukin|Given SC
224019927|NCT02757391|DRUG|Cyclophosphamide|Given IV
224019928|NCT02757391|OTHER|Laboratory Biomarker Analysis|Correlative studies
224019929|NCT02757391|BIOLOGICAL|Pembrolizumab|Given IV
224019930|NCT02293031|DEVICE|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
224019931|NCT00901823|DRUG|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
224019932|NCT00901823|DRUG|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
224019933|NCT01043393|DRUG|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
224130585|NCT04261634|PROCEDURE|Platelet Rich Fibrin|Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
224130586|NCT02523326|DEVICE|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
224130587|NCT03176940|DIETARY_SUPPLEMENT|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
223398935|NCT04242446|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
223398936|NCT06783491|DRUG|Mitomycin (MM)|Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.
223551215|NCT00603941|DRUG|Paclitaxel|Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
224019934|NCT00645554|DRUG|Galantamine oral solution|
224019935|NCT02372136|DIETARY_SUPPLEMENT|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
224019936|NCT02372136|DIETARY_SUPPLEMENT|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
224019937|NCT00280943|BEHAVIORAL|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
224019938|NCT01775150|OTHER|health education|Health education via text messaging
224019939|NCT00985946|DRUG|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
224019940|NCT01080833|DEVICE|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
224130588|NCT06554392|DIAGNOSTIC_TEST|Blood sample|Blood sample from each subject to detect Glutathione Peroxidase 4.
223551216|NCT00828958|DRUG|Risperidone long-acting injectable|
223551217|NCT00128024|DRUG|lipid-lowering treatment|
224130589|NCT03440216|DRUG|blood sampling|"* temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
224130590|NCT03440216|DRUG|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
224130591|NCT03440216|DRUG|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
224130592|NCT03264508|BEHAVIORAL|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
224130593|NCT03264508|BEHAVIORAL|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature \>0.2°C.
223398937|NCT06783491|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|FOLFOX6 consists in oxaliplatin 85 mg/m2 iv. on day 1, 5FU 400 mg/m2 iv. in bolus followed by 2400 mg/m2 in a continuous infusion for 46 hours. Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours. Repeat every 2 weeks. Haematological recovery to ANC \>1.5x109/L and platelets \>75x109/L should be ensured prior to Day 1 of each 14-day cycle.
224019941|NCT04480125|DRUG|Azacitidine|100mg D1-7
224019942|NCT04480125|DRUG|Chidamide|30mg BIW PO
224019943|NCT03093077|DEVICE|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
224019944|NCT00585416|DRUG|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
224019945|NCT05880394|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
224019946|NCT05880394|DRUG|Copper-64 DOTATATE|Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.
224019947|NCT01538329|DRUG|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
224130594|NCT05048823|OTHER|Visceral Osteopathic Techniques|Generalized Discharge Technique of the Peritoneum and Intestinal Wings, Mobilization of the Cecum, Technique for the Root of the Mesentery, Release of the D1-D2 Angle, Technique for the Sigmoid Colon
224130595|NCT05048823|OTHER|Simulated visceral techniques|Simulated visceral techniques in the region of the gastrointestinal system
224130596|NCT00303108|DRUG|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
224130597|NCT00303108|DRUG|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
224130598|NCT00303108|DRUG|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
224130599|NCT02963714|BIOLOGICAL|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
224296895|NCT03501914|BEHAVIORAL|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome \& introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
223398938|NCT06783491|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women
223398939|NCT06790563|DEVICE|Neuromodulation|Neuromodulation by UCon
223398940|NCT05826808|DIAGNOSTIC_TEST|Polysomnography|The polysomnographic recordings include electroencephalogram (EEG), electrooculogram (EOG), electromyogram (EMG), electrocardiogram (ECG), pulse oximetry, transcutaneous capnography, nasal airflow and thoracic and abdominal respiratory effort.
223398941|NCT04708418|PROCEDURE|Biopsy Procedure|Undergo biopsy
223398942|NCT04708418|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223398943|NCT04708418|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223398944|NCT04708418|BIOLOGICAL|Pembrolizumab|Given IV
223398945|NCT04708418|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223398946|NCT04708418|PROCEDURE|Surgical Procedure|Undergo surgery
223398947|NCT04708418|DRUG|VLP-encapsulated TLR9 Agonist CMP-001|Given SC or intratumorally
223398948|NCT04821856|DRUG|Cannabidiol Oil|Cannabidiol (CBD) isolate 100mg/ml in MCT oil oral solution, manufactured by THC Pharma
224296896|NCT01797835|BEHAVIORAL|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
223398949|NCT04821856|DRUG|Placebo|MCT oil and flavoring solution, also manufactured by THC Pharma
223398950|NCT01947023|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223398951|NCT01947023|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223398952|NCT01947023|PROCEDURE|Computed Tomography|Undergo CT
223398953|NCT01947023|DRUG|Dabrafenib|Given PO
223398954|NCT01947023|DRUG|Dabrafenib Mesylate|Given PO
223398955|NCT01947023|PROCEDURE|Echocardiography Test|Undergo ECHO
223398956|NCT01947023|DRUG|Lapatinib|Given PO
223398957|NCT01947023|DRUG|Lapatinib Ditosylate|Given PO
223398958|NCT01947023|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223398959|NCT01947023|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223398960|NCT01947023|PROCEDURE|Positron Emission Tomography|Undergo PET
224019948|NCT01538329|DRUG|placebo|200mg / day once daily in the morning and at noon - oral administration -
224130600|NCT02963714|BIOLOGICAL|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
224130601|NCT02597023|DRUG|MitoQ|Mitoquinone pill, 20 mg/day
224130602|NCT02597023|DRUG|Placebo|Placebo pill with inert excipient, 1 time/day
224130603|NCT02253706|DEVICE|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
224130604|NCT02253706|DEVICE|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
224130605|NCT00894413|DRUG|Tadalafil|20 mg once daily for 10 - 14 days
224130606|NCT00894413|OTHER|Placebo Pill|Placebo
224296897|NCT01797835|BEHAVIORAL|usual care|Youth receive a brochure with information on AOD use.
223398961|NCT05420064|BEHAVIORAL|Intervention Arm At-risk Relative/ARR Contacts|Probands will give contact info for their ARR in the eDGP and indicate a date by which they will discuss the familial pathogenic variant with their ARR (can request a delay/halt to outreach). After this date the team will contact the ARR to invite them to review education and e-consent to the study. The study team will facilitate ARR cascade testing through telegenetics pre- and post-test counseling and saliva-based at home testing through MSK or a reference laboratory.
223398962|NCT05420064|BEHAVIORAL|MyGene Portal|Through the MyGene Portal, participants will be able to continually access their genetic test results, personalized medical management recommendations from the MSK CGS care team, an interactive pedigree for personal/family history updates, and tailored educational materials for patients with a VUS in an effort to promote sustained engagement and transparency.
223731556|NCT03992742|BEHAVIORAL|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
224019949|NCT05584969|BEHAVIORAL|Peer-led integrated nutrition education intervention delivered through Care Groups|The intervention comprised a peer-led integrated nutrition education training using the Care Group model developed by the TOPS program \[13\]. In the treatment arms, topics trained in the peer support groups included 1) group dynamics and social support, 2) infant feeding 3) adequate basic hygiene, 4) child growth and development, and 5) fathers' involvement. The training modules were adopted and modified from the community health extension workers (CHEWs) handbook \[14\] and the UNICEF IYCF counseling cards for community workers \[15, 16\]. Over the study, the intervention participants also engaged in cooking demonstrations targeting infant complementary foods preparation and backyard kitchen gardening.
224019950|NCT06015425|DEVICE|MINDD STIM+|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
224019951|NCT02471833|DRUG|Telmisartan 20mg|Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
224019952|NCT02471833|DRUG|Telmisartan 40mg|Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.
224019953|NCT02471833|DRUG|Placebo|Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
224019954|NCT02850211|DRUG|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
224019955|NCT02850211|DRUG|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
224019956|NCT02850211|DRUG|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
224130607|NCT01769690|OTHER|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
224296898|NCT01781819|PROCEDURE|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
224296899|NCT03001219|DRUG|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
224296900|NCT03001219|DRUG|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
223398963|NCT05420064|BEHAVIORAL|Standard of Care|Participants will received appropriate clinical care as outline by standard of care guidelines
224019957|NCT00002565|BIOLOGICAL|bleomycin sulfate|
224019958|NCT00002565|DRUG|CHOP regimen|
224019959|NCT00002565|DRUG|cisplatin|
224019960|NCT00002565|DRUG|cyclophosphamide|
224019961|NCT00002565|DRUG|cytarabine|
224019962|NCT00002565|DRUG|doxorubicin hydrochloride|
224019963|NCT00002565|DRUG|etoposide|
224019964|NCT00002565|DRUG|idarubicin|
224019965|NCT00002565|DRUG|ifosfamide|
224019966|NCT00002565|DRUG|mesna|
224019967|NCT00002565|DRUG|methylprednisolone|
224019968|NCT00002565|DRUG|mitoxantrone hydrochloride|
224019969|NCT00002565|DRUG|prednisone|
224019970|NCT00002565|DRUG|vincristine sulfate|
224019971|NCT04222361|PROCEDURE|Preventive recommendations for kidney disease: guidelines for improving overall outcomes (KDIGO) for AKI|Patients assigned to the treatment group will receive the AKI preventive recommendations from the KDIGO guide: withdraw nephrotoxics, ensure volemia and renal perfusion pressure by means of advanced hemodynamic monitoring-optimization (minimum monitoring objective: Unit algorithm based on volume systolic (VS) by pulse wave analysis - Flotrac® / ClearSight® system - or transpulmonary thermodilution - VolumeView® system -), monitor plasma creatinine and urinary expenditure, avoid hyperglycemia (serum blood glucose target: 110-149 mg / dl), and consider alternatives to diagnostic-therapeutic radiocontrast procedures.
224019972|NCT05606835|OTHER|Postural stability assessment|The Biodex Balance System SD (BDS) (Biodex Medical Systems Inc., Shirley, New York, USA) assesses postural stability (PS). Both static PS (SPS) and dynamic PS (DPS) will be assessed. In the DPS assessment, the platform can be tilted 20° in any direction. For static measurement, participants will be asked to stand barefoot on the platform, stand on one leg, keep the knees in 20-30° flexion. Meanwhile the contralateral knee will be asked to keep in 90° flexion, and stabilize their feet until the end of the test. Upon completion of the SPS assessment, the DPS assessment will be performed. The difficulty level of the DPS test will accepted as 4. For both SPS and the DPS assessment, the test consists of 3 trials of 20 seconds each with a 10-second break between trials.
224130608|NCT01769690|OTHER|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
224130609|NCT03542071|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
224130610|NCT03542071|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
224130611|NCT01588145|DRUG|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
223398964|NCT05457790|BEHAVIORAL|ACT Intervention|1-week baseline data collection period followed by an 8-week ACT intervention period focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
223398965|NCT05457790|BEHAVIORAL|Waitlist|1-week baseline data collection period followed by 8 weeks of maintaining usual routine followed by an 8-week intervention focusing on acceptance, cognition defusion (i.e., not letting thoughts about sleep control behavior), present moment awareness, perspective taking, values, and committed actions.
223398966|NCT04692103|DRUG|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
223398967|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo F-18 FES PET/CT
223398968|NCT04692103|PROCEDURE|Computed Tomography|Undergo F-18 FES PET/CT
223398969|NCT04692103|DRUG|Fludeoxyglucose F-18|Undergo FDG PET/CT
224019973|NCT05606835|OTHER|Frontal plan prjection angle|Frontal Plan Projection Angle (FPPA) is calculated as the angle between the thigh segment and the trunk segment based on the postural image, considering the position of the thigh and tibia. The FPPA will be evaluated using the Spark motion Pro™ application (2D). Before measurement, markers will be placed bilaterally at the SIAS, at the midpoint of the femoral condyles, and at the midpoint of the ankle bones. Participants will stand on the floor barefoot and arms crossed over the chest. Subjects will be asked to squat in a controlled manner and perform a 60° knee bend without losing balance before returning to the starting position. Test will be performed by using single leg squat test. The one-legged squat will be performed for 5 seconds at a standard pace with the researcher acting as the counter. Degrees smaller than 165 will be accepted as increase in knee valgus.
224019974|NCT05606835|OTHER|Foot and Ankle Ability Measure|The Foot and Ankle Ailability Measure (FAAM) is used to assess the self-reported overall functional level of patients with leg, foot, and ankle musculoskeletal injuries and conditions. It consists of 1) activities of daily living \[ADL\] and 2) sports \[S\] and can be scored from 0 to 100%. In the FAAM, there are 29 items that are scored from 0 to 4. There are 21 items related to various functional activities under the subtitle activities of daily living, and 8 items related to various activities related to participation in sports under the subtitle sports. Standardized response options are answered on five-point likert scales ranging from 0 (I cannot) to 4 (no difficulty). Point totals between 0 and 84 for the ADL subtitle and between 0 and 32 for the Sports subtitle are converted to percentage points.
224019975|NCT05606835|OTHER|Navicular Drop Test|The navicular drop test (NDT) is a clinical method for assessing the mobility of the medial longitudinal arch (MLA). The extent of navicular subsidence is assessed to determine the flexibility of the MLA and the position of the navicular with and without transfer of body weight. To assess navicular drop, the subtalar joint will be positioned in neutral position and the height of the navicular will be measured in non-weight bearing position. Then the measurement will be repeated in weightbearing position. The height difference between the two measurements in sitting and standing is recorded as the NDT value. Values more than 10mm is accepted as pathological.
224296901|NCT03001219|DRUG|Placebo|Participants will receive intravenous infusion of placebo.
224296902|NCT03001219|DRUG|RO7123520|Participants will receive intravenous infusion of RO7123520.
223398970|NCT04692103|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
223398971|NCT04692103|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
223398972|NCT04692103|OTHER|Laboratory Biomarker Analysis|Correlative studies
223398973|NCT05633511|PROCEDURE|Split Mouth Design|PRF on one side of mouth and CTG on the other side of participant's mouth.
223398974|NCT04665765|DRUG|Carboplatin|Given IV
223398975|NCT04665765|DRUG|Etoposide|Given IV
223398976|NCT04665765|DRUG|Ifosfamide|Given IV
223398977|NCT04665765|DRUG|Polatuzumab Vedotin|Given IV
223398978|NCT04665765|BIOLOGICAL|Rituximab|Given IV
223398979|NCT03150329|OTHER|Laboratory Biomarker Analysis|Correlative studies
223398980|NCT03150329|BIOLOGICAL|Pembrolizumab|Given IV
223398981|NCT03150329|DRUG|Vorinostat|Given PO
223398982|NCT06848075|DRUG|Elismetrep (K-304) Dose Level 1|Administered orally
223398983|NCT06848075|DRUG|Elismetrep (K-304) Dose level 2|Administered orally
223398984|NCT06848075|DRUG|Elismetrep (K-304) Dose level 3|Administered orally
224019976|NCT05606835|OTHER|Calcaneotibial Angle Measurement|Measurement of the calcaneotibial angle (CTA) is one of the methods used in the evaluation of the foot and ankle. By measuring this angle, it is assessed whether the ankle problems are related to the hindfoot. In the CTA measurement, the angle between the vertical axis of the calcaneus and the longitudinal axis of the achilles tendon is measured in the standing and prone positions, and the differences will be recorded. Values more than 8 degrees is accepted as calcaneal valgus.
224019977|NCT05606835|OTHER|Tibial Torsion Angle|Tibial torsion is a rotational deformity which can be measured between the long axis of the tibia and the transmalleolar axes. This measurement can be used to determine the extent to foot malalignment is due to bone torsion. Measurement will be done by a goniometer. Participants will be asked to lie prone and will be positioned with the knee joint in 90° flexion and the ankle joint in a neutral position. Normal alignment is 20 degrees external rotation. Any increase or decrease accepted as pathological.
224019978|NCT05606835|OTHER|Femoral internal and external rotation measurement|Accurate assessment of hip joint range of motion (ROM) is an important component in the overall clinical evaluation of lower extremity injuries, particularly those of the hip and groin. The expected hip rotational range of motion for internal rotation (IR) is 45°, and for external rotation (ER) is 0° to 45°. In this study, a smartphone-based inclinometer will be used to measure femoral IR and ER. The inclinometer will be placed vertically so that the top edge is just below the tibial tuberosity and the bottom edge is pointed at the midpoint of the medial and lateral malleoli.
224019979|NCT02105623|BEHAVIORAL|Standard Therapy|Risk factor control Diet Exercise for 24months
224019980|NCT02105623|DRUG|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
224019981|NCT05939531|BEHAVIORAL|BOUNCE Program|Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.
224019982|NCT05939531|BEHAVIORAL|Standard Care|Standard post-stroke care
224019983|NCT02673515|BEHAVIORAL|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
224019984|NCT03103490|DRUG|18F-FSPG|Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.
224019985|NCT02271776|DIETARY_SUPPLEMENT|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
224019986|NCT02271776|DIETARY_SUPPLEMENT|maltodextrin|
224019987|NCT05221359|DEVICE|ExOlin®|"Implantation of ExOlin® device, safety follow-up followed by a treatment period in which device is used to administer insulin.~Device explanted with a safety follow-up."
224019988|NCT05221359|DRUG|Insulin aspart|Use of NovoRapid insulin during all periods of the clinical investigations
224019989|NCT04322877|PROCEDURE|Temporary pacing Study|Temporary delivery of CRT
224019990|NCT04322877|RADIATION|Thoracic CT|As part of non-invasive mapping protocol
224019991|NCT04322877|DIAGNOSTIC_TEST|Acute hemodynamic study|Measurement of invasive dP/dTmax
224019992|NCT04322877|DIAGNOSTIC_TEST|Non-invasive body surface mapping|Cardioinsight body surface mapping
224019993|NCT04322877|DIAGNOSTIC_TEST|Invasive catheter-based mapping|Invasive electroanatomical mapping
224019994|NCT04892914|DEVICE|Embr thermal device|Participants use the Embr thermal device for 4 weeks
224019995|NCT02770417|DIETARY_SUPPLEMENT|beta-alanine|Patients receive beta-alanine
224019996|NCT02770417|DIETARY_SUPPLEMENT|placebo|Patients receive placebo
224019997|NCT02770417|OTHER|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
223398985|NCT06848075|DRUG|Elismetrep (K-304) Dose level 4|Administered orally
223398986|NCT06848075|DRUG|Placebo|Administered orally
224019998|NCT03397732|PROCEDURE|aorto-bifemoral bypass and aorta stentgraft|Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
224019999|NCT00490724|DRUG|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
224130612|NCT03201198|BEHAVIORAL|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
223398987|NCT06519149|DEVICE|Slow Wave UASD|An oral appliance for the treatment of OSA and snoring
223551218|NCT02120768|PROCEDURE|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
223551219|NCT06521827|RADIATION|short course radiotherapy|short course palliative radiotherapy
223551220|NCT01789086|DRUG|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
223551221|NCT01789086|DRUG|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
223551222|NCT03797066|DRUG|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA\> 800,000 iu/ml or baseline NS5A resistance.
223551223|NCT05069597|DRUG|CREON|Capsule; Oral
224020000|NCT00490724|DRUG|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
224020001|NCT00490724|DRUG|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
223398988|NCT02853214|GENETIC|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
223398989|NCT03284385|DRUG|Adavosertib|Given PO
223398990|NCT04860453|GENETIC|WES via Illumina NextSeq 550 sequencing system|Sequencing will be performed on an Illumina sequencing system
223398991|NCT04860453|DIAGNOSTIC_TEST|Blood Draw|Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
223398992|NCT04860453|DIAGNOSTIC_TEST|Skin biopsy|Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
223398993|NCT04860453|DIAGNOSTIC_TEST|Saliva Sample|Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
223398994|NCT06565195|DRUG|LY3962681|IT injection
223398995|NCT06565195|OTHER|Placebo (aCSF)|IT injection
223398996|NCT06565260|OTHER|Exercise Intervention|Participate in exercise program
223398997|NCT06565260|OTHER|Medical Device Usage and Evaluation|Wear an activity tracker
223398998|NCT06565260|OTHER|Nutritional Intervention|Participate in nutrition program
223551224|NCT05087433|OTHER|Progressive Relaxation Exercises|The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
223551225|NCT02705105|BIOLOGICAL|Mogamulizumab + Nivolumab|i.v. administration
223551226|NCT02840188|OTHER|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
224020002|NCT05793008|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) analysis|18F-FDG-PET/CT imaging will be performed 3 months after the acute event at the Department of Nuclear Medicine of Fondazione Policlinico Universitario A. Gemelli IRCCS using an integrated scanner. Intravenous 18F-FDG (370 MBq) will be given following an overnight fast. Three-dimensional PET imaging will be performed after 1 h of quiet waiting. A non-gated, non-contrast CT will be acquired for attenuation correction. Brain structures analyzed will include the neocortex, limbic system (insula, amygdala, cingulate cortex, and hippocampus), reticular formation, brainstem, and spinal cord.
223551227|NCT03389698|DEVICE|GRASP Dynamic Contrast-Enhanced (DCE) MRI|Golden-angle Radial Sparse Parallel (GRASP) DCE MRI is an MRI sequence designed to improve spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
224020003|NCT05793008|DIAGNOSTIC_TEST|Blood samples collection|"At the time of coronary angiography for patients with primary or secondary TTS and within the first 48 hours for patients with sepsis or septic shock, arterial blood samples will be collected in 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes. Furthermore, a hair sample of 6 cm will be collected for hair cortisol assay.~For patients with primary or secondary TTS blood samples will be collected by venipuncture with 1 Vacuette® 9 mL CAT Serum Clot Activator tube and 4 Vacuette® 6 mL EDTA tubes also at 3 months follow-up.~Blood samples will be immediately centrifuged to obtain whole blood, serum, and plasma samples, and then aliquoted into Eppendorf-type tubes. All samples will then be stored at -80°C until the analysis."
223398999|NCT06565260|OTHER|Physical Performance Testing|Ancillary studies
223551228|NCT03389698|DEVICE|3T Brain Scan|Up to 60 minutes, a portion of which uses the GRASP DCE-MRI sequence.
223551229|NCT03389698|DRUG|Gadolinium-based Contrast Agent (GBCA) for MRI|Gadavist/Gadobutrol is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.
224020004|NCT05793008|OTHER|Clinical follow up visit|Participation in this study requires for patients with primary vs secondary TTS, a follow-up visit at 3 months (90 +/- 5 gg) after enrollment to assess a Positron Emission Tomography (PET) analysis, and during the same visit, venous blood sampling as described above will be further performed.
224020005|NCT04709952|DEVICE|Transcranial direct current stimulation_High real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in high real stimulation group (2mA).
224020006|NCT04709952|DEVICE|Transcranial direct current stimulation_Low real|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in Low real stimulation group (1mA).
224020007|NCT04709952|DEVICE|Transcranial direct current stimulation_Sham|Transcranial DCS (tDCS) is applied to patients with depressive disorder taking antidepressants in sham stimulation group (0mA).
224020008|NCT03384277|DRUG|Steroid|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
224020009|NCT03384277|DRUG|Rituximab|375mg/m2 for one dose
224020010|NCT03384277|DRUG|Cyclophosphamide|cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
224130613|NCT03201198|BEHAVIORAL|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
224130614|NCT02390336|OTHER|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
223399000|NCT06565260|OTHER|Questionnaire Administration|Ancillary studies
223399001|NCT05702229|DRUG|Rilvegostomig|an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion
223399002|NCT05702229|DRUG|Volrustomig|an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion
223399003|NCT05702229|DRUG|FOLFOX|5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2
223399004|NCT05702229|DRUG|XELOX|capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1
223399005|NCT05702229|DRUG|AZD7789|an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion
224020011|NCT05616000|DRUG|Acetyl-l-carnitine, folic acid|Acetyl-l-carnitine 2gm once a day\& folic acid will be given to 43 primary infertile men
224020012|NCT02697370|DRUG|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
224020013|NCT00994682|DRUG|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
223399006|NCT05702229|DRUG|AZD0901|an anti Claudin18.2 ADC; IV infusion
223399007|NCT05702229|DRUG|5-Fluorouracil|5-FU, IV infusion, Q3W
223399008|NCT05702229|DRUG|Capecitabine|Oral take, Q3W
223399009|NCT05580666|DRUG|Azithromycin Oral Tablet|Antimicrobial therapy
223399010|NCT05580666|DRUG|Placebo oral tablet|Inert ingredients
223399011|NCT03321643|DRUG|Atezolizumab|Given IV
223399012|NCT03321643|PROCEDURE|Biopsy Procedure|Undergo biopsy
223399013|NCT03321643|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224020014|NCT00994682|DRUG|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
224020015|NCT00994682|DRUG|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
224020016|NCT00083213|BIOLOGICAL|ziv-aflibercept|
224020017|NCT03278860|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
224020018|NCT03278860|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
224020019|NCT03278860|DRUG|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
223399014|NCT03321643|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223399015|NCT03321643|PROCEDURE|Computed Tomography|Undergo CT or PET-CT
223399016|NCT03321643|DRUG|Gemcitabine|Given IV
223399017|NCT03321643|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399018|NCT03321643|DRUG|Oxaliplatin|Given IV
223399019|NCT03321643|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
224020020|NCT03278860|DRUG|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
224020021|NCT04567277|PROCEDURE|External ventricular drainage (EVD) conversion into ventriculo-peritoneal shunt (VPS)|EVD in high grade SAH patients were converted into VPS with 7-10 days of EVD insertion
224020022|NCT03795259|DRUG|Rocuronium|After induction, rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%.
224020023|NCT03795259|DRUG|Sugammadex|Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given intravenously.
224020024|NCT03211767|DIETARY_SUPPLEMENT|Aged garlic extract|Each capsule contains 600mg of aged garlic extract powder
224020025|NCT03211767|DIETARY_SUPPLEMENT|Placebo|Each capsule contains cellulose as a filler.
224020026|NCT03580668|DRUG|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
224020027|NCT01272128|DRUG|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
224130615|NCT02390336|OTHER|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
223399020|NCT03321643|BIOLOGICAL|Rituximab|Given IV
223731557|NCT03992742|BEHAVIORAL|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- \& 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
224020028|NCT06445413|OTHER|Tai Chi|Ten weekly 60-minute Tai Chi classes
224020029|NCT03720743|OTHER|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
224020030|NCT03760445|DRUG|HDM201|2.5 mg and 10mg capsules, given orally
224020031|NCT03760445|DRUG|cytarabine|20mg or 1000 mg or other strengths as locally available given intravenously
224020032|NCT03760445|DRUG|anthracycline|20mg or other strength as locally available given intravenously
224020033|NCT03760445|DRUG|midostaurin|25mg capsules given orally
224020034|NCT03760445|DRUG|liposomal cytarabine/daunorubicin|100mg/44mg or other strength as locally available given intravenously
224020035|NCT03760445|DRUG|posaconazole|100mg delayed release tablet or other strength as locally available given orally
224130616|NCT03112213|DRUG|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
224130617|NCT03112213|DRUG|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
224130618|NCT02674737|DRUG|dexmedetomidine, tramadol and flurbiprofen|
224020036|NCT03760445|DRUG|midazolam|2mg/mL oral solution or in other strength as locally available
224130619|NCT02674737|DRUG|tramadol and flurbiprofen|
224130620|NCT01579981|PROCEDURE|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
224130621|NCT03054077|OTHER|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
224130622|NCT02467387|DRUG|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
223399023|NCT00739882|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
224020037|NCT05352659|BEHAVIORAL|Face-to-face and online LGBTQ+ training|The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.
223399024|NCT00739882|DRUG|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
224020038|NCT05352659|BEHAVIORAL|On-line training|This study arm receives only links to publicly available on-line LGBTQ training.
224020039|NCT02111317|DRUG|ASP015K|oral
224020040|NCT02111317|DRUG|verapamil|oral
224020041|NCT03341689|DRUG|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
224020042|NCT03341689|DRUG|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
224020043|NCT03341689|DRUG|Placebo|microcrystalline cellulose capsule
224020044|NCT03495947|BEHAVIORAL|high flow nasal cannula|24 hours of continuous use in the immediate post-extubation period.
224020045|NCT00903682|DRUG|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
224020046|NCT00903682|DRUG|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
224020047|NCT00359125|DRUG|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
224020048|NCT00359125|OTHER|Placebo|Placebo, 600 mg/day for 1 week.
224020049|NCT02589561|DEVICE|Remote fitting|remote fitting of hearing aids
224020050|NCT02589561|DEVICE|Face to face fitting|face to face fitting of hearing aids
224020051|NCT03671694|PROCEDURE|Erbium-YAG laser vaginal treatment|Erbium-YAG laser vaginal treatment
224130623|NCT02467387|DRUG|Lactated Ringer's Solution|One time infusion 1.5mL/kg
224130624|NCT02427477|DEVICE|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
224130625|NCT02427477|DEVICE|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
224130626|NCT06554925|PROCEDURE|Cardiac surgery|The difference in males and females undergoing cardiac surgery of all types
223399025|NCT02593279|GENETIC|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
224020052|NCT04783831|DEVICE|Biodegradable stent|Biodegradable stent (polymeric prostheses) is placed from the pancreatic duct to the jejunum. Duct-to-mucosa end-to-side anastomosis is performed for the pancreaticojejunal anastomosis.
224020053|NCT06171347|OTHER|Oral cold spray (tap water)|Oral cold spray (tap water)
224020054|NCT03228745|BEHAVIORAL|Pre-operative MBSR|A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
224020055|NCT00066014|PROCEDURE|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
224020056|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
224020057|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
224020058|NCT06907173|DRUG|Levetiracetam (LEV) (60 mg/Kg)|"The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.~All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded."
224020059|NCT05569720|DRUG|ApTOLL|"ApTOLL will be administered as follows:~* Day 1: a dose of 0.1mg/kg will be administered intravenously as a slow infusion.~* Day 2: a dose of 0.1mg/kg will be administered intravenously as single bolus injection.~* Day 3: a dose of 0.2mg/kg will be administered intravenously as single bolus injection."
224020060|NCT00932113|DRUG|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
224020061|NCT00932113|DRUG|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
224020062|NCT06472193|PROCEDURE|Shanfield implantation technique in Mitroffanof procedure|a stab incision of the bladder wall 1-2 cm above the trigone is deepened down to the mucosa without penetrating it. The prolapsed mucosa is grasped through this window and incised. The spatulated appendix-Mitrofanoff is advanced through the window to the interior of the bladder and its lower lip is anchored to the trigone 1-2 cm distal to the stab wound with an appropriate size (4/0-6/0) vicryle suture using a U-stich. The stitch passes initially through the bladder wall to its interior, looping full thickness through posterior lip of the appendix, then back through the full thickness of the bladder wall to be knotted outside. Supplementary stitches are added externally between the adventitia of the conduit and the detrusor to stabilise the tube-bladder intersection. The detrusorotomy is closed over loosely forming a short subdetrusor tunnel. This technique will be done by open lower midline incision or by laparoscopy using 3 or 4-port access.
224130627|NCT05199350|OTHER|Device Name: ANSiscope|Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
223399026|NCT02593279|GENETIC|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
223731558|NCT03992742|BEHAVIORAL|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
223731559|NCT03992742|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
224130628|NCT00385567|DRUG|PEHRG214|
223399027|NCT00780377|DRUG|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
223399028|NCT06360198|OTHER|No intervention|No intervention was applied to the group.
223399029|NCT05325177|DRUG|Standard Dose Ibuprofen|(10-5-5 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
223399030|NCT05325177|DRUG|High Dose Ibuprofen|(20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
223731560|NCT03992742|BEHAVIORAL|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
224020063|NCT01403610|DRUG|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
224130629|NCT03445858|DRUG|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
223399031|NCT04021914|DEVICE|EnChroma glasses|Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
224020064|NCT01403610|DRUG|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
224020065|NCT01403610|DRUG|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
224020066|NCT05657886|OTHER|Half swaddle|Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
224130630|NCT03445858|DRUG|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
224130631|NCT03445858|RADIATION|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
224130632|NCT01214746|DRUG|Placebo|1 tablet Unikalk 1 time pr day for 5 days
224130633|NCT01214746|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
224130634|NCT04422665|OTHER|Resistance exercise|Single-legged resistance exercise
224130635|NCT06115434|PROCEDURE|cystectomy|cystectomy either radical or salvage involves removal of urinary bladder together with prostate, seminal vesicles and urethra with lymph node dissection.
223399032|NCT03995537|BIOLOGICAL|blood sample|"Samples will be collected at the inclusion and repeated if necessary before LT, including one 4 mL EDTA sample and one 4 mL Heparin sample and one 2.5 mL PAXgene® sample, allowing the HLA-DR assay to be performed with also plasma aliquots and messenger RNAs.~Same samples will also be collected :~* between inclusion and LT in case of major clinical change~* During the pre-transplant follow-up 3 months after inclusion, for patients who have not been transplanted within 3 months after inclusion~* at day 1 after LT~* 2 times a week after the LT for a maximum of 1 month~Biological data will be collected at those different times."
223399033|NCT01506037|DRUG|Desloratadine|Desloratadine ODT 5 mg
223399034|NCT04033861|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
223399035|NCT04033861|DRUG|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
223399036|NCT05299177|DEVICE|InControl|Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
223399037|NCT04941651|BEHAVIORAL|OBE-COACH program|"OBE-COACH works through private exchanges between the user and an automatic generator of recommendations, advice and messages of encouragement. Web focus groups are propoposed by specialist to respond to the questions of the participants and a tele-interview at 6 months with a dietetician to encourage and assist the patient to make the best use of the program.~The program is divided into missions to perform. These missions are grouped into 10 families. The completion of each mission and the correct answers to the quiz offer points and bonuses.~To promote better adherence to the program, missions are not repetitive. They are proposed to surprise the user and constantly renew his desire to connect to the program and achieve goals.~The intensity level of the program is selected by the user at any time."
223399038|NCT04941651|DEVICE|Connected devices|"Connected devices provide to patient are auto-tensiometer and balance. These devices will not be connected to the OBE-COACH program.~The auto-tensiometer (Tensio-screen, Terraillon) is a connected tensiometer allowing the patient to measure by himself with an armband his systolic and diastolic blood pressure and his heart rate.~The balance (Web coach premium, Terraillon) is a connected scale to collect body weight."
223399039|NCT04941651|DEVICE|Connected Activity Tracer|The Activity Tracer (activi-T band, Terraillon) is a a wristband connected activity tracer worn on the wrist that tracks the patient's physical activity and calculates the number of steps, distance traveled and calories burned. The Activity Tracer will not be connected to the OBE-COACH program.
223399040|NCT04941651|BEHAVIORAL|e-learning program|e-learning program with free access via the web to advice sheets, a menu generator and a catalog of physical activity (resources made available by the site www.mangerbouger.fr ; Public Health France, Ministry of Health)
223399041|NCT04969406|OTHER|Brillouin Spectroscopy via BOSS System|Biomechanical Imaging of the Cornea and Lens
223399042|NCT03349060|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
223399043|NCT03349060|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
223399044|NCT03349060|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
223399045|NCT03793114|DIAGNOSTIC_TEST|Cosyntropin stimulation test|Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
224130636|NCT04748224|DRUG|Bupivacaine 0.25% Injectable Solution|a local anesthetic drug
224130637|NCT04748224|DRUG|bupivacaine plus dexmedetomidine|bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
224130638|NCT04827836|PROCEDURE|Cooled eye drops and povidone-iodine|Cooled oxybuprocaine HCl 0.4% and lidocaine HCl 2% eye drops and cooled povidone-iodine (cul-de-sac 5% povidone-iodine and 10% povidone-iodine).
223399046|NCT03793114|DIAGNOSTIC_TEST|Baseline blood tests|Medication-fasting morning levels of adrenocortical hormones.
223399047|NCT03793114|DEVICE|30-hour ambulatory sampling of intestinal fluid|30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
223731561|NCT03992742|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
223731562|NCT03992742|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
224130639|NCT01693458|BEHAVIORAL|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
224130640|NCT00267332|DRUG|Modafinil|
223731563|NCT05604690|BIOLOGICAL|Avacc 10|Intranasal application of either low dose or high dose of Covid 19 vaccine.
223731564|NCT05604690|COMBINATION_PRODUCT|Outer Membrane Vesicles (OMV) : OMV alone in vehicle|OMV will be administered via intranasal route.
223731565|NCT05604690|OTHER|Placebo|Placebo will be administered via intranasal route.
223399048|NCT03793114|OTHER|Blood test|Cardiovascular and inflammatory biomarker profiles
223399049|NCT00183404|DRUG|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
223399050|NCT02861586|BIOLOGICAL|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
223399051|NCT02861586|BIOLOGICAL|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
223731566|NCT03218007|BIOLOGICAL|blood samples|to evaluate expression and functionnaly activity of A2AR
224020067|NCT05657886|OTHER|Kangaroo care|The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
224020068|NCT00626678|DRUG|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
224020069|NCT00626678|DRUG|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
224020070|NCT00626678|DRUG|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
224020071|NCT04123392|DRUG|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
224020072|NCT04123392|DRUG|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
224020073|NCT04123392|DRUG|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
224020074|NCT03296033|DRUG|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
224020075|NCT03296033|DRUG|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
224020076|NCT04660630|DIAGNOSTIC_TEST|Gene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseases|According to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
224130641|NCT00077337|DRUG|romidepsin|
223399052|NCT02861586|BIOLOGICAL|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
223731567|NCT06089928|PROCEDURE|vertical augmentation|sandwich osteotomy with an Interpositional inlay graft
223731568|NCT02931968|DEVICE|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
223731569|NCT00261664|DEVICE|telehomecare|
223731570|NCT05585697|OTHER|None - crossectional|None - crossectional
223731571|NCT00725023|DEVICE|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
223731572|NCT00725023|DEVICE|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
223731573|NCT04140851|DIETARY_SUPPLEMENT|Dietary fiber intervention|Dietary intervention
223731574|NCT04140851|DIETARY_SUPPLEMENT|Normal diet|Normal diet
223731575|NCT03459248|OTHER|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
223731576|NCT03459248|OTHER|Monotherapy|10 mg metoclopramide
223731577|NCT03459248|OTHER|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
224020077|NCT04660630|BEHAVIORAL|Regular follow-up and patient education|The subjects received regular follow-up and patient education.
224130642|NCT05420688|OTHER|Heart Failure Group|This is a single-center, prospective, observational study. The assessment and reporting will be followed the Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) checklist.
224130643|NCT03496363|DIAGNOSTIC_TEST|TSH , T4|Thyroid stimulating hormone
224020078|NCT04178044|BIOLOGICAL|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
224020079|NCT04178044|BIOLOGICAL|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
224020080|NCT04178044|BIOLOGICAL|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
224020081|NCT04178044|BIOLOGICAL|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
224020082|NCT04178044|BIOLOGICAL|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
224020083|NCT00718354|DRUG|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
224020084|NCT00718354|DRUG|Standard Chemotherapy|Investigator's discretion
224020085|NCT03076333|DIAGNOSTIC_TEST|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
224020086|NCT00896051|DRUG|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
224020087|NCT00896051|DRUG|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
224020088|NCT00896051|DRUG|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
224130644|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
223731578|NCT04307693|DRUG|Lopinavir/ritonavir|Lopinavir / Ritonavir tablet
224296903|NCT02302664|PROCEDURE|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
224020089|NCT00896051|DRUG|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
223399053|NCT02861586|BIOLOGICAL|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
223399054|NCT06577389|OTHER|Enhanced recovery after surgery|The ERAS program for lumbar fusion surgery will be implemented.
223399055|NCT03356938|BEHAVIORAL|Sleep restriction|Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
223399056|NCT03356938|BEHAVIORAL|Sleep deprivation|Sleep deprivation during first night of sleep laboratory examination
223399057|NCT00485732|BIOLOGICAL|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223399058|NCT00485732|BIOLOGICAL|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
223399059|NCT03808155|DRUG|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
223399060|NCT03808155|DRUG|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
223399061|NCT03109067|OTHER|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
223399062|NCT04183348|BEHAVIORAL|Training Protocol n°1 first at Visit 1, then, Training Protocol n°2 at Visit 2|"During Protocol 1 (visit 1), participants of Group A will perform auditory spatial localization tasks with sensory feedback and during Protocol 2 (visit 2), they will perform auditory tasks without any notion of spatial localization. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
224020090|NCT00896051|DRUG|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
224020091|NCT00896051|DRUG|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
224020092|NCT00944177|DRUG|Metformin HCl|
223551230|NCT04430608|DEVICE|Dexcom G6|"The investigational device is a CGM Dexcom G6. The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. The device-system consists of a sensor, the Dexcom G6 device/sender, and connects to a smart device like a cellphone. The Dexcom G6 CGM system is probably the most precise system on the market and with no need for daily calibration with finger prick glucose. The Dexcom G6 sensor can last for 10 days without calibration and is approved for diabetes treatment decision making. Dexcom G6 has been extensively tested and is safe and approved even for pregnant women.~The CE Marking confirms that the G6 system meets the Essential Requirements of the Medical Device Directive MDD 93/42/EEC as amended by 2007/47/EC."
223551231|NCT06070389|DEVICE|Sansa device|The Sansa device will be used during a single overnight polysomnography study.
223551232|NCT03180580|BEHAVIORAL|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
223731579|NCT04307693|DRUG|Hydroxychloroquine sulfate|Hydroxychloroquine sulfate tablet
223731580|NCT04766801|PROCEDURE|Laparoscopic adjustable gastric banding|Weight-loss surgery, with the use of gastric banding
223731581|NCT05525143|PROCEDURE|Pregnant women who have given birth vaginally or by cesarean section|Full-term pregnant women who have given birth vaginally or by cesarean section with PPH. Descriptive statistics and possible causal factors
224020093|NCT02935452|BEHAVIORAL|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
223399063|NCT04183348|BEHAVIORAL|Training Protocol n°2 first at Visit 1, then, Training Protocol n°1 at Visit 2|"During Protocol 2 (visit 1), participants of Group B will perform auditory tasks without any notion of spatial localization and during Protocol 1 (visit 2), they will perform auditory spatial localization tasks with sensory feedback. The 2 visits will be spaced at least 2 weeks (Wash-out).~The effects of each of the protocols on spatial location hearing abilities will be specifically assessed by comparing the results of the different assessments (SPHERE and Visual Discrimination Test) obtained before and after each protocol."
223399064|NCT06342700|DRUG|Rilzabrutinib crystalline form|Pharmaceutical form:Film coated tablet Route of administration:Oral
223399065|NCT06342700|DRUG|Rilzabrutinib amorphous form|Pharmaceutical form:Film coated tablet Route of administration:Oral
223399066|NCT01857037|OTHER|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
223399067|NCT05775900|DRUG|Cetuximab|Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.
223399068|NCT05775900|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)
223731582|NCT00380614|DRUG|Lamivudine|
224020094|NCT03217643|DRUG|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
224020095|NCT03133754|PROCEDURE|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
224020096|NCT03133754|PROCEDURE|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
223731583|NCT05744453|DIETARY_SUPPLEMENT|Olive Leaf Extract|experimental arm
223731584|NCT05744453|DIETARY_SUPPLEMENT|Cellulose|placebo comparator arm
223731585|NCT00850668|BIOLOGICAL|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
223731586|NCT04604821|BEHAVIORAL|Enhanced Milieu Teaching|A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.
223731587|NCT04604821|BEHAVIORAL|Parent Education|Parents receive information on child developmental milestones.
223731588|NCT04395469|DRUG|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
223731589|NCT03032094|PROCEDURE|connective tissue graft|palatal connective tissue graft to attain root coverage
224020097|NCT00876928|DRUG|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
224020098|NCT00876928|DRUG|placebo|medium chain triglyceride given once per week
223731590|NCT02888522|BIOLOGICAL|immunomodulation|Immunomodulation depending on chimerism
223731591|NCT03251066|OTHER|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
224130645|NCT01458509|BEHAVIORAL|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
224020099|NCT00044538|DRUG|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
224020100|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
224020101|NCT01476774|DRUG|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
224020102|NCT00451880|DRUG|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
224020103|NCT00451880|DRUG|famotidine|single dose, supplied as 20-mg or 40-mg tablets
224020104|NCT05052866|BEHAVIORAL|Social Robot|Participants will interact with a social robot companionbot for a period of 8-10 weeks. The robot will stay in participants' apartments.
224020105|NCT00433524|PROCEDURE|computed tomography|
224020106|NCT00978796|DRUG|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
224020107|NCT00978796|DRUG|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
224130646|NCT01458509|BEHAVIORAL|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
224130647|NCT01458509|BEHAVIORAL|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
224130648|NCT01767194|BIOLOGICAL|Dinutuximab|Given IV
224130649|NCT01767194|DRUG|Irinotecan Hydrochloride|Given IV
224020108|NCT03970460|DEVICE|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
224020109|NCT03970460|DEVICE|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
224020110|NCT05165797|BIOLOGICAL|platelet activation factors|platelet activation factors of subject blood
224130650|NCT01767194|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223399069|NCT03125421|PROCEDURE|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
223731592|NCT02519192|DEVICE|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
223731593|NCT02519192|PROCEDURE|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
223731594|NCT02519192|PROCEDURE|ostomy bag|Non Vac Arm will receive ostomy bag applications.
223731595|NCT02519192|PROCEDURE|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
223731596|NCT05351762|DRUG|Nimotuzumab Combined With Neoadjuvant Chemotherapy|The study arm received nimotuzumab (400mg, every three weeks, for 2 weeks) combined with TPF chemotherapy
224020111|NCT00123552|DRUG|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
224020112|NCT00123552|DRUG|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
224020113|NCT00123552|DRUG|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to \< 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; \>35 kg:4 tabs per dose
224020114|NCT00258063|DRUG|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
224020115|NCT00306696|DRUG|Rosiglitazone|
224020116|NCT00306696|DRUG|spironolactone|
224020117|NCT00306696|DRUG|hydrochlorothiazide|
224020118|NCT00306696|DRUG|frusemide|
224020119|NCT03010930|OTHER|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
223399070|NCT03125421|PROCEDURE|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
223399071|NCT01880554|DEVICE|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
223399072|NCT05679570|DRUG|Satralizumab (Genetical Recombination)|"Efficacy Evaluation Period:~The study drug will be administered at a dose of 120 mg subcutaneously at initial, 2-week, 4-week, and 4-week intervals thereafter. Efficacy will be assessed after 24 weeks of study drug administration. Subjects who demonstrate efficacy and wish to continue treatment will receive the study drug for 24 weeks and moving to the continuous treatment period. In all other cases, the study will be terminated after 24 weeks of the efficacy evaluation period without the administration of study drug.~Continuation Dosing Period\[1\]:~Subjects who demonstrate efficacy during the efficacy evaluation period and wish to continue will receive continued 28 weeks (52 weeks total) treatment with satralizumab.~Continuation Dosing Period\[2\]:~Subjects completed continuation dosing period\[1\], clinically capable of continued administration, and wish to continue will receive continued treatment with satralizumab until the end of this study period."
223731597|NCT05489055|DRUG|Iopamidol|A contrast bolus of iopamidol-370 (370 mg I/ml) (iopamidol injection; Consun Pharmaceutical, China) was injected at a ﬂow rate of 4.5-6 mL/s through an 18-20-gauge intravenous antecubital catheter by using a power injector (Ulrich, Germany). The total dose of iopamidol-370 was approximately 0.9 ml /kg body weight.
223731598|NCT03922425|OTHER|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
224020120|NCT03010930|OTHER|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
224020121|NCT02445950|BEHAVIORAL|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
223399073|NCT06734156|OTHER|No intervention: observational study|No intervention: observational study
224020122|NCT02445950|BEHAVIORAL|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
223399074|NCT03629977|DEVICE|CRRT|Continuous Renal Replacement Therapy
223399075|NCT01251874|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223399076|NCT01251874|DRUG|Carboplatin|Given IV
223399077|NCT01251874|PROCEDURE|Computed Tomography|Undergo PET/CT
223399078|NCT01251874|OTHER|Fluorothymidine F-18|Given FLT
223399079|NCT01251874|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224130651|NCT01767194|BIOLOGICAL|Sargramostim|Given SC or IV
223399080|NCT01251874|DRUG|Veliparib|Given PO
223399081|NCT06801665|COMBINATION_PRODUCT|FMT+QL1706+Bevacizumab+XELOX|Participants will receive FMT combined with QL1706+Bevacizumab+XELOX for 6 cycles. If there is no progression of the disease after 6 cycles of the first-line treatment, then patients will enter the maintenance treatment stage. The therapy of maintenance treatment stage was at the discretion of the investigator.
223399082|NCT06509009|DRUG|Nimotuzumab|nimotuzumab, toripalimab, gemcitabine, cisplatin
223731599|NCT03355651|DIETARY_SUPPLEMENT|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
223731600|NCT05745779|DIAGNOSTIC_TEST|HbA1c, Vitamin D, Vitamin B12|Serum HbA1c, Vitamin D, Vitamin B12 values of the patients who applied for gingival treatment in the last 3 months from the date of application were found from the hospital archive and serum was not taken from the patients again for the study.
223731601|NCT04049123|DRUG|LY900014|Administered SC
223731602|NCT04049123|DRUG|Insulin Lispro|Administered SC
223731603|NCT04672928|DRUG|paclitaxel|80mg/m\^2,iv,Q4W
223731604|NCT04672928|DRUG|IBI318|300mg,iv,Q4W
223731605|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|50,000 units of Vitamin D3 weekly
224020123|NCT05031169|PROCEDURE|interdental papilla surgical reconstructiion|Surgical treatment of receding interdentalpapillae
224020124|NCT01001923|DRUG|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
224020125|NCT01001923|DRUG|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
224020126|NCT01095263|DEVICE|DBS|130Hz, 90us pulsewidth, 4V Amplitude
224020127|NCT01095263|DEVICE|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
223731606|NCT01169142|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 units weekly
223731607|NCT01466855|DRUG|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
223731608|NCT00137748|DRUG|CMV-Ig|Drug: CMV-Ig
223731609|NCT04620720|DRUG|capule gabapentin|neuropathic analgesic
224130652|NCT01767194|DRUG|Temozolomide|Given PO
224130653|NCT01767194|DRUG|Temsirolimus|Given IV
224130654|NCT00883480|DRUG|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
224130655|NCT00883480|DRUG|Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
223551233|NCT06242990|BEHAVIORAL|Y-PATH NI|"The Y-PATH NI intervention provides a whole of school approach with student, teacher, parent and guardian components. Student components: Y-PATH resources delivered by physical education teachers (6 lesson plans, resource cards to use as teaching prompts), student handbook. Posters are also displayed in the sports hall/ PE department.~Teacher components: Teachers will receive online and in-person training to deliver the Y-PATH programme. This component also targets all non-specialist PE teachers and includes workshops, information leaflets, development of a physical activity promotion charter and a step challenge.~Parent/guardian components: Information session and leaflets distributed across the intervention period."
224020128|NCT06347653|DRUG|linperlisib combined with CHOP regimen|"Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles."
224020129|NCT01648738|OTHER|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
224130656|NCT00883480|DRUG|Gemcitabine|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
224130657|NCT00883480|DRUG|Erlotinib|Erlotinib 150 mg/day x 21 days
224130658|NCT00066625|DRUG|oxaliplatin|Given IV
224130659|NCT00066625|DRUG|bortezomib|Given IV
224130660|NCT00066625|OTHER|laboratory biomarker analysis|Correlative studies
224130661|NCT00066625|OTHER|pharmacological study|Correlative studies
224130662|NCT00001439|BIOLOGICAL|gp100 human melanoma peptide|
224130663|NCT02474667|DRUG|ANG-3777|
224130664|NCT02474667|OTHER|Placebo|
224130665|NCT05846997|DIAGNOSTIC_TEST|Liquid biopsy and imaging|Liquid biopsy and imaging
224130666|NCT05831059|RADIATION|Pulsed radio frequency therapy|Pulse Radio Frequency mode is a high voltage and low temperature Radio Frequency mode formed by discontinuous and pulsed current around nerve tissue
224130667|NCT05831059|OTHER|sham operation|The means to achieve double-blind treatment had no practical effect on the subjects
224130668|NCT02764632|PROCEDURE|Digital facilitation|
224130669|NCT06679621|BEHAVIORAL|Telehealth intervention|This telehealth intervention will be made using human centered design methods
224130670|NCT02490150|DRUG|Corifollitropin alfa|
224130671|NCT00755352|DRUG|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
223731610|NCT00432471|PROCEDURE|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
223731611|NCT01579175|OTHER|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
224020130|NCT01648738|OTHER|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
224020131|NCT02490553|OTHER|heteroevaluation scale by a nurse or doctor|
224020132|NCT01838252|PROCEDURE|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
224020133|NCT01838252|PROCEDURE|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
224020134|NCT00261768|BEHAVIORAL|Digital noise reduction|
224020135|NCT04252768|DRUG|Eftilagimod Alpha|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.
224020136|NCT04252768|DRUG|Paclitaxel|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
224130672|NCT00755352|DRUG|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
224130673|NCT04215081|DEVICE|Gait training using ExoAtlet exoskeleton|Subjects will learn to use the ExoAtlet II exoskeleton, with the assistance of a trained medical professional, to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
224130674|NCT00443339|DRUG|Darbepoetin|
224130675|NCT04645017|BEHAVIORAL|Intergenerational Music Program|Music activities will be lead by adolescent musicians for older adult participants.
224130676|NCT06889870|PROCEDURE|Pectoral Nerve Block|In the PEC group, the PECS II block will be performed by the same anesthesiologist and will be performed before the skin incision, using the technique described by Blanco at al, 2012. 10 ml of ropivacaine solution (0.3%) will be administered into the fascia between the pectoralis major and pectoralis minor muscles and 20 ml of the same anesthetic solution between the pectoralis minor and serratus muscles.
224130677|NCT06889870|PROCEDURE|Local Anesthesia|In the LOC group, local infiltration will be carried out by the surgeon before the surgical incision. Adrenaline 1:20000 will be added to the anesthetic solution in the LOC group for the surgeon's convenience in order to better control per operative bleeding. In the PEC group, a solution of adrenaline in the same concentration in 0.9% saline will be infiltrated, also just to control bleeding in the surgical field.
224130678|NCT04183842|DIETARY_SUPPLEMENT|LACIME Anti-hangover|"LACIME Anti-hangover contains the following excipients:~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~LACIME Anti-hangover contains the following plant extracts and vitamin:~* Curcuma longa rhizome extract (Curcuma),~* Panax quinquefolius extract (Ginseng panax),~* Malpighia punicifolia extract (Acerola),~* Silybum marianum extract (Milk thistle),~* Desmodium adscendens extract (Desmodium),~* Pyridoxine chlorhydrate (Vitamin B6)."
224130679|NCT04183842|OTHER|Placebo|"Placebo contains the following excipients :~* Purified water,~* Xanthan gum,~* Glycerin,~* Potassium sorbate (as a preservative)~* Citric acid (acidity regulator)~* Aroma (flavouring agent)~Placebo contains :~\- Carrot juice"
224020137|NCT02336178|DRUG|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
224020138|NCT05504863|DRUG|Ferric carboxymaltose|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
224020139|NCT05504863|DRUG|Iron isomaltoside|As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
224020140|NCT05504863|DRUG|Ferric Sulfate|As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
224020141|NCT01108250|GENETIC|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
224020142|NCT03181750|BEHAVIORAL|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
223399083|NCT05762172|OTHER|early 18F-FDOPA uptake|"During the usual patient care protocol for the 18F-FDOPA TEP examination, a 10 min acquisition starts after a 15 minutes waiting period following the injection of the radiotracer. This allows the reconstruction of a single late image volume. In the framework of this project, the patient is placed in the machine at the time of injection so as to acquire early 18F-FDOPA uptake and then reconstruct intermediate image volumes in addition to the usual final volume.~The total duration of the patient's examination is therefore not changed."
223399084|NCT04214262|DRUG|Atezolizumab|Given IV
223551234|NCT02501967|OTHER|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
223731612|NCT03164252|RADIATION|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
224020143|NCT02781272|PROCEDURE|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
224020144|NCT02781272|PROCEDURE|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
224020145|NCT02781272|PROCEDURE|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
224130680|NCT06754982|OTHER|Myofascial release|Nine myofascial release techniques will be applied to each group: Transverse hamstring play; Transverse hamstring and adductor magnus play: posterior to anterior pressure; Transverse gastrocnemius-soleus play; Tibia bone clearing: posterior tibia; Tibia bone clearing: prone grip with half chisel; Lateral fascial distraction of the tibia; Lateral elongation of the peroneal tissue; Cross-friction of the gastrocnemius-soleus musculotendinous junction; Manipulation of the plantar fascia.
223399085|NCT04214262|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399086|NCT04214262|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223399087|NCT04214262|OTHER|Fludeoxyglucose F-18|Undergo FDG PET/CT
223399088|NCT04214262|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223399089|NCT04214262|OTHER|Quality-of-Life Assessment|Ancillary studies
223399090|NCT04214262|OTHER|Questionnaire Administration|Ancillary studies
223399091|NCT04214262|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223399092|NCT05230628|DEVICE|Active TENS|Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
223399093|NCT05230628|DEVICE|Sham TENS|Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
223551235|NCT01149005|DRUG|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
223551236|NCT01149005|DRUG|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
223551237|NCT05447520|DRUG|Montelukast|Montelukast 10 mg oral tablet once daily for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
223551238|NCT05447520|DRUG|Placebo|Oral tablet once daily
223551239|NCT05447520|DRUG|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
223551240|NCT01449396|OTHER|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
223731613|NCT03164252|RADIATION|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
224020146|NCT04552483|DRUG|Nitazoxanide|Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.
224020147|NCT04552483|DRUG|Placebo|Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
223399094|NCT03985800|OTHER|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
223551241|NCT01449396|PROCEDURE|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
224020148|NCT00618982|DRUG|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
224020149|NCT03637985|DEVICE|resistive exercise|resistive exercise by elastic band for 12 weeks
224020150|NCT03637985|DEVICE|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
223551242|NCT01449396|PROCEDURE|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
224020151|NCT05692297|DRUG|Denosumab|The patients in the denosumab group received subcutaneous injection of denosumab 60mg once every 6 months for 24 months.
224138703|NCT00817401|DEVICE|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
224296904|NCT02302664|PROCEDURE|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
224296905|NCT03932123|DRUG|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin，cefotaxime|Efficacy and safety of antibiotics
223399095|NCT03985800|OTHER|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
223551243|NCT00922376|DEVICE|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
223551244|NCT02519478|BEHAVIORAL|Helmetless Tackling Training (HuTT)|see previous sections
223551245|NCT00219193|DRUG|aliskiren|
223551246|NCT05126511|DEVICE|Application of CES via ear clips|Use of 100µA CES for one hour per day over PR program
223551247|NCT05126511|DEVICE|Sham: No application of CES via ear clips|Use of Sham CES for one hour per day over PR programm
223551248|NCT00037518|DRUG|AMG 073|
223551249|NCT03465137|BEHAVIORAL|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
224020152|NCT05692297|DRUG|Non-denosumab|Taken other medications, such as diphosphonates, active vitamin D and/or active vitamin D analogue, calcimimetics, calcitonin, estrogen receptor agonists, etc.
224020153|NCT02394951|DRUG|Pregabalin|Anticonvulsant
224020154|NCT02394951|DRUG|Placebo|Identical, matching inactive substance
224020155|NCT01200420|DRUG|miravirsen|SC injection
224020156|NCT01200420|DRUG|saline|SC injection
224020157|NCT06209346|OTHER|TeleRehab Group|"The duration of treatment for the Experimental Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the ET program and respiratory control practices.All the sessions mentioned above will be in online format, through the TRAK platform."
224020158|NCT06209346|OTHER|Advices Group|They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. Participants in the Control Group will have the same follow-up evaluations as the Experimental Group and will receive informative material. They will not have access to the audiovisual material generated for the Experimental Group.
223399096|NCT05799378|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg capsules. Administered orally.
223399097|NCT05799378|DRUG|Placebo|Hydroxychloroquine-matching placebo capsule. Administered orally.
223399098|NCT06843226|OTHER|No Intervention|This is a non-interventional study.
223399099|NCT06154915|OTHER|medical treatments|All patients will follow the medical treatments, as recommended by the multidisciplinary clinical team (for example revascularization or ulcer debriding) according to the best standard of care
223399100|NCT05867849|DRUG|Cannabidiol|Cannabinoid
223399101|NCT05867849|OTHER|Placebo|Inactive substance
223399102|NCT05904626|DRUG|ELGN-2112|To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
223399103|NCT05904626|DRUG|Placebo|A placebo formulation consisting of the same inactive ingredients as ELGN-2112.
223399104|NCT05469009|DRUG|Aducanumab|Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening
224020159|NCT05708404|BEHAVIORAL|Outpatient treatment of severe and enduring anorexia nervosa|A novel outpatient treatment of severe and enduring anorexia nervosa, aiming at enhancing quality of life and minimizing harm
224020160|NCT04536753|PROCEDURE|Induction of labour|Induction of labour using amniotomy, vaginal prostaglandin administration and syntocinon in combination as per protocol.
224020161|NCT04439721|DRUG|γδT Cell infusion agent|γδT
224020162|NCT05114577|BEHAVIORAL|Recovery Sleepers program.|Attend two, 90-minute remote discussion groups (\~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
224020163|NCT05114577|BEHAVIORAL|Email recommendations|Receive recommendations (via email) to help improve sleep
224020164|NCT06349746|OTHER|therapeutic exercises|stretching exercise to posterior capsule and progressive resistance exercise for rotator cuff and scapula stabilizer and home exercise 3 sessions per week for 6 week.
224020165|NCT06349746|OTHER|mobilization exercise|cervical unilateral antero-posterior mobilization and thoracic central postro-anterior mobilization
224020166|NCT00871299|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
224020167|NCT00871299|BEHAVIORAL|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
224020168|NCT01789151|DEVICE|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
224020169|NCT06268223|OTHER|Chewing Exercise Training|All groups will implement the Functional Chewing Exercise, consisting of 5 sets per day, 5 days a week, for 12 weeks. Additionally, the study group will participate in an Action Observation Training program, conducted via telerehabilitation, involving 1 set per day, 3 days a week, for 12 weeks, with the guidance of a physiotherapist.
224020170|NCT01776541|BIOLOGICAL|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
224020171|NCT04408261|DRUG|Buqitongluo Granule|Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
224020172|NCT04408261|DRUG|Buqitongluo Granule Placebo|Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
224020173|NCT04408261|OTHER|Standard care|Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
224020174|NCT01280162|DRUG|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
223399105|NCT05469009|DEVICE|Exablate Model 4000 Type 2|The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.
223399106|NCT05469009|DRUG|Lecanemab|Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening
224020175|NCT03051243|DRUG|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
224020176|NCT03051243|DRUG|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
224020177|NCT02715349|BEHAVIORAL|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
224020178|NCT04084184|DRUG|HGP1812|Dapagliflozin (Forxiga) 10mg
224020179|NCT04084184|DRUG|HGP1602|Dapagliflozin 10mg
224020180|NCT06055348|DRUG|SC0191|SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
224020181|NCT06055348|DRUG|Gemcitabine|Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
224020182|NCT06055348|DRUG|Paclitaxel|Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
223399107|NCT06484660|PROCEDURE|Minimally Invasive Approach In The Mucosal Advancement Flap Technique|Surgical treatment of complex perianal fistula. Less tissue damage. Electrocoagulation source with 75% lower power. Better de-epithelialization of the intra-sphinteric tract. More precise closure of orifice. More consistent mucosal flap
223551250|NCT01709110|DRUG|Teriparatide|Administered SC
223551251|NCT01709110|DRUG|Risedronate|Administered orally
224138704|NCT05779332|OTHER|survey application|Children's OHRQoL was measured by the Child Perceptions Questionnaire (CPQ8-10). Oral examination of children were conducted for presence and severity of MIH, dental caries experience and oral hygiene status.
224138705|NCT01136421|DRUG|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
224296906|NCT00001993|DRUG|Butyldeoxynojirimycin|
224296907|NCT00001993|DRUG|Zidovudine|
223551252|NCT01709110|DRUG|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
223551253|NCT01709110|DRUG|Calcium|Administered orally
223551254|NCT01709110|DRUG|Vitamin D|Administered orally
223551255|NCT02145052|OTHER|Continuous suture|A continuous suture is considered standard of care.
223551256|NCT02145052|OTHER|Interrupted suture|Interrupted sutures are considered standard of care.
224020183|NCT05443152|BEHAVIORAL|Fetal movement and position tracking training|In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
224020184|NCT04603651|DRUG|Bamlanivimab|Administered intravenously (IV).
224020185|NCT02316860|OTHER|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
224020186|NCT00737373|DRUG|Docetaxel|50mg/m2 qd15
224020187|NCT00737373|DRUG|5-Fluorouracil|2600mg/m2 qd15
224020188|NCT00737373|DRUG|Oxaliplatin|85mg/m2 qd15
224020189|NCT00737373|DRUG|folinic acid|200mg/m2 qd15
224020190|NCT04991532|OTHER||
224020191|NCT05753371|DRUG|Metformin Hydrochloride 500 MG|Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
224020192|NCT00156819|DRUG|fluticasone|fluticasone (100 microgram twice daily) treatment
224020193|NCT00156819|DRUG|montelukast|Montelukast (5 or 10 mg each night).
224020194|NCT00156819|DRUG|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
224020195|NCT00461838|PROCEDURE|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
224020196|NCT00461838|OTHER|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
224020197|NCT02529631|DRUG|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
223399108|NCT06253104|DIAGNOSTIC_TEST|BodyMetrix Body Composition Ultrasound|We will use a BodyMetrix Pro A-mode ultrasound device (BodyMetrix Pro, Intelametrix Inc., Livermore, CA) which is a lay imaging tool designed specifically to assess body composition. Images will be taken at two sites; the lateral thigh and bicep on the dominant side if able to identify, or else on the right side. On each visit, five images will be taken at each site (the lateral thigh and bicep). Participants will be measured 2-3 days from initiation in study, then 7 days after, and then weekly from the first measurement until time of advanced therapy, discharge, or death. This measurement sequence will then be repeated following advanced therapy up until discharge or death. Each measurement session will last about 20-30 minutes. This will be performed by the PI or members of the study team who have been trained by the research coordinator.
224130681|NCT06758128|GENETIC|Evaluation of HS1,2 polymorphisms|"Echocardiograms will be performed by experienced operators of the echocardiography service.~Inflammatory profile. A single additional blood sample (3 cc) will be collected. Plasma will be isolated from whole blood to determine pro-inflammatory cytokines.~Immunoprofile: Circulating lymphocytes will be separated according to Ficoll gradient (into the two different components of immunity (B and T lymphocytes) with different inflammatory phenotypes.~Evaluation of HS1,2 polymorphisms and estrogen levels: DNA purifications and amplifications will be performed from an aliquot of the single whole blood sample. Genomic DNA will be isolated using the QIAamp DNA Mini and Blood Mini kit (QIAGEN Hilden, Germany) according to the manufacturer's protocol. 9 single nucleotide polymorphisms (SNPs) in four specific polymorphic regions of the 3'-1 Regulatory Region (3'RR-1) of the human immunoglobulin (IgH) heavy chain locus will be sequenced."
224130682|NCT03437538|DEVICE|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
223399109|NCT03317392|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223399110|NCT03317392|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399111|NCT03317392|PROCEDURE|Computed Tomography|Undergo CT
223399112|NCT03317392|OTHER|Laboratory Biomarker Analysis|Correlative studies
223399113|NCT03317392|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399114|NCT03317392|DRUG|Olaparib|Given PO
223399115|NCT03317392|OTHER|Quality-of-Life Assessment|Ancillary studies
223399116|NCT03317392|RADIATION|Radium Ra 223 Dichloride|Given IV
223399117|NCT06072274|OTHER|The virtual reality educational modules|The experimental group will participate in a dementia education program combining VR lasting approximately 2-3 hours. The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia.
223551257|NCT04251234|OTHER|Light intensity, ~30 lux|\~30 lux compared to very dim light baseline condition \<1 lux
223551258|NCT04251234|OTHER|Baseline light intensity, <1 lux|Very dim light condition
223551259|NCT02076529|DRUG|Ramosetron 0.3mg|
224020198|NCT02529631|DEVICE|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
224020199|NCT04533568|DRUG|Ibuprofen 400 mg|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
224020200|NCT04533568|DRUG|Dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
224296908|NCT05033574|DIAGNOSTIC_TEST|Biochemical study of hormone levels|Biochemical study of the level of follicle-stimulating hormone, luteinizing hormone, estradiol, total testosterone, prolactin, 17-hydroxyprogesterone, dehydroepiandrosterone sulfate, cortisol, insulin, thyroid-stimulating hormone, tetraiodothyronine, thyr
223399118|NCT04151186|BIOLOGICAL|TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy|"Specification: 30 mL-100 mL, cell density of about (1-10) x10\^6 cells/ml in each bag, number of T-cells about (1-10) x10\^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min."
224296909|NCT05033574|DIAGNOSTIC_TEST|Ultrasound examination|Ultrasound examination of the pelvic organs in girls and the scrotum organs in boys
224296910|NCT05033574|RADIATION|Radiography of the hands|Determination of bone age using radiography of the hands
223399119|NCT02611895|BIOLOGICAL|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
223399120|NCT04417010|PROCEDURE|Radiofrequency ablation|Both groups of patients underwent radiofrequency ablation
223399121|NCT00003624|DRUG|amifostine trihydrate|
223399122|NCT00003624|DRUG|cisplatin|
223399123|NCT00003624|DRUG|paclitaxel|
223399124|NCT02863185|DRUG|Pitavastatin|
223399125|NCT02863185|DRUG|Atorvastatin|
223399126|NCT05092958|DRUG|Avelumab|Given IV
223399127|NCT05092958|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
223399128|NCT05092958|PROCEDURE|Bone Scan|Undergo bone scan
223399129|NCT05092958|DRUG|Cabozantinib S-malate|Given PO
223399130|NCT05092958|PROCEDURE|Computed Tomography|Undergo CT
223399131|NCT05092958|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399132|NCT05092958|OTHER|Quality-of-Life Assessment|Ancillary studies
223399133|NCT05092958|OTHER|Questionnaire Administration|Ancillary studies
223399134|NCT05356013|DRUG|Caplyta|Atypical antipsychotic
223399135|NCT05356013|DRUG|Placebo|Pill that contains no medicine.
223399136|NCT05541835|DIAGNOSTIC_TEST|sampling|venous sampling of patient
223399137|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 1 for Cohort 1.
223399138|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 1 for Cohort 2.
223399139|NCT04281485|OTHER|Placebo|Placebo will be administered as a single IV infusion at Year 2 for Cohort 1.
223399140|NCT04281485|GENETIC|PF-06939926|PF-06939926 will be administered as a single IV infusion at Year 2 for Cohort 2
223399141|NCT01517945|BEHAVIORAL|AIM materials and assessments|"Phase 1 (complete) - dev of AIM materials targeting fear of cancer recurrence in BCS (n = 10).~Phase 2 (complete) - randomized, single-blind, placebo-controlled, proof-of-concept pilot trial.~Phase 3:~* Part 1 of Phase 3 (complete) - dev of of iThrive app for BCS~* Part 2 of Phase 3 (complete) - usability testing by observing navigation with BCS in a laboratory setting~* Part 3 of Phase 3 - acceptability of iThrive will be assessed through a small RCT (n=30)~Phase 4:~* Part 1 of Phase 4 (complete) - dev of iThrive app for RCS~* Part 2 of Phase 4 (complete) - usability testing completed by observing navigation with RCS remotely~* Part 3 of Phase 4 - acceptability of iThrive will be assessed through a small RCT (n=90)~For Phases 3 and 4, Part 3: We will work with participants to ensure that sessions are completed over \< 12 weeks if unavoidable delays occur. A follow-up session will be scheduled 3 months after completion of the last session."
223399142|NCT06569316|PROCEDURE|Biospecimen Collection|Undergo blood or saliva and leftover tissue sample collection
223399143|NCT06569316|OTHER|Communication Intervention|Receive care plan recommendations
223399144|NCT06569316|OTHER|Genetic Testing|Undergo genetic testing
223399145|NCT06569316|OTHER|Survey Administration|Ancillary studies
223399146|NCT05388760|DRUG|Tralokinumab|A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
223399147|NCT05036109|DRUG|Aspirin|by mouth every day for up to 90 days
223399148|NCT05036109|DRUG|Vitamin D|by mouth every day for up to 90 days
223399149|NCT05036109|DIETARY_SUPPLEMENT|Diet|Patients will receive counseling promoting a plant-based diet and avoidance of Western dietary patterns in a one on one session with a licensed dietitian prior to day 1.
223399150|NCT05036109|OTHER|Physical Activity|The exercise goal is to increase recreational physical activity from baseline by at least 10 MET hours per week, which is equivalent to 150 minutes of moderate activity weekly
223399151|NCT05036109|BEHAVIORAL|Behavioral Support Counseling Sessions|Patients will undergo a one-on-one counseling session prior to day 1
223399152|NCT06274658|BEHAVIORAL|High-intensity interval exercise|Three high-intensity exercise bouts, each at 100% of maximal power output for 20 seconds, interspersed with active recovery periods of 120 seconds at 10% of maximal power output.
223399153|NCT04992650|PROCEDURE|Fat grafting|Fat grafting
223399154|NCT01419756|DEVICE|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
223551260|NCT02076529|DRUG|Ramosetron 0.45mg|
223551261|NCT02076529|DRUG|Ramosetron 0.6mg|
223551262|NCT02740244|DEVICE|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
223551263|NCT02740244|DEVICE|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
224296911|NCT05033574|BEHAVIORAL|Consultation of a medical psychologist|Consultation with a medical psychologist to determine the patient's psychological condition and level of intelligence
224020201|NCT02090959|DRUG|Ataluren|Ataluren will be administered per the dose and schedule specified in the arm.
223551264|NCT04345484|BEHAVIORAL|Goal-management training|9-week goal-management program
224020202|NCT03480217|BEHAVIORAL|Multifaceted Implementation Strategy|"Key components include:~* educational presentations to primary care providers at grand rounds~* patient information materials on ABPM and HBPM~* training registered nurses to assist providers with teaching patients to conduct HBPM~* information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~* a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~* periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~* an accessible, culturally-adapted and locally tailored ABPM service"
223399155|NCT00127231|BEHAVIORAL|Brief alcohol intervention based on Project Treat|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
224020203|NCT03480217|OTHER|Usual care|Primary care clinicians diagnose hypertension according to usual care
224020204|NCT06063018|DRUG|RC48 + Tislelizumab|RC48: intravenous drip, 2mg/kg, D1, repeated once every 2 weeks. Tislelizumab: intravenous drip, fixed dose 600 mg, D1, repeated once every 6 weeks.
224020205|NCT00522873|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
224020206|NCT00522873|DRUG|0.5mg NETA / 1.0mg E2 (Activella)|One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
224020207|NCT02503878|DEVICE|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
224020208|NCT04871022|PROCEDURE|Double layer closure of the hysterotomy|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium and a second unlocked continuous suture that approximate the upper portion of the myometrium.
224020209|NCT04871022|PROCEDURE|Purse closure of the hysterotomy|Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium
223399156|NCT00127231|BEHAVIORAL|Standard care|Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
223551265|NCT04345484|BEHAVIORAL|Control|Healthy Lifestyle Program
223551266|NCT05757518|OTHER|Cryosauna|The intervention was Cryosauna - cryostimulation at -110°C for 1.5 minutes, for four consecutive days.
223731614|NCT03164252|RADIATION|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
224020210|NCT02732977|OTHER|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
224020211|NCT02190045|OTHER|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
224020212|NCT02190045|OTHER|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
224296912|NCT02860065|DRUG|CPC-201|solifenacin and donepezil
224296913|NCT02860065|OTHER|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
224296914|NCT01043120|DRUG|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
224296915|NCT01043120|DRUG|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
224296916|NCT01195103|DRUG|Fospropofol disodium|10 mg/kg bolus
224296917|NCT01195103|DRUG|Fospropofol disodium|6.5 mg/kg bolus
223399157|NCT03096314|DRUG|Vitamin D3|540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube
223399158|NCT03096314|DRUG|Placebo|A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
223399159|NCT00975117|DIETARY_SUPPLEMENT|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
223399160|NCT00975117|DIETARY_SUPPLEMENT|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
223551267|NCT05215470|DRUG|Nivolumab|Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
223551268|NCT05215470|DRUG|Ipilimumab|Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
223551269|NCT00504439|DRUG|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
223551270|NCT00504439|DRUG|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
223551271|NCT00504439|DRUG|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
223551272|NCT02410642|PROCEDURE|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
223731615|NCT00248014|DEVICE|Mandibular Advancement Via A Functional Appliance|Functional appliance
223731616|NCT01024452|DEVICE|DAWN AC|computerized dosing management system for anticoagulation clinics
224020213|NCT04762823|DEVICE|Cerebellar transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
224020214|NCT04762823|DEVICE|Sham cerebellar transcranial direct current stimulation|Uses weak electrical current (4 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo effects or participant expectation bias.
224020215|NCT02536391|DRUG|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
224020216|NCT02536391|DRUG|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
224020217|NCT04610437|PROCEDURE|Arthrodesis interphalangeal with intramedullary resorbable fixation system|Interphalangeal arthrodesis of lesser toes with two different fixation systems.
224020218|NCT04556461|DRUG|Tralokinumab|2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
224020219|NCT00326833|DRUG|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
224020220|NCT00677326|BIOLOGICAL|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
224020221|NCT00822172|DIETARY_SUPPLEMENT|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
224020222|NCT00822172|DRUG|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
224020223|NCT00700258|DRUG|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
224020224|NCT00700258|DRUG|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
224020225|NCT00700258|DRUG|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
224020226|NCT00700258|DRUG|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
224020227|NCT00700258|DRUG|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
224020228|NCT03169504|OTHER|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30\*25 mm, 0.30\*40 mm or 0.30\*50 mm will be used 3 times weekly for 12 weeks.
224020229|NCT03169504|DRUG|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
223399161|NCT03775265|DRUG|Atezolizumab|Given IV
223399162|NCT03775265|PROCEDURE|Biopsy of Bladder|Undergo a bladder biopsy
223551273|NCT04116983|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
223399163|NCT03775265|DRUG|Cisplatin|Given IV
223399164|NCT03775265|PROCEDURE|Computed Tomography|Undergo CT or MRI
223399165|NCT03775265|PROCEDURE|Cystoscopy|Undergo a cystoscopy
223399166|NCT03775265|DRUG|Fluorouracil|Given IV
223399167|NCT03775265|DRUG|Gemcitabine|Given IV
223399168|NCT03775265|PROCEDURE|Magnetic Resonance Imaging|Undergo CT or MRI
223399169|NCT03775265|DRUG|Mitomycin|Given IV
223399170|NCT03775265|OTHER|Quality-of-Life Assessment|Ancillary studies
223399171|NCT03775265|RADIATION|Radiation Therapy|Undergo 3DCRT or IMRT
223399172|NCT03775265|OTHER|Survey Administration|Ancillary studies
223399173|NCT03775265|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo a TURBT
223399174|NCT05079945|PROCEDURE|Spinal cord Tractography in order to differentiate spinal tracts.|Spinal cord tractography using DTI MRI sequences of the brain and spinal cord, in order to differentiate tracts at the spinal cord level; and by performing a stitching process between Brain and Spinal cord DTI sequences.
223551274|NCT00292526|DRUG|Enalapril|enalapril orally administered
223551275|NCT05922007|OTHER|Validation of the Questionnaire|Validation of the Czech version of the Patterns of Activity Measures-Pain scale (POAM-P/CZ)
224020230|NCT03169504|OTHER|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
224020231|NCT02349646|DEVICE|Implantation with the commercially available Axium neurostimulator|
224020232|NCT01666379|DRUG|Fentanyl|
224020233|NCT05057299|OTHER|retrospective data analysis|chart review, analysis and reporting outcomes
224020234|NCT02367820|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
224020235|NCT00889668|DEVICE|GlucoTrack|comparison of different glucose monitoring devices
224020236|NCT01703351|DRUG|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
224020237|NCT01703351|DRUG|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
224020238|NCT01638832|DEVICE|Transient Elastography (FibroScan), Echosens, Paris, France|
224020239|NCT01638832|DEVICE|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
224130683|NCT03437538|DEVICE|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
223731617|NCT01024452|DEVICE|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
223731618|NCT03334903|DRUG|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
223731619|NCT03254004|DRUG|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
224020240|NCT04261998|OTHER|Service-learning program|Intervention group will perform a service-learning program with real patients with heart transplantation, and will have to perform a physical therapy program adapted to a real patient. Two meetings will be performed in order to establish groups, explain the project and search information based on evidence in scientific databases. In addition, three meetings with patients will be stated in order to establish the adapted program based on the real patient's needs and characteristics.
224020241|NCT02072161|DRUG|ETC-1002|ETC-1002 capsules, taken once daily oral
224020242|NCT02072161|DRUG|Placebo|Placebo capsules, taken once daily oral
224296918|NCT01195103|DRUG|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients \<60 kg; 1.5 mg for patients ≥60 kg to \<90 kg; or 2 mg for patients ≥90 kg
224296919|NCT01195103|DRUG|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients \<60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
224296920|NCT00687310|BEHAVIORAL|Educational intervention|Tailored asthma education based on needs assessment
223399175|NCT01643577|PROCEDURE|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
223399176|NCT01643577|PROCEDURE|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
223399177|NCT02506868|DRUG|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
223399178|NCT05029791|OTHER|Tumor biopsy|2 cutaneous tumor biopsies before treatment initiation (D-28 to D-1) and under treatment (Month 1)
223399179|NCT05029791|OTHER|Blood sample|1 EDTA blood sample (8mL) before treatment initiation (D-28 to D-1)
223399180|NCT06315231|DRUG|Edaravone dexborneol sublingual tablet|Patients will receive one edaravone dexborneol sublingual tablet twice daily for 24 weeks
223399181|NCT06315231|DRUG|Placebo|Patients will receive one placebo twice daily for 24 weeks
223399182|NCT06963996|BEHAVIORAL|Sleep health education|"The intervention consists of three structured sessions delivered over three weeks, with additional online follow-ups. Each session lasts 1.5 hours and takes place in the evening, with a one-week interval between sessions.~Session 1 focuses on providing fundamental knowledge about sleep health. Session 2 introduces behavioral strategies to improve sleep health and asks participants to implement behavior change intentions.~Session 3 reviews the implementation of the intention, the changes made or not, and addresses the relationship between stress and sleep, along with coping strategies."
223551276|NCT05922007|OTHER|Prospective quantitative study - questionnaire survey|A questionnaire survey will be carried out using the questionnaire set three times
223551277|NCT00863044|PROCEDURE|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
223551278|NCT00863044|PROCEDURE|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
224296921|NCT02528123|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
224296922|NCT02528123|DRUG|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
224296923|NCT02528123|DRUG|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
224296924|NCT02528123|DRUG|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
224296925|NCT02528123|DRUG|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
224296926|NCT03733210|DRUG|Panitumumab-IRDye800|30 mg administered intravenously (IV)
223551279|NCT02243319|DRUG|HGP1201|
223551280|NCT02243319|DRUG|HGP0904|
223551281|NCT02243319|DRUG|HGP0904 and HGP1201 co-administraion|
224296927|NCT03733210|DRUG|89-Zirconium (Zr-89) Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
223551282|NCT06379503|OTHER|HEART YOGA|Heart yoga; It includes regular, balanced, safe light physical exercises, breathing exercises that provide breathing control, and meditation practices that include relaxation techniques.
223551283|NCT06379503|OTHER|routine nursing care|Basic nursing care after heart surgery
223551284|NCT02456207|DRUG|SCT400|
223551285|NCT02456207|DRUG|Rituximab|
223731620|NCT03949361|DIAGNOSTIC_TEST|Indirect calorimetry|Resting energy expenditure
223731621|NCT03949361|DIAGNOSTIC_TEST|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
223731622|NCT03949361|DIAGNOSTIC_TEST|Dual energy X-ray Absorptiometry (DXA)|Body composition
223731623|NCT03949361|DIAGNOSTIC_TEST|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
223731624|NCT03949361|DIAGNOSTIC_TEST|FDG-PET|Dynamic PET scanning of the neck-region
223731625|NCT03949361|DIAGNOSTIC_TEST|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
223731626|NCT03949361|DIAGNOSTIC_TEST|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
223731627|NCT06076057|DIAGNOSTIC_TEST|vital signs monitoring|Monitoring of vital signs using portable respiratory sleep monitors, NoxT3, carbon dioxide monitors, transcutaneous oxygen and carbon dioxide partial pressure monitors
223731628|NCT03032705|DEVICE|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
223399183|NCT06317987|BEHAVIORAL|Care Navigation|Care navigation is an intervention that seeks to help patients follow up on substance use treatment plans that are established by care coordinators in the health system by reducing barriers to accessing treatment. This includes advocating for patients to reduce disparities based on language, income or geographical barriers, and cultural preferences (i.e., linkage to available services); and using motivational enhancement techniques to help patients maintain their motivation to obtain substance use treatment while working through these barriers (i.e., motivational intervention). Thus, the care navigator's role is to take the care plan developed between the patient and the mental health care coordinator forward and connect the patient to available services and provide motivational enhancement techniques to help direct the patient toward completion of the care plan.
223399184|NCT06381154|PROCEDURE|Biopsy|Undergo biopsy
223399185|NCT06381154|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399186|NCT06381154|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223399187|NCT06381154|PROCEDURE|Endoscopic Ultrasound|Undergo EUS
223399188|NCT06381154|DRUG|Fluorouracil|Given IV
223399189|NCT06381154|DRUG|Irinotecan|Given IV
223399190|NCT06381154|DRUG|Leucovorin|Given IV
223399191|NCT06381154|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
223399192|NCT06381154|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223399193|NCT06381154|DRUG|Oxaliplatin|Given IV
223399194|NCT06381154|BIOLOGICAL|Pembrolizumab|Given IV
223399195|NCT06381154|DRUG|Photodynamic Therapy|Undergo intratumoral photoradiation
223399196|NCT06381154|PROCEDURE|Positron Emission Tomography|Undergo PET/CT and PET/MRI
223399197|NCT06381154|OTHER|Questionnaire Administration|Ancillary studies
223399198|NCT06381154|DRUG|Verteporfin|Given IV
223399199|NCT04968184|DRUG|Placebo|Participants will orally receive placebo matching to KBP-5074 tablets QD.
223399200|NCT04968184|DRUG|KBP-5074|Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD.
223551286|NCT04353375|DRUG|HMPL-453|Cohort\_1:HMPL-453 150mg QD continuously in 21-day cycles; Cohort\_2:HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \[Day 1 to 14\], followed by 7 days off \[Day 15 to 21\], 21 days as a treatment cycle)
223551287|NCT06032858|DRUG|Apremilast 30mg|Apremilast 30mg twice daily
223551288|NCT00998322|BIOLOGICAL|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
223551289|NCT00998322|DRUG|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
223551290|NCT04884217|DRUG|Pro-ocular™ Topical Gel|Pro-ocular™ Topical Gel 1% is applied dermally to the forehead twice-daily
223551291|NCT04884217|DRUG|Placebo Topical Gel|Placebo is a toopical gel without active ingredient applied dermally to the forehead twice-daily
223551292|NCT04556591|BEHAVIORAL|Just-in-time adaptive intervention (JITAI)|JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
223551293|NCT04556591|BEHAVIORAL|Control|Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period
223551294|NCT01540630|DRUG|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
223551295|NCT01540630|DRUG|Placebo|Double-blind placebo comparator for 28 days.
223551296|NCT02465723|DEVICE|MRI with IVIM DW-MRI|
223551297|NCT02465723|OTHER|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
223551298|NCT00033566|DRUG|S-3304|
223551299|NCT03332173|DRUG|Zanubrutinib|Oral administration using 80 mg capsules
223551300|NCT00408265|BEHAVIORAL|Contingency Management|
223551301|NCT00158626|BEHAVIORAL|pelvic floor muscle training|
223551302|NCT04404101|PROCEDURE|1). EUS-FNA plus MFB|The cyst will be punctured using a 19-G EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed and the wall of the cyst biopsied using the micro forceps passed through the 19 G needle under direct EUS visualization. A minimum of 4 cyst wall biopsies will be obtained to procure at least 4 visible tissue fragments. Cyst fluid will be aspirated and sent for CEA and cytology.
223551303|NCT04404101|PROCEDURE|2). EUS-FNA Alone|The cyst will be punctured using an EUS-FNA needle with a stylet. A transgastric approach will be used for PCLs located in body/tail region, and a transduodenal approach for PCLs in the head/neck region, or as determined by the endoscopist. The stylet will be removed, and cyst fluid will be aspirated and sent for CEA, and cytology.
223551304|NCT04792034|DRUG|Cocaine Hydrochloride Topical Solution|Topical Anesthetic
223551305|NCT00742521|PROCEDURE|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
223551306|NCT00742521|PROCEDURE|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
223551307|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
223551308|NCT00742521|PROCEDURE|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
223551309|NCT02417610|DEVICE|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
223551310|NCT02417610|DEVICE|Hyaluronic acid - HA - Ialart|Hyaluronic acid
223551311|NCT02168101|DRUG|MLN9708|"Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive MLN9708 orally (PO) as monotherapy on Days 1, 8, and 15 of each 28-day cycle for 6 cycles. Up to 18 patients will be enrolled in a dose-escalation phase to determine the maximum tolerated dose (MTD).~Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy. Dosing will start at 2.3 mg. If acceptable tolerability is demonstrated, escalations will be made to 3 mg and to a maximum-planned dose (MPD) of 4 mg."
223551312|NCT05361538|DEVICE|True circular microwave needle|Use true circular microwave needle for thermal ablation
223399201|NCT03943693|DEVICE|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
223399202|NCT03943693|DEVICE|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
223399203|NCT03162250|DRUG|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
223731629|NCT03032705|DEVICE|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
223731630|NCT04381598|DRUG|stevia rebaudiana bertoni|Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
223731631|NCT04381598|OTHER|placebo|A placebo without the active drug will be placed in the control sites.
223731632|NCT01479699|DIETARY_SUPPLEMENT|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
223731633|NCT01000441|DRUG|infliximab, etanercept, adalimumab|
223731634|NCT01000441|DRUG|abatacept, rituximab or tocilizumab|
223731635|NCT07063576|DRUG|Baclofen 10mg|Tablet baclofen 10mg three times daily along with conventional treatment
223731636|NCT07063576|DRUG|Placebo|Tablet placebo three times daily along with conventional treatment
223731637|NCT01331447|DRUG|exemestane|25 mg tablet
223399204|NCT03162250|DRUG|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
223399205|NCT03162250|DRUG|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
223551313|NCT01435694|BEHAVIORAL|Lokomat (Hocoma, Switzerland)|
223551314|NCT01435694|BEHAVIORAL|Conventional Therapy|
224296928|NCT03733210|DEVICE|Pinpoint IR IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
223551315|NCT03953677|DRUG|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
223551316|NCT03953677|DRUG|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
223551317|NCT05507567|DRUG|Neumifil|Liquid for intranasal spray administration
223551318|NCT05507567|DRUG|Placebo|Liquid for intranasal spray administration
223551319|NCT06513923|DRUG|Remimazolam|In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
223731638|NCT06770257|DRUG|daunorubicin, cytarabine liposomes|First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
223731639|NCT06770257|DRUG|Azacitidine|Given SC on days 1-7
223731640|NCT06770257|DRUG|Venetoclax|Given PO on days 1-14 or 1-21 or 1-28
223731641|NCT05700045|DRUG|Dexmedetomidine|each side dexmedetomidine 0.5ug/kg TAP block
223731642|NCT02759471|DEVICE|comfilcon A sphere lens (control)|contact lens
223731643|NCT02759471|DEVICE|comfilcon A asphere lens (test)|contact lens
223731644|NCT00707707|DRUG|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
223731645|NCT00707707|DRUG|Paclitaxel|Intravenous infusion over 1 hour
223731646|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
224020243|NCT02072161|DRUG|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
224020244|NCT03834051|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Rectal Administration Open Label
224296929|NCT03733210|DEVICE|SPY-PHI IR9000 fluorescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
223731647|NCT00940420|DRUG|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
223731648|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
223731649|NCT00940420|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
223731650|NCT00711854|DRUG|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
223731651|NCT00711854|DRUG|Linezolid|Linezolid (600 mg IV or PO twice daily)
223731652|NCT00711854|DRUG|Rifampicin|Rifampicin (600 mg IV or PO once daily)
224020245|NCT00710853|OTHER|YiRen Qi gong|One hour weekly class for 8 week duration
224020246|NCT00710853|OTHER|Tai Chi|One hour weekly class for 8 week duration
224020247|NCT00710853|OTHER|Hatha yoga|One hour weekly class for 8 week duration
224296930|NCT03733210|DEVICE|Explorer Air camera|Fluorescence camera manufactured by SurgVision
224296931|NCT03733210|DEVICE|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
224296932|NCT03733210|DEVICE|FIS-00 fluorescence imaging system (FIS)|Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
224296933|NCT03733210|DEVICE|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
224296934|NCT03733210|DEVICE|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
223551320|NCT06513923|DRUG|Flumazenil|Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
223551321|NCT06513923|DRUG|Propofol|For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
223551322|NCT04791657|PROCEDURE|Appendectomy|Surgical treatment for appendicitis
223731653|NCT05644522|DEVICE|Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)|The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
223731654|NCT03722537|PROCEDURE|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
223731655|NCT03722537|PROCEDURE|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
223731656|NCT02927080|DRUG|ACE-083|Recombinant fusion protein.
223731657|NCT02927080|DRUG|ACE-083 or placebo|Recombinant fusion protein or normal saline.
223731658|NCT02597348|PROCEDURE|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
223551323|NCT00910910|DRUG|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to \< 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
223731659|NCT00933309|DRUG|Exemestane|25 mg tablets orally once a day
223731660|NCT00933309|DRUG|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
223731661|NCT03618992|OTHER|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
223731662|NCT04142853|OTHER|Training intervention + Dance intervention|Training intervention + Dance intervention
223731663|NCT05872672|BEHAVIORAL|Sleep Program|Participants will complete the Headspace Health Sleep Program, which is an 18 day program based on CBTi, and includes the following intervention components: 1) a sleep diary to monitor sleep and associated factors; 2) cognitive interventions to address maladaptive thoughts related to sleep; 3) behavioral interventions to address maladaptive behaviors related to sleep (e.g., sleep hygiene, stimulus control, and sleep restriction); 4) de-arousal techniques (e.g., mindfulness, breathing, and muscle relaxation exercises).
223731664|NCT05872672|OTHER|Waitlist|Participants will continue their regular sleep routines for an 18 day period and will not be assigned to an intervention.
224020248|NCT05310149|DEVICE|Prosthetic intervention with maxillary obturator prosthesis|Prosthetic intervention with maxillary obturator prosthesis is necessary to restore the contours of the resected palate and to recreate the functional separation of the oral cavity and sinus and nasal cavities. Followings are the objectives of maxillary obturator Restoration of esthetics or cosmetic appearance of the patient, Restoration of function, Protection of tissues, Therapeutic or healing effect and psychological therapy.
224020249|NCT01610141|OTHER|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
224020250|NCT01610141|OTHER|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
224020251|NCT01148914|OTHER|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
224020252|NCT00738582|DRUG|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
224020253|NCT00738582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
224020254|NCT00738582|DRUG|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
224020255|NCT05344820|BEHAVIORAL|Art based mandala|To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.
224020256|NCT02416817|OTHER|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
224020257|NCT02416817|OTHER|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
224020258|NCT05039528|BEHAVIORAL|Personalized OSA messages|Participants will receive personalized OSA messages designed to nudge and navigate them toward evaluation and treatment for OSA. Participants will complete questionnaires at baseline and at study follow-up.
224020259|NCT05039528|OTHER|Control|Participants will complete questionnaires at baseline and at study follow-up. At the end of the study period, participants will receive the OSA message intervention.
224296935|NCT03733210|DEVICE|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
224296936|NCT03733210|DEVICE|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
223731665|NCT05877794|DEVICE|central venous catheter insertion|All patients were under trendlenburg position (10 degrees) and disinfected for CVC catheterization. After attaching 2 suture wings of 18G single catheter set to the insertion needle in the 7 Fr or 8 Fr central catheter set, check the IJV to be punctured with an ultrasonic probe. The IJV is punctured using a cross sectional image confirmed at the cricoid cartilage level. After confirming the needle tip on the ultrasound image and blood coming out, the guide wire is mounted on the IJV and then a CVC catheter (arrow international INC) ., USA) is inserted. All actions are performed by a specialist who has more than 30 CVC catheterization experiences using ultrasound, and the occurrence of side effects and the time from puncture to guide wire entry are recorded by another researcher. After the procedure, the researcher who directly performed the procedure records the difficulty or difference compared to when using a conventional needle that does not have a suture wing installed.
223399206|NCT04243889|DEVICE|NEOX Cord 1K|Under general anesthesia and tocolysis, in-utero repair begins with a laparotomy that is followed by exteriorization of the uterus. The fetus is then positioned by external cephalic version. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Then, fetoscopically the placode will be examined and dissected. The lesion will be repaired using NEOX Cord 1K® (HUC) for closure of the first layer over the neural placode. Primary closure of the skin will then occur, or NEOX Cord 1K® (HUC) will be used for skin closure at the discretion of the neurosurgeon. Finally, the laparotomy site will be sutured in multiple layers.
223551324|NCT00910910|DRUG|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
223731666|NCT03573895|OTHER|Foam-Roller|Application of foam roller in the posterior part of thigh.
223731667|NCT03573895|OTHER|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
223731668|NCT03573895|OTHER|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
224130684|NCT07072455|OTHER|Scales|"This observational study consists of data collection using a structured questionnaire based on an e-CRF, distributed by e-mail.~Four questionnaires were administered : the Revised Ritvo Autism and Asperger Diagnostic Scale (RAADS-R-Fr), the Adolescent/Adult Sensory Profile (AASP), the Coping Inventory for Stressful Situations (CISS) and the State-Trait Anxiety Inventory (STAI-Y).~Socio-demographic and treatments were collected."
224130685|NCT07072455|OTHER|High Intellectual Potential Scale|For participants with High Intellectual Potential, the total Intelligence Quotient (IQ) or General Ability Index (GAI), along with the index scores from the Wechsler scales (Verbal Comprehension Index, Perceptual Reasoning Index, Working Memory Index, and Processing Speed Index), will be extracted from the cognitive assessment previously completed by the participant prior to study enrollment.
224130686|NCT05943938|OTHER|Epic Sepsis Model Version - 1|The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
224130687|NCT05943938|OTHER|Epic Sepsis Model Version - 2|The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
224296937|NCT03733210|DEVICE|Odyssey CLx Imaging System|Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
224296938|NCT03733210|DEVICE|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
224296939|NCT03760250|DRUG|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
223399207|NCT05809869|DRUG|Durvalumab|Durvalumab 1500mg intravenous infusion on week 1, 5, 9, 13, 17, 21 and 25 for a total of 7 cycles
223551325|NCT01882712|DRUG|CD07805/47 Gel 0.5%|
223551326|NCT01882712|DRUG|CD07805/47 Gel Placebo|
223551327|NCT06123273|BEHAVIORAL|Exercise-oriented training|IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
223731669|NCT05415085|PROCEDURE|Culprit-first PCI|PCI to the culprit artery prior to the demonstration of the whole coronary tree.
223731670|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
224296940|NCT01237925|DRUG|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
224296941|NCT01237925|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
223731671|NCT03109301|DRUG|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
223731672|NCT03867604|PROCEDURE|Sham injection|Injection to the subcutaneous layer at upper trapezium level
223731673|NCT03867604|PROCEDURE|Fascia injection|Injection to the fascia below upper trapezium muscle
223731674|NCT02892760|DEVICE|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
224130688|NCT05943938|OTHER|Emory Sepsis Model|Emory internal algorithm
224130689|NCT06896240|DIETARY_SUPPLEMENT|Assigned Interventions|"The Green Smoothie Guide from the American College of Lifestyle Medicine contains guidelines for a 6-step smoothie to include whole and high fiber foods."
224130690|NCT07075848|PROCEDURE|vaginal delivery|follow up of progress of labour
224130691|NCT00380354|DRUG|GSK256066|
224130692|NCT07082595|OTHER|TASS Intervention (Sham)|Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. No auditory stimuli will be delivered.
224130693|NCT07082595|OTHER|TASS Intervention (Verum)|TASS: Participants will sleep with the portable EEG (TSB, Axo, Tosoo AG, Zurich, CH) during 15 days of their regular motor rehabilitation. Auditory stimuli will be delivered through the integrated headphones when non-rapid-eye-movement (NREM) sleep is detected during the night to induce TASS.
223731675|NCT05335564|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
224020260|NCT04520360|DRUG|Carisbamate|Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
223731676|NCT01304901|DRUG|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
223731677|NCT01304901|DRUG|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
223731678|NCT04843423|DRUG|Cariprazine|"At the screening visit, those who are eligible will enter an open-label trial with cariprazine in doses ranging from 1.5mg to 3 mg. The study will begin with a single week of cariprazine 1.5 mg oral tablets. After the first week the participants' dosage may be increased up to a maximum of 3 mg daily. This dose will remain fixed after 4 weeks of treatment until week 8, at which time the medication will be discontinued.~Because the drug is not yet available to market in Canada, participants will be dispensed the drug in appropriately labelled 7-day tablet containers with the appropriate dose, including 3 additional tablets to account for scheduling conflicts. Participants will be instructed to return the tablet containers at each Study Visit in order to assess drug compliance. They will then be newly dispensed the appropriate quantity according to their next scheduled study visit."
224020261|NCT00757588|DRUG|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
224020262|NCT00757588|DRUG|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
224020263|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
224020264|NCT01284686|OTHER|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
224020265|NCT01873820|DIETARY_SUPPLEMENT|Calcium ascorbate|
224020266|NCT01873820|DIETARY_SUPPLEMENT|Ascorbic acid|
224296942|NCT03728634|DRUG|ION-682884|ION-682884 administered SC
224296943|NCT03728634|DRUG|Placebo|Placebo comparator calculated volume to match ION-682884 administered SC
223731679|NCT02105792|DRUG|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
223731680|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
224296944|NCT03728634|DIETARY_SUPPLEMENT|Vitamin A|Oral supplement
223731681|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
223731682|NCT05491330|DRUG|Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)|2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
224296945|NCT03185234|DEVICE|anodal tDCS|2 mA, 10 min, 5 sessions
224296946|NCT03185234|DEVICE|sham tDCS|sham stimulation, 10 min, 5 sessions
224296947|NCT02302313|DEVICE|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
224296948|NCT03951896|BIOLOGICAL|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
224296949|NCT03951896|OTHER|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
223731683|NCT06221904|BEHAVIORAL|Simple Gymnastics Training|This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
223731684|NCT04850131|PROCEDURE|Desarda repair|Desarda is a new tissue-based technique developed from applying the externally oblique muscle aponeurosis in the form of an undetached strip making the posterior wall in the inguinal canal stiffer. This paper focuses on analyzing comparisons between mesh-free Desarda repair and the Lichtenstein technique for the treatment of hernia inguinalis
223731685|NCT02259582|DRUG|Pemetrexed|
223731686|NCT02259582|DRUG|Carboplatin|
223731687|NCT02259582|DRUG|demcizumab|
223731688|NCT00243789|DRUG|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
223731689|NCT02653391|DRUG|Part A Elamipretide 1.0% Ophthalmic Solution|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye.
223731690|NCT02653391|DRUG|Part B Elamipretide 3.0% Ophthalmic Solution|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both eyes.
223399208|NCT05809869|DRUG|Tremelimumab|Tremelimumab 300mg intravenous infusion on week 1 only.
223399209|NCT05809869|RADIATION|Yttrium-90 radioembolisation|Yttrium-90 radioembolisation on week 2 only.
223731691|NCT02653391|DRUG|Part A Placebo|Part A Each subject will receive one drop of vehicle ophthalmic solution BID in the paired eye of the randomly selected study eye.
223731692|NCT02653391|DRUG|Part B Placebo|Part B: Each subject will receive one drop of vehicle ophthalmic solution BID in both eyes.
223399210|NCT03673969|PROCEDURE|Gastric bypass|Surgical method of gastric bypass
223399211|NCT06575322|DRUG|Carboplatin（ neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223399212|NCT06575322|DRUG|Paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223399213|NCT06575322|DRUG|Anti-PD-1 Drugs|Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
223399214|NCT06575322|PROCEDURE|Surgical resection|Standard of care
223399215|NCT04614519|PROCEDURE|Conventional group|Insufflation pressure at 12mmHg and conventional instrumentation
223731693|NCT04213365|OTHER|Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.|12 weeks of cognitive stimulation sessions coupled with APA (Adapted Physical Activity) sessions.
223731694|NCT05620550|PROCEDURE|ozonated oil|Post operative scar treatment with ozonated oil
223399216|NCT04614519|PROCEDURE|Low impact laparoscopy group|Insufflation pressure at 7mmHg and micro-laparoscopy instrumentation
223731695|NCT05620550|PROCEDURE|non ozonated oil|Post operative scar treatment with non ozonated oil
224130694|NCT07084714|BEHAVIORAL|Moderate Aerobic Exercise|"Participants will complete moderate intensity aerobic exercise for 30 minutes per session, progressing from three to five days per week to meet the minimum recommended aerobic physical activity guideline of 150 minutes per week set by the American College of Sports Medicine (ACSM) over two menstrual cycles. Moderate intensity is defined as maintaining a heart rate within 40-59% heart rate reserve and a rate of perceived exertion of 11-14 light to somewhat hard on the Borg 6-20 scale."
223731696|NCT00531050|DRUG|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
224296950|NCT03538119|OTHER|High Intensity Interval Training Program|"The HIIT group performed 4 × 4-minute high-intensity intervals at 85%-95% HRpeak followed by a 1-minute recovery interval at 40% HRpeak, predicted with a supervised graded exercise test on a treadmill with the Bruce protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
223731697|NCT00531050|DRUG|Placebo|Single dose indacaterol matching placebo via Concept 1 device
223731698|NCT00531050|DRUG|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
223731699|NCT00132145|BEHAVIORAL|Vascular Management Program|
223731700|NCT00132145|BEHAVIORAL|Clinical Care Coordinators|
224296951|NCT03538119|OTHER|Moderate Intensity Continuous Training Program|"The MICT protocol (usual care) consisted of a continuous bout of moderate-intensity exercise to elicit 70-75% HRpeak, rating of perceived exertion 3 to 5 (fairly light to somewhat hard), for 27.5 minutes to equate the energy expenditure with the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of HRpeak) and a 3 to 5 minute calm return period at 50% of the HRpeak.~The supervised sessions will take place on treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
224296952|NCT04990596|BIOLOGICAL|additional blood sample|One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
223731701|NCT00132145|BEHAVIORAL|Web-based Vascular Tracker for Patient and Physician|
223731702|NCT00132145|BEHAVIORAL|Automated Telephone Reminder System|
223731703|NCT02031926|DEVICE|Positive expiratory pressure|
223731704|NCT01067456|RADIATION|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
223731705|NCT04384666|DRUG|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)|LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)
223731706|NCT04384666|OTHER|Neupro 4 mg / 24 Hr. Transdermal Patch|Neupro 4 mg /24 Hr. Transdermal Patch
223731707|NCT02671591|BEHAVIORAL|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
223731708|NCT02671591|BEHAVIORAL|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
224130695|NCT07082829|DRUG|ORX142 Tablets|ORX142 Tablets
224130696|NCT07082829|OTHER|Placebo Tablets|Placebo Tablets
224130697|NCT07083440|DRUG|Remimazolam|Intravenous bolus administered over 1 minute (prepared as a 1 mg/mL solution). Doses: 0.2 mg/kg, 0.3 mg/kg, or 0.4 mg/kg according to group allocation.
223731709|NCT04445324|BEHAVIORAL|Transitional Online Peer Support Group (n=20)|Trained Peer Support Workers (PSWs) from the Quebec Association of PSWs will organize and facilitate two series (one per condition) of 10 co-learning recovery workshops in a manner to simulate a typical peer support group. The difference of these transitional peer support groups to real community-based peer support groups is that (A) they will be facilitated by trained PSW, (B) they will have a personal-civic recovery focus, and (C) they will have a fixed, predetermined duration (10 weekly 60 to 90-minute online workshops). Typical Peer support groups bring together people who have similar concerns so they can explore solutions to overcome shared challenges and feel supported by others with similar experiences and who may better understand each other's situation. Peer support groups should ideally be independent from mental health and social services, although some services may facilitate and encourage the creation of (transitional) peer support groups, as is the case here. (WHO)
224020267|NCT05973695|OTHER|clamshell exercise|For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions
224020268|NCT05973695|OTHER|Gluteal Bridge exercises|Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
224020269|NCT04665999|DEVICE|Continuous Glucose Monitor|Data collection only
224020270|NCT06394232|DRUG|Eyecyte-RPE™|Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
224020271|NCT02907229|DEVICE|NCVC-CS1|Intervention Description
224130698|NCT07083440|DRUG|Propofol|Intravenous (10 mg/mL emulsion), initial titrated dose ranging from 0.5 to 2 mg/kg, administered slowly until MOAA/S ≤ 2. Supplemental 0.5 mg/kg boluses as needed.
223399217|NCT03749876|OTHER|Unfiltered Cigarettes|Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
223399218|NCT03749876|OTHER|Filtered Cigarettes|Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
223399219|NCT03842917|OTHER|Biological samples|Urine and blood samples
223399220|NCT03842917|OTHER|Blood pressure measurement|Home blood pressure self-measurement and hospital blood pressure measurement
223399221|NCT05457023|OTHER|Plasma Neurofilament Light (NF-L)|Plasma NF-L is a biomarker of axonal brain injury following sports-related head impacts.
223399222|NCT05457023|OTHER|Omega-3 Index|Omega-3 Index is the omega-3 fatty acid content of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) within the erythrocyte cell membrane. It is expressed as EPA+DHA as a percent of total identified fatty acids.
223399223|NCT05457023|OTHER|HeadCount Questionnaire|HeadCount is a web-based, structured, self-administered questionnaire to assess longer-term heading exposure during competitive play and is administered bi-weekly.
223399224|NCT05013710|OTHER|Complete Clinical Interaction|The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)
223399225|NCT01832064|BEHAVIORAL|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
223399226|NCT03915132|DRUG|Nimotuzumab|Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles
223399227|NCT03915132|RADIATION|VMAT|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
223399228|NCT04977375|DRUG|Pembrolizumab|Pembrolizumab 400mg administered intravenously on Day 1, and then beginning 6 weeks post-surgery, subjects will receive 400 mg pembrolizumab every 6 weeks
223399229|NCT04977375|RADIATION|Stereotactic Radiation Therapy|Standard of care stereotactic radiation of 24 grays over 3 days, administered beginning on Day 7
223399230|NCT04977375|PROCEDURE|Surgical Resection|Standard of care surgical resection of tumor on Day 10-28
223399231|NCT00319137|DRUG|GW274150|
224130699|NCT07083440|DRUG|Sufentanil|Intravenous dose of 0.1 µg/kg administered approximately 30 minutes before the start of the procedure.
224130700|NCT07082764|DRUG|Brimonidine gel|TAR-0520 gel
224130701|NCT07082764|OTHER|No intervantion|No treatment
223399232|NCT04439929|BIOLOGICAL|TUR01|Administered as a single 40 mg, subcutaneous dose
223399233|NCT04439929|BIOLOGICAL|Adalimumab-EU|Administered as a single 40 mg, subcutaneous dose
223399234|NCT03669380|OTHER||
223399235|NCT04703972|BEHAVIORAL|clinical assessment (mood relapses identification)|clinical assessment via psychometric scales physiological data acquired automatically via the connected device (wristwatch, wristband)
223399236|NCT04269369|DRUG|5-Fluorouracil|"The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature."
224130702|NCT07082842|DRUG|HEC585|HEC585 tablet, taken once daily
223731710|NCT04445324|OTHER|Control Group (pharmacotherapy and/or psychotherapy, n=10)|When individuals show up at the Emergency Department (T1) of the Montreal Mental Health University Institute, they are evaluated by the Evaluation and Liaison Module during their hospital stay when they are hospitalized. A diagnostic is established or confirmed by psychiatrists on the ward, and coded according to the World Health Organisation International Classification of Disease (ICD-10). According to these diagnoses, after discharge (T2) they are referred to a specialized outpatient clinic for an appointment (T3). Whether for (a) psychotic disorders or for (b) anxiety and mood disorders, pharmacotherapy or psychotherapy, or a combination of both, are then offered in accordance with guidelines of the Royal College of Physicians and Surgeons of Canada.
223399237|NCT04046887|DRUG|Lonsurf|Lonsurf will be administered orally twice a day on days 2-6 and 16-20 of every 28-day cycle at a dose of 25 mg/m2, 20 mg/m2 or 30 mg/m2 depending on cohort assignment.
223399238|NCT04046887|DRUG|Gemcitabine|Gemcitabine will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 800 mg/m2, 600 mg/m2 or 1000 mg/m2 depending on cohort assignment.
223399239|NCT04046887|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 100 mg/m2, 75 mg/m2 or 125 mg/m2 depending on cohort assignment.
223551328|NCT00974506|OTHER|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
223551329|NCT00974506|OTHER|Routine care therapy|Routine care therapy by general practitioner
223731711|NCT03344432|DIAGNOSTIC_TEST|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
223731712|NCT03344432|DIAGNOSTIC_TEST|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
223731713|NCT04566081|OTHER|iTALKbetter: deterministic|A word retrieval therapy application
223551330|NCT05016024|DEVICE|Colilen IBS|Patients will take Colilen IBS in First or Second Period
223551331|NCT05016024|OTHER|Placebo|Patients will take PlaceboS in First or Second Period
223551332|NCT02049346|DRUG|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
223551333|NCT02049346|DRUG|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
223551334|NCT02049346|DRUG|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
223551335|NCT03976050|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
223551336|NCT03096392|DRUG|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
223551337|NCT03096392|DRUG|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
223551338|NCT01973231|DRUG|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
223551339|NCT01973231|DRUG|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
223551340|NCT02084498|DEVICE|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
223551341|NCT02084498|BEHAVIORAL|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
223551342|NCT03024112|DEVICE|Heated humified high-flow nasal cannula Oxygen|
223551343|NCT03024112|OTHER|Standard oxygen therapy|
223551344|NCT06289894|DRUG|BRY805 injection|BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
223399240|NCT05104437|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
223399241|NCT05104437|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
223399242|NCT00629356|GENETIC|dengue fever|
224130703|NCT07082842|DRUG|Placebo|HEC585 Simulation Board, taken once daily
224130704|NCT07082842|DRUG|Pirfenidone|Pirfenidone, taken three times a day
224130705|NCT07083635|DRUG|Transdermal Ethinyl Estradiol/Norelgestromin Patch|Transdermal contraceptive patch containing ethinyl estradiol 600 micrograms and norelgestromin 6 milligrams per patch, manufactured by GEDEON RICHTER PLC and imported by Abbott.
223551345|NCT06014151|OTHER|questionnaires|we will use a quantitative and a qualitative approach. For the first one, a psychosocial approach on a large number (500 women and 500 men) of candidates to donation. Of course, gender and parenthood will be considered in the analyses, as in the previous study. We will use two questionnaires for this study: 1) the one that was validated for the previous study, including socio-demographic data, donors' motivations and representations, 2) the second exploring personality, the NEO-PR inventory, which was also used for the previous study.
223551346|NCT04380909|BEHAVIORAL|Internet-based self-help|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
223551347|NCT04380909|BEHAVIORAL|Internet-based self-help after 3 weeks|Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
223551348|NCT03969290|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
223551349|NCT03969290|DEVICE|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
223551350|NCT04349358|OTHER|FDG and FCH PET/CT|"* during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams"
223551351|NCT04579536|OTHER|Light curable resin modified glass ionomer varnish|Light curing resin-modified glass ionomer varnish (ClinproTM XT Vanish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used to seal 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
223551352|NCT04579536|OTHER|Vanish White Varnish|5% Sodium Fluoride (NaF) with Tri-Calcium Phosphate topical varnish (Vanish White Varnish, 3M ESPE, Dental Products, St. Paul, MN, USA) will be used on 84 first permanent molars at baseline, 3, 6, 12 and 18 months.
223731714|NCT04566081|OTHER|iTALKbetter: reactive|A word retrieval therapy application
223731715|NCT00475176|DRUG|Peginterferon alfa-2a|
223731716|NCT00475176|DRUG|Ribavirin|
223551353|NCT05878678|DEVICE|Fixed positions of arm down and arm up|In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
223551354|NCT03474913|DEVICE|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
223551355|NCT03474913|DEVICE|Standard MRI|standard of care closed 3T MRI
223551356|NCT05074680|DIAGNOSTIC_TEST|Blood sampling|Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)
223551357|NCT01989429|DRUG|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
223731717|NCT00475176|DRUG|S-adenosyl methionine for Chronic Liver Disease|
223731718|NCT03804879|DRUG|Nidufexor|50 mg (two 25 mg) LMB763 capsules for oral administration
223731719|NCT03804879|OTHER|Placebo|Placebo capsules for oral administration
223731720|NCT03804879|DRUG|Standard of Care (SoC)|Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
223731721|NCT00221754|DRUG|Pravastatin (drug)|
223731722|NCT01585428|DRUG|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223731723|NCT01585428|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
223731724|NCT01585428|BIOLOGICAL|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
224130706|NCT07083635|DRUG|Placebo Patch|Identical-appearing transdermal patches without active hormonal ingredients , manufactured and imported by Convatec.
224130707|NCT07083245|BEHAVIORAL|Psychosocial care|Psychosocial support to chemotherapy patients during their treatment sessions through conversations, board games, movies, and gift baskets
223731725|NCT01585428|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
223731726|NCT01655979|DIETARY_SUPPLEMENT|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
223731727|NCT01655979|OTHER|Control|Bed rest without dietary supplement
224130708|NCT07083648|RADIATION|Magnetic resonance Imaging-guided online adaptive radiotherapy|On each day of treatment, a new MRI scan in the treatment position will be acquired using the dedicated MR simulator, co-registered with the original one. The original target and organ at risk (OAR) contours will be propagated to the new image set using rigid and deformable image registration. The contours will be adapted to changes detected with MRI of the day. The original SBRT treatment plan will be adapted to the changed and hence adapted anatomy of targets and OARs by plan optimization. Dose calculation will be performed on the newly generated synthetic CT (preferred) or, if there is a contra-indication for synthetic CT, on the original image.
224130709|NCT07083453|OTHER|Comparator 1|$10 rebate offered with an online caries and periodontal risk assessment
224130710|NCT07083453|OTHER|Comparator 2|20 rebate offered without risk assessment
224130711|NCT07083453|OTHER|Comparator 3|$30 rebate offered without risk assessment
224130712|NCT07083453|OTHER|Comparator 4|$50 rebate offered without risk assessment
224130713|NCT07083453|OTHER|Control|$10 rebate offered with no risk assessment
223731728|NCT03206853|PROCEDURE|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
223399243|NCT01935609|BEHAVIORAL|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
223731729|NCT02635555|DRUG|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
224130714|NCT07082647|BEHAVIORAL|Mixed feedback method|Feedback (technical correction) method in which both visual and verbal feedback are predominantly used in the feedback given to the participants throughout the training program.
224130715|NCT07082647|BEHAVIORAL|Visual feedback method|Feedback (technical correction) method in which visual feedback is predominantly used in the feedback given to gymnasts throughout the training program.
224130716|NCT07082647|BEHAVIORAL|Verbal feedback method|Feedback (technical correction) method in which verbal feedback is predominantly used in the feedback given to gymnasts throughout the training program.
224130717|NCT07074236|DRUG|QLC7401 injection|QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.
224130718|NCT07074236|DRUG|RBD7022 injection|RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.
223399244|NCT00140868|DEVICE|Luminal stents|
223399245|NCT00140868|PROCEDURE|Minimally Invasive Surgical Bowel Diversion|
223399246|NCT00957801|DRUG|Testosterone injection|100 mg single IM injection
223399247|NCT00957801|DRUG|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
223399248|NCT00957801|DRUG|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
223399249|NCT03841864|OTHER|IV placement using ultrasound guidance vs traditional method|Ultrasound guided IV placement
223551358|NCT04595643|OTHER|Combination of different dysphagia training modalities|Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
223551359|NCT03010943|DEVICE|Virtual reality headset|Feasibility and tolerance
223731730|NCT03366376|RADIATION|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
223731731|NCT05474742|OTHER|The Nori Health app|The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
223731732|NCT04379089|OTHER|Observational study only|No Intervention
223731733|NCT03931421|BIOLOGICAL|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
224130719|NCT07075874|OTHER|PDPH|Observational analysis of preoperative inflammatory markers (e.g., NLR, PLR, SIRI) in relation to PDPH development following spinal anesthesia.
223399250|NCT00482768|BEHAVIORAL|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
223399251|NCT05098522|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
223399252|NCT05098522|DRUG|Placebo|Matching placebo for IRL201104
223551360|NCT01382914|OTHER|chlorhexidine 0.12%|twice daily, 10 ml, topical
223551361|NCT03731403|OTHER|MI varnish|CPP- ACP with 5 % sodium fluoride GC
223551362|NCT06012539|OTHER|Qualitative (interviews)|Interviews were held with participants at three different time points, approximately six months apart. Interviews were taped and analyzed for common themes.
223399253|NCT00448266|DRUG|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
223399254|NCT00448266|DRUG|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
223399255|NCT00002303|DRUG|Epoetin alfa|
223399256|NCT02124655|DRUG|Essential oils|
223399257|NCT02124655|DRUG|0.2% chlorhexidine|
223399258|NCT02124655|DRUG|Sterile water|
223399259|NCT04024670|OTHER|Arts Intervention|If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
223399260|NCT00225615|DRUG|sapropterin dihydrochloride|
223399261|NCT06534762|BIOLOGICAL|Mirabegron|To explore the efficacy and safety of milaberon combined with standard treatment in advanced solid tumors
223399262|NCT01692860|OTHER|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
223399263|NCT01171144|OTHER|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
223399264|NCT01171144|OTHER|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
223399265|NCT01171144|OTHER|Hospital discharge records|Reviewing the hospital discharge records
223399266|NCT05008744|PROCEDURE|Fetoscopic laser ablation|"Under ultrasound guidance, a 2 mm skin incision will be made and a 10Fr Cook Check Flow valve cannula and trocar will be introduced into the amniotic cavity.~The communicating vessels will be located endoscopically using a Storz straight or curved semirigid fetoscopes in a fetoscopic sheath, a Humanitarian Use Device, used with permission of the Federal Drug Administration under a Humanitarian Device Exemption agreement with Karl Storz, Inc, and will be ablated with a diode laser fiber that is passed through the operating channel of the endoscope."
223399267|NCT00256074|PROCEDURE|Enteral feeding formula|
223399268|NCT02450201|DRUG|Pyruvate|
223399269|NCT01778855|OTHER|IV t-PA and normothermia|
223399270|NCT01778855|DEVICE|IV-tPA and hypothermia|
223551363|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube plus bougie|"Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted."
223731734|NCT04902716|BEHAVIORAL|Design course|Precision nursing is a new trend in nursing in recent years. It is based on individual differences in disease type, gender, lifestyle, family, race, social and cultural factors, etc., to provide the most suitable empirical-based nursing treatment.Diverse courses include music, breathing exercises, cognitive training, hand-made knitting, etc.
224020272|NCT05352243|BEHAVIORAL|Expressive Disclosure|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write about their deepest thoughts and feelings surrounding their bereavement experience.
224130720|NCT07084441|DRUG|Dexamethasone|\*Please see description for dexamethasone + supportive care arm.
223731735|NCT05687422|PROCEDURE|100μm laser spot diameter micropulse laser|100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
223731736|NCT05687422|PROCEDURE|200μm laser spot diameter micropulse laser|200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
224130721|NCT07084441|OTHER|Supportive Care|\*Please see description for supportive care arm.
224130722|NCT07084155|BEHAVIORAL|Adaptive Cell Phone Support|Mobile health adherence promotion based on the supportive accountability model
224130723|NCT07082010|DEVICE|MBPS App|A MBPS web application designed and built on a customizable case management platform (CommCare) to support non-specialist providers will be used by study participants for approximately 3 months.
224130724|NCT07083869|BEHAVIORAL|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
224130725|NCT07083869|BEHAVIORAL|Sleep Well|Sleep Well is a website that is mobile enabled that provides psychoeducation about healthy sleep habits that is based on NIH Health Guide to Health Sleep and VA's Whole Health Change Your Habits to Sleep Better.
224130726|NCT07082855|DRUG|Minocycline 100mg|Capsules Minocycline 100mg po per day and placebo 100mg po per day for 12 months
224130727|NCT07082855|DRUG|Minocycline 200mg|Capsules Minocycline 100mg po twice a day for 12 months
224130728|NCT07082855|DRUG|Placebo|Capsules placebo 100mg po twice a day for 12 months
224130729|NCT07082049|PROCEDURE|Prostate surgery|Including but not limited to open radical prostatectomy, laparoscopic radical prostatectomy (LapRP) and robot-assisted radical prostatectomy (RARP).
223399271|NCT02079623|PROCEDURE|Electroporation/ Nano knife treatment|
223399272|NCT02079623|DEVICE|NanoKnife|
223399273|NCT06415708|DRUG|Obinutuzumab Combined With Bendamustine|"The treatment is divided into two phases: induction therapy and maintenance therapy Induction therapy: 6 cycles of obinutuzumab (1000 mg, IV) on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6 (28 days/cycle). Bendamustine (90 mg/m2, IV) on Days 1 and 2 of Cycles 1-6.~Maintenance therapy: Patients who achieved at least a partial response after 6 months of induction therapy were eligible to enter the maintenance phase, during which obinutuzumab (1000 mg, IV) was administered every 2 months for 2 years."
223399274|NCT00879307|DRUG|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
223399275|NCT00191477|DRUG|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
223399276|NCT00191477|DRUG|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
223399277|NCT06047730|PROCEDURE|operation ways|nothing
223399278|NCT00916084|DEVICE|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
223731737|NCT00660530|DRUG|Lanthanum Carbonate Chewable Product|Lanthanum carbonate 1 g to be chewed, three times daily with meals
223731738|NCT00660530|DRUG|Lanthanum carbonate crushed powder|Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
223731739|NCT03889158|BIOLOGICAL|Typhoid Vaccine|All participants will receive the typhoid vaccine.
223731740|NCT03889158|DIETARY_SUPPLEMENT|Ascorbic Acid|All participants will receive ascorbic acid.
223731741|NCT04273217|DRUG|AV-1|Single dose, administered by IV infusion (volume: 250 mL)
223731742|NCT04273217|DRUG|Placebo|0.9% sterile saline. Administered by IV infusion (volume: 250 mL)
223731743|NCT06208059|OTHER|manual acupuncture|In manual acupuncture, the scalp motor area on the lesion side will be needled and left in place for 30 minutes after obtaining qi. During the needle retention, the needles will be twisted intermittently for 2 minutes twice, at a frequency of approximately 200 r/min.
223731744|NCT06208059|OTHER|electroacupuncture|In electroacupuncture, the scalp motor area will be needled, and after obtaining qi, the treatment will involve applying electroacupuncture stimulation using a continuous wave with a frequency of 2 Hz. The intensity of the stimulation will be adjusted based on the patient's tolerance, and each treatment session will last for 30 minutes.
224130730|NCT07082049|BEHAVIORAL|LLM-assisted communication|Preoperatively, patients will communicate with the LLM, which will provide direct answers to their various questions, including but not limited to diagnosis, treatment options, operative risks, and complication management. To ensure the accuracy of LLM-generated responses in real-world clinical settings, all answers will undergo verification by the researchers before being provided to patients.
224130731|NCT07082049|BEHAVIORAL|Routine preoperative communication|Preoperatively, patients will attend a consultation with the attending surgeon and surgical team. This physician-led communication will comprehensively discuss, current disease status, treatment options, operative risks, potential complication. The surgical team will subsequently address patient inquiries, followed by executing the informed consent form.
223399279|NCT00916084|DEVICE|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
223399280|NCT02962492|DRUG|Exenatide/Exenatide extended release|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
223399281|NCT02962492|DRUG|Dapagliflozin|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
223399282|NCT02962492|DRUG|Placebo|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
223399283|NCT03992963|DEVICE|Hearing Aid without frequency lowering enabled|Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.
223399284|NCT03992963|DEVICE|Hearing Aid with frequency lowering enabled|Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
223399285|NCT02825017|DRUG|Coppertone (BAY 987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm\*2 test application.(Formulation-SR15-79\_Y73-161)
223399286|NCT03589417|OTHER|Assessments with Biodex Balance System®|Postural Stability, limits of stability and fall risk tests will be applied with the Biodex Balance System®
223399287|NCT06424613|DRUG|Lithium Carbonate|Participants must have been prescribed lithium for the past year and demonstrate at least 80% adherence to their lithium medication regimen during the first six months of the study period.
223399288|NCT06424613|DRUG|Non-lithium medication|No history of lithium use within the past year
223731745|NCT05352009|OTHER|Sling exercise training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of sling exercise training and 10 min treadmill training.
223731746|NCT05352009|OTHER|Conventional balance training|All participants will receive exercise training for 30 min/ session, 3 sessions/ week for 4 weeks (a total of 12 training sessions). The training includes 20 min of balance exercise training and 10 min treadmill training.
223731747|NCT00810290|BEHAVIORAL|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
223731748|NCT00584142|BEHAVIORAL|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
223731749|NCT05502328|DIETARY_SUPPLEMENT|Energy Study Product Usage|Participants will use their Radicle Energy study product as directed for a period of 4 weeks.
223731750|NCT04983992|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
223731751|NCT02947529|DRUG|Tranexamic Acid|intravenous dose
223731752|NCT02947529|OTHER|Placebo|intravenous dose
224130732|NCT07083609|DRUG|Dabigatran|Dabigatran will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.
224130733|NCT07083609|DRUG|Rivaroxaban|Rivaroxaban will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.
224130734|NCT07084415|OTHER|Postural correction exercise|Each participant will be given cervical thoracic spine correction exercises in the form of thoracic Roll Stretching Exercises, shoulder Bracing (Shoulder Retraction), superman Pose, chin Tuck (Cervical Retraction), five days a week for 4 weeks
223399289|NCT01571219|BIOLOGICAL|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
223399290|NCT00272077|DRUG|Insuline glargine|
223399291|NCT02455206|BEHAVIORAL|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
223399292|NCT02455206|BEHAVIORAL|Usual care|
223399293|NCT06576804|BEHAVIORAL|Eccentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week"
223399294|NCT06576804|BEHAVIORAL|Concentric cycling training|"Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week"
223399295|NCT00674648|BIOLOGICAL|CMV-Peptide-Specific T cells|"In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose."
223399296|NCT06008652|DRUG|DR-0201|DR-0201 is a bi-specific antibody
223399297|NCT06008652|DRUG|Placebo|Placebo
223551364|NCT06307392|PROCEDURE|First intubation attempt with endotracheal tube alone|"During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted."
223551365|NCT04767061|DRUG|Beta blockers|"The intervention is a two-arm crossover withdrawal/ reversal design (On \[A\] vs Off \[B\]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.~Subjects will be randomized into either ABAB or BABA sequences."
223551366|NCT03479450|DRUG|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
223551367|NCT00146861|DEVICE|sensor programming|
223551368|NCT04824703|DRUG|Oxygen|"* Decreasing fraction of inspired oxygen and its effect on mortality and myocardial function~* administered by invasive mechanical ventilation with fraction of inspired oxygen between 0.21 and 1"
223551369|NCT03182283|BEHAVIORAL|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
223551370|NCT03446963|BEHAVIORAL|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
223551371|NCT02253095|DRUG|Albendazole|
223551372|NCT02253095|DIETARY_SUPPLEMENT|Zinc|
223551373|NCT02253095|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplement|
223551374|NCT02253095|DRUG|Placebo|
223551375|NCT05970926|DEVICE|high-frequency ultrasound|The volunteers will be given a high-frequency ultrasound examination of the extremity arteries, which is non-invasive, and the parameters of arterial structure and blood flow will be measured.
223551376|NCT04805476|DEVICE|Non invasive mechanical ventilation|Prophylactic non invasive mechanical ventilation
223551377|NCT04805476|DEVICE|GP|GP subjects will receive oxygen therapy through a nasal cannula with 4 to 6 L / min of oxygen according to team routine and patient need.
223551378|NCT01288170|DRUG|Nebcinal Tobi|
223551379|NCT01288170|DRUG|Tobi Nebcinal|
223551380|NCT00260728|DEVICE|vascular access graft implantation|vascular access graft implantation
223551381|NCT00110045|DRUG|caspofungin acetate|
223551382|NCT06503627|PROCEDURE|bladder flap dissection|bladder flap dissection during caesarean section
224138706|NCT01136421|DRUG|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
223551383|NCT00161044|DRUG|Galantamine|
223731753|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
224138707|NCT00160394|DRUG|Duac® Gel / Differin® Gel|
223731754|NCT01988103|DRUG|Apremilast|20 mg tablet BID for 68 weeks
223731755|NCT01988103|DRUG|Placebo|Placebo tablet BID for 16 weeks
223399298|NCT01286467|DRUG|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
224138708|NCT00959530|PROCEDURE|lingualized occlusion|occlusal surface arranged by lingualized occlusion
224138709|NCT00959530|PROCEDURE|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
223731756|NCT02118389|DIETARY_SUPPLEMENT|Glucerna|Glucerna 52g meal replacement
224020273|NCT05352243|BEHAVIORAL|Expressive Helping|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their first two writing will remain confidential, and their final essay will be de-identified before being provided to newly bereaved young adults. Three writing sessions will be spaced 1-2 weeks apart. In the first two writing sessions, participants will receive a writing prompt that will instruct them to write about their deepest thoughts and feelings surrounding their bereavement experience. For the final writing session, participants will receive a writing prompt instructing them to provide advice and support for a newly bereaved young adult.
224130735|NCT07084415|DEVICE|Laser acupuncture|"A dermatograph pencil (COLOURED®) will be used to draw circles with diameters of 2 cm around the application points. Each point will be stimulated for 30 seconds.~The laser will be placed at the specific acupuncture points in shoulder and cervical regions.~Each woman in the study group will be treated by laser acupuncture for 7 minutes twice a week for 4 weeks.~Acupuncture points of the neck:~B10 (Tianzhu), GB 20 (Fengchi), GB 21 (jianjing), and EX-HN15 (jianzhongsgu). Acupuncture points of shoulder: LI 14 (Binao), LI 15 (Jianyu), TE 14 (Jianlio), LI 4 (Hegu),LI16 (Jugu), ST 38 (Tiaoko), SI 10 (Naoshu),LI 11 (Quchi),TE 15 (Tianliao),LU 1 (Zhongfu),~Parameter of laser:~wavelength: 808\[nm\], Operating mode: Continuous wave, Output power: 100 \[mW\], Power density: 333\[mW/cm\], area irradiated:0.3 cm2, Total time per point: 30\[s\], Angle of application:90 degree."
224130736|NCT07075900|OTHER|Dynamic Neuromuscular Stabilization Training|"According to the principles of Dynamic Neuromuscular Stabilization (DNS), proper activation of the integrated spinal stabilization system requires that the abdominal muscles expand not only in the caudal direction but also posteriorly and laterally.Therefore, firstly, the physiotherapist will assess the expansion of the entire abdominal wall and teach the patient to regulate intra-abdominal pressure through correct breathing techniques. During training and exercises, a belt will be used. Participants will be instructed to maintain abdominal expansion toward the belt during exercises performed in positions supported by proper alignment. A four-phase exercise protocol based on developmental kinesiology principles will be implemented for the DNS group, beginning with supine-position exercises appropriate for the 3-month developmental stage.~They will be instructed to repeat the exercises at least three times per day.Patients will record their home exercise program using an exercise diary."
224296953|NCT06014918|DEVICE|A new smart device application (Smart APS)|The application sends alarms to patients to enter their pain intensity and opioid-related side effects at the times set by the researcher. Additional entries for severe pain or opioid side effects are also available at any other time. Researchers can monitor the results in real-time via an integrated web program. If a red flag sign is observed during regular office hours, an anesthesiologist participating in the research will visit the patient for assessment and intervention. In addition, patients can watch pre-made perioperative pain-related educational videos through the smart APS.
224296954|NCT03880760|OTHER|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
223731757|NCT02363517|DRUG|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
223731758|NCT03267186|DRUG|Ibrutinib|Given PO
223731759|NCT03267186|OTHER|Laboratory Biomarker Analysis|Correlative studies
223731760|NCT05226325|DRUG|Dexmedetomidine|patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
224296955|NCT03880760|OTHER|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
223399299|NCT03779230|DRUG|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
223399300|NCT00917748|DRUG|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
223399301|NCT00917748|DRUG|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
223399302|NCT00917748|DRUG|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
223731761|NCT00314015|PROCEDURE|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
223731762|NCT00314015|PROCEDURE|Questionnaires|Questionnaires will be used
223731763|NCT01141907|BEHAVIORAL|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
223731764|NCT01141907|OTHER|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
223731765|NCT04320446|BEHAVIORAL|Test in the morning|The exercise test was performed between 8 a.m and 11 a.m
223731766|NCT04320446|BEHAVIORAL|Test in the afternoon|The exercise test was performed between 5 p.m. and 8 p.m.a
223731767|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
223399303|NCT01058642|DRUG|ADL5747|
223399304|NCT01058642|DRUG|Placebo|
223399305|NCT01058642|DRUG|Pregabalin|
223399306|NCT03825796|DRUG|Enasidenib Mesylate|Given PO
223399307|NCT03825796|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223399308|NCT01136057|BIOLOGICAL|Collection of Anti-Influenza A Immune Plasma|
223399309|NCT03906617|DRUG|Intercostal nerve block and wound infiltration with liposomal bupivacaine|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
223731768|NCT01214356|DIETARY_SUPPLEMENT|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
223731769|NCT04924647|DRUG|lenalidomide and dexamethasone|lenalidomide 25mg d1-21 and dexamethasone 20-40mg d1，8，15，22
223731770|NCT00198965|BEHAVIORAL|dietary education|
223731771|NCT00198965|BEHAVIORAL|dietary education and provided full fat snack foods|
224020274|NCT05352243|BEHAVIORAL|Fact-Writing|Prior to each writing session, participants will receive general instructions for completing the writing (e.g., write continuously for 20 minutes, do not worry about grammar, sentence structure, repetition), and be reminded that their writing will remain confidential. Three writing sessions will be spaced 1-2 weeks apart. A weekly writing prompt will instruct participants to write objectively about different time frames (e.g., routine for getting up in the morning, routine for going to sleep at night).
224020275|NCT02030301|BIOLOGICAL|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
224020276|NCT02030301|BIOLOGICAL|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
224020277|NCT02030301|BIOLOGICAL|PBS|Phosphate-buffered saline
224020278|NCT05217498|DRUG|Istradefylline|Consume 20mg tablet of istradefylline for 28 consecutive days.
223731772|NCT00198965|BEHAVIORAL|dietary education and provided fat free snack foods|
223731773|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC or intravenous injection.
223731774|NCT04998747|DRUG|AMG 701|AMG 701 will be administered as SC injection.
223731775|NCT00176826|PROCEDURE|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
223731776|NCT00176826|DRUG|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
223731777|NCT05704504|BEHAVIORAL|Group-based exercise intervention with EMA and personalized telephone support (SUP)|Participants in the SUP group will receive a 6-week group-based exercise intervention with EMA and personalized telephone support. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer and three 15-minute personalized telephone sessions delivered by research personnel. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and third group exercise sessions will include (1) reviewing exercise goals and EMA data, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
223731778|NCT05704504|BEHAVIORAL|Group-based exercise intervention (EXE)|Participants in the EXE group will receive a 6-week group-based exercise intervention. The intervention content includes three 120-minute group-based exercise training sessions delivered by a physical trainer at the Chinese University of Hong Kong. The first group exercise session will include (1) assessments of current physical fitness, (2) psychoeducation of depression, (3) education on the benefits of exercise on mental health, (4) demonstration and group low-intensity exercise training, and (5) smart goal setting. A booklet that summarizes the session content will be provided to participants. The second and the third group exercise sessions will include (1) reviewing exercise goals, (2) problem-solving barriers to exercise, (3) group discussion on exercise experience, (4) demonstration and group moderate-intensity exercise training, and (5) smart goal setting.
223731779|NCT02248389|DEVICE|Sonatherm 600i ablation system|HIFU ablation of tumor.
223399310|NCT03906617|DRUG|Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
223399311|NCT02593838|OTHER|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
223399312|NCT02137213|DRUG|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
223399313|NCT02137213|DRUG|Placebo|Normal saline will be added to oral methadone preparations as placebo.
223399314|NCT03732937|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography with biometry and TCD measurement
223425667|NCT04399109|DEVICE|TCC-COVID mHealth solution|Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.
224020279|NCT05217498|DEVICE|low oxygen therapy|Breath intermittent low oxygen 4 days/week over 2 consecutive weeks. Intermittent low oxygen consists of 15, 90-second episodes of breathing low oxygen at 10% oxygen with 60-second intervals at 21% oxygen.
224020280|NCT01052103|DRUG|LY2140023|40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
224020281|NCT01052103|DRUG|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
224138710|NCT01731613|DIETARY_SUPPLEMENT|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
224138711|NCT02268006|RADIATION|IMRT-SIB|
224138712|NCT02268006|DRUG|Capecitabine|
224138713|NCT02268006|PROCEDURE|Surgery|
223731780|NCT04840290|DRUG|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin|Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
223731781|NCT00094627|DRUG|gaboxadol|Duration of Treatment - 6 weeks
223731782|NCT00094627|DRUG|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
224130737|NCT07075900|OTHER|Pelvic Floor Muscle Training|"Participants in the PFMT group will undergo a structured pelvic floor muscle training program supervised by a physiotherapist. The training will include verbal and manual instructions to ensure correct identification and isolated activation of the pelvic floor muscles without compensatory movements from the gluteal, abdominal, or thigh muscles using a NeuroTrac Simplex EMG-Biofeedback device.~The exercise protocol will consist of both slow and fast contractions, focusing on endurance, strength, and coordination.~The exercises will be performed in various positions (e.g., supine, sitting, standing) and will gradually progress in intensity and complexity over time, following the principles of motor learning stages. They will be instructed to repeat the exercises at least three times per day. Patients will record their home exercise program using an exercise diary."
224130738|NCT07083752|DRUG|Botulinum toxin application|Hemiplegic stroke patients who received upper extremity botulinum toxin will be evaluated retrospectively. Information regarding upper extremity motor recovery, spasticity levels, and muscle thickness measured by ultrasound before and one month after botulinum toxin administration will be obtained from file records.
224130739|NCT07082101|OTHER|temporal interference|In this intervertion, patients with SEEG operation will take temporal interference (TI) stimulation and the deep brain EEG will be monitorated through the entire experiment.
223399315|NCT04973150|BEHAVIORAL|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children.|To explore whether pretreatment with eye covering can reduce the incidence of acute delirium and the score of delirium after general anesthesia in ophthalmology pre-age children. Methods A total of 300 preschool-age children who underwent general anesthesia of selective ophthalmic surgery in a 3A grade hospital from August 2019 to July 2020 were selected as the research object, who were divided into experimental group and control group with 150 cases each by random number table. Children in the control group received regular education on cartoon animation videos before surgery; children in the experimental group received eye-covering pretreatment on the basis of cartoon animation videos. The differences in preoperative anxiety degree score, postoperative acute delirium incidence, delirium degree score, and postoperative nursing care difficulty score were compared between the two groups.
223399316|NCT03876743|OTHER|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
223399317|NCT03876743|OTHER|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
223399318|NCT03876743|OTHER|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
223399319|NCT03876743|OTHER|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
223399320|NCT00092118|DRUG|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
223731783|NCT03109587|DIETARY_SUPPLEMENT|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
224138714|NCT06281145|BEHAVIORAL|Heart-rate variability biofeedback intervention|Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
223731784|NCT03109587|DIETARY_SUPPLEMENT|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
223731785|NCT06267950|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224138715|NCT05414305|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
224138716|NCT00173693|BEHAVIORAL|exercise for strength, balance, health education|
224138717|NCT01794247|DRUG|Magnesium sulfate|
224138718|NCT01794247|DRUG|Fentanyl|
224138719|NCT01794247|DRUG|Lidocaine|
224138720|NCT05970744|BIOLOGICAL|RSV/Flu-01E low dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
224138721|NCT05970744|BIOLOGICAL|RSV/Flu-01E high dose|Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
224138722|NCT05970744|BIOLOGICAL|Placebo|Participants will receive single intranasal injection of Placebo
224138723|NCT02793895|DEVICE|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
223731786|NCT06267950|DEVICE|intermittent oro-esophageal tube feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223731787|NCT06267950|DEVICE|gastric tube feeding|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223731788|NCT02256228|DRUG|Ropivacaine|Active Group
224020282|NCT01052103|DRUG|Standard of Care|United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
224020283|NCT02947893|DRUG|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
223399321|NCT00092118|DRUG|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
223399322|NCT01139125|DRUG|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
224020284|NCT02947893|DRUG|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
224020285|NCT04800432|BEHAVIORAL|ADAPT+|ADAPT+ is designed as an 6-week intervention. For each session, children and parents participate in separate 1.5-hour group meetings, followed by a joint goal setting session. Practical strategies related to improving diet and physical activity as well as the role of dealing with parent stress-related factors related to making long-lasting behavioral changes in the family are addressed.
223399323|NCT04768816|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
223399324|NCT04768816|BIOLOGICAL|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Autism Spectrum Disorder for safety and effect evaluation.
223399325|NCT03751098|DRUG|Tropicamide/Phenylephrine ophthalmic solution (TR/PE)|Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
223399326|NCT03751098|DRUG|Placebo|Eyewash administered with the Optejet microdose dispenser
223399327|NCT01908075|DRUG|FP/SAL|
223399328|NCT01908075|DRUG|BDP/FOR|
223551384|NCT01277822|DRUG|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
223551385|NCT01277822|DRUG|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
223551386|NCT01277822|DRUG|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
223731789|NCT02256228|DRUG|Saline|Placebo Comparator
223731790|NCT01012856|BEHAVIORAL|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
223731791|NCT01012856|BEHAVIORAL|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
223731792|NCT00001482|DRUG|Lamotrigine (Lamictal® (Registered Trademark)|
223731793|NCT00001482|DRUG|Gabapentin (Neurontin® (Registered Trademark))|
224020286|NCT04800432|BEHAVIORAL|EUC|Enhanced Usual Care is an abbreviated version of the full ADAPT+ intervention in which parents are engaged in a one-time, two hour information session to also learn knowledge and skills to improve the health and lifestyle behaviors for their child and for themselves.
224296956|NCT00999765|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
223399329|NCT04970147|OTHER|Gastrostomy care bundle|Gastrostomy care bundle
223399330|NCT06052566|DRUG|Efinopegdutide|Subcutaneous injection administered at a dose of 7 mg
223399331|NCT02659410|OTHER|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
223399332|NCT02659410|OTHER|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
223399333|NCT02659410|OTHER|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
223399334|NCT02659410|OTHER|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
223399335|NCT02659410|OTHER|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
223399336|NCT02659410|OTHER|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
223399337|NCT02659410|OTHER|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
223399338|NCT02659410|OTHER|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
223399339|NCT02659410|OTHER|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
223399340|NCT02659410|OTHER|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
223551387|NCT01277822|DRUG|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
223551388|NCT00650663|DRUG|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
223551389|NCT00650663|DRUG|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
223551390|NCT02923531|DRUG|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
223551391|NCT02923531|DRUG|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
223551392|NCT05802420|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
223551393|NCT02198859|DRUG|Lithium Carbonate|
223731794|NCT03003936|BEHAVIORAL|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
223731795|NCT04606173|OTHER|Team Education for Adopting Changes in Healthcare (TEACH)|TEACH, an educational strategy which includes evidence-based strategies to improve task-specific teamwork will occur across 4 brief (20-30 minutes) team meetings over a 12-week period.
223731796|NCT00637507|OTHER|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., \>10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 \>150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
224296957|NCT01554826|BIOLOGICAL|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
223399341|NCT02659410|OTHER|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
223399342|NCT02659410|OTHER|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
223399343|NCT02659410|OTHER|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
223731797|NCT01818908|DRUG|DA-EPOCH|DA-EPOCH regimen
223731798|NCT03743389|DEVICE|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
223731799|NCT03743389|DEVICE|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
223731800|NCT03905603|DRUG|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
223731801|NCT03905603|DRUG|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
223731802|NCT02468323|DRUG|Placebo|Patients will receive regular spinal anesthesia
223731803|NCT02468323|DRUG|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
223731804|NCT02468323|DRUG|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
223731805|NCT03086889|OTHER|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
223731806|NCT03086889|OTHER|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
223731807|NCT02566655|BIOLOGICAL|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
223731808|NCT04397653|DRUG|Evolocumab|In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
223731809|NCT04397653|DRUG|Placebo|In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
223731810|NCT04397653|DRUG|Ezetimibe|Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
224296958|NCT01554826|BIOLOGICAL|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
224296959|NCT00977730|DIETARY_SUPPLEMENT|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
224296960|NCT00977730|DIETARY_SUPPLEMENT|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
224296961|NCT00727948|DRUG|Aspirin|325 mg tablets, once daily for 45 days
223399344|NCT02659410|OTHER|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
223425668|NCT04150211|DIETARY_SUPPLEMENT|Polyherbal Exten(d) vs Placebo|Supplementation during 4 weeks
223425669|NCT02222545|BIOLOGICAL|OMS721|
223425670|NCT03723161|DEVICE|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
223425671|NCT06436898|DEVICE|Combined overground gait exoskeleton and FES applied to lower limb|Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.
223425672|NCT06436898|DEVICE|Overground gait exoskeleton|Gait rehabilitation for persons with stroke, with an overground exoskeleton.
223425673|NCT04954794|DRUG|Sintilimab|Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
223399345|NCT02659410|OTHER|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
223731811|NCT00311623|DRUG|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
223731812|NCT00311623|DRUG|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
224130740|NCT06509789|DEVICE|Transcranial magnetic stimulation (TMS) - Theta burst stimulation (TBS) protocol|This procedure uses magnetic fields to stimulate nerve cells in the brain involved in various neurological functions, such as motor control. Theta burst stimulation is a patterned form of TMS protocol.
223399346|NCT03966417|OTHER|Exercise training|Continuous exercise training 2 times per week for a period of 12 weeks.
223399347|NCT06005272|OTHER|Questionnaire|Interviewer assisted completion of questionnaire.
223551394|NCT00761982|PROCEDURE|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
223731813|NCT00311623|PROCEDURE|Radical prostatectomy|Radical prostatectomy performed on Day 15
223731814|NCT05757947|PROCEDURE|Сoronary bypass surgery according to the I-graft method|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and the formation of an anastomosis of the stump of the right internal mammary artery and end-to-end saphenous vein graft."
223731815|NCT05757947|PROCEDURE|Сoronary bypass surgery by the method of free conduit|"Revascularization of the right coronary artery basin will be performed using no-touch SVG and anastomosis of the saphenous vein graft to aorta."
223731816|NCT00005970|DRUG|Aromatase Inhibition Therapy|Given orally
223731817|NCT00005970|DRUG|Cyclophosphamide|Given IV
223731818|NCT00005970|DRUG|Doxorubicin Hydrochloride|Given IV
223731819|NCT00005970|OTHER|Laboratory Biomarker Analysis|Correlative studies
223731820|NCT00005970|DRUG|Paclitaxel|Given IV
223399348|NCT02608216|DRUG|[18F]FLT|\[18F\]FLT PET/CT scan, imaging tracer
223399349|NCT02608216|DEVICE|PET/CT|\[18F\]FLT PET/CT scan
223731821|NCT00005970|DRUG|Tamoxifen Citrate|Given orally
223731822|NCT00005970|BIOLOGICAL|Trastuzumab|Given IV
223731823|NCT02095587|DRUG|IPI-145|25 mg single oral capsule
223731824|NCT01293721|DEVICE|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
223731825|NCT03998189|OTHER|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
223731826|NCT03998189|OTHER|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
223731827|NCT03998189|OTHER|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
223731828|NCT03998189|OTHER|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
223731829|NCT03998189|OTHER|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
223731830|NCT03998189|OTHER|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
223731831|NCT05322304|DIETARY_SUPPLEMENT|Almond|Intervention (almond supplementation) and Isocaloric diets (control)
223731832|NCT01125384|OTHER|additional swabbing|physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
223731833|NCT00292695|OTHER|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
223731834|NCT05683379|DIAGNOSTIC_TEST|AAV8 DetectCDx|An in vitro diagnostic assay to detect antibodies to AAV8 in human serum specimens.
224130741|NCT05145244|OTHER|NO intervention|No intervention
223399350|NCT02608216|DRUG|ribociclib|therapeutic
223399351|NCT02608216|DRUG|paclitaxel|therapeutic
223399352|NCT05342194|DRUG|Toripalimab|240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
223399353|NCT05342194|DRUG|Lenvatinib mesylate capsules|8 mg orally (po) once daily (QD)
223399354|NCT05342194|DRUG|Placebo IV|Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
223399355|NCT05342194|DRUG|Oral placebo|Oral placebo po QD continuously
223551395|NCT05530902|OTHER|Multidisciplinary Primary Rehabilitation Care|As described by the Policy Regulation 'Innovation' (NZa). The MPRC is a structured treatment program following the biopsychosocial approach, aiming to optimize functioning and participation in CMP patients. The treatment program is provided by paramedical specialists and, in cases that are more complex, a rehabilitation physician will be involved. The program has a diagnostic phase, a treatment phase (6-12 weeks) and a follow-up (12 months).
223551396|NCT00997984|DRUG|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
223551397|NCT00997984|DRUG|placebo|dosed in the AM or PM
223551398|NCT00997984|DRUG|extended-release guanfacine hydrochloride|Dosed in the PM
223551399|NCT04023760|DRUG|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
223551400|NCT03584126|DIAGNOSTIC_TEST|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
223551401|NCT06467786|DRUG|Irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection combined with platinum
223551402|NCT03954886|DEVICE|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
223551403|NCT03081663|PROCEDURE|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
223551404|NCT03081663|PROCEDURE|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
223731835|NCT02986399|OTHER|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
223731836|NCT03330808|OTHER|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
223731837|NCT02405845|RADIATION|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
223731838|NCT01607086|DRUG|Cherry lamotrigine ODT|25mg, taken orally on one study visit
223731839|NCT01607086|DRUG|Cherry Placebo|Taken orally on one study visit
223731840|NCT03089450|DEVICE|CGBio stent|Percutaneous Coronary Intervention
223731841|NCT03089450|DEVICE|Biomatrix flex|Percutaneous Coronary Intervention
223731842|NCT04822064|DRUG|Intranasal dexmedetomidine and ketamine|Additional intranasal administration of dexmedetomidine (2mcg/kg) and ketamine (3mg/kg) to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
223731843|NCT04822064|DRUG|Oral chloral hydrate|Additional oral chloral hydrate (50mg/kg) administration to induce rescue sedation (pediatric sedation state scale = 1,2,3) after failed sedation attempt (PSSS=4,5) with oral chloral hydrate (50mg/kg)
223731844|NCT03686371|PROCEDURE|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
223731845|NCT00471744|DRUG|Treatment with levetiracetam or sulthiame over a six-month period.|
223731846|NCT05629624|DIETARY_SUPPLEMENT|Chickpea based RUSF|One group will receive locally produced RUSF, approximate at 50-100 kcal/kg/day, two of 50g packets daily (42) until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for maximum 3 months then immediately 1 packet / day SQLNS will be given throughout the study till the end of 2 years of follow-up.
223731847|NCT05629624|DIETARY_SUPPLEMENT|E-RUSF|The other group will receive the E-RUSF at 50-100 kcal/kg/day which in this age group approximates one 92 g sachet daily until anthropometric recovery ( WHZ \> - 1SD) has been achieved or for a of maximum 3 months, then immediately E-SQLNS 1 packet daily provided throughout the study till the end of 2 years of follow-up.
223731848|NCT05629624|DIETARY_SUPPLEMENT|Outcome reference group/RUSF|We will also recruit 70 three-year-old previously untreated MAM children WHZ \<-2 and ≥-3 z-score, and/or MUAC \<12.5 and ≥11.5 cm as an outcome reference group for a singular assessment. All children (both case \& control) will undergo a baseline nutritional, medical, biological and neuropsychological assessment (EF, ER, EEG and fNIRS). After all the assessments chick-pea based RUSF will be given for 2 months for nutritional rehabilitation.
223731849|NCT04492839|DEVICE|Intestinal adsorbent|Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.
224020287|NCT03929445|DEVICE|Endotracheal tube introducers|"Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie."
223731850|NCT03348033|BIOLOGICAL|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
223731851|NCT03664557|DEVICE|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
223731852|NCT03414424|DEVICE|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
223731853|NCT03414424|DEVICE|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
223731854|NCT01923220|DRUG|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
223731855|NCT01923220|OTHER|Aloe Vera Jel|To be applied topically once daily
223731856|NCT00877877|PROCEDURE|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
223731857|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily custom insulin titration instructions.
223731858|NCT05081011|DEVICE|Voice Assistant Device|Voice AI-enabled smart speaker device delivers daily generic insulin reminders.
223731859|NCT02610179|DIETARY_SUPPLEMENT|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
223731860|NCT02610179|DIETARY_SUPPLEMENT|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
223731861|NCT01970449|BIOLOGICAL|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
223731862|NCT01970449|BIOLOGICAL|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10\^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
223731863|NCT01970449|BIOLOGICAL|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
223399356|NCT05342194|DRUG|Oxaliplatin for injection|85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
224130742|NCT01865435|GENETIC|cord blood sample|
224130743|NCT04104906|OTHER|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
224130744|NCT04104906|OTHER|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
223731864|NCT01970449|BIOLOGICAL|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
223731865|NCT01970449|BIOLOGICAL|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
223399357|NCT05342194|DRUG|Gemcitabine hydrochloride|1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
223399358|NCT05342194|DRUG|Cisplatin|25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
223399359|NCT04598009|DRUG|Binimetinib|Taken orally (PO) twice a day (BID)
223731866|NCT01970449|BIOLOGICAL|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10\^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
223731867|NCT01970449|BIOLOGICAL|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
223731868|NCT01970449|DEVICE|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
224020288|NCT00539565|DRUG|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
223551405|NCT04130776|DIAGNOSTIC_TEST|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from \<1% to \>95% of a man having aggressive cancer in a prospective biopsy.
223551406|NCT02182778|DRUG|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
223551407|NCT02182778|DRUG|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
223399360|NCT04598009|DRUG|Imatinib|Taken orally (PO) once a day (QD)
223399361|NCT05538897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399362|NCT05538897|PROCEDURE|Computed Tomography|Undergo CT scan
223551408|NCT00925665|DEVICE|Glidescope|Patients are to be intubated using the Glidescope technique
223551409|NCT00925665|DEVICE|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
223551410|NCT02261064|DRUG|Telmisartan/Amlodipine low dose|
223551411|NCT02261064|DRUG|Telmisartan/Amlodipine high dose|
223551412|NCT02261064|OTHER|Japanese meal|
223551413|NCT02521038|DRUG|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
224020289|NCT00539565|DRUG|placebo|
224020290|NCT04280302|BEHAVIORAL|Virtual Reality-based Rehabilitation|VR-based eye stabilization exercises and balance exercises
223551414|NCT03232827|BEHAVIORAL|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
223399363|NCT05538897|DRUG|Ipatasertib|Given PO
223399364|NCT05538897|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399365|NCT05538897|DRUG|Megestrol Acetate|Given PO
223399366|NCT06742840|DRUG|HRS-2129|HRS-2129.
223399367|NCT06742840|DRUG|HRS-2129 placebo|HRS-2129 placebo.
223399368|NCT06309251|OTHER|ketogenic diet (as per clinical practice)|Patients recruited receive a ketogenic diet. The prescription, the type of KD protocol and the route of administration will depend, essentially, on the patient's ability and willingness to feed spontaneously and independently, as well as on compliance with the therapies set and the severity of the clinical conditions.
223551415|NCT03232827|BEHAVIORAL|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
223551416|NCT03232827|BEHAVIORAL|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
224020291|NCT04280302|BEHAVIORAL|Conventional Therapy|Conventional rehabilitation therapy based on eye stabilization exercises and balance exercises
224020292|NCT00888628|BIOLOGICAL|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
224020293|NCT00888628|DRUG|Etanercept|Given as induction for islet cell transplant
224020294|NCT05811923|OTHER|Venous Blood Collection|Within each supplementation condition, study participants will have their venous blood collected on six different occasions: 0, 30, 60, 90, 120, and 180 minutes after ingestion of their assigned study agent. Blood will be collected via a forearm vein using standard phlebotomy techniques using either an indwelling catheter or single venipunctures. All blood samples will be collected into ethylenediaminetetraacetic acid EDTA-coated Vacutainer™ tubes and gently inverted ten times before being centrifuged at 3000 revolutions per minute (rpm) (MegaFuge XFR, Thermo Fisher Scientific, Waltham, MA, USA) at 4oC for 20 minutes. After centrifugation, 400 μl aliquots of plasma will be removed and frozen at -80oC within four hours of collection.
224130745|NCT05408312|BIOLOGICAL|Experimental Vaccine 1|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
223399369|NCT03045016|DRUG|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
223399370|NCT02199964|DRUG|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
223399371|NCT02199964|DRUG|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
223399372|NCT01664637|DRUG|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
223399373|NCT01664637|DRUG|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
224020295|NCT05811923|OTHER|Resting Metabolic Rate Determination|During all study visits and on six occasions during each of the seven experimental conditions (0, 30, 60, 90, 120, and 180 minutes after supplement ingestion), resting metabolic rates will be determined in a thermoneutral laboratory environment.
224130746|NCT05408312|BIOLOGICAL|Experimental Vaccine 2|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
224130747|NCT05408312|BIOLOGICAL|Experimental Vaccine 3|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
224130748|NCT05408312|BIOLOGICAL|placebo|Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
224130749|NCT01895491|BIOLOGICAL|VM206DNA|
224130750|NCT01895491|BIOLOGICAL|VM206Ad|
224130751|NCT04836819|DRUG|Lidocain|IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
223399374|NCT06818669|BEHAVIORAL|CVD-FIT|The structured incentive will include monthly supplemental income plus weekly reimbursement for the purchase of healthy food options. Education for CVD risk reduction will include mailed education and telephone calls with a trained health educator.
223399375|NCT06818669|BEHAVIORAL|Enhanced Usual Care|Education for CVD risk reduction will include mailed education and telephone calls with a trained health educator.
223399376|NCT05387473|BEHAVIORAL|Cognitive behavioral therapy for insomnia (CBT-I) integrated in best-evidence usual care (CBTi-UC)|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly CBT-I. This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
223399377|NCT05387473|BEHAVIORAL|Best-evidence usual care (UC) plus information sessions|In the first two weeks, the participants will receive three sessions of education and advice based on current best-practice guidelines. In the following three weeks, the participants will be provided with once weekly exercise therapy and once weekly general information sessions (general education sessions in line with recommendations from best-practice guidelines and recent evidence). This is then spread out more over the next five weeks in which participants will receive once weekly sessions of either CBT-I or exercise therapy in alternating order. In the last four weeks of the intervention period, the participants will receive once weekly exercise therapy.
223399378|NCT06973603|OTHER|Blood samples|24mL blood sample (3 dry tubes with 8mL)
223551417|NCT03232827|BEHAVIORAL|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
223551418|NCT02805959|DEVICE|MTS2|
223551419|NCT03132558|DRUG|Radiopaque Media|
223551420|NCT04951375|PROCEDURE|arthroscopic repair|arthroscopic repair
223551421|NCT05011253|OTHER|Electronic Trigger Microhematuria Alert|To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
223551422|NCT03977545|DIAGNOSTIC_TEST|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
223731869|NCT05109039|DIETARY_SUPPLEMENT|Creatine|Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
223551423|NCT02356523|DIAGNOSTIC_TEST|Confusion Assessment Method|Administration of Confusion Assessment Method at patent over 65 years at admission and every day until discharge
224020296|NCT05811923|OTHER|Mood State|Participants will complete electronic versions of the Profile of Mood States (POMS) questionnaire to evaluate perceptual responses. The Profile of Mood States (POMS) is a 65-item validated scale that uses a 5-point Likert scale with each individual area being scored and summed into profiles for tension, anger, vigor, fatigue, depression, and confusion. Finally, a total mood disturbance score will be calculated by summing all categories and subtracting the vigor score.
224130752|NCT04836819|DRUG|Ketamine|IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
224296962|NCT02293330|DRUG|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
223399379|NCT06055790|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin) PET/CT|"PET/CT protocol:~All patients will be instructed to fast for 4 hr. prior to the scan. CT imaging of the head will be performed using GE Discovery MI Digital PET/CT (Boston, Massachusetts) prior to the injection of 18F-fluciclovine. While the patient is in a supine position on the PET table, 5 mCi (185 MBq) of 18F-fluciclovine will be administrated intravenously, followed by a saline flush. At the time of the injection, a continuous dynamic PET images lasting 60 min will be performed using 3D-dynamic and list-mode acquisition: 2.0 mm slice thickness, number of frames(f) x time in seconds(s) and minutes(m) of: 4f x 15s, 4f x 30s, 6f x 2m, 5f x 3m, and 6f x 5m. PET images at 0-5 (flow), 15-25 (early), 25-35 (mid), 45-60 min (delayed) post-injection will be reconstructed using Qclear 500 and OSEM iterative reconstruction with TOF (VPFX): 8 iterations, 5 subsets, 440 image matrix, 4 mm Gaussian filter, TOF. \[24, 27\]."
223399380|NCT06321133|OTHER|High flow nasal cannula immediate ending|High flow is immediately ended
223399381|NCT06321133|OTHER|High flow nasal cannula weaning|High flow is gradually weaned by reducing the flow rate
223551424|NCT01119066|RADIATION|total body irradiation|dose of 1375-1500 cGy
223551425|NCT01119066|DRUG|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
223551426|NCT01119066|DRUG|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
223551427|NCT01119066|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
223551428|NCT01119066|DRUG|Melphalan|70mg/m2/day x 2
223551429|NCT01119066|DRUG|Fludarabine|25mg/m2/ day x 5
223551430|NCT01119066|DRUG|Clofarabine|20mg/m2/ day x 5 (or, for children \<18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
223551431|NCT01119066|PROCEDURE|(CliniMACS) T-cell depleted PBSC Transplant|
223551432|NCT04789473|GENETIC|Polygenic Risk Score Generation|PRS will be calculated for gestational diabetes risk using both cohorts, participants wont have results returned to them during the study.
223731870|NCT05109039|DIETARY_SUPPLEMENT|Placebo|Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
223731871|NCT04155112|BEHAVIORAL|Physical activity|Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).
223731872|NCT04155112|BEHAVIORAL|Hypocaloric Mediterranean diet|Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.
223731873|NCT04333823|DRUG|Dapagliflozin 5mg|Dapagliflozin tablet
224020297|NCT05811923|OTHER|Visual Analog Scales|"Participants will complete electronic versions of the visual analog (VAS) scale to evaluate perceptual responses. Each VAS scale will be completed using a 100-mm line anchored by Lowest Possible and Highest Possible to assess subjective ratings of focus, anxiety, concentration, energy, restfulness, wakefulness, swagger, confidence, hunger, and appetite. The validity and reliability of VAS to assess fatigue and energy have been previously established (Lee, Hicks, et al. 1991) and our methods have been published elsewhere (Ziegenfuss, Habowski, et al. 2017, Ziegenfuss, Lopez, et al. 2017, Ziegenfuss, Kedia, et al. 2018, Zabriskie, Blumkaitis, et al. 2020)."
224020298|NCT05378971|DRUG|Pomalidomide|Pomalidomide, 2mg/d, d1-21; treatment cycles every 28days
223731874|NCT04333823|DRUG|Placebo|Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
223731875|NCT02159690|DRUG|Enzalutamide|160mg
223551433|NCT05059093|DIAGNOSTIC_TEST|Classification and segmentation deep learning models|Models that will be trained on retrospectively acquired data and run on the prospectively acquired data to extract biometric parameters and amniotic volume estimation.
223551434|NCT03079687|DRUG|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
223731876|NCT02159690|DRUG|Abiraterone acetate|1000mg
223731877|NCT02159690|DRUG|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
223731878|NCT02159690|DRUG|Dutasteride|0.5mg
223551435|NCT03936907|DRUG|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
223551436|NCT03936907|DRUG|Sativex|Sativex® Oromucosal Spray
223551437|NCT01876680|OTHER|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
223731879|NCT02159690|DRUG|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
223731880|NCT05854589|DRUG|Sodium Chloride Granules|Sodium Chloride crystals
223731881|NCT05854589|OTHER|Water|Plain distilled water
223731882|NCT05473338|DIAGNOSTIC_TEST|Stool and blood samples|fecal microbiome and metabolomics, as well as metabolites in plasma
223731883|NCT05473338|OTHER|Physical examination|physical examination performed by a physician to confirm CRPS diagnosis and assess patient's eligibility to participate in the study. The exam will include skin temperature measured using a laser/infrared skin thermometry.
223731884|NCT05473338|OTHER|Questionnaires|Questionnaires measuring pain level, sleep, mood and diet parameters.
223731885|NCT05313074|BIOLOGICAL|CoronaVac vaccine|An inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech.
224020299|NCT02999126|DRUG|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
224020300|NCT02999126|DRUG|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
224020301|NCT05273593|DEVICE|Confocal Laser Endomicroscopy (CLE)|Administration of fluorescein, intravesically and intravenously. CLE measurements with flexible and rigid probe of papillary bladder tumour and rigid probe-measurement of resection bed.
223731886|NCT00795522|DRUG|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
223731887|NCT04109755|DRUG|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
223731888|NCT04931108|DRUG|Nitrendipine/Atenolol|Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
223731889|NCT04931108|DRUG|Nitrendipine|Nitrendipine 5mg, oral tablet, one pill daily.
224130753|NCT04836819|DRUG|Dexmedetomidine|IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
223399382|NCT06596460|DIAGNOSTIC_TEST|TAVI planning CT (adapted)|TAVI planning CT (adapted) to obtain a standard assessment of the Left Ventricular Outflow Tract (LVOT), valve annulus, aortic root, and ascending aorta up to neck branches. There will be no requirement to scan the ilio-femoral arteries as per standard TAVI planning CT
223399383|NCT05715281|BIOLOGICAL|Atezolizumab|Given IV
223399384|NCT05715281|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223399385|NCT05715281|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399386|NCT05715281|PROCEDURE|Computed Tomography|Undergo CT scan
223399387|NCT05715281|PROCEDURE|Echocardiography Test|Undergo ECHO
223731890|NCT04931108|DRUG|Atenolol|Atenolol 25mg, oral tablet, one pill daily.
224130754|NCT01820078|DRUG|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
223399388|NCT05715281|DRUG|Tiragolumab|Given IV
223399389|NCT01108718|OTHER|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
223399390|NCT01108718|OTHER|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
223399391|NCT05095844|BIOLOGICAL|vaccinated|Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)
223551438|NCT01876680|OTHER|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
224130755|NCT01820078|OTHER|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
223399392|NCT03380429|DRUG|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
223399393|NCT03380429|DRUG|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
223399394|NCT03380429|DEVICE|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
223399395|NCT03380429|DEVICE|HCP Dashboard|The information from sensors will be reviewed by the HCP via an online dashboard.
223399396|NCT03380429|DEVICE|Sensors|Clip-on sensors will be fitted to electronically record the actuation data.
223399397|NCT04535141|DRUG|Olanzapine 5 MG|It will be a de-identified pill created by investigational drug services at University of North Carolina
223551439|NCT01896778|PROCEDURE|Hyperthermia Treatment|Undergo B-WARM
223399398|NCT04535141|DRUG|Placebo|It will be a de-identified pill created by investigational drug services at University of North Carolina
223399399|NCT03694080|COMBINATION_PRODUCT|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
223551440|NCT01896778|OTHER|Laboratory Biomarker Analysis|Correlative studies
223551441|NCT01653587|DEVICE|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
223399400|NCT05111782|OTHER|Symptom Modulation Approach, Movement Control Approach, Functional Optimization Approach|Based on the patients' symptoms and level of disability, either symptom modulation or movement control or functional optimization exercises will be used. The exercises will be provided on alternate days for a duration of 30 minutes in each session preceded by electrotherapeutic modalities for pain relief and muscle relaxation. These modalities will be given for 15 min in each session. The total no. of sessions will be based on the patient's progress for a maximum of 4 weeks.
223399401|NCT01014546|DRUG|Arsenic Trioxide|Given PO
223399402|NCT01014546|DIETARY_SUPPLEMENT|Ascorbic Acid|Given PO
223551442|NCT00821158|DRUG|Antioxidant|Antioxidant iv bolus
223551443|NCT00821158|OTHER|Placebo|Placebo tablet and iv
223551444|NCT00821158|DRUG|Anti-inflammatory drug|Anti-inflammatory tablet
223551445|NCT04424394|DEVICE|DualStim Therapy|6 DualStim Therapies over a period of 7 weeks.
223551446|NCT04424394|BIOLOGICAL|Umbilical cord-derived Wharton's Jelly|2 intracavernosal injections over a period of 7 weeks.
223731891|NCT04899414|DRUG|Dexamethasone, azacytidine, Pegaspargase, Tislelizumab|Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
224020302|NCT03768804|OTHER|SyncAV algorithm on|"Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings"
223731892|NCT03559153|OTHER|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
223731893|NCT03559153|OTHER|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
223731894|NCT02308852|DEVICE|tDCS|
223731895|NCT02677142|BEHAVIORAL|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
223399403|NCT01014546|OTHER|Laboratory Biomarker Analysis|Correlative studies
223731896|NCT02677142|BEHAVIORAL|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
223731897|NCT02734238|DRUG|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
223731898|NCT02734238|DRUG|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
223731899|NCT01949051|DRUG|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
223399404|NCT01014546|OTHER|Pharmacological Study|Correlative studies
223399405|NCT04633317|DEVICE|A pneumatic nebulizer|Inhaled colistimethate sodium generated by a pneumatic nebulizer
223399406|NCT04633317|DEVICE|A vibrating mesh nebulizer|Inhaled colistimethate sodium generated by a vibrating mesh nebulizer
223399407|NCT05717972|OTHER|Kombucha|"Kombucha is a fermented tea drink that originated in ancient Chinese civilization. It is made by combining tea, juice, and SCOBY (Symbiotic Culture of Bacteria and Yeast).~During the fermentation process, the yeast in the SCOBY breaks down the sugar in the tea releasing friendly probiotic bacteria, giving kombucha its fizzy body and its sweet and tangy taste."
223425674|NCT04954794|COMBINATION_PRODUCT|TACE|TACE is performed by using drug-eluting beads or using microspheres combined with Lipiodol-pirarubicin emulsion per Investigator's decision. TACE treatment starts at day 0. Sintilimab plus a bevacizumab biosimilar will be initiated on day 14 after TACE.
223731900|NCT01949051|DRUG|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
223731901|NCT01639651|OTHER|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
223731902|NCT01639651|OTHER|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
224020303|NCT03768804|OTHER|SyncAV algorithm off|ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
223551447|NCT04424394|OTHER|Saline|2 intracavernosal injections over a period of 7 weeks.
223551448|NCT01236261|OTHER|Non intervention|Non interventional study
223551449|NCT03636672|PROCEDURE|perturbation training|perturbation training during stationary bicycle riding
224020304|NCT05196568|DIETARY_SUPPLEMENT|Fasting mimicking diet|Women will be given three administrations of fasting mimicking diet once a month
224020305|NCT00480376|DRUG|ofloxacin|
224020306|NCT00480376|DRUG|gentamicin|
223551450|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
223551451|NCT00635141|DRUG|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
224020307|NCT02778854|GENETIC|detection of driver mutation|participants are received gene detection via the liquid biopsy
224020308|NCT05505331|RADIATION|three-Dimensional ultrasonography|transadominal and transvaginal examination
223551452|NCT01858441|DRUG|Abiraterone Acetate|
223551453|NCT02092727|BEHAVIORAL|Behavioral Interventions for Dialysis Facilities|"1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video"
223551454|NCT05198076|DEVICE|High Frequency Repetitive Transcranial Magnetic Stimulation|The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
223731903|NCT02969304|DRUG|dimethyl fumarate|"Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
223731904|NCT02935088|DEVICE|Fractional Flow Reserve|Measurement of physiologic parameters
223399408|NCT01739205|BEHAVIORAL|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
223731905|NCT03884218|OTHER|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
224020309|NCT05505331|RADIATION|Magnetic resonance imaging|multiplanar T2-weighted sequences and pre-contrast T1-weighted imaging in either the sagittal or axial plane
224130756|NCT04486963|DRUG|Sanhuangjingshimingwan|Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
224130757|NCT04486963|DRUG|Sanhuangjingshimingwan Placebo|Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
224130758|NCT03363334|DRUG|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
224130759|NCT03363334|DRUG|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
224130760|NCT03632252|DEVICE|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
224130761|NCT03021434|OTHER|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
224130762|NCT03021434|OTHER|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
223399409|NCT06258538|DEVICE|Robots can aid in distal UE rehabilitation through exoskeleton (EXO)|Exoskeleton robot-assisted therapy Each EXO robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Hand of Hope (HOH) robotic hand system . HOH is an exoskeleton type of robot that is worn on the dorsal side of the impaired hand with 2 surface EMG sensors attached to the extensor digitorum and flexor digitorum superficialis.
223399410|NCT06258538|DEVICE|End-effector robot-assisted therapy (EE)|Each EE robot-assisted therapy session consists of continuous passive motion (30 percent of duration), active-assisted training (30 percent of duration), and interactive training (40 percent of duration) using the Amadeo robotic system. Amadeo is an end-effector robot with 5 finger slides, which are attached to the fingertips and the thumb via magnetic finger pads. The integrated sensor for each finger allows the robot system to provide patients with real-time visual feedback of finger strengths and range of motion
223399411|NCT06258538|BEHAVIORAL|Unilateral task-oriented therapy|The therapy will focus on task-oriented therapy with the affected UE and the training tasks involve proximal or distal UE movement, such as ringing a bell, picking up coins, grasping and releasing various cups, and other functional movements involved in daily activities. The level of challenge will be adapted according to patient ability and improvement during training.
223551455|NCT00205153|BEHAVIORAL|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
223551456|NCT02531360|DRUG|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an \[18F\]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo \[18F\]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
224130763|NCT03021434|OTHER|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
223551457|NCT04119765|BIOLOGICAL|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
223551458|NCT04119765|BIOLOGICAL|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
223551459|NCT04119765|PROCEDURE|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
223551460|NCT04119765|PROCEDURE|central pressure measurement|central pressure will be measured thank to the Complior® device
223731906|NCT02821481|DIETARY_SUPPLEMENT|Beta-alanine|
223731907|NCT02821481|DIETARY_SUPPLEMENT|Placebo|
223731908|NCT02821481|BEHAVIORAL|Muscular endurance exercise|
224130764|NCT04092244|DIAGNOSTIC_TEST|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
223731909|NCT00965588|BIOLOGICAL|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
224020310|NCT05505331|PROCEDURE|myomectomy|myoma excision
224020311|NCT03170037|PROCEDURE|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
223731910|NCT04782089|DRUG|Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors|Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
224130765|NCT04141852|DEVICE|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
223399412|NCT06258538|BEHAVIORAL|Bilateral task-oriented therapy|The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
223399413|NCT06317389|OTHER|Questionnaires|Patients will benefit of supervision by the ONCORAL team in the usual way and their intervention will be limited to completing questionnaires.
223399414|NCT04760626|DRUG|Insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
223399415|NCT04760626|DRUG|Insulin Glargine 100U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
223399416|NCT04760626|DRUG|Insulin Degludec|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
223731911|NCT00492661|DRUG|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
224130766|NCT05483621|DRUG|Beta-hCG|Treatment of spermatogenesis
224130767|NCT04538092|OTHER|Enhanced Recovery After Surgery Protocol|The investigators have developed an Enhanced Recovery After Surgery protocol for complex spine surgery at UNC. This study will help elucidate the effects of multiple interventions tailored to help patients recover from complex surgery.
223399417|NCT04760626|DRUG|Insulin Glargine 300U/mL|Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
223399418|NCT02452944|DEVICE|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
223399419|NCT02452944|DEVICE|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
223399420|NCT03762265|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
223731912|NCT05248412|OTHER|COVID-19 outbreaks|The intervention of the study is the COVID-19 outbreaks in Hong Kong. The pre-and post-COVID-19 outbreak periods will be defined as 1 January 2010 - 31 December 2019 and 1 January 2020 - 31 December 2024, respectively.
223731913|NCT01848002|DRUG|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
224130768|NCT06412419|DIAGNOSTIC_TEST|Magnifying Endoscopy and Endoscopic Ultrasonography|The acquired magnifying endoscopy and endoscopic ultrasonography images were shared with artificial intelligence for machine learning, diagnostic modeling and optimization. In the real world evaluation phase, the high-risk population of early esophageal cancer who planned to undergo esophageal electronic endoscopy were prospectively enrolled. The artificial intelligence-assisted diagnosis system was used for prediction before surgery, and the postoperative pathological results were used as the gold standard to diagnose by grouping.
224130769|NCT00311181|DEVICE|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
224130770|NCT01672021|PROCEDURE|PET/MRI|PET/MRI
224130771|NCT02669862|DRUG|A-101 Solution 40|
224130772|NCT02669862|DRUG|A-101 Solution 45|
223399421|NCT03762265|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
223399422|NCT01805089|DRUG|Melatonin 3 mg|Melatonin vs. Placebo
223731914|NCT01848002|DRUG|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
223731915|NCT00541073|DIETARY_SUPPLEMENT|vitamin B12|
223399423|NCT00197782|BIOLOGICAL|Hib conjugate vaccine|
223399424|NCT04423991|DEVICE|COViage|Machine learning intervention
223399425|NCT00688350|BEHAVIORAL|Behavioral feedback|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
223399426|NCT00806403|DRUG|reteplase 10+10 U|comparison to primary PCI
223399427|NCT00806403|PROCEDURE|primary PCI|comparison to thrombolysis
223399428|NCT06337149|OTHER|neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)|neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task)
223399429|NCT01882985|DRUG|Docetaxel|Given IV
223399430|NCT01882985|DIETARY_SUPPLEMENT|Lycopene|Given PO
223399431|NCT05220852|COMBINATION_PRODUCT|Dry needling with exercise|"At the initial session, dry needling will be given to their upper trapezius muscles' hyperactive trigger sites, and EX will continue for a minimum of three times per week.~1. Cranio-cervical spine flexion is the exercise.~2. Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
223399432|NCT05220852|OTHER|Exercise|"patients in this group are going to have onley neck exercise for 2 weeks minimum 3 times a week.~1. Cranio-cervical spine flexion is the exercise.~2. Extension of the cranio-cervical spine Exercice 3 Shoulder Elevation 4-Retraining of the scapular muscles Every exercise should be done for 30 se"
223731916|NCT00541073|DRUG|cisplatin|
223731917|NCT00541073|DRUG|pemetrexed disodium|
223731918|NCT00541073|GENETIC|gene expression analysis|
223731919|NCT00541073|OTHER|laboratory biomarker analysis|
223731920|NCT00541073|OTHER|pharmacological study|
224130773|NCT02669862|DRUG|Vehicle Solution|
224130774|NCT02567617|DIETARY_SUPPLEMENT|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
224130775|NCT02567617|DIETARY_SUPPLEMENT|Placebo controlled|Starch capsules
223399433|NCT06307795|DRUG|ANS014004|Varying doses of ANS014004
223731921|NCT04905212|DRUG|Telitacicept 160mg|Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
223731922|NCT04905212|DRUG|Telitacicept 240mg|Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
223731923|NCT04905212|DRUG|Placebo|Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
223731924|NCT03296657|DRUG|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
223731925|NCT03622307|DEVICE|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
223399434|NCT01932333|DRUG|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
223551461|NCT01720303|DRUG|repaglinide|2 mg (tablets) before each main meal
223731926|NCT05913180|DRUG|Ascorbic Acid 1000 MG|1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
223731927|NCT05913180|DRUG|Placebo|Placebo tablet daily starting day of elective gynecological surgery for 10 days
223731928|NCT02097810|DRUG|Entrectinib|
223731929|NCT02950454|OTHER|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
223731930|NCT02950454|OTHER|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
223731931|NCT03766555|PROCEDURE|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
223731932|NCT03766555|PROCEDURE|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
223731933|NCT00132184|DRUG|Vitamin D|
224130776|NCT00444509|DRUG|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
224130777|NCT00444509|DRUG|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
224130778|NCT03000374|DRUG|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
223731934|NCT01926314|DEVICE|PHENIX Neuromuscular Stimulation Therapy System device|
223731935|NCT01926314|OTHER|usual home care without device|
224130779|NCT03000374|DRUG|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
223399435|NCT01932333|DRUG|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
223399436|NCT01932333|DRUG|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
223399437|NCT06258928|DIAGNOSTIC_TEST|Functional examination|Compared to nonoperated limb, after 6 months of early rehabilitation.
223551462|NCT01720303|DRUG|isophane human insulin|Injection s.c. (under the skin) at bedtime
223551463|NCT01720303|DRUG|insulin|Injection s.c. (under the skin) twice daily
223551464|NCT03584815|PROCEDURE|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
223551465|NCT03584815|OTHER|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
224130780|NCT03000374|DRUG|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
224130781|NCT03000374|DRUG|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
224130782|NCT01907984|DRUG|Diclofenac|
223551466|NCT06264466|DEVICE|POEM with Speedboat Ultraslim|POEM procedures, with or without fundoplication, will be conducted by expert endoscopists who have undergone prior training in the utilization of the ultraslim Speedboat. Incisions, whether anterior or posterior, submucosal tunneling, and myotomy will be performed using the Bipolar Radiofrequency Ablation (RFA) integrated into the device's tip. Additionally, for vessel coagulation, the microwave energy integrated into the device's tip will be employed. Successful myotomy will be confirmed by passage of the endoscope through the esophagogastric junction (EGJ) without restriction.
223551467|NCT00411385|DRUG|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
223551468|NCT00411385|DRUG|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
224130783|NCT01907984|DRUG|Midazolam|
224130784|NCT05138783|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
224130785|NCT05138783|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
224130786|NCT02566252|DRUG|PUL-042 Inhalation Solution|PUL-042
224130787|NCT02566252|DRUG|Cromolyn Sodium|Pre-treatment
224130788|NCT02566252|DRUG|Albuterol sulfate|Pre-treatment
223731936|NCT02592785|DRUG|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
223731937|NCT02611778|BIOLOGICAL|ranibizumab|
224130789|NCT02264899|OTHER|in Memento-VASCOD|"* Pulse wave velocity assessment~* Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~* Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~* Neuropsychological testing and behaviorial and mood scales~* Urinary albumin excretion measurement"
223399438|NCT03929523|DEVICE|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
223399439|NCT03929523|DEVICE|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
223399440|NCT03502733|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223399441|NCT03502733|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399442|NCT03502733|PROCEDURE|Computed Tomography|Undergo CT scan
223399443|NCT03502733|DRUG|Copanlisib|Given IV
223399444|NCT03502733|PROCEDURE|Echocardiography Test|Undergo ECHO
223399445|NCT03502733|BIOLOGICAL|Ipilimumab|Given IV
223399446|NCT03502733|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399447|NCT03502733|BIOLOGICAL|Nivolumab|Given IV
223399448|NCT01175993|OTHER|Elliptical exercise|Each participant with TBI will participate in an exercise intervention which will be done in the home. The exercise device in this protocol will be an elliptical trainer that requires coordinated reciprocal movements of both the legs and the arms. Primary emphasis will be placed on maintaining a near maximal speed of movement and to progressively increase this over time. Mild resistance to the leg motion will be provided initially and will be progressively increased once speed and coordination are optimized. The device will be loaned to them to use in the home, and will be delivered to the home fully assembled. Participants will be monitored by phone the first week and thereafter every two weeks and progressed as indicated. The exercise program will be performed 5 days a week for 30 minutes per session, for a total duration of 12 weeks. All will record the length, speed and resistance of each session on a paper-based log sheet.
223399449|NCT02043457|OTHER|phenotyping|
223399450|NCT06981832|BEHAVIORAL|Personalised support (advanced practice nurse and adapted physical activity teacher)|Personalised support (advanced practice nurse and adapted physical activity teacher)
223399451|NCT06981832|BEHAVIORAL|Standard support (advanced practice nurse)|Standard support (advanced practice nurse)
223399452|NCT05211882|OTHER|Immediate ENABLE nurse coaching, on top of usual care|Participants in the intervention arm will start on the ENABLE program at point of randomization
223399453|NCT05211882|OTHER|Usual Care|Participants on wait-list will continue on usual care and only start ENABLE 6 months after randomization.
223399454|NCT06980038|BIOLOGICAL|Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Given IV
223399455|NCT06980038|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223399456|NCT06980038|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399457|NCT06980038|BIOLOGICAL|Cemiplimab|Given IV
223399458|NCT06980038|PROCEDURE|Computed Tomography|Undergo CT scan
223731938|NCT04123054|DEVICE|Mobile App|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.
223731939|NCT04123054|DEVICE|Mobile App + Basal-Bolus Optimization Algorithm|Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.
223731940|NCT01930747|DRUG|rocuronium|measure effect on laparoscopic workspace
224130790|NCT03746223|DRUG|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
223399459|NCT06980038|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223399460|NCT06980038|PROCEDURE|Tumor Resection|Undergo resection surgery
223399461|NCT05562466|DRUG|QMF149|QMF149 75/40 μg o.d via Breezhaler
223399462|NCT05562466|DRUG|Budesonide|Budesonide 200 μg o.d via Breezhaler
223399463|NCT01041924|OTHER|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
223399464|NCT01041924|OTHER|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
223399465|NCT04817124|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 6 sessions with 20 minutes stimulation each (1,5 mA).
223399466|NCT04817124|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 6 sessions for approximately 20 min
223399467|NCT04817124|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 6 sessions with 30 sec stimulation each (1,5 mA) to ensure blinding of participants.
223425675|NCT03187847|DEVICE|Actigraph GT3X|"The primary outcomes are measured by the Actigraph GT3X (step counts) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).~The secondary outcomes are emotional status, measured by the hospital anxiety and depression scale (HADS) and quality of life, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS)."
224020312|NCT03170037|PROCEDURE|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
224020313|NCT03860285|OTHER|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
224130791|NCT03746223|DRUG|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
223399468|NCT06490224|BEHAVIORAL|Relevant Patient Reported Outcome Measures (PROMs)|Depending on the participant's complaint: Hip disability and osteoarthritis outcome score JR (HOOS JR), Knee disability and osteoarthritis outcome score JR (KOOS JR), Quick Disabilities of the Arm, Shoulder, and Hand, Quick Disabilities of the Arm, Shoulder, and Hand (QUICKDASH), Patient Health Questionnaire 9 (PHQ-9), General Anxiety Disorder-7 (GAD7), Patient Self-Efficacy Questionnaire (PSEQ-2), Patient-Reported Outcomes Measurement Information System (PROMIS Global 10)
223399469|NCT06490224|OTHER|My Whole Health Map|Short visual map of responses to 10 questions of subjective measures.
223399470|NCT02092870|DRUG|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
223399471|NCT02621359|DRUG|Nitazoxanide|Nitazoxanide 500 mg twice daily
223399472|NCT02621359|DRUG|Levofloxacin|Levofloxacin 500 mg once daily
223399473|NCT02621359|DRUG|Doxycyclin|Doxycyclin 100 mg twice daily
223399474|NCT02621359|DRUG|Omeprazole|Omeprazole 40 mg twice daily
223399475|NCT00779896|DRUG|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
223399476|NCT01383174|BEHAVIORAL|Peer Support Program|"* Work with a trained counselor who is a breast cancer survivor~* Meet 8 times in-person over the 8 week program with the counselor~* Counselor helps participant develop a personalized support program to help her improve her quality of life~* Receives information on breast cancer, its treatments, and stress management"
223399477|NCT01946750|BIOLOGICAL|Serum|
223399478|NCT01946750|BIOLOGICAL|Stools|
223399479|NCT01946750|BIOLOGICAL|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
223399480|NCT01946750|BIOLOGICAL|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
223399481|NCT04272788|DRUG|Infliximab|The CD patients at initial active stage without treatment of glucocorticoids, immunosuppressants and biological agents are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
223399482|NCT01787292|BEHAVIORAL|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
223399483|NCT01787292|BEHAVIORAL|Aerobic Exercise Intervention|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
223399484|NCT01787292|BEHAVIORAL|Self Monitoring|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
223399485|NCT04181619|DIETARY_SUPPLEMENT|Coffeeberry beverage|One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage prior to exercise session
223399486|NCT04181619|OTHER|Comparator beverage|One 300 ml still beverage, color and flavor matched to experimental beverage prior to exercise session
223399487|NCT05872789|DRUG|Diazepam 1% oral gel|Diazepam 1% used with topic oral gel on tongue and palate twice daily.
223399488|NCT05872789|DRUG|Placebo|Placebo oral gel used on tongue and palate twice daily.
223399489|NCT06129448|DIAGNOSTIC_TEST|transthoracic echocardiography|All echocardiographic studies will be performed by one physician (Merve Maze AYDEMIR) using a commercially available echocardiographic system (P4-2 probe, DC-60, Mindray, Shenzhen, China) in the back-to-top or left lateral decubitus position. All images will be digitally stored from three cardiac cycles as standard apical four-chamber and parasternal short-axis views.
223425676|NCT00761280|DRUG|trabedersen|
223425677|NCT00761280|DRUG|temozolomide|
223425678|NCT00761280|DEVICE|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
224020314|NCT00799513|DRUG|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
224020315|NCT04584775|OTHER|Treatment modalities of Traditional Chinese Medicine (Acupuncture, Chinese herbal medicine, Tunia, Chinese dietetics)|"Acupuncture is a physical treatment modality that uses thin needles to stimulate specific points on the body in order to manipulate neurologic mechanisms to control specific symptoms and/or physiologic processes.~Chinese herbal medicine is a phytotherapeutic treatment modality that uses herbs, minerals and rarely animal products which are orally administered.~Tuina is a form of massage and physical therapy. Chinese dietetics is a nutritional therapy according to the theoretical principle of traditional Chinese medicine."
224020316|NCT04584775|OTHER|Standard care|Standard care includes any medical intervention in palliative care that aims to promote and/or sustain the quality of life of patients suffering from advanced disease (in this case cancer). These may be of pharmaceutical, surgical, psychological and/or spiritual nature.
224130792|NCT03746223|DRUG|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
224130793|NCT05731843|DRUG|Cohort 1 BEM + Ruzasvir|Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
224130794|NCT05731843|DRUG|Cohort 2 Ruzasvir + BEM|Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
224130795|NCT05890118|DRUG|Stelara|A commercial formulation of ustekinumab for SC control (0.5mg)
224130796|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.5mg)|RaniPill capsule containing ustekinumab with a dose of 0.5mg
223731941|NCT01930747|DRUG|Sevoflurane|1 MAC sevoflurane inhalation is given
223731942|NCT01930747|DRUG|remifentanyl|remifentanyl is given in infusion
223731943|NCT02921698|DEVICE|FRED®|Flow Re-Direction Endoluminal Device
223731944|NCT02746016|OTHER|Infant Formula supplemented with Oligosaccharides|sole source nutrition
223399490|NCT00828217|OTHER|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
223399491|NCT06463990|OTHER|TyG index|association between TyG index and triglyceride to high-density lipoprotein cholesterol ratio with fetal macrosomia
224130797|NCT05890118|COMBINATION_PRODUCT|RT-111 (0.75mg)|RaniPill capsule containing ustekinumab with a dose of 0.75mg
223731945|NCT01311570|DRUG|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
223731946|NCT04356690|DRUG|Etoposide|Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
223399492|NCT06149975|OTHER|motor-cognitive training|"The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist."
223551469|NCT00411385|DRUG|Ribavirin|800mg/day for 24 weeks
223551470|NCT04092803|OTHER|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
223731947|NCT05938933|BEHAVIORAL|PHP|personalized health planning (PHP)
223399493|NCT01827111|DRUG|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
223731948|NCT05938933|BEHAVIORAL|SMA|shared medical appointments (SMAs)
223731949|NCT03682445|OTHER|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
223399494|NCT01827111|DRUG|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
223399495|NCT01827111|BEHAVIORAL|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
223399496|NCT03016884|BIOLOGICAL|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
223399497|NCT05975008|BEHAVIORAL|RECLAIM - Reconnecting to Civilian Life using Activities that Improve Mindfulness|Brief virtual mindfulness-based intervention
223731950|NCT02536196|DEVICE|Embolic Protection Device|Embolic protection
223731951|NCT02536196|PROCEDURE|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
223731952|NCT04857905|PROCEDURE|Microsurgical resection|Depending on the patient's choice, the microsurgical resection of the brain metastases will be performed.
223731953|NCT04857905|PROCEDURE|Gamma Knife radiosurgery|Depending on the patient's choice, the radiosurgical treatment of the brain metastases will be performed.
223731954|NCT04199572|DRUG|Diclofenac and Paracetamol|analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
223731955|NCT02145364|DEVICE|Ultherapy® treatment|Microfocused ultrasound treatment
223731956|NCT01619683|DRUG|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
223731957|NCT01619683|DRUG|Placebo|1 placebo capsule per day, oral
223731958|NCT05130619|DIETARY_SUPPLEMENT|Ethanol|Crossover meal study
223731959|NCT01876342|PROCEDURE|open repair|2-0 sutures
223731960|NCT01876342|PROCEDURE|endoscopic TEP repair|mesh
223731961|NCT02877823|BEHAVIORAL|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
223731962|NCT02877823|BEHAVIORAL|Control|Healthy Lifestyle Education
223731963|NCT03327649|DEVICE|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
223731964|NCT02226055|DEVICE|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
223731965|NCT04468204|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
223731966|NCT04468204|DEVICE|Sham SinuSonic Device|Sham positive expiratory pressure intervention using the SinuSonic Device.
223731967|NCT04937829|DRUG|BI 1569912|BI 1569912
223731968|NCT04937829|DRUG|Placebo|Placebo
224020317|NCT00624923|DRUG|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
224020318|NCT00624923|DRUG|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
224020319|NCT02312388|OTHER|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
224020320|NCT02312388|OTHER|Thin-wall needle technique|using 18 - 21 G introducer needle
224020321|NCT04459013|OTHER|Salivary samples|The salivary samples will be collected at 5 defined times
223551471|NCT05600829|BEHAVIORAL|BWLT+CR|Patients will attend twelve 2-hour group-based weekly sessions (over Zoom) in addition to their twice-weekly CR exercise sessions, followed by biweekly follow-up sessions alternating between individual phone-based sessions with a facilitator, and group-based sessions for an additional 12 weeks. The empirically validated ASPIRE BWLT was recently adapted for an AF population with obesity. Briefly, the BWLT was modified to incorporate education and practical strategies requested by patients, including AF risk factor management, pathophysiology, medications, and disease course; exercising with AF; and coping with difficult emotions regarding AF. Weekly treatment goals focus on nutrition and moderate calorie reduction while emphasizing adherence to an individualized CR exercise prescription. The BWLT program will be delivered by senior clinical psychology PhD students and supervised by a registered Clinical Health Psychologist.
223551472|NCT05600829|BEHAVIORAL|CR-Only|The CR program consists of education, medication management, risk factor modification and 12 weeks of twice-weekly supervised cardiovascular exercise sessions. Patients with AF undergo a symptom-limited graded exercise stress test at intake, 12-weeks, 24-weeks, and 1-year post-randomization, where cardiorespiratory fitness (i.e., peak metabolic equivalents \[METS\]) and cardiometabolic risk factors (blood pressure, blood lipid profile, BMI, waist circumference, depression and anxiety symptoms, tobacco use, and exercise volume) are assessed.
223551473|NCT01765036|DRUG|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
223731969|NCT01735513|DEVICE|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
223731970|NCT04803097|DIAGNOSTIC_TEST||We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
223731971|NCT03054389|OTHER|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
224130798|NCT00878631|DRUG|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
224130799|NCT00878631|DRUG|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
224130800|NCT03187912|DRUG|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
224130801|NCT04406935|DEVICE|treatment with the study device (NuEra)|"Multi-arm, prospective, multi-center, baseline-controlled study:~Arm 1: NuEra treatment using 475 KHz Arm 2: NuEra treatment using 1 MHz Arm 3: NuEra treatment using 2 MHz"
223731972|NCT03054389|OTHER|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
223731973|NCT06399978|BEHAVIORAL|Brain Blossom - Gamified Differential Outcome Training|Digital cognitive training with a gamified DOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
223399498|NCT02250898|OTHER|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
223399499|NCT02250898|OTHER|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
223399500|NCT02169271|DRUG|Aspirin|Given PO
223399501|NCT02169271|OTHER|Laboratory Biomarker Analysis|Correlative studies
223399502|NCT02169271|OTHER|Placebo|Given PO
223399503|NCT05289739|BEHAVIORAL|Exercise training|Exercise training during intensive cancer treatment. Training mainly consists of age-appropriate and personalized endurance, strength, flexibility, balance/coordination and gait training. Three to five weekly training sessions lasting 30 to 60 minutes each for about eight to ten weeks (depending on the course of the cancer treatment).
223399504|NCT04421560|DRUG|Ibrutinib|Capsule, taken by mouth daily
223399505|NCT04421560|DRUG|Pembrolizumab|Given as an intravenous injection through a vein (IV) every 3 weeks
223399506|NCT04421560|DRUG|Rituximab|Given as infusion into a vein (intravenous, IV)
223399507|NCT06605105|DRUG|CYB003|CYB003 is a deuterated psilocin analog
223399508|NCT06606990|PROCEDURE|Biopsy Procedure|Undergo biopsy
223399509|NCT06606990|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223731974|NCT06399978|BEHAVIORAL|Gamified Non-Differential Outcome Training|Digital cognitive training with a gamified NDOT task for 20 minutes per day 3-4 times a week for 6-8 weeks.
223731975|NCT05003076|DRUG|Methamphetamine|Participants will be given 20 mg of Methamphetamine.
223731976|NCT05003076|DRUG|Placebo|Participants will be given a placebo capsule that will only contain lactose.
223399510|NCT06606990|PROCEDURE|Computed Tomography|Undergo CT
223399511|NCT06606990|PROCEDURE|Echocardiography Test|Undergo ECHO
223399512|NCT06606990|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399513|NCT06606990|BIOLOGICAL|Pidnarulex|Given IV
223399514|NCT06409611|DEVICE|neuromuscular electrical stimulation|Application of neuromuscular electrical stimulation using the NeuroDyn III device (IBRAMED, Amparo - SP)
223399515|NCT06602739|DRUG|REGN5713|Administered per protocol
223399516|NCT06602739|DRUG|REGN5715|Administered per protocol
223399517|NCT06602739|DRUG|Placebo|Administered per protocol
223399518|NCT06595563|DRUG|Trastuzumab emtansine|T-DM1 will be administered IV at a dose of 3.6 mg/kg every 3 weeks. (21 days +/- 3 days) until disease progression, unacceptable toxicity or request of the subject to withdraw from the study. The total dose will depend on the subject's weight on day 1 of each T-DM1 cycle.
223399519|NCT06609096|BEHAVIORAL|Sexual counseling based on the PLISSIT model|Four sessions of sexual counseling based on the PLISSIT model will be provided. The intervention consisted of four consecutive sessions, with one session per week. Each session is 30 minutes on average.
223399520|NCT06609096|BEHAVIORAL|Sexual counseling based on the BETTER model|A total of four sessions of sexual counseling based on the BETTER model will be provided. The intervention consists of four consecutive sessions, one session per week. Each session is 30 minutes on average.
223399521|NCT05541016|PROCEDURE|Biospecimen Collection|Undergo blood and saliva specimen collection for NavDx testing
223399522|NCT05541016|DRUG|Cisplatin|Given IV
223399523|NCT05541016|PROCEDURE|Computed Tomography|Undergo CT scan
224130802|NCT05812469|BEHAVIORAL|Brain Awareness Intervention|effect of brain awareness intervention on metacognition, self-efficacy and treatment motivation in patients with alcohol and substance use disorders
224130803|NCT05812469|BEHAVIORAL|Being Healthy Education|This training included trainings on Healthy Nutrition, Sexually Transmitted Diseases, Importance of Physical Activity and Personal Hygiene prepared by the researcher in the form of presentations for the patients in the control group.
224130804|NCT02546427|RADIATION|Helical TomoTherapy (HT)|
224130805|NCT02546427|RADIATION|CyberKnife SBRT|
224130806|NCT02546427|RADIATION|Permanent Prostate Implant (PPI)|
224130807|NCT02546427|RADIATION|HDR brachytherapy|
224130808|NCT01985373|DRUG|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
223399524|NCT05541016|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Undergo DART
223399525|NCT05541016|DRUG|Docetaxel|Given IV
223399526|NCT05541016|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
223399527|NCT05541016|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223399528|NCT05541016|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223399529|NCT05541016|PROCEDURE|Modified Barium Swallow Study|Undergo MBSS
223399530|NCT05541016|OTHER|Observation|Undergo observation
223551474|NCT05043181|BIOLOGICAL|Low Density Lipoprotein Receptor mRNA Exosomes|"The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase."
223551475|NCT05270018|DRUG|Bacterial Lysates|14mg once a day
223551476|NCT05270018|OTHER|normal saline|14.0ml once a day
223551477|NCT03870373|DEVICE|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
223399531|NCT05541016|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223399532|NCT05541016|OTHER|Quality-of-Life Assessment|Ancillary studies
223399533|NCT05541016|OTHER|Questionnaire|Ancillary studies
223399534|NCT06661720|BIOLOGICAL|Pembrolizumab|Given intravenously
223399535|NCT06661720|DRUG|Tivozanib|Given orally
223551478|NCT00149539|DRUG|Buprenorphine/naloxone|
223551479|NCT00271856|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
223551480|NCT00271856|BEHAVIORAL|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
223551481|NCT01954459|DEVICE|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
223399536|NCT06661720|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223399537|NCT06661720|PROCEDURE|MRI|Undergo MRI
223399538|NCT06661720|PROCEDURE|Computed Tomography|Undergo CT scan
224130809|NCT01142609|BEHAVIORAL|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
223399539|NCT06661720|PROCEDURE|Biopsy|Undergo biopsy
223399540|NCT06661720|OTHER|Questionnaire Administration|Ancillary studies
223399541|NCT06986434|GENETIC|CAR19BCMA-T cells|"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg."
223399542|NCT06986434|DRUG|fludarabine and cyclophosphamide|"Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells.~Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells."
223399543|NCT06984094|BIOLOGICAL|SCB-1019T|SCB-1019T (bivalent recombinant RSV vaccine candidate) consists of two recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)) and RSV B strain (SCB-1019T(B)).
223399544|NCT06984094|BIOLOGICAL|SCB-1022|SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).
223399545|NCT06984094|BIOLOGICAL|SCB-1033|SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate) consists of four recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), hMPV (SCB-1021) and PIV3 (SCB-1020).
223399546|NCT06860178|OTHER|Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months|in the intenvention arm, the children will get the vaccine R21 Matrix M together with the CPS
224130810|NCT03499080|BEHAVIORAL|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
224020322|NCT05398237|OTHER|Solar Simulated Light (SSL)|Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.
224020323|NCT03843931|BEHAVIORAL|GLA:D|The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.
224130811|NCT03499080|BEHAVIORAL|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
224130812|NCT03499080|BEHAVIORAL|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
224130813|NCT00228150|DRUG|SR57667B|
224130814|NCT00818207|OTHER|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
224130815|NCT00818207|OTHER|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
224130816|NCT05364229|RADIATION|MR-guided Radiotherapy Boost|IMRT/VMAT prostate whole gland SBRT to 30 Gy in 5 fractions. MRL focal boost of 15 Gy in 1 fraction will be delivered either before or after whole gland SBRT.
224130817|NCT02616185|BIOLOGICAL|PF-06755992|PF-06755992 will be administered on Day 1 of Cycles 1 and 2.
224130818|NCT02616185|BIOLOGICAL|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
224130819|NCT02616185|DEVICE|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
223399547|NCT06990321|DRUG|Intermediate-dose Cytarabine in Combination with Venetoclax|Elderly patients with Middle- and High-risk Acute Myeloid Leukemia who received the Intermediate-dose Cytarabine in Combination with Venetoclax at the First Hospital of Jilin University from March 1, 2024 to December 31, 2026.
224130820|NCT02616185|BIOLOGICAL|Tremelimumab|PF-06753388 will be administered every 28 days.
223399548|NCT04846400|DEVICE|ssNPA|The ssNPA is a self-supporting nasopharyngeal airway, a stent that is a non-surgical alternative to treat severe OSA
223399549|NCT03142737|OTHER|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
223399550|NCT03142737|OTHER|Eggs intake|Each participant will consume 2 cooked large eggs.
223399551|NCT03142737|OTHER|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
223399552|NCT03142737|OTHER|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
223399553|NCT03142737|OTHER|Intact beef intake|Each participant will consume 2 ounces of intact beef.
223399554|NCT04252651|OTHER|Blood Draw|This study will involve blood draws to test for specific cytokines
223399555|NCT00659191|DRUG|GSK1265744|
224130821|NCT02616185|BIOLOGICAL|PF-06801591|PF-06801591 will be administered every 28 days.
224130822|NCT02616185|BIOLOGICAL|PF-06753512|Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab
223399556|NCT02641093|DRUG|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
223399557|NCT02641093|PROCEDURE|Surgery|gross total surgical resection
223399558|NCT02641093|RADIATION|Radiation Therapy|60-66 Gy over 6 weeks
223399559|NCT02641093|DRUG|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
223399560|NCT06576973|DRUG|Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib|Adbelimumab 1200mg Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Apatinib 250mg Po Day 2-4. Preoperative neoadjuvant therapy for 4 cycles, one cycle every 21 days.
223551482|NCT01954459|DEVICE|Continuous glucose sensor|Glucose sensor inserted without warming patch
223551483|NCT00480831|DRUG|bevacizumab|Intravenous repeating dose
223551484|NCT00480831|DRUG|carboplatin|Intravenous repeating dose
223551485|NCT00480831|DRUG|paclitaxel|Intravenous repeating dose
223551486|NCT00480831|DRUG|placebo|Intravenous repeating dose
223551487|NCT00480831|DRUG|PRO95780|Intravenous repeating dose
223551488|NCT01123031|DRUG|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
223551489|NCT01123031|DRUG|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
223551490|NCT04364815|DRUG|Hydroxychloroquine plus standard preventive measures|Hydroxychloroquine and standard preventive measures
223551491|NCT04364815|DRUG|Placebo plus standard preventive measures|Placebo tablet plus standard preventive measures as defined by PGH-HICU
223551492|NCT05895123|DRUG|Rosuvastatin 20 mg|patients will receive one tablet rosuvastatin 20 mg every night
223551493|NCT05895123|DRUG|Atorvastatin 40mg|patients will receive one tablet Atorvastatin 40 mg every night
223551494|NCT05600985|PROCEDURE|FS-LASIK|Laser-assisted in situ keratomileusis, commonly referred to laser eye surgery or laser vision correction, is a type of refractive surgery for the correction of myopia, hypermetropia, and astigmatism.
223551495|NCT04762836|DRUG|D-cycloserine|Antibiotic medication that augments the function of NMDA-receptors
223551496|NCT04762836|BEHAVIORAL|Conditioning|During nocebo acquisition trials, the conditioned stimulus (i.e., activation of a sham electrode that can increase pain sensitivity, is paired to unconditioned high-pain stimuli (nocebo trials). During control trials of the acquisition phase, moderate-pain stimuli are paired to no sham electrode activation.
224020324|NCT03843931|DRUG|Intra-articular saline injection|"Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible."
224130823|NCT02494778|DRUG|Pridopidine|45 mg BID
224130824|NCT03617029|DEVICE|Microcoil|Needle localization with microcoil
224130825|NCT03617029|DRUG|Lipiodol|Needle localization with contrast injection
224130826|NCT05610917|COMBINATION_PRODUCT|CBRM (community-based rehabilitation management)|The case group patients will undergo drug treatment (Selective Serotonin Reuptake Inhibitors), health education, cognitive-motor dual task training, cognitive-training.
224130827|NCT05610917|COMBINATION_PRODUCT|TAR(treatment as routine)|Patients in control group will be treated rountinely which includes drug treatment (SSRIs) and traditional health education.
224130828|NCT01617512|DEVICE|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
224130829|NCT02827994|OTHER|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
224130830|NCT04117568|OTHER|Blood sampling|Blood sampling at 3-5 occasions per admission
224130831|NCT00418730|DRUG|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
224130832|NCT02168881|DRUG|Misoprostol|
223399561|NCT06576973|PROCEDURE|Esophagectomy|Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive IvorLewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy. The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.
223399562|NCT06576973|OTHER|Collecting samples from participant|Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 20 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and after surgery.
223399563|NCT04805905|OTHER|FACE-Q patient reported outcome|"As both interventions of treatment are gold standards and clinical equipoise exists if one intervention is superior to the other, there is no true control group. However, for the purpose of the application, the local flap group will be chosen as the control group.~Skin graft (Experimental): Participants in the experimental group will receive a skin graft and receive the FACE-Q skin cancer questionnaire pre- and post-treatment. There will also be photos taken of the patient's face along with the distributed questionnaires.~Local flap (Control): Participants in the experimental group will receive a local flap and receive the FACE-Q questionnaire pre- and post-treatment."
223399564|NCT02852174|BEHAVIORAL|Mindfulness meditation training|Mindfulness meditation training
223399565|NCT06988553|DRUG|AZD5004|AZD5004 will be administered as an oral tablet once daily.
223399566|NCT06988553|DRUG|Placebo|Placebo will be administered as an oral tablet once daily.
223399567|NCT06613438|DEVICE|eGERD device|"The eGERD device is a novel device developed by GerdCare Medical for reducing symptoms of GERD. The device is noninvasive and designed for self-use in the home environment. It is applied on the abdominal skin and generates electrical stimulation pulses.~For optimized effect, the stimulation is synchronized with the breathing phase, such that it is active mainly during inhalation. The stimulation intensity can be adjusted by the user."
223399568|NCT06613438|DEVICE|eGERD_Sham|The eGERD\_Sham is a sham version of the eGERD device. It is capable of inducing sensation of electrical stimulation pulses in the target abdominal muscles without a therapeutic effect. Aside from this difference, the eGERD\_Sham is identical to the eGERD device.
223399569|NCT01924689|BIOLOGICAL|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
223399570|NCT05326750|DEVICE|Gamma tACS (40 Hz) over the superior parietal cortex|Single session of gamma tACS (40 Hz) over the superior parietal cortex
223399571|NCT04585958|PROCEDURE|Biopsy Procedure|Undergo biopsy
223399572|NCT04585958|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
223399573|NCT04585958|PROCEDURE|Computed Tomography|Undergo CT
223399574|NCT04585958|PROCEDURE|Echocardiography Test|Undergo echocardiography
223399575|NCT04585958|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223399576|NCT04585958|DRUG|Olaparib|Given PO
223399577|NCT04585958|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223399578|NCT03307980|BIOLOGICAL|PF-06838435 (formerly SPK-9001)|Gene Therapy: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
223399579|NCT06671834|DRUG|PF-07905428|Topical solution of PF-07905428 0.08% or PF-07905428 0.24%
223399580|NCT06671834|DRUG|Placebo|Topical solution of placebo
224130833|NCT02168881|DRUG|Dinoprostone|
224130834|NCT01992666|GENETIC|Blood sampling|Immunologic and genetic analysis from a single blood sample.
224130835|NCT03705312|DEVICE|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
223551497|NCT04762836|BEHAVIORAL|Extinction|During nocebo extinction, moderate pain stimulations are administered both after the administration of the conditioned stimulus (i.e., activation of the sham electrode) and the control stimulus (no activation of the sham electrode), in order to evoke nocebo responses to the sham hyperalgesic procedure.
223551498|NCT04762836|OTHER|fMRI|In both arms of the study, BOLD response data will be collected with fMRI during the acquisition and extinction of nocebo effects on pain.
224130836|NCT03705312|OTHER|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
224130837|NCT02376595|DRUG|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
224130838|NCT01915108|DRUG|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
223399581|NCT06517602|DIETARY_SUPPLEMENT|Supplementation of Moringa oleifera leaf powder|Women in the experimental group were asked to consistently take the prescribed oral hypoglycemic therapy and to maintain their lifestyle and eating habits. In addition, for the duration of the study (3 months), the experimental group was provided with 10 g of Moringa oleifera leaf powder daily to be consumed with main meals.
223399582|NCT05793164|OTHER|no intervention|no intervention
223399583|NCT01790074|OTHER|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
223399584|NCT01790074|OTHER|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
223399585|NCT03267212|DEVICE|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
223551499|NCT04762836|DRUG|Placebo|Placebo control in oral form
223551500|NCT05216939|OTHER|Flannel mask with ear loops|Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
223551501|NCT05216939|OTHER|Flannel mask with ties|Participants will have a mask fit test and will wear a flannel mask with ties. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
223731977|NCT03638024|DIAGNOSTIC_TEST|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
223731978|NCT04447261|DRUG|BI 1356225|BI 1356225
223731979|NCT04447261|DRUG|Placebo|Placebo
223731980|NCT05733624|DRUG|SCAI-001 0.01% eyedrop|BID for 12weeks
224130839|NCT04006912|PROCEDURE|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
223731981|NCT05733624|DRUG|SCAI-001 0.02% eyedrop|BID for 12weeks
223731982|NCT05733624|DRUG|Restasis 0.05% eyedrop|BID for 12weeks
223731983|NCT00036504|DRUG|Insulin Lispro low mixture|
223731984|NCT02956486|DRUG|Elenbecestat|Oral tablet.
223731985|NCT02956486|DRUG|Placebo|Oral tablet.
223731986|NCT03876431|DEVICE|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
223731987|NCT03876431|OTHER|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
223731988|NCT05202743|OTHER|Observational for ALS patients|Open to ALS patients interested in mindfulness training.
224296963|NCT02293330|DRUG|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
223731989|NCT00044356|GENETIC|Allovectin-7®|
223731990|NCT01905384|DEVICE|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
223731991|NCT01905384|DEVICE|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
223731992|NCT03325075|BIOLOGICAL|VAL-181388|Escalating dose levels
224130840|NCT00218140|DRUG|nicotine transdermal system|
224130841|NCT02366741|RADIATION|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
224130842|NCT01539278|PROCEDURE|Adenotonsillectomy|Tonsils and adenoids are surgically removed
224130843|NCT01539278|OTHER|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
224130844|NCT05446623|DRUG|Dexmedetomidine|Opioid free anesthesia (OFA) consists in the simultaneous administration of alpha2-agonist (for example the dexmedetomidine), sodium channel blocker (lidocaine), and NMDA antagonists receptors (Ketamine). Its aim is to control de cardiovascular nociceptive response to the surgical stimulation.
224130845|NCT05446623|DRUG|Sufentanil|The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
224130846|NCT00735124|DRUG|Gabapentin|1200 mg single dose gabapentin
224130847|NCT00735124|OTHER|placebo|Injection of placebo/sham
224296964|NCT04629768|DEVICE|PuraStat|Purastat is applied to the EMR defect
223731993|NCT03325075|OTHER|Placebo|Saline
223731994|NCT06080607|BEHAVIORAL|Patient Reported Outcome (PRO)|Quality of Life evaluation
223731995|NCT00422591|DRUG|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age \<60 years) or days 1-3 (age \> 60 years).
223731996|NCT00422591|DRUG|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
223731997|NCT00345254|PROCEDURE|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
224020325|NCT01234753|OTHER|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
223399586|NCT03267212|DEVICE|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
223399587|NCT03267212|OTHER|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
223399588|NCT00063011|BEHAVIORAL|Calcium rich diet|
224020326|NCT02661087|PROCEDURE|Hysteroscopic resection with bipolar energy|Hysteroscopic resection with bipolar energy
224130848|NCT01122628|DEVICE|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
223399589|NCT00063011|BEHAVIORAL|Weight bearing exercise|
223399590|NCT05481632|OTHER|Endoangel assisted the process of colonoscopy|Endoangel assisted doctors to detect polyps
223399591|NCT05481632|OTHER|Colonoscopy was performed without endoangel assistance|Polyps were detected without ENDOANGEL assistance
223399592|NCT01560975|DEVICE|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
223399593|NCT04106427|DEVICE|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
223399594|NCT04106427|DEVICE|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
223551502|NCT05216939|OTHER|Twill mask with ear loops|Participants will have a mask fit test and will wear a twill mask with ear loops. While wearing the twill mask with ear loops, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
223731998|NCT03579589|DRUG|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
223731999|NCT02985164|RADIATION|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
223399595|NCT04106427|BEHAVIORAL|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
223399596|NCT04106427|BEHAVIORAL|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
223399597|NCT03139851|DRUG|Cyclophosphamide 50mg|One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223732000|NCT02985164|RADIATION|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
223732001|NCT00041327|BIOLOGICAL|filgrastim|5 ug/kg/d
223732002|NCT00041327|BIOLOGICAL|recombinant interferon alfa|9 mU subcutaneously per day for one year
223732003|NCT00041327|DRUG|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
223732004|NCT00041327|DRUG|cyclophosphamide|750 mg/m2 IV on day 5
223732005|NCT00041327|DRUG|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
223732006|NCT00041327|DRUG|lamivudine|150 mg bid
223732007|NCT00041327|DRUG|prednisone|60 mg/m2 given orally days 1-5
223732008|NCT00041327|DRUG|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
223732009|NCT00041327|DRUG|zidovudine|300 mg bid
224020327|NCT02661087|PROCEDURE|Hysteroscopic resection with monopolar energy|Hysteroscopic resection with monopolar energy
224020328|NCT03280667|DRUG|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
224130849|NCT00200252|DRUG|oxytocin|
224130850|NCT02140359|BEHAVIORAL|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
224130851|NCT04224896|DIAGNOSTIC_TEST|UPPER ENDOSCOPY|UPPER ENDOSCOPY
224296965|NCT00574925|DRUG|Esomeprazole|
223399598|NCT03139851|DRUG|Pembrolizumab 100 MG in 4 ML Injection|IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223399599|NCT04208100|DEVICE|PicoPlus|The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery. The 595nm and 660nm wavelengths of the Lutronic PicoPlus Laser system are used for the treatment of benign pigmented lesions.
223732010|NCT02769325|DRUG|Atropine|IV atropine 0.1%, 10 ml
223732011|NCT02769325|DRUG|Placebo|IV saline, 10 ml
223732012|NCT02769325|DRUG|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
223732013|NCT02769325|DRUG|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
223399600|NCT04132973|BEHAVIORAL|Compassion for Skin Conditions|Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
223399601|NCT05575973|DRUG|Mitoxantrone Hydrochloride Liposome|Drug: Mitoxantrone hydrochloride liposome (20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
223399602|NCT05575973|DRUG|Rituximab|Drug: Rituximab (375 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.
223399603|NCT05575973|DRUG|Lenalidomide|Drug: Lenalidomide (25 mg) will be taken orally from day 1 to day 8 of each 28-day cycle.
223399604|NCT02537561|DRUG|Cisplatin|
223399605|NCT02537561|DRUG|Gemcitabine|
223399606|NCT02537561|DRUG|Talazoparib|
223399607|NCT02841137|DRUG|Progesterone|comparison of different dosages of drug towards the active comparator
223399608|NCT07009080|OTHER|motor imagery|The researcher will explain to the players what MI is and how it works. Following the explanation, players will seated in a comfortable armchair facing the researcher, will ask to minimize distracting thoughts, and to be as mindful as possible without speaking for five minutes, and to imagine themselves executing the correct angles during a landing.
223732014|NCT02769325|DRUG|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
223732015|NCT02769325|DRUG|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
224020329|NCT04459247|DRUG|Vit D|Oral liquid formulation of 60000 IU
224020330|NCT00666679|DRUG|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
223399609|NCT07008599|OTHER|Pulpal Blood Sample|Biochemical markers were measured in blood samples using enzyme-linked immunosorbent assay (ELISA).
223399610|NCT05913336|DRUG|Remimazolam Tosilate|Loading dose: 0.08mg/kg , Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1-0.2mg/kg/h
223425679|NCT00761280|PROCEDURE|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
223425680|NCT00761280|DRUG|carmustine|
223425681|NCT00761280|DRUG|lomustine|
223425682|NCT04121065|PROCEDURE|Blood withdrawal|Blood withdrawal of maximum 60 ml performed to each enrolled patient during the study for primary and secondary endpoints evaluation.
223425683|NCT06402448|DIAGNOSTIC_TEST|muscle pain , joint pain and nerve pain.|to discover the percentage of each tissue that causing pain even it is muscle, joint or nerve in patients with spinal disorders.
223425684|NCT04639102|OTHER|PATH Intervention|"Patients will receive an enhanced level of care and service:~1. Discharge planning- PATH clinicians will develop an individualized treatment plan at time of ED discharge. Each patient will receive next-day phone call to monitor status. There will be additional patient and family education, triage of new or worsening symptoms, and additional telephone contact as determined in treatment plan. There will be communication with home health teams as needed.~2. Care coordination- PATH clinicians will arrange necessary primary medical doctor and specialty appointments. They will also communicate treatment plan to outpatient provider and arrange transportation for patients.~3. Home monitoring/ Home Health Services- If patients are eligible and consent to home health services, they will be enrolled in Penn Medicine Home Health (PMHH). This will include virtual home monitoring, skilled nurse care, home physical and occupational therapists, social work services, and wound care."
223732016|NCT02769325|DRUG|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
223425685|NCT03875482|DRUG|Risankizumab|Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
223732017|NCT02769325|DRUG|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
223732018|NCT06024421|DRUG|favipiravir|Light yellow, film-coated tablet, each containing 200 mg of favipiravir
223732019|NCT06024421|DRUG|Placebo|Light yellow, film-coated tablet
223732020|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv BID
223732021|NCT00668044|DRUG|Ciprofloxacin (BAYO9867)|400 mg iv TID
223732022|NCT03173599|DRUG|PNA 40mg|The beginning dose is 40mg.
223732023|NCT03173599|DRUG|PNA 80mg|The single dose is 80mg.
223732024|NCT03173599|DRUG|PNA 160mg|The single dose is 160mg.
223732025|NCT03173599|DRUG|PNA 240mg|The single dose is 240mg.
223732026|NCT03173599|DRUG|PNA 360mg|The single dose is 360mg.
223732027|NCT03173599|DRUG|PNA 480mg|The single dose is 480mg.
223732028|NCT03173599|DRUG|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
223732029|NCT05247268|DRUG|Megestrol Acetate 160 MG Oral Tablet|At a dosage of 160 mg/day
223732030|NCT05247268|DRUG|Medroxyprogesterone Acetate 500 MG|At a dosage of 500 mg/day
224020331|NCT00666679|DRUG|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
224020332|NCT00666679|DRUG|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
224020333|NCT02702726|OTHER|Congee and juice with coconut gel|25g coconut oleogel
224020334|NCT02702726|OTHER|Congee and juice with coconut oil|25g coconut oil
224020335|NCT02702726|OTHER|Congee and juice with sunflower gel|25g sunflower oleogel
224020336|NCT02702726|OTHER|Congee and juice with sunflower oil|25g sunflower oil
223425686|NCT03875482|DRUG|Placebo solution for risankizumab|Placebo solution in prefilled syringes, self-administered subcutaneously
223425687|NCT00949403|DRUG|Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate|injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
223732031|NCT05247268|DRUG|Triprorelin Acetate|Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses
224020337|NCT04317703|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
223732032|NCT05247268|DRUG|Letrozole 2.5mg|At a dosage of 2.5mg/day and no more than 24 weeks
224020338|NCT04317703|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
223732033|NCT01454869|DRUG|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
223732034|NCT01454869|DRUG|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
224020339|NCT02370810|BEHAVIORAL|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
224020340|NCT01080495|PROCEDURE|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
224020341|NCT00276029|DRUG|Etanercept|
223732035|NCT05534529|DRUG|Rezafungin Acetate|This is a Phase 1, multicentre, open-label, single-dose study. The study will be conducted at 10 sites across at least 3 countries in Europe.
223732036|NCT04419454|DEVICE|BodyTite|retrospectively evaluate this novel treatment approach to improve the appearance of cellulite on the thighs and buttocks by tightening the SFS using RFAL.
223732037|NCT00676351|PROCEDURE|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
223425688|NCT01275508|DRUG|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
223732038|NCT06297733|OTHER|Translating the Questionnaire into Turkish and Related Processes|The first step is the translation from the original language to the other language. The ideal target in the translation phase is to use people who are familiar with the structure of the original language and who are familiar with the language. Two forward translation and one reverse translation methods will be applied after obtaining the written permission of the authors. After the completion of this phase, the terminological differences arising from the translators in the translation process from the original language to Turkish will be collected and discussed on the questions. The cultural adaptation study will be terminated by determining the equivalence between the Turkish version of the inventory and the English original. The final version of the questionnaire and the necessary changes will be arranged specific to the investigator's society and the authors of the original questionnaire will be consulted and the questionnaire will be finalized.
223732039|NCT06297733|OTHER|Validity|The inventory will be applied by face-to-face technique and convergent validity will be evaluated. Construct validity will be evaluated through exploratory and confirmatory factor analysis. Coefficients of fit will be calculated.
223732040|NCT06297733|OTHER|Reliability|The reliability of the items will be tested with Cronbach alpha. Test-retest reliability will be measured by ICC.
223732041|NCT02211001|OTHER|Pilates Group|The exercises were applied once a week during eight weeks.
223732042|NCT02211001|OTHER|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
223732043|NCT02211001|OTHER|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
224020342|NCT01490671|DRUG|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
224020343|NCT01490671|DRUG|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
224130852|NCT01469806|DEVICE|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
224130853|NCT02320695|DRUG|Saline|
224130854|NCT02320695|DRUG|Isopropyl Alcohol|
224130855|NCT02320695|DRUG|Pain Relieving Cream|
224130856|NCT02320695|DRUG|Antibiotic/Pain Relieving Ointment|
224130857|NCT02320695|DRUG|Original Ointment|
224130858|NCT02320695|DRUG|Pain Relief Ointment|
224130859|NCT06552858|DRUG|Fluzoparib|150mg oral bid. A PARP inhibitor that mainly exerts its inhibitory effect on tumor cells by inhibiting DNA repair.
223425689|NCT06684015|DRUG|İNTRATECHAL MORPHİNE GROUP|Addition of intrathecal morphine as an adjuvant to local anesthesia in routine spinal anesthesia application and multimodal analgesia applications
223425690|NCT06684015|PROCEDURE|Erector Spinae Plane Block|Application of erector spinae plane block and multimodal analgesia applications at the end of the operation after routine spinal anesthesia application
223425691|NCT02890485|DEVICE|Dry Needling|Dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. This technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function. Dry needling will be performed in the gluteal or the quadriceps muscle groups depending upon group randomization.
223399611|NCT07005960|OTHER|Art Therapy for Anxiety in Hemodialysis Patients|"Patients in the experimental group will be administered the Volunteer Information and Consent Form, the Patient Information Form, and the State-Trait Anxiety Inventory prior to the intervention.~Then, for four weeks, the experimental group will participate in art therapy sessions involving drawing and painting for approximately 30 minutes, twice a week. In the first week, patients will be asked to paint a given picture. In the second week, they will be given a different picture to paint. In the third week, they will be asked to draw and paint a picture of their choice. In the fourth week, they will again be asked to draw and paint a picture of their choice. At the end of the fourth week, the scales will be completed again.~After this, there will be a one-month break from art therapy, during which no intervention will be conducted. At the end of this month, the same scales will be administered again to the experimental group."
223732044|NCT04224311|BIOLOGICAL|Menactra|0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.
223732045|NCT05201560|DRUG|Butorphanol Tartrate Injection|Patients of this group will receive Butorphanol Tartrate Injection
224130860|NCT06552858|DRUG|Dalpiciclib|150mg oral qd d1-21, q4w. Inhibitor of Cyclin D-CDK4/6 that can inhibit the cell cycle, thereby inducing cell apoptosis.
224130861|NCT01432197|OTHER|ADL intervention|1\) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
224130862|NCT00488579|DRUG|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
223399612|NCT07005960|OTHER|Art Therapy for Resilience in Hemodialysis Patients|"Patients in the experimental group will be administered the Volunteer Information and Consent Form, the Patient Information Form, the Brief Resilience Scale, prior to the intervention.~Then, for four weeks, the experimental group will participate in art therapy sessions involving drawing and painting for approximately 30 minutes, twice a week. In the first week, patients will be asked to paint a given picture. In the second week, they will be given a different picture to paint. In the third week, they will be asked to draw and paint a picture of their choice. In the fourth week, they will again be asked to draw and paint a picture of their choice. At the end of the fourth week, the scales will be completed again.~After this, there will be a one-month break from art therapy, during which no intervention will be conducted. At the end of this month, the same scales will be administered again to the experimental group."
223399613|NCT03446430|DEVICE|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
223399614|NCT06550947|GENETIC|Immunohistochemistry|Immunohistochemical expression of ALDOA in bladder urothelial carcinoma
223399615|NCT06411223|BEHAVIORAL|Collaborative drug therapy management model|CDTM+ is an interdisciplinary approach to patient care in which clinicians collaborate with pharmacists to provide and manage patient drug therapy.
224130863|NCT06238245|DRUG|Cyclophosphamid|ATG (anti-thymocyte globulin, rabbit; 5 mg/kg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg/kg, day -5; 2.5 mg/kg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg/kg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.
223399616|NCT06411223|DRUG|Cabotegravir/Rilpivirine|Long-acting injectable treatment prescribed to treat HIV-1 infection in people 12 years and older and who weigh at least 77 lbs (35kg), to replace their current HIV-1 medicines when their healthcare provider determines they meet certain requirements.
223399617|NCT04444440|DRUG|Ciprofloxacin|Fluoroquinolone antibiotic.
223399618|NCT04444440|OTHER|Placebo Pill|Placebo Pill
223551503|NCT05216939|OTHER|Twill mask with ties|Participants will have a mask fit test and will wear a twill mask with ties. While wearing the twill mask with ties, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.
223732046|NCT05201560|DRUG|Fentanyl|Patients of this group will receive Fentanyl
223732047|NCT03107325|OTHER|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
223732048|NCT03107325|DRUG|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
224020344|NCT02877836|OTHER|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
224020345|NCT06359834|DRUG|Remimazolam besylate|Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion. Remimazolam 2mg is added in case of inadequate sedation.
224020346|NCT06359834|DRUG|Propofol|Patients in this group receives 1mg/kg of propofol to induce sedation prior to endoscope insertion. Propofol 20mg is added in case of inadequate sedation.
224020347|NCT02468180|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
224020348|NCT02468180|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
224020349|NCT02468180|DRUG|N-butyl-2-cyanoacrylate|
224020350|NCT02468180|DRUG|Lauromacrogol|
224020351|NCT01529203|DRUG|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
224020352|NCT01529203|DEVICE|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
224020353|NCT03690232|DRUG|glucose water|3 sessions of 6cc 25% glucose injection with a 2-week interval
224020354|NCT03690232|DRUG|hyaluronic aicd|intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
224020355|NCT04037618|DRUG|[14C]-EYP001a|Oral drinking suspension
223732049|NCT00264329|OTHER|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
223732050|NCT02308254|DRUG|Lixisenatide|Abdominal administration
223732051|NCT02308254|DRUG|Placebo|Abdominal administration
224020356|NCT05936294|DIAGNOSTIC_TEST|Optimization of CRT Device|Each patient will have atrial pacing 10% higher than the sinus rate or atrial pacing at a rate of 60 bpm if significant sinus bradycardia is present. Each patient will have six ECGs and echocardiographic sequences performed in the same session. In addition six electrical activation evaluations by the Medtronic ECG belt will be done as well. The first study will always be with no ventricular pacing. One study will be echocardiography-optimized BIV pacing and four studies for echocardiography-optimized (?) adaptive RV-only pacing with different AV intervals. A random-sequence will be performed to determine the order for the rest of the studies.
224020357|NCT04023500|BEHAVIORAL|Motivational interview vs. prevailing education|"In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care."
224020358|NCT04261491|PROCEDURE|scaling and root planing|scaling and root planing
224130864|NCT02004587|DRUG|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
224130865|NCT04980352|OTHER|real world treatment by doctors|real world treatment by doctors
223399619|NCT07011420|DEVICE|Experimental socket with 4 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. Only 4 channels will be active during this condition.
223399620|NCT07011420|DEVICE|Experimental socket with 8 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. Only 8 channels will be active during this condition.
224020359|NCT00691327|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
224020360|NCT05062759|DRUG|Tezepelumab|210 mg SC injection Q4W.
224020361|NCT05062759|DRUG|Placebo|SC injection Q4W.
224020362|NCT02791425|DEVICE|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
224020363|NCT02791425|OTHER|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
224130866|NCT02702518|DRUG|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
224130867|NCT02702518|DRUG|Vehicle|Drug vehicle 4 times a day for 8 weeks
224130868|NCT00074724|PROCEDURE|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
224130869|NCT00074724|DRUG|Modern medical management|Therapies with evidence-based recommendations.
224130870|NCT00074724|DEVICE|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
224130871|NCT00074724|DRUG|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
224130872|NCT04004559|OTHER|No interventions|As this is a patient registry, there are no interventions.
223399621|NCT07011420|DEVICE|Experimental socket with up to 16 untargeted channels active|Participants will utilize the experimental socket made with untargeted EMG channels. Untargeted sites will ideally be located by creating a band of electrode pairs at the largest muscular circumference distal to the elbow. All16 channels (or the maximum number of channels based on limb size) will be active during this condition.
223399622|NCT07011420|DEVICE|Experimental socket with 8 targeted channels active|Participants will utilize the experimental socket made with targeted EMG channels. This socket will follow Coapt's clinical instructions for targeted site location to identify and mark locations for 8 targeted EMG channels.
224138724|NCT02793895|OTHER|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia. Inc) cardiac rhythm monitoring device.
224138725|NCT02793895|DEVICE|CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device|The CardioSTAT device is a wearable adhesive cardiac rhythm monitoring system which is low-profile, water-resistant, and is adhered onto the skin surface with 2 electrodes. This wearable adhesive device is designed for one-time use only. Each CardioSTAT device will provide 14 days of cardiac rhythm monitoring. For subjects randomized to the intervention group who will be monitored by the CardioSTAT device, they will receive 28 days of continuous cardiac rhythm monitoring.
224138726|NCT02195817|DRUG|Selincro® 18 mg with continuous psychosocial support: Cohort A|
224138727|NCT02195817|OTHER|Initial psychosocial support: Cohort B|
224138728|NCT02438215|DRUG|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
224138729|NCT04653142|DRUG|BI 765063|BI 765063
224138730|NCT04653142|DRUG|BI 754091|BI 754091
224138731|NCT01372449|DRUG|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but \<60 kg, and 6 mg for subjects weighing ≥ 20 kg but \< 40kg.
224138732|NCT01372449|DRUG|Placebo|
224138733|NCT02491398|DRUG|Bendamustine + Rituximab|
223732052|NCT04052893|PROCEDURE|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
224020364|NCT04317365|OTHER|Women receiving extra remembering by healthcare|Women receiving extra remembering by healthcare in covid infection
224020365|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
223732053|NCT04052893|PROCEDURE|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
223732054|NCT01878058|OTHER|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
223732055|NCT04465539|DRUG|Hydroxyethyl Starch 130-0.4 60 MG/ML [Voluven]|Hydroxyethyl starch dose is 500 cc in 6 hours
223732056|NCT04465539|DRUG|Hydrocortisone|Hydrocortisone dose is 200-300 mg /day intravenously
223732057|NCT04465539|DRUG|Placebo|received the standard ALP treatment according to TUPTC protocol as follows: patient resuscitation, care of airway, breathing and circulation, gastric decontamination with 2 ampoules sodium bicarbonate (each ampoule 25 ml containing 2.1 gm sodium bicarbonate) followed by activated charcoal in dose of 1 g/Kg orally, adequate hydration, normal saline administration (0.9% Sodium Chloride IV), vasopressors IV infusions, inhalation of 100% oxygen, ranitidine IV, magnesium sulfate IV infusion and other supportive treatment.
224020366|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
224130873|NCT02123563|OTHER|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
224138734|NCT02623296|DRUG|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
223732058|NCT05529043|BEHAVIORAL|MINISTOP app|The MINISTOP app is a behavioural change program aiming to promote healthier diet and physical activity behaviours in pre-school children. The program consists of features such as information, monitoring and feedback (dietary variables, physical activity, and screen time) and it is built around 13 themes. The participants will have access to the app for 12-months.
223732059|NCT05529043|BEHAVIORAL|MINISTOP Plus Program|Consists of the MINISTOP app and the Community Group Mini. The Community Group Mini consists of group activities to promote physical activity for both children and parents. The Community Group Mini will meet once per week in different playgrounds and nature reserves and will be organized by a trained group leader.
223732060|NCT03238508|PROCEDURE|Deferred stenting|Previously described
223732061|NCT01950845|DEVICE|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
223732062|NCT01950845|DEVICE|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
223732063|NCT01408914|DRUG|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
224020367|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
224138735|NCT02623296|DRUG|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
224138736|NCT02623296|DRUG|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
224020368|NCT01174732|DRUG|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
224020369|NCT01174732|DRUG|Placebo|placebo, lactose inhalation carrier
224020370|NCT01174732|DRUG|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
224020371|NCT01174732|DRUG|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
224020372|NCT01220518|DRUG|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
224020373|NCT01812434|DRUG|Sildenafil|20mg three time daily for 28 days
224020374|NCT01812434|DRUG|Placebo|20 mg three times daily for 28 days
224020375|NCT02234973|BEHAVIORAL|Quality Improvement|Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
224296966|NCT04421586|BEHAVIORAL|VISTA|VISTA will be an educational intervention.
224020376|NCT01683929|OTHER|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
223732064|NCT02312895|OTHER|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
224130874|NCT02123563|OTHER|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
224130875|NCT01782794|OTHER|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
224130876|NCT05140954|DRUG|co-formulated 25mg TAF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 25 mg TAF/ 200mg FTC
224130877|NCT01146249|OTHER|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
224130878|NCT05267912|PROCEDURE|Biopsy|We need a biopsy for PDO: PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient.
224130879|NCT02288624|DIETARY_SUPPLEMENT|Processed orange juice|3 different formulation of edible orange drinks
224130880|NCT03472235|DEVICE|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
224130881|NCT03489616|BIOLOGICAL|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
224130882|NCT03489616|DRUG|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
224130883|NCT03489616|RADIATION|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
224130884|NCT03489616|DRUG|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
224296967|NCT05451186|OTHER|Eye patch and headphones|Patients in the experimental group will be asked to use an eye mask and earplugs from 22:30 to 6:30 in the morning on the 1st, 2nd and 3rd nights.
223399623|NCT07011420|DEVICE|Coapt EMG Cuff|This device is the commercially available Coapt EMG Cuff. This armband cuff with electrodes can be strapped onto the user's arm to connect with the Coapt app and play virtual games with their EMG signals.
223399624|NCT06870344|DRUG|Dihydroartemisinin piperaquine|Taken orally. 11 kg to less than 17 kg 1 tablet per day for 3 days 40 mg 320 mg 17 kg to less than 25 kg 1½ tablets per day for 3 days 60 mg 480 mg 25 kg to less than 36 kg 2 tablets per day for 3 days 80 mg 640 mg 36 kg to less than 60 kg 3 tablets per day for 3 days 120 mg 960 mg 60 kg to less than 80 kg 4 tablets per day for 3 days 160 mg 1280 mg 80 kg or more 5 tablets per day for 3 days 200 mg 1600 mg For patients weighing less than 11 kg, alternative formulations supplying lower amounts of active substance should be preferred
223732065|NCT02312895|OTHER|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
223732066|NCT02312895|OTHER|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
224296968|NCT03121430|DEVICE|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
224130885|NCT01648452|BIOLOGICAL|NT-501 CNTF-releasing implant|20 ng/day released into the eye
223399625|NCT06870344|COMBINATION_PRODUCT|Dihydroartemisinin piperaquine + Bacillus thuringiensis israelensis|Study staff will provide adult participant with LLIN(s), DP and with an 8-oz packet of Bti, a pair of latex gloves, a teaspoon, and a tracking form. A staff member will then survey an area (50 m radius) around the house and demonstrate appropriate application in up to 5 potential breeding sites.
223399626|NCT06870344|OTHER|Long-lasting Insecticidal Net|Distribution of Long-lasting Insecticidal Net to all households on the study.
223399627|NCT06873009|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT) for Smoking Cessation|"A structured three-session group intervention (1.5 hours per session over three weeks) using cognitive-behavioral and motivational strategies to enhance motivation, manage cravings, and prevent relapse.~Associated Arm: CBT Group"
223399628|NCT06873009|OTHER|Health Education Session on Tobacco Use|"A single-session group intervention (1 hour) providing information on the health risks of tobacco use, addiction mechanisms, and the long-term benefits of quitting smoking.~Associated Arm: Health Education Group"
223399629|NCT06625775|DRUG|BBO-10203|Participants will receive assigned dose of BBO-10203 orally once daily
223399630|NCT06625775|DRUG|Trastuzumab|Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
223399631|NCT06625775|DRUG|Fulvestrant|Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
223732067|NCT06249425|BEHAVIORAL|Comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223732068|NCT06249425|DEVICE|Intermittent Oro-esophageal Tube Feeding|All patients are given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223732069|NCT06249425|DEVICE|Transcranial direct current stimulation|In this study, transcranial direct current stimulation is performed using a battery-powered constant current stimulator. This device delivers the current through two electrodes immersed in saline solution. Specifically, a 50mm\*50mm anodal electrode pad is placed at the center of the healthy side swallowing sensory-motor cortex of the patient. According to the positioning method of the international 10-20 electrode system, the swallowing sensory-motor cortex of the left brain is located at the midpoint between C3 and T3, while that of the right brain is located at the midpoint between C4 and T4. The cathode is placed on the opposite shoulder, using a current of 1mA, once a day, for 20 minutes each time, and 5 days a week. The instruments used for placebo patients will not have any actual effect.
224130886|NCT01396993|PROCEDURE|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
224130887|NCT01396993|PROCEDURE|Breast Surgery|Breast conserving therapy without defect correction
224130888|NCT03144583|BIOLOGICAL|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
224130889|NCT01726413|DRUG|GRC 17356|
224130890|NCT01726413|DRUG|Matching Placebo|
224130891|NCT05151679|DRUG|Chelated Iron|"Treatment will be started 24rh after initial visit women will be randomized used random sequence computer generated list in such a way that every patient had equal chance to be among any of the two groups either to group 1 , where they will receive I.V ferrous sucrose in the E.U in Women's Health Hospital Assuit University as an i.v infusion in 250 ml 0.9% sodium chloride slowly over 30 minutes.~The total required dose of iron will be divided into three doses, which will be given every 3 days, and the maximum daily dose is 200mg ( 2 ampoules )."
224130892|NCT05151679|DRUG|Iron sucrose|to group 2 where they will receive chelated oral iron, they will be given iron chelated amino acid containing 15 mg of elemental iron once daily for 6 weeks. the women will be advised to take 1 tab of iron chelated amino acid containing 15mg of elemental iron once daily with meals for 6 weeks from the day of recruitment.
224130893|NCT02737735|DRUG|standard chemotherapy medicine combined with Chinese herbs|
224130894|NCT02737735|DRUG|standard chemotherapy medicine|
224130895|NCT00132236|DRUG|nicotine sublingual tablets|
224130896|NCT00132236|BEHAVIORAL|low and high behavior support|
224130897|NCT01000727|DRUG|Darapladib 160 mg|Lp-PLA2 inhibitor
224130898|NCT01000727|DRUG|Placebo|Placebo administered
224130899|NCT01000727|OTHER|Standard Therapy|Guideline mandated therapy for individual's condition
224130900|NCT03481127|BEHAVIORAL|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
223399632|NCT06625775|DRUG|Ribociclib|Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
223399633|NCT06625775|DRUG|FOLFOX|Patients will receive FOLFOX as infusion every 14 days
223399634|NCT06625775|DRUG|Bevacizumab|Patients will receive bevacizumab as infusion every 28 days
223399635|NCT07013539|DIETARY_SUPPLEMENT|plant extract|hard shell capsule containing plant extract
223399636|NCT07013539|DIETARY_SUPPLEMENT|Placebo|hard shell capsule containing maltodextrine
223399637|NCT06689852|DEVICE|Enriched|To be used twice a day
223399638|NCT06689852|DRUG|Loceryl 5%|To be used once a week
223399639|NCT01904695|DRUG|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
223732070|NCT05526612|OTHER|Group 1 Motor imagery and Bobath Therapeutic Approach (BTA+MI)|Motor imagery (MI) is the mental rehearsal of motor abilities to improve function. Without revealing any movement in the body, the representation of the movement is created in the mind, the person imagines that he/she is performing the movement. Eating activity will be applied in motor imagery. Individualized therapy sessions in the Bobath Therapeutic Approach will also be received by the Physiotherapist along with Motor imagery. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
223732071|NCT05526612|OTHER|Group 2 Motor imagery, Bobath Therapeutic Approach and Physical practice (BTA+MI+PP)|Individualized therapy sessions in the Bobath Therapeutic Approach with motor imagery will be performed by the physiotherapist, and in addition to these, 5 repetitions of the eating activity used in motor imagery will be practiced. 2 days a week, 30 minutes session will be applied for a total of 8 weeks.
223399640|NCT01904695|DRUG|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
223399641|NCT06874426|PROCEDURE|Endoscopic endonasal skull base surgery|This intervention will be performed as part of the standard-of-care for patients scheduled for endoscopic endonasal skull base surgery for lesions in the (para)sellar region
223732072|NCT04987957|OTHER|Music Therapy|Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
223732073|NCT05395468|OTHER|photographs of each eye|All subjects included will take 5 photographs of each eye according to a standardised procedure in terms of distance, lighting and framing
223732074|NCT04060550|BIOLOGICAL|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
223732075|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 30 ug/day|
223732076|NCT01723852|DIETARY_SUPPLEMENT|Vitamin D at 10 ug/day|
223732077|NCT00330616|DRUG|323U66 SR|
223732078|NCT00862745|DRUG|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
223732079|NCT00862745|DRUG|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
223732080|NCT03893422|OTHER|WB-010|Medical food formulation
223732081|NCT03893422|OTHER|WB-011|WB-011 medical food product
223732082|NCT03893422|OTHER|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
223732083|NCT05332509|DEVICE|C-BRACE|The C-BRACE is a custom made Knee-Ankle-Foot-Orthosis with a microprocessor-controlled hydraulic knee-joint articulation. The C-BRACE technology offers to a patient with knee locking deficiencies the following advantages: approximation of the physiological gait pattern, stability while standing and walking, adaptation to various surfaces, inclines, gait situations and walking speeds.
223732084|NCT05332509|DEVICE|SCO|The SCO is a custom made Knee-Ankle-Foot-Orthosis with a knee-joint locked during stance phase and released during swing phase.
223732085|NCT02689024|DRUG|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
223732086|NCT02689024|DRUG|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
223732087|NCT02689024|DRUG|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
223732088|NCT02689024|DRUG|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
223732089|NCT02689024|DRUG|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
223732090|NCT02689024|DRUG|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
224130901|NCT03481127|OTHER|Surveys|"* NCCN Distress Thermometer~* PROMIS Depression \& Anxiety~* Quality of Life (SF-12)~* Brief COPE~* Patient awareness and satisfaction survey"
224130902|NCT03481127|PROCEDURE|Blood draw|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* Enrollment, 3 months after enrollment, and 6 months after enrollment"
224130903|NCT03481127|PROCEDURE|Fresh tissue from ovary|"* For patients with ovarian, fallopian tube, or primary peritoneal cysts~* Optional~* At time of standard of care surgery"
224130904|NCT02694627|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
224130905|NCT01938690|DEVICE|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
224296969|NCT03121430|DEVICE|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
224296970|NCT05214963|DEVICE|NTX100 Neuromodulation System - Active|Noninvasive peripheral nerve stimulation device programmed to active mode
223399642|NCT04030338|DRUG|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
223399643|NCT04030338|DRUG|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
224020377|NCT01683929|OTHER|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
224020378|NCT04020705|DEVICE|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
224130906|NCT03137121|DRUG|Olanzapine|Olanzapine is used as an anti-emetic.
224130907|NCT03137121|OTHER|Placebo|The placebo is a non-anti-emetic.
224130908|NCT03448978|BIOLOGICAL|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
224130909|NCT03448978|DRUG|Fludarabine|intravenous fludarabine
224130910|NCT03448978|DRUG|Cyclophosphamide|intravenous cyclophosphamide
224130911|NCT06226688|PROCEDURE|Biofeedback device and other group control group|Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
224130912|NCT06226688|PROCEDURE|Control group|Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
224130913|NCT02207478|PROCEDURE|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
223732091|NCT02689024|DRUG|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
224130914|NCT02207478|PROCEDURE|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
224130915|NCT00380211|BIOLOGICAL|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
224296971|NCT05214963|DEVICE|NTX100 Neuromodulation System - Sham|Noninvasive peripheral nerve stimulation device programmed to sham mode
223732092|NCT02689024|DRUG|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
223732093|NCT02689024|DRUG|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
223732094|NCT02689024|DRUG|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
223732095|NCT06522048|OTHER|Observational studies do not require intervention|This is an observational retrospective study and does not require any intervention.
223732096|NCT01831999|BEHAVIORAL|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
223732097|NCT03993431|DRUG|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
223732098|NCT03993431|DRUG|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
223732099|NCT05422599|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
223732100|NCT05422599|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
223732101|NCT05822219|BEHAVIORAL|COVID-19 vaccine and booster training, and importance|COVID-19 vaccine and booster information training
223732102|NCT02730325|OTHER|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
223732103|NCT02730325|OTHER|Placebo|
223732104|NCT03371992|DRUG|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
223732105|NCT03371992|DIAGNOSTIC_TEST|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
223732106|NCT03371992|OTHER|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
223732107|NCT04062721|DRUG|Chemotherapy|Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
224020379|NCT04020705|OTHER|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
224020380|NCT05937334|DIAGNOSTIC_TEST|Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma|lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
224130916|NCT00380211|BIOLOGICAL|Fluarix|
224130917|NCT02236728|DRUG|Pramipexole|
224130918|NCT00048399|DRUG|Fludarabine|
224130919|NCT00048399|DRUG|CAMPATH 1H|
224130920|NCT00048399|DRUG|FK506|
224130921|NCT00048399|PROCEDURE|Stem Cell Transplantation|
224130922|NCT00414778|DRUG|LHT344|
224130923|NCT02178293|DRUG|Benzidamine hydrochloride|
224130924|NCT02178293|DRUG|Ketoprofen lysine salt|
224296972|NCT01246622|DRUG|cytarabine|Given IV
224296973|NCT01246622|DRUG|lenalidomide|Given PO
224020381|NCT01248065|DRUG|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
224020382|NCT01248065|DRUG|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
224020383|NCT05956639|DRUG|6-month course of antiandrogen drugs|6-month course of Rezvilutamide and ADT + chemotherapy
224020384|NCT05956639|DRUG|Long-term course of antiandrogen drugs|Long-term course of Rezvilutamide and ADT + chemotherapy
224296974|NCT02963441|DEVICE|LumineticsCore (formerly IDX-DR)|Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
224296975|NCT02399735|BIOLOGICAL|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
223399644|NCT04030338|DIAGNOSTIC_TEST|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan. Upon completion of imaging and at the discretion of the investigator, the patient may be asked to void and get back in the scanner for 1 additional image of the pelvis.This additional image allows investigator's to see an unobstructed view of the prostate/prostate bed
223399645|NCT06694480|DRUG|FID-022|Advanced solid tumors
223399646|NCT07022717|BEHAVIORAL|Brief youth overdose prevention education|Providers in the intervention group will inform youth participants about: the risk factors for overdose, how to stay safe and prevent overdose, how to recognize an overdose, and how to respond to an overdose.
223399647|NCT07022717|OTHER|Information about Naloxone|Providers in the intervention group will inform youth participants how to use naloxone and offered a kit to take home.
223399648|NCT07022717|OTHER|Usual standard of care|Participants will be provided usual care by providers in the control group.
223399649|NCT00226499|BIOLOGICAL|Priorix-tetra™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
223399650|NCT00226499|BIOLOGICAL|Priorix™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
223399651|NCT00226499|BIOLOGICAL|Varilrix™|1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
223399652|NCT05584618|OTHER|Education|education
223399653|NCT00583765|DRUG|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
223399654|NCT05327400|OTHER|Pathological|The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
223399655|NCT02851017|OTHER|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
223399656|NCT06686342|OTHER|No intervention|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
223399657|NCT06686342|OTHER|No Intervention: Observational Cohort|The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
223399658|NCT06444399|DRUG|Deucravacitinib|6 mg administered orally twice daily for 24 weeks.
223399659|NCT07032467|OTHER|Psychosocial and Behavioral Assessment|Participants completed validated self-report questionnaires to assess levels of social media addiction and compulsive exercise behaviors. No therapeutic or experimental intervention was administered. Data were collected through surveys for observational analysis.
223551504|NCT05407116|OTHER|NCI PRO-CTCAE Questionnaire / EORTC QLQ-C30 Questionnaire|"PROs data will be collected prospectively via electronic questionnaires (PRO-CTCAE™), which is a patient-reported outcomes measurement system created to assess symptomatic toxicity in patients of cancer clinical research. PRO-CTCAE items evaluate frequency, severity, interference, amount, presence/absence symptoms. Each symptomatic adverse effect is measured by 1-3 features. GI items included nausea, vomiting, flatulence, bloating of the abdomen, constipation, diarrhea, abdominal pain, and loss of control of bowel movements. Urinary symptoms include the urge to urinate suddenly, frequency, urine colour change, loss of urine control (leakage).~Patients will also self-report health-related quality of life (QoL) in real-time, electronic PRO questionnaires (EORTC QLQ CX24, EN 24, C30) about QoL. Question 29 and 30 ask the patients to rate their overall health and QOL respectively during the past week on a scale between 1-7, where one is equivalent to very poor and seven is excellent."
223551505|NCT02366923|DEVICE|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
223551506|NCT02366923|DEVICE|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
223551507|NCT02200926|OTHER|Loaded breathing training|7 days/weeks, for 8 weeks
223551508|NCT02200926|OTHER|Unloaded breathing training|7 days/week, for 8 weeks
224020385|NCT02875886|DRUG|Amiloride|Combined with hydrochlorothiazide
224020386|NCT02875886|DRUG|Hydrochlorothiazide|Combined with amiloride
224020387|NCT02875886|OTHER|Low-sodium diet|
224020388|NCT04498091|BIOLOGICAL|Biological data|Biological data
224020389|NCT04498091|OTHER|Clinical data|Clinical data
224020390|NCT01830959|DRUG|Roflumilast|Roflumilast
224020391|NCT01830959|DRUG|Placebo|Placebo one a day
224020392|NCT03203031|PROCEDURE|General anesthesia|Standard general anesthesia
224020393|NCT03203031|PROCEDURE|Quadratus lumborum block|Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
224296976|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
224020394|NCT00584649|PROCEDURE|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
224020395|NCT05682391|OTHER|Bed rest|Strict bed rest ordered after surgery that does not allow the participant to elevate the head of bed over 30 degrees
224020396|NCT00893984|DRUG|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
224020397|NCT01820013|DEVICE|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
224020398|NCT01820013|DEVICE|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
223399660|NCT07035158|DIAGNOSTIC_TEST|Libra Oral Solution|EVOC Probe
223399661|NCT07032935|BEHAVIORAL|Virtual Reality Glasses will be used DURING CORONARY ANGIOGRAPHY APPLICATION|Virtual Reality Glasses will be used DURING CORONARY ANGIOGRAPHY APPLICATION
224020399|NCT01762501|DRUG|Azilsartan|Azilsartan 20mg/day
224020400|NCT01762501|DRUG|Amlodipine|Amlodipine 5mg/day
224020401|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
224020402|NCT01418989|DRUG|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
224020403|NCT02220673|DRUG|BHT 0.1%|
224020404|NCT02220673|DRUG|BHT 0.5%|
224020405|NCT02220673|DRUG|Placebo for RMT-B|
224020406|NCT02220673|DRUG|Placebo for HFA-MDI|
224020407|NCT02781844|DRUG|25mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
224296977|NCT02399735|BIOLOGICAL|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
223399662|NCT06707844|OTHER|Conventional treatment|"Conventional treatment will include:~* Stretching exercises (5Reps with 15sec hold): Gastrocnemius-soleus stretch, TA stretch.~* Strengthening exercises (5Sets, 5Reps, 5sec hold): Weight-bearing lunges, Short-foot exercise.~* Maitland mobilization Grade 2 \& 3 (3 Sets, 20Reps) at Talonavicular joint."
223399663|NCT06707844|OTHER|Myofascial release|"* Myofascial release is a manual therapy applying sustained pressure on the calf muscles to release fascial restrictions.~* Protocol: 3 sets of 2-minute pressure applications with a 1-minute break between sets~* Performed twice weekly for 3 weeks"
223551509|NCT02200926|OTHER|Placebo|7 days/week, for 8 weeks
223551510|NCT06554119|PROCEDURE|Huanlei Huang|tricuspid valve replacement or plasty
223551511|NCT02902445|BIOLOGICAL|rotavirus rapid screen test|According to routine care
223551512|NCT02902445|GENETIC|polymorphism exploration|from an oral swab collected after parents consent
223551513|NCT06373900|PROCEDURE|wound closure|Group A wound will be closed with Polypropylene and Group B wound will be closed with Polyglactin 910 suture. both wound closure followed for healing, infection and scar formation till 30th post operative day.
223551514|NCT01759342|BEHAVIORAL|Aerobic exercise|
223551515|NCT01759342|BEHAVIORAL|Resistance exercise|
223551516|NCT01759342|BEHAVIORAL|Flexibility and postural exercise|
223551517|NCT01759342|BEHAVIORAL|Balance exercise|
223551518|NCT03087604|PROCEDURE|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
223551519|NCT03087604|PROCEDURE|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
223551520|NCT03087604|DRUG|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
223551521|NCT00181818|DRUG|bupropion SR (sustained-release)|
223551522|NCT06192290|BEHAVIORAL|Home-based transitional Cardiac Telerehabilitation|This comprehensive series is divided into 16 parts, each addressing crucial aspects of open-heart surgery recovery. Part 1 introduces open-heart surgery, heart disease symptoms, and preoperative preparations for elderly patients. Part 2 delves into cardiac rehabilitation, defining objectives and detailing recovery stages. Part 3 covers care for surgical incisions and infection signs. Part 4 explores sleep and rest, while Part 5 guides patients on a healthy post-surgery diet. Part 6 focuses on nursing interventions for dyspnea, and Part 7 addresses post-surgery cough. Part 8 discusses nursing interventions for thrombosis prevention
223551523|NCT01460706|DRUG|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
223551524|NCT04300660|OTHER|neuropathic pain after thoracic surgery|analysis of perioperative factors implicated in the onset of postoperative pain after chest surgery and the incidence of neuropathic pain
223551525|NCT05227495|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
223551526|NCT05227495|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
223551527|NCT05075733|OTHER|Survey|Survey was sent to all the Americas Hepato-Pancreato-Biliary Association's members
223551528|NCT02840305|OTHER|Evaluation of visual function|
223551529|NCT02840305|OTHER|Magnetic Resonance Imaging|
223551530|NCT04884880|DRUG|Luo-Fu-Shan Plaster|Luo-Fu-Shan Plaster 10g，once daily，4 weeks
223399664|NCT06707844|OTHER|Tissue flossing|"Tissue flossing involves wrapping a latex band around the calf muscles with 50-75% elongation, followed by active ankle movements (dorsiflexion, plantarflexion, circles, heel raises).~Protocol: 4 sets of 8 repetitions, 10-second rest between sets Performed twice weekly for 3 weeks."
223399665|NCT07135687|DRUG|Losartan|Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.
223399666|NCT07135687|OTHER|Placebo|The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.
223551531|NCT04884880|DRUG|The placebo 10g|Placebo 10g，once daily，4 weeks
223551532|NCT02110485|OTHER|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
223551533|NCT00843440|DRUG|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
223551534|NCT04808713|BEHAVIORAL|Treatment|The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
223551535|NCT04212715|RADIATION|Pelvic SABR with intra-prostatic SABR|SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions to MR nodule
223551536|NCT03973112|DRUG|HLX10 3mg/kg|anti-PD-1
223551537|NCT03973112|DRUG|HLX04 5mg/kg|anti-VEGF, a biosimilar to Avastin
223551538|NCT03973112|DRUG|HLX04 10mg/kg|anti-VEGF, a biosimilar to Avastin
223551539|NCT04178928|DRUG|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
223732108|NCT04062721|PROCEDURE|Radiofrequency ablation (RFA)|Complete macroscopic ablation by RFA.
223732109|NCT04062721|DRUG|In situ immunotherapy|Hydrogel combining TLR or NOD2 agonist and GM-CSF will be injected in 1, 2 or 3 distinct lesions after RFA.
223732110|NCT00811473|DRUG|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
223732111|NCT00811473|DRUG|Placebo|Oral treatment once daily in the evening
223732112|NCT01163487|DRUG|Dichloroacetate|25-50mg/kg per day; oral
223732113|NCT01163487|DEVICE|EF5|21 mg/kg; IV
223732114|NCT04801108|PROCEDURE|Robotic or VATS lobar fissure completion|The lobar fissure adjacent to the target lobe will be completed using a surgical stapler through robotic or video-assisted thoracic surgery.
223732115|NCT04801108|DEVICE|Endobronchial valves placement|Endobronchial valves will be placed in the target lobe after the fissure completion.
223732116|NCT04127331|DEVICE|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
223732117|NCT03038230|DRUG|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
223732118|NCT03103607|DIAGNOSTIC_TEST|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
223732119|NCT03103607|DIAGNOSTIC_TEST|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
223732120|NCT00366288|DRUG|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
223732121|NCT00548925|DRUG|ABT-894|6 mg BID tablets, 8 weeks of treatment
223732122|NCT00548925|DRUG|placebo|BID tablets, 8 weeks of treatment
223732123|NCT01177917|OTHER|Infant Formula|
224020408|NCT02781844|DRUG|50mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
223399667|NCT07137117|OTHER|Behavioral Treatment|"Patients in the experimental group will be administered a Patient Information Form on the morning of surgery. Standard discharge education will be provided within 72 hours after surgery. After discharge, patients will be contacted at 1, 2, 3 weeks, and 2, 4, and 5 months for informational purposes only; no assessment will be administered. During this period, regular follow-up and support will be provided to enhance patient compliance with post-surgical care. The Interview Information Collection Form will be used during telephone interviews with patients to collect and evaluate current health data. This practice will ensure systematic and accurate recording of patients' current conditions. Patients will be contacted at 1, 3, and 6 months to complete the Medication Adherence Scale and the Nutrition and Exercise Attitude Scale, collecting data on medication adherence and behavioral attitudes. These assessments will be used as a systematic approach to monitoring patient adherence t"
223399668|NCT07137572|OTHER|Art Prescription|Any of the art interventions (theatre, dance, visual arts, music or cinema)
223732124|NCT01680705|OTHER|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
223732125|NCT02403154|PROCEDURE|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
223732126|NCT02403154|PROCEDURE|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
223732127|NCT03764865|PROCEDURE|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
223399669|NCT06715735|BEHAVIORAL|Theory-based health behaviour change intervention|The online individual education sessions are related to MetS, CKD, healthy dietary and PA, displayed in the form of texts and pictures, and online instant conversations via WeChat. The online group music-paced brisk walking training includes a 5-minute warm-up, 30-minute music-paced brisk walking, and 5-minute stretching exercises to promote cool-down. The group discussion is related to current health status, recommended dietary regimens, and exercise and personal goals. The telephone follow-up after the group discussion is to reinforce the predetermined goals and the practice of healthy dietary and music-paced brisk walking, and to provide opportunities for answering any questions related to the practice of healthy dietary and music-paced brisk walking. All the education session contents are based on a well-structured health handbook. The self-music-paced brisk walking is required to be performed for 30 minutes/day, 5 days/week.
223732128|NCT03764865|PROCEDURE|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
223732129|NCT03336853|DEVICE|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
223399670|NCT07035990|DRUG|SION-451|"* Pharmaceutical form: tablet~* Route of administration: oral"
223399671|NCT07035990|DRUG|SION-2222|"* Pharmaceutical form: capsule~* Route of administration: oral"
223732130|NCT03336853|OTHER|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
223732131|NCT00667368|DRUG|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
223732132|NCT01448811|DEVICE|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI\>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.
223732133|NCT01448811|PROCEDURE|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
223732134|NCT01585194|BIOLOGICAL|Ipilimumab|Given IV
223732135|NCT01585194|OTHER|Laboratory Biomarker Analysis|Correlative studies
223732136|NCT01585194|BIOLOGICAL|Nivolumab|Given IV
224020409|NCT02781844|DRUG|100mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
224020410|NCT05970679|DRUG|Ezetimibe/Atorvastatin 10/5 mg|DW1125
223732137|NCT05089760|OTHER|No intervention|This is a prospective observational cohort study. The purpose of the study was to compare the incidence of mortality, complications, and other outcomes between infants with multi-resistant bacteria sepsis and infants with sepsis caused by non-multi-resistant bacteria, and compare the incidence of complications and other outcomes between infants with sepsis-related death and infants who survive.
223732138|NCT04326348|DRUG|TQ05105|TQ05105 is a JAK2 inhibitor.
223732139|NCT00732615|DRUG|Placebo|Placebo for subcutaneous injection
223732140|NCT00732615|DRUG|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
223399672|NCT07035990|DRUG|SION-109|"* Pharmaceutical form: tablet~* Route of administration: oral"
223399673|NCT07035990|DRUG|Placebo SION-451|Placebo matched to SION-451
223399674|NCT07035990|DRUG|Placebo SION-2222|Placebo matched to SION-2222
223399675|NCT07035990|DRUG|Placebo SION-109|Placebo matched to SION-109
223399676|NCT07040033|OTHER|There will be no intervention|There will be no intervention
223732141|NCT05240456|DRUG|Beta3-Agonists, Adrenergic|The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
223732142|NCT05240456|DRUG|Anticholinergic drug, Solifenacin|Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
223732143|NCT01269060|PROCEDURE|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
223732144|NCT02310945|OTHER|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
223732145|NCT01341262|DRUG|Thalidomide|"* INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~* AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~* AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
224020411|NCT05970679|DRUG|Atorvastatin 5mg|DW1125A
224020412|NCT05970679|DRUG|Ezetimibe 10mg|DW1125E
224020413|NCT05970679|DRUG|Atorvastatin 10mg|DW1125A-1
223399677|NCT07040033|BEHAVIORAL|There will be no intervention|There will be no intervention
223399678|NCT01288963|DRUG|IL-2|Observation only
223399679|NCT06703437|DRUG|Dehydrated alcohol|Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.
223399680|NCT06703437|DRUG|Lidocaine IV|By periprostatic injection, 2mL
223399681|NCT02556229|DRUG|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
224020414|NCT05970679|DRUG|DW1125 placebo|Ezetimibe/Atorvastatin 10/5 mg placebo
223732146|NCT01341262|DRUG|Dexamethasone|"* INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~* AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
224296978|NCT01338649|DEVICE|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
223399682|NCT07047703|DRUG|Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers|Participants in Part A will receive a single dose of GRWD0715 on Day 1 only.
223399683|NCT07047703|DRUG|Part B - Multiple Ascending Dose (MAD) in participants with axSpA|Participants in Part B will receive GRWD0715 for 28 days
223399684|NCT07047703|DRUG|Part C - Safety expansion cohort in participants with axSpA|Participants in Part C will receive GRWD0715 for 12 weeks
223399685|NCT07047703|DRUG|Part D - Randomised, placebo-controlled, expansion cohort in participants with axSpA|Participants in Part D will receive GRWD0715 or placebo-to-match for 12 weeks
223399686|NCT03910400|DIAGNOSTIC_TEST|Computation of quantitative flow ratio|"After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR."
223732147|NCT01341262|DRUG|Zoledronic acid|"* INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
223732148|NCT01341262|DRUG|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
223732149|NCT01341262|DRUG|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
223732150|NCT02507674|DEVICE|ultrasound|
223732151|NCT06313931|DEVICE|cognitive training via immersive virtual reality|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using the cupboard task application.
223732152|NCT06313931|OTHER|cognitive training via paper and pencil|20 minutes per session, twice a week for six weeks (totaling 12 sessions), using cards.
223732153|NCT06313931|OTHER|motor stimulation|motor stimulation for 12 sessions (20 minutes per session)
223732154|NCT02539277|DRUG|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
223732155|NCT02539277|DRUG|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
223732156|NCT02539277|DRUG|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
223732157|NCT02539277|DRUG|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
224020415|NCT05970679|DRUG|DW1125A placebo|Atorvastatin 5mg placebo
224020416|NCT05970679|DRUG|DW1125E placebo|Ezetimibe 10mg placebo
224020417|NCT05970679|DRUG|DW1125A-1 placebo|Atorvastatin 10mg placebo
224020418|NCT00236093|DRUG|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
224020419|NCT02725801|DEVICE|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
224020420|NCT02725801|DEVICE|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
224020421|NCT04903587|DEVICE|Ultrasonography and MRI|Abdominal Ultrasonography and axial MRI
224020422|NCT00140751|DRUG|Lopinavir/ritonavir (drug)|
223732158|NCT01683955|DRUG|Tranexamic acid|Topical tranexamic acid (2g/100mL 0.9% saline)
223732159|NCT01683955|DRUG|Placebo|100mL 0.9% sterile saline
223732160|NCT00539409|PROCEDURE|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
223732161|NCT00293644|DRUG|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
223732162|NCT04337983|DEVICE|Transpulmonary thermodilution|Obtained by averaging the results of three thermodilution measurements. Each thermodilution is performed by injecting a bolus (15 mL) of cold saline (less than 10°C)
223732163|NCT04337983|DEVICE|Echocardiography|Daily echocardiography evaluation
224020423|NCT02518490|DEVICE|Sapphire Lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
224020424|NCT02518490|DEVICE|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
224020425|NCT02162589|PROCEDURE|POEM|Per oral endoscopic myotomy
224020426|NCT04078633|BEHAVIORAL|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
223399687|NCT07052084|DRUG|Vasopressin administration|Low dose of vasopressin (0.02ui /min), maximum 5 days
223399688|NCT07052084|DRUG|Sodium chloride administration|NaCl 0.9 %, maximum 5 days
224020427|NCT02349373|BEHAVIORAL|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
224020428|NCT02349373|BEHAVIORAL|16 week training period|Receipt of a weekly running schedule through an online training diary.
224020429|NCT03010176|DRUG|Ulevostinag|IT injection
224020430|NCT03010176|BIOLOGICAL|Pembrolizumab|IV infusion
224020431|NCT01749904|DRUG|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
224020432|NCT01749904|DRUG|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
224296979|NCT01338649|DEVICE|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
223732164|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 1|Containing macro and micronutrients
223732165|NCT02051777|DIETARY_SUPPLEMENT|Oral Nutritional Supplement 2|Containing macro and micronutrients
224020433|NCT01749904|DRUG|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
224020434|NCT01176279|PROCEDURE|Manual and automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.~In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.~Additional line washing is made through the fast flow valve of the system BD DTXPlus ™."
223399689|NCT00946920|DRUG|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
223399690|NCT00946920|DRUG|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
223399691|NCT07055594|DRUG|SOA101|Participants will receive SOA101. The RP2D will be determined based on the results of the Phase I study. During the dose expansion phase, participants will receive SOA101 at the RP2D regimen.
223399692|NCT04401215|BEHAVIORAL|Technology Augmented Treatment for Screening, Brief Intervention, Referral, and Treatment (SBIRT)|This group will answer to questions on the iPad at baseline visit and will receive up to 4 text messages per day asking about their Health and treatment during 30 days.
223399693|NCT01597973|DRUG|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
223551540|NCT01872585|BEHAVIORAL|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
223551541|NCT03544593|DEVICE|Revolve System|Fat grafting system
223551542|NCT00319202|DRUG|Candesartan|32 mg/d for 6 months
223551543|NCT00319202|DRUG|Placebo|Placebo administration for 6 months
223551544|NCT05129163|BEHAVIORAL|Exercise|The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.
223551545|NCT05129163|BEHAVIORAL|Nutrition activities|The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
223551546|NCT00293930|DRUG|Tacrolimus|
223551547|NCT03448016|RADIATION|[C-11]|Radiolabel
223551548|NCT03448016|DRUG|NOP-1A|Tracer
223551549|NCT05808582|DRUG|chidamide，fulvestrant|chidamide combined with fulvestrant
223551550|NCT02408679|PROCEDURE|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
223551551|NCT02408679|OTHER|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
223551552|NCT03890523|PROCEDURE|Airway stent implantation|The segmented airway stent modified with 3D printing were implanted to treat gastro-respiratory fistula involving carina and distal bronchi. The stents were removed because of stent-related complications or tracheobronchial healing.
223551553|NCT01740258|RADIATION|Radiation Therapy|
223551554|NCT01740258|DRUG|Temozolomide|
223551555|NCT01740258|DRUG|Bevacizumab|
223551556|NCT01437111|DRUG|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
223551557|NCT03107858|DRUG|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
223551558|NCT03107858|DRUG|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
223551559|NCT05116956|OTHER|non interventional|Multinational prospective, standard care data collection, non-interventional, study not involving human subjects
223551560|NCT01918241|DRUG|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
223551561|NCT01918241|DRUG|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
223551562|NCT01918241|DRUG|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
223551563|NCT01918241|DRUG|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
223551564|NCT02131311|DEVICE|disposable, single-use pessary|
223732166|NCT02051777|DIETARY_SUPPLEMENT|Dietary Advice|
223732167|NCT02095574|DRUG|[14C]ABT-199 (GDC-0199)|\[14C\]ABT-199 will be administered as a single oral administration
223732168|NCT01443988|DEVICE|iStent|Implantation of two iStent devices
223732169|NCT01443988|DRUG|Travoprost|Travoprost drops
223399694|NCT01597973|DRUG|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
223732170|NCT00241813|BEHAVIORAL|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
223732171|NCT00241813|BEHAVIORAL|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
223399695|NCT04777227|DRUG|Lidocaine injection|2% (20mg/ml) lidocaine solution
223399696|NCT04777227|DRUG|Physiological water injection|0.9% sterile sodium chloride water
223399697|NCT04777227|PROCEDURE|Debridement|A debridement was completed using a scalpel and number 15 blade, a podiatry drill and a spherical podiatry burr.
223399698|NCT04777227|PROCEDURE|Needle insertion|A 27-gauge needle on a 3 mL syringe was inserted at 10 to 15 degrees with the bevel facing up approaching from the IPK's right side
223399699|NCT05129774|PROCEDURE|Radical surgery with PALND|sufficient resection margins of the tumor, D3 dissection of the regional lymph nodes and para-aortic lymph node dissection from the bifurcation of iliac artery to the left renal vein via laparoscopic approach
223399700|NCT05129774|PROCEDURE|Radical surgery without PALND|surgery includes sufficient resection margins of the tumor and D3 dissection of the regional lymph nodes without PALND
223399701|NCT02353182|DRUG|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
223399702|NCT02353182|DRUG|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
223399703|NCT02353182|DRUG|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
223399704|NCT02353182|DRUG|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
223399705|NCT04382729|OTHER|Neuromuscular Electrical Stimulation|The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
223399706|NCT04382729|OTHER|Physical Therapy Exercise|The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
223399707|NCT00185289|DRUG|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
223399708|NCT00537173|PROCEDURE|Core Biopsy|biopsy
223399709|NCT00537173|PROCEDURE|Blood Collection|Blood/serum sample
223399710|NCT00537173|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
223732172|NCT00241813|BEHAVIORAL|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
223399711|NCT00537173|DRUG|Avastin|Avastin 10 mg/kg IV, day 1 and 15
223399712|NCT04435873|OTHER|"Survey using Your Home Dialysis Care Experience tool."|Validation of a new survey instrument to capture the experience of care by home dialysis patients.
223732173|NCT01334814|DEVICE|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
223732174|NCT00267384|DRUG|Oral N-Acetylcysteine|
223399713|NCT05192239|DRUG|THC 5|5 milligrams of THC in gummy form
223399714|NCT05192239|DRUG|Placebo|Commercially available non-THC fruit snack
223399715|NCT01654640|DRUG|Metformin|metformin 500mg p.o. bid for 24 weeks
223399716|NCT01654640|DRUG|Placebo (for metformin)|placebo 1T bid
223399717|NCT04108286|DEVICE|1-DAY ACUVUE MOIST|TEST
223399718|NCT04108286|DEVICE|DAILIES AQUA COMFORT PLUS|CONTROL
223399719|NCT04098341|DIAGNOSTIC_TEST|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
223399720|NCT03223350|DRUG|Capsaicin 0.1% Cream|Topical application
223399721|NCT03223350|DRUG|Placebos|placebo cream
223399722|NCT02983019|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
223399723|NCT00054795|DRUG|Motexafin Gadolinium|
223399724|NCT04133012|OTHER|Samplings|"* blood samples~* rectal biopsies~* nodes biopsies~* cutaneous fat tissues biopsies~* semen sample"
223732175|NCT00191789|DRUG|gemcitabine|1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
223732176|NCT00191789|DRUG|doxorubicin|60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)
223732177|NCT00191789|DRUG|cisplatin|70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)
223732178|NCT00191789|PROCEDURE|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
223732179|NCT05999136|OTHER|Pulses diet|Subjects in the PulD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PulD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with servings of pulses.
223732180|NCT05999136|OTHER|Plant proteins diet|Subjects in the PPD group will be assigned a personalized diet prepared based on their own eating habits as established by 7-day food diary recalls. Energy values of habitual diets will be kept unchanged during the PPD intervention. The diet will be characterized by isocaloric and isoprotein substitutions, replacing habitual servings of red meat or processed meat with a mixture of pulses and plant-based meat substitutes.
224130925|NCT01062568|DRUG|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
224130926|NCT01062568|DRUG|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
224296980|NCT02694471|BEHAVIORAL|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
224296981|NCT06219590|PROCEDURE|Acetylcholine Iontophoresis|Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
223399725|NCT05405816|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy for obesity
223399726|NCT05117216|BEHAVIORAL|Parental Vigilant Care (Parental training)|
223399727|NCT05117216|BEHAVIORAL|Technological Parental Monitoring|
223399728|NCT00993538|PROCEDURE|Blood sampling|
223399729|NCT00993538|PROCEDURE|Bone marrow aspiration|
223399730|NCT03398564|PROCEDURE|Erector Spinae Plan Block|The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
223399731|NCT03398564|PROCEDURE|Oblique subcostal TAP|ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
223551565|NCT00418093|DRUG|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
223551566|NCT00418093|DRUG|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
223551567|NCT00418093|DRUG|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
223551568|NCT00414323|DRUG|Duloxetine|
223399732|NCT03883321|OTHER|Cognitive behavioral stress management|Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
223399733|NCT02172443|DRUG|tiotropium inhalation powder capsules|
223399734|NCT02172443|DRUG|Atrovent|
223399735|NCT02172443|DRUG|placebo to Atrovent|
223399736|NCT02172443|DRUG|placebo to tiotropium inhalation capsules|
223399737|NCT00203333|DEVICE|Medtronic REVEAL|
223399738|NCT05683704|DRUG|AK105，Anrotinib hydrochloride|AK105 administered IV at day 1 every 3 weeks for 8-12 cycles Anrotinib administered PO at day 1-14 every 3 weeks for 8-12 cycles
223551569|NCT00414323|DRUG|Escitalopram|
223551570|NCT00414323|DRUG|Placebo|
223551571|NCT02623205|DRUG|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission. This additional 4-week treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
223551572|NCT02623205|DRUG|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders. This treatment option is something offered to participants outside the clinical trial, and therefore was not treated as part of the main study.
223551573|NCT03162796|DRUG|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
223732181|NCT05999136|OTHER|Habitual diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
223732182|NCT01922206|BEHAVIORAL|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
224130927|NCT01308723|DRUG|RO5323441|escalating doses iv
224130928|NCT01308723|DRUG|RO5323441|iv every 2 weeks
224130929|NCT01308723|DRUG|sorafenib|400 mg orally twice daily to once every other day
224138737|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at \<3-day and placebo supplementation at 6-wk postpartum.
224138738|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (6 wk postpartum)|Placebo supplementation at \<3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
224138739|NCT02043223|DIETARY_SUPPLEMENT|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at \<3-day and 6-wk postpartum
224138740|NCT02043223|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation, both at \<3-day and 6-wk postpartum.
224130930|NCT04498819|BEHAVIORAL|Wearable Activity Trackers, Exercise Prescription and Virtual Care|"The intervention is merging wearable activity trackers and tailored aerobic exercise prescriptions into the PCDSP's virtual STAND (a biweekly, evidence based, lifestyle medicine) program.~Participants will wear activity trackers for a week to collect baseline step data (used to create tailored step prescriptions). Biweekly, new step prescriptions will be tailored to each participant based on the previous two week's step count data. The intervention will add onto STAND classes by using activity tracker data into the class discussion for learning opportunities, as well as goal setting and action planning. The day of class, participants will receive a summary email new prescription and encouragement to continue to work hard, using the previous weeks' data to reinforce motivation. The activity tracker will provide instant feedback about step goals, sedentary behaviour and exercise minutes. Individual calls every other week will ensure adherence to exercise regime."
224130931|NCT05258708|BIOLOGICAL|mRNA-1273 COVID-19 vaccine|two doses of mRNA-1273 vaccine at 28-day intervals
223399739|NCT03961737|PROCEDURE|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
223399740|NCT03521011|DEVICE|MSCT|Non enhanced MSCT Abdomen
223551574|NCT03162796|DRUG|Placebo|Participants will receive matching placebo as SC injection.
223551575|NCT00190736|DRUG|Atomoxetine Hydrochloride|
223551576|NCT00190736|DRUG|placebo|
223399741|NCT06634420|BIOLOGICAL|NTLA-2002|CRISPR/Cas9 gene editing system delivered by lipid nanoparticle (LNP) for intravenous (IV) administration
223399742|NCT06634420|BIOLOGICAL|Normal Saline IV Administration|The administration of intravenous (IV) normal saline
223399743|NCT07065149|OTHER|1)0.1% Pinorox® Cream 2)1% Pinorox® Cream 3)Base cream 4)Positive control 5)Negative control|0.04 gm of each Test Products along with positive control (1% SLS) and negative controls will be applied on the back of subjects i.e. between the scapula and waist through finn chamber patch.
223399744|NCT00463372|DRUG|PF-02545920|
223399745|NCT01805063|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
223399746|NCT01805063|PROCEDURE|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
223551577|NCT01979718|DEVICE|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
223551578|NCT02342288|PROCEDURE|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
224020435|NCT01176279|PROCEDURE|Automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.~With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.~With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.~Line washing will be made through the fast flow valve of the system BD DTXPlus ™."
224020436|NCT04256629|DRUG|Verinurad|Randomized subjects will receive oral dose of verinurad
224020437|NCT04256629|DRUG|Placebo|Randomized subjects will receive oral dose of placebo
224020438|NCT04256629|DRUG|Allopurinol|Randomized subjects will receive oral dose of allpurinol (Treatment A and B)
224020439|NCT01404195|DIETARY_SUPPLEMENT|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
224020440|NCT00614601|BIOLOGICAL|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
224020441|NCT00140192|DRUG|creatine|
224020442|NCT00386373|DRUG|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
224020443|NCT02738944|BEHAVIORAL|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
224130932|NCT03711006|OTHER|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
224130933|NCT03586245|DIETARY_SUPPLEMENT|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
224130934|NCT03586245|DIETARY_SUPPLEMENT|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
224130935|NCT03586245|DIETARY_SUPPLEMENT|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
224296982|NCT06219590|PROCEDURE|Shame Acetylcholine Iontophoresis|Shame Acetylcholine Iontophoresis 15 min/ three sessions/ week for two weeks.
223399747|NCT06031090|DRUG|Clonidine Injection|intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
223399748|NCT06031090|DRUG|Granisetron Injection|intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.
223399749|NCT06031090|DRUG|Normal Saline 10 mL Injection|intravenous 10 ml normal saline 20 minutes before spinal anesthesia
223399750|NCT02433184|DRUG|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
223399751|NCT02433184|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
223399752|NCT02433184|DRUG|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
223399753|NCT02433184|DRUG|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
223399754|NCT02433184|DRUG|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
223399755|NCT02433184|DRUG|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
223399756|NCT01238159|RADIATION|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
223399757|NCT04968730|OTHER|Postoperative rehabilitation nursing|Make postoperative rehabilitation plan according to nursing experience for group A Develop rehabilitation process according to the activity plan for group B
223399758|NCT02817763|PROCEDURE|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
223399759|NCT02817763|PROCEDURE|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
223399760|NCT02817763|DRUG|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
223399761|NCT02724319|DEVICE|SpartanRX|A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
223399762|NCT00496717|DEVICE|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
223399763|NCT06778551|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A therapeutic exercise protocol will be carried out, consisting of 2 sessions per week for 8 weeks, supervised and guided by a physiotherapist. The objective is to improve thoracic mobility, as well as the strength and motor control of the scapular retractor and protractor muscles (middle and lower trapezius, rhomboids, and serratus anterior) and the rotator cuff.
223551579|NCT02342288|PROCEDURE|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
223551580|NCT02795299|DRUG|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
223551581|NCT02795299|DRUG|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
223551582|NCT02795299|DRUG|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
223551583|NCT02795299|DRUG|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
223551584|NCT02112539|OTHER|platelet aggregation measurement|
223551585|NCT01219101|DRUG|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
223551586|NCT01219101|DRUG|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
223551587|NCT01019122|RADIATION|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
223551588|NCT04032925|DEVICE|PICSO|"PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure."
223551589|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|"Fasting blood glucose (FBG), postprandial blood glucose, total cholesterol (CHO), triglycerides (TG), high-density lipoprotein cholesterol and low-density lipoprotein cholesterol (LDL-C), urea, creatinine, and uric acid by point colorimetric assay.~Serum irisin."
223551590|NCT05144672|OTHER|Anthropometric measurements|Height, weight, waist circumference, and hip circumference were taken as a way of assessing the nutritional status and BMI
223551591|NCT05144672|PROCEDURE|Electrocardiogram and Fundus examination|Fundus examination by direct ophthalmoscope
223551592|NCT05144672|OTHER|Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR) was calculated by EPI equation.
223551593|NCT05144672|OTHER|Brachial index|The ankle-brachial index test compares the blood pressure measured at your ankle with the blood pressure measured at your arm
223732183|NCT00759811|DRUG|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
223732184|NCT00759811|DRUG|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
223732185|NCT00721552|DRUG|Sitagliptin 100 mg|28 days administration of 100 mg daily
223732186|NCT00721552|DRUG|Prednisolone 30 mg|14 days administration of 30 mg daily
223732187|NCT00721552|DRUG|Sitagliptin-placebo|28 days administration once daily
223732188|NCT00721552|DRUG|Prednisolone-placebo|14 days administration once daily
223732189|NCT03577353|BEHAVIORAL|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
223732190|NCT03577353|BEHAVIORAL|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
223732191|NCT02236195|DRUG|Mocetinostat|
223732192|NCT00992576|DRUG|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
223732193|NCT00992576|DRUG|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
223732194|NCT02468544|OTHER|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
223732195|NCT00375076|DRUG|enoxaparin|
223732196|NCT03151460|DRUG|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
224020444|NCT02738944|BEHAVIORAL|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (\<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
224020445|NCT00536783|DRUG|Quetiapine|
224130936|NCT00000417|PROCEDURE|Counseling intervention|
223732197|NCT01822405|DRUG|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
223732198|NCT01822405|OTHER|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
223732199|NCT06145776|OTHER|tDCS + tredmill training (Standart trehab training)|Standart Rehab training will consist in 20 min treadmill gait training associated to active atDCS F3 2mA for 20 min.
224130937|NCT00000417|DEVICE|Informational film|
224130938|NCT02512744|PROCEDURE|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
224130939|NCT02512744|DEVICE|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
224130940|NCT04350229|DRUG|Drug omission|Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
224130941|NCT04350229|OTHER|Control group|No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
223399764|NCT06778551|OTHER|Control (Standard treatment)|The protocol will include the application of therapeutic ultrasound. For this application, ultrasound gel will be used to reduce friction and improve the transmission of waves. Using a 5 cm² transducer, pulsed ultrasound will be applied at a frequency of 3 MHz and an intensity of 1 W/cm² for 10 minutes. Patients will be informed that they should not feel any sensation during the procedure, and if they do, the intensity will be reduced. Finally, kinesitherapy will be applied through classic shoulder mobility exercises.
223399765|NCT05232383|DEVICE|polychromatic light|Application of polychromatic light at different times of day
223399766|NCT05232383|DEVICE|polychromatic light|Application of polychromatic light for 2h30 at different times of day with sleep
223399767|NCT05232383|DEVICE|red light|Application of red light at different times of day
224130942|NCT01026389|DRUG|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
224130943|NCT01026389|DRUG|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
224130944|NCT04812418|DIETARY_SUPPLEMENT|Noctesia|3 tablets every day at bedtime with a large glass of water
224130945|NCT04812418|DIETARY_SUPPLEMENT|Placebo|3 tablets every day at bedtime with a large glass of water
224130946|NCT00836277|DRUG|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
224130947|NCT00836277|DRUG|Irinotecan|125mg/m2 IV Day 1 and Day 8
224130948|NCT01995136|DRUG|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
224130949|NCT04482699|BIOLOGICAL|RAPA-501-Allo off-the-shelf Therapy of COVID-19|Allogeneic off-the-shelf RAPA-501 cells
224130950|NCT04482699|OTHER|Placebo|RAPA-501-Allo cell placebo
224130951|NCT00970528|DRUG|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
224130952|NCT00970528|DRUG|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
224296983|NCT02715544|OTHER|Healthy lifestyle|The families will receive a designed for these purposes intervention
224296984|NCT02715544|OTHER|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
224296985|NCT00967044|DRUG|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
223399768|NCT05232383|DEVICE|red light|Application of red light at different times of day with sleep
223399769|NCT05232383|DEVICE|green light|Application of green light at different times of day
223399770|NCT05232383|DEVICE|green light|Application of green light at different times of day with sleep
223399771|NCT07067736|OTHER|Cefazolin antibiotic prophylaxis|Determination of cerebrospinal fluid concentration
223399772|NCT07068139|OTHER|AI-Based Predictive Modeling|This is not a therapeutic or diagnostic intervention. The study uses a retrospective dataset of radiologic and pathological records to train and validate a deep learning model designed to predict tumor stage and survival in patients with non-small cell lung cancer (NSCLC). No experimental procedure is applied to participants.
223399773|NCT02389829|DRUG|Hydromorphone|
223399774|NCT02389829|DRUG|Prochlorperazine|
223551594|NCT05144672|DIAGNOSTIC_TEST|Laboratory tests|Glycosylated haemoglobin. ACR,urinary albumin (mg) and creatinine (g).
223551595|NCT05144672|RADIATION|Abdominal ultrasound.|It will be performed for patients only.
223551596|NCT05707338|PROCEDURE|Gastrectomy with lymph node dissection|"prospective randomized comparative clinical trial study analyzing outcomes of gastrectomy for early gastric cancer using laporoscopy versus open approach. This will be a prospective comparative study at Sohag University Hospital, Egypt and National Cancer Institute(NCI), Cairo university ,Egypt.~Patients were divided randomizly into two groups; the first group included patients who will have laparoscopic gastrectomy (Lap group), and the second group included patients will receive open gastrectomy (Open group)."
223551597|NCT03200483|OTHER|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
223551598|NCT03200483|OTHER|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
223551599|NCT03200483|OTHER|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
223551600|NCT03082677|DRUG|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
223551601|NCT04230616|PROCEDURE|total knee arthroplasty|total knee arthroplasty
223551602|NCT04230616|RADIATION|CT scan|The first 52 participants will recieve a pre- and postoperative CT scan of the hip, knee and ankle.
223399775|NCT02389829|DRUG|Diphenhydramine|
223399776|NCT01950468|DRUG|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
223399777|NCT01950468|DRUG|DaTscan|A single intravenous dose of 3 to 5 mCi
223399778|NCT02165163|OTHER|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
223399779|NCT00181727|DRUG|divalproex sodium extended release|
223399780|NCT03764774|DRUG|LY3463251|Administered SC
223399781|NCT03764774|DRUG|Placebo|Administered SC
223399782|NCT02362360|DEVICE|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
223399783|NCT02362360|DEVICE|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
223551603|NCT01110525|DRUG|AZD1981|4X100 mg per oral, twice daily for 28 days
223551604|NCT01110525|DRUG|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
223551605|NCT01110525|DRUG|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
223551606|NCT01027962|OTHER|ICBT Program|Intensive Computerized Brain Training.
223551607|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
223551608|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
223551609|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
223551610|NCT01181804|DRUG|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
223551611|NCT03996681|DRUG|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
223551612|NCT03163134|DEVICE|Lumbar Drain|
223732200|NCT06145776|OTHER|Cognitite-motor Dual Task Training (DT training)|The dual-task training protocol (DT) will consist in cognitive exercises (verbal fluency, mental screening tasks, discrimination, decision-making and reaction time tasks) and motor exercises (walking while carrying a tray with only one empty glasscarrying a glass while walks, change peaces from one pocket to another, looking from one side to another while walking)
224020446|NCT00321373|BIOLOGICAL|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
224020447|NCT00321373|BIOLOGICAL|FluarixTM|Single dose, Intramuscular injection
224020448|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
224020449|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
223732201|NCT05532839|OTHER|High intensity interval training|The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
224020450|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
224020451|NCT01383499|DRUG|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
224020452|NCT06098456|DRUG|EGCG, FA, HA, B12|Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg
224020453|NCT05600296|DRUG|Levobupivacaine|Evaluation the postoperative analgesic effects by using ultrasound-guided spermatic cord block (SCB) and IINB in children scheduled for elective open inguinal herniotomy. The study hypothesized that, the combined block with SCB and IINB would result in more effective postoperative analgesia than the use of IINB alone.
224020454|NCT05600296|PROCEDURE|Ilioinguinal/iliohypogastric nerve block (IINB)|Ilioinguinal/iliohypogastric nerve block (IINB)
223732202|NCT05532839|OTHER|Moderate intensity continuous training|The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
223732203|NCT06001476|PROCEDURE|Cold snare polypectomy|For eligible patients, use cold snare polypectomy to resect 5-9mm short-pedicled, broad-pedicled or sessile small bowel polyps
223732204|NCT02454881|DRUG|Dexmedetomidine|
223732205|NCT02454881|DRUG|Oxycodone|
223732206|NCT05008250|DRUG|Tongmai Yangxin Pill (TMYXP)|"TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction."
223399784|NCT07067827|OTHER|Self-administered questionnaire|The self-administered questionnaire was previously prepared by the research team for another project. It includes 14 questions addressing the dentition, fractures, joint hypermobility, height, and eye abnormalities present in the participants or their relatives. This questionnaire covers the clinical manifestations of rare bone diseases such as osteogenesis imperfecta, pycnodysostosis, hypophosphatasia, and osteopetrosis. This self-administered questionnaire will be filled online by participant. Average completion time of 20 minutes.
223732207|NCT05008250|DRUG|metoprolol tartrate|metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
223732208|NCT05008250|DRUG|placebo|simulated pills
224020455|NCT05600296|PROCEDURE|IINB+ Spermatic cord block|IINB+ Spermatic cord block
224020456|NCT01774487|DRUG|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
223732209|NCT02425657|BEHAVIORAL|Training of junior doctors|Training program
223732210|NCT01487226|DRUG|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks \* 6 cycles
224020457|NCT05690113|PROCEDURE|CATS scale|During the inclusion visit (J0), enrolled children will complete the CATS scale as well as the SCARED (Screen for Child Anxiety and Related Disorders). Their parents will also complete the CATS and the SDQ (Strength and Difficulties Questionnaire).
224296986|NCT00967044|DRUG|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
224020458|NCT04695743|OTHER|Online Cognitive Stimulation Therapy|Participants will attend 14 x 1 hour online CST sessions that involve a variety of activities to stimulate the brain and focus on cognitive strengths based on a variety of themes i.e. childhood, using money, etc. This will aim to be multisensory and give choice and empowerment to participants. Benefits of face to face CST are shown to slow cognitive decline and improve quality of life. Adapting it for online use will investigate whether participants can still benefit in this way.
224020459|NCT02843893|DEVICE|Measure the minimum intensity of a painful stimulation|With Neurolight device.
224020460|NCT00731809|RADIATION|FDG PET CT|FDG PET CT
224020461|NCT05220787|BIOLOGICAL|Cold stored platelets in 100% plasma stored for 10-14 days|Subjects will receive cold stored platelets from the start of surgery until 24 hours after the end of surgery
224020462|NCT05220787|BIOLOGICAL|Room temperature stored platelets in 100% plasma stored for up to 7 days|Subjects will receive room temperature stored platelets from the start of surgery until 24 hours after the end of surgery
224020463|NCT00346632|DRUG|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
224020464|NCT00616057|DIETARY_SUPPLEMENT|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
224020465|NCT00616057|DIETARY_SUPPLEMENT|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
224020466|NCT00918580|BIOLOGICAL|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
224296987|NCT00469157|DRUG|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
223399785|NCT07067827|OTHER|Family tree|For the family tree, this step is done by a telephone interview lasting a maximum of 45 minutes, depending on the size of the participant's family. The researcher will be able to reconstruct the family history with the index case. The family tree will then contain the family history up to the second degree of kinship with respect to the index cases. The information collected through the index cases when creating the family tree must include, for each relative, biological sex, as well as information on the presence or absence of a rare or genetic bone disease and clinical signs associated with these diseases, such as short stature, bone deformities, deafness, eye problems, etc.
223399786|NCT00133016|PROCEDURE|Amniotomy|
223732211|NCT01487226|DRUG|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks \* 6 cycles"
223732212|NCT00353912|DRUG|valsartan + amlodipine|
224020467|NCT00277576|BIOLOGICAL|ppdpSC18 administered by PMED|
224020468|NCT06208098|DIAGNOSTIC_TEST|Salivary cortisol dosage|saliva sample at 8 - 9h \& at T30
224020469|NCT03897764|PROCEDURE|Intraoperative superior hypogastric plexus block|SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
224020470|NCT04253080|BIOLOGICAL|Blood sample|Blood sample before treatment, 3 months after treatment and after 1 year or relapse or resumption of disease progression.
223399787|NCT04748562|DRUG|Progesterone|Taking prontogest vaginally
223399788|NCT01467297|DRUG|ceftidoren|ceftidoren 200 mg bid for 5 days
223399789|NCT01467297|DRUG|levofloxacin|levofloxacin 500 mg once daily for 7 days
223399790|NCT01738347|DRUG|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
224020471|NCT04253080|BIOLOGICAL|Cutaneous melanoma biopsy|Cutaneous melanoma biopsy before treatment, 3 months after treatment and relapse or resumption of disease progression.
223399791|NCT02084225|PROCEDURE|ultrasound guided regional nerve block|participants were the physicians performing the procedure
223551613|NCT01916824|DRUG|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
223551614|NCT04513769|BEHAVIORAL|Vegan diet|Participants will receive a behavioral intervention on a vegan diet in partnership with a local vegan soul food restaurant
223551615|NCT05475028|OTHER|RRBS|Reduced Representation Bisulfite Sequencing
223551616|NCT01626573|DRUG|Itacitinib|
223551617|NCT01626573|DRUG|Itacitinib Placebo|
223551618|NCT00109252|DRUG|Raptiva (efalizumab)|
223551619|NCT04758286|PROCEDURE|Emergency surgical procedures|COVID-19 patients who had presented to the Emergency Department were evaluated for their emergency surgical conditions and were managed appropriately
223551620|NCT00771927|DRUG|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
223551621|NCT00935506|DRUG|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
223551622|NCT00935506|DRUG|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
223551623|NCT06005558|DRUG|Normal saline|100 ml 0.9% Nacl over 20 minutes, followed by continuous infusion of normal saline for 72 hours.
223551624|NCT06005558|DRUG|Methylene Blue low dose|A bolus of MB 1mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
223551625|NCT06005558|DRUG|Methylene Blue high dose|A bolus of MB 4mg/kg in 100ml 0.9% Nacl over 20 minutes followed by continuous infusion of 0.25mg/kg/hour for 72 hours.
223551626|NCT04102904|OTHER|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
223551627|NCT06354348|DIAGNOSTIC_TEST|USG, Grip strength, Chair stand test (CST)|Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
223551628|NCT01559337|PROCEDURE|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
223551629|NCT00183144|BEHAVIORAL|Contingency management|
223551630|NCT00876707|DEVICE|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
223551631|NCT00876707|DEVICE|ReSTOR implant|Implant of multifocal IOL ReSTOR
223551632|NCT00876707|DEVICE|ReZoom implant|Implant of multifocal IOL ReZoom
223551633|NCT02645032|BIOLOGICAL|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
223732213|NCT00940251|DRUG|Mersina|capsule, 3g/day, 3 months
224020472|NCT05074797|DIAGNOSTIC_TEST|laboratory|laboratory data
224130953|NCT03544268|DEVICE|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
224130954|NCT03544268|DRUG|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
224130955|NCT04627116|DRUG|Tecarfarin|Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.
224130956|NCT01480492|DRUG|Telbivudine|600mg,1/d,one year
223732214|NCT00807157|DIETARY_SUPPLEMENT|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
223732215|NCT00807157|DIETARY_SUPPLEMENT|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
223732216|NCT00081380|DRUG|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
223732217|NCT00081380|DRUG|lithium (mood stabilizer)|
223732218|NCT00081380|DRUG|divalproex (mood stabilizer)|
223732219|NCT01922089|DRUG|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
223732220|NCT05083104|DIAGNOSTIC_TEST|laboratory investigations on coagulation profiles|CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
223732221|NCT04010682|OTHER|urine sample collection|no drug/devise intervention. sample collection study only
223732222|NCT05682781|DIETARY_SUPPLEMENT|Oral Nutritional Supplement|Oral Nutritional Supplement
223732223|NCT05682781|OTHER|Dietary Counseling|Dietary Counseling
223732224|NCT04458233|PROCEDURE|long axis FNA method|"). A long-axis view (i.e., a longitudinal image of the needle) is obtained by placing the US probe in a parallel position relative to the course of the needle. Short-axis and long-axis views can be used for both US assistance and guidance of FNA procedure. Correspondingly, approaching the nodule with the needle from the lateral or frontal aspect results in either a long axis or short axis view of the needle on the US screen"
223732225|NCT02662946|PROCEDURE|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
223732226|NCT02662946|PROCEDURE|No angiography|Extension of resection based on subjective measures
223732227|NCT04853979|OTHER|PRONE POSITION|Any combination of prone or side position for 3 hours, 3 times a day for 3 days
223732228|NCT05200520|BEHAVIORAL|Appetite Self-Regulation Intervention|The intervention will consist of content from Appetite Awareness Training (AAT), a cognitive-behavioral intervention to promote intuitive eating and the Diabetes Prevention Program (DPP)20, a behavioral lifestyle intervention. The goal of AAT is to enable participants to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants to reduce binge and overeating. Participants are taught to respond to external cues to eat (e.g., social gatherings), self-monitor the participant's adherence to biological signals of hunger and satiety, and to develop appropriate coping skills to manage urges to eat when not physically hungry.
224020473|NCT05277103|BEHAVIORAL|Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD|The intervention, Stay-Play-Talk with iPad, incorporates SGD instruction and peer training, both demonstrated to be effective in increasing communication and social interactions of preschool-age children with ASD. Children with ASD will be provided with an iPad with Touch Chat voice output app (the SGD) to use throughout the project. Two peers are recruited for each child with ASD. Research staff will implement peer training for three 30-min sessions, with peers taught to: STAY - sit close; PLAY- share and take turns; and TALK with iPad - look and listen/push and talk. After peers are trained, they will take turns engaging in common preschool games and preferred play activities with one assigned child with ASD (1 child:1 peer). Treatment will be provided for 15-20 min, twice per week for 8 weeks in the classroom.
224020474|NCT01159002|DEVICE|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
224130957|NCT00012896|BEHAVIORAL|Telephone Care + Educational (AV Materials)|
224130958|NCT04410198|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm description.
224130959|NCT05310994|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
223732229|NCT03716882|DEVICE|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
223732230|NCT02904473|OTHER|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
223732231|NCT02619292|BEHAVIORAL|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
223732232|NCT03241251|OTHER|questionnaire|Questionnaire of psychosocial risk factors
223732233|NCT02234453|DEVICE|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
223732234|NCT04903626|DRUG|Glecaprevir/Pibrentasvir (GLE/PIB)|Oral tablets
223732235|NCT05246761|DEVICE|Balloon catheter|In the two groups, if their bishop score \<6, they will receive the cervical riening by the balloon catheter, and then the oxytocin if necessary.
223732236|NCT01701557|OTHER|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
223732237|NCT01701557|OTHER|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
223732238|NCT03030508|OTHER|No intervention|
223732239|NCT04317131|DIAGNOSTIC_TEST|Research Diagnostic Criteria of Functional Disorders of the Masticatory System BKD / ZCURNŻ - Polish version|Interview and clinical examination of stomatognathic system based on standardized tool BDK/ZCURNŻ.
223732240|NCT04317131|DEVICE|Clinical examination of the stomatognathic system (structural and functional)|Examination with the use of JMA+Analyser (Jaw Motion Analyser) to analyse movement and function of the temporomandibular joints, mandibular position, condyle position (EPA), and access the muscle action potentials through bipolar skin surface electrodes EMG, assessment of occlusion by visual method according to Angle Classification.
223732241|NCT04317131|DEVICE|3D examination of the body posture|Comprehensive, three- dimensional examination of the body posture (static and dynamic) in the area of the spine, lower limbs and feet, performed by photogrammetric method (4th Generation MORA) and non- invasive image acquisition technology with the aid of infrared (Kineod) and The CQElektronik system.
223732242|NCT04317131|DEVICE|Functional assessment of the spine and lower limbs|Functional assessment of the spine and lower limbs mobility trough a wireless motion sensor Moover.
223732243|NCT04317131|DEVICE|Complementary tests|Anthropometric measurements (height, weight, waist and hip circumference, skin folds), foot pressure on the ground and body balance accessed by pedobarograph FreeMed, body mass components measured by the Tanita MC 980 MA (BIA method), evaluation of 7-days of physical activity by accelerometer ActiGraph GT3X-BT, blood pressure measurement by Medel Connect Cardio MB 10 monitor.
223732244|NCT03748758|COMBINATION_PRODUCT|Drug: OP0201|Drug OP0201
224020475|NCT01452659|DRUG|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
224020476|NCT01452659|DRUG|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
224020477|NCT01452659|DRUG|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
224020478|NCT01452659|DRUG|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
223732245|NCT03748758|COMBINATION_PRODUCT|Drug: Placebo|Placebo
224020479|NCT01079663|DRUG|Chlorhexidine 2.5 mg|
223551634|NCT02645032|BIOLOGICAL|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
224020480|NCT01079663|DRUG|Placebo chip|
224020481|NCT02372500|DIETARY_SUPPLEMENT|Chewing gum|Sugar free chewing gum
224020482|NCT05416541|BEHAVIORAL|social media|ASA I-II, who speaks and writes Turkish and do not have psychiatric illness patients will attend the study.
224020483|NCT03421626|DEVICE|Xpert BCR-ABL Ultra|Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
224020484|NCT03657654|OTHER|No intervention: observational only|No intervention: observational only
224020485|NCT04125732|BIOLOGICAL|AdVEGFXC1|AdVEGFXC1 at one of 4 doses
224020486|NCT02768311|PROCEDURE|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
224020487|NCT02768311|PROCEDURE|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
224020488|NCT02768311|PROCEDURE|hand files k-files|Procedure: hand files k-files
224020489|NCT03831373|OTHER|Physical exercise|Three physical exercise programs, two of resistance training with elastic bands and one of stretching exercises, all performed in a sitting position.
224020490|NCT03131583|DRUG|Colchicine|Day-14\~Day16 qd
224020491|NCT03131583|DRUG|Febuxostat|Day1 and Day8 qd
224020492|NCT03131583|DRUG|SHR4640|Day3\~Day8 qd
224020493|NCT00297232|DRUG|Natalizumab|
224020494|NCT04367012|OTHER|Abdominal Ultrasound|patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm
224130960|NCT05310994|DIETARY_SUPPLEMENT|Wasabi Leaf Extract Drink|consume 1 bottle per day
224130961|NCT05690334|DRUG|Crystalloid - 0 ml/kg|No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223551635|NCT02645032|BIOLOGICAL|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
223551636|NCT00169702|BEHAVIORAL|weight management program|12 sessions, psychoeducation
223551637|NCT00169702|BEHAVIORAL|weight management program|2 weekly, 12 sessions, psychoeducational weight management
223551638|NCT04651686|OTHER|Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery|All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
223551639|NCT00996957|BIOLOGICAL|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
223551640|NCT03884387|OTHER|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
223551641|NCT02961504|BIOLOGICAL|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
223551642|NCT02961504|BIOLOGICAL|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
223551643|NCT03711370|OTHER|Clear Bottle|These mothers received usual care from their pediatric providers and each mother was given 12 conventional, clear bottles of various sizes (4-12 ounces) that were compatible with a variety of different nipples manufactured by leading bottle companies. Mothers were also given handouts about proper formula preparation and paced bottle-feeding, which included messages about feeding in response to infant cues.
223551644|NCT03711370|OTHER|Opaque Bottle|These mothers received everything provided to the clear group, but instead received 12 opaque bottles of various sizes (4-12 ounces). These bottles were stainless steel and compatible with a variety of different nipples manufactured by a leading bottle company. Mothers in the intervention group also received an additional handout that contained safety tips for their opaque bottles (e.g., never microwave your bottle).
223551645|NCT00407602|DEVICE|Implant of Argus II Retinal Prosthesis|epiretinal implantation of device
223551646|NCT02063984|BEHAVIORAL|Intensive Outpatient Treatment (IOP) + Contingency Management (CM)|Multiple group sessions weekly, one individual counseling session weekly with teen to review and discuss contingency management abstinence-based incentives
223551647|NCT02063984|BEHAVIORAL|Working Memory Training|25 computer-delivered sessions of neurocognitive training
223551648|NCT03743714|OTHER|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
223732246|NCT00718952|DRUG|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
224130962|NCT05690334|DRUG|Crystalloid - 5 ml/kg|5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
224130963|NCT05690334|DRUG|Crystalloid - 10 ml/kg|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
224130964|NCT01044420|DRUG|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
223732247|NCT00718952|DRUG|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
223732248|NCT00718952|DRUG|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
223732249|NCT03971058|BIOLOGICAL|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
223732250|NCT04429139|DRUG|photodynamic therapy|PDT with Visudyne® was performed under general anesthesia according to the standard TAP study with some modifications: Verteporfin (6 mg/m2, Visudyne®; Novartis International AG, Basel, Switzerland) was injected intravenously with a standard 10-min infusion followed by followed by application of diode laser (Opal Photoactivator; Coherent Medical Group, Santa Clara, USA) (689 nm, 50 J/cm2, 600 mW/cm2) for 200 seconds to generate 120 J/cm2.
223732251|NCT04231357|DRUG|platelet rich plasma|platelet rich plasma prepared from peripheral blood using single spin centrifugation
223732252|NCT05613595|BEHAVIORAL|Positive Psychotherapy|"Positive Psychotherapy is an effective treatment for many mental disorders and depression is primary empirical target. Its primary goal is to build positive emotion, engagement, and meaning in life that will alleviate depression and other mental health disorders. Thus PPT may offer a new way to treat and prevent mental health issues.~Interventions sessions included, Session Records Session One: Positive Introduction and Gratitude Journal Session Two: Character Strengths and Signature Strengths Session Three: Practical Wisdom , Session Four: A Better Version of Me , Session Five: Open and Closed Memories, Session Six: Forgiveness Session Seven: Maximizing versus Satisficing, Session Eight: Gratitude ,Session Nine: Hope and Optimism, Session Ten: Posttraumatic Growth, Session Eleven: Slowness and Savoring, Session Twelve: Positive Relationships, Session Thirteen: Positive Communication, Session Fourteen: Altruism , Session Fifteen: Meaning and Purpose"
223732253|NCT05613595|BEHAVIORAL|Counseling Group|Caregivers in control group only regular counseling will be provided (psychoeducation). it will be based upon the insight of cerebral palsy and training based on Adaptive skill functioning of the CP child of the caregivers
223732254|NCT01895569|DRUG|Metformin|Metformin will be added to therapy for the first threre months.
224130965|NCT02543398|PROCEDURE|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
224130966|NCT01830543|DRUG|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
224130967|NCT01830543|DRUG|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
224130968|NCT01830543|DRUG|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
224130969|NCT01830543|DRUG|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
224130970|NCT01830543|DRUG|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
224130971|NCT01830543|DRUG|clopidogrel|One 75 mg tablet once daily for up to twelve months
223732255|NCT01895569|DRUG|Pioglitazone|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin, pioglitazone will be added.
223732256|NCT01895569|DRUG|Sitagliptin|In patients not well controlled (glycated hemoglobin \>6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
223732257|NCT04011761|OTHER|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
223732258|NCT00280098|DRUG|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
223732259|NCT01074112|DEVICE|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
223732260|NCT01074112|DEVICE|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
224130972|NCT01830543|DRUG|prasugrel|One 10 mg tablet once daily for up to twelve months
224130973|NCT01830543|DRUG|ticagrelor|One 90 mg tablet twice daily for up to twelve months
224130974|NCT03487900|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy for CD patients in clinical remission
224130975|NCT05806047|DRUG|chidamide combined with fulvestrant|chidamide combined with fulvestrant
224130976|NCT04513834|OTHER|GP will receive the educational outreach visit by a DAM (healthcare representative).|GP will receive the educational outreach visit by a DAM (healthcare representative).
224130977|NCT04513834|OTHER|Patient education material on PPI deprescribing will be sent to the patients|Patient education material on PPI deprescribing will be sent to the patients
223399792|NCT06582654|DEVICE|Sampling|"Collection of first-void urine (i.e. the initial stream of the urine) with the Colli-Pee device (Novosanis, Belgium) (6-21 samples over a period of 36 days).~Collection of blood samples (2 samples, at day 1 and 36 of the study)."
223399793|NCT06701591|OTHER|Kinesiotaping|Participants will be seated on a chair, KT will be applied bilaterally at the end of the expiration on the fifth to sixth and ninth to tenth intercostal muscles transversally and on the anterior and posterior axillary line longitudinally with 50% tension. In order to stimulate the muscle and support the function, the stimulation technique is usually applied from the origin to the insertion of the muscle with the recommended stretching of 25 to 50%.
223732261|NCT01074112|PROCEDURE|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
223399794|NCT06701591|OTHER|chest physical therapy|The chest physical therapy program is consisted of deep breathing exercises, postural drainage, and cough.
223551649|NCT04816981|DEVICE|EBUS-Elastography|Patients undergoing LN staging for lung cancer with EBUS-TBNA will have digital images and biopsy of every LN obtained in accordance with standards of care. Prior to the lymph node biopsy by EBUS-TBNA, elastography will be performed. The relative strain of tissues in the scanned area of the LNs will be displayed as a colour map, with stiffer areas in blue and softer tissue in red. Elastography and B-mode images will be displayed side by side and images recorded and saved onto an external drive for analysis. Elastography images will be fed to the NeuralSeg algorithm which has a network architecture similar to the standard U-Net for image segmentation. The automatically identified regions of interest will be overlaid onto the EBUS Elastography images to extract the LN stiffness measurements. After overlaying, NeuralSeg will determine the proportion of the LN area within 9 previously defined stiffness thresholds.
223551650|NCT04492241|DRUG|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.
223551651|NCT04492241|DRUG|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution|TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.
223732262|NCT01074112|DEVICE|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
223732263|NCT01074112|DEVICE|Cardiac Ultrasound|Ultrasound views of the heart
223732264|NCT02870296|BEHAVIORAL|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
223732265|NCT02206334|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
223732266|NCT00165776|DRUG|BOTULINUM TOXIN TYPE B|
223399795|NCT06650150|DIAGNOSTIC_TEST|maximal inspiratory pressure|maximal inspiratory pressure (mip) will be measured with a specific device
223551652|NCT02517398|DRUG|MSB0011359C|Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
223732267|NCT06501768|DRUG|Genistein|Escalation genistein dosing, followed by wash-out period
223732268|NCT00492583|DRUG|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
224020495|NCT04635592|DIAGNOSTIC_TEST|SARS-CoV2 nasal swab|SARS-CoV2 nasal swab and venous blood for SARS-CoV2 antibodies
224020496|NCT03562650|BEHAVIORAL|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
224020497|NCT03562650|BEHAVIORAL|Present Centered|Participants are asked to try to increase their focus on the present.
224130978|NCT03157973|OTHER|Education intervention|eHealth tool and standardized nurse-led follow-up.
223399796|NCT06650150|DIAGNOSTIC_TEST|maximal expiratory pressure|MEP will be measured with a specific device
223399797|NCT06650150|DIAGNOSTIC_TEST|6 minute walk test|6mwt will be done by a phsyotherapist
223399798|NCT05491317|BIOLOGICAL|GEN1042|Intravenous
223399799|NCT05491317|DRUG|Pembrolizumab|Intravenous
223399800|NCT05491317|RADIATION|Radiotherapy|Radiotherapy
223399801|NCT06370676|DIAGNOSTIC_TEST|Oesophageal temperature measurement|Oesophageal temperature measurement
223399802|NCT06065098|BEHAVIORAL|Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD|The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
223399803|NCT03854474|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223732269|NCT00492583|DRUG|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
224020498|NCT05337358|PROCEDURE|endocrown|endocrown
224020499|NCT05729178|OTHER|observational study|analysis of biomarkers of interest (DNA-RNA and proteins) in MNC purified from the subjects' blood
224020500|NCT03619070|OTHER|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
224020501|NCT03619070|OTHER|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
224020502|NCT03619070|OTHER|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
224020503|NCT03619070|OTHER|Control group, CG|The CG groups do not will performed the exercise.
224020504|NCT04684251|PROCEDURE|Coil embolisation of hemorrhoidal arteries.|Coil embolisation of hemorrhoidal arteries as previously described.
224020505|NCT04962243|PROCEDURE|Repair surgery for Achilles tendon rupture|Repair surgery for Achilles tendon rupture
224020506|NCT00946101|BIOLOGICAL|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
224130979|NCT00120120|DRUG|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
224130980|NCT01321931|DRUG|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
224130981|NCT01321931|DRUG|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
224130982|NCT01321931|DRUG|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
224020507|NCT00946101|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
224020508|NCT04224571|DRUG|Bortezomib Injection|Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
223399804|NCT03854474|PROCEDURE|Computed Tomography|Undergo CT
223732270|NCT00442078|DEVICE|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
223732271|NCT00767637|DRUG|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
223732272|NCT04673864|DRUG|CKD-386|QD, PO
223732273|NCT04673864|DRUG|D012, D326, D337|QD, PO
224020509|NCT04224571|DRUG|rituximab injection|Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
224020510|NCT00992433|BIOLOGICAL|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
224020511|NCT02236104|DEVICE|Plethysmography opto electronic|
224020512|NCT02236104|PROCEDURE|respiratory parameters|
223732274|NCT06431490|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
223732275|NCT03330769|DRUG|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
223732276|NCT00251550|DRUG|Pemetrexed|
223732277|NCT00251550|DRUG|Cisplatin|
223732278|NCT00479076|DRUG|aflibercept (AVE0005)|intravenous infusion
223732279|NCT00479076|DRUG|S-1|oral administration
223732280|NCT00408356|DRUG|Zinc|
223732281|NCT03053804|RADIATION|MR/PET|MR/PET with contrast media and FDG-18
223732282|NCT02622321|DRUG|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
223732283|NCT02622321|DRUG|rFVIIa|Participants will continue to receive rFVIIa.
224020513|NCT02318992|BIOLOGICAL|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
223399805|NCT03854474|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224020514|NCT00994500|DRUG|vorinostat|Given orally
223399806|NCT03854474|BIOLOGICAL|Pembrolizumab|Given IV
223399807|NCT03854474|DRUG|Tazemetostat|Given PO
223399808|NCT05639465|BEHAVIORAL|JoH-C19|Journey of Hope- COVID 19 (JoH-C19) includes eight, 1-hour consecutive sessions delivered in groups of 8 children during the school day and in after school settings. The 1.5 hour JoH-C19 caregiver workshop is delivered with groups of 8 parents prior to the child JoH-C19 curriculum
223551653|NCT04114916|DIETARY_SUPPLEMENT|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
223551654|NCT04114916|DIETARY_SUPPLEMENT|maltodextrina|Two capsules daily at breakfast and dinner.
223551655|NCT04884750|BEHAVIORAL|ECA-ACE Vaccination Promotion Intervention|A smartphone-based embodied conversational agent that educates users and motivates them to obtain vaccinations for SARS-CoV-2 and Influenza, according to Boston Public Health Commission guidelines.
223551656|NCT01574287|DRUG|FACBC|Drug is give intravenously over 2 minutes at time of scan
223551657|NCT00005947|BIOLOGICAL|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
223551658|NCT00005947|BIOLOGICAL|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
223551659|NCT02137018|DEVICE|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
223551660|NCT02137018|DEVICE|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
223551661|NCT06305780|DRUG|IVIG + Coordinated Care|Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
223732284|NCT02622321|DRUG|aPCC|Participants will continue to receive aPCC.
223732285|NCT04464369|DRUG|itopride|itopride is a gastroprokinetic drug that has previously been evaluated in the treatment of functional dyspepsia and which is available in a number of countries worldwide
223732286|NCT04464369|DRUG|Placebo|placebo pills matching the look and weight of the itopride tablets
223732287|NCT00349804|OTHER|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
223732288|NCT00886899|DEVICE|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
224020515|NCT00994500|DRUG|bortezomib|Given IV
224020516|NCT00994500|OTHER|pharmacological study|Correlative studies
224020517|NCT00994500|OTHER|laboratory biomarker analysis|Correlative studies
224020518|NCT02196454|OTHER|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
224020519|NCT01925287|DIETARY_SUPPLEMENT|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
223732289|NCT04120545|DEVICE|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
223732290|NCT04120545|DEVICE|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
223732291|NCT00965718|BIOLOGICAL|Activated T lymphocyte|Intravenous dripping of 200 ml (109\~2 1010 lymphocytes/60 kg adult) for 1 hour.
223732292|NCT00241280|DEVICE|etafilcon A|
224020520|NCT02358759|PROCEDURE|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
223732293|NCT00241280|DEVICE|galyfilcon A|
224020521|NCT04490382|DEVICE|32 channel external stimulator|Patients will be stimulated by the 32 channel external stimulator via leads placed as part of standard care neuromodulation. Then patients will undergo various tasks.
223732294|NCT02835404|DRUG|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
223732295|NCT02835404|RADIATION|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
223732296|NCT02835404|RADIATION|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
224020522|NCT05370001|OTHER|Entotracheal tube size|Compare the levels of carbon dioxide and if it is related to ETT size when using size 9 (routine) or size 8 (intervention).
223732297|NCT00138203|DRUG|vorinostat|Given PO
223732298|NCT00138203|OTHER|laboratory biomarker analysis|Correlative studies
223732299|NCT02148198|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
223732300|NCT02148198|DIETARY_SUPPLEMENT|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
223732301|NCT01092611|PROCEDURE|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
223732302|NCT01092611|BIOLOGICAL|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
223732303|NCT05712616|DRUG|Strontium Ranelate|Dual mode of action, anabolic and anti-resorptive
223732304|NCT05712616|DRUG|Lacto-N-Hexaose|Placebo look alike drug
223732305|NCT00969202|RADIATION|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
223732306|NCT02820272|PROCEDURE|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
223732307|NCT02820272|PROCEDURE|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
223732308|NCT02820272|PROCEDURE|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
223732309|NCT00144092|PROCEDURE|stem cell source|
223732310|NCT00140595|DRUG|rituximab|
223732311|NCT00140595|DRUG|doxorubicin|
223732312|NCT00140595|DRUG|cyclophosphamide|
223732313|NCT05117320|DEVICE|AI support|Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
223732314|NCT00438113|DRUG|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
223732315|NCT01194180|BIOLOGICAL|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
223732316|NCT01194180|BIOLOGICAL|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
223732317|NCT02715674|DEVICE|Plasti-med TRIFLO|
223732318|NCT02715674|DEVICE|BIPAP VISION|
223732319|NCT02715674|DEVICE|Plasti-med oxygen therapy mask|
223732320|NCT03383172|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
224020523|NCT05490719|DRUG|QL1706|QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
224020524|NCT03391401|PROCEDURE|Bariatric surgery|Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
224020525|NCT04810143|DEVICE|Mitra Microsampler|an FDA Class I medical device for direct specimen collection of blood or other biological fluids
224020526|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
224020527|NCT00552240|DRUG|tenofovir DF 300 mg QD|300 mg QD
223732321|NCT02418026|OTHER|hypnosis|Conversational hypnotic induction and therapeutic suggestions
223732322|NCT00147199|DRUG|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
223732323|NCT00147199|DRUG|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
223732324|NCT03066271|OTHER|Exercise +|Usual care
223732325|NCT03066271|OTHER|Control +|Usual care
224020528|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
224020529|NCT00552240|DRUG|emtricitabine 200 mg QD|200 mg QD
224020530|NCT00552240|DRUG|Nevirapine 200 mg BID|200 mg BID
224020531|NCT00552240|DRUG|Atazanavir 300 mg|300 mg QD
224020532|NCT00552240|DRUG|Ritonavir 100 mg|100 mg QD
224130983|NCT02059213|DRUG|Ibrance|
224130984|NCT02059213|DRUG|Bicalutamide|
224130985|NCT02059213|DRUG|Zoladex|
223732326|NCT04570150|DRUG|Sugammadex|Subjects who are randomized to into the sugammadex arm (Arm I) will receive sugammadex for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm II (neostigmine group).
223399809|NCT05639465|BEHAVIORAL|Switch off Get Active|Switch off Get Active covers 4 topics, and its eight, 1- hour sessions are delivered in groups of 8 children. The 1.5 hour Switch Off Get Active caregiver workshop is delivered with groups of 8 parents prior to the Switch off Get Active child curriculum
223732327|NCT04570150|DRUG|Neostigmine|Subjects who are randomized into the neostigmine arm (Arm II) will receive neostigmine for reversal of neuromuscular block at the completion of their anesthetic; Outcomes measures will be recorded and compared with those from Arm I (sugammadex group).
224020533|NCT02822313|DRUG|Coppertone (BAY987518)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-76\_V27-006)
223732328|NCT04712305|OTHER|No intervention required|No intervention required
224020534|NCT01453803|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
224020535|NCT00681460|DRUG|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
224020536|NCT00681460|DRUG|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
224020537|NCT06020742|PROCEDURE|Autologous USC mitochondrial oocyte transplantation|Mitochondria are isolated from urine derived stem cells from fresh middle urine of the subjects, and injected into the cytoplasm of mature oocytes together with sperm
224020538|NCT02784951|DRUG|Red blood cells (0Rh D-neg)|Fresh produced RBC
224020539|NCT02784951|DRUG|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
224020540|NCT02784951|DRUG|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
224020541|NCT00801931|DRUG|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
223732329|NCT01850524|DRUG|Ixazomib|IXAZOMIB capsules.
223732330|NCT01850524|DRUG|Placebo|IXAZOMIB matching-placebo capsules.
223732331|NCT01850524|DRUG|Dexamethasone|Dexamethasone tablets.
223732332|NCT01850524|DRUG|Lenalidomide|Lenalidomide capsules.
223551662|NCT06305780|DRUG|IVIG Placebo + Coordinated Care|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.~Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator."
223551663|NCT06305780|DRUG|Ivabradine + Coordinated Care|Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
223551664|NCT06305780|DRUG|Ivabradine Placebo + Coordinated Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator."
223551665|NCT06305780|DRUG|IVIG + Usual Care|Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
223551666|NCT06305780|DRUG|IVIG Placebo + Usual Care|"Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.~Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration."
223551667|NCT06305780|DRUG|Ivabradine + Usual Care|Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
223551668|NCT06305780|DRUG|Ivabradine Placebo + Usual Care|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration."
223551669|NCT00402129|PROCEDURE|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
223732333|NCT00368355|DRUG|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
223732334|NCT00368355|DRUG|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
223732335|NCT00368355|BIOLOGICAL|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
223732336|NCT00368355|RADIATION|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
224020542|NCT00801931|RADIATION|Total Body Irradiation|
224020543|NCT00801931|DRUG|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
224020544|NCT00801931|DRUG|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration \>0.5 mg/mL), through a central venous access device over 2 hours.
224020545|NCT00801931|DRUG|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
224020546|NCT00801931|DRUG|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
223551670|NCT05287243|OTHER|inspiratory muscle training|Participants will complete inspiratory muscle training daily in their homes for 12 weeks. The dosage will depend on their initial maximum pressure. At the end of the 12 week intensive period, participants will reduce the inspiratory resistance by a third and continue a maintenance training for an additional 12 weeks.
223551671|NCT05043948|DIAGNOSTIC_TEST|Blood samples|for evaluation of the genome-wide association study
224130986|NCT02059213|DRUG|Lupron Depot|
224130987|NCT03605719|DRUG|Carfilzomib|Given IV
223399810|NCT07074145|BEHAVIORAL|Heart Health and Nutrition for Life (HHNL)|The CHW-led educational intervention will draw on two evidence-based programs, Healthy for Life (American Heart Association) and Your Heart, Your Life (NHLBI). Both curricula are designed to be facilitated by community health workers/promotores de salud and have been tested in both English and Spanish. Study-adapted curricular elements will include 12 core educational activities, delivered in six, two-hour, in-person sessions. In the context of expected family and work obligations alongside limited resources of FNCH patients, the investigators anticipate structuring sessions over, at most, 2 months with a class size of approximately 5-15 patients. In the CHW-led educational intervention, participants will learn about topics such as understanding risk for heart disease, the importance of physical activity, affordable healthy eating, and how family members can support health.
223399811|NCT07074145|BEHAVIORAL|Self-Measured Blood Pressure|Self-measured blood pressure (SMBP) is a proven, cost-effective strategy to improve blood pressure control by promoting patient engagement and medication adherence. All study participants will receive the same validated BP monitor, with cuff sizes adjusted as needed, selected from the US Blood Pressure Validated Device Listing. Patients will be trained using the AMA's 7-Step SMBP Quick Guide, consistent with FNCH clinical education practices. They will be asked to record baseline BP readings and complete at least one SMBP cycle per month during the 12-month study. Each cycle includes at least three consecutive days of morning and evening BP measurements.
223399812|NCT02208362|BIOLOGICAL|Arm 1: IL13Ra2-specific CAR Tcm cells|Given via intratumoral catheter
223399813|NCT02208362|BIOLOGICAL|Arm 2: IL13Ra2-specific CAR Tcm cells|Given via intratumoral/intracavitary catheter
223399814|NCT02208362|BIOLOGICAL|Arm 3: IL13Ra2-specific CAR Tcm cells|Given via intraventricular catheter
223399815|NCT02208362|BIOLOGICAL|Arm 4: IL13Ra2-specific CAR Tcm cells|Given via intratumoral or intracavitary, and via intraventricular catheter
223399816|NCT02208362|BIOLOGICAL|Arm 5: IL13Ra2-specific CAR Tn/mem cells|Given via intratumoral or intracavitary, and via intraventricular catheter
223399817|NCT02208362|OTHER|Laboratory Biomarker Analysis|Correlative studies
223399818|NCT02208362|PROCEDURE|Magnetic Resonance Imaging|Correlative studies
223551672|NCT03091088|OTHER|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
223732337|NCT00368355|PROCEDURE|Stem Cell Infusion|Stem cells are infused on day 0
223732338|NCT01847417|DRUG|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
223732339|NCT01847417|DRUG|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
223732340|NCT01847417|DRUG|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
223732341|NCT01847417|DRUG|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
223732342|NCT00210002|DRUG|Darbepoetin alfa (Aranesp®)|
223399819|NCT02208362|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Correlative studies
223399820|NCT02208362|OTHER|Quality-of-Life Assessment|Ancillary studies
223399821|NCT04052555|DRUG|Berzosertib|Given IV
223551673|NCT03091088|OTHER|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
223551674|NCT00429182|DRUG|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
223551675|NCT00429182|DRUG|Cyclophosphamide|1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
223551676|NCT00429182|DRUG|Thiotepa|120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
223732343|NCT00210002|DRUG|Ferric saccharose(Venofer®)|
223732344|NCT03579160|DRUG|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
223732345|NCT03579160|OTHER|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
223399822|NCT04052555|PROCEDURE|Biospecimen Collection|Correlative studies
223399823|NCT04052555|OTHER|Quality-of-Life Assessment|Ancillary studies
223399824|NCT04052555|OTHER|Questionnaire Administration|Ancillary studies
223399825|NCT04052555|RADIATION|Radiation Therapy|Undergo RT
223551677|NCT00429182|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0.
223551678|NCT04982705|DRUG|[Part 1.1] IDG-16177|\[Part 1.1\] Subjects will receive a single oral dose of IMP. Dose strenght for each cohort (Cohort 1-5) is planned as 0.5, 1, 2, 5, 10mg, respectively.
223551679|NCT04982705|DRUG|[Part 1.1] Placebo of IDG-16177|\[Part 1.1\] subjects will receive a single oral dose of IMP.
223551680|NCT04982705|DRUG|[Part 2] Sitagliptin|Administration of Sitagliptin 100mg once daily for 4 weeks.
223551681|NCT04982705|DRUG|[Part1.2] IDG-16177|\[Part 1.2\] Administration once daily for 14 days; Dose strenght for each cohort (Cohort 6-8) is planned as ≤ 2, ≤ 4, ≤ 8mg, respectively.
224130988|NCT03605719|DRUG|Dexamethasone|Given IV
224130989|NCT03605719|BIOLOGICAL|Nivolumab|Given IV
224130990|NCT03605719|BIOLOGICAL|Pelareorep|Given IV
223399826|NCT06046066|DRUG|NM6603|NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
223399827|NCT07077174|OTHER|Permissive lung-protective ventilation|The goal is to achieve the lowest possible respiratory rate (RR) according to a guideline in which the target RR is estimated by combining the baseline RR with the results of arterial blood gas analysis (ABG), determined by the highest acceptable partial pressure of carbon dioxide (PaCO2) of ≤ 8.5 kPa (64 mmHg) but limited by the lowest acceptable arterial pH (pHa) of \> 7.20. The RR is gradually decreased, in steps of 2 breaths every 10 minutes, based on continuous end-tidal CO2 monitoring. To ensure that the pHa does not fall below 7.20, following randomization, ABGs are repeated every hour until the target RR is reached, for at least 6 hours. Thereafter, blood gas analyses are repeated at least every 8 hours (at the start of every nursing shift). Down-titration of RR stops at a rate of 4 breaths per minute. This approach continues until the switch to spontaneous breathing. Of note, when the pHa is \> 7.50, this must first be decreased to ≤ 7.50 based on local protocol.
223399828|NCT07077174|OTHER|Conventional lung-protective ventilation|Following randomization, which should happen within 1 hour after start of ventilation in the ICU, the RR is set according to standard of care, based on continuous end-tidal CO2 monitoring, to target a normal PaCO2 (4.7-6.4 kPa or 35-48 mmHg) combined with a pHa within the range of 7.35 to 7.45. Following randomization, blood gas analyses are repeated every hour for at least 6 hours, and thereafter at least every 8 hours (at the start of every nursing shift). This approach continues until the weaning phase.
223399829|NCT05319574|RADIATION|SBRT|Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy
223399830|NCT05319574|DRUG|Tislelizumab|200mg q3w for two cycles administrated concurrently with chemotherapy
223399831|NCT03746431|DRUG|[111In]-FPI-1547 Injection|\[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
223399832|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection multi-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
223399833|NCT03746431|BIOLOGICAL|FPI-1175 Infusion|FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
223399834|NCT03746431|DRUG|[225Ac]-FPI-1434 Injection single-dose|\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
223399835|NCT06929312|OTHER|Tabletop simulation based teaching|a pre tested and validated questionnaire was used as a tabletop simulation method on Cholera outbreak.
223399836|NCT06929312|OTHER|conventional class room teaching|conventional class room lecture using power point was delivered on Cholera outbreak.
223399837|NCT06930495|DRUG|Weight loss SOC Treatment with second generation anti-diabetic medications|To determine the best incretin-based drug for the treatment \[done as part of regular standard of care (SOC) treatment\], participants will go to UTSW weight wellness clinic and undergo a comprehensive history and physical exam to evaluate their overall health. This information is used to create an individualized approach to the participants weight loss regimen. As part of the regimen, participants will receive guidance on initiating lifestyle modifications including diet and exercise and may be referred to a clinical psychologist for evaluation and management of factors like stress, anxiety and depression, and exercise which may influence their health behaviors and body weight.
223399838|NCT06618222|DEVICE|Wingspan stent system|All patients had received Percutaneous transluminal angioplasty and stenting with Wingspan stent system.
223399839|NCT03798028|BIOLOGICAL|UC-MSCs|The UC-MSCs will be administrated by intravenous injection at the dose of 1×10\^6 cells/kg.
223399840|NCT07084389|BEHAVIORAL|FinSoc|Financial Social Work intervention (FinSoc) The FinSoc intervention is a structured financial social work program designed for families experiencing complex financial difficulties. It consists of five modules, each delivered in a one-on-one session with a trained social worker. The modules focus on key areas such as budgeting, emotional and relational aspects of money, financial decision making, building long-term financial capability. The intervention aims to reduce financial anxiety, strengthen economic self-efficacy, and support overall wellbeing. Motivational interviewing techniques and client-centred approaches are used throughout to encourage active participation and goal-setting.
223551682|NCT04982705|DRUG|[Part 2] IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
223551683|NCT04982705|DRUG|[Part 1.2] Placebo of IDG-16177|\[Part 1.2\] Administration once daily for 14 days.
223551684|NCT04982705|DRUG|[Part 2] Placebo of IDG-16177|\[Part 2\] Administration once daily for 4 weeks.
223551685|NCT06197074|OTHER|Ultrasound assessment|The morphological characteristics of the quadriceps muscle of the participants will be assessed using ultrasound.
223551686|NCT03939338|OTHER|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
223551687|NCT05878977|DRUG|Immune checkpoint inhibitor|Identification of novel predictive and prognostic biomarkers for immunotherapy treatment response in metastatic melanoma
223732346|NCT02317068|DEVICE|HBR|
224020547|NCT00801931|DRUG|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
224020548|NCT00801931|DRUG|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG \[horse\]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
224296988|NCT03382314|COMBINATION_PRODUCT|HDDO-1614|"* Combination drug (Bazedoxifene + Cholecalciferol)~* Incrementally modified drug~* Not market authorized product"
224296989|NCT03382314|DRUG|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
223732347|NCT02317068|DEVICE|DD|
224020549|NCT00801931|DRUG|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
224296990|NCT03823014|DEVICE|Elator|Measurement for device, use of device
223732348|NCT01488682|PROCEDURE|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
223732349|NCT01488682|PROCEDURE|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
223732350|NCT05148754|DRUG|Elsulfavirine|Elsulfavirin 200 mg tablets.
223399841|NCT07095218|DEVICE|Application of Tacs|In this study, a single 20-minute session of tACS will be administered over the bilateral dorsolateral prefrontal cortex (DLPFC) at various gamma frequencies (40 Hz, 80 Hz, individual gamma frequency) and in a theta-gamma coupling range (6-80 Hz). A sham stimulation group will also be included. The anodal surface electrode will be placed over the left DLPFC (F3 according to the 10-20 system), and the cathodal electrode over the right DLPFC (F4). Pre- and post-stimulation cognitive performance will be assessed using neuropsychological tests, while EEG will be used to evaluate theta-gamma phase-amplitude coupling and oscillatory changes.
223732351|NCT00735956|BEHAVIORAL|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
223732352|NCT01622153|PROCEDURE|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
223732353|NCT01622153|PROCEDURE|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
223732354|NCT04867538|OTHER|no intervention|No intervention
223732355|NCT00194064|DRUG|Olanzapine|
223732356|NCT00860964|DRUG|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
223732357|NCT00860964|DRUG|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
223732358|NCT01563003|OTHER|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
223399842|NCT05081063|COMBINATION_PRODUCT|Routine labs|Routine labs will be performed with CBC, BMP, Fox screen, ROTEM viscoelastic test, PT/INR, PTT and venous lactate for standard of care for all patients.
223399843|NCT07096895|PROCEDURE|EDEE (EUS-directed transenteric ERCP)|Technical aspects of EUS-guided anastomosis and ERCP via LAMS (Lumen apposing metal stent)
223399844|NCT07104695|BEHAVIORAL|Solomiya App - CBT-based self-help intervention|"Solomiya App - CBT-based self-help intervention~The Solomiya app is a mobile-based self-help intervention designed to reduce and cope with depressive symptoms and improve sleep in individuals exposed to chronic stress. It has been created within the Solomiya project and is based on preliminary work in other international health settings (Böge 2022) where it has shown to improve depressive symptoms as part of a Stepped Care and Collaborative Model (SCCM). It includes psychoeducational multimedia modules on stress management and sleep problems, along with cognitive behavioral therapy (CBT)-based tools such as guided relaxation exercises, mindfulness practices, and behavioral activation strategies. The app also offers symptom tracking using the PHQ-9 to support user self-monitoring. Participants are instructed to engage with the app regularly over a 4 week period. The intervention is entirely self-guided and does not involve therapist support. App usage and adherence data will be collect"
223399845|NCT04685512|DRUG|tenofovir disoproxil and emtricitabine|Experimental drugs administration of 7-day short course TDF/FTC
223399846|NCT07110740|DRUG|UI009|inhale UI009 twice a day on Day 1 and Day 8.
223399847|NCT07110740|DRUG|UIC202005|inhale UIC202005 twice a day on Day 1 and Day 8.
223399848|NCT07112417|DEVICE|Augmented Reality|Participants in this group will undergo mini-screw placement assisted by augmented reality (AR) technology. A customized AR system will guide the clinician in real-time to ensure optimal screw positioning, improve accuracy, and minimize placement errors.
223399849|NCT07112417|PROCEDURE|Conventional screw placement|Participants in this group will receive mini-screw placement using the conventional freehand method without augmented reality assistance. The screws will be placed according to standard clinical protocols based on anatomical landmarks and clinician experience
223399850|NCT07110974|BEHAVIORAL|Diabetes Distress scale 17 and Quality Of Life Instrument|questionnaire that assesses the distress resulting from being diabetic patient type 1 and another questionnaire that assesses the quality of life among type 1 diabetic Sohag University students
223399851|NCT07113340|DEVICE|Carina™ Surgical Platform, developed by Ronovo Surgical, Inc|A modular surgical robot that offers greater flexibility in the number of instrument arms and surgical layout options.
223732359|NCT01563003|OTHER|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
223732360|NCT01885143|RADIATION|Digital Breast Tomosynthesis|
223732361|NCT02856230|DEVICE|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
223732362|NCT01322360|DRUG|Morphine Sulfate|
223732363|NCT00967525|PROCEDURE|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
223732364|NCT04874727|PROCEDURE|Mandible slacked and captured with Correct Plus™ Impression Material Superfast|In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
223732365|NCT03731988|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
223732366|NCT03731988|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
224020550|NCT00801931|DRUG|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
224020551|NCT02783768|DEVICE|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
224020552|NCT02783768|OTHER|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
224020553|NCT02783768|DRUG|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
224020554|NCT02783768|DRUG|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
224020555|NCT01934361|DRUG|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
224020556|NCT01934361|DRUG|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
224020557|NCT01934361|DRUG|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
224296991|NCT00361335|DRUG|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
223399852|NCT07112105|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive procedure in which administering a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention (active and sham) will be administered in 30 sessions across 2 weeks. The brain region targeted is the dorsolateral prefrontal cortex.
223399853|NCT07112105|DEVICE|Sham rTMS|Subjects randomized to sham rTMS will undergo the same procedures on the same equipment as subjects assigned to active rTMS, but no active magnetic stimulation will be delivered.
223399854|NCT07111806|DRUG|Tirofiban|Tirofiban is administered as a loading dose and continuous intravenous infusion as soon as possible after the randomization.
223399855|NCT07111806|DRUG|Placebo|Matched placebo will be infused in a similar fashion.
223399856|NCT01276860|DEVICE|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
223551688|NCT05104866|DRUG|Dato-DXd|Experimental drug. Provided in 100mg vials. IV infusion.
223551689|NCT05104866|DRUG|Capecitabine|Tablet. Oral route of administration. Active comparator
223551690|NCT05104866|DRUG|Gemcitabine|IV Infusion. Active comparator
223551691|NCT05104866|DRUG|Eribulin|IV Infusion. Active comparator
223551692|NCT05104866|DRUG|Vinorelbine|IV Infusion. Active comparator
223551693|NCT01010672|DRUG|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
223551694|NCT04201639|DEVICE|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
223551695|NCT01718158|BIOLOGICAL|Peginterferon Lambda-1a|
223551696|NCT01718158|BIOLOGICAL|Peginterferon Alfa-2a|
223551697|NCT01718158|DRUG|Ribavirin|
223551698|NCT01718158|DRUG|Daclatasvir|
223551699|NCT01718158|DRUG|Telaprevir|
223551700|NCT04187248|DRUG|Asparaginase|
223551701|NCT00790582|DRUG|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
223551702|NCT04335448|OTHER|No intervention is planed|No intervention is planed
223551703|NCT01582334|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
223551704|NCT04535089|DRUG|Dexmedetomidine injection|receive IV bolus dose of 0.5 ug/kg dexmedetomidine diluted in 10ml saline 1% over 15 minutes followed by continuous infusion of 0.5 ug/kg/h
223551705|NCT04535089|DRUG|Lidocaine Iv|IV bolus dose of 1mg/kg lidocaine 1% over 15 minutes followed by continuous infusion of 1.5mg/kg/h
223551706|NCT00459641|DRUG|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
223551707|NCT00459641|OTHER|Standard of Care|Bone marrow aspirate or steroids
223551708|NCT02494635|OTHER|Laboratory Biomarker Analysis|Biomarker analysis
223551709|NCT04980469|OTHER|Vitex negundo + Zingiber officinale|200 mg/ Capsule
223551710|NCT04980469|OTHER|Placebo (MCC)|200 mg/ Capsule
223551711|NCT05312606|OTHER|Aftoral Oral gel|Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
223551712|NCT05312606|OTHER|Unidea Chlorhexidine digluconate mouthwash 0.20%|Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
223551713|NCT05498740|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
223551714|NCT03228784|PROCEDURE|LASIK|
223551715|NCT04345692|DRUG|Hydroxychloroquine|oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
223551716|NCT02214901|DRUG|BIBW 2948 BS for oral inhalation|
223551717|NCT02214901|DRUG|Placebo|
223732367|NCT03731988|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
223399857|NCT07111780|OTHER|"Coordinative-Based Physical Activity Practices training group"|In the first session, participants were asked to fill in an information form, including demographic information. They were asked to complete the Brunel Mood Scale and the International Physical Activity Questionnaire (IPAQ). participants' height and body weight were measured. Participants' height was measured with a portable statiometer. Body weight was measured with a digital scale witha precision of 0.1 kg. In the second session, Go/No-Go and mental rotation tests, which are used to evaluate the cognitive functions of the participants, were administered to the participants. The KTK3+ motor competence test was used to determine the motor competence of the participants.The tests were administered to the participants in the same order and by the same researchers. Before the assessment of KTK3+ test of 5 minutes of running and 5 minutes of dynamic stretching was performed. Coordination-based physical activity applied to the exercise group continued for 25-30 minutes twice for 8 weeks.
223399858|NCT07111351|OTHER|Without intervention|Without intervention
223732368|NCT03731988|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
223732369|NCT03731988|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
223732370|NCT00029614|DRUG|Atomoxetine|
223551718|NCT00976157|PROCEDURE|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
223551719|NCT05207748|DIAGNOSTIC_TEST|Bone mineral density|Bone mineral density (BMD) will be measured on the lumbar spine (L1-L4) and femoral neck by dual X-ray absorptiometry (DXA) method.
223551720|NCT00270751|PROCEDURE|1 apical pleurectomy|
223551721|NCT00270751|PROCEDURE|2 pleural abrasion + minocycline pleurodesis|
223551722|NCT00329576|BIOLOGICAL|Hepatitis B vaccine|
223551723|NCT03130998|BEHAVIORAL|Remote Knowledge Broker (rKB)|The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.
223551724|NCT03130998|BEHAVIORAL|Emails|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
223551725|NCT00848237|DEVICE|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
223551726|NCT03877003|OTHER|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
223551727|NCT00981162|DRUG|sorafenib tosylate|Given PO
223551728|NCT00981162|DRUG|everolimus|Given PO
223551729|NCT00981162|OTHER|laboratory biomarker analysis|Correlative study
223732371|NCT01973166|DEVICE|Picosecond Q-switched Laser Treatment|
223732372|NCT01973166|DEVICE|Nanosecond Q-switched Laser Treatment|
223732373|NCT03156673|BIOLOGICAL|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
224020558|NCT01934361|DRUG|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
224020559|NCT02845206|PROCEDURE|Patient specific cutting blocks|'MyKnee' Instrumentation
224020560|NCT02845206|PROCEDURE|Conventional cutting blocks|Standard Instrumentation
224020561|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
224020562|NCT02476279|OTHER|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
224296992|NCT00361335|DRUG|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
223551730|NCT00981162|OTHER|pharmacogenomic studies|Correlative study
223551731|NCT00981162|OTHER|pharmacological study|Correlative study
223551732|NCT02013349|DEVICE|coronary intervention|
223551733|NCT00540930|DRUG|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
223399859|NCT07112131|BEHAVIORAL|Non-Diet Nutrition Education Program|The intervention is an 8-week online nutrition education program based on non-diet approaches, including intuitive eating, rejecting diet mentality, honoring hunger, body acceptance, and well-being. Each weekly session is 60 minutes long and involves interactive discussions and home practices.
223399860|NCT06512935|OTHER|Increase in the PEEP followed by decrease in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
223399861|NCT06512935|OTHER|Decrease in the PEEP followed by increase in the PEEP|Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
223551734|NCT05782985|DIAGNOSTIC_TEST|Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)|Blood samples from the myeloproliferative neoplasms cases and the controls will be tested with Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) and K (HNRNPK) genes.
223732374|NCT06304753|DEVICE|Telebot|"This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses."
223732375|NCT00396591|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
223732376|NCT03393741|DRUG|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
223732377|NCT03393741|DRUG|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
223732378|NCT03393741|DRUG|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
223732379|NCT03393741|DRUG|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
223732380|NCT03393741|DRUG|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
223732381|NCT00525707|DRUG|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
223732382|NCT02724306|BEHAVIORAL|Active Lifestyle Programme|
224020563|NCT02938533|BEHAVIORAL|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
224020564|NCT04247087|DRUG|phytomenadione|phytomenadione 10 mg (1 vial in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
224020565|NCT04247087|DRUG|placebo solution|1 vial of placebo solution (solution for injection in the venous line of the extracorporeal hemodialysis circuit) post hemodialysis 3 times a week for 12 months
224020566|NCT01323647|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration
224020567|NCT01323647|BIOLOGICAL|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
224020568|NCT00954486|DRUG|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
224020569|NCT06227143|PROCEDURE|Anesthesia depth monitoring|Anesthesia depth monitoring during opioid-free anesthesia
224020570|NCT04847076|BEHAVIORAL|m-health version of WWWT intervention|m-health version of Chilean adaptation of WWWT intervention: a) Psychoeducational information for understanding and managing infant behavior and on parenting. b) Contact with the program facilitator. c) A virtual group meeting
224020571|NCT04847076|OTHER|Treatment as usual|TAU for children under one year of age include routine health checks by health professionals (nurse or doctor), every month from 0 to 4 months of age, and at 6, 8 and 12 months of age
223399862|NCT05652153|OTHER|Single-/paired-pulse transcranial magnetic stimulation|Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
223399863|NCT06939972|DIETARY_SUPPLEMENT|Topical Analgesic with Camphor and Menthol|Participants will apply the product directly to the lower abdomen or back during menstrual cycles, following specific application instructions. The product provides analgesic and cooling effects to reduce discomfort.
223399864|NCT06106269|DEVICE|Rectal Artery Embolization|Subjects will undergo planned rectal artery embolization (RAE) in Vascular and Interventional Radiology per standard clinical protocol.
223399865|NCT05966584|DRUG|Benralizumab|Benralizumab 30mg subcutaneously on day -1.
223399866|NCT05966584|DRUG|fulvestrant or AIs) and PI3K inhibition (alpelisib)|SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
223551735|NCT05749367|DRUG|Ropivacaine + saline solution|SIFIB with 30 ml of 0.5% ropivacaine and PENG Block plus LFCNB with 20 ml and 10 ml of saline solution, respectively.
223551736|NCT05749367|DRUG|Saline solution + Ropivacaine|SIFIB with 30 ml of saline solution and PENG Block plus LFCNB with 20 ml and 10 ml of 0,5% ropivacaine, respectively.
223732383|NCT01013701|DRUG|fluticasone furoate|nasal steroid spray
223732384|NCT01013701|OTHER|placebo|nasal steroid vehicle without drug
224296993|NCT00361335|DRUG|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
224020572|NCT04295876|BEHAVIORAL|The BRIDGES Project Intervention|The BRIDGES Project will use Peer Navigators, who are other women living with HIV who have had similar experiences and have been successful in accessing care, to help other women living with HIV to access HIV care and stay in HIV care. The BRIDGES Project will also provide support to women through group sessions co-facilitated by a licensed clinical therapist and Peer Navigator. Through participation in BRIDGES, women will: (1) build skills to cope with HIV care and treatment barriers (e.g., violence, trauma, adverse mental health, substance use); (2) be connected to HIV treatment and other support services (e.g., domestic violence, mental health, substance use); and (3) learn interpersonal skills to connect with support (e.g., service providers, peers, friends, family) when faced with new or ongoing barriers.
223732385|NCT04358653|OTHER|fall prevention exercise program|The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
223732386|NCT00848367|BEHAVIORAL|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
223732387|NCT02855333|OTHER|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
223732388|NCT00298051|PROCEDURE|Delayed umbilical cord clamping|
224020573|NCT00149760|BEHAVIORAL|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
223399867|NCT05759182|DEVICE|Powered Exoskeleton Gait Training|A trained medical professional will adjust the exoskeleton to fit each participant and tailor the program(sit to stand, stand to sit, standing balance and weight shift, walk in place, walk forward) according to their physical condition and specific needs. Based on each participant's walking ability, appropriate safety devices (such as crutches, canes, or a harness) will be used during the intervention.
223399868|NCT03967522|DRUG|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
223399869|NCT04137081|BEHAVIORAL|App-based mindfulness training|Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (\~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.
223399870|NCT01894308|DRUG|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
223399871|NCT01894308|DEVICE|Pump Sprayer|A dose of product solution is delivered by means of a metered pump spray.
223399872|NCT00955409|BIOLOGICAL|ACC-001(3µg) + QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
223399873|NCT00955409|BIOLOGICAL|ACC-001(10µg) + QS21|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
223399874|NCT00955409|BIOLOGICAL|ACC-001(30µg) + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
223399875|NCT00803790|DRUG|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
224020574|NCT00149760|BEHAVIORAL|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
224020575|NCT02262624|DRUG|Telmisartan|
224020576|NCT02262624|DRUG|Hydrochlorthiazide (HCTZ)|
224020577|NCT02262624|DRUG|Telmisartan/HCTZ fixed combination|
224020578|NCT04206033|OTHER|Observational study|Observational study
224020579|NCT00238147|DRUG|capecitabine|
224020580|NCT00238147|DRUG|carboplatin|
224020581|NCT00238147|DRUG|docetaxel|
224020582|NCT00238147|PROCEDURE|conventional surgery|
224020583|NCT00238147|PROCEDURE|neoadjuvant therapy|
224020584|NCT00238147|RADIATION|radiation therapy|
224020585|NCT00458991|DRUG|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
224020586|NCT05358106|BIOLOGICAL|AntiBKV|AntiBKV neutralising antibody
224020587|NCT05358106|BIOLOGICAL|Placebo|Solution with no active ingredients
224020588|NCT04589949|BIOLOGICAL|ConvP|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
224020589|NCT04589949|BIOLOGICAL|FFP|Infusion of thawed non-convalescent plasma Plasma will be administered according to the Erasmus Medical Center quality protocol regarding the use of blood products
224020590|NCT03293693|OTHER|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
223399876|NCT00803790|DRUG|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
223399877|NCT00803790|DIETARY_SUPPLEMENT|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
223399878|NCT06552416|DRUG|MT-401-OTS|MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.
223399879|NCT06554652|PROCEDURE|Lymph node tracer navigated selective neck dissection|Selective lateral lymph node dissection (after injection of tracer, lymph nodes in compartment III-IV are dissected; if there is dyed lymph node in compartment IIA, then IIA is dissected).
223399880|NCT06554652|PROCEDURE|Modified neck dissection|Lymph nodes in compartment IIA, IIB, III, IV, VB are dissected.
223399881|NCT06219148|BEHAVIORAL|Music Therapy Telehealth|Music Therapy: delivered via Zoom by a board-certified music therapist (MT-BC) 30-min 2x/week for 4 weeks (8 sessions total); follows the Clinical Practice Model, which guides customizations of various music experiences (e.g., singing, songwriting, movement, relaxation, lyric discussion, improvisation, instrument play, etc.) per participants' strengths, interests, preferences, culture, and momentary responses. Each participant works with the same MT-BC throughout the study.
223399882|NCT06219148|BEHAVIORAL|Non-Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed social worker (SW) or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. SWs operate independently from MT-BCs to identify possible participant service referral needs using the Aging and Memory Quality of Life Survey (AMQoL), baseline data, SW session interactions, and SW Referral Worksheet. Each participant works with the same SW throughout the study.
223399883|NCT06219148|BEHAVIORAL|Collaborative Social Work Telehealth|Social Work: delivered via Zoom by a licensed SW or supervised SW graduate student 3x for 30-min: 1) after 2 weeks MT (assessment), 2) after 4 weeks MT (service referral), 3) 2-week follow-up. In addition to the AMQoL, baseline data, SW session interactions, and the SW Referral Worksheet, SWs collaborate fully with MT-BCs, have full access MT session notes, and can discuss participants' needs with MT-BC to identify possible participant service referral needs. Each participant works with the same SW throughout the study.
223399884|NCT05597943|BEHAVIORAL|Malama App|The Malama smartphone application is a gestational diabetes management app that syncs directly with commercially-available glucometers via Bluetooth, enabling both automatic blood glucose logging and providing interactive diet management/diet education tools. We aim to perform a pilot study assessing the impact of the Malama smartphone application on perinatal and postpartum outcomes in patients with GDM.
223399885|NCT06131788|BEHAVIORAL|Educational hand hygiene intervention|The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
223399886|NCT03457948|PROCEDURE|Arterial Embolization|Undergo TAE
223399887|NCT03457948|BIOLOGICAL|Pembrolizumab|Given IV
223399888|NCT03457948|BIOLOGICAL|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
223399889|NCT03457948|DEVICE|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
223399890|NCT04522336|DRUG|Docetaxel|Given IV
223399891|NCT04522336|DRUG|Fluorouracil|Given IV
223399892|NCT04522336|DRUG|Oxaliplatin|Given IV
223399893|NCT04522336|BIOLOGICAL|Pembrolizumab|Given IV
223399894|NCT04522336|RADIATION|Radiation Therapy|Receive radiation therapy
224020591|NCT03293693|OTHER|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
223399896|NCT05773092|DRUG|Oral S-1 + Oral Osimertinib|S-1 (40mg) will be given orally twice a day (daily) from Day 1 to 14 (21 day cycle), and Osimertinib (80mg) will be given orally daily continuously.
223399897|NCT06358326|OTHER|Dry needling|In addition to stretching, nerve mobilization and tendon gliding exercises, a total of 5 sessions of dry needling will be performed for fascial mobilization, 2 days a week for 3 weeks.
223399898|NCT06358326|OTHER|Control group|The physiotherapist will teach stretching, neuromobilization and tendon shifting exercises and will be asked to do them regularly for 3 weeks.
223399899|NCT02466191|DRUG|Memantine|
223399900|NCT02466191|DRUG|Gabapentin|
223551737|NCT04554732|DRUG|Keratinocyte growth factor|At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
223551738|NCT04310319|DIETARY_SUPPLEMENT|Sodiumchloride|Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
223551739|NCT04310319|DIETARY_SUPPLEMENT|Protein|Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
223551740|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (salt)|Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
223551741|NCT04310319|DIETARY_SUPPLEMENT|Placebo comparator (protein)|Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
223551742|NCT01170234|DEVICE|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
223551743|NCT01599598|BEHAVIORAL|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
223551744|NCT01599598|BEHAVIORAL|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
223551745|NCT02798744|DRUG|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
223551746|NCT02798744|BEHAVIORAL|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
223551747|NCT02798744|DRUG|Placebo|Placebo once daily for the duration of the study (24 weeks)
224130991|NCT06317233|BEHAVIORAL|Chronic Pelvic Pain Treatment Guide|The treatment guide includes mobile and web-based resources and applications specifically chosen to empower patients with information and to promote self-efficacy. The treatment guide is designed to be easily understood, visually appealing, and largely translatable from institution to institution. Patients using the treatment guide will be followed with a clearly defined follow up schedule, which includes touch points between appointments to aid with resource navigation.
224130992|NCT06553677|PROCEDURE|Tunneled coronal advanced flap with connective tissue graft|Tunneled coronal advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites.
223732389|NCT01502189|OTHER|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
223732390|NCT01355341|DRUG|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
223732391|NCT03590379|DRUG|CHF 5993 DPI|BDP/FF/GB DPI
223732392|NCT03590379|DRUG|CHF5993 pMDI|BDP/FF/GB pMDI
223732393|NCT03590379|DRUG|CHF 1535 pMDI|BDP/FF pMDI
223732394|NCT03590379|DRUG|Placebo DPI|CHF 5993 DPI matched placebo
223732395|NCT03590379|DRUG|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
223732396|NCT00378196|DRUG|Ranibizumab|0.3 mg/0.05 ml dose
223732397|NCT00378196|DRUG|Ranibizumab|0.5 mg/0.05 ml dose
223732398|NCT00931814|OTHER|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
223732399|NCT04211051|DEVICE|LungBrella marker implantation and VATS partial lobe resection|The enrolled patients will receive a plain chest CT scan,then the data be loaded into JediVision software. The JediVision software can navigate the location of nodule and facilitate the implantation of LungBrella marker in the operating room after general anesthesia,then the patients will receive VATS partial lobe resection .
223732400|NCT04400240|BEHAVIORAL|CALLS|The CALLS program will consist of 12 weeks of service delivery that will include one standard educational session by telephone or in-person meeting every week. The weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. Weekly content will be adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study, and further tailored according to prominent barriers to care in the scientific literature. Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6) Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation.
223732401|NCT01075945|DRUG|Dihydroartemisinin- piperaquine|three tablets per day
224020592|NCT03293693|OTHER|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
224020593|NCT03270397|BEHAVIORAL|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
224130993|NCT06553677|PROCEDURE|Coronally advanced flap with connective tissue graft|Coronally advanced flap with connective tissue graft to treat isolated RT2 gingival recession sites
224138741|NCT06414538|OTHER|Digital Mind Map Technique|"Students determined as a result of randomization will be given a pre-test before entering the Family Planning course planned according to the academic calendar. The determined topics will be explained to the students using the digital mind map technique. A post-test will be administered to the students 1 week after the end of the subject and a satisfaction survey of the digital mind map technique will be administered. Permanence test will be applied 35 days after the last test application."
223551748|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
223551749|NCT00099502|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
224020594|NCT05319782|OTHER|Urethral stenosis assesment|Auto-questionnaires + Clinical examination + Flow metry and post-mictional residue
224020595|NCT05494177|DIAGNOSTIC_TEST|bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS|"All participants will be assessed on the following clinical indexes:~1. Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~2. Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~3. Binocular uncorrected near reading acuity (bUNVA) at 40 cm~4. Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~5. Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity \& Reading Test (DDART)."
223551750|NCT00099502|DRUG|Copaxone|20 mg administered s.c. once daily.
223551751|NCT00543270|DEVICE|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
223551752|NCT00543270|PROCEDURE|Open Surgery|Open surgical abdominal aortic aneurysm repair
223551753|NCT02195700|DRUG|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
223551754|NCT02195700|DRUG|Placebo|Placebo tablets taken twice daily for 12 weeks.
223551755|NCT02713113|DRUG|sugammadex reversal of neuromuscular blockade|
223551756|NCT01915537|DRUG|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX\>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
223732402|NCT01075945|DRUG|artemether- lumefantrine|twenty tablet in eight doses
223732403|NCT04772755|DEVICE|Buzzy® and Electronic Game|Buzzy® was applied according to manufacturers directions and an electronic game was played. The participant was observed for 20 minutes post vaccination.
223732404|NCT00258531|DEVICE|Olympus ScopeGuide®, 3-dimentional magnetic imager|
223732405|NCT02915276|PROCEDURE|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
223732406|NCT02915276|PROCEDURE|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
223732407|NCT05071989|BEHAVIORAL|Sleep Education|A single-blind school- based randomized controlled design
223732408|NCT01905657|BIOLOGICAL|Pembrolizumab|IV infusion
223551757|NCT01915537|DRUG|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
223732409|NCT01905657|DRUG|Docetaxel|IV infusion
223732410|NCT05063747|OTHER|No intervention.|Observational study. No intervention.
223732411|NCT02589951|OTHER|admission to non-psychiatric service|
223732412|NCT01778881|OTHER|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
223732413|NCT01778881|OTHER|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
223732414|NCT01778881|OTHER|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
223732415|NCT01778881|OTHER|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
223732416|NCT05486858|OTHER|MSK ultrasonograpy|MSK ultrasonography was used to measure the thickness of diaphragm muscle in supine and sitting position and in a relaxed and in a contracted state.
224130994|NCT06433518|DRUG|recombinant hCG|"Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups."
224130995|NCT00455130|DRUG|Inhaled mannitol|
224130996|NCT03009201|DRUG|Doxorubicin Hydrochloride|Given IV
224130997|NCT03009201|OTHER|Laboratory Biomarker Analysis|Correlative studies
224130998|NCT03009201|OTHER|Pharmacological Study|Correlative studies
223551758|NCT02970591|OTHER|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
223551759|NCT02970591|OTHER|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 23 energy % proteins and 67 energy % fat.
223551760|NCT02970591|OTHER|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
223551761|NCT03948893|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
223551762|NCT03948893|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
223551763|NCT04285554|DEVICE|iRF System Hepatic Denervation|The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
223551764|NCT01941654|RADIATION|preemptive local ablative therapy|
223551765|NCT01941654|DRUG|Oral TKI|
223551766|NCT02931838|DRUG|BMS-986165|
223551767|NCT02931838|DRUG|Placebo for BMS-986165|
223732417|NCT05486858|OTHER|sitting Functional and Lateral Reach Test|Sitting reach tests were used to measure the stability limits of the trunk in different directions. Functional reach test is for testing the forward direction and lateral reach tests are for testing the right and the left directions.
223732418|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
223732419|NCT01949350|DIETARY_SUPPLEMENT|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
223732420|NCT01949350|DIETARY_SUPPLEMENT|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
223732421|NCT05928897|DRUG|Disitamab Vedotin combined with Sintilimab|Disitamab Vedotin combined with Sintilimab
223732422|NCT03388879|DEVICE|Taylor Spatial Frame|Circular external fixator
223732423|NCT03388879|DEVICE|Intramedullary nail|Antegrade intramedullary nail
223732424|NCT04358133|DRUG|Chlorhydrate de morphine|The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
223732425|NCT04358133|DRUG|NaCl 0,9%,|The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
223732426|NCT04953221|DRUG|YJ001|Skin spray
223732427|NCT00875251|DEVICE|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
223551768|NCT06715020|DRUG|18F-FDG|All study participants will undergo one 18F-FDG PET scan.
223732428|NCT01259323|BIOLOGICAL|REGN668|Dose 1: REGN668 or placebo
223732429|NCT01259323|BIOLOGICAL|REGN668|Dose 2: REGN668 or placebo
223732430|NCT01259323|BIOLOGICAL|REGN668|Dose 3: REGN668 or placebo
223732431|NCT02568150|BIOLOGICAL|Single group, open-label|
223732432|NCT04702997|DRUG|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
223732433|NCT04702997|DRUG|Placebo oral capsule|Capsule containing an inert placebo
224130999|NCT03009201|DRUG|Ribociclib|Given PO
224296994|NCT04310813|DIAGNOSTIC_TEST|Multimodal spectroscopic analysis|During time of bladder or prostate resection, freshly excised cold cup biopsies of both bladder cancer or healthy bladder mucosa were taken and sent for inspection through label-free multimodal fiber optic spectroscopy (MFOS) within 30 minutes
224296995|NCT00753818|OTHER|DHA and ARA|various levels of DHA and ARA
223732434|NCT01305902|BEHAVIORAL|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
223732435|NCT01880840|DRUG|205.5 mcg of azelastine hydrochloride|nasal spray
224296996|NCT00753818|OTHER|Control|
223399901|NCT03315390|OTHER|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
223399902|NCT03315390|OTHER|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
223399903|NCT03981796|BIOLOGICAL|Dostarlimab|Participants will be administered dostarlimab
223399904|NCT03981796|DRUG|Placebo matching dostarlimab|Participants will be administered placebo matching dostarlimab
223399905|NCT03981796|DRUG|Carboplatin|Participants will be administered carboplatin
223551769|NCT06718309|DRUG|Chemotherapy|Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin. The chemotherapy treatment lasts 3 cycles.
223551770|NCT06718309|DRUG|Immunotherapy|Investigators choose PD-1 or PD-L1 according to drug indication and the immunotherapy lasts 3 cycles preoperatively and 1 year after surgery.
223551771|NCT06718309|PROCEDURE|Radical resection of lung cancer|Radical resection of lung cancer with lymph node dissection
223551772|NCT06718309|RADIATION|SBRT|SBRT for primary lung lesion 8Gy\*3F after first cycle of chemoimmunotherapy
223551773|NCT03110029|DRUG|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
223551774|NCT03110029|OTHER|Application of Nail Polish|Application of Nail Polish
223551775|NCT01866748|DRUG|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
223551776|NCT01866748|DRUG|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
223551777|NCT01866748|DRUG|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
223551778|NCT01866748|DRUG|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
223551779|NCT00994825|DRUG|Levosimendan|
223551780|NCT00994825|DRUG|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
223732436|NCT01880840|DRUG|137 mcg of azelastine hydrochloride|nasal spray
223551781|NCT01043744|DRUG|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)"
223551782|NCT01189344|DRUG|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
223551783|NCT04525144|DRUG|Tebonin Forte|Dietary supplement: Gingko biloba EGb 761
223732437|NCT01300598|PROCEDURE|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
223732438|NCT01065623|DRUG|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
223399906|NCT03981796|DRUG|Paclitaxel|Participants will be administered paclitaxel
223399907|NCT03981796|DRUG|Niraparib|Participants will be administered niraparib
223399908|NCT03981796|DRUG|Placebo matching Niraparib|Participants will be administered placebo matching Niraparib
223732439|NCT00358124|DRUG|insulin glargine|
223732440|NCT00358124|DRUG|rosiglitazone|
223732441|NCT00358124|DRUG|metformin|
223732442|NCT03276156|DRUG|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
223732443|NCT04769544|DEVICE|total knee arthroplasty with medial pivot tibial insert or symmetrical insert|standard surgical implantation of total knee arthroplasty
223732444|NCT05541952|BIOLOGICAL|BCG|Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
224020596|NCT05494177|DIAGNOSTIC_TEST|Contrast sensitivity|Contrast sensitivity is assessed with the Pelli-Robson test.
224020597|NCT03375216|BEHAVIORAL|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
224020598|NCT03375216|BEHAVIORAL|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
223399909|NCT05454735|PROCEDURE|coronary artery bypass surgery|coronary artery bypass surgery
223399910|NCT05454735|PROCEDURE|aortic valve replacement surgery|aortic valve replacement surgery
223399911|NCT05161481|DRUG|Avenciguat (BI 685509)|Participants received Avenciguat twice daily (BID) throughout the study. Up-titration depended on the assigned dose group. At Visit 2 (Week 1), each dose included one 1 mg Avenciguat tablet. At Visit 3 (Week 2), the dose was increased to one 2 mg Avenciguat tablet per dose. From Visit 4 onward (Week 3+), participants received one 3 mg Avenciguat tablet per dose. This regimen continued for 24 weeks, with all doses taken with water, with or without food.
224020599|NCT05396482|DIAGNOSTIC_TEST|Pure tone audiometer|Pure tone audiometer
224020600|NCT05097222|DEVICE|BioFlex Dualport System|The device consists of a laptop computer preprogrammed with the Bioflex® Practitioner+ Software, the Bioflex® DUO 180+ array pad that has 180 bicolour Light Emitting Diodes (LED) that emit red and near infrared light, and two laser probes, the LD-R 100 that emits red light, and the LD-I 200 that emits near infrared light.
224020601|NCT05097222|DEVICE|Sham device|Control
224020602|NCT01935180|DEVICE|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
223732445|NCT06284291|DIAGNOSTIC_TEST|transcranial magnetic stimulation (TMS)|The STM9000 Standard-BI stimulator with 70 mm refrigerated butterfly stimulator (EB Neuro, Florence, Italy) controlled by Galileo Netbrain 9000 hardware and software (EB Neuro, Florence, Italy) is used. EMG data are recorded from the contralateral dorsal first interosseous muscle using gelled surface electrodes. EEG data are recorded by using the BE PLUS PRO Advanced EEG/EMG/EP amplifier (EB Neuro, Florence, Italy IT).
223732446|NCT00179634|BEHAVIORAL|Visualization relaxation|
223399912|NCT05161481|DRUG|Placebo matching Avenciguat (BI 685509)|Participants received matching placebo twice daily (BID) throughout the study. At Visit 2 (Week 1), each dose included one 1 mg and one 2 mg placebo tablet (four tablets daily). A pseudo up-titration was applied at Visit 3 (Week 2), maintaining the same tablet composition to preserve blinding. From Visit 4 (Week 3) onward, a second pseudo up-titration adjusted each dose to one 2 mg and one 3 mg placebo tablet (four tablets daily). All doses were taken with water, with or without food.
223732447|NCT00179634|BEHAVIORAL|Visual Milieu Enhancement (Fine art photograph)|
223732448|NCT01892228|BEHAVIORAL|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
224020603|NCT05069103|DEVICE|Intervention|"Similar to the original TWIST trial , patients will receive access to the online tool hosted on the ISLA platform until postoperative day 30 which is composed of two parts:~1. A series of simple questions related to the detection of surgical wound infection (e.g. redness, swelling, fluid leakage, etc). These questions would be expected to be routinely asked during in-person assessment, and these questions have been previously developed and tested within the TWIST trial (the only change being the addition of questions specifically relating to the change in these symptoms).~2. At least one image of their surgical wound(s)."
224020604|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
224020605|NCT01236339|PROCEDURE|LVP|Large Volume Paracentesis
223399913|NCT06096246|PROCEDURE|Pulmonary vein isolation|The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
223399914|NCT06096246|PROCEDURE|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
223399915|NCT06096246|DEVICE|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
223399916|NCT06096246|PROCEDURE|Femoral sheath insertion|Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
223399917|NCT06033547|DRUG|Cabotegravir Formulation F|Cabotegravir Formulation F will be administered
223399918|NCT06033547|DRUG|Cabotegravir Formulation G|Cabotegravir Formulation G will be administered
223399919|NCT01536808|OTHER|Cardiac RMI|Cardiac RMI
223399920|NCT01536808|OTHER|Analysis telomere|Analysis telomere
223399921|NCT01536808|OTHER|Stress test|Stress test
223399922|NCT01536808|OTHER|echocardiography|echocardiography
223399923|NCT06527365|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
223399924|NCT02742506|OTHER|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
223399925|NCT06382168|DRUG|DFP-10917|DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.
223399926|NCT06382168|DRUG|Venetoclax|Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.
223399927|NCT05674812|DIAGNOSTIC_TEST|Multimodal pre-extubation risk assessment in elderly surgical patients|This observational cohort study evaluates risk factors for extubation failure in elderly surgical patients. All participants receive standard pre-extubation clinical assessments per institutional protocol, including LUS、DE and oxygenation index (PaO₂/FiO₂), arterial blood gas analysis, and the patients'laboratory results before and after surgery. The association between these parameters and extubation failure will be analyzed.
223551784|NCT01042158|DRUG|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
223551785|NCT06488690|OTHER|All patients who were pregnant and underwent cesarean section|Our study aims to evaluate the use of early warning scores as a screening tool to predict obstetric mortality and morbidity in pregnant women who will undergo cesarean section.
223551786|NCT00921115|DRUG|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
223551787|NCT00921115|DRUG|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
223551788|NCT05712577|OTHER|Questionnaire|Rosenberg Self- Esteem scale
223551789|NCT05712577|OTHER|Questionnaire|Short Form 36 scale
223551790|NCT05712577|OTHER|Questionnaire|Coping orientation to the problems experienced - New Version in Italian
223551791|NCT05712577|OTHER|Questionnaire|Outcome Questionnaire - version 42.5
223551792|NCT02400970|OTHER|malignant cells|
223551793|NCT04244695|DRUG|Dexamethasone Oral|To compare oral dexamethasone 16 mg vs 8 mg vs placebo in pateints undergoing unilateral TKA
223551794|NCT02025634|DRUG|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
223732449|NCT01386554|DRUG|Repository Corticotropin Injection|Acthar given SC for 6 months
223732450|NCT01386554|DRUG|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
223399928|NCT06514495|OTHER|Therapy|Cognitive behavioral psychotherapy with exposure
223551795|NCT02025634|DRUG|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
224020606|NCT01236339|DEVICE|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
224020607|NCT02042222|DRUG|Hydroxyurea|
224020608|NCT02054741|OTHER|Comprehensive Geriatric Assessment|Complete geriatric assessment
224020609|NCT02054741|OTHER|Quality-of-Life Assessment|Ancillary studies
223399929|NCT05733312|DEVICE|InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system|Focused ultrasound which targets energy to a specific area in the brain based on imaging and disrupts the blood brain barrier which keeps certain drugs and other molecules out of the brain.
223551796|NCT01327235|DRUG|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
223551797|NCT01327235|DRUG|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
223399932|NCT05632484|BIOLOGICAL|Cord blood sampling|Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing
223399933|NCT05632484|BIOLOGICAL|Cord blood sampling|Collection of 50 to 100 mL of cord blood from the cord blood collection bag
223551798|NCT05823974|BIOLOGICAL|F2C22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551799|NCT05823974|BIOLOGICAL|F2B22A/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223399934|NCT05632484|BIOLOGICAL|Cord sampling|Collection of 20 centimeters (cm) of umbilical cord
223399935|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19
223399936|NCT04324606|BIOLOGICAL|MenACWY|Standard single dose of MenACWY vaccine delivered intramuscularly
223399937|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 full boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 5x10\^10vp of ChAdOx1 nCoV-19
223399938|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 half boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10\^10vp of ChAdOx1 nCoV-19
223551800|NCT05823974|BIOLOGICAL|F2B22B/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551801|NCT05823974|BIOLOGICAL|F2B22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551802|NCT05823974|BIOLOGICAL|F2B22D/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551803|NCT05823974|BIOLOGICAL|F2B22E/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551804|NCT05823974|BIOLOGICAL|F2F22A/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551805|NCT05823974|BIOLOGICAL|F2F22B/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551806|NCT05823974|BIOLOGICAL|F2F22C/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551807|NCT05823974|BIOLOGICAL|F2F22D/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551808|NCT05823974|BIOLOGICAL|F2F22E/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551809|NCT05823974|COMBINATION_PRODUCT|Control 1|Control vaccine was administered intramuscularly in Phase 1, at Day 1.
223551810|NCT05823974|BIOLOGICAL|F2F23D/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
223551811|NCT05823974|BIOLOGICAL|F2F23A/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
223551812|NCT05823974|BIOLOGICAL|F2F23B/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
223551813|NCT05823974|COMBINATION_PRODUCT|Control 2|Control vaccine was administered intramuscularly in Phase 2, at Day 1.
223551814|NCT05823974|BIOLOGICAL|F2F23C/DL001Z-NH|Study intervention was administered intramuscularly in Phase 2, at Day 1.
223551815|NCT05823974|COMBINATION_PRODUCT|Control 3|Control vaccine was administered intramuscularly in Phase 2, at Day 1.
223551816|NCT05823974|BIOLOGICAL|F2F22F/DL001Z|Study intervention was administered intramuscularly in Phase 1, at Day 1.
223551817|NCT05835505|DRUG|BRS201|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
223551818|NCT05835505|DRUG|Placebo|Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
223551819|NCT05364775|OTHER|Focus group|Focus group
223551820|NCT00316706|BIOLOGICAL|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
223551821|NCT00316706|BIOLOGICAL|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
223551822|NCT06788197|DRUG|SHR-A1811+ Fulvestrant|SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular
223551823|NCT06788197|DRUG|SHR-A1811+ Fulvestrant+HS-10352|SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular ； HS-10351 is administered orally
223551824|NCT06464380|DIETARY_SUPPLEMENT|Saffranal|HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.
223551825|NCT06464380|DIETARY_SUPPLEMENT|Placebo|HCC patients will receive Placebo in dose of once per day for six months.
223551826|NCT00346281|DEVICE|32P BioSilicon|
223551827|NCT01500915|DRUG|Ranibizumab|0,5mg intravitreal ranibizumab
223551828|NCT05551923|OTHER|intestinal flora disturbance|To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
223551829|NCT02220855|DRUG|BKM120|
223551830|NCT03280303|OTHER|non-interventional|
223399939|NCT04324606|BIOLOGICAL|MenACWY boost|A standard dose of MenACWY followed by a boost dose of MenACWY
223399940|NCT04324606|DRUG|Paracetamol|1g every 6 hours for 24 hours
223399941|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 followed by a boost dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp)
223399942|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine (LV)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of 5x10\^10vp of ChAdOx1 nCoV-19
224131000|NCT06087042|DIAGNOSTIC_TEST|serum and unstimulated salivary samples|"Participants were told to cease smoking, eating, or drinking before the collection of samples by about half an hour. Obtaining the sample was done by demanding the individual to swallow then incline his head forward to expectorate saliva in a sterile tube for about 3 min. Afterwards the samples were coded by serial numbers then stored at -20°C until being assessed.~Under aseptic circumstances and using plain tubes, 5ml peripheral venous blood samples were collected from all participants by standard venipuncture. Samples were transported to biochemistry laboratory and centrifuged followed by filtration of the clarifying supernatant and then stored at -20ºC"
224131001|NCT01248910|BEHAVIORAL|Alpine Skiing|
224131002|NCT04143620|PROCEDURE|Procedure|Triple procedure
223399943|NCT04324606|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10^10vp) late vaccine two (LVT)|A dose of ChAdOx1 nCoV-19 0.5mL (3.5-6.5x10\^10vp) 9 months after receiving a single or double dose of MenACWY, then a boost 4-12 weeks later
223399944|NCT05773404|OTHER|Passive Neurodynamics and Passive axial hip mobilisation/distraction|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.
223399945|NCT05773404|OTHER|Active therapy|Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves
223399946|NCT05773404|OTHER|2.5.3. Combined therapy|The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
223399947|NCT06173024|BIOLOGICAL|TAK-577|TAK-577 as IV injection at dose calculated based on the participant's body weight.
223399948|NCT06320938|OTHER|Neuroscience-Based Pain Education Combined with Home Exercise Program|Neuroscience-Based Pain Education and Home Exercises will be applied.
223399949|NCT06320938|OTHER|Myofascial Induction Techniques Combined with Home Exercise Program|Myofascial Induction Techniques and Home Exercises will be applied.
223399950|NCT06320938|OTHER|Home Exercises Group|Home Exercises wiil be applied
223399951|NCT04199676|DIAGNOSTIC_TEST|Glucose tolerance test|Oral administration of a 75g glucose tolerance test during the postpartum hospitalization
223399952|NCT03753490|OTHER|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
223399953|NCT03753490|OTHER|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
223399954|NCT04643015|DIAGNOSTIC_TEST|MRI|"Briefly, new MRI sequences will be used on a patient who is undergoing a scheduled, clinically necessary MRI exam. Any new research sequence will be scanned in addition to the clinically required sequences and will not interfere with the clinical scan other than requiring five to ten minutes of additional table time. There will be no invasive measures under this protocol."
223399955|NCT06325020|OTHER|The assessment of patients with possible angina using the ORACLE pathway|"Participants will complete a digital health questionnaire, at home, that asks about their risk factors for coronary artery disease, past medical history and their symptoms.~Patients will then have a standard 12 lead ECG and perform their own personal ECG. They will then have high sensitivity cardiac troponin measured.~The results of all of the above will allow patients to be started as low, intermediate or high risk for future cardiovascular events."
223399956|NCT04815083|DRUG|Aminolevulinic Acid Hydrochloride|PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
223551831|NCT06492902|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in four weeks using patches (four sessions), each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. The patch with the needle will remain in place for one week.
223551832|NCT06492902|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is conducted weekly for four weeks using patches (four sessions), each with a square shape and a side length of 10 mm. The patches will not contain any needles and will remain in place for one week.
223551833|NCT03830476|BEHAVIORAL|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents of children with (any kind of) disabilities.
223551834|NCT03830476|BEHAVIORAL|Treatment as usual.|Treatment as usual within outpatient disability services.
223551835|NCT03459534|DRUG|Radotinib HCl|"1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature."
223551836|NCT03419897|DRUG|Tislelizumab|Administered intravenously
223732451|NCT04810845|DEVICE|Application of Class II A device SmartCardia|Application of SmartCardia monitor patch 30 minutes before coronary angiography (2/3 devices per-patients would be applied). Non invasive recording of single-lead ECG, respiratory rate, pulse transit time, heart rate would occur pre, during and post (30 minutes) primary angioplasty procedure
223732452|NCT00355693|DEVICE|Pump for propofol delivery|
224131003|NCT00377611|BIOLOGICAL|Fluarix™|
224131004|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
223551837|NCT04327362|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 min. of either sham or active tDCS prior to PE sessions using a 1 x 1 tDCS device with a ring electrode configuration that allows relatively excitatory and focal stimulation of the dorsomedial prefrontal cortex (dmPFC). Electrodes consist of sponges in a silicone rubber holder with a metal mesh conductor saturated with normal saline. A center anode (2.5 cm diameter) and a ring-shaped cathode (diameter inner/outer: 9.2/11.50 cm) will be centered over the dmPFC, with the anode placed the midline at 15% of the Fz to FPz distance. Active stimulation will commence with a 15 sec. ramping up period to target current (1.5 mA), followed by constant current for 20 min., and a 15 sec. ramping down period. For all sham sessions, stimulation will be immediately ramped down over a 15 sec. period following the initial ramping up period, and subsequently ramped up over 15 sec. prior to the final ramping down period.
223732453|NCT05286281|DRUG|PF-07265803|PF-07265803 is a p38 inhibitor formulated for oral delivery.
223732454|NCT00929799|DRUG|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
223732455|NCT01823185|DRUG|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
223399957|NCT04815083|DEVICE|Eagle V1.2 Imaging System|Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.
223399958|NCT04815083|DRUG|Placebo|Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
223399959|NCT06023069|OTHER|Number of steps recorded by mobile phone as a proxy for physical activity|This cohort is likely to have patients with many steps/day (high activity) and few steps/day (low activity)
223399960|NCT06251323|OTHER|iPATH implementation approach|A multi-level, multi-component, customized, standardized, technology enabled, person-centered, and team-based care practice transformation strategy.
223399961|NCT03911700|DEVICE|Phasix™ Mesh|Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).
223399962|NCT04465409|DEVICE|Intrastromal implantation of CorVision bioengineered corneal inlay for correction of presbyopia.|Presbyopia is an age-related progressive loss of crystalline lens accommodation power resulting in the decreased ability to see near objects. CorVision® is a tissue-mimetic device primarily intended to be used as a corneal inlay in the management of presbyopia and low hypermetropia. The inlay is inserted into the patient's cornea via a minimally invasive laser pocket procedure to modify corneal surface topography and corneal optical performance.
223399963|NCT06463782|DRUG|68Ga-LNC1007 Injection|The participant will receive a single intravenous injection with 0.05 mCi/kg (according to the participants' body weight) 68Ga-LNC1007 Injection on the scan bed. The final dose of the drug is allowed to fluctuate within the 20% range, but not below 3 mCi. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
223399964|NCT01038986|BIOLOGICAL|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
223399965|NCT02348736|DEVICE|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
223732456|NCT01823185|DRUG|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
223732457|NCT00349284|DRUG|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
223399966|NCT05785910|DIAGNOSTIC_TEST|IUDS|a battery of neuropsychological test
223732458|NCT03018171|DRUG|Clonidine|Intrathecal clonidine addiction
223732459|NCT03018171|DRUG|Sufentanil|Intrathecal
223732460|NCT06998225|DIETARY_SUPPLEMENT|Dietary intervention using cookies containing milk or egg low dose.|Baked Group 1: consumed a daily fixed low dose of baked milk or egg (0.0375 g of milk protein or 0.11 g of egg protein) for 6 months, followed by an additional increase at that time (0.075 g or 0.22 g).
223732461|NCT06998225|DIETARY_SUPPLEMENT|Dietary intervention with cow's milk or egg baked cookies high dose|Baked Group 2: continued a daily high dose of baked milk (0.55 g of milk protein or 1.1g egg protein) for 6 months. An increase dose is given at that time (1.1g cow's milk or 2g egg protein).
223732462|NCT02879305|DRUG|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
223732463|NCT02879305|DRUG|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
223732464|NCT02879305|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
223732465|NCT02879305|DRUG|Iron therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
223732466|NCT04649125|RADIATION|dose escalation|single fraction dose escalation to the tumour
223732467|NCT00459173|DRUG|rimonabant (SR141716)|
223732468|NCT00001596|DRUG|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
223732469|NCT00001596|DRUG|Placebo|Placebo (3 pills), three times daily.
223732470|NCT05302154|BEHAVIORAL|Distraction by dentist|Basic behavior orientation techniques (tell-show-do) is applied by the dentist during the treatment.
224020610|NCT02054741|OTHER|Survey Administration|Ancillary studies
224020611|NCT03418831|DRUG|Raloxifene Hydrochloride|60 mg per capsule (1 tablet daily) for 12 weeks
224020612|NCT03418831|OTHER|Placebo|1 tablet daily for 12 weeks
224020613|NCT02610127|BIOLOGICAL|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
224020614|NCT01130584|OTHER|Pyruvate kinase isoform M2|
224020615|NCT00163306|DRUG|Pantoprazole|
223732471|NCT05302154|BEHAVIORAL|Distraction by cartoon movie|Children watch cartoons on a screen mounted dental unit during the treatment.
224131005|NCT03183830|DIETARY_SUPPLEMENT|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
224131006|NCT03563456|BEHAVIORAL|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
224131007|NCT03563456|BEHAVIORAL|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
224131008|NCT02066753|PROCEDURE|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
223399967|NCT05961033|DEVICE|Virtual Reality based exercises|Play VR games
224131009|NCT05738694|DRUG|Axitinib plus Toripalimab|Preoperative treatment with axitinib will be given for 3 months, 5 mg twice daily, orally. Preoperative treatment with Toripalimab will be given for 4 cycles (3 weeks considered one cycle), 240 mg, Q3W.
224131010|NCT05738694|PROCEDURE|nephrectomy|nephrectomy
224131011|NCT05732844|DEVICE|Intervention group with Enna pelvic ball|"The home guideline for placement of the vaginal spheres will be as described in next:~st-2nd week 15 minutes, 1 time a day nd-4th week 30 minutes, 1 time a day 4th-8th week 1 hour, 1 time a day 8th-12th week 2 hours, 1 time a day 12th-16th week 3 hours, 1 time a day"
224131012|NCT05732844|OTHER|Control group|According to the PERFECT score, a daily home guideline for the performance of PFMT will be requested three times a day, two types of exercises (endurance and strength), and eight repetitions of each.
224131013|NCT03986775|DIETARY_SUPPLEMENT|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
223399968|NCT03266861|DIAGNOSTIC_TEST|Exercise oximetry|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
223399969|NCT03800199|OTHER|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
223399970|NCT00152061|DRUG|3TC and FTC|
223399971|NCT05884385|OTHER|Simulated exercises|as detailed in arm description
223399972|NCT05884385|OTHER|Mental Visualisation|as detailed in arm description
224131014|NCT03986775|DIETARY_SUPPLEMENT|sucrose|conventional beverage with sucrose
223732472|NCT05302154|BEHAVIORAL|Distraction by virtual reality glasses|During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
224131015|NCT04095806|OTHER|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
224131016|NCT04343313|DEVICE|Half Moon TMVr System|The Half Moon Transcatheter Mitral Valve Repair (TMVr) System is designed for transfemoral access and transseptal delivery of a self-expanding implant that restores competency in a regurgitant mitral valve.
224131017|NCT05611840|PROCEDURE|Robotic surgery|one-stage robotic common bile duct exploration and cholecystectomy
224131018|NCT05611840|PROCEDURE|Endo-laparoscopic surgery|Two-stage therapeutic ERCP plus interval laparoscopic cholecystectomy
224131019|NCT00905723|DRUG|estradiol|1 mg daily for 6 months
224131020|NCT00905723|DRUG|isoflavone|150 mg isoflavone daily for 6 months
224131021|NCT00905723|DRUG|Placebo|sugar pill daily for six months
224131022|NCT02683694|DEVICE|iOCT|the number of subjects that can be peeled without dye are assessed
224131023|NCT04949906|DRUG|Raise serum brain granules|Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
224131024|NCT04949906|DRUG|No nourishing serum brain granules are used|No nourishing serum brain granules are used
224131025|NCT01493986|DRUG|Ropivacaine|Dosage. Onset time
224131026|NCT00236119|DRUG|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
223399973|NCT00010335|PROCEDURE|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
223399974|NCT00010335|DEVICE|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
223399975|NCT04323410|PROCEDURE|Cast immobilization|Cast immobilisation is done using finger trap traction. The fractured forearm is splinted above elbow with dorsal cast without attempted reduction.
223732473|NCT02936245|OTHER|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
224131027|NCT00236119|DRUG|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
223732474|NCT02033122|OTHER|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
223399976|NCT04323410|PROCEDURE|Percutaneus pinning|Reduction under fluoroscopic guidance and fixation using two crossing 1.6mm K-wires.
223732475|NCT02033122|OTHER|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
223732476|NCT01909154|BIOLOGICAL|Mesenchymal stromal cell therapy|Stem cells administration locally
223732477|NCT00463346|DRUG|Acamprosate|Acamprosate 1998 mg tid
223732478|NCT00463346|DRUG|Placebo|Placebo
223732479|NCT05072561|DIAGNOSTIC_TEST|Sentinel lymph node scintigraphy|"During the surgery, right after the identification of the primary, 18-37 MBq of 99mTc-Nanocolloids in two ml will be injected at four peritumoral locations. After a brief waiting time (5-10'), the thoracic surgeon will perform the clinical intervention, including the lobectomy (the injection sites will be resected alongside the tumour) and lymphadenectomy, according to the best clinical practice. All the excised lymph nodes will be ex vivo counted using a gamma probe: those with a detectable activity (at least 10% of the hottest lymph node) will be considered as SLN. Thereafter, the mediastinum will be scanned using the gamma probe and a handheld gamma-camera (the latter will not be employed in case of robotic-assisted surgery); any further source of radioactivity will be investigated and, should further lymph nodes be identified, these will be also resected and classified in SLN or non-SLN, based on ex vivo activity."
223732480|NCT01882621|DRUG|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
223732481|NCT01882621|DRUG|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
223732482|NCT03879655|DRUG|VTS-270|Administered IT via LP infusion of VTS-270
224020616|NCT01945060|DEVICE|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server."
224020617|NCT01945060|OTHER|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
224020618|NCT04002193|OTHER|volume expansion|To assess fluid responsiveness
223399977|NCT04167319|OTHER|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
223732483|NCT02785107|BEHAVIORAL|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
223732484|NCT02310685|OTHER|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
223732485|NCT02123498|DRUG|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
223732486|NCT02123498|DRUG|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
223732487|NCT02123498|DRUG|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
224131028|NCT00236119|DRUG|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
224131029|NCT00236119|DRUG|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
224131030|NCT06463548|DRUG|irinotecan hydrochloride liposome injection|Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.
223399978|NCT06396117|OTHER|mTESE (microscopic testicular sperm extraction)|"Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves:~1. Testicular biopsy: Removing a small sample of testicular tissue.~2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production.~3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue.~This technique allows for:~* More accurate identification of sperm-containing areas~* Lower risk of damage to surrounding testicular tissue~* Potential for higher sperm retrieval rates compared to conventional method"
224131031|NCT06463548|DRUG|Capecitabine|Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.
224131032|NCT06463548|DRUG|Lenvatinib|Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
223732488|NCT02123498|PROCEDURE|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
224131033|NCT00498238|DRUG|Levothyroxine|
224131034|NCT04831515|DEVICE|Lens A|daily disposable soft contact lens - test lens
224131035|NCT04831515|DEVICE|Lens B|daily disposable soft contact lens - control lens
223732489|NCT02123498|PROCEDURE|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
223732490|NCT05563233|OTHER|Helfer skin tap technique|Using the Helfer skin tap technique during intramuscular injection to the ventrogluteal region.
223732491|NCT05563233|DEVICE|Shot Blocker|Shot Blocker will be used during intramuscular injection to be applied to the ventrogluteal region.
223732492|NCT05063669|BEHAVIORAL|Cognitive Occupational Therapy|In the sessions, activities aimed at reasoning and empathy skills, problem solving, evaluating emotional cues, evaluating events from different perspectives, providing personal control, delaying reactions, motor planning, visual perception and prolonging attention span were applied. The interventions were varied according to the personal characteristics of the individuals. In group interventions with three or four participants, group games in the form of cooperation or competition were planned to develop motor planning and cognitive strategy and it was aimed to improve children's rapid decision making and adaptation skills.
223732493|NCT00850824|BEHAVIORAL|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
223732494|NCT02045368|DRUG|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
223732495|NCT00489398|DRUG|epinastine HCL and olopatadine HCL|
224020619|NCT01704768|BEHAVIORAL|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
224131036|NCT02698618|PROCEDURE|Diagnostic|"Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
223732496|NCT00672789|BEHAVIORAL|Blood smear education|education at baseline and three month follow-up
223732497|NCT00672789|OTHER|standard education|standard education
223732498|NCT01941901|DRUG|Calcium electroporation|Intratumoral injection, once only treatment.
223732499|NCT01941901|DRUG|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
223399979|NCT06071364|DIAGNOSTIC_TEST|Ultrasonography imaging and Hand-held dynamometer (HHD)|"Ultrasound imaging system will be used to evaluate the thickness, cross -sectional area and fat infiltration of lumbar extensors lumbar multifidus , erector spinae and quadratus lumborum muscles.~The hand-held dynamometer assessing isometric lumbar muscles strength"
223399980|NCT00471081|BIOLOGICAL|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
223399981|NCT04145050|OTHER|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
223399982|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
223732500|NCT04067544|DEVICE|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
224131037|NCT02698618|DRUG|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
223399983|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
223399984|NCT00277238|DRUG|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
223399985|NCT00277238|DRUG|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
223399986|NCT04382495|OTHER|survey|online survey
223399987|NCT05472025|OTHER||
223399988|NCT01997788|DRUG|The intrathecal morphine injection|A single injection of morphine intrathecally
223399989|NCT01997788|DRUG|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
223399990|NCT01997788|DRUG|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
224131038|NCT02698618|PROCEDURE|PCI|"1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
223399991|NCT03205722|OTHER|Non-Interventional|Non-Interventional
224131039|NCT05016869|DRUG|fruquintinib plus capecitabine|"Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W"
223399992|NCT05727839|DRUG|JCXH-211 Injection|JCXH-211 administered once every 28 days
223399993|NCT00083382|DRUG|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
223399994|NCT00083382|DRUG|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
223399995|NCT00083382|DRUG|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
223399996|NCT02852135|DEVICE|LMA Proseal|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
224020620|NCT01704768|BEHAVIORAL|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
224020621|NCT02754817|DRUG|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
224020622|NCT00402597|DRUG|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
223732501|NCT02655562|DRUG|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO\<25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO\<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
224020623|NCT00402597|DRUG|Placebo|1 placebo tablet twice daily for 6 months.
224131040|NCT02854904|DRUG|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
224131041|NCT02854904|DRUG|Placebo|Placebo controlled
223399997|NCT02852135|DEVICE|LMA Supreme|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
224296997|NCT04969718|OTHER|LEADS Plus educational posters|This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
224296998|NCT04969718|OTHER|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
223399998|NCT05995574|BEHAVIORAL|avatar communication training|Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
223399999|NCT00959114|BIOLOGICAL|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
223400000|NCT00959114|BIOLOGICAL|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
223400001|NCT00578019|PROCEDURE|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith \& Nephew supracondylar nail.
223400002|NCT00578019|PROCEDURE|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes \[USA\], Paoli, PA, USA).
223400003|NCT05650684|OTHER|data collection|continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)
223732502|NCT04615923|DRUG|Pridopidine|"Administration: Oral~Dose: 45mg twice daily"
223732503|NCT04615923|DRUG|Matching Placebo|"Administration: Oral~Dose: one capsule twice daily"
223732504|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
223732505|NCT03621488|OTHER|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
223732506|NCT00308503|DRUG|eplivanserin (SR46349)|oral administration
223732507|NCT00308503|DRUG|placebo|oral administration
223732508|NCT02282020|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
224131042|NCT06153082|DIAGNOSTIC_TEST|ROTEM|In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
223400004|NCT03779217|OTHER|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
223400005|NCT03779217|PROCEDURE|mastoplasty and breast fat excission|As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
223400006|NCT01059422|DRUG|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
223400007|NCT04370171|OTHER|care modalities|For these patients the consultation has been postponed for 6 months. No specific intervention for this group of patient.
223551838|NCT04327362|BEHAVIORAL|Prolonged Exposure Therapy|All participants will receive 10 weekly sessions of standard Prolonged Exposure Therapy, or PE, which is a gold standard trauma-focused cognitive behavioral treatment for PTSD. The first sessions (1-2) predominately consist of psychoeducation about PTSD and the rationale for treatment, whereas subsequent sessions (3-10) consist of imaginal and in vivo exposure, involving repeated, prolonged, systematic, and deliberate practice approaching trauma reminders, as well as cognitive and emotional processing reactions to an index trauma memory.
223551839|NCT04769323|DEVICE|Virtual Reality|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
223732509|NCT02282020|DRUG|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
224131043|NCT06153082|DIAGNOSTIC_TEST|Thromboelastography|Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
223400008|NCT04370171|OTHER|Teleconsultation either by phone or by computer consultation|Management of diabetic patients by telemedicine with a teleconsultation either by phone or by computer consultation
223551840|NCT04769323|OTHER|Traditional home exercises|Vestibular rehabilitation is an exercise-based program, designed by a specialty-trained vestibular physical therapist, to improve balance and reduce problems related to dizziness.
223551841|NCT06315413|PROCEDURE|Socket preservation using xenograft and composite plug|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.
224131044|NCT06220630|OTHER|Breast cancer|Male patients who were microscopically diagnosed as primary breast cancer.
224131045|NCT03338114|DRUG|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
224131046|NCT03639012|DIETARY_SUPPLEMENT|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
224131047|NCT03059719|BIOLOGICAL|Exenatide injection(Byetta)|
224131048|NCT03059719|BIOLOGICAL|PB-119 injection|
223400009|NCT04335123|DRUG|Losartan|25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion
223400010|NCT00076726|DRUG|Infliximab|
223400011|NCT05025358|DRUG|LP-118 tablet|Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.
223551842|NCT06315413|PROCEDURE|Socket preservation using xenograft and intentionally exposed d-PTFE|Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
223551843|NCT06532071|DRUG|[68Ga]CBP8|Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8
223551844|NCT06532071|DRUG|Gadoterate Meglumine|Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
223551845|NCT04986566|OTHER|Best Practice|Use standard reporting procedures
223551846|NCT04986566|BEHAVIORAL|Health Education|Use Aetonixx app
223551847|NCT04986566|OTHER|Medical Device Usage and Evaluation|Wear Vivofit 4
223551848|NCT04986566|OTHER|Quality-of-Life Assessment|Complete questionnaires
223551849|NCT03654170|DRUG|BI 425809 mixed with [C-14] BI425809|Oral Solution
223551850|NCT04941183|DRUG|NTR-441|NTR-441
223732510|NCT05990101|BEHAVIORAL|Awake prone position (APP)|Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
224296999|NCT04969718|OTHER|Screening by Professionals programme plus educational posters|This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
224297000|NCT04969718|OTHER|educational posters|Six educational posters will be displayed in all schools in this cluster.
223400012|NCT01146639|RADIATION|DynaCT|One extra set of images with DynaCT including one extra injection of contrast medium.
223732511|NCT02244489|DRUG|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
224020624|NCT00402597|DRUG|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
224020625|NCT00440258|DRUG|Cabergoline|
223400013|NCT01146639|DRUG|Iodixanol|One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
223400014|NCT01283464|DRUG|Retinol|1.0% cream
223400015|NCT01283464|DRUG|Tretinoin|0.02% cream
223400016|NCT06122792|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
223551851|NCT04941183|DRUG|Placebo|Placebo
223400017|NCT06122792|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic injection of tissue adhesives will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new endoscopic injection of tissue adhesives will be performed."
223400018|NCT02626026|DRUG|Tirabrutinib|Capsules administered orally.
223551852|NCT02700035|OTHER|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
223551853|NCT03574610|DEVICE|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
223551854|NCT03654924|DEVICE|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
223551855|NCT00377845|PROCEDURE|Regular Tampax used in 3 hours|
223551856|NCT00005077|DRUG|oxaliplatin|
223551857|NCT02428751|DRUG|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
223551858|NCT02428751|DRUG|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
223551859|NCT02428751|DRUG|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
223551860|NCT02428751|DRUG|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
223551861|NCT02428751|DRUG|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
223551862|NCT02428751|DRUG|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
223551863|NCT01032954|DRUG|Botulinum toxin|"Drug: Botulinum toxin~Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:~Upper face:~* Crow's feet wrinkles - 70 units~* Glabella - 50 units~* Forehead - 40 units~Mid face:~* Lower eyelid - 5 units~* Nasal wrinkles - 20 units~* Malar wrinkles - 10 units~Lower face:~* Peri-oral wrinkles - 15 units~* Asymmetric smile or gummy smile - 5 units~* Cellulitic chin - 20 units~* Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs."
223551864|NCT06000462|DRUG|Dapagliflozin 10mg Tab|Mentioned in detailed description.
223551865|NCT06000462|DRUG|Metformin 1000 mg (ttd)|A dose of 1000 mg, PO, once daily, given over 8 months period
223551866|NCT06000462|OTHER|Placebo|a non-medicated pill will be used as a placebol
223551867|NCT01541735|DRUG|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
223551868|NCT01541735|DRUG|placebo|Placebo 40 mg dose.
223551869|NCT06444854|PROCEDURE|early chest tube removal|Chest tube removal
223551870|NCT06378632|DEVICE|Hearo App|No intervention - only data collection
223732512|NCT02244489|DRUG|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
224020626|NCT00440258|PROCEDURE|MR|
224020627|NCT00440258|PROCEDURE|Ultrasound|
224020628|NCT00440258|PROCEDURE|Blood Analysis|
224020629|NCT00250926|DRUG|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
224020630|NCT00250926|DRUG|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
224020631|NCT00250926|DRUG|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
224020632|NCT01208441|DRUG|letrozole|
224020633|NCT01208441|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
224020634|NCT01208441|PROCEDURE|therapeutic conventional surgery|
224020635|NCT01208441|PROCEDURE|breast biopsy|
223400019|NCT02626026|DRUG|Placebo|Capsules administered orally.
223551871|NCT03947281|OTHER|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
223551872|NCT03947281|OTHER|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
223400020|NCT00687726|BEHAVIORAL|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
223400021|NCT00687726|BEHAVIORAL|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
223400022|NCT04289025|OTHER|Exercise|A set of exercises are provided to each patient.
223400023|NCT03563599|DRUG|Telacebec (Q203)|High, Mid, Low dose of telacebec
223551873|NCT04473950|DRUG|Naloxone Hydrochloride|An intramuscular (IM) injection of naloxone will be given.
223551874|NCT04473950|DRUG|Placebo|An IM injection of 0.9% normal saline will be given.
223551875|NCT06353633|DIETARY_SUPPLEMENT|formula|The calories needed by the person are calculated and half of the calories are provided by formulas and the other half based on the elimination diet
223551876|NCT06353633|BEHAVIORAL|exclusion diet|In this group, only the elimination diet is considered as an intervention
223551877|NCT00202215|BEHAVIORAL|Chrysalis Day Program|
223551878|NCT02777450|PROCEDURE|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
223551879|NCT02634775|OTHER|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
223551880|NCT05139745|DEVICE|BTL-899|BTL-899 treatment
224020636|NCT01208441|OTHER|diagnostic laboratory biomarker analysis|
224020637|NCT01208441|OTHER|pharmacological study|
223551881|NCT04704297|DRUG|Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.|We are testing which of the three arms is superior for the treatment of Myofascial Pain Syndrome of the Low Back. Pain will be measured using a 10 cm visual analogue scale (VAS) at baseline and 30-minutes after treatment.
223551882|NCT04704297|DRUG|Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.|Evaluation of functional ability using a patient centered functional score known as the MODI. The MODI will be scored at baseline and 30-minutes after treatment.
224020638|NCT02319525|OTHER|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
223400024|NCT03563599|DRUG|Rifafour e-275|RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
223551883|NCT04704297|DRUG|Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.|60-72 after treatment in the Emergency Department, a member of the study team will follow up with participants to repeat a measurement of pain and functional ability on VAS and MODI respectively. This will be compared to baseline measurements.
223551884|NCT03573206|DEVICE|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
223551885|NCT00416494|BIOLOGICAL|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
223551886|NCT00416494|DRUG|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
223400025|NCT06578000|DRUG|Magnesium sulfate|Iontophoresis therapy (MgO4 will be applied to the active positive electrode and the treatment will be repeated twice a week for four weeks) + conventional therapy (Splint + Stretch + strength).
223400026|NCT06578000|OTHER|conventional therapy|conventional therapy (Splint + Stretch + strength) twice a week for six weeks
223400027|NCT03491293|BEHAVIORAL|Behavioral Weight Loss + Text|Participants will attend weekly one hour classes on line. They will type their input and responses within the chat room. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide feedback to reinforce or shape new behaviors and to identify high risk situations for problem solving.
223400028|NCT03491293|BEHAVIORAL|Behavioral Weight Loss + Video|Participants will attend weekly one hour classes on line. They will have audio and video within the chat room, and will talk with their facilitator and classmates during their weekly meeting. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide
223400029|NCT01275365|DRUG|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
223400030|NCT01275365|DRUG|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
223551887|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
223551888|NCT00416494|DRUG|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
223551889|NCT02222688|DRUG|cirmtuzumab|
223551890|NCT05711706|OTHER|Su Jok Application|Su Jok massage appplication
223551891|NCT05562518|DRUG|Estrogen|1 vaginal ovule daily for three consecutive weeks, followed by 1 vaginal ovule 2 times per week
223551892|NCT05562518|DRUG|dehydroepiandrosterone|1 vaginal ovule daily
224020639|NCT02319525|OTHER|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology \[ACR\]) regarding lupus and its treatments, that explained risks and benefits of various treatments
224020640|NCT03005964|DRUG|AM001 Cream, 7.5%|Active Cream
224020641|NCT03005964|DRUG|Vehicle Cream|Placebo
224020642|NCT05312788|OTHER|Effect of Barley Supplemented Wheat Bread on markers of Cardiovascular and Renal Health|Intervention will involve intake of 50% barley substituted wheat bread.
224297001|NCT04969718|OTHER|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
224297002|NCT02774096|DRUG|xenon|
223400031|NCT01427348|PROCEDURE|with assistant|head extension by an assistant during direct laryngoscopy
223400032|NCT01427348|PROCEDURE|without assistant|without head extension by an assistant during direct laryngoscopy
223400033|NCT00873392|DRUG|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
223400034|NCT00873392|OTHER|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
223400035|NCT05505435|DRUG|Depot-Medroxyprogestereone Acetate|subcutaneous depot medroxyprogesterone acetate
223551893|NCT05562518|DRUG|Estrogen + probiotics|1 vaginal ovule daily for 12 consecutive days, followed by 1 vaginal ovule 2 times per week
223551894|NCT05562518|DRUG|Moisturizer|1 vaginal ovule daily for 14 consecutive days, followed by 1 vaginal ovule every three days
223551895|NCT03844672|BEHAVIORAL|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
223551896|NCT03844672|BEHAVIORAL|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
223551897|NCT03844672|BEHAVIORAL|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
224020643|NCT04246320|OTHER|Goal directed therapy (GDT)|Goal directed therapy (GDT) hemodynamic management (MAP \> 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
223551898|NCT03844672|BEHAVIORAL|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
224020644|NCT04890925|BEHAVIORAL|Community Support Network (CSN) intervention|The SOAR Community Support Network (CSN) intervention is a multi-pillar, interdisciplinary system platform focused on improving higher order cognitive functions through aerobic exercise, mindfulness meditation, counselling, quality of life tracking, and cognitive exercises. The goal is to improve cognitive functions such as executive function, reasoning, and memory among those experiencing the effects of brain injury. Individually tailored protocol is administered to each participant. Goals are set daily, weekly, and monthly, and accomplishments tracked in a database. The CSN seeks to test and evaluate the success of the program when applied, and tailored, to survivors of brain injury in intimate partner violence.
224131049|NCT01819311|BEHAVIORAL|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
224131050|NCT01819311|BEHAVIORAL|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
224297003|NCT03449836|COMBINATION_PRODUCT|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
223400036|NCT05505435|DRUG|Depot-Medroxyprogestereone Acetate|intramuscular depot medroxyprogesterone acetate
223400037|NCT01616836|OTHER|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
223400038|NCT01616836|OTHER|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
224297004|NCT03449836|COMBINATION_PRODUCT|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
224297005|NCT03449836|OTHER|placebo|nasal spray based on isotonic solution
224297006|NCT00006235|DRUG|carboplatin|
224297007|NCT00006235|DRUG|pegylated liposomal doxorubicin hydrochloride|
223400039|NCT01616836|OTHER|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
223551899|NCT04248712|DRUG|Famotidine|40 mg tab twice daily by mouth for 12 week duration
223551900|NCT04248712|DRUG|Loratadine|10 mg tab once daily by mouth for 12 week duration
223551901|NCT04248712|DRUG|Placebo|Contains no active ingredient
223551902|NCT02656966|DEVICE|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
223551903|NCT01277705|BIOLOGICAL|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
223551904|NCT01277705|BIOLOGICAL|Boostrix™|Intramuscular, single dose
223551905|NCT01277705|BIOLOGICAL|GSK Biologicals' IPV vaccine|Intramuscular, single dose
223551906|NCT01277705|BIOLOGICAL|Revaxis®|Intramuscular, single dose
224297008|NCT04205019|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
224297009|NCT04192279|DIAGNOSTIC_TEST|lactate clearance|Lactate clearance rate was monitored within 6 hours after admission
224297010|NCT04004143|OTHER|No intervention|No intervention.
223732513|NCT02244489|DRUG|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
224297011|NCT04852900|OTHER|Decompression with 30%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
224297012|NCT04852900|OTHER|Decompression with 40%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
224020645|NCT04890925|BEHAVIORAL|Usual care|Participants in this group will receive dose-equivalent usual care based on the findings of a recent survey of the Canadian Rehabilitation Clinicians for concussion management, scoping review and clinical studies. Based on the evidence, usual care in this study will consist of education and aerobic exercises. Education includes information about the injury, recovery, management, nutrition, hydration, sleep, reassurance and goal setting that will be adapted to make appropriate to the population of this study. Aerobics include stationary cycling and treadmill exercises.
224020646|NCT00824811|DRUG|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
224020647|NCT00824811|DRUG|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
223732514|NCT05620004|DRUG|Bifidobacterium Bifidum Oral Product|experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
224020648|NCT00824811|DRUG|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
224020649|NCT00938860|DRUG|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
224020650|NCT00938860|DRUG|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
223732515|NCT02305108|OTHER|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
224020651|NCT02222051|BEHAVIORAL|Tai Chi|traditional chinese martial art meditative movement technique
224020652|NCT02222051|BEHAVIORAL|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
224020653|NCT03035266|OTHER|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
224020654|NCT03035266|OTHER|Standard rehabilitation|Standard of care for post-operative condition
224020655|NCT02982733|OTHER|ABS|Ankaferd Blood Stopper
224020656|NCT02982733|DEVICE|TR Band|Transradial band
224020657|NCT02982733|OTHER|CS|Sterile Gauze
224020658|NCT06318767|PROCEDURE|hemodynamic measure of the Systolic Time Rise|The hemodynamic measure of the Systolic Time Rise will be added in the routine doppler echography, planned in preoperative, postoperative and at 6 months of following up. This measure is taken on the foot, with ultrasound probe.
224131051|NCT01844622|OTHER|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
224131052|NCT03721393|DEVICE|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
224131053|NCT01640925|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
223551907|NCT01132950|BEHAVIORAL|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
223551908|NCT01132950|OTHER|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
223551909|NCT06138600|DRUG|Cabotegravir Injection [Apretude]|White to slightly pink free flowing suspension suspension for injection contained in a brown coloured vial. Each vial is for single use and does not require dilution prior to administration.
223551910|NCT06138600|DRUG|Tenofovir disoproxil fumarate / emtricitabine (or lamivudine)|TDF/FTC is currently available as standard of care for PrEP in the public sector as per the department of health guidelines.
223551911|NCT00867958|DEVICE|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
223551912|NCT00463138|BEHAVIORAL|Crisis intervention|
223551913|NCT03337867|DEVICE|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
223551914|NCT03337867|DEVICE|Magstim Super Rapid2 System|Sham stimulation
223551915|NCT03752996|DEVICE|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
223551916|NCT03759639|DRUG|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
223551917|NCT04517695|DEVICE|BVA-100|The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin.
223551918|NCT04517695|DEVICE|Transpulmonary Thermodilution (TPTD)|TPTD consists of placing a thermistor-equipped catheter in a central artery (usually the femoral or axillary artery) and injecting cold saline solution into a central vein through a central venous catheter.
223551919|NCT04517695|DEVICE|Sublingual Microcirculation|With incident dark field imaging, the CytoCam device can record digital image sequences using a handheld camera. In the current study the camera will be used to non-invasively record images of the sublingual microcirculation.
223551920|NCT01322854|RADIATION|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
223551921|NCT04454320|OTHER|INTUSSUSCEPTION IN CHILDREN|the seasonal variation and management outcomes of childhood intussusception.
223551922|NCT00149240|BIOLOGICAL|Botulinum toxin type A|
223400040|NCT03549078|BEHAVIORAL|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
223400041|NCT03657420|DRUG|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
223400042|NCT03657420|DRUG|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
223551923|NCT01461499|DRUG|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
223551924|NCT01461499|DRUG|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP \< 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
223551925|NCT05960643|OTHER|Training and application in breast modeling|BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.
223551926|NCT05960643|OTHER|Control|No intervention will be made against people in this group.
223551927|NCT02467127|DIETARY_SUPPLEMENT|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
223551928|NCT00479570|DRUG|PF-00446687|Single 200mg dose
223551929|NCT00479570|DRUG|Placebo|
223551930|NCT03005561|BEHAVIORAL|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
223551931|NCT00958360|OTHER|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
223551932|NCT00958360|OTHER|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
223551933|NCT03107052|DRUG|Fremanezumab|Fremanezumab
223551934|NCT00321243|BEHAVIORAL|Visual clues|
223551935|NCT06534047|DEVICE|Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member."
223551936|NCT06534047|DRUG|Nicotine replacement|"Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)"
224131054|NCT01640925|OTHER|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
223400043|NCT03657420|DRUG|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
223551937|NCT06547333|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
223551938|NCT06547333|DRUG|Placebo|Placebo
223551939|NCT01404143|PROCEDURE|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
223551940|NCT01404143|PROCEDURE|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
223551941|NCT02453152|OTHER|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
223400044|NCT02964520|BEHAVIORAL|Neurofeedback training|uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
224131055|NCT02343276|DRUG|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
224131056|NCT02343276|OTHER|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
224131057|NCT05004142|DRUG|FCN-437c+Fulvestrant|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Fulvestrant, C1D1 and C1D15 and Day 1 of each cycle, 500mg/day, intramuscularly.
224131058|NCT05004142|DRUG|FCN-437c+Letrozole+Goserelin|FCN-437c 200mg, oral administration under fasting conditions, QD, for 21 days, with 7-day discontinuation, 28 days for 1 cycle; Letrozole 2.5 mg, QD, for continuous dosing; Goserelin 3.6 mg, subcutaneously, once every 28 days.
224131059|NCT01679093|DRUG|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
223400045|NCT02964520|BEHAVIORAL|Sham comparator: Sham neurofeedback training|in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
223400046|NCT03005704|DRUG|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
223400047|NCT00582101|BEHAVIORAL|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
223400048|NCT00582101|BEHAVIORAL|General Health Promotion|7 hour one-day workshop on general health promotion topics
223400049|NCT03432104|DIETARY_SUPPLEMENT|Oxxynea®|Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.
223400050|NCT03432104|DIETARY_SUPPLEMENT|Placebo|Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.
223400051|NCT03638804|DIAGNOSTIC_TEST|89Zr-KN035|Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.
223400052|NCT03922308|OTHER|Placebo|Participants will receive injection of placebo matched to SHP655.
223400053|NCT03922308|DRUG|SHP655|Participants will receive injection of SHP655.
223400054|NCT03922308|OTHER|Standard of Care|Participants will receive PEX as Standard of Care (SOC).
223400055|NCT06354036|PROCEDURE|the Transhiatal Tunnel Valvuloplasty technique|The ThTV esophagogastrostomy procedure involved placing a lengthy gastric tube into the lower mediastinum, firmly bound to the esophagus.
223400056|NCT05428774|OTHER|Test product 1|Participants will receive TP1 during one experimental visit.
223400057|NCT05428774|OTHER|Test product 2|Participants will receive TP2 during one experimental visit.
223551942|NCT02453152|OTHER|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
223551943|NCT02453152|OTHER|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
223551944|NCT02453152|OTHER|Peak cough flow|Subjects' strongest coughs will be measured.
223551945|NCT02453152|OTHER|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
223551946|NCT02453152|OTHER|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
223551947|NCT02453152|OTHER|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
223551948|NCT05993988|OTHER|Exercise|Muscle relaxing Technique
223551949|NCT02064049|DRUG|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
223551950|NCT03922672|BEHAVIORAL|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
223551951|NCT00879034|DRUG|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
223551952|NCT00879034|DRUG|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
224131060|NCT01679093|DRUG|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
224131061|NCT01679093|DRUG|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
224131062|NCT00003026|DRUG|bicalutamide|
224131063|NCT00003026|DRUG|flutamide|
223400058|NCT05428774|OTHER|Placebo|Participants will receive placebo during one experimental visit.
223400059|NCT03340597|DRUG|F901318|F901318 tablet
223400060|NCT01994408|OTHER|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
223400061|NCT06255119|DEVICE|3D Therapy Thrive|A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
223400062|NCT03376789|DRUG|MYL-1501D product using manufacture process V|MYL-1501D product using manufacture process V
223400063|NCT03376789|DRUG|MYL-1501D product using manufacture process VI|MYL-1501D product using manufacture process VI
223551953|NCT00879034|DRUG|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
223551954|NCT00425022|PROCEDURE|thoracoscopy|
223551955|NCT02719691|DRUG|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
224131064|NCT00003026|DRUG|triptorelin|
224131065|NCT00003026|RADIATION|radiation therapy|
224131066|NCT00731263|DRUG|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
223732516|NCT02305108|OTHER|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
224020659|NCT06529510|BEHAVIORAL|REThink therpeutic game|REThink is an online therapeutic game aimed at enhancing the emotional health of young people, grounded in Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who guides players through seven levels, each focused on teaching a specific emotional regulation skill. Each level has three sub-levels that progressively increase in difficulty. REThink can be used as a standalone intervention, an adjunct to self-help psychotherapeutic approaches, or for targeted skills training.
224020660|NCT05912582|RADIATION|Intensity modulated radiation therapy (IMRT) combined with chemotherapy|Intensity modulated radiation therapy (IMRT) combined with chemotherapy
223732517|NCT02747706|BEHAVIORAL|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
223400064|NCT04787913|BEHAVIORAL|herdimm|In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.
223732518|NCT04941235|DEVICE|ultrasound and nerve stimulator|nerve stimulator and ultrasound guided interscalene brachial plexus block
224131067|NCT03441893|DIAGNOSTIC_TEST|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
224131068|NCT03441893|DRUG|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
223400065|NCT04787913|BEHAVIORAL|guardianmeasles|A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated
223400066|NCT04787913|BEHAVIORAL|theotheredmundmeasles|A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4
223400067|NCT04787913|BEHAVIORAL|sbsnewsgeneric|A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles
223400068|NCT04787913|BEHAVIORAL|publichealthagencycanadaflu|A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html
223400069|NCT04787913|BEHAVIORAL|robertkochgeneric|A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/
223400070|NCT01118741|DRUG|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
223732519|NCT00082355|DRUG|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
223732520|NCT06443840|DEVICE|AutonHome® device|The experimental group will have to carry out the programme of self-rehabilitation and tele-rehabilitation with the AutonHome® device in addition to conventional rehabilitation.
223732521|NCT01051050|BEHAVIORAL|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
223732522|NCT01051050|BEHAVIORAL|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
223732523|NCT01207765|DRUG|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
224131069|NCT03441893|DRUG|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
223400071|NCT04812041|OTHER|CAM-ICU 7 score|A 7-point rating scale (0-7) was derived from the CAM-ICU and RASS assessments 0-2: no delirium, 3-5: mild to moderate delirium, and 6-7: severe delirium.
223400072|NCT04812041|OTHER|4C Mortality Score|4C Mortality Scores of the patients will be calculated, according to age, gender, number of comorbidities, respiratory rate, SpO2, GCS, urea, and CRP parameters
223400073|NCT05214690|DRUG|DW1809-T2|pelubiprofen 25mg
223400074|NCT05214690|DRUG|DW1809-1|pelubiprofen 30mg (PELUBI tab.)
223400075|NCT00529503|DRUG|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
223400076|NCT00529503|DRUG|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
223400077|NCT00529503|DRUG|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
223400078|NCT00529503|DRUG|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
223400079|NCT00529503|DRUG|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
223400080|NCT00529503|DRUG|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
223400081|NCT04051671|DEVICE|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
223400082|NCT04501237|BEHAVIORAL|Bruxers with sleep hygiene instructions|the test group will receive instructions of sleep hygiene, limited use of screens and a relaxation audio.
223400083|NCT03693638|DRUG|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
224020661|NCT02388243|BEHAVIORAL|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
224020662|NCT02388243|BEHAVIORAL|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
224131070|NCT03441893|DRUG|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
224131071|NCT03441893|DRUG|Placebo tabletes|Tab. Placebo (shugar pills) will be given to the participants
224131072|NCT00839878|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
224131073|NCT03837353|DRUG|DKN-01|DKN-01 is a large molecular weight protein that will be given as a flat dose on a Days 1 and 15 of a 21-day cycle in Dose-Escalation Cohort 1A and Dose-Expansion Cohort 1B. DKN-01 will be given on Days 1 and 15 on a 28-day cycle in Dose-Escalation Cohort 2A and Dose-Expansion Cohort 2B. The dose of DKN-01 will be administered as an intravenous (IV) infusion over 60 (±) 15 minutes.
223400084|NCT03693638|DRUG|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
223400085|NCT04177095|DIAGNOSTIC_TEST|Allosure|Monthly monitoring of dd-cfDNA levels in blood
224297013|NCT04852900|OTHER|Decompression with 50%|"* Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks"
223551956|NCT02719691|DRUG|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
223551957|NCT05420181|OTHER|Short 10hr fast|Participants will fast from 11pm the night before the study day
223551958|NCT05420181|OTHER|Long 16h fast|Participants will fast from 5pm the night before the study day
223551959|NCT02159898|DEVICE|EndoMAXX Endoluminal Valve Technology (EVT)|
223400086|NCT04177095|DRUG|Immunosuppression reduction|Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
223400087|NCT04177095|DIAGNOSTIC_TEST|Trugraf|Monthly monitoring of Trugraf result
223400088|NCT00777296|DRUG|ARIKACE™|Study start date is before Jan 18, 2017.
223400089|NCT00777296|DRUG|Placebo|Study start date is before Jan 18, 2017.
223400090|NCT04082923|OTHER|Liquid meal|Four-hour liquid mixed meal test
223400091|NCT04082923|OTHER|Solid meal|Four-hour solid mixed meal test
223400092|NCT04665219|BEHAVIORAL|HBM-based text messages|"The intervention in the test group will consist of a set of text messages developed based on the HBM to be sent to the parents regularly in the following 48 weeks.~During the first 24 weeks, parents will receive a text message (and feedback if deemed appropriate) each week. In the next 24 weeks, the parents will receive a text message every 4 weeks, altogether 30 messages will be sent to the parents. All messages will be sent to the parents individually through free mobile App by a research assistant."
223551960|NCT02159898|DEVICE|EndoMAXX|
223551961|NCT02033629|DRUG|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
223551962|NCT02033629|DRUG|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
223551963|NCT02033629|DRUG|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
223551964|NCT00336284|OTHER|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
223551965|NCT00336284|OTHER|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
223551966|NCT06304181|DRUG|Paracetamol and Mannitol Injection|Paracetamol and Mannitol Injection 500mg
223551967|NCT06304181|DRUG|Parecoxib|40mg of parecoxib
223551968|NCT01185314|PROCEDURE|Testing for mutation status|EGFR mutation test
223551969|NCT02810912|OTHER|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
223551970|NCT03017872|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
223551971|NCT03017872|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
223551972|NCT03017872|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
223551973|NCT03017872|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
223551974|NCT01498744|DRUG|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole \[bactrim\] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
223551975|NCT00769171|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
223400093|NCT04665219|BEHAVIORAL|Standard text message|Parents in the control group will receive an oral health education pamphlet produced by the Oral Health Education Division in the Department of Health, the Government of Hong Kong SAR. In order to maintain a double-blind design in the present study, the pamphlet will be distributed in an electronic form and sent via a text message.
223400094|NCT05382819|DRUG|FRTX-02 Capsule|DYRK-1A Inhibitor
223400095|NCT05382819|DRUG|Placebo|Matching Placebo
223400096|NCT00350090|DRUG|Epoetin Alfa|
223400097|NCT00210418|DIETARY_SUPPLEMENT|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ \<-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
223400098|NCT00210418|BEHAVIORAL|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
223732524|NCT01207765|DRUG|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
223732525|NCT00759863|BEHAVIORAL|Lifezig|Personalized Reminiscence Video
223732526|NCT02729974|PROCEDURE|ROTEM|rapid testing of blood clot formation
223732527|NCT02729974|PROCEDURE|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
224020663|NCT02388243|BEHAVIORAL|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
223732528|NCT00294073|PROCEDURE|Fascia Iliaca Block|
223732529|NCT00294073|PROCEDURE|Femoral Block (with stimulating catheter)|
224297014|NCT05194878|DRUG|neoadjuvant chemotherapyI|mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.
224297015|NCT05194878|PROCEDURE|Colectomy|Radical colectomy
224297016|NCT05194878|DRUG|adjuvant chemotherapy|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
223400099|NCT02967315|PROCEDURE|Cardiac Magnetic Resonance Imaging (CMRI)|"There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast."
223732530|NCT00294073|PROCEDURE|Femoral Block (without stimulating catheter)|
224297017|NCT01327261|DRUG|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
223400100|NCT02967315|PROCEDURE|Central venous line placement|An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
223400101|NCT02967315|PROCEDURE|Chest X-ray|A chest X-ray will be performed for safety reasons to rule out pneumothorax (\< 1% risk) after central line placement.
223400102|NCT02967315|PROCEDURE|Fluid administration|Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
223400103|NCT02967315|PROCEDURE|Blood Draw|One to two teaspoons of blood will be drawn for basic metabolic panel.
223732531|NCT04309656|DRUG|Pretomanid|"1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered."
223732532|NCT01678092|BIOLOGICAL|omalizumab|
223400104|NCT02967315|PROCEDURE|Pregnancy test|A urine pregnancy test will be performed in female subjects.
223400105|NCT02967315|PROCEDURE|Electrocardiogram|12 lead ECG
223400106|NCT01644071|DRUG|cipralex|one time 10 mg, tablet
223732533|NCT02164747|DEVICE|Residents of nursing homes with telemedicine after implementation of telemedicine|
223732534|NCT01003509|PROCEDURE|modified shouldice and double|one arm modified shouldice, other one is double repair
223732535|NCT02395718|OTHER|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
223732536|NCT02395718|OTHER|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
223732537|NCT03694860|OTHER|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
223732538|NCT04804943|DEVICE|NOA-001|NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
224020664|NCT02388243|BEHAVIORAL|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
223400107|NCT00123760|PROCEDURE|Positron Emission Tomography (PET) scan|
223400108|NCT05984901|DEVICE|The continuous ambulatory vestibular assessment (CAVA) system|"The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).~The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack.~The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS."
223400109|NCT04282941|DRUG|Ibuprofen in continuous (24 hours) iv infusion and EchoG|The first dose of ibuprofen will be 10 mg / kg to be administered as a continuous infusion for 24 hours. An echocardiogram will be performed before each of the following 2 doses of 5 mg / Kg and will only be administered if it meets echocardiographic criteria that indicate open DA (observation of ductus permeability with color Doppler regardless of its size). Each dose will be administered as a 24-hour continuous infusion.
223400110|NCT04282941|DRUG|IV bolus Ibuprofen slow (15 minutes) and EchoG|The first dose of ibuprofen of 10 mg / Kg to be administered in slow iv bolus (15 minutes). Before each of the following 2 doses of 5 mg / Kg, echocardiography will be performed and will only be administered if it meets the echocardiographic criteria indicated by open DA (observation of ductus permeability in color Doppler regardless of its size). Each dose will be administered in iv boluses in 15 minutes
223400111|NCT06364917|DRUG|Pembrolizumab|The dosing regimens for Pembrolizumab (200 mg Q3W), are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
223400112|NCT06364917|DRUG|Carboplatin|The combination therapy dosages for Carboplatin are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
224131074|NCT03837353|DRUG|Docetaxel|Docetaxel will be administered as an IV infusion over approximately 60 (±15) minutes on day 1 of a 21-day cycle in Cohorts 1A and 1B. In Cohort 1A, docetaxel must be dosed at 75 mg/m2 on cycle 1 day 1. Docetaxel can be dosed at 75 mg/m2 or 60 mg/m2 in subsequent cycles depending on clinical discretion and dose modification guidelines. Regardless of dose, docetaxel must be dosed in 21-day cycles. In Cohort 1B, cycle 1 day 1 dosing of docetaxel will either be 75 mg/m2 or 60 mg/m2 depending on clinical discretion.
224131075|NCT04673136|DEVICE|GI-GENIUS Medtronic|Colonoscopy assisted by GI-GENIUS device
224131076|NCT04673136|OTHER|Colonoscopy|Standard colonoscopy
223400113|NCT06364917|DRUG|Paclitaxel|The combination therapy dosages for Paclitaxel are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
223400114|NCT06364917|DRUG|Pemetrexed|The combination therapy dosages for Pemetrexed are aligned with standard chemotherapy protocols for NSCLC, tailored to minimize toxicity while maintaining therapeutic efficacy. This dosing strategy is justified by previous phase 3 trials demonstrating the effectiveness and safety of these regimens in advanced NSCLC patients.
223551976|NCT00769171|DRUG|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
223732539|NCT04464343|OTHER|no intervention|This is an observation study, with no intervention
224020665|NCT04303715|PROCEDURE|No SLNB|BCS only. Ommission of SLNB by axilla ultrasonography among selective breast cancer patients
224020666|NCT04303715|PROCEDURE|SLNB|BCS with SLNB(+/-ALND)
224020667|NCT01818583|DRUG|Potassium chloride|
224020668|NCT01818583|DRUG|Glucose 50 MG/ML|
224131077|NCT03623334|RADIATION|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
224131078|NCT04624035|PROCEDURE|Implantable Collamer Lens (ICL) in treatment of myopia in adults.|ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
224131079|NCT04624035|PROCEDURE|Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.|IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
224131080|NCT00192439|BEHAVIORAL|High Risk Respiratory Disease|
224297018|NCT00601809|OTHER|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
224297019|NCT00601809|DRUG|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
224131081|NCT03372668|OTHER|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
223400115|NCT06364917|DRUG|Nivolumab|The dosing regimens for Nivolumab (360 mg Q3W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
223400116|NCT06364917|DRUG|Ipilimumab|The dosing regimens for Ipilimumab (1 mg/kg Q6W) are based on established FDA-approved dosages for the treatment of NSCLC, ensuring a balance between efficacy and tolerability. These doses are selected based on extensive clinical experience indicating optimal response rates with manageable safety profiles in the target population. The route of administration (intravenous) is chosen for its direct delivery into the bloodstream, ensuring maximum bioavailability and consistency of dosing.
223732540|NCT02408939|DRUG|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
223732541|NCT01548092|DRUG|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
223732542|NCT01971450|DRUG|Iloprost (Ventavis, BAYQ6256)|
223732543|NCT00303498|DRUG|Sitexsentin sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
224131082|NCT01030458|DRUG|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
224131083|NCT01030458|DRUG|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
224131084|NCT03604237|DIAGNOSTIC_TEST|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
224131085|NCT02420223|DRUG|Propranolol|
224131086|NCT04785079|PROCEDURE|Graston Instrument assisted Soft tissue Mobilization|Instrument assisted soft tissue mobilization using the Graston tool and technique for 3 minutes on each of the three locations
224131087|NCT01836744|DEVICE|Survival rate dental implant (OsseoSpeed™)|
224131088|NCT00985556|DRUG|capecitabine|Given orally
223551977|NCT01388049|DEVICE|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
223551978|NCT00861757|DRUG|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
223551979|NCT00861757|DRUG|Placebo|PO, QD (30 min after meal) for 12 weeks
223551980|NCT00861757|DRUG|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
223551981|NCT01230996|DRUG|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
223732544|NCT00303498|DRUG|Placebo|placebo identical to the study drug in description, dose and duration
224297020|NCT05065983|BIOLOGICAL|CHIKV VLP, adjuvanted|Adjuvanted formulation includes aluminum hydroxide
223732545|NCT00891722|OTHER|biologic sample preservation procedure|
223732546|NCT00891722|OTHER|laboratory biomarker analysis|
223732547|NCT00891722|OTHER|questionnaire administration|
223732548|NCT05027412|DEVICE|En bloc TURBT Collins Loop|En bloc TURBT Collins Loop
223732549|NCT05027412|DEVICE|Conventional TURBT|Conventional TURBT
224131089|NCT00985556|DRUG|oxaliplatin|Given IV
224131090|NCT00985556|DRUG|tegafur-gimeracil-oteracil potassium|Given orally
224131091|NCT04466501|DEVICE|ACR LAB|"The ACR \| LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The device combines a urine stick kit with an easy to use smartphone application using an image recognition algorithm."
224131092|NCT02353039|DRUG|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
224131093|NCT02353039|DRUG|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
224131094|NCT02353039|DRUG|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
224131095|NCT02353039|DRUG|Placebo|Administer placebo t.i.d for 2 weeks
224020669|NCT05965804|DIAGNOSTIC_TEST|McMurray knee examination test|The McMurray test will be performed in different knee flexion and rotation angles.
224020670|NCT01808326|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
224020671|NCT06131489|OTHER|Segmental bowel resection combined with the DEP regimen|Segmental bowel resection combined with liposomal doxorubicin, etoposide, and methylprednisolone administered in 2 week cycles for 2 cycles
224020672|NCT00577577|DRUG|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
223732550|NCT03629821|OTHER|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
223551982|NCT01230996|RADIATION|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
223732551|NCT00293696|DRUG|bicalutamide (Casodex), goserelin (Zoladex)|
223732552|NCT02784990|BIOLOGICAL|Lipase, amylase and CRP (C-reactive protein) dosages|
223732553|NCT02015780|DRUG|Fasiglifam|Fasiglifam tablets
223732554|NCT02015780|DRUG|Placebo|Fasiglifam placebo-matching tablets
224020673|NCT00577577|DRUG|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
224131096|NCT06100484|DIAGNOSTIC_TEST|Echocardiography|Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
224131097|NCT00980785|DRUG|Ramipril|Ramipril 5 mg/day
224131098|NCT00980785|DRUG|Placebo|Matching Placebo
224131099|NCT03173482|OTHER|questionnaire|asking about details of indication of cesarean section
224131100|NCT05024877|DRUG|Hetrombopag|Hetrombopag would be given started with 5mg/day and increased by 2.5mg/day every 2 weeks if the platelet count remains less than 20×10e9/L and reduced if the platelet count reaches over than 150×10e9/L, the maximum dosage is 15mg/day)
224131101|NCT05024877|DRUG|Stanozolol Tablets|Stanozolol would be given 2mg tid.
223400117|NCT05113550|OTHER|Surgical remove|liver hydatid cyst (LHC) treated by total or partial pericystectomy
223400118|NCT02472106|DEVICE|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
223400119|NCT05989256|DIAGNOSTIC_TEST|EndoTool|EndoTool is a vendor based glucose management software
224131102|NCT00165061|PROCEDURE|Esophagectomy|
223400120|NCT05989256|OTHER|glucose management team|comparison group will be services that have not yet implemented EndoTool
223400121|NCT05989256|OTHER|standard of care glucose management|providers adjusting insulin and consulting the Glucose Management Team at their discretion
223551983|NCT01230996|PROCEDURE|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
223551984|NCT03308968|DRUG|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
223551985|NCT03308968|DRUG|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
223551986|NCT05223179|BIOLOGICAL|CODA-VAX H1N1|Intramuscular Live Attenuated Influenza H1N1 Vaccine
223551987|NCT05223179|BIOLOGICAL|Flucelvax Quad|Licensed Seasonal Injectable Influenza Vaccine
223551988|NCT05223179|OTHER|Saline|Saline
223551989|NCT02812264|BEHAVIORAL|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
223551990|NCT02812264|BEHAVIORAL|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
223551991|NCT02812264|BEHAVIORAL|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
223551992|NCT02812264|BEHAVIORAL|scale|Connected scale that will transfer weight information to app
223551993|NCT05456373|DEVICE|ClearEdge device|ClearEdge tissue imaging device uses a new technology to detect tissue abnormalities at the surgical margins of a surgically excised breast tissue specimen. Adding the use of the imaging device has the potential to assist the surgeon in identifying DCIS or invasive cancer involved margins of the excised specimen.
223551994|NCT01964157|DRUG|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
223732555|NCT02015780|DRUG|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
223732556|NCT00279734|DRUG|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
223732557|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
223732558|NCT00279734|DRUG|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
224131103|NCT00165061|PROCEDURE|Chemoradiation|
224131104|NCT04050813|BEHAVIORAL|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
223732559|NCT00279734|DRUG|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
223732560|NCT04532099|DEVICE|Lehfilcon A contact lenses|Investigational soft contact lenses for daily wear worn in Part A of the study
223732561|NCT04532099|DEVICE|Senofilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part A of the study
223732562|NCT04532099|DEVICE|Comfilcon A contact lenses|Commercially available soft contact lenses for daily wear worn in Part B of the study
223732563|NCT04532099|DEVICE|Hydrogen peroxide-based cleaning and disinfecting solution|For nightly cleaning and disinfecting of contact lenses in Part A and Part B of the study
223732564|NCT00460031|DRUG|ketoconazole|400 tid
223732565|NCT00460031|DRUG|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
223732566|NCT00460031|DRUG|therapeutic hydrocortisone|20mg qam 10mg qhs
223732567|NCT04852458|DRUG|Intravenous (IV) hydrocortisone|"Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg."
223732568|NCT00660582|DRUG|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
223732569|NCT00660582|DRUG|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
223732570|NCT01194479|DRUG|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
224131105|NCT03737604|DRUG|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
224131106|NCT03737604|DRUG|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
224131107|NCT02875821|DRUG|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
224131108|NCT02875821|DRUG|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
224131109|NCT03397277|BEHAVIORAL|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
223400122|NCT04835662|BEHAVIORAL|Complementary feeding promotion|The intervention engaged fathers through community meetings, religious services, and mobile phone text and voice messages. Mothers received home visits from community health extension workers (CHEWs), which fathers also could attend. Social behavior change communication materials included TV and radio messages, sermon guides, counseling cards, pamphlets, posters, and feeding bowls.
223425692|NCT02890485|DEVICE|Sham Dry Needling|"The same overall procedures will be used as in the true dry needling groups and applied to the same muscle groups (gluteal or quadriceps) depending upon ground randomization. Sham dry needling will be performed using a commercially available sham needling system commonly.This set-up utilizes a blunt tipped needle. When the sham needle is pressed downward, the barrel of the needle retracts into the handle, giving the appearance of insertion of the needle through the skin. This also creates pressure on the subject's skin, increasing the sensation of dry needling. Patients will not be allowed to observe the areas being needled or sham needled."
224131110|NCT03397277|BEHAVIORAL|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
224131111|NCT01536977|OTHER|quality-of-life assessment|Ancillary studies
224131112|NCT01536977|OTHER|questionnaire administration|Ancillary studies
223732571|NCT01194479|OTHER|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
223732572|NCT04002531|OTHER|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
223732573|NCT04002531|OTHER|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
224131113|NCT01536977|BEHAVIORAL|management of therapy complications|Undergo BBT-I
224131114|NCT01536977|BEHAVIORAL|cognitive assessment|Ancillary studies
224131115|NCT01536977|BEHAVIORAL|educational intervention|Undergo BBT-I
224131116|NCT03474406|OTHER|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
224131117|NCT06444243|DRUG|Psilocybin|Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi.
223732574|NCT04002531|PROCEDURE|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
223732575|NCT04002531|PROCEDURE|Echocardiogram|A non-invasive sonogram of the heart
223732576|NCT04002531|PROCEDURE|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
223732577|NCT04002531|PROCEDURE|Urine collection|Urine will be collection to evaluate renal function (kidney health)
223732578|NCT04002531|PROCEDURE|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
223732579|NCT04002531|OTHER|Brief Pain Inventory questionnaire|A questionnaire about daily pain
223732580|NCT04002531|OTHER|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
224020674|NCT03913780|OTHER|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
223732581|NCT02086864|DRUG|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
223732582|NCT02086864|DRUG|Placebo lactose/sucrose pill|
224020675|NCT03572387|DRUG|5-Azacitidine|subcutaneously on days 1-5 at a dose of 40 mg/m\^2
224020676|NCT03572387|DRUG|all trans retinoic acid|45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses
223732583|NCT02086864|BEHAVIORAL|Homeopathic consultation|
223732584|NCT05683288|OTHER|IASTM|IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.
223732585|NCT05683288|OTHER|Myofascial Release|Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.
223732586|NCT05683288|OTHER|250W infrared application|For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm
223732587|NCT05683288|DEVICE|TENS|TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
223732588|NCT05683288|OTHER|Home exercise|Cervical strengthening and stretching exercises five days a week will given
223732589|NCT04103632|DIAGNOSTIC_TEST|EVH test|"* Spirometry~* Skin prick test~* Peripheral blood test~* FeNO measurement"
223732590|NCT00326443|BIOLOGICAL|CVD 909|5 X 10\^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
224020677|NCT03572387|DRUG|Lupron|7.5 mg x 1
224020678|NCT02458703|OTHER|Cardiopulmonary exercise test|"Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis."
224020679|NCT01856868|DRUG|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
224020680|NCT00968227|BIOLOGICAL|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
224020681|NCT00672191|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
224020682|NCT04901260|DEVICE|AMAZE™ Disease Management Platform|The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
223732591|NCT00326443|DRUG|Placebo|Buffer placebo administered on Day 0.
223732592|NCT00326443|BIOLOGICAL|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
223732593|NCT05547074|PROCEDURE|pancreatic cancer surgery|Surgical resection of pancreatic cancer，including radical or palliative surgery
224297021|NCT01765582|DRUG|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m\^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m\^2, followed by a 46-hour continuous infusion (2400 mg/m\^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
224020683|NCT01581138|DRUG|VX-222|400 mg tablets twice daily for oral administration
224020684|NCT01581138|DRUG|telaprevir|1125 mg tablets twice daily for oral administration
224020685|NCT01581138|DRUG|ribavirin|1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
224020686|NCT04987736|DIAGNOSTIC_TEST|RT-PCR|COVID 19 diagonostic test
224020687|NCT03367390|DEVICE|AID System|AID system
224020688|NCT03367390|DRUG|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
224020689|NCT00906945|DRUG|G-CSF|
224020690|NCT00906945|DRUG|Plerixafor|
224020691|NCT00906945|DRUG|Mitoxantrone|
224020692|NCT00906945|DRUG|Etoposide|
224020693|NCT00906945|DRUG|Cytarabine|
224020694|NCT03386110|BEHAVIORAL|Couples Health Project (CHP)|The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
224020695|NCT03386110|BEHAVIORAL|Education|The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
224020696|NCT03915704|DEVICE|Shotblocker|Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
224020697|NCT03915704|PROCEDURE|Control|No intervention was made in the children.
223732594|NCT04588402|BIOLOGICAL|The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.|"Women will be approached one time only, when they will attend the gynecology out-patients department for various reasons. After signing the informed consent, the participants will fill in a risk factor questionnaire to study the socio-demographic information, sexual history and HPV vaccination history and the determinent of HPV infection. The questionnaire will be administered by a trained social worker or nurse.~A gynecologist will collect cervical cells from the participant's cervix during a gynecological examination. The cervical specimen will be examined for presence of specific HPV genotypes and Chlamydia infection."
223732595|NCT02450032|BIOLOGICAL|G17DT|
223732596|NCT03454919|DRUG|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
223732597|NCT03860428|DRUG|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
223551995|NCT05439174|OTHER|Intradialytic Parenteral Nutrition|"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."
224020698|NCT03915704|DEVICE|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
223551996|NCT03890926|RADIATION|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
223551997|NCT01337843|OTHER|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
223732598|NCT03860428|DRUG|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
224020699|NCT03770533|OTHER|MR-proADM guided|MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
224020700|NCT01184261|BEHAVIORAL|behavioral intervention|8 session behavioral intervention.
224131118|NCT06444243|DRUG|Niacin|"A nutrient in the vitamin B complex that the body needs in small amounts to function and stay healthy. Niacin helps some enzymes work properly and helps skin, nerves, and the digestive tract stay healthy. Niacin is found in many plant and animal products.~Niacin will be used at a concentration of 250mg as an active control."
224131119|NCT00922194|DRUG|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
224131120|NCT04738500|PROCEDURE|PENG Block combinated with PCA|After spinal anesthesia PENG block will be performed
223732599|NCT03860428|OTHER|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
223732600|NCT03893136|BIOLOGICAL|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
223732601|NCT03893136|DRUG|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
223732602|NCT02604524|DEVICE|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
223732603|NCT02604524|OTHER|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
223732604|NCT03034421|BEHAVIORAL|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
224131121|NCT04738500|PROCEDURE|PCA|PCA will be applied after surgery
223732605|NCT02607436|DRUG|Sarpogrelate|Sarpogrelate
224131122|NCT05062616|PROCEDURE|Toenail surgery|modified Winograd procedure
223551998|NCT01337843|OTHER|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
223551999|NCT05769855|DRUG|HR18034|HR18034 380mg
223552000|NCT05769855|DRUG|ropivacaine HCl|ropivacaine HCl 75mg.
223552001|NCT05769855|DRUG|Sodium Chloride Physiological Solution|Sodium Chloride Physiological Solution 20ml
223552002|NCT01814319|DRUG|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
223732606|NCT02607436|DRUG|Aspirin|Aspirin
223732607|NCT03380585|PROCEDURE|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
223732608|NCT03380585|PROCEDURE|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
223732609|NCT05217407|OTHER|Genomic sequence|Genomic sequence
223552003|NCT01814319|DRUG|Placebo|Matching placebo oral twice daily
223552004|NCT06221761|DRUG|not using antibiotic|no antibiotic application
223552005|NCT06221761|DRUG|using antibiotic|antibiotic application
223400123|NCT06187012|OTHER|Hypertensive pregnancy|Participants will attend one visit lasting approximately 3-4 hours on a single day or split over multiple visits to complete all measures. Participants will first be asked to provide written informed consent for the study. Participants' anthropometric measures (waist-to-hip ratio, height and weight, hip and waist circumference and left arm circumference and resting blood pressures will then be taken. After this, the participants will undergo cardiopulmonary exercise testing, followed by magnetic resonance imaging, echocardiography, retinal imaging and vascular imaging of the ear. The study visit will conclude with participants being provided with a wrist-worn physical activity monitor to wear for 7-9 days following the visit. These monitors will provide objective measures of physical activity while people go about their normal activities.
224297022|NCT01765582|DRUG|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
223400124|NCT01592786|DRUG|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
223400125|NCT00287534|DRUG|Anastrozole|oral
223732610|NCT05667922|DRUG|Tacrolimus|0.05-0.10mg/kg/d, twice orally, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it is effective.
223732611|NCT02106728|BEHAVIORAL|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
223732612|NCT02106728|BEHAVIORAL|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
223732613|NCT03675490|BEHAVIORAL|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
223732614|NCT06609902|BEHAVIORAL|Future Self-BD|The Future Self group will attend 6 virtual sessions during which they will be encouraged to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. All participants will complete the adjusting amount discounting task. All participants will also receive brief, CBT-based smoking cessation counseling. This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
223400126|NCT00287534|DRUG|Tamoxifen|oral
223400127|NCT00108264|BIOLOGICAL|Tumor RNA transfected dendritic cells|
223552006|NCT05961241|OTHER|runnin training program|gradual training program
223552007|NCT00678769|DRUG|Cixutumumab|Given IV
223552008|NCT00678769|OTHER|Laboratory Biomarker Analysis|Correlative studies
223552009|NCT00678769|OTHER|Pharmacological Study|Correlative studies
223552010|NCT00678769|DRUG|Temsirolimus|Given IV
223552011|NCT00776594|DRUG|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
224020701|NCT03995693|DIETARY_SUPPLEMENT|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
224020702|NCT03995693|BEHAVIORAL|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
223552012|NCT00776594|DRUG|bicalutamide|50mg orally daily for 6 months
223552013|NCT00776594|DRUG|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
223552014|NCT01017744|DEVICE|Anesthetic Conserving Device|"* Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~* Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
223552015|NCT05993429|DIAGNOSTIC_TEST|The sampling method selected in patients with suspected hilar cholangiocarcinoma|The appropriate sampling approach was selected as EUS-FNA/B or ERCP with or without POCS-TB based on experts' overall evaluation. This study will compare the histopathological diagnosis of the selected sampling method with the final diagnosis.
224020703|NCT03995693|PROCEDURE|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
224020704|NCT03995693|PROCEDURE|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
224020705|NCT03995693|PROCEDURE|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
223552016|NCT01961297|DRUG|Sodium oxybate|Sodium oxybate
224020706|NCT03995693|BEHAVIORAL|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
224020707|NCT03995693|DIAGNOSTIC_TEST|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
223400128|NCT02183558|OTHER|OGTT by randomization|
223400129|NCT02183558|OTHER|OGTT by indication|
223400130|NCT04798911|OTHER|Phase 1 Observational Interviews|Qualitative interviews with patients with SS
223400131|NCT04349228|DRUG|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200mg/day
223400132|NCT04349228|DRUG|Placebo oral tablet|Placebo of Hydroxychloroquine (HCQ) without any active substance
223400133|NCT00061997|DIETARY_SUPPLEMENT|inositol|
223400134|NCT04908774|BEHAVIORAL|Fasting Mimicking Diet|"The mobile application Salufast provides standardised fasting packages for 5 days of approx. 500 kcal and accompanies the participants during all fasting days."
224020708|NCT03995693|DIAGNOSTIC_TEST|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
224020709|NCT03995693|DIAGNOSTIC_TEST|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
224297023|NCT01765582|DRUG|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
224297024|NCT01765582|DRUG|irinotecan|Participants will receive IV infusion of 165 mg/m\^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m\^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
223400135|NCT04202120|OTHER|Age-related stereotyping priming|The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
223552017|NCT03489655|BEHAVIORAL|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
223552018|NCT01651819|PROCEDURE|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
223552019|NCT06058429|OTHER|no intervention|This is an observation study after vaccination, no intervention will be used
223552020|NCT02661555|OTHER|Aerobic exercise|
223552021|NCT01932229|DRUG|Afatinib treatment|
223552022|NCT00446823|DEVICE|XCell cellulose wound dressing|
223732615|NCT06609902|BEHAVIORAL|Daily Check-Ins|The Daily Check-Ins (DCI) group will attend 6 virtual sessions during which they will complete the adjusting amount discounting task and receive brief, CBT-based smoking cessation counseling (consistent with counseling received by Future Self-BD). This group will involve one follow-up session one month after the sixth session. Each session will be conducted on HIPAA-compliant Zoom and led by the PI, Dr. Gold.
223732616|NCT06151158|BEHAVIORAL|Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+)|Stanley Brown Safety Planning completed in the emergency department with 3 follow-up contacts after discharge
223552023|NCT00446823|DEVICE|Impregnated gauze dressing|
223732617|NCT06151158|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)|Five session crisis focused version of IPT for adolescents.
223732618|NCT04644627|DRUG|Gentamicin Sulfate|Topical gentamicin ointment on wounds once daily for 6 weeks
223732619|NCT01967121|DEVICE|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
223732620|NCT01967121|OTHER|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
223732621|NCT05488431|DRUG|Bempedoic acid|Bempedoic Acid is an oral first-in-class small molecular adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor which lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Inhibition of ACL by bempedoyl-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of LDL receptors and concomitant suppression of hepatic fatty acid biosynthesis. BA has been studied in \>4300 individuals and is currently being studied in \>14,000 individuals in CLEAR Outcomes (NCT02993406).
223732622|NCT05488431|OTHER|Placebo|Placebo
223732623|NCT01847222|BIOLOGICAL|SANGUINATE™|PEG-bHb-CO
223732624|NCT01847222|DRUG|Normal Saline Solution|Placebo
223732625|NCT04779840|OTHER|anemia assessment|evaluation of anemia status
223732626|NCT03353493|BEHAVIORAL|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams \& Teasdale (2013).
223732627|NCT03353493|OTHER|TAU|Treatment as usual (TAU)
223732628|NCT00002862|DRUG|perillyl alcohol|
223732629|NCT02023398|DEVICE|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
223732630|NCT02023398|DEVICE|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
224297025|NCT01765582|DRUG|folinic acid|Participants will receive IV infusion of 200 mg/m\^² (Arm A) or 400 mg/m\^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m\^2 in the maintenance therapy.
224020710|NCT03995693|PROCEDURE|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
224020711|NCT03587077|DRUG|Misoprostol|vaginal application
223732631|NCT06571799|OTHER|BENEV Exosome Regenerative Complex+|BENEV Exosome Regenerative Complex+® is an intensive dual-action complex formulated to absorb quickly into the skin and scalp delivering the concentrated power of stem cell derived lyophilized exosomes, potent growth factors, peptides, coenzymes, minerals, amino acids and vitamins.
223732632|NCT02776423|PROCEDURE|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
224131123|NCT04423900|DIAGNOSTIC_TEST|smart phone application|Participants will be asked to provide information about their sociodemographic characteristics, chronic diseases, the history of the ankle injury, trauma, and surgery, the severity of the foot pain via using the mobile application.The app will be downloaded from the Google Play Store and available offline. Information from the patient will be stored in an SQLite database.The usability test will be carried out on the mobile application so that the latest releases contain clear, effective, loyal to the strategy, and easily understood messages by the intended audience and do not produce unwanted responses.Direct observation, individual interviews, and satisfaction surveys will be used to identify areas of improvement in a cross-sectional manner.Investigation of pes cavus, pes planus and ankle range of motion will be determined by image processing.All data can be analyzed and stored by Heel Analysis Systems established on an external server.The data will be transferred securely over HTTPS.
224131124|NCT01540461|DRUG|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
224297026|NCT01765582|DRUG|oxaliplatin|Participants will receive 85 mg/m\^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
223732633|NCT01564121|DRUG|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
223732634|NCT05554094|DRUG|Psilocybin|Participants will receive 15 mg of oral psilocybin in the first session and 25 mg in the second session.
223732635|NCT00430690|PROCEDURE|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
223732636|NCT00644995|BEHAVIORAL|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
223732637|NCT00644995|BEHAVIORAL|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
224020712|NCT03587077|DRUG|Placebos|vaginal application
223552024|NCT02482298|DRUG|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
223552025|NCT02482298|DRUG|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
223552026|NCT00455819|PROCEDURE|home treatment|
223552027|NCT00752739|DIETARY_SUPPLEMENT|selenium|Given orally
223552028|NCT00752739|OTHER|placebo|Given orally
223552029|NCT05788419|DIAGNOSTIC_TEST|sonography|imaging method, functional test of hip joint
224020713|NCT03587077|DRUG|isosorbide mononitrate|vaginal application
224020714|NCT01195051|OTHER|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
223552030|NCT06538051|OTHER|lying positions|All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
223552031|NCT03576196|OTHER|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
224131125|NCT01993862|OTHER|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
224020715|NCT02041234|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
224020716|NCT02041234|DRUG|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
224020717|NCT02041234|DRUG|Xenical|Xenical: Up to 120 mg tds
224020718|NCT02041234|DRUG|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
224131126|NCT00330863|DRUG|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
224131127|NCT00330863|DRUG|Risperidone|Target dose is 4 mg/day.
224131128|NCT00330863|DRUG|Olanzapine|Target dose is 15 mg/day.
224131129|NCT00330863|DRUG|Quetiapine|Target dose is 600 mg/day.
224131130|NCT00330863|DRUG|Ziprasidone|Target dose is 120 mg/day.
224131131|NCT00330863|DRUG|Aripiprazole|Target dose is 20 mg/day.
223400136|NCT04202120|OTHER|Non age-related stereotype priming|he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
223400137|NCT03061136|DRUG|Clonazepam|
224131132|NCT00330863|DRUG|Paliperidone|Target dose is 6 mg/day.
224131133|NCT04131517|DRUG|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)
223400138|NCT03061136|DRUG|Placebo|
223400139|NCT04889443|PROCEDURE|Surgical cartilage repair procedure requiring harvest procedure or Autologous Stromal Cell Implantation|Any surgical cartilage repair procedure of the knee that requires a harvest biopsy of knee cartilage, which will leave a controlled small cartilage injury
223400140|NCT02393157|DRUG|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
223400141|NCT02393157|DRUG|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
223400142|NCT02393157|DRUG|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
223400143|NCT02393157|DRUG|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
223400144|NCT02393157|DRUG|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
223400145|NCT06292065|DIAGNOSTIC_TEST|Point-of-care gastric ultrasound|Using ultrasound to visualise the gastric antrum in supine position and right lateral decubitus.
223400146|NCT04418167|DRUG|JSI-1187|JSI-1187 capsules for oral administration
223400147|NCT04418167|DRUG|Dabrafenib|Dabrafenib capsules for oral administration
223400148|NCT00328497|DRUG|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
223552032|NCT03576196|OTHER|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
224020719|NCT02041234|DRUG|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
224020720|NCT02439073|BEHAVIORAL|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
224131134|NCT04131517|DRUG|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
224131135|NCT02867449|BEHAVIORAL|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
223400149|NCT06643299|DRUG|Probiotic Agent|BlueBiology: Ultimate Care probiotic pill taken once daily for a four-month period.
223400150|NCT06643299|OTHER|Placebo|Placebo produced to be identical in taste and appearance to the probiotic agent, taken once daily for a four-month period.
223552033|NCT05723731|DEVICE|taVNS|"Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)"
224131136|NCT02867449|BEHAVIORAL|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
224131137|NCT02134327|DRUG|Combination of Dexmedetomidine with Midazolam|
224131138|NCT01321840|PROCEDURE|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
224131139|NCT02405585|DRUG|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
224131140|NCT02405585|BIOLOGICAL|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
224131141|NCT02405585|RADIATION|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
223732638|NCT04517474|BEHAVIORAL|CANreduce|"CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying no to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised."
223732639|NCT04517474|BEHAVIORAL|psychological support|psychological support
223732640|NCT03606733|PROCEDURE|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
223732641|NCT03369392|OTHER|Panda application|A smartphone-based postoperative pain management tool
223732642|NCT03303534|DIETARY_SUPPLEMENT|ScandiShake|weight gain supplement low in protein
224297027|NCT01074762|BEHAVIORAL|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
224297028|NCT00986180|DRUG|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
223400151|NCT02172664|PROCEDURE|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
223400152|NCT02172664|PROCEDURE|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
223400153|NCT02172664|DEVICE|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
223400154|NCT06105632|DRUG|PF-07220060 CDK4 inhibitor|Experimental
223400155|NCT06105632|DRUG|Fulvestrant|Experimental and Active comparator
223400156|NCT06105632|DRUG|Everolimus|Active Comparator
223400157|NCT06105632|DRUG|Exemestane|Active Comparator
223732643|NCT02226406|OTHER|A: Chair - Leg Cycle ergometer|
223732644|NCT02226406|OTHER|B: Chair - Arm Cycle ergometer|
223732645|NCT02226406|OTHER|C: Walk in place|
223732646|NCT04920370|DRUG|ALXN1720 SC|ALXN1720 will be administered via SC route.
223732647|NCT04920370|DRUG|ALXN1720 IV|ALXN1720 will be administered via IV route.
223400158|NCT05840224|BIOLOGICAL|GS-4528|Administered intravenously
223400159|NCT05840224|DRUG|Zimberelimab|Administered intravenously.
223732648|NCT04920370|DRUG|rHuPH20|rHuPH20 will be administered via SC route.
223732649|NCT04920370|DRUG|Placebo SC|Placebo will be administered via SC route.
224020721|NCT06231446|OTHER|No intervention|This was an observational cohort study with no intervention for all enrolled patients.
224020722|NCT04897906|BEHAVIORAL|Education Group|Mother care, newborn care and breastfeeding education will be provided to pregnant women in the third trimester of pregnancy.
224020723|NCT02919904|DEVICE|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~* NREM and REM sleep frequency and duration~* Duration and number of arousal~* Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~* Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~* Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~* Apnea/hypopnea index and respiratory disturbance index"
224020724|NCT03631160|DEVICE|TAES treatmen|"In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment."
224020725|NCT03631160|DEVICE|Sham TAES treatmen|"Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output ."
223400160|NCT06703996|OTHER|Discussion|Participate in check-in/goal-setting discussions
223400161|NCT06703996|OTHER|Medical Device Usage and Evaluation|Wear the InBody Band 3 fitness tracker
223400162|NCT06703996|OTHER|Questionnaire Administration|Ancillary studies
223400163|NCT02638142|DRUG|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
223732650|NCT04920370|DRUG|Placebo IV|Placebo will be administered via IV route.
223732651|NCT00004196|BIOLOGICAL|recombinant interferon alfa|
223732652|NCT00004196|PROCEDURE|lymphangiography|
223732653|NCT00004196|DRUG|Observation|
223732654|NCT02066870|DRUG|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
223732655|NCT02066870|DRUG|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
223732656|NCT01813578|OTHER|Exercise|Intensive aerobic and muscle endurance exercise
223732657|NCT05557604|DRUG|Decapeptyl|STAD androgen deprivation
223732658|NCT00399776|RADIATION|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
223732659|NCT04233645|OTHER|5-minute educational video|The 5-minute educational video depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
223732660|NCT04233645|OTHER|Usual Care|The groups will be given a standard scripted verbal and identical written instructions as per usual care.
223732661|NCT04904887|PROCEDURE|phacoemulsification|phacoemulsification with implantation of EYEHANCE IOL
223732662|NCT05854732|OTHER|Inclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a experimental group with fixed speed of 5.0 mph and increased inclination of 1% after every one minute. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and increased inclination of 1% after every one minute for 30 minutes ending with Cool down for 5 minutes.
223732663|NCT05854732|OTHER|Uninclined Treadmill Training|Research subjects will be included in the study according to the inclusion criteria and would be randomized into 2 groups, namely inclined treadmill training group and uninclined treadmill training group and will receive intervention for 6 weeks. The participants will be considered as a active comparator with fixed speed of 5.0 mph and fixed inclination. FIIT FORMULA will be considered while providing intervention for 5 days per week to the subjects of each group. The FITT program for the participants will be starting with Warmup of 5 mints with Frequency of 5days/week for 6 weeks with fixed speed of 5.0 mph and fixed inclination for 30 minutes ending with Cool down for 5 minutes.
223732664|NCT06157723|OTHER|None (Observational study)|"Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent)."
223732665|NCT00064376|DRUG|paricalcitol|
223732666|NCT02482987|DEVICE|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
223732667|NCT02482987|DEVICE|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
223732668|NCT02482987|PROCEDURE|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
223732669|NCT02482987|PROCEDURE|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
223732670|NCT01493570|DRUG|BI 409306|Film-coated tablet
223732671|NCT01493570|DRUG|Placebo|Film-coated tablet
223732672|NCT03157258|BEHAVIORAL|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
224020726|NCT02690922|DRUG|Dasatinib|100mg (d1-d84)
223732673|NCT03157258|BEHAVIORAL|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
223732674|NCT01149824|DRUG|Salvinorin A|
223732675|NCT01149824|DRUG|Placebo|
223732676|NCT02891083|DRUG|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
223400164|NCT02638142|DRUG|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
223400165|NCT06798948|DIETARY_SUPPLEMENT|Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra|Oral combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
224020727|NCT02690922|DRUG|prednisone|60mg/m2 d1-24
224020728|NCT02690922|DRUG|dexamethasone|10mg/d 3-7days
224020729|NCT02690922|DRUG|methotrexate|3g/m2 1day
224020730|NCT02290730|OTHER|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
223400166|NCT06798948|OTHER|Placebo maltodextrin|The patient takes two tablets of the placebo maltodextrin every day
223400167|NCT06948929|DIETARY_SUPPLEMENT|SCV09|SCV09 consists of a blend of four probiotic species from the Bifidobacterium and Lactobacillus genera (20 billion CFU in 1 sachet per day), prebiotic compounds including galacto-oligosaccharides, xylo-oligosaccharides and inulin, vitamin B6, B9, B12 and vitamin D.
223400168|NCT06333171|DRUG|4-Aminopyridine|Active study drug
223400169|NCT06333171|OTHER|Placebo|Placebo comparator
223400170|NCT05816785|DRUG|Cetuximab|Week 1: loading dose of 400mg/m2; Week 2: 250mg/m2
223400171|NCT05816785|DRUG|Imatinib|400 mg orally daily
224020731|NCT03186131|DRUG|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
224020732|NCT03186131|DRUG|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
224020733|NCT04201782|DRUG|There are no disallowed treatments|Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
224020734|NCT00300898|PROCEDURE|Nucleoplasty|
223400172|NCT05836584|BIOLOGICAL|Atezolizumab|Given IV
223400173|NCT05836584|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224020735|NCT00300898|PROCEDURE|Percutaneous decompression|
223400174|NCT05836584|DRUG|Capecitabine|Given PO
223400175|NCT05836584|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223400176|NCT05836584|DRUG|Docetaxel|Given IV
223400177|NCT05836584|PROCEDURE|Echocardiography Test|Undergo ECHO
223400178|NCT05836584|DRUG|Fluorouracil|Given IV
224020736|NCT00300898|PROCEDURE|Intervertebral electrothermal disc decompression (IDET)|
223732677|NCT02891083|RADIATION|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
224020737|NCT00300898|BEHAVIORAL|Conservative treatment|
224020738|NCT03300115|DRUG|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
224020739|NCT02990312|DRUG|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
223400179|NCT05836584|DRUG|Leucovorin Calcium|Given IV
223400180|NCT05836584|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
223400181|NCT05836584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223400182|NCT05836584|DRUG|Oxaliplatin|Given IV
223400183|NCT05836584|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223400184|NCT05836584|PROCEDURE|Surgical Procedure|Undergo surgery
223400185|NCT06974773|DEVICE|NettleEndo|The NettleEndo device is a portable, home-use transcranial direct current stimulation (tDCS) system designed to deliver low-intensity electrical stimulation to targeted brain regions. The device delivers a constant current of 2 mA in the active stimulation group, targeting the left primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC) through pre-set electrode positioning.
223552034|NCT05723731|DRUG|Laxative Agent|Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
223552035|NCT01188551|DRUG|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
223552036|NCT01188551|DRUG|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
223552037|NCT01188551|DRUG|Midazolam|Sedative given pre-op.
223552038|NCT05117684|PROCEDURE|Novel|Balloon- Occlusion thrombolysis was done in adjunct to thrombus maceration, balloon sweeping and thrombosuction.
223552039|NCT05117684|PROCEDURE|Conventional|Continuous catheter directed thrombolysis (Continuous urokinase infusion) was done along with thrombus maceration, balloon sweeping and thrombosuction.
223552040|NCT05369364|DRUG|Zanubrutinib|Zanubrutinib 80mg qd po, 6 consecutive weeks
223552041|NCT05369364|DRUG|Dexamethasone|Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
223552042|NCT02681653|DRUG|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
223552043|NCT02681653|DRUG|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
223552044|NCT03585725|DRUG|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
223552045|NCT00000277|DRUG|Mazindol|
223552046|NCT02837471|DEVICE|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
223552047|NCT05756023|PROCEDURE|the pregnancy rate at IVF / ICSI cycles|To study and compare other parameters between the PCOS and non PCOS group, and inside the PCOS group itself eg ; patients with PCOS who have ovarian drilling and non drilling PCOS
223552048|NCT00883948|BEHAVIORAL|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
223552049|NCT00883948|BEHAVIORAL|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
223552050|NCT04789954|BIOLOGICAL|Eptacog alfa, activated|A dose sequence for each injection will be randomly selected from the following doses: 10 μg/kg, 30 μg/kg, 90 μg/kg, or 270 μg/kg, separated by a wash-out period of 3 days.
223552051|NCT05484466|DRUG|ZM-H1505R|There are three groups in this study. ZM-H1505R will be used in group A and Group B ，Subjects can use it for 48 weeks Group A: 30 subjects； ZM-H1505R 50 mg QD +ZM-H1505R placebo； Group B: 30 subjects； ZM-H1505R 100 mg QD
223552052|NCT05484466|OTHER|ZM-H1505R placebo|There are three groups in this study. ZM-H1505R will be used in group A and Group C ，Subjects can use it for 48 weeks Group A: 30 subjects；ZM-H1505R 50 mg +ZM-H1505R placebo 50mg QD ； Group C: 30 subjects；ZM-H1505R placebo 100mg QD
223552053|NCT05484466|COMBINATION_PRODUCT|Baraclude|All subjects were orally administered once a day at night ： Baraclude® 0.5 mg QD，60weeks
223552054|NCT03346187|DRUG|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
223552055|NCT03346187|DRUG|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
223552056|NCT05243121|DIAGNOSTIC_TEST|MRI|undergoing enhanced MRI
223552057|NCT05315934|OTHER|Upper body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the arm-crank ergometer.
223552058|NCT05315934|OTHER|Lower body aerobic exercise|Participants will perform 30 minutes of continuous exercise on the cycle ergometer.
223552059|NCT00400218|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
223732678|NCT02891083|OTHER|Control group (Surgery alone)|
223732679|NCT05586529|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol is vitamin D derivative and as our population already vit D deficient so post-operative hypocalcemia can be prevented.
223732680|NCT02809456|DRUG|Nicorandil|oral intake
223732681|NCT05376969|DRUG|DWP16001|DWP16001 Tablets
223732682|NCT01503268|DEVICE|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
223732683|NCT01503268|PROCEDURE|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
223732684|NCT01503268|PROCEDURE|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
223732685|NCT02899910|BEHAVIORAL|Health education|Education on lifestyle changes for treatment of metabolic syndrome
223400186|NCT06974773|DEVICE|Sham NettleEndo Device|The sham version of the NettleEndo device is visually identical to the active device and is used under the same schedule. The device is pre-programmed to deliver a brief 2 mA current for 20 seconds at the beginning of each session to mimic the initial skin sensations of active stimulation, after which no current is delivered for the remainder of the session. This allows participants to remain blinded to their group assignment. The device is used with the same electrode positioning as the active version.
223400187|NCT06976242|PROCEDURE|Elastic Resistance Training|The type of resistance exercises in which the participants use the Thera Band of yellow and red colours (weight about 2-2.5 kg with full elongation) for resistance training
223732686|NCT02899910|BEHAVIORAL|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
223732687|NCT05120297|DRUG|AK101|Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.
223732688|NCT05120297|DRUG|Placebo|Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.
223732689|NCT02279901|BEHAVIORAL|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~1. OSA program~2. CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
223400188|NCT06976242|PROCEDURE|Free Weight Exercises|The type of resistance exercises in which the participants use weight cuffs (weight 2-2.5 kg) tied to their lower leg for resistance training
223400189|NCT06976242|PROCEDURE|Conventional Training|The conventional training includes side-lying hip abductions, standing weighted abductions, and lateral step-ups exercises.
223732690|NCT02279901|BEHAVIORAL|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
223732691|NCT02066233|DEVICE|EG Scan II (transnasal endoscopy)|
223732692|NCT02066233|PROCEDURE|Standard Endoscopy|
223732693|NCT04484792|OTHER|green tea mouthwash|green tea bags in 100 ml warm water for 5 min
223400190|NCT03285152|OTHER|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
223400191|NCT03285152|OTHER|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
223400192|NCT06974656|DRUG|Dexmedetomidine|Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of n 0.3-0.5 μg/kg/h.
223400193|NCT06974656|DRUG|Lidocaine|Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5-2 mg/kg/h.
223400194|NCT06238128|BEHAVIORAL|Opioid Rapid Resonse System (ORRS) training|ORRS is on online system to train citizen responders to administer NARCAN to save the lives of opioid overdose victims. It capitalizes on the innovative PulsePoint technology to connect responders to overdose events. PulsePoint is an app that connects 911 requesting assistance for cardiac arrests to responders with Cardiopulmonary Resuscitation (CPR) training. ORRS allows us to partner with PulsePoint users to expand its reach to opioid overdoses, which share the need for a quick response that emergency responders are often unable to provide. ORRS has the advantage of expanding the population of responders with NARCAN, rescue breathing, and CPR training that can be connected to overdose events, increasing the likelihood of saving overdose victims' lives through a quick, efficient response. ORRS is delivered through an interactive, digital platform containing sequential, multi-media modules.
223400195|NCT06238128|BEHAVIORAL|Non-active opioid overdose response training|"Investigators will provide online training about opioid prevalence in US, opioid mechanism, side effect, and addiction. However, Investigators do not provide any knowledge about opioid overdose management and naloxone in this training.~Once the project is completed, participants will receive online Naloxone training."
223732694|NCT04484792|OTHER|green tea mouthwash|, in Group B its prepared by soaking tea bags in 100 ml hot water followed by ice addition.
224131142|NCT02405585|DRUG|Gemcitabine|"Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
224131143|NCT00288860|BEHAVIORAL|Telephone monitoring|Three months of biweekly telephone monitoring and support
224131144|NCT00288860|OTHER|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
224131145|NCT04329611|DRUG|Hydroxychloroquine|COVID19
224297029|NCT00986180|DRUG|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
223400196|NCT05586321|BIOLOGICAL|GEN1056|GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1.
223732695|NCT04484792|OTHER|placebo|Plain water
223732696|NCT00295906|OTHER|educational intervention|
223732697|NCT00295906|OTHER|internet-based intervention|
223732698|NCT03815331|DRUG|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
223732699|NCT03815331|DRUG|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
223400197|NCT04424719|OTHER|Blood test|"High risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. Signature of the informed consent of SALOME study, inclusion in the study and risk-adjusted surveillance schedule :~(i) Liver MRI every 6 months performed at the expert center for UM (according to guidelines).~(ii) For enucleated patients, a blood sample (3 x 6 ml EDTA tubes) is taken every 6 months according to the schedule below. Plasma and mononucleated cells will be isolated and preserved for bio-markers research.~* M0 : during the first medical oncology visit.~* At each imaging assessment, every 6 months for at least 5 years (M6 to M60) and 10 years maximum (M120).~* At the diagnosis of metastasis.~* At each significant event during the metastatic disease (surgery, treatment response or progression)."
223732700|NCT00103142|BIOLOGICAL|falimarev|Given subcutaneously and intradermally
224297030|NCT03318276|DRUG|SID142|SID142 is administrated to patients with PAD for 12 weeks
223400198|NCT02861417|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
223400199|NCT02861417|DRUG|Busulfan|Given IV
223400200|NCT02861417|DRUG|Cyclophosphamide|Given IV
223400201|NCT02861417|DRUG|Fludarabine|Given IV
223400202|NCT02861417|DRUG|Fludarabine Phosphate|Given IV
223400203|NCT02861417|OTHER|Laboratory Biomarker Analysis|Correlative studies
223400204|NCT02861417|DRUG|Mycophenolate Mofetil|Given PO
223400205|NCT02861417|OTHER|Pharmacological Study|Correlative studies
223400206|NCT02861417|DRUG|Tacrolimus|Given IV or PO
223400207|NCT02861417|DRUG|Thiotepa|Given IV
223400208|NCT06048575|PROCEDURE|Cholecystectomy|Early or late surgery, ambulatory, emergency, or differed.
223400209|NCT02415101|PROCEDURE|Resective surgery|
223400210|NCT04426006|OTHER|PRO-SERO-COV|"At inclusion, 3 months and 12 months :~* blood sample (2 x 5ml)~* self-administered questionnaire"
223400211|NCT06778330|DRUG|Dapagliflozin (DAPA)|Control group: receive dapagliflozin in addition to standard therapy
223400212|NCT06778330|DRUG|Sildenafil|Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy
223400213|NCT06041204|DRUG|Letrozole 2.5mg|Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
223400214|NCT06041204|DRUG|Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet|Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
223400215|NCT05280470|DRUG|Ifinatamab Deruxtecan (I-DXd)|I-DXd will be administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (every Q3W).
223400216|NCT05548062|OTHER|Hydroxyurea|Prospective observational study. There is no treatment allocation. Patients prescribed with Hydroxyurea are eligible to enroll into this study.
223400217|NCT05548062|OTHER|Ruxolitinib|Prospective observational study. There is no treatment allocation. Patients prescribed with Ruxolitinib are eligible to enroll into this study.
223400218|NCT04666740|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 week. After the first 6 months (8 cycles), on C9D1 Pembrolizumab 400 mg IV every 6 week.
223400219|NCT04666740|DRUG|Olaparib|Olaparib 300 mg twice day orally daily continuously (POLAR) as a maintenance therapy. After the first 6 months (8 cycles), on C9D1 olaparib 300 mg twice a day orally will be continued.
223732701|NCT00103142|BIOLOGICAL|inalimarev|Given subcutaneously and intradermally
223732702|NCT00103142|BIOLOGICAL|sargramostim|Given subcutaneously
223732703|NCT00103142|BIOLOGICAL|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
223732704|NCT03838640|DEVICE|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
223732705|NCT00628992|OTHER|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
223732706|NCT00628992|OTHER|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
224020740|NCT03356457|DRUG|Dichloroacetate|Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
224020741|NCT03356457|DRUG|Placebo oral capsule|A Placebo oral capsule identical in shape and color to those with active ingredient.
223400221|NCT03266627|DRUG|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
223552060|NCT04098185|DEVICE|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
223732707|NCT00628992|OTHER|Cycloergometer training|Muscular rehabilitation of the leg
223732708|NCT00628992|OTHER|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
223732709|NCT02772081|COMBINATION_PRODUCT|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief insertion of a thin catheter into the trachea
223732710|NCT02772081|DRUG|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube), followed by rapid extubation
223732711|NCT05370222|BEHAVIORAL|Dietary weight loss intervention|Based on an energy assessment from the data collected at T0 (energy intake, physical activity level, and resting metabolism), individualized nutritional advice will be given during an interview in order to propose a dietary rebalancing and a light caloric restriction. Caloric restriction will be generated to decrease body weight by ≈ 0.5 to 1 kg per week, as advised in several publications. As for the dietary rebalancing, it will concern in particular the distribution of macronutrients and their nature (glycemic index, nature of lipids), the fibers intake, or the reduction of consumption of refined and/or energy-dense foods based on the ANSES Recommended Dietary Allowances and on the food consumption guidelines of the National Nutrition and Health Program.
223732712|NCT04261751|OTHER|Clinician Questionnaire|Nurses will take the Clinician Questionnaire electronically
223732713|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care group|Self-hypnosis/self-care
223400222|NCT03745209|DEVICE|Ultrasound|Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
223400223|NCT05352750|BIOLOGICAL|SON-1010|SON-1010 multiple ascending dose
223400224|NCT05671341|DIAGNOSTIC_TEST|Assessment|Tandem walking test, Tandem Stance test, Activity-specific Balance Confidence Parkinson's Disease Quality of Life-8 N/L ratio Tinetti Balance Test UPDRS
223400225|NCT03268083|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
223400226|NCT03268083|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
223552061|NCT04789629|DEVICE|low level laser therapy|3 session per week laser with exercises
223552062|NCT01717196|OTHER|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
223552063|NCT01861704|DEVICE|Lyric|Extended wear hearing instrument
223400227|NCT03268083|BIOLOGICAL|EV71 vaccine ([1 μg total protein ] per dose)|Two vaccinations at 28 days apart
223552064|NCT01861704|DEVICE|Lyric2|Extended wear hearing instrument
223552065|NCT00292279|DRUG|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
223552066|NCT00292279|DRUG|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
223400228|NCT03028428|BIOLOGICAL|Placenta Derived Mesenchymal Stem Cell|1ml 1\*10\^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
223732714|NCT04218227|BEHAVIORAL|Music/self-care|Music-therapy/self-care
223732715|NCT04218227|BEHAVIORAL|Self-care|Self-care
223732716|NCT04218227|BEHAVIORAL|Psycho-education|Psycho-education
223732717|NCT04218227|BEHAVIORAL|Self-hypnosis/self-care motivation|Motivation to learn self-hypnosis/self-care
223732718|NCT00490854|DRUG|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
223732719|NCT00490854|DRUG|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
224020742|NCT01987141|OTHER|EMR Intervention|Electronic medical record flag/notification in the patient's chart
224020743|NCT04720872|OTHER|Manual therapy and vestibular rehabilitation treatment|The experimental group received manual therapy and vestibular rehabilitation treatment.
224020744|NCT01986075|BEHAVIORAL|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
224020745|NCT01986075|DRUG|Mixed-Amphetamine Salts- Extended Release (MAS-ER)|80 mg/day of Mixed-Amphetamine Salts- Extended Release (MAS-ER) and computer -assisted CBT
224020746|NCT01986075|DRUG|Placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
224020747|NCT02104843|DRUG|Daclatasvir, Asunaprevir and BMS-791325 FDC|
224020748|NCT02104843|DRUG|BMS-791325|
224020749|NCT02104843|DRUG|Rosuvastatin|
224131146|NCT02711709|OTHER|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~1. muscle weakness~2. fatigue~3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
224131147|NCT02711709|OTHER|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
223732720|NCT02598076|BEHAVIORAL|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
223732721|NCT02598076|BEHAVIORAL|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
223732722|NCT04030754|COMBINATION_PRODUCT|amniotic membrane|amniotic membrane is a biological dressing
223732723|NCT04030754|COMBINATION_PRODUCT|duoderm dressing|duoderm dressing is a synthetic dressing
223732724|NCT00770796|DRUG|Atorvastatin|80 mg die
223732725|NCT00770796|DRUG|Placebo|
223732726|NCT00191555|DRUG|olanzapine|
223732727|NCT00191555|DRUG|haloperidol|
223732728|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
223732729|NCT01946425|BIOLOGICAL|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
223732730|NCT03876912|DRUG|GnRH antagonist|18F-PSMA 1007 PET/CT before, 3 weeks after ADT, at 1 year and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 20 patients before ADT.
224020750|NCT04242251|OTHER|SPARKLE Model of care|Patients will receive the SPARKLE model of care in addition to usual oncologist-led care. The SPARKLE model will be led by a palliative medicine doctor and administered by nurses and staff without specific nursing or medical training. It utilizes a stepped care approach where all patients will initially have low-intensity model focused on weekly symptom monitoring through a patient-reported questionnaire. If any problems are identified, then patients step up to a higher-intensity care model where a nurse will conduct a phone assessment of the symptom problems. If the presence of symptoms is confirmed, patients step up again to an even higher-intensity care model where treatment of symptoms will be initiated by the SPARKLE nurse, depending on the severity of the problems. If the symptoms are not fully resolved, the patients will then step up to the highest-intensity care model which is an existing palliative care service- either palliative care outpatient clinic or home hospice.
223732731|NCT05248945|DRUG|Evobrutinib|Participants will receive a single dose of film-coated evobrutinib tablet (TF2) on Day 1 and Day 19.
223732732|NCT05248945|DRUG|Carbamazepine|Participants will receive carbamazepine tablet twice daily from Days 2 to 25.
223732733|NCT03264495|OTHER|Weight the food served minus the left-overs|
224297031|NCT03318276|DRUG|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
223732734|NCT01137045|BIOLOGICAL|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
223732735|NCT01982747|DRUG|MGN-Placebo|
223732736|NCT01982747|DRUG|Placebo-MGN|
223732737|NCT03731884|OTHER|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
223732738|NCT06065033|BEHAVIORAL|Exercise|"Patients will perform 5 days of supervised stationary cycling exercise (with EKG telemetry) per week over a period of 4 weeks. Training heart rates will be determined based on the pre-testing VO2peak and peak heart rate (PHR).~* Of the 5 sessions, 3 will be HIIT sessions and 2 will be MOD sessions.~* Subjects exercising on the HIIT day will start with eight intervals of 2-min duration at 80-85% of PHR, separated by 2 min of recovery at 50% of PHR, progressing to four, 4-min intervals at 90-95% PHR, separated by 3 min at 50% PHR by the end of week 2.~* Subjects exercising on the MOD days will perform uninterrupted for 40 minutes duration at 60-65% of PHR progressing to 40 minutes duration at 70-75% of PHR by the end of week 2.~* Each training session will begin with a 10-min warm-up at 50% PHR and end with a 5-min cool down at 50% PHR. Exercise progression may have to be modified according to individual subject exercise tolerance."
223732739|NCT05104034|BEHAVIORAL|Osteoporosis screening and treatment as needed|All residents underwent screening using the Fracture Risk Assessment Tool (FRAX) and Mobile dual-energy X-ray absorptiometry (DXA) (Horizon Wi, Hologic Inc., Bedford, MA). Our study nurses actively assisted osteoporosis treatment if indicated.
223732740|NCT05104034|BEHAVIORAL|Sarcopenia|Sarcopenia assessment adhered to the 2019 Consensus Update on Sarcopenia Diagnosis and Treatment by the Asian Working Group for Sarcopenia guideline. Following screening, individuals identified with sarcopenia underwent tailored interventions involving exercise and nutrition as deemed necessary.
223732741|NCT05104034|BEHAVIORAL|Exercise|TheraBand (resistance band) was utilized as the exercise tool within the community. T
223732742|NCT05104034|DIETARY_SUPPLEMENT|Nutrition|Nutrition Nutritional education programs aim to increase protein food serving and the choice of those with insufficient dietary intake. Protein supplement was added if indicated.
223732743|NCT05104034|BEHAVIORAL|Pharmaceutical care|We collected drug information of the elderly. Detailed and real-time prescription drug information was retrieved from the National Health Insurance PharmaCloud System. A pharmaceutical care team performed patient-centered drug review and discussion every three to six months.
224020751|NCT05994404|PROCEDURE|ACDF|
224020752|NCT05994404|PROCEDURE|Posterior Cervical Fusion|
224297032|NCT00729274|DRUG|normal saline solution|Two 4ml nebulizations with 30 minute interval
224297033|NCT03710720|BEHAVIORAL|TIPS app|Psycho-educational electronic application
224297034|NCT03710720|BEHAVIORAL|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
224020753|NCT05994404|PROCEDURE|Cervical Laminoplasty|
224020754|NCT03789838|OTHER|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
224297035|NCT00074776|DRUG|Lithium|Participants will receive lithium.
224297036|NCT00074776|DRUG|Lamotrigine|Participants will receive lamotrigine.
224131148|NCT02711709|OTHER|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
223400229|NCT03028428|DRUG|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
223552067|NCT03861104|OTHER|medical educational video|information based on visual and auditory communication
223552068|NCT00556608|DEVICE|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
224020755|NCT05363462|DRUG|Vancomycin 1000 MG|Application of vancomycin in powder in the surgical site of treatment before closure of surgical wound
224020756|NCT05790577|DRUG|Metformin and Nicotinamide vs Kligman Formula|Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
223732744|NCT00638313|BIOLOGICAL|Placebo|Subjects will be given either Placebo or PF-04603629.
223732745|NCT00638313|BIOLOGICAL|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
224020757|NCT06424405|PROCEDURE|titration procedure for MAD treatment|The OSAHS patients referred for MAD treatment will experience either the objective titration procedure or the subjective titration procedure.
223732746|NCT05243225|PROCEDURE|Laparoscopic versus open surgical management of post cholecystectomy bile duct injury|Comparison between laparoscopic and open surgical management of post cholecystectomy bile duct injury.
223732747|NCT04251598|BEHAVIORAL|I Am Protecting My Child from the Sun|"The parents in the intervention group were administered the I Am Protecting My Child from the Sun program for a period of six weeks.~Intervention groups received Sun Protection Guide for Parents, Developmental, Characteristics of 3-6 Age Group Children Brochure, Melanoma Brochure, Video, Frame, Key chain, Magnet, Puzzle, Sunscreen product, T-shirt, hat and UV testing wristband."
223732748|NCT04251598|BEHAVIORAL|SMS for sun protection|While the education+SMS group, in addition to the program, also received a total of 25 short text messages twice a week.
224020758|NCT02842450|DEVICE|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
223732749|NCT03630575|PROCEDURE|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
224131149|NCT02711709|OTHER|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
224020759|NCT02842450|OTHER|definitions only|
224020760|NCT05128994|DEVICE|User-controlled FES system|Wearable FES sleeve with non-invasive user controls
224131150|NCT05154149|OTHER|Neck Disability Pain Index|Single time collection of the data
224131151|NCT03969797|DEVICE|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
224131152|NCT06457984|DIETARY_SUPPLEMENT|Selenium nutritional supplementation|Selenium yeast, as a safe from supplementation, could be a new nutritional intervention for lifecycle regulation of type 2 diabetes.
224131153|NCT06203730|BEHAVIORAL|dyadic psychological intervention strategy|an intervention strategy for both patients and caregivers that combines psychotherapy techniques and health management
224131154|NCT04361643|DRUG|Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.|Patients will receive Lenalidomide as a 5 mg capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
224131155|NCT04361643|DRUG|Placebo|Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
224131156|NCT03791437|DEVICE|Digital chest drainage system|patients who received Digital chest drainage system
224297037|NCT01691820|PROCEDURE|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
223400230|NCT06403176|OTHER|No intervention|No intervention
223400231|NCT03982290|OTHER|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
223400232|NCT03982290|OTHER|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
223400233|NCT02828579|PROCEDURE|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
223400234|NCT03215212|OTHER|eye mask|eye mask administered from 10 pm to 7 am
223552069|NCT00556608|DEVICE|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
223552070|NCT01669252|DRUG|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
224020761|NCT05851053|DIAGNOSTIC_TEST|Echocardiography|"During echocardiography, the following parameters will be assessed:~* Dimensions~* Left ventricle function~* Right ventricle function~* Valves: Aorta valve and pulmonic valve~* Other findings such as: frequency, rhythm, quality"
224020762|NCT03148444|DRUG|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
224020763|NCT06529055|OTHER|Oral Pouch - Nicotine|Ingestion of a randomized oral nicotine pouch
224020764|NCT06529055|OTHER|Oral Pouch - Caffeine|Ingestion of a randomized oral caffeine pouch
224020765|NCT06529055|OTHER|Oral Pouch - Placebo|Ingestion of a randomized oral placebo pouch
224020766|NCT03965351|DRUG|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
224020767|NCT03965351|OTHER|Placebo|placebo
224020768|NCT03479762|DRUG|Liraglutide|No treatment given
224020769|NCT05832697|DRUG|Ursodeoxycholic Acid 250 Mg Oral Tablet|Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
224131157|NCT03791437|DEVICE|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
223732750|NCT03485768|PROCEDURE|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
223732751|NCT03485768|PROCEDURE|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
223732752|NCT02852408|PROCEDURE|Laparoscopic cholecystectomy|
223732753|NCT05188690|OTHER|Data collection from medical records|Data collection from medical records
223552071|NCT06234579|DIAGNOSTIC_TEST|Biopsy (tissue or liquid)|"At the time of diagnosis, all newly diagnosed ALK+ NSCLC patients eligible for first line treatment with alectinib or brigatinib or lorlatinib will be considered for the study.~In case of progression, a multidisciplinary team (oncologists, interventional pneumologists and radiologists, surgeons) will discuss case-by-case the feasibility to procure an adequate biopsy from progressing lesions. Repeat biopsies will be performed within 2 weeks from multidisciplinary evaluation and before the start of subsequent treatment. If repeat biopsies are not technically or safely feasible or fail to yield sufficient material for genomic analysis, we will collect a whole blood drawn by venepuncture for the analysis of ctDNA."
223732754|NCT00826215|DEVICE|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
223732755|NCT00826215|DEVICE|Sham laser acupuncture|Sham laser acupuncture
223400235|NCT03215212|OTHER|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
223552072|NCT02077777|DRUG|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
223732756|NCT04675840|PROCEDURE|Robotic-assisted hysterectomy|Robotic-assisted surgery
223732757|NCT01988831|DRUG|Propranolol hydrochloride|This intervention apply to Propranolol group
224020770|NCT00169377|PROCEDURE|deep brain stimulation|Stimulator on followed by off
223400236|NCT03215212|OTHER|ear plug|ear plug administered from 10 pm to 7 am
223400237|NCT02050386|OTHER|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
223552073|NCT03286829|DRUG|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
223552074|NCT03286829|DRUG|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
223552075|NCT03286829|DRUG|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
223732758|NCT01988831|DRUG|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
224020771|NCT00169377|PROCEDURE|No stimulation|Stimulator off followed by on
224020772|NCT01638351|BEHAVIORAL|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
224020773|NCT01638351|BEHAVIORAL|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
223400238|NCT02050386|OTHER|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
223732759|NCT06131008|DIAGNOSTIC_TEST|Diastology|We will follow American Society of Echocardiography criteria to determine the degree of diastolic dysfunction after performing each focused echocardiogram.
224020774|NCT04021329|BEHAVIORAL|CBT Therapy|information added previously
224020775|NCT04824495|DIAGNOSTIC_TEST|Blood sample|Blood samples at different timepoints during SARS-CoV2 infection
224020776|NCT05179213|DRUG|Azacitidine|75 mg/m2 subcutaneously on days 1-7
224020777|NCT05179213|DRUG|Chidamide|20mg orally per week continuously
223400239|NCT04083638|DIAGNOSTIC_TEST|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
223400240|NCT03786848|OTHER|MiniPDX Group|Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This test can provide sensitivities of single drug or drug combination within 7 days to screen out the optimal individualized regimens for each patient.
223400241|NCT00051051|DRUG|CI-1033|
223400242|NCT06101966|RADIATION|external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)|Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age consideration and patients' desires.
223400243|NCT02946463|BIOLOGICAL|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
223400244|NCT02946463|BIOLOGICAL|Eculizumab|All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
224020778|NCT05731453|GENETIC|Polygenetic risk score|Polygenetic risk score assessment for breast cancer
223400245|NCT06577246|PROCEDURE|scaling root planing|periodontal treatment in all groups was performed using ultrasonic and hand instruments (#15/30, #6/7) by the same physician (UGE) who was blind to the study groups.
223400246|NCT06577246|BEHAVIORAL|Three-Dimensional Animation (video1-2)|"The video used in the study was created by DentalMaster (MD Stimulation Ltd) by combining their own footage (http://www.mdsimulation.com/). This video is divided into three parts, summarized below:~* i. Overview of the causes and symptoms of periodontal disease (section 1)~* ii. Treatment of periodontal disease and daily oral care practices for individuals (section 2)"
223400247|NCT06577246|BEHAVIORAL|Three-Dimensional Animation (video 3)|iii.Consequences of periodontal disease (such as gingival recession and tooth loss) that individuals may face if periodontal diseases are not treated and if they do not perform regular oral care (section 3). In this group, patients watch the video together with the physician (SG), who is familiar with the randomized patient groups.
223400248|NCT06577246|BEHAVIORAL|Periodontal Disease Prediction (PDP)|The patients in the test group viewed sections 1 and 2 videos in the same manner as the 3DA group. However, unlike the 3DA group, they did not view section 3. Instead, they were shown estimates of their current condition and potential future periodontal tissue loss (gingival recession) for 1-5 years, 5-10 years, and 10-20 years. These projections were presented to the patients in three dimensions with PDP visualisation.
223400249|NCT03447925|DRUG|Medicinal Plant|Medicinal Plant Extract with vaseline cream
223400250|NCT03447925|DRUG|Salicylate|Salicylate 10% with vaseline cream
223400251|NCT03447925|DRUG|Vaseline|Vaseline cream
223400252|NCT02491840|PROCEDURE|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
223400253|NCT06022406|BIOLOGICAL|FMT capsules|Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).
223400254|NCT06022406|BIOLOGICAL|Placebo capsules|Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.
223400255|NCT04737889|DRUG|Rituximab|Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
223400256|NCT04737889|DRUG|Lenalidomide|"Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles."
223400257|NCT04737889|DRUG|Methotrexate|Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
223552076|NCT03286829|DRUG|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
223552077|NCT06318078|OTHER|eCHIS|The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).
223732760|NCT06131008|BEHAVIORAL|Diastology-Guided Diuresis|If the daily urine output or weight loss are less than study-specified targets, then the research team will recommend changes to the diuretic regimen based on the degree of diastolic dysfunction.
223400258|NCT04737889|DRUG|Temozolomide|Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
223732761|NCT06131008|BEHAVIORAL|Usual Care|Clinicians will rely on usual care metrics and parameters to guide diuresis.
223732762|NCT04003922|OTHER|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
223552078|NCT04245267|BEHAVIORAL|DIABEMPIC|Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
223732763|NCT02428946|DRUG|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
224020779|NCT00924261|OTHER|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
224297038|NCT01691820|PROCEDURE|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
224297039|NCT01691820|PROCEDURE|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
223400259|NCT03399045|PROCEDURE|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
223400260|NCT03399045|PROCEDURE|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
223400261|NCT07121179|BEHAVIORAL|Beighton Scoring system|The Beighton Scoring system is commonly used to distinguish individuals with generalized joint hypermobility from those without. The Beighton Scoring system includes the following assessments: passive dorsiflexion of the fifth metacarpophalangeal joint, passive hyperextension of the elbow, passive hyperextension of the knee, passive apposition of the thumb to the flexor aspect of the forearm, and forward flexion of the trunk. A Developmental Physiotherapy and Pediatric Rehabilitation specialist will evaluate the joint hypermobility assessment of infants.
224020780|NCT00924261|OTHER|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
224020781|NCT03765008|OTHER|Water intake manipulation|for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
224020782|NCT02877888|DRUG|fluoride varnish 22600ppm|topical application on teeth every 6months
224020783|NCT04727268|OTHER|No intervention|No interventions present in this study.
224020784|NCT01409304|DEVICE|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
224020785|NCT01364103|OTHER|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
224020786|NCT02169167|DEVICE|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
224020787|NCT02169167|DEVICE|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
224020788|NCT00126230|DRUG|docetaxel and samarium|
224131158|NCT04043182|PROCEDURE|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
223400262|NCT07121179|BEHAVIORAL|Brief Infant Sleep Questionnaire|"Infant sleep problems are among the most common problems presented to pediatricians. The extended version of the Brief Infant Sleep Questionnaire is a questionnaire developed by Sadeh to assess sleep problems and their causes in early childhood."
223400263|NCT05292001|DRUG|Iron-Dextran Complex Injection [InFed]|single 1000mg dose
223400264|NCT05292001|OTHER|Saline Placebo|Normal saline
223400265|NCT07135115|BEHAVIORAL|Digikost report baseline only|The Digikost report will be made available for the participant immediately after completing of the Digikost questionnaire at baseline.
223400266|NCT07135115|BEHAVIORAL|Digikost report intensive with individual counselling and webinars|The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months. Additionally, the participant is offered an individual lifestyle counselling meeting by telephone at baseline and invited to inspirational webinars on cancer preventive lifestyle every 6 months.
223400267|NCT07135115|BEHAVIORAL|Digikost report intensive|The Digikost report will be made available for the participant each time after completion of the Digikost questionnaire every 6 months.
223400268|NCT05881863|OTHER|No intervention|This is an observational study
223400269|NCT06644781|DRUG|Ifinatamab deruxtecan|Intravenous administration
223400270|NCT06644781|DRUG|Docetaxel|Intravenous administration
223552079|NCT02058004|PROCEDURE|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
223552080|NCT01489501|PROCEDURE|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
223552081|NCT04954300|OTHER|no intervention|No intervention
223552082|NCT04661111|DEVICE|Hymovis® ONE (32 mg/4 ml)|Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
223552083|NCT02601430|OTHER|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
223552084|NCT01434628|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
223552085|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
223552086|NCT05274516|DRUG|HRS-2261 tablet、placebo|HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
223552087|NCT03978611|DRUG|Relatlimab|Specified dose on specified days
223552088|NCT03978611|DRUG|Ipilimumab|Specified dose on specified days
223552089|NCT05159687|DRUG|Atomoxetine Hydrochloride|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine
223552090|NCT05159687|DRUG|Placebo|Placebo Comparator: Placebo Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
223552091|NCT02793973|DEVICE|shoe lifts|
223552092|NCT02205268|PROCEDURE|Near infrared spectroscopy neurofeedback training|
223552093|NCT01736423|DRUG|YM060|oral
223552094|NCT04760483|DEVICE|SoracteLite(TM) TPLA for BPH|see prior section
223552095|NCT01103440|DRUG|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
223552096|NCT01103440|DRUG|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
223552097|NCT06275828|DEVICE|slow beat mesic listening by headphone|classic slow beat type from researcher
224020789|NCT03427853|DRUG|LY06006|LY06006 18mg, 60mg, 120mg subcutaneous injection
224020790|NCT03427853|DRUG|Placebos|Placebo subcutaneous injection
224131159|NCT00209599|DRUG|fospropofol disodium|
224297040|NCT05757882|OTHER|4 hours of fasting time|Oral intake is not allowed for 4 hours before sedation including water.
223732764|NCT00805103|RADIATION|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
223732765|NCT05512611|DIAGNOSTIC_TEST|Finger photoplethysmography|Finger photoplethysmography in tested hand, noninvasive blood pressure and heart rate during blood donation.
223400271|NCT06644781|DRUG|Paclitaxel|Intravenous administration
223732766|NCT01569178|PROCEDURE|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
223732767|NCT04276597|DRUG|177Lu-DOTATOC|177Lu labeled somatostatin receptors targeting ligand
223732768|NCT02389348|DRUG|DSM265|Single oral doses of DSM265
223732769|NCT02389348|DRUG|OZ439|Single oral doses of OZ439
223732770|NCT03715010|DIETARY_SUPPLEMENT|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
223732771|NCT03476694|PROCEDURE|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
224020791|NCT02677428|BEHAVIORAL|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
224020792|NCT02677428|BEHAVIORAL|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation \& Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C\&P office where issues pertaining to an individual Veteran's specific application are addressed.
224131160|NCT06288776|DIAGNOSTIC_TEST|Herbal based mouthwash|Herbal based mouthwash will be used to treat the tooth sensitivity in participants having VAS score values of tooth sensitivity ranging between 30-80
224131161|NCT02976376|OTHER|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
224131162|NCT04137276|DRUG|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
224131163|NCT04137276|DRUG|vitamin B1|thiamine 200 mg/12 hours for 3 days
224131164|NCT00337376|DRUG|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
224131165|NCT00337376|DRUG|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
224131166|NCT02645383|DEVICE|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
224131167|NCT02645383|DEVICE|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
224131168|NCT01901731|PROCEDURE|transjugular coil embolisation of pelvic veins|
224131169|NCT01901731|PROCEDURE|endovenous treatment of leg varicose veins|
223400272|NCT06644781|DRUG|Irinotecan hydrochloride (HCl)|Intravenous administration
223400273|NCT06812884|OTHER|Education|The mobile application will be introduced to the group to be trained and the application will be downloaded to their phones, tablets or computers.
223732772|NCT03140384|BIOLOGICAL|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
223400276|NCT03155620|PROCEDURE|Biopsy Procedure|Undergo biopsy
223400277|NCT03155620|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400278|NCT03155620|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow and/or biopsy
223400279|NCT03155620|PROCEDURE|Bone Scan|Undergo a bone scan
223400280|NCT03155620|PROCEDURE|Computed Tomography|Undergo CT, PET/Ct, and/or CT/MRI
223400281|NCT03155620|DRUG|Ensartinib|Given PO
223400282|NCT03155620|DRUG|Erdafitinib|Given PO
223400283|NCT03155620|OTHER|Laboratory Biomarker Analysis|Undergo molecular analysis
224020793|NCT00943111|DRUG|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (\<) 5 nanogram per milliliter \[ng/mL\] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (\>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
224131170|NCT05524441|OTHER|Circadian Disruption - Quasi-Experimental|2 conditions: comparing trips with circadian disruption to trips without circadian disruption
224131171|NCT01027208|DRUG|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
224131172|NCT02689232|BIOLOGICAL|Fresh Frozen Plasma|
224131173|NCT02689232|BIOLOGICAL|Platelets Concentrate|
224131174|NCT02689232|BIOLOGICAL|Cryo Precitipitate|
224131175|NCT02132234|DRUG|Etanercept|biological treatment according to rheumatologic indication
224131176|NCT02132234|DRUG|Adalimumab|biological treatment according to rheumatologic indication
224131177|NCT02132234|DRUG|Certolizumab|biological treatment according to rheumatologic indication
224297041|NCT05757882|OTHER|2 hours of fasting time|Oral intake is not allowed for 2 hours before sedation including water.
223400284|NCT03155620|DRUG|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
223400285|NCT03155620|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI, PET/MRI, and/or CT/MRI
223400286|NCT03155620|PROCEDURE|Mutation Carrier Screening|Undergo tumor tissue mutation screening
223400287|NCT03155620|DRUG|Olaparib|Given PO
223400288|NCT03155620|DRUG|Palbociclib|Given PO
223400289|NCT03155620|OTHER|Pharmacological Study|Correlative studies
223400290|NCT03155620|PROCEDURE|Positron Emission Tomography|Undergo PET, PET/CT, and/or PET/MRI
224131178|NCT02132234|DRUG|Infliximab|biological treatment according to rheumatologic indication
224131179|NCT03918603|OTHER|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
224297042|NCT05467046|DEVICE|Smartwatch system|The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
223400291|NCT03155620|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
223400292|NCT03155620|DRUG|Samotolisib|Given PO
223400293|NCT03155620|DRUG|Selpercatinib|Given PO
223400294|NCT03155620|DRUG|Selumetinib Sulfate|Given PO
223400295|NCT03155620|DRUG|Tazemetostat|Given PO
223400296|NCT03155620|DRUG|Tipifarnib|Given PO or via nasogastric or gastric tube
223400297|NCT03155620|DRUG|Ulixertinib|Receive PO
223400298|NCT03155620|DRUG|Vemurafenib|Given PO
223400299|NCT03155620|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223400300|NCT06882876|DRUG|JS014 Combined With Toripalimab and TACE|JS014 (60μg/kg,QW)+Toripalimab (240mg , Q3W)+ dTACE (60mg/m2)
223400301|NCT04750954|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224297043|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane blend|1.8 gram per day of lions mane, consisting of 3 x 600mg capsules
224297044|NCT06406946|DIETARY_SUPPLEMENT|Lion's mane and reishi blend|1.8 gram per day of lions mane and reishi blend, consisting of 3 x 600mg capsules
224297045|NCT06406946|DIETARY_SUPPLEMENT|Placebo|1.8-gram microcrystalline cellulose placebo powder, 3x600mg capsules
223400302|NCT04750954|PROCEDURE|Computed Tomography|Undergo CT
223400303|NCT04750954|DRUG|Lutetium Lu 177 Dotatate|Given IV
223400304|NCT04750954|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223400305|NCT04750954|DRUG|Peposertib|Given PO
223400306|NCT06982222|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223400307|NCT06982222|PROCEDURE|Bone Scan|Undergo technetium TC-99m bone scan
223400308|NCT06982222|PROCEDURE|Computed Tomography|Undergo PET/CT, SPECT/CT and PSMA PET/CT
223400309|NCT06982222|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223400310|NCT06982222|PROCEDURE|PSMA PET Scan|Undergo PSMA PET/CT
223400311|NCT06982222|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223400312|NCT06982222|RADIATION|Technetium TC-99m|Undergo technetium TC-99m bone scan
223400313|NCT06982222|RADIATION|Tin Sn 117m Pentetate|Given IV
223400314|NCT06574906|OTHER|Parameters of Early Warning Scores|Parameters of Early Warning Scores
223552098|NCT06046092|BIOLOGICAL|H7HLAII|DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules
223552099|NCT00729443|DRUG|AZD3241|single oral dose
223552100|NCT00729443|DRUG|Placebo|
223552101|NCT03835182|DEVICE|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
223552102|NCT03835182|DEVICE|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
223552103|NCT03835182|OTHER|Control group|superficial heat, analgesic physical modality and exercise only
223552104|NCT04224441|DRUG|Chlorpromazine Pill|The experimental treatment involves the combination of chlorpromazine to the standard treatment with temozolomide solely in the adjuvant phase (after radio-chemotherapy, temozolomide for 5 days every 28, at a dose of 150-200 mg/mq for 6 cycles) of the Stupp protocol. Chlorpromazine will be administered at a dose of 50 mg/day concomitantly with the adjuvant treatment with temozolomide
223552105|NCT00514722|OTHER|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
223552106|NCT03012828|DRUG|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
223552107|NCT03012828|OTHER|Placebo|
223552108|NCT03900728|DEVICE|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
224131180|NCT01374776|DRUG|intravenous iron carboxymaltose|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
224131181|NCT04829019|RADIATION|Osimertinib and whole-brain irradiation|Osimertinib at a dose of 80 mg once per day, and WBI
224131182|NCT04829019|DRUG|Osimertinib|Osimertinib at a dose of 80 mg once per day, until unacceptable adverse events or disease progression occurred. WBI could be given to patients in experimental arm at any time base on investigator's decision after treatment initiated.
224131183|NCT06395428|DRUG|Haloperidol|Intramuscular injection of drug
224131184|NCT06395428|DRUG|Ketorolac Tromethamine|Intramuscular injection of drug
224131185|NCT02887833|OTHER|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
224131186|NCT03860545|DIAGNOSTIC_TEST|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
224131187|NCT05514652|DRUG|Low opioid anesthesia|Multimodal low-dose opioid protocol for anesthesia based on ketamine, lidocaine and dexmedetomidine
224131188|NCT00207259|BEHAVIORAL|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
224131189|NCT04017442|DRUG|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
223552109|NCT03900728|DEVICE|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
223552110|NCT03900728|DEVICE|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
223552111|NCT00003776|BIOLOGICAL|filgrastim|
223552112|NCT00003776|DRUG|cisplatin|
223552113|NCT00003776|DRUG|doxorubicin hydrochloride|
223552114|NCT00003776|DRUG|ifosfamide|
223552115|NCT00003776|DRUG|leucovorin calcium|
223552116|NCT00003776|DRUG|methotrexate|
223552117|NCT00003776|DRUG|trimetrexate glucuronate|
223552118|NCT00003776|PROCEDURE|surgical procedure|
223552119|NCT04994639|DEVICE|BP management with HPI guidance|The hemodynamic condition of the HPI group will be managed by HPI guidance which is derived by arterial pressure waveform information, including Eadyn, SVV, dP/dt.
224131190|NCT04017442|DRUG|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
224131191|NCT04755712|DRUG|Rachianesthesia|Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
224131192|NCT04755712|DRUG|Sodium Chloride Injection|"Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2)."
224131193|NCT04755712|DRUG|Morphine|Morphine via pump (patient controlled analgesia)
224297046|NCT05885191|OTHER|2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture|Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.
224297047|NCT03261960|DRUG|BLI4700|Oral bowel preparation
224297048|NCT03261960|DRUG|Magnesium bowel preparation|Oral bowel preparation
223552120|NCT02100930|BIOLOGICAL|Anti-GD2 3F8 Monoclonal Antibody|
223552121|NCT02100930|DRUG|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
223552122|NCT02100930|DRUG|oral isotretinoin|
223552123|NCT00763256|DRUG|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
223552124|NCT00763256|DRUG|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
223552125|NCT03115411|DEVICE|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
223552126|NCT02522169|DRUG|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year."
223552127|NCT00693927|PROCEDURE|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
223552128|NCT00693927|PROCEDURE|CD8-depleted PBSC after nonmyeloablative conditioning|
223552129|NCT00205517|PROCEDURE|Daily interruption of sedation versus sedation algorithm|
223552130|NCT02544750|DRUG|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
223400315|NCT06656143|OTHER|Traditional Physical therapy|"The exercise program included the strengthening of the deep cervical flexor and shoulder retractor muscles and also stretching of the pectoralis and cervical extensor muscles.~(3 sets of 12 repetitions) Strengthening Deep Cervical Flexors Lying chin tuck Lying chin tuck with head lift. Strengthening Shoulder Retractors Standing shoulder pull back with elastic Shoulder pull back with weight Stretch Cervical Extensors Chin drop Stretch Pectoralis Muscle Bilateral Pectoral stretch"
224020794|NCT00943111|DRUG|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was \<5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was \>=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
224020795|NCT05660759|PROCEDURE|Portal vein embolization|Portal vein emboliazation with either NBCA or micro particles.
224131194|NCT04182698|DRUG|Simultaneous chemoradiotherapy for An Luo|"Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.~. Group II: 10 mg po qd, Group III: 12 mg po qd;~Combined chemotherapy:~Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).~The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD."
223400316|NCT06656143|OTHER|Diaphragmatic Myofascial Release|To release the diaphragm, the patient was positioned in the supine position. The therapist stood at the head of the patient. The therapist made manual contact bilaterally under the costal cartilages of the lower ribs (7th to 10th) with hypothenar regions of the hands and last three fingers. During the patient's inspiration, the therapist was gently pulling the points of hands contacts toward the head and slightly laterally, while elevating the ribs simultaneously. During exhalation, the therapist deepened hand contacts towards the inner costal margins Exercise Program (3 sets of 12 reps) Strengthening deep cervical flexors Strengthening shoulder retractors Stretching Cervical Extensors Stretching Pectoralis Muscle
223400317|NCT06692192|DRUG|Psilocybin|25mg of psilocybin
223552131|NCT03825640|BEHAVIORAL|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
223552132|NCT01838460|DRUG|sublingual nicotine tablets|6 mg = 3 tablets
223552133|NCT01838460|OTHER|Smokeless tobacco|Swedish type moist snuff
223552134|NCT05439343|OTHER|Pain scores (numerical rating scale at rest and motion)|As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
223552135|NCT05439343|OTHER|Secondary outcomes|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
223552136|NCT03751371|DEVICE|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
223732773|NCT02992106|OTHER|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~* Children aged 0-6 years old:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Ages and Stages Questionnaire~ 5. Strengths and Difficulties Questionnaire~ 6. Questionnaire on developmental milestones~ 7. Questionnaire on behaviour~* Children older than 6 years:~  1. Questionnaire on socio-demographic characteristics~ 2. Dutch Eating Behaviour Questionnaire~ 3. Food Frequency Questionnaire~ 4. Pediatric Quality of Life Questionnaire~ 5. Children's Behaviour Questionnaire in Dutch~ 6. Questionnaire on developmental milestones~ 7. Developmental Coordination Disorder Questionnaire~ 8. Strengths and Difficulties Questionnaire"
223732774|NCT02992106|OTHER|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
224131195|NCT00144755|DRUG|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
223400318|NCT06692192|DRUG|Psilocybin|1mg of psilocybin
223400319|NCT06692192|DRUG|Midazolam|The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.
223732775|NCT02992106|OTHER|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
223732776|NCT02992106|OTHER|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
223732777|NCT02992106|OTHER|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
223732778|NCT02992106|OTHER|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
223732779|NCT02992106|OTHER|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
223732780|NCT01083394|DEVICE|PTA|PTA using a conventional balloon
223732781|NCT01083394|DEVICE|PTA with PEB|PTA using a paclitaxel eluting balloon
223732782|NCT01083394|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
223732783|NCT03227029|BIOLOGICAL|RSV ΔNS2/Δ1313/I1314L|10\^6 plaque-forming units (PFU); administered as nose drops
223732784|NCT03227029|BIOLOGICAL|RSV 276|10\^5 PFU; administered as nose drops
223732785|NCT03227029|BIOLOGICAL|Placebo|Isotonic diluent, administered as nose drops
223732786|NCT00367094|DRUG|Benazepril plus hydrochlorothiazide|
223732787|NCT02234089|DRUG|Degarelix|According to medical practice
223732788|NCT02234089|DRUG|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
224020796|NCT03069001|DRUG|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
224020797|NCT03069001|DRUG|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
224020798|NCT04512859|PROCEDURE|Stellate Ganglion Block|Stellate ganglion block under ultra-guide will be administered using 0.25% ropivacaine 10mL
224020799|NCT04512859|PROCEDURE|Placebo|Stellate ganglion block under ultra-guide will be administered using 0.9% saline 10mL
224020800|NCT02608957|DEVICE|Latella Knee Implant System|
224020801|NCT02174666|DIETARY_SUPPLEMENT|Red clover extract|Aglycone isoflavones 80mg/d
224131196|NCT01153191|PROCEDURE|Normal saline pressurized irrigation|same
223400320|NCT06692192|DRUG|Saline|Saline will be administered as a placebo for midazolam
223732789|NCT01250262|OTHER|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
223732790|NCT01250262|OTHER|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
224020802|NCT02174666|DIETARY_SUPPLEMENT|Supplementation (placebo)|
224020803|NCT04890119|DIAGNOSTIC_TEST|tenosynovial tissue biopsy|Biopsy of tenosynovial tissue during surgery for amyloid aggregate search
224020804|NCT04556721|DRUG|Sugammadex|On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
224020805|NCT04006353|DRUG|ABT|320 mg, Intravenous infusion
224131197|NCT01153191|DRUG|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
224131198|NCT00970957|DRUG|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
224131199|NCT00970957|DRUG|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
223400321|NCT06983223|DIETARY_SUPPLEMENT|Sucrosomial® Vitamin B12|Sucrosomial® B12 is an advanced oral vitamin B12 supplement formulated with Sucrosomial® technology to enhance absorption. Participants in this group will receive 1,000 mcg of Sucrosomial® B12 (single sachet of orally dissolving powder) once daily for 4 weeks.
223400322|NCT06983223|OTHER|Placebo (Oral)|Participants in the placebo group will receive an identical powder that matches the Sucrosomial® B12 in appearance, packaging, and administration. The placebo will be administered once daily for 4 weeks.
223400323|NCT06986174|DRUG|Pacritinib|Kinase inhibitor, capsule, taken orally per protocol.
223400324|NCT06467760|DEVICE|InDx CMC Implant|The InDx CMC Implant is a hemiarthroplasty device for the CMC joint which consists of a unified assembly of three components: metacarpal stem, polyethylene liner, and articulating head. Because the device functions as a hemiarthroplasty, it does not link or constrain the CMC joint
223732791|NCT01250262|OTHER|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
223732792|NCT03280420|PROCEDURE|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
223732793|NCT03280420|PROCEDURE|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
223732794|NCT00390858|DRUG|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
223732795|NCT02349581|PROCEDURE|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
223732796|NCT02349581|DRUG|Bupivacaine|
224020806|NCT04006353|DRUG|RIF|600mg q.d.
224020807|NCT01322997|DEVICE|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
224131200|NCT02326207|DEVICE|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
223732797|NCT03468257|BEHAVIORAL|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
223732798|NCT03879122|DRUG|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
223732799|NCT03879122|DRUG|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
223732800|NCT03879122|DRUG|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
223732801|NCT03879122|DRUG|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
223732802|NCT06112444|OTHER|scale|The scale of Short Western Ontario Rotator Cuff İndex
223732803|NCT01113801|DRUG|LY2382770|Subcutaneous injection given monthly for 12 months
223732804|NCT01113801|DRUG|Placebo|Subcutaneous injection given monthly for 12 months
223732805|NCT00403663|DRUG|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
223732806|NCT02953054|DRUG|DMTS|DMTS applied before surgery and worn for 72 hours
223732807|NCT02953054|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
223732808|NCT03080311|DRUG|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
224131201|NCT04903184|BIOLOGICAL|RUTI® vaccine|Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli in a total volum of 0,3mL.
223732809|NCT01406431|DRUG|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
223732810|NCT01406431|DRUG|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
223732811|NCT02225990|OTHER|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
223732812|NCT02225990|OTHER|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
223732813|NCT02225990|OTHER|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
224020808|NCT01322997|BEHAVIORAL|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
224020809|NCT01322997|DEVICE|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
224020810|NCT01541098|BIOLOGICAL|Lyophilized Plasma|Licensed plasma that has been lyophilized.
223732814|NCT02225990|OTHER|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
223732815|NCT01506479|BEHAVIORAL|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
223732816|NCT01506479|BEHAVIORAL|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
223732817|NCT01506479|BEHAVIORAL|No Intervention|No-exercise control (i.e., usual care);
224020811|NCT01541098|BIOLOGICAL|Licensed Plasma|Plasma that has been authorized for transfusion.
224020812|NCT03753737|OTHER|Questionnaires and semi-structured interview|"* Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~* Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder."
224020813|NCT01810601|DRUG|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
224020814|NCT00001689|DRUG|Vincristine|
224020815|NCT02239900|DRUG|Ipilimumab|"Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.~Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.~Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4"
224131202|NCT04903184|BIOLOGICAL|Placebo|Physiological serum, 0.9% NaCl, will be used as a placebo.
224131203|NCT06555211|PROCEDURE|MRI|MRI will be performed
224131204|NCT06555211|PROCEDURE|PET/CT|PET/CT will be performed
224131205|NCT02586233|DRUG|DS-1040b|DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period
224131206|NCT02586233|DRUG|Placebo|0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
224131207|NCT04191291|BEHAVIORAL|Lunch period length|We are randomly allocating a 10 minute or 20 period of seated lunch time.
224131208|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
224020816|NCT02239900|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.~Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.~Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1."
224020817|NCT02882529|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
223732818|NCT03978429|OTHER|Community-based Pre-eclampsia/Eclampsia Detection and Management|Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
223732819|NCT03978429|OTHER|Strengthened Referral Network from Community to Referral hospital levels|ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
223732820|NCT01548482|OTHER|Laboratory Biomarker Analysis|Correlative studies
223732821|NCT01548482|OTHER|Pharmacological Study|Correlative studies
223732822|NCT01548482|DRUG|Temsirolimus|Given IV
224020818|NCT05586139|DIETARY_SUPPLEMENT|Microbiome-directed food - MAM|Each MAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
224020819|NCT05586139|DIETARY_SUPPLEMENT|Ready-to-use supplementary food (RUSF)|Each MAM child will be supplemented with RUSF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
223732823|NCT01548482|BIOLOGICAL|Trebananib|Given IV
223732824|NCT03886376|OTHER|Deep Massage|The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
223732825|NCT03886376|OTHER|Superficial Massage|The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
223732826|NCT01782859|DRUG|Prednisone|
223732827|NCT01782859|DRUG|Hydrocortisone|
223732828|NCT01782859|DRUG|Placebo (for Prednisone)|
223732829|NCT04905173|OTHER|Squat-to-stand maneuver|Subjects will squat for 5 seconds and then stand. The squat-to-stand exercise will be done up to 10 times, and then immediately undergo echocardiographic imaging.
223732830|NCT04905173|DRUG|Amyl nitrite inhalation|Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
223732831|NCT04905173|OTHER|Valsalva|Subjects will undergo echocardiographic imaging while performing the Valsalva maneuver. This is according to current laboratory protocol and is part of standard of care.
223732832|NCT02838563|OTHER|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
223732833|NCT06220422|PROCEDURE|Standard Department procedure for managing direct-acting oral anticoagulants|Standard Department procedure for managing direct-acting oral anticoagulants (NACO \< 50 ng/mL) in the management of fractures before September 2021
224020820|NCT05586139|DIETARY_SUPPLEMENT|Microbiome-directed food (MDF) - SAM|Each SAM child will be supplemented with MDF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
224020821|NCT05586139|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|Each SAM child will be supplemented with RUTF for a maximum of 12 weeks. He will be followed subsequently up to 24 weeks.
224020822|NCT01453868|OTHER|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
224020823|NCT01453868|OTHER|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
224020824|NCT02377141|PROCEDURE|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
224020825|NCT02377141|PROCEDURE|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
224020826|NCT06487611|BEHAVIORAL|A humanoid social robot|A humanoid social robot-mediated programme, including human-robot interactions, listening songs and daily news, doing physical activities and play memory games
223732834|NCT06220422|PROCEDURE|New Department procedure for managing direct-acting oral anticoagulants|New Department procedure for managing direct-acting oral anticoagulants (NACO \< 100 ng/mL) in the management of fractures after September 2021
223732835|NCT04994522|DRUG|Belzutifan|Three 40 mg tablets given as a single oral 120 mg dose.
223732836|NCT05944341|DRUG|articaine hydrochloride 4% with epinephrine 1:100 000|Local anesthetic agent
223400325|NCT06818045|PROCEDURE|Non Surgical Periodontal Treatment|This procedure will be applied to all patients. All patients received nonsurgical periodontal treatment. Scaling root planing and subgingival debridement were performed.
224020827|NCT05357118|BEHAVIORAL|Suppress Stigma, Support Services|Women living with HIV/AIDS (WLHA) will attend an initial group preparation session in Month 1 to form a network with peers and prepare for the following online support groups. During Month 2-4, study investigators will teach cognitive, emotional, and behavioral strategies to cope with stigma and utilize social support to seek healthcare services through online group activities. During Month 4-6, WLHA will self-administer the online support groups without the intervention of study investigators
224020828|NCT05334251|OTHER|combined spinal-epidural anesthesia|Combined spinal and epidural anaesthesia is a regional anaesthetic technique, which combines the benefits of both spinal anaesthesia and epidural anaesthesia and analgesia. The spinal component gives a rapid onset of a predictable block. The indwelling epidural catheter gives the ability to provide long lasting analgesia and to titrate the dose given to the desired effect.
223732837|NCT05944341|DRUG|Lidocaine hydrochloride 2% with epinephrine 1:100 000|Local anesthetic agent
224020829|NCT03218540|PROCEDURE|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV \> 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg
224020830|NCT02097940|OTHER|proprioceptive exercises|Exercises with movements, jumping and imbalance.
224020831|NCT01134952|DRUG|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
224020832|NCT03888053|BIOLOGICAL|BB-101|Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
224020833|NCT01055301|DRUG|bortezomib|
224020834|NCT01055301|DRUG|cisplatin|
224131209|NCT01757405|BIOLOGICAL|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
223732838|NCT05953246|BEHAVIORAL|Neutral labels|Participants view neutral labels (QR codes with and without neutral text) for menu items
223732839|NCT05953246|BEHAVIORAL|Numeric text-only sustainability labels|Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item
223732840|NCT05953246|BEHAVIORAL|Endorsement text-only sustainability labels|Participants view labels using text to endorse menu items as having low environmental impact
223732841|NCT05953246|BEHAVIORAL|Endorsement icon-only sustainability labels|Participants view labels using icons to endorse menu items as having low environmental impact
223732842|NCT05953246|BEHAVIORAL|Endorsement text-plus-icon sustainability labels|Participants view labels using text and icons to endorse menu items as having low environmental impact
223732843|NCT01465087|OTHER|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
223732844|NCT03711045|BEHAVIORAL|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
224131210|NCT04089813|DRUG|Metformin|Patients use metformin to control blood sugar
223732845|NCT03294733|PROCEDURE|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
223732846|NCT03318315|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
223400326|NCT06818045|OTHER|Periodontal measurements will be performed|Periodontal measurements will be performed on all patients (plaque index, gingival index, bleeding on probing, periodontal pocket depth, clinical attachment loss).
223400327|NCT06818045|OTHER|biochemical measurements|Serum and gingival crevicular fluid (GCF) samples will be collected from patients for biochemical evaluations.
223400328|NCT06818045|OTHER|No medication will be administered to patients.|No medication will be administered to patients.
223400329|NCT04064827|DRUG|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
224020835|NCT01055301|DRUG|cyclophosphamide|
224020836|NCT01055301|DRUG|dexamethasone|
224020837|NCT01055301|DRUG|doxorubicin hydrochloride|
224020838|NCT01055301|DRUG|etoposide|
224020839|NCT01055301|DRUG|lenalidomide|
224020840|NCT01055301|DRUG|melphalan|
224020841|NCT01055301|DRUG|thalidomide|
224020842|NCT01055301|GENETIC|gene expression analysis|
224020843|NCT01055301|GENETIC|microarray analysis|
224020844|NCT01055301|OTHER|laboratory biomarker analysis|
224020845|NCT01055301|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|
224020846|NCT04452760|OTHER|Physical exercise|Physical exercise intervention
224020847|NCT04452760|OTHER|Testing sessions|Testing sessions
224020848|NCT00063752|DRUG|PI-0824|
224020849|NCT03422198|RADIATION|Vaginal Cuff Brachytherapy|Undergo standard of care vaginal cuff brachytherapy
224020850|NCT03422198|RADIATION|Short course vaginal cuff brachytherapy|Undergo short course vaginal cuff brachytherapy
224020851|NCT04635475|BEHAVIORAL|RISE Bundle|Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
224131211|NCT04447703|OTHER|Interview|Attend Interview
224131212|NCT04447703|OTHER|Internet Based Intervention|Use web-based genetic education tool online
224131213|NCT04447703|OTHER|Survey Administration|Ancillary Studies
224131214|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
224131215|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
223400330|NCT03440229|OTHER|Emulsifier-containing diet|CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
223400331|NCT04010565|DIETARY_SUPPLEMENT|Aged black garlic extract|"Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias."
223400332|NCT04010565|DIETARY_SUPPLEMENT|Placebo|Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
223400333|NCT05694793|DEVICE|Glean Urodynamics System|Wireless, catheter-free urodynamics system
223400334|NCT05694793|DEVICE|Glean Urodynamics System|Wireless and catheter free urodynamics system
223732847|NCT03318315|BIOLOGICAL|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
223732848|NCT03318315|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
223732849|NCT03318315|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
223732850|NCT02475577|DEVICE|Peripherals with HealthInterlink technology|home remote monitoring
223732851|NCT03946033|DIAGNOSTIC_TEST|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
224020852|NCT00466375|GENETIC|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
223732852|NCT01362374|DRUG|5-FU|5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
223732853|NCT01362374|DRUG|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
224131216|NCT04447703|OTHER|Survey Administration|Ancillary Studies
223732854|NCT01362374|DRUG|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
223732855|NCT01362374|DRUG|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
223732856|NCT01362374|DRUG|Leucovorin|Leucovorin at a dose level of 400 mg/m\^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
224131217|NCT04447703|OTHER|Genetic Counseling|Receive in-person, telehealth, or over-the-phone genetic counseling
224131218|NCT04447703|OTHER|Internet-Based Intervention|Use web-based genetic education tool online
224131219|NCT04447703|GENETIC|Genetic Testing|Undergo genetic testing
223552137|NCT03751371|OTHER|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
223552138|NCT04396795|DRUG|Autologous Platelet Rich Plasma|Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.
223552139|NCT04396795|OTHER|Saline solution|Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
223552140|NCT00000673|DRUG|Ganciclovir|
223552141|NCT05088434|DIETARY_SUPPLEMENT|Anaerobically Cultivated Human Intestinal Microbiota (ACHIM)|One vial of ACHIM suspension (ACHIM Biotherapeutics AB, Vallingby, Sweden), containing 30 x 109 colony forming unit (CFU) of bacteria, was given through the work channel of a gastroscope into the lower part of duodenum.
223732857|NCT01362374|DRUG|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
223732858|NCT01362374|DRUG|Paclitaxel|Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
223732859|NCT03327311|DEVICE|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis \& deep dermis).
224020853|NCT00466375|GENETIC|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
224020854|NCT04227704|DRUG|Ketamine 50 MG/ML|Administration of a 0.5 mg/kg dose of ketamine at cesarean delivery by one of two routes (subcutaneous or 40-minute IV infusion).
224020855|NCT04227704|DRUG|Control|Administration of 0.9% Sodium Chloride (N/S)
224020856|NCT03599609|DRUG|Simvastatin 40mg|Simvastatin 40mg, once daily
224131220|NCT04447703|OTHER|Survey Administration|Ancillary Studies
224131221|NCT01434641|OTHER|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
224131222|NCT05910541|BEHAVIORAL|Mindful breathing|30 minutes of mindful breathing session for 4 consecutive days, guided by investigators in addition to standard care.
224131223|NCT05910541|OTHER|Standard care (control)|Standard care such as pain control, oxygen supplement.
224131224|NCT00996021|DRUG|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
224131225|NCT00996021|DRUG|Placebo Suspension|Placebo is a liquid with no drug in it.
224131226|NCT00996021|DRUG|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
224131227|NCT00082758|BIOLOGICAL|hu14.18-Interleukin-2 fusion protein|Given IV
224131228|NCT02598518|BEHAVIORAL|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
224131229|NCT02598518|BEHAVIORAL|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
224131230|NCT02767453|PROCEDURE|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
224131231|NCT02767453|PROCEDURE|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
223732860|NCT00970333|DRUG|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
223732861|NCT00407823|PROCEDURE|Central venous oxygen saturation continuous monitoring|
223732862|NCT02064647|OTHER|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
224131232|NCT00238303|DRUG|vorinostat|Given orally
223400335|NCT03811691|DIAGNOSTIC_TEST|MRI exam|Pacing system safety and stability under MRI scan environment
223732863|NCT02064647|OTHER|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
223400336|NCT04899180|DRUG|99mTc-PYP|Radioisotope used by SPECT/CT imaging
223732864|NCT04124120|PROCEDURE|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
223732865|NCT04124120|PROCEDURE|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
224131233|NCT00238303|PROCEDURE|conventional surgery|Patients undergo surgery to remove tumor
224131234|NCT03298152|PROCEDURE|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
224131235|NCT03298152|PROCEDURE|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
224131236|NCT04876989|PROCEDURE|US-SGB|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.
224297049|NCT02668926|DRUG|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
223400337|NCT06676098|PROCEDURE|IANBD 3D guided approach|The IANBD will be used to administer the dental anesthetic 2mm medial to the lingula
223400338|NCT04300062|PROCEDURE|Rebiopsy|Biopsy will be carry out with flexible bronchoscopy as usual practice under local anesthesia: under endobronchial ultrasound, punction under CT scan or ultrasonography, percutaneous pleural puncturing.
223400339|NCT07013630|DIETARY_SUPPLEMENT|Clarity Placebo Control|Participants will use their Clarity Placebo Control as directed for a period of 6 weeks.
223732866|NCT03941431|DRUG|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
223732867|NCT03941431|DEVICE|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
223732868|NCT03941431|DEVICE|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
223732869|NCT03941431|DRUG|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
223732870|NCT03941431|DEVICE|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
223732871|NCT03941431|DEVICE|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
223400340|NCT07013630|DIETARY_SUPPLEMENT|Clarity Active Product|Participants will use their Clarity Active Product as directed for a period of 6 weeks.
223400341|NCT06683534|DIETARY_SUPPLEMENT|Quercetin (dietary supplement)|Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.
223400342|NCT06683534|DRUG|Placebo|Subjects randomized to receive placebo will be administered a standard placebo sugar pill.
223732872|NCT02059460|DRUG|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
223732873|NCT02059460|DRUG|placebo|
223732874|NCT03593707|DRUG|Metformin|Metformin
223732875|NCT03593707|DRUG|PF-06865571|PF-06865571
223732876|NCT03779464|DRUG|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
223732877|NCT05766982|OTHER|Platelet Rich Plasma|Platelet rich plasma will be applied to assess rate of wound healing.
223732878|NCT00940394|BEHAVIORAL|mutual support group|bi-weekly, 12-session, family-led mutual support group
223732879|NCT00940394|BEHAVIORAL|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
223732880|NCT00940394|OTHER|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
223732881|NCT00000233|DRUG|Buprenorphine|
223732882|NCT00229632|DRUG|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
223732883|NCT01035203|BEHAVIORAL|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
223732884|NCT01035203|BEHAVIORAL|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
224131237|NCT04876989|PROCEDURE|US-TPVB|Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.
224131238|NCT02090192|PROCEDURE|WBV training|
224131239|NCT02090192|PROCEDURE|PRT training|
223552142|NCT05088434|DIETARY_SUPPLEMENT|Donor fecal microbiota transplantation|Only 60 ml of sterile 0.9% normal saline were added to a stool specimen, collected from the respective donor, with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
223552143|NCT05088434|DIETARY_SUPPLEMENT|Placebo|Only 60 ml of sterile 0.9% normal saline were added to the patient's own stool specimen with a weight of \~30 g and homogenized manually. Then 60 ml of feces-suspension (screened from the patients view) were instilled through the work channel of a gastroscope into the lower part of the duodenum.
223552144|NCT02108327|PROCEDURE|surgical blade|Using surgical blade all the time of surgery
223732885|NCT01727973|DRUG|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
223732886|NCT01676844|DRUG|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
223552145|NCT02108327|PROCEDURE|electrocautery|Using electrocautery all the time except at skin incision
223552146|NCT02827344|BIOLOGICAL|blood sample collection for CTC and MDSC analysis|"* Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~* Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~* Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
223552147|NCT02113423|RADIATION|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID\*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID\*2F
223552148|NCT01833910|OTHER|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
223552149|NCT01833910|OTHER|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
223552150|NCT04706780|OTHER|ESP block|ESP block performed using ultrasound guidance. Diaphragmatic excursion was measured using M-mode ultrasound during normal breathing, deep breathing and with the sniff manoeuvre.
223552151|NCT03060993|DRUG|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
223552152|NCT03060993|DRUG|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
223732887|NCT01676844|DRUG|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
223732888|NCT03394807|DRUG|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
223732889|NCT03394807|DRUG|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
223732890|NCT00455364|DRUG|Voriconazole|
223732891|NCT04790760|DIETARY_SUPPLEMENT|Supplement Consumption|Participants will consume one 500 mg cinnamon capsule and one 300 mg aloe vera capsule twice per day for weeks 3-6.
223732892|NCT04790760|DEVICE|Continuous Glucose Monitors|Participants will wear a CGM on the back of their left and right arm for weeks 1-6.
223732893|NCT01455142|DRUG|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
224131240|NCT01235286|PROCEDURE|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
224131241|NCT02351843|DEVICE|MECTA Spectrum 5000Q|
223732894|NCT03753529|OTHER|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
223732895|NCT03753529|OTHER|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
223732896|NCT03753529|OTHER|control group|Stretching and transcutaneous electrical nerve stimulation
223732897|NCT06363006|DRUG|TKI+Cardunilimab|Cardonilizumab 6mg/kg, IV, Q2W + lenvatinib 8mg (body weight \< 60kg) or 12mg(body weight ≥60kg) PO, QD, / Sorafenib 400mg, PO, BID/ Regorafenib 160mg, PO, QD/ Donafenib 200mg, PO, BID。 omniscience
223732898|NCT02986568|PROCEDURE|Cervical cancer|"If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
223732899|NCT02986568|PROCEDURE|Uterine cancer|"Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy."
223732900|NCT02986568|PROCEDURE|Cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy."
223732901|NCT02986568|PROCEDURE|Non-cervical cancer, pelvic sidewall invasion|"Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type."
223732902|NCT04197934|PROCEDURE|Biospecimen Collection - blood samples|Undergo collection of blood samples
223732903|NCT04197934|PROCEDURE|Biospecimen Collection - CSF samples|Undergo collection of CSF samples
223400343|NCT06686979|OTHER|No Intervention: Observational Cohort|The patients with R/M SGC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.
223400344|NCT00156403|DRUG|amlodipine (drug)|
223400345|NCT03212274|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223732904|NCT04197934|PROCEDURE|Computed Tomography|Undergo CT
223732905|NCT04197934|DRUG|EGFR/EGFRvIII Inhibitor WSD0922-FU|Given PO
223732906|NCT04197934|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223732907|NCT04197934|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223732908|NCT03222050|OTHER|Distraction technique|
223732909|NCT02354989|DEVICE|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
223732910|NCT02354989|DEVICE|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
223732911|NCT00231595|DRUG|topiramate|
223732912|NCT02396901|OTHER|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
223732913|NCT03491241|DIETARY_SUPPLEMENT|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
224131242|NCT02623595|RADIATION|Stereotactic body radiotherapy|A type of radiation therapy
224131243|NCT02623595|DRUG|rhGM-CSF|Immune modulating agents
223400346|NCT03212274|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400347|NCT03212274|PROCEDURE|Computed Tomography|Undergo a CT scan
223400348|NCT03212274|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
223400349|NCT03212274|DRUG|Olaparib|Given PO
223400350|NCT04123431|DEVICE|Total Hip Replacement|Primary elective total hip replacement
223400351|NCT06681181|DRUG|GSK4528287|GSK4528287 will be administered.
223400352|NCT06681181|DRUG|Placebo|Placebo will be administered.
223400353|NCT06680258|DRUG|TPST-1120|TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα)
223400354|NCT06680258|BIOLOGICAL|Atezolizumab|Atezolizumab is an IV administered biologic.
223400355|NCT06680258|BIOLOGICAL|Bevacizumab|Bevacizumab is an IV administered biologic.
223400356|NCT06874322|OTHER|Voiceitt|Participants will use Voiceitt App
223400357|NCT05691712|DRUG|Tirzepatide|Administered SC
223400358|NCT05691712|DRUG|Placebo|Administered SC
224131244|NCT03287752|DEVICE|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
224131245|NCT03287752|DEVICE|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
224131246|NCT05329779|DRUG|brexanolone|Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.
224131247|NCT05329779|DRUG|placebo|The placebo is a 0.45% sodium chloride infusion.
224131248|NCT01833741|DRUG|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
224131249|NCT00208494|DEVICE|Total Hip Replacement|Total hip replacement
224131250|NCT00208494|DEVICE|Total hip replacement|Total hip replacement
223400359|NCT05199701|DEVICE|Mammography|All subjects who are indicated for a screening or diagnostic mammogram or breast biopsy will undergo an investigational exam in a new mammography device.
223400360|NCT05584449|OTHER|Counseling|Attend online group facilitated by two oncology social workers
223400361|NCT05584449|PROCEDURE|Discussion|Discuss survivorship issues/concerns
223400362|NCT05584449|OTHER|Informational Intervention|Receive young adult cancer survivorship information
223400363|NCT05584449|OTHER|Medical Chart Review|Ancillary studies
223400364|NCT05584449|OTHER|Quality-of-Life Assessment|Ancillary studies
223400365|NCT05584449|OTHER|Questionnaire Administration|Ancillary studies
223400366|NCT02603588|PROCEDURE|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
223400367|NCT02603588|PROCEDURE|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
223400368|NCT06687421|OTHER|High-risk treatment SOC|radiotherapy (RT) + ADT (3 years) + Abiraterone acetate (2 years), with radical prostatectomy being an option if contraindication for RT exists)
223400369|NCT06687421|OTHER|Active monitoring|Followed with PSA measurements
223400370|NCT06687421|PROCEDURE|Radical prostatectomy|Radical prostatectomy
223400371|NCT06687421|RADIATION|Radiotherapy|Radiotherapy
223400372|NCT06687421|DRUG|Androgen deprivation therapy|GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel
224131251|NCT01358877|DRUG|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
224131252|NCT01358877|DRUG|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
224131253|NCT01358877|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
223400373|NCT06689163|DRUG|HRS-1167 tablets|HRS-1167 tablets
223400374|NCT06689163|DRUG|Abiraterone Acetate tablets（II）|Abiraterone Acetate tablets（II）
223400375|NCT06689163|DRUG|Prednisone Acetate tablets|Prednisone Acetate tablets
223400376|NCT06696131|DRUG|TNK|TNK will be delivered into the site of the intracerebral hemorrhage via a brain catheter.
223400377|NCT07025824|DRUG|Treosulfan (Treo)|10 g/m2 intravenous
223400378|NCT07025824|DRUG|Melphalan (Mel)|140 mg/m2 intravenous
223400379|NCT07025824|DRUG|Fludarabine (Flud)|30 mg/m2 intravenous
223400380|NCT07026981|DRUG|[Ga-68]MTP220 PET/CT Scan|Participants will undergo PET/CT imaging after they have received an injection of the targeted PET tracer drug, \[Ga-68\]MTP220.
223400381|NCT03171376|PROCEDURE|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
223400382|NCT00697632|DRUG|MGCD265|Oral daily administration without interruption
223552153|NCT06039215|OTHER|Ventilatory adjustments by nurses|Respirator settings are adjusted by nurses according to a pre-established care protocol that complies with international recommendations. The nurse assesses the patient's respiratory status and readjusts the artificial respirator settings if necessary, at least twice a day.
223552154|NCT01098331|PROCEDURE|Radical Prostatectomy|
223552155|NCT01098331|PROCEDURE|Brachytherapy|
223552156|NCT00039039|DRUG|carboplatin|
223552157|NCT00039039|DRUG|chemotherapy|
223552158|NCT00039039|DRUG|cisplatin|
223552159|NCT00039039|DRUG|paclitaxel|
223552160|NCT00039039|RADIATION|radiation therapy|
223552161|NCT03744195|OTHER|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~1. The skin will be cleaned properly with alcohol~2. The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~3. A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10\~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
223552162|NCT03744195|OTHER|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10\~30 reps)
223552163|NCT00886327|PROCEDURE|Colonic capsule endoscopy|
223552164|NCT04820062|OTHER|Content Validity|For the validity of built, it is generally advisable to include a ratio of 100 participants for 30 questionnaire items. In order to have a suitable questionnaire, we will limit ourselves to 30 items which will be the size of our questionnaire. It was therefore planned to include 100 participants The selection of experts will be based on experience in this area, knowledge and availability. It will be a rescimant physician and an infectious disease doctor. Each expert will be invited in isolation to comment on the items in the questionnaire
223552165|NCT03127696|PROCEDURE|Fecal Microbiota Transplantation|FMT
223552166|NCT03127696|BEHAVIORAL|Lifestyle Modification Program|Lifestyle
223552167|NCT03127696|PROCEDURE|Sham|Sham
224020857|NCT04092361|DEVICE|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
224020858|NCT02760277|DRUG|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
223400383|NCT06216275|BEHAVIORAL|Integrated Snoezelen-Aromatherapy-Personal Item Therapy|"Intervention Description:~This unique intervention combines three distinct therapeutic approaches specifically tailored for Arab elderly patients with dementia experiencing agitation.~Snoezelen Therapy: Customized sessions in a Snoezelen environment - a specialized room designed to deliver controlled multi-sensory stimuli. This room features adaptable lighting, colors, sounds, and textures to provide a soothing and stimulating experience. Sessions are personalized based on each patient's response and preference, under the guidance of trained professionals.~Aromatherapy: Carefully selected essential oils known for their calming properties are used in a culturally sensitive manner. These oils are diffused in the environment or used during individual sessions to provide a relaxing olfactory experience. The choice of oils and method of delivery are standardized"
224020859|NCT02760277|DRUG|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
223400384|NCT03479580|OTHER|Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
223400385|NCT07028294|COMBINATION_PRODUCT|Combined exercise and nutrition intervention|Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks). Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol. Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
224020860|NCT02760277|DRUG|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
224020861|NCT02760277|DRUG|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
223400386|NCT00352742|DRUG|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
223400387|NCT05828498|DIETARY_SUPPLEMENT|THE Mediterranean diet|The Mediterranean diet was applied to the patients with bacterial vaginitis selected randomly. diet content and application techniques were explained to the patient.
223400388|NCT03161353|DRUG|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
223552168|NCT05576298|BIOLOGICAL|Insulin degludec injection, RD15003|single dose, s.c. injection
223552169|NCT05576298|BIOLOGICAL|Insulin degludec, Tresiba|single dose, s.c. injection
224131254|NCT01358877|DRUG|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
223552170|NCT00298298|BIOLOGICAL|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
224131255|NCT01358877|DRUG|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
223552171|NCT00995098|DIETARY_SUPPLEMENT|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
223552172|NCT00995098|DIETARY_SUPPLEMENT|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
223552173|NCT00848835|DEVICE|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
223552174|NCT04861272|BEHAVIORAL|Survey|Online survey
223552175|NCT04099498|BEHAVIORAL|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
223552176|NCT04099498|BEHAVIORAL|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
223552177|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
223552178|NCT02968498|DIETARY_SUPPLEMENT|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
223552179|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
223552180|NCT02968498|DIETARY_SUPPLEMENT|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
223552181|NCT02968498|DIETARY_SUPPLEMENT|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
224131256|NCT01358877|DRUG|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
223732914|NCT01896531|DRUG|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
223732915|NCT01896531|DRUG|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
223732916|NCT01896531|DRUG|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
223732917|NCT01896531|DRUG|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
223732918|NCT01896531|DRUG|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
224131257|NCT01358877|DRUG|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
224131258|NCT01358877|DRUG|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
224131259|NCT01358877|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
224131260|NCT01358877|DRUG|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
224131261|NCT05296850|OTHER|Manual Release|Individuals are placed in the prone position with their knees extended. The calcaneus is kept in eversion while maintaining talocrural dorsiflexion. As the toes are stretched in dorsiflexion, the therapist slides the big toe distally and proximally along the plantar fascia and flexor hallucis longus. Soft tissue mobilization depth will be applied according to the patient's tolerance and reactivity.
224131262|NCT05296850|OTHER|Kinesio Taping|"In the first technique, an I tape will be applied on the plantar surface of the foot from the metatarsal heads to the popliteal fossa. First, the middle of the band is attached to the inferior of the calcaneus as the first anchor, then the ankle is dorsiflexed and the upper part of the band is applied with 15-25% tension until the popliteal fossa. The plantar fascia is placed in a stretched position by dorsiflexing the ankle and fingers, and the ends of the tape, which is divided into 4 parts, are applied separately to the metatarsal heads with 75-100% tension. In the second technique, the application is made with an I tape. The initial anchor starts from the dorsal aspect of the 5th metatarsal on the lateral aspect of the foot. Then, the tape passes to the medial side of the foot with 75-100% tension and is adhered to the medial side of the foot and ankle over the navicular. The end anchor is applied without tension."
224131263|NCT04769635|DEVICE|CPAP therapy|All studied patients were received CPAP therapy with average cumulative adherence ⩾4 h/day of \>70% nights \[380\] obtained from device download with AHI\<5 /hr
224297050|NCT02668926|DRUG|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
223732919|NCT05354752|DRUG|VC005 tablets|VC005 groups repeat administration for 7 days
224297051|NCT02668926|DRUG|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
224297052|NCT04768166|DRUG|Miglustat 100 MG|100mg/TID in 4w then 200mg/TID in 8 w
223732920|NCT05354752|DRUG|VC005 Placebo tablets|VC005 placebo groups repeat administration for 7 days
223732921|NCT03612297|DIAGNOSTIC_TEST|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
223732922|NCT00073554|DRUG|Alfimeprase|
223732923|NCT02011737|DRUG|naftopidil 75mg|
223732924|NCT05810623|DRUG|Intravesical Solution|Intravesical single dose instillation of chemotherapy within 24h from uretero-renoscopy
223732925|NCT02697786|DEVICE|Transcranial doppler|Prolonged de airing to decrease the number of MES
223732926|NCT00632411|DRUG|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
223732927|NCT00632411|BEHAVIORAL|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
223732928|NCT03233906|DIETARY_SUPPLEMENT|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
223732929|NCT03012425|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
223732930|NCT03012425|PROCEDURE|Acupuncture|
223732931|NCT03012425|BEHAVIORAL|questionnaires|
223732932|NCT03012425|OTHER|Diurnal Cortisol|saliva test
223400389|NCT03161353|DRUG|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
223400390|NCT03161353|DRUG|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
223400391|NCT03161353|DRUG|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
223400392|NCT03161353|DRUG|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
223552182|NCT02968498|DIETARY_SUPPLEMENT|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
223552183|NCT03196596|OTHER|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
223552184|NCT02514291|BEHAVIORAL|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
223552185|NCT05533944|OTHER|Simulation training in Boškoski-Costamagna ERCP Trainer|Coached simulation training in Boškoski-Costamagna ERCP Trainer, by participating in three intensive courses during the first three months of training, with a monthly basis
223552186|NCT00180557|DEVICE|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
223552187|NCT01501890|DRUG|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
223552188|NCT01501890|DRUG|Placebo|0.9% NaCl
223552189|NCT04717271|OTHER|Movement Guidance Group|"Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
223732933|NCT00042172|DRUG|Donepezil|
223732934|NCT00042172|DRUG|Ginkgo Biloba Extract|
223732935|NCT03153254|DEVICE|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
223732936|NCT03153254|DEVICE|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
223732937|NCT06405061|DRUG|Adebrelimab|Adebrelimab: 1200 mg, IV, q3w
223732938|NCT00770289|OTHER|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
223732939|NCT01858090|DRUG|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
223732940|NCT01858090|DRUG|Group Fentanyl|
223732941|NCT01858090|DRUG|Group sufentanil|
223732942|NCT01858090|DRUG|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to \<100 mmHg, fluid loading and ephedrine (5 mg) were administered.
223732943|NCT01858090|DRUG|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
223732944|NCT01858090|DRUG|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
223732945|NCT01858090|DRUG|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
223732946|NCT01858090|DRUG|Diphenhydramine|for severe pruritus
223732947|NCT01858090|DRUG|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
223732948|NCT01858090|DRUG|Diclofenac sodium|as additional analgesic among cases in which VAS\>3(Postoperatively)
223732949|NCT05670990|OTHER|Equine assisted therapy|"A structured program that has been developed under several years at Humlamaden horse farm, for further information see under the description of the experimental group."
223732950|NCT02659631|DRUG|PF-06671008|Dose Escalation Phase - Part 1
223732951|NCT02659631|DRUG|PF-06671008|Dose Expansion Phase - Part 2
224020862|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle|"The Mercury™ MPD applies negative pressure to one of the two goggles inducing an IOP reduction of 10 mmHg. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
224020863|NCT04433702|DEVICE|Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle|"The Mercury™ MPD applies no negative pressure to one of the two goggles eliciting no IOP reduction. This is randomized for each subject in the trial.~The Mercury™ MPD consists of:~1. Goggles: seal against the bony orbit with straps around head. The goggles separately enclose each eye, with each eye individually connected to a pressure-modulating pump.~2. Programmable pump: applies negative pressure inside the goggles via clear tubing attached to a handheld device"
224020864|NCT02892084|DEVICE|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
224020865|NCT02892084|DEVICE|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
223732952|NCT02377466|DRUG|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
223732953|NCT02377466|DRUG|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
223732954|NCT00495170|DRUG|Carboplatin|2 area under curve (AUC) by vein Weekly
223732955|NCT00495170|RADIATION|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
223732956|NCT00495170|DRUG|Paclitaxel|50 mg/m\^2 by vein Weekly
223732957|NCT00103181|RADIATION|3-dimensional conformal accelerated partial breast irradiation|
224297053|NCT06431165|DRUG|Lidocaine IV|After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
223732958|NCT00103181|RADIATION|brachytherapy|
223732959|NCT00103181|RADIATION|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
223732960|NCT00103181|RADIATION|MammoSite or other single-entry intracavitary device|
223732961|NCT04210310|DRUG|Oxytocin|The investigational product, oxytocin nasal spray (45 units/0.1mL for 38mL) is composed of: oxytocin powder (0.3080g), magnesium chloride crystals (2.3100g), citric acid anhydrous gran. (0.1080g), sodium citrate powder (2.1500g), sterile water for irrigation (38.000mL), and Pcca Mucolox liquid base (3.8000mL). Subjects will be asked to self-administer the study medication with 1 puff in one nostril 4 times per day
223732962|NCT04210310|OTHER|Placebo nasal spray|A placebo nasal spray, consisting of magnesium, chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both active drug and the placebo will appear identical in the glass bottles. The placebo will be administered in the same manner as the active study drug, with 1 puff in one nostril four times per day.
223732963|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 65 mg|"Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
223732964|NCT04465851|DIETARY_SUPPLEMENT|Curcumin|"HydroCurc™ 500 mg formulated curcumin~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
224297054|NCT04493320|DRUG|Carbidopa/levodopa|150-450mg carbidopa/levodopa 3 times daily
224297055|NCT04493320|DRUG|Placebo|Carbidopa/levodopa-matched placebo tablet 3 times daily
224297056|NCT05746065|DRUG|PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.
223400393|NCT03161353|DRUG|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
223732965|NCT04465851|OTHER|Placebo (Ferrous Sulphate)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
223732966|NCT04465851|OTHER|Placebo (Curcumin)|"Microcrystalline cellulose~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)"
223732967|NCT04465851|DIETARY_SUPPLEMENT|Ferrous Sulphate 18mg|"Oral ferrous salt supplement~Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content)~Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)~At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules"
223732968|NCT03894579|BIOLOGICAL|Study Product: SNK01|SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
223732969|NCT05845684|OTHER|Physiotherapy application|massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.
223732970|NCT05845684|OTHER|Control Group|standard daily applications will be performed on patients
223732971|NCT00063973|DRUG|cilengitide|Given IV
223732972|NCT00063973|OTHER|laboratory biomarker analysis|Correlative studies
224020866|NCT01300962|DRUG|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
223400394|NCT06694805|DRUG|CAB LA + RPV LA|Intramuscular injection administered monthly for first 2 initiation doses then every 2 months.
224020867|NCT01300962|DRUG|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
224020868|NCT01300962|DRUG|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
224020869|NCT01300962|DRUG|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
224020870|NCT01300962|DRUG|Lapatinib|lapatinib daily for 21 days in each cycle.
224020871|NCT01324596|DRUG|Intravenous|Chemoimmunotheraphy
223400395|NCT06694805|DRUG|Oral ART|Oral medication provided to participants by the site/their regular healthcare professional (HCP) as part of their standard of care (SOC) treatment.
223400396|NCT06719440|RADIATION|Radiotherapy (CTV=10mm)|Radiotherapy with reduced irradiation volume CTV=10mm
223400397|NCT06719440|RADIATION|Radiotherapy (CTV=15mm)|Radiotherapy with standard irradiation volume CTV=15mm
223400398|NCT07048288|OTHER|Multi-angle isometrics|Multi angle exercises include cervical flexion training, Cervical extension training, and Cervical lateral flexion training
223400399|NCT07048288|OTHER|Kinesio taping|Kinesio taping is a therapeutic technique used in rehabilitation to support muscles and joints without restricting movement.
223400400|NCT07048288|OTHER|Dynamic exercise|The dynamic exercise program included dynamic cervical flexion, dynamic cervical extension, and dynamic lateral flexion.
223400401|NCT07048288|OTHER|Conventional Physiotherapy|Conventional physiotherapy included transcutaneous electrical nerve stimulation
223400402|NCT04636788|PROCEDURE|Venous sampling|venous sampling of 12ml
224020872|NCT01324596|DRUG|Bortezomib|Chemoimmunotheraphy
223732973|NCT06193369|BEHAVIORAL|Digital Peer Navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for cancer. Participants will be matched through a digital app with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Patients will communicate with their peer navigator through digital direct messaging, videoconference or by telephone. Participants will also have access to a health resource library on the digital app that contains local and national resources about cancer.
223732974|NCT06504758|OTHER|Breathing Retraining Program|"* 1st to 5th week - Breathing Retraining 10 repetitions (Pursed Lip Breathing, Diaphragmatic Breathing)~* Two days / a week The total duration of 5 weeks."
223732975|NCT06504758|OTHER|Postural Exerises Program (Stretching and Strengthening Exercises)|"* TheraBand® or Free Weight~* 1st week - neck isometrics, chin tuck, SCM - upper trapezius - pectoral major stretching, scapular retraction without weight, rowing with yellow TheraBand®, wall squat / mini squat (5 repetitions - 15 second hold for stretching exercises, 10 repetitions for strengthening exercises)~* 2nd and 3rd week - same exercises (5 repetitions - 15 second hold for stretching exercises, 15 repetitions for strengthening exercises)~* 4th and 5th week - same exercises (10 repetitions - 15 second hold for stretching exercises, 20 repetitions for strengthening exercises)~* Two days / a week,The total duration of 5 weeks"
224020873|NCT01771640|BIOLOGICAL|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
224131264|NCT06093282|BEHAVIORAL|ARCH|"ARCH is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* A 12-session adaptation of Behavioral Activation Treatment for Depression~* Weekly contacts from an outreach worker~* Optional resources aimed at promoting physical activity and weight management"
224131265|NCT06093282|BEHAVIORAL|Traditional Health Outreach|"The Traditional Health Outreach comparator is a 4-month health outreach intervention that includes the following components:~* Screening and referral to address social determinants of health~* Support calls from an outreach worker at least once every 3 weeks"
224297057|NCT05676086|BEHAVIORAL|indoor light intervention|"Persons allocated to the indoor light intervention arm will be given a lamp to be placed at home with specific instructions to install it in a room where they spend most of their time, in order to supplement the existing indoor lighting. Thus, all people of the intervention arm will be equipped with the LUMIE Halo lamp. Utilizing both warm-white and cool-white LEDs, Lumie Halo delivers 10,000 lux at 20 cm at maximum brightness in Day Mode. The touch slider allows the user to adjust the brightness while mixing the color temperature of the light."
224297058|NCT05676086|BEHAVIORAL|no indoor light|Persons allocated to the control group will receive no indoor light supplementation and will undergo assessment procedures only. Exposure to the outdoor intervention will be taken into account in the analysis in three ways, (1) by locating the distance between people's home and the modified outdoor light, (2) by a question about the awareness of the change in outdoor light, timing, and duration of exposure and what they think of it, and (3) by recording the amount of light exposure over the 24 hours during two weeks at baseline and after the 1-year light interventions
224297059|NCT02745886|DRUG|metformin 0.85 twice daily for 6 months|
224297060|NCT02745886|BEHAVIORAL|Calorie restriction|
223400403|NCT07044479|DRUG|Enlicitide|Single dose of enlicitide is administered orally on day 1 of each testing period
223400404|NCT05756595|DRUG|HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)|This group will inject once a week. Evaluation of pain score after 30 seconds and 3 hours.
223400405|NCT06741683|BIOLOGICAL|TDV|TDV SC injection.
223400406|NCT06741683|OTHER|Placebo|Placebo SC injection.
223400407|NCT07053800|BIOLOGICAL|Obecabtagene autoleucel|Obecabtagene autoleucel (obe-cel) given as a single infusion
223400408|NCT06896578|PROCEDURE|Lateral lymph node dissection|Removal of lateral lymph nodes in the obturator and internal iliac compartment including fatty tissue, but excluding vascular and nervous tissue
223400409|NCT02225431|DRUG|sodium chloride infusion|
224297061|NCT03205930|BIOLOGICAL|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
224297062|NCT02453906|OTHER|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
224297063|NCT02453906|OTHER|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
224131266|NCT06381349|DIAGNOSTIC_TEST|Gastric Alimetry test|Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
224131267|NCT04183179|BEHAVIORAL|Happy Family, Healthy Kids Program|"The 14-week healthy eating program activities including four components:~1. A 14-week parent Facebook-based program focusing on stress management and healthy eating to reduce emotional eating and increase parents' capacity to initiate healthy eating practices at home~2. Three parent face-to-face or virtual meetings at Head Start centers to connect parents with each other in person, offer healthy cooking tools/classes, and discuss behavioral change strategies and challenges~3. 14-week child Eat My ABCs program at Head Start centers to provide an age-appropriate, healthy eating program to children~4. Weekly child letter to parents to connect child learning at the Head Start center with parental practices at home"
224131268|NCT03575884|BEHAVIORAL|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
224131269|NCT06097650|OTHER|cold snare polypectomy|Histological analyses suggest that cold snare polypectomy causes less damage to blood vessels in the submucosal layers, which results in a reduced incidence of hemorrhage
223400410|NCT06793800|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|TAVSS is an application system that uses an electrical transcutaneous stimulation device placed on the concha or tragus of the ear. Functional Magnetic Resonance Imaging studies have shown that stimulation of these areas activates the ipsilateral nucleus tractus solitarius (NTS) via vagal projections to the brainstem and forebrain. Unlike cervical vagus nerve stimulation, TAVSS utilizes a physiological pathway to activate the NTS and the dorsal motor nucleus, which subsequently sends impulses bilaterally to the heart surface via efferent cervical vagus nerves. Therefore, this technique eliminates the possibility of directly and asymmetrically stimulating cardiac motor efferent fibers, which could lead to adverse cardiac events. TAVSS combines advantageous qualities such as being non-invasive, cost-effective, convenient, and efficient.
223400411|NCT05063552|BIOLOGICAL|Atezolizumab|Given IV
223400412|NCT05063552|BIOLOGICAL|Bevacizumab|Given IV
223400413|NCT05063552|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400414|NCT05063552|DRUG|Carboplatin|Given IV
223400415|NCT05063552|BIOLOGICAL|Cetuximab|Given IV
223400416|NCT05063552|DRUG|Cisplatin|Given IV
223400417|NCT05063552|PROCEDURE|Computed Tomography|Undergo CT scan
223400418|NCT05063552|DRUG|Docetaxel|Given IV
223400419|NCT05063552|PROCEDURE|Echocardiography Test|Undergo ECHO
223400420|NCT05063552|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223400421|NCT05063552|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223400422|NCT03640494|DEVICE|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
223400423|NCT01422980|OTHER|1- Test dairy product containing specific ingredients|
223400424|NCT01422980|OTHER|2- Control dairy product without specific ingredients|
223400425|NCT05142280|OTHER|Decision-aid for cardiovascular disease risk|The active choice intervention aims to promote an active choice regarding coping with an increased risk of cardiovascular disease. This means that individuals should (a) become aware of a discrepancy between the current and desired situation; (b) understand what the CVD risk means, and what its causes and consequences are; (c) evaluate the pros and cons of the different options to cope with the risk; and (d) are clear about their values regarding the choice.
223400426|NCT05142280|OTHER|Control|The control condition contains information that resembles usual care by a GP regarding CVD prevention
223400427|NCT01223391|OTHER|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
223400428|NCT01223391|OTHER|No abdominal binder|Standing without abdominal binder for 3 minutes
223400429|NCT00656552|DRUG|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
223400430|NCT05928312|DRUG|Fruquintinib Combined With Chemotherapy|"1.Security introduction period:~\[1\] Safety introduction period (N=6), fruquintinib combined with three-week regimen:~1\. Fruquintinib: Three-week regimen of combined chemotherapy: 4mg/d, orally, once a day, taking the drug for 2 weeks and stopping the drug for 1 week, 3 weeks as a treatment cycle.~\[2\] Safety introduction period (N=6), fruquintinib combined 2-week regimen:~1. Fruquintinib: two-week combination chemotherapy regimen: 4mg/d, orally, once a day, taking the drug for 3 weeks and stopping the drug for 1 week, 4 weeks as a treatment cycle.~2. Dose expansion phase design(N=60) Cohort 1 (30 patients) : Fruquintinib combined with oxaliplatin. Cohort 2 (30 patients) : Fruquintinib combined with irinotecan ."
223552190|NCT04717271|OTHER|No Movement Guidance Group|"Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames."
224297064|NCT02453906|OTHER|Control 2|stimulation at 5 control points
223400431|NCT00003627|DRUG|cisplatin|
223400432|NCT00003627|DRUG|fluorouracil|
223400433|NCT00003627|RADIATION|radiation therapy|
223732976|NCT01450839|DRUG|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
223732977|NCT01450839|DRUG|Placebo|Matching Placebo tablets and tape
223552191|NCT04855240|DRUG|ACP-044 Dose A|Oral dose of ACP-044 Dose A
223552192|NCT04855240|DRUG|ACP-044 Dose B|Oral dose of ACP-044 Dose B
223552193|NCT04855240|DRUG|Placebo|Oral dose of placebo
223552194|NCT01222819|DRUG|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
224297065|NCT02453906|OTHER|Control 3|no stimulation at 5 control points
224297066|NCT00004218|DRUG|chlorambucil|
224297067|NCT00004218|DRUG|cyclophosphamide|
223400434|NCT04071834|DIAGNOSTIC_TEST|ELISA|Detection of blood orphanin and norepinephrine in patients
223400435|NCT06157008|DRUG|General Anesthetics|General anesthetics used in spinal cord electrical stimulator insertion surgery
223400436|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
224297068|NCT00004218|DRUG|doxorubicin hydrochloride|
224297069|NCT00004218|DRUG|fludarabine phosphate|
223400437|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions BID over 14 days
223400438|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
223400439|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
224297070|NCT00004218|DRUG|prednisolone|
224297071|NCT00004218|DRUG|vincristine sulfate|
223400440|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every QD over 14 days
223400441|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
223400442|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
223400443|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
223400444|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
223400445|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
223400446|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
223400447|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
223400448|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
223400449|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
223400450|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
223400451|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
223732978|NCT00697203|DRUG|Placebo|po daily for 12 weeks
223732979|NCT00697203|DRUG|Pravastatin|40mg po daily for 12 weeks
223732980|NCT00697203|DRUG|Dalcetrapib|300mg po daily for 12 weeks
224297072|NCT04642937|DRUG|Treatment with hP1A8|Treatment with hP1A8
223400452|NCT05807490|DRUG|PF-07328948|Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
223400453|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions QD over 14 days
223400454|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions QD over 14 days
223552195|NCT00705770|DRUG|Anecortave Acetate|"Low dose~Sustained release depot suspension"
223552196|NCT00705770|DRUG|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
223400455|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
223400456|NCT05807490|DRUG|Placebo|Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
223400457|NCT05807490|DRUG|PF-07328948|PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
223400458|NCT00204490|DIETARY_SUPPLEMENT|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
223400459|NCT00204490|DIETARY_SUPPLEMENT|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
223400460|NCT06551493|OTHER|Observation of postnatal wound assessment|Observation of postnatal wound assessment
223400461|NCT06551493|OTHER|Interview|Interview to elicit individual perspectives of wound assessment
223400462|NCT02901938|PROCEDURE|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
223552197|NCT00705770|DRUG|Anecortave Acetate|"High dose~Sustained release depot suspension"
223552198|NCT00705770|DRUG|Placebo|Placebo treatment with vehicle
223552199|NCT02827760|DIETARY_SUPPLEMENT|Synergy1|Inulin type fructans
223552200|NCT02827760|DIETARY_SUPPLEMENT|Maltodextrin|
223552201|NCT02385903|OTHER|Flammacerium|
223552202|NCT02385903|OTHER|Standard dressing procedure|
223552203|NCT03672851|DRUG|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
223552204|NCT01580709|PROCEDURE|Multiple brushings|Seven consecutive brush samples for cytology.
223552205|NCT01580709|PROCEDURE|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
223552206|NCT03902392|DIETARY_SUPPLEMENT|NaturOx Group (A)|Comparison between dietary supplement and placebo
223552207|NCT03902392|OTHER|Placebo Group (B)|Comparison between dietary supplement and placebo
223552208|NCT03450239|OTHER|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
223552209|NCT03700840|DEVICE|Interdental brushes|interdental brush at 4 sites and PCR analysis
223552210|NCT02808325|DRUG|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
223552211|NCT02808325|DRUG|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
223552212|NCT02110186|DEVICE|Dynamic Stabilization|
223552213|NCT02110186|PROCEDURE|Discectomy|
223552214|NCT02110186|DEVICE|Instrumentation and fusion|
223552215|NCT04014894|DRUG|ET019003-T Cells|Fludarabine 25 mg/day on day -5, -4 and -3; Cyclophosphamide 250 or 300 mg/day on day -5, -4 and -3; ET019003-T Cells on day 0.
223552216|NCT04550780|DRUG|Mepolizumab|The first administration of mepolizumab.
223552217|NCT00263432|PROCEDURE|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
223732981|NCT00697203|DRUG|Dalcetrapib|600mg po daily for 12 weeks
223732982|NCT00697203|DRUG|Dalcetrapib|900mg po daily for 12 weeks
223732983|NCT03438812|DIETARY_SUPPLEMENT|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
223732984|NCT00164190|PROCEDURE|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
223732985|NCT05544240|DRUG|SV-101|SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
224297073|NCT02158611|OTHER|Lifestyle counseling|
223400463|NCT02901938|DEVICE|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
223732986|NCT03447132|DRUG|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
223732987|NCT03447132|DRUG|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
223732988|NCT03447132|DRUG|Goserelin 3.6 MG|Only for pre or peri menopausal patient
223732989|NCT03447132|DRUG|Placebos|Placebo
223732990|NCT01765205|DEVICE|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
224020874|NCT01522469|DRUG|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
224020875|NCT04831073|PROCEDURE|Surgery on the ascending aorta with or without repair of the aortic root and/or aortic arch|Surgical repair of the ascending aorta with or without surgical repair of the aortic root and/or aortic arch
224020876|NCT05860634|PROCEDURE|Catheter self-discontinuation|Self-discontinuation of a transurethral catheter
223732991|NCT00363922|BEHAVIORAL|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
223732992|NCT00363922|BEHAVIORAL|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
223732993|NCT00363922|BEHAVIORAL|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
223732994|NCT02604108|BEHAVIORAL|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
223732995|NCT02604108|BEHAVIORAL|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
223732996|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
223732997|NCT03706781|DRUG|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
223732998|NCT02398851|BEHAVIORAL|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
224020877|NCT03432260|DRUG|DUR-928 30 mg|Lowest dose of 3 dose escalation arms.
224020878|NCT03432260|DRUG|DUR-928 90 mg|Middle dose of 3 dose escalation arms.
224020879|NCT03432260|DRUG|DUR-928 150 mg|Highest dose of 3 dose escalation arms.
223400464|NCT01497028|PROCEDURE|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
223400465|NCT04214977|PROCEDURE|Spinal Anesthesia for Anorectal Surgeries in Prone Position|Spinal anesthesia in sitting position was done under complete aseptic technique through a standard midline approach. One and a half millilitres of 0.5% bupivacaine (7.5 mg) was injected through a 25 Gauge pencil-point needle into the subarachnoid space at L3-L4 or L4-L5 interspace. All patients were kept in a head-up position for 3 minutes. The patient was then asked to turn him- or herself into the prone position on the surgical table with the help of the surgical and anesthetic teams.
223400466|NCT04214977|PROCEDURE|General Anesthesia Using Laryngeal Mask Airway for Anorectal Surgeries in Prone Position|General anesthesia was induced using fentanyl 2 mcg/kg and Propofol 2-3 mg/kg. Any stomach contents were then suctioned through an oro-gastric tube to reduce the risk of regurgitation. Proper (weight-based) classic laryngeal mask airway was then blindly inserted. laryngeal mask airway was then properly fixed to the face and anesthesia was maintained with isoflurane 1-2% in 50% Oxygen/air mixture.
223400467|NCT01582776|DRUG|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
223400468|NCT00238966|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223732999|NCT02398851|BEHAVIORAL|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
224020880|NCT04763421|DEVICE|ENSEAL X1 Curved Jaw|ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
224020881|NCT05677997|BEHAVIORAL|Intervention|Sessions to go through goals, problem areas, areas they want to improve.
224020882|NCT05910944|PROCEDURE|Shunt surgery|Shunt surgery according to each local centers routine
223400469|NCT06325826|DIAGNOSTIC_TEST|General Evaluation Score (GES)|According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points)
223400470|NCT02257710|DEVICE|Orsiro|
223400471|NCT02397512|DRUG|application of lactulose|Subjects will ingest 50g of lactulose once
223400472|NCT02397512|OTHER|application of sucrose|Subjects will ingest 50g of sucrose once
223733000|NCT05911776|DRUG|Nasal packing Dexmedetomidine|patients will receive nasal packing Dexmedetomidine (1.5 μg/kg intranasal dexmedetomidine diluted with saline) and Intravenous infusion saline.
223400473|NCT05460338|DRUG|Cholecalciferol|native form of Vitamin D.
223733001|NCT05911776|DRUG|Intravenous Dexmedetomidine|patients will receive 0.5 μg/kg bolus over 10 min then 0.1- 0.4 μg/kg Intravenous infusion Dexmedetomidine and nasal packing with saline.
223733002|NCT00132587|DEVICE|cement Palacos R40 and LV40|
223733003|NCT02703389|BEHAVIORAL|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
223733004|NCT02703389|BEHAVIORAL|Pamphlet|Contains same information as video.
223733005|NCT01031732|PROCEDURE|MIS-2 THA|MIS two-incision THA
223400474|NCT05952102|DRUG|Nigella Sativa Oil capsule|Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
223400475|NCT00146302|BIOLOGICAL|Bacille Calmette Guerin (BCG)|
223400476|NCT00480337|PROCEDURE|In Vitro Maturation of immature oocytes|
223552218|NCT01321853|OTHER|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
223552219|NCT01321853|OTHER|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
223400477|NCT04073537|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
223733006|NCT01031732|PROCEDURE|MIS-WJ|MIS-Watson Jones THA
223733007|NCT01031732|PROCEDURE|MIS-AL THA|Transgluteal approach
223733008|NCT01031732|PROCEDURE|MIS-PL THA|Posterolateral approach
223733009|NCT00187811|PROCEDURE|Delta amino leavulinic acid photodynamic therapy|
223733010|NCT00446290|DRUG|Docetaxel, Capecitabine and Oxaliplatin|
223400478|NCT04073537|DRUG|Placebos|Anlotinib blank analog capsule.
223400479|NCT04073537|DRUG|Paclitaxel|Paclitaxel 175 mg/m\^2 IV on Day 1 of each 21-day cycle.
223400480|NCT04073537|DRUG|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
223400481|NCT02166333|DIETARY_SUPPLEMENT|200 IU/d cholecalciferol|
223400482|NCT02166333|DIETARY_SUPPLEMENT|1000 IU/d cholecalciferol|
223400483|NCT02166333|DIETARY_SUPPLEMENT|2000 IU/d cholecalciferol|
223552220|NCT01537471|DRUG|Placebo|Placebo
223552221|NCT01537471|DRUG|Meclizine|Meclizine 12.5 mg
223552222|NCT01537471|DRUG|Meclizine|Meclizine 25 mg
223552223|NCT00244725|DRUG|Odiparcil|
223552224|NCT00244725|DRUG|Warfarin|
223552225|NCT00244725|DRUG|Coumadin|
223552226|NCT03409952|DEVICE|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
223552227|NCT03409952|DEVICE|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
223552228|NCT04358146|OTHER|Experimental Infant formula|Exclusive formula feeding with the new infant formula thickened with fibers
223400484|NCT02166333|DIETARY_SUPPLEMENT|4000 IU/d cholecalciferol|
223400485|NCT01853215|DEVICE|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
223400486|NCT00495573|DRUG|acyclovir|400 mg acyclovir, orally three times a day for 5 days
223400487|NCT02604095|DIETARY_SUPPLEMENT|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
223400488|NCT03551990|PROCEDURE|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
223552229|NCT04358146|OTHER|Infant formula thickened with locust bean gum|Exclusive formula feeding with the formula thickened with locust bean
223552230|NCT01737983|DIETARY_SUPPLEMENT|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10\^10 colony-forming units) for 6 months.
223733011|NCT04006197|OTHER|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
223733012|NCT00670865|OTHER|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
224020883|NCT04062968|OTHER|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
223400489|NCT00682786|DRUG|5FU|
223400490|NCT00682786|RADIATION|Radiation|
223400491|NCT00682786|PROCEDURE|Surgery of resectable lesions|
223400492|NCT00682786|DRUG|Irinotecan|
223400493|NCT02252835|DRUG|Arhalofenate|800 mg once daily orally for four weeks
223400494|NCT02252835|DRUG|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
223400495|NCT02252835|DRUG|Arhalofenate|600 mg once daily orally for four weeks
223400496|NCT02252835|DRUG|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
223400497|NCT02252835|DRUG|Colchicine|0.6 mg daily
223400498|NCT00839488|DRUG|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
223400499|NCT00839488|DRUG|famotidine 20 mg iv|famotidine 20 mg q12h
223400500|NCT05782933|DRUG|Rituximab|Rituximab combined with or without cyclosporine
223400501|NCT05782933|DRUG|Modified Ponticelli regimen|Corticosteroid and cyclophosphamide
223400502|NCT02673177|PROCEDURE|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
223400503|NCT02673177|PROCEDURE|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
223552231|NCT01737983|DIETARY_SUPPLEMENT|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
224020884|NCT01775124|DRUG|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
224020885|NCT06116864|DEVICE|Endocuff and GI Genius|Endocuff is a polyp-detecting colonoscope attachment device. GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
224020886|NCT06116864|DEVICE|GI Genius|GI Genius is and Computer-Aid Detection (CADe) system to detect polyps
224020887|NCT05267340|BEHAVIORAL|TARA|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA)
224020888|NCT05267340|BEHAVIORAL|Psycho-Education|This will be a 12-week group meditation training - Training for Awareness, Resilience, and Action (TARA) without the mindfulness meditation components
224020889|NCT05256446|DRUG|AMG 701|
224020890|NCT02359682|OTHER|No intervention|No Intervention
224020891|NCT01277367|BEHAVIORAL|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
223400504|NCT01294774|DRUG|KRP203 - 1.2mg|
223400505|NCT01294774|DRUG|Placebo to KRP203 - 1.2 mg|
223400506|NCT03099031|DRUG|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
223400507|NCT05359744|DIAGNOSTIC_TEST|Performance testing|Performance testing on a bicycle ergometer.
223400508|NCT02380586|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
223400509|NCT00359424|DRUG|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
223400510|NCT00359424|OTHER|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
223400511|NCT01210534|OTHER|No intervention|No intervention
223552232|NCT00348959|BEHAVIORAL|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
223400512|NCT01461837|DRUG|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
223400513|NCT05479786|OTHER|Expectant management|Follow-up with beta-HCG dosages and transvaginal ultrasound scans
223552233|NCT02655952|DRUG|Foxy-5|
223552234|NCT05079802|DRUG|Double antibiotic paste mixed with chitosan nanoparticles|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with chitosan nanoparticles gel
223552235|NCT05079802|DRUG|Double antibiotic paste mixed with propylene glycol|Lesion sterilization and tissue repair in non-vital primary molars with double antibiotic paste mixed with propylene glycol
223552236|NCT05710731|OTHER|Use of simulation in urinary catheterization training|To train students on urinary catheterization by using one of 3 different simulation methods.
223552237|NCT05473455|PROCEDURE|Experimental: Follicular aspiration with addition of follicular flushing.|Follicular flushing if necessary up to 5 times using a double lumen needle for oocyte recovery
223552238|NCT06519240|RADIATION|18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography (18F-FDG PET CT)|Each participant will prepare for their study PET CT by following an initial 18 hour of zero carbohydrate diet followed by another 18 hours of fasting (water allowed). After confirming preparation, each study participant will have a single rest rubidium and 18F-FDG PET CT scan.
223552239|NCT05145751|OTHER|Simple inflammatory biomarkers measurement|In patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection the values of simple inflammatory biomarkers such NLR will be measured
223552240|NCT03248167|DRUG|Cannabidiol|600 mg daily
224020892|NCT01277367|BEHAVIORAL|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
223733013|NCT04152603|BEHAVIORAL|BRIEF Educational Module|The BRIEF Educational Module for research recruitment team members is intended to teach evidence-based approaches to improving participant experiences with research recruitment. It has three components: (1) asynchronous pre-work, including multimedia materials and an individual worksheet (approx. 30 min); (2) one synchronous in-person (or virtual if necessary) session, including didactics, discussions, and practice scenarios (approx. 90 min); and (3) an asynchronous, individual follow-up phone call to review individual questions (approx. 15 min).
223733014|NCT03181854|BEHAVIORAL|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
223733015|NCT03181854|BEHAVIORAL|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
223733016|NCT05284149|DIETARY_SUPPLEMENT|Hirsutella Sinensis Nutrient Supplements|"This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement."
223733017|NCT05284149|DIETARY_SUPPLEMENT|Placebo|"We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo."
223733018|NCT00007657|PROCEDURE|Intensive medical therapy|
223733019|NCT00007657|PROCEDURE|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
223733020|NCT02049957|DRUG|Sapanisertib|Sapnisertib capsules
224020893|NCT01277367|BEHAVIORAL|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
223733021|NCT02049957|DRUG|Fulvestrant|Fulvestrant IM injection.
224131270|NCT06097650|OTHER|hot snare polypectomy|According to current clinical guidelines, hot snare polypectomy is the recommended standard technique for the resection of pedunculated colorectal polyps.
223400514|NCT05479786|PROCEDURE|Salpingectomy|Removal of the affected Fallopian tube by laparoscopy
223400515|NCT05479786|PROCEDURE|Salpingostomy|Removal of the ectopic pregnancy from the Fallopian tube, without removing the whole Fallopian tube, by laparoscopy
223733022|NCT02049957|DRUG|Exemestane|Exemestane tablets.
223733023|NCT01180491|DEVICE|K101 nail solution|
223733024|NCT04358380|OTHER|Liver injury|LFTs elevation or liver decompensation
223733025|NCT04939402|DIAGNOSTIC_TEST|Serological testing|Antibody testing for Sars-CoV-2 specific antibodies in blood + T cell immunity
223733026|NCT04940351|PROCEDURE|GROUP - A: PIEZOCISION GROUP|This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
224020894|NCT01277367|BEHAVIORAL|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
224020895|NCT01277367|BEHAVIORAL|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
224131271|NCT05935215|DRUG|Iptacopan|Open Label
224131272|NCT06368622|DEVICE|Surpass Evolve Flow Diverter System|Endovascular treatment with Surpass Evolve Flow Diverter System was performed in patients diagnosed with intracranial aneurysms
224131273|NCT05613049|OTHER||If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
224131274|NCT05585645|BIOLOGICAL|Stimus (NNG-DEPO)|Nanogen's Darbepoetin alfa 10µg/0.4mL, 20µg/0.5mL, 40µg/0.4mL, 60µg/0.3mL, prefilled syringe
224131275|NCT06376916|DRUG|Magnesium Sulfate 2 G|Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
223400516|NCT01831635|OTHER|Methodological pens|Randomisation of branded pen, non-branded pen and no pen
223400517|NCT01831635|OTHER|Methodological compensation|Randomisation of a £10 monetary reimbursement for expenses on completion of the study
223400518|NCT01831635|OTHER|Methodological trolley tokens|Trolley tokens to be randomly assigned to half of cases and General Practice controls.
223400519|NCT02716714|DRUG|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
223400520|NCT02716714|DRUG|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
223400521|NCT05790395|OTHER|Theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention|The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.
223400522|NCT05790395|OTHER|health-risk behaviors|The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. The participants will also receive follow-up for outcome assessments with the same schedule as those in the intervention group.
223400523|NCT06065163|OTHER|Diuretic de/escalation based on ultrasound findings (VExUS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)
223400524|NCT06065163|OTHER|Diuretic de/escalation based on clinical findings (CCS Score)|Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)
223400525|NCT00240708|DRUG|risperidone|
223733027|NCT04940351|PROCEDURE|GROUP- B: MICRO-OSTEOPERFORATION GROUP|This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
223733028|NCT02645110|DEVICE|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
223733029|NCT02645110|DEVICE|Tap water|Washing hand with water alone in comparison to hand washing with soap
223400526|NCT01163838|BIOLOGICAL|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223400527|NCT01163838|BIOLOGICAL|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223733030|NCT00503802|PROCEDURE|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
223733031|NCT00503802|PROCEDURE|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
223733032|NCT01877499|OTHER|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~1. Treatment time (up to 4 hours per session);~2. Blood flow rate (up to 400 mL/min;~3. Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
223733033|NCT05677724|DIAGNOSTIC_TEST|HBV DNA Sequencing|"Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed."
223733034|NCT05070299|BEHAVIORAL|Psychosexual Educational Partner Program (PEPP)|A communication and intimacy promotion kit consisting of three modules devoted to information sharing, partner communication and activities for building intimacy.
223733035|NCT01958008|DRUG|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
223733036|NCT01958008|DRUG|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
223733037|NCT01958008|DRUG|BI 113608 high dose b.i.d.|Film-coated tablet
223733038|NCT01958008|DRUG|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
223733039|NCT01958008|DRUG|BI 113608 low dose b.i.d.|Film-coated tablet
223733040|NCT01958008|DRUG|BI 113608 medium dose b.i.d.|Film-coated tablet
223733041|NCT03552263|DRUG|T89 capsule|T89 capsules (75mg), orally, twice daily.
223733042|NCT03552263|DRUG|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
224020896|NCT01277367|BEHAVIORAL|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
223400528|NCT01163838|BIOLOGICAL|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223400529|NCT01163838|BIOLOGICAL|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223400530|NCT01163838|BIOLOGICAL|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223400531|NCT01163838|BIOLOGICAL|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223400532|NCT01163838|BIOLOGICAL|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
223733043|NCT01634360|DRUG|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
224020897|NCT04731519|BEHAVIORAL|Continuous Identity Cognitive Therapy (CI-CT)|CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The recovery oriented CI-CT for post acute suicidal episode Veterans includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
224131276|NCT06376916|DRUG|Magnesium Sulfate 4 G|Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
224131277|NCT06376916|DRUG|Saline|The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
223733044|NCT06121687|PROCEDURE|Shaeer-I|Ligation of the internal pudendal vein under the Gluteus Maximus muscle as it courses above the scar-spinous ligament.
223733045|NCT06121687|PROCEDURE|PPI|Penile prosthesis implantation (PPI) will be performed
223733046|NCT02385552|BEHAVIORAL|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
223733047|NCT02028065|DRUG|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
223733048|NCT02028065|DRUG|Placebo|Placebo administered as a single IV bolus over 10 seconds
224131278|NCT05967468|BEHAVIORAL|Family Based, Internet-Based Cognitive Behavioral Therapy|Family-based cognitive behavioral therapy employing internet-delivered modules and videos
223400533|NCT05969184|DRUG|CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)|CDK4/6 inhibitor (Qilu) have got the cFDA approval and Trastuzumab (Hanquyou) have few data on combination use, this two drugs need clinical treatment data
223400534|NCT01801943|BEHAVIORAL|Cognitive Remediation Therapy Group|30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
223733049|NCT03498300|BIOLOGICAL|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
223733050|NCT02563353|OTHER|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
223733051|NCT02563353|DRUG|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
223733052|NCT01414855|DRUG|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
223733053|NCT01414855|DRUG|cyclophosphamide|750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
224131279|NCT05967468|BEHAVIORAL|Bibliotherapy, low therapist contact SPACE|Parent-based bibliotherapy for treating anxiety disorders in youth
224131280|NCT05967468|OTHER|Relaxation and Mentorship|Relaxation based treatment
223400535|NCT01801943|BEHAVIORAL|Walking Intervention (WI) Group|60 min Walking Intervention + 30 min low interface reading 3x week
223400536|NCT01801943|BEHAVIORAL|Combination Group|30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
223400537|NCT01801943|BEHAVIORAL|Healthy Living Group|60 Min Healthy Living class + 30 min low interface reading 3x week
223400538|NCT03059017|DRUG|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
223400539|NCT03059017|DRUG|Niosomes|Niosomes
223400540|NCT00310999|DEVICE|Shikani Optical Stylet|
223400541|NCT03690700|OTHER|BFRE|BFR will be performed in the aBFRE group by use of pneumatic occlusion cuffs placed proximally on the thigh close to the inguinal fold, using an occlusion pressure corresponding to 40 % of seated arterial occlusion pressure (AOP). The individual AOP will be documented at baseline using doppler ultrasound (Siemens ACUSON S2000TM). Previous studies have shown that this pressure level can promote significant muscle adaptations to a similar degree and are associated with significantly less discomfort than higher occlusion pressures. The occlusion pressure of the participants in sham BFRE group will be 10mmHg.
223400542|NCT03830333|DRUG|Ceftolozane/Tazobactam|Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive ceftolozane 500 mg / tazobactam 250 mg.
223400543|NCT03830333|DRUG|Metronidazole|Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
223400544|NCT03830333|DRUG|Meropenem|Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
223400545|NCT03830333|DRUG|Placebo|Saline by IV infusion every 8 hours for 4 to 14 days.
223733054|NCT01414855|DRUG|doxorubicin|50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.
223733055|NCT01414855|DRUG|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
223733056|NCT01414855|DRUG|vincristine|1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.
223733057|NCT01441505|DRUG|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
223733058|NCT01441505|DRUG|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
223733059|NCT00830596|OTHER|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
223733060|NCT00830596|OTHER|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
223733061|NCT00830596|OTHER|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
223733062|NCT05877781|DIETARY_SUPPLEMENT|Palmitoylethanolamide|8-week treatment 3x400 mg per day
223733063|NCT03912116|OTHER|CLARIX FLO|100mg CLARIX FLO
223733064|NCT03912116|OTHER|Saline|Saline
223733065|NCT03236974|DRUG|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
223733066|NCT03236974|DRUG|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
223733067|NCT00877383|DRUG|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
223400546|NCT03077477|DRUG|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
223400547|NCT03077477|DRUG|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
223400548|NCT00131612|DRUG|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
223400549|NCT03805412|DEVICE|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
223400550|NCT00160823|PROCEDURE|Self-administered leaflet|
223400551|NCT04231617|DRUG|glibenclamide|Oral administration of glibenclamide or placebo. To investigate the role of CGRP on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
223400552|NCT04231617|DRUG|CGRP infusion|CGRP infusion
223400553|NCT04231617|DRUG|Placebo|placebo
223400554|NCT02816346|BIOLOGICAL|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
223400555|NCT01974518|DRUG|Rituximab and Cyclophosphamide IV|
223400556|NCT05454319|DEVICE|Biofeedback|Home-based biofeedback with medical device
223400557|NCT05488743|BEHAVIORAL|educational intervention|The program consists of five 50-minutes sessions conducted in person as scheduled during weekly class meetings. Educators will conduct workshops with PowerPoint presentations and worksheets dedicated to in-class activities.
223733068|NCT00877383|DRUG|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
224131281|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), active condition.|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the active condition, participants have to switch between immersion of the hand into cold water and complex mental arithmetic operations.
224131282|NCT05595434|PROCEDURE|Acute Maastricht Stress Test (MAST), placebo condition|The MAST is a standardized stress protocol combining a 5 min preparation phase and 10 min acute stress phase. The last phase is composed by an alternation of physical and psychosocial stressors. In the placebo condition, participants have to switch between immersion of the hand into tempered water and simple mental arithmetic counts.
224131283|NCT05872152|DIAGNOSTIC_TEST|FTIR results|Weekly transmission of FTIRS typing of ESBL-E to centers
224131284|NCT06470685|BEHAVIORAL|Qualitative Research Interviews|Research Interviews
223400558|NCT00824200|BEHAVIORAL|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.
223400559|NCT00824200|DRUG|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
224131285|NCT06060223|OTHER|Teach Back Method|"Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary."
223733069|NCT00877383|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
224297074|NCT01268605|PROCEDURE|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
223733070|NCT00905398|DRUG|Nilotinib|400mg, Oral, Bid, Daily for three years
223733071|NCT04851314|DEVICE|ICU certified ventilator|Examine anesthetic consumption rates
223733072|NCT04851314|DEVICE|Non-ICU certified ventilator|Examine anesthetic consumption rates
223400560|NCT00824200|DRUG|placebo|tamsulosin placebo
223400561|NCT00824200|BEHAVIORAL|placebo|placebo behavioral intervention
223425693|NCT02890485|OTHER|Physical Therapy|Physical Therapy and exercise as determined by the examining clinician based on the patients specific impairments and functional limitations. All subjects enrolled in this study will receive an initial physical therapy (PT) evaluation and then 2 additional PT sessions a week a part. Interventions and prescribed home exercises will be specific to the patients' primary individual impairments as determined during the initial PT evaluation. These interventions reflect current evidence, but will not be restrictive to specific exercises; prescribed exercises will be deemed appropriate based on the treating PTs' examination, evaluation, and identification of each patients' primary deficits, impairments, functional limitations, and current literature.
223425694|NCT02938988|PROCEDURE|Antimicrobial photodynamic therapy|Described in arm/group
223425695|NCT02938988|PROCEDURE|Scaling and root planning|Described in arm/group
223733073|NCT03027778|OTHER|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
223733074|NCT04255524|DEVICE|Optic coherence tomography angiography (OCTA)|Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map
223733075|NCT00718224|DRUG|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
223733076|NCT00718224|DRUG|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
223733077|NCT00718224|DRUG|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
223400562|NCT05164770|DRUG|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX|"Zanubrutinib+R-CHOP Regimen: Zanubrutinib 160mg bid; R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg /m2 d1, Doxorubicin 50mg /m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg /m2 or Vindesine 3mg /m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-DA-EPOCH Regimen: Zanubrutinib 160mg bid; R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/ m2, Epirubicin 15mg/ m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~Zanubrutinib+R-HD MTX Regimen: Zanubrutinib 160mg bid; R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
223400563|NCT05164770|DRUG|R-CHOP; R-DA-EPOCH; R-HD MTX|"R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy."
223400564|NCT03695783|OTHER|Online decision aid called IBD&me|Patients randomized to IBD\&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
223400565|NCT03695783|OTHER|Standardized educational material|Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
223400566|NCT04107545|BEHAVIORAL|athletes|Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
223400567|NCT01992627|DEVICE|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
223400568|NCT01769573|BIOLOGICAL|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
223400569|NCT01769573|DRUG|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
223425696|NCT02938988|DEVICE|red laser|658nm; 0.1W; 2229J/cm², 10s per point
223425697|NCT02938988|DRUG|methylene blue dye|
223425698|NCT03121196|OTHER|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
223733078|NCT03012256|OTHER|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
223733079|NCT03669172|BIOLOGICAL|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
224020898|NCT04731519|BEHAVIORAL|General Health Education|General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
224020899|NCT05623176|OTHER|Standardised laparotomy care|This is a cohort study and no intervention as part of the study has been introduced. We are studying two groups and comparing the two before and after the introduction of a standardised laparotomy care protocol as part of a clinical quality improvement measure.
224020900|NCT05746208|DRUG|Lenvatinib|Given orally
223425699|NCT06575088|OTHER|Standard tourniquet pressure (250 mmHg)|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
223425700|NCT06575088|OTHER|Limb occlusion pressure|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
223425701|NCT06575088|OTHER|Cotton Pad|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
224020901|NCT05746208|DRUG|Pembrolizumab|Given IV
224020902|NCT05746208|DRUG|Hyperpolarized 13C-Pyruvate|Given IV
224020903|NCT06544512|OTHER|progressive relaxation exercise|looking at pain and anxiety by practicing progressive relaxation exercises
223425702|NCT06575088|OTHER|Elastic stockinette|The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
223425703|NCT04865601|OTHER|resectomy of the colon|The patient scheduled for colon resectomy are included in the study
223425704|NCT06668857|DIAGNOSTIC_TEST|video-oculography|All participants will receive quantitative oculomotor and pupillomotor measurements using two different video-oculography devices. Thereby both pursuit eye movements, saccades and pupillary responses to light will be assessed. In addition, there will be a quantitative assessment of the angular vestibulo-ocular reflex (aVOR) by use of video-head-impulse testing and a hearing test.
223733080|NCT04631081|PROCEDURE|coverage of the fingertips with bipedicled palmar island flap|The initial step is wound debridement. To design the flap, a longitudinal line is drawn at the junction of the volar and dorsal parts of the finger, starting from the distal part of the proximal interphalangeal joint flexion crease. It will be harvested from distal to proximal dissecting the digital canal plane. By releasing the Cleland and Grayson ligaments, the neurovascular bundle will be dissected. On the intermediate phalange, the dorsal branch of the neurovascular bundle must be preserved to maintain blood flow to the dorsal skin. Dissection is completed at the junction between the palmo-dorsal arteries and the collateral neurovascular bundles on both sides of the finger. A triangle may be resected at the distal edge of the flap to reshape of the pulp. Bone may be resected if needed to allow tension-free closure of the distal part of the flap. No Immobilization will be necessary.
224020904|NCT03620331|PROCEDURE|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
224020905|NCT03620331|PROCEDURE|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
224020906|NCT00031551|DRUG|Etanercept|
224020907|NCT00031551|DRUG|Placebo|
224020908|NCT02823535|BEHAVIORAL|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
223400570|NCT05402189|DRUG|Ketodex, Fentanyl|"The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline."
223400571|NCT03441412|DRUG|Ticagrelor 90mg|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
224020909|NCT05717608|OTHER|high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects|oral ingestion of food supplement for 4 weeks
224020910|NCT02330146|DRUG|RCT-01|
224020911|NCT02330146|DRUG|Placebo|
223400572|NCT03441412|DRUG|Epinephrine|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
223400573|NCT03441412|DRUG|Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
223400574|NCT01886677|BEHAVIORAL|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
223400575|NCT01886677|BEHAVIORAL|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
223400576|NCT02413905|BIOLOGICAL|Stool samples|Stool samples
223400577|NCT06436976|DRUG|LT-002 (Lactobacillus reuteri ATG-F4|The group that will be consuming probiotics for 12 weeks.
223400578|NCT07071441|DRUG|Indomethacin 100 MG|All patients without contraindications should receive 100mg rectal indomethacin within 30mins before ERCP procedure
223400579|NCT07071441|DRUG|Diclofenac 100mg|All patients without contraindications should receive 100mg rectal diclofenac within 30mins before ERCP procedure
224020912|NCT03788083|DRUG|Trimix|Intratumoral TriMix injection
224020913|NCT03788083|DRUG|Placebo|Intratumoral placebo injection
224020914|NCT03527368|BEHAVIORAL|Time-restricted feeding|Participants consume food earlier in the day
224020915|NCT03527368|BEHAVIORAL|Usual feeding pattern|Participants consume food later in the day
224020916|NCT00409773|DRUG|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
224020917|NCT00409773|DRUG|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
224297075|NCT01268605|PROCEDURE|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
224131286|NCT04431661|PROCEDURE|Optical Coherence Tomography|OCT (DragonFly, Abbott Vascular) will be performed after angiography. OCT images will be acquired using the 6F guide catheter compatible DragonFly System (Abbott Vascular, Santa Clara, USA). The catheter will be introduced into the first coronary artery via a standard 0.014-inch angioplasty wire, after prior injection of an intracoronary bolus of nitro-glycerine (according to the hemodynamic conditions of the patient). To remove all blood adequately from the imaging site, nonocclusive flushing will be performed using continuously inject via an automated power injector, and the OCT catheter will be pulled back at a speed of 18 mm/second to guarantee sufficient time to acquire images of a 54 mm long segment (frame density: 10 frames/mm).
224131287|NCT04431661|PROCEDURE|Coronary Angiography|The coronary angiography will be performed according to the strategies described in the consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups.Transradial or transfemoral 6F/7F approaches are recommended. The choice of diagnostic catheters, guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation is let to the investigator's discretion.
224131288|NCT04431661|PROCEDURE|Per cutaneous coronary intervention|Based on coronary angiography and OCT analyses by the investigators, PCI will be performed, preferentially for the identified culprit lesion(s) only. The guiding catheters, guidewires, pre-dilatation, atherectomy devices, and post dilatation are left to physician discretion. The use of semi- or non-compliant balloons number and diameter of drug eluting stent(s) will also be left to the physician discretion, but post dilation will be strongly recommended in case of PCI. OCT can eventually be performed after stent implantation to guide, post dilation strategy.
223400580|NCT01188031|DRUG|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
224131289|NCT05457933|DRUG|Dapagliflozin|Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
224131290|NCT05457933|DRUG|Glargine|Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
224131291|NCT01911845|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
224131292|NCT01911845|DRUG|ABT-333|Tablet
224131293|NCT01911845|DRUG|Ribavirin (RBV)|Tablet
224131294|NCT04005898|DEVICE|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
224131295|NCT01994226|DRUG|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
223400581|NCT01188031|DRUG|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
223400582|NCT06765733|DRUG|Aleeto|"Aleeto is a nerve repair protein developed by Darwin Start (Beijing) Biopharmaceutical Co., Ltd. It is a group of specific microenvironmental protein polymers secreted under the emergency conditions of stem cells. It has the advantages of selective assembly, targeted delivery, efficient repair of damaged tissues, high safety, chemical stability, easy storage, etc., and has a powerful neural repair function. According to the groups, patients would be treated with Aleeto via intrathecal injection or intravenous injection."
223400583|NCT05057130|DRUG|Doxorubicin, Cisplatin, Methotrexate|IV
223552241|NCT03248167|DRUG|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
223552242|NCT02955108|PROCEDURE|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
223552243|NCT02955108|PROCEDURE|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
223400584|NCT05057130|DRUG|Doxorubicin, Cisplatin|IV
223552244|NCT02122146|DRUG|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
223552245|NCT02122146|DRUG|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
223552246|NCT04297150|DRUG|Apixaban|Drug indicated for the treatment of NVAF
223552247|NCT04297150|DRUG|Edoxaban|Drug indicated for the treatment of NVAF
223552248|NCT04297150|DRUG|Rivaroxaban|Drug indicated for the treatment of NVAF
223552249|NCT04297150|DRUG|Dabigatran|Drug indicated for the treatment of NVAF
223552250|NCT06365658|DIAGNOSTIC_TEST|Psychological assessment|Psychological assessment of memory, learning and language
223552251|NCT00000788|DRUG|Methadone hydrochloride|
223552252|NCT00000788|DRUG|Fluconazole|
223552253|NCT06238336|DRUG|CAR-T cell therapy|The application of CAR-T therapy in the clinic generally involves the in vitro preparation and in vivo infusion of CAR-T, and the specific experimental process is divided into five steps: (1) isolation of T cells from the peripheral blood of the cancer subjects or single harvested single nucleated cells; (2) use of genetic engineering to transfer CAR structural genes that can specifically recognise the tumour cells into the T cells; (3) in vitro cultivation and expansion of CAR-T cells to the desired infusion dose (4) Non-myeloablative chemotherapy is administered prior to the infusion of CAR-T cells, which is used to remove immunosuppressive cells and reduce the tumour load so as to enhance the efficacy of the treatment; (5) CAR-T cells are infused according to the expected dosage, and the efficacy of the treatment is observed and the adverse reactions are closely monitored.
224020918|NCT00409773|DRUG|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose \& 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
224020919|NCT00081406|BEHAVIORAL|Individual Child CBT|
224020920|NCT00081406|BEHAVIORAL|Family CBT|
224020921|NCT00081406|BEHAVIORAL|Education/Support/Attention|
224020922|NCT01047423|DRUG|Simvastatin|40mg encapsulated once daily for 12 weeks
224020923|NCT01047423|DRUG|Placebo|Encapsulated oral once daily for 12 weeks
224020924|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
224131296|NCT01994226|DRUG|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
223552254|NCT05096143|DRUG|Sacubitril/valsartan|Participants who were prescribed with Sacubitril/valsartan
223552255|NCT05096143|DRUG|ACEi/ARB|Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
223552256|NCT04114708|DIAGNOSTIC_TEST|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
223552257|NCT04114708|DIAGNOSTIC_TEST|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
223552258|NCT03472495|DRUG|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is \<60 kg)
224138742|NCT06414538|OTHER|Classic Method Group|After the students in the control group are determined, a pre-test will be conducted before the subject is given training. The same knowledge test will be repeated as a final test after students have received classical course training and completed the subject. Students will be given a retention exam 35 days after the last exam. After the retention test application, the mind map method will be explained to the students in the control group and the determined topics of the course will be explained with the prepared digital mind map technique. In this way, all students participating in the study will also have access to the additional educational materials used.
224138743|NCT00269737|DRUG|Fentanyl Transdermal Therapeutic System (TTS)|
223400585|NCT07073794|DRUG|Cancer Therapeutic Procedure|Given standard of care cancer treatment in clinic
223400586|NCT07073794|DRUG|Cancer Therapeutic Procedure|Given standard of care cancer treatment in home
223400587|NCT07073794|OTHER|Health Care Delivery|Receive in home cancer treatment with CCBW
223552259|NCT03472495|DRUG|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
223552260|NCT03260855|OTHER|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
223552261|NCT03260855|OTHER|Human blood sample|The intervention is based on blood test.
223400588|NCT07073794|OTHER|Questionnaire Administration|Ancillary studies
223400589|NCT07071714|DRUG|SHR-8068 Injection|SHR-8068 injection.
223400590|NCT07071714|DRUG|Adebrelimab Injection|Adebrelimab injection.
223400591|NCT07071714|DRUG|Bevacizumab Injection|Bevacizumab injection.
223400592|NCT07079683|OTHER|Toothpaste Product|BioFresh toothpaste containing a blend of alpha-amylase and gluco-amylase enzymes to be used twice a day, morning and evening, (one minute) at a dose of approximately 1.5 g/toothbrushing (full ribbon of toothpaste) for the 28-day study duration.
223400593|NCT07079683|OTHER|Toothpaste Product|Placebo toothpaste containing no enzymes to be used twice a day, morning and evening, (one minute) at a dose of approximately 1.5 g/toothbrushing (full ribbon of toothpaste) for the 28-day study duration.
223400594|NCT06903793|OTHER|cervical manipulation|Cervical upglide/rotation manipulation targeted to C5/C6 on the dominant shoulder side
223552262|NCT05521347|BEHAVIORAL|caffeine|we employed a randomized crossover design to divide participants into a caffeine trial (CAF) and a placebo trial (PL). The CAF group took capsules with 3 mg/kg of caffeine, whereas the PL group took a placebo capsule. After a 1-h rest, the Stroop task, visual search ability test, and the shooting ability test were conducted.
223552263|NCT00117780|DRUG|insulin detemir|
223552264|NCT00117780|DRUG|insulin aspart|
223552265|NCT00330980|DRUG|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
223552266|NCT00330980|DRUG|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
223552267|NCT00330980|DRUG|Placebo|Participants will receive placebo for 6 months.
223552268|NCT00232323|BEHAVIORAL|simulation training|
223552269|NCT02388464|DRUG|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
223552270|NCT02388464|DRUG|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
223552271|NCT02388464|DRUG|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
223552272|NCT02388464|DRUG|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
223552273|NCT04148703|OTHER|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
223552274|NCT04148703|OTHER|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
223552275|NCT02882438|DRUG|infected group|Ginkgo Biloba in different dosage forms
223552276|NCT02882438|DRUG|control group|placebo without Ginkgo Biloba
223552277|NCT04294381|BEHAVIORAL|Decision tool|participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
223552278|NCT04294940|OTHER|Wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients"
224138744|NCT04182256|DEVICE|MS|Magnetic Spiderman (MS) is a novel surgical instrumentIt. It consists of a circular neodymium iron boron magnet packed in a stainless-steel case with a spring and a jagged clamp, which gives it a spider-like appearance.
223400595|NCT06181630|DIAGNOSTIC_TEST|Breast milk, plasma, and blood samples|Although this study is non- interventional regarding treatment with ozanimod, the study is considered interventional due to the collection of breast milk and plasma from the lactating women and blood samples from their breastfed infants and the additional diagnostic and monitoring procedures required for the study.
223400596|NCT04423627|DRUG|Clonidine|Clonidine 0.2 mg/day oral tablet
224138745|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
224138746|NCT00441103|DRUG|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
224138747|NCT00441103|DRUG|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
223400597|NCT04423627|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 37.5 mg/day oral tablet
223400598|NCT04423627|DRUG|Placebo|Placebo
223400599|NCT06193902|BIOLOGICAL|LEU011|Immunotherapy
223400600|NCT06908681|PROCEDURE|Bilateral Intertransverse Process Block (ITPB)|A bilateral intertransverse process block (ITPB) will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine per side prior to coronary artery bypass grafting. The block targets the dorsal rami of thoracic spinal nerves to provide postoperative analgesia.
223400601|NCT06908681|PROCEDURE|placebo saline injection|A bilateral placebo injection (20 mL of 0.9% saline per side) will be administered at the same anatomical site under ultrasound guidance prior to coronary artery bypass grafting, mimicking the ITPB procedure without active drug.
223400602|NCT06905093|OTHER|Standard care|Standard care including rehabilitation sessions three times per week.
223400603|NCT06905093|OTHER|Eccentric training of the non-immobilized arm|The training protocol involves 3 sessions per week, separated by 24-48 hours. Each session includes 4-6 sets of 10 repetitions of elbow flexion/extension exercises on the non-immobilized arm at 60-90% of 1-RM, depending on the week. Eccentric actions are performed with controlled contraction duration (4 seconds) using a metronome. Rest periods of 2 seconds between repetitions and 2 minutes between sets are provided.
223400604|NCT06905093|OTHER|Concentric training of the non-immobilized arm|The training protocol involves 3 sessions per week, separated by 24-48 hours. Each session includes 4-6 sets of 10 repetitions of elbow flexion/extension exercises on the non-immobilized arm at 60-90% of 1-RM, depending on the week. Concentric actions are performed with controlled contraction duration (4 seconds) using a metronome. Rest periods of 2 seconds between repetitions and 2 minutes between sets are provided.
223400605|NCT06909006|DRUG|Semaglutide 2.4mg|The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator
223400606|NCT06909006|DRUG|Semaglutide placebo|Visually identical and same label as the active comparator intervention
223400607|NCT05223400|DRUG|Clindamycin Injection|it is a clindamycin use evaluation study
223400608|NCT06480240|DRUG|OBI-992|OBI-992 is an antibody-drug conjugate
223552279|NCT04294940|OTHER|Use the mobile application CardiCare™ and wear an actigraph|"Between visits, tha patient will have to:~* Follow the hygiene-dietetic recommendations given by their centre.~* Wear the actigraph night and day Patients~* wear their smartphone everyday and use the mobile application CardiCare™"
223552280|NCT00834600|DRUG|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
223552281|NCT00834600|DRUG|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
223552282|NCT04671563|DRUG|Tenofovir Disoproxil Fumarate 300 MG|One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
223400609|NCT05359822|OTHER|Image-Based Report|Participants will receive the new coronary artery calcium score risk report plus the old report
223400610|NCT03625037|BIOLOGICAL|Epcoritamab|Administered as specified in the treatment arm.
223400611|NCT06098144|DRUG|Nicorette|"Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition."
223400612|NCT06098144|BEHAVIORAL|Tobacco Quit-line|The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.
223400613|NCT06098144|BEHAVIORAL|Brief Behavioral Counseling|"The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the 5A's for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes."
223552283|NCT04074083|BEHAVIORAL|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
223552284|NCT04074083|BEHAVIORAL|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
223552285|NCT05619120|DRUG|Mexiletine|Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
223552286|NCT05619120|OTHER|Conventional therapy|Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
223552287|NCT04930913|DIAGNOSTIC_TEST|Three-dimensional Ultrasound|women suspected of having adhesions will perform 3D US
223552288|NCT00287001|DEVICE|Cold air cooling|
223552289|NCT05147532|PROCEDURE|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6
223733081|NCT04631081|OTHER|occlusive dressing|patients will be evaluated on admission and benefit from wound irrigation, debridement and placement of a simple dressing with Adaptic or Jelonet, either in the Emergency department or in the Hand Surgery department. At 48 hours, they will be addressed to the Hand Surgery department to place a self-adhesive polyurethane film. Follow-up will include a visit at 1 week for dressing change, and then weekly for further dressing change until healing. Skin proximal to the injury will be degreased to increase adherence of the dressing. Distally, the film leaves a pocket to collect wound exudate. During treatment, the foul-smelling liquid produced by the wound and clots collected in the occlusive dressing will not be removed. A gauze covers the occlusive dressing to protect the liquid pocket and cover potential smell.
223733082|NCT03544502|DEVICE|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
223400614|NCT06098144|BEHAVIORAL|Intensive Behavioral Counseling|Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.
223400615|NCT07095595|OTHER|Patient Safety Educational Program based on WHO Curriculum|This study involves a structured 5-day educational program targeting nursing leaders and educators, with each day comprising 2 to 3 hours of instructional sessions. it will will include a combination of lectures, videos, group discussions, and case study analyses to enhance engagement and practical learning
223400616|NCT05425927|DEVICE|SyMRI 15 (3D)|Neurological MRI image collection
223400617|NCT07098351|DRUG|Remitch|Nalfurafine 2.5μg daily for 2 weeks. Afterwards, the dose can be increased to 5μg daily if necessary (maximum dose not exceeding 5μg daily), continued for another 2 weeks.
223733083|NCT03544502|DEVICE|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
224131297|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
223400618|NCT06876415|OTHER|P0.1 and delta Poeso integration into the decanulation decision|P0.1 and delta Poeso integration into the decanulation decision
223400619|NCT07094984|OTHER|Fecal microbiota transplantation (FMT)|FMT administered after antibiotic pre-treatment and bowel cleansing. Delivered either in capsule form or via colonoscopy to restore healthy gut microbiota and support decolonization of ARB.
223400620|NCT07094984|DIETARY_SUPPLEMENT|Probiotic Therapy|Oral administration of a high-dose multistrain probiotic containing Lactobacillus, Bifidobacterium, and Streptococcus strains for 20 days following bowel cleansing.
223400621|NCT07094984|OTHER|Gut Microbiota Boosting Diet|A structured 38-day diet designed to promote eubiosis and support spontaneous ARB decolonization. Meals are tailored and delivered to patients based on clinical nutrition protocols.
223400622|NCT05636267|DRUG|AK119|AK119 IV every 3 weeks.
223400623|NCT05636267|DRUG|AK112|AK112 IV every 3 weeks.
224297076|NCT00500747|BIOLOGICAL|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
223400624|NCT05636267|DRUG|Pemetrexed|Pemetrexed IV every 3 weeks.
223400625|NCT05636267|DRUG|Carboplatin|Carboplatin IV every 3 weeks.
223400626|NCT04960592|DEVICE|Spinal Cord Stimulation|Temporary implantation of a clinical available neurostimulator.
223400627|NCT02836691|DEVICE|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
223400628|NCT02996227|PROCEDURE|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
223400629|NCT02996227|PROCEDURE|Epidural analgesia|Epidural catheters will be inserted preoperatively.
223400630|NCT02996227|DRUG|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
223400631|NCT02996227|DRUG|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
223400632|NCT07098234|DRUG|Vitamin D3|Neonates were given vitamin D3 (cholecalciferol) in an oral drops formulation (400 IU/drop), at a dose of 400 IU once a day until the serum bilirubin level was out of phototherapy range or a maximum of 72 hours as an adjuvant therapy to phototherapy.
223400633|NCT07098234|PROCEDURE|Phototherapy|Neonates received only phototherapy until the serum bilirubin level was out of phototherapy range or a maximum of 72 hours.
223733084|NCT03544502|DEVICE|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
223733085|NCT03544502|PROCEDURE|Ambient operating room noise|patients were exposed to the ambient operating room noise.
223733086|NCT03735225|DRUG|Dasiglucagon|Dasiglucagon injection
223733087|NCT03735225|DRUG|Placebo|Placebo for Dasiglucagon injection
223733088|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223733089|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223733090|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223733091|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223552290|NCT01813201|DRUG|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
223552291|NCT01813201|DRUG|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
223733092|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223733093|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224138748|NCT03852121|BEHAVIORAL|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
224297077|NCT00500747|DRUG|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
223400634|NCT05303233|PROCEDURE|Selective tibial nerve block|The selective tibial nerve block will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position at the popliteal crease to visualize the popliteal artery and the tibial nerve in short axis. A 21-gauge 50mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound bean from a medial to lateral direction. Once the needle tip is adjacent to the tibial nerve, 5 ml of ropivacaine 0.75% will be injected to achieve an adequate spread of local anaesthetics around the nerve.
223400635|NCT05303233|PROCEDURE|IPACK|The IPACK will be performed on the popliteal crease following sterilization of the area. The probe will be placed in a transverse position proximal to the popliteal crease to visualize the popliteal artery in short axis. A 21-gauge 100 mm insulated facet tip needle (SonoPlex® STIM, Pajunk, Geisingen, DE) will be inserted in-plane with the ultrasound beam, in a lateral to medial direction, between the popliteal artery and the posterior capsule, where twenty mL of ropivacaine 0.2% will be injected under ultrasound guidance. The distribution of local anaesthetics will be observed above the posterior capsule.
223400636|NCT06865053|OTHER|Heart failure screening pathway|Heart failure screening pathway in general medicine consultations (questionnaire, NT-proBNP level, echocardiographic examination)
223400637|NCT07101263|DIETARY_SUPPLEMENT|Standard whey|A typical whey protein is given that differs in chemical structure from the atypical whey protein used in the experimental group
223552292|NCT02188940|BEHAVIORAL|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
223552293|NCT02188940|BEHAVIORAL|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
223552294|NCT02188940|BEHAVIORAL|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
223733094|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223400638|NCT07101263|DIETARY_SUPPLEMENT|Hydrolyzed whey|This type of whey has different chemical structure from typical wheys such as that used in this nstudy's control group
223733095|NCT01678677|BIOLOGICAL|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223733096|NCT01678677|DRUG|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223733097|NCT06201702|DIETARY_SUPPLEMENT|pomegranate extract|Drink 2 mL of pomegranate extract three times a day for 10 days during the 3 menstrual cycles (from 7 days before to 3 days after the estimated onset of menstruation).
223733098|NCT02402127|DEVICE|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
223733099|NCT02402127|DEVICE|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
223733100|NCT02402127|DEVICE|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
223733101|NCT02107482|DEVICE|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
223733102|NCT02107482|DEVICE|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
223733103|NCT04740502|PROCEDURE|Parahtyroidectomy|Parathyroidectomy
223733104|NCT04868890|BIOLOGICAL|Ampion|Inhaled Ampion
223733105|NCT04868890|OTHER|Placebo|Inhaled Placebo
223733106|NCT01008007|DIETARY_SUPPLEMENT|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
223733107|NCT01008007|DRUG|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
224138749|NCT02098057|DIETARY_SUPPLEMENT|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
223400639|NCT07097818|BEHAVIORAL|T1D team, structured education, peer support , and diabetes technologies|Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.
223400640|NCT07097818|BEHAVIORAL|Routine Management|Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.
223400641|NCT07103070|DEVICE|Arch supports|Set of 3 arch supports supplied by Good Feet
223400642|NCT03488082|BEHAVIORAL|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
223733108|NCT00228059|DRUG|Licarbazepine|
223733109|NCT00867009|DRUG|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
223400643|NCT02970487|DEVICE|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
223400644|NCT07104929|DIETARY_SUPPLEMENT|Beta Glucan|12 weeks of supplementation with two capsules daily of BWH Labs Beta Glucan 500
223400645|NCT04982848|DRUG|Talzenna|Talzenna treatment under Korea regulatory approval indication/dosage
223400646|NCT07103356|BEHAVIORAL|Water Pitcher Filtration System|Table-top water pitcher filtration system
223400647|NCT07106580|OTHER|lyophilized FMT capsules|A total of 18 capsules made from the initial 80 g of donor stool given through 3 days (three capsules twice daily)
223733110|NCT00867009|DRUG|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
223400648|NCT07106580|OTHER|Placebo capsules|18 capsules of identical appearance and weight given in the same way as FMT capsules
223400649|NCT06873659|DRUG|SON-DP|Solution for IV administration
223400650|NCT06208306|DRUG|Itepekimab (SAR440340)|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
223400651|NCT06208306|DRUG|Placebo|Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous
223400652|NCT04708054|DRUG|Busulfan|Given IV
223400653|NCT04708054|DRUG|Cladribine|Given IV
223400654|NCT04708054|DRUG|Fludarabine Phosphate|Given IV
223400655|NCT04708054|PROCEDURE|Hematopoietic Cell Transplantation|Undergo stem cell transplantation
223400656|NCT04708054|DRUG|Thiotepa|Given IV
223400657|NCT04708054|DRUG|Venetoclax|Given PO
223400658|NCT01956201|DRUG|Atorvastatin 20mg|\[Atorvastatin Run-in Period\] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) \[Treatment Period\] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) \[Extension Period\] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
223400659|NCT01956201|DRUG|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
223400660|NCT01956201|OTHER|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
223733111|NCT00867009|DRUG|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
223733112|NCT02381249|DRUG|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
223733113|NCT02381249|DRUG|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
223733114|NCT02727751|DRUG|Tenapanor|
223733115|NCT01641770|OTHER|Nutritional beverage 10003RF|2 sachets per day
223733116|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
223733117|NCT01641770|OTHER|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
223733118|NCT04342364|OTHER|Vitrification via slush nitrogen|oocytes will be vitrified using slush nitrogen
223733119|NCT04342364|OTHER|Vitrification via liquid nitrogen|oocytes will be vitrified using liquid nitrogen which is currently routine practice
223733120|NCT00774644|DRUG|Clarithromycin 500mg|
223733121|NCT03358290|DRUG|JTE-051|Active drug tablets containing JTE-051
223733122|NCT03358290|DRUG|Placebo|Placebo tablets identical in appearance to the active drug tablets
223733123|NCT05552560|OTHER|Questionnaire|"A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection before the first consultation with the centre's psychologist.~This questionnaire includes questions on the socio-demographic characteristics, the motivations, as well as the procreative history of the patients."
223733124|NCT03585608|PROCEDURE|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
223733125|NCT06323278|BEHAVIORAL|Cognitive training|The training, provided by normal clinical practice, will consist of two cycles of cognitive stimulation (8 sessions each) structured and aimed at maintaining and learning compensatory strategies that take advantage of the integrated cognitive skills.
223400661|NCT07112326|BEHAVIORAL|Community Gardening Program|Participants will take part in a 26-week community gardening program with Ecosource, which involves cooking classes, as well as nutrition and type 2 diabetes education. These weekly sessions will be led by Ecosource and take place in community gardens across different sites in Mississauga and at Ecosource's teaching kitchens. Diabetes education sessions will take place once per month (6 times/program) and will be led by subject matter experts including dietitians/diabetes educators. The delivery format for these sessions may be virtual or in-person depending on the topic covered and participant availability. Participants will be invited to a WhatsApp Community Chat to stay motivated and engaged with the study over the 26-week period.
223400662|NCT07110857|PROCEDURE|Cervical plexus block with 0.2 % Naropeine|Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.2 % ropivacaine (Naropeine) uni- or bilateral depending on the surgical incision
224020925|NCT01944150|BEHAVIORAL|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
224020926|NCT00676377|DRUG|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
223733126|NCT01596608|DEVICE|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
223733127|NCT01403714|PROCEDURE|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
224131298|NCT01591772|OTHER|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
224131299|NCT04064320|BEHAVIORAL|Lullaby intervention|Listening to lullabies, and accompanied by lullabies touching their abdomen and think about their babies of hospitalized women with high-risk pregnancy
224131300|NCT05700955|DRUG|Pembrolizumab and Temozolomide|Characterize the safety and immunologic/genomic/metabolomic effects of neoadjuvant Pembrolizumab and Temozolomide in recurrent glioblastoma.
224131301|NCT04333121|OTHER|weight|we can monitoring the growth of the infants by weight gain degree
223400663|NCT07110857|PROCEDURE|Cervical plexus block with saline placebo|Under ultrasound guidance, a superficial cervical plexus block is performed immediately after induction and before skin incision by injecting 15-25 mL of 0.9 % saline uni- or bilateral depending on the surgical incision
223400664|NCT07112430|DRUG|Fentanyl Citrate (Intranasal)|Fentanyl citrate will be administered intranasally at a dose of 2 mcg/kg via a mucosal atomization device, 5 minutes prior to ROP screening. Used in conjunction with standard non-pharmacologic comfort strategies.
223400665|NCT07112430|DRUG|Normal Saline (Placebo, Intranasal)|An equivalent volume of intranasal normal saline will be administered using a mucosal atomization device, 5 minutes prior to ROP screening.
223552295|NCT02188940|OTHER|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
223733128|NCT02388945|OTHER|APD|PDGO APD machines used in the PD patients for 8 weeks
224020927|NCT00676377|DRUG|Saline|Saline Placebo
224020928|NCT02359877|DRUG|BCD-054|
224020929|NCT02359877|DRUG|Rebif|
224020930|NCT02359877|DRUG|Avonex|
224020931|NCT01919814|DIETARY_SUPPLEMENT|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
224020932|NCT01919814|OTHER|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
224020933|NCT04623970|PROCEDURE|Dental Treatment|Comprehensive dental care (restorative treatmen, crowns, pulp therapy, fissure sealant and teeth extraction for pediatric patients under the deep sedation
224020934|NCT02164383|DRUG|Nicotine patch|4-week starter kit of nicotine patch
223400666|NCT07113041|DEVICE|Combined (Robotic balance training and high-definition transcranial direct current stimulation)|The robotic platform will train the participants to maintain dynamic balance in the sagittal and transverse planes (mediolateral and anterior-posterior directions) and engage in core stability and trunk control with seated balance exercises. In addition, high-definition transcranial direct current stimulation (HD-tDCS) will be used as an adjuvant to robotic balance training by priming the corticospinal circuits.
223400667|NCT07113041|OTHER|Standard of Care Balance Training|Participants in this group will receive a standard-of-care balance training (dose matched to the experimental group) administered by the Physical therapist.
223733129|NCT02388945|OTHER|CAPD|CAPD used in the PD Patients for 8 weeks
223400668|NCT07113353|DEVICE|Brain4Care|Non-invasive intracranial pressure monitor
223400669|NCT07112027|OTHER|Behavioral and MR scanning|After enrollment, participants will be screened on the basis of the inclusion and exclusion criteria. Subsequently, during the single study, participants will be administered a series of questionnaires (Edinburgh Handedness Inventory - Short Form; Evaluation of social related abilities, competences, and traits: Autism Quotient Test, DASS-21, SIAS, DERS, Ekman test; SET; I-TIPI, and conceptual ratings on semantic dimensions (moral, social, political). Then, an MR acquisition without contrast will be performed. Specifically, we will acquire structural, resting state and functional (BOLD) sequences, in the latter case during the administration of a semantic categorization task. The task is aimed to ascertain participants' responses time and accuracy in processing abstract concepts. Participants will be required to indicate the category of each of the visually presented words by means of button press. The study visit will last 3 hours in total.
223552296|NCT02188940|OTHER|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~\*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
223552297|NCT01602601|DRUG|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
223552298|NCT01602601|DRUG|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
223552299|NCT02136004|DEVICE|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
223552300|NCT01107392|DRUG|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
223552301|NCT01107392|DRUG|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
223733130|NCT01952431|DEVICE|Total Lung Capacity (TLC) testing|Comparison of TLC results
223733131|NCT01339429|DEVICE|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
223733132|NCT06340815|DEVICE|Radiation: Proton Therapy System (ProBeam)|"All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam). The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.~And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA."
223733133|NCT01849380|DRUG|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
223733134|NCT01849380|DRUG|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
223733135|NCT01103791|DRUG|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
223733136|NCT05470426|OTHER|COVID-19 Omicron Recurrence|COVID-19 Omicron Recurrence
224020935|NCT02164383|BEHAVIORAL|Cessation Counseling|5 brief counseling sessions
224020936|NCT02164383|DEVICE|Mobile Games|
224020937|NCT02334501|DRUG|Lansoprazole|
223552302|NCT02777359|PROCEDURE|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
223552303|NCT04168164|OTHER|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
223552304|NCT04168164|OTHER|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
223552305|NCT04168164|OTHER|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
224020938|NCT02334501|DRUG|Neratinib|
224020939|NCT02345785|OTHER|urologic surgery and caudal block|
224020940|NCT04834453|DIAGNOSTIC_TEST|transcranial ultrasound|\- Transcranial Doppler sonography will be performed with the patients in the supine position., using low frequency probe of 2 MHz will be placed on temporal bone- will be performed daily
224020941|NCT03531970|DRUG|2% lidocaine with 1:80,000 epinephrine|Anesthetic solution
224020942|NCT03531970|DRUG|Dexamethasone|Corticostroide
224020943|NCT03531970|DRUG|Placebo|Placebo
224020944|NCT01813370|OTHER|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
223400670|NCT07112560|DIAGNOSTIC_TEST|Standard screening procedure for amblyopia|"The standard examination for amblyopia screening consists of three steps:~A monocular visual acuity assessment using optotypes from the LEA scale, presented from the simplest to the most complex in front of each eye via an alternating occlusion mask.~A cover/uncover test, during which the child is required to fixate on an image A Lang I stereopsis test performed under binocular vision."
223400671|NCT07112560|DIAGNOSTIC_TEST|New amblyopia screening method using a virtual reality headset.|The examination with the virtual reality headset consists of three main steps: A monocular visual acuity assessment using optotypes from the LEA scale, presented from the simplest to the most complex in front of each eye via an alternating occlusion mask. The eye-tracking system analyzes fixation and the visual response of the stimulated eye. A cover/uncover test, during which the child is required to fixate on an image projected inside the headset. Eye movements are tracked to detect any deviations or abnormalities in ocular coordination. A Lang I stereopsis test performed under binocular vision, in which the child must identify three-dimensional images hidden within a virtual board. The eye-tracking system detects fixation on the images and allows evaluation of depth perception
223400672|NCT07112183|DRUG|Oral treprostinil (UT-15C) sustained release tablets|30 patients with symptomatic primary or secondary Raynaud's phenomenon (RP) resistant to standard vasodilatory therapy will be enrolled. Prior to treatment, subjects will record each day for 42 days the number of RP attacks as well as the duration of each RP attack, considered to be baseline data. After the 6-week baseline run in, all subjects will receive oral treprostinil sustained release tablets. Dose escalations can occur every 48 hours in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 3mg three times daily over a 6-week period. Titration can be done as quickly as tolerated. Once at goal dose subjects will enter the 26-week treatment phase. Throughout the study (6-week titration - 26-week treatment phase) subjects will record each day the number of RP attacks.
223400673|NCT07112820|OTHER|perfusion ultrasound|"During the examination, the power of the probe will be increased in order to assess myocardial perfusion.~The contrast agent bubbles are destroyed by applying a 'flash', i.e. a temporary increase in the power of the ultrasound beam. Systole after systole, on a recorded loop, the filling velocity of the myocardium, which depends on myocardial blood flow, is analysed. The assessment of perfusion is visual and qualitative."
223400674|NCT07112274|DRUG|Empagliflozin 10 MG|Treatment group will receive empagliflozin 10 mg tablet once daily
223400675|NCT07112274|OTHER|Placebo Tablet|control group will receive placebo tablet.
223400676|NCT07113080|DRUG|lavender essential oil inhaled using face mask|participants will inhale lavender essential oil via nebulizer before local anesthesia administration
223400677|NCT07113080|DRUG|lemongrass essential oil inhaled using face mask|participants will inhale lemongrass essential oil via nebulizer before the local anesthesia administration
223400678|NCT07111429|DIAGNOSTIC_TEST|Novel severity grading system of stoma-related complication in cancer patients|Over 5000 stoma patients treated at 26 centers between 2022 and 2023 were classified according to SITI-CD Classification.
223733137|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
223400679|NCT07111091|OTHER|GAIT AND BALANCE EVALUATION|"In our study, participants' walking assessments were made with GAITRite electronic walking path (CIR System INC. Clifton. NJ. USA.).~In the postural balance assessments of the participants, the Bertec Balance Check Screener™ BP5050 20x20 inch (Bertec Comporation Columbus, OH, USA) force platform was used. The Bertec force platform is a three-component balance platform that is based on objectively measuring instantaneous changes in vertical force and center of pressure (CoP). Bertec was designed to evaluate the ability to maintain balance while standing.~The assessments were made in all participants without an orthosis, with unilateral AFO and with bilateral AFO. In our study, participants were given a 10-minute rest period between assessments."
223733138|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
223733139|NCT00459667|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
224020945|NCT02050152|BEHAVIORAL|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
223400680|NCT07111520|DRUG|BNT326|intravenous (IV) infusion
223400681|NCT07111520|DRUG|BNT327|IV infusion
223400682|NCT07111520|DRUG|Pembrolizumab|IV infusion
223400683|NCT07111520|DRUG|SoC|IV infusion. Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin). Chemotherapy will be selected according to the indication.
223400684|NCT07112664|DEVICE|Fully Guided Dental Implant Placement Using Surgical Guide|All participants will undergo fully guided dental implant placement using a 3D-printed surgical guide (tooth-supported or mucosa-supported). The surgical guide is designed and fabricated based on preoperative CBCT and intraoral scan data. Implant site preparation and fixture insertion are performed entirely through the guide using manufacturer-specific guided surgery kits.
223400685|NCT07112898|PROCEDURE|Platelet-Rich Plasma (PRP)|Autologous PRP (approximately 4-6 mL) will be prepared using a double centrifugation technique and activated with 10% calcium gluconate. It will be administered by injecting 0.1-0.2 mL/cm² subdermally into the recipient bed and intradermally into the graft prior to placement.
223400686|NCT07112898|PROCEDURE|Standard Skin Grafting|Grafts will be placed on a clean, vascularized wound bed, secured with nonabsorbable sutures, and covered with standard postoperative dressings. No PRP will be applied.
223400687|NCT07113145|DRUG|Oral intake of medication|● Group A: Received Citalopram hydrobromide, starting with 10 mg once daily for 1 week, followed by 20 mg once daily for 10 weeks, and 10 mg daily during the final week (tapered).
223400688|NCT07113145|DRUG|Oral intake of medication|● Group B: Received Silodosin 4mg, administered orally once daily.
223733140|NCT04140292|DRUG|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
223400689|NCT07113145|DRUG|Oral intake of medication|● Group C: Received Dapoxetine hydrochloride 30 mg, taken 2 hours before intercourse, on-demand, minimum of 8 times/month for 3 months.
223733141|NCT04140292|DRUG|Vitamin D3|"D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment~Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result"
223400690|NCT07113145|DRUG|Oral intake of medication|● Group D: Received Dapoxetine hydrochloride 30 mg, administered daily.
223400691|NCT07111208|BEHAVIORAL|Green Space Activity Group - Daily Physical Activity|Participants in this group will be instructed to take a brisk 30-minute walk each day in designated urban green spaces (e.g., parks, forested areas). Physical activity will be monitored using Fitbit Alta wristband sensors to track duration, intensity, and steps.
223400692|NCT07111208|BEHAVIORAL|Mediterranean Diet Group - Dietary Intervention|Participants in this group will follow the principles of the Mediterranean diet, including increased consumption of fruits, vegetables, whole grains, legumes, nuts, and olive oil, and reduced intake of red meat and processed foods. They will receive dietary guidance and support for meal planning throughout the 7-day intervention.
223733142|NCT05652946|DEVICE|Tyromotion, Fourier Intelligence, Thera-Trainer, EKSO Bionics|Participants to receive at least 5 sessions with advanced rehabilitation technology including at least one, or multiple, of the following devices: Amadeo, Diego, Myro, Arm Motus EMU, Pelma Motus, Tigo, Balo, EKSO NR. Sessions are 45 (+/- 5) minutes
223400693|NCT07110792|OTHER|Mindfulness-based Cognitive Therapy for Life (MBCT-L)|"The MBCT-L (Bernard, Cullen \& Kuyken, 2017) intervention is an 8-week group intervention, comprising a pre-course orientation session, eight 2-hour sessions, and a half-day silent session.~MBCT-L was delivered synchronously online. MBCT-L group were led by one MBCT-L instructor"
223400694|NCT07112638|OTHER|immersive technology-based intergenerational intervention to improve movement patterns in older adults|Intervention group The intervention consists of 60-minute supervised sessions conducted once per week for 12 weeks. Each session begins with a 10-minute warm-up, followed by 15 minutes of strength training. Four structured session types (A, B, C, and D) were designed and are being rotated throughout the 12-week period. These sessions incorporate upper and lower body exercises performed using body weight and/or resistance bands, adapted to each participant's physical function.
223400695|NCT07111689|BEHAVIORAL|Conventional Occupational Therapy Interventiın|1-2. Week: Occupation-based interventions for visual skills 3-6. Week: Social Skills Training 7-8. Week: Interventions for participation problems in ADLs
223733143|NCT05652946|OTHER|Standard inpatient rehabilitation therapy|Standard inpatient rehabilitation therapy without advanced rehabilitation technology
223425705|NCT06623123|DEVICE|Oto Smartphone Application (Oto Health Ltd)|The smartphone application delivers personalized tinnitus therapy combining evidence-based CBT with mindfulness, patient education as well as physical therapy such as stretches and exercises. There are additional sounds available to listen to from the sound library. There will be a structured programme that the participants can work through however they are encouraged to personalise their own therapy.
223733144|NCT02241174|DRUG|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
223733145|NCT05548829|BIOLOGICAL|Disease severity|Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
223733146|NCT05945914|PROCEDURE|Oncoplastic Entirely Robot-Assisted Approach (OPERA)|Robotic-assisted surgery in both mastectomy and free DIEP flap harvest, so-called Oncoplastic Entirely Robot-Assisted Approach (OPERA).
223733147|NCT04065906|BEHAVIORAL|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
223425706|NCT06623123|BEHAVIORAL|Tinnitus Retraining Therapy (TRT)|Tinnitus-retraining therapy will be offered in the control arm which represents the standard evidence-based intervention on the NHS. (2) Participants enrolled to this arm will undertake tinnitus retraining therapy with a trained audiologist. The sessions will last 30 minutes with the option for further sessions should the patient which to have more support with their tinnitus to mimic the NHS programme as much as possible. These sessions will encompass a brief audiological history followed by therapy tailored to the patient's needs allowing for patient-centred optimisation of tinnitus burden and secondary comorbidities. This may include relaxation, CBT and advice surrounding sound as well as white noise masking therapy.
223733148|NCT04065906|DRUG|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
223733149|NCT03314402|DRUG|Jaktinib Dihydrochloride Monohydrate|Active Substance
223733150|NCT03314402|DRUG|placebo|Placebo
223733151|NCT02045134|DIETARY_SUPPLEMENT|Placebo|Soluble corn flour not rich in anthocyanins
223425707|NCT04797741|OTHER|IDEA3 Intervention|Delivery of IDEA3 intervention, a 12-hour online sexual assault resistance intervention for college women.
223425708|NCT02895113|DRUG|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
223425709|NCT02895113|OTHER|Placebo|Patients in this arm will be treated with placebo
223425710|NCT03764826|DEVICE|CAABT|The sound generators with CAABT will be used 15 min each session, three times a day
223425711|NCT03764826|DEVICE|TMT|The sound generators with TMT will be used 15 min each session, three times a day
224020946|NCT02050152|DRUG|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
223425712|NCT01570972|BEHAVIORAL|Group Cognitive Behavioral Therapy|weekly
223425713|NCT01570972|BEHAVIORAL|Multifamily Group Psychoeducation|twice monthly
223733152|NCT02045134|DIETARY_SUPPLEMENT|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
224020947|NCT04102306|OTHER|reliability and validity construct of the TMIQ|comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
224020948|NCT00575029|DRUG|megestrol acetate|600 mg by mouth daily
223400696|NCT07111689|BEHAVIORAL|Virtual Reality İntervention|In this study, the Xbox 360 gaming console and Kinect sensor were utilized for the virtual reality (VR) intervention. The Xbox 360 functions as an interactive gaming platform, while the Kinect sensor is a motion-detection device that captures users' positions and movements through an integrated camera and sensors. The selection of games for the VR intervention was conducted in collaboration with experts from various disciplines. The evaluation process considered the cognitive and functional demands required for successful gameplay, the potential skills each game could enhance, and the overall therapeutic purpose of the selected games. Following an independent assessment of each game, nine games were identified as suitable for the intervention. Given that all selected games shared similar functional requirements, participants were provided access to the full set of games to optimize engagement and motivation.
224020949|NCT03929744|DRUG|LY3502970|Administered orally.
224020950|NCT03929744|DRUG|Placebo|Administered orally.
223733153|NCT05070533|BEHAVIORAL|Individual treatment|Participants will receive 7 home visits to implement the program.
223733154|NCT05070533|BEHAVIORAL|Groupal treatment|Subjects will participate in groups of about 8 - 12 to implement the program.
223733155|NCT01494194|OTHER|Air Structuring Protein|A novel food protein preparation
223733156|NCT01494194|OTHER|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
223733157|NCT05018299|BIOLOGICAL|FB704A placebo|Placebo
223733158|NCT05018299|BIOLOGICAL|FB704A|Anti-IL-6 antibody
223733159|NCT01659463|OTHER|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
223733160|NCT01659463|BEHAVIORAL|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
223733161|NCT05545215|DEVICE|Dexyane Med|Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
223733162|NCT05759650|OTHER|Execution of different motor tasks typical of daily life and work|Patients with obesity will carry out different motor tasks typical of daily life and work and, using optoelectronic systems based on passive markers, force platforms and electromyographic systems, kinematic and kinetic parameters of movement will be recorded and analysed for the implementation of an integrated protocol for the clinical evaluation of subjects with obesity.
223733163|NCT04744142|DRUG|Ketone supplementation|Subjects receive either placebo or ketone ester supplementation
224131302|NCT02841319|OTHER|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
224131303|NCT06133634|DIETARY_SUPPLEMENT|Fisetin|Fisetin dietary supplement
223733164|NCT04744142|DIETARY_SUPPLEMENT|Increased protein intake|Subjects receive either normal or increased protein intake
223733165|NCT00556712|DRUG|erlotinib [Tarceva]|150mg po daily
223733166|NCT00556712|DRUG|Placebo|po daily
224020951|NCT03929744|DRUG|Atorvastatin|Administered orally.
224131304|NCT06133634|OTHER|Placebo|Placebo capsules identical in appearance to fisetin capsules
224131305|NCT05923424|DRUG|REGN17092|Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
223733167|NCT04608526|DIAGNOSTIC_TEST|Fractal analysis|Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
223733168|NCT02006745|DRUG|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
223733169|NCT02006745|DRUG|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA \>25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA \>1000 iU/mL at week 4).
223733170|NCT01961388|DRUG|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
223733171|NCT01961388|DRUG|Metformin|Oral, dosage of Metformin as per the directions of treating physician
223733172|NCT02031731|DRUG|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
223733173|NCT02031731|DRUG|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
223733174|NCT02031731|DRUG|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
224020952|NCT03929744|DRUG|Simvastatin|Administered orally.
224020953|NCT03929744|DRUG|Midazolam|Administered orally.
224020954|NCT01893294|DRUG|gemcitabine hydrochloride|Given IT
224020955|NCT01893294|DRUG|fluorouracil|Given IV
224020956|NCT01893294|RADIATION|radiation therapy|Undergo radiation therapy
224020957|NCT01893294|OTHER|laboratory biomarker analysis|Correlative studies
224020958|NCT02831387|DRUG|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
224020959|NCT02831387|DRUG|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
224020960|NCT06071403|OTHER|(enteral feeding volume/ total fluid volume)*100%|(enteral feeding volume/ total fluid volume)\*100%. Total fluid volume is defined as enteral feeding volume + parenteral fluid volume + other fluid volume
224020961|NCT01321385|OTHER|laboratory biomarker analysis|
224020962|NCT01321385|OTHER|study of socioeconomic and demographic variables|
223400697|NCT07111299|DIETARY_SUPPLEMENT|Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.|Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, plant extracts, amino acids, and other bioactive compounds designed to support hair growth and scalp health in women.
224020963|NCT00192647|DRUG|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
224020964|NCT00192647|DRUG|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
224020965|NCT00862147|BEHAVIORAL|ICDP|Parent training group
223733175|NCT04299412|DEVICE|DPP Fever Panel II assay|Multiplex lateral flow immunoassay (DPP® Fever Panel II Assay) that is able to detect (i) antigens produced by Dengue, Zika, Chikungunya, Malaria and Burkholderia and (ii) IgM directed against Dengue, Zika, Chikungunya, Leptospira, Rickettsia typhi and Orientia tsutsugamushi. The assay comes with a reader that provides results interpretation to the operator in a few seconds
223733176|NCT04832685|DEVICE|BrainSonix Pulsar 1002|Device that delivers low intensity focused ultrasound
223733177|NCT03229161|BEHAVIORAL|IWT-group|
223400698|NCT07111299|OTHER|Placebo Control|Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
223733178|NCT00425451|DRUG|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
223733179|NCT00811551|DEVICE|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
223733180|NCT04097808|DIETARY_SUPPLEMENT|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
223733181|NCT01962207|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
223733182|NCT00847704|DEVICE|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
223733183|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
223733184|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
223733185|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops|Single intranasal dose on Day 1, by intranasal drops
223733186|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops|Intranasal dose on Day 1 by intranasal drops. Followed by a second, identical dose on Day 36 by intranasal drops
223733187|NCT04798001|BIOLOGICAL|Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray|Single intranasal dose on Day 1, by intranasal spray
223733188|NCT00820131|PROCEDURE|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
223733189|NCT00820131|PROCEDURE|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
223733190|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Hyoid Bone(DSHB)|Hyoid bone-skin distance Other Name: DSHB
224020966|NCT00862147|BEHAVIORAL|Treatment as usual|Parent and/or child focused interventions
224020967|NCT01828073|DRUG|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
224020968|NCT00206661|DRUG|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
224020969|NCT00206661|DRUG|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
224020970|NCT00925431|BEHAVIORAL|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
223425714|NCT02878564|DRUG|Praziquantel|40 mg/kg, PO (orally administered tablets)
223425715|NCT06684171|PROCEDURE|Echocardiographic guidance|After detailed evaluation, patients randomized in this group will undergo TEER procedure under guidance of fully echocardiography but any fluoroscopy in the entire process.
223425716|NCT06684171|PROCEDURE|Fluoroscopic guidance|After detailed evaluation, patients randomized in this group will undergo TEER procedure under combined guidance of echocardiography and fluoroscopy in the entire process.
223425717|NCT02338219|OTHER|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
223425718|NCT02338219|OTHER|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
223733191|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Vocal Cord Anterior Commissura(DSAC)|Vocal cord anterior commissura-skin distance Other Name: DSAC
223733192|NCT05833347|DIAGNOSTIC_TEST|Distance between Skin-Epiglottic(DSE)|Skin-epiglottic distance Other Name: DSE
223733193|NCT00863603|OTHER|oxygen|5 Liter/minute by nasal cannula for 6 wks
223733194|NCT04926350|BEHAVIORAL|Resistance Exercise|8 total resistance exercises that target all major muscle groups
223733195|NCT04768231|DRUG|Rifampin|The target dose of 35mg/kg will be reached supplementing fixed-dose combination tablets (standard dose) with rifampin-only tablets.
224020971|NCT00925431|BEHAVIORAL|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
224020972|NCT00202293|DRUG|Olanzapine|
224020973|NCT00202293|DRUG|Lithium|
224020974|NCT00202293|DRUG|Chlorpromazine|
224020975|NCT02943291|BEHAVIORAL|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
223733196|NCT03684954|OTHER|Prf|Take 10 cc blood from patient and gain prf
223733197|NCT03145350|OTHER|High-fat, low-carbohydrate|Dietary intervention: 4 week
223733198|NCT03145350|OTHER|Low-fat, high-carbohydrate|Dietary intervention: 4 week
223733199|NCT01214954|OTHER|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
223733200|NCT01214954|OTHER|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
223733201|NCT03715166|DRUG|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
223733202|NCT03715166|DRUG|Placebo|Oral Solution Taken twice daily
223733203|NCT04532957|DRUG|KBP-7072|QD oral capsules
223733204|NCT04532957|DRUG|Placebo|matching placebo capsules
223400699|NCT07112703|OTHER|Incentive spirometer exercises|The study group was instructed to use an incentive spirometer, which should be held upright, sealed around the mouthpiece, and taken slowly and deep breaths. They will be motivated to achieve a preset volume through visual feedback. The child will hold their breath for 2-3 seconds at full inspiration and, after each set of 10 breaths, cough to clear mucus from the lungs. The exercise duration is 15 minutes.
223733205|NCT05459324|DEVICE|HD Study Electrode|The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
224020976|NCT02943291|BEHAVIORAL|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
224020977|NCT02275000|OTHER|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
224020978|NCT02275000|OTHER|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
223552306|NCT05340946|PROCEDURE|general anaesthesia|intraoperative general anaesthesia followed by postoperative IV patient analgesia
224020979|NCT00000241|DRUG|Flupenthixol|
224131306|NCT05923424|DRUG|Matching Placebo|Single ascending IV or SC administration per the protocol
224131307|NCT06204068|DEVICE|Spica cast|Spica cast is a cast that is placed while the child is sedated or under anesthesia, covering lower part of belly, waist, and both legs made up of fiberglass, also keeps legs in abduction and flexion. This device will be used as intended and is commonly used for the treatment of DDH.
223400700|NCT07112703|OTHER|Diaphragmatic breathing|The child will lie on their back, place one hand on their belly and one on their chest, and use a balloon or doll to fill both belly and chest up like a balloon. Inhale deeply, let the hands on the belly rise, then exhale slowly, making the belly down. The exercise will last for 10 minutes.
223400701|NCT07112703|OTHER|Pursed lip breathing:|Sit in a seated position with crossed legs or knees. Inhale slowly through the nose for three seconds, then exhale through pursed lips, similar to blowing out birthday candles.
223552307|NCT05340946|PROCEDURE|spinal anaesthesia|patient received spinal followed by continuous ultrasound guided femoral never block.
223552308|NCT01023685|BIOLOGICAL|CAD106|
223552309|NCT03952767|OTHER|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
223733206|NCT03444519|DRUG|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
223733207|NCT06187727|DRUG|Henagliflozin|After primary PCI, Henggliflozin or Placebo was administered within 24 hours, followed by daily oral administration until 6 months post-acute myocardial infarction.
223733208|NCT04411875|DRUG|Amlodipine 10 mg|The subjects randomly received single oral administration of amlodipine 10 mg.
224020980|NCT05157165|BIOLOGICAL|Convalescent plasma|Hyperimmune plasma from convalescent COVID-19 donors with titre 1:80 or more
224020981|NCT02110615|OTHER|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
224020982|NCT03624348|BEHAVIORAL|meditation|10 minute per day, 8 week digital meditation
223733209|NCT04411875|DRUG|Levamlodipine 5 mg|The subjects randomly received single oral administration of levamlodipine 5 mg.
223733210|NCT03668314|DRUG|RDN-929|Single dose from 2 mg to TBD
223733211|NCT03668314|DRUG|Placebo oral capsule|Matching placebo Single dose
223733212|NCT03668314|DRUG|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
223733213|NCT03668314|DRUG|RDN-929|Multiple dose based on results of previous cohorts
223733214|NCT03668314|DRUG|Placebo oral capsule|Matching placebo multiple dose
223733215|NCT01518166|DRUG|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
223733216|NCT01518166|DRUG|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
223733217|NCT01518166|DRUG|atorvastatin|One single dose of 40 mg. Tablet
223733218|NCT01518166|DRUG|lisinopril|One single dose of 20 mg. Tablet
223733219|NCT01518166|DRUG|griseofulvin|One single dose of 500 mg. Tablet
223733220|NCT01518166|DRUG|digoxin|One single dose of 1 mg. Tablet
223733221|NCT03438175|BEHAVIORAL|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
223733222|NCT00001576|DRUG|Melphalan|
223733223|NCT00001576|DRUG|Floxuridine|
223733224|NCT00001576|DRUG|Leucovorin|
223400702|NCT07112703|OTHER|Costal breathing exercises|The study involves conducting Costal breathing exercises for children. The exercises involve placing hands on the apical region of the lung, turning the child's head, relaxing the shoulder and neck muscles, taking a deep breath, pushing the hand out, holding, and exhaling slowly. The hands provide pressure and resistance after initiation of inspiration, and the children rest for 2 minutes between exercises. The duration of the exercise varies between the control and study groups.
223733225|NCT04980859|DRUG|Zebutinib&BR or Zebutinib&FCR|Introduction period: Zebutinib 160 mg bid oral treatment for 3 months;Joint stage :6 sessions of Zebutinib FCR( under 60 years of age,Fludarabine 25 mg/m² Q3W, Cyclophosphamide 250 mg/m² Q3W,Rituximab 375 mg/m² Q3W) or BR (over 60 years of age, )(28 days and 1 cycle);Maintenance treatment: after the end of the combined phase, continue the treatment of zebutinib.
223733226|NCT04802460|DEVICE|Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)|Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
223733227|NCT02123745|DEVICE|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
223733228|NCT00003623|DIETARY_SUPPLEMENT|multivitamin|
223733229|NCT00003623|OTHER|Placebo|
223733230|NCT04080297|DRUG|oral capsule of Q-122|
223733231|NCT01010516|DRUG|High-dose rosuvastatin|40 of rosuvastatin daily
224131308|NCT06204068|DEVICE|Rhino brace|Hip abduction brace will be used, which keeps the legs abducted and flexed. A hip brace is a special type of brace that is designed to hold the hips in a flexed and abducted position. This position allows the hip joint to develop properly while it heals. This device will be used as intended and is commonly used for the treatment of DDH.
224131309|NCT04427761|BEHAVIORAL|Measurement of Transitions in Cancer Scale (MOT-CA) Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
223400703|NCT07113470|DEVICE|The Salvia PRIMUS implantable neurostimulator System|The Salvia PRIMUS implantable neurostimulator System is designed to provide subcutaneous neurostimulation to the V1 branches of the Trigeminal nerves (supra-orbital and supra-trochlear nerves) and the branches of the Greater Occipital Nerves. It is intended to modulate headaches' neural networks by utilizing mild electrical pulses. There are 2 stimulation waveforms options: the Salvia burst waveform providing paresthesia-free stimulation and Tonic waveform, providing paresthesia-provoking stimulation. The PRIMUS System comprises a 25 cm (forehead) and a 17cm (back of the head) subcutaneous implant, a MySalvia device, a programmer, and surgical tooling.
223400704|NCT07113002|BEHAVIORAL|Emotional Freedom Technique (EFT)|Emotional Freedom Technique (EFT) is a psychological intervention that uses tapping on acupuncture points combined with cognitive techniques to reduce stress and anxiety. Participants received EFT sessions for 4 weeks.
223552310|NCT01539070|BEHAVIORAL|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
223552311|NCT02515968|DRUG|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
223552312|NCT02515968|DRUG|Propofol|
223552313|NCT02368600|BEHAVIORAL|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
223552314|NCT01908543|DRUG|Ferrous sulphate 200mg oral tablet|Administration by mouth
223552315|NCT03495141|BEHAVIORAL|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
223552316|NCT04171908|OTHER|Conventional therapy|Conventional Physical therapy for the upper limb
223733232|NCT01010516|DRUG|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
223733233|NCT01010516|DRUG|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
223733234|NCT03363204|DEVICE|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
223733235|NCT03130868|OTHER|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
223733236|NCT01953133|BEHAVIORAL|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
223733237|NCT01606345|DRUG|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
223733238|NCT05168410|OTHER|Alvarado Score|The Alvarado Score assesses patient symptoms to enable optimal triage and management of cases with suspected acute appendicitis.a
223400705|NCT07113184|DEVICE|dual sr|Dual Stentriever
223400706|NCT07113184|DEVICE|single sr|Single Stentriever
223400707|NCT07112261|OTHER|Avatar Therapy|The Avatar Intervention will take place over 10 consecutive weeks, with one session per week. Each session will last approximately 60 minutes. The goal of the intervention will be to help you reduce cravings related to your cannabis use with the use of virtual reality and avatars. The goal of the therapy is to develop strategies to improve mood and promote the fulfillment of social functioning.
223400708|NCT07111728|DIAGNOSTIC_TEST|Spectra-BREAST system in Invasive Breast Cancer|"Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities~Hyperspectral imaging (HSI):~HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma.~Point-wise Raman spectroscopy (RS):~RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected hotspots flagged by HSI as at risk. RS will be acquired on the surface of the specimens confirming the possible presence of positive margins~Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed."
223425719|NCT04392128|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine is an anti-malarial drug also used as anti-inflammatory treatment for systemic lupus erythematosus and rheumatic disorders. HCQ also inhibits pH-dependant replication stages of diverse types of viruses including flavivirus, retrovirus and coronaviruses.
223425720|NCT04392128|DRUG|Azithromycin 250 MG Oral Capsule|Azithromycin is amacrolide antibiotic.
223425721|NCT04392128|DRUG|Placebo oral tablet|Placebo of Hydroxychloroquine Sulfate 200 MG \[Plaquenil\].
223733239|NCT01491503|DRUG|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
223733240|NCT01491503|DRUG|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
223733241|NCT01491503|DRUG|Montelukast & levocetirizine|Montelukast sodium 10mg \& levocetirizine dihydrochloride 5mg PO. Single dose.
223733242|NCT03059654|PROCEDURE|tracheostomy|
223733243|NCT04481633|DIAGNOSTIC_TEST|COVID 19 serology|Diagnosis of Covid-19 past infection will be made by serology
223733244|NCT04481633|OTHER|COVID 19 Self-Questionnaire|COVID 19 Self-Questionnaire
223733245|NCT03493009|DEVICE|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
223733246|NCT01409655|BEHAVIORAL|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
223733247|NCT01220882|RADIATION|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
223733248|NCT02397759|OTHER|Blood draw and cerebrospinal fluid draw|
223733249|NCT02978261|DRUG|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
223733250|NCT02018328|DIETARY_SUPPLEMENT|Curcumin|
223733251|NCT03300479|DRUG|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
224020983|NCT00690443|DRUG|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
224020984|NCT00690443|DRUG|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
224020985|NCT05444153|DRUG|Semaglutide|Participants will receive 1 tablet of oral semaglutide once daily.
224020986|NCT05444153|DRUG|Empagliflozin|Participants will receive 1 tablet of empagliflozin once daily.
224020987|NCT00095732|DRUG|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
224020988|NCT00095732|DRUG|Placebo|Administered orally in either Size 2 or Size 5 capsules
223425722|NCT04392128|DRUG|Placebo oral capsule|Placebo of Azithromycin capsules.
223425723|NCT02045862|DRUG|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
223425724|NCT02045862|DRUG|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
223425725|NCT02045862|DRUG|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
223425726|NCT02045862|DRUG|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
223425727|NCT06665711|PROCEDURE|3% Hypertonic Saline|In this arm of the study, participants will receive nebulized 3% hypertonic saline as the primary treatment for bronchiolitis. The administration of hypertonic saline is aimed at reducing airway edema and improving mucociliary clearance in infants experiencing respiratory distress due to bronchiolitis.
223425728|NCT06665711|PROCEDURE|Intervention: Salbutamol (Ventolin)|In this arm of the study, participants will receive nebulized Salbutamol, a bronchodilator commonly used in the management of bronchospasm associated with respiratory conditions, including bronchiolitis. The objective is to evaluate the effectiveness of Salbutamol in comparison to 3% hypertonic saline in improving the clinical outcomes of infants with bronchiolitis.
223425729|NCT03156842|DRUG|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
223425730|NCT03156842|DRUG|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
223425731|NCT03156842|DRUG|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
223425732|NCT01813253|DRUG|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
224020989|NCT02819466|DEVICE|3D echography|ultrasound visualization of the stomach in fasting patients.
224020990|NCT06408974|DRUG|Ketamine|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and ,1 mg/kg ketamine added in group A under sterile condition
224020991|NCT06408974|DRUG|dexamethasone|. Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and iv dexamethasone will be added
224131310|NCT04427761|BEHAVIORAL|Distress Thermometer Survey|These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
224131311|NCT04906902|DRUG|Acalabrutinib|Tablet taken by mouth twice daily
223400709|NCT07111728|DIAGNOSTIC_TEST|Spectra-BREAST system in DCIS Breast Cancer|"Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected hotspots flagged by HSI as at risk. RS will be acquired on the surface of the specimens and using a special needle probe 2 mm below the tissue surface thus confirming the possible presence of positive margins.~Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed"
223733252|NCT03300479|DRUG|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
223733253|NCT04711408|DEVICE|SootheVR: AppliedVR, Los Angeles, California a head-mounted displa|"For the study group, virtual reality content will be administered to the participant for the duration of the examination through a head-mounted display, RelieVRTM. The VR content for the trial will be swimming with dolphins."
223733254|NCT00011076|DRUG|Pirfenidone|
223733255|NCT03799770|DIAGNOSTIC_TEST|Optic nerve sheath diameter by ultrasound at 5 minutes post-reperfucion|"Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by average 4 measured values.~We measured the ONSD at 4 timings: (T1) Post induction and before surgical incision, (T2) Portal vein clamping, (T3) 5 minutes after reperfusion, and (T4) 30 min after reperfusion."
223733256|NCT02299700|OTHER|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
223400710|NCT07110883|DRUG|SYS6023|SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
223400711|NCT07113197|RADIATION|conventional angiography|"* Peak systolic velocity (PSV)~* Velocity ratios~* Segment visualization quality~* Degree of stenosis"
223400712|NCT07112157|DRUG|Oliceridine|After entering the room, the patient was intravenously injected with oselidine at a dose of 0.08mg/kg during anesthesia induction
223400713|NCT07112157|DRUG|Sulfentanil|After the patient entered the room, sufentanil was injected intravenously during anesthesia induction with a dose of 0.4 μ g/kg
223400714|NCT07113405|DIETARY_SUPPLEMENT|Protein and Polyphenols|Participants in this group will receive 10 times a recovery drink containing protein and polyphenols.
223400715|NCT07113405|DIETARY_SUPPLEMENT|Protein|Participants of this group will receive ten times a recovery drink containing only protein without polyphenols.
223400716|NCT07113405|DIETARY_SUPPLEMENT|Placebo|Participants of this group will receive 10 times a placebo containing no protein nor polyphenols.
223400717|NCT07111442|DIAGNOSTIC_TEST|renal artery fractional flow reserve measurement|Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).
223400718|NCT07111442|DRUG|dopamine|Administer dopamine at 50 µg/kg via the renal artery to induce hyperemic.
223400719|NCT07111442|DEVICE|renal artery stent|Stent will be treated for the stenotic renal artery for patients randomized to stenting group
223400720|NCT07111442|OTHER|sham stenting|For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines.
223400721|NCT07112677|DIAGNOSTIC_TEST|Brucella Antibody Testing (ELISA)|Serological testing for Brucella antibodies using the SERION ELISA classic Brucella IgG/IgM/IgA kit (Institut Virion\\Serion GmbH, Würzburg, Germany). The test detects Brucella-specific IgG, IgM, and IgA antibodies in serum samples to assess current or past exposure. All samples were processed and interpreted according to the manufacturer's instructions. This diagnostic intervention was used for both the low back pain group and the control group.
223733257|NCT01808989|OTHER|Exercise oxymetry|
223733258|NCT00818818|DRUG|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
223733259|NCT02309502|DEVICE|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
223733260|NCT02309502|DEVICE|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
223733261|NCT06036771|DEVICE|Voice-activated Intelligent Personal Assistant (VIPA)|Apple HomePod mini is selected as the intervention medium of this study as it is the only available smart speaker that supports Cantonese
224131312|NCT05800431|DEVICE|Non-invasive neuromodulation through the Nesa device|patients receive non-invasive neurostimulation through the Nesa device
224131313|NCT04322994|DEVICE|Transnasal Humidified Rapid-Insufflation Ventilatory Echange|The use of high-flow nasal cannula to augment the ability to oxygenate and ventilate a patient under general anesthesia.
224131314|NCT02306603|PROCEDURE|Endoscopic Mucosal Resection|
223400722|NCT07113106|BIOLOGICAL|CD40.Pan.CoV Low dose(0.25mg)|SC Injection in deltoid of Low dose (LD; 0.25 mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.
223400723|NCT07113106|BIOLOGICAL|CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®|SC injection in deltoid of LD (0.25 mg) CD40.Pan.CoV vaccine Hiltonol® adjuvanted at Day 0.
223400724|NCT07113106|BIOLOGICAL|CD40.Pan.CoV High dose (1mg)|SC injectionin deltoid of High dose (HD; 1mg) CD40.Pan.CoV vaccine non adjuvanted at Day 0.
223552317|NCT04171908|OTHER|semi-inversive tech|Conventional Physical therapy for the upper limb plus Semi-inversive tech
223552318|NCT02998671|BIOLOGICAL|CJM112|
223552319|NCT02998671|OTHER|Placebo|
223552320|NCT04560686|DRUG|Bintrafusp Alfa|Given IV
223552321|NCT04560686|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223552322|NCT02038946|DRUG|Nivolumab|
223400725|NCT07113106|BIOLOGICAL|CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol®|SC injection in deltoid of HD (1mg) CD40.Pan.CoV vaccine Hiltonol® adjuvanted at Day 0.
223400726|NCT07110870|PROCEDURE|Cognitive Physical Dual task training|"Randomized Control Group (A)/ Cognitive Physical Dual Task Training Participants in control group will perform cognitive physical dual task training to improve working memory, attention and executive function in elderly with mild cognitive impairment. Dual-task training involved eight programs consist from simple dual-task to more complex dual-task tasks.~Cognitive task involves verbal fluency, attention, Forward digit span task, backward digit span task, calculation tasks and memory, aerobic exercise including performing actions like dragging the foot and placing it on floor markers (Marked from 1 to 5), Drawing any letters with their feet while seated, range of motion exercise while standing, forward walking, backward walking, tandem walking and stair climbing and strengthening exercise consisting of Thera-band with low intensity training by arms and by legs and passing/throwing a ball (0.1kg, 0.4kg) will be used for physical tasks. Eight programs will be repeated thrice, resultin"
223552323|NCT01864681|DRUG|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
223552324|NCT01864681|DRUG|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
223552325|NCT01211977|DRUG|XOMA 052|
223733262|NCT00833885|DEVICE|Masks|Wearing of surgical masks
224131315|NCT02315287|DRUG|Pioglitazone|Comparison of two different thiazolidinediones
224131316|NCT02315287|DRUG|Lobeglitazone|Comparison of two different thiazolidinediones
224131317|NCT04718181|DRUG|risdiplam|Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
224131318|NCT04718181|DRUG|omeprazole|Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
223552326|NCT05653401|DRUG|Magnesium sulfate and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 1 g of Magnesium Sulfate solution diluted in 10 ml of saline solution administered over 2 to 4 minutes
223552327|NCT05653401|DRUG|Lidocain and diclofenac|Intramuscular injection of 75 mg/ 3 ml of Diclofenac solution Intravenous injection of 10 ml of Lidocaine 1% solution administered over 2 to 4 minutes.
223733263|NCT00833885|DEVICE|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
223733264|NCT00833885|OTHER|Control|General information about virus transmission in households and basic means to prevent it
223733265|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level|50g added sugar
223733266|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage|90 grams added sugar
223733267|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage|130 grams added sugar
224131319|NCT01241838|DEVICE|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
223552328|NCT05653401|DRUG|Placebo and diclofenac|Intramuscular injection of 75 mg of Diclofenac solution and 10 ml Intravenous injection of serum saline ( as a Placebo Comparator ) administered over 2 to 4 minutes.
223552329|NCT00369850|OTHER|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
223552330|NCT00369850|PROCEDURE|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
223552331|NCT00369850|PROCEDURE|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
223552332|NCT05631314|PROCEDURE|operative treatment|Operative treatment can consist of open reduction and volar and/or dorsal plating or closed reduction and fixation with K-wires, external fixateur.
223552333|NCT05631314|PROCEDURE|non-operative treatment|Non-operative treatment will consist of immobilization in a below the elbow cast for 4-6 weeks with or without prior closed reduction.
223733268|NCT04933656|DIETARY_SUPPLEMENT|one 24 hr cycle of meals at a 2000 kcal level + three serving sugar sweetened beverage|170 grams added sugar
223733269|NCT00602706|BIOLOGICAL|sargramostim|
223733270|NCT00602706|DRUG|melphalan|
224131320|NCT03963245|BEHAVIORAL|Meaningful Activities and Recovery|"MA\&R is a new rehabilitation program for people with psychiatric disabilities. MA\&R aims to enable participation in everyday activities that are meaningful to the individual.~MA\&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA\&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA\&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
223552334|NCT05689489|OTHER|Puzzle Method|While preparing the puzzle to be used in the study, the puzzle preparation program will be used (Crossword Puzzle Maker). Students in the initiative group will be asked to solve a total of 6 puzzles, one puzzle each week. The answers to the prepared puzzles will cover the theoretical course topics of psychiatric nursing. In the puzzles, students will be expected to place their answers in the specified rows and columns. Students will be asked to solve puzzles individually. In addition, the answer to each puzzle will be found on the reverse on the back page. Students will be reminded that there is no time limit for solving the puzzles. Researchers will guide students while students solve puzzles.
223552335|NCT05689489|OTHER|Ongoing Education|Students in the control group will only take the theoretical course of psychiatric nursing.
223552336|NCT06089733|DRUG|Part A ABSK201 and Itraconazole|Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
223552337|NCT06089733|DRUG|Part A ABSK201 and Rifampicin|Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
223552338|NCT02272036|PROCEDURE|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
223552339|NCT02272036|DEVICE|mobile phone|SMS received by mobile phone
223552340|NCT01013324|DRUG|XL147 (SAR245408)|dosed as capsules taken orally daily
223552341|NCT03582046|DEVICE|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) actively measured and recorded every four hours, and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels ≥ 60 mmHg.
223552342|NCT03582046|DEVICE|Mean Arterial Pressure (MAP)|Intra-abdominal Pressure (IAP) recorded passively in device, but not measured or reviewed by physician. Patient will be treated with sepsis standard of care, maintaining mean arterial pressure (MAP) of ≥ 65 mmHg.
223552343|NCT04628702|BEHAVIORAL|tablet training|1.5 year training period
223552344|NCT01301053|OTHER|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
223552345|NCT01301053|OTHER|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose \<70 mg/dl)and severe hypoglycemia (blood glucose\<50 mg/dl)."
223552346|NCT04428255|DRUG|HBM9161 Dose A|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
223552347|NCT04428255|DRUG|HBM9161 Dose B|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
223552348|NCT04428255|DRUG|Placebo|HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
223552349|NCT04539054|DIETARY_SUPPLEMENT|ENGN Shred|ENGN Shred is a multi-ingredient pre-workout supplement.
223552350|NCT04539054|DIETARY_SUPPLEMENT|Nutricost caffeine powder|Caffeine powder.
223552351|NCT04539054|DIETARY_SUPPLEMENT|Crystal Light|Non-caloric Crystal Light matched for the pre-workout in terms of flavor and consistency.
223552352|NCT06026540|BEHAVIORAL|Pilates Exercise|"After the first measurements were made and the groups were determined; Students in the experimental group will be given pilates exercises 2 days a week for 6 months. Pilates mat, pilates circle, tiny pilates ball and pilates band will be used during the pilates exercise. The duration of the Pilates exercise is 30 minutes in total, and the peer-guided application via Zoom includes the following order:~Stretching 5 minutes, superman 1 minute, quodratus stretch 2 minutes, marble 1 minute, half plank kick 4 minutes, side kick 4 minutes, pelvic curl 2 minutes, cat pose 1 minute, spine stretch 2 minutes, one leg circle 3 minutes, side leg lift 3 minutes, single leg kick 2 minutes."
223552353|NCT00187538|BEHAVIORAL|Dietary|dietary
223552354|NCT03456258|DIAGNOSTIC_TEST|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
223552355|NCT04609605|DEVICE|speckle tracking echocardiography|speckle tracking echocardiography of right ventricle
223552356|NCT02594228|BEHAVIORAL|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
223552357|NCT02594228|BEHAVIORAL|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
223552358|NCT02473471|DEVICE|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
223552359|NCT01928290|DRUG|Irinotecan|
223552360|NCT01928290|DRUG|Trastuzumab|
223552361|NCT01928290|DRUG|Oxaliplatin|
223733271|NCT00602706|PROCEDURE|autologous hematopoietic stem cell transplantation|
223733272|NCT00602706|PROCEDURE|peripheral blood stem cell transplantation|
223400727|NCT07110870|PROCEDURE|Binaural Beats and Cognitive physical dual task training|"In experimental group, Binaural beats will be given 03 min before performing a dual task.~Participants will be in a quiet room and two tones of different frequencies will be generated through the Audacity Program (Version 3.4.2) via stereo headphones presenting a different tone to each ear.~Phase-I: A warm-up at the beginning of each session (05 min) with supervised walking exercises on a flat surface.~Phase II: Binaural beats will be induced thrice a week, for 08 weeks. Alpha, and gamma waves, over 30 min, split into two sub-sessions lasting 12 min each. Participants will be allowed to take a 6-minute rest between sub-sessions. Alpha BB (10 Hz), (R: 410 Hz, L: 400 Hz) and gamma BB (30 Hz) (R: 430 Hz, L: 400 Hz) will be provided.~Phase-III: Return to calm (05 min) with relaxation and breathing exercises, lying on the floor.~The stimulus volume, played through stereo headphones will be set by the participants at the start of the session to a comfortably loud level."
223400728|NCT03257280|OTHER|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
223400729|NCT05668663|DIAGNOSTIC_TEST|Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample|"If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.~The blood sample will be collected up to 3 days after admission"
223400730|NCT07112833|DRUG|Induction stage：Adebrelimab+TC；Treatment stage: TC/PF+ radiation therapy；Maintenance stage: Adebrelimab|"Induction stage：Adebrelimab+TC： Adebrelimab : 1200mg d1, iv, q3w ； TC : paclitaxel 135mg/m2, or nab-paclitaxel paclitaxel 180mg/m2, d1, iv，carboplatin AUC=5, d1, iv, q3w，2 cycles.~Treatment stage: TC/PF+ radiation therapy:~PET-CT responders (SUV (PETr) reduction ≥35%)：~TC/PF+ radiation therapy:~TC : paclitaxel 50mg/m2, nab-paclitaxel paclitaxel 60mg/m2, d1, iv; carboplatin AUC=2, d1, iv, qw，5 cycles.~PF : fluorouracil 750-1000mg/m2, CIV 96 hours，cisplatin 75mg/m2, d1, iv, q4w，2 cycles.~Radiation therapy: 50.4Gy-60Gy/28-33f.~PET-CT non-responders (SUV (PETr) reduction \<35%)：(switch to a different chemotherapy drug which not used during the earlier induction phase)~PF/TC+ radiation therapy:~dose same as above.~Maintenance stage: Adebrelimab:~Adebrelimab: 1200mg d1, iv, q3w , until disease progression or unacceptable toxicity occurs（Up to one year）."
223400731|NCT07110909|OTHER|HPV Education|HPV Education
224131321|NCT03963245|BEHAVIORAL|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
224131322|NCT02669004|DRUG|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
224131323|NCT02669004|DRUG|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
224131324|NCT03346369|DRUG|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
224131325|NCT04548687|PROCEDURE|carbon dioxide insufflation|Carbon dioxide insufflation at a rate of 5 l / min. through the Redon drainage during cardiac surgery (minimally invasive or repeated) during cardiopulmonary bypass
224131326|NCT04548687|PROCEDURE|No carbon dioxide insufflation|standard methods of deaeration of cardiac cavities: manual method, change in body position, through the cannula of the ascending aorta, through the drainage of the left ventricle
224131327|NCT01435239|DEVICE|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
223552362|NCT01928290|DRUG|Leucovorin|
223552363|NCT01928290|DRUG|Fluorouracil|
223552364|NCT05301621|OTHER|Akcelerometry follow up|The patients and control group will be followed up with single accelerometer.
223552365|NCT01726543|PROCEDURE|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
223552366|NCT01726543|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
223552367|NCT02209792|DRUG|Placebo|
223552368|NCT02209792|DRUG|BIBR 796 BS, 5 mg|
223552369|NCT02209792|DRUG|BIBR 796 BS, 20 mg|
223733273|NCT00602706|RADIATION|samarium Sm 153 lexidronam pentasodium|
223733274|NCT02200445|DRUG|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
223733275|NCT04646889|DRUG|AR882 Single Dose|A single dose of AR882
223733276|NCT04646889|DRUG|AR882 Multiple Dose|AR882 taken once daily for 14 days
224131328|NCT01435239|DEVICE|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
224131329|NCT06197945|OTHER|Mulligan bent leg raise|Mulligan bent leg raise
224297078|NCT02870387|OTHER|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
224297079|NCT02870387|OTHER|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
224297080|NCT04370951|PROCEDURE|Erector Spinae Plane Block - Ultrasound guided|20mls 0.25% Levobupivicaine ultrasound guided bilaterally
224297081|NCT02218970|BEHAVIORAL|strength training|
224297082|NCT02218970|BEHAVIORAL|no training (control)|
224297083|NCT01011244|BIOLOGICAL|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
224297084|NCT04492865|DEVICE|MSCT|"-Laboratory tests: All routine indicators of CBC are evaluated~* Nasopharyngeal and oropharyngeal swabs are obtained from each patient to confirm the positivity to Covid-19 by performing RT-PCR to detect the viral RNA.~* MSCT Chest images of all patients are evaluated by three radiologists with variable experiences in CT chest interpretation. The readers are blinded of the RT-PCR results and the CBC indices of the patients and they have access only to the epidemiological history, clinical symptoms, and signs. By consensus, the radiologists score the chest CT as positive or negative for COVID-19 viral pneumonia. When the chest CT is classified as positive, the main CT features are recorded as present or absent (ground-glass opacity, crazy paving, consolidation, nodules, air bronchogram, air trapping, halo sign, reversed halo sign, bronchial wall abnormalities, vascular enlargement, pleural effusion, and lymphadenopathy."
224297085|NCT00076804|BEHAVIORAL|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
223400732|NCT07111988|DRUG|Valbenazine|Selective vesicular monoamine transporter 2 (VMAT2) inhibitor
223733277|NCT01031069|BIOLOGICAL|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
223733278|NCT01031069|BIOLOGICAL|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
223733279|NCT05526495|BEHAVIORAL|Reducing preoperative low-value test ordering|A multi-component approach will be used:1) An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing non-urgent surgery will be ordered at the discretion of an anesthesiologist based on their clinical assessment. Adoption of the policy change will be facilitated by a local champion using an engagement and education program for anesthesiologists, surgeons, pre-admission clinic nurses and administrative staff; 2) The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies. A train-the-trainer model will be used; 3) The departments will commit to supporting the change in policy. Nurses within preoperative clinic will be coached to feel comfortable calling the anesthesiologist about any pre-op tests ordered, and the Pre-Admission Unit will have the authority to cancel tests that deem unnecessary. Check boxes will be removed from medical order forms
223733280|NCT01659515|DRUG|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
223733281|NCT04802278|BIOLOGICAL|COVID-19 vaccine|Any COVID-19 vaccine
223733282|NCT02893878|OTHER|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
223733283|NCT00155350|DRUG|pioglitazone|
223733284|NCT03755492|OTHER|Absorbent pad for urinary incontinence|6 month supply provided to patients as needed for urinary incontinence after radical prostatectomy
224131330|NCT06197945|OTHER|Mulligan bent leg raise with Bowen therapy|Mulligan bent leg raise with Bowen therapy
224297086|NCT04677881|OTHER|Intervention group|intervention group: bread with sourdough control group: bread with yeast
224297087|NCT01284296|DRUG|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
223400733|NCT07111988|DRUG|Placebo|Pill that contains no medicine
224131331|NCT05820100|OTHER|Observational|"The goal of this observational study is to assess the reliability and validity of the multi-luminance Y-Mobility Test (MLYMT) and multi-luminance shape description test (MLSDT) for evaluation of subjects with severe vision impairment due to RP.~Normally sighted subjects will provide a control group. The MLYMT consists of two LED panels, one of which is illuminated at multiple luminance levels, positioned at the end of Y-configuration. Seven obstacles are placed ahead of the panels, which the test subject should detect and avoid before reaching and touching the lit panel."
223552370|NCT01331746|DRUG|APD515|20 mg oromucosal-oral administration qds for 7 days
224131332|NCT04322630|OTHER|Change in Soluble MER Concentration|Measuring change in soluble MER Concentration post compared to pre bypass for each patient.
223552371|NCT01331746|DRUG|Placebo|qds for 7 days
223552372|NCT00006695|DRUG|carmustine|300 mg/m2 IV on Day -6
223552373|NCT00006695|DRUG|cytarabine|100 mg/m2 BID on Days -5 through -2
223552374|NCT00006695|DRUG|etoposide|100 mg/m2 BID on Days -5 through -2
223552375|NCT00006695|DRUG|melphalan|140 mg/m2 IV on Day -1
223552376|NCT00006695|PROCEDURE|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
223552377|NCT00006695|RADIATION|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
223552378|NCT00410969|DEVICE|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
223552379|NCT00003566|PROCEDURE|videothoracoscopy|
223552380|NCT06270446|OTHER|Community based physiotherapy|Physiotherapy at community rehabilitation center
223552381|NCT06270446|OTHER|Outpatient physiotherapy|Physiotherapy at hospital
223552382|NCT03611218|DEVICE|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
223552383|NCT02761681|BEHAVIORAL|ACT-CL Web-based guided self-help|
223552384|NCT02761681|BEHAVIORAL|Control Web-based guided self-help|
223552385|NCT02059564|DRUG|HM11260C|doses of 6 mg, 16 mg
223552386|NCT02059564|DRUG|Placebo|Normal saline solution
223552387|NCT02059564|DRUG|Victoza|doses of 1.8 mg
223552388|NCT00096642|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
224131333|NCT03664193|RADIATION|SIBRT|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
224131334|NCT00375115|DRUG|Sambucol|
224131335|NCT03625362|DIETARY_SUPPLEMENT|Hydrogen|Hydrogen-rich water
224131336|NCT03625362|DIETARY_SUPPLEMENT|Placebo|Tap water
224131337|NCT01938781|DRUG|entecavir|antiviral therapy
224297088|NCT01284296|DEVICE|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
224131338|NCT01938781|DRUG|Peg-IFN|antiviral and antifibrosis therapy
224297089|NCT02408068|DRUG|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
224297090|NCT02408068|DRUG|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
223552389|NCT01650948|DEVICE|RetnaGene AMD LDT|
223552390|NCT02569567|PROCEDURE|Smart-Shear Wave(SSW) imaging|"1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
223552391|NCT02569567|PROCEDURE|Transient elastography(TE)|"1. Using the M probe in patients with BMI \<30 kg/m2.~2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
223552392|NCT05015647|DIETARY_SUPPLEMENT|LP group|LP group patients replaced pasta, bread, biscuits etc. with low protein substitutes. We allowed them to consume more animal products than NP, preferring white meat to red meat and trying to limit cold cuts as much as possible. Furthermore, they were advised to prefer fresh or frozen fish, instead of dried or smoked one as well as to prefer fresh cheeses to seasoned ones. As for legumes, we advised to combine them with bread or normal cereals, for protein complementarity.
223552393|NCT05015647|OTHER|NP group|NP group was given the indication to try to eat the second dish only once a day or to split the portion of the second plate between lunch and dinner, if they wanted to keep the habit of making the meal complete. It was also given the indication to prefer, among protein sources, those of plant origin. We also indicated to alternate or replace cow's milk with plant substitutes such as: rice, almonds' or oats' drinks. Furthermore, we suggested to prefer white meat and to avoid offal and processed meat. Moreover, we indicated to substitute dried or smoked fish with fresh or frozen one.
223552394|NCT02725476|BIOLOGICAL|XmAb5871|
223552395|NCT05659043|OTHER|overnight fasting|All blood samples were taken on the day of cardiac catheterization after overnight fasting.
223552396|NCT01116466|DEVICE|ActiGait|ActiGait - implantable drop foot stimulator
223552397|NCT03955328|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
223552398|NCT02977429|OTHER|standardized fluid therapy|The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
223552399|NCT02977429|OTHER|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
223552400|NCT04809519|OTHER|Integrative Nursing based Multimodal Interventions for Uncontrolled Hypertensives|In this study, multimodal interventions including yoga, meditation, and breathing techniques, compliance training for hypertension treatment, and home blood pressure measurement training will be applied to the experimental group.
224297091|NCT02408068|DRUG|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
224297092|NCT02408068|DRUG|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
223733285|NCT01906151|DEVICE|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
223400734|NCT07111468|DRUG|YHP2401|Total 7 days of treatment and The daily dose is tid.(YHP2401 + Placebo of YHR2402 + Placebo of YHR2403)
223733286|NCT00700661|DRUG|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
223733287|NCT00700661|DRUG|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
223400735|NCT07111468|DRUG|YHR2402|Total 7 days of treatment and The daily dose is tid.(Placebo of YHP2401 + YHR2402 + Placebo of YHR2403)
223400736|NCT07111468|DRUG|YHR2403|Total 7 days of treatment and The daily dose is tid.(Placebo of YHP2401 + Placebo of YHR2402 + YHR2403)
223400737|NCT07106970|PROCEDURE|Linear ablation|Linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device.EIVOM could be performed additionally before or after PFA at the operator's discretion.
223400738|NCT07106970|PROCEDURE|PVI alone|Undergo PVI with the study device
223400739|NCT07109518|BIOLOGICAL|uCD7 CART|Subjects screened to meet the requirements for uCD7 CART use will enter clinical trials. Subjects were assessed at baseline. Fludarabine (Flu) and cyclophosphamide (CTX) based preconditioning should be performed within 1 week prior to uCD7 CART infusion: Flu 30mg/m2 ×3 days; CTX 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and etoposide. Infusion of uCD7 CART must be performed 24 hours after completion of chemotherapy preconditioning. uCD7 CART can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
223400740|NCT07116915|DRUG|HRS-9821 Powder for Inhalation.|HRS-9821 Powder for Inhalation.
223552401|NCT04809519|OTHER|Ongoing treatment|The ongoing health service of the control group will continue. In addition, the control group will be directed to a specialist doctor and standard brochures prepared by the Ministry of Health for hypertensive individuals will be given.
223552402|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
223552403|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
223552404|NCT01608737|DRUG|BI 201335|BI 201335 once daily high dose for 12 weeks
223552405|NCT01608737|DRUG|PegIFN/RBV|PegIFN/RBV for 48 weeks
223552406|NCT01608737|DRUG|BI 201335|BI 201335 once daily low dose for 24 weeks
223552407|NCT01326806|BEHAVIORAL|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
223552408|NCT01326806|BEHAVIORAL|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
223552409|NCT03336086|COMBINATION_PRODUCT|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
223552410|NCT00536718|GENETIC|gene expression analysis|
223552411|NCT00536718|GENETIC|molecular diagnostic method|
223552412|NCT00536718|GENETIC|polymorphism analysis|
223552413|NCT00536718|GENETIC|protein expression analysis|
223552414|NCT00536718|OTHER|medical chart review|
223552415|NCT00536718|OTHER|questionnaire administration|
223552416|NCT04389710|DRUG|Convalescent Plasma|One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
223552417|NCT05733741|DRUG|Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)|"For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
223552418|NCT05733741|DRUG|Preservative-free Sodium hyaluronate 0.2% (Polyfresh unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt).|"The other eye was treated with preservative-free Sodium hyaluronate 0.2%. The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Sodium hyaluronate 0.2% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use."
223552419|NCT04087031|OTHER|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
223552420|NCT04087031|OTHER|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
223552421|NCT04087031|OTHER|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
223552422|NCT03857932|PROCEDURE|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
223733288|NCT00353262|DRUG|Avastin|7.5mg/kg iv (cycle 3 only)
223733289|NCT00353262|DRUG|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
223733290|NCT00353262|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
224020992|NCT04778241|PROCEDURE|Micro-osteoperforation|Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental group before placing the initial leveling arch wire. MOPs were placed at three sites i.e., interproximally between mandibular canine and lateral incisor on both sides and between central incisors in the midline on labial aspect of mandible.
224020993|NCT02335177|BEHAVIORAL|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
224020994|NCT00706199|PROCEDURE|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
223733291|NCT05782608|DRUG|IV ibuprofen|Group 1 will receive IV ibuprofen 400mg \\ 6 hours the first dose will be administrated immediately post operative.
223733292|NCT05782608|DRUG|IV ketorolac|Group 2 will receive 20 mg IV ketorolac\\ 6 hours the first dose will be administrated immediately post operative
223733293|NCT05286307|DRUG|IPACK block|IPACK block with 20 mL of 0.25% Bupivacaine injected into the Interspace between the Popliteal Artery and Capsule of the Knee
223733294|NCT01103284|DRUG|DiaPep277|1.0 mg dose in 0.5 mL of solution
223733295|NCT01103284|DRUG|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
223733296|NCT01182493|DEVICE|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
223733297|NCT01853826|DRUG|Afatinib|Patients received a daily dose of 40 milligrams (mg) of afatinib (Giotrif®), in the form of film-coated tablet over a 28 day cycle. Afatinib was taken orally with 250 milliliters (mL) of water at the same time of the day and without eating anything for at least 3 hours. Patients continued on treatment for as long as there was no disease progression or no other trial withdrawal criteria. The dose was reduced to 30 mg or 20 mg once daily when the initial dose was not tolerated by the patient.
224020995|NCT02872831|DEVICE|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
224020996|NCT02872831|DEVICE|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
224020997|NCT01350336|DEVICE|Alair System|Treatment of airways with the Alair System
224020998|NCT02203123|DEVICE|Ultrasound|
224020999|NCT02203123|DRUG|normal saline|
223552423|NCT05978349|DRUG|adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro|Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
224021000|NCT03390920|OTHER|Umbilical Allograft|The umbilical allograft is regulated by the FDA and comes from a lab that is FDA registered.
224021001|NCT02835326|BEHAVIORAL|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
223552424|NCT01689987|DRUG|Cyclophosphamide|Given IV
223552425|NCT01689987|DRUG|Dexamethasone|Given PO
223733298|NCT03517761|BIOLOGICAL|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate. Patients will be repositioned in the prone position to then receive upper cervical injections to C0-C3 ligaments and facets.Patients will receive 2 of these treatment procedures 3 months apart.
223733299|NCT03517761|OTHER|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.Patients will also receive small skin punctures to the back of the neck to mimic ligament and facet injections. Patients will receive 2 of these procedure 3 months apart.
223733300|NCT06099327|DEVICE|Image-based vital sign monitoring|Unobtrusive, vital signs measurements with remote photoplethysmography
223733301|NCT01157936|DRUG|Allopurinol|daily dosage
223733302|NCT01157936|OTHER|placebo|daily dosage
223733303|NCT04767204|BEHAVIORAL|peer co-delivered vocational rehabilitation service|The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
223552426|NCT01689987|DRUG|Hydroxychloroquine|Given PO
223552427|NCT01689987|OTHER|Laboratory Biomarker Analysis|Correlative studies
223552428|NCT01689987|OTHER|Pharmacological Study|Correlative studies
223552429|NCT01689987|DRUG|Sirolimus|Given PO
223552430|NCT04739319|OTHER|N/A Observational study|N/A Observational study
223552431|NCT01958580|DRUG|Gemcitabine Hydrochloride|Given IV
223552432|NCT01958580|DRUG|Docetaxel|Given IV
223552433|NCT01958580|RADIATION|Internal Radiation Therapy|Undergo brachytherapy
223552434|NCT01958580|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223733304|NCT03572140|DIAGNOSTIC_TEST|RAVS In relapsed and resistent cases|assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
223733305|NCT00121550|DRUG|clarithromycin|
223733306|NCT02549183|DEVICE|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
223733307|NCT04138420|DRUG|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
223733308|NCT04365920|COMBINATION_PRODUCT|Recovery Management Checkups (RMC)|"The RMC model was designed to improve treatment linkage, engagement, and long-term treatment retention. The conceptual framework was based on the public health theory of chronic disease management, which utilizes ongoing assessment and monitoring through regular face-to-face checkups and early (re)intervention to facilitate detection of relapse, reduce the time to treatment re-entry, and consequently, improve long-term outcomes. The original RMC model includes: 1) a fixed schedule of face-to-face quarterly checkups to assess need for SUD treatment, 2) personalized feedback based on an assessment and motivational interviewing to increase treatment motivation, 3) problem solving around barriers to treatment access and retention, and 4) assistance with scheduling and linkage to treatment. Individuals were deemed to be in need of treatment if they reported weekly, or more frequent, substance use since the last checkup, any past-month SUD symptoms, or self-perceived need for treatment."
223733309|NCT04365920|COMBINATION_PRODUCT|RMC-Adaptive|"Participants in the RMC-Adaptive group will receive face-to-face monthly checkups during the first 2 months post-release with additional face-to-face checkups dependent upon the participant's progress. Based on the data presented in the prior section, as long as participants need treatment, they will receive monthly checkups.~In addition, for every checkup that a participant does NOT need treatment, the number of months before the next checkup will be increased by 1 month (e.g., after 2 checkups without need, they will receive the next checkup 2 months later, after 3 it will be 3 months, after 4 it will be 4 months, and so on). Based on these decision rules, individuals who have NO treatment need over 24 months will still receive 5 checkups."
223733310|NCT05615779|OTHER|Placebo Comparator: Randomized pectin diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin
224297093|NCT04809935|DRUG|98% dehydrated alcohol|"* coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol."
223733311|NCT05615779|OTHER|Randomized B-fructan diet|UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan
223733312|NCT05615779|OTHER|Personalized pectin diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline
223733313|NCT05615779|OTHER|Personalized B-fructan diet|UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
223733314|NCT03723928|OTHER|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
224297094|NCT04809935|DEVICE|19G EUSRA needle, Taewoong Medical, Korea|"* 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan"
224297095|NCT05778552|DEVICE|Home-based pelvic muscle training devices or traditional PFMT at hospital|Performed home-based pelvic muscle training devices at home or traditional PFMT at hospital
224297096|NCT05279365|BIOLOGICAL|Pfizer/BioNTech (BNT162b2)|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
224297097|NCT05279365|BIOLOGICAL|Moderna|participants will receive a booster dose (1st booster or 2nd booster) of vaccine
224021002|NCT02835326|BEHAVIORAL|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
224021003|NCT01553097|OTHER|Neurocognitive impairment observation|None - observational
224021004|NCT03775070|DRUG|Simvastatin|"* Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~* Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~* The basic anti-congestive medication will be kept as the same.~* The dosage may be titrated to a lesser dose by investigators according to the patient's condition."
224021005|NCT03967639|PROCEDURE|Elective cardiac surgery|Elective cardiac surgery
224021006|NCT04292678|BEHAVIORAL|Progressive muscle relaxation|The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.
224021007|NCT04292678|OTHER|Attention matched control|Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
224021008|NCT00003600|BIOLOGICAL|epoetin alfa|
224021009|NCT00003600|OTHER|placebo|
224021010|NCT00842270|DRUG|AB1010|3 mg/kg/day
224021011|NCT00842270|DRUG|AB1010|4,5 mg/kg/day
224021012|NCT00842270|DRUG|AB1010|6 mg/kg/day
224021013|NCT00842270|DRUG|placebo|matching placebo to AB1010 dosages
224021014|NCT05769127|OTHER|Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)|DPP lifestyle intervention program DSMT education on diabetes and lifestyle changes
224021015|NCT03013660|OTHER|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
224021016|NCT02071667|OTHER|Blood draw|
223400741|NCT07116915|DRUG|HRS-9821 Powder for Inhalation placebo|HRS-9821 Powder for Inhalation placebo
224021017|NCT02066428|BIOLOGICAL|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
224021018|NCT02066428|BIOLOGICAL|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
224021019|NCT03279263|DRUG|MLR-1023|MLR-1023 Tablets
223733315|NCT03723928|OTHER|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 4-8 weeks without imaging
223733316|NCT03723928|OTHER|Quality-of-Life Assessment|Ancillary studies
223733317|NCT03723928|OTHER|Anxiety Questionnaire Administration|Ancillary studies
223733318|NCT04959279|OTHER|ED-TREAT|Patients will be assessed and treated based on a clinical decision support system.
223733319|NCT04267926|DRUG|20 mg MitoQ|a third of subject will receive 20mg of oral MitoQ
223733320|NCT04267926|DRUG|Placebo|Subject will receive Placebo
223733321|NCT04267926|DRUG|40mg of MitoQ|a third of subjects will receive 40mg of MitoQ
223733322|NCT05177419|DRUG|Lysergic Acid Diethylamide|100 micrograms LSD base
224021020|NCT03279263|OTHER|Placebo|Matching Placebo Tablets
224021021|NCT00491543|DRUG|ALT-2074|
224021022|NCT03719170|BEHAVIORAL|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
224021023|NCT05392153|OTHER|Myofascial therapy|Running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. Myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. The aim of our study is to investigate the effect of Myofascial therapy on sportive performance balance and injury risk in runners. The study will carry out on runners with a 3-month running history.
223733323|NCT05177419|DRUG|Lysergic Acid Diethylamide|Low dose of LSD base
223733324|NCT04338295|DEVICE|Tattoo machine (SOL Nova Device)|A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.
223733325|NCT00001339|DRUG|doxorubicin, vincristine, and etoposide with mitotane|
224021024|NCT05342220|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning through inflation of a blood pressure cuff to pressure values \> 200mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
224131339|NCT02125006|BEHAVIORAL|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
224131340|NCT03367130|BEHAVIORAL|Mobile phone reminder|Intervention described already in arm/group descriptions.
223400742|NCT07116915|DRUG|Moxifloxacin Hydrochloride Tablets|Moxifloxacin Hydrochloride Tablets
223400743|NCT06925737|DRUG|Ifinatamab deruxtecan|Administered via intravenous (IV) infusion every 3 weeks (q3W) until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
223400744|NCT06925737|DRUG|Docetaxel|Administered via IV infusion q3W until disease progression, unacceptable adverse events (AEs), or other cessation of treatment
223400745|NCT06925737|DRUG|Prednisone|Oral tablet administered once per day or per approved product label
223400746|NCT06931327|DRUG|Test Drug|AJU-C711
223400747|NCT06931327|DRUG|Reference Drug|C711R
223400748|NCT03923647|DEVICE|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
223400749|NCT07140289|DIAGNOSTIC_TEST|Ultrasound of gastric contents|An ultrasound examination of the abdomen to observe and measure gastric contents
223733326|NCT00360828|DRUG|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride \[CPT-11; CAMPTOSAR\] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
223733327|NCT00360828|DRUG|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
223733328|NCT02932033|PROCEDURE|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
223733329|NCT02932033|PROCEDURE|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
223733330|NCT01346839|BEHAVIORAL|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
223733331|NCT01133054|PROCEDURE|revascularization|surgery or stenting
223733332|NCT01968590|DRUG|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
224021025|NCT05342220|PROCEDURE|Sham preconditioning|Inflation of a blood pressure cuff to pressure values \~ 10mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion
224021026|NCT02744326|BEHAVIORAL|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
224021027|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
224021028|NCT02079610|BEHAVIORAL|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
224021029|NCT00285337|PROCEDURE|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
224021030|NCT01688674|DRUG|10% dextrose|
224021031|NCT05084443|DIETARY_SUPPLEMENT|Drink|Roselle and placebo drink for 6 months
224021032|NCT00261911|DRUG|sibutramine|
224021033|NCT02826330|OTHER|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
224021034|NCT04788498|PROCEDURE|Laparoendoscpoic single site surgery LESS|• A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp
224021035|NCT04788498|PROCEDURE|Conventional multiport laparoscopy|• It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
224021036|NCT02204176|OTHER|Exercise info|"Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries"
224131341|NCT03047148|OTHER|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
224131342|NCT00407264|DRUG|Fluticasone propionate|
224131343|NCT06335368|OTHER|Nutrition and Growth Status|Nutrition and Growth Status
223400750|NCT07142356|DRUG|RTN-001|A potent and selective PDE5 inhibitor.
223552435|NCT01958580|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223552436|NCT01958580|OTHER|Laboratory Biomarker Analysis|Correlative studies
223552437|NCT01631487|DRUG|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
223552438|NCT01631487|DRUG|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
223400751|NCT07142356|DRUG|Matching placebo control|The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.
223400752|NCT07142369|PROCEDURE|Synovial Fluid withdrawal at the preoperative clinic visit|Synovial Fluid withdrawal at the preoperative clinic visit
223400753|NCT07142369|PROCEDURE|Platelet-Rich Plasma (PRP) preparation and injection|Platelet-Rich Plasma (PRP) preparation and injection
223400754|NCT07142369|PROCEDURE|Synovial fluid withdrawal at the time of surgery|Synovial fluid withdrawal at the time of surgery
223400755|NCT07142369|PROCEDURE|3mL synovial fluid withdrawn at the preoperative visit|3mL synovial fluid withdrawn at the preoperative visit
223425733|NCT01813253|DRUG|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
223425734|NCT03857451|DIAGNOSTIC_TEST|Clinical gait analysis|Three dimensional gait analysis consisting of joint kinematics, kinetics and dynamic EMG data will be introduced into the diagnostic scheme
223552439|NCT01631487|DRUG|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
223552440|NCT01631487|DRUG|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
223552441|NCT01018173|DRUG|placebo|sc weekly
223552442|NCT01018173|DRUG|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
223552443|NCT01875393|DRUG|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
223552444|NCT03619577|BEHAVIORAL|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
223552445|NCT02619591|OTHER|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
223552446|NCT00133263|BEHAVIORAL|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
223552447|NCT00133263|BEHAVIORAL|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
223552448|NCT01595971|BEHAVIORAL|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
223552449|NCT01595971|OTHER|usual care|Received the usual care provided
223552450|NCT05822947|OTHER|Active manual therapy|Soft tissue mobilization of the lumbar paraspinal musculature (3 to 4 minutes).
223552451|NCT05822947|OTHER|Control manual therapy|Light touch and a breathing exercise (3 to 4 minutes).
223552452|NCT04511143|OTHER|muscle strength and ultrasound imaging measurement|hamstring muscle strenght measured by hand held dynamometer. The long head of Biceps Femoris, Semitendinosus, Semimembronosus were evaluated by B-mode ultrasound imaging.
223552453|NCT05279924|DRUG|Prophylaxis with Emicizumab|Prophylaxis with Emicizumab in Ivoirian boys with severe hemophilia A
223552454|NCT02455336|DRUG|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
223552455|NCT02455336|OTHER|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
223552456|NCT02094378|DRUG|Esketamine|84 mg esketamine administered intranasally
223552457|NCT02094378|DRUG|Placebo|Placebo administered intranasally
223552458|NCT04409561|DEVICE|Blood collection|9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits
223733333|NCT01988259|PROCEDURE|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
223733334|NCT01988259|PROCEDURE|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
223733335|NCT01988259|PROCEDURE|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
223733336|NCT01988259|PROCEDURE|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
223733337|NCT06406673|DRUG|Cadonilimab+EC/ET+RT|Cohort\_1 patients with no history of previous systemic treatment for ES-SCLC received cadonilimab with EC/EP for two cycles (induction phase), then, those who did not progress received concurrent palliative RT and two cycles of cadonilimab with EC/EP (combination phase). Afterward they received cadonilimab every 3 weeks for a maximum of 2 years after study enrolment (maintenance phase).
223733338|NCT06406673|DRUG|Cadonilimab+vorolanib|Cohort\_2 patients with recurrent SCLC and after at most one systemic treatment received cadonilimab plus vorolanib, until disease progression or unacceptable toxicity.
223733339|NCT05828199|DRUG|Ketamine Hydrochloride|Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
223733340|NCT05828199|DRUG|Dexmedetomidine|bolus dose of dexmedetomidine 0.5-1 μg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr
223733341|NCT05373420|OTHER|Education level|Educational level was classified using the International Standard Classification of Education (ISCED) : ISCED0 (less than primary education), ISCED1 (primary education), ISCED2 (lower secondary school), ISCED3 (upper secondary school), ISCED4 (post-secondary non tertiary education), ISCED5 (short-cycle tertiary education), ISCED6 (bachelor's or equivalent level), ISCED7 (master's or equivalent level), ISCED8 (doctoral or equivalent level). We merged these different categories into three main education level : low (ISCED0 to ISCED2), middle (ISCED3 to ISCED4) and high (ISCED5 to ISCED 8). This information is provided by STATBEL.
223733342|NCT05373420|OTHER|Household net income|Income information is available as deciles of the net income of the whole household. This indicator is further categorized into low income (deciles 1 to 4), middle income (deciles 5 to 7), and high income (deciles 8 to 10). This information is provided by STATBEL.
223733343|NCT05373420|OTHER|Gender|Male or female. This variable is obtained from the Belgian national registry.
223733344|NCT05373420|OTHER|Migration background|Migration background is based on the first nationality and the parents' country of origin. This variable distinguishes between native-born individuals, second-generation migrants, first-generation European migrants, and first-generation non-European migrants. This information is provided by STATBEL.
223733345|NCT05373420|OTHER|Household type|Household type provides a partial picture of the social environment and is distinguished between one person, couples, couples with children, single parents, other, collectivity (prison, nursing homes, religious community, etc.). This information is provided by STATBEL.
223733346|NCT05373420|OTHER|Health literacy|Having a health care degree is used as a proxy for health literacy and is provided by CoBRHA. The scientific and medical background can lead to more preventive and responsible behaviors towards infectious diseases. Moreover, being a health professional can lead to the need to protect patients and themselves against infections, without necessarily having very advanced knowledge of infectious diseases and vaccines.
224021037|NCT02204176|OTHER|Implementation intentions|"Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans"
223733347|NCT00893087|DEVICE|Triggering mode of the ventilator|10 min of each triggering mode
223733348|NCT00893087|DEVICE|Triggering method of the ventilator|Flow triggering
223733349|NCT00893087|DEVICE|Triggering method of the ventilator|Pressure triggering
224021038|NCT02204176|OTHER|Industriousness|"Discussion of:~* realistic monitoring of efforts related to exercise~* reaching and pushing past thresholds for sustained effort for exercise"
224021039|NCT02204176|DEVICE|pedometer|
224131344|NCT01676402|BIOLOGICAL|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
223733350|NCT00893087|DEVICE|Triggering method of the ventilator|NAVA triggering
223733351|NCT03420118|PROCEDURE|Tumour tissue collection|"Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~* A previous surgery for the disease,~* A biopsy for diagnosing the disease,~* Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~* Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~* At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~* New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens."
224021040|NCT03969550|OTHER|Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
224021041|NCT01111474|OTHER|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval) at the cervical region of the sensitive tooth
224021042|NCT01111474|RADIATION|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm\^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
224021043|NCT02466438|DRUG|Piperacillin-tazobactam|"* Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~  * Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~ * Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~* Acute Kidney injury : Dosing as prescribed by treating physician"
224021044|NCT04266665|DRUG|Dexmedetomidine|Dexmedetomidine 2 μg/ml will be given as bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
223400756|NCT07142148|DIAGNOSTIC_TEST|CDAT - phase 1|"The English version of the Celiac Dietary Adherence Test (CDAT) will be translated into Polish using the forward-backwards-forward translation model, with the author's consent (already obtained by the applicants). The Polish translation will be performed by two native bilingual speakers of Polish and English. Both translations will be compared and standardised. The Polish version will then be translated into English by two native bilingual speakers of English who are unfamiliar with the original English version. The translation and original will be compared to clarify discrepancies and ensure conceptual equivalence between the versions. The agreed-upon translation will be culturally adapted, if necessary. The items will be reviewed by five experts, and an I-CVI of at least 0.78 will be considered satisfactory content validity."
223400757|NCT07142148|OTHER|CDAT - phase 2|"In the next step, 10 coeliac disease (CD) patients aged 10 years and older and 10 caregivers/parents of CD patients under 10 years of age will be asked to rate the clarity of each statement on a Likert scale \[1 = unclear to 5 = very clear\]. Questions with a mean score \<4.0 will be rephrased and re-evaluated.~Internal consistency analysis using Cronbach's alpha and the mean inter-item correlation (AIC) will be used to assess reliability. Convergent validity will be assessed by comparing scale scores with serological marker levels. Confirmatory factor analysis (CFA) will be conducted, taking into account the SRMR fit index."
223425735|NCT01432912|BEHAVIORAL|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
223425736|NCT03721055|RADIATION|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
223733352|NCT03420118|PROCEDURE|Blood draws|"Blood samples will be collected at the following different times points:~* All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~* Before starting a new line of treatment for the disease,~* One week after starting a new line of treatment for the disease,~* During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~* At the time the disease worsens or relapses (comes back)~* During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
223733353|NCT00473460|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
223733354|NCT00473460|DRUG|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
223733355|NCT00982488|DRUG|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
223733356|NCT00982488|DRUG|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
223733357|NCT00320099|DRUG|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
223733358|NCT00320099|DRUG|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
223733359|NCT00320099|DRUG|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
223733360|NCT00320099|DRUG|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
223733361|NCT04345796|DRUG|Carvedilol+Empagliflozin|Group A
223733362|NCT04345796|DRUG|Carvedilol|Group B
223733363|NCT04345796|DRUG|Empagliflozin|Group C
223733364|NCT04345796|DRUG|Placebo|Group D
223733365|NCT00165893|DEVICE|Accu-Spina Device/IDD therapy|
223733366|NCT00165893|PROCEDURE|Physical Therapy|
223733367|NCT00084981|DRUG|decitabine|Given IV
223733368|NCT00084981|DRUG|valproic acid|Given PO
223733369|NCT00084981|OTHER|pharmacological study|Correlative studies
223733370|NCT00084981|OTHER|laboratory biomarker analysis|Correlative studies
223733371|NCT05482633|OTHER|Inspiratory muscle training (IMT)|Treatment group will perform IMT every day for eight weeks. Initial load is going to be set as the 60% of maximal inspiratory pressure (PImax) and is going to be increased by %10 of the initial load every two weeks.
223733372|NCT06288464|DIETARY_SUPPLEMENT|Soluble Fibre|Patients will be assigned to stoma feeding by the Colorectal Surgeon, which will be managed by the stoma nurses for the duration, approximately 4 weeks, of feeding. For the final 7-14 days (minimum 7 days) of feeding, 10g of soluble fibre will be added to 100ml of Ensure™ (or equivalent liquid nutrient feed) before instillation into the stoma on a daily basis. The soluble fibre will be provided in 10g portions and should be added to the newly-opened bottle of ensure and shaken to mix well.
223733373|NCT03867981|BEHAVIORAL|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
223733374|NCT03867981|BEHAVIORAL|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
223733375|NCT03867981|BEHAVIORAL|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
223733376|NCT05439408|DRUG|Dasatinib ASD 100 mg|XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 100 mg Test Formulation
223733377|NCT05439408|DRUG|Dasatinib 140 MG [Sprycel]|SPRYCEL® (dasatinib) 140 mg Film-Coated Tablets
223733378|NCT04465331|OTHER|Questionnaires|completion of Exercise Adherence Rating Scale (EARS)
223733379|NCT04348734|DIAGNOSTIC_TEST|pleural ultrasound|Patients will benefit from a daily pleural ultrasound for 96 hours, D1 being the day of hospitalization. The therapeutic course of action will depend on the presence or not, and on the type of pleural effusion according to a pre-established algorithm
223733380|NCT04785014|PROCEDURE|interventional|In the aspirated group, the popliteal fossa areas were sterilized and BC content was aspirated from the popliteal fossa percutaneously under USG guidance with a 21-gauge needle (Figure 1). If the BC was septal, aspiration was performed from several different levels of the cyst so that the cyst content could be completely emptied.
223733381|NCT03502044|DEVICE|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
224131345|NCT01676402|BIOLOGICAL|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
224131346|NCT01157416|DRUG|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
223733382|NCT03502044|DEVICE|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
223733383|NCT05325151|OTHER|Educational Intervention|Receive GCPP intervention videos
224131347|NCT01157416|DRUG|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
224021045|NCT04266665|OTHER|Normal saline|Equivalent doses for a solution containing 2mcg/ml of the tested drug calculating for a bolus 1mg/kg for 10 minutes with a maintenance dose of 0.8μg/kg/h until surgery completion
224021046|NCT04931186|OTHER|retrospective analyis|retrospective analysis of data
224131348|NCT01157416|BEHAVIORAL|CBT|12-session CBT protocol, called Youth PTSD Treatment.
224131349|NCT04087421|DEVICE|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
223400758|NCT07141992|OTHER|Active Neural Mobilzations|Participants in this group will receive active neural mobilization in the form of neural flossing techniques. These involve controlled, repeated movements performed actively by the patient to mobilize peripheral nerves without placing them under excessive tension. The goal is to restore neural mobility, reduce mechanosensitivity, and relieve neuropathic symptoms such as burning pain.
223400759|NCT07141992|OTHER|Passive Neural Mobilzations|Participants in this group will receive passive neural mobilization using neural tensioning techniques. These techniques involve therapist-applied passive limb movements that place a controlled tensile load on the neural structures. The objective is to improve neural gliding, reduce nerve compression, and decrease neuropathic pain, particularly in cases of restricted neural tissue mobility.
223400760|NCT06930300|OTHER|Hypertonic 3% saline|Participants receive 10 ml/kg body weight of 3% saline infused over 1 hour. The aim is to stimulate copeptin release.
223400761|NCT06930300|OTHER|Water|Participants ingest 20 ml/kg water over 1h. The aim is to suppress copeptin release.
223400762|NCT06942143|BIOLOGICAL|Super1 TCR-T|All participators received lymphoid-depleted preconditioning before Super1 TCR-T cells infusion. Super1 TCR-T cells were infused 3 days later. Concomitant administration of interleukin for 7 consecutive days.
223400763|NCT06940349|DRUG|Palbociclib|Palbociclib and Sunitinib
223400764|NCT06940349|DRUG|Sunitinib|Palbociclib and Sunitinib
223400765|NCT02496663|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400766|NCT02496663|PROCEDURE|Computed Tomography|Undergo CT scan
223400767|NCT02496663|PROCEDURE|Echocardiography Test|Undergo ECHO
223400768|NCT02496663|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
223400769|NCT02496663|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223552459|NCT00391430|DRUG|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
223552460|NCT00391430|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
223552461|NCT01095991|DRUG|AZD1656|Oral tablet bd,
223552462|NCT01095991|DRUG|Sitagliptin|Oral tablet od
223552463|NCT04368299|OTHER|Telemedicine|Videoconferencing for follow-up
223552464|NCT04368299|OTHER|Standard care|Standard in-person outpatient follow-up
223552465|NCT06426563|PROCEDURE|Ablation treatment of thyroid nodule|Use Radiofrequency or Microwave ablation device to treat thyroid nodule
223552466|NCT02467192|DEVICE|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
223552467|NCT02308592|BEHAVIORAL|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~1. Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~2. (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~3. A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
223552468|NCT02308592|BEHAVIORAL|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
223552469|NCT00989846|OTHER|biomarker|measuring serum-biomarkers
223552470|NCT05586906|DEVICE|Multiple Breath Washout (MBW) tests|LCI measurements (EXHALYZER® D with Nitrogen Washout System, ECO Medics AG) will be performed every month during follow-up beginning 3 months after lung transplantation.
223552471|NCT05007899|DRUG|Ferrous sulfate|Alternate day dosing of ferrous sulfate
223552472|NCT02894723|DIETARY_SUPPLEMENT|L-arginine|30 ml arginoline contains 5 gr l-arginine
223552473|NCT02894723|DIETARY_SUPPLEMENT|syrup|The same bottle of the experimental group, but without l-arginine
223552474|NCT02922816|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
223552475|NCT02922816|PROCEDURE|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
223552476|NCT02922816|PROCEDURE|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
223552477|NCT02922816|OTHER|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
223552478|NCT00771212|OTHER|Observational pain control study|Observational pain control study
223552479|NCT05084248|DRUG|Ergocalciferol Capsules|Capsules of ergocalciferol at 400 IU and 4000 IU
223552480|NCT01922882|BEHAVIORAL|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
223552481|NCT03146663|DRUG|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
223552482|NCT03146663|DRUG|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
223733384|NCT05325151|OTHER|Genetic Counseling|Receive genetic counseling
223733385|NCT05325151|OTHER|Survey Administration|Ancillary studies
223733386|NCT02744235|DEVICE|Polysomnography Data|
224021047|NCT03404830|OTHER|HIIT group, MICT group|"The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching."
224021048|NCT00782522|PROCEDURE|Eccentric training program|Eccentric training program
223733387|NCT02744235|DEVICE|Jawbone UP®|
223733388|NCT02744235|DEVICE|Fitbit Charge ®|
224021049|NCT00782522|PROCEDURE|Traditional training program|Traditional training program
224021050|NCT03681704|DRUG|HuangQi Decoction|HuangQi Decoction 150ml twice a day for 24 weeks
224021051|NCT03681704|DRUG|HuangQi Decoction placebo|traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
224021052|NCT01016977|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
223400770|NCT02496663|BIOLOGICAL|Necitumumab|Given IV
223400771|NCT02496663|DRUG|Osimertinib|Given PO
223400772|NCT06941025|OTHER|Not applicable- observational study|Not applicable - observational study
223400773|NCT07141147|RADIATION|Radiation|"1. Technique:Linear accelerator with volumetric modulated arc therapy for irradiation.~2. Target Volume Delineation (Two-phase irradiation):~Clinical Target Volume 1 (CTV1):Encompasses tumor bed (preoperative MRI/CT-defined ACC extent) + regional lymphatics (ipsilateral para-aortic nodes).~Clinical Target Volume 2 (CTV2):Tumor bed only (preoperative MRI/CT-defined ACC extent).~Planning Target Volume (PTV):PTV1: CTV1 + 0.6 cm margin.PTV2: CTV2 + 0.6 cm margin.~4.Organs at Risk (OARs):Stomach, liver, bilateral kidneys, pancreas, spinal cord, and bowel/colon within radiation fields.~5.Prescription Dose: Phase 1: PTV1 → 45 Gy in 25 fractions (1.8 Gy/fraction), 5 fractions/week. Phase 2: PTV2 → 10 Gy in 5 fractions (2.0 Gy/fraction), 5 fractions/week."
223400774|NCT07141472|DIETARY_SUPPLEMENT|GB|GLP-1 Booster (GB) is a composition designed to increase the endogenous production of GLP-1, improve the activity of GLP-1, enhance the body's response to GLP-1, and thus eventually help people reduce glucose, suppress food intake and lose body fat. GB contains Green tea (Camellia sinensis) leaf extract, Gardeniae (Gardenia jasminoides Ellis) fructus extract, Turmeric (Curcuma longa) root extract, Black pepper (Piper nigrum) extract,Fenugreek (Trigonella foenum-graecum) seed extract, Ginseng (Panax ginseng) root extract, and White kidney bean (Phaseolus vulgaris) extract. Each of these ingredients has been commonly consumed by humans as food sources or supplements and thus has an undebatable safety profile.
223552483|NCT05529082|OTHER|Opioid Attitudes|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
223552484|NCT05529082|OTHER|Beliefs survey|Participants will complete a questionnaire about your feelings/beliefs on prescription pain medication and your experience with opioids/pain medication. Demographic information about you (such as your age, gender, race, ethnicity, and so on) will also be collected.
223552485|NCT04362306|BEHAVIORAL|Planned Intervention|Intervention with a member of the medical physics team to review the process of simulation, treatment planning, and subsequent treatment. This meeting will last approximately 15 minutes and at this time, the team member will explain that they are the primary resource for all the technical aspects related to the patient's treatment. Additionally, they will identify and address any concerns that patients or their caregivers have with radiation treatment and the patient will be shown the simulation infographic.
224021053|NCT01016977|DRUG|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
224021054|NCT02179723|DEVICE|Leukosan Adhesive|Leukosan adhesive applied to one wound
224021055|NCT02179723|DEVICE|Transcutaneous suture|Transcutaneous suture applied to one wound
224131350|NCT04087421|DRUG|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
224131351|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
224131352|NCT01503476|DEVICE|Bravo® pH Monitoring System|Bravo pH monitoring
224131353|NCT02345252|DRUG|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
223400775|NCT07141472|DIETARY_SUPPLEMENT|Placebo|Placebo is a product that resemble active GB but does not contain any of the active ingredients
223552486|NCT04362306|BEHAVIORAL|No planned intervention|Anxiety and patient satisfaction questionnaires will be completed prior to CT simulation.
223733389|NCT00511615|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
223733390|NCT00496093|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
223733391|NCT04372680|DIAGNOSTIC_TEST|CTUS examination|fully bedside ultrasonographic assessment of lung, cardiac and diaphragm functions
223733392|NCT03026010|PROCEDURE|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
223733393|NCT01694641|OTHER|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
223733394|NCT00289315|BEHAVIORAL|Primary (Environmental) Weight Gain Prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
223733395|NCT00289315|BEHAVIORAL|Secondary (Behavioral) Weight Gain Prevention|School-based environmental program to promote healthy eating and physical activity in the overweight students.
223733396|NCT00289315|BEHAVIORAL|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
224021056|NCT02430974|DRUG|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
224131354|NCT02345252|DRUG|FTC/RPV/TDF Placebo|Tablets administered orally once daily
224131355|NCT02345252|DRUG|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
223733397|NCT03599024|PROCEDURE|PCEA|The patients were able to control the administration of analgesics by themselves.
223733398|NCT03599024|PROCEDURE|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
223733399|NCT03599024|PROCEDURE|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
223733400|NCT03590236|OTHER|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
223733401|NCT03590236|OTHER|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
223733402|NCT04279951|OTHER|Resistance exercise|High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)
224297098|NCT04412265|OTHER|Relation between frailty and clinical outcomes in elderly patients with COVID-19.|"To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration."
224297099|NCT01549106|DRUG|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
224297100|NCT01549106|DRUG|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
223733403|NCT04279951|DIETARY_SUPPLEMENT|Omega-3|1 gram of omega-3 per day for 20 weeks
223733404|NCT04279951|DIETARY_SUPPLEMENT|Placebo|1 gram of sunflower oleic oil per day for 20 weeks
223733405|NCT00237757|BEHAVIORAL|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
223733406|NCT00237757|BEHAVIORAL|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
223733407|NCT00180414|DEVICE|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
223733408|NCT03095391|DEVICE|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
223733409|NCT03095391|DEVICE|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
224021057|NCT02768051|PROCEDURE|AF Ablation|
224297101|NCT01983709|BIOLOGICAL|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10\^6 cells/kg or a maximum dose of 1 x 10\^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10\^6 cells/kg or a maximum dose of 2 x 10\^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
224297102|NCT05437367|OTHER|Scapular Stabilization exercises|Therapeutic exercises
224297103|NCT05437367|OTHER|Postural correction exercises|Therapeutic exercises
224297104|NCT01053234|DIETARY_SUPPLEMENT|Standardised meals|
224297105|NCT02303041|DRUG|Buparlisib|Administered orally at starting dose of 80 mg/day
224297106|NCT02303041|DRUG|Sonidegib|Administered orally at starting dose of 200 mg/day
224297107|NCT02908035|DRUG|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
224297108|NCT02908035|DRUG|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
224297109|NCT00211965|BIOLOGICAL|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
224297110|NCT00211965|BIOLOGICAL|placebo|single dose IM
223733410|NCT04383808|DIAGNOSTIC_TEST|Injected radiotracer with PET Insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
223733411|NCT04383808|DIAGNOSTIC_TEST|Pre-injected group with PET insert|"1. Informed consent will be obtained before beginning any study procedures.~2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed."
223733412|NCT00306761|DEVICE|Dynamic Wheelchair Seating System|
223733413|NCT00812370|DRUG|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
224021058|NCT05419362|DRUG|GEN-001|The capsules taken by mouth once a daily. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)
224021059|NCT05419362|DRUG|Avelumab|800 mg given by intravenous (IV) infusion once every 2 weeks
224021060|NCT02306486|OTHER|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
223733414|NCT05485298|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223733415|NCT06678113|DRUG|BSG005|Single arm dose escalation in patients with invasive fungal infection
223733416|NCT04704167|OTHER|fixation of double barrel vascularised fibula|3D titanium miniplate or 3D titanium mesh tray are used as a method of fixation for double barrel vascularized fibula
223733417|NCT06216145|OTHER|formative evaluation|"Before the skills exam, the 'Self-Efficacy Survey in the Most Commonly Used Skill-Requiring Practices in Nursing' will be administered. Apart from the end-of-term skill exam, students will be given a different skill exam than the control group, in which they will not receive any grades. For applications requiring invasive interventions, a skill test will be administered in the laboratory.~For applications that do not require invasive intervention, a skill test will be administered in the clinical environment. At the end of the semester, students will be asked to fill out the 'Self-Efficacy Survey in Practices Requiring the Most Commonly Used Skills in Nursing'. At the end of the semester, students will be evaluated with 2 skill applications and skill exam scores to be selected by written exam and lottery method"
223733418|NCT01798199|OTHER|The training by Verve System|
223733419|NCT02949492|DRUG|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
223733420|NCT02161627|DEVICE|Saluda Medical External Trial System|
223733421|NCT02161627|DEVICE|Saluda Medical External Trial System|
224021061|NCT01481389|DIETARY_SUPPLEMENT|Theobromine|200 ml drink with added theobromine (no cocoa added)
223400776|NCT07148791|BIOLOGICAL|Anti-BCMA-CD19 CAR-T cells|Anti-BCMA-CD19 CAR-T cell injection is an autologous, dual-target chimeric antigen receptor T-cell therapy designed to target CD19 and BCMA antigens. Peripheral blood mononuclear cells (PBMCs) are collected from each participant and modified ex vivo using lentiviral transduction to express the CAR construct. Lymphodepletion with cyclophosphamide (250 mg/m\^2/day, IV) and fludarabine (30 mg/m\^2/day, IV) is administered for 3 days (Day -5 to Day -3). The doses of fludarabine and cyclophosphamide may be adjusted based on the patient's clinical condition. CAR-T cells are infused intravenously on Day 0 at one of three dose levels (1x10\^6, 2x10\^6, or 3x10\^6 CAR+ T cells/kg, ±20%). This product is being investigated in patients with relapsed or refractory IgG4-related disease (IgG4-RD) to assess safety and preliminary efficacy.
224131356|NCT02345252|DRUG|FTC/RPV/TAF Placebo|Tablets administered orally once daily
223400777|NCT02702128|DRUG|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
223400778|NCT02702128|DRUG|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
224021062|NCT01481389|DIETARY_SUPPLEMENT|Cocoa|200 ml drink with cocoa (no theobromine added)
224021063|NCT01481389|DIETARY_SUPPLEMENT|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
224131357|NCT00661401|BIOLOGICAL|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
223400779|NCT06952348|BEHAVIORAL|Stair and brisk walking combined|See arms.
224021064|NCT01481389|DIETARY_SUPPLEMENT|Placebo|200 ml drink (no added theobromine or cocoa)
224021065|NCT03413657|PROCEDURE|Increase in intrathoracic pressure|Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
224021066|NCT04186299|DRUG|Clonidine|Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.
224021067|NCT04186299|DRUG|Articaine Hydrochloride + Epinephrine|Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
224021068|NCT00093171|DRUG|rFIX|
224131358|NCT00084916|DRUG|temsirolimus|Given IV
224131359|NCT00084916|OTHER|laboratory biomarker analysis|Correlative studies
223400780|NCT06952348|BEHAVIORAL|Brisk walking|See arms.
223400781|NCT06952348|BEHAVIORAL|Standard care|See arms.
223400782|NCT07142031|OTHER|BioHPP|Onlay restorations fabricated from BioHPP polymer will be applied to 20 patients. Following the 6- and 12-month follow-ups, the collected data will be analyzed according to clinical evaluation criteria.
223400783|NCT07142031|OTHER|Lithium Disilicate|Onlay restorations fabricated from lithium disilicate will be applied to 20 patients and will serve as the control group for comparison with the BioHPP onlay restorations. Following the 6- and 12-month follow-ups, the collected data will be analyzed according to clinical evaluation criteria.
223400784|NCT07143630|DEVICE|Neuromuscular Electrical Stimulation|NMES will be applied to the abdominal muscles using a multichannel stimulator. Each session will last approximately 20 minutes, administered 5 times per week for a total of 15 sessions, in addition to core stabilization exercise program performed with the same frequency.
223400785|NCT07143630|BEHAVIORAL|Core Stabilization Exercises|Participants will perform a structured core stabilization exercise program. The program will be administered 5 times per week for a total of 15 sessions.
223400786|NCT07142278|BIOLOGICAL|DUVAX 200 µg|Intramuscular injection of 200 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22
223400787|NCT07142278|BIOLOGICAL|DUVAX 400 µg|Intramuscular injection of 400 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22
224021069|NCT02954640|BIOLOGICAL|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
224021070|NCT01019512|OTHER|questionnaire administration|Ancillary studies
224021071|NCT01019512|OTHER|lymphedema management|
224021072|NCT03641612|OTHER|one shape|canal fluid sample before and after root canal instrumentation
224297111|NCT03325465|DRUG|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
223400788|NCT07142278|BIOLOGICAL|Placebo (Adjuvant only)|Intramuscular injection of placebo consisting of Adjuvant formulation in phosphate-buffered saline without active antigen, administered at Weeks 0, 4, and 22
223400789|NCT07149246|OTHER|Nutrition intervention|Frequent follow-up from a dietitian during ICU and hospital stay, and after discharge, up to 6 months after ICU admission.
223400790|NCT07091916|DEVICE|Defibrillation using the Extravascular ICD|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
223400791|NCT07101250|DRUG|Acetazolamide 500 MG Extended Release Oral Capsule|Active Drug
223400792|NCT07101250|DRUG|Placebo|Inactive Drug
223400793|NCT07153289|BIOLOGICAL|CD318-CAR-T cells|Autologous T cells collected by leukapheresis, genetically modified using a GMP-manufactured lentiviral vector encoding a fully human CD318-specific chimeric antigen receptor (CAR), and expanded on the CliniMACS Prodigy system. After lymphodepleting chemotherapy (fludarabine/cyclophosphamide), participants receive (Phase I) a single CAR-T infusion per BOIN dose-escalation to determine MTD/RP2D; (Phase IIa) an expansion at RP2D with a predefined dual-dosing schedule (two infusions) separated by a protocol-defined interval.
223425737|NCT04613141|DEVICE|WalkingTall-PD|Smart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program.
223425738|NCT04613141|OTHER|Mobility-plus|Active 'pseudo placebo' comparator using a paper-based body weight exercise program.
224021073|NCT03641612|OTHER|protaper next|canal fluid sample before and after root canal instrumentation
224021074|NCT00009841|BIOLOGICAL|EGFR antisense DNA|
224021075|NCT00009841|BIOLOGICAL|growth factor antagonist therapy|
224297112|NCT03325465|DRUG|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
224297113|NCT04580121|DRUG|RO7283420|RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
224297114|NCT04580121|DRUG|RO7283420|RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
224297115|NCT04580121|DRUG|Tocilizumab|Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
224297116|NCT04580121|DRUG|Dasatinib|Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily \[BID\] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
223425739|NCT04722744|PROCEDURE|screwmented metal frameworks|Intervention group: in which the edentulous area will be restored with 3-implant, screwmented CAD/CAM frameworks constructed based on planned implant positions
223425740|NCT04139512|PROCEDURE|guided surgery|placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
224021076|NCT00009841|DRUG|DC-cholesterol liposome|
224021077|NCT04988815|DRUG|Ropeginterferon alfa-2b|Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
224021078|NCT02057978|PROCEDURE|EXCEL DES implatation|Implant DES for CAD cases
224021079|NCT02057978|PROCEDURE|EXCEL-II DES implantation|Implant DES for CAD cases
224021080|NCT06059781|OTHER|Rhtyhmical auditory stimulation and Visual cues (Experimental group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~For visual stimulation, white chalk will use to draw visual signals on the ground. For gait recovery, a 10-meter walkway will draw on the floor with parallel lines 2.5cm broad and 90cm long. Interline distance will maintain at 110% of the length of the initial step.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Experimental group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
224297117|NCT04580121|DRUG|Dexamethasone|20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
223425741|NCT04139512|PROCEDURE|conventionnel implant placement|placement of dental implant with conventionnal freehand technic
223425742|NCT06059430|OTHER|no intervention|no intervention
223425743|NCT06337916|BEHAVIORAL|Cervical Stabilization Exercise|The cervical stabilization exercise group will receive cervical stabilization exercises 1 session a day, 3 days a week for 6 weeks. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
224021081|NCT06059781|OTHER|Rhtyhmical auditory stimulation (Control group)|"For auditory stimulation, walking exercises are performed on a flat floor walking path without rhythmic or musical influence. Rhythmical auditory stimulation (RAS) is produced by using Metronome App on a mobile phone.~Routine recovery treatment includes a range of motion exercises for the lower extremity, passive stretching of tight muscles and conventional march exercises including marching, forward, backward and sideways walking.~Control group will be treated for 45 minutes per session, 3 days per week for 6 weeks."
223733422|NCT01399138|DIETARY_SUPPLEMENT|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
223733423|NCT01572909|DRUG|Bendavia (MTP-131)|0.05 mg/kg/hr
224021082|NCT02863471|DRUG|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
224021083|NCT02938260|DRUG|Metoprolol vs Diltiazem|
223733424|NCT01572909|DRUG|Placebo|Identically appearing placebo
224021084|NCT04617210|OTHER|Neurocognitive tests and blood taking|Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
224021085|NCT05496946|OTHER|Head bathing skill|A group of students will practice the head bathing skill in a model with low proximity to reality, while the students in the other group will practice on a healthy individual (Standardized patient) pretending to be patient.
224021086|NCT02970474|DEVICE|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
224021087|NCT02970474|DEVICE|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
224021088|NCT03237039|RADIATION|X-ray examination|Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.
224131360|NCT03014167|DRUG|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
224131361|NCT04026152|BEHAVIORAL|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
224131362|NCT04026152|BEHAVIORAL|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
224297118|NCT04580121|DRUG|Paracetamol/acetaminophen|500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
224297119|NCT04580121|DRUG|Diphenhydramine|25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
224297120|NCT06148064|OTHER|Collaplug with low level laser|Immediate implant placement with applying a collaplug material in the jumping gap followed by low level laser application using Siro laser (660 nm, avg. power density: 0.5-WATT) circular spot diameter and area: 0.71 cm/0.4cm2) applied in six points in contact mode with peri-implant soft tissue (1.23 minutes in each point of application; dose per point 11 J) before bone perforation and after suturing.
224297121|NCT06148064|OTHER|Collaplug|Implant of suitable diameter and height was placed in the fresh extracted socket immediately after extraction and the jumping gap was augmented by the collaplug followed by healing abutment placement.
224297122|NCT00281606|DRUG|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
223733425|NCT03641651|OTHER|Rehabilitation technology|"* Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~* With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~* A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~* The training can take place in an outpatient or inpatient setting.~* Training will be organized in individual one-to-one or group session"
223733426|NCT02180633|OTHER|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
223733427|NCT02792556|DEVICE|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
223733428|NCT02734381|OTHER|Elderly patients|Elderly patients who visited the Emergency Department
223733429|NCT04779489|RADIATION|personalized ultrafractionated stereotactic ablative radiotherapy|next-generation stereotactic ablative radiotherapy to bladder and enlarged lymph nodes
223733430|NCT02984189|OTHER|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
223733431|NCT00623727|BIOLOGICAL|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
223733432|NCT00623727|BIOLOGICAL|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
223733433|NCT04813094|OTHER|Internet-Based integrated-management Program|The Internet-based integrated management Program system have five domains that included patient's information collection, AF knowledge area, instructions on anticoagulation medicine, self-monitoring of symptom area, and professional consultation. Everyone have their own area to ensure the privacy of participants. The research nurse has sent messages every day to care about the participant's condition. In this area, when the participant have an emergency, it not only provided textual information, but also provided telephone coaching.
223400794|NCT07151170|OTHER|Telerehabilitation Pelvic Floor Muscle Training (TR-PFMT) Group|The program will be delivered online in small groups by a physiotherapist. The program includes diaphragmatic breathing, pelvic mobility (pelvic tilts, hip circles, cat-cow), stretching (butterfly, child pose, deep squat), and progressive strengthening of phasic and tonic fibers through stationary PFMT (10-sec moderate-hold + 3 quick flicks, 8 sets in weeks 1-3, 10 sets in weeks 4-6, 10-sec rest) and home-based PFMT (10 fast contractions and 10 moderate-hold contractions, 2 sets in weeks 1-2 with weekly set increases, 10-sec rest), performed in prone lying, supine hook-lying, butterfly, sitting, and standing positions. All sessions will be recorded, and participants will submit weekly exercise diaries.
223733434|NCT04813094|OTHER|Control group|Patients in the control group will receive standard nurse consultations and three-time telephone coaching.
223733435|NCT00951665|DRUG|paclitaxel|Intravenous repeating dose
224021089|NCT03237039|OTHER|fall-risk assessment|This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.
224131363|NCT03616665|OTHER|CBASPersonalized|"In addition to CBASPersonalized patients will receive algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After completion of the six-week inpatient treatment, patients will be offered the six-to-twelve-week blended-online-aftercare CBASPersonalized@home.~Patients are allowed to attend additional inpatient groups like creative and sports therapy. The participation in these groups is documented."
224131364|NCT02036593|BEHAVIORAL|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
224131365|NCT02167841|BEHAVIORAL|Knee-Chest Position|
224131366|NCT02991157|DRUG|Nimodipine|
224131367|NCT06210191|PROCEDURE|Intramedullary headless screw fixation|fixation of fractures of metacarpals and phalanges by intramedullary headless screws
223733436|NCT00951665|DRUG|pertuzumab [Perjeta]|Intravenous repeating dose
224131368|NCT03959449|BEHAVIORAL|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
223733437|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
223733438|NCT00951665|DRUG|paclitaxel|Intravenous escalating dose
224131369|NCT03959449|BEHAVIORAL|Motor imagery|Motor imagery of running
224297123|NCT02277678|DRUG|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
224297124|NCT02277678|DRUG|Opioid administration morphine|
224297125|NCT00363753|DRUG|aspirin versus clopidogrel|
224297126|NCT00210613|DRUG|Dapoxetine|
223733439|NCT00951665|DRUG|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
223733440|NCT01575665|DEVICE|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
223733441|NCT01199289|DRUG|AMG 827|SC injection.
223733442|NCT01199289|DRUG|Placebo|SC injection.
223733443|NCT03980457|DEVICE|Indego Exoskeleton|Powered generated orthosis
223733444|NCT03980457|OTHER|Standard Rehabilitation|Standard Rehabilitation
223733445|NCT02074787|DEVICE|Thermography|Standard thermographic images
223733446|NCT02074787|DEVICE|Laser Doppler|standard laser doppler analysis
223733447|NCT02074787|DEVICE|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
223733448|NCT01657279|OTHER|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome \[i.e. from low (\<10%) to high (\>50%) expected risk death at 30 days\].
224131370|NCT03959449|BEHAVIORAL|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
224131371|NCT04507867|DIETARY_SUPPLEMENT|Nutritional support system (NSS)|"1. Combination of three B vitamins (B1, B6 and B12) Neurobion 10 mg solution for IM injection, One every 24 hours for the first 5 days.~2. Probiotics Saccharomyces boulardii CNCM I-745 Floratil. One morning and one evening 250 mg capsule during the first 6 days~3. One envelope of NSS-1 in the morning and one envelope in the afternoon mixed with 400 ml of water each, contain nutritional support system."
224297127|NCT03573960|DRUG|Lenvatinib|Lenvatinib capsules.
224297128|NCT02828592|DRUG|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
224297129|NCT02828592|DRUG|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
224297130|NCT02828592|RADIATION|Total Body Irradiation|300 cGy x1 dose (Day -1)
224297131|NCT02828592|DRUG|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
224021090|NCT03237039|OTHER|gait cycle analysis|This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
224021091|NCT01184144|DRUG|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
224021092|NCT00599885|DRUG|telmisartan|telmisartan 40-80mg once per day for 8 months
224021093|NCT00599885|DRUG|valsartan|valsartan 80-160mg once per day for 8 months
224021094|NCT00406523|DEVICE|JANUS Stent|
224021095|NCT02634489|DRUG|Tamsulosin HCl|Oral
224021096|NCT02634489|DRUG|Solifenacin Succinate|Oral
224021097|NCT02634489|DRUG|EC905|Oral
224131372|NCT04507867|OTHER|Conventional nutritional support designed by hospital nutritionists|Diet designed by the nutrition department according to comorbidities and intubation probability. Food will be established according to the provisions of the ISSEMYM Toluca Arturo Montiel Rojas Medical Center.
224138750|NCT02098057|DRUG|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
224297132|NCT02828592|DRUG|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
224021098|NCT01122251|DRUG|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
224021099|NCT01122251|DRUG|Lercanidipine or Valsartan|L10, L20, V80, V160
224021100|NCT01122251|DRUG|Placebo|Placebo of Lercanidipine and Valsartan
224297133|NCT05741645|OTHER|Kinesiotaping|During the kinesio taping of the erector spina vs multifidus muscles, the patient is in a standing position. Kinesiotape is applied with 50% tension and stays in the patient for 30 minutes.
224297134|NCT05741645|OTHER|Sham Kinesiotaping|The elastic taping will be randomly applied to a place outside the area to be measured, without stretching, and without causing any effect.
223400795|NCT07151170|OTHER|Supervised Pelvic Floor Muscle Training (S-PFMT) Group|In the supervised group, the protocol will be delivered by a physiotherapist in a clinical environment by face-to-face. The standardized Pelvic Floor Muscle Training protocol will be monitored exactly the same as Telerehabilitation group (TR-PFMT).
223552487|NCT01728142|DEVICE|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
223552488|NCT01728142|OTHER|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
223552489|NCT01709552|BEHAVIORAL|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
223552490|NCT01709552|BEHAVIORAL|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
223552491|NCT04853771|BEHAVIORAL|progressive muscle relaxation exercise training|Progressive muscle relaxation exercises (PKGE); 16 large muscles (right hand and forearm, right upper arm, left hand and forearm of left arm, left upper arm, forehead, upper cheek and nose, chin, neck, abdomen, upper right arm, which people can do on their own after learning) leg, right calf, right foot, left upper leg, left thigh and left foot), followed by the contraction and then relaxation and accompanied by deep breathing, is a preferred method for reducing pain, anxiety and depression in individuals.The relaxation will be required to take 10-20 before stretching the next muscle group. In this way, the muscle groups in the hands, arms, neck, shoulder, chest, abdomen, hips, feet and fingers, face and the whole body will be voluntarily stretched and relaxed, and pregnant women will be relieved.
223552492|NCT01276548|DRUG|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
223552493|NCT01276548|DRUG|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
223552494|NCT03318445|DRUG|Rucaparib|All participants will take rucaparib by mouth
223552495|NCT03318445|DRUG|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
223552496|NCT03089047|BIOLOGICAL|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
223552497|NCT03089047|BIOLOGICAL|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
223552498|NCT05305898|DRUG|Metformin|"Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation."
223552499|NCT02332785|OTHER|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
223552500|NCT02615418|DEVICE|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
223552501|NCT03599518|DRUG|DS-1205c|DS-1205c 200 mg capsule for oral administration
223552502|NCT03599518|DRUG|Gefitinib|Gefitinib 250 mg tablet for oral administration
223400796|NCT07152054|DEVICE|virtual forest bathing|"Virtual reality (VR) is an advanced computer technology and a novel technique used in healthcare to alleviate pain and provide patient comfort. It enables individuals to interact with a 360-degree virtual environment through a headset device. It has been observed that painful or emotionally stressful stimuli from the external world are diminished within the VR environment, with the individual's attention redirected and focused on this immersive setting.~In our study, a 20-minute VR video will be used, providing the sensation of walking through a calming 360-degree virtual forest environment accompanied by natural sounds, viewed through VR headsets. Unlike some commercially available VR headsets, the Oculus Quest 2 model will be utilized, as it serves as both the computer and display system, eliminating the need for a smartphone. This device is preferred for its ability to deliver high-quality video without interruptions that might negatively affect the VR experience.~After explaining"
223733449|NCT06299774|OTHER|Emergency care at home|A mobile integrated health paramedic under the direction of a remote emergency care physician will arrive at the patient's home and deliver emergency care.
223733450|NCT06299774|OTHER|Emergency care at a brick-and-mortar emergency department|Standard emergency care delivered in a brick-and-mortar emergency department.
223733451|NCT01978587|DRUG|JTZ-951|
223733452|NCT01586169|DRUG|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
223733453|NCT06376747|PROCEDURE|In line sampling|closed technique of sample collection
223733454|NCT06376747|PROCEDURE|Standard blood sampling technique|Blood draws using standard steps: blood withdrawal for catheter, decontamination (disposed),blood draw for laboratory analysis,catheter flush
223733455|NCT04711473|BEHAVIORAL|Colonoscopy Only|Mailed letter asking participants to complete CRC screening by colonoscopy
223733456|NCT04711473|BEHAVIORAL|Choice|Mailed letter and FIT test asking participants to complete CRC screening by their choice of either colonoscopy or mailed FIT
223733457|NCT04711473|BEHAVIORAL|FIT Only|Mailed letter and FIT test asking participants to complete CRC screening by mailed FIT
223733458|NCT05569187|DRUG|Ribociclib|Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
224021101|NCT04491669|DIAGNOSTIC_TEST|GFR - Glomerular Filtration Rate|"Chronic Renal Failure staging according to GFR by Chronic Renal Failure EPI is:~* Stage1 in which GFR\>90 mil/min but evidence of kidney damage.~* Stage 2 GFR 60-89 mil/min.~* Stage 3 GFR 30-95 mil/min.~* Stage 4 GFR 15-29 mil/min.~* Stage 5 GFR\<15 mil/min."
224297135|NCT05483387|DEVICE|Treatment with HBS 2 Resorb Mg|Treatment of fractures, arthrodesis or pseudarthroses of small bones and bone fragments
224297136|NCT04355949|DIAGNOSTIC_TEST|Serum vitamin D, vitamin B12, folic acid|Serum vitamin D, vitamin B12, and folic acid levels will be assessed
224297137|NCT05146349|OTHER|Minnesota RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
224297138|NCT01095679|DRUG|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
224297139|NCT01095679|DRUG|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
223400797|NCT07112170|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered as per institutional standard.
223733459|NCT04983576|PROCEDURE|spinal fusion|patients undergoing spinal fusion
223733460|NCT02602860|RADIATION|[11C]UCB-J|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 20 mCi~* Route of Administration: iv"
223733461|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 10 mg/ml~* Route of Administration: iv"
224021102|NCT05314790|OTHER|intervening Educational Program|The implementation of an EP is based on meetings within the Department, coordinated by an outside tutor (outreach visit model). The EP content was defined beforehand by a Scientific Board, on the basis of evidence-based guidelines (EBGs) and an up-to-date literature review, but also with a specific focus on any departures from standard clinical practice recommendations (CPRs) identified at each IM department in phase 1;
223733462|NCT02602860|DRUG|Levetiracetam|"* Pharmaceutical form: Sterile solution for intravenous infusion~* Concentration: 100 mg/ml~* Route of Administration: iv"
223733463|NCT02602860|DRUG|Brivaracetam|"* Pharmaceutical form: Tablets for oral intake~* Concentration: 25 mg~* Route of Administration: oral"
224021103|NCT00477334|DRUG|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
224021104|NCT00477334|DRUG|Placebo|oral; two tablets twice a day; single day treatment
224021105|NCT05985421|OTHER|Fecal collection|approximate volume of 2 ml
224021106|NCT05985421|OTHER|Blood sampling|1 EDTA tube (7 ml) to test for chronic low-grade inflammation + 1 EDTA tube (7 ml) to test for intestinal inflammation, digestive permeability and microbial translocation
224021107|NCT05985421|OTHER|Polysomnography|Polysomnography
224297140|NCT01227655|DRUG|BIA 9-1067|Capsules will be used.
224021108|NCT05985421|OTHER|Auto questionnaires|International RLS Study Group Severity Scale, Epworth Sleepiness Scale, Insomnia Severity Index, Beck Depression Inventory-II, Autonomic symtoms scale (SCOPA-AUT)
224297141|NCT01227655|DRUG|Placebo|comparator
224297142|NCT01227655|DRUG|Levodopa|
224297143|NCT01227655|DRUG|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
224297144|NCT01227655|DRUG|Benserazide|DOPA decarboxylase inhibitor
224021109|NCT04593927|DRUG|Mayzent|There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
224021110|NCT02270918|DRUG|Kcentra|IV infusion
224021111|NCT02270918|DRUG|Apixaban|
224021112|NCT02270918|DRUG|Placebo|
224021113|NCT04686201|DEVICE|Diabetes Mobile Application|incorporating mobile application usage in managing diabetes mellitus patient in health clinics
223733464|NCT05581537|OTHER|Systematic Desensitization|"Systematic desensitization: 2 techniques~1. Jacobson's technique (progressive muscle relaxation):~   It involves tensing and releasing muscles that progress through the body throughout focusing on mental relaxation throughout releasing muscle tension~2. Guided imagery (vividly imagining):~It includes 2 types of imagery training/mental practice (MP) which includes visual imagery is based on the sensory (visual) perception of the imagined movement and Kinesthetic imagery is based on sensory-motor information (proprioceptive). MP will be conducted in a quiet room, where each patient will be given detailed instructions to perform both visual and kinesthetic practice"
223400798|NCT07153328|DRUG|Silver Diamine Fluoride (SDF, 38%) and Sodium Fluoride Varnish (NaF, 5%)|Application of 38% silver diamine fluoride (SDF) to all active carious lesions at baseline and every 6 months (months 0, 6, 12, and 18, 24). In addition, a 5% sodium fluoride varnish (NaF) is applied to all teeth at 3-month intervals (months 3, 9, 15, 21). Applications are performed by a dentist using standard microbrush or applicator techniques, ensuring lesions coverage for SDF and full dentition coverage for NaF varnish. This alternating protocol evaluates whether combining periodic SDF with regular fluoride varnish enhances caries arrest in primary teeth compared to semiannual SDF alone.
223400799|NCT07153328|DRUG|Silver Diamine Fluoride (SDF, 38%)|Application of 38% silver diamine fluoride (SDF) to all active carious lesions at baseline and every 6 months (months 0, 6, 12, and 18, 24). Applications are performed by a dentist using a microbrush to directly cover the lesion surface until fully saturated. No additional fluoride varnish is provided in this arm. The protocol evaluates the effectiveness of semiannual SDF application alone for arresting active caries in primary teeth of young, uncooperative pediatric patients.
223400800|NCT07151144|OTHER|Massage|During the active phase of labor (cervical dilation of 4-7 cm), participants received 15-minute sessions of light-pressure massage to the lower back, sacrum, and lumbar area at regular intervals.
223400801|NCT07151144|OTHER|Shower|During the same phase, participants were assisted to take a warm shower for approximately 20 minutes.
223400802|NCT07152119|DRUG|Litfulo|as provided in real world practice.
223400803|NCT03525678|DRUG|Belantamab mafodotin frozen liquid|Belantamab mafodotin will be available as frozen liquid. Frozen liquid will be available as 30 milligram (mg)/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. Belantamab mafodotin will be administered as IV solution over at least 30 minutes. Frozen belantamab mafodotin will be diluted in 0.9 percent saline and administered via infusion pump.
223733465|NCT06368960|RADIATION|Radiotherapy|Radiation： Hypofractionated radiotherapy
223733466|NCT06368960|DRUG|BM201 injection|BM201 injection：Dose escalation：24mg to 240mg
223733467|NCT02723084|DRUG|ABT-493/ABT-530|Co-formulated tablet
223733468|NCT02723084|DRUG|sofosbuvir (SOF)|Tablet
224021114|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
223733469|NCT02723084|DRUG|ribavirin (RBV)|Capsule
223400804|NCT03525678|DRUG|Belantamab mafodotin lyophilized powder|Belantamab mafodotin will be available as lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 3.4 mg/kg. Lyophilized belantamab mafodotin will be reconstituted using water for injection and diluted with saline before use.
223733470|NCT02659709|DEVICE|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
223733471|NCT05029986|BEHAVIORAL|Socialization phase|Control condition: does not involve speech-related exercises
223400805|NCT02747108|BEHAVIORAL|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
223400806|NCT02747108|BEHAVIORAL|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
223733472|NCT05029986|BEHAVIORAL|Speech breathing intervention|Experimental condition: involves speech-related exercises
223733473|NCT04748315|OTHER|SEMT(1:1)|Soccer trainning protocolo will be performed on an work to rest ratio 1:1 and the trainning volume will consist of 1 set and 6 repetitions per set
223733474|NCT04748315|OTHER|SEMT (1:3)|Soccer trainning protocolo will be performed on an work to rest ratio 1:3 and the trainning volume will consist of 1 set and 6 repetitions per set
223733475|NCT02290509|BIOLOGICAL|Flublok Quadrivalent|Intramuscular injection of study vaccine
223733476|NCT02290509|BIOLOGICAL|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
223733477|NCT01718847|DRUG|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
223733478|NCT02533037|OTHER|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
224021115|NCT00913237|DRUG|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
224021116|NCT05202639|OTHER|Questionnaire|"A questionnaire will be sent by e-mail to the mother and to the father separately. A return of the completed questionnaire is expected within 6 weeks via a secure internal platform pertained to the HCL (Hospices Civils de Lyon).~The aim of this questionnaire is to identify the factors associated with the continuation or not of pregnancy after diagnosis of severe fetal pathology and after legal authorization of medical termination of pregnancy given by the Multidisciplinary Center of Prenatal Diagnosis."
224297145|NCT05291455|DRUG|Lacosamide|lacosamide will be given
224297146|NCT05291455|DRUG|Phenobarbital|phenobarbital will be given
223733479|NCT02533037|OTHER|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
223733480|NCT04900688|DEVICE|LithoVue Elite|LithoVue Elite is a disposable flexible ureteroscope that offer novel pressure sensory capacity
223733481|NCT04430933|DRUG|NC318|NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
223733482|NCT04430933|DRUG|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
223733483|NCT04430933|DRUG|Nab paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
223733484|NCT04430933|DRUG|Docetaxel|Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle
223733485|NCT01950923|DRUG|sildenafil citrate|Given PO
223733486|NCT01950923|OTHER|placebo|Given PO
223733487|NCT01950923|PROCEDURE|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
223733488|NCT00002670|DRUG|chemotherapy|
223733489|NCT00002670|DRUG|cisplatin|
223733490|NCT00002670|RADIATION|low-LET cobalt-60 gamma ray therapy|
223733491|NCT00002670|RADIATION|low-LET electron therapy|
223733492|NCT00002670|RADIATION|low-LET photon therapy|
223733493|NCT05577676|DRUG|Ultrasound-guided Hydrodissection of the Median Nerve|Hydrodissection for CTS includes injecting fluid around the median nerve (MN) with 5 ml volume, 3 ml of which is given in between the transverse carpal ligament \& MN, and 2 ml below the MN under Ultrasound guidance in-plane ulnar approach.
223733494|NCT00139399|PROCEDURE|Coronary artery bypass graft (CABG) surgery|Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
223733495|NCT06074913|OTHER|infrared thermography (IRT)|Temperatures and infrared thermograms were recorded in the region of the extremities of three groups of subjects by using an infrared thermographic camera.
223733496|NCT06074913|PROCEDURE|Basal therapy+EA|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen. 2. Acupoints: Qihai (RN6), Guanyuan (RN4), Xuehai (SP10), Yanglingquan (GB34), Zusanli (T36), Yinlingquan (SP9), Sanyinjiao (SP6), Xuanzhong (GB39), Jiexi (ST41), Zulinqi (GB41), Taichong (SP41). The electrode will be connected Yanglingquan (GB34) and Sanyinjiao (SP6), electrode wire will be connected to the electro-acupuncture apparatus using continuous wave with a frequency of 2Hz at an intensity suitable for the comfort of the subject.
223733497|NCT06074913|OTHER|Basal therapy|After specialist treatment, blood glucose is managed through hypoglycemic medications or insulin. Patients with both hypertension and hyperlipidemia are prescribed antihypertensive and lipid-lowering drugs. Additional medications are determined based on the patient's current medication regimen.
223733498|NCT04012385|BEHAVIORAL|lifestyle counseling|Nutritional plan and Physical activity goals
223733499|NCT02680028|DEVICE|targon pft nail|220 mm vs 175mm nail
223733500|NCT06245590|DRUG|Albumin|20 grams/ week Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (\>75 mm and \<90).
223733501|NCT06245590|DRUG|Midodrine|Midodrine
223733502|NCT06245590|OTHER|Standard of Care|Standard of Care
224021117|NCT00226031|PROCEDURE|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
224021118|NCT01028937|DEVICE|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
224021119|NCT02868385|DRUG|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
224021120|NCT02868385|DRUG|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
224021121|NCT02354508|DRUG|Pasireotide LAR|Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
224021122|NCT02907645|BEHAVIORAL|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
224021123|NCT02907645|BEHAVIORAL|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
224021124|NCT03587974|BEHAVIORAL|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
224021125|NCT00628004|DEVICE|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
224021126|NCT00628004|DEVICE|Local best practice|"N/A - since intervention is local best practice"
224021127|NCT01493232|OTHER|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
224021128|NCT03700073|OTHER|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
224021129|NCT03700073|OTHER|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
224021130|NCT02290132|DRUG|Rabbit Anti-human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
224021131|NCT03543657|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
224021132|NCT03543657|DRUG|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
223733503|NCT00876954|PROCEDURE|Normothermia|Warming without increase in core temperature
223733504|NCT00876954|PROCEDURE|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
223733505|NCT06371053|BEHAVIORAL|Community Intervention|"The intervention includes Cognitive Training: Activities targeting memory, attention, language, and executive functions to maintain cognitive abilities. This could involve cognitive games, memory exercises, and daily tasks.~Life Skills Training: Assistance in maintaining or relearning daily life skills such as personal hygiene, dressing, eating, and household chores. This could be through structured training programs and daily guidance.~Physical Exercise: Providing appropriate physical activities and exercises to maintain physical health and function, including walking, balance training, and light strength training.~Social Support: Organizing social activities and support groups to facilitate interaction and reduce social isolation and loneliness.~Emotional Support: Offering mental health support and psychosocial services to help individuals cope with emotional challenges such as anxiety and depression."
224021133|NCT03543657|DRUG|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
223733506|NCT03362398|DRUG|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
223733507|NCT03362398|DRUG|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
223733508|NCT01453257|DRUG|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
223733509|NCT04500834|BIOLOGICAL|Metal Panel T.R.U.E. Test|Diagnostic patch test
223733510|NCT03281954|DRUG|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~\+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
223733511|NCT03281954|DRUG|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~\+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
223733512|NCT00127712|DRUG|Amiodarone|
223733513|NCT02526407|BEHAVIORAL|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
223733514|NCT02526407|BEHAVIORAL|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
223733515|NCT03197506|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
223733516|NCT03197506|OTHER|Laboratory Biomarker Analysis|Correlative studies
223733517|NCT03197506|BIOLOGICAL|Pembrolizumab|Given IV
223733518|NCT03197506|RADIATION|Radiation Therapy|Undergo radiation therapy
224131373|NCT01643759|DRUG|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
224021134|NCT03543657|DRUG|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
224131374|NCT02403830|DRUG|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
224131375|NCT02403830|OTHER|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
224131376|NCT02403830|DRUG|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
224131377|NCT02403830|DRUG|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
224131378|NCT01261806|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
223400807|NCT06066749|OTHER|Filtration of all PM and VOC's|"During each exposure session, participants will wear a modified MaxAIR controlled air pressure respirator (CAPR) manufactured by Syntech International (BMD), Irvine, CA, USA, that will deliver filtered woodsmoke directly to the participant. The MaxAIR CAPR is a NIOSH approved (TC 21C-1050) powered air purifying respirator used for infectious disease control in laboratory and medical settings.~In the modified MAXAIR CAPR used during this study's exposure sessions, an external pump and different filtering media. For this intervention, virtually all particulate matter (PM) and volatile organic compounds (VOC's) will be removed using commercially available P100/VOC respirator filters (3M cartridge; 60925 or equivalent)."
223733519|NCT03197506|DRUG|Temozolomide|Given PO
223733520|NCT03197506|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224021135|NCT02438501|RADIATION|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
224021136|NCT02438501|RADIATION|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
223733521|NCT05140031|OTHER|PNE4Adults|"It is a clear and concise program, that consists of a manual for the physiotherapist delivering the education and a board game to enhance engagement and participant involvement. It not only provides the physiotherapist with a clear how-to manual but also provides an easy and accessible way for the patient to grasp the difficult and complex concept of pain."
224021137|NCT04447846|DRUG|Cannabidiol|Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
224021138|NCT00461032|DRUG|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
223733522|NCT05686447|OTHER|Observational studies, no intervention|Observational studies, no intervention
223733523|NCT05497713|OTHER|Mindsets|The primary objective of this trial is to determine whether mindsets sustain the feasibility of taking cold showers over a 3-month period.
223733524|NCT03433768|GENETIC|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
223733525|NCT06346964|OTHER|Health education|Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
223733526|NCT02642614|DRUG|BI 1026706|
223733527|NCT02642614|DRUG|Placebo|
223733528|NCT02642614|DRUG|Placebo|For blinding purposes
223733529|NCT01326416|DIETARY_SUPPLEMENT|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
223733530|NCT01326416|OTHER|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
223733531|NCT02450903|DRUG|LDK378|Oral LDK378 750mg once daily
223400808|NCT06066749|OTHER|Filtration of VOC's|"During each exposure session, participants will wear a modified MaxAIR controlled air pressure respirator (CAPR) manufactured by Syntech International (BMD), Irvine, CA, USA, that will deliver filtered woodsmoke directly to the participant. The MaxAIR CAPR is a NIOSH approved (TC 21C-1050) powered air purifying respirator used for infectious disease control in laboratory and medical settings.~In the modified MAXAIR CAPR used during this study's exposure sessions, an external pump and different filtering media. For this intervention, virtually all particulate matter (PM)will be removed using commercially available P100 respirator filters (DM; cat. # 2097)."
223400809|NCT06401421|DIAGNOSTIC_TEST|ctDNA MRD test|Blood and tissue samples will be collected for the ctDNA MRD test
223400810|NCT06299592|COMBINATION_PRODUCT|PET/MRI using [18F]FEPPA tracer|PET/MRI scans with \[18F\]FEPPA radiotracer selective for translocator protein (TSPO) binding, which is elevated in activated microglia
223400811|NCT03775174|DRUG|Mepsevii|
223400812|NCT06364488|DEVICE|TrueBlue App|The use of the TrueBlue App, to generate automated measures of mood that can be assessed for agreement with validated clinical scales eg. PHQ9.
223733532|NCT00604539|DRUG|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
223733533|NCT00604539|DRUG|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
223733534|NCT04412720|OTHER|Aerobic and Breathing Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, Buteyko Breathing Technique also will be performed during 20 minutes each exercise, in the same treatment session. During the first two weeks, the patient will learn the technique supervised by a physical therapist. In addition, the patients will receive a breathing exercise booklet for in-home training. Before and after each session, patients will be evaluated in relation to blood pressure, heart rate, oxygen saturation and asthma symptoms.
224021139|NCT00461032|DRUG|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
224131379|NCT01261806|BEHAVIORAL|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
224131380|NCT01288898|DRUG|ASP1941|Oral
224021140|NCT00760006|DRUG|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
224021141|NCT00760006|OTHER|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
224131381|NCT01288898|DRUG|Placebo|Oral
224131382|NCT01858155|DRUG|Melatonin|
224131383|NCT02417909|OTHER|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
223400813|NCT05585606|DRUG|Placebo|Volume Matched Placebo
223400814|NCT05585606|DRUG|scp776 (1.9 mg/kg)|"Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 1.9 mg/kg"
223400815|NCT05585606|DRUG|scp776 (3.8 mg/kg)|"Cohort 2 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~\- 3.8 mg/kg"
223400816|NCT05585606|DRUG|scp776 (4.8 mg/kg)|Cohort 3 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes - 4.8 mg/kg
223400817|NCT05585606|DRUG|scp776 (all dose levels)|A composite group encompassing all participants who received any dose level of the investigational drug under evaluation.
223400818|NCT01205815|OTHER|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
223400819|NCT03267433|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
224021142|NCT02355080|BEHAVIORAL|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
224021143|NCT02355080|BEHAVIORAL|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
223733535|NCT04412720|OTHER|Aerobic and Stretching Exercises|Aerobic exercises will be performed on a treadmill, twice a week, totaling 20 sessions of 60 minutes each. The initial intensity will be 50% to 60% of maximum heart rate and the progression will take place according to the level of effort (Borg) in the last two sessions. In addition, following the aerobic training, stretching exercises will be performing for major muscle groups, during 30 seconds each one. The patients will receive a stretching exercise booklet for in-home training.
223733536|NCT00421538|DRUG|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
223733537|NCT00421538|DRUG|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
223733538|NCT03767530|DEVICE|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
223733539|NCT03767530|OTHER|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
223733540|NCT03967964|DRUG|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
224021144|NCT01455805|DEVICE|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
224138751|NCT04935047|OTHER|Multilingual Support|Multilingual Support is a classroom intervention, which is designed to be delivered in classes of adult learning of a new language. The intervention involves the use of a language assistant, who is at minimum independent user (B1) in the language to be learned (in this case Norwegian), according to the language proficiency scale of the Common European Framework of Reference (CEFR) for languages, learning, teaching, assessment (Little, 2006). The language assistant will be in the classroom for seven hours a week, collaborating with the teacher in providing language training. In classrooms where participants have different primary languages, the language assistant(s) must cover all languages represented in the classroom.
223733541|NCT03967964|DRUG|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
223733542|NCT03967964|DRUG|Testosterone|Vaginal ring with 35 mg testosterone.
223733543|NCT03967964|DRUG|Testosterone Topical Gel|Gel containing 1% testosterone.
224138752|NCT00005023|BIOLOGICAL|HER-2/neu peptide vaccine|
223400820|NCT03267433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400821|NCT03267433|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow biopsy and aspirate
223400822|NCT03267433|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspirate
223400823|NCT03267433|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223400824|NCT03267433|PROCEDURE|Positron Emission Tomography|Undergo PET or PET/CT
223400825|NCT03267433|BIOLOGICAL|Rituximab|Given IV
223400826|NCT03267433|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
223733544|NCT03967964|DRUG|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
223733545|NCT03951740|DEVICE|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
223733546|NCT03951740|DEVICE|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
223733547|NCT03951740|DEVICE|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
223400827|NCT04756063|DRUG|Ascorbic acid|Intravenous vitamin C
223733548|NCT01164956|DRUG|methylphenidate|
223733549|NCT01164956|OTHER|Placebo|
223400828|NCT04756063|OTHER|Placebo|Normal Saline
223400829|NCT06104488|DRUG|Avutometinib|Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
223733550|NCT04693325|PROCEDURE|Prolonged normothermic machine perfusion|First, a cohort of DCD kidneys (n=6) will be subjected to 1 hour of NMP and subsequently transplanted \[NMP1\]. Before extending the duration, secondary endpoints will be evaluated. Thereafter, the duration of NMP will be prolonged to 3 hours (n=6) \[PNMP3\] and consequently 6 hours (n=6) \[PNMP6\].
223733551|NCT05796765|BIOLOGICAL|Micronized DHACM 40 mg|Injection of 40 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
223733552|NCT05796765|BIOLOGICAL|Micronized DHACM 100 mg|Injection of 100 mg allogeneic micronized dehydrated human amnion chorion membrane (DHACM) suspended in 2.5 mL, 0.9% Sodium Chloride, USP
224021145|NCT01455805|PROCEDURE|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
224021146|NCT04910607|OTHER|Questionnaire|"Questionnaire with 4 axes:~sociological, reflexive medical, prospective medical, transversal"
224021147|NCT04910607|OTHER|Interview|Interview concerning health pathways, experience of confinement, consequences of confinement on health, representations of obesity.
224021148|NCT00160862|DRUG|SLV317|
224021149|NCT00074971|DRUG|Fabrazyme (agalsidase beta)|
224021150|NCT03212300|BEHAVIORAL|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
224021151|NCT00767975|DRUG|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
224021152|NCT00767975|DRUG|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
223733553|NCT05796765|DRUG|Saline|Injection of 2.5 ml, 0.9% Sodium Chloride, USP
223733554|NCT03218553|DRUG|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
223733555|NCT03218553|DRUG|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
223733556|NCT02941965|PROCEDURE|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
223733557|NCT02941965|PROCEDURE|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
223733558|NCT01320085|DRUG|MEK162|
223733559|NCT06293170|OTHER|DETECT|DETECT periodically processes real-time data from the corresponding electronic medical record system to screen for a combination of coma, indicated by a Richmond Agitation Sedation Scale (RASS) score of - 4 or - 5 or Glasgow Coma Scale (GCS) score of 6-3, along with manually assessed absence of bilateral pupillary light reflexes. Both findings are considered early indicators of impending ILBF. In case of positive screening results, an automated notification will be sent via the hospital's email server to the corresponding transplant coordinators and intensivists. The email sent aims to prompt clinical assessment of the reported patient and, if necessary, initiate a guideline-based ILBF examination.
223400830|NCT06087445|DEVICE|NeuroLife EMG-FES Sleeve System|Participants will complete a 12-week training protocol (3x/week, 1-2 hours/session) which includes an activity-based upper extremity training paradigm where participants will complete multiple repetitions attempting functional tasks in different categories (grip, grip with rotation, pinch, and pinch with rotation) while using the closed-loop EMG-FES system on one forearm/hand. Each category includes \~10 functional tasks (e.g., grip - open a jar; pinch with rotation - nuts and bolts) that progressively increase in difficulty. Each session will include massed practice of 3 functional tasks (20-minute blocks for each task) with rest breaks as needed to avoid fatigue. Sessions will include \~60 minutes of task practice, but they may last 1-2 hours to account for setup time and rest breaks.
223400831|NCT03777215|DRUG|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
223400832|NCT03777215|DRUG|Saline|Saline will be used as the placebo comparator.
223400833|NCT06792981|OTHER|Universal primary prevention program based on ICTs|"The intervention adopts a multicomponent approach, addressing three agents in the prevention and management of eating disorders: parents, teachers and students.~1. Intervention with parents:~   Parents will receive specific materials, including an informative guide on early identification of warning signs, promoting healthy lifestyle habits, and fostering effective communication with their children.~2. Intervention with teachers:~   A two-hour in-person session will train teachers on platform use and provide tools for eating disorder prevention through role-playing techniques. Online resources will complement the training, while researchers ensure adherence via weekly follow-ups and parent reminders.~3. e-Preta program: The intervention for minors is delivered through an online platform, structured into 9 sessions of 45 minutes each, over 3 months. Weekly, platform-guided activities are proposed for classroom use with minimal teacher interaction, along with voluntary at-home activities."
223400834|NCT05763407|DEVICE|NORM™ System|NORM™ System
223733560|NCT06293170|OTHER|Conventional care|Conventional care
223733561|NCT03626922|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
223733562|NCT03626922|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
223733563|NCT03626922|DRUG|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
223733564|NCT03626922|DRUG|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
223733565|NCT03626922|DIETARY_SUPPLEMENT|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
223733566|NCT03626922|DIETARY_SUPPLEMENT|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
223733567|NCT03187093|DRUG|Vortioxetine|10-20 mg once daily for 8 weeks
223733568|NCT03187093|DRUG|Escitalopram|10-20 mg once daily for 8 weeks
223733569|NCT03807466|BEHAVIORAL|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
223733570|NCT03807466|BEHAVIORAL|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
223733571|NCT03966378|OTHER|Grape seeds extract|Grape seeds extract powder
223733572|NCT03966378|OTHER|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
223733573|NCT03060239|OTHER|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
223733574|NCT04949126|BEHAVIORAL|questionnaire|questionnaires of precarity, dental anxiety, self medication, pain
224021153|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 6 months
224021154|NCT03486457|OTHER|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
224021155|NCT03486457|DRUG|Tofacitinib|tablets, 5 mg BID x 3 months
224021156|NCT05657015|DRUG|Lepidium Sativum|2 ml of LS in situ gel at baseline
224021157|NCT05657015|DRUG|Simvastatin|1.2% of SMV in situ gel at baseline
224021158|NCT00038168|DRUG|Estramustine|Intravenous dose
223733575|NCT05956860|PROCEDURE|abdominopelvic vascular intervention through the radial artery access|"According to the pathological changes and needs of the subjects (any abdominal and pelvic arterial intervention that can be performed through the radial artery access, including but not limited to:~1. hepatic intervention, such as transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), etc.;~2. Other visceral intervention, such as spleen, kidney, mesentery, etc.;~3. Pelvic intervention, such as uterine artery embolism, prostatic artery embolism, etc.;~4. Others, such as preoperative embolization of bone tumors (lumbar, sacral vertebra), etc."
223733576|NCT04235049|DRUG|Glecaprevir/pibrentasvir|Treatment for HCV Infection
223733577|NCT03785431|DEVICE|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
223733578|NCT00618059|DRUG|Pilocarpine|
223733579|NCT02329561|DRUG|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
223733580|NCT02329561|BEHAVIORAL|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
223733581|NCT02329561|DRUG|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
223733582|NCT00454610|BEHAVIORAL|FLOW|
223733583|NCT00454610|BEHAVIORAL|SelfHelp|
223733584|NCT05947812|DRUG|Tafenoquine Oral Tablet|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
223733585|NCT05947812|DRUG|Placebo|Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and then weekly (Days 10 ± 1 day, 17 ± 2 days, 24 ± 2 days, 31 ± 2 days and 38 ± 2 days) until sustained clinical recovery.
223733586|NCT01317082|DEVICE|Acupressure|P 6 Pressure Point
224021159|NCT00038168|DRUG|Taxol|Intravenous dose
224021160|NCT00372229|DRUG|Valganciclovir CMV Prophylaxis|900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.
223733587|NCT05411679|DRUG|EP0057|EP0057 is an investigational nanoparticle-drug conjugate with a Camptothecin payload, that is administered intravenously
223733588|NCT05411679|DRUG|Olaparib tablets|Olaparib is a PARP inhibitor (poly \[adenosine diphosphate-ribose\] polymerase inhibitor) Other names: Lynparza
223733589|NCT01549093|DRUG|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
224131384|NCT05290142|OTHER|Digital Training with Coaching (DT-C)|An identical digital training course and helpline will be available for the participants in this group. In addition to receiving the same digital training resources as the DT group, participants in DT-C will receive weekly individualized telephone calls from a coach who will motivate them and troubleshoot towards course completion. The focus will be on clarifying learning objectives and redirecting participants to relevant materials rather than providing new learning opportunities. Participants will also be able to send text messages to coaches with queries related to course content, progress and technical difficulties. Coaches will reply to participants' messages within one working day and send reminders about upcoming telephone sessions, as well as prompts if the participant has not logged into the course for 3 consecutive days.
224131385|NCT05290142|OTHER|Self-Guided Digital Training|Participants will be enrolled in a digital training course that addresses non-specific counselling skills and skills specific to an evidence-based problem-solving intervention. The course will be available offline and online on a smartphone app (called 'Sangath Training') as well as a website (https://training.sangath.in/login/index.php) that can be accessed through an internet-enabled device. The training will be delivered through didactic lectures, role-play demonstrations, and recommended readings spread across 16 modules. Participants will be provided with automated feedback on their learning through self-assessment quizzes after each module. Modules will be available sequentially and unlocked after accessing all content in the preceding module, over a period of 4 weeks. Technical helpline: Participants will also have an option to message a centralized helpline for assistance with accessing and navigating the digital interface.
223733590|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
223733591|NCT01549093|DRUG|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
224021161|NCT00372229|DRUG|Valganciclovir (Pre-emptive CMV Therapy)|If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
224021162|NCT00372229|DRUG|Ganciclovir|If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
223733592|NCT02029625|DRUG|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
223400835|NCT04563754|DIAGNOSTIC_TEST|mHRME (Mobile High resolution microendoscope)|"Standard of care (SOC) high-resolution anoscopy (HRA) with Lugol's iodine will be performed. The unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~1. contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)),~2. the mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both SOC HRA and experimental mHRME imaging."
223733593|NCT02029625|DRUG|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
223733594|NCT04669483|OTHER|evidence-based informed consent form|Evidence-based informed consent forms for total knee arthroplasty and related anesthesia procedures will be developed. The design of the evidence-based informed consent forms will be guided by an existing guideline on how to present evidence-based health information (guideline evidence-based health information) and nocebo research. The information will be presented in plain language. Benefits and harms of the procedures will be presented in absolute risk formats and in comparison with other interventions or placebo. Verbal presentations of risks lead to overestimations of risks and therefore, will not be applied exclusively. Gain and loss framing will be combined. To visualize important aspects, pictograms will be used. Information on uncertainty, missing or low quality evidence will be provided.
224021163|NCT00283218|DRUG|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
224131386|NCT01078701|BIOLOGICAL|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
224131387|NCT01078701|BIOLOGICAL|Placebo|SPGN buffer
224131388|NCT04357119|PROCEDURE|One-anastomosis gastric bypass|"Laparoscopic single anastomosis gastric bypass is reported to be a safe alternative to LRYGB, showing comparable efficacy in weight reduction and resolution of metabolic complications with reduced surgical complications.~The advantages with this technique as claimed by those speaking in favor of it are many: fewer sites for leakage and internal hernia, easier and faster to learn and perform, easy to reverse and revise, and with results at least comparable with the result following standard Roux-en-Y gastric bypass (RYGB).~The length of the biliopancreatic limb in single anastomosis gastric bypass as reported by Rutledge is fixed 200 cm starting at the duodenojejunal junction, neglecting the length of the common limb.~Because of deficient data regarding the effect of common limb length on the outcome of LSAGB, so a clinical trial shall add new knowledge regarding sufficient weight loss, rate of complications and the need for revision."
224131389|NCT01790971|DRUG|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
224131390|NCT01790971|DRUG|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
223733595|NCT00258882|BIOLOGICAL|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
223733596|NCT01973647|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
223733597|NCT01973647|BEHAVIORAL|COPD Education|Six weekly sessions of COPD education
223733598|NCT01973647|BEHAVIORAL|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
223400836|NCT04563754|DRUG|Proflavine Hemisulfate|Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
223400837|NCT04563754|DIAGNOSTIC_TEST|High resolution anoscopy|Standard of care (SOC) HRA with Lugol's iodine will be performed.
223400838|NCT06313970|DRUG|QL1706|QL1706 5mg/kg，IV，D1, Q3W
223400839|NCT06313970|DRUG|Nab-paclitaxel|Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W
223400840|NCT06313970|DRUG|Gemcitabine|gemcitabine，1000mg/m2，IV，D1、8；Q3W.
223733599|NCT02845245|OTHER|3D printed plastic model prototype|
223733600|NCT02845245|OTHER|3D CT scan|
223733601|NCT02845245|OTHER|Plain film radiographs|
223733602|NCT02040454|DRUG|Paclitaxel|
223733603|NCT02040454|PROCEDURE|Standard Therapy|
223733604|NCT04791566|DRUG|Dexamethasone 1 mg/kg|Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
223733605|NCT04791566|DRUG|Physiologic saline|100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
223733606|NCT02014896|OTHER|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
223733607|NCT00953446|PROCEDURE|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
223733608|NCT00834860|DRUG|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
223733609|NCT03645980|DRUG|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
223733610|NCT03645980|DRUG|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
223733611|NCT03645980|DRUG|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
224021164|NCT01378923|BEHAVIORAL|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
224021165|NCT01378923|BEHAVIORAL|TAU|have access to standard jail programs and services
224021166|NCT00783900|OTHER|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
224021167|NCT03133052|BEHAVIORAL|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
223552503|NCT00709150|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
223733612|NCT01842256|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* 3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
223733613|NCT01842256|DRUG|atorvastatin 40mg|"* 1 Tablet (atorvastatin 40mg),~* oral intake, once in a period~* over the period Ⅰ\&Ⅱ(crossover)"
223733614|NCT02328755|DRUG|peg-IFN-α|
223733615|NCT02328755|PROCEDURE|Hematopoietic Cell Transplant (HCT)|
224021168|NCT03133052|BEHAVIORAL|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
223733616|NCT02328755|DRUG|Tacrolimus|Calcineurin inhibitor administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis. Cyclosporine may be substituted if patients cannot tolerate tacrolimus.
223733617|NCT02328755|DRUG|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
223733618|NCT03253887|DRUG|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
223733619|NCT03877289|DRUG|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
223733620|NCT03877289|OTHER|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
223733621|NCT03877289|DRUG|Antibiotics|"All patients in treatment and control arms were treated as a co-intervention with an oral antibioitic, the type of which was chosen by the child's attending physician.~Possible prescribed antibiotics include: trimethoprim and sulfamethoxazole (Septra), Cefalotin, Cephalexin, Cefapirin, Cefdroxil, Cefazolin, Cefradine, Cefacetrile, Cefaloridine, Cefroxadine, Cefatrizine, Cefuroxime, Cefixime, amoxicillin/clavulanic acid (Clavulin), and Nitrofurantoin."
224131391|NCT03416738|BEHAVIORAL|Semantically focused treatment|"Tasks are as follows:~1. Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~2. Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~3. Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
223400841|NCT06313970|DRUG|Bevacizumab|bevacizumab, 7.5mg/kg，IV，D1；Q3W.
223400842|NCT04023396|DRUG|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks."
223733622|NCT03838133|DRUG|TLC590|TLC590, a sustained-release formulation of the local anesthetics with lipid-based excipients
223733623|NCT03838133|DRUG|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
223400843|NCT06452940|OTHER|Exercise|A 16-week clinical pilates exercise program will be applied 3 days a week for 60 minutes each session. It will consist of a warm-up, main exercise and a cool-down period.Exercises will start with 10 repetitions and will be gradually increased in 3-week periods.
223400844|NCT06500845|OTHER|Bevel marginal design endocrown for endodontically treated teeth|Bevel marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
223400845|NCT06500845|OTHER|Butt marginal design endocrown for endodontically treated teeth|Butt marginal design will be prepared for endodontically treated teeth and restores with Peek endocrown
223400846|NCT05127226|DRUG|ION582|ION582 will be administered by IT injection.
223733624|NCT03838133|DRUG|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
223733625|NCT03838133|DRUG|Bupivacaine|Bupivacaine 50 mg (0.5%, 10 mL)
224138753|NCT00005023|BIOLOGICAL|sargramostim|
224138754|NCT04612153|OTHER|Epidemiologic|Epidemiologic study. Observational, transverse study
223400847|NCT03140748|OTHER|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
223400848|NCT04075825|OTHER|Placebo|Darvadstrocel placebo-matching eASCs intralesional injection received in previous ADMIRE-CD II study. No drug administration in this study.
223400849|NCT04075825|BIOLOGICAL|Darvadstrocel|Allogenic expanded adipose-derived stem cells (eASCs) 5 million cells/ml - suspension for injection darvadstrocel received in previous ADMIRE-CD II study. No drug administration in this study.
223552504|NCT00709150|BEHAVIORAL|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
224021169|NCT02619487|OTHER|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
224021170|NCT02619487|OTHER|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
224021171|NCT06153953|DEVICE|vacuum device|use of vacuum device in dressing of diabetic wounds
224021172|NCT06153953|OTHER|conventional dressing therapy|us of conventional dressing with betadine and iruxol in diabetic wounds
224021173|NCT02797574|PROCEDURE|Punch Biopsy at a Lesional Site|
224021174|NCT02797574|PROCEDURE|Punch Biopsy at a Non- Lesional site|
223400850|NCT04428554|RADIATION|Experimental arm|Consolidative radiotherapy (pelvic irradiation and/or metastases irradiation) + standard of care +/- previous transurethral resection of bladder tumor
223733626|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
224021175|NCT04298021|DRUG|AZD6738|"* In AZD6738+Durvalumab cohort~  \- AZD6738 240 mg bid on D15-D28 Every 4 weeks~* In AZD6738+ Olaparib cohort - AZD6738 160 mg qd on D1-7 Every 4 weeks"
224021176|NCT04298021|DRUG|Durvalumab|Durvalumab 1500 mg iv on D1 Every 4 weeks
224021177|NCT04298021|DRUG|Olaparib|Olaparib 300 mg bid on D1-28 Every 4 weeks
224021178|NCT00139191|PROCEDURE|C-11 acetate PET scan|
224021179|NCT05248074|OTHER|High-fat meal (over 900 kcal)|High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
223733627|NCT00129454|BEHAVIORAL|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
223733628|NCT02046356|PROCEDURE|MESS-RFA|
223733629|NCT05087784|COMBINATION_PRODUCT|Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps|Patient-centered, technology-supported integrated survivorship- and care management
223733630|NCT00060112|BIOLOGICAL|oblimersen sodium|Given IV
223733631|NCT00060112|DRUG|gemcitabine hydrochloride|Given IV
223733632|NCT00060112|OTHER|pharmacological study|Correlative studies
223733633|NCT00060112|OTHER|laboratory biomarker analysis|Correlative studies
223733634|NCT05060159|OTHER|Hemofiltration|Postdilutional Hemofiltration
224021180|NCT05248074|DRUG|ABN401 (investigational product)|The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
224131392|NCT03416738|BEHAVIORAL|Phonologically focused treatment|"Tasks are as follows:~1. Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~2. Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~3. The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
224131393|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
224021181|NCT04059419|BEHAVIORAL|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
224131394|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
223400851|NCT05972018|DRUG|Liposomal bupivacaine|Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)
223400852|NCT05972018|DRUG|Ropivacaine|Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)
223400853|NCT05972018|DRUG|Bupivacain|Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)
223400854|NCT04907097|DIETARY_SUPPLEMENT|Monomeric and oligomeric flavanols|Monomeric and oligomeric flavanols will be derived from Vitis vinifera seeds extract.
223400855|NCT04907097|OTHER|Placebo|Placebo capsuled will be used as a comparator.
223400856|NCT01820117|OTHER|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
223400857|NCT01820117|OTHER|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
223400858|NCT01820117|OTHER|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
223400859|NCT01820117|OTHER|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
223733635|NCT00003514|DRUG|antineoplaston A10|
223733636|NCT00003514|DRUG|antineoplaston AS2-1|
223733637|NCT00003514|PROCEDURE|alternative product therapy|
223733638|NCT00003514|PROCEDURE|biological therapy|
223733639|NCT00003514|PROCEDURE|biologically based therapies|
223733640|NCT00003514|PROCEDURE|cancer prevention intervention|
223733641|NCT00003514|PROCEDURE|complementary and alternative therapy|
223733642|NCT00003514|PROCEDURE|differentiation therapy|
223733643|NCT05022784|DRUG|Nintedanib|Nintedanib
223733644|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose|50μg/dose
223733645|NCT05549206|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high dose|100μg/dose
223733646|NCT05549206|DRUG|Placebo|Saline solution
224021182|NCT04059419|BEHAVIORAL|Geriatric Care|Remain under geriatric care as usual
224131395|NCT01506752|DRUG|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
223400860|NCT01820117|OTHER|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
223733647|NCT01711177|DRUG|placebo|Placebo
224021183|NCT01878214|BEHAVIORAL|Targeted messaging|6 targeted mailed messages and 6 booster text messages
224021184|NCT01878214|BEHAVIORAL|Standard messaging|1 informational letter
224021185|NCT03568331|DRUG|Tradipitant|Oral Capsule
224021186|NCT03568331|DRUG|Placebo|Oral Capsule
223400861|NCT01820117|OTHER|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
223400862|NCT01820117|OTHER|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
223400863|NCT01820117|OTHER|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
223400864|NCT01820117|PROCEDURE|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
223400865|NCT01820117|OTHER|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
223400866|NCT00351624|BEHAVIORAL|DHA|
223400867|NCT00351624|BEHAVIORAL|placebo|
223400868|NCT04871542|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223400869|NCT04871542|OTHER|Questionnaire Administration|Complete questionnaires
223400870|NCT03589261|DEVICE|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
223400871|NCT04975152|DRUG|Cemiplimab-Rwlc|Flat dose of cemiplimab-rwlc 350 mg IV every 3 weeks, up to 9 cycles.
223400872|NCT04597359|DRUG|Placebo Administration|Given PO
224021187|NCT01553305|OTHER|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
224021188|NCT01553305|OTHER|Exercise programme|Supervised exercise programme
223400873|NCT04597359|OTHER|Quality-of-Life Assessment|Ancillary studies
224021189|NCT03363763|DRUG|Sirolimus 0.2%|Ointment for topical administration hs x 12 weeks
224131396|NCT01506752|DRUG|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
224131397|NCT05792670|PROCEDURE|Changing mechanic ventilatation parameters|The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
224131398|NCT04273399|OTHER|High-impact exercise intervention|"* Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading"
223400874|NCT04597359|OTHER|Questionnaire Administration|Ancillary studies
223400875|NCT04597359|DRUG|Sinecatechins|Given PO
223400876|NCT04433234|DRUG|DS-5141b|Administered via subcutaneous injection once weekly
223400877|NCT05801029|DRUG|Osimertinib|Osimertinib will be administered as 80 mg oral tablet once daily (from Day 2) until progression of disease or until a study intervention discontinuation criterion is met.
223552505|NCT01596712|DRUG|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
223552506|NCT01596712|DRUG|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
223552507|NCT01973010|OTHER|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
223552508|NCT01973010|DRUG|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
223552509|NCT01927523|BEHAVIORAL|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
223552510|NCT01927523|OTHER|Match|An intensive math tutoring program.
223552511|NCT02175485|DRUG|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
223552512|NCT00153595|DRUG|EWO1|
223552513|NCT01658605|DRUG|GSK1605786|500 mg twice daily administered orally
223552514|NCT01658605|OTHER|Placebo|500 mg twice daily administered orally
223552515|NCT05013021|OTHER|Sprint Interval Training|"The Sprint Interval Training (SIT) training consists of 3 successive blocks of 5 training sessions each. The sessions are 24 to 48 hours apart.~. One block lasts two weeks. After the end of one block, the following block begins the day after.~The Sprint Interval Training lasts 6 weeks.~Each session consists of a series of sprints, the number of which varies from 8 to 14. Thus a session will last from 30 to 45 min approximately~So, the time frame of this study is Baseline, Block 1, Block 2 and Block 3 (Not in day or week or month)"
223552516|NCT03144336|BEHAVIORAL|Information provision|All study participants will receive weekly messages with HIV prevention information.
223552517|NCT03144336|BEHAVIORAL|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
223552518|NCT03144336|BEHAVIORAL|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
223552519|NCT01413295|DRUG|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
224021190|NCT03363763|DRUG|Sirolimus 0.4%|Ointment for topical administration hs x 12 weeks
224131399|NCT04273399|OTHER|Acute response to high-impact exercise|"* First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise"
224131400|NCT03892330|DRUG|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
224131401|NCT03892330|DRUG|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
223733648|NCT01711177|DRUG|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
223733649|NCT02295150|DRUG|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
224131402|NCT03892330|DRUG|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
224131403|NCT03892330|DRUG|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
223400878|NCT05801029|DRUG|Amivantamab|Amivantamab will be administered as an IV infusion at 1050 mg (\< 80 kg body weight) or 1400mg (≥ 80 kg body weight) (in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1 to 2) and then every 2 weeks in subsequent cycles) until progression of disease or until a study intervention discontinuation criterion is met. The first cycle dose is spilt over 2 days- 350 mg on day 1 and 700 mg \[body weight \< 80 kg\] or 1050 mg \[body weight ≥ 80 kg\] on day 2.
223400879|NCT06830395|BIOLOGICAL|CM313|CM313(SC) injection
223552520|NCT01413295|OTHER|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
223733650|NCT05195112|DRUG|MT921|Active ingredient
223733651|NCT05195112|DRUG|Placebo|Normal Saline
223733652|NCT03020407|PROCEDURE|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
223733653|NCT03020407|DRUG|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
223733654|NCT03020407|DRUG|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
223733655|NCT05715008|OTHER|Kefir|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
224131404|NCT03892330|DRUG|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
224131405|NCT03892330|DRUG|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
224131406|NCT05315232|OTHER|survey and interview|qualitative assessment
224131407|NCT02850991|RADIATION|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
223400880|NCT06830395|DRUG|Placebo|Matched placebo
223400881|NCT01815541|DRUG|teicoplanin|
223552521|NCT01625416|BEHAVIORAL|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
223552522|NCT00508105|PROCEDURE|subscapularis peel|"Detachment of the subscapularis tendon from its insertion on the lesser tuberosity the peel."
223552523|NCT00508105|PROCEDURE|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
223733656|NCT05715008|OTHER|Placebo|Comparison of kefir and placebo consumption for 2 weeks on various parameters in healthy adult subjects
223733657|NCT05951010|DEVICE|Transcranial Direct Current Stimulation|Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
223733658|NCT03835585|DEVICE|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
223733659|NCT03835585|OTHER|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
224021191|NCT03363763|DRUG|Placebo ointment|Placebo ointment comparator for topical administration hs x 12 weeks
224021192|NCT01365949|GENETIC|microarray analysis|
224021193|NCT01365949|GENETIC|protein analysis|
224021194|NCT01365949|OTHER|immunohistochemistry staining method|
224021195|NCT01365949|OTHER|laboratory biomarker analysis|
224021196|NCT04513184|DRUG|IV Dexamethasone|6 mg from Day 1 to 10 after randomization
224021197|NCT04513184|DRUG|Nasal Dexamethasone|0.12 mg/kg/daily for 3 days from day 1, followed by 0.06 mg/kg/daily from day 4 to 10 after randomization.
224021198|NCT02878681|DRUG|Ranibizumab|0.5 mg intravitreal injections
224131408|NCT02850991|RADIATION|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
224131409|NCT03349541|OTHER|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
224131410|NCT04894786|OTHER|Mulligan Internal Rotation Mobilization|Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
224131411|NCT04894786|OTHER|Post Isometric Relaxation Technique|Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
223733660|NCT03835585|BEHAVIORAL|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
223733661|NCT03835585|BEHAVIORAL|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
223733662|NCT00607529|OTHER|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
223733663|NCT05221814|DIAGNOSTIC_TEST|gross pathologic photo based deep learning model|Whether apply gross pathologic photo based deep learning model to predict pathologic subtype
223733664|NCT06085079|DRUG|Ixekizumab Prefilled Syringe|Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.
223733665|NCT04375189|OTHER|High Risk Clinic|"Subgroup of primary care clinic where patients have longer time slots, supervision by one longitudinal attending, bedside presentations"
224131412|NCT02215408|BEHAVIORAL|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
224131413|NCT06402812|OTHER|Interview|A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
224131414|NCT00301028|BIOLOGICAL|Cetuximab|Beginning weekly dose 400 mg/m\^2 IV over 1-2 hours, and 250 mg/m\^2 weeks 2-6.
224131415|NCT00301028|DRUG|Carboplatin|AUC 2 weekly for 6 courses.
224131416|NCT00301028|DRUG|Paclitaxel|135 mg/m\^2 weekly for 6 courses.
224131417|NCT00301028|PROCEDURE|Conventional Surgery|Following induction in second part of study.
224131418|NCT00301028|RADIATION|Radiation Therapy|Following induction in second part of study.
224131419|NCT00000150|PROCEDURE|Subfoveal Choroidal Neovascularization Removal|
224131420|NCT03363412|DEVICE|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
224131421|NCT01954251|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
224131422|NCT01954251|BIOLOGICAL|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
224131423|NCT01345344|BEHAVIORAL|Cognitive Behavioral Therapy|Practicing certain cognitive and behavioral pain self-management strategies such as relaxation and changing negative thoughts about pain.
224131424|NCT01345344|BEHAVIORAL|Disease Education|Providing information about fibromyalgia, including its potential causes and management approaches.
224131425|NCT01899859|DRUG|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
224131426|NCT01899859|DRUG|Placebo|GR-MD-02 Placebo
224131427|NCT05108220|DIETARY_SUPPLEMENT|Cannabidiol (CBD)- containing consumer products|Oils or capsules containing CBD which could be purchased commercially within the U.S.
223733666|NCT00708162|DRUG|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
223733667|NCT00708162|DRUG|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
223733668|NCT00708162|DRUG|EVG placebo|Placebo to match elvitegravir administered orally once daily
223733669|NCT00708162|DRUG|RAL placebo|RAL placebo administered orally twice daily.
223733670|NCT00708162|DRUG|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
223733671|NCT02425150|PROCEDURE|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
223733672|NCT02425150|PROCEDURE|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
223733673|NCT05590065|DEVICE|ABLE Exoskeleton|The ABLE Exoskeleton is a lower-limb overground robotic exoskeleton intended for SCI patients for rehabilitation in a clinical setting.
224131428|NCT00877669|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
224131429|NCT00877669|PROCEDURE|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
224131430|NCT01413841|DRUG|Nasal oxygen|3 l oxygen
224131431|NCT01413841|DRUG|Regular nasal air|3 l nasal air
224131432|NCT02701686|BEHAVIORAL|quit immediately (QI)|advise to quit immediately using the AWARD model
223400882|NCT05681767|BEHAVIORAL|Motivational multicomponent lifestyle intervention + Treatment as usual|"Study intervention and treatment as usual~The study intervention is a multicomponent lifestyle intervention that targets exercise, diet, and stress management, and is conducted by motivational interviewing. The study nurse provides the study intervention. The intervention is conducted by motivational interviewing and includes the key elements of lifestyle interventions identified as effective (assessment of behavior at the baseline, giving information and advising, individualized goal setting, setting an action plan, monitoring a behavioral change, and giving feedback).~The intervention consists of individual appointments (2 x 45-60 min) and a telephone session ( 2 x 15 min) for three months. The participants receive a short educational guide (A4) on the lifestyle behavior recommendations."
224131433|NCT02701686|BEHAVIORAL|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
224131434|NCT00779324|DRUG|Amantadine Hydrochloride|100 mg every morning and noon
224131435|NCT00779324|DRUG|Placebo|one placebo tablet every morning and 12 Noon
223400883|NCT05681767|OTHER|Treatment as usual|Treatment as usual
223400884|NCT06514261|DRUG|Azacitidine|Given IV or SC
223400885|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223400886|NCT06514261|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400887|NCT06514261|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223400888|NCT06514261|PROCEDURE|Buccal Swab|Undergo buccal swab
223733674|NCT03858088|PROCEDURE|Liver transplantation|Liver transplantation from deceased donors
223733675|NCT04320381|BEHAVIORAL|Qualitative Interview|2 Semi-Structured Qualitative Interviews
223733676|NCT00830843|DRUG|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
223733677|NCT00830843|DRUG|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
223733678|NCT04212247|BEHAVIORAL|Well-Being Therapy|Well-Being Therapy (WBT) is a short-term psychotherapeutic strategy, that emphasizes self-observation with the use of a structured diary, interaction between patients and therapists and homework. WBT was based on the model of psychological well-being that was originally developed by Jahoda in 1958 and further refined by Ryff in 2014. The standard number of sessions is 8. The initial phase is concerned with self-observation of psychological well-being. Then, the patient is encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of wellbeing. The final part involves cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
224021199|NCT02878681|DRUG|Aflibercept|2 mg intravitreal injections
224021200|NCT00129597|DRUG|ketalar|
224021201|NCT00093808|BIOLOGICAL|trastuzumab|
224021202|NCT00093808|DRUG|capecitabine|
224021203|NCT00093808|DRUG|vinorelbine tartrate|
223400889|NCT06514261|DRUG|Iadademstat|Given PO
223400890|NCT06514261|DRUG|Venetoclax|Given PO
223400891|NCT02978625|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223400892|NCT02978625|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400893|NCT02978625|PROCEDURE|Computed Tomography|Undergo CT
223400894|NCT02978625|OTHER|Laboratory Biomarker Analysis|Correlative studies
224021204|NCT02647866|DRUG|KHK4083|IV Infusion
224021205|NCT02647866|DRUG|Placebo|IV Infusion
224021206|NCT02931071|DRUG|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
224021207|NCT02931071|DRUG|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
224021208|NCT04061538|DIETARY_SUPPLEMENT|zinc sulfate|zinc 20mg tablets
224021209|NCT04061538|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
224021210|NCT02222636|DRUG|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
223400895|NCT02978625|BIOLOGICAL|Nivolumab|Given IV
223400896|NCT02978625|PROCEDURE|Positron Emission Mammography|Undergo PET/CT
223400897|NCT02978625|BIOLOGICAL|Talimogene Laherparepvec|Given IT
223400898|NCT06414590|DRUG|Tebentafusp-Tebn|Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.
223400899|NCT05557292|DRUG|RMC-5552|Given IV
224131436|NCT05667792|DEVICE|Microsoft Kinect 360|Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
224131437|NCT05667792|OTHER|Pediatric Rehabilitation|Bobath therapy
223733679|NCT04212247|BEHAVIORAL|Control condition|The control condition will include 8 sessions that will inform participants about well-being and lifestyles which can influence it. They will be articulated as follows. Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drug misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
223733680|NCT02699554|PROCEDURE|Single-event multilevel surgery|
223733681|NCT00708643|DEVICE|Habitual Silicone Hydrogel Contact Lens|contact lens
224021211|NCT02222636|DRUG|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
224021212|NCT02222636|DRUG|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
223400900|NCT06039358|DIETARY_SUPPLEMENT|Caffeine.|Ingestion of opaque capsules with a total dose of 6mg/kg of caffeine, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
223400901|NCT06039358|DRUG|Cellulose.|Ingestion of opaque capsules with cellulose, 60 minutes before the beginning of the assessed exercises. A crossover with the other intervention will be done in the next/previous session (depending on the arm).
223400902|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg QD hard capsules
223400903|NCT03874858|DRUG|Nilotinib|Nilotinib oral 300 mg BID hard capsules
223400904|NCT03874858|DRUG|Asciminib|Asciminib orally at a dose of 40 mg BID film-coated tablets (FCT)
223400905|NCT05279651|DRUG|Ivabradine|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
223400906|NCT05279651|DRUG|Placebo|Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
223400907|NCT06308614|DRUG|20 mg estetrol monohydrate|Active treatment
223400908|NCT06308614|OTHER|Placebo|Matching Placebo to E4
223400909|NCT06682871|PROCEDURE|Analgesia|Postoperatively, patients will be given analgesia
223400910|NCT05599581|BEHAVIORAL|Tu'Washindi|"Tu'Washindi consists of 3 primary components:~1. PrEP Adherence Support Clubs: Eight 2-hour sessions that occur over the intervention period: twice per month for the first 2 months \& once per month for the remaining 4 months. Sessions will use structured \& unstructured activities designed to improve outcomes expectations, increase self-efficacy to use PrEP safely \& consistently, increase peer support for PrEP use, provide access to community IPV resources \& provide skills for healthy communication \& PrEP disclosure with male partners.~2. Community Male Sensitization conducted weekly over the first 3 months of the intervention period aimed to increase PrEP knowledge, reduce stigma, \& promote healthy relationship communication.~3. Buddy Days, which take place 3 months into the intervention period, designed to bring participants \& their male partners together to learn about PrEP, discuss community attitudes \& concerns regarding PrEP use, \& promote HIV prevention \& family well-being."
223400911|NCT04772131|DEVICE|Desara® One Single Incision Sling|Single incision sling
223400912|NCT04772131|DEVICE|Desara® Blue Transobturator Sling|Standard mid-urethral sling
223400913|NCT06057038|BIOLOGICAL|GEN1042|Intravenous
223400914|NCT06057038|DRUG|Pembrolizumab|Intravenous
224021213|NCT02222636|DRUG|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
223733682|NCT00708643|DEVICE|narafilcon A|contact lens
223400915|NCT06057038|DRUG|Cisplatin|Intravenous
224021214|NCT02222636|DRUG|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%\~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
224021215|NCT02769546|OTHER|Surveys|
223400916|NCT06057038|DRUG|Carboplatin|Intravenous
223400917|NCT06057038|DRUG|5-Fluorouracil|Intravenous
223400918|NCT06169449|BEHAVIORAL|Weight management--diet|The diet structure adopts an energy-limited balanced diet. In this structure, the total daily energy intake is reduced by 500\~1000 kcal based on the target energy intake; however, the balance is maintained for the energy supply ratio of the three major nutrients (with carbohydrate, protein, and fat accounting for 55\~60%, 10\~20%, and 15\~30% of the total daily energy, respectively). Combined with the patient's eating habits, the food exchange portion method is used as a guide; each portion providing 90 kcal is considered as one portion. Specific recipes are formulated after calculating the ideal weight and the total daily calorie intake based on activity intensity, determining the number of six food exchange portions and the distribution of three meals according to the total calorie and diet structure, and combining the equivalent food exchange table based on individual tastes and preferences; this ensures patient acceptability and implementation.
224021216|NCT02052089|PROCEDURE|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
224021217|NCT02052089|PROCEDURE|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (\<0.2 mJ/mm2) or high energy (\>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
223733683|NCT03506607|OTHER|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
223733684|NCT03506607|OTHER|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
223733685|NCT03506607|OTHER|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
223733686|NCT02989675|DRUG|10% dextrose|Bolus of 10% dextrose 5mls/kg
223733687|NCT04345263|PROCEDURE|MTA pulpotomy|Cutting the coronal portion of the pulp to the level of canal orifices and applying the dressing and restoration
224021218|NCT02052089|PROCEDURE|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
224021219|NCT02052089|PROCEDURE|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
224021220|NCT04687449|DIETARY_SUPPLEMENT|Curcumin therapy|Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).
224131438|NCT02207556|DRUG|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use."
223552524|NCT00513084|BEHAVIORAL|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
223552525|NCT00148486|DRUG|NS 2330|
223552526|NCT02069821|DRUG|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
223400919|NCT06169449|BEHAVIORAL|Weight management--exercise|Exercise goals are divided into four levels based on individual health conditions and personal preferences; these include: cultivating exercise habits, improving cardiopulmonary function, enhancing muscle strength, and improving flexibility. Individualized exercise prescriptions that specify the exercise type, intensity, time, and frequency are formulated.
224131439|NCT03558555|DRUG|Acetaminophen IV Soln|1000mg of IV acetaminophen
224131440|NCT03558555|DRUG|Oral Acetaminophen|oral acetaminophen 975mg pills
223400920|NCT06169449|BEHAVIORAL|Weight management--accompany|This component involves the inclusion of patients in online management. Online groups are established, daily feedback is obtained regarding weight management implementation, self-sharing is encouraged, and peer support is established; a total of 6 sessions of online health education are provided once every 4 weeks for 20-60 minutes at each session. This includes information regarding the risks associated with overweightness and obesity; weight management benefits; knowledge regarding diet and nutrition, exercise and sports, and behavioral styles; and problem exchange and sharing, among others. Professional support is provided by weekly communication with patients one-on one via WeChat or telephonic conversations. The patient's diet and exercise record sheet are checked, patients are asked questions regarding implementation of the current program and any discomfort or difficulties; corresponding guidance is provided as appropriate.
223552527|NCT02398136|DRUG|Ketamine|
223552528|NCT02398136|DRUG|Midazolam|
223552529|NCT05690399|RADIATION|Radiotherapy|Effect of radiotherapy on patients
223552530|NCT02320864|PROCEDURE|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
224131441|NCT03558555|DRUG|Placebo Pills|placebo match to acetaminophen
223552531|NCT06374888|DRUG|Neratinib maleate in combination with capecitabine|Neratinib maleate tablets，Tablets, 40mg/ tablet, 180 tablets/bottle, orally, 240mg once daily, sealed, stored not above 25℃
223552532|NCT05082519|BEHAVIORAL|IDEAL2 Intervention|Intervention of diet and exercise to improve outcomes for ALL patients
223552533|NCT03132961|OTHER|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
224131442|NCT03558555|DRUG|Saline|Intravenous saline
224021221|NCT04687449|OTHER|Placebo|Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.
224131443|NCT01958125|DEVICE|gammaCore|Vagal stimulation
223400921|NCT06169449|BEHAVIORAL|Weight management--refresh|According to the dietary nutrition guidelines for Chinese residents, patients are advised to drink 2500 ml or more of water daily; they are also advised to work and rest regularly to ensure sufficient sleep time, ensure smooth bowel movements, take deep breaths when waking up in the morning, pay attention to the work-rest balance, avoid being sedentary, and stand up and move around at least once every 50 minutes, maintain physical vitality by adjusting daily living habits.
223400922|NCT06169449|BEHAVIORAL|Control group|The relationship between overweightness and obesity and endometrial cancer risk was explained to patients in the control group and their willingness for self-weight management was respected. Communication was maintained with patients from treatment initiation to 3 and 6 months after treatment; patients' questions regarding weight reduction were answered and suggestions were provided regarding nutrition, exercise, and lifestyle management.
223400923|NCT04514484|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400924|NCT04514484|DRUG|Cabozantinib S-malate|Given PO
223400925|NCT04514484|PROCEDURE|Computed Tomography|Undergo CT
223400926|NCT04514484|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223400927|NCT04514484|BIOLOGICAL|Nivolumab|Given IV
223400928|NCT05063656|DRUG|Gabapentin|8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily
223400929|NCT06211673|OTHER|Semi-structured interviews|"3 semi-structured interviews will be administered to the legal guardians or legal representative of the patient:~* Vineland Adaptive Behavior Scales II (VABS-II): assessment of adaptive skills;~* Kiddie-SADS-Lifetime Version (K-SADS-PL): assessment of general psychopathology;~* Autism Diagnostic Interview-Revised (ADI-R): assessment of autistic symptoms. The K-SADS-PL will be administered directly to the participant provided the participant is of an equivalent age of at least 5 years 11 months for receptive language and expressive language on the VABS-II, with raw scores of 35 and 92, respectively."
223400930|NCT06211673|OTHER|Heteroquestionnaires|7 heteroquestionnaires assessing: Hyperactivity symptoms and behavioral disorders measured by the ABC Attention deficit/hyperactivity symptoms measured by the Conners 3 scale and the SAID-P Psychotic symptoms measured by the adapted GPS-ID Sensory peculiarities measured by the Sensory Profile 2 Anxiety symptoms measured by the ADAMS Sleep disorders measured by the SDSC For children, the questionnaires: ABC, Sensory Profile 2, ADAMS, SDSC will be completed collectively by the legal guardians, and the questionnaires: Conners 3, SAID-P, adapted GPS-ID will be independently completed by each legal guardian. The same for adult patients with possible second caregiver. The questionnaires Conners 3, SAID-P and adapted GPS-ID will be completed twice, with a 28-day interval, at the time of inclusion and then after the semi-structured interviews.
223552534|NCT05762042|OTHER|dietary supplement|"Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally."
223552535|NCT01266330|DIETARY_SUPPLEMENT|Low Dairy|Less than 0.5 standard servings of dairy products per day
223552536|NCT01266330|DIETARY_SUPPLEMENT|Adequate Dairy|3.5 standard servings of dairy foods per day
223552537|NCT04232982|PROCEDURE|Transscleral cyclphophotocoagulation using the Micropulse system ( IRIDEX IQ810 Laser systems, Mountain View, CA).|Treatment will be applied over the limbal area to treat the ciliary body. The treatment will be delivered with an energy of 2000mW, a cycle of 31,33% and an on/off time of 0,5ms and 1,1ms. It will be delivered around a 360° surface with avoidance of the 3 and 9 o'clock areas. The treatment will be delivered during 80 secondes in each hemisphere and will be repeated twice, for a total of 320 secondes.
223552538|NCT04232982|PROCEDURE|G-Probe transscleral cyclphophotocoagulation (Iris Medical Instruments, Montain View, CA)|"Treatment will be applied over the limbal area to treat the ciliary body. Sixteen (16) shots in total, which is four (4) shorts per quadrants, will be transmitted with a power from 1750 to 2000mV (titrating according to an audible pop) for a length of 2,0 secondes per shots. Treatment will be delivered around a 360° surface and avoiding the 3 and 9 o'clock areas."
223552539|NCT05737823|BEHAVIORAL|Carers-ID online support programme|The Carers-ID online programme, which consists of ten modules which cover topics including: promoting resilience, reducing anxiety, managing stress, accessing local supports, managing family conflict and information for siblings who are carers.
223552540|NCT05737823|BEHAVIORAL|Carers-ID online support programme - Wait-list control|The same programme as above delivered to the wait-list control after the T2 follow-up data has been collected.
223552541|NCT04350801|DIAGNOSTIC_TEST|home-based cognitive monitoring|a newly developed home-based cognitive monitoring (about 3-5 minutes per test; total score ranges from 0\~30; higher score indicates better cognition)
223552542|NCT02648009|DRUG|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
223552543|NCT02648009|DRUG|Gadolinium|MRI with Gadolinium
223733688|NCT00788151|BIOLOGICAL|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
224021222|NCT04687449|OTHER|Standard care|The standard of care for COPD.
224021223|NCT00850785|BIOLOGICAL|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
224021224|NCT01331486|DIETARY_SUPPLEMENT|Hawthorn|Hawthorn standardized extract liquid capsule
224021225|NCT01331486|DIETARY_SUPPLEMENT|Placebo capsule|Matched placebo liquid capsule
224021226|NCT01944371|DRUG|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
224021227|NCT01245985|RADIATION|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
224131444|NCT03925311|PROCEDURE|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
224131445|NCT01073280|PROCEDURE|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
224131446|NCT02352610|PROCEDURE|LRTI|
223400933|NCT05411016|DRUG|Placebo|Placebo is administered single dose or multiple dose by IV or SC injection
223400934|NCT05411016|DRUG|KK4277|KK4277 is administered single dose or multiple dose by IV or SC injection
223400935|NCT05439005|DRUG|Dexmedetomidine|Dexmedetomidine+Lidocaine
223400936|NCT06008782|DEVICE|HEARS-SLP device|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
223400937|NCT06008782|BEHAVIORAL|HEARS-SLP program|Tailored aural rehabilitation for participant and communication partner
223400938|NCT05782400|RADIATION|CT scan|CT scan at baseline and then every three months as per clinical practice. The standardization of the procedure of images' collection through a CT- acquisition's protocol has been planned to control bias.
223552544|NCT04224103|DRUG|Inhaled nitric oxide|"Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation."
223552545|NCT00589173|BEHAVIORAL|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
223552546|NCT00589173|BEHAVIORAL|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
223552547|NCT00562432|DEVICE|Plexisyl-AF|Plexisyl-AF implants
223552548|NCT00562432|OTHER|No Treatment|CABG without the experimental treatment
223552549|NCT06353152|DRUG|Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection|single-/multiple-dose infusion
223552550|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
223552551|NCT01752556|PROCEDURE|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
223552552|NCT00693446|DRUG|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
223552553|NCT00693446|DRUG|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
223552554|NCT04893512|DRUG|Orally Suspension of CoV2-OGEN1|CoV2-OGEN1 will be supplied as a 10mL oral suspension in a plastic bottle containing 50-200 mcg of formulated drug
223552555|NCT02701764|DRUG|Pregabalin|
223552556|NCT02701764|DRUG|Placebo|
223552557|NCT02317198|DRUG|Clopidogrel|
223552558|NCT02317198|DRUG|Ticagrelor or Prasugrel|
223552559|NCT05238272|DEVICE|Transcranial random noise stimulation (tRNS)|There will be 20 minutes of stimulation (real tRNS or sham tRNS), 40 minutes of MT (unilateral or bilateral) and 30 minutes of functional task training.
223552560|NCT05238272|DEVICE|sham tRNS|the electrode placement will be the same as the real stimulation conditions. The current will first turn up for 30 seconds and subsequently turn off in the next 30 seconds
223552561|NCT05238272|BEHAVIORAL|the unilateral MT|For the unilateral MT, the participants will practice movements using only the unaffected arm while the affected arm will remain relaxed behind the mirror during MT training. The training therapists will instruct the participants to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task.
224021228|NCT01415531|DRUG|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
224021229|NCT01415531|DRUG|Placebo|Dose-match placebo
224021230|NCT04315051|DRUG|Cohort 1 J. Lividum|Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
224021231|NCT04315051|OTHER|Placebo Gel|Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
224131447|NCT02352610|DEVICE|Biotenodesis Screw|
224297147|NCT04445220|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
224297148|NCT05351814|OTHER|Exercise|While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
224021232|NCT04891822|PROCEDURE|ERAS protocol|E: ERAS protocol C: control
223400939|NCT05782400|BIOLOGICAL|Plasma collection|● Blood samples will be collected at baseline, at 1 month and at the first PD. Sixteen ml of blood will be collected in EDTA tubes and centrifuged at 1900×g for 10 min at 4 °C within 2 h after drawing to collect plasma, which will be stored at -80°C until analysis. Plasma samples will be sent to the Laboratory of Pharmacogenetics - Unit of Clinical Pharmacology and Pharmacogenetics - University Hospital of Pisa. Plasma samples will be used to isolate cell free DNA (cfDNA) and microvesicles-derived RNA for molecular analysis.
223400940|NCT04357769|OTHER|PSS (Perceived Stress Scale)|Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks
223400941|NCT04357769|OTHER|GAD-7 (7-item Generalized Anxiety Disorder)|Self-administered scale for the evaluation of anxiety symptoms in the last weeks
223400942|NCT04357769|OTHER|PHQ-9 (9-item Patient Health Questionnaire)|Self-administered scale for the evaluation of depressive symptoms in the last weeks
223400943|NCT04357769|OTHER|SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales|Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks
223400944|NCT04357769|OTHER|Zaritt Burden Interview|Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
223400945|NCT00998504|DIETARY_SUPPLEMENT|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
223400946|NCT00998504|DIETARY_SUPPLEMENT|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
223733689|NCT00788151|BIOLOGICAL|Pneumococcal polysaccharide vaccine|0.5 mL, SC
223733690|NCT03324854|PROCEDURE|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
223733691|NCT03324854|PROCEDURE|Drainage|Placement of active-close drainage in surgical site.
223733692|NCT03324854|DRUG|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
223733693|NCT00503009|DRUG|fluticasone propionate/salmeterol|comparator
223733694|NCT00503009|DRUG|fluticasone propionate|Comparator
224021233|NCT04175821|RADIATION|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
224021234|NCT03404141|OTHER|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
224021235|NCT03404141|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
223733695|NCT00503009|DRUG|placebo|Placebo
223733696|NCT03724539|DEVICE|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
223733697|NCT03724539|OTHER|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
223733698|NCT00534989|PROCEDURE|FDG PET|FDG PET
223733699|NCT01558388|DRUG|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
223733700|NCT01558388|DRUG|Placebo|One vaginal tablet daily for 10 days.
223733701|NCT04275440|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
223733702|NCT04275440|BEHAVIORAL|Caloric restriction|"1. In the first two weeks, participants would reduce their daily energy intake to 100% -110% of his or her basal metabolic energy under instruction, and stick to it till the end of the intervention.~2. According to the dietary recommendation proposed by Chinese government, participants are required to take in cereals, vegetables, fruits, meat and eggs, while minimize the consumption of sugar-sweeten beverages.~3. Participants are instructed to arrange their three meals according to the recommended energy distribution (3:4:3)."
223733703|NCT00141076|BEHAVIORAL|low vs high glycemic index diet|
224131448|NCT04987853|DIAGNOSTIC_TEST|Clinical and functional analysis|"General blood analysis - Complete blood count on an analyzer with differentiation of 5 classes of cells, the ratio of neutrophils to lymphocytes; Blood chemistry - ALT, AST, total bilirubin, direct, LDH, CRP, alpha-amylase, creatinine, urea, glucose, ferritin, glycosylated hemoglobin, vitamin 25 - OH vitamin D, vitamin B12; Coagulogram - D-dimers, fibrinogen, INR, APTT; Other - NT-pro BNP, Homocysteine, IL 6, Troponin, blood group determination; Linked immunosorbent assay - Determination of IgG and IgM antibodies to SARS-CoV-2 coronavirus (COVID-19) in blood serum, RBD; Functional diagnostics • ECG~* EchoCG + strain~* CT scan of the lungs~* Holter~* SMAD~* Kidney ultrasound~* Ultrasound~* Doppler ultrasonography of veins and arteries~* Chalder Scale, EQ Questionnaire"
223733704|NCT02935322|DRUG|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
224021236|NCT03742921|DRUG|Istodax|Istodax
224297149|NCT05747521|DRUG|Anrotinib hydrochloride combined with adriamycin|To evaluate the efficacy of anrotinib hydrochloride combined with doxorubicin in the neoadjuvant treatment of high-grade soft tissue sarcoma
224297150|NCT04297995|DRUG|HLX10|Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.
224297151|NCT04297995|DRUG|HLX07|Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.
223733705|NCT02935322|DRUG|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
223733706|NCT02935322|DRUG|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
223733707|NCT02935322|OTHER|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
223733708|NCT03367481|DEVICE|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
223733709|NCT03351179|COMBINATION_PRODUCT|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
224131449|NCT04987853|DIAGNOSTIC_TEST|Neurological analysis|"Neurological examination with the isolation of neurological syndromes (motor, cognitive impairments, sleep disorders, asthenic-depressive syndromes, etc.).~2\. Neuropsychological methods - research on the scales of anxiety and depression, MMSE, etc.~3\. Instrumental method - EEG, polysonography, ultrasound of the neck vessels, CT perfusion.~4\. Laboratory research methods:~1. The study of antibodies to some neurospecific antigens - myelin basic protein (MBP), neurospecific enolase (NSE).~2. Study of cellular immunity (CD3 +, CD4 +, CD8 +) and general indicators of humoral immunity (IgG, IgA, IgM, circulating immune complexes)."
223400947|NCT01078935|DIETARY_SUPPLEMENT|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
223400948|NCT01078935|DIETARY_SUPPLEMENT|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
223400949|NCT05627245|DRUG|Belinostat|Given IV
223400950|NCT05627245|PROCEDURE|Biopsy Procedure|Undergo biopsy
223400951|NCT05627245|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400952|NCT05627245|PROCEDURE|Computed Tomography|Undergo CT scan
223400953|NCT05627245|OTHER|Pharmacokinetic Study|Pharmacokinetic study
223400954|NCT05627245|PROCEDURE|Positron Emission Tomography and Computed Tomography Scan|Undergo PET-CT
223400955|NCT05627245|DRUG|Tazemetostat|Given PO
223400956|NCT03807791|PROCEDURE|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
223400957|NCT03984448|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223400958|NCT03984448|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223400959|NCT03984448|PROCEDURE|Computed Tomography|Undergo CT scan
223400960|NCT03984448|DRUG|Cyclophosphamide|Given IV
223400961|NCT03984448|DRUG|Doxorubicin Hydrochloride|Given IV
223400962|NCT03984448|DRUG|Etoposide|Given IV
223400963|NCT03984448|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223400964|NCT03984448|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223400965|NCT03984448|DRUG|Prednisone|Given PO
223400966|NCT03984448|BIOLOGICAL|Rituximab|Given IV
223400967|NCT03984448|DRUG|Venetoclax|Given PO
223400968|NCT03984448|DRUG|Vincristine Sulfate|Given IV
223400969|NCT02284074|OTHER|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
223400970|NCT02284074|OTHER|Experimental: Nasal LPS spray 1µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
223400971|NCT02284074|OTHER|Experimental: Nasal LPS spray 10 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
223400972|NCT02284074|OTHER|Experimental: Nasal LPS spray 30 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
223400973|NCT02284074|OTHER|Experimental: Nasal LPS spray 100 µg|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed.
223400974|NCT01817868|OTHER|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
223400975|NCT01220843|DRUG|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
223400976|NCT01220843|DRUG|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
223400977|NCT04225715|DRUG|Nucleos(t)ide (NUC)|Nucleos(t)ide (NUC) will be administered orally
224131450|NCT04987853|DIAGNOSTIC_TEST|Immunological analysis:|A comprehensive immunological analysis will be carried out to determine the level of the immune response. Calculation of the level of CD4 +, CD8 + and NK cells. The level of antibodies of the IgG and IgM classes to the proteins of the coronavirus S1, RBD and N was determined
224131451|NCT04987853|DIAGNOSTIC_TEST|Genetic analysis:|Isolation (extraction) of DNA will be performed from whole blood using commercial kits according to the manufacturer's instructions. To analyze a large number of genetic markers, it is planned to carry out genome-wide sequencing followed by analysis of genetic polymorphisms of candidate genes encoding coronavirus receptors and immunological factors.
224131452|NCT02919488|OTHER|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
224131453|NCT02919488|OTHER|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
223400978|NCT04225715|DRUG|CpAM (RO7049389)|CpAM (RO7049389) will be administered orally
223400979|NCT04225715|DRUG|TLR7 (RO7020531)|TLR7 (RO7020531) will be administered orally
223400980|NCT04225715|DRUG|siRNA (RO7445482)|siRNA (RO7445482) will be administered subcutaneously
223733710|NCT04461171|PROCEDURE|Enhanced Recovery After Surgery|Undergo an enhanced recovery after surgery program
223733711|NCT05949242|DEVICE|OMNI canaloplasty|OMNI device is used to catheterize Schlemm's canal for 180 degrees and perform canaloplasty. Viscoelastic is eluded upon retraction of the catheter performing viscodilation of the canal
223733712|NCT05949242|DEVICE|Hydrus microstent|Hydrus stent is introduced into Schlemm's canal to scaffold open the canal
223733713|NCT01545284|DRUG|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
223733714|NCT05916391|GENETIC|FT-003|Administration via intraocular injection
223733715|NCT01349803|DRUG|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
223733716|NCT01349803|DRUG|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
223400981|NCT04225715|DRUG|PEG-IFN|PEG-IFN will be administered subcutaneously
223400982|NCT04225715|DRUG|PD-L1 LNA (RO7191863)|PD-L1 LNA (RO7191863) will be administered subcutaneously
223552562|NCT05238272|BEHAVIORAL|the bilateral MT|For the bilateral MT, the participants will be encouraged to move the affected arm as symmetrically and simultaneously as the unaffected hand during MT training. At the same time, participants will also be instructed to look at the mirror reflection of the unaffected arm and imagine that it is the affected arm performing the task. The activities practiced during MT will include intransitive movements (e.g., flexion and extension of the wrist) and transitive movements (e.g., picking up a pen).
223552563|NCT02779868|DIETARY_SUPPLEMENT|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
223552564|NCT02779868|DIETARY_SUPPLEMENT|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
223552565|NCT02136225|BEHAVIORAL|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
223552566|NCT01027650|DRUG|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
223400983|NCT03152773|PROCEDURE|MRI Heart guidewire catheterization|to conduct left and right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary left and right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
223400984|NCT02936297|DIETARY_SUPPLEMENT|High dose Gluten|
223552567|NCT01027650|DRUG|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
223733717|NCT01349803|DRUG|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
223733718|NCT01349803|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
223733719|NCT05829889|PROCEDURE|FFR-Guided PCI|Fractional Flow Reserve-Guided PCI
223733720|NCT05829889|PROCEDURE|Angiography-Guided PCI|Angiography-Guided PCI
223733721|NCT02260050|DRUG|WAL 801 CL dry syrup new formulation|
223733722|NCT02260050|DRUG|WAL 801 CL dry syrup conventional formulation|
223733723|NCT04378140|OTHER|zirconia wing bridge|The zirconia wing bridge consists of an artificial tooth made out of zirconia and porcelain on the front side with two zirconia wings that are bonded (glued) onto the back of the two adjacent teeth in the patient's mouth.
223400985|NCT02936297|DIETARY_SUPPLEMENT|Low dose Gluten|
223733724|NCT00100815|BIOLOGICAL|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
223733725|NCT00100815|DRUG|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
223733726|NCT00100815|DRUG|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
223733727|NCT01305850|DRUG|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
224131454|NCT04758429|DEVICE|Machine-learning Algorithm|System technology/Software
224131455|NCT03192072|DIAGNOSTIC_TEST|Host Gene Expression|comparison to retrospective clinical adjudication
224131456|NCT00677690|OTHER|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
224131457|NCT00677690|OTHER|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
224131458|NCT03704441|DRUG|Bupivacaine|bupivacaine dose
224131459|NCT06330597|DIAGNOSTIC_TEST|Echocardiography and lung ultrasound|All patients will undergo non-invasive echocardiogram and lung ultrasound at times of assessment of hemodynamic parameters as needed by usual clinical management.
224297152|NCT04297995|DRUG|HLX07 placebo|HLX07 placebo 1000 mg every three weeks
223733728|NCT01305850|DRUG|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
223733729|NCT01305850|DRUG|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
223733730|NCT01305850|DRUG|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
223733731|NCT00815945|DRUG|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
223733732|NCT00815945|DRUG|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
223733733|NCT01710033|DRUG|Placebo|Placebo tables twice daily (BID) for 28 days
223733734|NCT01710033|DRUG|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
223733735|NCT01710033|DRUG|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
223733736|NCT01710033|DRUG|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
223733737|NCT05933512|BIOLOGICAL|SCTV01E-2|intramuscular injection
223733738|NCT05933512|BIOLOGICAL|SCTV01E|intramuscular injection
223733739|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
223733740|NCT01141439|DRUG|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
223733741|NCT01141439|DRUG|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
223733742|NCT01141439|DRUG|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
223733743|NCT01141439|DRUG|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
223733744|NCT01141439|DRUG|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
223733745|NCT00996047|GENETIC|cytogenetic analysis|
223733746|NCT00996047|GENETIC|fluorescence in situ hybridization|
223733747|NCT05615571|GENETIC|Establishment of mitochondrial markers|Establishment of mitochondrial markers from fibroblasts in culture, obtained from a skin biopsy. Establishment of yeast models to show biochemical mitochondrial alterations: introduction of missense variants in the pantothenate kinase yeast gene Cab1 whose deletion is lethal, followed by growth of mutant strains on fermentation and respiratory media.
223400986|NCT02936297|DIETARY_SUPPLEMENT|Lactose free placebo|
223733748|NCT05615571|GENETIC|Sequencing tests|sequencing tests of a panel of 22 genes (9 already known and 13 new genes) using a dedicated custom capture and a medium throughput sequencing protocol.
224131460|NCT00781599|DRUG|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
224131461|NCT00781599|BEHAVIORAL|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
223400987|NCT05662072|BEHAVIORAL|Motor imagery|Mental imagery of respiratory exercises
223400988|NCT05662072|BEHAVIORAL|Action observation|Action observation of respiratory exercises
223400989|NCT05662072|OTHER|Placebo Intervention|Placebo observation
223400990|NCT05131841|DRUG|Cipterbin Combined With Vinorelbine|"1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer"
223733749|NCT02880189|DEVICE|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
223733750|NCT02880189|PROCEDURE|Endoscopic Ultrasound Guided Core Liver Biopsy|
223733751|NCT01647282|DRUG|locally-applied minocycline HCl (1 mg)|
223733752|NCT01647282|PROCEDURE|scaling and root planing (Sc/RP)|
223733753|NCT04976166|BEHAVIORAL|Education|More informed and detailed education
224021237|NCT03430531|DRUG|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
224021238|NCT02344004|DRUG|LAI (Liposomal Amikacin for Inhalation) 590 mg|LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
224021239|NCT01994668|DRUG|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
224131462|NCT00781599|BEHAVIORAL|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
224131463|NCT00275925|DRUG|Oxcarbazepine|
223733754|NCT04976166|BEHAVIORAL|Education|Shared decision making
223733755|NCT04976166|BEHAVIORAL|Education|education as usual
223733756|NCT02956265|DEVICE|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
223733757|NCT00394628|DRUG|AQ4N|
223733758|NCT00394628|DRUG|Temozolomide|
223733759|NCT00394628|PROCEDURE|Radiotherapy|
224021240|NCT01994668|DRUG|Placebo|A single intravenous administration of 0.9% saline over 1 minute
224021241|NCT01583231|OTHER|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
223400991|NCT05251337|DRUG|Essential oils|Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.
224021242|NCT02777385|DRUG|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
224021243|NCT02777385|DRUG|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
224021244|NCT02777385|RADIATION|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
224021245|NCT04651517|DEVICE|XACT ACE Robotics study arm|Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
224021246|NCT03495570|DIAGNOSTIC_TEST|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
223400992|NCT05251337|DRUG|Placebo|Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
223400993|NCT05014659|DIETARY_SUPPLEMENT|Creatine monohydrate|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
223400994|NCT05014659|DIETARY_SUPPLEMENT|Placebo|4 x 5g doses daily for 5 days, followed by 1 x 5g dose daily for 23 days.
223552568|NCT05807412|DRUG|PrabotulinumtoxinA-Xvfs|"All subjects will receive one injection of 4 units or 0.1 cc of prabotulinumtoxin A into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of prabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
223552569|NCT05807412|DRUG|OnabotulinumtoxinA|"All subjects will receive one injection of 4 units or 0.1 cc of onabotulinumtoxinA into the frontalis at a single point 2.5 cm above the orbital rim at the mid-pupillary line.~The preparation of the 100-unit vial of onabotulinumtoxinA will be reconstituted gently and without shaking with 2.5 cc of 0.9% preserved normal saline solution. The investigator performing the injections will reconstitute study vials.~Subjects will be injected intramuscularly using a hubless tuberculin syringe. Injections will be done at a 90-degree angle or perpendicular to the skin surface. The target sites will be the mid-line of the pupil and 2.5 cm above the orbital rim."
223552570|NCT04212130|OTHER|BCA method for assessing environmental cleanliness|"Evaluating the effectiveness and usability of BCA method which is a new approach in evaluating the effectiveness of environmental cleanliness in intensive care units.~In this study, fluorecan labeling, microbiological sampling and BCA methods will be compared in order to evaluate the effectiveness and usability of BCA method"
223552571|NCT04831476|OTHER|Patients with Benign Prostate Hyperplasia|patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
223552572|NCT05174338|OTHER|Registry|Observational, data collection
223552573|NCT00912782|DRUG|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
223552574|NCT00912782|DRUG|Placebo|Placebo one time per week for 3 weeks
223552575|NCT03569358|DEVICE|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
223552576|NCT03569358|DEVICE|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
223552577|NCT05978336|BEHAVIORAL|Health Coaching Program|"The HC program will be delivered over 26-weeks. Participants will have an initial hour-long HC session where the BAP coach will conduct a brief physical assessment and work with the participant to establish their physical activity goals and develop a plan. After the initial consult, coaches will conduct 8 x 20-minute phone calls with participants over the 26-week trial decreasing from bi-weekly phone calls in weeks 1-12 to monthly phone calls in weeks 13-26.~Participants in the HC group will have an overall goal of increasing their weekly participation in moderate to vigorous physical activity by 50 minutes, via 5-, 7-, or 10-minute bouts of progressive exercises, at a rate of perceived exertion range of 13-14 (somewhat hard) by week 16. Participants will have access to specific exercise sessions made available by YouTube and/or hardcopy manuals created by the research team."
224021247|NCT03333239|BEHAVIORAL|psychodynamic psychotherapy|the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann \& Wulf, 2013)
224021248|NCT03333239|BEHAVIORAL|cognitive behavioral psychotherapy|the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, \& Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, \& Petermann, 2015)
224021249|NCT03333239|BEHAVIORAL|psychodynamic family intervention|the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, \& Plass, 2011)
224021250|NCT04698941|DRUG|Albumin Paclitaxel|Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.
224021251|NCT04698941|DRUG|Simvastatin|20mg daily oral tablet taken.
224021252|NCT04780022|OTHER|Clinical events at last follow-up|Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up
224131464|NCT01106625|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
223733760|NCT02105428|BEHAVIORAL|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
223733761|NCT00826020|DRUG|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
223733762|NCT00128570|BEHAVIORAL|behavioral dietary intervention|
223733763|NCT00128570|OTHER|educational intervention|
224021253|NCT01568437|PROCEDURE|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
223733764|NCT00128570|OTHER|internet-based intervention|
223733765|NCT00128570|OTHER|preventative dietary intervention|
223733766|NCT00128570|PROCEDURE|evaluation of cancer risk factors|
223733767|NCT00678119|BIOLOGICAL|AGS-003|Dendritic cell Immunotherapeutic
223733768|NCT00678119|DRUG|Sunitinib|An approved drug for the treatment of RCC
223733769|NCT06066645|DRUG|Travoprost Intraocular Implant|anchored intracameral implant containing travoprost in subjects who successfully received iStent infinite
223733770|NCT06066645|OTHER|Sham procedure|Sham procedure (to mimic placement of travoprost intraocular implant) in subjects who successfully received iStent infinite
223733771|NCT06066645|DEVICE|iStent infinite|Successful iStent infinite surgery
223733772|NCT06398054|DRUG|Ibuprofen 400 mg|Ibuprofen 400 mg tablet
223733773|NCT06398054|DRUG|Hyoscine N-Butil Bromide|Hyoscine N-Butil Bromide 10 mg two tablets
223733774|NCT06398054|DRUG|placebo|Two tablets
223733775|NCT05931250|DEVICE|DC-Stimulator Plus (NeuroConn GmbH, Germany)|Transcranial alternating current stimulation
223733776|NCT05931250|DEVICE|Sooma direct current stimulator (Sooma, Finland)|Transcranial direct current stimulation
223733777|NCT06120816|DRUG|Nitric Oxide|Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days. The intervention solution will be poured into their mouth from a medication cup containing 20 mL of the solution. Total exposure to study intervention will be a maximum of 63 treatments totaling 1,260 mL. All participants will be monitored for 7 days post-last treatment dose (to Day 28).
224021254|NCT01568437|OTHER|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
223733778|NCT01244906|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
223733779|NCT00111618|DRUG|AS1404 (DMXAA)|
223733780|NCT06430138|DIETARY_SUPPLEMENT|300ml Orange Juice|Acute intervention in populations with and without colon
223733781|NCT00388635|DRUG|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
223733782|NCT00388635|DRUG|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
223733783|NCT00388635|DRUG|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
223400995|NCT04934813|OTHER|Alveolar ridge preservation|application of different bone graft and sealing means after tooth extraction
223400996|NCT01715532|DRUG|Huachansu|
223400997|NCT01715532|OTHER|TACE|
223400998|NCT00887575|DRUG|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
223400999|NCT00887575|DRUG|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
223733784|NCT03878914|DRUG|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
223733785|NCT03794414|PROCEDURE|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
223733786|NCT05551494|DIAGNOSTIC_TEST|Urinary sample|"At study entry, we will collect urinary samples from women. Participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS).~In addition, women will be asked to report about their habits about consumption of plastic"
223733787|NCT00517621|DRUG|Paclitaxel|
224021255|NCT04705129|DRUG|Zanubrutinib|160mg Bid, D1-21, po
223401000|NCT00887575|DRUG|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
223401001|NCT01044407|DEVICE|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
224021256|NCT04705129|DRUG|Tislelizumab|200mg, D1, ivgtt
224021257|NCT02300441|OTHER|ECG, blood pressure and oximetry|
224021258|NCT01332773|PROCEDURE|Artery first procedure|early identification of SMA to evaluate infiltration
224021259|NCT01332773|PROCEDURE|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
224021260|NCT00598273|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
224021261|NCT00598273|DRUG|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
224021262|NCT00598273|DRUG|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
224021263|NCT04667832|DIAGNOSTIC_TEST|selective coronary artery angiography|Radial approach, invasive selective coronary angiography with selective contrast injection and filming in coronary arteries
223733788|NCT00517621|DRUG|EPO|
223733789|NCT02505620|PROCEDURE|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
223733790|NCT02505620|PROCEDURE|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
223733791|NCT00204347|DRUG|risperidone|
223733792|NCT05559255|OTHER|Counterstrain manual manipulative treatment|"The steps required to perform counterstrain in any region of the body are as follows:~1. Find the tender point.~2. Assess the tenderness using a pain scale.~3. Passively and gently place the patient in a position-of-comfort that results in the greatest reduction of tenderness at the tender point. Approximate the position first, then fine-tune through small arcs of movement. Aim to achieve at least 70% tenderness reduction, with the goal of 100%.~4. Maintain the position for 90 seconds while continuing to monitor the patient's tender point.~5. Passively return the patient to a neutral position.~6. Re-test for tenderness at the tender point."
223733793|NCT03772847|DRUG|ginkgolide|ginkgolide plus alteplase
224021264|NCT03770910|OTHER|GIP receptor antagonist|GIP receptor antagonist
223401002|NCT02011685|BEHAVIORAL|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
223401003|NCT02011685|BEHAVIORAL|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
223401004|NCT06509737|BEHAVIORAL|Face to face group|With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase by providing Life with Food Allergy Training based on the Health Promotion Model with face-to-face training in parents of children diagnosed with food allergy.
223401005|NCT06509737|BEHAVIORAL|social mediagroup|With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase in parents of children diagnosed with food allergy by providing Life with Food Allergy Education based on the Health Promotion Model through social media.
223401006|NCT03684707|DRUG|Metformin Hcl 500Mg 24Hr Sa Tab|Glucophage 500 mg once daily
223401007|NCT03684707|OTHER|starch tablet|starch tablets
223401008|NCT02741661|OTHER|No intervention. Observational study|No intervention
223401009|NCT06362083|OTHER|Questionnaires and data collection|It is a non-interventional, single-center, non-randomized, prospective observational study obtaining data and patient-reported outcomes.
223401010|NCT03318861|GENETIC|KITE-585|A single infusion of KITE-585 autologous anti-BCMA CAR T cells
223401011|NCT03318861|DRUG|Cyclophosphamide|Administered intravenously
223401012|NCT03318861|DRUG|Fludarabine|Administered intravenously
223401013|NCT02623933|RADIATION|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
223401014|NCT00917852|DEVICE|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
223401015|NCT02932488|DRUG|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
223401016|NCT02059655|DRUG|Bimatoprost|
223401017|NCT02059655|DRUG|Eye drop solution|Artificial tear drops
224021265|NCT03770910|OTHER|GIP receptor agonist|GIP(1-42)
224021266|NCT03770910|OTHER|Saline|Placebo (vehicle for infusions)
224021267|NCT03989518|BEHAVIORAL|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
224021268|NCT03989518|BEHAVIORAL|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
224021269|NCT03989518|BEHAVIORAL|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
224021270|NCT01607632|BEHAVIORAL|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
224021271|NCT02097901|PROCEDURE|Microfracture|Rotator Cuff Repair AND Microfracture
224021272|NCT02097901|PROCEDURE|NO microfracture|Rotator Cuff Repair without microfracture
224021273|NCT00623402|DRUG|Sorafenib|2x 400 mg orally per day (4 tablets)
224021274|NCT00623402|DRUG|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
224021275|NCT04540250|OTHER|questionnaire|conventional intra-oral examination and questionnaire
224021276|NCT06149910|OTHER|Multiple Myeloma Pathway|Use and adherence to a multiple myeloma pathway.
224021277|NCT06149910|OTHER|All4Cure Platform|Participant in the All4Cure platform.
224021278|NCT06149910|OTHER|Documentation Pathway|Use of multiple myeloma pathway through written documentation.
224021279|NCT03871023|DEVICE|Smith & Nephew PICO Negative wound pressure versus standard dresing|To investigate if negative wound pressure improves wound outcome
224021280|NCT03871023|DEVICE|PREVENA Negative pressure wound versus standard dressing|To investigate if negative wound pressure improves wound outcome
224021281|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
224021282|NCT04040504|DEVICE|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
224021283|NCT03426605|DRUG|Open Label LAM-003|LAM-003
223552578|NCT05978336|BEHAVIORAL|Health Education Program|Participants will begin with a one-hour, group-based, interactive education session on falls prevention delivered either in-person or by Zoom. Following the initial education session, ED participants will receive additional group education sessions (in-person or by Zoom) with the same duration and schedule as the HC program covering a variety of healthy aging topics.
223552579|NCT03340285|DIETARY_SUPPLEMENT|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
223552580|NCT03340285|DIETARY_SUPPLEMENT|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
223552581|NCT02474576|PROCEDURE|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
223552582|NCT04301661|OTHER|Blood collection|Blood will be collected from participants at defined time points during the study to measure drug levels and assess platelet activity.
223552583|NCT04301661|DRUG|Abacavir/lamivudine|Participants who are already taking abacavir/lamivudine as part of standard HIV care will continue taking their therapy.
223552584|NCT04301661|DRUG|Tenofovir alafenamide/emtricitabine|Participants who are already taking tenofovir alafenamide/emtricitabine as part of standard HIV care will continue taking their therapy.
223552585|NCT04301661|DRUG|Switch|Participants who are planning to switch from abacavir/lamivudine as part of standard HIV care will change therapy to per the discretion of their HIV provider.
223552586|NCT06100146|DIETARY_SUPPLEMENT|Folic acid and vitamin B12 fortified flour|Standard bags of fortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. The dose of vitamins will be added to the flour of the intervention group and mixed with batch mixing technique. The concentration of folic acid and vitamin B12 per 1kg of flour will be 2mg and 0.02mg, respectively. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
223552587|NCT06100146|OTHER|Unfortified cereal flour|Standard bags of unfortified cereal-based flours will be prepared at local mills from the common staple cereal food in the area. Participants will be supplied with 6 kg bags of flour, which will be enough for 30 days, and 1.5kg bags of flour will be delivered to their home on a weekly basis and lasting for 6 months. Instructions on the preparation of meals and frequency of intake with a weekly compliance sheet will be provided for monitoring the intervention.
223552588|NCT06472037|DRUG|Cadonilimab|10mg/kg，IV，D1，Q3W
223552589|NCT06472037|DRUG|Gemcitabine|1000mg/m2，IV，D1、D8、D15，Q4W
223552590|NCT06472037|DRUG|Nab-Paclitaxel|125mg/m2，IV，D1、D8、D15，Q4W
223552591|NCT00000428|DRUG|Amitriptyline|Amitriptyline 25 mg po
223552592|NCT00000428|DRUG|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
223552593|NCT01186042|OTHER|Observational|No intervention
223552594|NCT06108726|DRUG|Envafolimab Injection|Local injection of Envafolimab 5mg/kg plus platinum-based chemotherapy under fiberoptic bronchoscopy, Q2W.
223552595|NCT04224831|COMBINATION_PRODUCT|Source of growth factors: autologous platelet-rich plasma (aPRP) + repetitive electromagnetic stimulation for iontophoresis|"Autologous platelet rich plasma is containing many types of growth factors (GFs) such as epithelial growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF).~Repetitive high frequency electromagnetic stimulation (rEMS) creates a stimulated focus in the tissue by increasing blood flow and platelets at the capillary level. Electromagnetic stimulation along with growth factors has shown synergetic effects toward enhanced epithelial integrity and neural functions. With the addition of possible iontophoresis effects in the rEMS, the passage of the various active molecules can be augmented at the tissue level thereby increasing the widespread effect of the GFs in the damaged choroidal and outer retinal microenvironment."
223552596|NCT00277810|DRUG|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extension to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
224021284|NCT01258413|PROCEDURE|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
224021285|NCT01258413|PROCEDURE|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
224021286|NCT03816267|DEVICE|Nebulizer|Nebulization via mask
224021287|NCT03816267|DRUG|Salbutamol|Delivery of appropriate dose according to weight
224021288|NCT03816267|DEVICE|Metered dose inhaler and spacer|Medication will be delivered through inhaler and spacer
224021289|NCT05578144|OTHER|Patients Decision Aids (PDA)|Patient Decision Aids (PDA) administer to case group
224021290|NCT06409429|DRUG|Nimotuzumab|Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
224131465|NCT01106625|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
224131466|NCT01106625|DRUG|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
224131467|NCT01106625|DRUG|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
224131468|NCT00011713|OTHER|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
224131469|NCT04385147|OTHER|Endoscopic management according to standard of care|Endoscopic management according to standard of care by ERCP or EUS according to the indication in each case
224131470|NCT05917366|OTHER|Exercises|Stretching exercise for the piriformis and iliopsoas muscles. strengthening exercises for pelvic floor muscles
224131471|NCT05917366|OTHER|Coccyx Manipulation|Application of manipulation to relax the levetor ani muscle
224131472|NCT03160105|DRUG|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
224021291|NCT06409429|DRUG|GX|Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.
224131473|NCT03160105|OTHER|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
224131474|NCT03995628|DRUG|Dexamethasone|One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
224131475|NCT03995628|DRUG|Placebo|One dose of placebo on post-operative day 3 after tonsillectomy
224297153|NCT04297995|DRUG|Cisplatin/Carboplatin|Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.
224021292|NCT06409429|DRUG|Placebo|Patients will receive placebo 400 mg weekly or placebo 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
224131476|NCT02951611|PROCEDURE|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
224131477|NCT02951611|PROCEDURE|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
223401018|NCT03285516|BEHAVIORAL|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
224021293|NCT01096277|DRUG|Sitagliptin|oral tablets 100 mg per day for two weeks
224021294|NCT01096277|DRUG|Placebo|oral tablet, one per day for two weeks
224021295|NCT01096277|OTHER|Control|no intervention
224021296|NCT02666846|DRUG|Ibuprofen|
223401019|NCT04386655|BEHAVIORAL|Brain Injur Coping Skills - Telemedicine|"BICS sessions (both in-person and telemedicine) will occur once a week for 12 weeks. Each session will last two hours.~Modules of BICS include: Introduction to Brain Injury, Expectations for Recovery, Tips on Managing Challenging Problems, Learning about Depression after the Brain Injury, The 4 R's of Stress Management, Communicating Effectively with Professionals"
223401020|NCT05776784|PROCEDURE|dental procedure|questionnaire for patient with dental procedure
223401021|NCT01265108|DRUG|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
223401022|NCT01265108|DRUG|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
223401023|NCT03768908|DRUG|Artemether-lumefantrine|Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
224021297|NCT02666846|DRUG|Diclofenac|
223401024|NCT03768908|DRUG|Artesunate + Amodiaquine|Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
223552597|NCT02349659|DEVICE|Implantation with the commercially available Axium neurostimulator|
223552598|NCT03461549|DEVICE|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
223552599|NCT01020409|PROCEDURE|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
224021298|NCT02666846|DRUG|Methyl-salicylate / Menthol|
224021299|NCT02666846|DRUG|Placebo|
224131478|NCT02509598|DRUG|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
224131479|NCT02509598|DRUG|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
224131480|NCT02509598|PROCEDURE|Lymph Node Mapping|Intraoperative lymph node mapping will occur 15 minutes to 8 hours after Tc99m tilmanocept injection
224131481|NCT02196038|BEHAVIORAL|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
224131482|NCT02196038|BEHAVIORAL|Attention Control|Usual care with bi-weekly contact from study staff
224131483|NCT05931016|DIAGNOSTIC_TEST|6-MWT|Measurement of saturation and blood gas parameters under 6-MWT with different masks.
224131484|NCT05931016|DIAGNOSTIC_TEST|Spiroergometry|Measurement of saturation and blood gas parameters under spiroergometry with different masks.
224297154|NCT04297995|DRUG|5-FU|5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.
224297155|NCT02496819|OTHER|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
224021300|NCT03019731|BEHAVIORAL|Therapist-directed Behavioral Therapy|The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
223733794|NCT04659889|DIAGNOSTIC_TEST|Blood sampling (venesection)|"All study participants will have a single blood test to analyse the following parameters:~(i) Serum biochemistry, CRP, Thyroid function and liver enzymes (ii) FBC, d-Dimer, ESR, Blood film (iii) SARS-CoV2 antibody status and serum save (iv) Peripheral blood immunophenotyping."
223733795|NCT03720470|DRUG|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
223733796|NCT03720470|DRUG|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~1. In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~2. In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
224021301|NCT03019731|BEHAVIORAL|Home-based DVD Therapy|In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
223733797|NCT03720470|DRUG|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
224131485|NCT02569411|OTHER|Financial Incentive|money
223733798|NCT03720470|DRUG|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~1. In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~2. In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
223401025|NCT01131364|DRUG|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
223401026|NCT00123838|DEVICE|Calypso® 4D Localization System|Localization of prostate irradiation.
223552600|NCT01295138|DRUG|Lactulose|Lactulose liquid. 15mls twice daily
223733799|NCT03720470|DRUG|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
224131486|NCT05950477|DIAGNOSTIC_TEST|Depression Questionnaires|Center of Epidemiological Studies-Depression Scale (CES-D) Patient Health Questionnaire (PHQ-9) Diabetes Treatment Satisfaction Questionnaire (DTSQ) Well-Being Index (WHO-5)
224131487|NCT03661268|OTHER|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
224131488|NCT01811849|DRUG|Insulin LISPRO|
223733800|NCT01702701|DRUG|Montelukast|montelukast 10mg po pill q day for 12 weeks
223733801|NCT01702701|DRUG|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
223733802|NCT02959047|DRUG|Alirocumab|150mg SQ every 2 weeks
223733803|NCT02959047|DRUG|Matching placebo|SQ every 2 weeks
223733804|NCT01226446|DRUG|vitamin D|Vitamin D on top of the standard treatment
223733805|NCT05394987|DEVICE|Spectacles|"Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by \>+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., \>50% of waking hours) for the duration of the study."
223552601|NCT04009018|OTHER|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
223552602|NCT03611816|BIOLOGICAL|Blood taken|Collection of clinical data
223552603|NCT03611816|GENETIC|Blood taken|Collection of DNA
223552604|NCT03611816|GENETIC|Blood taken|Collection of plasma
223552605|NCT05572606|BEHAVIORAL|Hypnotherapy|Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
223552606|NCT06145035|BIOLOGICAL|umbilical cord-derived mesenchymal stromal cells (UC-MSCs)|The study product will consist of 100 million UC-MSCs suspended in a final volume of 60 ml given at a rate of 3.3 million cells/min. The product will be infused into vein via intravenous line placed in the arm.
224021302|NCT04771949|DIAGNOSTIC_TEST|Full periodontal chart|A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
223733806|NCT04028596|DRUG|Paracetamol|once, 1000mg, 2 h before ECT session
223733807|NCT04028596|DRUG|Nimotop|once, 60mg, 2 h before ECT session
223733808|NCT00453921|DRUG|Methylphenidate|Dosage dependent on weight
223733809|NCT00453921|BEHAVIORAL|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
223733810|NCT00453921|OTHER|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
224021303|NCT04771949|OTHER|Questionnaires|"After the periodontal chart, patients will be administered the italian version of 4 questionnaires regarding:~1. Adherence to Mediterranean Diet (Gnagnarella et al. 2018);~2. International Physical Activity Questionnaire (IPAQ) (Mannocci et al. 2010);~3. Pittsburgh Sleep Quality Index (PSQI) (Curcio et al. 2013);~4. Italian Perceived Stress Scale (Fossati, 2010)."
224021304|NCT02901782|PROCEDURE|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
224131489|NCT01811849|DRUG|Insulin LISPRO|
224131490|NCT01811849|DRUG|Insulin LISPRO|
223733811|NCT05780112|OTHER|breathing exercise|"* Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand."
223733812|NCT03071770|DRUG|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
223733813|NCT04446910|BEHAVIORAL|SMS Text Messaging|SMS text messaging intervention for a period of 90 days to promote attendance at community-based substance use or dual diagnosis treatment appointments through motivational messages.
223733814|NCT04446910|BEHAVIORAL|Standard of Care Engagement Practices|Standard of care engagement practices, such as communicating with youth and caregivers, as needed, through texting but frequency of contact and content of messaging varies according to individual needs.
223733815|NCT06215040|PROCEDURE|Endoscopic retrograde cholangiopancratography|common bile duct stone removal
223733816|NCT01988792|DIETARY_SUPPLEMENT|Human milk fortifiers|
223733817|NCT04290884|DRUG|Tranexamic Acid|The recruited patients will be randomly assigned to two groups, 50% chance to the experimental group (use of tranexamic acid) and 50% chance to the control group (use of normal saline). After the reduction of the intertrochanteric fracture, 10ml of tranexamic acid is injected under the deep fascia around the fracture area before inserting a drain. As for the control group, 10ml of normal saline is injected instead. Blood will be taken on the third day post operation, and the patient will be seen at 6 weeks, and 3 months.
223733818|NCT04897360|BEHAVIORAL|Increased breathing|hyperventilation to lower ETCO2
223733819|NCT04897360|OTHER|sharpened Romberg test (SRT)|Balance test conducted by standing with feet in front of each other, heel-to-toe in line while the right hand is on the left shoulder and the left hand is on the right shoulder.
223733820|NCT05625009|PROCEDURE|Procedure/Surgery: Transversus Abdominis Plane Block (TAPB)|Patients received TAPB postoperatively
224131491|NCT04091282|OTHER|No intervention|No intervention
224131492|NCT03596359|BEHAVIORAL|Education with Teach-Back method|
224131493|NCT03596359|OTHER|Received routine treatment|
224131494|NCT03027804|PROCEDURE|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
224297156|NCT02496819|OTHER|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
223401027|NCT06134284|DRUG|Orelabrutinib combined with rituximab|This is a single-arm trial. Patients with relapsed/refractory marginal zone lymphoma will be treated with the OR regimen. The treatment plan is as follows: Orelabrutinib 150mg oral administration once a day, Day 1-21; Rituximab 375mg/m² intravenous infusion, Day 1. Each cycle is 21 days. PET-CT evaluation will be conducted after 4 cycles. If a partial response (PR) or better is achieved, the patient will receive further treatment with the OR regimen for an additional 4 cycles before transitioning to single-agent maintenance therapy with either rituximab or obinutuzumab. If a PR or better is not achieved after 4 cycles, the patient will discontinue from the trial.
223401028|NCT02844933|DRUG|Cannabidiol|Oral solution
223401029|NCT02844933|DRUG|Placebo|Matching oral solution
223401030|NCT04403724|DRUG|Bupivacaine-fentanyl-Morphine.|2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
223401031|NCT02845024|DRUG|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
223733821|NCT05625009|PROCEDURE|Procedure/Surgery: Erector Spinae Plane Block (ESPB)|Patients received ESPB postoperatively
223733822|NCT04742933|OTHER|There is no intervention in this observational trial|There is no intervention in this observational trial
223733823|NCT06061653|COMBINATION_PRODUCT|IPT plus HD-tDCS|psychotherapy plus device
223733824|NCT06061653|COMBINATION_PRODUCT|IPT plus sham HD-tDCS|psychotherapy plus sham device
223733825|NCT05890937|DIAGNOSTIC_TEST|Oral and practical exam|Oral and practical exam that performed at the end of the semester
223733826|NCT03742154|DRUG|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
223733827|NCT03784404|PROCEDURE|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
224021305|NCT06255327|OTHER|I COUGH care program|"The I COUGH program, initiated 10 hours after surgery, emphasizes the following elements:~Incentive spirometry: Encouraging patients to use the Flow-IS device ten times every two hours for three days.~Coughing and deep breathing: Participants should perform 3-5 coughs and deep breaths every 2 hours for 3 days.~Oral care: Brushing teeth and using mouthwash twice daily between 8:00 a.m. and 8:00 p.m. Mouth brushes should be sterile, and non-alcoholic mouthwash is recommended.~Understanding (education): Patients and their relatives receive instructions on the care program and steps to follow.~Getting out of bed: Patients are encouraged to sit in a chair at least once and walk at least 3 times per day in the room and corridor with assistance as needed.~Head-of-bed elevation: Keeping the head of the bed elevated more than 30 degrees."
224021306|NCT02628496|DRUG|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
224021307|NCT02628496|DEVICE|Confocal laser microlaryngoscopy|
224021308|NCT02628496|PROCEDURE|Biopsy (standard of care)|
224021309|NCT02628496|PROCEDURE|KTP laser photoablation (standard of care)|
224131495|NCT05233696|DRUG|Nab-paclitaxel|All patients are encouraged to receive nab-paclitaxel 100 mg/m2 IV D1 and D8 every 21 days (in combination with pembrolizumab) for at least 4-6 cycles per institutional standards and treating physicians' recommendations.
224131496|NCT05233696|DRUG|Paclitaxel|Paclitaxel can be substituted for nab-paclitaxel at the discretion of the treating physician 80 mg/m2 IV D1 and D8 every 21 days.
224131497|NCT05233696|RADIATION|Radiation Therapy|The treating radiation oncologist will select 1-4 sites of metastatic disease to target with radiation. All sites of disease may be targeted with radiation. Sites of metastatic disease planned to be biopsied should not be radiated.
224131498|NCT05233696|DRUG|Pembrolizumab|Patients will receive pembrolizumab 200 mg D1 every 21 days.
224131499|NCT02642887|PROCEDURE|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
224131500|NCT05391984|OTHER|Activity oriented treatment|15 patients will be treated with activity oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
224131501|NCT05391984|OTHER|Structural oriented treatment|15 patients will be treated with structural oriented therapy. All subjects will receive 20 therapeutic sessions, 5 times a week over the time span of 4 weeks.
224131502|NCT00093093|DRUG|Viramidine|
224131503|NCT00093093|DRUG|Ribavirin|
224131504|NCT00093093|DRUG|pegylated interferon alfa-2a|
224131505|NCT03213626|DRUG|Cabozantinib 40 MG|To be taken orally once daily
224131506|NCT03213626|DRUG|Erlotinib 100Mg Tab|To be taken orally once daily
224131507|NCT06088316|DRUG|group A : Amoxicillin Esomeprazole HDDT|"Group A - Amoxicillin 1gm 8 hourly after meal \& esomeprazole 40mg 8 hourly 30 minutes before meal for 14 days.~Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days."
223401032|NCT02845024|DRUG|placebo Group|Oral placebo was taken within 15 days
223401033|NCT04682808|DRUG|FCN-338|FCN-338 will be given orally in ascending doses starting at 50 mg QD until the maximum tolerated dose or recommended dose is reached.
223733828|NCT03784404|PROCEDURE|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
223733829|NCT03784404|DRUG|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
223733830|NCT01132157|DRUG|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
223733831|NCT01132157|DRUG|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
223733832|NCT00878527|DEVICE|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
223733833|NCT00279890|DRUG|Topical SR-01|
223733834|NCT04766125|BEHAVIORAL|Adverse event information|All patients have access to the standard material about adverse events related to the surgery. One arm will additionally receive elaborated adverse event information from a nurse and a surgeon
223733835|NCT05309564|DRUG|Botulinum toxin type A|Single intervention
223733836|NCT01065233|GENETIC|DNA extraction|DNA extraction of blood sample for DNAship analysis
224021310|NCT03587051|DIETARY_SUPPLEMENT|Low glycemic index post-exercise diet|Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise
224021311|NCT03587051|DIETARY_SUPPLEMENT|High glycemic index post-exercise diet|Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
224021312|NCT05636605|DIAGNOSTIC_TEST|Multiomics analysis|Genome, proteomics, single cell RNA sequencing, and space transcriptome sequencing，etc
224131508|NCT06088316|DRUG|group-B : Levofloxacin triple therapy|Group-B - Levofloxacin 500mg once daily after meal, Amoxicillin 1gm 12 hourly after meal \& Esomeprazole 20mg 12 hourly 30 minutes before meal for 14 days.
224131509|NCT00163150|DRUG|Atorvastatin|
224297157|NCT02496819|OTHER|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
223733837|NCT06471894|RADIATION|Magnetic resonance imaging scanning|Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals
223733838|NCT06471894|DRUG|FMT Protocol|Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
223733839|NCT03254927|DRUG|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
223733840|NCT00993291|PROCEDURE|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
223733841|NCT00993291|PROCEDURE|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
224021313|NCT00537693|PROCEDURE|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
224021314|NCT01457989|DRUG|retigabine/ezogabine|dose range up to 1200 mg/day
224131510|NCT04363489|DEVICE|Wearable Medical Device (Empatica E4)|A wearable medical device (Empatica E4) which is a smart wristband that detects skin temperature, heart rate and sleep. It is CE and FDA approved.
224131511|NCT04363489|DIAGNOSTIC_TEST|COVID-19 PCR Swab|COVID-19 PCR Swab will be self-taken by doctors every day. Fischer nasopharyngeal PCR Swabs
224131512|NCT04363489|DIAGNOSTIC_TEST|Pulse Oximeter|Participants will measure their oxygen saturations every day, and report them on the survey. Pulmolink A310 pulse oximeters
224131513|NCT06273657|OTHER|Medisinstart|Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
224131514|NCT03570281|DRUG|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
224131515|NCT03570281|DRUG|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance \<30 mL/min), for 90 days.
223401034|NCT03781908|DRUG|Silver Nitrate|First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.
223401035|NCT03781908|DEVICE|Indwelling Pleural Catheter|"First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture."
223401036|NCT04977804|OTHER|Exercise|The interventions are a form or exercise, specifically resistance exercise.
223401037|NCT04977804|OTHER|Eccentric plus blood-flow restriction|Eccentric plus blood-flow restriction
223733842|NCT01490957|OTHER|Database|Database
223733843|NCT03740958|DRUG|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
223733844|NCT03740958|DRUG|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
223401038|NCT05053633|PROCEDURE|Combined spinal epidural anesthesia|The Anxiety (Visual Analogue Scale for Anxiety), pain (Visual Analogue Scale), and the Analgesia Nociception Index (ANI) assessments are conducted at four specific time points: lateral position, local anesthesia, epidural needle puncture and 2 minutes after puncture.
223401039|NCT04815070|PROCEDURE|Ultrasonic measurement of antral area|"Ultrasound exam is done before the induction of spinal anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~The cross-sectional area (CSA) of antrum is shown by the following formula: CSA = AP x CC x ㅠ/4.~Antral area will correspond to the average of the three measures."
223401040|NCT00922077|BEHAVIORAL|standard physical therapy program with emphasis on dynamic balance exercises|
223401041|NCT00000292|PROCEDURE|Cocaine|
223733845|NCT01214018|OTHER|Questionnaires and interview|Questionnaires and interview
223733846|NCT01554150|BEHAVIORAL|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
223733847|NCT02763189|OTHER|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
223733848|NCT02763189|OTHER|Self-study|All subjects will receive self-study
223733849|NCT03950648|BEHAVIORAL|Spatial Cognitive Training|map reading and route-learning skills
224021315|NCT02309255|OTHER|no intervention|
224021316|NCT03009760|DRUG|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
224021317|NCT03009760|DRUG|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
224021318|NCT03009760|DRUG|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
224131516|NCT01249872|DRUG|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
224297158|NCT04272476|OTHER|acupuncture and moxibustion|
224297159|NCT04272476|DRUG|Fluoxetine|
223733850|NCT00530764|DRUG|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
223733851|NCT00530764|DRUG|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
223733852|NCT00530764|DRUG|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
223733853|NCT03929575|DIETARY_SUPPLEMENT|Placebo of calcium|Ingestion of 250 mg of calcium
223733854|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola|Ingestion of 250 mg of Rhodiola
223733855|NCT03929575|DIETARY_SUPPLEMENT|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
223733856|NCT00573534|DRUG|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
223733857|NCT02966990|DEVICE|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
223733858|NCT02650362|OTHER|fMRI|
223733859|NCT01572220|OTHER|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
224021319|NCT03009760|DRUG|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
224021320|NCT01981772|DRUG|4% lidocaine with 1:100,000 epinephrine|see arm/group description
224021321|NCT01981772|DRUG|4% buffered lidocaine with 1:100,000 epinephrine|see arm/group description
223733860|NCT04565860|OTHER|Bulk-fill composite resin. (Dental Composite Resin Materials) (Dental filling materials)|"Bulk-fill composites that were introduced in recent years are dental filling materials. Traditionally, the composite resins are placed in increments of 2 mm that are cured separately (incremental technique). Bulk-fill composites can be described as composites that are sufficiently polymerizable in a single layer up to 4 mm thick.~In this study, each bulk-fill composite resin was used both in bulk-filing and incremental techniques for the same patient. The study set to 4 groups and 20 restorations in each group (a total of 80 restorations)."
224021322|NCT02125747|OTHER|No Respiratory Therapy|Patients received conventional treatment.
224021323|NCT02125747|OTHER|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
224021324|NCT00609765|DRUG|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
224131517|NCT01249872|DRUG|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
224131518|NCT01249872|DRUG|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
224131519|NCT01249872|DRUG|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
224297160|NCT02856009|OTHER|completion of a quality of life questionnaire|
223401042|NCT03439241|DEVICE|Coloplast ostomy device|the test product is a newly developed Coloplast ostomy device
223401043|NCT04678518|DIAGNOSTIC_TEST|Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF|1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
223401044|NCT02881853|DRUG|XmAb7195|
223401045|NCT02881853|DRUG|Placebo|
223401046|NCT04719572|OTHER|Basic treatment group|A total of 60 subjects were recruited in the group.
223401047|NCT04719572|OTHER|Basic treatment+ anti-osteoporosis drug group|A total of 60 subjects were recruited in the group.
223401048|NCT04719572|OTHER|Basic treatment + non-drug treatment group|A total of 60 subjects were recruited in the group.
223733861|NCT02908503|OTHER|Placebo Film|placebo vaginal films
223733862|NCT00310791|DRUG|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
223733863|NCT00310791|OTHER|Placebo (Sugar Pill)|Placebo (sugar pill)
223733864|NCT00310791|DRUG|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
223733865|NCT03180151|PROCEDURE|piezotome assisted orthodontic tooth movement|"Surgical procedure~1. After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~2. The incisions will be kept minimal.~3. The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~4. A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~5. As we will not use bone graft so we don't need use suturing after cortication.~6. We give patient antibiotic and analgesic cover."
224021325|NCT00609765|DRUG|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
224021326|NCT00609765|DRUG|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
224131520|NCT01249872|DRUG|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
223733866|NCT03528993|OTHER|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
224021327|NCT00609765|DRUG|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
224021328|NCT00609765|DRUG|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
224021329|NCT00609765|DRUG|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
224021330|NCT02526147|OTHER|Cash|
224131521|NCT01249872|DRUG|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
224131522|NCT05323968|DIAGNOSTIC_TEST|Abdominal Ultrasonography|The result of the Abdominal Ultrasonography will be compared with that of the Abdominal Computerized Tomography
224131523|NCT05323968|DIAGNOSTIC_TEST|Abdominal Computerized Tomography|The result of the Abdominal Computerized Tomography will be compared with that of the Abdominal Ultrasonography
224131524|NCT02349334|DEVICE|Percutaneous Tibial Nerve Stimulation|
223401049|NCT04830631|DEVICE|Cathodal transcranial direct current stimulation (tDCS) over the contralesional motor cortex|Cathodal tDCS will be applied to the contralesional motor cortex with 2mA intesntisy for 30 mins/day. Total 10 sessions will be applied.
223401050|NCT00338416|DRUG|Epoetin alfa|
223401051|NCT02544438|DRUG|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~1. 0.5 gr/m2 (0.3 age\>50) 3~2. 1.5 gr/m2(0.8age\>50) 3~3. 3.0 gr/m2(1.5 age\>50) 3~4. 4.5 gr/m2(2.3 age\>50) 6~5. 4.5 gr/m2 (no age limit) 3 up to 6~6. 6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
223401052|NCT02629315|OTHER|Carnoy's solution|
223401053|NCT02629315|OTHER|10% neutral buffered formaldehyde|
223401054|NCT04578301|OTHER|No Intervention|No Intervention
223401055|NCT01211834|DRUG|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
223401056|NCT01211834|DRUG|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
223401057|NCT01211834|DRUG|Placebo|intravenously over 1 hour infusion every 4weeks
223401058|NCT01211834|DRUG|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
224131525|NCT04335266|DRUG|SHR2554|SHR2554
223733867|NCT03528993|OTHER|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
224131526|NCT00003117|DRUG|carboplatin|
223733868|NCT03528993|OTHER|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
223733869|NCT06379178|PROCEDURE|Oral colostrum application 2 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
223733870|NCT06379178|PROCEDURE|Oral colostrum application 4 hours|Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
224131527|NCT00003117|DRUG|paclitaxel|
224131528|NCT04020484|BEHAVIORAL|Making Mindfulness Matter© (M3)|Making Mindfulness Matter© (M3) is an interactive online parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3E is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
224131529|NCT05422352|DIETARY_SUPPLEMENT|Carnosine|Patients who will receive carnosine supplementation 500mg capsules (Now foods) in combination with Vitamin B complex (B1+B6+B12, 150 mg+100 mg+1 mg, respectively, Neurovit, European Egyptian Pharm. Ind., Egypt), two tablets per day
224131530|NCT03302793|DEVICE|BreEStim|BreEStim will applied for 10 to 20 minutes.
224131531|NCT03302793|DEVICE|tDCS|tDCS will be applied for 20 minutes.
224131532|NCT03302793|DEVICE|tDCS sham|
224021331|NCT02526147|OTHER|Voucher|
224021332|NCT02526147|OTHER|Food|
223401059|NCT00803608|DEVICE|TrueContour® Insole|Novel designed insole
223401060|NCT00803608|DEVICE|Current standard of care insole|Current Medicare approved A5513 insole
223401061|NCT04537078|DRUG|Duphaston|will be used for pituitary suppression in the first arm:20 mg/day will be started from the first day of the ovulation induction in the follicular phase and in the luteal phase will be started the next day after oocyte pickup at 20 mg/day.
223401062|NCT04537078|DRUG|Gonadotropin|will be used for controlled ovarian hyperstimulation in both arms
224021333|NCT03970070|OTHER|Informational Intervention|Complete Perioperative Ostomy Self-Management Telehealth program
224021334|NCT03970070|OTHER|Quality-of-Life Assessment|Ancillary studies
224021335|NCT03970070|OTHER|Questionnaire Administration|Ancillary studies
224021336|NCT03970070|OTHER|Survey Administration|Ancillary studies
224131533|NCT04574297|BEHAVIORAL|smoking and alcohol assumption|documenting the change of smoking and drinking status during the follow-up period
224021337|NCT00464009|BEHAVIORAL|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
223733871|NCT05281185|DRUG|Extended half-life FVIII concentrates with PK-guided dosing|Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
223733872|NCT05281185|DRUG|standard half-life FVIII concentrates with weight-based dosing|standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
223733873|NCT00959621|DRUG|Aspirin|ASA 100 mg once daily per os
224021338|NCT05801744|BEHAVIORAL|Operant conditioning|In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
224021339|NCT02094755|OTHER|Blood draw only|Blood draw only
223733874|NCT00959621|DRUG|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
224021340|NCT03548246|DRUG|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
224021341|NCT03548246|DRUG|Placebo|Daily placebo for 2 years.
224021342|NCT03548246|DRUG|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
223401063|NCT04537078|DRUG|Cetrotide Injectable Product|will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
223552607|NCT03980743|BEHAVIORAL|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
224131534|NCT04574297|DIAGNOSTIC_TEST|genetic sequencing|sequencing the susceptibility genes for CP, including serine protease inhibitor Kazal type 1, cationic trypsinogen, cystic fibrosis transmembrane conductance regulator, chymotrypsin C, etc.
224131535|NCT00870831|OTHER|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
224131536|NCT01947244|BEHAVIORAL|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
224131537|NCT01947244|BEHAVIORAL|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
224131538|NCT01192750|OTHER|immunohistochemistry staining method|
223401064|NCT04537078|DRUG|Decapeptyl|will be used for ovulation triggering.in the first arm:in a dose of 2 ampules of 0.2 mg will be administered when leading follicle \>18 mm in diameter. in the second arm:in a dose of 2 ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter in the first cycle only.
223401065|NCT04537078|DRUG|Chorionic Gonadotropin|will be used in the second cycle of the second arm for ovulation triggering in a dose of 10,000 IU when the leading follicle \>18 mm in diameter.
223401066|NCT04537078|DRUG|Combined Oral Contraceptive|luteal phase priming from day 21 of the cycle before controlled ovarian stimulation for one week .
223552608|NCT03980743|BEHAVIORAL|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
223733875|NCT00959621|DRUG|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
223733876|NCT06034236|OTHER|Resistance training|"Task oriented resistance training will be performed, there will be 10 workstations:~1. Sitting at a table and reaching in different directions for objects located beyond arm's length.~2. Sit to stand from various chair heights~3. Stepping forward, backward and sideways onto blocks of various heights.~4. Heel lifts in standing~5. Standing with narrow base of support, feet in parallel and tandem stance and reaching for objects, including down to the floor.~6. Reciprocal leg flexion and extension.~7. Sit ups~8. Standing up from chair, walking a short distance and returning to the chair.~9. Walking races between participants~10. Walking over various surfaces and obstacles"
224021343|NCT03548246|DRUG|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
224131539|NCT01192750|OTHER|laboratory biomarker analysis|
224131540|NCT01192750|OTHER|medical chart review|
224131541|NCT00121511|DRUG|Efudex (5-fluorouracil)|
224131542|NCT03524833|DRUG|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
224021344|NCT02622009|PROCEDURE|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
223733877|NCT06034236|OTHER|Otago Exercises|"It has total 17 exercises, out of which 12 exercises are performed to improve balance and 5 are performed to improve strength.~1\. First component of intervention starts with head movements followed by neck movements, back extension, trunk movements and ankle movements.~2\. Second component is muscle strengthening exercises, it includes: i. Front knee strengthening exercise ii. Back knee strengthening exercise iii. Side hip strengthening exercise iv. Calf raises (with support and without support) v. Toe raise (with support and without support). 3. Third component is balance exercises, it includes: i. Knee bends ii. Backward walking iii. Heel toe standing iv. Heel toe walking v. One leg stand vi. Heel walking vii. Sideways walk viii. Toe walking ix. Heel toe walking backwards x. Walk and turn around (figure of 8) xi. Sit to stand xii. Stair walks"
223733878|NCT02697032|DRUG|Bicalutamide|150mg
224021345|NCT00577356|DRUG|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
224021346|NCT00577356|BIOLOGICAL|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
223733879|NCT02697032|PROCEDURE|FDHT PET|PET scan
223733880|NCT03383198|DRUG|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
223733881|NCT03383198|DRUG|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
224021347|NCT00882687|DRUG|Lifitegrast|Ophthalmic Solution
224021348|NCT00882687|OTHER|Placebo|Ophthalmic Solution
224021349|NCT05405452|DEVICE|Vibration Anesthesia Device by Blaine Labs|Device which vibrates on top of skin
224131543|NCT03524833|DRUG|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
224131544|NCT04705558|OTHER|continuous moderate intensity aerobic training|continuous moderate intensity aerobic exercises with ketogenic diet group underwent supervised moderate-intensity exercised on a treadmill at 50%-70% of heart rate reserve for three month
224131545|NCT04705558|OTHER|ketogenic diet|Ketogenic diet: a low carbohydrate high-fat diet consisted of the following nutrient conformation: 80% fat, 15% protein and 5% carbohydrates, entire daily intake was estimated to be 20-30 g of carbohydrates for three month.
224131546|NCT03532555|DIETARY_SUPPLEMENT|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
224021350|NCT05405452|DRUG|Gebauers Ethyl Chloride 100% Topical Spray|Sterile ethyl chloride spray
224131547|NCT03532555|OTHER|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
224297161|NCT03528785|DRUG|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"* Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
224131548|NCT07010822|BIOLOGICAL|nOPV2|nOPV2 will be administered at birth and Wk 14 of age depending on the study arm.
224131549|NCT06625723|PROCEDURE|Standard postoperative care|This will include medications, rehabilitation schedules, and follow-up visits as normally scheduled.
224131550|NCT06625723|DEVICE|Surgical Recovery Systems Sleep Aid|Sleep assistive device
224131551|NCT03175003|OTHER|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
224297162|NCT01274806|OTHER|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
224297163|NCT06304649|DEVICE|Cast or brace alternative|Waterproof alternative to a cast or brace for broken bones
224297164|NCT02006537|DRUG|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
223401067|NCT04537078|DRUG|Cyclo-Progynova|Starting from cycle Day 3 of the intented cycle for thawed embryo transfer, patients will receive the white tablets of Cyclo-Progynova daily. From Day 10 onwards, endometrium growth will be monitored by transvaginal ultrasound.
223401068|NCT04537078|DRUG|progesterone|in the intended cycle of embryo transfer when endometrial thickness ≥ 7 mm. Progesterone administration (as 800 mg/day vaginal suppositories per day and 100 mg ampule IM every other day) will be continued until pregnancy testing 18 days after embryo transfer and in pregnant cases will continued till the 12 weeks of gestation.
224297165|NCT01405131|DRUG|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
223401069|NCT02154607|DEVICE|CO2-Laser Treatment|
223401070|NCT00357292|DRUG|Azithromycin (T1225)|
223401071|NCT03892798|OTHER|No interventions are planned|No interventions are planned
223401072|NCT03068377|DIETARY_SUPPLEMENT|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
223401073|NCT03068377|DIETARY_SUPPLEMENT|Placebo|soft gel capsules without test material
223401074|NCT00121914|PROCEDURE|percutaneous ethanol instillation (PEI)|
223401075|NCT04886843|OTHER|Cold pack|Five minutes cold pack was applied on the affected side dorsiflexor muscle skin, a five-minute break was given and a further 5-minute cold application was repeated
223401076|NCT04886843|DEVICE|NMES|NMES was applied to the nonaffected side ankle dorsiflexors
223401077|NCT01033903|DRUG|misoprostol|800 micrograms intravaginally ONCE
223401078|NCT04298970|DIETARY_SUPPLEMENT|Intervention|Freeze-dried Brassica oleracea var. acephala
223401079|NCT04298970|DIETARY_SUPPLEMENT|Placebo|Placebo product
223401080|NCT05682209|DRUG|Octreotide Injection|100µg of octreotide intravenously 8-hourly for 5 days from the first post-operative day
223401081|NCT05682209|OTHER|Sterile water|1ml of sterile water intravenously 8-hourly for 5 days from the first post-operative day
224297166|NCT01405131|DRUG|methylprednisolone|tablets 32 mg single dose
224131552|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
224131553|NCT03499951|BEHAVIORAL|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
224131554|NCT02126111|BIOLOGICAL|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
224021351|NCT01958307|BEHAVIORAL|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
223733882|NCT01935271|DIETARY_SUPPLEMENT|Muscle Armor Supplement|
223733883|NCT01935271|DIETARY_SUPPLEMENT|Placebo|
223733884|NCT02759679|OTHER|Human breath samples|
223733885|NCT03123653|DRUG|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
223733886|NCT05037591|DRUG|Sea grapes extract 1.68 g/70kg BW|Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
223733887|NCT05037591|DRUG|Placebo|placebo lactose powder (1.68 g/70kg BW day-1).
223733888|NCT02814851|DEVICE|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
223733889|NCT02814851|DEVICE|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
224021352|NCT05342025|OTHER|PNF|PNF will be applied to the trunk and upper extremities combined with breathing, 3 times a week, 1 hour a day for 6 weeks. Breathing PNF patterns, pressure, and stretches will be applied inward and upwards into the rib cage so that they do not cause pain. Diaphragmatic stimulation will be performed on both sides with repeated contractions, hand contacts, and stabilization techniques. Facilitation techniques will be used to stimulate the intrinsic respiratory muscles. Again, with respect to inspiration, the patterns will be studied in neck extension, upper and lower trunk extension, and upper extremities flexion patterns. Neck flexion, upper and lower trunk flexion, and extension patterns of the upper extremities will be applied in relation to expiration. The physiotherapist will apply pressure and stretches to the chest wall and diaphragm for 20 seconds by giving verbal commands to the patient for the inspiration/expiratory phases.
224021353|NCT05342025|OTHER|Breathing exercises|Breathing exercises: diaphragmatic breathing, thoracic expansion, pursed-lip breathing and respiratory control for 15 minutes a day, every day of the week.
224021354|NCT05169138|OTHER|Aromatherapy application /massage with lavender oil|The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.
224021355|NCT05169138|OTHER|Aromatherapy application / inhalation with lavender oil|The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
224131555|NCT02126111|BIOLOGICAL|DEPIGOID Placebo|Placebo for subcutaneous administration
223401082|NCT06577311|COMBINATION_PRODUCT|Aminolevulinic acid hydrochloride 10% topical gel with Red Light|Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®), followed by red light therapy administered for 13 minutes and 30 seconds to deliver the total desired light dose to the SCCis lesion.
224131556|NCT02017678|BIOLOGICAL|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
224131557|NCT07034963|DRUG|Determine the ED50 and ED95 of esketamine|According to Dixon's up-and-down sequential design, esketamine will be initiated at 0.3 mg∙kg-1 intravenously, followed by dose adjustments (0.02 mg∙kg-1 increments/decrements) based on somatic responses to cervical dilation (positive: any movement; negative: no movement). The tests will continued until six crossover pairs are achieved.
224131558|NCT07034963|DRUG|Intravenous the dose of esketamine ED95|The intervention group will be injected with the dose of esketamine ED95.
224131559|NCT07034963|DRUG|Intravenous remifentanil 1μg∙kg-1|The control group will be injected with remifentanil 1μg∙kg-1.
224297167|NCT04960319|DEVICE|Intravascular Lithotripsy|Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
223401083|NCT04940273|DRUG|Remifentanil Injection [Ultiva]|Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.
223401084|NCT02479451|DRUG|Theophylline|The study medication will be provided by Foundation Care.
223401085|NCT02525120|DEVICE|Triojection|Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
223401086|NCT02525120|PROCEDURE|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
223401087|NCT02044120|DRUG|niraparib|
223401088|NCT02044120|DRUG|Temozolomide|
223401089|NCT02044120|DRUG|Irinotecan|
223733890|NCT02814851|DEVICE|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
223733891|NCT02814851|DEVICE|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
224021356|NCT03594604|DRUG|Norethindrone|Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.
223733892|NCT04205071|DRUG|Lorcaserin|Given PO
224131560|NCT06712420|DRUG|neoadjuvant chemotherapy|NACT group will receive gemcitabine and platinum combination. Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days. In case of renal compromise, carboplatin was used. Response was assessed using CECT abdomen and PET scan. Chemotherapy related toxicity will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 5 .0. PAtients will undergo curative surgery after neoadjuvant chemotherapy
224131561|NCT06712420|PROCEDURE|curative surgery|Patient being taken up for surgical exploration will undergo staging laparoscopy followed by exploration and interaortocaval lymphnode sampling. After ruling out distant metastasis, local resectability will be reassessed and curative surgery will be performed. . Post-operative complications were recorded and graded according Clavien Dindo classification
224131562|NCT06330844|BEHAVIORAL|Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)|RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.
224131563|NCT06330844|BEHAVIORAL|Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)|"ME-CCT focuses on:~1. Cognitive training, psychotherapeutic, and lifestyle techniques.~2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving).~3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations."
224131564|NCT06104228|DRUG|129Xe Hyperpolarized|Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490
224131565|NCT06077292|BEHAVIORAL|15% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 15% less potent than baseline
224131566|NCT06077292|BEHAVIORAL|35% THC Potency Reduction|Participants will be incentivized to use THC products that are at least 35% less potent than baseline
224131567|NCT00228969|DRUG|RWJ-333369|
224131568|NCT03522350|DEVICE|EmbryoScope|Standard of care arm
223552609|NCT06835322|DRUG|Finerenone|50 patients with biopsy proven glomerulonephritis who will receive 10 - 20 mg finerenone once daily orally in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
223552610|NCT06835322|DRUG|Placebo|50 patients with biopsy proven glomerulonephritis who will receive placebo once daily in addition to their regular treatment protocol (RAAS blockers ± immunosuppression) for 6 months.
223552611|NCT05143593|DIAGNOSTIC_TEST|results of SSBD are used to guide antibiotics adjustment|secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
223552612|NCT03740399|PROCEDURE|spinal anesthesia|Investigators will perform spinal anesthesia for section
223552613|NCT03702062|DIAGNOSTIC_TEST|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
224131569|NCT03522350|DEVICE|EmbryoScope+|Experimental arm
224131570|NCT00786032|DEVICE|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
224131571|NCT04573127|OTHER|descriptive study|Retrospective analysis of existing data collected as a part of the regular follow-up
223552614|NCT00294671|DRUG|diflunisal|given twice daily for 24 months
223552615|NCT00294671|OTHER|placebo|an inactive substance given twice daily for 24 months
223552616|NCT01966354|PROCEDURE|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
224021357|NCT03594604|DRUG|oral contraceptive pill|Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
224021358|NCT01708993|DRUG|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
223733893|NCT04205071|DRUG|Lorcaserin Hydrochloride|Given PO
223733894|NCT04205071|OTHER|Questionnaire Administration|Ancillary studies
223733895|NCT05255406|DRUG|Furmonertinib (160mg)|160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).
223733896|NCT04053205|DRUG|Gentuximab|Administered intravenously (IV)
223733897|NCT04053205|DRUG|Paclitaxel|Administered intravenously (IV)
223733898|NCT02630498|PROCEDURE|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
223733899|NCT05909098|COMBINATION_PRODUCT|autologous NK cell|autologous NK cell
224021359|NCT01708993|DRUG|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
224021360|NCT01708993|DRUG|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
224021361|NCT01708993|DRUG|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
224021362|NCT02418221|DIETARY_SUPPLEMENT|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
224021363|NCT02418221|PROCEDURE|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure \& pulse
223733900|NCT00875225|BEHAVIORAL|DVD|Control group will receive usual care DVD from health professionals
224131572|NCT02307669|BEHAVIORAL|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
223733901|NCT00875225|BEHAVIORAL|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
224021364|NCT01251731|DRUG|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
224021365|NCT01251731|DRUG|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
224131573|NCT02307669|BEHAVIORAL|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
223552617|NCT01234038|DRUG|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
223552618|NCT01234038|DRUG|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
223552619|NCT01234038|DRUG|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
223552620|NCT01234038|DRUG|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
223552621|NCT01234038|DRUG|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
223552622|NCT02810288|BEHAVIORAL|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
223552623|NCT02346903|DRUG|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
223552624|NCT01047137|BEHAVIORAL|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
223552625|NCT01047137|BEHAVIORAL|General Supportive Therapy|There is no focus on stress intervention.
223552626|NCT04830306|BEHAVIORAL|Exercise|Completion of exercise in accordance with assigned protocol
223552627|NCT00109213|PROCEDURE|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
223552628|NCT00109213|PROCEDURE|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
223552629|NCT04627090|OTHER|Data collection|Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
223552630|NCT06089863|OTHER|PAMPERO program|"This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation"
223552631|NCT04348812|BEHAVIORAL|ABMT|mobile attention bias modification training for anxiety, using the app Personal Zen
223552632|NCT04348812|OTHER|Transcranial direct current stimulation|Soterix 1X1 tDCS Limited Total Energy (LTE) Stimulator
223552633|NCT04367155|DRUG|Tranexamic acid injection|hemostatics use
223552634|NCT03753360|BEHAVIORAL|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
223552635|NCT03753360|BEHAVIORAL|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
223733902|NCT05633121|PROCEDURE|Rheopheresis|Technique of apheresis in double filtration, allowing the extraction of molecules of high molecular weight, and thus the improvement of the rheological conditions of microcirculation. The expected effect is the improvement of tissue oxygenation and the acceleration of the healing of skin lesions, with the consequent reduction of infectious complications.
223733903|NCT00102882|DRUG|fluticasone propionate/salmeterol|
223733904|NCT00102882|DRUG|salmeterol xinafoate|
223733905|NCT04925128|OTHER|Moderate Physical Activity + Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain Moderate physical activity on treadmill, brisk walk was performed 5 days a week for 30 minutes at 4 mph speed (3-6 METs) with warm up for a 5 minutes at low speed and then at the end speed was also decreased for a 5 minutes"
223733906|NCT04925128|OTHER|Conventional Physical Therapy|"Hot pack and TENS for 10 minutes at the affected shoulder. Passive shoulder mobilizations were performed initially at pain free range in anterior, posterior, and inferior direction (10 reps x 1 set).~Shoulder rolls, pendulum stretch, cross body arm stretch and towel stretch (10 reps x 1 set) were actively performed by the patient with-in limits of pain"
223733907|NCT00467259|DRUG|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
223733908|NCT00467259|DRUG|Placebo patch|placebo patch, changed twice a week for 52 weeks
223733909|NCT03655197|DRUG|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
223733910|NCT00258245|DIETARY_SUPPLEMENT|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11
223733911|NCT00258245|DRUG|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
223733912|NCT00258245|DRUG|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
223733913|NCT00258245|DRUG|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
223733914|NCT00258245|DRUG|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
223733915|NCT00258245|DRUG|Aspirin|Aspirin - 325 mg by mouth (PO) every day
223733916|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
223733917|NCT00611286|DRUG|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
223733918|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
223733919|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
224021366|NCT01251731|DRUG|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
224021367|NCT01251731|DRUG|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
224021368|NCT02592408|DRUG|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
224021369|NCT02592408|DRUG|SDPQ|single dose primaquine on day 2
224021370|NCT02592408|DRUG|14DPQ|14 day primaquine starting on day 2
224021371|NCT02592408|DRUG|14DPQ on Day 42|14 day primaquine starting on day 42
224021372|NCT01063660|DRUG|Treosulfan|14 g/m²/d day -6 to -4
224021373|NCT04828200|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|The ultrasonographic assesment will be used to examine the rectus femoris, gastrocnemius medailalis and rectus abdominis subcutaneous and muscle thickness. Additionally, fascicle length and pennation angle were measured between the two parallel aponeuroses of the gastrocnemius muscle (bulkiest part of medial head) in the longitudinal view when subjects were in prone position with their ankles at 90°.
224021374|NCT04828200|DIAGNOSTIC_TEST|Dual-X-ray absorptiometry|The muscle masses of the patients were evaluated by measuring the fat mass (Fat Mass-FM), fat mass index (FMI), lean body mass (LBM) and skeletal muscle index (SMI) calculated by DEXA. Appendicular muscle mass (ASM) is calculated by summing the lean soft tissue of the two upper limbs and the two lower limbs. Skeletal muscle mass index is calculated by dividing the appendicular lean mass by the square of the neck height \[SMI = ASM / height2 (kg / m2)\].
224021375|NCT04828200|DIAGNOSTIC_TEST|Isokinetic dynamometer|Quadriceps-hamstring Peak Torque (PT) values and the ratio of PT values to body weight (PT / VA) (at 60 and 180 ° / sec speeds) were evaluated with an isokinetic dynamometer
224021376|NCT00729872|BIOLOGICAL|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
224021377|NCT00729872|OTHER|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
224131574|NCT02457182|OTHER|Mindfulness-based Stress Reduction (MBSR)|
224131575|NCT02457182|OTHER|Usual medical therapy|
224131576|NCT00304265|BIOLOGICAL|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
224131577|NCT04436809|PROCEDURE|Sentinel Node Biopsy|"Colloidal radiotracer (99Tc) is injected into the breast near the cancer. The radiotracer moves in the lymph ducts to accumulate in the first lymph nodes (almost always in the axilla) to receive lymph from the breast area containing the cancer. Lymphoscintigraphy is used to check for the presence of radioactivity in the axilla. Some hours later, during breast surgery, a radioactivity-detecting probe is used to identify hot lymph nodes (sentinel nodes) and aid their surgical removal from the axilla. These nodes are examined histologically (intraoperatively) for the presence of cancer. If they are disease-free the axilla will be left intact (no further axillary treatment given); if they contain cancer most lymph nodes in the axilla will be removed surgically (axillary dissection)."
224021378|NCT02649946|DEVICE|Covera Vascular Covered Stent following PTA|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
224131578|NCT04436809|PROCEDURE|Axillary Dissection|Axillary dissection is the surgical removal of all Berg level I and II lymph nodes present in the axilla. The operation is carried out, at our Institute, during the surgery to treat the cancer in the breast (either breast-conserving surgery - quadrantectomy, or mastectomy).
224131579|NCT02294318|BEHAVIORAL|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
224131580|NCT02294318|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
224131581|NCT00000585|DRUG|penicillin|
224131582|NCT01832012|OTHER|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
224131583|NCT01832012|OTHER|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
223401090|NCT06070467|OTHER|Mixed Methods Research (MMR) using quantitative (QUAN) and qualitative (QUAL) tools|"A Mixed Methods Research (MMR) using quantitative (QUAN) Vision Related-QoL (VR-QoL = FVQ-CYP and VQoL-CYP) tools and psychosocial PEM-CY, and qualitative (QUAL) socio-anthropologic investigations can capture reliably children's and teenagers' Patient-Reported Outcome (PRO).~The QUAN study is a cross-sectional study including short-term re-test repetition (children/teenagers only) using the following PROMs for children/teenagers:~1. Self-reported questionnaires for patients (FVQ-CYP and VQoL-CYP)~2. For caregivers: PEM-CY questionnaires~The QUAL study will rely on the following instruments:~1. Semi-directive interviews,~2. Focus groups,~3. Field observation."
223401091|NCT01568892|DRUG|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
223401092|NCT01568892|DRUG|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
223552636|NCT06468891|OTHER|Incontinence Symptom Severity Index|"* The ISSI consists of eight items that assess different aspects of urinary incontinence symptoms, including emptying difficulties, nocturia, daytime frequency, stress incontinence, urge incontinence, leakage with activity, and pad use.~* Each item is scored on a scale of (0 to 3) or (0 to 4), depending on the severity of the symptom. Higher scores indicate more severe symptoms.~* The total ISSI score is obtained by summing the scores of all eight items, resulting in a range of 0 to 32 or 0 to 40, depending on the version used.~* The severity of urinary incontinence symptoms can be categorized based on the total ISSI score"
223552637|NCT06468891|OTHER|Force platform|"Use the provided software or tools to analyze the recorded force data, including Step Cycle Duration (ms), Time of Contact (ms), Swing Duration (ms), Single Step Duration (ms), Double Support Duration (ms), Initial Contact (ms) , Loading Response (ms), Mid Stance (ms), Terminal Stance (ms), Step Cycle Length, Half Step Length for left and right lower limbs.~* Interpret the data to draw conclusions about the forces exerted during the subject's movements or activities."
223552638|NCT06468891|OTHER|The STT three-dimensional motion analysis (3DMA) system|The STT three-dimensional motion analysis (3DMA) system (STT Systems Company, Zuatzu Business Park, Easo Building, 2nd Floor, San Sebastián, Spain) was used for the assessment of spatiotemporal characteristics of gait. It is an indoor optical system that consists of four cameras, fifteen markers, and computer software for automatic three-dimensional motion capture and analysis. CLINICAL 3DMA V.6.11 is professional software with highly accurate marker tracking. The STT Helen Hayes protocol was used for the gait analysis in this study.
223733920|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
223733921|NCT00611286|DRUG|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
223733922|NCT00611286|DRUG|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
223733923|NCT00611286|DRUG|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
223733924|NCT04885972|DRUG|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
223733925|NCT04885972|DRUG|Zilretta|Zilretta is an extended-release corticosteroid approved to manage osteoarthritis knee pain.
223733926|NCT04885972|DRUG|Placebo|Vehicle solution
224131584|NCT01116687|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
223733927|NCT01516346|DRUG|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
224021379|NCT02649946|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon|Treatment of stenoses with PTA only
224131585|NCT01116687|OTHER|laboratory biomarker analysis|Correlative studies
223401093|NCT01762644|DRUG|Oral Cyclosporine and Oral Omeprazole|
223401094|NCT01762644|DRUG|Oral Omeprazole|
223401095|NCT01567774|DRUG|Atorvastatin|os, 20 mg, once per day, for 30 days
224131586|NCT04265170|DEVICE|BlastX with negative pressure therapy|Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
224131587|NCT03294408|DIAGNOSTIC_TEST|multimodal imaging|
224131588|NCT01187784|BEHAVIORAL|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
224131589|NCT04082468|DIAGNOSTIC_TEST|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T \& B lymphocyte panel at above time points
224131590|NCT01313520|DRUG|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
224131591|NCT01313520|DRUG|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
223733928|NCT01516346|DRUG|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
223733929|NCT01516346|DRUG|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
223733930|NCT04600674|PROCEDURE|Delayed cord clamping|DCC performed at 60 sec after birth
223733931|NCT04600674|PROCEDURE|Early cord clamping|ECC performed at 15 sec after birth
223733932|NCT04541862|OTHER|Intensive care|intensive care for critically ill patients in the intensive care units
223733933|NCT04357678|OTHER|Qi Gong Programme|"Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week."
223733934|NCT04357678|OTHER|Short Form Sun Style Tai Chi|"Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session."
223733935|NCT01915082|DRUG|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
223733936|NCT01915082|DRUG|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
223733937|NCT01150981|DRUG|Rosiglitazone|One 8mg capsule daily for 6 weeks.
223733938|NCT01150981|DRUG|Placebo|One capsule daily for 6 weeks.
223401096|NCT01567774|DRUG|Rosuvastatin|os, 10 mg, once per day, for 30 days
223401097|NCT04503148|DRUG|Propofol|Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
223401098|NCT04503148|DRUG|Inhaled General Anesthetics|Sevoflurane or desflurane for induction and maintenance of anesthesia
223401099|NCT02199431|DRUG|Lu AF11167|
223552639|NCT02515799|DRUG|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
223552640|NCT02515799|OTHER|Placebo|Inhaled Placebo
223552641|NCT06014853|DRUG|SOL-804-F|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
223552642|NCT06014853|DRUG|Zytiga|All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
224131592|NCT00506571|DRUG|S-1, irinotecan, oxaliplatin|
224131593|NCT05841264|BEHAVIORAL|good feeding, cleaning|taking healthy food which contain minerals, vitamins essential for normal growth
224131594|NCT00789191|DRUG|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
224131595|NCT00789191|DRUG|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
223401100|NCT02199431|DRUG|Itraconazole|
223401101|NCT00094731|PROCEDURE|Memory Training|
223401102|NCT01836731|BEHAVIORAL|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
223401103|NCT01836731|BEHAVIORAL|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
223401104|NCT02182492|DRUG|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
223401105|NCT02182492|DRUG|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
223401106|NCT02865967|OTHER|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
223552643|NCT02378233|DIETARY_SUPPLEMENT|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
223552644|NCT02378233|DIETARY_SUPPLEMENT|Placebo|Patients are given a non-iodine containing multivitamin tablet
223552645|NCT01282242|DRUG|IV rt-PA|open-label
223552646|NCT05313269|OTHER|ISAFE technique for adductor canal catheter insertion|Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.
223401107|NCT02865967|OTHER|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
224021380|NCT02783521|BEHAVIORAL|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
224131596|NCT00789191|DRUG|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
223733939|NCT05988099|DIETARY_SUPPLEMENT|Complex product|400 mg of chokeberry extract in liposomal formulation and L-arginine, vitamin E, vitamin A, folic acid, chromium
223733940|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in liposomal formulation|400 mg of chokeberry extract in liposomal formulation
223733941|NCT05988099|DIETARY_SUPPLEMENT|Chokeberry extract in traditional formulation|400 mg of chokeberry extract in traditional formulation
224131597|NCT00789191|DRUG|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
223401108|NCT03027635|DEVICE|PleurX, peritoneal tunnelated catheter|A permanent catheter
223401109|NCT03027635|DEVICE|Large Volume Paracentesis|Short time drainage
223401110|NCT03027635|DRUG|Ciprofloxacin 500Mg Tablet|SBP prophylaxis
223401111|NCT06142604|DRUG|Flecainide|Single 300mg dose of oral flecainide
223401112|NCT00249301|DRUG|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
223401113|NCT06348069|BEHAVIORAL|Pharmacy-based PrEP refill and gift voucher|The intervention arm of this study introduces the opportunity for a pharmacy-based PrEP refill system for sex workers, coupled with financial incentives to increase adherence. Participants receive PrEP medications from selected pharmacies, a strategy designed to improve PrEP access and enhance privacy/discretion. Additionally, participants in the intervention are awarded escalating gift card values for each successful refill collection at study pharmacies, aiming to incentivize continued PrEP use for effective HIV prevention. The intervention seeks to enhance convenience and motivate adherence through financial rewards.
223401114|NCT06348069|BEHAVIORAL|Control (Standard of care)|For sex workers in the control group, PrEP refill pick-up will be available through CESHHAR's existing network of clinical sites. There is no gift card incentive and no pick-up at private pharmacies.
223401115|NCT02809729|DRUG|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
223401116|NCT02809729|DRUG|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
223401117|NCT02809729|PROCEDURE|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
223401118|NCT02809729|OTHER|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
223401119|NCT01659983|PROCEDURE|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
223401120|NCT01256450|DRUG|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
223733942|NCT05988099|OTHER|Placebo|Placebo
223733943|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
223733944|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
223401121|NCT01256450|DRUG|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
223401122|NCT06468085|PROCEDURE|premixed Bioceramic NeoPUTTY®|Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
223401123|NCT06468085|PROCEDURE|Biodentine™|Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic or Biodentine™ according to the corresponding group then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
223401124|NCT06468085|PROCEDURE|Root canal treatment|Root canal treatment will be performed to the control group followed by composite restoration. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
223401125|NCT04915313|DEVICE|Remote ischemic conditioning (RIC)|RIC is a non-invasive therapy which is performed by automated pneumatic cuffs placed on bilateral arms. The RIC protocol include five cycles of 5-min inflation to 200mmHg and 5-min deflation.
224021381|NCT02783521|BEHAVIORAL|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
223733945|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
223733946|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
223733947|NCT02654730|DRUG|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
223733948|NCT05449652|OTHER|To prescribe exercise prescription for CVD patients|To prescribe exercise intensity, frequency, session duration, program duration, and exercise type (endurance or strength training) for the same three patient cases
223733949|NCT02703662|DEVICE|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
223401126|NCT04915313|DEVICE|Sham remote ischemic conditioning (Sham-RIC)|The Sham-RIC protocol include five cycles of 5-min inflation to 60 mmHg and 5-min deflation by placing automated pneumatic cuffs on bilateral arms.
223401127|NCT03426618|OTHER|Non-interventional|Non-interventional
223733950|NCT02703662|DEVICE|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
223733951|NCT00002014|DRUG|Zidovudine|
223733952|NCT00002014|DRUG|Didanosine|
223733953|NCT00828347|DRUG|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
223733954|NCT00828347|DRUG|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to \< 150 pg/mL by initial maxacalcitol therapy.
223733955|NCT01411904|DEVICE|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
223733956|NCT02012075|DRUG|Extended-Release Carvedilol Sulfate|
223733957|NCT02012075|DRUG|Sustained-release Metoprolol Succinate|
224021382|NCT03687047|DEVICE|New complete dentures|Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
224021383|NCT00407277|DRUG|Nicotine patch|21 mg of nicotine via a dermal patch
224021384|NCT00407277|OTHER|placebo|placebo via a dermal patch
224021385|NCT00407277|BEHAVIORAL|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
224131598|NCT04534036|DIETARY_SUPPLEMENT|PDS-08|PDS-08 is a novel synbiotic comprised of nine probiotic bacterial strains and FOS-inulin as a prebiotic.
223733958|NCT03471130|DRUG|MT-8554 Low dose|Oral, 7 days
223733959|NCT03471130|DRUG|MT-8554 High dose|Oral, 7 days
223733960|NCT03471130|DRUG|Placebo|Oral, 7 days
223401128|NCT06155929|BEHAVIORAL|Flight|The participants are flying to turkey and back home. The flights are the intervention.
224131599|NCT04534036|OTHER|Placebo|Placebo sachets will contain potato or tapioca maltodextrin.
224297168|NCT04068974|DRUG|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
224297169|NCT04068974|DRUG|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
223401129|NCT00566241|DRUG|recombinant human IGF-1|rhIGF-1
223401130|NCT00566241|DRUG|Placebo|Placebo
223401131|NCT02183324|DRUG|Low dose of BI 1356 BS|
223401132|NCT02183324|DRUG|Medium dose of BI 1356 BS|
223401133|NCT02183324|DRUG|High dose of BI 1356 BS|
223401134|NCT02183324|DRUG|Placebo|
223401135|NCT01867125|DRUG|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
223733961|NCT03019133|DEVICE|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
223733962|NCT03019133|DEVICE|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
223733963|NCT05862415|OTHER|therapeutic Exercise|"The circular training method was used in the resistance training phase. During the aerobic training phase, a series of movements from moderate intensity to vigorous intensity was performed. The step loading periodization principle was taken into account in both resistance training and aerobic exercises.~The RT lasted approximately 20-25 min per session and included two sets of 8-20 repetitions, with a rest interval of 1-2 min. The RT exercises included: squat, barbell bent-over row, overhead press, plank, lateral pull down, triceps push down, barbell curl, leg extension, leg curl, lunge, barbell bench press, crunches etc.~For the aerobic training: Intensity was established between 50-65% and 80-85% of HRmax for both groups (SAG and ASG). Aerobic training includes walking and running periods and was carried out on a 400 m outdoor track. In periodization, especially 1st-4th."
223733964|NCT00002416|DRUG|Emtricitabine|
223733965|NCT00002416|DRUG|Lamivudine|
224021386|NCT03862846|DRUG|REN001|Once daily
223552647|NCT05313269|OTHER|Conventional technique for adductor canal catheter insertion|Adductor canal block catheter tip located lateral to the femoral artery.
223733966|NCT00304993|DRUG|fenofibrate|
223401136|NCT01867125|DRUG|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
223552648|NCT02263326|DRUG|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
223552649|NCT02263326|DRUG|lamivudine|300 mg tablet by mouth once daily for 48 weeks
223401137|NCT05188261|DRUG|IW-3300|A single dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
223401138|NCT05188261|DRUG|Placebo|A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
223552650|NCT02263326|DRUG|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
223552651|NCT01893411|DRUG|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
223552652|NCT01893411|DRUG|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
223552653|NCT01893411|DRUG|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
223733967|NCT00304993|DRUG|niacin|
223733968|NCT00304993|DRUG|rosiglitazone|
223733969|NCT05655962|OTHER|STARS|STARS is a structured framework for assessment of rehabilitation and sicklisting, applied by primarily the rehabilitation coordinators working at the primary health care centers.
223733970|NCT01129960|DRUG|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
223733971|NCT01129960|DRUG|Placebo|Tablets will be used.
224021387|NCT04097392|OTHER|Experimental|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
224021388|NCT04097392|OTHER|Active comparator|Isolated high-intensity inspiratory muscle training during 8 weeks
224021389|NCT02102477|PROCEDURE|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
224021390|NCT02102477|OTHER|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
223733972|NCT00050518|BIOLOGICAL|Aventis Pasteur Smallpox Vaccine|
223733973|NCT03259776|OTHER|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
223401139|NCT03690128|BEHAVIORAL|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
223401140|NCT03690128|BEHAVIORAL|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
223401141|NCT00965211|DEVICE|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
223401142|NCT06575283|OTHER|No intervention will be performed in this cohort study|Deep learning classification models will be used for automatic prediction of cerebral palsy. Machines will be used to assist doctors in cerebral palsy risk evaluation.
223401143|NCT05966077|OTHER|IMPACT OF SENDING AN SMS|"Each subject of the experimental group will receive, in addition to the usual procedure of the VigilanS Lorraine device, an SMS 48 hours before the telephone call for evaluation at 3 months, warning him of this call.~The time of this SMS has been set at 1:00 p.m. for all the people included in this group.~At the end of this evaluation call, the caller will pass a satisfaction questionnaire to the subject in relation to the sending of the SMS"
223401144|NCT03280524|OTHER|reflexology|
223401145|NCT03280524|OTHER|self-care guidelines with feet|
223552654|NCT01520649|DRUG|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
223552655|NCT01520649|DRUG|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
223552656|NCT01680354|PROCEDURE|ReLEx|
223552657|NCT01680354|PROCEDURE|LASIK|
223733974|NCT00892762|DRUG|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
223733975|NCT00892762|DRUG|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
223733976|NCT02790203|DRUG|Celecoxib|NSAIDS
223733977|NCT02790203|DRUG|Placebo|Placebo
223733978|NCT02974517|DEVICE|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
224021391|NCT01871701|DRUG|Escitalopram|Escitalopram
224021392|NCT01871701|DRUG|Quetiapine|Quetiapine
224021393|NCT01871701|DRUG|Moxifloxacin|Moxifloxacin
224021394|NCT01871701|OTHER|Placebo|Placebo
224021395|NCT00950950|DRUG|Romosozumab|Administered by subcutaneous injection
224021396|NCT00950950|DRUG|Placebo|Administered by subcutaneous injection
224021397|NCT02639598|DRUG|Flunarizine|"as in arm descriptions"
224021398|NCT02639598|DRUG|Topiramate|"as in arm descriptions"
224021399|NCT04612374|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
224021400|NCT04612374|BEHAVIORAL|Revised Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Please see arm/group descriptions
224021401|NCT00491829|DRUG|50 mg qhs|flibanserin 50 mg
224021402|NCT00491829|DRUG|100 mg|flibanserin 100mg
224021403|NCT00491829|DRUG|placebo|placebo
223733979|NCT04450368|DEVICE|Sylvee|The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
223733980|NCT00563979|DIETARY_SUPPLEMENT|VitaluxPlus®|1 tablet daily
223552658|NCT02397915|DRUG|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
223552659|NCT02397915|DRUG|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
223552660|NCT03292874|DIAGNOSTIC_TEST|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
223552661|NCT04354948|BEHAVIORAL|Pain (hypertonic saline)|A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
223552662|NCT04354948|BEHAVIORAL|No pain (Hypotonic saline)|A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the right quadriceps femoris of the quadriceps femoris muscle 1 minute before performance of the 3 min wall squat exercise
223552663|NCT00933608|DRUG|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
223552664|NCT00933608|DRUG|Placebo|participants will be asked to take 2 tablets per day to match active drug
223552665|NCT04479059|OTHER|follicular fluid flushing|Follicular fluid obtained during OPU will be used for endometrial cavity flushing.
223552666|NCT01485731|DRUG|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
223552667|NCT01485731|DRUG|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
223552668|NCT01485731|RADIATION|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
223552669|NCT01485731|RADIATION|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
224021404|NCT02957526|BEHAVIORAL|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
224297170|NCT02159170|BIOLOGICAL|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
223733981|NCT00563979|DIETARY_SUPPLEMENT|Omega 3|1 tablet daily
223733982|NCT02010554|BEHAVIORAL|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
223733983|NCT02010554|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
223733984|NCT04285879|DEVICE|Blood Flow Restriction using Delfi Personalized Tourniquet System|The Delfi Tourniquet System is designed to be used in conjunction with exercise. The system automatically determines the degree of occlusion and allows for safe regulation of pressure. Patients will then complete exercises with the use of this device following the Owens Recovery Science Protocol
223733985|NCT02056340|DRUG|Atorvastatin|
223733986|NCT02056340|DRUG|Placebo|
223552670|NCT01485731|PROCEDURE|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
223733987|NCT05740644|DEVICE|CM-1600|Healthy subjects undergoing a manual blood loss of up to 500mL followed by an infusion of 1 liter of normal saline will be connected to the CM-1600 device.
223733988|NCT01817621|BEHAVIORAL|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
223733989|NCT01817621|BEHAVIORAL|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
224297171|NCT05994820|BEHAVIORAL|Happy Baby Programme -Vaccine Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi.
224297172|NCT05994820|BEHAVIORAL|Happy Baby Programme- Vaccine ++ Campaign|The Happy Baby Programme is a WhatsApp based Chatbot designed to promote childhood vaccination in Hindi as part of a holistic healthy baby approach that includes nutrition and sanitation.
223733990|NCT06163313|OTHER|Observation of patients suffering from kidney stones who undergo endoscopic surgery|Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
223733991|NCT03009578|DRUG|Iron Sucrose Injection|iron Intramuscular injections
223733992|NCT03009578|DRUG|Ferrous Bisglycinate|oral iron tablets
223733993|NCT01681225|OTHER|Esophageal-pressure guided mechanical ventilation|
223733994|NCT01681225|OTHER|High PEEP mechanical ventilation|
223733995|NCT05606497|DRUG|Corticosteroid|Antenatal corticosteroids are administered to pregnancies at risk for preterm birth in order to reduce risks of neonatal morbidity and mortality following preterm birth.
223733996|NCT05838105|DRUG|GnRH agonist|125 mcg once at the day mentioned
223733997|NCT05838105|DRUG|hCG|dose as mentioned
223733998|NCT05838105|DRUG|Progesterone 100Mg Vag Tab|dose as mentioned
224021405|NCT02957526|BEHAVIORAL|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
224021406|NCT01809002|BIOLOGICAL|Processed Nerve Allograft (human)|
223552671|NCT01485731|PROCEDURE|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
223552672|NCT01485731|PROCEDURE|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
223552673|NCT01485731|PROCEDURE|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
223552674|NCT01485731|PROCEDURE|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
223733999|NCT05289180|OTHER|Questionnaires|A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
223734000|NCT02852785|BEHAVIORAL|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
223734001|NCT02852785|BEHAVIORAL|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
223734002|NCT02852785|BEHAVIORAL|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
223734003|NCT02852785|BEHAVIORAL|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
223734004|NCT05696678|DRUG|Intrathecal Morphine|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
224021407|NCT01809002|DEVICE|Collagen Nerve Cuff|Bovine collagen based nerve cuff
224021408|NCT01047293|DRUG|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
224021409|NCT01047293|DRUG|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
223734005|NCT05696678|DRUG|Ropivacaine 0.2%|Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
223734006|NCT01185132|RADIATION|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
223734007|NCT01185132|RADIATION|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
224021410|NCT01047293|DRUG|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
224021411|NCT00104663|DRUG|Quinacrine|
224021412|NCT01235104|PROCEDURE|Total nephrectomy|Total nephrectomy
224297173|NCT05750147|OTHER|Blood Sample Collection|Blood for DNA and biomarker analysis
224297174|NCT02980250|DRUG|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
223734008|NCT04455802|DRUG|Buprenorphine or Placebo|The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
224021413|NCT00784355|PROCEDURE|Laparoscopic cholecystectomy|Surgery
224021414|NCT04137094|BEHAVIORAL|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
224021415|NCT02375178|DRUG|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
224021416|NCT02375178|DRUG|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
223734009|NCT04455802|DRUG|Morphine or Placebo|If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
223734010|NCT04900220|DRUG|Betamethasone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of betamethasone (6 mg)
223734011|NCT04900220|DRUG|Methylprednisolone|The volume of the doses of steroid to be given will be standardized to 1 injection of 1 cc of methylprednisolone (40 mg)
223734012|NCT02291198|DEVICE|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
223734013|NCT04432896|OTHER|Dietary protocol|Dietary protocol to manage symptoms related to Systemic Nickel Allergy Syndrome.
223401146|NCT02810041|DIETARY_SUPPLEMENT|yoghurts enriched with XXS|
223734014|NCT00089765|DRUG|Ranibizumab|
223401147|NCT02810041|DIETARY_SUPPLEMENT|yoghurts non enriched with XXS|
223552675|NCT01485731|PROCEDURE|Proctoscopy|Optional. Pre-Treatment
223552676|NCT01485731|PROCEDURE|Cytoscopy|Optional. Pre-Treatment
223734015|NCT02742324|DRUG|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
224131600|NCT04158089|BEHAVIORAL|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.)."
224131601|NCT02201381|DRUG|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
224131602|NCT03497429|DRUG|Niraparib|Niraparib capsule
224131603|NCT01975077|DRUG|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
224131604|NCT01009983|BIOLOGICAL|panitumumab|Given IV
224131605|NCT01009983|DRUG|paclitaxel|Given IV
224131606|NCT01009983|DRUG|carboplatin|Given IV
223552677|NCT01485731|PROCEDURE|Renal Ultrasound|Optional. Pre-Treatment
224131607|NCT01009983|PROCEDURE|laboratory biomarker analysis|Correlative study
224131608|NCT01009983|PROCEDURE|immunohistochemistry staining method|Correlative study
224131609|NCT02101840|DRUG|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
224131610|NCT02101840|DRUG|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
223401148|NCT04171336|BEHAVIORAL|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
223401149|NCT01731132|DRUG|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
223401150|NCT00228436|DRUG|peginesatide|
223401151|NCT04973267|BEHAVIORAL|Game Plan for PrEP|See arm description.
223401152|NCT04973267|BEHAVIORAL|Attention-Matched Control Lifestyle Habits Videos|Web-based videos providing information on sleep hygiene and proper diet.
223401153|NCT00590213|DRUG|Casodex 150mg|
223401154|NCT00590213|PROCEDURE|Radiotherapy|
223401155|NCT00590213|PROCEDURE|Haematology|
223552678|NCT01485731|PROCEDURE|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
223552679|NCT01485731|PROCEDURE|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
224021417|NCT02375178|DRUG|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
224021418|NCT02192021|DRUG|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
224131611|NCT02101840|DRUG|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
224131612|NCT05522894|DRUG|AK104|10mg/kg IV every 3 weeks (Q3W)
224131613|NCT05522894|DRUG|Cisplatin|75mg/m2 IV every 3 weeks (Q3W)
224131614|NCT05522894|DRUG|Paclitaxel|175mg/m2 IV every 3 weeks (Q3W)
224297175|NCT02980250|DRUG|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
223734016|NCT02742324|DRUG|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
223734017|NCT01447602|BEHAVIORAL|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
224021419|NCT05441241|DEVICE|Leap Motion Controller|The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm
223734018|NCT04899921|DRUG|Ipilimumab|Intravenous injection
224131615|NCT04775472|PROCEDURE|Early left atrial septostomy within 12 hours after VA-ECMO implantation|Early left atrial septostomy group will routinely receive left atrial septostomy within 12 hours after VA-ECMO implantation. Left atrial septostomy will be done using percutaneous technique.
224131616|NCT04775472|PROCEDURE|Selective left atrial septostomy|Left atrial septostomy will be done in cases of deleterious effect of increased LVEDP after VA-ECMO implantation, such as refractory pulmonary edema, abnormal opening of aortic valve, left ventricular dilatation, refractory ventricular tachycardia or fibrillation.
224131617|NCT00506948|DRUG|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
224131618|NCT00506948|DRUG|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
224131619|NCT00506948|DRUG|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
224131620|NCT00506948|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
224131621|NCT00917085|BEHAVIORAL|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
224131622|NCT03258047|COMBINATION_PRODUCT|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
224131623|NCT04370964|OTHER|Lausanne Trilogy Play|"Trilogical game of Lausanne (Lausanne Trilogue Play in English abbreviated LTP), which allows an evaluation of the family alliance. This systematic observation provides a snapshot of the family structure and its adaptive abilities. It is based on the assumption that the ability to solve small tasks is representative of the ability to solve more important tasks.The LTP consists of modelling the different possibilities of interaction in a triad according to a four-part scenario: 1) one parent plays with the child, the other parent is simply present; 2) the parents switch roles; 3) both parents play together with the child; and 4) both parents have to talk together."
223734019|NCT04899921|DRUG|Nivolumab|Intravenously (IV) into the vein
224131624|NCT04370964|OTHER|Lausanne Family Play|Lausanne Family Play (LFP) is a game situation adapted to families with more than one child. Thus, like the LTP, the LFP takes place in four phases:1) one parent plays with siblings while the other is in a third-observer position; 2) the parents reverse their roles;3) children play while parents are talking and 4) family members play together.
224131625|NCT00215436|DRUG|Formoterol Fumarate|
224131626|NCT04839536|DRUG|Sevoflurane inhalant product|Sevoflurane will be delivered in an incremental dose to throughout procedure to achieve clinical sedation endpoint OAAS 3.
223401156|NCT03889418|BEHAVIORAL|Electronic medical recorded clinical decision support [EMR CDS]|The opioid management tool has quick links to the Opioid Risk Tool (ORT), health maintenance reminders for risk mitigation tasks (pain management agreements; urine drug screening; prescribing naloxone); Pain Scale and depression/anxiety screen. The frequency with which providers are prompted to complete mitigation tasks is based on patients' level of risk for aberrant drug behavior defined by the ORT score. Additionally, the EMR CDS flags patients as high risk if one of the following criteria are met: (1) co-prescriptions for benzodiazepines; (2) active diagnosis of substance abuse in the last 12 months; or (3) MEDD \>=90 mg. The ORT score, morphine equivalent daily dose (MEDD), and hyperlinks to the Louisiana pharmacy drug monitoring program data are visible in the prescription writer. If MEDD \>=90 mg, the calculated MEDD is displayed in red font to alert the prescribing provider of high dosage. An Epic banner appears in charts to alert providers of existing pain management agreements.
223734020|NCT04899921|DRUG|Troriluzole|Taken orally
223734021|NCT04899921|DRUG|Placebo|Taken orally
223734022|NCT05466526|PROCEDURE|High frequency deep sclerotomy (HFDS)|The surgery was performed using the abee® glaucoma tip of Oertli phacoemulsiﬁcation machine (Cata-rhex3, Switzerland) and goniolens. During the procedures, nasal six pockets penetrating 1mm deep from the trabecular meshwork to Schlemm's canal will be formed to promote the aqueous humor outflow.
223734023|NCT05810142|DRUG|furquimatinib and sintilimab|furquimatinib and sintilimab
223734024|NCT03907553|DIAGNOSTIC_TEST|targeted genome sequencing|
224131627|NCT00695708|BEHAVIORAL|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
223734025|NCT04856774|DRUG|SHR-1701；BP102|"Drug: SHR-1701 IV infusion~Drug: BP102 IV infusion~Phase Ib: SHR-1701 30mg/kg + BP102 15mg/kg Q3w as starting dose, until recommended phase 2 dose is determined."
223734026|NCT05678894|OTHER|Scanner and EOS imaging|Cross-sectional imaging and 3D reconstruction to measure and compare acetabular anteversion in 4 functional pelvic positions.
223734027|NCT02563275|OTHER|motion analysis system|
223734028|NCT02563275|OTHER|parabolic flight|
223734029|NCT01706081|PROCEDURE|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
224131628|NCT00695708|BEHAVIORAL|Cogpack|Computer-aided cognitive program for cognitive abilities
224021420|NCT05441241|OTHER|Traditional distraction techniques|Common distraction techniques will be used (i.e., visual stimulation, lecture)
223734030|NCT01706081|PROCEDURE|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
223734031|NCT05178524|DRUG|BIFICO|Live combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
224021421|NCT02528383|BEHAVIORAL|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~1. Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~2. Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~3. Impact of treatment on quality of life"
223552680|NCT05087368|BIOLOGICAL|ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
224021422|NCT04818333|DRUG|SHR-A1811|Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1
224131629|NCT02030444|PROCEDURE|PET-MRI and EBUS-TBNA|
224131630|NCT03308162|BEHAVIORAL|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
223552681|NCT05087368|BIOLOGICAL|CoronaVac (Sinovac Biotech)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
223552682|NCT05087368|BIOLOGICAL|Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)|Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
223552683|NCT00455091|DRUG|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/\> 105 copies/mL and ALT \> 2.0 x UNL
223552684|NCT02975739|DEVICE|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
224131631|NCT02884830|DEVICE|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
224131632|NCT02021825|DRUG|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
223734032|NCT06395454|DIAGNOSTIC_TEST|Shorten antibiotics duration based on procalcitonin test levels|procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
223734033|NCT05397756|OTHER|observer tool|The observer tool used will be the Anaesthetist Non-Technical Skills (ANTS) tool previously published by Fletcher et al. and translated in French. The ANTS scoring system uses four categories assessing task management, teamworking, situation awareness and decision-making. The observers will use an observer tool it when they will be not role role-playing
223734034|NCT02999854|BIOLOGICAL|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
223734035|NCT02999854|DRUG|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
223734036|NCT02999854|PROCEDURE|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
223734037|NCT02999854|PROCEDURE|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
224021423|NCT02054520|DRUG|HyperAcute®-Melanoma (HAM) Immunotherapy|
224021424|NCT02054520|DRUG|Ipilimumab|
224021425|NCT02054520|DRUG|Pembrolizumab|
224021426|NCT02054520|DRUG|Nivolumab|
224021427|NCT05320549|BEHAVIORAL|Community Programme|Participants have the opportunity to engage in face-to-face and/or online exercise classes. Attendance will be recorded.
224131633|NCT00825019|DRUG|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
223552685|NCT05317715|OTHER|Group A, who will complete a questionnaire before receiving information about intrauterine devices|Group A will complete a questionnaire before receiving information about intrauterine devices and a demonstration of insertion/removal on a plastic dummy uterus.
223552686|NCT05317715|OTHER|Group B who will answer a questionnaire after having the information about the intrauterine devices|Group B will complete a questionnaire after receiving information about IUDs and a demonstration of insertion/removal on a plastic dummy uterus.
223552687|NCT04873141|DRUG|Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)|Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).
223552688|NCT06328270|OTHER|Ozone - oxygen Therapy|Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
223552689|NCT06328270|OTHER|Corticosteroid|1 ml betamethasone
223552690|NCT01685242|DRUG|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
223552691|NCT01685242|DRUG|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
223552692|NCT04060069|OTHER|Ringer Lactate|Fluids
223552693|NCT01697475|BEHAVIORAL|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
224021428|NCT02660463|OTHER|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
224131634|NCT00825019|DRUG|placebo|oral administration in 12h intervals
224021429|NCT01272804|DRUG|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
224021430|NCT01272804|DRUG|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
224131635|NCT00825019|DRUG|paroxetine|oral administration of 20 mg/day
224131636|NCT03309787|BEHAVIORAL|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
224297176|NCT02980250|DRUG|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
223401157|NCT03889418|BEHAVIORAL|Stepped opioid collaborative care model [CCM]|The licensed clinical social worker (LCSW) will provide counseling services as indicated (behavioral activation, psychotherapy, crisis planning, facilitating connection to substance abuse counseling and treatment); meet weekly with the consulting psychiatrist for complex case review and care plan adjustments; and supervise the community health worker (CHW) case management and depression/anxiety care management activities. The CHW will update assets and barriers to recovery and self-management and help patients navigate community resources. The clinical pharmacist will review and reconcile active medication lists, assess medication side effects, drug interactions and adverse events; monitor analgesia; recommend algorithm based anti-depression medication titration as indicated. The consulting psychiatrist will directly co-manage patients with severe mental illness, substance abuse and complex medication regimens.
223401158|NCT00206271|BEHAVIORAL|neck collar; advice to act-as-usual; active mobilisation|
223401159|NCT03437863|DEVICE|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
223401160|NCT04459325|BIOLOGICAL|Tigerase® and best available care|Nebulised dornase alfa \[2.5 mg BID\] for 7 days
223401161|NCT04459325|OTHER|Best available care|Patients will receive the usual care in accordance with good practice.
223401162|NCT00672724|DRUG|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
223401163|NCT00672724|DRUG|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
223401164|NCT00952835|OTHER|regular treatment|regular treatment
223401165|NCT04494490|BEHAVIORAL|Clinical Practice Guidelines and Psychologically Informed Physical Therapy training/audit/feedback|The aim of the active training strategy is to improve the knowledge and skills of physical therapists with regard to evidence-based physical therapy with an emphasis on active treatments and PIPT for the treatment of patients with low back pain and to encourage increased adherence with CPGs. This Continuing Education (CE) training session will be offered to all therapists regardless of study participation. During the CE training session, focus will be placed on interventions that have been shown to be effective, such as interactive education and discussion, feedback, and reminders.
223401166|NCT03819972|DIETARY_SUPPLEMENT|Dose response of Capolac®|Capolac® (milk minerals high in calcium) dose is manipulated
223401167|NCT06234839|DIETARY_SUPPLEMENT|L. reuteri (DSM 17938 and ATCC PTA 5289) in form of oral tablets|Each subject of the experimental group was instructed to dissolve inside the mouth two tablets per day (in the morning and before going to bed at night), during the experimental period of 30 days. The tablets were provided by BioGaia ProDentis® (Stockholm, Sweden). The tablets contained two strains of L. reuteri (DSM-17938 and ATCC PTA 5289), at a dose of 2 x 108 CFU/tablet.
223401168|NCT06308458|OTHER|Breather Exerciser Trainer|Gradual intensity from 2-3 rate of perceived exertion (RPE) up to reach 5-7 RPE, with gradual frequency; 1st week 8 sets of 5 repetitions '1 minute rest', 2nd week be 9 sets, and 3rd week reach 10 sets of 5 repetitions. then from 4-8 weeks 'end of study protocol' will be 10 sets of 6 repetitions with 1 minute rest between sets.), along with conventional breathing exercises (Diaphragmatic breathing, Pursed-up breathing, and Exercise connected with respiration), for 5 sessions per week for eight weeks
223401169|NCT06308458|OTHER|Conventional Breathing Exercise|Diaphragmatic breathing; place one hand on upper chest and the other on belly. Patient Breathe in slowly through nose, letting the air in deeply towards lower belly then patient is asked to tighten abdominal muscles and let them fall inward during exhalation through pursed lips Pursed-up breathing; by inhales through nose and exhales over 4 and 6 seconds in a whistling position Exercise connected with respiration; repetitive bilateral shoulder flexion then repetitive bilateral shoulder abduction, synchronized with breathing
224131637|NCT00849251|DRUG|cyclophosphamide|Given IV or PO
224131638|NCT00849251|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
224131639|NCT00849251|DRUG|bortezomib|Given IV
224131640|NCT00849251|DRUG|dexamethasone|Given IV or PO
224131641|NCT00796094|OTHER|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
224131642|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for control|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry"
224131643|NCT05093257|DIAGNOSTIC_TEST|Laboratory investigations for patients|"1. Complete blood picture .~2. Erythrocyte sedimentation rate(ESR).~3. Liver function tests .~4. Kidney function tests.~5. Anti-nuclear antibodies test by immunoflourescence for ITP patients.~6. Bone marrow aspiration (for diagnosis of ITP).~7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry."
224131644|NCT05866653|DRUG|lidocaine transdermal patch|The topical pain-relieving treatment 5% lidocaine transdermal patch has been registered in the USA since 1999
224297177|NCT02980250|DRUG|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
224297178|NCT06052488|BEHAVIORAL|Strength After Breast Cancer|Individual physical therapy evaluation and 4 group-based exercise sessions led by a licensed physical therapist
224297179|NCT00402220|DRUG|TMS|Active Transcranial Magnetic Stimulation
223734038|NCT03993340|DEVICE|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
223734039|NCT02136524|DRUG|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
223401170|NCT02483221|DRUG|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
223401171|NCT02483221|DRUG|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
223401172|NCT03034447|OTHER|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
223401173|NCT03034447|OTHER|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
223401174|NCT03034447|OTHER|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
223401175|NCT00597662|DEVICE|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
223401176|NCT00597662|DEVICE|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
223401177|NCT06089564|BEHAVIORAL|Skit video, Pictorial, Sign language|Three oral health educational intervention groups, group A (skit video), group B (pictorial) and group C (sign language) by using Sequentially Numbered Sealed Opaque Envelopes (SNOSE). Children picked a sealed envelope randomly and assigned to oral health education intervention group A, B and C. Participants in group A were assigned a skit video method of oral hygiene intervention and shown 5 minute video on what to eat and how to brush their teeth. The video included that what is good and bad for teeth, and how to brush which includes method, time and duration of tooth brushing. Participants assigned to group B and C was provided same instructions for tooth brushing and eating habits in the form of pictures and sign language respectively. The children of Group A received instructions in the form of laminated cards and asked to take with them at home. Participants in group C were received instructions in sign language in the presence of teacher.
223401178|NCT05323409|BEHAVIORAL|OPTIMISE|OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
223734040|NCT02136524|DRUG|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
223734041|NCT02088255|PROCEDURE|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
223401179|NCT06852677|OTHER|Deep Squat position|"Participants assigned to the deep squat group will perform a cumulative total of 20 minutes of deep squatting per day, six days a week, for six weeks. The squatting time can be divided into multiple shorter sessions throughout the day, with a maximum interval of 48 hours between sessions. Participants will be instructed to maintain an upright posture with heels on the ground, feet shoulder-width apart, and knees aligned with toes. They will be encouraged to gradually increase their squat duration and comfort over time.~Before starting the intervention, participants will receive standardized instructions on proper squat form to ensure safety and maximize benefits. Their compliance will be monitored through a training diary in the experimental (Tulkit) app."
223401180|NCT06852677|OTHER|Cross-legged Sitting|"Participants assigned to the cross-legged sitting group will perform a cumulative total of 20 minutes of cross-legged sitting per day, six days a week, for six weeks. The squatting time can be divided into multiple shorter sessions throughout the day, with a maximum interval of 48 hours between sessions. Participants will be instructed to maintain an upright posture while sitting. They will be encouraged to gradually increase their cross-legged sitting duration and comfort over time.~Before starting the intervention, participants will receive standardized instructions on proper sitting form to ensure safety and maximize benefits. Their compliance will be monitored through a training diary in the experimental (Tulkit) app."
223401181|NCT04144894|DIAGNOSTIC_TEST|Shear Wave Elastography|Advanced ultrasound technique
223401182|NCT05697809|DRUG|OXU-001|Suprachoroidal sustained release dexamethasone acetate
223734042|NCT02088255|PROCEDURE|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
223734043|NCT01085591|DRUG|CB-183,315|
223734044|NCT01085591|DRUG|Placebo|
223734045|NCT01085591|DRUG|Vancomycin|
224021431|NCT05236478|OTHER|CoviMouv' program|"* An initiation to physical rehabilitation at the hospital center the first week, 3 sessions of 1 hour.~* A tele-rehabilitation program led by an Adapted Physical Activity (APA) teacher for 3 weeks with 3 sessions of 1 hour per week.~All the sessions are led by a professional of adapted physical activity and will be personalized and adapted to the functional tests carried out during the initial evaluation.~* Therapeutic education video-workshops weekly: about (i) the pathophysiology of fatigue in COVID-19, (ii) returning to work, (iii) lifestyle: sleep, physical activity and diet.~* The medical follow-up will be carried out remotely with 1 weekly teleconsultation with a physiologist.~* Psychological and / or dietetic follow-up, if necessary, during the program: 1 weekly teleconsultation At the end of the program, each participant is invited to contact the sport-health platform in order to continue the Adapted Physical Activity (APA) practice near home for 2 months."
224021432|NCT05236478|OTHER|Control|The CoviMouv' program is not presented to theses patients They have support for the resumption of an adapted physical activity in autonomy, according to the results of the aerobic and anaerobic tests carried out during the initial evaluation (delivery of a training booklet).
223734046|NCT01497132|DRUG|Vitamin D3|Oral drops 30000 IU weekly
224021433|NCT02318797|BEHAVIORAL|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
224021434|NCT02318797|BEHAVIORAL|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
223734047|NCT01497132|DRUG|Placebo|Matching placebo
223734048|NCT03102021|DRUG|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
223734049|NCT03102021|DRUG|saline|saline 10 ml for 3 days
223734050|NCT01744054|DEVICE|PET/MR|
223734051|NCT01744054|DEVICE|PET/CT|
223734052|NCT01879150|DEVICE|Cyclaplex bone anchor|Device implantation
223734053|NCT01040897|BEHAVIORAL|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
224021435|NCT05414487|DRUG|Ofatumumab|There is no treatment allocation. Patients with MS or NMOSD administered Ofatumumab by prescription will be enrolled. Participants will receive 20mg ofatumumab (20 mg/0.4 ml) by subcutaneous injection. Ofatumumab is administrated at baseline, Day 7, Day 14 and monthly thereafter until the end of the study.
224021436|NCT03172182|BEHAVIORAL|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
224021437|NCT02589860|OTHER|Melphalan kinetic study|Concentration of Melphalan in plasma samples
224131645|NCT06079957|PROCEDURE|Ergonomic training|"1\. Individuals will be given a copy of ergonomic guidelines to follow which includes:~* Organize workstation according to the primary , secondary and tertiary zones.~* Place frequently used items within the reach of an arm.~* Don't move head while reading documents instead raise or lower the eyes to read.~* Correct the monitor height such that the top of the screen is at or slightly lower than eye level.~* Keep reference material upright at desk.~* Avoid slouched postural habits, sit upright.~* Adjust chair height in such a way that it shouldn't compress the thigh.~* Arm rest should be at elbow flexion of 90 degrees.~* Phone must be cradled between neck and shoulder to avoid forward head posture."
224297180|NCT00402220|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
224021438|NCT02589860|GENETIC|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
224297181|NCT01056094|DRUG|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
223401183|NCT05697809|DEVICE|Semi-automated suprachoroidal illuminated microcatheter|Ophthalmic administration device
223401184|NCT05697809|DRUG|Ozurdex® Ophthalmic Intravitreal Implant|Ophthalmic dexamethasone intravitreal implant
223401185|NCT04612751|DRUG|Datopotamab deruxtecan|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
224297182|NCT03581513|PROCEDURE|Deferred or Immediate Stent Implantation|IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
224021439|NCT02589860|GENETIC|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
223401186|NCT04612751|DRUG|Durvalumab|Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle
223401187|NCT04612751|DRUG|Carboplatin|Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle
223401188|NCT04612751|DRUG|AZD2936|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
223734054|NCT01040897|BEHAVIORAL|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
223734055|NCT00003903|PROCEDURE|management of therapy complications|
224297183|NCT03399318|DRUG|Acetaminophen|"30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments"
224297184|NCT03399318|DRUG|Ibuprofen|10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
224297185|NCT03399318|DRUG|placebo for acetaminophen|"placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo"
223401189|NCT04612751|DRUG|MEDI5752|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
223401190|NCT04612751|DRUG|AZD7789|Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle
223401191|NCT04248452|DRUG|Capecitabine|Given PO
223401192|NCT04248452|DRUG|Fluorouracil|Given IV
223401193|NCT04248452|DRUG|Leucovorin|Given IV
223401194|NCT04248452|DRUG|Leucovorin Calcium|Given IV
223401195|NCT04248452|DRUG|Oxaliplatin|Given IV
223401196|NCT04248452|RADIATION|Radiation Therapy|Undergo radiation therapy
223552694|NCT02998879|DRUG|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
223552695|NCT03998514|DRUG|CB4211 Dose 1|Administered by subcutaneous injection
223552696|NCT03998514|DRUG|CB4211 Dose 2|Administered by subcutaneous injection
223552697|NCT03998514|DRUG|CB4211 Dose 3|Administered by subcutaneous injection
223552698|NCT03998514|DRUG|CB4211 Dose 4|Administered by subcutaneous injection
223552699|NCT03998514|DRUG|CB4211 Dose 5|Administered by subcutaneous injection
223552700|NCT03998514|DRUG|CB4211 Dose 6|Administered by subcutaneous injection
223552701|NCT03998514|DRUG|CB4211 Dose TBD|Administered by subcutaneous injection
223552702|NCT03998514|DRUG|Placebo|Administered by subcutaneous injection
224297186|NCT03399318|DRUG|placebo for ibuprofen|placebo for ibuprofen
224297187|NCT00531349|PROCEDURE|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
224297188|NCT00531349|DRUG|Sevoflurane|General anesthesia
224021440|NCT05077657|DEVICE|Early Bird® Bleed Monitoring System|The Early Bird Bleed Monitoring System is used in endovascular procedures to monitor and detect internal bleeding complications in real-time.
223734056|NCT04406961|PROCEDURE|Endoscopic transpapillary antegrade sphincterotomy developed by Dr. Dovbenko.|Sph. Oddi consists of a longitudinal and circular smooth muscle layers. Circular muscle fibers form the pancreatic and duodenal parts. Anatomical justification was cutting of only the circular layer of sph Oddi by special sphincterotome. Papillary stenosis and stenosis terminal part of common bile duct due to damage only circular layer sph Oddi. Anterograde direction and hooked form of sphincterotome (endoscopic antegrade sphincterotomy- ASD) allows to capture only need layer and control depth. Also ASD was performed patient with SOD (I-III) with preservation of the longitudinal muscular layer sph Oddi and septum of papilla.
224021441|NCT05077657|DEVICE|Impella®|Impella is an FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI.
223401197|NCT05182632|BEHAVIORAL|Group pelvic floor telerehabilitation|Multimodal group physiotherapy: 12 weeks of weekly group physiotherapy treatments including education and pelvic floor muscle exercises delivered online + home exercise program
224021442|NCT01736865|DRUG|Cholecalciferol|
224131646|NCT06079957|PROCEDURE|Neck Exercises|"Neck Exercises Strengthening exercises of Deep cervical flexors,rhomboids,lower Trapezius, Middle Trapezius, serratus anterior.~Neck Stretching of Suboccipitals,Sternocleidomastoid ,Scalenes,Upper trapezius, Levator scapulae,Pectoralis major and minor."
224131647|NCT06215222|OTHER|Microbiota Sampling|We will sample the Saliva, Feces, and intestinal microbiome for genetic microbiome analysis and bacterial isolation
223401198|NCT02683993|DEVICE|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
223401199|NCT04381143|DRUG|Aspirin 100 mg Oral Tablet|Aspirin 100 mg tablet daily
223401200|NCT04381143|DRUG|Matching Placebo|Matching Placebo 1 pill daily
223401201|NCT05029037|DRUG|High doses of intravenous vitamin C|Two (2) High doses of intravenous vitamin C for seven (7) days.
223401202|NCT05029037|DRUG|Dextrose 500 mL|"Application of a vial of LEV in 100 mL of water for injection, which is diluted in 400mL of 5% Dextrose for a final volume of 500mL of intravenous fluids, to be applied to the chosen patient, in a drip of 0.5 grams of the placebo solution per minute, for a total of 60 minutes.~Twice a day for seven days."
223401203|NCT06087848|BIOLOGICAL|Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)|100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min
223401204|NCT02749188|OTHER|Bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
223401205|NCT05821933|DRUG|RC108|RC108 plus Furmonertinib and/or Toripalimab
223401206|NCT06097364|DRUG|Odronextamab|Administered by intravenous (IV) infusion
223401207|NCT06097364|DRUG|Rituximab|Administered by IV infusion, or subcutaneous (SC)
223401208|NCT06097364|DRUG|Cyclophosphamide|Administered by IV infusion
223401209|NCT06097364|DRUG|Doxorubicin|Administered by IV infusion
223401210|NCT06097364|DRUG|Vincristine|Administered by IV infusion
223401211|NCT06097364|DRUG|Prednisone/Prenisolone|Administered orally (PO)
224131648|NCT00084812|DRUG|cisplatin|
224021443|NCT01736865|DRUG|Placebo|
224021444|NCT06062732|BEHAVIORAL|Face It|School-based intervention delivered over 6 weeks, including an intensive 5-day programme of activities, and pre-programme and post-programme group and 1:1 sessions. Each programme is tailored to participants' needs and uses art, storytelling, 1:1 and group experiential techniques, delivered by trained dramatherapists.
224021445|NCT06062732|BEHAVIORAL|Control|Services as usual
224021446|NCT04647812|BEHAVIORAL|Technology-assisted rehabilitation|Augmented exercise therapy with novel technology and home-based telerehabilitation
224021447|NCT04647812|BEHAVIORAL|Conventional rehabilitation|Traditional multidisciplinary in-patient rehabilitation
224021448|NCT05401760|PROCEDURE|Group A :combined phacoaspiration and angle surgery|"* Partial thickness scleral flap to access the canal of schlemm.~* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture.~* Using metal trabeculotomes to open thetrabecular meshwork after accessing the canal of schlemm.~* Suturing of scleral flap with 10-0 Nylon suture."
224021449|NCT05401760|PROCEDURE|Group B : phacoaspiration only|"* 2 side ports will be fashioned.~* Trypan blue will be injected to aid visualization of the anterior capsule \& continuous curvilinear anterior capsulorhexis of approximately 5.0 mm diameter will be done.~* The nucleus and cortex will be aspirated.~* Posterior capsulrehxis and limited anterior vitrectomy will be done.~* Corneal incisions will be sutured with 10-0 Nylon suture."
223401219|NCT06271785|DIAGNOSTIC_TEST|HR-EEG recording|All participants will have a HR-EEG recordings. It will be made at rest. Nap-like sleep is encouraged, but no sedatives will be given. Recording time will not exceed two hours.
223401220|NCT03608631|DRUG|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
223401221|NCT06169124|PROCEDURE|Biospecimen Collection|Undergo archived tissue and blood sample collection
223401222|NCT06169124|PROCEDURE|Chest Radiography|Undergo chest x-ray
223401223|NCT06169124|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223401224|NCT06169124|DRUG|Darolutamide|Given PO
223401225|NCT06169124|DRUG|Exemestane|Given PO
223401226|NCT06169124|DRUG|Leuprolide Acetate|Given IM
224021450|NCT02348762|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
224131649|NCT00084812|DRUG|safingol|
224131650|NCT03402152|DRUG|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
224131651|NCT03402152|DRUG|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
224131652|NCT03402152|DRUG|Placebo|Placebo oral capsule
224131653|NCT01690689|DEVICE|Implant surgery|surgery
224021451|NCT05143983|BEHAVIORAL|Positive valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excerpts, with positive valence characteristics (fast tempo, major key). They will be told to listen carefully in order to then answer a short questionnaire. The listening will be followed by an liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
224021452|NCT05143983|BEHAVIORAL|Neutral valence music|Subjects will have to listen to 3 minutes of unfamiliar musical excepts with neutral valence. They will be told to listen carefully in order to then answer to a short questionnaire. The listening will be followed by a liking scale (from 1 : not liked at all, to 5 : liked a lot) and a familiarity scale (from 1 : not familiar at all, to 5 : very familiar).
224131654|NCT04446026|DRUG|teneligliptin|teneligliptin 20mg PO qd for 24weeks
223734057|NCT04406961|DEVICE|The antegrade sphincterotome developed by Dr. Dovbenko.|A device is represented by a teflon catheter in the distal part of which a double tube of variable shape is created. The proximal part of the ASD sphincterotome consists of a handle, and a metal wire is located inside the teflon catheter for connection to an electrosurgical unit. On the distal part, the teflon catheter is formed of a double tube length is 10 to 35 mm. The metal wire exits the catheter at a distance 10 to 35 mm from the tip and enters into the tip the second teflon tube. The distal part of the knife is formed shape a hook. A metal cutting wire is located between two tubes. Moving the handle the metal wire is shifted. Pushing the metal wire or approaching in the distal part the second tube sets the depth of cut. The incision is made by moving on guidewire in bile duct. The power settings vary.
224021453|NCT02308020|DRUG|Abemaciclib|Administered orally
224021454|NCT02811185|DRUG|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
224021455|NCT02829788|OTHER|Non interventional|Peroperative data collection
224131655|NCT04446026|DRUG|Placebo|teneligliptin 20mg PO qd for 12weeks after placebo 1T PO qd for 12 weeks
223734058|NCT04406961|PROCEDURE|Endoscopic sphincterotomy.|Endoscopic standard sphincterotomy aims at opening bile duct or pancreatic duct by cutting the papilla and sphincter muscles. After deep bile duct cannulation, the standard sphincterotome is retracted until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary. The extent of the sphincterotomy is limited by the length of the intraduodenal portion of the common bile duct.
224131656|NCT01791699|DRUG|Moxonidine|
224131657|NCT01791699|DRUG|Placebo|
224021456|NCT01127269|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
224021457|NCT01048580|DRUG|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
223401227|NCT06169124|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224021458|NCT01048580|DRUG|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
224021459|NCT02376374|OTHER|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
223401228|NCT06169124|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223401229|NCT05946590|PROCEDURE|Frenotomy|Frenotomy in which clipping/incised of the lingual frenulum releases the tongue-tie performed by a health care professional
223401230|NCT05000788|BEHAVIORAL|Qigong|Eight-Section Brocades Practice: The treatment group will undergo an 8-week Eight-Section Brocades intervention program consists of a total of 16 group training sessions with two 1-hour sessions per week. The treatment group participants will be provided with health qigong exercise in a group format led by qualified qigong instructors. All the health qigong instructors will be trained by a certified Traditional Chinese Medicine (TCM) practitioner with an expertise in health qigong and they are required to pass the certification examination before delivering health qigong intervention at the clinical settings. The Eight-Section Brocades protocol will be used in this study because it is easy to learn by the participants and the clinical effects on psychosocial health were evidenced in previous RCTs. A complete cycle of the Eight-Section Brocades took 12 minutes for completion, which consists of eight sequential and simple forms of movements.
223401231|NCT05000788|BEHAVIORAL|Exercise|Exercise Program: Participants in the control group will attend a physical exercise program for 8 weeks (1-hour sessions, 2 times a week). The exercise program will incorporate aerobic fitness, strength training, body weight workouts, balance training, flexibility and stretching into the training plan. The exercise program is provided in a group format, which will be led by qualified physical trainer.
223401232|NCT06175325|PROCEDURE|Trans-radial embolisation of haemorrhoids|"Once patients have provided informed consent to participate, an assessment of symptom severity will be obtained during the initial visit using the a standardised set of 4 validated scoring systems used in research of haemorrhoidal disease. These include the French bleeding score (FBS), Goligher classification of internal haemorrhoids (GS), quality of life score (QoL) and Visual analogue score for pain (VAS). Routine blood tests will be taken. During the procedure, routine observations will be recorded on the paper CRF. The data collected on the paper CRF will be entered onto the electronic CRF.~The Transarterial fluoroscopically guided superior rectal artery embolization procedure will be performed on all participants. It is a day case procedure performed under local anaesthetic."
223401233|NCT03964285|OTHER|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
224021460|NCT04061395|BIOLOGICAL|Guselkumab|See study arm description.
224021461|NCT01964885|DIETARY_SUPPLEMENT|IQP-AS-105|
224021462|NCT01964885|DIETARY_SUPPLEMENT|Placebo|
224131658|NCT01818388|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
224131659|NCT00214968|DRUG|Modafinil|maximum dosage 400 mg/day (4 tablets)
224131660|NCT03222076|BIOLOGICAL|Ipilimumab|Given IV
224131661|NCT03222076|BIOLOGICAL|Nivolumab|Given IV
224131662|NCT00084942|DRUG|capecitabine|
224131663|NCT00084942|DRUG|gemcitabine hydrochloride|
223734059|NCT04406961|DEVICE|The standard sphincterotome.|"The standard sphincterotome, the Erlangen pull-type model, consists of a catheter containing a cautery wire exposed 15 to 25 mm near the tip of the instrument. The leading tip distal to the wire, the nose, is 5 to 10 mm in diameter. After deep bile duct cannulation, the sphincterotome is retracted slowly, until one fourth to one half of the wire length is exposed outside the papilla. The sphincterotome is slightly bowed so that the wire is in contact with the roof. The incision is made by lifting the sphincterotome against the papillary roof using the elevator and up-down controls while applying short bursts of current. The power settings vary."
224131664|NCT00931580|DIETARY_SUPPLEMENT|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
224131665|NCT06091020|BIOLOGICAL|IncobotulinumtoxinA|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl)
224131666|NCT06091020|BIOLOGICAL|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
224131667|NCT01566643|DRUG|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
223401234|NCT03964285|OTHER|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
223401235|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260
223401236|NCT04400838|BIOLOGICAL|MenACWY vaccine|Standard single dose of MenACWY vaccine
223401237|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by spectrophotometry at Abs260 and 2.2x10\^10vp ChAdOx1 nCoV-19 boost measured by qPCR 4-6 weeks later
223401238|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine|Two standard doses of MenACWY vaccine 4-6 weeks apart
223401239|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 (qPCR)|A single dose of 5x10\^10vp of ChAdOx1 nCoV-19 measured by qPCR
223401240|NCT04400838|BIOLOGICAL|ChAdOx1 nCoV-19 0.5mL prime plus boost|Two dose ChAdOx1 nCoV-19 0.5mL (3.5 - 6.5 × 10\^10 vp Abs 260)
223401241|NCT04400838|BIOLOGICAL|Two dose MenACWY vaccine min. 4 weeks apart|Two standard doses of MenACWY vaccine minimum 4 weeks apart
223401242|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.5mL|Two dose ChAdOx1 nCoV-19 0.5mL (Covishield 0.9 x 10\^11 vp/mL), 4-6 weeks apart
223401243|NCT04400838|BIOLOGICAL|Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL|Two dose ChAdOx1 nCoV-19 (Covishield 0.9 x 10\^11 vp/mL), 0.25mL prime and 0.5mL boost 4-6 weeks apart
223401244|NCT05574101|DRUG|Cemiplimab|Participants will undergo baseline imaging, followed by two doses of neoadjuvant cemiplimab at a dose of 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days). Then, participants will receive concurrent cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) concurrently with RT to 70 Gy in 35 fractions over 7 weeks. Thereafter, participants will receive 38 weeks of cemiplimab 350 mg intravenously over 30 minutes every 3 weeks (+/-3 days) for a cumulative total of 12 months of cemiplimab.
223401245|NCT05574101|RADIATION|Radiotherapy|Participants will receive radiotherapy to 70 Gy in 35 fractions over 7 weeks concurrently with cemiplimab
223401246|NCT06325085|OTHER|compensatory and restorative rehabilitation techniques|"compensatory and restorative rehabilitation techniques Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
223401247|NCT06325085|OTHER|Traditional cognitive rehabilitation training|"Naming words ( ask patient to name food, states, family members) Counting numbers backwards, backward counting of days and months) Spell the word backwards, remembering a piece of information Frequency: 10 reps 2-3 times/week for 3 consecutive weeks then evaluation of the effects.~Continue the same techniques for 3 more weeks and then evaluate the retention effects of restorative and compensatory rehabilitation techniques will be evaluated by 9th week."
223401248|NCT05849493|BEHAVIORAL|Metacognitive Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry
223401249|NCT05849493|BEHAVIORAL|Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy|Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry
223734060|NCT02248194|DEVICE|Tactile electrosurgical ablation probe|
223734061|NCT02248194|DEVICE|Hysteroscopic endometrial ablation|
223734062|NCT01777256|DRUG|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
223734063|NCT01777256|DRUG|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
223734064|NCT01777256|DRUG|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
223734065|NCT01777256|DRUG|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
223734066|NCT01777256|DRUG|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
224131668|NCT01566643|DRUG|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
224131669|NCT01566643|DRUG|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
224131670|NCT00509496|DRUG|fludarabine phosphate|25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.
224131671|NCT00509496|DRUG|cyclophosphamide|60 mg/kg/day x 2 days intravenous
224131672|NCT00509496|BIOLOGICAL|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
224131673|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
224297189|NCT01430975|DRUG|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
223734067|NCT01972503|DRUG|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
223734068|NCT01972503|PROCEDURE|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
223734069|NCT05127473|DRUG|Mim8 B, 10 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
223734070|NCT05127473|DRUG|Mim8 B, 100 mg/mL|All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
223734071|NCT05127473|DRUG|Mim8 B, placebo|Placebo will be used to dilute the IMP to different Mim8 concentrations
223734072|NCT03852940|OTHER|Parenteral nutrition|
223734073|NCT03852940|OTHER|Enteral Nutrition|
223734074|NCT05908370|PROCEDURE|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)|Maxillary orthognathic surgery using 4 patient specific osteosynthesis (4-Plates)
224131674|NCT00509496|BIOLOGICAL|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
223401250|NCT06838767|OTHER|Conventional treatment|"10 min moist heat pack Self-assisted anterior capsular stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Self-assisted posterior capsular stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Self -assisted inferior capsule stretching Hold for 30 sec and repeat 5 times with 10 sec rest between each stretch Codman's pendular exercises 10 reps Muscle strengthening exercises (after 4 weeks)~* Internal rotators and External rotators isometrics Hold for 5-8 seconds and repeat 10 times~* chair press According to FIIT protocol 10 reps progressing to 20 and 30 repetitions in 5th and 6th week with two session in a day, three days per week for six consecutive weeks"
223552703|NCT05130905|DIETARY_SUPPLEMENT|RiteStart Supplement|RiteStart is a comprehensive multivitamin, multimineral, all-in-one daily supplement. Besides having comprehensive and balanced amounts of essential vitamins and minerals that the human body needs, RS includes many other health-promoting ingredients. For example, RS contains potent antioxidants, including vitamins A, C, and E, oligomeric proanthocyanidins from pinebark and grapeseed extracts, lutein, CoQ10, alpha-lipoic acid, and green tea. It is also a source of essential fatty acids from fish and plant oils. RS contains transfer factor (bovine colostrum and egg yolk extracts) that support immunity \[6, 7, 8\]. RS also includes a blend of maitake mushrooms, shiitake mushrooms, cordyceps, inositol hexaphosphate, olive leaf extract, and other ingredients that aim to further support immune function and overall health.
223552704|NCT03053440|DRUG|BGB-3111|160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
224131675|NCT02150473|DRUG|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
223734075|NCT00775645|DIETARY_SUPPLEMENT|acetyl-L-carnitine hydrochloride|Given orally
223734076|NCT00775645|OTHER|placebo|Given orally
223734077|NCT03036072|OTHER|Strict normothermia|
223734078|NCT03036072|DEVICE|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
223734079|NCT00924456|BEHAVIORAL|Transcendental Meditation program|a natural effortless mental technique
223734080|NCT04193657|OTHER|Daily and weekly triggered symptom monitoring|Participants are invited to complete a daily questionnaire, a weekly questionnaire, and to track daily activity with an electronic activity tracker.
223734081|NCT02484729|DRUG|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
223734082|NCT02484729|DRUG|Placebo, oral suspension|Matching placebo
223734083|NCT02484729|DRUG|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
223734084|NCT00541489|DRUG|Naproxcinod|750 mg, bid
223734085|NCT00541489|DRUG|Naproxen|500 mg, bid
223734086|NCT00541489|DRUG|Placebo|bid
224131676|NCT02150473|DRUG|Placebo|Placebo the same amount as adalimumab
224131677|NCT00062634|BEHAVIORAL|Female condom skills training|
223734087|NCT05899309|DIAGNOSTIC_TEST|liver and spleen stiffness test and laboratory test|Diagnosis of cirrhosis can be based on liver biopsy,radiological ,clinical or liver stiffness measurement (LMS)
223734088|NCT02389933|DRUG|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
223734089|NCT03194698|DEVICE|Intense Pulsed Light Treatment (IPL)|IPL is a high-intensity light source consisting of visible light in the wavelength range of 515-1200 nm, that is aimed at the eyes. Treatments are spaced four to six weeks apart for a total of 4 treatments.
223734090|NCT03194698|PROCEDURE|Meibomian Gland Expression|Manual expression of the meibomian glands by placing the thumb against the lid margin and press firmly against the eyeball to determine the percentage of meibomian pores that are blocked. This assessment is performed on both the upper and lower lid of each eye.
223734091|NCT02111850|BIOLOGICAL|Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
223734092|NCT02111850|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
223734093|NCT02111850|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2 /day intravenous piggy-back (IVPB) daily over 30 minutes for 5 days.
223552705|NCT03053440|DRUG|Ibrutinib|420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
224297190|NCT01430975|DRUG|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
224297191|NCT04130659|COMBINATION_PRODUCT|MARIAL® + PPI (generic Omeprazole)|"MARIAL® administration: 1 stick twice daily after meals from day 1 to 28.~Omeprazole administration: 20 mg cps once daily from day 1 to day 28"
223734094|NCT02111850|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
223734095|NCT02760667|DRUG|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
223734096|NCT02760667|DRUG|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
223734097|NCT02760667|DRUG|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
223734098|NCT02760667|PROCEDURE|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
223734099|NCT06138106|DIETARY_SUPPLEMENT|Natural Product Supplement|Participants will have blood drawn before and one hour after consuming the natural product supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
223734100|NCT06138106|DIETARY_SUPPLEMENT|Placebo control|Participants will have blood drawn before and one hour after consuming the placebo supplement. For 7-days the participants will perform load-bearing exercise and consume the supplement. On the final day, blood will be collected 4 hours after the final exercise bout.
223734101|NCT00616954|DRUG|ATG-F|ATG-f
223401251|NCT06838767|OTHER|Kinetic chain approach|Kinetic chain approach Shoulder flexion with ipsilateral anterior step-up, Shoulder-dump exercise Starting position with Body weight is on the contralateral-side leg with trunk flexion and rotation. Finishing position. With Body weight is on the ipsilateral-side leg with thoracic extension. Modified shoulder-dump Exercise Sternal-lift starting position with head and trunk flexed forward. Finishing position with emphasizing thoracic extension. Tubing fencing exercise starting position with body weight on the ipsilateral leg. Elbow is at the hip; thoracic extension and scapular retraction are encouraged, Athletic stance during ball-stabilization exercise. Axially loaded wall-slide exercise. Motion at the hips and trunk complements the sliding pattern of the hand.Perform each exercise for 3 Days (twice a day) a week for 6 weeks. 10 reps ,2 sets According to FITT protocol, 10 reps, two sessions per day, and three days per week for 6 consecutive weeks.
223401252|NCT06852248|PROCEDURE|Ureteric stenting|The ICE trial is a pilot study involving two methods for identifying the ureters (tubes connecting the kidneys to the bladder) during endometriosis surgery. One group will have conventional ureteric stenting (temporary tubes placed in the ureters)
223734102|NCT03293810|OTHER|Observational study|Post-Authorization Safety Study
223734103|NCT00665847|DRUG|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
223401253|NCT06852248|PROCEDURE|Indocyanine green (ICG) dye|The ICE trial is a pilot study involving two methods for identifying the ureters (tubes connecting the kidneys to the bladder) during endometriosis surgery. One group will receive indocyanine green (ICG) dye injected into the ureters to make them visible under a special light.
223401254|NCT06572384|BIOLOGICAL|Belimumab|Belimumab will be administered.
223401255|NCT06572384|OTHER|Placebo|Placebo will be administered.
223401256|NCT06574373|OTHER|Blood Collection Protocol for Patients with Indolent, Invasive, and Pancreatic Cancer-Associated IPMN Based on Clinical Course and Surgical Intervention|Blood will be collected from patients with indolent IPMN, invasive IPMN, and IPMN associated with pancreatic cancer, depending on their clinical course. Patients with indolent IPMN will be monitored by the gastroenterology units of their respective institutions, which will inform the patient. Patients with invasive IPMN and/or associated with cancer will undergo surgical resection as part of their standard clinical care, and blood will be collected after informed consent is obtained by the surgical teams at each institution.
223401257|NCT06079359|DRUG|ALXN1850|Participants will receive a ALXN1850 via subcutaneous (SC) injection.
224021463|NCT02475239|BEHAVIORAL|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
224021464|NCT02475239|BEHAVIORAL|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
224297192|NCT04130659|DRUG|PPI alone (generic omeprazole)|Omeprazole administration: 20 mg cps once daily from day 1 to day 28
224297193|NCT04130659|DEVICE|MARIAL® alone|MARIAL® administration: 1 stick twice daily after meals from day 29 to month 6.
223401258|NCT06079359|DRUG|Placebo|Participants will receive placebo via SC injection.
223401259|NCT05815511|DIETARY_SUPPLEMENT|Probiotic mixture|Oral capsule consumption once a day for 12 weeks
223401260|NCT05815511|DIETARY_SUPPLEMENT|Placebo|Oral capsule consumption once a day for 12 weeks
223401261|NCT04318977|DEVICE|high-frequency rTMS|repetitive transcranial magnetic stimulation
223401262|NCT04318977|DEVICE|TBS|theta burst stimulation
223401263|NCT04318977|DEVICE|placebo|placebo transcranial magnetic stimulation
223401264|NCT06616584|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223401265|NCT06616584|BIOLOGICAL|Cemiplimab|Given IV
223401266|NCT06616584|PROCEDURE|Computed Tomography|Undergo CT
223401267|NCT06616584|DRUG|Dexamethasone|Given PO
223401268|NCT06616584|DRUG|Docetaxel|Given IV
223401269|NCT06616584|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224021465|NCT06294132|PROCEDURE|Lumbar Manipulation|"The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed to the level to be manipulated, and the left foot is placed behind the right lower leg. The caregiver introduces rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver then rolls the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. If a cavitation pop is not heard the first time, a second attempt is made. The procedure is repeated on the opposite side."
224297194|NCT05727475|PROCEDURE|Minimal invasive restorative treatment|Composite veneer facing without drilling or removal of enamel
224297195|NCT05727475|PROCEDURE|Fluoride gel application|Fluoride gel application 1.23%
223401270|NCT06616584|BIOLOGICAL|Ramucirumab|Given IV
223401271|NCT01909934|DRUG|Brentuximab vedotin|Brentuximab vedotin IV infusion
223401272|NCT05907161|DEVICE|SRP+LASER (Dentsply Sirona - SIROLaser Blue)|adjunct irradiation with a diode laser (Dentsply Sirona - SIROLaser Blue) intrasulcularly to all sites with PD ≥ 4mm
223401273|NCT05907161|DEVICE|SRP+HA|adjunct hyaluronic acid (Regedent, HyaDENT Cross linked hyaluronic intrasulcularly to all sites with PD ≥ 4mm
223401274|NCT05907161|DEVICE|SRP|non-surgical periodontal therapy (SRP) with utrasonic device and curretes
223401275|NCT06090097|DEVICE|KneeBRIGHT System|The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
223401276|NCT06090097|OTHER|Control Exercise|The control group will complete a 10-week regimen of conventional PT exercise
223401277|NCT02795663|DEVICE|NIRS EEG HR recording|NIRS EEG HR recording
223401278|NCT05671172|DRUG|Hyaluronidase|hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS
223401279|NCT05671172|DRUG|Bupivacaine Injection|20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS
223401280|NCT06513091|DEVICE|OCS Lung|The TransMedics Organ Care System (OCS) Lung is an FDA approved portable extracorporeal lung perfusion and monitoring system.
223401281|NCT06443502|DRUG|Vedolizumab|Vedolizumab intravenous infusion.
223401282|NCT06443502|DRUG|Concomitant Antibiotic Therapy|Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
223401283|NCT06730555|BEHAVIORAL|ACCESS Intervention|Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.
223552706|NCT04976881|BEHAVIORAL|Medication Reconciliation (MedRec) Tool|Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.
223552707|NCT04976881|BEHAVIORAL|Provider Alert and Decision Support|During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.
223552708|NCT04976881|BEHAVIORAL|PREPSheet|When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.
223552709|NCT04976881|BEHAVIORAL|Text Messaging|Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
223552710|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
223552711|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
223552712|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
223552713|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
223401284|NCT06730555|BEHAVIORAL|Control Group|Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.
223552714|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
223734104|NCT00665847|DRUG|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir \[LPV\], darunavir \[DRV\], atazanavir \[ATV\] or saquinavir \[SQV\]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N\[t\]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
223401285|NCT05064709|DEVICE|Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.
223734105|NCT04890223|BEHAVIORAL|Brief MI intervention|Brief MI intervention
223734106|NCT04890223|BEHAVIORAL|Placebo intervention|Generic health advice consultations and self-help smoking cessation booklets
223401286|NCT05064709|DEVICE|OPTIMIZER™ Smart Mini System|The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
223401287|NCT06023602|DRUG|Generic cetrorelix acetate|Generic cetrorelix acetate (0.25 mg SC)
223401288|NCT06023602|DRUG|Reference cetrorelix acetate|reference cetrorelix acetate (0.25 mg SC)
223734107|NCT02584114|BEHAVIORAL|Peak app for memory training|
223734108|NCT02584114|BEHAVIORAL|Non-memory training group|
223734109|NCT04845789|OTHER|Non-interventional|Non-interventional. Interview would be conducted for data collection.
223734110|NCT00704158|DRUG|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
223734111|NCT02867787|DRUG|Botox arm|
224297196|NCT01520636|PROCEDURE|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
224021466|NCT06294132|PROCEDURE|Sham Lumbar Manipulation|The participant lies on the right side. The right leg is straightened at the knee. The left knee is flexed SLIGHTLY, and the left foot is placed behind the right lower leg. The caregiver DOES NOT introduce rotation of the participant's upper body down to the level to be manipulated. The caregiver then takes up an axillary hold. The caregiver places his right forearm in the region between the gluteus medius and maximus. The caregiver DOES NOT roll the participant towards them. Prior to thrusting, the caregiver applies a slight overpressure and holds the position for 10 seconds. If the participant does not experience any adverse effects, over-pressure is released, and the restrictive barrier re=engaged. The caregiver applies a HVLA thrust against the participant's buttocks by dropping their body. NO ROTATION OCCURS IN THE SPINE. The procedure is repeated on the opposite side.
224021467|NCT00241852|BEHAVIORAL|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
224021468|NCT00241852|BEHAVIORAL|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
223401289|NCT02593292|BEHAVIORAL|PROSPERO|"The intervention is carried out in 3 steps:~1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
223401290|NCT02593292|OTHER|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
223401291|NCT01841047|RADIATION|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
223401292|NCT06180122|DIAGNOSTIC_TEST|Duplex ultrasound|Vascular ultrasound scan of the left common iliac vein
223552715|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
223552716|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
223552717|NCT02574559|BEHAVIORAL|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
223552718|NCT02574559|BEHAVIORAL|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
223552719|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
223552720|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
223552721|NCT00391053|BIOLOGICAL|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
223552722|NCT00391053|BIOLOGICAL|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
223552723|NCT05002985|BEHAVIORAL|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
223552724|NCT05752097|DEVICE|[18F]AlF-NOTA-FAPI-04 PET/CT examination|The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
223552725|NCT05752097|PROCEDURE|Renal puncture biopsy|The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
223552726|NCT01458548|DRUG|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
223552727|NCT01458548|DRUG|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
223552728|NCT00785590|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
223552729|NCT04074070|OTHER|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
223552730|NCT02557776|GENETIC|Germline genetic testing of BRCA1 and BRCA2|
223734112|NCT05814939|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
223734113|NCT05814939|DRUG|Tofacitinib Citrate Tablets|Tofacitinib Citrate groups repeat administration for 12 weeks
223734114|NCT05814939|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
223734115|NCT03605303|DEVICE|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
223734116|NCT03605303|DEVICE|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
224021469|NCT03333837|BEHAVIORAL|Dance Group|Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
224021470|NCT03333837|BEHAVIORAL|Non-Group Dance|The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
224131678|NCT02673892|OTHER|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
223734117|NCT05368857|DRUG|Afamelanotide|Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
223552731|NCT02943070|DEVICE|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
224131679|NCT01734486|DRUG|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
224131680|NCT01734486|DRUG|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
223552732|NCT03391830|DRUG|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
223552733|NCT03391830|DRUG|Placebo|Placebo
223552734|NCT03789513|DIAGNOSTIC_TEST|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
223552735|NCT04123093|DEVICE|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
223552736|NCT04123093|DEVICE|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
223552737|NCT03516773|DRUG|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
223552738|NCT03516773|DRUG|NATPARA/NATPAR|A PTH replacement (PTH \[1-84\]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
223552739|NCT05421130|DEVICE|Selective Cerebral Perfusion Catheter|This product is intended to be placed in the branches of the aortic arch for the cerebral perfusion during surgery of aorta.
223552740|NCT00001106|DRUG|Zidovudine|
224131681|NCT02152670|DRUG|Methylphenidate|
223552741|NCT03096795|DRUG|MEDI3506|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
224131682|NCT02152670|DRUG|Alpha Methyl Para Tyrosine (AMPT)|
224131683|NCT02152670|OTHER|[11C]PHNO|
224131684|NCT02152670|OTHER|[11C]raclopride|
224131685|NCT01573507|OTHER|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
223734118|NCT03027726|BEHAVIORAL|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
224021471|NCT03333837|BEHAVIORAL|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
223734119|NCT03027726|OTHER|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
223734120|NCT01913912|DRUG|LDX.|"In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
223401293|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 1Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 1 Hz ThorS-MagNT, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
223734121|NCT01913912|DRUG|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
223734122|NCT01913912|DEVICE|computer task (Go/No-Go task)|
223401294|NCT05273788|DEVICE|2400 ThorS-MagNT Stimulations at 10Hz|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. 10Hz ThorS-MagNT involves delivering one train of 100 pulses per minute with 50-second rest intervals over twelve minutes on both right and left sides (total 1200 pulses/side).
223734123|NCT01913912|DEVICE|EEG|event-related potentials (ERP) and heart rate measurements
223734124|NCT01913912|DEVICE|pupil size measurements (by using eye tracking)|
223734125|NCT03705507|DRUG|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
223734126|NCT03705507|DRUG|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
223734127|NCT05557461|DEVICE|End-tifdal co2, systolic, diastolic blood pressure, ppv values and vci distensibility|"(0,1,3,5 minutes measurements will be taken) measured before and after the test will be recorded and compared.~Cardiac output and stroke volume variation, vci distensibility will be measured and recorded by a specialist cardiologist using siemens ocuson cv70 (Siemens AG Medical Solutions, Henkestrasse, the Germany) echocardiography before and after the test."
223401295|NCT05273788|DEVICE|Sham Stimulations|The inferior angles of the scapula will serve as landmarks for the T7 level. A mapping procedure is performed with subject in the seated position using a single-pulse stimulation circular 90- mm coil to determine the location and minimum intensity of stimulation left and right of the T7 spinous process required to achieve a motor evoked response (MEP) of 50 μV with 50% of trials (resting motor threshold) in the upper rectus abdominis or external oblique muscles. The intensity for ThorS-MagNT is set at 150% above motor threshold. Sham stimulations, one of 4 total trains is delivered over 5 minutes with 3-min rest intervals on both right and left sides (total 1200 pulses/side).
223552742|NCT03096795|DRUG|Placebo|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
223552743|NCT05134285|OTHER|blood pressure,BMI, blood sample|Blood pressure will be monitored. BMI will be measured. Blood samples will be tested.
223552744|NCT00654836|BIOLOGICAL|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
223552745|NCT00654836|DRUG|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
223552746|NCT00654836|DRUG|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
223552747|NCT04320212|PROCEDURE|lumber epidural analgesia|the lumber epidural analgesia will be given after induction of general anesthesia.
223552748|NCT04320212|PROCEDURE|erector spinae analgesia|the erector spinae analgesia will be given after induction of general anesthesia.
223552749|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
223552750|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
223734128|NCT05156489|DEVICE|Fractionated Laser (Pixel CO2-Alma)|The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
223734129|NCT00165243|PROCEDURE|Tangential radiation|Radiation given over 6 1/2 weeks
224131686|NCT04745793|OTHER|Hyperspectral and Fluobeam acquisition|"Once enough exposure of the operative site is achieved, an RGB (Red Green Blue) picture will be taken and the surgeon will depict the parathyroid glands on it, this picture will act as ground truth. At this point, without changing the surgical exposure, a second surgeon involved in the study will attempt once to detect the parathyroid glands intraoperatively using the HSI system and the Fluobeam® alternatively. The number and the position of the parathyroid glands visualized with each tool will be compared to the number and position of the glands previously visualized by the operating surgeon. The procedure will be repeated every time the surgeon attempts to visualize the parathyroid glands. The order of the detection tools randomized for each case will be preserved in case of repeated visualizations."
224131687|NCT01709136|DRUG|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
224131688|NCT00568958|BEHAVIORAL|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
223401296|NCT05112705|DIAGNOSTIC_TEST|Proximal lower limb ultrasound|Twice weekly proximal lower limb ultrasound
223401297|NCT05700942|DEVICE|High Dose Intervention-tsDCS|Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)
224131689|NCT00568958|DRUG|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
224131690|NCT00568958|DRUG|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
224131691|NCT02572258|OTHER|Nutritional cookie|
223401298|NCT05700942|DEVICE|Low Dose Intervention-tsDCS|Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
224131692|NCT00651404|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
223552751|NCT02777411|BIOLOGICAL|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
224131693|NCT00651404|DRUG|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
224131694|NCT01057069|DRUG|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
224131695|NCT01057069|DRUG|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
224297197|NCT01520636|PROCEDURE|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
224297198|NCT02790307|DEVICE|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
224297199|NCT02408328|DRUG|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
224297200|NCT02408328|DEVICE|Home monitor|Use of home monitor until 44 weeks postmenstrual age
224297201|NCT02408328|OTHER|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
224297202|NCT03866915|DIAGNOSTIC_TEST|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
223401299|NCT03670615|OTHER|tDCS|All study participants randomized to tDCS will receive active tDCS.
223401300|NCT03670615|OTHER|Exercise|Participants will exercise at TRI according to an individualized exercise prescription.
223401301|NCT03670615|OTHER|Exercise Education|Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
223401302|NCT03670615|OTHER|Sham tDCS|The same procedure for tDCS will be used for the sham condition, except without active current.
223401303|NCT02883816|OTHER|assessment of lung function|measurement of lung volumes and flow rates of bronchial
223401304|NCT05445102|PROCEDURE|autogenous demineralized dentin graft as bone substitute in treatment of intrabony defect|after extraction of tooth it will be grinded using hand bone mill and demineralized and placed in intrabony defect
223552752|NCT02777411|BIOLOGICAL|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
223552753|NCT02777411|BIOLOGICAL|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
223552754|NCT02777411|BIOLOGICAL|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
223552755|NCT02777411|BIOLOGICAL|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
223552756|NCT05072054|DRUG|Atorvastatin Oral Tablet|Atorvastatin 40 mg
223552757|NCT05072054|DRUG|Rosuvastatin Oral Tablet|Rosuvastatin 20 mg
223552758|NCT00130104|PROCEDURE|Transthecal Metacarpal Block|
223552759|NCT00273091|DEVICE|ICD with CRT therapy|permanently CRT pacing
223552760|NCT01845246|DEVICE|Prospective TDM Arm of colistin|
223552761|NCT00290719|DRUG|cisplatin|
223552762|NCT00290719|DRUG|gefitinib|
223552763|NCT00290719|DRUG|irinotecan hydrochloride|
223552764|NCT00290719|PROCEDURE|conventional surgery|
223552765|NCT00290719|PROCEDURE|neoadjuvant therapy|
223552766|NCT00290719|RADIATION|radiation therapy|
223552767|NCT02869581|OTHER|Data collection|
223552768|NCT01485796|BIOLOGICAL|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
224131696|NCT01057069|DRUG|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
224131697|NCT02607254|DRUG|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
224131698|NCT02607254|DRUG|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
224297203|NCT03866915|DIAGNOSTIC_TEST|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
224297204|NCT05607251|OTHER|No intervention|There is no intervention as this is an observational study
224297205|NCT03987594|PROCEDURE|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
224297206|NCT03987594|PROCEDURE|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
224297207|NCT02458092|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
223552769|NCT01485796|BIOLOGICAL|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
223552770|NCT04089527|DRUG|CC-95775|CC-95775
223552771|NCT03754556|DEVICE|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
224297208|NCT02458092|BIOLOGICAL|Rabipur|Rabipur is a licensed rabies vaccine.
224297209|NCT04316130|DEVICE|Uincare Homeplus|Interactive digital healthcare system
224297210|NCT04316130|OTHER|Brochure|Brochure
224297211|NCT03022474|BEHAVIORAL|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
224297212|NCT01825122|DRUG|Nadolol|
224297213|NCT01825122|DRUG|Placebo|
224297214|NCT03595163|DRUG|Sevoflurane|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
224297215|NCT03595163|DRUG|Propofol|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
224297216|NCT03329534|OTHER|Gluten free diet|A month long gluten free diet
224297217|NCT02760706|DEVICE|Computed Tomography scan|
224297218|NCT03852459|DRUG|S-Ibuprofen|Topical Gel 5%
224297219|NCT03852459|DRUG|Vehicle|Vehicle Gel
224297220|NCT01981499|DRUG|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
223552772|NCT01771991|DRUG|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
223552773|NCT01771991|DRUG|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
223552774|NCT04444271|DRUG|Mesenchymal stem cells|1\. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
223552775|NCT04444271|OTHER|Placebo|100 ml of normal saline will be given intravenously to control arm
223552776|NCT02143856|DRUG|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
223552777|NCT01188902|DIETARY_SUPPLEMENT|walnut|walnut consumption 48 g/d
223552778|NCT03130517|DRUG|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
223552779|NCT05237063|BIOLOGICAL|Blood and urine samples|Additional Blood and urine samples will be collected at inclusion, 1, 3 and 5 years follow up visits
223552780|NCT04291196|OTHER|VR-ECT 360o Video|Patients in the VR arm will be immersed in the ECT process in first person utilizing Google Cardboard headsets. Patients will experience in 360 entering the procedure room, IV insertion, pretreatment checks, anesthetic induction followed by induction of seizure, and recovery. The experience will also have voice-over narration simultaneously describing the procedure and its risks and benefits.
223552781|NCT04291196|OTHER|Standard Treatment|Patients will receive preparation for their ECT as per standard of care, i.e. a discussion with a Psychiatrist.
223552782|NCT00068263|RADIATION|radiation therapy|
223552783|NCT04901663|DRUG|Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG|Orally twice daily for 2 weeks
223552784|NCT04901663|DRUG|Vonoprazan 20 MG; Amoxicillin 1000 MG|Orally twice daily for 2 weeks
223552785|NCT05594771|PROCEDURE|epidural needle|the loading dose for labor analgesia administrated via epidural needle before the catheter insertion
224131699|NCT03791645|BEHAVIORAL|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (\~3 hours/day), followed by 4 weekly follow-ups (\~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
224297221|NCT01981499|DRUG|Placebo|Placebo tablets
224131700|NCT02929849|DIETARY_SUPPLEMENT|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
224297222|NCT01981499|DRUG|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
224131701|NCT02929849|DIETARY_SUPPLEMENT|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
224131702|NCT02929849|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
223401305|NCT00592306|DRUG|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
223401306|NCT00592306|DRUG|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
224297223|NCT01981499|DRUG|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
224297224|NCT01981499|DRUG|10 mg cetirizine|Single 10 mg dose of cetirizine
224297225|NCT01981499|DRUG|Placebo|Placebo tablets
224297226|NCT05010733|DEVICE|Total hip arthroplasty using the Exeter V40 cemented femoral stem|Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
224297227|NCT05010733|DEVICE|Total hip arthroplasty using the Müller Straight Stem|Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
224297228|NCT04629859|PROCEDURE|mandibular setback and maxillary advancement|12 patients will undergo mandibular setback and maxillary advancement
223401307|NCT03732664|DRUG|Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab|One to four doses of anti-PD-1 or anti-PD-L1 antibody will be administered to enrolled patients on Day -56, Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
223552786|NCT05594771|PROCEDURE|epidural catheter|the loading dose for labor analgesia administrated via epidural catheter
223401308|NCT00826969|DRUG|Ciclesonide|320µg Ciclesonide versus Placebo
223401309|NCT00826969|DRUG|Placebo|Placebo
223552787|NCT03809078|DRUG|68Ga RM2|PET radiopharmaceutical
223552788|NCT03809078|DRUG|68Ga-PSMA-11|PET radiopharmaceutical
223552789|NCT03809078|DEVICE|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
223552790|NCT01485276|PROCEDURE|DBS Surgery|
223552791|NCT04644146|GENETIC|GENETIC|It is a retrospective study on patients which has been hospitalized since the beginning of the COVID-19 pandemic in Lyon (march 2020). The blood samples have been collected I the frame of the regular follow-up of the patients and DNA extracted and conserved for the various research protocols ongoing in the University Hospital. The DNA will be analyzed by next generation sequencing
223552792|NCT01488461|GENETIC|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
223552793|NCT06260449|PROCEDURE|Surgical removal|Removal of the granuloma
223552794|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 3.2 mg/m² dose."
223552795|NCT05101265|DRUG|Lurbinectedin|"Patients will receive lurbinectedin as a 1-hour (-5/+20 min) i.v. infusion on Day 1 every three weeks (q3wk), over a minimum of 100 mL dilution on 5% glucose or 0.9% sodium chloride via a central line (or a minimum of 250 mL dilution if a peripheral line is used). Of note, Cycle 2 or subsequent will be administered every q3wk (+ 48 hours). Patients will receive a maximum of two cycles: a first mandatory cycle with all study assessments followed by a second optional cycle with lurbinectedin (this last optional for patients with clinical benefit as per Investigator's criteria).~After completing Cycle 2, those patients waiting for the compassionate use approval will continue on the study receiving lurbinectedin herein after until disease progression, unacceptable toxicity, consent withdrawal or while it is considered to be in their best interest, or until starting treatment with lurbinectedin under a Compassionate Use Agreement outside this study.~Lurbinectedin at a 1.6 mg/m² dose"
223552796|NCT04918381|DEVICE|CellFX System|Nano-Pulse Stimulation (NPS)
224297229|NCT04629859|PROCEDURE|mandibular setback|12 patients will undergo mandibular setback
224297230|NCT03629028|DIAGNOSTIC_TEST|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
224297231|NCT03629028|DIAGNOSTIC_TEST|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.
223734130|NCT00743314|OTHER|screening questionnaire administration|
224297232|NCT03629028|DIAGNOSTIC_TEST|Adjacent myometrium thickness|The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.
224297233|NCT03629028|DIAGNOSTIC_TEST|Niche Measurements (depth of niche, width of niche, length of niche)|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
223552797|NCT03634098|DEVICE|new quantitative imaging techniques with contast products|magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
223552798|NCT03634098|DIAGNOSTIC_TEST|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
223552799|NCT03634098|DIAGNOSTIC_TEST|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
223734131|NCT00743314|PROCEDURE|computed tomography|
223734132|NCT00743314|PROCEDURE|lymphoscintigraphy|
223734133|NCT00743314|PROCEDURE|single photon emission computed tomography|
223734134|NCT00743314|RADIATION|intensity-modulated radiation therapy|
224021472|NCT03333837|BEHAVIORAL|No Contact|The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
224021473|NCT04834856|DRUG|ensovibep|The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion.
223552800|NCT05366127|OTHER|IGA score|IGA score will be assessed by 2 blinded investigators
223552801|NCT05366127|OTHER|BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)|BPDAI will be assessed by 2 by 2 blinded investigators
223552802|NCT03688334|DRUG|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
223552803|NCT03688334|DRUG|Medical air (sham O2)|Medical air supplementation via Venturi mask
223734135|NCT00743314|RADIATION|technetium Tc 99m sulfur colloid|
223552804|NCT00606411|DRUG|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
223552805|NCT02526212|BEHAVIORAL|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
223734136|NCT05266742|OTHER|web based education|"An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF."
223734137|NCT02286505|DEVICE|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
223552806|NCT02526212|BEHAVIORAL|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
223734138|NCT02286505|OTHER|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
223734139|NCT04161560|DRUG|Cetuximab-IRDye800|does of Cetuximab-IRDye800
223734140|NCT04434794|BIOLOGICAL|mesenchymal stem cells|autologous mesenchymal stem cells
223734141|NCT04434794|OTHER|standard treatment|standard treatment according to clinical protocols
223734142|NCT00815009|BEHAVIORAL|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
224021474|NCT01906554|OTHER|Egg Dose|Different quantities of eggs
224021475|NCT04217122|OTHER|strawberry powder|Participants consume 2 packages of standard strawberry powder (13 g x 2) daily for 4 weeks
224021476|NCT04217122|OTHER|placebo powder|Participants consume 2 packages of placebo powder (13 g x 2) daily for 4 weeks
223734143|NCT00815009|BEHAVIORAL|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
224021477|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 (Triple Strength Fish Oil®)|The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
224021478|NCT05488223|DIETARY_SUPPLEMENT|AGPI ω-3 + MUFA (avocado oil)|AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
223734144|NCT00815009|BEHAVIORAL|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
223734145|NCT03414723|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
224021479|NCT05488223|DIETARY_SUPPLEMENT|MUFA (avocado oil) (1.8g)|MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
224021480|NCT02739295|DRUG|recombinant granulocyte - colony stimulating factor|
224021481|NCT02739295|DRUG|NaCl 0.9%|
224021482|NCT02270138|BEHAVIORAL|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
224021483|NCT04217590|DRUG|Sodium Zirconium Cyclosilicate|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
224021484|NCT04217590|DRUG|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
224021485|NCT02866097|OTHER|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
224021486|NCT02866097|OTHER|Supportive supervision|Strengthening of supportive supervision using DHIS2
223401310|NCT04091516|BEHAVIORAL|Low-fat plant-based diet|Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
223401311|NCT03696134|OTHER|questionnaire|questionnaire
223401312|NCT01442597|BEHAVIORAL|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
223401313|NCT01442597|BEHAVIORAL|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
223401314|NCT01442597|BEHAVIORAL|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
223401315|NCT04230928|OTHER|Very low carbohydrate diet|Participants will learn to follow a very low carbohydrate diet in modified versions of GLB modules 2,3,5 \& 10. Participants will learn to track carbohydrate intake
223401316|NCT04230928|OTHER|Standard DPP-GLB diet|Participants will learn to follow a very low fat, calorie-restricted diet and track fat grams and caloric intake in standard GLB modules 2,3,5, \& 10
223552807|NCT02526212|DRUG|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
224021487|NCT02866097|OTHER|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
224021488|NCT02949466|DRUG|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
224021489|NCT02949466|DEVICE|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
223552808|NCT03391557|DIAGNOSTIC_TEST|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
223552809|NCT01253694|DRUG|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
223552810|NCT04790669|PROCEDURE|Daily adjustable progressive resistance exercises (DAPRE)|Daily adjustable progressive resistance exercises (DAPRE) In Group A, 11 participants were received Conventional physiotherapy treatment in addition to DAPRE technique by leg extension machine. In DAPRE technique, four sets of exercises were performed. The first two sets of exercise consisted of ten and then six repetitions, per- formed against one-half and three-fourths of the previously established working weight. Working weight is the amount of weight a patient uses during an individual session. The full working weight was used on the third set, and the patient performed as many repetitions as possible. After performing each of the third and fourth sets, patients rested for 1 min.6 weeks (3 sessions per week)• Hot pack: 10 min• Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
224021490|NCT04294732|DRUG|Bupivacaine|"bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL."
223552811|NCT04790669|PROCEDURE|Close kinetic chain exercises (CKC).|Close kinetic chain exercises (CKC). In Group B, 11 participants was received Conventional physiotherapy treatment in addition to close kinetic chain exercises. Close kinetic chain exercises for extensor lag was seated leg press, double or single one third knee bend, step up and down exercise, wall slide with weight. Treatment time was 30 minutes and three session per week was applied on alternate day for up to 6 weeks. Pre interventional readings will be taken at baseline \& post interventional readings at 6th week. 6 weeks (3 sessions per week) • Hot pack: 10 min • Stretching of calf and hamstring muscle: 10 min. Assessment was done via WOMAC index, universal goniometer, numeric pain rating scale \& sphygmomanometer.
223552812|NCT00304616|DRUG|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
223552813|NCT01390298|OTHER|Observational|Observational study only
223552814|NCT04279119|DRUG|ARQ-151- cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
223734146|NCT03414723|DRUG|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
223734147|NCT04961554|OTHER|loco-regional anesthesia|demonstrate that the mouth opening (measured in millimeters) of a patient treated for mandibular surgery with a very limited opening (defined by a threshold less than 20mm, not allowing the passage of a video laryngoscope blade per route buccal) is more important after locoregional anesthesia of the V3 than before anesthesia.
223734148|NCT03388294|BEHAVIORAL|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
223734149|NCT00989339|DRUG|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
223734150|NCT02626520|DRUG|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
223734151|NCT02626520|DRUG|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
223734152|NCT02626520|RADIATION|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
223734153|NCT02626520|PROCEDURE|Definitive resection|Definitive surgical resection of primary tumor
223734154|NCT00492115|DEVICE|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
224021491|NCT04294732|DRUG|Only spinal anesthesia without peripheral nerve block|Only spinal anesthesia without peripheral nerve block
223734155|NCT00492115|DEVICE|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
224021492|NCT02437461|DRUG|Triamcinolone hexacetonide|intraarticular knee injection
224138755|NCT03529383|DEVICE|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
223552815|NCT01553682|BEHAVIORAL|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
223734156|NCT03564145|DRUG|S5G4T-1|Once a day topical cream
224021493|NCT01148147|DRUG|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
224021494|NCT01148147|DRUG|Placebo|Intracoronary Placebo administration
224021495|NCT02695303|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
224021496|NCT02433574|RADIATION|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
223734157|NCT03143569|DEVICE|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
223734158|NCT03143569|DEVICE|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
224021497|NCT06103968|DEVICE|LMA BLOCKBUSTER|In this study we wish to evaluate weather gastric tube inserted through LMA helps in maintaining the LMA blockbuster placement by comparing fibreoptic bronchoscope (FOB) scores recorded immediately after LMA placement and at the end of the surgical procedure.
224021498|NCT01856556|DRUG|NRX-1074|Single IV or PO administration
224021499|NCT01856556|DRUG|Placebo|Single IV or PO placebo administration
224021500|NCT02232243|DRUG|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
224021501|NCT02232243|DRUG|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
224021502|NCT01975870|OTHER|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
224021503|NCT04689282|BIOLOGICAL|Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).|Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
224021504|NCT04524026|DRUG|Letrozole 5 mg|recFSH and co-treatment with letrozole 5 mg/day from stimulation day 1 on cycle day 2 or 3 until the day before GnRH agonist administration to trigger final oocyte maturation. GnRH antagonist 0.25 mg/day from stimulation day 5 until day of GnRH agonist administration. No luteal phase support.
224021505|NCT04300075|DEVICE|CUSABT|Subject receives use of the CUSA Clarity Bone Tip product during cranial skull base bone removal surgery
224021506|NCT00080678|DRUG|Docetaxel|
224021507|NCT00080678|DRUG|Imatinib Mesylate|
224021508|NCT01959477|DRUG|busulfan|Given IV
224021509|NCT01959477|DRUG|etoposide|Given IV
224021510|NCT01959477|DRUG|cyclophosphamide|Given IV
224021511|NCT01959477|PROCEDURE|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
224021512|NCT01959477|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
224021513|NCT03130153|DRUG|Aspirin Powder|Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
224021514|NCT03130153|DRUG|Normal saline|Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
224021515|NCT06341660|DRUG|cadonilimab|Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
224021516|NCT00704405|DRUG|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
224131703|NCT06552715|DEVICE|Placement of resorbable HAp-based composite|The resorbable HAp-based composite device will be immersed in a saline solution for 15 minutes, allowing it to transition from a rigid state to a flexible and deformable one (Fig. 1). Subsequently, the device will be shaped appropriately on the resin model, ensuring proper placement within the bone defect to be regenerated. Patients will receive antibiotic prophylaxis of 1 g amoxicillin, 1 hour before the procedure (or 300 mg clindamycin in case of penicillin allergy). Before the surgical procedure, patients will rinse with 2% chlorhexidine for one minute to reduce the bacterial load in the oral cavity. For the surgical procedure, under local anesthesia with Articaine and Adrenaline 1:100000, mucoperiosteal flaps will be raised. The pre-shaped resorbable device will then be adapted to the defect and fixed with osteosynthesis screws, used according to clinical practice for this type of intervention. Finally, the flaps will be sutured to ensure primary intention closure.
224021517|NCT00704405|DRUG|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
224131704|NCT00052884|BIOLOGICAL|filgrastim|
224131705|NCT00052884|DRUG|amifostine trihydrate|
224131706|NCT00052884|DRUG|melphalan|
223401317|NCT04230928|BEHAVIORAL|Standard DPP-GLB program modules|Participants will learn standard DPP-GLB modules for other lifestyle modifications for stress, physical activity, etc. in sessions 1,4,6-9, 11-22
223401318|NCT06483009|DEVICE|Cryoablation|Cryoablation: For subjects assessed as stable disease (SD) after two cycles of medication, one session is performed under local anesthesia after assessment. The multidisciplinary team, including investigators and radiologists, evaluates the feasibility of tumor ablation based on the size, location, and proximity to major blood vessels. Criteria for eligible lesions include a maximum diameter \<5cm, relatively isolated lesion location, and not adjacent to major blood vessels or vital structures. Cryoablation is performed using a 17G IceRod Plus 1.5 cryoablation needle, guided by CT, and avoiding nearby anatomical structures using the Visual-ICE cryoablation system.
223401319|NCT03751176|DRUG|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
224131707|NCT00052884|PROCEDURE|bone marrow ablation with stem cell support|
223401320|NCT03751176|DRUG|Irinotecan|Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
223401321|NCT03751176|DRUG|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
223401322|NCT03751176|DRUG|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
224131708|NCT00052884|PROCEDURE|peripheral blood stem cell transplantation|
223552816|NCT01553682|BEHAVIORAL|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
223552817|NCT03645096|DRUG|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
223552818|NCT03645096|DRUG|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
223552819|NCT03645096|DRUG|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
223552820|NCT00040742|DIETARY_SUPPLEMENT|ginger|Given orally
223552821|NCT00040742|OTHER|placebo|Given orally
223552822|NCT00392834|BIOLOGICAL|filgrastim|given subcutaneously
223552823|NCT00392834|BIOLOGICAL|pegfilgrastim|given subcutaneously
223552824|NCT00392834|BIOLOGICAL|rituximab|given IV
223552825|NCT00392834|DRUG|cyclophosphamide|given IV
223552826|NCT00392834|DRUG|cytarabine|given intrathecally
223552827|NCT00392834|DRUG|doxorubicin hydrochloride|given IV
223552828|NCT00392834|DRUG|etoposide|given IV
223552829|NCT00392834|DRUG|ifosfamide|given IV
223552830|NCT00392834|DRUG|leucovorin calcium|given IV
223552831|NCT00392834|DRUG|liposomal cytarabine|given intrathecally
223552832|NCT00392834|DRUG|methotrexate|given intrathecally
223552833|NCT00392834|DRUG|therapeutic hydrocortisone|given intrathecally
223552834|NCT00392834|DRUG|vincristine sulfate|given IV
223552835|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
223552836|NCT00631124|DRUG|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
223552837|NCT03520920|DRUG|Zanubrutinib|Administered zanubrutinib 160 mg orally (PO) BID continuously
223552838|NCT03520920|DRUG|Rituximab|Administered rituximab 375 mg/m\^2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10. Each cycle was 28 days long.
223552839|NCT02370823|PROCEDURE|Regenexx SD|stem cell treatment
223552840|NCT00201422|OTHER|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
223552841|NCT03999099|DRUG|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
223552842|NCT03999099|DRUG|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
223552843|NCT03999099|DRUG|Placebo oral tablet|Placebo
223552844|NCT05025397|DRUG|Danavorexton|Danavorexton intravenous infusion.
223552845|NCT05025397|DRUG|Danavorexton Placebo|Danavorexton placebo-matching intravenous infusion.
223552846|NCT05025397|DRUG|Propofol|Propofol intravenous bolus.
224021518|NCT00704405|DRUG|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing \<=75 kg and 1200 mg for participants weighing \>75 kg.
224021519|NCT00704405|DRUG|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
224021520|NCT01395888|DRUG|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
224131709|NCT03904524|BEHAVIORAL|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
224131710|NCT01313806|DEVICE|Resonator|Treatment group vs. Placebo group
224131711|NCT01313806|DEVICE|Placebo|Inactive Resonator Device
224131712|NCT02939924|DEVICE|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
224131713|NCT05617404|DIAGNOSTIC_TEST|CT scan|Polytrauma patients with thoracic CT-scan
224131714|NCT02437058|OTHER|preidictive model|
223552847|NCT05025397|DRUG|Sevoflurane|Sevoflurane inhalation.
223552848|NCT05025397|DRUG|Propofol|Propofol intravenous infusion.
223552849|NCT00405392|DRUG|Ibandronate (SB743830HD)|
223552850|NCT01326091|OTHER|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
223552851|NCT04963036|OTHER|Entropy and NOL-Guided Goal Directed Anesthesia|Entropy-guided Anesthesia (Propofol infusion in order to maintain Entropy between 45 and 55) and NOL-guided Analgesia (Remifentanil infusion in order to maintain NOL-Index between 10 and 25).
223552852|NCT04963036|OTHER|Standard of Care Group (Entropy and blinded NOL)|"Entropy-guided Anesthesia (Propofol infusion in order to obtain Entropy between 45 and 55) and Remifentanil infusion at the discretion of the anesthetist in charge, based on current practice: patient vitals (Heart Rate, Blood Pressure, Respiratory Rate…), movements, spontaneous breathing, experience....~In this group, nociception monitor screen will be concealed and the NOL index will not be available for guidance of remifentanil dosing)."
223552853|NCT02870517|OTHER|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
223552854|NCT02870517|OTHER|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
223552855|NCT03685318|DEVICE|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
223552856|NCT03685318|DEVICE|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
223552857|NCT00833963|DRUG|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
223552858|NCT00833963|DRUG|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
223552859|NCT00833963|DRUG|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
223552860|NCT00412958|DRUG|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
223552861|NCT00412958|DRUG|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
223552862|NCT00412958|DRUG|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
223552863|NCT00412958|DRUG|Placebo|Intravitreal injection of placebo
223552864|NCT01118403|DRUG|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
223552865|NCT00955643|OTHER|oxygen|
223552866|NCT00955643|OTHER|other|
223552867|NCT02032758|DRUG|Propranolol|Single oral dose of 10 mg propranolol
223552868|NCT02032758|DEVICE|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
223552869|NCT02032758|PROCEDURE|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
223552870|NCT02032758|DEVICE|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
224021521|NCT01395888|DRUG|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
224021522|NCT02136082|BEHAVIORAL|Asha Support + Training|
224021523|NCT02136082|BEHAVIORAL|Asha Support + Food|
224021524|NCT02136082|BEHAVIORAL|Asha Support + Training + Food|
224021525|NCT02136082|BEHAVIORAL|Asha Support Only|
224021526|NCT03031145|BIOLOGICAL|Felis Domesticus|Nasal Administration of Felis Domesticus
224021527|NCT02650687|PROCEDURE|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
224021528|NCT03438500|DEVICE|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
224021529|NCT03218397|DEVICE|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
224021530|NCT03218397|DEVICE|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
224021531|NCT06460753|DIAGNOSTIC_TEST|CT of the chest organs, blood biochemical parameters|Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.
223401323|NCT02816736|DRUG|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
223401324|NCT02816736|DRUG|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR \< 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~\* At Investigator discretion, study drug may be started at the low dose if there are any concerns regarding tolerability.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
223552871|NCT05036655|PROCEDURE|Perioperative glycemic management pathway|The PGMP is a shared-care pathway. It starts at the decision to undergo surgery, and includes preoperative planning, intraoperative management, the postoperative inpatient stay, and post-admission coordination of care to manage patients undergoing surgery based on a logic model for postoperative hyperglycemia. The PGMP identifies patients at high-risk of postoperative hyperglycemia at the time of surgical triaging using hemoglobin A1c (HbA1c) screening, based on Diabetes Canada recommendations. HbA1c screening estimates an individual's three-month average blood glucose, and is used to screen, diagnose, and titrate medications for diabetes. The PGMP then guides team members to monitor blood glucose postoperatively using POCT, and to manage hyperglycemia in high-risk patients using standardized care plans.
223734159|NCT04521075|BIOLOGICAL|Fecal Microbial Transplantation by capsules|"Cohorts A and B - Patients will receive 30 oral capsules per administration for two consecutive days (Days 1-2) Cohort C - Patients will receive FMT via colonscopy (Day 1), followed the day after by adnistration of 12 oral capsules (Day 2)~Combination cycles: 6 combined cycles Q2W of FMT maintenance followed by treatment with anti-PD1. Anti-PD-1 will be administered at least one day and up to 3 days after the FMT.~Maintenance of FMT by oral capsules: 12 capsules per administration. Anti PD-1 therapy: A dose of 240 mg Nivolumab will be administrated by intravenous infusion."
223734160|NCT01572545|DRUG|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
223734161|NCT01572545|DRUG|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
223734162|NCT05937204|OTHER|Nursing Teaching|A nursing teaching scheme refers to a systematic and structured plan developed by nurses to provide teaching and instruction to patients. The components of a nursing teaching scheme typically include assessing learning needs, setting learning objectives, developing teaching materials, delivering information using various teaching methods, demonstrating skills, providing written instructions, assessing learning outcomes, and conducting follow-up
224021532|NCT01027832|DRUG|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
224021533|NCT05769569|BIOLOGICAL|VRC07-523LS|VRC07-523LS is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site. Intravenous infusion of 10 mg/kg VRC07-523LS will be administered on Week 0.
224021534|NCT05769569|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region. Intravenous infusion of 20 mg/kg PGDM1400LS will be administered on Week 0.
224021535|NCT05769569|BIOLOGICAL|N-803|N-803 is a recombinant human superagonist interleukin-15 (IL-15) complex. N-803 at 6 ug/kg will be administered via subcutaneous injection to the trunk on Weeks 1, 4, 7, 39, 42 and 45.
224021536|NCT05769569|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV is a tetravalent vaccine comprising Ad26.Mos1.Env, Ad26.Mos2S.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol. Ad26.Mos4.HIV at 5x1010 viral particles (per 0.5 mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 11.
223734163|NCT03915496|DRUG|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
224131715|NCT01021072|DRUG|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
223552872|NCT02919202|PROCEDURE|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
223552873|NCT02919202|PROCEDURE|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
223552874|NCT05648617|DIETARY_SUPPLEMENT|SUSTINEX Hydrolyzed Whey Protein|Participants will receive 30g of SUSTINEX Hydrolyzed Whey Protein. The participants will be asked to add it to = to reach the goal of consuming 30g daily. SUSTINEX Whey Protein Plus is an authorized protein supplement which is manufactured and made in Malaysia by Nova Laboratories Sdn. Bhd. (179832-D). It consists of whey protein isolate and whey protein hydrolyze to achieve sufficient protein requirement.
223552875|NCT02544035|OTHER|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
223552876|NCT02544035|OTHER|Play Partner|Each child will first play alone then play with parent.
223734164|NCT03915496|DRUG|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
224131716|NCT01705197|DRUG|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
224131717|NCT03001154|BEHAVIORAL|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
223401325|NCT02816736|DRUG|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
223552877|NCT02620423|BIOLOGICAL|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
223552878|NCT02620423|DRUG|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
223734165|NCT03915496|DRUG|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
224131718|NCT03001154|BEHAVIORAL|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
224297234|NCT01978210|DEVICE|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
223401326|NCT02816736|DRUG|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
223401327|NCT03835923|BEHAVIORAL|lifestyle intervention|"intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback."
223401328|NCT03835923|BEHAVIORAL|usual care|Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
223401329|NCT05863663|OTHER|questionnaire|cross sectional questionnaire
223401330|NCT01139775|DRUG|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
223401331|NCT01139775|DRUG|Cisplatin|Administered intravenously as a continuous 1-hour infusion
223401332|NCT01139775|DRUG|LY2603618|Administered intravenously as a continuous 1-hour infusion
223401333|NCT02774941|DEVICE|Jet Nebulizer|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
223552879|NCT02620423|DRUG|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
223552880|NCT02620423|DRUG|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
223552881|NCT02620423|DRUG|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
223552882|NCT02620423|DRUG|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
223552883|NCT02620423|DRUG|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
223552884|NCT03492957|OTHER|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
223734166|NCT00763308|BEHAVIORAL|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
223734167|NCT01705288|PROCEDURE|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
223734168|NCT01705288|DRUG|intravenous narcotics|given for pain management after surgery per physician orders
224131719|NCT03001154|OTHER|Waiting-list|Weekly assessments of public speaking
224131720|NCT01354353|DRUG|LY2140023|Administered orally
224131721|NCT01354353|DRUG|Aripiprazole|Administered orally
224131722|NCT03117166|DRUG|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
224131723|NCT03117166|DRUG|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
224131724|NCT05175937|DEVICE|smartphone APP based remote monitoring|smartphone APP to monitor remotely patients implanted with ICD
223734169|NCT01705288|DRUG|standard anesthesia|inhalant or intravenous during surgery
223734170|NCT01705288|DRUG|regional anesthesia|given by spinal or epidural infusion
224021537|NCT05769569|BIOLOGICAL|MVA-BN-HIV|MVA-BN-HIV is a single vector recombinant Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) expressing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol. MVA-BN-HIV at 2x108 infectious unit (per 0.5mL dose) will be administered through intramuscular injection in the quadriceps muscle at Week 35.
224021538|NCT05769569|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine. A244d11 gp120 at 300 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
223734171|NCT01705288|DRUG|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
223734172|NCT02835274|DEVICE|BSC Deep Brain Stimulation System with Directional Lead|
224021539|NCT05769569|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic monophosphoryl lipid A (MPLA, 3D-PHAD®) with the addition of QS-21. ALFQ at 200 ug will be administered as an intramuscular injection in the quadriceps muscle at week 11 and week 35.
224021540|NCT05769569|COMBINATION_PRODUCT|Antiretroviral Therapy (ART)|This study will enroll PLWH aged 18-50 years who initiated ART during Fiebig I-V AHI and are virologically suppressed (HIV RNA \<50 copies/ml for ≥48 weeks) on uninterrupted ART, who meet study inclusion criteria in Bangkok, Thailand.
224021541|NCT02965677|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
224021542|NCT02965677|DEVICE|Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
224021543|NCT02859324|DRUG|CC-122|
224021544|NCT02859324|DRUG|Nivolumab|
223734173|NCT04208906|DEVICE|Masimo O3|"After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2."
223734174|NCT03342976|OTHER|My-AHA platform|ICT strategy for early detection of frailties
223734175|NCT00733044|BEHAVIORAL|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
224021545|NCT01796548|DRUG|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
224131725|NCT05175937|DEVICE|bedside transmitter based remote monitoring|bedside transmitter to monitor remotely patients implanted with ICD
224021546|NCT03170791|DEVICE|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
224021547|NCT04876235|PROCEDURE|endoscopic ultrasound|All patients were implanted with stents（DPPS or LAMS）under the EUS
224021548|NCT04876235|DEVICE|lumen-apposing metal stent|In the LAMS group, patients were stented with LAMS
224021549|NCT04876235|DEVICE|double-pigtail plastic stents|In the DPPS group, patients were stented with DPPS
224021550|NCT03229590|PROCEDURE|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
224021551|NCT03567824|DRUG|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
224021552|NCT03567824|DRUG|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
224131726|NCT02681055|DRUG|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
224297235|NCT02687360|DEVICE|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
224297236|NCT02687360|DEVICE|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
224021553|NCT01052129|DRUG|Naproxen sodium|Naproxen Sodium Tablets 550 mg
224021554|NCT00335439|DRUG|ketorolac tromethamine 0.5% (Acular®)|
224131727|NCT02695524|OTHER|Scapula-focused exercises|
224131728|NCT02695524|OTHER|Motor control exercises|
224131729|NCT00127530|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
224131730|NCT00127530|DRUG|Placebo|sugar pill, twice a day (b.i.d.)
224131731|NCT00396240|DRUG|Rosuvastatin|
224131732|NCT00396240|PROCEDURE|Initiatives to improve compliance|
224297237|NCT04774952|DRUG|RMC-5552|RMC-5552 for IV administration
224297238|NCT06453239|DIAGNOSTIC_TEST|Pro-Neurotensin level as a Serum Biomarker|Pro-Neurotensin mediates the development of fatty liver disease. Neurotensin (NT) is a 13-amino acid peptide secreted by the neuroendocrine cells of the small intestine in response to fat ingestion, which facilitates fatty acid absorption through the gut in relation to food lipid content.
224297239|NCT01440439|DRUG|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
224297240|NCT01440439|DRUG|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
224297241|NCT01474902|DRUG|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
224297242|NCT03244423|DRUG|Normal saline at induction|0.5 ml/kg
224297243|NCT03244423|DRUG|Normal saline infusion|1ml/kg/hr. during surgery for six hours
224021555|NCT02940184|DRUG|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
224021556|NCT02940184|OTHER|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
224021557|NCT02861469|OTHER|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
224297244|NCT03244423|DRUG|Intravenous tranexamic acid|50 mg/kg
224021558|NCT00547768|DRUG|Fexofenadine HCI|
223401334|NCT02774941|DEVICE|Vibrating Mesh Nebulizer|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
223401335|NCT01542242|DRUG|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
223401336|NCT06583174|BEHAVIORAL|Breastfeeding Attitudes|Relationship between Breastfeeding Attitudes and Nutrition Knowledge Levels
223401337|NCT04752852|DRUG|Dexamethasone|8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
223401338|NCT04752852|DRUG|Placebo|2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
223401339|NCT00357981|DRUG|ORTHO EVRA, the contraceptive patch|
223401340|NCT05047692|BIOLOGICAL|AdCLD-CoV19-1|Replication deficient adenoviral vector based COVID-19 prevention vaccine containing recombinant gene of SARS-CoV-2 spike protein
223401341|NCT05784233|BEHAVIORAL|Relevance (Likelihood Salient Item is Target)|The proportion of trials, when the salient visual item is present in the array, where the salient item is the search target.
223552885|NCT02402205|BEHAVIORAL|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
223552886|NCT05978440|PROCEDURE|onlay preparation|CAD-CAM onlay restorations will be fabricated using rubber dam scanning techniques and evaluated clinically up to 12 months
223552887|NCT02074670|OTHER|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
223552888|NCT02818764|PROCEDURE|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
223552889|NCT02818764|PROCEDURE|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
223552890|NCT02818764|DEVICE|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
223552891|NCT02818764|DEVICE|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
223552892|NCT03826654|DIETARY_SUPPLEMENT|fortified oil|35 g fortified sunflower oil
223552893|NCT03826654|DIETARY_SUPPLEMENT|Placebo|plain oil
223552894|NCT06287541|PROCEDURE|Urine biomarker -Guided without reTURBT|Participants will proceed without reTURBT
223401342|NCT01770769|DEVICE|Hemi - arthroplasty|modular hemiarthroplasty
223401343|NCT01770769|DEVICE|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
223401344|NCT01753310|BIOLOGICAL|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
223401345|NCT01753310|DRUG|Placebo|Up to 2mL
223401346|NCT00473317|BEHAVIORAL|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
223401347|NCT04079647|DRUG|Immunotherapy|Patients receive immunotherapy for cancer treatment
223401348|NCT03193853|DRUG|Tak-228 & Tak-117|Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
223401349|NCT03193853|DRUG|Cisplatin & Nab Paclitaxel|following Tak-228 \& Tak-117 standard nab paclitaxel 175-220 mg/m2 plus cisplatin 60-75 mg/m2 infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
223401350|NCT05488340|DRUG|LBP-EC01 0.1 x IV dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
223401351|NCT05488340|DRUG|LBP-EC01 0.01x IV Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
223401352|NCT05488340|DRUG|LBP-EC01 IV Infusion Dose|Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
223552895|NCT04904419|DIAGNOSTIC_TEST|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e|Intraoperative Rapid Detection mutation of IDH, TERT and BRAF v600e
224021559|NCT00465387|BEHAVIORAL|Falls, Fractures & Osteoporosis Risk Assessment & Management|
224021560|NCT03698812|COMBINATION_PRODUCT|Colonoscope|take off specimen
224021561|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
224021562|NCT01946438|BIOLOGICAL|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
224021563|NCT01946438|BIOLOGICAL|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
224021564|NCT01946438|BIOLOGICAL|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
224021565|NCT04474509|BEHAVIORAL|FACT Module Engagement|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
224021566|NCT04474509|BEHAVIORAL|FACT Module Openness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
224297245|NCT03244423|DRUG|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
224297246|NCT03244423|DRUG|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
223734176|NCT00733044|OTHER|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
223552896|NCT06310642|OTHER|Immediate descent from altitude.|Immediate descent from altitude for severe symptoms or anyone who wished to discontinue their participation in the study.
223734177|NCT05024058|DRUG|Ligelizumab|Ligelizumab treated groups and arms
223734178|NCT05024058|OTHER|Placebo|Placebo treated groups and arms
224021567|NCT04474509|BEHAVIORAL|FACT Module Awareness|Focused- Acceptance and Commitment Therapy. Third-wave Cognitive Behavioral Therapy (Psychological intervention)
224021568|NCT05790330|DRUG|Methotrexate|As per usual standard of care
224021569|NCT05790330|DRUG|Dupilumab|As per usual standard of care
223401353|NCT05488340|DRUG|Placebo|Dose regimen selected from Part 1 of placebo (Tris buffer).
223401354|NCT05488340|DRUG|LBP-EC01|Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
224021570|NCT04289012|DIAGNOSTIC_TEST|Helicobacter Pylori screening by UBT|The UBT is based on the fact that Hp produces urease, which catalyzes the urea molecule into ammonia (NH3) and carbon dioxide (CO2). After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (tube, bag or breath card). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and Hp diagnosis is made based on previously established cut-off levels for Hp infection.
223401355|NCT05488340|DRUG|TMP/SMX|TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
223401356|NCT06318416|DIAGNOSTIC_TEST|urine spectrophotometry for rifampin absorbance|All participants will received conventional weight-based TB therapy, standard of care for active TB disease. After enrollment, participants will be randomized to early Day 14 or delayed Day 21 dose modification of rifampin informed by urine spectrophotometry where absorbance is determined above or below a threshold. Below a threshold, single tablets of rifampin are added to conventional fixed drug combination standard of care, above a threshold, no additional rifampin is added. Dose adjustment of rifampin may be up to \~30mg/kg and will be continued through day-56.
223401357|NCT04886219|OTHER|Eye examination|"* Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~* orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~* ocular biometry~* corneal topography~* monocular photographs in photopic and scotopic condition"
223401358|NCT06482853|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
223401359|NCT06482853|DRUG|Saline|Saline will be used as the placebo comparator.
223401360|NCT06684951|DRUG|hCG|observe hCG effect on endometrial receptivity
223401361|NCT05797519|DEVICE|VDyne Transcatheter Tricuspid Valve Replacement System|The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System.
223401362|NCT05581641|BIOLOGICAL|BNT165b1|RNA vaccine for active immunization against malaria administered as intramuscular injection.
223401363|NCT05581641|OTHER|Placebo|Placebo matched to RNA vaccine administered as intramuscular injection.
223401364|NCT04935879|DRUG|Inclacumab|Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
223401365|NCT04935879|DRUG|Placebo|Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug
223401366|NCT03872427|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223552897|NCT06310642|DRUG|Diphenhydramine|Diphenhydramine was available to counteract any potential extrapyramidal side effects of the study drug. The use of Diphenhydramine for this purpose is well established.
223552898|NCT06310642|DRUG|Prochlorperazine 10 mg|Subjects in the Prochlorperazine arm were administered 10mg PO Prochlorperazine immediately prior to ascent
223552899|NCT02596568|DEVICE|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
224021571|NCT02144727|PROCEDURE|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
224021572|NCT02144727|PROCEDURE|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
224021573|NCT03256981|RADIATION|SBRT|SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
224021574|NCT03256981|DRUG|TKI|Continued background TKI alone
224021575|NCT04625179|OTHER|Melatonin and hyaluronic acid and sinus membrane elevation|3 mg melatonin powder mixed with 0.2% hyaluronic acid gel will be placed to fill the sinus space and around the implant apex.
224021576|NCT04625179|PROCEDURE|sinus membrane elevation without any materials|No materials will be placed at the sinus space.
224021577|NCT04472000|DRUG|Vitamin C|Study participants in the verum group receive one capsule of Burgerstein Vitamin C retard 500mg b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
224021578|NCT04472000|DRUG|Placebo|The placebo group receives one placebo capsule b.i.d. with treatment starting in the evening on the day of the operation for a total of 50 days.
224021579|NCT00353249|BEHAVIORAL|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
224297247|NCT03244423|DRUG|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
223734179|NCT04972084|DEVICE|Powerscope group|Treatment of Class II malocclusions using Powerscope appliance
223734180|NCT02428881|DRUG|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
223734181|NCT04821206|DRUG|DMARDs|New Initiation of a DMARDs
223734182|NCT04821206|DRUG|biologic DMARDs|New Initiation of a biologic DMARDs
223734183|NCT04821206|DRUG|JAK Inhibitor|New Initiation of a JAK Inhibitor
223734184|NCT01758783|DRUG|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
223734185|NCT00501293|DRUG|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
223734186|NCT00925418|PROCEDURE|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
224131733|NCT03916172|BEHAVIORAL|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
223734187|NCT04571775|DEVICE|Qi-Shield user group|real device Qi-Shield (treatment)
223734188|NCT04571775|DEVICE|Sham Qi-Shield user group|sham device (placebo)
223734189|NCT00967798|DRUG|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
223734190|NCT06208891|PROCEDURE|Robotic myomectomy|Robotic assisted laparoscopic myomectomy
223734191|NCT05100524|OTHER|Motivational interview|The motivational interviewing technique is a client-focused, directive form of counseling to create behavior change. Its main goal is to discover and solve ambivalence. This method is especially useful for people who are reluctant or ambivalent to change.
223734192|NCT05100524|OTHER|Ongoing treatment|Patients with total knee replacement receive standard nurse care. Treatment is applied. He does his own exercises at home.
224297248|NCT01366378|DRUG|methylnaltrexone|
223734193|NCT03316131|DRUG|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
223734194|NCT03316131|DRUG|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
223734195|NCT03316131|DRUG|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
223734196|NCT03316131|OTHER|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
223734197|NCT02352714|DRUG|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
223734198|NCT02352714|DRUG|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
223734199|NCT01409564|DRUG|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
223734200|NCT01409564|DRUG|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
223734201|NCT06036459|OTHER|uterine peristalsis|Transabdominal us followed by Transvaginal ultrasonography scans (Sono Ace R5 ) of uterine peristalsis will performed on the day of embryo transfer while the patient lying relaxed in lithotomy position. The probe will be introduced into the vagina as gently as possible to avoid stimulating the cervix. After scanning the mid-sagittal plane of the uterus, the probe will be fixed as steady as possible while a 3 min video of uterine peristalsis will be recorded simultaneously. The records will be analyzed at 4X regular speed using a Video player application by two independent experienced observers. The uterine peristaltic wave frequency will be the mean of the results from each observer.
223734202|NCT00478569|DRUG|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
223734203|NCT02566226|DRUG|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
223734204|NCT02566226|DRUG|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
223734205|NCT01486914|DRUG|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
224297249|NCT01764282|BEHAVIORAL|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
224297250|NCT01148641|DIETARY_SUPPLEMENT|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
224297251|NCT03235869|DRUG|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
224297252|NCT03235869|RADIATION|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
224297253|NCT04309214|DIETARY_SUPPLEMENT|MCT fats|Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
224297254|NCT04739150|DRUG|nintedanib|nintedanib
224297255|NCT04341649|OTHER|Manual Head Massage|Duration 10 minutes.
224297256|NCT04341649|DEVICE|BREO Helmet Massager|Duration 10 minutes.
224297257|NCT04341649|DEVICE|Low Laser Therapy (LLT)|Duration 7 minutes.
224297258|NCT04341649|DEVICE|Sham LLT|Duration 7 minutes.
224297259|NCT04341649|DEVICE|TENS ear stimulation|Duration 7 minutes.
223734206|NCT03021421|PROCEDURE|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
223734207|NCT03021421|PROCEDURE|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
223734208|NCT02070692|DRUG|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
224021580|NCT03738345|OTHER|HFNC flow|HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
224021581|NCT00038012|DRUG|Thrombopoietin|
224021582|NCT00038012|PROCEDURE|Platelet-pheresis|
224021583|NCT00038012|DRUG|Carboplatin|
224021584|NCT02745574|PROCEDURE|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
223401367|NCT03872427|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223401368|NCT03872427|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223401369|NCT03872427|OTHER|Pharmacodynamic Study|Correlative studies
223401370|NCT03872427|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223401371|NCT03872427|DRUG|Telaglenastat Hydrochloride|Given PO
223552900|NCT02596568|OTHER|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
223552901|NCT00297960|DRUG|ziprasidone or olanzapine|
223552902|NCT00297960|PROCEDURE|hyperinsulinaemic euglycaemic clamp|
223552903|NCT00297960|PROCEDURE|microdialysis (skeletal muscle)|
223552904|NCT04603313|OTHER|tele-advice system|The intervention consists of setting up in each participating center an infectious disease tele-advice system available to general practitioners via a dedicated mobile telephone line.
223552905|NCT03641781|OTHER|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
223552906|NCT00321074|DRUG|TACROLIMUS|Immunosuppression
223552907|NCT04378491|OTHER|Collection of clinical measurements|"Collection of clinical measurements:~* Active and passive range of motion (ROM) of the knee, hip and ankle Joint bilaterally.~* Passive patellar translation in 30° of flexion billaterally in quadrants of translation.~* Patellar apprehension test (Fairbank's Test) and the Moving Patellar Apprehension (MPAT) test for the diagnosis of patellar instability. The Fairbank's Test is performed in 30° of Flexion while the MPAT is performed while flexing the knee from 0° to 90°."
223552908|NCT04378491|OTHER|Collection of data for muscle strength|"Collection of data for muscle strength:~* Muscle strength will be measured bilaterally using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA). For the knee, maximum isokinetic Flexion and extension torques will be collected between full extension and full flexion at a movement speed of 60°/s (3 x 5 repetitions) Maximum joint torques in each movement direction will be recorded for each joint and normalized to body weight"
223552909|NCT04378491|OTHER|Collection of EMG Data|"Collection of EMG Data:~* Surface electrodes will be placed bilaterally on the vastus medialis and lateralis rectus femoris, biceps femoris and semitendinosus muscles following the guidelines of the SENIAM project (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles). Simultaneously with the muscle strength measurements, EMG data will be collected using a 12-channel EMG system (myon AG, Schwarzenberg, Switzerland, sampling rate 2400 Hz)."
223552910|NCT04378491|OTHER|Collection of Clinical Scores|"Collection of Clinical Scores:~* patient's pain, range of motion and ability to perform daily living activities will be assessed using the Kujala Anterior Knee Pain Scale, Lysholm Knee Score, visual analog scale score (VAS) and the Tegner Activity Score"
223552911|NCT04378491|OTHER|Collection of Imaging Data - Radiological measurements|Collection of Imaging Data - Radiological measurements: Xrays and MRIs which were already performed as part of the original diagnostic and follow-up procedures pre- and postoperative will be reviewed and analysed.
223552912|NCT00969306|DRUG|Chloroquine, A-CQ 100|"Administration:~* Orally~* Timing: Once daily~* Tablets of 100 mg~* During or after meals~* In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~* Patients should always note date and time of intake on the chloroquine monitoring form."
223552913|NCT05614258|DRUG|ADG206|All participants in this study will receive the study drug ADG206 in one of the designed dosage level. ADG206 will be administered by intravenous infusion over 60-90 minutes on Day 1 of each treatment cycle until disease progression, intolerable toxicities or withdrawal of consent, or up to 2 years.
223552914|NCT01703091|DRUG|Ramucirumab|Administered IV
223552915|NCT01703091|DRUG|Placebo|Administered IV
223552916|NCT01703091|DRUG|Docetaxel|Administered IV
223552917|NCT01809509|PROCEDURE|Endometrial biopsy|
224021585|NCT02745574|PROCEDURE|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
224021586|NCT00531700|OTHER|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
224021587|NCT00531700|OTHER|Health messages|community level health messages unrelated to the study originating exposures
224021588|NCT00567034|DRUG|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
224021589|NCT00567034|DRUG|placebo|lactose placebo, 1 capsule every day for 12 weeks
224021590|NCT00974376|DRUG|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
224021591|NCT00974376|DRUG|Placebo|1200mg/day of placebo for 12 weeks
224131734|NCT03712501|BEHAVIORAL|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
224131735|NCT01467648|DRUG|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
224131736|NCT01467648|DRUG|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
224131737|NCT01206478|DRUG|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
223401372|NCT05112185|BEHAVIORAL|Healthy Drinks, Healthy Futures|The Healthy Drinks, Healthy Futures intervention consists of increased access to healthy beverages in childcare centers and education directed to children and their families to increase the intake of healthy beverages, including motivational beverage counseling for families and lessons for children in childcare centers.
223401373|NCT06983730|DIETARY_SUPPLEMENT|Vitamin B3|1000mg once a day orally for two days, once the day before the exercise session, and once the day of the exercise session.
223401374|NCT05976386|DRUG|Dupilumab (SAR231893)|Injection solution Subcutaneous
223401375|NCT06657144|DRUG|CHS-114|Solution for infusion
223401376|NCT06657144|DRUG|Toripalimab|Solution for infusion
223401377|NCT06657144|DRUG|5 Fluorouracil|Solution for infusion
223401378|NCT06657144|DRUG|Cisplatin|Solution for infusion
223401379|NCT06985706|PROCEDURE|Subthreshold Micropulse Laser (SML)|SML will be applied in line with the DAME Guideline and follow the DAME participant pathway.
223401380|NCT06985706|DRUG|Anti-VEGF Monotherapy (standard care)|Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites. The anti-VEGF should be administered in line with the summary of product characteristics (SmPC).
223401381|NCT06982365|DIETARY_SUPPLEMENT|Enovita® (Grape Seed Extract)|Enovita® is a standardized grape seed extract containing polyphenols, known for their antioxidant and vasodilatory properties. Participants in this group will take 150 mg of Enovita® orally, twice daily (total daily dose: 300 mg) for 8 weeks.
223401382|NCT06982365|OTHER|Placebo Capsule|Participants in this group will receive a matching placebo capsule identical in appearance to the Enovita® capsule, taken orally, twice daily for 8 weeks.
223401383|NCT06983184|OTHER|MC-synced NTP|Menstrual cycle-synced neuromuscular training program
223401384|NCT06983184|OTHER|Blinded NTP|Blinded neuromuscular training program
223401385|NCT03993626|DRUG|CXD101 in Combination With Nivolumab|HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
223401386|NCT00126750|BEHAVIORAL|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
223401387|NCT01400490|DIETARY_SUPPLEMENT|EPA-DHA Study|6 weeks of dietary supplementation
223401388|NCT01087125|DRUG|No Interventions|No Interventions
223401389|NCT06824688|PROCEDURE|Single-port robotic total mesorectal excision|Single-port robotic total mesorectal excision
223401390|NCT06824688|PROCEDURE|Multi-port robotic total mesorectal excision|Multi-port robotic total mesorectal excision
223552918|NCT02459431|OTHER|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
223552919|NCT02459431|OTHER|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
223552920|NCT02184091|DRUG|Nevirapine|
223552921|NCT04904744|OTHER|Low tailored message|2 low tailored text or phone message reminders that child is overdue for well child check visit
223552922|NCT04904744|OTHER|No message|No reminders are sent
223552923|NCT04904744|OTHER|Low tailored message plus COVID-19 vaccine message|2 low tailored text or phone message reminders that child is overdue for well child check visit and that COVID-19 vaccine is available
223552924|NCT05965583|DRUG|BI 1815368|BI 1815368
223552925|NCT05965583|DRUG|Itraconazole|Itraconazole
223552926|NCT00899821|BIOLOGICAL|aldesleukin|
223552927|NCT00899821|BIOLOGICAL|recombinant interleukin-12|
223552928|NCT00899821|BIOLOGICAL|sargramostim|
223552929|NCT00899821|OTHER|immunologic technique|
223552930|NCT00899821|PROCEDURE|biopsy|
223552931|NCT02777047|OTHER|Anticoagulation Coordinated Care|see above
223552932|NCT05449340|DEVICE|BEAUTIFY application|Interview with the coordinating nurse in the postoperative period to install the BEAUTIFY application on the patient's smartphone and to train her to record any Patients will monitor their symptoms weekly. In case of toxicity grade \> 2, the nurse will contact the patient for further information.
223552933|NCT01869036|DRUG|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
223552934|NCT01869036|DRUG|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
223552935|NCT04610619|OTHER|Immunological challenge|In vitro immunological study of subjects with RYR1 related MH/rhabdomyolysis. Studying of circulating cytokines and cytokines production after in vitro stimulation
223552936|NCT05342012|DIETARY_SUPPLEMENT|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
223552937|NCT05342012|DIETARY_SUPPLEMENT|Nitrate depleted beetroot juice|(Nitrate depleted beetroot juice
223552938|NCT00346879|DRUG|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
223552939|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
223552940|NCT00840268|DRUG|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
223552941|NCT01016717|DRUG|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
223552942|NCT01016717|DRUG|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
223552943|NCT04813614|DEVICE|STYLAGE M Lidocaine|Injection in the lips
223734209|NCT02070692|DRUG|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
223734210|NCT01389544|DRUG|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
223734211|NCT01389544|DRUG|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
223552944|NCT04813614|DEVICE|Active control group|Injection in the lips
223552945|NCT01794312|DEVICE|T4020|
223552946|NCT01794312|DEVICE|Vehicle|
223734212|NCT01389544|DRUG|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
223734213|NCT04733092|DRUG|Lipiodol|Lipiodol in emulsion with contrast agent
223734214|NCT04906044|DRUG|Sintilimab|Sintilimab combined withTotal Neoadjuvant Treatment
223552947|NCT03277001|DRUG|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and \< 50 ml/min) po.
223552948|NCT03277001|DRUG|Enoxaparin|Enoxaparin 40mg IH
223552949|NCT04896619|OTHER|Kori tofu bread|34.5 grams of Kori-tofu, mixed in 3 slices of wheat bread.
223552950|NCT04896619|OTHER|Whey protein bread|Matched whey protein, soy oil and maltodextrin/cellulose, mixed in 3 slices of wheat bread
223552951|NCT02180685|OTHER|Anchor fixation|
223552952|NCT02364245|DEVICE|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
223552953|NCT02364245|OTHER|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
223552954|NCT02364245|OTHER|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
223552955|NCT01220102|DRUG|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
223734215|NCT04154020|PROCEDURE|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
223734216|NCT03398395|PROCEDURE|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
223734217|NCT03398395|PROCEDURE|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
223734218|NCT02184182|PROCEDURE|VLS ablation/portal ligation/hepatectomy|"Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~\- laparoscopic/laparotomic right trisectionectomy"
223734219|NCT03857191|DIETARY_SUPPLEMENT|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
223734220|NCT00108667|DRUG|IV Levodopa|
224021592|NCT00974376|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
224021593|NCT01668901|DRUG|warfarin|anticoagulation
224021594|NCT01668901|DRUG|Aspirin|antiplatelet
224021595|NCT02547259|PROCEDURE|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
224021596|NCT02547259|PROCEDURE|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
224021597|NCT01193426|OTHER|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
224131738|NCT01206478|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
224131739|NCT01206478|DRUG|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
224131740|NCT00180141|DRUG|Elidel-Creme|
223552956|NCT02984670|BEHAVIORAL|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
223552957|NCT02984670|BEHAVIORAL|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
223552958|NCT02984670|BEHAVIORAL|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
223552959|NCT00989508|DRUG|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
223552960|NCT00989508|DRUG|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
223552961|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
223552962|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
223552963|NCT01309789|DRUG|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
223734221|NCT00108667|DRUG|Talampanel|
223734222|NCT00726076|BEHAVIORAL|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
223734223|NCT00726076|BEHAVIORAL|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
224021598|NCT01614535|DRUG|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
224021599|NCT03217682|OTHER|Music Therapy|Music therapy sessions
224131741|NCT01000779|DRUG|Propranolol|upto 320mg/day maximum
224131742|NCT01000779|DEVICE|multi band ligator for esophageal varices|to obliterate esophageal varices
224131743|NCT00900172|BIOLOGICAL|bevacizumab|
224021600|NCT03217682|OTHER|Massage Therapy|Massage therapy sessions
223401391|NCT05963191|DEVICE|Colorectal cancer screening with CAD EYE colonoscopy|"The colonoscopy procedure for each patient will be no different from a conventional colonoscopy examination. A colonoscopy is considered complete if the endoscope reaches the appendicular orifice or the terminal ileum. In line with recommendations, water lavage (using a lavage pump) and aspiration of food residues will be performed on ascent and/or descent to visualize the entire colonic mucosa.~In the CAD EYE group, descent is performed under white light, with the CAD EYE system switched on. When polyps are detected, they are rigorously described and histological predictions of endoscopist and CAD EYE will be reported separately. Then polyps will be removed by polypectomy or mucosectomy. Removed polyps are then sent for anatomopathological analysis."
224021601|NCT03861208|OTHER|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
224131744|NCT00900172|DRUG|carboplatin|
223401392|NCT05238298|DEVICE|repetitive Transcranial Magnetic Stimulation|A technique that involves the use of electrical coils on the head to generate a brief magnetic field which reaches the cerebral cortex.
223401393|NCT00097097|PROCEDURE|Neonatal Resuscitation|
223401394|NCT06478498|BIOLOGICAL|Necator americanus L3 larvae|Necator americanus L3 larvae
223401395|NCT06162598|OTHER|Ventriloquist Puppet|one day preparation intervention applied by researcher for children under the inhaler treatment. Preparation will be 30 minutes long
223401396|NCT07001410|OTHER|Age group|Observation of the outcomes by age groups.
223401397|NCT01555749|DRUG|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
223401398|NCT01555749|DRUG|placebo|One injection administered subcutaneously (s.c., under the skin)
223552964|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
223552965|NCT01309789|DRUG|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
224131745|NCT00900172|DRUG|paclitaxel|
224131746|NCT00900172|GENETIC|gene expression analysis|
224131747|NCT00900172|GENETIC|polymerase chain reaction|
223401399|NCT06589570|DEVICE|Removable Partial Denture|A removable partial denture (RPD) is a dental prosthesis designed to replace one or more missing teeth in the mouth. Unlike full dentures, which are used when all teeth are missing, an RPD is specifically made for patients who still have some of their natural teeth remaining. It restores both function and aesthetics, allowing patients to chew, speak, and smile with greater confidence.
223401400|NCT07038746|DRUG|Inhaled Epinephrine|"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."
223401401|NCT06724614|DRUG|VDPHL01|VDPHL01 Extended Release (ER) Tablet
223401402|NCT06724614|DRUG|Placebo|Placebo
223401403|NCT03221647|OTHER|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
223552966|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
223552967|NCT01309789|DRUG|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
223552968|NCT01309789|DRUG|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
223552969|NCT01309789|DRUG|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
223552970|NCT02065934|OTHER|cardio-pulmonary resuscitation|
223552971|NCT02613520|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
224131748|NCT00900172|GENETIC|polymorphism analysis|
224131749|NCT00900172|OTHER|laboratory biomarker analysis|
223552972|NCT02613520|OTHER|Normal Saline|0.9% Sodium chloride
224131750|NCT04010890|BEHAVIORAL|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
224131751|NCT02156492|DRUG|Evacetrapib|Administered orally.
224131752|NCT02156492|DRUG|Simvastatin|Administered orally.
224131753|NCT02156492|DRUG|Atorvastatin|Administered orally.
224131754|NCT03102359|DRUG|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
224131755|NCT03102359|DEVICE|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
224131756|NCT05464862|DRUG|Popliteal Plexus Block with 10 ml|Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
224131757|NCT05464862|DRUG|Popliteal Plexus Block with 20 ml|Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
224131758|NCT05464862|DRUG|Popliteal Plexus Block with 30 ml|Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
224131759|NCT05464862|DRUG|Femoral Nerve Block|Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
224297260|NCT04341649|BEHAVIORAL|Deep and Slow breathing|A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.
223734224|NCT04900194|BEHAVIORAL|mindfulness-based sexual counseling|Mindfulness-based sexual counseling was planned as 2 sessions per week for 4 weeks, in total 8 sessions. Each session lasted 30-40 minutes on average. The sessions were carried out individually by determining the appropriate days of pregnant women in the pregnancy class.In the study, the meditation techniques of the Mindfulness Therapy constituted the backbone/framework of the psychoeducation program. Body and breath, body scanning, mindfulness movement and three-minute respiration techniques were practiced during the psychoeducation program, practically every session in accordance with the researchers' directives.
223734225|NCT05744947|OTHER|Data collection|"Specific Readapt -DISCO complementary questionnaire rehabilitation"
224021602|NCT03861208|OTHER|usual diet|foods representing the usually provided foods at childcare are offered
224021603|NCT01540331|DEVICE|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
224021604|NCT02951364|DRUG|LDV/SOF|90/400 mg tablet administered orally once daily
224297261|NCT04341649|BEHAVIORAL|Relaxed Reading time|Duration 10 minutes.
224297262|NCT04183647|DEVICE|whole body vibration / local vibration|Both the whole-body vibration application and the local vibration application will be applied to the patients in our cross-over study. Between the two applications will be given a washout period of one week. Patients will be evaluated both local and whole body vibration applications, 1 minute and 60 minutes after the end of the applications. After the evaluation, the patient will be rested in the sitting position until the evaluation at the 60th minute.
223401404|NCT03901677|OTHER|Tai-chi training|Group exercise apply with physiotherapist
223401405|NCT00503698|DRUG|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
223401406|NCT00503698|DRUG|placebo|Placebo injected s.c (under the skin)
223401407|NCT03523520|DRUG|Methylnaltrexone Bromide 150 mg Oral Tablet|Methylnaltrexone Bromide 150 mg Oral Tablet
223401408|NCT03523520|DRUG|Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1|Methylnaltrexone Bromide 12 MG Subcutaneous Solution
223401409|NCT03523520|DRUG|Naloxegol 25 MG Oral Tablet|Naloxegol 25 MG Oral Tablet
223401410|NCT03083327|DIETARY_SUPPLEMENT|Parenteral nutrition.|Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).
223401411|NCT03083327|OTHER|Pragmatic standard care.|Nutrition support will be provided as per usual care.
223401412|NCT04389229|DRUG|cyclophosphamide|600mg/m2/day for 3 days ( on day -5, -4, -3)
223401413|NCT04389229|DRUG|fludarabine|30mg/m2/day for 3 days ( on day -5, -4, -3)
223401414|NCT04389229|DRUG|IL-2 (Proleukin)|Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion
223401415|NCT04389229|GENETIC|Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)|Single dose at 5 x 10\^9 - 5 x 10\^10
223401416|NCT04389229|GENETIC|Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)|Single dose at 2 x10\^9 (+/- 20%) (engineered TIL)
223401417|NCT00868920|OTHER|patient control of pump|Patient controls sedation pump during colonoscopy.
223401418|NCT00868920|OTHER|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
224297263|NCT05336110|OTHER|Postponing surgery|Postponing surgery for patients with Sars-cov-2 infection
223401419|NCT05895448|DRUG|velpatasvir and sofosbuvir once daily for 12 weeks (brand or branded generic) .|Directly active antiviral therapy (velpatasvir 100 mg+sofobuvir 400 mg) once daily
223401420|NCT05667090|OTHER|Vitamin D|Oral supplementaiton of 576,000 IU once a week of vitamin D3 for 4 weeks
223401421|NCT05667090|OTHER|Placebo|Oral supplementaiton of placebo once a week for 4 weeks
223401422|NCT04667637|DRUG|edaravone dexborneol|Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.
223401423|NCT00548678|DRUG|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
223401424|NCT00548678|DRUG|ketorolac|intravenous ketorolac
223401425|NCT00548678|DRUG|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
223401426|NCT00548678|DRUG|aspirin|oral aspirin
223401427|NCT04083547|DIAGNOSTIC_TEST|iCellate|New method of circulating tumour cell detection and capture.
223401428|NCT02381847|PROCEDURE|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
223401429|NCT05684874|RADIATION|Neoadjuvant RT|"Dosimetric CT scan with contrast injection for treatment planning. Radiation therapy at a dose of 50Gy in 25 fractions, 5 fractions per week. Daily pre-treatment positioning tomographic imaging (either high energy (MVCT) or cone beam computed tomography (CBCT)).~Delineation of the tumor volume and evaluation of its evolution. In case of change of volume and if medically relevant, new dosimetric scan and collection of the tumor volume."
223401430|NCT05684874|OTHER|Pre-radiotherapy mpMRI|"Performed less than 14 days before the dosimetric scan. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
223401431|NCT05684874|OTHER|Post-radiotherapy mpMRI|"Performed 4 to 6 weeks after the end of the radiotherapy. Conventional morphological T1-weighted, T2-weighted, and T1-weighted imaging sequences after injection of contrast agent.~Quantitative imaging sequences including multiple b-value diffusion imaging. Chemical shift sensitized sequences."
223401432|NCT05684874|PROCEDURE|Tumor resection|Performed 6 to 8 weeks after the end of radiotherapy. An anatomopathological observation of the surgical specimen will be performed.
223401433|NCT01611727|DRUG|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
223401434|NCT00396682|DRUG|Cyclophosphamide|150 - 250 - 350 mg
223734226|NCT04028076|BEHAVIORAL|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
223734227|NCT03707314|PROCEDURE|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
223734228|NCT05931679|DEVICE|VR Headset|A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
223734229|NCT05931679|OTHER|Traditional Theatre-based simulation|Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
223734230|NCT01120912|DRUG|Oshadi Oral Insulin|Oral insulin single administration
223734231|NCT01436981|PROCEDURE|CABG|Preparation of artery mammaria interna
223734232|NCT04488289|OTHER|Lifestyle|Cardiovascular risk and lifestyle
223734233|NCT00818233|DEVICE|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
224021605|NCT01406964|OTHER|CAT test|A CAT test is performed in order to diagnose tubal factor causes
224021606|NCT01406964|OTHER|Histerosalpingography|A Histerosalpingography is performed.
224021607|NCT03169101|DRUG|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
224021608|NCT03169101|BEHAVIORAL|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
224021609|NCT05337085|DRUG|Dexmedetomidine|Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery
224131760|NCT05464862|DRUG|Sciatic Nerve Block|Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
224131761|NCT01319110|DRUG|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
224297264|NCT04150198|DEVICE|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
224131762|NCT01319110|DIETARY_SUPPLEMENT|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
224131763|NCT00442013|DRUG|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
224131764|NCT00442013|DRUG|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
224297265|NCT06798571|DRUG|Elagolix Oral Tablet|2 x 200 mg tablet
224297266|NCT06798571|DRUG|Estradiol patch|0.05 mg/day patch
224297267|NCT06798571|OTHER|cellulose placebo|placebo tablet
224297268|NCT06798571|OTHER|placebo patch|placebo patch
224297269|NCT06927882|OTHER|WBV Therapy Group|"* Frequency: 3 sessions per week for 12 weeks.~* Duration: 25 minutes per session.~* Vibration Parameters: Participants will undergo whole body vibration therapy at a frequency of 30 Hz, for 25 minutes per session, 3 times a week, with an amplitude of 1-2 mm, over a duration of 12 weeks."
224297270|NCT06927882|OTHER|Placebo Group:|• Participants will stand on a non-vibrating platform and perform similar static and dynamic exercises for the same duration. The platform will mimic the active intervention's noise and display settings to maintain blinding.
224297271|NCT06927882|OTHER|Control|Only assessment at baseline, after 12 weeks and 6 months.
224297272|NCT06928870|OTHER|MAP 55-65 mmHg|MAP will be maintained between 55-65 mmHg during anesthesia.
224297273|NCT06928870|OTHER|MAP 66-75 mmHg|MAP will be maintained between 66-75 mmHg during anesthesia.
223734234|NCT02063490|BEHAVIORAL|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~\+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
223734235|NCT02600377|OTHER|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
223734236|NCT03413566|OTHER|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
223734237|NCT01356745|DRUG|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
224021610|NCT05337085|DRUG|Midazolam|Midazolam
224131765|NCT04703127|DRUG|Tadalafil and Combined Dapoxietine|Group 1 was given on-demand 30 mg dapoxetine and 10 mg tadalafil 1 h before intercourse.
223734238|NCT01356745|DRUG|medical air|inhalation gas for inhalation use
223734239|NCT03914781|BEHAVIORAL|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
223734240|NCT03619187|DRUG|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
223734241|NCT01813539|DRUG|ARGX-110|ARGX-110 will be administered as an IV infusion.
223734242|NCT03191760|BEHAVIORAL|Behavioral Activation|Participants will be asked to attend 6 in-person or phone-mediated therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
223734243|NCT03959020|PROCEDURE|Anti-reflux surgery|Anti-reflux surgery for verified GERD
223734244|NCT05726812|BEHAVIORAL|Plan My Life Together|A group training for adolescents with ADHD in which they learn to plan and organize. The training consists of 8 weekly sessions of 90 minutes for the adolescent and 2 parent sessions of 90 minutes.
223734245|NCT06495346|OTHER|self-questionnaires exploring|At each stage, subjects are asked to fill in self-questionnaires exploring the quality of their sleep, their potential distressing symptoms, their psychological state and the quality of their life at that moment. They complete the self-questionnaires at t
224021611|NCT03143946|DIETARY_SUPPLEMENT|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
223401435|NCT07062380|PROCEDURE|Curative liver resection|Standard radical hepatectomy performed according to 2024 HCC guidelines. No neoadjuvant or adjuvant therapies administered. Follows institutional surgical protocols for BCLC 0-A HCC.
223401436|NCT07062380|PROCEDURE|Real-world multimodal therapy|Curative resection combined with clinically indicated therapies (e.g., TACE, targeted drugs, immunotherapy) as per treating physician's decision. Treatments recorded but not protocol-mandated.
223401437|NCT05383131|DRUG|HEC585|Mulltiple doses of HEC585 for up to 10 days
223401438|NCT05383131|DRUG|Pirfenidone|Mulltiple doses of Pirfenidone for up to 3 days
223401439|NCT05383131|DRUG|Nintedanib|Mulltiple doses of Nintedanib for up to 7 days
223401440|NCT02282540|PROCEDURE|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
223401441|NCT04290364|OTHER|Palliative care|The patients in the prospective part of the study are seen on home-visits and offered standard palliative care within three weeks of diagnosis.
223401442|NCT01845441|DRUG|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
223734246|NCT03255486|BIOLOGICAL|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
223734247|NCT01565785|BEHAVIORAL|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
223734248|NCT05846061|OTHER|Prevalence study population|No intervention
223401443|NCT01845441|DRUG|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
223401444|NCT01845441|DRUG|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
223401445|NCT03026634|BEHAVIORAL|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
223401446|NCT05828381|DRUG|Envafolimab|300mg,sc,d1,q3w; for a total of 2 cycles.
223401447|NCT05828381|DRUG|Abraxane|100mg/m2,ivgtt, D1、D8,q3w ,for a total of 2 cycles
223401448|NCT05828381|DRUG|Cisplatin|75 mg/m2 vigtt D1 , q3w , for a total of 2 cycles
223734249|NCT05570565|PROCEDURE|Erector spinae plane block|ultrasound guided injection of local anesthestics drugs (mixture of lidocaine and bupivacaine) in the Erector spinae plane which lies between the Erector spinae muscle and lumbar transverse process
223734250|NCT05570565|PROCEDURE|local field block|infiltration of local anesthestic drugs( mixture of lidocaine and bupivacaine) in the surgical field before surgical incision
224021612|NCT03143946|OTHER|Diet advice|
224021613|NCT02845362|OTHER|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
224021614|NCT00355485|DEVICE|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
223401449|NCT06284369|BEHAVIORAL|Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign|To explore how smokers reacted to the gain-framed and loss-framed video ad
223401450|NCT06284369|BEHAVIORAL|Health Message Framing|Gain- framed messages in health communication are constructed by framing a particular outcome as either a benefit or a cost, relative to a specific reference poin
223734251|NCT05047679|BEHAVIORAL|Perioperative Pain Neuroscience Education|Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.
223734252|NCT05047679|BEHAVIORAL|Perioperative Biomedical Education|Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
223734253|NCT02537054|DRUG|Aflibercept|Intravitreal injection
223401451|NCT00762710|DRUG|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
223401452|NCT00762710|DRUG|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
224021615|NCT03865264|OTHER|Recovery Enhancement Program|Behavioral, nutritional, physical and opioid-reduction pain medication
224021616|NCT03510585|OTHER|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
224131766|NCT04703127|DRUG|Dapoxietine and Combined Lidocaine 5% Spray|Group 2 was given on-demand 30 mg dapoxetine 1 h before intercourse and apply lidocaine 5% spray on the glans penis 10 minutes the wash before intercourse.
223401453|NCT02462603|DRUG|PTC-589|PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
223401454|NCT02218138|BEHAVIORAL|Learning 2 BREATHE|Mindfulness-based group program
223401455|NCT02218138|BEHAVIORAL|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
223401456|NCT02569879|OTHER|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
223401457|NCT03160937|OTHER|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
223401458|NCT00907361|DEVICE|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
223401459|NCT03309137|DEVICE|Chlorhexidine flush|"1. For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~   After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~2. Discard the syringe and device in biohazard waste.~3. Blue Cap the IV as per routine practice."
223401460|NCT01235754|DRUG|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
223401461|NCT01235754|DRUG|placebo gel|once daily transdermal placebo gel
223401462|NCT00720551|OTHER|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
223401463|NCT07059793|DEVICE|MITRIS RESILIA Mitral Valve|Surgical replacement of native or prosthetic mitral valve.
223401464|NCT07063823|DRUG|HB-2121|HB-2121 taken once orally.
223401465|NCT00648882|DRUG|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
223401466|NCT00648882|DRUG|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
223552973|NCT02613520|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
223552974|NCT06448130|DRUG|Henagliflozin 5mg|Henagliflozin 5mg + lifestyle intervention
223401467|NCT01370629|DRUG|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
223552975|NCT06448130|DRUG|Henagliflozin 10mg|Henagliflozin 10mg+ lifestyle intervention
223552976|NCT06448130|DRUG|Placebo|Placebo+ lifestyle intervention
223552977|NCT00003322|DRUG|cisplatin|
223401468|NCT00025025|OTHER|sample testing|
223401469|NCT05160922|DRUG|crizotinib|crizotinib oral treatment
223401470|NCT06498648|DRUG|Abemaciclib|Given PO
223401471|NCT06498648|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223401472|NCT06498648|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223401473|NCT06498648|PROCEDURE|Computed Tomography|Undergo PET/CT
223552978|NCT00003322|DRUG|paclitaxel|
223552979|NCT00003322|PROCEDURE|quality-of-life assessment|
223552980|NCT03121300|OTHER|CT Scan|Quantitative lung SPECT-CT
223552981|NCT03121300|OTHER|Lung CT|CT lung ventilation
223552982|NCT03121300|OTHER|MRI|DCE MRI
224021617|NCT03510585|OTHER|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
224021618|NCT02641496|BEHAVIORAL|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
224021619|NCT02641496|BEHAVIORAL|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
224021620|NCT05458700|OTHER|Collect information|Collect information from the patients to support the design of innovate clinical trials
224131767|NCT04903964|OTHER|family-centered nutrition education|There is a training program prepared by the researcher to increase the nutritional knowledge of mothers with children aged 0-3. The definition and importance of nutrition in the session, respectively, adequate and balanced nutrition, insufficient and unbalanced nutrition damages, grouping of nutrients, feeding 0--6 months old baby, feeding premature baby, breastfeeding, situations to be considered while breastfeeding, starting additional foods, 9-12 monthly baby nutrition, 1-3 years old child nutrition and nutritional nutrition support.
223734254|NCT06320795|DEVICE|SOUNDI|Continuous monitoring of vital signs for diagnosis and follow-up of sleep-disordered breathing in adults.
224297274|NCT06928987|OTHER|Touch Massage|"The practitioner performs the touch-massage for 15 minutes on clothed personnel in a seated position on an ergonomic massage chair. The massage focuses on the back, neck and arm areas. It's a precise, technical sequence of pressure, stretching and sweeping movements that follows the following pattern:~* Basic anti-stress maneuvers to relieve tension,~* Relaxation of the upper torso with weightless movements to loosen shoulders and arms,~* Stretching,~* Redynamization through rapid friction on the back.~Burnout, anxiety, affect, and musculoskeletal disorders (MSDs) will be assessed in participants using the following questionnaires at different times of the study."
224297275|NCT06731374|BIOLOGICAL|PCV15|VAXNEUVANCE (Merck, Sharp \& Dohme LLC, a subsidiary of Merck \& Co, Inc., Rahway, NJ, USA \[MSD\]) is a 15-valent PCV containing capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F adjuvanted with aluminium phosphate.
223552983|NCT03121300|OTHER|Walk Test|6 minute hall walk test
223552984|NCT03121300|OTHER|SGRQ|St. George Respiratory Questionnaire
223552985|NCT03121300|OTHER|Biological Sample Collection|Blood Draw
223552986|NCT03121300|OTHER|Toxicity|Toxicity Evaluation
223552987|NCT03121300|OTHER|Cardiac Assessment|Cardiac MRI Scan
224297276|NCT06731374|BIOLOGICAL|Streptococcus pneumoniae serotype 3|Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.
224297277|NCT06731374|BIOLOGICAL|Placebo|The placebo consists of 0.9% sodium chloride for injection
224297278|NCT01706874|OTHER|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
224297279|NCT06912906|PROCEDURE|BIPAPasynchro: byphaisc positive pressure modality without any synchronisation|Patients will be switched to byphaisc positive pressure modality without any synchronisation (BIPAPasynchro) as soon as they are considered to be ready to initiate the weaning phase from mechanical ventilation. Lausanne adult intesive care physicians will be provided a protocol to help guide them with the setting of BIPAPasynchro, as this is different from standard clinical pratice.
224297280|NCT01021241|BIOLOGICAL|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
224297281|NCT06928285|OTHER|Technology Enriched Rehabilitation|The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants should attend a minimum of two times per week and can more frequently for the two hour group based circuit class.
224297282|NCT00551382|DRUG|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
224297283|NCT00551382|DRUG|Placebo|Look alike tablets or granules 1 per day for 12 weeks
224297284|NCT05480891|PROCEDURE|Transnasal Esophagoscopy (TNE)|"While seated in an upright position a topical numbing medicine will be sprayed in your nose and the back of your throat.~A thin, flexible tube less than ¼ inch in diameter, will be placed in one of your nostrils and advanced to the back of your throat. When the tube reaches the back of the throat you will be asked to drink sips of water to help move the tube into and down the esophagus as it is advanced. The tip of the tube has a small light and camera built in that allows the doctor to see the structures of the mouth and esophagus as the tube is advanced. Once the tube is in the esophagus, the physician will examine your esophagus for any abnormal changes.~Once the visual inspection is complete the tube will be gently removed through your nose. The procedure will take approximately 10-15 minutes of time."
224297285|NCT03261102|BIOLOGICAL|Adalimumab|
223401474|NCT06498648|DRUG|Docetaxel|Given IV
223401475|NCT06498648|OTHER|Fluorothymidine F-18|Given IV
223401476|NCT06498648|DRUG|Gemcitabine|Given IV
223401477|NCT06498648|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223401478|NCT03067727|DRUG|Dinoprostone|The DVI contains 10 mg Dinoprostone
223401479|NCT03067727|DRUG|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
223401480|NCT02092376|DRUG|Cholecalciferol|
223401481|NCT02092376|DRUG|Placebo|
223401482|NCT02805920|DRUG|Bupivacaine|comparison of different volumes-dosages of 0.25% Bupivacaine
223401483|NCT05888220|OTHER|warm salt water bath|Warm water and warm salt water bath were applied to the hands and feet of the patients. It is a non-pharmacological intervention
223401484|NCT00004330|DRUG|luteinizing hormone-releasing factor|
223401485|NCT01626001|PROCEDURE|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
223401486|NCT05774067|DRUG|Saline|patient received normal saline 4ml/kg/hr with deflation of tourniquet
223401487|NCT05774067|DRUG|Norepinephrine|patient received noradrenaline infusion at rate 0.1 mcg/kg/min. with deflation of tourniquet
223401488|NCT05774067|DRUG|glypressin|patient receive glypressin infusion at rate 2 mcg/kg/hr.
223401489|NCT03312244|DRUG|Pyridostigmine Bromide|Pyridostigmine 180mg/day p.o.
223401490|NCT03312244|DRUG|Placebo|Placebo
223552988|NCT04075305|RADIATION|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
224021621|NCT01391039|DRUG|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
224021622|NCT03542773|DRUG|18F-DCFPyL Injection|18F-DCFPyL with whole body PET/CT scan
224131768|NCT05641038|OTHER|Peloid treatment|The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.
224131769|NCT05641038|OTHER|Paraffin treatment|The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
223401491|NCT02044263|BEHAVIORAL|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
223401492|NCT02044263|BEHAVIORAL|face-to-face CBT-i|
223401493|NCT00304850|BEHAVIORAL|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
223401494|NCT00304850|DRUG|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
223401495|NCT05079672|DRUG|Dexmedetomidine|Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
223401496|NCT05079672|DRUG|0,9% Saline|Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
223401497|NCT01591096|DRUG|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
223401498|NCT02227563|DEVICE|Active tDCS|repetitive daily tDCS sessions for a period of one week
223401499|NCT02227563|DEVICE|control|
223401500|NCT04321746|DRUG|Ketamine|ketamine will be administered at a dose of 0.3 mg/kg in normal saline at 0.9% (250 mL)
223552989|NCT04209023|DEVICE|Transcranial Magnetic Stimulation|Individual pulses (100% motor threshold intensity, continuous temperature of 24 degrees C) will be delivered upon the presentation of the stimulus or the verbal command for the language tasks. Two research coordinators will perform the intervention, with one coordinator presenting the stimulus/giving commands, and the other positioning the TMS coil and delivering the individual pulse or pulse trains. The stimulus presentation will last for a duration of 1 second, in conjunction with the time-course of the pulse's disruption. One or both research coordinators must track the successful or unsuccessful inhibition of task completion for each trial. The number of trials may vary depending on task and region-of-interest; however the intervention is not to exceed a total of 20 minutes.
223552990|NCT01296971|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
223552991|NCT01296971|DRUG|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
223552992|NCT01296971|DRUG|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
223552993|NCT04959227|OTHER|Sema activity|sema activity 3 days a week for at least a year
223552994|NCT02819297|DRUG|BLI400 Laxative|21 gm BLI400 powder
223552995|NCT02819297|DRUG|BLI400 Placebo|Equivalent amount of placebo powder
223552996|NCT06128850|OTHER|disease|compare to diseases
223552997|NCT03419637|OTHER|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
223552998|NCT02993627|DIETARY_SUPPLEMENT|Spirulina|2 g(4\* 500 mg tablets) daily intake of Spirulina Platensis
223552999|NCT02993627|OTHER|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
223553000|NCT04981301|DRUG|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions using 10% povidone iodine, the convex probe will be covered with a sterile sheath and a 22G, 100 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles with the anterior approach, the needle will be punctured in the Petit triangle and 5 ml of saline will be injected into the anterolateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
223553001|NCT06421714|DRUG|Venglustat|Pharmaceutical form:Capsule-Route of administration:Oral
223553002|NCT06421714|DRUG|Itraconazole|Pharmaceutical form:Capsule-Route of administration:Oral
224021623|NCT01243632|DRUG|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
224021624|NCT01417650|RADIATION|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
224021625|NCT01417650|RADIATION|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
224021626|NCT02072915|PROCEDURE|Suction|
224021627|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|1000 pulses at 60 mj, 10 Hz
223734255|NCT00350636|DRUG|Oxybutynin topical gel|1 application daily to skin for 12 weeks
223734256|NCT00350636|OTHER|Placebo topical gel|1 application daily to skin for 12 weeks
223734257|NCT05939375|BEHAVIORAL|FCC educational training|An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
223734258|NCT03012412|BEHAVIORAL|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
224131770|NCT04625894|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|To irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate. Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy). Sequence of irradiation for multiple metastases will be at the discretion of the investigators based on their experience.
224131771|NCT04625894|DRUG|Camrelizumab for injection (200 mg, iv), D1, Q2W, 14-day cycle|Administration of Carrelizumab will be started within one week upon SABR completion, and will be continued for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
224297286|NCT03755336|OTHER|Administered Slip Perturbations|Participants will be exposed to a series of 12 unannounced slip perturbations while walking overground. These perturbations will be delivered at 3 different times within the gait cycle - early phase, middle phase, and late phase.
224297287|NCT01777919|DRUG|Temozolomide|already included
224297288|NCT01777919|DRUG|Disulfiram|already included
224297289|NCT01777919|DRUG|Copper|already included
224297290|NCT06436404|OTHER|Hammock intervention|It is a hammock made of 100% cotton fabric that prevents heat loss and has an internal apparatus to support the position, which can be adapted to the incubator by the researchers.
224297291|NCT06436404|OTHER|Kangaroo care intervention|In the clinic, the baby will receive kangaroo care with his mother in a quiet room with reduced lighting.
224297292|NCT05060380|OTHER|Exercise training|Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.
224297293|NCT06422130|OTHER|Pregnant women and their offspring without intervention|Pregnant women and their offspring with those exposures of interest determined in specific research based on the database
224297294|NCT03821935|DRUG|Livmoniplimab|Liquid for intravenous infusion.
224297295|NCT03821935|DRUG|Budigalimab|Lyophilized powder for solution for intravenous infusion.
223401501|NCT04321746|OTHER|Placebo|the control group will receive only normal saline at 0.9%, with the same physical characteristics of the ketamine solution
223401502|NCT00000377|DRUG|Nortriptyline|
223401503|NCT03451253|OTHER|amino acid mixture beverage|commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
223401504|NCT03451253|OTHER|glucose-based sports drink|Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
223401505|NCT03875053|DIAGNOSTIC_TEST|Monitoring Device|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
223401506|NCT03875053|OTHER|Quality-of-Life Assessment|Ancillary studies
223401507|NCT03875053|OTHER|Questionnaire Administration|Ancillary studies
223401508|NCT02573051|DRUG|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
223401509|NCT02573051|DRUG|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
223401510|NCT02573051|OTHER|placebo|
223401511|NCT05563454|DRUG|BAY2395840|Administration of dosage form 1 under diet 1 condition
223401512|NCT04382547|BIOLOGICAL|Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
223401513|NCT04382547|OTHER|Standard treatment according to the Clinical protocols|Standard treatment according to the Clinical protocols
224021628|NCT05187468|DEVICE|Extracorporeal Shockwave Therapy|2000 pulses at 60 mj, 10 Hz
224021629|NCT05187468|DEVICE|Ultrasound therapy, Massage, Heat pack|Ultrasound therapy 5 min, 1,2W/cm2, 10 min Massage, 10 min heat pack
224021630|NCT04949347|BIOLOGICAL|glaucoma drainage device implantation|Glaucoma drainage device implantation, a 350 mm2 Baerveldt (BG 101-350) GDD (Johnson and Johnson, Santa Ana, CA, USA) was performed using glycerin-preserved, human-donor, corneoscleral tissue ( the remaining from a heterologous, human-donor corneal button, obtained from the International Eye Bank of Thailand, after a clear corneal graft had been used for penetrating keratoplasty.) The tissue had been preserved in glycerin using the sterile technique and kept in a medical refrigerator for no longer than 6 months.
224021631|NCT03686332|DRUG|Arm A: Atezolizumab and Radiotherapy|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
224021632|NCT03686332|DRUG|Arm B: Atezolizumab|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
224021633|NCT03450226|DRUG|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
224021634|NCT01843894|BIOLOGICAL|RU-101|Recombinant human serum albumin
224021635|NCT02523599|DRUG|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
224021636|NCT02523599|OTHER|Placebo|Plain collagen implant (vehicle)
224131772|NCT01262612|DRUG|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
224131773|NCT01262612|DRUG|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
224131774|NCT03179280|DRUG|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
223734259|NCT03164343|DEVICE|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
223734260|NCT05852743|DEVICE|shear wave and strain elastography|shear wave elastography is a quantitative technique , while strain elastography is qualitative technique
223734261|NCT03356951|PROCEDURE|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
223734262|NCT03356951|PROCEDURE|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
223734263|NCT04396990|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
223734264|NCT04396990|DRUG|Topical Prednisolone|Standard of care topical drop treatment
223734265|NCT04890639|PROCEDURE|Acute Intermittent Hypoxia|Four hypoxia sessions, consisting of 15 cycles of hypoxia (21%, 17%, 13% or 9% O2), each of which lasts up to 60 seconds, interspersed with up to 90-second normoxic episodes.
224131775|NCT02823678|PROCEDURE|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
223401514|NCT05106140|OTHER|Magnetic Resonance Imaging (MRI)|A research MRI will be performed at 6-weeks post-stroke to document stroke lesion location and size.
223401515|NCT05106140|DEVICE|Kinarm Robotic Exoskeleton Assessment|"The Kinarm Robotic Exoskeleton is a device used to provide therapy and assessment. The device has framework that supports the arms and these supports are adjustable to ensure a comfortable fit. Motors attached to the framework move the arms and record shoulder and elbow movements.~The assessment involves performing a number of tasks using the Kinarm to measure proprioceptive and motor impairment, adaptation to force and visual disturbances, and retention after 24 hours."
223401516|NCT05106140|OTHER|Clinical Assessment|The clinical assessment will be performed by a qualified stroke therapist and include a number of verified measurements to examine: reflexes, strength, apraxia, somatosensation, physical abilities, and cognition.
223401517|NCT01445730|DIETARY_SUPPLEMENT|Fructose|3 month fructose diet 75 g/day
223401518|NCT00520065|OTHER|enteral nutritional formula|Meal glucose tolerance test
223401519|NCT00520065|OTHER|Diabetes specific enteral product|Meal Glucose tolerance test
223401520|NCT05507073|PROCEDURE|Manual Total Hip Replacement|Implantation of a hip Device to alleviate pain and recover range of movement
223734266|NCT03009565|OTHER|coronary artery disease|
223734267|NCT01042236|DRUG|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
223734268|NCT04138329|PROCEDURE|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
223734269|NCT04138329|PROCEDURE|Onstep Technique|In this group was used the Onstep technique for inguinal repair
223734270|NCT05959330|OTHER|Neural Tension Technique(ulnar, median, radial)|Neural Tension Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
223734271|NCT05959330|OTHER|Neural Slider Technique (ulnar, median, radial)|Neural Slider Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
223734272|NCT05959330|OTHER|Neural Tension Technique and Neural Sliding Technique(ulnar, median, radial)|Neural Tension and Sliding Technique for 4 weeks (6 successive sessions). Three sets will be provided in every session; Each set will be performed in a slow, oscillatory manner with 10 seconds rest between the sets. Posttest measurement will be taken after 4 weeks of treatment
223734273|NCT05767892|DRUG|YK-209A tablet|YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.
223401521|NCT05507073|PROCEDURE|Robot-Assisted Total Hip Replacement|Robot assisted Implantation of a hip Device to alleviate pain and recover range of movement
223401522|NCT00734994|DEVICE|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
223734274|NCT05767892|DRUG|Pemetrexed+carboplatin/Cisplatin|Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
223734275|NCT05554757|DEVICE|conventional rubber dam system|rubber dam is a protective sheet with a hole that a dental professional positions over a tooth during an endodontic procedureEndodontists . This allows to isolate the treatment area with a dental clamp around the tooth. The dental sheet is placed around the in the Dental Rubber Dams and then a u-shaped device is hooked around. This isolates the single tooth where dental treatment will be conducted.
223734276|NCT05554757|DEVICE|OPTRADAM|OptraDam Plus is a three-dimensional rubber dam that is flexible and has an anatomical shape, automatically stretched in an oral direction, an automatic hold of the device in the oral cavity is ensured.
223734277|NCT01525550|DRUG|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
224131776|NCT01978158|DRUG|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
223401523|NCT00734994|DRUG|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
223401524|NCT02081027|DRUG|Riluzole|
223401525|NCT02081027|OTHER|placebo|
223401526|NCT01358929|DRUG|Placebo|Placebo to RO6807952
223553003|NCT03149159|DRUG|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
223553004|NCT03149159|DRUG|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
223553005|NCT03149159|RADIATION|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
223553006|NCT02487758|PROCEDURE|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
223553007|NCT02317497|OTHER|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
223553008|NCT02317497|DRUG|Vasopressors to maintain normal blood pressure values, if needed|
223553009|NCT02317497|DRUG|Osmotherapeutics to lowr intracranial pressure, if needed|
224131777|NCT00503360|DRUG|SAD448|
224131778|NCT01332019|DRUG|peginterferon beta-1a|Administered as specified in the treatment arm
224131779|NCT04791267|BEHAVIORAL|Community Health Navigator Program|Patients will be matched to a community health navigator (CHN) who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (e.g., social, financial, insurance), helping patients set health-related goals, facilitating health care referrals and appointments, and monitoring appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in-person or over the telephone using motivational interviewing principles.
224131780|NCT02325947|DEVICE|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
224131781|NCT02325947|DEVICE|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
223401527|NCT01358929|DRUG|RO6807952|Escalating subcutaneous dose
223401528|NCT05925647|DRUG|Messenchymal stem cell secretome|Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
223401529|NCT05925647|DRUG|Placebo|NaCl 0,9% infusion
223401530|NCT06780007|DIETARY_SUPPLEMENT|Probiotic|The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
223401531|NCT06780007|DIETARY_SUPPLEMENT|Placebo|The trial phase of the study will last 12 weeks and each subject will make 4 follow-up visits (day 0, week 4, week 8 and week 12).
223401532|NCT01199627|DRUG|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
223401533|NCT01199627|DRUG|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
223401534|NCT01199627|DRUG|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
223401535|NCT06854783|DRUG|Cannabidiol|Cannabidiol
223401537|NCT07071649|OTHER|blood withdrawal|blood withdrawal
223734278|NCT00111592|PROCEDURE|current usual care|current usual care
223734279|NCT00111592|PROCEDURE|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
223734280|NCT03593265|OTHER|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
224021637|NCT00510237|BEHAVIORAL|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
224021638|NCT04406740|DEVICE|TwitchView EMG Unit|The TwitchView device is a new generation electromyographic monitor that uses a disposable electrode array that combines stimulating and recording electrodes.
224021639|NCT04406740|DEVICE|Novel QTOF Device|The QTOF consists of an electrical stimulator that is just like the stimulator in the traditional TOF devices that are commonly used (both accelerometric and EMG-based), combined with a novel sensor that sticks to the belly of the muscle being measured (most commonly the adductor pollicis, the thumb muscle in the palm of the hand).
224021640|NCT02457169|BEHAVIORAL|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
224021641|NCT02457169|BEHAVIORAL|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
224131782|NCT04043715|DEVICE|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
224131783|NCT04043715|DEVICE|Epidural spinal stimulation|Physical therapy to improve standing and walking
224131784|NCT02791087|OTHER|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
224131785|NCT02791087|OTHER|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
224131786|NCT05436886|DRUG|Neurogabin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
223401538|NCT07068204|DEVICE|2% Calcium Hypophosphite Toothpaste|Oral hygiene instruction and regular application of the 2% Calcium Hypophosphite Toothpaste at home (twice daily over a period of 546 days, i.e., 18 months).
223401539|NCT07068204|DEVICE|Sodium Fluoride Toothpaste (1450 ppm F)|Oral hygiene instruction and regular application of the Sodium Fluoride Toothpaste at home (twice daily over a period of 546 days, i.e., 18 months).
223401540|NCT03989128|OTHER|Medical Chart Review|Undergo medical chart review
223401541|NCT03989128|OTHER|Survey Administration|Complete survey
223401542|NCT02985580|DIETARY_SUPPLEMENT|Blueberry|
224021642|NCT02807103|DRUG|Rituximab|1 g intravenous pulse at day1 and day15
224131787|NCT05436886|DRUG|Parketin (Gabapentin) 400 mg capsule|All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
224131788|NCT05684601|DEVICE|Third molar surgery|It was extracted one impacted mandibular third molar per patient with piezoelectric or rotating drills device
223401543|NCT02985580|DIETARY_SUPPLEMENT|Placebo|
223553010|NCT02317497|PROCEDURE|Endovascular stroke care to treat brain vessel occlusions, if needed|
223553011|NCT02317497|PROCEDURE|Decompressive neurosurgery, if needed|
223553012|NCT00413673|PROCEDURE|PRK|PRK
224131789|NCT04868370|OTHER|Assessment of the upper limb (VPIT + PPIT)|Assessment of the upper limb sensorimotor function (VPIT and PPIT)
224131790|NCT00089453|DRUG|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
224131791|NCT00089453|DRUG|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
224131792|NCT00089453|DRUG|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period \<or= 20 minutes on day -1.
224131793|NCT00089453|DRUG|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
224297300|NCT05633706|DEVICE|fluid biopsy capsule|Collection of a fluid biopsy from the small intestine via ingestible capsule
223553013|NCT05912491|DIAGNOSTIC_TEST|Transperineal ultrasonography|Transperineal ultrasound (TPU) with a Voluson E6 (GE Medical systems, Milwaukee, WI, USA). The probe was oriented to coaxially visualise the pubic symphysis on one side and the anus and rectum on the other side of the 2D image. Next, 3D/4D ultrasound was performed to obtain an image in the coronal plane at the level of the arms of the levator ani muscle, showing the pubic symphysis and the anus. All measurements were performed in three states: during pelvic muscle relaxation, during Valsalva manoeuvre, and during perineal squeezing.
223553014|NCT02858440|BIOLOGICAL|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
223553015|NCT04023383|DRUG|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
223553016|NCT04023383|DRUG|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
223734281|NCT02261714|BIOLOGICAL|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
223734282|NCT02261714|BIOLOGICAL|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
223734283|NCT06244225|DRUG|Donafenib； Sintilimab； HAIC|"Drug: Sintilimab Q3W 200mg IV d1, Q3W~Drug: Donafenib 200 mg BID d1-21, Q3W~other: HAIC Q3W Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h."
223734284|NCT05372848|DIAGNOSTIC_TEST|Manual toothbrush|volunteers who used manual toothbrush for at least 2 years
223734285|NCT05372848|DIAGNOSTIC_TEST|Electric toothbrush|volunteers who used electric toothbrush for at least 2 years
223734286|NCT03633487|DRUG|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
223734287|NCT06031454|DRUG|Midazolam|oral
223734288|NCT06031454|DRUG|Omeprazole|oral
224131794|NCT00089453|DRUG|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
223734289|NCT06031454|DRUG|Rosuvastatin|oral
223734290|NCT06031454|DRUG|Verapamil|oral
223734291|NCT06031454|DRUG|Rifampin|oral
223734292|NCT06031454|DRUG|Leritrelvir|oral
223734293|NCT04743427|OTHER|hot pack and exercises|20-minute hot pack,and three active exercises: (a) chin tucks in supine lying with the head in contact with the floor, (b) active Standing Shoulder pull back , and (c) scapular plane shoulder elevation. (3 sets of 10 repetitions for all the 3 exercises)
224021643|NCT02807103|DRUG|Placebo-rituximab|intravenous pulses at day1 and day15
224021644|NCT02807103|DRUG|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
224021645|NCT02807103|DRUG|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
224131795|NCT00089453|PROCEDURE|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
223734294|NCT04743427|DEVICE|body blade(BB)|The Body-blade (Classic, Mad Dogg Athletics, USA), an elastic pole exercise tool with 122 cm in length, 0.68 kg, 4.3 cm in width,based on oscillatory/vibration motions that have been used in training or rehabilitation.The body blade works by rapidly changing directions at a low-frequency rhythm of approximately 4.5 Hz (cycles per second )
223734295|NCT04833621|DEVICE|NMES GROUP|The effects of NMES and muscle strengthening and standard physiotherapy exercises on the development of ICU-AW were observed
223734296|NCT03686163|DRUG|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
223734297|NCT03686163|DRUG|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
223734298|NCT06154954|DIAGNOSTIC_TEST|Semen analysis|Semen analysis for extracellular matrix proteins analysis
224021646|NCT02798965|BIOLOGICAL|serodiagnosis|
224021647|NCT03801473|OTHER|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
224021648|NCT03801473|OTHER|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
224131796|NCT00089453|DRUG|Interleukin|2 at 3x10x6 IU on days +1 to 13.
223734299|NCT01843751|DRUG|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
223734300|NCT03474120|PROCEDURE|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
223734301|NCT03113019|BIOLOGICAL|Immunotherapy based on dendritic cells|Intravenous injection of cells
224131797|NCT00089453|PROCEDURE|Infusion #1|Infusion of donor NK Cells #1 on day 0
224131798|NCT00089453|PROCEDURE|Leukapheresis #2|on day +2
224131799|NCT00089453|PROCEDURE|Infusion #2|on day +2
223734302|NCT03040466|DEVICE|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
224021649|NCT04328454|OTHER|retrospective analysis|The investigators retrospectively analyzed the hospitalized patients with COVID-19
224021650|NCT04377750|DRUG|Tocilizumab|The placebo treatment arm will include 100 ml of normal saline administered along 60 min
224131800|NCT00089453|PROCEDURE|Auto Graft|on day +14
224131801|NCT00871377|DRUG|Placebo|corn oil (n-6 fatty acids)
224131802|NCT00871377|DRUG|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
224131803|NCT00871377|DRUG|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
224131804|NCT03698188|PROCEDURE|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
224131805|NCT03698188|PROCEDURE|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
224297301|NCT00285948|DEVICE|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
223734303|NCT03040466|DEVICE|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
223401544|NCT03153163|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
223734304|NCT04237090|DRUG|Diphenhydramine|Drug identification number : 02369567
223734305|NCT04237090|DRUG|Cetirizine|Drug identification number : 02231603
223734306|NCT04237090|DRUG|Lactose pill|Natural product number : 00501190
223734307|NCT04237090|DRUG|Sodium chloride 0.9%|Drug identification number : 00037796
223734308|NCT02492620|DRUG|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
223734309|NCT02594839|DRUG|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
224021651|NCT02112747|OTHER|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
223401545|NCT05689164|BIOLOGICAL|fordadistrogene movaparvovec|gene therapy administered in a previous study.
223401546|NCT03878095|PROCEDURE|Biopsy Procedure|Undergo tumor biopsies
223401547|NCT03878095|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223401548|NCT03878095|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223401549|NCT03878095|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223401550|NCT03878095|DRUG|Ceralasertib|Given PO
223401551|NCT03878095|PROCEDURE|Computed Tomography|Undergo CT scans
223401552|NCT03878095|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
223401553|NCT03878095|DRUG|Olaparib|Given PO
223553017|NCT02283892|OTHER|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
223553018|NCT02283892|OTHER|Conventional evaluation|Physician evaluation without the use of checklists
223553019|NCT04642118|PROCEDURE|Pulmonary recruitment maneuver|Using setting pressure form ventilator to increase pulmonary pressure by compress balloon bag 5 times, 5 seconds per time
223553020|NCT06502522|OTHER|Whole-body electrical stimulation|"Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes."
223553021|NCT01670279|DRUG|Brexpiprazole|up to 3mg oral dose once daily
223553022|NCT01670279|DRUG|Placebo|
223734310|NCT02594839|DRUG|Placebo|intravenous infusion of 400 mL saline
223734311|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 10 mg, once daily
223734312|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 30 mg, once daily
223734313|NCT01142700|DRUG|BMS-824393|Capsule, Oral, 100 mg, once daily
224021652|NCT06147050|DRUG|Metformin|Metformin is an FDA-approved antidiabetic agent that manages high blood sugar levels in type 2 diabetes patients. However, emerging evidence may suggest a benefit to COVID recovery.
224131806|NCT04428658|BEHAVIORAL|Supplemental video visits|Receiving home-based video visits with a pediatric endocrinologist monthly as a supplement to regular diabetes clinic visits.
224131807|NCT04428658|BEHAVIORAL|Standard of Care|Usual quarterly visits with the UCD Pediatric Diabetes Clinic.
224131808|NCT04428658|BEHAVIORAL|Supplemental remote monitoring|Receiving remote glucose monitoring with monthly outreach from a pediatric endocrinologist as a supplement to regular diabetes clinic visits.
223401554|NCT06560463|DEVICE|Access to Dexcom G7 CGM Data|Eligible patients will undergo Continuous Glucose Monitoring using the Dexcom G7
223401555|NCT04802759|DRUG|Giredestrant|30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
223401556|NCT04802759|DRUG|Abemaciclib|150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
223401557|NCT04802759|DRUG|Ipatasertib|400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
223401558|NCT04802759|DRUG|Inavolisib|9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
223401559|NCT04802759|DRUG|Ribociclib|600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
223401560|NCT04802759|DRUG|Everolimus|10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
223553023|NCT02202967|DRUG|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
223553024|NCT02202967|DRUG|Placebo|Placebo contains lactose granules
223734314|NCT01142700|DRUG|Placebo|Capsule, Oral, 0 mg, once daily
223734315|NCT01142700|DRUG|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
223734316|NCT01142700|DRUG|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
223734317|NCT00723892|BIOLOGICAL|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg\^kg\^week
224021653|NCT06147050|OTHER|Placebo|Patients will receive matching placebo control twice daily.
223734318|NCT00723892|DRUG|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
223734319|NCT00723892|BEHAVIORAL|Psychotherapy support program|Each site has implemented a psychotherapy support program.
224021654|NCT02743026|BEHAVIORAL|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
224021655|NCT00790751|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
223734320|NCT04609787|DEVICE|Immersive Virtual Reality|Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
223734321|NCT01622699|DEVICE|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
223734322|NCT01622699|OTHER|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
223734323|NCT00001960|DEVICE|Pacemaker therapy|
223734324|NCT03809442|DRUG|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
224021656|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
223734325|NCT03809442|DRUG|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
223734326|NCT03809442|DRUG|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
224131809|NCT06240494|PROCEDURE|Maxillary nerve and mandibular nerve pulsed radiofrequency|"For maxillary nerve pulsed radiofrequency, the lineer transducer is placed distal and parallel to the zygomatic arch, bridging the coronoid and condylar processes and a 22 gauge 6 mm RF cannula was inserted into the target area. With sensory stimulation, patients experienced a distinct sensation in upper jaw, teeth, and palate. Then, PRF treatment was performed at 42 °C for 240 seconds.~For mandibular nerve pulsed radiofrequency, the transducer was placed distally and parallel to the zygomatic arch, bridging the coronoid and condylar processes. The pterygopalatine fossa was visualized and the needle was inserted to target area. With sensory stimulation, patients experienced a distinct sensation in the lower jaw and teeth. With motor stimulation, a throwing movement of the jaw was observed with contraction of the masseter and temporal muscles. PRF treatment was performed at 42 °C for 240 s."
224131810|NCT04781569|OTHER|data collection|Health-related personal data such as year of birth, sex, Body Mass Index (BMI), infection classification, concomitant infections, comorbidities according to medical chart, standard diagnostic markers (CRP, blood differential plots, creatinine, ...), medication, treatment start, treatment end and discharge from hospital will be collected.
224131811|NCT04781569|DIAGNOSTIC_TEST|blood draw|2 blood drawing events (in total 22.5 ml) will be performed in the patient. 1 blood drawing events will be performed in the healthy proband.
224131812|NCT04781569|DIAGNOSTIC_TEST|nose swabs|2 nose swabs will be taken in the patient. 1 nose swab will be performed in the healthy proband.
224131813|NCT04781569|DIAGNOSTIC_TEST|Intraoperative tissue samples|Intraoperative tissue samples from the site of infection during surgery will be taken in the patient.
223734327|NCT03809442|DRUG|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
223734328|NCT03809442|DRUG|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
224131814|NCT01590394|DEVICE|Large plastic biliary stent|Stent placement for bile duct obstruction.
223734329|NCT03809442|DRUG|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
223734330|NCT00785109|DIETARY_SUPPLEMENT|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
223734331|NCT02901535|OTHER|Spirometry|Spirometry in baseline
223734332|NCT02901535|OTHER|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
223734333|NCT02901535|OTHER|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
223734334|NCT02901535|OTHER|Spirometry - 20 weeks|Spirometry (20 weeks)
224021657|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
224021658|NCT00790751|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
224021659|NCT03716700|BIOLOGICAL|CUVITRU|CUVITRU
224021660|NCT01389505|PROCEDURE|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
224021661|NCT01389505|PROCEDURE|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
224021662|NCT05614986|OTHER|5 minute Montreal Cognitive Assessment (mini MoCA)|The mini MoCA will be completed by the patient before TAVR, and 30 days and 6 months after TAVR
224021663|NCT00350233|DEVICE|ExAblate 2000|
224021664|NCT00165373|DRUG|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
224021665|NCT03237546|PROCEDURE|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
224021666|NCT03237546|PROCEDURE|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
224021667|NCT00098501|DRUG|pelitinib|
224021668|NCT00098501|DRUG|temsirolimus|Given PO
224021669|NCT06606301|DIAGNOSTIC_TEST|BioSB EGFR antibody|Appropriate sections from the tumor will be selected basing the choice on tumor content and viability eventually followed by EGFR application which will reveal a brown membrane positivity for the tumor. Total score for RGFR will be calculated by the histopathologists.
224021670|NCT05287711|BEHAVIORAL|Motivational Enhancement Therapy|In Session 1, the therapist provides personalized feedback on a range of assessment variables, including alcohol consumption levels, negative consequences from alcohol use, and family risk of alcoholism. Sessions 2-4 are follow-through sessions in which the therapist attempts to help the Veteran participant establish or reaffirm a commitment to an action plan for addressing alcohol concerns.
224131815|NCT05828732|OTHER|Using a mobile app that integrates with wearable devices|Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis.
224131816|NCT01724112|DRUG|LY2940094|Administered orally
224131817|NCT01724112|DRUG|Placebo|Administered orally
224131818|NCT00658710|BEHAVIORAL|physical therapy sessions|two physical therapy sessions per week for two months
223401561|NCT04802759|DRUG|Samuraciclib|360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
223401562|NCT04802759|DRUG|PH FDC SC|On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
223401563|NCT04802759|DRUG|Palbociclib|125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
223401564|NCT04802759|DRUG|Atezolizumab|840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
224131819|NCT05257577|PROCEDURE|Breast conserving surgery|Patients receive standard of care breast surgery and subsequent whole breast irradiation
224131820|NCT00930605|DRUG|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
224131821|NCT00930605|DRUG|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
224131822|NCT00810056|OTHER|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
223553025|NCT03719001|DRUG|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
223553026|NCT03719001|DRUG|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
223553027|NCT03719001|DRUG|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
223553028|NCT03719001|OTHER|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
223553029|NCT03719001|OTHER|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
223553030|NCT03719001|DRUG|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
223553031|NCT01901614|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
223553032|NCT01901614|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
223553033|NCT01901614|DRUG|Retrobulbar Block or General Anesthesia|
223553034|NCT01901614|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
223553035|NCT01901614|DRUG|Topical Anesthesia|
223553036|NCT01901614|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
223553037|NCT05801146|DRUG|Botulinum Toxin Type A Injection [HG102]|Single administration, Day 0, 20 units
223553038|NCT05801146|DRUG|Botulinum Toxin Type A Injection [Botox]|Single administration, Day 0, 20 units
223553039|NCT02506855|DRUG|Ropivacaine|
223553040|NCT02506855|OTHER|Placebo|
223553041|NCT02506855|PROCEDURE|Transversus Abdominis Plane Block|
223553042|NCT02478814|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
223401565|NCT04517409|PROCEDURE|Goal-directed hemodynamic therapy|Eligible patients were equally randomized into two study groups: 1) Standard perioperative (Control group ) and 2) hemodinamic management based using radial artery pulse contour analysis (GDHT group). Randomization was performed the day before surgery by the study member responsable for anesthesia delivery using sealed opaque envelope technique stored in non-transparent containers with group allocation in a 1:1 ratio. Only patients were blinded to group allocation. Care providers and investigators could not be blinded due to the presence of the cardiac index trending monitor
223734335|NCT04975360|DIETARY_SUPPLEMENT|Caffeine|The 160 mg caffeine pulsatile-release formulation was manufactured using a drug layering process. Caffeine and the excipients are dispersed in the coating media and then sprayed onto inert microcrystalline cellulose spheres using a fluid bed through a Wurster tube with continuous inlet air that dries the liquid in the dispersion, to obtain various layers consisting of caffeine and release-controlling polymers. The applied release-controlling polymeric system is based on methacrylate copolymers, which control the release of caffeine in pH-dependent and pH-independent manner. The release mechanism of the polymeric system is mainly driven by the swellability and permeability of the copolymers. The final micropellets are then encapsulated into hydroxypropylmethylcellulose capsules.
223734336|NCT04975360|OTHER|Placebo|Identical hydroxypropylmethylcellulose capsules without containing caffeine micropellets.
223734337|NCT05248841|DRUG|HEC-Glargine|Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
223734338|NCT05248841|DRUG|US-Lantus|Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
223734339|NCT00119392|BIOLOGICAL|rituximab|Given IV
223734340|NCT00119392|DRUG|cyclosporine|Given orally
223734341|NCT00119392|DRUG|fludarabine phosphate|Given IV
223734342|NCT00119392|DRUG|mycophenolate mofetil|Given orally
224131823|NCT00810056|BEHAVIORAL|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
223734343|NCT00119392|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223734344|NCT00119392|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation
223734345|NCT00119392|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
223734346|NCT00119392|RADIATION|total-body irradiation|Undergo TBI
223401566|NCT04517409|PROCEDURE|Control|"Before hepatic resection (Static phase) all patiens received continuous infusion of balanced crystalloid with the goal of CVP of 5 mmHg.~After hepatic resection (Dynamic phase), the patiens received colloid solution, vasopressors, and inotropes at the discretion of the anaesthetist, acording to CVP, MAP and orine output. In this group, CO monitoring was not performed. Intraoperative treatment goals in the control arm were flexible to avoid both extremes of clinical practice and practice misalignment."
223401567|NCT05615727|DRUG|Dexmedetomidine|2 mcg/kg of undiluted dexmedetomidine \[= 0.02 ml/kg\] and oral placebo tablet
223401568|NCT05615727|DRUG|Zolpidem|zolpidem 10 mg and intranasal saline 0.02 ml/kg
223734347|NCT01782807|PROCEDURE|Salpingectomy or Fimbriectomy|
223734348|NCT01237873|DRUG|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
223734349|NCT06291051|DEVICE|Electrical spinal cord stimulation|electrical spinal cord stimulation in Parkinson's patients presenting with painful camptocormia
223734350|NCT03030573|PROCEDURE|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
223734351|NCT02411292|DRUG|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
223734352|NCT00361855|DRUG|NX-CP105|
223401569|NCT05615727|OTHER|Placebo|a placebo oral tablet and intranasal saline at 0.02 ml/kg
223734353|NCT02526888|DRUG|ACT-541468|Oral capsule (25 mg) as single dose
223734354|NCT02526888|DRUG|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
224131824|NCT06270355|PROCEDURE|Risk based screening|Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
223734355|NCT00966173|DEVICE|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
224131825|NCT05014048|DIETARY_SUPPLEMENT|Vitamin D3|20 mikrog vitamin D3 daily
223734356|NCT03816085|OTHER|Shoes|Shoes with different heel heights
223734357|NCT02149927|DRUG|Sevoflurane|
223734358|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
224131826|NCT05014048|DIETARY_SUPPLEMENT|Placebo|Placebo
224131827|NCT05161351|DRUG|Baclofen|Baclofen is the only selective GABA-B agonist licensed for human use. Originally developed as a potential anti-epileptic in the 1920s, it was found to have anti-spastic effects and is currently used for the treatment of spastic movement, especially in instances of spinal cord injury, spastic diplegia, multiple sclerosis, and amyotrophic lateral sclerosis.
224131828|NCT05161351|DRUG|Vitamin D3|Placebo tablets will be vitamin D3, (colecalciferol).
224131829|NCT05479409|RADIATION|Neoadjuvant radiotherapy|radiation therapy combined with chemotherapy prior to surgery
224131830|NCT02600325|DRUG|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
224131831|NCT00264602|DRUG|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
224131832|NCT03201146|DRUG|Apatinib|Doses to be determined following the completion of Phase I of the study.
223734359|NCT06199102|DIETARY_SUPPLEMENT|cholecalciferol/ Devikap|Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
223734360|NCT00048295|DRUG|Alicaforsen|
224131833|NCT03201146|DRUG|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
224131834|NCT03201146|DRUG|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
224131835|NCT03201146|DRUG|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
223734361|NCT02816840|RADIATION|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
223734362|NCT02816840|RADIATION|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
223734363|NCT04145999|PROCEDURE|PRP application|The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
223734364|NCT04145999|OTHER|Placebo PRP application|Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
224131836|NCT03201146|DRUG|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
224131837|NCT03271385|DIAGNOSTIC_TEST|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
224131838|NCT06312449|OTHER|The side-lying position with the peanut ball during the second stage of labor.|"The usage of the peanut ball is divided into two stages:~Stage one: The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The peanut ball is placed between the legs, allowing for leg separation. The parturient can choose to lie on either the left or right side according to preference.~Stage two: When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides. The peanut ball is then positioned between the legs with the knees bent together, for pushing"
224131839|NCT06312449|OTHER|During the second stage, the patient is placed in a lateral position|The parturient assumes a side-lying position with the bed elevated to a 30-degree angle. The parturient can choose to lie on either the left or right side according to preference.When the fetal presenting part reaches 1 centimeter below the ischial spine (+1 Station), still in a side-lying position with the bed elevated to a 30-degree angle, the parturient has the option to switch sides, for pushing
224131840|NCT06139679|PROCEDURE|ASD closure with fenestrated/non-fenestrated patch|A PTFE patch is used to surgically close the interatrial defect. If closure with fenestrated patch is deemed necessary, a small opening is created on the patch
223401570|NCT07129785|BEHAVIORAL|Dynamic Surface Exercise Training (DSET)|DSET involves performing multi-planar trunk activation, postural control, and balance exercises on unstable surfaces such as Swiss/gym balls, bolsters, trampolines, and platform swings. Each session lasts 60 minutes, four times per week, for six weeks. Activities include optimal arousal (bouncing), high sitting with one- and two-hand reaching, sit-to-stand transitions, and lateral weight-shifting. The unstable surface provides postural perturbations that stimulate vestibular, proprioceptive, and visual systems to improve gross motor function and balance in children with spastic diplegic cerebral palsy.
223401571|NCT07129785|BEHAVIORAL|Static Surface Exercise Training (SSET)|SSET consists of functional strength, posture, and balance exercises performed on stable surfaces such as mats, benches, or stools. Each session lasts 60 minutes, four times per week, for six weeks. Activities include transfers between sitting and quadruped, high sitting with functional reaching, static and dynamic standing balance, ball-catching and kicking, and trunk activation tasks. Exercises aim to enhance gross motor function and balance through controlled, stable postural activities in children with spastic diplegic cerebral palsy.
223734365|NCT04145999|RADIATION|Photobiomodulation|Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
223734366|NCT04145999|OTHER|Placebo Photobiomodulation|Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
223734367|NCT02034955|RADIATION|Post-operative Adaptive Radiation Therapy|
223734368|NCT02820896|DRUG|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
223734369|NCT02820896|DRUG|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
223734370|NCT04352855|DRUG|Ceftolozane/tazobactam|Administration
223734371|NCT01367574|DRUG|SC MNTX|Dose 1
223734372|NCT01367574|DRUG|SC MNTX|Dose 2
223734373|NCT01367574|DRUG|SC MNTX|Dose 3
224131841|NCT02456870|OTHER|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
224131842|NCT00741143|OTHER|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
224297302|NCT03664648|BIOLOGICAL|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
223734374|NCT03413813|DEVICE|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
223734375|NCT02232425|DRUG|IX-01|
223734376|NCT02232425|DRUG|Placebo|
224131843|NCT04685070|DRUG|HS-10296 (Almonertinib)|Neoadjuvant treatment stage: HS-10296 110mg, qd, po, 4 weeks per cycle, 2-4 cycles in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: HS-10296 110mg, qd, po, up to 48 weeks (including neoadjuvant stage). PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
223734377|NCT01908257|DRUG|lesinurad 400 mg|
223734378|NCT01908257|DRUG|ranitidine 150 mg|
223734379|NCT01908257|DRUG|lesinurad 400 mg + ranitidine 150 mg|
223734380|NCT05766774|OTHER|Low-added sugar, high-fat diet|Consist of \<5% kcal from added sugars as recommended by the American Heart Association, and the glycemic index will be 45 or lower (25% lower than typical CF diet). The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
223734381|NCT05766774|OTHER|High-added sugar, high-fat CF diet|Consist of ≥13% kcal from added sugars and the glycemic index will be \>60. The macronutrient composition of both study diets will reflect the general CF recommendations for macronutrients: 35-40% of total kcal from fat and 15-20% total kcal from protein.
223734382|NCT04946357|RADIATION|Protons|proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
223734383|NCT04946357|RADIATION|carbon ions|carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
223734384|NCT01108133|DRUG|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
223734385|NCT01108133|DRUG|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
223734386|NCT01108133|DRUG|Placebo|Placebo
223734387|NCT00665353|DRUG|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
223734388|NCT00665353|DRUG|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
223734389|NCT00665353|DRUG|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
224131844|NCT01104584|DRUG|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
223734390|NCT05749302|DRUG|Al18F-NOTA-FAPI|Al18F-NOTA-FAPI was injected into the patients before the PET/CT scans
223734391|NCT01953341|DRUG|AMG 333|Oral administration available in varying dose strength.
223734392|NCT01953341|DRUG|Placebo|Placebo containing no active drug
223734393|NCT00000999|DRUG|Zidovudine|
223734394|NCT00257647|OTHER|SV40 vectors carrying siRNA|in vitro only use of gene therapy
223734395|NCT03678532|DRUG|Midazolam|
223734396|NCT05245708|DRUG|Intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
224131845|NCT03247660|OTHER|PFM training|See information included in arm/group descriptions.
224131846|NCT03247660|OTHER|HE|See information included in arm/group descriptions.
223734397|NCT05245708|DRUG|intranasal placebo|Each subject will be assigned to intranasal placebo.
223734398|NCT01076881|BEHAVIORAL|exercise training|
223734399|NCT01938911|DRUG|Syntocinon-Spray|Intranasal oxytocin (24 IU)
223734400|NCT01938911|DRUG|Placebo of syntocinon|Intranasal administration
223734401|NCT01938911|BEHAVIORAL|Social support|Social support from the best friend
223734402|NCT05636930|OTHER|Test the accuracy of the wearable device|No intervention was done for the subjects
223734403|NCT03200496|DRUG|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
223734404|NCT03200496|DRUG|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
223734405|NCT03200496|DRUG|TALION®|Reference drug : Talion®
223734406|NCT01526265|BEHAVIORAL|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
223734407|NCT01526265|BEHAVIORAL|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
223734408|NCT01526265|BEHAVIORAL|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
223734409|NCT01526265|BEHAVIORAL|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
224131847|NCT03247660|BEHAVIORAL|Educational strategy|See information included in arm/group descriptions.
224131848|NCT01833767|DRUG|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
224131849|NCT00904540|DRUG|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
224297303|NCT02418143|DEVICE|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
224297304|NCT04041622|DIAGNOSTIC_TEST|Endoscopy and biopsy|Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
223401572|NCT02298777|PROCEDURE|- Skin biopsy - Urine sample - Blood sample|
223734410|NCT01526265|BEHAVIORAL|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
223734411|NCT06279689|OTHER|Ultrasound scans|Ultrasound scans connected with an application enabling the measurement of the force applied.
223734412|NCT04983056|PROCEDURE|Necrotesectomy associated with cleanleness stoma|Excision of all necrotised tissues after stool diversion and wound dressing using
223734413|NCT00368056|DRUG|Eszopiclone|eszopiclone 3 mg
223734414|NCT00368056|DRUG|Placebo|Placebo tablet
223734415|NCT01978665|DRUG|prednisone|similar size tablets
223734416|NCT01058889|DEVICE|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
223734417|NCT00189657|PROCEDURE|5FU/LV Mayo Clinic or LV5FU2|
223734418|NCT00189657|PROCEDURE|LV5FU2 + irinotecan|
223734419|NCT00498602|BIOLOGICAL|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
224021671|NCT05287711|BEHAVIORAL|Alcohol Education Control|Will consist of 4 weekly individual sessions, approximately 60 minutes each. AE therapists will explain that their job is to provide the Veteran participants with information and education about the effects of alcohol, and that it is up to the Veteran participant to use this information as he sees fit. In each session, the Veteran participant will watch an educational videotape in a comfortable consulting room and will be given an opportunity to discuss the videotape with the project therapist for approximately 10 minutes. Written educational materials will supplement the information provided in the videos, and the therapist will ask several structured questions to determine whether the Veteran participant understood the material presented in the video.
224021672|NCT05287711|BEHAVIORAL|Treatment as Usual|Supportive telephone monitoring sessions that ensure equal spacing between assessments across conditions and equal number of therapist contacts.
223734420|NCT00498602|BIOLOGICAL|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
223734421|NCT00498602|OTHER|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
223734422|NCT00498602|BIOLOGICAL|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
223734423|NCT02456142|DRUG|caudal bupivacaine|
223734424|NCT02456142|DRUG|intravenous morphine|
224021673|NCT05287711|BEHAVIORAL|Strength at Home|IPV intervention which consists of 12 weekly, 2-hour cognitive-behavioral sessions offered in a closed group format and co-led by doctoral level male and female therapists. Strength at Home is based on a social information processing model of trauma and IPV and provides material covering psychoeducation regarding trauma and IPV, conflict and anger management skills, assertiveness training, and skills in stress management and communication.
224131850|NCT03428412|DRUG|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
224138756|NCT03529383|BEHAVIORAL|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached."
224138757|NCT04436874|DEVICE|endoscopy|transplant infusion of feces from healthy donors into affected subjects
224138758|NCT00400439|DRUG|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
224138759|NCT00400439|DRUG|placebo|po daily for 24 weeks
223401573|NCT00809562|DRUG|Placebo|po daily for 10 days
223401574|NCT00809562|DRUG|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
223401575|NCT06564311|DRUG|Obexelimab|Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity
223401576|NCT06564311|DRUG|Placebo|Placebo
223734425|NCT01382017|DRUG|Lacosamide|Lacosamide 200 or 400 mg
223734426|NCT01382017|DRUG|Placebo|Placebo
223734427|NCT01382017|DRUG|Carbamazepine|Carbamazepine 600 mg
223734428|NCT04411589|DEVICE|magnifying endoscopy with optical enhancement system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. After visualization in white light mode, the stomach was reinspected by using OE mode2. Then, in vivo diagnoses of lesions were made by using OE mode1 according to VS theory. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
223734429|NCT04411589|DEVICE|white light endoscopy system|A complete screening examination was first performed with white light endoscopy. Additionally, the types of endoscopic GIN and EGC were recorded according to the Paris Classification. For all suspicious areas, a minimum of one biopsy specimens were first taken in a targeted fashion.
223734430|NCT05874661|OTHER|External Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an external focus being thinking about a target or outcome in the environment.
223734431|NCT05874661|OTHER|Internal Focus of Attention|Focus of attention refers to what a person is thinking about during a task, with an internal focus being thinking about what one's body is doing.
223401577|NCT05505591|DRUG|Cangrelor|Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
223734432|NCT01011660|DRUG|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
223734433|NCT01879241|DRUG|Rasagiline|
224021674|NCT06610565|DIETARY_SUPPLEMENT|FASTING-MIMICKING DIET PROGRAM|Nutritional intervention via fasting-mimicking diet. Patients receiving adjuvant therapy with aromatase inhibitors will be randomized 1:1 into two arms: one intervention, where will receive nutritional counseling and the study diet for 5 days each month for 6 months,and a control one, where they will receive only nutritional counseling.
223401578|NCT00435331|DRUG|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
223401579|NCT07079826|DEVICE|Sparrow Link (Active tAN)|Participants will receive the Sparrow Link device with active transcutaneous auricular neurostimulation (tAN) in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.
223734434|NCT01879241|DRUG|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
223734435|NCT01364662|DRUG|SPN-810|administered orally
223734436|NCT01364662|DRUG|Placebo|administered orally
224021675|NCT06609395|BEHAVIORAL|Brief online CBT targeting excessiv worry|The intervention with a focus on excessive worry lasted five weeks and was delivered through five online modules with therapist support. Modules covered psychoeducation, problem-solving, reducing excessive media consumption, detached mindfulness, and shifting focus from worry. The final module offered relapse prevention strategies.
223401580|NCT07079826|DEVICE|Sparrow Link (Sham tAN)|Participants will receive the Sparrow Link device with sham (non-active) stimulation in addition to standard hospital-based opioid withdrawal management. Standard care may include pharmacologic treatments such as methadone, buprenorphine, full agonist opioids (e.g., oxycodone), and non-opioid medications, as clinically indicated.
223401581|NCT06830629|DRUG|MZE829|Capsules for oral administration
223734437|NCT04937621|DIAGNOSTIC_TEST|ECG data analysis|Baseline ECG as well as follow-up ECG are analysed
223734438|NCT04937621|DRUG|Treatment data collect|Baseline treatment data as well as follow-up treatment data are collected
224021676|NCT06610435|PROCEDURE|Manual Therapy|Various soft tissue and joint mobilizations, intramuscular stretches, trigger point treatments, and intraoral applications for the temporomandibular joint were performed in 15 randomly selected bruxism patients. Soft tissue mobilization techniques were applied bilaterally on the trigger points in the masseter, temporal, lateral and medial pterygoid muscles of the masticatory muscles in the transverse direction from inside and outside the mouth. In addition, deep friction massage and myofascial relaxation techniques were applied to suprahyoid and infrahyoid muscles, sternocleidomastoid, scalene, upper trapezius, levator scapula and suboccipital muscles until relaxation was felt. In addition, distraction and bridging techniques were applied in the suboccipital region to release the tissue and fascia techniques were applied in the cervical region to loosen the fascia. The manual therapy procedure, which was applied in the supine position and lasted approximately 40 minutes for 8 weeks
224021677|NCT06610435|PROCEDURE|Home Exercise|The exercise group consisted of 15 randomly selected bruxist individuals and aimed to reduce pain, decrease involuntary contractions of masticatory muscles, increase their nutrition, flexibility and coordination, and strengthen weak muscles with exercise therapy. These exercises consist of resistant isometric jaw movements to increase coordination and relaxation of the masticatory muscles (post isometric relaxation technique), Rocabado exercises, stretching and posture exercises for temporal, masseter and suprahyoid muscles as well as neck muscles. All individuals in this group were taught the programmed exercises practically and were asked to repeat the home exercises (lasting approximately 25 minutes) three times a week for 8 weeks. In addition, a video explaining the exercises in detail was shared with all participants in the group in order to ensure that the exercises were not forgotten and to achieve accuracy and standardization among the participants.
224021678|NCT06609525|DRUG|CTO0303-A|eye drop, 1 drop 3 times (every 5 minutes) a day
224021679|NCT06609525|DRUG|CTO0303-B|eye drop, 1 drop 3 times (every 5 minutes) a day
223734439|NCT04937621|BIOLOGICAL|Biological check-up data collect|Baseline Biological check-up data as well as follow-up data are collected
223734440|NCT04937621|OTHER|Collection of clinical events of interest|Clinical events of interest at the baseline as well as follow-up clinical events are collected
223734441|NCT02615054|DEVICE|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
224021680|NCT06609525|DRUG|CTO0303-C|eye drop, 1 drop 3 times (every 5 minutes) a day
224138760|NCT00223288|DRUG|Lexapro|
224138761|NCT02584465|DRUG|Tamoxifen|Tamoxifen: 40 mg/day
224138762|NCT02584465|DRUG|Regorafenib|Stivarga; 120mg/day
224138763|NCT03471481|OTHER|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
224138764|NCT00835107|DRUG|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
223734442|NCT02615054|DEVICE|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
223734443|NCT01369576|DRUG|Placebo|3.75-7.5mg 14 doses 4 weeks
223734444|NCT01369576|DRUG|Zopiclone|3.75-7.5mg 14 doses 4 weeks
223734445|NCT02601742|OTHER|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
223734446|NCT02601742|OTHER|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
223734447|NCT00866411|PROCEDURE|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
224021681|NCT06610500|OTHER|Questionnaires|Questionnaires investigating the prescription and dispensing of clozapine.
224021682|NCT06610773|BIOLOGICAL|hUC-MSCs|1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min.
224138765|NCT00835107|DRUG|placebo|placebo comparator, oral capsules, BID, for one month
224131851|NCT03428412|DRUG|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
223734448|NCT00866411|PROCEDURE|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
223734449|NCT06397898|OTHER|Educational video|Viewing an educational video before Novasure treatment
223734450|NCT01800240|DRUG|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
223734451|NCT02208947|BEHAVIORAL|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
223734452|NCT02208947|BEHAVIORAL|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
223734453|NCT00585819|PROCEDURE|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
223734454|NCT00585819|PROCEDURE|Freebreathing in Body fix mold|Freebreathing in Body fix mold
223734455|NCT01721616|DRUG|Azithromycin|
224131852|NCT03983928|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
224131853|NCT03983928|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
224131854|NCT06215456|DEVICE|Virtual reality therapy|VR therapy will be applied using a head mounted display, the PICO G2 4K headset (Barcelona, Spain). For VRD de application'SyncVR Relax \& Distract' (SyncVR Medical, Utrecht, The Netherlands) will be used. This application contains a wide range of relaxation games, relaxing 360 videos, and relaxation exercises each with a duration of 5-20 minutes. Patients can choose videos, games, or exercises according to their own preferences. For VRH sessions, the application HypnoVR (Strasbourg, France) will be used. This app contains several hypnotic narratives integrating sequences of controlled breathing, cardiac coherence, and hypnotic suggestions. Each VRH sessions can be personalized through selecting different environments and musical compositions.The first VRH session will be set to last 20 minutes and the second VRH session will be set to the continuous setting.
224131855|NCT04365816|OTHER|Interview|A survey was created, aiming to collect information about prior history of chronic disease, the Self-Evaluation of Food Intake, dysregulations (anosmia, ageusia...), anthropometric data, food data during and after hospitalisation, healthcare consumption since the discharge from hospital
224131856|NCT05853523|COMBINATION_PRODUCT|Gas ozone|The application of ozone was performed with the HealOzone System X4 (HealOzon, Kavo, Germany). The dentist adapted the silicon cup stricken on the cervical surface of the teeth. The pumping system created the vacuum and the machine applied high dosage of ozone, equal to 32 g/m3, for 30 second.
224138766|NCT04035265|PROCEDURE|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
224138767|NCT02107430|BIOLOGICAL|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
224138768|NCT02107430|RADIATION|Standard radiotherapy|radiotherapy
224138769|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
224297305|NCT04845074|PROCEDURE|TSA-group|Anatomical total shoulder arthroplasty followed by standard rehabilitation.
223401582|NCT06889168|DRUG|Imatimib Mesylate|Participants will take Imatinib mesylate (imatinib), an FDA approved drug for leukemia, orally 400 mg (twice daily)
223401583|NCT06889168|DRUG|Placebo|Placebo will be administered in the same dosage and manner as the study drug. The placebo looks like the study drug but contains no active ingredients.
223734456|NCT01721616|DRUG|Cefazolin|
223734457|NCT04417881|OTHER|MEESSI score|MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
223734458|NCT02375568|OTHER|103024-F|mesenchymal stem cell isolation
223734459|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
223734460|NCT01220323|DEVICE|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
223734461|NCT04954963|DIAGNOSTIC_TEST|Reduce metal artifacts examination|patients undergo reduce metal artifacts examination
223734462|NCT03034720|BEHAVIORAL|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
223734463|NCT03644199|OTHER|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
223401584|NCT07122986|DRUG|E coli vaccine 1 Dose A|Candidate E coli vaccine 1 Dose A, administered according to a 0, 6-month interval
223401585|NCT07122986|DRUG|E coli vaccine 1 Dose B|Candidate E coli vaccine 1 Dose B, administered according to a 0, 6-month interval
223401586|NCT07122986|DRUG|E coli vaccine 2|Candidate E coli vaccine 2, administered according to a 0, 6-month interval
223401587|NCT07122986|DRUG|E coli vaccine 3|Candidate E coli vaccine 3, administered according to a 0, 6-month interval
224021683|NCT06610773|BIOLOGICAL|Saline+albumin|Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs
224021684|NCT06610513|BEHAVIORAL|Guided imagery|"First meeting: The women will be introduced to the clinic, the purpose of the study will be explained, and a written consent form will be filled out. A Personal Information Form and the Pregnancy Stress Assessment Scale (GSDS-36) and the Richard-Campbell Sleep Scale will be filled out. After the questionnaires are filled out, the vital signs of the pregnant woman will be measured and then a 15-minute guided imagery video will be shown. The vital signs of the patient will be measured again 10 minutes after the guided imagery video is watched."
224021685|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the morning|The patients in this group underwent impacted tooth surgery at 08:30 in the morning.
224021686|NCT06610383|PROCEDURE|Surgical extraction of wisdom teeth in the afternoon|Impacted tooth surgery was performed on the patients in this group at 15:30.
224021687|NCT02533141|DEVICE|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
224021688|NCT02533141|DEVICE|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
224021689|NCT02533141|DRUG|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
224021690|NCT02533141|OTHER|Placebo|Placebo, once daily for 4 weeks
224021691|NCT00230087|PROCEDURE|blood donation|phlebotomy until iron depleted
224021692|NCT00112047|DRUG|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
224021693|NCT00112047|DRUG|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
224021694|NCT00112047|DRUG|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
224021695|NCT00112047|DRUG|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
223401588|NCT07122986|DRUG|E coli Vaccine 4 Dose A|Candidate E coli vaccine 4 Dose A, administered according to a 0, 6-month interval
223401589|NCT07122986|DRUG|E coli Vaccine 4 Dose B|Candidate E coli vaccine 4 Dose B, administered according to a 0, 6-month interval
223401590|NCT07122986|DRUG|E coli Vaccine 4 Dose C|Candidate E coli vaccine 4 Dose C, administered according to a 0, 6-month interval
223401591|NCT07122986|DRUG|E coli Vaccine 5 Dose A|Candidate E coli vaccine 5 Dose A, administered according to a 0, 6-month interval
223401592|NCT07122986|DRUG|E coli Vaccine 5 Dose B|Candidate E coli vaccine 5 Dose B, administered according to a 0, 6-month interval
223401593|NCT07122986|DRUG|Placebo|Placebo administered according to a 0, 6-month interval
223401594|NCT07085507|DRUG|VT7208|a small synthetic molecule capsule, oral
223401595|NCT07085507|DRUG|Placebo|capsule, oral
224138770|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
224138771|NCT01354431|BIOLOGICAL|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
223401596|NCT06902389|BIOLOGICAL|Super Hi-TCR-T cells|"Intravenous infusion of 3.0×10⁶ cells/kg of Super Hi-TCR-T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP.~The expression levels of Nectin4, NKG2DL, TROP2, B7H3, GPC3 and FAP were detected by immunohistochemistry. Meanwhile, 20ml peripheral blood was extracted to evaluate the quality of T cells. Patients with positive expression rates of at least 2 targets (excluding FAP) \>10% and qualified T cell quality could be considered for inclusion.~Peripheral blood lymphocytes were collected and Hi-TCR-T cells targeting three targets (including FAP) were prepared. After pretreatment with fludarabine + cyclophosphamide chemotherapy (FC regimen), the prepared Hi-TCR-T cells were transfused back, in which the dose of Hi-TCR-T cells at each target was 3.0x106 cells/kg body weight (the dose was the extended therapeutic dose obtained in the previous clinical trial), and the drug was administered by peripheral intravenous infusion."
223401597|NCT05467501|DEVICE|Theraputic ultrasound|Therapeutic ultrasound
223401598|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* 2 cervical takings~* 2 sampling of blood before and after the total hysterectomy"
223401599|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* cervical taking during the cervical conization~* 2 sampling of blood before and after the intervention"
223553043|NCT06268184|DIETARY_SUPPLEMENT|D3 LAB SYRUP|omega 3 suplementation
223553044|NCT06268184|DIETARY_SUPPLEMENT|placebo syrup|placebo syrup contains purified water, glycerin, xanthan gum, tween 80, methyl paraben, propyl paraben, sorbitol solution70% and apple flavor.
223553045|NCT05937386|DRUG|AGMB-129|Oral capsule
223553046|NCT05937386|DRUG|MDZ|Pre-filled oral syringes
223553047|NCT00110435|DRUG|MK0653A, ezetimibe (+) simvastatin|
223553048|NCT00110435|DRUG|Duration of Treatment: 4 wk placebo run in then 6 wk active|
223553049|NCT00110435|DRUG|Comparator: atorvastatin|
223553050|NCT03138525|OTHER|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
223553051|NCT03138525|OTHER|Blood sampling (controls)|Blood samples will be collected once at enrollment.
223553052|NCT05700058|OTHER|Dietary protein supplement|3 different doses of super-whey protein supplements will be given in a randomised crossover fashion to participants
223553053|NCT04916392|DRUG|Liposomal bupivacaine|5ml of 1.33% liposomal bupivacaine with 5 ml of 0.9% normal saline will be given to treatment group.
223553054|NCT01569737|DRUG|ella|ella, single intake, tablet 30mg
223553055|NCT01538576|DRUG|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
223553056|NCT03742570|BEHAVIORAL|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
223553057|NCT01823198|BIOLOGICAL|Aldesleukin|Given SC
223401600|NCT00682812|OTHER|2 cervical takings and 2 sampling of blood|"* cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation~* 2 sampling of blood before and after the intervention"
223734464|NCT03644199|OTHER|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
223401601|NCT05044117|DRUG|Capecitabine|Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
223401602|NCT01073085|BEHAVIORAL|"Web-based automated coaching by e-mails"|
223401603|NCT01073085|BEHAVIORAL|Self-help guide|
223734465|NCT03103919|DEVICE|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
223734466|NCT03103919|DEVICE|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
223734467|NCT03103919|DRUG|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
223553058|NCT01823198|BIOLOGICAL|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
224131857|NCT05853523|COMBINATION_PRODUCT|Diode laser and desensitized gel|"The dentist applied desensitized gel (JW-Desensitizing Gel, Heydent Gmbh, Germany) directly on the cervical zone of the teeth. Subsequently the irradiation was performed with Wiser III (Wiser, Doctor Smile, Italy) in the desensitizing assisted mode (preprogramed protocol). The protocol provides consecutively steps (not in contact) with 20 second of interval, 808 wavelength, and power incrementation, from 0,2 till 0,6 W. radiating the entire desensitize surface second using the black tip (400 micron). The procedure continued maintaining the tip of the laser on contact with the dentine surface making movement of lawn mowing (brushing technique) for 30 second. Then the surface was rinsed, and the irradiation applied again without the gel."
223553059|NCT01823198|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
223553060|NCT01823198|DRUG|Busulfan|Given IV
223553061|NCT01823198|DRUG|Fludarabine Phosphate|Given IV
223553062|NCT01823198|OTHER|Laboratory Biomarker Analysis|Correlative studies
223553063|NCT01823198|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
223553064|NCT01823198|OTHER|Pharmacological Study|Correlative studies
223734468|NCT04220008|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
223734469|NCT04220008|DRUG|Busulfan|Given IV
223734470|NCT04220008|DRUG|Clofarabine|Given IV
223734471|NCT04220008|DRUG|Cyclophosphamide|Given IV
223734472|NCT04220008|DRUG|Gemcitabine|Given IV
223734473|NCT04220008|DRUG|Mycophenolate Mofetil|Given IV
223734474|NCT04220008|BIOLOGICAL|Rituximab|Given IV
223734475|NCT04220008|DRUG|Tacrolimus|Given IV
223734476|NCT04220008|DRUG|Vorinostat|Given PO
224131858|NCT00121069|DRUG|Escitalopram|
223401604|NCT05412953|OTHER|Questionnaire Administration|Complete questionnaire
223401605|NCT05412953|BEHAVIORAL|Tonation Breathing Technique|Participate in tonation breathing techniques
223553065|NCT02648594|DEVICE|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
223553066|NCT05272722|DIAGNOSTIC_TEST|ECG,|Holter monitoring
223553067|NCT04672980|DRUG|RTX-321|RTX-321 monotherapy
223553068|NCT02546726|BEHAVIORAL|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
223553069|NCT02546726|BEHAVIORAL|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
223553070|NCT00637624|DRUG|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
223553071|NCT00637624|DRUG|Placebo|Placebo once every 3 weeks intravenous saline fluid
223553072|NCT01262638|DRUG|ETC-1002|ETC-1002 daily for 12 weeks
223553073|NCT01262638|DRUG|Placebo|Placebo daily for 12 weeks
223553074|NCT04773288|OTHER|Live feedback during handwashing|Live feedback provided during handwashing on display
223734477|NCT04444596|DIAGNOSTIC_TEST|Conjunctival swab and nasopharyngeal swab|Both conjunctival swab and nasopharyngeal swab for SARS-COV 2 are conducted in patients with COVID-19.
223734478|NCT06678529|DEVICE|active tDCS|The active-tDCS group will receive a 15-second ramp up phase at the start, 2 mA of tDCS for 20 minutes and a 15-second ramp down phase at the end.
223553075|NCT04079231|DRUG|Brolucizumab|Intravitreal Injection
223553076|NCT04079231|DRUG|Aflibercept|Intravitreal injection
223553077|NCT04732442|DIETARY_SUPPLEMENT|Immunonutrition|Impact Oral® Nestle, Switzerland
223553078|NCT04732442|DIETARY_SUPPLEMENT|Standard Oral Nutritional Support|Fortimel Compact Protein® Nutricia, United Kingdom
223553079|NCT00894699|DRUG|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
223553080|NCT00894699|DRUG|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
224131859|NCT05929417|OTHER|END-IT intervention for the community setting|The intervention was described in the arm/group descriptions.
223401606|NCT01546025|BEHAVIORAL|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
223401607|NCT01546025|BEHAVIORAL|Relaxation training|One hour training in relaxation techniques
223553081|NCT01122446|OTHER|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
223553082|NCT01122446|DRUG|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
223553083|NCT00814021|DRUG|sunitinib malate|
223553084|NCT04820114|OTHER|Proprioceptive wrist exercises|Exercises for recognition of writs position and thumb force sense.
223553085|NCT04820114|OTHER|Wrist exercises|Passive and active exercises for improve range of motion in flexion, extension, ulnar and radial deviation
223553086|NCT01268540|DEVICE|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
223553087|NCT01268540|DEVICE|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
223553088|NCT05509062|PROCEDURE|Pressure|Subjects are randomized to one of three treatment groups
223734479|NCT06678529|DEVICE|sham tDCS|The sham-tDCS group will only receive the 15-second ramp up phase at the beginning and the 15-second ramp down phase at the end of each session, without the continuous 2 mA current for 20 minutes
223734480|NCT06196333|DEVICE|Non-contact specular microscopy|using specular microscope to do morphological examination of corneal endothelial cells
223734481|NCT04057391|DIAGNOSTIC_TEST|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
223734482|NCT01426880|DRUG|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
224131860|NCT03105206|PROCEDURE|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
223401608|NCT07080476|OTHER|Decongestive lymphatic therapy|"Decongestive lymphatic therapy (DLT) is the current standard of care for lymphoedema management as recommended by the International Society of Lymphology (ISL). It consists of manual lymphatic drainage (MLD), skin care (education), compression therapy using a properly fitted compression bra, and supervised exercise therapy. Sessions last 45 minutes and are delivered two times per week for a period of four weeks.~On non-treatment days, participants are encouraged to perform home exercises and document self-care practices in a diary."
223401609|NCT07080476|OTHER|Kinesio tape|"Kinesio tape will be applied by trained physiotherapists twice a week. The kinesio tape remains in place for three consecutive days and is replaced once a week. After six days of continuous use, patients will have one rest day without kinesio tape to allow the skin to recover. This cycle will be repeated for the duration of the intervention period.~The kinesio tape will be applied using a standardised fan-cut technique to ensure consistent application across all study sites. Tape length will be individually tailored. Each application will consist of three fan-shaped strips:~1. Breast: Anchored at the ipsilateral axilla and directed vertically over the affected breast.~2. Ventral anastomosis: Originating from the contralateral axilla and applied horizontally over the chest.~3. Dorsal anastomosis: Also anchored at the healthy axilla and applied horizontally over the back.~Patients will be instructed in safe self-application for potential use during follow-up."
223553089|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 2 of Cycles 3-6
223553090|NCT02243371|BIOLOGICAL|CRS-207|1 × 10\^9 CFU administered IV on Day 1 of Cycles 3-6
223553091|NCT02243371|DRUG|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
223553092|NCT02243371|BIOLOGICAL|GVAX|5x10\^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
223553093|NCT02243371|DRUG|CY|200 mg/m\^2 administered IV on Day 1 of Cycles 1 and 2
223734483|NCT01426880|DRUG|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
223734484|NCT04199611|PROCEDURE|Liposuction|This is a type of fat removal procedure used in plastic surgery.
223734485|NCT04199611|BEHAVIORAL|Cognitive Behavioral Therapy|This is a psycho-social intervention that aims to improve mental health.
224131861|NCT02561299|DEVICE|Peripheral Orbital Atherectomy System|Orbital Atherectomy
224131862|NCT02561299|DEVICE|014 Drug Coated Balloon|Drug Coated Balloon
224131863|NCT02600000|RADIATION|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
224131864|NCT02600000|DEVICE|Cardiopulmonary test|Assessment of maximal functional capacity
224131865|NCT02600000|DEVICE|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
224131866|NCT02600000|DEVICE|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
224131867|NCT05338281|DEVICE|Negative Pressure Wound Therapy|The negative pressure wound therapy will be placed in addition to usual care of the abdominal donor site, such as closure with resorbable sutures, drain placements.
224138772|NCT03530202|DRUG|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
224138773|NCT03530202|DRUG|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
223401610|NCT07080476|OTHER|Compression bra (sub-study)|In a subset of participants, different types of commercially available compression bras are tested for pressure and comfort. Each bra is worn for a period of one week without compromising the outcomes of the primary objective. The pressure exerted by the garment is measured using the PicoPress device on the first day of wear. The wearing comfort is evaluated using an adjusted version of the ICC compression questionnaire after one week of wearing the compression bra.
223734486|NCT06319508|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development\[. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.
223734487|NCT06319508|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223401611|NCT04545112|DEVICE|CABG|"Elective, coronary artery bypass (CABG) surgery. Each study subject will receive an left internal mammary artery (LIMA) conduit to the left anterior descending (LAD) coronary artery. Patients with uncompromised saphenous veins will receive a SVG to the LCX or RCA and the XABG to the remaining territory. Patients with compromised arterial and/or saphenous veins, (i.e., no-vein patients), will receive one XABG to the LCX or RCA to achieve incomplete revascularization."
223401612|NCT06850662|OTHER|Backward walking observation training|Backward treadmill training after watching a video of backward walking.
223401613|NCT06850662|OTHER|Non-motor observational backward walking training|Backward treadmill training after watching a video of landscape without any movements.
223401614|NCT06775886|OTHER|myPACE+ algorithm|myPACE+ algorithm with mono-fractional exponent
223401615|NCT04117074|DRUG|Liposomal bupivacaine|Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
223401616|NCT04117074|OTHER|Thoracic epidural analgesia (bupivacaine)|Perioperative bupivacaine based thoracic epidural placed preoperatively.
223401617|NCT07087587|DEVICE|CPAP|CPAP will be randomized 2 weeks on 2 weeks off for 12 weeks total
223401618|NCT02321033|DIETARY_SUPPLEMENT|soft drinks|soft drinks with palatinose and maltodextrin
223401619|NCT02051582|PROCEDURE|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
223401620|NCT02051582|PROCEDURE|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
223734488|NCT06319508|DRUG|Lidocaine hydrochloride|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Once a day.
223734489|NCT06319508|PROCEDURE|Placebo injection|The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. 1 milliliter of normal saline will be used for injection.
223734490|NCT00398060|BEHAVIORAL|Cognitive-behavioral life-style counseling|
223734491|NCT01773382|BEHAVIORAL|weight reduction|"1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary"
223734492|NCT03846011|OTHER|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
223734493|NCT03512509|OTHER|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
223734494|NCT03512509|OTHER|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
223734495|NCT04462549|BEHAVIORAL|Resource Facilitation|"RF involves working one on one with a brain injury specialist. This specialist is called a Resource Facilitator and works with clients to help set and achieve their own goals along with a team of professionals that specialize in this kind of injury. This may include brain injury education, family education, needs assessments, and service identification."
224021696|NCT00112047|DRUG|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
224021697|NCT00112047|DRUG|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
224021698|NCT01307579|DRUG|Caspofungin Acetate|Given IV
224021699|NCT01307579|DRUG|Fluconazole|Given IV or PO
224021700|NCT01307579|OTHER|Laboratory Biomarker Analysis|Correlative studies
223734496|NCT00814528|DRUG|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
223401621|NCT04521881|DRUG|Tranexamic Acid 500 MG|given once as an intramuscular injection
223401622|NCT06338514|OTHER|Real dry needling|dry needling into the muscle under ultrasound guidance.
224131868|NCT03996109|BEHAVIORAL|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 6 months. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
223401623|NCT06338514|OTHER|Sham dry needling|dry needling into the subcutaneous fatty tissue under ultrasound guidance.
223401624|NCT04751370|PROCEDURE|Computed Tomography|Undergo CT
223553094|NCT05710003|BEHAVIORAL|breathing exercises|"A-breathing exercises: 20 times per hour. While setting down, deep breathing is taken from the nose while mouth is closed, breath holding for at least ten seconds, then slow maximal exhalation for at least 10 seconds.~B-Upper Limb Endurance Exercises (low weight and high repetition) : Study participants will be educated to perform upper limb exercises every 4 hours. Three exercises will be repeated 10×3 times with 1 minute rest in between.~Breathing exercise and upper limb endurance exercises is explained in the reminder in details"
224131869|NCT03996109|BEHAVIORAL|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 6 months. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
224131870|NCT04185883|DRUG|Sotorasib|Sotorasib administered orally as a tablet.
224131871|NCT04185883|DRUG|Trametinib|Trametinib administered orally as a tablet.
223553095|NCT05020834|OTHER|Functional Electrical Stimulation|Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.
223553096|NCT05020834|OTHER|TheraTogs Orthotic Undergarment|TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
224131872|NCT04185883|DRUG|RMC-4630|RMC-4630 administered orally as a capsule.
223553097|NCT02148536|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
223553098|NCT01234454|DRUG|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
223553099|NCT01234454|DRUG|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
223553100|NCT01369199|DRUG|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
223734497|NCT00814528|DRUG|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
223734498|NCT03383679|DRUG|Darolutamide|treatment with darolutamide
223734499|NCT03383679|DRUG|Capecitabine|treatment with capecitabine
223734500|NCT01654094|DEVICE|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
223734501|NCT01654094|OTHER|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
223734502|NCT00480597|DRUG|gemcitabine|
223734503|NCT00480597|DRUG|cisplatin|
223734504|NCT00480597|DRUG|vinorelbine|
223734505|NCT00480597|DRUG|capecitabine|
223734506|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
223734507|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
223734508|NCT01291173|DRUG|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
223734509|NCT01291173|DRUG|Placebo|Placebo capsule taken once daily for up to 11 weeks
224131873|NCT04185883|DRUG|Afatinib|afatinib administered orally as a tablet.
224131874|NCT04185883|DRUG|Pembrolizumab|pembrolizumab administered as an intravenous (IV) infusion.
224131875|NCT04185883|DRUG|Panitumumab|Panitumumab administered as an IV infusion.
223401625|NCT04751370|BIOLOGICAL|Ipilimumab|Given IV
223401626|NCT04751370|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223401627|NCT04751370|BIOLOGICAL|Nivolumab|Given IV
223401628|NCT04751370|RADIATION|Radiation Therapy|Undergo short-course radiation therapy
223401629|NCT04751370|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
223401630|NCT04751370|PROCEDURE|Total Mesorectal Excision|Undergo TME
223401631|NCT04092270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223401632|NCT04092270|PROCEDURE|Computed Tomography|Undergo CT scan
223401633|NCT04092270|PROCEDURE|Echocardiography Test|Undergo ECHO
223401634|NCT04092270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223401635|NCT04092270|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223401636|NCT04092270|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223401637|NCT04092270|DRUG|Peposertib|Given PO
223401638|NCT06349512|PROCEDURE|68Ga-FAPI-46 PET/CT imaging|The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
223401639|NCT07091357|DRUG|SHR-1819 Injection|SHR-1819 injection.
223553101|NCT00628459|DIETARY_SUPPLEMENT|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
223553102|NCT01071252|DRUG|AIN457|
223553103|NCT01071252|DRUG|Placebo|
223553104|NCT04169516|DIAGNOSTIC_TEST|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
223553105|NCT00303654|PROCEDURE|biopsy|
223553106|NCT00303654|PROCEDURE|therapeutic conventional surgery|
223553107|NCT03928418|BEHAVIORAL|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
223553108|NCT03928418|BEHAVIORAL|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
223734510|NCT03913793|OTHER|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.\[19\] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
223734511|NCT00504933|DRUG|bilastine|20 mg (encapsulated) tablets QD/14days
224021701|NCT03612583|PROCEDURE|Lung- and Diaphragm-Protective Ventilation|Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
224021702|NCT04064398|PROCEDURE|Aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
224021703|NCT04973787|BIOLOGICAL|biological disease-modifying antirheumatic drugs (bDMARDs)|bDMARD therapy (TNF inhibitors), according to the Portuguese recommendations for the use of biological therapies in patients with axSpA and RA
224131876|NCT04185883|DRUG|Carboplatin, pemetrexed, docetaxel, paclitaxel|Carboplatin, pemetrexed, docetaxel administered as an IV infusion.
224131877|NCT04185883|DRUG|Atezolizumab|Atezolizumab administered as an IV injection.
224131878|NCT04185883|DRUG|Palbociclib|Palbociclib administered orally as a tablet.
224131879|NCT04185883|DRUG|MVASI® (bevacizumab-awwb)|MVASI® (bevacizumab-awwb) administered as an IV infusion.
223401640|NCT07091357|DRUG|SHR-1819 Injection Placebo|SHR-1819 injection placebo.
223401641|NCT06193603|OTHER|True dry cupping therapy|In the intervention group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. The therapist will perform 5 minutes of dry cupping therapy, moving the cups up and down using both hands. Participants will also receive routine physiotherapy, including a 20-minute session of transcutaneous electrical stimulation with a frequency of 100 pulses per second and a duration of 60 microseconds. The stimulation intensity will be adjusted for sensory stimulus. Stabilization exercises like abdominal hollowing and bridging will be included. The treatment will consist of 10 sessions, three times per week.
223734512|NCT00504933|DRUG|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
224021704|NCT02869100|OTHER|Blood sample|
223734513|NCT00504933|DRUG|Placebo|(encapsulated) Tablets QD/14 days
223734514|NCT04665284|DRUG|Empagliflozin|Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
223734515|NCT04665284|DRUG|Usual care group|Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
223734516|NCT05522101|DEVICE|Mini-sized MCE|AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application
223734517|NCT05522101|DEVICE|Normal-sized MCE|Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
223734518|NCT01883843|DEVICE|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
224021705|NCT02869100|PROCEDURE|Sodium fluoride Positron Emission Tomography|
224131880|NCT04185883|DRUG|TNO155|TNO155 administered orally as a capsule.
223401642|NCT06193603|OTHER|Sham cupping therapy|In the control group, participants will lie in a prone position, and the lumbar area between L1-L5 will be oiled. Two cups with a diameter of 4.5-5 cm will be placed bilaterally, parallel to the lumbar spine. However, unlike the intervention group, the cups in the control group will not be moved and will remain stationary for 5 minutes. The cups will have small holes (\<2mm in diameter) to release negative pressure quickly. Double-sided tapes will be used to secure the cups and maintain contact with the skin.
223734519|NCT01883843|DEVICE|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
223734520|NCT03833973|BEHAVIORAL|Overtraining Monitoring|Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
223734521|NCT01862198|DEVICE|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
223734522|NCT06495047|DRUG|Long-acting bronchodilator therapy (LABD)|Long-acting inhaler therapy
224021706|NCT02869100|OTHER|Magnetic Resonance Imaging|
223401643|NCT05514873|DRUG|zilucoplan (RA101495)|Subcutaneous injection
223401644|NCT07102641|DRUG|Acetaminophen|Acetaminophen 1000 mg q6H
223401645|NCT07102641|DRUG|NSAID (Ketorolac/Ibuprofen)|NSAID (ketorolac 30 mg q6H for first 24 hours post-op followed by ibuprofen 600 mg q6H)
223401646|NCT06911749|DIAGNOSTIC_TEST|MSOT with ICG|Application of Multispectral Optoacoustic Tomography (MSOT) in combination with the oral contrast agent Indocyanine Green (ICG) to measure gastrointestinal transit time
223553109|NCT03928418|BEHAVIORAL|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
223553110|NCT04743219|PROCEDURE|Selective removal to soft dentin, Biodentine|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
223553111|NCT04743219|PROCEDURE|Selective removal to soft dentin, No Base|"Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication."
223553112|NCT00315952|DRUG|Exubera|
223553113|NCT01584791|DRUG|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
223553114|NCT01584791|DRUG|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
224021707|NCT02869100|OTHER|Radiography|
224021708|NCT06727643|OTHER|trunk muscle strength|force that represents the endurance of the body.
223401647|NCT06911749|DIAGNOSTIC_TEST|MRI|Non-invasive MRI imaging technique will be employed to assess the peristalsis of intestinal segments
223553115|NCT04875377|DIETARY_SUPPLEMENT|Reformulated pizza|Reformulated food with 400ug of iodine per meal, three times per week (to achieve 122% of weekly recommended intakes - average 140ug/day).
223734523|NCT06495047|DRUG|Short-acting bronchodilator therapy (SABD)|Short-acting inhaler therapy
224021709|NCT06727643|OTHER|Core Strength|back and abdominal muscle endurance
224021710|NCT06727643|OTHER|Balance|steady state
224021711|NCT06728826|PROCEDURE|Posterior Pericardiotomy|The surgeon will perform a posterior pericardiotomy while the patient is on cardiopulmonary bypass. In detail, the surgeon will use cautery to make a 4- to 5-cm opening in pericardium between the left inferior pulmonary vein and the diaphragm. Then a soft channel drain will be placed through the posterior pericardium, the pericardiotomy and into the left pleural space.
223734524|NCT02527460|DRUG|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
224021712|NCT03103451|DRUG|BCD-121|
224021713|NCT03103451|OTHER|Placebo|
224021714|NCT01877473|PROCEDURE|Ablation|
224021715|NCT01586637|OTHER|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
224021716|NCT01586637|OTHER|Walking|The group walked twice a week during one hour.
224021717|NCT06907745|PROCEDURE|Bimaxillary Osteotomy|Maxillary LeFort I osteotomy and mandible osteotomy (BSSO) without intermediate splint.
224021718|NCT05545865|OTHER|Low Flavanol Cocoa Powder|Measure the response 2 and 6 hours post low flavanol cocoa intake
224021719|NCT05545865|OTHER|High Flavanol Cocoa Powder|Measure the response 2 and 6 hours post high flavanol cocoa intake
224021720|NCT05545865|OTHER|Vine to Bar Chocolate - 2 servings|Measure the response 2 and 6 hours post chocolate intake
224021721|NCT05545865|OTHER|Vine to Bar Chocolate - 1 serving|Measure the response 2 and 6 hours post chocolate intake
224021722|NCT05545865|OTHER|Vine to Bar Chocolate covered almonds|Measure the response 2 and 6 hours post chocolate covered almond intake
224021723|NCT06905938|OTHER|no intervention|no intervention
223401648|NCT07111117|PROCEDURE|18F-MFBG PET/CT imaging|Participants will receive the 18F-MFBG tracer and undergo a PET/CT imaging.
223734525|NCT04025307|DRUG|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
223401649|NCT00109174|DEVICE|3T and 7T device|3T and 7T device
223401650|NCT07113509|PROCEDURE|mechanical polishing|mechanical polishing of implant resin crowns with polishing paste and discs
223401651|NCT07113509|PROCEDURE|glazing|glaze liquid application followed by light-curing of the resin implant crowns
223401652|NCT07114900|BEHAVIORAL|PA4Health app physical activity intervention|PA4Health app intervention Arm Description: During the app intervention consists of six components: 1) Goal setting and monitoring, 2) Tailored motivational messages based on survey data on barriers and facilitators of physical activity, 3) Education, which consists of twenty-two physical activity (PA) related topics, 4) a semi-structured chatroom where 3-5 participants per chatroom interact with one another to receive and provide peer support for PA, 5) Locator, which provides information about community resources (e.g., community parks, museums) based on participant's zip code, and 6) Steps, which allow participant to monitor their daily level of exercise. Participants wear a Fitbit tracker during the program
223401653|NCT07114900|BEHAVIORAL|Wellness Text Messaging Program|Participants set goal for PA and are encouraged to monitor their level of physical throughout the program. They receive a daily wellness related message during the program as a contact control. They also wear Fitbit tracker during the program.
223401654|NCT05927545|PROCEDURE|Patient education and preventive exercise|Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
223401655|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with Manual Therapy protocol|Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
223553116|NCT04875377|DIETARY_SUPPLEMENT|Control pizza|Control (placebo) meal to consume thrice weekly (no iodine supplementation).
223553117|NCT04875377|DIETARY_SUPPLEMENT|Seaweed capsule|Capsules containing seaweed extract, the iodine-rich ingredient in the reformulated pizza, 400ug iodine per capsule, to be consumed three times per week (122% of weekly recommended intake).
223553118|NCT04875377|DIETARY_SUPPLEMENT|Control capsule|Empty capsules (placebo)
223734526|NCT01846507|DRUG|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
223401656|NCT05927545|PROCEDURE|Patient education, preventive exercise combined with BETY approach|BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
223401657|NCT07118878|DRUG|AGMB-129|AGMB-129
223401658|NCT07118878|OTHER|Placebo|Placebo
223401659|NCT07120152|DRUG|Subcutaneous infliximab CT-P13 Remsima®SC|Subcutaneous infliximab
223553119|NCT05719350|OTHER|Exercises for Knee|Four exercises for strengthening and mobility of the knee joint two in a sitting position and two in a standing position for a total of 20-25 minutes
223553120|NCT03513315|BEHAVIORAL|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
223553121|NCT03513315|BEHAVIORAL|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
223553122|NCT03976505|OTHER|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
223734527|NCT02360956|DRUG|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
223734528|NCT02360956|DRUG|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
223734529|NCT06228378|OTHER|Raman microspectroscopy|Raman microspectroscopy is a non-destructive method for observing and characterising the molecular composition and external structure of a biological sample based on the phenomenon of inelastic light scattering (Raman effect).
223734530|NCT04667520|BEHAVIORAL|Lifestyle Physical Activity (LPA)|This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
223734531|NCT04667520|BEHAVIORAL|Fitbit Only|Participants are provided with a Fitbit during their study participation.
223734532|NCT04053959|DRUG|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
223734533|NCT04053959|DRUG|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
224021724|NCT02943811|DEVICE|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
224021725|NCT03520946|DRUG|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
224021726|NCT03520946|DRUG|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
223401660|NCT06932302|DEVICE|Electrical Stimulation|Electrical stimulation of the dorsal genital nerve will be accomplished using the UCon system and patch electrodes developed by InnoCon. The UCon system includes a programmable control unit; leads that connect to the control unit and electrodes; a silicone surface electrode; a reference electrode; and a remote control for quick on and off toggling of stimulation.
223401661|NCT06932302|DEVICE|Smart vibrator|Subjects will use a smart vibrator at home twice a week during the study. The Lioness smart vibrator records physiological responses during use.
223401662|NCT07126522|OTHER|Discussion|Ancillary studies
223401663|NCT07126522|OTHER|Internet-Based Intervention|Use the HERCaRE app
223401664|NCT07126522|OTHER|Interview|Ancillary studies
223401665|NCT07126522|OTHER|Survey Administration|Ancillary studies
223401666|NCT06936527|BIOLOGICAL|Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI|XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
223401667|NCT06936527|BIOLOGICAL|Drug: XS-03|XS-03 orally
223401668|NCT06936527|BIOLOGICAL|Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI|Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously
223401669|NCT02147977|DIETARY_SUPPLEMENT|dietary supplement: n-3 PUFA|
223401670|NCT02147977|DIETARY_SUPPLEMENT|olive oil|
223401671|NCT06356688|DRUG|Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab|Paclitaxel Polymeric Micelles for Injection:Cycle 1: 230mg/m2, IV ≥3 hours; Cycles 2-4: If the patient has a neutrophil nadir ≥1.0 x 109/L along with a platelet nadir ≥80 x 109/L after Cycle 1 dosing and has not experienced grade II-IV non-hematologic toxicity, then give 260mg/m2, IV ≥3 hours, d1, q3w; Cisplatin: 25mg/m2/d x d1-3, IV drip, q3w; Cadonilimab: 10mg/kg, IV drip, d3, q3w;
223401672|NCT06946823|DEVICE|Just-In-Time Adaptive Intervention for Adolescent Anxiety|A JITAI smartphone app to reduce anxiety levels among rural adolescents by delivering somatic-based activity recommendations
223401673|NCT03825354|BEHAVIORAL|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
223401674|NCT06946290|PROCEDURE|Intertransverse process block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle. ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml 0.25% levobupivacaine is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume of study medication.
223553123|NCT03976505|OTHER|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
223553124|NCT03976505|OTHER|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
223553125|NCT03976505|OTHER|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
223553126|NCT03976505|OTHER|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
224021727|NCT05053607|BEHAVIORAL|Digital Health Coaching Program|consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
224021728|NCT05053607|DEVICE|Fitbit|A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
223401675|NCT06946290|PROCEDURE|Sham block|All blocks are performed by an anaesthesiologist who had previously performed ≥50 successful ITPB blocks, using Philips EPIQ ultrasound system, with a curved array transducer (C5-1), and 80mm echogenic nerve block needle (SonoTAP; PAJUNK, Germany). ITPB is performed with the patients positioned in a lateral decubitus position. The target intervertebral level (T4-5) is identified and marked in the preview ultrasound scan. The transducer is placed 2-3 cm lateral to the spinous process. Under strict asepsis, a single-level (T4-5) ultrasound-guided ITPB is performed with the in-plane insertion of the block needle from lateral to medial direction until its tip is at the medial aspect of the retro-SCTL space. After confirming the needle position by distension of the retro-SCTL space after a test bolus injection of 1-2 ml 0.9% normal saline, 20 ml placebo is injected via the nerve block needle in small aliquots. The same procedure is repeated on the other side with the same volume study drug.
223401676|NCT07141862|DIAGNOSTIC_TEST|RT-qPCR|Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using RT-qPCR
223401677|NCT07141862|DIAGNOSTIC_TEST|ddPCR|Detection of MRD of neuroblastoma and Ewing sarcoma in ovarian and testicular tissues using ddPCR
223553127|NCT03082443|OTHER|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
223553128|NCT00283101|DRUG|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
224021729|NCT01170611|DEVICE|PACEMAKER SYMPHONY 2550|
224021730|NCT06905951|OTHER|Exercise|Mouth, tongue, and throat exercise to strengthen the airway, reducing its collapsibility.
223401678|NCT07152977|OTHER|Radiological evolution of ano-perineal lesions by MRI|Patients selected retrospectively will have benefited from an MRI at diagnosis and a control MRI during follow-up. They will be selected during a follow-up consultation or a biotherapy injection in a day hospital. Patients selected consecutively are monitored at the Rouen University Hospital for perineal Cohn's disease, treated with Biotherapy: Infliximab, Adalimumab, Ustekinumab, Vedolizumab.
223401679|NCT07152275|DEVICE|Percussive Therapy|"Percussive therapy will be administered using the Hypervolt Go 2 Black, a massage gun commonly used in clinical and athletic settings.~Participants will lie in a prone position on a treatment table. To promote hamstring muscle relaxation, a support roll will be placed under the ankle. The intervention will be delivered by the same researcher for all participants to ensure consistency. Using the round head attachment, percussive therapy will be applied longitudinally along the hamstring muscle group (from proximal to distal) for a total of 120 seconds per leg. Specifically, 60 seconds will be applied to the semitendinosus and semimembranosus, and 60 seconds to the biceps femoris. The same procedure will then be repeated on the opposite leg."
223401680|NCT07151313|DEVICE|Bee Venom Phonophoresis|Ultrasound therapy device
223401681|NCT07151313|DRUG|Standard Care (oral decongestants + saline nasal irrigation)|(oral decongestants + saline nasal irrigation)
223401682|NCT07151313|BIOLOGICAL|Bee Venom Phonophoresis|bee venom extract prepared for topical use)
223401683|NCT07152665|BEHAVIORAL|Video-Based Education|Parents of children in the intervention group were informed that the educational videos used in the study aimed to reduce the child's pain, fear, and anxiety.
223553129|NCT04031248|DEVICE|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices \[Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)\]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
223553130|NCT04031248|OTHER|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
223553131|NCT00470262|DRUG|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
223553132|NCT00470262|DRUG|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
223553133|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ H.|Vegan Capsules with active product, GutMagnific™ high dose
223553134|NCT04741841|DIETARY_SUPPLEMENT|GutMagnific™ L.|Vegan Capsules with active product, GutMagnific™ low dose
223553135|NCT04741841|DIETARY_SUPPLEMENT|Placebo|Vegan capsules identical to active product in taste and appearance but without probiotic
223553136|NCT03901625|DEVICE|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
223401684|NCT07152314|DIAGNOSTIC_TEST|Digital plaque quantification using intraoral scanner|Participants will undergo three-dimensional intraoral scanning at three time points during a single session: initial scanning (T0), after biofilm disclosure with plaque disclosing solution (T1), and after supervised toothbrushing (T2).
223401685|NCT07152483|DIETARY_SUPPLEMENT|High resistant starch staple foods|Participants in the intervention group will intake high resistant starch staple foods (achieving daily intake of ≥28g resistant starch)
223401686|NCT07152483|DIETARY_SUPPLEMENT|Regular starch staple foods|Participants in the control group will intake isocaloric regular starch staple foods
223401687|NCT07152457|OTHER|No intervention|None intervention
223401688|NCT07152873|DRUG|AD-117|AD-117 1Tab., Per Oral
223401689|NCT07152873|DRUG|AD-117A|AD-117A 1Tab., Per Oral
223553137|NCT03901625|DEVICE|Dental floss|A dental floss is used to clean inter-proximal areas.
223553138|NCT03901625|DEVICE|Waterjet|A waterjet is used to clean inter-proximal areas.
223553139|NCT03901625|DEVICE|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
224021731|NCT04310891|RADIATION|Markerless Tumour Tracking|Intrafraction Kolovoltage X-ray Imaging using Fiducials
224021732|NCT01548079|DRUG|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
224021733|NCT03368469|DEVICE|transcranial direct current stimulation|The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
223553140|NCT03626012|DRUG|BIIB078|Administered as specified in the treatment arm.
223553141|NCT03626012|DRUG|Placebo|Administered as specified in the treatment arm.
224021734|NCT05003726|PROCEDURE|non-pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
224021735|NCT05003726|PROCEDURE|pharmacological treatment|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
223553142|NCT03824873|PROCEDURE|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
224021736|NCT01236248|BEHAVIORAL|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
224021737|NCT00183365|BEHAVIORAL|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
223401690|NCT07152509|OTHER|Observational Assessment|The demographic, clinical, and personal characteristics of the individuals will be collected and recorded through a questionnaire. For all participants, body fat percentage (%), skeletal muscle mass percentage (%), visceral fat percentage (%), and resting metabolic rate (kcal), measured using the Omron Body Composition Monitor, will be recorded. Waist and hip circumference will be measured with a tape measure; lower extremity muscle strength (M. Quadriceps) will be assessed with a muscle hand-held dynamometer; grip strength will be assessed with a hand grip dynamometer; physical activity level will be evaluated using the International Physical Activity Questionnaire-Short Form (IPAQ-SF); functional capacity will be measured with the 6-Minute Walk Test (6MWT); postural stability and balance will be assessed with the Biodex Balance System; clinical balance will be assessed with the Berg Balance Scale; quality of life will be evaluated using the Nottingham Health Profile (NHP)
223553143|NCT03824873|PROCEDURE|cesarean hysterectomy|cesarean hysterectomy
224021738|NCT00183365|BEHAVIORAL|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
224021739|NCT04605887|DRUG|Angiotensin 1-7|Ang 1-7 subcutaneously 500 mcg/kg /day
224021740|NCT03996499|DIAGNOSTIC_TEST|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
224021741|NCT00195858|BEHAVIORAL|aerobic and resistance exercise|aerobic and resistance exercise
224021742|NCT01592500|DRUG|MOD-4023|Once weekly subcutaneous injection
224021743|NCT01592500|DRUG|Somatropin|Once daily subcutaneous injection of Genotropin
223734534|NCT01811173|OTHER|Nurse-physician comprehensive care|"Components of the intervention include:~1. Complete assessment of the patient's and family's needs conducted by the nurse.~2. Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~3. Multimorbid care plan integrating all care aspects.~4. Action Plan for patients, supporting self management~5. Proactive monitoring according to the plan."
223734535|NCT01412346|OTHER|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
223734536|NCT00549523|DRUG|Placebo|Capsules containing 0 mg bid (placebo)
223734537|NCT00549523|DRUG|Low Dose|Capsules containing 400 mg bid of L. frutescens.
223401691|NCT07151495|DIAGNOSTIC_TEST|Speckle tracking and 2D echocardiography|The study will involve only the collection of data obtained from routine clinical procedures and a telephone follow-up. Preoperative echocardiographic data and pre-operative left atrial speckle tracking data will be retrieved
223553144|NCT01565408|DRUG|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
223553145|NCT01565408|DRUG|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
223553146|NCT01877681|PROCEDURE|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
223553147|NCT01877681|PROCEDURE|Active comparator|Usual care as specified in the PU practice guideline
223553148|NCT04089852|DRUG|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
223734538|NCT00549523|DRUG|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
223734539|NCT00549523|DRUG|High Dose|Capsules containing 1200 mg bid of L. frutescens.
223734540|NCT00938379|DRUG|20% deet insect repellent|skin-applied repellent lotion
223734541|NCT00938379|DRUG|placebo control|Identical base formulation of lotion but without any deet active
223734542|NCT04375137|DIAGNOSTIC_TEST|Oxidative Stress ELISA Kit|Checking oxidative stress markers and redox system status
223734543|NCT01042704|DRUG|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
223734544|NCT01042704|DRUG|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
223734545|NCT01042704|DRUG|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
223734546|NCT01042704|DRUG|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
223734547|NCT01042704|DRUG|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
223734548|NCT01042704|DRUG|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
223734549|NCT01042704|OTHER|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
224021744|NCT02502097|DRUG|Gefapixant|Gefapixant 50 mg tablet, administered by mouth
223734550|NCT01042704|OTHER|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
223734551|NCT01042704|OTHER|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
224021745|NCT02502097|OTHER|Placebo|Matching placebo to gefapixant, tablet administered by mouth
224021746|NCT00567710|DRUG|BL - 1020|10 mg/day
224021747|NCT00567710|DRUG|BL - 1020|BL 1020 20-30 mg/day
224021748|NCT00567710|DRUG|Placebo|Capsules
223401692|NCT07152171|BEHAVIORAL|Pain Neuroscience Education During Aerobic Exercise|Participants will cycle on an ergometer for 20-30 minutes at light intensity (Borg CR10 = 3; 40-50% HRmax). During cycling, they will receive interactive pain neuroscience education delivered by a therapist, including neurobiology of pain, central sensitization, and self-management strategies. Visual aids and metaphors will be used to facilitate understanding.
223734552|NCT01042704|OTHER|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~* Physical exam~* Performance status (check of ability to perform daily functions)~* Recording of any new symptoms and any new medications being taken~* Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~* Urine test (24hr urine)~* Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~* A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
223734553|NCT00687765|DRUG|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
223734554|NCT02436356|DEVICE|Osteoprobe-Reference Point Indentation (RPI)|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
223734555|NCT02436356|RADIATION|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
223734556|NCT02436356|RADIATION|MRI|Determines bound water and pore water of bone.
223734557|NCT03120819|BEHAVIORAL|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
223401693|NCT07152171|BEHAVIORAL|Aerobic Exercise Alone|Participants will perform 20-30 minutes of supervised cycling on an ergometer at light intensity (Borg CR10 = 3; 40-50% HRmax). No educational content will be provided. Sessions will include warm-up, main phase, and cool-down, matched in duration and intensity to the experimental group.
223734558|NCT03120819|BEHAVIORAL|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
223734559|NCT04577118|DEVICE|iotaSOFT Insertion System|Enrolled subjects undergoing cochlear implant surgery will have the iotaSOFT Insertion System used by the surgeon to assist with implantation of the implant electrode array during the procedure.
223734560|NCT03410940|DEVICE|CLS Brevius stem with Kinectiv technology|
223734564|NCT00810407|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
223734565|NCT04995133|DRUG|Colistin|intravenous administration
224021749|NCT00567710|DRUG|Risperidone|Capsules
224021750|NCT02186223|DEVICE|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
224021751|NCT01201317|DRUG|AZD2423|20 mg tablet
224021752|NCT01201317|DRUG|AZD2423|150 mg tablet
224021753|NCT01201317|DRUG|Placebo|Placebo
224021754|NCT02293148|DRUG|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
224021755|NCT02293148|DRUG|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
224021756|NCT02293148|DRUG|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
223401694|NCT07152444|DRUG|QLS1410 (CYP11B2 inhibitor)|QLS1410 tablets
223401695|NCT07152444|DRUG|placebo|Matching placebo tablets
223401696|NCT07151560|DRUG|6 cycle RC48 and JS001|Different medication cycles
223401697|NCT07151560|DRUG|12 cycle RC48 and JS001|Different medication cycles
223401698|NCT07151664|OTHER|Quality of life progression after parathyroidectomy|Study the progression of quality of life
223401699|NCT07152587|DRUG|Low dose steroids|Receive 0.5mg/kg Methylprednisolone
223401700|NCT07152587|DRUG|Moderate dose steroids|Receive 1.0mg/kg Methylprednisolone
223401701|NCT07152587|DRUG|Saline (0.9% NaCl)|Saline 100ml
224021757|NCT02293148|DRUG|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
224021758|NCT02293148|DRUG|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
223401702|NCT07152366|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
223401703|NCT07152366|DRUG|Glucocorticoids|500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
223553149|NCT04089852|DRUG|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
223553150|NCT04133662|BEHAVIORAL|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
223553151|NCT05078515|DIAGNOSTIC_TEST|PREDICT score|Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
223553152|NCT05870462|DRUG|Semaglutide Pen Injector|"* 0.25 mg/week (non-therapeutic dose) during Weeks 1-4~* 0.50 mg/week during Weeks 5-8~* 1.0 mg/week during Weeks 9-24~Participants experiencing side effects (e.g. nausea, stomach pain, constipation, diarrhea, vomiting) at the maximum dose (1.0 mg/week) may be down-titrated to 0.50 mg/week.~Participants who had been receiving a dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin) will stop taking their DPP-4 inhibitor upon randomization to this arm."
223553153|NCT05547087|BIOLOGICAL|VN-0200|VN-0200 (antigen: VAGA-9001a, adjuvant: MABH-9002b) administered as an intramuscular injection; 2 shots in 4 weeks.
223734566|NCT06456060|DRUG|Alvogyl|Alvogyl soaked in a sterile gauze will be applied to cover the socket.
224021759|NCT05384444|OTHER|Fasting mimicking diet|The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
224021760|NCT04028882|OTHER|Signaling, metabolomic and transcriptomic analysis|Signaling, metabolomic and transcriptomic analysis
224131881|NCT04185883|DRUG|IV Chemotherapy (Regimen 1)|Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
224021761|NCT05283486|DRUG|MYMD-1 600MG|Cohort 1: 600mg drug
224131882|NCT04185883|DRUG|IV Chemotherapy (Regimen 2)|IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
223401704|NCT07152756|PROCEDURE|Esophagogastroduodenoscopy|Assess the gastric retention and the endoscopic mucosal visibility score during esophagogastroduodenoscopy
223553154|NCT01994746|DRUG|Nasal Glucagon|
223553155|NCT01994746|DRUG|Intramuscular Glucagon|
223553156|NCT05096975|OTHER|Evaluation of the CBCL-A-A-A and HiPIC in children with ADHD and with ED or without ED|"The intervention involves the completion of two questionnaires by parents at child psychiatry unit of Montpellier University Hospital when children come to participate in a psychometric assessment or when parents or children participate in therapeutic group.~All parents completed Child Behavior Checklist (CBCL; Achenbach \& Rescorla, 2001), a 118-item questionnaire to measure emotional and behavior problems in 4 to 18-years-old children in the past six months and Hierarchical Personality Inventory for Children (HiPIC, Mervielde \& De Fruyt, 1999, a 144-item questionnaire to obtain a profile of the personality of 6 to 12-year-old children."
223553157|NCT00641355|PROCEDURE|No intervention|No intervention
223553158|NCT05849194|DIAGNOSTIC_TEST|POCUS examination|Point of care ultrasound examination
223553159|NCT05028699|OTHER|Snack|Participants will consume 32 g of a common bean baked snack per day for 28 days during the intervention stage.
223553160|NCT03820336|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
223553161|NCT03820336|DIETARY_SUPPLEMENT|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
223734567|NCT06456060|DRUG|Honey|Honey soaked in a sterile gauze will be applied to cover the socket.
223734568|NCT01337947|DRUG|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
223734569|NCT05548231|DRUG|LY3437943|Administered SC
224021762|NCT05283486|DRUG|MYMD-1 750mg|Cohort 2: 750mg drug
224021763|NCT05283486|DRUG|MYMD-1 900mg|Cohort 3: 900mg drug
224021764|NCT05283486|DRUG|MYMD-1 1050mg|Cohort 4: 1050mg drug
224131883|NCT04185883|DRUG|BI 1701963|BI 1701963 administered orally
224131884|NCT04185883|DRUG|AMG 404|AMG 404 administered as an IV infusion.
224131885|NCT04185883|DRUG|Everolimus|Everolimus administered orally.
224131886|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using ND:YAG laser|A free running, pulsed, 1064 nm wavelength-specific ND:YAG laser will be used. A thin 300 μm laser fiber optic will be placed parallel to the root surface, allows easy access into deep periodontal pockets. The initial pass with the laser is known as Laser Troughing, and it is done with a micro-short duration pulse, with a 4.0 watt power, 150 μs duration in pulsed mode and 20Hz frequency. Ultrasonic scaler will be then used to remove calculus. The second pass is carried out with 650 μs pulse duration, 10-30 seconds for each tooth, 4.0 watt power and 20HZ frequency, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed. Relieving the occlusion is the last step of the LANAP protocol.
223553162|NCT04657705|PROCEDURE|High power ablation|High power ablation parameters (50-55 W)
223553163|NCT04657705|PROCEDURE|Standard ablation power|Standard ablation power parameters (40-45 W)
223553164|NCT05713981|PROCEDURE|Meibomian gland (MG) expression|The procedure is performed with a sterile cotton tip applicator once in the upper and lower eyelids of the subject's choosing.
223734570|NCT05548231|DRUG|Placebo|Administered SC
223734571|NCT04208399|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally in fed condition.
223734572|NCT05703256|DEVICE|Amygdala real-time fMRI neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
224021765|NCT05283486|DRUG|placebo 600mg|Cohort 1: 600mg placebo
224021766|NCT05283486|DRUG|placebo 750mg|Cohort 2: 750mg placebo
224021767|NCT05283486|DRUG|placebo 900mg|Cohort 3: 900mg placebo
223401705|NCT07182747|BEHAVIORAL|Nursing students' intervention programme|12-week intervention programme conducted by nursing students and students trained in Sciences of Physical Activity and Sport (CAFYD). Participants will receive weekly three sessions of 45-60 minutes. It will include physical exercise and occupational therapy sessions aimed at improving frailty and other related outcomes in the participating older adults through interdisciplinary collaboration and ongoing monitoring. Nursing students will implement personalised intervention programmes designed by a multidisciplinary team comprising CAFYD students, an occupational therapist, and nurses experienced in the care of older adults.
223553165|NCT00140712|DRUG|Ropinirole Immediate Release|Ropinirole Immediate Release
223553166|NCT05695794|OTHER|the group with a bed head height of 45 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving a 45 degree head height to 30 patients determined by Randomizer.org.
223553167|NCT05695794|OTHER|the group with a bed head height of 30 degrees|Edema, ecchymosis, respiratory function and sleep quality will be evaluated by giving 30 degrees of bed head height to 30 patients determined by Randomizer.org.
223553168|NCT05576324|DRUG|Elexacaftor / Ivacaftor / Tezacaftor|Elexacaftor / Ivacaftor / Tezacaftor is a triple drug therapy that modulates CFTR availability at (apical) cell membranes and increases opening probability.
223553169|NCT01632592|DRUG|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
223553170|NCT01632592|DRUG|Placebo|placebo given by injection 2mg subcutaneously daily
223553171|NCT05363501|DRUG|IM Naloxone Injection|Single 0.4 mg IM naloxone injection will be administered (1 mL of 0.4 mg/mL injection, into the gluteus maximus muscle using a 23-gauge needle).
223553172|NCT05363501|DRUG|Naloxone Nasal Spray|Single 4 mg intranasal naloxone spray will be administered in one nostril (0.1 mL of 4 mg/0.1 mL spray, based on the prescribing information and approved Instructions for Use).
223553173|NCT05363501|DRUG|Naloxone Nasal Swab|4 mg naloxone nasal swab administered in nostril
223553174|NCT05363501|DRUG|Naloxone Nasal Swab|8 mg naloxone nasal swab administered in nostril
223553175|NCT05363501|DRUG|Naloxone Nasal Swab|12 mg naloxone nasal swab administered in nostril
223553176|NCT05363501|DRUG|Naloxone Nasal Swab|12.5 mg naloxone nasal swab administered in nostril
223553177|NCT05466084|PROCEDURE|tissue Glue for mesh fixation|one arm of the study had their mesh fixed with tissue glue applied at multiple sites
223553178|NCT05466084|PROCEDURE|Metallic Tackers for mesh fixation|in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
223553179|NCT05933967|DRUG|Orelabrutinib+R-CHOP|Orelabrutinib 150mg qd PO. Rituximab 375 mg/m2 IV on Day 0 of each 21-day cycle. The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.
223553180|NCT00532311|DRUG|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
223553181|NCT00532311|DRUG|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
223553182|NCT05561101|OTHER|Caregivers burden|Assessment of caregiver burden after admision at Emergency Department of their elderly relative
223553183|NCT06554977|OTHER|Laboratory|CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
223553184|NCT03311581|DRUG|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
223553185|NCT03311581|DEVICE|Sevoflurane|sevoflurane inhalation 2\~4%
223553186|NCT04022629|PROCEDURE|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
223553187|NCT04022629|PROCEDURE|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
223553188|NCT01490216|DRUG|lisdexamfetamine|20mg q.d. to 70mg b.i.d
223553189|NCT00553436|DEVICE|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
223553190|NCT04188834|DEVICE|Customized version of DAVID device|A customized version of the DAVID device will be used to expose participants to sensory flicker. The device consists of opaque glasses containing LEDs to present flickering light, as well as earbuds or headphones to present flickering sound.
223553191|NCT04188834|DEVICE|Blackrock CereStim|The Blackrock CereStim is a fully programmable neurostimulator. The current pulses generated by the Blackrock CereStim are intended to stimulate neurons in proximity to a set of electrodes.
223734573|NCT05703256|DEVICE|Sham feedback|Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
223553192|NCT01030952|DRUG|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
223553193|NCT01030952|DRUG|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
223553194|NCT03932318|BIOLOGICAL|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
223553195|NCT03932318|DRUG|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
223553196|NCT03932318|DRUG|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
223553197|NCT05343689|PROCEDURE|Pneumatic compression|Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
223401706|NCT07182747|BEHAVIORAL|Standard care from Public Andalusian Health Service|They will receive the standard care provided by the Andalusian Health Service as part of its portfolio of services offered to older adults residing in institutions, as well as the standard care provided by the institutions in which they live. As part of these services, older adults receive support such as accommodation, laundry, health promotion activities, health monitoring, assistance with activities of daily living, individual, group, and community social care, as well as means of communication with the outside world. The action plans or protocols established in care processes for older adults living in nursing homes do not include externally delivered multidisciplinary intervention programmes.
223401708|NCT07184489|OTHER|implementation strategies|"1. Analysis of barrier factors: A focus group interview will be conducted. Purposive sampling was used to include senior nurses in the ward, members of the evidence-based group, and doctors for the analysis of barrier factors. Then the CFIR-ERIC matching tool will be used to develop implementation strategies based on the barrier factors.~2. The best - worst scaling method will be used to generate relatively reliable and valid preference evidence of stakeholders for implementation strategies from CFIR-ERIC matching tool.~3. The implementation strategies will be developed specifically by an expert group. This group includes nursing managers and experts in evidence-based practice.~4. Implement the strategies."
223401709|NCT07183345|OTHER|Dynamic Pain Assessment and Management System|Personalized nursing education was adopted. These measures include the use of preoperative analgesic drugs, postoperative Traditional Chinese Medicine (TCM) fumigation, and wrist-ankle acupuncture for pain relief.
223401710|NCT07183345|DRUG|Routine drug analgesia|adopted routine drug analgesia and conventional nursing education
223401711|NCT07183930|PROCEDURE|Tubeless Percutaneous Nephrolithotomy (PCNL)|Mini-PCNL with tract dilation up to 18 Fr and stone fragmentation by pneumatic lithotripsy. Following clearance, a double-J stent is placed; no nephrostomy tube is inserted.
223401712|NCT07183930|PROCEDURE|Standard Tube Percutaneous Nephrolithotomy (PCNL)|Mini-PCNL with tract dilation up to 18 Fr and stone fragmentation by pneumatic lithotripsy. Following clearance, a 14 Fr nephrostomy tube and a double-J stent are placed.
223553198|NCT01539122|DEVICE|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
223553199|NCT01539122|DEVICE|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
223553200|NCT01271907|DRUG|fludarabine|Fludarabine 25 mg/m\^2 x 5 days
223553201|NCT01271907|DRUG|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
223734574|NCT04843774|DRUG|SARS-COV-2 mRNA Vaccine|Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
223734575|NCT02826031|DRUG|Sodium Hyaluronate Injection|
223734576|NCT02826031|DRUG|DICL-SR|
223553202|NCT01271907|DRUG|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
223734577|NCT00439426|DRUG|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
224021768|NCT05283486|DRUG|placebo 1050mg|Cohort 4: 1050mg placebo
224021769|NCT04238065|DEVICE|Caterna Virtual Reality|"Vivid interactive games of perceptual learning content, with artificial intelligent sound and scores to feedback vision and actions results, which can be connected to the supervision of cellphone softwareWechat to upload vision acuity and choose 2 eyes' video output automaticly."
224021770|NCT04238065|DEVICE|Spectacles(Best optical corrected distance vision)|Each eye has best corrected vision spectacles with best corrected optical lens.
224021771|NCT04238065|DEVICE|Patch|2 hours patch to the non-amblyopia eye if the other amblyopia eye is mild or moderate amblyopia; 6 hours patch to the non-amblyopia eye if the other amblyopia eye is severe abmlyopia
224021772|NCT00252733|DRUG|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
224021773|NCT00004660|RADIATION|Radiotherapy|
223401713|NCT07182500|OTHER|Probiotic|Daily 6-drops of Bifidobacterium longum subsp. infantis M-63, B. breve M-16V, and B. longum BB536 in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1.5 × 109 CFU/day)
223401714|NCT07182500|OTHER|Placebo|Daily 6-drops of non-GMO corn starch in medium-chain triglyceride oil
223401715|NCT07182942|DRUG|Xiqing|oral intervention of Xiqing
223401716|NCT07182942|DRUG|probiotics|oral intervention of probiotics
223553203|NCT01271907|DRUG|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
223553204|NCT04900246|PROCEDURE|Visual Inspection|"The examiners will evaluate the surfaces included in the study independently and without knowledge of the results of the other examiner, after prophylaxis, using a mouth mirror and a WHO probe or Ball point. The evaluations will be carried out in a dental chair with the aid of a reflector. The teeth will be examined moist, and afterwards, they will be dried for 5 seconds with the use of a triple syringe.~For visual inspection, the International Caries Detection and Assessment System (ICDAS) evaluation system will be used. Complete ICDAS has seven categories, the first for healthy teeth (code 0) and the next two for limited enamel caries, white/brown stain (codes 1 and 2). The following two categories (codes 3 and 4) are considered to be caries that extend to the enamel without exposed dentin. And the two remaining categories (codes 5 and 6), are considered caries with exposed dentin."
223553205|NCT04900246|RADIATION|BWX Radiographic Assessment|Participants will be radiographed with a digital X-ray device (DIOX-602, Micro Imagem, Indaiatuba, Brazil) with a regulation of 60 kV and 2 mA and exposure time of 0.10s. The technique used will be the interproximal/bitewing (BWX), with the FIT T1 Digital Sensor (external dimensions: 36.7mm x 24.3mm/sensitive area dimensions: 30.0mm x 20.0mm - 600mm²) and the sockets will be standardized with use of Han-Shin radiographic positioners (Jon, São Paulo, Brazil).
223734578|NCT00439426|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
223734579|NCT00988455|RADIATION|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
223734580|NCT01080690|PROCEDURE|EGD|In this arm EGD will be performed before EUS.
223734581|NCT01080690|PROCEDURE|EUS|In this arm EUS will be performed before EGD.
224021774|NCT00004660|RADIATION|Sham treatment|
224021775|NCT01874301|OTHER|High quantity probiotic|The intervention type is food product
224021776|NCT01874301|OTHER|Low quantity probiotic|The intervention type is food product
224021777|NCT01874301|OTHER|placebo|
223401717|NCT07182734|DEVICE|Supervised and minimally-supervised therapy with ReHandyBot and RehabCoach|"During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a therapist or researcher. Minimally-supervised therapy means that participants try to perform therapy independently with the device, while the supervisor is present to provide assistance only if problems occur or if participants have questions.~A few days after the study begins, participants are introduced to the RehabCoach application, which provides conversational support, reminders, and educational content throughout the intervention.~During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. In each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes."
223401718|NCT07182734|DEVICE|Unsupervised Therapy with ReHandyBot and RehabCoach|"After the familiarization phase, participants continue training without direct supervision at the clinic until discharge and then at home for six weeks. If the therapist considers the participant capable of training safely and effectively with the device, the participant will keep training with the ReHandyBot unsupervised, both at the clinic and at home, while supported by the RehabCoach application. RehabCoach provides reminders, motivational support, and educational material to guide the home-based therapy.~If participants are not considered ready for unsupervised therapy with the device, they will not proceed to the unsupervised phase."
223401719|NCT07183631|OTHER|Platelet rich fibrin|Platelet-rich fibrin (PRF) was prepared according to the manufacturer's instructions. A blood sample was collected from the cubital vein in 10 ml tubes without anticoagulant and centrifuged at 3000 rpm for 10 minutes using a GLO GT416 table centrifuge (GLO Glotech Co. Ltd, Korea) and GLO PRP collection kit (GLO PRP-Kit, Glotech Co, Asan Choong-nam, Korea/ Glofinn, Finland).
223401720|NCT07183631|OTHER|Enamel matrix derivate|"In the control group, the root surface was conditioned with 24% ethylenediaminetetraacetic acid (EDTA) gel for two minutes, washed with physiological saline solution, dried, and treated with enamel matrix derivative (EMD), (Emdogain, Straumann, Switzerland) per manufacturer recommendations."
223401721|NCT07182968|OTHER|Questionnaire study|Questionnaire application
223401722|NCT05679401|DRUG|Imlifidase|Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
223401723|NCT05679401|PROCEDURE|Plasma exchange (PLEX)|PLEX removes the patient's pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
223401724|NCT05679401|DRUG|Cyclophosphamide (CYC)|Cyclophosphamide's main mechanism of action (i.e. crosslinking of strands of DNA and RNA) results in inhibition of protein synthesis. Hence treatment prevents formation of new anti-GBM antibodies.
223401725|NCT05679401|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
223401726|NCT06141902|OTHER|Jing Si Herbal Drink|Jing Si Herbal Drink
223401727|NCT06776848|OTHER|Observation phase|Start of the observation phase for all patients for a period of 6 months. Group B: continuation of the observation phase for a further 6 months
223401728|NCT06776848|DRUG|Lithium treatment|The daily dose of lithium will be increased until the target lithiaemia is reached, while monitoring tolerance and possible adverse effects.
223401729|NCT06776848|BIOLOGICAL|biological monitoring|"The blood level of lithium will be monitored by regular blood tests~\- every 4 days until a targeted blood level is obtained"
223401730|NCT03834155|OTHER|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application.
223401731|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application.
223401732|NCT03834155|OTHER|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages.
223401733|NCT03834155|OTHER|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, plus encouraging nudge messages.
223401734|NCT05372640|DRUG|Abemaciclib|Given PO
223401735|NCT05372640|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223401736|NCT05372640|PROCEDURE|Biopsy Procedure|Undergo biopsy
223401737|NCT05372640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223401738|NCT05372640|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging evaluation
223401739|NCT04783428|OTHER|No intervention|Access to any treatment is through authorized commercial use and not as part of this DMP
223401740|NCT05542381|DRUG|Loteprednol Etabonate Ophthalmic Gel [Lotemax]|Loteprednol (ophthalmic corticosteroid) will be stored in the clinic according to the instructions on the package. The vial will be stored upright between 15°-25°C (59°-77°F). In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
223401741|NCT05542381|OTHER|Refresh Lubricant Eye Drops [Artificial Tears]|REFRESH® Brand Lubricant Eye Drops are artificial tears. In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
223553206|NCT04900246|DEVICE|Assessment of the iTero Element 5D scan|For scanning, the iTero 5D (Align Technology) equipment featuring NIRI Technology will be used. The Infrared Imaging Technology (NIRI) is a diagnostic tool that allows the detection of interproximal and occlusal caries in several stages, from the initial enamel caries to lesions in the amelo-dentin junction, without the use of ionizing radiation. Infrared is the region of the electromagnetic spectrum between 0.7 and 2.0 micrometers (µm). The iTero Element 5D imaging system uses wavelength light (= 850 nm) in an electromagnetic spectrum that, in interaction with the hard tooth tissue, provides additional data on its structure.
223553207|NCT01369472|DRUG|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
223401742|NCT05866094|BEHAVIORAL|Nutritional Intervention|"Nutrition training will be provided to home care staff to deliver the intervention via the participating Home Care Providers from two localities (South and North of England).~This phase will involve identification of people with dementia on their caseload, preliminary assessment of potential impact via collection of quantitative data at baseline (pre-intervention), and at 4 months follow-up (4 months after the first visit by trained home care workers, following baseline).~A process evaluation will be conducted to gather data on intervention fidelity and implementation (quantitative and qualitative)."
223401743|NCT04219254|DRUG|BI1206|"BI-1206 administrated either IV or SC every third week. Pembrolizumab 200mg administered IV every third week as a fixed dose will be used in Phase 1 and IIa.~The mTPI2 Design will be used for both the IV and SC cohorts. ivRP2D and scRP2D to be used in Phase"
224131887|NCT06358937|DEVICE|Laser Assisted New Attachment Procedure using diode laser|"Diode laser (Biolase) with 940 nm wavelength, a thin flexible fiber-optic cable 300 μm attached with a power average set at 0.5-1.5 watt will be used.~The first pass laser troughing is done using a thin flexible fiber-optic cable 300 μm placed parallel to the root surface, attached with a power average set at 0.5-1 watt, in continuous mode. Ultrasonic scaler will be then used to remove calculus which present on the root surface. The second pass is carried out with 1-1.5 watt power in continuous mode, 10-30 seconds for each tooth, and, to improve the ability to generate a fibrin clot. The fibrin clot is then compressed in order to enhance the healing"
223401744|NCT05681039|DRUG|Tiragolumab|Given by IV (vein)
223401745|NCT05681039|DRUG|Atezolizumab|Given by IV (vein)
223401746|NCT05681039|BEHAVIORAL|Standard of Care|after care from surgery
223401747|NCT05681039|BEHAVIORAL|Questionnaires|Quality of life
223553208|NCT05619094|OTHER|Corrective exercise program|"Strengthening exercises for deep cervical flexor muscles and shoulder retractors.~Stretching exercises for cervical extensors and pectoral muscles."
223553209|NCT00003321|PROCEDURE|psychosocial assessment and care|
223553210|NCT00003321|PROCEDURE|quality-of-life assessment|
223553211|NCT04467229|BEHAVIORAL|Focus group|5 to 10 adolescents will participate in a discussion group lead by a paediatrician and a psychologist from the Centre de la Douleur de Trousseau. Two groups will be organized, the length of the group discussion being one hour. These focus groups will explore the adolescents' perception of the questionnaire and of different elements of the screening. The group will undergo full transcription. The verbatim will be anonymous and will be analysed through qualitative methods.
223734582|NCT05681455|DEVICE|Neuromodulation NESA NXSIGNAL® device|"Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®.~The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire.~The directional electrode will be placed in the cervical area at the superficial level between C6 and C7."
223734583|NCT04528979|OTHER|BioRoot RCS® root canal sealer|Root canal obturation with guttapercha and BioRoot RCS® root canal sealer
223734584|NCT04528979|OTHER|AH Plus® root canal sealer|Root canal obturation with guttapercha and AH Plus® root canal sealer
224131888|NCT06358937|PROCEDURE|Scaling and Root Planing using ultrasonic and curettes|Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
224131889|NCT02860637|OTHER|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
224131890|NCT03809221|DRUG|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
223734585|NCT03208842|RADIATION|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
223734586|NCT00385879|BEHAVIORAL|Case management|
224131891|NCT05352906|DIAGNOSTIC_TEST|Intraocular pressure|Measurements of intraocular pressure in millimeter mercury (mmHg).
223401748|NCT05681039|RADIATION|Cisplatin|Given by IV (vein)
223401749|NCT05681039|RADIATION|Carboplatin|Given by IV (vein)
223401750|NCT06242080|BEHAVIORAL|Mindfulness|Mindfulness meditation has been described as a behavioral technique involving the intentional self-regulation of attention to present-moment experience, combined with release of cognitive fixation on thoughts (whether simple images or complex story lines) regarding the past or future. Through training in mindfulness, individuals learn to evoke and sustain a non-judgmental state of present-moment awareness.
223401751|NCT06015529|DIAGNOSTIC_TEST|4PEPS strategy|"Physicians of the participating centers in the intervention group will have the recommendation to apply the 4PEPS strategy. Using 12 variables, 4PEPS defines four levels of CP that rule out a PE, namely~1. based only on clinical data (very low CP: PEPS \< 0),~2. based on a D-dimer level \< 1000 μg/L (low CP: PEPS ≥ 0 and \< 5),~3. based on a D-dimer level with an age-adjusted cut-off value (moderate CP: PEPS ≥ 5 and \<12), or~4. the diagnosis cannot reliably be ruled out based on a D-dimer test (high CP: PEPS ≥ 12)"
223401752|NCT05673200|PROCEDURE|Biopsy Procedure|Undergo biopsy
223401753|NCT05673200|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223553212|NCT02833584|DRUG|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
223401754|NCT05673200|PROCEDURE|Computed Tomography|Undergo CT
223401755|NCT05673200|DRUG|Decitabine and Cedazuridine|Given PO
223401756|NCT05673200|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223734587|NCT00674661|DRUG|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
223401757|NCT05673200|DRUG|Paclitaxel|Given IV
223401758|NCT05673200|BIOLOGICAL|Pembrolizumab|Given IV
223734588|NCT00674661|DEVICE|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
223734589|NCT01028365|OTHER|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
224021778|NCT02738736|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
224021779|NCT00128076|PROCEDURE|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
224021780|NCT00128076|PROCEDURE|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
224021781|NCT00666523|DIETARY_SUPPLEMENT|phytalgic|3/day
224021782|NCT00666523|DIETARY_SUPPLEMENT|placebo|3/Day
223553213|NCT02833584|DRUG|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
223553214|NCT04984395|DIAGNOSTIC_TEST|Post-treatment CT-guided bone marrow biopsy|At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.
224021783|NCT01491672|DRUG|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
224021784|NCT02391272|DRUG|rhTPO|
224021785|NCT06108882|OTHER|Experimental: Manual Ischemic Compression with Strain Counter Strain technique|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
223401759|NCT05881759|BEHAVIORAL|Revised ESBA|Four intervention site staff will implement the ESBA-FFYF feeding curriculum in classes using standardized implementation protocols. Two of the four intervention sites will also participate in the Food Rx program. The control group sites will receive the existing ESBA curriculum. All program materials will be available in English and Spanish. Study participation will be maintained via weekly phone calls/text messaging by the Extension staff. For the online feeding practices content, participants will receive messages to visit the project website and watch the videos, participate in online activities, and engage in facilitated online discussions. For the Food Rx arm, participants will receive a 'Food Rx' card for bi-weekly redemption of \~30 lbs of fresh produce, plus whole grains, lean protein and low-fat dairy at a co-located Houston Food Bank food pantry. The prescription will be eligible for redemption every two weeks for 3 months, for a total of 6 redemptions.
223553215|NCT01519544|DRUG|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
223553216|NCT01519544|DRUG|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
223553217|NCT03357029|DEVICE|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
223553218|NCT03357029|DEVICE|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
223553219|NCT04593186|PROCEDURE|Trans-oral magnifying endoscopy with NBI|"Endoscopic procedures would be performed by endoscopists with expertise on performing magnifying NBI endoscopy. Topical local anaesthetic will be applied to the oropharynx and nasopharynx. In addition, intravenous sedation by use of Midazolam and Fentanyl would be given. Endoscopes with magnification and NBI function would be used (GF-H290Z, Olympus Medical Corporations, Tokyo, Japan). A soft black hood would be attached to the tip of the endoscope for better focal length adjustment.~Upon insertion through a mouthpiece, the scope will then be retroflexed into the nasopharynx and the lateral walls into the Fossa of Rosenmuller and the posterior nasopharyngeal wall will be systematically examined with white light and NBI. Target suspicious areas would be examined by use of magnification with the power up to 80X. Biopsy would be taken if suspicious lesion is identified during the procedure."
223553220|NCT05466136|BEHAVIORAL|Mental fatigue condition|In mental fatigue condition, the mental fatigue manipulation will use a modified Stroop task with complete incongruent trials, which is wildly used to induce a mentally fatigued state in previous studies. The Stroop task included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), the color of the word will paint inconsistent with the semantic meaning of the word (e.g., red word printed in green). The task consisted of five 6-minute blocks and 1080 incongruent trials for each block. The total duration will be 30-min.
223734590|NCT06175403|DRUG|Niacin|Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
223734591|NCT01968668|DRUG|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
223734592|NCT01968668|DRUG|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
223734593|NCT01968668|DRUG|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
223734594|NCT01968668|DRUG|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
223734595|NCT01968668|DRUG|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
223734596|NCT01968668|DRUG|Placebo|Placebo tablet once daily in the morning
223401760|NCT01176578|OTHER|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
223734597|NCT01968668|DRUG|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
223734598|NCT01968668|DRUG|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
223401761|NCT05738174|DEVICE|high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold
223734599|NCT00614315|DEVICE|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
223734600|NCT03108027|DRUG|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
223734601|NCT03108027|DRUG|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
223734602|NCT03108027|DRUG|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
223734603|NCT04777695|OTHER|Decibel Monitor|Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
223734604|NCT02426892|BIOLOGICAL|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
223734605|NCT02426892|DRUG|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
223734606|NCT04967157|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose
223734607|NCT04967157|DIETARY_SUPPLEMENT|Citicoline supplement|Cognizin ®
224021786|NCT06108882|OTHER|Active Comparator: Manual Ischemic Compression|The duration of intervention will be 6 weeks, 3 sessions a week, a total of 18 sessions will be given to the study participants. Each session will last for 30 to 45 minutes.
224021787|NCT02550470|DEVICE|Carbon Dioxide Absorbents|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
224021788|NCT02550470|DEVICE|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
223401762|NCT05738174|DEVICE|sham high-dose accelerated intermittent theta burst stimulation|1200 pulses of iTBS per session with five sessions per day applied at five days (Monday-Friday) with 120% resting motor threshold with angled coil
223401763|NCT05452642|BEHAVIORAL|DASH diet|Participants in this arm will be taught a DASH diet plus psychological skills to support dietary adherence.
223401764|NCT05452642|BEHAVIORAL|Very low-carbohydrate diet|Participants in this arm will be taught a very low-carbohydrate diet plus psychological skills to support dietary adherence.
223401765|NCT04857372|DRUG|IAG933|Capsule
223734608|NCT06397105|BEHAVIORAL|Problem Management Plus|"Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy will comprise a digital support program that participants can access via the internet."
223734609|NCT05426226|DEVICE|laser acupuncture|using laser acupuncture device on sleep acupoints during sleep
223734610|NCT05426226|DEVICE|sham device|using sham device on sleep acupoints during sleep
223734611|NCT04447079|BEHAVIORAL|Assertive Community Treatment (ACT)|"Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction"
223734612|NCT05922787|OTHER|Reiki|In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
223734613|NCT01002469|OTHER|sodium [1-13C] acetate|
223734614|NCT02382679|DIETARY_SUPPLEMENT|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
223734615|NCT02382679|DIETARY_SUPPLEMENT|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
223734616|NCT05405205|DIETARY_SUPPLEMENT|synbiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, acacia gum (gum arabic), maltodextrin, sucralose and flavour twice a day resolved in drinking water
223734617|NCT05405205|DIETARY_SUPPLEMENT|probiotic|Consumption of 6 g powder consisting of the strains Lactobacillus fermentum K7-Lb1, L. fermentum K8- Lb1, L. fermentum K11-Lb3, maltodextrin, sucralose and flavour twice a day resolved in drinking water
223734618|NCT05405205|DIETARY_SUPPLEMENT|placebo|Consumption of 6 g powder containing microcrystalline cellulose, maltodextrin , sucralose and flavour twice a day, resolved in drinking water
224021789|NCT02550470|DRUG|Sevoflurane|
223401766|NCT06437444|BEHAVIORAL|The implementation strategy to encourage the adoption of the Care Pathway|"1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Integration of information and communication tools into electronic health records to facilitate the recording and the standardized implementation of recommended practice.~3. Audit \& Feedback (A\&F) data reports, sent monthly, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~4. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~5. Distribution of reminder posters in paediatrics consultations, PEDs and health centers."
223401767|NCT04660344|DRUG|Atezolizumab|ctDNA positive participants will receive 1680 mg intravenously every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
223401768|NCT04660344|OTHER|Placebo|ctDNA positive participants will receive placebo intravenously Q4W on Day 1 of each 28-day cycle
223401769|NCT04660344|DEVICE|Signatera|Signatera will be used to evaluate whether circulating tumor DNA (ctDNA) is detected during serial monitoring of peripheral blood samples for participants enrolled in surveillance. Participants with a ctDNA positive result will be screened for inclusion in the treatment phase. Participants who remain ctDNA negative at 12 months from the date of cystectomy will not be randomized to treatment and will enter follow-up.
223401770|NCT04971980|DRUG|hUC-MSC infusion (BC-U001)|The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
223401771|NCT05282394|PROCEDURE|Abdominal massage|abdominal massage
223401772|NCT05282394|OTHER|Reading|guidance given to parents about reading with baby
223734619|NCT02608749|BEHAVIORAL|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
223734620|NCT02608749|BEHAVIORAL|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
224021790|NCT03244085|DRUG|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
224021791|NCT06176677|DEVICE|Videolaryngoscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
224021792|NCT06176677|DEVICE|Boroscope|We set as endpoint the time from insertion of each laryngoscope through the mouth to complete visualization of the glottis (T1) and the time to complete intubation manoeuvre(T2)
224021793|NCT05680064|BEHAVIORAL|Tongue, lip, chin exercise group|In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
223401773|NCT05104736|DRUG|PT-112|PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle,
223401774|NCT06955221|PROCEDURE|Ultrasound-guided aspiration and alcohol sclerotherapy|Ultrasound-guided puncture and alcohol sclerotherapy
223401775|NCT06226610|DRUG|Dupilumab|injection every two weeks while on study
223401776|NCT06226610|OTHER|Placebo|injection every two weeks while on study
223553221|NCT05466136|BEHAVIORAL|Control condition|Similar to mental fatigue conditions, the modified Stroop task with complete congruent trials will be used, The Stroop task also included four colored words presented in traditional Chinese (i.e., red, green, blue, and yellow), but the color of the word will paint consistent with the semantic meaning of the word (e.g., red word printed in red) in order to set up the match condition of relative less cognitive demanding for participants. Same with the mental fatigue condition, the task consisted of five 6-minute blocks and 1080 congruent trials for each block. The total duration will be 30-min.
223553222|NCT03774043|OTHER|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
223734621|NCT02608749|BEHAVIORAL|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
223401777|NCT06833970|OTHER|Colgate use|An evaluation of Colgate total toothpaste currently in use will be provided.
223401778|NCT06833970|OTHER|Curaprox use|An evaluation of Curaprox toothpaste currently in use will be provided.
223401779|NCT06833970|OTHER|ROCS use|An evaluation of ROCS toothpaste currently in use will be provided.
223401780|NCT06833970|DEVICE|Fixed orthodontic treatment|For standard fixed orthodontic treatment, orthodontic brackets and mechanics will be applied.
223401781|NCT06064929|DRUG|Felzartamab|Administered IV
224021794|NCT04657419|OTHER|survey|"Self-questionnaires will be completed by the participants :~* General health and mental health~* Fatigue~* Burn-Out~* Sleepiness~* Sleep hygiene~* Symptoms of COVID"
224021795|NCT04130529|BEHAVIORAL|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
223401782|NCT05510128|OTHER|Pharmacist management|"When a patient comes to the pharmacy with signs of urinary burning, the following will follow:~* Completion of the acute cystitis symptoms score (ACSS) questionnaire.~* Measure the temperature.~* Perform a urine dipstick.~If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made."
223734622|NCT05548842|DIETARY_SUPPLEMENT|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill|The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks
223734623|NCT05548842|DIETARY_SUPPLEMENT|Placebo group|Placebo 1,000 mg/day for 4 weeks
223734624|NCT01737788|PROCEDURE|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
223734625|NCT00098085|BIOLOGICAL|HSPPC-96|
223734626|NCT04688710|BEHAVIORAL|Self-Hypnosis (HYP)|"Self-Hypnosis (HYP) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn new strategies for influencing fatigue and its effects on their lives. The Self-Hypnosis recordings will start with a relaxation hypnotic induction (e.g., Notice how with each breath, you are feeling more and more relaxed …) followed by hypnotic suggestions (e.g., for experiencing more energy, improved sleep, more comfort or less pain, etc.). The goal of Self-Hypnosis is to change participant's experiences. To the extent that participants respond to the suggestions, participants would then get more control over their feelings of energy, sleep quality, and comfort levels."
223734627|NCT04688710|BEHAVIORAL|Mindfulness Meditation (MM)|"Mindfulness Meditation (MM) teaches skills people with MS can use to effectively self-manage symptoms related to fatigue. Recordings are designed to help participants learn about a new way to live with chronic fatigue and new ways to relate to how fatigue may influence their thoughts, feelings, and behavior. The mindfulness techniques train the mind to non-judgmentally observe experience (e.g., symptoms of fatigue or pain, etc.) on a moment-to-moment basis, with an attitude of acceptance. The goal of Mindfulness Meditation is not to alter experiences, but rather to change how someone responds to their experiences. With practice, automatic, kneejerk reactions to symptoms are replaced with mindful choices about how best to respond to symptoms. This will lighten the load of living with the symptoms, moving participants in the valued direction of their choosing."
223734628|NCT05991076|OTHER|Latin Dance|The Activate Bailando class is a dance-focused exercise class that is offered once per week for one hour. The program has been developed by dance educators in the Madison area.
223734629|NCT03499223|DRUG|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
223734630|NCT03499223|DRUG|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
223734631|NCT03499223|DRUG|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
223401783|NCT01015417|DRUG|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
223401784|NCT01015417|OTHER|No medication|no postoperative antibiotics
223401785|NCT04829136|DIETARY_SUPPLEMENT|Kate Farms 1.0|Given enteral nutrition via nasoenteric feeding
223401786|NCT04829136|DIETARY_SUPPLEMENT|Standard of Care Nutritional Support|Given standard of care, which may be parenteral nutrition
223401787|NCT04829136|OTHER|Survey Administration|Ancillary studies
223401788|NCT04829136|DIETARY_SUPPLEMENT|Dietary Supplement|Receive fiber supplementation orally or enterally
223401789|NCT04829136|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
223401790|NCT04829136|OTHER|Electronic Health Record Review|Ancillary studies
223401791|NCT04829136|OTHER|Fiber and Dietary Assessments|Ancillary studies
223401792|NCT02908061|PROCEDURE|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
223401793|NCT02908061|PROCEDURE|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
223401794|NCT05590988|OTHER|Tablet-based training|"Each task is performed for one minute, followed by a 2-minute break. After the task has been performed three times, there is a 5-minute break. The training block is then carried out twice more. This means that three blocks are carried out for each therapy unit."
223401795|NCT05590988|OTHER|ergotherapeutic training|A task is performed for one minute at a time, followed by a 2-minute break. Once three rounds have been completed, there is a 5-minute break. As in the intervention group, there are a total of three training blocks.
223401796|NCT04559139|DRUG|Cisplatin|Given IV
223401797|NCT04559139|DRUG|Gemcitabine Hydrochloride|Given IV
223401798|NCT04559139|PROCEDURE|Lymphadenectomy|Undergo portal lymphadenectomy
223401799|NCT04559139|PROCEDURE|Partial Hepatectomy|Undergo partial hepatectomy
223401800|NCT04763915|OTHER|Correlative Studies (Survey)|Administer surveys
223401801|NCT04763915|OTHER|Correlative Studies (Interview)|In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
223734632|NCT04498611|DIAGNOSTIC_TEST|contrast-enhanced breast MRI|Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
223734633|NCT00268996|DRUG|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
223734634|NCT00268996|DRUG|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
223734635|NCT03681392|DIETARY_SUPPLEMENT|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
223734636|NCT05073991|PROCEDURE|Lung surgery|Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
223734637|NCT05073991|PROCEDURE|Open aortic surgery|Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
223734638|NCT05073991|PROCEDURE|TEVAR|Patients underwent TEVAR.
223734639|NCT05073991|PROCEDURE|EVAR|Patients underwent EVAR.
223401802|NCT04763915|BEHAVIORAL|GeneSHARE|Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.
223734640|NCT03448822|PROCEDURE|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
223734641|NCT00679146|DRUG|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
223734642|NCT00679146|DRUG|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
223734643|NCT05230810|DRUG|Alpelisib|Orally twice a day
223734644|NCT05230810|DRUG|Tucatinib|Orally once a day
223734645|NCT05230810|DRUG|Fulvestrant|"500 mg intramuscularly into the buttocks slowly~\*Fulvestrant will be administered only in patients with HR+/HER2+ metastatic breast cancer"
223734646|NCT01096225|BIOLOGICAL|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
223734647|NCT05356247|BEHAVIORAL|Lausanne Trialogue Play Brief|The brief treatment program will consist of an LTP family assessment with video feedback to caregivers to address family interaction patterns and child mental health. Families will participate in four sessions conducted online using the Zoom for Healthcare platform. In the first session, families will engage in a family assessment in different groupings that will be recoded on zoom and used later in the treatment. In the second session, taking place one week later, families will take part in a mini assessment to learn more about the difficulties of the child. In the third session, the clinical team will share videos of the family assessment to the parents and discuss the families strengths, concerns, and goals for moving forward. In the fourth session, taking place one month after the third session, families will participate in a check-in session, debriefing the family assessment.
223734648|NCT01037608|DRUG|Sativex(Registered Trademark)|
224138774|NCT06166355|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
223401803|NCT04763915|BEHAVIORAL|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
223401804|NCT04763915|BEHAVIORAL|Standard-of-care & Adaptive Intervention|Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.
223401805|NCT04763915|OTHER|Access to Education Materials|Receive access to VUS educational materials
223401806|NCT05679674|RADIATION|Stereotactic Ablative Body Radiation (SABR)|50 Gy in 5 fractions, once per day for 5 days
223401807|NCT05679674|DEVICE|Tumor Treating Fields (TTF)|Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
223401808|NCT05053191|BEHAVIORAL|Partnership, Assessment, Care and Transition training intervention|Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
223734649|NCT01037608|DRUG|THC|
223734650|NCT04902456|PROCEDURE|Power chain and Crimpable hook fro En-masse Retraction|"Retraction will start on a 0.017x0.025 stainless steel wire using elastomeric chain ( for applied will be 212 g per side ) extending between the cripmable hooks and the miniscrew"
223734651|NCT04902456|PROCEDURE|T-loop|closing retraction T-loops will be fabricated using 0.017x0.025 TMA wire. The loop will be positioned halfway the extraction space and the canine.
223734652|NCT01986660|DRUG|Ibuprofen Cream (SST-0225)|
223734653|NCT01202305|PROCEDURE|Lymph node biopsy|Inguinal lymph node biopsy
223734654|NCT04735380|DEVICE|TCM-5 Flex monitor connected to a Sensor 84 (Radiometer Medical Aps, Brønshøj, Denmark)|Patients undergo 2-3 hrs of observation while wearing the device.
223734655|NCT00483808|DEVICE|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
224021796|NCT04130529|OTHER|Sleep lectures|Lectures on the topic of sleep.
224021797|NCT01902056|PROCEDURE|One layer allograft|The acellular dermal matrix was placed on the facial surface.
224021798|NCT01902056|PROCEDURE|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
224021799|NCT01690312|DIETARY_SUPPLEMENT|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil \[620 mg of DHA and 150 mg of EPA\], providing a total daily dosage of 4000 mg of fish oil \[3080 mg of DHA+EPA\].
224021800|NCT01690312|DIETARY_SUPPLEMENT|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
224021801|NCT03575767|OTHER|Myeloablative Hematopoietic Stem Cell Transplantation|Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.
224138775|NCT06166355|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
224138776|NCT06166355|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
223401809|NCT06148246|BEHAVIORAL|Family Fit Condition|Dyads in the Family Fit condition will use the Family Fit app and a Fitbit for 12 weeks, working to increase their moderate- to vigorous-intensity physical activity.
223401810|NCT05067868|BIOLOGICAL|Replagal|Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
223401811|NCT04362527|DRUG|Milrinone 1 Mg/mL Solution for Injection|Blinding procedure will be set up for the administration of the treatment
223401812|NCT04362527|DRUG|Saline solution for injection|Blinding procedure will be set up for the administration of the treatment
223401813|NCT06637293|DEVICE|DeepECG plateform diagnosis & recommendations|EchoNeXT\& ECG-AI algorithm
224021802|NCT03939455|OTHER|Mobile Augmented Screening tool|Tablet-based intervention
223734656|NCT02913391|OTHER|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
223734657|NCT02913391|OTHER|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
224021803|NCT03507374|DRUG|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
224021804|NCT03507374|DRUG|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
223734658|NCT00784992|PROCEDURE|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
223401814|NCT03425838|DRUG|CDK 4/6 inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
223553223|NCT03774043|OTHER|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
223553224|NCT05912894|PROCEDURE|Videolaparoscopic cholecystectomy|Evaluation of Rouvière's Sulcus Anatomical Variation.
223553225|NCT04751994|DIETARY_SUPPLEMENT|Iron drops/Ferrous sulphate|participant will consume daily drops of iron
223553226|NCT04751994|DIETARY_SUPPLEMENT|Placebo drops|Participants will consume daily drops of placebo
223553227|NCT02119429|DIETARY_SUPPLEMENT|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
224021805|NCT01669304|DRUG|Verapamil|
224021806|NCT01669304|DRUG|Sertraline|
224021807|NCT06115551|COMBINATION_PRODUCT|Fasting Mimicking Diet|FMD is a 5-day low calorie fasting-mimicking diet.
224021808|NCT00473941|BEHAVIORAL|Expressive writing|Behavioral intervention using writing about cancer to improve quality of life outcomes
223401815|NCT03425838|DRUG|Non-Steroidal Aromatase Inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
223553228|NCT02119429|DIETARY_SUPPLEMENT|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
223553229|NCT01455922|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
223553230|NCT01455922|DRUG|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
223553231|NCT05962645|DRUG|Vapendavir|This study will measure and compare how VPV is absorbed in the blood, broken down in the body and eliminated when two 250 mg VPV tablets (500mg) are given in three different ways: A single dose, once a day, under fasted conditions (without any food); twice a day, for 7 days; and a single dose, once a day under fed conditions, after consuming a high-fat meal.
223553232|NCT01576939|RADIATION|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to \< 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
223553233|NCT02791035|DRUG|Oral administration of Ipragliflozin|
224021809|NCT03310268|OTHER|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
224021810|NCT03310268|OTHER|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
224021811|NCT03310268|OTHER|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
224021812|NCT00679237|BEHAVIORAL|smoking cessation|NRT and varenicline
224021813|NCT00679237|DRUG|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
224021814|NCT00679237|DRUG|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
224021815|NCT00679237|BEHAVIORAL|training|daily walking
224021816|NCT00679237|BIOLOGICAL|influenza vaccine|vaccine (FLuarix, Influvac etc)
224021817|NCT00679237|DRUG|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
224021818|NCT00679237|BEHAVIORAL|weight reduction|diet tips
224021819|NCT02564354|DRUG|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
224138777|NCT03375905|DEVICE|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
223734659|NCT02140229|DEVICE|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
223734660|NCT02140229|OTHER|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
223401816|NCT03425838|DRUG|Fulvestrant|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
223401817|NCT06058585|DRUG|Finerenone|Finerenone 10mg or 20mg tablets, oral, once daily
223401818|NCT06058585|DRUG|Placebo Finerenone|Finerenone matched placebo tablets, oral, once daily
223401819|NCT02511028|DRUG|Ferumoxytol|510mg (17mL) IV
223401820|NCT06392841|DRUG|Androgen Deprivation Therapy (ADT)|Medical castration per ADT with GnRH agonist or antagonist (or surgical castration per orchiectomy)
223401821|NCT06392841|DRUG|Niraparib/Abiraterone Acetate DAT|Niraparib 200 mg/ Abiraterone acetate 1000 mg orally
223401822|NCT06392841|DRUG|Abiraterone Acetate|1000 mg orally
223734661|NCT02140229|OTHER|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
223734662|NCT06166849|DEVICE|Experimental Fluoride Application|The two-step system, consisting of Component A and Component B, will be applied once on the white spot lesions
223734663|NCT03035708|DRUG|Varenicline|1 mg BID
223734664|NCT03035708|DRUG|Placebo oral capsule|1 mg BID
224021820|NCT04417946|BEHAVIORAL|PrEP messages|The peer leaders and the study staff will post PrEP related health messages
224021821|NCT04417946|BEHAVIORAL|Heath messages|The peer leaders and study staff will post general health messages that are not related to sexual health
223401823|NCT06392841|DRUG|Prednisone|5 mg orally
223401824|NCT06392841|DRUG|Docetaxel|75 mg/m2 IV
223401825|NCT04327063|DRUG|Saline|Injection of the solution of Saline not exceeding 30 mL of maximal volume.
223401826|NCT04327063|DRUG|Ropivacaine|Dilution of Ropivacaine 7.5 mg/ml to 5 mg/ml not to exceed 3 mg/kg of maximal dose and 30 ml of maximal volume
223401827|NCT05926661|OTHER|NCC Support Toolkit|"Pre-discharge intervention-~* Set expectations for parents/caregivers to spend time bedside and attend rounds~* iPad for the families to use the Nemours App, download education materials and Facetime communication with medical personnel.~* Download Nemours App and teach them how to use it~* Education materials- to ease the use of medications, Oxygen and feeding~* Assistance with transportation, child care, parental work schedule for discharge teaching~Post Discharge intervention (Day 1-2):~• Video/Facetime call with the family to check equipment, home environment and answer questions about medications and formula~Post discharge intervention (Day 3-7):~• Phone call to the family to ensure transportation for their first follow-up appointment, answer questions about medications, Oxygen and feeding."
223401828|NCT06310746|DRUG|GARP/TGF-β1 monoclonal antibody|It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
223401829|NCT06310746|DRUG|Placebo|It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
223401830|NCT05380531|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
223401831|NCT05433064|DEVICE|Epidural Stimulator|Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
224021822|NCT06071273|OTHER|Group A: online real-time home based exercise using the online platform|"Patients that will be randomly assigned to this group will be exercising at home by providing data of their vital signs during exercise and at rest. To succeed this, they will be provided with the appropriate equipment (e.g., a smart watch able to assess the electrical signs of the heart (i.e., ECG) and heart rate, an automated blood pressure monitor, and an electrical body scale) which will be directly linked to the online platform.~The online real-time supervised home-based exercise program is identical to Group B, the only difference is that it is performed at home. Each session has a duration of 60 minutes consisting of 40 mins of aerobic exercise and 20mins of resistance training. The overall intensity is kept to moderate based on ratings of perceived exertion (i.e., 13-14 in Borg's scale 6-20). The program will last for 6 months with exercise sessions taking place thrice per week."
224021823|NCT06071273|OTHER|Group B: supervised community based exercise intervention|Identical exercise program to Group A, the only difference is that Group performs the supervised exercise in community based health clubs/gyms.
224021824|NCT00706433|DRUG|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
224021825|NCT00706433|OTHER|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
224021826|NCT06026228|DIETARY_SUPPLEMENT|Limosilactobacillus reuteri|"The BioGaia® Gastrus probiotic capsule contains the following components: L. reuteri DSM 17938, L. reuteri ATCC PTA 6475) at 10\^8 CFU\*/day, fully hydrogenated palm oil; ascorbic acid; tangerine flavour and mint flavour.~\*Colony forming Unit"
224021827|NCT06026228|OTHER|Placebo|The placebo capsules have the same external appearance and composition as the BioGaia® Gastrus Limosilactobacillus reuteri probiotic capsule (combination of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475), but without the active ingredient.
224021828|NCT01782118|DIETARY_SUPPLEMENT|Lactobacillus GG|
224021829|NCT04450017|DIAGNOSTIC_TEST|The demographic, clinical, laboratory, and instrumental data|Measurement of the demographic, clinical data, laboratory data, and instrumental data
223401832|NCT06951477|PROCEDURE|Revision Total Knee Arthroplasty|Study participants must be scheduled to receive a revision TKA.
223401833|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 6 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 8 stimuli (the Fully Learned stimuli). Each of the 8 Fully Learned stimuli will be produced 60 times over the 6 training sessions.
223401834|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 1 training session|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During the training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 60 times.
223734665|NCT03779789|DRUG|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index \[ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose\]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
223734666|NCT03779789|DRUG|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
223553234|NCT06531187|OTHER|Evidence-Based Practice (EBP) Teaching|"The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP)."
223553235|NCT04346173|PROCEDURE|furlow z plasty with buccinator myomucosal flap|using furlow palatoplasty technique accompanied with addition of buccinator myomucosal flap for closure of primary unilateral cleft palate
223553236|NCT00207623|BEHAVIORAL|Arthritis Basics for Change Education program|
223553237|NCT04022525|DRUG|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
223553238|NCT01814046|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
223553239|NCT01814046|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
223553240|NCT01814046|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
223553241|NCT01814046|BIOLOGICAL|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
223553242|NCT00979966|DRUG|Temsirolimus|25 mg intravenously, once weekly infusion
223734667|NCT03779789|DRUG|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
223734668|NCT03779789|DRUG|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
223734669|NCT03779789|DRUG|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
223734670|NCT03779789|DRUG|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
223734671|NCT03779789|DRUG|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
223734672|NCT00869531|OTHER|wholegrain|wholegrain wheat vs. refined wheat products
223734673|NCT00869531|OTHER|refined wheat|refined wheat products
223734674|NCT06478160|DEVICE|Closed-Blood Sampling Devices|blood collection with Closed-Blood Sampling System (CBSD)
223734675|NCT06478160|OTHER|Waste discard volume|Blood collection without CBSD, usual practice, need to waste discard volume
223734676|NCT01637467|OTHER|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
223734677|NCT01637467|OTHER|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
223734678|NCT00568750|DRUG|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
224021830|NCT03590405|PROCEDURE|uterus transplantation surgery and IVF|IVF before surgery living donor uterus transplantation ET
223734679|NCT05404919|DRUG|Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide|Anti-hepatitis B medications
223734680|NCT02597322|DRUG|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
223734681|NCT03342287|OTHER|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
224021831|NCT02698605|DEVICE|Usability test study of the MirrorPath|"The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch."
224021832|NCT01850732|OTHER|Ultrasound of aorta|
223734682|NCT03342287|OTHER|cognitive evaluation|Administration of online cognitive battery
223734683|NCT03342287|OTHER|Blood|Measurement of cytokines/inflammatory biomarkers
223734684|NCT03342287|OTHER|Fecal sample|Measurement of the gut microbiome
224297306|NCT04845074|OTHER|Exercise-group|The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
224297307|NCT03174951|DRUG|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
223401835|NCT05437159|BEHAVIORAL|Learning of novel multisyllabic nonwords|Each trial of the training sessions (total of 6 training sessions over 2 days) will follow a simple reaction time protocol in which a nonword stimulus formed by 2 or 3 syllables that are legal in American English is presented auditorily to the participant, who then produces the stimulus as quickly and accurately as possible. During training, each participant will repeatedly produce 6 nonwords, with each nonword produced a total of 60 times over the 6 training sessions.
223734685|NCT01435109|BEHAVIORAL|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
223734686|NCT01435109|BEHAVIORAL|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
223734687|NCT01435109|BEHAVIORAL|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
223734688|NCT00451321|DRUG|Otelixizumab|Infusion
223734689|NCT00114465|DRUG|VSL#3|VSL#3 1 sachet twice a day
223734690|NCT00114465|OTHER|Placebo|Placebo 1 sachel twice a day
223734691|NCT05173740|OTHER|Individually tailored rehabilitation intervention|Individually tailored rehabilitation intervention
223734692|NCT05173740|OTHER|Usual care|Usual care
224297308|NCT04626453|BEHAVIORAL|2-month home moderate-intensity exercise|The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
224297309|NCT06520579|BEHAVIORAL|Proactive pharyngeal-laryngeal Exercise Program|This program consists of daily proactive pharyngeal-laryngeal exercises and weekly sessions with a speech-language pathologist post surgery. One week prior to surgery participants will begin daily proactive pharyngeal-laryngeal exercises and continue these daily exercises for 6 weeks post surgery. Beginning approximately one week after surgery, participants will meet with the speech-language pathologist. Sessions will occur weekly, for approximately 6 weeks, and will last approximately 45 minutes.
223734693|NCT00641862|DIETARY_SUPPLEMENT|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
223734694|NCT00641862|OTHER|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
223734695|NCT06377956|OTHER|Observation without intervention|Observation of gut length, food intake, fecal and urine calories, body composition, microbiota, metabolic rate, metabolomics.
224021833|NCT05288153|DRUG|Metformin|Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
224021834|NCT05288153|DRUG|Folate|Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
224297310|NCT06520579|DIETARY_SUPPLEMENT|Premier Protein Clear ® High Protein|Premier Protein Clear ® High Protein (20 grams of protein and 90 calories per 16.9 oz. drink) 1 drink daily for 7 weeks.
223401836|NCT05437159|DEVICE|Anodal tDCS|Continuous anodal tDCS is delivered to a speech processing area of the brain during a 19-minute speech training session. The tDCS stimulation will ramp up to its maximum value (2 milliamperes) in the minute prior to the training session and maintained at that level throughout the session.
223401837|NCT05437159|DEVICE|Sham tDCS|Sham tDCS stimulation is delivered to a speech processing area of the brain during a 19-minute speech training session. During the minute prior to training onset, the tDCS stimulator is ramped up to 2 milliamperes and then back down to 0.
223734696|NCT03933202|DRUG|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
224021835|NCT05867316|BEHAVIORAL|Unified Protocol|Unified Protocol based treatment, modified for use in brief treatment on inpatient units
224021836|NCT05960565|DRUG|Glucagon|A micro-dose of glucagon is added exactly at the same site as insulin is injected.
223401838|NCT05437159|BEHAVIORAL|Learning of non-native phoneme combinations: 8 training sessions|Each trial of the training sessions will follow a simple reaction time protocol in which a nonsense syllable containing novel consonant clusters (e.g., GDADK) is produced as quickly and accurately as possible after an auditory prompt presented via earphones. During each training session, the participant will practice producing a set of 3 stimuli (the Fully Learned stimuli). Each of the 3 Fully Learned stimuli will be produced 120 times over the 8 training sessions.
223401839|NCT05721755|DRUG|Carboplatin|Given IV
223401840|NCT05721755|DRUG|Cisplatin|Given IV
223734697|NCT04797793|DRUG|Adapalene Gel 0.1%|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
224021837|NCT04300998|BEHAVIORAL|Activities of Daily Living/ADLs|7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14
224021838|NCT04300998|BEHAVIORAL|Instrumental Activity of Daily Living|8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.
223734698|NCT04797793|DRUG|Placebo Control|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
224021839|NCT04300998|BEHAVIORAL|Timed Up and Go|Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (\<10 seconds, 10-20 seconds, \>20 seconds)
223734699|NCT04797793|DRUG|Differin® Gel (Adapalene 0.1%, Galderma)|The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
223734700|NCT00811538|PROCEDURE|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
223401841|NCT05721755|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223401842|NCT05721755|DRUG|Fluorouracil|Given IV
223401843|NCT05721755|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223401844|NCT05721755|DRUG|Paclitaxel|Given IV
224021840|NCT04300998|BEHAVIORAL|Cognition|Mini-Cognition test: CDT and 3-word recall
223734701|NCT00811538|PROCEDURE|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
223734702|NCT05451147|DRUG|Chhinnavahni Kashaya Vati along with Agnimantha Kwatha|Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months
223734703|NCT05451147|DRUG|Metformin Hydrochloride|Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
224021841|NCT04300998|BEHAVIORAL|Geriatric Depression Scale|Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of \>/=1 is usually indicative of depression.
224297311|NCT06520579|BEHAVIORAL|Hydration Counseling|Daily hydration goals are based on recommended guidelines for adults, by gender, from The United States National Academy of Medicine (US NAM) and the European Food Safety Authority (ESFA) (\~2.0 L/day for women; \~2.5 L/day for men of fluid intake, accounting for 20% daily fluid intake from food sources). Patients will be required to track via paper log whether they met their hydration goals daily.
224297312|NCT04816630|DEVICE|CBC-Diff Monocyte Volume Width Distribution|MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
224297313|NCT03074396|DEVICE|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
224297314|NCT03074396|DEVICE|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
223401845|NCT05721755|BIOLOGICAL|Pembrolizumab|Given IV
223734704|NCT05479955|OTHER|5 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.
223734705|NCT05479955|OTHER|60 minutes skin to skin contact|Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
223734706|NCT05725850|OTHER|EG (Experimental A. Oleracea extract gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the EG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
223401846|NCT05721755|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223734707|NCT05725850|OTHER|GP (Gel placebo)|Prior to bleaching treatment with 35% hydrogen peroxide, the GP group also received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
224297315|NCT02522403|PROCEDURE|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
224297316|NCT02522403|DEVICE|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
224297317|NCT05568979|BIOLOGICAL|Quadrivalent Influenza Vaccine|Intramuscular or subcutaneous administration
223734708|NCT03577704|DRUG|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
223734709|NCT03577704|DRUG|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
223734710|NCT03577704|DRUG|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
223734711|NCT01528254|DRUG|Placebo of vildagliptin|
223734712|NCT01528254|DRUG|vildagliptin|One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
224297318|NCT05568979|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|Intramuscular administration
224297319|NCT03340064|DRUG|Levetiracetam|levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
224297320|NCT06133803|DRUG|Lovenox|A low-molecular-weight heparin, 40mg daily injection.
224297321|NCT06133803|DRUG|Aspirin|Aspirin 81mg daily tablet.
224297322|NCT06133803|PROCEDURE|Embryo transfer|Embryo transfer
224297323|NCT02151812|DEVICE|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
224297324|NCT02151812|DEVICE|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
224297325|NCT01475006|DRUG|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
224297326|NCT04798365|BEHAVIORAL|Intervention group|medical education and distribution of educations materials
224297327|NCT01369017|DRUG|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
224297328|NCT01369017|DRUG|Placebo|Injection of NS
224297329|NCT06224322|OTHER|Assesment Scale|Caregiving burden will be assessed with Turkish validated scoring tools such as the Zarit scale and the Pediatric Quality of Life Inventory (PEDSQL) Family Impacts module before and after surgery.
224297330|NCT04386174|OTHER|Neurofeedback|Information about activity in pain-related regions of the brain will be shown to participants to determine if receiving this information is helpful in learning different thinking strategies (such as shifting attention, imagery, mantra meditation, etc.) that may help people with SCI change their experience of neuropathic pain.
224297331|NCT00856973|DRUG|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
224297332|NCT00856973|DRUG|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
224297333|NCT00856973|DRUG|Placebo|1 tablet per day for 12 weeks
224297334|NCT03582761|BIOLOGICAL|EV71 vaccine|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
224297335|NCT03257033|DRUG|Gemcitabine|Chemotherapy
224297336|NCT03257033|DRUG|nab-paclitaxel|Chemotherapy
224297337|NCT03257033|DEVICE|RenovoCath|Intra-arterial catheter
224297338|NCT05079386|DEVICE|New Voice Prosthesis|Replacement of the current prosthesis with the experimental device and use the New Voice Prosthesis for the duration of two weeks with the option of leaving the device in situ until replaced for device failure or other reason, with a maximum of 12 months.
224297339|NCT02664363|BIOLOGICAL|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
224297340|NCT02813057|PROCEDURE|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
224297341|NCT02813057|PROCEDURE|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
224297342|NCT00865618|DRUG|Eplerenone 50 mg Tablets Sandoz Inc., USA|
224297343|NCT00865618|DRUG|Inspra 50 mg Tablets GD Searle LLC, USA|
224297344|NCT00409318|DRUG|Etanercept|50 mg SC q week
224297345|NCT00409318|DRUG|Placebo|SC q week
224297346|NCT02431819|DEVICE|contention socks|Patients wear contention socks during 15 days.
224297347|NCT05795179|BEHAVIORAL|Cold-Pressor Task (CPT)|CPT is a physiological stress task in which participants continuously submerge their hand and forearm in ice-water (0-4°C) for 3 minutes.
223401847|NCT05721755|OTHER|Quality-of-Life Assessment|Ancillary studies
223401848|NCT05721755|RADIATION|Radiation Therapy|Undergo radiation therapy
223401849|NCT06557876|PROCEDURE|Pulmonary vein isolation by pulse field ablation|Pulse Field Ablation (PFA) is a non-thermal energy based on high voltage, ultra-short energy pulses applied selectively to cardiomyocytes.
223401850|NCT06557876|PROCEDURE|Pulmonary vein isolation by cryoablation|Cryoablation is a conventional thermal energy, also delivered with a single-shot cryoballoon device.
224297348|NCT05795179|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a psychosocial stressor that requires participants perform a short speech and solve math problems in front of 2 evaluative judges.
223734713|NCT01528254|DRUG|Metformin|Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
223734714|NCT03540966|COMBINATION_PRODUCT|CapulinTM|a kind of camouflage agent
223734715|NCT03540966|OTHER|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
223734716|NCT02408458|DEVICE|MIROMESH®|
224021842|NCT04300998|BEHAVIORAL|Social Support|Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.
224021843|NCT04300998|BEHAVIORAL|Brief Test of Attention|assess selective auditory attention.
224021844|NCT04300998|BEHAVIORAL|Trail Making Test|Assesses visual scanning, graphomotor speed, and set shifting.
224021845|NCT04300998|BEHAVIORAL|Controlled Oral Word Association Test|A timed test of verbal fluency
224021846|NCT04300998|BEHAVIORAL|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.
223401851|NCT06644417|DRUG|TQA3605 tablets plus NAs|TQA3605 tablets is core protein regulator
223734717|NCT05747781|BEHAVIORAL|Pilot Phase: standardized behavioral task|"Pilot Phase:~* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.~* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.~* Ability to drive (UFOV and DVFAT psychophysical tests)."
223734718|NCT05747781|BEHAVIORAL|Validation Phase: standardized behavioral task|"Validation Phase:~* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.~* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.~* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test)."
223734719|NCT02642952|OTHER|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
223734720|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 11
223734721|NCT05497674|DRUG|Rifampin|QD for 10 days
223734722|NCT05497674|DRUG|Rongliflozin|oral administration, single dose on Day 1 and Day 6
223734723|NCT05497674|DRUG|Probenecid|twice a day, for 5 days
223734724|NCT00923598|DRUG|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
223401852|NCT06644417|DRUG|TQA3605 Placebo plus NAs|Placebo without drug substance
223401853|NCT04137757|OTHER|Lower Body Negative Pressure|Lower body negative pressure will be applied.
223401854|NCT04137757|OTHER|Sham Pressure|Noise will be turned on but no pressure will be applied.
223401855|NCT03773770|DRUG|Triheptanoin|Liquid for oral (PO) or enteral tube administration
223734725|NCT00976092|DRUG|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
223734726|NCT00976092|DRUG|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
223734727|NCT00976092|DRUG|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
223734728|NCT00976092|DRUG|Heparin|i.v. bolus of 70-100 IU/kg body weight
223734729|NCT05392998|DEVICE|Cataract surgery with Vivity intraocular lens implantation|Cataract surgery with Vivity intraocular lens implantation
223734730|NCT00149084|DRUG|Lansoprazole, clarithromycin, amoxicillin|
224021847|NCT04300998|OTHER|Blood draw|collection of blood tests
223734731|NCT04694144|DEVICE|telescoping intramedullary nail|All osteogenesis imperfecta patients with lower limb skeletal deformities corrected with multiple corrective osteotomies and insertion of two parts male and female segments of intramedullary telescoping nail
224021848|NCT01236365|DRUG|Atorvastatin|10 or 20 mg daily
224021849|NCT01236365|DRUG|Atorvastatin Placebo|10 or 20 mg daily
223401856|NCT04877691|DRUG|Medi-546|Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.
223401857|NCT04877691|DRUG|Placebo|Solution for injection in aPFS
223401858|NCT03492372|OTHER|Waste tissues are collected at the time of spinal surgery.|This is a single visit study. Waste tissues are collected at the time of spinal surgery.
223401859|NCT00979238|GENETIC|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
223734732|NCT03068481|DRUG|KDT-3594|Oral administration
223734733|NCT03068481|DRUG|Placebo|Oral administration
223734734|NCT02196558|DRUG|E6011|
223734735|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
223734736|NCT00452010|DEVICE|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
223734737|NCT00150982|DRUG|Mechanism of action of alefacept|
223734738|NCT00136617|DRUG|chlordiazepoxide|
223734739|NCT06170723|DRUG|BMS-986368|Specified dose on specified days
223734740|NCT06170723|DRUG|Itraconazole|Specified dose on specified days
223734741|NCT06170723|DRUG|Famotidine|Specified dose on specified days
223734742|NCT05532007|DIETARY_SUPPLEMENT|Peanuts|2-3 ounces of peanuts to replace 20% of total daily energy intake
223734743|NCT05532007|OTHER|Habitual Diet|continue with habitual diet and abstain from eating peanuts
224021850|NCT06079125|PROCEDURE|Posterior fossa decompression with duraplasty|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
224297349|NCT05795179|BEHAVIORAL|Modified Non-Stress CPT|The modified non-stress CPT involves participants continuously submerging their hand and forearm in warm water for 3 minutes.
223734744|NCT02638727|DRUG|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
223401860|NCT00979238|DRUG|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
223734745|NCT02638727|DRUG|placebo|This group treat with placebo dayley
223734746|NCT03725280|PROCEDURE|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
223401861|NCT06377852|DRUG|Palbociclib 125mg|Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
223401862|NCT06377852|DRUG|Ribociclib 600mg|Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)
223401863|NCT06377852|DRUG|Ribociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
223401864|NCT06377852|DRUG|Palbociclib|Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
223401865|NCT05918835|DEVICE|High-frequency repetitive transcranial magnetic stimulation (active rTMS)|HF-rTMS is applied with a figure-of-8 coil using the Magstim TMS System. Participants receive one administration of HF-rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). HF-rTMS is delivered at a frequency of 10 Hz for approximately 37 minutes (3000 total pulses).
224021851|NCT06079125|PROCEDURE|PFDD with tonsillar resection/reduction|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.
223734747|NCT05803005|OTHER|inflammatory marker in autism spectrum disorder|Evaluate some Inflammatory markers \[IL-6, IL-8, TNF\_alpha\] in children with autism spectrum disorder
223734748|NCT01090960|DRUG|GDC-0068|Oral repeating dose
223734749|NCT02947997|DEVICE|OFDI capsule|Imaging of esophagus using OFDI capsule and system
223401866|NCT05918835|DEVICE|Sham repetitive transcranial magnetic stimulation (sham rTMS)|Sham rTMS is applied with a figure-of-8 sham coil using the Magstim TMS System, which is identical to the active coil, replicates the sounds of HF-rTMS, and is designed to mimic sensations of HF-rTMS. Participants receive one administration of sham rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). Sham rTMS is delivered for approximately 37 minutes (3000 total pulses).
223401867|NCT04874454|DIAGNOSTIC_TEST|ultrasound|evaluate the vocal cord movement among the stroke patients
223401868|NCT03298893|DRUG|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
223401869|NCT03298893|DRUG|Cisplatin|40 mg/m2, once a week during radiotherapy
223401870|NCT03298893|RADIATION|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
223401871|NCT06634524|DRUG|Dexmeditomidine|Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
223401872|NCT06634524|DRUG|Normal saline|Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion.
223401873|NCT06636435|DRUG|CBA-1205 Part 1|CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)
223734750|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
223734751|NCT03502408|PROCEDURE|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
224297350|NCT05795179|BEHAVIORAL|Modified Non-Stress TSST|For the modified non-stress TSST, participants are asked to prepare for a speech that they will practice alone to themselves and complete math problems alone on a piece of scrap paper.
223401874|NCT06636435|DRUG|CBA-1205 Part 2|CBA-1205: 20 mg/kg and 30 mg/kg (Intravenous solution)
223734752|NCT03728660|DEVICE|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
224021852|NCT04415723|OTHER|supportive care management programme|nurse-led management programme
224021853|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
224021854|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
224021855|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
223734753|NCT03728660|DEVICE|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
224021856|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
224021857|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
224021858|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
224021859|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
223734754|NCT03553667|DEVICE|Standard group|Use radial arterial line to monitor mean arterial pressure
224021860|NCT00717067|DRUG|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
224021861|NCT00717067|DRUG|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
224021862|NCT00717067|DRUG|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
224297351|NCT05795179|DEVICE|Functional Magnetic Resonance Imaging (fMRI)|Participants will complete the self-control task in the fMRI scanner.
224297352|NCT01432418|OTHER|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
224021863|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
223401875|NCT06636435|DRUG|CBA-1205 Part 3|CBA-1205: 30 mg/kg (Intravenous solution)
224021864|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
224021865|NCT00717067|DRUG|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
224021866|NCT03489473|DIAGNOSTIC_TEST|18F-FES PET CT scan|PET CT scan with estrogen tracer
224021867|NCT00898898|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
224021868|NCT04751708|PROCEDURE|endovascular treatment|For patients randomized to endovascular treatment arm, EVT has to be initiated within 12 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. The endovascular procedures allowed by the steering committee include mechanical thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation, or any combination of above procedures. We recommend applying ADAPT as the first choice of treatment. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.
224021869|NCT04751708|OTHER|best medical management|best medical management
224021870|NCT02808143|BIOLOGICAL|BCG Solution|Given intravesically
224021871|NCT02808143|OTHER|Laboratory Biomarker Analysis|Correlative studies
224021872|NCT02808143|BIOLOGICAL|Pembrolizumab|Given intravesically
224021873|NCT02808143|OTHER|Pharmacological Study|Correlative studies
224021874|NCT04964388|DRUG|GLP-1 receptor agonist|Diabetes medication
224131892|NCT01248130|DRUG|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
224131893|NCT04922788|BIOLOGICAL|Nanocovax|Recombinant Protein spike (s) SARS-CoV-2 and 0,5 mg Aluminum adjuvant
224131894|NCT04922788|BIOLOGICAL|Placebo|0,5 mg Aluminum adjuvant
224131895|NCT05311644|OTHER|Telephone survey|All participants are interviewed by telephone, and are asked to answer a survey.
224131896|NCT04235257|BIOLOGICAL|HPV vaccine|Gardasil 9 Bivalent HPV VLP Vaccine, one-fifth dose Nonavalent HPV VLP Vaccine, one-fifth dose
224131897|NCT05041478|PROCEDURE|Cold Snare Endoscopic mucosal resection with adjuvant snare tip soft coagulation|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare. Following this defect margins are treated with electrocautery to create a rim of ablated tissue.
223401876|NCT06636435|DRUG|CBA-1205 Part 4|CBA-1205: 20 mg/kg (Intravenous solution)
223401877|NCT06636435|DRUG|CBA-1205 Part 5|CBA-1205: 10 mg/kg (The initial cohort, Intravenous solution)
223553243|NCT00979966|DRUG|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
223553244|NCT05793801|OTHER|Dressing change|"The patient circuit corresponds to that of usual care.~Not part of usual patient management:~* The rhythm of PICCline dressing changes, which differed between the two groups.~* The collection of pain on a visual analog scale at each dressing change."
223553245|NCT00958347|DEVICE|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
223553246|NCT05139953|OTHER|No intervention|No intervention
223553247|NCT06110364|DEVICE|Low-Level Tragus Stimulation|Low-Level Tragus Stimulation via TENS unit will be monitored with a Holter.
223553248|NCT06110364|BEHAVIORAL|Heart Rate Variability- Biofeedback|Heart Rate Variability- Biofeedback will be monitored with a Holter.
223553249|NCT06110364|OTHER|Conventional Medical Therapy|Conventional Medical Therapy by Beta Blockers will be added to subjects usual care by their doctor if they are not already taking this medication.
223553250|NCT03770741|OTHER|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
223553251|NCT03770741|OTHER|Treatment as usual|Monitoring and treatment according to local guidelines and practice
223553252|NCT05894356|OTHER|Study chart review|Evaluation of 4250 sperm DNA fragmentation samples with the goal of defining a cut-off age beyond which SDF levels increase significantly
223553253|NCT02941328|DRUG|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
223553254|NCT02941328|DRUG|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
223553255|NCT02598869|DRUG|Triamcinolone Acetonide|injection of triamcinolone acetonide
223553256|NCT02368093|DRUG|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
223553257|NCT05783128|OTHER|Airway management techniques (exposure)|The exposure reffers to the different methods of airway management during general or regional anesthesia.
223553258|NCT00229697|DRUG|Gefitinib|
223553259|NCT00229697|DRUG|Tamoxifen|
223553260|NCT02474303|DRUG|Truvada|Demonstration Study
223553261|NCT05710796|BEHAVIORAL|Difference in gender, response to disease, diagnostic test values|Gender difference: Prevalence of disease in male vs female Response to disease: Which group is more prone to cardiac involvement Diagnostic tests: Diagnostic confirmation of disease
223553262|NCT01735734|DEVICE|Air cooling to CM site|
223553263|NCT04643587|BIOLOGICAL|CSL787|Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer
223553264|NCT04643587|DRUG|Placebo|Normal saline (0.9% NaCl)
223553265|NCT01393795|DRUG|Qutenza|8% patch
223553266|NCT01393795|DRUG|Tegaderm|No active drug
223734755|NCT03553667|DEVICE|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
223401878|NCT06026046|OTHER|Adapted sport program based on fencing|"This adapted sport program includes 3 to 5 sessions per week of adapted fencing (excluding weekends and public holidays), carried out either by a fencing master trained in adapted sport, or by an APA teacher trained in adapted fencing by the fencing master.~Sessions can last from 10 to 30 minutes. The course of the session is validated by the fencing master and adapted to each patient. The limiting factors are taken into account, in order to direct towards a specific practice.~The sessions are progressive with very short and varied sequences calling on the imagination and experience of the fencing masters."
223734756|NCT00039364|DRUG|imatinib mesylate|
223734757|NCT03487029|OTHER|Short duration|exercise Short duration high intensity training
223401879|NCT06351800|BEHAVIORAL|Predictplusprevent intervention|The intervention is based on validated risk algorithms to predict depression and anxiety and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps participants to develop their own personalized plans to prevent (PPP) depression and/or anxiety; 3) eight intervention modules (the core of the system) including activities to prevent depression and anxiety, to be proposed and monitoring by the DSS. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6, 9 and 12 months.
223401880|NCT06351800|OTHER|Psychoeducational intervention|To know the level of risk of experiencing depression and/or anxiety in the next 12 months. In addition, participants assigned to this intervention will have free access to the 24 self-help pamphlets for preventing depression and anxiety.
223401881|NCT01104805|BEHAVIORAL|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
223401882|NCT01104805|BEHAVIORAL|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
223734758|NCT03487029|OTHER|Long duration|exercise Long duration high intensity training
223734759|NCT02118051|DRUG|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle\> 14mm.
223734760|NCT02118051|DRUG|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles\> 17 mm are observed
223734761|NCT02118051|DRUG|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
223734762|NCT06507592|DIAGNOSTIC_TEST|Saliva samples collection|The first sample of saliva was be taken before the start of the treatment and considered as the control sample (T0); the second sample was be taken one month after the start of the treatment (T1) and the third one after three months (T2).
223734763|NCT03697629|DRUG|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
223734764|NCT04698902|DEVICE|Intracoronary lithotripsy|Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
223734765|NCT05040997|DIAGNOSTIC_TEST|Small airways assessment|Small airways assessment
223734766|NCT01026467|DRUG|cisplatin|Given IV
223734767|NCT01026467|DRUG|carboplatin|Given IV
223734768|NCT01026467|OTHER|questionnaire administration|
223734769|NCT03041545|DEVICE|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
223734770|NCT03935906|OTHER|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
223734771|NCT03935906|OTHER|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
223734772|NCT01803919|DEVICE|Silver Alloy-Coated Urinary Catheters|
223734773|NCT01803919|DEVICE|Conventional Urinary Catheter|
223734774|NCT04474704|DEVICE|Cheetah® non-invasive cardiac monitoring system|Cheetah® non-invasive cardiac monitor system will be used to individually determine the duration of magnesium sulfate postpartum (guided by timing of reduction in Systemic Vascular Resistance (SVR))
223734775|NCT04474704|OTHER|Standard of care|24 hours of postpartum magnesium sulfate
223734776|NCT01988805|OTHER|Blood Draw|
223734777|NCT02669433|DRUG|RVT-101 35 mg|once daily, oral, 35-mg tablets
223734778|NCT02669433|DRUG|RVT-101 70 mg|once daily, oral, 35-mg tablets
223734779|NCT02669433|DRUG|Placebo|once daily, oral, matching tablets
223734780|NCT06498947|OTHER|This study was observational with no intervention.|This study was observational with no intervention.
223734781|NCT02229747|DRUG|Meloxicam|
223734782|NCT02229747|DRUG|Diclofenac|
223734783|NCT02229747|DRUG|Nimesulide|
223734784|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
223734785|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
223734786|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
224297353|NCT04125121|DRUG|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
223401883|NCT03876535|OTHER|Nanomix eLab® System molecular diagnostic test (non-interventional)|This is not an interventional study. It involves performance equivalence demonstration of a point of care diagnostic system to FDA cleared predicate devices currently used in sepsis and SIRS diagnosis.
223401884|NCT05486637|BEHAVIORAL|Perception of acoustic cues to emotion|Using novel methodologies and stimuli comprising both controlled laboratory recordings and materials culled from databases of ecologically valid speech emotions (e.g., from publicly available podcasts), the team aims to collect perceptual data to build a statistical model to test the hypothesis that experience-based changes in emotion identification by pediatric and adult CI recipients is mediated by improvements in cue-optimization.
223401885|NCT05486637|BEHAVIORAL|Production of acoustic cues to emotion|The team will acoustically analyze vocal emotion productions by participants, quantify acoustic features of spoken emotions, and obtain behavioral measures of how well normally hearing listeners can identify those emotions.
223401886|NCT01734135|OTHER|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
223401887|NCT02895750|DRUG|Metformin|Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
223401888|NCT04462406|BIOLOGICAL|Ipilimumab|Given IV
223401889|NCT04462406|BIOLOGICAL|Nivolumab|Given IV
224131898|NCT05041478|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy. Lesion then removed with a stiff thin-wired snare.
224131899|NCT06683365|PROCEDURE|Sural Nerve Graft to the Substantia Nigra|Participants assigned to this arm will have the sural nerve biopsied from one of their ankles. This cellular tissue will be deposited bilaterally into the substantia nigra area of their brain by a specialized cannula via bilateral scalp incisions and skull burr holes.
224131900|NCT06683365|PROCEDURE|Sham surgery|Participants assigned to this arm will have the sural nerve from one of their ankles biopsied in the same fashion as the experimental arm. Bilateral incisions will be made on the participants scalp but no burr holes into the skull and no cannula passes into the brain will occur.
224297354|NCT00033813|DRUG|Oxatomide (tinset)|
223401890|NCT04462406|OTHER|Patient Observation|Undergo active surveillance
223401891|NCT04462406|BIOLOGICAL|Pembrolizumab|Given IV
223401892|NCT03026062|BIOLOGICAL|Durvalumab|Given IV
223401893|NCT03026062|BIOLOGICAL|Tremelimumab|Given IV
223401894|NCT04449666|DIAGNOSTIC_TEST|Neuropsychological assessment and structural MRI|Complex neuropsychological assessment testing attentional and memory functions. Additionally, a structural MRI is measured.
223553267|NCT02008149|OTHER|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
223553268|NCT03287323|OTHER|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
223553269|NCT03463863|PROCEDURE|rectus sheath midurethral sling|
223553270|NCT04491435|DIAGNOSTIC_TEST|Summated Xerostomia Inventory|structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)
223553271|NCT04491435|DIAGNOSTIC_TEST|Sialometry|unstimulated whole saliva (UWS) flow measurement
223553272|NCT01962428|DRUG|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
223553273|NCT04944238|DEVICE|Ankoris|Implantations of test lens using standard phaco surgical technique, with aim for in-the-bag implantation.
223553274|NCT02561481|DRUG|Sulforaphane|See under active arm description
223553275|NCT02561481|DRUG|Placebo|See under placebo arm description
223553276|NCT00511628|DRUG|Risperidone|As prescribed
223553277|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
223553278|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
223553279|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
223553280|NCT01831466|DRUG|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
223553281|NCT01831466|DRUG|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
223553282|NCT01831466|DRUG|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
223553283|NCT01131806|DRUG|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
223553284|NCT01131806|DRUG|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
223553285|NCT03790813|DIAGNOSTIC_TEST|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
223553286|NCT03790813|DIAGNOSTIC_TEST|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
223553287|NCT00577694|DRUG|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
223553288|NCT00577694|DRUG|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
223553289|NCT01667250|DEVICE|GammaCore Active Device|
223553290|NCT01667250|DEVICE|GammaCore Sham Device|
223553291|NCT04348071|DRUG|Ruxolitinib|Participants will receive 10 mg ruxolitinib twice daily.
223553292|NCT03902795|DIAGNOSTIC_TEST|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
223553293|NCT03902795|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
223553294|NCT01290146|DRUG|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
223734787|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single iv dose
223734788|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
223734789|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
223734790|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
223734791|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
223734792|NCT00928681|BIOLOGICAL|Single dose-group A|PF-00547659, single dose
223734793|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
224021875|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
224021876|NCT01689337|DRUG|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
224021877|NCT01689337|DRUG|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
224021878|NCT05902182|DEVICE|ConvaFoam|ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
224021879|NCT01638234|DIETARY_SUPPLEMENT|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
224297355|NCT02526511|PROCEDURE|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
224297356|NCT02526511|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
224297357|NCT02526511|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
224297358|NCT02526511|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
224297359|NCT03734211|DRUG|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
224297360|NCT03734211|DRUG|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
224297361|NCT00054548|BIOLOGICAL|oblimersen sodium|Given IV
224297362|NCT00054548|DRUG|paclitaxel|Given IV
224297363|NCT00054548|OTHER|laboratory biomarker analysis|Correlative studies
224297364|NCT00054548|OTHER|pharmacological study|Correlative studies
224297365|NCT04802902|OTHER|home-based hospitalization|management in a hospital-at-home programme of patients treated by immunotherapy and chimiotherapy combo for bronchial cancer
224297366|NCT02016261|DRUG|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
224297367|NCT05001464|DEVICE|reflectance pulse oximeter|Wearing reflectance pulse oximeter at the same time on the night of PSG examination
224297368|NCT05807516|OTHER|Single-cell RNA sequencing (scRNAseq), whole-exome sequencing (WES)|Combined both retrospective and prospective observational design
224297369|NCT00001045|DRUG|Nevirapine|
224297370|NCT00001045|DRUG|Zidovudine|
224297371|NCT00001045|DRUG|Didanosine|
224297372|NCT00225121|DRUG|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
224297373|NCT02751359|DRUG|Cannabidiol|200, 400, or 800 mg Cannabidiol
224297374|NCT02751359|DRUG|Placebo|0 mg Cannabidiol
224297375|NCT04993300|DEVICE|transcranial magnetic stimulation (TMS)|The methamphetamine user will undergo a one-month TMS intervention. In Week 1, subjects will attend continuously 5 daily TMS sessions. From Week 2 to Week 4, subjects are treated once a week. Each session will have 40 repeats of 4-second train and 15-sec train interval.
224297376|NCT02002000|DRUG|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
224297377|NCT02002000|DRUG|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
224297378|NCT04859842|OTHER|Pulse Electromagnetic Field|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.
224297379|NCT04859842|OTHER|Interferential Current|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.
224297380|NCT04859842|OTHER|Sham|Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
223734794|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
223734795|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
224021880|NCT01638234|DIETARY_SUPPLEMENT|Placebo|starch pill
224021881|NCT02207881|DRUG|VDO gel|VDO gel
224021882|NCT02207881|DRUG|placebo|matching placebo gel
224297381|NCT06091852|DIETARY_SUPPLEMENT|Intrinsically labelled milk protein|20 grams of protein dissolved in 500 mL of water
224297382|NCT00728442|DEVICE|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
224297383|NCT01558336|DRUG|praziquantel|praziquantel 40 mg/kg oral tablets
223401895|NCT04721769|PROCEDURE|Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
223553295|NCT01290146|DRUG|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min"
223553296|NCT05312684|PROCEDURE|cardiac surgery|cardiovascular surgery including valve repair/replacement or CABG or combined procedures
223553297|NCT04530305|DRUG|Upadacitinib <15 MG [Rinvoq]|Patients with RA for who the introduction of upadacitinib has been decided will be proposed the study. If they accept, they will be followed for 6 months with 3 visits (baseline, 3 and 6 months) which is the usual standard care. In addition to routine markers, stool and blood will be collected at baseline and 3 months specifically for the study.
223553298|NCT00389376|DRUG|Placebo|Placebo
223553299|NCT00389376|DRUG|Silymarin|140 mg every 8 hours
223553300|NCT00389376|DRUG|Silymarin|280 mg single dose
223553301|NCT00389376|DRUG|Silymarin|280 mg single dose + every 8 hours
223553302|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
223553303|NCT00389376|DRUG|Silymarin|560 mg single dose + every 8 hours
223553304|NCT00389376|DRUG|Silymarin|280 mg every 8 hours
223553305|NCT00389376|DRUG|Silymarin|700 mg single dose + every 8 hours
223734796|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
223734797|NCT00928681|BIOLOGICAL|Multiple dose- Group B|PF-00547659, multiple dose
223401896|NCT04721769|PROCEDURE|Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy|Endoscopic strip craniectomy is a surgical procedure performed to remove pathologic bone of the calvarium that includes the fused suture. Lateral osteotomies, also known as barrel-stave osteotomies, are performed by some surgeons because of their perceived benefit in regard to cranial expansion. Following surgery, orthotic helmet therapy is performed in order to mold the calvarium with the goals of optimizing contour.
223401897|NCT06335966|DEVICE|Screening with swallowable esophageal cell-collection devices (SECD)|All participants who enroll in this study and provide their consent will undergo screening with an FDA approved swallowable esophageal cell-collection device (SECD)
223401898|NCT02972060|DRUG|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
223401899|NCT02972060|DRUG|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
223553306|NCT02991898|BIOLOGICAL|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
223553307|NCT00778167|BIOLOGICAL|cixutumumab|Given IV
223553308|NCT00778167|DRUG|erlotinib hydrochloride|Given PO
223734798|NCT00928681|BIOLOGICAL|Multiple dose-Group B|PF-00547659, multiple dose
223734799|NCT00576927|DRUG|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
223734800|NCT00576927|DRUG|Placebo|
223734801|NCT02886520|DEVICE|PVDF transobturator tape|
223734802|NCT02886520|DEVICE|Polypropylene transobturator tape|
223734803|NCT03266094|DEVICE|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
223553309|NCT00778167|OTHER|laboratory biomarker analysis|Correlative studies
223553310|NCT02046837|BEHAVIORAL|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
223553311|NCT02046837|BEHAVIORAL|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
223553312|NCT02046837|BEHAVIORAL|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
223553313|NCT06454279|OTHER|Dual Task Training|"Exercise which combines cognitive task with motor task e.g Backward counting during sit ups.~Calculation questions during stationary cycle for 10 mins. Sequentially perform movements on commands like normal standing (bipedal support with feet separated at shoulder width, Feet together (bipedal support with feet side by side), Semitandem stance, Tandem stance, one leg support on the dominant leg, one leg support on the nondominant leg by first laterally moving the trunk with shoulder abducted at least above 60 degree"
223734804|NCT05071456|OTHER|Collects of skin's hydration|Collects of skin's hydration will be made by using patch using electrochemistry.
223734805|NCT01622972|DRUG|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
223734806|NCT04661657|OTHER|Transthoracic echocardiogram (TTE)|Subjects will undergo TTE imaging.
223734807|NCT04661657|OTHER|Cardiovascular Magnetic Resonance (CMR) Imaging|Subjects will undergo CMR Imaging using a gadolinium based contrast agent (GBCA).
224021883|NCT05306405|DRUG|Vaginal Tablet|"Misoprostol alone will be repeated every 4 h in both groups for a maximum of 5 doses, reaching Bishop score \>8, rupture of membranes or occurrence of labor pain.~Cervical evaluation will be done using Bishop's score. A score \< 5 will be taken as unfavorable Cervix will be termed as ripped when Bishop's score equal 8 or more.~The endpoint of the study will be initiation of active phase of 1st stage of labor which commence from 6cm to full cervical dilatation"
223734808|NCT03128892|DEVICE|Oxygen Reserve Index - RD Lite Sensors|
223734809|NCT04684355|OTHER|Real-time colonoscopic optical diagnosis for colorectal neoplasm|Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
223734810|NCT02707510|OTHER|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
223734811|NCT03774511|OTHER|High-Intensity Interval Exercise & Moderate Intensity Interval Exercise|Different Interval intensities Exercise
223734812|NCT05999045|OTHER|Singing activity|The singing activity will involve a 1-hour performance, rehearsal, or lesson.
224021884|NCT05323201|BIOLOGICAL|fhB7H3.CAR-Ts|fhB7H3.CAR-Ts will be transhepatic arterial infused after lymphodepletion. Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.
224021885|NCT05323201|DRUG|Fludarabine|30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3)
223734813|NCT02250365|OTHER|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
223734814|NCT02250365|OTHER|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
223734815|NCT02429895|DRUG|ABT-122|Injection
223734816|NCT00379574|DRUG|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
224021886|NCT05323201|DRUG|Cyclophosphamide|750 mg/m2 i.v. for once (Day -5)
224021887|NCT02742259|DEVICE|Blood Draw|Blood draws only - non-diagnostic, non-treatment
224021888|NCT06298552|BIOLOGICAL|Efgartigimod IV|Intravenous infusion of efgartigimod
224021889|NCT06298552|OTHER|Placebo IV|Intravenous infusion of placebo
224021890|NCT02184650|OTHER|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
224021891|NCT00003382|BIOLOGICAL|filgrastim|
224021892|NCT00003382|DRUG|gemcitabine hydrochloride|
224021893|NCT00003382|DRUG|topotecan hydrochloride|
224297384|NCT05387707|DRUG|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg tablets administered twice daily
224297385|NCT05387707|DRUG|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg tablets administered twice daily
224297386|NCT05387707|DRUG|TCS Cream|TCS cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
224297387|NCT05387707|DRUG|Placebo|Oral Placebo tablets administered twice daily
224297388|NCT05387707|DRUG|Vehicle Cream|Vehicle Cream applied by study subjects to skin lesions once a day until control is achieved, then as needed
224297389|NCT00912093|DRUG|Icatibant|Single subcutaneous injection of icatibant, 30 mg
224297390|NCT00912093|DRUG|Placebo|Single subcutaneous injection of matching placebo
224297391|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Individualized|Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
224297392|NCT05777161|BEHAVIORAL|Cognitive Behavior Therapy|Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.
224297393|NCT05777161|BEHAVIORAL|Parent Coached Exposure Therapy - Group (removed from study)|Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
224297394|NCT02470793|PROCEDURE|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
223401900|NCT06334705|OTHER|blood test, food collection, hair collection, calcium scan, etc.|everything is specified during the phone call and in the consent form to be signed
223401901|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Erector Spinae block|Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
224297395|NCT02470793|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
224297396|NCT01314378|BEHAVIORAL|Mindfulness Training|Eight session intensive behavioral training program for smokers
224297397|NCT01314378|BEHAVIORAL|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
224297398|NCT03124862|DEVICE|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
224297399|NCT02370225|OTHER|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
224297400|NCT00605735|DRUG|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
223401902|NCT04827030|DRUG|Ropivacaïne Hydrochloride by Paravertebral block|Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
223401903|NCT02563327|DRUG|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
223401904|NCT02563327|DRUG|Moxifloxacin|A fluoroquinolone
223553314|NCT06454279|OTHER|Task Specific Training|"Wide based gait training.~Auditory forward digit span:~Remember as many as possible of the number/letter forward sequence, you were told~Auditory backward digit span:~Remember as many as possible of the number/letter back sequence, you were told~Visual forward digit span:~Remember as many as possible of the number forward sequence shown to you by means of cardboard~Visual backward digit span:~Remember as many as possible"
223553315|NCT00952328|DIETARY_SUPPLEMENT|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
223553316|NCT05402254|OTHER|Pharmacovigilance Program|Knowledge of the risks in the use of the drug, identification and notification of ADE
223734817|NCT00379574|DRUG|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
223734818|NCT00379574|DRUG|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
223734819|NCT00379574|DRUG|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
223734820|NCT00379574|DRUG|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
223734821|NCT00379574|DRUG|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
223734822|NCT02850029|OTHER|Observational study, no intervention|
223734823|NCT02980445|BEHAVIORAL|Outdoor activity 1|40-minute outdoor activity
223734824|NCT02980445|BEHAVIORAL|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
223734825|NCT04757064|OTHER|standard rehabilitation protocol|they will receive knee flexion exercises and increase the extensor strength
223734826|NCT00459108|DRUG|dasatinib|Given orally
223734827|NCT00097110|DRUG|Vitamin C and E|
223734828|NCT04887051|OTHER|pulmonory based home exercises|web based telerehablitation
223734829|NCT00788476|OTHER|Survey|"Survey packets to adult (\>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
223734830|NCT02654522|DRUG|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
223734831|NCT00268957|DRUG|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
224297401|NCT00605735|DRUG|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
223401905|NCT02563327|DRUG|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
223734832|NCT00268957|DRUG|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
223734833|NCT03910608|DEVICE|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
223734834|NCT03265275|OTHER|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
223734835|NCT06474585|DEVICE|Plantar orthosis|Plantar orthosis taken in sitting position Plantar orthosis taken in standing position
223734836|NCT00426491|DRUG|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
223734837|NCT01239654|DEVICE|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
223734838|NCT03680573|DRUG|Control: Lacated Ringers|This site will serve as the control site
223734839|NCT03680573|DRUG|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
223734840|NCT03680573|DRUG|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
223734841|NCT03680573|DRUG|BH4|This site will be use to locally supplement BH4.
223734842|NCT03680573|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
223734843|NCT03680573|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
223401906|NCT02563327|DRUG|Isoniazid|An anti-tuberculosis agent
223401907|NCT02563327|DRUG|Pyrazinamide|An anti-tuberculosis agent
223401908|NCT02563327|DRUG|Ethambutol|An anti-tuberculosis agent
223401909|NCT02563327|DIETARY_SUPPLEMENT|Pyridoxine|An essential vitamin
223401910|NCT05301192|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
223401911|NCT05301192|DRUG|Saline|Saline will be used as the placebo comparator.
223401912|NCT05338489|DRUG|Selpercatinib|Administered orally.
223401913|NCT05338489|DRUG|Itraconazole|Administered orally.
223734844|NCT03680573|DRUG|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
223401914|NCT05338489|DRUG|Rifampin|Administered orally.
223401915|NCT05974774|DRUG|iMAB|no treatment until significant PSA increase as per treating physician at which point patient restarts ADT (LHRH agonist or antagonist) + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide). Once PSA \< 0.2 ng/mL, treatment stops again.
223401916|NCT05974774|DRUG|cMAB|LHRH agonist or antagonist + ARPI (abiraterone or enzalutamide or apalutamide or darolutamide)
223401917|NCT02818595|DEVICE|electroencephalogram (HR-EEG)|
223401918|NCT02818595|DEVICE|Near Infra Red Spectroscopy (NIRS)|
223553317|NCT03365063|OTHER|Active Knowledge Translation|"1. Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~2. Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~3. Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
223553318|NCT02591472|PROCEDURE|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223734845|NCT05248022|PROCEDURE|Drug-eluting beads bronchial arterial chemoembolization|"Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days."
223734846|NCT05248022|DRUG|Programmed Cell Death Protein 1 Inhibitor|Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
223734847|NCT06231615|OTHER|Fascia exercises|Fascia exercises are slow and calm movements similar to yoga performed by the person herself/himself.
223734848|NCT06231615|OTHER|Conventional physiotherapy and breathing exercises|Head and neck exercises and breathing exercises
223734849|NCT03626623|DEVICE|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
223734850|NCT03626623|OTHER|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
223734851|NCT01457521|DRUG|Ibuprofen|Ibuprofen
223401919|NCT05404737|OTHER|transthoracic echocardiography (TTE)|In order to evaluate the interchangeability of RV-LSF, a TTE will be performed just after the placement of general anesthesia, when the patient is under mechanical ventilation
223401920|NCT05404737|OTHER|transoesophageal echocardiography (TEE).|During cardiopulmonary bypass surgery patients is monitored by a TEE as recommended.
223401921|NCT02615600|DEVICE|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): \<100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
223734852|NCT02042885|DRUG|OPB-111001|
223734853|NCT01880385|BIOLOGICAL|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
223734854|NCT01880385|DRUG|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
223734855|NCT01880385|DRUG|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
223734856|NCT01880385|DRUG|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
223734857|NCT01880385|DRUG|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
223401922|NCT01727388|PROCEDURE|lateral decubitus|
223401923|NCT01727388|PROCEDURE|supine decubitus|
223734858|NCT01880385|BIOLOGICAL|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
223734859|NCT03473808|BEHAVIORAL|task-practice therapy|Standardized hand therapy program
223734860|NCT03473808|OTHER|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
223734861|NCT02075450|DEVICE|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
223734862|NCT02075450|OTHER|Just in Time Video|CPR Just in Time training video administered before the simulation case
223401924|NCT06475859|OTHER|Montreal Imaging Stress Test|A mental stress test that induces stress via a series of arithmetic tasks participants need to solve in a few seconds.
223401925|NCT06475859|OTHER|Relaxation breathing|3 short sessions (4 minutes) of relaxation breathing
223401927|NCT06055361|DRUG|BxC-I17e (primed iMSC derived Extracellular vesicles(EV))|Pharmaceutical form : solution for injection
223401928|NCT06055361|DRUG|Placebo|Pharmaceutical form : solution for injection
223401929|NCT05796479|DRUG|Amlitelimab DP1|"Injection solution 1~Subcutaneous"
223401930|NCT05796479|DRUG|Amlitelimab DP2|"Injection solution 2~Subcutaneous"
223734863|NCT02853578|DRUG|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
223401931|NCT03294954|GENETIC|GINAKIT Cells|"Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~* Dose Level 5 = 3 x 10\^8~* Dose Level 6 = 1 x 10\^9"
223401932|NCT03294954|BIOLOGICAL|GINAKIT cells + Etanercept|"Four dose levels of GINAKIT cells in combination of Etanercept will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~* Combination Dose level 1: 3 x 10\^6 + Etanercept\*~* Combination Dose level 2: 1 x 10\^7 + Etanercept\*~* Combination Dose level 3: 3 x 10\^7 + Etanercept\*~* Combination Dose level 4: 1 x 10\^8 + Etanercept"
223401933|NCT03289520|DRUG|Clopidogrel|
223401934|NCT03289520|DRUG|Placebo|
223401935|NCT03787784|OTHER|AI presentation|Automatic diagnosis information of AI is visible to endoscopist
223401936|NCT01822639|DRUG|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
223401937|NCT01822639|DRUG|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
223401938|NCT01822639|DRUG|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
223553319|NCT02591472|PROCEDURE|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
223734864|NCT00128778|DRUG|Pegylated liposomal doxorubicin|
223734865|NCT01009125|OTHER|$2 cash|$2 cash incentive will be included in the mailed survey
223734866|NCT01009125|OTHER|$5 cash|$5 cash incentive will be included in the mailed survey
223734867|NCT02315378|BEHAVIORAL|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
223734868|NCT02315378|BEHAVIORAL|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
223734869|NCT02157298|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
223734870|NCT02157298|DRUG|Placebo tablet|Placebo tablet. Oral dose
223734871|NCT04576832|BEHAVIORAL|Mindfulness-Based Attention Training (MBAT) web-course|Pre-recorded weekly sessions for 4 weeks. Each session will consist of approximately 2 hours of video content per week and weekly mindfulness exercises. This video will include MBAT program lectures, pre-recorded testimony from military leaders, and teaching materials. The course will also include 15-min daily mindfulness practice drills.
223734872|NCT06469866|DEVICE|low-pressure pneumoperitoneum|low-pressure pneumoperitoneum (LPP) with deep NMB.
223734873|NCT06469866|DEVICE|standard-pressure pneumoperitoneum|standard-pressure pneumoperitoneum (SPP) with moderate NMB.
223734874|NCT02723669|DRUG|AR10|effervescent tablet
223734875|NCT02723669|DRUG|acetylcysteine|oral solution
223734876|NCT02384889|DRUG|Difluoromethylornithine|Active Therapy with DFMO
223734877|NCT02384889|DRUG|Placebo|Placebo Comparitor
223734878|NCT03171415|DRUG|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
223401939|NCT04446338|DIAGNOSTIC_TEST|Antibody Test|Presence and Titer of Anti-Sars-CoV-2 Antbodies
223401940|NCT01256489|DRUG|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
223553320|NCT02591472|OTHER|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223553321|NCT02591472|OTHER|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223734879|NCT03171415|DRUG|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
223734880|NCT04128176|DRUG|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
223734881|NCT02739204|DRUG|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
223734882|NCT03763123|DRUG|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
223734883|NCT03763123|DRUG|Paclitaxel|paclitaxel 80mg/m2 as a \> 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
223734884|NCT03763123|DRUG|Topotecan|topotecan 4 mg/m2 as a \>30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
223553322|NCT02591472|OTHER|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223553323|NCT02591472|OTHER|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223734885|NCT03176251|OTHER|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
224297402|NCT05029401|DRUG|DMX-1002|Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)
224297403|NCT05029401|DRUG|Placebo|Matching placebo to the IMP (DMX-1002)
223553324|NCT02591472|OTHER|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
224297404|NCT02017730|DRUG|BMS-986020|
224297405|NCT02017730|DRUG|[11C]BMT-136088|
223734886|NCT01397032|BEHAVIORAL|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
223734887|NCT01397032|BEHAVIORAL|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
223734888|NCT00491998|DRUG|V1512|6 doses of IMP at 2-hourly intervals
223734889|NCT00491998|DRUG|V1512|3-hourly dosing
223734890|NCT00491998|DRUG|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
223734891|NCT04867603|DRUG|[Ga-68]PSMA|The injectable activity will be a maximum of 210 MBq (6.0 mCi) \[Ga-68\]PSMA at the time of injection and is administered to subjects by intravenous injection.
223734892|NCT04867603|DEVICE|PET/CT imaging|PET/CT imaging procedure
223734893|NCT03677505|DEVICE|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
223734894|NCT03677505|DEVICE|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
223734895|NCT05146401|OTHER|Plasma fatty acid concentration|Plasma concentrations of fatty acids were measured by gas chromatography - mass spectrometry (Agilent 7890B gas chromatography coupled with an Agilent 5977A Series mass spectrometry). Individual fatty acids with relative concentrations ≥ 0.05% were used to derive fatty acid patterns through principle components analysis.
223734896|NCT04059094|DRUG|BI 1265162|Inhalation solution
223734897|NCT04059094|DRUG|Placebo|Inhalation solution
223734898|NCT02994979|OTHER|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
224297406|NCT01280409|DRUG|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
224297407|NCT01280409|DRUG|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
224297408|NCT04171271|BEHAVIORAL|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
224297409|NCT04171271|BEHAVIORAL|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
224297410|NCT04397445|DRUG|Ranitidine|Ranitidine 300 mg
224297411|NCT04397445|DRUG|Placebo|Oral placebo tablet
224297412|NCT04397445|OTHER|Low nitrite/NDMA meals|Meals containing low levels of nitrites and NDMA
224297413|NCT04397445|OTHER|High nitrite/NDMA meals|Meals containing higher levels of nitrites and NDMA
224297414|NCT03921151|DRUG|Mirtazapine 15 MG Oral Tablet|The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
224297415|NCT02214368|OTHER|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
224297416|NCT02214368|DEVICE|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
223401941|NCT04851028|BEHAVIORAL|Music Therapy|Music therapy is a non-pharmacological intervention, in which music and its elements are used professionally as an intervention in medical, educational, and everyday environments with individuals, groups, families, or communities who seek to optimize their quality of life and improve their physical, social, communicative, emotional, intellectual, and spiritual health and wellbeing. This therapy has shown to provide significant benefits for individuals with cognitive decline living in care homes, enhancing social-cognitive functions and reducing behavioural symptoms (Brotons \& Koger, 2000; Hsu et al., 2015; Zhang et al., 2017).
223401942|NCT02467738|RADIATION|Brachytherapy|Undergo brachytherapy with Cesium-131
223401943|NCT02467738|DRUG|Cesium-131|Undergo brachytherapy with Cesium-131
223401944|NCT02467738|PROCEDURE|Conventional surgery|Undergo surgical resection
223401945|NCT02863055|DRUG|Nintedanib|Nintedanib 200 mg administered twice daily
223734899|NCT02994979|OTHER|Sham comparator|Usual care plus sham visits by CNA
223401946|NCT02863055|DRUG|Placebo|Matching placebo administered twice daily
223401947|NCT04050163|BIOLOGICAL|MiSaver®|Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
223734900|NCT04490538|DIAGNOSTIC_TEST|Transthoracic echocardiography|Conventional transthoracic echocardiographic examination at the intensive care unit.
223734901|NCT04825418|DEVICE|Artic Sun|"1. Induction phase A. Temperature using by esophageal or bladder thermometer. B. Application of a surface cooling device (Arctic Sun) C. Target temperature: 35 ± 0.5 °C D. Induction should be initiated as soon as possible after surgery (less than 6 hours)~2. Maintain phase A. Maintain duration : at least 72 hours and duration can be prolonged according to patient's clinical status B. Use the bedside shivering assessment scale (BSAS) and anti-shivering protocol C. Neuromuscular blocker can be used according to the discretion of the attending physician D. Lung-protective ventilation strategies including low-tidal volume are recommended E. Prophylactic antibiotics can be used to prevent pneumonia during hypothermia~3. Rewarming phase A. Rewarming rate: 0.05 - 0.1 ℃/hr (about 20 - 40 hours) to 37 ℃"
224131901|NCT05456204|DRUG|Pharmacological cardioversion with Refralon|"1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight."
223401948|NCT00858455|DRUG|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
223401949|NCT00858455|DRUG|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
223401950|NCT00858455|DRUG|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
223401951|NCT00858455|DRUG|GSK1349572|A single dose of GSK1349572
223401952|NCT06273514|OTHER|TECAR|"TECAR therapy performs using a WINBACK® 1s device (Daeyang Medical Co. Ltd, South Korea) with a maximum power of 100W. A 500 kHz frequency capacitive electrode is applied directly to the active MTrP in the UT. The closed electrode is placed distally on the arm. Lowpulse modulation use during treatment with half-second pauses. This enables the application of the current directly into the MTrP without enrolling the entire muscle. The single exposure last for 10 min. The current dose participant-dependent and ranged from 40 to 60% (100% = 100 Watts).~Each time, before and after treatment, and 30 days after the first therapy, the following features will be asses: pain intensity, muscle strength, and ROM."
223401953|NCT06273514|OTHER|Dry needling|"Dry needling performs using SOMA needles (25 mm x 0.3 mm). During the therapy, the participant is in a prone position. The affected UT region is disinfect before needling. The taut band localizes between the thumb and index finger of the researcher. The needle within the plastic guide tube is place over the MTrP at the UT. The needle directly inserts into the MTrP. A local twitch response confirms the accuracy of the puncture. Needling performs using Hong's fast in, fast out technique. The needle will be withdrawn if no twitching will observe."
223401954|NCT00980239|DRUG|Irinotecan|Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
224131902|NCT05312710|DRUG|APG-157|Treatment
223401955|NCT00980239|DRUG|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
223401956|NCT00980239|DRUG|Oxaliplatin|Starting dose 60 mg/m\^2 by vein over 2 hours on Days 1 and 15 of every cycle.
223401957|NCT00980239|DRUG|Cetuximab|500 mg/m\^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
223401958|NCT03091543|DRUG|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
223401959|NCT03091543|DRUG|Placebo|2 capsules of placebo
223401960|NCT03091543|DRUG|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
223401961|NCT03091543|DRUG|BIA 6-512 50 mg dose|2 capsules of 25 mg
223401962|NCT03091543|DRUG|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
224131903|NCT04209647|OTHER|REHIT Exercise|"-Start with warm-up period --\> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes"
224131904|NCT04209647|OTHER|Continuous Aerobic Exercise|At %50 of maximum heart rate, 30-60 minutes aerobic exercise
224131905|NCT03075176|DEVICE|Wavefront optimized LASIK|Wavefront optimized laser vision correction
223401963|NCT03091543|DRUG|BIA 6-512 200 mg dose|2 capsules of 100 mg
224131906|NCT03075176|DEVICE|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
224131907|NCT03075176|DEVICE|Topography-guided LASIK|Topography-guided laser vision correction
224021894|NCT02314182|PROCEDURE|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~* Within 3 weeks after randomization~* Immunonutrition given 7 days prior to PT resection~* Mechanical bowel preparation performed before surgery according to the local practices~* Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~* Must be performed within 4 weeks after surgery~* CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~* Within 4 weeks after the surgery~* Chemotherapy administered according to the usual scheme for the chosen protocol~* All validated and/or registered perioperative rectal cancer treatments authorized~* The duration of one treatment cycle depending on the type of treatment administered~* Radiotherapy is allowed after randomization if indicated"
224021895|NCT02314182|DRUG|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
224131908|NCT03075176|DEVICE|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
223401964|NCT05043974|OTHER|Dry immersion|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
223401965|NCT05177484|DRUG|oral ferric maltol|The intervention group will commence a course of oral ferric maltol provided oral intake has recommenced and the control group will receive standard care. All patients will have blood tests checked again at day 3 and day 5 postoperatively if they remain as an inpatient. If they are found to be anaemic on either of these two blood tests they will, at this stage, enter their allocated treatment pathway. If a patient shows no evidence of anaemia on either day 2, 3 or 5 blood tests they will be withdrawn from the study. Patients will continue treatment according to their randomisation allocation until 12 weeks after the operation, at which point the patient attends a routine surgical outpatient follow-up clinic. During the outpatient visit the participants will undergo their final blood testing and questionnaire completion.
223401966|NCT04446013|OTHER|Optic Nerve Sheath Diameter Measurement|The change in intracranial pressure via optic nerve sheath diameter measurement
224021896|NCT00559702|DRUG|natalizumab|natalizumab
223401967|NCT04947384|DIAGNOSTIC_TEST|To discern micro-RNA specific for right and left heart induced PH|While undergoing other procedures, the investigators will be collecting a total of three blood samples. The first sample will be obtained on arterial cannulation before the initiation of the intervention, the second sample will be collected upon the end of the procedure prior to leaving the procedure room, and the third sample will be collected on the day of discharge from the hospital.
223401968|NCT03426124|DEVICE|EkoSonic Endovascular System with thrombolytic|The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
223401969|NCT03132935|PROCEDURE|Telemedical support|Telemedical support by a physician in a telemedicine centre
223401970|NCT01129440|DEVICE|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
223553325|NCT02591472|OTHER|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223553326|NCT02591472|OTHER|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
224021897|NCT00559702|OTHER|standard of care|standard of care as determined by the Investigator and Treating Neurologist
223553327|NCT02591472|OTHER|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
223553328|NCT06004154|DIAGNOSTIC_TEST|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries|Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries added to the usual follow-up at 1, 3, 6 and 12 months
223553329|NCT06379633|BEHAVIORAL|In vivo exposure|Exposure in vivo involves the confrontation with fear-evoking situations in real life.
224021898|NCT05015933|PROCEDURE|Pump refill procedure at home|Implantable pump refill is performed at home
224021899|NCT03856554|PROCEDURE|Unilateral Transforaminal Interbody fusion|TLIF via unilateral factectomy and insertion of one cage
223734902|NCT03876197|BIOLOGICAL|Autologous adipose-derived mesenchymal stem/stromal cells|Autologous adipose-derived mesenchymal stem/stromal cells
223401971|NCT01129440|DEVICE|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
223553330|NCT06379633|BEHAVIORAL|(Virtual reality) exposure|Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
223734903|NCT03876197|OTHER|Placebo|Isotonic NaCl (0,9mg/ml) and human albumin (HA) 1%
223734904|NCT00102102|DRUG|[18F]SPA-RQ|
224021900|NCT03856554|PROCEDURE|Bilateral Transforaminal Interbody fusion|TLIF via bilateral factectomy and insertion of two cages
224131909|NCT03223857|PROCEDURE|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
224131910|NCT03134651|DEVICE|Monitoring brain function|
224131911|NCT03134651|DRUG|propofol|
224131912|NCT03217773|PROCEDURE|ESD|Refer to arm description
224131913|NCT03217773|PROCEDURE|TAMIS|Refer to arm description
224131914|NCT01955850|BEHAVIORAL|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
223401972|NCT02393950|DRUG|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
223401973|NCT02393950|DRUG|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
223401974|NCT05079035|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
224021901|NCT02952378|DRUG|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
224021902|NCT02070003|BEHAVIORAL|Motivational Interviewing and Physician Guided Opioid Weaning|
224021903|NCT02842606|OTHER|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
224021904|NCT00398736|PROCEDURE|sonographic measurement of inferior caval vein diameter|
224021905|NCT03406260|DRUG|Lasmiditan|Administered orally.
224021906|NCT03406260|DRUG|Placebo|Administered orally.
224021907|NCT00871780|DRUG|BG00002 (natalizumab)|
224021908|NCT02799953|DEVICE|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
224021909|NCT01562509|OTHER|Implementation tools|"* Professionals receive audit \& feedback~* Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~* Standardization of diagnostic and evaluative request forms and reports for clinicians.~* Supporting material for standardizing the procedure for multidisciplinary meetings."
224021910|NCT01562509|OTHER|Standard intervention|Standard intervention consists of audit\&feedback
224021911|NCT00221169|PROCEDURE|Surgical resection|pet ct prior to surgery
224021912|NCT05030987|PROCEDURE|Renal Denervation|Renal denervation in patients with HFpEF and uncontrolled hypertension
224021913|NCT05030987|PROCEDURE|Sham|Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
224131915|NCT01929655|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
224131916|NCT00501046|DRUG|Placebo|9g /day (3 times a day)
224131917|NCT00501046|DRUG|AST-120|9g /day (3 times a day)
223401975|NCT05079035|BIOLOGICAL|Saline|2 mL Sterile, preservative free 0.9% NaCl
223401976|NCT05085548|DRUG|ProAgio Dose Levels (DL) 1,2,3|ProAgio is administered to study participants by intravenous injections once every 14 days.
223401977|NCT05085548|DRUG|ProAgio Dose Levels (DL) 4,5,6|ProAgio is administered to study participants by intravenous injections once every 7 days.
223553331|NCT04014751|OTHER|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
223553332|NCT02811120|OTHER|venepuncture only|single venepuncture
223553333|NCT01899638|DRUG|UMEC/VI 125/25 mcg|Combination in high dose
223553334|NCT01899638|DRUG|UMEC/VI 62.5/25 mcg|Combination in low dose
223553335|NCT01899638|DRUG|UMEC 125 mcg|LAMA mono in high dose
223553336|NCT01899638|DRUG|UMEC 62.5 mcg|LAMA mono in low dose
223553337|NCT01899638|DRUG|VI 25 mcg|LABA mono
223553338|NCT00331916|DRUG|quinolone|
223553339|NCT05318495|DEVICE|Standard Colonoscopy|The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).
223553340|NCT05318495|DEVICE|CAD-EYE|CAD-EYE is an artificial intelligence software, used in real-time during the colonoscopy procedure for aiding the identification and characterization of polyps and adenomas.
223553341|NCT05318495|DEVICE|G-EYE|The G-EYE® balloon is a reusable (reprocessable) balloon permanently installed on the distal tip of a standard colonoscope, and is also intended to assist in flattening colonic folds and control the colonoscope's field of view and tip positioning.
223553342|NCT02870985|DEVICE|Coronary Stent|
223553343|NCT05745337|DRUG|As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)|Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
223553344|NCT03675113|OTHER|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
223553345|NCT03675113|OTHER|Control Group|Deep breathing exercises combinated with arm movements
223553346|NCT01446887|OTHER|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
223553347|NCT01552837|DRUG|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
223401978|NCT05085548|DRUG|ProAgio Dose Levels 4a,5a,6a|ProAgio is administered to study participants by intravenous injections once every 7 days with a drug holiday after every 5 administrations. Optional co-administration of gemcitabine (Gem) during dose expansion beginning with Cycle 2.
223401979|NCT06234384|OTHER|Sarcoidosis diagnosis|Participants have been diagnosed with sarcoidosis.
223401980|NCT00001258|DRUG|Oxygen-15 Water|
223401981|NCT05216861|OTHER|Demand and ability protocol|"The intervention consists of a structured conversation between the patient and his immediate manager under the guidance of licensed medical staff (in this case REKO) with knowledge of the requirements of the patient's work and his/her current functional ability. The intervention takes about 90 minutes excluding preparation time for REKO.~DAP consider the following domains; 1) mental and cognitive ability, 2) basic skills and social ability, 3) tolerance for physical conditions, 4) ability to work dynamically, 5) ability to work statically and 6) to be able to work certain times.~Based on the above domains, a structured review is made of the balance between requirements and function in current work in order to identify possible adaptations and measures at the workplace. During the intervention, the work requirements and the patient's function/ability are identified on a three-point scale and in domains where there is thus an imbalance adjustments or changed tasks are identified."
223401982|NCT05216861|OTHER|Collaborative interventions as usual|The rehabilitation coordinator conduct collaborative interventions as usual with patient and employer. This might be through phone calls are unstructured meetings.
223401983|NCT02849145|BIOLOGICAL|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
223401984|NCT04213885|COMBINATION_PRODUCT|PXL 330 Platinum device/Riboflavin|30mW, 5 sec, 5 sec off, 10 minutes of illumination
223401985|NCT05486091|BEHAVIORAL|App-Enhanced Brief Cognitive-Behavioral Therapy|BCBT is a cognitive-behavioral intervention designed to target core skills deficits among suicidal individuals. App-enhanced BCBT incorporates the use of a SmartPhone app during the therapy sessions.
223401986|NCT06686485|DEVICE|FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems|"The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath.~The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium."
223401987|NCT05929664|BIOLOGICAL|Cemiplimab|Given IV
223401988|NCT05929664|PROCEDURE|Computed Tomography|Undergo CT scan
223401989|NCT05929664|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223401990|NCT05929664|OTHER|Quality-of-Life Assessment|Ancillary studies
223401991|NCT05929664|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223401992|NCT05929664|PROCEDURE|Biopsy|Undergo biopsy
223401993|NCT06112860|DEVICE|Over the counter hearing aid|An over the counter hearing aid is a device that provides amplification appropriate for individuals with mild to moderate hearing loss. Participants will receive the devices with typical directions and have one scheduled remote visit one week after receiving devices with an audiologist.
223401994|NCT06112860|BEHAVIORAL|Communication Strategies Information/Counseling|Communication Strategies provide information meant to help an individual compensate for hearing loss. The information provides tips both for the individual with hearing loss and for those communicating. People who choose not to pursue hearing aids will typically be given communication strategies information to help them manage their hearing loss. Participants will receive the counseling information in the mail and then have a 1 week follow-up appointment with an audiologist.
223401995|NCT04423211|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
223553348|NCT03693144|OTHER|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
223401996|NCT04423211|DRUG|Apalutamide|Given PO
223401997|NCT04423211|PROCEDURE|Computed Tomography|Undergo PET/CT
223401998|NCT04423211|DRUG|Degarelix|Given SC
223401999|NCT04423211|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223553349|NCT03693144|OTHER|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
223553350|NCT03693144|OTHER|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
223553351|NCT00087984|BIOLOGICAL|MB-002|Dendritic Cell Immunotherapy
223402000|NCT04423211|OTHER|Fluciclovine F18|Given IV
223402001|NCT04423211|DRUG|Goserelin Acetate|Given SC
223402002|NCT04423211|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
223402003|NCT04423211|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223402004|NCT04423211|DRUG|Leuprolide Acetate|Given IM
223402005|NCT04423211|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR
223402006|NCT04423211|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MR
223402007|NCT04423211|OTHER|Quality-of-Life Assessment|Ancillary studies
223553352|NCT05572879|BIOLOGICAL|EuCorVac-19|COVID-19 vaccine
223553353|NCT05572879|BIOLOGICAL|ChAdOx1 nCoV-19|COVID-19 vaccine
223553354|NCT02861339|DEVICE|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
223553355|NCT01823081|DRUG|Intravitreal injection of bevacizumab (Avastin)|
223553356|NCT01823081|DRUG|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
223553357|NCT00967681|DIETARY_SUPPLEMENT|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
223553358|NCT00967681|DIETARY_SUPPLEMENT|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
223553359|NCT01603225|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
223553360|NCT02311881|DRUG|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
223402008|NCT04423211|OTHER|Questionnaire Administration|Ancillary studies
223734905|NCT02406482|BEHAVIORAL|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
223734906|NCT02406482|BEHAVIORAL|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
223734907|NCT05781607|COMBINATION_PRODUCT|Patient education combined with drug therapy|Receive a health education by a specialist therapist, including explaining the anatomy and function of TMJ; Explain the etiology, prognosis, treatment plan and prognosis of TMD; Correct the patients' daily oral habits, such as unilateral chewing, habitual clenching, eating too much hard food, etc; Instruct the patient to understand the rest position of the temporomandibular joint and correct the bad posture of the neck and shoulder. At the same time, corresponding medication should be given, and NSAIDS should be taken orally or externally for patients with pain.
223734908|NCT05781607|COMBINATION_PRODUCT|Individualized comprehensive physical therapy|Physical factor therapy and/or manual therapy
223734909|NCT03457129|DRUG|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
224021914|NCT01333163|BIOLOGICAL|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
224021915|NCT01333163|BIOLOGICAL|Isotone NaCl|2 hours IV infusion.
223402009|NCT04423211|DRUG|Relugolix|Given PO
223402010|NCT04423211|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223402011|NCT04423211|DRUG|Triptorelin|Given IM
223402012|NCT04423211|RADIATION|Volume Modulated Arc Therapy|Undergo VMAT
223402013|NCT04884815|GENETIC|UX701|Nonreplicating, recombinant gene transfer vector
223402014|NCT04884815|DRUG|Standard of Care (SOC)|SOC treatment (i.e., copper chelators and/or zinc) administered according to standard regimens.
223402015|NCT02909777|DRUG|CUDC-907|
223402016|NCT06343090|DRUG|CD19 CAR T-cell|Murine-derived CD19 CAR T cells
223402017|NCT06343090|DRUG|CD22 CAR T cells|humanized CD22 CAR T cells
223553361|NCT02311881|DRUG|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
224021916|NCT01746680|DRUG|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0\~week4, 2mg for week4\~week8, 3mg for week8\~week24 with MTX ≤20mg/week
223402018|NCT06343090|PROCEDURE|hematopoietic stem-cell transplantation|allo-HSCT
223402019|NCT04290988|DEVICE|EEG Neurofeedback|Active EEG neurofeedback
223402020|NCT04290988|DEVICE|Sham Feedback|Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
223553362|NCT02311881|DRUG|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
223553363|NCT04799457|OTHER|Suture technique|We wil apply additional sutures to classical caesarean procedure.
223553364|NCT02178319|PROCEDURE|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
223553365|NCT02178319|PROCEDURE|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
223402022|NCT03971071|DRUG|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
223402023|NCT03971071|DRUG|Erenumab 140 mg|Erenumab once every 4 weeks. Subcutaneous injection.
223402024|NCT03971071|DRUG|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
223402025|NCT03697148|DIAGNOSTIC_TEST|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
223402026|NCT05766267|DRUG|Rifabutin|Rifabutin (Rb) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
223402027|NCT05766267|DRUG|Delamanid|Delamanid (D or DLM) is added to the bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z), (BMZ) regimen for first 8 weeks and continued for next 9 weeks with bedaquiline (B or BDQ) and moxifloxacin (M)
223402028|NCT05766267|DRUG|Bedaquiline|Bedaquiline is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
223402029|NCT05766267|DRUG|Moxifloxacin|Moxifloxacin is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ).
223402030|NCT05766267|DRUG|Pyrazinamide|Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).
223402031|NCT05766267|DRUG|Isoniazid|Isoniazid is part of control regimen (HRZE).
223402032|NCT05766267|DRUG|Rifampin|Rifampin is part of control regimen (HRZE).
223402033|NCT05766267|DRUG|Ethambutol|Ethambutol is part of control regimen (HRZE).
223553366|NCT04318054|OTHER|Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.|fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
223553367|NCT00819156|DRUG|degarelix|Degarelix was given as subcutaneous injections.
223734910|NCT01038050|DRUG|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
223402034|NCT05889650|PROCEDURE|External Lumbar drainage|ELD @ 15 or 20mmHg based on intervention arm with maximum of 10ml/hour drainage
223402035|NCT02185196|DRUG|Vitamin D3|20,000 IU vitamin D3 in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
223402036|NCT02185196|DRUG|Placebo|20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
223402037|NCT00443690|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
223402038|NCT00443690|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
223402039|NCT03209271|DRUG|Ringer's Acetate (warm)|Body temperature fluid
223402040|NCT03209271|DRUG|Ringer's Acetate (cold)|Room temperature fluid
223402041|NCT04827095|OTHER|Web-Based Support and Education Program 1|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
223402042|NCT04827095|OTHER|Web-Based Support and Education Program 2|The classes will discuss topics related to caregiving for someone with a spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about one hour per week that relate to the topics discussed in class.
223402043|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
223402044|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
223734911|NCT00901160|PROCEDURE|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
223734912|NCT00883116|DRUG|Ixabepilone|
224297417|NCT02214368|DRUG|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
224297418|NCT02214368|OTHER|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.
224297419|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
224297420|NCT00759239|DRUG|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
224297421|NCT00771381|DRUG|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
224297422|NCT00771381|DRUG|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
224297423|NCT00548938|DRUG|Gliadel wafer|Implanted at surgery
224297424|NCT00548938|DRUG|Temozolomide|During External Beam Radiation
224297425|NCT00548938|RADIATION|External Beam Radiation Therapy|60 Gy
224297426|NCT04309318|PROCEDURE|Low pneumoperitoneum (10-12 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 10-12 mmHg intra-abdominal pneumoperitoneum pressure
224297427|NCT04309318|PROCEDURE|High pneumoperitoneum (13-15 mmHg) pressure range group|Patients who have elective laparoscopic surgery with 13-15 mmHg intra-abdominal pneumoperitoneum pressure
224297428|NCT00941057|DRUG|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
224297429|NCT00941057|DRUG|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
224297430|NCT00941057|DRUG|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
224297431|NCT00797329|OTHER|chart review|"* cholesterol~* cognitive profiles~* violent behavior"
224297432|NCT06271720|OTHER|visceral manipulation|"visceral manipulation: A palpation technique will be applied till the barrier is felt and it will be applied until release is felt.~integrated neuromuscular inhibition: ischemic compression will be applied to trigger point of upper trapezius"
224297433|NCT06271720|OTHER|integrated neuromuscular inhibition|It involves applying direct sustained digital pressure to the TrP with sufficient force over dedicated time duration, to slow down the blood supply and relieve the tension within the involved muscle. The pressure is gradually applied, maintained and the gradually released
223734913|NCT00883116|DRUG|Doxorubicin|
223734914|NCT00883116|DRUG|Paclitaxel|
223734915|NCT06232811|BEHAVIORAL|Assessment|Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
223734916|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D and calcium|
224297434|NCT01124357|DEVICE|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
224297435|NCT01124357|DEVICE|thermachoice|ThermachoiceTM III thermal balloon ablation
223402045|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
223402046|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
223734917|NCT02662491|DIETARY_SUPPLEMENT|Vitamin D|
223402047|NCT00728455|DRUG|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
223402048|NCT00728455|DRUG|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
223402049|NCT00728455|DRUG|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
223402050|NCT00728455|DRUG|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
223402051|NCT00728455|DRUG|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
223402052|NCT00728455|DRUG|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
223402053|NCT00626002|DRUG|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
223402054|NCT04656821|DRUG|Control Rx|Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed
223402055|NCT04656821|PROCEDURE|Erector Spinae Block|Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
223402056|NCT04656821|PROCEDURE|Thoracic Paravertebral Block|Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
223402057|NCT03389932|BEHAVIORAL|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
223402058|NCT01894386|DRUG|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
223402059|NCT01894386|DRUG|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
223402060|NCT01894386|DRUG|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
223402061|NCT01894386|DRUG|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
223553368|NCT05626140|DRUG|Lacosamide 50 MG Oral Tablet [Vimpat]|Oral tablet lacosamide is a 3rd generation anti convulsant drug. it is given in a dose of 50 mg 12 hourly for 15 days. It has a longer half life than the other two drugs in comparison and fewer drug interactions as it doesnot interact with the hepatic cytochrome enzymes.hence it is seen to have better pharmacokinetics and pharmacodynamics than the other drugs in study
223553369|NCT05626140|DRUG|Codeine Phosphate|Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
223553370|NCT05626140|DRUG|Diclofenac Sodium|Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
223553371|NCT02130674|DRUG|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
223734918|NCT02662491|DIETARY_SUPPLEMENT|Calcium|
223734919|NCT02662491|DIETARY_SUPPLEMENT|Placebo|
223734920|NCT01574040|BEHAVIORAL|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
223734921|NCT01574040|BEHAVIORAL|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
223734922|NCT01574040|BEHAVIORAL|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
224021917|NCT06082089|BEHAVIORAL|Divorce Adjustment Program (DAP)|This is a brief group intervention program for divorced women. It consists of 6 sessions for participants with children and 5 sessions for participants without children. Each session lasts approximately 2.5-3 hours focusing on one of the difficulties experienced by women after divorce (i.e., self-perception, emotions and emotion regulation, social problems, family-related problems, problems with ex-spouse and children (for participants with children)). In this study, the DAP will be implemented in online format.
224021918|NCT03354806|PROCEDURE|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
224021919|NCT03354806|PROCEDURE|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
224021920|NCT02873143|OTHER|No intervention|No intervention
224021921|NCT03956823|DRUG|telmisartan|Telmisartan group: telmisartan 80 mg once a day
224021922|NCT03956823|DRUG|amlodipine|amlodipine group: amlodipine 5 mg once a day
224021923|NCT05467397|DRUG|[11C]acetate|Positron Emission Tomography (PET)
224021924|NCT00151957|DRUG|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
224131918|NCT06018610|OTHER|Rehabilitation|In addition to conventional rehabilitation, relaxation exercises and classical massage of the sole of the foot will be applied to the study group.
223553372|NCT05712980|DEVICE|Implanted pulse generator for SCS with different programming modalities|"Surgical technique~Patients recruited will be scheduled for the implantation of the SCS system in two phases. The implant procedure will be performed following our standardized clinical practice under local anesthesia and moderate sedation.~Clinical parameters~Clinical evaluation of study subjects shall include, in addition to demographic parameters, the assessment of parameters related to pain experience, disability, quality of life, as well as other psychological variables. All these parameters will be evaluated at different times of the study.~Sample processing~10 ml of peripheral blood will be obtained per venopuncture at different moments, always at the same time of day and in the same anatomical location.~Expression arrays~After a manual removal of RNA the expression arrays and the scanning of the crystals will be carried out after hybridization"
223553373|NCT00803595|DRUG|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
223553374|NCT00803595|DRUG|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
223553375|NCT00803595|DRUG|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
223553376|NCT05963243|OTHER|Ultrasound Scans|Ultrasound scans collected by experts in ultrasound-guided regional anaesthesia.
224131919|NCT06018610|OTHER|Control|Conventional rehabilitation will be applied to the control group.
224131920|NCT04638712|OTHER|Microbiopsy sample|before and after chemotherapy
224131921|NCT04638712|OTHER|Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level|before and after chemotherapy
224131922|NCT03520816|OTHER|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
223553377|NCT02229708|BEHAVIORAL|Healthy Lifestyle Group|
223553378|NCT04171505|DRUG|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
223553379|NCT05214066|DRUG|Rabbit ATG|ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.
223553380|NCT00731861|DRUG|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
223553381|NCT02250469|DEVICE|Treatment with the Axium SCS system|
223553382|NCT02250469|DEVICE|Treatment with the Medtronic SCS System|
223553383|NCT02990975|DRUG|ketamine|
224131923|NCT05166746|DRUG|Clindamycin|Oral clindamycin 300mg/2xdaily in 7 days. LACTIN-V applicators 1x at night in 7 days, then 2xper week at night for 7 weeks.
224131924|NCT05166746|OTHER|Placebo|"The Clindamycin placebo appear identical to active clindamycin by filling capsules with Mannitolium.~The LACTIN-V placebo product has no intrinsic effect and is used to study the effect of the therapeutically active product. It is supplied as a pre-filled vaginal applicator packaged under nitrogen gas with one desiccant packet (0.25 g) in a sealed foil pouch. Each applicator contains 200 mg of LACTIN-V placebo powder containing the inactive ingredients of the LACTIN-V drug product, but not Lactobacillus crispatus CTV-05 (CTV-05), the active ingedient. The excipients used in the manufacture of LACTIN-V placebo are identical to those in the LACTIN-V drug product. Each placebo applicator contains the following constituents: maltodextrin, trehalose, xylitol, colloidal silicon dioxide, and sodium ascorbate"
224297436|NCT03187366|OTHER|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
224021925|NCT01966393|OTHER|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
224021926|NCT02700945|DEVICE|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
224297437|NCT04070586|DEVICE|4DCBCT images|Images are acquired and assessed offline
224297438|NCT01608386|PROCEDURE|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
224297439|NCT00425334|DRUG|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
224297440|NCT00425334|DRUG|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
224297441|NCT03054558|OTHER|Pelvic ultrasound both two dimensional and three dimentional|
224297442|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
224131925|NCT01478438|DEVICE|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
224297443|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
224021927|NCT01450254|DEVICE|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
223553384|NCT05523557|BEHAVIORAL|Urban Training|1\) one-to-one motivational interview for a maximum of 1h; 2) exercise following a dossier containing various maps of Urban Training walking trails, previously used in patients with COPD with a recommendation of doing a minimum of 1 circuit/day; or in case of living faraway from Urban Training walking trails, the instructions will be to walk at least 30 minutes per day ⩾5 days per week, at a pace reaching a dyspnoea Borg scale score of 4 -6; 3) a FitBit Inspire (FitBit, San Francisco, United States) to obtain direct feedback on the step count and intensity of PA; and 4) a motivational follow-up visit, in group, once per month during the follow-up period.
223553385|NCT00804050|DRUG|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
223553386|NCT00804050|DRUG|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
223553387|NCT02032576|DEVICE|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
223553388|NCT02981862|OTHER|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
223553389|NCT02816268|OTHER|Pulmonary vein isolation|
223553390|NCT00002108|DRUG|Lamivudine|
223553391|NCT00002108|DRUG|Zidovudine|
223553392|NCT04029428|DRUG|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
223553393|NCT04029428|DRUG|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
223553394|NCT04029428|DRUG|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
223553395|NCT03212508|DEVICE|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
223553396|NCT05253755|BIOLOGICAL|DBI-001|Topical application of DBI-001 gel on skin affected with atopic dermatitis.
224021928|NCT01450254|OTHER|Control|No intervention will be prescribed to the control group during participation in the study.
224021929|NCT05963490|DRUG|Regorafenib|Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
224021930|NCT05963490|DRUG|Toripalimab|240 mg intravenously every 3 weeks
224297444|NCT00616941|BIOLOGICAL|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
224297445|NCT05914935|DRUG|Recombinant L-IFN adenovirus injection|The Ommaya reservoir was surgically implanted, and multiple intracapsular injections were given medicine. On the second day after Ommaya reservoir implantation, CT examination confirmed that the implantation was successful, and the experimental drug injection was started.
224297446|NCT03438825|PROCEDURE|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
224297447|NCT00173875|DRUG|Iressa|
223553397|NCT05253755|BIOLOGICAL|Aqueous gel|Topical application of aqueous gel on skin affected with atopic dermatitis.
224021931|NCT05963490|RADIATION|Radiotherapy|hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).
224021932|NCT05963490|DRUG|Regorafenib|Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
224021933|NCT02428764|DRUG|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
224021934|NCT02428764|DRUG|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
224021935|NCT02428764|DRUG|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
224297448|NCT00755859|DRUG|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
224297449|NCT00755859|DRUG|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
224297450|NCT03045159|BEHAVIORAL|Strong Families Strong Forces|Parenting program
224297451|NCT03045159|BEHAVIORAL|Strong Parents|self-care program
224297452|NCT03311100|OTHER|immunohistochemistry assay|biomarkers expression
224297453|NCT00435396|BIOLOGICAL|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
224297454|NCT02824718|DRUG|Teriparatide|human recombinant parathormone
224297455|NCT02824718|DRUG|Thiazide|Diuretic
224297456|NCT02824718|DRUG|Potassium sparing diuretic|Diuretic
224297457|NCT02824718|DRUG|Alfacalcidol|Belongs to the class of vitamin D and analogues
223402062|NCT04268225|PROCEDURE|US guided dynamic needle tip positioning peripheral intravenous cannulation|Catheterizations will be performed by one of three pediatric intensivists with vast experience in both traditional and US guided DNTP techniques for peripheral intravenous access. The operator will be allowed to independently choose which peripheral vein to cannulate. If necessary, patients will be given supplemental dose of sedation and analgesia in addition to the already given continuous infusions for invasive mechanical ventilation. Before puncture, the limb will be taped and maintained in an optimal position. A tourniquet will be placed proximal to the planned cannulation site. The site of puncture will be disinfected with Chlorhexidine gluconate 0.5% w/v, Alcohol 70% v/v. The choice of catheter will be left to the discretion of the operator. Available PIV cannulas include : 14 GA, 2X45 mm; 17 GA, 1.4X45 mm; 18 GA 1.2X45 mm; 20 GA 1X32mm BD Venflon™ and 24 GA, 0.7X19 mm; 26 GA 0.6X19 mm BD Neoflon™ (Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden).
223402063|NCT04268225|PROCEDURE|Traditional peripheral intravenous cannulation|For traditional insertion technique insertion attempt will be blind or tactile.
223553398|NCT01159678|BEHAVIORAL|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~1. Important of sexuality to quality of life. \& Definitions of sexual desire and arousal.~2. Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~3. Sexual beliefs.~4. Mindfulness.~5. Genital anatomy and physiology.~6. Body Image.~7. Relationship satisfaction and communication.~8. Body-oriented mindfulness exercises (focusing and self-observation).~9. Using Thought records.~10. Mindfulness and the thought stream.~11. Sexual aids to boost arousal.~12. Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
223553399|NCT01530503|DRUG|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
223553400|NCT01530503|DRUG|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
223734923|NCT01574040|BEHAVIORAL|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
223734924|NCT04339127|OTHER|Description and analysis|Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
223734925|NCT03352622|OTHER|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
223734926|NCT03352622|OTHER|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
223734927|NCT06220682|DIAGNOSTIC_TEST|The specific genetic PCR laboratory test were performed for all selected patients for eNOS SNPs|using Real-Time PCR (QuantStudioTM 3 Real-Time PCR) with an allele-specific fluorogenic oligonucleotide probe and a TaqMan pre-designed SNP Genotyping assay
223734928|NCT01554553|PROCEDURE|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
223734929|NCT00432107|DRUG|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
223734930|NCT06357598|DRUG|Tislelizumab|Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
223734931|NCT06357598|DRUG|Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)|Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
224021936|NCT02428764|PROCEDURE|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
224021937|NCT03476707|OTHER|Anemia|Hematocrit less than 0.39
224021938|NCT02699034|PROCEDURE|ablation for typical atrial flutter|
224297458|NCT04408599|DRUG|NC410|NC410 is an experimental antibody drug that may make the immune response more active against cancer
224297459|NCT01297387|OTHER|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
224297460|NCT06156345|DEVICE|Conservative with Denneroll|Denneroll cervical traction orthodontic traction for 3 to 15 minutes once daily with conservative management of stretching and relaxation.
224297461|NCT06156345|OTHER|Conservative|conservative management of stretching and relaxation with placebo traction.
223553401|NCT01504893|PROCEDURE|Protective one lung ventilation|Low tidal volume, PEEP and alveolar recruitment maneuver
223734932|NCT06357598|DRUG|Carboplatin or Cisplatin|"Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles."
223734933|NCT06357598|PROCEDURE|Surgery|Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
223734934|NCT05029440|OTHER|Pulsed Electromagnetic Field|PEMF was administered to the whole body for PEMF groups using a 1.8×0.6m mat 30 minutes/day, 3 times/week for 3 months.
223734935|NCT05029440|OTHER|Exercise Program|The exercise training program included treadmill and aerobic exercises for hip and upper limb and performed for 50 minutes.
224021939|NCT02699034|DEVICE|Vision-MR ablation catheter|
224021940|NCT05019378|PROCEDURE|SVF treatment|autologous SVF (10E8 cells)
224021941|NCT05815095|OTHER|PREAUT grid|Patient with abnormal results in this evaluation would be referred to a specialized center early for advice and treatment if necessary
224021942|NCT03805087|PROCEDURE|Transarterial coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
223402064|NCT06577324|BEHAVIORAL|Live group music therapy|The intervention will involve the use of live music in a group of patients during their quimiotherapy session. The intervention will last approximately forty minutes and will be organized into three stages: Opening (10 min), Body Awareness and Movement (7-10 minutes), Intervention Development (20 minutes). Genres and songs are performed based on the group's preferences and suggestions. The instruments used for the group intervention are the same as those mentioned earlier; participants are provided with percussion instruments, accompanied by the music therapist's voice and the participants' voices. The intervention encourages active participation, with users playing the instruments, singing, engaging in dialogue, and/or reflecting between songs.
223734936|NCT05029440|OTHER|Pulsed High Laser Therapy|High Laser was delivered with a total dose of energy of 3000 J was delivered in two treatment phases. The initial phase was performed with fast manual scanning at 510, 610, and 710 mJ/cm2 in three successive subphases and 500 J in each subphase for a total of 1500 J. The final phase was the same as the initial phase except that the scanning was slow. The average area for the upper thigh or lower back was 200 cm2 with an average fluency of 15 J/cm2 and the application time for each area was 18 min. HILT was applied using a HIRO 3 device (ASA, Arcugnano, Vicenza, Italy).
223734937|NCT00177398|DRUG|Glargine insulin vs regular insulin|
223402065|NCT02538575|OTHER|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
223402066|NCT03489642|BEHAVIORAL|Telehealth Program|Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
223402067|NCT06081842|OTHER|Contraceptive counseling strengthening intervention package|Development of contraceptive counseling strengthening intervention package that strengthens existing family planning services and is effective, safe, sustainable, scalable, and culturally appropriate.
223402068|NCT01775111|BEHAVIORAL|Cognitive Training|
223402069|NCT01775111|BEHAVIORAL|Strength Training|
223402070|NCT01775111|DIETARY_SUPPLEMENT|FortiFit|
223402071|NCT04089631|DRUG|Capecitabine|6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
223402072|NCT05396027|OTHER|Audio-guided deep breathing|2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
223402073|NCT04261829|PROCEDURE|Autologous Fat Transfer|Female breast cancer patients who were surgically treated with mastectomy could opt for a full breast reconstruction with Autologous Fat Transfer in combination with external expansion.
223402074|NCT05602844|PROCEDURE|PSI Lapidus|Design of PSI: DICOM files will be imported into the Model Intestinal Microflora in Computer Simulation (MIMICS 21.0) 3D image processing software (Materialize, Belgium) for 3D rendering. The segmented bone images will be used for design of the computer-aided modelling (CAM) surgical jigs. 3D printing of PSI jig. PSI-assisted Lapidus Surgery.
223553402|NCT03173989|DEVICE|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
223553403|NCT03173989|BEHAVIORAL|Orientation|Orientation for home.
223553404|NCT03863561|BEHAVIORAL|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
223553405|NCT04446221|OTHER|phone survey|A questionnaire about the current symptoms and satisfaction for received treatment will be conducted over the phone for patients.
223553406|NCT06659848|OTHER|high intensity interval training|The subjects in the four groups performed 12 weeks of supervised HIIE program on a motorized treadmill (h/p/cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) with a rate of three sessions weekly. The session commenced with a 5 min warming-up and concluded with a 5 min cooling down period. The exercise effort component consisted of 5 intervals of HIIT. Each interval continues for four min of HIIT with exercise intensity ranging from 75% to 90% of the peak heart rate. Each active recovery period between exercise intervals included moderate exercise at intensity of 50% to 60% of the peak heart rate. Every 3 weeks, the exercise intensity was increased by 5% starting with 75% of the HRmax in the first 3 weeks, 80% in the following 3 weeks and progressed to 90% the HRmax in the last 3 weeks. The subject's heart rate throughout the HIIT session was monitored using a polar heart rate monitor (Polar, Kempele, Finland).
223734938|NCT06023420|DRUG|4 Herbs Formula|4 herbs formula dose: 5g/day
223734939|NCT03715764|OTHER|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
223734940|NCT03715764|OTHER|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
223553407|NCT05356273|PROCEDURE|Baby massage|Starting from the baby's face first, then the abdomen and chest, back, upper extremities and finally the lower extremities were massaged with semi-circular movements, respectively.
223553408|NCT00257569|DRUG|Cetirizine Dry Syrup|
223734941|NCT02859675|OTHER|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
223553409|NCT02781961|OTHER|cellvizio|pCLE during gastroscopy
223553410|NCT06715098|DEVICE|RoboGait|RoboGait: robotic-assisted gait training
224131926|NCT02311699|BEHAVIORAL|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
224131927|NCT00316342|DEVICE|Back supports|
224131928|NCT02190747|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
224131929|NCT02190747|DRUG|Placebo|
224131930|NCT06252259|BEHAVIORAL|Choose to Move|As described under study arm description
223553411|NCT06715098|DEVICE|RehaWalk|RehaWalk: body weight-supported treadmill training
223553412|NCT06715098|OTHER|Conventional|Conventional: conventional walking training
224021943|NCT01928251|BEHAVIORAL|Informed early monetary incentive|"Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
224131931|NCT05503654|BEHAVIORAL|Nutrition education|Those interventional groups will take nutrition education by Gada System leaders for 6 consecutive months
223553413|NCT03436498|DRUG|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223734942|NCT02859675|BIOLOGICAL|blood sampling|sampling of 2 mL
223734943|NCT02859675|OTHER|Questionnaires|Stunkard, PrefQuest
223734944|NCT02856503|DRUG|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
223734945|NCT03149185|BEHAVIORAL|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
223734946|NCT03149185|BEHAVIORAL|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
223734947|NCT00667004|DRUG|ecabet ophthalmic solution|sterile ophthalmic solution
223734948|NCT00667004|DRUG|placebo|sterile ophthalmic solution
223553414|NCT03436498|DRUG|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223734949|NCT01326689|DRUG|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
223734950|NCT01326689|DRUG|Placebo|
223734951|NCT01654731|DRUG|Bezafibrate|
223734952|NCT01654731|DRUG|placebo|
223734953|NCT03445650|DRUG|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
223734954|NCT03445650|DRUG|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
223734955|NCT00512993|DRUG|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
224131932|NCT06388993|DEVICE|Bone Marrow Collection|Comparing the two collection systems for bone marrow aspirate
224131933|NCT00139685|DRUG|Depo-Provera Contraceptive Injection - DP150CI|
224131934|NCT01480141|DRUG|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
224131935|NCT01609179|DRUG|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
224131936|NCT06532929|DEVICE|Orthopaedic surgeries (ankle)|ankle lateral ligament reconstruction in ligamentoplasty procedures
224131937|NCT06532929|DEVICE|Orthopaedic surgeries (shoulder)|rotator cuff repair
224131938|NCT06532929|DEVICE|Orthopaedic surgeries (knee)|knee cruciate ligaments reconstruction in ligamentoplasty procedures
224131939|NCT06532929|DEVICE|Orthopaedic surgeries|rotator cuff repair or closure of capsule after arthroplasty surgery
224297462|NCT05842096|DIAGNOSTIC_TEST|Measurement and comparison of leucocytosis and concentrations of CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare the above parameters of peripheral blood in both arms of the study
223553415|NCT06844604|PROCEDURE|robotic colorectal procedures|any colorectal procedure planed robot-assisted
223553416|NCT06844604|PROCEDURE|laparoscopic colorectal procedures|any colorectal procedure planed laparoscopically
223553417|NCT06844604|PROCEDURE|open colorectal procedures|any colorectal procedure planed open
223734956|NCT03969394|DIAGNOSTIC_TEST|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
224131940|NCT06532929|DEVICE|Orthopaedic surgeries (foot)|stabilization of metatarsal and phalangeal osteotomies during treatment of hallux
224131941|NCT05834803|PROCEDURE|Renal artery stenting|Optimal medical therapy and percutaneous transluminal renal angioplasty with stent placement.
223734957|NCT02543008|PROCEDURE|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
223734958|NCT02543008|PROCEDURE|Physical activity|Information already included in arm/group descriptions.
223734959|NCT02543008|PROCEDURE|Placebo|Information already included in arm/group descriptions.
224021944|NCT01928251|BEHAVIORAL|Uninformed early monetary incentive|"Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
223734960|NCT04212104|OTHER|watch a mukbang|watch the dim sum mukbang
223402075|NCT05602844|PROCEDURE|Conventional Lapidus|exposure of the 1TMTJ via a 3-5cm medial longitudinal skin incision and capsulotomy. Freehand creation of the fusion surface with fluoroscopic assistance. Fixation of the Lapidus arthrodesis will be performed with two 3.5mm headless compression screws
223402076|NCT01697748|DEVICE|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
223402077|NCT01697748|DEVICE|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
223402078|NCT02694172|OTHER|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
223553418|NCT01059357|DEVICE|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
223553419|NCT04068454|DEVICE|Virtual reality device|Functional exercises will be done by virtual reality group
224131942|NCT05834803|PROCEDURE|Sham treatment|Optimal medical therapy and sham treatment.
224131943|NCT00002358|DRUG|Sorivudine|
223734961|NCT04212104|OTHER|watch a non-food video|watch the Big Bang Theory video
223734962|NCT01320761|DRUG|ATX-101-BA-free|ATX-101-BA-free
223734963|NCT01320761|DRUG|ATX-101-BA|ATX-101-BA
224131944|NCT02517827|DEVICE|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
224131945|NCT02517827|PROCEDURE|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
223402079|NCT03512769|DEVICE|Restful Jaw Device|The Restful Jaw device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. If needed, the dental assistant also holds the jaw in a slightly forward position to maintain an open airway. This device replicates the dental assistant in holding the jaw during dental procedures.
223402080|NCT04412967|DEVICE|Dynamic ultrasound-guided short-axis needle tip navigation|placement of peripheral venous catheters using ultrasound guided technique
223402081|NCT04412967|OTHER|Standard technique of placing a PVC|Standard technique with palpation or Visual inspection of the pvc placement site
223402082|NCT00553839|DRUG|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
223402083|NCT02684864|OTHER|Non-interventional|
223402084|NCT01965756|DRUG|Metformin|
223402085|NCT01965756|DRUG|Placebos|
223553420|NCT04068454|OTHER|EBM rehabilitation exercises|scapular exercises will be done
223553421|NCT02088125|OTHER|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
223553422|NCT02088125|OTHER|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
223553423|NCT03464526|DRUG|Orvepitant|Tablet, once daily, oral
223734964|NCT03835494|OTHER|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
223734965|NCT00162201|DRUG|Abatacept|Parenteral, IV, 500 mg if \< 60 kg; 750 mg if \> 60 \& \< 100 kg; 1000 mg if \> 100 kg, Monthly, 4 months.
223734966|NCT01045512|DRUG|fluvastatin|40-80mg once daily
223734967|NCT01537029|DRUG|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
224131946|NCT00436566|BIOLOGICAL|trastuzumab|
224131947|NCT00436566|DRUG|cyclophosphamide|
224131948|NCT00436566|DRUG|doxorubicin hydrochloride|
224131949|NCT00436566|DRUG|lapatinib ditosylate|
224131950|NCT00436566|DRUG|paclitaxel|
224131951|NCT00436566|GENETIC|gene expression analysis|
224131952|NCT00436566|GENETIC|reverse transcriptase-polymerase chain reaction|
224131953|NCT00436566|OTHER|fluorophotometry|
224131954|NCT00436566|OTHER|laboratory biomarker analysis|
224131955|NCT00436566|OTHER|mass spectrometry|
223402086|NCT02245399|BEHAVIORAL|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
223402087|NCT02245399|BEHAVIORAL|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
223402088|NCT00259870|DRUG|SB-773812|
223402089|NCT00259870|DRUG|Olanzapine|
223402090|NCT01898507|OTHER|Low nicotine cigarettes|15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
223402091|NCT00425932|BIOLOGICAL|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
223402092|NCT03247231|DEVICE|Endoscopic band ligation without resection|Endoscopic treatment of subepithelial tumors: autoamputation by endoscopic band ligation without resection.
223402093|NCT03247231|PROCEDURE|SINK|To obtain sample tissue biopsies after the endoscopic band ligation without resection, performing a single-incision with a needle-knife.
223402094|NCT05915663|OTHER|nasogastric tube and orogastric tube|nasogastric tube in period 1 and orogastric tube in period 2
223402095|NCT05915663|OTHER|orogastric tube and nasogastric tube|orogastric tube in period 1 and nasogastric tube in period 2
223402096|NCT02338323|DRUG|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
223402097|NCT02338323|DRUG|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
223402098|NCT01009450|PROCEDURE|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
223553424|NCT03464526|DRUG|Placebo|Tablet, once daily, oral
224131956|NCT00436566|PROCEDURE|adjuvant therapy|
224131957|NCT00436566|PROCEDURE|quality-of-life assessment|
223553425|NCT03469167|DEVICE|CEGP003|Application of CEGP003 to peptic ulcer bleeding
223553426|NCT03469167|DEVICE|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
224131958|NCT01188564|DRUG|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
224131959|NCT01188564|DRUG|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
224131960|NCT00588250|OTHER|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
224131961|NCT03972358|DRUG|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
223553427|NCT04661605|DIAGNOSTIC_TEST|Recurrent Neural Network|We will propose a similar Moiré feature analyzing approach based on Recurrent Neural Network to process the measured Slip Pulse wave-images with 'Chun', 'Guan' and 'Chy' in order to prepare this visualization engineering platform.
223553428|NCT04150289|DRUG|Farydak|non-interventional study
223553429|NCT01715389|OTHER|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
223553430|NCT02743767|PROCEDURE|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
223553431|NCT01575808|DEVICE|GP1101|Endovascular stent graft implantation
223553432|NCT05754411|DRUG|[14C]STI-1558|Fasting oral administration of 600 mg \[ 14C \] STI-1558 ( about 100 μCi ) solution.
223553433|NCT04436445|COMBINATION_PRODUCT|dry cupping|represents the location and clinical importance of each acupoint. First, the position of the patient will be supine lying for SP6, SP9, KI6, GB34 and CV6 acupoints and it will be prone lying for B23 acupoint. Second, the skin will be cleaned by alcohol then cups will be placed on the acupoints. Dry cupping for SP6, SP9, KI6 and GB34 acupoints will be applied using small cups while dry cupping for CV6 and B23 will be applied using large cups. Third, a negative pressure will be applied with a manual handle. Finally, the cups will be removed after 5 to 15 minutes by pressing one side of the skin with a finger to release the vacuum slowly.
223553434|NCT04436445|OTHER|Life style modification|Life style modification
223553435|NCT03961555|BIOLOGICAL|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
223553436|NCT03961555|BIOLOGICAL|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
223553437|NCT03961555|BIOLOGICAL|Rabies vaccine|it should be administered in deltoid muscle
223553438|NCT02465476|PROCEDURE|telemedicine|treatment pathway organized by telemedicine
223553439|NCT02242058|OTHER|Quantitative sensory testing|
223553440|NCT01527045|DRUG|Atorvastatin Calcium|Given PO
223553441|NCT01527045|DRUG|Cyclosporine|Given PO
223553442|NCT01527045|DRUG|Fludarabine Phosphate|Given IV
223553443|NCT01527045|OTHER|Laboratory Biomarker Analysis|Correlative studies
223553444|NCT01527045|DRUG|Mycophenolate Mofetil|Given PO or IV
223553445|NCT01527045|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
223402099|NCT01009450|PROCEDURE|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
223402100|NCT06283381|DRUG|Esomeprazole|oral administration, tablets, 40 mg
223402101|NCT01704495|DRUG|AZD5069|AZD5069 oral capsules self-administered twice daily.
223553446|NCT01527045|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
223402102|NCT01704495|DRUG|Placebo|Placebo oral capsules self-administered twice daily.
223402103|NCT03886610|OTHER|Healthy controls|individuals without spinal cord injury
223402104|NCT03886610|OTHER|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
223553447|NCT01527045|RADIATION|Total-Body Irradiation|Undergo TBI
223553448|NCT01218217|DRUG|SQ109|SQ109 150 mg tablet
223553449|NCT01218217|DRUG|Rifampicin|Rifampicin 150 mg capsules
223553450|NCT01769976|OTHER|Periodic fasting|
223553451|NCT01769976|OTHER|Energy restriction|
223553452|NCT01769976|OTHER|Energy balance diet|
223553453|NCT04951011|DIAGNOSTIC_TEST|Serum beta HCG|Raising numbers of S BHCG or decreasing with different management of tubal Ectopic Pregnancy
223553454|NCT00649285|DRUG|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
224021945|NCT03951506|OTHER|Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
224021946|NCT03951506|OTHER|Conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
224021947|NCT04994353|DIETARY_SUPPLEMENT|No supplementation|1st Week: No supplementation
224021948|NCT04994353|DIETARY_SUPPLEMENT|High Performance (HP) Inulin|2nd Week: Subjects consumed 20% v/v HP Inulin. Ingredients: 20 gram HP-Inulin diluted with 100 ml distilled water.
224021949|NCT04994353|DIETARY_SUPPLEMENT|Isomalto-oligosaccharide (IMO)|3rd Week: Subjects consumed 20% v/v Isomalto-oligosaccharide (IMO). Ingredients: 20 gram IMO diluted with 100 ml distilled water.
224021950|NCT04994353|DIETARY_SUPPLEMENT|Combination HP-Inulin and IMO|"4th Week: Subjects consumed20% v/v combination of HP-Inulin and Isomalto-oligosaccharide (IMO).~Ingredients: 20 gram IMO-HP Inulin Mix diluted with 100 ml distilled water."
223402105|NCT03886610|OTHER|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
223402106|NCT04735523|DRUG|Dabigatran|Dabigatran dispensing claim is used as the exposure group
223402107|NCT04735523|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
223402108|NCT05533593|DRUG|Aminoglycoside|Inpatients using aminoglycoside
223402109|NCT04369144|OTHER|Dynamic Scapular Recognition exercise|The intervention group received continual vertical downward correction using a standardized rigid tape. A hypoallergenic tape (Hypafix; BSN Medical GmbH, Hamburg, Germany) was used with 50% to 75% tension. Two rigid tapes were applied; the first one is placed from just superior to the midpoint of the superior border of the scapula to the level of T12 and the second tapes were placed from just superior to the superior angle of the scapula to the level of T12. The level of T12 was used as the end of both taps to increase the lever arm of the applied force and to decrease the incidence of peeling off of the tape. No tape was applied from the lateral angle of the scapula because it might impair the upward rotation of the scapula. Both taps were performed after each session and removed immediately before the next session
223402110|NCT05936060|BIOLOGICAL|INMUNOCEM|Mesenchymal Stromal Cell suspension intraarticularly injected
223553455|NCT00649285|DRUG|Macrobid® Capsules 100 mg|100mg, single dose fed
223553456|NCT01922362|DEVICE|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
223553457|NCT01922362|DEVICE|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
223553458|NCT00193011|DRUG|Docetaxel|Docetaxel
223553459|NCT00193011|DRUG|Cyclophosphamide|Cyclophosphamide
223553460|NCT00193011|DRUG|Methotrexate|Methotrexate
223553461|NCT00193011|DRUG|5-Fluorouracil|5-Fluorouracil
223553462|NCT04089670|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
223553463|NCT02351063|DRUG|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
224021951|NCT04994353|DIETARY_SUPPLEMENT|Dextrose solution|5th Week:Subjects consumed20% v/v Dextrose solution. Ingredients: 20 gram Dextrose powder diluted with 100 ml distilled water.
223734968|NCT01537029|DRUG|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
223734969|NCT02204163|DRUG|Eutropin|
223402111|NCT05936060|DRUG|PLACEBO COMPARATOR|Administration of plasmalyte as a vehicle for MSC
223402112|NCT01967966|DRUG|GDC-0032|Single oral dose
223402113|NCT01967966|DRUG|GDC-0032|Single IV dose
223402114|NCT00802230|DRUG|Terbutaline Infusion|
223402115|NCT05780125|DRUG|FibCLOT|30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration
223553464|NCT05516797|DEVICE|Continuous Glucose Monitoring (CGM)|Use of CGM (FreeStyle Libre 2) compared to BGM for glucose monitoring
223553465|NCT05641961|BEHAVIORAL|Survivorship mobile application|Mobile phone application
223734970|NCT02204163|DRUG|Genotropin|
224021952|NCT04994353|DIETARY_SUPPLEMENT|Glucose solution|6th Week:Subjects consumed 20% v/v Glucose solution. Ingredients: 20 gram glucose diluted with 100 ml distilled water.
224021953|NCT04242953|DRUG|SCO-120|"Part A: single oral administration~Part B: single oral administration in Period 1 and Period 2 (crossover design)~Part C: multiple oral administration (14 day dosing)"
224021954|NCT04242953|DRUG|matching placebo|"Part A: single oral administration~Part C: multiple oral administration (14 day dosing)"
224021955|NCT00069108|DRUG|5 FU|As prescribed, in 2 week cycles
224021956|NCT00069108|DRUG|Leucovorin|As prescribed, in 2 week cycles
224131962|NCT03972358|DRUG|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
223402116|NCT05780125|DRUG|RiaSTAP|30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration
223734971|NCT04637789|BEHAVIORAL|the whole body vibration|most people stand on the platform with knees bent at about a 30-degree angle, while the surface beneath their feet vibrates an astounding 30 times per second.
223402117|NCT03866512|BEHAVIORAL|Forearm immobilization|Two days of forearm immobilization
223734972|NCT04637789|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity,bands, weighted bars or dumbbells.
223734973|NCT02245490|DRUG|Tamsulosin HCl controlled release capsules|
223734974|NCT02245490|DRUG|Matching placebo capsule|
223734975|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
223734976|NCT00818662|BIOLOGICAL|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
223734977|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
224021957|NCT00069108|DRUG|Oxaliplatin|As prescribed, in 3 week cycles
224021958|NCT00069108|DRUG|Oxaliplatin|As prescribed, in 2 week cycles
224021959|NCT00069108|DRUG|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
224021960|NCT02611791|DEVICE|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
224131963|NCT05532098|PROCEDURE|Dry Needling|Dry Needling will be done for the patients with ADD of TMJ in the retrodiscal tissue and superior joint space .
224131964|NCT05532098|PROCEDURE|PRP|Patients with ADD are administered with 1ml of PRP into the retrodiscal tissue and the superior joint space. PRP will be prepared by method proposed by Okuda et al., 2003. Reinjection will be given after 2 weeks if required.
224131965|NCT00204997|PROCEDURE|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
223402118|NCT06254118|DRUG|Polyunsaturated Fatty Acids|1000mg omega-3 fatty acids taken once daily with meals for 12 months
223402119|NCT06254118|DIETARY_SUPPLEMENT|olive oil|1000mg olive oil taken once daily with meals for 12 months
223402120|NCT02328313|BEHAVIORAL|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
223402121|NCT03328507|DRUG|BLI4900|BLI4900 Bowel Preparation
223402122|NCT03328507|DRUG|PEG Control|Polyethylene glycol-based bowel preparation
223402123|NCT02262715|DRUG|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
223402124|NCT02262715|DRUG|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
223402125|NCT02262715|OTHER|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
223402126|NCT00997373|DRUG|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
223553466|NCT05641961|OTHER|Questionnaires|Questionnaires assessing cancer knowledge and system usability will be delivered to participants via Survivorship App
223553467|NCT06844058|BEHAVIORAL|Islamic-Oriented Ericksonian Hypnotherapy (IEH)|"This intervention involves 12 weekly sessions (60 minutes each) of Ericksonian hypnotherapy integrated with Islamic religious elements. Sessions incorporate:~Quranic metaphors and Islamic imagery Spiritual affirmations to enhance relaxation and emotional regulation Faith-based guided hypnosis adapted to cultural and religious beliefs Techniques such as indirect suggestions, therapeutic storytelling, and guided imagery The intervention is designed for Muslim participants with mild to moderate anxiety and depression."
223553468|NCT06844058|BEHAVIORAL|Standard Ericksonian Hypnotherapy (SEH)|"Participants receive 12 weekly sessions (60 minutes each) of standard Ericksonian hypnotherapy, which includes:~Metaphorical storytelling and guided imagery Indirect hypnotic suggestions to promote psychological flexibility Relaxation techniques to reduce anxiety and depressive symptoms Unlike the Islamic-Oriented Hypnotherapy (IEH), this intervention does not integrate religious or faith-based elements."
223402127|NCT05209867|DRUG|CBD oil|"* Each participant will be provided two 30mL(Milliliters) bottles (2000mg CBD per bottle) with a syringe dropper during their initial (baseline) visit with instructions to administer the solution under the tongue (0.5 cc \~1/2 dropper) twice per day (BID) 8-12 hours apart (morning and evening) at the prescribed daily dosage (63mg/day).~* The investigators plan to collect samples from five patients over three time points: baseline (no CBD), and after one and two months of CBD-administration"
223553469|NCT04113044|OTHER|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.
223553470|NCT06040008|GENETIC|blood collection|"* 3 blood collections over a period of 6 weeks~* V0 - Inclusion~* V1 - 3 weeks ± 14 days~* V2 - 3 weeks ± 14 days~* 1 EDTA 4 ml tube, 1 PAXgene RNA tube 2,5 ml and drops of blood from finger-prick are taken at each visit~* Clinical information obtained at each visit"
223402128|NCT01129063|DRUG|Clopidogrel|"Pharmaceutical form : tablet~Route of administration: oral"
223553471|NCT04433741|DRUG|Oxytocin|Oxytocin administered intravenously
223553472|NCT04433741|DRUG|Placebo|Placebo administered intravenously
223553473|NCT06525402|OTHER|Sodium Bicarbonate Group (Usual care)|In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group, the control group, will receive routine oral care in the clinic with sodium bicarbonate. Oral care will be applied 4 times a day for 14 days.
223553474|NCT06525402|OTHER|Saline Group|The second group, the experimental group, will first receive oral care routinely applied in the clinic. Then, oral care will be given in the form of 5 ml mouthwash with saline. Oral care will be applied 4 times a day for 14 days.
223734978|NCT00818662|BIOLOGICAL|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
223734979|NCT01472081|BIOLOGICAL|Nivolumab|
223734980|NCT01472081|BIOLOGICAL|Pazopanib|
223734981|NCT01472081|DRUG|Sunitinib|
223734982|NCT01472081|BIOLOGICAL|Ipilimumab|
223734983|NCT02632539|PROCEDURE|Manual air-impingement operation|A method which we invented to clear subglottic secretion
223734984|NCT02632539|PROCEDURE|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
223734985|NCT04881708|DEVICE|Remote Monitoring|Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
223734986|NCT03689803|PROCEDURE|sleeve gastrectomy|sleeve gastrectomy.
223734987|NCT03689803|PROCEDURE|gastric bypass|gastric bypass
223734988|NCT00630279|DRUG|Placebo|Placebo
223734989|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
223734990|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
223734991|NCT00630279|DRUG|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
223734992|NCT01183897|BIOLOGICAL|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
223734993|NCT01705652|DRUG|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
223734994|NCT05325450|PROCEDURE|Program A|Presentation of the sentence to the implant alone
223553475|NCT06525402|OTHER|Black Mulberry Syrup Group|The third group, the experimental group, will first receive oral care routinely applied in the clinic. Then black mulberry syrup will be applied. Then, oral care will be given in the form of 5 ml mouthwash with black mulberry syrup. Oral care will be applied 4 times a day for 14 days.
223553476|NCT04150640|DRUG|Nal-IRI|chemotherapy drug
223734995|NCT05325450|PROCEDURE|Program B|Presentation of the sentence to the implanted ear, associated for the non-implanted ear
223734996|NCT05325450|PROCEDURE|Control|Presentation of the sentences alternately to the most recently implanted ear and both implanted ears at the same time
223734997|NCT02269345|OTHER|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
223734998|NCT02269345|OTHER|Standard Treatment|Standard Treatment alone.
223734999|NCT00935844|DRUG|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
223735000|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
223735001|NCT01686633|DRUG|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
223735002|NCT01686633|DRUG|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
223735003|NCT03404557|OTHER|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
224021961|NCT02611791|DEVICE|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
223553477|NCT04150640|DRUG|Oxaliplatin|chemotherapy drug
224021962|NCT04413773|OTHER|Treatment as usual + Video|Additionally to treatment as usual a video is shown to participant about procedures on the ward before, during and after surgery
224021963|NCT04413773|OTHER|Treatment as usual|Explanation of standard procedures before, during and after surgery by nurse
224021964|NCT05026333|OTHER|Cognitive Stress Testing|Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
224021965|NCT05318547|OTHER|standard-gamble technique|"Participants will be asked to imagine a scenario in which they are experiencing one of the 4 described conditions in the long-term. They will declare their preference between (a) keeping this long-term condition as is, or using a painless hypothetical cure that is associated with some risk of death, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision whether to take the treatment or not. The utility will be calculated as 1 - the obtained risk of death of the point of equipoise. Health states will be evaluted in different orders across participants.~The elicitation of health state utilites by the standard-gamble technique is further clarified."
224131966|NCT01182948|BEHAVIORAL|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
224131967|NCT01182948|BEHAVIORAL|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
224131968|NCT05093413|BEHAVIORAL|Sleep deprivation|Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
224131969|NCT00617409|DRUG|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
223402129|NCT00323453|DEVICE|Open appendectomy using Alexis Wound Retractor followed by standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
223402130|NCT00323453|PROCEDURE|Open appendectomy with standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
223402131|NCT06258941|BEHAVIORAL|MF-HIIT|Two 10-min MF-HIIT sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
223402132|NCT06258941|BEHAVIORAL|HIIT-only|Two 10-min HIIT-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
223402133|NCT06258941|BEHAVIORAL|MF-only|Two 10-min MF-only sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
223402134|NCT06258941|BEHAVIORAL|Sedentary activity|Two 10-min sedentary sessions every school day during the 12-week intervention period. One session in the morning and one session in the afternoon.
223402135|NCT05583617|DRUG|Cevostamab|"Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles."
223402136|NCT05583617|DRUG|Lenalidomide|Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.
223402137|NCT05583617|DRUG|Tocilizumab|Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
223402138|NCT05583617|DRUG|Iberdomide|Iberdomide will be administered PO on days 1-14 of a 21-day cycle.
223735004|NCT01441310|PROCEDURE|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
223402139|NCT05583617|DRUG|Dexamethasone|Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
223402140|NCT06967610|DRUG|Pirtobrutinib|Given PO 200mg daily
223402141|NCT06967610|DRUG|Venetoclax|Given PO daily
223735005|NCT01364207|OTHER|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
223402142|NCT06967610|DRUG|Obinutuzumab|Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15
223553478|NCT04150640|DRUG|5-FU|chemotherapy drug
223553479|NCT04150640|DRUG|Trastuzumab|immunotherapy
223553480|NCT04150640|DRUG|Pembrolizumab|immunotherapy
223553481|NCT04150640|DRUG|Nivolumab|immunotherapy
223553482|NCT04012827|DRUG|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
223553483|NCT05936840|DEVICE|Mira Monitor tracking|Using the Mira monitor to track the menstrual cycle
223553484|NCT02805634|OTHER|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
223402143|NCT03827993|BEHAVIORAL|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
223402144|NCT00607074|DRUG|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
223402145|NCT00607074|DRUG|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
223402146|NCT00607074|DRUG|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
223402147|NCT06184204|DRUG|Trombix® (Rivaroxaban)|20mg or 15 mg as per the doctor's prescription
223402148|NCT06061809|DRUG|Bevacizumab|Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
223553485|NCT02805634|DEVICE|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
223553486|NCT04359524|DIETARY_SUPPLEMENT|Vitamin D3 (1200 IU/30µg)|
223553487|NCT04359524|DIETARY_SUPPLEMENT|Placebo|Placebo oil capsule
223553488|NCT00332579|DRUG|Naltrexone|daily
223553489|NCT00332579|DRUG|Placebo|daily
223553490|NCT05663177|DRUG|Almonertinib and metronomic oral vinorelbine|Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.
223735006|NCT01364207|OTHER|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
223735007|NCT05780567|DRUG|TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen|"TQB3616 is a novel Cyclin-dependent kinase (CDK) 4/6 inhibitor and currently being used in the treatment of a variety of malignant solid tumors.~Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer."
223735008|NCT05780567|DRUG|Placebo capsules, Letrozole, Anastrozole, Tamoxifen|Letrozole combined with Anastrozole and Tamoxifen is an endocrine therapy that involves adding, blocking, or removing hormones. It can be used for conditions that affect hormone levels, such as breast cancer.
223735009|NCT04982198|PROCEDURE|ROSA assisted TKA|Robotic assisted total knee arthroplasty
223735010|NCT00099346|DRUG|MK0457, VX-680 (Aurora Kinase Inhibitor)|
224297463|NCT05842096|DIAGNOSTIC_TEST|Evaluation of the impact of subclinical hypothyroidism, with present/ absent antithyroid antibodies, on the balance between anti- and pro-inflammatory factors in women in both study arms|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha depending on the blood concentrations of TSH, a-TPO and a-TG in women in both study arms
223402149|NCT06061809|DRUG|PD-L1 t-haNK|Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
223402150|NCT06061809|DRUG|N-803|Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
223402151|NCT06061809|DEVICE|Tumor Treating Fields (TTFields, 200 kHz)|"TTFields (OPTUNE Gio®), for the treatment of newly diagnosed and/or recurrent GBM, is a portable battery or power supply operated device which produces alternating electrical fields, called tumor treatment fields (TTFields) within the human body/brain. TTFields are applied to the patient by electrically-insulated surface transducer arrays. TTFields disrupt the rapid cell division exhibited by cancer cells. TTFields is comprised of two main components: (1) an Electric Field Generator and (2) INE Insulated Transducer Arrays (the transducer arrays). Patients carry the device in an over-the-shoulder bag or backpack and receive continuous treatment without changing their daily routine."
223553491|NCT05856929|OTHER|no Intervention|no intervention
223553492|NCT05129657|OTHER|Product A|Usual Brand (UB) filtered, non-menthol or menthol cigarette
223553493|NCT05129657|OTHER|Product B|P1012914, A nicotine pouch product with 4 mg of nicotine
223553494|NCT05129657|OTHER|Product C|P1012915, A nicotine pouch product with 8 mg of nicotine
223553495|NCT05129657|OTHER|Product D|P1012919, A nicotine pouch product with 12 mg of nicotine
223553496|NCT05129657|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
223553497|NCT02931643|OTHER|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
223735011|NCT06508216|DRUG|Dato-DXd|Patients in module 1 \& 2 will receive Datopotamab Deruxtecan (Dato-DXd) 6mg/kg every 21 days
223735012|NCT06508216|DRUG|Durvalumab|Patients in module 2 only will receive Durvalumab 1120mg every 21 days
223735013|NCT06458608|DEVICE|virtual reality glasses|virtual reality glasses
223735014|NCT01832025|PROCEDURE|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
223735015|NCT01832025|PROCEDURE|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
223735016|NCT01148745|DRUG|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
223735017|NCT03510286|DIAGNOSTIC_TEST|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
223402152|NCT05755438|DRUG|Ruxolitinib Cream|Ruxolitinib cream 1.5% twice daily (BID) during the vehicle controlled (DBVC)and open label treatment period (OLE).
223402153|NCT05755438|DRUG|Vehicle Cream|Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle controlled period (DBVC).
223402154|NCT06455137|DEVICE|Epidural Stimulator|Participants will have a 16-electrode epidural array implanted in the C4-C7 and T11-L2 areas of the spinal cord. Following a 2 weeks recovery period, patients will engage in a structured training of physical rehabilitation and electrical stimulation.
223402155|NCT05981989|DEVICE|Epidural electrical stimulation (EES)|Subjects will undergo a surgical procedure to implant a system that provides epidural electrical stimulation (EES) of the cervical spinal cord. After surgery, subjects will undergo a structured physical rehabilitation program and electrical stimulation.
223402156|NCT06668558|DRUG|Azacitidine (AZA)|"Dosing is 75 mg/m2 x 7 days (Q28days) After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
223402157|NCT06668558|DRUG|Venetoclax|"Dosing: 400 mg daily After 2 courses, a first decision-making for allo-HCT based on bone marrow MRD assessment will be performed. After 4th course, a new MRD assessment will be performed.~For cohort 1 treatment may continue up to cycle 12 (prioritized over allo-HCT). For cohort 2 treatment may continue up to cycle 24 (prioritizing allo-HCT)"
223553498|NCT02931643|OTHER|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
223553499|NCT05315674|DIAGNOSTIC_TEST|Frequent assessment of biomarker panel|During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
223553500|NCT06169787|PROCEDURE|sentinel lymph node biopsy|sentinel lymph node biopsy
223553501|NCT06169787|PROCEDURE|comprehensive pelvic lymphadenectomy|comprehensive pelvic lymphadenectomy
223553502|NCT02761473|OTHER|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
223553503|NCT02761473|OTHER|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
223553504|NCT03574376|DRUG|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
223553505|NCT03574376|DRUG|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
224131970|NCT00617409|BIOLOGICAL|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
223553506|NCT02331589|DRUG|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
223735018|NCT02756884|BIOLOGICAL|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
223735019|NCT02756884|BIOLOGICAL|adipose derived stem cells|control arm will only received the adipose derived stem cells.
223553507|NCT02331589|DRUG|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
223553508|NCT03162744|BEHAVIORAL|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
223553509|NCT06440122|DIAGNOSTIC_TEST|FDG-PET Scan|Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
223553510|NCT02407080|DRUG|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
223735020|NCT00397982|BIOLOGICAL|Bevacizumab|Given IV
223735021|NCT00397982|OTHER|Laboratory Biomarker Analysis|Correlative studies
223735022|NCT00397982|DRUG|Temsirolimus|Given IV
223735023|NCT00397982|PROCEDURE|Therapeutic Conventional Surgery|Undergo tumor resection
223402158|NCT06622850|OTHER|Acupressure|"In acupressure, cun is used as the unit of measurement to determine the points to be applied. In order to find the acupressure points correctly, measurements should be made using the individual\&#39;s own fingers. The thumb widths of the individuals participating in the study will be measured and converted as centimeter 1 cun unit. The points to be used in acupressure will be Shen Men (HT7) located in the transverse wrist crease, in the small depression between the pisiform and ulna bones, (LI11) located at the end of the crease when the elbow is bent, and Hegu (LI4) located in the space between the thumb and index finger will be marked by the certified researcher (GB) with an acetate pen in the patients in the study group. And the application will be performed by the certified researcher (GB)."
223402159|NCT06972901|BIOLOGICAL|Early faecal calprotectin dosage|An early dosage of faecal calprotectin will be done for the active arm group.
223402160|NCT05781295|DEVICE|TaurolockTM|The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
223735024|NCT05113186|DRUG|Lenvatinib Pill|"The design of study is summarized as follows:~* Neoadjuvant phase with lenvatinib for 21 days (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)~* PA of HCC in a curative intent (radiofrequency, microwave or electroporation)~* Adjuvant phase with lenvatinib for 3 months (rationale: compromise between expected benefit and acceptable tolerance without compromising ablation procedure)"
223735025|NCT01269697|DIETARY_SUPPLEMENT|Nutrof Total|2 capsules 2 times per day during 6 month
223735026|NCT01269697|DIETARY_SUPPLEMENT|Placebo Nutrof total|2 capsules 2 times per day during 6 month
223735027|NCT04244786|DEVICE|Transcranial direct current stimulation|tDCS is a low-cost, portable, well-tolerated, non-invasive form of brain stimulation that delivers a low current to a specific area of the brain via electrodes.
223735028|NCT04244786|OTHER|No intervention|No intervention for participants who discontinued prior to randomization
223735029|NCT05584696|OTHER|Green light exposure|The experimental group wears green color glasses ten minutes before surgery until it ends.
223735030|NCT05584696|OTHER|Normal light exposure|The control group wears green color glasses ten minutes before surgery until it ends.
223735031|NCT02659527|DRUG|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
223735032|NCT02659527|DEVICE|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
223735033|NCT01101347|DEVICE|Aneurysm-Embolization System|
223735034|NCT05693714|DIAGNOSTIC_TEST|Pcr|Polymerase chain reaction
223735035|NCT01424254|DEVICE|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
223735036|NCT01424254|PROCEDURE|Push-Enteroscopy|currently recommended standard
223735037|NCT00264641|DRUG|Human insulin|Hyperinsulinaemic induced hypoglycaemia
223735038|NCT02107027|DEVICE|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
223735039|NCT02107027|DEVICE|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
223735040|NCT03376854|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
223735041|NCT03376854|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
223402161|NCT05781295|DEVICE|Physiological serum|The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
223735042|NCT03376854|DEVICE|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
223735043|NCT00074087|DRUG|pegylated liposomal doxorubicin hydrochloride|
223735044|NCT03032367|DRUG|bedaquiline|
223735045|NCT01238679|DRUG|PF-04958242|Administered as specified in the treatment arm
223735046|NCT01238679|DRUG|Placebo|Administered as specified in the treatment arm
223735047|NCT02703909|DRUG|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
223735048|NCT02703909|DEVICE|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
223735049|NCT01830582|PROCEDURE|Advanced MR Imaging|
223735050|NCT00613938|DRUG|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
223735051|NCT00613938|DRUG|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
223735052|NCT00613938|DRUG|oxycodone|10mg capsule q4-6 hrs for 3 days
223735053|NCT00613938|DRUG|placebo|1 capsule q4-6 hrs for 3 days
223735054|NCT00480272|DRUG|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
223735055|NCT00480272|DRUG|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
223735056|NCT02939235|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
224021966|NCT05318547|OTHER|time trade-off technique|Participants will be asked to declare their preference between 50 years of life with the symptoms of 1 of the conditions, or 50-X years without these symptoms, with the help of a visual aid on a laptop or tablet. A ping-pong technique will be applied until the point of equipoise is reached, when there is indecision on the preference of the 2 choices. The utility will be calculated as the 50-x/50 obtained at this point of equipoise. Health states will be evaluted in different orders across participants.
224021967|NCT02873091|PROCEDURE|Epidural analgesia|
224131971|NCT00617409|DRUG|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
224021968|NCT02873091|PROCEDURE|Continuous epidural infusion|
224021969|NCT02873091|PROCEDURE|Intermittent epidural bolus|
224021970|NCT02873091|DRUG|ropivacaine|
224021971|NCT02873091|DRUG|sufentanil|
224021972|NCT04677166|DEVICE|Negative pressure wound therapy coupled with instillation|Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.
224021973|NCT04677166|DEVICE|Standard Negative Pressure Wound Therapy|standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
224021974|NCT03869151|DIAGNOSTIC_TEST|CBC|lymphocyte and monocyte count
224021975|NCT00569556|OTHER|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
224021976|NCT05126758|BIOLOGICAL|Deramiocel (CAP-1002)|Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
223402162|NCT00832702|PROCEDURE|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
223402163|NCT03523416|DEVICE|Transcatheter Atrial Shunt System|Transcatheter treatment of symptomatic left heart failure patients
224021977|NCT05126758|BIOLOGICAL|Placebo|Placebo
224021978|NCT00116337|PROCEDURE|Spinal Cord Stimulation to restore cough|Participants will have small electrodes (metal discs) placed - by a routine surgical procedure - over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
224021979|NCT00116337|DEVICE|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
223402164|NCT04712474|BEHAVIORAL|In-home decluttering practice|"The in-home decluttering intervention comprises 10, 1.5-hour home-visits over the course of 10 weeks.~These home visits are personalized, goal-oriented and focused on decluttering. They include 1) a brief check-in, 2) guided unclutter time 3) a reflective period during which participants share their thoughts and objectives for the coming week, and 4) homework assignments."
224021980|NCT05379660|DEVICE|transcutaneous electrical acupoint stimulation|Basing on the theory of traditional Chinese medicine, bilateral Zusanli (ST 36), Shangjuxu (ST 37) and Sanyinjiao (SP 6) are elected as the acupuncture points,the electrode pads with wire are attached to the corresponding acupoints, which are connected with Hwato electric acupuncture treatment instrument,TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s, and the intensity 5 \~ 12mA,on the first and second days after surgery, the doctor who is responsible for acupuncture will arrive at the ward in the morning and afternoon to administer TEAS stimulation at the same acupoints for 30 min in the TEAS groups
224021981|NCT03775889|BEHAVIORAL|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
224021982|NCT03486847|PROCEDURE|Repetitive recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.
224131972|NCT05632627|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to improvements in cognition, TBI-related symptoms, pain, sleep, depression, anxiety, and peripheral markers of inflammation and oxidative stress.
224131973|NCT05632627|DRUG|Placebo|Placebo arm
223553511|NCT02407080|DRUG|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
223553512|NCT00002848|PROCEDURE|psychosocial assessment and care|
223553513|NCT00002848|PROCEDURE|quality-of-life assessment|
224021983|NCT03486847|PROCEDURE|One recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
223553514|NCT01827436|BEHAVIORAL|Conventional physical therapy|
223553515|NCT01827436|BEHAVIORAL|Asymmetrical gait training|
223553516|NCT01193634|DEVICE|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
223553517|NCT01581229|PROCEDURE|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
223553518|NCT01581229|PROCEDURE|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
224021984|NCT02208999|DEVICE|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
224021985|NCT01468467|DRUG|AC220|Oral Liquid
224021986|NCT00319839|DRUG|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
223553519|NCT04491682|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
223553520|NCT04491682|DRUG|Rosuvastatin|At a dosage of 10 mg/day
223553521|NCT04510987|DRUG|BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5|Tablet, oral
223553522|NCT04510987|OTHER|BAY2433334 on dialysis treatment day|Tablet, oral
223553523|NCT02895672|DRUG|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
224021987|NCT00319839|DRUG|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
224021988|NCT03287531|OTHER|conventional therapy|Exercise therapeutic Ultrasound
223402165|NCT05534009|OTHER|Follow up of the first known immunization event|"The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved.~HCWs can be enrolled in the category of:~(i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection."
223402166|NCT05279027|DRUG|Zirconium Zr 89 Crefmirlimab Berdoxa|Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation
223402167|NCT05832671|PROCEDURE|Erector Spinae muscle block|In the ESB group, the patient will be placed in the lateral position. The site of surgery is upward. After skin preparation using 10% povidone-iodine, a high-frequency linear ultrasound transducer will be placed over the ipsilateral site of surgery 1-2 cm lateral to the spine at the T10 level, counting upward from the sacrum. After identifying the erector spinae muscles and transverse process, a needle will be inserted with an in-plane technique in the craniocaudal direction
223735057|NCT02939235|DRUG|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
224021989|NCT03287531|OTHER|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
224021990|NCT02814201|BEHAVIORAL|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
224021991|NCT02826915|DEVICE|Near Infra Red Spectroscopy (NIRS)|
224021992|NCT02826915|DEVICE|Electroencephalogram (EEG)|
224131974|NCT03638661|DIETARY_SUPPLEMENT|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
224131975|NCT03638661|DIETARY_SUPPLEMENT|soybean oil|soybean oil used formula
223402168|NCT05832671|PROCEDURE|caudal block|In the CB group, patients will be placed in a lateral position. An ultrasound transducer is first placed transversely at the midline to obtain a transverse view of the 2 cornua, the sacrococcygeal ligament, sacral bone, and sacral hiatus. At this position, the ultrasound transducer will be twisted to 90° to obtain longitudinal views of the sacrococcygeal ligament and sacral hiatus and will be subsequently placed between the 2 cornua and on visualization of the frog sign (the 2 sacral cornua identified as 2 hyperechoic reverse U-shaped structure) the needle will be inserted into the sacral canal under direct real-time longitudinal visualization. After negative aspiration for blood or cerebrospinal fluid, bupivacaine (0.25%) 2.5 mg/kg will be injected over a one minute period while observing an ultrasound longitudinal image.
223402169|NCT04579848|DRUG|Methotrexate Tablets|Methotrexate 2.5mg oral tablet.
223402170|NCT04579848|DRUG|Placebo|Placebo capsule
223402171|NCT04579848|DRUG|Folic Acid 1 MG|Folic acid
223402172|NCT04556890|DEVICE|Active rTMS/Active iTBS DFPLC/Sham Pain M1|Active rTMS treatment for depression (600 pulses of active intermittent theta burst (iTBS) administrated at 120% MT to the left DLPFC) and sham treatment for pain at M1
223402173|NCT04556890|DEVICE|Active rTMS/Active iTBS|Active rTMS treatment for both, depression and pain (600 pulses of iTBS to left DLPFC followed by 600 iTBS + 1500 pulses of 10 Hz to M1
223402174|NCT05267236|OTHER|Intervention #1: Treatment Group Receiving On-Demand TYRO Services|Treatment group participants receive TYRO Couples curriculum in an on-demand format that is delivered in five 2-hour weekly sessions for a total of 10 hours.
223402175|NCT05267236|OTHER|Intervention #2: Control Group Receiving In-Person TYRO Services|Control group participants receive TYRO Couples curriculum in a live format (virtual or in-person) that is delivered in five 2-hour weekly sessions for a total of 10 hours.
223402176|NCT04876157|DIAGNOSTIC_TEST|Artificial intelligence-aimed point-of-care ultrasound image interpretation system|improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
224131976|NCT00407914|DEVICE|Aquamid|Subcutaneous injection
224131977|NCT00407914|DEVICE|Restylane|Injection in dermis
223553524|NCT02715830|PROCEDURE|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
223553525|NCT04771416|BIOLOGICAL|PBKR03|Single dose of PBKR03, via intra cisterna magna
223553526|NCT02800694|DRUG|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
223553527|NCT02681419|PROCEDURE|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
223553528|NCT02681419|PROCEDURE|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
223553529|NCT02358161|DRUG|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
224131978|NCT04124536|BEHAVIORAL|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
224131979|NCT03164512|DRUG|Oral or vaporized cannabidiol|Acute drug exposure
224131980|NCT03164512|DRUG|Placebo|Placebo capsule/vapor
223402177|NCT06572917|DRUG|Indomethacin|Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
223402178|NCT06572917|DRUG|Placebo|Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
223402179|NCT03210714|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223735058|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of right HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of right HS-tunnel randomized to active treatment.
223402180|NCT03210714|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo a bone marrow aspiration and/or biopsy
223402181|NCT03210714|PROCEDURE|Bone Scan|Undergo a bone scan
223402182|NCT03210714|PROCEDURE|Computed Tomography|Undergo a CT scan
223402183|NCT03210714|DRUG|Erdafitinib|Given PO
223402184|NCT03210714|OTHER|Laboratory Biomarker Analysis|Correlative studies
223402185|NCT03210714|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223402186|NCT03210714|OTHER|Pharmacological Study|Correlative studies
223402187|NCT03210714|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223402188|NCT03210714|PROCEDURE|Radionuclide Imaging|Undergo radionuclide imaging
223402189|NCT03210714|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223402190|NCT05691166|BEHAVIORAL|High-intensity progressive resistance training|Supervised high-intensity progressive resistance training twice per week for 12 months
223402191|NCT05691166|OTHER|General practitioner care|Referred to general practitioner (GP) for further follow-up. The GPs will be informed about participants sarcopenia status with results from assessments of muscle strength, muscle mass, and physical performance. The management of the sarcopenia is at the GPs own discretion.
223735059|NCT04508374|PROCEDURE|1470 nm intra-lesional diode laser treatment of left HS tunnel|Ten patients: 1470 nm intra-lesional diode laser treatment of left HS-tunnel randomized to active treatment.
223735060|NCT02636868|DRUG|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
223735061|NCT02636868|DRUG|nCPAP|Nasal CPAP
223402192|NCT06807463|DRUG|TEV-53408|Solution for subcutaneous (sc) injection
223402193|NCT06807463|DRUG|Placebo|Solution for subcutaneous (sc) injection
223402194|NCT03969004|DRUG|Cemiplimab|Intravenous (IV) infusion over 30 minutes
223402195|NCT03969004|DRUG|Placebo|Intravenous (IV) infusion over 30 minutes
223402196|NCT06982573|DEVICE|Effects of applying magnetic stimulation|The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients with End-Stage Renal Disease (ESRD)
223402197|NCT06820099|DRUG|HRS-7535 tablet|HRS-7535 tablet.
223402198|NCT06820099|DRUG|HRS-7535 tablet placebo|HRS-7535 tablet placebo.
223402199|NCT01956773|OTHER|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
223402200|NCT00450437|BIOLOGICAL|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
223402201|NCT00450437|BIOLOGICAL|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
223402202|NCT00486785|DRUG|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
223402203|NCT05880875|BEHAVIORAL|Reflective Supervision Enhancement|The Reflective Supervision enhancement is a professional development series designed to train and support directors and education coordinators supervising state pre-kindergarten classrooms in using a reflective supervision approach with their staff.
223402204|NCT06661629|DEVICE|Nerve stimulation|The intervention is testing the effect of unilateral versus bilateral hypoglossal nerve stimulation on upper airway collapsibility during drug-induced sleep endoscopy
223402205|NCT06859918|BEHAVIORAL|TUNE In: Training to Understand and Navigate Emotions and Interactions|A cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, and social skills.
223402206|NCT03839069|PROCEDURE|minor salivary gland transplantation|The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
223402207|NCT03585569|BIOLOGICAL|Abobotulinumtoxin A|Treating Patients with Multiple Sclerosis with lower extremity spasticity using Dysport (Abobotulinumtoxin A)
223402208|NCT05114889|BIOLOGICAL|BSI-045B|BSI-045B will be administered weekly, subcutaneously
223402209|NCT06669780|DEVICE|AMMO PTH DTx|An online cognitive behavioral therapy program accessed through a online program.
223402210|NCT06669780|DEVICE|AMMO SHAM|Online activities not including CBT in the AMMO online program.
223402211|NCT05263245|OTHER|Light breakfast|Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
223553530|NCT06084754|DEVICE|pulsed electromagnetic field|pulsed electromagnetic field will be over the site of osteomyelitis where patient in supine lying position. the treatment parameters will be set as10 HZ frequency , 20 gauss amplitude, duration about 120 minutes.
223553531|NCT06084754|DRUG|Antibiotics|Vancomycin IV injection 1gm divided 250mg every 6hours
223553532|NCT02403817|BEHAVIORAL|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
223553533|NCT02403817|BEHAVIORAL|Eye Motor Training|Game play will be controlled by the player's eye movements (via an eye tracking device)
223553534|NCT02403817|BEHAVIORAL|Hand Motor Training|Game play will be controlled by the player's hand movements (via a joystick).
223553535|NCT04699695|OTHER|Biologic therapy versus no biologic therapy|Biologic therapy administered per standard of care
223553536|NCT02603237|OTHER|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
223553537|NCT02603237|OTHER|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
223402215|NCT06864351|OTHER|OptiThyDose|"OptiThyDose is an iterative mathematical model applied at each patient visit, consisting of three components: (i) a disease-specific pharmacometrics (PMX) model, (ii) an empirical Bayesian estimation (EBE) component, and (iii) an optimal control theory (OCT) component. It calculates the optimal LT4 or CMZ/MMZ dose to maintain Free Thyroxine (FT4) levels within the upper half of the age-specific reference range, integrating past clinical and lab data.~Dosing follows international guidelines, with physicians able to consult OptiThyDose for individualized dosing within recommended ranges. At each outpatient visit, the physician can either (A) prescribe a dose within OptiThyDose's suggested range or (B) choose a dose based on personal experience."
223402216|NCT01502657|DEVICE|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
223402217|NCT05382793|DIETARY_SUPPLEMENT|Control|No iodine
223402218|NCT05382793|DIETARY_SUPPLEMENT|Iodide (150 μg/day)|A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide
223402219|NCT05382793|DIETARY_SUPPLEMENT|Iodine (300 μg/day)|Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide
223402220|NCT05429372|GENETIC|PF-06939926|All participants will receive a single dose of PF-06939926 on Day 1.
223402221|NCT05137119|DRUG|Cefazolin|Cefazolin
223402222|NCT05137119|DRUG|Penicillin|benzylpenicillin
223402223|NCT05137119|DRUG|Clindamycin|Clindamycin
223402224|NCT05137119|DRUG|Vancomycin|Vancomycin or Daptomycin
223402225|NCT05137119|OTHER|Effectiveness of early switch to oral antibiotics|This involves testing a strategy rather than individual antibiotic agents
223553538|NCT05360693|PROCEDURE|immediate implant placement without bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done \& patients will receive an immediate post-extraction implant without any grafting material in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
223735062|NCT00590109|OTHER|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
223735063|NCT00590109|OTHER|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
223402226|NCT05137119|RADIATION|Whole body FDG PET/CT Imaging|Whole body FDG PET/CT imaging will be performed using a standardised protocol describing patient preparation and minimum specifications for radiopharmaceutical production, quality control, and PET/CT acquisition.
223402227|NCT04524533|BEHAVIORAL|Experimental smoking cessation video|Participants who are randomized to the intervention group will watch an educational video that includes tips on quitting smoking during a dental cleaning. The video is approximately 10 minutes long and tailored to readiness to quit at the time of the dental visit.
223402228|NCT04524533|BEHAVIORAL|Control video|Participants randomized to the control group will watch a 10 minute video.
223402229|NCT04524533|OTHER|Brochure of smoking cessation EBTs|All participants will receive identical print materials on EBTs consistent with smoking cessation standard clinical care.
223402230|NCT04524533|BEHAVIORAL|Tailored text message program|Participants randomized to the intervention group will be enrolled in a 4-week tailored text message program which includes assessment questions in addition to text messages geared towards motivating and facilitating EBT utilization for individuals ready to quit smoking and individuals who are not ready to quit smoking.
223402231|NCT04524533|OTHER|Assessment text messages|Participants randomized to the control group will be enrolled in a different 4-week text message program that includes only assessment questions.
223402232|NCT02792010|DEVICE|Hip cartilage MRI|Hip cartilage MRI
223735064|NCT02443012|DRUG|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
223735065|NCT02443012|PROCEDURE|Laser|Grid/Focal Laser Photocoagulation
223735066|NCT05124951|RADIATION|Whole-ventricle irradiation|Whole-ventricle irradiation will be applied in patients with localized basal ganglia germ cell tumors after induction chemotherapy
223735067|NCT05124951|DRUG|Carboplatin/etoposide|Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
223735068|NCT05124951|DRUG|Ifosfamide/cisplatin/etoposide|Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
223402233|NCT07003295|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223735069|NCT05124951|PROCEDURE|Second-look surgery|Second-look surgery would be applied to patients who presented residue disease after induction chemotherapy.
223402234|NCT07003295|PROCEDURE|Computed Tomography|Undergo PET/CT
223735070|NCT01288950|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
223735071|NCT03220217|DRUG|Satoreotide trizoxetan 5-20μg|Positron emission tomography (PET) imaging agent
223735072|NCT03220217|DRUG|Satoreotide trizoxetan 30-45μg|Positron emission tomography (PET) imaging agent
223735073|NCT01755923|DRUG|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
223735074|NCT01755923|DRUG|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
223735075|NCT00376909|OTHER|educational intervention|
224021993|NCT02652871|DRUG|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
224021994|NCT02652871|DRUG|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients \> 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
223402235|NCT07003295|BIOLOGICAL|Glofitamab|Given IV
223402236|NCT07003295|BIOLOGICAL|Obinutuzumab|Given IV
223402237|NCT07003295|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223402238|NCT07004556|DIAGNOSTIC_TEST|Preoperative blood sampling for determining Phoenixin 14 levels|In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected.
223402239|NCT07004556|DIAGNOSTIC_TEST|Postoperative blood sampling for determining Phoenixin 14 levels|In addition to routine blood draws for postoperative controls, 5 ml of blood will be collected.
223402240|NCT02583451|DRUG|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
223402241|NCT02583451|DRUG|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
223402242|NCT02583451|DRUG|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
223402243|NCT02583451|DRUG|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
223402244|NCT02583451|DRUG|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
223402245|NCT02583451|DRUG|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
223402246|NCT05556772|PROCEDURE|Biospecimen Collection|Collection of blood; urine; cervical, anal, vaginal samples
223402247|NCT05556772|OTHER|Interview|Attend interview
223553539|NCT05360693|PROCEDURE|immediate implant placement with socket bone grafting|After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
223553540|NCT03277430|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
223553541|NCT03277430|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
223735076|NCT00376909|OTHER|study of socioeconomic and demographic variables|
223735077|NCT04759872|OTHER|Hyperinsulinemic-euglycemic Clamp|Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
224021995|NCT02652871|DRUG|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age \< 60 years). In patients \> 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
224021996|NCT05784220|BEHAVIORAL|DPP Curriculum for Lifestyle Intervention|See arms.
223402248|NCT06864780|OTHER|Posture Correction Exercises|This intervention focuses on improving forward head posture (FHP) through a series of corrective exercises aimed at enhancing cervical alignment, reducing muscle strain, and reinforcing proper posture habits. The exercises include chin tucks, cervical retraction with resistance bands, shoulder blade squeeze, and wall posture alignment. Participants will receive hot pack therapy (15-20 mins) for cervical muscle relaxation and TENS (10 mins) for pain relief before and after exercises. These exercises target deep cervical flexors and postural stabilizers to help retrain the neck and upper back muscles, promoting long-term postural correction. The intervention will be performed 3 times per week for 6 weeks under supervision, with a focus on maintaining correct postural alignment during daily activities.
223402249|NCT06864780|OTHER|Strengthening and Stretching Exercises|This intervention aims to address muscle imbalances associated with forward head posture (FHP) by incorporating stretching of tight muscles (upper trapezius, levator scapulae) and strengthening of weak postural muscles (deep neck flexors, scapular stabilizers). The exercises include upper trapezius stretch, levator scapulae stretch, deep neck flexor strengthening, and scapular retraction with resistance bands. Participants will undergo hot pack therapy (15-20 mins) for cervical muscle relaxation and TENS (10 mins) for pain relief before and after exercises. The stretching exercises will help release tension in overactive muscles, while strengthening exercises will restore muscular balance, improving posture and reducing neck discomfort. The intervention will be conducted 3 times per week for 6 weeks with supervised sessions to ensure proper technique and progressive improvement in flexibility and strength.
223402250|NCT05111561|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223402251|NCT05111561|DRUG|Binimetinib|Given PO
223402252|NCT05111561|PROCEDURE|Biopsy Procedure|Undergo biopsy
223402253|NCT05111561|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223402254|NCT05111561|PROCEDURE|Computed Tomography|Undergo CT
223402255|NCT05111561|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223402256|NCT01019343|PROCEDURE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
223402257|NCT01019343|DEVICE|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
223402258|NCT01019343|DEVICE|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
223402259|NCT01019343|OTHER|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
224021997|NCT03017300|DEVICE|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
224021998|NCT03017300|DEVICE|PFLEX®|A device used to offer resisive to inspiratory muscle
223402260|NCT01019343|OTHER|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
223402261|NCT01019343|DEVICE|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
223402262|NCT01019343|DEVICE|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
223402263|NCT01019343|DIAGNOSTIC_TEST|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion-tracking system that is designed to measure various aspects of a person s gait.
223402264|NCT01019343|DEVICE|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non-significant risk device by the CNS IRB.
223402265|NCT01019343|PROCEDURE|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2-inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
223402266|NCT01019343|OTHER|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non-exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
223402267|NCT01019343|PROCEDURE|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see sub-section EMG 7.1.3.1 for the details of the procedure).
223402268|NCT01019343|PROCEDURE|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
223402269|NCT01019343|PROCEDURE|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
223402270|NCT01019343|PROCEDURE|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
223553542|NCT03277430|DRUG|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
223553543|NCT04545866|DRUG|budesonide (Pulmicort nebulizing suspension).|The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
223553544|NCT04545866|DRUG|surfactant (poractant alfa;Curosurf)|The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
224021999|NCT02847247|DRUG|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
224022000|NCT04694443|PROCEDURE|Multidisciplinary tele-health intervention (physical therapy, neurologist, nurse, psychologist)|Non-pharmacological and pharmacological treatment provided by telemedicine plus in-office visits
224022001|NCT04694443|OTHER|Standard in-office medical care|Non-pharmacological and pharmacological treatment provided in-office visits
224022002|NCT05973435|OTHER|Blood sampling|Blood sample would be taken from the participants in the study for these analyses on three occasions in 3 test tubes (before cesarean section, during cesarean section and after cesarean section).
224022003|NCT01049295|DIETARY_SUPPLEMENT|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
224022004|NCT01049295|OTHER|corn oil pearls|corn oil pearls 3 times a day
224022005|NCT05485467|DIAGNOSTIC_TEST|coronary CT angiography|Coronary CT angiography will be performed on multislice Siemens Somat Force CT scanner
224022006|NCT01246739|PROCEDURE|Adrenalectomy|Adrenalectomy (open or laparoscopic)
224022007|NCT05279001|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
224131981|NCT04281342|DRUG|Aprocitentan 25 mg|Repeated administration of a 25 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
224131982|NCT04281342|DRUG|Aprocitentan 100 mg|Repeated administration of a 100 mg oral dose of aprocitentan, once daily from Day 1 to Day 10, followed by 18 days of observation.
223402271|NCT01019343|PROCEDURE|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square-wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
223402272|NCT01019343|PROCEDURE|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
224022008|NCT04100031|DEVICE|bandage contact lenses|wear bandage contact lensesfor a week after cataract surgery.
224022009|NCT04100031|PROCEDURE|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
224022010|NCT02199704|OTHER|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders \& Turner, 1999) and up to ten sessions of support. This is a case series study."
224022011|NCT04912271|DRUG|Granisetron transdermal patch|Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting.
224022012|NCT04912271|DRUG|Palonosetron|Palonosetron is a second-generation 5-HT3 receptor antagonist with proposed higher efficacy and sustained action for prophylaxis of postoperative nausea and vomiting (PONV).
224131983|NCT04281342|DRUG|Matching placebo|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 10, followed by 18 days of observation.
224131984|NCT04281342|OTHER|Moxifloxacin control to establish assay sensitivity|Repeated administration of an oral dose of aprocitentan-matching placebo, once daily from Day 1 to Day 9. On Day 10, oral administration of one single 400 mg moxifloxacin tablet open-label, followed by 18 days of observation.
224131985|NCT03314441|BEHAVIORAL|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
224131986|NCT00459485|DIETARY_SUPPLEMENT|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
224131987|NCT00459485|DIETARY_SUPPLEMENT|Placebo|Daily placebo for 3 weeks
224131988|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10\^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
223402273|NCT01019343|PROCEDURE|Trancutaneous spinal direct current stimulation (tsDCS)|Direct current (DC) stimulation is a non invasive tool used to promote plasticity of the central nervous system. Recently, DC stimulation has been applied to the human spinal cord, and known as transcutaneous spinal direct current stimulation (tsDCS).
223402274|NCT03958747|DIAGNOSTIC_TEST|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
223402275|NCT03958747|PROCEDURE|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
224022013|NCT04912271|DRUG|Aprepitant|Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors.
224022014|NCT04912271|DRUG|Fosaprepitant|Fosaprepitant is a neurokinin-1 receptor antagonist, approved for the prevention of chemotherapy-induced nausea and vomiting.
224022015|NCT04912271|DRUG|Dexamethasone|Dexamethasone, one of the glucocorticoids, has been suggested as a first-line drug for preventing low-level emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting.
224131989|NCT03038243|BIOLOGICAL|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10\^11 Sf2WC cells administered orally on Days 0, 28, and 56
224131990|NCT03038243|OTHER|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
224022016|NCT04894487|BEHAVIORAL|THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY|Using of baby mobile and listening Brahms Lullaby during sternum dressing process
224022017|NCT04086654|DIAGNOSTIC_TEST|International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version|The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
224131991|NCT01879176|DEVICE|CytoSorb|
224131992|NCT01226355|DEVICE|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
224131993|NCT02843646|DEVICE|Walk Aide training|
224131994|NCT02864966|DEVICE|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
224131995|NCT01763021|DRUG|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
224131996|NCT01763021|DRUG|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
224131997|NCT03357146|DEVICE|Optical coherence tomography angiography|OCTA scans per built-in device protocol
224131998|NCT04596280|PROCEDURE|Colonic Resection|Resection of the colonic tract which has been interested by the acute diverticulitis
224131999|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 20J|120W Lumenis Holmium:YAG laser 20J
224132000|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 40 J|120W Lumenis Holmium:YAG laser 40J
223402276|NCT03958747|OTHER|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
224132001|NCT04699552|DEVICE|120W Lumenis Holmium:YAG laser 60 J|120W Lumenis Holmium:YAG laser 60J
224132002|NCT02918409|DRUG|Colistin|
224132003|NCT02918409|DRUG|Tobramycin|
224022018|NCT06414694|PROCEDURE|Direct Oral Challenge|Direct oral challenge to penicillin at a goal dose of 45 mg/kg given in a 10%/90% dose
224022019|NCT02285465|DRUG|ASP3700|Oral
224022020|NCT02285465|DRUG|Placebo|Oral
223735078|NCT03854656|OTHER|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
223735079|NCT06308120|DEVICE|Ion Endoluminal System|Participants in the test arm will undergo a diagnostic bronchoscopy with ION™ Endoluminal System.
223735080|NCT06308120|DEVICE|superDimension Navigation System and Accessories|Participants in the control arm will undergo a diagnostic bronchoscopy with superDimension Navigation System and Accessories.
224022021|NCT02796157|DEVICE|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
224022022|NCT02796157|DEVICE|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
224132004|NCT05236881|DEVICE|ANíMATE mobile application|mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
224132005|NCT00139425|BEHAVIORAL|Disease Management Assessment|
224132006|NCT00209521|DRUG|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
224132007|NCT00209521|DRUG|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
223402277|NCT03958747|OTHER|Blood draw|12 ml blood sample will be taken
223402278|NCT03958747|DIAGNOSTIC_TEST|Nerve Conduction Study|Sural and tibial nerve assessments
223402279|NCT03958747|OTHER|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
223553545|NCT03989375|DEVICE|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
224132008|NCT04090905|OTHER|Standard clinical monitoring|Standard observation in either a surgical ward (utilizing the National Early Warning Score) or the intensive care unit with continuous respiratory and circulatory monitoring.
224132009|NCT04090905|DIAGNOSTIC_TEST|Holter monitoring|Cardiac rhythm monitoring before, during, and until hospital discharge (preferably ≥72 hours after abdominal surgery)
224132010|NCT06498752|DRUG|PD-1 monoclonal antibody consolidation therapy|PD-1 monoclonal antibody-based consolidation therapy for 1 year after completion of radiotherapy (or combination chemotherapy up to 4 cycles if less than 4 cycles of chemotherapy). Specific dosing: PD-1 monoclonal antibody, 200mg every 3 weeks.
224132011|NCT03741725|OTHER|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
224132012|NCT03741725|OTHER|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
223402280|NCT07036523|DRUG|BI 765423|BI 765423
223402281|NCT07036523|DRUG|Placebo|Placebo to BI 765423
223402282|NCT06708936|BIOLOGICAL|KSD-201|Patients will receive approximately 5x10\^6 cells/dose DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.
223402283|NCT06882746|DRUG|BI 765049|BI 765049
223553546|NCT05204576|BEHAVIORAL|CBT4CBT COPES|Individuals will receive standard agonist treatment plus access to the CBT4CBT-COPES website plus daily IVR assessment calls
223735081|NCT01384396|DRUG|KW-3357|Intravenous infusion once a day
223735082|NCT03025542|DRUG|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
223735083|NCT03025542|OTHER|Placebo|Subjects will receive injections of Placebo.
223735084|NCT02635828|DRUG|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
223735085|NCT02635828|DRUG|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
223735086|NCT02635828|DRUG|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
223735087|NCT03745937|DRUG|MEDI0382|Subcutaneous dose of MEDI0382 will be up-titrated weekly once daily up to 8 weeks during the uptitration period and thereafter once daily in 3-week TEP.
223735088|NCT03745937|DRUG|Placebo|Subcutaneous dose of placebo matched to MEDI0382 will be administered once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
224022023|NCT04262973|OTHER|education|six-hour dementia care course
224022024|NCT04262973|OTHER|education and workshop|six-hour dementia care course, half-day interprofessional education workshop, and interprofessional practice
224022025|NCT04256577|DIAGNOSTIC_TEST|serum ceramides level in blood|Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
224132013|NCT06027931|PROCEDURE|Conservative Access Opening, Traditional Access Opening|Conservative Access Opening will be used and evaluated for cleaning ability versus Traditional Access Opening.
223402284|NCT06707766|OTHER|Oculomotor Exercise along with conventional Therapy|"Oculomotor Exercises: Saccadic eye movement, Smooth pursuit, Adaptation X1, Adaptation X2.~Time duration will be 2 minutes for each exercise.~conventional therapy: hot pack 20 mins Kendall exercises: Strengthening the deep cervical flexor, Stretching the cervical extensors, Strengthening shoulder retraction, Stretching of the pectoralis major muscle strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~Total duration of treatment would be 4 weeks, 3 days a week with total 12 sessions."
223402285|NCT06707766|OTHER|sub-occipital muscle energy technique along with Conventional Therapy|"Sub-occipital muscle energy technique (PIR) 3 rep \* 1 set with 20 sec hold~conventional therapy: hot pack 20 mins Kendall exercises: Strengthening the deep cervical flexor, Stretching the cervical extensors, Strengthening shoulder retraction, Stretching of the pectoralis major muscle~strengthening exercise: 12 repetitions\* 3 sets, 2-8 sec hold stretching exercise was: 3 reps\* 30 seconds' hold~Total duration of treatment would be 4 weeks, 3 days a week with total 12 sessions."
223402286|NCT02858999|DRUG|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
223402287|NCT06884202|DEVICE|Delefilcon A contact lenses with different base curves and diameters|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
223402288|NCT06884202|DEVICE|Delefilcon A contact lenses with standard base curves and diameters|Silicone hydrogel contact lenses for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to approximately 1.50 diopters (D) of astigmatism that does not interfere with visual acuity.
223402289|NCT06888323|RADIATION|Actinium Ac 225 Lintuzumab|Given IV
223402290|NCT06888323|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223402291|NCT06888323|PROCEDURE|Buccal Swab|Undergo buccal swab
223402292|NCT06888323|PROCEDURE|Computed Tomography|Undergo SPECT/CT
223402293|NCT06888323|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223402294|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 5 mg QW|IIb：Efsubaglutide Alfa 5 mg QW
223402295|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 10 mg QW|Efsubaglutide Alfa 10 mg QW
223402296|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 20 mg QW|Efsubaglutide Alfa 20 mg QW
224132014|NCT01053117|OTHER|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
224132015|NCT04665791|BIOLOGICAL|Intranasal inoculation with Neisseria lactamica|Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.
223402297|NCT06921486|DRUG|Phase IIb：Efsubaglutide Alfa 20 mg Q2W|Efsubaglutide Alfa 20 mg Q2W
224132016|NCT06569147|DRUG|Elranatamab|Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
223402298|NCT06921486|DRUG|Phase IIb：Placebo|Placebo
223402299|NCT06921486|DRUG|Phase III：Recommended Phase 3 Dose High Dose|The Recommended Phase 3 Dose High Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
223735089|NCT06036576|DRUG|Levothyroxine Pill|all participants will receive levothyroxine treatment of 1.6 micrograms per kg per day early in the morning on empty stomach.
223735090|NCT00616460|DRUG|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
223735091|NCT06051188|DEVICE|Flow-controlled ventilation|Flow-controlled ventilation (FCV)
223735092|NCT00239707|DRUG|GIP|One-time 20 ng/kg/min infusion over 3 hours
223735093|NCT00239707|DRUG|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
224132017|NCT03106194|OTHER|case management|
224132018|NCT01611350|OTHER|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
224132019|NCT01611350|OTHER|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
224132020|NCT01611350|OTHER|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
224132021|NCT00503880|BIOLOGICAL|filgrastim|subcutaneously one day prior to treatment
223402300|NCT06921486|DRUG|Phase III：Recommended Phase 3 Dose Low Dose|The Recommended Phase 3 Dose Low Dose confirmed by the IDMC (Independent Data Monitoring Committee) based on the safety and efficacy data results from the 18-week Phase IIb.
223402301|NCT06921486|DRUG|Phase III：Placebo|Placebo
224132022|NCT00503880|DRUG|clofarabine|single IV dose over 1 hour daily for 5 days
223402302|NCT06925750|BIOLOGICAL|Sotatercept|SC injection administered every 3 weeks
223402303|NCT06925750|DRUG|Background PAH Therapy|Background PAH therapy may consist of the following drug classes: single, double, or triple combination of therapy with endothelin-receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase stimulators, and/or prostacyclin analogs or receptor antagonists
223402304|NCT06885671|RADIATION|Multiple Fraction PBI|Participants randomized to Arm 1 will receive PBI with a dose of 26 Gy in 5 daily fractions.
223402305|NCT06885671|RADIATION|Single Fraction PBI|Participants randomized to Arm 2 will receive PBI in a single fraction with a dose of 13 Gy.
223402306|NCT06736691|DRUG|emodepside (BAY 44-4400)|Treatment with single dose of oral 15 mg emodepside
223402307|NCT06736691|DRUG|matching placebo of emodepside|Treatment with single dose of oral emodepside matching placebo
223735094|NCT00239707|DRUG|Normal Saline|one-time infusion over 3 hours
224022026|NCT00262951|BIOLOGICAL|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
224132023|NCT00503880|DRUG|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
223402308|NCT06736691|DRUG|Mebendazole|Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
223553547|NCT05236452|OTHER|Training for traditional and modern care providers|The intervention arm includes training for traditional and modern care providers, patient education, screening, and referring to TB suspected cases plus the usual care. The training will be provided three times which will be delivered every three months. In the first round, traditional practitioners will be trained for 5 days. In this round, the training will be also delivered to modern health care providers on how to communicate and work with traditional care providers for 2-day. Then, a one-day interactive discussion session will be prepared for both traditional and modern care providers. In the second round and third rounds, one-day training will be carried out at three and six months. TB suspected cases at traditional foster and holy water and patients who need spiritual support from health care providers will be screened every case in every day for one year. Referring to TB suspected cases will also apply for every case every day for one year
224132024|NCT00503880|GENETIC|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
223402309|NCT06736691|DRUG|similar placebo to mebendazole|Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
223402310|NCT06643598|BEHAVIORAL|Abecedarian Approach|The Abecedarian Approach is an early childhood behavioral education program that aims to improve the learning and cognitive development of children in high-risk or at-risk communities. This study will test the efficacy of implementing this approach in a virtual format.
223402311|NCT03283384|DRUG|Letrozole|Letrozole 2.5 mg daily.
223402312|NCT03283384|DRUG|Chemotherapy|Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
223553548|NCT03891914|DRUG|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
223553549|NCT03891914|DRUG|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
223735095|NCT03880656|BIOLOGICAL|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
224022027|NCT00262951|DRUG|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
223553552|NCT04125329|DRUG|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
223553553|NCT04495530|OTHER|Non-interventional study|semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
223553554|NCT06188598|BEHAVIORAL|Time-restricted eating|Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
223553555|NCT03419312|DEVICE|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
223553556|NCT03419312|DEVICE|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
223402313|NCT03283384|DRUG|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
223553557|NCT04512677|DEVICE|Timed Inspiratory Effort (TIE index)|Conventional clinical treatment and using the Timed Inspiratory Effort (TIE index), which guided the decision to ventilate weaning and extubation.
223553558|NCT01502514|PROCEDURE|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
223553559|NCT03979469|DRUG|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
223553560|NCT03979469|DRUG|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
223553561|NCT04916977|OTHER|FD patients|Patients with Fabry disease diagnosis
224132025|NCT00503880|PROCEDURE|biopsy|bone marrow biopsy
224132026|NCT05311293|DIAGNOSTIC_TEST|Endoscopy|Observe the extent of colonic lesions and obtain intestinal mucosal samples
223402314|NCT06741410|DRUG|Ephedrine|Intravenous boluses of ephedrine
223402315|NCT06741410|DRUG|Phenylephrine|Intravenous continuous infusion of phenylephrine
224022028|NCT00262951|DRUG|fluorouracil|administered at a dose of 175 mg/m\^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m\^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
224022029|NCT00262951|RADIATION|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
224132027|NCT01831206|PROCEDURE|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
224132028|NCT03013244|BEHAVIORAL|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
224132029|NCT02129335|OTHER|stress|stress level and survival
224132030|NCT02236949|BEHAVIORAL|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
224132031|NCT00542724|DRUG|VIAject™|Dosage as individually required
224132032|NCT00542724|DRUG|Regular Human Insulin|Dosage as individually required
224132033|NCT01244347|DRUG|folic acid|
224132034|NCT01244347|DRUG|folic acid|
223402316|NCT07053891|DRUG|Voclosporin (LUPKYNIS)|In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil.
223402317|NCT06780306|BIOLOGICAL|TTAX03|Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
223402318|NCT06780306|BIOLOGICAL|Saline (NaCl 0,9 %) (placebo)|300 mL Sterile, preservative free 0.9% NaCl
223402319|NCT02492867|RADIATION|Response-driven Adaptive Radiation Therapy|
223402320|NCT02492867|DRUG|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
223402321|NCT02492867|DRUG|Paclitaxel|40 mg/m\^2 IV concurrent with RT; 200 mg/m\^2 during consolidation. Given IV
223402322|NCT02492867|DEVICE|FDG-PET|
223553562|NCT03353038|DEVICE|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
223553563|NCT04106128|DIAGNOSTIC_TEST|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
224022030|NCT00262951|PROCEDURE|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
224022031|NCT05976893|DRUG|Evolocumab|Evolocuma:420 mg every 4 weeks
223735096|NCT03790527|PROCEDURE|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
224132035|NCT00668200|DRUG|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
224132036|NCT00668200|DIETARY_SUPPLEMENT|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
223402323|NCT02492867|DEVICE|V/Q SPECT|
223402324|NCT02492867|DRUG|Durvalumab|10 mg/kg during consolidation. Given IV
223402325|NCT03296527|DRUG|Follitropin alfa|GONAL-F dose was fixed for the first 5 stimulation days.
223402326|NCT03296527|DRUG|Follitropin delta|REKOVELLE (FE 999049) was fixed throughout the stimulation period.
223402327|NCT05366166|BIOLOGICAL|Pembrolizumab|In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
223553564|NCT02789358|OTHER|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
224022032|NCT05976893|DRUG|Statin|The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).
224022033|NCT01577745|BIOLOGICAL|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
224022034|NCT01927029|DRUG|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
224022035|NCT01927029|DRUG|Placebo|
224132037|NCT00668200|DIETARY_SUPPLEMENT|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
223402328|NCT05366166|DRUG|Olaparib|In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
223402329|NCT05366166|DRUG|Cisplatin|"In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly."
223402330|NCT05366166|RADIATION|IMRT (intensity modulated radiation therapy)|In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
223402331|NCT04987151|OTHER|Experimental-Strength training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength training exercise involving the major muscle groups
223402332|NCT04987151|OTHER|Experimental-Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to brisk walking.
224022036|NCT00361010|DRUG|Levetiracetam|
224022037|NCT02923687|DRUG|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
224022038|NCT02923687|DRUG|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
224132038|NCT05273840|DIETARY_SUPPLEMENT|Ivital Control|Patients in the intervention group will take 2 sachets of nutritional supplements(Ivital Control) once a day in lieu of one meal, besides receiving lifestyle interventions.
224132039|NCT05273840|BEHAVIORAL|lifestyle intervention|Patients will receive lifestyle interventions.
224132040|NCT01793519|DRUG|Etanercept|Subcutaneous
224132041|NCT01793519|DRUG|Infliximab|Infusion
223402333|NCT04987151|OTHER|Experimental-Strength/Aerobic training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching), 15 minutes are allocated to brisk walking and 25 minutes are allocated to strength training involving the major muscle groups.
223402334|NCT00122382|DRUG|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
223402335|NCT00122382|DRUG|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
223402336|NCT00122382|DRUG|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
224022039|NCT03553680|BEHAVIORAL|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
224022040|NCT05574491|BEHAVIORAL|Super Skills for Life: traditional version|"Structured and manualized intervention with a manual for the therapist and a workbook for the children.~The intervention will be administered by trained clinical psychologists in SSL. Sessions will be held once a week for eight weeks, with each session lasting approximately forty five minutes.~The program includes emotional education, social skills training, cognitive restructuring, relaxation techniques, self-observation, problem solving and behavioural activation. These contents are learned through playful exercises, activities, readings, and role-playing.~Both modalities of intervention will be in-person.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández."
224022041|NCT05574491|BEHAVIORAL|Super Skills for Life: computerized version|Structured and manualized intervention with a manual for the therapist and multimedia material for the children.
224132042|NCT01793519|DRUG|Adalimumab|Subcutaneous
224132043|NCT01793519|DRUG|Placebo|Matching Placebo
223402337|NCT05243160|OTHER|medication review|The intervention consist of a medication review by a clinical pharmacologist.
223402338|NCT01099592|DRUG|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not \< 8, the dose will increase to 40 mg.
223402339|NCT02748746|DEVICE|Bio Impedance Analysis Measurement|Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.
223402340|NCT02748746|DEVICE|Tissue Dielectric Constant Measurement|In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
223402341|NCT02588963|OTHER|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
223553565|NCT02789358|OTHER|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
223553566|NCT02789358|DEVICE|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
223553567|NCT02789358|DRUG|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
223553568|NCT02789358|DEVICE|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
224132044|NCT01891422|OTHER|Non-interventional.|
224132045|NCT05662228|DRUG|Lorazepam|Lorazepam will be administered as an oral pill over the first 15 days of study in a daily titration, starting at 0.5 mg BID and increasing to up to 2 mg three times daily, as tolerated. Dosing will continue at the maximum tolerated dose through the 12-week endpoint. Participants will be titrated off lorazepam over at least four weeks after completing the endpoint visit. Taper will be tailored to individuals for safety reasons with a goal of decreasing dosage by 25% weekly. Phone check ins will be conducted every three days to monitor patient.
224132046|NCT05662228|DRUG|Intravenous immunoglobulin (IVIG)|IVIG will be administered as a series of four intravenous infusions at a dose of 1 mg/kg with pre-infusion medications of 1 mg/kg diphenhydramine and 15 mg/kg acetaminophen. The first two infusions occur at baseline and one day after (induction dosing), followed by one infusion at 4 weeks and one infusion at 8 weeks.
224132047|NCT05662228|DRUG|Tofacitinib|Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.
224132048|NCT01496430|DRUG|Placebo|
224132049|NCT01496430|DRUG|Azilsartan medoxomil|
224132050|NCT01496430|DRUG|Azilsartan medoxomil|
223553569|NCT04908384|BEHAVIORAL|Improving Asthma Care Together (IMPACT)|IMPACT is a novel health application and wearable device
224022042|NCT05812287|OTHER|Detection of biological samples based on multi-omics analysis|In this study, we combined microbiological (16SrRNA) and metabolomic mass spectrometry to study the changes in microbial populations and metabolic profiles of various samples such as feces, serum, and saliva, and screen key differential markers.
224132051|NCT04982120|DEVICE|Repris Needle|Injection of Botox
224132052|NCT03772938|BIOLOGICAL|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
224132053|NCT00997321|DRUG|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
224132054|NCT00997321|DRUG|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
224022043|NCT02483585|DRUG|Erenumab|Administered once a month by subcutaneous injection
224022044|NCT02483585|DRUG|Placebo|Administered once a month by subcutaneous injection
224022045|NCT04226885|DRUG|fentanyl|nebulized fentanyl 2μg/kg body weigh
224022046|NCT04226885|DRUG|midazolam|nebulized midazolam 0.2 mg/kg body weight 30 min before surgery.
224022047|NCT04226885|DRUG|dexmedetomidine|nebulized dexmedetomidine 2 μg/kg body weight 30 min before surgery.
224022048|NCT06336954|DRUG|Adibelimab|Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)
224022049|NCT01485055|DRUG|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
224022050|NCT04001231|DRUG|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
223735097|NCT03790527|PROCEDURE|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
223735098|NCT04096625|DEVICE|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
223735099|NCT04096625|BEHAVIORAL|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
223735100|NCT04096625|DEVICE|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
224022051|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
224022052|NCT00825916|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
224022053|NCT00825916|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
224132055|NCT05110040|DRUG|immunosuppressive agent|patients with TAO recruited in this study will administrated with immunosuppressive agent per day
224132056|NCT00188877|PROCEDURE|intensity modulated radiation therapy|
223735101|NCT02013648|DRUG|Dasatinib|
223735102|NCT02013648|DRUG|Cytarabine|
223735103|NCT02013648|DRUG|Daunorubicin|
223735104|NCT02013648|DRUG|Idarubicin|
223735105|NCT01459965|PROCEDURE|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
223735106|NCT01459965|PROCEDURE|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
223735107|NCT04901494|DRUG|SSRI|Selective serotonin reuptake inhibitor
223735108|NCT03595033|DEVICE|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
223402342|NCT02588963|OTHER|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
223402343|NCT02588963|OTHER|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
223402344|NCT02890602|DRUG|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
223402345|NCT02890602|DRUG|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
223402346|NCT00708890|BEHAVIORAL|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
223402347|NCT01702064|DRUG|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.~Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
223402348|NCT01702064|DRUG|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
223402349|NCT04042506|DRUG|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
223402350|NCT04042506|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
223402351|NCT02463370|OTHER|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
223402352|NCT02463370|OTHER|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
223402353|NCT02463370|OTHER|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
223402354|NCT02463370|OTHER|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
223402355|NCT02873793|GENETIC|Extraction of total RNA from healthy and tumour tissues|
223402356|NCT05850611|DRUG|Methylene Blue|The first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks.
223402357|NCT05850611|OTHER|Milk (control)|Group B will receive 200 ml of milk for 4 weeks.
223402358|NCT05850611|DRUG|Methylene Blue and Platelet-Rich Plasma-Fibrin Glue|Group C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue.
223402359|NCT05850611|OTHER|Milk and Platelet-Rich Plasma-Fibrin Glue (control)|Group D will be treated only with fibrin glue and 200 ml of milk for 4 weeks.
223402360|NCT02040805|BEHAVIORAL|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
224022054|NCT01653067|DRUG|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
224022055|NCT00638781|DRUG|Desmoteplase|Desmoteplase 62.5 µg/kg BW
223402361|NCT02040805|BEHAVIORAL|Peer Facilitated Support Group|Fifteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
223402362|NCT01008605|OTHER|delivery system|syringe
223402363|NCT07061379|DRUG|Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity|Cohort A: Carboplatin/Cisplatin+Pemetrexed+Pembrolizumab/Cemiplimab (Keynote 189, EmpowerLung 3) for 4 cycles and then maintenance with Pemetrexed+Pembrolizumab/Cemiplimab up to 2 years or disease progression or unacceptable toxicity
223402364|NCT07061379|DRUG|Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity|"Cohort B:~Carboplatin/Cisplatin+Pemetrexed+Nivolumab+Ipilimumab (CheckMate9LA) for 2 cycles and then maintenance with Nivolumab q21 and Ipilimumab q42 up to 2 years or disease progression or unacceptable toxicity"
223402365|NCT02884362|OTHER|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
223402366|NCT02582229|DEVICE|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
223402367|NCT01213966|DRUG|OZ439|po, single dose
223402368|NCT06817304|BEHAVIORAL|Tiny Heroes|This is a four modules online intervention based on cognitive behavioral therapy directed at parets of anxious children 3-6 years
223402369|NCT05354167|OTHER|muscle energy technique|the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
223402370|NCT05354167|OTHER|oscillating manual energy therapy|It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
224022056|NCT00638781|DRUG|Desmoteplase|Desmoteplase 90 µg/kg BW
224022057|NCT00638781|DRUG|Desmoteplase|Desmoteplase 125 µg/kg BW
224022058|NCT00638781|DRUG|Placebo|Placebo
224022059|NCT04831294|DRUG|Cannabidiol|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
224132057|NCT00188877|DRUG|cisplatinium and fluorouracil - standard treatment|
223402371|NCT00405561|DRUG|AMT2003|
223553570|NCT04923737|DRUG|Dexmedetomidine|patients will receive a loading dose of IV Dexmedetomidine1μg/kg slowly just before induction of anesthesia, then Dexmedetomidine infusion started at a rate of 0.5μg/kg/h.
223553571|NCT04923737|DRUG|0.9% sodium chloride|patients will receive an equal volume of 0.9% sodium chloride (both the loading, and the infusion
223553572|NCT01050023|DEVICE|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
224022060|NCT04831294|DRUG|Placebo|Administered orally. Participants will place the liquid in their mouth for 45 seconds before swallowing it.
224022061|NCT03475615|DRUG|Oxaliplatin|130mg/m2, d1, q3w
223402372|NCT06301074|DRUG|HS-10509|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
223553573|NCT01050023|DEVICE|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
223553574|NCT02110433|DEVICE|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
223553575|NCT02110433|DEVICE|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
223553576|NCT02110433|DEVICE|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP \< 100 pg/ml or remaining stable (\< 30% increase).
223735109|NCT06110988|DEVICE|Pan-vascular interventional robotic system|Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.
223735110|NCT05098145|BIOLOGICAL|FCR001|Enriched hematopoietic stem cell infusion
224132058|NCT00932529|DRUG|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
224132059|NCT00932529|DRUG|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
224132060|NCT00932529|DRUG|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
224132061|NCT00932529|DRUG|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
224132062|NCT01806246|BEHAVIORAL|integrative rehabilitation program|
224132063|NCT01545908|OTHER|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
224132064|NCT01545908|OTHER|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
223735111|NCT02801942|PROCEDURE|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
223735112|NCT02801942|PROCEDURE|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
223735113|NCT02801942|PROCEDURE|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
223735114|NCT02801942|OTHER|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
224022062|NCT03475615|DRUG|Paclitaxel|40mg/m2 ip，d1、8 ,q3w
224022063|NCT03475615|DRUG|S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)|40mg/m2 Bid po，d1-14,q3w
224022064|NCT02963103|DRUG|Tacrolimus|Oral
224022065|NCT02671370|OTHER|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
224022066|NCT02910154|DIETARY_SUPPLEMENT|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
224022067|NCT02910154|BEHAVIORAL|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
224022068|NCT02910154|DRUG|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
224022069|NCT00912301|DRUG|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
224132065|NCT04229550|BEHAVIORAL|Festival participation|One week's participation in Roskilde Festival 2016 or living a normal daily life.
224132066|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 25 mg b.i.d
224132067|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg qhs
224132068|NCT00360243|DRUG|flibanserin|Experimental: flibanserin 50mg b.i.d.
224132069|NCT00360243|DRUG|placebo|placebo
224132070|NCT02697513|BEHAVIORAL|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
223553577|NCT05664503|OTHER|Assigned Interventions STOMA-M|The training, which includes information on stoma care, maintenance of daily life activities, and complication management, was given to the patients in the experimental group via the STOMA-M.
223553578|NCT00430989|OTHER|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
223553579|NCT00430989|OTHER|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
224022070|NCT00912301|OTHER|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
224022071|NCT00662506|DRUG|Cediranib Maleate|Given PO
224022072|NCT00662506|PROCEDURE|Diffusion Tensor Imaging|Undergo DTI
224022073|NCT00662506|PROCEDURE|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
223735115|NCT02260284|OTHER|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
224022074|NCT00662506|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
224022075|NCT00662506|RADIATION|Fludeoxyglucose F-18|Undergo 18 FDG PET
224022076|NCT00662506|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224022077|NCT00662506|OTHER|Laboratory Biomarker Analysis|Correlative studies
224022078|NCT00662506|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo PWI
224022079|NCT00662506|PROCEDURE|Positron Emission Tomography|Undergo 18 F FDG-PET
224022080|NCT00662506|DRUG|Temozolomide|Given PO
224022081|NCT01324440|BIOLOGICAL|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
224022082|NCT01324440|BIOLOGICAL|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
224022083|NCT05175638|GENETIC|Gene Expression|the expression of specific CNS enzyme (enolase), proinflammatory cytokines MIF and apoptotic marker caspase-3 in the umbilical blood of infants delivered for Covid positive mothers.
223735116|NCT02260284|OTHER|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
224022084|NCT01759576|DRUG|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
224022085|NCT01810120|BIOLOGICAL|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
224132071|NCT02217319|DRUG|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
223735117|NCT02260284|OTHER|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
223735118|NCT02187588|DRUG|Eschscholtzia Californica - low dose|
223735119|NCT02187588|DRUG|Eschscholtzia Californica - high dose|
223735120|NCT02187588|DRUG|Ibuprofen|
223735121|NCT02187588|DRUG|Eschscholtzia Californica - low dose Placebo|
223735122|NCT02187588|DRUG|Eschscholtzia Californica - high dose Placebo|
224022086|NCT00159276|PROCEDURE|Induced Sputum|
224022087|NCT05220384|BEHAVIORAL|In-person Motivational Interview combined with Self-Management techniques|"This is an approximately 30 mins in-person, semi-structured, semi-personalized physical activity focused Motivational Interviewing treatment with self-management techniques. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) During the interactive treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. This in-person therapy at the hospital is followed by two booster sessions via phone at the 1st week post meeting date and 1 month post meeting date."
224022088|NCT05220384|BEHAVIORAL|Video-based Motivational Interview combined with Self-Management techniques|"This is a series of three videos comprising a structured activity focused Motivational Interviewing treatment with self-management techniques. The videos' thematic follow the semi-structured interview elements to ensure that it is a true sham of the in-person one. (This therapy is an add on to the usual therapy that is given to the adolescents who present at the hospital.) This first video is going to be watched by adolescents at the hospital. During the interactive video-treatment a self-management workbook will be filled out by the adolescent for the purpose of further data collection. The second video is going to be sent to the participants via e-mail on the 1st week post meeting date and the third video is on the 1-month post meeting date."
224022089|NCT01657513|DRUG|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~1. infliximab or~2. adalimumab or~3. etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
224022090|NCT04196101|DRUG|EDP-938|Four tablets daily for 5 days
224022091|NCT04196101|DRUG|Placebo|Four tablets daily for 5 days
224022092|NCT00601094|BIOLOGICAL|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
224022093|NCT00394082|DRUG|ABI-007|125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
224022094|NCT00394082|DRUG|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
224022095|NCT00369720|PROCEDURE|Titration of oxygen in delivery room|
224022096|NCT00903630|DRUG|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
224022097|NCT00903630|DRUG|liposomal doxorubicin|administered at a fixed dose of 40 mg/m\^2 intravenously (IV) on day 1 of each 28 day cycle
224132072|NCT02217319|DRUG|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
224132073|NCT02512068|DRUG|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
224132074|NCT02512068|DRUG|Placebo|Placebo Tablets
224132075|NCT02528097|DRUG|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
224022098|NCT03293641|DIETARY_SUPPLEMENT|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
224022099|NCT03293641|DRUG|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
224132076|NCT02528097|DRUG|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
224132077|NCT02316756|DRUG|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
224132078|NCT02316756|DRUG|Placebo|Placebo which will be given as oral suspension
224132079|NCT06145685|PROCEDURE|Minimally invasive non-surgical periodontal therapy|Minimally invasive non-surgical periodontal therapy
223402373|NCT06301074|DRUG|Placebo|"In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined."
223402374|NCT04145765|OTHER|correlation|the subjects completed the questionnaires
223402375|NCT03591874|DRUG|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
223402376|NCT03591874|DRUG|Placebos|Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
223402377|NCT05157412|DRUG|Doxycycline 100 mg Oral Tablet|Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
223402378|NCT05157412|DRUG|Prednisolone 20 mg|Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
223402379|NCT05278312|OTHER|Otago Exercise Program|A Home-based Exercise Program to improve strength and balance and prevent falls.
223402380|NCT05106179|DRUG|Atenolol Pill|Atenolol is a second-generation hydrophilic β-1-selective adrenergic antagonist, which is primarily metabolised by the kidneys.
223402381|NCT05106179|DRUG|Propranolol Pill|Propranolol is highly lipophilic, nonselective β-blockers, which is primarily metabolised by the liver.
223402382|NCT03046732|OTHER|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
223402383|NCT00980252|BEHAVIORAL|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
224132080|NCT06145685|PROCEDURE|Conventional non-surgical periodontal therapy|Conventional non-surgical periodontal therapy
223402384|NCT04390607|DIAGNOSTIC_TEST|leukocyte esterase electrochemical assay|A sample of blood drawn for routine standard of care laboratory assessments will be used to also test the new electrochemical assay. This is a validation study and the results of the electrochemical assay will not be used to treat patients
223402385|NCT06196437|OTHER|Acupuncture|Participants will receive acupuncture.
223402386|NCT06196437|OTHER|Sham Acupuncture|Participants will receive sham acupuncture.
223402387|NCT01729273|OTHER|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
223402388|NCT03958929|OTHER|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q\&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
223402389|NCT01228682|DRUG|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
223402390|NCT00318773|DRUG|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
223402391|NCT02245516|DRUG|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
223402392|NCT02245516|DRUG|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
223402393|NCT03644342|DRUG|Nirapaib|(see treatment regimen and method of treatment assignment)
223402394|NCT04163003|BEHAVIORAL|Targeted Approaches for Promoting Adolescent Sleep (TAPAS)|The targeted intervention is a three part sleep program, involving a 2- minute psychoeducation video, an in-person session with a clinician focusing on sleep, and web-based goal setting related to sleep behaviors. Intervention approaches to promoting adolescent sleep and reducing insufficient sleep use a motivational interviewing style, rooted in cognitive-behavioral strategies for improving sleep.
223553580|NCT02727595|DEVICE|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
223553581|NCT03531164|OTHER|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
223553582|NCT03531164|OTHER|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
223553583|NCT01270932|DRUG|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
223553584|NCT01380678|DRUG|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
223553585|NCT01380678|DRUG|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
223553586|NCT03993444|BEHAVIORAL|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
223553587|NCT03993444|BEHAVIORAL|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
223735123|NCT02187588|DRUG|Ibuprofen Placebo|
224132081|NCT00590018|DRUG|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
224132082|NCT00590018|DRUG|Placebo|Placebo for 5 days intravenously.
224132083|NCT03168256|DRUG|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
224132084|NCT03168256|DRUG|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
224132085|NCT03168256|DRUG|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
224132086|NCT03168256|DRUG|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
224022100|NCT04076839|BEHAVIORAL|Goal Management Training|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
224132087|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Unilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
224132088|NCT04801342|RADIATION|Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Bilateral Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
223402395|NCT04163003|BEHAVIORAL|Sleep Monitoring Only|Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
223402396|NCT04147364|OTHER|no intervention|only retrospective reviews for medical records
223402397|NCT03718988|BEHAVIORAL|Meat products|Traditional meat products (beef burger patties, pork sausage, etc.)
223553588|NCT03050450|DRUG|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
224132089|NCT04801342|DRUG|Memantine Hydrochloride|Start from day 1 of WBRT orally for 24 weeks and escalating doses over the first 4 weeks
224132090|NCT01133431|DRUG|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
224132091|NCT01133431|DRUG|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
224132092|NCT03399175|DRUG|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
223553589|NCT03050450|DRUG|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
223553590|NCT03050450|DRUG|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
223553591|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
224132093|NCT04365985|DRUG|Naltrexone|Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
224132094|NCT04365985|DRUG|Ketamine|Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
223553592|NCT03050450|DRUG|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
223402398|NCT03718988|BEHAVIORAL|Plant Alternative products|Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
223402399|NCT04872686|DRUG|0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient|"Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software."
223553593|NCT01370941|DIETARY_SUPPLEMENT|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
223553594|NCT01370941|DIETARY_SUPPLEMENT|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
223553595|NCT01642901|DRUG|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
224022101|NCT00464607|DRUG|hMG-IBSA|
224022102|NCT00464607|PROCEDURE|Ovarian stimulation|
224022103|NCT00292721|DRUG|Celecoxib|celecoxib: loading and maintenance for 6 months
224022104|NCT05068245|BEHAVIORAL|Preselected classical music|Preselected classical music
224022105|NCT03377309|DRUG|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
224022106|NCT03154060|DEVICE|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
223402400|NCT04872686|DRUG|0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity|"Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software"
224022107|NCT02325557|DRUG|ADXS31-142|ADXS31-142 IV infusion
224022108|NCT02325557|DRUG|Pembrolizumab|Pembrolizumab IV infusion
224022109|NCT00176397|PROCEDURE|Percutaneous coronary intervention (left main)|
224022110|NCT04384315|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
223735124|NCT04538066|DRUG|Bryostatin 1|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
223735125|NCT04538066|OTHER|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks, followed by a second identical course of treatment beginning 30 days after completion of the first 7-dose course.
224132095|NCT04365985|OTHER|Placebo|Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
223402401|NCT04872686|DRUG|0.6% PVP-I Oral and nasal spray to healthy volunteer|"Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software"
223402402|NCT04872686|OTHER|Oral and nasal spray by distilled water to control group|Placebo comparator: Distilled Water Oral and Nasal spray will be provided by Distilled water to control group
223402403|NCT03113812|DRUG|ABvac40|
223402404|NCT03113812|DRUG|Placebo|
223402405|NCT01875523|DRUG|Serelaxin|
223402406|NCT03531775|DIAGNOSTIC_TEST|Upright MRI|Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
223553596|NCT01642901|DRUG|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
223553597|NCT05724862|DEVICE|Needle-less jet anaesthesia|Infiltration anesthesia without needle depending on injection pressure
223553598|NCT05724862|DEVICE|Conventional Injection Anesthesia|Regular Infiltration local anesthesia
223553599|NCT06446375|OTHER|exercise|FIFA 11+ KIDS Training Protocol consists of seven different exercises: three for unilateral, dynamic stability of the lower limbs (hopping, jumping and landing); three for whole body and trunk strength/stability; and one exercise on falling technique.
223553600|NCT06446375|OTHER|Regular daily activity|Regular physical activity
223735126|NCT02331225|OTHER|No intervention given|There is no intervention for this study
224022111|NCT04778423|OTHER|Avatar Therapy|In the first session (assessment), participants will create a computerised representation of the eating disorder voice (avatar) on a computer. They will be able to manipulate the facial and voice characteristics of the avatar and will be asked to provide examples of the critical eating disorder comments most often spoken by the avatar. In the following sessions (6-8 therapy sessions), participants will interact with the avatar displayed on the computer screen for 5-10 minutes.The main goal during the interaction with the avatar is for participants to stand up to the critical comments made by the avatar and build a sense of power, control and self-awareness in the context of the eating disorder voice. The sessions will be conducted remotely, using a personal laptop or computer. This will provide patients with the opportunity to practise answering back to the eating disorder voice during a meal, a time at which the eating disorder voice is loudest.
224022112|NCT01139060|BEHAVIORAL|organized care program for chronic or recurrent depression|
224022113|NCT01932554|DRUG|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
224022114|NCT01932554|DRUG|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
224022115|NCT01932554|OTHER|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
224022116|NCT01932554|DRUG|Ibuprofen|Scheduled ibuprofen,\~10 mg/kg every 6-8 hours
224132096|NCT02362087|OTHER|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
223553601|NCT02448992|RADIATION|hippocampal-sparing WBRT|
224022117|NCT01932554|DRUG|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
224022118|NCT01932554|OTHER|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
223735127|NCT00696696|DRUG|Gemcitabine|1000 mg/m\^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
223553602|NCT04012502|OTHER|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
223402407|NCT04417452|OTHER|Basic data collection (online survey or written form)|Basic data collection is carried out by means of a questionnaire that participants can fill in outside the study centre. It contains questions about the current life situation, sleep and activity behaviour.
223402408|NCT04417452|OTHER|Physical examination|The physical examination takes place at the study centre and includes the measurement of height, current weight and body fat, as well as the recording of heart and circulation parameters (e.g. blood pressure measurement or determination of vascular health by means of ultrasound). General metabolic and hormonal parameters are analysed by means of a blood sample. In addition, a sugar test for diabetes diagnosis will be carried out.
223402409|NCT04417452|BEHAVIORAL|Psychometric examination|Psychometric examination is carried out at the study centre with the help of a RIAS (Reynolds Intellectual Assessment Scales and Screening) test.
223553603|NCT04012502|OTHER|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
223402410|NCT04417452|DIAGNOSTIC_TEST|Recording of the adrenergic stress reaction (saliva test)|The adrenergic stress reaction is recorded by a saliva test.
223402411|NCT02772133|PROCEDURE|Primary PCI|
223402412|NCT04302870|DRUG|Memantine Hydrochloride Oral Solution|Memantine hydrocholoride taken once daily
223402413|NCT04302870|DRUG|Trazodone Hydrochloride oral solution|Trazodone Hydrochloride taken once daily
223402414|NCT04302870|DRUG|Placebo oral solution|Placebo taken once daily
223553604|NCT02220803|DRUG|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
223553605|NCT02220803|DEVICE|nasal Continuous Positive Airway Pressure (nCPAP)|
223553606|NCT02676700|BEHAVIORAL|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
223553607|NCT02676700|BEHAVIORAL|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
223553608|NCT06190470|DRUG|Cannabis|Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
223553609|NCT06190470|DRUG|Placebo|Placebo is similar to Cannabis product but do not contain THC.
223553610|NCT04744220|OTHER|Yoga Training Program (exercises)|Training: Before the yoga program, the patients will be informed about the bronchiectasis disease and its symptoms, as well as all the parameters used in the evaluation, tests and the content of the yoga session. The patients will start with breathing exercises, then relaxation exercises, warm-up exercises, asanas (posture exercises) and finally the yoga training program will be completed with deep relaxation technique.
223553611|NCT04004338|DRUG|Kyprolis|Patients receiving kyprolis (carfilzomib)
223553612|NCT00422448|GENETIC|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
223553613|NCT00596674|BEHAVIORAL|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
223553614|NCT00596674|OTHER|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
223553615|NCT06093269|BIOLOGICAL|Blood samples|"For all subjects (short kinetics):~* Pre-injection of cefazolin~* Start of next dialysis~* Two hours after start of subsequent dialysis~* End of next dialysis, before cefazolin administration~Only in hospitalized subjects (rich kinetics):~* 30 minutes, 1h and 2h after cefazolin injection, to describe the cefazolin peak and possible post-dialysis rebound~* 12h, 24h and 36h after cefazolin injection, to better describe cefazolin elimination and distribution"
223553616|NCT05536557|OTHER|Bilateral External Oblique İntercostal (EOI) Plane Block|External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.
223553617|NCT05536557|OTHER|Standard perioperative and postoperative multimodal analgesia|Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
223553618|NCT04589572|PROCEDURE|XLIF|the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
223553619|NCT04589572|PROCEDURE|PLIF|open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
223553620|NCT05944588|OTHER|Pulmonary Ultrasound|2 pulmonary ultrasound exams, one before respiratory weaning test, and one other at the end of the respiratory weaning test, before extubation
223553621|NCT01761006|DEVICE|NIOX MINO®|
223553622|NCT01701362|DRUG|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
223553623|NCT01701362|DRUG|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
224022119|NCT01932554|OTHER|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
224022120|NCT02665637|DRUG|Trastuzumab|Each patient may receive single dose by intravenous infusion
224022121|NCT06391060|PROCEDURE|Impact of Gender on Davinci rectal surgery|gender-specific considerations in the surgical management and post-operative care of rectal cancer patients undergoing robotic surgery
223402415|NCT04302870|DRUG|Amantadine Hydrochloride Oral Solution|Amantadine Hydrochloride taken once daily
224022122|NCT00411346|PROCEDURE|Nurse-led telemonitoring|
223402416|NCT04302870|DRUG|Tacrolimus 1Mg Cap|Tacrolimus 1Mg overencapsulated tablet taken once daily
223402417|NCT04302870|DRUG|Placebo capsule|Placebo taken once daily
223402418|NCT00677937|BEHAVIORAL|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
223402419|NCT03655405|OTHER|Individual Deprescribing Intervention|The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
223402420|NCT05669105|DIAGNOSTIC_TEST|Specimen sample|Participants will have up to 100 mL of whole blood collected.
223402421|NCT03936205|DRUG|Dexmedetomidine|Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
223402422|NCT02206854|DRUG|R-flurbiprofen|200 mg gelatine capsule once orally
223402423|NCT00019773|DRUG|capecitabine|
223402424|NCT00019773|DRUG|oxaliplatin|
223402425|NCT04988269|DIAGNOSTIC_TEST|Blood sampling|Assessment of circulating levels of plasma ACTH, plasma aldosterone and serum interleukin -6 levels at day 1
223402426|NCT04988269|DIAGNOSTIC_TEST|Saliva sampling|Assessment of diurnal variation of cortisol and DHEA levels in the saliva at 4 different time points during the day (0.800, 12.00, 18.00, 22.00) at day 2.
223402427|NCT02288403|BEHAVIORAL|Aerobic interval training|
224022123|NCT03482154|PROCEDURE|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
224132097|NCT01962714|BEHAVIORAL|Loving-Kindness Meditation|12-week loving-kindness meditation course
224132098|NCT01962714|BEHAVIORAL|Cognitive Processing Therapy|12-week CPT course
223402428|NCT02288403|BEHAVIORAL|Continuous training|
223402429|NCT00450879|DRUG|Pazopanib Hydrochloride|Given PO
223402430|NCT00450879|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
223402431|NCT00450879|OTHER|Pharmacological Study|Correlative studies
223402432|NCT00450879|OTHER|Laboratory Biomarker Analysis|Correlative studies
223402433|NCT03601013|OTHER|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
223402434|NCT02045264|DRUG|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
223402435|NCT01991743|DRUG|Group 2.5|Administration of bupivacaine 2.5 mg.
223553624|NCT04347512|DRUG|Hydroxychloroquine and azithromycin treatment arm.|"Patient allocated in this arm receive hydroxychloroquine and azithromycin for 5 days.~For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~For azithromycin, there is a loading dose of 500 mg per day at D1, followed by 250 mg per day D2-D5.~Every patient receive as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
224132099|NCT03498781|OTHER|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
223402436|NCT01991743|DRUG|Group 5|Administration of 5 mg bupivacaine
223402437|NCT01991743|DRUG|Group 7.5|Administration of 7.5 mg bupivacaine
223402438|NCT01991743|DRUG|Group 10|Administration of 10mg bupivacaine.
223402439|NCT05523102|DRUG|Paracetamol|Intravenous paracetamol/acetaminophen
223402440|NCT05523102|DRUG|Ketorolac|Intravenous ketorolac/NSAID
223735128|NCT00696696|DRUG|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
224022124|NCT04463017|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
224132100|NCT03498781|OTHER|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
224132101|NCT02456181|BEHAVIORAL|JumpMath|
223402441|NCT01657838|DRUG|Isavuconazole|oral
223402442|NCT01657838|DRUG|Ketoconazole|oral
223402443|NCT02641795|DEVICE|Minimally invasive robotic cochlear implantation|
223402444|NCT03218995|DRUG|Eteplirsen|Infusion for intravenous use.
223402445|NCT00039559|OTHER|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
223402446|NCT00147875|DRUG|Prednisone|
223402447|NCT00147875|DRUG|Vinblastine|
223402448|NCT00147875|DRUG|Doxorubicin (Adriamycin)|
223402449|NCT00147875|DRUG|Gemcitabine|
223402450|NCT00108459|BEHAVIORAL|Low Carbohydrate Diet|
223402451|NCT03440242|DEVICE|JJVC Contact Lens|etafilcon A with PVP DD
223402452|NCT03440242|DEVICE|Marketed Contact Lens|nelfilcon A DD
223402453|NCT00616837|OTHER|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
223402454|NCT00616837|OTHER|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
224022125|NCT03226236|RADIATION|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
224132102|NCT03589105|DRUG|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
224132103|NCT03589105|DRUG|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
224132104|NCT03508635|DRUG|CORT125134|Oral capsules
224132105|NCT03508635|DRUG|Matching Placebo of CORT125134|Placebo
224132106|NCT03508635|DRUG|Mifepristone|Active comparator
224132107|NCT03508635|DRUG|Prednisone|Challenge agent
223402455|NCT05643937|BEHAVIORAL|Routine health education|The control group received routine health education after catheterization, including introducing the purpose, method, advantages and complications of PICC insertion to patients before catheterization and signing informed consent. During catheterization, PICC assistant explained relevant matters needing attention and cooperative actions to the patient. After catheterization, patients were instructed to carry out grip training and limb activities.
223402456|NCT05643937|BEHAVIORAL|Routine health education + precise health education|On the basis of routine health education in the control group, the experimental group screened the high-risk behaviors of patients through the questionnaire of daily life behavior habits, and formulated the precise and concrete health education program for their high-risk behaviors
223402457|NCT05794100|OTHER|Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator|One pack of each product (1 to 10) will be consumed on a separate occasion
223402458|NCT02822937|DRUG|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
223402459|NCT02822937|DRUG|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
223402460|NCT02822937|OTHER|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
223402461|NCT02822937|DRUG|Placebo|Sugar pill
223402462|NCT00546533|DRUG|Etanercept|
223402463|NCT02859337|DRUG|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
223402464|NCT02859337|DRUG|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
223402465|NCT02871154|OTHER|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
223402466|NCT01622647|OTHER|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
223402467|NCT05135065|OTHER|Artificial Intelligence-Assisted Supervision Protocol|Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
223402468|NCT03134144|DEVICE|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
223402469|NCT01167140|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
223402470|NCT02680704|OTHER|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set \> 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
223402471|NCT04494386|BIOLOGICAL|Umbilical Cord Lining Stem Cells (ULSC)|IV infusion of allogeneic ULSC (100 million cells per dose) in sterile saline for injection
223402472|NCT04494386|OTHER|Placebo (carrier control)|IV infusion of carrier control consisting of sterile saline for injection
224022126|NCT03226236|BIOLOGICAL|Autologous DC vaccine|The first dose (7 to 14 x 10\_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
224132108|NCT03508635|DRUG|Glucose|
223402473|NCT05814263|DEVICE|HIS/LBB pacing|3830 lead to HIS or LBB
223402474|NCT05814263|DEVICE|LV pacing|LV lead in a CS branch
223402475|NCT06301763|DEVICE|Intermittent Oral-esophageal Tube Feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The observation group receives Intermittent Oral-esophageal Tube Feeding for enteral nutrition support (developed by the Dysphagia Institute of Zhengzhou University, CN201821314797.2), which is made of silicone material, 40 cm long, with an inner diameter of 0.54 cm.
223553625|NCT04347512|DRUG|Hydroxychloroquine|"Patient allocated in this arm receive hydroxychloroquine for 5 days. For hydroxychloroquine, there is a loading dose of 800 mg per day at D1, followed by 400 mg per day D2-D5.~Every patient receives as well antibiotic (ceftriaxone 1-2 g per day IV), and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc)."
223553626|NCT04347512|DRUG|Control arm|In this arm, no experimental treatment is prescribed. Patients receive IV antibiotics and standard of care (oxygen therapy, analgesics, antipyretics, heparin, etc).
223553627|NCT00570778|DRUG|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
223553628|NCT00570778|DRUG|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
223735129|NCT00696696|DRUG|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
224022127|NCT03226236|DRUG|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
224022128|NCT00866853|DRUG|TMC435|
223735130|NCT00791245|BIOLOGICAL|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
224022129|NCT02534038|DRUG|AVP-786|d6-DM/Q
224022130|NCT02534038|DRUG|Placebo|matching placebo
224022131|NCT02925026|DIETARY_SUPPLEMENT|Lactoferrin|
224022132|NCT02925026|DIETARY_SUPPLEMENT|Lysozyme|
223402476|NCT06301763|DEVICE|nasogastric tube feeding|During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on the health condition.The control group is provided with nutritional support as nasogastric tube feeding, performed 6-10 times per day according to relevant guidelines, with an interval of more than 2 hours between every two feedings, and a feeding volume not exceeding 200 ml per time.
224022133|NCT02925026|DIETARY_SUPPLEMENT|Placebo|
223402477|NCT02913118|DRUG|Andrographolid Sulfonate Injection (AS Injection)|
223402478|NCT02913118|DRUG|Cephalosporin|
223402479|NCT02913118|DRUG|Azithromycin, Minocycline or Doxycycline|
224022134|NCT01038063|DRUG|Artemether-lumefantrine combination|
224022135|NCT04253574|DIAGNOSTIC_TEST|Imaging with 18F-FDG PET/CT and/or Ultrasound|All patients were all examined by 18F-FDG PET/CT, 176 patients additionally by US (peripheral lymph nodes (pUS) and/or abdomen (aUS)) in the search of primary tumors or metastases of their malignant melanomas.
223402480|NCT02913118|DRUG|Amoxicillin-clavulantic acid|
224022136|NCT03952429|BEHAVIORAL|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
224022137|NCT03952429|BEHAVIORAL|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
224022138|NCT04942730|DRUG|Fludarabine|30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT
224022139|NCT04942730|DRUG|Bendamustine Hydrochloride|130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT
224022140|NCT04942730|DRUG|Busulfan|1 mg/kg po qid x 3 days, Days -5 through -3
224022141|NCT04942730|DRUG|Cyclophosphamide|50 mg/kg iv x 2 days, Days +3 through +4
224022142|NCT04942730|DRUG|Mycophenolate Mofetil|45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35
224022143|NCT04942730|DRUG|Tacrolimus 5Mg Cap|0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
224022144|NCT00010985|PROCEDURE|Acupuncture|
223402481|NCT02913118|DRUG|Fluoroquinolones|
223402482|NCT02913118|DRUG|Placebo|
223402483|NCT04390113|BIOLOGICAL|Posoleucel (ALVR105)|Administered as 2-4 milliliter infusion, visually identical to placebo
223402484|NCT04390113|BIOLOGICAL|Placebo|Administered as 2-4 milliliter infusion, visually identical to Posoleucel (ALVR105)
223402485|NCT05605418|BEHAVIORAL|CHESS intervention|The multi-faceted CHESS intervention includes: (1) home blood pressure monitoring (HBPM) for patients, and the data will be uploaded to central electronic health records (EHR) automatically; (2) a Smart Reminder and Alert System (SRAS) to send educational messages and reminders to support patients on HBPM, improve blood pressure medication adherence and lifestyle modification; (3) a decision support system (DSS) to provide physicians with antihypertensive medications prescriptions and referral recommendations; (4) regular quality assessment reports will be provided to health care providers automatically to improve the quality of hypertension management at PHC level.
223402486|NCT07061951|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223402487|NCT07061951|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223735131|NCT04061200|DRUG|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
223735132|NCT04061200|OTHER|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
224022145|NCT00010985|PROCEDURE|Chiropractic|
224022146|NCT00010985|PROCEDURE|massage|
224022147|NCT02493543|OTHER|Blood collection|Blood collection from the subject's arm
224022148|NCT02052830|BEHAVIORAL|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
224022149|NCT00055523|DRUG|Adalimumab (D2E7)|
224022150|NCT03690648|OTHER|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
224022151|NCT03690648|GENETIC|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
224022152|NCT03690648|GENETIC|Blood collection|Collection of 20 ml of blood with kit of blood collection
224022153|NCT03869723|PROCEDURE|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
224022154|NCT03869723|PROCEDURE|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
224022155|NCT00000263|DRUG|30% Nitrous oxide|
224022156|NCT00000263|OTHER|0.25 g/Kg ethanol|
224022157|NCT00000263|OTHER|0.5 g/KG ethanol|
223402488|NCT07061951|PROCEDURE|Computed Tomography|Undergo CT
224022158|NCT00000263|OTHER|0 g/Kg ethanol|
224022159|NCT05521945|BEHAVIORAL|Intermittent Fasting|16 hours fasting and 8 hours eating window
223402489|NCT07061951|PROCEDURE|Echocardiography Test|Undergo echocardiography
223402490|NCT07061951|DRUG|Mirdametinib|Given PO
223402491|NCT04020666|DRUG|Urinary Kallidinogenase|
223402492|NCT00195143|GENETIC|Surgical infusion of AAV-GAD into the subthalamic nucleus|
224022160|NCT05521945|BEHAVIORAL|Calorie Restricted Diet|The customized diet plan will be given to the participants according to their calorie intake requirements
224022161|NCT05521945|BEHAVIORAL|Normal dietary intake|normal diet without any customization
223402493|NCT01611883|DRUG|Ezetimibe|10 mg oral dose once daily for 24 weeks
223402494|NCT01611883|DRUG|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
223402495|NCT00396071|DRUG|vildagliptin|vildagliptin 100 mg
223402496|NCT00396071|DRUG|Placebo|matching placebo
223402497|NCT04125147|DEVICE|Experimental: Montage Bone Hemostat|Use of Montage bone hemostat on the cut surfaces of bone at the osteotomy site
224022162|NCT00277706|PROCEDURE|Periodontal surgery|
223402498|NCT07067567|DRUG|AK146D1 for injection|AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate
223402499|NCT01170429|DRUG|Procaterol hydrochloride|25µg BID for 8 weeks
223402500|NCT01170429|DRUG|Meptin placebo|25µg BID for 8 weeks
223402501|NCT03242473|OTHER|Fluid Management|The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
223402502|NCT03126968|DRUG|Topical epinephrine|Prophylactic topical epinephrine
223402503|NCT03126968|DRUG|Placebos|Topical placebo (normal saline)
223402504|NCT00030901|DRUG|L-selenomethionine|Randomization between active L-selenomethionine and placebo
223402505|NCT00030901|DRUG|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
223402506|NCT00052572|DRUG|ixabepilone|
223402507|NCT01598272|DIETARY_SUPPLEMENT|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
223402508|NCT01598272|DIETARY_SUPPLEMENT|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
223402509|NCT05897281|PROCEDURE|SHOOT exercise group|In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.
223402510|NCT05897281|PROCEDURE|routine training group|The control group will continue their routine training
223402511|NCT01955928|BEHAVIORAL|Online Cognitive behavioral treatment for insomnia|
223402512|NCT05290883|DIETARY_SUPPLEMENT|Novel yoghurt drink containing Polar Lipids|Postprandial decreased platelet activation/aggregation in subjects, after the yoghurt drink consumption
224022163|NCT00277706|DRUG|FORTEO|parathyroid hormone; self-administration for 6 weeks
224022164|NCT00277706|DRUG|Placebo|placebo; self administration for 6 weeks
223402513|NCT05632861|DRUG|HuHuangLianzonggan capsule|HuHuangLianzonggan capsule, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
224022165|NCT00277706|DIETARY_SUPPLEMENT|Vitamin D and Calcium|PO, QD, for six weeks
224022166|NCT03174912|PROCEDURE|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
224132109|NCT02559154|DRUG|Bortezomib|
223402514|NCT05632861|DRUG|HuHuangLianzonggan capsule placebo|HuHuangLianzonggan capsule placebo, 4 pills(120 mg per pill), take orally after meals, 2 times a day for 12weeks
223402515|NCT02153177|PROCEDURE|Rotator cuff repair|Arthroscopic procedure
223402516|NCT02153177|DRUG|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
223402517|NCT02153177|DRUG|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
223402518|NCT00369954|DRUG|carboplatin|
223402519|NCT00369954|DRUG|gemcitabine hydrochloride|
223402520|NCT02576847|DRUG|Omiganan|Topical gel
223402521|NCT04014205|DRUG|Orelabrutinib (ICP-022)|ICP-022 The drug product is a white, round, uncoated tablet
223402522|NCT01724697|OTHER|BMSC transplantation|Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
223402523|NCT01724697|OTHER|conventional treatment & antivrial treatment|Participants will recieve conventional treatment and antivrial treatment.
223402524|NCT01806051|DRUG|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
223402525|NCT06545851|OTHER|Oxygen therapy - constant oxygen flow|During five exercise training sessions, oxygen therapy is delivered via prescribed constant oxygen flow
223402526|NCT06545851|OTHER|Oxygen therapy - automatic titrating oxygen flow|During five exercise sessions, oxygen therapy is delivered via an automatically titrated oxygen flow rate to maintain an SpO2 target of 90-94%.
223553629|NCT00570778|DRUG|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
223553630|NCT05524857|DRUG|Fedratinib Oral Capsule 300 mg|300 mg by mouth, once daily
223553631|NCT05524857|DRUG|Decitabine 20 mg/m2|20 mg/m2 for injection, for intravenous use
223553632|NCT05524857|DRUG|Fedratinib Oral Capsule 400 mg|400 mg by mouth, once daily
223553633|NCT06391008|RADIATION|Stereotactic radiotherapy|Targeting primary lung lesions and irradiable mediastinal lymph nodes, stereotactic large segment radiotherapy was performed to complete the prescribed dose, PTV (planned target area): 5Gy x 3f
223553634|NCT06391008|DRUG|Evoximab|Evoximab (20mg/kg, Q3W)
223553635|NCT06391008|DRUG|Pemetrexed|Pemetrexed (500mg/m2, Q3W)
223735133|NCT04061200|DRUG|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
224022167|NCT01136772|DRUG|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
224022168|NCT01136772|DRUG|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
224022169|NCT04658082|DEVICE|H.G.R (GWave) non-invasive glucometer|Glucose tolerance test
224022170|NCT06164067|OTHER|abortus within 24 hours or 24-48 hours|second trimester medical termination
223735134|NCT02507505|PROCEDURE|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
223735135|NCT02507505|PROCEDURE|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
223735136|NCT00002054|DRUG|Pentamidine isethionate|
223735137|NCT05407467|DIETARY_SUPPLEMENT|Curcumin and virgin coconut oil extract (KurCo Smart)|we give 2 tablets of curcumin and virgin coconut oil extract thrice a day for 30 days and evaluate the result
223402527|NCT03550677|PROCEDURE|general anesthesia|The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
223402528|NCT03550677|PROCEDURE|ankle block|ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
223402529|NCT01205776|DEVICE|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
223402530|NCT01205776|PROCEDURE|CABG|Those patients receiving CABG
223402531|NCT00000162|PROCEDURE|Macular Argon Laser Photocoagulation|
223402532|NCT00000162|PROCEDURE|Peripheral Scatter Argon Laser Photocoagulation|
223402533|NCT00000162|PROCEDURE|Scatter Argon Laser Photocoagulation|
223553636|NCT06391008|DRUG|Albumin Paclitaxel|Albumin Paclitaxel 260 mg/m2, Q3W
224022171|NCT00279786|PROCEDURE|Blood draw|blood drawn
223735138|NCT03182829|DIAGNOSTIC_TEST|DOAC Dipstick|"Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]"
223735139|NCT03026608|BEHAVIORAL|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
223735140|NCT00254540|DRUG|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
223735141|NCT00225251|DRUG|bupropion XL|Antidepressant medication
223553637|NCT06391008|DRUG|Carboplatin|Carboplatin (AUC5, Q3W)
223735142|NCT00225251|OTHER|Placebo|Placebo
223735143|NCT04778579|DRUG|ARI-0001 cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z
223735144|NCT06825806|DEVICE|Femoral artery Doppler|Right common femoral artery will be examined before and after spinal anesthesia to evaluate pulsatility index, resisitive index, and waveform morphology
223553638|NCT00711594|DRUG|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
223553639|NCT00711594|DRUG|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
223553640|NCT00711594|DRUG|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
223553641|NCT00711594|DRUG|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
224022172|NCT05508620|DRUG|Sirolimus for Injection (Albumin-bound)|Intravenous infusion
224022173|NCT02943226|DEVICE|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
224022174|NCT02943226|DEVICE|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
224022175|NCT04068259|DRUG|PBI-4547|PBI-4547 tablet
224022176|NCT04068259|OTHER|Placebo|Placebo tablet
224132110|NCT02559154|DRUG|Dexamethasone|
224132111|NCT02559154|DRUG|Doxorubicin|
224132112|NCT02559154|DRUG|Cyclophosphamide|
224132113|NCT02559154|DRUG|Mitoxsnteone|
224132114|NCT02559154|DRUG|Thalidomide|
224132115|NCT01098461|BIOLOGICAL|albiglutide|subcutaneous injection of albiglutide
224132116|NCT01098461|BIOLOGICAL|placebo|subcutaneous injection of placebo to match albiglutide
224132117|NCT02019524|BIOLOGICAL|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
223402534|NCT03945227|DRUG|standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001|drug: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
223735145|NCT04850690|DIAGNOSTIC_TEST|2D Gait analysis|"The gait with four different conditions (single gait, Cognitive Task, Motor Task and Cognitive Task\&Motor Task) was evaluated by Kinovea video analysis method on a 10-meter course.~* Single: Walking without task at a self-selected speed~* Cognitive Task (CT): Walking while counting down rhythmically from 20 in threes~* Motor Task (MT): Walking while carrying an empty box~* CT + MT: Walking while carrying an empty box and counting down rhythmically from 20 in threes"
223735146|NCT05631886|BIOLOGICAL|TP53-EphA-2-CAR-DC|5\~10 × 10\^6 CAR DCs per dose will be administered by intravenous injection.
224022177|NCT02295657|DEVICE|standard double-lumen tube|intubation using standard double-lumen tube
224022178|NCT02295657|DEVICE|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
223735147|NCT05631886|DRUG|Abraxane|Intravenous abraxane 125 mg/m\^2/day on day-5.
224297464|NCT05842096|DIAGNOSTIC_TEST|Assessment of the impact of imbalance between anti- and pro-inflammatory factors in women with different PCOS and HPOD phenotypes on ovarian reserve indices|A venous blood sample of approximately 10 ml will be collected in the morning after 8 hours of fasting to determine and compare blood levels of leukocytosis, CRP, procalcitonin, fibrinogen, ferritin, IL-1, IL-6, IL-10, TNF-alpha and AMH, FSH in women in both study arms
223402535|NCT03945227|DRUG|PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001|drug:PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. -For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
223735148|NCT05631886|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.
223735149|NCT05631886|DRUG|anti-PD-1 antibody|Intravenous anti-PD-1 antibody 200 mg/day.
223735150|NCT05631886|DRUG|Anti-CTLA4 Monoclonal Antibody|Intravenous anti-CTLA4 antibody 1 mg/kg/day
223735151|NCT06401616|DRUG|OAC will be discontinued for the duration of the trial|Discontinuation of warfarin, dabigatran, rivaroxaban, apixaban or edoxaban
223735152|NCT05752201|BIOLOGICAL|Gamma Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
223735153|NCT05752201|BIOLOGICAL|Omicron Variant RBD-based ARVAC-CG vaccine|Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
223735154|NCT05752201|BIOLOGICAL|Bivalent RBD-based ARVAC-CG vaccine|Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
223735155|NCT05752201|OTHER|Placebo (Alum)|Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
224022179|NCT06001931|OTHER|handgrip force and bioimpedance values in healthy Turkish children.|Demographic characteristics, calf circumference , Hand grip strength , TANITA BIA analysis
224022180|NCT05210218|DIETARY_SUPPLEMENT|Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)|The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)
224022181|NCT05210218|DIETARY_SUPPLEMENT|placebo|cellulose
224022182|NCT05336331|PROCEDURE|SG or a RYGB|operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
224022183|NCT05864261|DRUG|JT1801 60ug|JT1801, 60ug, IV injection
224022184|NCT05864261|DRUG|NESP 60ug|NESP, 60ug, IV injection
224022185|NCT01041352|DEVICE|laryngeal mask|LMA Proseal
224022186|NCT01041352|DEVICE|endotracheal tube|Unomedical endotracheal tube
224022187|NCT03741569|DEVICE|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
224022188|NCT04101604|OTHER|Collection of blood samples|Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
224022189|NCT00676819|DRUG|insulin aspart|
223735156|NCT04533308|BEHAVIORAL|Relaxation in virtual reality|Natural 360-degrees scenes from different locations in the world with or without interactions with animals in the virtual reality
223735157|NCT05633524|OTHER|blood sample analysis|All subjects went through a routine ocular examination, and the peripheral venous blood samples were collected and analyzed
223735158|NCT01577823|DEVICE|Foley Catheter|
223735159|NCT04358666|PROCEDURE|surgery and focal radiosurgery of the surgical bed|hypofractionned radiosurgery of the lesion
223735160|NCT00005892|DRUG|cyclophosphamide|
223735161|NCT00005892|PROCEDURE|Allogeneic Bone Marrow Transplantation|
223735162|NCT01138631|DEVICE|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
223735163|NCT00536601|DRUG|etoposide|Given IV
223735164|NCT00536601|DRUG|cyclophosphamide|Given IV
224022190|NCT00676819|DRUG|human insulin|
223402536|NCT05159531|DRUG|PrEP|Participants will receive Descovy® 200/25mg 1 tablet once daily for 72 weeks.
223402537|NCT05159531|OTHER|mHealth Model of Care|Freddie® allows for asynchronous contact between patients and care providers, meaning that it does not require both groups to be connected in real time, instead allowing communication over a number of days.
223735165|NCT00536601|DRUG|carmustine|Given IV
223735166|NCT00536601|DRUG|melphalan|Given IV
223735167|NCT00536601|DRUG|busulfan|Given IV
223735168|NCT00536601|DRUG|carboplatin|Given IV
223735169|NCT00536601|DRUG|thiotepa|Given IV
223735170|NCT00536601|RADIATION|total-body irradiation|Undergo TBI
223735171|NCT00536601|PROCEDURE|autologous hematopoietic stem cell transplantation|Undergo ASCT
223735172|NCT00536601|PROCEDURE|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
223735173|NCT03045328|DRUG|Ibrutinib|Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.
223735174|NCT03045328|DRUG|Venetoclax|Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).
223735175|NCT02529514|DRUG|Baclofen|25 mg for 7 days at 10 pm every day
223735176|NCT02529514|DRUG|Placebo|Placebo for 7 days at 10 pm every day
223735177|NCT04090645|DEVICE|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
223735178|NCT01313767|DRUG|Botulinum toxin type A|Botulinum toxin type A
223735179|NCT01313767|DRUG|Botulinum Toxin type A|Botulinum Toxin type A
223735180|NCT00320983|DRUG|Topotecan|Topotecan
223735181|NCT00320983|DRUG|Cisplatin|Cisplatin
223735182|NCT06280573|COMBINATION_PRODUCT|Wim Hoff method|breathing exercises, cold exposure, and meditation
223402538|NCT05159531|OTHER|Standard of Care|Delivery of PrEP care through the local standard of care
223735183|NCT01648907|OTHER|Imaging exams|"Radiological examinations:~* Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~* MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~* Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~* Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~* Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
223735184|NCT01453634|DRUG|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
223735185|NCT01453634|DRUG|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
223735186|NCT04466254|DRUG|CPGJ602|Q2W/QW iv
223735187|NCT04466254|DRUG|cetuximab|QW iv
223735188|NCT01223989|OTHER|hypocaloric diet balanced + nutrition education + ruled physical activity|
223735189|NCT03733691|DRUG|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
223735190|NCT03733691|DRUG|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
223735191|NCT00277888|PROCEDURE|Femoral route for hemodialysis|
223735192|NCT00277888|PROCEDURE|Jugular route for hemodialysis|
224297465|NCT00354341|DRUG|Epoetin beta|
223735193|NCT01819077|PROCEDURE|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
223735194|NCT01287897|DRUG|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
223735195|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
223735196|NCT01287897|DRUG|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
223735197|NCT00507754|OTHER|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
223735198|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
223735199|NCT01610947|DRUG|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
223735200|NCT00468572|BEHAVIORAL|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
223735201|NCT00468572|BEHAVIORAL|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
223735202|NCT03916757|BIOLOGICAL|V-Boost|Open label setting
223735203|NCT00484211|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
223735204|NCT05217433|OTHER|Olive leaf extract|The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
223735205|NCT05217433|OTHER|Placebo|The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
224022191|NCT05997888|BEHAVIORAL|At-Home Strength Training Intervention|A six-week strength training intervention in which participants will choose workouts to complete on their own. These workouts are 20-25 minutes light-intensity strength training with light strength bands. Exercises will have multiple options to account for various levels of ability. Additionally, there will be a group counseling session once per week via Zoom and a group strength training program.
223735206|NCT05870709|OTHER|sacubitril/valsartan|There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
223402539|NCT00964574|DRUG|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
223735207|NCT04332354|OTHER|routine care. No intervention|no intervention
223735208|NCT00492687|DRUG|carboplatin|
223735209|NCT00492687|DRUG|tamoxifen citrate|
223735210|NCT00492687|DRUG|temozolomide|
223735211|NCT00492687|PROCEDURE|adjuvant therapy|
223735212|NCT00492687|RADIATION|radiation therapy|
223402540|NCT00964574|DRUG|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
223402541|NCT04191174|OTHER|Hyperpolarized 129Xe MRI|Hyperpolarized 129Xe MRI to evaluate ventilation heterogeneity
223553642|NCT00443872|DRUG|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
223553643|NCT06290531|DEVICE|Buzzy device (cold and vibration)|The device produces cold and vibration to act on the gate control theory and provide painless injection by nerve distraction
223553644|NCT06290531|DEVICE|Buzzy device (vibration only)|The device produces vibration to act on the gate control theory and provide painless injection by nerve distraction
223553645|NCT06290531|OTHER|precooling|Ice cubes used for applying coolness at the injection area
223735213|NCT05882240|OTHER|choice of initial position|current practice of correct application and interpretation of the PLR in critical care patients
223553646|NCT06290531|OTHER|Flavored Benzocaine topical anesthetic gel 20%|Topical anesthetic gel
223735214|NCT04146025|BEHAVIORAL|Nature Coach Intervention|"1. Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~2. Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~3. Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
223735215|NCT04474067|OTHER|No intervention|This is an observational study, with no intervention.
223735216|NCT00065507|DRUG|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
223735217|NCT00065507|DRUG|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
223735218|NCT03054545|DRUG|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
224022192|NCT00002428|BIOLOGICAL|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
224022193|NCT00002428|BIOLOGICAL|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
224022194|NCT02354443|BIOLOGICAL|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
224022195|NCT03622554|OTHER|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
224022196|NCT03622554|OTHER|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
224022197|NCT02996565|OTHER|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~1. Improved recognition of uncontrolled BP at primary care encounters,~2. Therapeutic action to address uncontrolled BP at primary care encounters,~3. Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
223402542|NCT04191174|OTHER|Technegas V SPECT|Technegas V SPECT to evaluate ventilation heterogeneity
223402543|NCT04191174|OTHER|Sputum Induction|Sputum induction to evaluate luminal cellular inflammation
223553647|NCT05292495|DRUG|HR17031 injection|HR17031 injection; administered subcutaneously.
223553648|NCT02661386|DEVICE|Motility Procedure|The use of esophageal manometry device during general anesthesia
223553649|NCT03093948|PROCEDURE|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
223553650|NCT00483054|DRUG|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
223553651|NCT00483054|DRUG|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
223735219|NCT02169739|DEVICE|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
223735220|NCT03635957|BIOLOGICAL|Pegloticase|pegloticase administered intravenously (IV)
223735221|NCT03635957|DRUG|Methotrexate (MTX)|oral MTX
224022198|NCT02996565|OTHER|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~1. Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~2. Systematic home BP telemonitoring with data transmitted into patient medical record~3. Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email"
224022199|NCT03463967|DIETARY_SUPPLEMENT|Lycopene-enriched tomato juice|Energy-restricted diet supplemented with Lycopene-enriched tomato juice
223402544|NCT04853082|DRUG|Limonene capsule|All the recruiters will be given treatment under the guidance of basic diet. Basic dietary guidelines include high-quality protein and fresh green leafy vegetables. It need to controlled sugar, various sweets and high-calorie foods, frying and other foods with high oil content and foods with high cholesterol content. Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
223402545|NCT04853082|DRUG|Limonene capsules(Placebo)|Limonene capsules(Placebo)
223402546|NCT03268980|OTHER|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
223402547|NCT03268980|OTHER|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
223402548|NCT02021929|DRUG|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:~* Unresectable hepatocellular carcinoma~* Advanced renal cell carcinoma~* Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
223402549|NCT02021929|DRUG|Placebo|
223402550|NCT02596360|DRUG|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
223402551|NCT02596360|DRUG|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
224022200|NCT03463967|OTHER|Energy-restricted diet|
224022201|NCT00829582|DRUG|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
223402554|NCT06848530|OTHER|Prescribed Medications|participant's movement disorders medications, prescribed by their treating physician
223402555|NCT06848530|OTHER|Deep brain stimulation adjustment|Deep brain stimulator parameters may be adjusted within normal clinical limits
223402556|NCT04093310|DEVICE|Word Catheter|Use of the Word catheter to remove the Bartholin's abscess
223402557|NCT04093310|PROCEDURE|Incision-drainage|Incision-drainage to remove the Bartholin's abscess
223402558|NCT06676943|PROCEDURE|XEOS AURA 10 specimen PET-CT scan of tumour specimens|Participants will be injected with a small amount of radioactive tracer at the beginning of their cancer operation. This tracer will attach itself to the cancer cells. Once the surgical specimen is removed it will be placed into the specimen PET-CT scanner so that the surgeon can see the cancer within the specimen and assess the margin.
224022202|NCT00829582|OTHER|placebo|single intravenous infusion
224022203|NCT05158556|OTHER|Myofascial Release Technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. Deep pressure will be applied and glided medially towards the thoraco-lumbar region.
224022204|NCT05158556|OTHER|Instrument Assisted Soft tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
224022205|NCT03493841|DRUG|Alpha Lipoic Acid|Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
223402559|NCT05609630|DRUG|Upadacitinib|Oral tablet or Oral solution
223402560|NCT05609630|DRUG|Tocilizumab|Subcutaneous injection or Intravenous infusion
223402561|NCT03757312|DIAGNOSTIC_TEST|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
223402562|NCT06930716|DEVICE|Transcutaneous vagus nerve stimulation (taVNS)|A non-invasive nerve stimulator that stimulates the vagus nerve through the ear.
224022206|NCT02202005|DRUG|Nevirapine|Nevirapine 400mg PR tablet
224022207|NCT02202005|DRUG|Viramune®|Viramune® 400 mg Retardtabletten
224022208|NCT01602562|DRUG|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
224022209|NCT00502827|BEHAVIORAL|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
223402563|NCT06930716|DEVICE|Physical therapy using Hocoma|Progressive verticalization and mobilization using a robotic tilt table with robotic stepping (Erigo, Hocoma)
223553652|NCT00146926|DRUG|kétamine 20mg|
223553653|NCT00146926|DRUG|ephedrine 3mg|
223553654|NCT00146926|DRUG|lidocaine 40mg|
223553655|NCT02217423|OTHER|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
223553656|NCT02217423|OTHER|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
223553657|NCT05092828|DRUG|Intrathecal Morphine Injection|In addition to standard post-operative pain management, Intratechal morphine will be given to patients in this group.
223553658|NCT05092828|DRUG|Pain Relieving|Patient in this group will receive standard postoperative pain medications other than inthrathecal injection of morphine
223553659|NCT03962088|DIAGNOSTIC_TEST|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at -80 °C."
223553660|NCT02685566|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
223553661|NCT02685566|DEVICE|FFDM|FujiFilm Aspire Cristalle System
223553662|NCT00694577|RADIATION|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
223402564|NCT06930716|BEHAVIORAL|Standard of Care|Standard of care with no study interventions. This will include observation of whatever rehabilitation or medical care the patient is currently receiving.
223402565|NCT06928402|OTHER|No intervention|no interventions will be performed by the research team
223402566|NCT06903884|DRUG|3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion|This arm is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution
223402567|NCT06903884|DRUG|0.1% Cyclosporin A cationic ophthalmic emulsion|This arm is a control group to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution
224022210|NCT00502827|OTHER|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
224022211|NCT05065333|OTHER|Septic Shock Clinical Decision Support|The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models \[Ref 1, 2\]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
224022212|NCT05065333|OTHER|Clinical Diagnosis Only|Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
224022213|NCT00828880|DEVICE|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
224022214|NCT01340820|DRUG|AERAS-422|rBCG
224022215|NCT01340820|DRUG|BCG Tice|1-8 x 10\^5 CFU
224022216|NCT00606970|DIETARY_SUPPLEMENT|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
224022217|NCT00606970|DIETARY_SUPPLEMENT|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
223402568|NCT06907784|DIAGNOSTIC_TEST|Pharmacogenomic testing|The PGx testing will analyse genetic variants across 16 key pharmacogenes in each given DNA sample, all of which focus on variants with established implications for drug response as recommended by published Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) guidelines Testing will be performed immediately in the intervention arm or at three months in the standard of care arm.
223402569|NCT06807021|DRUG|IP1 control cream (Vehicle base)|Without FS2
224022218|NCT00891345|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
224022219|NCT03075007|RADIATION|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
224022220|NCT03075007|PROCEDURE|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
223402570|NCT06807021|DRUG|IP2 - 0.5% w/w FS2|FS2 in pharmaceutical compounding base
223402571|NCT04351958|BEHAVIORAL|"Experimental: Augmented Reality (No Time Wasted)"|"No Time Wasted will be an innovative, immersive intervention using novel technology that will captivate the target audience with narrative and gaming elements to scaffold the educational message."
223402572|NCT02873637|DEVICE|under sartorial catheter|
223402573|NCT02873637|DEVICE|femoral catheter|
223553663|NCT00694577|RADIATION|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
223553664|NCT00694577|RADIATION|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
223553665|NCT01508377|BEHAVIORAL|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
223553666|NCT01508377|BEHAVIORAL|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
223553667|NCT00485758|DRUG|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
223553668|NCT00485758|DRUG|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
223553669|NCT00434980|BEHAVIORAL|Family-Directed Cognitive Adaptation Program|
223735222|NCT03635957|DRUG|Standard Gout Flare Prophylaxis|It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.
223402574|NCT06237920|DRUG|Nivolumab|Induction with immune checkpoint blockade nivolumab on day 1. Nivolumab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
223402575|NCT06237920|DRUG|Relatlimab|Induction with immune checkpoint blockade nivolumab and relatlimab on day 1. Nivolumab and relatlimab will also be administered on day 29. Response evaluation will be after the last cycle of checkpoint inhibition.
223402576|NCT06906042|RADIATION|Imaging examinations|"* Cardiovascular MRI~* Hepatic MRI~* Hepatic ultrasound"
223402577|NCT06906042|OTHER|Paramedical examinations|"* Urinary pregnancy test for women of childbearing age.~* Blood sample for cardiometabolism profiling~* Blood samples for biobanking (according to the information and consent form)~* Impedancemetry~* AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device."
223402578|NCT06906042|OTHER|Medical examination|"* Review of risk factors~* Review of previous history~* Recording of current medication (dci, dose, start date)~* Recording of medication in the last 6 months and discontinued since (dci, dose, start date)"
223402579|NCT06906042|OTHER|Echocardiography|Echocardiography including: 12-lead digital ECG
223402580|NCT03929289|BEHAVIORAL|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scans, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
223735223|NCT03635957|DRUG|Infusion Reaction (IR) Prophylaxis|For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.
223735224|NCT03635957|DIETARY_SUPPLEMENT|Folic Acid|Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
224022221|NCT04551625|DEVICE|High Resolution Colonic Manometry and 3D-Transit system.|Not performed as an intervention, the study is observational.
224022222|NCT03881553|DEVICE|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
224022223|NCT03881553|DEVICE|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
224022224|NCT01517646|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223402581|NCT06928272|DRUG|Pirfenidone|"Initial dose titration:~First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day)~Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day)~Maintenance dose:~Third week and thereafter (days 15-90): 3 capsules (801 mg), 3 times daily (2403 mg/day)"
223402582|NCT06928272|DRUG|Placebo for pirfenidone|"First week (days 1-7): 1 capsule, 3 times daily~Second week (days 8-14): 2 capsules, 3 times daily~Third week and thereafter (days 15-90): 3 capsules, 3 times daily"
223402583|NCT06928272|DRUG|Upadacitinib|1 capsule (15 mg), once daily for 90 days
223402584|NCT06928272|DRUG|Placebo for upadacitinib|1 capsule, once daily for 90 days
223402585|NCT05944562|DRUG|Tulmimetostat|Patients should take DZR123 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following DZR123 dosing). Each dose of DZR123 should be taken with a glass of water and consumed over as short a time as possible.
223402586|NCT07103850|DIAGNOSTIC_TEST|Suicidal Crisis Syndrome Checklist (SCS-C)|The Suicidal Crisis Syndrome Checklist (SCS-C) is a clinician-rated tool designed to diagnose Suicidal Crisis Syndrome (SCS), a suicide-specific state associated with imminent risk. It includes Criterion A (entrapment)-a required symptom-and Criterion B, which requires at least one symptom from each of four domains: affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal. The checklist offers a structured assessment for identifying acute suicide risk, complementing traditional risk evaluations.
223402587|NCT07103850|DIAGNOSTIC_TEST|Suicide Crisis Inventory-Revised (SCS-2)|The Suicide Crisis Inventory-Revised (SCS-2) is a 61-item self-report scale developed to assess the severity of Suicidal Crisis Syndrome (SCS), a clinical state associated with imminent suicide risk. Items are rated on a Likert scale and grouped into five empirically derived factors: entrapment, affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal. The SCS-2 has shown strong internal consistency and predictive validity for suicidal behavior within weeks of discharge. It is currently undergoing cultural adaptation and psychometric validation in Spanish for use in high-risk psychiatric populations in Chile.
223402588|NCT06572605|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223402589|NCT06572605|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223402590|NCT06572605|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223402591|NCT06572605|PROCEDURE|Computed Tomography|Undergo CT and/or PET/CT
223402592|NCT06572605|OTHER|Electronic Health Record Review|Ancillary studies
223402593|NCT06572605|RADIATION|External Beam Radiation Therapy|Undergo EMD-EBRT
223402594|NCT06572605|PROCEDURE|Image Guided Biopsy|Undergo image-guided EMD biopsy
223402595|NCT06572605|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223402596|NCT06572605|BIOLOGICAL|Talquetamab|Given SC
223402597|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered either as monotherapy or in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
223735225|NCT01214161|DRUG|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
223735226|NCT01214161|OTHER|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
223735227|NCT02445482|PROCEDURE|Biopsy|archival tissue or fresh biospsy
223735228|NCT00227903|BEHAVIORAL|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
223735229|NCT00227903|BEHAVIORAL|Brief Advice|Advice and education
223735230|NCT02133027|PROCEDURE|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
223735231|NCT02133027|DEVICE|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
223735232|NCT01475331|DRUG|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
223553670|NCT02745704|DRUG|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
223553671|NCT00460694|BIOLOGICAL|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
223553672|NCT03181061|OTHER|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
223553673|NCT04176991|BIOLOGICAL|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
223553674|NCT04176991|BIOLOGICAL|Placebo|Placebo Comparator
223553675|NCT06162559|DRUG|Tucatinib|Tucatinib 300mg is taken orally twice daily
223553676|NCT06162559|DRUG|Trastuzumab|Trastuzumab 6mg/kg is administered intravenously on day 1 (loading dose 8mg/kg) or subcutaneously 600mg on day 1 of each cycle
223553677|NCT06162559|DRUG|Pertuzumab|Pertuzumab 420mg is administered intravenously on day 1 (loading dose 840mg) or subcutaneously 600mg/kg (loading dose 1200mg) on day 1 of each cycle
223553678|NCT04150666|DIETARY_SUPPLEMENT|Hydration|the same with arm descriptions
223553679|NCT05337111|OTHER|Cardiorespiratory fitness test|Progressive submaximal exercise test on a treadmill to predict cardiorespiratory fitness
223553680|NCT05337111|OTHER|Resting measure of fat oxidation|Use of ventilated hood attached to automated metabolic cart to measure substrate oxidation at rest
223553681|NCT05337111|OTHER|Maximum fat oxidation test|Progressive exercise test to determine maximum fat oxidation during exercise
223735233|NCT01475331|DRUG|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
223735234|NCT01475331|DRUG|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
223735235|NCT01197053|BIOLOGICAL|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
223735236|NCT01197053|BIOLOGICAL|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
223735237|NCT02334007|DRUG|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
223735238|NCT02334007|OTHER|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
223553682|NCT04551963|DRUG|Zanubrutinib|Capsules administered at a dose and frequency as specified in the treatment arm
223553683|NCT04551963|DRUG|Fluconazole|Capsules administered at a dose and frequency as specified in the treatment arm
223553684|NCT04551963|DRUG|Diltiazem|Capsules administered at a dose and frequency as specified in the treatment arm
223553685|NCT04551963|DRUG|Voriconazole|Capsules administered at a dose and frequency as specified in the treatment arm
223553686|NCT04551963|DRUG|Clarithromycin|Capsules administered at a dose and frequency as specified in the treatment arm
223553687|NCT03379259|DRUG|BGB-A333|Anti-PD-L1 antibody
223553688|NCT03379259|DRUG|BGB-A317|Anti-PD-1 antibodies
223553689|NCT00211354|DRUG|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
223553690|NCT04907825|DRUG|Oral anticoagulant|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
224022225|NCT02288533|DEVICE|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
224022226|NCT01046890|DRUG|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
224022227|NCT01098565|DEVICE|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
223735239|NCT06176573|PROCEDURE|Chlorhexidine|Pre-operative and post-operative vaginal cleansing.
223735240|NCT05356455|BEHAVIORAL|motivational interview technique|Difference between pre-test and post-test
223735241|NCT04853927|DRUG|Proxalutamide|Proxalutamide 300mg q.d suspension
223735242|NCT04853927|DRUG|Placebo|Proxalutamide 300mg q.d placebo
223735243|NCT00562939|BIOLOGICAL|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
223735244|NCT00562939|BIOLOGICAL|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
224132118|NCT02019524|BIOLOGICAL|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
224297466|NCT06004219|BEHAVIORAL|Peer counseling group|A community advisory board (CAB) will be set up for need assessment and to design the peer support program. Virtual meetings will be held quarterly for year 1 and 2. The group will consist of (up to 12 members) and will include at least 2 patient partners (patients with a recently diagnosed ulcer), 2 peer pals (patients with a healed DFU), family members or caregivers (limited to only 1 person per family represented on the CAB), healthcare workers (podiatrist, nurse, or case manager), medical equipment company representatives, and others. We will ask them about potential barriers at the first meeting, have flexible meeting times, and intentionally limit the number of healthcare providers. At the last meeting, we will seek feedback and input from the CAB. In addition, this group will have the opportunity to participate in a focus group which will be moderated with a trained, bilingual assistant and will last 40-60 minutes.
224297467|NCT02047175|DRUG|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
223735245|NCT01533233|PROCEDURE|thoracoscopic lobectomy and mediastinal lymph node dissection|
223735246|NCT06246318|OTHER|virtual reality|The virtual reality protocol here is based on perceptual-motor activities, supported by Nintendo Wii resources. The user will be able to control a game character in a virtual environment using a remote control with a motion sensor. Wii Fit Plus requires the use of the Wii Balance Board that the player stands on during gameplay. The Wii Balance Board is not a wobbly balance board, but is able to detect and track the user's center of balance, a feature used extensively in the game. Wii Fit Plus includes more than 40 activities including yoga, strength training, aerobics and balance games. During the virtual reality application, different games will be preferred in each session depending on the duration of the games. Virtual reality application will be carried out in a corner prepared for virtual reality application in the room where the conventional occupational therapy session is held. Families have the right to observe and attend all sessions whenever they wish.
224022228|NCT03322787|DEVICE|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher\&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
224022229|NCT00536536|BEHAVIORAL|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
224022230|NCT01959516|DRUG|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
224022231|NCT01959516|DRUG|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
224022232|NCT01959516|DRUG|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
224022233|NCT01959516|DRUG|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
223402598|NCT06537310|DRUG|RO7567132 and Atezolizumab|RO7567132 will be administered in combination with atezolizumab at a dose and schedule as specified for the respective cohort.
223402599|NCT06439836|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223402600|NCT06439836|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223402601|NCT06439836|PROCEDURE|Computed Tomography|Undergo CT
223402602|NCT06439836|BIOLOGICAL|Emavusertib|Given PO
223402603|NCT06439836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223402604|NCT06439836|BIOLOGICAL|Pembrolizumab|Given IV
223402605|NCT06439836|PROCEDURE|Positron Emission Tomography|Undergo PET
223402606|NCT07107763|OTHER|short foot exercise|The short foot exercise group will receive stretching exercises and short foot exercises, administered three sessions per week for a duration of six weeks.
223402607|NCT07107763|OTHER|Mobilization|The mobilization group will undergo a program consisting of 3 sessions per week for a duration of 6 weeks. The sessions will begin with stretching exercises, followed by subtalar joint mobilization.
223402608|NCT07107763|COMBINATION_PRODUCT|Short foot exercise and mobilization|The combined intervention used in this group will include both of the approaches applied in the other two groups.
224022234|NCT02241954|DEVICE|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
224022235|NCT04834349|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT
223735247|NCT06246318|OTHER|conventional occupational therapy|"Sensory integration and gross motor training approaches will be used in the conventional occupational therapy program. A manualized protocol based on Ayres sensory integration principles will be followed (Schaaf et al., 2012). The intervention will be carried out by a licensed occupational therapist trained in sensory integration.~This approach suggests that if a child engages in individually adapted sensorimotor activities, the nervous system is better able to modulate, organize, and integrate sensory information and is also more likely to use sensory information in adaptive ways (Ayres, 1972). Components of the intervention include a sensory-rich, playful, child-centered approach, providing a decision challenge, and facilitating increasingly complex adaptive behaviors by engaging the child in individually tailored, developmentally appropriate play interactions"
223735248|NCT00383279|OTHER|counseling intervention|
223735249|NCT00383279|OTHER|study of socioeconomic and demographic variables|
223735250|NCT02054416|DEVICE|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
223735251|NCT05322642|BEHAVIORAL|UPA|UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
223735252|NCT05322642|BEHAVIORAL|Active control condition (Progressive Relaxation Training)|Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
224022236|NCT04834349|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
224022237|NCT04834349|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224022238|NCT04834349|BIOLOGICAL|Pembrolizumab|Given IV
224022239|NCT04834349|OTHER|Quality-of-Life Assessment|Ancillary studies
224022240|NCT04834349|OTHER|Questionnaire Administration|Ancillary studies
224022241|NCT04834349|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224022242|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
224022243|NCT03174548|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
224022244|NCT01477333|DRUG|UT-15C SR|Initiated at 0.125 mg BID, titrated as clinically indicated.
224022245|NCT01477333|DRUG|Tyvaso Inhalation Solution|Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
224022246|NCT05064189|DEVICE|Lacrimera|A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
224022247|NCT00482950|DRUG|PHX1149T|
224022248|NCT02501538|DEVICE|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
224022249|NCT03035903|DEVICE|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
223402609|NCT07103720|DIAGNOSTIC_TEST|Skin Testing|Participants will undergo skin prick testing and intradermal test injections at 5 increasing concentrations of midazolam, ketamine and/or ondansetron during one single study visit.
223402610|NCT07110844|DRUG|Teclistamab|Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
223402611|NCT07110844|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.
223402612|NCT06922630|BEHAVIORAL|WIN|Weight-neutral health intervention
223402613|NCT06955104|DRUG|JW0108 + C2407|JW0108 + C2407
223402614|NCT06955104|DRUG|JW0108 + C2407 placebo|JW0108 + C2407 placebo
223402615|NCT07151768|DIAGNOSTIC_TEST|Observational Study|"* assignment of PVD-B65 score derived from standard of care testing~* no therapeutic intervention or other treatment"
223402616|NCT07151482|DIETARY_SUPPLEMENT|Collagendep|The purpose of this study is to evaluate the improvement of quality of life, vulvovaginal atrophy (VVA) and of initial Urinary Incontinence (UI) in menopausal women with GSM symptoms following oral administration of a food supplement treatment containing 2.5 g of BCP® and other functional ingredients taken once daily over a period of 16 weeks.
223402617|NCT07151690|DRUG|anti-BCMA/CD3 bispecific antibody|CM336 is a bispecific T-cell engager targeting B-cell maturation antigen (BCMA) and CD3. In this study, CM336 is administered subcutaneously with a step-up dosing strategy in Cycle 1 (3 mg Day 1, 20 mg Day 4, 40 mg Day 8 and onwards weekly). Patients who achieve ≥VGPR by Cycle 4 may switch to 80 mg every two weeks from Cycle 5. The total treatment duration is up to 12 cycles (28 days per cycle), with follow-up for safety and efficacy endpoints including hematologic and organ response.
223402618|NCT07152405|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
223402619|NCT07152405|DRUG|Investigator's choice of chemotherapy|Administration by intravenous infusion for a cycle of 2 or 3 or 4 weeks.
223402620|NCT07152899|OTHER|Unilateral anodal tDCS|Evaluates the effects of unilateral, anodal tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia
223402621|NCT07152899|OTHER|Bihemispheric anodal tDCS|Evaluates the effects of bihemispheric, anodal tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia and in Parkinson's disease-related dysphagia
223402622|NCT07152899|OTHER|Sham tDCS|Evaluates the effects of Sham tDCS applied to the swallowing motor cortex in post-stroke patients with dysphagia and in Parkinson's disease-related dysphagia
223402623|NCT07152899|OTHER|NMES + swallowing therapy|Examines the effects of NMES therapy on swallowing function in both post-stroke and Parkinson's disease patients
223402624|NCT07152899|OTHER|Sham NMES + swallowing therapy|Examines the effects of Sham therapy on swallowing function in both post-stroke and Parkinson's disease patients
223735253|NCT03683758|OTHER|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
223735254|NCT03683758|OTHER|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
223735255|NCT01172847|DRUG|oseltamivir [Tamiflu]|multiple oral doses
223735256|NCT01172847|DRUG|rimantadine|multiple oral doses
223735257|NCT01163279|BEHAVIORAL|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
223735258|NCT01163279|BEHAVIORAL|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
223735259|NCT03304574|BEHAVIORAL|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
223735260|NCT02657707|DEVICE|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
223735261|NCT02657707|DEVICE|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
223735262|NCT00882193|DRUG|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
223735263|NCT00882193|DRUG|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
223735264|NCT00882193|DRUG|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
223735265|NCT01912417|OTHER|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
223735266|NCT03864471|OTHER|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
223735267|NCT03864471|OTHER|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
223735268|NCT01042730|DRUG|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
223735269|NCT01981447|DRUG|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
224297468|NCT02047175|DRUG|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
224297469|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
224297470|NCT02047175|DRUG|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
224297471|NCT05340777|DEVICE|Training Obstetric staff on Ellavi UBT|The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to ensure staff are trained on the newly registered and provided medical device. We will gather feedback on how to improve the training curriculum from participants. We will also gather information from the healthcare workers immediately post-use of an Ellavi UBT device following their management of a refractory PPH case. These surveys will help us to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of PPH care.
224297472|NCT01335373|DRUG|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
224297473|NCT01732874|DRUG|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
223402625|NCT07151404|PROCEDURE|Acupuncture at LU7 (Lieque) + Electroacupuncture|Participants will receive filiform needle acupuncture at Lieque (LU7) combined with electroacupuncture at Jiaji (Ex-B2, C4-C7) and neck-shoulder acupoints including Fengchi (GB20), Jianjing (GB21), Tianzhu (BL10), and Dazhu (BL11). Sterile disposable filiform needles (0.3 × 25 mm) will be inserted at LU7 using standard manual acupuncture technique. Electroacupuncture will be delivered with continuous wave stimulation at 60 Hz for 30 minutes per session. Treatment will be performed once daily for a total of 20 sessions over approximately 4 weeks, excluding Sundays.
223402626|NCT07151404|PROCEDURE|Electroacupuncture Only|Participants will receive electroacupuncture at Jiaji (Ex-B2, C4-C7) and neck-shoulder acupoints including Fengchi (GB20), Jianjing (GB21), Tianzhu (BL10), and Dazhu (BL11), without acupuncture at Lieque (LU7). Electroacupuncture will be delivered with continuous wave stimulation at 60 Hz for 30 minutes per session. Treatment will be performed once daily for a total of 20 sessions over approximately 4 weeks, excluding Sundays.
223402627|NCT07152210|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
223402628|NCT07153133|BIOLOGICAL|albumin platelet rich fibrin|sixteen teeth extraction socket filled by albumin platelet rich fibrin
223402629|NCT07151976|DEVICE|PCI|PCI with athero-thrombotic aspiration and subsequent pathological analysis: Pathologic Characteristics of Athero-Thrombotic AsPirated Material of OCT-Verified Culprit Lesion in Acute Coronary Syndrome
223402630|NCT07184424|DRUG|lenalidomide|For patients with hepatocellular carcinoma who have experienced disease progression after receiving standard clinical treatment with lenvatinib in combination with PD-1 inhibitors, the addition of lenalidomide capsules to the three-drug combination therapy was followed by a 2-month follow-up liver imaging examination to observe changes in the target lesion and whether new lesions had developed in other areas.
223553691|NCT04791215|OTHER|Observational|All patients will be treated with standard of care pembrolizumab. After obtaining written informed consent, NSCLC participants will have serial blood collection. The blood collection (26 ml) should coincide with routine clinical blood draw to minimize participant discomfort if possible. No additional procedures will be performed other than phlebotomy. If additional biopsies or tumor resection are performed as part of routine standard of care throughout the course of the study, an additional 26 ml blood collection may be drawn for the study. Participants will remain on the study for as long as they are being followed or treated at Columbia University Irving Medical Center. Participants can withdraw from the study at any time.
223553692|NCT06090812|OTHER|Ultrasound evaluation|Ultrasound evaluation of volume status, right heart function, and pulmonary edema.
223735270|NCT01601626|DRUG|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
223735271|NCT01601626|DRUG|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
223402631|NCT07184099|DRUG|Phloroglucinol|Phloroglucinol was administered as intravenous stat infusion with Ringer Lactate infusion.
223553693|NCT04021316|OTHER|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
223553694|NCT04021316|OTHER|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
223553695|NCT00700622|DRUG|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
223735272|NCT01601626|DRUG|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
223735273|NCT01601626|DRUG|Isoniazid|300 mg orally once daily from entry through Week 24.
223735274|NCT01601626|DRUG|Pyridoxine|25 mg orally once daily from entry to Week 24.
223735275|NCT01601626|DRUG|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
223735276|NCT01601626|DRUG|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
223735277|NCT01601626|DRUG|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
223735278|NCT01601626|DRUG|Rifampin|Weight-based dose; for weight \< 45 kg: 450 mg orally once daily; for weight \> 45 kg: 600 mg orally once daily, from entry to week 24.
223735279|NCT06053073|DEVICE|Cervical rippening at home|The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction
223735280|NCT06053073|DEVICE|Cervical rippening in the hospital|The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
223735281|NCT04432662|DRUG|Darbepoetin Alfa|Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
224297474|NCT01732874|DRUG|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
223735282|NCT01623323|DRUG|Fluticasone Propionate|Fluticasone Propionate 400 μg
223735283|NCT04585022|DEVICE|Magnum, Zimmer Biomet, Warsaw, IN|
223735284|NCT04585022|DEVICE|Recap, Zimmer Biomet, Warsaw, IN|
223735285|NCT02632552|BEHAVIORAL|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
223735286|NCT02632552|BEHAVIORAL|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
223735287|NCT05503147|DRUG|Sativex|Sativex® is administered as an oromucosal spray and consists of 2.7 mg tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD) per dosis spray (Cannabis sativa L. extract, cannabis leaf and flower). The dose (3 sprays) is administered twice, at breakfast and lunch, respectively, with approximately 4 hours between each administration.
223735288|NCT05313594|DIAGNOSTIC_TEST|Mixed meal challenge test|Mixed meal consumption followed by postprandial blood sampling
223735289|NCT05313594|DIAGNOSTIC_TEST|MRI|MRI imaging
223735290|NCT05313594|DIAGNOSTIC_TEST|DEXA|DEXA scan
223735291|NCT05313594|DEVICE|Freestyle Libre|Continuous blood glucose measurement
223735292|NCT05313594|DEVICE|ActivPAL3|Continuous physical activity measurement
223735293|NCT04864379|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01: 300 mcg per peptide
223402632|NCT07182136|PROCEDURE|Pancreaticoduodenectomy|Retrospective study evaluating postoperative NAFLD and metabolic outcomes in patients with stage I-II pancreatic cancer after PD.
223402633|NCT07182955|BEHAVIORAL|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Remote 4 weeks of high-intensity interval exercise training on three non-consecutive days of the week.
223553696|NCT00700622|DRUG|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
223735294|NCT04864379|OTHER|GM-CSF|GM-CSF: 40 mcg
223402634|NCT07182682|DRUG|sunvozertinib|Participants will receive oral administration of sunvozertinib 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
223402635|NCT07182682|DRUG|Matching Placebo|Participants will receive oral administration of placebo 200 mg QD following randomization, with each treatment cycle defined as 21 days, until meeting any treatment discontinuation criteria (i.e, objective disease recurrence, intolerable adverse event \[AE\], completion of 3-year \[156-week\] treatment period, study termination, death, treatment or study withdrawal by participants, whichever occurs first).
223402636|NCT07184346|OTHER|Control|Control Group
223402637|NCT07184346|DEVICE|Intra Oral Scanner|Experimental group 1
223402638|NCT07184346|DEVICE|Mod Jaw|4 D Jaw Tracker
223553697|NCT00700622|DRUG|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
223553698|NCT02069873|BEHAVIORAL|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
223553699|NCT03198091|DRUG|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
223553700|NCT01138085|DRUG|GSK1120212|MEK inhibitor
223553701|NCT01138085|DRUG|GSK2141795|AKT Inhibitor
223735295|NCT04864379|DRUG|PD-1|PD-1: 200mg administered by intravenous infusion every 2 weeks.
223735296|NCT04864379|PROCEDURE|RFA|Radiofrequency ablation surgery
223735297|NCT05325528|DRUG|Tislelizumab in Combination with Oxaliplatin and Tegafur|6 cycles of Tislelizumab plus SOX regimen every 21 days
223402639|NCT07182877|DEVICE|Closed-type peripheral cannula|We will use closed-type peripheral catheters (BD Nexia Closed IV Catheter System.
223402640|NCT07182877|DEVICE|Open type peripheral cannula|We will use POLYMED Ultra Intravenous cannula in the control arm
223402641|NCT07183072|OTHER|Questionnaire and functionality application for child and adult scleroderma patients|Scales and functionality tests will be applied to cases diagnosed with scleroderma
223553702|NCT00792311|PROCEDURE|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
223553703|NCT02444507|DRUG|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
223553704|NCT02444507|DRUG|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
223553705|NCT04096950|BIOLOGICAL|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
223735298|NCT01324336|DRUG|6-Mercaptopurine|75 mg/m2/dose/day
224022250|NCT03035903|DEVICE|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
224022251|NCT05121987|PROCEDURE|Erector Spinae Plane block|An ultrasound linear probe is going to be placed in a longitudinal orientation 3 cm lateral to the T6 spinous process corresponding to the T5 transverse process. . Local infiltration with 2% of lignocaine at the site of needle insertion is going to be administered. Using in plane approach an 18 G Tuohy needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane, and on injection of 5 ml of normal saline.
224022252|NCT05121987|PROCEDURE|Continuous Wound Infusion|Towards the end of surgery, a multiholed 15-cm Anesthesia catheter will be placed in the preperitoneal space (the subfascial space between the peritoneum and posterior fascia) under direct vision and to be tunneled via the rectus sheath to the skin, rolled out and exiting laterally and stabilized with an adhesive tape on skin.
224022253|NCT00100386|PROCEDURE|Intensive Control Strategy|
224022254|NCT00100386|BEHAVIORAL|Standard Control Strategy|
224022255|NCT02088346|OTHER|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
224022256|NCT00979784|BEHAVIORAL|Better Weight|Standard cognitive behavioral treatment focused on dietary \& exercise behavior
224022257|NCT00979784|BEHAVIORAL|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
224022258|NCT02316366|DEVICE|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
224022259|NCT04129918|BEHAVIORAL|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
223402642|NCT07182981|OTHER|Questionnaire application for child and adult scleroderma patients|Scales will be applied to cases diagnosed with scleroderma
223402643|NCT07183865|RADIATION|radiotherapy|25-40Gy/5Fx or 15-30Gy/5Fx (previous pelvic radiation) for pelvic recurrence. 25-50GY/5Fx for all metastasis tumors. Dose Constraints are based on SABR-COMET 10 trial.
223402644|NCT07183865|DRUG|Irinotecan Hydrochloride Liposome|70mg/m2 (UGT1A1\*28 6/6) or 55mg/m2 (UGT1A1\*28 6/7), IV, q2w
223402645|NCT07183865|DRUG|5-FU|400 mg/m\^2 bolus over 2 hours followed by 2400 mg/m\^2 continuous infusion over 48 hours d1, q2w
223402646|NCT07183865|DRUG|Leucovorin|400mg/m2, IV, q2w
223402647|NCT07183865|DRUG|SG001|240mg, IV, q2w
223402648|NCT07183865|DRUG|C225|500 mg/m2, IV, q2w
223402649|NCT07183865|DRUG|Bevacizumab|5mg/kg, IV, q2w
223553706|NCT05134610|DEVICE|AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE|Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
223735299|NCT03145285|DRUG|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
223735300|NCT00703079|DRUG|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
223735301|NCT00703079|PROCEDURE|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
223402650|NCT07183982|DIAGNOSTIC_TEST|MoCA: Montreal Cognitive Assessment (MoCA) and Positive and Negative Syndrome Scale (PANSS)|"MoCA: A 30-point screening tool assessing attention, memory, language, visuospatial and executive functions; quick and sensitive to mild cognitive deficits.~PANSS: A 30-item scale rating positive, negative, and general psychopathology symptoms in psychotic disorders; widely used to track severity and change."
223402651|NCT07183982|BEHAVIORAL|Rehabilitation program in the form of : psychodynamic group therapy, music and art therapy , cognitive stimulation techniques|"Participants received a structured 6-month program designed to address persistent psychotic symptoms and associated deficits. The intervention included:~Art Therapy: Weekly sessions promoting self-expression, emotional regulation, and enhancement of social interaction.~Cognitive Stimulation: Structured group exercises aimed at improving attention, memory, executive functions, and problem-solving.~The program was delivered by a multidisciplinary team in a group of 10 patients, ensuring active participation, individualized support, and integration of therapeutic modalities."
223553707|NCT04498286|DIAGNOSTIC_TEST|Testing of SARS-CoV-2 antibodies|Sars-CoV-2 RBD total antibody test developed by Sanquin
223402652|NCT07183202|OTHER|Case-based learning (CBL)|"During the training session, students were given a detailed explanation of an artificial intelligence (AI)-assisted case presentation structured according to the ERAS protocol. They were briefed on the data collection tools they would need to complete before and after the session. A convenient time was set, considering all participants' accessibility, and students were provided a link they could access from their mobile phones, tablets, or computers. Students participated in the AI-assisted case session online using this link.~During the training process, a case scenario developed by the researchers and optimized with AI was presented to students on a digital platform. The case encompassed the entire patient care process, from diagnosis to discharge, simulating a real-life clinical environment. On the AI-assisted platform, students followed the case flow step by step, actively participating by entering their own responses at each stage of the clinical decision-making process. The plat"
223402653|NCT07176546|DRUG|Avacopan|BID dose of 30 mg TAVNEOS (3-10mg capsules)
223402654|NCT07176546|DRUG|Placebo|BID dose of 30mg TAVNEOS-matching placebo (3-10mg capsules)
223553708|NCT01822769|OTHER|Cardiopulmonary rehabilitation|See Arm Description
223553709|NCT01822769|OTHER|Standard of care|See Arm Description
223553710|NCT04968626|RADIATION|PI-LL|The pelvic parameters were collected including PI, pelvic tilt (PT), sacral slope (SS) and LL ,and compared between IS patients and the AS group. Besides, spinopelvic malalignment was defined as an absolute value of PI-LL greater than 10.In the IS group,the clinical symptoms were assessed with the Japanese Orthopaedic Association (JOA) score and the visual analogue scale (VAS). We compared spinopelvic parameters between the asymptomatic adults and the IS patients. Additionally, we investigated correlations between spinopelvic parameters and clinical symptoms.
223735302|NCT01453712|RADIATION|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
224132119|NCT02019524|BIOLOGICAL|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
224132120|NCT06441812|DRUG|SHR-1703 Injection|SHR-1703 Injection
223553711|NCT01229046|DRUG|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants \< 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
223553712|NCT01487538|BEHAVIORAL|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
223553713|NCT01487538|BEHAVIORAL|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
223553714|NCT01487538|BEHAVIORAL|Discussion Boards|forum to exchange information and experiences
223735303|NCT01453712|RADIATION|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
223735304|NCT02728895|DRUG|Vedolizumab|Vedolizumab Injection.
223402655|NCT07183163|OTHER|Clinical and biochemical assessment|Assessment of peri-implant clinical parameters (probing depth, bleeding on probing, plaque index) and biochemical markers (IL-1β, TNF-α, MMP-8) in peri-implant crevicular fluid. No therapeutic or experimental intervention administered.
223402656|NCT07182890|DRUG|Clostridium butyricum|"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily."
223402657|NCT07182890|DRUG|placebo|"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency)."
223402658|NCT07183787|DRUG|Letrozole|Letrozole 2.5 mg orally once daily for 12 weeks.
223553715|NCT01487538|BEHAVIORAL|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
223735305|NCT04698720|BEHAVIORAL|Muscle Relaxation with Guided Imagery|Relaxation intervention session begins with diaphragmatic breathing, followed by Jacobson's progressive muscle relaxation, which involves the contraction and subsequent relaxation of the 16 muscle groups of the body (forearm, arm, upper forehead, eye, mouth, jaw and throat, neck, shoulder, chest, stomach, thigh, leg and foot).The contraction is performed for 7 seconds while the relaxation lasts for about 40 to 50 seconds.The relaxation of the foot muscle group is only performed on the healthy foot, because dressing and bandages may bandage the foot with the DFU, which together with the typical joint stiffness of the diabetic foot, make it difficult to perform. After muscle relaxation, begins the guided imagery focused on DFU healing. The patient is instructed to think about his/her current state of health and to imagine the DFU as a dark area and the healing relaxation as a light associated to pleasant sensations, which will focus on the foot with DFU to heal it.
223735306|NCT04698720|BEHAVIORAL|Hypnosis with Guided Imagery|"In the beginning of the first session we apply the Eye-Roll Test for Hypnotizability of Herbert Spiegel. Each session follows the Hypnotic Protocol with the following steps:Pre-talk/Absortion/Ratification/Aliciation/Dissociation/Awakening.~The four sessions train the participants in visual, auditory and kinesthetic perception on ulcer healing. The protocol also promotes medical treatment acceptance."
224022260|NCT04417374|OTHER|Description of groups caracteristics|Comparison of the two groups on all the following criterias : age, sex, if the patient lives alone, the matter of hospitalization, its lengh, their primary psychiatric diagnostic, the use of toxics at the moment of the hospitalization and if this psychiatric decompensation happens in a context of treatment interruption.
224022261|NCT03812497|BEHAVIORAL|Individualized Education Program|The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
224022262|NCT00669799|DRUG|gentamyacin|topical internasal
224022263|NCT00669799|DRUG|gentamyacin|intranasal
224022264|NCT00553956|BEHAVIORAL|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
224022265|NCT06081023|BEHAVIORAL|Psycho-educational weight reduction program|This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
223402659|NCT07183787|DRUG|danazol|Danazol 200 mg orally twice daily for 12 weeks.
223553716|NCT02890745|DRUG|Empagliflozin|
223553717|NCT02890745|DRUG|Placebo|
223553718|NCT00385385|DRUG|Rifalazil|
223553719|NCT00383331|DRUG|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
223553720|NCT00383331|DRUG|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
223553721|NCT06224907|BIOLOGICAL|Valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
223402660|NCT07184268|PROCEDURE|full mouth non-surgical scaling|All patients will receive a full mouth scaling using ultrasonic scalers and hand instrumentation
223402661|NCT07184242|OTHER|Shoulder Exercise & Proprioceptive Training Program|"The study includes two intervention modalities. The experimental group will combine conventional treatment with a structured 12-week therapeutic exercise program, with two supervised group sessions per week (50-60 minutes), which will include proprioceptive somatosensory work, multi-joint strength exercises, and adapted specific movements. Progression will be individually adjusted based on each participant's pain tolerance, physical condition, and clinical progress, complemented by home activities and supporting educational materials.~The control group will receive only conventional treatment provided at their rehabilitation center and general guidelines on the benefits of physical activity according to WHO recommendations for people over 60 years of age."
223402662|NCT07182214|OTHER|Collect blood sample|Collect venous blood sample from subjects prior fasting, any operation or treatment
223553722|NCT06200597|DRUG|LAD603|LAD603 SC injection.
223553723|NCT06200597|OTHER|Placebo|Matching placebo SC injection.
223553724|NCT00375427|DRUG|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
223553725|NCT06351982|DEVICE|Electro Medical Systems AIRFLOW® Prophylaxis Master Device|"1. Disclosure of biofilm with erythrosine,~2. Removal of supragingival and subgingival (up to 4 mm) biofilm and stains with the use of AIRFLOW® Master Piezon® with AIRFLOW® PLUS powder (EMS- Dental, Nyon Switzerland).~3. Supra- and sub- gingival debridement by using the AIRFLOW® Master Piezon® device with Piezon NO PAIN® (EMS-Dental) technology."
224022266|NCT00144651|DRUG|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
224022267|NCT06394440|COMBINATION_PRODUCT|Self-Adhesive Bulkfill Composite (Surefil One)|It is a new self-adhesive bulkfill composite that requires no previous adhesive steps.
223402663|NCT07184372|OTHER|Radiofrequency and manual tecniques|"We apply manual tecniques while we use the radiofrequency, the treatment is divided into 3 phases:~* PHASE 1: With the patient in the supine position, treatment was performed along the diaphragm for 10 minutes, of which 5 minutes were spent with the capacitive electrode and the other 5 minutes with the resistive electrode. The plate was placed on the back at the level of the diaphragm.~* PHASE 2: The patient was placed in the lateral decubitus position on their right side and 3 minutes were spent with the capacitive electrode and 7 minutes with the resistive electrode. The patient was asked to breathe costal-diaphragmatically throughout the entire duration of the resistive electrode. The plate was placed on the right side, at lung level.~* PHASE 3: The same procedure was performed as in the second phase, only this time on the contralateral side, i.e., on the left side."
223735307|NCT04698720|BEHAVIORAL|Neutral Guided Imagery|This placebo consists of neutral guided imagery focused on themes of the patient's daily life before having DFU. Each session has a theme associated with the patient's life - family, work, friends, and leisure. Initially, the patient is asked to think about an event related to the theme of the session of his/her choice, positive or negative, which occurred before patient has the current DFU. Then, the patient is asked about a number of questions regarding the chosen episode in order to promote a more detailed reconstruction of the event. The patient is asked to imagine according to the instructions given by the Psychologist. When the whole episode is remembered, the patient is asked to tell what he or she imagined/remembered regarding each of the questions.
223735308|NCT05735392|OTHER|Both blood and tissues collection for patients with metastatic breast cancer HER2+ pretreated with no more than one line of anti-HER2 therapy for advanced breast cancer.|Both blood and tissues will be obtained duringT-DM1 treatment of enrolled patients at the participating Sites at the study specific timelines.
223735309|NCT01428089|DRUG|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
223735310|NCT01428089|DRUG|Placebo|Placebo
223735311|NCT00989794|DEVICE|GelrinC|Applied once during surgery
223735312|NCT03643276|DRUG|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
223735313|NCT03643276|DRUG|Bortezomib|Experimental therapy in randomization R-eHR
223735314|NCT03643276|DRUG|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
223735315|NCT03643276|DRUG|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
223735316|NCT03643276|DRUG|Daunorubicin|Part of standard chemotherapy
223735317|NCT03643276|DRUG|Myocet|Part of intensification block Myocet-FLA for patients with very high relapse risk
223735318|NCT03643276|DRUG|Dexamethasone|Part of standard chemotherapy
223735319|NCT03643276|DRUG|Doxorubicin|Part of standard chemotherapy
223735320|NCT03643276|DRUG|Etoposide|Part of standard chemotherapy
223402664|NCT07184372|OTHER|Manual tecniques|Manual techniques are used to increase inspiratory capacity, working on the diaphragm and rib cage to increase their mobility along with breathing exercises.
223402665|NCT07184372|OTHER|Placebo|The radiofrequency is turn off
223402666|NCT07184307|BIOLOGICAL|Platelet-Rich Plasma|Autologous platelet-rich plasma prepared from approximately 50 milliliters of venous blood using a two-step centrifugation protocol. Ten milliliters of platelet-rich plasma are obtained and injected into the sub-urothelial layer of the bladder wall during cystoscopy under anesthesia.
223402667|NCT07184307|DRUG|Intravesical Botulinum Toxin Injection|Botulinum toxin (100 units) reconstituted in 10 milliliters of saline and injected into the bladder detrusor muscle at multiple sites under cystoscopic guidance, sparing the trigone.
223402668|NCT07183358|BEHAVIORAL|Family-supervised Multimodal Prehabilitation|"A comprehensive prehabilitation program initiated at the start of neoadjuvant chemotherapy and continued until the day before surgery. The intervention includes:~1. Nutritional support: individualized dietary counseling and supplementation plans supervised by clinical nutritionists;~2. Exercise training: home-based aerobic and resistance exercises monitored via wearable devices and weekly video/phone follow-ups;~3. Psychological support: structured counseling sessions to reduce anxiety, improve treatment adherence, and enhance quality of life.~Family members are trained to assist with supervision and compliance. The total duration is approximately 10-16 weeks, depending on the chemotherapy schedule."
223553726|NCT06351982|OTHER|Hand and ultrasonic scalers and curettes|Combination of ultrasonic and hand instrumentation only. Pockets ≥4 mm will be subgingivally debrided using the piezo device according to manufacturer's instructions, and hand curettes will be used until the operator considers the surfaces to be sufficiently clean and free of deposits.
223735321|NCT03643276|DRUG|Fludarabine Phosphate|Part of intensification block Myocet-FLA for patients with very high relapse risk
223553727|NCT00133159|BIOLOGICAL|Grass MATAMPL|
223553728|NCT04434547|BIOLOGICAL|PRP|During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
223553729|NCT02540512|PROCEDURE|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
223553730|NCT02540512|DEVICE|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
223553731|NCT02540512|PROCEDURE|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
223553732|NCT02540512|DRUG|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
223553733|NCT02540512|DRUG|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
223735322|NCT03643276|DRUG|Ifosfamide|Part of standard chemotherapy
223735323|NCT03643276|DRUG|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
224132121|NCT04358042|OTHER|Brief Psychiatric Rating Scale|The Abbreviated Psychiatric Rating Scale is a clinical scale for measuring symptomatic change in psychiatric inpatients for various conditions. It includes an accurate and complete description of the major characteristic symptoms. It is based both on patient responses and on observations made during the interview by the clinician. The usual reference period is the last two weeks.
223735324|NCT03643276|DRUG|Methotrexate|Part of standard chemotherapy
223735325|NCT03643276|DRUG|Pegaspargase|Part of standard chemotherapy
223735326|NCT03643276|DRUG|Prednisolone|Part of standard chemotherapy
223402669|NCT07183358|OTHER|Standard Care|Standard neoadjuvant chemotherapy followed by radical gastrectomy with standard ERAS-based perioperative management, without any additional prehabilitation intervention. Participants receive routine nutritional, nursing and medical care according to hospital guidelines. The aim is to maintain current clinical practice as the control condition for comparison with the experimental prehabilitation program.
223402670|NCT07183059|DIAGNOSTIC_TEST|Electromyography|"we will perform questionnaire, clinical neurological exam, nEMG and if applicable short exercise test on patients with variants in genes associated with mus-cular channelopathies.~Safety Monitoring and reporting: Needle EMG is generally well-tolerated, but transient mild proce-dural pain and discomfort are widespread and the most frequent side effect that patients will ex-perience. Hematomas are infrequent and, in most cases, asymptomatic and selflimiting. Moreover, the bleeding risk is reduced by the investigator's experience, testing superficial muscles (avoiding complications like compartment syndrome), and by not conducting an EMG when patient is treated with anticoagulants. Infectious complications at the site of needle insertion are extremely infre-quent since disposable needle electrodes are used. Needle insertion is avoided in in-jured/potential infected skin and will not be performed in immune-compromised patients and endocarditis risk."
223402671|NCT07182786|DEVICE|LMA Gastro|LMA Gastro, is a laryngeal mask airway device that is specifically designed for air way management in GIT endoscopic procedures due to having a channel dedicated for endoscope introduction. the safety and efficacy of LMA Gastro was researched in many studies, but its role in preventing Hypercarbia during ERCP procedures is yet to be researched and tested.
223402672|NCT07183540|PROCEDURE|operation opportunity-within 6 weeks after the DC operation.|The autologous skull repair surgery will be completed within 6 weeks after the DC operation.
223402673|NCT07183540|PROCEDURE|operation opportunity-within 90 to 180 days after the DC operation.|The autologous skull repair surgery should be completed within 90 to 180 days after DC.
223402674|NCT06085781|OTHER|fMRI|Functional Magnetic Resonance Imaging
223402675|NCT06085781|OTHER|Oral Pimonidazole|200 mg and 300 mg tablets
223402676|NCT07183605|PROCEDURE|catheter flushing techniques|"Two catheter flushing techniques will be compared:~* Method A: A 5 mL flush performed with a syringe over 5 seconds.~* Method B: A 5 mL flush using a vacuum tube (standard discard tube)."
223402677|NCT04413097|PROCEDURE|Delayed Cord Clamping with Low Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and low oxygen concentration (FiO2 0.30) will be provided.
223402678|NCT04413097|PROCEDURE|Delayed Cord Clamping with High Oxygen concentration|During delayed umbilical cord clamping of 90 seconds, breathing assistance with CPAP/PPV and high oxygen concentration (FiO2 1.0) will be provided.
223553734|NCT00678171|DEVICE|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
223402679|NCT03631017|DRUG|[18F]- PARPi|injection of a microdose (\< 100 ug) of \[18F\]- PARPi
223402680|NCT03631017|DIAGNOSTIC_TEST|PET/CT Scans|"Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
223402681|NCT05945251|OTHER|Internet-delivered cognitive behavioral therapy|Ten weekly modules for children and ten weekly modules for parents. Exposure-based cognitive behavioral therapy delivered online with asynchronous support via text messages from psychologists.
223402682|NCT01812031|OTHER|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
223553735|NCT00127491|PROCEDURE|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
223553736|NCT00127491|OTHER|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
223553737|NCT00127491|OTHER|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
223553738|NCT03371576|DEVICE|intraocular lenses|
223553739|NCT03614598|PROCEDURE|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
223553740|NCT03614598|PROCEDURE|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
223553741|NCT03614598|PROCEDURE|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
223553742|NCT04817839|BEHAVIORAL|3-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 3-weeks post operation.
223735327|NCT03643276|DRUG|Tioguanin|Part of standard chemotherapy
223735328|NCT03643276|DRUG|Vincristine|Part of standard chemotherapy
223735329|NCT03643276|DRUG|Vindesine|Part of standard chemotherapy
223735330|NCT03643276|DRUG|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
223553743|NCT04817839|BEHAVIORAL|6-week post-operative activity restriction|Participants will be given postoperative instructions which include refraining from lifting anything over 20 pounds, avoiding strenuous exercise, running, or performing high-impact aerobic activities for 6-weeks post operation.
223735331|NCT02402309|DRUG|Active topical NS2 1% dermatologic cream|
223735332|NCT02402309|DRUG|Vehicle placebo 0.0% NS2 dermatologic cream|
223553744|NCT01598714|DEVICE|Darco shoe|Darco shoe
223553745|NCT01598714|DEVICE|Podalux shoe|Podalux shoe
223553746|NCT01598714|DEVICE|Standard dressing shoe|Standard dressing shoe
223553747|NCT00348738|DRUG|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of \>14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
223553748|NCT04833660|DEVICE|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a safe, noninvasive, and effective therapeutic intervention that uses an electromagnetic coil applied to the scalp to produce a magnetic field. rTMS induces changes in cortical excitability at the stimulation site and transsynaptically at distant areas. Cortical excitability is increased by high-frequency (≥5 Hz) stimulation and is decreased by low-frequency (1 Hz) stimulation. The application of high-frequency unilateral rTMS to the motor cortex in patients is reported to have a potential to control various types of pain, such as neuropathic pain, fibromyalgia, and musculoskeletal origin pain (myofascial pain syndrome, shoulder pain, and lower back pain).
223735333|NCT03826979|OTHER|Pliates method treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
223735334|NCT00256373|PROCEDURE|Mod. functional restoration-Individ. dynamic back-muscle|
223553749|NCT01903122|DRUG|Cevimeline|
223553750|NCT03274947|DEVICE|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
223553751|NCT03274947|DEVICE|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
223553752|NCT04501601|DIETARY_SUPPLEMENT|Fruit and vegetable solid drink|weight loss program supplement
223553753|NCT04797689|BEHAVIORAL|Trauma Informed Yoga|One licensed yoga instructor, trained in trauma-informed yoga delivery, will lead the online sessions. Participants will be instructed to engage in the class from a mat or chair in their home or move between them as the class unfolds. The instructor will begin the class by introducing the week's theme (e.g. grounding and safety, non-attachment, imprints of the past and impacts on our reactions to COVID-19, connection to nature), followed by a breath practice (10 min), a yoga practice (50 min), a meditation practice (10 min), and closing words (10 min).
223553754|NCT04797689|BEHAVIORAL|Trauma Informed Psychotherapy|Two licensed counsellors (MSW-trained) will co-facilitate the online version of this program. Facilitators will begin the session by introducing the week's theme (e.g. setting goals while working from home, being mindful, health coping) (10 min), followed by a lecture and activity to integrate learning (e.g. large and small group discussion using Zoom break out rooms, journaling) (70 min), and closing words (10 min).
223553755|NCT05631171|BEHAVIORAL|Adhera® Fatigue Digital Program|"Adhera® Fatigue Digital Program, that includes an application and a smartwatch, is a digital health solution based on emotional and behavioral change techniques. Patient adaptative self-management content (e.g. psycho-educational content, activities for mental wellbeing, personalized motivational messages), and the personalization is based on Adhera® Health Recommender System.~Wearable devices and the mobile app will be used to collect real-time data for 3 months to detect biometric and psychometric (patient-reported outcomes) information."
223735335|NCT03264209|BEHAVIORAL|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
223735336|NCT04542655|OTHER|Ergometer Cycling followed by treadmill running|The participants undergo ergometer cycling, treadmill running and rest.
223735337|NCT04542655|OTHER|Treadmill Running followed by ergometer cycling|The participants undergo treadmill running, ergometer cycling and rest.
224297475|NCT05876455|PROCEDURE|Conventional Subgingival Instrumentation|On the conventional non-surgical periodontal therapy side, a power-driven piezo-electric ultrasonic scaling device with scaling tips will be used the majority of the time to debride subgingival biofilm and calculus, and manual standard Gracey curette instruments (Gracey curettes Hu-Friedy, Chicago, IL, USA) will be used to remove residual deposits from the root surface.
223735338|NCT04542655|OTHER|Rest|The participants undergo ergometer cycling, treadmill running and rest.
223735339|NCT00427258|DRUG|MOA-728|
223735340|NCT01243970|DRUG|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg \*~\* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
223735341|NCT01243970|DRUG|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. \*~\* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
223735342|NCT02140788|DRUG|Metformin|
223735343|NCT02140788|DRUG|Fish Oil|
223735344|NCT01093807|DRUG|Placebo|once daily for 10 weeks
223735345|NCT01093807|DRUG|Lercanidipine|10 mg once daily for 10 weeks
223553756|NCT04976790|BEHAVIORAL|Chinese Tuina therapy|Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
223735346|NCT01093807|DRUG|Lercanidipine|20 mg once daily for 10 weeks
223553757|NCT04976790|DRUG|Flurbiprofen Cataplasms group (FCG).|One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
223735347|NCT01093807|DRUG|Enalapril|10 mg once daily for 10 weeks
223735348|NCT01093807|DRUG|Enalapril|20 mg once daily for 10 weeks
223553758|NCT01243008|DRUG|Application of SHB001|"* Cohort 1: Application of SHB001 on the skin of right thigh~* Cohort 2:~  1. Application of SHB001 on the skin of right thigh~ 2. punch biopsies of treated skin areas"
223735349|NCT01093807|DRUG|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
223735350|NCT01093807|DRUG|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
223402683|NCT06449144|OTHER|Mindfulness education|The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.
223402684|NCT06270485|PROCEDURE|PEEP|Application of different PEEP-Levels during invasive mechanical ventilation
223402685|NCT03576326|BEHAVIORAL|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
223402686|NCT05830266|BEHAVIORAL|"Mindful with your Baby group-based therapist-guided intervention"|"This 8-sessions long intervention is one of very few interventions that actively includes the baby in the therapy sessions. The intervention includes the following sessions: Becoming aware of the autopilot, Practice to really look at your baby, Getting back in touch with yourself, Responding sensitively to your baby, Taking care of yourself in the difficult moments, Distance and proximity: it's both part of it, Dealing with expectations of yourself and the environment and Mindful parenting: trial and error. The intervention is a group-based therapist-guided intervention via a video-conferencing tool (e.g., Zoom)."
223553759|NCT03086616|DRUG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
223553760|NCT03306472|DRUG|Megestrol Acetate 40 MG|Progesterone Agonist
223553761|NCT03306472|DRUG|Megestrol Acetate 160 MG|Progesterone Agonist
223402687|NCT05830266|BEHAVIORAL|"Mindful with your baby self-guided online intervention"|"This 8-sessions long intervention includes the following sessions: Autopilot, Fresh view, At home in your body, Responsive versus reactive parenting, Kindness to yourself, Distance and proximity, Boundaries and taking care of yourself and Mindful parenting - day by day. The intervention is an individual self-guided online intervention."
223402688|NCT03357536|PROCEDURE|Human biological samples|"* Blood sample~* Skin biopsy~* Saliva"
223402689|NCT06963710|DRUG|ALG-000184|300 mg tablet
223553762|NCT03306472|DRUG|Letrozole|Aromatase Inhibitor
223553763|NCT03061877|OTHER|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
223553764|NCT03066323|OTHER|Rice with tea extract|Rice with tea extract
223553765|NCT03066323|OTHER|Rice without tea extract|Rice without tea extract
223553766|NCT05075018|OTHER|Observational|Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
223553767|NCT02729116|DRUG|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
223553768|NCT02729116|DRUG|Ertapenem|Patients are given IV ertapenem for 14 days
223553769|NCT03850093|DRUG|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
223553770|NCT03850093|DRUG|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
223553771|NCT03850093|DRUG|placebo|patients received oral placebo 2 hrs preoperative
223735351|NCT01093807|DRUG|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
223735352|NCT01093807|DRUG|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
223735353|NCT02968563|DRUG|Tirabrutinib|Tablets administered orally
223735354|NCT02968563|DRUG|Idelalisib|Tablets administered orally
223735355|NCT02968563|DRUG|Obinutuzumab|Administered intravenously
223735356|NCT02536352|DRUG|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
223735357|NCT02536352|DIETARY_SUPPLEMENT|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
223402690|NCT06963710|DRUG|TDF|300 mg tablet
223402691|NCT05740280|DRUG|iCP-NI|20 mg/mL iCP-NI solution for intravenous injection
223402692|NCT05740280|DRUG|Placebo|Placebo solution for intravenous injection
223735358|NCT00017992|DRUG|Lopinavir/Ritonavir|
223735359|NCT00017992|DRUG|Emtricitabine|
223735360|NCT00017992|DRUG|Stavudine|
223553772|NCT04852055|BEHAVIORAL|Advance Care Planning Video|Clinical assistants determine who is the correct person to receive the informational materials. If the patient is the correct recipient, clinicians will send the informational materials to the patient at the assisted living center. If the proxy is the correct recipient, the clinical assistant will determine whether or not the proxy is using the existing online portal. If the proxy is using the portal, the informational materials will be sent electronically. If the proxy does not access the portal, the informational materials will be sent to their residences.
223553773|NCT01204905|DRUG|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart"
223735361|NCT00702819|DRUG|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
223735362|NCT05133947|OTHER|Non interventional|Non interventional
223735363|NCT03124433|DRUG|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
223735364|NCT04382573|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
223735365|NCT00374725|BEHAVIORAL|Administration of probiotic (L. rhamnosus and L. acidophilus)|
224132122|NCT04358042|OTHER|Depression, Anxiety and Stress Scale|"evaluation of 3 dimensions of psychological distress: depression, anxiety and stress. The scale consists of 21 items and the patient is instructed to choose for each item the one that best corresponds to his or her experience over the past week, on a scale of 0 (does not apply to me at all) to 3 (applies entirely to me, or the vast majority of the time). A score is calculated for each dimension according to a predefined rating."
223402693|NCT06011434|BEHAVIORAL|Mammography Screening Conversation Aid|"Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points."
223402694|NCT04069299|DRUG|68Ga-DOTATATE|The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection
223402695|NCT04069299|DIAGNOSTIC_TEST|Positron Emission Tomography (PET) Scan|PET scan is an imaging test using radioactive tracers.
223402696|NCT06708351|OTHER|Best Practice|Receive standard care
223402697|NCT06708351|OTHER|Health Promotion and Education|Receive instructions on how to use HPV self-testing kit
223402698|NCT06708351|PROCEDURE|HPV Self-Collection|Undergo HPV self-collection
223402699|NCT06708351|OTHER|Text Message-Based Navigation Intervention|Receive text messages for HPV testing results and triage and treatment reminders
223402700|NCT05142722|DRUG|Placebo|placebo tablet made to resemble active
223402701|NCT05142722|DRUG|Obicetrapib|10mg obicetrapib tablet
223402702|NCT01339195|BEHAVIORAL|French adaptation of NINDS-Canadian Stroke Network battery|"* clinical: post-stroke neurological follow-up assessment~* neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~* MRI"
223402703|NCT05680805|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day in 3 divided dose for 24 weeks
223402704|NCT04417660|DRUG|M7824|Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
223402705|NCT03339128|DRUG|Eluxadoline|Oral tablets
223402706|NCT03339128|DRUG|Placebo|Oral tablets
223402707|NCT06467357|DRUG|Gemcitabine|Standard of care chemotherapy by intravenous infusion
223402708|NCT06467357|DRUG|Cisplatin|Standard of care chemotherapy by intravenous infusion
223402709|NCT06467357|DRUG|Durvalumab|Standard of care immunotherapy by intravenous infusion
223402710|NCT06467357|DRUG|Trastuzumab deruxtecan|Experimental therapy by intravenous infusion
223402711|NCT06467357|DRUG|Rilvegostomig|Experimental therapy by intravenous infusion
223402712|NCT06467357|DIAGNOSTIC_TEST|Agilent HercepTest™ mAb pharmDx|"A semi-quantitative immunohistochemical assay to determine HER2 overexpression in FFPE breast cancer tissues routinely processed for histological evaluation.~Based on a primary monoclonal rabbit antibody which visualises Her2 overexpression utilising a fully automated IHC platform (Dako Omnis)."
223402713|NCT06467357|DIAGNOSTIC_TEST|Ventana PD-L1 SP263 assay|A qualitative immunohistochemical assay to determine the level of PD-L1 expression in FFPE non-small cell lung cancer (NSCLC) tissues routinely processed for histological evaluation. Based on a rabbit monoclonal anti-PD-L1 clone SP263 which visualises PD-L1 protein using a VENTANA BenchMark ULTRA instrument
223402714|NCT04486118|DRUG|Lisinopril Pills|Tablets will be taken by oral administration daily, based on titration
223402715|NCT04486118|DRUG|Benazepril Pill|Tablets will be taken by oral administration daily, based on titration
223402716|NCT05865054|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|Combined orbital and cranial vessel wall MRI
223402717|NCT06291376|DRUG|Ravulizumab|Participants will receive ravulizumab via weight-based intravenous (IV) infusion.
223402718|NCT06291376|DRUG|Placebo|Participants will receive placebo via weight-based IV infusion.
223402719|NCT03555162|OTHER|fMRI|Imaging examination
223402720|NCT05774691|DRUG|Protamine sulfate|Routine protamine administration in a ratio of 1 mg per 100 IU of unfractionated heparin
223402721|NCT05774691|DRUG|Protamine sulfate|Selective protamine administration, in case of (threatening) bleeding
223402722|NCT04103762|PROCEDURE|laparoscopic cholecystectomy|laparoscopic cholecystectomy
223402723|NCT04103762|DIAGNOSTIC_TEST|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
223402726|NCT04059822|OTHER|Slow and deep breathing|Please see arm description
223402727|NCT04355572|DRUG|Vitamin D 4000IU daily|Randomized to receive vitamin D 4000IU daily
223402728|NCT04355572|DRUG|Placebo|Randomized to placebo daily
224022268|NCT04065009|DRUG|Ropivacaine|Experimental drug will be administered intraperitoneally
223735366|NCT02574247|PROCEDURE|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
224022269|NCT04065009|DRUG|Saline Solution|Placebo will be administered intraperitoneally
223402729|NCT06144684|DRUG|GUB014295|GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
223553774|NCT04196855|DRUG|Teriparatide|"Terrosa 20 micrograms/80 microliters solution for injection. Each dose of 80 microliters contains 20 micrograms of teriparatide.~One cartridge of 2.4 mL of solution contains 600 micrograms of teriparatide (corresponding to 250 micrograms per mL).~Teriparatide, rhPTH(1-34), produced in E. coli, using recombinant DNA technology, is identical to the 34-N-terminal amino acid sequence of endogenous human parathyroid hormone."
223735367|NCT04758754|OTHER|Training|8-weeks iso-volume active (SLKE) or passive static stretching training (PST) involving lower limb muscles
223735368|NCT02087475|DRUG|Irinotecan|
224022270|NCT00928746|DEVICE|Ipratropium bromide|
224022271|NCT02711618|DEVICE|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
223402730|NCT06144684|DRUG|GUB014295-PLACEBO|GUB014295-PLACEBO is matching GUB014295 in appearance, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
223402731|NCT05880706|DRUG|BL-B01D1|Administration by intravenous infusion
223402732|NCT05880706|DRUG|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets will be administered at a fixed dose of 80mg daily.
223402733|NCT06230796|DEVICE|FES-cycling|30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
223402734|NCT06230796|DEVICE|SHAM-cycling|30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
223402735|NCT06417684|DRUG|Amitriptyline|25 mg prescribed to be taken once daily for 90 days each evening.
223402736|NCT06417684|BEHAVIORAL|Lifestyle Modification|Written and video instructions to instruct the participant to improve restful sleep, exercise, avoidance of dietary triggers, and mealtime regularity.
223402737|NCT04445649|DIAGNOSTIC_TEST|Coma-Recovery-Scale-Revised (CRS-R)|CRS-R assessments (15 minutes) are repeated weekly after study entry
223402738|NCT03896503|DRUG|Berzosertib|Given IV
223402739|NCT03896503|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
223402740|NCT03896503|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223402741|NCT03896503|PROCEDURE|Computed Tomography|Undergo a CT scan
223402742|NCT03896503|DRUG|Topotecan Hydrochloride|Given IV
223402743|NCT04594551|BIOLOGICAL|Purified vero rabies vaccine - serum free|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
223402744|NCT04594551|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried - Route of administration: intramuscular
223402745|NCT04594551|BIOLOGICAL|Human rabies immunoglobulins|Pharmaceutical form:liquid/solution in 2 mL vials - Route of administration: intramuscular
223402746|NCT06835387|DRUG|Nanoliposomal irinotecan|Nanoliposomal Irinotecan 50 mg/m2 will be administered over 90 minutes (± 10 minutes) IV. All subjects must be pre-medicated prior to nanoliposomal irinotecan infusion with standard doses of dexamethasone and a 5-HT3 antagonist, or equivalent other anti-emetics (according to standard institutional practices).
223402747|NCT06835387|DRUG|Oxaliplatin|Oxaliplatin 60 mg/m2 will be administered over 120 minutes (± 10 minutes) IV. Institutional standards may be used for all aspects of oxaliplatin administration including premedication administration.
223402748|NCT06835387|DRUG|5 fluorouracil|5-FU will be administered as a continuous infusion over 46 hours. Subjects will go home with an infusion pump and return to clinic at the end of infusion for removal of the pump or, if possible, the pump may be removed at the subject's home (except on Cycle 1 Day 3).
223402749|NCT06835387|DRUG|Leucovorin|Leucovorin 400 mg/m2 will be administered over 30 minutes IV.
223402750|NCT06065748|DRUG|Giredestrant|Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.
223402751|NCT06065748|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.
224022272|NCT00523042|DRUG|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
224022273|NCT00523042|DRUG|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
224022274|NCT03559998|OTHER|lecture|"* Empathy (1 hour)~* Doctor- patient relationship (1, 5 hour)"
224022275|NCT03559998|OTHER|Simulation using Role play|"* serious illness announcement~* abuse demand management~* reticent patient management"
223553775|NCT04565340|OTHER|Mode of delivery, maternal and neonatal outcomes/complications|Mode of delivery, maternal and neonatal outcomes/complications
223553776|NCT03415581|DRUG|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
223553777|NCT03415581|BEHAVIORAL|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
224022276|NCT03559998|OTHER|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
224022277|NCT03559998|OTHER|Simulation using Simulated patient|"* HIV announcement~* Refuse of antibiotic prescription"
224022278|NCT06475872|DRUG|Crecheck Tablet 2.5 mg|2 tablets orally once a day
223735369|NCT02087475|DRUG|5-fluorouracil|
223402752|NCT06065748|DRUG|Abemaciclib|If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.
223402753|NCT06065748|DRUG|Palbociclib|If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
224022279|NCT06475872|DRUG|Crestor Tablet 5 mg|1 tablet orally once a day
223402754|NCT06065748|DRUG|Ribociclib|If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.
223735370|NCT02087475|RADIATION|Local radiotherapy|
223735371|NCT02087475|PROCEDURE|R0 resection|
223735372|NCT03178773|BEHAVIORAL|TExT-MED|messages designed to inspire motivation and behavior change
223735373|NCT03178773|BEHAVIORAL|FANS|SMS delivered messages to family members to improve social support
223735374|NCT00252954|DRUG|Levetiracetam|Tablets 2000-3000 mg per day
223735375|NCT05688046|DRUG|Immune checkpoint inhibitors plus angiogenesis inhibitors|PD-(L)1-based therapy plus Bevacizumab or Anlotinib
224022280|NCT04217928|PROCEDURE|Arthroscopic Debridement|Arthroscopic debridement will be performed under portal site local anaesthesia.
223735376|NCT05688046|DRUG|Immune checkpoint inhibitors without angiogenesis inhibitors|PD-(L)1-based therapy
223735377|NCT01382446|DRUG|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
223735378|NCT01382446|OTHER|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
223735379|NCT06542120|DIAGNOSTIC_TEST|Heart Auscultation and Echocardiography|Heart auscultation will be done by pediatrician and echocardiography by echocardiologist
223735380|NCT06542120|DIAGNOSTIC_TEST|Chest Auscultation and Chest imaging examinations|Chest auscultation will be done by pediatrician and chest imaging examinations by radiologist
223735381|NCT06542120|DIAGNOSTIC_TEST|Abdominal Auscultation and Abdominal imaging examinations|Abdominal auscultation will be done by pediatrician and chest imaging examinations by radiologist
223735382|NCT01248377|PROCEDURE|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
223735383|NCT06800430|RADIATION|Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography|Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), within 28 days (+/- 28 days) of their CABG surgery and again at 12 month follow-up.
223402755|NCT06065748|DRUG|LHRH Agonist|Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.
223402756|NCT06065748|DIAGNOSTIC_TEST|FoundationOne Liquid CDx Assay (F1LCDx)|F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \[ESR1m\] vs. no mutation detected \[ESR1nmd\]).
223402757|NCT03083548|DIAGNOSTIC_TEST|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
223735384|NCT06800430|RADIATION|Hybrid [18F]-GP1, [68Ga]-DOTATATE, [68Ga]-FAPI total-body positron emission tomography and coronary computed tomography coronary angiography|Patients undergo hybrid \[18F\]-GP1, \[68Ga\]-FAPI and \[68Ga\]-DOTATATE total body PET-CT imaging (Biograph Vision Quadra, Siemens) and contrast-enhanced electrocardiogram gated CT coronary angiogram (CTCA), prior to their clinical invasive coronary angiography.
223735385|NCT02715323|OTHER|Cross-sectional study|
223735386|NCT02335164|BIOLOGICAL|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
223735387|NCT02335164|BIOLOGICAL|Advax1|Delta inulin adjuvant formulation 1
223735388|NCT02335164|BIOLOGICAL|Advax2|Delta inulin adjuvant formulation 2
223735389|NCT05894733|OTHER|study group|Calling with phone frequently(15.th day, 1 month , 3 month, 6 month ) and face to face interwiew on first, 3 th and 6th month
223735390|NCT05894733|OTHER|control group|first and sixth month face to face interwiew
223735391|NCT05303207|DIETARY_SUPPLEMENT|YOUR SUPER Detox Bundle|During days 1-5, participants will complete the 5-day Your Super Detox, consuming 2 smoothies daily (breakfast and dinner) containing Your Super Detox superfood powders.
223735392|NCT04923204|DIAGNOSTIC_TEST|Pharmacogenomic-testing with NEUROPHARMAGEN|"This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information."
224022281|NCT04217928|PROCEDURE|Arthroscopic Hemi-Trapeziectomy with Mini TightRope|Anaesthesia, position and arthroscopy will be performed in the same way as for arthroscopic debridement, except the distal part of the trapezium will be resected to a depth of 3-4mm together with protruding osteophytes.
223402758|NCT03083548|DIAGNOSTIC_TEST|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
223735393|NCT04941248|DEVICE|total-body PET/CT(uEXPLORER , United Imaging Healthcare, China)|This prospective study will enroll twenty-five patients, including nine healthy volunteers, sixteen patients with decreased cardiac function . All of them will have a whole-body PET/CT(uEXPLORER , United Imaging Healthcare, China) in our department, Renji Hospital.
223735394|NCT05389345|BEHAVIORAL|Transcranial direct current stimulation|Participants will receive bilateral prefrontal anodal stimulation with cathode placed on the back of the upper neck. Transcranial direct current stimulation (tDCS) will be delivered by a research assistant under the supervision of a psychiatrist.
223402759|NCT03083548|DIAGNOSTIC_TEST|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
223402760|NCT05952726|OTHER|Expiratory cycling change at different levels of pressure support ventilation|"Four different levels of expiratory cycling will be randomly applied at 3 different degrees of pressure support.~Three end-inspiratory and three end-expiratory occlusion manoeuvres will be carried out at the end of 10 minute steps of ventilation during each set value expiratory cycling and pressure support level.~Total study time will be about 120 minutes. Levels of pressure support wil be clinical pressure support ± 4 cmH2O; expiratory cycling percentages applied for each pressure support step will be 15%, 30%, 45% and 60% of peak inspiratory flow."
223735395|NCT05389345|BEHAVIORAL|Executive function training|The Executive Training (ET) aspect of the study will be completed by all participants. ET sessions consist of 50% of the session practicing computerized cognitive training exercises, and 50% of the session developing cognitive strategies to use in the computerized exercises. Participants are encouraged to complete 40 minutes of computerized training per day, and complete strategy worksheets, on the unit or in the library at Ontario Shores between sessions. ET will be delivered virtually and group sessions will be conducted using the online platform Zoom. For any group sessions, a PHIPA and PIPEDA compliant license will be used. This means that participants will not be able to record their screen using Zoom or a third-party program. Dr. Best will also go through some rules during the first group Zoom session regarding the use of third-party equipment and the importance of confidentiality.
223735396|NCT01727453|DRUG|warfarin|Warfarin in anticoagulant dose
223735397|NCT01727453|DRUG|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
223735398|NCT01396720|DRUG|fluvoxamine|Fluvoxamine 100mg daily, 7 days
223735399|NCT01396720|DRUG|citalopharm|Citalopharm 20mg daily, 7 days
223735400|NCT04084301|PROCEDURE|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
223735401|NCT05787691|OTHER|Individualised pain management|"TPS pain management consists in an evaluation by a pain physician, followed by specific measures for patients identified as having a particularly high risk of CPSP. The choice of these measures will be individualised according to specific risk factors and left to the discretion of the pain physician.~Potential measures: patient education, adjustment of analgesic therapy, referral to a psychiatrist or psychologist, cognitive behavioural therapy, hypnosis, use of locoregional analgesia for surgery, infusions of ketamine and/or lidocaine, introduction of gabapentins and/or antidepressants."
223735402|NCT01705821|DEVICE|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
223735403|NCT01705821|PROCEDURE|Removal of pituitary tumor using modified curette|
223735404|NCT04035681|BEHAVIORAL|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
224022282|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Newborns (Aged 1-7 Days)|Neonatal blood samples will be taken from healthy infants no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards.
224297476|NCT05876455|PROCEDURE|minimally invasive non-surgical periodontal therapy|minimally invasive non-surgical periodontal therapy will undergo careful scaling and root planing under magnification (use of 3.5 X magnification loupes) with mini curettes and using an ultrasonic device with specific thin and delicate tips. These instruments will be carefully inserted through the periodontal pocket of the affected tooth to reach the root surface for debridement. Caution will be taken to preserve the stability of soft tissues.
223735405|NCT04035681|OTHER|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
223735406|NCT00075049|BIOLOGICAL|RTS,S with AS02A/AS01B adjuvant|
223735407|NCT04270123|OTHER|EORTC QLQ-BR45 questionnaire|The EORTC QLQ-BR23 questionnaire has been updated with a further twenty-two items to create the EORTC QLQ-BR45. This updated questionnaire contains items to encapsulate advancements in knowledge about the epidemiology of breast cancer and side effects experienced with new treatments. This study will test the psychometric properties of the EORTC QLQ-BR45 as a measure of quality of life in patients with breast cancer.
223735408|NCT02911181|OTHER|BIVA measurement|
223735409|NCT00859768|OTHER|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
223735410|NCT02786251|OTHER|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
223735411|NCT02786251|OTHER|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (\~26-28°C).
223402761|NCT05579314|DRUG|XW014|Oral tablets
223402762|NCT05579314|DRUG|Placebo|Matched oral placebo tablets
223402763|NCT05579314|DRUG|XW014|Oral capsules
223402764|NCT05579314|DRUG|Placebo|Matched oral placebo capsules
223735412|NCT05901779|DRUG|live combined Bifidobacteriun, Lactobacillus and Enterococcus capsules|Probiotics capsules containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Each capsule contained\>10,000,000 colony-forming units (CFUs). This drug can treat endoxemia caused by imbalance of intestinal flora.
223735413|NCT00845169|PROCEDURE|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
223735414|NCT05945693|DIETARY_SUPPLEMENT|Placebo|The participants will be supplemented with 5 capsules per day of a placebo-filled gelatin capsule for 16 weeks.
223402765|NCT06328608|DRUG|PRX-102 1 mg/kg every two weeks|Drug: PRX-102 1 mg/kg every two weeks
223735415|NCT05945693|DIETARY_SUPPLEMENT|Omega-3|The participants will be supplemented with 5 capsules per day of Omega UP (Newscience, Chile) equivalent to 2.5 g/d of DHA and 0.5 g/d of EPA for 16 weeks.
223402766|NCT06639451|DEVICE|RANGER™ Paclitaxel Coated Balloon Catheter|A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon coated with paclitaxel at the end of it. When the tube is in place, it inflates to open the blood vessel, so that normal blood flow is restored. The tube is then removed.
223553778|NCT04917367|PROCEDURE|exploratory surgery|"For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies."
223553779|NCT02830854|OTHER|Molecular Hydrogen|
223735416|NCT05945693|DIETARY_SUPPLEMENT|Aerobic exercise|The participants will perform aerobic-type exercise training three times per week, on non-consecutive days, with a total time of 20-60 minutes per day for 16 weeks.
223735417|NCT03903731|DEVICE|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
223735418|NCT01588808|BEHAVIORAL|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
223735419|NCT01182545|PROCEDURE|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
223735420|NCT00765375|DRUG|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
223735421|NCT00765375|DRUG|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
224132123|NCT04358042|OTHER|Impact of Event Scale-Revised|is a 22-item self-questionnaire that measures perceived stress in reference to a traumatic event during the previous 7 days. Each item is rated on a scale ranging from 0 (not at all) to 4 (extremely) and 3 sub-scores of post-traumatic symptoms are calculated: Revivification, Avoidance, Psychophysiological Activation, as well as a total score of severity of the state of stress. Acute Stress Disorder (ASD) and Post-Traumatic Stress Disorder (PTSD) share the same symptoms, the former lasting between 3 days and one month, while the latter is diagnosed when symptoms persist beyond one month. Since the exposure to the stressful event will have occurred less than a month ago, this questionnaire here will help identify a state of acute stress. A total R-ESI score equal to or greater than 33 suggests a significant level of symptoms
224132124|NCT04358042|OTHER|Connor-Davidson Resilience Scale 10 items (CD-RISC 10)|"Self-questionnaire composed of 10 items, evaluating the resilience capacities of patients. Resilience may act as a moderator against the symptoms of PTSD. This instrument uses a 5-point Likert-type response scale ranging from 0 Not true at all to 4 True most of the time."
224132125|NCT05715645|PROCEDURE|Unilateral prosthetic knee surgery|Unilateral prosthetic knee surgery
224132126|NCT05715645|PROCEDURE|Analgesia|Analgesic management by adductor canal block
223402767|NCT02512497|DRUG|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
223553780|NCT01308645|DRUG|SB injection|Infusion SB injection of 21.87 ml/m\^2, IV route, 24 times for 4 months
223553781|NCT03577340|OTHER|implant of cardiac device as per guidelines|Observation of performance to validate matrix
223553782|NCT03638050|OTHER|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
223553783|NCT05659914|DRUG|olaparib+durvalumab|olaparib: 300 mg tablets taken orally twice daily and durvalumab: 1500 mg via IV infusion q4w
223553784|NCT02583633|DRUG|Transdermal nitroglycerin|
223553785|NCT02583633|DRUG|nifedipine|
223735422|NCT01486628|DRUG|ND0612|levodopa and carbidopa solution for subcutaneous administration
223735423|NCT01486628|DRUG|Placebo|Saline solution for SC continuous administration
223735424|NCT03692364|DEVICE|Ceramic-on-ceramic uncemented hip arthroplasty|
223735425|NCT03692364|DEVICE|Metal-on-polyethylene uncemented total hip arthroplasty|
223735426|NCT06135987|DEVICE|TLC-NOSF dressings (D'URGOSTART PLUS® BORDER, URGOSTART PLUS® PAD and URGOSTART INTERFACE®)|Clinical evaluation of the dressing in the local treatment of chronic wounds (DFU and VLU)
224132127|NCT06531083|BEHAVIORAL|Early physical therapy intervention|Physical therapy including manual therapy, home exercises for the neck and jaw, and use of a jaw stretching device.
224297477|NCT00896909|GENETIC|gene expression analysis|
224297478|NCT00896909|GENETIC|mutation analysis|
224297479|NCT00896909|GENETIC|polymerase chain reaction|
223402768|NCT02512497|DRUG|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
223402769|NCT02512497|DRUG|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
223402770|NCT02512497|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
223402771|NCT02512497|DRUG|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
223402772|NCT02899819|OTHER|meconium|The meconium will be sampled in the first 2 days of life
223402773|NCT05734157|DEVICE|Peripheral PTA with a drug coated balloon|Peripheral artery angioplasty
223402774|NCT06454240|DRUG|lunsekimig|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
223402775|NCT06454240|DRUG|placebo|Pharmaceutical form:solution for injection-Route of administration:subcutaneous
223402776|NCT05743595|BIOLOGICAL|Personalized Neoantigen DNA vaccine|The sites of immunization may be rotated for each of the immunizations.
223402777|NCT05743595|BIOLOGICAL|Retifanlimab|Retifanlimab will be supplied by Incyte.
223402778|NCT05743595|DEVICE|TDS-IM v 2.0 electroporation device|Each DNA vaccination will be 1 mL vaccine administered intramuscularly using an integrated electroporation administration system
223402779|NCT00236340|DEVICE|Syringe aspiration|It consists of performing successive aspirations using a 50ml syringe connected to the needle by a flexible tube.
223402780|NCT00236340|DEVICE|Wall suction|The tubing is connected to the centralized suction system by continuous vacuum, the value of the applied vacuum is 250mmHg
223402781|NCT06205706|DRUG|BI-1910|BI-1910 administered as a flat-dose IV infusion once every 3 weeks
223402782|NCT06205706|DRUG|Pembrolizumab|Pembrolizumab be administered as an IV infusion at its standard flat dose (200 mg) once every 3 weeks prior to the BI-1910 infusion
223402783|NCT04670068|DRUG|CAR.B7-H3|Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
223402784|NCT04670068|DRUG|Fludarabine|30 mg/m\^2 IV for 3 consecutive days
223402785|NCT04670068|DRUG|Cyclophosphamide|300 mg/m\^2 IV for 3 consecutive days
223402786|NCT06515145|PROCEDURE|High Volume Therapeutic Plasma Exchange|Experimental- High Volume Therapeutic Plasma Exchange at (8 - 9 litres of plasma would be exchanged in each patient over 6 - 8 hours)
223402787|NCT06515145|PROCEDURE|Standard volume therapeutic plasma exchange|Active Comparator - The standard volume strategy would be performed centrifugation technique with Plasma volume varying from 1.5 - 2.5 times the plasma - volume along with Standard Medical Treatment.
223402788|NCT05523544|BEHAVIORAL|schematherapy|psychotherapy
223402789|NCT03682081|DEVICE|Isometric tongue strengthening facilitated by Iowa Oral Performance Instrument (IOPI)|An air-filled pressure bulb is placed on the surface of the oral tongue and pressed against the hard palate during exercise. Each patient is given a target pressure value to aim for as determined by the baseline one repetition maximum (1RM) lingual pressures. During week one of the regimen, the target value of each repetition will be 60% of the 1RM. For the remaining seven weeks, the target value will be increased to 80% of the 1RM. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
223402790|NCT03682081|DEVICE|Biotene Oral Balance Gel|Participants will be instructed to apply an amount equivalent to about 1 cm of Biotene® Oral Balance Gel with a finger to the tongue and most intensely affected areas of the oral cavity three times a day after brushing their teeth for 8 weeks.
223402791|NCT01368094|PROCEDURE|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
223402792|NCT01368094|PROCEDURE|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
223402793|NCT05794906|DRUG|Darolutamide (BAY1841788, Nubeqa)|Coated tablet, 300 mg / tablet, oral.
223402794|NCT05794906|OTHER|Placebo matching darolutamide|Coated tablet, oral
223402795|NCT05794906|OTHER|ADT|Luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonists
223402796|NCT06647069|DRUG|DR-0201|DR-0201 is a bispecific antibody
223553786|NCT03226249|PROCEDURE|Computed Tomography|Undergo FDG-PET/CT
223553787|NCT03226249|DRUG|Dacarbazine|Given IV
223553788|NCT03226249|DRUG|Doxorubicin Hydrochloride|Given IV
223553789|NCT03226249|RADIATION|Fludeoxyglucose F-18|Undergo FDG-PET/CT
223553790|NCT03226249|OTHER|Laboratory Biomarker Analysis|Correlative studies
223553791|NCT03226249|BIOLOGICAL|Pembrolizumab|Given IV
223402797|NCT02770235|OTHER|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
223402798|NCT02770235|OTHER|AGE measurement|By AGE-ReaderTM
223402799|NCT05546866|DRUG|Osimertinib|Subjects successfully enrolled into the study will receive 80mg osimertinib QD p.o. until completion of planned treatment duration, recurrence of disease, or other treatment discontinuation criteria is met. The maximum treatment duration period is 3 years.
223402800|NCT03915366|DRUG|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
223402801|NCT03915366|DRUG|Tuberculostatic Agents|Treatment for tuberculosis
223553792|NCT03226249|PROCEDURE|Positron Emission Tomography|Undergo FDG-PET/CT
223553793|NCT03226249|DRUG|Vinblastine Sulfate|Given IV
223735427|NCT00357487|DEVICE|peroperative scintillating probe|
223402802|NCT04700631|DIAGNOSTIC_TEST|urinary extracellular vesicle concentration|urinary extracellular vesicle concentration will be determined in urine samples from CRF and healthy patients
223402803|NCT04700631|DIAGNOSTIC_TEST|blood sample|blood sample in order to determine creatin level
223402804|NCT06100289|DRUG|Vedolizumab IV|Vedolizumab IV injection.
223402805|NCT06100289|DRUG|Vedolizumab SC|Vedolizumab SC injection.
223402806|NCT02979587|DEVICE|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 Model HTPV254952 is not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
223402807|NCT01539967|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
223402808|NCT05372393|PROCEDURE|Local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
223402809|NCT05372393|PROCEDURE|Distal median nerve block with local infiltration anaesthesia in carpal tunnel release|The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
223402810|NCT06084364|DRUG|Injection of triamcinolone acetonide into the CMC-1 joint|intraarticular injection with triamcinolone acetonide
223402811|NCT06084364|BEHAVIORAL|Multimodal Occupational therapy for CMC-1 joint OA|Patient education, instructions about hand exercises, orthosis and training
223402812|NCT06084364|DRUG|Placebo|Intraarticular injection with saline
223402813|NCT05814549|DIAGNOSTIC_TEST|NavDx|"Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints~o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase."
223402814|NCT05795101|DRUG|Trastuzumab deruxtecan|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
223553794|NCT00179062|DRUG|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
223553795|NCT01532921|PROCEDURE|Tricuspid valve repair|
223553796|NCT01532921|PROCEDURE|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
223553797|NCT01532921|DEVICE|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
223553798|NCT04535817|DRUG|Omalizumab Injection [Xolair]|300mg via 2 subcutaneous injections every 4 weeks
223735428|NCT00357487|DEVICE|operative gamma camera|
223735429|NCT00913003|DRUG|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
223735430|NCT00913003|DRUG|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
223402815|NCT05795101|DRUG|Durvalumab|via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
223402816|NCT01467713|DRUG|Ramelteon SL|Ramelteon sublingual (SL) tablets
223402817|NCT01467713|DRUG|Placebo|Ramelteon sublingual (SL) placebo-matching tablets
223553799|NCT04539613|DRUG|HPFSH & HMG|. Various gonadotropin preparations
223553800|NCT00070109|DRUG|trabectedin|Given IV
223553801|NCT00070109|OTHER|pharmacological study|Correlative studies
223553802|NCT01231334|DRUG|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
223553803|NCT01231334|DRUG|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
223553804|NCT02303756|DEVICE|Pillcam® COLON Capsule|colonoscopy
223553805|NCT01865318|DRUG|insulin degludec|Administered subcutaneously (s.c., under the skin)
223553806|NCT00624468|DRUG|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
223553807|NCT00624468|DRUG|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
223553808|NCT04081402|BIOLOGICAL|HU-014|Hutox Inj(Clostridium botulinum type A)
223553809|NCT04081402|BIOLOGICAL|Botox Inj|Botox Inj(Clostridium botulinum type A)
223735431|NCT05301426|OTHER|Stretching of the hamstring muscles.|Passive stretching of the hamstring muscles.
223735432|NCT05301426|OTHER|Neural slippage of the sciatic nerve.|Neurodynamic technique on the sciatic nerve.
224297480|NCT00896909|OTHER|diagnostic laboratory biomarker analysis|
223735433|NCT05301426|OTHER|Passive upper limb mobilisations.|Passive mobilisations performed on the upper limbs used as a placebo.
223735434|NCT02308410|PROCEDURE|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
223735435|NCT05982509|DEVICE|EasyDew Regen MD Cream|For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.
223735436|NCT01859754|BIOLOGICAL|Octagam 5%|Intravenous immunoglobulin 5%
223735437|NCT01859754|BIOLOGICAL|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
223735438|NCT00101114|DRUG|sorafenib tosylate|Given PO
223735439|NCT00101114|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
223735440|NCT00101114|OTHER|laboratory biomarker analysis|Optional correlative studies
224297481|NCT02736877|PROCEDURE|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
223402818|NCT03433170|PROCEDURE|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
223402819|NCT03433170|PROCEDURE|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
223402820|NCT00210210|DRUG|Ketamine|
223402821|NCT00210210|DRUG|Saline solution|
223735441|NCT04426682|DIAGNOSTIC_TEST|urodynamics parameters|"Urodynamics evaluation is performed in the preoperative period in patients whose operation is planned due to incontinence.~Urodynamics evaluation is performed again in patients who applied with postoperative relapse due to surgery failure or different reasons.~It will be shown whether there is a difference between the urodynamics parameters of preoperatively examined patients and those of urodynamics examined in case of postoperative failure."
223735442|NCT04226274|DRUG|REN001|Once daily for 12 weeks
224022283|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Children Aged 8 Days - 7 Years|Blood samples will be taken from healthy childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards
224297482|NCT02736877|PROCEDURE|Conventional Microscope|corneal transplantation guided by Conventional Microscope
223735443|NCT01288794|DRUG|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
223402822|NCT04026490|BEHAVIORAL|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
223402823|NCT04026490|BEHAVIORAL|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
223402824|NCT03096418|DRUG|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
223402825|NCT02932956|GENETIC|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10\^7/m2~DL2: 3x10\^7/m2~DL3: 1x10\^8/m2~DL4: 3x10\^8/m2~DL5: 1x10\^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
223402826|NCT02932956|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
223402827|NCT02932956|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
223402828|NCT04580810|BEHAVIORAL|CBT4CBT in the Black Church|Use of Computer Based Treatment for Cognitive Behavioral Therapy for alcohol use disorder offered in a Black church setting
223402829|NCT04367181|DEVICE|Diffuse Correlation Spectroscopy (DCS)|Diffuse correlation spectroscopy uses light in the near infrared spectral region to quantify non-invasively cerebral blood flow. The DCS device will be use to monitor blood flow changes over time in all ELGA enrolled babies
223735444|NCT01288794|DRUG|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
223735445|NCT05581849|BEHAVIORAL|Prolonged Nightly Fasting|"Participants will engage in 14+ hours a night of fasting and no calorie containing food or beverages for 8 weeks. Participants will be allotted one cheat day per week, during which they will not need to fast (or track their times)- the day may change weekly and will be based on participant preference. Study staff and study participants will engage in a weekly coaching call (via phone; 5-10 minutes). Weekly coaching calls will last through the duration of the 8-week intervention."
224297483|NCT00325377|PROCEDURE|MME Procedure|
224297484|NCT00557076|BEHAVIORAL|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
224022284|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From Healthy Children Aged 8-18 Years|Blood samples will be taken from healthy childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs) for LC-MS/MS analysis. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers until analyzed by LC-MS/MS in accordance with standards from the Institute of Clinical and Laboratory Standards
224022285|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk Newborns (Aged 1-7 Days)|Blood samples will be taken from high-risk infants no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers.
224297485|NCT00557076|BEHAVIORAL|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
223735446|NCT05581849|BEHAVIORAL|Health Education Control|Participants in this group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks. Participants will be asked to review the video at their convenience, prior to their weekly coaching call (5-10 minutes) with the study staff. Weekly topics will be as follows: Week 1: Sleep hygiene, Week 2: Sun safety, Week 3: Home safety, Week 4: Driving safety, Week 5: Hydration, Week 6: Dental health, Week 7: Working environment, Week 8: Communication.
223735447|NCT00764153|PROCEDURE|Bipolar hemiarthroplasty|Lateral approach. FWB.
223402830|NCT04367181|DEVICE|Amplitude Integrated Electroencephalography (aEEG)|Amplitude Integrated Electroencephalography like EEG it is used clinically to monitor brain function in intensive care settings over longer periods of time. aEEG data will be correlated with CBF variation over time
223402831|NCT06578481|OTHER|Exercises|Individuals in the first group underwent cervical stabilization (CS) exercises and additional scapular and lumbopelvic stabilization (SLPS) exercises three times a week for 6 weeks. The second group was treated with only CS exercises for the same period. In addition, stretching exercises and a 20-minute hot pack were applied to the muscles around the neck of all patients.
223735448|NCT00764153|PROCEDURE|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
223735449|NCT05776654|DEVICE|Biometric wearable devices|Passive data collection using biometric wearable devices.
223735450|NCT03574740|OTHER|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
223735451|NCT05167734|DRUG|Iron Dextran|1000 mg IV
223735452|NCT05167734|DRUG|Erythropoietin (EPO)|40,000 units subcutaneous
223735453|NCT01198054|DRUG|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
223402832|NCT03354351|BEHAVIORAL|Stepped-care model|The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
223735454|NCT03432546|OTHER|Non-interventional|Non-interventional
223735455|NCT01510379|DEVICE|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
223735456|NCT01510379|DRUG|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
223735457|NCT01510379|DRUG|IV promethazine 25 mg q 6 hours prn|
223735458|NCT01510379|DRUG|Elixir promethazine 25 mg q 6 hours prn after discharge|
223735459|NCT03536403|RADIATION|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
223735460|NCT03536403|OTHER|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
223735461|NCT03024723|DEVICE|nasal mask CPAP|CPAP and ventilation administered via nasal mask
223735462|NCT01163708|DEVICE|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
223735463|NCT01163708|DEVICE|Navigation System|
223735464|NCT02604212|DRUG|ARC-520|
223735465|NCT02604212|OTHER|Placebo|
223735466|NCT02604212|DRUG|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
223735467|NCT02604212|DRUG|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
223735468|NCT02604212|DRUG|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
224297486|NCT05420974|PROCEDURE|NIR fluorescence imaging of the vascular perfusion of the meniscus using ICG|NIR fluorescence imaging of vascular perfusion using the Arthrex NIR fluorescence scope and Indocyanin Green
224297487|NCT06126068|DRUG|Use of magnesium sulfate to prevent and stop fits in pre-eclampsia and Eclampsia|Loading dose magnesium sulfate versus the Pritchard regimen
224297488|NCT00573404|DRUG|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
223735469|NCT03559946|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
223735470|NCT03559946|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
223735471|NCT05580341|BIOLOGICAL|Zerun HPV-9|Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months
223735472|NCT05580341|BIOLOGICAL|GARDASIL ®9|GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
223735473|NCT03927183|OTHER|person-centred practice|The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
223735474|NCT03353831|DRUG|Bevacizumab|Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period
223735475|NCT03353831|DRUG|Atezolizumab|Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period
223735476|NCT03353831|DRUG|Chemotherapy|Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
223735477|NCT03353831|DRUG|Placebos|Placebo will be administered by intravenous route q14 during the treatment period
223735478|NCT02058576|DRUG|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
223735479|NCT02058576|DRUG|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
223735480|NCT04883190|OTHER|Fulfilling Questionaires|Fulfilling Questionaires PHQ-D (brief) and FSMC
223735481|NCT05891314|PROCEDURE|Botox Injectable Product|one group will have botox injection in the internal sphincter
223735482|NCT05891314|PROCEDURE|Internal sphincterotomy|this group will have internal sphincterotomy
223735483|NCT00514033|BIOLOGICAL|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
223735484|NCT01119131|DRUG|Vitamin D3|Vitamin D3 at 10,000 IU a day
223735485|NCT01119131|DIETARY_SUPPLEMENT|calcium|1000mg calcium daily
223735486|NCT01119131|OTHER|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
223735487|NCT04443504|BEHAVIORAL|The Connected Family Series|The intervention is an online, self-paced post-adoption family intervention that occurs over a 4-week period to support adoptive families post-adoption.
223735488|NCT05283057|DRUG|Empagliflozin 25 MG|single dose of the SGLT inhibitor Empagliflozin was given
223735489|NCT05283057|DRUG|placebo|single dose of placebo that is similar to Empagliflozin in physical appearance
223735490|NCT01661192|DRUG|AAT( Alpha 1 Antitrypsin)|
223735491|NCT01166763|DRUG|vitamin D3|oral capsules, 10,000 IU per week for 6 months
223735492|NCT04339296|DEVICE|Spencer|The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
223735493|NCT02232542|DRUG|Duloxetine - low dose|
223735494|NCT02232542|DRUG|Duloxetine - high dose|
223735495|NCT02232542|DRUG|Placebo|
223735496|NCT01909479|DRUG|MOD-4023|Individualized once weekly dose of MOD-4023
223735497|NCT01909479|OTHER|Placebo|Once weekly administration of placebo
223735498|NCT04320485|DIAGNOSTIC_TEST|Active Anthrax Detect™ Plus (AAD Plus)|A lateral flow immunoassay rapid test (AAD Plus) for early and presumptive diagnosis of inhalational anthrax.
223735499|NCT02502539|PROCEDURE|Controlled physical activity|
223735500|NCT04571580|DRUG|Normal Saline|intracoronary infusion with normal saline
223735501|NCT04571580|DRUG|Reteplase Injection 9mg|low-dose intracoronary fibrinolytic therapy with reteplase 9mg
223735502|NCT04571580|DRUG|Reteplase Injection 18mg|low-dose intracoronary fibrinolytic therapy with reteplase 18mg
223735503|NCT01032876|PROCEDURE|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (\>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
224297489|NCT00573404|DRUG|sunitinib malate|
224297490|NCT00573404|OTHER|pharmacological study|
224022286|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk childrens (Aged 8 Days- 7 years)|Blood samples will be taken from high-risk childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers
224132128|NCT05289804|DEVICE|NITESGON|"NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain."
224297491|NCT03994718|OTHER|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
223735504|NCT01032876|PROCEDURE|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
223402833|NCT04451057|DEVICE|high flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
223402834|NCT04451057|DEVICE|low flow nasal cannula therapy|Once extubation has taken place, the child will be placed either on conventional oxygen therapy or high flow nasal cannulae according to randomization
223402835|NCT05340088|PROCEDURE|Retrograde intrarenal surgery after DJ stent placement|Patients who underwent RIRC for 2-4 weeks after DJ stent placement for passive dilatation
223402836|NCT01506115|DRUG|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
223402837|NCT05560568|OTHER|Sleep parameters data collection|Sleep parameters collected before and after hybrid close-loop pump activation. Data collected with adequate devices (i.e. actigraph and Dreem Band).
223402838|NCT01100086|DRUG|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
223402839|NCT01100086|DRUG|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
223402840|NCT03532425|DRUG|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
223402841|NCT03532425|DRUG|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
223402842|NCT03532425|DRUG|B/F/TAF Placebo|Tablet taken orally once daily
223402843|NCT03532425|DRUG|Atripla Placebo|Tablet taken orally once daily
223402844|NCT04148586|OTHER|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
223402845|NCT04741750|OTHER|Simplified HCV care within a mobile medical unit|Delivers guideline-based care for HCV in a stream-lined manner on a mobile medical unit
223402846|NCT03090334|DIAGNOSTIC_TEST|De-escalation|Antifungal therapy will be stopped according with BG results
223402847|NCT04967924|OTHER|neuromuscular training|Treatments will be provided in 30 mins per week for 3 consecutive weeks Proprioceptive Neuromuscular Facilitation (PNF)
223402848|NCT04967924|OTHER|Sports specific training|Treatments will be provided in 30 mins per week for 3 consecutive weeks. Weight programs include closed chain exercises (squats, pushups) and open chain exercises (leg press, chest fly using dumbbell) Stretch shortening cycle (enhances performance through storage of elastic energy during eccentric phase and activation of stretch reflex).
223402849|NCT01707810|PROCEDURE|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
223402850|NCT01707810|PROCEDURE|conventional method|
223402851|NCT03019861|BEHAVIORAL|Ayurvedic nutritional counseling|
223553810|NCT04878510|DRUG|Dexmedetomidine|Dexmedetomidine is an α2-adrenergic agonist sedative commonly used in invasive mechanical ventilation that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and when compared to γ-aminobutyric acid receptor agonists like benzodiazepines, reduces delirium.
223553811|NCT04878510|OTHER|Placebo|Normal saline placebo will be given as continuous infusion.
223553812|NCT05034042|DRUG|Fezolinetant|oral
223402852|NCT03019861|BEHAVIORAL|Conventional nutritional counseling|
223402853|NCT03600961|DEVICE|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
223402854|NCT05413213|PROCEDURE|Ambulatory rehabilitation program|Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
223402855|NCT05872854|DRUG|Hypericin|HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment
223402856|NCT05872854|OTHER|Visible Light|After application of HyBryte (0.25% hypericin ointment), participants will be placed in a light booth containing fluorescent light bulbs to activate the HyBryte.
223553813|NCT05034042|DRUG|Placebo|oral
223553814|NCT01252160|DRUG|QUTENZA|Cutaneous patch
223553815|NCT02531139|OTHER|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
223553816|NCT02531139|OTHER|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
223553817|NCT00190229|DRUG|Cyclophosphamide|Cyclophosphamide
223553818|NCT03813758|DIAGNOSTIC_TEST|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
223553819|NCT05952973|BEHAVIORAL|SkillTalk|Online Educator Mircoskill Training and Parent Microskill Training
223553820|NCT00146016|DRUG|Amantadine|
224022287|NCT05910151|DIAGNOSTIC_TEST|Obtaining Dry Blood Spots From High-risk childrens (Aged 8 - 18 years)|Blood samples will be taken from high-risk childrens no earlier than 3 hours after feeding by heel prick with a heel stick. Five drops of whole blood (\~75 µl each) will be applied to Guthrie cards, Ahlstrom 226 filter paper, PerkinElmer 226 Five-Spot Card (PerkinElmer Health Sciences, Greenville, USA) to form dried blood spots (DBSs). The sample must be taken before transfusion therapy (or blood is taken no earlier than 48-72 hours after the transfusion) or extracorporeal membrane oxygenation. Samples will be dried for 4 hours at room temperature and then stored at 4°C in individually labeled zippered plastic bags with desiccants or other sealed containers
224022288|NCT01181427|DRUG|ABT-267|See arm description
223735505|NCT00212030|DRUG|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
224297492|NCT03994718|OTHER|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
223402857|NCT06296771|OTHER|Dietary energy restriction group (D)|"The participants allocated to the dietary energy restriction group will receive instructions to change their usual dietary intake and maintain their regular physical activity routine for the duration of eight weeks.~The dietary energy restriction depends on a total calorie deficit of 5000 kcal per week, achieved by the consumption of reduced meal portions. This deficit is computed by subtracting the participants\&#39; energy expenditure, as measured by ActiheartTM, rather than relying on reported energy intake. This approach is employed to reduce potential difficulties arising from participants under-reporting their food consumption. The energy deficit is calculated by multiplying the weight of each food item recorded over a 5-day period by an individual factor obtained from energy expenditure data. This calculation enables the determination of the required energy intake for the intervention period."
223402858|NCT06296771|OTHER|Dietary energy restriction and exercise group (D+E)|"The individuals within the dietary energy restriction and exercise group will be instructed to reduce their habitual energy intake by 5,000 kcal per week while taking part in physical exercise with a frequency of three sessions per week of HIIT and two sessions per week of resistance exercise throughout a duration of 8 weeks. Sessions can be performed in any order, but we will recommend alternating HIIT and resistance training days and taking the two rest days separately to allow for recovery.~The exercise programme will start the session by participating in a gentle stretching routine with the objective of reducing the effects of exercise-induced shoulder discomfort. The treatment focuses on the four main muscle groups in the upper body: the latissimus dorsi, the triceps, the rhomboid, the pectoral, and the upper trapezius. Each pose is held in the stretched position for a length of 15 seconds throughout each set, for a total of 4 sets."
223402859|NCT04986345|OTHER|High-intensity interval training (HIIT)-4|4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.
223402860|NCT04986345|OTHER|High-intensity interval training (HIIT)-10|10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.
223402861|NCT04986345|OTHER|Rest|Participants are to stay seated for 30 minutes while reading or watching television.
223402862|NCT05448274|BIOLOGICAL|Placebo|The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
223402863|NCT05448274|BIOLOGICAL|Ruminococcus torques|10\^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline
223402864|NCT01611935|DRUG|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
223402865|NCT00162110|DRUG|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
223402866|NCT00951743|DRUG|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
223402867|NCT03914716|DIAGNOSTIC_TEST|Study group|Subjects will have physical, imaging examinations and provide samples for biological markers
223553821|NCT02766439|DRUG|etanercept|25-mg etanercept injection subcutaneously twice a week
223553822|NCT02360670|OTHER|control imaging|
223553823|NCT02360670|OTHER|additional multimodal imaging|
223553824|NCT02550288|DRUG|Ezetimibe 10 mg|
223553825|NCT02550288|DRUG|Atorvastatin 10 mg|
224297493|NCT03994718|OTHER|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
223553826|NCT02550288|DRUG|Placebo for Ezetimibe 10 mg tablet|
223553827|NCT02550288|DRUG|Placebo for Atorvastatin 10 mg capsule|
223553828|NCT02550288|BEHAVIORAL|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
223553829|NCT04131322|DRUG|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
224022289|NCT01181427|DRUG|Placebo|See arms description
224022290|NCT01181427|PROCEDURE|Blood Sample Collection|See arm description
224022291|NCT01181427|DRUG|Cytochrome P450 inhibitor|See arm description
224022292|NCT02581631|BIOLOGICAL|Nivolumab|
224022293|NCT02581631|DRUG|Brentuximab Vedotin|
224022294|NCT01690598|DRUG|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
224297494|NCT03358745|OTHER|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
224297495|NCT03358745|OTHER|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
223735506|NCT00212030|DRUG|placebo|Control
223735507|NCT04446377|DRUG|Apilimod Dimesylate Capsule|LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.
223735508|NCT04446377|OTHER|Placebo|Microcrystalline cellulose in Swedish orange, Size 0 capsules
223735509|NCT01733407|DRUG|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
223735510|NCT01733407|DRUG|placebo|400mg/kg/d divided TID for year 1 only.
223735511|NCT04810676|DRUG|CKD-501, D745, D150|QD, PO
223735512|NCT04810676|DRUG|CKD-383|QD, PO
223735513|NCT05483855|OTHER|Objective 1 Only: Telehealth Satisfaction Survey|Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
223735514|NCT05483855|OTHER|Objective 2 Only: ArthritisPower Joint Assessment|RA patients must complete a self-assessment examination of their joints using the ArthritisPower app prior to their in-office visit, where a repeat joint assessment is performed by participating physician.
223735515|NCT01328821|DRUG|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
223735516|NCT01328821|DRUG|CTP-499|400 mg immediate release capsule
223735517|NCT01936103|DRUG|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
223735518|NCT01936103|DRUG|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
223735519|NCT00006080|DRUG|fenretinide|
223735520|NCT01060930|DRUG|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
223402868|NCT01735916|DEVICE|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
223735521|NCT04804410|DEVICE|LCR Meter (Brand: Keysight, Serial Number:E498AL)|The LCR meter is used for electric property analysis of tissues. It works by measuring impedance on multiple sections of excised tissue and translating those measurement into dielectric properties.
223735522|NCT00235898|DRUG|CoFactor|
223735523|NCT00235898|DRUG|5-FU|
223735524|NCT00235898|DRUG|Leucovorin|
223402869|NCT01735916|DEVICE|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
223735525|NCT03557151|OTHER|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is \< 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
223735526|NCT03557151|BEHAVIORAL|Transdisciplinary Care-In Person & Telehealth|TC participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face or telehealth delivery of TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
223735527|NCT03283228|DIAGNOSTIC_TEST|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
223735528|NCT01414075|DRUG|Roxadustat|Tiered, weight-based dosing per schedule specified in the arm.
223735529|NCT01414075|DRUG|Oral Iron|Administered per oral dose and schedule specified in the arm.
223735530|NCT01414075|DRUG|IV Iron|Administered per IV dose and schedule specified in the arm.
224297496|NCT03358745|OTHER|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
223735531|NCT03847233|DEVICE|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
223735532|NCT01133301|DRUG|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
223735533|NCT01133301|DRUG|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
223735534|NCT02645214|OTHER|Non-antiseptic scrubs|
223735535|NCT02645214|OTHER|Antiseptic scrubs|
223735536|NCT04715763|DRUG|Telmisartan Oral Product|Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
223735537|NCT04715763|DRUG|Placebo|Gelatin capsules filled with an inactive ingredient
223735538|NCT00645073|DRUG|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
223735539|NCT00645073|DRUG|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
223735540|NCT02394847|DRUG|propofol|
224022295|NCT01690598|DRUG|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
224022296|NCT02731053|BEHAVIORAL|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
223735541|NCT01763216|OTHER|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
223735542|NCT01763216|OTHER|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
223402870|NCT02004366|DRUG|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
223402871|NCT02004366|DRUG|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
223402872|NCT02004366|DRUG|Linagliptin|Patients with admission A1C \< 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
223402873|NCT02004366|DRUG|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
223735543|NCT04057014|DRUG|Amoxicillin|Antibiotic given at different dosages and durations.
223402874|NCT02004366|DRUG|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
223402875|NCT03476889|OTHER|Infant formula|Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
223402876|NCT03158038|BIOLOGICAL|Monovalent Influenza Vaccine|A single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\] will be administered as intranasal spray on Day 1.
223402877|NCT03158038|OTHER|Placebo|A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
223735544|NCT04057014|PROCEDURE|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
223735545|NCT04425174|PROCEDURE|Quadratous lumborum block|Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.
223402878|NCT01130376|BIOLOGICAL|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
223402879|NCT01130376|DRUG|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
223402880|NCT01130376|DRUG|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
223402881|NCT01130376|DRUG|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
223402882|NCT05980624|DIETARY_SUPPLEMENT|oral nutrition supplement|patients receive ONS 300kcal in daily basis
223402883|NCT01219426|OTHER|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
223402884|NCT02527746|DRUG|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
223402885|NCT02527746|DRUG|EC regimen|Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
223402886|NCT02275546|DRUG|Placebo vaginal ring|Drug-free placebo vaginal ring
223402887|NCT02275546|DEVICE|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
223402888|NCT01962012|DEVICE|AcceleDent Aura|
223402889|NCT01962012|DEVICE|Sham Device|
223402890|NCT02955355|BIOLOGICAL|HYQVIA|Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
223402891|NCT02612623|DRUG|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
223735546|NCT04425174|PROCEDURE|Epidural anesthesia|Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
223735547|NCT03022565|DRUG|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
223735548|NCT00713154|DRUG|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
223735549|NCT00713154|DRUG|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
223735550|NCT05569200|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|The device used in this trial will be Haifu Focused Ultrasound tumor therapeutic System. In Uterine benign tumor female, the investigators will observe the possibility of complication and tumor response of treatment.
223735551|NCT05612178|BIOLOGICAL|3BNC117-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
224132129|NCT05289804|DRUG|Lidocaine / Prilocaine Topical Cream|A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
224132130|NCT05289804|DEVICE|C5/C6 stimulation|The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
224132131|NCT05289804|DEVICE|Sham NITESGON|Sham NITESGON
224132132|NCT03615469|DEVICE|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
223402892|NCT02612623|DRUG|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
223402893|NCT05891093|DRUG|Fluzoparib|Fluzoparib 50mg bid orally for 1 year.
223402894|NCT05891093|DRUG|Anastrozole|1mg, qd orally
223402895|NCT05891093|DRUG|Letrozole|2.5mg, qd orally
223402896|NCT05891093|DRUG|Exemestane|25mg, qd orally
223402897|NCT05891093|DRUG|Tamoxifen|10mg, bid orally
223402898|NCT05891093|DRUG|Toremifene|60mg, qd orally
223402899|NCT05891093|DRUG|Abemaciclib|150mg/100mg/50mg, bid orally for 2 years
223402900|NCT05891093|DRUG|LHRH agonist|Leuprorelin acetate, goserelin acetate
223402901|NCT04831411|PROCEDURE|Total Knee Arthroplasty|The extremities of patients admitted to the operating room to be applied TKA will be determined using a safe surgical Fast-Track recovery protocol. Patients will be operated by the same surgical team using the same technique. Spinal anaesthesia or general anaesthesia will be applied to the patients according to the evaluations of the anesthesiologists.
223402902|NCT04831411|OTHER|Whole Body Vibration|Whole Body Vibration
223402903|NCT04831411|OTHER|Progressive Resistance Training|Progressive Resistance Training
223402904|NCT01798810|PROCEDURE|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
223402905|NCT06685003|BEHAVIORAL|Digital Tutorial overview|Self study of a digital tutorial covering an overview of CRAFT designed to be reviewed within 7 weeks and revisited over 6 months.
223402906|NCT06685003|BEHAVIORAL|Digital Tutorial plus training Materials|Self study of a digital tutorial covering an overview of CRAFT and deeper materials designed to be reviewed within 7 weeks and revisited over 6 months.
223402907|NCT06685003|BEHAVIORAL|Digital Tutorial plus training Materials plus feedback and Coaching|Self study of a digital tutorial covering an overview of CRAFT and deeper materials designed to be reviewed within 7 weeks and revisited over 6 months. Plus group coaching and feedback on audio recordings of CRAFT procedures used in sessions
223402908|NCT06056037|BEHAVIORAL|Experimental: Making ART Work|A culturally tailored, theoretically grounded provider-facilitated group-based social support intervention (4 sessions) that emphasizes a collective approach to ART adherence and includes establishing a common understanding of ART, identifying potential barriers to ART adherence with a focus on social and structural barriers (e.g., stigma, relationship influences, family support, economic stressors), developing practical strategies to increase self-esteem and self-efficacy to enhance ART adherence, and generating and maintaining peer norms and support for ART adherence within one's social group. These sessions will include SGM youth-specific video vignettes that address the social/contextual realities faced by SGM YLWH in Brazil. Lastly, the intervention includes daily SMS text messaging that serve as both reminders and cognitive cues to take medication as prescribed.
223402909|NCT06056037|BEHAVIORAL|Standard of Care|Prior to randomization, all participants will meet briefly with a counselor to assess current needs for standard HIV primary care and referrals to social and/or health (including mental health) services. If participants do not have a primary HIV care provider, they will be linked to a provider at INI-Fiocruz or their preferred clinic, where they can access free HIV care through the no-cost universal access program of the Brazilian Public Health System. Additionally, the counselor will provide necessary referrals as needed, e.g., for social, general health and/or mental health services. Additionally, in order to provide a baseline level of standardized adherence information, all participants will receive a brief adherence educational session, which consists of a review of medications and recommended dosing, adherence expectations, toxicity expectations, and medication misperceptions.
223402910|NCT05883072|BEHAVIORAL|Exploring AI-Chatbot|All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
223402911|NCT05649839|OTHER|garment|patient randomized in the experimental arm will wear the specially designed garment
223402912|NCT00801385|DRUG|erlotinib hydrochloride|
223402913|NCT00801385|DRUG|sorafenib tosylate|
223402914|NCT00801385|GENETIC|DNA analysis|
223402915|NCT00801385|GENETIC|mutation analysis|
223553830|NCT04131322|DRUG|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
223553831|NCT01454609|DRUG|0.9% Normal saline|Saline
223553832|NCT01454609|DRUG|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
224132133|NCT03615469|DEVICE|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
223402916|NCT00801385|GENETIC|polymerase chain reaction|
223402917|NCT00801385|GENETIC|protein analysis|
223402918|NCT00801385|GENETIC|protein expression analysis|
223402919|NCT00801385|OTHER|immunohistochemistry staining method|
223402920|NCT00801385|OTHER|laboratory biomarker analysis|
223402921|NCT03204786|DRUG|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
223402922|NCT03204786|DRUG|Placebo|Placebo Nasal Spray
223553833|NCT01454609|DEVICE|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
223553834|NCT02998411|OTHER|Titration|
223553835|NCT05142917|DEVICE|Transcranial Direct Current Stimulation|Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
223553836|NCT05142917|BEHAVIORAL|Hand motor task|Various type of hand motor tasks are applied to stroke patients.
223553837|NCT00072046|BIOLOGICAL|bevacizumab|10mg/kg IV infusion on Days 1 \& 15 of each cycle
223553838|NCT00072046|BIOLOGICAL|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
223553839|NCT00456625|BIOLOGICAL|Engerix™-B|Intramuscular injection, 1 dose
223402923|NCT05765539|DEVICE|echOpen O1 Handheld Ultrasound device|"The performance of the Handheld ultrasound device (echOpen O1 device) will be assessed during these visits for all evaluation criteria.~* One examination with the US machine by the midwife focused on 4 targets ;~* One examination with a classic US machine by the same midwife (comparator) including the search for the four targets ;~* One examination with the US machine by a second operator ; Review of the images obtained by the US machine by the referring radiologist at a separate point of time.~The mode of delivery and the vital status of the mother and newborn will also be collected.~Operator A will start by using either the echOpen O1 device or the US machine (random order, via sealed envelopes) and will then perform the other type of examination.~Another operator (Operator B) will come to perform an examination with the Handheld ultrasound device (blind to the result of the first operator).~The switch between operators A and B will also be random."
223735552|NCT05612178|BIOLOGICAL|10-1074-LS|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10- 1074-LS (dosed at 10 mg/kg) or placebo at weeks 0, 20 and 40.
224132134|NCT01925859|DRUG|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
223735553|NCT05612178|OTHER|Sterile Saline|Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) or placebo at weeks, 20 and 40.
223735554|NCT01187043|DRUG|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
224132135|NCT04041388|OTHER|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
224132136|NCT01153763|DRUG|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
224132137|NCT05942937|OTHER|Education Intervention (The HepPEd Program)|"All healthcare providers, correctional officers, and people in prison (HepPEd Program target audience groups) at each participating site are anticipated to be exposed to the HepPEd Program over the course of the three-month education intervention phase.~The HepPEd Program involves a suite of multi-modal resources targeting each target audience group and a peer education program (for correctional officer and people in prison groups only). The HepPEd Program resources will be delivered in an informal, mass education-style, as well as in peer to peer format."
224132138|NCT06297343|PROCEDURE|Creation of an arteriovenous fistula|Patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day (outpatient care, or an overnight stay in hospital if they live a long way from the hospital, have multiple pathologies or are socially isolated). An arteriovenous fistula is created under local or general anaesthetic. On the day of the operation, the type of arteriovenous fistula created, the side of the arteriovenous fistula, the location of the arteriovenous fistula and the patency of the arteriovenous fistula will be collected.
223402924|NCT04167540|BIOLOGICAL|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
223402925|NCT05779020|BIOLOGICAL|Quadrivalent Influenza Vaccine (split virion, inactivated)|Quadrivalent Influenza Vaccine (split virion, inactivated) from Instituto Butantan (dose 0.25ml and 0.50ml)
223402926|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Victoria lineage/dose 0.50ml
223402927|NCT05779020|BIOLOGICAL|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage|Trivalent Influenza Vaccine (split virion, inactivated) containing Influenza B virus - Yamagata lineage/dose 0.25ml
223402928|NCT04489173|DRUG|trifluridine/tipiracil|"Study medication should be started within 3 days after completion of screening and continue until a study treatment discontinuation criterion is met.~Trifluridine/tipiracil will be administered orally BID on days 1 through 5, with the first dose administered in the morning of day 1 of each cycle and the last dose administered in the evening of day 5, followed by a recovery period from day 6 through day 7. Trifluridine/tipiracil will be administered orally BID on days 8 through 12, with the first dose administered in the morning of day 8 of each cycle and the last dose administered in the evening of day 12, followed by a recovery period from day 13 through day 28. Each cycle will be 28 days."
223402929|NCT06451263|BEHAVIORAL|Nudge|Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
223402930|NCT06474143|DEVICE|Apneal device|Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
223402931|NCT06188715|DRUG|Moxidectin 2 mg Oral Tablet|Tablets of 2 mg moxidectin
223402932|NCT06188715|DRUG|Albendazole 400 mg Oral Tablet|Tablets of 400 mg albendazole
224297497|NCT03358745|OTHER|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
224297498|NCT02571166|BIOLOGICAL|HSV529|Live, Replication-defective HSV-2 virus
223402933|NCT06188715|DRUG|Placebo Moxidectin|Placebo tablets for moxidectin
223402934|NCT06188715|DRUG|Placebo Albendazole|Placebo tablets for albendazole
223735555|NCT04087876|DRUG|derazantinib|derazantinib will be administered orally
223735556|NCT04195685|PROCEDURE|Neurofeedback (NFB)|Participants are seated in a comfortable chair and have common EEG electrodes with a pre-application of EEG adhesion conductive paste placed on scalp. The participant will receive coaching as they look at the game training screen and focus on the image. The game training screen provides almost instantaneous feedback (within 200 milliseconds) to participants about brain functioning. Twenty, one-hour, NFB training sessions will be provided by a trained NFB specialist over an 8-10-week period with up to 5-sessions but usually 3 sessions a week. The specific NFB special use system that will be used is the Cygnet NFB System from Bee Medic Corporation. The latest technological advances in this system has enabled training frequencies in the infra-low frequency range as well as in all other relevant frequency ranges which is a breakthrough capacity not available on any other NFB system. This will enable the individualized training to the person's brain training preference.
223402935|NCT04077593|DEVICE|RRate Mobile app|Test respiratory rate with RRate application
223402936|NCT01365871|PROCEDURE|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
223402937|NCT00843765|OTHER|acupuncture, massage and basic TCM treatment|"1. During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~2. After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
223402938|NCT00843765|OTHER|rehabilitation and WM basic treatment|"there two steps:~1. during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~2. After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
223402939|NCT05849532|DEVICE|Functional Electrical Stimulation|12-weeks of training sessions that include initial screening and clinical assessment (Week 1-2), onsite training sessions (Week 3-4), home training sessions (Week 4-8). There will also be pre (Week 1), mid (Week 7) and post-training (Week 12) assessment. Each session will consist of a 10-minute warm-up session with 5-6 stretching exercises. Warm-up will be followed by a 30 minute training session comprising of mobility, balance and walking exercises with FES. This will be followed by a cool down session for 10-minutes comprising of 5-6 muscle stretches. The participant will first watch video of the each exercise on the android tablet and then perform the exercises.
223735557|NCT04576429|PROCEDURE|venous puncture|"Venous punctures will be performed:~for patients of cohort A and B1:~* before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline);~* between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion);~* each 3 months up to 12 months.~for patients of cohort B2:~* before the radiotherapy;~* within the 6 weeks after the end of radiotherapy;~* at the 2 following evaluations (every 3 months)."
223735558|NCT04576429|PROCEDURE|tumoral biopsy|Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
223735559|NCT02151760|DRUG|18F-DCFPyL|
223553840|NCT03998800|DIETARY_SUPPLEMENT|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
223553841|NCT03998800|BEHAVIORAL|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
223735560|NCT00086320|DRUG|Paliperidone ER|
223553842|NCT01419600|DRUG|AZD8683|Single Dose Inhaled IMP via Turbuhaler
224132139|NCT05986643|BEHAVIORAL|Exergame+Neurofeedback|Electroencephalography (EEG) is a device that measures the electrical activity of the brain (brain waves). There are several frequencies of brain waves when we are awake; alpha (medium), beta (fast), and theta (slow). Alpha frequencies of brain activity are linked to maintaining balance, with more alpha activity being associated with poorer balance. EEG neurofeedback treatment involves placing electrodes on a person's head to monitor and change brain activity by giving cued audio or visual feedback. It has been used in PwP to show improvements in balance and walking. Other preliminary research in PwP has shown that exercise can also improve balance.
223735561|NCT04226378|DEVICE|Omnipod|Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.
223553843|NCT01419600|DRUG|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
223553844|NCT02596256|DRUG|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
223735562|NCT04226378|OTHER|MDI|Continued use of MDI therapy (traditional basal/bolus insulin regimen).
223735563|NCT03796429|DRUG|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
223735564|NCT02278198|DRUG|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
223735565|NCT02573298|DEVICE|ice|local ice application for 30 minutes
223735566|NCT02573298|DEVICE|cold gas|local cold gas application for 2 minutes
223735567|NCT04658277|DRUG|Clarithromycin|Patients in the intervention arm will take Clarithromycin 250mg daily.
223553845|NCT02596256|DRUG|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
223553846|NCT04490213|OTHER|Allevyn, Aquacel and Tegaderm, Mediskin|Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
223553847|NCT05483231|BEHAVIORAL|Family integrated care intervention group|If the very low birth weight infants' vital signs are stable at 32 weeks of corrected gestational age, parents who have been fully trained will provide all non-medical care measures and developmental care for the VLBWIs in the NICU for not less than 6 hours per day for at least 3 weeks, and other medical practice and care measures will be the same as the routine group.
223735568|NCT04658277|OTHER|Usual care|Patients will receive usual medical care
223735569|NCT01092559|DRUG|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
223735570|NCT00851383|BIOLOGICAL|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
223735571|NCT00851383|BIOLOGICAL|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
223735572|NCT01020851|BEHAVIORAL|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
223735573|NCT01020851|BEHAVIORAL|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
223735574|NCT03578601|OTHER|Thyroid surgery|Patient undergoing thyroid surgery
223735575|NCT06437899|DRUG|intravesical botulinum toxin A injection unter local anaesthesia|"Arm1: Botulinum toxin A injection under local anesthesia according to standard protocol:~Retrograde filling of the empty urinary bladder with a 1:1 mixture of 50 ml lidocaine 1% mixed with 50 ml sodium bicarbonate 8.4%, leave the local anesthetic mixture in the bladder for 15 minutes.~Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10 ml NaCl 0.9% into the detrusor at 10 points using a rigid 70 degree cystoscope~Arm 2: botulinum toxin A injection in sedoanalgesia according to the anesthesia standard protocol:~Intravenous administration of remifentanil (0.05-0.15µg/kg/min) and propofol. Transurethral, intravesical injection of a total of 100IE botulinum toxin A dissolved in 10ml NaCl 0.9% into the detrusor."
223735576|NCT04463095|PROCEDURE|PER ORAL ENDOSCOPY MYOTOMY (POEM)|Peroral endoscopic myotomy (POEM)combines thelong-term efficacy of a myotomy with the benefits of an endoscopic, minimally invasive procedure.Other therapeutic options include endoscopic balloon dilatation and surgical myotomy. Endoscopic balloon dilatation is still widely performed because of its relative non-invasiveness and simplicity, but it has a relatively lower success rate and often requires multiple treatment sessions. Surgical myotomy has been thought to be the curative therapeutic choice for symptomatic achalasia. However, it requires skin incisions and additional anti-reflux surgical intervention.Unlike surgical myotomy, POEM preserves the anatomical integrity of the LES and possibly minimizes postoperative reflux.
223735577|NCT00755287|DRUG|insulin glargine|starting dose 10 IU daily
223735578|NCT00755287|DRUG|metformin|As prescribed
223735579|NCT00755287|DRUG|taspoglutide|10 mg once weekly
223735580|NCT00755287|DRUG|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
223402940|NCT03596957|DRUG|Tolvaptan|At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
223402941|NCT03096860|OTHER|Active alcohol consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
223402942|NCT03096860|OTHER|Placebo consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
223402943|NCT05344560|DEVICE|soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore|TEST Lens
223402944|NCT05344560|DEVICE|ACUVUE OASYS 1-Day for Astigmatism|CONTROL Lens
223402945|NCT06573684|DIAGNOSTIC_TEST|Electromyography|All of groups will have assessment of electromyography result
223402946|NCT03426592|DRUG|Vitamin D3, 10000 Intl Units Oral Capsule|"Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
223553848|NCT05483231|BEHAVIORAL|Routine nursing care group|Routine practice and in-hospital education will be given to the very low birth weight infants and parents. All care measures will be led by the nursing staff, without the participation of parents.
223553849|NCT03886194|PROCEDURE|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
223553850|NCT01360424|DRUG|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
223553851|NCT05003973|BEHAVIORAL|home-based anti-resistance exercise|It is a 12-week, middle-level, home-based, anti-resistance exercise. Exercise was recommended 1-2 times per day for 15-20 mins per session.
223735581|NCT00403793|DRUG|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
223735582|NCT00403793|DRUG|Placebo|42 or 44 weeks with placebo implant and placebo injections
223735583|NCT00478985|BEHAVIORAL|Imatinib ending|Interruption of the treatment by Imatinib
223735584|NCT02716064|BEHAVIORAL|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
223735585|NCT03748147|DRUG|Misoprostol|prostaglandin e1
224297499|NCT02571166|DRUG|Valacyclovir|500 mg orally, once daily for 4 weeks
223402947|NCT03426592|DRUG|Placebo oral capsule|"Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
223735586|NCT01634971|PROCEDURE|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
223735587|NCT00533195|DRUG|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
223735588|NCT00533195|DEVICE|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
223735589|NCT01119885|DRUG|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
224297500|NCT02870179|DEVICE|Pulse Oximeter|Measurement of physiological parameters
223402948|NCT04714424|DEVICE|Virtual Reality Headset|Virtual reality (VR) - a 3-D reality right in a headset
223402949|NCT04689035|DRUG|AVLX-144|Test drug
223402950|NCT04689035|DRUG|Placebo|Placebo
223402951|NCT03517176|DRUG|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
224022297|NCT04288999|DRUG|Chemotherapy|"Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours"
224022298|NCT04288999|RADIATION|Preoperative radiotherapy|"Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)"
223402952|NCT03517176|DRUG|Nab-paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
224022299|NCT04288999|OTHER|Procedure|"Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection"
224022300|NCT00336895|DRUG|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
224022301|NCT06182943|OTHER|electroacupuncture combined with surrounding acupuncture|electroacupuncture combined with surrounding acupuncture
223402953|NCT03517176|DRUG|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
224022302|NCT06182943|OTHER|sham electroacupuncture|sham electroacupuncture
224022303|NCT06182943|OTHER|ice compress combined with brake rest|ice compress combined with brake rest
224022304|NCT05692479|OTHER|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data|Premenstrual Syndrome Scale, Women's Physical Activity Self-Worth Inventory, Descriptive data
224022305|NCT04120636|DRUG|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
224022306|NCT02013960|DRUG|Cytotec|Cytotec medication compared with cytotec and laminaria
224132140|NCT05986643|BEHAVIORAL|Exergame [alone]|"The exergame, delivered in virtual reality, involves travelling down a road (to give optic flow) whilst dodging balls that move towards the participant by either shifting their body either to the left or right. They are also be instructed to stand still and catch stars that appear and these will be used to score points and are associated with a monetary reward, ensuring motivation.~This group will receive SHAM feedback."
223402954|NCT03197480|DRUG|Aflibercept Injection [Eylea]|All subjects will receive 4 monthly intravitreal injections of aflibercept
223402955|NCT00360282|DRUG|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
223402956|NCT00360282|OTHER|Placebo|In an unlabeled pill given once on one of two visits.
223402957|NCT05244057|DRUG|Hepalatide|6.3mg, s.c., qd for 48 weeks
223402958|NCT05244057|DRUG|Placebo of Hepalatide|s.c., qd for 48 weeks
223402959|NCT05244057|DRUG|Tenofovir Alafenamide Tablets|25mg, p.o., qd for 48 weeks
223402960|NCT05244057|DRUG|Pegylated Interferon alfa 2a|90ug, s.c., qw for 48 weeks
223402961|NCT01481948|BEHAVIORAL|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
223402962|NCT05565248|COMBINATION_PRODUCT|VCTX211|CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
223402963|NCT03035825|DIETARY_SUPPLEMENT|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
223402964|NCT03035825|OTHER|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
223402965|NCT03634969|DRUG|BMS-986224|Specified dose on specified days
224132141|NCT04960345|DEVICE|Brainlab Knee 3|Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
223402966|NCT06058546|DRUG|Jiuweihuaban Pill placebo|Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
223402967|NCT06058546|DRUG|low dose Jiuweihuaban Pill|Low dose Jiuweihuaban pill 1 bag(3 g placebo per bag and 9 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
223553852|NCT05003973|BEHAVIORAL|usually care|The leaflet of the lymphedema self-care, including skin care and manual lymphatic drainage
223553853|NCT04154644|DEVICE|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
223553854|NCT01937663|DRUG|KWA-0711|
223553855|NCT06406400|DRUG|AZD4041|"Part 1a: Healthy participants will receive AZD4041 (Dose 1) orally on Day 1 and Day 9.~Part 1b: Healthy participants will receive AZD4041 (Dose 2) orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive daily doses of AZD4041 from Days 1 to 7."
223553856|NCT06406400|DRUG|Itraconazole|Healthy participants will receive itraconazole orally from Days 6 to 8 in Period 2 and Days 9 to 21 in Period 3.
223553857|NCT06406400|DRUG|Buprenorphine|Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.
223735590|NCT01119885|DRUG|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
223402968|NCT06058546|DRUG|high dose Jiuweihuaban Pill|High dose Jiuweihuaban pill 1 bag(12 g Jiuweihuaban pill ),p.o.,tid,for 12weeks.
223402969|NCT01380912|DRUG|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
223402970|NCT01207024|OTHER|knee MRI|knee MRI before surgery (inclusion) and one year after
223402971|NCT02290756|BEHAVIORAL|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
224132142|NCT03674203|BIOLOGICAL|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
224132143|NCT01474746|DRUG|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
223402972|NCT02290756|BEHAVIORAL|Low cost evidence based toolkit|"The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information"
223402973|NCT03658785|BIOLOGICAL|TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
223402974|NCT03658785|DRUG|Aldesleukin|IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks
223402975|NCT03658785|DRUG|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
223402976|NCT03658785|DRUG|Fludarabine|Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
223402977|NCT01654185|DRUG|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
223402978|NCT01654185|DRUG|Aromatase Inhibitor|1 tablet per day
223553858|NCT06406400|DRUG|Buprenorphine / Naloxone|Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7
223553859|NCT06406400|DRUG|Hydromorphone|Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.
223553860|NCT06406400|DRUG|Placebo|"Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7."
223553861|NCT06447155|DIETARY_SUPPLEMENT|Bolus feeding|The babies fed with bolus feeding during TH composed this group
223553862|NCT06447155|DIETARY_SUPPLEMENT|Continuous feeding|The babies fed with continuous feeding during TH composed this group
223553863|NCT06447155|DIETARY_SUPPLEMENT|Placebo|The babies who were not fed during TH composed this group
223553864|NCT00803361|DRUG|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
223553865|NCT00803361|DRUG|Placebo|placebo capsules, oral, once a day for 15 weeks
223553866|NCT02014662|OTHER|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
223553867|NCT04764097|DRUG|Dapagliflozin|SGTL2 Inhibitor
223553868|NCT04764097|DRUG|Placebo|Placebo
223553869|NCT04727996|DRUG|Sitravatinib|120 mg will be administered orally once daily
223553870|NCT04727996|DRUG|Tislelizumab|200 mg will be administered intravenously (IV) once every 3 weeks
223553871|NCT03136653|BIOLOGICAL|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
223553872|NCT00191399|DRUG|Olanzapine|
223553873|NCT00191399|DRUG|Fluoxetine|
223553874|NCT01946633|DEVICE|magnetic-controlled capsule endoscopy(Navicam)|
223402979|NCT04727905|DIETARY_SUPPLEMENT|energy drink|The explosive force and muscle endurance of the lower limbs were tested first, and then the special training intervention for fire rescue was performed. Solution supplementation was carried out. The experiment group was divided into the control group and only drank 1 liter of pure water, and the sports drink group supplemented with commercially available sports drinks (using commercially available treasures). Mineral water powder configuration), mint-flavored sports drink group supplemented with mint-flavored commercially available sports drinks (using commercially available treasure mineral water powder configuration plus edible flavor 0.01% menthol)
223553875|NCT01976702|BEHAVIORAL|Enhanced Behavioral Skills Training|
223553876|NCT01836536|DRUG|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
223553877|NCT03629223|DRUG|Tepotinib TF2|Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
223553878|NCT03629223|DRUG|Tepotinib TF3|Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
223553879|NCT01534351|DRUG|Finasteride|Finasteride 5 mg oral tablet taken once daily.
223553880|NCT01534351|DRUG|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
223553881|NCT01534351|DRUG|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
223553882|NCT01534351|DRUG|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
223553883|NCT04635150|BEHAVIORAL|Close Collaboration with Parents|Close Collaboration with Parents Training Program is an educational intervention for multidisciplinary NICU staff initially developed and implemented at Turku University Hospital to promote FCC. The intervention consists of four phases lasting 4 to 5 months each. First the healthcare staff learn to observe infant behavior. This phase aims at identifying the individual needs and features of each infant. After that, the staff observe infant behavior with the parents and learn to actively listen to parents' perceptions about their infant. During the phase III, staff learn to know the individual story of the family and their infant, which supports partnership between staff and parents. Finally, staff learn to integrate parents in decision-making and collaboratively plan the transition to home. The training is delivered through facilitator-network model in which local mentors are trained by the trainer mentors and supervisors.
223553884|NCT02024425|DIETARY_SUPPLEMENT|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
223553885|NCT02024425|DIETARY_SUPPLEMENT|Control supplement|
224132144|NCT01474746|DRUG|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
224132145|NCT00400829|DRUG|eribulin mesylate|Given IV
223402980|NCT03817853|DRUG|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
223402981|NCT03817853|DRUG|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
223402982|NCT03817853|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
223402983|NCT03817853|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
223402984|NCT03817853|DRUG|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
223402985|NCT03817853|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
223402986|NCT03264183|DIAGNOSTIC_TEST|Transesophageal Echocardiography|TEE measures of right ventricular function
223402987|NCT03264183|DIAGNOSTIC_TEST|Transthoracic Echocardiography|TTE measures of right ventricular function
223402988|NCT04760977|DRUG|Drugs administration|Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
223402989|NCT04760977|DEVICE|Resuscitative endovascular balloon occlusion of the aorta|Resuscitative technique for exsanguinating traumas
223402990|NCT04760977|BIOLOGICAL|Blood transfusions|Transfuion of transported blood products for exsanguinating traumas
223553886|NCT03522415|DRUG|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
223553887|NCT03522415|DRUG|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
223553888|NCT02702609|DEVICE|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
223553889|NCT02702609|DEVICE|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
223553890|NCT06341595|DRUG|Sintilimab|Sintilimab: 200mg iv q3w d1, 4-6 cycles
223553891|NCT06341595|RADIATION|Extraperitoneal radiation therapy|Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)
223402991|NCT04760977|OTHER|Prehospital management|Stay and play strategy vs scoop and run
223402992|NCT04760977|DEVICE|Prehospital eFAST|Prehospital thorax/abdomen extended focused assessment sonography for trauma
223402993|NCT03035383|PROCEDURE|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
223402994|NCT03035383|PROCEDURE|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
223402995|NCT02992353|PROCEDURE|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
223402996|NCT02992353|PROCEDURE|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
223553892|NCT06341595|DRUG|Oxaliplatin|oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles
223553893|NCT06341595|DRUG|S-1|S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles
223553894|NCT06005012|DRUG|Semaglutide|Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) that is FDA-approved for the treatment of obesity (as Wegovy) or T2DM (as Ozempic).
223553895|NCT06005012|DRUG|Placebo|Placebo
223735591|NCT00945048|DEVICE|electrical velocimetry|determination of cardiac output by electrical velocimetry
223735592|NCT00945048|DEVICE|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
223735593|NCT00945048|DEVICE|spirometry|spirometry for testing the ventilatory function
223402997|NCT02544620|OTHER|Does fulfil of discharge criteria on the day of the surgery|
223402998|NCT02544620|OTHER|Does not fulfil of discharge criteria on the day of the surgery|
223402999|NCT01496677|DRUG|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
223403000|NCT01496677|DRUG|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
223553896|NCT00773643|OTHER|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
223735594|NCT00945048|DEVICE|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
223403001|NCT03902262|PROCEDURE|appendicectomy|
224022307|NCT01602107|OTHER|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
224022308|NCT02481947|DRUG|BLI400 Laxative|21 gm BLI400 powder
224022309|NCT02481947|DRUG|Lubiprostone|24 mcg capsule bid
224022310|NCT00647491|BIOLOGICAL|adalimumab|20 mg sc eow
224022311|NCT00647491|BIOLOGICAL|adalimumab|40 mg sc eow
224022312|NCT00647491|BIOLOGICAL|adalimumab|80 mg sc eow
224022313|NCT00647491|BIOLOGICAL|placebo|placebo sc eow
224022314|NCT03945682|OTHER|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
224132146|NCT03847155|DRUG|Nicotine patch|The patients will receive a nicotine patch for the period of a maximum of 7 days.
223735595|NCT03198234|BIOLOGICAL|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
223403002|NCT05477264|DRUG|Tislelizumab|"Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance."
223403003|NCT06189196|DEVICE|BLOW BOTTLE|Blow Bottle PEP' is the cost-effective device comparative to other PEP devices. Treatment (CPT) along with BBPEP twice a day. Therapist made a cost-effective BBPEP which generates 10 cm of H2O PEP and it was given for 10 breaths, 3 sets with 5 second hold.
223403004|NCT06189196|OTHER|ACBT|Active cycle of breathing technique (ACBT) is an alternative airway clearance technique. A typical ACBT cycle consists of breathing control, three to four thoracic expansion exercises, and a forced expiratory technique (huffing). ACBT has been shown to improve short-term secretion clearance in patients with chronic lung disease. It is also flexible, tolerated, and accepted well by patients. Although ACBT is widely used in patients with respiratory conditions characterized by chronic sputum production.
223403005|NCT00563693|DEVICE|ASV|Adaptive servo ventilator
223403006|NCT00563693|OTHER|without Autoset CS2|without Autoset CS2
223403007|NCT04121819|DRUG|Cytarabine|cytarabine 100mg/m2 d1-5 subcutaneous
223403008|NCT06563453|DEVICE|transcranial alternating current stimulation|Transcranial Alternating Current Stimulation (tACS) is a tool that administers a weak alternating current (in the range of 0.1 to 4 mA), most often with a sinusoidal waveform, between electrodes placed over target areas. This can entrain the subjacent neuronal networks favouring the firing at specific frequencies of interest, in certain cases, with effects outlasting the stimulation duration up to 70 min.
223403009|NCT05990374|DRUG|Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc|The study compared patients taking different types of GLP-1(Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc) with taking placebo.
223553897|NCT05538377|OTHER|Focal Vibration|This group will receive a multicomponent exercise program based on specific literature for effective training. In addition, this group will perform the strength and endurance exercises with focal vibration on the vastus internus, externus and biceps femoris. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
223553898|NCT05538377|OTHER|Control Group|This group will receive the same multicomponent exercise program than the other group based on specific literature for effective training. There will be 2 sessions per week, with a duration of 60 minutes per session and a treatment duration of 6 months.
223553899|NCT02674464|BEHAVIORAL|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. The RICH LIFE Project provides the health systems with the logic to build practice and provider level hypertension (HTN) dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as \<140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
223553900|NCT02674464|BEHAVIORAL|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
223553901|NCT02674464|BEHAVIORAL|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
223735596|NCT01573975|DRUG|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
224132147|NCT03847155|OTHER|Placebo patch|The patients will receive a placebo patch for the period of a maximum of 7 days.
224132148|NCT02742922|BEHAVIORAL|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
224132149|NCT00396708|DEVICE|myomo e100 neurorobotic elbow brace|
224132150|NCT01766336|DRUG|Group 1 ELND005|
224132151|NCT01766336|DRUG|Group 2 ELND005|
224132152|NCT00901537|DRUG|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
224132153|NCT02605447|DRUG|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
224132154|NCT02605447|DEVICE|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
224132155|NCT00039195|BIOLOGICAL|filgrastim|
224132156|NCT00039195|BIOLOGICAL|rituximab|
223553902|NCT02674464|BEHAVIORAL|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, nurse, or social worker care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
223553903|NCT02674464|BEHAVIORAL|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
223553904|NCT02674464|BEHAVIORAL|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
223553905|NCT00003587|DRUG|carboplatin|AUC=5.5 day 1 every 21 days X 3
223553906|NCT00003587|DRUG|cisplatin|IV cisplatin 100 mg/m\^2 day 1 every 21 days X 3
223553907|NCT00003587|DRUG|docetaxel|IV docetaxel 75 mg/m\^2 day 1 every 21 days X 3
223553908|NCT00003587|DRUG|gemcitabine|IV gemcitabine 1,000 mg/m\^2/day, days 1 and 8 every 21 days X3
223553909|NCT00003587|DRUG|paclitaxel|IV paclitaxel 225 mg/m\^2/day, day 1 every 21 days X 3
223553910|NCT00003587|DRUG|vinorelbine|IV vinorelbine 25 mg/m\^2/day, days 1 and 8 every 21 days X 3
223553911|NCT02078024|DRUG|IVM plus ALB|
223553912|NCT02078024|DRUG|IVM|
223553913|NCT03246516|OTHER|Questionnaire|"Auto and hetero questionnaires:~* STAI Y B, State-Trait Anxiety Inventoriage~* Brief COPE~* RHHI-24, Revised Health Hardiness Inventory~* IPQ-R, Illness Perception Questionnaire"
223553914|NCT00783835|DRUG|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
223553915|NCT06436222|DEVICE|HVNI|Preterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.
223553916|NCT06233162|DRUG|Febuxostat-Test product|Febuxostat 80 mg tablets Manufactured by: Zydus Lifesciences Limited, India
223553917|NCT06233162|DRUG|Febuxostat-Reference product|Febuxostat 80 mg tablets Manufactured by: Patheon France, France
223553918|NCT05503706|OTHER|1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo|dandruff shampoo
223553919|NCT03287882|DIETARY_SUPPLEMENT|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
223553920|NCT03287882|BEHAVIORAL|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
224132157|NCT00039195|DRUG|carboplatin|
224132158|NCT00039195|DRUG|cyclophosphamide|
224132159|NCT00039195|DRUG|doxorubicin hydrochloride|
223553921|NCT04414813|BIOLOGICAL|Human Amniotic Epithelial Stem Cells|Stereotactic transplantation of hAESCs for participants with PD.
223553922|NCT04277546|DRUG|Brazikumab Maintenance Dose|Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
224132160|NCT00039195|DRUG|etoposide|
224132161|NCT00039195|DRUG|ifosfamide|
223553923|NCT04277546|DRUG|Brazikumab Induction Dose|Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
223553924|NCT04817475|OTHER|Point-of-care ultrasound with tele-supervision|Point-of-care ultrasound of patients with a out-of-hospital cardiac arrest will be performed with tele-supervision.
223553925|NCT03794440|DRUG|Sintilimab|200mg IV d1， Q3W
223553926|NCT03794440|DRUG|IBI305|15mg/kg IV d1， Q3W
223553927|NCT03794440|DRUG|Sorafenib|400mg PO BID
223553928|NCT02968446|DIETARY_SUPPLEMENT|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
223553929|NCT02968446|DIETARY_SUPPLEMENT|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
223553930|NCT02968446|DRUG|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
223553931|NCT02697981|BEHAVIORAL|nutrition counseling|nutrition counseling and guidance.
223553932|NCT00758693|DRUG|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
223553933|NCT00758693|DRUG|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
224132162|NCT00039195|DRUG|prednisone|
224132163|NCT00039195|DRUG|vincristine sulfate|
224132164|NCT00039195|PROCEDURE|peripheral blood stem cell transplantation|
224132165|NCT00039195|RADIATION|radiation therapy|
224297501|NCT05537194|DRUG|dihydropyridine calcium channel inhibitors use|administration of dihydropyridine calcium channel inhibitors
224297502|NCT04289597|DIAGNOSTIC_TEST|Distance between hyoid bone-skin (DSHB)|Distance between hyoid bone-skin
223403010|NCT06193317|DEVICE|Transauricular vagus nerve stimulation (taVNS)|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN).
223735597|NCT01573975|DRUG|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
223735598|NCT01573975|DRUG|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
223735599|NCT06347614|PROCEDURE|Two-step Radical Prostatectomy|The first step was the enucleation of the hyperplastic adenoma, followed by the anterograde radical prostatectomy of residual tissue
223735600|NCT04258722|OTHER|Resuscitation Personnel|Type of resuscitation team
223735601|NCT00303277|DRUG|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
223735602|NCT00303277|DRUG|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
223735603|NCT04352504|OTHER|Almond|Consume 1.5 oz. serving almonds (246 calories) daily for 12 weeks
223735604|NCT04352504|OTHER|Pretzel|Consume 2 oz. serving of pretzels (216 calories) daily for 12 weeks
223735605|NCT01636804|DEVICE|Quicksite|St. Jude Medical produced lead called Quicksite
223735606|NCT01636804|DEVICE|Quickflex|St. Jude Medical produced lead called Quickflex
223735607|NCT04081311|DEVICE|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
223735608|NCT06204718|OTHER|Standard pelvic floor exercises|Pelvic floor muscle exercises will be given as 2 separate exercises including fast and slow contractions. For fast contractions, participants will be asked to contract their pelvic floor muscles strongly, hold them contracted for 5 seconds, and then relax them. For slow contractions, participants will be asked to gradually contract the pelvic floor muscles, hold them at maximum contraction for 5 seconds, and relax them gradually. Participants will be asked to perform 10 slow contractions after every 10 fast contractions. The aim is to train strength, coordination, endurance, and symmetry of pelvic floor muscles, motor learning and control, dynamic lumbopelvic stability, pelvic floor, and abdominal co-contraction. Every day, 10 fast, and 10 slow contractions with a total of 20 repetitions will be applied without changing the number by modifying the exercises every week. It will be applied for a total of 12 weeks.
223735609|NCT06204718|OTHER|Involuntary reflexive pelvic floor exercises|Reflexive exercises (jump, squat jump, etc.) with 20 repetitions per day will be applied to the participants for 12 weeks with modifications every week.
223735610|NCT03939884|DRUG|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
223735611|NCT03939884|DRUG|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
223735612|NCT03939884|DRUG|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
223735613|NCT04472624|OTHER|Fasting|Acute fasting for 72 hours
223735614|NCT04472624|OTHER|Ketogenic diet|Intake of a ketogenic diet for 14 days
223735615|NCT01361464|DRUG|Tipifarnib|Given PO
223735616|NCT01361464|OTHER|Laboratory Biomarker Analysis|Correlative studies
223735617|NCT04617444|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223735618|NCT04617444|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
223735619|NCT04489212|OTHER|Medical Chart Review|Review of medical chart
223735620|NCT04489212|OTHER|Patient Observation|Undergo observation
223735621|NCT04489212|OTHER|Quality-of-Life Assessment|Ancillary studies
223735622|NCT04489212|OTHER|Questionnaire Administration|Ancillary studies
223735623|NCT04520737|BEHAVIORAL|Physical Prehabilitation|The prehabilitation program consists of the following interventions: in-hospital high-moderate intensive exercise training, nutritional assessment and high-protein supplementation, smoking cessation, psychological support and Comprehensive Geriatric Assessment.
223735624|NCT00671502|DRUG|Carisoprodol SR|700 mg twice daily
223735625|NCT00671502|DRUG|Carisoprodol SR|500 mg twice daily
223735626|NCT00671502|DRUG|Placebo|Placebo tablet
223735627|NCT05778123|OTHER|Type of disease|Different types of pathogen: brain injury by trauma or hydrocephalus due to various diseases.
223735628|NCT01537744|DRUG|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~1. Each cycle will last 28 days.~2. Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~3. On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~4. Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
223735629|NCT05047510|DRUG|Anti-GPC3-IRDye800CW|Drug Injection: Anti-GPC3-IRDye800CW
223735630|NCT02651727|DRUG|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
223735631|NCT02651727|DRUG|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
223403011|NCT04756882|DRUG|AbobotulinumtoxinA 500 UNT|"Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes"
223403012|NCT06492759|RADIATION|Radiation Therapy|Undergo radiation therapy
223403013|NCT06492759|BIOLOGICAL|Pembrolizumab|Given IV
223553934|NCT05600361|DRUG|hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy|In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
223553935|NCT01279811|OTHER|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
223553936|NCT00001335|DRUG|ADR-529|
223553937|NCT00001335|DRUG|Topotecan|
223553938|NCT00001335|DRUG|G-CSF|
223553939|NCT02450435|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
223553940|NCT02450435|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
223553941|NCT01296893|BEHAVIORAL|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
223553942|NCT05435807|BEHAVIORAL|Therapeutic Neuroscience Education|Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
223553943|NCT04071431|OTHER|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
223553944|NCT04508933|DEVICE|Extravascular Lung Water Index|Measurement of the EVLWI
223553945|NCT04508933|DEVICE|Pulmonary Vascular Permeability Index|Measurement of the PVPI
223553946|NCT01919073|BEHAVIORAL|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
223553947|NCT01919073|BEHAVIORAL|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
223403014|NCT06492759|DRUG|Nab-paclitaxel|Given IV
223553948|NCT02463396|BEHAVIORAL|MBCT for ADHD|
223553949|NCT01301287|DRUG|Chlorella|
223553950|NCT01168830|DEVICE|AMS-3.0|
223553951|NCT01650649|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
223553952|NCT01650649|DRUG|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
223403015|NCT06492759|DRUG|Paclitaxel|Given IV
223403016|NCT06492759|DRUG|Carboplatin|Given IV
223403017|NCT06492759|DRUG|Gemcitabine|Given IV
223403018|NCT06492759|PROCEDURE|Biopsy|Undergo biopsy
223403019|NCT06492759|PROCEDURE|Computed Tomography|Undergo CT
223403020|NCT06492759|PROCEDURE|Bone Scan|Undergo bone scan
223403021|NCT06492759|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223403022|NCT06492759|OTHER|Medical Chart Review|Ancillary studies
223735632|NCT02651727|DRUG|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
223735633|NCT03007381|DRUG|Ketorolac Tromethamine|Intravenous analgesic
224297503|NCT04289597|DIAGNOSTIC_TEST|Vocal cord anterior commissura-skin distance (DSAC)|Vocal cord anterior commissura-skin distance
223735634|NCT03007381|DRUG|Normal Saline|Sham comparator
223735635|NCT04855825|DEVICE|Robotic Exoskeleton Rehabilitation|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
223735636|NCT04855825|OTHER|Conventional Gait Therapy|Participants will be randomly assigned to one of the two groups. Each participant will receive 8 sessions of gait rehabilitation and therapy via traditional therapy techniques of using the robotic exoskeleton. This training will be provided by a licensed physical therapist.
223735637|NCT03736291|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
223735638|NCT01898728|DRUG|topical povidone-iodine after premedication with topical liquid eye drops|
223735639|NCT01898728|DRUG|topical povidone-iodine after premedication with topical gel|
224022315|NCT05332431|DEVICE|Optical coherence tomography (OCT)|"Patient with different types of migraine and age and sex matched control group will be subjected to OCT in the ophthalmology department in Assiut University Hospital to assess the following parameters:~Optic nerve head parameters and retinal nerve fibre layer thickness and measuring macular thickness in migraine patients will be measured using optical coherence tomography (OCT) after pupillary dilatation. Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°) will be measured by OCT."
224132166|NCT03516019|OTHER|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
224132167|NCT03516019|OTHER|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
224132168|NCT03516019|OTHER|am notices|notifications sent at 7 am.
223735640|NCT01106898|DRUG|cyclophosphamide|Given IV
223735641|NCT01106898|DRUG|paclitaxel|Given IV
223735642|NCT01106898|BIOLOGICAL|trastuzumab|Given IV
223735643|NCT01106898|OTHER|laboratory biomarker analysis|Correlative studies
223735644|NCT01722071|DRUG|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
223735645|NCT01722071|DRUG|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
223735646|NCT04348929|OTHER|Self-administered questionnaires|Self-administered questionnaires once during the post-natal hospitalization and a second time 7 to 9 weeks after the delivery (at home)
223735647|NCT02671994|OTHER|G8 screening|
223735648|NCT02671994|OTHER|Geriatric assessment|
223735649|NCT03463343|OTHER|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
223735650|NCT03463343|OTHER|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
223735651|NCT03463343|OTHER|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
223735652|NCT00541034|BIOLOGICAL|rituximab|
223735653|NCT00541034|DRUG|cyclophosphamide|
223735654|NCT00541034|DRUG|pentostatin|
223735655|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with fish oil capsules (3 capsules daily. Containing EPA+DHA: 1.8 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: EPA+DHA: 1.8 g.
223735656|NCT05068557|DIETARY_SUPPLEMENT|Dietary plan along with chia/linseed oil capsules (3 capsules daily. Containing ALA 1.6 g).|Subects within the Intervention group will be provided with a dietary plan along with fish oil capsules. Subjects will be asked to consume three capsules per day. Every capsule contains: ALA 1.6 g).
223735657|NCT00002667|OTHER|cytology specimen collection procedure|
223735658|NCT00002667|OTHER|immunoenzyme technique|
223735659|NCT00002667|PROCEDURE|study of high risk factors|
223735660|NCT02392741|OTHER|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
223735661|NCT01929850|PROCEDURE|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
223735662|NCT01929850|BEHAVIORAL|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
223735663|NCT01505868|DRUG|Cabazitaxel|Given IV
223735664|NCT01505868|DRUG|Carboplatin|Given IV
223735665|NCT01505868|OTHER|Laboratory Biomarker Analysis|Correlative studies
223735666|NCT01382979|BEHAVIORAL|AlcoholEdu for College|Online course for college freshmen.
223735667|NCT02062879|DRUG|Ketamine|Ketamine administered as patient-controlled analgesia.
223735668|NCT02062879|DRUG|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
223735669|NCT02188212|DEVICE|NobelProcera Crown Shaded Zirconia|
223735670|NCT01692327|DIETARY_SUPPLEMENT|High fat meal|
223735671|NCT01410045|PROCEDURE|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
223735672|NCT01894451|DRUG|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
224022316|NCT02033161|BEHAVIORAL|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
223403023|NCT03390023|BEHAVIORAL|Focus Group|Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.
223403024|NCT01146119|BIOLOGICAL|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
223403025|NCT01146119|BIOLOGICAL|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
223403026|NCT01146119|BIOLOGICAL|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
223403027|NCT01146119|BIOLOGICAL|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
224022317|NCT02865980|OTHER|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
223403028|NCT03415932|BEHAVIORAL|health education|Health information by a multimodal team
223403029|NCT04652115|DRUG|Defibrotide|Deibrotide via IV
223553953|NCT04839458|DEVICE|Dental Prescale II|"The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end."
223553954|NCT00356772|DRUG|Azithromycin|
224132169|NCT03516019|OTHER|pm notices|notifications sent at 7 pm.
224132170|NCT03516019|OTHER|weekday notices|notifications sent on Wednesday
223553955|NCT05066152|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG (ATCC 53103)|One probiotic drop contained a formulation of 1x109 Cfu Lactobacillus rhamnosus GG (LGG; ATCC 53103)
224132171|NCT03516019|OTHER|weekend notices|notifications sent on Saturday
223403030|NCT00314340|BEHAVIORAL|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
223403031|NCT00314340|DRUG|ER Morphine|
223403032|NCT00314340|DRUG|hydrocodone plus acetaminophen|
223403033|NCT00314340|DRUG|placebo|
223553956|NCT05066152|DIETARY_SUPPLEMENT|Placebo|Carrier material of probiotic product, not containing bacterial strain, similar appearance as the probiotic
223403034|NCT03227289|OTHER|Stayed in NRDS|The neonates with NRDS are stayed in NRDS.
223403035|NCT03227289|OTHER|Converted to ARDS|The neonates with NRDS are converted to ARDS.
223403036|NCT00916669|DRUG|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
223403037|NCT00916669|DRUG|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
223403038|NCT00916669|DRUG|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
223403039|NCT00607620|BEHAVIORAL|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
223553957|NCT00751959|DRUG|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
223553958|NCT00751959|DRUG|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
223553959|NCT04147429|BEHAVIORAL|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
223553960|NCT04691245|DEVICE|3D US|3D US guided access to femoral artery
223553961|NCT04691245|DEVICE|2D US|2D US guided access to femoral artery
223553962|NCT00887367|DRUG|GSK598809|Two 175 mg doses of GSK598809 will be given.
224132172|NCT02110121|DEVICE|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
224132173|NCT02110121|DEVICE|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
224132174|NCT02303951|DRUG|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
224132175|NCT02303951|DRUG|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
224132176|NCT02303951|DRUG|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
224132177|NCT00944606|DIETARY_SUPPLEMENT|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
224132178|NCT00944606|OTHER|Placebo candy|candy gum drops
223735673|NCT01894451|PROCEDURE|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
223735674|NCT01894451|PROCEDURE|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
223735675|NCT01894451|PROCEDURE|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
224022318|NCT02865980|OTHER|Betadine|in control group, will be washed the Catheter with Betadine
224297504|NCT04289597|DIAGNOSTIC_TEST|minimum distance of the trachea to the skin at the level of suprasternal notch|Distance of the trachea to the skin at the level of suprasternal notch
223403040|NCT01620138|DRUG|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
223735676|NCT02289079|DRUG|Bupivacaine|
223403041|NCT01620138|DRUG|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
223403042|NCT05487443|DRUG|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors|Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors for first-line treatment of advanced biliary malignancies
223553963|NCT00887367|OTHER|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
223553964|NCT05163327|PROCEDURE|Oxygen-enhanced Cardiac MRI|The MRI scan will include assessment of cardiac function. Myocardial magnetic properties (T1, T2, T2\*) will be measured while patients are breathing room air, oxygen and during an infusion of adenosine. The scan will last for approximately 60 minutes. Prior to the scan patients will have an intravenous cannula (venflon) placed in an arm vein.
223553965|NCT02989116|BEHAVIORAL|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
223553966|NCT02989116|BEHAVIORAL|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
223553967|NCT02989116|BEHAVIORAL|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
223553968|NCT02989116|BEHAVIORAL|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
223553969|NCT02989116|GENETIC|Saliva collection|Collection of a saliva sample for genotyping
223553970|NCT02989116|PROCEDURE|Brain Magnetic Resonance Imaging|Structural and functional MRI
223553971|NCT02989116|BEHAVIORAL|Cognitive testing|Battery of cognitive and academic tasks on executive functions
223735677|NCT02289079|DRUG|liposomal bupivacaine|
223735678|NCT03163550|DRUG|ACHN-383|Oral dose
224022319|NCT02743156|PROCEDURE|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
224022320|NCT02743156|PROCEDURE|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
224022321|NCT00831337|DIETARY_SUPPLEMENT|VSL3|2 times daily 450 billion live bacteria (in each saschet)
224022322|NCT02754986|OTHER|Analysis of the holter electrocardiogram|
224297505|NCT04289597|DIAGNOSTIC_TEST|Thyroid isthmus-skin distance (DSI)|Thyroid isthmus-skin distance
224297506|NCT04289597|DIAGNOSTIC_TEST|Skin-epiglottic distance (DSE)|Skin-epiglottic distance
224297507|NCT01877044|DIETARY_SUPPLEMENT|NAXUS|
223553972|NCT04621994|OTHER|Dermabond|Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
223553973|NCT04621994|OTHER|Steri Strips|Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
223553974|NCT02382874|BIOLOGICAL|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
223553975|NCT04802031|BIOLOGICAL|Rapid Infusion Isatuximab|Given IV
224297508|NCT01877044|DIETARY_SUPPLEMENT|Placebo|
223735679|NCT03163550|DRUG|ACHN-789|Oral dose
223735680|NCT03163550|DRUG|Placebo|Oral dose
223735681|NCT02922608|OTHER|simulation practice|simulation session
223735682|NCT00110825|BEHAVIORAL|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
223735683|NCT04203953|OTHER|Early mobilization program|Early mobilization will be defined as any active exercise where the patients could assist with the activity using their own muscle strength and control that occurred within the first 7 days of trauma ICU admission and will be intended to maintain or restore overall function as well as being scored using the ICU mobility scale.15 The ICU mobility scale includes rolling, bridging, sitting, standing and walking, and upper and lower limb flexion and extension. In-bed therapies will include active or active-assist range of motion, bridge exercise, quadriceps setting, straight leg raising, rolling exercises and facilitation.
223403043|NCT06150937|BEHAVIORAL|AEGIDA intervention arm|The intervention arm has 4 sessions facilitated one-on-one by trained staff and lasting \~40 minutes. The first session focuses on establishing rapport, assessing HIV risk, and educating/training participants on HIV self-testing/PEP/PrEP. The second session on peer education/training, barriers to and facilitators of testing, and supporting peers in receiving reactive and/or indeterminate HIV test results, as well as self-care. The third session on stigma and discrimination and techniques to cope with and resist stigma. The final session is a culminating one focused on reviewing key skills and health promotion planning conducted in first three sessions. The intervention arm applies anti-intersectional stigma, empowerment, and harm reduction approaches. All participants will receive/have access to HIV self-test kits every three months.
223403044|NCT06150937|BEHAVIORAL|AEGIDA control arm|The control arm has 4 sessions via one-on-one facilitation by a trained facilitator and lasting \~40 minutes. It includes basic information on self-screening for common adverse health conditions among women in Kazakhstan, including STIs and HIV, as well as information on testing and risk reduction. All participants will receive/have access to HIV self-test kits every three months.
223403045|NCT02647008|DEVICE|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
223403046|NCT01444664|PROCEDURE|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
223553976|NCT04573439|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary supplement: Protein intake|"Oral consumption of hourly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates and fats from a protein-free formula mixture.~The last 4 meals will contain labelled 13C phenylalanine."
223553977|NCT05954208|OTHER|Vısual Arts Group Therapy Based On Watson's Human Care Model|VAGT-WHCM was applied to the intervention group, consisting of six sessions, lasting 90 minutes on average, once a week in three groups.
223553978|NCT05954208|OTHER|Ongoing treatment|The control group participated only in the routine follow-up, treatment and practices in the institution.
223553979|NCT00776542|DRUG|Minocycline 100mg Tablets|
223553980|NCT06104007|DEVICE|Genoss® DCB|This study includes patients with coronary in-stent restenosis (ISR) who have undergone percutaneous coronary intervention (PCI) according to standard treatment protocols using the Genoss® DCB and have agreed to participate in the clinical research. The decision on which drug-coated balloon (DCB) to use during PCI is entirely based on the patient's condition and the characteristics of the coronary lesions identified through angiography. Thus, it's not possible to determine in advance to use the Genoss® DCB before the procedure, nor can the number of drug-coated balloon catheters to be used during the procedure be known or decided upon beforehand.
223553981|NCT04413214|DRUG|Carrimycin|The study involves three dose groups: 200mg, 400mg and 600mg. Three patients are planned for each dose group. Starting from the low dose group, the treatment to three patients in the 200mg dose group: 200mg of Carrimycin after meals every morning (po) for three weeks, and then discontinue for one week, the tolerance and efficacy evaluation will be performed after the 4 weeks. DLT will be recorded during the 4 weeks.
223553982|NCT01060904|DRUG|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
223553983|NCT01060904|DRUG|doxorubicin|25 mg/m2 IV every 2 weeks
223553984|NCT01060904|DRUG|vinblastine|6 mg/m2 IV every 2 weeks
223553985|NCT01060904|DRUG|dacarbazine|375 mg/m2 IV every 2 weeks
223553986|NCT01060904|DRUG|bleomycin|10 units/m2 IV every 2 weeks
223553987|NCT01060904|DRUG|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
223553988|NCT00729911|PROCEDURE|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
223553989|NCT00729911|DRUG|Amiodarone|Taken orally on a daily basis.
223735684|NCT01105195|OTHER|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
223553990|NCT04351607|DIETARY_SUPPLEMENT|Oleovital® Eisen Forte|60 mg daily oral Supplementation for 3 to 6 weeks
223553991|NCT06389344|DRUG|Esketamine|Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
223553992|NCT06389344|DRUG|normal saline|Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
223553993|NCT06385379|DEVICE|WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system|The WeFlow-Tribranch embedded aortic Triple-branch arch Stent Graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system, the aortic extension stent graft system and the branch stent system.
223735685|NCT01105195|OTHER|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
223735686|NCT04741061|BIOLOGICAL|Sputnik Light|"Sputnik-Light vector vaccine:~Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose."
223735687|NCT04741061|OTHER|Placebo|Placebo
223735688|NCT05001074|DRUG|Extended release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
223403047|NCT04025099|OTHER|Internal Cues|"The intuitive eating curriculum that was pilot tested and adapted has been modified for use for the Internal Cues group with college-aged females for delivery over a 10-week time period.~The classes will be delivered by two Registered Dietitians and Certified Intuitive Eating Counselors from the University of Delaware, Julia Katcher and Maryann Eastep.~During the Internal Cues group's intuitive eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn the intuitive eating principles taught in class.~The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Jones, RYT."
223403048|NCT04025099|OTHER|External Cues|"The 10-week traditional healthy weight program for the External Cues group was created by a Graduate Assistant based on MyPlate principles.~The External Cues classes will be delivered by two Registered Dietitians from the University of Delaware, Julia Katcher and Maryann Eastep.~During the External Cues group's healthy eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn how to properly portion their meals to meet their caloric needs, in line with traditional education about weight control.~Students randomized to the External Cues group will receive a UD fitness pass and will be able to choose from select cardio-based fitness classes in order to meet public health recommendations for physical activity."
223403049|NCT05316207|OTHER|Telenursing|From the end of the first week after discharge to the end of the first month, patients were counseled over the phone during the home process. Complications were followed up.
223403050|NCT04273347|OTHER|standard of care for patient with brain trauma and spinal cord injury|neurological examination, examination of articulation, infectious status, respiratory status, inflammatory status,kinesitherapy
223403051|NCT04268771|BIOLOGICAL|Experimental: Arm A: DRL_RI|Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
223403052|NCT04268771|BIOLOGICAL|Arm B: Rituxan®/Mabthera®|Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
223403053|NCT03602378|DIAGNOSTIC_TEST|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
223403054|NCT03602378|DEVICE|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
223403055|NCT03602378|DEVICE|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
223403056|NCT03602378|DEVICE|AGE reader|for measuring Advanced Glycation End products (AGEs)
223403057|NCT01982513|DEVICE|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
223403058|NCT00483015|BEHAVIORAL|smoking|
223403059|NCT00279071|DEVICE|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
223403060|NCT02551562|OTHER|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
223403061|NCT02551562|OTHER|Placebo|Basic skin care regimen
223403062|NCT00141492|DRUG|Androgel (testosterone gel)|
223403063|NCT01237574|OTHER|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
223403064|NCT00006429|PROCEDURE|body weight-supported treadmill training|
223403065|NCT03970629|DEVICE|PERSONA Total Knee|Primary Total Knee Arthroplasty
223403066|NCT00449865|DRUG|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
223403067|NCT00449865|OTHER|placebo|an inactive substance
223553994|NCT05640050|OTHER|Audit Implementation|The feasibility of establishing and implementing an acceptable and robust audit system with community representation at secondary health facilities to improve maternal and perinatal outcomes. The implementation phases follow the standard World Health Organization (WHO) audit system.
223553995|NCT03255889|DRUG|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
223553996|NCT03255889|OTHER|Placebo|Sunflower oil emulsion of equal calories.
223553997|NCT01201824|PROCEDURE|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
223553998|NCT04650230|DEVICE|nasal continuous positive airway pressure / nasal positive pressure ventilation (NCPAP/NPPV) and high flow nasal cannula (HFNC) devices|
223553999|NCT02942836|DEVICE|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
223554000|NCT04748679|BEHAVIORAL|Worry Intervention|The worry intervention is weekly individual therapy with a trained therapist
223554001|NCT04748679|BEHAVIORAL|Befriending|The worry intervention is weekly individual therapy with a trained therapist
223554002|NCT01901484|DRUG|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
223554003|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
223554004|NCT01802593|DRUG|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
223554005|NCT03835481|DRUG|BI 730357|Film-coated tablet
223554006|NCT03835481|DRUG|Placebo to match BI 730357|Film-coated tablet
223554007|NCT05561283|DIAGNOSTIC_TEST|Self-questionnaires|Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
224132179|NCT03979105|DRUG|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
223403068|NCT02491866|OTHER|to develop and validate a Computerized Adaptative Testing|"* Elaboration of a pool of items, based on literature review and interview with patients.~* Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~* Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~* Metrological validation of the CAT.~* Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
223403069|NCT00133848|DRUG|SB-275833 ointment, 1%|
223403070|NCT04197466|OTHER|Pelvic Floor Exercise Group|The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
223403071|NCT04197466|OTHER|Kinesio tape|Kinesio tape application will be performed by ligament technique to the sacral region.
223554008|NCT04239261|DIETARY_SUPPLEMENT|SBI|Serum-derived Bovine immunoglobulin/protein isolate 10.0 g once daily
223554009|NCT04239261|DIETARY_SUPPLEMENT|Placebo|Hydrolyzed gelatin 10.0 g once daily
223554010|NCT04180098|BEHAVIORAL|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
223554011|NCT04180098|OTHER|No intervention|Participants in the control group are placed on a waiting list.
223554012|NCT02727816|DEVICE|filcon IV I (BC 8.6)|control lens
223554013|NCT02727816|DEVICE|filcon IV I (BC 8.7)|control lens
223554014|NCT02727816|DEVICE|ocufilcon D|test lens
223403072|NCT04197466|OTHER|Electrical stimulation|External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
223403073|NCT06309992|DRUG|Survodutide|Survodutide
223403074|NCT06309992|DRUG|Placebo|Placebo matching survodutide
223403075|NCT04412031|OTHER|non applicable|non applicable
223554015|NCT02727816|DEVICE|methafilcon A (BC 8.6)|control lens
223554016|NCT02727816|DEVICE|methafilcon A (BC 8.7)|control lens
223554017|NCT02727816|DEVICE|somofilcon A|test lens
223554018|NCT03020004|DRUG|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
223554019|NCT03020004|DRUG|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
223554020|NCT03020004|DRUG|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
223554021|NCT03020004|DRUG|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)
223554022|NCT01113177|DEVICE|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
223554023|NCT00889850|DRUG|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
224132180|NCT04382859|PROCEDURE|Transversus abdominis plane (TAP) block with liposomal bupivacaine|Transversus abdominis plane (TAP) blocks are safe and effective procedures for the provision of postoperative pain management following abdominal procedures (3) and have been widely used across specialties with reduction in postoperative pain and narcotic use (4-7).
223554024|NCT00889850|DRUG|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
223554025|NCT03763695|OTHER|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
223554026|NCT03763695|OTHER|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
223554027|NCT01906411|DIETARY_SUPPLEMENT|Dopamine depletion vs. Balanced aminoacid drink|
223554028|NCT00255723|DRUG|carboplatin|Given IV
223554029|NCT00255723|DRUG|etoposide|Given IV
223554030|NCT00255723|DRUG|ifosfamide|Given IV
223554031|NCT00791050|DEVICE|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
223554032|NCT03076489|OTHER|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
223554033|NCT03076489|OTHER|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
223554034|NCT03076489|DEVICE|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
224132181|NCT01425073|OTHER|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
223403076|NCT00629252|DRUG|Sertindole|oral 12-20 mg/day
223403077|NCT00629252|DRUG|Risperidone|oral 2-6mg / day
223554035|NCT04644198|BIOLOGICAL|Convalescent Plasma Infusion|250 mls of convalescent plasma on day 1 \& 2.
224132182|NCT05475821|DRUG|ABBV-990|Oral Tablet
224132183|NCT05475821|DRUG|Placebo for ABBV-990|Oral Tablet
224022323|NCT02968082|DRUG|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
223403078|NCT05739383|DRUG|Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL|Subcutaneous injection in pre-filled syringe.
223403079|NCT05739383|DRUG|Placebo in 1.5ml|Matching placebo in 1.5ml solution for injection
223403080|NCT05509894|DRUG|Ngenla|As provided in real world practice
223403081|NCT02933385|BEHAVIORAL|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
223403082|NCT02933385|BEHAVIORAL|Web-based health discussions|Create interactions between the employees.
223403083|NCT02933385|BEHAVIORAL|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
223403084|NCT02933385|BEHAVIORAL|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
223403085|NCT02933385|BEHAVIORAL|Closing events|these aim to motivate the employees to continue into the program.
223403086|NCT02933385|BEHAVIORAL|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
223403087|NCT02933385|BEHAVIORAL|Social Health platform|
223403088|NCT02933385|BEHAVIORAL|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
223403089|NCT04969328|OTHER|ParTNer-STEPs|"The intervention is a transfer program (ParTNer-STEPs), offered to the parents 1½ - ½ year before their child´s transfer to adult care.~ParTNer-STEPs consist of~1. an informative website available for parents from recruitment until follow-up.~2. online educational events for parents. The teaching events are offered twice a year as a web based seminar with short presentations on different topics. The seminars will not be available for parents after their child has transferred to adult care.~3. transfer consultations across the paediatric and adult department. The transition consultations consist of:~   * a preparatory consultation (3-6 months before transfer) with the paediatric nurse.~  * a farewell consultation with the paediatric nurse (0-3 months before transfer).~  * a joint consultation (at transfer) where both the pediatrician and the adult physician will be present.~  * a welcoming consultation with the nurse from the adult care (0-3 months after transfer)."
223403090|NCT05916937|DRUG|omalizumab 300 mg every four weeks|"Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
223403091|NCT05916937|DRUG|omalizumab 300 mg every six weeks|"Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12."
223403092|NCT03252535|BIOLOGICAL|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
223403093|NCT03252535|BIOLOGICAL|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
223403094|NCT03252535|OTHER|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
223403095|NCT05900388|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain
223403096|NCT05900388|DRUG|Standard of care (SOC)|Retrospective cohort analysis using National health registers in Denmark and Sweden; Système National Des Données De Santé (SNDS) in France and Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primària (SIDIAP) in Spain. SOC including heparins, Vitamin K antagonists (VKAs) and Other Direct oral anticoagulants (DOACs).
223403097|NCT06966479|DRUG|Verekitug|Verekitug subcutaneous injection.
223403098|NCT06966479|DRUG|Placebo|Verekitug matching placebo.
223403099|NCT01346059|DRUG|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
223403100|NCT01346059|DRUG|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
223403101|NCT01354652|DRUG|entecavir, lamivudine|"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
223403102|NCT02613832|OTHER|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
223554036|NCT00191945|DRUG|Atomoxetine Hydrochloride|
223554037|NCT00191945|DRUG|placebo|
223554038|NCT02749201|DEVICE|Gastrisail|Light Intensity and gastric wall thickness assessment
223554039|NCT01662557|BEHAVIORAL|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
223554040|NCT01662557|OTHER|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
223554041|NCT01882387|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
223735689|NCT05001074|DRUG|Immediate release tacrolimus|de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
224022324|NCT02968082|DRUG|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
224022325|NCT04085965|BEHAVIORAL|Boys and Girls Club summer day camp|Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
223403103|NCT02613832|OTHER|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
223403104|NCT00521820|DRUG|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
223403105|NCT00521820|DRUG|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
223403106|NCT03754868|DIAGNOSTIC_TEST|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
223403107|NCT06529822|BIOLOGICAL|Synthetic long peptide personalized cancer vaccine|Neoantigen vaccines will be provided on a patient-specific basis
223403108|NCT06529822|DRUG|Poly ICLC|Poly-ICLC will be supplied by Oncovir, Inc.
223554042|NCT02674113|DRUG|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
223554043|NCT02674113|DRUG|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
223554044|NCT05293600|DRUG|Placebo|Placebo capsule 30 min before bedtime
223554045|NCT05293600|DRUG|Acetazolamide|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
223554046|NCT05293600|DRUG|Trazodone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
223554047|NCT05293600|DRUG|Atomoxetine and eszopiclone|The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
223554048|NCT03034005|DRUG|Budesonide|1600 ug inhaled daily for 6 weeks
223554049|NCT01267864|DRUG|Metoclopramide|10mg IVSS
223554050|NCT01267864|DRUG|Ketorolac|30g IVSS
223554051|NCT01267864|DRUG|Valproate|1gm IVSS
223554052|NCT03775824|DRUG|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
224022326|NCT06385431|OTHER|observational study|obeservational study with none intervention
223403109|NCT06529822|DEVICE|Signatera assay|Signatera is a clinically validated, personalized, tumor-informed, multiplex-PCR and next-generation sequencing (NGS) based clinical trial assay targeting 16 tumor-specific mutations. It is intended for the detection of ctDNA isolated from anticoagulated peripheral whole blood from post-surgical patients previously diagnosed with localized or advanced solid tumors to aid physician assessment and treatment decision-making, together with other clinical factors
223554053|NCT03775824|DRUG|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
223554054|NCT05404191|DEVICE|low level laser therapy|"Low level laser therapy will be performed for 30 min 3 times per week for 8 weeks on the wound area.~Wound area was irradiated by a red 655 nm light, 150 mW, 2 J/cm2 at the bed of the wound."
223554055|NCT05330390|DRUG|Levetiracetam|Epilepsy, treatment with levetiracetam
223554056|NCT00581399|DEVICE|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
223554057|NCT00581399|DEVICE|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
223554058|NCT02763813|DEVICE|Herbst (propulsion type oral appliance)|Oral appliance
223554059|NCT02763813|DEVICE|Retention type appliance (ORM)|
223554060|NCT02295696|BEHAVIORAL|EMMA|Consultations using dialogue tools
223554061|NCT06525688|OTHER|Bone, Serum and Plasma sample|Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
223554062|NCT00333411|DRUG|BIRT 2584 XX|
223554063|NCT00333411|DRUG|Placebo|
223554064|NCT05729113|BEHAVIORAL|Distraction technique|Distribution of an anti-stress ball before the moment of cannulation of the vascular access and instructing to place it in hand opposite the limb of the vascular access
223554065|NCT03931850|PROCEDURE|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
223735690|NCT03382392|OTHER|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
223735691|NCT02867033|PROCEDURE|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
223735692|NCT02867033|OTHER|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
223554066|NCT05992844|OTHER|KB Exercises Program|"Kinesthetic Brain Exercises will carried out for 3 weeks, lasting 45 minutes on average, 5 sessions a week, they will participate in a total of 9 sessions of kinesthetic brain exercises, 3 sessions a week lasting 30 minutes on average.~Kinesthetic Brain Exercises Program; The kinesthetic brain exercises program basically consists of 3 phases: warm-up phase, exercise phase and cool-down phase."
223554067|NCT05992844|OTHER|Conventional Rehabilitation program|Conventional Rehabilitation program; strengthening exercises, balance/gait training, Proprioceptive Neuromuscular Facilitation techniques, neuromuscular electrical stimulation.
223554068|NCT00785187|DEVICE|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
223735693|NCT02867033|PROCEDURE|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
223735694|NCT02867033|PROCEDURE|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
223735695|NCT02867033|OTHER|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
223735696|NCT02867033|PROCEDURE|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
223735697|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
223735698|NCT00680043|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
223735699|NCT00680043|DRUG|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
223403112|NCT05883293|DRUG|Cell Free Fat Extract(CEFFE)|The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
223554069|NCT02012855|BEHAVIORAL|Exercise|
223554070|NCT02012855|OTHER|Diet (meal type)|
223735700|NCT01114321|BEHAVIORAL|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
223735701|NCT01757054|DIETARY_SUPPLEMENT|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
223735702|NCT00023543|BEHAVIORAL|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
223735703|NCT00023543|BEHAVIORAL|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
223735704|NCT03263494|DEVICE|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
223735705|NCT04108520|OTHER|Exercise|Exercise with respiratory training
223403119|NCT05600283|DIAGNOSTIC_TEST|Swab kit (COBAS HPV 4800 Assay -Evalyn brush)|Patient self-sampling swab kit to collect a vaginal sample for HPV testing
223403120|NCT05600283|DIAGNOSTIC_TEST|Clinician-collection of cervical sample for HPV testing|Speculum exam and collection of a cervical specimen using standard endocervical brush and spatula placed into ThinPrep medium for HPV testing (Evalyn brush)
223735706|NCT03402789|DRUG|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
223735707|NCT03402789|DRUG|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
223735708|NCT05107687|BEHAVIORAL|Smoking cessation|"Assisted Smoking Cessation- Subject is provided professional support provided by tobacco cessation specialist.~Unassisted Smoking Cessation- Subject provided resources and attempts to quit smoking without professional support.~The subject selects their preferred intervention."
223403121|NCT06463886|BEHAVIORAL|STEP-AD|This in-person STEP-AD intervention will consist of 10 sessions. Session 1: Life Steps Adherence Session 2: Psychoeducation on the treatment model Session 3: Substance Use and Enhancing Resilience Session 4: Trauma Impact Session 5: Cognitive Restructuring Session 6: Racial Discrimination Impact and Coping Session 7: HIV Stigma Impact and Coping Session 8: Gender-related Stressors and Coping Session 9: Body Image and Healthy Relationships Session 10: Practice, Review, and Relapse Prevention. Each session lasts for about 40 to 60 minutes.
223554071|NCT01356498|BIOLOGICAL|pegloticase|8 mg intravenous infusion
223554072|NCT03954548|DEVICE|CB-17-08 CADe|CB-17-08 Augmented Endoscopy System with Computer Aided Detection (CADe) function
223554073|NCT01230190|DIETARY_SUPPLEMENT|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
223554074|NCT01230190|DIETARY_SUPPLEMENT|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
223403122|NCT06463886|BEHAVIORAL|Enhanced treatment as usual (E-TAU)|Participants assigned to the E-TAU condition will receive 10 in person sessions to ensure comparable contact time with study staff and identical incentives. The first session will consist of a session on healthy living with HIV (CDC content on HIV 101 \[highlights importance of engaging in care, adhering to medication, finding support\], nutrition, and physical activity. The remaining 9 sessions will consist of neutral (daily events) writing. Women will be asked to write a description of their plans for the next 24 hours.
223403123|NCT06509763|DEVICE|ECGI system during LBBP implant|ECGI system to create non-invasive ventricular maps during the screwing steps of the LBBP electrode
223554075|NCT00720967|PROCEDURE|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
223554076|NCT00720967|PROCEDURE|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP \>75 mmHg, CVP \> 12 mmHg, Htc \> 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at \~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
223554077|NCT00720967|PROCEDURE|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs \< 75 kg, and 4 hours if \> 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
223554078|NCT03734926|DRUG|ZSP1241|ZSP1241 tablets for oral administration.
223554079|NCT02901249|DRUG|sertraline|
223554080|NCT02901249|DRUG|Nortriptyline|
223554081|NCT02901249|DRUG|Lithium|
223554082|NCT06279117|BEHAVIORAL|therapeutic touch|Individuals who undergo therapeutic touch will receive therapeutic touch for 20 minutes 30 minutes before the exam.
223554083|NCT01541007|DRUG|Cabazitaxel|25 mg/m2 every three weeks
223554084|NCT01541007|DRUG|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
223554085|NCT02413476|PROCEDURE|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
223554086|NCT02413476|PROCEDURE|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
223554087|NCT01169701|DRUG|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
223554088|NCT01169701|DRUG|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
223554089|NCT01169701|DRUG|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
223554090|NCT01245686|BEHAVIORAL|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
223554091|NCT01846962|DRUG|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
223554092|NCT01846962|DRUG|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
223554093|NCT01846962|BEHAVIORAL|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
223554094|NCT01846962|DRUG|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
223554095|NCT00025792|DRUG|Pramipexole|
223554096|NCT03180333|DRUG|PNA|
223554097|NCT03180333|DRUG|PNA placebo|
224022327|NCT04555382|DIAGNOSTIC_TEST|Blood and Urine|Blood and urine samples are collected every twelve hours when the patients are included in the study during observation period.
223403124|NCT05966662|DEVICE|IVL with Shockwave C2+ 2Hz Coronary IVL Catheter|Lithotripsy-enabled, low-pressure balloon dilatation of severely calcified, stenotic de novo coronary arteries prior to stenting.
223403125|NCT04341597|OTHER|cervical ultrasound|All volunteer patients for whom a cervical ultrasound is indicated will have with a first operator the performing the usual technic, and with a second operator performing the trans perineal technic without being aware of the first measurement.
223403126|NCT05445609|DRUG|VLP-encapsulated TLR9 Agonist CMP-001,|Given SC or IT
223735709|NCT03855098|OTHER|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
223735710|NCT00553150|DRUG|everolimus|
223735711|NCT00553150|DRUG|temozolomide|
223735712|NCT00553150|RADIATION|radiation|
223735713|NCT03061331|DRUG|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
223735714|NCT03061331|DRUG|Placebo|No Active Drug
223735715|NCT06128395|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
223735716|NCT05491954|DEVICE|Dexcom G6|Continuous glucose monitoring
223403127|NCT05445609|BIOLOGICAL|Nivolumab|Given IV
223554098|NCT01664611|PROCEDURE|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
223554099|NCT01664611|PROCEDURE|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
223735717|NCT02447549|RADIATION|WBRT|One RT plan with whole bladder treated to standard dose.
223735718|NCT02447549|RADIATION|SART|Three plans (small, medium \& large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
223735719|NCT02447549|RADIATION|DART|Three plans (small, medium \& large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
223735720|NCT02344160|OTHER|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
223403128|NCT03831932|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223403129|NCT03831932|PROCEDURE|Computed Tomography|Undergo CT scan
223554100|NCT03279159|OTHER|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
223554101|NCT03279159|OTHER|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
223554102|NCT00241410|BIOLOGICAL|OralvacB2MPL|Comparison of different dosages of drug
223735721|NCT03128333|OTHER|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
223735722|NCT03128333|OTHER|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
223735723|NCT00696176|DRUG|STAT 3 DECOY|single administration to a head and neck tumor
223735724|NCT02484742|BEHAVIORAL|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
223735725|NCT05756374|BEHAVIORAL|OUT to IN|OUT to IN comprises 20 body-oriented biweekly 40-minute sessions facilitated by a psychomotor therapist in a pedagogical partnership with the preschool teacher. Sessions are implemented outdoors. All sessions are framed in a context of freedom and self and mutual bodily resonance, according to the following structure: First, children are invited to engage in exercise play activities. Second, children engage in ludic relaxation proposals. Finally, children are asked to reflect on their bodily experiences and express themselves through different expressive mediators. Preschool teachers also participate in a 25-hour training focused on the underlying principles of OUT to In and participate in 20 body-oriented biweekly 20-minute relaxation sessions, facilitated by a psychomotor therapist.
223735726|NCT02998840|BIOLOGICAL|B244|odorless suspension
223735727|NCT02998840|BIOLOGICAL|Vehicle|odorless suspension
223735728|NCT05181423|OTHER|Biomarkers|Different serum and radiological biomarkers neonates undergoing abdominal surgery.
223403130|NCT03831932|PROCEDURE|Magnetic Resonance Elastography|Undergo MRI
223403131|NCT03831932|DRUG|Osimertinib|Given PO
223403132|NCT03831932|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223403133|NCT03831932|DRUG|Telaglenastat Hydrochloride|Given PO
223403134|NCT03831932|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223403135|NCT06820957|PROCEDURE|Biopsy Procedure|Undergo bone marrow aspiration and biopsy
223403136|NCT06820957|PROCEDURE|Biospecimen Collection|Undergo tissue and/or blood sample collection
223403137|NCT06820957|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223403138|NCT06820957|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223403139|NCT06820957|PROCEDURE|Computed Tomography|Undergo CT
223554103|NCT03755219|PROCEDURE|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
223735729|NCT01980875|DRUG|Idelalisib|150 mg tablet administered orally twice daily
223735730|NCT01980875|DRUG|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
223735731|NCT01980875|DRUG|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
223735732|NCT05114785|DIAGNOSTIC_TEST|Multi Parametric Cardiac Magnetic Resonance|Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics
223735733|NCT02966587|BIOLOGICAL|Durvalumab|Given IV
223403140|NCT06820957|DRUG|Cyclophosphamide|Given IV
223403141|NCT06820957|DRUG|Doxorubicin Hydrochloride|Given IV
223403142|NCT06820957|PROCEDURE|Echocardiography Test|Undergo echocardiography
223403143|NCT06820957|DRUG|Etoposide|Given IV
223403144|NCT06820957|OTHER|Fludeoxyglucose F-18|Given FDG
223554104|NCT03755219|PROCEDURE|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
223735734|NCT02966587|OTHER|Laboratory Biomarker Analysis|Correlative studies
223735735|NCT02143869|DEVICE|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
223735736|NCT03195088|DRUG|BI 473494|Solution for injection
223735737|NCT03195088|DRUG|Placebo|Solution for injection
223735738|NCT02625259|DRUG|TAK-117|TAK-117 capsules
223735739|NCT02625259|DRUG|Lansoprazole|Lansoprazole capsules
224022328|NCT04803331|DIAGNOSTIC_TEST|SPIO-enhanced MRI|SPIO is peritumorally injected. A T2\*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
223403145|NCT06820957|DRUG|Ifosfamide|Given IV
223735740|NCT02625259|DRUG|TAK-117|TAK-117 tablets
223735741|NCT05941923|OTHER|respiratory critical care support|Patients in the intervention group will be received respiratory critical care support
223735742|NCT00513474|DRUG|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
223735743|NCT00513474|DRUG|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
223735744|NCT00513474|DRUG|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
223403146|NCT06820957|DRUG|Irinotecan Hydrochloride|Given IV
223403147|NCT06820957|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223403148|NCT06820957|PROCEDURE|Positron Emission Tomography|Undergo FDG PET
223735745|NCT00513474|DRUG|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
223403149|NCT06820957|OTHER|Questionnaire Administration|Ancillary studies
223735746|NCT00513474|DRUG|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
223735747|NCT00513474|DRUG|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
223735748|NCT00513474|DRUG|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
223403150|NCT06820957|RADIATION|Radiation Therapy|Undergo radiation
223403151|NCT06820957|DRUG|Regorafenib|Given PO
223403152|NCT06820957|PROCEDURE|Surgical Procedure|Undergo surgery
223403153|NCT06820957|DRUG|Vincristine Sulfate|Given IV
223403154|NCT06982235|DEVICE|Ureteroscope system|LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System with intrarenal pressure monitoring
223403155|NCT06982235|DEVICE|Laser system|Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology
223554105|NCT06421064|PROCEDURE|Perforation repair|All patients were operated with slight difference but all had perforation repaired.
223735749|NCT00513474|DRUG|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
223735750|NCT00513474|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223735751|NCT00513474|PROCEDURE|peripheral blood stem cell transplantation|
223735752|NCT00513474|RADIATION|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
223554106|NCT00389545|PROCEDURE|Intracoronary infusion of autologous bone-marrow derived stem cells|
223735753|NCT00513474|DRUG|fludarabine|Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
223554107|NCT01143363|BEHAVIORAL|resting - control|
223554108|NCT01143363|BEHAVIORAL|Moderate intensity exercise|
223554109|NCT01143363|BEHAVIORAL|High intensity intermittent training|
223554110|NCT01143363|BEHAVIORAL|Short sprint|
223554111|NCT02101996|OTHER|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
223735754|NCT00513474|DRUG|allopurinol|Allopurinol per institutional guidelines
223735755|NCT04573907|DRUG|Drug Levothyroxine 100 mcg|Administration of a 600 mcg levothyroxine dose
223735756|NCT04573907|DRUG|Drug Eutirox 100 mcg|Administration of a 600 mcg levothyroxine dose
223735757|NCT01325389|DIETARY_SUPPLEMENT|Myo-Mel|
223735758|NCT01325389|DIETARY_SUPPLEMENT|Placebo|
223735759|NCT02192814|DRUG|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
223735760|NCT02530554|DRUG|CHG|Single application
223735761|NCT04771507|DRUG|Ibrutinib|Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
223735762|NCT04432857|DRUG|AN0025|oral administration
223735763|NCT04432857|DRUG|Pembrolizumab|Infusion
223735764|NCT03228589|DIETARY_SUPPLEMENT|probiotic strain|8 weeks of treatment with probiotic strain
223735765|NCT03228589|DIETARY_SUPPLEMENT|Placebo|8 weeks of treatment
223735766|NCT01082406|DRUG|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
223403156|NCT01815775|OTHER|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
223403157|NCT06600412|DRUG|R3R01|R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.
223403158|NCT06600412|DRUG|Placebo|Please refer to arm/group description for further information.
223403159|NCT02839473|DEVICE|Castalie water spray|
223403160|NCT02839473|DEVICE|Hydrogel Hydrosorb®|
223403161|NCT05188183|DEVICE|M1 anodal home-based tDCS|During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10 mA.
223403162|NCT05188183|BEHAVIORAL|Somatosensory Training|The somatosensory training will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks. Sessions will start with relaxation exercises using a body scan technique, whereby subjects in a relaxed state will be instructed to sequentially interchange their mind to different regions of the body while perceiving it and establishing contact with the body part. Subjects will be asked to concentrate on any feeling (kinetic, kinesthetic or exteroceptive) related to each body part. Phantom exercises will involve the use of imagined movements of the phantom limb. Therefore, patients will be asked to perform general exercises with their phantom limb. Exercises will include hip, knee, ankle, and toe movements.
223403163|NCT05188183|OTHER|Usual Care|Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
223403164|NCT06980688|PROCEDURE|Propofol titration|Induction starts with propofol target-controlled Infusion (TCI) (Schnider model) at target effect-site drug concentration (Cet) 0.5-1.0 µg/mL and remifentanil TCI (Minto model) at Cet 0.5 ng/mL. If loss of consciousness (LOC) is not reached, propofol Cet is increased in 0.5-1.0 µg/mL steps. For intubation, remifentanil Cet increases up to 6.0 ng/mL.
223554112|NCT00603096|DEVICE|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
223554113|NCT05533294|DRUG|ARO-RAGE Injection|ARO-RAGE injection for sc administration
223554114|NCT05533294|DRUG|Placebo|normal saline (0.9% NaCl) by sc injection
223554115|NCT05322291|BEHAVIORAL|Mobil Application|The mobile application developed will be installed on the phones of hemodialysis patients
223554116|NCT01723046|DEVICE|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
223554117|NCT02388477|DRUG|Doxycycline|antibiotic used to treat infection
223403165|NCT06980688|PROCEDURE|Conventional propofol induction|Induction starts with propofol TCI at Cet 4-8 µg/mL and remifentanil TCI at Cet 2.5-3.5 ng/mL.
223403166|NCT05604066|DIAGNOSTIC_TEST|Magnetic Resonance (MR) Elastography|Magnetic resonance imaging (MRI) imaging technique that creates a visual map (Elastogram) to show the stiffness of body tissues
223403167|NCT05604066|DIAGNOSTIC_TEST|MRI structural imaging|MRI structural imaging will be done at the same time as MR elastography.
223554118|NCT02388477|DRUG|sugar pill|placebo with no pharmacologic effect
223554119|NCT04044196|PROCEDURE|Rotator cuff repair|Rotator cuff repair performed arthroscopically
223554120|NCT04620772|DRUG|Cyclophosphamide injection|Cyclophosphamide vs placebo
223554121|NCT04305509|OTHER|no intervention|no intervention
223554122|NCT00564902|DRUG|3R 3'R Zeaxanthin|8 mg per day during 12 months
223554123|NCT00564902|DIETARY_SUPPLEMENT|Lutein|9 mg of Lutein during 12 months
223554124|NCT00564902|DIETARY_SUPPLEMENT|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
223554125|NCT04031898|OTHER|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
223735767|NCT01082406|DRUG|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
223735768|NCT00437554|DRUG|Glimepiride|
223735769|NCT04878588|OTHER|patients received high resolution impedance manometry|patients received the above two examination at the same time
223735770|NCT00005972|DRUG|gemcitabine hydrochloride|
223735771|NCT00005972|DRUG|irinotecan hydrochloride|
223735772|NCT02890446|BEHAVIORAL|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
223735773|NCT06459908|OTHER|Robot Glove Hand Training|Robot Assisted group will perform hand exercises with the help of robotic glove assistance for 3 times per day/ 4 times per week, 45 minutes per session for 6 consecutive weeks. Total Number of Sessions will be 72 Hours.
223735774|NCT06459908|OTHER|Conventional Hand Rehabilitation Exercises|Conventional therapy group will perform hand exercises without the help of robotic gloves 3 times per day/ 4 times per week, 45 minute session for 6 consecutive weeks.Total number of sessions will be 72.
223403168|NCT03945240|PROCEDURE|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, \~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
223403169|NCT03945240|PROCEDURE|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, \~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
223403170|NCT03945240|PROCEDURE|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, \~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~* Subgroup 1: 10 minutes at 5 mW~* Subgroup 2: 10 minutes at 15 mW~* Subgroup 3: 10 minutes at 32 mW~* Subgroup 4: 15 minutes at 5 mW~* Subgroup 5: 15 minutes at 15 mW~* Subgroup 6: 15 minutes at 32 mW"
223403171|NCT04048239|PROCEDURE|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
223403172|NCT04048239|OTHER|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
223735775|NCT05328791|BEHAVIORAL|Dietary and mindfulness intervention|"Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program"
223403173|NCT04048239|OTHER|electromyograph|electromyographic verification of the facial nerve
223403174|NCT05754190|DEVICE|SOMA pain manager smartphone application|SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
223403175|NCT06860594|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223554126|NCT06041009|DIAGNOSTIC_TEST|Pancreatic elastase-1 in blood serum|Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
223554127|NCT03539393|DRUG|Fremanezumab|For patients who enter this program, the monthly dose of fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the patient's weight every 3 months.
223554128|NCT04767581|DRUG|KHK7791|oral administration
223554129|NCT04767581|DRUG|Placebo|oral administration
223554130|NCT02723916|BEHAVIORAL|ezParent Program|Tablet-based behavioral parent training program.
223554131|NCT02723916|BEHAVIORAL|Health-e Kids Control App|Tablet based health promotion information App
223735776|NCT02987920|DRUG|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
223735777|NCT02987920|DRUG|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
223735778|NCT02987920|DRUG|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
223403176|NCT06860594|PROCEDURE|Computed Tomography|Undergo CT
223403177|NCT06860594|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223403178|NCT06860594|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223554132|NCT06367166|DRUG|"Venarus® (diosmin and hesperidin)"|"Venarus® (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months"
223554133|NCT06367166|PROCEDURE|Endovenous laser ablation (EVLA) with miniphlebectomy|Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.
223554134|NCT06367166|OTHER|Elastic compression|All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment
223554135|NCT06367166|OTHER|Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores|The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment
223554136|NCT06643858|OTHER|No intervention|This study does not involve any interventions.
223554137|NCT05613322|DIAGNOSTIC_TEST|Resistell Phenotech|Resistell Phenotech IVD device used to assess susceptibility of Gram negative bacteria to antibiotics.
223735779|NCT02987920|DRUG|Oxycodone|Multimodal analgesic regimen to Group A and Group B
223735780|NCT02987920|DRUG|Celecoxib|Multimodal analgesic regimen to Group A and Group B
223735781|NCT02987920|DRUG|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
223735782|NCT02987920|DRUG|Ketorolac|Multimodal analgesic regimen to Group A and Group B
223735783|NCT02987920|DRUG|Gabapentin|Multimodal analgesic regimen to Group A and Group B
223735784|NCT02987920|DRUG|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
223735785|NCT02707250|DRUG|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
223735786|NCT02707250|DRUG|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
223735787|NCT02707250|DRUG|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
223735788|NCT02707250|DRUG|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
224297509|NCT06524856|DEVICE|Lung Master (Pulmonary Exerciser)|During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.
224297510|NCT01370213|DRUG|Preparative Regimen|"Preparative Regimen:~1\) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
223735789|NCT04915833|DIAGNOSTIC_TEST|Standard high-definition colonoscopy|"Evaluation of the colonic mucosa with a high definition colonoscope (EPKi7010 video processor).~The endoscopy images will be seen on a 27inch, flat panel, high-definition LCD monitor (Radiance™ ultraSC-WU27-G1520 model) only by one expert endoscopist, randomly assigned.~The number, location and polyps' features (Paris classification) will be recorded by the operator. If a polyp is detected, the endoscopist will remove the polyp endoscopically with a cold snare and forceps biopsy."
224022329|NCT03735212|BEHAVIORAL|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
224297511|NCT01370213|BIOLOGICAL|NK Cells|CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
224297512|NCT01370213|DRUG|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
224297513|NCT01370213|BIOLOGICAL|CD34 Graft/Anti-thymocyte globulin|Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
224297514|NCT01370213|BIOLOGICAL|Donor TCR α/β-depleted Graft/ATG|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
224297515|NCT04647669|DRUG|Remdesivir|200 mg intravenous loading dose on Day 1, and 100mg intravenous once-daily for subsequent doses from Day 2 up to Day 10.
224297516|NCT04647669|DRUG|Acalabrutinib|100 mg capsules twice daily every 12 h for 10 days taken with or without food.
224297517|NCT04647669|DRUG|Interferon beta-1a|Interferon ß-1a will be administered intravenously at the dose of 10 μg once daily for 6 days if oxygen dependent or subcutaneously at 44 ug Day 1, Day 3, and Day 6
224297518|NCT04647669|OTHER|Standard of Care|Treatment according to local hospital protocol
224297519|NCT00488670|DRUG|Escitalopram|See Detailed Description.
224297520|NCT00568815|DRUG|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
224297521|NCT00953641|DRUG|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
224297522|NCT00953641|DRUG|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
224297523|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder \[one 20 U, two 20 U and one 40 U cartridges)
224297524|NCT01365117|DRUG|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder \[one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)\])
224297525|NCT04463303|OTHER|lung ultrasound|patient with or without weaning induced pulmonary adema
224297526|NCT05297695|DRUG|Triple therapy for H. pylori infection|Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks
224297527|NCT01283594|DRUG|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
224297528|NCT01283594|DRUG|Placebo|White-coated, modified-oval placebo tablets.
224297529|NCT01283594|DRUG|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
224297530|NCT01283594|DRUG|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
224297531|NCT01283594|DRUG|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
224297532|NCT01283594|DRUG|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
224297533|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
224297534|NCT01704794|DRUG|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
224297535|NCT01704794|DIETARY_SUPPLEMENT|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
224297536|NCT01071447|OTHER|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
223403179|NCT06860594|DRUG|Triapine|Given PO
223403180|NCT06998680|OTHER|VitaGreen Capsule A+VitaGreen Tonic|VitaGreen Capsule A+VitaGreen Tonic,use 24 weeks
223403181|NCT06998680|OTHER|VitaGreen Capsule B+VitaGreen Tonic|VitaGreen Capsule B+VitaGreen Tonic,use 24 weeks
223403182|NCT06998680|OTHER|Capsule Placebo+VitaGreen Tonic|Capsule Placebo+VitaGreen Tonic,use 24 weeks
223403183|NCT06998680|OTHER|Capsule Placebo+Tonic Placebo|Capsule Placebo+Tonic Placebo,use 24 weeks
223403184|NCT04933721|DRUG|berotralstat|BCX7353 capsules or granules administered orally once daily
223554138|NCT03334708|DIAGNOSTIC_TEST|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~* For draw amounts up to 50mL, there is no required hemoglobin threshold.~* For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing \< 50kg~* For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
224132184|NCT04544709|DRUG|Low back intradiscal injection of platelet rich plasma (PRP)|SOC Intradiscal Lumbar PRP Procedure : A small amount of blood is drawn from you, then it is spun in a centrifuge to obtain only the platelets and few other cells. After being spun the small amount of platelets will be injected into the specific disc that is believed to be causing pain in an attempt to help reduce inflammation and pain at the site. The injection will be done under fluoroscopic guidance (x-ray) that allows very careful and precise placement of the needle.
224132185|NCT04482491|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection
224132186|NCT01503073|DEVICE|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
224132187|NCT02045212|DRUG|RPh201|SC injection twice a week during 13/26 weeks
224132188|NCT02045212|DRUG|Placebo|SC injection twice a week during 13/26 weeks
224132189|NCT04591795|DRUG|Sahastara remedy extract|The concentration of SHT extract is 100 mg per capsule
224132190|NCT04591795|DRUG|Diclofenac|Diclofenac sodium, 25 mg enteric-coated tablets
224132191|NCT00145249|DRUG|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
224132192|NCT00145249|DRUG|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
224132193|NCT03224975|OTHER|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
224132194|NCT04056364|BIOLOGICAL|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
224132195|NCT00403858|DRUG|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
223554139|NCT03334708|DIAGNOSTIC_TEST|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
223554140|NCT03334708|DIAGNOSTIC_TEST|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
223554141|NCT04116411|DRUG|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
223554142|NCT04116411|DRUG|Temozolomide 120 mg|Chemotherapy
223554143|NCT04116411|RADIATION|Radiotherapy 60 Gy|Radiation therapy
224132196|NCT00403858|DRUG|Lactulose|
224132197|NCT03188679|DEVICE|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
224132198|NCT03085212|BEHAVIORAL|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
224297537|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
223554144|NCT04116411|DRUG|Placebo oral tablet|Placebo treatment of glioblastoma
223554145|NCT03374735|DEVICE|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
223554146|NCT01423695|DRUG|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
223554147|NCT02881411|OTHER|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
223554148|NCT02881411|OTHER|Fibromyalgia coping skills programme|Exercise, education programme
223554149|NCT01295151|DRUG|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
223554150|NCT01295151|DRUG|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) \< 60kg = 500 mg~\> or equal to 60kg and \< or equal to 100kg = 750 mg \> 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
223735790|NCT04915833|DIAGNOSTIC_TEST|Colonoscopy with real-time AI assisted automated polyp detection|The same patient will be submitted to a second, same session, computed aided real-time colonoscopy using the DISCOVERY, AI assisted polyp detector. Colonoscopy will be performed by a same-level-of-expertise operator in comparison to the initial procedure. Any polyp or lesion detected with the AI system will be recorded and endoscopically removed and considered as a missed lesion from standard colonoscopy.
223735791|NCT01792674|OTHER|In situ simulation|
223735792|NCT01792674|OTHER|Off site simulation|
223735793|NCT02138760|PROCEDURE|MRI UroNav fusion biopsy|
223735794|NCT06395974|OTHER|fetal ultrasound|2D, 3D , Doppler ultrasound
223554151|NCT01295151|BIOLOGICAL|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
223735795|NCT00195676|DRUG|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
223735796|NCT03359447|DRUG|Weekly Ferrous Sulfate|Drops
223554152|NCT01295151|DRUG|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
223735797|NCT03359447|DRUG|Daily Ferrous Sulfate|Drops
223735798|NCT01189812|DRUG|Lithium Carbonate|300 mg one time per day for 4 weeks
223735799|NCT01189812|DRUG|Placebo|Take one time daily for 4 weeks
223735800|NCT01189812|DRUG|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
223735801|NCT01031940|DEVICE|macintosh laryngoscope|intubate with the macintosh laryngoscope
223735802|NCT01031940|DEVICE|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
223735803|NCT01031940|DEVICE|Airtraq device|intubate with the Airtraq device
223735804|NCT05886608|DEVICE|AI 500™ SINGLE-DOSE GEL|AI500™ SINGLE-DOSE GEL is a hydrogel to be applied to intact skin, intended to provide relief in cases of pain due to tension in muscles and adjacent tissues, to improve movement and function.
223735805|NCT03287505|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
223735806|NCT01806753|PROCEDURE|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
223735807|NCT01806753|PROCEDURE|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
223735808|NCT02891460|DEVICE|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
224022330|NCT02822586|RADIATION|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
224297538|NCT01360827|DRUG|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
224297539|NCT02014077|PROCEDURE|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
224297540|NCT02014077|PROCEDURE|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
224297541|NCT05574231|PROCEDURE|Periodontal treatment|It includes surgical and non-surgical procedures depending on patient as well as tooth level.
224297542|NCT00671073|DRUG|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
224297543|NCT00671073|DRUG|Placebo|Placebo, oral administration, once daily for 12 weeks
224297544|NCT00671073|DRUG|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
224297545|NCT00671073|DRUG|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
224297546|NCT03941353|OTHER|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
224297547|NCT03688178|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
224297548|NCT03688178|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
224297549|NCT03688178|BIOLOGICAL|Varlilumab|Varlilumab is an agonist anti-CD27 monoclonal antibody
224297550|NCT03688178|BIOLOGICAL|Td|A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
224297551|NCT03688178|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
224297552|NCT02477774|DEVICE|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
224297553|NCT00177463|DRUG|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
224297554|NCT05116748|BIOLOGICAL|COVID19 mRNA vaccine|Administration of COVID19 mRNA vaccine
223735809|NCT02891460|DEVICE|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
223403185|NCT07004998|PROCEDURE|Cricoid Pressure (30 N)|Manual application of posterior pressure on the cricoid cartilage at a standardized force of 30 newtons. The pressure is applied by a trained operator using one or two fingers, with the goal of compressing the esophagus against the cervical spine. The maneuver is performed after induction of general anesthesia and immediately before videolaryngoscopy. A still image of the glottic view is captured during pressure application.
223403186|NCT07004998|PROCEDURE|Left Paratracheal Pressure (30 N)|Manual application of pressure to the left paratracheal region, lateral to the trachea and inferior to the thyroid cartilage, at a standardized force of 30 newtons. The pressure is applied by a trained operator using the thumb or fingers. The maneuver is performed after induction of general anesthesia and immediately before videolaryngoscopy. A still image of the glottic view is captured during pressure application.
223403187|NCT06679946|DRUG|Vutrisiran|Vutrisiran administered SC q3M
223403188|NCT06871072|OTHER|Telerehabilitation|EG performed using an artificial intelli-gence (AI) application called RehBody, which detects body segments, assists in cor-recting the technique and monitoring the exercise, number of sets and repetitions done, and the adherence percentage
223403189|NCT06871072|OTHER|Exercise program|CG participants followed the exercise program and trained at home with images and videos as support.
223403190|NCT06866964|DRUG|Low-dose ASA|81 mg by mouth daily for 26 weeks
223403191|NCT07010354|DEVICE|Stenting|Endovascular treatment of stenosed or occluded iliac arteries: Permanent intraluminal placement of a covered stent
223403192|NCT06095505|DRUG|Alisertib|Alisertib enteric-coated tablets
223403193|NCT07011056|DRUG|Purinostat Mesylate for Injection|"The subjects in the experimental group will receive treatment with Purinostat Mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous infusion on days 1, 4, 8, and 11. The administration cycle lasts for 21 days, and the total treatment cycle is 6 cycles.~After 6 cycles, the investigator will assess whether the subjects can continue to benefit, whether they can sustain the treatment with the investigational drug, and adjust the frequency of continuous administration based on the evaluation results of the efficacy over these 6 cycles."
223554153|NCT01295151|DRUG|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
223554154|NCT01295151|DRUG|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
223554155|NCT01295151|DRUG|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
223554156|NCT03583359|DEVICE|Radiesse (+)|Radiesse (+) for jawlines.
223554157|NCT00375505|DRUG|Zoledronic acid|
223554158|NCT00375505|DRUG|Placebo|Placebo
223554159|NCT03329625|BEHAVIORAL|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
223554160|NCT03329625|BEHAVIORAL|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
223554161|NCT04173286|PROCEDURE|antibiotherapy|\< 7 days
223554162|NCT06299865|OTHER|Ungrouped|Ungrouped
223554163|NCT03092999|DRUG|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
223554164|NCT00002050|DRUG|Thymopentin|
223554165|NCT00801073|PROCEDURE|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
223554166|NCT03907176|DRUG|HTX-011|300 mg
223554167|NCT03907176|DEVICE|Luer lock applicator|Applicator for instillation
223554168|NCT03907176|DRUG|Ibuprofen|600 mg
223554169|NCT03907176|DRUG|Acetaminophen|1 g
223554170|NCT02470585|DRUG|Veliparib|Capsules for oral administration
223554171|NCT02470585|DRUG|Paclitaxel|Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
223554172|NCT02470585|DRUG|Carboplatin|Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
223554173|NCT02470585|OTHER|Placebo to Veliparib|Capsules for oral administration
223735810|NCT02022098|DRUG|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
223735811|NCT02022098|RADIATION|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
223735812|NCT02022098|DRUG|Debio 1143|Debio 1143 solution
223735813|NCT02022098|DRUG|Placebo|Matching placebo solution
223735814|NCT00051402|DRUG|Isoflavones|
224022331|NCT02822586|DRUG|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
224022332|NCT00669448|BEHAVIORAL|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
224022333|NCT00006260|DRUG|cisplatin|cisplatin IV over 30 minutes on days 1-3.
224022334|NCT00006260|DRUG|etoposide|etoposide IV over 60-90 minutes on days 1-3.
223403194|NCT07011056|DRUG|Selinexor Tablets|The recommended dose of selinexor tablets is 60 mg per administration, taken orally on the 1st and 3rd day of each week (for example, Monday and Wednesday, or Tuesday and Thursday), with a 4-week course as one treatment cycle. Patients who achieve partial response (judged by the investigator as the best expected response for the subject) or have better efficacy can switch to maintenance treatment, with a maintenance dose of 60 mg taken orally once a week.
223403195|NCT06877702|DRUG|BMS-986460|Specified dose on specified days.
223403196|NCT06880562|DEVICE|Splanchnic Nerve Denervation|Catheter-based endovascular denervation (CDN) of renal arteries and splanchnic nerves (celiac + SMA) using radiofrequency ablation
223403197|NCT06880562|DEVICE|Renal Denervation Only|Catheter-based endovascular denervation (CDN) of renal arteries only, without splanchnic nerve denervation
223403198|NCT06881823|DRUG|AAA602|\[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.
223403199|NCT06881823|DRUG|AAA802|\[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion
223403200|NCT06881823|DRUG|Gallium (68Ga) gozetotide|Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.
223403201|NCT06881823|DRUG|Piflufolastat (18F)|Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.
223403202|NCT06881823|DRUG|Flotufolastat F 18|Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.
223403203|NCT06881823|DRUG|18F-PSMA-1007|Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.
223403204|NCT07038343|DRUG|AVZO-1418|Specific dose in protocol specified schedule
223554174|NCT05771129|DEVICE|Pulse electric field ablation system developed by Zhouling (Shanghai) Medical Appliance Co., Ltd.|Pulsed electric field ablation instrument is a therapeutic instrument based on the irreversible electroporation (IRE) mechanism. The high frequency short duration energy is delivered via a disposable pulse ablation catheter through the bronchoscope and act on the bronchial mucosa, through which goblet cell hyperplasia and airway mucus secretion will be alleviated. The entire treatment consists of two procedure sessions that will be performed one month apart. The first treatment procedure consists of a baseline biopsy of the airway mucosa followed by the treatment of the right lung. The second procedure consists of a biopsy of the treated airway, followed by the left-side treatment. A third bronchoscopy will be performed three months following the first treatment and mucosa-biopsy will be conducted to evaluate the histopathological change in mucus producing cells after treatment. Subjects will also be required to fill questionnaire and complete several examinations during follow-up.
223554175|NCT03392428|OTHER|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
223554176|NCT03392428|DRUG|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
223554177|NCT05183074|DEVICE|MR-linac|1.5-Tesla MR-linac based SBRT
223735815|NCT01671189|OTHER|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
223735816|NCT01506427|RADIATION|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
223735817|NCT02331836|DEVICE|Arc Endocuff (AEC 110, 120, 130, 140)|
223735818|NCT02331836|DEVICE|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
223735819|NCT02331836|DEVICE|Standard colonoscope|
223735820|NCT02463474|BEHAVIORAL|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
223735821|NCT02970409|DEVICE|saline|catheter lock using saline
223735822|NCT02970409|DEVICE|Heparin|catheter lock using Heparin
223735823|NCT00703989|DIETARY_SUPPLEMENT|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
224022335|NCT00006260|DRUG|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
224022336|NCT00006260|DRUG|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
224022337|NCT06302517|DEVICE|BIS-guided|underwent intraoperative monitoring of BIS anesthesia depth
224022338|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
223403205|NCT07038343|DRUG|Combination Agent 1|Per label based on combination agent used
223403206|NCT07038343|DRUG|Combination Agent 2|Per label based on combination agent used
223403207|NCT07039708|BEHAVIORAL|E-MinD Life Semantic|The E-MinD Life programme is designed to teach semantic memory strategies. The memory strategies are applied to 12 common daily activities required for community living, e.g. meal preparation, laundry activities, and built into the E-MinD Life programme on a computer-based platform. The intervention runs over 9 weeks with one 45-minute individual face-to-face or online healthcare-professional-led session and two 30-minute, family-assisted home sessions per week. During the home sessions, participants will complete the same activities as those learnt during the healthcare-professional-led sessions. Family members or carers will be invited to join the healthcare-professional-led sessions as observers and support the participants in the home sessions if needed.
224022339|NCT01815138|DRUG|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
224022340|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
224022341|NCT00948051|DIETARY_SUPPLEMENT|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
223403208|NCT07039708|BEHAVIORAL|Cognitive stimulation|Participants will receive stimulation for visual attention and memory through activities such as playing a game that requires them to find missing pieces, and auditory attention and memory through activities such as remembering a song. The intervention will adopt a similar structure as the E-MinD Life Semantic group, with one 45-minute individual face-to-face or online healthcare-professional-led session and two 30-minute, family-assisted home sessions per week for 9 weeks.
223403209|NCT06719245|PROCEDURE|Targeted Muscle Reinnervation (TMR)|In short: each transected nerve is identified after amputation and is dissected proximally for length. A nerve stimulator is used to identify functional motor nerve branches. Near the point where the motor branch enters the muscle, the motor nerve branch is transected and an end-to-end coaptation is performed with a nearby amputated nerve.
223403210|NCT06719245|PROCEDURE|Standard neurectomy|During the amputation a standard neurectomy will be performed based on the surgeons preference. Standard neurectomy will include cutting of the nerve, with or without traction, with or without coagulation, and with or without infiltration with a local anesthetic (i.e., ropivacaine) or phenol. Ligation of the nerve will not be allowed.
223403211|NCT06716801|DRUG|Cenobamate|Adult patients affected by epilepsy with focal-onset seizures with or without secondary generalization who have not been adequately controlled despite a history of treatment with 2 or 3 anti-seizure medications.
223554178|NCT02309658|DRUG|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
223554179|NCT02309658|DRUG|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
223554180|NCT02309658|RADIATION|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
223735824|NCT03212612|DIAGNOSTIC_TEST|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
223735825|NCT00805311|PROCEDURE|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
224132199|NCT03005977|PROCEDURE|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
224132200|NCT02512692|DEVICE|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
224297555|NCT01797484|DRUG|Ranolazine|Improvement of myocardial microcirculation
223554181|NCT01970228|DIAGNOSTIC_TEST|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
223554182|NCT04543916|DRUG|Venetoclax 50 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
223554183|NCT04543916|DRUG|Venetoclax 100 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
223554184|NCT04543916|DRUG|Venetoclax 200 MG|Escalating doses to determine recommended phase 2 dose (RP2D)
223554185|NCT04543916|DRUG|Venetoclax 400|Escalating doses to determine recommended phase 2 dose (RP2D)
223554186|NCT04543916|DRUG|Venetoclax 600|Escalating doses to determine recommended phase 2 dose (RP2D)
223554187|NCT04543916|DRUG|Irinotecan 60 mg/m2|Intravenously (IV), days 1, 8, and 15
223554188|NCT04543916|DRUG|Venetoclax (RP2D)|orally, once per day
223554189|NCT00167375|DRUG|eszopiclone 3 mg qHS|
223554190|NCT00167375|BEHAVIORAL|General cognitive/behavioral interventions for insomnia|
223554191|NCT04181229|PROCEDURE|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
223554192|NCT03497039|DRUG|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
223403226|NCT05585476|DEVICE|C02 microablative laser|The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.
223403227|NCT05585476|COMBINATION_PRODUCT|Regenerative topical treatment|It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.
223403228|NCT07042412|BEHAVIORAL|Ta'am Mustadam Intervention|"The Ta'am Mustadam intervention, guided by the BCW and BCT, will be implemented over six weeks with a four-week follow-up among adults in the CMHS canteen.~The intervention will consist of the following elements:~1. Education: The educational messages will be shared via WhatsApp on Fridays \&Tuesdays, with additional dietary tips on Wednesdays, timed before main meal. Moreover, weekly video recipes will be shared on Saturdays~2. Behavioral Practice: This component engages participants withs sustainable eating habits through biweekly cooking competitions and hands-on meal preparation activities held on Thursdays.~3. The environmental restructuring component aims to promote sustainable food choices at CMHS canteen by enhancing healthy food availability, appeal, and visibility through local produce, improved dish palatability, and visual/nutritional cues via QR codes, tray mats, and banners.~The evaluation of Ta'am Mustadam intervention will be guided by RE-AIM framework."
223735826|NCT00805311|DRUG|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
223735827|NCT05200533|OTHER|Task-sharing and shifting model between family physicians and physiotherapists|Medical consultations for acute low back pain patients are shifted from family physicians to physiotherapists.
224132201|NCT02512692|DRUG|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
224132202|NCT02512692|DRUG|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
223403229|NCT06705946|BEHAVIORAL|Aqua vest group|Participants in this group will perform Dynamic Stability Training (DST) sessions twice a week for 12 weeks while wearing an aqua vest. Each session will focus on dynamic stability exercises aimed at improving balance, lower limb joint moment distribution, and gait. Each session will last for 50 minutes
223403230|NCT06705946|BEHAVIORAL|Weight vest group|Participants in this group will perform the same Dynamic Stability Training (DST) sessions twice a week for 12 weeks, but with a weight vest instead of an aqua vest. Each session will focus on balance, lower limb joint moment distribution, and gait, lasting for 50 minutes
223403231|NCT06264531|DRUG|Bevacizumab|Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections
223403232|NCT06264531|DRUG|Placebo|NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections
223403233|NCT03875781|DRUG|Chemotherapy|"Arm A : Experimental~* Intervention Type : Drug~* Intervention Name : Modified FOLFIRINOX (experimental arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
223403234|NCT03875781|DRUG|Radiochemotherapy|"Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor."
223403235|NCT06750809|DEVICE|PermeaDerm Biosynthetic Wound Matrix|Study participants randomized (1:1) to this arm will receive PermeaDerm Biosynthetic Wound Matrix prior to skin graft.
223403236|NCT06750809|DEVICE|Frozen Human Cadaveric Allograft (FHCA)|Study participant randomized (1:1) to this arm will receive Frozen Human Cadaveric Allograft (FHCA) prior to skin graft.
223554193|NCT03497039|OTHER|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
223554194|NCT02146131|DEVICE|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
223554195|NCT02146131|DEVICE|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
223735828|NCT05200533|OTHER|Usual care|Medical consultations for acute low back pain patients are performed by family physicians
223735829|NCT05054959|OTHER|consolidation chemotherapy|6 cycles CAPOX after chemoradiotherapy
223735830|NCT05054959|OTHER|induction chemotherapy|4 cycles CAPOX before and 2 cycles CAPOX after chemoradiotherapy
223735831|NCT00717340|DRUG|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
223735832|NCT01710254|DRUG|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
223735833|NCT01710254|DRUG|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
223735834|NCT03164200|OTHER|High fat breakfast|High fat breakfast
224297556|NCT05681312|DRUG|systemic proteolytic enzyme (Tibrolin)|Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)
224297557|NCT05681312|DRUG|Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg|Amoxicillin is given with metronidazole 500mg 1\*3' Doliprane 1000mg is given 1\*1
223403237|NCT07058883|DEVICE|Juläine|Juläine is a sterile injectable implant containing poly-L-lactic acid microspheres, intended for intradermal use to improve skin depressions from acne scars.
223403238|NCT07058883|OTHER|Sterile Saline (Placebo)|Sterile saline solution used as a placebo control, administered in the same volume and schedule as Juläine.
223403239|NCT05516862|OTHER|Dragons acupuncture|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 needles placed in head, upper back, lower back and ankles."
223403240|NCT05516862|OTHER|Dragons acupressure|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and have 7 small acupressure adhesive bandages placed on head, upper back, lower back and ankles."
223554196|NCT04140786|DRUG|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
223735835|NCT03164200|OTHER|Higher carbohydrate breakfast|Higher carbohydrate breakfast
223554197|NCT02748876|OTHER|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
223554198|NCT06435988|BEHAVIORAL|Training in the pecha kucha technique|Providing labor training to pregnant women with the Pecha Kucha technique
223554199|NCT00434993|DRUG|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
223554200|NCT00434993|PROCEDURE|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
223554201|NCT00434993|DRUG|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
223554202|NCT03221465|BEHAVIORAL|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
223735836|NCT00535223|BEHAVIORAL|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
223735837|NCT00535223|BEHAVIORAL|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
223735838|NCT02953314|DRUG|TEZ|
223735839|NCT02953314|DRUG|TEZ/IVA|
223735840|NCT02953314|DRUG|IVA|
223735841|NCT04269980|OTHER|MAP|MAP
223735842|NCT02024620|BEHAVIORAL|Behavioral activation plus mobile app|
223735843|NCT02024620|BEHAVIORAL|Standard behavioral activation|
223735844|NCT02032966|PROCEDURE|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
223735845|NCT02032966|PROCEDURE|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
223735846|NCT01421758|BEHAVIORAL|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
223735847|NCT01421758|BEHAVIORAL|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
224132203|NCT04650932|DEVICE|Deep brain stimulation|Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
224022342|NCT02364791|DEVICE|standard techniques used to achieve air leak control|
224022343|NCT02364791|DEVICE|Hemopatch|
224022344|NCT03426267|DRUG|SDN-037|twice daily
224297558|NCT01421121|BIOLOGICAL|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
224297559|NCT01421121|BIOLOGICAL|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
224297560|NCT01421121|BIOLOGICAL|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
224297561|NCT01421121|BIOLOGICAL|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
224297562|NCT01421121|BIOLOGICAL|Placebo|0.5ml placebo, two doses, 28 days interval
223403241|NCT05516862|OTHER|Dragons placebo|"The treatment we are studying is supposed to help the rational and emotional brain effectively communicate, so that the emotional brain can finally realize the trauma experienced is no longer a threat. We call this re-processing. It does not take away the memory but it allows the rational brain to see the memory as just a memory without the emotional brain initiating your fight, flight or freeze system. This allows the mind to take the file off the messy desk and put it away. The treatment was named by the Chinese and is called External and Internal Dragons. According to the Chinese, the External Dragons represent all the bad (traumatic) things that happen to us. The Internal Dragons live inside us, and fight off the External Dragons.~Subject will lay on your stomach and the doctor will touch 7 points on head, upper back, lower back and ankles."
223403242|NCT06270082|DRUG|IK-595|Oral tablet administered in 28-day or 30-day cycles until treatment discontinuation criteria are met.
223554203|NCT03221465|BEHAVIORAL|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
223554204|NCT04170998|DRUG|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
223554205|NCT04170998|DRUG|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
223554206|NCT04170998|DRUG|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
223554207|NCT04170998|DRUG|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
223554208|NCT00465972|DRUG|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
223554209|NCT00465972|DRUG|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
223554210|NCT00465972|DRUG|Placebo|Placebo capsule nightly for duration of study
223554211|NCT04910529|OTHER|Yoga|Hatha yoga, which is one of the most basic yoga methods, will be applied to the students in the study. During each practice within the scope of Hatha yoga, students; breathing exercises, relaxation techniques and warm-up exercises will be applied respectively. In addition to these, asanas (yoga postures) with balance, stretching, relaxation and strengthening components will be applied to the students.
223554212|NCT04803175|DRUG|Sacubitril-Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
223554213|NCT04803175|DRUG|Valsartan|Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months. The investigator does not assign specific interventions to the study participants.
223554214|NCT02840942|BEHAVIORAL|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
223554215|NCT02840942|BEHAVIORAL|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
223554216|NCT05561816|DRUG|Hydroxymethylquinoxalindioxyde|Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
223554217|NCT05561816|DRUG|Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium|Miramistin®, topical solution 0.01% (Infamed K LLC, Russia)
223554218|NCT00861692|DRUG|argatroban|
223554219|NCT03292640|DRUG|DFD-03 (0.1% tazarotene) Lotion|DFD-03 Lotion (0.1% tazarotene) - twice daily application
223554220|NCT03292640|DRUG|DFD-03 (0% tazarotene) Lotion (Placebo)|DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
223554221|NCT01543282|DEVICE|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
223554222|NCT00061854|DRUG|soblidotin|
223554223|NCT02218697|BIOLOGICAL|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
223554224|NCT02218697|BIOLOGICAL|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
223554225|NCT02218697|BIOLOGICAL|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
223554226|NCT05521009|OTHER|Control grup, sticky tube holder|In patients using adhesive tube holders and non-adhesive tube holders, it will be investigated whether there is bacterial growth on the tube.
223554227|NCT04256278|OTHER|Spermotrend|oral administration of antioxidants for three months
223554228|NCT06291337|DRUG|Inhibition of Sweet Taste by Ibuprofen Oral Rinses|Participants rinse the mouth with ibuprofen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
223554229|NCT06291337|DRUG|Inhibition of Sweet Taste by Naproxen Oral Rinses|Participants rinse the mouth with naproxen and the impact on perceived sweet taste elicited by sugar solutions in the mouth was assessed
223554230|NCT05441215|DRUG|nirmatrelvir|nirmatrelvir/ritonavir
223554231|NCT05441215|DRUG|ritonavir|nirmatrelvir/ritonavir
223554232|NCT02886507|DIETARY_SUPPLEMENT|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
223554233|NCT02886507|DIETARY_SUPPLEMENT|Placebo|The placebo capsules contain microcrystalline cellulose.
224132204|NCT01707212|BEHAVIORAL|Pain management education|Education about pain management during infant immunization
223403243|NCT02269098|OTHER|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
223403244|NCT02155127|BEHAVIORAL|walking|
223403245|NCT01766076|OTHER|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
223403246|NCT01766076|DRUG|Placebo|PBMC collected for immune activation assays using flowcytometry
223403247|NCT00893880|DRUG|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
224132205|NCT01707212|BEHAVIORAL|No pain management education|Control - no education about pain management during infant immunization
224132206|NCT01583322|DRUG|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
224297563|NCT05099484|DRUG|The MedMilk study|This observational, pragmatic PK study will enroll lactating women who are taking medications that were prescribed by their treating medical provider or as an over-the-counter medication.
224297564|NCT05466279|DRUG|remazolam|Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.
223403248|NCT04848155|OTHER|socially assistive robot|"The intervention group will work with the ReMIND-system. This ReMIND-system consists of:~1. An existing socially assistive robot called James® that will be adapted based on the needs of the older adults and the robot's own functionality. For example, exercise videos and games to stimulate physical and cognitive activity will be developed and made available on the robot. The robot has to be programmed by the researcher using the ZBOS Control© application on a separate tablet that is connected to the robot.~2. The Keosity-app, an application specifically designed to support people in telling, documenting and sharing their life stories with others. This application will be available on the robot."
223403249|NCT04211688|BEHAVIORAL|Group Schema therapy|Bimonthly outpatient psychotherapy delivered in individual setting
223403250|NCT04211688|BEHAVIORAL|Individual Schema therapy|weekly outpatient psychotherapy delivered in group setting
223403251|NCT04903431|BEHAVIORAL|Crisis Response Planning for Suicide Risk|Crisis Response Planning is focused on creating personalized set of steps for individuals to follow in case of a crisis and includes individuals' personal warning signs of distress, behavioral coping strategies, reasons for living, social supports to contact, and contact information for professional services, including emergency services. Personalization of the Crisis Response Plan is encouraged, and individuals are instructed to handwrite each step of the Crisis Response Plan on an index card to review.
223403252|NCT02075567|PROCEDURE|Experimental|
223403253|NCT02201004|DRUG|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
223403254|NCT02201004|DRUG|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
223403255|NCT02201004|DRUG|placebo|Pharmaceutical form:tablet Route of administration: oral
223403256|NCT06414941|DRUG|Dexmedetomidine administration|atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
223554234|NCT05602454|OTHER|Digital Heart Failure Medication Titration|Story Health Platform, which is a remote, digital tool that provides treating clinicians collected data to make clinical decisions regarding heart failure medication titration.
223554235|NCT04136587|OTHER|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
223554236|NCT04380753|DRUG|AMG 510|Subjects will be enrolled and will receive AMG 510 PO QD.
223554237|NCT05892419|OTHER|No intervention|There is no intervention
223554238|NCT04979026|DEVICE|active ankle pumping with a regular watch alarm|In addition to the active ankle pumping exercise for the operative limb, the patients were reminded to exercise at specific time points with a vocal alarm and vibration through a wrist watch during the hospitalization period and at home after discharge.
223554239|NCT04979026|DEVICE|intermittent pneumatic compression|In this group, intermittent pneumatic compression was applied to the operative low limb during hospitalization, while active ankle pumping exercise was adopted without any reminder after discharge.
223554240|NCT03644225|DEVICE|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
223554241|NCT03644225|DEVICE|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
223554242|NCT02569424|BEHAVIORAL|Patient's position|Supine or Trendelenburg strict -20°)
223554243|NCT05083611|OTHER|GraMI|The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
223554244|NCT05964348|PROCEDURE|CT-Scan|semi-automated analyse by anatomical landmarks with a dedicated fully automated software
223554245|NCT00460460|DRUG|AZD4877|
223554246|NCT01948479|DEVICE|Optimised instant offloading insole|
224297565|NCT05466279|DRUG|Propofol|Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus
223403257|NCT06414941|DRUG|Dexmedetomidine plus low-dose esketamine administration|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
223403258|NCT06414941|DRUG|Dexmedetomidine plus high-dose esketamine administration|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
224297566|NCT05466279|DRUG|Midazolam|Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
224297567|NCT06098287|DEVICE|Residential mechanical ventilation system (Exhaust)|Exhaust-only ventilation system
223403259|NCT05341219|PROCEDURE|Light needle therapy|The study participants will receive 12 sessions of light needle therapy within 4 weeks using a gallium aluminum arsenide Physiolaser olympic (maximal power, 60mW; wavelength, 655 nm; area of probe, 0.008 cm2; power density, 7.5 W/cm2; pulsed-wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). Those in the experimental group received a total 135 J of energy delivered from 6 light needles being placed between LU7 and LU9. The light needle therapy was applied to each point for 15 min.
223403260|NCT05341219|PROCEDURE|Sham light needle therapy|The study participants will receive 12 sessions of sham light needle therapy, without any laser output (no stimulation), within 4 weeks using a gallium aluminum arsenide Physiolaser olympic. Those in the control group received 0 J of energy delivered from 6 light needles being placed between LU7 and LU9 for 15 min.
223403261|NCT02028663|DRUG|CJ-12420|Once daily, Oral administration
223403262|NCT02028663|DRUG|Esomeprazole|Once daily, Oral administration
223554247|NCT05329753|DEVICE|Mobile health application|Health intervention through a smartphone application that favors the process of learning
223554248|NCT00293228|DRUG|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
223554249|NCT00293228|DRUG|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
223554250|NCT04105959|DRUG|RIST4721|RIST4721 oral solution
223554251|NCT04105959|DRUG|Placebo|Placebo oral solution
223554252|NCT04068948|DRUG|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
223554253|NCT04068948|DRUG|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
223554254|NCT04068948|DRUG|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
223554255|NCT05761808|OTHER|exercises|Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. First of all, exercises to learn transversus abdominis activation will be performed in patients. They will then be included in the stretching and strengthening exercise program. Stretching and strengthening exercises were planned as dynamic abdominal bracing, finding and maintaining neutral position, and exercises on all fours. Exercise therapy will be applied by the same physiotherapist 3 days a week for 5 weeks. Patients will continue to exercise for 7 more weeks as a home program. During this period, they will be called once a week by phone.
223554256|NCT05761808|OTHER|neuromuscular electrical stimulation|NMES intensity will be planned individually according to the patients. Before being included in the study, the multifudus muscle thickness at the L4-L5 level of each patient will be measured ultrasonographically. NMES application will be applied by a specialist physiotherapist 3 days a week for 5 weeks, for a total of 15 sessions. Exercises will be applied 3 days a week for 5 weeks, accompanied by a physiotherapist. Patients will continue to exercise for 7 more weeks as a home program. In this process, patients will be called once a week by phone.
223554257|NCT03306433|DEVICE|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
223554258|NCT03021655|BEHAVIORAL|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
223554259|NCT03021655|BEHAVIORAL|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
223554260|NCT03021655|BEHAVIORAL|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
223554261|NCT01597908|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily orally
223554262|NCT01597908|DRUG|Vemurafenib|Vemurafenib 960 mg twice daily orally
223554263|NCT01597908|DRUG|Trametinib|Trametinib 2 mg once daily orally
223554264|NCT03530254|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
223554265|NCT03530254|DIAGNOSTIC_TEST|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
223554266|NCT02709577|DEVICE|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
224022345|NCT03426267|DRUG|Placebo|twice daily
224297568|NCT06098287|DEVICE|Residential mechanical ventilation system (CFIS) and air filtration upgrades|Central-fan-integrated-supply ventilation system and air filtration upgrades (MERV 10)
224297569|NCT06098287|DEVICE|Residential mechanical ventilation system (ERV) and air filtration upgrades|Balanced energy recovery ventilation system and air filtration upgrades (MERV 10)
223403263|NCT06250296|OTHER|New model of psychiatric inpatient care|"The intervention envisages major structural changes in wards, in particular the reorganization of clinical discussion and decision-making spaces, as well as the medical and nursing referral system, and the inclusion of relatives in care:~* Treatment planning involving the patient, with a focus on his or her needs and resources.~* Care by referral teams, present every day of the week, to ensure continuity and consistency of care.~* As few decisions as possible made without the patient, and transparency in decision-making.~* Emphasis on the subjective meaning of illness, beyond symptoms.~* Greater visibility of care planning for patients, who will benefit from weekly agendas~* Closer collaboration with relatives, through open invitations to all clinical discussions, telephone hotlines and meeting times.~* Openness to the network and community care, by promoting communication and exchanges between all stakeholders, and the development of early warning tools such as the joint crisis plan."
224297570|NCT02172352|DRUG|Ba 679 BR low dose|
224297571|NCT02172352|DRUG|Ba 679 BR middle dose|
224297572|NCT02172352|DRUG|Ba 679 BR high dose|
224297573|NCT02172352|DRUG|Placebo inhalation powder|
224297574|NCT00697606|DEVICE|Seprafilm®|Seprafilm® placed at time of primary cesarean
223403264|NCT03205319|DEVICE|e-learning|The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
223403265|NCT00170781|DRUG|Lumiracoxib|
224297575|NCT00697606|OTHER|Control|no Seprafilm® used at primary cesarean
224297576|NCT00384878|DRUG|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
223403266|NCT04088812|OTHER|Placebo meat derivative + Placebo satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
223403267|NCT04088812|OTHER|Placebo meat derivative + Satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
223403268|NCT04088812|OTHER|Experimental meat derivative + Placebo satiating control|Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
223403269|NCT05521581|OTHER|Hand massage|Hand massage will be applied to primiparous mothers who gave birth by cesarean section and its effect on pain, comfort and gas release times will be evaluated.
223403270|NCT02371538|DIETARY_SUPPLEMENT|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
223403271|NCT05011838|OTHER|1. Health Services Redesign|"1.1. Healthy Hearts service: a nursing station providing blood pressure measurement, cardiovascular risk assessment, preventive counselling and effective follow-up in extended opening hours.~1.2. Hypertension screening: All adults attending health care facilities who did not have their blood pressure measured in the previous year will be referred to the Healthy Hearts Service for screening.~1.3. Clinical management: 1.3.1. Creation of the cardiovascular risk team: a group of doctors supervising hypertension management and coordinating improvement.~1.3.2. Guideline-based standardized diagnostic and treatment protocols: a simplified diagnostic and treatment algorithm will identify a core set of primary and secondary antihypertensive medications.~1.3.3. Availability of antihypertensive medications: it will be assured through procurement mechanisms and its availability will be communicated to clinicians at the beginning of each week and ad hoc in case of stock-outs."
223554267|NCT02709577|OTHER|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
223554268|NCT06197152|OTHER|Nasopharyngeal swabs and biological collection|"* Nasopharyngeal PCR~* Blood and virological samples taken as part of the research will be included in a biological collection"
223554269|NCT00721760|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
223554270|NCT00721760|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
223554271|NCT00721760|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
223554272|NCT00948857|DIETARY_SUPPLEMENT|Dehydroepiandrosterone|25 mg PO TID
223554273|NCT00948857|DIETARY_SUPPLEMENT|Placebo|Blinded placebo
223554274|NCT05742516|DIETARY_SUPPLEMENT|Bimuno Daily|Galactooligosaccharide supplement within Bimuno Daily
223554275|NCT05742516|DIETARY_SUPPLEMENT|Placebo|Maltodextrin powder
223554276|NCT04739553|DEVICE|His Pacing|The patients will receive a pacemaker implant with a traditional right ventricular pacing lead and an additional His pacing lead in a basal high septal position at the level of the proximal electrical conduction system (His). An atrial lead is implanted if dual chamber pacing is needed. All leads are connected to a biventricular pacemaker with the His lead in the LV port.
223554277|NCT00585442|DRUG|calcitriol|1.0 mcg daily
223554278|NCT00585442|DRUG|Placebo|Placebo
223554279|NCT03871101|PROCEDURE|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
223554280|NCT03871101|DEVICE|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
223554281|NCT02156284|BEHAVIORAL|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
223554282|NCT06349343|BIOLOGICAL|CD19/BCMA CAR-T cell therapy|CD19/BCMA CAR-T cell will be infused intravenously at 3 doses: Dose A, Dose B, Dose C.
223554283|NCT01373008|DRUG|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
223735848|NCT05192551|OTHER|Bowel-prep (Plenvu as experimental arm)|In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
224132207|NCT01583322|DRUG|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
223403272|NCT05011838|OTHER|2. Clinical Staff Training|"2.1. Training on good clinical management of hypertension: focused on correct blood pressure measurement, use of evidence-based guidelines, cardiovascular risk assessment, use of a standardized diagnostic and treatment algorithm, correct prescription of pharmacological and non-pharmacological treatment, patient counselling, and how to tackle clinical inertia.~2.2. Training on communication skills and patients' needs assessment for all health workers involved in hypertension care. This training will be designed under the patient-centred medicine framework, aiming at equipping health providers with tools for understanding patients' feelings and experience of illness, and to improve their capacity to address social, psychological, and behavioural dimensions of hypertension care."
223403273|NCT05011838|OTHER|3. Patient and Community Engagement|"3.1. Patient empowerment: expert hypertensive patients , under the supervision of a social worker, will provide support and transmit their know-how to other patients in need, particularly those newly diagnosed or non-adherent to treatment or presenting uncontrolled hypertension.~3.2. Community engagement: a Community Hypertension Outreach Group will be set up, composed of existing voluntary community health workers, who will be trained and certified. This group will conduct blood pressure measurements in selected public areas of the commune, referring those with positive screening to the nearest health facility for diagnosis confirmation. It will also provide health information with emphasis on healthy lifestyles. Existing local communication channels such as the community radio and the local newspaper will be engaged."
223403274|NCT03194542|DRUG|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
223403275|NCT03695900|OTHER|Targeting SpO2 at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours
223403276|NCT03695900|OTHER|Targeting SpO2 at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
223403277|NCT03514732|DRUG|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
223403278|NCT04274933|DRUG|Venetoclax|Tablet; Oral
223403279|NCT04274933|DRUG|Capecitabine|Tablet; Oral
223403280|NCT03047187|DIAGNOSTIC_TEST|ACLR|"* quadriceps and hamstring isometric muscles test~* single hop for distance~* IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
223403281|NCT00155597|BEHAVIORAL|home physical therapy|
223403282|NCT01381211|DRUG|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
223403283|NCT01381211|DRUG|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
223403284|NCT00056927|BEHAVIORAL|Anti-smoking Socialization Program|
223403285|NCT04762160|DRUG|Tazemetostat|Study Drug
223403286|NCT04762160|COMBINATION_PRODUCT|Rituximab|Partner Drug
223403287|NCT02540382|DEVICE|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions\* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
223403288|NCT02540382|DEVICE|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
223403289|NCT02976129|DRUG|V565|Daily dosing of V565 three times a day orally for 6 weeks
223403290|NCT02976129|DRUG|Placebo|Daily dosing of placebo three times a day orally for 6 weeks
223403291|NCT04366492|OTHER|Prevalence of blood borne viral infections (HBV/HCV/HIV)|rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire
223403292|NCT04924192|DRUG|TQB3616 capsules|A CDK4/6 kinase inhibitor
223403293|NCT04924192|DRUG|Anlotinib Hydrochloride capsules|A multi-target receptor tyrosine kinase inhibitor
223403294|NCT04924192|DRUG|Irinotecan Hydrochloride for Injection|An inhibitor of DNA topoisomerase Ⅰ
223403295|NCT06244329|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain. TMS uses a small electromagnetic coil controlled by a computer program to deliver short, powerful pulses of magnetic energy focused precisely on parts of the brain's pre-frontal cortex. High-frequency repetitive TMS can enhance the excitability of the stimulated region.
223403296|NCT02475473|OTHER|Exercise Training|Chronic High-Intensity Resistance Training
223403297|NCT04823065|DRUG|Loperamide Pill|4 mg Imodium, per os
223403298|NCT04823065|DRUG|hyoscine-n-butylbromide|3 X 20 mg Buscopan, intravenous
223403299|NCT03277287|RADIATION|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
223735849|NCT04974710|DIAGNOSTIC_TEST|Outpatient MRI|All participants will undergo a standardised imaging protocol in a MRI scanner. This will take place during the same visit or following the transvaginal ultrasound (TVUS) and in advance of any surgical procedure (laparoscopy).
224132208|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
224132209|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
224132210|NCT03712163|DRUG|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
223554284|NCT06358573|DRUG|INT230-6|"INT230-6 is a formulation consisting of an proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplatin and vinblastine sulfate.~The IMP is without marketing authorization in Switzerland and anywhere in the world."
224132211|NCT03712163|DRUG|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
224132212|NCT03712163|DRUG|Placebo Oral Capsule|Placebo
224132213|NCT03437772|BEHAVIORAL|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
224132214|NCT01053546|BEHAVIORAL|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
224132215|NCT01053546|OTHER|questionnaire administration|Ancillary study
223554285|NCT06358573|OTHER|neoadjuvant immuno-chemotherapy|Standard of care
223554286|NCT01223651|PROCEDURE|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
223554287|NCT01324050|BEHAVIORAL|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
223554288|NCT01324050|BEHAVIORAL|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
223554289|NCT02709460|PROCEDURE|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
223554290|NCT02709460|PROCEDURE|Cervical occlusion|Cervical occlusion of the uterine artery
223554291|NCT03102827|DRUG|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
223554292|NCT03102827|OTHER|Placebo|Ambient air without high-flow therapy administered during first night
223554293|NCT01475643|DRUG|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
223554294|NCT01475643|DRUG|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
223554295|NCT03770208|DRUG|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
223554296|NCT03770208|DRUG|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
223554297|NCT06416878|DEVICE|Brief ES at the time of decompression for cauda equina syndrome|In patients operated for acute cauda equina syndrome with autonomic dysfunction epidural ES will be delivered utilising SCS trial electrode. It will be delivered for 10 minutes caudal to compression site and for 60 mins cranial to compression site while the wound is closed and patient recovered.
223554298|NCT06416878|DEVICE|Brief ES to facilitate mcturition/removal of catheter|In patients who do not fully recover function following decompression, brief ES will be applied before second micturition attempt.
223554299|NCT04314700|DEVICE|OCT- based investigational imaging device|Excised breast lumpectomy tissue will be imaged and images reviewed on an investigational Wide-Field OCT (WF-OCT) device.
223554300|NCT02978157|DRUG|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
223554301|NCT02978157|DRUG|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
223554302|NCT05911360|DRUG|DTG/3TC|DTG/3TC FDC will be administered once daily.
223554303|NCT02120781|BIOLOGICAL|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
223554304|NCT02120781|DRUG|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
223554305|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
223554306|NCT00705445|DIETARY_SUPPLEMENT|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
223554307|NCT00705445|OTHER|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
223554308|NCT01661751|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
223403300|NCT01465412|DRUG|Preladenant|After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
223403301|NCT03241849|PROCEDURE|Modified surgical technique for placenta accreta|suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
223403302|NCT05951413|DRUG|Sildenafil Citrate|a potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5),
223403303|NCT05951413|DRUG|estradiol|estradiol in form of Cycloprogynova white pills starting dose is one pill t.i.d may be increased to two pills t.i.d according to endometrial thickness in day 9 measured by vaginal ultrasound.
223403304|NCT06416943|OTHER|3D printed educational model|Slide-based presention plus 3D printed port-A catheter model
223403305|NCT01351649|BEHAVIORAL|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
223403306|NCT05607784|BEHAVIORAL|Formative Research- Content Translation|"This formative research includes brainstorming translation of content and reviewing wireframe prototypes generated from this process. It also includes attending to cultural, developmental, and gender considerations.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
223403307|NCT05607784|BEHAVIORAL|Formative Research- Content Feedback and Acceptability|"This formative research includes providing feedback on the proposed content and ensure contextual acceptability in schools.~The design development cycles will begin with advisory focus group feedback about how the existing activities convey the content (i.e., what and how they are learning). They will advise on activity design for the remaining content (sexual health and content connecting this with ER) to ensure these are engaging, appropriate, and informative. They will also provide perspectives about design, structure, navigability, and approach"
223403308|NCT04750499|PROCEDURE|Adipose tissue injection associated with endorectal advancement flap.|"Injection of adipose tissue will be associated with endorectal advancement flap technique. In blind fistulas and special cases, in which the flap is not indicated, alternative techniques will be used. In all cases, autologous, micro-fragmented and minimally manipulated adipose tissue, obtained with a standardized procedure, previously validated and authorized, will be injected. This procedure uses the Lipogems ® device (Lipogems International SpA, Milan, Italy), with which a well-characterized adipose tissue is obtained with the maximum safety guarantees."
223403309|NCT03815500|BEHAVIORAL|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
223403310|NCT06469905|DEVICE|Erector Spina Plan Block|ESPB will be applied to the patients in the study group. Stabilization exercises will be applied together with ESPB treatment. The needle will be inserted between the erector spinae muscle and the transverse process structures.The local anesthetic will be monitored to spread along the erector spinae muscle.
223403311|NCT06469905|OTHER|Stabilization exercises|Stabilization exercises will be practiced to control group
223403312|NCT04628247|DEVICE|Spring gravity bar|"1. contain two wooden board length (160 cm) and width (15 cm)~2. contain pair of spring at every end of board~3. two wooden board connect in the middle"
223403313|NCT04044989|DEVICE|Laser|Diode laser device was used for photobiomodulation
223403314|NCT04044989|DEVICE|light-emitting diode (LED)|LED device was used for photobiomodulation
223403315|NCT04044989|DEVICE|Placebo|Diode laser device was used for placebo effect
223403316|NCT03585933|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|Echocardiography: assessment of aortic stenosis severity, evaluation of LV diastolic and systolic function; CMR: chambers quantification, LGE, T1 mapping; Intraoperative myocardial tissue biopsy for patients undergoing SAVR; DPD scintigraphy: assessment of cardiac transthyretin amyloidosis
223403317|NCT00925951|DEVICE|Wet Cupping|Wet cupping (Seongho trade \& company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
223403318|NCT00925951|DRUG|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
223403319|NCT00571727|DRUG|mecasermin|injections BID of rhIGF-1, mecasermin
223554309|NCT01661751|BIOLOGICAL|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
223554310|NCT03667807|DEVICE|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
223554311|NCT00760435|DRUG|Infliximab|5 mg/kg IV over 2 hours once
223554312|NCT00760435|DRUG|Placebo|Placebo (same volume as active drug)
223554313|NCT05358418|OTHER|AIS,START with films transferring|Excluding patients with incomplete clinical data of treatment
224022346|NCT04602416|BEHAVIORAL|Training sessions|
224022347|NCT04010825|OTHER|Hypnosis intervention focused on the emotional dimension of the dyspnea|Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
224022348|NCT01474928|BEHAVIORAL|patient role played community video|Group two viewed the patient role played community video
224022349|NCT01474928|BEHAVIORAL|both videos group|Group three viewed both the knowledge and community videos
224022350|NCT01474928|BEHAVIORAL|Pamphlet group|Group four read an educational pamphlet only
224022351|NCT01474928|BEHAVIORAL|physician-led knowledge video|Group one viewed a physician-led knowledge video
223554314|NCT05820568|BEHAVIORAL|ICBT-IU|Internet delivered Cognitive Behavior Therapy for Generalized Anxiety Disorder based on the Intolerance of uncertainty model of worry
223554315|NCT00654745|DRUG|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
223735850|NCT01765153|BEHAVIORAL|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
223735851|NCT01765153|BEHAVIORAL|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
223735852|NCT06032000|BIOLOGICAL|LEM-mR203|mRNA vaccine using Lemonex's Drug Delivery System (DDS), DegradaBALL
224132216|NCT01053546|PROCEDURE|quality-of-life assessment|Ancillary study
224132217|NCT04371172|OTHER|cognitive research battery, MRI, laboratory values|cognitive research battery, MRI, laboratory values
223554316|NCT00654745|DRUG|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
223554317|NCT00654745|DRUG|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
223554318|NCT05511376|DEVICE|AURICULAR VAGUS NERVE STIMULATION|For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
223554319|NCT05511376|BEHAVIORAL|DIET|For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
223554320|NCT05511376|BEHAVIORAL|EXERCISE|Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
223554321|NCT02364115|RADIATION|Stereotactic Body Radiotherapy|
223554322|NCT04685720|DEVICE|LungFit|LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
223554323|NCT06259487|BIOLOGICAL|Coordinated Vaccination|Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)
223554324|NCT06259487|BEHAVIORAL|Following recommendations|Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
223735853|NCT06032000|BIOLOGICAL|Placebo|0.9% Sodium Chloride Solution
223735854|NCT05257681|PROCEDURE|Interlobar fissure completion and pleural adhesiolysis|A video-assisted thoracic surgery or robotic approach will be used to perform pleural adhesiolysis and the lobar fissure adjacent to the previously targeted lobe during bronchoscopic lung volume reduction will be completed using a surgical stapler.
224132218|NCT02021058|OTHER|Experimental Formula|Experimental formula
224132219|NCT02021058|OTHER|Standard control formula|Standard Infant formula
224132220|NCT00269191|DRUG|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
224132221|NCT00269191|DRUG|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
223554325|NCT05384106|DIETARY_SUPPLEMENT|(R)-1,3-butanediol|Avela™ (R)-1,3-butanediol is intended to induce ketosis in the general adult population. Avela™ (R)-1,3-butanediol is GRAS for use in beverages, bars, and gels
223554326|NCT03890354|PROCEDURE|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
223554327|NCT02013557|BEHAVIORAL|Text-message reminder|
223554328|NCT02912494|DRUG|JR-131|
223554329|NCT02912494|DRUG|Darbepoetin alfa|
223554330|NCT00984165|PROCEDURE|Single fraction radiation|8-Gy fraction of radiation
223554331|NCT00984165|BIOLOGICAL|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
223554332|NCT00984165|PROCEDURE|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
223554333|NCT02939820|DRUG|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
224132222|NCT00252486|DRUG|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
224297577|NCT04458493|BEHAVIORAL|satiety|satiety ratings, appetite and desire to eat (10-point visual analogue scale) will be measured at 30, 60 and 120 minutes after each meal replacement drink
224297578|NCT04458493|DIETARY_SUPPLEMENT|Dietary Supplement: Generation UCAN supplementation|meal replacement, Generation UCAN supplement, 400ml, 20% solution
224297579|NCT00000607|DEVICE|Left ventricular assist device|A type of implantable heart pump
223554334|NCT06329752|PROCEDURE|Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)|Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
223735855|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
223735856|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
223735857|NCT00829231|DRUG|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
223735858|NCT04700618|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
223735859|NCT02554812|DRUG|Avelumab|Anti-PD-L1 antibody
223735860|NCT02554812|DRUG|Utomilumab|Anti-4-1BB antibody
223735861|NCT02554812|DRUG|PF-04518600|OX40 Agonist
223735862|NCT02554812|DRUG|PD 0360324|Anti-M-CSF
223735863|NCT02554812|DRUG|CMP-001|TLR9 agonist
223735864|NCT03229668|DRUG|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
223403320|NCT06900413|PROCEDURE|Group ESP|"Experienced anesthesiologists with at least five years of expertise in regional anesthesia will perform the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe (Affiniti 50; Philips) will be used. The ESP block will be applied at the T8 level on the right side, using an in-plane approach, while the patient is in a sitting position. The probe will be placed 2-3 cm lateral to the vertebra in a sagittal position to visualize the erector spinae muscle and transverse processes.~A 22G, 100 mm block needle (Stimuplex® Ultra, Braun, Germany) will be advanced in a craniocaudal direction. The correct needle position will be confirmed by injecting 0.5-1 mL of isotonic NaCl and observing the spread via hydrodissection. Finally, 0.3 mL/kg of 0.25% bupivacaine will be administered, ensuring cranial and caudal spread of the local anesthetic."
223554335|NCT04883294|DIAGNOSTIC_TEST|Electronic Nose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. Failed breath tests were excluded from analysis; the reason for failure was documented.
224132223|NCT05311280|OTHER|high intensity interval training plus myotherapy|"High intensity interval training (HIIT) has been proved its same effect on lower down body fat as moderate intensity continuous training (MICT). In addition, HIIT has the additional benefit of being a time-efficient program which can increase exercise adherence and the participants were more likely to intend to continue. Previous two studies show that HIIT could improve the severity of OSA in both obese adults and obese children.~Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas."
223403321|NCT06900413|PROCEDURE|Group EXORA|Experienced anesthesiologists with at least five years of expertise in regional anesthesia will administer the blocks under ultrasound guidance. A 4.0-12.0 MHz linear ultrasound probe will be placed laterally to the xiphoid process on the parasternal line in a sagittal position. The probe will be moved craniocaudally to identify the 6th rib and further advanced caudally to locate the 8th rib. Once the rectus abdominis muscle and 8th costal cartilage are identified, a 22G, 100 mm block needle will be used to administer 0.3 mL/kg of 0.25% bupivacaine. The correct spread of the local anesthetic will be confirmed via ultrasound.
223735865|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation
223735866|NCT03229668|DRUG|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
223735867|NCT01448278|PROCEDURE|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
223735868|NCT01448278|PROCEDURE|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
223554336|NCT06312410|OTHER|VIA Family 2.0|Multidisciplinary team based preventive intervention. For details, please see arm/group description.
223554337|NCT00500565|DRUG|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
223554338|NCT00500565|DRUG|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
223554339|NCT00529776|PROCEDURE|Continuous lateral rotation therapy|
223554340|NCT00466947|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
223554341|NCT00466947|BIOLOGICAL|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
223554342|NCT00466947|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
223554343|NCT00466947|BIOLOGICAL|Infanrix hexa|Intramuscular injection,3 doses
223554344|NCT00466947|BIOLOGICAL|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
223554345|NCT05402007|OTHER|Pulmonary rehabilitation exercises at the Rehabilitation Center|Face-to-face intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will prescribe pulmonary rehabilitation exercises that will be performed at the pulmonary rehabilitation center.
223735869|NCT04108533|BEHAVIORAL|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
223735870|NCT04114851|DEVICE|NoL|NoL active
223735871|NCT02960776|BEHAVIORAL|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
223735872|NCT02081690|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
223554346|NCT05402007|OTHER|Home Intervention|Home Intervention (12 weeks): Using the participants' assessment and personal characteristics, the therapist will provide a portfolio of self-explanatory exercises, and guide participants on safety precautions.
223554347|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered orally
223554348|NCT06102512|DRUG|LOXO-783|Administered orally
223554349|NCT06102512|DRUG|[¹⁴C]-LOXO-783|Administered IV
223554350|NCT01995526|DRUG|Insulin Peglispro|
223554351|NCT02363777|PROCEDURE|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
223554352|NCT02363777|PROCEDURE|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
223735873|NCT04057404|DEVICE|Alivecor Heart Monitor|
223735874|NCT03425617|DRUG|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
223735875|NCT03425617|OTHER|PLACEBO|PLACEBO via Respimat® single dose
223735876|NCT00959842|DRUG|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
224132224|NCT05311280|OTHER|home exercise plus myotherapy|Home exercise: ambulation by patients themselves Myotherapy: MT is composed of isotonic and isometric exercise related to oral, oropharyngeal, and respiratory exercise. Based on previous review and meta-analysis, MT can decrease not only AHI score, but also ESS score. It means that MT is beneficial to release the symptom of sudden apnea and hypopneas.
224132225|NCT03901612|DRUG|Ropivacaine 0.2%|Continuous post operative regional analgesia
224132226|NCT03901612|DRUG|saline 09%|Continuous post operative regional analgesia
223403322|NCT06568016|OTHER|Best Practice|Receive clinical care consistent with current practice
223403323|NCT06568016|OTHER|Communication Intervention|Receive standardized communication from FIT QI champion
223403324|NCT06568016|OTHER|Communication Intervention|Receive coordination from GI liaisons
223403325|NCT06568016|OTHER|Coordination|Receive enhanced GI care coordination
223403326|NCT06568016|OTHER|Educational Intervention|Watch pre-colonoscopy educational video
223403327|NCT06568016|OTHER|Electronic Health Record Review|Undergo FIT result review by Primary Care FIT Tracker
223403328|NCT06568016|OTHER|Electronic Health Record Review|Ancillary studies
223403329|NCT06568016|OTHER|Informational Intervention|Undergo generation and review of GI FIT Tracker report
223554353|NCT00924612|DRUG|Oral testosterone undecanoate (containing 300 mg T)|
223403330|NCT06568016|OTHER|Informational Intervention|Receive informational sheet
223403331|NCT06568016|OTHER|Interview|Ancillary studies
223403332|NCT06568016|BEHAVIORAL|Patient Navigation|Receive navigation from GI liaisons
223403333|NCT06568016|OTHER|Referral|Receive referral
223403334|NCT06568016|OTHER|Referral|Receive referral per standardized template
223403335|NCT06568016|OTHER|Text Message-Based Navigation Intervention|Receive follow-up text message
223554354|NCT06442566|DRUG|Buprenorphine Patch|Buprenorphine patch dosing will be individualized based on each participant's current morphine-equivalent dose (per package insert/recommendations; between 5mcg and 20mcg per hour). Dosage based on baseline MEQ (\<30 MEQ = 5mcg/hr patch, 30-80 MEQ =10-15mcg/hour patch; \>80 MEQ = 20mcg/hour patch), which will remain on for 7 days (Phase Ia Days 1-7), as tolerated
224132227|NCT00899743|GENETIC|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
224132228|NCT00899743|GENETIC|western blotting|western blotting
223403336|NCT06899282|BEHAVIORAL|Jigsaw method|"Jigsaw/puzzle method is one of the collaborative learning techniques. The Jigsaw technique requires each student to focus on a particular aspect of the topic, become an expert on that topic and teach it to their peers. Once the students have learned the topic in their expert group, they return to the original group and teach what they have learned back to them as if solving a jigsaw puzzle (Geiselman et al., 2024). For the application of the technique, the Jigsaw Technique Application Directive was prepared as a training material to be delivered to the students."
223403337|NCT06899282|BEHAVIORAL|The theoretical training|The theoretical training will be conducted in 2 sessions. The first session will cover the definition, prevalence and importance of pressure ulcers, etiology and classification, risk assessment and pressure ulcers in special patient groups. The second session will cover prevention and treatment of pressure ulcers.
223403338|NCT07081646|DRUG|AZD0120|Participants will receive AZD0120 via intravenous (IV) infusion.
223554355|NCT06442566|DRUG|Placebo|double-blinded randomization to placebo or transdermal buprenorphine
223554356|NCT06442566|DEVICE|Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to REAL intermittent theta burst (iTBS) rTMS
224132229|NCT00899743|OTHER|immunologic technique|immunologic technique
223403339|NCT07084922|OTHER|No interventions. This is an observational study where participants undergo assessments of plantar pressure and postural balance without any treatment or intervention.|No interventions. This is an observational study where participants undergo assessments of plantar pressure and postural balance without any treatment or intervention.
223403340|NCT01358461|BIOLOGICAL|Blood sampling|Blood sampling
223403341|NCT01358461|OTHER|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
223403342|NCT03817190|DRUG|DS107|DS107 Capsule
223403343|NCT03817190|DRUG|Placebo|Placebo capsule
223554357|NCT06442566|DEVICE|Sham Transcranial Magnetic Stimulation (TMS)|double-blinded randomization to SHAM intermittent theta burst (iTBS) rTMS
223554358|NCT02755662|DEVICE|Mandibular Retention Device|
223554359|NCT04099355|DRUG|Dronabinol 5mg Cap|1 QAM and 2 QHS PO 14 days
223554360|NCT04099355|DRUG|Non-active comparator|1 QAM and 2 QHS PO 14 days
223554361|NCT02220192|PROCEDURE|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
223554362|NCT02082444|OTHER|Skipping lunch|
223554363|NCT00924001|DRUG|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3
223554364|NCT00924001|DRUG|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
223554365|NCT00924001|DRUG|Fludarabine|25 mg/m\^2/day intravenously x 5 days
223554366|NCT00924001|DRUG|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
223554367|NCT02644252|DRUG|Day 1: Cisplatin 75 mg/m2|
223403344|NCT01622673|DRUG|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
223554368|NCT02644252|DRUG|Day 1: Vinorelbine 25 mg/m2|
223554369|NCT02644252|DRUG|Day 8: Capsule vinorelbine 50 mg/m2|
223554370|NCT02644252|DRUG|Day 1: Carboplatin AUC=5|
224132230|NCT00899743|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
224297580|NCT00000607|DEVICE|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
223403345|NCT01622673|DRUG|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
223403346|NCT01622673|DRUG|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
223403347|NCT04146012|DEVICE|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
223403348|NCT06302400|DEVICE|166Holmium microspheres (QuiremSpheres®)|QuiremSpheres® are a biocompatible microsphere that contain the radionuclide holmium-166 (166Ho), which emits gamma-radiation (81 keV) and high-energy (1.81 MeV) beta-particles.
223403349|NCT06746129|PROCEDURE|embryo transfer|transfer of embryo(s) into the uterine cavity
223403350|NCT03026140|DRUG|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
223403351|NCT03026140|DRUG|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
223403352|NCT03026140|DRUG|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
223403353|NCT03026140|DRUG|BMS-986253|BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
223554371|NCT02644252|DRUG|Day 1: Vinorelbine 30 mg/m2|
223554372|NCT02644252|DRUG|Day 8: Capsule vinorelbine 60 mg/m2|
223735877|NCT01566955|PROCEDURE|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
223735878|NCT05305872|DRUG|Gandouling|The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.
223735879|NCT00084565|DRUG|estramustine phosphate sodium|
224297581|NCT04923711|BEHAVIORAL|Moderate intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 60-69% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 50-59% reserve heart rate or the heart rate at the anaerobic threshold."
223403354|NCT03026140|DRUG|BMS-986016|Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29, in cohort 7 160mg on day 1, day 29 and day 57
223403356|NCT06053801|OTHER|Xolair|Prospective observational cohort study. There is no treatment allocation. Patients administered Xolair by prescription will be enrolled.
223403357|NCT01215773|DRUG|Placebo|Matching to HEA 200 mg tablet, oral administration
223403358|NCT01215773|DRUG|BI 671800|High dose oral administration
223403359|NCT01215773|DRUG|BI 671800|Medium dose oral administration
223735880|NCT00084565|DRUG|paclitaxel|
223735881|NCT00084565|DRUG|topotecan hydrochloride|
223403362|NCT06290778|BEHAVIORAL|Brief Unified Protocol|The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.
223403363|NCT06290778|BEHAVIORAL|Psychoeducation|Psychoeducation regarding mental health challenges in fire service.
223403364|NCT06907875|BIOLOGICAL|EPI-321|EPI-321 IV Infusion
223403365|NCT07090148|BIOLOGICAL|pTVG-HP DNA vaccine|The vaccine will be injected into the outer side of the upper area of the arm in two adjacent sites, with 0.25 mL administered at each site.
223403366|NCT07090148|DRUG|Anti-PD-1 monoclonal antibody|Nivolumab is a potent human immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Participants will receive two 10mg doses.
223403367|NCT07137728|DEVICE|Dual Frequency Low-Level Laser Therapy|DF-LLLT (830 nm, 100 mW/cm², 9.12 Hz, 5 J/cm²) applied over each identified trigger point for 3 minutes 9 seconds per point, twice weekly for 4 weeks.
223554373|NCT02644252|DIETARY_SUPPLEMENT|Tocotrienol 300 mg x 3 daily until progression|
223554374|NCT02644252|DRUG|Placebo 1 capsule x 3 daily until progression|
223554375|NCT01720589|DIETARY_SUPPLEMENT|Melt (test oil)|
223554376|NCT01720589|DIETARY_SUPPLEMENT|Corn oil (control)|
223554377|NCT06273722|DEVICE|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner|Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner (Michelson Diagnostics Maidstone, Kent, UK; resolution \<7.5 µm lateral, \<5 µm axial; depth of focus 1.0 mm; scan area 6 × 6 mm).
223554378|NCT05289492|DRUG|EOS884448|EOS884448 will be administered in arm A,B and C
223554379|NCT05289492|DRUG|Iberdomide|Iberdomide will be administered in arm B and C
223554380|NCT05289492|DRUG|Dexamethasone|Dexamethasone will be administered in arm C
223554381|NCT05689918|OTHER|No intervention|No intervention
223735882|NCT03204981|DEVICE|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
223735883|NCT03204981|PROCEDURE|Ablation|standard ablation
223735884|NCT01662908|DRUG|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
223735885|NCT01662908|DRUG|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
223735886|NCT01662908|DRUG|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
223735887|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
223735888|NCT05767632|DRUG|Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)|1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
223735889|NCT05767632|DRUG|Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)|1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
223735890|NCT05240404|DRUG|Toripalimab|toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
223735891|NCT05240404|PROCEDURE|Thermal ablation|The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm.
223403368|NCT07137728|DEVICE|Sham Laser|Inactive laser device identical in appearance and sound to the active laser but without light emission, applied for 3 minutes 9 seconds per point, twice weekly for 4 weeks.
223403369|NCT07137728|OTHER|Conventional Therapy (Stretching and Strengthening Program)|A standardized physiotherapy program including stretching and strengthening exercises for the cervical and shoulder muscles. The program is performed under physiotherapist supervision twice weekly for 4 weeks. Exercises are identical across both study arms and include stretching of the upper trapezius and strengthening of the neck and scapular stabilizer muscles.
223735892|NCT00312494|DRUG|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
223735893|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
223403370|NCT05649943|DRUG|APA + ADT|"All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment."
223554382|NCT03387709|BEHAVIORAL|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
223554383|NCT03387709|BEHAVIORAL|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
223554384|NCT00004215|BIOLOGICAL|filgrastim|
223735894|NCT00312494|DRUG|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
223554385|NCT00004215|BIOLOGICAL|leridistim|
223554386|NCT00004215|DRUG|cytarabine|
223554387|NCT00004215|DRUG|daunorubicin hydrochloride|
223735895|NCT01862887|DRUG|PH-797804|Tablet, 24 mg, single dose
223735896|NCT01862887|DRUG|Moxifloxacin|Tablet, 400 mg, single dose
224297582|NCT04923711|BEHAVIORAL|High intensity exercise prescription|"Exercise Intensity： Low-risk patients: the lower of 70-85% reserve heart rate or the heart rate at the anaerobic threshold.~Moderate-risk or high-risk patients: the lower of 60-70% reserve heart rate or the heart rate at the anaerobic threshold."
223735897|NCT01862887|DRUG|Placebo|Tablet, PH-797804 matched placebo, single dose
223735898|NCT05138679|PROCEDURE|Revascularization|Endovascular or surgical restoration of arterial blood flow.
223735899|NCT05138679|PROCEDURE|Primary major amputation|Primary below- or above knee major amputation without prior revascularization.
223735900|NCT05138679|OTHER|Best medical treatment|Conservative treatment of acute lower limb ischemia - without prior revascularization.
223735901|NCT04592965|BEHAVIORAL|Clinical and neuropsychological assessments|The assessment of disease state, clinical condition, and of cognitive and neuropsychological attributes.
223735902|NCT04592965|BEHAVIORAL|Induction of PH and associated bodily states|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls
223735903|NCT04592965|OTHER|Resting-state fMRI acquisition|Investigation of neural mechanisms at rest, that are potentially disrupted at different degrees, for the different clinical groups of PD patients, compared to the healthy aged-matched controls
223735904|NCT04592965|OTHER|Induction of PH and associated bodily states (MRI)|Assessment of subjective sensitivity to the induction of the PH and associated bodily states, for different populations of PD patients and healthy aged-matched controls Assessment and comparison of the neural mechanisms responsible for the induction of the PH and associated bodily illusions, in different groups of PD patients and healthy aged-matched controls
223735905|NCT04471753|BEHAVIORAL|Coma Recovery Scale-Revised|Data were collected according to the Coma Recovery Scale-Revised operation guideline, the sum of the highest score on the evaluated subscales was taken as the final score, and the final diagnosis of patients was obtained (the highest score of each subscale was recorded). All participants were diagnosed by using CRS-R five times at least within 7 days. According to the results of the Coma Recovery Scale-Revised assessment, minimally conscious state and unresponsive wakefulness syndrome were distinguished.
223735906|NCT04800003|DIAGNOSTIC_TEST|Gonial angle and submandibular fossa depth measurements from CBCT images|CBCT images were obtained from dry human mandibles
223735907|NCT04792632|DEVICE|Veye Lung nodules|Veye Lung Nodules
223735908|NCT05424042|BEHAVIORAL|In-Person Caloric Restriction|20% CR delivered in-person by dietitian/coach
223735909|NCT05424042|BEHAVIORAL|Remote Caloric Restriction|20% reduction in caloric intake, meeting schedule, and physical activity goal delivered remotely.
224022352|NCT01474928|BEHAVIORAL|Community video group|Group two viewed the patient role played community video
224022353|NCT01474928|BEHAVIORAL|knowledge video|Group one viewed a physician-led knowledge video
224297583|NCT01312311|DRUG|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1
223735910|NCT05424042|BEHAVIORAL|Time-restricted|8-hour TRE with ad libitum caloric intake. This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake.
223735911|NCT00539448|DRUG|insulin glargine|in combination with insulin Glulisine as bolus regimen
223735912|NCT00539448|DRUG|insulin glulisine|in combination with insulin Glargine as bolus regimen
223735913|NCT03558399|OTHER|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
223735914|NCT03558399|OTHER|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
223735915|NCT01942187|DRUG|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
223735916|NCT01942187|DRUG|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
223735917|NCT01942187|BEHAVIORAL|Problem Solving Therapy|Weekly specialized psychotherapy
223735918|NCT01437215|DEVICE|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
223735919|NCT00429507|DRUG|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
223735920|NCT00429507|BEHAVIORAL|Questionnaire|Questionnaires taking about 15 minutes to complete.
223735921|NCT00429507|PROCEDURE|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
224297584|NCT02387593|DEVICE|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
224297585|NCT02514161|OTHER|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
223403371|NCT05649943|PROCEDURE|Local Treatmetn RT or RP|"Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks)."
223403372|NCT06909071|DEVICE|Hybrid Closed-Loop Artificial Pancreas System|The total daily insulin requirement is calculated as 0.3 - 0.6 U/(kg·d) according to patient's weight. The system automatically adjusts the basal rate during operation. Nurses enter bolus dose orders in AAPS software as directed by physicians. Blood glucose is monitored via continuous glucose monitoring and 4 daily fingerstick measurements (fasting and 2 hours after each meal).
223735922|NCT02734810|DRUG|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
223735923|NCT00353405|BEHAVIORAL|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
223735924|NCT00353405|BEHAVIORAL|Mass media|Mass media provides messages that support sexual health skills.
223735925|NCT00353405|BEHAVIORAL|Control|Control group received no social skills training and no media mass media messages.
223735926|NCT03042247|DIAGNOSTIC_TEST|FDG PET/TC and FDG PET/MRI|Combined assessment with FDG PET/TC and PET/MRI
223735927|NCT05164042|BIOLOGICAL|Allogeneic CD19 CAR-T cells|infusion of allogeneic CD19 CAR-T cells
223735928|NCT02480543|DRUG|Misoprostol (cytotec)|
223735929|NCT00528398|DRUG|cytarabine|
223735930|NCT00528398|DRUG|idarubicin|
223735931|NCT06268093|DRUG|Thalidomide|Thalidomide 50 - 200 mg once at nightime
223735932|NCT00488345|DRUG|Tygacil|
223735933|NCT02101645|PROCEDURE|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
223735934|NCT02101645|PROCEDURE|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
223735935|NCT03781609|BEHAVIORAL|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
223735936|NCT03781609|BEHAVIORAL|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
223735937|NCT03781609|BEHAVIORAL|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
223735938|NCT05330338|BIOLOGICAL|Genetic analyses: whole genome sequencing|Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
224022354|NCT03946150|DIAGNOSTIC_TEST|P/FP Ratio|PaO2/Fio2 X PEEP
224022355|NCT02550665|DRUG|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
224022356|NCT03614910|DEVICE|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
224022357|NCT01762891|DRUG|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
223735939|NCT04851886|DEVICE|BURT|Robot-assisted upper-limb individual (i.e. one-on-one) rehabilitation will be delivered using the BURT system by Barrett Technology
223403373|NCT07102615|DRUG|Intracervical injection of Vasopressin|Intracervical injection of Vasopressin
223403374|NCT07102615|DRUG|Intracervical Injection of saline|Intracervical Injection of saline
223403375|NCT06773767|DRUG|150 mg trazodone hydrochloride|To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.
223735940|NCT04851886|DEVICE|BURT + PostureCheck|Robot-assisted upper-limb group (i.e. up to three subjects) rehabilitation will be delivered using the BURT system by Barrett Technology + PostureChek (a camera-based system to track the quality of the exercises)
223403376|NCT06773767|DRUG|300 mg trazodone hydrochloride|To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state
223554388|NCT05432596|DRUG|ATI-1777 2.0% w/w|ATI-1777 topical solution 2.0% w/w
223554389|NCT05432596|DRUG|ATI-1777 1.0% w/w|ATI-1777 topical solution 1.0% w/w
223554390|NCT05432596|DRUG|ATI-1777 0.5% w/w|ATI-1777 topical solution 0.5% w/w
223735941|NCT05541549|BIOLOGICAL|CE-VST01-JC|CE-VST01-JC at a dose of 1 × 10\^8 cells administered as an intravenous (IV) infusion every 28 days for 4 total infusions
223735942|NCT02143908|DIETARY_SUPPLEMENT|lysine supplementation|
223735943|NCT02143908|DIETARY_SUPPLEMENT|Placebo|
223735944|NCT02138903|OTHER|trans thoracic echocardiography|
223735945|NCT03541018|PROCEDURE|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
223735946|NCT03626714|DRUG|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
223735947|NCT03070379|PROCEDURE|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
223735948|NCT05919303|RADIATION|CT Scan|CT scan study of abdomen
223735949|NCT00654173|DRUG|Rosuvastatin|
223735950|NCT00654173|DRUG|Simvastatin|
223735951|NCT00654173|DRUG|Atorvastatin|
223735952|NCT02626637|OTHER|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
223554391|NCT05432596|DRUG|Vehicle|Vehicle topical solution
223554392|NCT02466477|GENETIC|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
223554393|NCT02466477|GENETIC|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
223735953|NCT00860912|PROCEDURE|Collagen Matrix|surgical/reinforcing material
223735954|NCT02211573|OTHER|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
223554394|NCT02466477|OTHER|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
223554395|NCT01458743|DRUG|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
223554396|NCT01458743|DRUG|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
223554397|NCT05349968|DRUG|Lipovirtide for injection|Multiple dosing of Lipovirtide
223554398|NCT00005987|DRUG|carmustine|
223554399|NCT00005987|DRUG|cyclophosphamide|
223554400|NCT00005987|DRUG|dexamethasone|
223554401|NCT00005987|DRUG|etoposide|
223735955|NCT05734079|OTHER|Standard of care|A written hand out containing all information required for bowel preparation
223554402|NCT00005987|DRUG|filgrastim|
223554403|NCT00005987|DRUG|mitoxantrone hydrochloride|
223554404|NCT00005987|DRUG|recombinant interferon alfa|
223735956|NCT05734079|OTHER|Standard of care + Video call|Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
223735957|NCT05734079|OTHER|Standard of care + Video call + Educational video film|Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
223735958|NCT02127567|OTHER|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
224022358|NCT01762891|DRUG|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
223403383|NCT06921317|DRUG|GVB-2001-high dose|GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of high dose GVB-2001 will be injected intracamerally to the target interventional eye.
223403384|NCT06921317|DRUG|GVB-2001-low dose|GVB-2001 is a self-complementary adeno-associated viral vector (scAAV) injection to deliver human dnRhoA gene to trabecular meshwork cells in patients with primary open angle glaucoma. A single dose of low dose GVB-2001 will be injected intracamerally to the target interventional eye.
223403385|NCT07115680|OTHER|human participants, data or material|Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies
223403386|NCT07114380|DEVICE|Cold snare polypectomy|Unlike traditional hot snare polypectomy or endoscopic mucosal resection, which use electrocautery to resect larger or pedunculated polyps, cold snare polypectomy uses mechanical transection alone without cautery. The procedure is performed using a dedicated cold snare by experienced endoscopists.
223403387|NCT07116148|OTHER|The Homeostasis-Enrichment-Plasticity (HEP®) Approach|The HEPApproach intervention and clinical reasoning process follow a systematic order based on the data-driven decision-making model. There are 11 phases to the HEP Approach process. Phase 1 involves referral to the program. Phase 2 includes a meeting with the family to introduce them to the HEP Approach. Phase 3 is a comprehensive assessment of the child and family systems. Phase 4 is the identification of family and child strengths and challenges based on the assessment. Phase 5 involves formulating hypotheses about how underlying factors or systems impact the child's challenge areas. Phases 6 and 7 include collaborative goal setting and outcome measure identification with the family. Phase 8 is intervention planning. Phase 9 implements the intervention through an individualized process that generally involves four steps that prioritize different areas of need (e.g., self-regulation and homeostasis of the child, adaptation of the physical and social home environment to support succes
223403388|NCT05009602|DIAGNOSTIC_TEST|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
223403389|NCT05009602|DIAGNOSTIC_TEST|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery.
223403390|NCT05009602|DIAGNOSTIC_TEST|Exercise Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the dorsalis pedis and posterior tibial artery, following the participant completing 50 consecutive repetitions of active dorsiflexion whilst standing.
223403391|NCT05009602|DIAGNOSTIC_TEST|Audible handheld Doppler|Audible CW Doppler interrogation of the dorsalis pedis and posterior tibial artery.
223403392|NCT05009602|DIAGNOSTIC_TEST|Visual handheld Doppler|Visual CW interrogation of the dorsalis pedis and posterior tibial artery was performed using the handheld Huntleigh Digital Dopplex device.
223554405|NCT00005987|DRUG|sargramostim|
223554406|NCT00005987|PROCEDURE|bone marrow ablation with stem cell support|
223554407|NCT00005987|PROCEDURE|peripheral blood stem cell transplantation|
223554408|NCT00005987|PROCEDURE|radiation therapy|
223554409|NCT01482806|BEHAVIORAL|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
223554410|NCT01482806|BEHAVIORAL|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
223554411|NCT02160249|BEHAVIORAL|Community-based rehabilitation|
223554412|NCT02160249|OTHER|Facility based care|
223554413|NCT02229825|DRUG|Duloxetine|Capsule
223554414|NCT02229825|DRUG|Placebo|Capsule
223554415|NCT03352999|PROCEDURE|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
223554416|NCT03694340|OTHER|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
223554417|NCT03200197|OTHER|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
223554418|NCT03200197|OTHER|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
223554419|NCT00104416|DRUG|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
223403393|NCT05009602|DIAGNOSTIC_TEST|Podiatry Ankle Duplex scan (PAD-scan)|"Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.~To be used in 3 participating centers only."
223403394|NCT07139990|RADIATION|Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)|Radiographic response-adapted thoracic tumor radiotherapy given as single doses ('pulses') before standard of care chemoimmunotherapy cycles. Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction) Adaptive Changes Allowed: Tumor target (size/shape), # of doses (reduction)
223403395|NCT07139990|RADIATION|Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)|"Intervention: Fractionated stereotactic radiosurgery (SRS, 5 doses total) for brain metastasis given in two pulses (3 fractions + 2 fractions) with second pulse adapted to interim radiographic response Adaptive Changes Allowed: Omission of 2nd pulse in \>=25% responders or tumor target size/shape change in remainder"
223735959|NCT02127567|OTHER|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
223403396|NCT07137585|DRUG|Placebo|RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.
223403397|NCT07137585|DRUG|RO7204239|RO7204239 will be administered as per the schedule specified in the treatment arm.
223554420|NCT00104416|DRUG|Placebo|Placebo control
223554421|NCT03637361|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
223554422|NCT03637361|DRUG|Placebo|
223554423|NCT00909441|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
223554424|NCT03839225|OTHER|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~* Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~* The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~* Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
223554425|NCT02047422|DRUG|Furosemide|furosemide (doubling previous furosemide dose)
223554426|NCT02047422|DRUG|metolazone|metolazone (add 2.5mg qod)
223554427|NCT02047422|DRUG|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
223554428|NCT02047422|DRUG|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
223554429|NCT04242576|DEVICE|Right Left Judgement|It is an application by Noigroup (Neuro Orthopedic Institute), adapted to different devices.
223554430|NCT04242576|OTHER|Action Observation|Videos of cervical movements.
223554431|NCT04242576|BEHAVIORAL|Exercise|Evidence based exercises for the neck.
223735960|NCT05578287|DRUG|Anti-HER2 ADC|Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid
223554432|NCT04597645|OTHER|Therapeutic elastic band resistance training|A16-week therapeutic program using Elastic Thera Band will be taught. The exercises are designed to train specific major muscle groups, strengthen the motivation of participants, and facilitate home-based compliance. The program will be performed two times per week (once supervised and guided by a trained physical therapist and the other supervised by educational trainers) over 16 weeks for a total of 32 sessions. Each session supervised by a physical therapist last for 60 minutes, including a 5-minute warm-up consisting of light-intensity aerobic and dynamic stretching exercises, followed by 50 minutes of EB exercise and a 5-minute period of cool-down and static stretching exercises.
223554433|NCT03493061|DRUG|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
223554434|NCT03493061|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
223554435|NCT03493061|DRUG|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
223554436|NCT01309997|DRUG|imatinib mesylate|Given PO
223554437|NCT01309997|BIOLOGICAL|rituximab|Given IV
223554438|NCT01500785|DRUG|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
223554439|NCT01500785|DRUG|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
223554440|NCT03570242|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
223735961|NCT04250571|OTHER|"information about No treatment group"|Participants will receive no pills and will be told that they are in the no treatment group
224022359|NCT01762891|DRUG|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
223403398|NCT05484570|OTHER|Interval History|"The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements"
223403399|NCT05484570|OTHER|Physical Examination|A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
223403400|NCT05484570|OTHER|ECAB Assessment|"An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported"
223403401|NCT05484570|OTHER|Gait Assessment|"For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking"
223403402|NCT05484570|OTHER|Specimen Sample Collection|"Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred."
223403403|NCT01125397|BEHAVIORAL|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
223403404|NCT07139106|DRUG|Ketamine hydrochloride infusion|single racemic ketamine hydrochloride 0.5 mg/kg infusion
223403405|NCT07141446|DRUG|Neem gel|1.5% Neem Gel in orabase formulation, twice daily application for 3 months
223403406|NCT07141446|DRUG|Triamcinolone Acetonide|0.1% oral paste to be applied twice daily for 3 months
223403407|NCT06944535|PROCEDURE|Modified Lip Repositioning Surgery (Retrospective)|Patients previously underwent a modified lip repositioning surgery technique without frenectomy and without myotomy. For this retrospective study, only existing medical records and clinical photographs were reviewed. No new surgical intervention was performed.
223403408|NCT05863351|PROCEDURE|Computed Tomography|Undergo CT
223403409|NCT05863351|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223403410|NCT05863351|OTHER|Questionnaire Administration|Ancillary studies
223554441|NCT04970823|DEVICE|The somatosensory interactive game for preschool children|The somatosensory interactive game, an independent nursing intervention, promotes pain relief for preschool children.
223554442|NCT04970823|DEVICE|A VR (virtual reality) game for school-age children|A VR (virtual reality) game environment promotes pain relief for school-age children.
223554443|NCT02807389|DRUG|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
223403411|NCT05863351|PROCEDURE|Stereotactic Ablative Radiotherapy|Undergo SAbR
223554444|NCT05290506|DRUG|Dipeptidyl-Peptidase IV Inhibitors|All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
223735962|NCT04250571|OTHER|imaginary pill technique|Participants will be instructed to take an imagined pill. This instruction consists of a procedure including five steps (i.e., identifying the IP sensitive problem, building trust/belief/reality of the IP, constructing a personally meaningful IP, taking the IP, suggestions for self-administering the IP in real life, and building adherence). Participants in this group receive daily e-mail reminders.
223403412|NCT05863351|PROCEDURE|Systemic Therapy|Given standard of care systemic therapy
223554445|NCT04384705|OTHER|research specific blood sample|"* one blood sample before the epidemic phase~* one blood sample during epidemic phase~* one blood sample after epidemic phase"
223554446|NCT03018197|OTHER|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
223554447|NCT00243945|DRUG|Rotigotine|
223554448|NCT03540706|DIAGNOSTIC_TEST|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
224022360|NCT01762891|DRUG|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
224022361|NCT05522621|DRUG|TJAOA102|Once enrolled, participants will be administrated TJAOA102
224022362|NCT02874274|BEHAVIORAL|Standard of Care|
224022363|NCT02874274|BEHAVIORAL|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
224022364|NCT00527592|DRUG|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
223735963|NCT04250571|OTHER|open label placebo|"Participants will have the information that they are receiving inert pills (i.e. P-Dragees, containing Placebo), combined with the following scientific rationale: (a) deceptive as well as open label placebos have been found to be effective in relieving symptoms in a variety of clinical conditions namely anxiety, depression, chronic pain (the placebo effect is powerful), (b) classical conditioning are one of the possible mechanism of this effect (the body automatically responds), (c) positive expectations may help but are not necessary, (suspend disbelief), (d) compliance with these instructions are important for outcome (taking the pills faithfully is important).~Participants in this group receive daily e-mail reminders."
223403413|NCT05723094|RADIATION|Ga-Al-As diode laser (Ilase, USA)|The laser parameter used in previous study： Laser type：Ga-Al-As Wavelength：940 nm Emission type：Continuous Irradiation dosage/per tooth：75J/cm2 Application technique：Direct contact with the mucosa Exposure time per point：6 second Laser classification：3B Laser application time：Once in a month (4-week intervals) for the maxilla and mandibular incisors and canines Output：100Mw Diameter of the optical fiber：0.04 cm2
223403414|NCT05723094|OTHER|placebo|Before the orthodontic retention phase, those who did not apply the Ga-Al-As diode laser (Ilase, USA) were the control group.
223403415|NCT01226160|PROCEDURE|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
223403416|NCT01226160|PROCEDURE|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
223403417|NCT06948825|DRUG|Metformin Hcl 850Mg Tab|Participants randomized to Metformin will have a prescription of Metformin 850mg orally twice a day. The participant will get blood drawn for testing, undergo a urine pregnancy test, and meet with the study provider to discuss the medication.
223403418|NCT06948825|BEHAVIORAL|Lifestyle Intervention|Participants in the Lifestyle Intervention will meet once a week via zoom with the study health counselor to go over lesson plans. After 4 weeks, participants will meet via zoom every other week.
223554449|NCT04238091|DRUG|Fecal material transfer therapy|"Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not."
223735964|NCT06294418|DEVICE|Field Cycling Imaging (FCI)|FCI scan
223735965|NCT02751515|OTHER|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
223735966|NCT02751515|OTHER|Untreated skin|One site is patched without treatment as control
223735967|NCT03754712|DIETARY_SUPPLEMENT|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
223735968|NCT02065232|DRUG|Tilmanocept|
223735969|NCT02065232|DRUG|Sulfur Colloid|
223735970|NCT01161914|DRUG|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
223735971|NCT01161914|DRUG|ISU302|administered by IV infusion for a dose of 60 U/kg
223735972|NCT00258453|OTHER|metabolic assessment|
223735973|NCT00258453|OTHER|physiologic testing|
223735974|NCT00258453|PROCEDURE|biopsy|
223735975|NCT00258453|PROCEDURE|computed tomography|
223735976|NCT00258453|PROCEDURE|conventional surgery|
223735977|NCT00258453|PROCEDURE|magnetic resonance imaging|
223403419|NCT06948825|BEHAVIORAL|Enhanced Lifestyle Intervention|Participants in the Enhanced Lifestyle Intervention will meet every other week, and will get a free instacart membership to have access to free grocery delivery. Additionally, participants in this intervention will have a 1:1 virtual meeting focused on meal planning with the study health counselor.
223735978|NCT00258453|PROCEDURE|management of therapy complications|
223735979|NCT00258453|PROCEDURE|psychosocial assessment and care|
223735980|NCT00258453|PROCEDURE|quality-of-life assessment|
223735981|NCT00258453|RADIATION|radiation therapy|
223735982|NCT01188694|DRUG|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
223735983|NCT01188694|BEHAVIORAL|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
223403420|NCT04409145|DRUG|VT30|VT30 gel is intended as a topical treatment of cutaneous VMs, LMs, or VLMs that driven by inappropriate PI3K activation. In the skin, VT30 is rapidly metabolized to VT10, an active drug form, and is intended to sufficiently permeate the stratum corneum and achieve target engagement. It is expected that VT30 will lead to amelioration of the signs and symptoms of cutaneous VMs, LMs and/or VLMs.
223403421|NCT02573597|DRUG|Bupivacaine|Continuous or bolus administration
223735984|NCT01188694|BEHAVIORAL|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
223735985|NCT06429501|DRUG|Bupivacaine/Epinephrine|injection
223735986|NCT06429501|DRUG|Saline|injection
223735987|NCT00772356|DEVICE|Accu-Chek Spirit Insulin Pump|
223735988|NCT00772356|DEVICE|Comparator insulin pump|
223735989|NCT01871610|DRUG|[18F]AV-45 PET amyloid binding imaging|
223735990|NCT00903617|DRUG|GSK256073|5 mg for 8 weeks
223735991|NCT00903617|DRUG|GSK256073|50 mg for 8 weeks
223735992|NCT00903617|DRUG|GSK256073|150 mg for 8 weeks
223735993|NCT00903617|DRUG|Placebo|placebo for 8 weeks
223735994|NCT00903617|DRUG|Niaspan|1500 mg for 8 weeks
223403422|NCT02573597|DRUG|Sufentanil|Continuous or bolus administration
223403423|NCT03285347|DEVICE|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
223403424|NCT07140809|BIOLOGICAL|JMT202 injection|Subcutaneous injection
223403425|NCT07140809|OTHER|Placebo|Matching Placebo
223403426|NCT07148245|PROCEDURE|Blood Sample|Blood samples will be collected
223403427|NCT07148245|OTHER|Health Related Quality of Life Questionnaires (HRQoL)|Participants may be given HRQoLs during the course of data collection
223403428|NCT07148245|OTHER|Medical Chart Review|Participants will undergo medical charts review during the course of data collection
223403429|NCT06952894|DEVICE|RUS Lung|The RUS Lung is an endoscopic imaging treatment planning software program. It creates a patient-specific simulation of the thoracic surgical environments, allowing for the visualization of tumor, bronchovascular structures and thoracic organs during the surgical planning process and the operation. RUS Lung utilizes preoperative CT images of the patients to segment tumor, organs, blood vessels, and bronchus and reconstructs them into a 3D model. Although there is no direct intervention on the patient, the surgeon uses RUS Lung as a surgical navigation tool to simulate the surgery before performing the actual procedure.
223554450|NCT04238091|PROCEDURE|4mm Punch Biopsy of Scalp|For the skin biopsy, the doctor will select an appropriate area on the scalp (or skin) as the biopsy site. The area will then be numbed (anesthetized). The study doctor or his/hers designee will then use a cylindrical instrument with a sharp edge (similar to a small cookie-cutter) to remove a 4mm cylinder of skin (smaller than the size of a pencil eraser). After the skin is removed, the biopsy site will be closed with absorbable stitches when appropriate. Approximately 2 to 4 stitches may be placed at the wound site to improve healing. Multiple skin punch biopsies may be taken throughout the entire length of the study
223554451|NCT04238091|DIAGNOSTIC_TEST|Blood draw|Blood will be collected by a standard venipuncture procedure. 60-80cc of blood will be drawn from a patient per blood draw occurrence. Blood samples will be transferred to the research facility. Samples will be used to either stained with cell surface antibodies for fluorescence acquisition cell sorting (FACS) analysis (FACS experiments will allow for assessment of the subset and activation status of immune cells involved in AA or other cutaneous disorder pathology) or to extract DNA for the purposes of exome or genomic sequencing or genotyping of disease associated genes
223554452|NCT04238091|PROCEDURE|Skin Microbiome sampling|Skin microbiome will be collected using skin swabs at the time of recruitment according to established protocols outlined by the Human Microbiome Project. Sterile (germ-free) techniques will be used for collection of all specimens, with careful avoidance of contamination of collection area by gloved hands. The sites that will be sampled are (in sequence): Lesional AA skin, non-lesional scalp skin, retro-auricular crease, ante-cubital fossa, and anterior nares. Skin surface specimens will be collected with a Catch-All Sample Collection Swab swab that looks similar to a q-tip and is, moistened with sterile solution. Skin will be swabbed approximately 50 times along the scalp, behind your ear and on your arm, and twisted 2 times around the front of the nose.
223554453|NCT04238091|PROCEDURE|Hair Microbiome Sampling|Hair follicle microbiome (bacteria that live in the hair follicle) will be collected as follows: several hairs will be plucked from the scalp at a time using tweezers, once plucked the bulbs of the hairs will be cut using sterile surgical scissors and processed. Approximately 10-15 hairs will be plucked for processing. The number of hairs plucked may be increased depending on the number of hairs containing bulbs. Up to 50 hairs may be plucked, as long as the subject is able to tolerate it. Only several hairs will be plucked at a time in order to minimize pain and discomfort of the procedure.
223554454|NCT04238091|DRUG|Pre-FMT Antibiotic Cocktail|For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
223554455|NCT04238091|DRUG|Bowel Prep|The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
223554456|NCT03462641|DRUG|Flumazenil|1mg in 10cc normal saline
223554457|NCT03462641|DRUG|Placebo|10 cc normal saline
223554458|NCT05130385|DEVICE|High-resolution optical coherence tomography (High-Res-OCT)|Imaging with high-resolution optical coherence tomography
223554459|NCT05130385|DEVICE|Standard spectral domain OCT (SD-OCT)|Imaging with standard spectral domain OCT
223735995|NCT00903617|DRUG|GSK256073|x mg for 8 weeks based from data from Part A
223735996|NCT00903617|DRUG|GSK256073|optional dose based on data from Part A
223735997|NCT01577667|DEVICE|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
223735998|NCT03197233|OTHER|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
223735999|NCT00730782|BIOLOGICAL|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
223736000|NCT01200628|BEHAVIORAL|DEPITAC|heteroevaluation scale by a nurse during hospitalization
223403430|NCT06953583|DRUG|Omaveloxolone|Administered as specified in the treatment arm.
223403431|NCT06953583|DRUG|Placebo|Administered as specified in the treatment arm.
223403432|NCT07151677|DEVICE|tDCS (active)|The investigators will administer active tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For active tDCS, the current will slowly be increased to 2mA and applied for 20 minutes.
223736001|NCT00545857|DRUG|pioglitazone|Pioglitazone daily; dose varies with size
223736002|NCT00545857|DRUG|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
223736003|NCT06460896|OTHER|pharmacokinetic study|Multicenter pharmacokinetic study of the bioavailability of four compounds in GBP patients: candesartan, amlodipine, metformin and rosuvastatin.
223736004|NCT01104636|DRUG|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
223736005|NCT06061393|DRUG|Venofer 200 MG Per 10 ML Injection|treat anemia with venofer up to 5 doses
223736006|NCT06061393|DRUG|Ferinject|ferinject 500 mg, once a week for 2 weeks
223403433|NCT07151677|BEHAVIORAL|Attention-focused sentence comprehension treatment|This is a specific type of speech-language therapy that focuses on simultaneously improving auditory comprehension and behavioral attention. Participants will receive 10 sessions of this treatment.
223403434|NCT07151677|BEHAVIORAL|Sentence comprehension treatment|This is a specific type of speech-language therapy that focuses on improving auditory comprehension . Participants will receive 10 sessions of this treatment.
223403435|NCT07151677|DEVICE|tDCS (sham)|The investigators will administer sham tDCS to left dorsolateral prefrontal cortex (DLPFC) during 10 sessions of behavioral treatment. For sham tDCS, the current will slowly be increased to 2mA over the course of 30 seconds and then immediately ramped back down to zero.
223403436|NCT07151430|DEVICE|Service Package Group|patients receive comprehensive multimorbidity management service package (digital tools, MDT decision support, lifestyle interventions, long-term management tools).
223403437|NCT07152990|OTHER|Transcutaneous Oxy-Capnography|Patients will be monitored using transcutaneous oxy-capnography to evaluate the prevalence of nocturnal alveolar hypoventilation in these population. Nocturnal alveolar hypoventilation is defined with PTcCO2 \> 49 mmHg more than 10% of the time of capnographic recording.
223403438|NCT07152990|OTHER|Quality of life questionnaires|"Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and the Patient-Reported Hypoventilation Questionnaire."
223403439|NCT07152990|OTHER|Arterial gasometry|Arterial blood gas analysis will be performed only in patients presenting nocturnal hypoventilation.
223403440|NCT07152990|OTHER|Body plethysmography|Plethysmography will be performed only in patients presenting nocturnal hypoventilation. It will be used to measure lung volume and assess pulmonary function. This non-invasive procedure involves the patient breathing into a device that measures changes in pressure within a sealed chamber.
223403441|NCT07152990|OTHER|Spirometry with reversibility test|The intervention will be performed only in patients presenting nocturnal hypoventilation. Spirometry with a reversibility test will be performed to assess lung function and evaluate the response to bronchodilators. The procedure involves measuring forced expiratory volume and forced vital capacity before and after the administration of a bronchodilator.
223403442|NCT07152990|OTHER|Clinical examination|Clinical exam will be performed only in patients presenting nocturnal hypoventilation. It will consists of standard interview/clinical examination: vital signs, cardiological, pulmonary, abdominal, neurological examination, search for clinical signs of nocturnal hypoventilation, search for signs of hypoxia/hypercapnia, pulmonary auscultation.
223403443|NCT07151898|DIAGNOSTIC_TEST|68Ga-MY6349 PET/CT|Each participant will receive an intravenous injection of 68Ga-MY6349 and undergo PET/CT imaging at baseline and following two and/or four cycles of Trop2-ADC therapy.
223403444|NCT07152145|DEVICE|Active stimulation tSCS|Active transcutaneous spinal cord stimulation (tSCS) delivered with the SCONE™ device. Electrical currents are applied non-invasively through surface electrodes placed on the skin over the spine. Sessions are combined with standardized upper limb rehabilitation therapy. Participants receive stimulation twice per week for 12 weeks.
223403445|NCT07152145|DEVICE|Sham: stimulations using a non-active electric stimulation|Sham stimulation delivered with the SCONE™ device, using identical setup and procedures as the active intervention but without effective current. This procedure is designed to mimic the sensation and experience of active stimulation while delivering no therapeutic neuromodulation. Participants also perform standardized upper limb rehabilitation therapy twice per week for 12 weeks.Transcutaneous Spinal Cord Stimulation (tSCS) - Sham (SCONE™)
223403446|NCT07152145|BEHAVIORAL|Occupational/Upper Limb Rehabilitation Therapy|Standardized occupational therapy program focused on upper limb function. Sessions are delivered in combination with either active or sham transcutaneous spinal cord stimulation.
223403447|NCT07153146|DRUG|PN-881 Oral Solution|PN-881 Oral Solution
223403448|NCT07153146|DRUG|PN-881 Oral Tablet|PN-881 oral tablet
223403449|NCT07153146|DRUG|Placebo|Placebo
223554460|NCT01562392|DIETARY_SUPPLEMENT|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
223403450|NCT07152392|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 500-mg glass vials as a Injection solution containing.
223736007|NCT05947136|BEHAVIORAL|Interpretation of the results from the detection visit|"\- An interpretation of the results of the detection tests concerning~* the 7 complications of interest assessed at T1, T2, T3 and T4 ;~* the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;"
223403451|NCT07152392|OTHER|Follew-up|recived follow-up every six months
223403452|NCT07153120|DEVICE|Erich Arch Bars|Stainless steel plates with hooks for wire placement are adapted over the facial aspect of teeth so the wires would be inserted to go around the necks of teeth (circumdental wiring), then both maxillary and mandibular plates are ligated to each other in order to achieve MMF.
223554461|NCT01562392|DIETARY_SUPPLEMENT|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
223554462|NCT00496678|BEHAVIORAL|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
223554463|NCT00496678|BEHAVIORAL|Standard of Care|Cancer patients receive standard of care for their cancer treatment
223554464|NCT02402504|OTHER|Control|Non pulse extruded snack
223554465|NCT02402504|OTHER|Small particle size pea flour|Pulse extruded snack
223736008|NCT05947136|BEHAVIORAL|Explaining detection results and referrals to the patient|"Explanation of results and directions to the patient using plain language;The aims of this call are as follows:~* Clearly explain the results of the detection visit and the action to be taken for each referral;~* Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;~* Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications."
223736009|NCT05947136|BEHAVIORAL|Early medical care through the network|Early, proactive medical care through a network of dedicated healthcare professionals.
223554466|NCT02402504|OTHER|Large particle size pea flour|Pulse extruded snack
223554467|NCT02402504|OTHER|Lentil flour|Pulse extruded snack
223736010|NCT05947136|BEHAVIORAL|Transmission of results from each detection visit to the referring onco-haematologists - Control Group|For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.
223736011|NCT04472936|PROCEDURE|Single catheter approach|Single venous femoral access will be obtained and the ablation will be performed similar to Group A. After the ablation line is over, we will confirm CTI block using the PRI. During atrial pacing (10 V, 1.5 ms) at a stable cycle length (range 500-700ms) from the tip of the ablation catheter with a sweep speed of 300mm/s, the ablation catheter will be placed first at 5 o'clock (medial to CTI line), then at 7 o'clock (lateral to CTI line), and finally at 9 o'clock position, and the corresponding PRIs will be measured for each pacing site. CTI block is assumed when: (i) the PRI at 7 o'clock is \>80ms longer than that at pacing sites of 5, and (ii) the PRI at 9 o'clock is shorter than the PRI at 7 o'clock.
223403453|NCT07153120|DEVICE|Hybrid Arch Bars|Screw retained titanium plates with hooks for wires are adapted properly then self drilling self locking screws will be drilled in between roots of teeth to avoid injury, after fixation both jaws will be wired to accomplish MMF
224022365|NCT00527592|DRUG|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
223403454|NCT07153120|DEVICE|IMF Screws|A total of four self drilling screws two in the maxilla and the other two in the mandible will be inserted in the bone above and below teeth roots apices to avoid injury, to be ligated to each other in a vertical and an X pattern to achieve MMF.
223403455|NCT07152769|DRUG|Iparomlimab and Tuvonralimab + GC|Iparomlimab and Tuvonralimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w
223403456|NCT07152769|DRUG|Sintilimab + GC|Sintilimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w.
223403457|NCT07152574|DEVICE|TAVR using a tele-operated Robot|TAVR procedure with TAVIPILOT tele-operated robot by Caranx Medical enhancing the precision of transcatheter aortic valve positioning during TAVR.
223403458|NCT07151326|DRUG|Cabozantinib|All patients will be treated with cabozantinib at 60 mg once daily.
223403459|NCT07152041|DRUG|olverembatinib|"All Ph+-ALL patients will uniformly use the 3rd generation of TKI olverembatinib (OVB) instead of dasatinib throughout the regimen.~OVB is combined with Vincristine and Prednisone (VP) during the first 2 weeks and with blinatumomab during the last 4 weeks of remission induction in this protocol.~Patients will receive blinatumomab for 28 days as induction instead of CAT to improve induction response and avoid toxicity.~All patients will receive two cycles of HDMTX+Blina-14 and 4 times of triple intrathecal therapy (TIT) throughout the consolidation 1 phase.~To decrease the toxicities of high-dose AraC, the dosage will be reduced to 1 g/m2 in the consolidation 2 phase in contrast to 2 g/m2 in 2020 protocol.~Throughout the early Maintenance Therapy, dexamethasone and vincristine combination will be added with either venetoclax or daunorubicin alternatively for five cycles, given after MTX and 6-MP."
223403460|NCT07151092|BEHAVIORAL|Adolescent Grief Group|The intervention will include psycho-education, peer-support, and professional supportive counseling from licensed clinicians.
223403461|NCT07152236|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
223403462|NCT07152522|OTHER|cross sectional observational|the therapist measured ROM in six directions: flexion, extension, right and left side bending, and right and left rotation to investigate the association between NDI and ROM of cervical spine
223403463|NCT07152925|DEVICE|Beta-frequency transcranial alternating current stimulation|Active beta-frequency transcranial alternating current stimulation: 20 Hz tACS delivered through a 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak, 100 % intensity, gradually ramped up over 30 s, maintained for 20 min, then ramped down over 30 s; two sessions per day with at least 4 h between sessions, repeated for 7 consecutive days (14 total sessions).
223403464|NCT07152925|DEVICE|sham beta-frequency transcranial alternating current stimulation|Sham transcranial alternating current stimulation: identical 4×1-ring high-definition electrode montage centered on left DLPFC (F3), 2 mA peak-to-peak current ramped up over 30 s and immediately ramped down to 0 mA, followed by 19.5 min of no stimulation to match the 20-min session duration of active tACS; delivered twice daily (≥4 h apart) for 7 consecutive days (14 total sessions).
223403465|NCT07151755|PROCEDURE|Vitrectomy + Direct Intra-Arterial Microneedle Thrombolysis + Standard Care|The patients will receive standard pars plana vitrectomy (PPV) combined with direct intra-arterial microneedle thrombolysis under microscopic visualization, in addition to standard clinical treatment for RAO. A 47G microneedle will be used to deliver thrombolytic agent intra-arterially per protocol.
223403466|NCT07151755|PROCEDURE|Standard Clinical Care Only|The patients will receive standard clinical treatment for RAO without vitrectomy or intra-arterial microneedle thrombolysis.
223403467|NCT07152639|BIOLOGICAL|5μg/ml EEC|0.1ml, one time, containing high dose 5μg/ml of active ingredients
223403468|NCT07152639|BIOLOGICAL|5 unit（U） EC|0.1 ml , one time, containing 5U of active ingredients
223403469|NCT07152639|BIOLOGICAL|5 IU TB-PPD|0.1 ml , one time, containing 5IU of active ingredients
223403470|NCT07152639|DIAGNOSTIC_TEST|IGRA|96-well/plate x 2 plates; 100 tubes/box x 1 box
223403471|NCT07152626|DRUG|LITFULO|Following central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype).
223403472|NCT07152626|PROCEDURE|LITFULO and UVB|Following central randomization, patients will be assigned to receive either ritlecitinib 100mg daily (QD) or a combined therapy using ritlecitinib 100mg QD + twice weekly narrowband UVB treatment for a duration of 52 weeks. At the end of this period, all participants will continue for the open-label phase, receiving ritlecitinib 100mg QD. Eligible participants will be stratified by Fitzpatrick Skin Type (FST, also known as phototype).
223403473|NCT07151287|DIAGNOSTIC_TEST|TCCD|Patients receive non-invasive assessments of TCCD using bedside ultrasound.
223403474|NCT07151287|DIAGNOSTIC_TEST|ONSD|Patients receive non-invasive assessments of ONSD using bedside ultrasound.
223403475|NCT07151287|DIAGNOSTIC_TEST|ODH|Patients receive non-invasive assessments of ODH using bedside ultrasound.
223403476|NCT07151287|DIAGNOSTIC_TEST|Invasive ICP|Patients receive invasive assessments of ICP.
223403477|NCT07151950|DEVICE|One-week trial of Obi Medical device, which provides robotic assistance with feeding to persons with upper extremity impairments who are unable to self-feed in the traditional manner using utensils|"This study explores the stakeholders' experiences in recommending and using Obi. Stakeholders/Participants include:~1. Persons with disabilities or conditions which prevent them from successfully using their upper extremities (UE) to self-feed independently~2. Caregivers of the persons with disabilities described above~3. Providers (OT, SLP, PT, ATP, etc.) who provide services to persons with disabilities"
223403478|NCT07166224|DEVICE|Oral-B Powered toothbrush|"Intervention Group B:~Participants receive standardized oral hygiene instructions and use an Oral-B iO powered toothbrush during the test period.~The Oral-B iO is an advanced powered toothbrush that combines oscillating-rotating and micro-vibrating bristle movements with real-time feedback technology. It is CE-marked for home use and designed to improve plaque removal and overall oral hygiene compared to manual toothbrushing. The device incorporates pressure sensors and guided brushing modes to support optimal brushing technique and patient adherence, which may contribute to improved periodontal outcomes."
223403479|NCT07166224|DEVICE|Dual-Light aPDT Treatment - Lumoral|"Intervention Group A:~Participants receive standardized oral hygiene instructions and use only a manual toothbrush during the test period, with the addition of an adjunctive antimicrobial photodynamic therapy (aPDT) device (Lumoral®).~The Lumoral® treatment device is a CE-marked antibacterial device intended for home use. It is designed to support the treatment and prevention of oral diseases caused by bacterial biofilms. The device functions by emitting light at a specific wavelength, which activates a CE-marked photosensitizing mouthrinse, Lumorinse®. This light-activated process enhances antibacterial efficacy, targeting pathogenic microorganisms in the oral cavity and supporting improved oral hygiene outcomes."
223403480|NCT07170800|DRUG|JDB0131 100mg|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
223403481|NCT07170800|DRUG|JDB0131 200mg|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~JDB0131 (J): 200 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
223403482|NCT07170800|DRUG|Delamanid (D)|"Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw.~Delamanid (D): 100 mg bid.~Linezolid (L): 600 mg qd.~Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd.~Moxifloxacin (M): 400 mg qd.~Clofazimine (C): 100 mg qd."
223403483|NCT05687136|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223554468|NCT02402504|OTHER|Navy bean flour|Pulse extruded snack
223554469|NCT02402504|OTHER|Pinto bean flour|Pulse extruded snack
223554470|NCT04715828|OTHER|Cryopreserved semen|sperm will be frozen in Cryosperm® cryoprotectant medium (Origio). The samples will be packaged in previously identified high security straws (Cryobiosystem). Slow freezing of the straws will be carried out using the Nanodigicool® programmable device (Cryobiosystem).
223403484|NCT05687136|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223403485|NCT05687136|PROCEDURE|Computed Tomography|Undergo CT
223403486|NCT05687136|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223403487|NCT05687136|DRUG|Peposertib|Given PO
223403488|NCT05687136|PROCEDURE|Positron Emission Tomography|Undergo PET
223403489|NCT05687136|DRUG|Tuvusertib|Given PO
223403490|NCT07182318|DIAGNOSTIC_TEST|The FIGO Nutrition Checklist|patient fulfilled the questionnaire twice. period of time 2-3 days
223403491|NCT07183566|DEVICE|Ct|Ct volume measurement of HCC after TACE or MWA
223403492|NCT07182305|DRUG|Efficacy of albendazole for early stage intervention of alveolar echinococcosis|Participants in the treatment arm will be treated with albendazole, 2 x 400 mg daily for the duration of the study. Treatment may be prolonged beyond the end of the study if clinically appropriate.
223403493|NCT07182864|DRUG|MH004 0.1% Ointment|MH004 0.1% ointment applied topically to the affected area as a thin film.
223554471|NCT04715828|OTHER|Acute and low irradiation|sperm sample will be placed on the scanner's processing table to be exposed for 1 to 2 seconds. Several dose levels will then be made in order to limit the value of 17 mGy
223554472|NCT04715828|OTHER|Long and low irradiation|sperm sample will be exposed to gamma radiation by adding a solution of Tc99m for 3 hours.
223554473|NCT04715828|OTHER|Long and medium irradiation|sperm sample will be exposed to gamma radiation by adding a solution of I131 for 3 hours
223554474|NCT05509647|DRUG|Unfractionated heparin|Patients are treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa levels of 0.3-0.7 iE/ml
223554475|NCT04075006|DRUG|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
223554476|NCT01513187|DRUG|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
223554477|NCT04741321|OTHER|VascuQol-6 questionnaire Spanish version|VascuQol-6 questionnaire was translated by two professional translators into Spanish.
223403494|NCT07182864|DRUG|MH004 0.3% Ointment|MH004 0.3% ointment applied topically to the affected area as a thin film.
223403495|NCT07182864|DRUG|MH004 1.0% Ointment|MH004 1.0% ointment applied topically to the affected area as a thin film.
223403496|NCT07182864|DRUG|MH004 3.0% Ointment|MH004 3.0% ointment applied topically to the affected area as a thin film.
223403497|NCT07182864|DRUG|Vehicle Ointment|Matching vehicle ointment applied topically to the affected area as a thin film.
223403498|NCT07182006|BEHAVIORAL|Aerobic Exercise|Submaximal cardiovascular endurance testing on a treadmill
223554478|NCT05245110|BEHAVIORAL|tele-exercise training|a 12-week tele-exercise training program
224022366|NCT01771120|OTHER|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
224022367|NCT00002209|DRUG|CPI-1189|
223736012|NCT04472936|PROCEDURE|Traditional approach|Double venous femoral access will be obtained. A duodecapolar catheter will be positioned in the right atrium around the tricuspid valve annulus (TVA) to record activation sequence around the tricuspid annulus. An ablation catheter will be positioned using fluoroscopic guidance in the central CTI, 6 o'clock in a left anterior oblique view. The distal ablation electrode position will then be adjusted toward or away from the TVA, based on the ratio of atrial and ventricular electrogram amplitudes with an optimal ratio of 1:2 or 1:4 at the TVA. After the ablation catheter is positioned, it will be very slowly withdrawn during ablation toward the inferior vena cava while radiofrequency energy is applied continuously. CTI block will be evaluated after ablation by determining the right atrial activation sequence during pacing from the low lateral right atrium and coronary sinus ostium.
223736013|NCT01508975|OTHER|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
223403499|NCT07182773|BEHAVIORAL|Exercise|The exercise programme will be prescribed at a moderate intensity (Target Heart rate: 60%-65% Heart Rate Reserve + resting heart rate) for 30 minutes immediately prior to infusion therapy, on their treatment days over 12- weeks. Exercise will be completed on a stationary cycle ergometer. Target heart rate will be adjusted to 50-55% Heart Rate Reserve + resting heart rate if patient is complaining of fatigue/nausea, is on beta-blockers or if haemoglobin \<9g/dL. Heart rate monitoring by chest strap using the polar heart rate monitor will allow participants to self-regulate their exercise intensity. Participants should discontinue exercise and await medical review if they develop chest pain, dizziness or pre-syncope, cyanosis or pallor appearance, new musculoskeletal pain.
223403500|NCT07182461|DEVICE|Dynamic Tape|Dynamic Tape is a viscoelastic tape designed to assist movement and absorb load. The material is composed of either Nylon/Lycra or Recycled PET/Lycra.
223403501|NCT07182461|DEVICE|Swiss Ball|A 75 cm diameter Swiss ball was used to provide an unstable surface during the exercise intervention.
223554479|NCT03338478|DIAGNOSTIC_TEST|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
223554480|NCT01222988|DIETARY_SUPPLEMENT|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
223554481|NCT03652766|BEHAVIORAL|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
223554482|NCT03995745|BEHAVIORAL|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
223554483|NCT03186443|DRUG|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
223554484|NCT03186443|DRUG|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
223554485|NCT05143528|DRUG|Nilotinib BE 84mg|84 mg capsule
223736014|NCT00407563|DRUG|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
223736015|NCT00407563|DRUG|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
223736016|NCT02920268|OTHER|Dance and yoga intervention|
223736017|NCT05268159|OTHER|Cognitive assessment|Assessment of unilateral spatial neglect, attention, executive functions and memory
223736018|NCT02855749|PROCEDURE|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
224022368|NCT03801915|DRUG|MVT-5873|1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
224022369|NCT03801915|PROCEDURE|pancreatectomy or hepatectomy|Pancreatectomy or hepatectomy
223403502|NCT07182461|DEVICE|Dumbbells|During the exercise intervention, 1 kg and 2 kg dumbbells were used as external resistance.
223736019|NCT03786016|BEHAVIORAL|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
223736020|NCT05192746|OTHER|control group|Exercise Therapy and hot pack This tendon exercise program is very effective if done consistently. There are five steps to the program: warm up, stretching exercise, strengthening exercise, stretching exercise, and heat.
223554486|NCT05143528|DRUG|Nilotinib BE 112 mg|112 mg capsule
223554487|NCT05143528|DRUG|Placebo|placebo capsule
223554488|NCT01032434|DRUG|sertraline|sertraline: 50-200mg/day
223554489|NCT00436046|BIOLOGICAL|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
223736021|NCT05192746|DEVICE|extracorporeal shock wave therapy|Shock Master 500 device will be applied once a week for four weeks in total. Each treatment consists of 2000 shocks 3 bar pressure, 20 Hz. Each rESWT session will take about 10 minutes. rESWT application will be performed on the supraspinatus trigger point. In successive treatments, there will be using of an energy density equal to 0.28 mJ/mm2
224022370|NCT06244446|OTHER|No intervention|No intervention. It is an observational study
224022371|NCT04438577|DRUG|Lidocaine mucilage-ICG|Lidocaine mucilage-ICG as an agent for intraoperative tumor delineation
224022372|NCT03056989|DRUG|SPX-101|Inhalation solution twice daily for 7 days.
224022373|NCT02912676|DRUG|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Oral 6-thioguanine is added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
223554490|NCT00436046|BIOLOGICAL|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
223554491|NCT02579148|BIOLOGICAL|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.'
223403503|NCT07182461|DEVICE|Visual Feedback Laser Device|A headband was prepared to attach the laser pointer securely, allowing participants to wear it . This visual feedback laser device was used during proprioceptive training to provide real-time feedback.
223403504|NCT07182149|DRUG|NRM-823|NRM-823 is a bispecific T-Cell Engager
223403505|NCT07183917|BEHAVIORAL|Forest Therapy and Mindfulness|Weekly 2-hour guided sessions for 8 consecutive weeks in natural forest environments. Each session includes mindful walking, multisensory awareness (sight, sound, smell, touch), breathing exercises, and guided relaxation practices. Facilitated by certified Forest Therapy and Mindfulness instructors. The intervention is non-invasive, focused on stress reduction, emotional regulation, and improved subjective well-being through mindful immersion in nature.
223403506|NCT07183917|BEHAVIORAL|Indoor Wellness Control|Weekly 2-hour structured sessions for 8 consecutive weeks conducted indoors (classroom or wellness center). Activities include health education talks on stress and wellness, guided music-based relaxation, and eco-friendly culinary tasting experiences. Designed to provide an active comparator condition controlling for attention, group interaction, and wellness-related content without exposure to forest environments or formal mindfulness practices.
223403507|NCT07183397|DIAGNOSTIC_TEST|VExUS & Cardiac Ultrasound|The VExUS system provides a semi-quantitative assessment of systemic venous congestion by integrating ultrasound evaluations of the inferior vena cava diameter, hepatic vein flow, portal pulsatility, and renal venous flow, offering a practical and comprehensive bedside tool
223403508|NCT07183007|OTHER|Low gluten diet|Systemic lupus erythematosus patients with HLA-DQ2 or DQ-8 positive will be randomized to dietary intervention group or control group. Those who are randomized to dietary intervention group will get dietary planning and intervention from a nutritionist with low gluten diet
223403509|NCT07182604|OTHER|educational program on the POP prevention|During a regular prenatal class meeting, parents belonging to this group received information about POP and how to prevent it (a presentation by a physiotherapist, a video shown to all centers participating in the study, practical demonstrations of activities using a doll, and a brochure with prevention tips). The children were then assessed at birth to rule out congenital disorders and at 3 months to detect any POP and associated postural problems. They were then sent a questionnaire to assess their perceived quality of the educational intervention carried out by the physiotherapist during the prenatal course.
223554492|NCT02579148|BIOLOGICAL|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'
223554493|NCT00752934|DRUG|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
223554494|NCT00752934|DRUG|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
223554495|NCT02096952|DRUG|Methylphenidate extended-release liquid formulation|
223554496|NCT04693702|DEVICE|Corneal treatment by a low vision aid device|Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
223554497|NCT02051751|DRUG|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
223554498|NCT02051751|DRUG|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
223554499|NCT00954564|OTHER|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
223554500|NCT00954564|OTHER|medical chart review|Observational only
223554501|NCT00954564|OTHER|questionnaire administration|Observational only
223554502|NCT00954564|PROCEDURE|assessment of therapy complications|Observational only
223554503|NCT05790044|DRUG|Bupivacaine|intra-oral infra-orbital nerve block with bupivacaine alone
223554504|NCT05790044|DRUG|Clonidine|intra-oral infra-orbital nerve block with bupivacaine and clonidine
223554505|NCT00920361|DRUG|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
223554506|NCT06400589|DRUG|tanfanercept|TNF inhibitor
223554507|NCT06400589|DRUG|Vehicle|Same composition as tanfanercept but without the active ingredient
223554508|NCT02739386|BIOLOGICAL|Ipilimumab|Intravenous monoclonal antibody injection
223554509|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
223554510|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
223554511|NCT03647345|DEVICE|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
223554512|NCT00392158|DEVICE|Closed-loop anesthesia system|
223403510|NCT07183254|OTHER|administration of questionnaires|"During this visit, the investigator will again explain the study objectives and procedure. Once these explanations have been provided, healthy volunteers will be able to give their informed consent to participate.~After signing the consent form, the following will be conducted during this visit:~* A medical examination.~* An electronic questionnaire including two consumption frequency assessment tools, adapted in French, to measure daily sugar and artificial sweetener intake.~* Five tests assess the level of dependence on alcohol, drugs (cannabis, solvents, tranquilizers, barbiturates, cocaine, stimulants, hallucinogens, or narcotics), gambling, video games, and possible eating disorders. Volunteers with a score deemed above the norm for at least one of these six tests will be excluded from this study.~* A urine screening test for drug use (cannabis, opiates, amphetamines, cannabinoids, benzodiazepines, cocaine) will be performed during this visit."
223736022|NCT05192746|DEVICE|high power pain threshold ultrasound|"High-power, pain-threshold, ultrasound therapy application (in W/cm2) in continuousmodes, to elicit threshold pain, the ultrasound probe must be kept static on the tendon.~Intensity will be gradually increased to the level of maximum pain the patient could bear. It will be kept at that level for 4 to 5 seconds and then will be reduced to the half-intensitylevel for another 15 seconds. This procedure will be repeated 3 times.High-power,"
223736023|NCT04814134|DEVICE|CPNS Therapy|Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
223403511|NCT07183254|OTHER|carrying out a MRI scan|"A functional exploration using resting-state fMRI and microstructural tissue organization using DTI will take place in the days following the inclusion visit, depending on the availability of research slots in the Department of Radiology and Imaging, Clermont-Ferrand University Hospital."
223403512|NCT07183254|DIETARY_SUPPLEMENT|"Can distribution visit for subjects in the non/low sweetener consumption group"|During this visit, scheduled following the MRI, subjects will go to the PIC/CIC where they will be given cans for the 5 weeks of the nutritional intervention (660 ml of sweetened beverage, or 2 cans per day). Subjects will be advised to arrive by car if possible and to park in the PIC/CIC parking lot at the foot of the building. Drinks will be provided to the subject in one or two batches (with an additional visit to the center to pick up any missing drinks) at the subject's convenience. They will also receive instructions for completing the electronic questionnaire to assess daily sugar and sweetener consumption. Subjects will complete this questionnaire weekly, which they will receive by email. Their email address will be collected during this visit.
223403513|NCT07183254|OTHER|carrying out a MRI scan|"A functional exploration using resting-state fMRI and microstructural tissue organization using DTI, post-nutritional intervention (5 weeks) in non- and low-sugar consumers: this exploration will take place depending on the availability of research slots at the Department of Radiology and Imaging, Clermont-Ferrand University Hospital."
223403514|NCT07182643|DIAGNOSTIC_TEST|Endometrial fluid|Endometrial fluid collection in the day of OPU
223403515|NCT07182643|DIAGNOSTIC_TEST|Endometrial biopsy|Endometrial biopsy on the OPU day, Pipelle
223403516|NCT07182643|DIAGNOSTIC_TEST|Follicular fluid|Follicular fluid sampling on the OPU day
223403517|NCT07183228|BEHAVIORAL|Lifestyle Intervention for Obesity|A multimodal obesity lifestyle program delivered via the Eatit app. The dietitian-led intervention consists of 11 structured modules with weekly dietitian support (video consultations and messaging) during the first 11 weeks, followed by monthly video consultations up to six months. The program integrates behavior change techniques with individualized nutrition counseling provided by licensed dietitians.
223403518|NCT07183735|DIETARY_SUPPLEMENT|BEAM Dream Powder|A powdered sleep supplement. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 3-6.
223403519|NCT07183735|DIETARY_SUPPLEMENT|Placebo Control|A powdered placebo product. Administered daily, mixed with 8-12 oz hot water, 30 minutes before bedtime during Weeks 1-2.
223403520|NCT07183267|DEVICE|Photobiomodulation|Participants will received a daily treatment of photobiomodulation via a LED photobiomodulation device alongside their proton or photon treatment fraction. The photobiomodulation will be administered to the skin in the site of the patients proton or photon therapy treatment area.
223554513|NCT05941208|PROCEDURE|continuous fascia iliaca compartment block|ultrasound Patients were in supine position and the puncture site was selected at 1 cm below the junction point at 1/3 of the connection of anterior superior spine and pubic tubercle. An ultrasound apparatus (Sonosite) high-frequency probe was placed in parallel to the inguinal fold to distinguish the femoral fascia and fascia iliaca, the needle was inserted with out-of-plane technique at an angle of 45° and the tip of the needle was pointed to the head. Once needle-tip placement under the fascia iliaca by hydrolocation was confirmed, the probe was rotated 90° into a longitudinal parasagittal orientation to visualize the needle tip in-plane and to track cephalad spread of the injectate under fascia iliaca, identification of the fascia iliaca plane through the linear probe and introducing epidural catheter 18 G , continuous infusion of bupivacaine 0.25% by a set rate of 7 ml per hour for 24 hours,
223554514|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
223554515|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
223554516|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 3|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
223554517|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 4|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
223554518|NCT02220153|BIOLOGICAL|UCB7665 Intravenous 5|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: intravenous infusion"
223736024|NCT04814134|OTHER|Standard of care|Available standard treatment
223736025|NCT05438056|OTHER|education with mobile application|providing training to mothers of premature babies with a mobile application
223736026|NCT02512237|DRUG|ARX788|ARX788, an antibody drug conjugate
223736027|NCT03055260|DEVICE|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
223736028|NCT03055260|DEVICE|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
223736029|NCT00366145|BIOLOGICAL|Prochymal®|2 infusions of 2 million cells/kg per week for 4 weeks
223736030|NCT00366145|DRUG|Placebo|2 infusions per week for 4 weeks
223736031|NCT00366145|DRUG|Standard of Care for GVHD|Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)
223736032|NCT06184815|BEHAVIORAL|Educational programme 12|Consists of 12 lessons, diabetes education slides and patient materials, with a duration of 4 months and multidisciplinary treatment
223736033|NCT06184815|BEHAVIORAL|Standard education and treatment|Outpatient management and education in the office and consultation referral to nutrition and psychology
223736034|NCT04900831|DIAGNOSTIC_TEST|Omnipolar Eletroanatomical mapping|Analyse intracardiac EGMs collected with the HD Grid catheter (Abbott, Chicago, IL) during routine Atrial Flutter ablation using the Omnipolar algorithm.
223736035|NCT06092489|OTHER|graded motor imagery|The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.
223736036|NCT06092489|OTHER|traditional physiotherapy method|This protocol included stretching and strengthening exercises. Self-stretching will encapsulate the upper trapezius, pectoralis minor, posterior. Each stretch will consist of 3 repetitions of 30 seconds with a 30 second break between repetitions. Strengthening exercises will be performed using elastic resistance bands (Theraband ®) with 4 levels of resistance (red, green, blue and grey). Sets can be easily changed (without the person reporting muscle fatigue) and progressed with resistance. The therapist will ask about the level of effort required for exercise exercises and whether it would be possible to increase the resistance level. The exercise consists of three sets of 10 repetitions and is completed with 1 rest between them. Strengthening exercises will include prone extension, prone external rotation with abduction, side lying external rotation and serratus anterior strengthening.
223403521|NCT07182578|OTHER|Aquatic Occupational Therapy|Aquatic Occupational Therapy sessions will be 60 minutes long, with 45 minutes spent in the pool. Sessions will include a gentle floating, stretching, or aqua yoga warm-up and an ai chi cooldown. Exercises in the first month will include a focus on balance, breathing, and sensory work. Exercises in the second month will focus on building strength and endurance, while the third month will combine all of the above with dual-task completion. Activities will be graded down (made less difficult) or graded up (made more challenging) according to individual participant needs.
223403522|NCT07183943|OTHER|Proprioceptive neuromuscular facilitation (PNF)|Training was performed in different positions (decubitus, sitting, and standing) according to the specific exercise. the participants performed 10 minutes of diagonal scapula exercises (anterior and posterior elevation) and 30 minutes of upper limb diagonals (Flexion-Abduction-External Rotation and Extension-Abduction-Internal Rotation), including the 5 initial minutes of stretching.
223403523|NCT07183943|OTHER|Visual reality (VR)|The site of the intervention was a 20-square-meter room equipped with a multimedia projector, which projected the image on the wall at a height of 1 m and 20 cm. A professional physical therapist supervised the treatment continuously, and every participant received prior instructions on the conduct of the games. The therapeutic protocol included 4 electronic games: Balance Bubble Plus, Rhythm Parade, Tennis, and Box.
223403524|NCT07183943|OTHER|PNF and VR|The total duration of the sessions remained consistent. The participants performed 5 minutes of scapula diagonals and 15 minutes of upper limb diagonals in the weekly session. The games for the PNF/VR group were the same as those for the VR group, except for their duration. Whereas they were performed for 20 minutes each in the VR group, the session including 5 minutes of stretching.
223403525|NCT07184320|BEHAVIORAL|AI-Based Video Education on Denture Care|The intervention consists of an AI-based educational video module, approximately 8 minutes in duration, designed to improve denture care practices. It uses step-by-step, visually engaging demonstrations with AI-guided narration to enhance understanding, recall, and adherence.
223554519|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 1|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
223403526|NCT07184320|BEHAVIORAL|Conventional Oral Health Instruction|Participants in the control group will receive conventional oral health education delivered verbally and chairside by the prosthodontic team. The standardized instruction includes information on denture hygiene techniques, appropriate storage of dentures overnight, mucosal care
223403527|NCT07184294|OTHER|Best Practice|Receive no massage therapy
223403528|NCT07184294|PROCEDURE|Biospecimen Collection|Undergo saliva sample collection
223403529|NCT07184294|PROCEDURE|Massage Therapy|Receive FL therapy
223554520|NCT02220153|BIOLOGICAL|UCB7665 Subcutaneous 2|"* Active substance: UCB7665~* Pharmaceutical form: solution~* Concentration: 140 mg/mL~* Route of Administration: subcutaneous infusion"
223736037|NCT03596528|PROCEDURE|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
223736038|NCT04246060|DRUG|Cysteamine Bitartrate|ERT
223736039|NCT00426192|DRUG|i.v. mannitol|
223736040|NCT00426192|PROCEDURE|hemofiltration|
223736041|NCT00592839|DRUG|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
223736042|NCT00592839|DRUG|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
223736043|NCT04893603|DEVICE|Transcatheter Aortic Valve System|Procedure: Transcatheter aortic valve replacement
223736044|NCT05152901|DRUG|EpiPen ®.|A single dose of 0.3 mg epinephrine via intramuscular injection into the anterolateral aspect of the thigh on Day 1 Visit 2.
223736045|NCT05152901|DRUG|Epinephrine (0.3mg) inhaled|Participants will be administered 0.3mg of first inhaled dose of epinephrine once daily on day 2 of Visit 2
223736046|NCT05152901|DRUG|Epinephrine (1.3mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 1.3 mg epinephrine.
223736047|NCT05152901|DRUG|Epinephrine (4mg)|A single inhaled dose or split into 2 administrations (administered less than 1 minute apart) of a planned dose of 4 mg epinephrine
223554521|NCT02220153|BIOLOGICAL|Intravenous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: intravenous infusion"
223554522|NCT02220153|BIOLOGICAL|Subcutaneous Placebo|"* Active substance: Placebo~* Pharmaceutical form: solution~* Concentration: 0.9 % saline~* Route of Administration: subcutaneous infusion"
223403530|NCT07184294|PROCEDURE|Massage Therapy|Receive HNS therapy
223403531|NCT07184294|PROCEDURE|Massage Therapy|Receive HA therapy
223554523|NCT04325295|PROCEDURE|Laparoscopic ovarian drilling|LOD will be done in the follicular phase.Follow up will be done on the next cycle by performing a TVUS examination at CD 13 and measuring the dominant follicles. Ovulation is considered if a follicle reached \> 17 mm and is confirmed by measuring serum progesterone at CD 21.If ovulation is not achieved in the cycle following LOD, women will be prescribed Letrozole by the dose of 2.5 mg daily for 5 days starting from CD 3, and ovulation monitoring will be done similarly. If ovulation is not achieved, the dose is increased by 2.5 mg daily in the subsequent cycle until reaching the maximum dose of 7.5 mg daily for a total of 3 cycles.With persistent resistance to Letrozole in inducing ovulation, Gn will be prescribed for 3 cycles as in Gonadotrophin strategy
223554524|NCT04325295|DRUG|Recombinant FSH (rFSH)|A low-dose step-up protocol will be implemented. This starts on CD 3,The rFSH will be given through (IM) or(SC) injections with 75 IU and will be given once daily.Monitoring of the treatment will be done on CD 7 by TVUS and serum E2. Monitoring is individualized according to the response. Depending on the response and follicular growth, the dose may be adjusted by increasing 37.5 IU. If follicular growth failed, the dose is furtherly increased by the same amount until at least one follicle reaches 10 mm. The dose is maintained until at least one follicle reaches a diameter of 18 mm and no more than 2 follicles are bigger than 15 mm. Once reaching the desired diameter, the rFSH will be stopped and a trigger of ovulation by an IM injection of 5000 IU of hCG and sexual intercourse is encouraged on the day of trigger and the next day. Then serum P will be done 7 days after hCG injection to detect the occurrence of ovulation.
223554525|NCT00437957|DRUG|Temozolomide|75 Mg/m2/day for all Cohorts
223554526|NCT00437957|DRUG|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
223554527|NCT00437957|PROCEDURE|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
223554528|NCT02684617|BIOLOGICAL|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35. Each cycle is 21 days.
223554529|NCT02684617|DRUG|dinaciclib|dinaciclib 7 mg/m\^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m\^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m\^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35. Each cycle is 21 days.
223554530|NCT03394651|DRUG|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
223554531|NCT03394651|PROCEDURE|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
223554532|NCT02579421|DRUG|Progesterone|generic progesterone
223554533|NCT02579421|DRUG|placebo|placebo
223554534|NCT04301934|DEVICE|Mona Lisa Touch|Fractional CO2 LASER
223554535|NCT04301934|DRUG|Conjugated estrogen|Current standard treatment for recurrent UTIs in postmenopausal women
223554536|NCT04301934|DRUG|Estradiol|Current standard treatment for recurrent UTIs in postmenopausal women
223554537|NCT03660865|DEVICE|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
223554538|NCT03660865|DEVICE|Control IOL|Fellow eye will receive control IOL
223554539|NCT00235235|PROCEDURE|Biopsy|core biopsy
223554540|NCT00235235|PROCEDURE|Serum Collection|serum collection
223554541|NCT00235235|PROCEDURE|Urine Collection|urine collection
223554542|NCT00235235|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
223554543|NCT00235235|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
223554544|NCT00235235|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
223554545|NCT00235235|DRUG|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
223554546|NCT00235235|DRUG|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
223554547|NCT04102800|DRUG|Benralizumab|subcutaneous injection
223554548|NCT02553200|DEVICE|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
223554549|NCT02553200|DEVICE|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
223554550|NCT02553200|DEVICE|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
223554551|NCT00690690|BEHAVIORAL|Video (group-delivered video-based intervention)|group-delivered video-based intervention
223554552|NCT00690690|BEHAVIORAL|HCT|Offer of HIV counseling and testing
223554553|NCT01823159|DRUG|retigabine|Single oral administration of a 400 mg tablet.
223554554|NCT01823159|DRUG|placebo|Single oral administration of a tablet
223554555|NCT03729583|BEHAVIORAL|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
223554556|NCT01555853|DRUG|Abraxane|
223403532|NCT07184294|PROCEDURE|Massage Therapy|Receive combination FL, HNS, and HA therapy
223554557|NCT06644833|DEVICE|Transcranial magnetic stimulation|Transcranial Magnetic Stimulation (rTMS) sessions, targeting the dorsolateral prefrontal cortex, at a frequency of 10 Hz. Each session will last approximately 30 minutes, with 5 sessions per week for 4 to 6 weeks.
223554558|NCT06644833|DRUG|Antidepressant|Selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants, SNRIs
223554559|NCT05894135|DRUG|BG2109 100mg|One tablet of BG2109 100mg , oral , once daily
223403533|NCT07184294|OTHER|Questionnaire Administration|Ancillary studies
223403534|NCT07182357|BEHAVIORAL|Dementia Care Management Checklist for Hospice Transitions|"Intervention: After appropriate care partners of hospice-eligible PLWD are identified who will be receiving the checklist intervention, care managers will perform telephonic outreach to engage them in a conversation about care needs (as they would in typical clinical practice). The telephonic outreach will be followed up with a recommendation for follow up by a medical provider who may conduct a hospice care assessment and engage the care partner in decision-making surrounding the hospice referral and enrollment process.~This intervention was co-designed with care partners, home healthcare professionals, administrators, and medical providers. It is meant to be comprehensive and speak to the needs of all relevant parties engaged in the care of persons with dementia. It is developed so that it can be scaled and implemented widely."
223554560|NCT05894135|DRUG|BG2109 200mg|One tablet of BG2109 200mg, oral , once daily.
223403535|NCT07184021|DRUG|Gemcitabine and Cisplatin (DD GC)|Participants will receive neoadjuvant ddGC, consisting of gemcitabine and cisplatin administered at shortened intervals (e.g., gemcitabine 1200 mg/m² on days 1 and 8, fractionated cisplatin 35 mg/m² on day 1and 8, every 14 days) with appropriate growth factor support. A total of four cycles are planned before radical cystectomy.
223403536|NCT07183904|PROCEDURE|Hematoma Block|Injection of 5-10 mL of 2% mepivacaine directly into the fracture hematoma under aseptic conditions.
223554561|NCT05894135|DRUG|ABT(E2 1 mg / NETA 0.5 mg)|One tablet of ABT(E2 1 mg / NETA 0.5 mg), oral, once-daily
223554562|NCT05894135|DRUG|BG2109 100mg Placebo|One tablet of BG2109 100mg Placebo, oral , once daily.
223736048|NCT05047328|BIOLOGICAL|inolimomab|"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."
223736049|NCT00851812|BEHAVIORAL|Exercise|Standard care monitoring
223403537|NCT07183904|PROCEDURE|Median Nerve Block|Injection of 3-5 mL of 2% mepivacaine adjacent to the median nerve at the wrist, using anatomical landmarks.
223554563|NCT05894135|DRUG|BG2109 200mg Placebo|One tablet of BG2109 200mg Placebo, oral , once daily.
223554564|NCT05894135|DRUG|ABT Placebo|One tablet of ABT Placebo, oral, once-daily
223403538|NCT07175467|OTHER|Haptic-asissted virtual simulation|The virtual reality application will be developed using the Unity game engine. The VR simulation environment, which will progress through scenarios, will include taking vital signs, performing aspiration, performing a nasogastric catheterization, oxygen therapy, performing physical examinations, and performing subcutaneous injections.
223554565|NCT00000149|DRUG|Beta Blocker|
223554566|NCT00000149|PROCEDURE|Trabeculectomy|
223554567|NCT00000149|PROCEDURE|Argon Laser Trabeculoplasty|
223554568|NCT03037359|BIOLOGICAL|Bivigam|Human immune globulin
223554569|NCT03037359|BIOLOGICAL|Other|Human immune globulin
223554570|NCT03122678|DRUG|Thiamine|
223554571|NCT03122678|DRUG|Placebos|
223554572|NCT04082845|OTHER|Education|Web-based patient education
223554573|NCT04534179|PROCEDURE|Vacuum myofascial therapy and physical activity program.|"This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 30 minutes.~Then they carried out the physical activity program"
223554574|NCT04534179|OTHER|Physical activity program.|Active Comparator: Physical activity The exercise protocol would last 5 weeks, performing 3 exercise sessions per week, with an effective work time of 20 minutes per session. The exercises would be directly focused on activating the core stabilizing muscles.
223736050|NCT00851812|BEHAVIORAL|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
223736051|NCT00319917|DRUG|tacrolimus|oral
223736052|NCT00319917|DRUG|placebo|oral
223403539|NCT07182526|DRUG|Quercetin|Quercetin 500 mg capsule daily after meal for three months
223403540|NCT07182526|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha lipoic acid 600mg SR capsule daily after meal for three months period.
223554575|NCT06556875|BEHAVIORAL|HIIT|high intensity interval training
223554576|NCT06556875|BEHAVIORAL|HIIT combined IET|high intensity interval training combined with isometric exercise training
223554577|NCT04651439|DRUG|Filgrastim|"Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)"
223554578|NCT04651439|DRUG|Placebo|"Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* \> 150kg = 20mL of Glucose 5% solution (by IV)"
223554579|NCT04904406|DRUG|Dolutegravir / Lamivudine Oral Tablet|Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
223554580|NCT00332020|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
223554581|NCT00332020|DRUG|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
223554582|NCT01175265|OTHER|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
223554583|NCT06635434|DEVICE|AR Pain assessment|Age-stratified (age 7-11 and age 12-17 years old) augmented reality app to evaluate for pain and opioid-related adverse events with equivalent English and Spanish text, audio, and narration
223554584|NCT06435416|OTHER|No intervention|No intervention
223403541|NCT07182526|DRUG|MetFORMIN 500 Mg Oral Tablet|metformin 500 mg daily for three months
223403542|NCT07183553|OTHER|maintenance training|information has been provided in accordance with the content of the training booklet.
223403543|NCT07182071|BEHAVIORAL|Physical Activity Program|Three 60-minute supervised group exercise sessions per week for 10 weeks, led by a certified instructor.
223403544|NCT07182071|BEHAVIORAL|Waitlist for Physical Activity Program|Three 60-minute supervised group exercise sessions per week for 10 weeks, led by a certified instructor.
223403545|NCT07183683|DEVICE|group 1: electrical stimulation of acupuncture points plus routine care|The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min electrical stimulation per foot with 10Hz and an intensity up to individual tolerance level.
223403546|NCT07183683|OTHER|group 2: acupressure plus routine care|The acupuncture points Spleen 6 and Kidney 3 will be stimulated twice daily with a up to 30min massage per foot
223403547|NCT07182201|BEHAVIORAL|Foot core control training|(1) Toe Yoga : When MTPJ1 actively dorsiflexes, the other four toes remain in contact with the ground. The subject lifts the big toe while the remaining four toes stay on the ground; conversely, when the big toe contacts the ground, the other four toes lift upward, alternating this pattern. (2)Doming: While keeping MTPJ1 in contact with the ground, elevate the foot arch. This exercise strengthens intrinsic foot muscle strength, helping stabilize the arch and first metatarsal. The subject tightens the toes, bringing the forefoot toward the heel to form and enhance the arch. Maintain all toes firmly planted on the ground, ensuring no ankle inversion, no forced flexion or extension of toes, and hold at maximum position. Perform training seated to avoid compensatory movements by external muscles during exercise. (3) Toe Abduction Exercises（4）Dynamic Exercise Progression
223403548|NCT07182201|BEHAVIORAL|CPF Conventional training|The key points of the exercise are as follows: (1) Fascia ball release of plantar fascia (2) Plantar fascia stretching (3) Gastrocnemius muscle stretching (4) Toe grab towel
223403549|NCT07181967|DRUG|Sodium Fluoride Varnish (5%)|Topical application of 5% sodium fluoride varnish (22,600 ppm fluoride) to cavitated dentin caries lesions (ICDAS 3-5) on the contralateral side of the mouth. Applied once using a disposable applicator per manufacturer's instructions. This distinguishes it from lower-concentration fluoride gels or multiple-application protocols in other clinical trials.
223403550|NCT07181967|DRUG|Silver Diamine Fluoride (38%)|"Topical application of 38% silver diamine fluoride solution (44,800 ppm fluoride) to cavitated dentin caries lesions (ICDAS 3-5) on the assigned side of the mouth. Applied once with a microbrush for 1 minute, per manufacturer's instructions, without subsequent rinsing. This concentration and protocol distinguish it from other concentrations of SDF or repeated-application protocols used in other clinical studies."
223403551|NCT07182435|BIOLOGICAL|personalized neoantigen mRNA tumor vaccine|RH125 is a personalized neoantigen mRNA tumor vaccine which is constructed based on the results of patients' neoantigen sequencing.
223403552|NCT07183774|DIAGNOSTIC_TEST|Sarcopenia will be assessed using the STAR (Sonographic Thigh Adjustment Ratio) method.|A detailed evaluation of shoulder MRI scans will be conducted. The presence and severity of supraspinatus tendon tears, as well as the presence of muscle atrophy (assessed using the tangent sign), will be recorded. In addition, tears in other rotator cuff tendons, signs of tendinitis, and any other pathological findings will also be documented.
223403553|NCT07176442|BEHAVIORAL|MOOC (E-Learning)|Participants complete a structured Massive Open Online Course (MOOC) hosted on Canvas. The course includes four 4-5 minute video modules on diabetic ketoacidosis, with interactive quizzes between modules.
223554585|NCT04482439|DEVICE|Vivity Extended Depth of Focus intraocular lens (IOL)|Bilateral implantation of the Vivity lens after cataract surgery, with slight myopia planned in the non-dominant eye.
223554586|NCT03018535|DRUG|Rituximab|Rituximab,1 g IV, day 1 and day 15
223554587|NCT03018535|DRUG|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
223554588|NCT03018535|DRUG|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
223554589|NCT02318368|DRUG|Ficlatuzumab|
223554590|NCT02318368|DRUG|Erlotinib|
223554591|NCT02318368|DRUG|placebo|
223554592|NCT02201329|DRUG|Azacitidine|Azacitidine (subcutaneous)
223554593|NCT02201329|DRUG|Volasertib|Volasertib escalating doses (intravenous)
223554594|NCT04280016|BEHAVIORAL|Exercise|Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
223554595|NCT06425913|OTHER|Kinesio Taping (KT)|KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
223554596|NCT06425913|OTHER|Cold Therapy (CT)|The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, …). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
223554597|NCT06425913|OTHER|standardized home exercise program|All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
223554598|NCT05178836|DRUG|F520+F007|"Drug: F007~F007 is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC).~Drug: F520~F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)."
223554599|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 1 mg|Singel-dose; Subcutaneous
223403554|NCT07176442|BEHAVIORAL|Simulation Training|Participants take part in a high-fidelity simulation session using a mannequin programmed for diabetic ketoacidosis management. Each session is followed by a structured debriefing led by the instructor.
223403555|NCT07176442|BEHAVIORAL|Educational Escape Game|Participants join a 30-minute educational escape game with 10 puzzles that guide them through the diagnosis and management of diabetic ketoacidosis. The activity emphasizes collaboration and problem-solving.
223403556|NCT07182110|DRUG|Dexamethasone enhanced TAP Block|20 ml Marcaine containing 0.25% bupivacaine + 4 mg dexamethasone + normal saline
223403557|NCT07182110|DRUG|Marcaine- 0.25%|20 ml solution containing 0.25% bupivacaine + normal saline
223403558|NCT07174726|BIOLOGICAL|Adeno-associated virus vector expressing a human RPGR gene|Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501
223736053|NCT02366845|BIOLOGICAL|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
223736054|NCT02366845|DIAGNOSTIC_TEST|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
223736055|NCT02366845|DIAGNOSTIC_TEST|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
223403559|NCT07172009|OTHER|Chlorhexidine mouthwash|Rinsing the mouth with chlorhexidine mouthwash for 2 minutes before consuming 50 g of carbohydrates
223403560|NCT07172009|OTHER|Placebo mouthwash|Rinsing the mouth with placebo mouthwash for 2 minutes before consuming 50 g of carbohydrates
223403561|NCT07184359|BEHAVIORAL|Traditional Learning|All participants will have access to the conventional teaching-learning process (lecture-based classes). These theoretical classes will be delivered as part of the Dental Radiology course. During the semester, the topics covered will include intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
223403562|NCT07184359|BEHAVIORAL|Passive Social Media|The second group (Passive Social Media Supplement Group) will participate in the conventional teaching-learning process, supplemented by the passive consumption of educational content on social media, produced by the third group. The materials consumed will include the following content: intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
223403563|NCT07184359|BEHAVIORAL|Active Social Media|The third group (Active Social Media Engagement Group) will participate in the conventional teaching-learning process, supplemented by the creation of educational audiovisual materials, which will subsequently be shared on social media and accessed both by their own group and by the second group. The materials will cover the following topics: intraoral radiographic techniques, radiographic processing, intraoral radiographic anatomy, and dental and periodontal alterations and lesions.
223403564|NCT07183618|PROCEDURE|Mental training group|"Mental Training Group: Residents in the Mental Training group received a mental preparation session led by an anaesthesia physician qualified in medical pedagogy. Inspired by the Breathe, Talk, See, Focus procedure"
223403565|NCT07183332|BEHAVIORAL|High frequency follow-up|Patients in the high-frequency group received regular follow-ups at a high frequency after discharge.
223403566|NCT07182721|DRUG|SKB264 Plus Inetetamab|SKB264: 5 mg/kg administered on Day 1 of each 2-week cycle. Inetetamab: an initial loading dose of 6 mg/kg is administered, followed by subsequent maintenance doses of 4 mg/kg. Dosing occurs on Day 1 of each 2-week cycle.
223403567|NCT07184463|OTHER|Evaluation of chronic pain at 3 and 6 months after thoracic surgery|The presence of persistent postoperative pain, defined as ipsilateral chest pain (on the same side as the surgery) occurring at rest and/or with coughing on a daily basis. Assessed by a 'yes' or 'no' response when asked at 3 and 6 months postoperatively.
223403568|NCT07183020|DIAGNOSTIC_TEST|Oligoclonal bands and kappa free light chains (KFLC)|Comparison of oligoclonal bands and kappa free light chains (KFLC) in patients with multiple sclerosis (MS) / clinically isolated syndrome (CIS)
223403569|NCT07183722|OTHER|Microbiota analysis|Analysis of microbiota in patients admitted to the following departments: General Anesthesia and Resuscitation, Cardio-Thoracic-Vascular Anesthesia and Resuscitation, Internal Medicine, and MeCAU.
223403570|NCT07184255|OTHER|Patient Education Video Intervention|Animated video with high-contrast visuals and audio narration in the patient's preferred language, covering diagnosis, surgical steps, and post-operative positioning.
223554600|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 4 mg|Singel-dose; Subcutaneous
223554601|NCT06422624|DRUG|Semaglutide Extended-release for Injectable Suspension, 8 mg|Singel-dose; Subcutaneous
223554602|NCT01158443|BEHAVIORAL|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
223554603|NCT01158443|BEHAVIORAL|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
223554604|NCT01168843|OTHER|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
223554605|NCT02429193|DRUG|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
223554606|NCT02429193|DRUG|Enzalutamide|Enzalutamide (160 mg/day p.o.)
223736056|NCT03861715|DIAGNOSTIC_TEST|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
223736057|NCT00223951|DRUG|R89674 (generic name not yet established)|
223736058|NCT01531374|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
223736059|NCT05369455|PROCEDURE|erector spinae plane block|determine the efficacy and safety of ultra-sound guided erector spine plane block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
223403571|NCT07183462|DRUG|Intravenous Ampicillin followed by Oral Amoxicillin|This intervention consists of intravenous Ampicillin 2 grams every 6 hours for 48 hours, followed by oral Amoxicillin 500 mg every 8 hours for 5 days
223403572|NCT07183462|DRUG|Ampicillin/Amoxicillin plus single-dose IV Azithromycin|This intervention includes intravenous Ampicillin 2 grams every 6 hours for 48 hours, followed by oral Amoxicillin 500 mg every 8 hours for 5 days, plus a single dose of intravenous Azithromycin 1 gram administered once at the start of treatment
224132231|NCT05678413|PROCEDURE|DVIU with paclitaxel injection|Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the length of each incision into healthier appearing tissue for a total of 5 mL.
223403573|NCT07172581|BEHAVIORAL|Online low-FODMAP diet|Participants were invited to follow the online low-FODMAP diet offered by SOSCuisine®, characterized by three specific features. First, participants received customized weekly low-FODMAP menus based on the Monash University protocol. Second, a virtual assistant accompanied participants from the beginning to the end of the diet implementation, providing personalized recommendations tailored to individual's preferences and intensity of symptoms. For the reintroduction phase, the assistant guided individuals through the process of testing specific FODMAP subgroups, offering food suggestions based on individual preferences, and portion sizes. The last feature of the platform was the access to a peer support group on Facebook©, designed to foster communication among participants. This group allowed individuals to ask questions and receive valid answers, as the group was moderated by a FODMAP-specialized registered dietitian.
223403574|NCT07182331|DEVICE|Continuous Theta Burst Stimulation to Bilateral DLPFC|Participants receive continuous theta burst stimulation (cTBS) targeting both the left and right dorsolateral prefrontal cortex (DLPFC) during each session. Each hemisphere is stimulated with 600 pulses (triplets at 50 Hz repeated at 5 Hz) over \~40 seconds, at 80% of the individual's active motor threshold. Sessions are administered once daily over 10 treatment days.
223403575|NCT07182331|DEVICE|Sham Continuous Theta Burst Stimulation|Participants receive sham continuous theta burst stimulation (cTBS) to both the left and right dorsolateral prefrontal cortex (DLPFC) using a placebo coil that mimics the auditory and tactile sensations of real stimulation but does not produce a magnetic field capable of affecting brain activity. Coil positioning, session timing, and procedure match the active cTBS protocol, including consecutive stimulation to both hemispheres. Both participants and TMS technicians wear earplugs to mask subtle sound differences between active and sham coils. This setup maintains participant and operator blinding and controls for placebo-related effects.
223554607|NCT00574392|DEVICE|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
223554608|NCT00442494|DRUG|intravenous hydrocortisone|
223554609|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
223554610|NCT00711282|DEVICE|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
223554611|NCT01060748|BIOLOGICAL|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
223554612|NCT01060748|BIOLOGICAL|Placebo|Placebo
223554613|NCT05879393|DIETARY_SUPPLEMENT|OMNi-BiOTiC® Active|Multistrain probiotic
223554614|NCT05879393|OTHER|Placebo|rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
223554615|NCT01926951|DEVICE|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
223554616|NCT03571360|OTHER|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
223554617|NCT00858728|BEHAVIORAL|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
223554618|NCT00858728|BEHAVIORAL|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
223554619|NCT02284256|DRUG|Fibrocaps|
223554620|NCT02284256|DRUG|TachoSil|
223554621|NCT01995500|DEVICE|BioNIR|drug-eluting stent
223554622|NCT01995500|DEVICE|Resolute|drug-eluting stent
223554623|NCT05777668|RADIATION|Volumetric modulated radiotherapy|
223554624|NCT04320056|OTHER|Standard administration of oxygen flow|"The investigator recommended SpO2 target of 90-94%. The investigator will recommend that low/high SpO2 alarms be set at 88% and 96% if continuous oximetry is used.~In this group the SpO2 was recorded any time with FreeO2 device - recording mode"
223554625|NCT04320056|DEVICE|Automated oxygen administration - FreeO2|In this group, oxygen administration will be delivered with FreeO2 (automated oxygen titration) with SpO2 target set at 92% (to maintain oxygenation in the recommended SpO2 target: 90-94%)
223554626|NCT00061035|BIOLOGICAL|Transgenic Lymphocyte Immunization Vaccine (TLI)|
224132232|NCT05678413|PROCEDURE|DVIU|DVIU
224132233|NCT00190203|PROCEDURE|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
224132234|NCT00190203|PROCEDURE|hemicraniectomy|hemicraniectomy
224132235|NCT02496637|BEHAVIORAL|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
223403576|NCT07183501|PROCEDURE|Combined hystroscopic and laparoscopic repair|Hystroscopic isthmoplasty will be done first to ensure removal of chronically inflamed Unhealthy edges of niche, then laparoscopic exison of scar will be dine, followed by repair of the defect
223736060|NCT05369455|PROCEDURE|ultrasound guided caudal block|determine the efficacy and safety of ultra-sound guided caudal block for providing postoperative analgesia in pediatric patients scheduled for lower limb surgeries as regard pain score , duration of analgesia and total postoperative analgesic requirement as a primary outcome as well as their safety as regard hemodynamics, adverse events local complications as secondary outcomes.
223736061|NCT00934154|DRUG|Thalidomide|100 mg/day continuously for 12 months
224132236|NCT02496637|BEHAVIORAL|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
224132237|NCT01291329|GENETIC|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
224132238|NCT02733614|DRUG|SRX246|novel V1a receptor antagonist
224132239|NCT02733614|DRUG|Placebo|matching placebo
223403577|NCT07184411|OTHER|Activities-based locomotor training|Activities-based locomotor training involves placing the child in a partial body-weight supported (PBWS) system over a treadmill. The child is given assistance by trained clinicians to attempt standing and walking on the treadmill for 1 hour. The child then participates in play-based activities aimed to foster independence in an overground (regular) environment for 1 hour. The final hour of the 3-hour session is conducted in the PBWS system with a focus on standing and walking.
223403578|NCT07184411|OTHER|physical therapy|In this intervention, the child will attend their usual physical therapy sessions.
223736062|NCT00934154|DRUG|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
223736063|NCT04895215|DRUG|AB-2004|Taken 3 times daily with food
223736064|NCT04895215|DRUG|Placebo|Take 3 times daily with food
223403579|NCT07183189|DRUG|SHR-A2009 ; Aumolertinib|SHR-A2009 administered intravenously, Aumolertinib administered orally.
223403580|NCT07183189|DRUG|Aumolertinib|Aumolertinib administered orally
223403581|NCT07183514|BIOLOGICAL|eggshell-derived calcium hydroxyapatite|eggshell-derived calcium hydroxyapatite will be placed as an indirect pulp capping material after chemo-mechanical caries removal and before final restoration with glass ionomer cement and composite resin.
223736065|NCT03577743|DRUG|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
223736066|NCT05789979|DEVICE|The resident-handling device|Care staff will perform resident-handling tasks using the new resident-handling devices. For low dependency during trial, the device helps care staff to assist residents in making a transition from a sit to a standing posture, vice versa. This device is used for functional activities and transferring and lifting participants. For high dependency during trial, when care staff are performing resident-handling tasks, the device moves with little force in any direction.
223736067|NCT03331679|BEHAVIORAL|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
223736068|NCT00229099|DRUG|GerEPO|
223736069|NCT06380088|OTHER|Isometric Task|The exercise required participants to keep their arm flexed at a 90° angle while holding a dumbbell loaded to 80% of their 1RM (One Rep Max) in a supine position on the dominant side of the body for as long as possible.
223736070|NCT02622516|OTHER|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
224132240|NCT02334332|OTHER|Educational Intervention|Receive educational brochure
223403582|NCT07183514|BIOLOGICAL|Calcium hydroxide|Calcium hydroxide will be placed as an indirect pulp capping material after chemo-mechanical caries removal and before final restoration with glass ionomer cement and composite resin.
223403583|NCT07183111|OTHER|Instructions given via artificial intelligence chatbot in form of voice instructions at chair side with Customized chatbot for remote home support|Instructions given via artificial intelligence chatbot in form of voice instructions at chair side with Customized chatbot for remote home support
223403584|NCT07183111|OTHER|Control group instructions given by chair side orthodontist verbally and written pamphlet as home care support|Control group instructions given by chair side orthodontist verbally and written pamphlet as home care support
223403585|NCT07184333|BEHAVIORAL|Interprofessional Education with Digital Case Management for Home-Based Elder Care|A structured interprofessional education programme for nursing and physiotherapy students that includes: (1) a 3-hour workshop on frailty assessment, digital case documentation, and care planning; (2) a 30-minute orientation on home visit safety and communication; (3) supervised home visits to older adult participants involving health and fitness assessments, medication support, and health education; (4) use of a tablet-based digital case management platform for collaborative care documentation; and (5) a 4-week follow-up with personalised mobile health messages and a final home visit. The intervention aims to enhance students' clinical, collaborative, and digital competencies in community-based elder care.
223403586|NCT03117179|OTHER|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
224132241|NCT02334332|PROCEDURE|Standard Follow-Up Care|Receive standard post-operative care
224132242|NCT02334332|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224132243|NCT05941949|DIETARY_SUPPLEMENT|Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E|2 softgels per day
224132244|NCT05941949|DIETARY_SUPPLEMENT|Placebo|2 softgels per day
224132245|NCT00331370|BEHAVIORAL|GP training and Health Education|
224132246|NCT01574222|BIOLOGICAL|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
223403587|NCT05630781|DRUG|Belsomra|randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional approximately 7 days and then scanned a final time.
223403588|NCT05630781|DRUG|Placebo|comparator taken for approximately 10 days
223403589|NCT05630781|DRUG|Methylphenidate|Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
223736071|NCT02622516|OTHER|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
224132247|NCT05005741|DRUG|Beinaglutide|Patients received beinaglutide subcutaneously three times a day for 16 weeks, the dose of beinaglutide escalate from 0.06mg to 0.2mg per 3-7 days according to subject's specific situation.
223403590|NCT04960579|BIOLOGICAL|P-BCMA-ALLO1 CAR-T cells|Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
223403591|NCT04960579|DRUG|Rimiducid|Safety switch activator
223403592|NCT06131372|DRUG|Cagrilintide|Participants will receive Cagrilintide subcutaneously.
223403593|NCT06131372|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
223403594|NCT06131372|DRUG|Placebo|Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.
223403595|NCT06528353|DIAGNOSTIC_TEST|HPV16-E6 serology and HPV ctDNA|"In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance."
223403596|NCT02710448|DRUG|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
223403597|NCT06787690|DEVICE|Cohealyx|Cohealyx application, followed by autologous split-thickness skin graft
223403598|NCT04222010|DRUG|loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
223403599|NCT04222010|DRUG|Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
223403600|NCT04222010|DRUG|Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)|Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
223403601|NCT06215716|DRUG|Efruxifermin|Administered by subcutaneous injection
223403602|NCT06215716|DRUG|Placebo|Administered by subcutaneous injection
223403603|NCT06388733|DRUG|Niraparib|Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR
223403604|NCT06388733|DRUG|Temozolomide|Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
223403605|NCT06548542|DRUG|Risankizumab|Subcutaneous Injection
223403606|NCT06548542|DRUG|Lutikizumab|Subcutaneous Injection
223403607|NCT06548542|DRUG|ABBV-382|Intravenous Infusion
223403608|NCT06548542|DRUG|Risankizumab|Intravenous Infusion
223403609|NCT06548542|DRUG|ABBV-382|Subcutaneous Injection
223403610|NCT04252950|BEHAVIORAL|CB-SET|Community-based structured exercise therapy (CB-SET) programs for PAD have potential merit as an alternative to hospital-based SET, as they may provide similar benefit to hospital-based programs but in a convenient location for the exercise to be completed
223403611|NCT04252950|PROCEDURE|Revascularization|Endovascular revascularization is a primary treatment option for patients with PAD
223403612|NCT05582122|BIOLOGICAL|HPV16 Ct-DNA dosing|"Droplet based digital PCR (ddPCR) technology is a novel method for performing digital PCR. A sample is fractionated into 20,000 droplets, PCR amplification of the template molecules occurs in each individual droplet.~ddPCR allows to generate quantitative and accurate data without standard curves and also present higher sensitivity compared to conventional quantitative PCR (qPCR). Indeed, this method is based on the realization of millions of single-molecule PCRs in parallel in independent compartment (here droplets of an emulsion) and consequently avoids the bias seen in conventional PCR.~ddPCR offers an optimized approach for the sensitive detection and quantification of low-target-abundance biological samples.~DNA extraction will be planned on 1 mL of plasma, which will further increase the sensitivity of our technique initially based on only 200µL of DNA extracted plasma."
223403613|NCT06326255|BEHAVIORAL|laughter yoga|each class, including warm-up exercises, laughter yoga exercises, breathing and a relaxation session and sharing
223403614|NCT05506254|DRUG|hLB-001|hLB-001 gene therapy
223403615|NCT06843434|DRUG|Balstilimab|Balstilimab is a fully human monoclonal IgG4 antibody designed to block PD-1 binding to PD-L1 and PD-L2
223736072|NCT04202991|OTHER|Exposure - pain|Groups are defined by their naturally occurring exposure to pain or not
223736073|NCT05800795|DEVICE|Er: YAG laser|surface treatment with Er: YAG laser for heating abutments
223736074|NCT05800795|DEVICE|plasma spray|surface treatment with plasma spray for heating abutments
223736075|NCT03940664|OTHER|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
223736076|NCT00249444|DRUG|Mirtazapine|Mirtazapine
223403616|NCT06843434|DRUG|Botensilimab|Botensilimab is a novel fully human fragment crystallizable (Fc)-engineered immunoglobulin 1 kappa (IgG1κ) anti-CTLA-4 immunoglobulin G1 (IgG1) antagonist antibody that is designed to optimally promote fragment-crystallizable gamma receptor (FcγR) effector functions that are important for enhancing T cell priming and regulatory T cell (Treg) depletion.
223403617|NCT06205784|OTHER|Prehabilitative exercise|3-4 weeks of heavy resistance exercise
223403618|NCT03461900|OTHER|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
223554627|NCT05023291|DIAGNOSTIC_TEST|Positron Emissie Tomografie - Computer Tomografie|In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
223554628|NCT06285045|DRUG|Roujin Formula|48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
223554629|NCT04665427|OTHER|bilioenteric anastomosis i|The creation of communication between a bile duct and a segment of the digestive tract, often to restore a flow of bile in the digestive tract,
223554630|NCT01945996|BEHAVIORAL|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
223554631|NCT01945996|BEHAVIORAL|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
223554632|NCT01066104|DRUG|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
223554633|NCT01066104|DRUG|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
223736077|NCT00249444|DRUG|Placebo|placebo
223736078|NCT03081507|BEHAVIORAL|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
223736079|NCT03081507|BEHAVIORAL|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
223736080|NCT05502393|DRUG|JS107|JS107, i.v., q3w
223736081|NCT05502393|DRUG|Toripalimab|Toripalimab i.v., q3w
223736082|NCT05398601|OTHER|MOBILIZATION with MOVEMENT|"They would be receiving conventional treatment as follow:~TENS (Transcutaneous electrical nerve stimulation) applied asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold - 10 mins Hot Pack - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive MWM techniques for Knee~1. Medial glide~2. Medial+ Internal rotation glide~3. Lateral Glide+ Internal Rotation glide~4. Anterior glide~5. Posterior glide"
223736083|NCT05398601|OTHER|Periosteal electrical dry needling|"They would be receiving conventional treatment as follow:~TENS (asymmetrical, biphasic waveform, pulse duration at 100 ms, intensity 10 percent below the motor threshold) - 10 mins HOT PACK - 10 mins ULTRASOUND - 10 mins~Additionally, the would receive periosteal electrical dry needling 4 point technique for Knee~Four sterile, single-use 30-gauge dry needles would be inserted into the following locations of the symptomatic knee(s) until they touch bone:~1. Medial femoral condyle~2. Lateral femoral condyle~3. Flare of the tibia~4. Head of the fibula Needles would be stimulated with 100 Hz for 30 minutes. The intensity of the stimulus would be adjusted so that it would be clearly felt but would not cause discomfort. The stimulus intensity would be adjusted periodically so that it is perceptible for the entire 30 minutes of PST."
223736084|NCT00026351|BIOLOGICAL|rituximab|
223736085|NCT00026351|DRUG|pentostatin|
224132248|NCT05005741|DRUG|Dulaglutide|Patients received 1.5mg Dulaglutide subcutaneously once-weekly for 16 weeks.
223403619|NCT03461900|OTHER|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
223403620|NCT06846476|OTHER|Insole|"The production process of the insoles will be produced by Computer Aided Design and Computer Aided Manufacturing (CAD-CAM) method by making plantar pressure analysis and physical evaluation of the individual.~The insoles will be designed to reduce the load in areas where the pressure is high with off loading technique. The design of the insoles to be produced individually will be made by the researcher (expert orthotist). The materials to be used in the production of insoles will be determined according to the needs of the participant and materials suitable for diabetic individuals will be preferred. In this context; mostly Ethyl Vinyl Acetate (EVA) and materials with cellular air permeability on the upper surface will be used."
223403621|NCT06846476|OTHER|Demographic Information and Anamnesis Form|Demographic information and anamnesis form; demographic information of the participant, disease history, physical condition of the foot, skin condition, medications used, allergic status, surgical history, presence of edema, discolouration and temperature increase.
223403622|NCT06846476|OTHER|Pedobarographic analysis|"Pedobarographic analysis and evaluation of postural balance are widely used by clinicians and researchers to examine the foot structure and to determine the loading patterns of the foot. The data are obtained with electronic sensors placed on the platform where the gait takes place. The sensors are directly connected to the platforms and the computer system programmed to perform foot analysis. With the pedobarography device, pressure distribution data in the foot are obtained in both static and dynamic conditions.~Foot plantar pressure analysis and postural balance will be performed using the EsCoSCAN® static and dynamic pedobarographic assessment device.~During the analysis, the individual will be made to stand without moving while looking straight ahead in the standing position for static analysis. This evaluation will be performed before and 3 months after the use of insoles."
223403623|NCT06846476|OTHER|Postural balance|Postural balance assessment in the study will be performed with 'Becure Balance System (Becure Global GmbH)'. Individuals will be evaluated for balance on the device with eyes open-closed, single foot-double foot. This evaluation will be performed before and 3 months after the use of insoles.
223403624|NCT06846476|OTHER|The Foot Functional Index (FFI)|"The Foot Functional Index (FFI) consists of pain, disability and activity limitation and contains a total of 23 items. Pain and disability titles consist of 9 questions each. The pain item measures the severity of foot pain in different situations. The 9 items in the inability heading assess the severity of the difficulty in performing functional activities due to the person's foot problems.~The activity limitation heading consists of 5 items and measures the activity limitations of the person due to foot problems. AFI is a self-completed scale. Individuals answer the questions with a Visual Analogue Scale (VAS), taking into account their foot condition one week ago. A high score indicates more pain, inability and activity limitation. This evaluation will be performed before and 3 months after the use of insoles."
223403625|NCT06846476|OTHER|Sensory Evaluation|"Diabetic foot ulcer (DFU), which is one of the microvascular complications of diabetes, frequently occurs in association with loss of protective sensation due to peripheral neuropathy, ischaemia due to peripheral arterial insufficiency, poor foot care and infection. Loss of pressure sensation caused by peripheral nerve damage will be evaluated with 'Semmes Weinstein' monoflaments. The 5.07 nylon monoflament used in the test was produced to bend when 10 g force was applied. This pressure is applied to specific points on the plantar and dorsal aspect of the foot.~This evaluation will be performed before and 3 months after the use of insoles."
223554634|NCT04852549|OTHER|Oculomotor exercise|"1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions."
223554635|NCT06493643|OTHER|Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb|The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
223554636|NCT00069134|DIETARY_SUPPLEMENT|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
223554637|NCT02096250|OTHER|NaFeEDTA|
223554638|NCT02096250|OTHER|Ferrous fumarate|
224022374|NCT00001984|DRUG|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
224022375|NCT03159533|BEHAVIORAL|CHW Intervention|Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).
224022376|NCT03159533|BEHAVIORAL|Wait List Control Group|4 education sessions beginning 6-12 months later.
223403626|NCT06846476|OTHER|Orthotic Satisfaction Questionnaire- Q-YTKMD (QUEST 2.0)|It is a standardised and widely used questionnaire developed to examine the satisfaction of individuals using orthotics with the device they use. In 2020, a Turkish validity and reliability study was conducted. QUEST 2.0 consists of 12 items. Of these, 8 items question the assistive device and 4 items question service satisfaction. Scale scoring is calculated with a 5-point Likert scale (1=Not satisfied at all, 5=Very satisfied). This evaluation will be performed after the use of insoles.
223403627|NCT06846476|OTHER|6 Minute Walk Test (6MWT)|Participants will walk for 6 minutes at a speed of their choice in a flat and suitable area of 30 metres. The distance walked in 6 minutes will be recorded in metres.
223403628|NCT06846476|OTHER|Pulse Oximeter Heart Rate and Oxygen Saturation|Heart rate and oxygen saturation (SpO2) will be recorded by pulse oximetry before and after the 6MWT. The pulse oximeter is a non-invasive device that attaches to a person's fingertip.
223403629|NCT03932786|PROCEDURE|Biospecimen collection|Collection of tissue and saliva samples
223403630|NCT03932786|OTHER|Vision assessment|Undergo vision assessment
223403631|NCT03932786|OTHER|Questionnaire administration|Complete questionnaires
223403632|NCT03932786|OTHER|Quality of life assessment|Complete questionnaires
224022377|NCT03809741|OTHER|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
224022378|NCT04619251|DRUG|BI 1323495|BI 1323495
224022379|NCT04619251|DRUG|Placebo|Placebo
224132249|NCT00695591|OTHER|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
224132250|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
223403633|NCT03932786|OTHER|Laboratory Biomarker Analysis|Correlative studies
223403634|NCT04026477|BEHAVIORAL|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
223403635|NCT04026477|BEHAVIORAL|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
223403636|NCT03982836|DIETARY_SUPPLEMENT|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
223403637|NCT05731700|DEVICE|Drug Eluting Balloon|PCI of in-stent restenosis
223403638|NCT06423573|DRUG|Filsuvez|Topical gel
223403639|NCT06434935|COMBINATION_PRODUCT|CABA|Coronary Bypass
223403640|NCT05735080|DRUG|INX-315|Oral administration
223403641|NCT05735080|DRUG|Fulvestrant|Fulvestrant will be combined with INX-315
223554639|NCT02096250|OTHER|NaFeEDTA + ferrous fumarate|
223554640|NCT05454462|DRUG|IMP Application KM-001|KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
223554641|NCT05454462|DIAGNOSTIC_TEST|Chemistry|patients will provide a blood sample for a chemistry blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
223554642|NCT05454462|DIAGNOSTIC_TEST|Hematology|patients will provide a blood sample for a hematology blood test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
223554643|NCT05454462|DIAGNOSTIC_TEST|Urinalysis|Patients will provide a blood sample for a urine test on days -14 (screening visit), Day 7(visit 3), day 28 (end of treatment) or at ET visit.
223403642|NCT05735080|DRUG|Abemaciclib|Abemaciclib will be combined with INX-315
223403643|NCT05094297|BEHAVIORAL|Investigate the effects of an exercise intervention on U.S. Veterans.|Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
223403644|NCT05538663|DRUG|Gemcitabine|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
223403645|NCT05538663|DRUG|Docetaxel|Intravesical once a week for 6 consecutive weeks followed by monthly instillations during maintenance for 2 years
223403646|NCT05538663|DRUG|Bacillus Calmette Guerin|intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
223403647|NCT06385678|DRUG|HRS-4642|administrated per dose level in which the patients are assigned
223403648|NCT06385678|DRUG|Adebrelimab|administrated per dose level in which the patients are assigned
223403649|NCT06385678|DRUG|SHR-9839|administrated per dose level in which the patients are assigned
223403650|NCT06385678|DRUG|Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection|administered as prescribed by the investigator.
224022380|NCT04619251|DRUG|Itraconazole|Itraconazole
224022381|NCT02730949|DIETARY_SUPPLEMENT|D-chiro-inositol|Treated group
224022382|NCT02730949|DIETARY_SUPPLEMENT|Folic Acid|Control group
224022383|NCT02003573|DRUG|decitabine iv|decitabine iv fixed dose
224022384|NCT02003573|DRUG|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
224022385|NCT00803751|DEVICE|Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
224022386|NCT00803751|DEVICE|Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
223403651|NCT06385678|DRUG|Cetuximab Solution for Infusion|administrated per dose level in which the patients are assigned
223554644|NCT05454462|DIAGNOSTIC_TEST|Serelogy|Patients will provide a blood sample for serelogy test at day -14 (screening visit)
223736086|NCT06125015|DIAGNOSTIC_TEST|Hearing Thresholds Assessments|Auditory Neuropathy Spectrum Disorder (ANSD) is a type of hearing disorder that affects the transmission of sound signals from the inner ear to the brain. In individuals with ANSD, the outer hair cells in the cochlea, which are responsible for amplifying sound, typically function properly. However, there is a disruption in the transmission of auditory information from the cochlea to the auditory nerve and then to the brain. It is characterized by a mismatch between the results of objective hearing tests, such as Auditory Brainstem Response (ABR), and subjective hearing experiences. In ABR tests, the responses of the auditory nerve to sounds may be abnormal, while the individual perceives their hearing to be better than suggested by the test results. In this study we showed ANSD patients with abnormal ABR results by using ABR, Otoacoustic Emissions, Tympanometry and behavioral test batteries.
223736087|NCT04886050|DRUG|LC350189 Tablet|Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
223736088|NCT04886050|DRUG|LC350189 Capsule|Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
223736089|NCT01969240|OTHER|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
223736090|NCT04489667|OTHER|+STEP Implementation|All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
223736091|NCT01938599|DRUG|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
223736092|NCT01938599|DRUG|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
223736093|NCT04843644|DIETARY_SUPPLEMENT|honey|"Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
223736094|NCT04843644|DIETARY_SUPPLEMENT|propolis|"Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period"
224132251|NCT00369668|BEHAVIORAL|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
224132252|NCT00369668|BEHAVIORAL|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
224132253|NCT03992768|DEVICE|Hamamatsu NanoZoomer S360MD Digital Slide Scanner System|Detection of pathology features using whole slide imaging
224132254|NCT04068558|DEVICE|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
223554645|NCT05454462|DIAGNOSTIC_TEST|12-Lead ECG|patients will undergo an ECG examination on days -14 (screening visit), and day 28 (end of treatment visit).
223554646|NCT05454462|DIAGNOSTIC_TEST|Pregnancy test|Women of child-bearing potential only will provide at all the on-site visits b-hCG concentration will be tested
223736095|NCT04843644|BEHAVIORAL|Control|usual care
223736096|NCT00936910|DRUG|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome \[2 mg/ml\]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
223736097|NCT04436185|BEHAVIORAL|Comparisons of procedural pain|This randomized experimental study with placebo and control groups
223736098|NCT00412854|BIOLOGICAL|Infanrix™/Hib|
223736099|NCT00412854|BIOLOGICAL|Infanrix|
223736100|NCT00412854|BIOLOGICAL|Hiberix|
224132255|NCT04068558|DEVICE|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
224132256|NCT00321100|DRUG|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
224132257|NCT00321100|DRUG|cetuximab|Cetuximab 400mg/m2 IV initial dose (cycle 1 day 1 only), then 250mg/m2 IV weekly each 21 day cycle
224132258|NCT00321100|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
223403652|NCT02422017|DRUG|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
223403653|NCT02422017|OTHER|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
223403654|NCT06572657|OTHER|cognitive stimulation|cognitive stimulation
223403655|NCT06572657|OTHER|physical exercise|physical exercise
223554647|NCT05454462|DIAGNOSTIC_TEST|Blood PK sampling|PK test will be performed on day 1, 7, 28, 35 and on ET visit
223554648|NCT05454462|PROCEDURE|Physical Examination|patients will undergo a physical examination on all the clinical visits
223554649|NCT05454462|PROCEDURE|Vital signa|patient's vital signs will be measured on all the clinical visits
223554650|NCT05454462|DIAGNOSTIC_TEST|Investigator's Global Assessment|patient's disease evaluations will be evaluated on all the clinical visits
223403656|NCT05365295|OTHER|DRM (Deese, Roediger et McDermott task)|"Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes."
223403657|NCT06571383|DRUG|Semaglutide|Participants will receive semaglutide s.c(under the skin) once weekly.
224132259|NCT00321100|DRUG|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
223403658|NCT04910269|BIOLOGICAL|Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|The hIVIG product is administered as a single dose of 3.5 grams, or 35 milliliter at a concentration of 0.1 grams/milliliter.
223403659|NCT04910269|OTHER|Placebo|Infusion of 35 milliliters standard isotonic saline
223403660|NCT06534918|OTHER|Fitbit|Participants will be provided with a Fitbit. Self-reported physical activity, location, vital sign and sleep stage information will be collected and monitored every day for up to eight (8) weeks. Data will be synced to the My Wellness Research Software Platform, resulting in a weekly text or phone call check-in, based on participants preference.
223403661|NCT06534918|BEHAVIORAL|Nutrition Course: Group Sessions|The nutrition course will follow a combined asynchronous and synchronous approach. The asynchronous component will consist of a pre-recorded session covering educational nutrition content, which will be made available to participants for self-paced learning. This will be followed by a synchronous, 30-60 minute live group education class on nutrition information for cancer survivors, held once per week.
223736101|NCT00745147|DRUG|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
223736102|NCT00745147|DRUG|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
223736103|NCT03483883|DRUG|Avelumab|Avelumab IV 10 mg/kg every 2 weeks
223736104|NCT03483883|DRUG|Gemcitabine|Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
223736105|NCT05109507|BEHAVIORAL|Visitor Mindset|Single-session, self-guided intervention
224132260|NCT02290535|PROCEDURE|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
224132261|NCT02290535|PROCEDURE|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
223403662|NCT06534918|BEHAVIORAL|Physical Activity Program: Group Sessions|The Physical Activity Program will be held virtually or in-person. This will be a 1-hour biweekly group education class on aerobic and resistance exercise recommendations for cancer survivors.
223403663|NCT06534918|BEHAVIORAL|Nutrition Course: One on One Sessions with Registered Dietitian|Participants will be referred to weekly one on one nutrition counseling sessions with a Registered Dietitian. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual.
223403664|NCT06534918|BEHAVIORAL|Physical Activity Program: One on One Sessions with an Exercise Physiologist|Participants will be referred to weekly one on one exercise training sessions with an Exercise Physiologist. The one on one sessions are anticipated to last 30-60 minutes, based on the needs of the individual
223403665|NCT06534918|BEHAVIORAL|Nutrition and Physical Activity Prescription|Participants will receive a lifestyle medicine prescription pad, developed by the investigators, which serves as a checklist to assist participants in effectively monitoring their dietary habits and physical activity routines. Participants will also receive an 8-week text messages program which will direct participants to a webpage with nutrition and physical activity content.
223403666|NCT05943964|BEHAVIORAL|Virtual exercise and rehabilitation program|"Participants will have two 30-minute sessions per week for 12 weeks. The program will focus on aerobic exercises and stretching exercises. When applicable, stretching exercises will focus on areas of contractures, and joints with limited range of motion (ROM).~Sessions will be completed by a team of Physical Therapists using the established telemedicine platform at Children's Healthcare of Atlanta, as used routinely in the blood and marrow transplant clinic for clinical care (Epic). Adherence to the program will be encouraged during monthly standard clinic visits."
223403667|NCT06369025|BEHAVIORAL|Interaction Competencies with Children|"Interaction Competencies with Children - for Teachers (ICC-T) Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.~Interaction Competencies with Children - for Parents (ICC-P) Core training components include parents-child interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the home"
223403668|NCT04166318|PROCEDURE|Biopsy|Undergo tissue biopsy
223403669|NCT04166318|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223403670|NCT04166318|DRUG|Capecitabine|Given PO
223403671|NCT04166318|PROCEDURE|Computed Tomography|Undergo PET/CT
223403672|NCT04166318|OTHER|Fludeoxyglucose F-18|Receive FDG
223736106|NCT05109507|BEHAVIORAL|Relaxing with Nature|Single-session, self-guided intervention
223736107|NCT02561650|DRUG|COV155|COV155 tablets
223736108|NCT03077802|OTHER|Modified Seldinger technique, Experienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
223736109|NCT03077802|OTHER|Seldinger technique, Experienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioners who are board-certified anesthesiologist staffs and have experience of more than 50 central venous catheterizations in both techniques.
223736110|NCT03077802|OTHER|Modified Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
223736111|NCT03077802|OTHER|Seldinger technique, Inexperienced group|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
223736112|NCT03077802|OTHER|Long-axis technique|Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.
223736113|NCT03077802|OTHER|Short-axis technique|Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
223736114|NCT02986789|DEVICE|In vivo SpHb and PVi Monitoring|Pulse oximeter finger sensor that simultaneously monitors noninvasive hemoglobin (SpHb) and pleth variability index (PVi)
223736115|NCT02452346|DRUG|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
223736116|NCT04898257|DIETARY_SUPPLEMENT|Multistrain probiotic|After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).
223736117|NCT03529240|DEVICE|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
223736118|NCT00704925|DRUG|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
223736119|NCT02461901|OTHER|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
223736120|NCT02461901|OTHER|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
223736121|NCT02461901|OTHER|Fecal sampling|Collection of fecal samples for C. difficile spores
223736122|NCT05967611|DIAGNOSTIC_TEST|Trendelenburg hip abduction test|The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.
223736123|NCT04483011|DIETARY_SUPPLEMENT|RiaGev|Dietary supplementation
223736124|NCT04225351|PROCEDURE|MCAF+CM|CAF procedure + collagen matrix
223736125|NCT04225351|PROCEDURE|MCAT+CM|Tunnel procedure + collagen matrix
223736126|NCT05793320|PROCEDURE|Carpal Tunnel Release Surgery|Carpal tunnel release surgery used to take a biopsy to diagnose amyloidosis and determine whether or not carpal tunnel syndrome can predict who's at risk for having amyloidosis.
223736127|NCT05548166|OTHER|Interview and scale development|Interview and scale development
223403673|NCT04166318|DRUG|Fluorouracil|Given IV
223736128|NCT05003154|OTHER|Digitalized management|"In addition to conventional management, Patients also receive digitalized management, which provides personalized guidance in diet, excercise, prenatal visit, blood glucose monitoring,etc., from artificail intelliegence (AI) supevised by obstetricians, through a smartphone application and some werable devices (like sports bracelet).~The pivotal AI are based on clinical experience from obstetricians, therapeutic principle from official Guidelines and abundant data in previous work, and it will works under strict supervision."
223403674|NCT04166318|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223403675|NCT04166318|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MRI
223403676|NCT04166318|DRUG|Mitomycin|Given IV
223736129|NCT05187793|DRUG|Olokizumab|Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
223736130|NCT05187793|DRUG|Standard therapy|"Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV"
223736131|NCT04425265|PROCEDURE|Plasma radiofrequency ablation|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.
223736132|NCT04425265|PROCEDURE|Electrocautery block resection|Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
223736133|NCT03637972|OTHER|Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
223736134|NCT03637972|OTHER|Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
223403677|NCT04166318|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224132262|NCT00920608|DRUG|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
224132263|NCT00920608|DRUG|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
223403678|NCT04166318|OTHER|Quality-of-Life Assessment|Ancillary studies
223403679|NCT04166318|OTHER|Questionnaire Administration|Ancillary studies
223403680|NCT06445101|OTHER|Participatory Approach|The participatory approach is a stepwise, collaborative approach to the analysis and solvation of bottlenecks that cause stress in employees.
223403681|NCT04495946|BEHAVIORAL|Sepsis Transition and Recovery (STAR) program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
223403682|NCT04495946|BEHAVIORAL|Usual care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
223403683|NCT05530525|DIAGNOSTIC_TEST|The Computerized Adaptive Testing system of the Functional Assessment of Stroke|The Computerized Adaptive Testing system of the Functional Assessment of Stroke comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper limb, 11 items from the Fugl-Meyer Assessment-Lower limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. Results are automatically reported as Rasch scores (i.e., the minimum and maximum values are negative and positive infinity, respectively). A higher score indicates greater physical functions.
223403684|NCT05530525|DIAGNOSTIC_TEST|The Barthel Index|The Barthel Index has 10 items, and the total score ranges from 0 to 100. Higher score indicates less disability on activity of daily living functions.
223403685|NCT05530525|DIAGNOSTIC_TEST|The National Institutes of Health Stroke Scale|The National Institutes of Health Stroke Scale comprises 11 items and was used to monitor the severity in the patients with stroke. The total score ranges from 0 to 42, with a higher score indicating greater severity. A National Institutes of Health Stroke Scale score of 1-5 indicates mild severity; 6-14, mild to moderate severity; 15-24, severe severity; and equal to or greater than 25, very severe severity.
223554651|NCT05454462|DIAGNOSTIC_TEST|Itch Assessment via PP-NRSj|patient's disease evaluations will be evaluated on all the clinical visits
223554652|NCT05454462|OTHER|E-diary data|The patient will record IMP adminidsration and AE events in a diary every day throughout the all study period
224132264|NCT02473133|RADIATION|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
224132265|NCT02473133|RADIATION|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
224132266|NCT01868178|DEVICE|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
224132267|NCT00734786|OTHER|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
224132268|NCT02731703|DEVICE|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
224132269|NCT00006708|BIOLOGICAL|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
224297586|NCT02514161|OTHER|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
223554653|NCT05469425|BEHAVIORAL|Preoperative home-based exercise training|"Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program."
223554654|NCT01160133|OTHER|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
223554655|NCT01160133|OTHER|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
224132270|NCT00006708|BIOLOGICAL|rituximab|
224132271|NCT00006708|DRUG|carboplatin|
224132272|NCT00006708|DRUG|etoposide|
224132273|NCT00006708|DRUG|ifosfamide|
224297587|NCT03356028|BEHAVIORAL|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
224297588|NCT03356028|OTHER|salivary biological collection|Saliva sampling will be done using a specific kit
223736135|NCT03637972|OTHER|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
223403686|NCT05975671|BEHAVIORAL|Multifaceted de-implementation strategy to reduce vancomycin overuse|"* Clinical guidelines and group-level feedback on vancomycin use will be provided to clinicians/sepsis stakeholders at each site.~* The semi-structured interviews will be performed by a trained member of the research team, under the supervision of a medical sociologist who is one of the co-investigators. A semi-structured interview guide will be used during the interviews. Interviews will be recorded and transcribed, then uploaded to a qualitative analysis software for management and coding. Names will not be recorded, and pseudonyms will be used in notes, communications about the study, and any presentations. Verbal consent will be obtained before conducting and recording the interviews.~* The surveys will be performed using REDCap survey software, and participation will be voluntary. No identifiers will be collected."
223403687|NCT03245892|DRUG|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
223403688|NCT03245892|DRUG|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
223403689|NCT03245892|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery
223403690|NCT03245892|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
223403691|NCT03381183|DRUG|Durvalumab|Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).
223403692|NCT03381183|DRUG|IRX-2 Regimen|"Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m\^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units)."
223554656|NCT04660552|DEVICE|Cognilum TM: Light Treatment Condition|The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 8 weeks.
223554657|NCT01055717|OTHER|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
223554658|NCT01816191|DRUG|Diltiazem Hydrochloride Cream and Oral Diltiazem|
223554659|NCT04930120|OTHER|Inter ICU long distance patient transfer|Individual or grouped transportation between ICU of severely ill patients using ambulance, plane, helicopter, train or boat, with specialist medical assistance.
223554660|NCT04769271|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
223554661|NCT04769271|DRUG|Scaling and Root Planing with tea tree oil|Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied
223554662|NCT04558541|OTHER|Sensitivity to phonological rules|Assess whether children with developmental language disorder (DLD) are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon; children with speech sound disorder (SSD) are not predicted to be sensitive to the same phonological patterns.
223554663|NCT04558541|OTHER|Sensitivity to semantic category cues.|Assess whether all children, including those with DLD, show improved learning of OR rules when a semantic category cue is used.
223554664|NCT00586040|PROCEDURE|tissue bonding|application of rose bengal and treatment with green light
223554665|NCT00586040|PROCEDURE|sutures|interrupted superficial sutures
223554666|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
223554667|NCT01297803|DRUG|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before \&after scleral flap dissection
223554668|NCT01150786|DIETARY_SUPPLEMENT|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
223554669|NCT01150786|OTHER|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
223554670|NCT01699126|DEVICE|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
223554671|NCT01699126|DRUG|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
223554672|NCT00488020|PROCEDURE|stem cells transplant|
223554673|NCT02728648|DRUG|Oxycodone|Pain Management
223554674|NCT00008801|DRUG|hOKT3gamma1 (Ala-ala)|
223554675|NCT05712785|DEVICE|Use of shuotong ureteroscopy|Treatment of patients with ureteral stones using the Shuotong-scopy
223554676|NCT02732795|OTHER|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
223554677|NCT05780801|DRUG|Allogeneic Microbiota in Glycerol (10%) (AMG)|Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
223554678|NCT02442505|DEVICE|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
223736136|NCT03637972|OTHER|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
223554679|NCT02771574|DRUG|Lyo avexitide|Lyophilized avexitide (Lyo avexitide) administered subcutaneously (sc)
223554680|NCT02771574|DRUG|Liq avexitide|Liquid avexitide (Liq avexitide) administered subcutaneously (sc)
224132274|NCT03072121|DRUG|Shexiang Baoxin pill|Conventional western medicine \& shexiang baoxin pill
224132275|NCT03072121|DRUG|SBP placebo|Conventional western medicine \& placebo (for shexiang baoxin pill)
224132276|NCT03072121|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
224132277|NCT03072121|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
224132278|NCT03072121|DRUG|Atorvastatin Calcium|10 mg tablet, two tablets each night.
224132279|NCT03072121|DRUG|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
224132280|NCT03072121|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
224132281|NCT03072121|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
224132282|NCT04178681|OTHER|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
223403693|NCT05208931|PROCEDURE|Anti-vascular endothelial growth factor therapy|0.05 ml anti-VEGF, intravitreal, monthly
223403694|NCT04343495|DEVICE|Wearable Ultra Violet (UV) and blue-light sensors|Non-blinded
223403695|NCT04698395|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy for children with cerebral palsy
223403696|NCT04698395|BEHAVIORAL|Regular care|customary or usual care given to any infant/toddler with cerebral palsy
223403697|NCT06431932|DRUG|Fisetin|Subjects will receive fisetin corresponding to 20 mg/kg/day for two consecutive days.
223403698|NCT06431932|DRUG|Placebo|Subjects will receive a corresponding number of placebo capsules for two consecutive days.
223403699|NCT00921609|DIAGNOSTIC_TEST|Oral glucose tolerance test|An oral glucose tolerance test is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
223403700|NCT01016951|DRUG|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg."
223403701|NCT01016951|DRUG|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
223403702|NCT03906760|OTHER|Magnetic resonance imaging (MRI)|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
223403703|NCT04010760|DIAGNOSTIC_TEST|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
223403704|NCT05608915|OTHER|No Cue|There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
223403705|NCT05608915|OTHER|Conventional Cue|Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
223554681|NCT01225133|OTHER|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
223736137|NCT04128384|DIAGNOSTIC_TEST|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
223736138|NCT03439020|PROCEDURE|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
223736139|NCT03439020|PROCEDURE|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
223736140|NCT03657758|DRUG|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
223403706|NCT05608915|OTHER|Constant Cue|The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
223736141|NCT03657758|DRUG|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
223403707|NCT05608915|OTHER|Patient hand-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
223554682|NCT01225133|OTHER|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
223554683|NCT03985462|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
223554684|NCT04103944|PROCEDURE|Core Decompression|10 patients will be randomized chosen in this group
223736142|NCT01857466|PROCEDURE|Floseal|
223736143|NCT01857466|PROCEDURE|Bipolar coagulation|
223736144|NCT03518073|DRUG|Zagotenemab|Administered IV
223736145|NCT03518073|DRUG|Placebo|Administered IV
223736146|NCT00658593|DRUG|capecitabine|
223736147|NCT00658593|DRUG|gemcitabine hydrochloride|
223736148|NCT00658593|PROCEDURE|quality-of-life assessment|
223736149|NCT03959293|DRUG|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
223403708|NCT05608915|OTHER|Patient eye-triggered|The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
223736150|NCT03959293|DRUG|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
223736151|NCT03959293|DRUG|FOLFIRI Protocol|"* Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
223736152|NCT01108601|DRUG|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
223736153|NCT03531307|OTHER|Data correlation|Correlation between lactate levels and Ki-67 index
223736154|NCT03045081|BEHAVIORAL|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
224132283|NCT04178681|OTHER|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
223736155|NCT05400954|PROCEDURE|Breast reconstruction with silicone breast implant|(i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.
224022387|NCT02688907|DRUG|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
224297589|NCT03356028|BEHAVIORAL|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
224297590|NCT03356028|BEHAVIORAL|Parenthood|Parenting Sense of Competence (PSOC) questionnaires completed online.Two visits will be realized: a first in the month preceding the start of the trial and a second in the month following the end of the trial
224297591|NCT03356028|BEHAVIORAL|Cognitive alterations|Episodic memory will be assessed using Grober and Buschke. The evaluation of the cognitive alterations will include two stages: a first in the month preceding the start of the trial and a second in the month following the end of the trial. For child and parents
224297592|NCT03356028|BEHAVIORAL|Impact on schooling|collect of several data about the number of absences of the child, the number of exclusions and hours of detention of the child, as well as the school reports of the child
223403709|NCT05608915|OTHER|Examiner-triggered|The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
223403710|NCT02184338|DRUG|BIBR 1017 BS powder|
224022388|NCT03102645|DRUG|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
223403711|NCT02184338|DRUG|Placebo|PEG 400
223403712|NCT03225209|OTHER|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
223403713|NCT02565628|DRUG|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
223403714|NCT02565628|DRUG|Placebo|Placebo
223403715|NCT06187688|OTHER|Questionnaire|Patients to complete a questionnaire on measurement of pain intensity.
223403716|NCT03892044|DRUG|Duvelisib|Given PO
224297593|NCT03356028|BEHAVIORAL|Sleep disorders and associated somatizations|Evaluation of sleep disorders and associated somatizations by connected watche and sleep questionnaire
223403717|NCT03892044|BIOLOGICAL|Nivolumab|Given IV
223403718|NCT02281435|DEVICE|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
223403719|NCT01259622|DRUG|saline|intravenous infusion
223403720|NCT01259622|DRUG|K201|intravenous infusion
223403721|NCT04568915|OTHER|Dry Needling|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, DN
223403722|NCT04568915|OTHER|Maitland Mobilization|TENS 10 minutes, Stretching, Strengthening(girdle),Neck Isometrics, Maitland joint mobilization
223403723|NCT03795961|DEVICE|transcranial direct current electrical stimulation|anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
223403724|NCT04267289|BEHAVIORAL|Beating the Blues|Automated, cognitive behavioral therapy delivered via a website. There are 8 sessions, each taking one to 1.5 hours to complete. Sessions are prerecorded and sequenced. Sessions are based on the principles of cognitive behavioral therapy and include techniques such as cognitive restructuring and behavioral activation. The entire program takes about 8 to 12 weeks to complete.
223403725|NCT05367609|DIAGNOSTIC_TEST|Preoperative Genotyping|Genotype based risk prediction and personalized pain management
223403726|NCT04785066|DRUG|Administration of dornase alfa|Patient treated for a cerebral thrombectomy will be administred dornase alfa treatment by intravenous
223403727|NCT05826509|OTHER|Surgery alone|Radical prostatectomy with lymph node dissection will be performed.
223554685|NCT04103944|PROCEDURE|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
223554686|NCT04423679|DEVICE|Evalyn Brush|a standard brush-based cervicovaginal self-collection device
223554687|NCT02593903|DRUG|Septra|
224022389|NCT03102645|DRUG|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
224022390|NCT05110768|DRUG|Triferic AVNU|Triferic AVNU is an iron salt that is approved for the maintenance of Hgb in chronic kidney disease patients on hemodialysis. It is experimental in this study because it has not yet been approved for patients receiving home infusion therapy
224022391|NCT05110768|OTHER|Placebo|normal TPN solution without FPC on alternate days with TPN supplemented with multivitamins.
224297594|NCT00701974|BIOLOGICAL|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
224297595|NCT00701974|BIOLOGICAL|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
223554688|NCT01026090|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
223554689|NCT01026090|DRUG|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
223554690|NCT03263910|DRUG|NPO-11|20 ml NPO-11
223554691|NCT03263910|DRUG|Placebo|20 ml NPO-11(Placebo)
223554692|NCT04322474|DEVICE|Catheter-based left atrial appendage occlusion|Catheter-based implantation of left atrial appendage occluder
223554693|NCT02742233|DRUG|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
223554694|NCT02742233|DRUG|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
224297596|NCT00188227|DRUG|Midazolam (sedative)|
224297597|NCT00188227|DRUG|Piritramid (analgetic)|
224297598|NCT00188227|BEHAVIORAL|Cognitive exercises|
223736156|NCT05400954|PROCEDURE|Breast conserving surgery/Mastectomy/Autologous reconstruction|(iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,
223403728|NCT05826509|DRUG|Peri-operative darolutamide + surgery.|"Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment."
223403729|NCT06421753|DEVICE|SDSS|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
223736157|NCT05400954|PROCEDURE|Breast Augmentation|(vii) cosmetic augmentation with silicone breast implants
223736158|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of the tracer [99mTc] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml)|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
223554695|NCT06151613|DEVICE|continuous eCTG monitoring using the NFMS|Eligible women will be prospectively included in the cohort receiving standard treatment: CTG monitoring intermittent up to three times a day. From these eligible women, a random sample (464) of the prospective cohort (511) will be offered to receive a new monitoring method: 24/7 eCTG monitoring with NFMS. In order to strengthen the comparison between the two groups (eCTG and standard treatment), additional data from 1400 women who received standard treatment in 2014-2019 will be collected retrospectively.
223554696|NCT05006976|OTHER|NSAC health only|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health only, clinicians are provided survey information on potential health problems only."
223736159|NCT04492995|DIAGNOSTIC_TEST|injection via TUMIR of [99mTc] Tc-albumin nanocoloid (6mCi, 8ml).|"The day before the surgery, a new scan (planar and SPECT / CT) will be performed after the injection via TUMIR of the tracer \[99mTc\] Tc-albumin nanocoloid-ICG (6 mCi, 4 ml) or the injection via TUMIR of \[99mTc\] Tc-albumin nanocoloid (6mCi, 8ml).~The two lymphatic maps will be compared and the number of sentinel nodes identified in each study and the territories of drainage and the difference between them (in number and territories) will be established.~On the day of surgery, a cervical injection of methylene blue will be performed at the start of surgery according to usual methodology (2 ml diluted to 50%). Intraoperative detection of the sentinel nodes will take place by visual inspection, using the gammadetector probe and NIR optics. Sentinel node biopsies will be processed according to the usual processing methodology and analysis for the detection of metastases."
223736160|NCT03186833|OTHER|no intervention|no intervention
223736161|NCT05660564|PROCEDURE|DIGU Dorsal inlay preputial graft urethroplasty|"Using a scalpel, a midline incision is made from the meatus to the end of the plate .~The edge of the distal glans should not be incised to avoid meatal stenosis. The depth of this relaxing incision depends on the plate's width and depth, but in all cases, it extends down to the corpora cavernosa. Degloving of the penile skin to the penoscrotal junction If a minimal chord is present, it should be corrected.~From the inner prepuce, a free graft was measured, harvested, defatted, and stitched to the UP. With interrupted 6/0 polyglactin sutures running from the old meatus to the tip of the glans, the graft was secured to the medial edges of the incised plate. Depending on the location of the meatus, the characteristics of the UP, and the depth of the midline incision, the graft width and length varied in each case."
223736162|NCT05881603|OTHER|" VExUS score  (Venous Excess Ultrasound Score)"|" VExUS score  (Venous Excess Ultrasound Score)"
223736163|NCT01378351|OTHER|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
223736164|NCT02977689|DRUG|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
223736165|NCT00002418|DRUG|Emivirine|
223736166|NCT00002418|DRUG|Hydroxyurea|
223736167|NCT00002418|DRUG|Nevirapine|
223736168|NCT00002418|DRUG|Stavudine|
223736169|NCT00002418|DRUG|Didanosine|
223736170|NCT01485640|DRUG|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
223736171|NCT01802723|DRUG|Drug: salmeterol xinafoate|
223736172|NCT01802723|DRUG|Drug: Placebo|
223736173|NCT01397123|OTHER|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
223736174|NCT05992610|OTHER|Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy|"Chemotherapy based on carboplatin 6 AUC + paclitaxel 75 mg/m2.~Radiotherapy:~D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later)."
223736175|NCT01853046|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
223736176|NCT05359666|DEVICE|Irrisept|"Irrisept® is a manual, self-contained irrigation device designed for wound cleansing and irrigation. The solution is 0.05% Chlorhexidine Gluconate (CHG) in sterile water for irrigation, USP (99.95%). Irrisept contents include the solution, a 450 mL bottle, and the Irriprobe applicator. Irrisept is a manual, self-contained irrigation device that can produce 7-8 psi of pressure for effective wound cleansing and irrigation. The user squeezes the bottle to create streams of solution and directs the fluid from the applicator onto a wound. The mechanical action of the streams of fluid being applied over a wound removes particulates and debris.~Subjects randomized to Irrisept on study protocol IRR-CT-901-2013-01 used the device, per the provided Instructions for Use. Those randomized to SoC received routine care, per the discretion of the investigator, and in accordance with the institution's guidelines."
223736177|NCT05359666|DEVICE|Standard of Care|"Subjects randomized to SoC on study protocol IRR-CT-901-2013-01 used any SoC type, per the investigator's discretion. SoC types were not standardized. Sites recorded SoC information as free text. The following were recorded as SoC types: Saline (recorded as normal, warm and/or sterile saline or saline solution); Sodium Chloride (recorded as sodium chloride (NACL) or NACL 0.9%); SoC; Irrisept (recorded as normal saline \& Irrisept and Irrisept); Chloraprep; Gentamicin \& saline; unknown; and none."
223736178|NCT03823352|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
223736179|NCT01647412|DRUG|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
223736180|NCT01647412|DIETARY_SUPPLEMENT|Nutraceutical Combination|
223736181|NCT01647412|OTHER|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
223736182|NCT01647412|OTHER|Placebo Growth Hormone|
224132284|NCT04178681|OTHER|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
223736183|NCT03017950|DRUG|CKD-330|
223736184|NCT03017950|DRUG|D086|
223736185|NCT03017950|DRUG|CKD-330 + D086|
223736186|NCT03586388|OTHER|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
223736187|NCT04528654|OTHER|Mobile Health Application|The participants will be given instructions to use their smartphone or tablet to download the hypertension tracking app. They will follow the instructions provided within the app and use it to track their blood pressure over the next six months.
223736188|NCT00911495|DRUG|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
224297599|NCT04576182|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
223736189|NCT03459742|BEHAVIORAL|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
223736190|NCT04634747|DRUG|PVX-410|PVX-410 in combination with pembrolizumab and chemotherapy
223736191|NCT00149487|BEHAVIORAL|Tailored Problem Solving Intervention|
223736192|NCT00149487|BEHAVIORAL|Family Education Intervention|
223736193|NCT05584176|DEVICE|iCura COVID-19 Antigen Rapid Home Test|Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.
223736194|NCT05584176|DEVICE|RT-PCR Test|High sensitivity RT-PCR COVID-19 Test
223736195|NCT01772303|DRUG|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
223736196|NCT05283798|DEVICE|IUD|Postpartum intra-caesarean section insertion of copper T380 versus multiload 375
223736197|NCT02057198|DRUG|Fidaxomicin|
223736198|NCT02057198|DRUG|Metronidazole|
223736199|NCT02057198|DRUG|Vancomycin|
224132285|NCT00184106|DRUG|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
224132286|NCT00142519|DRUG|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
224132287|NCT00142519|DRUG|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
224132288|NCT05478044|DRUG|Ascorbic acid|Ascorbic acid IV ampoules (20%).
224132289|NCT05478044|OTHER|saline|saline (0.9%)
224132290|NCT04406246|DRUG|Nitazoxanide 500Mg Oral Tablet|Health workers affected by SARS-CoV-2 will receive the next doses of nitazoxanide: 500 mg every 6 hour for two days and then every 12 hours for four days.
224132291|NCT06199440|DRUG|Group I|First group are chronic periodontitis patients with diabetes mellitus type II who received scaling and root planning.
223403730|NCT06421753|DEVICE|Standard Electrical Stimulation During Functional Electrical Stimulation|Each session begins with a 3-minute warm-up phase, followed by a 3-minute stimulation phase. The motor rotates the legs at 50 rpm during both phases. The type of stimulation used in the first phase is chosen randomly. After a 20-minute break, the second warm-up and stimulation phases are carried out During the second session, the order of the stimulation phases is reversed.
223403731|NCT06585514|DRUG|CD19 CAR-T cells|Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
223403732|NCT05745831|OTHER|Therapeutic decision tool|A therapeutic decision tool will be used and its usefulness, comprehension and satisfaction will be evaluated
223403733|NCT05442216|DRUG|Tagraxofusp (Cycles 1-2)|12 mcg/kg intravenously Days 1-5
223403734|NCT05442216|DRUG|Azacitidine|75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
223403735|NCT05442216|DRUG|Tagraxofusp (Cycles 3-12)|12 mcg/kg intravenously Days 1-3
223403736|NCT02617342|BEHAVIORAL|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
223736200|NCT04388267|DRUG|Fluid challenge|"All patients who met the inclusion criteria will receive a standardised bolus of 250 ml of crystalloid in 5 minutes administered by hand with a 50 ml syringe.~During the study period, hemodynamic parameters and analysis by pressure recording analytical method obtained with the MostCare will be collected for 20 minutes prior to the intervention (fluid challenge), during the fluid challenge and 25 minutes after completion.~The total duration of the intervention (fluid loading) is 5 min. The total duration of hemodynamic parameters recording is 60 min."
223403737|NCT05603897|OTHER|Mann Assessment of Swallowing Ability (MASA) (dysphagia screening tool)|Upon 1-2 days of admission to inpatient rehabilitation, the MASA will be administered for approximately 20 minutes during initial speech language pathology evaluation. The MASA will be administered at bedside as a cognitive/speech language evaluation as well as oropharyngeal function examination.
223403738|NCT05603897|OTHER|Non-standardized clinical swallow evaluation|Participants will receive current standard of care for dysphagia screening and treatment.
223403739|NCT05388227|OTHER|Pole walking|The intervention will consist of group sessions held at the participating communities, 2-3 times per week, for 20-60 minutes per session, over a 12-week period. Pole walking exercises are tailored for participants and progressive in nature. Sessions will be led by trained peer, staff, or student instructors and conducted outdoors (indoors if weather conditions do not permit).
223403740|NCT03375918|OTHER|CONSULT-BP Educational Intervention|CONSULT-BP is a two sessions training provided to healthcare trainees over a 5-week period. The first session focused on (1) didactic overview of healthcare disparities, social drivers of health, implicit bias and systemic racism and (2) interactive discussions and patient storytelling videos to raise awareness of the bi-directional role of racial and ethnic identity among clinicians and patients. The second session focused on skill building and included (1) bias mitigation strategies based on the RELATE bias mitigation tool and (2) skill practice using 2 standardized patient simulated clinical encounters focusing on hypertension management challenges.
224297600|NCT04576182|BEHAVIORAL|Emotions-Focused treatment|Sixteen weeks of a brief experiential therapy for depression that combine client-centered relational elements (unconditional positive regard, congruence, and empathy) with marker-guided experiential interventions designed to facilitate and deepen emotional processing and emotion regulation.
224297601|NCT05758220|DEVICE|MRI|Structural MRI volumetry, resting functional MRI \& MR spectroscopy
223403741|NCT04874012|DRUG|Active comparator Taurine|Participants will receive 3 g taurine, twice a day, as a powder for oral suspension (3 g/packet) for 12 weeks. Participants will be recommended to take the taurine immediately before the breakfast and dinner.
223403742|NCT04874012|OTHER|Placebo Comparator|Participants will receive the same treatment regimen and intake recommendation, but packets with the same appearance and size from those taurine ones will contain a vehicle
223403743|NCT06120166|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion
223554697|NCT05006976|OTHER|NSAC health + MBW|"NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In NSAC health + MBW clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors."
223554698|NCT02589028|DIETARY_SUPPLEMENT|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
223554699|NCT02589028|OTHER|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
223554700|NCT04020471|OTHER|Pain Scale/Medication Log|Daily recording of pain level after surgery and recording of medication taken for pain relief.
223554701|NCT00249652|BEHAVIORAL|TAP|12-session motivational interviewing-based telephone intervention.
223554702|NCT00249652|OTHER|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
223736201|NCT01985581|DRUG|Guanfacine extended release|
224297602|NCT03647631|PROCEDURE|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
223554703|NCT01162824|DRUG|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
223736202|NCT01985581|DRUG|Placebo|
223403744|NCT05746390|BEHAVIORAL|Home Alone|See Home Alone description.
223403745|NCT06449209|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
223403746|NCT06449209|DRUG|BNT327 Dose Level 2 (DL2)|IV infusion
223403747|NCT06449209|DRUG|Etoposide|IV infusion
223403748|NCT06449209|DRUG|Carboplatin|IV infusion
223403749|NCT06449209|DRUG|Paclitaxel|IV infusion
223403750|NCT06449209|DRUG|Topotecan|IV infusion or oral capsules
223403751|NCT06798623|BIOLOGICAL|Autologous Mesenchymal Stromal Cells|Autologous mesenchymal stromal/stem cells extracted from the subject during a routine standard of care ACL reconstruction surgery and reintroduced in one clinic visit approximately 21 days after completion of the surgery. After being removed from the patient, the cells will be cultured, modified, and harvested to become the final investigational product. Each subject will receive 1.5 ml of the investigative drug. This will contain 5x10\^7 (50 million) autologous MSCs.
223554704|NCT01162824|DRUG|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
223554705|NCT02269813|OTHER|MammaPrint|
223554706|NCT02269813|OTHER|BluePrint|
223554707|NCT02269813|OTHER|TargetPrint|
223736203|NCT01985581|DRUG|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
223736204|NCT01264146|PROCEDURE|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
223736205|NCT01264146|PROCEDURE|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
223736206|NCT00022451|DRUG|tipifarnib|
223403752|NCT00437021|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax® Vaccinia Vaccine (\~10\^5 \[plaque forming units (pfu)/dose\] given via scarification, titer 10\^8 pfu per mL after reconstitution).
223403753|NCT00437021|BIOLOGICAL|MVA Smallpox Vaccine|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10\^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
223403754|NCT00437021|OTHER|Placebo|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia \[Sterile Saline Placebo (SSP)\].
223403755|NCT00437021|OTHER|Placebo|Physiologic normal saline for injection.
223403756|NCT04478084|BIOLOGICAL|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form:freeze-dried Route of administration: intradermal
223403757|NCT04478084|BIOLOGICAL|Purified inactivated rabies vaccine|Pharmaceutical form:freeze-dried Route of administration: intradermal
223403758|NCT04478084|BIOLOGICAL|Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)|Pharmaceutical form: liquid/solution in 5 mL vials Route of administration: intramuscular
223403759|NCT04478084|BIOLOGICAL|Human rabies immunoglobulins (HRIG) (only Group 5 and Group 6)|Pharmaceutical form: liquid/solution in 2 mL vials Route of administration: intramuscular
223403760|NCT06482957|OTHER|Surveys|Complete surveys
223403761|NCT06482957|OTHER|Blood Collection|Undergo blood collection
223403762|NCT06482957|OTHER|Saliva Collection|Undergo salvia collection
223403763|NCT06482957|OTHER|Urine Collection|Undergo urine collection
223403764|NCT06482957|OTHER|Stool Collection|Undergo stool collection
223403765|NCT06482957|OTHER|Tissue collection|Undergo tissue collection
223403766|NCT06482957|OTHER|Physical Activity Monitoring|FitBit will be worn to track physical activity
223403767|NCT02194842|DRUG|Ra223|
223403768|NCT02194842|DRUG|Enzalutamide|
223403769|NCT05381532|BEHAVIORAL|Controlled sleep|Duration and timing of sleep will be assigned and monitored in a controlled laboratory environment.
223403770|NCT05791812|DEVICE|home-based transcranial direct current stimulation (tDCS)|2mA of tDCS for 20 min every weekday for six weeks
223403771|NCT03936361|DRUG|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
223403772|NCT06341998|DRUG|sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children|The planned treatment protocol comprised four cycles of the S-TIC regimen, which included sirolimus administered orally at a dose of 1 mg/m² from day 1 to day 21-28, nab-paclitaxel at a dose of 200 mg/m² on day 1, ifosfamide at a dose of 1200 mg/m² from day 2 to day 5, and carboplatin at a dose of 400 mg/m² on day 2. Additionally, mesna and sulfamethoxazole were prescribed to prevent hemorrhagic cystitis and Pneumocystis Jirovecii Pneumonia (PJP), respectively. Each cycle spanned a duration of three to four weeks. AFP levels were evaluated at the end of each cycle, and radiological assessments were conducted every two cycles. Surgical intervention decisions were made based on the results of these assessments.
223403773|NCT05933200|DRUG|Triheptanoin|Liquid for oral (PO) or enteral feeding tube administration
223403774|NCT05933200|DIETARY_SUPPLEMENT|MCT Oil|Liquid for oral (PO) or enteral feeding tube administration
223403775|NCT06424769|OTHER|Enhanced Digital Care|Participants will receive brief check-in surveys about their IBD symptoms once a month, via text messaging. If the survey response indicates significant symptoms, an alert will be sent to the participant's IBD care team and participant will receive more frequent surveys (weekly) over the next month. Participants and their IBD clinical team will be able to communicate by text for non-emergency IBD-related questions.
223403776|NCT06424769|OTHER|Education|Participants will receive education texts about IBD from trusted sources approximately twice a week. Topics will include: diet, medication adherence, fatigue, preventative care and other relevant issues.
223403777|NCT05607173|DRUG|Fexinidazole (HOE239)|Route of administration: oral; pharmaceutical form: tablet
223736207|NCT03878745|DEVICE|Terumo Nanopass® 34G pen needle|Insulin pen needle
223736208|NCT03878745|DEVICE|BD Nano™ PRO 32G pen needle|Insulin pen needle
223736209|NCT04309643|DRUG|CTP-543|Investigational Drug
223736210|NCT04309643|DRUG|Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)|Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
223736211|NCT00001929|DRUG|Eliprodil|
224132292|NCT06199440|DRUG|Group II|Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.
224132293|NCT06199440|DRUG|Group III|"Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol."
224132294|NCT03108144|BEHAVIORAL|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
223403778|NCT05990296|BEHAVIORAL|Multiprong CDS with referral to pharmacist co-management|Accepting the clinician-facing BPA default recommendation will have eligible patients within this arm referred to embedded pharmacist co-management. Pharmacists are expected to meet with patients and optimize GDMT through a collaborative practice agreement with clinicians. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
223403779|NCT05990296|BEHAVIORAL|Multiprong CDS with GDMT order set|Accepting the clinician-facing BPA default recommendation will open an order set for GDMT that lists common recommended options in such a way that facilitates optimal prescribing. Clinicians will also be exposed to an interruptive advisory upon chart entry as a notification to physicians on GDMT consideration. Patient responses to a pre-visit questionnaire encouraging them to ask about better treatment options will also be shown to clinicians within the interruptive BPA if completed in advance by the patient.
223403780|NCT05990296|BEHAVIORAL|Focused education|A series of focused, interactive education sessions will train clinicians in why, when, and how to prescribe GDMT to patients, with incentives such as continuing medical education (CME) credits, and with virtual and recorded options available to those who are unable to attend in-person meetings.
223403781|NCT06850571|DRUG|Bevacizumab Injection [Avastin]|1.25 mg intravitreal injection given once monthly for three consecutive months.
223403782|NCT06850571|DRUG|Aflibercept 2Mg/0.05Ml Inj,Oph|2.0 mg intravitreal injection given once monthly for three consecutive months.
223403783|NCT05897775|DEVICE|Deep brain stimulation|"Thalamic coordinated reset DBS (CR-DBS) which uses different patterns of stimulation at lower currents and can address the limitations of traditional DBS (T-DBS) that uses continuous high amplitude, high frequency stimulation.~Each participant will receive both the new intervention and the standard of care intervention, each for a week."
223403784|NCT05531773|OTHER|follow up of COVID-19 Patients|"In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed."
223403785|NCT06376500|DEVICE|tDCS with cognitive training programme|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes and it is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
223554708|NCT02662504|DEVICE|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
223554709|NCT02662504|PROCEDURE|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
223554710|NCT02662504|DRUG|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
223554711|NCT02091362|DRUG|LY2409021|Administered orally
223554712|NCT02091362|DRUG|Placebo|Administered orally
223554713|NCT02091362|DRUG|Metformin|Administered as background therapy.
223736212|NCT03540147|DEVICE|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
223736213|NCT03540147|DEVICE|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
224132295|NCT00234858|DRUG|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
224132296|NCT00234858|DRUG|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
224132297|NCT04561635|DIETARY_SUPPLEMENT|Multiple-micronutrients supplement|Multiple-micronutrients supplement with 15 micronutrients
224132298|NCT01201096|RADIATION|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
224132299|NCT01201096|PROCEDURE|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
224132300|NCT04068467|OTHER|Smartphone App|The application consists of content areas focused on mental health.
224132301|NCT04068467|OTHER|Waitlist Control|Waitlist control
224132302|NCT05518734|DRUG|VX-708|Solution for intravenous (IV) administration.
224132303|NCT05518734|DRUG|Itraconazole|Solution for oral administration.
224132304|NCT05518734|DRUG|Midazolam|Solution for oral administration.
224132305|NCT05518734|DRUG|Placebo|Placebo matched to VX-708 for IV administration.
224132306|NCT01005732|DEVICE|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and \<5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
224132307|NCT02596711|DRUG|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
224132308|NCT02596711|BEHAVIORAL|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
224132309|NCT02596711|OTHER|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
223554714|NCT00924794|PROCEDURE|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
223554715|NCT02304887|DRUG|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
223554716|NCT04094493|DRUG|vit D|preoperative intra muscular vit D injection
223554717|NCT00690430|DRUG|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
223554718|NCT00690430|DRUG|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
223554719|NCT01967797|BEHAVIORAL|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
223554720|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
223554721|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
223554722|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
223554723|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
223554724|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
223554725|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
224132310|NCT02596711|BEHAVIORAL|Health Education and Handouts|Participants receive general health education and handouts.
224297603|NCT05311761|OTHER|CogMe Personal Assistant (PA)|Twice a day, in the morning and evening, the electronic tablet with the CogMe PA will be given to the patient by the research assistant. Patients will be asked to respond to a short question and answer (Q\&A) session of approximately 5-10 minutes duration. This intervention will continue throughout the hospitalization period, estimated at approximately 5 days.
223554726|NCT00824889|OTHER|Biopsy and sample of blood|Biopsy and sample of blood
223554727|NCT01021176|OTHER|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
223554728|NCT01021176|DRUG|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
223554729|NCT06181838|PROCEDURE|Lesion extraction|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
223554730|NCT06181838|DRUG|Tretinoin|Tretinoin and benzoil peroxide used concurent in both groups as standard therapy
223554731|NCT00617097|DRUG|lidocaine|paracervical block with lidocaine
223554732|NCT00617097|DRUG|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
223554733|NCT04807088|PROCEDURE|Tactile-kinesthetic Stimulation|
223554734|NCT04807088|OTHER|Placebo|
223554735|NCT04322331|OTHER|no intervention|no intervention
224297604|NCT05449509|DIAGNOSTIC_TEST|Abdominal aortic Duplex ultrasound|All patients will undergo bedside Duplex ultrasound in order to measure infrarenal abdominal aortic diameter.
223554736|NCT05319899|DRUG|ALXN1840|ALXN1840 (60 milligrams) was administered orally as non-coated capsules at Hour 0 on Day 1.
223554737|NCT05319899|DRUG|Omeprazole|Omeprazole (20 milligrams) was administered orally as a delayed-release capsule in the morning of Days -5 to -1 and at Hour -1 on Day 1.
224132311|NCT02596711|BEHAVIORAL|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
224132312|NCT02596711|BEHAVIORAL|Counseling Sessions|Participants attend 3 counseling sessions during the study.
224132313|NCT01552928|DRUG|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
224132314|NCT01552928|DRUG|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
224132315|NCT01552928|DRUG|Moxifloxacin|400 mg Moxifloxacin single oral dose
224132316|NCT01552928|DRUG|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
224132317|NCT02558153|DEVICE|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
224132318|NCT02558153|DEVICE|standard PTA|Percutaneous angioplasty performed with a standard balloon
224132319|NCT03218254|DRUG|Methylphenidate|Titration of MTP for treatment of fatigue
224132320|NCT03218254|DRUG|Placebo|Placebo
224297605|NCT06213714|DEVICE|5G Tele-Robotic-Assisted PCI|The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
223403786|NCT05391841|DRUG|NOVOCART Inject|Autologous Chondrocyte Implantation
223403787|NCT04979793|DRUG|L-citrulline|3 gram sachet, L-citrulline
223403788|NCT04979793|DRUG|Placebo|Milk powder placebo
223403789|NCT04604873|OTHER|Hospital day care follow-up|Regular follow up every month in hospital day care
223403790|NCT05853107|DEVICE|AuTNA I|AuTNA I means Au nanoparticle-decorated TiO2 Nanowire Arrays, a retinal prothesis designed for subretinal implantation.
223403791|NCT03133455|OTHER|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
223403792|NCT05997264|BIOLOGICAL|AV7909 Full Dose (0.5 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
223403793|NCT05997264|BIOLOGICAL|AV7909 Half Dose (0.25 mL)|AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
223403794|NCT05468164|DRUG|Selpercatinib|Administered orally
223403795|NCT05468164|DRUG|Omeprazole|Administered orally
223403796|NCT02438306|BIOLOGICAL|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
223403797|NCT02438306|OTHER|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
223403798|NCT03007147|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
223403799|NCT03007147|DRUG|Calaspargase Pegol|Given IV
223403800|NCT03007147|DRUG|Cyclophosphamide|Given IV
223403801|NCT03007147|DRUG|Cytarabine|Given IV, SC, or IT
223403802|NCT03007147|DRUG|Daunorubicin Hydrochloride|Given IV
223403803|NCT03007147|DRUG|Dexamethasone|Given PO or IV
223403804|NCT03007147|DRUG|Dexrazoxane Hydrochloride|Given IV
223403805|NCT03007147|DRUG|Doxorubicin|Given IV
223403806|NCT03007147|DRUG|Etoposide|Given IV
223403807|NCT03007147|BIOLOGICAL|Filgrastim|Given SC or IV
223403808|NCT03007147|DRUG|Ifosfamide|Given IV
223403809|NCT03007147|DRUG|Imatinib Mesylate|Given PO
223403810|NCT03007147|OTHER|Laboratory Biomarker Analysis|Correlative studies
223403811|NCT03007147|DRUG|Leucovorin Calcium|Given PO or IV
224132321|NCT01395095|OTHER|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
224297606|NCT02030314|DRUG|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
224297607|NCT02519621|DEVICE|NPWT PRO without irrigation|NPWT PRO without irrigation.
224297608|NCT02519621|DEVICE|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
223403812|NCT03007147|DRUG|Levoleucovorin|Given PO or IV
223403813|NCT03007147|DRUG|Mercaptopurine|Given PO
223403814|NCT03007147|DRUG|Mercaptopurine|Given PO
223403815|NCT03007147|DRUG|Methotrexate|Given IT
223403816|NCT03007147|DRUG|Methylprednisolone|Given IV
223403817|NCT03007147|DRUG|Pegaspargase|Given IV
223403818|NCT03007147|DRUG|Prednisolone|Given PO
223403819|NCT03007147|OTHER|Questionnaire Administration|Ancillary studies
223403820|NCT03007147|DRUG|Therapeutic Hydrocortisone|Given IT
223403821|NCT03007147|DRUG|Thioguanine|Given PO
223403822|NCT03007147|DRUG|Vincristine Sulfate|Given IV
223403823|NCT04854122|BEHAVIORAL|Combined exercise intervention|The exercise intervention will last 12 weeks and will consist of a supervised combined aerobic and resistance training program with a frequency of 3 days/week. Aerobic exercise will be part of all three sessions, with resistance exercise during two out of three sessions. Training sessions will be supervised by personal trainers to ensure the safe use of the equipment and the correct form when performing each exercise. The first 3 weeks of the intervention will be familiarization with the exercises and the program. After a warm-up, the participant will perform 30 min of aerobic exercise at a heart rate of 65% of the participant's maximum heart rate \[43\], which increases to 65-85% during weeks 4-12 of the intervention. The resistance exercise part will include all major muscle groups, both upper and lower body.
223403824|NCT04854122|BEHAVIORAL|Usual care / Sham intervention|The control condition consists of usual activities.
223403825|NCT06370143|BEHAVIORAL|Questionnaire|The questionnaire on clinical, environmental, lifestyle, and dietary risk factors will be administered
224132322|NCT01395095|OTHER|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
223403826|NCT05573464|DRUG|BGF MDI HFO 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
223403827|NCT05573464|DRUG|BGF MDI HFA 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
223403828|NCT05763290|OTHER|Affective Response to Exercise|Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
224132323|NCT01395095|OTHER|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
224132324|NCT04030104|DEVICE|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
223403829|NCT06044454|OTHER|qXR|a software product that uses artificial intelligence to triage, prioritise, and (for tuberculosis only) diagnose based upon identified abnormalities within the CXR.
223403830|NCT04294628|PROCEDURE|Biopsy Procedure|Undergo biopsy
223403831|NCT04294628|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223403832|NCT04294628|PROCEDURE|Computed Tomography|Undergo CT scan
223403833|NCT04294628|PROCEDURE|Echocardiography Test|Undergo ECHO
223403834|NCT04294628|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223403835|NCT04294628|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223403836|NCT04294628|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223403837|NCT05443490|DIETARY_SUPPLEMENT|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.|Sachets containing a probiotic mixture at concentrations equal to or greater than 1x10\^9 colony forming unit (CFU) per dose, with maltodextrin as excipient.
223403838|NCT05443490|OTHER|Placebo comparator with maltodextrin as a carrier.|Sachets containing maltodextrin
223403839|NCT03413384|DRUG|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
223403840|NCT03413384|OTHER|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
223403841|NCT00261209|DRUG|Collagenase|Collagenase injection into adhesion restricting tendon gliding
223403842|NCT00261209|DRUG|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
223403843|NCT02449486|DRUG|Ropivacaine|
223554738|NCT01430143|BEHAVIORAL|Exercise|Daily exercise for 12 weeks.
223554739|NCT04963855|DRUG|GT300|SIngle oral dose
223554740|NCT04963855|DRUG|Microcrystalline cellulose|placebo
223554741|NCT03933683|DEVICE|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
223554742|NCT05641012|OTHER|data collection|helioderma evaluation
223554743|NCT00244868|OTHER|counseling intervention|
223554744|NCT00244868|OTHER|educational intervention|
223554745|NCT02030769|DRUG|Pronase|use pronase to improve visibility during endoscopical iodine staining
223403844|NCT04560270|DIAGNOSTIC_TEST|Blood samples|Blood samples to determine ctDNA levels during chemotherapy
223403845|NCT05294237|BEHAVIORAL|Happy program|The Happy program consists of handball specific warm-up components and resistance training components and will be available online.
223403846|NCT05294237|BEHAVIORAL|Support|The support consists of a coach workshop at the beginning of the season and the opportunity for additional support for the coaches throughout the season.
223403847|NCT04846569|BEHAVIORAL|Transition Theory-based Intervention|The behavioral intervention is a theoretically driven curriculum focused on supporting mothers from pregnancy through postpartum in order to promote sustained HIV treatment adherence. Sessions utilize motivational interviewing and consist of a range of topics including motherhood, preparing for baby, disclosure, HIV education, adherence, birth experiences, support systems, and living positively.
223403848|NCT04846569|BEHAVIORAL|Enhanced Standard of Care Control|In addition to standard of care, participants receive the first session of the Transition Theory-based Intervention curriculum which focuses on motherhood and preparation for baby but does not discuss the transition from pregnancy to postpartum or the postpartum period.
223403849|NCT04158167|DRUG|oxytocin|24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
223403850|NCT00382200|DRUG|decitabine|
223403851|NCT00382200|DRUG|tretinoin|
223403852|NCT00382200|GENETIC|DNA methylation analysis|
223403853|NCT00382200|GENETIC|cytogenetic analysis|
223403854|NCT00382200|GENETIC|microarray analysis|
223403855|NCT00382200|OTHER|flow cytometry|
223403856|NCT00382200|OTHER|immunohistochemistry staining method|
223554746|NCT02030769|DRUG|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
223554747|NCT02125838|DEVICE|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For \<50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
223554748|NCT02125838|DEVICE|Endotracheal Tube|ETT
223554749|NCT04227626|DEVICE|GlucoSTAT|Closed-loop blood glucose control using intravenous insulin and dextrose
223554750|NCT05247450|DEVICE|Functional electrical stimulation therapy (FES-t)|Functional electrical stimulation therapy (FES-t) that will use a multichannel device (MyndSearch device).
223554751|NCT05247450|OTHER|Conventional physiotherapy|Conventional physiotherapy is the current standard of care for rehabilitation of C5 palsy
224022392|NCT01413087|BIOLOGICAL|Biological/Vaccine: BC-819|"Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)"
224297609|NCT02519621|DEVICE|KCI Ulta|KCI Ulta NPWT without irrigation
224297610|NCT06102408|OTHER|second line investigations for uveitis etiological workup|Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).
224297611|NCT05302570|RADIATION|Hypofractionated Proton Beam Therapy|5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
224297612|NCT00631852|DRUG|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
224297613|NCT05859399|OTHER|Laughter yoga|Although the history of laughter yoga dates back to ancient times, its use in medicine has become widespread in the 21st century, while it is used to reduce pain, anxiety, stress, depression and fatigue, it is also a method that can be used to accelerate immunity, quality of life, happiness, sleep quality and recovery.
224297614|NCT00621036|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
224297615|NCT00621036|BIOLOGICAL|sargramostim|
224297616|NCT00621036|DRUG|methotrexate|
224297617|NCT00621036|DRUG|thiotepa|
224297618|NCT00621036|RADIATION|radiation therapy|
224297619|NCT06537804|RADIATION|Screening by low-dose CT scan|Screening for lung cancer by low-dose CT scan
224297620|NCT06172855|DEVICE|Electroacupuncture at ST36|Electroacupuncture at ST36, which located at the anterior aspect of the lower leg, 3 cun below ST 35, one finger-breadth (middle finger) from the anterior crest of the tibia. Twice or 3 times per week, for 6 weeks.
224297621|NCT04571892|BIOLOGICAL|Super circulating tumor infiltrating lymphocytes(ScTIL)|"Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion."
224297622|NCT04121650|BEHAVIORAL|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
224297623|NCT02836834|BIOLOGICAL|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
224297624|NCT04683237|DRUG|Liraglutide Injection|Initiate liraglutide with a dose of 0.6 mg daily for one week. After one week at 0.6 mg per day, increase the dose to 1.2 mg daily in a week, and increase the dose to 1.8 mg daily after at least one week of treatment with the 1.2 mg daily dose. If the patients can not tolerate 1.8mg per day, decrease the dose to the max tolerable dose.
224297625|NCT04683237|DRUG|Megestrol Acetate 160 MG|160mg po qd
224297626|NCT03380559|DRUG|Injection, botulinum toxin + corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
224297627|NCT03380559|DRUG|Injection, placebo of toxin + corticoid|"* Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
224297628|NCT03380559|DRUG|Injection, botulinum toxin + placebo corticoid|"* Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
224297629|NCT04309253|DRUG|PMPBB3|F-18 PMPBB3 PET Imaging
224297630|NCT04309253|DRUG|AV45|F-18 AV45 PET Imaging
224297631|NCT04952532|OTHER|Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)|The proposed study aims to collect pilot data to test the feasibility and acceptability of adjunctive neuroplasticity-based cognitive remediation on key treatment targets. The intervention will be delivered via telehealth to a sample of 36 Veterans with MDD and a history of a suicide attempt. The intervention will be delivered in 20 90-min sessions (2x/week for 10 weeks). Pre-, post, and follow-up assessments will be conducted to assess changes in neurocognitive, clinical, social, and real-world functioning.
224297632|NCT03692143|DRUG|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
224297633|NCT03692143|PROCEDURE|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
224297634|NCT03692143|DRUG|Alendronate|Alendronate Sodium, oral, 70mg, once a week
224297635|NCT00534794|DRUG|Elestat|Elestat BID for 2 days
224297636|NCT00534794|DRUG|Pataday|Pataday QD for 2 days
224297637|NCT02549794|PROCEDURE|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
224297638|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
224022393|NCT00928018|DRUG|Sirolimus|Taken orally for at least 12 months
224022394|NCT00928018|DRUG|Methotrexate|Given intravenously on the first, third and sixth day after transplant
224022395|NCT00928018|DRUG|Tacrolimus|Taken orally or given intravenously for at least 6 months
224022396|NCT00928018|DRUG|Cyclosporine|Taken orally or given intravenously for at least 6 months
224022397|NCT00928018|DRUG|MMF|Taken orally for about 2 months
223736214|NCT05555212|DRUG|QLH11811|"In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D."
223736215|NCT05275764|PROCEDURE|primary or secondary intraocular lens implantation surgery|primary or secondary intraocular lens implantation surgery
223736216|NCT04934345|DIAGNOSTIC_TEST|Fluid challenge|The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
223736217|NCT03885141|DRUG|Zolpidem|Zolpidem or Placebo if there is a wake up during the night
223736218|NCT03585179|DRUG|Oral Tranexamic Acid|Participants will take a pill of 250 mg bid for 12 weeks
223736219|NCT03585179|DRUG|5% topical tranexamic acid|Participants will apply a layer of gel on the affected skin bid for 12 weeks
223736220|NCT03585179|DRUG|4% hydroquinone|Participants will apply a layer of cream on the affected skin once at night
223736221|NCT03462550|DEVICE|Laryngeal mask|LMA insertion
223736222|NCT03800927|DEVICE|Long duration ultrasound|Low-intensity long duration ultrasound treatment
223554752|NCT01088204|PROCEDURE|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
223554753|NCT01088204|PROCEDURE|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
223736223|NCT02307955|DEVICE|firefly|
223736224|NCT02307955|OTHER|Standard of care|
223736225|NCT03721315|BEHAVIORAL|Intervention|"The health literacy enhancement will comprise of the following:~* Practical day to day information to help manage the disease~* Benefits of medication and adherence~* Tips to improve managing shortness of breath~* Proper use of inhalers (if applicable)~* Managing daily activities"
223736226|NCT02489344|DRUG|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
223554754|NCT05195086|DRUG|endoxan|Immunosuppressant
223554755|NCT05195086|DRUG|cellcept|Immunosuppressant
223554756|NCT00787839|OTHER|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
223736227|NCT05308745|DIETARY_SUPPLEMENT|Yakult®|Fermented milk drink containing over 6.5×10\^9 CFUs of L. casei Shirota/65 ml
223736228|NCT05308745|DIETARY_SUPPLEMENT|Placebo|Taste, appearance, component, and number of calories are the same as Yakult®, non-fermented milk product
223736229|NCT03287167|DRUG|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
224297639|NCT02549794|PROCEDURE|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
224297640|NCT03748394|BEHAVIORAL|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
224297641|NCT03748394|BEHAVIORAL|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
224297642|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
223736230|NCT03287167|DRUG|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
223736231|NCT00312091|DRUG|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
223736232|NCT00312091|DRUG|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
223736233|NCT00312091|DRUG|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
223736234|NCT00312091|DRUG|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
223736235|NCT04178746|DEVICE|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
223736236|NCT06847698|DRUG|AVR-48|Investigational drug reconstituted in normal saline will be administered via IV
223736237|NCT06847698|DRUG|Placebo|Normal saline will be administered via IV
223736238|NCT01995084|DRUG|[F-18]HX4|400 MBq \[F-18\]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
224132325|NCT04030104|DEVICE|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
223403857|NCT06189937|BEHAVIORAL|Culturally Adapted Cognitive Behavioral Therapy (CA-CBT)|"In this study, an 8- session (90 to 120 minutes) group version of the transdiagnostic intervention CA-CBT tailored for earthquake survivors will be applied.~Contents of the sessions are:~1. Education on psychological trauma and its treatment, and basics of emotion regulation techniques~2. Education on anxiety and depressive disorders and their treatment~3. Muscle relaxation and stretching exercises~4. Education about depressive and grief-related disorders and disturbing memories protocol~5. Interoceptive exposure: head rotation and hyperventilation~6. Anxiety, worry, and stress~7. Anger and anger protocol; breathing exercises~8. Somatic complaints, sleep disturbance, and closing~There will be one facilitator and one co-facilitator. Groups will consist of 12-13 participants."
223403858|NCT04671420|DRUG|HLX01|Patients will receive HLX01 intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
223403859|NCT04671420|DRUG|Mabthera®|Patients will receive Mabthera® intravenous (IV) infusion once a week for 4 weeks induction treatment (on Days 1, 8, 15, and 22), and then continue to receive maintenance treatment at Weeks 12, 20, 28, 36, and 44.
223403860|NCT00536939|DRUG|Enzastaurin|1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression
223403861|NCT00536939|DRUG|Bevacizumab|10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression
223403862|NCT00536939|DRUG|Paclitaxel|90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
223403863|NCT00536939|DRUG|Placebo|Oral, daily, until disease progression
223403864|NCT06576349|BEHAVIORAL|Compassionate And Loving Mindset towards Heart Health Risk (CALM Hearts) Intervention|Self-compassion and health behaviour change intervention for women at risk for cardiovascular disease
223403865|NCT02989870|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
223403866|NCT02989870|DRUG|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
223403867|NCT02989870|DRUG|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
223403868|NCT01529333|DEVICE|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
223403869|NCT02840123|BIOLOGICAL|Autologous dendritic cells|
223403870|NCT03391219|DRUG|injection bevacizumab|1.25 mg/0.05 cc bevacizumab
223403871|NCT03391219|DRUG|injection Combined Bevacizumab and Fasudil|1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
223554757|NCT00787839|OTHER|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
223554758|NCT03201575|DEVICE|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
223554759|NCT03201575|DEVICE|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
223554760|NCT01389726|BEHAVIORAL|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
223736239|NCT01020279|DRUG|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
223554761|NCT01389726|BEHAVIORAL|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
223554762|NCT01389726|BEHAVIORAL|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
223736240|NCT01020279|DRUG|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
223736241|NCT04384510|PROCEDURE|Planned Cesarean hysterectomy|This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy
223736242|NCT04384510|PROCEDURE|Conservative management|This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
224022398|NCT00126503|BIOLOGICAL|Bevacizumab|Given IV
224022399|NCT00126503|DRUG|Sorafenib Tosylate|Given PO
224022400|NCT00126503|OTHER|Pharmacological Study|Correlative studies
224022401|NCT00126503|OTHER|Laboratory Biomarker Analysis|Correlative studies
224022402|NCT00061139|BEHAVIORAL|Pediatric Constraint-Induced Movement therapy|
224022403|NCT00061139|BEHAVIORAL|Conventional pediatric motor rehabilitation therapy|
224022404|NCT00203762|BEHAVIORAL|Public sector antiretroviral treatment programmes|
224022405|NCT05408832|BEHAVIORAL|Personalized Trial ABCCBA|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (ABCCBA), where A=mindfulness meditation, B=yoga, and C=brisk walking.
224022406|NCT05408832|BEHAVIORAL|Personalized Trial CBAABC|Participants will receive links for 30-minute videos for all three interventions, for 2 weeks each, 3 times per week, in a specified order (CBAABC), where A=mindfulness meditation, B=yoga, and C=brisk walking.
223554763|NCT05940064|DRUG|Zanubrutinib, Polatuzumab Vedotin, Rituximab|Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
223554764|NCT02383186|PROCEDURE|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
223736243|NCT06012045|BEHAVIORAL|Enhanced Cue Exposure Therapy|The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. Session #1 will be used to introduce to the participant the rationale and procedures of E-CET to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. Sessions #2 to #5 will be in vivo exposures. The interventionist will prompt the participant to evaluate the CS-US expectancy to facilitate the violation of the CS-US expectancy maintaining NEE. Between-session homework exposures will be planned and conducted by the participant in their naturalistic environment. They will also be reviewed at the beginning of the following session to consolidate learning. The final session will consist of consolidation of treatment gains and relapse prevention.
223736244|NCT06012045|BEHAVIORAL|Behavioral Lifestyle Intervention|The BLI will consist of six weekly sessions of behavioral counselling integrating behavioral strategies for participants to make dietary changes. These behavioral strategies will include education about healthy and balanced diets, goal-setting, problem-solving, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.
224132326|NCT04030104|DEVICE|Mammography|Mammography as available per standard of care
224132327|NCT02270892|DEVICE|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
223554765|NCT02383186|PROCEDURE|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
223736245|NCT01812824|BEHAVIORAL|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
224132328|NCT06553417|OTHER|Aqua posae and microresyl|"* This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
224132329|NCT06553417|OTHER|Urea 10%|"Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects."
224132330|NCT05126524|OTHER|NO INTERVENTION|Observational study, no intervention performed
224132331|NCT03105596|DRUG|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
224297643|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
224297644|NCT01550276|OTHER|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
224297645|NCT01550276|OTHER|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
223554766|NCT06071598|OTHER|Surgical specimens of CRC-affected patients|Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
223554767|NCT01591434|DEVICE|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
223554768|NCT01591434|DEVICE|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
223403872|NCT04747119|OTHER|muscle energy technique|the patient was supine and the therapist fix the lower limb of the affected side then ask the patient to perform isometric contraction for abductors maintained for 3-5 seconds, then the patient was instructed to stop, exhale and relax then the therapist perform further adducted the patient's knee of the affected side as a stretching exercise for Three to five repetitions of these directions were performed.
223554769|NCT01693198|PROCEDURE|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
223736246|NCT01290640|DEVICE|DePuy fixed-bearing Total Condylar III (TC3) TKA|
224297646|NCT03922074|PROCEDURE|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
223736247|NCT01290640|DEVICE|DePuy PFC Rotating Platform TC3 TKA|
224132332|NCT04950881|PROCEDURE|Ultrasound guided vagus nerve block|Before the operation starts, patients received the ultrasound guided vagus nerve block. A 50mm Braun nerve stimulation needle is guided by the ultrasonic beam to insert into the carotid sheath and 10ml of lidocaine or ropivacaine is injected.
224132333|NCT04950881|DRUG|Bradycardia Treatment|If the OVR happens because the surgical stimulation, the operation suspends and atropine (0.01-0.02mg/kg) or isoproterenol (1-2 μg/per time)is given intravenously to increase the heart rate.
224297647|NCT03922074|PROCEDURE|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
224297648|NCT05636566|DRUG|Sevoflurane|inhalational anaesthesia for maintenance
224297649|NCT05636566|DRUG|Propofol infusion for maintance|propofol infusion after induction for maintenance of anaesthesia
223554770|NCT04826263|OTHER|Home Exercise Program|All patients will be instructed to follow a home exercise program for 3 weeks. Patients will be informed about the exercises by giving an exercise sheet describing the exercises and an exercise diary prepared to mark the days they exercise. The home exercise program will include previously recommended exercises such as Achilles tendon and plantar fascia stretching and toe curl exercises. Patients will be instructed to perform these exercises 10 repetitions each and 3 times per day for three weeks.
224297650|NCT05636566|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia
224297651|NCT01401257|DRUG|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
224297652|NCT01401257|DRUG|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
223554771|NCT04826263|OTHER|Low-Level Laser Therapy (LLLT)|Patients in the LLLT group will receive gallium-aluminum-arsenide (Ga-Al-As) low-level laser treatment with Chattanooga Vectra Genisys Transport model (Chattanooga Group) with a wavelength of 850 nm and a power of 100 mW. The LLLT treatment will be applied 3 times a week, a total of 10 sessions. A maximum energy density of 5.6 j/cm2 will be reached by delivering a continuously increasing dose of energy to each tender spot for one minute. The LLLT will be performed with patients in the prone position and will be applied to 5 points on the plantar fascia by positioning the laser head perpendicular to the treatment area.
224132334|NCT03563703|DEVICE|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
224297653|NCT01401257|DRUG|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
223403873|NCT04747119|OTHER|conventional selected physical therapy|"1. life style modification~2. Transcutaneous electrical nerve stimulation (TENS)~3. Flexibility stretching exercises to the hip flexors"
223403874|NCT02350491|OTHER|Collection of biological samples|collection of biologic samples ( blood and urine) befor and after woman pregnacy
223403875|NCT02954601|DRUG|ORMD-0801 (qd)|Dose 1 = ORMD-0801 (qd)
224297654|NCT01401257|OTHER|Placebo|Liquid,5 ml, twice a day, 12-month treatment
224297655|NCT04873531|DRUG|Neostigmine|"For the N group, neostigmine (0.03 mcg / kg) and glycopyrrolate with a 5:1 ratio will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
223736248|NCT01170507|DRUG|vitamin D3 1000 IU orally daily for 5 months|
223736249|NCT01170507|DRUG|vitamin D3 3000 IU orally daily for 5 months|
223736250|NCT01170507|DRUG|vitamin D3 5000 IU orally daily for 5 months|
223736251|NCT01170507|DRUG|Placebo orally daily for 5 months|
223736252|NCT05284669|OTHER|Experimental e-learning|Interactive lecture based on the guidelines for the management of LBP with a focus on self-management and patient's reassurance
223736253|NCT05284669|OTHER|Traditional e-learning|Traditional lecture based on the guidelines for the management of LBP with a focus on diagnostic triage and specific cause of LBP
223736254|NCT01431560|DEVICE|fixation of the ankle fracture (Solco )|fixation with metallic implant
224297656|NCT04873531|DRUG|Normal saline|"For the NS group, neostigmine normal saline (0.09 cc/kg; the same volume of the group N) will be administered just after tracheal intubation.~Investigators evaluate the quality of signal of IONM during the surgery."
224297657|NCT06105320|OTHER|LCHF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 10-25 E%; Fat 50-70 E%; Protein: 20-25 E%; Alcohol 0-5 E%"
224297658|NCT06105320|OTHER|HCLF|"A diet intervention with the following macronutrient targets:~Carbohydrates: 50-60 E%; Fat 25-30 E%; Protein: 15-20 E%; Alcohol 0-5 E%"
224297659|NCT02217631|DRUG|BI 653048 BS H3PO4|
224297660|NCT02217631|DRUG|Prednisolone low dose|
224297661|NCT02217631|DRUG|Prednisolone high dose|
224297662|NCT02217631|DRUG|Placebo|
223403876|NCT02954601|DRUG|ORMD-0801 (bid)|Dose 2 = ORMD-0801 (bid)
224297663|NCT01918631|DRUG|tenofovir disoproxil fumarate|
224297664|NCT01918631|DRUG|Entecavir|
224297665|NCT02311920|BIOLOGICAL|Ipilimumab|Given IV
224297666|NCT02311920|OTHER|Laboratory Biomarker Analysis|Correlative studies
223403877|NCT02954601|DRUG|ORMD-0801 (tid)|Dose 3 = ORMD-0801 (tid)
223403878|NCT02954601|OTHER|Placebo|fish oil placebo
223403879|NCT03667222|DRUG|minocycline topical gel|Once daily administration of BPX-04 minocycline gel for 12 weeks
223403880|NCT03667222|DRUG|topical gel vehicle|Once daily administration of BPX-04 gel vehicle for 12 weeks
223736255|NCT01431560|DEVICE|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
223403881|NCT04341493|DRUG|Nitazoxanide 500 MG|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
223403882|NCT04341493|DRUG|Hydroxychloroquine|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
223403883|NCT01438905|OTHER|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
223403884|NCT01438905|OTHER|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
223403885|NCT04391673|BEHAVIORAL|Vestibular rehabilitation|Vestibular rehabilitation (treatment as usual).
223403886|NCT05904873|PROCEDURE|Mandibular Third Molar Surgery|All surgical procedures were carried out by a single dental(maxillofacial) surgeon different from the clinician performing the cold testing. A total of 4 cc of local anesthetic solution containing 40 mg/ml articaine and 0.005 mg/ml epinephrine was applied to the inferior alveolar and buccal nerve blocks before the surgical procedure. In all cases, the mucoperiosteal flap was raised and bone was removed from the buccal and distal parts of the impacted tooth with burs, while protecting the papilla between the first and second molars during flap design. Before extraction, if necessary, the third molar was divided and tooth extraction was performed with elevators. The flap was brought to its original position and closed with silk suture material.
223403887|NCT00188773|DRUG|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
223403888|NCT06572059|OTHER|assesments for once|"* EDSS score (patient reports recorded in the physician's record will be used.)~* Demographic information~* Fatigue Severity Scale (FSS)~* Beck Depression Inventory (BDI)~* Kinesthetic and Visual Imagery Questionnaire (KSVI)~* Mental Chronometer Test (Nine-Hole Peg Test (DDPT)) will be used.)~* Jebson-Taylor Hand Function Test (JHEFT)~* Manual Ability Test (MAM-36)~* Multiple Sclerosis Impact Scale (MSIS-29)"
223403889|NCT00778219|DEVICE|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
223403890|NCT05801536|DEVICE|SCONE|This is a noninvasive (nonsurgical) electrical neuromodulation device to reactivate and retrain the neurons and neural networks in the spinal cord to improve function after neurological trauma. The device will be used to stimulate the cervical spinal cord as participants practice tasks involving upper limb control.
223403891|NCT01853813|DRUG|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
223554772|NCT04826263|OTHER|Extracorporeal Shockwave Therapy (ESWT)|Patients in the ESWT group will receive treatment with a radial ESWT system (EMS Swiss Dolor Clast), which transforms kinetic energy into a shock wave, which is then applied to the target tissue with pressure varying from 1 to 10 bar and penetrating up to 40 mm. The ESWT treatment will be administered to the patients once a week for three weeks, for a total dose of 2000 mJ/mm2 pulse per application. ESWT will be applied to the patients in prone position with their foot inverted. Ultrasound gel will be applied to the patient's heel The area of tenderness will be palpated and 1000 shock wave impulses were applied to this area, and 1000 pulses will be applied over the plantar fascia.
223554773|NCT04929353|OTHER|Systematic symptom assessment|"* Systematic symptom assessment~* Conventional symptom assessment"
223554774|NCT04342676|DEVICE|k ras|K ras
223554775|NCT04342676|DRUG|Panitumumab|vectibex in stage iv
223554776|NCT02812238|DIETARY_SUPPLEMENT|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
223554777|NCT02812238|DRUG|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
223554778|NCT01008761|DRUG|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
223554779|NCT01008761|DRUG|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
223554780|NCT02303210|DEVICE|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
223736256|NCT05798429|OTHER|compassion education|6 weeks of compassion training
223736257|NCT06094673|OTHER|No intervention|No intervention
223736258|NCT02054221|PROCEDURE|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
223403892|NCT04875221|COMBINATION_PRODUCT|Connectivity-based neurofeedback|Real-time fMRI neurofeedback will be used to non-invasively regulate neural network connectivity patterns associated with symptoms and emotional arousal among patients with PTSD and healthy individuals, with the aim to induce lasting neuronal effects and reduce symptoms.
223736259|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
223736260|NCT02054221|PROCEDURE|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
223403893|NCT04744649|DRUG|XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
223403894|NCT04744649|DRUG|JS001+XELOX or SOX|"XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA"
223403895|NCT05668416|OTHER|education|The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
223403896|NCT06212414|BEHAVIORAL|Mind Programme|Intervention based on Acceptance and Commitment Therapy, mindfulness, and compassion approaches
223403897|NCT06212414|BEHAVIORAL|Support Group|This intervention promotes the sharing of cancer-related experiences, active listening, and a sense of community between participants
223403898|NCT03215290|PROCEDURE|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
223403899|NCT06310733|DRUG|LGG|Participants will take 10 mL of a suspension of freeze-dried LGG ATCC53103 in excipients in an aqueous solution, supplied in a 10-mL dark bottle with a delivery cap.
223403900|NCT06310733|DRUG|Placebo|Participants will take 10 mL of an identical aqueous solution in appearance and taste but without LGG, supplied in a 10-mL dark bottle.
223403901|NCT05172284|OTHER|Questionnaires|This is a collection of data from normal clinical routine: patients will be asked to record the assessments they undergo during their course of treatment, without changing clinical practice in any way. Data inherent to the following procedures will be collected: examinations, laboratory tests, imaging tests, questionnaires and rating scales.
223403902|NCT03466463|GENETIC|GNT0003|Intravenous infusion, single dose
223403903|NCT01220466|DEVICE|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
223403904|NCT01158846|DRUG|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
223403905|NCT01158846|DRUG|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
223736261|NCT00546637|DRUG|Fesoterodine|Fesoterodine 4mg or 8mg
223736262|NCT00546637|DRUG|Placebo|Placebo
223736263|NCT05853198|OTHER|ctDNA analysis|ctDNA amount and mutations analysis
223736264|NCT03817177|PROCEDURE|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
223736265|NCT03817177|PROCEDURE|nasal prong|conventional nasal prong application in PACU
223736266|NCT03165279|PROCEDURE|Zenith Alpha Abdominal stentgraft|
223736267|NCT01433601|BEHAVIORAL|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
223736268|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
224132335|NCT03563703|DEVICE|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
223736269|NCT01074450|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
223736270|NCT04938557|DEVICE|Automated closed-loop insulin delivery (AiD)|Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
223736271|NCT04938557|DEVICE|A standard insulin delivery system|Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
223736272|NCT03909412|DRUG|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
223736273|NCT03909412|DRUG|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
224132336|NCT04570657|BIOLOGICAL|MEDI3506|Participants will receive multiple doses of MEDI3506 at dose level 1 or dose level 2
224132337|NCT04570657|DRUG|Placebo|Participants will receive multiple doses of placebo
224132338|NCT00330720|DEVICE|Emergency Response System (Device)|
224132339|NCT04961372|OTHER|Survey|PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
224297667|NCT02311920|BIOLOGICAL|Nivolumab|Given IV
224297668|NCT02311920|DRUG|Temozolomide|Given PO
223403906|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg \[S,S\]-reboxetine for 5 and one half weeks.
223403907|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg \[S,S\]-reboxetine for 5 and one half weeks.
223403908|NCT00636246|DRUG|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
223403909|NCT00636246|DRUG|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
223403910|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks.
223403911|NCT00636246|DRUG|Placebo|Tablets, orally once per day for 8 weeks
223403912|NCT00636246|DRUG|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg \[S,S\]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg \[S,S\]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg \[S,S\]-reboxetine for 5 and one half weeks
223403913|NCT00636246|DRUG|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
223403914|NCT02271646|DRUG|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
223403915|NCT05003310|DEVICE|Active Stimulation|Stimulation will be turned ON and applied during each day of the period.
223403916|NCT05003310|DEVICE|Sham Stimulation|Sham stimulation will be provided during the period
223403917|NCT05003310|DRUG|Baricitinib|Baricitinib (2 mg) is administered daily during the period.
223403918|NCT05003310|DRUG|Background Treatment|Stable dose of standard background treatment (e.g., csDMARD therapy)
223554781|NCT02303210|DEVICE|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
223554782|NCT05793359|DRUG|Methylprednisolone|methylprednisolone applied as intravenous infusions or intramuscularly
223554783|NCT00068315|DRUG|bortezomib|Given IV
223554784|NCT00068315|DRUG|fludarabine phosphate|Given IV
223554785|NCT00068315|BIOLOGICAL|rituximab|Given IV
223554786|NCT05243979|RADIATION|DEXA scan|bone study
223554787|NCT02538536|DRUG|PBI4050|
223554788|NCT03441022|DEVICE|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
223554789|NCT03441022|DEVICE|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
223554790|NCT05066750|BEHAVIORAL|Mindful breathing|Participants watch a 10 minute mindful breathing video
223554791|NCT05066750|BEHAVIORAL|Control video|Participants watch a 10 minute control video
223554792|NCT00783653|DRUG|Sunitinib|25 mg or 37,5 mg daily dose until DLT
223554793|NCT01970241|DRUG|NPH|NPH given per study table based on steroid dose and patient weight in kg.
223554794|NCT01970241|DRUG|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
223554795|NCT01769664|DRUG|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
223554796|NCT01769664|DRUG|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
223554797|NCT01769664|DRUG|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
223554798|NCT02672189|BEHAVIORAL|EVA-Online|Internet-based cognitive behavioral therapy
223554799|NCT05891535|PROCEDURE|Robot assisted radical cystectomy without mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
223554800|NCT05891535|PROCEDURE|Robot assisted radical cystectomy with mono J ureteral stent placement|Robot assisted radical cystectomy with/without ureteral mono J stent placement during uretero-neobladder anastomosis
223554801|NCT03578926|DEVICE|fanfilcon A toric lens|contact lens
223554802|NCT03578926|DEVICE|senofilcon A toric lens|contact lens
223554803|NCT05127408|PROCEDURE|Interventional Endoscopy|correct defects of the gastrointestinal tract.
223554804|NCT01786382|DRUG|PPI-668|
223554805|NCT01786382|DRUG|Midazolam|
223554806|NCT01786382|DRUG|Omeprazole|
223554807|NCT01786382|DRUG|Telaprevir|
223554808|NCT02700620|BEHAVIORAL|Internet-delivered CBT|Guided internet treatment
223554809|NCT03628066|DRUG|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
223554810|NCT03628066|DRUG|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
223554811|NCT03628066|DRUG|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
223554812|NCT03628066|DIAGNOSTIC_TEST|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
223736274|NCT03909412|DRUG|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
223736275|NCT03909412|DRUG|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
223736276|NCT00350714|OTHER|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
223736277|NCT00963287|DRUG|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
223736278|NCT04751344|DRUG|Liposomal bupivacaine|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 8cc of liposomal bupivacaine (13.3mg/mL) will be injected around the surgical site.
223736279|NCT04751344|DRUG|Bupivacaine HCl|Prior to procedure, surgeon will administer 15cc of Lidocaine 2% plain. After the procedure is finished, 10cc of bupivacaine HCl (5mg/mL) will be injected around the surgical site.
223736280|NCT03020680|DIETARY_SUPPLEMENT|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
223736281|NCT05677971|DRUG|Fazirsiran Injection|Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
223736282|NCT05677971|OTHER|Placebo|Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
223736283|NCT00000381|DRUG|Fluoxetine|
224297669|NCT04323020|DIAGNOSTIC_TEST|CT Perfusion|CT Perfusion
224297670|NCT02413931|OTHER|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
224297671|NCT01591889|DRUG|Tinidazole|500 mg tablet
224297672|NCT01591889|DRUG|Tinidazole|500 mg tablet
224297673|NCT03776292|OTHER|monitoring|Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
224297674|NCT00112346|DRUG|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
224297675|NCT00112346|DRUG|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
224297676|NCT00767065|RADIATION|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate \<70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
224297677|NCT00767065|OTHER|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
224297678|NCT02635217|DEVICE|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
224297679|NCT02635217|DEVICE|room air insufflation|using standard care room air will be infused on demand
224297680|NCT02635217|PROCEDURE|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
224297681|NCT02635217|PROCEDURE|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
223403919|NCT05970510|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg|orally once a day
223403920|NCT05970510|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg|orally once a day
223403921|NCT05970510|DRUG|placebo|orally once a day
223403922|NCT04227197|OTHER|Down Syndrome Clinic to You (DSC2U)|DSC2U is a web-based tool for families to get up-to-date, personalized health and wellness information, based on national guidelines and expert consensus, for a person with Down syndrome.
223403923|NCT00839683|DRUG|simvastatin|Tablets, Oral, 20 mg, Single Dose
223403924|NCT00839683|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
223403925|NCT00839683|DRUG|simvastatin|Oral, 40 mg, Single Dose
223736284|NCT01730209|DRUG|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
223736285|NCT01730209|DRUG|Placebo|
223736286|NCT00775151|DRUG|amlodipine 10 mg tablet|
223736287|NCT04231539|DRUG|Nicotine|Vape different flavor nicotine products
223736288|NCT04231539|DEVICE|Vaporizer Device|Take puffs from vaporizer filled with different flavors
223736289|NCT03680950|DEVICE|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
224297682|NCT05485519|DRUG|Dexmedetomidine|Infusion start at 0.5 mcg/kg/hour. Titrate to effect (up to1.5 mcg/kg/hour)
224297683|NCT05485519|DRUG|Midazolam|(1 mcg/kg/minute. up to a maximum of 5 mcg/kg/minute.
224297684|NCT00970008|OTHER|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
223736290|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the upper arm
223736291|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the lower abdomen
223403926|NCT00839683|DRUG|valsartan|Tablets, Oral, 320 mg, Single Dose
223403927|NCT00333983|DEVICE|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
223403928|NCT00333983|OTHER|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
223403929|NCT04558801|DEVICE|Mobile application-based lifestyle change program|Usage of the Mobile application-based lifestyle change program
223403930|NCT06041854|PROCEDURE|Freeze-dried bone allograft combined with Enamel Matrix derivative|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft mixed with enamel matrix derivative.~Enamel matrix derivatives are natural proteins that are produced in the developing dental follicle.The major components of EMD are amelogenins, a family of hydrophobic porcine tooth-derived proteins. They account for more than 95% of the total EMD protein content. Other proteins found in the enamel matrix include enamelin, ameloblastin, amelotin, apin and various proteinases, which have found in trace amounts in EMD. EMD adsorbs on decontamined root surfaces and alveolar bony defects and forms an insoluble scaffold complex."
223403931|NCT06041854|PROCEDURE|Freeze-dried bone allograft|"The intrabony defects will be treated by minimally invasive surgical technique or modified minimally invasive surgical technique depending on defect extension, and the defects will be filled by freeze-dried bone allograft .~Allogeneic bone graft refers to bony tissue that is harvested from one individual and transplanted to a genetically different individual of the same species, principally osteoconductive, although it may have some osteoinductive capability, depending on how it is processed."
223403932|NCT00763425|PROCEDURE|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
223403933|NCT00763425|PROCEDURE|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
223403934|NCT06413628|OTHER|screw tapered appliance|The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.
223403935|NCT00277225|DRUG|Abatacept|
223403936|NCT00570141|DEVICE|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
223554813|NCT05965050|DIAGNOSTIC_TEST|Myofascial Release Technique|myofascial release therapy, the therapist applies light pressure by hand to find myofascial areas that feel stiff instead of elastic and movable. These stiff areas, or trigger points, are thought to limit muscle and joint movements, which can play a part in widespread muscle pain.
223554814|NCT05965050|OTHER|Ultrasound Therapy|Ultrasound physical therapy is a branch of ultrasound, alongside diagnostic ultrasound and pregnancy imaging. It's used to detect and treat various musculoskeletal issues you may have including pain, tissue injury, and muscle spasms
223554815|NCT04803864|DRUG|Roxadustat|Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.
223554816|NCT04819529|BEHAVIORAL|Early and Intensive Occupational Therapy|"Occupational therapists will implement the following activities:~* Polysensory stimulation: external stimulation for increasing the level of alertness. It will be implemented with SAS 1 one session each 48 h and SAS 2 one session each 24 h.~* Cognitive stimulation: bundle of exercises for activating mental functions, i.e: alertness, visual perception, memory, calculus, problem solving, praxis, language. Patients with SAS 3, 4 and 5. In SAS \<2, 6\> environmental orientation will be considered~* Basic activities of daily living (BADLs): promotion of independence that initially practice hygiene, personal grooming. Patients with SAS 3, 4 and 5~* Motor function Stimulation: exercises to keep the patient's upper extremities active and functional. Patients with SAS with 3,4 and 5. Patients with SAS 1 and 2 will use adaptations to prevent edema and bedsores on vulnerable body areas~* Education: daily visits by trained family members and health staff about the intervention process"
223554817|NCT05082766|DRUG|enhanced DefenAge 8-in-1 BioSerum|DefenAge is a topical skincare brand containing a composition of biologically active natural molecules, named defensins, that repair skin damage associated with aging.
223554818|NCT05799703|DEVICE|electrical stimulation device|the device has 2 channels ,4 electrodes with multiple ems programs
223554819|NCT05799703|OTHER|kinesio taping|kinesio tape a therapeutic tape that's applied strategically to the body to provide support, lessen pain, reduce swelling, and improve performance
223554820|NCT03235882|DIAGNOSTIC_TEST|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
223554821|NCT02959294|PROCEDURE|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
223554822|NCT02959294|DEVICE|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
223554823|NCT02959294|PROCEDURE|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
223554824|NCT01294111|BEHAVIORAL|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
223554825|NCT02585986|DIETARY_SUPPLEMENT|Probiotic|daily intake of 1 capsule probiotic
223554826|NCT02585986|DIETARY_SUPPLEMENT|Placebo|daily intake of 1 capsule containing placebo
223736292|NCT04091373|COMBINATION_PRODUCT|cotadutide multidose pen injection|SC injection in the thigh
223736293|NCT01869296|PROCEDURE|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
223736294|NCT01869296|PROCEDURE|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
224022407|NCT05408832|BEHAVIORAL|Stress Management Techniques with No Randomization Sequence (or order)|Participants will have access to all 30-minute videos for A=mindfulness meditation, B=yoga, and C=brisk walking, during the 12-week phase of the study. They will be limited to 12 total views per stress management technique.
224022408|NCT02457559|DRUG|Tirabrutinib|Tablets or capsules administered orally
223403937|NCT06505707|BEHAVIORAL|Health Seeking Behavior Training Based on Motivational Interviewing Techniques|The Effect of Health Seeking Behavior Training Based on Motivational Interviewing Techniques on Health Seeking Behavior, Illness Self-Management and Anxiety in Migrant Elderly Women with Chronic Diseases.
223736295|NCT04702477|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
223736296|NCT03016962|DEVICE|cap-assisted colonoscopy|cap-assisted colonoscopy
223736297|NCT03016962|DEVICE|Standard colonoscopy|Standard colonoscopy
223736298|NCT00441311|BEHAVIORAL|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
223736299|NCT00579956|DRUG|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
223736300|NCT00579956|DRUG|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
223736301|NCT05048446|OTHER|observational|Non intervention
223736302|NCT02612935|DEVICE|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
223736303|NCT00680745|DRUG|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
223736304|NCT00680745|DRUG|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
223736305|NCT00680745|DRUG|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
224132340|NCT04413435|OTHER|File Scanning|The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
223403938|NCT03783819|OTHER|Hypericum perforatum oil|Ointment containing Hypericum perforatum oil
223554827|NCT00682903|DEVICE|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
223554828|NCT00191568|DRUG|Gemcitabine|
223554829|NCT00191568|DRUG|Oxaliplatin|
223554830|NCT00191568|PROCEDURE|Radiotherapy|
223554831|NCT04796272|OTHER|Adapted and individualized physical training program|Physical training program adapted and individualized according to each patient in this group
223736306|NCT00680745|DRUG|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
223736307|NCT00680745|DRUG|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
223736308|NCT05874076|BEHAVIORAL|Physiotherapy|Physiotherapy
223736309|NCT03704961|BEHAVIORAL|music and audiobook listening|
223736310|NCT00352521|DRUG|bevacizumab|
223403939|NCT03783819|OTHER|Placebo|Ointment containing plant oils used in Hypericum perforatum oil production and dye
223403940|NCT03783819|PROCEDURE|SLS induced irritation|60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
223403941|NCT03783819|PROCEDURE|Tape-stripping|Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
223554832|NCT04796272|OTHER|traditional training program|Same training program for all patients in this group
223554833|NCT03141125|OTHER|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
223554834|NCT03141125|OTHER|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
223554835|NCT01564212|OTHER|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
223554836|NCT01564212|OTHER|laminar airflow with surgical drapes|
223554837|NCT01564212|OTHER|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
223554838|NCT01564212|OTHER|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
223736311|NCT00352521|DRUG|irinotecan|
223736312|NCT00352521|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223736313|NCT02612428|BIOLOGICAL|ELAD System|An extracorporeal human hepatic cell-based liver treatment
223736314|NCT02612428|OTHER|Standard of Care (Control)|Standard medical treatment as defined by the protocol
224022409|NCT02575859|DRUG|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
224022410|NCT02575859|PROCEDURE|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
224022411|NCT02010853|OTHER|IRMf|"evaluation in resting state fMRI during three successive visits:~* During the acute phase within 24 hours~* In 72 hours~* In 3 months"
224022412|NCT00231946|DRUG|VP4896|
223403942|NCT03783819|PROCEDURE|UV radiation|UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
223403943|NCT03783819|PROCEDURE|Intact skin|Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
223403944|NCT02992236|DRUG|VAS203|Infusion of NO-Synthase inhibitor VAS203
223736315|NCT06123650|DEVICE|Repetitve transcranial magnetic stimulation|"The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor  Hot spot , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days."
223736316|NCT06123650|DEVICE|Sham transcranial magnetic stimulation|Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.
223736317|NCT04846621|DRUG|Potassium Channel Opener|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
223736318|NCT04846621|DRUG|Calcium channel blocker|Randomized Controlled comparative clinical trial between two drugs as a tocolytic agent in preterm labor
223736319|NCT02211521|BIOLOGICAL|PRP|3ml of PRP
223736320|NCT02211521|DRUG|Hyaluronic acid|3ml hyaluronic acid
223736321|NCT00330941|DRUG|lidocaine|
223736322|NCT00829881|DRUG|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
223736323|NCT00829881|DRUG|Placebo Capsule|A single placebo capsule
223736324|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & Flu A/B test|Swab Samples for Diagnostic test
223736325|NCT05268939|DIAGNOSTIC_TEST|LumiraDx SARS-CoV-2 & RSV test|Swab Samples for Diagnostic test
223736326|NCT00742001|BIOLOGICAL|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
223403945|NCT02992236|DRUG|Saline|Infusion of saline
223403946|NCT06578533|DRUG|Sodium Zirconium Cyclosilicate|"The recommended starting dose of Lokelma is 10 g, administered three times a day.~If, at any time during the study, sK is \> 6.5 mEq/L, treatment for acute hyperkalemia will be started following common clinical practice and local protocols, and investigator will consider RAASi / MRA withdrawal, or downtitration. In this case (confirmed sK \> 6.5 mEq/L despite the maximum SZC dose) patient will leave the IP and will be counted as a treatment failure.~If sK is ≤ 3.0 mEq/L, discontinue SZC. The subject should immediately receive appropriate medical intervention.~If sK is between 3.1-5.1 mEq/L, pause SZC and re-evaluate in a week. This one-week SCZ treatment temporary discontinuation can only be applied once; if a new sK value between 3.1-5.1 mEq/L is detected, patient will leave the IP permanently.~Depending on the serum potassium levels at each visit, the dose of SZC will be adjusted."
223403947|NCT04358185|DRUG|Itacitinib (INCB039110)|Novel and small molecule selective inhibitor of JAK1
223403948|NCT03469856|DRUG|Prasugrel monotherapy|A multicenter, single arm, open-label trial of in patients with chronic stable angina
223403949|NCT06574113|DEVICE|Perin Health Patch|The Perin Health Patch (PHP)is a multimodal wearable health patch, which combines auscultation, electrocardiography (ECG), pulse oximetry via photoplethysmography (PPG), bioimpedance (BioZ), skin temperature, and motion and tilt sensors. The PHP integrates multiwavelength PPG (MWPPG) with blue, green, red, and IR LEDs, allowing for precise calculation of PTT, PWV, and related unique parameters, that are used for the calculation of cuffless blood pressure.
223403950|NCT06240169|PROCEDURE|DPC with MTA in AGEI|DPC using MTA in 18-40 years
223403951|NCT06240169|PROCEDURE|DPC with BD in AGEI|DPC using BD in 18-40 years
223403952|NCT06240169|PROCEDURE|DPC with MTA in AGEII|DPC using MTA in 41-60Years
223403953|NCT06240169|PROCEDURE|DPC with BD in AGEII|DPC using BD in 41-60Years
223403954|NCT02946372|PROCEDURE|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
223403955|NCT05939960|DIAGNOSTIC_TEST|CGT test|GCT、PRP-CT、PPP-CT monitor
223403956|NCT03446027|DEVICE|NMES|NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
223403957|NCT05687396|DEVICE|virtual reality|virtual reality designed as cycling in the forest
223403958|NCT05687396|OTHER|conventional pulmonary rehabilitation|pulmonary rehabilitation
223403959|NCT03097341|DRUG|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
223403960|NCT03097341|DRUG|xisomab 3G3-Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
223403961|NCT03097341|DRUG|xisomab 3G3-Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
223736327|NCT04532866|BEHAVIORAL|Isolation and Confinement|Eight months of isolation and confinement in the spaceflight analog NEK in Moscow
223736328|NCT04573816|OTHER|Use of an internet plateform|Use of an internet platform for remote monitoring of patients.
223736329|NCT00795756|DRUG|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
223736330|NCT00795756|DRUG|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
223736331|NCT00137423|DRUG|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
223736332|NCT01928329|DRUG|Exenatide (Bydureon®)|
223403962|NCT03097341|DRUG|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
223403963|NCT03097341|OTHER|Placebo|Participants will receive a single intravenous dose of placebo.
223403964|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
223736333|NCT01928329|DRUG|Placebo|
223736334|NCT03388333|PROCEDURE|Catheter Ablation|
223736335|NCT04512209|PROCEDURE|MRI|"Patients will undergo an MR scan before undergoing cytoreductive surgery. If neoadjuvant chemotherapy is administered, an extra MR scan is planned before the start of the neoadjuvant chemotherapy.~During surgery, tissue samples will be taken for interstitial fluid pressure (IFP) measurement, immunohistochemistry (IHC) and characterization of biophysical properties (viscoelastic properties and hydraulic conductivity)."
223554839|NCT06158464|OTHER|Functional Capacity Evaluation|In a FCE, an occupational therapist will evaluate a patient's ability to perform work-related tasks, using a battery of tests. Depending on the circumstances, he/she will for instance test fatigue, ask the patient to kneel, lift objects, or assess concentration. This assessment lasts ± 4 hours and includes physical tests and tests related to the (previous or reference) profession of the client. This means that an explicit match is made between the functional capacities of the patient (what is he/she capable of) and the demands of a certain job (what is he/she expected to do). Following this assessment, the occupational therapist will explain the results of this assessment to the patient. The evaluation will therefore take place during one or two visits.
223554840|NCT06398002|OTHER|Dialysate calcium 1.50 mmol/L|Increased dialysate calcium of 1.50 mmol/L (as compared to standard dialysate calcium of 1.25 mmol/L)
223736336|NCT03219489|OTHER|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs \> or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records."
223554841|NCT01001767|DRUG|Lovaza|Lovaza one gram twice a day for 24 weeks
223554842|NCT01001767|DRUG|Placebo|Placebo
223554843|NCT01878578|DRUG|Eslicarbazepine acetate|Tablets containing ESL 600 mg
223554844|NCT01878578|DRUG|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
223554845|NCT01878578|DRUG|Placebo|Tablets containing matching placebo
223554846|NCT03776318|DRUG|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
223736337|NCT03187262|DRUG|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
223736338|NCT03611790|DEVICE|NeVa VS|mechanical dilatation
224297685|NCT00970008|OTHER|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
224297686|NCT00970008|OTHER|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
224297687|NCT00970008|OTHER|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
224297688|NCT05495113|DEVICE|YMS-201B (Device: Mind STIM)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
224297689|NCT05495113|DEVICE|Sham stimulation using YMS-201B|Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
224297690|NCT04010019|BEHAVIORAL|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
224297691|NCT04010019|BEHAVIORAL|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
224297692|NCT00238849|DRUG|Oxaliplatin|
224297693|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
224297694|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
223554847|NCT04875455|DEVICE|POD F GF (BVI Medical), POD F (BVI Medical), Panoptix (Alcon Inc) IOL implantation|In this study, patients have already received treatment, after receiving the consent, the routinely collected pre-, intra- and postoperative data will be pseudonymized and evaluated.
223554848|NCT04077489|PROCEDURE|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
223554849|NCT06246838|DIAGNOSTIC_TEST|Ga-68 V/Q PET/CT|Head-to-head comparison of Ga-68 V/Q PET/CT vs Tc-99m V/Q SPECT/CT
223554850|NCT00005097|DRUG|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
223554851|NCT01111734|DIETARY_SUPPLEMENT|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
223554852|NCT01111734|DRUG|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
223554853|NCT04306458|PROCEDURE|Minimally invasive esophagectomy|Conventional minimally invasive esophagectomy
223554854|NCT04306458|DEVICE|daVinci Xi system|robot assisted minimally invasive esophagectomy
223736339|NCT05811390|DEVICE|erythritol jet|Use of an erythritol jet in the non-surgical treatment of periimplantitis together with systemic metronidazole
223736340|NCT05811390|DEVICE|Manual instrumentation|Use of manual instrumentation in the non-surgical treatment of periimplantitis together with systemic metronidazole
223736341|NCT00819351|DRUG|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
223736342|NCT00819351|DRUG|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
224132341|NCT04873024|DEVICE|cMAP Flow V 2.0|"Breathing data collected by the device will be processed by a machine learning algorithm to predict obstructive apnea events. When obstructive apnea events are predicted, the algorithm triggers the CPAP device to respond to the apnea event ahead of its onset.~For the control treatment, the device will operate as its conventional treatment."
224132342|NCT00437606|DRUG|GK Activator (2)|100mg po
224297695|NCT04732364|PROCEDURE|ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy|Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle
223554855|NCT02578134|OTHER|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
223554856|NCT02578134|OTHER|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
223554857|NCT02371785|DEVICE|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
223554858|NCT05684692|DRUG|Siltuximab|A chimeric immunoglobulin G mAb, via intravenous infusion.
223554859|NCT05684692|DRUG|Erenumab-Aooe|Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
223554860|NCT05684692|DRUG|Siltuximab Matching Placebo|Dextrose 5% in water, via intravenous infusion.
223554861|NCT05684692|DRUG|Erenumab-Aooe Matching Placebo|0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
223554862|NCT01667133|DRUG|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
223554863|NCT01667133|DRUG|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
223554864|NCT02548910|PROCEDURE|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
223554865|NCT02548910|DEVICE|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
223554866|NCT04483193|DIAGNOSTIC_TEST|Duplex ultrasound|Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
223554867|NCT00626886|DRUG|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
223554868|NCT00626886|DRUG|placebo collagen sponge|collagen
223554869|NCT04107740|DRUG|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
223554870|NCT04107740|DRUG|Placebo|BID, 10mg per day, for 24 weeks
223554871|NCT01849393|OTHER|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
223554872|NCT00116038|DEVICE|Femoral implant (Versys Fiber Metal Taper®)|
223554873|NCT02784158|DRUG|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
223554874|NCT00289289|DEVICE|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
223554875|NCT03732716|DIAGNOSTIC_TEST|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
223554876|NCT00631813|DRUG|Prucalopride|0.5 mg bid
223736343|NCT03863990|DRUG|PAH medication|Any PAH-targeted medication
223736344|NCT00528099|DRUG|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
223554877|NCT00631813|DRUG|Prucalopride|1 mg bid
223554878|NCT00631813|DRUG|Prucalopride|2 mg bid
223554879|NCT00631813|DRUG|Placebo|bid
223554880|NCT04174859|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
223736345|NCT02617511|DIETARY_SUPPLEMENT|Omega-3 Supplementation|
223736346|NCT02617511|DIETARY_SUPPLEMENT|Placebo|
223736347|NCT00807807|DIETARY_SUPPLEMENT|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
223736348|NCT00807807|DRUG|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
223736349|NCT02423538|DRUG|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
223736350|NCT02423538|DRUG|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
223736351|NCT01613625|PROCEDURE|Elastography|
223736352|NCT01893073|BEHAVIORAL|Mindful walking program|
223736353|NCT00034333|DRUG|MTC-DOX for Injection|
224132343|NCT00437606|DRUG|Ethanol|40g po
223403965|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
223403966|NCT03284814|DIETARY_SUPPLEMENT|Single dose intervention with Investigational product (IP)|syrup, 100 mg
223403967|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
223403968|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
223403969|NCT03284814|DIETARY_SUPPLEMENT|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
223403970|NCT01209949|DRUG|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
223403971|NCT03683225|COMBINATION_PRODUCT|CTC-413|pramipexole ER, given with aprepitant
223403972|NCT01067781|BIOLOGICAL|Heat-Labile Enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
223403973|NCT01067781|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
223403974|NCT05736016|DEVICE|medial wedge insoles ((corrective insoles are equipped with hard 10-degree medial wedge, while sham insoles are equipped with pliable 10-degree medial wedge)|All study participants will be instructed to use insoles for exercising, walking, and other everyday activities.
223554881|NCT05726331|OTHER|Chiropractic Care|Chiropractic care will be delivered by community-based chiropractors that meet pre-set qualifications. Chiropractic treatment protocol will be multimodal and will follow predefined standard operating procedures including the following 6 components: 1) Posture correction and spinal stabilization exercises; 2) Soft tissue release techniques; 3) Manual spinal manipulation; 4) Condition-specific education; 5) Myofascial strengthening and motor control training; 6) Ergonomic and lifestyle modifications/advice. Subjects randomized to chiropractic treatment groups will receive up to 10 chiropractic sessions over 16 weeks.
223554882|NCT05726331|OTHER|Tai Chi|Tai Chi (TC) will be delivered by community based Tai Chi schools that meet pre-set qualifications. TC programs will emphasize core principles including biomechanically efficient alignment, relaxed integrated movements, deep breathing, and heightened body awareness. Subjects randomized to TC treatment group will attend at least one TC class per week for 16 weeks.
223554883|NCT05726331|OTHER|Enhanced Usual Care|Enhanced Usual Care will include educational materials about neck pain provided by the study, in addition to usual medical care for CNNP. Usual care for CNNP generally includes medications (non-narcotic analgesics, NSAIDs, muscle relaxants), interventional pain management (e.g., steroid injections), and self-care exercises (all of which will be monitored and recorded in all three study arms).
223554884|NCT04895930|DRUG|Furmonertinib|80mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (40mg).
223554885|NCT04895930|DRUG|Anlotinib|10mg/day orally from day 1 to 14 of a 21-day cycle. If subjects suffer from AEs, they can get declined dosage (8mg).
223554886|NCT01656707|BEHAVIORAL|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
223554887|NCT01656707|BEHAVIORAL|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
223554888|NCT02567799|DRUG|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
223554889|NCT02567799|DRUG|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
223554890|NCT02567799|DRUG|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart."
223736354|NCT01602250|DRUG|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
223736355|NCT01602250|DRUG|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
224132344|NCT02848690|BEHAVIORAL|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
223403975|NCT04428697|PROCEDURE|Sungurtekin Technique|Sungurtekin technique was performed through the base of the posterior fissure; thus, no additional incision was necessary in the lithotomy position. The mucosa was dissected along the submucosal plane, starting at the hypertrophic papilla, and extended for 1.5 cm, a 0.5-cm section of the bottom part of the internal anal sphincter was measured and marked with a ruler. Next, the internal sphincter bundle was measured with a sterile scale and a mark was placed at 1 cm towards the proximal end. The internal sphincter cut with cautery .
223403976|NCT00729612|DRUG|carboplatin|
223403977|NCT00729612|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223403978|NCT00729612|GENETIC|protein expression analysis|
223403979|NCT00729612|OTHER|immunoenzyme technique|
223403980|NCT00729612|OTHER|immunohistochemistry staining method|
223403981|NCT00729612|OTHER|laboratory biomarker analysis|
223403982|NCT01125241|DRUG|wuling capsule|orally, three tablets each time,three times a day
223403983|NCT01125241|DRUG|placebo of wuling capsule|orally, three tablets each time and three times a day
223403984|NCT02483039|BEHAVIORAL|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
223403985|NCT01414582|DEVICE|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
223403986|NCT01414582|OTHER|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
223403987|NCT00003909|DRUG|motexafin gadolinium|Given IV
223403988|NCT00003909|RADIATION|radiation therapy|Undergo radiation therapy
223403989|NCT00003909|OTHER|pharmacological study|Correlatives studies
223403990|NCT00006339|DRUG|Indinavir sulfate|
223403991|NCT00006339|DRUG|Ritonavir|
223403992|NCT00006339|DRUG|Hydroxyurea|
223403993|NCT00006339|DRUG|Stavudine|
223403994|NCT00006339|DRUG|Didanosine|
223554891|NCT02567799|RADIATION|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
223554892|NCT05449041|DEVICE|Bulbicam|Measurement of eye pressure; Accuracy diagram; Contrast chart; Visual field, Pupil size
224132345|NCT02848690|OTHER|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI\> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
223403995|NCT03029403|DRUG|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
223403996|NCT03029403|BIOLOGICAL|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
223403997|NCT03029403|DRUG|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
223403998|NCT05464524|OTHER|Main questionnaire|10-15 minute questionnaire asking about environmental factors (i.e daily lifestyle questions), quality of life, comorbidities among others.
223403999|NCT05464524|OTHER|Optional 12-week follow up questionnaire|A 5-minute questionnaire asking about changes to the quality of life and DFU status since the initial questionnaire.
223404000|NCT06123286|DRUG|Tart Cherry|1 ounce of Tart Cherry Concentrate (King Orchard) mixed with 8 ounces of water daily for 12 weeks
223404001|NCT06123286|DRUG|Omega 3 FA (Fish Oil)|2 capsules of Omega 3 FA (Fish Oil) (Nordic Naturals Ultimate Omega) \[650 mg EPA and 450 mg DHA per capsule\] daily for 12 weeks
223404002|NCT06200545|OTHER|PrEP eligibility assessment|PrEP eligibility assessment
223404003|NCT06200545|DIAGNOSTIC_TEST|Rapid HIV antibody testing prior to provision and/or refill of PrEP|Rapid HIV antibody testing prior to provision and/or refill of PrEP
223404004|NCT06200545|OTHER|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines|PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
223404005|NCT06200545|BEHAVIORAL|Evaluation of barriers and facilitators to ongoing PrEP use|Evaluation of barriers and facilitators to ongoing PrEP use
223404006|NCT06200545|OTHER|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement|Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
224132346|NCT00563836|DRUG|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
223404007|NCT06200545|OTHER|Tracing for any missed PrEP visits|Tracing for any missed PrEP visits
223404008|NCT06200545|OTHER|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"|"Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period"
223404009|NCT05493709|DRUG|Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide|All subjects will be pediatric patients with central precocious puberty. They will be injected twice with a depot formulation containing 42 mg of Leuprolide. The first dose on day 0 the second dose on week 24 (six months apart).
223404010|NCT05095818|OTHER|PrEP-RN|Patients randomized to the intervention arm will be counseled on HIV risk factors in general, their HIV risk factors in particular, and prevention methods, inclusive of PrEP (Emtricitabine 200 mg/Tenofovir disoproxil fumarate 300 mg).
223404011|NCT06159166|DRUG|Mirdametinib|This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
223554893|NCT00364650|DRUG|Probiotic Supplement|2 capsules twice daily
224132347|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
224132348|NCT02822443|BEHAVIORAL|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
224132349|NCT01887249|DRUG|Clarithromycin|
224132350|NCT01887249|DRUG|metronidazole|
223554894|NCT00364650|OTHER|Placebo|placebo
223554895|NCT00311025|PROCEDURE|intensive endurance, strength and balance exercises|
223554896|NCT02781571|DRUG|SOF/VEL|400/100 mg tablet administered orally once daily
223554897|NCT00348998|BIOLOGICAL|bevacizumab|
223554898|NCT00348998|DRUG|bicalutamide|
223554899|NCT00348998|DRUG|goserelin acetate|
223554900|NCT00348998|RADIATION|radiation therapy|
224132351|NCT01887249|DRUG|esomeprazole|
223404014|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant into the anterior chamber of the study eye.
223404015|NCT04499248|OTHER|Lumigan|Control Treatment in Fellow Eye Lumigan 0.01% is a topical eye drop that is a solution containing 0.1 mg/mL bimatoprost
223404016|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar intracameral insertion location on eye as AGN-193408 SR.
223404017|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 2.
224297696|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
223404018|NCT04499248|DRUG|AGN-193408 SR|An implant containing preservative-free AGN-193408 dispersed in a biodegradable polymer matrix. Implants are preloaded into an applicator to facilitate insertion of the implant in the study eye.
223404019|NCT04499248|OTHER|Sham Administration|Needleless applicator contacting similar insertion location on eye as AGN-193408 SR.
223404020|NCT04499248|OTHER|Lumigan Vehicle|Vehicle eye drops (for masking) will be administered once daily in the evening starting on Day 1 in the study eye during Cohort 3.
223404023|NCT04521361|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).
223404024|NCT04293393|DRUG|Doxorubicin|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
223404025|NCT04293393|DRUG|Cyclophosphamide|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
223404026|NCT04293393|DRUG|Taxane|Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
223404027|NCT04293393|DRUG|Letrozole|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
223404028|NCT04293393|DRUG|Abemaciclib|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
223404029|NCT04293393|DRUG|LHRH Analogue|Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
223404030|NCT02075203|BIOLOGICAL|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK \& a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 \& saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
223404031|NCT02075203|DRUG|Placebo|Saline
223404032|NCT02075203|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
223404033|NCT01077297|DRUG|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
223404034|NCT05266053|DEVICE|PICO 7 dressing|The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.
223404035|NCT05266053|OTHER|Standard wound dressing|Standard abdominal dressing at the time of cesarean
223404036|NCT02767167|OTHER|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
223404037|NCT02996968|PROCEDURE|Self-removal|Self-discontinuation of a transurethral catheter
223404038|NCT03943043|DRUG|nab-paclitaxel|"Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~\- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~1. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~2. level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D."
223404039|NCT04029584|DRUG|rifampin IV|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
223404040|NCT04029584|DRUG|Rifadin 300Mg Capsule|Rifadin 600mg by mouth as two 300mg rifadin capsules
223404041|NCT04029584|DRUG|Fluvastatin 20 MG|one oral dose of fluvastatin (Lescol ) 20mg capsule
223404042|NCT00444535|DRUG|lapatinib|1500 mg oral lapatinib (once daily)
223404043|NCT00444535|DRUG|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
224297697|NCT00899470|DRUG|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
223404044|NCT03898453|BEHAVIORAL|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
223404045|NCT03898453|BEHAVIORAL|support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
223404046|NCT04610801|DRUG|Nasal Spray|Randomized to placebo and Xlear
223736356|NCT05287867|BIOLOGICAL|Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)|Approx 161-420cc autologous blood is drawn and processed into PPP, PRP, and PL, amount dependent on condition. Using sterile technique with patient sedated, US or x-ray is used to guide needles bilaterally into multifidus, specifically LM, TF, IAF. Once the lamina is reached the physician injects 2.5 cc of PPP into the multifidus muscle on one side and then repeat this on the opposite side for each level. The physician guides a needle into the supraneural transforaminal space to perform an epidural injection with 2cc of 4x PL and 1 cc of 0.5% ropivacaine. Next, a needle will then be guided into the facet joint to perform an intra-articular injection with 1cc of 14x PRP. Any tendon insertion areas will be injected using ultrasound guidance with platelet lysate dextrose. The supraspinous/interspinous, SI ligaments at the involved degenerative levels will be injected with 4x PL/12.5% dextrose/0.125% ropivacaine. If L5/S1 is involved, the iliolumbar ligaments will also be injected.
223404047|NCT00000122|DRUG|5-Fluorouracil|
223404048|NCT04730596|DRUG|Ketamine|Ketamine at a dose of 0.3 mg/kg dissolved in normal saline.
223736357|NCT05287867|OTHER|Sham procedure|"Approximately 161-420 cc of autologous blood is drawn to maintain patient blinding. While lying prone, the patient's back will be exposed and prepped sterilely.~Provider puts patient in conscious sedation and several needles are placed into the low back. The provider inserts needle into the facet joint and then removes. Then inserts the needle midline to ligament and removes (1 needle per level) mimicking normal needle placement, but not injecting anything."
223554901|NCT04476446|DRUG|Esketamine|Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
223736358|NCT03442907|PROCEDURE|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
223736359|NCT03442907|PROCEDURE|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
223736360|NCT06342531|BEHAVIORAL|eDASA+APP FI|A CDSS for nurses to assist in their daily short-term violence risk assessment and management, is integrated into an EPIC-based EHR system.
223736361|NCT01636401|DRUG|aclidinium bromide 400 μg|
223736362|NCT01636401|DRUG|aclidinium bromide placebo|
224132352|NCT05253313|OTHER|MRI scan|Patients will be randomized to a pre-operative scan or not. The MRI scan will evaluate the local extent of the tumor and especially focus on identifying possible liver metastases unseen on the CT-scan.
223404049|NCT04730596|DRUG|Dexmedetomidine|Dexmedetomidine at a dose of 0.5 ug/kg dissolved in normal saline.
223404050|NCT04730596|DRUG|Normal saline|Normal saline in a labeled syringe
223404051|NCT06304987|COMBINATION_PRODUCT|Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor|In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
223404052|NCT06304987|COMBINATION_PRODUCT|Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor|In long-course chemoradiotherapy (CRT) + PD-1 inhibitor for LARC patients, the experimental group used concurrent PCSK9 inhibitor, and the active comparison group did not use PCSK9 inhibitor.
223554902|NCT06214676|DEVICE|OCT angiography|Detection of microvascular changes in patients with primary open angle glaucoma by using Optical Coherence Tomography Angiography
223736363|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
223736364|NCT01529840|DRUG|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
224132353|NCT02390115|OTHER|Elastic tape application in shoulder|
224132354|NCT00480922|BEHAVIORAL|Low glycemic load diet|Outpatient behavioral counseling
224132355|NCT00480922|BEHAVIORAL|Low fat diet|Outpatient behavioral counseling
224132356|NCT02366663|RADIATION|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
224132357|NCT02366663|DRUG|Carmustine|Given IV
224132358|NCT02366663|DRUG|Etoposide|Given IV
223404053|NCT05289336|PROCEDURE|Transoral Laser Microsurgery|
223404054|NCT05005507|DRUG|JNJ-73763989|JNJ-73763989 will be administered subcutaneously once every 4 weeks.
223404055|NCT05005507|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a will be administered subcutaneously once weekly.
223404056|NCT05005507|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally once daily.
223404057|NCT05005507|DRUG|TAF|TAF film-coated tablet will be administered orally once daily.
223404058|NCT05005507|DRUG|ETV|ETV film-coated tablet will be administered orally once daily.
223554903|NCT00349349|DRUG|ofatumumab|Intravenous infusion
223554904|NCT04898348|DRUG|KBL697|3 capsules twice a day dosing of KBL697
223554905|NCT04898348|DRUG|Placebo|3 capsules twice a day dosing of Placebo
223554906|NCT02122666|PROCEDURE|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
224132359|NCT02366663|DRUG|Cytarabine|Given IV
224132360|NCT02366663|DRUG|Melphalan|Given IV
224132361|NCT02366663|PROCEDURE|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
224132362|NCT02366663|BIOLOGICAL|Rituximab|Given IV
223736365|NCT01614054|OTHER|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
224132363|NCT01469494|PROCEDURE|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
223404059|NCT05584956|DRUG|L_carnitine|l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[
223404060|NCT05584956|DRUG|Sildenafil|selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.
223404061|NCT00942578|DRUG|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
223404062|NCT00942578|DRUG|Lenalidomide|Once daily days 1-14 of every 21
223404063|NCT00942578|DRUG|Docetaxel|75 mg/m\^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
223404064|NCT00942578|DRUG|Prednisone|10 mg orally every day
223404065|NCT04116840|DRUG|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
223404066|NCT04114929|OTHER|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
223404067|NCT04114929|OTHER|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
223404068|NCT01984333|BEHAVIORAL|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
223554907|NCT00192764|DRUG|high-dose cyclophosphamide|
223404069|NCT02556775|BIOLOGICAL|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
223404070|NCT02556775|BIOLOGICAL|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
223404071|NCT01510301|DEVICE|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~* Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~* Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
223404072|NCT00558467|DRUG|pramipexole immediate release (IR)|
223404073|NCT00558467|DRUG|Placebo|
223404074|NCT00698672|DEVICE|charnley OGEE|charnley OGEE
223404075|NCT00698672|DEVICE|Spectron Reflection CoCr|Spectron Reflection CoCr
223404076|NCT00698672|DEVICE|Spectron XLPE CoCr|Spectron XLPE CoCr
223404077|NCT00698672|DEVICE|Spectron Reflection Oxinium|Spectron Reflection Oxinium
223404078|NCT00698672|DEVICE|Spectron XLPE CoCR|Spectron XLPE CoCR
223404079|NCT06311916|DRUG|HAIC + Tirelizumab +lenvatinib +liver resection|Patients in the neoadjuvant group received two cycles of neoadjuvant hepatic arterial infusion chemotherapy (HAIC, adoption of the FOFOLX6 program, Folinic acid+5-fluorouracil+Oxaliplatin, 21 days between second HAIC treatments with a window of ±3 days) + Tirelizumab (First treatment with Tirelizumab was started 0-1 days after HAIC, 200 mg IV, followed by a second treatment 21 days later)+ lenvatinib (Oral 8 mg or 12mg once a day depending body weight). Assessment of tumor status and surgical safety after receiving neoadjuvant therapy, and eligible patients then underwent surgical resection.
223404080|NCT06311916|PROCEDURE|liver resection|Direct liver resection or laparoscopic liver resection depending on tumor status.
223554908|NCT03148379|DEVICE|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
223554909|NCT03148379|DEVICE|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
223554910|NCT01854775|DRUG|E/C/F/TAF|Tablets administered orally with food.
223554911|NCT01854775|DRUG|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered once daily orally with food.
223554912|NCT04450706|OTHER|Precision Medicine|"The tissue from the participant sample will be used for genome sequencing and organoid establishment for drug screening. Both solid tumor genome analysis (commercial and Welm genome) must be performed on tissue from the same biopsy. After the biopsy, the patient will begin uninformed therapy (standard of care or investigational in the context of a separate existing active clinical trial), as selected and directed by the treating physician. Once the results from the genome sequencing and drug screening are available, they will be returned to the treating physician. Upon progression on the uninformed line of therapy, the patient will begin a new therapy as directed by the treating physician. If the patient begins a therapy recommended by the precision oncology results then the next line of therapy will be deemed informed. While receiving the therapy, response assessments will be conducted until documented radiographic or clinical progression."
223554913|NCT04450706|OTHER|Physican Decision Making|"The results from the drug screening and mutation testing will be summarized and returned to the treating physician before the assignment of on study, second-line therapy. Before and after returning results, the treating physician will be administered a survey to assess the potential effect that the precision medicine results have on the selection of the following line of therapy. If a patient begins a therapy that was recommended by the precision medicine results, the therapy will be defined as the informed line of therapy."
223554914|NCT05111002|DRUG|Lefamulin|600mg tablet orally twice daily
223554915|NCT05111002|DRUG|Doxycycline|100mg tablet orally twice daily
223554916|NCT02822183|OTHER|Online Survey|
223554917|NCT03913013|BEHAVIORAL|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
223404081|NCT01780090|OTHER|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
223404082|NCT00034281|DRUG|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
223404083|NCT02344238|OTHER|ID Capsule|Capsule containing ingestible sensor
223404084|NCT02344238|DIETARY_SUPPLEMENT|Riboflavin|50mg
223404085|NCT02344238|BEHAVIORAL|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
223736366|NCT03533179|DRUG|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
223404086|NCT02840539|DRUG|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
223404087|NCT05002790|DIAGNOSTIC_TEST|Data collection group|"Magnetic resonance imaging (MRI) allows measurement of the axes described to suggest which head and neck position would provide best anatomical alignment to reduce anterior impingement.~All the MRI scans will be conducted using 3.0 Tesla (Optima 750w, GE Medical, Milwaukee, WI, USA) using the cervical spine section of the coil. T2-weighted images in the sagittal plane will be acquired using a fast recovery fast spin echo (FRFSE) technique. The scans will take around two and half minutes and a member of the anaesthetic investigator team will be present to facilitate positional changes and maintain consistency. MRI scanning will be performed in following 3 head and neck positions:~Neutral position, Sniffing position and the Extension position."
223736367|NCT03533179|DRUG|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
223736368|NCT03533179|DRUG|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
223736369|NCT03533179|DRUG|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
223404088|NCT01549587|DRUG|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
223404089|NCT01549587|DEVICE|toothbrush|brush thoroughly twice daily
223404090|NCT01549587|DEVICE|dental floss|floss the whole mouth once daily
223404091|NCT01549587|DRUG|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
223404092|NCT01549587|DEVICE|toothbrush|twice daily brush thoroughly for 2 minutes
223404093|NCT01549587|DRUG|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
223404094|NCT01549587|DEVICE|dental floss|floss the whole mouth once daily
223404095|NCT01532856|DRUG|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
223736370|NCT01341964|DRUG|Clopidogrel|600mg (2 pills)
223736371|NCT01341964|DRUG|Aspirin|325mg (1 pill)
223736372|NCT01341964|DRUG|Aspirin|81mg (1 pill)
223736373|NCT00909389|DRUG|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
223404096|NCT01532856|DRUG|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
223404097|NCT01532856|DRUG|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
223404098|NCT02941211|DEVICE|Aqueduct -100|
223404099|NCT01698892|DRUG|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
223404100|NCT01698892|DRUG|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
223404101|NCT05031611|BEHAVIORAL|Intuitive Eating Treatment|"Participants received a brief web-based intervention for disordered eating which focused on a style of eating behavior called intuitive eating. Please see arm description for more details."
223404102|NCT04016129|BIOLOGICAL|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
223404103|NCT06534593|OTHER|Standard medical treatment|Standard medical treatment
223404104|NCT06534593|DEVICE|Lumbar Traction|Lumbar traction using traction table
223404105|NCT06534593|OTHER|Mckenzie Extension Protocol|Mckenzie Extension Exercises
223404106|NCT06534593|DEVICE|Interferential Therapy|Interferential Therapy for 20 minutes
223404107|NCT06534593|DEVICE|Heat Therapy|Heat Therapy for 20 minutes
223404108|NCT06534593|OTHER|Sustained Natural Apophyseal Glides (SNAGs)|3-5 reptations of Mulligan's lumbar extension Sustained Natural Apophyseal Glides (SNAGs)
223404109|NCT03540316|COMBINATION_PRODUCT|Two short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 2 minutes.
223736374|NCT02184689|DRUG|fexinidazole|
223736375|NCT03505944|DRUG|Venetoclax|venetoclax + lenalidomide + rituximab
223736376|NCT02859207|DRUG|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
223736377|NCT04264598|BIOLOGICAL|sIPV|The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
223736378|NCT04264598|BIOLOGICAL|Commercialized sIPV|The commercialized sIPV was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.The antigen contents of type I, type II and type III polioviruses in the commercialized sIPV were 30 DU, 32 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
223736379|NCT04264598|BIOLOGICAL|Commercialized IPV|The commercialized Salk IPV was manufactured by Sanofi Pasteur S.A.The antigen contents of type I, type II and type III polioviruses in the commercialized IPV were 40 DU, 8 DU and 32 DU. The vaccine was in liquid form, 0.5 ml per dose.
223736380|NCT04565301|DRUG|Dexamethasone|adductor canal block
223736381|NCT04565301|DRUG|neostigmine|adductor canal block
223736382|NCT04565301|OTHER|NaCl solutions|adductor canal block
223736383|NCT00003492|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223736384|NCT01045642|DRUG|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
223736385|NCT01314833|DRUG|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6"
223736386|NCT01314833|DRUG|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3"
223736387|NCT01314833|DRUG|Epirubicin Cyclophosphamide Paclitaxel|"1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4"
223736388|NCT03350633|DRUG|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
223736389|NCT03350633|DRUG|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
223736390|NCT01516424|DRUG|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
223736391|NCT01516424|DRUG|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
223736392|NCT04993989|DRUG|Iberogast (STW5, BAY98-7411)|Survey without any intervention assigned in the study.
223736393|NCT05347550|OTHER|Graduated Compression Stockings - Thromboembolic deterrent stockings|Centres randomised to the intervention arm will consist of participants receiving GCS.
223736394|NCT02100059|OTHER|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
223736395|NCT00597766|DRUG|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
223736396|NCT00597766|DRUG|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
223736397|NCT00597766|DRUG|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
223736398|NCT00597766|DRUG|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
223736399|NCT06296108|OTHER|acute kidney injury|The incidence of acute kidney injury was determined in patients included to the study
223736400|NCT00778089|DEVICE|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
223736401|NCT04680442|DRUG|Trastuzumab|Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.
223404110|NCT03540316|COMBINATION_PRODUCT|Two short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 4 minutes.
223404111|NCT03540316|COMBINATION_PRODUCT|Four short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 2 minutes.
223404112|NCT03540316|COMBINATION_PRODUCT|Four short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 4 minutes.
223404113|NCT02025725|DRUG|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
223404114|NCT02025725|DRUG|Placebo Nasal Spray|nasal spray formulation with vehicle only
223404115|NCT06504914|BEHAVIORAL|Assigned Interventions|Behavioral: RN-CHeFRx The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
223404116|NCT05708118|DIAGNOSTIC_TEST|Echocardiographic assessment.|Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
223404117|NCT05708118|DIAGNOSTIC_TEST|Computed-tomography assessment|All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
223404118|NCT06374238|BEHAVIORAL|CBT+ Health coach|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in CBT w/ Health coach group will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. In addition participants will have weekly contact with a peer health coach.
223404119|NCT06374238|BEHAVIORAL|CBT w/o Health Coach ( self-guided)|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants CBT w/o Health coach groups will engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool.
223404120|NCT06374238|BEHAVIORAL|Usual Care|Participants will complete the pre-enrollment clinical screening measures (PHQ-9M, GAD-7, and PEG-3) and will repeat those assessments, as well as outcome assessments, at 3 months, 6 months, and 12 months. Participants in the UC group will be asked to engage with the CaRISMA app to complete a daily pain and mood e-diary, daily record of opiate use, and weekly assessment of pain via the Painimation tool. All other care will be at the discretion of their treating provider
223736402|NCT04680442|DRUG|Pertuzumab|Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
223736403|NCT04680442|DRUG|Trastuzumab emtansine|Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
223736404|NCT03505983|DEVICE|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
223736405|NCT03505983|DEVICE|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
223736406|NCT03505983|DEVICE|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
223736407|NCT02908048|OTHER|Blood samples|Blood samples collected at varying intervals over a two to three year period.
223736408|NCT05528796|DIAGNOSTIC_TEST|Whole genome sequencing|"The investigators will study the genes in a fetus' or child's DNA using a test called genome sequencing. Genes are the instructions passed from individuals to a child, and genes determine how bodies are built and grow. Some medical conditions are caused by differences in genes, and the genome sequencing test looks for changes in genes and other parts of a person's genetic sequence (the genome).~Genetic material will be extracted from bio-specimens. Genome sequencing for this study will be performed at the UCSF Genomic Medicine Laboratory at UCSF. When the genome sequencing results are available, the investigators will arrange an in person or telehealth meeting to explain the test results and what the results mean for the fetus, pregnancy, and family."
223736409|NCT06407518|DRUG|Midazolam oral solution|Each individual administers the midazolam oral solution nightly from enrollment to the surgry.
223736410|NCT06407518|OTHER|Placebo|Each individual administers placebo solution nightly from enrollment to the surgry.
223736411|NCT05340374|DRUG|Cabazitaxel|Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
223736412|NCT05340374|DRUG|177Lu-PSMA-617|Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.
223736413|NCT04157608|DEVICE|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
223736414|NCT04157608|DEVICE|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
223736415|NCT05951868|BEHAVIORAL|Continuum of support on breastfeeding.|A continuous support program for women from antenatal period till 6 months after delivery to initiate early breastfeeding, exclusively breastfeeding for 6 month and to continue breastfeeding till 2 years and beyond.
223736416|NCT04319120|OTHER|questionnaires online|Each month, the nurse will contact the patients included, by mail or telephone, to fill out their questionnaires online or by mail, and to make a photo of the ulcer if it is healed. A dedicated telephone line and e-mail address will be used as a support if necessary (for questionnaires, emails or sending photos). The referring nurse and the clinical research assistant of the service will be in charge of centralizing the data collected.
223404121|NCT00343044|DRUG|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
223404122|NCT00343044|DRUG|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
223404123|NCT04806243|DRUG|Regorafenib Pill&Camrelizumab|Regorafenib，80 mg，QD，Q3w Camrelizumab，200 mg，IV，Q3w
223404124|NCT02508350|DRUG|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
223736417|NCT01463319|OTHER|air insufflation|air insufflation during insertion phase colonoscopy
223736418|NCT01463319|OTHER|warm water irrigation|warm water irrigation during insertion phase colonoscopy
224297698|NCT00899470|DRUG|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
224297699|NCT00899470|DRUG|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
223404125|NCT02508350|OTHER|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
223404126|NCT01308021|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
223404127|NCT01308021|BIOLOGICAL|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
223404128|NCT01308021|BIOLOGICAL|Placebo|Placebo entero-coated capsules
223404129|NCT05047211|DRUG|Ferrous sulfate|one tablet 325 milligrams three times a day
223404130|NCT05047211|DRUG|Iron dextran|1000 mg intravenous infusion
223404131|NCT05103618|DRUG|[F-18] Fluorodopa Positron Emission Tomography|Subjects will receive FDOPA imaging at baseline and 2-3 months after practicing the OM Meditation for evaluation of the dopamine function, \[F-18\] Fluorodopa (FDOPA), dose (5-10 mCi, ± 20%) will be injected intravenously into an antecubital vein. In accordance with the standard imaging protocol for FDOPA; subjects will be pre-medicated with 200 mg of carbidopa orally approximately one hour prior to injection.
223404132|NCT05103618|BEHAVIORAL|OM Meditation|Couple pairs will engage in OM Meditation together approximately 3-4 times a week approximately 2-3 months.
223404133|NCT06575985|OTHER|Heat acclimation and exercise training|10-day intervention consisting of daily 60-min exercise sessions aimed to induce increases in core body temperature, conducted in a climactic chamber set to 35°C and 50% relative humidity.
223404134|NCT06575985|OTHER|Thermo-neutral exercise training group|10-day intervention consisting of daily 60-min exercise sessions conducted in a climactic chamber set to 23°C and 50% relative humidity.
223404135|NCT05791136|RADIATION|Radiotherapy|95% PGTV56-60Gy/28-30 fractions, 2Gy/1 fractions; 95% PTV50.4-54Gy/28-30 fractions, 1.8Gy/1 fractions; 5 days a week; 6 weeks.
223404136|NCT05791136|DRUG|Toripalimab|Toripalimab (200 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision
223404137|NCT06278077|DRUG|Neurexan|The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.
223736419|NCT05414279|DIAGNOSTIC_TEST|Sodium determination|Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
223736420|NCT02771158|DRUG|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
223404138|NCT06278077|DRUG|Placebo|Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.
223404139|NCT01513005|PROCEDURE|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~* position of 4 trocars and insertion of a nasogastric tube~* dissection and mobilization of the greater curvature of the stomach~* preparation of the stomach for division~* gastric partition~* extraction of the gastric remnant~* postoperative surveillance"
223404140|NCT03598842|DIETARY_SUPPLEMENT|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
223404141|NCT03598842|DIETARY_SUPPLEMENT|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
223736421|NCT02771158|DRUG|placebo|placebo will be administered to double blind the study
223736422|NCT02671279|DIETARY_SUPPLEMENT|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
223404142|NCT03598842|DRUG|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
223404143|NCT05900336|DRUG|Sodium Naproxen|One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
223404144|NCT05900336|DRUG|Placebo|One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).
223404145|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
223404146|NCT02521012|DIETARY_SUPPLEMENT|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
223404147|NCT05004051|DEVICE|ViTAA Analysis|Imaging Analysis Software
223404148|NCT05958121|BIOLOGICAL|IMA402 (Phase Ia)|Intravenous infusions in escalating dose levels
223404149|NCT05958121|BIOLOGICAL|IMA402 (Phase Ib)|Treatment at MTD and/or RDE (Phase Ib)
223404150|NCT05958121|BIOLOGICAL|IMA402 (Phase II)|Treatment at MTD/RDE based on a manageable/favorable safety profile and initial signs of anti-tumor activity of selected ISEC (Phase II)
223404151|NCT02867592|DRUG|Cabozantinib|Given PO
223404152|NCT02867592|DRUG|Cabozantinib S-malate|"Given PO~Note: Capsule formulation (Cometriq) not used in this trial."
223404153|NCT02867592|OTHER|Pharmacological Study|Correlative studies
223404154|NCT04821635|DEVICE|Rower assisted by electrostimulation (FES-ROW)|"1. Pre-inclusion visit~2. Inclusion visit~3. Phase 1 Rower-FES with lower limbs (Month 0 to Month 3: M0-M3):~   Training on a rower with solicitation of the electrostimulated lower limbs only for a period of 3 months at the rate of 3 sessions of 30 minutes per week~4. Interim assessment visit at Month 3 (M3)~5. Phase 2 Rower-FES with lower limbs + upper limbs (Month 3 to Month 6: M0-M6):~   Training on with solicitation of the electrostimulated lower and upper limbs for a period of 3 months at the rate of 3 sessions of 30 minutes per week~6. Final assessment visit at Month 6 (M6)~7. End of clinical research visit, 3 months after the end of training (Month 9, M9)"
223404155|NCT06084481|DRUG|ABBV-400|Intravenous (IV) Infusion
223404156|NCT06084481|DRUG|Itraconazole (ITZ)|Oral Solution
223736423|NCT05453344|DEVICE|DexCom one|Provision of DexCom One for glucose monitoring
223736424|NCT04124289|OTHER|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
223736425|NCT00991055|DRUG|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
223736426|NCT02250755|OTHER|MRI T1 T2 sequences|MRI
223736427|NCT00737282|DRUG|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
223736428|NCT00737282|DRUG|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
223736429|NCT01129648|DRUG|Placebo|Administered daily for 21 days
223736430|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736431|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736432|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736433|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
223736434|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
224132364|NCT01469494|PROCEDURE|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
224132365|NCT02558738|DEVICE|ear spray|
223404157|NCT06094192|DEVICE|High definition transcranial electrical current stimulation|Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
223404158|NCT02655614|DRUG|GDC-0134|GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
223404159|NCT02655614|DRUG|Placebo|Placebo matching to GDC-0134
223404160|NCT02655614|DRUG|Rabeprazole|Rabeprazole 20 mg twice daily orally
223404161|NCT02655614|DRUG|Midazolam|2mg of liquid formulation of midazolam orally
223404162|NCT02655614|DRUG|Caffeine|100 mg tablet or solution of caffeine orally
223404163|NCT00519116|DRUG|Rapamune® (Sirolimus)|
223404164|NCT00519116|DRUG|Tacrolimus|
223404165|NCT00519116|DRUG|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
223404166|NCT06209190|RADIATION|total marrow and total lymphoid irradiation|doses of 12 Gy on days -3 to -1 divided into 6 fractions of 2 Gy every 12 hours for 3 days, which will be administered through a computed tomography tomotherapy system plus conditioning scheme of our institution
223404167|NCT02992041|DRUG|VVZ-149 Injections|IV infusion of 900 or 1100 mg of VVZ-149
223404168|NCT02992041|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
223404169|NCT00594165|DRUG|Rotigotine|"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
223404170|NCT02618291|OTHER|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
223404171|NCT02618291|OTHER|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
223404172|NCT02734537|DRUG|Cisplatin|Given IV
223404173|NCT02734537|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223404174|NCT02734537|OTHER|Laboratory Biomarker Analysis|Correlative studies
223404175|NCT04006639|PROCEDURE|Analgesic Technique|Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
223404176|NCT06575166|DEVICE|Abdominal wall tension|"Abdominal wall tension measurement All patients will have the tension of their abdominal wall measured during surgery using a tension scale or tensiometer."
223404177|NCT06575166|DEVICE|Intra-abdominal pressure|Intra-abdominal pressure All patients will have their intra-abdominal pressure continuously monitored using Sentinel's FDA approved TraumaGuard catheter, a pressure-sensing urinary catheter.
223404178|NCT06505993|BEHAVIORAL|Health Communication|Participants will experience a coordinated social marketing campaign including targeted messaging related to vaccine education, self-efficacy, and informative resources to receive the COVID-19 vaccine. The intervention messaging will be strategically layered and disseminated to this intervention arm predominately via Facebook by trusted and local communicators in the study counties.
223736435|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736436|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736437|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
223736438|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736439|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736440|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736441|NCT01129648|DRUG|BCX4208|Administered daily for 21 days.
223736442|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223736443|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
223554918|NCT05148650|DIAGNOSTIC_TEST|Standard laboratory coagulation tests and rotational thromboelastometry measurements|"Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM."
224132366|NCT06692595|DIAGNOSTIC_TEST|digital PCR|digital PCR quantification of subgingival plaque samples
223554919|NCT04776720|BEHAVIORAL|Yoga Practice Program|3 month group yoga classes
223554920|NCT04776720|BEHAVIORAL|Physical Conditioning Program|3 month group physical conditioning classes
224132367|NCT06692231|BEHAVIORAL|Pharmacist intervention|Patient will have an interview with a clinical pharmacist to explain the role of each medication. The pharmacist will also explain the best moment to take each medication.
223554921|NCT02147730|PROCEDURE|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
223554922|NCT02147730|PROCEDURE|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
223554923|NCT05053399|DEVICE|Model Series ZXT|Investigational intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
223554924|NCT06399315|DRUG|ZE46-0134 or placebo|The patients will receive ZE46-0134 or placebo
223554925|NCT06399315|DRUG|Rabeprazole, 20mg oral|Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered
223554926|NCT06399315|DRUG|Itraconazole (200 mg)|Itraconazole 200 mg BID
223554927|NCT05356910|BEHAVIORAL|OPPEN|OPPEN training sessions (three small-group and two one-on-one sessions) build skills for effective peer PrEP outreach through didactic instruction, group discussions, role-play exercises, and goal planning and problem-solving activities.
223554928|NCT05356910|BEHAVIORAL|Control Condition|Control sessions (three small-group and two one-on-one sessions) build skills for diet and nutrition behavior change through didactic instruction, group discussions, and goal planning and problem-solving activities.
223554929|NCT03377179|DRUG|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
223554930|NCT03377179|DRUG|Hydroxychloroquine Sulfate 200 MG|HCQ tablets will be taken at a dose that will be determined
223554931|NCT06107530|OTHER|semi structured interview|Women fulfilling the inclusion / exclusion criteria will be asked to participate to a semi structured interview with a psychiatrist or a psychologist
223554932|NCT04196530|DRUG|BDB001 (EIK1001)|BDB001 (EIK1001) is an immunotherapy agent.
223554933|NCT04196530|DRUG|Atezolizumab|Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
223554934|NCT00000325|BEHAVIORAL|Gonadorelin|
223554935|NCT02599311|DEVICE|transvaginal synthetic mesh|transvaginal synthetic mesh
223554936|NCT02599311|DRUG|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
223554937|NCT04083703|PROCEDURE|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
223554938|NCT01433042|DEVICE|capsule endoscopy|capsule endoscopy procedure
223736444|NCT01129648|DRUG|Allopurinol|Administered daily for 21 days.
224132368|NCT06692777|DIETARY_SUPPLEMENT|Bergavit|Subjects treated with Bergavit capsule intake of 150 mg/die of pure flavonoids for 4 months.
223554939|NCT05582512|OTHER|sequelae tracking|"An integrated outpatient clinic for Long COVID-19 Syndrome in Children will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial flora, immune function and incidence of allergic diseases after long-term COVID-19 infection"
223554940|NCT05317026|PROCEDURE|Vertebroplasty|"SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume.~The vertebroplasty will be performed according to the usual procedure at the center in the angiography suite under local anesthesia and conscious sedation~* Introduction of a vertebral needle, under biplanar fluoroscopic guidance, polymethylmethacrylate (PMMA) cement injection.~* Cone-beam volume-CT at the end of the procedure, with the angiography table and c-arm, to evaluate the cement distribution and detect any leak.~* Decubitus position for 2 hours following procedure, then hospital discharge on the same day."
223554941|NCT05317026|PROCEDURE|Stereotactic Body Radiation Therapy only|SBRT consists of radiotherapy treatments hypofractionated in 1 to 5 fractions, at doses considered curative at a precise target volume
224132369|NCT06692777|DIETARY_SUPPLEMENT|Placebo|Subjects will take capsule equivalent amount of maltodextrin for 4 months.
223554942|NCT02848456|PROCEDURE|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
223736445|NCT01129648|DRUG|BCX4208|Adminstered daily for 21 days
224132370|NCT04871633|DRUG|Remdesivir|Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
224132371|NCT04871633|DRUG|Conventional|IV Steroids Antibiotics
224132372|NCT06692049|PROCEDURE|Gonadectomy|Gonadal tissue being removed for risk of malignancy may be cryopreserved for fertility preservation
224132373|NCT00382096|DRUG|Vildagliptin|
224132374|NCT00382096|DRUG|Metformin|
224132375|NCT00382096|DRUG|Vildagliptin + Metformin|
224132376|NCT05112016|PROCEDURE|Total mesorectal excision for rectal cancer|
224132377|NCT05928806|DRUG|Botensilimab|Botensilimab 75mg IV
224132378|NCT05928806|DRUG|Balstilimab|Balstilimab 450mg IV
224132379|NCT05928806|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV
223736446|NCT00477282|DRUG|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
223736447|NCT00477282|DRUG|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
223736448|NCT00528658|DRUG|Paracetamol|1g qid
223736449|NCT00528658|DRUG|Ibuprofen|400mg tid
223736450|NCT00528658|DRUG|Paracetamol Placebo|equivalent to 1g qid
223736451|NCT00528658|DRUG|Ibuprofen placebo|Equivalent to 400mg tid
223404179|NCT06505993|BEHAVIORAL|Health Communication + Structural|This multi-level intervention will include the defined health messaging intervention components, as well as a combination of structural-level intervention strategies targeted to better facilitate access to community-based vaccination delivery. Health organizations will receive a toolkit, which will include community-specific resources and training modules such as: up to date evidence-based vaccination guidance that can be delivered to patients; strategies for navigating conversations with patients about vaccination; any applicable reimbursement, insurance, or qualifying enrollment information specific to the healthcare organization; identifying locations that facilitate access for the community members; provided advertising to promote the locations and timing of the vaccinations; and generating community-based branding for all vaccination delivery based on the trusted information sources identified.
223736452|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fed state .
223736453|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 10/100/1000 mg in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 10/100/1000 mg in the fast state.
223736454|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment S HR20031 FDC 5/50/750 mg\*2 in the fast state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state.
223736455|NCT05692934|DRUG|HR20031 FDC|Subjects will receive treatment HR20031 FDC 5/50/750 mg\*2 in the fed state followed by 7 days washout ，then receive treatment HR20031 FDC 5/50/750 mg\*2 in the fast state.
224132380|NCT05928806|DRUG|Nivolumab|Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
224132381|NCT06490354|DEVICE|Lightback group|Use of the patented Lightback device to relax the gluteal musculature and prevent hamstring injuries.
224132382|NCT06490354|OTHER|Conventional treatment|Conventional treatment to relax the gluteal musculature and prevent hamstring injuries.
224132383|NCT04588883|BEHAVIORAL|Kuja Pamoja - HIV|Information has been provided in the treatment arm description.
224132384|NCT06691945|COMBINATION_PRODUCT|Saline delivered using an intrauterine pressure catheter (IUPC)|An intrauterine pressure catheter (IUPC) will be placed in participants after membrane rupture, or at 4 cm if membranes previously ruptured. A 300cc bolus of normal saline will be administered. A continuous rate of 100 cc/hr of normal saline will continue until delivery to prevent Postpartum Hemorrhage. If the IUPC is dislodged, it will be replaced by a trained clinician.
224132385|NCT06692647|DRUG|MK-4318|Oral administration
224132386|NCT06692647|DRUG|Diltiazem|Oral administration
223404180|NCT02127515|PROCEDURE|Non Invasive Prenatal Testing|
223404181|NCT02127515|PROCEDURE|Invasive Prenatal Testing|
223404182|NCT04826757|OTHER|Coordinated care|"Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)"
223404183|NCT06323421|BEHAVIORAL|Mindfulness|Participants attend seven 60-90 min group mindfulness sessions each week and a 1/2 day retreat, with three sessions in-person and six sessions remote, led by a mindfulness interventionist. Additionally, participants will be encouraged to engage for at least 30 minutes per week in asynchronous mindfulness activities through a web-based program to increase exposure to mindfulness practices beyond group sessions.
223736456|NCT00278655|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
223736457|NCT05065177|BIOLOGICAL|Investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
223736458|NCT05065177|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
223736459|NCT04101825|DEVICE|Auralya|Hyaluronic Acid-Dermal Filler
223736460|NCT04399577|BIOLOGICAL|Candida antigen|Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention
223736461|NCT03719976|OTHER|Group-based educational intervention|The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
223736462|NCT02810392|DRUG|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
223736463|NCT02810392|DRUG|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
223736464|NCT05752903|DRUG|Dexmedetomidine-propofol|1 microgram/kg dexmedetomidine+2.5 mg/kg propofol intravenous (IV) bolus, 0.5 microgram g/kg/h dexmedetomidine+2.5 mg/kg/h propofol infusion
223736465|NCT05752903|DRUG|Ketamine-Propofol|1 mg/kg ketamine+2.5 mg/kg propofol iv bolus, 0.25 mg/kg/h ketamine+2.5mg/kg/h propofol infusion
223736466|NCT00240253|DRUG|pramlintide acetate|Clear, colorless, sterile solution for SC injection
223736467|NCT00840294|DRUG|Ciprofloxacin|
223736468|NCT06014489|DRUG|azacitidine|during run-in and extention phase: from Cycle 1 until relapse
223736469|NCT06014489|DRUG|Venetoclax|during run-in and extention phase: from Cycle 1 until relapse
223736470|NCT06014489|DRUG|Cobicistat|"during run-in phase: from cycle 2 until relapse~during extension phase: from cycle 1 until relapse"
223736471|NCT00447642|DRUG|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
224132387|NCT02197039|DRUG|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
223404184|NCT07133399|DRUG|vicadrostat / empagliflozin combination 1|vicadrostat / empagliflozin combination 1
223404185|NCT07133399|DRUG|vicadrostat / empagliflozin 2|vicadrostat / empagliflozin 2
223404186|NCT06594848|DIETARY_SUPPLEMENT|Black rice extract|Black rice extract is rich in a specific type of anthocyanins, cyanidin. It has been shown by our group that cyanidin-rich food can have beneficial health effects
223404187|NCT06594848|OTHER|Placebo|The placebo for this study is composed by maltodextrin and food colorant
223404188|NCT06595498|DIAGNOSTIC_TEST|Plasma- SeqSensei™ Solid Cancer IVD Kit (Sysmex)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the NGS Plasma-SeqSensei™ Solid Cancer IVD Kit (Sysmex) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles). Data analysis will be performed using Plasma-SeqSensei™ IVD Software (Sysmex).
223404189|NCT06595498|DIAGNOSTIC_TEST|cobas® EGFR Mutation Test v2 (Roche)|The patients' blood has already been collected in Streck tubes for circulating DNA and the plasma has been stored at -80°C as per the procedure for the routine diagnostic test cobas EGFR Mutation Test v2. No further blood sampling will be required from patients. Circulating DNA/RNA will be extracted from 2-5 ml of plasma. The extracted cfDNA will be quantified. The libraries will be prepared using the cobas® EGFR Mutation Test v2 (Roche) and will be evaluated at the Tapestation (Agilent) to verify their quality and quantity using D1000 Screentapes. The libraries consisting of approximately 16 samples each will then be sequenced on an Illumina NextSeq 500 sequencer using the Illumina NextSeq 500/550 Mid Output Kit v2.5 (150 Cycles).
223404190|NCT07000123|DRUG|AZD0780|Participants will receive daily oral dose of AZD0780
223404191|NCT07000123|DRUG|Placebo|Participants will receive daily oral dose of placebo
223404192|NCT04204655|DIAGNOSTIC_TEST|BIA|Bioelectrical Impedance Analysis
223404193|NCT06588348|DRUG|Steroid treatment|All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.
223404194|NCT06588348|PROCEDURE|Esophageal Manometry|On the final day of Prednisone use, all subjects will undergo esophageal manometry testing to assess for treatment response.
223554943|NCT02848456|PROCEDURE|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
223554944|NCT02848456|PROCEDURE|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
223554945|NCT02254044|DRUG|bivatuzumab mertansine|
223554946|NCT02518165|DIETARY_SUPPLEMENT|Proprietary spearmint extract|Water extracted spearmint extract
223554947|NCT02518165|OTHER|Placebo|Microcrystalline Cellulose
223554948|NCT01949571|DRUG|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
223554949|NCT01147159|OTHER|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
223554950|NCT02510469|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
223554951|NCT03122145|DRUG|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
223736472|NCT00447642|OTHER|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
223736473|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
223736474|NCT01512082|DEVICE|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
223404195|NCT06588348|OTHER|Survey|All enrolled subjects will be asked to complete follow-up Eckardt and BEDQ surveys.
223736475|NCT05980650|OTHER|Reiki implication|Reiki will be implicate by researcher by putting hands on patient
223736476|NCT05117398|DRUG|Dalbavancin administration|"A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg."
223736477|NCT05117398|DRUG|Standard antibiotic therapy|Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
223736478|NCT01526616|DRUG|Metformin|Metformin 850 mg twice a day for six months
223736479|NCT01526616|DRUG|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
224132388|NCT02197039|PROCEDURE|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
223404196|NCT06593678|OTHER|Telerehabilitation Program|Participants in the intervention group will receive a home-based rehabilitation program delivered via an asynchronous digital telerehabilitation platform. The multimodal program is accessible at online platform and it is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
223404197|NCT06593678|OTHER|Booklet-based rehabilitation program|Participants in the control group will receive a booklet-based rehabilitation program at home, provided through a detailed printed guide (explanatory booklet). This guide includes instructions in pictures and text for the multimodal program. It is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
224132389|NCT06692582|OTHER|Electrolysed saline rinse|EOS ph = 7, 200 ppm free available Chlorine
224132390|NCT06753383|OTHER|To the Virtual Reality Based Exercise|After posterior fusion surgery, a rehabilitation program will be applied to individuals with AIS using Kinect Sports Ultimate for 30 minutes per day for a total of 6 weeks, 2 days a week.
224132391|NCT06753383|OTHER|Routine physiotherapy and rehabilitation program|14 patients with posterior fusion AIS routinely in the postoperative clinic for 6 weeks. the physiotherapy program used will be applied.
223404198|NCT06674733|PROCEDURE|Botox administration|Treatment for bruxism
223404199|NCT06674733|PROCEDURE|Aromatherapy|treatment for stress-bruxism
223404200|NCT06674733|PROCEDURE|Clinical evaluation|Before the procedure, and at 1 month and 3 months after the procedure, the Fonseca questionnaire, symptom assessment questionnaire, and Basic Scale on Insomnia Complaint and Quality of Sleep (BaSIQS) will be administered. At the 1st month and 3rd month, Subject Global Aesthetic Improvement Scale (GAIS), and satisfaction questionnaire will be administered
223554952|NCT03122145|DEVICE|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
223404201|NCT06674733|PROCEDURE|Imaging Time|Ultrasonography and shear wave elastography examination will be performed before the procedure, one month after, and three months after the procedure.
223404202|NCT05666726|OTHER|Pain|Thermal pain
223554953|NCT01637532|DRUG|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
223554954|NCT01637532|DRUG|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
223554955|NCT04807608|OTHER|Usability Assessment|A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.
223554956|NCT02323685|BIOLOGICAL|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
223554957|NCT00837161|DEVICE|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
223554958|NCT02082964|OTHER|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
223554959|NCT02082964|OTHER|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
223554960|NCT02353013|DIETARY_SUPPLEMENT|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
224132392|NCT06898060|DRUG|QLG2128|Recommended dosage is 80 μg subcutaneously once daily，52week
224132393|NCT06898060|DRUG|Teriparatide Injection|Recommended dosage is 20μg subcutaneously once daily，52week
224132394|NCT06898892|DIAGNOSTIC_TEST|Fetal MRI|all participant will undergo MRI fetal weight estimation
224132395|NCT06898541|DEVICE|Coronary sinus reducer|Implantation of a Coronary Sinus Reducer device
223404203|NCT05666726|OTHER|Stress|Stress state induction
223404204|NCT05666726|BEHAVIORAL|Craving|Snack craving induction
223404205|NCT05666726|BEHAVIORAL|Frustration|Real effort task
223404206|NCT05666726|BEHAVIORAL|Negative valence emotion|Passive video watching with emotional valence
223404207|NCT03820063|DRUG|PTC-Pz|"* Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~* Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~* Carboplatin AUC 6mg•ml/min administered intravenously on day 1~* Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~* Treatment cycles are repeated on day 22~In case of non pCR; Adjuvant T-DM1, 3.6mg/kg Q 22 days, for 14 cycles."
223404208|NCT04118062|BEHAVIORAL|Questionnaires|Questionnaires
224132396|NCT06898541|OTHER|Sham CSR procedure|Patients will undergo a complete sham CSR implantation procedure without actual deployment of the CSR.
224132397|NCT06899256|OTHER|Horticultural Activity Program|Prior to the commencement of the horticultural intervention program, the nursing home was visited to assess its physical environment and to inform staff about the program's objectives. Participants were recruited, and baseline data was collected. The program was structured around weekly activities and visits, with a three-day interval between each session. Activities included plant identification, gardening tasks, and nature-based art projects. The program was designed to foster social interaction, cognitive stimulation, and physical activity, while promoting a sense of accomplishment and well-being among participants. Throughout the program, regular assessments were conducted to monitor participants' progress and satisfaction.
223404209|NCT04118062|BEHAVIORAL|Semi-structured individual interviews|Semi-structured individual interviews
223554961|NCT02353013|DIETARY_SUPPLEMENT|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
224132398|NCT06899100|BEHAVIORAL|Primary Services|Participants receive 26 hours of Next Level Fatherhood curriculum, 2 hours of child maltreatment workshops, 2 hours of anger management workshops, and 2 hours of optional legitimation workshops. Participants also receive ongoing case management and support services.
224132399|NCT06899178|DRUG|Atomoxetine|Initial dose 40 mg, day 7 dose 60 mg, day 14 dose 80 mg, day 21 dose 100 mg (target dose)
224132400|NCT06899178|DRUG|Placebo|Matching placebo oral capsule
224132401|NCT03754608|DIAGNOSTIC_TEST|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
224132402|NCT01739777|BIOLOGICAL|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
224132403|NCT01739777|OTHER|Controls|Autologous Serum will administrated as placebo
223404210|NCT04118062|OTHER|Focus Group|Focus Group
223554962|NCT01142050|BIOLOGICAL|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
223554963|NCT06018077|BEHAVIORAL|Dietary İntake, Biochemical parameters, Antropometric measuruments|Nutritional status of individuals will be evaluated with a 24-hour retrospective food consumption record and food consumption frequency questionnaire. After 8-12 hours of fasting, body composition analysis will be performed and within the scope of anthropometric measurements, body weight, height length, BMI measurements will be taken. Then, venous blood will be taken from the participants C-reactive protein (CRP), albumin and chemerin level will be analyzed.
223554964|NCT04114071|BEHAVIORAL|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
223554965|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
223554966|NCT01659996|BIOLOGICAL|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
223554967|NCT01659996|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
223554968|NCT00479102|DRUG|Ferripel-3 - iron polysaccharide complex for prevention|
223554969|NCT06658509|BEHAVIORAL|HIIT|High-intensity interval training
223554970|NCT06658509|BEHAVIORAL|SIT|Sprint interval training
223554971|NCT00675623|DRUG|Dimebon|Dimebon, 5 mg orally three times daily for six months
223554972|NCT00675623|DRUG|Dimebon|Dimebon 20 mg orally three times daily for six months
223554973|NCT00675623|DRUG|Placebo|Placebo three times daily for six months
223554974|NCT06007508|DRUG|Insulin Glargine|Long-acting insulin
223554975|NCT06536543|OTHER|Acute Respiratory Distress Syndrom (ARDS) treated with Prone Position (PP) equipped with Electrical Impedance Tomography (EIT)|Positive End-Expiratory Pressure (PEEP) will be titrated with PEEP-EIT method as it is already done in usual care. A classical low flow Pression Volume (PV) curve will be done in order to detect airway closure and measure compliance, the acquisition of EIT data during PV curve will be analysed secondary with a dedicated software. Reconstruction of EIT derived PV curve will determine the regional airway opening pressures and compliances of the 2 lungs. Two decremental PEEP-EIT titrations will be compared, one in supine and the other just after turning in prone.
223404211|NCT04118062|OTHER|DELPHI Consensus Method|DELPHI Consensus Method
223404212|NCT06684106|DRUG|Ursodeoxycholic acid (UDCA) 500 mg|UDCA together with statin in eligible participants
223554976|NCT00325260|BIOLOGICAL|Influvac; subunit influenza vaccine|
223554977|NCT00993863|DRUG|Placebo|single dose
223554978|NCT00993863|DRUG|ADL5859 30 mg|single dose
223404213|NCT06684106|DRUG|Placebo|placebo together with statin in ASCVD patients
223554979|NCT00993863|DRUG|ADL5859 100 mg|single dose
223554980|NCT00993863|DRUG|ADL5859 200 mg|single dose
223554981|NCT00993863|DRUG|ibuprofen 400 mg|single dose
223554982|NCT02297711|PROCEDURE|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
223554983|NCT02297711|PROCEDURE|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
223554984|NCT00978419|DRUG|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
223404214|NCT06695949|OTHER|Percutaneous neuromodulation.|Percutaneous neuromodulation therapy involves inserting several fine needle electrodes 2 cm to 5 cm deep into the skin to target the muscle and surrounding soft tissues. A low-voltage electric current is then passed through these needles, which is hypothesized to improve muscle function by altering the pain signals traveling from the painful muscle to the brain, enhance blood flow to the painful area to promote healing, reduce inflammation and soreness, and increase muscle endurance, strength, and balance.
223404215|NCT06695949|OTHER|Therapeutic Exercise.|These participants (n=50) will engage in resistance training for the cervical flexor muscles, following a progressive exercise program in a supine position with the head comfortably supported, as described by Falla et al. (2008). Participants will perform these exercises with a frequency of 3 days a week for 6 weeks, with each session lasting 30 minutes.
223404216|NCT04577807|BIOLOGICAL|Lerapolturev|Lerapolturev administered via direct lesion injection
223404217|NCT04577807|BIOLOGICAL|Anti-PD-1 Checkpoint Inhibitor|Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions
223404218|NCT01774682|PROCEDURE|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
223404219|NCT06441331|DRUG|Lutetium Lu 177-Edotreotide|lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks
223404220|NCT06441331|OTHER|Amino Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
223554985|NCT00978419|DRUG|Placebo|Placebo administered every day for up to 28 days
223554986|NCT03267784|BIOLOGICAL|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
223554987|NCT06415760|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
223554988|NCT00343005|BIOLOGICAL|AMA1-C1|
223554989|NCT00343005|DRUG|AMA1-C1/alhydrogel Malaria Vaccine|
223554990|NCT00451958|DRUG|Degarelix 80 mg / Degarelix 80 mg|
223554991|NCT00451958|DRUG|Degarelix 160 mg / Degarelix 160 mg|
223554992|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 80 mg|
223554993|NCT00451958|DRUG|Leuprolide 7.5 mg / Degarelix 160 mg|
223554994|NCT04720755|DEVICE|Low-Intensity Extracorporeal Shock Wave Therapy|Twice-weekly treatments for 6 weeks, of 0.2mL/mm\^2 administered for 500 shocks per treatment site, for a total of 3000 shocks per week.
223554995|NCT06659120|DRUG|Fremanezumab|Initiation of anti-CGRP mAb (fremanezumab) treatment according to the Summary of Product Characteristics (SmPC) during clinical routine as a treatment of their physician (no study-specific intervention). This means that patients have to fulfil criteria for treatment with anti-CGRP mAbs in Switzerland, i.e. they have at least 8 days of migraine per month in the last three months.
223736480|NCT06242587|DEVICE|Pericoccygeal nerve block|The coccygeal corneas are visualised with a linear probe under ultrasound guidance. The pericoccygeal nerves are located medial to the cornu and a combination of local anaesthetic and dexamethasone is injected.
223736481|NCT06242587|PROCEDURE|Impar ganglion block|The sacrum is visualised with fluoroscopy. A needle is inserted through the sacrococcygeal junction. The optimal image is obtained by administering contrast material. A combination of local anaesthetic and dexamethasone is injected.
223554998|NCT06893224|OTHER|Coastal exposure|"This is a real-life exposure to the coastal environment, in which participants walk to a bench, sit there for 15 minutes, followed by a walk of approximately 30 minutes. After the 15 minute sitting period, a saliva sample is collected. During the walk, participants are equipped with wearable sensors. The walking route is indicated on a map."
223554999|NCT06893224|OTHER|Urban exposure|"This is a real-life exposure to the urban environment, in which participants walk to a bench, sit there for 15 minutes, followed by a walk of approximately 30 minutes. After the 15 minute sitting period, a saliva sample is collected. During the walk, participants are equipped with wearable sensors. The walking route is indicated on a map."
223555000|NCT07071090|DRUG|DC50292A|DC50292A tablet
223555001|NCT07061496|BEHAVIORAL|Moderately intense exercise|Structured moderate-intensity aerobic activity (e.g., brisk walking) for 30-45 minutes/day, 5 days/week, for 12 weeks.
223555002|NCT07061496|DRUG|MetFORMIN 500 Mg Oral Tablet|Participants will receive oral metformin 500 mg twice daily for 12 weeks.
223555003|NCT06895863|DEVICE|MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.|"Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administered over five consecutive days.~On each intervention day, patients will undergo five high frequency iTBS sessions (each lasting approximately 10 minutes, excluding preparation) with about 50 minutes of rest between sessions. Each iTBS session delivers 1,800 pulses, resulting in a total of 25 sessions and 45,000 pulses over the course of a standard work week."
223555004|NCT06895863|DEVICE|Device: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil.|Intermittent theta burst stimulation (iTBS) targeting the left inferior parietal lobule (IPL) will be administered over five consecutive days using the stimulation pattern described in the active DLPFC arm.
223555005|NCT06895863|DEVICE|Sham stimulation of the MagVenture MagPro XP Orange Edition Prototype flipping the active side of the MagVenture Cool-B65 coil|"Device: Sham stimulation of the left DLPFC or IPL will be administered using the same stimulation duration and repetition as the active iTBS.~To match the subjective experience of iTBS, the sham CoMPACT uses a dedicated (Active/Placebo) stimulation coil that has both active and sham functions, generating the same sound level regardless of the type of stimulation."
223736482|NCT05081401|COMBINATION_PRODUCT|Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z|A-SOC: 4Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z/5Lfx(Mfx)+Cfz(Cs)+E+Z During the intensive phase: Bedaquiline(Linezolid);Levofloxacin(Moxifloxacin) All treatment is taken orally
223736483|NCT05081401|COMBINATION_PRODUCT|A1|9Bdq(6m)+Fq+Lzd+Cs+Cfz
223736484|NCT05081401|COMBINATION_PRODUCT|A2a|9Bdq(6m)+Fq+Lzd(600mg)+Cs+Z
223404221|NCT06874959|DEVICE|Ear acupuncture|"(According to the guidelines provided in the BFA - Acupuncture Manual of the USAF Center for Integrative and Complementary Medicine.)~Procedure:~* Practitioner: Traditional medicine doctor with a practicing certificate.~* Tools: Khanh Phong auricular acupuncture needles (license: 287/BYTYDCT)~* Before needling: Disinfect the skin on both outer ears.~* Insertion depth: Auricular needles penetrate the skin to a depth of 1.3 mm. Insert the auricular needles alternately on the right and left sides at the following acupoints: Cingulate gyrus, Subcortex, Omega 2, Shen Men, and Zero point. The insertion process stops when one of the following three criteria is met: (1) The patient experiences a 40% reduction in pain on the Visual Analog Scale (VAS), (2) The patient refuses to continue the insertion, or (3) A total of 10 needles have been inserted.~* After needling: Patient may feel slight pain in the ear area or de qi (a sensation of aching, warmth, and redness at the needling site)."
223404222|NCT06874959|DEVICE|Electro-acupuncture|"According to the Guidelines for the Diagnosis and Treatment of Diseases by Traditional Medicine, combining Traditional Medicine with Modern Medicine - 2020 - Ministry of Health of Viet Nam.~Procedure:~* Practitioner: Traditional medicine doctor with a practicing certificate.~* Tools: Khánh Phong ARLO acupuncture needles, size 0.3 x 25 mm (lincense: TKHQ:102664344900)~* Disinfect the lumbar region skin.~* Needle insertion: Insert needles perpendicular to the patient's skin, to a depth of 20 mm. Location: Dai truong du (BL25), Than du (BL23), Jiaji at L4-L5, L5-S1 (Ex-B2), Uy trung (BL40), Yeu duong quan (GV3). After insertion, attach the electrode clips to the needle ends.~* Electric stimulation: Use a current of 100Hz for 20 minutes - mixed wave.~* Post-needling: Patient may feel a sensation of de qi (aching, warmth, and redness at the needling site)."
223404223|NCT06874959|DRUG|Paracetamol 500 mg|"According to the Guidelines for the Diagnosis and Treatment of Diseases by Traditional Medicine, combining Traditional Medicine with Modern Medicine - 2020 - Ministry of Health of Viet Nam.~* Prescriber: Traditional medicine doctor with a practicing certificate.~* Paracetamol 500mg x 9 tablets: Take 1 tablet per dose, to be used when the pain score on the Visual Analog Scale (VAS) is ≥ 30mm, not exceeding 6 tablets/day. (If the patient still has medication from the previous visit, only prescribe the total amount needed to make up 9 tablets)."
223404224|NCT06874959|DEVICE|Sham ear acupuncture|"Study uses patches with non-skin-penetrating cotton, at the intervention acupoint areas. Using acupoints matching with the intervention group helps reduce the patients' ability to predict their study group, and the non-penetrating and non-rotating cotton ensure that there is no analgesic effect on the lumbar area caused by auriculotherapy.~Acupoint location: Cingulate gyrus, Subcortex, Omega 2, Shen Men, and Zero points"
223404225|NCT07029932|DRUG|BWC0977|"SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability, and PK data from SAD and previous MAD cohorts. Daily dosing will continue for a total of 7-10 consecutive days (as per schedule)."
223555006|NCT07073456|DIAGNOSTIC_TEST|Viscoelastic Coagulation Monitoring measurements|Peripheral venous blood samples will be obtained for the assessment of the eight following parameters utilizing the VCM (Viscoelastic Coagulation Monitor) device: clot time, clot formation time, alpha angle, amplitude at 10 minutes, amplitude at 20 minutes, maximum clot formation, lysis index at 30 minutes, and lysis index at 45 minutes. These parameters will be measured at the Emergency Department and subsequently on a daily basis for three consecutive days, if the patient is hospitalised.
223736485|NCT05081401|COMBINATION_PRODUCT|A2b|9Bdq(6m)+Fq+Lzd(2m)+Cs+Z
223736486|NCT05081401|COMBINATION_PRODUCT|A2c|9Bdq(6m)+Fq+Lzd(600mg-300mg)+Cs+Z
223736487|NCT05081401|COMBINATION_PRODUCT|A3|9Bdq(6m)+Fq+Lzd+Cfz+Z
223736488|NCT05081401|COMBINATION_PRODUCT|A4|9Bdq(6m)+Fq+Cfz+Cs+Z
223555007|NCT06831851|BEHAVIORAL|Storytelling Sessions|Children will participate in structured storytelling sessions, held once a week for 30 minutes per session. The sessions will use interactive narrative techniques, including voice modulation, gestures, and visual aids, to enhance cognitive, linguistic, and socio-emotional development. The intervention is designed to promote active engagement, stimulate imagination, and improve attention and language skills in early childhood.
223555008|NCT06831851|BEHAVIORAL|Music Education Sessions|Children will participate in structured music education sessions, conducted twice per week for 40 minutes each. The sessions will include rhythm exercises, vocalization, body percussion, and instrumental exploration using age-appropriate musical instruments. Activities will be designed to enhance cognitive, motor, and socio-emotional development by fostering auditory discrimination, fine and gross motor coordination, and social interaction. The intervention follows an interactive and play-based methodology, ensuring active engagement and progressive learning.
223736489|NCT05081401|COMBINATION_PRODUCT|A5|9Fq+Lzd+Cfz+Cs+Z
223736490|NCT05081401|COMBINATION_PRODUCT|B-SOC|6Bdq+Lzd+Cs+Cfz/14Lzd+Cfz+Cs
223736491|NCT05081401|COMBINATION_PRODUCT|B1|9Bdq(6m)+Lzd+Cs+Cfz+Z
223736492|NCT02348541|DEVICE|CollaGUARD|
223736493|NCT05443932|DRUG|Dapagliflozin|10mg Dapagliflozin daily for 8 weeks
223736494|NCT05443932|DRUG|Hydrochlorothiazide|50mg Hydrochlorothiazide daily for 8 weeks
223736495|NCT03121547|DRUG|Tapentadol 50 mg Oral Tablet|1 tablet administered
223736496|NCT03121547|DRUG|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
223736497|NCT03121547|DRUG|Placebo Oral Tablet|calcium tablet
223736498|NCT00220402|DRUG|SPM 907|
223736499|NCT01166724|DRUG|Sirolimus|Tacrolimus to Sirolimus
223736500|NCT01166724|DRUG|Tacrolimus|dosage per trough level
223736501|NCT03129243|DIAGNOSTIC_TEST|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
223736502|NCT05982626|RADIATION|68Ga/131I-SGMIB-ZT-199|68Ga-SGMIB-ZT-199: PET imaging; 131I-SGMIB-ZT-199: SPECT imaging.
224132404|NCT07073664|PROCEDURE|The surgical side of Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES)|Surgery was performed by Endoscope Ethmoid Infundibulum Expansion Surgery (EEIES) . Stapokibart from two weeks after the operation, subcutaneous injection of Stapokibart was administered once every two weeks for six consecutive months, a total of 12 times.
223404226|NCT07029932|DRUG|Placebo|SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive a matching placebo.
223404227|NCT06499129|BEHAVIORAL|Sensory ball, progressive relaxation exercise, training|The effect of sensory ball use on fatigue, peripheral neuropathy and anxiety will be examined
223404228|NCT07027046|PROCEDURE|Robotic surgical staging|The intervention includes hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node mapping, with possible lymphadenectomy or omentectomy, depending on histology.
223404229|NCT07036692|DIETARY_SUPPLEMENT|Placebo|To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
223404230|NCT07036692|DIETARY_SUPPLEMENT|FibreGum|To chew every day during a period of 4 months 3 chewing gums (morning, noon and evening) for at least 20 minutes each.
223404231|NCT06713369|DRUG|Saruparib (AZD5305)|PARP-inhibitor
223404232|NCT06713369|DRUG|[14C]-AZD5305 microtracer|IV radiolabeled microtracer
223404233|NCT06713369|DRUG|[14C]-AZD5305 (therapeutic dose)|IV radiolabeled PARP inhibitor
223404234|NCT04948580|BEHAVIORAL|Interaction Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
223404235|NCT00259181|PROCEDURE|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
223404236|NCT02448485|PROCEDURE|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
223404237|NCT01357837|DRUG|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
223404238|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
223404239|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
223555009|NCT06831851|BEHAVIORAL|Parental Guidance Sessions|Parents or guardians will attend 8 biweekly training sessions (60 minutes each) designed to equip them with strategies for cognitive, linguistic, and socio-emotional stimulation in early childhood. The sessions will include practical guidance on storytelling techniques, musical interaction, and play-based learning to reinforce the intervention at home. The goal is to create continuity between structured intervention activities and the home environment, maximizing developmental outcomes for the children. Sessions will be interactive, combining theoretical content with practical exercises and demonstrations
223555010|NCT06831851|BEHAVIORAL|Standard Daycare Activities|Children in this group will participate in regular daycare activities, including artistic and pedagogical tasks such as drawing, painting, and modeling. These activities are part of the standard curriculum and do not include structured storytelling or music education interventions
223555011|NCT05227976|BEHAVIORAL|Patient education (Theory)|"Theory/Lectures (1h/week)~Interventions given once weekly for 10 weeks."
224132405|NCT07073664|PROCEDURE|The surgical side of Endoscopic Sinus Surgery (ESS)|Description: Surgery was performed by Endoscopic Sinus Surgery (ESS). Stapokibart from two weeks after the operation, subcutaneous injection of Stapokibart was administered once every two weeks for six consecutive months, a total of 12 times.
223404240|NCT01357837|DRUG|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
223404241|NCT01825473|DRUG|Erythromycin|
223404242|NCT01825473|DEVICE|Multi-channel intra-luminal impedance (MII) pH monitoring|
223404243|NCT01825473|DRUG|Placebo (D5W)|
223555012|NCT05227976|BEHAVIORAL|Physical training|"Physical training group (1 hour/week)~Interventions given once weekly for 10 weeks."
223555013|NCT05227976|BEHAVIORAL|Mindfulness and medical yoga in group|"Mindfulness/medical yoga in group (1hour/week)~Interventions given once weekly for 10 weeks."
223555014|NCT07071454|BEHAVIORAL|Patient intervention|Patient intervention has 2 components. 1) The investigators will send patients a letter that promotes screening and contains targeted messages based on the individual's demographic characteristics. 2) Study staff who is trained in patient navigation will call each patient up to 3 times to confirm receipt of the letter and conduct one-on-one education about screening using a standardized script.
223736503|NCT04251819|DRUG|Placebos|Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
223404244|NCT05359354|BIOLOGICAL|Personalized neoantigen tumor vaccine|Biological: neoantigen tumor vaccine with or without PD-1 In dose escalation phase, subjects will receive neoantigen tumor vaccine only. In dose expansion phase, subjects will receive neoantigen tumor vaccine combination with PD-1
223404245|NCT00722969|DRUG|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
223404246|NCT05479864|PROCEDURE|anterior cervical corpectomy and fusion|removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
223404247|NCT03048214|PROCEDURE|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
223404248|NCT03048214|PROCEDURE|General anaesthesia|Usual practice for upper limb surgeries.
223404249|NCT03177291|DRUG|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
223736504|NCT04251819|DRUG|Baclofen 5 mg|Participants will receive 5mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
223736505|NCT04251819|DRUG|Baclofen 10mg|Participants will receive 10mg of baclofen in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
223736506|NCT03272490|PROCEDURE|Medartis|Surgery using the medartis implant
223736507|NCT03272490|PROCEDURE|Synthes|Surgery using the Synthes implant
223404250|NCT03177291|DRUG|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
223736508|NCT04453033|DEVICE|Celeste Specialized Phototherapy Device|Ocular phototherapy light panel
223404251|NCT03177291|DRUG|Paclitaxel|200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
223404252|NCT03177291|DRUG|Pemetrexed|500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
223404253|NCT06104020|OTHER|Intraoperative fluid management stratigies.|"Regimens of different intraoperative fluid management The restrictive fluid group (RG) aims to achieve a net zero fluid balance and involves a 2 mL/kg bolus at anesthesia induction, followed by an intraoperative crystalloid infusion at a rate of 4 mL/kg/hr.~The other group of patients, the liberal group (LG), will receive a 10 ml/kg bolus at anesthesia induction,followed by an intraoperative crystalloid infusion at a rate of 8 ml/kg/hr."
223736509|NCT01979484|DRUG|PPI-668 capsule|
223404254|NCT06379997|DIETARY_SUPPLEMENT|Collagen, Hyaluronic Acid, Vitamin C, and Manganese|The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
223404255|NCT06379997|DRUG|Intra-articular infiltration|Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
223404256|NCT06802185|DRUG|ADA Liquid Filled Capsules (Test Product)|ADA liquid filled capsules containing 125 mg ibuprofen and 250 mg acetaminophen.
223404257|NCT06802185|DRUG|ADA Caplets (Reference Product)|ADA Caplets containing 125 mg ibuprofen and 250 mg acetaminophen.
223404258|NCT06802185|DRUG|Advil Liqui-gels (Reference Product)|Advil Liqui-gels containing 200 mg ibuprofen.
223404259|NCT06745908|DRUG|N-803|N-803 1.2 mg SC
223404260|NCT06745908|DRUG|Tislelizumab|Tislelizumab 200 mg IV
223555015|NCT07071454|BEHAVIORAL|PCP intervention|PCP intervention has 2 components. 1) PCPs of patients who are randomized to this group will receive an initial email that provides a list of all patients assigned to the PCP who are randomized to the PCP intervention. PCPs will be specifically informed which patients are high-risk. The email will also include a personal report card with the percentage of patients assigned to the provider who are up-to-date with CRC screening in two age groups: 45-49 years and 50-75 years. Subsequently, PCPs will receive weekly emails with a list of patients randomized to the PCP intervention who are scheduled for a clinic visit with them. 2) The investigators will design a local clinical dashboard using Microsoft Power BI that allows PCPs to view a list of their patients who are randomized to the PCP intervention as well as provide a link to this in each email. High-risk patients will be specifically marked.
223555016|NCT03606291|RADIATION|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
223555017|NCT03108521|DRUG|Sitagliptin|100mg.QD for 3 months
223555018|NCT01070134|BEHAVIORAL|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
223555019|NCT01070134|BEHAVIORAL|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
223555020|NCT05629312|PROCEDURE|Maxillary expansion|The upper jaw is expanded with a removable expansion plate
223555021|NCT05629312|PROCEDURE|Extraction of deciduous upper canines|Both deciduous upper canines are extracted in this group
223555022|NCT06895226|BEHAVIORAL|Exercise|Exercise and physical activity program and usual care
223555023|NCT06895226|OTHER|Usual Care|Usual cara and Exercise and PA recommendations
223555024|NCT06895473|PROCEDURE|Biospecimen Collection|Undergo CSF sample collection
223555025|NCT06895473|DRUG|Cytarabine|Given IT
223555026|NCT06895473|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
223555027|NCT06895473|DRUG|Methotrexate|Given IT
223555028|NCT06895473|DRUG|Therapeutic Hydrocortisone|Given IT
223555029|NCT06897228|DRUG|PANK-003 cell injection|PANK-003 cell injection
223555030|NCT04088968|BEHAVIORAL|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
223555031|NCT03262805|DIETARY_SUPPLEMENT|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
223555032|NCT03262805|OTHER|Placebo|Microcrystalline cellulose
223736510|NCT01979484|DRUG|PPI-668 tablet|
223736511|NCT00453544|OTHER|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
223736512|NCT00453544|OTHER|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
223736513|NCT02457910|OTHER|Biomarker Analysis|Correlative studies
223736514|NCT02457910|DRUG|Enzalutamide|Given PO
223736515|NCT02457910|OTHER|Pharmacological Study|Correlative studies
223736516|NCT02457910|DRUG|Taselisib|Given PO
223736517|NCT05683054|BIOLOGICAL|Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels|In the dose tapering arm, adalimumab dosing frequency will be lowered to 40 mg every 3 weeks in patients who have supratherapeutic serum trough levels of adalimumab (33% reduction). If patients still have a good clinical response and supratherapeutic adalimumab serum trough levels, will be further tapered to a dose regimen of 1 subcutaneous injection (40mg) every 4 weeks (50% dose reduction).
223404261|NCT06745908|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV
223555033|NCT06899737|OTHER|MOMS Postpartum Course|Online professional development training for CHWs on outreach and support for high-risk postpartum mothers
223736518|NCT05683054|PROCEDURE|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab
223404262|NCT07087834|OTHER|CASEM (Cancer Screenings Education for Men)|"Experimental Group After the initial meeting, pre-tests will be administered to the individuals in the experimental group. Subsequently, the days and times of the training sessions will be determined, taking into account the working hours and schedule of the institution and the availability of the employees. The four planned training sessions will then be conducted once a week. The post-test (Cancer Screening Perception Scale, Cancer Screening Attitude Scale, Cancer Screening Knowledge Scale) will be administered to the experimental group one month and three months after the final training session.~Content and Materials of the Training to Be Provided to the Experimental Group The intervention described in the appendix will be applied to the experimental group. This intervention is an educational intervention consisting of three sessions aimed at increasing men's perceptions, attitudes, and knowledge levels regarding cancer screening. ... It covers basic information about cancer, commo"
223404263|NCT02975245|PROCEDURE|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
223404264|NCT04200937|DEVICE|Tactra Malleable|The Tactra™ Penile Prosthesis is a sterile, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in adult males who are suitable candidates for implantation procedure.
223404265|NCT04200937|DEVICE|Spectra™ Concealable Penile Prothesis|The Spectra Penile Prothesis is a sterile, non-pyrogenic, single-use implant that is intended for use in the treatment of chronic, organic, erectile dysfunction (impotence) in men who are determined to be suitable candidates for implantation surgery.
223404266|NCT04200937|DEVICE|AMS Ambicor™ Inflatable Penile Prosthesis|The AMS Ambicor inflatable penile prothesis intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence) in adult men who are determined to be suitable candidates for implantation surgery.
223404267|NCT04200937|DEVICE|AMS 700™ Inflatable Penile Prosthesis w/Momentary Squeeze (MS) Pump|The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
223555034|NCT06896058|OTHER|Written and verbal training given to caregivers|Education was provided with a brochure containing information on practices regarding care of stroke patients with PEG, prepared by the researcher in line with literature information.
223555035|NCT01308840|DRUG|Panitumumab|Day 1 and 15 = 6 mg/kg IV
223555036|NCT01308840|DRUG|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
223555037|NCT01308840|DRUG|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
223555038|NCT00526539|OTHER|Total hip replacement, Spectron and Taperloc|
223555039|NCT06196996|PROCEDURE|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.|The method of islet transplantation is through percutaneous transhepatic portal vein puncture.After transplantation, rabbit anti human thymocyte immunoglobulin (ATG) or basiliximab was used as induction therapy and low-dose tacrolimus combined with sirolimus or mycophenolate mofetil were used as immunosuppressive maintenance therapy.
223555040|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
223555041|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - medium|
223555042|NCT01706653|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
223555043|NCT01706653|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
223555044|NCT01084343|BIOLOGICAL|MYM-V101|"* Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
223555045|NCT03281629|DEVICE|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
223555046|NCT03281629|DEVICE|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
223555047|NCT01088295|DRUG|Telmisartan|
223555048|NCT06926946|OTHER|Intervention Arm- Cerebral Oximetry + Treatment Guideline|if the cerebral oximeter shows low values, a pre designed treatment guideline will be followed and corrective actions taken.
223555049|NCT06928545|DEVICE|Side-to-side duodenal-ileal anastomosis|Side-to-side duodenal-ileal anastomosis formed by magnetic compression using the GT Metabolic MagDI System.
223555050|NCT00939887|DRUG|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
223555051|NCT02175277|DRUG|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
223555052|NCT00652275|BIOLOGICAL|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
223555053|NCT00652275|BIOLOGICAL|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
223736519|NCT05683054|OTHER|Dermatology Life Quality Index (DLQI)|The impact of the disease on the patient will be assessed using the dermatology life quality index (DLQI).
223736520|NCT05683054|OTHER|EQ-5D-5L questionnaire|The EQ-5D-5L which is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments will be assessed.
223555054|NCT01968538|RADIATION|Radiation Therapy|
223555055|NCT03833557|PROCEDURE|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
223555056|NCT03833557|PROCEDURE|MTA pulpotomy|Angleus grey MTA
223555057|NCT03833557|PROCEDURE|Formocresol Pulpotomy|Buckley's Fromocresol. diluted full strength foromocresol
223555058|NCT03815448|DRUG|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
223555059|NCT03815448|OTHER|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
223555060|NCT03501901|DIAGNOSTIC_TEST|Antibiotic susceptibility test|
223736521|NCT05683054|PROCEDURE|Dried blood spot sampling|A subset of patients will sample additionally by using dried blood sampling after the first drug injection post-inclusion.
223736522|NCT03434054|DRUG|Losartan|blood pressure medication
223736523|NCT03434054|OTHER|Placebo|non-active sham intervention
223736524|NCT06477458|OTHER|Single inspiratory phase computed tomography.|Utilizing deep learning technology in conjunction with single inspiratory phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
223736525|NCT06477458|OTHER|Respiratory dual-phase computed tomography.|Utilizing deep learning technology in conjunction with respiratory dual-phase computed tomography images to accurately predict the pulmonary function indicators of preoperative thoracic surgery patients.
223736526|NCT01331954|DEVICE|Ultrasonic ablation device|One or two HIFU procedures
223736527|NCT05076474|DRUG|Orlistat 60mg Cap|Subjects completed a 5-day run-in period (baseline) and then were randomized to receive the first of 3 treatments; each treatment period lasted 10 days followed by a 4-day washout period between treatments.
223736528|NCT02223273|BEHAVIORAL|Multifaceted Strategy|"1. Simulation Based Team Training~2. Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~3. Reminders -~4. Check lists - decision support algorithm~5. Distribution of educational materials: guidelines and recommendations for best practices"
223736529|NCT03630003|DEVICE|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
223736530|NCT03630003|OTHER|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
223736531|NCT04304807|DRUG|Melatonin 20 mg|Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
223736532|NCT04304807|DRUG|Traditional antibiotic treatment|Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
223404268|NCT04200937|DEVICE|AMS 700™ Inflatable Penile Prosthesis w/Tenacio™ Pump|The AMS 700 Inflatable Penile Prosthesis is intended for use in the treatment of chronic, organic, male erectile dysfunction (impotence).
223404269|NCT06764849|PROCEDURE|CONVENTIONAL OPEN EXCISIONAL HEMORRHOIDECTOMY|Hemorrhoidectomy performed based on the conventional technique described by Milligan-Morgan
223736533|NCT00438087|DRUG|methylprednisolone|methylprednisolone administrated intra and post operatively
223736534|NCT01096264|OTHER|SSI and SphygmoCor® evaluations|"* SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~* SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
223736535|NCT02315170|DEVICE|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
223736536|NCT02315170|DEVICE|standard lid speculum|standard wire lid speculum
223736537|NCT00619801|DRUG|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
223736538|NCT00619801|DRUG|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
223736539|NCT03721276|BEHAVIORAL|EQuIP (Empowering Queer Identities in Psychotherapy)|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
223736540|NCT05604131|DRUG|Deferiprone Tablets|Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
223736541|NCT05604131|DRUG|Placebo|Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
223404270|NCT06764849|PROCEDURE|MINIMALLY INVASIVE OPEN EXCISIONAL HEMORRHOIDECTOMY|Hemorrhoidectomy performed based on the tecnique described by Milligan Morgan, using a minimally invasive approach.
223404271|NCT07084558|DIAGNOSTIC_TEST|blood sample for Signatera (TM) test|ctDNA: Evaluation of ctDNA-status prior to treatment start (ctDNA not detected or ctDNA-positive) until the last of five follow-up visit
223736542|NCT03744923|PROCEDURE|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
223404272|NCT07084558|DIAGNOSTIC_TEST|biopsy for Ki-67 assessment|Ki67: Evaluation of Ki-67-value after 3 weeks of aromatase inhibitor
223404273|NCT07084558|DIAGNOSTIC_TEST|FFPE tumor sample for Signatera (TM) test (archived)|Evaluation of ctDNA status prior to treatment start
223404274|NCT00775853|DRUG|6-[18F]Fluorodopamine|
223404275|NCT00775853|DRUG|6-[18F]Fluorodopa|
223404276|NCT00775853|DRUG|13N-Ammonia|
223404277|NCT07092553|DEVICE|C-arm PCD-CBCT|A single research PCD-CBCT scan will be performed directly after the participant's SOC scan.
223736543|NCT03744923|PROCEDURE|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
223736544|NCT01257997|BIOLOGICAL|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
223736545|NCT05723237|OTHER|Breast Cancer Education|The women in the experimental group (n=60) will be given 16 hours of breast cancer screening training, two days a week, two hours a day (60 min+60 min) for four weeks, by the researchers.
223404278|NCT07093073|DRUG|ssCART-19|Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.
223736546|NCT03128775|BEHAVIORAL|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~1. arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~2. Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
223736547|NCT03128775|BEHAVIORAL|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
223404279|NCT06027632|OTHER|Cognitive exercises with supervision|"The experimental group will receive a 12-week intervention consisting of three 20-minute online cognitive stimulation sessions per week along with a weekly 30-minute centralized online remote supervision session with a neuropsychologist. Patient will also have access to the PRESCO program of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
223404280|NCT06027632|OTHER|Cognitive exercises without supervision|"Patient will have access to the program named PRESCO of the HAPPYNeuron-Pro software, which is designed to train up to 12 different cognitive domains, including attention, memory, executive functions and processing speed"
223404281|NCT04982497|BEHAVIORAL|Video game based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated prevention program based on the model by Lewinsohn et al. (1985). The cognitive stimulation component is based on cognitive reserve (Tucker \& Stern, 2011) and neuroplasticity (Shapiro, 2001), the cognitive stimulation model by Spector et al. (2006), and the causes of age-related memory failures (Light, 1991) (e.g., decrease in the processing resources, semantic coding deficit, difficulties in deliberate information retrieval). The healthy habits promotion component is based on the social learning and social cognitive theories (Bandura, 1986; Spiegler, 2016).
223404282|NCT04982497|OTHER|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
223404283|NCT06365268|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.
223404284|NCT07088757|DRUG|standard dose indomethacin|Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.
223555061|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 1.
223555062|NCT03974932|DRUG|Ibuprofen|NSAID.
223555063|NCT03974932|DRUG|Acetaminophen|Analgesic.
223555064|NCT03974932|DRUG|Celecoxib|NSAID.
223555065|NCT03974932|DRUG|+/- Bupivacaine HCl|Local anesthetic.
223555066|NCT03974932|DEVICE|Luer Lock Applicator|Applicator for instillation.
223555067|NCT03974932|DRUG|HTX-011|Dual-acting local anesthetic. Dose 2.
223555068|NCT04453826|DRUG|Camrelizumab plus chemo-radiotherapy|"1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
224022413|NCT02762149|DEVICE|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
224022414|NCT00875602|DEVICE|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
223736548|NCT03128775|BEHAVIORAL|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
223736549|NCT03973385|DEVICE|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
224022415|NCT04873739|DIAGNOSTIC_TEST|Anterior Segment OCT|AS-OCT for SLE patients with dry eye, SLE patients without dry eye and compare them with normal subjects.
223736550|NCT01340898|BIOLOGICAL|Meningococcal vaccine GSK 134612|Intramuscular injection
223736551|NCT01340898|BIOLOGICAL|SynflorixTM|Intramuscular injection
223736552|NCT01340898|BIOLOGICAL|Infanrix-IPV/HiberixTM|Intramuscular injection
223736553|NCT02417701|OTHER|Laboratory Biomarker Analysis|Correlative studies
224022416|NCT00998335|DRUG|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
223404285|NCT07088757|DRUG|low dose indomethacin|Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.
223404286|NCT07095920|DEVICE|Device: Q Therapeutic System (BQ 3.0) - Active|The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.
223404287|NCT07098715|DEVICE|Kerecis fish skin|To assess shot-term outcomes (rates of healing) using Kerecis intact fish skin to heal cryptoglandular fistula-in-ano and associated chronic non-healing draining wounds.
223404288|NCT05272176|BEHAVIORAL|Coping Long Term with Active Suicide Program (CLASP)|Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
223404289|NCT07096271|BEHAVIORAL|Get Better Together (GBT)|"Get Better Together is a couple-based, primary prevention program designed to reduce risk for suicidal thoughts and behaviors, problematic alcohol use, and intimate partner violence by addressing two transdiagnostic drivers: emotion dysregulation and relationship conflict. The intervention is an adaptation of the empirically supported Prevention and Relationship Enhancement Program (PREP), modified in collaboration with military stakeholders to meet the unique cultural and contextual needs of military couples.~The GBT curriculum includes approximately 10 hours of structured content presented using didactic instruction, video demonstrations, group discussions, and guided couple exercises. Skills focus on interpersonal emotion regulation (e.g., emotion identification, acceptance, reappraisal, and problem solving) and evidence-based communication strategies (e.g., structured communication strategies, conflict de-escalation)."
223404290|NCT07107906|BEHAVIORAL|The CONNECT Program|A group-based telehealth intervention grounded in Acceptance and Commitment Therapy (ACT), self-compassion, and successful aging theories, aimed at reducing social isolation, loneliness, and mental health symptoms among adults 55+. Delivered over six weeks via group phone or Zoom sessions. The CONNECT Program includes 6 weekly 90-minute group sessions, with structured workbooks and homework. The CONNECT Program is delivered in two modalities (group telephone or Zoom videoconferencing).
223404291|NCT07107906|BEHAVIORAL|Community Participation as Usual (Service as Usual)|These community-based programs may include social, educational, or recreational group sessions that are already offered by local organizations - either in person, by phone, or virtually.
223404292|NCT07117240|DRUG|lixisenatide + glargine|Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
223404293|NCT07117240|DRUG|Intensive insulin therapy|Participants assigned to Group 1 will receive standard insulin therapy. Those in Group 2 will be treated with a combination of insulin glargine and lixisenatide, with dosages individually adjusted based on current glucose levels. All participants will be trained in insulin administration and dose adjustment based on glucose readings.
223404294|NCT07117539|DEVICE|visual bronchial blocker (VBB)|lung isolation with visual bronchial blocker
223736554|NCT02417701|OTHER|Pharmacological Study|Correlative studies
223736555|NCT02417701|DRUG|Sapanisertib|Given PO
223736556|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
224022417|NCT00998335|DRUG|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
223736557|NCT01214629|DRUG|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
223736558|NCT01214629|DRUG|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
223404295|NCT07117539|DEVICE|double-lumen endotracheal tube (DLT)|lung isolation with double-lumen endotracheal tube
223404296|NCT03374865|OTHER|Facetalk|Area of interest: communication during Facetalk consultations
223736559|NCT05135897|DEVICE|Electroconvulsive therapy|Treatment with Electroconvulsive therapy
223404297|NCT03374865|OTHER|Face-to-face consultation|Area of interest: communication during face-to-face consultations
223404298|NCT05132517|DIAGNOSTIC_TEST|Kölner Neuropsychologische Screening für Schlaganfall-Patienten|The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.
223404299|NCT01954576|DEVICE|NovoTTF-100A|
223404300|NCT01954576|PROCEDURE|Quality-of-life assessment|
223404301|NCT01954576|GENETIC|Laboratory biomarker analysis|
223404302|NCT06918964|DEVICE|transcutaneous auricular vagus nerve stimulation device|Place the stimulation device on the left auricle and set the stimulation parameters according to the following conditions: a. Waveform: biphase, square wave; b. Wave width: 200 μs; c. Frequency: Alternating between low frequency (4 Hz for 4 s), high frequency (40 Hz for 8 s), and a 4 s pause; d. Intensity: The maximum intensity that induces the strongest sensation the individual can tolerate without causing pain, usually 1.5-3.5 mA; e. Treatment duration: Each treatment lasted 30 minutes, twice daily (8:00, 16:00) for 10 days.
223555069|NCT04453826|DRUG|Chemo-radiotherapy alone|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy"
223555070|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids Supplementation|
223736560|NCT05135897|DEVICE|rTMS|repetitive Transcranial Magnetic Stimulation
223736561|NCT05573789|GENETIC|Tumor molecular profiling|Tumor molecular profiling was assessed using the ForeSENTIA® Prostate panel developed by NIPD Genetic
223736562|NCT01594879|DEVICE|MIrena(LNG-IUS), oral MPA|"1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
224022418|NCT02374671|DEVICE|VisAbility Micro Insert|Subjects are implanted with the VisAbility Micro Insert (Model SGP-046) and followed for 24 months.
224022419|NCT00457808|DRUG|Rapamycin, sirolimus|
224022420|NCT02942433|BEHAVIORAL|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
223404303|NCT06918964|DEVICE|Sham device|The sham taVNS group received the same parameters with a current intensity of 0.06 mA.
223404304|NCT07116499|DRUG|Placebo|Single oral dose of matching placebo
223404305|NCT07116499|DRUG|K-645 dose level 1|Single oral dose of K-645 dose level 1
223404306|NCT07116499|DRUG|K-645 dose level 2|Single oral dose of K-645 dose level 2
223404307|NCT07125157|BEHAVIORAL|Task-Specific Training with Biofeedback|Participants in this group will undergo task-specific training focused on improving balance and reducing fall risk. Real-time biofeedback (e.g., visual or auditory cues) will be integrated into the training to enhance motor learning and postural adjustments. Sessions will be supervised and conducted multiple times per week over the intervention period.
223404308|NCT07125157|BEHAVIORAL|Task-Specific Training without Biofeedback|Participants will receive task-specific training aimed at improving balance and fall prevention without any biofeedback assistance. The same set of functional exercises and session frequency will be followed as in the experimental group, ensuring the only difference is the absence of feedback stimuli.
223404309|NCT07133633|DRUG|Tulisokibart|Subcutaneous (SC) administration
223404310|NCT07133633|DRUG|Placebo|SC administration
223404311|NCT07139873|DRUG|DZD8586|Orally, 50 mg, once daily until treatment discontinuation criterion is met.
223404312|NCT07139873|DRUG|Bendamustine|Administered intravenously
223404313|NCT07139873|DRUG|Idelalisib|Administered orally
223404314|NCT07139873|DRUG|Rituximab|Administered intravenously
223555071|NCT01777048|DIETARY_SUPPLEMENT|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
223555072|NCT06008262|OTHER|Cold Application|An ice pack will be applied to the posterior upper neck regions of patients with nausea in Group-I, with an interval of 5 minutes. The vital signs of the patients will be recorded. The severity of nausea and pain of the patients will be evaluated with a numerical rating scale. The effectiveness of its application as perceived by the patient will be evaluated.
223555073|NCT01163396|DRUG|Bevacizumab|
223555074|NCT01163396|DRUG|Irinotecan|
223555075|NCT01163396|DRUG|Oxaliplatin|
223555076|NCT01163396|DRUG|5-fluorouracil/leucovorin|
223404315|NCT07137312|PROCEDURE|Blood Draw|"Participants have a standard blood draw or apheresis on study. Some participants may provide a specimen via apheresis one time (the blood draw group) and then elect to provide a second optional specimen via a standard blood draw (the apheresis draw group) or vice versa."
223404316|NCT07137312|PROCEDURE|Apheresis|"Participants have a standard blood draw or apheresis on study. Apheresis is a procedure where blood is drawn from your body, specific components like plasma, platelets, and/or white blood cells are separated out, and the rest of the blood is returned. Some participants may provide a specimen via apheresis one time (the apheresis group) and then elect to provide a second optional specimen via a standard blood draw (the blood draw group) or vice versa."
223404317|NCT03581292|RADIATION|Radiation Therapy|Undergo radiation therapy
223404318|NCT03581292|DRUG|Temozolomide|Given PO
223404319|NCT03581292|DRUG|Veliparib|Given PO
223404320|NCT06934122|OTHER|manipulation with classical massage and spinal manipulation technique|All participants will first receive a massage to relax the muscles and then be manipulated with a spinal manipulation technique.
223555077|NCT04001439|DRUG|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
224022421|NCT02942433|BEHAVIORAL|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
224022422|NCT02942433|BEHAVIORAL|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
224132406|NCT06898294|DIAGNOSTIC_TEST|EIT kidney function assessment|The product under investigation is named Gense EIT-kidney device. This kidney device is a portable and non-invasive imaging modality capable of capturing the cross-sectional bioelectrical impedance distribution of the kidney at multiple current injection frequencies using electrical impedance tomography (EIT). Currently, the kidney device employs a band consisting of 16 equally distributed electrodes around the abdomen. The electrode band is connected to a control unit that switches the electrode stimulation and measurement pairs, then sends the collected measurement to a computational unit for image reconstruction. The images are then post-processed to extract functional kidney images for diagnosis. This kidney device has a large LED screen, allowing the functional images to be produced and visualized.
223404321|NCT06934187|PROCEDURE|Carpal tunnel release|The operating surgeons will make a skin incision distally from the distal wrist crease and ulnar to the thenar crease. The appropriate tissues, including the subcutaneous tissue, palmar fascia, flexor retinaculum, and antebrachial fascia, will then be divided in CTR group. Haemostasis will be achieved using bipolar coagulation. The skin will be closed, and an appropriate dressing will be applied.
223404322|NCT06934187|PROCEDURE|Placebo surgery|Only an skin incision will be made and the same time as CTR operation takes will be waited until skin closure. An appropriate dressing will be applied.
223404323|NCT06934603|OTHER|Clear Aligner Treatment|This study is observational. Only patients who are previously scheduled to receive clear aligner treatment from their orthodontic provider will be recruited.
223404324|NCT07140874|DRUG|Zinc citrate|Oral zinc citrate 30 mg daily
223404325|NCT07140874|DRUG|Placebo|Placebo
223404326|NCT07141277|OTHER|None (Observational study)|Not applicable since it's an observational study.
223404327|NCT06936462|DRUG|topical cyclosporine eyedrops and hyaluronic eyedrops|topical cyclosporine eyedrops and hyaluronic eyedrops
223404328|NCT06932081|DRUG|SGLT2 inhibitors|Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
223555078|NCT04122846|BEHAVIORAL|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
223555079|NCT05799391|DRUG|SJC|Soothing cream jel
223555080|NCT05799391|OTHER|Placebo|Placebo cream jel
223555081|NCT00922246|DEVICE|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
223555082|NCT02477917|BIOLOGICAL|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
223555083|NCT03538886|PROCEDURE|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
223555084|NCT03538886|PROCEDURE|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
223555085|NCT04051294|DIETARY_SUPPLEMENT|Commercial kombucha tea|Commercially-available kombucha tea.
223555086|NCT04051294|DIETARY_SUPPLEMENT|Brewed kombucha tea|Kombucha tea brewed
223555087|NCT04051294|OTHER|Control: Tea|Tea brewed in our lab.
223555088|NCT04051294|OTHER|Control: Water|Tap water
223555089|NCT02044224|DRUG|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
223555090|NCT02509364|OTHER|No intervention|
223555091|NCT07081269|OTHER|observation alone|No interventions will be conducted during the observation period, maintaining participants' normal daily living conditions.
223555092|NCT04090957|DRUG|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
223555093|NCT04090957|DRUG|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
223555094|NCT03226327|DIETARY_SUPPLEMENT|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (\<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
223404329|NCT06880523|DRUG|STRIDE (durvalumab + tremelimumab)|As first treatment
223404330|NCT06880523|DRUG|Durvalumab|monotherapy every 4 weeks
223555095|NCT00375674|DRUG|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
223555096|NCT00375674|OTHER|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
223555097|NCT03269539|OTHER|MRI Imaging|
223555098|NCT00298441|DRUG|chondroitin sulfate-iron colloid|
223555099|NCT03038971|BIOLOGICAL|Dose Level 1|Short and Tall Ragweed Mix
223555100|NCT03038971|BIOLOGICAL|Dose Level 2|Short and Tall Ragweed Mix
223555101|NCT03038971|BIOLOGICAL|Placebo|Saline with 0.4% Phenol
223555102|NCT00284635|PROCEDURE|Fast track vs conventional|
223555103|NCT05455580|BEHAVIORAL|Nurses Taking On Readiness Measures (N-TORM)|The intervention will begin with instructing the participant to complete the Family Disaster Plan booklet. The principal investigator will talk about the different sections of the booklet and instruct the participants how to fill out their emergency plans. Participants will write their medical history, medications, physician, next of kin, pharmacy contact information, evacuation plan information, family communication plan, and insurance policy numbers and contact information. The booklet includes household emergency preparedness recommendations, evacuation zone information, a disaster supply kit contents list, local utility company contact information, shelter locations, and special needs and priority utility restoration registry information. The participants will be provided with a disaster supply kit after successful completion of the booklet. The disaster supply kit is part of the intervention and is not considered compensation.
223555104|NCT01312025|PROCEDURE|conventional laparoscopic cholecystectomy|
223555105|NCT01312025|PROCEDURE|modified laparoscopic cholecystectomy|
223736563|NCT02297074|OTHER|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
223404331|NCT06880523|DRUG|Lenvatinib|Daily
223404332|NCT06737536|DRUG|NNC0662-0419|Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.
223404333|NCT06737536|OTHER|Placebo (NNC0662-0419)|Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.
223404334|NCT05042102|COMBINATION_PRODUCT|Donepezil + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
223404335|NCT05042102|COMBINATION_PRODUCT|Donepezil + Placebo CRT|Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.
223555106|NCT03744910|BIOLOGICAL|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
223555107|NCT03744910|DRUG|Physiologic saline solution|Normal saline
223555108|NCT05631769|DRUG|Dual antiplatelet agent duration|"Patients who receive percutaneous coronary intervention for coronary artery disease will be randomized to arms with different DAPT strategies.~The randomization will be stratified according to the High bleeding risk (defined according to the ARC-HBR criteria)."
223555109|NCT05322512|DRUG|18F-FDG|All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
223555110|NCT04234529|DIETARY_SUPPLEMENT|AMATEA™|"AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine."
223555111|NCT04234529|DIETARY_SUPPLEMENT|Caffeine|1.08g of microcellulose and 270mg of caffeine.
223555112|NCT04234529|OTHER|Placebo|1.35g of microcellulose
224022423|NCT03854045|OTHER|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
223404336|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Cognitive remediation therapy (CRT)|Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
223555113|NCT04328753|DRUG|Super Oxide water|Microsafe®, a recently available super-oxidized solution for gingival care, offers a completely improved approach for treatment of gingivitis. The neutral pH, super oxidized water was certified as an antiseptic .
223555114|NCT04328753|DRUG|Chlorhexidine mouthwash|CHX is a regular bisbiguanide artificial antiseptic containing of two biguanide groups and four chlorophenyl rings linked by a hexamethylene bridge. The dicationic nature of CHX makes it interacting strongly with anions, which is related to its safety, efficacy, and side effects. It is available in three forms, digluconate, acetate and hydrochloride salts. CHX has broad spectrum antimicrobial activity
223555115|NCT04328753|OTHER|Distilled water|act as a negative control in this study
223555116|NCT06785454|DRUG|Lorundrostat|Lorundrostat tablet.
223555117|NCT06785454|DRUG|Placebo|Lorundrostat matching placebo tablet.
223555118|NCT00064259|BIOLOGICAL|oblimersen sodium|Given IV
223555119|NCT00064259|DRUG|cisplatin|Given IV
223555120|NCT00064259|DRUG|fluorouracil|Given IV
223555121|NCT02953093|DRUG|Acarbose|see arm description
223555122|NCT02953093|OTHER|Placebo|See arm description
223555123|NCT01132651|OTHER|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
223555124|NCT01132651|OTHER|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
223736564|NCT02297074|OTHER|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
223404337|NCT05042102|COMBINATION_PRODUCT|Placebo medication + Placebo CRT|Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.
223404338|NCT01047527|DRUG|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
223404339|NCT06941441|OTHER|Home exercise program|A tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring
223404340|NCT06941532|DIETARY_SUPPLEMENT|GMP Intervention Product|Condition specific GMP based intervention product
223404341|NCT06182241|BEHAVIORAL|Retention in cervical cancer care intervention|Aim 1 data will inform this intervention, however the participant intervention will likely be one or two sessions, conducted in-person, coupled with text- or phone-based client navigation with women who received abnormal high-risk Pap smear results. We anticipate that the intervention may integrate (1) information to improve awareness of cervical cancer susceptibility and treatment, (2) motivational interviewing to assess pros and cons of attending a follow-up appointment and completing treatment; (3) brief cognitive behavioral therapy (CBT) skills to reduce individual-level barriers, (4) problem-solving to increase social support, and (5) patient navigation tools to mitigate clinic-level challenges.
223404342|NCT06943469|OTHER|Test formula|Partially hydrolyzed formula with synbiotics
223404343|NCT06943469|OTHER|Control formula|Intact protein formula without synbiotics
223404344|NCT02002572|OTHER|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
223404345|NCT07139236|PROCEDURE|Preoperative Endoscopic Ultrasound Elastography (EUS Elastography)|"All enrolled patients will undergo a preoperative EUS-E examination within one weeks prior to pancreaticoduodenectomy. The EUS-E will be performed by experienced endosonographers using a radial or linear array echoendoscope connected to a compatible ultrasound processor. Both qualitative (color mapping) and quantitative (strain ratio, strain histogram) data will be obtained. Multiple measurements of the strain ratio will be taken from a region of interest within the pancreatic parenchyma adjacent to the lesion. The mean strain ratio will be recorded for analysis. Standard EUS imaging will also be recorded.~Standard pancreaticoduodenectomy will be performed . Intraoperative pancreatic texture will be subjectively assessed by the surgeon and recorded. Postoperative monitoring for pancreatic fistula will follow established clinical guidelines."
223404346|NCT06944353|BEHAVIORAL|STIRRED|"The STIRRED intervention is a behavioral intervention directed at the treating ED clinicians.~An Our Practice Advisory (OPA) will alert the clinician to the radiology finding of hepatic steatosis at the time of preparing the discharge materials. The OPA will prompt the clinician to discuss this finding with the patient and will automatically add hepatic steatosis to the discharge diagnoses and insert patient-facing discharge information about hepatic steatosis. It will additionally prompt the clinician to refer the patient for follow-up which will be stratified based on their fibrosis risk level."
223404347|NCT06948084|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223555125|NCT06034873|DRUG|Propofol injection and fentanyl|The sequence will be to inject fentanyl 1 μg•kg-1•min-1 first within 1 min and then inject propofol 2 mg•kg-1•min-1.
223555126|NCT06034873|DRUG|Bupivacain|Patients will be anesthetized with ultrasound-guided pericapsular nerve group block (PENG block) using 20 ml of 0.25% bupivacaine.
223555127|NCT06257667|OTHER|Respiratory Support|Treatment with High Flow Nasal Cannula
223555128|NCT03983265|OTHER|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
223555129|NCT03900104|PROCEDURE|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
223555130|NCT03900104|PROCEDURE|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
223736565|NCT02297074|OTHER|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
223555131|NCT02897037|DRUG|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
223555132|NCT02897037|DRUG|heparin|heparin monotherapy
223555133|NCT04331340|OTHER|Pharmacist review of LUTS|Pharmacist review and recommendations, including education, behaviour, lifestyle, or medications
223555134|NCT04331340|OTHER|Pharmacist Provision of healthy aging leaflets|Pharmacist will inquire about presence of LUTS and provide patient with healthy aging leaflets
223555135|NCT03541967|DEVICE|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
223555136|NCT00006447|PROCEDURE|Social Support|
223555137|NCT02753907|DIETARY_SUPPLEMENT|Low LA|Individuals who replaced 10 mL soy oil with one apple
223736566|NCT02297074|OTHER|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
224132407|NCT06897722|DIAGNOSTIC_TEST|TNF-α analysis in GCF|The primary intervention will involve the non-invasive collection of GCF samples using Periopaper strips. The strips will be placed into the gingival sulcus for 30 seconds and then stored at -80°C until analysis. The analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
223404348|NCT06948084|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223404349|NCT06948084|DRUG|Carfilzomib|Given IV
223404350|NCT06948084|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
223404351|NCT06948084|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
223404352|NCT06948084|DRUG|Dexamethasone|Given PO or IV
223404353|NCT06948084|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG PET/CT
223404354|NCT06948084|DRUG|Pomalidomide|Given PO
223404355|NCT06948084|DRUG|Teclistamab|Given SC
223404356|NCT03293537|DIAGNOSTIC_TEST|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
223404357|NCT06893029|DIAGNOSTIC_TEST|Postural Response upon physical optokinetic stimulation|The physical optokinetic stimulation consists of rotating stimulation in either direction using a physical disc (de Vestel, et al., 2022; Guerraz et al., 2001; van Ombergen et al., 2016). The assessment is conducted in complete dark, unless the fluorescent dots (approx. 11% covered of the disc area.). The disc has a diameter of 1 m. Stimulation time per trial will be 30 s.
223404358|NCT06893029|DIAGNOSTIC_TEST|Postural Response upon virtual optokinetic stimulation|The virtual optokinetic stimulation is implemented in virtual reality goggles (Meta Quest 3, Meta Platforms, Menlo Park, CA, USA) applying oscillating and rotating stimulation in frontal and vertical axis with coherent or incoherent stimuli. The assessment in the virtual environment will be as similar as possible compared the physical stimulation. Hence, the virtual environment simulation complete dark, unless the fluorescent dots (approx. 15% covered of the disc area.). In addition to the rotating condition, the virtual dots are able to oscillate on the horizontal or vertical axis to create a more sensitive evaluation method than the physical one (Laurens et al., 2011). Stimulation time per trial will be 30 s.
223555138|NCT02753907|DIETARY_SUPPLEMENT|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
223555139|NCT06355947|OTHER|Cognitive cycling training|Cycling training conducted with cognitive tasks
223555140|NCT06355947|OTHER|Cognitive treadmill training|Treadmill training conducted with cognitive tasks
223555141|NCT02973204|DRUG|Sorafenib|
223555142|NCT02973204|PROCEDURE|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
223555143|NCT02973204|DRUG|Everolimus|
223555144|NCT02973204|DRUG|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
223555145|NCT05205538|OTHER|Sprint interval exercise training|A 10-minute sprint interval exercise training protocol that is performed three times per week for a total of 12 weeks.
223555146|NCT02727387|DRUG|TEMIRI|Window therapy frontline for VHR patients
223555147|NCT02727387|DRUG|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
223555148|NCT02727387|DRUG|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
223555149|NCT02727387|DRUG|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
223555150|NCT02727387|DRUG|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
223404359|NCT07140731|DEVICE|Symani Surgical System|To assess the safety and effectiveness of the Symani Surgical System
223404360|NCT07151833|DIETARY_SUPPLEMENT|GlucoBites (with Gynura procumbens)|Participants receive 4 cookies per day for 12 weeks. The cookies contain standardized Gynura procumbens extract.
223555151|NCT02727387|DRUG|BUMEL|Consolidation phase
223555152|NCT02727387|DRUG|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
223555153|NCT05151432|DEVICE|Pulsed Ultrasound|Active US therapy will be administered using a device 4cm², 1- MHz US with a sound-head area of effective 4cm, radiating area of 3.5 to a beam non-uniformity ratio of cm². 5:1, and a therapeutic dose of approximately 112.5J/ That is, the pulsed US will be delivered for 9.5 minutes with a peak intensity of 1W/cm² at a 20% duty cycle, to achieve a spatial-temporal average intensity of 0.2W
223555154|NCT05151432|DEVICE|Pulsed Electromagnetic field|The patient's knee will be placed between 2 plates coil applicator generating a magnetic field intensity of 1.5 mT and a frequency of 75Hz.
223555155|NCT05151432|OTHER|Traditional exercise program|Stretching exercises, Isometric quadriceps exercise, Straight leg raising (SLR) exercise, Isometric hip adduction exercise, Hip abductor strengthening, Hip extensor strengthening, Hip external rotator strengthening
223555156|NCT05151432|DEVICE|Sham Pulsed US & Electromagnetic field|The patients will receive Sham Pulsed US \& Electromagnetic field.
223555157|NCT06035575|BEHAVIORAL|Educational video|Development of the original video used a systematic approach that included a review of literature and current pain management guidelines and input from emergency physicians, geriatricians, and experts in pharmacology, physical therapy, and risk communication. The video offers information about the pharmacologic management of acute musculoskeletal pain (MSP) and recovery-promoting behaviors. Each video section is followed by a multiple-choice question to promote interaction and reinforce learning. The actress for the 13-minute video is a 56-year-old mixed-race woman who presents herself as a healthcare provider. The video script will typically be shown to the patient within 48-72 hours of the acute care visit, with a maximum window of 5 days post visit.
223555158|NCT03430843|DRUG|Tislelizumab|200 mg administered intravenously (IV)
223736567|NCT02297074|OTHER|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
223404361|NCT07151833|DIETARY_SUPPLEMENT|Control Cookies (without Gynura procumbens)|Participants consume 4 cookies per day for 12 weeks. The cookies are identical in packaging, size, weight, and flavor to the GlucoBites cookies but do not contain Gynura procumbens.
223404362|NCT07151885|DIAGNOSTIC_TEST|SHAPE|Use an ultrasound probe to scan the liver to locate the portal vein and hepatic vein. In the angiography mode, the portal vein and hepatic vein of the same depth were selected for measurement respectively. Ultrasound contrast agent was injected through the elbow vein to observe the changes of sub-harmonic signals in the portal vein and hepatic vein. Collect the sub-harmonic signal data of the portal vein and hepatic vein, and calculate the difference between the two, that is, the SHAPE gradient.
223555159|NCT03430843|DRUG|Paclitaxel|135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
223555160|NCT03430843|DRUG|Docetaxel|75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
223555161|NCT03430843|DRUG|Irinotecan|125 mg/m\^2 administered IV
223736568|NCT02297074|OTHER|Glucose|50 g of glucose were administered as a reference
223555163|NCT03608371|DRUG|BTRX-246040|oral capsule
223555164|NCT03608371|DRUG|Placebo|oral capsule matching BTRX-246040 capsule
223555165|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
223555166|NCT03415594|DRUG|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
223555167|NCT03415594|DRUG|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
223555168|NCT06067685|OTHER|Observation|Prospective Observation only. Will record serum triglyceride, fingerstick blood triglyceride measurements, cord c-peptide, and neonatal body fat composition measurements in the first 6 months.
223736569|NCT00165347|DRUG|PTK787/ZK222584|
223736570|NCT02083952|OTHER|Swaddle Blanket|Two arms involve varying time spent in blanket
223736571|NCT00874965|DEVICE|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
223736572|NCT00874965|DEVICE|Sham stimulation|30 min; 5 times / week
223555169|NCT05244603|BEHAVIORAL|Ideal binary mask|Speech in noise processed by ideal binary mask to reduce background noise
223555170|NCT00800696|PROCEDURE|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
223555171|NCT03944564|BEHAVIORAL|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
223555172|NCT03944564|BEHAVIORAL|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
223555173|NCT03944564|BEHAVIORAL|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
223555174|NCT02752919|DRUG|Galunisertib|Administered orally
223555175|NCT00708136|BEHAVIORAL|water based training program to improve balance|
223555176|NCT02679937|BEHAVIORAL|Fit4Duty|Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
223736573|NCT01286181|BEHAVIORAL|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
223736574|NCT04489329|DEVICE|Ingestible Capsule|Participants will swallow capsule and undergo X-rays to establish transit
223736575|NCT04489329|DIETARY_SUPPLEMENT|Probiotic|Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
223736576|NCT04334720|OTHER|Comprehensive treatment of tumor|According to the pathologic types and TNM stage of tumor，specialists chose one or more of the interventions in surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.
224022424|NCT02776384|OTHER|Observational study|
224022425|NCT04230291|BEHAVIORAL|Verbal consultation|Verbal consultation only without written information before receiving written action plan
224022426|NCT04230291|BEHAVIORAL|Written Action Plan|Written handout of treatment plan and disease management strategies
224022427|NCT00441662|DRUG|Sub-Tenon triamcinolone 40mg|
224022428|NCT00462332|DRUG|Fludarabine|Induction therapy
224022429|NCT00462332|DRUG|Campath|Induction therapy
224022430|NCT00462332|PROCEDURE|Transplant|Post-induction therapy
223736577|NCT02323477|BIOLOGICAL|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
223736578|NCT02520401|OTHER|Probiotic - BioGaia|Use of a probiotic tablet
223736579|NCT02520401|OTHER|Placebo|Use of a placebo tablet
223736580|NCT01829230|DEVICE|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
223555177|NCT02679937|OTHER|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
223736581|NCT01907204|DRUG|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
223555178|NCT05984745|DRUG|Coenzyme Q10 Forte® capsules|Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
223555179|NCT06788106|BEHAVIORAL|high-intensity aerobic exercise + synchronous music|This group will be intervened under high-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
223555180|NCT06788106|BEHAVIORAL|medium-intensity aerobic exercise + synchronous music|This group will be intervened under medium-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
223555181|NCT06788106|BEHAVIORAL|low-intensity aerobic exercise + synchronous music|This group will be intervened under low-intensity aerobic training with synchronous music for 8 weeks, 3 times every week, 40 minites each time.
223555182|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 1|"Participants will complete 4 cycles. For each cycle they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Inulin."
223555183|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 2|"Participants will complete 4 cycles. For each cycle they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Resistant Starch."
223555184|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 3|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Inulin."
223555185|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 4|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Beta-Glucan."
223555186|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 5|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Resistant Starch."
223555187|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 6|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Arabinoxylan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Beta-Glucan."
223555188|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 7|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Inulin."
223736582|NCT01907204|DRUG|Budesonide|Budesonide by metered dose inhaler
223736583|NCT01907204|DRUG|Budesonide|Budesonide by nebulization
223736584|NCT01272414|DRUG|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
223736585|NCT01272414|DRUG|Saline injection|Injection of 0.4cc 0.9% normal saline
223736586|NCT00045123|DRUG|tarenflurbil|
223736587|NCT00045123|PROCEDURE|adjuvant therapy|
223736588|NCT04969120|DRUG|Metoclopramide 10mg|this group receive 10mg intravenous metoclopramide slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
223736589|NCT04969120|DRUG|Placebo (0.9 sodium chloride)|this group receive 10mg intravenous placebo(0.9 sodium chloride) slowly over 2 minutes the medication will be repeated every 2 hours for a maximum three doses
223736590|NCT03144362|PROCEDURE|Bilateral Sliding Techniques|Bilateral Sliding Techniques
223736591|NCT03144362|PROCEDURE|Unilateral Sliding Techniques|Unilateral Sliding Techniques
223736592|NCT00757744|BEHAVIORAL|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
223736593|NCT00757744|BEHAVIORAL|Drug counseling|individual drug counseling
223736594|NCT00783250|DRUG|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
223736595|NCT00783250|DRUG|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
223736596|NCT01243879|OTHER|Stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
223736597|NCT01243879|OTHER|No stimuli of food smell and vision|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
223736598|NCT01463553|PROCEDURE|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
223736599|NCT06320028|DEVICE|Non-Invasive Transcranial Focused Ultrasound|The ultrasound will be delivered for 10 minutes per treatment session targeting to the participant's amPFC.
223404363|NCT07151612|DRUG|Esculin and Digitalisglycosides Eye Drops|Interventions were performed using esculin and digitalis glycosides eye drops (Pharma Stulln GmbH). The carer instructed the patient to apply 1 drop to the affected eye three times a day and to strictly follow aseptic techniques to prevent contact of the dropper with the ocular surface. The treatment lasted for 1 month.
223404364|NCT07151612|DRUG|Normal saline solution|Sterile, preservative-free, and non-irritating dropper saline was used. The carer instructed the patient to apply 1 drop to the affected eye three times a day and to strictly follow aseptic techniques to prevent contact of the dropper with the ocular surface.
223555189|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 8|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Resistant Starch."
223555190|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 9|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Arabinoxylan."
223555191|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 10|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Inulin."
223555192|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 11|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Resistant Starch."
223736600|NCT04501666|DRUG|Nemolizumab 30 mg|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
223736601|NCT04501666|DRUG|Placebo|Participants received matching placebo as SC injection.
223736602|NCT04337125|OTHER|Neuropsychological and attachment/parenting assessment|"Children assessments:~Mental health assessment, Intellectual functioning assessment, Sleep patterns assessment, Behavior assessment, Severity of ADHD symptoms assessment, child attachment assessment, parenting practices assessment, emotional regulation assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment~Parents assessments:~Mental health assessment, Intellectual functioning assessment, ADHD symptoms assessment, Depression symptoms assessment, Attachment style assessment, Direct measures of attention and executive functions assessment, Indirect measures of attention and executive functions assessment."
223736603|NCT03021265|DRUG|T80/A5/H12.5 FDC|Drug
223736604|NCT05072574|OTHER|Specific dietary treatment and follow-up using coaching techniques|Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
223736605|NCT05712928|BEHAVIORAL|Dance/movement therapy (eMove)|Ten weekly 60-minute individual dance/movement therapy telehealth sessions (eMove) delivered by a board-certified dance/movement therapist. eMove treatment protocol integrates movement techniques, creative embodiment, the non-verbal aspects of self-awareness and interpersonal communication in treatment. eMove sessions focus on helping the participant to increase physical activity level, increasing participants' energy levels and motivation to stay active and better cope with everyday activities, improving overall functioning; reducing severity of negative symptoms of schizophrenia; and providing participants with a sense of connection and social support by connecting with a therapist. In addition, sessions are individualized to the participant's presenting needs.
223736606|NCT00642941|DRUG|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
223736607|NCT01338493|PROCEDURE|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
223736608|NCT03834701|DEVICE|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
223736609|NCT00941473|DRUG|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
223736610|NCT05339594|DEVICE|NeuraGen|NeuraGen nerve guide is an absorbable implant for the repair of peripheral nerve gaps.
223736611|NCT05339594|DEVICE|NeuraGen 3D|NeuraGen 3D Nerve guide matrix is a resorbable implant for the repair of peripheral nerve gaps.
223736612|NCT01778829|PROCEDURE|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
223736613|NCT01778829|PROCEDURE|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
223736614|NCT02269020|PROCEDURE|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
223736615|NCT00656474|DRUG|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
223736616|NCT00656474|DRUG|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
223736617|NCT00447161|DRUG|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
223736618|NCT00447161|DRUG|Placebo|Matched placebo
223736619|NCT01988857|BIOLOGICAL|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
223736620|NCT02567942|DRUG|propofol group|Patient will be anesthetized by using propofol infusion during operation
223736621|NCT02567942|DRUG|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
223736622|NCT04506489|OTHER|Psychological investigation|Psychological tests, psychological interviews.
223736623|NCT06376799|OTHER|Self-questionnaire|Provision of a self-questionnaire in digital or paper format for the patient. The patient will be asked to indicate their preferences regarding the primary and secondary objectives of the study.
223736624|NCT01614067|DRUG|Ganirelix acetate|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
224022431|NCT00462332|DRUG|Campath|Post-induction therapy
224022432|NCT00462332|DRUG|Fludarabine|Induction therapy
224022433|NCT00462332|DRUG|Campath|Induction therapy
224132408|NCT06897722|DIAGNOSTIC_TEST|IL-17A analysis in GCF|The primary intervention involves the non-invasive collection of GCF samples using periopaper strips. Periopaper strips are placed into the gingival sulcus for 30 seconds, then stored at -80°C until analysis. Analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
223404365|NCT07152782|DRUG|Neratinib|Neratinib, as an irreversible pan-HER tyrosine kinase inhibitor (TKI), holds a unique position in the treatment of HER2-positive breast cancer. From a molecular perspective, Neratinib irreversibly binds to the intracellular kinase domains of HER1 (EGFR), HER2, and HER4 through covalent bonds, comprehensively blocking signal transduction of the HER family. This mechanism of action is markedly different from reversible TKIs such as lapatinib. Neratinib's irreversible binding characteristic allows for a more sustained inhibition of target activity, maintaining anti-tumor effects even after drug plasma concentrations have decreased. This feature is particularly important for HER2-positive breast cancer, which requires continuous suppression of proliferative signals.
223555193|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 12|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Beta-Glucan. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Arabinoxylan."
223555194|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 13|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Arabinoxylan."
223736625|NCT02152839|BEHAVIORAL|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
223736626|NCT03838822|DIETARY_SUPPLEMENT|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
223736627|NCT05695690|DEVICE|Ultrasonography|Comparing between value of ultrasound vs MRI in uterine fibroids
223736628|NCT00751244|BEHAVIORAL|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford \& Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
223736629|NCT00751244|BEHAVIORAL|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
223736630|NCT00751244|OTHER|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
224022434|NCT00462332|DRUG|Campath|Post-induction therapy
224022435|NCT00067509|DRUG|emergency contraception (estrogen/progesterone)|
224022436|NCT01261637|DRUG|Saline placebo|20ml saline
224132409|NCT06897722|DIAGNOSTIC_TEST|YKL-40 analysis in GCF|The primary intervention involves the non-invasive collection of GCF samples using periopaper strips. Periopaper strips are placed into the gingival sulcus for 30 seconds, then stored at -80°C until analysis. Analysis of TNF-α levels in gingival crevicular fluid (GCF) will be performed using ELISA.
224022437|NCT01261637|DRUG|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
224022438|NCT01049932|DRUG|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
224022439|NCT02700477|DIETARY_SUPPLEMENT|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
224022440|NCT02700477|OTHER|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
224022441|NCT02918227|PROCEDURE|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
224022442|NCT02822144|DRUG|Etomidate|
224022443|NCT02822144|DRUG|Succinylcholine|
224022444|NCT02822144|DRUG|Propofol|
224022445|NCT02822144|DRUG|Remifentanil|
224022446|NCT02822144|DRUG|Lidocaine|
224022447|NCT02250092|DEVICE|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
223404366|NCT07152782|DRUG|Trastuzumab Deruxtecan|"Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 monoclonal antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor (an exatecan derivative). It targets and binds to HER2-positive tumor cells, internalizes, and releases cytotoxic drugs to induce DNA damage and apoptosis. It also has a bystander effect that can kill neighboring tumor cells with low HER2 expression, enhancing anti-tumor activity. T-DXd has shown significant efficacy in HER2-positive advanced breast cancer, with key clinical trials (such as DESTINY-Breast03) confirming that its progression-free survival (PFS) and overall survival (OS) are superior to traditional second-line treatments, with a median PFS reaching 28.8 months. Additionally, for HER2-low-expressing (IHC 1+ or 2+/ISH-) metastatic breast cancer (in the DESTINY-Breast04 study), T-DXd can extend PFS and OS, becoming the first targeted therapy to alter the survival outcomes of such patients"
223404367|NCT07151625|OTHER|Diet, whole food provided to participants over 5 x 9 day period|5 diets provided to participants over 9 days each and whole body protein synthesis, protein breakdown and protein balance assessed after each period.
224022448|NCT02250092|DEVICE|Placebo Comparator|
223555195|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 14|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Inulin. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Beta-Glucan."
223736631|NCT02415751|BEHAVIORAL|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
223736632|NCT03627754|DRUG|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
223736633|NCT04892888|BIOLOGICAL|COVID-19 Vaccine|COVID-19 Vaccine Intramuscular Injection
223736634|NCT03935191|DEVICE|Dexcom CGM System|Dexcom CGM System
224132410|NCT06897722|DIAGNOSTIC_TEST|TNF-α analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
224132411|NCT06897722|DIAGNOSTIC_TEST|İL-17A analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
224132412|NCT06897722|DIAGNOSTIC_TEST|YKL-40 analysis in Serum|The intervention will involve venous blood collection for serum analysis. Venous blood will be drawn, allowed to clot, will be centrifuged at 3,000 rpm for 10 minutes, and will be stored at -80°C until analysis.
224132413|NCT06897722|DIAGNOSTIC_TEST|Periodontal assesment|Comprehensive periodontal assessments will be conducted, including Plaque Index (PI), Bleeding on Probing (BOP), Probing Pocket Depth (PPD), and Clinical Attachment Level (CAL).
224132414|NCT03273738|DIAGNOSTIC_TEST|folate level measurement|the level of folate measured in plasma with homocysteine
223736635|NCT00563511|PROCEDURE|adherence intervention|
224132415|NCT03273738|DIAGNOSTIC_TEST|B12|B12 measurement in blood
224132416|NCT02813798|DRUG|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
224132417|NCT07080125|DRUG|Ofev®|Ofev®
224132418|NCT07082231|OTHER|Blood sample|3 blood samples
223404368|NCT07151625|OTHER|Diet|5 different diet types
223404369|NCT07153211|DIAGNOSTIC_TEST|Immunological Factors|Assessment of interleukins and other molecues in CSF and blood of patients with SCS.
223555196|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 15|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Beta-Glucan."
223736636|NCT00563511|PROCEDURE|intervention without adherence advice|
223736637|NCT00563511|PROCEDURE|control|
223736638|NCT06136923|DEVICE|CT-100-D-004-A|Attention Biases App CT-100-D-004-A Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
223736639|NCT06136923|DEVICE|CT-100-D-004-B|Attention Biases App CT-100-D-004-B Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to redirect and strengthen attention processes. This intervention can help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli.
223736640|NCT04053192|PROCEDURE|BAV|BAV
223736641|NCT04053192|PROCEDURE|BAV + TAVR|BAV + TAVR
223736642|NCT04053192|PROCEDURE|SAVR|Surgical aortic valve replacement (SAVR)
223736643|NCT00056407|DRUG|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
224022449|NCT03997084|OTHER|phone interviews|phone interviews
224022450|NCT01911598|DRUG|5-FU|5-FU will be administered as per schedule specified in the respective arm.
224022451|NCT01911598|DRUG|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
224022452|NCT01911598|DRUG|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
224022453|NCT01911598|DRUG|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
224022454|NCT01911598|DRUG|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
224132419|NCT07082231|PROCEDURE|biopsy|3 pairs of biopsy realised during the coloscopy
224132420|NCT07083310|BEHAVIORAL|Health Education|Structured group education focused on breast cancer awareness, risk reduction, and early detection.
223404370|NCT07152717|DEVICE|A connected-health, pressure-sensing system for monitoring sub-bandage pressure during compression therapy|The Tight Alright system, developed by FeelTect Limited, consists of a wearable, pressure sensing device that measures sub-bandage pressure at three regions along the length of the lower leg. The wearable device transmits data wirelessly to a mobile app on a smart device, which then displays the data in real-time. The mobile app is also capable of transmitting data to a remote cloud database, via the internet, where it can be viewed on a remote dashboard (i.e., via a secure webpage).
223404371|NCT07151638|DEVICE|Implantation (injection) of a new biomatrix for soft tissue support.|Implantation of a new injectable medical device, Fractomer Biomatrix, to study the safety of the product in healthy human participants.
223404372|NCT07151781|OTHER|Video-guided Mindfulness Exercise|Mindfulness interventions are emerging as effective, low-risk approaches to managing depression and enhancing emotional and maternal well-being in pregnant women. Rooted in ancient meditative practices that originated from Buddhist religion and traditions and adapted for clinical use, mindfulness intervention cultivates present-moment awareness and nonjudgmental acceptance of thoughts, emotions, and bodily sensations. Mostly, mindfulness interventions include elements such as mindful breathing and body scanning and have shown effectiveness in reducing depressive symptoms and enhancing emotional regulation. It is the ability to maintain attention to an immediate experience with a sense of adopting an open and accepting attitude toward that experience. However, further research is important to evaluate its effectiveness across diverse sociodemographic and socioeconomic settings.
223404373|NCT07152288|DRUG|HSK39297 tablets|oral
223404374|NCT07152288|DRUG|HSK39297 tablets|oral
223404375|NCT07152288|DRUG|HSK39297 tablets|oral
223404376|NCT07153185|DEVICE|Dental Barrier Membrane|Patients treated with creos xenoprotect dental barrier membrane in the past
223404377|NCT07151729|DEVICE|Anodal tDCS|This anodal tDCS is applied over the contralateral dorsal premotor cortex (instead of the ipsilateral motor cortex in previous studies).
223404378|NCT07151729|DEVICE|Sham tDCS|Sham tDCS is applied
223404379|NCT07151352|OTHER|Starting Condition - Barefoot|Participants walk barefoot along a 10-meter walkway without wearing shoes or socks.
223404380|NCT07151352|OTHER|Barefoot-Style Footwear|Participants walk along a 10-meter walkway wearing minimalist footwear with a 3 mm flexible sole, 0 mm heel drop, wide toe box, and no rigid heel counter.
223404381|NCT07151352|OTHER|Conventional Footwear with Heel Drop|Participants walk along a 10-meter walkway wearing structured footwear with a rigid sole (12 mm heel / 7 mm forefoot), 5 mm heel drop, reinforced heel counter, and narrow toe box.
223404382|NCT07152561|DRUG|Zirconia crown cemented with Predicta® Bioactive Cement|• For the bioactive cement group (Predicta® Bioactive Cement), the prepared tooth will be dried using compressed air but not desiccated. Cement will be dispensed through the auto-mixtip directly into the crown, and the crown will be properly positioned over the tooth; cement will be allowed to self-set for 20 seconds while maintaining gentle pressure on the crown. Buccal and lingual margins will be flash-cured for 10 seconds each using a light-curing unit to immediately cure the excess cement for easier removal, and buccal and lingual surfaces will then be light-cured for an extra 10 seconds each.
223404383|NCT07152561|DRUG|Zirconia crown cemented with resin-cement|• For the resin-cement group, the tooth will be dried with compressed air but not desiccated. The sealant will be applied with the syringe; then, the crown will be appropriately positioned over the tooth, and cement will be allowed to self-set for 2 minutes and cured while maintaining gentle pressure on the crown. Excess cement will be removed before the cement is completely set.
223404384|NCT07152600|DRUG|Saline (0.9%, sterile, for infusion)|Sailine as control
223404385|NCT07152600|DRUG|low dose Methylprednisolone|Methylprednisolone 0.5mg/kg ivgtt qd
223404386|NCT07152600|DRUG|Moderate dose Methylprednisolone|Methylprednisolone 1.0mg/kg ivgtt qd
223404387|NCT07151209|DRUG|Iparomlimab and Tuvonralimab combined with lenvatinib and SOX|Iparomlimab and Tuvonralimab:5 mg/kg Q3W lenvatinib:8 mg/day orally SOX：oxaliplatin (130 mg/m² Q3W intravenous infusion), and S-1 (40 mg/m² BID orally on days 1-14)
223404388|NCT07151157|DRUG|add-on sirolimus therapy|On the basis of the existing treatment, oral sirolimus will be added at a dose of two capsules per day, one in the morning and one in the evening.
223404389|NCT07152964|DEVICE|Caliper|Measure medial rectus tendon width with caliper intraoperative
223404390|NCT07152886|DRUG|Clostridium butyricum capsules|Clostridium butyricum capsules , 6 capsules tid (each capsule containing ≥6.3 × 10⁶ CFU of Clostridium butyricum).
223404391|NCT07152886|OTHER|placebo capsules|Oral administration of placebo capsules, 6 capsules tid., containing corn starch. The appearance and weight of the placebo capsules are identical to those of intervention group.
223736644|NCT00056407|DRUG|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
223736645|NCT04646798|OTHER|Hemiarthroplasty|standard surgical approaches to repair of fractured elbows
223736646|NCT04646798|OTHER|Total elbow arthroplasty|standard surgical approaches to repair of fractured elbows
223736647|NCT02158104|PROCEDURE|Deep dry needling|
223736648|NCT03666845|PROCEDURE|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
224132421|NCT07083310|BEHAVIORAL|Motivational Interviewing|Individual counseling sessions using motivational interviewing to enhance screening behavior.
223736649|NCT02967497|DRUG|YQ1|Oral administered powder
223736650|NCT03447756|DRUG|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
223736651|NCT03447756|DRUG|Placebo oral capsule|placebo to match
223736652|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
223736653|NCT00616655|DRUG|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
223736654|NCT00616655|DRUG|Placebo|Placebo total daily dose 0.9 mg
223404392|NCT07151599|DEVICE|Microneedling|Microneedling performed with an electronic pen and sterile disposable cartridge with 12 needles and 2mm depth, three treatment sessions at four-week intervals.
223404393|NCT07151599|DEVICE|Fractionated Er:Glass Laser combined to Fractionated Thulium Laser|Fractional Erbium:Glass laser will be applied first, focused on scarred areas (50 mJ, 15 ms e 100 PPA) , followed immediately by fractional Thulium 1927 nm over the full face (10 mJ, 1 ms e 100 PPA), three treatment sessions at four-week intervals.
223404394|NCT07153159|DRUG|Etrasimod|Oral 2 milligrams tablet, once a day for 7 days
223404395|NCT07151742|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|"Participants in this arm will receive a 12-week intradialytic combined exercise program, performed three times per week during the first two hours of hemodialysis. Each session will begin with a 10-minute warm-up and end with a 10-minute cool-down (stretching and breathing exercises).~Aerobic component: Supine cycling using a portable ergometer at 45-70% of maximum heart rate, monitored with pulse oximetry and Borg scale, progressively increased every 1-2 weeks.~Resistance component: Exercises with elastic bands and ankle weights targeting major upper and lower extremity muscle groups (non-fistula arm). Performed in 2 sets of 8-12 repetitions, with progressive loading based on ACSM guidelines.~All sessions will be supervised by trained physiotherapists and dialysis staff to ensure safety and adherence"
223404396|NCT07151443|PROCEDURE|Conventional approach to infraclavicular block|Conventional approach to infraclavicular block will be performed on the patients using 20 ml of 0.5% bupivacaine 5ml of %2 lidocaine under ultrasound guidance.
223404397|NCT07151443|PROCEDURE|Retroclavicular approach to the infraclavicular block|Retroclavicular approach to the infraclavicular block will be performed on the patients using 20 ml of 0.5% bupivacaine 5ml of %2 lidocaine under ultrasound guidance.
223404398|NCT07149415|DRUG|Omaveloxolone|Oral capsules
223404399|NCT07149415|DRUG|Omeprazole|Oral tablet
223555197|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 16|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Inulin."
223736655|NCT00867425|BEHAVIORAL|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
223736656|NCT02181439|DEVICE|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
224132422|NCT07084545|DEVICE|CT LUCIA 621P Intraocular Lens Implantation|The intervention consists of bilateral implantation of the CT LUCIA 621P intraocular lens (IOL) during routine cataract surgery in patients with a history of myopic corneal laser vision correction. The CT LUCIA 621P IOL is an approved, single-piece, hydrophobic acrylic lens designed to provide improved visual quality and refractive stability. Implantation is performed following each investigator's standard surgical procedures, including preoperative preparation, operative technique, and postoperative care. IOL power calculation uses the ZEISS Cataract Workflow platform with the VERACITY system and Barrett True-K with TK formula, incorporating the VERION Optical Coherence (VOC) technology.
224132423|NCT07082088|DEVICE|the test group were placed in an Argon plasma reactor|the test group were placed in an Argon plasma reactor
223736657|NCT00003150|BIOLOGICAL|rituximab|
223736658|NCT00003150|DRUG|CHOP regimen|
223736659|NCT00003150|DRUG|cyclophosphamide|
223736660|NCT00003150|DRUG|doxorubicin hydrochloride|
223404400|NCT07152418|BIOLOGICAL|Lecanemab 10 mg/kg|Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.
223404401|NCT07152418|DRUG|Conventional anti-dementia treatment group|Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.
223404402|NCT07153354|DEVICE|patient-specific screw holes locating surgical guide and pre-bent plates|Virtual reduction of the fracture will be done, followed by 3D printing of the corrected mandible model. Plates will be pre-bent on the model, then scanned in position to create a surgical guide for accurate screw hole placement during surgery.
223404403|NCT07153354|DEVICE|2 titanium per-bent mini plates|The fixation will be performed according to established surgical principles for managing class iv mandibular fractures, without patient-specific planning
223555198|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 17|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Inulin. On cycle 4, they will take 20g per day of Arabinoxylan."
223736661|NCT00003150|DRUG|prednisone|
223736662|NCT00003150|DRUG|vincristine sulfate|
223736663|NCT03474354|DEVICE|chemoembolization|correlation of necrosis with the deposition of beads
223736664|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics|pharmacogenomics
223736665|NCT04207385|DIAGNOSTIC_TEST|pharmacogenomics & therapeutic drug monitoring|pharmacogenomics \& therapeutic drug monitoring
223404404|NCT07152028|OTHER|Exercise program with supervised and home-based components|The 12-week program targets balance, muscular strength, core endurance, and cardiovascular fitness. Weeks 1-6 are supervised; weeks 7-12 are home-based via a video catalogue. Walking ≥30 min on ≥2 non-training days is advised. Intensity, repetitions, and sets are individualized using Borg CR-6-20. Adherence is monitored via exercise diaries and weekly phone calls with adjustments as needed.
223736666|NCT04207385|DRUG|Venlafaxine|Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning
223404405|NCT07152028|OTHER|Fully supervised exercise program|The 12-week program is fully supervised and includes warm-up, balance, aerobic, strength, and core exercises. Walking ≥30 min on ≥2 non-training days is included. Intensity, repetitions, and sets are individualized using Borg CR-6-20. Adherence is monitored by a physiotherapist using exercise diaries.
223404406|NCT07152067|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT to the macroscopic prostate tumor component defined at MRI
223404407|NCT07151859|DEVICE|PN30 (RDM16)|PN30 is a viscoelastic, sterile gel, in a disposable prefilled syringe for intradermal infiltration.PN30 contains polynucleotides (3%). The polynucleotides contained in the device are substances of natural, fish-derived origin, highly purified.
223404408|NCT07153094|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
223404409|NCT07155746|OTHER|Incremental walking exercise on an AlterG treadmill (anti-gravity)|One visit with their current weight (BW) One visit with simulated weight loss in adolescents to determine their normal weight (NW-SBW) One visit with simulated weight loss in adolescents to determine their overweight status (OW-SBW).
223555199|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 18|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Resistant Starch. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Inulin."
223555200|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 19|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Beta-Glucan."
223555201|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 20|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Resistant Starch. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Arabinoxylan."
223555202|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 21|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Arabinoxylan."
223555203|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 22|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Beta-Glucan. On cycle 3, they will take 20g per day of Arabinoxylan. On cycle 4, they will take 20g per day of Resistant Starch."
223555204|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 23|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Beta-Glucan. On cycle 4, they will take 20g per day of Resistant Starch."
223555205|NCT03925597|DIETARY_SUPPLEMENT|Fiber cycles ARM 24|"Participants will complete 4 cycles. For each cycle, they will take 20g per day fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks.~On cycle 1, they will take 20g per day of Inulin. On cycle 2, they will take 20g per day of Arabinoxylan. On cycle 3, they will take 20g per day of Resistant Starch. On cycle 4, they will take 20g per day of Beta-Glucan."
223555206|NCT05355909|PROCEDURE|Individualized high intensity preoperative fitness training|The individualised training program consists of stamina training, interval training and strength training. The personalised fitness training will be designed based on the FITT-VP (frequency, intensity, time, type, volume, progression) of the American College of Sports Medicine (ACSM) and will contain 6 training session within 2 weeks under supervision of professional sport physicians.
223555207|NCT05275608|DIETARY_SUPPLEMENT|VLCKD diet with replacing meals|Patients will receive an accurate teaching + brochure on VLCKD diet from an expert dietician and freely receive the correct amount of supplements provided from Labotaoire Therascience (4 or 5 meals). The supplements contain (in total) between 600 and 800 kcal, mainly fats, 1,2/1,5 g/body weight of proteins, very low amount of charbohydrates (\<30/40g/die), 10-20g fibers, + minerals and vitamins covering the needings of patients. After 6-8 weeks, 1 meal will be replaced with a natural dish rich in proteins.
223555208|NCT05275608|BEHAVIORAL|Hypocaloric mediterranean Diet|Patients will receive an accurate teaching + brochure on an hypocaloric Mediterranean style diet (LARN 2014) from an expert dietician. Patients will follow the istructions on grams and foods to eat. The calories will be around minus 400-500 kcal from energy requirement (measured by indirect calorimetry \* physical activity score).
223555209|NCT06320678|OTHER|Nursing Students Education|Effect of Concept Mapped Blended Learning Self-Directed Learning
223555210|NCT00497419|PROCEDURE|fast track|
223555211|NCT05056805|OTHER|Aerobic Exercise|Receive aerobic exercise encouragement
223555212|NCT05056805|OTHER|Dietary Intervention|Consume high protein snack/meal/shake
223555213|NCT05056805|OTHER|Nutritional Intervention|Receive nutritional consultation and guidelines
223555214|NCT05056805|OTHER|Quality-of-Life Assessment|Ancillary studies
223555215|NCT05056805|OTHER|Questionnaire Administration|Ancillary studies
223555216|NCT05056805|OTHER|Resistance Training|Complete strengthening exercise
223404410|NCT07151131|OTHER|Watching Cartoons|"Cartoon Group Intervention Children assigned to the cartoon group will be taken from the clinic to the preoperative room. Approximately 30 minutes before being transferred to the operating room, children will be allowed to watch a cartoon of their choice on a 60-inch screen TV placed approximately 200 cm away. The duration of the cartoon viewing session will be limited to 20 minutes.~The measurement tools used in the study will be administered at five different time points:~Immediately before watching the cartoon,~Immediately after watching the cartoon but before being transferred to the operating room,~In the postoperative period at the 60th minute,~At the 120th minute postoperatively,~And finally, at the discharge phase."
223736667|NCT05969873|OTHER|Pilates exercise|Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
223736668|NCT05969873|OTHER|Balance training|Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
223736669|NCT01455337|DRUG|pentoxifylline|400mg tid
223736670|NCT01455337|DRUG|Prednisolone|40mg qd
223736671|NCT05067582|DRUG|L1-79|tyrosine hydroxylase inhibitor
223736672|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(non freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
223736673|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine(freeze-dried)|Live Attenuated Influenza Vaccine Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
223736674|NCT05284851|BIOLOGICAL|Live Attenuated Influenza Vaccine placebo|Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
223736675|NCT04274426|DRUG|Carboplatin|Carboplatin will administered by intravenous route
223736676|NCT04274426|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD will be administered by intravenous route
223404411|NCT07151131|OTHER|Reflexology|"Massage Group Intervention Children assigned to the massage group will be transferred from the clinic to the preoperative room. Approximately 30 minutes before being taken to the operating room, reflexology massage will be applied by the researcher physician Xxx XXXXX, who holds a valid reflexology certification. The massage will be administered to both the right and left feet, with 10 minutes per foot, for a total duration of 20 minutes.~The measurement tools used in the study will be applied at five distinct time points:~Before the massage,~Immediately after the massage but before operating room transfer,~In the postoperative period at the 60th minute,~At the 120th minute postoperatively,~And finally, during the discharge phase."
223404412|NCT07152340|DRUG|IBI311|IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
223404413|NCT07152340|DRUG|Glucocorticoids|500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
223404414|NCT07151300|DEVICE|Ultrasound therapy unit|Ultrasound therapy unit
223736677|NCT04274426|DRUG|Gemcitabine|Gemcitabine will be administered by intravenous route
223736678|NCT04274426|DRUG|Paclitaxel|Paclitaxel will be administered by intravenous route
223736679|NCT04274426|DRUG|Mirvetuximab Soravtansine|Mirvetuximab Soravtansine will be administered by intravenous route
224138778|NCT01422811|BEHAVIORAL|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~1. Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~2. Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
223404415|NCT07151300|BIOLOGICAL|Bee venom topical preparation (for phonophoresis)|Bee venom topical preparation (for phonophoresis)
223736680|NCT00319644|DEVICE|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
223736681|NCT05646797|DRUG|ASP2074|intravenous (IV) infusion
223736682|NCT01152086|OTHER|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~* Endurance training (performed within 70-85% of the maximum heart rate)~* Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~* Stretching after hiking (ca. 5 min)~* Short break at half-time (ca. 15 min)"
223736683|NCT02663674|DRUG|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
223736684|NCT02663674|OTHER|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
223736685|NCT02894931|DIETARY_SUPPLEMENT|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
223736686|NCT02894931|DIETARY_SUPPLEMENT|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
223736687|NCT02894931|DIETARY_SUPPLEMENT|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
223736688|NCT02894931|DIETARY_SUPPLEMENT|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
223736689|NCT02894931|OTHER|Control- water|Chilled water flavored with lemon juice as control
223736690|NCT05563896|OTHER|No intervention|No intervention
223736691|NCT03500445|DRUG|Daratumumab|"Daratumumab (16 mg/kg) will be administered as an IV infusion:~* Cycle 1-2: 16 mg/kg weekly~* Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~* Cycles 9-24: 16 mg/kg IV infusion Day 1"
223736692|NCT03500445|DRUG|Carfilzomib|"Carfilzomib will be given as an IV infusion over 30 minutes:~* Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~* Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~* Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16"
223404416|NCT07153172|DRUG|INV-347|Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.
223404417|NCT07151456|DRUG|Conventional 24-week glucocorticoid regimen|Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5 - 6: Prednisolone 0.8mg/kg/day (max 60mg); Weeks 7 - 8: Prednisolone 0.6mg/kg/day (max 50mg); Weeks 9 - 10: Prednisolone 0.5mg/kg/day (max 40mg); Weeks 11 - 12: Prednisolone 0.4mg/kg/day (max 30mg); Weeks 13 - 16: Prednisolone 0.3mg/kg/day (max 25mg); Weeks 17 - 20: Prednisolone 0.2mg/kg/day (max 15 Weeks 21 - 24: Prednisolone 0.1mg/kg/day (max 10mg).
223736693|NCT03500445|DRUG|Lenalidomide|"Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21"
223736694|NCT03500445|DRUG|Dexamethasone|"Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~* Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~* Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1"
223736695|NCT06426108|DRUG|Fluoride Varnishes|the investigators will utilize a fluoride varnish with a concentration of 22,600 ppm F. The application will be facilitated using a microbrush, ensuring thorough coverage over the entire length of the lesion for a duration of 30 seconds. Following application, the varnish will be finished with water to create a film on the tooth surface. After completing the interventions, patients will receive instructions to refrain from consuming hard foods and to postpone tooth brushing for at least four hours, adhering to the manufacturer's recommendations.
223404418|NCT07151456|DRUG|short-term course (12 week) glucocorticoid regimen|Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5-8: Prednisolone 1mg/kg/day (max 80mg) on alternate days; 9-12: Prednisolone 0.5mg/kg/day (max 40mg) on alternate days
223404419|NCT07151911|DRUG|abemaciclib, olaparib and endocrine therapy|Patients receiving abemaciclib, olaparib and endocrine therapy.
223404420|NCT07154368|DRUG|Pemetrexed injection|Randomization to either JYP0322 or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (JYP0322: platinum-based doublet-chemotherapy) ratio
223404421|NCT07154368|DRUG|Cross-over to JYP0322|Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by BICR, they will be given the opportunity to begin treatment with JYP0322 150mg tid. These subjects may continue treatment with JYP0322 if they are continuing to show clinical benefit until disease progression as judged by the investigator.
223404422|NCT07154368|DRUG|JYP0322 tablets|JYP0322, 150 mg, administered orally three times daily (tid) after meals; sample size (N) = 60.
223555217|NCT06959264|OTHER|Virtual reality|Patients in the study group will be shown a video with virtual reality glasses during the procedure. Patients will be asked to wear a virtual reality goggles (VR Shinecon G12 3d Virtual Reality Goggles Black 4.5-7.0 Inch) compatible with a mobile phone (Xiaomi Redmi Note 8 Pro 2019 model) with android operating system in supine position and minimizing sound loss. With the virtual reality goggles, nature landscapes with a relaxing music background will be watched by adjusting the volume at the level desired by the patient. Virtual reality goggles will be applied during the urodynamic procedure.
223555218|NCT01152125|OTHER|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
223555219|NCT01905943|DRUG|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
223555220|NCT01905943|DRUG|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
223555221|NCT01905943|DRUG|Cyclophosphamide|Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
223555222|NCT01905943|DRUG|Fludarabine|Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
223736696|NCT06426108|DRUG|Varnishes placebo|the investigators will apply a placebo varnish without the active ingredient (fluoride), ensuring that it is packaged identically to the fluoride varnish and has the same taste and texture, thus maintaining consistency in application. The varnish will be applied using a microbrush, spreading it evenly over the entire length of the lesion for a duration of 30 seconds. Following the interventions, patients will receive instructions to avoid consuming hard foods and to delay tooth brushing for at least four hours after applying the varnish.
223736697|NCT06426108|RADIATION|Low-Intensity Laser 1J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 1 Joule, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
223736698|NCT06426108|RADIATION|Low-Intensity Laser 2J|The tooth will undergo low-intensity laser irradiation in continuous mode, employing a wavelength of 808 nm, a power output of 100 mW, a dose of 2 Joules, and a fluence of 35 J/cm\^2. The laser will be positioned perpendicular to the tooth surface, targeting the cervical third of the buccal surface (both mesial and distal aspects), as well as the center of the lesion.
223404423|NCT07153302|OTHER|Prunus dulcis (sweet almonds)|Almonds are functional food items that contain bone essential micronutrients.
223404424|NCT07151183|OTHER|No intervention|No intervention
223404425|NCT06546488|BEHAVIORAL|Assessments|A standardized assessment battery will be administered. It will consist of cognitive, functional and motor assessments.
223736699|NCT05698446|PROCEDURE|Modified Broström + Suture tape augmentation operation|Patients with CLAI and GJL will accept the Modified Broström + Suture tape augmentation operation
223736700|NCT05698446|PROCEDURE|Anatomic reconstruction operation|Anatomic reconstruction operation
223736701|NCT05698446|PROCEDURE|Open Modified Broström procedure|Open Modified Broström-Gould surgery
223736702|NCT03645655|DIAGNOSTIC_TEST|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
223736703|NCT00087581|DRUG|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m\^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
223736704|NCT00087581|DRUG|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
223736705|NCT00087581|DRUG|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
223736706|NCT01357265|BIOLOGICAL|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
223404426|NCT07152379|DEVICE|INTERCEPT RBCs|Transfusion of fresh (≤14 days old) allogeneic INTERCEPT RBCs.
223404427|NCT07152158|OTHER|multicomponent training combined with multi-professional intervention|The MCT protocol consisted of an initial three-week period of neuromotor adaptation characterized by low volume and intensity. In the subsequent weeks, a gradual progression of volume and intensity was implemented (Table 1), following a classic linear periodization model (Fleck \& Kraemer, 2017; Prestes et al., 2016).
223404428|NCT07151651|PROCEDURE|Endoscopic lumbar discectomy|Uniportal and boportal endoscopic lumbar discectomy (transforaminal or interlaminar)
223555223|NCT01905943|DRUG|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
223555224|NCT02574078|DRUG|Nivolumab|
223555225|NCT02574078|DRUG|Bevacizumab|
223404429|NCT07152678|DRUG|Nivolumab (240 mg)|After the first cycle of nivolumab administered in the screening phase (1st cycle), nivolumab in the study phase was administered intravenously over 30 minutes at a dose of 240 mg every 2 weeks for at least 2 doses, with 1 cycle after to first brachytherapy (2nd cycle), and 1 more cycle after to second brachytherapy (3rd cycle) if feasible. (each cycle was 2 weeks), until disease progression assessed by the investigator per RECIST version 1.1, or unacceptable toxicity.
223736707|NCT02809690|DEVICE|CAT|Undergo 18F-FMAU PET/CT
223736708|NCT02809690|DRUG|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
223555226|NCT02574078|DRUG|Pemetrexed|
223555227|NCT02574078|OTHER|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
223404430|NCT07152678|RADIATION|Brachytherapy|Brachytherapy protocol starts within 3 weeks after first cycle of nivolumab was administered. After brachytherapy applicator placement, CT simulation scan(s) with dummy source in place will be done for further planning procedure, including adjustment of the applicator and 3D treatment planning. High-dose-rate (HDR) 5-Gy per fraction is delivered to the gross tumor volume (GTV) of esophageal tumor(s), second treatment if applicable will be finished within 2 weeks after the first fraction, a total of 5-12 Gy in 1-2 fractions will be delivered. GTV coverage D90 should equal 100% of prescription. Efforts should be made to spare the adjacent normal organ and to avoid hot spot on normal esophageal mucosa. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.
223404431|NCT07152795|DIETARY_SUPPLEMENT|Probiotic|During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
223555228|NCT02574078|DRUG|nab-Paclitaxel|
223555229|NCT02574078|DRUG|Paclitaxel|
223555230|NCT02574078|DRUG|Docetaxel|
223555231|NCT02574078|DRUG|Gemcitabine|
223555232|NCT02574078|DRUG|Erlotinib|
223555233|NCT02574078|DRUG|Crizotinib|
223555234|NCT02574078|DRUG|Carboplatin|
223736709|NCT02809690|OTHER|Laboratory Biomarker Analysis|Correlative studies
223736710|NCT02809690|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
223736711|NCT02809690|DEVICE|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
223736712|NCT02809690|DEVICE|Ultrasound|Undergo TRUS-guided biopsy
223736713|NCT02071355|DRUG|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
223736714|NCT02071355|DRUG|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
223736715|NCT05885074|DRUG|Empagliflozin Arm|The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
223736716|NCT05885074|OTHER|Control Arm|The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
223736717|NCT05885074|OTHER|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
223736718|NCT05885074|OTHER|Exercise Challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
223736719|NCT00415909|DRUG|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
223736720|NCT00415909|DRUG|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
223736721|NCT03226431|DRUG|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
223736722|NCT03981081|DRUG|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
223736723|NCT05657665|OTHER|Observational measurements of skin tone|Objective and subjective skin tone measurements will be performed.
223736724|NCT04526483|DEVICE|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System|Laparoscopic gastrectomy with Intelligent Navigation 4K UHD 3D Endoscopic Imaging System
223736725|NCT00786487|DRUG|20% lipid infusion|1.5 ml/min for 6 hours
224297700|NCT03902652|PROCEDURE|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
223404432|NCT07152795|DIETARY_SUPPLEMENT|Placebo|During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
223404433|NCT07151872|DRUG|QLS31905 for Injection|QLS31905 for Injection
223404434|NCT07151872|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine Hydrochloride for Injection
223404435|NCT07151872|DRUG|Cisplatin for Injection|Cisplatin for Injection
223404436|NCT07151872|DRUG|QL2107 Injection|QL2107 Injection
223404437|NCT07151872|DRUG|Oxaliplatin Injection|Oxaliplatin Injection
223404438|NCT07151872|DRUG|Capecitabine Tablets|Capecitabine Tablets
223555235|NCT04806061|DRUG|Sodium bicarbonate|sodium bicarbonate 8.4% to achieve urinary pH \>7.5
223555236|NCT04806061|DRUG|standard care|standard care
223555237|NCT03195218|DEVICE|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
223404439|NCT07151989|PROCEDURE|Mitral valve replacement|"All operations were performed through median longitudinal sternotomy or mini-sternotomy.~Intraoperative transesophageal echocardiography (TOE) was used in all patients. Arterial cannulation was central and venous cannulation was achieved with a common two-stage cannula in the right atrium. Left ventricle was vented through the right superior pulmonary vein. In minimally invasive procedures, venous cannulation was achieved percutaneously. Myocardial protection was achieved by administration of cold crystalloid or blood cardioplegia at the surgeon's discretion in an antegrade (indirect or selective) or retrograde fashion. The removal of the calcified cusps and the decalcification of the annulus was performed according to traditional techniques. All the prosthesis were be implanted with supranular technique and 2-0 U-shaped pledgeted sutures."
223555238|NCT04119804|DIAGNOSTIC_TEST|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
223555239|NCT04071340|DEVICE|non-contrast MSCT|non-contrast multi-slice computed tomography
223555240|NCT04071340|DEVICE|Abdominal ultrasonography|Abdominal ultrasonography
223555241|NCT04071340|DIAGNOSTIC_TEST|Urine analysis|Urine analysis
223555242|NCT04071340|DIAGNOSTIC_TEST|Urine culture|Urine culture
223555243|NCT05088330|DRUG|Daratumumab|treatment with D-VRD in NDMM
223555244|NCT01940367|DEVICE|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
223736726|NCT00786487|DRUG|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
223736727|NCT03279328|DRUG|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
223736728|NCT03279328|OTHER|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
223736729|NCT03279328|DRUG|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
223404440|NCT07153068|BIOLOGICAL|supCD7 CART cells|Subjects screened to meet the requirements for supCD7 CART cells use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to supCD7 CART cells infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of supCD7 CART cells must be performed 24 hours after completion of chemotherapy preconditioning. supCD7 CART cells can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.
223555245|NCT01940367|DEVICE|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level"
223555246|NCT01162954|DRUG|DA-6034|
223555247|NCT01162954|DRUG|Placebo|
223555248|NCT00779428|DRUG|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
223736730|NCT06309212|OTHER|Observation|Analyse of data from adults with respiratory tract infections who were tested for various respiratory viruses using a multiplex PCR assay
223736731|NCT01714154|DRUG|danoprevir|100 mg orally every 12 hours
223736732|NCT01714154|DRUG|ritonavir|100 mg orally every 12 hours
223736733|NCT01714154|DRUG|setrobuvir|200 mg orally every 12 hours
223736734|NCT00785395|DRUG|Oxytocin infusion|Up-down dosing determination
223736735|NCT02097407|DRUG|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
223736736|NCT02097407|DRUG|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
223736737|NCT04563689|OTHER|CHX0.12+CPC0.05 oral rinse (PerioAidActive Control)|rinse 15 ml during 1 min during 5 days, twice daily
223555249|NCT03695614|OTHER|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
223736738|NCT04563689|OTHER|placebo rinse|destilled water rinse 15 ml during 1 min during 5 days, twice daily
223555250|NCT02321787|PROCEDURE|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
223736739|NCT05851950|OTHER|group rumination focused cognitive behavioural therapy|Psychotherapy
223736740|NCT05851950|OTHER|Treatment as usual|opus treatment
223736741|NCT00016146|BIOLOGICAL|GPI-0100|
223736742|NCT00016146|BIOLOGICAL|MUC-2-Globo H-KLH conjugate vaccine|
223736743|NCT03658850|DRUG|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
223736744|NCT03658850|DRUG|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
223736745|NCT04299204|PROCEDURE|Percutaneous nephrolitotomy|Pediatric PCNL
223736746|NCT05783115|PROCEDURE|Tibial Transportation Combined With Autologous mesenchymal stem cells Local Infusion|transverse bone transport with bone marrow cell transplantation
223736747|NCT05783115|PROCEDURE|Tibial Transportation|transverse bone transport
223736748|NCT05652998|BIOLOGICAL|C. albicans antigen|a test dose (0.1 ml) of the C. albicans antigen will be injected intradermally into the skin of the forearm. A reaction will be considered positive in presence of ≥5 mm erythema and induration after 48-72 hr. Only reactors will be included. patients will receive intralesional injection of candida antigen at a dose 0.1 ml of 1/1000 solution into the largest wart at 3 weekly intervals for a total of 3 doses.
223736749|NCT05652998|OTHER|autologous PRP|patients will receive intralesional autologous PRP injection every month until a complete clearance or for a maximum of 2 sessions. 20 cc blood will be collected under a complete aseptic condition in citrate tubes . The lower 2-4 cc of the plasma will be provided as PRP concentrate after centrifugation. 0.1 ml of PRP will be injected intralesional with an insulin syringe.
223736750|NCT05652998|OTHER|saline|patients will receive intralesional saline at a dose of 0.3ml into the largest wart at 2-week intervals until complete clearance is achieved or for a maximum of five treatment
223736751|NCT02355691|DEVICE|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
224132424|NCT05676528|OTHER|Exercise intervention|The participants will carry out a physiotherapeutic exercise intervention over a period of 6 weeks. The exercise intervention is stored in a smartphone app (PhysiApp) and consists of different neck and shoulder exercises. The investigators will provide the training material to the participants and they may keep it after the end of the study. Participants can choose which and how many exercises they would like to do. However, the investigators ask participants to exercise at least three times a week for 20 minutes each time (a total of one hour per week) and to document the training afterwards in the smartphone app. In the first, third and sixth week, the investigators train together with the participants via a virtual platform (e.g. video call via Microsoft Teams) so that the correct execution of the exercise can be checked and questions can be clarified.
223404441|NCT07152223|BIOLOGICAL|CAR-T|Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.
223404442|NCT03598309|DRUG|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
223404443|NCT03598309|DRUG|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
223404444|NCT03598309|OTHER|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
223404445|NCT07156786|DRUG|N-acetylcysteine (NAC)|N-Acetylcysteine effercescent 1200 mg orally twice a day for 7 days. One day before cisplatin based chemotherapy, on the chemotherapy day, and five days after.
223404446|NCT07156786|DRUG|Placebo|Patient will get placebo
223404447|NCT07160153|DIAGNOSTIC_TEST|Neurocognitive assessment|"Neurocognitive battery:~TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs~Other psychometrics:~The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)"
223404448|NCT07160153|DIAGNOSTIC_TEST|Urine toxicological assessment|Urine toxicological assessment
223404449|NCT07168928|BEHAVIORAL|School-Based Nutrition Education Program|The intervention consisted of an eight-week, school-based nutrition education programme delivered to fourth-grade students by a school dietitian. Sessions were conducted once per week and included interactive lectures, games, and educational activities focusing on healthy eating, food groups, balanced meals, and the risks of processed food consumption. In addition, parents of students in the intervention group received a four-week educational programme on child nutrition, meal planning, and healthy lifestyle practices.
223404450|NCT07153055|DRUG|Lurbinectedin|Two lurbinectedin does of 3.2 mg/m2 or 2.6 mg/m2. The initial starting dose is 3.2 mg/m2. Patients will receive lurbinectedin, until disease progression or unacceptable toxicity, once every 21 days.
223404451|NCT07153055|DRUG|Osimertinib|Two osimertinib does of 80 mg or 40 mg orally once daily, as assigned by the dose de-escalation cohort for each 21 day cycle.
223404452|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|Randomized in a 1:1 ratio through the randomization system, and assigned to medium-pressure group or low-pressure group.
223404453|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|"In the high weight group, 8 subjects will receive a high dose of Dexmedetomidine hydrochloride Microneedles.~In the high weight group, 8 subjects will receive a low dose of Dexmedetomidine hydrochloride Microneedles."
223404454|NCT07168720|DRUG|placebo|In the high weight group, 8 subjects will receive Dexmedetomidine hydrochloride Microneedles blank preparation.
223404455|NCT07168720|DRUG|Dexmedetomidine hydrochloride Microneedles|"In the low weight group, 8 subjects will receive a low dose of Dexmedetomidine hydrochloride Microneedles.~In the low weight group, 8 subjects will receive a high dose of Dexmedetomidine hydrochloride Microneedles."
223404456|NCT07168720|DRUG|Placebo|In the low weight group, 8 subjects will receive Dexmedetomidine hydrochloride Microneedles blank preparation.
223404457|NCT07174440|DRUG|Ropivacaine (Epidural analgesia)|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care
223404458|NCT07174440|DRUG|Dexmedetomidine|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care
223404459|NCT07174440|DRUG|Iohexol|The block solution will consist of 1% ropivacaine 3 mg/Kg ideal body weight (IBW) mixed with dexmedetomidine 0.5 mcg/Kg IBW and diluted with 10 mL iohexol 300 mg/mL and normal saline for a total volume of 40 mL. All medications used are standard of care except for iohexol which is used for study purposes.
223404460|NCT07174440|PROCEDURE|QST Procedure|The QST procedure (test of buzzing sensation and temperature sensation through pads applied to your skin) to assess the numb areas.
223404461|NCT07183293|DRUG|Peginterferon alfa-2b combined with NAs|Subcutaneous injection therapy,Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.
223404462|NCT07183293|DRUG|NAs|Treatment will continue for 48 weeks, with follow-up assessments conducted every 12 weeks. The dosage will be adjusted based on the patient's disease status.
223404463|NCT07184450|BIOLOGICAL|BCMA/CD70-targetd CAR-T|Subjects underwent lymphocytetion cheotherapy and then received a single intravenous cell infusion
223404464|NCT07182708|DRUG|Firmonertinib Mesilate Tablets|Firmonertinib Mesilate Oral administration 160 mg once daily for 3 months before surgery. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment. After surgery, the treatment plan was determined by the researchers, with options including Firmonertinib Mesilate Tablets: Oral administration once daily, 80mg per dose, for 3 years or until disease progression or intolerable toxicity occurs.
223404465|NCT07182708|DRUG|Bevacizumab injection|Bevacizumab injection (intravenous infusion, 7.5 mg/kg) administered every 21 days as one cycle, for a total of 2 cycles. Radical tumor resection will be performed at least 6 weeks after completion of Bevacizumab treatment.
223404466|NCT07183761|BIOLOGICAL|Experimental Group|On day 0, day 7, and day 28 after enrollment, the study subjects will receive intramuscular injections of hUC-MSCs suspension in normal saline into the medial and lateral muscle groups of both lower legs. Concurrently, all patients will continue to receive conventional therapy.
223736752|NCT03554226|BEHAVIORAL|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
223404467|NCT07183761|DRUG|Conventional therapy group|The conventional therapy include fundamental blood glucose management, basic treatment for diabetic neuropathy along with pain management therapy, as well as management of comorbidities and risk factors.
223404468|NCT07183215|DRUG|Curcuminoid Standardized Turmeric Capsules|Samples were made from extracted turmeric and then optimized. The capsule formulation is made from turmeric rhizome extract which contains 30 mg of curcuminoids per capsule. In the study, standardized curcuminoid turmeric extract was given in capsules at 30 mg 3 times a day for 3 weeks
223404469|NCT07183215|OTHER|Placebo|The capsule formulation is made from maltose which contains 10 mg of curcuminoids per capsule. In the study, the capsule was given in capsules at 30 mg 3 times a day for 3 weeks.
223404470|NCT07182656|DRUG|CIGB-814 (single-dose group)|CIGB-814, single ascending dose, SC injection
223404471|NCT07182656|DRUG|CIGB-814 placebo (single-dose group)|CIGB-814 placebo, single ascending dose, SC injection
223404472|NCT07182656|DRUG|CIGB-814 (multiple-dose group)|CIGB-814, multiple ascending dose, SC injection
223404473|NCT07182656|DRUG|CIGB-814 placebo (multiple-dose group)|CIGB-814 placebo, multiple ascending dose, SC injection
223404474|NCT07183696|OTHER|breathing exercises|"* breathing exercises as needed 3 times per week during dialysis sessions.~* chest percussion as needed 3 times per week during dialysis sessions.~* vibration as needed 3 times per week during dialysis sessions."
223404475|NCT07182253|DIETARY_SUPPLEMENT|KSM-66 Ashwagandha® capsule|Single off-white capsule contains 300 mg Ashwagandha root extract powder only
223555251|NCT06036355|DRUG|Oral NMN combined with DC cell vaccine|The whole intervention cycle was treated with NMN (Vital NAD) 600mg/day for at least 50 days. During this period, the first DC cell injection was given on the 10th day, and then another DC cell injection was given at 2 weeks, 4 weeks and 6 weeks after the first injection.
223555252|NCT06429046|OTHER|LIDOCAINE GEL|To LG group patients, 20 ml lidocaine gel will be applied intrarectally (double application: 5cc to the perianal region, covering the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed in the rectum.
223555253|NCT06429046|OTHER|COLD LIDOCAINE GEL|In CLG group patients, 20 ml of cold lidocaine gel kept in the refrigerator at +4 0C will be applied intrarectally (double application: 5cc to the perianal region, including the anal sphincter, the remaining 15cc into the rectum) 5 minutes before the transrectal ultrasound probe is placed into the rectum.
223555254|NCT04990063|DRUG|Chemotherapy|Standard chemotherapy drug
223555255|NCT04990063|BIOLOGICAL|Adoptive TKC transfer therapy|TKC: co-cultured autologous NK cells and γδT cells
223555256|NCT02371577|DRUG|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
223555257|NCT03037476|BEHAVIORAL|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
223555258|NCT03037476|BEHAVIORAL|Assessment Only|The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
223736753|NCT03575312|DRUG|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
223736754|NCT06197815|BEHAVIORAL|The assistance type during ERCP|The senior trainer guides the trainees during ERCP procedure outside the operating room using communication equipment and the screen displaying an endoscopic view.
223736755|NCT04645641|DEVICE|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
223736756|NCT02937779|DRUG|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
223404476|NCT07182253|OTHER|Identical Placebo capsule|Single off-white capsule contains starch powder only
223404477|NCT07184073|BEHAVIORAL|assessment Mini mental state examination|pre operatively four weeks postoperatively
223404478|NCT07184073|BEHAVIORAL|assessment FRAIL scale|pre operatively four weeks postoperatively
223404479|NCT07184073|OTHER|collecting cerebrospinal fluid during regional anesthesia|In the operating room regional anesthesia was administered according to the surgical plan
223404480|NCT07183280|OTHER|operation|Enucleation, spleen-preserving distal pancreatectomy, or duodenum-preserving pancreatic head resection, etc
223404481|NCT07183124|DIAGNOSTIC_TEST|AI-Assisted 3D Imaging Model for Tumor and CRM Assessmen|This study uses an AI-assisted 3D imaging model to analyze existing CT and MRI images of stage II-III locally advanced rectal cancer patients. The system reconstructs tumor boundaries and spatial relationships, predicts circumferential resection margin (CRM) status, and supports staging assessment. No interventions are performed on participants, and all data are collected retrospectively from routine clinical care.
223404482|NCT07183670|DIAGNOSTIC_TEST|decannulation protocol|"Step 1: The patient's clinical stability is confirmed. Step 2: Tolerance to the speaking valve is assessed. Step 3: The wearing time of the speaking valve is extended continuously for 4 h, and no tracheostomy cannula is used for sputum suction within 4 h.~Step 4: Cough strength is evaluated to be good before decannulation. Decannulation Criteria: Pass Step 1 + Step 2 + Step 3 + Step 4"
223404483|NCT07183085|BEHAVIORAL|Intervention|Digital mental health program incorporating personalized physical and mental health exercises focused on physical activity, sleep hygiene, and mindfulness.
223404484|NCT07183878|DRUG|Venetoclax|Venetoclax is administered orally at 400 mg/day for participants ≥14 years or 360 mg/m²/day for those aged 12-14 years, from day -14 to -8 before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dose is adjusted to 100 mg/day (or 90 mg/m²/day for pediatric patients) if used with strong CYP3A4 inhibitors such as posaconazole.
223404485|NCT07183878|OTHER|None-placebo|Participants in this arm will not receive venetoclax as part of their conditioning regimen. They will undergo standard myeloablative conditioning with BUCY (busulfan, cyclophosphamide, and MeCCNU), prior to allogeneic hematopoietic stem cell transplantation. This arm serves as the active comparator to evaluate the addition of venetoclax in the experimental arm.
223404486|NCT07183176|DEVICE|Chattanooga CEFAR Tens|"* The patient will be assigned to one of two groups:~  1. The intervention group: called the REAL TENS group (R- TENS)~ 2. The control group: called the FAKE TENS group (F-TENS)~     Step 2: The doctor investigator 1 will place the TENS on the painful area identified by the patient, following the model proposed in appendix 1.~     Step 3: The doctor investigator 1 will explain to patients in both groups that they may feel a slight tingling sensation or no sensation at all.~     Step 4: The doctor investigator 1 will make the following settings on the TENS:~* For the interventional group (REAL TENS) a combined setting will be used:~  1. Tens Burst (P2) at 2Hz and 180 µs with an action on muscle pain.~ 2. Tens gate control (P9) at 100 Hz and 250 µs with an action focused on nociceptive pain.~* For the control group (FAKE TENS), the doctor will not make any real adjustments.~The patient will not be able to see the settings made by the doctor investigator 1.~Stage 5: The doctor investigator"
223404487|NCT07183423|OTHER|Novel barrier repair topical product|Novel barrier product (containing ceramide, virgin coconut oil, cholesterol)
223404488|NCT07183423|OTHER|Petrolatum|Petrolatum application
223404489|NCT07182422|DRUG|AST-120 (Kremezin®)|AST-120 (Kremezin®) Dosage: 6 g/day (2 g TID, oral) Duration: 14 days Background treatment: Standard post-AKD care
223404490|NCT07184138|DRUG|Interleukin-23 Inhibitors (IL-23i)|Adult patients will receive treatment with an interleukin-23 inhibitor (IL-23i), including guselkumab or risankizumab, as prescribed in routine clinical practice in China. This observational study does not mandate dosing, administration schedule, or concomitant medications; treatments follow standard of care. Patients will be prospectively monitored for clinical effectiveness, endoscopic outcomes, and safety over 52 weeks.
223404491|NCT07183488|OTHER|Propionate followed by Butyrate|The participants will consume Short-chain fatty acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).
223404492|NCT07183488|OTHER|Butyrate followed by Propionate|• The participants will consume Short-chain fatty acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).
224132425|NCT07082972|DRUG|Botulinum toxin injection|Patients will receive a total of 20 units of botulinum toxin type A (Botox) injected into each masseter muscle. The injections will be administered at three standardized sites on each side using a fine needle to ensure accurate delivery. Muscle activity will be recorded using electromyography (EMG) before the injection, and follow-up EMG measurements will be taken at one month and four months post-treatment to evaluate changes in muscle activity and treatment efficacy.
224132426|NCT07082972|DEVICE|Occlusal splint|Patients with myofascial pain syndrome will receive custom-made occlusal splints to wear during sleep. These splints help reduce abnormal muscle activity and relieve pain by redistributing bite forces. EMG measurements will be taken before and during treatment to monitor changes in muscle activity.
223404493|NCT07183488|OTHER|Propionate followed by Butyrate|• The participants will consume Short-Chain Fatty Acid propionate (SCFA-PRO) followed by Short-Chain Fatty Acid Butyrate (SCFA-BUT).
223736757|NCT02937779|DEVICE|Rapid tests HBe Ag|For all HBs Ag positive women
223736758|NCT04063956|BEHAVIORAL|multi-domain internet-based adaptive training program|The training paradigms include a time perception task, visual search task, rapid serial presentation task, delayed match to sample task, paired-associate recall task, attention span task, digit span task, go-no go task, Stroop task, task switching, auditory span task and n-back working memory task. Each task has several difficulty levels. The tasks are grouped in different cognitive domains including: processing speed, attention, perception, long-term memory, working memory, calculation, executive control, reasoning, and problem-solving. Participants in the cognitive training group will complete 40 min of training daily, 4 days a week for 12 weeks. When a high accuracy (80%) is achieved for each task, the level of difficulty will be upgraded for that task.
223404494|NCT07183488|OTHER|Butyrate followed by Propionate|The participants will consume Short-Chain Fatty Acid Butyrate (SCFA-BUT) followed by Short-Chain Fatty Acid Propionate (SCFA-PRO).
223404495|NCT07182370|DIETARY_SUPPLEMENT|Capsules containing plant extracts, including resveratrol, ellagic acid and isoflavones|Eight-week intake of three capsules per day, containing a total of 2.1 g of plant extracts (PPs), including 150 mg of resveratrol (found in grapes and red wine), 100 mg of ellagic acid (present in strawberries, walnuts, pomegranate, etc.), and 50 mg of the isoflavone daidzein, among others (found in soy, red clover, etc.).
223404496|NCT07182370|DIETARY_SUPPLEMENT|Consumption of placebo|Daily intake of three capsules (2.1 g/day) of microcrystalline cellulose for eight weeks
223404497|NCT07182279|DRUG|Brachytherapy|All patients will receive a single fraction of HDR-B (15Gy) 4-8 weeks prior to RALP. Patients with high genomic risk or node positivity will receive short course adjuvant AAB.
223404498|NCT07183748|DRUG|Psilocybin (drug)|0.4 grams
223404499|NCT07183748|OTHER|Placebo|Placebo
223404500|NCT07183410|DIAGNOSTIC_TEST|Blood culture taken from an arterial catheter|Blood culture taken from an arterial catheter (instead of peripheral venous puncture)
223404501|NCT07182344|DEVICE|Intermittent Theta Burst Stimulation to Right DLPFC|Participants receive intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC). The protocol consists of 600 pulses delivered in bursts of 3 pulses at 50 Hz, repeated at 5 Hz for 2 seconds, every 10 seconds, over approximately 3 minutes per session. Stimulation is delivered at 80% of the participant's active motor threshold. Ten sessions are administered across two weeks.
223404502|NCT07182344|DEVICE|Sham Intermittent Theta Burst Stimulation|Participants receive sham intermittent theta burst stimulation (iTBS) to the right dorsolateral prefrontal cortex (DLPFC) using a placebo coil. The coil replicates the sound and scalp sensation of active stimulation without generating sufficient magnetic output to alter cortical excitability. Session length, coil placement, and stimulation parameters are matched to the active iTBS condition. To preserve blinding, both participants and administering staff wear earplugs to minimize auditory differences between sham and active coils. This condition serves as a placebo control for evaluating iTBS effects on attention in children with ADHD.
223555259|NCT05156099|DEVICE|Ultrasound Scanning|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
223555260|NCT05156099|DEVICE|Ultrasound Scanning - 2 months later|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance.
223736759|NCT04063956|BEHAVIORAL|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
223736760|NCT03037255|OTHER|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
223736761|NCT02338960|DRUG|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
223404503|NCT07181980|OTHER|Intercostal mulligan mobilization with shoulder abduction|"Intercostal mulligan mobilization with shoulder abduction: is mulligain technique where the patient was Side lying with affected side up and the therapist Therapist placed ulnar side of his hand along the intercostal space of affected rib in oblique direction on the patient's wall of chest. Therapist's other hand hold the patient's elevated arm close to his abdomen 3sets 10 reptations~* Assistive range of motion exercises (AAROME): Two sets of 15 repetitions of each exercise were performed for AAROME .~* Active stretching: Two sets of 10 repetitions with 15- sec hold and relax times were performed for active stretching.~* Strengthening exercises for the shoulder joint: Two sets of 15 repetitions of each exercise .~* Postural correction exercises: 3 sets of postural correction were performed with 3-5 repetitions per set.~* Scapular strengthening exercises : two sets of ten repetitions~* The Intervention protocol: 45 to 50 minutes sessions 3 days per week for 8 week"
223404504|NCT07181980|OTHER|Exercise|"1.3.b. Therapeutic Exercise:~* Therapeutic exercise included: (prior to 3 month post mastectomy).~* Assistive range of motion exercises (AAROME): Two sets of 15 repetitions of each exercise were performed for AAROME .~* Active stretching: Two sets of 10 repetitions with 15- sec hold and relax times were performed for active stretching. .~* Strengthening exercises for the shoulder joint: Two sets of 15 repetitions of each exercise .~* Postural correction exercises: 3 sets of postural correction were performed with 3-5 repetitions per set. .~* Scapular strengthening exercises : Strengthening exercises performed using weights were initiated with two sets of ten repetitions, beginning with a weight of 0.5kg and progressed to 0.75 and then 1 kg.~* The Intervention protocol: 45 to 50 minutes sessions 3 days per week for 8 week"
223736762|NCT02338960|DRUG|Placebo|Placebo
223736763|NCT03210870|BEHAVIORAL|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
223736764|NCT01472250|DRUG|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
223736765|NCT00462761|DRUG|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
223736766|NCT05685082|BEHAVIORAL|Standardized patient simulation|The standardized patient simulation participants will receive a simulation with standardized patients on how to identify social determinants of health in an individual
223736767|NCT05685082|BEHAVIORAL|Manikin-based simulation|The manikin-based simulation participants will receive a simulation with manikins on how to identify social determinants of health in an individual
223736768|NCT02345811|DEVICE|Sapphire|silicone-hydrogel contact lens
223736769|NCT02345811|DEVICE|senofilcon A|contact lens
223736770|NCT06146933|DIAGNOSTIC_TEST|Glucometer Test|blood glucose measurement using finger tip capillary blood using BGM
223736771|NCT06146933|DIAGNOSTIC_TEST|Refernce Measurement|blood glucose measurement using finger tip capillary blood using reference method
223736772|NCT05383560|BIOLOGICAL|mRNA-1273.214 Vaccine|Omicron Variant-Matched Vaccine
223736773|NCT05383560|BIOLOGICAL|MRNA-1273 Vaccine|Moderna's commercial COVID-19 Vaccine
223736774|NCT05383560|BIOLOGICAL|Placebo|Normal Saline for injection
223736775|NCT05383560|BIOLOGICAL|MRNA-1273.222 Vaccine|Moderna's commercial COVID-19 Vaccine
223736776|NCT02877082|BIOLOGICAL|Thymoglobulin|Given IV
223736777|NCT02877082|DRUG|Bortezomib|Given IV
223736778|NCT02877082|DRUG|Tacrolimus|Given IV and PO
223736779|NCT02522286|BEHAVIORAL|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
223736780|NCT02522286|BEHAVIORAL|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2\) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3\) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
223736781|NCT02848014|BEHAVIORAL|Writing task|
223736782|NCT01175733|DRUG|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
223736783|NCT04952142|OTHER|minimal water exchange|Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
223736784|NCT01700855|PROCEDURE|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
223736785|NCT01700855|PROCEDURE|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3\~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
223736786|NCT00774228|DEVICE|I-ZIP Ocular Bandage|
223736787|NCT00774228|DEVICE|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
223736788|NCT04922983|DRUG|Botulinum toxin type A|A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).
223736789|NCT04922983|BEHAVIORAL|Isometric Yoga-like exercise|Extended torso and legs held diagonally by one straight arm, back against wall if necessary
223736790|NCT04922983|BEHAVIORAL|Placebo|Used as placebo
223736791|NCT06053138|DIETARY_SUPPLEMENT|Ketone monoester|Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement
224132427|NCT07082972|COMBINATION_PRODUCT|Botulinum toxin + Occlusal splint combined|Patients will receive both botulinum toxin injections (20 units per masseter muscle, injected at three standardized points per side) and will use occlusal splints during sleep. EMG measurements will be conducted before treatment, and at follow-up visits to assess the combined effect of pharmacological and mechanical therapy on muscle activity.
223404505|NCT07182292|DIETARY_SUPPLEMENT|Anti-Inflammatory Supplement|"A daily oral dose of Alisenoc™, an anti-inflammatory nutritional supplement specifically designed for older adults. Alisenoc™ contains olive oil polyphenols, omega-3 fatty acids (EPA/DHA), leucine-enriched protein, and antioxidant micronutrients to target inflammaging, sarcopenia, and nutritional deficiencies.~Participants will be followed at 12 weeks, and at 6 and 12 months for functional, biochemical, and clinical outcomes."
223404506|NCT07182292|DIETARY_SUPPLEMENT|Conventional Nutritional Supplement|"they will receive a conventional oral nutritional supplement that is isocaloric and protein-equivalent to the experimental product, but without anti-inflammatory ingredients.~This standard supplement reflects routine nutritional support typically provided in geriatric clinical practice for malnourished patients. It contains energy, protein, and micronutrients but no specific anti-inflammatory components such as olive polyphenols or omega-3 fatty acids."
223404507|NCT07184112|BEHAVIORAL|The Embedded Micro-Scenario Simulations (EMSS)|he Embedded Micro-Scenario Simulations (EMSS) for nursing students include a series of engaging clinical cases designed to bridge the theory-practice gap. In Prioritization of Care, students must prioritize three patients with varying degrees of urgency, honing their critical thinking skills. The Patient Education on Discharge scenario tasks them with effectively communicating self-care instructions. In End-of-Life Care, students provide compassionate support to a terminally ill patient and facilitate family discussions.
223404508|NCT07183475|DIAGNOSTIC_TEST|Return to sports test|"The return-to-sport-tests are based on validated procedures commonly used in sports orthopedics, particularly following the stepwise testing concept described.~Initially, the participant's individual sport level is determined via structured anamnesis. This is then followed by level-specific functional testing. Participants who do not perform Level 1 testing correctly will not proceed to Level 2 testing-even if their anamnesis suggests a higher sport level. This stepwise approach ensures safety and prevents injury during the testing process."
223555261|NCT00758368|DRUG|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
223555262|NCT04622891|DRUG|Clarithromycin 500mg|clarithromycin 500
223555263|NCT04622891|DRUG|Azithromycin|azithromycin group
223736792|NCT06053138|DIETARY_SUPPLEMENT|Placebo|The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
223736793|NCT03480750|DRUG|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
223736794|NCT03480750|DRUG|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
223736795|NCT03480750|DRUG|carboplatin|carboplatin AUC 4 IV D1
223736796|NCT00798044|BEHAVIORAL|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
223736797|NCT00798044|BEHAVIORAL|Patient Feedback|Weekly feedback reports provided to counselors
223555264|NCT04622891|DRUG|Placebo|control group
223736798|NCT03896555|DEVICE|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
223555265|NCT00005643|DRUG|pegylated liposomal doxorubicin hydrochloride|
223555266|NCT05010486|PROCEDURE|rectal surgery|
223736799|NCT04057079|COMBINATION_PRODUCT|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
223736800|NCT04057079|COMBINATION_PRODUCT|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
223736801|NCT00366158|DEVICE|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
223736802|NCT00366158|DEVICE|Ventricular Intrinsic Preference|Programming of pacemaker
224138779|NCT01422811|OTHER|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
223555267|NCT03023579|OTHER|The star excursion balance test|
223736803|NCT04930354|DRUG|ECP-1014|Patients will be selected who (1) have failed all standard of care therapy (relapsed/refractory) or (2) have relapsed and are not a candidate for an available standard of care therapy as assessed by the investigator (such as, but not limited to, colorectal cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), head and neck, etc.) with COX-2 overexpression, ultimately resulting in elevated production of prostaglandin E2 (PGE2).
223736804|NCT00605813|DRUG|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
223736805|NCT05771142|DEVICE|Smart t-shirt|24h ECG Monitoring with the smart t-shirt under study
223736806|NCT05771142|DEVICE|ECG Holter|24h ECG Monitoring with ECG Holter
223736807|NCT05771142|DEVICE|Smartwatch|24h ECG Monitoring with a smartwatch
223736808|NCT01857349|OTHER|Chlora Prep|Surgical Scrub skin preparation
223736809|NCT01857349|OTHER|Dura Prep|Surgical Scrub skin preparation
223404509|NCT07182812|BEHAVIORAL|Blood Flow Restriction Sit-to-Stand Exercise|Participants perform sit-to-stand (STS) exercises with blood flow restriction applied using a pneumatic cuff placed on the thigh. Cuff pressure is set at 60-80% of the participant's systolic blood pressure. Sessions are supervised by a physiotherapist twice per week for six weeks.
223736810|NCT04599920|DIETARY_SUPPLEMENT|Partial replacement of red meat with legume-based foods|560 g of cooked and boneless red meat is replaced with legume-based foods providing the equal amount of protein.
223736811|NCT00735774|DRUG|11C-ORM-13070|Single dose of i.v. solution
223736812|NCT04022447|DRUG|Dupilumab|retrospective data collection
223736813|NCT00575913|DRUG|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
223404510|NCT07182812|BEHAVIORAL|Sit-to-Stand Exercise without Blood Flow Restriction|Participants perform the same sit-to-stand (STS) exercise protocol as the experimental group, but without blood flow restriction. Sessions are supervised twice weekly for six weeks, and outcomes are assessed before and after the program.
223736814|NCT06113432|DIAGNOSTIC_TEST|Arterial blood gases|Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
223736815|NCT06113432|DIAGNOSTIC_TEST|Respiratory rate (RR)|Measurement of respiratory rate by waveform analysis using a ventilator
223736816|NCT06113432|DIAGNOSTIC_TEST|Pulseoximeter|Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
223404511|NCT07183098|OTHER|Participiants at high risk of malnutrition who received standard nutritional care|The overall clinical managment of people by ward's staff includes also nutritional care. Within 24-48 h after hospitalization, the ward's nursing staff screens people for nutritional risk using the Malnutrition Universal Screening Tool (MUST) tool. The attending ward's physician prescribes nutritional support and laboratory analyses in accordance with people's clinical needs and the underlying disease. Ward's physician cllinical judgement guides the decision to reassess and monitor the people's nutritional risk and status.
223404512|NCT07183098|OTHER|Participiants at high risk of malnutrition who received specialized nutritional care|People referred to the Dietetic and Clinical Nutrition Service (DCNS) receive a structured, evidence-based diagnostic and therapeutic nutritional support. A dietitian performs a dietary assessment and the attending physicians of the DCNS prescribe a baseline set of laboratory analyses relevant for nutritional status. People referred to the DCNS are monitored regularly and systematically, daily or weekly according to the people's clinical condition and nutritional problems.
223404513|NCT07183098|OTHER|3 month-post discharge evaluation|Three months after discharge (follow-up), participiants of both groups were monitored through telephone interview to collect data regarding rate of hospital readmission, number of emergency department admissions, general practitioner visits, outpatient visits, diagnostic tests, daily medication use and survival.
223404514|NCT07182448|OTHER|Saliva and serum sampling|"Saliva were collected to analyze the selected markers as unstimulated samples during the early hours of the day. The saliva was centrifuged and then transferred into Eppendorf tubes.~Venous puncture was performed after saliva collection and 10 mL of blood samples were collected by qualified staff (MFD) from each participant. Saliva and serum were then stored at -80 °C until analysis."
223736817|NCT06113432|DIAGNOSTIC_TEST|Assessment of accessory respiratory muscles work|Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
223736818|NCT06113432|DIAGNOSTIC_TEST|Esophageal pressure measurement|Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
223736819|NCT06113432|DIAGNOSTIC_TEST|Discomfort Visual Analog Scale (VAS)|From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
223736820|NCT06113432|DIAGNOSTIC_TEST|Noninvasive blood pressure|Noninvasive blood pressure
223736821|NCT06113432|DIAGNOSTIC_TEST|Heart rate|Heart rate calculation using electrocardiogram monitoring
223736822|NCT03195114|DIAGNOSTIC_TEST|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
223736823|NCT04020679|BEHAVIORAL|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
223736824|NCT03900000|OTHER|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
223736825|NCT00524550|DIETARY_SUPPLEMENT|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
223736826|NCT00527007|OTHER|External cooling|External cooling
223736827|NCT00082654|PROCEDURE|psychosocial assessment and care|
223736828|NCT02647086|DRUG|Dupilumab|
223736829|NCT02647086|DRUG|Midazolam|Cytochrome P450 substrate
223736830|NCT02647086|DRUG|Omeprazole|Cytochrome P450 substrate
223736831|NCT02647086|DRUG|Warfarin|Cytochrome P450 substrate
223736832|NCT02647086|DRUG|Caffeine|Cytochrome P450 substrate
224132428|NCT03732391|DRUG|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
223404515|NCT04536974|DIAGNOSTIC_TEST|SEFI tool|Detect the risk of malnutrition with the SEFI tool
223555268|NCT04379479|DRUG|Dialyzable Leukocyte Extract|Experimental Intervention. Dialyzable Leukocyte Extract
223555269|NCT04379479|DRUG|Placebo oral|Placebo
223736833|NCT02647086|DRUG|Metoprolol|Cytochrome P450 substrate
223404516|NCT01747031|DEVICE|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization--A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
223555270|NCT02136758|BEHAVIORAL|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
223555271|NCT00002249|DRUG|Levofloxacin|
223555272|NCT06272838|OTHER|Biodex balance system|In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.
223736834|NCT01132482|DRUG|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
223555273|NCT06272838|OTHER|The conventional balance exercise program|The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
223736835|NCT01132482|DRUG|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
223736836|NCT04278547|DIAGNOSTIC_TEST|ELISPOT IFN-γ assay|"ELISPOT IFN-γ diagnostic test: Evaluation of specific cellular immune response against the IE-1 antigen and the CMV pp65, using the technique ELISPOT IFN-γ and individualize the preventive strategy according to the result. In patients with a ELISPOT of low risk will be made advance therapy (preemptive therapy) guided by PCR of CMV In patients with a high risk ELISPOT, universal prophylaxis with valganciclovir will be performed oral (900 mg / 24h) or intravenous ganciclovir (5-10 mg / Kd / day) in case the oral route is not available."
223736837|NCT04025658|DRUG|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
223736838|NCT04623918|OTHER|Iron-biofortified rice|Iron-biofortified rice (IR68144-2B-2-2-3)
223736839|NCT04623918|OTHER|Control rice|Control rice (C4), identical in appearance
223404517|NCT04519372|DIAGNOSTIC_TEST|Testing for SARS-CoV-2|All Patients admitted to the hospital were routinely tested for SARS-CoV-2 within 72 hours of admission by nasopharyngeal swabs.
223404518|NCT00426946|DRUG|Reboxetine|
223555274|NCT05655559|OTHER|Questionnare|Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
223555275|NCT05655559|DEVICE|Moxy Muscle Oxygen Monitor|Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
223555276|NCT03863470|BEHAVIORAL|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
223555277|NCT02110537|PROCEDURE|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
223555278|NCT02110537|PROCEDURE|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
223736840|NCT01837979|PROCEDURE|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
223736841|NCT01578395|RADIATION|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
223736842|NCT01578395|RADIATION|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
223736843|NCT01578395|OTHER|No radiation exposure|Subjects not undergoing any radiation exposure
223736844|NCT03348020|PROCEDURE|Blood Donation|Subjects will donate blood within \~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
223736845|NCT04102215|DEVICE|HEARO|Robotic system for otological procedures
223404519|NCT03633123|DRUG|D_PLEX|D\_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
223736846|NCT04102215|DEVICE|OTOPLAN|Otological surgical planning software
224022455|NCT03073954|OTHER|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
224022456|NCT03073954|BEHAVIORAL|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
224022457|NCT01545154|DEVICE|Transperineal Ultrasound|
223404520|NCT03633123|OTHER|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
223404521|NCT04554810|OTHER|Medication Management Service|Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
223404522|NCT02298153|DRUG|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
223404523|NCT02298153|DRUG|epacadostat|epacadostat: Oral daily dosing
223404524|NCT01575951|RADIATION|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
223404525|NCT02127840|DRUG|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
223404526|NCT05783440|BEHAVIORAL|direct patient feedback|"Participants in the intervention group report postoperative pain scores and other pain related outcomes with their own smartphone. Pain scores reported by smartphone \> 3 (NRS 0-10) are immediately passed on to the nurse who will receive a notification on a smartphone.~All patient reported pain-scores by smartphone are stored in a database that is not accessible to medical or nursing staff from the nursing ward."
223404527|NCT04860648|OTHER|lung ultrasound|doctors treat the patients combining the Lus results and clinical practice
223404528|NCT00275743|PROCEDURE|MRI|
223404529|NCT00502385|DRUG|AZD2171|
223404530|NCT04547985|DRUG|Naltrexone HCl 50 MG Oral Tablet|Generic, oral tablet.
223404531|NCT04547985|DRUG|Placebo|Composed of filler material and encapsulated to appear identical to naltrexone.
223736847|NCT06219057|BEHAVIORAL|The Wise Adolescent|The program encompasses 20 individual weekly sessions manualized. Its main objective is to help adolescents to create affiliative feelings towards themselves and to develop a more compassionate inner voice. Sessions are organized across 6 main domains: (1) placing ourselves in the challenges of life: evolutionary roots of our mind, how social circumstances and life experiences shape us; the 3-affect regulation systems; (2) understanding difficulties: compassion focused therapy case formulation; (3) understanding compassion: the three flows of compassion, its three pillars (caring commitment, wisdom, strength and courage); (4) compassionate mind training: cultivating the compassion skills (compassionate attention, imagery, reasoning, and behavior); (5) working with difficulties: fears, blocks and resistances to compassion; multiple selves; shame and self-criticism; (6) sustaining a compassionate mind: reviewing the gains and relapse prevention.
223736848|NCT03130166|PROCEDURE|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
224132429|NCT03766087|PROCEDURE|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
223404532|NCT00019929|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
223736849|NCT03130166|PROCEDURE|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
223736850|NCT05584644|DRUG|Palbociclib plus hormonal treatment - first line treatment|Palbociclib plus hormonal treatment
223736851|NCT05584644|DRUG|Palbociclib plus hormonal treatment - second line treatment|Palbociclib plus hormonal treatment
223404533|NCT00019929|PROCEDURE|adjuvant therapy|
223404534|NCT01616238|DRUG|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
223404535|NCT05460819|OTHER|Acupuncture treatment|"Acupoint selection: Hegu-Yinxi acupoint group (clearing heat and relieving sweat), Sanyinjiao-Fuliu acupoint group (nourishing yin and tonifying kidney), Tianshu-uteri acupoint group (special effect points) (12 acupoints on both sides).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes."
223555279|NCT02110537|DRUG|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
223555280|NCT01675297|DRUG|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
223555281|NCT01675297|DRUG|Risedronate|Risedronate once a week
223555282|NCT06641115|BEHAVIORAL|HOPE Therapy|Helping Opioid Use and PTSD with Exposure (HOPE) therapy is an integrated 10-12 week treatment for opioid use disorder and trauma/posttraumatic stress disorder
223736852|NCT03853447|DIAGNOSTIC_TEST|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
223736853|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system
223736854|NCT00974909|DEVICE|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
223736855|NCT02493608|DEVICE|scalpel|used to cut the abdominal wall.
223736856|NCT02493608|DEVICE|Diathermy|Diathermy used to cut , coagulate the tissue
224132430|NCT01086046|DRUG|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
224132431|NCT05693090|DRUG|Tipifarnib|Oral administration
224132432|NCT05693090|DRUG|Osimertinib|Oral administration
224132433|NCT02243917|DRUG|CB-5083|
224022458|NCT04780347|DRUG|Albumin-bound paclitaxel plus capecitabine|Albumin-bound paclitaxel plus capecitabine: Albumin-bound paclitaxel 260mg/m2, IV , D1, q3w； capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
224022459|NCT04780347|DRUG|capecitabine|capecitabine: capecitabine 1000 mg/m2, PO，bid, D1-14,q3w.
224022460|NCT05322746|DEVICE|Focal muscle vibration|Focal muscle vibration (FMV) defined as a technique that applies a vibratory stimulus to a specific muscle or its tendon using a mechanical device. FMV generates the Ia inputs as a consequence of the activation primary ending of the muscle spindle leading to alteration of corticospinal pathways results in activation of Ia inputs by FMV. The vibration of a specific muscle can increase the motor evoked potential, enhance the changes in corticospinal excitability and produces involuntary contraction in the vibrated muscle
224022461|NCT03106909|RADIATION|pulmonary computed tomography (CT)|Pulmonary CT imaging
223404536|NCT05460819|OTHER|Sham Acupuncture treatment|"Selecting acupoints: Select the side opening positions of the 6 acupuncture points in the real acupuncture group, and select non-meridian and non-points (points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes."
223404537|NCT04989478|OTHER|Fasting|After the standardized breakfast meal, all participants will only consume water for 24 hours
223404538|NCT01904526|DRUG|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
223404539|NCT05323812|DRUG|TW001|daily dose of 100 mg TW001/placebo
223404540|NCT05323812|DRUG|Placebo|daily dose of 100 mg TW001/placebo
223404541|NCT03912064|DRUG|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
223404542|NCT03912064|BIOLOGICAL|CD25hi Treg depleted DLI|Donor lymphocyte product
223404543|NCT04556305|BEHAVIORAL|Mind|See arm description.
223404544|NCT04556305|BEHAVIORAL|Move|See arm description.
223404545|NCT03606785|DRUG|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
223404546|NCT03606785|DRUG|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
223404547|NCT00632060|PROCEDURE|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
223404548|NCT05353465|PROCEDURE|Radiofrequency denervation of the cervical facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the cervical facet joint with a three-tined expandable needle.
223404549|NCT00392366|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
223404550|NCT01646372|OTHER|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
223404551|NCT01646372|OTHER|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
223404552|NCT01595880|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
223404553|NCT01595880|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
223404554|NCT03125967|OTHER|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
223555283|NCT05935657|DRUG|Remimazolam|0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
223555284|NCT05935657|DRUG|Dexmedetomidine|1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
223555285|NCT03388866|DRUG|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
223555286|NCT03388866|OTHER|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
223555287|NCT00501592|DRUG|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
223555288|NCT00501592|DRUG|Placebo|Placebo
223555289|NCT00919750|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223736857|NCT00854074|DEVICE|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
223736858|NCT01517009|DRUG|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
223736859|NCT01517009|DRUG|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
224022462|NCT02817022|OTHER|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
223404555|NCT03125967|OTHER|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
223404556|NCT02323412|DRUG|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
223404557|NCT02323412|DRUG|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
223404558|NCT04903119|DRUG|Nilotinib 100mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 100mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
224022463|NCT05330312|DEVICE|Digital cognitive behavioral therapy|Therapy for patients with pulmonary fibrosis
224022464|NCT02549014|DRUG|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
224022465|NCT02549014|DRUG|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
223404559|NCT04903119|DRUG|Nilotinib 200mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 200mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
223404560|NCT04903119|DRUG|Nilotinib 300mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 300mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
223404561|NCT04903119|DRUG|Nilotinib 400mg|Patients will begin dabrafenib (150mg PO BID) and trametinib (2mg PO once daily) or encorafenib (450 mg PO) and binimetinib (45 mg PO BID) on day one and will continue for 28 days. After 7 days, nilotinib will be added at 400mg PO BID and will continue for 21 days. For each subsequent cycle, nilotinib will be given for 28 days.
223404562|NCT04903119|DRUG|Dabrafenib|All patients will begin dabrafenib (150mg PO BID) on day one and will continue for 28 days.
224132434|NCT00810459|DEVICE|Trilogy Ventilator|Exposure to one hour on the Trilog ventilator
224132435|NCT00810459|DEVICE|Standard of Care|Exposure of one hour on the Participants prescribed ventilator
223404563|NCT04903119|DRUG|Trametinib|All patients will begin trametinib (2mg PO once daily) on day one and will continue for 28 days.
223404564|NCT04903119|DRUG|Encorafenib|encorafenib will be administered orally 450mg once daily for 28 consecutive days
223404565|NCT04903119|DRUG|Binimetinib|binimetinib will be administered orally 45mg twice daily for 28 consecutive days
223404566|NCT03808948|DEVICE|VFI|The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
223404567|NCT04704310|BEHAVIORAL|Enhancing exercise training for adults with COPD: The roles of peers and functional tasks|A proof-of-concept online 8-week exercise training program for adults with COPD that incorporates both a peer mentorship and a functional tasks component.
223404568|NCT04152135|PROCEDURE|vena cava inferior diameter measurement|Ultrasound equipment with convex probe will be used to measure IVC diameters of the patients in supine position.The IVC sagittal section is described with the probe in the area of subxiphoid. IVC diameters at the junction point of the IVC and right atrium (2cm caudal) are standardized measurement.
223404569|NCT02389478|PROCEDURE|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
223404570|NCT02389478|PROCEDURE|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
223404571|NCT02554071|OTHER|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
223404572|NCT03035617|DRUG|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
223404573|NCT03035617|OTHER|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
223404574|NCT01828723|BIOLOGICAL|SVF|
223404575|NCT03214224|DEVICE|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
223404576|NCT03214224|DEVICE|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
223404577|NCT05506618|DIAGNOSTIC_TEST|Nasal Swab|Collection of one more nasal swabs
223404578|NCT05506618|DIAGNOSTIC_TEST|Nasopharyngeal swab|Collection of one more nasopharyngeal swabs
223404579|NCT02715193|BIOLOGICAL|REMD-477|
223404580|NCT02715193|BIOLOGICAL|Placebo Comparator|
223404581|NCT02595918|PROCEDURE|Metastasectomy|Undergo metastasectomy
223736860|NCT01517009|DRUG|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
224022466|NCT01078454|DRUG|melphalan|Given PO
224022467|NCT01078454|DRUG|dexamethasone|Given PO
224022468|NCT01078454|DRUG|bortezomib|Given IV
224022469|NCT00756691|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
223404582|NCT02595918|PROCEDURE|Nephrectomy|Undergo nephrectomy
223404583|NCT02595918|BIOLOGICAL|Nivolumab|Given IV
223404584|NCT01310842|BEHAVIORAL|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
223404585|NCT01310842|DRUG|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
224022470|NCT02902939|DEVICE|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
224022471|NCT02902939|PROCEDURE|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
224132436|NCT03750071|BIOLOGICAL|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
224132437|NCT03750071|BIOLOGICAL|Avelumab|Monoclonal anti-PD-L1 Antibody
224132438|NCT05274828|DEVICE|H7-Coil Deep TMS for CUD|The Study group will receive dTMS treatment three times a day for ten days.
224132439|NCT00171028|DRUG|valsartan|
224132440|NCT00040547|DRUG|Farnesyl Protein Transferase Inhibitor|
224132441|NCT02906956|BEHAVIORAL|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
224132442|NCT03992209|OTHER|Standard care|Usual operating room practice
224132443|NCT03992209|OTHER|Protocolized care|Hand washing per protocol
223736861|NCT01517009|PROCEDURE|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
223736862|NCT01462721|DEVICE|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
223736863|NCT04079153|DEVICE|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
223404586|NCT01310842|BEHAVIORAL|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
223736864|NCT00049101|DRUG|erlotinib hydrochloride|
223736865|NCT00049101|DRUG|fluorouracil|
223736866|NCT00049101|DRUG|leucovorin calcium|
223736867|NCT00049101|DRUG|oxaliplatin|
223736868|NCT02695745|DRUG|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
223736869|NCT02695745|DRUG|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
223736870|NCT02695745|DRUG|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
223736871|NCT02695745|DRUG|Capsaicin|1% administered topically
223736872|NCT03445819|PROCEDURE|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
223736873|NCT03445819|OTHER|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
223736874|NCT04086290|PROCEDURE|RARP|Radical prostatectomy + extended pelvic lymph node dissection
223736875|NCT04086290|RADIATION|SBRT|Stereotactic body radiotherapy to osseous lesions
223736876|NCT04086290|DRUG|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
223736877|NCT04358887|PROCEDURE|piezoelectric surgery|after flap reflection bone and root end cutting are done with piezoelectric surgical insert
223736878|NCT04358887|PROCEDURE|conventional bur|after flap reflection bone and root end cutting are done with surgical bur
223736879|NCT02190227|DEVICE|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
223736880|NCT05128877|OTHER|relaxation techniques|Mitchell's physiological relaxation technique is based on reciprocal inhibition and involves diaphragmatic breathing and a series of ordered isotonic contractions.
223736881|NCT05757921|DEVICE|Perisolv (A)|Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
223404587|NCT04666987|DRUG|Insulin degludec and liraglutide (IDegLira)|Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
223404588|NCT00101270|DRUG|irinotecan hydrochloride|Given IV
223404589|NCT00101270|DRUG|oxaliplatin|Given IV
223736882|NCT05757921|OTHER|Standard (B)|Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
223736883|NCT00174915|DRUG|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
223736884|NCT00174915|DRUG|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
223736885|NCT00174915|DRUG|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
223736886|NCT00174915|DRUG|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
223736887|NCT00174915|DRUG|Placebo|Placebo, orally, once daily for up to 28 weeks.
223736888|NCT03632278|BEHAVIORAL|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
223736889|NCT00183092|DRUG|Quinacrine|100mg by mouth three times a day
223736890|NCT00183092|DRUG|Placebo|100mg by mouth three times a day
223736891|NCT02451410|OTHER|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
223736892|NCT03060447|DRUG|Vesatolimod|Tablets Administered orally
223736893|NCT03060447|DRUG|Placebo|Tablets Administered orally
223736894|NCT03060447|DRUG|ART|ART regimens administered in accordance with their prescribing information. The following agents are allowed as part of the ART regimen: nucleoside reverse transcriptase inhibitors, raltegravir, dolutegravir (DTG), rilpivirine, and maraviroc.
223736895|NCT01763437|DRUG|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
223736896|NCT01988142|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
223736897|NCT06340438|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
223736898|NCT06340438|OTHER|Cowhage|25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
223736899|NCT00573755|DRUG|anastrozole|given orally
223404590|NCT05928078|BEHAVIORAL|intervention|Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks. The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.
223404591|NCT02712320|DRUG|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
223404592|NCT01729390|OTHER|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
223404593|NCT05313503|OTHER|ketogenic diet|We propose a type of KD named MAD (Modified Atkins Diet) characterized by the following percentages of macronutrients: 65% fats, 27% proteins and 8% carbohydrates.
223404594|NCT05227859|PROCEDURE|Piezocision|After anesthesia, three vertical incisions will be made (3-mm depth and 8-10 mm length) mesial and distal the upper canine as well as at an equal distance from the upper canine and 2nd premolar. The surgical procedures will be repeated after six weeks (only the mesial and distal canine incisions will be done)
223404595|NCT05227859|DEVICE|Low-level laser|GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) will be applied around the upper canine in 10 sites from buccal and palatal. The middle of the extraction site will be also irradiated in 4 sites (2 buccally and 2 palatally). The LLLT will be applied 5 times in the first month of canine retraction, then every two weeks until class I canine relationship will be achieved.
223404596|NCT05227859|DEVICE|Conventional treatment|The upper canine destalization will be done using NiTi springs. The force level will be controlled every 2 weeks. Retraction will be stopped when a class I canine relationship in both sides.
223404597|NCT00685100|OTHER|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
223404598|NCT06016205|PROCEDURE|intrathecal morphine injection|Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia
223555290|NCT01568151|BEHAVIORAL|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
223555291|NCT01568151|BEHAVIORAL|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
223736900|NCT00573755|DRUG|exemestane|given orally
223736901|NCT00573755|DRUG|letrozole|given orally
223404599|NCT06016205|PROCEDURE|ultrasound guided PECS2 block|ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%
223404600|NCT04324424|DRUG|HMS5552|single dose of HMS5552 25mg
223404601|NCT02885545|DEVICE|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
223404602|NCT02885545|DRUG|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
223404603|NCT00491283|DEVICE|Swab Specimen Collection (QuickVue)|
223404604|NCT03982511|BEHAVIORAL|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
223555292|NCT01432145|DRUG|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
223555293|NCT01432145|DRUG|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
223555294|NCT05946044|BEHAVIORAL|Diet and Exercise|Group and individual weight loss and weight maintenance sessions combined with exercise throughout the 48 months.
223555295|NCT05844943|DEVICE|ReHeal glove with Negative Pressure Wound Therapy (NPWT)|ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
223736902|NCT00573755|DRUG|sorafenib tosylate|given orally
223736903|NCT00573755|OTHER|placebo|given orally
223736904|NCT02976623|OTHER|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
223736905|NCT00000278|DRUG|Disulfiram|
223736906|NCT00010465|PROCEDURE|Craniosacral Osteopathic Manipulative Treatment|
223736907|NCT00010465|DRUG|Botanicals|
223736908|NCT03345667|DRUG|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
223736909|NCT03025061|OTHER|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
223736910|NCT01109225|BIOLOGICAL|blood sample|
223736911|NCT01109225|PROCEDURE|MRI|
223736912|NCT01109225|PROCEDURE|echocardiography|
223736913|NCT01109225|BIOLOGICAL|urine sample|
223736914|NCT01109225|PROCEDURE|pulmonary echography|
223736915|NCT01109225|PROCEDURE|vascular check|
223404605|NCT00568451|DRUG|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
223404606|NCT00568451|DRUG|paclitaxel|100mg/m\^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
223404607|NCT00568451|DRUG|temozolomide|150mg/m\^2 at cycle 1, 200mg/m\^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
223404608|NCT02509819|DEVICE|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
223404609|NCT01593670|DRUG|Decitabine|administered intravenous (IV), 10 mg/m\^2/day over 1 hour on days 1-5.
223404610|NCT01593670|DRUG|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
223404611|NCT01593670|BIOLOGICAL|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
223404612|NCT01593670|OTHER|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
223404613|NCT04463407|OTHER|Educational talk about physical activity and nutritional recommendations before a critical period of fat gain in university students|An intervention was performed emulating a traditional nutritional session from a primary healthcare center (public health system). Traditionally, this session lasts around 20 minutes and includes a body composition measurement, nutritional assessment, and a brief educational talk about healthy eating. Just the intervention group received a series of healthy recommendations specially focused on the National Holiday.
223404614|NCT05459961|DIETARY_SUPPLEMENT|oral spermidine|oral supplement
223404615|NCT05645848|DEVICE|Ultrasonography|Abdominal ultrasound in pregnant women with placenta previa
223404616|NCT03630926|DIAGNOSTIC_TEST|NV-VPAC1 PCa Urine Diagnostic Test|The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
223404617|NCT03079986|OTHER|Standard care irrespective of CL|Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.
223555296|NCT05417451|OTHER|Acupuncture|All participants will receive a semi-standardized acupuncture protocol (standardized points for pain, fatigue, depression, anxiety, sleep disturbance, with additional points for patient's particular pain location)
223555297|NCT04898894|DRUG|Venetoclax|Given orally (PO)
224022472|NCT02330289|BEHAVIORAL|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
224132444|NCT01159509|BEHAVIORAL|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
223404618|NCT03079986|OTHER|Dietary treatment (MCT-diet)|Dietary treatment with MCT-diet until resolution of CL.
223404619|NCT05990322|BEHAVIORAL|Project EMPOWER|Experimental Condition
223404620|NCT03514524|OTHER|PET-MR imaging|Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
223404621|NCT01343043|DRUG|NY-ESO-1(c259)T Cells|Lymphodepleting chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
223404622|NCT01343043|DRUG|Fludarabine|Fludarabine will be used as lymphodepleting chemotherapy.
223555298|NCT04898894|DRUG|Selinexor|Given Orally (PO)
223404623|NCT01343043|DRUG|Cyclophosphamide|Cyclophosphamide will be used as lymphodepleting chemotherapy.
223404624|NCT01294176|DRUG|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
223404625|NCT04122300|DRUG|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
223404626|NCT04122300|DRUG|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
223555299|NCT04898894|DRUG|Cytarabine|Given in to the vein (IV) or intrathecal (IT)
223555300|NCT04898894|DRUG|Fludarabine|Given in to the vein (IV) - Because of the ongoing nationwide shortage of fludarabine, this agent may be omitted during the dose expansion phase of the trial.
223555301|NCT04898894|BIOLOGICAL|Filgrastim|Given subcutaneous (SubQ, SC)
223555302|NCT04898894|DRUG|Methotrexate|Given intrathecal (IT)
223555303|NCT04898894|DRUG|methotrexate/hydrocortisone/cytarabine|Given intrathecal (IT)
223555304|NCT01525862|DEVICE|Balloon sinus dilation|
223555305|NCT04193709|DEVICE|Spinal Cord Epidural Stimulation|For arm 2, optimal stimulation parameters (cathode/anode configuration, stimulation frequency and voltage; placement of electrode from L1 to S1) will be identified for blood pressure and bladder pressure to achieve a bladder capacity in the target normative range of 400-450 mLs. Spinal cord epidural stimulation will then be used in a controlled lab setting for the regulation of blood pressure and heart rate to maintain normative values (target systolic pressure of 110-120 mmHg) and bladder pressure below 10 cmH2O during bladder filling up to the targeted capacity (fill volume of 400 mLs).
223404627|NCT01071642|DRUG|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
223404628|NCT01071642|DRUG|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
223404629|NCT02556320|DRUG|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
223404630|NCT02556320|BIOLOGICAL|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
223404631|NCT02300831|OTHER|Data Collection|Non interventional prospective data collection
223404632|NCT06449729|DIAGNOSTIC_TEST|Blood sample and urine collection|Blood sample and urine collection as per clinical practice
223404633|NCT02771067|PROCEDURE|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
223404634|NCT05310682|OTHER|Data informed Platfrom for health|The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
223736916|NCT01109225|PROCEDURE|renal echography|
223736917|NCT04328324|PROCEDURE|Endoscopy|Diagnostic upper Git endoscopy
223736918|NCT04159233|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
223736919|NCT02681120|PROCEDURE|Biopsy|
223736920|NCT02681120|PROCEDURE|Blood draw|
223736921|NCT02681120|PROCEDURE|Mammogram|
223736922|NCT02681120|PROCEDURE|MRI|
223736923|NCT03733288|BEHAVIORAL|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
223736924|NCT03733288|BEHAVIORAL|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
224132445|NCT02214485|BEHAVIORAL|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
224132446|NCT02214485|BEHAVIORAL|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
223404635|NCT04231526|DRUG|Pembrolizumab|2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)
223736925|NCT03733288|BEHAVIORAL|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
224132447|NCT03201367|DRUG|Rivaroxaban|Rivaroxaban 10 mg/12 hour
224132448|NCT03201367|OTHER|symptomatic therapy for ascites, abdominal pain|
224132449|NCT02604810|BIOLOGICAL|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
223404636|NCT04231526|PROCEDURE|Surgery|Standard of care surgery
223404637|NCT03017404|DRUG|Doxorubicin Hydrochloride Liposome Injection|
223404638|NCT03017404|DRUG|Cyclophosphamide|
223404639|NCT03017404|DRUG|docetaxel|
223404640|NCT06476301|DRUG|Rivaroxaban|To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin
223404641|NCT06465862|DEVICE|TruTag System|TruTag technology system, consisting of microparticle-tagged Biktarvy and companion smartphone app.
224132450|NCT02604810|BIOLOGICAL|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
224132451|NCT05718206|DEVICE|Magnetocardiography|Both arms underwent magnetocardiogram examination, and three experts interpreted magnetocardiogram results independently.
223404642|NCT06465862|DRUG|Biktarvy Pill|Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
223404643|NCT04283240|DRUG|Sildenafil|50 mg sildenafil, one dose
224138780|NCT01688167|BEHAVIORAL|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
223736926|NCT03733288|DEVICE|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
223736927|NCT05778396|PROCEDURE|Active spinal manual therapy protocol|The chiropractor will start by (1) placing one hand over L4-L5 or L5-S1 and then will apply a high-velocity, low-amplitude (HVLA) thrust with a therapeutic line of drive. Side-lying lumbar manipulation will be performed bilaterally, with the treating clinician choosing any suitable technique and with or without occurrence of the characteristic audible joint cavitation associated with spine manipulation. The chiropractor will then perform (2) prone lumbar mobilisation by placing the contact hand and applying downward pressure over L4-L5 or L5-S1 with the other hand guiding a manual flexion-distraction piece to apply therapeutic mobilization of the lumbar spine. The chiropractor will deliver (3) a prone thoracic manipulation by placing two hands over the transverse processes of T5-T6 or T6-T7 and applying a HVLA thrust in a posterior-to-anterior direction.
223736928|NCT05778396|PROCEDURE|Control spinal manual therapy protocol|(1) Control side-lying lumbar manipulation will be operationalised as the application of a low-velocity broad push manoeuvre to the gluteal region following a non-therapeutic line of drive. The chiropractor will then perform (2) control prone lumbar mobilisation, consisting of a non-therapeutic manual manoeuvre involving minimal oscillations (0 to ±2°) of the flexion-distraction piece with light touch over the lumbar spine region, and (3) control prone thoracic mobilisation consisting of two-handed left and right scapula pushes with a nontherapeutic line of drive.
223736929|NCT03674918|DIAGNOSTIC_TEST|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
223736930|NCT02629341|DIETARY_SUPPLEMENT|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
223736931|NCT02629341|DIETARY_SUPPLEMENT|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
223736932|NCT02990208|BEHAVIORAL|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens \& Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
224132452|NCT00796042|OTHER|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
224138781|NCT05010993|DIAGNOSTIC_TEST|Nine Hole Peg Test|Each person will be tested by the Nine Hole Peg Test (3 attempts per subtest)
223404644|NCT04283240|DRUG|Placebo|Placebo
223404645|NCT00925704|DRUG|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
223404646|NCT00925704|DRUG|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
223404647|NCT00925704|DRUG|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
223404648|NCT04980430|DEVICE|Virtual Reality|Virtual Reality Demonstration
223404649|NCT05602168|OTHER|experimental:Acute leukemia/myelodysplastic or myeloproliferative disease|blood sampling, bone marrow aspirate and buccal swab
223404650|NCT00581672|BEHAVIORAL|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
223404651|NCT02930772|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z46-100)"
223404652|NCT01244568|BEHAVIORAL|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
223404653|NCT01772810|DRUG|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
223404654|NCT06114381|OTHER|Home Based Physical Exercise|"Home Exercise protocol consists of one hour divided to 3 minutes warm up,9 minutes' full body (lower limbs, abdomen, back and upper limbs) exercise composed of (aerobic and strengthening) and 3 minutes cool down 4 times per day and 15 minutes for each session 6 days with one day recovery and, with every day follow up with each patient to ensure they did the whole sets and instructed them the ways to each exercise, The total duration was 36 sessions (6 weeks) for each patient. Daily communication with all subjects through sending mobile messages 3 times every day. The message was to remind the participants and confirmation of their response."
223736933|NCT02990208|BEHAVIORAL|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger \& Pauli, 2011)
223404655|NCT06114381|DIETARY_SUPPLEMENT|Vitamin D3 Supplements|Vitamin D3 supplement (400mg) once daily.
223404656|NCT06114381|OTHER|Diet Management|Patients receive weekly diet program contains dietary sources of Vitamin D such as yolk eggs, tuna and milk.
223404657|NCT06114381|BEHAVIORAL|Sun Exposure|Patients regular exposure to sun once a day 30 minutes of sun exposure, between 10 a.m. and 4 p.m. daily. Exposure to the face, arms, hands, and legs without sunscreen
223404658|NCT03454334|DEVICE|multifocal intraocular lens IOLs|clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
223404659|NCT00216125|DRUG|Cisplatin|Cisplatin 50 mg/m2 day 1, 8, 29, 36
223404660|NCT00216125|DRUG|Etoposide|Etoposide 50 mg/m2, days 1-5, 29-33
223555306|NCT00931125|DRUG|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
223555307|NCT00931125|PROCEDURE|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
223555308|NCT01498692|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
223555309|NCT01292122|DEVICE|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
223555310|NCT03956992|OTHER|Mouth gel|Stop using the mouth gel
223555311|NCT00352469|DRUG|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
223555312|NCT04916561|DIAGNOSTIC_TEST|RT-PCR|Detection of Covid-19 in bone, articular fluid and muscle samples using RT-PCR
223555313|NCT02045888|DEVICE|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
223555314|NCT02045888|BIOLOGICAL|Placebo|Placebo is visually matched solution
223555315|NCT00590122|DRUG|Parcopa|at subjects current stable dose of comparator
223555316|NCT00590122|DRUG|carbidopa-levodopa (Sinemet)|at subjects current stable dose
223555317|NCT04719481|DRUG|Pravastatin Sodium 80 MG|daily oral administration of 80mg
223555318|NCT04719481|DRUG|Placebo|daily oral administration
223555319|NCT03441529|DRUG|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
223555320|NCT03441529|DRUG|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
223555321|NCT00907322|DRUG|Dimebon|Oral tablet; 20 mg Dimebon, single dose
223736934|NCT06353880|OTHER|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.|Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
224138782|NCT05010993|DIAGNOSTIC_TEST|Purdue Pegboard Test|Each person will be tested by the Purdue Pegboard Test (3 attempts per subtest)
224138783|NCT05010993|DIAGNOSTIC_TEST|Box and Block Test|Each person will be tested by the Box and Block Test (3 attempts per subtest)
223404661|NCT00216125|RADIATION|Radiation|Radiation 5940 cGy (180 cGy/day)
223404662|NCT00216125|DRUG|Docetaxel|docetaxel 75mg/m2 q3wk x 3 cycles
223404663|NCT05885425|BEHAVIORAL|Telemedicine correction of medical treatment|On the basis of telemedicine data, the doctor will remotely correct medical treatment by adjusting the dose or supplementing or by omitting the medicine in order to improve the state of health, or to alleviate the symptoms of the disease monitored by telemedicine
223404664|NCT05885425|BEHAVIORAL|Education for proper lifestyle|Based on telemedicine data, the doctor can consider periodic education of the patient with the innervated group in order to improve lifestyle
223404665|NCT02044302|DRUG|Bupivacaine|
223404666|NCT02044302|DRUG|Botulinum Toxins|
223404667|NCT02044302|DRUG|Analgesics|
223404668|NCT03322202|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
223555322|NCT00907322|DRUG|Dimebon|Oral tablet; 40 mg Dimebon, single dose
223555323|NCT00907322|DRUG|Dimebon|Oral tablet; 60 mg Dimebon, single dose
223555324|NCT00907322|DRUG|Dimebon|Oral tablet; placebo, single dose
223555325|NCT04300205|DEVICE|High intensity LED light device|Participant wounds are treated with LED light device for 10 minutes, 4 times over the course of 2 months
223555326|NCT04300205|DEVICE|Sham LED light device|Participants have the light treatment moved off their wound after masking
223555327|NCT00408707|PROCEDURE|local infiltration analgesia|
223555328|NCT02653443|BIOLOGICAL|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
223555329|NCT02653443|BIOLOGICAL|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
223404669|NCT01618175|DEVICE|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
223555330|NCT01208324|DRUG|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
223555331|NCT01208324|DRUG|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
223555332|NCT01208324|DRUG|Placebo Patch|placebo
223555333|NCT01208324|DRUG|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
223736935|NCT06525766|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223736936|NCT06525766|PROCEDURE|Bone Scan|Undergo bone scan
224022473|NCT05188339|DRUG|4% sodium citrate|"Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8.~A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months."
224132453|NCT00796042|OTHER|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
224132454|NCT04438772|OTHER|Check the condition of intubation with LPEC compared with a sham procedure in the general anesthesia|Intubation with Left Paratracheal Esophagus Compression (LPEC) or sham procedure and evaluation of intubation's condition
224132455|NCT01125657|DRUG|YM150|oral
224132456|NCT00488995|DRUG|CP-675,206|
223404670|NCT03971032|PROCEDURE|Hysteroscopy|Diagnostic procedure
223404671|NCT03971032|DEVICE|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
223404672|NCT01387087|DRUG|ASP015K|oral
223555334|NCT05940857|DEVICE|OCS Liver|The TransMedics® Organ Care System (OCS) Liver is an FDA approved portable extracorporeal liver perfusion and monitoring system.
223404673|NCT01387087|DRUG|Placebo|oral
223736937|NCT06525766|DRUG|Capecitabine|Given PO
223555335|NCT02236234|BIOLOGICAL|HPV vaccine|HPV vaccine
223736938|NCT06525766|PROCEDURE|Computed Tomography|Undergo CT
223736939|NCT06525766|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223736940|NCT06525766|OTHER|Questionnaire Administration|Ancillary studies
223736941|NCT05681585|OTHER|Implementation support program|"The intervention consists of:~I Implementation strategies:~1.1 Ensuring leadership commitment 1.2 Responsive evaluation 1.3 Whole ward approach 1.4 Train the trainer model 1.5 Sustainability after the study~II Implementation interventions 2.1 Implementation team 2.2 ACP coordinator 2.3 Training and supervision: Kick-off, training of resource persons and health care personnel including practical exercises, network conferences 2.4 Toolkit and shared resources: ACP guideline, teaching material, information leaflets, documentation templates etc. 2.5 Structured fidelity measurements of the implementation level of a) the implementation interventions and b) the clinical intervention, with tailored feedback and supervision~III Clinical intervention: Advance Care Planning 3.1 Routine information and invitation to Advance Care Planning to all eligible patients 3.2 Written information to patients and relatives 3.3 Documentation and collaboration with other health care levels"
223736942|NCT06441552|OTHER|non-interventional|non-interventional
223736943|NCT02343042|DRUG|Selinexor|Oral tablets
223736944|NCT02343042|DRUG|Dexamethasone|Oral tablets
223736945|NCT02343042|DRUG|Lenalidomide|Oral capsule
223736946|NCT02343042|DRUG|Pomalidomide|Oral tablets
224138784|NCT00435032|PROCEDURE|early appendectomy|Appendectomy within 24 hours of admission
224138785|NCT00435032|PROCEDURE|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
223736947|NCT02343042|DRUG|Bortezomib|Subcutaneous Injection (single use vial)
223736948|NCT02343042|DRUG|Daratumumab|Intravenous Infusion
223404674|NCT02374970|OTHER|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
223404675|NCT02374970|OTHER|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
223736949|NCT02343042|DRUG|Carfilzomib|Intravenous infusion
223736950|NCT02343042|DRUG|Ixazomib|Oral capsule
223736951|NCT02343042|DRUG|Elotuzumab|Intravenous infusion
223736952|NCT02343042|DRUG|Clarithromycin|Tablets
223736953|NCT02343042|DRUG|Belantamab Mafodotin|Intravenous infusion
223736954|NCT02343042|DRUG|Mezigdomide|Oral Capsules
223736955|NCT05707871|DRUG|SPECTRUM cigarettes|SPECTRUM cigarettes have varying amount of nicotine content
223736956|NCT05707871|OTHER|usual brand of Cigarettes|Usual Brand of Cigarettes
223404676|NCT00000807|DRUG|Etoposide|
223404677|NCT01918488|DIETARY_SUPPLEMENT|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
223404678|NCT01918488|DRUG|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
223404679|NCT02158156|BEHAVIORAL|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
223404680|NCT03207815|DRUG|Filgotinib|Tablet(s) administered orally
223404681|NCT03207815|DRUG|Placebo to match filgotinib|Tablet(s) administered orally
223404682|NCT03207815|DRUG|Prednisone|Tablet(s) administered orally
223404683|NCT04092556|DEVICE|transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
223404684|NCT04798794|OTHER|ECMO for neonates|Neonates (\<28 j) supported by ECMO for severe respiratory failure
223404685|NCT02444208|BEHAVIORAL|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
223555336|NCT01101282|DEVICE|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
223555337|NCT06520696|BEHAVIORAL|MILC application|Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
223736957|NCT02684760|DRUG|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
223736958|NCT02007018|DEVICE|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
224132457|NCT01047046|OTHER|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
223404686|NCT02444208|BEHAVIORAL|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
223736959|NCT02007018|OTHER|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending \> 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
223404687|NCT05261087|OTHER|No intervention|Individuals will not receive any interventions
223404688|NCT02899182|DRUG|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
223404689|NCT02899182|OTHER|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
223404690|NCT04646265|OTHER|periodontal treatment|non-surgical root debridement
223736960|NCT06366321|OTHER|relining technique|construction of complete denture by flasking and casting the relining impression
224022474|NCT05188339|DRUG|heparin group|Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.
223404691|NCT00391768|DRUG|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
223404692|NCT00452296|DRUG|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
223404693|NCT00452296|PROCEDURE|tight glycemic control|treatment with basal and bolus insulin
223404694|NCT04644523|OTHER|Dermoscopy|"dermoscopy is currently used in daily practice in dermatology, for melanoma screening. Dermoscopy will be used in this study on peri-ungueal area.~This is a non-invasive and painless exam."
224022475|NCT03957889|OTHER|Educational simulation|
224022476|NCT01720680|RADIATION|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
223404695|NCT05846100|PROCEDURE|Preprocedural spinal ultrasound|a preprocedural spinal ultrasound was performed in a non sterile manner with a sitting position.Both paramedian and transverse planes The intersection of the longitudinal and transverse lines is the point of needle insertion The distance from the skin to the dura mater is noted
223404696|NCT05846100|PROCEDURE|fictional preprocedure spinal ultrasound|fictional preprocedure spinal ultrasound Fictional ultrasound identification Screen device shut down
223404697|NCT04161469|PROCEDURE|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
223404698|NCT04161469|PROCEDURE|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
223404699|NCT00998920|DRUG|S-equol|oral, BID, 14 days
223404700|NCT00998920|DRUG|Placebo|oral, BID, 14 days
223404701|NCT06117839|PROCEDURE|using antibiotic loaded cement and regular cement after total knee arthroplasty in primary knee osteoarthritis.|-There are 2 groups ,first group is patients will betreated with regular bone cement ,the second one is patient will be treated with antibiotic loaded bone cement, commonly used antibiotics include Gentamycin powder .
223404702|NCT01868737|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
223404703|NCT01868737|DIETARY_SUPPLEMENT|Placebo|MCT oil
223404704|NCT01109485|DRUG|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
223404705|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223404706|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223404707|NCT03191383|BIOLOGICAL|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223404708|NCT03191383|DRUG|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223404709|NCT00070005|PROCEDURE|conventional surgery|
223404710|NCT00070005|PROCEDURE|management of therapy complications|
223404711|NCT00172198|DRUG|Omegaven 10%|
223404712|NCT03956979|DRUG|JM-010 group A|JM-010 fixed combination drug (Group A) + Placebo 2
223404713|NCT03956979|DRUG|JM-010 group B|JM-010 fixed combination drug (Group B) + Placebo 1
223404714|NCT03956979|DRUG|Placebos|Placebo 1 + Placebo 2
223404715|NCT01585415|DRUG|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
223404716|NCT01585415|BIOLOGICAL|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
223404717|NCT01585415|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
223404718|NCT01585415|DRUG|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
223404719|NCT01585415|DRUG|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
223404720|NCT01912092|DEVICE|Askina Calgitrol paste|
223404721|NCT03984500|OTHER|Education|SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
223404722|NCT01492907|RADIATION|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
223736961|NCT06366321|OTHER|CAD/CAM milling technique|construction of complete denture by milling of the scanned relining impression
224022477|NCT01720680|DEVICE|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
224022478|NCT04672629|DEVICE|echocardiography|follow up echocardiography
224022479|NCT06071559|PROCEDURE|Laparoscopic Roux-en-y gastric bypass|Obesity surgery
224022480|NCT06298669|DEVICE|Biventricular Pacing|The CRT device will be reprogrammed to coordinate contractions of the left and right ventricles.
224022481|NCT06298669|DEVICE|Right Ventricular Pacing|The CRT device will be reprogrammed for right ventricular contractions.
224132458|NCT05000814|DEVICE|DLT|VDLT versus the use of DLT with fiberoptic bronchoscope
224132459|NCT03297307|BEHAVIORAL|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
223404723|NCT01492907|PROCEDURE|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
223404724|NCT04545671|OTHER|trifocal lens|not applicable as patients are already implanted with the trifocal lens
223404725|NCT04598061|DRUG|Dexmedetomidine IV|Dexmedetomidine IV
223404726|NCT05423288|PROCEDURE|Distal pancreatectomy (DP)|Any scheduled distal pancreatectomy performed for any diagnosis
223404727|NCT04208451|DIETARY_SUPPLEMENT|Alixir 400 Protect|During 30 days all patients take every day 30ml of Alixir 400 protect
223404728|NCT01412567|DRUG|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
223404729|NCT01412567|DRUG|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
223404730|NCT06181214|DIETARY_SUPPLEMENT|AG1 - Nutritional Supplement|A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients
223404731|NCT06181214|DIETARY_SUPPLEMENT|Placebo|Maltodextrin placebo
223404732|NCT04022057|DRUG|Ropivacaine injection|Local anesthetic injection
224132460|NCT02458157|DRUG|Furosemide (Furix)|"* Loading dose: 40 mg I.V.~* Infusion rate 40 mg/h~* Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
223555338|NCT06520696|BEHAVIORAL|Usual care|"Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect."
223555339|NCT06288308|DIAGNOSTIC_TEST|fibronigin to albumin ratio|"To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes.~b. Secondary (subsidiary):~To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression"
223555340|NCT00140179|DRUG|valnoctamide|
223555341|NCT02707965|DRUG|Oxcarbazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555342|NCT02707965|DRUG|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555343|NCT02707965|DRUG|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555344|NCT02707965|DRUG|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223736962|NCT04718441|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
223736963|NCT05880303|PROCEDURE|Nonsurgical periodontal therapy|Oral Hygiene education, scaling and root surface debridement at baseline and 3 months
223404733|NCT04022057|DRUG|Dextrose 5|Sham Injection
223404734|NCT00406367|DRUG|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
223404735|NCT00406367|DRUG|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
223404736|NCT06256601|DEVICE|Theracal (calcium silicate)|selective removal to soft dentin, restorations with calcium silicate
223404737|NCT06256601|DEVICE|Dycal (calcium hydroxide)|selective removal to soft dentin, restoration with calcium hydroxide
223404738|NCT06204263|OTHER|finger feeding|The fathers of premature babies in intensive care will be interviewed and an educational booklet will be prepared about finger feeding, cleaning, hygiene, hand washing, the importance of sucking, and the rules to be followed to prevent infection in the newborn, and how to apply it will be explained by the researcher. Babies will be breastfed three times a day for seven days.
223404739|NCT00261586|DRUG|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
223404740|NCT01286610|DEVICE|ProMedVi Vibrosphere|vibration therapy
223404741|NCT01286610|DEVICE|schwa-medico MUSKELaktiv|Electrical muscle stimulation
223404742|NCT01286610|DEVICE|Galileo Home Plus (ICU)|vibration therapy
223404743|NCT00171210|DRUG|Deferasirox|Tablets taken orally once a day.
223404744|NCT00253435|BIOLOGICAL|Filgrastim|Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC \>=1500/uL for three consecutive days.
223555345|NCT02707965|DRUG|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555346|NCT02707965|DRUG|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555347|NCT02707965|DRUG|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555348|NCT02707965|DRUG|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
223555349|NCT03970876|BIOLOGICAL|ATGC-100|Clostridium Botulinum Type A
223555350|NCT03970876|BIOLOGICAL|Botox®|Clostridium Botulinum Type A
223555351|NCT01635270|RADIATION|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
223555352|NCT01635270|RADIATION|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
223555353|NCT03862612|PROCEDURE|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
223555354|NCT01687543|DIETARY_SUPPLEMENT|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
223736964|NCT00583804|DEVICE|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
223404745|NCT00253435|DRUG|Carboplatin|"The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y."
223555355|NCT01687543|OTHER|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
223555356|NCT00079261|DRUG|CHOP regimen|
223555357|NCT00079261|DRUG|cyclophosphamide|
223555358|NCT00079261|DRUG|doxorubicin hydrochloride|
223555359|NCT00079261|DRUG|gemcitabine hydrochloride|
223555360|NCT00079261|DRUG|prednisone|
223555361|NCT00079261|DRUG|vincristine sulfate|
223555362|NCT00705497|PROCEDURE|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
223555363|NCT01738815|DRUG|Valproic Acid|500 mg orally, once daily for up to 30 days
223555364|NCT00249808|DRUG|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
223555365|NCT03685474|BEHAVIORAL|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
223555366|NCT03685474|BEHAVIORAL|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
223555367|NCT04497363|DEVICE|Brainsonix Pulsar 1002|Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
223555368|NCT00954629|DRUG|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
223736965|NCT06506227|BEHAVIORAL|Low risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine
223736966|NCT06506227|BEHAVIORAL|Medium risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces
223736967|NCT06506227|GENETIC|High risk experimental group|Guiding + Manipulation + Traditional Chinese Medicine + Specific Exercise Therapy + Orthopedic Braces + Specialized Inpatient Rehabilitation
223736968|NCT06506227|BEHAVIORAL|Control group COBB 10-20°|Specific Exercise Therapy
223736969|NCT06506227|BEHAVIORAL|Control group COBB 20-45°|Orthopedic Braces + Specific Exercise Therapy
223736970|NCT06506227|BEHAVIORAL|Control group COBB >45°|Orthopedic Braces + Specific Exercise Therapy + Recommended Surgery
223404746|NCT00253435|DRUG|Etoposide|The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR \>= 100 ml/min/1.72 m\^2, a dose of 300 mg/m\^2/day (10 mg/kg/day if child is \< 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m\^2, the etoposide will be administered at a dose of 160 mg/m\^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of \< 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
223404747|NCT00253435|DRUG|Melphalan|For patients in either the normal GFR strata (\>=100 ml/min/1.73 m\^2), or reduced GFR strata (60-99 ml/min/1.73m\^2), melphalan shall be administered at a dose of 60 mg/m\^2/day (2 mg/kg/day if child is \< 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration \< 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m\^2.
223404748|NCT00253435|PROCEDURE|Peripheral blood stem cell infusion|Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10\^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10\^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10\^8 mononuclear cells/kg must be available.
223404749|NCT00253435|RADIATION|131I-MIBG|Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
223736971|NCT06506227|OTHER|Experimental group (AIS group)|Molecular marker exploration and validation
223404750|NCT00253435|RADIATION|Radiation therapy|Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC \> 1000/uL, platelets \> 30,000 / uL, and is \> 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
223404751|NCT05917535|BEHAVIORAL|Mentalizing course|6 hour mental health education course about mentalizing.
223404752|NCT03910036|BIOLOGICAL|platelet rich plasma|Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
223404753|NCT04087993|DRUG|Polyglucoferron|intravenous administration
223404754|NCT04087993|DRUG|Ferric carboxymaltose|intravenous administration
223404755|NCT04087993|DRUG|Ferrous Sulfate|oral administration
223404756|NCT03632928|OTHER|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
223404757|NCT03632928|OTHER|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
223404758|NCT03187301|DRUG|APL-130277|APL-130277 single dose
223404759|NCT03187301|DRUG|Placebo|Placebo single dose
223404760|NCT03187301|DRUG|Moxifloxacin|moxifloxacin 400mg single dose
224022482|NCT02864030|DRUG|ERIBULIN MESYLATE|"Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin."
224022483|NCT05428930|DRUG|CKDB-501B|Intramuscular injection CKDB-501B
224022484|NCT05428930|DRUG|Botox®50U|Intramuscular injection Botox®50U
224022485|NCT02641574|OTHER|compare complication|
224132461|NCT02458157|OTHER|Continuous renal replacement therapy (CRRT)|"* Initiated in case of contraindications or inadequate effect of furosemide.~* Fluid removal is started at 2 ml/kg/h~* The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
224138786|NCT02528968|BEHAVIORAL|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
223404761|NCT03324568|BEHAVIORAL|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
223404762|NCT03324568|BEHAVIORAL|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
223404763|NCT02498704|PROCEDURE|Dry Needling|Trigger point dry needling to hamstring muscle group.
223404764|NCT02498704|OTHER|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
223404765|NCT03790501|OTHER|No intervention|As an observational study, no intervention will be associated with the study group.
223404766|NCT04553939|DRUG|Toripalimab|Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
223404767|NCT04553939|DRUG|Gemcitabine|Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
223404768|NCT00133419|DRUG|Vitamin + Zinc + micronutrient mixture|
223736972|NCT06506227|OTHER|Control group (healthy control)|Molecular marker exploration and validation
224022486|NCT02390050|DRUG|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
223404769|NCT00133419|DRUG|Vitamin A|
223404770|NCT00133419|DRUG|Vitamin A + Zinc|
224022487|NCT02390050|DRUG|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
223404771|NCT00304096|BIOLOGICAL|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
223404772|NCT03827499|DIETARY_SUPPLEMENT|HMB dietary supplementation|Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
223404773|NCT03827499|OTHER|Multicomponent physical exercise program|Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
223404774|NCT02790099|DRUG|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
223404775|NCT02790099|DRUG|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
223404776|NCT02158585|DRUG|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, and 100 mg twice a day during titration; 150mg twice a day for the 12-week study period; 150mg once a day for Week 1 of the taper; and 75mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
223404777|NCT02158585|DRUG|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
223404778|NCT05178615|OTHER|preoperative education|Education about knee anatomy, patophysiology, total knee arthroplasty surgery, pain neurophysiology, management of pain, the importance of exercise
224022488|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. The first enrolled 8 patients will undergo serial whole-body PET/CT scans at multiple time points (5, 15, 30, 45, 60, and 120 min) after injection of Al18F-NOTA-LM3. The following patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
224022489|NCT06056362|DIAGNOSTIC_TEST|68Ga-DOTATATE|All patients in arm A will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-DOTATATE. 68Ga-DOTATATE PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
224022490|NCT06056362|DIAGNOSTIC_TEST|Al18F-NOTA-LM3|40 patients will be enrolled in this arm. All patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.
224022491|NCT06056362|DIAGNOSTIC_TEST|68Ga-NODAGA-LM3|All patients in arm B will undergo a whole-body PET/CT scan 40-60 minutes after injection of 68Ga-NODAGA-LM3. 68Ga-NODAGA-LM3 PET/CT and Al18F-NOTA-LM3 PET/CT should be performed within a week and the interval between the two scans at least 24h.
224022492|NCT06438497|PROCEDURE|RIRS with f-UAS, lateral position|In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
223404779|NCT01072773|DRUG|bortezomib|1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days
223404780|NCT01072773|DRUG|cyclophosphamide|300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
223404781|NCT01072773|DRUG|dexamethasone|40 mg, orally, on days 1, 8, 15 \& 22 every 28 days
223404782|NCT05808374|DRUG|HRS-5635|50mg HRS-5635；100mg HRS-5635；200mg HRS-5635；400mg HRS-5635；600mg HRS-5635；800mg HRS-5635
223404783|NCT05808374|DRUG|HRS-5635|100mg HRS-5635，Q4W；200mg HRS-5635 ，Q4W；400mg HRS-5635，Q4W；200mg HRS-5635, Q2W
223404784|NCT05808374|DRUG|HRS-5635|200mg HRS-5635，Q4W
223404785|NCT05808374|DRUG|Placebo|Placebo
223404786|NCT04005430|DRUG|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
223404787|NCT00925444|DEVICE|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
223404788|NCT00925444|DEVICE|Stapling|Stapling alon or associated with sealants
223404789|NCT02770794|DRUG|Infliximab|Discontinue infliximab; receive Infliximab when relapse
223555369|NCT00954629|DRUG|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
223555370|NCT03292549|PROCEDURE|Robotic partial surgery|Robotic partial surgery
223404790|NCT02848144|OTHER|blood samples|
223404791|NCT02848144|OTHER|Collection of nosocomial infections|
223404792|NCT04943146|DRUG|Prednisone 10 MG+aspirin 100MG|Discontinue medication based on early pregnancy outcome
223404793|NCT00169572|DRUG|Aprepitant|
223404794|NCT00169572|DRUG|Ondansetron|
223404795|NCT00169572|DRUG|GW679769|
223404796|NCT00169572|DRUG|Dexamethasone|
223555371|NCT06516081|DIETARY_SUPPLEMENT|Micronutrient powder (Sprinkles®)|
223555372|NCT02789345|DRUG|Ramucirumab|Administered IV
223555373|NCT02789345|DRUG|Necitumumab|Administered IV
223555374|NCT02789345|DRUG|Osimertinib|Administered orally
223555375|NCT00046761|DRUG|ONO-2506|
223555376|NCT02437630|PROCEDURE|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
223555377|NCT02437630|PROCEDURE|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
223404797|NCT04873921|OTHER|sterile kinesio taping|Application area will be cleaned and dried prior to application to increase the adhesiveness of the tape and application will be done by an experienced physiotherapist during ACLR surgery.
223404798|NCT01223118|PROCEDURE|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
223736973|NCT06506227|OTHER|Controlled follow-up before and after AIS|Construction and validation of AIS risk prediction model completed
223404799|NCT02450149|DRUG|sorafenib|
223404800|NCT01047059|DRUG|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
223404801|NCT01047059|DRUG|Fluoro-D-glucose|Tracer for PET imaging
223555378|NCT02437630|OTHER|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
223555379|NCT02437630|PROCEDURE|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
223555380|NCT02437630|PROCEDURE|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
223555381|NCT02437630|OTHER|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
223555382|NCT04387006|OTHER|OMT|OMT techniques were focused on correcting the dysfunctions found during the initial physical examination and included articular and myofascial techniques, balanced ligamentous tension, visceral manipulations and osteopathy in the cranial field
223555383|NCT04387006|OTHER|MP|MP treatment was performed by the same osteopaths who performed OMT and was carried out in the same hospital setting. P treatment consisted of a passive touch without joint mobilization in a protocolled order. The osteopaths were standing next to the bed, they touched lumbar and dorsal spine of the subjects in prone position for 10 minutes, and then in supine position, they touched for 10 minutes the shoulders, the hips, then the neck, the sternum and the chest were touched for 5 minutes each. Another researcher on the placebo protocol specifically trained the osteopaths.
223555384|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
223555385|NCT03043352|DIETARY_SUPPLEMENT|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC \< 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
223736974|NCT04954274|DRUG|Cyclic peptide Fertiline|"Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.~After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide."
223736975|NCT00705081|DRUG|ezetimibe|10 mg once daily
223736976|NCT00705081|DRUG|statin|
223736977|NCT02988921|DEVICE|MRI and CT|
223736978|NCT02988921|RADIATION|Ratiotherapy|
223736979|NCT02988921|DRUG|Paclitaxel, platinum-based drug|
223736980|NCT04967170|BIOLOGICAL|Autologous Platelet-Rich Plasma (PRP)|Two intralesional injections of approximately 5-6mL given approximately 6 weeks apart
223736981|NCT04967170|OTHER|Sham Procedure|Intralesional needle insertion without any injectate.
223736982|NCT06107712|OTHER|Online yoga exercise|"The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week."
223404802|NCT01047059|DRUG|Fluoro-L-thymidine|FLT-PET tracer for imaging
223404803|NCT01047059|DRUG|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
223404804|NCT04644432|DRUG|Medication (A specification is listed under each arm)|Study drugs and dosages are listed in the description of arms.
223404805|NCT04644432|OTHER|Patient reported outcomes measurement|"PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events.~The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital.~For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish."
223404806|NCT02762942|DRUG|Misoprostol|Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
223404807|NCT02762942|DEVICE|Foley catheter|Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
223404808|NCT01555632|DRUG|atorvastatin calcium|Given PO
223404809|NCT01555632|DRUG|placebo|Given PO
223404810|NCT04381728|DEVICE|Womed Leaf|Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
223404811|NCT01545531|DRUG|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration \[13\]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
223404812|NCT05184205|DEVICE|Nasal Photodisinfection|The procedure is initiated by swabbing the Formulation Applicator, pre-saturated with photosensitizer formulation, inside the patient's nares. The operator then connects the Nasal Light Illuminator (NLI) to the Light Source and inserts the NLIs into the patient's nostrils. The Light Source is turned on, and a 4-minute illumination cycle provides two channels of diffused red light (one for each nostril) to activate the applied formulation. Illumination stops automatically upon completion of the 4-minute cycle. The process is then repeated using two new Formulation Applicators to ensure full disinfection coverage.
223404813|NCT05184205|DEVICE|Sham Comparator: Control|Patients who are SARS-CoV-2 positive whose PCR levels are followed but no active intervention will be done. Saline will be used in their nose and the light device will be inserted but not turned on. Patient will be wearing light protecting glasses.
223404814|NCT02592577|BIOLOGICAL|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
223404815|NCT06209723|OTHER|Vegetarian diet|Participants will follow a vegetarian diet during a period of five weeks
223404816|NCT05017350|PROCEDURE|radiofrequency ablation|Under the ultrasound guidance, the electrode is inserted into the bleeding focus of the liver and the bleeding focus is ablated.
223555386|NCT05119374|DEVICE|SenseGuard Investigational Device|"SG is a wireless, wearable medical device, which includes nano-based sensors. It can seamlessly measure patient's tidal breathing during daily activities. SG extracts series of critical respiratory parameters, including; Respiration Rate (RR), Inhalation and Exhalation duration and ratio (I/E), as well as novel biomarkers. SG parameters are applicable to evaluate COPD patients' condition, or for monitoring patients with other respiratory conditions.~SG components are:~* RSM (Respiratory Sensing Module): non-invasive module with sensors that can detect the exhaled humidity and condensation. The RSM is a non-sterile, disposable, single patient use.~* ECU (Electronic Control Unit): a re-usable, wireless data acquisition and transmission unit. The ECU is connected to the RSM during the measurement and transmits the data via Bluetooth to the SG software.~* SenseGuard™ Software: for data management, acquisition, processing, logging and presentation of the digital respiratory signals."
223555387|NCT02520869|PROCEDURE|swim-up technique|swim-up technique used
223555388|NCT02520869|PROCEDURE|zeta test technique|zeta test technique used
223555389|NCT03487588|DRUG|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
223555390|NCT00301392|OTHER|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
223555391|NCT00301392|DRUG|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
223555392|NCT03139981|DRUG|ASN002|Daily dose of ASN002 for 28 days
223555393|NCT03139981|DRUG|Placebo Oral Tablet|Placebo for ASN002 for 28 days
223555394|NCT04693273|OTHER|Decision Aid for Surgical Modality Choice|A novel decision aid that helps surgical patients choose between Wide-Awake carpal tunnel release and traditional tourniquet surgery. It involves an orientation-memory-concentration test to test if patients are cognitively capable of making decisions, then the decision aid table that has similarities and differences between the two modalities, and a few survey questions that help the investigators know what the patients prefer. Finally, patients finish the decision conflict test to see how confident these patients are about their preference.
223555395|NCT04972682|PROCEDURE|Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy|Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
223555396|NCT02245269|DRUG|Tipranavir|
223555397|NCT02245269|DRUG|Ritonavir|
223555398|NCT02245269|DRUG|Atorvastatin|
223555399|NCT02245269|DRUG|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
223555400|NCT01163357|DRUG|bortezomib|Given IV
224022493|NCT06438497|PROCEDURE|RIRS with f-UAS, lithotomy position|In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A f-UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS. The tip of the UAS has good flexibility and deformability. It can passively bend with the bending of the flexible ureteroscope (f-URS).
223555401|NCT01163357|DRUG|fludarabine phosphate|Given IV
223555402|NCT01163357|OTHER|melphalan|Given IV
223555403|NCT01163357|RADIATION|total marrow irradiation|Undergo TMI
223555404|NCT01163357|DRUG|tacrolimus|Given IV and orally
223555405|NCT01163357|DRUG|sirolimus|Given orally
223555406|NCT01163357|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
223555407|NCT01163357|OTHER|laboratory biomarker analysis|Correlative studies
223404817|NCT00152334|DRUG|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
223404818|NCT05859919|DRUG|"The drug Rutan 0.1."|"Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: Rutan 0.1 100mg. Excipients: potato starch, calcium stearate, lactulose."
223404819|NCT05859919|OTHER|Basic treatment|"Basic treatment without the drug Rutan 0.1."
223404820|NCT05759741|DRUG|MIYAIRI 588|4 tablets of MIYAIRI 588 were inserted into the distal ileostomy once a week for 6 months
223404821|NCT03174535|DRUG|Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.|The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
223404822|NCT00636519|BIOLOGICAL|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
223404823|NCT00636519|BIOLOGICAL|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
223404824|NCT02182843|BIOLOGICAL|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
223404825|NCT01330823|DIETARY_SUPPLEMENT|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
223404826|NCT01330823|DIETARY_SUPPLEMENT|Placebo|tartaric acid same dose like L-Carnitine as placebo
223404827|NCT05388279|DRUG|JS012|JS012, i.v., q3w
223555408|NCT03684837|DIETARY_SUPPLEMENT|Vitamine D supplementation|a vitamine D dose for week
223555409|NCT03684837|OTHER|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
223555410|NCT05377476|OTHER|Motor Imagery training|Individuals included in this group will receive 20 minutes of motor imagery training in addition to 40 minutes of standard rehabilitation.
223555411|NCT05377476|OTHER|Action Observation training|Individuals included in this group will receive 20 minutes of action observation training in addition to 40 minutes of standard rehabilitation.
223555412|NCT05377476|OTHER|standard rehabilitation|40 minutes of standard rehabilitation.
223555413|NCT00135330|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
223555414|NCT00135330|DRUG|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
223555415|NCT04920071|DEVICE|Visual acuity and contrast sensitivity measurement|Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
223555416|NCT04512820|DEVICE|TRUCLEAR tissue removal system|evacuation of POC using the TRUCLEAR tissue removal system
223555417|NCT05780008|BEHAVIORAL|Eat My ABCs|"The Eat My ABCs curriculum incorporates senses into learning (hear, see, smell, taste) and includes two sessions/week: 1) healthy eating learning; and 2) mindful food taste-testing activities to expose children to the one fruit, one vegetable, and relevant food items made from the one fruit and one vegetable to teach children the creative ways to make fruit/vegetable healthy and tasty.~Child Letter to Parents. Every week, each child will create one letter, using stickers, regarding the one fruit and one vegetable presented in the program that he/she tasted or wanted to try at home.~Program Cookbook. The investigators have developed a targeted program cookbook for low-income families. The program cookbook contains all budget-friendly recipes for healthy breakfasts, family meals, quick-fixes, kid-friendly snacks, and occasional sweets. In addition, the cookbook contains creative ways of making fruit/vegetable healthy, tasty, and kid-friendly at home."
224022494|NCT06438497|PROCEDURE|RIRS with traditional UAS, lateral position|In this intervention, patients were placed on operating table in lateral position. The coronal plane of the patient body was perpendicular to the operating table. The upper limbs were extended and fxed with brackets. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
224022495|NCT06438497|PROCEDURE|RIRS with traditional UAS, lithotomy position|In this intervention, patients were placed on operating table in lithotomy position. This position is common and standard. A traditional UAS is placed under the pelvi-ureteric junction (PUJ) in RIRS.
224022496|NCT06487845|DRUG|BAY3283142|IR tablets, oral
224022497|NCT06487845|DRUG|Placebo|Placebo matched to BAY3283142
224022498|NCT03912376|DIAGNOSTIC_TEST|Quest Hyperspectral Imaging System|In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
224022499|NCT06144970|BIOLOGICAL|TG-C High Dose|High Dose - 1 mL of the combined TG-C cells
224022500|NCT06144970|BIOLOGICAL|TG-C Mid Dose|Middle Dose - A volume of 2 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
224022501|NCT06144970|BIOLOGICAL|TG-C Low Dose|Low Dose - A volume of 9 mL CS10 and 1 mL combined TG-C cells. 1.0 mL volume of the mixed TG-C cells is injected
224022502|NCT06144970|BIOLOGICAL|Sham Control|Single subcutaneous injection of normal saline
223404828|NCT05388279|COMBINATION_PRODUCT|JS012 combine with chemotherapy|JS012 i.v., q3w combine with chemotherapy
223404829|NCT02375971|DRUG|Ranibizumab|Administered as an intravitreal injection
223404830|NCT02375971|PROCEDURE|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
223404831|NCT01729078|DIETARY_SUPPLEMENT|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
223404832|NCT00302380|RADIATION|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
223404833|NCT06574776|OTHER|Observation and collecting data|In that single cohort we will collect data on MDRO infection and colonization prevalence, clinical characteristics, infections, causative organisms and mortality.
223404834|NCT00754104|DRUG|ABT-869|0.25 mg/kg. daily.
223404835|NCT00754104|DRUG|Tarceva|150mg, daily.
223404836|NCT02667704|DRUG|Bosentan|
223404837|NCT02667704|DRUG|Nintedanib|
223555418|NCT04505319|DEVICE|DEFINISSE CORE FILLER|"DEFINISSE CORE FILLER volume will be injected between 4.0 of 5.0 ml on the whole face (at the discretion of the treating physician to achieve an optimal aesthetic result).~A touch-up will be possible at the first follow-up visit (after one month) with a amount of product between 4.0 and 5.0 ml on the whole face"
223555419|NCT02350335|DRUG|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
223555420|NCT00372619|DRUG|clofarabine|Given IV for 5 days
223555421|NCT00372619|DRUG|cytarabine|Given IV
223555422|NCT00372619|DRUG|methotrexate|Given intrathecally or IT age based dosage
223555423|NCT00372619|OTHER|laboratory biomarker analysis|
223555424|NCT00066222|DRUG|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
223555425|NCT00066222|DRUG|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
223555426|NCT00066222|RADIATION|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
223555427|NCT01157338|PROCEDURE|diagnostic cardiac catheterization|coronary intervention: angiography
223555428|NCT01157338|PROCEDURE|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
223555429|NCT02767869|DRUG|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
223404838|NCT01640119|DIETARY_SUPPLEMENT|Bicarbonate|bicarbonate administration
223404839|NCT01504464|BIOLOGICAL|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
223404840|NCT01504464|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
223404841|NCT05874128|DEVICE|Prospective evaluation of HeartFocus Device (Software)|The primary objective of the study is to evaluate if exams, performed with the HeartFocus software by novices, are of sufficient quality to analyze visually
223404842|NCT00832455|DRUG|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
223404843|NCT02463903|BEHAVIORAL|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
223404844|NCT04653181|DRUG|Ferric carboxymaltose|Iron-arm treated with Ferric carboxymaltose, non-iron arm without
223555430|NCT02767869|DRUG|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
223555431|NCT03125031|DEVICE|Rainbow adhesive adult/pediatric sensor|
223555432|NCT03125031|DEVICE|Rainbow adhesive adult/neonatal sensor|
223555433|NCT02250508|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
223555434|NCT02250508|BIOLOGICAL|Haemate P® (Human Coagulation Factor VIII)|
223555435|NCT01933698|DRUG|amoxicillin|Comparison of pharmacokinetics of both formulations
223555436|NCT05996965|OTHER|HemoVista|additional attatchment of non-invasive hemodynamic monitoring HemoVista with FloTrac
223555437|NCT03575663|DIAGNOSTIC_TEST|Indirect bronchial challenge|Mannitol dry powder inhalation
223555438|NCT03575663|OTHER|Sham bronchial challenge|Mock dry powder inhalation
223555439|NCT02293967|DRUG|MT-1303|
223555440|NCT01748461|BEHAVIORAL|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
223555441|NCT01748461|BEHAVIORAL|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
223555442|NCT02888691|OTHER|Low carbohydrate diet|
223555443|NCT02888691|OTHER|High carbohydrate diet|
223555444|NCT06199375|BEHAVIORAL|Routine treatment|The routine treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.)
223555445|NCT06199375|BEHAVIORAL|Rehabilitation training|The Participants with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected based on the patient's specific limb function impairment, conducted by experienced rehabilitation therapists.
223555446|NCT06199375|BEHAVIORAL|Modified mirror therapy|The patients were instructed to watch the recorded video and imitate the movements of their affected limbs. After the video ended, only the instructions and synchronized music were played. The patient was required to sit in front of a mirror table, with the mirror placed between both arms and facing the healthy side. The patient was required to recall the video based on the verbal instructions while using the healthy side to perform movement training. They were also asked to observe the reflected motion of the healthy limb in the mirror, simultaneously imagining the affected limb moving in sync (the patient focused on the front of the mirror, avoiding direct eye contact with the healthy hand, to create the sensation that it was the affected hand performing the movements).
223555447|NCT01524224|DRUG|LY2495655|administered intravenously
223555448|NCT02746887|OTHER|Preterm/term cohort|
224022503|NCT01737554|OTHER|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
223404845|NCT04687839|PROCEDURE|Induction of suction blister|For each subject, 2 superficial wounds will be made on the inner aspect of each forearm using the suction blister model.
223404846|NCT04687839|OTHER|Transepidermal water loss (TEWL)|"* At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application"
223736983|NCT06107712|OTHER|Face-to-face yoga exercise|"The basic yoga poses of Shivananda Yoga included in the face-to-face yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath."
223404847|NCT04687839|OTHER|Macrophotography|"* At V1, before blister suction use (T0) and after blister withdrawal before product application (T1)~* For subsequent visits, before product application"
224022504|NCT06602635|DIAGNOSTIC_TEST|ECG and clinical score|The Hybrid Score (HS), detailed in previous literature involves a sum of points based on clinical and ECG characteristics. Points are assigned as follows: one point each for being over 50 years old, male, and having arterial hypertension. ECG-based points are allocated according to QRS transition: 3 points for a transition in V1, 2 points for V2, 1 point for V3 if the R-wave in V3 is greater than 1 mV; 1 point is subtracted if V3 has an R-wave less than 1 mV, and further deductions or additions apply for transitions up to V6. A score ≤ 1 suggests an RVOT origin, whereas ≥ 2 suggests an LVOT origin.
224022505|NCT01372423|DRUG|Lubiprostone|24 mcg capsules
223404848|NCT04687839|DEVICE|Wound healing medical device|Twice daily application on superficial wounds
223404849|NCT00223041|DRUG|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
223404850|NCT04424043|PROCEDURE|neo-TACE-HAIC+Surgery|transartery chemoembolization with lipiodol and EADM, FOLFOX (Oxa 85mg/m2 2h+CF 400mg/m2 2h +5FU 400mg/m2 10min+5FU 1200mg/m2 23h)-based artery infusion chemotherapy, followed by hepatic resection
223404851|NCT04424043|PROCEDURE|Surgery alone|hepatic resection remove the liver tumors
224022506|NCT01372423|DRUG|Placebo|24 mcg capsules
224022507|NCT01064661|DIETARY_SUPPLEMENT|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10\^10 cfu total bacteria per day)
224022508|NCT01064661|DIETARY_SUPPLEMENT|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10\^10 cfu total bacteria per day)
223404852|NCT01316003|OTHER|Optical coherence tomography|Optical coherence tomography
223555449|NCT05398159|DEVICE|Trim II|"Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment)."
223555450|NCT03525301|RADIATION|standard treatment|3000 cGy in 10 daily fractions
223555451|NCT03525301|RADIATION|short course treatment|1800 cGy in 4 fractions administered twice a day
223555452|NCT02659033|DRUG|ceftriaxone|ceftriaxone (1 gram per day)
223555453|NCT02659033|DRUG|Cefotaxime|cefotaxime (1 gram every 8 hours)
223555454|NCT03235895|OTHER|Educational material|Educational material given as a part of CME activity as through enhanced internet method
223555455|NCT00101920|DRUG|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
223555456|NCT05578989|DEVICE|Virtual reality glasses|watching a video with music with virtual reality glasses.
223555457|NCT03960060|BIOLOGICAL|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
223555458|NCT06501547|GENETIC|Leucocyte Telomere Length from blood draw|blood draw, PCR method to see leucocyte telomere length
223555459|NCT04461873|OTHER|Reiki|Reiki by touching
223736984|NCT03117712|DIAGNOSTIC_TEST|Delirium Scores|"* Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5"
224022509|NCT04018638|OTHER|B-FREE|Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
224022510|NCT06727981|DRUG|ICI plus Chemothearpy|This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.
223404853|NCT01328990|DRUG|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
223404854|NCT00963300|PROCEDURE|blood-oxygen-level-dependent functional magnetic resonance imaging|
223404855|NCT00963300|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223555460|NCT04461873|OTHER|Sham Reiki|Sham reiki by gesturing and mimic imitation through touching
223555461|NCT01834950|OTHER|Blood test|
223404856|NCT00963300|PROCEDURE|magnetic resonance spectroscopic imaging|
223404857|NCT00963300|PROCEDURE|tissue-oxygen-level-dependent functional magnetic resonance imaging|
223404858|NCT06428279|BEHAVIORAL|Survey|survey
223555462|NCT04145921|PROCEDURE|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
223555463|NCT04145921|PROCEDURE|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
223555464|NCT05634694|OTHER|No interventions.|No interventions.
223555465|NCT01370200|PROCEDURE|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
223555466|NCT05416164|RADIATION|Omission of radiotherapy|Omission of radiotherapy
223404859|NCT01311271|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~* Real: unaffected M1 hotspot~* Sham: coil perpendicular to scalp"
223404860|NCT05710653|BEHAVIORAL|Exercise training intervention|The intervention will consist in adhering to high-intensity interval training and/or resistance training three times a week
223404861|NCT00001030|DRUG|Clarithromycin|
223404862|NCT00001030|DRUG|Rifabutin|
223404863|NCT02562001|DEVICE|Outpatient active group|active tDCS during 20 minutes before Lokomat training for outpatients
223404864|NCT02562001|DEVICE|Outpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for outpatients
223736985|NCT03117712|DIAGNOSTIC_TEST|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB"
223404865|NCT02562001|DEVICE|Inpatient active group|active tDCS during 20 minutes before Lokomat training for inpatients
223404866|NCT02562001|DEVICE|Inpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for inpatients
223404867|NCT04389164|PROCEDURE|Tissue-engineered skin grafts of autologous scar dermal scaffolds|"1. scar excision. The thickness of scar tissue in the middle of scar is removed with a roller cutter and the thickness is about 0.01 -- 0.02mm.~2. take autologous skin slices of the patient with an electric skin knife, cut out a small piece of skin, and prepare autologous epidermal basal cell suspension for use;The rest of the skin should be the same size as the wound.~3. the prepared autogenous scar dermal stent was grafted onto the scar resection wound surface, and the prepared autoepidermal basal cells were sprayed between the mesh and on the dermal stent, and autologous skin slices were grafted onto the wound surface and fixed with pressure bandaging;~4. after the operation, the outer dressing should be changed regularly according to the conventional treatment, and the wound surface condition should be observed and recorded according to the experimental scheme."
223404868|NCT04903158|DRUG|test SHR3680 tablets|Subjects receiving a single oral dose of SHR3680 tablets with 240mg (80mg\*3)
223404869|NCT04903158|DRUG|reference SHR3680 tablets|subjects receiving a single oral dose of SHR3680 tablets with 240mg (100mg\*2+20mg\*2).
223404870|NCT02439541|BIOLOGICAL|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10\^7)
223404871|NCT03078764|OTHER|Mobile health system|Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.
223404872|NCT03078764|OTHER|E-mail reports and technical support for mHealth system|Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
223404873|NCT01411800|DRUG|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
223404874|NCT01411800|DRUG|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
223404875|NCT05496270|PROCEDURE|total mesorectal excision|
223404876|NCT00753285|DEVICE|Renal Denervation|
223404877|NCT01610674|OTHER|Tailored improvement strategy|"A step-wise implementation model is applied:~1\) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
223404878|NCT01438892|DRUG|tDMARDs|Traditional DMARDs for RA
223404879|NCT01438892|DRUG|biodmards|Biologic DMARDs
223404880|NCT03794648|BEHAVIORAL|Mobile Interactive Supervised Therapy (MIST)|MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.
223404881|NCT02462772|DRUG|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
223404882|NCT02462772|DRUG|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
223404883|NCT05028790|DEVICE|Single vision contact lens|Participants will wear a single vision soft contact lens during the study visit
223404884|NCT05028790|DEVICE|Multifocal contact lens|Participants will wear a multifocal soft contact lens during the study visit
223404885|NCT05473832|OTHER|Day Cream cosmetic product compared to untreated side|Applied once daily in the morning
223404886|NCT05473832|OTHER|Night cream cosmetic product compared to untreated side|Applied once daily in the evening
223404887|NCT05473832|OTHER|Eye cream cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening around the eye area
223404888|NCT05473832|OTHER|Serum cosmetic product compared to untreated side|Applied twice daily in the morning and in the evening
223404889|NCT04394949|BEHAVIORAL|Center for Independent Living SEEKS Team|Center for Independent Living (CIL) consumers randomized to work with a group of CIL employees who received training in SOAR, Customized Employment, Supported Employments, and Benefits Planning (CWIC).
223404890|NCT04394949|OTHER|Usual Care|Consumers will get same CIL services they would get if they were not enrolled in the study.
223404891|NCT05408208|DRUG|Intralesional Injection of Methotrexate|"One psoriatic lesion will treated with Intralesional injection of methotrexate (25mg /ml) at dosage of 0.1 ml /cm Another plaque will treated with intralesional ingection of distilled water as controlled plaque.~Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment ."
223404892|NCT05408208|DRUG|Triamcinolone Acetonid|One lesion will treated with Intralesional injection of trimethinolone acetonide (10mg/ml) at dosage of 0.1 ml/ cm2 . another plaque will treated with Intralesional injection of distilled water as controed plaque Patients will take 6 sessions every 2 weeks for 3 months and will followed up at 2 month and 3 months after treatment .
223404893|NCT00905983|DRUG|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
223404894|NCT01149980|DRUG|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
223404895|NCT02724657|OTHER|Buteyko Method|Intervention will be held twice a week during 3 weeks.
223404896|NCT05760196|DRUG|GM-CSF|PD1 antibody is held every three weeks, and GM-CSF is used once every three weeks on days 1-14. Until the patient progresses disease or intolerable toxicity.
223404897|NCT01314339|DRUG|Desloratadine|Desloratadine Tablets, 5 mg
223404898|NCT06418022|DEVICE|Trendelenburg positioning VTI|"There are essentially two arms, whereby the patients is being compared to themselves. The intervention arm is the same patient undergoing TP from the baseline supine position to determine the change in VTI after subjecting to TP.~We will be using a Sonosite PX ultrasound system, which is intended for diagnostic ultrasound imaging or fluid flow analysis of the human body and, more specifically, for our echocardiographic measurements of velocity time integral (VTI; surrogate for stroke volume and cardiac output). The Sonosite PX is a general-purpose ultrasound system intended for use by qualified physicians and healthcare professionals, for evaluation by ultrasound imaging or fluid flow analysis of the human body. This is an FDA-cleared (510K# K200964) commercial device legally marketed in the United States that is being used in accordance with labeling."
223404899|NCT00122837|DRUG|Duloxetine|
223404900|NCT00122837|DRUG|venlafaxine|
223404901|NCT00122837|DRUG|placebo|
223404902|NCT00561392|DRUG|Rivastigmine 5 and 10 cm^2 patch|
223404903|NCT03293992|DRUG|0.01% RO7058584|Once daily morning administration for 7 days
223404904|NCT03293992|DRUG|0.1% RO7058584|Once daily morning administration for 7 days
223555467|NCT05976815|BEHAVIORAL|Combined Aerobic and Resistance Exercise|Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
223555468|NCT03689608|OTHER|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
224132462|NCT02458157|OTHER|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~* Mottling beyond the edge of kneecaps~* Hypotension (MAP \< 50) resistant to inotropes and vasopressors~* Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~1. Fluid removal is paused~2. A crystalloid fluid bolus of 250-500 ml is given~3. Circulatory status is reevaluated within 30 minutes~4. Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~5. Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
224132463|NCT02458157|OTHER|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~* Hyperkalaemia (p-K+ \> 6 mmol/l)~* Severe metabolic acidosis attributable to AKI (pH \< 7.25 and standard base excess \< -10 mmol/l) resistant to IV bicarbonate infusion~* Severe respiratory failure with PaO2/FiO2 \< 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~* Progressive azotaemia and a blood urea nitrogen (BUN) \> 25 mmol/l."
223404905|NCT03293992|DRUG|1% RO7058584|Once daily morning administration for 7 days
223404906|NCT03293992|DRUG|Matching Placebo|Once daily morning administration for 7 days
223404907|NCT03293992|DRUG|Latanoprost 0.005%|Once daily morning or evening dosing
223404908|NCT00771342|DRUG|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
223404909|NCT00771342|DRUG|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
223404910|NCT02276755|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
223404911|NCT02276755|OTHER|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
223404912|NCT02254590|PROCEDURE|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
223404913|NCT05730361|BIOLOGICAL|ScTIL injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion."
223404914|NCT05730361|BIOLOGICAL|ScTIL injection and B lymphocytes adjuvant|B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is \> 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
223555469|NCT03689608|OTHER|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
224022511|NCT06727981|DRUG|Chemotherapy|This intervention involves the administration of standard chemotherapy alone.
223404915|NCT01927315|DRUG|Fenofibrate 145 mg|Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.
223404916|NCT01927315|DRUG|Placebo|Oral Placebo tablets once daily
223404917|NCT05175391|OTHER|Meat based protein with added spice; Plant based protein with added spice|Either meat or plant based protein entrees will have herbs and spices added (in addition to salt and pepper in the base recipe) to intensify the flavor profile in order to see if protein consumption is affected.
223404918|NCT03948412|DEVICE|Closed Incision Negative Pressure Wound Therapy (Prevena)|Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
223404919|NCT03948412|OTHER|Control - Standard Dressings|Standard wound dressings applied to closed wound at completion of operation.
223404920|NCT06392659|DRUG|VX-993|Suspension for Oral Administration.
223404921|NCT06392659|DRUG|Gemfibrozil|Tablets for Oral Administration.
223404922|NCT06392659|DRUG|Itraconazole|Capsules for Oral Administration.
223404923|NCT06392659|DRUG|Midazolam|Solution for Oral Administration.
223404924|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Vision Screening module of Easy Vision application"|"The presenting visual acuity will be assessed using the Vision Screening module of the Easy Vision application."
223404925|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Test Yourself module of Easy Vision application"|"The presenting visual acuity will be assessed using the Test Yourself module of the Easy Vision application."
223404926|NCT04936100|DEVICE|"Assessment of distance and near visual acuity using Peek Acuity application"|"The presenting visual acuity will be assessed using the Peek Acuity application."
223404927|NCT04936100|OTHER|Assessment of distance and near visual acuity using the conventional methods|"The presenting visual acuity will be assessed using the conventional methods \[Chart: Tumbling E optotype for assessing distance visual acuity and Handheld chart: Tumbling E Near Point Vision Chart for assessing near visual acuity\]"
223404928|NCT00669500|BEHAVIORAL|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
223404929|NCT01741688|BIOLOGICAL|Tocilizumab|Tocilizumab was administered according to the local label.
223404930|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
223404931|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
224022512|NCT05978115|PROCEDURE|implant supported prosthesis|Group A: short dental implant placement + Removable partial denture Group B: Short implant placement + Fixed partial denture Group c: Bone Augmentation + Implant placement + Fixed Partial denture
224022513|NCT06728839|DRUG|1L PEG + 50g magnesium sulfate|Subjects in Group A will use a regimen combining magnesium sulfate and polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. 1 litter of polyethylene glycol is taken at 8pm the day before the colonoscopy and 50 gram of magnesium sulfate is taken 4-6 hours before the colonoscopy, and then drink 2000 ml of water within 2 hours.
224022514|NCT06728839|DRUG|3L PEG|Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
224022515|NCT06728839|DRUG|4L PEG|Subjects in Group C will use a regimen with 4L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 4 liters of polyethylene glycol solution is taken in split dosing, with 2 liters taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
224022516|NCT06727916|BEHAVIORAL|BBT-I|Participants in the intervention group will receive BBT-I in 4 consecutive sessions in addition to standard care. Healthcare provider provided BBT-I to the patients.
223404932|NCT01834742|DRUG|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
223404933|NCT01834742|DRUG|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
223404934|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
223404935|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
223404936|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
223404937|NCT01834742|DRUG|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
223404938|NCT00002691|BIOLOGICAL|filgrastim|
223404939|NCT00002691|DRUG|asparaginase|
223404940|NCT00002691|DRUG|cyclophosphamide|
223404941|NCT00002691|DRUG|cytarabine|
223404942|NCT00002691|DRUG|daunorubicin hydrochloride|
223404943|NCT00002691|DRUG|dexamethasone|
223404944|NCT00002691|DRUG|etoposide|
223404945|NCT00002691|DRUG|leucovorin calcium|
223404946|NCT00002691|DRUG|mesna|
223404947|NCT00002691|DRUG|methotrexate|
223404948|NCT00002691|DRUG|vincristine sulfate|
223404949|NCT01548040|DEVICE|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
223404950|NCT01548040|DEVICE|Quadriceps TENS|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
224022517|NCT06727916|OTHER|Non BBT-I|Patients in the control group will receive standard care.
224022518|NCT06727656|COMBINATION_PRODUCT|Nitrate + Hypoxia|The combined effect of nitrate supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
224022519|NCT06727656|DIETARY_SUPPLEMENT|Placebo + Hypoxia|The combined effect of placebo supplementation and hypoxia training on both performance and health at sea-level and altitude conditions.
224022520|NCT06727656|OTHER|Control|The combined effect of placebo supplementation and normoxia training on both performance and health at sea-level and altitude conditions.
224132464|NCT06249256|BIOLOGICAL|Fast CAR T cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
224132465|NCT02389712|DRUG|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
224022521|NCT06729307|DRUG|Oral ondansetron and dyclonine hydrochloride mucilage|Patients will take 8 mg oral ondansetron 2 hours prior to EGD process in addition to dyclonine hydrochloride mucilage to be gurgled 15 minutes prior to EGD process.
224297701|NCT03902652|PROCEDURE|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is \>60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains \<60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains \<60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
224297702|NCT04435106|DRUG|Opaganib|Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care
223404951|NCT01514292|DEVICE|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
223404952|NCT01742988|DRUG|fimepinostat|
223404953|NCT01742988|DRUG|Rituximab|
223404954|NCT01742988|DRUG|venetoclax|
223404955|NCT01441557|DRUG|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
223404956|NCT04155619|BEHAVIORAL|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
223404957|NCT04155619|BEHAVIORAL|No change in light exposure|Participants will not change their light exposure habits.
223404958|NCT04155619|BEHAVIORAL|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
223404959|NCT04155619|BEHAVIORAL|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
223404960|NCT05970523|OTHER|Core Stabilization Exercises|Core stabilization exercises are known as a very effective exercise method based on the motor learning principle, performed with the individual's own body weight to strengthen the muscles, improve balance, posture, trunk muscle endurance and flexibility.Each exercise was performed for 7-8 seconds with 10 repetitions. Progression in the exercises was achieved by increasing the difficulty level of the exercises according to the participant's condition once every two weeks.
223404961|NCT00274300|BIOLOGICAL|pPJV7630 administered by PMED|
223404962|NCT02391922|BEHAVIORAL|First aid course|
224132466|NCT02389712|DRUG|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed \> 40mg.
224132467|NCT02909998|OTHER|Blood sample|Conservation at the end of the blood sample
224297703|NCT04435106|DRUG|Standard of Care|Study participants received Standard of Care
223404963|NCT02391922|BEHAVIORAL|First aid instructions by mobile phone|
223404964|NCT01116271|DRUG|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
223404965|NCT01116271|DRUG|Irinotecan|180mg/m2, IV, Day 1\& 15 of each cycle
223404966|NCT01742546|DEVICE|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
223555470|NCT03689608|OTHER|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
224022522|NCT06729307|DRUG|Dyclonine hydrochloride mucilage|Patients will be instructed to gurgle 10 mL of dyclonine chloride mucilage (0.01 g/mL) and gurgle for 1 minute 15 minutes prior to endoscopic process.
224022523|NCT06729788|DRUG|ICON resin infiltration Material group in vivo|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK).
223555471|NCT03763812|PROCEDURE|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
224022524|NCT06729788|DRUG|Resin-based fissure sealant group in vivo|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael)
223404967|NCT06214195|DRUG|Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)|Ginseng 6g , Ophiopogon japonicus 12g ,Schisandra chinensis 5g , other secondary Chinese medicines can be added according to the doctor's judgment and the patient's condition，decoction in water, one dose and two decoctions, taken twice a day, continuously for 7 days from the start of each chemotherapy cycle (± 3 days), including anthracyclines and taxanes (the frequency and dosage of medication can be adjusted according to adverse reactions in the later stage); The total duration of medication interventionis 7 days per cycle, with a total of 8 cycles. If the chemotherapy is less than 8 cycles, continue taking for 7 consecutive days from the start of each subsequent trastuzumab cycle (the frequency and dosage can be adjusted based on adverse reactions) until a total of 8 cycles are reached.
223404968|NCT05733169|OTHER|Frequency lowering intervention|Modified parametrization of the current frequency lowering parametrization.
223404969|NCT05733169|OTHER|Frequency lowering reference|Current frequency lowering parametrization
223555472|NCT03763812|PROCEDURE|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery"
223555473|NCT04923633|DEVICE|Quantifiable Soft Tissue Manipulation (QSTM)|Quantifiable soft tissue manipulation (QSTM) is a force sensing device system that can be used by a clinician to apply a massaging force while the system monitors objective metrics, i.e., the amount, rate, and angle of force applied.
223555474|NCT03517371|OTHER|mHealth delivered exercise program|"Participants in the mobile health condition have up to 8 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
223555475|NCT03517371|OTHER|Exercise only|Participants in the control group have up to 8 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
223555476|NCT05358886|DRUG|BPN14770/ zatolmilast|25mg BID BPN14770
223555477|NCT05358886|DRUG|Placebo|Placebo
223555478|NCT06544785|DRUG|Zanubrutinib Oral Product|"Zanubrutinib drug product is supplied as 80 mg strengths in capsules for oral administration.~In both arms A and B, zanubrutinib 320 mg will be taken qDay with or without food. Patients will take zanubrutinib with water at approximately the same time every day."
223555479|NCT06544785|DRUG|Obinutuzumab|"Each dose of obinutuzumab is 1000 mg administered intravenously, per institutional standards, with the exception of the first infusion in Cycle 2 (arm A) or Cycle 13 (arm B). It is recommended that the initial 1000 mg dose be administered over Day 1 (100 mg) and Day 2 (900 mg). For subjects who tolerate the initial 100 mg dose well and required no dose interruption or modification of the infusion rate, the treating physician may opt to administer the remaining 900 mg on Day 1.~Arm A: patients will receive obinutuzumab on days 1 (100 mg), 2 (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 2 of zanubrutinib treatment, and on the day 1 of cycles 3-7 (1000 mg).~Arm B: patients will receive obinutuzumab on days 1 (100 mg), 2 ( (or day 1 continued, 900 mg), 8 and 15 (1000 mg) of the cycle 13 of zanubrutinib treatment, and on the day 1 of cycles 14-18 (1000 mg)."
223555480|NCT05486884|PROCEDURE|Maintain MAP ≥ 90 mmHg|Maintain MAP ≥ 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
223555481|NCT05486884|PROCEDURE|Maintain MAP ≥ 65 mmHg|Maintain MAP ≥ 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine
223555482|NCT05352516|BIOLOGICAL|HLX14|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14."
223555483|NCT05352516|BIOLOGICAL|Prolia®|"Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14."
223555484|NCT05300477|DRUG|Acetazolamide|Carbonic Anhydrase Inhibitor
223555485|NCT05300477|DRUG|Erythropoietin|Hormone for red blood cell
223555486|NCT03078543|DEVICE|ANTHEM™ PS Total Knee System implant|"The ANTHEM™ PS Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ PS Total Knee System consists of the following components:~* Cobalt-Chrome (Co-Cr) femoral components - Posterior stabilised~* Titanium primary tibial components~* Posterior-stabilised ultra-high molecular weight polyethylene (UHMWPE)~* Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
223555487|NCT05420961|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
223555488|NCT05420961|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension
223555489|NCT05420961|BIOLOGICAL|PPSV23|Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
223736986|NCT03117712|DIAGNOSTIC_TEST|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation"
224022525|NCT06729788|DRUG|ICON resin infiltration in vitro|The fissure of selected teeth will be sealed with ICON resin infiltration Material (DMG Dental UK) in vitro
224022526|NCT06729788|DRUG|Resin-based fissure sealant in vitro|The fissure of selected teeth will be sealed with resin-based fissure sealant (Heliosael) in vitro
223404970|NCT06095921|BEHAVIORAL|Self Management Intervention Program|SSc, the course of the disease, symptoms and coping strategies, medications and treatment methods? The importance of exercise for individuals with SSc, and how to create an action plan for an exercise? were discussed. What are fatigue and its symptoms? How can we protect our articular-energy and how should a quality rest be? What is pain and what are coping approaches? What is the pain-related area of influence? What are body image problems, how to use problem solving approach and what is its importance? What is Stress? What is mindfulness? What are mindfulness exercises? What are the ways to cope with stress? What are the daily life occupations and how can we facilitate them? How can we solve problems in difficult occupations? How to create an occupation plan to facilitate daily occupations? What are oral stretching exercises and how to do them? What are the factors affecting sleep? What is advocacy and why is it important? Answers to these questions were sought.
223404971|NCT02892890|PROCEDURE|Muscle Magnetic Resonance Imaging (RMI) evaluation|
223404972|NCT02892890|DEVICE|MRI|
224022527|NCT05366426|OTHER|EMG biofeedback program:|Superficial electrodes and EMG-guided biofeedback will be applied to the perineal region 3 days a week for 8 weeks, so that patients can receive visual and auditory feedback during exercise.
223404973|NCT02480569|OTHER|FFR Measurement|
223404974|NCT02523508|BEHAVIORAL|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
223404975|NCT02523508|OTHER|Control group|Passive limb mobilization which did not involve the spine
223404976|NCT03991650|BEHAVIORAL|Monitoring with a device|Participants will be monitored by an App.
223404977|NCT06476119|DRUG|Adjuvant chemotherapy|adjuvant chemotherapy according to local/ national guidelines
223404978|NCT06476119|OTHER|No adjuvant chemotherapy|no adjuvant chemotherapy
223404979|NCT04039568|BEHAVIORAL|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
224022528|NCT05366426|OTHER|Sham EMG biofeededback:|3 days a week for 8 weeks; Surface electrodes will be attached as in the EMG Biofeedback group, but unlike the EMG biofeedback group, they will exercise without any visual and auditory feedback (1).
224297704|NCT02677649|OTHER|cranberry|the effect of cranberry on the gut microbiota
223404980|NCT04039568|BEHAVIORAL|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
224022529|NCT05366426|OTHER|Pelvic floor muscle training home exercise program:|Pelvic floor muscle training home exercise program: A home exercise program was given to all patients who had learned to perform correct pelvic floor muscle contraction with the pre-treatment evaluation. In the home exercise program, patients in three positions (sitting, lying and standing) are required to perform two to three rapid contractions of 15 repetitions in each set, three times a day, followed by slow contractions by keeping the PTC tense for 8-10 seconds, and then give a 10-second rest period after slow contractions. has been told. All 3 groups received PTK exercise program.
223404982|NCT06974279|DEVICE|Precision TMS with SFA|Excitatory TMS delivered using a precision site finding approach and intermittent theta burst stimulation protocol
223404983|NCT06974279|DEVICE|Control TMS with SFA|Excitatory TMS using intermittent theta burst stimulation delivered to a control vertex site.
223555490|NCT06378918|PROCEDURE|puncture|Local anesthesia is previously carried out with 2-5 cc of 1% lidocaine. The puncture is then carried out using a 16 gauge needle. Antibiotic coverage will be offered. A work stoppage is recommended until the day after the puncture/aspiration but the duration is left to the discretion of the surgeon. A visit is systematically realised 15 days after the puncture/aspiration with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. In the event of fistulization following the puncture, associated with discharge and skin necrosis, local nursing care is recommended. The definitive resection procedure is then planned 4 to 6 weeks after the puncture/aspiration if the evolution is favorable.
224297705|NCT02677649|OTHER|placebo|the effect of placebo on the gut microbiota
223404984|NCT04956120|DEVICE|Citrate Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
223404985|NCT04956120|DEVICE|Standard Dialysate|Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
223404986|NCT04697940|BIOLOGICAL|Decitabine-primed Tandem CAR19/20 engineered T cells|"Phase I dose escalation (3+3) : dose 1 (0.5 × 10\^6 cells per kg) dose 2 (2 × 10\^6 cells per kg) dose 3 (5 × 10\^6 cells per kg)~Phase II: Appropriate dose"
223404987|NCT04697940|DRUG|Fludarabine|Intravenous fludarabine 25-30 mg/m\^2/day on days -5, -4, and -3.
223404988|NCT04697940|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
223404989|NCT06624293|DIAGNOSTIC_TEST|BNP|Blood collected during this study will be tested on separate IUO BNP assay on a separate protocol. No active interventions will occur during this study.
223404990|NCT06967480|DRUG|Ravulizumab|Participants will receive Ravulizumab.
223404991|NCT02600156|PROCEDURE|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
223404992|NCT04322097|DEVICE|Lingual Muscle Stimulation|Tongue protrudor muscles will be stimulated
223404993|NCT04322097|OTHER|Mandibular advancement|Outcome variables will be assess with and without mandibular advancement
223404994|NCT04322097|OTHER|Postural maneuvers|Outcome variables will be measured with and without postural maneuvers
223404995|NCT04322097|OTHER|Digital Morphometrics|A digital camera with laser pointers will be used to capture a series of craniofacial photographs (frontal, profile and neck extended) and intra-oral photographs (junction of the hard and soft palate, airway, or base of tongue).
224022530|NCT06906432|DIAGNOSTIC_TEST|Multi-disciplinary assessment|Multi-disciplinary assessment including blood tests, CSF test, electrocardiograms, ultrasound, imaging, etc
224022531|NCT03123042|PROCEDURE|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
224132468|NCT05286073|PROCEDURE|Endodontic Root Canal Treatment|Root canal shaping procedures were performed. Irrigation was done after each three pecks of endodontic file. After instrumentation (Groups 1-3), the canals were dried with sterile paper points. The dentinal walls were then coated with Sealapex. For vertical root fracture resistance testing, sample preparation was done in acrylic blocks. Then roots were coated with polyvinylsiloxane impression material. After that roots were inserted again into acrylic resin blocks. The acrylic blocks with the vertically aligned roots were mounted in the Instron testing machine. 0.5 mm diameter round tip stainless-steel rod was fixed to the universal testing machine. The universal testing machine was adjusted and vertical compressive force was applied at a crosshead speed of 1mm/min. The Instron tester applied a slowly increasing force, until the root fractured. The maximum amount of force necessary to fracture every sample was recorded in Newton (N).
224132469|NCT02625324|DEVICE|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
224132470|NCT02823041|BEHAVIORAL|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
223404996|NCT04322097|OTHER|Tongue Force Exercise|The patient will place a small bulb behind their lower incisors and will press using their tongue as hard as possible for two seconds. This exercise will be repeated four times, with 30 seconds of rest in between each attempt. The patient will then be instructed to press and hold their tongue against the bulb as hard as possible for 35 seconds. This exercise will be repeated three times, with 2 minutes of rest in between each attempt.
223555491|NCT06378918|PROCEDURE|incision of the abscess|This is carried out according to the habits of the department: in the operating room under general or local anesthesia or in consultation (or emergencies) under local anesthesia. The procedure is carried out on an outpatient basis but, if necessary, short-term hospitalization is carried out. Daily drying is then carried out with nursing care at home until healing. A work stoppage is recommended for a period of approximately 10 days. A visit is systematically realised 15 days after the incision with a recommendation for earlier consultation in the event of persistence of redness, discharge, pain or onset of fever. If these symptoms recur or persist, it is recommended to make an incision with packing. The definitive resection procedure is then planned 4 to 6 weeks after the initial operation if the evolution is favorable.
223555492|NCT05735704|DIAGNOSTIC_TEST|Blood sampling for HemaChip screening/diagnostic testing|"Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA, and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom-targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed."
223555493|NCT04283656|DRUG|Doravirine/Lamivudine/Tenofovir|100mg/300mg/300mg orally for one dose, daily
223555494|NCT04283656|DRUG|Spironolactone 100mg|200mg orally for two doses, twice-daily
223555495|NCT04283656|DRUG|Estradiol 2mg|4mg orally for two doses, twice-daily
223555496|NCT04283656|OTHER|Placebo|Placebo for one dose, daily
223404997|NCT04322097|OTHER|Magnetic resonance imaging (MRI)|The patient will undergo an MRI scan of the head and neck.
223404998|NCT04322097|OTHER|Polysomnography (PSG) - Split Night|The patient will undergo a polysomnography (PSG). The PSG study will include monitoring of EEG, submental EMG, EOG, SpO2, tidal airflow, thoraco-abdominal efforts, and body position. The patient will spend half of the night at baseline (i.e. no intervention), and the second half with lingual muscle stimulation activated.
223404999|NCT02251821|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
223405000|NCT02251821|DRUG|Busulfan|Given IV
223405001|NCT02251821|DRUG|Cyclophosphamide|Given IV
223405002|NCT02251821|DRUG|Fludarabine Phosphate|Given IV
223405003|NCT02251821|OTHER|Laboratory Biomarker Analysis|Correlative studies
223555497|NCT04896047|PROCEDURE|Meal test and muscle biopsies|"The FGF19 parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal.~A muscle biopsies by a needle will be performed before and after the Flexmeal."
223555498|NCT06484179|BEHAVIORAL|Targeted Self-Help|In addition to usual care participants will receive a self-help booklet specific for their cancer type. There are five booklets available, written at a 5-6th grade reading level and targeted by cancer type, that explain the connection between smoking and each cancer type, describe the benefits of quitting smoking after cancer, and address some of the barriers cancer patients face to quit smoking when fighting cancer. Each booklet also includes four testimonials inspired from conversations with patients.
223555499|NCT06484179|BEHAVIORAL|Usual Care|Participants will receive the standard care typically offered for smoking cessation.
224022532|NCT03887390|BEHAVIORAL|Depression Medication Choice|The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
224132471|NCT02823041|BEHAVIORAL|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
223405004|NCT02251821|DRUG|Melphalan|Given IV
223405005|NCT02251821|DRUG|Methotrexate|Given IV
224132472|NCT02823041|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
223405006|NCT02251821|DRUG|Mycophenolate Mofetil|Given IV or PO
223405007|NCT02251821|DRUG|Ruxolitinib|Given PO
223405008|NCT02251821|DRUG|Tacrolimus|Given IV or PO
223405009|NCT02251821|RADIATION|Total-Body Irradiation|Undergo TBI
223405010|NCT02251821|PROCEDURE|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
223405011|NCT05405504|DEVICE|Remote Dielectric Sensing (ReDS)|Non-invasive device designed for the measurement of lung fluid using extremely low power electromagnetic waves. The ReDS Pro System V2.7 system has CE approval (3900874CE01) and FDA clearance.
223405012|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
223555500|NCT05279040|DRUG|Trikafta|Elexacaftor/Tezacaftor/Ivacaftor combination therapy
223555501|NCT04754269|BEHAVIORAL|Beverage Intervention|Parents will watch a video that promotes optimal beverage practices for young children including discouraging consumption of sugar-sweetened beverages and fruit juice and encouraging consumption of water and unsweetened milk. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
223405013|NCT01262872|BIOLOGICAL|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
223405014|NCT01262872|BIOLOGICAL|Synflorix™|Intramuscular injection
223555502|NCT04754269|BEHAVIORAL|Reading Intervention|Parents will watch a video that promotes reading to children and includes specific ideas and techniques for how to make reading interactive and engaging. Parents will receive 24 text messages over a 12 week period that reinforce and expand on the messages in the video.
223555503|NCT04999384|DRUG|AN4005-dose level 0|50mg BID
223555504|NCT04999384|DRUG|AN4005-dose level 1|100mg BID
223555505|NCT04999384|DRUG|AN4005-dose level 2|200mg BID
223555506|NCT04999384|DRUG|AN4005-dose level 3|400mg BID
223555507|NCT04999384|DRUG|AN4005-dose level 4|600mg BID
223555508|NCT04999384|DRUG|AN4005-food effect|Dose to be determined upon the MTD determination
224132473|NCT02823041|BEHAVIORAL|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
224132474|NCT01828918|GENETIC|microRNAs|
223405015|NCT01262872|BIOLOGICAL|Prevnar13™|Intramuscular injection
223405016|NCT01262872|BIOLOGICAL|Tritanrix™-HepB/Hib|Intramuscular injection
223405017|NCT01262872|BIOLOGICAL|Polio Sabin™|Orally
223405018|NCT01262872|BIOLOGICAL|M-Vac™|Intramuscular injection
223405019|NCT01262872|BIOLOGICAL|Stamaril™|Intramuscular injection
223405020|NCT03807427|BEHAVIORAL|READY-Nepal|Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
223405021|NCT03332355|DRUG|PAC-1 Compound|PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
223405022|NCT02254317|DIETARY_SUPPLEMENT|0 mg placebo|Not containing GSE (Placebo)
223405023|NCT02254317|DIETARY_SUPPLEMENT|300 mg GSE|300 mg GSE
223405024|NCT02254317|DIETARY_SUPPLEMENT|600 mg GSE|Containing 600 mg of GSE
223405025|NCT02254317|DIETARY_SUPPLEMENT|900 mg GSE|Containing 900 mg of GSE
223405026|NCT04849403|PROCEDURE|CTSP|In all patients Carter Thomasson Suture Passer (CTSP) were used for closing fascial defect peroperatively
223405027|NCT02843048|BEHAVIORAL|Exercise training program|"Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance."
223405028|NCT02843048|BEHAVIORAL|Standard medical care|Standard follow-up medical care following bariatric surgery
223405029|NCT00097448|DRUG|prednisone|Oral, 19 days
223405030|NCT00097448|DRUG|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
223555509|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
223555510|NCT00394329|DRUG|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
223555511|NCT00394329|DRUG|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
223555512|NCT01184677|DEVICE|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
223555513|NCT01184677|DEVICE|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
223555514|NCT04491903|PROCEDURE|REBOA|Endovascular balloon occlusion of the aorta
224132475|NCT01446679|DRUG|atrovastatin|oral
224132476|NCT06209814|DEVICE|Conventional denture|Patients in this group received conventional maxillary and mandibular complete dentures. The patients used these dentures for 45 days. Then, the conventional maxillary denture was replaced by open faced denture with soft acryl resin wing.
223736987|NCT03155074|BEHAVIORAL|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
223736988|NCT04518150|DEVICE|Bakri balloon|the Bakri balloon was inserted into the lower uterine segment through the uterine incision by passing the balloon shaft through the cervix with an assistant pulling vaginally
223405031|NCT06302673|DEVICE|Laserpuncture|Laserpuncture : using RJ Laser with Nogier B wave setting, frequency 584 Hz, power 50 mW, wavelength 785 nm, and energy of 2 Joules at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan)
223405032|NCT06302673|DEVICE|Sham Laserpuncture|Sham Laserpuncture: The laser is turned on but not activated at each acupuncture point ( PC6 Neiguan and CV12 Zhongwan).
223736989|NCT04518150|PROCEDURE|Bilateral Uterine Artery Ligation|The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
223736990|NCT00873756|DRUG|FOLFOX regimen|Intravenous repeating dose
223405033|NCT06119776|PROCEDURE|Whipple over the splenic artery|Treatment for pancreatic ductal cell adenocarcinoma
223736991|NCT00873756|DRUG|bevacizumab|Intravenous repeating dose
223736992|NCT00873756|DRUG|dulanermin|Intravenous repeating dose
223736993|NCT01635972|DRUG|Isavuconazole|oral
223736994|NCT01635972|DRUG|bupropion hydrochloride|oral
223736995|NCT02228785|BIOLOGICAL|G17DT|
223736996|NCT04415255|OTHER|EABPI plus IABPI|If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
224022533|NCT03218748|BEHAVIORAL|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session~1. Considering the pros and cons of disclosure:~   Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~2. Different ways to disclose:~   Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~3. Telling one's story:~   Practice how to tell one's story, identifying peers who might be helpful with the coming out process~4. Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
223405034|NCT06119776|PROCEDURE|Total pancreatectomy|Treatment for pancreatic ductal cell adenocarcinoma
223405035|NCT03410576|PROCEDURE|Carotid artery stenting|Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.
223405036|NCT03410576|PROCEDURE|Carotid endarterectomy|Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
223405037|NCT02839304|DEVICE|Cryoablation System|Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
223405038|NCT04845750|DEVICE|Rodeo Micro Mapping Catheter|The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
223405039|NCT00686608|DIETARY_SUPPLEMENT|glucose|0.3mg/kg of glucose
223405040|NCT00686608|DIETARY_SUPPLEMENT|fructose|fructose IV bolus
223405041|NCT00686608|DIETARY_SUPPLEMENT|saline|IV saline
223405042|NCT00365794|DRUG|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
223405043|NCT02123264|DRUG|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
223405044|NCT03504319|OTHER|Exposure to high-fat smoothie|Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
223405045|NCT02615782|DRUG|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
223405046|NCT03238560|DRUG|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
223405047|NCT00745901|DRUG|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
223405048|NCT04059835|OTHER|OptiBra study|compare two different bra after breast cancer surgery
223405049|NCT00929370|DRUG|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
223405050|NCT00515970|PROCEDURE|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
224022534|NCT05598073|BEHAVIORAL|Vinyasa yoga session|One hour of vinyasa yoga will be completed.
223405051|NCT00515970|PROCEDURE|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
223405052|NCT00515970|PROCEDURE|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
223736997|NCT04415255|OTHER|IABPI-alone|If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
223736998|NCT03274440|DRUG|Cannabis|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
223736999|NCT03274440|OTHER|Placebo|Placebo control group, not receiving THC or CBD.
223737000|NCT00622960|OTHER|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
223737001|NCT00622960|OTHER|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
224022535|NCT05353335|OTHER|Re-timing of anti-hypertensive drug|The intervention will consist of shifting the anti-hypertensive medication from morning/early dose to an evening/later dose
223737002|NCT05540301|OTHER|Modified sleeper stretching|Modified sleeper stretching was performed on shoulder joint to increase internal rotation range of motion.
224022536|NCT05353335|OTHER|Current regimen|The participants will begin on their current regimen.
224022537|NCT05027594|DRUG|NMS-03597812|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 in repeated 4-week cycles.
224022538|NCT05027594|DRUG|NMS-03597812 + dexamethasone|All patients will receive NMS-03597812 administered orally once daily on Days 1-21 and Dexamethasone administered orally once a week on Days 1, 8, 15 and 22 in repeated 4-week cycles.
223737003|NCT05540301|OTHER|Modified cross-body adduction stretch|Modified cross-body adduction stretching was performed on shoulder joint to increase internal rotation range of motion.
224022539|NCT05664893|DRUG|Ribociclib Oral Tablet|"600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance"
224022540|NCT05562895|DEVICE|Ion Endoluminal System and Cios Spin|Integrated version of the Ion Endoluminal System and Cios Spin
224022541|NCT04963439|DRUG|Macitentan|Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
224022542|NCT06032832|OTHER|soy protein concentrate-meat analog|Baked Meat analogs-soy protein concentrate containing 57Fe as ferrous sulfate
223737004|NCT06230068|OTHER|Expressive writing|See description under arm/group description.
224022543|NCT06032832|OTHER|soy protein concentrate-meat analog_dephytinization|Baked dephytinized\_Meat analogs-soy protein concentrate containing 58Fe as ferrous sulfate
224022544|NCT06032832|OTHER|pork meat|Meals made with minced pork meat labelled with 57Fe.
224022545|NCT02937233|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine|
224022546|NCT02937233|OTHER|Placebo|
224022547|NCT00926549|DEVICE|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
224022548|NCT05134441|DRUG|IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
224022549|NCT05134441|DRUG|Placebo matching IMU-838 tablets|Patients are randomized to IMU-838 or placebo in ratio 1:1
224022550|NCT00346268|DRUG|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
224022551|NCT00346268|DRUG|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
224022552|NCT03190447|DEVICE|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
224022553|NCT03190447|DEVICE|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
223737005|NCT02646280|OTHER|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
223737006|NCT02646280|OTHER|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
223737007|NCT04880512|DRUG|SYHX 1901 tablets|SYHX 1901, oral tablets, in fasted state
223737008|NCT04880512|DRUG|Placebo|Matching placebo, oral tablets, in fasted state
223737009|NCT00649701|BEHAVIORAL|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
223737010|NCT00649701|BEHAVIORAL|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
223737011|NCT00649701|BEHAVIORAL|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
223737012|NCT00649701|BEHAVIORAL|Both Videos|Morning After and Talking About HIV videos
223737013|NCT00450450|PROCEDURE|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
223737014|NCT00450450|OTHER|laboratory biomarker analysis|Correlative studies
223737015|NCT00450450|BIOLOGICAL|filgrastim|Given IV
224022554|NCT03190447|DEVICE|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
224022555|NCT03190447|DEVICE|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
224022556|NCT03190447|DEVICE|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
224022557|NCT02871856|DIAGNOSTIC_TEST|Low dose CT|low-dose screening CT of chest for lung cancer detection
224022558|NCT01133951|DRUG|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
224022559|NCT01133951|DRUG|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
223405053|NCT00515970|PROCEDURE|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
223405054|NCT02365441|DRUG|Regorafenib|
223555515|NCT03410719|OTHER|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be \<55 (Low-GI group) or \>70 (Hi-GI group).
223405055|NCT02365441|DRUG|imatinib|
223405056|NCT02631642|DRUG|HMPL-689|selective PI3Kδ inhibitor
223555516|NCT02692768|OTHER|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
223405057|NCT02631642|DRUG|HMPL-689 placebo|placebo of HMPL-689
223737016|NCT04984993|DEVICE|MED3000 (Male)|Gel formulation
223737017|NCT04984993|DRUG|Tadalafil 5mg (Male)|Tablets
223737018|NCT04984993|DEVICE|MED3000 (Female)|Gel formulation
223737019|NCT04984993|DRUG|Tadalafil 5mg (Female)|Tablets
224022560|NCT01149356|DRUG|Exemestane|Given orally
223737020|NCT05707078|PROCEDURE|Neck dissection|Based on PET/CT scan patients will undergo neck dissection.
223737021|NCT05647473|BEHAVIORAL|Routine treatment|Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.Concomitant treatment with cholinesterase inhibitors, memantine, or both was allowed.
223737022|NCT05647473|DRUG|add-on low dose Astragalus|Participants received an additional 10g of astragalus per day.
224022561|NCT01149356|DRUG|Gamma-Secretase Inhibitor RO4929097|Given orally
224022562|NCT01149356|DRUG|Goserelin Acetate|Given subcutaneously to premenopausal patients
224022563|NCT05428761|OTHER|TP1|Participants will receive TP1 during one experimental visit.
224022564|NCT05428761|OTHER|TP2|Participants will receive TP2 during one experimental visit.
223405058|NCT02449031|DRUG|TOBI® PODHALER®|
223405059|NCT02449031|DRUG|TOBI®|tobramycin inhalation solution, USP
223405060|NCT02449031|DRUG|Bethkis®|tobramycin inhalation solution
223405061|NCT02449031|DRUG|Cayston®|aztreonam for inhalation solution
224022565|NCT05428761|OTHER|Placebo|Participants will receive placebo during one experimental visit.
224022566|NCT03407443|OTHER|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
224022567|NCT03407443|OTHER|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
224022568|NCT05257031|DRUG|SmofKabiven extra Nitrogen|SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
224022569|NCT03457038|BIOLOGICAL|Blood Test|"Addition to the current care but during the normal follow-up visit :~* At the entrance to the service: search for bacterial 16S RNA in the blood~* Additional blood tests (4) at T6-12-18 and 36h~* At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~* 1 time per day: Assay of CRP and PCT from samples taken in common practice~* J30: Assessment of the vital status of the patient"
223405062|NCT04900428|BIOLOGICAL|COVI-DROPS|COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2
223405063|NCT04900428|DRUG|Placebo|Diluent solution
223405064|NCT06140056|OTHER|Airway pressure release ventilation|Mechanical ventilation mode
223405065|NCT06140056|OTHER|Volumen controlled mechanical ventilation|Mechanical ventilation mode
223405066|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by single urine filtration|The urine samples of children participating in the initial screening will be tested with a single urine filtration by human microscopy.
224022570|NCT05252052|OTHER|Interviews/Surveys|This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
224022571|NCT00743275|BIOLOGICAL|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
224022572|NCT01672723|DRUG|Naltrexone|
223405067|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by quintuple urine filtration|Five urine samples will be collected from children participating in the diagnostic study over five days. Each of the five urine samples collected per participant will be tested with a single urine filtration by human microscopy.
223405068|NCT06808750|DIAGNOSTIC_TEST|S. haematobium egg detection by artificial intelligence (AI) microscopy|The urine samples collected on Day 5 of the diagnostic study will be tested with artificial intelligence (AI) microscopy.
223405069|NCT06808750|DIAGNOSTIC_TEST|Haematuria assessment using reagent strips|The urine samples collected from children participating in the initial screening and in the diagnostic study, respectively, will be tested with reagent strips.
223405070|NCT06808750|DIAGNOSTIC_TEST|S. haematobium antigen detection by up-converting reporter particle-lateral flow circulating anodic antigen assay (UCP-LF CAA)|The urine samples collected on Day 5 of the diagnostic study will be tested with the up-converting reporter particle-lateral flow circulating anodic antigen assay (UCP-LF CAA).
223405071|NCT06808750|DIAGNOSTIC_TEST|S. haematobium DNA detection by recombinase polymerase amplification assay (RPA)|The urine samples collected on Day 5 of the diagnostic study will be tested with the recombinase polymerase amplification assay (RPA).
223405072|NCT06808750|DIAGNOSTIC_TEST|S. haematobium DNA detection by qPCR|The urine samples collected on Day 5 of the diagnostic study will be tested with qPCR
223405073|NCT06983275|DEVICE|Vibrational stimulation|Fifteen minutes before bedtime, participants will wear a vibration stimulation device on the forehead while lying down in a comfortable position. The stimulation intensity will be set to 60% of the device's maximum output. Participants will receive a 15-minute session of 40 Hz vibration stimulation with a 50% duty cycle: 15 seconds of stimulation followed by 15 seconds of rest, repeated continuously. After the session, participants will remove the device and prepare for sleep immediately.
223405074|NCT06983275|OTHER|Sham|Fifteen minutes before bedtime, participants will lie down in a comfortable position and listen to the 40 Hz noise generated by the vibration device (without receiving actual vibration). After the session, they will remove the device and prepare for sleep immediately.
223405075|NCT06983938|DEVICE|Double Perclose Proglide|Upon completion of valve replacement, closure will proceed using two Perclose Proglide devices.
223405076|NCT06983938|DEVICE|Single Perclose Proglide plus Angioseal|Upon completion of valve replacement, closure will proceed using one Perclose Proglide device plus one Angioseal device.
223405077|NCT06650865|OTHER|Traditional Exercise Group|"It is important for the therapist to organize a exercise program to provide pain control. The exercise program should be specific and clear to the patient.~Exercises will be applied to this group. The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
223555517|NCT02692768|OTHER|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
223555518|NCT02692768|OTHER|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
223555519|NCT01062789|DEVICE|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
223737023|NCT05647473|DRUG|add-on high dose Astragalus|Participants received an additional 20g of astragalus per day.
223737024|NCT02865187|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D 600IU/day
223405078|NCT06650865|OTHER|Baduanjin Exercise Group|"In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
223405079|NCT06650865|OTHER|Telerehabilitation Group|"Baduanjin exercise will be applied simultaneously with the telerehabilitation method. In addition to the standard physical therapy program, Baduanjin will be applied for 30 minutes.~The exercise steps will be continued 3 days a week for 6 weeks. All scales and tests will be completed again at week 12 for long-term follow-up."
223405080|NCT01862978|DRUG|Heparin|
223405081|NCT01862978|DRUG|Nadroparin|
223405082|NCT01862978|DRUG|Placebo|
223405083|NCT06509087|PROCEDURE|Transarterial microembolization (TAME)|TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
223737025|NCT02865187|DRUG|Hormonal contraception|Hormonal contraceptives
223737026|NCT00001054|DRUG|Valacyclovir hydrochloride|
223737027|NCT00067366|BEHAVIORAL|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
223737028|NCT00067366|BEHAVIORAL|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
223405084|NCT04299815|DRUG|Oral Sodium Lactate|25 grams of D/L lactate dissolved in 300mL water.
223405085|NCT04299815|DRUG|Intravenous sodium lactate|intravenous sodium lactate + oral sodium-chlorid solution
223405086|NCT03152877|DRUG|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
223737029|NCT03311958|DRUG|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
223737030|NCT00144976|DRUG|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
224022573|NCT01966380|DEVICE|Leia|
224022574|NCT04191018|DIAGNOSTIC_TEST|Liver elastography|Liver stiffness measurement
223737031|NCT05041504|BEHAVIORAL|Peer navigation|Participants in the intervention group will receive ongoing support from a trained peer navigator for 3 months after completing treatment for prostate cancer via the True North Peer Navigation website. Participants will be matched with a trained peer navigator who assesses needs and barriers to care, provides practical, informational, and emotional support, and empowers them to take a proactive role in their health. Participants will also have access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer.
223737032|NCT05041504|OTHER|Active wait list control|Participants in the active wait list control group will receive usual care and access to a health resource library on the True North Peer Navigation website that contains local and national resources about prostate cancer. After completion of the study, patients in the active wait list control group will be matched with a peer navigator.
223737033|NCT01110707|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
223737034|NCT01110707|DRUG|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
223737035|NCT05069454|BIOLOGICAL|COVID-19 vaccine Observation of individuals who receive the COVID-19 vaccine|To measure the effectiveness of COVID-19 vaccines against symptomatic laboratory-confirmed SARS-CoV-2 infection amongst hospital level health workers eligible for vaccination.
223737036|NCT00000954|DRUG|Bleomycin sulfate|
223737037|NCT00000954|DRUG|Vincristine sulfate|
223737038|NCT00000954|DRUG|Doxorubicin hydrochloride|
223737039|NCT00000954|DRUG|Zalcitabine|
223737040|NCT00000954|DRUG|Didanosine|
223737041|NCT04265274|DRUG|Disulfiram|dosing 400mg daily
223405087|NCT03152877|DRUG|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
223405088|NCT05782140|DEVICE|Mayo Clinic Watch Device|Mayo Clinic remote monitoring platform (Omni) that utilizes a wearable device with integrated physiological monitoring capabilities.
223405089|NCT06543277|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Participants will receive 18 goal-directed upper extremity rehabilitation therapy sessions with paired taVNS over six weeks, followed by a 90-day home exercise program.
223405090|NCT06979609|DRUG|Oral Vancomycin Prophylaxis|125mg PO BID for the duration of antibiotic re-exposure + 125mg PO QD for 7 days
223405091|NCT06979609|DRUG|Placebo|2 capsules PO BID for the duration of antibiotic re-exposure + 1 capsule PO QD x 7 days
223405092|NCT06611839|DRUG|Ivosidenib, Venetoclax, Azacitidine|"phase I: Induction therapy：Ivosidenib 、Venetoclax、Azacitidine~Dose climbing stage: adopt the 3 + 3 design principle, and the dose level 0,-1and 1 are set as follows~dose level 0: Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1,800mg d1-14 Azacitidine 75mg/m2/d, d1-7~dose level -1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1, 600mg d1-14 Azacitidine 75mg/m2/d, d1-5~dose level 1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1 800mg d1-21 Azacitidine 75mg/m2/d, d1-7~Consolidation therapy intermediate-dose cytarabine regimen ： 3 courses~If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;~Maintenance treatment:~Azacitidine、Venetoclax 、Ivosidenib： 6 courses~phase II: dose based on phase I results"
223737042|NCT04265274|DRUG|Vinorelbin|25mg/m2 day 1 and 8,
223737043|NCT04265274|DRUG|Cisplatin|75mg/m2 day 1
223737044|NCT04265274|DRUG|Copper|2 mg of elementary Copper daily
223737045|NCT02051829|OTHER|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
224022575|NCT04191018|DIAGNOSTIC_TEST|Splenic elastography|Splenic stiffness measurement
223737046|NCT03032666|DRUG|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
223405095|NCT03228667|DRUG|N-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
223737047|NCT02982967|OTHER|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
223737048|NCT01444326|OTHER|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
223737049|NCT02766062|OTHER|metabolic syndrome|metabolic syndrome
223737050|NCT03654950|OTHER|No intervention|Interviews and questionnaires
223737051|NCT04787029|DEVICE|Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))|Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
224022576|NCT04191018|DIAGNOSTIC_TEST|Gastrointestinal endoscopy|Gastrointestinal endoscopy
224022577|NCT02882724|BEHAVIORAL|Exercise|8-week aquatic exercise training program
224022578|NCT02882724|BEHAVIORAL|Control|Control group did not do the exercise training.
224022579|NCT03674463|DRUG|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
224022580|NCT00619762|DEVICE|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
224022581|NCT04815967|DRUG|Phase 2; Low Dose MYOBLOC|Intramuscular injections on Day 1
224022582|NCT04815967|DRUG|Phase 2; High Dose MYOBLOC|Intramuscular injections on Day 1
224022583|NCT04815967|DRUG|Phase 2; Placebo|Intramuscular injections on Day 1
224022584|NCT04815967|DRUG|Phase 3; MYOBLOC|Intramuscular injections on Day 1
224022585|NCT04815967|DRUG|Phase 3; Placebo|Intramuscular injections on Day 1
223405096|NCT03228667|DRUG|N-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
223405097|NCT03228667|DRUG|N-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
224132477|NCT06209814|DEVICE|Maxillary open-faced denture|Patients in this group received a maxillary open faced denture with soft acryl resin wing and a conventional mandibular complete denture. The patients used these dentures for 45 days. Afterward, the maxillary open-faced denture was replaced by one with a conventional construction.
224132478|NCT05665621|OTHER|Eight-week in-school strength and balance training program|Training program consisting of two 1-hour strength and balance training sessions per week.
224132479|NCT02337595|BIOLOGICAL|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
224297706|NCT04107142|BIOLOGICAL|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
224297707|NCT03097588|DRUG|Netupitant|300 mg, Given PO, QD
223405098|NCT03228667|DRUG|N-803 + Avelumab|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
223405099|NCT03228667|DRUG|N-803 + Durvalumab|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
223405100|NCT03228667|DRUG|N-803 + Pembrolizumab + PD-L1 t-haNK|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
223405101|NCT03228667|DRUG|N-803 + Nivolumab + PD-L1 t-haNK|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
223405102|NCT03228667|DRUG|N-803 + Atezolizumab + PD-L1 t-haNK|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
223405103|NCT03228667|DRUG|N-803 + Avelumab + PD-L1 t-haNK|Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
223405104|NCT03228667|DRUG|N-803 + Durvalumab + PD-L1 t-haNK|Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
223405105|NCT03228667|DRUG|N-803 + Docetaxel + Pembrolizumab|The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).
223405106|NCT03228667|DRUG|N-803 + Docetaxel + Nivolumab|The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
223405107|NCT07110610|DRUG|LTG-321|active investigational drug
223405108|NCT07110610|OTHER|Placebo|Placebo-to-match LTG-321
223405109|NCT07006727|DRUG|225Ac-ETN029|Radioligand therapy
223405110|NCT07006727|DRUG|111In-ETN029|Radioligand imaging agent
223405111|NCT06680622|DRUG|bemarituzumab, paclitaxel, ramucirumab|Cohort 2 will receive bemarituzumab plus SOC treatment with paclitaxel and ramucirumab
223405112|NCT06680622|DRUG|bemarituzumab, irinotecan|Cohort 1 will receive bemarituzumab plus SOC treatment with irinotecan
223405113|NCT06680622|DRUG|bemarituzumab, trifluridine/tipiracil|Cohort 3 will receive bemarituzumab plus SOC treatment with trifluridine/tipiracil
223555520|NCT04482777|DRUG|Corticosteriod for treated patients|Drug given to some patients with autoimmune disease
223555521|NCT06264908|BEHAVIORAL|Integrated self-management programme|"8 weeks integrated management programme with three educational sessions. Group therapy sessions (6-8 participants per group) delivered by occupational therapists and rheumatology nurses.~1. Disease pathology and Pain management~2. Joint protection and stretching exercise~3. Psychosocial education~4. Aids prescription Each session will consist of education session, exercise session and group sharing sessions."
223555522|NCT03440515|DRUG|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
223555523|NCT04744948|DEVICE|Treadmill exercise|high intensity interval training
223555524|NCT04744948|OTHER|low caloric diet|low caloric diet (1200ca/lday)
223555525|NCT04949516|DRUG|Aspirin|Aspirin is discontinued the day after drug-eluting stent implantation
223555526|NCT04949516|DRUG|Colchicine|Colchicine is started the day after drug-eluting stent implantation
223555527|NCT03449563|COMBINATION_PRODUCT|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
223555528|NCT03449563|COMBINATION_PRODUCT|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
223555529|NCT03449563|OTHER|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
223555530|NCT00935493|DRUG|Guanfacine|Guanfacine 0.1 mg po qhs
223555531|NCT00935493|DRUG|Guanfacine|Guanfacine 0.5 mg po qhs
223555532|NCT00935493|DRUG|Placebo|Placebo po qhs
223405114|NCT06686056|COMBINATION_PRODUCT|AIM-CHD Mobile Health Intervention|The AIM-CHD platform synchronizes data from hospitalization records, questionnaires, AI-powered voice follow-ups, and wearable devices to perform risk stratification and manage uncontrolled risk factors. It provides individualized follow-up plans, medication reminders, and lifestyle education, with real-time assessments of vital health metrics to prompt necessary in-person consultations. The app offers online consultation access and emergency services through Fuwai Hospital. Additionally, it delivers personalized patient education, aligning with the latest clinical guidelines.
223405115|NCT06686056|COMBINATION_PRODUCT|Usual post-discharge care|Usual post-discharge care includes oral and written instructions on sustained pharmacotherapy regimens, recommended follow-up frequency, and lifestyle modifications.
223405116|NCT07030257|DRUG|CP-383|Novel anti-cancer agent inhibiting pyrimidine synthesis in cancer cells
223405117|NCT06263153|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223405118|NCT06263153|PROCEDURE|Computed Tomography|Undergo CT
223405119|NCT06263153|BIOLOGICAL|Durvalumab|Given IV
223405120|NCT06263153|DRUG|Futibatinib|Given PO
223405121|NCT06263153|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223405122|NCT06263153|PROCEDURE|Radical Cystectomy|Undergo radical cystectomy
223555533|NCT03003754|BEHAVIORAL|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
223555534|NCT03003754|BEHAVIORAL|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
223555535|NCT05719779|DEVICE|Ronco-Onco and MAD|Comparison of active over a neutral mandibular advacement oral appliance to assess tolerance and efficacy in oropharyngeal cancer individuals in managing snoring and sleep apnea following radiotherapy of oropharynx.
223555536|NCT02441907|DRUG|aflibercept|
223555537|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
223555538|NCT01607463|PROCEDURE|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
223555539|NCT03715140|DRUG|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
223555540|NCT03715140|DRUG|Placebo|Placebo
223555541|NCT04093193|PROCEDURE|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
223555542|NCT02853552|DRUG|Misoprostol|800mcg misoprostol taken sublingually
223555543|NCT01555073|DRUG|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
223555544|NCT01555073|DRUG|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
223555545|NCT01555073|DRUG|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
223555546|NCT01555073|DRUG|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
223405125|NCT06707012|DRUG|Metformin Hydrochloride|"Participants will be divided in 2 groups~1 group will receive metformin and 2nd group will receive placebo"
223405126|NCT03231813|PROCEDURE|Sodium lauryl sulphate induced irritation|Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
223405127|NCT03231813|OTHER|Emollient, moisturizing cream|Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
223555547|NCT05746013|DIETARY_SUPPLEMENT|Lipid Emulsion|The oral lipid emulsions will contain water, sucrose, emulsifier, flavouring, and the corresponding fat (50 g/m2 of body surface area): milk cream (SFA) or refined olive oil (MUFA) with or without a dose of omega-3 PUFA, which will consist of 920 mg of EPA and 760 mg of DHA.
223555548|NCT03910790|DEVICE|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
223555549|NCT04475523|DRUG|CI-8993|CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand
223555550|NCT03256669|PROCEDURE|umbilical incision|exploration through umbilical incision
223555551|NCT02492308|PROCEDURE|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
223555552|NCT02492308|DRUG|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
223555553|NCT03786224|BEHAVIORAL|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
223555554|NCT03116906|DRUG|BI 685509|to be given for a total of up to 15 days
223555555|NCT03116906|DRUG|Placebo|to be given for a total of up to 15 days
223555556|NCT01442337|DRUG|ASP8597|one time IV dose
223555557|NCT01442337|DRUG|Placebo|one time IV dose
223555558|NCT01741233|GENETIC|VitDgen|
223555559|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|200 mg dose daily for 12 weeks.
224297708|NCT03097588|DRUG|Palonosetron Hydrochloride|0.5 mg, Given PO, QD
224297709|NCT03097588|OTHER|Questionnaire Administration|Ancillary studies
223405128|NCT05710328|DRUG|Chemotherapy|Receive standard of care chemotherapy
223555560|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|400 mg dose daily for 12 weeks.
223555561|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|600 mg dose daily for 12 weeks.
223405129|NCT05710328|PROCEDURE|Computed Tomography|Undergo PET/CT
223405130|NCT05710328|OTHER|Fludeoxyglucose F-18|Given IV
223737052|NCT04990414|OTHER|Cognitive Behavioural Therapy|Sessions 1-4 were focused on engagement, assessment of presenting problems, identification of treatment goals and normalization/ psychoeducation. Sessions 5- 14, focused on techniques to manage dissociative responses and/or increase perceived controllability of dissociation. Although further work on dissociation and/or trauma was encouraged, the targets for intervention in subsequent sessions (15-22) and the strategies selected depended on individual formulation of clients' difficulties and negotiation with the client. This could include re-appraisals on negative beliefs about dissociative experiences, cognitive and/or behavioural change strategies targeting core appraisals of voices leading to related distress, trauma-related techniques (e.g., imagery techniques,), or consolidation of a developmental/longitudinal psychological formulation of the client's difficulties. The final two sessions focused on plans for relapse prevention and maintenance of gains.
223405131|NCT05710328|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223405132|NCT05710328|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
223405133|NCT06469437|BEHAVIORAL|Providing the physicians with a proposed glycated hemoglobin target|"Through the geriatric assessment, the investigators will categorize the groups proposed by the Diabetes Canada Clinical Practice Guidelines Expert Committee guideline recommendations into functionally independent, functionally dependent and frail. The investigators will provide the physician with the glycated hemoglobin target proposed by the guideline."
223405134|NCT06758596|DRUG|Placebo Oral Capsule|A capsule that contains only dextrose filler administered during the first or second laboratory visit.
223405135|NCT06758596|DRUG|THC|A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
223555562|NCT00566553|DIETARY_SUPPLEMENT|Grape Seed Extract|800 mg dose daily for 12 weeks.
223555563|NCT03177512|BEHAVIORAL|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
223555564|NCT04334135|DIETARY_SUPPLEMENT|MitoQ|Four to eight 20mg capsules (depending on body mass)
223555565|NCT01781806|DRUG|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
223555566|NCT02244307|DRUG|alpha-adrenergic blocker|
224022586|NCT03195738|OTHER|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
224022587|NCT03435523|PROCEDURE|Recruitment maneuver|"the ventilator was switched to pressure-control ventilation with a driving pressure of 20 cmH2O. After a 3 min equilibration, PEEP was applied in steps of 5,10,15 and 20 cmH2O every five respiratory breaths; subsequently, after setting a driving pressure of 15 cmH2O, PEEP was stepwise reduced, starting from 15 cmH2O, by 2 cmH2O every 2 minutes. The recruiting pressure of 20/20 was applied for six breaths. During the decremental PEEP trial, CRS was measured at every step. The PEEP level corresponding to highest CRS during the decremental trial was identified as the best PEEP. Subsequently, the lungs were recruited again and the best PEEP was applied."
224022588|NCT01681056|BEHAVIORAL|Autosuggestion for 30 days|
224022589|NCT02972463|DIETARY_SUPPLEMENT|Immunoglobulin Y|
223555567|NCT04736212|DEVICE|Bed sensor monitoring system|Respiratory patterns in the post-anesthesia care unit will be assessed using a validated, modified under bed weighing scale placed under the patient's bed in the PACU.
223555568|NCT02977910|PROCEDURE|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
223555569|NCT06012747|OTHER|Questionnaire|The patients receive a questionnaire every 6 hours during the first 24 hours after their cesarean section, and again after 2, 7, and 30 days.
224022590|NCT02972463|OTHER|Placebo|
224022591|NCT02070133|DRUG|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
224022592|NCT02070133|DRUG|Placebo|Placebo once a day during 12 weeks
224022593|NCT01845220|DRUG|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
224022594|NCT01845220|DRUG|Placebo|80% acetone
223555570|NCT03084094|DEVICE|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
223555571|NCT00083954|DRUG|Quetiapine Fumarate|
223555572|NCT04880746|DRUG|BEAC|Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
223555573|NCT04880746|DRUG|Cladribine combined with BEAC|Cladribine, 6mg/m2，-5～-2d, two hours before Cytarabine Semustine, 300 mg/m2，-6d； Etoposide, 100 mg/m2，-5～-2d； Cytarabine, 100mg/m2，q12h，-5～-2d； Cyclophosphamide, 1.5g/m2，-5～-2d
223555574|NCT01599312|DEVICE|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
223555575|NCT03335904|OTHER|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
223405136|NCT07060950|BIOLOGICAL|Blood sampling C1|"Blood samples will be collected at four key time points :~* baseline (T1),~* first scan assessment (T2),~* second scan assessment (T3),~* and progression (T4)."
223405137|NCT07061613|OTHER|NeoThelium FT (HCT/P 361)|NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue.
223405138|NCT07059975|DRUG|Idarubicin Hydrochloride|Idarubicin is given in combination with fludarabine and cytarabine for Ida-FLA, and in combination with venetoclax and cytarabine for VIA.
223405139|NCT07059975|DRUG|Fludarabine|Fludarabine is given in combination with idarubicin and cytarabine for Ida-FLA.
223405140|NCT07059975|DRUG|Cytarabine (Ara-C)|Cytarabine is given in combination with other chemotherapy agents in every cycle and both arms.
223405141|NCT07059975|DRUG|Venetoclax|Venetoclax is given in combination with idarubicin and cytarabine for VIA.
223405142|NCT07059975|DRUG|Etoposide|Etoposide is given in combination with cytarabine for AE, as Intensification 1 for IR patients.
223405143|NCT07059975|DRUG|Asparaginase Erwinia Chrysanthemi (recombinant)|Rylaze is given in combination with cytarabine for Intensification 3 for IR patients.
223555576|NCT03335904|OTHER|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
223555577|NCT03335904|OTHER|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
223555578|NCT03335904|OTHER|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
223555579|NCT03335904|DRUG|Losartan|Losartan, 50mg, BID
223555580|NCT03335904|DRUG|Placebo|Placebo, 50mg, BID
223555581|NCT00479817|DRUG|AMG 386|10mg/kg
223555582|NCT00479817|DRUG|AMG 386|3 mg/kg
223555583|NCT00479817|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
223555584|NCT00479817|DRUG|AMG 386 Placebo|AMG 386 Placebo
223555585|NCT04181593|DRUG|Omega 3 fatty acid|Omega 3 fatty acid Softgels
223555586|NCT04181593|DRUG|Placebos|Mineral oil Softgels
223555587|NCT05731635|DIAGNOSTIC_TEST|plantar pressure values|Walking enables for extremely accurate and pointwise ground response force measurement because to plantar pressure measurement (pedobarography). It allows for the objective comparison and evaluation of the dynamic pressure put on the ground by the foot in contact with it. It is often used in clinics to assess foot mechanics and associated disorders that affect the foot sole. Additionally, plantar pressure analysis is useful for identifying, treating, and monitoring conditions that impact the lower extremity's axial alignment.
224022595|NCT02314910|OTHER|Sample histology|
224022596|NCT06280326|OTHER|Sunflower oil|In the experimental group, patch removal will be performed using sunflower oil.
223405144|NCT07059975|DRUG|Intrathecal triple|Methotrexate, hydrocortisone and cytarabine are combined into one preparation for intrathecal administration at multiple time points during treatment.
223405145|NCT07059975|OTHER|SOC|Low-Risk Patients will receive Texas childern's Hospital practice standard for de novo AML.
223405146|NCT07058467|OTHER|Joint Manipulation|"A joint manipulation is defined as a manual treatment by a clinician that uses controlled force to improve joint function. For the purpose of this study, the terms manipulation and mobilization may be used interchangeably. The knee joint is specifically defined as the tibiofemoral articulation for the purpose of this study.~All knee joint manipulation in this study will coincide with grade III or IV manipulations. This category coincides with evidence that mobilizations at or above grade III has the greatest impact on somatosensation and are most likely to produce a positive effect on neurocognitive function. Joint manipulation(s) will be delivered with a vector corresponding to the functional deficits found with manual joint palpation and will only occur with the involved ACLR knee. If both knees have experienced an ACL injury, the most recently injured knee will be manipulated."
223555588|NCT02575872|BEHAVIORAL|Exercise Intervention|Participate in physical activity behavioral intervention
223555589|NCT00140153|DRUG|testosterone gel (Androgel)|
223555590|NCT01111383|DRUG|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
223555591|NCT02565147|PROCEDURE|PPCI|PPCI for treatment of participants presenting with large STEMI.
223555592|NCT02565147|DRUG|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
223555593|NCT02565147|DRUG|Heparin|Heparin is an anticoagulant.
223555594|NCT03443856|DRUG|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
224022597|NCT06280326|OTHER|Slicone based spray|In the control group, clinical routine procedure will be used to remove the patch (silicone based spray.
224022598|NCT05041036|DRUG|Nirogacestat (Gamma Secretase Inhibitor)|Patients will receive nirogacestat tablets to be taken orally.
223555595|NCT03443856|OTHER|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
223555596|NCT03587428|DRUG|Zinc-A toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
223555597|NCT03587428|DRUG|Zinc-B toothpaste|Participants received 6.0 grams (g) \[± 0.3g\] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 \[generally 7\] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
223555598|NCT03587428|OTHER|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 \[generally 7\] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
224022599|NCT03200379|OTHER|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
223405147|NCT03746847|DRUG|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
223405148|NCT06409273|OTHER|Hybrid course on medical thesis for post graduates general practice students|Students randomised to the intervention group will log on to interactive online teaching for a maximum time of 2.5 hours, and then follow face-to-face socio-constructivist teaching in small groups (n=22 max), building on the knowledge they have acquired. The aim of this peer-to-peer face-to-face teaching is to develop problem-solving skills.
223405149|NCT06409273|OTHER|Face-to-face teaching on medical thesis for post graduates general practice students|Students randomised to the control group will be taught entirely face-to-face in small groups (n=22 max). The course duration and teaching objectives are identical to those of the intervention group. Student consent and randomization will be carried out on the morning of the course to avoid contamination and attrition bias.
223405150|NCT00361647|PROCEDURE|Diagnostic screening for occult malignancy|
223405151|NCT00528047|DRUG|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
223737053|NCT03585439|PROCEDURE|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
223737054|NCT02369341|BIOLOGICAL|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
223737055|NCT00295347|DRUG|Spironolactone|
224022600|NCT04502628|PROCEDURE|Hyperbaric oxygen therapy|Patients with hemorrhagic cystitis (HC) after allo-HSCT will receive hyperbaric oxygen therapy (HBOT) on the next day of the HC diagnosis was determined. Then HBOT will be scheduled every day until symptoms of HC vanished. Other classic measures to treatment HC such as hydration, alkalization, and bladder irrigation will also be carried out at the same time.
224022601|NCT02157922|DRUG|alginate oligosaccharide|Inhalation
224022602|NCT04832425|DRUG|PRAX-114|40 mg once daily
224022603|NCT04832425|DRUG|Placebo|Placebo once daily
224022604|NCT05603130|OTHER|routinely collected clinical information|medical history, epidemiological characteristics, clinical examination, biological assessment (blood glucose, NFS, CRP, D-dimer,etc...)
224022605|NCT00199940|DRUG|Ziprasidone|
224297710|NCT05873361|OTHER|Questionnaire|The questionnaire is about hypocalcemia, dysphonia and anxiety. It will be carried out by phone call for 10 minutes
223405152|NCT06767813|DRUG|TQB2868 injection|TQB2868 injection is an anti-PD 1/growth factor (GF)-β Receptor Type II (TGF-βRII) bifunctional fusion protein.
223405153|NCT06767813|DRUG|Gemcitabine injection|Gemcitabine injection
223405154|NCT06767813|DRUG|Albumin paclitaxel injection|Albumin paclitaxel injection
223405155|NCT06767813|DRUG|Anlotinib capsules|Anlotinib capsules
223405156|NCT02565680|DRUG|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
223405157|NCT02565680|DRUG|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
223405158|NCT03783767|BEHAVIORAL|Leadership Intervention|Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
223405159|NCT00000967|DRUG|Interferon alfa-2a|
223405160|NCT00000967|DRUG|Zidovudine|
223405161|NCT02082015|DEVICE|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
223405162|NCT00673439|DRUG|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
223405163|NCT00673439|DRUG|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
223405164|NCT02074241|OTHER|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
223405165|NCT01938638|DRUG|BAY1143572|
223405166|NCT06776250|DRUG|Tarlatamab|Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.
223405167|NCT01804946|DRUG|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
223405168|NCT01804946|DRUG|Oseltamivir|Safety and Efficiency in treatment of Influenza
223405169|NCT04012021|DIAGNOSTIC_TEST|7T Magnetic Resonance Imaging|"* T1-weighted and T2-weighted sequences~* quantitative magnetic resonance imaging approach~* proton spectrum analyses"
223405170|NCT01066832|DRUG|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
223405171|NCT02729259|BEHAVIORAL|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
223405172|NCT02729259|BEHAVIORAL|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
223737056|NCT00295347|DRUG|fludrocortisone|
223737057|NCT00295347|DRUG|escitalopram|
224022606|NCT01647269|PROCEDURE|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
224022607|NCT05023421|OTHER|no intervention|no intervention
223405173|NCT02729259|BEHAVIORAL|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
223405174|NCT06456775|BEHAVIORAL|Tele-SSM|Tele-SSM an individual-level psychosocial intervention based on cognitive behavior therapy principles and non-violent communication. The intervention consists of the following 10 sessions delivered through 10 weekly coaching calls delivered by Zoom (audio only).
223405175|NCT00722137|DRUG|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
223405176|NCT00722137|DRUG|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
223405177|NCT00722137|DRUG|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
223405178|NCT00722137|DRUG|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
223405179|NCT00722137|DRUG|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
223405180|NCT00722137|DRUG|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
223405181|NCT06189300|OTHER|Education and counseling intervention|In addition to standard training, training and consultancy will be provided to individuals with stoma intermittently within a month.
223405182|NCT04033354|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
223405183|NCT04033354|DRUG|carboplatin and nab paclitaxel|chemotherapeutics
224022608|NCT05757284|DIAGNOSTIC_TEST|Lower Limb Lymhedema assessment|assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
224022609|NCT03720873|DRUG|erlotinib or gefitinib or icotinib|Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
224022610|NCT03720873|DRUG|Anlotinib|Patients will be treated with Anlotinib 12mg po d1-14 Q21d
224022611|NCT03058835|DRUG|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
224022612|NCT05991843|BEHAVIORAL|Instructions of breathing|Breathing normally, slowly and rapidly for 30 seconds with an open and a closed mouth.
224022613|NCT04361188|PROCEDURE|MAC anesthesia|Patients receives DBS under monitored anesthesia care.
223405184|NCT04033354|DRUG|Placebo|Placebo
223405185|NCT01160705|DRUG|docetaxel|
223405186|NCT01160705|GENETIC|RNA analysis|
223555599|NCT03102450|DRUG|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
224022614|NCT04361188|PROCEDURE|AAA anesthesia|Patients receives DBS under asleep-awake-asleep anesthesia.
224022615|NCT01218893|DRUG|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
224022616|NCT01218893|BIOLOGICAL|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
224022617|NCT01218893|BIOLOGICAL|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
224022618|NCT01218893|DRUG|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
224022619|NCT02802826|BEHAVIORAL|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
224022620|NCT02418676|DRUG|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
224022621|NCT02418676|DRUG|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
224132480|NCT06483763|OTHER|SmokerFace App from the Education Against Tobacco (EAT) program|The SmokerFace App utilizes photo-aging technology that requires users to take a selfie. This selfie is processed by the software to generate four images depicting the consequences of smoking (or not smoking) one pack a day over both a one-year and 15 years. The app provides explanations of these smoking beauty-reducing visual outcomes and educates users about the aesthetic impacts of smoking, along with potential health consequences.
223405187|NCT01160705|GENETIC|reverse transcriptase-polymerase chain reaction|
223405188|NCT01160705|OTHER|circulating tumor cell analysis|
223405189|NCT01160705|OTHER|laboratory biomarker analysis|
223405190|NCT02853877|BEHAVIORAL|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
223405191|NCT03525080|DIAGNOSTIC_TEST|PET imagery|Every patients will have a PET imagery in addition to standard MRI
223405192|NCT06231225|BEHAVIORAL|Incentive Spirometer respiratory training|The incentive spirometer is a handheld mechanical breathing device that uses a one-way valve to prevent exhalation. It consists of a corrugated tube and a nozzle connected to three consecutive plastic chambers, each containing a ball. The external chambers are marked with the minimum flow required to raise the ball internally. The ball rises when the patient performs slow, deep breathing through the nozzle. If the patient breathes too quickly, the balls in the chambers rise to the top, and if breathing is too slow, the balls fall to the bottom. The number of increasing balls measures the volume of inhaled air. When all three balls reach the top of the chambers, the patient's flow rate can reach 1200 ml/s. After the patient has maximized their inhalation, they are asked to hold the balls in the same position for more than 3 sec.
223405193|NCT02308930|DIETARY_SUPPLEMENT|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
223405194|NCT02308930|DIETARY_SUPPLEMENT|Vitamins supplement (Vitamins A,D, E and corn oil)|
223405195|NCT00836225|DRUG|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
223405196|NCT07069400|OTHER|No intervention|This is an observational study
223405197|NCT02514486|BEHAVIORAL|Questionnaire|
223405198|NCT00400023|DRUG|S-1|"During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
223405199|NCT00400023|DRUG|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
223405200|NCT05482217|BEHAVIORAL|Psychoeducation, problem solving and rehearsal (cognitive behavioural intervention)|"The highlights of the intervention.~Session 1: Rapport building and knowledge of HIV~Session 2: Identifying and Dealing with barriers to good adherence~Session 3: Identifying and dealing with problems in relation to depression and adherence:~Session 4: Identifying and dealing with negative cognitions, handling privacy, accessing social Support, and adjusting to HIV and antiretroviral treatment~Session 5: Rehearsal of practical tips on adherence, handling slips, and strategies to improve quality of life.~All sessions involved brief periods of relaxation, homework, and a homework review. The last session was concluded with the assessment of satisfaction with the program. The programs were conducted for 60 minutes weekly for five weeks.~They were delivered by a trained lay counselor and supervised by the principal investigator for five weeks."
223405201|NCT05090436|OTHER|Schroth Exercise|two month (three session per week)
223555600|NCT03204604|DIETARY_SUPPLEMENT|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
223555601|NCT03204604|DIETARY_SUPPLEMENT|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
223555602|NCT03204604|PROCEDURE|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
223555603|NCT03204604|BEHAVIORAL|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
223737058|NCT03287804|BIOLOGICAL|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
223405202|NCT05090436|OTHER|Functional Electrical Stimulation (physiotherapy techniques)|two month (three session per week)
223405203|NCT05395117|DRUG|AZD5462|"Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin"
223405204|NCT05395117|DRUG|Midazolam|Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.
223405205|NCT05395117|DRUG|Rosuvastatin|Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
223737059|NCT02044744|BEHAVIORAL|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
223405206|NCT05395117|DRUG|Digoxin|Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
223405207|NCT00848718|DRUG|MK-2206|MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
223405208|NCT00848718|DRUG|docetaxel|Administered as an IV infusion on Day 1 of each 21-day cycle
223405209|NCT00848718|DRUG|erlotinib|Administered daily (QD) PO in each 21-day cycle
223405210|NCT00848718|DRUG|carboplatin|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
223737060|NCT00385996|DRUG|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
223737061|NCT03913650|PROCEDURE|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
223737062|NCT04921254|DRUG|BSG005 or placebo|"SAD part is a single IV infusion of ascending doses of BSG005 or placebo - a 30 minutes infusion that may be extended to 2 hours if infusion reactions occur.~The MAD part is single daily infusions of the cohort dose over 30 minutes (that may be delayed up to 2 hours in case of infusion reactions) and which will be repeated daily for 7 days. Objective is safety, tolerability and PK on day 1 and day 7 and to establish steady state plasma level."
223737063|NCT03028831|DIETARY_SUPPLEMENT|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
223737064|NCT03028831|DIETARY_SUPPLEMENT|Resistant starch|70g high-amylose maize starch
223737065|NCT01273402|DRUG|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
223737066|NCT01109199|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
223737067|NCT01109199|DIETARY_SUPPLEMENT|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
223737068|NCT04093219|DRUG|IV acetaminophen|use of IV tylenol for pain
223737069|NCT04093219|OTHER|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
223737070|NCT06829979|BEHAVIORAL|Access to napping/relaxation room|During the night shift, study participants will have access to the hospital unit's napping/relaxation room with a sound machine, diffusers for aromatherapy, a massage chair that can be used for napping, and snacks.
223737071|NCT06829979|OTHER|Blue and green light blocking glasses|During the night shift, participants will be asked wear study-provided blue and green light blocking glasses.
223737072|NCT06003348|DIETARY_SUPPLEMENT|OHCit- standard dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
223737073|NCT06003348|DRUG|Potassium Citrate|10 mEq Extended-release tablets for oral use
223737074|NCT06003348|DRUG|Placebo|Placebo
223737075|NCT06003348|DIETARY_SUPPLEMENT|OHCit- low dose|Hydroxycitrate Over-the-counter supplement, not FDA approved or regulated.
223737076|NCT02758015|OTHER|Standardized Meal|
223737077|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
223737078|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
223405211|NCT00848718|DRUG|paclitaxel|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
223405212|NCT00848718|DRUG|corticosteroid|Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
223737079|NCT02758015|DIETARY_SUPPLEMENT|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
223737080|NCT03193931|DRUG|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
223737081|NCT03193931|DRUG|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
223737082|NCT01662518|DEVICE|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
223737083|NCT00981955|DIETARY_SUPPLEMENT|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
223737084|NCT05626595|BEHAVIORAL|Project Group - PRO-ECO Project|The PRO-ECO project will be tailored to individual sites. Through collection of focus group and baseline data, the project will be further refined to provide site-specific adjustments, such as specific materials in the built environment design modification or targeted training. Identified features of effective projects outlined in the literature have informed the development of the project foundation and potential tailoring.
223737085|NCT05626595|BEHAVIORAL|Wait List Group - Normal Daily Practice|ELCCs that are randomly assigned to the waitlist group will participate in their normal daily practice, including standard curriculum and outdoor play time. Once post-data collection is complete, wait list sites will be given the PRO-ECO project.
224132481|NCT06483763|OTHER|The use of standardized school-based educational module|This module is designed to promote a tobacco- and nicotine-free environment and is validated by at least three experts in related fields (27). The intervention will be customized to fit the Omani sociocultural context and will be administered in the classrooms of respective schools by the same team of trained medical students
223405213|NCT04253418|DEVICE|Nano-Pulse Stimulation (NPS)|Electrical pulses (nanosecond duration) applied directly to target SH lesions using sterile single-patient use treatment tips with microneedles.
223405214|NCT02689154|DEVICE|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
223737086|NCT00939081|BEHAVIORAL|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
223737087|NCT00939081|BEHAVIORAL|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
224022622|NCT02418676|DRUG|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
224132482|NCT05585086|OTHER|Peppermint Oil Inhalation|Peppermint oil will be given by diluting 1/10 in wheat oil so that it does not cause skin irritation. Application; by inhalation method, 2 cc lavender essential oil + 100 cc water (2%) will be in the form of two drops for 20 minutes. Since the effectiveness of essential oils decreases over time and the desired dose cannot be applied at the same time; Peppermint oil will be applied to the individual for a total of 5 times every 30 minutes.
224132483|NCT00823524|BIOLOGICAL|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
223405215|NCT06219811|DEVICE|Two implant -retained overdenture reinforced with Co-Cr framework|The intervention is made from polymethylmethacrylate reinforced with cobalt chromium ( Co-Cr) framework.
224132484|NCT05602012|BEHAVIORAL|Mindfulness based cognitive counseling group|Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
224132485|NCT01196650|DRUG|IN 10 003 formulation A|
223555604|NCT03204604|BEHAVIORAL|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
223555605|NCT03204604|BEHAVIORAL|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
223555606|NCT03204604|BEHAVIORAL|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
223555607|NCT02936869|BEHAVIORAL|Performance-based monetary incentives|
223555608|NCT03400046|DRUG|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
223555609|NCT00335738|DRUG|liposomal vincristine sulfate|Given IV
224132486|NCT01196650|DRUG|IN 10 003 formulation B|
224132487|NCT01196650|DRUG|Placebo capsules|
224132488|NCT02065596|DRUG|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
224132489|NCT02065596|PROCEDURE|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
224132490|NCT04342182|BIOLOGICAL|Convalescent plasma|"Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products"
223405216|NCT06219811|DEVICE|Two implant -retained overdenture reinforced with PEEK framework|The intervention is made from polymethylmethacrylate reinforced with Polyetherketoneketone ( PEEK) framework.
223405217|NCT06231329|DEVICE|ultrasound elastography|examining patient's testis with ultrasound elastography technique and collect data and results
223555610|NCT00335738|DRUG|carboplatin|Given IV
224022623|NCT01604629|DRUG|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
224022624|NCT01604629|DRUG|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
224132491|NCT00834704|DRUG|PEGPH20|PEGylated recombinant human hyaluronidase
224132492|NCT00625898|DRUG|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
223405218|NCT06261489|DRUG|THC|Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.
223405219|NCT06261489|DRUG|CBD|Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.
223555611|NCT00335738|DRUG|etoposide|Given IV
223555612|NCT02688270|DRUG|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
223555613|NCT02688270|DRUG|Vehicle Cream (placebo)|Vehicle administered topically
223555614|NCT04047615|OTHER|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
224022625|NCT04845243|BEHAVIORAL|Emotionen Verstehen und Ausdrücken (E.V.A.)|The online training is focused on the strengthening of socioemotional competences and consists of different training tasks (up to 3 million) presented to the participant as mini games. These training tasks are specifically designed according to empirical findings to match the socio-emotional recognition needs of people with ASD. During these games, an adapted Elo-Algorithm allows to automatically evaluate the participants' performance and adapts the difficulty levels throughout the users' progress in the training.
224022626|NCT03183700|DEVICE|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
224022627|NCT03183700|OTHER|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
224022628|NCT03536143|BIOLOGICAL|Topical beremagene geperpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
223405220|NCT01879384|DEVICE|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
223555615|NCT00745290|DRUG|Bupivacaine HCl|200 mg bupivacaine HCl
223555616|NCT00745290|DRUG|SKY0402|600 mg SKY0402 (study drug).
223555617|NCT03423238|OTHER|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
223555618|NCT03423238|BEHAVIORAL|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
223737088|NCT02977988|BEHAVIORAL|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
223737089|NCT02977988|BEHAVIORAL|Brain and Recovery (B&R)|B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
224022629|NCT03536143|BIOLOGICAL|Placebo gel|Placebo gel
224022630|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
224022631|NCT01059123|DRUG|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
224022632|NCT01174160|DRUG|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
224132493|NCT00625898|DRUG|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
224132494|NCT00625898|DRUG|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
224132495|NCT00625898|DRUG|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
224132496|NCT00625898|DRUG|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
224132497|NCT00625898|DRUG|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
224132498|NCT00625898|DRUG|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
223405221|NCT06368297|DIETARY_SUPPLEMENT|Ketone Monoester Supplementation|Exogenous ketones are a class of ketone bodies that are ingested using nutritional supplements or foods. This class of ketone bodies refers to the three water-soluble ketones (acetoacetate, β-hydroxybutyrate \[β-HB\], and acetone).
223405222|NCT06368297|DIETARY_SUPPLEMENT|Ketogenic diet|The ketogenic diet typically reduces total carbohydrate intake to less than 50 grams a day-less than the amount found in a medium plain bagel-and can be as low as 20 grams a day. Generally, popular ketogenic resources suggest an average of 70-80% fat from total daily calories, 5-10% carbohydrate, and 10-20% protein.
223405223|NCT01421979|DIETARY_SUPPLEMENT|Energy Drink, Taurine, Caffeine|
224022633|NCT01174160|DRUG|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
224022634|NCT00146354|BEHAVIORAL|Hospitalists Results Manager|
224022635|NCT03452358|PROCEDURE|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
224132499|NCT00734344|DRUG|Raltegravir|Raltegravir 400 mg. BID
224132500|NCT00734344|DRUG|Efavirenz|600 mg once daily
224132501|NCT00734344|DRUG|Emtricitibine|200mg once daily
223405224|NCT02431676|DRUG|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
223405225|NCT02431676|BEHAVIORAL|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
223405226|NCT02431676|BEHAVIORAL|Self-control weight loss|
223405227|NCT01018927|DEVICE|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
223405228|NCT02448394|OTHER|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
223405229|NCT06833190|DRUG|REGN5381|Administered per the protocol
223405230|NCT06833190|DRUG|Placebo|Administered per the protocol
223405231|NCT02576080|DRUG|Imatinib|
223405232|NCT02576080|OTHER|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
223555619|NCT03423238|OTHER|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
223555620|NCT03423238|DIETARY_SUPPLEMENT|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, \<30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
223555621|NCT03423238|BEHAVIORAL|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals.
223737090|NCT05028439|DEVICE|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
223405233|NCT06319989|OTHER|Biplane Ultrasound|During a standard of care caudal epidural block, biplane ultrasound will be used.
223405234|NCT06319989|OTHER|Single plane ultrasound|During a standard of care caudal epidural block, single plane ultrasound will be used.
223405235|NCT03859479|PROCEDURE|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
223555622|NCT03423238|OTHER|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
223555623|NCT03423238|OTHER|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
223555624|NCT04646252|OTHER|Perfused Boundary Region of sublingual microvessels|Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
223555625|NCT05070312|BIOLOGICAL|MEDI3506|MEDI3506
223555626|NCT05070312|DRUG|Placebo|Placebo
223737091|NCT05028439|DRUG|Chemotherapy drug|Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
224132502|NCT00734344|DRUG|Tenofovir disoproxil once daily|300mg once daily
224132503|NCT00734344|DRUG|Tenofovir disoproxil twice daily|300mg twice daily
224132504|NCT00424528|DRUG|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
224132505|NCT00424528|DRUG|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
224132506|NCT00424528|DRUG|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
223405236|NCT03859479|PROCEDURE|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
223405237|NCT03721874|DRUG|Dapagliflozin 10mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2."
223405238|NCT03721874|DRUG|Placebo matching to Dapagliflozin 10 mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2."
223405239|NCT01057147|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
223405240|NCT01057147|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
223405241|NCT05053945|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|"To set up a prospective study and registry (HAR-P) for patients with H. pylori infection, atrophic gastritis or intestinal metaplasia to evaluate their clinical features and outcomes. The objectives include:~1. Assess the short- and long-term patient outcomes of H. pylori patients~2. Characterize factors involved in the progression or regression of pre-neoplastic lesions, namely atrophic gastritis and intestinal metaplasia~3. Gather information for a better understanding on the efficacy and role of surveillance~4. Potential for the development of new screening/surveillance strategies and tools for better risk stratification of patients~5. Establish a biobank for H. pylori, atrophic gastritis and intestinal metaplasia patients"
223555627|NCT04700085|DEVICE|ReMotion Knee|The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
224132507|NCT00424528|DRUG|Placebo|Placebo inhalation solution and placebo inhalation powder
224132508|NCT02278640|DEVICE|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
224132509|NCT01159626|DRUG|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
223405242|NCT06649955|DEVICE|Multi-site direct current stimulation (DCS)|The MyoRegulator® treatment is a non-invasive intervention that suppresses motor neuron hyperexcitability and activates protein degradation pathways through the use of multi-site direct current stimulation (multi-site DCS).
223405243|NCT05189977|DRUG|Propranolol|"Propranolol (tablet, oral ): 40 mg QD Day 3 and Day 21~Intervention 1 is a single dose of prazosin administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
223405244|NCT05189977|DRUG|Prazosin|"Prazosin (tablet, oral): 1 mg QD Day 2 and Day 20~Intervention 2 is a single dose of propranolol administered in the presence of sertraline alone at steady state or in the presence of sertraline + brexpiprazole at steady state."
223405245|NCT07071909|BIOLOGICAL|Commercial CAR-T|Twenty subjects will receive investigational CAR-T through a University of North Carolina at Chapel Hill clinical trial.
223405246|NCT07071909|BIOLOGICAL|Investigational CAR-T|Thirty subjects will receive investigational CAR-T through a University of North Carolina at Chapel Hill clinical trial.
223405254|NCT06506916|DRUG|bimekizumab|Study participants receive bimekizumab (BKZ) administered subcutaneously at pre-specified timepoints during study.
223405255|NCT06752876|DRUG|CB-010|CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
223405256|NCT07074249|PROCEDURE|"Anatomical Accuracy of Blind Dry Needling Procedures on the Lumbar Paraspinal Muscles: An Ultrasonography-Assisted Observational Study"|"* All interventions will be performed by a physical medicine and rehabilitation specialist with clinical experience.~* Targeted muscles:~* \*Iliocostalis lumborum (ICL)\*~* \*Longissimus thoracis (LT)\*~* \*Multifidus (M)\*~* Interventions will be performed from the right side, between the L2-L5 levels.~* A total of \*three different dry needling applications\* will be performed for these three muscles for each participant."
223405257|NCT07074249|PROCEDURE|"Anatomical Accuracy of Blind Dry Needling Procedures on the Lumbar Paraspinal Muscles: An Ultrasonography-Assisted Observational Study"|\*All interventions will be performed by a physical medicine and rehabilitation specialist with clinical experience. \* Targeted muscles: \* \*Iliocostalis lumborum (ICL)\* \* \*Longissimus thoracis (LT)\* \* \*Multifidus (M)\* \* Interventions will be performed from the right side, between the L2-L5 levels. \* A total of \*three different dry needling applications\* will be performed for these three muscles for each participant. After each intervention, the needle tip position will be evaluated by a second specialist with \*high-resolution linear probe ultrasound\*.
223405258|NCT07079033|PROCEDURE|Blinded Dry Needling|Dry needling is performed using anatomical landmarks without ultrasound guidance. Needle placement is then confirmed via ultrasound imaging.
223405259|NCT07075081|OTHER|Ceremony|Lifecourse ceremony led by Elders that used to be offered to everyone prior to colonization
224132510|NCT01159626|DRUG|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
224132511|NCT01159626|DRUG|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
224132512|NCT01159626|DRUG|Placebo|Oral single dose as matching placebo
224132513|NCT01159626|DRUG|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
224132514|NCT01159626|DRUG|Placebo|Oral multiple doses as matching placebo for 7 days
224132515|NCT02221271|DRUG|NPB-01|
224132516|NCT03824548|OTHER|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
223737092|NCT03872219|COMBINATION_PRODUCT|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
223737093|NCT02015650|DRUG|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
223737094|NCT02015650|DRUG|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
223405260|NCT07078019|OTHER|Voice Recording Procedure|"Participants will be asked to read a standardized one-minute text aloud in a quiet room. Their voices will be recorded using a high-quality microphone. The recordings will later be analyzed for acoustic features such as pitch, speech rate, pauses, and intonation.~This procedure is non-invasive and does not involve any clinical or pharmacological intervention."
223555628|NCT03807050|DIETARY_SUPPLEMENT|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
223555629|NCT01009970|DRUG|Rituximab|375 mg/m2 day 1
223555630|NCT01009970|DRUG|Cyclophosphamide|750 mg/m2 day 2
223555631|NCT01009970|DRUG|Vincristine|1,4 mg/m2 (max 2 mg) day 2
223555632|NCT01009970|DRUG|Prednisone|40 mg/m2 day 2-6
223555633|NCT01009970|DRUG|Doxorubicin|50 mg/m2 day 2
223555634|NCT06137885|BEHAVIORAL|Cardiac rehabilitation|Cardiac rehabilitation is a comprehensive model of care involving prescribed exercise, medication management, lifestyle modification, and psychosocial counseling to help people with heart diseases resume and enhance their psychosocial and vocational status.
224022636|NCT03616197|PROCEDURE|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
223405261|NCT07077616|BIOLOGICAL|Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;|"TAMAVAQ Vaccine plus Poly-ICLC, cGAMP, Granulocyte-macrophage colony stimulating factor (GM-CSF), imiquimod, CpG oligodeoxynucleotides, saponins and monophosphoryl lipid A (MPLA)~* TAMAVAQ VACCINE : Each one of our TAMAVAQ VACCINE is consisted of 1-35 (LIMPs, ASPs, and bEPTs) Personalised Synthetic Neoantigenic Peptides mixed with GBM TAAs, including MAGE-1, HER-2, gp100, AIM-2, TRP-2, EphA2,105 survivin50, IL13Rα2, heat-shock peptide protein complex-96 (HSPPC-96), and Smac-TLR7/8 peptides.~* TAMAVAQ vaccine products are composed of 1-35 peptides from the Biogenea Pharmaceuticals Ltd warehouse.~* TAMAVAQ vaccine will be applied before maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 14 before the first maintenance TMZ cycle, patients will receive 7 vaccinations with TAMAVAC VACCINE"
223555635|NCT06137885|OTHER|Active post-market surveillance of devices|Active post-market surveillance of devices is an essential and ongoing process that involves systematic monitoring and assessment of medical devices once they are available on the market. It involves continuous data collection and analysis, early detection of issues, risk assessment, compliance with regulatory requirements, adaptive decision-making, and transparent communication with healthcare professionals and patients.
223555636|NCT06137885|OTHER|Multi-omics approach to precision medicine|Multi-omics analysis refers to the collective analysis of extensive biological data from multiple omics sources to gain a holistic understanding of an individual's health status, disease susceptibility, and response to therapies. By considering a broad spectrum of genetic and molecular information, multi-omics precision medicine aims to deliver more accurate diagnoses, predict disease risks, select optimal treatment options, and monitor therapeutic responses with a high degree of specificity, ultimately improving patient outcomes and minimizing adverse effects.
223555637|NCT06137885|OTHER|The prescription pattern analysis|The prescription pattern analysis refers to the systematic examination and evaluation of the types, dosages, frequencies, and trends in medications prescribed to patients with cardiovascular conditions. By scrutinizing prescription patterns, researchers and healthcare professionals can identify prevalent medications, assess adherence to treatment guidelines, uncover potential gaps or areas for improvement in patient care, and gain insights into the evolving landscape of cardiovascular therapies.
223555638|NCT04186533|BEHAVIORAL|Default Option|The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
223555639|NCT04186533|BEHAVIORAL|Nutrition Education|The nutrition education materials were adapted from materials currently utilized by the Supplemental Nutrition Assistance Education Program
223737095|NCT03016286|OTHER|vibration|Whole body vibration at 25Hz frequency
223737096|NCT00003644|DRUG|carboplatin|
223737097|NCT00003644|DRUG|paclitaxel|
223737098|NCT04249310|DRUG|Tiotropium/Olodaterol|Soft Mist Inhaler product
224132517|NCT00223691|DRUG|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
223555640|NCT01290042|DRUG|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
223555641|NCT01290042|OTHER|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
223737099|NCT04249310|DRUG|Tiotropium|Soft Mist Inhaler product
223737100|NCT01797692|OTHER|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
224022637|NCT03879837|DRUG|Fluticasone propionate pressurized metered dose inhaler|110 mcg per actuation
223405262|NCT06858839|DRUG|Maridebart Cafraglutide|Maridebart cafraglutide will be administered SC.
223405263|NCT06858839|DRUG|Placebo|Placebo will be administered SC.
223405264|NCT05649748|DRUG|Treprostinil Palmitil|Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler.
223405265|NCT05649748|DRUG|Placebo|Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
223405266|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, low dose|injection
223405267|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, medium dose|injection
223405268|NCT07080034|BIOLOGICAL|anti-TL1A monoclonal antibody, high dose|injection
223405269|NCT07080034|OTHER|Placebo|injection
223737101|NCT00590447|DRUG|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
223405270|NCT07076199|DRUG|Insulin icodec|Insulin icodec will be administered as subcutaneous injection
223405271|NCT07076199|DRUG|Insulin glargine|Insulin glargine will be administered as subcutaneous injection.
223405272|NCT07076199|DRUG|Insulin aspart|Insulin aspart will be administered as a subcutaneous injection.
223405273|NCT07086794|DRUG|Placebo|The effects of placebo will be determined.
223405274|NCT07086794|DRUG|Cocaine (IV)|The effects of IV Cocaine will be determined.
223405275|NCT07086794|DRUG|Pentoxifylline|The effects of pentoxifylline will be determined.
223405276|NCT06834997|DRUG|Dronabinol Capsules|Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.
223405277|NCT06834997|DRUG|Placebo|Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.
223405278|NCT06019169|OTHER|Yoga arm|Participation in YOGA classes performed by Mme Laura BOGANI from The Blue Fish LAB Association. There are 4 sessions of 45 minutes (2 face-to-face and 2 remote) per month for 3 months. An attendance sheet will be completed at each session.
223405279|NCT06019169|OTHER|storytelling activities|Participate in workshops around storytelling led by the association of storytellers l'Age D'or. 4 sessions are planned (2 face-to-face and 2 remotely) per month for 3 months. An attendance sheet will be completed at each session.
223405280|NCT05346198|DRUG|CART-BCMA|The CART-BCMA (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
223405281|NCT06300190|PROCEDURE|Biceps tenodesis alone|Biceps tenodesis in superior labrum anteroposterior lesion type IV
223405282|NCT06300190|PROCEDURE|Biceps tenodesis and labrum repair|Biceps tenodesis and labrum repair by anchors in superior labrum anteroposterior lesion type IV
223405283|NCT02864888|RADIATION|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
223405284|NCT02864888|DRUG|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
223405285|NCT02864888|DRUG|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
223555642|NCT01930422|DEVICE|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
223555643|NCT01930422|DEVICE|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
223555644|NCT06378333|PROCEDURE|patients who underwent coronary angiography|All patients included in the ICAR project (Montpellier - Nîmes) benefit from a consultation at one year (12+or - 2 months), as they are systematically reviewed in our department: data will therefore be collected in the patient's medical record. Clinical biological parameters and events during the hospital phase are also collected in the patient's computerized record. Normal patient management remains unchanged.
223555645|NCT00992056|DRUG|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
223555646|NCT00992056|DRUG|Metoprolol|Metoprolol 50 mg titrated to 100 mg
223555647|NCT00075855|DRUG|therapeutic testosterone|
223555648|NCT00075855|OTHER|placebo|
223555649|NCT01483235|BEHAVIORAL|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
223555650|NCT01483235|BEHAVIORAL|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
224022638|NCT03879837|DRUG|Flovent HFA pressurized metered dose inhaler|110 mcg per actuation
223405286|NCT04434729|DEVICE|Fetal embolization of vein of Galen malformation using Target XL and XXL Detachable Coils|The study involves a single fetal intervention of maternal transuterine, fetal transcranial torcular puncture and median prosencephalic vein embolization. Detachable platinum coils (Target XL and XXL Detachable Coil, Stryker Neurovascular) will be used to pack the prosencephalic varix.
223405287|NCT05198154|DIAGNOSTIC_TEST|ctDNA detection|High-depth sequencing method is used to detecting ctDNA.
223405288|NCT07091318|BEHAVIORAL|Sleep quality improvement therapy|8 virtual CBTi sessions will be provided through a therapist weekly for the first four weeks and every other week for the last eight weeks of the study.
223405289|NCT07091318|BEHAVIORAL|Healthy Living|Health education emails and brief coaching calls will be provided weekly. The phone coaches will not provide counseling or goal setting but can clarify what participants had questions on like terms and concepts.
223405290|NCT01305421|PROCEDURE|grip test|Muscle strength measurement by hand-held dynamometer
223405291|NCT00188474|BEHAVIORAL|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
223737102|NCT00590447|DRUG|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
223737103|NCT05206994|BEHAVIORAL|Close to Home|Close to Home (C2H), a community mobilization model developed in Boston and adapted for California, is specifically designed to prevent SV by strengthening community social connections and engaging whole communities in dialogue and action to transform social norms. The C2H model guides communities through four phases: 1) Assess, 2) Talk, 3) Build, and 4) Act. C2H mobilizes diverse groups of people residing in a shared geography and linked by social and political ties to engage in joint actions for SV prevention
223737104|NCT04877470|OTHER|Consultation at spine-centre|All patients who visited the spine-centre for the first time in 2019 are included in this group.
223737105|NCT05858359|BEHAVIORAL|ImPACT program|"During the ImPACT program, the brain cancer survivor and a carer collaborate on:~1. Becoming aware of the patient's core strengths and difficulties~2. Helping the patient to be optimally responsive to the guidance of the carer, and~3. Creating compensatory strategies to respond to real-world manifestations of the patient's difficulties and helping the patient implement these strategies at home."
223405292|NCT07022483|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg IV Q3W.
223405293|NCT07022483|DRUG|Chemotherapy|Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W followed by chemoradiotherapy.
223405294|NCT07104292|BEHAVIORAL|PFMT|The motivation-informed intervention will tackle both exercise engagement and exercise adherence. Participating women will be introduced to the app and its videos following training. The participants will be introduced not only to muscle training, but also to muscle relaxation. The training will be recommended three to four times a week during pregnancy with further continuity after giving birth.
223405295|NCT07104292|BEHAVIORAL|Standard care|Standard care
223737106|NCT02588170|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
223737107|NCT02588170|OTHER|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
223737108|NCT06505577|OTHER|No additional intervention|All patients are scheduled to undergo standard breast surgery as part of their routine clinical care. No additional interventions are administered specifically for this study.
224022639|NCT03879837|DRUG|Placebo pressurized metered dose inhaler|no active content
224022640|NCT02621320|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
224022641|NCT02621320|DIETARY_SUPPLEMENT|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
224022642|NCT02927860|OTHER|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
224022643|NCT02527343|DRUG|volanesorsen|300 mg of volanesorsen administered subcutaneous (SC) injection, once-weekly (QW).
224022644|NCT02527343|DRUG|Placebo|Volanesorsen-matching placebo administered SC injection.
224022645|NCT02593409|DRUG|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
224022646|NCT01814202|OTHER|PTM202|
224022647|NCT01814202|OTHER|Placebo|
223405296|NCT06675565|DRUG|ALN-AGT01 RVR|ALN-AGT01 RVR will be administered subcutaneously (SC)
223405297|NCT06675565|DRUG|Placebo|Placebo will be administered SC
223405298|NCT06777433|DRUG|RAD101 (18F-FPIA)|A single dose of 18F-RAD101 with a maximum of 370 MBq (10 mCi) administered as a slow IV bolus injection over a maximum of 30 seconds, followed by a saline flush.
223405299|NCT03350282|DIETARY_SUPPLEMENT|GAA-creatine|
223405300|NCT03350282|DIETARY_SUPPLEMENT|Creatine|
223405301|NCT03646383|PROCEDURE|Radiofrequency ablation|The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
223405302|NCT06914921|DIETARY_SUPPLEMENT|Peppermint Oil|"Enteric-coated peppermint oil capsules (\~180 mg total peppermint oil/ capsule) to ensure release in the small intestine.~1 capsule three times daily, 30 minutes before meals, for 12 weeks."
224022648|NCT00701220|DRUG|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
224022649|NCT03965325|OTHER|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
224022650|NCT00214838|DRUG|Atiprimod|
223405303|NCT06914921|DRUG|A standard antispasmodic|A standard antispasmodic (e.g., mebeverine 135 mg). 1 tablet three times daily, before meals, for 12 weeks.
223405304|NCT06932965|BEHAVIORAL|Cervical Stabilization Group|Participants performed supervised cervical stabilization exercises for 8 weeks, 3 sessions per week.
223405305|NCT06932965|BEHAVIORAL|combined group|Participants performed both exercise protocols as described above over the same period
223405306|NCT06931145|DRUG|Benmelstobart|Benmelstobart injection, 1200 mg/dose, given once every 21 days, intravenously.
223405307|NCT06931145|DRUG|Anlotinib|"Anlotinib hydrochloride capsules, 8 mg/dose, administered orally for 2 consecutive weeks and stopped for 1 week.~During the course of the study, subjects may be adjusted upward to a dose of 12 mg if well tolerated, as determined by the investigator, and the dose of anlotinib hydrochloride may be adjusted downward during the course of the study due to drug-related adverse events."
223405308|NCT06931145|DRUG|Carboplatin or cisplatin|Carboplatin for injection, administered on day 1, AUC 5 mg/mL/min, intravenously (maximal dose used is 750 mg); or cisplatin administered on day 1, 75-80mg/m2, IV.
223405309|NCT06931145|DRUG|Etoposide|Etoposide injection, 100mg/m2 on days 1, 2 and 3, IV.
223405310|NCT06934512|DEVICE|Needleless jet injector|To assess the pain score through (VAS) scale of needleless jet injector for local anesthesia. Scale has minimum zero number that indicates best outcome and maximum number is ten that indicates worst outcome.
223405311|NCT06934512|PROCEDURE|Conventional needle injection|To assess the pain score through (VAS) scale of traditional needle injection for local anesthesia. Scale has minimum zero number that indicates best outcome and maximum number is ten that indicates worst outcome.
223405312|NCT06934590|DRUG|RX001|Subjects will receive a single RX001 (AAV-hRUNX3) treatment via Intra-tumoral injection
224022651|NCT04294069|DRUG|Azithromycin 500 mg|500mg azithromycin PO for seven days starting on admission
224022652|NCT04294069|DRUG|Azithromycin Oral Product|1000mg azithromycin PO once at admission
224297711|NCT03138447|DEVICE|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
223405313|NCT06940479|PROCEDURE|GAE procedure|Genicular artery embolization
223405314|NCT06939764|OTHER|Geriatric Screening using the sG8 scale|Geriatric screening using the sG8 scale
223405315|NCT06941064|DIAGNOSTIC_TEST|Anthropometric and sports performance assessment|"According to the International Society for the Advancement of Kinanthropometry (ISAK) standards, sixteen anthropometric variables have been assessed to characterize the athlete's anthropometric profile. The counter-movement jump assessments were conducted using a ForceDecks Max platform. During matches, the players' GPS-derived external Load Metrics were monitored using 18 Hz WIMU Pro GPS units. Normality tests of all variables will be performed.~Certificated anthropometrists performed the anthropometric assessment twice. A third measurement will be performed if the difference between these measures exceeds 5% for skinfolds and 1% for all other variables. Countermovement jump tests were conducted in duplicate, and the higher measurements were recorded. In-match GPS-derived external load metrics of different matches will be downloaded and analyzed."
223555651|NCT06030973|BEHAVIORAL|Filling in an online survey|Professionals are asked to complete questions regarding 1) the degree of current participation in a registry, 2) the need for a European registry, 3) the items that should be collected and 4) access to the European registry.
223555652|NCT04308655|OTHER|Interview|Semi-structured interviews
223555653|NCT04308655|OTHER|Surveys|Validated surveys on pain, fear, anxiety, depression, beliefs
223737109|NCT00842283|OTHER|skin tissue sample|skin tissue sample
224022653|NCT00156884|DRUG|strontium-89|
224022654|NCT00156884|DRUG|cisplatin|
224022655|NCT00440999|DRUG|Pyronaridine artesunate|
223555654|NCT04812782|DIETARY_SUPPLEMENT|EVOO supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with EVOO
223555655|NCT04812782|DIETARY_SUPPLEMENT|Butter supplementation|We will administer to both groups (healthy and T1D subjects) a high glycemic index meal enriched with butter
223555656|NCT02279368|BEHAVIORAL|Family Counselling and safeguarding|
223555657|NCT00002032|DRUG|Rifabutin|
223555658|NCT06365255|OTHER|questionnaires|filling in questionnaires
223555659|NCT00057759|DRUG|sildenafil citrate|
223555660|NCT00057759|OTHER|Placebo|Placebo
223737110|NCT04790344|DEVICE|Investigational LUX-Dx ICM Implant|All subject will receive an investigational version of the LUX-Dx ICM device.
223737111|NCT05587400|BEHAVIORAL|passive leg raising|transfer a patient from semi-recumbent position to supine position with a 45° leg lifting
223737112|NCT05587400|DRUG|dobutamine test|infusion dobutamine
223737113|NCT05587400|DRUG|inhaled nitric oxide|nitric oxide inhalation
224022656|NCT00440999|DRUG|Chloroquine|
224022657|NCT04745026|DRUG|GWP42003-P|GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)
224022658|NCT04745026|DRUG|Placebo|Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
224022659|NCT05577598|DEVICE|Implantation of a DBS therapy system|"The system is called Reclaim DBS Therapy for OCD und is marketed by Medtronic (Minneapolis, Minnesota). It has a HDE status by the FDA. The system consists of two quadripolar electrodes (Medtronic Reclaim DBS) as well as a generator (Medtronic Activa PC), which will be implanted into a subcutaneous pocket below the clavicula."
224022660|NCT06498544|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 nights at an altitude of 3600 m.
224297712|NCT05480592|DRUG|HS-10380|Administered orally as a tablet
224297713|NCT05480592|DRUG|Placebo|Administered orally as a tablet
223405316|NCT06941103|OTHER|Spinal stabilization exercise training and recommendation|"Spinal stabilization exercise training will be applied 3 days a week for 8 weeks under the supervision of a specialist physiotherapist. Exercises consist of a 5-10 minute warm-up period, 40 minutes SSET and a 5-10 minute cool-down period.~Within the scope of the recommendation, information will be given about the definition of constipation, risk factors, and treatment methods.. A brochure will be prepared to be distributed to individuals regarding these issues."
223405317|NCT06941103|OTHER|Recommendation|Within the scope of the recommendation, information will be given about the definition of constipation, risk factors, and treatment methods.. A brochure will be prepared to be distributed to individuals regarding these issues.
223405318|NCT06940856|OTHER|Incomplete response|"Infants died before 36 weeks PMA, infants diagnosed to have BPD at 36 weeks PMA and infants developed major complications before 36 weeks PMA:~1. \>Stage 2 necrotizing enterocolitis according to Bell classification~2. Hemodynamically significant patent ductus arteriosus~3. \>Grade 2 intraventricular hemorrhage,~4. Retinopathy of prematurity, ICROP classification stage \>2~5. \>Stage 2 cystic periventricular leukomalacia~6. Ventricular dilatation/hydrocephalus requiring intervention"
223405319|NCT06940856|OTHER|Complete response|"Infants discharged before 36 weeks PMA and infants who reached 36 weeks PMA without BPD and major complications:~1. \>Stage 2 necrotizing enterocolitis according to Bell classification~2. Hemodynamically significant patent ductus arteriosus~3. \>Grade 2 intraventricular hemorrhage,~4. Retinopathy of prematurity, ICROP classification stage \>2~5. \>Stage 2 cystic periventricular leukomalacia~6. Ventricular dilatation/hydrocephalus requiring intervention"
223405320|NCT06940856|OTHER|Bad response|Infants died before 36 weeks PMA and infants diagnosed to have BPD at 36 weeks PMA
223405321|NCT06940115|OTHER|titanium trapezoidal plates|ORIF subcondylar fracture using trapezoidal titanium plates
223405322|NCT06940115|OTHER|PEEK trapezoidal plates|ORIF subcondylar fracture using trapezoidal PEEK plates
223405323|NCT06940700|DRUG|SHR4597|SHR4597
223555661|NCT03777046|BEHAVIORAL|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
223555662|NCT03777046|BEHAVIORAL|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
223555663|NCT00763295|OTHER|T-Spot.TB test|diagnostic test
223555664|NCT03358420|DIAGNOSTIC_TEST|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
223555665|NCT06162273|DEVICE|IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company|Patients underwent endovascular treatment for reconstruction of internal iliac artery in abdominal aortic aneurysm/iliac aneurysm repair. The lesion will be treated by IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore Company.
223555666|NCT01888783|OTHER|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
223555667|NCT05076773|PROCEDURE|Ultrasound guided block|Giving one regional block
223555668|NCT05076773|DRUG|IV morphine|given when VAS\>3
223405324|NCT06940700|DRUG|Budesonide inhalant|Budesonide inhalant
223405325|NCT06939829|DRUG|treatment with CAZ-AVI|Randomize subjects to receive CAZ-AVI via either continuous infusion or intermittent infusion. The total daily dose and dosing interval should be determined according to the subject's body weight, renal function, and estimated drug clearance based on standard prescribing guidelines. Regardless of administration method, the same criteria for dose adjustment (including indications for modification and monitoring parameters) must be consistently applied to both control and experimental groups.
223405326|NCT06940362|BEHAVIORAL|Changing narrative intervention modules|Training and mentoring of 12-16 year old youth in non-violent personal/career trajectories, supported by a social media campaign and a community steering committee.
223555669|NCT05092997|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
223555670|NCT05092997|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
223555671|NCT04053972|DRUG|Lenvatinib|oral lenvatinib after hepatectomy
223555672|NCT00902850|DEVICE|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
223555673|NCT00902850|DEVICE|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
223555674|NCT03745638|DRUG|Ruxolitinib Cream|Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
223555675|NCT03745638|DRUG|Vehicle Cream|Matching vehicle cream applied topically to the affected area as a thin film twice daily.
223555676|NCT04470050|DRUG|Dexmedetomidine|Sublingual Film of Dexmedetomidine
223555677|NCT04470050|DRUG|Placebo|Sublingual Placebo film
223555678|NCT01447342|DEVICE|Cryo-Touch II|Percutaneous treatment with the device
223555679|NCT05053074|DEVICE|Nasal High Flow (NHF)|Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
223737114|NCT06560970|BEHAVIORAL|COPPEhR Intervention|Participants will receive access to the COPPEhR system which will provide social support and engagement among older adults diagnosed with HIV.
223737115|NCT06560970|BEHAVIORAL|Device-only Control Condition|Participants will have access to a device only without the COPPEhR system.
224132518|NCT00223691|DRUG|Acarbose|25-100 mg, PO. Single dose.
224132519|NCT00223691|DRUG|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
224132520|NCT00223691|DRUG|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
224132521|NCT00223691|DRUG|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
224022661|NCT01795664|RADIATION|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
223737116|NCT02316067|OTHER|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
223737117|NCT03806959|OTHER|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
223737118|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by M4|High or low risk of being an ectopic pregnancy
223737119|NCT03461835|DIAGNOSTIC_TEST|Risk classification of PUL by NICE|High or low risk of being an ectopic pregnancy
223737120|NCT01838993|DRUG|Lidocaine inhalation|Lidocaine inhalation before intubation
223405327|NCT06940570|DRUG|PCA plus methadone (Experimental)|This study is novel. There are no other interventions to distinguish in this or another study.
223405328|NCT06940570|DRUG|PCA Alone (SOC)|PCA Alone (Control) arm. PCA opioid will include morphine OR hydromorphone (if patient has a sensitivity or is unable to tolerate or allergic to morphine).
223555680|NCT04397367|DRUG|Ruxolitinib 10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
223737121|NCT01838993|DRUG|Placebo|
223737122|NCT06163846|DIAGNOSTIC_TEST|Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification|Assess the combination of baseline and follow-up image mining, together with ctDNA, in predicting disease relapse and progression.
224022662|NCT01795664|DRUG|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
224022663|NCT01795664|DRUG|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
224022664|NCT01795664|DRUG|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
224022665|NCT01795664|DRUG|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
224022666|NCT03259451|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|
224022667|NCT01568853|DRUG|Norepinephrine|Intravenously, 10 ug/min, 24 hours
223405329|NCT06941116|DIAGNOSTIC_TEST|Steroid-Based Screening (LC-MS/MS)|This diagnostic intervention is a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based steroid profiling assay. It measures a panel of 21 adrenal steroid hormones (e.g., aldosterone, 18-hydroxycortisol, 18-oxocortisol, corticosterone) from plasma samples. In this study, it is used to screen for Primary Aldosteronism (PA) while patients remain on their usual antihypertensive medications. By comparing these steroid profiles against standard aldosterone-renin measurements, the method aims to reduce the need for medication washout and improve diagnostic accuracy for PA.
223555681|NCT04397367|DRUG|Ruxolitinib 5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
223737123|NCT01477840|DRUG|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
223737124|NCT03904433|OTHER|Coconut oil|Coconut oil given in coffee with cream
223737125|NCT03904433|DIETARY_SUPPLEMENT|Caprylic acid|Caprylic acid given in coffee with cream
223737126|NCT03904433|OTHER|Sunflower oil|Sunflower oil given in coffee with cream
223737127|NCT03904433|OTHER|Glucose|Glucose dissolved in water
223737128|NCT05092685|GENETIC|AAVLK03hOTC|Peripheral intravenous infusion of AAVLK03hOTC.
223737129|NCT05826184|BEHAVIORAL|Time restircted eating|8 hour time restricted eating alone
223737130|NCT05826184|BEHAVIORAL|Time restricted eating + prebiotic|8 hour TRE with a prebiotic supplement
223737131|NCT04502030|BIOLOGICAL|Panzyga|Panzyga is a 10% IVIG produced from a pool of human fresh frozen plasma donations
223737132|NCT04502030|OTHER|Placebo|Placebo
223737133|NCT00750711|PROCEDURE|Radiofrequency ablation for atrial flutter by catheters|
224022668|NCT01568853|PROCEDURE|Open abdomen|IAH \>=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
224022669|NCT01568853|OTHER|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
224022670|NCT01568853|OTHER|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
224022671|NCT04426851|DRUG|BI 1358894|Tablet
224022672|NCT04426851|DRUG|BI 1358894 (C-14) intravenous solution|BI 1358894 mixed with \[carbon labelled (C-14)\] BI 1358894
224022673|NCT04426851|DRUG|BI 1358894|Oral suspension
224132522|NCT00223691|DRUG|placebo|PO.Single dose.
224132523|NCT00223691|DRUG|Modafinil|50-400 mg PO. Single dose
224132524|NCT00223691|DRUG|Octreotide|5-50 µg, S.C. Single dose.
224132525|NCT00223691|OTHER|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
224132526|NCT00223691|DRUG|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
224132527|NCT00223691|DRUG|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
223405330|NCT06940102|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day)
223405331|NCT06940102|DRUG|TKI-Based Therapy|TKI-Based Therapy
223555682|NCT04397367|DRUG|Ruxolitinib 5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
223555683|NCT04397367|DRUG|Ruxolitinib 2.5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
223555684|NCT01590745|DEVICE|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
223555685|NCT06269692|DEVICE|MRI screening|Cardiac Magnetic Resonance imaging for the quantification of the infarct intramural scar
223555686|NCT06269692|DEVICE|Implantable Loop Recorder|Inplantation of the Implantable Loop Recorder (ILR) for the patients assigned to the experimental group
223555687|NCT06269692|DEVICE|Implantable Cardioverter Defibrillator|Inplantation of the Implantable Cardioverter Defibrillator (ICD) for the patients assigned to the control group, according to the current guidelines
223555688|NCT02038972|GENETIC|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
223555689|NCT01596140|DRUG|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
223555690|NCT01596140|DRUG|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
223555691|NCT01596140|DRUG|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
223555692|NCT02846792|BIOLOGICAL|Nivolumab|Given IV
223555693|NCT02846792|DRUG|Plinabulin|Given IV
223555694|NCT05944068|BEHAVIORAL|midfulness training|For this study we chose for a mindfulness based intervention. Mindfulness is defined as the ability to notice and observe details about one's present internal and external environment with the goal of non-judgemental and non-elaborative awareness of cognitions, emotions and physical sensations. The goal of the mindfulness intervention will be to teach patients a way of coping with negative emotions without acting on them, letting patients take control of their disease related behaviour and come to better disease acceptance. Where medical treatments fail to take away all disabling symptoms, psychological interventions like mindfulness could offer patients a coping method through which symptoms are experienced as less disabling and patients regain their quality of life. This research may further strengthen the need for a multidisciplinary approach in patients with Crohn's disease.
223555695|NCT06354530|DRUG|anlotinib|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: anlotinib 8 mg/day orally (from days 1 to 14 in a 21-day cycle) for 2 cycles"
223555696|NCT06354530|RADIATION|Thoracic radiotherapy|"Drug: Camrelizumab 200mg on Day 1 of each 3-week cycle for 2 cycles during the neoadjuvant period~Drug: Carboplatin Area under the curve of 5 on Day 1 of each 3-week cycle for 2 cycles~Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles~Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles~Thoracic radiotherapy RT once daily (from cycle 1 \[C1D1\], 41.4Gy/23Fx, 1.8Gy daily, for 4.6 weeks, 5 days/week)"
223555697|NCT06485713|DRUG|trifluridine/tipiracil combined with fufuquitinib|trifluridine/tipiracil combined with fufuquitinib
223555698|NCT06485713|DRUG|fufuquitinib|fufuquitinib
223555699|NCT06485713|DRUG|Trifluridine/tipiracil|Trifluridine/tipiracil
224022674|NCT03256851|BEHAVIORAL|Telephone-Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week telephone call with an investigator."
224132528|NCT00223691|DRUG|Tranylcypromine|5 - 40 mg PO. Single dose
224132529|NCT00223691|DRUG|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
223405332|NCT00901550|DRUG|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
223405333|NCT00901550|DRUG|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
223555700|NCT03604172|BEHAVIORAL|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
224132530|NCT00223691|DRUG|Celecoxib|50-200 mg PO. Single dose
224132531|NCT00223691|DRUG|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
224132532|NCT00223691|DRUG|Methylphenidate|5 or 10 mg PO. Single dose.
224132533|NCT00223691|DRUG|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
224132534|NCT00223691|DRUG|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
224132535|NCT00223691|DRUG|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
224132536|NCT00223691|DIETARY_SUPPLEMENT|Bovril|6-10 g, PO. Single dose.
223405334|NCT05871281|PROCEDURE|Pelvic floor muscle exercises|Pelvic floor muscle exercises were performed from different body positions. Duration of interventions - 4 weeks. Frequency - 2 times per week, number of individual contact sessions - 8 .
223405335|NCT07151378|DRUG|LECIG (levodopa, carbidopa, entacapone intestinal gel)|intestinal L-Dopa + entacapone (Lecigon®)
224297714|NCT03021252|DEVICE|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), three times per day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
223405336|NCT07151378|DRUG|Best oral medication|Best oral medication
223405337|NCT07151703|PROCEDURE|Intranasal Injection of Autologous PRP|Under topical anesthesia and decongestion, approximately 1 mL of freshly prepared autologous platelet-rich plasma will be injected into multiple sites of the olfactory cleft mucosa bilaterally using a 25-gauge needle under endoscopic guidance. Single treatment session.
223405338|NCT07151703|PROCEDURE|Carrier-Assisted Topical Application of Autologous PRP|Four pieces of sterile, bioabsorbable carrier (Gelfoam sponge) will be soaked with approximately 5 mL of freshly prepared autologous platelet-rich plasma. Under endoscopic guidance, two pieces will be placed gently into each olfactory cleft, ensuring contact with the olfactory mucosa. Carriers will remain briefly to allow PRP diffusion before dissolving naturally or being removed. Single treatment session.
223405339|NCT07151703|COMBINATION_PRODUCT|platelet-rich plasma|This study adopts a fully automated, closed-system PRP preparation technique to ensure the stability of the blood product. A total of 60 mL of whole blood is drawn and processed using the Phoenix Q1 centrifuge (TFDA Medical Device Manufacturing License No. 004461) for blood component separation in a closed, sterile environment. An optical sensor identifies and automatically collects the buffy coat layer (rich in platelets and monocytes), yielding approximately 6 mL of autologous platelet-rich plasma (PRP). The centrifugation and PRP collection process takes about 5 minutes. Compared with traditional methods requiring manual identification and collection, this approach enhances the precision and safety of centrifugation-based preparation.
223555701|NCT03604172|BEHAVIORAL|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
223555702|NCT03993886|DEVICE|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
223555703|NCT03993886|OTHER|Activity Monitor|commercially available accelerometer to be worn on wrist
223555704|NCT03993886|OTHER|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
223555705|NCT03993886|OTHER|ECG|Commercially available electrocardiogram machine
223555706|NCT03993886|OTHER|respiratory rate sensor|Commercially available respiratory rate sensor.
223555707|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
223555708|NCT02676895|BIOLOGICAL|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
223555709|NCT02676895|BIOLOGICAL|Menveo|One injection of Menveo was administered in subjects in the Control Group.
223555710|NCT02676895|BIOLOGICAL|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
223555711|NCT04905524|DIETARY_SUPPLEMENT|VIOME Precision Nutrition Program|Diet and supplements recommendations
223555712|NCT01642056|DRUG|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
223555713|NCT01642056|DRUG|Placebo|
223555714|NCT02168062|BEHAVIORAL|Behavioral Dietary Intervention|Receive individualized nutrition counseling
223555715|NCT02168062|OTHER|Counseling|Receive individualized symptom management service counseling
223555716|NCT02168062|OTHER|Educational Intervention|Review educational modules
223555717|NCT02168062|BEHAVIORAL|Exercise Intervention|Receive individualized exercise counseling
223555718|NCT02168062|DRUG|Goserelin Acetate|Given SC
223555719|NCT02168062|OTHER|Laboratory Biomarker Analysis|Correlative studies
223555720|NCT02168062|DRUG|Leuprolide Acetate|Given SC or IM
223555721|NCT02168062|OTHER|Quality-of-Life Assessment|Ancillary studies
223555722|NCT02168062|DRUG|Triptorelin Pamoate|Given IM
223737134|NCT02710045|BIOLOGICAL|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
224297715|NCT03021252|DEVICE|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, three times a day, during 8 weeks.
223555723|NCT04166370|OTHER|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
223555724|NCT04166370|OTHER|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
224297716|NCT00838708|DRUG|SRD174 Cream|topical SRD174 Cream
224297717|NCT00838708|OTHER|vehicle cream|topical vehicle cream
223405340|NCT07151703|DEVICE|olfactory training|Participants will perform olfactory training for 12 weeks following the PRP intervention. Training is conducted twice daily using four odor bottles containing standardized odorants from Sigma-Aldrich (Germany): lemon (citronellal, #27470), rose (phenylethanol, #77861), clove (eugenol, #W246700), and eucalyptus (eucalyptol, #C80601). Each odor is sniffed gently for about 20 seconds, with a 20-second pause between bottles. Participants will record the perceived intensity of each odor in a training diary after every session.
223405341|NCT07151417|DRUG|PAI|Standard PAI: 30 mg Toradol/ketorolac (30mg/ml), 49.25ml 0.5% ropivacaine (5mg/ml), and 0.5 mg
223405342|NCT07151417|DRUG|PAI + steroid|Standard PAI + 40mg methylprednisolone (n = 40)
224022675|NCT03256851|BEHAVIORAL|In-Person Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week visit to the laboratory to work with a physical therapist or trained team member."
223405343|NCT07151417|DRUG|PAI + zilretta|Standard PAI + 32mg Zilretta (triamcinolone acetonide extended release injectable suspension)
224022676|NCT02502123|OTHER|No Intervention|No intervention was administered in this study.
224132537|NCT00223691|DRUG|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
224132538|NCT00223691|DRUG|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
223405344|NCT07151586|DRUG|Sacituzumab Govitecan / Trastuzumab Deruxtecan|"Sacituzumab govitecan is administered intravenously at a dose of 10 mg/kg on Day 1 and Day 8 of each 3-week cycle. In this study, patients receive two cycles of sacituzumab govitecan followed by two cycles of trastuzumab deruxtecan, alternating throughout the study.~Trastuzumab deruxtecan is administered intravenously at a dose of 5.4 mg/kg on Day 1 of each 3-week cycle. In this study, patients receive two cycles of trastuzumab deruxtecan followed by two cycles of sacituzumab govitecan, alternating throughout the study.~Both Treatment are continued until disease progression as defined by RECIST 1.1, unacceptable toxicity, withdrawal of consent, or the end of the study."
223555725|NCT04166370|OTHER|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
223555726|NCT06414343|OTHER|Observational - no intervention|Observational - no intervention
223555727|NCT04637724|DEVICE|transcranial direct current stimulation (tDCS)|10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
223555728|NCT01740921|DRUG|Liraglutide|Administered once daily
223555729|NCT01740921|OTHER|diet|reduction of caloric intake to promote weight loss
223555730|NCT01740921|DRUG|Aspirin|300mg of Aspirin per day
223555731|NCT00976716|DRUG|Celecoxib|"Day 1~* The first dose: Celecoxib 400mg~* The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~\- Celecoxib 200mg twice daily"
223555732|NCT01471769|BEHAVIORAL|Pain management video|6-minute video
223555733|NCT01471769|BEHAVIORAL|Falls Prevention Video|6-minute video
223555734|NCT04175340|DEVICE|BL-300-PFM04|Preservative Free Lubricating and Rewetting Drops for use during contact lens wear
223555735|NCT04175340|DEVICE|OPTI-FREE|Replenish Rewetting Drops
223555736|NCT03353987|BEHAVIORAL|Cognitive training|"Procedure~1. A therapist will go through the daily routine of the participants at home before starting the intervention~2. Selections of exercise items based on familiar items/ activities at home~3. Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~4. Taught on how to perform the exercises~5. Perform at least one hour per day~6. Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~7. Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~8. The difficulty of the exercise will be adjusted weekly~List of exercises:~1. Memorizing a set of lists, household items, names and numbers~2. Summarising the contents of newspaper cuttings within a set of time~3. Searching and listing sets of words from newspaper cuttings"
223555737|NCT01014936|DRUG|MSC2156119J|
223555738|NCT03459469|DRUG|Tegavivint|This is an Investigational drug
223555739|NCT03028129|DRUG|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
223555740|NCT03028129|DRUG|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
223555741|NCT04222699|DRUG|Mupirocin calcium ointment, 2%|Mupirocin nasal ointment is used to treat or prevent infections in the nose due to certain strains of Staphylococcus aureus bacteria. This medicine works by killing bacteria or preventing their growth.
223555742|NCT04222699|DRUG|Topical Chlorhexidine, 4%|"Chlorhexidine is an antiseptic that fights bacteria.~Topical chlorhexidine is used to clean the skin to prevent infection that may be caused by surgery, injection, or skin injury."
223737135|NCT02710045|BIOLOGICAL|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
223737136|NCT02710045|BIOLOGICAL|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
224132539|NCT00223691|DRUG|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
224132540|NCT00223691|DEVICE|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
223405345|NCT07153198|OTHER|VIPP-SD|Consists of four sessions (with the option of one or two additional booster sessions), held biweekly, depending on the family's needs and availability. Specifically, VIPP-SD addresses disciplinary strategies alongside sensitivity themes through: (1) the differentiation between attachment and exploration behaviors; interpretation of child's behavior and significance of a sensitive response to it; and the importance of sharing emotions (2) the application of distraction and induction as non-coercive techniques in response to challenging child behaviours or conflict-prone situations; (3) the utilization of positive reinforcement, whereby parents praise adaptive behaviours and ignore maladaptive, attention-seeking actions; (4) the implementat of a sensitive interaction pause to de-escalate conflict or temper tantrums; and (5) the demonstration of empathy towards the child in conjunction with consistent disciplinary approaches and explicit boundary-setting
224132541|NCT00223691|DEVICE|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
223405346|NCT07152353|DEVICE|Proton Beam Therapy (PBT)|PROTEUS® PLUS
223405347|NCT06529419|DRUG|AZD8630|The drug will be administered by inhalation
223405348|NCT06529419|DRUG|Placebo|The placebo will be administered by inhalation
223405349|NCT06529419|DEVICE|Inhaler|The drug/placebo will be administered by inhalation using the inhaler
223405350|NCT07163221|DEVICE|Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1|Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 1 for 20 minutes once per day
223555743|NCT05370027|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Vagus nerve stimulation will be applied with the Vagustim device for 20 (10+10) minutes, with a biphasic frequency, a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current intensity where the participant feels the current comfortably.
223555744|NCT00768846|DEVICE|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
223555745|NCT00768846|DEVICE|Xience V Stent|Everolimus-eluting Xience V Stent
223555746|NCT03522935|DRUG|Elafin|Elafin subcutaneous.
223555747|NCT03522935|DRUG|Placebo|Placebo subcutaneous.
223555748|NCT00923351|DRUG|Tumor Purged/CD25 Depleted Lymphocytes|
223555749|NCT00923351|BIOLOGICAL|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
223555750|NCT00923351|DRUG|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
223555751|NCT00923351|BIOLOGICAL|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
223555752|NCT04982315|PROCEDURE|Standard Acupuncture|The standard acupuncture intervention is based on classical Chinese acupuncture therapy. Participants randomized to standard acupuncture will receive up to 15 acupuncture treatments over 3 months with the total number being determined by the patient and acupuncturist together. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
223555753|NCT04982315|PROCEDURE|Enhanced Acupuncture|The enhanced acupuncture intervention includes the 3 months of standard acupuncture plus an additional 3 months of maintenance acupuncture. Participants randomized to enhanced acupuncture will receive up to 21 acupuncture treatments over 6 months. The maintenance acupuncture treatment sessions are expected to consist of the same intervention used in the first 3 months of care described in the standard acupuncture arm, plus up to 6 treatments during the maintenance phase. All treatments will include acupuncture needling only. They will be provided at medical facilities or in private acupuncturists' offices.
224132542|NCT01825980|DRUG|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
224132543|NCT01825980|DRUG|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
224132544|NCT01825980|DRUG|Placebo|Placebo
224132545|NCT00371111|DRUG|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
224132546|NCT00371111|DRUG|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
223405351|NCT07163221|DEVICE|Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2|Subjects will receive daily noninvasive ultrasound stimulation of the spleen using Ultrasound Treatment Setting 2 for 20 minutes once per day
223405352|NCT07163221|DEVICE|Sham ultrasound stimulation (control)|Sham ultrasound stimulation for 20 minutes once per day
223405353|NCT07163221|DRUG|Conventional Synthetic DMARD|All subjects will take at least one type of conventional synthetic DMARD at the same stable dose for at least 8 weeks prior to the treatment period and continuing through study close out
223405354|NCT07155317|PROCEDURE|Biopsy Procedure|Undergo tumor tissue biopsy
223405355|NCT07155317|PROCEDURE|Biospecimen Collection|Undergo check swab and blood sample collection
223405356|NCT07155317|PROCEDURE|Computed Tomography|Undergo CT
223405357|NCT07155317|BIOLOGICAL|Ipilimumab|Given IV
223405358|NCT07155317|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223555754|NCT01674049|DIETARY_SUPPLEMENT|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
223555755|NCT01674049|DIETARY_SUPPLEMENT|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
223555756|NCT01674049|OTHER|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
223555757|NCT00940290|OTHER|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
224132547|NCT02483702|OTHER|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
224132548|NCT02483702|OTHER|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
223405359|NCT07155317|OTHER|Medical Device Usage and Evaluation|Wear an actigraphy device
223405360|NCT07155317|BIOLOGICAL|Nivolumab|Given IV
223405361|NCT07155317|OTHER|Questionnaire Administration|Ancillary studies
223405362|NCT01573481|OTHER|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
224132549|NCT02962219|BEHAVIORAL|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
224132550|NCT02962219|BEHAVIORAL|Home Exercise Programme (HEP)|Written advice on exercise at home
224132551|NCT05069805|PROCEDURE|PECS II block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to PECS II block
223405363|NCT01573481|OTHER|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate \> or equal to 12 breath per min).
223405364|NCT07166081|DRUG|BGM0504|Administered orally
223405365|NCT07166081|DRUG|BGM0504|Administered orally
223405366|NCT07166081|DRUG|BGM0504|Administered orally
223405367|NCT07166081|DRUG|Placebo|Administered orally
223405368|NCT07166081|DRUG|BGM0504|Administered orally
223405369|NCT07174115|DRUG|HTMC0658|HTMC0658 tablet
223405370|NCT07173985|BEHAVIORAL|Standard FIT kit|Receive a standard FIT kit
224132552|NCT05069805|PROCEDURE|ESP block|Patients will receive standard general anesthesia with sevoflurane and fentanyl associated to ESP block
224132553|NCT02776956|DRUG|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
224132554|NCT02776956|DRUG|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
223405371|NCT07173985|BEHAVIORAL|Enhanced FIT kit|Receive a enhanced FIT kit that includes a video brochure, disposable gloves, and a disposable stool collection device
223405372|NCT07173985|BEHAVIORAL|Telephone patient navigation|Receive telephone-based patient navigation
223405373|NCT07173985|BEHAVIORAL|Text message patient navigation|Receive text message-based patient navigation
223405374|NCT07174271|OTHER|Patient satisfaction survey upon completion of anterior composite restorations and during follow-up sessions|"This study focuses on evaluating patient satisfaction with anterior composite restorations immediately after treatment and during subsequent follow-up visits. A structured questionnaire, based on modifications of the Fédération Dentaire Internationale (FDI) criteria, was administered to patients. Since the original FDI criteria were primarily designed for dentist-based evaluation, the questions were adapted into a patient-friendly format.~Participants were asked to rate restorations across multiple domains, including esthetic anatomical form, color harmony and translucency, surface smoothness, the condition of the adjacent mucosa, and post-operative sensitivity and tooth vitality. Each parameter was scored on a numerical scale ranging from 0 to 10, allowing patients to express their subjective perception of treatment outcomes.~By collecting these patient-reported outcomes both immediately after the procedure and during follow-up sessions, the study aims to provide a comprehensive under"
223405375|NCT07182032|DRUG|ketamine|Participants will receive general anesthesia with protocoled ketamine infusion
223405376|NCT07183852|DRUG|Autologous Tumor Infiltrating Lymphocytes (TIL)|Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion
223405377|NCT07183852|DRUG|Melphalan|1 mg/kg, IV
223405378|NCT07183852|DRUG|Interleukin-2|2 MIU, subcutaneous twice daily for up to 14 days.
223405379|NCT07183969|OTHER|lower limb muscle strength training program|"Each plyometric training session consists of warm-up stretching, lower limb plyometrics, and gentle stretching.~Warm-up stretching, there are 6 movements, push the window, pull the rope, hands up, stretch from side to side, lift one foot and open and close both feet. Do 10 repetitions of each movement, 2 rounds, and keep breathing normally for a few repetitions.~Lower Extremity Plyometrics: 3 rounds of 6 plyometrics with 1 minute of recovery time between each round. The six lower body plyometrics exercises are performed by gradually increasing the load in a manner that increases the number of seconds the exercise is held.~Gentle Stretching: Continuous training of muscles makes them tense, stretching can lengthen muscle fibers, increase muscle elasticity, and improve blood circulation to eliminate post-training fatigue (H.K. Chen, 2022). Perform each gentle stretching movement left and right once, hold for 30 seconds each time, and keep breathing normally (no shutting up of breath)."
223405380|NCT07182396|PROCEDURE|Experimental Group|"VIDEO GAME-TAPD: Week 1st-6th: Start with kids level and progress upto expert level and Participants will automatically progress to advanced level based on their individual ability and progress in game in progressing weeks.~(kids level to expert level: according to game levels) Hand eye coordination game:Tap changing illuminating squares. Week1- 3 repetitions(2sets),Week2- 4 repetitions(2 sets),Week3- 5 repetitions(2 sets),Week4- 6 repetitions(2 sets),Week5- 7 repetitions(2 sets),Week6- 8 repetitions(2 sets) Ball tossing intervention:Week 1-2 (Exercise 1 (2 sets, 20/30/40 repetitions) and Exercise 2(2 sets, 20/30/40 repetitions) with ground tap catch Week 3-4 (Exercise 2 (2 sets, 20/30/40 repetitions) with direct catch and Exercise 3 (2 sets, 20/30/40 repetitions) Week 5-6 (Exercise 1 (2 sets, 50 repetitions) , Exercise 2 (2 sets, 50 repetitions) with direct catch and Exercise 3 (2 sets, 50 repetitions) Number of reps adjusted according to session number per week"
223555758|NCT02016495|DIETARY_SUPPLEMENT|Magnesium plus alpha-lipoic acid|
223555759|NCT02016495|DRUG|Placebo|
223555760|NCT01889264|OTHER|Observational|Observational, Translational non-treatment study
224132555|NCT00151125|DRUG|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
224132556|NCT00151125|DRUG|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
224132557|NCT00151125|DRUG|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
224132558|NCT00129194|DRUG|KP-1461|
223405381|NCT07182396|PROCEDURE|Control Group|"Week 1-2 (Exercise 1 (2 sets, 20/30/40 repetitions) and Exercise 2(2 sets, 20/30/40 repetitions) with ground tap catch Week 3-4 (Exercise 2 (2 sets, 20/30/40 repetitions) with direct catch and Exercise 3 (2 sets, 20/30/40 repetitions) Week 5-6 (Exercise 1 (2 sets, 50 repetitions) , Exercise 2 (2 sets, 50 repetitions) with direct catch and Exercise 3 (2 sets, 50 repetitions) Number of reps adjusted according to session number per week e.g~* Day 1: 20 reps per week~* Day 2: 30 reps per week~* Day 3: 40 reps per week Progression: Participants will progress to advanced level based on their individual ability and progress. Levels of complexity will be adjusted according to patient progress."
223405382|NCT07175961|OTHER|Multicomponent telehealth care coordination|Participants randomised into the intervention group will be assigned a recovery navigator prior to discharge from hospital. The recovery navigator will provide the participant with a study tailored discharge summary, arrange the patients first appointment with their general practitioner and will ensure medications are reconciled prior to hospital discharge. The recovery coordinator will arrange weekly calls with the participant for the first 4 weeks and then fortnightly until week 12 to set recovery goals and assess recovery goals and navigator further primary care support if required. Participants will also be called at Day 90 and 180 by outcome assessors to collected patient reported outcomes.
223405383|NCT07183527|BEHAVIORAL|CARES|Integrated screening and stepped collaborative care
223405384|NCT07183527|BEHAVIORAL|Standard of Care (SOC)|Screening and referral of patient to provider in the community or cancer center
223405385|NCT07182916|OTHER|No intervention|Only observation
223405386|NCT07183033|BEHAVIORAL|VR-Based Resistance Training Intervention|"Participants in the intervention group will engage with a self-developed VR resistance training program entitled Kitten Crossing the Bridge. This program is designed to guide older adults through static lower-limb resistance exercises, while integrating rhythm control, spatial judgment, and visual feedback. The intervention will be administered over 4 weeks, with two sessions per week; each session will last approximately 20 minutes (excluding equipment setup and rest periods). All training sessions will be supervised by qualified staff to ensure participant safety and provide necessary support."
223405387|NCT07183033|BEHAVIORAL|Standardized Leg-Raising Training|Participants in the control group will implement a standardized leg-raising exercise protocol, which is designed to match the intensity and rhythm of the VR-based intervention. Training will be guided by pre-recorded verbal prompts and demonstration videos developed by the research team, ensuring procedural uniformity. Each session will last approximately 20 minutes (excluding equipment setup and rest periods), with two sessions per week over a 4-week duration. All sessions will be supervised by trained staff, who will monitor participant adherence and ensure safety throughout the process.
223405388|NCT07182825|BEHAVIORAL|Modified Multifidus Lift Exercise (MLE)|A supervised stabilization exercise protocol designed to selectively activate the lumbar multifidus muscle. In the quadruped position, the contralateral knee is maintained approximately 10 cm above the ground while the participant performs controlled trunk stabilization. Sessions are conducted twice weekly for 6 weeks, each including warm-up (5 minutes brisk walk, mobilization, hamstring stretch), the modified Multifidus Lift Exercise with progressive repetitions (weeks 1-2: 8-10, weeks 3-4: 10-12, weeks 5-6: 12-15), and cool-down (static stretches). All sessions are supervised to ensure correct form, breathing control, and safety.
223405389|NCT05672602|DIAGNOSTIC_TEST|Measurement of ncRNAs and cytokines|Measurement of lncRNAs in PBMCs samples and miRNAs in plasma samples.
223405390|NCT00000427|DRUG|Parathyroid hormone|
223405391|NCT00000427|DRUG|Alendronate|
223405392|NCT06089343|DIAGNOSTIC_TEST|Coronary CT angiography|Comprehensive hemodynamic and plaque features derived from CTA and verified by OCT of all culprit and non-culprit lesions to predict ACS.
223405393|NCT05736120|OTHER|No treatment given|No treatment given
223405394|NCT04286269|OTHER|Music Based Intervention|Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.
223405395|NCT04286269|OTHER|Sham Treatment|Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
223405396|NCT05709678|OTHER|Standard Education|Sport nutrition education
223405397|NCT05709678|OTHER|Enhanced Education|Sport nutrition education with peer testimonials on negative effects of REDs
223555761|NCT02669394|BEHAVIORAL|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
223555762|NCT02669394|BEHAVIORAL|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
223737137|NCT00010075|DRUG|fluorouracil|
223737138|NCT00010075|DRUG|leucovorin calcium|
224022677|NCT03168607|DRUG|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
224022678|NCT01875549|DEVICE|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
224022679|NCT01875549|PROCEDURE|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
224022680|NCT05537831|DEVICE|Ultrasound|The ultrasound will be used to assist with the delivery of a hematoma block in patients with distal forearm fractures.
224022681|NCT03765099|BEHAVIORAL|Animal-Assisted Interactions|Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
224022682|NCT04528927|DRUG|HCQ|600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
224297718|NCT06682962|DEVICE|Transcorneal electrical stimulation (TES) with the OkuStim 2 System|Retinal stimulation is achieved through transcorneal current application: using a thread electrode, a weak current (≤ 1mA) is introduced onto the surface of the eye, which spreads through the eye towards the retina.
224022683|NCT04528927|DRUG|Azithromycin|500 mg (1st day) then 250 mg / D for 4 days
224022684|NCT04528927|DRUG|Doxycycline|200 mg per day for 10 days
224022685|NCT04528927|DIETARY_SUPPLEMENT|Zinc|220 mg per day for 10 days
224132559|NCT03900806|BEHAVIORAL|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
223737139|NCT00010075|DRUG|mitoxantrone hydrochloride|
224132560|NCT00967226|DRUG|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
224132561|NCT00967226|DRUG|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
224132562|NCT03476382|DEVICE|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
223737140|NCT03456674|DEVICE|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
223737141|NCT04215380|DIETARY_SUPPLEMENT|Acacia Senegal extract|Oral Digestion of Gum Arabic dissolved in 200 ml of water to be consumed early morning in daily basis for 12 weeks
223737142|NCT04215380|DIETARY_SUPPLEMENT|Pectin|Oral Digestion of Pectin to be consumed early morning in daily basis for 12 weeks
223737143|NCT00158509|DRUG|Valacyclovir|
224132563|NCT01059396|DRUG|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
223737144|NCT02987400|DRUG|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
223737145|NCT02987400|DRUG|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
223737146|NCT05217329|OTHER|smart phone App rehabilitation|stroke subjects use smart phone to complete therapeutic tasks 5 min/session total 8 sessions/day with affected arm or bilateral arm movement for 6 weeks
224132564|NCT01059396|DRUG|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
224132565|NCT01059396|DRUG|placebo|placebo propranolol / carvedilol
224132566|NCT00505804|DRUG|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
223405398|NCT05234905|DRUG|Recombinant human adenovirus type 5＋Camrelizumab|"Recombinant human adenovirus type 5: one lesion was selected for intratumoral injection.Intratumoral injection of H101 was performed on day 1 and day 4 of each cycle, and was repeated once every 3 weeks. H101 dose:~① Tumor maximum diameter ≤5cm, 1.5×1012vp (3 injections) on day 1, 1.0×1012vp (2 injections) on day 4.~② Tumor maximum diameter \>5cm but ≤10cm, 3.0×1012vp (6 injections) on day 1 and 2.0×1012vp (4 injections) on day 4.~③ Tumor maximum diameter \>10cm, 4.5×1012vp (9 injections) on day 1 and 3.0×1012vp (6 injections) on day 4.~H101 intratumoral injection until the tumor is completely regressed to stop the drug, but not more than 5 cycles at most.~Camrelizumab: administered after H101 on day 1 of each cycle and repeated for 3 weeks. Camrelizumab dose: 200 mg IV."
223405399|NCT06229561|COMBINATION_PRODUCT|Acellular Dermal Matrix|Feasibility of soft tissue graft after immediate implant placement
223737147|NCT05217329|OTHER|conventional rehabilitation|stroke subjects receive conventional rehabilitation home program for 6 weeks(30min/day)
223737148|NCT01054781|DRUG|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
223737149|NCT02128633|DRUG|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
223405400|NCT01912586|OTHER|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
223737150|NCT02128633|DRUG|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
223737151|NCT02128633|DRUG|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
223737152|NCT04778189|DRUG|Placebo|while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia
223737153|NCT04778189|DRUG|i.v dexmethasone|patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia
223737154|NCT01275833|DEVICE|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
223737155|NCT04923087|DEVICE|Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements|"Validate the evaluation criteria Do you hear the biscuit crunch? and Is it a pleasure?"
223737156|NCT02808026|DRUG|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
223737157|NCT00304564|BEHAVIORAL|Music Listening|subjects listen to music
223737158|NCT03307720|DRUG|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
223737159|NCT03307720|DRUG|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
223737160|NCT01411709|DRUG|Vitano|two 200mg tablets per day for 14 days
223737161|NCT05098860|OTHER|Home Exercise Program|Educational training program includes active stretching, strengthening, and stabilization exercises of head and neck muscles as well as relaxation and breathing exercises.
224132567|NCT00505804|DRUG|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
224132568|NCT01768338|DRUG|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
224132569|NCT05246241|DEVICE|magnetic resonance imaging|Preoperative magnetic resonance imaging
224132570|NCT01708707|DRUG|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
224132571|NCT01708707|DRUG|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
223737162|NCT05098860|OTHER|Manual Therapy Combined with Home Exercise Program|Manual Therapy program includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae.
223405401|NCT01015365|PROCEDURE|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
224022686|NCT03081754|RADIATION|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
224022687|NCT04637854|PROCEDURE|Operating microscope|Third molar extraction using microscope
224022688|NCT04637854|PROCEDURE|Surgical loupes|Third molar extraction using loupes with co-axial illumination
223405402|NCT05931172|OTHER|Dual tasking|"Dual-task training is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Dual tasking is given by therapist in unexpected directions to challenge patients reactive balance. In this study dual tasking will be given manually and on hurdles.~Daily 45 mins of exercise sessions of dual-task training like walking with talking , walking with a filled cup of water, walking with looking on clock performed for total eight weeks and 5 days a week."
223405403|NCT05931172|OTHER|PNF(proprioceptive neuromuscular facilitation exercises)|"PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session will be given to patients. 45 mins session/each day for 5 days a week."
223405404|NCT02346838|DIETARY_SUPPLEMENT|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
223405405|NCT02346838|DIETARY_SUPPLEMENT|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
223405406|NCT03804450|PROCEDURE|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
223405407|NCT00513045|BEHAVIORAL|IRT|Cognitive behavior intervention
223405408|NCT00513045|BEHAVIORAL|Exposure|Exposure intervention
223405409|NCT06531941|DRUG|400 µg of MBX 2109 once-weekly by subcutaneous injection|"Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients who received Placebo in the Phase 2 MBX-2H1002 study, will initiate treatment with 400 µg subcutaneous MBX 2109 once-weekly"
223405410|NCT06531941|DRUG|200-1600 µg of MBX 2109 once-weekly by subcutaneous injection|"Supplied as 1.5 mg per vial, to be reconstituted in 1.4 mL water for injection (diluent) to a concentration of 1.0 mg/mL.~Patients treated with MBX 2109 in the Phase 2 MBX-2H1002 study will continue at the screening visit in the extension study on the same dose they were receiving at the Week 11 Visit in Study MBX-2H1002.~The maximum allowed dose is 1600 μg weekly administered subcutaneously in the abdomen, rotating injection sites. Doses of MBX 2109 study drug greater than 1000 μg will be administered subcutaneously in two separate, equal injections."
223405411|NCT02025140|DEVICE|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
223405412|NCT02025140|DEVICE|conventional anesthesia syringe|Active control
223405413|NCT05404646|OTHER|Thoracic mobility exercises with conventional physical therapy for cervical radiculopathy|Thoracic mobility exercises These techniques include mobilization, manipulation and glides to check and treat the joints. Here, these techniques will be used to mobilize the thoracic spine. In this treatment mobility exercises (Unilateral posterior anterior, Central posterior anterior and transverse glides) + hot pack (10 min) + neck stretching (neck flexors, extensors, side benders) + cervical Traction will be given to patient. A total session time will be 45 min and thrice a week on alternate days for three weeks.
223737163|NCT05098860|OTHER|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. Patients will apply active cervical and thoracic region mobilizations called self-mobilization.
223737164|NCT02870660|OTHER|Registry|
224022689|NCT04637854|PROCEDURE|Naked eyes|Third molar extraction using naked eyes
224022690|NCT01414140|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
224022691|NCT01532895|DRUG|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
224022692|NCT05960617|DRUG|Empagliflozin|"Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count \> 1.0 × 10\^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above."
224022693|NCT05782023|BEHAVIORAL|Digital empowerment|The intervention will consist of a minimal interaction face-to-face before hospital discharge for risk factors profiling followed by actions for health empowerment, delivered through an ad-hoc developed web platform, which include: a) periodic delivery of email messages with links to educational, motivational and supportive materials for secondary prevention, b) access to a message box for questions and answers and c) possibility of video-calls with the preventive team.
224022694|NCT05147961|OTHER|Digital Health|Automated behavioral intervention via e-mail, web, and mobile phone
224022695|NCT05147961|OTHER|Standard care|Conventional recommendations on diet and exercise
224022696|NCT03832413|DIAGNOSTIC_TEST|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
224022697|NCT04866498|DRUG|Infusion Intravenous|
223737165|NCT06399588|BEHAVIORAL|Intervention for Adolescent Tobacco Initiation Prevention (IATIP)|The IATIP is an evidence-based tobacco prevention program tailored for Bangladeshi adolescents, integrating Behavior Change Techniques, the Behavior Change Wheel, and the Theoretical Domains Framework. Utilizing the Arena Blended Connected (ABC) model ensures effective delivery. Six key learning types are integrated to optimize knowledge acquisition, concept exploration, collaboration, discussions, practical application, and skill development. The curriculum comprises three core components addressing adolescents' challenges: the information curriculum cultivates factual awareness, the social competence curriculum strengthens refusal skills and social competencies, and the social influence curriculum builds resilience against tobacco-promoting social influences.
223737166|NCT00879281|BEHAVIORAL|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
223737167|NCT01747941|DRUG|PF-06305591|single dose, solution
223737168|NCT01747941|DRUG|Placebo|matching placebo
223737169|NCT01747941|DRUG|PF-06305591|single dose, solution
223737170|NCT01747941|DRUG|Placebo|matching placebo
223737171|NCT01747941|DRUG|PF-06305591|single dose, solution
223737172|NCT01747941|DRUG|Placebo|matching placebo
224022698|NCT01821287|OTHER|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
224022699|NCT01990560|DRUG|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
224022700|NCT01778023|DRUG|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
224138787|NCT02802878|DEVICE|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
223737173|NCT04400786|PROCEDURE|intermittent treatment|According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
223737174|NCT04400786|PROCEDURE|continuous treatment|The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
223737175|NCT03830060|DIAGNOSTIC_TEST|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
223737176|NCT04244279|OTHER|Ergonomic workshop|Participants will participate in a single meeting workshop regarding ergonomic principles in baby care.
223737177|NCT04244279|OTHER|Brochure|Participant will receive a brochure summarizing the main contents of the workshop.
223737178|NCT04244279|OTHER|Videos|During the next three months after the beginning of the research, they will receive videos that will be a reminder of the principles learned in the workshop.
223737179|NCT04495842|OTHER|Essential Oil Blend|5 drops of on a tester strip
223737180|NCT04495842|OTHER|Control Blend|5 drops on a tester strip
223737181|NCT00321282|PROCEDURE|Atrial Fibrillation|
223737182|NCT05199467|BEHAVIORAL|Health Coaching|Health coaches help people focus on goals, identify strengths and values, and work towards building the kind of life they wish to live.
223737183|NCT05199467|BEHAVIORAL|VA Benefits Information|Printed materials with information on VA benefits.
223737184|NCT05549934|DRUG|PF-06651600|tablets containing active drug (a combined JAK3/TEC inhibitor)
223737185|NCT04861155|DEVICE|SIVA-P3|Digital cough recording: Participants receive a small, wearable data recorder, wear it during waking hours and keep it on the nightstand during sleep for 7x24 hours. The data is sent to a smartphone application, where a cough detection algorithm converts it into time-stamped cough events. Participants respond to questions on their smartphone once a day for additional context data. The cough events and context data are sent to a secure online database for further evaluation. For the first 24 hours, segments of audio data are sent to be able to validate the performance of the cough detection algorithm. Afterwards, only cough events and context data are sent from the participant's smartphone.
223737186|NCT04890327|OTHER|Web-based family health history tool|Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
223737187|NCT02519530|BEHAVIORAL|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
223737188|NCT02116244|DRUG|Civamide Nasal Spray|
223737189|NCT05106374|PROCEDURE|Biospecimen Collection|Undergo collection of blood and stool samples
223737190|NCT05106374|PROCEDURE|Cognitive Assessment|Complete thinking test
223737191|NCT05106374|OTHER|Physical Performance Testing|Complete walking test
223737192|NCT05106374|OTHER|Quality-of-Life Assessment|Ancillary studies
224022701|NCT04733521|DRUG|SC-43|SC-43 oral, every day of 21-day cycle
224022702|NCT04733521|DRUG|Cisplatin|cisplatin 75mg/m2 on day 1 of 21-day cycle
224022703|NCT00140309|DRUG|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
224022704|NCT03875846|DIAGNOSTIC_TEST|Intraoperative Hemodynamic Pressures|Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
224297719|NCT03493776|BIOLOGICAL|VZV subunit vaccine|VZV subunit vaccine
223737193|NCT05106374|OTHER|Questionnaire Administration|Complete questionnaire
223737194|NCT02850393|OTHER|Functional magnetic resonance imaging|
223737195|NCT02850393|BEHAVIORAL|behavioral measures|
224022705|NCT03875846|DIAGNOSTIC_TEST|Contrast Flow Rate|A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
223555763|NCT05971368|PROCEDURE|thoracic paravertebal block|"o Group A: Patients will receive ultrasound guided thoraxic paravertebral block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~A high-frequency linear ultrasound probe will be placed between transverse processes from the T4 level (the level of port introduction) in the paramedian plane while patients is in the lateral decubitus position. The transverse processes, superior costotransverse ligaments, and pleura will be well visualized. The block needle (22 gauge) will be advanced until it crosses the superior costotransverse ligament. The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) in the thoracic paravertebral space. Depression of the pleura will be observed as a result of the spread of local anesthetic."
224022706|NCT06063811|OTHER|Ablation|VT ablation
223737196|NCT02850393|OTHER|physiological measurements|
223737197|NCT03008083|DRUG|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
223737198|NCT03008083|DRUG|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
223737199|NCT06336460|PROCEDURE|Pericapsular Nerve Group (PENG) Block|"Under sterile technique, physician will identify relevant landmarks including the femoral artery, femoral vein, femoral nerve, ileopubic eminence (IPE), anterior inferior iliac spine (AIIS), psoas tendon (PT). Target area is bony space between AIIS and IPE adjacent to PT.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting fascial plane below the psoas tendon, above ilium bone. Landmark lies between the AIIS and IPE, just lateral to psoas tendon.~As needle tip reaches target, small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, lifting the psoas tendon from ilium, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush line of remaining anesthetic. Needle will then be withdrawn."
223737200|NCT06336460|PROCEDURE|Fascia Iliaca Compartment (FIC) Block for Patients with Isolated Hip Fractures|"Under sterile technique, physician will identify relevant landmarks, including femoral artery, femoral vein, femoral nerve, iliacus muscle with overlying fascia iliaca.~Using in-plane technique with constant visualization, needle will be inserted through skin and soft tissue targeting the fascial plane above iliacus muscle.~As needle tip reaches the target, a small volume of normal saline will be injected to hydrodissect tissue. Fluid will start to spread along fascial plane, confirming proper positioning.~Normal saline will then be switched to anesthetic (30mL of Bupivacaine 0.25%).~After full volume of anesthetic has been injected, a small volume (5mL) of normal saline will be injected to flush the line of remaining anesthetic. The needle will then be withdrawn."
223737201|NCT04994990|DRUG|OnabotulinumtoxinA Standard Dose|Active comparator group will be treated for full upper face wrinkles with standard recommended doing of onabotulinumtoxinA
224022707|NCT02979392|DRUG|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
224022708|NCT06189586|DRUG|aerosol inhalation of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
224132572|NCT05271903|BEHAVIORAL|MAMA Intervention|"The MAMA intervention will be based on PRONTO International's simulation training program to improve obstetric care delivery. The PRONTO curriculum is based on simulation and debrief of clinical scenarios, case-based learning, skills stations, and interactive teamwork and communication activities. Through the training, providers review and learn clinical skills related to obstetric care and emergencies, while reflecting on and practicing principles of respectful maternity care. The simulation exercises give providers and opportunity to act as the patient and develop empathy for the patient experience, and debriefing after simulation includes a reflection and discussion about RMC principles. The training will be two full days, followed by a refresher training in the clinical setting after one month."
224132573|NCT06342570|OTHER|There is no Intervention name to describe.|There is no Intervention name to describe.
224132574|NCT00450164|PROCEDURE|esofagic varices ligation|
223737202|NCT04994990|DRUG|OnabotulinumtoxinA Half Standard Dose|Experimental group will be treated for full upper face wrinkles with half of the standard recommended doing of onabotulinumtoxinA
223737203|NCT05190380|OTHER|HIGH INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
224132575|NCT00450164|DRUG|Nadolol|
224132576|NCT00450164|DRUG|Isosorbide mononitrate|
224132577|NCT00450164|DRUG|Prazosin|
224132578|NCT02174861|DRUG|Erenumab|Administered by subcutaneous injection once a month
224132579|NCT01541527|BIOLOGICAL|blood test|One blood test entering in the usual follow-up of the patient
224132580|NCT05510778|DIETARY_SUPPLEMENT|Charcocaps|250 mg capsules containing Activated charcoal, Gelatin, Titanium Dioxide, and Carmine
224132581|NCT05510778|OTHER|Placebo|capsules containing \~250 mg cellulose
224132582|NCT03555084|DEVICE|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
224132583|NCT03555084|DEVICE|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
224132584|NCT00914602|DRUG|Sinemet 25-100 Oral Tablet|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
224132585|NCT00914602|DRUG|XP21279|Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
224132586|NCT00914602|DRUG|Carbidopa Pill|
224132587|NCT05765695|PROCEDURE|Radiofrequency ablation performed with a 19 gauge STARmed needle.|The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
224132588|NCT00314652|DRUG|Buprenorphine transdermal delivery system|
224132589|NCT05446025|DIAGNOSTIC_TEST|Blood sample|Orexigenic hormones (appetizing) Orexin, galanin and anorexigenic hormones (decreasing appetite) aMSH and CART blood levels will be measured
224132590|NCT00484536|DRUG|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
224132591|NCT00484536|DRUG|placebo|capsules, once daily
224132592|NCT00484536|DRUG|CDP323|250 mg Capsules, 500 mg, once daily
224132593|NCT00165841|DRUG|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
224132594|NCT05208203|OTHER|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
224132595|NCT06129396|OTHER|Aerobic exercise|The aerobic exercise consists of: (1) 5 min warm-up exercise, (2) 20 min aerobic exercise with HR at target zone (one research assistant will be onsite to monitor whether the HR is around the range of moderate intensity), and (3) 5 min cool-down exercise.
223737204|NCT05190380|OTHER|LOW INTENSITY PROGRESSIVE RESISTED EXERCISE|"Intervention:Leg presses, knee extension, hip adduction and hip abduction exercises will be performed by patients. There will be a warm up sets for 1 repetition maximum with 2 min gap between both sets (leg press + knee extension exercises) (hip abduction and hip adduction) patients will ask to perform.~Both groups will receive routine physical therapy (Tens, Hot pack, Deep friction massage) in addition with experimental interventions"
223737205|NCT04352114|DRUG|LY3461767 - SC|Administered SC.
224132596|NCT06129396|OTHER|Video-watching|The video-watching group will be asked to watch a nature documentary for 30 mins
224132597|NCT03874624|DIAGNOSTIC_TEST|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
224132598|NCT01925638|DRUG|BAY86-9766|
224132599|NCT01925638|DRUG|Ketoconazole|
224132600|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
224132601|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC Solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
223405414|NCT05404646|OTHER|Thoracic stretching exercises with conventional physical therapy for cervical radiculopathy|Thoracic stretching exercises Thoracic stretching exercises. Thoracic stretching exercises are used to correct the musculature of thoracic region. In this treatment group stretching exercises (passive stretches and therapist facilitated exercises) +hot pack (10 min) +neck stretching (neck flexors, extensors, side benders) + tractions will be given to patient. A total of 45 min session thrice a week on alternate days for three weeks will be given. Only the eligible patients who fulfil the inclusion criteria will be included in the study.
223405415|NCT06667219|BEHAVIORAL|A relevant physical fitness training program intervention|"54children who participated in after-school sports activities in Guangzhou Kindergarten (Guangzhou, China) were randomly selected as the experimental group.~Intervention group Length:12 weeks, 40 minutes, twice a week.~Intervention content:~The intervention will be conducted using a relevant physical fitness training program , as follows: Week 1 / 4 first: Run quickly;Durian ball;Throw;Fast jogging (200 m) Week 1 / 4 second: Dodge run,Raise your legs high and go over the small hurdles; Durian ball (standing on one foot);standing long jump Week 2 / 5 first: Bow step transformation jump;Throw;Turn back 10 meters Week 2 / 5 second: Hop ;Stand on one foot with your eyes open Week 3 / 6 first:Skip over the small hurdles;Durian ball (standing on one foot);Throw; Fast jogging (200 m) Week 3 / 6 second:Jump on your feet and dodge running;Durian ball (squat);Jump support Weeks 7-12,Repeat the above content. FMS index was tested before the experiment, and once after the intervention."
223405416|NCT06667219|BEHAVIORAL|control group,Physical exercise using kindergarten standards|"54 children who did not participate in after-school sports activities were selected as the control group.~control group Duration: 12 weeks. Content: Physical exercise using kindergarten standards. FMS index was tested the same to intervention group before the test and FMS index was measured once again after 12 weeks."
223405417|NCT02946476|OTHER|prognostic impact of non cardiac comorbidities|
223405418|NCT01120184|DRUG|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
223405419|NCT01120184|DRUG|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
223405420|NCT01120184|DRUG|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
223405421|NCT01120184|DRUG|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
224132602|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
224132603|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
224132604|NCT00254293|DRUG|Abatacept or Placebo (both as IV & SC solution)|Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
224132605|NCT00254293|DRUG|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
224297720|NCT05483582|DEVICE|4-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
223555764|NCT05971368|PROCEDURE|serratus anterior muscle block|"Group B: Patients will receive ultrasound guided serratus anterior muscle block with 0.25% bupivacaine 0.4 ml/kg (max. 40 ml and not exceeding toxic dose of bupivacaine 2.5mg/kg) after induction of anesthesia.~While the patient is in the supine position, a high-frequency linear ultrasound probe will be placed horizontally on the mid-axillary line at the level of 4th or 5th ribs on the side of the block. The serratus anterior, latissimus dorsi, and intercostal muscles will be identified. The block needle (22-gauge) will be advanced below the serratus anterior muscle (SAM) towards the fifth rib (using in-plane technique). The prepared 0.25% bupivacaine will be administered at 0.4 mL/kg (max. 40 mL) between the SAM and the rib. It will be observed that the solution of local anesthesia will spread between the SAM and the rib."
223555765|NCT00601614|DRUG|temozolomide|
224297721|NCT05483582|DEVICE|2-channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
223555766|NCT00601614|DRUG|vandetanib|
223555767|NCT00601614|OTHER|immunoenzyme technique|
223555768|NCT00601614|OTHER|laboratory biomarker analysis|
223555769|NCT05100355|PROCEDURE|Physiological serum injection|In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray
223555770|NCT05100355|PROCEDURE|Contrast agent injection|In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
223555771|NCT03628105|BEHAVIORAL|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger \& Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
223555772|NCT03628105|BEHAVIORAL|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
223555773|NCT05024253|DRUG|Tranexamic acid injection|. TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
223555774|NCT05024253|OTHER|Saline|mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
223555775|NCT01099748|DRUG|Methadone|Methadone 50 - 150 mg QD (Day 1)
223555776|NCT01099748|DRUG|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
223555777|NCT05970536|OTHER|Apple vinegar or EDTA 17%|Application of each chelating agent for 5 minutes for dentin conditioning followed by placement of MTA on the pulp chamber.
223555778|NCT02910752|DRUG|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
223555779|NCT01473199|DEVICE|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
223555780|NCT03780621|DIETARY_SUPPLEMENT|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
224297722|NCT03885882|DRUG|E0302 SR1|E0302 SR1, oral tablet.
223555781|NCT03780621|DIETARY_SUPPLEMENT|Placebo|Visually identical placebo capsule
223555782|NCT05720052|DRUG|MS-553|MS-553 oral tablet BID x 28-days
224297723|NCT03885882|DRUG|E0302 SR3|E0302 SR3, oral tablet.
223555783|NCT04873258|DIAGNOSTIC_TEST|Bioimpedence Vector Analysis|Bioimpedence vector analysis
223555784|NCT05542095|DRUG|Simvastatin|Compounded simvastatin that is suspended within a nasal saline irrigation will be utilized throughout this study. Participants will suspend the contents of the simvastatin capsules (0.1mg, 0.25 mg, 0.5 mg, and 1 mg) into the sinus rinse bottle containing nasal saline. All participants will receive an 8-ounce sinus rinse bottle and a 4-week supply of USP Grade Sodium Chloride \& Sodium Bicarbonate Mixture (pH balanced, Isotonic \& Preservative \& Iodine Free) commercially prepared packets. Participants will either need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation.
223555785|NCT04393597|DRUG|DWJ1458 (fasted)|Subjects take single dose of DWJ1458 on a fated condition
224297724|NCT03885882|DRUG|E0302 SR2|E0302 SR2, oral tablet.
224297725|NCT03885882|DRUG|E0302 IR|E0302 IR, oral tablet.
224297726|NCT04668976|DEVICE|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
224297727|NCT04668976|DRUG|Floxuridine (FUDR)|Please see Detailed Description.
224297728|NCT04668976|DRUG|Gemcitabine|Please see Detailed Description.
224297729|NCT04668976|DRUG|Oxaliplatin|Please see Detailed Description.
224297730|NCT04668976|DRUG|Irinotecan (CPT-11)|Please see Detailed Description.
224297731|NCT04668976|DRUG|Fluorouracil|Please see Detailed Description.
224297732|NCT04668976|DRUG|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
223405422|NCT01120184|DRUG|trastuzumab [Herceptin]|trastuzumab \[Herceptin\] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
223405423|NCT01120184|DRUG|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
223405424|NCT04216290|PROCEDURE|Biopsy of Bladder|Undergo bladder biopsy
223405425|NCT04216290|PROCEDURE|Biospecimen Collection|Undergo tumor tissue and blood sample collection
223405426|NCT04216290|DRUG|Cisplatin|Given IV
223737206|NCT04352114|DRUG|LY3461767 - IV|Administered IV.
224022709|NCT06189586|DRUG|intravenous injection of glucocorticoids|Patients with severe AECOPD were continuously recruited from the care unit of Respiratory and Critical Care Medicine Department of the First Hospital of Jilin University to conduct a randomized cohort study, which was divided into aerosol inhalation group and intravenous glucocorticoid group. Subjects in the intravenous hormone group received 40mg methylprednisolone (dissolved in 0.9% normal saline /5% glucose injection 50ml) intravenously once a day. It lasts for 5 days. The atomized inhalation
224022710|NCT01098097|BIOLOGICAL|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
223737207|NCT04352114|DRUG|Placebo - SC|Administered SC.
224022711|NCT01098097|DRUG|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
223737208|NCT04349488|DEVICE|Anodal Transcranial Direct Current Stimulation|Subjects received a micro-current through their scalp to induce cortical and subcortical changes
223737209|NCT06319339|DRUG|Vumerity|diroximal fumarate 462 mg (2 capsules)
223737210|NCT06319339|OTHER|Placebo|Microcrystalline cellulose 462 mg (2 capsules)
223737211|NCT06553885|DRUG|Enfortumab Vedotin|Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.
223737212|NCT05393141|BEHAVIORAL|diet and biopsychosocial exercise intervention|dietary intervention: biopsychosocial exercise intervention:
223737213|NCT01679379|PROCEDURE|Absorbable suture group|Skin is closed with subcuticular stitches using \[Polyglactin 910 absorbable, synthetic, braided suture\]
223737214|NCT01679379|PROCEDURE|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
224022712|NCT03999320|OTHER|Sophrology sessions|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
224022713|NCT03999320|OTHER|usual care|usual care
224022714|NCT06352164|OTHER|Acupuncture treatment|The investigators selected acupoints including Zhongwan (CV12) and bilateral Shangjuxu (ST37), Sanyinjiao (SP6), Gongsun (SP4), Taichong (LR3), Taixi (KI3), Hegu (LI4), and Quchi (LI11)17 according to the World Health Organization standard. Single-use 0.30×40 mm or 0.30×25 mm acupuncture needles (Hwato, Suzhou, China) were vertically inserted into each acupoint to 20-30 mm depth to obtain a deqi sensation (a soreness, distention, numbness or heaviness sensation). Bilateral Zusanli (ST36) and Tianshu (ST25) were selected for moxibustion. Pure moxa sticks (diameter: 2.8 cm; Hanyi, Nanyang, China) were ignited and fixed on a moxibustion stand at a distance of 3-5 cm to the surface of acupoints. The temperature of skin surface at the acupoints was maintained at 43 ± 1°C and monitored with a miniature infrared thermometer (Fluke 62, Fluke Corporation, Everett, WA, USA). Acupuncture and moxibustion were concomitantly performed for 30 min.
224022715|NCT04193488|BEHAVIORAL|MTP block|In the MTP Group, a high frequency HFL-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Using the parasagital scan, the block needle (50 mm 22 Gauge) will be advanced from the caudal to the cervical target of the paravertebral space. When the needle tip reaches the midpoint between the transverse process and the pleura, 1 ml saline is performed. Once the needle tip has been confirmed, 20 ml of 0.25% bupivacaine will be given to the block. The same procedure will be applied 3 cm later than the incision line.
223737215|NCT04142021|DIAGNOSTIC_TEST|Coronary computed tomography angiography|Surgery planning done based solely on coronary computed tomography angiography.
224132606|NCT05566652|DEVICE|Neural Pressure Support|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
224132607|NCT05566652|DRUG|Pressure Support Ventilation|To evaluate WOB and asynchronies in patients with low respiratory system compliance undergoing either PSV and NPS.
223737216|NCT04336982|DRUG|CC-90009|Injection
223737217|NCT04336982|DRUG|Venetoclax|Tablet
223737218|NCT04336982|DRUG|Azacitidine|Injection
223737219|NCT04336982|DRUG|Gilteritinib|Tablet
224132608|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Test Drug|Coated Tablets
224132609|NCT04193852|DRUG|Dienogest 2.0 mg and Ethinyl estradiol 0.03 mg Reference Product|Coated Tablets
223737220|NCT05319795|BEHAVIORAL|Effortful Swallow Maneuver|Repeated practice of the Effortful Swallowing Maneuver generated by pushing the tongue with increased effort against the palate at the point of swallow initiation.
223737221|NCT03720496|BIOLOGICAL|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10\^6 CAR+ T cells/kg body weight.
223737222|NCT05395806|OTHER|Health App|The intervention will include training health teams and patients in accessing and using a gamified health App 2-3 times a week. The App is based on a gamified character that improves its health if a patient checks its App, complies with her therapy, does regular exercise, and introduces normal levels of blood pressure, lipids level, and HbA1c levels. On the other hand, the character gets sick if the patient does not comply with her therapy or does not achieve certain levels of physical activity (i.e. 30 min moderate exercise 5 times a week or 2.5 hs a week or more than 9000 steps/day).
223737223|NCT05395806|OTHER|Usual Care|In this group, participants will receive their usual cardiovascular care according to the national guidelines. All patients receive free care at the primary care clinics and also receive free medications prescribed according to the national guidelines at the clinics. In addition, participants in this group will receive specific written information to improve their medication compliance, level of physical activity, blood pressure, HbA1c, and lipids level control.
223737224|NCT04844632|BIOLOGICAL|Vaccine anti-Covid19|Vaccination with AstraZeneca or Pfizer-Biontech anti-Covid19 vaccine
224132610|NCT05248971|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is an evidence-based treatment method for children and adolescents who have been exposed to trauma and experience posttraumatic stress symptoms. The treatment model has a family and caregiver focus, and non-offending caregivers are included in the treatment. TF-CBT is normally provided through 8-12 treatment sessions.
224132611|NCT01487096|DRUG|Teriflunomide|"film-coated tablet~oral administration"
224132612|NCT01487096|DRUG|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
224132613|NCT03986008|DRUG|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
223737225|NCT02707991|BEHAVIORAL|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
223737226|NCT03542344|DRUG|BI 1015550|Single rising oral dose
223737227|NCT03542344|DRUG|Placebo|Single rising oral dose
223405427|NCT04216290|PROCEDURE|Computed Tomography|Undergo CT
223405428|NCT04216290|PROCEDURE|Cystoscopy|Undergo cystoscopy
223555786|NCT04393597|DRUG|DWJ1458 (fed)|Subjects take single dose of DWJ1458 after high-fat diet
223737228|NCT05115734|DIAGNOSTIC_TEST|Serum acylcarnitine profiling|"Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA)."
223737229|NCT02741882|OTHER|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
223737230|NCT05756946|PROCEDURE|periodontal dressing (coe-pak)|Guided tissue regeneration and periodontal dressing
223737231|NCT05756946|PROCEDURE|Guided Tissue Regeneration|Regeneration of lost periodontal tissues
223737232|NCT02464345|BEHAVIORAL|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
223737233|NCT02464345|BEHAVIORAL|CBT-E|CBT-E therapy
223737234|NCT06108791|DRUG|FIO2=0.8|the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air
223737235|NCT06108791|DRUG|FIO2=0.33|the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air
223555787|NCT01536561|BIOLOGICAL|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
223737236|NCT00442975|BIOLOGICAL|Fluarix|
223737237|NCT02733991|DEVICE|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
224022716|NCT04193488|BEHAVIORAL|ESP block|In the ESP group, a high-frequency 15-6 megahertz linear ultrasound probe will be placed vertically approximately 3 cm laterally from the midpoint of the incision line in the midline. Once the erector spinae muscle and transver projections have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml saline injection, this plane will open. Twenty milliliters of 0.25% bupivacaine will be given for the block. The same procedure will be applied from the other 3 cm lateral of the incision line.
223405429|NCT04216290|BIOLOGICAL|Durvalumab|Given IV
223555788|NCT05287958|DIAGNOSTIC_TEST|EIT|EIT comprises a chest belt that is connected to a computer via a universal serial bus (USB) or an Ethernet cable. The chest belt captures EIT data, which is transmitted via the USB or Ethernet cable to the computer. Tomography-like impedance images of the lungs are computed and displayed on the computer. The impedance images will be used to evaluate lung recruitment and other pulmonary function parameters that are currently measured using standard-of-care PFT devices.
223555789|NCT02443246|DRUG|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
223555790|NCT02443246|DRUG|Placebo|
223737238|NCT02733991|DEVICE|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
223405430|NCT04216290|DRUG|Fluorouracil|Given IV
223405431|NCT04216290|DRUG|Gemcitabine Hydrochloride|Given IV
223405432|NCT04216290|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223405433|NCT04216290|DRUG|Mitomycin|Given IV
223405434|NCT04216290|OTHER|Patient Observation|Undergo observation
223737239|NCT04404075|OTHER|SkinTracker Mobile App|a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
223737240|NCT01862562|PROCEDURE|Open surgery|Conventional technique
223737241|NCT01862562|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
223405435|NCT04216290|RADIATION|Radiation Therapy|Undergo radiation therapy
223405436|NCT02525783|DEVICE|Aequalis Pyrocarbon Humeral Head|Hemi Shoulder Arthroplasty
223405437|NCT01508611|OTHER|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children."
223405438|NCT01508611|BEHAVIORAL|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
223737242|NCT05533450|DEVICE|Multi-focal rigid scleral contact lens|True scleral lenses rest on the sclera and do not touch the cornea and limbus, leaving a clear area between the contact lens and the cornea.
223737243|NCT05533450|DEVICE|Rigid gas permeable contact lens|"RGP contact lens is designed from a special rigid hydrophobic material. Patients wear RGP contact lens to form a contact lens-tear-cornea system to correct irregular astigmatism, reduce aberrations, provide good visual quality, and control the development of the disease through mild shaping effect."
223405439|NCT00209261|DRUG|MINIRIN Oral Lyophilisate|
223405440|NCT00209261|DRUG|Minirin tablet|
223405441|NCT03611647|DIETARY_SUPPLEMENT|Probiotic|Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.
223405442|NCT03611647|DIETARY_SUPPLEMENT|Placebo|Placebo, taken by mouth once daily for 4-6 weeks.
223405443|NCT05058482|DEVICE|embolism|Cerebral arteriovenous malformation embolism
224297733|NCT03184220|PROCEDURE|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~* Suboccipital induction~* Posterior elongation of the cervical fascia in Supine position~* Assisted cervical fascia~* Myofascial induction of sternocleidomastoid"
223555791|NCT00822159|DEVICE|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
223555792|NCT03757624|PROCEDURE|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
223555793|NCT03583268|OTHER|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
223737244|NCT03189758|OTHER|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
223737245|NCT03189758|OTHER|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
223737246|NCT05273138|OTHER|Blood sampling and skin biopsy|Blood sampling and skin biopsy
223737247|NCT01523574|DRUG|Vitamin E|Vitamin E 400mg PO orally
223737248|NCT01523574|DRUG|Placebo|Placebo, given orally
223737249|NCT03627689|OTHER|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
223555794|NCT00429676|DRUG|Haloperidol|
223555795|NCT00602225|DRUG|clofarabine|Given IV
223737250|NCT03627689|OTHER|Sham air purifier|control arm
223737251|NCT03737747|PROCEDURE|induced hypothermia|
223737252|NCT03366402|DIAGNOSTIC_TEST|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
223737253|NCT04191499|DRUG|Inavolisib|Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.
223737254|NCT04191499|DRUG|Placebo|Participants will receive oral placebo on Days 1-28 of each 28-day cycle.
223737255|NCT04191499|DRUG|Palbociclib|Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.
223405444|NCT01537601|PROCEDURE|Circumcision|Circumcision
223405445|NCT01537601|OTHER|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
223405446|NCT05717296|OTHER|anxiety survey|surgery and anesthesia anxiety questionnaire
223405447|NCT05717296|OTHER|scale of satisfaction|scale of satisfaction of multimedia
223405448|NCT05717296|OTHER|Multimedia Information|"Patients randomized to the with multimedia support arm will have access to educational videos focused on the vascular surgery they are to receive."
223405449|NCT00005055|DRUG|glufosfamide|
223405450|NCT03711708|DRUG|Zoloft Oral Solution|Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water
223405451|NCT03711708|DRUG|Zoloft tablets|Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
223405452|NCT00866281|DRUG|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
223405453|NCT01074801|OTHER|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
223405454|NCT01074801|OTHER|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
223405455|NCT01894841|BEHAVIORAL|Coping Long Term with Active Suicide (CLASP)|6 month behavioral telephone-based intervention. Calls assess risk, problem solve any immediate issues, and case management
223737256|NCT04191499|DRUG|Fulvestrant|Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
223405456|NCT01894841|OTHER|Safety Assessment and Follow Up Evaluation|enhanced risk monitoring with full assessment protocol at 3, 6, 9, and 12 month follow up. Results sent as a note to the patient's VA mental health provider
223737257|NCT03246113|DRUG|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
223737258|NCT03246113|DRUG|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
223737259|NCT03246113|RADIATION|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
223737260|NCT06807099|DEVICE|Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)|Target Lesion treated with WRAPSODY CIE
223405457|NCT02235064|DRUG|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
223405458|NCT02235064|DRUG|Placebo|Capsule containing cellulose powder of same color as experimental arm
223405459|NCT06516237|PROCEDURE|to determine molecular and epigenetic biomarkers|In addition, up to 8 biopsies will be performed, at clinical judgment, in distal colon to determine molecular and epigenetic biomarkers.
223737261|NCT02465801|DRUG|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
223737262|NCT02465801|DRUG|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
224022717|NCT04193488|BEHAVIORAL|No Block group|No regional plan block will be applied to the control group. Conventional analgesic methods were applied.
224022718|NCT04485182|OTHER|Underwater jet massage (Tangentor)|"Underwater jet massage (Tangentor) would be performed in a tub developed for this purpose, where the water temperature: 33-35 ° C. The treatments lasting from 15 atm and 15 cm for 15 minutes.~They take a minimum of 10 treatments for approx. under 2 weeks."
223405460|NCT02678793|DRUG|CNTX-4975|
223405461|NCT04542486|PROCEDURE|"Excision of gingival hyperplasia using Soft tissue trimmer ."|Gingivoplasties and removal of excess gingival tissues using Soft tissue trimmer.
223405462|NCT04542486|PROCEDURE|Excision of gingival hyperplasia using the conventional scalpel technique|Excision of gingival hyperplasia in gingivoplasties using the conventional technique reverse bevel using 15c blade.
223405463|NCT01174823|DRUG|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
223405464|NCT01174823|DRUG|placebo comparator ophthalmic solution|sterile ophthalmic solution
223405465|NCT00730483|DRUG|PVA microporous hydrospheres/doxorubicin hydrochloride|
223737263|NCT02465801|DRUG|GCSF|GCSF 5 mcg/kg/day
223737264|NCT02141997|BIOLOGICAL|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
223737265|NCT02141997|BIOLOGICAL|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
223737266|NCT03124914|OTHER|Neuromuscular tests|Neuromuscular tests
223737267|NCT02158338|OTHER|Asthma|mothers who have children that have been diagnosed with respiratory issues
224022719|NCT06033014|OTHER|PM HeartIHD prediction|The calculated prediction and the explainability factors will be made available to the physician, which the physician then can decide to take into his/hers evaluation about further treatment.
224022720|NCT03656523|OTHER|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
224022721|NCT03086213|DRUG|Propofol|anaesthetic
224022722|NCT03086213|DRUG|Sulfentanyl|anaesthetic
224022723|NCT03086213|DRUG|Dexmedetomidine|anaesthetic
224022724|NCT03086213|DRUG|Lidocaine|local anaesthetics
224022725|NCT03086213|DRUG|Ropivacaine|local anaesthetics
224022726|NCT02067117|DRUG|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
223405466|NCT02767011|OTHER|Tele-Health Electronic Monitoring (THEM)|Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
223405467|NCT00529087|DRUG|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
223405468|NCT00529087|OTHER|placebo|placebo
223405469|NCT03538860|BEHAVIORAL|Active comparator: Human interpreter|A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.
223405470|NCT03538860|BEHAVIORAL|Intervention: Asynchronous Telepsychiatry|A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
223405471|NCT04001725|DRUG|Dexamethasone|A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
223555796|NCT00602225|DRUG|cytarabine|Given IV
223555797|NCT00602225|BIOLOGICAL|filgrastim|Given subcutaneously
223555798|NCT03657134|DIAGNOSTIC_TEST|CoVa-2 Monitoring System|Upon completion of EP procedure, CoVa-2 monitoring system will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloud-based system and analyzed retrospectively.
223555799|NCT02231528|DEVICE|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
223555800|NCT02231528|DEVICE|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
223555801|NCT00009880|BIOLOGICAL|filgrastim|
223555802|NCT00009880|DRUG|cisplatin|
223737268|NCT02158338|OTHER|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
223737269|NCT02630355|OTHER|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
223737270|NCT01180673|BEHAVIORAL|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
224022727|NCT00284986|DRUG|Prochymal®|Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
224022728|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
224022729|NCT01553331|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
223555803|NCT00009880|DRUG|fluorouracil|
223555804|NCT00009880|DRUG|paclitaxel|
223555805|NCT00009880|RADIATION|radiation therapy|
223737271|NCT01180673|BEHAVIORAL|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
223737272|NCT02981719|PROCEDURE|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment
224022730|NCT04293380|PROCEDURE|amniosyntesis|
223555806|NCT01894724|DEVICE|NeuroSave device|
223737273|NCT02981719|PROCEDURE|irreversible electroporation|percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.
223555808|NCT04306562|DIETARY_SUPPLEMENT|enteral nutrition supplement|enteral nutrition supplement to reach a target of total dietary protein intake of 1.5 g/kg/day for at least 14 days from a preanesthetic clinic visit to a day of surgery.
223555809|NCT04566939|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
223555810|NCT04566939|PROCEDURE|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the shoulder at the physician's discretion.
223555811|NCT04566939|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Gyunwoo (LI15), Gyunryo(TE14), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
224132614|NCT03986008|DRUG|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
224132615|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
223555812|NCT04566939|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223555813|NCT04566939|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223555814|NCT04566939|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
223555815|NCT04566939|PROCEDURE|Herbal hot pack|Herbal hot pack treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223737274|NCT02336022|DEVICE|Respiratory Motion Inc|
223737275|NCT01782261|DRUG|Liraglutide|once daily subcutaneous injection
223737276|NCT01782261|DRUG|Saxagliptin|once daily tablet
223737277|NCT03688477|DEVICE|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
223737278|NCT04061096|DIAGNOSTIC_TEST|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
223737279|NCT04061096|DIAGNOSTIC_TEST|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
223737280|NCT04061096|DIAGNOSTIC_TEST|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
223737281|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with one DEXTENZA (lower eye lid canaliculus) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
224022731|NCT02080741|OTHER|Blood sample of 12 ml|
224022732|NCT01798251|DRUG|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
224022733|NCT01798251|DRUG|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
224022734|NCT00972452|BEHAVIORAL|Exercise|short period of exercise training (5-10 days)
224022735|NCT03253965|OTHER|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
224022736|NCT03253965|OTHER|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
224022737|NCT03253965|OTHER|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
224022738|NCT03253965|OTHER|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
224022739|NCT03253965|OTHER|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
224022740|NCT03253965|OTHER|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
224022741|NCT03253965|OTHER|No Auditory cueing|Steps are not timed with any auditory cue.
224022742|NCT05949112|DEVICE|soft bristle toothbrush|manual toothbrushes
224022743|NCT05949112|DEVICE|mechanical toothbrush|sonic toothbrush
224022744|NCT00699920|DRUG|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
224022745|NCT00699920|DRUG|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
224022746|NCT00966277|DRUG|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
224022747|NCT00062049|BIOLOGICAL|recombinant interleukin-7|
224022748|NCT00311285|DEVICE|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
224022749|NCT03609684|OTHER|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
223555816|NCT04566939|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
223555817|NCT04566939|PROCEDURE|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
223555818|NCT02406469|DIETARY_SUPPLEMENT|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
223555819|NCT02077829|BEHAVIORAL|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
223555820|NCT03960567|DEVICE|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
224022750|NCT03609684|OTHER|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
223555821|NCT04922372|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
223555822|NCT05175430|DRUG|Paroxetine|Paroxetine (per os) will be used as pharmacological tool to downregulate 5-HT1/2 receptors.
224022751|NCT03609684|OTHER|Sedentary Group|People who are not interested in any sports and don't do any exercises
224022752|NCT01488487|DRUG|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
224132616|NCT04863417|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
223555823|NCT05175430|DRUG|Lysergic Acid Diethylamide|LSD (per os) will be used to see if 5-HT 1/2 receptors were downregulated by paroxetine.
223555824|NCT05175430|DRUG|Placebo|Placebo (per os) for the Paroxetine condition will be used to compare the data from the study day with LSD between both arms.
223555825|NCT05269771|DRUG|Ruxolitinib|Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator.
223555826|NCT00972517|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Three intramuscular injections
223555827|NCT00542126|DRUG|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
223555828|NCT04486547|BEHAVIORAL|Information-Motivation-Behavioral Skills model-based intervention|Home visits were made to the study group and nursing interventions were administered in accordance with the components of the Information-Motivation-Behavioral Skills model
223555829|NCT02606071|DEVICE|CRT-D|HF patients treated in clinical practice with a CRT-D device
223555830|NCT03215719|RADIATION|Standard Radiation Treatment|An interval scan at 4 weeks to assess for a good response defined as \>40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (\>40% nodal shrinkage). Those with nodal shrinkage and clearance of circulating plasma HPV DNA shall undergo further treatment de-escalation.
223737282|NCT04501367|DRUG|Dexamethasone Intracanalicular Insert, 0.4 mg|To determine post-surgical resolution of pain, inflammation, and cystoid macular edema outcomes when treated with two DEXTENZA (upper and lower canaliculi) compared to topical steroid treatment in patients who undergo vitrectomy with internal limiting membrane peel surgery
223737283|NCT04501367|DRUG|Prednisone acetate 1%|To reduce post-surgical pain and inflammation in patients who undergo vitrectomy with internal limiting membrane peel surgery
223737284|NCT00631527|DRUG|Leuprolide|Injections given through a needle in the muscle every 3 months.
223737285|NCT00631527|DRUG|Goserelin|Subcutaneous injections given once every 3 months.
224022753|NCT01488487|DRUG|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
224022754|NCT01874860|DRUG|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
224022755|NCT01874860|DRUG|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
224022756|NCT01874860|OTHER|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
224132617|NCT03933423|DEVICE|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
224132618|NCT04768335|BEHAVIORAL|cognitive experiments' session|The aim of this unique session of cognitive experiments is to study the links between source memory deficits and externalization abilities in healthy control subjects. Results of this Arm 2 will be compared to those of Arm 1.
224132619|NCT04717193|DRUG|Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.
224132620|NCT04717193|PROCEDURE|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine|Infiltration of local anesthetic at incision sites.
224132621|NCT02860845|DEVICE|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
224132622|NCT02860845|DRUG|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
223405472|NCT04001725|DRUG|Metformin|A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
223405473|NCT01346566|DEVICE|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
223737286|NCT00631527|DRUG|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
223737287|NCT00631527|DRUG|Casodex|Once a day by mouth for 2 weeks.
223405474|NCT00318474|DRUG|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
223405475|NCT00318474|DRUG|MMF Placebo|Placebo only, oral administration
223405476|NCT00318474|DRUG|ACEi|Administer same as pre-treatment regimen.
223405477|NCT00318474|DRUG|FOS|Administer same as pre-treatment regimen
223405478|NCT01888172|BEHAVIORAL|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
223405479|NCT01888172|DEVICE|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
223405480|NCT01888172|BEHAVIORAL|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
223405481|NCT02063061|DEVICE|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
223737288|NCT00631527|RADIATION|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
223737289|NCT03063476|DRUG|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
223737290|NCT03063476|DRUG|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
223737291|NCT04105998|DRUG|Oxytocin|Oxytocin 10 IU
223737292|NCT04105998|DRUG|Placebo|Placebo
223737293|NCT02646176|BEHAVIORAL|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
223737294|NCT05665062|DRUG|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
223737295|NCT05665062|DRUG|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
223737296|NCT05665062|DRUG|Cyclophosphamide|lymphodepletion
223737297|NCT05665062|DRUG|Fludarabine|lymphodepletion
223737298|NCT05128851|PROCEDURE|HTO|Hight Tibial Osteotomy
223737299|NCT05128851|PROCEDURE|Arthroscopy treatment|Arthroscopy treatment
223737300|NCT05128851|PROCEDURE|Micro fractures|Micro fractures
224022757|NCT01874860|OTHER|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
224022758|NCT01874860|DRUG|Clindamycin|Recommended for daily use if rash returns (Topical cream)
224297734|NCT03184220|PROCEDURE|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
224297735|NCT05198882|PROCEDURE|Laser technology for intracerebral thermocoagulation|One intervention : LITT (Laser Interstitial Thermal Treatment), technology that uses laser energy to thermally destroy (photo-thermal treatment) a brain injury under continuous MRI control (Validated by FDA - CE marking). The operator console + surgical laser generator + software that manages the power delivered by the laser is connected to an MRI - Provided by MEDTRONIC - FDA approved and CE certified.
224297736|NCT02782494|OTHER|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
224297737|NCT04757701|OTHER|Social Behavioral surveys, interviews, and focus groups|Surveys with dentists/hygienists, interviews/focus groups with service learning center directors and key staff at federally qualified health centers.
224297738|NCT03456960|DRUG|TAK-438ASA|TAK-438ASA tablet.
224297739|NCT03456960|DRUG|TAK-438|TAK-438 tablet.
224297740|NCT03456960|DRUG|Aspirin|Aspirin enteric-coated tablet.
224297741|NCT02989168|DRUG|GBT440|GBT440: Capsules which contain GBT440 drug substance in Swedish orange
224297742|NCT05739968|OTHER|Usual care + oncology case manager (OCM) care|Usual care + oncology case manager (OCM) care
224297743|NCT05739968|OTHER|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care|Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
223737301|NCT04822207|PROCEDURE|acupuncture|Patients undergo acupuncture at the beginning of embryo transfer cycle three times a week until 14 days after embryo transfer. Every acupuncture lasts 20 minutes.
224022759|NCT01874860|DRUG|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
224297744|NCT02099604|DRUG|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
224297745|NCT05897268|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
224297746|NCT05897268|DRUG|Tislelizumab|a PD-1 immune check inhibitor
224297747|NCT05897268|DRUG|Lenvatinib|Lenvatinib capsules
223737302|NCT06259240|OTHER|Prone plank exercises|Patients in this group will recieve prone plank exercises, three times a week, for eight weeks, and with a moderate hard intensity. During the first four weeks, the exercises session began with light walking for five minutes followed by corrected exercises. Firstly, women will perform stable prone plank exercises. Secondly, women will be asked to apply the unilateral position of prone plank. Thirdly, using a 65 cm diameter Swiss ball, women will be asked to assume the prone bridge position. During the last four weeks, women will be asked to repeat the same program noting that the progressive prone plank exercises should be applied in a dosage of 20 repetitions, three sets, holding the contraction for one minute, and taking a break for two minutes.
223737303|NCT06259240|DEVICE|Electrical Stimulation|Electrical Stimulation
223737304|NCT05025488|DRUG|Peptide-based vaccine|ten (10) doses of Mutant-CALR peptides with KLH as helper peptide (in the first vaccine only). Mutant-CALR vaccine will administered every 2 weeks for the first 4 doses and then every 4 weeks for additional 6 doses. Maintenance Treatment The protocol allows for a continued administration of up to four (4) additional Mutant-CALR vaccine and four (4) Poly-ICLC administrations, 12 weeks apart.
223737305|NCT05025488|DRUG|Poly ICLC|ten (10) doses of Poly-ICLC. Poly-ICLC will be given on weeks 1, 3, 5, 7, 11, 15, 19, 23, 27 and 31. each Poly-ICLC dose must be given the day after the corresponding Mut-CALR vaccination.
223555831|NCT03215719|RADIATION|Dose-Deescalated Treatment|Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
223737306|NCT02621411|DRUG|Substance use|Patients are found use of substances by preoperative screen
223737307|NCT04800692|DRUG|Tetrahydrobiopterin 10 mg/kg|10mg/kg of Tetrahydrobiopterin daily.
223737308|NCT04800692|DRUG|Tetrahydrobiopterin 20 mg/kg|20mg/kg of Tetrahydrobiopterin daily.
223737309|NCT04800692|DRUG|L-Ascorbate|3300 mg of l-ascorbate once daily
223737310|NCT04800692|DRUG|L-Arginine|3400mg of l-arginine once daily
224022760|NCT01008215|OTHER|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
224022761|NCT03488641|DIAGNOSTIC_TEST|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
224022762|NCT04084470|DIETARY_SUPPLEMENT|Different types of bread|Two studies comprising a double-blind randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive three different types of bread in a randomized order for 1 day each, with a wash-out period of at least 7 days in between. Before test days 2 and 3, there is also a run-in period of three days.
224022763|NCT01684267|DEVICE|Robotic Gait Rehabilitation (RGR) Trainer|
224022764|NCT00264953|DRUG|Adriamycin|
224022765|NCT00264953|DRUG|Bleomycin|
224022766|NCT00264953|DRUG|Vinblastine|
224132623|NCT02860845|DRUG|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
223555832|NCT03215719|DRUG|Cisplatinum|Standard of care chemotherapy
223555833|NCT05123989|BEHAVIORAL|Personalized move goals|Personalized move goals delivered by the Welltory mobile app
223737311|NCT05651451|DEVICE|Laser acupuncture|24 activated laser acupuncture treatments. Treatments was performed 3 times per week for 8 weeks.Laser acupuncture was applied withwavelength of 810 nm, power output of 150 mW in continuous wave mode and energy density laser of 4 J/cm2 with irradiation time 3 min/point
223737312|NCT05651451|DIETARY_SUPPLEMENT|energy-restricted diet|All post-menopausal women followed an energy-restricted diet for 8 weeks. Meal plan that creates an energy deficit of 500 to 1000 Kcal per day less than the individual's average daily intake was suitable for weight reduction.Each post-menopausal woman followed Dietary Approaches to Stop Hypertension (DASH) which : low in total fat, cholesterol, red meat, sweets and sugar containing beverages, emphasize fish, nuts, fruits, vegetables and whole grains and it also rich in Potassium(6900mg), Calcium(1200-1500mg) and Magnesium, as well as vitamins A, C and E
223737313|NCT00563251|DRUG|Azithromycin|
223737314|NCT00563251|DRUG|Placebo tablet|
224022767|NCT00264953|DRUG|DTIC|
224022768|NCT00264953|DRUG|Etoposide|
224022769|NCT00264953|DRUG|Procarbazine|
224022770|NCT00264953|DRUG|Prednisone|
224022771|NCT00264953|DRUG|Vincristine|
224022772|NCT00264953|RADIATION|radiation therapy|20 or 30Gy IF-RT
224022773|NCT02993484|DRUG|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
224022774|NCT02993484|BIOLOGICAL|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
224022775|NCT02993484|OTHER|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
224022776|NCT02993484|OTHER|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
224022777|NCT05736991|DIAGNOSTIC_TEST|PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
224022778|NCT04460677|BEHAVIORAL|Emotional Support Plan|The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
224022779|NCT04460677|BEHAVIORAL|Daily Monitoring|The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.
224022780|NCT05729880|DIAGNOSTIC_TEST|MRI, MRS|Scan of right calf and thigh
224022781|NCT05729880|DIAGNOSTIC_TEST|Ultrasound|Scan of right calf and thigh
224138788|NCT02802878|DEVICE|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
223555834|NCT05123989|BEHAVIORAL|Constant move goals|Static move goal delivered by the Welltory mobile app
224138789|NCT01599754|DRUG|Axitinib|Axitinib 5 mg twice daily
224138790|NCT01599754|DRUG|Placebo|Placebo twice daily
223555835|NCT05553769|OTHER|Resistance training, detraining, retraining|Participants (healthy untrained men and women, age 18-40) start with a 3-week familiarization and baseline measurement period. After that, they are randomized to two intervention groups, where other group will conduct 10-week RT intervention and a 10-week DT period and again the exact same 10-week RT intervention again whereas the other group start with a 10-week non-training period and then continues with a 20-week RT intervention. RT consists of two training sessions per week of total body workouts. Same measurements are conducted for both groups with the same time intervals.
224022782|NCT02475174|OTHER|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
224022783|NCT02475174|OTHER|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
224022784|NCT00001024|DRUG|Zidovudine|
224022785|NCT00001024|DRUG|Didanosine|
223405482|NCT02063061|DEVICE|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
223405483|NCT03208335|DRUG|recombinant human endostatin|The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
223405484|NCT03628664|RADIATION|CT scan|Assessment of the actual posterior condylar angle using the CT scan
223405485|NCT06436911|DRUG|COVIGENIX VAX- 002|ENTVAX-001-01
223405486|NCT06577688|OTHER|Blood pressure measurement|Blood pressure measurement using a standard cuff device and a smartphone
223555836|NCT00984594|OTHER|Primary injury site|Autograft will be placed in the primary defect site.
223555837|NCT00984594|OTHER|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
223555838|NCT00132990|DEVICE|Deep brain stimulation|
223555839|NCT03841851|PROCEDURE|sub epithelial connective tissue graft|"* Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate"
223555840|NCT05461586|DEVICE|Refractive Technique (MR #1)|Fogging method that employs fogging lens to ensure there is sufficient visual defocus to induce blur.
223555841|NCT05461586|DEVICE|Refractive Technique (MR #2)|Duochrome method that employs the chromatic aberration of the eye, with the shorter wavelengths (green) focused in front of the longer (red) wavelengths
223555842|NCT00851890|DRUG|ABT-333|50 mg capsules
223555843|NCT00851890|OTHER|Placebo for ABT-333|Capsule
223555844|NCT00851890|DRUG|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
223555845|NCT00851890|DRUG|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
223555846|NCT04118075|DRUG|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
223555847|NCT03135431|PROCEDURE|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
223555848|NCT03135431|PROCEDURE|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
223555849|NCT02059629|DEVICE|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
223555850|NCT02059629|DEVICE|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
223555851|NCT05620810|BEHAVIORAL|neuropsychiatric symptoms|neuropsychiatric symptoms
223555852|NCT06140251|DRUG|Sodium-glucose cotransporter 2 inhibitor|Patients identified with heart failure (both reduced ejection fraction and preserved) who are on optimal standard therapy and are candidates for treatment with SGLT2 inhibition will be identified from local heart failure databases, and local heart failure clinics. Following signed, informed consent and screening, patients will be allocated a first appointment where baseline clinical assessment and biomarker analysis will be obtained along with commencement on a SGLT2 inhibitor. Repeat assessment will be performed following a minimum period of 26 weeks.
223555853|NCT01941381|PROCEDURE|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
223555854|NCT01042587|OTHER|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
223555855|NCT01042587|OTHER|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
223555856|NCT05117567|COMBINATION_PRODUCT|Personal protection package|A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
224022786|NCT02825862|BEHAVIORAL|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
224022787|NCT02825862|BEHAVIORAL|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
224022788|NCT02955147|DRUG|Ustekinumab|Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
224022789|NCT02955147|DRUG|Prednisone|Prednisone is an anti-inflammatory medication
224297748|NCT04300829|DRUG|cicaderma + simple hygiene rules|Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
224297749|NCT04300829|OTHER|Simple hygiene rules and a maximum of one topical treatment|Simple hygiene rules according to the site recommandations including eventually a maximum of one topical treatment
223405487|NCT01775813|DRUG|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
223405488|NCT01775813|DRUG|Placebo|Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
224022790|NCT06441500|OTHER|Daily tooth brushing programme|Implementing the toothpaste/toothbrushing scheme involving free daily toothbrushing to every 3 - 5-year old child attending nursery. Free distribution of toothpaste/toothbrush packs to every child every 3 months. Collection of routine monitoring data linked with national data sets from the previous survey regarding caries prevalence and risk factors.2.Monitor caries activity - net caries increment for initial, moderate, and extensive caries severity.
224022791|NCT01969370|BEHAVIORAL|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
224022792|NCT05597462|DRUG|Minocycline hydrochloride capsules|Minocycline hydrochloride capsules, 40 mg will be administered orally once daily for 16 weeks.
224022793|NCT05597462|OTHER|Placebo|Placebo capsules will be administered orally once daily for 16 weeks.
224022794|NCT06437587|OTHER|Home-based rehabilitation appropriate technology (S-HRAT) training|The S-HRAT training instruction consists of two phases: in-hospital training and post-discharge remote home training. Based on the S-HRAT list, we select individualized home rehabilitation training exercises for the participants and conduct five offline training instruction sessions one week before discharge to ensure that the participants master the correct method for each exercise and clarify precautions. At discharge, participants will receive an S-HRAT brochures, which will include detailed text, pictures and video demonstrations of exercises, to visualize the rehabilitation instructions and make them easy to understand. Participants learn how to use the S-HRAT booklet and follow a daily training program to complete the prescribed content. They will be asked to record a video of their training and send it to the researcher via WeChat for monitoring purposes and feedback.
224022795|NCT04129216|DRUG|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
224022796|NCT04129216|DRUG|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
224022797|NCT04129216|DRUG|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
224022798|NCT04129216|DIAGNOSTIC_TEST|Blueprint|studies the genomics of the tumor and tumor behavior
224022799|NCT04129216|DIAGNOSTIC_TEST|Mammaprint|studies the genomics of the tumor
223555857|NCT04504344|DEVICE|Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)|We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
223555858|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
223555859|NCT00777595|DRUG|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
223555860|NCT00777595|DRUG|Placebo|Inhaled solution, single dose of placebo
223555861|NCT00777595|DRUG|Moxifloxacin|Tablet, oral, 400mg, single dose
223555862|NCT00482040|DEVICE|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
223555863|NCT02997696|DRUG|ONO-4474|
223555864|NCT02997696|DRUG|Placebo matching ONO-4474|
223555865|NCT04054921|DRUG|PTG-300|PTG-300 is a hepcidin Mimetic
223555866|NCT00998452|BEHAVIORAL|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
223555867|NCT01872975|RADIATION|regional nodal XRT|
224022800|NCT02835300|BEHAVIORAL|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
224022801|NCT02835300|BEHAVIORAL|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
224297750|NCT06310265|OTHER|Retrospective observational study|Our study includes child earthquake victims, regardless of gender, between the ages of 0-18, who applied to our clinic within six months after the February 6, 2023 earthquake and underwent surgery.
223555868|NCT01872975|RADIATION|chestwall XRT|
223555869|NCT01872975|RADIATION|WBI|
223555870|NCT06040424|COMBINATION_PRODUCT|Ipratropium / Levosalbutamol Fixed Dose Combination|New combination test treatment
223555871|NCT06040424|DRUG|Ipratropium + Levosalbutamol Free Dose Combination|Free combination control treatment
223555872|NCT03934580|OTHER|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
223555873|NCT03934580|OTHER|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
223555874|NCT01186887|DRUG|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
223405489|NCT05953519|BEHAVIORAL|Unified Protocol|The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
223405490|NCT03252977|OTHER|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
223405491|NCT03252977|OTHER|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
223405492|NCT06026735|OTHER|lung cancer with brain /leptomeningeal metastasis|Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
223555875|NCT01186887|DRUG|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
223555876|NCT03794427|OTHER|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
223555877|NCT03794427|OTHER|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
223555878|NCT03794427|OTHER|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
224022802|NCT01477554|OTHER|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
224022803|NCT02004353|DEVICE|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
224297751|NCT05419115|DRUG|SQIN-Furosemide|The investigational furosemide formulation (SQIN-Furosemide) is a Captisol®buffered solution of 80mg furosemide in 2.7 mL (30 mg/mL) at pH 7.4 (range: 7.0 to 7.8). SC infusion will be performed using the SQIN-Infusor which will deliver 2.7 mL of the SQIN-Furosemide formulation (80mg) over approximately 5 hours, using a biphasic delivery profile.
223405493|NCT02680808|DRUG|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
223405494|NCT03821454|DRUG|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
223555879|NCT03794427|OTHER|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
223405495|NCT03821454|DRUG|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
223405496|NCT04031040|DEVICE|Genio(TM) system therapy|Hypoglossal nerve stimulation system
223405497|NCT01164189|BIOLOGICAL|Bevacizumab|Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
223405498|NCT01164189|DRUG|Temozolomide|Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
223405499|NCT02918565|BEHAVIORAL|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
223405500|NCT02918565|BEHAVIORAL|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
223405501|NCT02918565|BEHAVIORAL|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
223405502|NCT02918565|BEHAVIORAL|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
223555880|NCT02544867|BEHAVIORAL|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
223555881|NCT02384044|DEVICE|Crest® Sensi-Stop™ Strips|
223555882|NCT02384044|DEVICE|Colgate® Sensitivity Relief Pen|
223555883|NCT01795976|GENETIC|NY-ESO-1 T cells|
223555884|NCT01795976|DRUG|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
223555885|NCT01795976|DRUG|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
223555886|NCT01795976|BIOLOGICAL|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
223555887|NCT00281099|DEVICE|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
223555888|NCT03425435|OTHER|QoL and developed questionnaires for healthcare research|Questionnaires
223737315|NCT04170257|DIAGNOSTIC_TEST|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
223737316|NCT05142865|DRUG|Camrelizumab|Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6) and maintenance phase ,until PD.
223737317|NCT05142865|DRUG|Etoposide|100mg/m2 IV continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
223737318|NCT05142865|DRUG|Carboplatin|AUC 5 mg/mL/min IV on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4/6)
223737319|NCT05142865|DRUG|Cisplatin|25mg/m2，continuously on Day 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4/6)
223737320|NCT05142865|DRUG|Apatinib|250 mg given orally, once daily in 21-day cycle
223737321|NCT03586856|DEVICE|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
223737322|NCT03586856|DEVICE|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
223737323|NCT03954951|OTHER|Multimodality behavioral strategy|"* On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~* Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
223737324|NCT02168179|PROCEDURE|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
223737325|NCT02168179|OTHER|questionnaire administration|Ancillary studies
223737326|NCT02630433|PROCEDURE|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
224022804|NCT06119672|DRUG|Probiotic Blend Oral capsules|probtiotic bend oral tablets from biovia will be adminestrated containing 4 strains ( twice daily) in addition to topical clobetasol application twice daily
224022805|NCT06119672|DRUG|Corticosteroids for Local Oral Treatment|topical clobetasol probionate in orabase application 4 times daily
223555889|NCT06231875|DEVICE|Press|Fabrication of clear aligners using press machine (Mini-star)
223555890|NCT00593177|DRUG|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
223555891|NCT04822818|DRUG|BEVA+SOC|Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
223555892|NCT04822818|DRUG|SOC|patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
223555893|NCT03082911|OTHER|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
223555894|NCT03082911|OTHER|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
223555895|NCT00271921|BEHAVIORAL|Calorie controlled diet|
223555896|NCT01141998|DRUG|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
223737327|NCT02630433|PROCEDURE|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
223737328|NCT04471012|OTHER|Individual counselling program|"An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session."
223737329|NCT00134160|DRUG|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
223737330|NCT00134160|DRUG|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
223737331|NCT03030690|OTHER|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
223737332|NCT03030690|OTHER|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
223737333|NCT03030690|OTHER|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
223737334|NCT01608659|DRUG|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
223737335|NCT04958005|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
224022806|NCT00898027|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
224022807|NCT04580576|PROCEDURE|Hematopoietic stem cell transplantation|Allogeneic or autologous bone marrow transplant
224022808|NCT00819390|DRUG|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
224022809|NCT00819390|DRUG|Placebo|Taken orally, once daily for 12 weeks.
224022810|NCT01651442|BEHAVIORAL|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
223555897|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. Week 0-10.
224022811|NCT01651442|DRUG|Zolpidem|5mg or 10mg
223405503|NCT04679766|PROCEDURE|Ice cream cone technique with immediate implant as a flapless bone regenerative method in management of patients with labial plte dehiscence|Atraumatic extraction will be done The extraction socket will be debrided to remove any residual debris using surgical curettes Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence. Implant placement will be done. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability Resorbable collagen membrane will be cut confirming to the size and shape of the defect of labial bone plate dehiscence. The membrane will be placed against internal surface of the extraction socket against the remaining buccal plate of bone. The gap between the collagen membrane and the implant fixture will be filled with xenograft particulates.The membrane will be folded in palatal direction to seal the socket in an ice cream cone shape, then will be secured using non-resorbable sutures
223405504|NCT03481868|BIOLOGICAL|Collection of blood and bone marrow|Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
223405505|NCT04455412|PROCEDURE|Laser Assisted ICSI|using OCTICS laser device to do small opening or zona thinning to improve ICSI outcome
223555898|NCT01141998|RADIATION|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
223555899|NCT01141998|RADIATION|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
223555900|NCT01141998|DRUG|Cholecalciferol|38 micrograms daily. From week 14 to 52.
223555901|NCT06006936|BEHAVIORAL|Coping with Infertility Self-Help Program|"The CWI program consists of seven 10-minute videos, each with accompanying homework assignments.~The first module, cognitive restructuring, includes instructions on challenging extreme or unhelpful automatic thoughts. The second module, challenging negative core beliefs, includes looking for patterns in thinking that illustrate core beliefs. The third module features behavioural activation techniques and emphasizes the importance of regular pleasure and skill-based activities. The fourth module highlights coping with grief and factors that contribute to grief, such as individual differences in grieving style. The fifth module supports strengthening relationships through responding to requests for affection and outlines several common relationship mistakes. The sixth module demonstrates how to identify and use values to make decisions and guide behaviour. The seventh module summarizes how thoughts, actions, and interactions can contribute to well-being when experiencing infertility."
223555902|NCT05457153|OTHER|Well-Being Process Program (WEBEPROP)|Technology-Based Well-Being Process Program (WEBEPROP)
223555903|NCT06125171|DRUG|Tucidinostat, Apatinib|"Tucidinostat:~age≥18years, 30mg, po., biw, q4w; age≥10years，\<18years，0.5mg/kg, biw, q4w~Apatinib:~BSA≥1.2m\^2, 500mg, qd, q4w BSA\<1.2m\^2, 250mg, qd, q4w"
223555904|NCT02748421|PROCEDURE|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
223555905|NCT02748421|PROCEDURE|Conventional Microscope|macular membrane dissection without OCT RESCAN
223555906|NCT05275088|DEVICE|Prizvalve® system|Transcatheter atrioventricular valve replacement
223555907|NCT05170477|PROCEDURE|apical patency|In Gp A, apical patency will be maintained till obturation using electronic apex locator confirmed radiographically. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration.
223555908|NCT05170477|PROCEDURE|Non-apical surgery|in Gp B apical patency will not be maintained. Finally, Root canals will be obturated using cold lateral compaction technique. The molars will be permanently restored using composite resin restoration and will be scheduled for extra coronal restoration
223555909|NCT02855879|OTHER|Collection of biological data|
223555910|NCT02855879|OTHER|Collection of clinical data|
223555911|NCT04472481|DRUG|Ergocalciferol 1.25 mg tablet|weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
224022812|NCT01651442|DRUG|Trazodone|50mg to 150mg
224022813|NCT01651442|BEHAVIORAL|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
224022814|NCT06199674|DEVICE|photobiomodulation therapy|Patients in the PBM group will be delivered a portable PBM device (PBM Healing Ortho) at the beginning of orthodontic treatment and will be instructed to use it daily at home for 8 minutes (4 min per arch) after tooth brushing.
223555912|NCT04893317|DEVICE|Ablation in the ventricles with the Adagio Medical VT Cryoablation System|The Adagio Medical VT Cryoablation System is indicated for the treatment of monomorphic ventricular tachycardia by ablation of arrhythmogenic tissue that drives and maintains these arrhythmias
223555913|NCT04192669|DEVICE|Heart rate monitoring|The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
223555914|NCT06982261|OTHER|Voice-activated smart speakers|"Participants will attend a single 90 to 120-minute in-person baseline visit to complete standardized questionnaires and review a list of smart speaker-based tasks. They will select three tasks; all will receive an Echo Show and a Fitbit Versa. Additional digital health devices (e.g., blood pressure monitor, in-home motion sensors) will be provided based on their selections. Participants will learn to interact with Alexa, followed by a second home visit one week later for task-specific setup and device installation.~The team will conduct weekly or bi-weekly check-in calls for two months, with additional home visits as needed. At two months, a home visit will include questionnaires and a 30-60 minute interview on intervention feasibility. Participants will then use the devices independently for one month, with a final home visit at three months for questionnaires and a closing interview."
223737336|NCT03398291|PROCEDURE|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
223737337|NCT03398291|DRUG|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
223737338|NCT01275391|BEHAVIORAL|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
223737339|NCT04566224|DEVICE|Macintosh size 2 blade|intubate with Macintosh size 2 blade
223737340|NCT04566224|DEVICE|Macintosh size 3 blade|intubate with Macintosh size 3 blade
224022815|NCT06199674|OTHER|orthodontic fixed-appliance|All eligible patients will receive orthodontic treatment with a pre-adjusted fixed appliance (0.022'' × 0.028'' slot system, MBT, 3M Unitek) provided by the same practitioner. At the start of treatment, a cantilever auxiliary arch bent with a 0.017'' × 0.025'' Stainless Steel wire (3M Unitek) will be used to apply a 100 g intrusion force to the premolars that will be extracted in 3 months. All other teeth will undergo regular orthodontic treatment with a standard archwire protocol (0.014'' NiTi, 0.016'' NiTi, 0.018'' NiTi, 0.017'' × 0.025'' NiTi, 0.019'' × 0.025'' NiTi, and 0.019'' × 0.025'' SS, 0.019'' × 0.025'' TMA) for alignment, leveling, space closure, detailing, and finishing. For en masse retraction, a 150 g force will be applied by coil springs, allowing bracket slots to slide along the 0.019'' × 0.025'' SS.
223737341|NCT03067649|BEHAVIORAL|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
224022816|NCT01845909|OTHER|ECG and survey screening|
224022817|NCT04768374|OTHER|Virtual Reality with Kinect|"In the study it was conducted a 12 week-intensive VR intervention (twice a week, 45 minutes each) and compared the results in the 12th week to investigate the effects of rehabilitation and follow-up assessments were made in the 16th and 24th weeks. From the beginning of the VR intervention, each game was played in equal durations by each participant. However, the difficulty of the games varied depending on the child's performance.~Microsoft Kinect Games-Carnival Games was used as VR intervention. In meeting held with the authors to determine which games would be used in the VR program, 5 games were chosen and the remaining games were removed from the program because of their similar contents."
224022818|NCT04768374|OTHER|Conventional Occupational Therapy (COT)|"The COT based on neurodevelopmental treatment was carried out by the same occupational therapist. The treatment goals aimed at increasing the use of participant's extremities and improving the independence in ADL. The activities in the treatment were chosen in view of children's motor skills and daily living activities such as getting dressed, solving puzzles, and writing etc.~Both groups received COT while the control group received COT only for 12 weeks."
224022819|NCT05660460|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is noninvasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
224022820|NCT05054153|OTHER|refined carbohydrate breakfast|After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
224022821|NCT05054153|OTHER|whole grain breakfast|After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
224022822|NCT05054153|OTHER|intermittent fasting|The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.
224022823|NCT04448197|OTHER|Chinese Medicine|Dialectical treatment of traditional Chinese medicine according to different constitution
224022824|NCT03554668|DIAGNOSTIC_TEST|Blood draw|We take blood samples at pre-op and subsequent time points, up to three months post op.
224022825|NCT00212160|PROCEDURE|omentectomy|RYGB with omentectomy
224022826|NCT05455515|PROCEDURE|IVL procedures|Intravascular Lithotripsy (IVL)
224022827|NCT05234112|BEHAVIORAL|Community mobilisation for hrHPV self-testing|use of social media, written media, theatre and other sources of communication to reach women, and relatives, to convince them of importance of screening.
224022828|NCT05234112|DIAGNOSTIC_TEST|hrHPV self-testing|use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.
224022829|NCT05234112|BEHAVIORAL|Follow-up after testing|based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up
224022830|NCT05234112|DIAGNOSTIC_TEST|VIA|Test offers insight into existence of dysplasia of the cervix by colouring the transition area
224022831|NCT05234112|PROCEDURE|Thermo-ablation or cryotherapy for dysplasia|Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix
224022832|NCT05234112|DIAGNOSTIC_TEST|Pap smear cytology|Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
224022833|NCT04271501|PROCEDURE|Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB)|Application of melanocytes (aka melanocyte-keratinocyte transplantation procedure or MKTP) to surgically prepared depigmented areas
223405506|NCT04815811|OTHER|Blood collection|Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.
224022834|NCT04271501|DEVICE|RECELL 1:5 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
224022835|NCT04271501|DEVICE|RECELL 1:10 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
224022836|NCT04271501|DEVICE|RECELL 1:20 and Ultraviolet Lamp (UVB)|Skin cell suspension dilution prepared using the RECELL System applied to a surgically prepared area of depigmentation
223405507|NCT04815811|OTHER|Stool collection|Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
223405508|NCT06247605|DRUG|AL8326 tablets|10mg/tablet, Oral administration, once daily.
223405509|NCT06247605|DRUG|placebo|Oral administration, once daily.
223555915|NCT06658418|PROCEDURE|Erector Spinae Plane Block|dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.
223555916|NCT06660043|OTHER|physical activity|40 min circuit training session
223555917|NCT06660043|OTHER|analgesic physical therapy|physical therapy with massage and Transcutaneous Electrical Nerve Stimulation in a 40min session
223555918|NCT06660043|OTHER|analgesic physical therapy AND physical activity|25 min circuit training session and 15 min physical therapy
223555919|NCT06662253|DRUG|Anti-Xa Guided Dosing of Low Molecular Weight Heparin|Participants will receive Enoxaparin 0.5 mg/kg twice daily (rounded up or down to the nearest 10 mg) the initial starting dose. Dose adjustments will be made based on trough levels drawn between the 3rd and 4th dose. The target anti-Xa level range is between 0.1 and 0.2 IU/mL. If the patient is below the target range, then the next Enoxaparin dose will be increased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. If the patient is above the target range, then the next Enoxaparin dose will be decreased by 10 mg per dose with a new trough anti-Xa level 24 hours after dose modification. This dose will be maintained until hospital discharge.
223555920|NCT06662253|DRUG|Standard of Care Dosing|Participants will receive Enoxaparin dosed at the discretion of the most responsible physician (MRP). In cases of severe renal insufficiency (CrCl \&lt; 30mL/min\^:), the LMWH may dose reduced or changed to Heparin at the discretion of the MRP.
223555921|NCT06662110|DIAGNOSTIC_TEST|PSRscore|PSRscore calculated based on baseline serum immune proteomics
223555922|NCT06660680|DRUG|Methylene Blue|Received MBI treatment to their surgical incisions upon completion of surgery
223737342|NCT03067649|BEHAVIORAL|Information only control|Participants are provided with a pamphlet containing referral information
223737343|NCT03407105|BIOLOGICAL|MDX-010|Specified dose on specified days
224022837|NCT02628782|DEVICE|InSeal's Vascular Closure Device|Intravascular closure device
224022838|NCT05664867|OTHER|Mainstream Genetic Testing Model|Mainstream Genetic Testing Model of Cancer Genetics Service Delivery
224022839|NCT05664867|OTHER|Enhanced Standard of Care Model|Enhanced Standard of Care Model of Cancer Genetic Service Delivery
224022840|NCT04651075|OTHER|music listening|The music selected by the participants was played to the music listening group.
224022841|NCT04651075|OTHER|individual training|Individual training group was trained on coronary angiography.
224022842|NCT00479492|DRUG|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
223405510|NCT00457145|DRUG|Ranibizumab|
223405511|NCT02348788|DRUG|Artemether-lumefantrine + Primaquine|
223405512|NCT02348788|DRUG|Chloroquine + Primaquine|
223405513|NCT00833105|DEVICE|AMES treatment|The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
223737344|NCT05850572|DRUG|Fecal microbiota transplantation(FMT)|Subjects will receive FMT capsules (10\^12 CFU/capsule) in addition to their usual antidepressant treatment. Subjects will continue to receive FMT capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
224022843|NCT00479492|DRUG|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
224022844|NCT00479492|DRUG|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
224022845|NCT00479492|DRUG|placebo|placebo administered QD for 84 days
224022846|NCT00617474|DRUG|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
224022847|NCT00617474|DRUG|Placebo|placebo
224022848|NCT03861377|DRUG|Remifentanil R2|0,7 microg/kg
224022849|NCT03861377|DRUG|Remifentanil R4|1,1 microg/kg
224022850|NCT03861377|DRUG|Remifentanil R8|1,7 microg/kg
224022851|NCT00334035|DRUG|Quetiapine|
224022852|NCT02733393|PROCEDURE|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
224022853|NCT02733393|DRUG|lidocaine|
224022854|NCT05205915|DEVICE|tDCS intervention applied by Starstim device|Stimulation will be applied using the Starstim device, with current delivered via four Starstim Pi electrodes (circular electrodes with a contact of area of 3.14 cm2) embedded in the headpiece. All study subjects will use the same fixed montage (electrode locations and currents). The montage has been designed to optimize anodal stimulation in the desired target area while avoiding stimulation off target.
224132624|NCT05015205|OTHER|Muscle Energy Technique|Post isometric relaxation technique MET was applied in two muscle groups; Lumbar Extensors (Erector Spinae) and Hip Flexors (Iliopsoas). The muscle was positioned in position and patient was asked to apply 20% force isometrically and hold the isometric contractions for 7-10 seconds. Then the patient was asked to relax for about seconds. On exhalation, therapist takes muscle to new restriction barrier. Hold this position for 30 seconds at the end barrier as an end-stretch with 3 repetitions.
224132625|NCT05015205|OTHER|Postural Correction Exercises|: Postural Correction Exercises was applied to one group. Exercises performed included stretching and strengthening exercises. Hip flexors and back extensors were stretched while hip extensors and abdominals were strengthened. Seated hip flexion used to stretch back extensors while lunge position used to stretch hip flexors. The abdominals were strengthened by using curl up exercises while hip extensors were strengthened by resisted contractions in prone lying.
224022855|NCT04490187|BEHAVIORAL|Motor Learning|"Over three consecutive days, each child will perform five blocks of Purdue Pegboard Test: one block before, three blocks during, and one block after tDCS. Each block consists of three repetitions of Purdue Pegboard Test with the right hand. The children have to place pins into a pegboard as fast as they can in 30 seconds. It will take up to 10 minutes of brain stimulation time.~After the Purdue Pegboard Test, each child will receive cognitive-based intervention for printing skills for 20 minutes while receiving tDCS. Printing Like a Pro! (Montgomery 2017) -a cognitive approach to teaching printing to primary school-age children-will be used to teach letters which each child has the most difficulty printing legibly as identified on a formal assessment of handwriting-ETCH (manuscript) (Amundson 1995)."
224022856|NCT00461136|DRUG|Aliskiren|
224022857|NCT02805881|DEVICE|Neurolief system|Non-invasive cephalic neurostimulation device
224022858|NCT03139110|BEHAVIORAL|Presence of a mediator in the emergency departments|"The mediator tasks are :~* Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~* Have a proactive attitude towards patients showing nervousness signs~* Report patients expressing the will to leave the emergency departments before medical care~* Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
224022859|NCT01599715|BEHAVIORAL|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
224022860|NCT01599715|BEHAVIORAL|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
224022861|NCT02641678|DEVICE|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
224138791|NCT02028546|PROCEDURE|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
224138792|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
224138793|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
224022862|NCT04302441|DRUG|Vinorelbine|vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks
223405514|NCT01262222|OTHER|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
223405515|NCT06208839|DEVICE|SBIRT/eIntervention for those with moderate risk drug or alcohol use|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~* Online view of the referrals made for them e.g. to healthcare provider~* Secure messaging with the referring provider~* Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~* Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~* Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
224297752|NCT05419115|DEVICE|SQIN-Infusor|The investigational device (SQIN-Infusor) is an on-body delivery system that consists of a RU, DU, plus a charger (Figure 2). For the purpose of SUBCUT-HF II trial, the RU will be used for multiple infusions for a single participant. The DU will be used only once per infusion and disposed of. The RU must be charged after each use and will not restart for the next infusion without charging. Charging takes up to 15 minutes. SQIN-Infusor is a bespoke system, adapted from the design of a SC insulin pump. The RU consists of the drive-unit, the controllers, the rechargeable battery, and the user interface.
224297753|NCT02337140|DEVICE|Pacemaker SORIN Group KORA DR|
224022863|NCT04302441|DRUG|Capecitabine|Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle
224022864|NCT02872883|PROCEDURE|Expectant management|
224022865|NCT02872883|PROCEDURE|Minimal Vaginal examinations (only when necessary)|
224022866|NCT02872883|PROCEDURE|Active management|
224022867|NCT02872883|PROCEDURE|Routine vaginal examinations|
224022868|NCT02957864|DRUG|tenofovir alafenamide|
224022869|NCT02957864|DRUG|abacavir|
224022870|NCT02925637|OTHER|FaCoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
224138794|NCT03205917|BIOLOGICAL|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
224022871|NCT06004011|OTHER|ARROW strategies|ARROW strategies are peer-to-peer support at the patient, provider and health system levels
224022872|NCT06004011|OTHER|One-time education|The comparison group will receive a one-time education campaign that will provide informational brochures to adolescents and young adults living with HIV and HIV providers
223405516|NCT06208839|DEVICE|SBIRT/eIntervention those assessed with high risk.|"The Connections App is available on iOS or Android and will be offered to the patient during the referral process and contains the following functionalities:~* Online view of the referrals made for them e.g. to healthcare provider~* Secure messaging with the referring provider~* Secure messaging with the destination provider(s) to support them to adhere to the referral, and/or the patient can seek assistance with the destination provider,~* Informative multimedia content filtered from a library to fit the patient including testimonial content from peers thus showing the patient that others like them have shared their addiction experience and successfully received treatment and achieved recovery,~* Capture structured feedback from the patient~The patient may access more functionality within the Connections App for those who wish to modify behavior using eTherapy and eRecovery. eRecovery includes ecological momentary assessments (EMA) selected by the provider."
223405517|NCT06208839|OTHER|SBIRT/TAU for those with moderate risk drug or alcohol use|Treatment as usual
223405518|NCT06208839|OTHER|SBIRT/TAU for those assessed with high risk.|Treatment as usual for high risk group
224022873|NCT05822778|DEVICE|Formaderm Dermal Filler Injection|Dermal filler injection to facial areas
224297754|NCT02337140|PROCEDURE|transcatheter aortic valve implantation (TAVI)|
223405519|NCT00312273|DRUG|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
223555923|NCT06660160|OTHER|Exercise program supported by audiovisual media|"The intervention group will perform the group exercise protocol during HD sessions. The videos with the exercises will be broadcast on all televisions simultaneously, so that the volunteers perform the exercises along with the person in the video.~* The first level of difficulty includes 5 exercises for the lower limbs and 3 exercises for the upper limbs. One set of 10 repetitions will be performed for each exercise per session.~* The second level includes 3 exercises for the lower limbs and 2 exercises for the upper limbs. These consist of proprioceptive neuromuscular facilitation diagonals for both the lower and upper limbs. One set of 10 repetitions will be performed for each exercise, once per week, for 3 weeks.~* The third level includes 8 combined lower and upper limb exercises performed simultaneously. One set of 20 repetitions will be performed for each exercise.~Exercises will be performed 3 times per week over a 4-week period, for a total of 12 planned exercise sessions."
223555924|NCT06657963|DIETARY_SUPPLEMENT|Opuntia ficus-indica Supplementation|Participants are required to consume oral supplementation of OFi fine powder packaged in individual sachets (LifeGreenTM, LifeTree Asia, Selangor, Malaysia) at the dosage of 1500 mg once daily for 3 months.
223555925|NCT00025207|DRUG|gefitinib|Given orally
223555926|NCT00025207|OTHER|laboratory biomarker analysis|Correlative studies
223555927|NCT01465880|OTHER|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
223555928|NCT04608383|OTHER|Additional and minimal collection of products of the human body carried out during a sample for standard of care|"* Swab of the peritoneal fluid for traces of COVID19. The collection of peritoneal fluid is a standard care practice.~* Swab from the laparoscopy filter"
223555929|NCT03828760|BEHAVIORAL|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
223555930|NCT06221943|BEHAVIORAL|Group-based Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in a group setting.
223555931|NCT06221943|BEHAVIORAL|One-on-one Naturalistic Developmental Behavioral Intervention|Naturalistic Developmental Behavioral Intervention (Utilized NDBI-Fi as the fidelity criteria of the intervention) provided in an one-on-one setting
224022874|NCT05822778|DEVICE|"Q-MED RESTYLANE"|Dermal filler injection to facial areas
224022875|NCT01211288|DEVICE|Astra implants|Root form OsseoSpeed TX Astra Tech Implant System
224022876|NCT01600573|DRUG|pazopanib in combination with weekly topotecan|"* Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
224022877|NCT02521220|DIETARY_SUPPLEMENT|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
224022878|NCT02521220|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
224022879|NCT01981395|DRUG|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
224022880|NCT01981395|DRUG|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
224022881|NCT00482560|DRUG|Sucrose solution 30%1 ml|
224297755|NCT04887246|BIOLOGICAL|COVID-19 vaccines|COVID-19 vaccines available at Colombia
224022882|NCT00482560|BEHAVIORAL|Breastfeeding|
224297756|NCT00877357|BIOLOGICAL|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
224297757|NCT03746548|DEVICE|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
224297758|NCT03746548|DEVICE|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
224022883|NCT02800239|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
223405520|NCT01448473|OTHER|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
223405521|NCT01448473|OTHER|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
223405522|NCT01739231|BIOLOGICAL|ACE527|"3x10\^9 cfu ACE527 vaccine strain. Comprised of three genetically attenuated and engineered strains of E. coli, with antigen profiles covering a wide range of ETEC surface colonization factor antigens (CFA/I, CFA/II \[CS1, CS2, CS3\] and CFA/IV \[CS5, CS6\]) and also expressing LTB, the inactive subunit of LT (ETEC heat labile toxin). The constituent strains of ACE527 were:~* ACAM2025: a live, attenuated, CFA/I, LTB positive strain~* ACAM2022: a live, attenuated, CS5, CS6, LTB positive strain, and~* ACAM2027: a live, attenuated, CS1, CS2, CS3, LTB positive strain."
223405523|NCT01739231|BIOLOGICAL|dmLT|A derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (13). These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
223555932|NCT06221943|BEHAVIORAL|ASD Diagnosis|Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
223555933|NCT01760616|DRUG|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
224022884|NCT00073866|DRUG|celecoxib|
224022885|NCT00073866|DRUG|docetaxel|
224022886|NCT00073866|DRUG|irinotecan hydrochloride|
224022887|NCT01270971|DRUG|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
224022888|NCT01270971|DRUG|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
224022889|NCT01924520|DRUG|FK949E|Oral
224022890|NCT00519311|BEHAVIORAL|Health Intervention Package|CHAP and Ask Diary
224022891|NCT02539953|DEVICE|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
224022892|NCT05566496|DIAGNOSTIC_TEST|Brain MRI|All participants receive brain MRI evaluation and clinical evaluation of tic severity.
224022893|NCT01958970|DRUG|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
224022894|NCT01958970|DRUG|Placebo|"Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
224138795|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
224297759|NCT06309446|DEVICE|Zoralan Wound|Topical application of approximately 0.2 g per test field (approx. 1.2 cm in diameter each) once daily during a 12-day treatment period (11 treatments).
224297760|NCT03828448|DRUG|Ublituximab|\- anti-CD 20 monoclonal antibody administered via IV infusion
224297761|NCT03828448|DRUG|Umbralisib|\- PI3K Delta Inhibitor oral daily dose
224297762|NCT01565265|DRUG|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
224022895|NCT03802942|DIETARY_SUPPLEMENT|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
224022896|NCT02457208|DRUG|Isoniazid (H)|
224022897|NCT02457208|DRUG|Rifampicin (R)|
224138796|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
224138797|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
224297763|NCT01565265|DRUG|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
224138798|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
224138799|NCT03205917|BIOLOGICAL|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
224138800|NCT03002116|OTHER|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
224138801|NCT04498533|OTHER|forearm strap (counterforce brace)|
224138802|NCT04498533|OTHER|Kinesio tape application|
224138803|NCT03286088|DIAGNOSTIC_TEST|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
224138804|NCT03286088|DIAGNOSTIC_TEST|Cardiac Magnetics Resonance|imaging as standard practice
224138805|NCT03286088|DIAGNOSTIC_TEST|MitraClip|imaging as standard practice
224138806|NCT03233100|OTHER|FMT|fecal microbiota transplantation
224138807|NCT03036332|BEHAVIORAL|Aerobic interval training|Carried out 3 times per week for 16 weeks
224138808|NCT05459389|OTHER|targeted antibiotics therapy|targeted antibiotics therapy guided by resistance genotyping (n=24)
224138809|NCT01029002|DRUG|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
224138810|NCT01029002|OTHER|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
224138811|NCT03623139|BEHAVIORAL|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
224138812|NCT03623139|BEHAVIORAL|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
224138813|NCT03696264|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
224022898|NCT02457208|DRUG|Pyrazinamide (Z)|
224022899|NCT02457208|DRUG|Ethambutol (E)|
224022900|NCT00978653|DRUG|allopurinol|150 mg once a day
224022901|NCT01762033|DRUG|ASONEP|Intravenous infusion
224022902|NCT05008861|PROCEDURE|Capsulized Fecal Microbiota Transplant|Capsules contained washed fecal microbiota.
224022903|NCT05008861|DRUG|Anti-programmed cell death protein 1/programmed death-ligand 1 monoclonal antibody|Standard dose of one of anti-PD-1/PD-L1 mAbs administered as a 1 hour infusion every 3 weeks.
224022904|NCT05008861|DRUG|Platinum based chemotherapy|Standard dose of Platinum based Chemotherapy every 3 weeks.
224022905|NCT00711893|DEVICE|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
224022906|NCT04524325|OTHER|Trans men|We are studying the effects of testosterone taken by trans men on mechanisms of blood pressure control and comparing those results to cisgender women that have normal (ie lower) testosterone levels.
224022907|NCT03188757|OTHER|hyperglycaemic clamp|2h hyperglyceamic clamp
224022908|NCT01789736|DRUG|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
224022909|NCT01789736|DRUG|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
224022910|NCT01789736|DRUG|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
224022911|NCT03759860|COMBINATION_PRODUCT|R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy|Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
224022912|NCT02722720|PROCEDURE|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
224022913|NCT02722720|PROCEDURE|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
224022914|NCT02859363|GENETIC|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
224022915|NCT00690118|DRUG|pioglitazone|45 mg/day, 18 months
224022916|NCT00690118|DRUG|placebo|once daily, 18 months
224022917|NCT01751074|DRUG|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
224022918|NCT01751074|DRUG|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
224022919|NCT02411357|BEHAVIORAL|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
224138814|NCT00702052|DRUG|Everolimus|Everolimus tablets
223405524|NCT01739231|BIOLOGICAL|CeraVacx placebo|CeraVacx® is used to neutralize gastric acidity upon ingestion of vaccine. It was also used as the placebo in this study. CeraVacx® was prepared from the commercial product (Cera Products, Inc.); 9.5 grams were added to sterile water for each dose and mixed. Each dose contained 7 grams of rice syrup, 2 grams of sodium bicarbonate, and 0.5 grams of trisodium citrate.
223405525|NCT01739231|BIOLOGICAL|H10407 challenge strain|Approximately 2 x 10\^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
223405526|NCT02649491|OTHER|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
224022920|NCT02411357|BEHAVIORAL|WHO contraception protocol|World Health Organization's contraception protocol
223405527|NCT03656068|DRUG|Nitazoxanide 500mg BID|Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
223405528|NCT02040103|DEVICE|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
223405529|NCT05326529|OTHER|Hospital Based Cardiac Rehabilitation Exercise Classes|Participants will attend 8 Hospital based CR exercise sessions. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
223405530|NCT05326529|OTHER|Web-based Cardiac Rehabilitation Exercise Sessions|Participants will complete 8 weeks of Web-based CR exercise sessions using the MyHeart app. QOL and Hospital anxiety and Depression scores through questionnaires and incremental Shuttle Walk tests will be carried out pre and post intervention.
224022921|NCT02411357|BEHAVIORAL|Incentives|Financial incentives contingent on follow-up visit attendance
224138815|NCT01577160|DRUG|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
224138816|NCT02296996|DRUG|Dabrafenib + Trametinib|
224138817|NCT00475462|DRUG|metoprolol|
223737345|NCT05850572|OTHER|Placebo|Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antidepressant treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. New SSRI antidepressants (fluoxetine, citalopram, escitalopram, sertraline, paroxetine, and fluvoxamine) recommended by current treatment guidelines can be used during this period, and the effective therapeutic dose of the drugs can be added within 1 week.
224022922|NCT04237766|OTHER|Experimental group|"The intervention will consist of the visualization of the movement through the Mirror Therapy application, or through the reproduction of an immersive 360º video emitted on a mobile device and visualized with virtual reality glasses.~The movements observed with both technologies will be the same. The knee extension and dorsal ankle flexion movements (quadriceps and triceps sural), together with the elbow flexion (elbow flexors) will be the movements to be performed, based on their functional need (ambulation and feeding, respectively)."
224132626|NCT02791971|BEHAVIORAL|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~* Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~* Printed materials for recipients to keep and/or share with friends.~* Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~* Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
224132627|NCT02791971|BEHAVIORAL|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
224132628|NCT02638896|DRUG|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
224132629|NCT02638896|DRUG|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
224132630|NCT02638896|DRUG|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
224022923|NCT01588496|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224022924|NCT01588496|DRUG|Placebo|Administered by subcutaneous injection
224022925|NCT00549133|DRUG|Irbesartan|
224022926|NCT06115447|PROCEDURE|lung suturing with polyglactin|lung suturing with polyglactin
224132631|NCT02638896|DRUG|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
224132632|NCT05123898|PROCEDURE|Soft tissue augmentation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Ostem dental implant (Osstem Implant Co., Ltd.)~3. Modeling of sterile collagen matrix according to the shape of the recipient bed~4. Fixation of the collagen matrix to the vestibular flap~5. Suturing the wound tightly"
224132633|NCT06018935|OTHER|No intervention|No intervention
224132634|NCT03196193|PROCEDURE|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
224132635|NCT03196193|DEVICE|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
224132636|NCT03196193|DEVICE|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
224132637|NCT03925961|OTHER|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
224132638|NCT02709083|DRUG|Dasatinib|Given orally
223555934|NCT00475085|DRUG|aprepitant|Given orally or IV
224132639|NCT02709083|DRUG|Imatinib Mesylate|Given orally
224132640|NCT02709083|DRUG|Nilotinib|Given orally
224132641|NCT05551598|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 12 weeks (Q12W)
224132642|NCT02029352|DRUG|Sinecatechins 10%|
224132643|NCT02029352|DRUG|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
224138818|NCT00475462|DRUG|conventional treatment|
224138819|NCT03000816|RADIATION|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
223555935|NCT00475085|DRUG|dexamethasone|Given orally or IV
224022927|NCT06115447|PROCEDURE|ung suturing with polypropylene|ung suturing with polypropylene
224022928|NCT03126045|DEVICE|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
224138820|NCT00101192|BIOLOGICAL|cetuximab|
224138821|NCT00101192|DRUG|cisplatin|
223555936|NCT00475085|DRUG|granisetron hydrochloride|Given orally or IV
223555937|NCT00475085|DRUG|palonosetron hydrochloride|Given orally or IV
223555938|NCT00475085|DRUG|prochlorperazine|Given orally or IV
223555939|NCT00475085|DRUG|placebo|Given orally
223555940|NCT03297684|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
223555941|NCT06625138|DEVICE|Latex Band|Hemorrhoid banding with latex band
223555942|NCT06625138|DEVICE|Non-Latex Band|Hemorrhoid banding with non-latex bands
223405531|NCT02590549|PROCEDURE|Corneal Collagen Crosslinking|"Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,"
223405532|NCT02590549|DEVICE|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
223405533|NCT01534442|DRUG|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
223405534|NCT01534442|DRUG|Placebo|
223555943|NCT06171139|OTHER|Counseling Tool|Non-therapeutic educational intervention
223555944|NCT06171139|OTHER|Questionnaires|Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
223555945|NCT06688006|OTHER|climate change short animation film|For the short animated film, a scenario will be created that describes climate change, risk factors that threaten human health as a result of climate change, adverse health effects of climate change, adverse effects on maternal and foetal health, precautions to be taken to protect against and adapt to the adverse effects of climate change. In the short animation film, visual materials will be created that show the adverse effects of climate change by using developing technology. The created scenario will be prepared as a two-dimensional (2D) animation film with the support of Selçuk University SERATEM (Selçuk University Radio and Television Application Center). All lines, colours, decorations and characters used in the creation phase of the short animation film will be determined by the researchers. Once the drawing and animation phases are complete, the voice-over actors will be selected after a further review. The short animated film should be about 2-3 minutes long.
223555946|NCT02483091|BEHAVIORAL|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
223555947|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
224022929|NCT03126045|DEVICE|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the CHU of Saint-Etienne. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
224022930|NCT04470466|DEVICE|short pulse and Q-switched ND-YAG laser with topical carbon|application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face
224022931|NCT04470466|DEVICE|fractional CO2 laser|single pass of fractional CO2 laser on the other side of the face
223405535|NCT01379768|DEVICE|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
223555948|NCT01059864|DRUG|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
223555949|NCT01059864|DRUG|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
224022932|NCT03433053|BEHAVIORAL|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
224022933|NCT03433053|BEHAVIORAL|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
224022934|NCT01551212|DRUG|Everolimus|tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
224022935|NCT01551212|DRUG|Tacrolimus|capsule containing 0.5, 1.0, or 5.0mg
224022936|NCT01551212|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
224022937|NCT03601533|DRUG|Phenol|1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
224022938|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
224022939|NCT01436188|PROCEDURE|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
224022940|NCT01436188|PROCEDURE|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
224022941|NCT01436188|PROCEDURE|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
224138822|NCT02421367|BIOLOGICAL|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
223405536|NCT01379768|DEVICE|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
223405537|NCT01379768|DEVICE|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
223405538|NCT01513720|DRUG|Lamotrigine|Lamotrigine Tablets 200 mg
223405539|NCT01513720|DRUG|Lamictal®|Lamictal® 200 mg Tablets
223405540|NCT03748173|COMBINATION_PRODUCT|Aerosolized Infasurf|Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
223405541|NCT00781040|OTHER|Severe sepsis vs. non-severe sepsis|To compare these two groups
223405542|NCT03647618|OTHER|Ultrasound|Ultrasound-guided regional anaesthesia
223555950|NCT01059864|DRUG|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
223555951|NCT06873633|DRUG|Remdesivir|Remdesivir (RDV) has shown potent antiviral activity against RSV A in an animal model. Remdesivir has been also shown to be a safe treatment option in pediatric patients hospitalized with COVID-19. Based on previous clinical evidence and preclinical data, to address the unmet medical need for safe and effective RSV therapy, this study is being conducted to investigate remdesivir in infants and children (aged 0 days to \<2 years) as a potential treatment for RSV infection.
224022942|NCT01436188|PROCEDURE|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
224297764|NCT05506722|DEVICE|Testes shocker|It is a device that give electric shocks (up to 5 milli Amperes) and it is designed to contain both the testes within it.
224297765|NCT01520974|OTHER|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
224297766|NCT01520974|OTHER|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
223555952|NCT06440252|DRUG|Grape Seed Extract|One daily dose of 1 capsule containing 600mg grape seed extract
223555953|NCT06440252|DRUG|Maltodextrin|One daily dose of 1 capsule
223555954|NCT06712706|PROCEDURE|Feeding jejunostomy placement|Placement of feeding jejunostomy at staging laparoscopy
223555955|NCT06712706|PROCEDURE|Feeding jejunostomy placement at esophagectomy|Placement of feeding jejunostomy at esophagectomy
223555956|NCT05313607|OTHER|Designed physical therapy|Attention is given to improve motor function, conducted for 30 minutes
223555957|NCT05313607|OTHER|Occupational therapy|included exercises facilitating hand skills, conducted for 30 minutes
223555958|NCT05313607|OTHER|Conventional Therapy|aimed to improve the affected upper extremity function, conducted for 30 minutes
223555959|NCT05313607|OTHER|Plyometric training|basically focuses on upper extremity strength training conducted for 30 minutes
223555960|NCT04912089|BEHAVIORAL|COGENT|COGENT is based on a working memory capacity task, which requires individuals to memorize stimuli while simultaneously completing a secondary puzzle task.
223555961|NCT06878001|DIETARY_SUPPLEMENT|Carotenoids|CaroRite capsule containing carotenoids with sunflower oil. 1 capsule to be taken each day for 12 weeks.
223555962|NCT06878001|OTHER|Placebo|Placebo capsule containing sunflower oil. 1 capsule to be taken each day for 12 weeks.
223555963|NCT07070765|DRUG|Sodium-glucose transport-2 (SGLT-2) inhibitors|Dapagliflozin 10mg in addition to standard clinical care
223555964|NCT07070765|OTHER|Standard medical treatment|Standard clinical care
223555965|NCT07062549|DRUG|111In-XYIMSR-01|Unite Dose: 10.5±1 mCi of 111In-XYIMSR-01 Route of administration: Intravenous catheter placed in an antecubital vein or an equivalent venous access
223555966|NCT06782932|DRUG|AGEN2373|"1. Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be tested in Phase I to determine the dose to be used in Phase II. AGEN2373 will be administered as a 60 minute IV infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV"
223555967|NCT06782932|DRUG|Balstilimab|"1. 450 mg will be administered as a 30 minute IV Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV"
223555968|NCT06782932|DRUG|Cyclophosphamide|"1. 200 mg/m2 will be administered as a 30 minute IV infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 200 mg/m2 IV"
223555969|NCT06782932|DRUG|GVAX|"1. Vaccine (5 × 108 cells) will be administered on Day 2 of each cycle for a total of 6 cycles of treatment. Six intradermal injections will be given in the upper thighs and non-dominant arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: GVAX"
224297767|NCT06126965|DRUG|KX-826-（5%） BID|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized active drug would be administered to the scalp once in the morning and once in the evening.
224297768|NCT06126965|OTHER|Placebo|Dosage and administration: Topical application, 7 sprays (approximately 1 ml)/time, in the target area of the scalp, starting from the center of the affected area and massaging with hands until absorption. It should be used when the hair and scalp are completely dry. Wash hands after use. The randomized matching placebo would be administered to the scalp once in the morning and once in the evening.
224297769|NCT01145131|OTHER|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
224297770|NCT02037165|DRUG|Placebo to BI 1026706|Placebo tablet
224297771|NCT02037165|DRUG|Pregabalin|Pregabalin hard capsule
224297772|NCT02037165|DRUG|BI 1026706|BI 1026706 oral solution
224297773|NCT02037165|DRUG|Celecoxib|Celecoxib hard capsule
224297774|NCT00005765|DRUG|nicotine|
224297775|NCT00005765|DRUG|alcohol|
224022943|NCT04654065|DRUG|IN-C004|One time dose of IN-C004 taken orally.
224022944|NCT00705523|DRUG|varenicline|1.0 mg BID for 12 weeks
224022945|NCT00705523|DRUG|placebo|BID 12 weeks
224022946|NCT04250441|DEVICE|Focused Transcranial Ultrasound|The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
224022947|NCT02464033|DRUG|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
224022948|NCT02464033|DRUG|Vitamin D|
224297776|NCT03591939|DIAGNOSTIC_TEST|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
224297777|NCT00532935|DRUG|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an \~32 wk treatment period
223555970|NCT06782932|DRUG|AGEN2373 (RP2D)|"1. Drug: Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be administered as a 60 minute IV. Infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV"
223555971|NCT06782932|DRUG|Balstilimab|"1. 450 mg will be administered as a 30 minute IV. Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV"
223555972|NCT06782932|DRUG|mKRASvax|"1. mKRASvax will be administered on Day 1 of each cycle and on Day 8 of Cycle 1 only. mKRASvax is given as 5 subcutaneous injections administered in the upper thighs and arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
223555973|NCT05314179|BEHAVIORAL|Doula - Patient engagement|"Ubuntu ambassador/Doula and Patient will decide on details of engagement. The components to be included will be: 1) emotional support, 2) practical assistance, 3) family support, and/or 4) legacy building projects as per study protocols.~The nature and type of visits will be determined by the patient and doula."
223555974|NCT01477710|PROCEDURE|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
223555975|NCT01477710|PROCEDURE|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
224022949|NCT02464033|DRUG|Etanercept|
224022950|NCT03178929|DRUG|S-Adenosyl Methionine|2000mg, po
224022951|NCT03311542|BIOLOGICAL|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
224022952|NCT05225350|BEHAVIORAL|Dietary Intervention|"See previous text~Dietary intervention consisiting och each family recieving foodpackages for 5 dinner meals during three months."
223555976|NCT01477710|PROCEDURE|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
223555977|NCT02840435|BEHAVIORAL|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
223555978|NCT02840435|BEHAVIORAL|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
223555979|NCT02423525|DRUG|Afatinib|
224022953|NCT00568945|DRUG|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
224022954|NCT03616925|BIOLOGICAL|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
224022955|NCT03616925|PROCEDURE|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
224022956|NCT03218241|BIOLOGICAL|PRT064445|Intravenous
224022957|NCT03218241|DRUG|Placebo|Intravenous to mimic PRT064445
224022958|NCT05685589|BEHAVIORAL|MINDful TIME|The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
224022959|NCT01013285|BIOLOGICAL|bevacizumab|
224022960|NCT01013285|DRUG|temozolomide|
224022961|NCT01013285|RADIATION|external beam radiation therapy|
223405543|NCT03773406|DEVICE|Offline tDCS-before therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
223405544|NCT03773406|DEVICE|Sham tDCS|Stimulation will be given for a total 30 seconds (including ramp-up and ramp-down of current) and then the tDCS device will be turned off. The brief stimulation will produce tDCS-induced sensation so that participants will not be aware when the tDCS was turned off .We will use standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
223405545|NCT03773406|DEVICE|Offline tDCS-after therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
223405546|NCT03773406|DEVICE|Online tDCS|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
223555980|NCT03800524|DRUG|Tauroursodeoxycholic Acid|"* Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
223555981|NCT03800524|DRUG|Placebo|"* Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months"
224022962|NCT03667976|BEHAVIORAL|SATHI|see above
224022963|NCT01648335|DEVICE|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
224022964|NCT01648335|DEVICE|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
224022965|NCT06185647|OTHER|No intervention. Observational retrospective study|No intervention.
224022966|NCT03975166|DRUG|Test Product|2 inhalations in one study period
224022967|NCT03975166|DRUG|Reference Product|2 inhalations in one study period
224022968|NCT04547283|OTHER|Usual Care|No clinical team recommendation, patients will remain in their natural choice of position
224022969|NCT04547283|OTHER|APPS|Clinical team guidance on prone positioning of patients
224022970|NCT02518126|OTHER|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
224022971|NCT01445587|DRUG|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
224022972|NCT01445587|DRUG|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
224022973|NCT01445587|DRUG|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
224022974|NCT01445587|DRUG|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
224022975|NCT03814772|PROCEDURE|Liver transplant|blood transfusion
224022976|NCT03402490|BEHAVIORAL|Motivational interviewing|
224138823|NCT03562585|DIAGNOSTIC_TEST|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
224138824|NCT05528497|OTHER|VR+|Use of a virtual reality helmet during ovocyte retrieval
224138825|NCT00672529|DIETARY_SUPPLEMENT|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
223737346|NCT05993260|BEHAVIORAL|Behavioural science-informed text messages|Behaviourally-informed content in vaccination eligibility reminder text messages
223737347|NCT05993260|BEHAVIORAL|Control|Control vaccination eligibility reminder text message
223737348|NCT04827927|PROCEDURE|Procedure: INTELLiVENT-ASV|With INTELLiVENT-ASV, the patient's conditions, 'ARDS', 'Chronic Hypercapnia' or 'Traumatic Brain Injury' can be chosen, if applicable. The controllers for minute volume, PEEP and FiO2 are all activated, and the target shifts for etCO2 and SpO2 are adjusted, if necessary.
223405547|NCT05221151|DRUG|Melatonin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
223405548|NCT05221151|DRUG|Pregabalin|In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
223737349|NCT04827927|PROCEDURE|Procedure: Conventional ventilation|With conventional ventilation, the same etCO2 and SpO2 levels are targeted as with INTELLiVENT-ASV, but here the caregiver is fully responsible for choosing the settings.
223737350|NCT05893433|DEVICE|Bedside cycling|"participants receive daily cycling once the patient is relatively stable by weaning off the ventilator and off the require inotropic support and continued to the discharge from the hospital.~Duration progression if the following conditions are reached:~1. Initially increase the duration by up to15 min of low exercise time and then increase the intensity after the patient can complete 15- 20 min.~2. Complete 15min with a medially stable condition gradually until reaching 20 minutes besides the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment."
223405549|NCT05221151|DRUG|Ondansetron 4 MG|before spinal anaesthesia
223405550|NCT04527289|DRUG|Amantadine (100mg) as add on therapy.|Amantadine (100mg) as add on therapy to the management regimen of traumatic brain injury - 100mg twice daily Oral or feeding tube
223405551|NCT04527289|DRUG|Placebo|patients will be managed with placebo as add on to the standard regimen.
223555982|NCT04362488|PROCEDURE|Preoperative evaluation|"Preoperative evaluation using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
223555983|NCT04362488|PROCEDURE|Postoperative evaluation|"Postoperative evaluation at 4 months of follow up after surgery using differents clinical evaluation tests, questionnaires, and instrument:~* Delos system (computerized oscillating platform)~* Foot and Ankle Ability Measure (FAAM), l'American Orthopaedic Foot and Ankle Score (AOFAs), SF12 questionnaires~* modified Star Excursional Balance Test (mSEBT) and Short Physical Performance Battery (SPPB)"
223555984|NCT04964648|DEVICE|shear wave elastography|Shear wave elastography (SW-EG), a form of ultrasound elastography used in transabdominal ultrasonography, can measure tissue elasticity by generating shear waves inside the organ using the acoustic radiation force impulse (ARFI) The ultrasound machine monitors shear wave propagation and measures the velocity. The shear wave velocity, displayed in kilopascals (kPa) or meters per second
223555985|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
223737351|NCT05893433|OTHER|control|the routine physical therapy protocol of breathing exercises, coughing techniques, chest wall vibrations, and mobilization is common during the first postoperative days, The two most frequently used breathing techniques were deep breathing exercises and incentive spirometry and the medical treatment.
223737352|NCT01490476|DRUG|RAD001|10 mg per os / day or 05mg per os / day with 12 month
223737353|NCT02814513|DEVICE|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
223737354|NCT02814513|DEVICE|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
224132644|NCT02568345|DRUG|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
223737355|NCT02814513|DEVICE|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
223737356|NCT02814513|DEVICE|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
223737357|NCT02814513|DEVICE|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
223737358|NCT00001889|PROCEDURE|Myocardial contrast echocardiography|
224022977|NCT01453829|PROCEDURE|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
224022978|NCT02019303|PROCEDURE|FNA and Core biopsy|Both procedures will be performed on the same lymph node
224132645|NCT04262401|BEHAVIORAL|Standard health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
224132646|NCT04262401|BEHAVIORAL|Habit-focused health coaching|12 weekly sessions of standard health coaching followed by 4 monthly sessions
223405552|NCT00168363|DRUG|brimonidine|
223405553|NCT00708552|DRUG|SB-742457|investigational drug
224132647|NCT02998424|DRUG|Propofol|Continuous infusion
224132648|NCT02998424|DEVICE|Pupillary diameter measurement|Instantaneous measure
223405554|NCT00708552|DRUG|Donepezil|comparator
223405555|NCT00708552|DRUG|Placebo|comparator
223555986|NCT01422785|DRUG|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
223405556|NCT01257113|OTHER|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
223405557|NCT01257113|OTHER|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
223405558|NCT04163133|PROCEDURE|two days later trigger than regular timing|During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
223405559|NCT02418390|PROCEDURE|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
223405560|NCT06575504|DIAGNOSTIC_TEST|Ultrasonographical examination|Study size and Doppler / blood flow / of the suprarenal gland
223405561|NCT00020072|OTHER|laboratory biomarker analysis|
223405562|NCT04930744|DRUG|Isoniazid|Isoniazid, dose prescribed by participant's physician, will be taken by mouth daily. Isoniazid, is in a combination pill pack with the other standard ATT medications.
224022979|NCT03107234|OTHER|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
223405563|NCT04930744|DRUG|Rifampicin|Rifampicin, dose prescribed by participant's physician, will be taken by mouth daily. Rifampicin is in a combination pill pack with the other standard ATT medications.
223405564|NCT04930744|DRUG|Ethambutol|Ethambutol, dose prescribed by participant's physician, will be taken by mouth daily. Ethambutol is in a combination pill pack with the other standard ATT medications.
224022980|NCT05003427|DRUG|68Ga-FAPI-04|68Ga-FAPI-04 were injected into the patients before the PET/CT scans
223405565|NCT04930744|DRUG|Pyrazinamide|Pyrazinamide, dose prescribed by participant's physician, will be taken by mouth daily. Pyrazinamide is in a combination pill pack with the other standard ATT medications.
223405566|NCT04930744|DRUG|Metformin hydrochoride|Metformin hydrochloride 500 mg tablet once daily starting one week after the initiation of TB treatment, then increasing to study twice daily through study week-12 (11 weeks total metformin treatment).
224022981|NCT03358966|OTHER|Doubly-labelled water technique|
224022982|NCT03358966|OTHER|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
224022983|NCT04262752|DEVICE|intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device|"The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period."
224022984|NCT02908919|PROCEDURE|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
224132649|NCT00061919|DRUG|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
224132650|NCT00061919|DRUG|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
224132651|NCT00852189|DRUG|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
224132652|NCT00852189|DRUG|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
223405567|NCT04977895|DIAGNOSTIC_TEST|Minimal residual disease (MRD) monitoring|Minimal residual disease (MRD) assay using IgH-V(D)J NGS and FCM
223405568|NCT01323517|DRUG|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
223405569|NCT03312036|DEVICE|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
223737359|NCT00001889|PROCEDURE|Stress echocardiography with dobutamine|
224132653|NCT00852189|DRUG|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
223737360|NCT00376350|PROCEDURE|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
223737361|NCT00376350|PROCEDURE|Light Massage|light pressure massage of the low back.
224022985|NCT05709301|DRUG|Donepezil Hydrochloride|Donepezil 10mg once daily
224022986|NCT05709301|DRUG|Placebo|Matching placebo
224022987|NCT00112424|PROCEDURE|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
224022988|NCT00112424|PROCEDURE|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
224022989|NCT03347890|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo|Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
223555987|NCT01129765|DEVICE|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
223555988|NCT05081518|DRUG|Lu AG06466|Lu AG06466 - capsule
223555989|NCT05081518|DRUG|Placebo|Placebo - capsule
223555990|NCT00962741|DRUG|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
224022990|NCT03324451|BEHAVIORAL|TTM Intervention for Insulin Initiation|The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
224022991|NCT03324451|BEHAVIORAL|Usual care|Regular patient education on insulin injection at the control arm hospital.
224022992|NCT05777096|DIAGNOSTIC_TEST|Standardised Nordic questionnaires|participants will complete the SNQ online. Estimated time of participation per person: 15 minutes to fill in the questionnaires
224022993|NCT05023681|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
224022994|NCT05023681|DRUG|normal saline|Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
224132654|NCT03498417|DIAGNOSTIC_TEST|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
224132655|NCT04018196|OTHER|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
223555991|NCT01050920|BIOLOGICAL|Blood collection|
223555992|NCT03093207|PROCEDURE|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
223555993|NCT03093207|OTHER|Placebo|Placebo pills over a period of 180 days
223555994|NCT03093207|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
223555995|NCT03093207|DRUG|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
224022995|NCT02531347|BEHAVIORAL|Telemedical home blood pressure measurements|
224132656|NCT04018196|OTHER|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
224297778|NCT00532935|DRUG|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an \~32-wk treatment period.
224297779|NCT04977063|DEVICE|Atmo gas capsule|The Atmo Gas Capsule measures the capsules location and motility/transit times through gas sensing capabilities
223555996|NCT03397433|OTHER|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
223555997|NCT01326156|DEVICE|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
223555998|NCT05761106|OTHER|Oculomotor Therapy|It will consist exercise of a convergence technique and an accommodative technique.
223555999|NCT05761106|OTHER|Therapy for Temporomandibular Disorder|It will consist exercise of a ATM and cervical spine.
223556000|NCT05658159|DIAGNOSTIC_TEST|Vitamin D|Finger stick capillary blood sampling using test from ZRT Laboratories, Beaverton, OR
223556001|NCT05658159|DIAGNOSTIC_TEST|DXA scan|10 minute scan using scanner by GE Lunar, Madison, WI
223556002|NCT05658159|OTHER|Nutrition analysis|Analysis of 24-h recalls will be conducted by a registered dietician using Nutritionist Pro software by Axxya Systems, Redmond, WA
223556003|NCT03242564|DEVICE|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
223556004|NCT01807559|DEVICE|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
224022996|NCT02531347|BEHAVIORAL|Conventional blood pressure monitoring|
224022997|NCT02463110|DRUG|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
224022998|NCT02463110|DRUG|No treatment|
224022999|NCT02463110|DRUG|Placebo|
224023000|NCT02747199|DEVICE|SYNERGY stent|
224023001|NCT02747199|DEVICE|BVS ABSORB scaffold|
224023002|NCT04466995|DEVICE|manometer|cuff pressure to be measured with manometer
224023003|NCT02112708|OTHER|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
224023004|NCT02112708|OTHER|Control Group usual care|In the control group the dysthymia is treated as usual with the conventional treatment.
224132657|NCT04018196|OTHER|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
224297780|NCT04977063|DEVICE|SmartPill|The SmartPill measures the capsules location and motility/transit times through pH sensing
223737362|NCT00376350|PROCEDURE|Pulsed Ultrasound|5 minutes pulsed ultrasound
223737363|NCT01570374|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
224023005|NCT05780892|BEHAVIORAL|Emotional Wellbeing|Participants in this intervention will learn cognitive behavioral therapy tools to identify unhelpful beliefs and thought patterns, increase motivation through SMART goal making, and increase relaxation and stress management techniques through deep breathing, progressive muscle relaxation and pleasant activity scheduling. Additionally, participants will learn acceptance and commitment therapy tools to increase cognitive flexibility and resilience through acceptance and diffusion work, being present through contact with present moment and self as context and doing what matters through committed actions and value identification.
224023006|NCT05780892|BEHAVIORAL|EHR Skills Optimization|Participants in this intervention will learn how to better utilize the EHR by gaining knowledge and skills in the EHR. Session topics include, but are not limited to, understanding current usage patterns and behaviors in the EHR, optimization of the table of contents for easier chart navigation, integration of specialty-focused workflows with current EHR documentation and chart review tools, and recommendations to be more efficient and reduce amount of time spent in the EHR.
224132658|NCT04018196|OTHER|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
224297781|NCT05391334|DEVICE|Qumea|Contactless motion sensor (Qumea®) for bed-exit detection in combination with Qumea fall detection.
223405570|NCT03154541|DRUG|Synrinse|"Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse."
223405571|NCT04453319|PROCEDURE|Femoral Wound Closure and dressing|Femoral Wound Closure and dressing
223405572|NCT06250621|PROCEDURE|Implant placement|"Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing."
223405573|NCT04181021|BEHAVIORAL|Values Clarification and Attitudes Transformation (VCAT) Workshop|VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
223405574|NCT01985243|BEHAVIORAL|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
224023007|NCT05780892|BEHAVIORAL|Performance Improvement|This intervention focuses on improving participants perception of Keck Medicine as a positive workplace environment by supporting participants in gaining basic performance improvement knowledge and skills through didactic training, group discussions based on sociocultural learning theory, and hands on practice leading a performance improvement project. Sessions will review performance improvement concepts such as Lean wastes, systems thinking, change management and sustainability. Participants in this intervention will then identify a project area of focus that they want to improve and develop a project charter. Once a project area has been identified, participants will be put into breakout rooms to discuss successes and challenges as well as receive feedback on their project from peers.
224023008|NCT05780892|BEHAVIORAL|control|Participants randomly assigned to the control condition will continue as usual care and will not complete any intervention during the duration of the study.
224023009|NCT04054518|DRUG|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
224132659|NCT01697267|BIOLOGICAL|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
224297782|NCT00926016|DRUG|Pioglitazone (Actos)|pioglitazone 45 mg a day
223405575|NCT01985243|BEHAVIORAL|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings \& business literacy program for young female adolescents to encourage them to stay in school.
223405576|NCT00455403|DRUG|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
223405577|NCT00455403|DRUG|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
223405578|NCT04162743|DRUG|Trazodone|take trazodone 100mg before polysomnography
223405579|NCT04162743|DRUG|Placebo oral tablet|take placebo oral tablet before polysomnography
223405580|NCT01408290|BIOLOGICAL|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
223405581|NCT01408290|BIOLOGICAL|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
223405582|NCT01408290|BIOLOGICAL|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
223556005|NCT01630928|PROCEDURE|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
224023010|NCT05563285|BEHAVIORAL|Exercise and Mindfulness-Based Intervention|"1.Exercise Intervention~1st-2nd week: 15 min for Brisk walking. Intensity: HRmax (60%-65%); CR10 (5-6). 3rd-4th week: 20 min for Brisk walking. Intensity:HRmax (65%-70%); CR10 (6-7). 5th-6th week: 25 min for Brisk walking. BW: Intensity: HRmax(70%-75%); CR10 (6-7). 7th -8th week:30 min for Brisk walking.~Exercise Intervention basic content:~(1) Gradually increase the walking speed; (2) Slowly reduce the speed; (3) Rest for 5 min.~2\. Mindfulness-Based Intervention~1st-2nd week: 30 min for mindfulness training. 3rd-4th week: 35 min for mindfulness training. 5th-6th week: 40 min for mindfulness training. 7th-8th week: 45 min for mindfulness training.~Mindfulness-Based Intervention basic content:~(1) Yoga; (2) Mindful breathing; (3) Mindfulness meditation; (4) Body scan; (5) Mindfulness awareness; (6) RAIN technique; (7) Mindful Stretching; (8) Mindful walking; (9) Mindful running"
224023011|NCT05563285|BEHAVIORAL|Control Group|The control group maintained their classes as usual, usual physical education sessions, and usual daily life.
224297783|NCT02379286|OTHER|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
224297784|NCT06222541|BEHAVIORAL|"Nudges in Web-Based Supermarket"|"While shopping in the web-based supermarket, participants assigned to the nudge arm will see retail nudges to discourage sugary drink purchases and promote healthier substitutes."
224297785|NCT04750135|DRUG|metformin 500 mg TID Oral Tablet|biguanides derivatives
224297786|NCT04750135|DRUG|Placebo|Placebo
223405583|NCT01408290|BIOLOGICAL|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
223556006|NCT00760942|DIETARY_SUPPLEMENT|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
223556007|NCT00760942|DIETARY_SUPPLEMENT|Similac human milk fortifier|Powdered human milk fortifier.
223556008|NCT01814878|DRUG|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl \[75 mg\]/acetaminophen \[650 mg\]) will be administered at 0, 12, 24 and 36 hours
224023012|NCT00386269|DRUG|Codeine Phosphate Analgesia|
224023013|NCT03182452|OTHER|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
224023014|NCT03196895|BEHAVIORAL|Weight reduction training|6 one-hour sessions of conventional weight reduction training
224132660|NCT01697267|DRUG|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
224132661|NCT03677310|DRUG|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
224132662|NCT03677310|DRUG|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
224132663|NCT02909842|DIETARY_SUPPLEMENT|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
224132664|NCT02909842|DIETARY_SUPPLEMENT|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
224132665|NCT02909842|BIOLOGICAL|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
224297787|NCT05290324|DRUG|Midazolam|Midazolam infusion will be given after the surgery as 0.25 mg/kg/min.
223405584|NCT03015337|BEHAVIORAL|New physical education instructions|
223405585|NCT03513237|PROCEDURE|Cervical dilation|manual dilatation of the cervix using surgeon's finger.
223405586|NCT02391688|DRUG|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
223405587|NCT02391688|DRUG|Bupropion|
224023015|NCT03196895|BEHAVIORAL|PPG training|Four 90-minute sessions of glycemic load and exercise training
224023016|NCT03196895|BEHAVIORAL|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
224023017|NCT03196895|BEHAVIORAL|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
224023018|NCT04310033|OTHER|Questionnaires|Quality of life questionary: 36-Item Short Form Survey Instrument (36-SF) at 3 and 6 months from inclusion By phone
224023019|NCT00502086|DIETARY_SUPPLEMENT|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
224023020|NCT00502086|OTHER|Placebo|Placebo three sachets daily during 96 weeks
224023021|NCT03782220|OTHER|Kinesio tape|The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.
223405588|NCT02391688|DRUG|Fexofenadine|
223405589|NCT00350207|DRUG|Tiotropium bromide|
223405590|NCT00350207|DRUG|Placebo|
223405591|NCT00350207|DRUG|Salmeterol xinafoate|
223556009|NCT01814878|DRUG|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl \[37.5 mg\]/acetaminophen \[325 mg\]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
223737364|NCT04225728|DRUG|Iron Sucrose IV|"Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14."
224023022|NCT03782220|OTHER|Shame tape|For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
224297788|NCT05980286|BEHAVIORAL|Piano Improvisation|Piano Improvisation taught by a professional instructor for 16 weeks.
224297789|NCT05980286|BEHAVIORAL|Music Listening|Music Listening facilitated by a professional instructor for 16 weeks.
223737365|NCT04225728|DRUG|Ferric polymaltose hydroxide complex IM|Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
223737366|NCT04225728|OTHER|Saline solution|100 ml i.v. of normal saline administered at Day 0 and at day 14.
223737367|NCT06146426|DIETARY_SUPPLEMENT|Early diet resumption|Resuming oral diet at pace started from 2 hours after extubation from ventilator.
223737368|NCT02202642|PROCEDURE|collagenase|Cultured limbal stem cells transplantation
223737369|NCT04048824|BEHAVIORAL|Inhibitory Learning-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
223737370|NCT04048824|BEHAVIORAL|Habituation-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
223737371|NCT06067841|DRUG|BMS-986460|Specified dose on specified days.
223737372|NCT04340180|DRUG|Standard of Care (SOC) gadolinium Breast MRI|Standard of Care (SOC) gadolinium Breast MRI
223737373|NCT04340180|DRUG|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.|reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
223737374|NCT03918590|DRUG|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
223737375|NCT03918590|DRUG|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
223737376|NCT03918590|OTHER|patching|no drug/ patching
223737377|NCT05769543|PROCEDURE|WATSU application|20-minute application of WATSU
223737378|NCT05769543|OTHER|Lecture|20-minute lecture on WATSU technique
223737379|NCT06234007|DRUG|Fruquintinib, Adebrelimab, Oxaliplatin, Capecitabine|"Safety run-in phase: Fruquintinib 4mg/d, oral, once daily, continuous treatment for 2 weeks, 1 week off, q3w, 6 cycles; If the number of patients experiencing dose-limiting toxicity (DLT) was ≤1, the study would continue at that dose level. If the number of patients with DLTs was \>1, the dose of fruquintinib was decreased to 3mg/d, qd po, d1-14, q3w, and the dose expansion phase was continued；Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;~Dose expansion phase: Fruquintinib RP2D, qd po, d1-14, q3w, 6 cycles; Adebrelimab 1200mg, d1, IV infusion, q3W, 6 cycles; Capecitabine 1000 mg/m2, twice a day, po, d1-14, followed by 7 days of rest, q3W, 6 cycles; Oxaliplatin 130 mg/m2, d1, q3W, 6 cycles;"
223405592|NCT03342378|RADIATION|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.
223405593|NCT03342378|DIAGNOSTIC_TEST|PET-MRI|All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
223405594|NCT01492829|BEHAVIORAL|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
223737380|NCT00508625|DRUG|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
223737381|NCT00508625|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
223737382|NCT00508625|DRUG|Carboplatin|Standard platinum based chemotherapy
223737383|NCT00508625|DRUG|Paclitaxel|Standard taxane chemotherapy
223737384|NCT01744990|OTHER|Oral food challenges to multiple nuts|
223737385|NCT02614430|OTHER|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
223737386|NCT00383149|DRUG|Ixabepilone|Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
224023023|NCT05379582|OTHER|Implement nutrition therapy according a procedure assisted by gastrointestinal ultrasound|Once the critical ill patients is stable, enteral nutrition was initiated following a procedure assisted by gastrointestinal ultrasound.
224023024|NCT02746198|OTHER|probiotic dairy drink|
224023025|NCT02746198|OTHER|acidified milk|
224023026|NCT02858843|DRUG|lumacaftor-ivacaftor|Drug given for cystic fibrosis
224023027|NCT04757662|DRUG|Tadalafil|Tadalafil is commercially available and will be purchased by the Siteman Cancer Center and distributed to participants free of charge.
224023028|NCT00188786|PROCEDURE|daily Cone Beam CT for imaging guidance for radiotherapy|
223737387|NCT00383149|DRUG|Cetuximab|Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
223737388|NCT00604331|DRUG|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
224023029|NCT05206097|DEVICE|Accelerometer|For the following study, each patient will be asked to wear a portable device over a 7-day period. The accelerometer will be previously set up according to anthropometric data of the patient and scheduled to automatically start and stop accelerations registration. The patient will be asked to wear the sensor as frequently as possible, with the exception of sleep period and during aquatic activities. A diary will be delivered to the patient in order to notify any problem/issue observed during the evaluation week (for example forgetting to wear the sensor). The accelerometry assessment will be associated to a questionnaire. Each patient will have to fill in it during the evaluation week. The questionnaire is composed of various questions from three different questionnaires: Ricci \& Gagnon for subjective evaluation of PA level, CFQ-14+ for the evaluation of quality of life specifically in CF and EQ-5D for a more generic evaluation of quality of life.
223405595|NCT00495391|DRUG|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
223737389|NCT05589233|BIOLOGICAL|Vaccionation eighter started or full course|Vaccination against SARS-CoV-2 at any number of doses
223737390|NCT04626232|PROCEDURE|N-SLEEVE technique|The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).
223737391|NCT04626232|PROCEDURE|SLEEVE|SLEEVE Technique : Removal of 2/3 of the stomach
223737392|NCT04294511|DRUG|Camrelizumab in Combination With Neoadjuvant Chemotherapy|camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
223737393|NCT04997785|PROCEDURE|Ultrasound-guided Pericapsular Nerve Group (PENG) Block|PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
223737394|NCT06020365|OTHER|sequential fecal microbiota transplant combined with small intestinal fluid transplant|for eligible patients, the investigator use rifaximin, three times daily, 0.4 g each time, lasting 6 days followed by fecal microbiota transplant combined with small intestinal fluid transplant for 6 days. These procedures were repeated every 28 days.
223737395|NCT00450333|DRUG|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
223737396|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
223405596|NCT00495391|DRUG|Placebo|One oral placebo tablet twice daily for 52 weeks.
223737397|NCT00450333|DRUG|Dynepo|subcutaneous, QW for 24 weeks
224132666|NCT05874687|DRUG|hypotension + treat|Heart Rate and Mean Arterial Pressure (MAP) will be recorded throughout the procedure (every 2 minutes for the first 15 minutes). Ephedrine (in 6 mg increments) will be used as well as the isotonic balanced crystalloid solution to treat hypotension defined as a decreased SAB greater than 20% of baseline, a decreased MAP below 90 mmHg, or a MAP of 65 mmHg (250 mL bolus). The Ephedrine dose will be recorded. Bradycardia, which is defined as a heart rate less than 50 beats per minute, will be treated with intravenous Atropine (0.5 mg).
223405597|NCT00495391|BIOLOGICAL|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
223405598|NCT00495391|DRUG|Ribavirin|1000 mg (if \<75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
223405599|NCT03813173|PROCEDURE|lymph node dissection|The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
223405600|NCT01366924|DIETARY_SUPPLEMENT|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
223405601|NCT01366924|OTHER|Endurance exercise|60 minute endurance exercise session
223556010|NCT02186379|BEHAVIORAL|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
223556011|NCT02186379|BEHAVIORAL|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
223737398|NCT00450333|DRUG|Dynepo|subcutaneous, Q2W for 24 weeks
223737399|NCT00616681|DRUG|Oxcarbazepine|
223737400|NCT05931354|OTHER|HPV test and Pap Smear|HPV test and Pap Smear
223737401|NCT00230230|DRUG|SCH 486757|
223737402|NCT04100304|DIAGNOSTIC_TEST|resection|CT volumetry,liver function,biopsy before resection
223737403|NCT03659305|BIOLOGICAL|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
223737404|NCT03659305|BIOLOGICAL|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
223737405|NCT02469454|DRUG|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
223737406|NCT02469454|DRUG|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
224023030|NCT01535755|DEVICE|protocol|In this group, the patients were weaned as the protocol.
224023031|NCT01535755|OTHER|physician's orders|In this group, the patients were weaned as the clinicians' order.
224023032|NCT03723252|DRUG|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd
224023033|NCT03723252|DRUG|Placebo|Participants will receive placebo po qd
224023034|NCT01242800|PROCEDURE|palliative surgery|Undergo standard palliative surgery
224023035|NCT01242800|PROCEDURE|therapeutic conventional surgery|Undergo early surgery
223556012|NCT04167059|BEHAVIORAL|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
223556013|NCT03645421|DRUG|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
223556014|NCT03645421|DRUG|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
223556015|NCT03645421|DRUG|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
223556016|NCT03645421|DRUG|PlaceboA|1.0 mL liquid formulation per Vial
223556017|NCT03645421|DRUG|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
223556018|NCT03645421|DRUG|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
223556019|NCT00428571|PROCEDURE|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
223556020|NCT00428571|PROCEDURE|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
223556021|NCT00428571|PROCEDURE|Intensive Medical Management|lifestyle, diet, medication optimization
223556022|NCT03048890|BEHAVIORAL|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
223556023|NCT00694837|DRUG|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
223556024|NCT03894982|OTHER|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
223556025|NCT01216709|DIETARY_SUPPLEMENT|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
223556026|NCT01216709|OTHER|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
223556027|NCT01216709|OTHER|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
223556028|NCT05359874|DRUG|Bevacizumab-IRDye800CW|In order to be able to detect this marker in vivo, special multispectral fluorescence-reflecting cameras (MFRI) were developed, which can be used for the intraoperative display of the tumor and potentially affected lymph nodes and which are now to be evaluated together with the fluorescence marker.
223556029|NCT05096247|DEVICE|TempSure|This device is an RF device.
223556030|NCT05096247|DEVICE|Icon|This device works with IPL (Intense Pulsed Light) handpieces.
223556031|NCT04220463|OTHER|Hypnosis + NIV|For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
223556032|NCT04220463|OTHER|NIV|In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
223556033|NCT05047939|DRUG|remimazolam-based TIVA|In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.
223556034|NCT05047939|DRUG|propofol-based TIVA|In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).
223556035|NCT01343186|DRUG|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
224023036|NCT01242800|RADIATION|palliative radiation therapy|Undergo standard palliative radiotherapy
224023037|NCT01242800|RADIATION|radiation therapy|Undergo radiotherapy
224023038|NCT00237289|DRUG|topiramate|
224023039|NCT00953745|DRUG|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
224023040|NCT00953745|DRUG|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
224023041|NCT00953745|DRUG|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
224023042|NCT00953745|DRUG|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
224023043|NCT03895905|DIAGNOSTIC_TEST|colposcopy and colposcopic biopsy|high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.
224023044|NCT01835418|DRUG|Amlodipine|crossover comparison of amlodipine vs lisinopril
224132667|NCT01507844|DEVICE|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
223556036|NCT01343186|DRUG|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
224023045|NCT02165254|BEHAVIORAL|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
224023046|NCT02165254|BEHAVIORAL|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
224023047|NCT02191410|PROCEDURE|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio \> 0.3, RR 60 breaths min-1 and a FGF of \< 2 L min-1, using a second identical ventilator with low compliant internal circuit
224023048|NCT02191410|PROCEDURE|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
224023049|NCT00127777|DRUG|Amantadine sulphate (in addition to standard treatment)|
224023050|NCT01534572|DIETARY_SUPPLEMENT|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
224023051|NCT01534572|DIETARY_SUPPLEMENT|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
224132668|NCT03076866|OTHER|observational follow-up:clinical, radiological et biological|
224132669|NCT02871193|DRUG|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
224132670|NCT02871193|DRUG|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
223556037|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
223556038|NCT01343186|DRUG|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
223556039|NCT04985201|DRUG|Irinotecan|Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.
223556040|NCT04985201|DRUG|Simvastatin|Simvastatin 40 mg daily oral tablet taken.
223556041|NCT03692754|DRUG|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 month
223556042|NCT03692754|DRUG|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 month
223556043|NCT03692754|DRUG|Dexamethasone|Dexamethasone will be given in 40mg po qd for 4 days
223556044|NCT00417378|DEVICE|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
223556045|NCT00417378|DEVICE|Intraaortic Balloon Pump|Counterpulsation
223556046|NCT05030519|DRUG|Pyrotinib|Pyrotinib 400 mg once daily(monotherapy or combined Trastuzumab/Inetetamab and chemotherapy)
223556047|NCT06523608|OTHER|Standard survillance protocol|Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
223556048|NCT06523608|OTHER|Stratified survillance protocol|"Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification."
224023052|NCT03527238|OTHER|PPM-based Computation Assisted Drug Dosing|Tacrolimus dosing based on application of PPM.
223556049|NCT06513039|DRUG|Erythropoietin carried on chitosan carrier|Patient will have extraction of teeth and placement of Erythropoietin carried on chitosan carrier for six months to enhance bone healing
223556050|NCT06513039|OTHER|chitosan carrier|inert scaffold agent
223556051|NCT06035952|DIAGNOSTIC_TEST|3D topographical scan|Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
223556052|NCT00748618|DIETARY_SUPPLEMENT|Standard vitamin D3 treatment|10,000 I.U./wk of vitamin D3 orally for 6 months
223556053|NCT00748618|DIETARY_SUPPLEMENT|High dose vitamin D3 treatment|50,000 I.U./wk of vitamin D3 orally for 6 months
223556054|NCT04338178|BEHAVIORAL|Cognitive Remediation Therapy (CRT)|This intervention consists of mental exercises aimed at improving executive function via practice. Simple cognitive tasks that encourage reflective learning and insight into patient's own thinking process are administered. Exercises target set-shifting (i.e., cognitive flexibility), estimating, organization and planning.
223556055|NCT04338178|BEHAVIORAL|Emotional Skills Training (EST)|EST places emphasis on the improvement of inner emotion awareness, facial and body expression recognition and intra- and interpersonal emotion regulation skills. Different modules and interactive exercises are designed to help patients learn about i) the functions and manifestations of emotions, ii) the identification and labelling of own's and others' emotions, iii) tolerating and communicating emotions, and iiii) balancing between negative and positive emotions.
224023053|NCT03527238|DRUG|Tacrolimus|Dosing of calcineurin inhibitor, tacrolimus
224023054|NCT03229070|OTHER|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
224132671|NCT02871193|OTHER|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
224132672|NCT04780958|OTHER|Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.|Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
224297790|NCT03738514|OTHER|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
224297791|NCT03738514|OTHER|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
223737407|NCT06296758|PROCEDURE|Regional anesthesia|ultrasound-guided suprainguinal fascia iliaca block with 40ml of ropivacaine local or ultrasound-guided femoral nerve block with 20ml of ropivacaine local anesthetic
223737408|NCT05429762|DRUG|Tusamitamab ravtansine|Pharmaceutical form: Concentrated solution for intravenous (IV) administration; Route of administration: IV infusion
223737409|NCT02670564|GENETIC|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
223737410|NCT02670564|OTHER|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~-\>For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~-\>For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-\> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
223737411|NCT02055690|DRUG|Pazopanib|Tyrosine Kinase Inhibitor
223737412|NCT02055690|DRUG|Fosbretabulin|Vascular Disrupting Agent
224023055|NCT03229070|OTHER|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
224023056|NCT00609375|DRUG|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
224023057|NCT00609375|DRUG|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
224023058|NCT03375567|PROCEDURE|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
224023059|NCT03375567|PROCEDURE|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
224023060|NCT02484053|DRUG|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
224023061|NCT04310280|DRUG|Insulin Glargine|Half of the wound surface is injected daily with topical glargine insulin
224023062|NCT04310280|DRUG|Saline|Half of the wound surface is injected daily with topical saline solution
224132673|NCT04908241|OTHER|TRAIL|"Each week has a specific focus for lower extremity rehabilitation:~Week 1) Building a base: 8 exercises, 10-15 repetitions x 2-3 sets~Week 2) Increasing repetitions: 8 exercises, 15-20 repetitions x 3 sets~Week 3) Building exercise tolerance:10 exercises, 15-20 repetitions x 3 sets~Week 4) Maximizing repetitions: 10 exercises, 30 seconds as many reps as possible x 2 sets~At the end of the second exercise session each week, the therapist and participants work collaboratively to develop an independent exercise action plan to be completed before the first session of the next week. The self-managed plans includes exercises selected from TRAIL, agreed upon by the participant and therapist, that are safe to perform without therapist oversight. The aims of the exercise action plan are to: i) Add exercise volume without using program resources (e.g., therapist time); and ii) Build capacity for self-management for long-term health and well-being after TRAIL has ended."
224132674|NCT04908241|OTHER|EDUCATION|"EDUCATION has a specific focus on:~Week 1) What is stroke (e.g., gaining an understanding of the function of the brain, types of stroke and how stroke affects physical function) and introduction to self-management;~Week 2) What is self-management;~Week 3) Self-management for post-stroke complications (e.g., activities of daily living);~Week 4) Self-management for secondary prevention (e.g., blood pressure, diet, medication, stress management).~Education therapists will be provided with lesson plans and manuals to be circulated with the participants, and will facilitate the educational session through interactive Powerpoint presentations. In addition, participants will be asked to complete 30-60 minutes of educational homework, which will be discussed at the commencement of the following session."
224132675|NCT01193816|DRUG|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
224132676|NCT01193816|DRUG|Placebo|Placebo
224132677|NCT03915236|DEVICE|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
224132678|NCT03915236|OTHER|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
224132679|NCT01650792|DRUG|Aspirin|
223405602|NCT06347224|PROCEDURE|Virtual placement of lag screws in both columns of the acetabulum on 3D pelvic CT models.|The intervention aims to simulate a percutaneous fixation technique that could be applied in a real surgical environment, offering insights into the potential for personalized surgical planning and optimization of outcomes for patients with acetabular fractures. This virtual approach allows for the exploration of various screw placement strategies without the ethical and practical constraints of direct clinical experimentation.
223405603|NCT04604756|DRUG|Losartan|administration of losartan (50 mg) (oral)
223405604|NCT04604756|DRUG|Placebo Oral Tablet|administration of placebo (oral)
223405605|NCT03566199|DRUG|Panobinostat Nanoparticle Formulation MTX110|Given IT
223405606|NCT03566199|DRUG|Convection-Enhanced Delivery (CED)|Undergo CED
224023063|NCT03174587|BIOLOGICAL|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10\^6cells/kg Step 1 dose : 2.0x10\^6cells/kg Step 2 dose : 3.0x10\^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
224023064|NCT05267431|DRUG|Biological Drug|Different biological drugs
223737413|NCT06073353|BEHAVIORAL|THRIVE-M|"THRIVE-M is a self-administered psychosocial mobile application for patients living with multiple myeloma that includes the following five modules:~1. Health module - teaching patients about physical symptoms and strategies to cope with physical symptoms~2. Relationships module - helping patients articulate different support needs and communication styles in navigating relationships~3. emotions module - helping patients identify connections between thoughts, feelings, and behaviors, as well as helpful states of mind and gratitude~4. Lifestyle module - helping patients practice skills for saving up energy and using self-care strategies~5. Reflection module - teaching patients to reflect on their lives, meaningful relationships, and sense of purpose.~Each module takes about 15-20 minutes to complete and participants will be instructed to complete all modules within an eight-week period."
224023065|NCT00016939|DRUG|alvocidib|
224023066|NCT03900364|PROCEDURE|partial nephrectomy|Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
224023067|NCT00982995|DRUG|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
224023068|NCT05681689|COMBINATION_PRODUCT|PyloPlus UBT System|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
224023069|NCT05681689|DIAGNOSTIC_TEST|Histology|Biopsy specimen fixed with 10% buffered formalin cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist.
224023070|NCT05681689|DIAGNOSTIC_TEST|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
224023071|NCT05681689|COMBINATION_PRODUCT|Comparator Breath Test|Breath will be analyzers for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
224132680|NCT04031404|DEVICE|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
224132681|NCT04826458|DEVICE|TreC-Onco|"At the baseline visit, each patient assigned to arm A will be provided with the electronic diary (installed on a smart phone or tablet), the oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the electronic diary, and the user manual will also be given. This app allows patients to record parameters related to their health state (e.g. medications, blood pressure, weight, fever, side effects or other symptoms) and through the alarm function, it reminds the patient to take the tablets, indicating the exact dosage. In addition, the patient can also indicate the dose reduction or the omission."
224132682|NCT04826458|OTHER|Paper diary|Patients assigned to arm B will be provided with a paper diary, oral medication for the first treatment cycle and the appointment for the next cycle. The patient will be instructed on how to use the paper diary.
224138826|NCT01334372|BEHAVIORAL|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
224138827|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
223405607|NCT02352571|BIOLOGICAL|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
223405608|NCT04509076|BEHAVIORAL|PrEP iT! (plus usual PrEP care)|"The PrEP iT! intervention is a mobile-optimized website, with the following components:~* PrEP Adherence, PrEP Appointment, and Sexual Activity Self-Monitoring~* Tailored feedback on PrEP adherence/non-adherence~* PrEP and sexual health information tailored for YMSM~* Text message reminders for PrEP adherence and healthcare appointments~* An ask the expert feature"
223405609|NCT04509076|BEHAVIORAL|Usual PrEP care|Clinic visits every 3 months in the initial period following PrEP initiation, including HIV/STI screening and laboratory toxicity testing
223405610|NCT06577168|OTHER|Levonogestrel Intrauterine system (LNG-IUS)|Contraception method
223405611|NCT03707223|BEHAVIORAL|The Interfaces Program|career development program
223405612|NCT03707223|BEHAVIORAL|IPS|supported employment using the individual placement and support (IPS) model
223737414|NCT00416078|BEHAVIORAL|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
224023072|NCT05681689|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patient's stool for H. pylori
223405613|NCT00459862|OTHER|laboratory biomarker analysis|Correlative study
223405614|NCT00459862|DRUG|pazopanib hydrochloride|Given orally
223405615|NCT05340764|DRUG|Infliximab|Infliximab is an effective and commonly used medication to treat patients with IBD
223405616|NCT01953302|PROCEDURE|"modified open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
223405617|NCT00038402|DRUG|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
223405618|NCT00038402|DRUG|Taxol|225 mg/m\^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
223405619|NCT00038402|DRUG|Fluorouracil|500 mg/m\^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
223405620|NCT00038402|DRUG|Cytoxan|500 mg/m\^2 on Day 1 of each cycle for 4 cycles.
223556056|NCT04338178|BEHAVIORAL|Cognitive Behavioral Therapy|CBT intervention aimed to manage food craving by teaching group members cognitive (e.g., restructuring of urge-related thoughts) and behavioural strategies (e.g., increasing awareness through food diaries, relaxation skills, identification of cues that trigger craving, avoidance of high-risk situations for craving, distraction).
224023073|NCT01632670|OTHER|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
223405621|NCT00038402|DRUG|Epirubicin|75 mg/m\^2 IV on Day 1 of each cycle for 4 cycles.
223556057|NCT04338178|PROCEDURE|Multidisciplinary outpatient program|Multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches. Patients are regularly followed and educated about the importance of lifestyle changes including healthy dietary habits and exercise in weight reduction and maintenance. Patients are also usually given information about nutritional value of various foods and few simple exercises for decreasing and maintaining body weight. This program is therefore planned as part of the usual care and responds to the recommendations of good practice for obesity
223556058|NCT04753346|OTHER|Physical Activity Level|International Physical Activity Questionnaire
223556059|NCT04753346|OTHER|Anxiety and Depression Assessment|Hospital Anxiety and Depression Scale
223556060|NCT04753346|DIAGNOSTIC_TEST|Exercise Capacity|6 Minute Walk Test
223556061|NCT04753346|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry
223556062|NCT04753346|DIAGNOSTIC_TEST|Cardiopulmonary Fitness Level|Cardiopulmonary Exercise Test
223556063|NCT04753346|OTHER|Cognitive Assessment|Montreal Cognitive Assessment
223556064|NCT06238895|DRUG|Tardyferon|Interval Dosing Strategy (Administration of oral iron every second day with double the standard dose instead of every day standard dose)
223556065|NCT05594485|DEVICE|Carebot AI CXR|Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
223556066|NCT05648877|DEVICE|Ureteroscope|Role Of Retrograde Intrarenal Surgery In Management Of Renal Stones: Single Center Experience
223737415|NCT00416078|BEHAVIORAL|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
224023074|NCT05369195|PROCEDURE|LAAC procedure with the use of transcatheter cerebral protection system|After aortography the cerebral protection system will be delivered to cerebral arteries through radial access before accessing the left atrium.
224023075|NCT05369195|PROCEDURE|LAAC procedure without the use of transcatheter cerebral protection system|Only the aortography through radial access will be done before accessing the left atrium.
224023076|NCT06448832|DIAGNOSTIC_TEST|Ultrasound|An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.
224023077|NCT02640157|DRUG|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
224023078|NCT02640157|DRUG|Sofosbuvir|Tablet
224023079|NCT02640157|DRUG|Daclatasvir|Tablet
223405622|NCT05392842|DIETARY_SUPPLEMENT|Corchorus Olitorius Buccal fast dissolving Films|Corchorus Olitorius Buccal fast dissolving Films
223405623|NCT05392842|DIETARY_SUPPLEMENT|plain mucoadhesive fast dissolving film|plain mucoadhesive fast dissolving film
223556067|NCT06019039|DRUG|Normal Saline Flush|Five milliliters of sterile saline will be administered as a flush through the needle while recording the color flow doppler images. The same procedure will be repeated with a slow injection of 5 mL of saline. The speed of injection will not be standardized.
223556068|NCT06019039|DEVICE|Doppler|"All color flow Doppler images will be performed with a Phillips CX50 ultrasound machine using a 5.0 MHz a low frequency curvilinear US probe. A two-dimensional transverse interspinous view was used to visualize the posterior complex (ligamentum flavum, epidural space and dura). After loss of resistance to normal saline, the color flow Doppler function will be turned on to examine flow through the epidural needle tip.~The ultrasound probe was positioned in the transverse axis slightly below the epidural needle but still in the interspinous space ."
223556069|NCT01826539|PROCEDURE|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
223556070|NCT00853710|OTHER|PSA assay|rapid prostate specific antigen assay.
223556071|NCT01132846|OTHER|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
223556072|NCT01132846|DRUG|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
223556073|NCT01132846|DRUG|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
223556074|NCT03075306|BEHAVIORAL|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
224023080|NCT06085001|DIAGNOSTIC_TEST|Lumella finger prick blood test|Finger prick blood test
224023081|NCT00839657|BEHAVIORAL|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
223405624|NCT05335837|PROCEDURE|Regional Anesthesia and Sedation|Preoperative ilioinguinal/iliohypogastric nerve block and moderate to deep intraoperative sedation.
223556075|NCT05480982|BEHAVIORAL|Cognitive functional therapy via tele rehabilitation|Participants in the CFT group will be treated by a physiotherapist with seventeen years of clinical experience and that has attended six CFT workshops with three of the international tutors of the method. She has completed 212 hours of training including workshops, patient examinations and a pilot study under the supervision of a physiotherapist with more than seven years of clinical experience in CFT. Another two physiotherapists, one with more than fifteen years and the other with more than ten years of clinical experience, and both with more than 106 hours of CFT training including CFT via tele physiotherapy, will complete the staff.
223556076|NCT05480982|OTHER|Pilates via tele rehabilitation|Physiotherapist will have the freedom to judge about the exercises´ progression and the need of adaptation considering both the level of difficulty to perform each exercise according to the original proposal and the individual´s demands. The treating physiotherapists will have at least 2 years of clinical practice in Pilates and clinical experience in Pilates via teleconference.
224023082|NCT00839657|BEHAVIORAL|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
223737416|NCT05977582|BEHAVIORAL|Spanish version eBodyProject|"The Spanish adaptation of the eBodyProject program will be modified (Stice et al., 2012b). This program consists of 4 modules adapted from the most recent version of the original program The Body Project, presented by the original authors who have given their consent and suggestions for the realization of the Spanish version.~The activities proposed through the different modules will be in written format or behavioral activities aimed at criticizing the ideal of feminine beauty imposed by today's society and promoting self-acceptance."
223737417|NCT05977582|BEHAVIORAL|Psychoeducationa Prevention Program|Participants in this group will receive a weekly newsletter with information about the beauty ideal, the costs of pursuing it, and tips for resisting the pressure to pursue this ideal, as well as tips for managing the emotions associated with it. However, they will not have to perform exercises related to this information, a psychoeducational intervention. Once the study is finished, these participants will receive an email again in case they are interested in taking part in the eBodyProject prevention program.
224023083|NCT00215735|DEVICE|debridement, dressing, and APC|ebridement, dressing, and APC
224023084|NCT04812275|PROCEDURE|Skin closure|Skin closure
224023085|NCT01308944|DRUG|Propranolol|
224023086|NCT04138693|DEVICE|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
224023087|NCT04138693|DEVICE|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
224132683|NCT03969043|OTHER|MRI|"The MRI examination will consist of a series of acquisition scans:~* Scanning Scan: for positioning the functional volume of interest.~* Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~* Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~* Resting state functional scan: for exploring cerebral activation during a rest activity.~* Diffusion Tension Imaging: for measuring structural connectivity.~* Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
223556077|NCT00163241|DRUG|celecoxib|
223556078|NCT00301145|BEHAVIORAL|smoking cessation intervention|
223556079|NCT00301145|DRUG|varenicline|
224297792|NCT03738514|OTHER|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
223556080|NCT00301145|OTHER|counseling intervention|
223556081|NCT00301145|OTHER|internet-based intervention|
223556082|NCT02854436|DRUG|Niraparib|Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
223556083|NCT02676674|DRUG|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
223556084|NCT02676674|DRUG|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
223556085|NCT06430242|DEVICE|Tele rehabilitation|In the active group, one of the co-investigators will install and demonstrate the use of the mobile app (Rehab App) on participants' mobile phone and explain the use of the software. The participants will be followed up for the duration of their enrolment in the e-health and tele-rehabilitation service, which can last up to 2 months.
223556086|NCT06430242|OTHER|Exercise|Participants in the control group will get the usual treatment from the clinical staff and in-person education, and they will be supervised by one of the assigned research team members every week.
223556087|NCT00232999|DRUG|Nebulized IVX-0142|
223405625|NCT02361099|OTHER|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
223405626|NCT00502242|DRUG|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
223405627|NCT00502242|DRUG|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
223737418|NCT04404751|COMBINATION_PRODUCT|Iodised salt with Iron, Folic acid and Vitamin B12|Fortified salt with either Iron and Iodine only or Fortified salt with Iodine, iron, Folic acid and Vitamin B12 compared with standard Iodized salt
223737419|NCT03594292|DEVICE|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
223737420|NCT03594292|PROCEDURE|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
223737421|NCT04156425|DRUG|Escitalopram+golimumab|Escitalopram will be administered at 10-20 mg/d during the acute phase. Golimumab will be administered at the dose of 50mg every month during the acute phase.
223405628|NCT02201693|DIETARY_SUPPLEMENT|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
223405629|NCT02201693|DIETARY_SUPPLEMENT|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
223405630|NCT00471224|OTHER|Observational Trial|No intervention is being used in this study.
223405631|NCT01808417|DRUG|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
223405632|NCT05261542|DIAGNOSTIC_TEST|flow cytometry|evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
223405633|NCT03827681|PROCEDURE|Trans Intrahepatic Portosystemic Shunt|"* The most common approach is through the right internal jugular approach.~* After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.~* A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.'~* A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein."
223405634|NCT03827681|PROCEDURE|Self Expanding Metallic Stent|"* At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.~* The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.~* The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.~* After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide."
223405635|NCT03827681|DRUG|Vasoactive Agent|Vasoactive Agent
223405636|NCT03425591|DRUG|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
223405637|NCT02529657|RADIATION|Low Level Laser Therapy|In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
223556088|NCT04283955|DRUG|High-dose MTX based chemotherapy|Patients received MTX therapy at the dose of 5g/m2 for 24 hours. Each dose of HD-MTX therapy was followed by 6\~7 times of leucovorin rescue 12 hours after the end of MTX infusion, at the dose of 15 mg/ m2 every 6 hours. The plasma MTX levels were monitored at 0, 24, 48, 72 hours from the initiation of HD-MTX infusion. To maintain the urine pH at approximately 7\~8, intravenous hydration and alkalization at the dose of 1,500ml/ m2 per day were achieved 12 hours prior to the initiation of HD-MTX administration (D0) and 3,000ml/ m2 per day lasted for the following 3 days (D1 to D3). CF was used to rinse mouth to prevent oral mucositis from D1 to D3. We closely monitored the volume and pH of the urine via routine test from D0 to D4.
224023088|NCT04138693|DEVICE|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
224023089|NCT00117923|DRUG|Resiquimod|
224023090|NCT02851225|OTHER|telemedicine transmission of biological results|telemedicine transmission of biological informations
223556089|NCT06547645|OTHER|Sub-Acute Rehab at Home|Patients randomized to the intervention group will receive skilled nursing and rehabilitative care at home upon discharge from the hospital, or when eligible for skilled-nursing facility care when requiring a step up in services at home. Home care will be delivered and overseen by a multidisciplinary clinical team, which will develop individualized care plans based on diagnosis, specific rehabilitation objectives, and broader goals of care.
224023091|NCT00271518|DRUG|growth hormone (somatropin)|dosing regimen is weight based.
224023092|NCT03858699|OTHER|Recording of electroencephalographic (EEG) data|Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.
223405638|NCT02529657|PROCEDURE|Placebo|In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
223405639|NCT04230551|PROCEDURE|PTSMA|Alcohol Septal Ablation
224023093|NCT01679405|DRUG|BIBW 2992|once daily per os
224023094|NCT02506517|DRUG|Afatinib|
224023095|NCT00417339|PROCEDURE|hemodialysis|individualised
224023096|NCT05860660|BEHAVIORAL|survey|questionnaires
224023097|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
224023098|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
224023099|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
224023100|NCT03952325|DRUG|Nivolumab|Nivolumab at 360 mg by intravenous infusion Q3W
224023101|NCT03952325|DRUG|Pembrolizumab|Pembrolizumab at 200 mg by intravenous infusion Q3W
224023102|NCT03952325|DRUG|Atezolizumab|Atezolizumab at 1,200 mg by intravenous infusion Q3W
224023103|NCT03952325|DRUG|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
224023104|NCT05253989|DEVICE|VR Intervention|VR Device that allows a patient to play games based on the EMG activity in the upper limb.
224023105|NCT05253989|DEVICE|FES|Functional Electrical Stimulation used to increase motor excitability whilst engaging in VR rehabilitation
224023106|NCT00271687|BEHAVIORAL|Exercise training|
224023107|NCT02142296|DRUG|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
224023108|NCT00914901|DRUG|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
223405640|NCT05598112|BIOLOGICAL|FMT capsules|FMT capsules containing extensively screened donor stool.
223405641|NCT05598112|OTHER|Placebo capsules|Placebo capsules that do not contain donor stool or any active drug.
223405642|NCT05338840|OTHER|MULLIGAN ROTATIONAL MOVEMENT|12 sessions over 6 weeks
223405643|NCT05338840|OTHER|Medial gapping technique|12 sessions over 6 weeks
223737422|NCT04156425|DIETARY_SUPPLEMENT|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d during the acute phase. Calcium tablet will be administered at 2000mg/d during the acute phase.
223737423|NCT04156425|DRUG|Escitalopram|Escitalopram will be administered at 10-20 mg/d during the acute phase.
223405644|NCT01540201|OTHER|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
223405645|NCT01540201|OTHER|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
223737424|NCT00643032|PROCEDURE|Transcutaneous iliohypogastric|
223405646|NCT05603871|PROCEDURE|ligamentoplasty of ligamentum teres|"An addition to the steps of the open reduction, the following were done:~1. Identification of ligamentum teres~2. Ligamentoplasty of ligamentum teres"
223405647|NCT01812109|DEVICE|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes \~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
223405648|NCT03285828|BEHAVIORAL|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :~1. Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~2. Lectures and the distribution of memory aids.~3. Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~4. Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
223405649|NCT03313180|DRUG|Nintedanib|Administered twice daily
223405650|NCT04276480|DRUG|Piperacillin-tazobactam|"At the time of ventilator-associated pneumonia diagnosis, patients will receive an initial 4g loading dose of piperacillin-tazobactam with a continuous maintenance dose of 16g per day the first day of treatment. The dose of the piperacillin-tazobactam administered the following days will be adjusted to the renal function.~The antimicrobial treatment will be adjusted to the narrower-spectrum agent after the antimicrobial susceptibility determination for a total length of treatment of seven days."
223405651|NCT05820529|PROCEDURE|adenotonsillectomy|removal of adenoid,tonsil in one session
223405652|NCT05820529|PROCEDURE|adenoidectomy|removal of adenoid
223405653|NCT05820529|PROCEDURE|tonsillectomy|removal of tonsil
223405654|NCT03389074|PROCEDURE|Radiofrequency catheter ablation|minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.
223737425|NCT00643032|PROCEDURE|Perioperative administration near the nerve|
223737426|NCT01879332|DRUG|Placebo|Matching placebo tablets for oral administration
223405655|NCT01966120|DRUG|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
223405656|NCT01966120|DRUG|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
223737427|NCT01879332|DRUG|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
223737428|NCT01879332|DRUG|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
223737429|NCT00461682|DRUG|SB-705498|
223737430|NCT00006344|RADIATION|radiation therapy|
223737431|NCT05562076|DEVICE|the spot stent(ZENFLEX ® Pinto) system|the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
223737432|NCT05562076|DEVICE|the bare stent( Everflex) system|the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
223737433|NCT04013724|BEHAVIORAL|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
223737434|NCT02593474|DRUG|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
223737435|NCT03305822|DRUG|LY900014|Administered SC
223737436|NCT03305822|DRUG|Insulin Lispro|Administered SC
223737437|NCT05815472|DEVICE|Fitbit charge|Internet of Things Technologies Device
223737438|NCT01772706|PROCEDURE|low level laser therapy|
223405657|NCT01966120|PROCEDURE|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
223405658|NCT06577129|OTHER|Ladder training|Players exercised three times a week for sixty minutes apiece on a ladder for eight weeks. The drills were divided into three categories: steady state drills, burst drills, and elastic reaction drills. While steady state training focused on agility and endurance, burst drills were more focused on fast foot movement. Elastic response drills targeted the reactive speed components of the lower leg.
223405659|NCT06577129|OTHER|Plyometric training|For eight weeks, the players performed a 60-minute plyometric training program three times a week. A fifteen-minute warm-up, stretching, and jogging session comes after the thirty minutes of plyometric training. The cool-down consists of fifteen minutes of light running and stretching.
223405660|NCT03977064|BEHAVIORAL|Life style change and weight reduction|Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
223405661|NCT00461630|DRUG|ER niacin/laropiprant|
223405662|NCT00461630|DRUG|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
223405663|NCT00461630|DRUG|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
223405664|NCT05468294|DRUG|F16IL2|F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
223405665|NCT05468294|DRUG|Nivolumab, fixed dose|Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.
223405666|NCT04062929|BEHAVIORAL|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
223405667|NCT04129489|DRUG|Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally
223405668|NCT05429801|OTHER|Ozone therapy|Rectal ozone treatment along with standard medical treatment was administered to the patients, in increasing doses for 5 sessions per week, 20 sessions in total for 4 weeks. First week: 25 mg/l, 100 ml; second week: 30 mg/l, 150 ml; third week: 35 mg/l, 200 ml; fourth week: 40 mg/l, 200 ml rectal ozone treatment was applied.
223405669|NCT04600765|DIAGNOSTIC_TEST|hsCRP serum measurement of inflammation|hsCRP inflammation change as result of non-contaminated diet
223556090|NCT05445921|DRUG|Stellate Ganglion Block|The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
223556091|NCT03975335|BEHAVIORAL|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
223556092|NCT03975335|OTHER|Carrier Guidance|Carrier opportunities and counselling
223556093|NCT03171584|DRUG|Terbinafine|oral antifungal drugs
223556094|NCT01977729|DRUG|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S\<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
223556095|NCT01977729|BEHAVIORAL|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
223737439|NCT01772706|PROCEDURE|placebo (laser low level energy nonfunctional)|
223405670|NCT06019546|OTHER|PEQUOD|During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.
223405671|NCT03489668|DRUG|MetFORMIN 500 Mg Oral Tablet|metformin administration 1500mg per day
223737440|NCT05625672|OTHER|Training|Hemovigilance module training
223737441|NCT02707874|DRUG|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
223405672|NCT01703572|DRUG|OMP-52M51|
223405673|NCT00444522|DRUG|Alprazolam thermal aerosol|
223405674|NCT05087264|DRUG|Indocyanine green|ICG retention test and clearance test: intravenous injection, 0.5mg/l. Liver blood flow measurement: intravenous drip, dissolve 25mg ICG in 100ml injection water, and drip at a constant speed for about 50min to make the ICG concentration reach equilibrium.
223405675|NCT04630002|DRUG|GSK3640254|GSK3640254 will be available as oral tablets.
223405676|NCT04630002|DRUG|Darunavir/Ritonavir (DRV/RTV)|DRV/RTV will be available as oral tablets.
223405677|NCT04630002|DRUG|Etravirine (ETR)|ETR will be available as oral tablets.
223405678|NCT01215396|DIETARY_SUPPLEMENT|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
223405679|NCT01215396|DIETARY_SUPPLEMENT|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
223556096|NCT01746381|DEVICE|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
223556097|NCT06410352|DRUG|Semaglutide, Empagliflozin|subcutaneous Semaglutide (GLP-1RA) 1 mg once a 7 day with oral Empagliflozin (SGLT-2i) 25 mg once a day
223737442|NCT02707874|DRUG|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
223405680|NCT01215396|DIETARY_SUPPLEMENT|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
223405681|NCT02920502|DIETARY_SUPPLEMENT|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
223405682|NCT02920502|DIETARY_SUPPLEMENT|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
223405683|NCT02920502|DIETARY_SUPPLEMENT|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
223405684|NCT02920502|OTHER|Arm 1: Placebo|One time dose of Placebo
223405685|NCT03872206|BIOLOGICAL|HPN536 Fixed IV 6 to 560 ng/kg|Fixed dose IV cohorts at doses from 6 to 560 ng/kg
223405686|NCT03872206|BIOLOGICAL|HPN536 1 Prime Step IV 600-1200 ng/kg Target|Step-dosing IV cohorts who received a single Prime Dose followed by the Target Dose (200/600 ng/kg, 200/1200 ng/kg, and 500/900 ng/kg)
223405687|NCT03872206|BIOLOGICAL|2 Prime Step IV 900-14000 ng/kg Target|Step-dosing IV cohorts who received 2 Prime Doses followed by the Target Dose (200/600/900 ng/kg and 200/600/1200 ng/kg; 500/900/1200 ng/kg, 500/900/1800 ng/kg, 500/900/3600 ng/kg, 500/900/7200 ng/kg, and 500/900/14400 ng/kg)
223405688|NCT02546375|DRUG|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
223405689|NCT06142500|GENETIC|Analysis of biological samples of saliva from testicular cancer patients and from their first-degree family members|The project aims to collect biological samples of saliva from testicular cancer patients and from their first-degree family members; demographic-clinical variables will be also collected in order to draft a comprehensive panel of genes and gene modifications related to the testicular cancer, combining this survey with a very detailed descprition of this cohort of patient in terms of clinical features and quality of life
223405690|NCT04640454|PROCEDURE|nipple sparing mastectomy|The investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (DTI), transversus rectus abdominis myocutaneous (TRAM) flap, latissimus dorsi myocutaneous (LD) flap, or LD with implant.
223405691|NCT04183296|DRUG|propofol|Anesthesia was induced with TCI of propofol (Ce of 4.0-4.5 μg/ml) and remifentanil (Ce of 4.0 ng/ml). Anesthesia was maintained with TCI of propofol and remifentanil. Anesthesia depth was adjusted to maintain a PSI of 25-50.
223405692|NCT04183296|DRUG|sevoflurane|Anesthesia was induced with an intravenous bolus of propofol 1.5-2 mg/kg and TCI of remifentanil (effect-site concentration \[Ce\] of 4.0 ng/ml). Anesthesia was maintained with sevoflurane (0.8-1 age-adjusted minimum alveolar concentration) and TCI of remifentanil
223405693|NCT05373732|BEHAVIORAL|meditation|meditation practice 20 minutes twice a day at home and attending classes at the clinic.
223405694|NCT05373732|BEHAVIORAL|Health education control|didactic based classes in CVD risk factor reduction and prevention
223405695|NCT04487015|BEHAVIORAL|MP|The app-based menu planner (MP) given to the participants has an automated carbohydrate periodisation menu planning tool, an educational and motivational nutrition content (infographics, video and text articles), and recipes. Participants using the app will input their training schedule into the app to produce their own menu plans. The behaviour change techniques (BCT) underlying the intervention are goal \& planning, feedback \& monitoring, shaping knowledge, natural consequences, comparison of behaviour, comparison of outcome, associations, repetitions, reward \& threat, regulation and antecedents.
223405696|NCT04487015|BEHAVIORAL|Call|A 30-45 minutes coaching consultation telephone/Skype call from the nutrition coaching to give social support. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
223405697|NCT04487015|BEHAVIORAL|MesC|Nutrition coach-led messaging (MesC) is where the mobile app (MP) has the text messaging feature activated, and the nutrition coach proactively initiates a conversation via text messaging up to three times a week to offer nutrition support to the participant. The BCT underlying the intervention is goal \& planning, social support, natural consequences.
223405698|NCT00442897|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
223405699|NCT00442897|DRUG|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
223405700|NCT00736697|DRUG|moxidectin|
223405701|NCT04498182|DRUG|AR-15512 Ophthalmic Solution|Ophthalmic solution administered via topical ocular instillation in one of two dose concentrations: 0.0014% (lower dose) or 0.003% (higher dose)
223405702|NCT04498182|DRUG|AR-15512 Ophthalmic Solution Vehicle|Ophthalmic solution vehicle administered via topical ocular instillation
223405703|NCT04396262|OTHER|Food-1|HTD-blueberry beverage with white bread.
223405704|NCT04396262|OTHER|Food-2|Sweetened water with white bread as a control.
223405705|NCT02564653|BEHAVIORAL|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
223405706|NCT02564653|BEHAVIORAL|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
223405707|NCT02986022|BEHAVIORAL|Resilience|Self-efficacy, optimism, altruism, goal setting
223405708|NCT02986022|BEHAVIORAL|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
223405709|NCT00513981|DRUG|leucovorin calcium|
223405710|NCT00513981|DRUG|methotrexate|
223405711|NCT00513981|OTHER|mass spectrometry|
223405712|NCT00513981|OTHER|pharmacological study|
223405713|NCT02907723|DEVICE|Sleep Recording|the device records movements during patients' sleep
223405714|NCT02368535|OTHER|Survey|25-item questionnaire on pereception of interdisciplinary rounds
223405715|NCT02367118|DRUG|Prednisone|
223405716|NCT02367118|DRUG|Placebo|
223405717|NCT01821235|DRUG|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
223405718|NCT01821235|DRUG|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
223405719|NCT01821235|DRUG|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
223405720|NCT01821235|DRUG|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
223405721|NCT05628935|PROCEDURE|peripheral nerve block|local anesthetic application to the brachial plexus
223405722|NCT05971784|OTHER|Telerehabilitation Group|The group that will receive upper extremity training via telerehabilitation in addition to an exercise program consisting of balance and walking activities
223405723|NCT05971784|OTHER|Control Group|The group that will receive an exercise program consisting of balance and walking activities
223405724|NCT05541003|DRUG|NBT-NM108|All patients will consume NBT-NM108 in the form of 2 muffins daily.
223405725|NCT06116188|DIAGNOSTIC_TEST|FDG-PET study|"Hyperinsulinemic, euglycemic clamp technique will be used to promote tissue glucose uptake and measure insulin sensitivity. Two cannulas will be inserted, one in a radial or an antecubital vein for PET tracer injection and infusion of glucose and insulin, another in the opposite radial or antecubital vein for blood sampling. In the clamp study subjects are administered intravenous insulin at a steady rate of 40 mU/m2/min and normoglycemia is maintained using a variable rate infusion of 20% glucose based on plasma glucose measurements, which are performed every 5min from arterialized venous blood. We will also collect samples to determine plasma insulin, serum free fatty acid and metabolic biomarkers during the study.~The clamp will be performed together with \[18F\]-FDG-PET/CT."
223405726|NCT03680378|DRUG|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
223405727|NCT02689193|OTHER|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
223405728|NCT00390871|DRUG|Fentanyl/Dexmedetomidine|
223405729|NCT00390871|DRUG|Fentanyl/Propofol|
223405730|NCT00390871|DRUG|Fentanyl|
223405731|NCT03986307|DIETARY_SUPPLEMENT|Omega-3 polyunsaturated fatty acid supplementation|Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
223405732|NCT03986307|OTHER|Resistance exercise|Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
224023109|NCT04966845|DIAGNOSTIC_TEST|measurement of concentration on exhaled Carbon Monoxide|exhaled carbon monoxide (eCO) concentration \[parts per million (ppm) was measured by a specific device \[Bedfont Scientific, Maidstone, Kent UK\]
223405733|NCT03986307|DIETARY_SUPPLEMENT|Placebo - appearance-matched oil supplementation|Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
223405734|NCT04725162|RADIATION|18F-FDG|All subjects received 18F-FDG PET examination.
223737443|NCT01852578|DRUG|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
223737444|NCT02066974|GENETIC|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
223737445|NCT03138395|DIAGNOSTIC_TEST|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
224023110|NCT04677179|DRUG|LY3471851|administered SC
223405735|NCT00618592|DIETARY_SUPPLEMENT|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
223405736|NCT02645240|DRUG|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
223405737|NCT00353509|DEVICE|Device Closure of a Septal Defect|
223737446|NCT06136754|DRUG|Varnishes, Fluoride|Fluoride varnish containing 5.0% NaF
223737447|NCT02703584|DRUG|Buseralin|
223737448|NCT02703584|OTHER|Placebo|
223737449|NCT02703584|DRUG|pregnyl|
223737450|NCT03750812|BEHAVIORAL|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
223737451|NCT03750812|BEHAVIORAL|Watching television|Sitting and watching television for 30 minutes
223405738|NCT01788631|DRUG|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-\[4-\[(methylamino)carbonyl\]-1H-pyrazol-1-yl\]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
223405739|NCT01788631|DRUG|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
223405740|NCT01764360|OTHER|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
223405741|NCT00256412|DRUG|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
223737452|NCT02234960|DRUG|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
224023111|NCT04677179|DRUG|Placebo|administered SC
224023112|NCT03546764|DEVICE|Percutaneous catheter|tube inserted to drain hemothorax
224023113|NCT00002674|BIOLOGICAL|filgrastim|
224023114|NCT00002674|DRUG|cytarabine|
224023115|NCT00002674|DRUG|etoposide|
224023116|NCT00002674|DRUG|hydroxyurea|
224023117|NCT00002674|DRUG|mitoxantrone hydrochloride|
224023118|NCT00002674|PROCEDURE|peripheral blood stem cell transplantation|
224023119|NCT01427595|DRUG|Metformin|500-2000 mg PO BID (X12 weeks)
224023120|NCT01427595|DRUG|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
223405742|NCT00256412|DRUG|Placebo|4 capsules of placebo each day
223405743|NCT00891020|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
223405744|NCT00891020|DRUG|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
223405745|NCT00891020|DRUG|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
223556098|NCT06410352|PROCEDURE|Minigastric bypass|Endovideososcopic techniques with the intraperitoneal using of synthetic/biological materials. MGB is performed to reduce the absorption surface of the gastrointestinal tract by shunting the greater part of the stomach, the duodenum and the initial section of the small intestine, which reduces the absorption of food and leads to a decrease in the production of gastrointestinal hormones.
223737453|NCT02548494|DRUG|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
223737454|NCT02548494|DRUG|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
224023121|NCT01427595|DRUG|estrace|oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
224023122|NCT04538690|OTHER|Shoulder Exercises|Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
224023123|NCT04538690|OTHER|Electrotherapy|TENS, US
223556099|NCT06410352|DIETARY_SUPPLEMENT|Analimentary detoxication|very-low-calorie-restriction diet ('Analimentary-detoxication') including \<100 kcal/day with fat-free vegetables (tomato/cucumber) and salt intake (5-6 g/day), optimum physical activity, and sexual self-restraint.
223737455|NCT02548494|OTHER|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
224023124|NCT04330352|BEHAVIORAL|"Mindfulness-based STOP touching your face practice"|1\. Remind yourself to STOP. Whatever you are doing in this moment (e.g. touching your month, pinching your nose, rubbing your eyes, resting your chin on your hands), pause for a minute. 2. Take a deep breath. This reconnects you with your body. Pay attention to your breathing and just allow yourself to continue to breathe normally and naturally. 3. Observe what is happening for you in this moment-including thoughts, feelings, and emotions (e.g. feel distracted, anxious or nervous?). What do you notice in your body (e.g. feel itchy or tingling on any part of your face)? You can be aware of anything: posture, sensations, tension in your body, or, once again, your breath. You might notice the sound around you. You might even notice your thoughts or emotions. 4. Proceed with whatever you were doing before you came to a STOP or something that you want to do in the moment (e.g. proceed with touching your face, or stop face-touching and take an alternative behavior).
223737456|NCT02548494|OTHER|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~* Administer 1-3 L during the first hour.~* Administer 1 L during the second hour.~* Administer 1 L during the following 2 hours~* Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
223737457|NCT03387839|OTHER|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
223737458|NCT00000210|DRUG|Buprenorphine|
223737459|NCT01269424|BIOLOGICAL|MGMTP140K-encoding retroviral vector|
224023125|NCT02926404|DEVICE|UNiD Rods|Spinal osteosynthesis
224023126|NCT04819776|DRUG|Iloperidone|Oral iloperidone
224023127|NCT04819776|DRUG|Iloperidone Placebo|Oral placebo
224023128|NCT00926627|DRUG|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight \< 40 kg/90 lb)
223405746|NCT00436189|PROCEDURE|Blood Draw|
223405747|NCT03188289|DRUG|Placebo gel|Placebo is the control group treated with a placebo gel.
223405748|NCT03188289|DRUG|Clorhexidine gel|Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
223405749|NCT03188289|DRUG|Clorhexidine-Chitosan gel|Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
223405750|NCT03188289|DRUG|Hyaluronic Acid gel|Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
223405751|NCT02042989|DRUG|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
223405752|NCT02042989|DRUG|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
223556100|NCT06410352|BEHAVIORAL|Ramadan fast's weight loss|"The participants adhered to fasting on RF season. They strictly adhered to two principles of nutrition during RF: 1) no blood, no smell of fat which means don't eat meat and don't eat fatty foods; 2) the 'Sehri time' (a meal eaten before dawn) included just 1.5-2.0 glass of water and fruits of 80-100 gr (apple, dates, and persimmon). Indeed, the patients followed a diet in which they ate one meal a day - participants have a meal during 'Iftar time' (a meal eaten after sunset)."
223556101|NCT00819000|DRUG|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
223556102|NCT03357796|DRUG|LY03005|80 mg, oral tablets, single dose
223556103|NCT03357796|DRUG|Pristiq|50 mg, oral tablets, single dose
223556104|NCT04360005|DRUG|Asciminib|Patients receive Asciminib
223556105|NCT01268046|DRUG|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
223556106|NCT01268046|DRUG|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
223737460|NCT01269424|DRUG|O6-benzylguanine|
223737461|NCT01269424|DRUG|temozolomide|
223737462|NCT01269424|OTHER|laboratory biomarker analysis|
223737463|NCT01269424|PROCEDURE|autologous hematopoietic stem cell transplantation|
223737464|NCT01269424|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
223737465|NCT01269424|RADIATION|radiation therapy|
223737466|NCT02667574|DRUG|ERIVEDGE|
223405753|NCT04737629|BEHAVIORAL|Expectancy and Water|In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).
223405754|NCT04737629|BEHAVIORAL|No Expectancy and Water|Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).
223405755|NCT04737629|BEHAVIORAL|No Water|Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
223405756|NCT01932060|DRUG|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
223405757|NCT00156780|DRUG|AI-700|
223405758|NCT01339260|DRUG|Netupitant and Palonosetron|
223737467|NCT03732001|DRUG|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
223405759|NCT01339260|DRUG|Palonosetron|
223556107|NCT01268046|DRUG|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
223556108|NCT01268046|DRUG|placebo oral capsule|placebo oral capsule administered daily for one month.
223737468|NCT03732001|DRUG|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
223737469|NCT03566251|OTHER|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
223737470|NCT03566251|OTHER|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
223737471|NCT03566251|OTHER|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
223405760|NCT01339260|DRUG|Dexamethasone|
224023129|NCT00926627|DRUG|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
224023130|NCT02691117|DRUG|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
224023131|NCT06212401|DRUG|Dexmedetomidine|Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr
224023132|NCT06212401|DRUG|Ketofole|Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion
224023133|NCT00476710|DRUG|Colesevelam HCl|
224023134|NCT00235482|DRUG|Coxsackievirus A21|
224023135|NCT01232179|PROCEDURE|conventional prp|pan retinal photocoagulation
224023136|NCT01232179|PROCEDURE|targeted prp|1200-1600 spot in far periphery retin, anterior equator
224023137|NCT03107832|PROCEDURE|thoracic epidural anesthesia procedure|general anesthesia procedure
224023138|NCT02244645|BEHAVIORAL|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
224023139|NCT02244645|BEHAVIORAL|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
224023140|NCT00682669|BEHAVIORAL|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
223405761|NCT03137160|BIOLOGICAL|Ixekizumab|Injection
223405762|NCT02318680|OTHER|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
223405763|NCT03291080|DRUG|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
223556109|NCT01821092|PROCEDURE|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
223556110|NCT01821092|DEVICE|osseointegrated implant|Osseointegrated Implant Insertion
223556111|NCT03415425|OTHER|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
223556112|NCT03415425|OTHER|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
223405764|NCT03291080|DRUG|Extracted capsules 13-CRA|Extracted capsules 13-CRA
223405765|NCT03853174|OTHER|Endurance Training ET|Endurance training were prformed. Intensity was gradually increased.
223405766|NCT03853174|OTHER|Resistance Training RT|Resistance training were prformed. Intensity was gradually increased.
223405767|NCT04110626|OTHER|Questionnaires|The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative
223405768|NCT04110626|OTHER|Non-directive Interviews|The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
223405769|NCT03114930|OTHER|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
223405770|NCT04504448|DRUG|HNC664 capsules Single dose|HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
223405771|NCT04504448|DRUG|HNC664 placebos Single dose|HNC664 placebos single ascending doses,PO,Single dose, matching placebo
223405772|NCT04504448|DRUG|HNC664 capsules FED|HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
223556113|NCT01557543|OTHER|Cell Therapy|Intramyocardial Injection of BMSCs
223405773|NCT04735601|PROCEDURE|Ahmed Valve|Ahmed valve implantation coated with poly lactic -co-glycolic acid (PLGA) saturated with Mitomycin-C in the management of adult onset glaucoma in Sturge Weber syndrome
223405774|NCT00285740|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) in a Group Format|
223405775|NCT06497530|DRUG|Serplulimab|"Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle for 4 cycles in the induction phase.~Serplulimab will be administered intravenously at a dose of 4.5 mg/kg on Day 1 of each 21-day cycle in the maintenance phase."
223405776|NCT06497530|DRUG|Lurbinectedin|Lurbinectedin will be administered intravenously at a fixed dose of 4 mg on Day 1 of each 21-day cycle in the maintenance phase.
223405777|NCT06497530|DRUG|Carboplatin|Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
223405778|NCT06497530|DRUG|Etoposide|Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
223405779|NCT03498430|DRUG|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
223405780|NCT04505930|BEHAVIORAL|Interventional HPV vaccination video modules|The study team provide participants in the intervention group with interventional education, using interactive video watch and dynamic discussion. The educational videos were aiming to reinforcement and improvement the awareness, knowledge, attitude, intention and actual uptake of HPV vaccination shots among Chinese parents.
223405781|NCT04505930|BEHAVIORAL|General Vaccination Education|Education session conducted using only handouts of vaccinations including HPV
223556114|NCT02253433|OTHER|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
224023141|NCT00682669|BEHAVIORAL|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
224023142|NCT00492362|BEHAVIORAL|ergometer exercise during hemodialysis|
224023143|NCT00492362|BEHAVIORAL|pedometer activity outside of hemodialysis|
224023144|NCT03494478|OTHER|Neuropsychological testing|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up
223556115|NCT02253433|OTHER|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
223556116|NCT03366025|DIAGNOSTIC_TEST|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
224023145|NCT03494478|OTHER|Actimetry|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
223556117|NCT02378077|PROCEDURE|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
224023146|NCT03494478|OTHER|Self-questionnaires on emotional topics|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
224023147|NCT04913389|DRUG|Acetazolamide|Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.
224023148|NCT04913389|DRUG|Placebo|Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.
224132684|NCT01593163|DRUG|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
223405782|NCT04412655|DEVICE|Percutaneous Coronary Revascularization for STEMI|Percutaneous Mechanical Reperfusion for STEMI
223405783|NCT00320710|DRUG|Zoledronic acid|4mg IV
223405784|NCT00320710|DRUG|Placebo|Placebo to zoledronic acid
223405785|NCT04944914|DRUG|camrelizumab|Patients receive camrelizumab(200mg, iv drip for over 60min) every 2 weeks from 2 weeks before radiotherapy
223405786|NCT04944914|RADIATION|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy for all oligometastatic lesions as radical therapy to control the disease and reduce any potential adverse impact to living quality. The dosage is based on published clinical studies.
223405787|NCT05029518|DRUG|SMP-100|In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
224023149|NCT02883127|BEHAVIORAL|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~1. Watch portion size - to be conscious about the amount of carbohydrates in each meal.~2. Eat mainly carbohydrates of low glycaemic index.~3. Reduce the intake of carbohydrate of high glycaemic index.~4. Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
223405788|NCT05372835|OTHER|La Chlogen mouthwash|Patients with periodontal disease were randomized into mouthwash group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the commercially available La Chlogen mouthwash in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
223405789|NCT05372835|OTHER|water|Patients without periodontal disease were selected as a control group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the intervention was asked participants to rinse the pure water in mouth without spitting. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
223405790|NCT05372835|OTHER|La Chlogen mouthwash and La Chlogen periodontal flosser|Patients with periodontal disease were randomized into mouthwash and periodontal flosser group. Before the intervention, participants were asked to rinse 5 ml of water to deplete the food debris and the other residues. After this, the La Chlogen mouthwash in conjunction with the La Chlogen periodontal flosser were applied in mouth without spitting for interventions. After 5 minutes, the participants spit out the liquid, and the saliva samples were collected for further analysis.
224023150|NCT04532554|DRUG|Growth Hormone|Recombinant growth hormone will be used
223405791|NCT03448419|DRUG|Empagliflozin|Film-coated tablet
223405792|NCT03448419|DRUG|Placebo|Film-coated tablet
223405793|NCT01534338|BEHAVIORAL|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
223405794|NCT01534338|BEHAVIORAL|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
223405795|NCT03053037|PROCEDURE|final apical size instrumentation|root canal instrumentation to two different final preparation sizes
223405796|NCT03010384|OTHER|Rehabilitation program|
223405797|NCT01915602|DRUG|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
223405798|NCT01915602|DRUG|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
223405799|NCT01117922|OTHER|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
223405800|NCT01117922|OTHER|Usual Care Group|
223405801|NCT04894825|DRUG|M108|Monotherapy: Accelerated titration method, IV infusion Q3W; Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q3W. (21-day cycles)
223405802|NCT04894825|DRUG|M108|IV infusion Q3W. (21-day cycles)
223556118|NCT02378077|PROCEDURE|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
223556119|NCT02378077|DIETARY_SUPPLEMENT|Fish Oil Supplement|Fish Oil supplementation for three months.
223556120|NCT00003065|BIOLOGICAL|filgrastim|
223556121|NCT00003065|DRUG|paclitaxel|
223556122|NCT00003065|DRUG|topotecan hydrochloride|
223556123|NCT06329466|OTHER|intervention (EFT) group|It is the group to which EFT is applied.
223556124|NCT00807586|DRUG|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
224023151|NCT04532554|DRUG|Placebo|Saline injection with the same amount
224023152|NCT03866473|DEVICE|Retilux|670nm wavelength light
224023153|NCT03866473|DEVICE|Sham Light Device|Broad spectrum light device
224023154|NCT01688687|PROCEDURE|Endoscopic submucosal dissection|
224023155|NCT01177982|BEHAVIORAL|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
224023156|NCT01177982|BEHAVIORAL|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
223405803|NCT02841995|DRUG|Belumosudil (KD025)|Pharmaceutical form: Capsules or Tablets Route of administration: Oral
223405804|NCT04287257|DEVICE|Fracture Healing Patch (FHP)|The Fracture Healing Patch (FHP) is an external silicone patch that contains inside micro-electronic modulus, which generates a pulsed electromagnetic field (PEMF) to enhance and improve fracture healing. The FHP is placed under the cast at the fracture site. Throughout the treatment period the FHP produces a pulsed electromagnetic field. The FHP houses a battery, a microelectronic module and a coil that produce the PEMF.
223405805|NCT02283424|DRUG|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
223405806|NCT02283424|DRUG|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
223405807|NCT02639624|DRUG|Low bicarbonate dialysate First|
223405808|NCT02639624|DRUG|Normal bicarbonate dialysate First|
223405809|NCT02639624|DRUG|Normal bicarbonate dialysate|
223405810|NCT02639624|DRUG|Low bicarbonate dialysate|
223556125|NCT00807586|DRUG|Placebo|Normal saline (1.6 cc)
223556126|NCT05273814|DRUG|Tislelizumab|Tislelizumab intravenous infusion 200mg d4
223556127|NCT05273814|DRUG|Pemetrexed|Pemetrexed intravenous infusion 500mg/m2 d1
223556128|NCT05273814|DRUG|Bevacizumab|Pemetrexed intravenous infusion 7.5mg/kg，d1
223405811|NCT01227590|DRUG|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
223405812|NCT06205914|PROCEDURE|fixation of patella fractures by craniofacial mesh plate osteosynthesis augmented by screws|patellar fracture fixation using MatrixNEURO Contourable Mesh plates (Synthes®). Made of titanium with an incredibly low profile
223405813|NCT06182202|DEVICE|Powered Prosthesis|Custom in-house powered prosthetic device (used in prior studies, see Citations).
223405814|NCT03097276|PROCEDURE|blood sample|blood sample will be collected
223405815|NCT03097276|RADIATION|CT scan|CT scan
223556129|NCT05618210|OTHER|regional anesthesia|"in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection."
223556130|NCT00969605|PROCEDURE|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
224023157|NCT01177982|BEHAVIORAL|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
223556131|NCT05233488|DEVICE|Pulsed Ultrasound Therapy|Ultrasound therapy is applied in the pulsed mode.
223556132|NCT00742222|RADIATION|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
223556133|NCT00742222|RADIATION|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
223556134|NCT06412835|OTHER|cooperative learning|Students working in groups
223556135|NCT02836717|DEVICE|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
224023158|NCT01177982|BEHAVIORAL|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
224023159|NCT01177982|BEHAVIORAL|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
224023160|NCT01177982|BEHAVIORAL|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
223405816|NCT02875626|DRUG|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
223405817|NCT04876326|BIOLOGICAL|Autologous Adipose Mesenchymal Stem Cell Implantation|"Before taking adipose tissue, each subject was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.~Adipose tissue was taken through 5 grams of subcutaneous fat biopsy from the abdomen of each subject and put into a transport medium and then sent to the RSCM-FKUI cGMP IPT Stem Cells Laboratory for immediate isolation of mesenchymal stem cells.~MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.~The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.~The MSC to be injected into the subject will be prepared in 2cc physiological NaCl transport medium just before implantation.~The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe."
223556136|NCT00086983|DRUG|becatecarin|Given IV
223556137|NCT00086983|DRUG|oxaliplatin|Given IV
223556138|NCT00086983|OTHER|pharmacological study|Correlative studies
223556139|NCT02140606|DRUG|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
223556140|NCT05476887|DRUG|KP104|KP104 intravenously (IV loading + subcutaneous \[SC\] maintenance every week \[QW\] or every 2 weeks \[Q2W\]) will be administered.
223556141|NCT00224120|DRUG|Silodosin|8 mg daily for 12 weeks
223556142|NCT00224120|OTHER|Placebo|One capsule daily for 12 weeks
223556143|NCT02654821|BIOLOGICAL|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
223556144|NCT02654821|PROCEDURE|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
223556145|NCT02654821|PROCEDURE|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
223556146|NCT00612378|DEVICE|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
223556147|NCT01844297|DRUG|TDF+3TC+EFV|
223556148|NCT00438360|DRUG|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
223556149|NCT00438360|DRUG|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
223405818|NCT04876326|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|"Before taking the umbilical cord tissue, a pregnant woman's donor was screened including HbSAg, Anti HbS, Anti HCV, HIC, MCV and syphilis tests.~Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.~The umbilical cord is transported to the GMP standard culture laboratory at the UPT TK Stem Cells RSCM-FKUI for isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.~MSC that has been isolated will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.~The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture.~The MSC to be injected into the subject will be prepared in a suitable transport medium just prior to implantation."
223405819|NCT04876326|BIOLOGICAL|Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation|"Before taking adipose and umbilical cord tissue, each subject was screened. -For Adipose tissue : The adipose secretion used is prepared in whole form as much as 10cc in a 10cc syringe.~-Uc-MSC : Immediately after delivery, the umbilical cord was collected and stored in a sterile specimen plate containing 0.9% NaCl at 4⁰C.~The umbilical cord is transported to the GMP standard culture laboratory to have isolation process of mesenchymal stem cells. Sample processing was carried out within 8 hours of delivery to maintain cell viability.~Later it will be cultured using the appropriate medium until it reaches the desired passage and the number of cells.The viability and proliferation ability of cultured cells were evaluated, then characterization of cell antigen expression was carried out using flow cytometry to confirm the success of MSC culture."
223405820|NCT01703260|DRUG|Roflumilast|Roflumilast dose
223405821|NCT01703260|DRUG|Pioglitazone|Pioglitazone dose
223405822|NCT01703260|DRUG|Placebo|Pioglitazone placebo-matching dose
223405823|NCT01703260|DRUG|Placebo|Roflumilast placebo-matching dose
223405824|NCT04181892|PROCEDURE|Coronally advanced flap + connective tissue graft|connective tissue graft covered by a coronally advanced flap with connective tissue graft apical of the cementoenamel junction level
223405825|NCT03227744|BEHAVIORAL|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
223405826|NCT03227744|OTHER|Surveys|MAX-PC, GAD and FACT-P
223556150|NCT05842434|DEVICE|Felix|Felix is a wrist-worn, noninvasive, transcutaneous neurostimulation system intended for daily use to suppress hand tremors. An artificial intelligence (AI) algorithm will automatically adjust the stimulation based on each patient's tremor throughout the day.
223556151|NCT04566952|DRUG|Anlotinib|Anlotinib will be treated with its minimum dose that is orally 8 mg daily on days 1-14 of a 21-days cycle.
223556152|NCT04566952|DRUG|Olaparib|Olaparib will be treated with a total daily dose of 450 or 300mg.
223556153|NCT05260138|OTHER|Gentle Body message|The intervention group received gentle body massage twice/day and position change from supine to lateral every two hours under the phototherapy for three consecutive days in addition to routine NICU care.
223556154|NCT05260138|OTHER|Routine NICU Care|received the conventional NICU care of infants undergoing phototherapy. Phototherapy was given by single Blue LEDs emitting light in a narrow spectrum (450-470 nm). Initially, phototherapy lamps were checked and adjusted at the height of 30 cm from the neonates who were kept naked in the incubator/crib except for the reproductive organs with shielded eyes. The neonates were positioned supine under the phototherapy. The treatment was given continuously, except while feeding and nursing for 30 minutes every 3 hours. The neonates' skin was cleaned with warm water without applying any sorts of ointments oils or creams. They were also observed for signs of dehydration.
223737472|NCT03566251|OTHER|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
223737473|NCT04666584|DEVICE|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon
224023161|NCT01177982|BEHAVIORAL|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
224023162|NCT01177982|BEHAVIORAL|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
224023163|NCT00415077|PROCEDURE|PRK|PRK
224023164|NCT00415077|PROCEDURE|MMC PRK|mitomycin C PRK
224023165|NCT00415077|PROCEDURE|LASEK|LASEK
223556155|NCT02422693|OTHER|Aquatic Exercises|Exercises performed in the water.
223556156|NCT02422693|OTHER|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
224023166|NCT00979810|DRUG|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
224023167|NCT02828878|BIOLOGICAL|Allogeneic MPBC transplantation from matched related donor|
224023168|NCT03110185|DEVICE|EEG|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
223405827|NCT02215369|DEVICE|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
223405828|NCT00003646|DRUG|allovectin-7|
223405829|NCT00413946|DRUG|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
223405830|NCT00413946|DRUG|saline|three doses of 1.0 ml saline per body weight
223405831|NCT05829538|BEHAVIORAL|SuJok|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale.
223405832|NCT05829538|BEHAVIORAL|Massage|Data were obtained by applying the Su Jok Efficiency Visual Analog Scale (VAS), Functional and Emotional Dysmenorrhea (Painful Menstruation) Scale, and SF-36 Quality of Life Scale
223405833|NCT02764814|OTHER|Cryopreserved amniotic membrane|subjects will receive cryopreserved amniotic membrane
223405834|NCT02146014|OTHER|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off."
223405835|NCT02146014|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
223405836|NCT03353714|OTHER|Pudendal block|Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
223405837|NCT04075214|DEVICE|transcutaneous auricular neurostimulation (tAN)|Phoenix tAN system
223405838|NCT04382781|DRUG|NO-Immunosuppressive|Patients not receiving immunosuppressive drugs
223405839|NCT04382781|DRUG|Immunosuppressive|Patients receiving immunosuppressive drugs (overall, and specific drugs)
223556157|NCT00282087|DRUG|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
223556158|NCT05556083|DRUG|Sildenafil 50 mg Oral Tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
223556159|NCT05556083|DRUG|Placebo oral tablet and Dapoxitine 3mg Oral tablet|Single blind placebo randomized controlled trial
223556160|NCT03072394|DRUG|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
223556161|NCT03072394|DRUG|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
223556162|NCT00740441|DRUG|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
223556163|NCT05330494|OTHER|transcutaneous electrical acupoint stimulation(TEAS)|transcutaneous electrical acupoint stimulation (TEAS), the modern therapies derived from traditional acupuncture, which could activate nerve endings or fibers and generate action potentials.s. TEAS uses self-adhesive electrodes placed on the surface of acupoints, instead of needles for electrical stimulation.The resulting stimulation signals, which are transmitted to the spinal cord and brain, stimulate the central nervous system to generate specific chemical mediators to induce relevant physiological effects.
224023169|NCT03110185|DEVICE|fcDOT|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
223405840|NCT04382781|DRUG|Immunoglubulins|Patients receiving immunoglubulins
223405841|NCT02756143|BEHAVIORAL|Exercise|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
223405842|NCT01203514|DRUG|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
223405843|NCT01203514|OTHER|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
223556164|NCT01260688|DRUG|cediranib maleate|Given orally
223556165|NCT01260688|DRUG|dasatinib|Given orally
223556166|NCT04919031|DEVICE|Inspiratory muscle trainer|POWER breathe IMT is a drug-free, hand-held breathing training device. The medical term for this type of breathing training is Inspiratory Muscle Training, or IMT. POWER breathe IMT exercises the main muscles you use to breathe in, primarily your diaphragm and intercostal
223405844|NCT00175123|DRUG|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
223405845|NCT03089723|BEHAVIORAL|Visual Analog Scale (VAS)|Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months
223556167|NCT04919031|OTHER|diaphragmatic release|diaphragmatic release is a manual technique use for restoring the ability of the diaphragm to go through a full range of motion
223556168|NCT04234009|OTHER|Healthy Lifestyle|"The physical activity guidelines for older consist of 150 minutes per week moderate-to-high intensity exercise, two times per week muscle and bone strengthening exercises, which are combined with balance exercises. Additional health benefits can be achieved with a longer exercise duration, frequency and/or intensity. Furthermore, the amount of time sitting should be minimised. The dietary guidelines are described in detail in the so-called The Wheel of Five. In brief, the circle is divided into four food groups and one beverage group. More than half of the circle is covered by fruits, vegetables, whole grain (containing) breads, cereals and potatoes. A much smaller part is compromised by animal source foods, spreads and cooking fats. Water, tea and coffee without sugar complete the circle."
223405846|NCT03089723|BEHAVIORAL|Range of Motion (ROM)|submitted to ROM at at baseline, 1 month, 3 months and 6 months
223405847|NCT03089723|BEHAVIORAL|Palmar grip strength|submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months
223405848|NCT03089723|BEHAVIORAL|Lateral grip strength|submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months
223405849|NCT03089723|BEHAVIORAL|Pulp-pulp pinch strength|submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months
223405850|NCT03089723|DRUG|Lavage with physiologic saline solution|Joint lavage with physiologic saline solution. After emptying of the joint, 1mL saline solution will be injected.
223405851|NCT03089723|DRUG|Lavage with physiologic saline solution and Osteonil® Mini|Joint lavage with physiologic saline solution and Osteonil® Mini
223405852|NCT03089723|BEHAVIORAL|Quick Dash|Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months
223405853|NCT03089723|BEHAVIORAL|Sollerman Test|Perform Sollerman Test at baseline, 1 month, 3 months and 6 months
223405854|NCT02445638|OTHER|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
223405855|NCT02445638|OTHER|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
223405856|NCT00967239|GENETIC|DNA analysis|
223405857|NCT00967239|GENETIC|polymorphism analysis|
223405858|NCT00967239|OTHER|laboratory biomarker analysis|
223737474|NCT04666584|DEVICE|Device: standard non-compliant balloon|Pre-dilatation with a standard non-compliant balloon
223737475|NCT05336955|OTHER|Intake and quarterly assessment:|The START Plan is designed to evaluate the mental health needs of persons with IDD and measure the capacity of the formal and natural support systems. Family caregivers, or the person primarily responsible for day-to-day care of the person, participate in a formatted interview conducted by START coordinators. The START coordinator completes the initial START Plan during intake and quarterly thereafter. Based on informant responses, an intensity rating is assigned to determine the type, frequency, and duration of services to be provided. Quarterly assessment is conducted to inform development or modification of the Cross-Systems Crisis Prevention and Intervention Plan (D.2.b.2.). Hypothesized causal pathway: Family caregiver engagement in assessment enables the START team to efficiently and effectively identify needs and socially valid solutions that strategically reduce use of emergency services and increase mental health stability.
223405859|NCT00967239|OTHER|pharmacogenomic studies|
223405860|NCT03137238|OTHER|Investigation of self-perception in Parkinson's disease|There is no therapeutic intervention.
223405861|NCT00619450|OTHER|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
223556169|NCT00140907|DRUG|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
223556170|NCT00140907|DRUG|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
223556171|NCT03938103|BEHAVIORAL|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
223556172|NCT03938103|BEHAVIORAL|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
223737476|NCT05336955|OTHER|Consultation & coping skills coaching:|Mental health service consultation is provided by START clinical and medical directors in order to prevent and de-escalate crises. Coping skills coaching, provided by START coordinators, helps to determine with the person, their family, and the system of care how to promote well-being and stability. Successful coping skills for the person are incorporated into the Cross-Systems Crisis Prevention and Intervention Plan. All methods are manualized and reported to meet model fidelity. Hypothesized causal pathway: Providing consultation and coping skills coaching to youth and young adults with IDD, their families, and their system of care increases capacity for crisis prevention and stabilization, reduces emergency service use, and increases quality of care, leading to long-term stability.
223405862|NCT00212550|PROCEDURE|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
223405863|NCT05739838|DEVICE|Biolase ;Low Level Laser|Low Level laser ,940 nm
223405864|NCT06340113|PROCEDURE|MCKENZIE AND STABILIZATION EXERCISES|"In this group 11 participants will receive McKenzie protocol with stabilization exercises. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week. At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold"
223556173|NCT05757440|OTHER|Icon resin application|Application of the low-viscosity resin infiltration (Icon) to the white spot enamel lesions
223556174|NCT01147250|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
223556175|NCT01147250|DRUG|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
223737477|NCT05336955|OTHER|24-hour urgent crisis response and intervention:|START teams have 24-hour, in-person mobile crisis intervention services. Emergency calls come from a variety of sources; clients, emergency rooms, service providers, families, and law enforcement. START provides immediate telephonic response and in-person evaluation within two hours of the initial contact. Hypothesized causal pathway: Real-time, immediate support enables the successful enactment of crisis evaluation and stabilization. This reduces severity of the crises and allows for diversion from emergency service use.
223405865|NCT06340113|PROCEDURE|MULLIGAN AND STABILIZATION EXERCISES|. The technique will include Self-sustained Natural Apophyseal Glide (SNAGs), Natural Apophyseal Glides (NAGs), and mobilization techniques.. The participants will receive three sets of Mulligan Mobilization, each set involving 10 repetitions of the exercise, with an interval of 15 to 20 seconds between the sets.At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold.
223405866|NCT05885503|BIOLOGICAL|RC-28E|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
223405867|NCT05885503|BIOLOGICAL|Aflibercept|Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
224023170|NCT03110185|DEVICE|fcMRI|Brain activity will be recorded to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
223405868|NCT01050933|DRUG|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
223405869|NCT05668208|DEVICE|E-CUBE i7 ultrasound system (Alpinion Medical Systems, Seoul, Republic of Korea)|ONSD measurement will be made using the E-CUBE i7 ultrasound system.
223405870|NCT06116279|DEVICE|Insertion of electrode during planned neurosurgery for epilepsy|A novel, 300 micrometer, ultraflexible, low-impedance electrode proposes to cause minimal parenchymal (brain tissue) damage, and provide multiple contacts at multiple depths to allow unit-level recordings for a period of 15 minutes.
223405871|NCT00937079|OTHER|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
223405872|NCT02531308|DRUG|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
223556176|NCT00851292|DEVICE|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
223556177|NCT01335256|DRUG|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
223556178|NCT01303718|DEVICE|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
223556179|NCT01303718|OTHER|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
223556180|NCT02569255|PROCEDURE|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
223556181|NCT05792982|BEHAVIORAL|12 hour fasting for 29 days|This study aims to determine the effects of fasting on serum FGF21 levels. For this reason, male adults who fasted during the Ramadan were included in the study.
223556182|NCT01032408|BIOLOGICAL|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
223556183|NCT01032408|BIOLOGICAL|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
223556184|NCT01071499|DRUG|Morphine|One dose of morphine (0.1 mg/kg)
223556185|NCT01071499|DRUG|Morphine|One dose of morphine (0.2 mg/kg)
223556186|NCT01071499|DRUG|Morphine|One dose of morphine (0.3 mg/kg)
223556187|NCT02346643|DEVICE|Implantation with the commercially available Axium Neurostimulator|
224023171|NCT02825784|DIETARY_SUPPLEMENT|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
224023172|NCT03049033|OTHER|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
224023173|NCT03049033|OTHER|Occupational Therapy|Occupational Therapy uses traditional motor training.
224023174|NCT03049033|OTHER|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
223405873|NCT02531308|DRUG|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
223405874|NCT02531308|DRUG|Cyclophosphamide|Interferes with DNA replication
223405875|NCT02531308|DRUG|Doxorubicin|anthracycline antitumor antibiotic
223405876|NCT02531308|DRUG|Vincristine|Inhibits cell mitosis causing cell death.
223405877|NCT02531308|DRUG|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
223405878|NCT02531308|DRUG|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
223405879|NCT04234490|PROCEDURE|Parenteral nutrition|Impact of parenteral nutrition on patient quality of life over time and impact on carer burden
223405880|NCT02825628|DRUG|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
223405881|NCT01937611|DRUG|Dexmedetomidine|Dexmedetomidine
223405882|NCT01937611|DRUG|Midazolam|Midazolam
223405883|NCT01056471|OTHER|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4\*10e6 cells/Kg.
223405884|NCT01056471|OTHER|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
223556188|NCT05319808|OTHER|Manual therapy|Individualized treatment of manual therapy provided by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
223556189|NCT05319808|DEVICE|Telehealth exercises|A novel, remote computer based cervical joint positioning exercise and cervical kinaesthetic exercise (CKE) program. A technical consultant monitors the data from the remote exercises and inform the PTs if someone has not done their exercises in over 2 weeks during the study period so subjects can be encouraged with a friendly reminder.
223556190|NCT05319808|OTHER|Non-computer based exercises|Home-exercises in the need of each subject (pragmatic approach) taught by MT PTs, graduates from Curtin University of Technology, Perth, Australia (2008)
223556191|NCT00231686|BEHAVIORAL|Supervised aerobic training|
223556192|NCT00231686|BEHAVIORAL|Supervised strength training|
223556193|NCT00231686|BEHAVIORAL|Unsupervised training|
223556194|NCT03334981|PROCEDURE|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
223556195|NCT00867802|BEHAVIORAL|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
223556196|NCT05141708|DRUG|Talazoparib|Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
223556197|NCT03985943|DRUG|Placebo|Placebo
223556198|NCT03985943|DRUG|Nemolizumab|Nemolizumab
224297793|NCT02212912|BEHAVIORAL|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
224297794|NCT02212912|BEHAVIORAL|no intervention|No intervention indicated that the physicians among control hospital provide routine
224297795|NCT00456495|DRUG|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
224297796|NCT01303536|DRUG|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
224297797|NCT02192164|BEHAVIORAL|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
224297798|NCT05147038|DEVICE|Tele-coaching|"The participants are instructed to use a Fitbit fitness tracker to record the number of steps. This device is compatible with the m-PAC App, which was developed for this specific group of participants (individuals suffering from a chronic lung disease). The participants receive a feedback via the m-PAC App every day and they also receive a week report to be albe to adjust their step goal. They are asked to increase or keep their week goal every Sunday after reviewing a weekly report. The participants also receive tips for their PA improvement and they are asked for medication change specification (every Wednesday)."
224297799|NCT01124708|DRUG|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
224297800|NCT01124708|DRUG|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
224297801|NCT03891017|OTHER|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
224297802|NCT03891017|OTHER|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
224297803|NCT06058221|DEVICE|simultaneous videolaryngoscopy|Two specialists perform tracheal intubation, one using a video laryngoscope to expose the vocal cords and the other using a fiberoptic bronchoscope.
224297804|NCT06058221|DEVICE|supraglottic airway|After inserting the supraglottic airway, the specialist performs intubation using a fiberoptic bronchoscope through the supraglottic airway.
224297805|NCT01300923|DRUG|Acamprosate|
224297806|NCT06327802|OTHER|Questionnaire|Participants will have to answer the socio-demographic questions (Age, weight, height, FEV1, FVC) and the Beck, Zarit, HAD, FAS CARERQOL-7D questionnaires
224297807|NCT01235702|BEHAVIORAL|12-week lifestyle modification|
224297808|NCT04870723|BEHAVIORAL|eHealth for Covid-19 prevention and support|3-session online peer-counseling intervention based on motivational interviewing and psychoeducation
224297809|NCT01568866|DRUG|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
224297810|NCT01568866|DRUG|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
223556199|NCT02319616|DRUG|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
223556200|NCT02319616|DRUG|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
223556201|NCT05368389|DEVICE|Healthdot attachment|"The wearable health monitoring device Healthdot 5 will be attached to the patient's skin at left lower rib and data like heart rate, respiratory rate, posture and activity will be collected for 10 days.~A questionnaire will be sent to patients to fill out at the 10th day after the device attachment."
223556202|NCT03277898|BEHAVIORAL|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
223556203|NCT03277898|BEHAVIORAL|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
223556204|NCT00338286|OTHER|Standard supportive care (packed RBC transfusion)|Per doctor prescription
224023175|NCT01993173|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
223556205|NCT00338286|DRUG|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
223556206|NCT01060449|OTHER|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
224297811|NCT01568866|DRUG|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
223556207|NCT05524623|OTHER|percutaneous microelectrolysis in myofascial trigger points of the trapezius|percutaneous microelectrolysis with or without current emission in the treatment of cervical pain in myofascial trigger points of the trapezius
224297812|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
223556208|NCT02290496|BEHAVIORAL|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
223556209|NCT02290496|BEHAVIORAL|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
223556210|NCT02029755|PROCEDURE|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
223556211|NCT02029755|PROCEDURE|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
223556212|NCT02029755|PROCEDURE|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
223556213|NCT00022763|DRUG|Enfuvirtide|
223556214|NCT04607512|DRUG|telaglenastat|glutaminase inhibitor
223556215|NCT04607512|OTHER|telaglenastat placebo|matching placebo for telaglenastat
223556216|NCT04607512|OTHER|moxifloxicin|positive control
223556217|NCT05929391|PROCEDURE|Recycling orthodontic brackets|"T0: The adhesive removal will be performed by high-speed hand piece with tungsten carbide bur. the bur will be changed every five attachments. T1: Control group of T0. T2: The adhesive removal will be performed by sandblasting via Micro-etcher.~T3: Control group of T2."
224023176|NCT01993173|BIOLOGICAL|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
224023177|NCT01993173|BIOLOGICAL|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
224023178|NCT05737537|DIAGNOSTIC_TEST|procalcitonin ,CRP and 1, 3- β -D- glucan in early diagnosis of invasive infections|using of blood biomarkers (CRP ,procalcitonin and 1, 3- β -D- glucan) in early differentiation between fungal and bacterial infections in pediatric cancer patients in comparison to blood culture.
224297813|NCT02816502|BEHAVIORAL|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
224297814|NCT02814435|OTHER|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
224297815|NCT02814435|OTHER|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
224297816|NCT03329079|BEHAVIORAL|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
224297817|NCT03329079|BEHAVIORAL|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
224297818|NCT06142370|OTHER|Descriptive|The patients will be asked by the recruiting physicians to perform a clinical examination looking for the LCV, which will take a total of five seconds. This is a self-test and not part of a regular clinical examination
224297819|NCT03340870|DRUG|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
224297820|NCT03376542|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
224297821|NCT01698775|DRUG|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
224297822|NCT01698775|DRUG|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
224297823|NCT01698775|DRUG|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
224297824|NCT01698775|DRUG|Placebo to glipizide|Matching placebo to glipizide daily
224297825|NCT01698775|BIOLOGICAL|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
223556218|NCT04829786|DRUG|palovarotene low-dose|oral capsules
223556219|NCT04829786|DRUG|palovarotene high-dose|oral capsules
223556220|NCT06537765|DRUG|Medical treatment|All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
223405885|NCT02721277|DRUG|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
224023179|NCT04967638|PROCEDURE|tumor resection and mandible reconstruction|The patients who underwent primary ablative tumor resection with segmental mandibulectomy and immediate VFF reconstruction were retrieved from the database
223405886|NCT04548193|BEHAVIORAL|Behavioral Dietary Intervention|Receive live phone call
223405887|NCT04548193|BEHAVIORAL|Behavioral Dietary Intervention|Receive IVR phone messages
224023180|NCT00416234|PROCEDURE|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
224023181|NCT00416234|PROCEDURE|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
223405888|NCT04548193|OTHER|Educational Intervention|Receive educational materials
224023182|NCT02571647|OTHER|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
224023183|NCT03443050|OTHER|Unstable|This group will train over unstable surfaces to enhance balance abilities
223405889|NCT04548193|OTHER|Questionnaire Administration|Ancillary studies
223405890|NCT04367545|DIAGNOSTIC_TEST|Saliva collection|Saliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)
224023184|NCT03443050|OTHER|Stable|This group will train over stable surface to enhance balance abilities
223405891|NCT03422068|DRUG|BI 1015550|Tablet formulation
223556221|NCT06537765|DEVICE|Therapeutic ultrasound (US)|Women will be asked to assume supine lying position, and the lower abdomen will be cleaned thoroughly with alcohol and dried well thereafter. Ultrasound gel will be distributed over the lower abdomen .The device will be adjusted to Frequency of 1MHz, Mode: continuous wave, Intensity: 1.5W/cm, duration of treatment: 15 minutes for the treatment site, then the skin will be cleaned again to remove ultrasound gel.
223556222|NCT06537765|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS electrodes will be placed on specific acupuncture points for women in supine position. These points include VB29, ST36, CV6, CV4, LV3, KD3, SP6, and SP9. The treatment aims to improve blood circulation, remove adhesions, regulate menstrual activity and hormones, and prevent new adhesions and menstrual reflux in endometriosis patients.
223556223|NCT03248531|DRUG|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
223556224|NCT03248531|DRUG|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
223556225|NCT03248531|OTHER|Placebo|Placebo will be provided matching Bimekizumab.
223556226|NCT03815695|DRUG|FT-4202/Placebo|Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
223556227|NCT02446678|DEVICE|PillCam ESO2|Capsule endoscopy
223556228|NCT02891902|OTHER|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
223556229|NCT04075513|DRUG|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
224023185|NCT00600886|DRUG|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
224023186|NCT00600886|DRUG|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
224023187|NCT05385432|DRUG|Rabbit Anti thymocyte globulin (rATG)|The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
224023188|NCT05385432|DRUG|Basiliximab|Simulect® IV 40mg D0 and D4
224023189|NCT00705861|DRUG|Placebo|Placebo as a substitute of SK3530 100mg
223405892|NCT03422068|DRUG|Placebo|Tablet formulation
223556230|NCT04075513|DRUG|Insulin degludec, 100U/ml|"Pharmaceutical form: solution for injection in a prefilled pen~Route of administration: SC injection"
223556231|NCT04075513|DRUG|Background therapy: Rapid acting insulin analogs|Route of administration: SC injection
223556232|NCT05292924|PROCEDURE|Early SCC|Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
223556233|NCT01326884|DEVICE|ZLP|ZLP Graft
223405893|NCT06574477|PROCEDURE|Planning of alignment with HoloLens 2|Planning of attachment position and traction direction with HoloLens 2 goggles
223405894|NCT06574477|PROCEDURE|No planning of alignment with HoloLens 2|No planning of attachment position and traction direction with HoloLens 2 goggles
223405895|NCT01193933|PROCEDURE|autologous HSCT|T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
223405896|NCT00630825|DRUG|LY2189265|
223405897|NCT00630825|DRUG|Placebo|
223405898|NCT05374122|DIAGNOSTIC_TEST|DSOC with AI biopsy guidance|Patients with a presumptive diagnosis of biliary malignancy will undergo DSOC + Artificial intelligence model (AIWorks) guidance for detection of neoplastic lesion during real-time procedure, tissue sampling acquisition, and histopathological analysis.
223405899|NCT05374122|DIAGNOSTIC_TEST|DSOC biopsy without AI guidance|"Patients with lesions suggestive of malignancy will undergo DSOC without AI guidance for sampling.~Based on the observer´s criteria regarding areas suggestive of malignancy, the collected tissue sample will be sent for histopathological studies."
223556234|NCT02341768|DEVICE|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
223556235|NCT03467893|DRUG|Antacids|number aof antacids treatment after PPI stop
224023190|NCT00705861|DRUG|SK3530|SK3530 100mg
224023191|NCT05191992|OTHER|CPR training with e-learning with a handmade mannequin.|The group, who was given theory training with the e learning method, will be taught to make pillows and plastic bottles and cpr mannequins, and they will be asked to practice. Knowledge and skills assessment will be made before, immediately after and 1 month after the training.
223737478|NCT05336955|OTHER|Service linkages, referrals, outreach, & training:|START teams work with stakeholders to develop and maintain linkage agreements. The purpose of these agreements is to enhance the capacity of the system as a whole and develop partnerships to reduce disparities and gaps in the service array. START coordinators conduct crisis prevention-focused outreach visits with the person and/or their system of care. Examples include training during home- and school-based visits, family caregiver coaching to implement new plans or strategies, and checking in with the person to monitor their level of stability. Hypothesized causal pathway: Increased person-centered collaboration and dialogue across systems of care promotes patient perceived quality of care, the identification of more effective strategies that support their mental health needs, and results in reduced use of emergency services.
223737479|NCT03867305|DEVICE|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
223737480|NCT04588792|DRUG|Nebulized Furosemide|Furosemide administered by nebulization through the ventilator circuit
223737481|NCT04588792|DRUG|Nebulized Saline|Saline administered by nebulization through the ventilator circuit
224297826|NCT01844999|BEHAVIORAL|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
223737482|NCT03087760|DRUG|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
223737483|NCT02511366|OTHER|Ileal infusion of casein|Intraileal infusion of casein
223737484|NCT02511366|OTHER|Ileal infusion of tap water|Intraileal infusion of tap water
223737485|NCT01131923|DRUG|Amlodipine|Amlodipine Tablets, 10 mg
224023192|NCT03075410|DRUG|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
224023193|NCT03075410|DRUG|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
224023194|NCT01026285|DRUG|Risperidone Long-Acting injectable or oral antipsychotics|According to label
223737486|NCT00894049|DRUG|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
223737487|NCT04128267|DEVICE|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
223737488|NCT04128267|DEVICE|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
223737489|NCT04128267|OTHER|Correlative Studies|Administration of questionnaires via computer
223737490|NCT05020990|DEVICE|Lens A (delefilcon A)|Daily disposable for one week
223737491|NCT05020990|DEVICE|Lens B (stenfilcon A)|Daily disposable for one week
223737492|NCT01000389|DEVICE|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
224023195|NCT03047304|DIAGNOSTIC_TEST|Trans abdominal sonography|Trans abdominal sonography in order to measure fetal PR interval.
224023196|NCT03716115|DIETARY_SUPPLEMENT|Colostrum high protein powder (Neovite)|Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.
224132685|NCT01593163|DRUG|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
224132686|NCT03480607|DRUG|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
224297827|NCT01844999|BEHAVIORAL|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
224297828|NCT01377675|OTHER|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
224297829|NCT00359788|DRUG|tiotropium|
224297830|NCT00359788|DRUG|Combivent (Ipratropium/Albuterol)|
223737493|NCT05821114|OTHER|Head elevation_H|High flow\_Head-elevation
223737494|NCT05821114|OTHER|Supine_H|High flow\_Supine
223737495|NCT05821114|OTHER|Head elevation_L|Low flow\_head elevation
223737496|NCT05821114|OTHER|Supine_L|Low flow\_supine
223737497|NCT06391723|DEVICE|Active rTMS|rTMS will be administered over the left dorsolateral prefrontal cortex (20 Hz, 90% resting motor threshold, 20 2 s trains with 60-s intervals, 800 pulses/session)
223737498|NCT06391723|DEVICE|Sham rTMS|Sham rTMS will be administered over the left dorsolateral prefrontal cortex
223737499|NCT02747901|OTHER|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
223737500|NCT02747901|OTHER|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
223737501|NCT03249298|DRUG|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
223737502|NCT03249298|DRUG|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
223737503|NCT06179797|DEVICE|remote ischemic conditioning|suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
224023197|NCT03716115|DRUG|N-Acetyl Glucosamine (GInNAC)|N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
224023198|NCT03716115|DRUG|Teduglutide|Teduglutide will be administered daily as subcutaneous injection
224023199|NCT03716115|DRUG|Budesonide|Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
224023200|NCT05984004|DRUG|0.9% NaCl isotonic saline solution|The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
224132687|NCT03480607|DRUG|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
224132688|NCT04850716|OTHER|non-intervention|non-intervention
224132689|NCT02704676|OTHER|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
224132690|NCT00375817|PROCEDURE|Myoblasts injection with MyoCath catheter|
224297831|NCT01869478|DRUG|Intravenous Thrombolysis|
224297832|NCT01869478|DEVICE|Endovascular Arterial Reperfusion|
224023201|NCT05984004|COMBINATION_PRODUCT|Bacillus subtilis DSM32444, inactivated|Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
223405900|NCT00351195|DRUG|Etoposide|
223556236|NCT05847660|DRUG|Progesterone antagonist|Group (A): Women in progesterone primed (PPOS) will prescribed 30 mg oral dose of dydrogesterone (duphaston, Abbott, Egypt) from the 2nd day of the cycle and continued until triggering day. Vaginal sonography will be done for all patients since the 6th day of the cycle.
223556237|NCT05847660|DRUG|conventional antagonist protocol|Group (B): Women in the antagonist group will be monitored by transvaginal ultrasonography till the size of dominant follicles reached to 12-13 mm, 0.25 mg of cetrotide (Merck-Serono ,Germany) will be injected subcutaneously daily and continued until triggering day, follow up for all patients in both groups by transvaginal ultrasound every other day.
224023202|NCT01427751|DRUG|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
224023203|NCT01427751|BIOLOGICAL|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
224023204|NCT00531102|OTHER|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
224023205|NCT00531102|OTHER|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
224023206|NCT01274832|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
224023207|NCT04191473|PROCEDURE|EMR-P|After submucosal injection, we use ESD knife or the tip of the entrapment device to loop around the lesion, and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
224023208|NCT04191473|PROCEDURE|CEMR|A liquid pad was formed by injecting 0.9% normal saline with meilan solution into submucosa,and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
224023209|NCT06416709|DRUG|mesenchymal stem cells|Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times
224023210|NCT06416709|OTHER|saline|10 ml saline is used as placebo once every three days and for three times
224023211|NCT06088147|DRUG|Methotrexate|A standard derma pen 12 pins with of 0,5 mm depth was used, dermapen as a tool of infusion of our treatments works in a few ways to target hair loss, firstly by breaking down the scar tissue that covers or compromises the hair follicles which are not growing, stimulating new hair growth and also by enhancing infusion of mesotherapy ingredients to increase hair follicle size and therefore hair volume ,here we will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then we will apply methotrexate topically (25 mg/ml) on half of the scalp at a dose of 0.02ml/cm2
223556238|NCT06110936|DEVICE|Transcutaneous Spinal Direct Current Stimulation|Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.
223556239|NCT00737217|BEHAVIORAL|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
224023212|NCT06088147|DRUG|Triamcinolone Acetonide|A standard derma pen 12 pins with of 0,5 mm depth was used, will use it by stamping technique, the procedure was practically painless and therefore no local anesthesia was used, however For those who will not want to tolerate pain, topical anesthesia with 2% lignocaine, under occlusion will applied, the patients will be followed up for 6 months after full course of treatment. Then Triamcinolone acetonide 40 mg/1ml after microneedking at dose 5mg/ml concentration;1/8/ 1:7 dilution
223556240|NCT02427386|DRUG|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
224023213|NCT04329507|DIAGNOSTIC_TEST|Breath test|collection of an exhaled breath sample
224023214|NCT05893628|OTHER|muscle length and muscle endurance assessment|Pectoralis Minor Length and muscle endurance evaluation
224023215|NCT04309136|DRUG|Anlotinib|All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment
224023216|NCT04309136|PROCEDURE|surgery|Perform surgery if operable after neoadjuvant therapy
224023217|NCT04309136|PROCEDURE|core needle biopsy|Perform core needle biopsy if inoperable after neoadjuvant therapy
224023218|NCT00539773|DRUG|BCG, Interferon|Chemotherapy
223405901|NCT00351195|DRUG|Oxaliplatin|
223556241|NCT02427386|DRUG|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
223556242|NCT01624961|BIOLOGICAL|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
223737504|NCT01266512|DRUG|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
223737505|NCT01266512|RADIATION|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
223405902|NCT00351195|DRUG|Capecitabine|
223405903|NCT00950014|OTHER|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
223405904|NCT04654195|GENETIC|polymorphism analysis|DNA will be purified from whole blood samples by commercial DNA isolation kits. Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR.
223556243|NCT04975984|DIAGNOSTIC_TEST|qualitative hCG levels and ultrasound criteria|detect upper limit of qualitative hCG levels associated with successful expectant management of ectopic pregnancy
223405905|NCT04654195|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
223556244|NCT01861691|PROCEDURE|Open surgery|Conventional technique
224023219|NCT01321151|DRUG|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
224023220|NCT01321151|DRUG|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
223556245|NCT01861691|PROCEDURE|Laparoscopic surgery|New minimum invasive technique
223737506|NCT01266512|DRUG|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
223737507|NCT02416440|OTHER|blood sample|blood sample
223737508|NCT04728061|DRUG|Gen1E-1124|Intravenously-infused Gen1E-1124 in vehicle.
224023221|NCT03815786|DIETARY_SUPPLEMENT|Symbiotic|2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
224023222|NCT03815786|DIETARY_SUPPLEMENT|Placebo|2-months oral administration of the placebo (2 bags/day) + 1 month washout
224132691|NCT02042729|DRUG|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
223405906|NCT03863639|DIAGNOSTIC_TEST|Neuroimaging Procedures|"Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures."
223556246|NCT06114914|DIAGNOSTIC_TEST|Tap Talk online program|Online hand and speech motor testing
223737509|NCT04728061|DRUG|Placebo|Intravenously-infused vehicle.
224297833|NCT03437915|RADIATION|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
223737510|NCT02649907|DIETARY_SUPPLEMENT|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
223737511|NCT02649907|OTHER|Nutritional counseling|nutritional counseling for healthy eating behaviour
223737512|NCT02649907|DIETARY_SUPPLEMENT|formula diet|formula diet to help weight loss
223737513|NCT01698047|BEHAVIORAL|Resiliency Class|See Arm Description
224132692|NCT02042729|DRUG|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
224297834|NCT03437915|PROCEDURE|Partial mastectomy|4-12 weeks post NIBB
223556247|NCT03748706|DRUG|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
223556248|NCT04356846|DRUG|LP-108 tablet|Taken orally within 30 minutes after a meal at the designated dose, once daily.
223556249|NCT03096639|DEVICE|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
223556250|NCT05621122|OTHER|This is an observational study|This is an observational study. The control group (omnivours) will be compared with all otgher groups
223556251|NCT00851331|GENETIC|genome analyzes (genetic defects and pathophysiological mechanisms )|
223737514|NCT01698047|OTHER|Case Management|See Case Management description
223737515|NCT00090311|DRUG|quetiapine fumarate|
223737516|NCT04080817|DEVICE|Neolexon|Application (Neolexon) on Tablet. Same frequency \& intensity as in the other interventions
223737517|NCT04080817|OTHER|Speech therapy|standard logopedic speech therapy. Same frequency \& intensity as in the other interventions
223737518|NCT04080817|OTHER|Self training|Same frequency \& intensity as in the other interventions
223737519|NCT01698801|DRUG|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
223737520|NCT01698801|DRUG|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
223556252|NCT00422877|DRUG|Taxoprexin|DHA-paclitaxel
223556253|NCT05294484|DRUG|Indapamide 1.5 MG SR|the effect of genetic variation of UGT2B7 on human response to treatment with indapamide and its correlation with pharmacokinetic parameters in Egyptian subjects
223556254|NCT00952861|DRUG|Doxycycline|200 mg QD in 5 days
223556255|NCT00952861|DRUG|Placebo (matching)|Placebo QD i 5 days
223556256|NCT06346431|COMBINATION_PRODUCT|DSPT - Digital Support for Problem-solving Therapy|Mobile app breaking major treatment and social needs into subtasks, providing information, prompts and in-app payment to complete those tasks.
223556257|NCT04010656|PROCEDURE|PVR-based self-catheterization|Home self-catheterization based on standard of care
223737521|NCT04343599|OTHER|Hypopressive exercises|The first two sessions will have as objective the correct and effective learning of the hypopressive technique. The rest of the sessions will be dedicated to the realization of an exercise protocol based on a progression of postures from standing to supine. Diaphragmatic apneas of approximately 7 seconds will be performed, alternating each apnea with three breaths.
223737522|NCT00815581|DEVICE|photorefraction,cycloautorefraction,cycloretinoscopy|
223737523|NCT01255657|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
224023223|NCT05806307|DRUG|Misoprostol|(15 patient): who will receive 800 microgram (tablet 200mcg X 4) misoprostol (Misotac 200 mcg, SIGMA pharmaceutical, Egypt) rectally one and half hour before operation.
224132693|NCT02042729|DRUG|E2022 Matching Placebo- Current Formula Tape|
224132694|NCT02042729|DRUG|E2022 Matching Placebo- New Formula Tape|
223556258|NCT00091741|DRUG|Etanercept (Enbrel)|
224132695|NCT00297362|DRUG|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
223405907|NCT03863639|DIAGNOSTIC_TEST|Neuropsychological Assessment Procedures|Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
223405908|NCT02478424|DRUG|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
223405909|NCT02478424|DRUG|cyclosporine|
223405910|NCT02478424|DRUG|Methotrexate|
223556259|NCT04563403|BEHAVIORAL|Projection-based augmented reality therapy (P-ARET)|"The intervention will be based on exposure therapy to cockroaches using P-ARET. The treatment will follow the guidelines of the one-session treatment (OST). Main components: Psychoeducation, Exposure to the feared object (cockroach), modeling (the therapist will interact with the phobic stimulus first and if possible, the patient will follow the same steps), cognitive challenge, and reinforcement and relapse prevention."
223556260|NCT03133819|DEVICE|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
223556261|NCT01094977|DRUG|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
223556262|NCT01094977|DRUG|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
223556263|NCT01094977|DRUG|Saline Placebo|
223405911|NCT05268224|DIAGNOSTIC_TEST|Schirmer Strip|A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
223556264|NCT05252494|OTHER|animal assisted therapy|In the intervention group, the child will be given to the mother's lap just before the invasive procedure. During the process, the aquarium with the fish will be placed on a shelf at a distance of about 50-60 cm, at an angle that the child can see. The camera on which the blood collection will be recorded will be placed on a tripod and placed on another shelf in such a way that the child can be seen completely. A video recording will be started 1 minute before the procedure, a pulse oximeter device will be attached to the child immediately after the child is seated on his mother's lap, physiological parameters, pain scores and stress will be determined. During the procedure, children's physiological measurements pain score and stress will be re-evaluated after the needle is inserted into the site. After the procedure, children's physiological measurements pain score and stress will be re-evaluated 1 minute after the needle is removed from the injection site
223556265|NCT05474703|OTHER|SF-36 Scores|"From the electronic database system of our hospital, patients who applied to the gynecology polyclinics of our hospital due to abnormal uterine bleeding between August 2020 and December 2021 and were administered oral dydrogesterone therapy or an intrauterine device releasing levonorgestrel for at least six months were reached using the phone numbers registered in the system.~The patients were informed about the study conducted by teleconference method, and the patients whose verbal consent was obtained were included in the study. After questioning the patients' sociodemographic characteristics such as age, marital status, educational status, income level, employment status, and obstetric history, the patients received the Short form 36 (P-36), consisting of 36 items; The Quality of Life Scale and the Female Sexual Function Scale (FSFI) composed of 19 items were applied."
223556266|NCT04545424|DEVICE|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
224023224|NCT05806307|DEVICE|Tourniquet|(15 patient): The operation will be performed with the use of Foleys catheter as an improvised tourniquet applied at the base of the uterus then infiltration myometrium overlying the leiomyoma with a solution composed of Bupivacaine Hcl 0.25% and 0.5 mg of epinephrine
224023225|NCT05806307|DRUG|Carbetocin|(15 patients): intramural; preparation of 100 μg of carbetocin ((Pabal, Ampoule 100 mcg in 1 ml, Carbetocin; FERRING, North York, Canada) diluted within 10 cm of saline (0.9%) in sterile syringe then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
223405912|NCT03577496|OTHER|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
223405913|NCT02000635|OTHER|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
224132696|NCT04766502|OTHER|Blood sample (20 ml) and EORTC QLQC30 survey|"Blood sample (20ml) will be taken before and 24h after PIPAC procedure~EORTC QLQC30 during pre operative consultation and at each post operative consultations"
224132697|NCT02834546|BIOLOGICAL|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
223405914|NCT00011141|DRUG|Oral lactobacillus administration|
223405915|NCT01396135|DRUG|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
223405916|NCT01396135|DRUG|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
223405917|NCT01396135|DRUG|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
223405918|NCT01396135|DRUG|Placebo|Single dose of placebo given as a matching number of oral tablets
223405919|NCT01396135|DRUG|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
223405920|NCT01396135|DRUG|Placebo|Multiple doses of placebo given as a matching number of oral tablets
223405921|NCT02275819|OTHER|Exercise|Exercise (walking 3 times a week for 60 minutes) or Inspiratory Muscle Therapy (breathing against an inspiratory resistive load 3 times a week for up to 60 minutes)
223405922|NCT00202124|DRUG|Tryptophan|
224023226|NCT05806307|DRUG|Oxytocin|(15 patients): who will receive oxytocin 40 I.U. intramyometrially (Syntocinon, Ampule 10 I.U. in 1 ml, Oxytocin; NOVARTIS, Basel, Switzerland) then will inject the substance into the multiple sites intramyometrial in a circumferential manner 1-2 cm away from the margins of the myoma in the planned uterine-incision site just before uterine incision for myoma extraction.
224023227|NCT05806307|DRUG|combined TXA and ethamsylate|(Patient 15): will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt) and 500 mg ethamsylate (2 ampoule of ethamsylate 250 mg, Dicynone, OM pharma, Geneva, Switzerland) IV 10 minutes before skin incision by slowly intravenous injection Then infusion was applied continuously for 24 hours within 1 liter of saline as 1 mg/kg/hour.
224023228|NCT05806307|DRUG|Vasopressin|15 patient intramyometrial injection of one ampoule of vasopressin containing 20 units in1 ml after dilution in 19 ml of normal saline during myomectomy.
223405923|NCT03892642|DRUG|Avelumab|"Induction phase:~* once weekly for weeks 1-6,~* once every 2 weeks at week 8, 10, and 12~Maintenance phase:~* Once every week for weeks 1-3~* Once every 2 weeks starting at week 5, until the next BCG treatment"
223405924|NCT03892642|BIOLOGICAL|BCG|"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"
223405925|NCT04084418|OTHER|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
223405926|NCT04084418|OTHER|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
223737524|NCT06209645|DEVICE|tDCS (Transcranial Direct Current Stimulation)|The tDCS group will be treated with non-invasive motor cortex stimulation. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region. If pain is bilateral, the most painful region will be chosen to be treated.
223737525|NCT06209645|DEVICE|tACS (Transcranial Alternating Current Stimulation)|The tACS group will be treated with non-invasive motor cortex stimulation. The stimulation series comprises six sessions spaced 2 weeks apart, the first session being placebo. A two-minute EEG recording will be made before each session, using the same electrodes as for stimulation. Stimulation frequency will be set according to the dominant frequency recorded over the motor area. Anodal stimulation of 2,0 mA will be delivered over the motor area contralateral to the painful region (C4 or C3 according to the international 10-20 system). The return electrode will be placed over the fronto-polar region (FP1 or FP2) ipsilateral to the painful region.
223737526|NCT03552146|DRUG|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
223737527|NCT03552146|DRUG|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
223405927|NCT01011816|BIOLOGICAL|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
223405928|NCT01011816|DRUG|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
223405929|NCT03929133|DEVICE|automatic screening machine on congenital heart disease|
223405930|NCT06574152|DEVICE|PBM treatment|Immediately after the apical microsurgery, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, North Carolina, USA), with an 8 mm tip diameter . The laser tip will be placed following the outline of the incision flap in a contact mode . The power output of the laser will be 50 milliwatt (mW) and verified by a Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2
223405931|NCT06574152|DEVICE|PBM sham treatment|Immediately after the apical microsurgery, sham therapy will be performed without activating the laser.
223737528|NCT03556189|DEVICE|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
223737529|NCT01863225|DRUG|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
223737530|NCT01863225|DRUG|Rosuvastatin|20 mg daily, 28-42 days
224023229|NCT05806307|DRUG|Bupivacaine Hydrochloride 0.5 % Injectable Solution epinephrine|15 patient infiltration of the serosa and / or myometrium overlying the leiomyoma before uterine incision with a solution composed of 50 ml Bupivacaine Hcl 0.25% (Bucain® Weimer pharma, for Actavis Group PTC) and 0.5 mg of epinephrine Hcl (2 vials of Epinephrine® 0.25mg/1ml Misr Co. for Pharmaceutical Industries).
224023230|NCT00807287|PROCEDURE|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
224023231|NCT00807287|PROCEDURE|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
224023232|NCT03166410|PROCEDURE|Cell injection|
224023233|NCT05503472|OTHER|observational|observational
223405932|NCT06574152|DEVICE|EMS|Patients will be anesthetized. All surgeries will be performed using a surgical microscope. After reflection of a mucoperiosteal flap, osteotomies will be performed to access the root apices and apical lesions. Root apices will be resected at 3 mm, and the pathological tissue curetted out. Next, root-end preparations will be made with ultrasonic tips and filled with calcium silicate-based materials. Methylene blue dye will be used for inspection after root-end resection before the root-end preparation and filling. After cleaning the osseous crypt, the wound margins will be reapproximated with 5-0 single interrupted sutures. A gauze will be placed for 30 minutes for wound compression. Sutures will be removed seven days postoperatively
223405933|NCT03870932|OTHER|Motor Imagery physical therapy|
224023234|NCT01741896|PROCEDURE|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
224023235|NCT02775695|DRUG|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
224023236|NCT05744752|OTHER|Lead Acetate|The oral LD50 of lead acetate is 390mg/kg body weight. The experimental group B, C, and D will receive a single dose of 19.5 mg/kg b.w (1/120th of LD50),31 daily dissolved in distilled water and given by oral gavage method for 12 weeks. Lead acetate Pb(CH3COO)2x3H2O, will be purchased from Sigma-Aldrich Chemie (Germany).
223405934|NCT03870932|OTHER|Conventional physical therapy|
223405935|NCT01472042|OTHER|Banyan Biomarkers|Biomarkers to detect specific proteins.
223556267|NCT04545424|DRUG|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
223556268|NCT04545424|DEVICE|Standard of care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
223556269|NCT04366830|DRUG|Remestemcel-L|Participants will receive remestemcel-L in two infusions of 2 x 10\^6 mesenchymal stromal cells per kilogram (MSC/kg), administered intravenously (IV).
223556270|NCT01407952|DEVICE|HydroCoil Embolic System|HydroCoil Embolic System
223556271|NCT01407952|DEVICE|Control (bare platinum coils)|bare platinum coils
223556272|NCT03323216|DIAGNOSTIC_TEST|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention."
223556273|NCT03323216|DIAGNOSTIC_TEST|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior and 6 months after the intervention."
223556274|NCT03323216|PROCEDURE|Blood collection|"Blood collection during surgery:~* coronary sinus~* arterial~* peripheral venous~Blood collection 6 months after surgery:~\- peripheral venous"
223556275|NCT04002050|BEHAVIORAL|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
223556276|NCT05151159|OTHER|immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3|
223556277|NCT04670263|DEVICE|Tear Film Imager|Tear Film Imager recording
223556278|NCT02281227|PROCEDURE|skin compression|skin compression with an indicator for determination of needle entry point
223556279|NCT03565250|OTHER|self understanding interview|semi-structured interview designed for assessment of identity according to Damon \& Hart's 7-dimension develomental model
223556280|NCT02889497|BIOLOGICAL|the first batch vaccine|
223556281|NCT02889497|BIOLOGICAL|the second batch vaccine|
223556282|NCT02889497|BIOLOGICAL|the third batch vaccine|
223556283|NCT04153981|DRUG|Insulin Glargine|Administered SC
223556284|NCT02003794|DRUG|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
223556285|NCT00021567|DRUG|Interferon Gamma for Aerosol|
223556286|NCT05679596|DIETARY_SUPPLEMENT|ketone monoester (R)-3-hydroxybutyl (R)-3- hydroxybutyrate|Provided twice a day between meals.
223556287|NCT05679596|DIETARY_SUPPLEMENT|carbohydrate-fat placebo (fructose, corn and canola oil 50:50 ratio)|Provided twice a day between meals.
223556288|NCT05033184|BEHAVIORAL|Brief Action Planning Exercise|The Brief Action Planning exercise is a previously developed goal-setting exercise which has been designed to incorporate aspects of motivational interviewing such as compassion, acceptance, evocation, and partnership. It is a tool that allows participants to identify an aspect of their life they would like to improve upon and guides them through the process of making a specific, measurable, achievable, realistic, and timely (SMART) goal. It also assesses their confidence in achieving this goal so as to assist with making alternative plans if confidence is low.
223556289|NCT05033184|BEHAVIORAL|Goal Setting Exercise|The Goal Setting exercise allows participants to identify an aspect of their life they would like to improve upon without incorporating aspects of motivational interviewing components or providing any guidance on how to set this goal.
223556290|NCT04964505|DRUG|Azacitidine|Given IV or SC
223556291|NCT04964505|DRUG|Uproleselan|Given IV
223556292|NCT04964505|DRUG|Venetoclax|Given PO
223556293|NCT00153673|DRUG|celecoxib|Celecoxib 200mg bd
223556294|NCT00153673|DRUG|Dologesics|Dologesics 2 tablets bd
223405936|NCT04670549|OTHER|Implementation of treatment guidelines|To improve knowledge of OA treatment recommendations among people with hip and knee OA, a lay language summary will be emailed all OA patient participants. A second summary of the treatment recommendations, targeting general practitioners (GPs) will also be emailed the OA patient participants. The patients will be encouraged to print and bring this summary to their GP at the next visit (user-initiated implementation). Barriers and facilitators for providing evidence-based OA care among primary care physiotherapists will be mapped through interviews. Thereafter, a tool-kit of strategies and practical aids intended to help overcome these barriers will be developed and made available for the physiotherapists.
223405937|NCT06163885|OTHER|Stoma care education with flipped classroom|Flipped classroom model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
223405938|NCT06163885|OTHER|Stoma care education with peer-supported education model|Peer-supported education model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
223405939|NCT02211209|DRUG|Volanesorsen|
223405940|NCT02211209|DRUG|Placebo|
223737531|NCT01863225|DRUG|Atorvastatin|40 mg daily, 28-42 days
223405941|NCT01544985|DRUG|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
223405942|NCT01544985|DRUG|placebo po|sterile water
223737532|NCT01863225|DRUG|Rosuvastatin|40 mg daily, 28-42 days
223405943|NCT01695174|DRUG|Xifaxan|
223405944|NCT05496647|OTHER|Virtual Reality|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Preferred video will be watched with Virtual Reality Glasses for approximately 20 minutes during the process, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form, Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; At the 1st hour after the procedure, Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale and Satisfaction Evaluation Form will be filled."
223405945|NCT05496647|OTHER|Music Therapy|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; During the procedure, the preferred music for Music Therapy will be played for approximately 20 minutes, After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
223405946|NCT05496647|OTHER|Stress Ball Application|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; the Stress ball will be played for approximately 20 minutes during the process.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure; Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
223405947|NCT05496647|OTHER|Control|"Before the surgical procedure; the Structured Patient Description Form, Fear of Pain Scale, Life Information Follow-up Form, State Anxiety Inventory, and Visual Comparison Scale forms will be filled by the researcher using a face-to-face interview technique with the woman.~During the process; Women in the control group will not undergo any intervention other than routine surgery.~After Daily Gynecological Surgery 1. Measurements; Immediately after the procedure, within the first 10 minutes; Life Information Follow-up Form and Visual Comparison Scale will be filled.~2\. Measurements After Daily Gynecological Surgery; In the 1st hour after the procedure, the Vital Information Follow-up Form and Visual Comparison Scale will be filled.~3\. Measurements After Daily Gynecological Surgery; In the 2nd hour after the procedure, the Life Information Follow-up Form, State Anxiety Inventory, Visual Comparison Scale, and Satisfaction Evaluation Form will be filled."
223405948|NCT04111120|DIAGNOSTIC_TEST|SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI|Coagulation assessment using heparinase treated SONOCLOT
223556295|NCT03489772|DRUG|ITI-214|Oral
223556296|NCT03489772|DRUG|Placebo|Oral
223556297|NCT04037449|PROCEDURE|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
223737533|NCT01863225|DRUG|Atorvastatin|80 mg daily, 28-42 days
224138828|NCT04895943|PROCEDURE|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too|bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
223405949|NCT03497520|BEHAVIORAL|asymmetric spinal stabilization exercise|"The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~* before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~* after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity"
223405950|NCT01719367|DRUG|Atenolol|
223405951|NCT01086631|DRUG|Rituximab|
223405952|NCT02792062|DRUG|TAK-385 40 mg|TAK-385 40 mg tablet
223405953|NCT04297748|COMBINATION_PRODUCT|89Zirconium-M7824|PET imaging agent
223405954|NCT04297748|DRUG|M7824|Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
223405955|NCT03220269|OTHER|Out-of-hospital cardiac arrest (OHCA)|Data collection
223405956|NCT03220269|OTHER|In-hospital cardiac arrest (IHCA)|Data collection
223405957|NCT04932369|BEHAVIORAL|Emotion Regulation training based on DBT|trained about emotion regulation and problem solving during eight 90-min group sessions
223405958|NCT00178672|DEVICE|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
223405959|NCT00178672|PROCEDURE|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
223405960|NCT00178672|DEVICE|stenting|stenting of carotid arteries
223405961|NCT04895657|DRUG|Piperacillin/Tazobactam Continuous infusion|Continuous infusion
223405962|NCT04895657|DRUG|Piperacillin/Tazobactam Intermittent infusion|Intermittent infusion
223405963|NCT00002596|BIOLOGICAL|bleomycin sulfate|
223405964|NCT00002596|BIOLOGICAL|filgrastim|
223405965|NCT00002596|DRUG|carboplatin|
223556298|NCT04037449|OTHER|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
223556299|NCT02603458|DRUG|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
223556300|NCT02603458|DRUG|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
223556301|NCT01731158|DRUG|Avastin in combination with Roferon-A|
223405966|NCT00002596|DRUG|cisplatin|
223405967|NCT00002596|DRUG|cyclophosphamide|
223405968|NCT00002596|DRUG|etoposide|
223405969|NCT00002596|PROCEDURE|autologous bone marrow transplantation|
223405970|NCT00002596|PROCEDURE|bone marrow ablation with stem cell support|
223405971|NCT00002596|PROCEDURE|conventional surgery|
223405972|NCT00002596|PROCEDURE|peripheral blood stem cell transplantation|
223405973|NCT00002596|RADIATION|radiation therapy|
223405974|NCT01216241|DRUG|Daptomycin|8 MG/KG IV
223405975|NCT01216241|OTHER|Saline Placebo|50 ml normal saline once daily
223405976|NCT01216241|DRUG|Daptomycin|8 mg/kg once daily
223405977|NCT04726696|BEHAVIORAL|ROLE-AP programme|The intervention group will be split in two groups of 7-8 primary care nurses each. These two groups will receive the ROLE-AP program over a three weeks period. Each workshop will be divided into two sessions of 90-120min. The first workshop focuses on the clarification of health promotion concepts and the discussion of the state of nursing practice in health promotion. Participants will discuss the misalignments between this description of nursing practice and the ideal one portrayed by the Ottawa Charter. The second workshop will allow the presentation of the objectives of the health care organization, showing its alignment with the Ottawa Charter areas of action. In addition, it will present a standardized instrument that reflects expectations about nurses' activities in health promotion that will serve for discussing and realigning participants' expectations on nurses' role in health promotion. The third workshop will continue with the discussion of nurses' expected activities.
223405978|NCT05598424|DRUG|Oral Glucocorticoids|Oral Glucocorticoids（methylprednisolone） 24mg qd, 2-week duration
223405979|NCT01626196|OTHER|No intervention|This was an observational study
223405980|NCT05711355|PROCEDURE|Use of Platelet-Rich Plasma after meningomyelocele sac repair|Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
223405981|NCT05711355|PROCEDURE|meningomyelocele sac repair|meningomyelocele sac repair without Platelet-Rich Plasma
223405982|NCT03895008|OTHER|Cardia and Non-cardia gastric cancer|We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
223405983|NCT00931255|DRUG|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
223405984|NCT00931255|DRUG|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
223405985|NCT00023855|DRUG|bortezomib|
223405986|NCT00023855|DRUG|doxorubicin hydrochloride|
223405987|NCT01448343|DEVICE|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
223556302|NCT01731158|DRUG|Afinitor|
223556303|NCT01731158|DRUG|TKI: Sutent, Nexavar or Votrient|TKI
223556304|NCT01355679|DEVICE|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
223556305|NCT05302869|OTHER|None intervention|None intervention
223737534|NCT03761147|OTHER|Paula exercises|structured exercises aimed to stimulate ring muscles
223737535|NCT01375985|DRUG|AVI-7100|Single intravenous administration
223737536|NCT01375985|DRUG|Placebo|Single intravenous administration
223405988|NCT02817295|OTHER|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
223405989|NCT04275739|BEHAVIORAL|Academic Episodic Future Thinking|Brief Academic goal related EFT intervention involving desirable outcomes of current academic goals
223405990|NCT04275739|OTHER|Vivid Memory Task|Matched for time control task involving recall of vivid memories of distinct events/actions from a children's story
223405991|NCT01483963|BIOLOGICAL|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
223405992|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
223405993|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
223405994|NCT01483963|BIOLOGICAL|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
223405995|NCT01483963|OTHER|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
223405996|NCT00131313|DRUG|Nipent, Cytoxan, Rituxan|
223405997|NCT04384003|DEVICE|Shear Wave Ultrasound Elastography|"Scanned protocols of sonographic imaging will be used in this study to measure extrinsic (FDL, FHL and PER) and intrinsic (AbdH, FDB and FHB) muscle CSA and thickness, and plantar fascia thickness (at heel, mid and forefoot sites).~The muscle stiffness will be calculated from the program provided by the US machine as shown real time elastography (RTE, unit: KPa)."
223405998|NCT04384003|DEVICE|The 3-D Motion Analysis|The 3-D Motion Analysis, Forceplates and EMG acquisition system and full body kinematic model (Bonita, VICON Corp, UK) in the Biomechanics and Motor Control Laboratory (BMCL).
223737537|NCT05184920|OTHER|P1012919 nicotine pouch|P1012919, a nicotine pouch with 12 mg of nicotine
223737538|NCT05184920|OTHER|P1012915 nicotine pouch|P1012915, a nicotine pouch with 8 mg of nicotine
223737539|NCT05184920|OTHER|P1012914 nicotine pouch|P1012914, a nicotine pouch with 4 mg of nicotine
223737540|NCT05184920|OTHER|P1013315 nicotine pouch|P1013315, a nicotine pouch with 8 mg of nicotine
223405999|NCT04384003|DEVICE|Electromyographic|Electromyographic activity (EMG) of AbdH, TA, PL, SO, gluteus medius (Glut Med) and gluteus maximus (Glut Max) will be recorded bilaterally using pairs of surface electrodes. Motor coordination of these muscles will be evaluated through assessment of temporal and spatial parameters of EMG during functional tasks such as kicking in one leg standing. The primary outcome measure will be percentage of EMG relative to maximal voluntary contraction (MVC) on the same side. In order to remove the potential for investigator bias, all data will be presented individually without identification of the muscle, order of trials or whether the trials precede or follow the intervention.
223406000|NCT04384003|DIAGNOSTIC_TEST|Foot intrinsic muscle assessment and training device|The main concept for this design is to provide the quantitative assessment of the foot intrinsic muscles and facilitation of intrinsic muscles of the fool during functional sporting activities such single-leg-standing.
223737541|NCT05184920|OTHER|P1013119 nicotine pouch|P1013119, a nicotine pouch with 12 mg of nicotine
224023237|NCT05744752|DIETARY_SUPPLEMENT|Moringa oleifera Extract|The method described by Hanaa Elgamily(32) with minor modifications. Fresh Leaves will be washed and dried in dry heat oven. All the preparation will be done in pharmacological department, University of Health Sciences in sterile environment. Dried leaves will be crushed to make fine powder. 1000 g powder of MO will be socked in 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Then mixture will be magnetically stirred for 24 hours and stored at 4oC for 48 hours to allow extraction of active ingredients. Then the mixture will be filtered twicely by using Whatman No 1 filter paper. The extract will be concentrated by rotary vacuum evaporator at 40 oC to evaporate the solvent. The extract will be freeze, dried and stored at -70 oC for use. Dose of MO extract will be 400 mg per kg.(33) body weight given daily in 1ml of distilled water by oral gavage method for 12 weeks.
224138829|NCT01380158|DEVICE|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
223406001|NCT00053690|BEHAVIORAL|Cognitive Behavior Treatment|
224138830|NCT05686616|DRUG|Dapagliflozin Propanediol Hydrate 12.3 mg|Forxiga 10mg will be added on the conventional treatment for SGL2 inhibitor group.
224138831|NCT00239317|DRUG|Tamusulosin|
223406002|NCT03710837|OTHER|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
223406003|NCT03710837|OTHER|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
223406004|NCT05775393|PROCEDURE|Serratus anterior plane block for MRM|"They will randomly assigned to two groups of 30 patients each, at 1:1 allocation ratio using computer-generated random numbers concealed in sealed opaque envelopes.~Group (A):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0 .25 % and dexamethasone 4 mg).~Group (B):~Patients will receive ultrasound-guided serratus anterior block using 30ml of (bupivacaine 0.25% and dexamethasone 4mg with ketamine 50 mg).~All the medications were prepared by an anesthesiologist not participating in the study."
223406005|NCT01822093|BIOLOGICAL|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results \> 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group"
223406006|NCT06213584|OTHER|conservative rehabilitation|Hotpack + TENS + streching exercises
223406007|NCT06213584|OTHER|mullgan mobilization techniques|Passive mobilization techniques during active movements
223737542|NCT05184920|OTHER|P1013218 nicotine pouch|P1013218, a nicotine pouch with 10 mg of nicotine
223737543|NCT05184920|OTHER|P1012818 nicotine pouch|P1012818, a nicotine pouch with 10 mg of nicotine
223737544|NCT05184920|OTHER|P1312915 nicotine pouch|P1312915, a nicotine pouch with 8 mg of nicotine
223737545|NCT05184920|OTHER|P1312914 nicotine pouch|P1312914, a nicotine pouch with 4 mg of nicotine
223737546|NCT05184920|OTHER|P1313015 nicotine pouch|P1313015, a nicotine pouch with 8 mg of nicotine
223737547|NCT05184920|OTHER|P1313314 nicotine pouch|P1313314, a nicotine pouch with 4 mg of nicotine
223737548|NCT05184920|OTHER|P1312815 nicotine pouch|P1312815, a nicotine pouch with 8 mg of nicotine
223737549|NCT01679977|DEVICE|Vibrational-proprioceptive Resistance Exercise Training|
223737550|NCT01679977|DEVICE|Neuromuscular Electrical Stimulation Training|
223406008|NCT06213584|OTHER|pnf|hold relax active movements
223406009|NCT05818501|DEVICE|The dysphagia cups|"After the training period of the one of dysphagia cups, participants will start using cup to consume water during a designated period of time every day.~Participants consuming water with Cup A will drink from a static position with their chins towards their chests, the so-called Chin-Tuck maneuver. This position leads epiglottal naturally covering the trachea and causes liquid only ﬂowing to the esophagus and thus stomach. The restoring force of the membrane ensures a constant level of liquid at the upper edge of the cup and thus enables this preferred and safe drinking position.~Cup B limits the maximum volume of water flowing out of the Cup B designated by the staff. Controlled liquid flow prevents overflowing the mouth and gulping, thus reduces the risk of choking and liquid aspiration. Participants can choose to drink the water from Cup B with a straw when necessary."
223406010|NCT04028609|BEHAVIORAL|Healthy at Home|In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.
223406011|NCT04028609|OTHER|Services as Usual|Routine medical services
223406012|NCT06286527|OTHER|anonymous self-administered online questionnaire|proposition to participate through billboards with a QR code leading to the questionnaire.
223406013|NCT03870269|DEVICE|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
223406014|NCT01681212|DRUG|Ipilimumab|
223406015|NCT01681212|DRUG|Dacarbazine|
223406016|NCT00730535|DRUG|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
223556306|NCT01978054|OTHER|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
223406017|NCT00730535|DRUG|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
223406018|NCT00730535|DRUG|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
223406019|NCT04519268|DIAGNOSTIC_TEST|Adult patients scheduled for an elective general surgical operation.|"The anesthesiologist, who is in charge of preoperative assessment at each hospital unit, will assess patients who are scheduled for elective surgery; and will inform senior anesthesiologists (with a minimum 3 years of experience) \& consultant anesthesiologists, about the patients' data.~Patients data with all requested preoperative investigations \& required preparations, peri-operative course and post-operative outcome will be collected."
223406020|NCT03378674|DRUG|Remifentanil Injectable Product|remifentanil: 0,15 mcg/kg/min
223556307|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking.
223556308|NCT04666558|OTHER|Exercise & Nutrition|App-based live group exercise classes, personalized follow-up asynchronous workouts, live group nutrition classes, and protein tracking. Additional one-one-one exercise and nutrition support is provided too.
223556309|NCT00175630|PROCEDURE|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
223556310|NCT03490292|COMBINATION_PRODUCT|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
224138832|NCT02325635|OTHER|Educational Training|Intervention/Training offered to endoscopists only.
223406021|NCT00113048|DRUG|CAMPATH (alemtuzumab)|
223406022|NCT01805466|DEVICE|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
223406023|NCT01805466|DEVICE|Conventional CPB|conventional miniature cardiopulmonary bypass technique
223406024|NCT03704025|BEHAVIORAL|Current guidelines rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
223556311|NCT03490292|DRUG|Carboplatin|Weekly Carboplatin (AUC2) \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
223556312|NCT03490292|DRUG|Paclitaxel|Weekly paclitaxel \[intravenous infusion on days 1, 8, 15, 22, \& 29\]
223556313|NCT03490292|RADIATION|Radiation|Radiation therapy \[23 fractions, M-F, estimated completion day 35\]
223556314|NCT00964002|DRUG|efavirenz|
223556315|NCT00002297|DRUG|Inosine pranobex|
223556316|NCT05700786|BEHAVIORAL|Mindful compassion for perfectionism|The intervention is a 8-week group psychotherapy in a hybrid format: 8 weekly online sessions lasting 2 hours plus an in presence half-day of silence lasting 4 hours.
223556317|NCT04751604|DIETARY_SUPPLEMENT|Nicotinamide|Daily oral administration of 1,000 mg nicotinamide \[1x 500-mg conventional nicotinamide tablet and 1x 500-mg tablet with controlled-ileocolonic-release nicotinamide (CICR-NAM)\] for 4 weeks
223556318|NCT04751604|DIETARY_SUPPLEMENT|Placebo|Daily oral administration of 2 matching placebo tablets for 4 weeks
224138833|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
224138834|NCT02638805|DRUG|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
224138835|NCT02638805|DRUG|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
224138836|NCT02638805|DRUG|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
224138837|NCT01076842|DRUG|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
223406025|NCT03704025|BEHAVIORAL|Mobile device guided rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
223737551|NCT06387745|DEVICE|Hepatoscope|The Hepatoscope is a non-invasive external ultrasound imaging device, intended for general purpose pulse echo ultrasound imaging, and soft tissue elasticity imaging of the human body. In addition, the Hepatoscope provides measurements of shear wave speed and tissue stiffness, ultrasound beam attenuation and estimates of speed of sound, in internal structures of the body.
223737552|NCT03038633|OTHER|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
223737553|NCT05598775|OTHER|Non Interventional long term safety follow up|Non Interventional long term safety follow up
223737554|NCT00099385|BEHAVIORAL|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg \& Kusche) curriculum.
223737555|NCT06242314|PROCEDURE|L_PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after L-PRF placing on palatal wounds
223737556|NCT06242314|PROCEDURE|A-PRF|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after A-PRF placing on palatal wounds
223737557|NCT06242314|PROCEDURE|Palatal stent|Palatal epithelialization, pain (Visual Analog Scale (VAS) recording), analgesic tablet use and Oral Health Impact Proﬁle-14 (OHIP-14) questionnaire scores were recorded after palatal stent placing on palatal wounds
223737558|NCT06502626|OTHER|Regular training|performed their routine programs
223737559|NCT06502626|OTHER|Sprint Interval Training|Sprint interval training will be given for 4 weeks. Each week consisted of three training sessions, separated by at least one resting day. Participants will complete a 15-minutes warm up before training session. The Sprint interval training group consisted of 30 s sprints at near maximal effort, with three minutes of rest between each sprint. The training intensity of Sprint interval training sessions was evaluated subjectively during sessions. During the first week, the Sprint interval training group performed five sprints per session. The number of sprints then increased gradually, until a total of 10 sprints per session. When the number of sprints reached seven, subjects were given six minutes of rest midway through the training session
224023238|NCT05744752|DIETARY_SUPPLEMENT|Allium sativum Extract|Fresh Allium sativum bulbs will be selected for study. The cloves will be peeled, washed with distilled water and dried under shed. Then it will be chopped into small pieces. 1000g of chopped garlic will be crushed by mortar and passel. The garlic paste will be mixed with 5000 ml of 70% ethanol (70% ethanol and 30% distilled water) for 72 hours at room temperature. Rest the procedure is same as mentioned in moringa extract. Dose of 500 mg per kg(34) body weight garlic extract will be given daily in 1ml of distilled water.
223737560|NCT03670550|DEVICE|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
223737561|NCT05482763|DRUG|Terbinafine Topical Gel|Topical application of terbinafine
223737562|NCT05482763|DRUG|Itraconazole 200 mg|systemic itraconazole pulse therapy
223406026|NCT01324986|PROCEDURE|Laparoscopic anti-reflux surgery|
223737563|NCT05482763|DRUG|Terbinafine 250 mg|systemic terbinafine
224023239|NCT05744752|OTHER|Placebo|1ml NaCl 0.9% daily for 12 weeks
224023240|NCT03810131|OTHER|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
224023241|NCT02112838|DRUG|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
224023242|NCT02112838|DRUG|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
224023243|NCT02112838|DRUG|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
223406027|NCT01905917|OTHER|Tele-rehabilitation|
223406028|NCT05229159|DIAGNOSTIC_TEST|Bioelectrical impedance analysis|Segmental multi-frequency bioelectrical impedance analysis are carried out at all patient admitted to our ICU for postoperative care after cardiac surgery with cardiopulmonary bypass. Our objective is to evaluate the relevance of phase angle to predict mortality or a prolonged hospital length of stay. Phase angle is evaluated at ICU admission and will be compared to well-known prognostic scores computed in preoperative (EuroSCORE II) and at day one after surgery (SOFA, CASUS and SAPS II).
223406029|NCT02854332|DEVICE|tDCS session|Direct current transcranial magnetic stimulation
223406030|NCT02854332|DEVICE|rTMS session|Repetitive transcranial magnetic stimulation.
223406031|NCT04173156|DEVICE|Labrida Bioclean|The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan
223406032|NCT04173156|DEVICE|Gracey Periodontal curettes|Regular commercially available area specific and medical grade steel Gracey periodontal curettes
223737564|NCT05482763|DRUG|Ciclopirox Topical Gel|Topical application of ciclopirox
223737565|NCT05482763|DRUG|Amorolfine 50 MG/ML|Topical application of amorolfine
223737566|NCT03437525|BEHAVIORAL|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
223737567|NCT01460420|DRUG|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
223406033|NCT01225016|DRUG|Definity contrast agent|Thyroid ultrasound using contrast agent
224023244|NCT03981562|DRUG|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
224023245|NCT03981562|DRUG|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
223406034|NCT01069510|DRUG|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
224132698|NCT03496467|COMBINATION_PRODUCT|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
223406035|NCT01069510|OTHER|Placebo|Placebo daily for 12 months
223406036|NCT05170048|DRUG|EG-301|The investigation drug, EG-301 Tablets 150mg, is for oral use.
223406037|NCT05170048|DIETARY_SUPPLEMENT|AREDS2 supplements|AREDS2 supplement is the stand of care
223406038|NCT02430246|DIETARY_SUPPLEMENT|Urex Plus|Probiotic
223406039|NCT02430246|OTHER|Placebo|capsule without active ingredient
223406040|NCT02430246|DIETARY_SUPPLEMENT|Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14|
223406041|NCT04817592|PROCEDURE|Corneal lenticule extraction for advanced refractive correction (CLEAR)|Routinely conducted procedure for correction of Myopia
223406042|NCT05698901|DRUG|Agalsidase beta|The treatment is following local reimbursement criteria and judge by physician
223406043|NCT02220764|DEVICE|Teeth abutment|
223406044|NCT02220764|DEVICE|Implant abutments|
223406045|NCT02996825|DRUG|Gemcitabine|Given IV
223406046|NCT02996825|DRUG|Gemcitabine Hydrochloride|Given IV
223406047|NCT02996825|OTHER|Laboratory Biomarker Analysis|Correlative studies
223406048|NCT02996825|BIOLOGICAL|Mirvetuximab Soravtansine|Given IV
223406049|NCT02996825|OTHER|Pharmacological Study|Correlative studies
223406050|NCT02464332|DRUG|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
223406051|NCT02198664|BIOLOGICAL|AR101 - Peanut protein capsule|Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
223406052|NCT06310655|RADIATION|Proton SBRT|Patients will receive SBRT over 5 days, either every day or every other day, to a dose of 25-50 Gy.
223406053|NCT04566978|DRUG|89Zr-DFO-REGN3767|89Zr-DFO-REGN3767 is comprised of the anti-LAG-3 antibody, REGN3767 labeled with the positron-emitter zirconium-89 (89Zr) through the chelator-linker DFO. REGN3767 is an investigational monoclonal antibody that target LAG-3 receptors.
223406054|NCT04566978|DIAGNOSTIC_TEST|PET/CT|"A PET/CT scan extending from top of skull to feet will be performed to determine the biodistribution.~Part A patients will be imaged at three time points post-injection to allow for selection of optimal imaging time and dosimetry determination. For these patients, top of skull to feet scans will be acquired:~* Within one to four hours following injection of tracer on Day 1~* 24-72 hours post-injection (Day 2-4)~* 20-168 hours post-injection (once during days 5-7)"
223406055|NCT04709562|DEVICE|High Velocity Nasal Insufflation (HVNI)|The purpose of this intervention is to evaluate the efficacy of HVNI in clinically stabilizing patients presenting with hypercapnic respiratory distress.
223406056|NCT04709562|DEVICE|Noninvasive Positive Pressure Ventilation (NIPPV)|The purpose of this intervention is to evaluate the efficacy of NIPPV in clinically stabilizing patients presenting with hypercapnic respiratory distress.
223406057|NCT06674226|DRUG|Ciprofol|0.25mg/kg for anesthesia induction ＋0.25\~1.5 mg/kg/h for maintenance
223406058|NCT06674226|DRUG|Propofol|1.0mg/kg for induction ＋1 \~ 6mg/kg/h for maintenace
223406059|NCT06866106|BEHAVIORAL|Positive Psychology (PP) Intervention|This is an adapted, optimized, phone-based, 9-week positive psychology (PP) intervention. Participants will complete 9 weekly phone sessions (30 minutes each) with a study interventionist in which they will review PP exercises that they have independently completed in between phone sessions. The PP exercises will be completed in a treatment manual that describes the PP exercise and provides space to write about the exercise and its effects, and to answer associated questions. A total of 9 sessions will be completed over the course of the program.
223406060|NCT06866106|BEHAVIORAL|Educational Intervention|This is an educational intervention that will match the PP intervention in terms of both time and attention. Participants will complete 9 weekly phone sessions (30 minutes each) with a study interventionist in which they will review educational exercises that they have independently completed in between phone sessions. The exercises will be completed in a treatment manual that describes the exercise and provides space to write about the exercise and its effects, and to answer associated questions. A total of 9 sessions will be completed over the course of the program.
223406061|NCT06625437|BEHAVIORAL|Acceptance and commitment therapy|Acceptance and commitment therapy is a psychotherapy focused at increasing psychological flexibility and an individual\&#39;s engagement in valued activities rather than focusing solely or primarily on reducing psychiatric symptoms
223406062|NCT07023224|OTHER|Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)|The Turkish adaptation of the Parkinson's Disease Dyskinesia Scale (PDYS-26) is administered to individuals diagnosed with Parkinson's disease who have a dyskinesia score of ≥1 based on the Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia item. The scale is used to evaluate dyskinesia severity and assess its clinical applicability in Turkish-speaking populations.
223556319|NCT03528122|PROCEDURE|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
223556320|NCT00904670|DRUG|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
223556321|NCT00904670|DRUG|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
223556322|NCT00904670|DRUG|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
223556323|NCT00161837|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
223556324|NCT00161837|BIOLOGICAL|Egg-derived Influenza Vaccine|
224023246|NCT01822301|PROCEDURE|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
223406063|NCT07138417|OTHER|Compassion-Based Family Therapy|"Draw ideas from traditional Chinese culture, the investigators have developed the compassion-based family intervention therapy to improve the mental health of both parents and children by enhancing their synchronization.~The 6-week program followed a progressive thematic structure. Week 1 focuses on introduction and connection, themed Setting Sail: The Additions and Subtractions for a Happy Family. Weeks 2 and 3 address self-compassion: Week 2 is themed Self-compassion: Embrace yourself with compassion here and now.; Week 3 is themed Self-compassion: Accepting growing pains.. Weeks 4 and 5 explored developing compassion for others: Week 4 is themed Listening to the heart: Enhancing communication, bringing us closer.; Week 5 is themed Building a harbor together: Managing conflict, creating happiness Week 6 involves integration and review, themed Integrating knowledge and action: Practicing compassion, lighting the path forward."
223406064|NCT01610817|OTHER|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
223406065|NCT06839222|DEVICE|Hydrogel OA 2%|Hydrogel OA 2% is a sterile, nonpyrogenic viscoelastic hydrogel suspension, designed using highly purified biopolymers in a phosphate-buffered saline solution. The main component is a cross-linked protein (ultra-pure bovine gelatin). The other main component is a polysaccharide cellulose nanocrystal (CNC) that acts as the crosslinker. Hydrogel OA 2% is supplied in pre-filled 2.25ml Luer lock syringe. Each package contains one syringe containing 2.0 mL Hydrogel OA 2%. Hydrogel OA 2% is designed to provide symptomatic relief by restoring joint lubrication and cushioning, potentially leading to reduced pain and improved joint function. The device is suitable for use in early and moderate OA (Kellgren and Lawrence, K\&L, II-III).
223406066|NCT06839222|DEVICE|Hyaluronic Acid (Durolane)|DUROLANE contains 20 mg/mL of stabilized non-animal hyaluronic acid in buffered physiological sodium chloride solution pH 7. DUROLANE is a sterile, transparent viscoelastic gel supplied in a 3 mL glass syringe.
223406067|NCT00753311|DRUG|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
223556325|NCT06086158|PROCEDURE|Nordic Reverse Protocol|The participant begins on their knees, with the trunk upright and fully aligned. At this moment, the soccer player slowly leans back, maintaining the starting position by means of a controlled flexion of the knees. This fall is executed at the lowest speed possible to maximize muscle load in the eccentric phase and reach the point of maximum flexion.
223556326|NCT05449912|OTHER|Collection of environmental exposure data|noise pollution air pollution proximity and accessibility to green spaces, blue spaces
223556327|NCT06279598|BEHAVIORAL|Prolonged Exposure therapy|This concerns a form of psychotherapy for PTSD.
223556328|NCT06279598|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|This concerns a form of psychotherapy for PTSD.
223556329|NCT06279598|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|This concerns a form of psychotherapy for PTSD.
224023247|NCT05216887|BIOLOGICAL|Aducanumab|Administered as specified in the treatment arm.
224023248|NCT03618368|DEVICE|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
224023249|NCT03618368|DEVICE|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
224023250|NCT03824782|DEVICE|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
223406068|NCT02264626|DRUG|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
223556330|NCT05304975|BEHAVIORAL|diet|Participants will be provided with written dietary education, meal plan, recipe ideas, tips and suggestions at their baseline visit. Participants will then meet online with the study nutritionist for around 90 minutes for personal dietary advice which will be based on the latest evidence from the MIND (Mediterranean-DASH diet Intervention for Neurodegeneration Delay) diet tailored for the target population. The nutritionist will support participants to set personal dietary goals and to monitor progress in changing towards the MIND diet. If weight loss is indicated, the nutritionist will also advise energy intake to facilitate 5-10% body weight reduction. Following the initial appointment, review meetings with the nutritionist will take place monthly in the first four months, either online or by telephone and lasting up to 60 minutes
223556331|NCT05304975|BEHAVIORAL|cognitive stimulation|Cognitive stimulation will be delivered using Brain HQ® (Posit Science), a computer based cognitive training platform, which utilises games to enhance attention, mental processing speed, learning, memory, and low mood. On 2 occasions during the first month participants will receive a 30-60min training. The aim is to familiarise participants with games and program processes to optimise engagement with the programme.The cognitive training application is available to download on a range of devices. Following training, participants will be asked to log in and complete the training session at least 4 days per week. Each session is expected to last 30 minutes. Individual cognitive training performance will be recorded centrally. Participants will receive feedback of percentage improvement in performance. The program allows remote monitoring of frequency of use and engagement. Therefore, performance, frequency, duration, and type of use will be recorded centrally throughout the study period
223737568|NCT01460420|DRUG|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
224023251|NCT04014491|PROCEDURE|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
224023252|NCT04014491|PROCEDURE|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
224023253|NCT04014491|OTHER|No intervention|No intervention
224023254|NCT01219868|BEHAVIORAL|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
224023255|NCT03430206|DEVICE|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
224023256|NCT03383315|DRUG|Tramadol|One dose of intravenous tramadol 50mg
223406069|NCT04712214|DEVICE|Intra-operative multispectral / hyperspectral analysis|During surgery, the operating surgeon will be using standard NHS neurosurgical equipment such as an endoscope and/or a microscope. This equipment is operated in exactly the same way as with any other procedure, but either the microscope or the endoscope in use will be connected to the system of camera and filters for multispectral/hyperspectral analysis. During each surgical intervention, tissue-specific spectral data will be collected at specific stages - mostly once the brain surface is exposed and at the end of the resection on the surgical cavity. The operation will be visually recorded in order to sync visual data with the spectral data obtained at the same moment in time. The video recording will not be patient identifiable and will be viewed only by members of the research team working on this project (see below). The use of video recording equipment will be included in the patient information sheet given to all patients prior to gaining consent
223406070|NCT00867659|DRUG|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
223406071|NCT01547429|DEVICE|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
223406072|NCT05510037|OTHER|no intervention|no intervention was needed
223406073|NCT04766177|DRUG|Bumetanide|bumetanide 0.5 mg twice daily
223406074|NCT04766177|DRUG|Placebo|placebo tablets twice daily
223406075|NCT06749457|DRUG|AZD7760|Participants will receive AZD7760 as a single intravenous infusion.
223406076|NCT06749457|OTHER|Placebo|Participants will be administered placebo through intravenous infusion.
223406077|NCT02565745|COMBINATION_PRODUCT|Skin dressing|Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
223556332|NCT05304975|BEHAVIORAL|physical activity|The exercise intervention will be delivered remotely. Participants will undergo a physical performance assessment at baseline and receive a home exercise written resource that has been designed for older adults and adapted for the current study. It is expected that participants will begin with a basic level of exercise that will increase in frequency and intensity over the first 4 weeks to reach a core required level. In week one, participants will meet online with the trained exercise instructor for around 60 minutes to plan a personalised exercise programme. The instructor will explain the basics of exercise prescription, the foundations of the personal home programme and safety aspects. The instructor will facilitate appropriate exercise goal setting and demonstrate the exercises within the personal programme. Participants will be advised to wear the study pedometer to record their walking activity and complete the exercise diary to record overall step count and daily exercise.
223556333|NCT05304975|OTHER|risk factor management|Metabolic and vascular risk factor management. At each study visit (baseline, month 4, month 6 and month 9), participants will be informed by the research nurse about their blood results, weight and blood pressure and will receive recommendations to visit their GP to change treatment as necessary
223406078|NCT02565745|OTHER|Moisturizing cream|It will be applied twice a day to the same skin areas as the experimental group
223406079|NCT03877380|OTHER|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
223406080|NCT04563663|PROCEDURE|Posteriorization of the talus.|Three sets of a 30-s grade IV anteroposterior mobilization.
223406081|NCT06760637|DRUG|PF-07220060|CDK4 inhibitor
223406082|NCT06760637|DRUG|letrozole|endocrine therapy
223737569|NCT05931939|PROCEDURE|Ileal Interposition|Bariatric surgery by laparoscopic Ileal Interposition
223737570|NCT05931939|PROCEDURE|Traditional surgical technique|Bariatric surgery by laparoscopic traditional technique
223737571|NCT02059057|DEVICE|LVRC System|
223737572|NCT02689401|DRUG|Ferumoxytol|
224023257|NCT03383315|DRUG|Metoclopramide|One dose of intravenous metoclopramide 10mg
224023258|NCT03383315|DRUG|Placebo|Sodium chloride 0.9%
224023259|NCT02570685|BEHAVIORAL|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
224132699|NCT03496467|COMBINATION_PRODUCT|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
223737573|NCT02689401|DEVICE|MRI 3T scanner|
223737574|NCT03443284|BEHAVIORAL|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
223406083|NCT06760637|DRUG|abemaciclib|CDK4/6 inhibitor
223406084|NCT06760637|DRUG|palbociclib|CDK4/6 inhibitor
223406085|NCT06760637|DRUG|ribociclib|CDK4/6 inhibitor
224023260|NCT02570685|BEHAVIORAL|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
224132700|NCT04762147|DRUG|paracetamol, the group P|The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
223406086|NCT03845686|DIAGNOSTIC_TEST|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
223406087|NCT03691454|DRUG|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
223406088|NCT03691454|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
223406089|NCT07060118|DIETARY_SUPPLEMENT|Gluten Free Diet in Hashimoto's Hypothyroidism|Gluten Free Diet in patients with Hashimoto's Hypothyroidism
223406090|NCT03622125|DIAGNOSTIC_TEST|Vital signs|Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
223406091|NCT02701465|OTHER|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
223406092|NCT02701465|OTHER|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
223406093|NCT02743325|PROCEDURE|SVT ablation by ALARA protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The usage of CartoUnivuTM allows a seamless combination of a fluoro image and Carto® 3 System maps into a single view.
223406094|NCT02743325|PROCEDURE|SVT ablation by conventional protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The convention Ablation procedure works without a 3D navigation System.
223406095|NCT01008566|BIOLOGICAL|Cixutumumab|Given IV
223406096|NCT01008566|OTHER|Laboratory Biomarker Analysis|Correlative studies
223406097|NCT01008566|DRUG|Sorafenib Tosylate|Given orally
223406098|NCT00970346|DRUG|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
223406099|NCT01344421|PROCEDURE|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
223406100|NCT01735084|BIOLOGICAL|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
223406101|NCT01735084|BIOLOGICAL|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
223406102|NCT04696302|BEHAVIORAL|Focus of attention|Individuals were asked to laterally weight shift while seated with either internal focus or external focus instructions.
223406103|NCT05348759|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry was performed by trained nurse at division of pulmonology, Vajira hospital. The forced vital capacity (FVC), forced expiratory volume in first second of exhalation (FEV1), forced mid-expiratory flow (FEF25-75%), and the FEV1/FVC ratio before and after bronchodilators (2 puffs of salbutamol via spacer) were collected in all cases. Total lung capacity (TLC) using the spirometry (Masterscreen PFT, Jaeger, Germany) and diffusion capacity of carbon monoxide was performed in selected case with abnormalities of lung parenchyma found from computed tomography of the chest.
223406104|NCT05348759|DIAGNOSTIC_TEST|Chest computer scan|High-resolution computed tomography (HRCT) was performed in a single breath-hold on a 128 slice multidetector computed tomography (MDCT) scanner (Philips Healthcare Nederland B.V, Ingenuity 128, Netherlands). HRCT was performed with the patient in the supine position during end-inspiration, supine position during end-expiration, and prone position during end-inspiration with 1 millimeter (mm) slice thickness.
223737575|NCT03443284|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
223737576|NCT04212260|BEHAVIORAL|Oropharyngeal exercises|Oro-pharyngeal exercises that improve oro-pharyngeal and tongue strength. Instructions will be delivered via a tablet-based app.
223737577|NCT04212260|BEHAVIORAL|Sham control|Simple mouth movements that have no impact of oro-pharyngeal strength. Instructions will be delivered via a tablet-based app.
223737578|NCT05153512|PROCEDURE|MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification
223556334|NCT04291690|OTHER|Physical Component of the Intervention|We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
224023261|NCT02570685|BEHAVIORAL|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
223406105|NCT03859427|DRUG|Carfilzomib|Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
224023262|NCT03681847|PROCEDURE|Normal saline|normal saline 0.9% 15 ml/kg over 15-20 minutes.
223406106|NCT03859427|DRUG|Carfilzomib|Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
223406107|NCT03859427|DRUG|Lenalidomide|Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
223406108|NCT03859427|DRUG|Dexamethasone|Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
223406109|NCT01111773|DRUG|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
223406110|NCT05059873|DRUG|Prednisone|Oral prednisone 40mg/day for five consecutive days
223406111|NCT05059873|DRUG|Placebo|Oral placebo of 40mg/day for five consecutive days
223406112|NCT03392727|DEVICE|Study Box|Baby box (bassinet) with infant items
223406113|NCT03392727|DEVICE|Community Box|Baby box (bassinet)
223406114|NCT03392727|BEHAVIORAL|Education Session|Face to face education and baby box orientation session
223406115|NCT03392727|BEHAVIORAL|Online Education|Online baby box education
223406116|NCT05328739|OTHER|home care|home care program
223556335|NCT04291690|OTHER|Cognitive Component of the Intervention|We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
223556336|NCT04291690|OTHER|Nutritional Component of the Intervention|We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
223737579|NCT02675413|DRUG|Dimethyl Fumarate|Open-label
223737580|NCT05278247|DIAGNOSTIC_TEST|NIRS|Performance of a NIRS to monitor abdominal tissue oxygen saturation in preterm infants
223737581|NCT03984604|DRUG|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
223737582|NCT03984604|DRUG|Placebo|Placebo is a vehicle oil will match CHI-921
223737583|NCT02242409|DRUG|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
223406117|NCT01700972|PROCEDURE|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
223406118|NCT02503540|DRUG|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
223406119|NCT02932501|PROCEDURE|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
223406120|NCT02932501|PROCEDURE|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
223406121|NCT02932501|PROCEDURE|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
223737584|NCT02914808|OTHER|Patients will undergo a lower limb MRI and blood tests|
223737585|NCT02872636|DEVICE|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
224023263|NCT03681847|PROCEDURE|hydroxyethyl starch|hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
224023264|NCT03681847|PROCEDURE|Hypertonic saline|hypertonic saline 3% (7ml/kg) over 15-20 minutes.
223737586|NCT01064791|DRUG|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
224023265|NCT03948555|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)|All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
224023266|NCT02973711|DRUG|Nilotinib|Nilotinib 300 mg BID
224023267|NCT02973711|DRUG|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
224023268|NCT05877313|OTHER|Sterile water foot bath|Participants will use the same foot bath and sterile water used in the treatment arm minus the active ingredients.
223406122|NCT01662492|BIOLOGICAL|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
223406123|NCT01662492|BIOLOGICAL|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
223406124|NCT01662492|DRUG|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
223406125|NCT01674881|OTHER|Mindfulness-Based Cognitive Therapy|"MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).~Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD."
223556337|NCT04291690|OTHER|Iron-Deficiency Anemia (IDA) Component of the Intervention|We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin \<130g/L in men or \<120g/L in women with (ii) a Ferritin \<100μg/L or a Ferritin \<300μg/L with a Saturation \<20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
223556338|NCT04868097|PROCEDURE|cervix biopsy|large loop electrosurgical cervix biopsy
223406126|NCT01674881|OTHER|Waitlist|Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
223737587|NCT01064791|DRUG|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
223406127|NCT04933019|GENETIC|Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR|Detection of Clindamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR
223406128|NCT05228223|DIAGNOSTIC_TEST|Neuromuscular monitoring|TOF monitoring
223406129|NCT05228223|OTHER|reverse of NMB with sugammadex|Patients reversed with Sugammadex 2mg/kg after TOF count is 1-2.
223406130|NCT05228223|OTHER|reverse of NMB with Sugammadex and neostigmin low dose|Patients reversed with Sugammadex 1mg/kg + Neostigmin 0.02 mg/kg
223737588|NCT01064791|DRUG|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
223737589|NCT01064791|DRUG|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
223737590|NCT05621668|DRUG|Cyclophosphamide|Given by IV (vein)
223406131|NCT05228223|OTHER|reverse of NMB with Sugammadex and neostigmin high dose|patients reversed with sugammadex 1.5 mg/kg + Neostigmin 0.02 mg/kg
223406132|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
223406133|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
223406134|NCT00550355|DRUG|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
223406135|NCT00550355|DRUG|Placebo|3 doses of Placebo administered over 12 weeks
223556339|NCT00002028|DRUG|Didanosine|
223737591|NCT05621668|DRUG|attIL2-T cells|Given by IV (vein)
223737592|NCT03900481|PROCEDURE|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
224023269|NCT05877313|DRUG|Nitric Oxide|Participants will use a foot bath filled with 500mL of NORS for 15 min. The solution's two components are mixed 1:1 to 500mL in the foot bath immediately before treatment. The solution contains NO at 68.9ppm\*hrs and 203.2ppm\*hrs for 1X and 2X solutions respectively, and it acts as a virucidal agent. Instructions for storage, handling, and use will be provided to site staff and participants.
224023270|NCT03503461|OTHER|exosomes analysis|Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
224023271|NCT01666457|OTHER|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
224023272|NCT01414985|BIOLOGICAL|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10\^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10\^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
224023273|NCT00232674|DRUG|Pulmicort (budesonide) Turbuhaler|
224023274|NCT02764216|RADIATION|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
224023275|NCT01991054|DIETARY_SUPPLEMENT|vitamin D3|
223556340|NCT05568160|DRUG|Vasopressin|The infusion is started at 5 ml hr-1, increased in increments of 1 ml hr-1 every 5 minutes to reach a maximum target rate of 30 ml hr-1
223406136|NCT03175536|OTHER|HDHP with PDL|Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of \>$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
223737596|NCT06175793|BEHAVIORAL|ASPIRE Intervention|In addition to usual care and a free blood pressure cuff, participants in the intervention arm will receive the ASPIRE components: (1) ASPIRE Tool Kit, (2) ASPIRE Coach, (3) SMBP EHR Documentation, and (4) screening and addressing SDOHs.
223406137|NCT02844413|OTHER|aerobic interval training|In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
223406138|NCT03588403|RADIATION|TOMO|Tomotherapy
223406139|NCT03588403|RADIATION|IMRT|Intensity modulated radiotherapy
223406140|NCT00605618|DRUG|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
223406141|NCT02442947|OTHER|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment \[charcoal base\], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
223406142|NCT04361773|RADIATION|Photobiomodulation|Treatment with a device with 144 light emitting diodes (LEDs) at wavelengths of 420, 660 and 850nm, 3J per point for 10 minutes.
223406143|NCT04361773|OTHER|Sham Photobiomodulation|Simulation of the LED application, with a device with external characteristics identical to that of the PBM group, for the same period of time.
223406144|NCT02590744|BEHAVIORAL|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
223406145|NCT02590744|BEHAVIORAL|non-eye patch|do not cover the sick eye with eye patch preoperatively
223406146|NCT05369897|DEVICE|VR training|The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.
223406147|NCT05369897|DEVICE|VR activity|High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
223406148|NCT02219880|DIETARY_SUPPLEMENT|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
223406149|NCT02219880|DIETARY_SUPPLEMENT|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
223406150|NCT05006079|DRUG|Morphine|immediate release oral 15mg dose
223406151|NCT05006079|DRUG|Alprazolam|oral 0.25mg dose
223406152|NCT05006079|DRUG|Placebo|Lactose
223406153|NCT02563054|DRUG|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m\^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
223406154|NCT02563054|DRUG|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
223737599|NCT05257499|BEHAVIORAL|On line debriefing|Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
223737600|NCT01119014|DRUG|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
223737601|NCT01119014|DRUG|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
223406155|NCT02563054|DRUG|Cisplatin|Participants will receive cisplastin, 80 mg/m\^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
223406156|NCT06136533|OTHER|Assessment-OHS|Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.
223556341|NCT05568160|DRUG|Norepinephrine|The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
223737602|NCT05232916|BIOLOGICAL|Placebo|0.9% Normal Saline
223737603|NCT05232916|BIOLOGICAL|GLSI-100|500 mcg/mL GP2 and 125 mcg/mL GM-CSF
223556342|NCT05568160|OTHER|Collection of clinical data|At D1, D2, D7, D30 or D60 and D90
223556343|NCT05568160|OTHER|Quality of Life Questionnaire EQ-5D|At the anesthesia consultation, discharge from intensive care, D7, D30 and D90
223556344|NCT00286091|BIOLOGICAL|Denosumab|Administered by subcutaneous injection
223556345|NCT00286091|BIOLOGICAL|Placebo|Same volume subcutaneous injection
223556346|NCT02192892|DIETARY_SUPPLEMENT|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
223737604|NCT05919329|DRUG|Piflufolastat|Given IV
223737605|NCT05919329|PROCEDURE|PSMA PET/CT Scan|Undergo PSMA PET/CT
223737606|NCT05919329|PROCEDURE|PSMA PET/MRI scan|Undergo PET/MRI
223737607|NCT05919329|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223737608|NCT05919329|OTHER|Electronic Health Record Review|Ancillary studies
223737609|NCT04202354|DRUG|ARO-HSD Injection|single or multiple doses of ARO-HSD by subcutaneous (sc) injections
223556347|NCT02192892|DIETARY_SUPPLEMENT|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
223556348|NCT02192892|DIETARY_SUPPLEMENT|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
223556349|NCT02192892|DIETARY_SUPPLEMENT|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
223737610|NCT04202354|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment, by sc injection
223737611|NCT01880567|DRUG|Ibrutinib|Given PO
223737612|NCT01880567|OTHER|Laboratory Biomarker Analysis|Correlative studies
223737613|NCT01880567|BIOLOGICAL|Rituximab|Given IV
223556350|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
223556351|NCT02192892|DIETARY_SUPPLEMENT|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
223556352|NCT02192892|DIETARY_SUPPLEMENT|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
223737614|NCT06320366|DEVICE|Sham TMS|The TMS Cool-B65 A/P coil on its placebo side delivers electrical stimulation to the scalp (e.g., mimicking sensations associated with real stimulation) but does not provide magnetic stimulation to the targeted cortical structure.
224023276|NCT02091453|BEHAVIORAL|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
224023277|NCT02091453|BEHAVIORAL|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
224023278|NCT04431167|BEHAVIORAL|Living well with Lupus|The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
223556353|NCT02192892|DIETARY_SUPPLEMENT|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
224023279|NCT03044925|PROCEDURE|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
224023280|NCT03044925|PROCEDURE|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
224023281|NCT00315900|DRUG|Depakote ER|depakote ER
224023282|NCT00315900|DRUG|Seroquel|seroquel
223556354|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge flour|Porridge from commercial porridge flour
223737615|NCT06320366|DEVICE|Active TMS|The TMS Cool-B65 A/P coil delivers magnetic stimulation to targeted cortical structure.
223737616|NCT04365855|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
223737617|NCT04365855|OTHER|Blood draw|Clinical blood tests with a focus on liver function parameters and diabetes
223737618|NCT04365855|PROCEDURE|Liver biopsy|If indicated per MRE results a biopsy will be taken of the liver.
223737619|NCT04365855|PROCEDURE|Fibro Scan|If indicated per MRE results a fibroscan will be performed of the liver.
223737620|NCT03471260|DRUG|Azacitidine|Given IV or SC
223737621|NCT03471260|DRUG|Ivosidenib|Given PO
223737622|NCT03471260|DRUG|Venetoclax|Given PO
223737623|NCT06095063|DEVICE|Active Brainsway H7-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
223737624|NCT06095063|DEVICE|Sham Brainsway H7-Coil Deep TMS System|In addition to the active H-coil, a sham coil is included in the system. The active and sham coils are connected to a control switch, which alternates between real and sham operation modes. The sham treatment will be administered daily for 4 consecutive weeks.
223737625|NCT06095063|OTHER|Cognitive Training|Cognitive training will be conducted using the BrainHQ software program.
223737626|NCT00813085|OTHER|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
223737627|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 40 or 60 mg selinexor oral tablets QW.
223737628|NCT04562389|DRUG|Selinexor|Participants will receive a dose of 60 mg selinexor oral tablets QW.
223737629|NCT04562389|OTHER|Placebo|Participants will receive a matching placebo of selinexor oral tablets QW
223737630|NCT04562389|DRUG|Ruxolitinib|Participants will receive a dose of 15 or 20 mg ruxolitinib oral tablets BID.
224023283|NCT06239636|BIOLOGICAL|UP421|Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
224023284|NCT04308395|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
223556355|NCT02192892|DIETARY_SUPPLEMENT|Commercial porridge bar|Porridge from commercial porridge bar
223556356|NCT02192892|DIETARY_SUPPLEMENT|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
223556357|NCT00750035|PROCEDURE|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
223556358|NCT00750035|PROCEDURE|Subtotal abdominal hysterectomy|
223556359|NCT04407156|OTHER|acute kidney injury|AKI in COVID positive cases
223556360|NCT02764359|DRUG|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
224023285|NCT05456802|OTHER|Standard of care treatment|Standard of care treatment including percutaneous interventions was performed in all participants.
224023286|NCT03534284|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
223406157|NCT06136533|OTHER|Assessment-Sarcopenic Obesity With OHS|The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
223406158|NCT03144661|DRUG|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
223406159|NCT02757053|DEVICE|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
224132701|NCT04762147|DRUG|fentanyl, group-F administered as an active comparator|The fentanyl 2mcg/kg was administered at the time induction of anaesthesia for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
224132702|NCT05583981|OTHER|Interview|Participate in interview
224132703|NCT01206010|DRUG|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
223406160|NCT02418182|DRUG|Acetaminophen|Acetaminophen total dose of 1000mg
223406161|NCT02418182|DRUG|placebo|subjects randomized to this group will be given placebo tablets
223406162|NCT02499731|BEHAVIORAL|Strong Hearts, Healthy Communities|"We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
223556361|NCT06351163|PROCEDURE|Laparoscopic reduction|A 1cm longitudinal transumbilical incision was made to insert a 5mm trocar for laparoscope placement. CO2 was injected at 10mmHg and a flow rate of 3L. Two 5-mm working trocars were inserted in the lower right and left abdomen under direct visualization, along with two grasping forceps. The ascending colon was manipulated to locate the intussusception mass. Atraumatic graspers were alternately utilized on the ascending colon to mobilize the intussusceptum, pushing it downward towards the cecum. The first visible part of the terminal ileum was grasped and pulled outward and downward, along with its mesentery, using the right grasper, while the left grasper pulled the intussusceptum's neck in the opposite direction. If resistance was encountered, the terminal ileum could be held with the left hand while the right grasper widened the intussusceptum's neck. After reduction, the intestines were examined for necrosis and possible lead points, followed by routine appendectomy and ileopexy.
223556362|NCT06351163|PROCEDURE|Transumbilical mini-open reduction|If laparoscopic reduction alone was unsuccessful or if bowel resection was required, the intussusceptum was fixed with grasping forceps and brought to the umbilicus for MOR. A 2cm transumbilical incision was created, and a skin retractor was inserted. The underlying fascia was longitudinally extended upward and downward along the linea alba. Upon division of the peritoneum, the actual opening could be expanded up to 5cm, while maintaining the skin incision at 2cm. If the initial incision site proved insufficient for exploration, lateral division of the rectus muscle around the umbilicus on both sides could be performed without cutting the skin, thereby enlarging the surgical field. Manual reduction of the intussusceptum was subsequently carried out, along with bowel resection and anastomosis as indicated.
224023287|NCT03534284|DRUG|Trazodone|trazodone tablet
224023288|NCT03534284|DRUG|Placebo|Inactive pill manufactured to mimic trazodone tablets.
224023289|NCT02831543|DRUG|Motireb 5/100 mg|
224023290|NCT02831543|DRUG|Mosapride citrate|
224023291|NCT02831543|DRUG|Placebo|
224132704|NCT01206010|DRUG|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
224132705|NCT01206010|DRUG|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
224132706|NCT04846751|BEHAVIORAL|TYPE OF EXERCISE (OR REST)|continous exercise in normal temperature, continous exercise in hot environment, intervallic exercise in normal temperature.
224132707|NCT00362791|BEHAVIORAL|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
224132708|NCT00362791|BEHAVIORAL|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
224132709|NCT00362791|BEHAVIORAL|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
224132710|NCT06196957|COMBINATION_PRODUCT|pursed lip breathing|pursed lip breathing
224132711|NCT04895163|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy performed for acute appendicitis
223406163|NCT02499731|BEHAVIORAL|Strong Hearts, Healthy Women|"The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.~Participants will learn and discuss techniques and strategies to improve personal health."
223406164|NCT03334344|DEVICE|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
223406165|NCT07065773|DRUG|Trichostatin A|Topical Study Drug
223556363|NCT04004221|DRUG|Tislelizumab|200mg intravenously (IV) every 3 weeks (Q3W)
223737631|NCT06202196|PROCEDURE|Risk prevention session|"The patient will have a consultation dedicated to information on the risks with the neurologist within 1 to 3 months (during this period, the patient must complete the seizure diary).~An appointment with the psychologist within 2 weeks +/- 1 week following the risk discussion consultation will also be scheduled. In this interval of 2 weeks, the patient will have the possibility of reaching the neurologist, the psychologist or the nurse by telephone if he feels the need.~Then participants will be proposed the therapeutic education session including a workshop called Recognizing and Managing the Risks of Epilepsy. The last visit 3 months after the last session will assess differents questionnaires/scales including the Epilepsy Self Management Scale (ESMS)."
223737632|NCT06202196|PROCEDURE|Usual Therapeutic Patient Education (TPE) management|The control group will have usual follow-up including consultations with the neurologist and follow-up of the usual TPE program, namely the individual interview and follow-up of the usual TPE workshops for each center.
223737633|NCT03028246|DEVICE|ExAblate 4000 System|Focused ultrasound
223737634|NCT05704205|DEVICE|NB-UVB phototherapy|Narrowband ultraviolet B irradiation 3 times a week
223737635|NCT05704205|COMBINATION_PRODUCT|Optimal topical therapy|A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
223737636|NCT03415750|DRUG|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
223737637|NCT03415750|DRUG|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
223556364|NCT03597204|DIAGNOSTIC_TEST|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for up to five years and follow-up colonoscopy was arranged for those with FIT positive result
223556365|NCT03597204|DIAGNOSTIC_TEST|Colonoscopy|Subjects in the retrospective cohort were allowed to choose one-off colonoscopy for CRC screening
223556366|NCT05135585|OTHER|Blood sample collection|Blood sample collection at 1 month and 6 months after vaccination
223406166|NCT04090229|DRUG|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
223406167|NCT04090229|DRUG|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
223556367|NCT05135585|OTHER|Questionnaires|data collection (health data, vaccination data, etc.)
223737638|NCT03415750|DRUG|Tacrolimus|
223737639|NCT03232281|DRUG|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
223737640|NCT03232281|DRUG|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
223737641|NCT00854698|OTHER|exercise training|subjects are asked to exercise 20 or 30 minutes.
223406168|NCT04774627|DRUG|PARP inhibitor|All patients treated at least with 1 PARPi
223406169|NCT01776437|DRUG|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
223406170|NCT06940466|OTHER|Online cognitive intervention|A 4 x 2-hour intervention with the following key components: education about menopause and cognition, cognitive strategies (memory, attention and executive functioning), CBT techniques and emotional support.
223406171|NCT06941558|DEVICE|INFINITY™ with ADAPTIS™ and EVERLAST™|The INFINITY™ with ADAPTIS™ and EVERLAST™ ankle replacement system is a development of the Infinity ankle implant, designed to attach to the bone better and to wear out more slowly.
223406172|NCT07153042|BEHAVIORAL|Biweekly monitoring and feedback (BMF)|School coordinators will monitor teachers' implementation progress biweekly and provide feedback to teachers.
223556368|NCT02483858|DRUG|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
223737642|NCT00854698|OTHER|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
223737643|NCT01403246|DRUG|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
223737644|NCT01924312|BEHAVIORAL|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
223737645|NCT02825927|OTHER|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
223737646|NCT05243368|DIETARY_SUPPLEMENT|Personalized Nutritional Intervention|Those with malnutrition criteria will also receive a nutritional supplement (e.g. fortimel cubitan, advanced or extra, Nutricia) or another of similar composition, in case of intolerance to the first option. The aim will be to provide at least 50% of the recommended intakes for the main nutrients related to wound healing.
223737647|NCT00261677|DRUG|epoetin alfa|
223737648|NCT06021015|DEVICE|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）|Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
223737649|NCT06021015|DEVICE|Irinotecan and HepaSphere Microspheres|Irinotecan and HepaSphere Microspheres
223737650|NCT01837992|DRUG|Primaquine|
223737651|NCT01837992|DRUG|delayed primaquine|
223737652|NCT04442204|OTHER|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health|Prospective study across two time-points examining the impact of viral mitigation protocols on mental health
223737653|NCT03634787|DIAGNOSTIC_TEST|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
223406173|NCT07153042|BEHAVIORAL|Site-based assistance and mentorship (SAM)|High-performing teachers will serve as team leaders and guide non-responding teachers on preparation and planning. The team leader will promote group activities and enhance interaction among teachers in these meetings.
223737654|NCT05648370|GENETIC|ctDNA testing and whole exome sequencing|Blood samples will be obtained for ctDNA testing and tumor tissue for whole exome sequencing.
223737655|NCT05249998|OTHER|Program combing APA, Nutrition, and Therapeutic Education|Patients will benefit from the activities already proposed as part of the usual practice and in addition a multidisciplinary staff will take place in order to interpret the assessments of the patients included and to direct the patients according to their phenotypic profile towards the different programmes of adapted physical activity.
224023292|NCT01543932|DRUG|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
223406174|NCT07153042|BEHAVIORAL|Enhanced site-based assistance and mentorship (Enhanced SAM)|A FOYC coach (with FOYC implementation and training experience) will provide tailored in-person support, facilitate goal-setting, opportunities to interact with consultants, supportive text messaging, continuing education, networking strategies, and monthly check-ins.
223556369|NCT05085041|BEHAVIORAL|Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE)|The investigators will provide 8 sessions of a multi-component education intervention to the participants in the intervention group. Each session will address parental nutrition knowledge, self-efficacy, and attitudes around feeding, parental modeling of healthy foods, and skill development to increase success in making behavioral changes. The intervention curriculum will be informed by Social Cognitive Theory to help parents guide young children to engage in healthy eating behaviors through modeling (Curriculum Design). The investigators will deliver the intervention using multicomponent to enhance and maximize the learning experiences of the participants for successful behavior changes. The intervention will be comprised of instructional videos, text messages with key information, online cooking activities, and telephone consultation (Modality).
223556370|NCT00056576|DRUG|Zonisamide|
223556371|NCT05631340|OTHER|Discharge education|Researcher's newly prepared discharge education supported by a booklet and mobile app
224023293|NCT01543932|DRUG|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
224023294|NCT01543932|DRUG|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
224023295|NCT05090280|DRUG|PF614 solution|PF614 solution is an oxycodone prodrug
224132712|NCT05958095|DEVICE|MamaLift Plus|MamaLift Plus is a digital therapeutic designed to augment usual care and support the treatment of mild-to-moderate postpartum depression (PPD). This mobile-based intervention is grounded on principles of Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) and includes key content areas for the treatment management of PPD. It also includes recent developments in acceptance and commitment-based therapies, specifically for the perinatal context.
223556372|NCT01754246|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
223556373|NCT04033614|DEVICE|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
223556374|NCT06117033|OTHER|video assisted mobilization training|Preoperative video-assisted mobilization training was given to patients undergoing coronary artery bypass graft surgery
223556375|NCT03556670|BEHAVIORAL|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
223556376|NCT03556670|OTHER|Control|Usual practice control
223556377|NCT03063723|DRUG|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
223556378|NCT03063723|DRUG|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
223556379|NCT05353114|OTHER|3D feet scan (smart-fitting by Podiapp - Podartis s.r.l Unipersonale-Crocceta del Montello (TV), Italy).|The 3D foot scan becomes a movile app that recommends a specific size and model of therapeutic footwear according to the measurements
223556380|NCT05281627|OTHER|Emergency Laparotomy|All patients undergoing Emergency Laparotomy
223556381|NCT05032677|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L2-3 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
223556382|NCT05032677|PROCEDURE|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|25G Dural Puncture Epidural Block at L2-3 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
224023296|NCT05090280|DRUG|Naltrexone Hydrochloride|Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.
224023297|NCT05090280|DRUG|Nafamostat Mesylate|Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.
224023298|NCT02059785|DRUG|Pinocembrin for Injection|
224023299|NCT00001750|DRUG|Stemgen|
224132713|NCT05958095|DEVICE|Digital Sham App|The digital sham app delivers content, tips, and suggestion for general wellbeing support.
223406175|NCT07153042|BEHAVIORAL|FOYC+CImPACT|"Focus on Youth in the Caribbean (FOYC) is an evidence-based, eight-session life skills curriculum designed to reduce risk-taking behaviors related to HIV/STI transmission and teen pregnancy. Woven throughout FOYC is a decision-making model that provides guidance and practice in problem solving with a focus on how to obtain factual information on sexual health.~CImPACT is a single-session intervention including a 24-min educational video filmed in The Bahamas. The video focuses on effective parent-adolescent communication and listening strategies related to difficult topics including safe-sex followed by two role-plays for the parent and youth, a discussion, and a condom demonstration."
223406176|NCT07163208|DEVICE|Low-Level Laser Therapy (LLLT)|Low-level laser therapy using the Omega XP Model with wavelengths of 675nm (30mW), 820nm (200mW), or 46-cluster LED probe (mixed wavelengths: 660nm, 950nm, 870nm, 880nm, 940nm, 820nm), applied three times weekly for 30 minutes over 6 weeks to target cervical lymphatic chain, musculature, and trigger points for pain relief in cervicogenic headache.
224023300|NCT03433079|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin (NGAL)|Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
223406177|NCT07163208|OTHER|Routine Physical Therapy (RPT)|Warm-up: Active cervical ROM (5-10 reps, pain-free range). Stretching: Upper trapezius, levator scapulae, SCM; hold 15-30 sec, 3-5 reps, NRS ≤ 3/10. Therapeutic exercises: cervical deep flexors, scapular stabilization (2-3 sets × 10-15 reps, Borg 11-13), progressed weekly. Modalities: Hot pack 15 min at 40-45°C; TENS 80-100 Hz, 50-100 µs pulse width, 20 min. Frequency: 3× weekly for 6 weeks. Safety: contraindications screened; pain/exertion monitored pre/post.
223406178|NCT07182617|BEHAVIORAL|Standard Coaching (SOC)|Participants received BetterNight's standard CPAP coaching program. Monitoring was conducted through manufacturer platforms (ResMed AirView, Philips Care Orchestrator) and BetterNight's internal Clarity dashboard. Coaches contacted patients at scheduled checkpoints (10, 20, 45, 60, and 80 days) to provide education, support, and troubleshooting to help patients achieve Medicare adherence.
223556383|NCT04784793|OTHER|App-based group|"Participants received home exercise programs by a postural alignment exercise mobile app we developed.~The postural alignment app included 3 main emerged themes were recorded as self-assessment, neck/shoulder, and upper back-specific exercise content, and motivational notifications.~Participants can evaluate themselves in the application thanks to the self-assessment, receive motivational notifications during the day, and exercise reminders on the days determined by them. They can apply the exercise program with the formed exercise content videos.~The exercise program consists of combined exercises that postural alignment plus exercises of neck spinal stabilization, stretching, and strengthening of neck/shoulders/upper back regions.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
223556384|NCT04784793|OTHER|Control group|"Participants received home exercise programs as a paper handout.~The exercise program was the same for app-based and control groups.~Both group participants were requested to do the exercises from the app/brochure 3 times a week, for 6 weeks."
223556385|NCT04742530|BEHAVIORAL|Fasted Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after a 7-hour period of fasting. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
223556386|NCT04742530|BEHAVIORAL|Fed Evening Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 18:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
223556387|NCT04742530|BEHAVIORAL|Fed Morning Exercise|A 45 minute exercise session will take place on a stationary cycle ergometer at 10:30, after having consumed a carbohydrate-containing meal (20% estimated energy requirements) 2 hours prior. This will consist of 30 minutes of steady state cycling at 60% of VO2max, followed by an exercise test during which participants will complete as much work as they can within 15 minutes.
223556388|NCT05182658|DRUG|Empagliflozin 10 MG|The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
223556389|NCT05182658|DRUG|Placebo|The proposed intervention will be administration of placebo for a period of 12 months. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
223556390|NCT02036580|BIOLOGICAL|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
223556391|NCT02036580|BIOLOGICAL|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
223556392|NCT02036580|OTHER|Placebo|
223556393|NCT06482827|DEVICE|Sham Repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
224023301|NCT03433079|DIAGNOSTIC_TEST|Arterial lactate|Arterial lactate level was assessed in all patients.
224023302|NCT03433079|DIAGNOSTIC_TEST|Interleukin-6 (IL-6)|The level of interleukin-6 was assessed in all patients.
224023303|NCT03433079|DIAGNOSTIC_TEST|Procalcitonin (PCT)|The level of procalcitonin (PCT) was assessed in all patients.
224023304|NCT03433079|DIAGNOSTIC_TEST|Myoglobin|The level of myoglobin was assessed in all patients.
224023305|NCT04939961|DIETARY_SUPPLEMENT|Hericium erinaceus|6 capsules per day, 3 times two after breakfast, lunch and dinner
224132714|NCT04876703|DEVICE|Multichannel Functional electrical stimulation|The Xcite system is a battery-powered stimulator with up to 12 channels of cyclical stimulation. It is a task-specific modality to enhance mass practice during neurological re-education.
224023306|NCT04939961|DIETARY_SUPPLEMENT|Placebo|6 capsules per day, 3 times two after breakfast, lunch and dinner
224023307|NCT01747993|DRUG|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
224023308|NCT01747993|DRUG|Placebo|(1 tablet / day for 6 days)
223406179|NCT07182617|BEHAVIORAL|MonitAir RPM|Participants received the standard BetterNight coaching program enhanced with the MonitAir remote patient monitoring platform. MonitAir enabled weekly reviews of CPAP usage data, automated text follow-ups, and at least one interactive telehealth visit per month. Coaches escalated issues such as poor adherence, high residual AHI, or mask leak to physicians as needed. The intervention aimed to improve CPAP adherence and patient satisfaction compared with standard care.
224132715|NCT04876703|OTHER|Standard motor training|Standard motor training is the conventional rehabilitation treatment
224132716|NCT02932189|DEVICE|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
224132717|NCT02119884|DRUG|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
224132718|NCT02119884|DRUG|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
224132719|NCT02796391|DRUG|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
223406180|NCT07184203|DRUG|Itraconazole (ITZ)|therapy for tinea capitis orally
224132720|NCT02796391|BEHAVIORAL|One on One Counseling|All participants will receive One on One Counseling.
224132721|NCT02231450|DRUG|Lu AE58054 encapsulated film-coated tablets|
224132722|NCT00483275|DRUG|Alfacalcidol|
223406181|NCT07183241|BEHAVIORAL|Physical exercise and cognitive exercises|The intervention will be based on the Vivifrail program, which is a multicomponent physical exercise program designed specifically for older adults.
223406182|NCT07183644|DEVICE|Pulse Dye laser|"Pulse Dye Laser (PDL) standard settings. This is the same procedure children would receive as standard of care if these individuals were not participating in this study.~The surgeon will perform 1 pass with the PDL over the area of the Port wine birthmark (PWB)."
223406183|NCT07183644|DEVICE|Pulse Dye Laser (PDL) pulse width stacking|"This procedure is used for some patients as standard of care depending on the severity and depth of the lesion.~The surgeon will perform 3 passes with the PDL over the PWB, gradually increasing the pulse duration with each pass to effectively target both superficial and deeper blood vessels."
223556394|NCT06482827|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2004 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
223556395|NCT00506454|DRUG|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
223556396|NCT00506454|DRUG|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
223556397|NCT05582356|DIETARY_SUPPLEMENT|Carbohydrate group (Group OC)|Carbohydrate group (Group OC)
223556398|NCT05582356|DIETARY_SUPPLEMENT|Placebo group (Group OP|Placebo group (Group OP
223556399|NCT00295334|DRUG|alcohol|
223556400|NCT05284500|PROCEDURE|Pediatric cardiac surgery with cardiopulmonary bypass|All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
223556401|NCT00124163|PROCEDURE|Imaging procedure of CT colonography|
223556402|NCT02584452|DRUG|Mepivacaine|20cc of 2% mepivacaine \<20 minutes prior to in room time.
223556403|NCT02584452|PROCEDURE|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
223556404|NCT02584452|DRUG|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
223406184|NCT07183644|DEVICE|Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser.|The combination of these two lasers is one of the investigational treatments. The surgeon will perform 1 pass per laser over the PWB. The 1st pass will be with the PDL to target the blood vessels closer to the top of the skin, followed by a 2nd pass with the Nd:YAG laser to target the blood vessels that deeper in the skin.
223406185|NCT07183644|DEVICE|IPL (Intense Pulsed Light) followed by Pulse Dye Laser (PDL)|The surgeon will perform 1 pass with the IPL followed by 1 pass with the PDL over the PWB
224132723|NCT00483275|BEHAVIORAL|Balance, gait and strength training|
224132724|NCT00483275|BEHAVIORAL|Patient education|
224132725|NCT05582265|DRUG|Tislelizumab（neoadjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224132726|NCT05582265|DRUG|Cisplatin （neoadjuvant）|Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224132727|NCT05582265|DRUG|Nab-paclitaxel （neoadjuvant）|Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224132728|NCT05582265|PROCEDURE|Surgical resection|Standard of care
224132729|NCT05582265|DRUG|Cisplatin（adjuvant）|Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224132730|NCT05582265|DRUG|Tislelizumab（adjuvant）|Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224132731|NCT05582265|RADIATION|Radiation|Recommended, standard of care
224132732|NCT05582265|DRUG|Carboplatin (neoadjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224132733|NCT05582265|DRUG|Carboplatin (adjuvant）|Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
224023309|NCT05317845|OTHER|No treatment given|The clinical management and prescribed treatment of diabetes and eASCVD/ASCVD risk factors are independent of this study and are part of the routine clinical practice at the discretion of the treating physician.
224023310|NCT04447196|OTHER|MDP|Multi dimensional dyspnea profile scores at rest and during non invasive ventilation
224023311|NCT04737187|DRUG|Trifluridine/Tipiracil|Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
224023312|NCT04737187|DRUG|Bevacizumab|administered every 2 weeks (Day 1 and Day 15)
223406186|NCT07183644|DEVICE|Cupping followed by Pulse Dye Laser (PDL)|The combination of these modalities is one of the experimental procedures. The surgeon will place a small suction cup over the PWB target region of the PDL for a few seconds to stop the blood flow and accumulate the blood in that spot. The PDL treatment will then quickly proceed. Since the PDL targets red blood cells, it will allow the laser to target the pooled blood in the abnormal blood vessels better.
223406187|NCT07183306|DRUG|HT-101|HT-101 given by subcutaneous injection.
224023313|NCT06259552|BIOLOGICAL|SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody|SPX- 303 Injection
224023314|NCT03071367|OTHER|Clinical Simulation|
223406188|NCT07183306|DRUG|HT-102|HT-102 given by subcutaneous injection.
224023315|NCT00415038|DRUG|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
224023316|NCT00415038|DRUG|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
224023317|NCT00415038|DRUG|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
224023318|NCT00415038|DRUG|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
224023319|NCT00415038|DRUG|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
224023320|NCT05635305|DRUG|Zoliflodacin Patheon|"Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1).~Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)"
224023321|NCT01791374|DRUG|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
224023322|NCT01791374|DRUG|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
224023323|NCT02274974|DRUG|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
223406189|NCT07184216|BEHAVIORAL|Person-centered care intervention|The intervention will be delivered by primary care nurses, in coordination with doctors, social workers, and psychologists from each center. Nurses, previously trained in person-centred care, will collect the family narrative regarding their experiences, needs, goals, and available resources. Based on this, a health plan will be co-created with the family, incorporating short- and long-term objectives, concrete actions, and the supports required. The plan will be reviewed and adapted in monthly follow-up consultations during a three-month period.
223406190|NCT07182799|DIAGNOSTIC_TEST|Plaque vulnerability assessment|"The purpose of the OCT-AGEM registry is to confirm the clinical utility of plaque OCT assessment over the standard coronary angiography evaluation. In particular, this ambispective cohort study aims to validate the predictive value of the OCT-based plaque vulnerability criteria:~* Minimum lumen area \<3.5 mm2;~* Fibrous cap minimum thickness \<65 µm;~* Lipid arc extension \>180°;~* Presence of macrophages;~* Superficial and deep calcified nodules~* Ulceration/Erosion/Dissection~* Layered tissue~* Optical flow ratio (OFR)"
223406191|NCT07182799|DIAGNOSTIC_TEST|Stent implantation optimization|The purpose of the OCT-AGEM registry is to confirm the clinical utility of OCT guidance during PCI over the standard coronary angiography evaluation. In particular, this ambispective cohort study aims to validate the predictive value of the OCT-derived plaque/stent parameters reported in expert consensus OCT documents, utilizing the cut-off points identified in the previous OCT registries
223406192|NCT07184437|DEVICE|OVD-F device Minivisc®PLUS 14 mg/ml|MINIVISC® PLUS 14 mg/ml is intended to protect, lubricate and support delicate ophthalmic cells or tissues, to assist in maintaining intraocular space and to enhance visualization during surgery.
223406193|NCT07182994|PROCEDURE|Elbow joint immobilization|Immobilization of the elbow joint during peripheral venous line cannulation in pediatric patients on the success of the technique
223556405|NCT02584452|PROCEDURE|adductor canal nerve block|ultrasound guided adductor canal nerve block
223556406|NCT02584452|DRUG|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
223556407|NCT02584452|DRUG|Propofol|Anesthesia induction will include a propofol bolus.
223556408|NCT02584452|DRUG|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
223556409|NCT02041390|OTHER|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
223556410|NCT02041390|OTHER|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
223556411|NCT06243328|DEVICE|negative wound pressure therapy|nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
224023324|NCT02274974|DRUG|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
224023325|NCT04993482|OTHER|No intervention|This project contains a longitudinal observational study design. The investigator will collect data out of a group with type 2 diabetes mellitus patients and out of group with control adults on three time points (baseline, follow-up after one year, and follow-up after two years). Therefore, the investigator will only collect observational data and the participants will not be exposed to a certain intervention.
224023326|NCT03756129|DRUG|MIJ821|Different dosages and different regimen for MIJ821
224023327|NCT03756129|DRUG|Placebo|Infusion
224023328|NCT03756129|DRUG|Ketamine|Infusion
224023329|NCT04289168|BEHAVIORAL|Music|Music class was provided for the intervention group
224023330|NCT01224392|OTHER|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
224023331|NCT01224392|RADIATION|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
224023332|NCT05451498|DIETARY_SUPPLEMENT|Creatine|Participants were matched according to fat-free mass to consume a placebo, or 5-g dose of creatine monohydrate within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
224023333|NCT05451498|DIETARY_SUPPLEMENT|Maltodextrin|Participants were matched according to fat-free mass to consume a placebo (maltodextrin) within one hour before training, or within one hour after training for 8 weeks while completing a weekly resistance training program. At each time point (before and after training), all participants co-ingested a 25-gram dose whey isolate and a 25-gram dose of carbohydrate powder along with their assigned supplement. Body composition using a 3-compartment field (3CFIELD), muscular strength (one-repetition maximum \[1RM\]) and endurance (repetitions to fatigue \[RTF\] at 80% 1RM) using bench press (BP) and back squat (SQ) exercises along with isometric mid-thigh pull (IMTP) were assessed before and after the 8-week supplementation period.
224023334|NCT06253598|DRUG|Recombinant Human Adenovirus Type 5|Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10\^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10\^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.
224132734|NCT02341118|GENETIC|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
224132735|NCT00621452|BIOLOGICAL|therapeutic autologous lymphocytes|Given IV
224132736|NCT00621452|DRUG|cyclophosphamide|Given IV
223406194|NCT07182994|PROCEDURE|Arm restraint without elbow immobilization|Use of arm restraint without immobilization of the elbow joint during peripheral venous line cannulation in pediatric patients.
223406195|NCT07183371|BIOLOGICAL|R21|A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein
223406196|NCT07183371|BIOLOGICAL|RH5.1|A soluble protein vaccine against the RH5 antigen
223406197|NCT07183371|BIOLOGICAL|R78C|A soluble RIPR EGF-CyRPA fusion protein vaccine
223406198|NCT07183371|BIOLOGICAL|Matrix-M™|A saponin-based vaccine adjuvant
223406199|NCT07183371|BIOLOGICAL|Rabivax-S|Rabivax-S is an inactivated, freeze-dried, single-dose vaccine. The vaccine contains purified, inactivated rabies antigen produced using Vero ATCC CCL 81 cells as the cell substrate, Pitman Moore (PM3218) as the virus strain, and sucrose, glycine and HSA (Human Serum Albumin) as excipients
223406200|NCT07183371|BIOLOGICAL|Menveo|Menveo is a tetravalent meningitis vaccine that consists of one vial of MenA powder and one vial of Men CWY solution.
223406201|NCT07183371|BIOLOGICAL|Avaxim 80|Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine. Each immunising dose contains 80 antigen units of inactivated hepatitis A virus (GBM strain).
223406202|NCT07183046|BEHAVIORAL|Implementation Intention Guide|The intervention is the addition of implementation intention guide document provided with the FIT. This is a one-page piece of paper that was developed by the investigator team and finalized with input/feedback from patient partners. The implementation intention guide includes instructions about the importance of developing a plan to complete FIT. It also includes fillable fields for participants to enter their plan for when to complete, where to store, when to return, and where to return their FIT. Participants will also be able to follow a QR code on the implementation intention guide document to a link to complete an anonymous, electronic version of the guide and share feedback on the intervention.
223406203|NCT07184125|DRUG|To measure anxiolysis, satisfaction level of patient after receiving Midazolam|Anxiety \& satisfaction
223406204|NCT07182539|OTHER|PRVC ventilation|Ventilation in PRVC mode.
223406205|NCT07182539|OTHER|VCV ventilation|Ventilation in VCV mode.
223406206|NCT07182552|DRUG|NTB003|NTB003 dose 1, dose 2, dose 3, dose 4
223556412|NCT04523623|DRUG|Oxycodone|oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen
223556413|NCT04523623|DRUG|Ibuprofen|ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
223406207|NCT07182552|DRUG|Placebo|Placebo dose 1, dose 2, dose 3, dose 4
223556414|NCT00654225|DRUG|Rosuvastatin|
223556415|NCT00654225|DRUG|Atorvastatin|
224132737|NCT00621452|BIOLOGICAL|aldesleukin|Given subcutaneously
223406208|NCT07183384|BIOLOGICAL|Mesenchymal Stem Cell-Derived Exosomes|Mesenchymal stem cell-derived exosomes isolated from adipose-derived stem cells (ASC). The exosomes contain bioactive molecules including microRNAs (particularly miR-126-3p), proteins, and lipids that promote endothelial repair and regeneration. The product is manufactured under GMP conditions and administered as a single Intravenous or Intramuscular infusion.
223406209|NCT07183384|OTHER|Placebo (Sterile Saline Solution)|Sterile saline solution (0.9% sodium chloride) administered Intravenous or Intramuscular as placebo control. The volume and administration method are identical to the active treatment to maintain blinding.
223737656|NCT05348382|PROCEDURE|Intradermal acupuncture|In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
223737657|NCT05348382|PROCEDURE|Sham intradermal acupuncture|In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
223737658|NCT05048121|OTHER|Cosmetic Active Ingredient CLS02021|Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days
224023335|NCT06253598|DRUG|Lenvatinib|Lenvatinib was administered orally once daily started on day 1 of cycle 1 of the study until disease progression or unacceptable toxicity occurred or meet the end point of the study. For patients weighing less than 60 kg, the recommended daily dose was 8 mg once daily. For patients weighing ≥60 kg, the recommended daily dose was 12 mg once daily
224132738|NCT00621452|GENETIC|polymerase chain reaction|Correlative studies
224132739|NCT00621452|GENETIC|gene rearrangement analysis|Correlative studies
223737659|NCT05048121|OTHER|Placebo PLC01021|Topical, face application of the cream base, two times a day in a period of 30 days
223737660|NCT05706363|PROCEDURE|Quadriceps graft|Using quadriceps graft as new medial patellofemoral ligament graft. Fixated with suture anchor
223737661|NCT06524882|DEVICE|Vivid Vision|dichoptic video games played through a virtual reality headset
223737662|NCT06524882|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
223406210|NCT03117478|OTHER|Magneto-encephalography (MEG)|Magneto-encephalography
223406211|NCT03117478|OTHER|Electro-encephalography (EEG)|Electro-encephalography
223406212|NCT03117478|OTHER|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
223406213|NCT03117478|OTHER|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
223737663|NCT06524882|DEVICE|Optical Correction|Glasses prescribed at investigator discretion
224023336|NCT06253598|DRUG|Tislelizumab|Tislelizumab 200mg was administered intravenously every 3 week started on day 1 of cycle 3 until disease progression or unacceptable toxicity occurred or meet the end point of the study.
224023337|NCT04858087|OTHER|Screening and treatment|Students were screened by mRDTs and treated with artemether-lumefantrine if positive
224023338|NCT06163911|DEVICE|ECG|Routine care 12-lead electrocardiogram
223406214|NCT03117478|OTHER|Meditation|Meditation
223406215|NCT05760989|DEVICE|Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System|Replacement of the native tricuspid valve through a transcatheter approach
223406216|NCT00570687|DRUG|Technosphere Insulin|Inhalation 15U/30U
224132740|NCT00621452|PROCEDURE|lymph node biopsy|Optional correlative studies
224132741|NCT00621452|BIOLOGICAL|genetically engineered lymphocyte therapy|Receive genetically modified T cells
224132742|NCT00621452|PROCEDURE|bone marrow aspiration|Optional correlative studies
224132743|NCT00621452|OTHER|flow cytometry|Correlative studies
224132744|NCT00621452|OTHER|laboratory biomarker analysis|Correlative studies
224132745|NCT00621452|OTHER|enzyme-linked immunosorbent assay|Correlative studies
224132746|NCT05059951|DRUG|Immune checkpoint inhibitor|Chemotherapy follow the guild line.
223406217|NCT06683131|DRUG|Tafolecimab|450mg of tafolecimab (150mg each one) was injected subcutaneously before primary PCI and then every month till totally 12 months.
223406218|NCT04707521|BEHAVIORAL|3M tape ship-shaped combined with strap fixing method|During fixation, the endotracheal intubation and dental pad were located in the center of the mouth, and one end of one piece of medical cloth adhesive was pasted on the patient's cheek near the side. When it reached one side of the mouth, the endotracheal intubation and dental pad were wound around twice, and then the other side of the adhesive tape was pasted on the cheek opposite the side from the other side of the mouth,The other is fixed in reverse with the same sticking method, and the two pieces of adhesive tape are finally crossed and fixed at the corners of the mouth.Finally, fasten it with a lacing
223406219|NCT01624740|DEVICE|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
223406220|NCT01624740|DEVICE|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
223406221|NCT05069116|OTHER|Training in surgery|The study evaluates the training process of general surgery residents - in classic surgery, as well as laparoscopic surgery, from hospital activity to extracurricular activities.
223406222|NCT00894439|DRUG|BLI-489/Piperacillin|
223406223|NCT00894439|DRUG|BLI-489|
223406224|NCT00894439|DRUG|Piperacillin|
223406225|NCT05125796|DRUG|paracetamol|1000 mg intravenous paracetamol in 100 mL normal saline
223406226|NCT05125796|DRUG|Dexketoprofen Trometamol|50 mg intravenous dexketoprofen Trometamol in 100 mL normal saline
223406227|NCT05125796|DRUG|Lidocaine topical|Application of 5 gr of 5% topical lidocaine
223406228|NCT05125796|DRUG|Placebo|100 mL intravenous normal saline infusion+ placebo topical pomade application
223406229|NCT06510270|DRUG|Dapagliflozin 10 mg once daily|Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group
223556416|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Non-obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
223556417|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Mild obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
223737664|NCT05864534|DRUG|Balstilimab|Balstilimab 450 mg IV over 30 minutes every 3 weeks
223737665|NCT05864534|DRUG|Botensilimab|Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
223737666|NCT05864534|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
224023339|NCT06163911|DEVICE|Echocardiography|Routine care echocardiography
223737667|NCT05864534|DEVICE|Sonocloud-9 (SC-9)|Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
223737668|NCT00075140|GENETIC|Mutation in the gene|
224023340|NCT04308343|DRUG|Methotrexate|Drugs to treat undisturbed ectopic pregnancies
224132747|NCT02155764|DEVICE|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
223737669|NCT04651452|BEHAVIORAL|Value Affirmation|Participants will complete writing tasks regarding their personal values.
223737670|NCT04651452|BEHAVIORAL|Reflective Journaling|Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
224132748|NCT02155764|DEVICE|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
224132749|NCT02155764|DEVICE|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
224132750|NCT01427283|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
223406230|NCT06510270|DRUG|Loop diuretics|Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group
223406231|NCT06510270|DRUG|Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)|Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
223737671|NCT00009854|DRUG|carmustine in ethanol|
223737672|NCT00009854|PROCEDURE|conventional surgery|
223737673|NCT01375907|DRUG|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
223737674|NCT04049968|DEVICE|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
223737675|NCT04049968|OTHER|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
223737676|NCT05139056|BIOLOGICAL|Neural Stem Cells-expressing CRAd-S-pk7|Given intracerebrally
223737677|NCT05139056|PROCEDURE|Resection|Undergo surgical resection
223737678|NCT02132767|DRUG|Amiodarone|"Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
223737679|NCT02132767|PROCEDURE|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
223737680|NCT02132767|DRUG|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
223737681|NCT00918658|OTHER|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
224023341|NCT04308343|DRUG|Letrozole|Drugs to treat undisturbed ectopic pregnancies
224023342|NCT04308343|DRUG|cetrotide|Drugs to treat undisturbed ectopic pregnancies
224023343|NCT03543800|DEVICE|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
224023344|NCT03543800|DEVICE|PRP kit|PRP kit legally marketed in Canada for PRP
224023345|NCT02904031|DRUG|5-fluorouracil|
224023346|NCT02904031|DRUG|oxaliplatin|
224023347|NCT02904031|DRUG|l-leucovorin|
224023348|NCT02904031|DRUG|panitumumab|
224023349|NCT06143436|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Using questionnaire to collect data from new lung cancer patients.
224132751|NCT01427283|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
224132752|NCT01427283|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
224132753|NCT00831441|DRUG|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
224023350|NCT06610318|BEHAVIORAL|imagery rescripting|This condition has three stages. In the first stage, participants were asked to select their most distressing memory related to their appearance (not physical or sexual trauma). They were asked to visualize the selected memory, in detail, as if it were happening to them again. Then, interventionists used a downward arrow technique to identify two-to-three maladaptive core schema. In the second stage, participants were asked to identify a real or imagined trusted adult. Then, they were asked to imagine what their younger self might need to cope with or feel calmer in the situation of their selected memory. In the third stage, the participant was instructed to imagine asking the trusted adult for what they need and to imagine the trusted adult providing their selected interventions and describe how they feel afterwards. These procedures were then repeated with participants' most distressing memory related to eating. This session was remote delivered via Zoom.
224023351|NCT06610318|BEHAVIORAL|nutrition education|The active control condition consisted of a time- and attention-matched general nutrition education session. The curriculum for this intervention included information from the United States Department of Agriculture's Dietary Guidelines (e.g., food labels, describing the benefits of macronutrients). This session was remote delivered using Zoom.
224023352|NCT03439423|RADIATION|CT with contrast agent|
224023353|NCT03439423|DIAGNOSTIC_TEST|MR without contrast agent|"on 1.5-T unit, with the following sequences:~* steady-state free-precession (true-FISP)~* half-Fourier single shot spin-echo (HASTE)"
224023354|NCT03439423|DIAGNOSTIC_TEST|Color-Doppler Ultrasound|
224023355|NCT03439423|OTHER|Questionnaire|regarding their perception of examinations
224023356|NCT00126477|PROCEDURE|cognitive assessment|
224023357|NCT00126477|PROCEDURE|management of therapy complications|
223406232|NCT01754350|DIETARY_SUPPLEMENT|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to \< 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
223406233|NCT01754350|DIETARY_SUPPLEMENT|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
223406234|NCT02999269|DEVICE|MECTA Spectrum 5000Q Amplitude|Current
223406235|NCT01102257|DRUG|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
223406236|NCT01102257|DRUG|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
223406237|NCT04003636|BIOLOGICAL|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
223406238|NCT04003636|DRUG|Gemcitabine|Gemcitabine by IV infusion
223406239|NCT04003636|DRUG|Cisplatin|Cisplatin by IV infusion
223406240|NCT04003636|DRUG|Placebo|Placebo to pembrolizumab
223406241|NCT04771572|DRUG|LP-118|novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
223406242|NCT03048747|DRUG|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
223406243|NCT04781803|DRUG|Cyclosporine|Cyclosporine 6 mg/kg and mycophenolic acid 1 gram orally on day 0 post-transplant
223406244|NCT02019316|DIETARY_SUPPLEMENT|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
223406245|NCT02019316|DIETARY_SUPPLEMENT|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
223406246|NCT05117502|DEVICE|intermittent Theta Burst Stimulation|intermittent Theta Burst Stimulation (iTBS) is a type of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered by the MagVenture MagPROX100 with MagOption Stimulator and MagPro Cool Coil B65 A/P. The MagPro Cool Coil B65 A/P can be switched from active to placebo.
223406247|NCT05117502|DEVICE|Placebo intermittent Theta Burst Stimulation|The placebo coil magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active iTBS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e. clicking) nearly identical to that of the active coil.
223406248|NCT02731352|DRUG|Apatinib|Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.
223406249|NCT02731352|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.
224023358|NCT00126477|PROCEDURE|psychosocial assessment and care|
224023359|NCT00126477|PROCEDURE|quality-of-life assessment|
223406250|NCT05749705|OTHER|Fat to Lean Mass Ratio|"The study will be conducted for people who suffer from excess fat mass and their age is over 18 years.~years will be calculated with G power"
223406251|NCT05225610|OTHER|Valsalva Manoeuvre|Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
223406252|NCT05225610|DRUG|Dexmedetomidine Injection [Precedex]|The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
223406253|NCT05225610|DRUG|normal Saline|5 ml saline will be administered.
223406254|NCT03531203|DIETARY_SUPPLEMENT|Soursop supplementation|The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
223406255|NCT03531203|OTHER|Placebo|Control group (without soursop group) was left without treatment during study period
223406256|NCT02014311|PROCEDURE|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
223406257|NCT02014311|PROCEDURE|CTA guided treatment strategy|CTA guided treatment strategy
223406258|NCT05651048|OTHER|Control Group|Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
223406259|NCT05651048|OTHER|BEMER Group|BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
224132754|NCT00831441|DRUG|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
224132755|NCT05674344|DEVICE|Masimo Temperature device|Non-invasive temperature device
223406260|NCT05651048|OTHER|Kinesiotape Group|Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
223406261|NCT05561270|DEVICE|White LED light|Exposure to white LED light for 1-2 hours/day x 10 weeks
223406262|NCT05561270|DEVICE|Green LED light|Exposure to green LED light for 1-2 hours/day x 10 weeks
223406263|NCT02838797|DRUG|RQ-00000010|orally administered serotonin 4 receptor partial agonist
223737682|NCT00918658|OTHER|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
224132756|NCT04719676|OTHER|Core strength training using unstable surface|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface"
223406264|NCT02838797|DRUG|Placebo|oral acetate buffer
223406265|NCT01964482|OTHER|Strength training|Strength training followed by intake of a protein drink
223406266|NCT02333344|DRUG|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
223406267|NCT05749744|OTHER|cardiac telerehabilitation program by videoconference|"* A video conference interview with an Adapted Physical Activity (APA) teacher before starting physical training~* Exercise training for 3 weeks via distance coaching~* Therapeutic patient education (TPE) workshops conducted remotely with 1 workshop per week.~* Medical follow-up via teleconsultation~* Psychological and/or dietetic follow-up if necessary.~* Final assessment at 1 month with evaluation of aerobic metabolism, functional evaluation and final shared educational assessment (BEP).~* Appointment with an association Cœur et Santé and Sport-Santé 42 or setting up of an individual physical activity"
223406268|NCT03809338|DIAGNOSTIC_TEST|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
223406269|NCT03160690|PROCEDURE|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
223406270|NCT00427102|DRUG|Oral MRX-1024|
223406271|NCT00427102|PROCEDURE|Standard Fractionation Radiation Therapy|
223406272|NCT00427102|DRUG|High-Dose Cisplatin Chemotherapy|
223406273|NCT02909335|DRUG|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~* between 6 and 10 ng / ml during the first 2 months,~* between 5 and 8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
223406274|NCT02909335|DRUG|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~* between 6 and 10 ng / ml during the first 2 months,~* between 5-8 ng / ml from the start of the end M3 and M6,~* and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
223406275|NCT02909335|DRUG|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
223406276|NCT02909335|DRUG|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
223406277|NCT05576272|DRUG|QL1706|5 mg/kg#D1#Q3W IV, 4-6 cycles
223406278|NCT05576272|DRUG|Carrelizumab|200mg#D1#Q3W IV, 4-6 cycles
223406279|NCT05576272|DRUG|Gemcitabine|1000mg/m2#D1\&D8#Q3W IV, 4-6 cycles
223406280|NCT05576272|DRUG|Cisplatin|80mg/m2#D1#Q3W IV, 4-6 cycles
223406281|NCT03349073|DRUG|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
223406282|NCT05416580|DRUG|UDCA (Ursodeoxycholic acid)|UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
223406283|NCT05416580|DRUG|Placebo|Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
223406284|NCT05416580|DRUG|Metformin|Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
223406285|NCT04452214|DRUG|CAN04|Administered intravenously
223406286|NCT04452214|DRUG|Pembrolizumab|Administered intravenously
223406287|NCT04452214|DRUG|Carboplatin|Administered intravenously
223406288|NCT04452214|DRUG|Pemetrexed|Administered intravenously
223406289|NCT01135329|DRUG|Fludarabine|30 mg/m\^2 IV daily on Day -6 through Day -2.
223406290|NCT01135329|DRUG|Busulfan|1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.
223406291|NCT01135329|DRUG|Cyclophosphamide|50 mg/kg IV daily on Day +3 and Day +4.
223406292|NCT01135329|DRUG|Mycophenolate Mofetil|15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.
223406293|NCT01135329|DRUG|Tacrolimus|Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
223406294|NCT03132857|OTHER|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.
223406295|NCT03942458|DRUG|Vicagrel 6mg|Vicagrel 24mg loading followed by 6mg/day for 6 days
223406296|NCT03942458|DRUG|Clopidogrel 75mg|Clopidogrel 300mg loading followed by 75mg/day for 6 days
223406297|NCT03850470|DIAGNOSTIC_TEST|clinical examination|Thorough examination including history, screening, motion testing, strength testing, special testing
223406298|NCT03850470|OTHER|MRI|Low field MRI .25 Tesla
223406299|NCT03040778|DRUG|Pentoxifylline|Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
223406300|NCT03040778|DRUG|Placebo|Placebo tablets
223406301|NCT03040778|DRUG|Tocopherol|Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
223406302|NCT04033731|BEHAVIORAL|Attention Network Task|The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
223406303|NCT00126256|DRUG|5-fluorouracil|
223406304|NCT00126256|DRUG|leucovorin|
223406305|NCT00126256|DRUG|irinotecan|
223406306|NCT00126256|DRUG|oxaliplatin|
223406307|NCT00070720|BEHAVIORAL|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
223406308|NCT06045455|DIAGNOSTIC_TEST|Multimodal brain CT|Multimodal brain CT includes NCCT, CTP, and CTA
223406309|NCT06045455|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|MRI examination will be performed between the 3rd and 7th day after the admission to the hospital
223406310|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d0.
223406311|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d8±1.
223406312|NCT04500990|RADIATION|MRI test|Patients will receive diagnostic MRI test on d30±2.
223406313|NCT06477133|DRUG|Magnesium sulfate|Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
223406314|NCT03829605|OTHER|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
223406315|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
223406316|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
224132757|NCT04719676|OTHER|The stable surface would be gym floor.|"Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor"
223406317|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
223406318|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
223406319|NCT01444339|BIOLOGICAL|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
223406320|NCT01444339|BIOLOGICAL|Placebo|0.5 mL, intramuscular
223406321|NCT03270657|DEVICE|IPG; RC+S|We will measure the effects of varying stimulation parameters on the neural activity in subjects with Parkinson's disease (PD).
223406322|NCT00810212|PROCEDURE|PLF with autograft|6 subjects
223406323|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects low dose
223406324|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects medium dose
223406325|NCT00810212|BIOLOGICAL|PLF with NeoFuse|6 subjects high dose
223406326|NCT00162981|DRUG|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
223406327|NCT00162981|DRUG|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
223406328|NCT00017810|BEHAVIORAL|Dietary intervention|"The dietary intervention focused on diarrhea management using skill-building techniques that provided subjects with knowledge and a sense of confidence about making food choices.~Behavioral dietary intervention (Condition 1: treatment) - a low-fat, lactose-free, low insoluble fiber, high soluble fiber, and caffeine-free diet based on normal foods"
223406329|NCT00017810|BEHAVIORAL|HIV Self-Care|Standard information regarding self-care and healthy living with HIV - focused on healthy living with HIV and did not include dietary restrictions or dietary information that could affect bowel movements.
223406330|NCT04181086|PROCEDURE|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
223406331|NCT00143442|DRUG|[S,S]-Reboxetine|
223406332|NCT01803672|BEHAVIORAL|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
223406333|NCT01803672|BEHAVIORAL|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
223406334|NCT03192449|DRUG|Albendazole.|Single dose 400mg orally
223406335|NCT02395250|BIOLOGICAL|anti-GPC3 CAR T|
223406336|NCT02498197|BEHAVIORAL|Participatory Intervention|
223406337|NCT02498197|BEHAVIORAL|Control|
223406338|NCT04769193|OTHER|Adipeau face cream|Adipeau face cream contains the natural actives Carthamus Tinctorius (Safflower) Seed Oil and Kaempferia Parviflora Rhizome Extract (Black Ginger).
223406339|NCT00780884|DEVICE|acupuncture|16 sessions of acupuncture treatment, twice a week.
223406340|NCT00784329|DEVICE|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
223406341|NCT02323373|DRUG|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
223406342|NCT02323373|DRUG|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
223406343|NCT02323373|DRUG|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
223406344|NCT03004781|BEHAVIORAL|Parenting program|
223406345|NCT05864703|PROCEDURE|Adjustment|Instrument-assisted, high velocity, low amplitude adjustment
223406346|NCT05864703|PROCEDURE|Sham|Instrument-assisted light touch to neck
223406347|NCT03195829|BEHAVIORAL|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
223406348|NCT03195829|BEHAVIORAL|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
223406349|NCT00375973|DRUG|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
223406350|NCT00375973|DRUG|Placebo|Sugar pill dose comparable to duloxetine
223406351|NCT02166931|DIETARY_SUPPLEMENT|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
223406352|NCT02364830|DRUG|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
223737683|NCT00918658|OTHER|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
223737684|NCT02074631|DRUG|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
223737685|NCT02074631|DRUG|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
223406353|NCT02364830|OTHER|Placebo|One Placebo Capsule/Day for 4 Weeks
223737686|NCT00778700|OTHER|Placebo Cream|Cream with no active drug
223737687|NCT00778700|DRUG|Ruxolitinib Phosphate|Ruxolitinib phosphate cream
223737688|NCT03895281|DIAGNOSTIC_TEST|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
223406354|NCT02364830|DRUG|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
223406355|NCT03074825|DRUG|Chiauranib|Take 50mg orally once daily
223406356|NCT06298448|DIAGNOSTIC_TEST|laboratory experiments before and after mepolizumab treatment|Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome
223556418|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Moderate obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
223737689|NCT04152720|DEVICE|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
223737690|NCT01606930|BEHAVIORAL|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
223737691|NCT00300937|DIETARY_SUPPLEMENT|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
224023360|NCT01588132|DRUG|Anfibatide|"1. To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~2. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
224023361|NCT06610084|OTHER|progressive muscle relaxation exercise)|"Applications for experimental group 2 (progressive muscle relaxation exercise) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, progressive muscle relaxation exercise was performed face-to-face.~Session 2 (Week 33-34): Progressive muscle relaxation exercise was repeated with online interview.~Session 3 Week 35: In Phase 3, the progressive muscle relaxation exercise was repeated face-to-face.~Session 4 Week 36: Progressive muscle relaxation exercise was repeated online. Session 5 Week 37: Progressive muscle relaxation exercise, repeated face-to-face.~Session 6 38.-40th Week: It was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The video prepared by the researcher was used for the progressive relaxation exercise training given to the mother. The researcher guided the mothers to perform the practice once a day and follow-up was ensured through daily telephone calls."
223406357|NCT02588612|DRUG|letetresgene autoleucel (GSK3377794)|letetresgene autoleucel (GSK3377794) as an IV infusion.
223406358|NCT02588612|DRUG|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
223406359|NCT02588612|DRUG|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
223406360|NCT02594293|DRUG|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
223406361|NCT04996901|OTHER|no intervention|no intervention
223406362|NCT03809663|DRUG|Tezepelumab|Solution for injection
223406363|NCT03809663|OTHER|Placebo|Placebo solution for injection
223406364|NCT05261516|DRUG|Magnesium Sulfate|The experimental intervention is the injection of magnesium sulfate. This will be done as soon as TetraGraph calibration is done and neuromuscular measurements are stable. Each patient will receive 60 mg/kg of magnesium sulfate as an intravenous perfusion over 5 minutes. Vital signs before, during and after the perfusion will be taken and documented.
223556419|NCT04980586|DIAGNOSTIC_TEST|CASA score protocol to Severe obstructive sleep apnea Group|CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
223737692|NCT03874897|DRUG|CAR-CLDN18.2 T-Cells|"Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
223737693|NCT03874897|DRUG|PD-1 Monoclonal Antibody|Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
224023362|NCT06610084|OTHER|Hypno-breastfeeding|"Practices for experimental group 1 (Hypno-breastfeeding) The research was conducted in a total of 6 sessions. Session 1 (32nd week): After the introduction, hypno-breastfeeding practice was performed face-to-face.~Session 2 (33rd-34th week): Hypno-breastfeeding practice was repeated with online interviews.~Session 3 (35th week): Hypno-breastfeeding practice was repeated face-to-face. Session 4 (36th week): Hypno-breastfeeding practice was repeated online. Session 5 (37th week): Hypno-breastfeeding practice was repeated face-to-face. Session 6 (38th-40th week): Hypno-breastfeeding practice was performed in the ward at the 8th hour postpartum.~Postpartum 2nd to 4th week: The audio recording prepared by the researcher was used for the hypno-breastfeeding application given to the mother. The researcher guided the mother to perform the application once a day and followed up with daily telephone calls."
224023363|NCT06708572|DRUG|Granulocyte Colony-Stimulating Factor|20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.
224023364|NCT02824419|DRUG|Methionine|Subject undergoes imaging studies with FDG and with methionine.
224023365|NCT02824419|DRUG|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
223406365|NCT04432610|DRUG|Bisoprolol versus Nebivolol|All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period
223406366|NCT03451890|DRUG|E2730|oral capsule
223556420|NCT06180499|DRUG|T-reg depleted DLI|Treg depleted Donor Lymphocytes Infusion
223556421|NCT01281384|OTHER|Advanced Imaging|
223556422|NCT01281384|OTHER|Standard Imaging|
223556423|NCT04346147|DRUG|Imatinib tablets|Imatinib 400 mg QD oral
223556424|NCT04346147|DRUG|Baricitinib Oral Tablet|Baricitinib 4 mg QD oral
223556425|NCT04346147|OTHER|Supportive tratment|Any therapeutic intervention aimed at the control of clinical deterioration is contemplated without initiating or having previously initiated any drug with potential beneficial effect previously described in vitro or in pre-clinical / clinical models against SARS-CoV-2 prior to patient recruitment.
223556426|NCT06284590|DRUG|L19IL2|Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
223737694|NCT03874897|DRUG|Chemotherapy|First-line systemic therapy according to physician's choice
223737695|NCT04192877|DIAGNOSTIC_TEST|Vagus Nerve Neurodynamic test|The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
223737696|NCT05717127|BEHAVIORAL|Time restricted feeding|Restricted feeding with 20 hours of fasting and a 4 hour window of feeding (between 4 and 8 PM or between 5 to 9 PM).
224023366|NCT06727890|DRUG|Danshen Dripping Pill|Danshen Dripping Pill, 10 pills once, three times a day
224023367|NCT06727890|DRUG|Placebo|Placebo, 10 pills once, three times a day
224023368|NCT03455608|BEHAVIORAL|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
224023369|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
223406367|NCT03451890|DRUG|Placebo|oral capsule
223406368|NCT03641014|OTHER|pH Effect on blastocyst formation|to investigate which pH is suitable for each stage of embryo development
223556427|NCT06284590|DRUG|L19TNF|Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
223556428|NCT06284590|DRUG|L19IL2/L19TNF|Arm 3: The amount of L19IL2/L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13MioIU L19IL2 + 400 μg L19TNF in a combined total volume of approximate 2 mL. In case that study drug-related, grade ≥ γ AEs are recorded after the first L19IL2/L19TNF dose administration, the L19TNF dose is reduced to 200 μg for the following administrations.
223737697|NCT05717127|BEHAVIORAL|Standard lifestyle|Standard lifestyle recommendations
223406369|NCT05772949|DEVICE|Experimental group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the experimental group at the first day of week 1 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the experimental group can use the smart hearing aids whenever they want during the trial period (i.e. from week 1 to week 6). For participants living in residential setting, caregivers will facilitate them to use the smart hearing aids upon request from the participants or when the caregivers deem the aids beneficial. For participants living in community setting, they will use the smart hearing aids when needed. Their caregivers shall provide assistance in facilitating the participants to use the smart hearing aids. The smart hearing aids do not require any payment from the study participants. They have to return the hearing aids after the study."
223406370|NCT05772949|DEVICE|Wait-list control group intervention|"The caregivers will calibrate the smart hearing aids for the participants in the wait-list control group at week 8 through the designated mobile application. Caregivers will help the participants to choose the amplification level which best suits their needs.~Participants in the wait-list control group will continue the current practice (i.e. using conventional hearing aids or no hearing aids) from week 1 to week 8, and will use the smart hearing aids from week 8 to week 14. Caregivers will facilitate the participants to use the smart hearing aids."
223406371|NCT03725306|DEVICE|Librata|Hyperthermic endomyometrial treatment via Librata catheter and balloon device
223406372|NCT00216580|DRUG|Risperidone, long-acting injectable|
223406373|NCT04911777|DRUG|Pentarlandir™ UPPTA|Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
223406374|NCT04911777|DRUG|Placebo|The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
223406375|NCT02485262|DRUG|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
223406376|NCT05358054|OTHER|Mobilization with movement lateral Glides and Conventional Physiotherapy|"(The Mobilization with movement technique is(lateral glide) applied to the patient by a physiotherapist to patients at supine level position.~First we identify pain free region each patients. The lateral humerus above the condyle of elbow joint are fixed by therapist. Then therapist ask to patients perform the active movement ten times. The same procedure repeats number of 3 sets, 10 number of repetition. The rest of interval fifteen to twenty seconds with in the sets Grip strength (pain Free Strength ) was evaluated in kilogram using a dynamometer. The measurements using dynamometer patients posture is erect sit position , the elbow at 90 degree flexion , shoulder would be abducted , rest of joint forearm and wrist in neutral during measurements.~conventional therapy list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching"
223406377|NCT05358054|OTHER|Progressive Resistance Exercises and Conventional Physiotherapy|4 STEPS Progressive resistive EXERCISES have a 4 step to application Step 1 Clenching fist strongly, resisted wrist Flexion, Extension, wrist rotation with a stick) Step 2 The therapeutic band exercised performed at wrist Flexion(WF), Wrist Extension(WE), Wrist Ulnar Deviation(WED) , and Wrist Radial Deviation(WRD).Step 3 Patient asked to perform combined wrist rotatory movements using e.g. table top as a support. Step 4 Soft ball compressing exercises, Transferring buttons from cup into another, Twisting a towel into the roll, Hand Rotating both directions at table AND CONVENTIONAL PHYSIOTHERAPY and list of conventional physiotherapy are therapeutic ultrasound , deep transverse friction massage and stretching
223556429|NCT06284590|DRUG|KEYTRUDA®|KEYTRUDA® will be administered by i.v. infusion as a dose of 200 mg on the first day of intralesional treatment with ICKs and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first. ICKs intralesional treatment will be administered 30-60 minutes post administration of KEYTRUDA®.
223556430|NCT00407368|PROCEDURE|Blood Sample|
223556431|NCT01712581|OTHER|Magnetic Resonance Imaging|
223556432|NCT02689206|DRUG|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
223556433|NCT02689206|DRUG|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
223556434|NCT00761384|DRUG|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
223556435|NCT05883995|OTHER|Phage therapy requests|Quantification of phage therapy requests received at the Hospices Civils de Lyon from 2015 to 2028
223556436|NCT00003352|DRUG|cyclophosphamide|600 mg/m2, IV, every 3 weeks
224023370|NCT03455608|BEHAVIORAL|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
223406378|NCT03387371|DEVICE|Ultrasonics|ultrasonic scalers
223406379|NCT03387371|DEVICE|Gracey Curettes|Spesific gracey curettes
224023371|NCT00642733|DRUG|erlotinib [Tarceva]|100mg po daily
224023372|NCT00642733|DRUG|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
223406380|NCT03387371|DEVICE|Er:YAG Laser|2940 nm wavelenght Er:YAG laser
223406381|NCT05951829|OTHER|Action Observation Therapy|Action Observation Therapy Mirror Therapy
223406382|NCT01707394|DRUG|Apixaban|Specified dose on specified days
223406383|NCT00294866|DRUG|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
223406384|NCT02042014|DRUG|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
223406385|NCT00551239|BIOLOGICAL|rituximab|Given IV
223406386|NCT00551239|DRUG|fludarabine phosphate|Given IV
223406387|NCT00551239|DRUG|pixantrone dimaleate|Given IV
223406388|NCT05017675|OTHER|High fructose diet|"4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5"
223406389|NCT05017675|OTHER|High saturated fat diet|"4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20"
223406390|NCT03309943|DRUG|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
223556437|NCT00003352|DRUG|Taxotere|60 mg/m2, IV, every 3 weeks
223556438|NCT00003352|DRUG|Adriamycin|60 mg/m2, IV, every 3 weeks
223737698|NCT03716921|OTHER|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
224023373|NCT05800015|DRUG|fianlimab|Administered intravenously (IV) every 3 weeks (Q3W)
224023374|NCT05800015|DRUG|cemiplimab|Administered IV Q3W
223406391|NCT03309943|DRUG|Placebo|Participants will take one dose of Placebo on two separate occasions.
223406392|NCT06362538|OTHER|International Physical Activity Questionnaire|Assessments of physical activity level and functional capabilities (aerobic capacity, muscular strength and power, flexibility
223406393|NCT06362538|OTHER|Six minute walking test|The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
223737699|NCT05353569|DIAGNOSTIC_TEST|OCT Device(s)|Results from standard-of-care examinations will be compared to research-only examination(s) (OCT device(s)).
223406394|NCT06362538|OTHER|SF-36, Euro-Qol 5D-5L, Perceived stress scale-10, Pittsburgh Sleep Quality Index, Depression Anxiety Stress scale- 21.|Evaluation of the quality of life, the psychological sphere (anxiety, stress, depression) and the quality of sleep
223406395|NCT06362538|OTHER|MEDAS|Evaluation of adherence to the Mediterranean diet
223737700|NCT05153044|OTHER|severe acute respiratory syndrome CoV-2 serology|diagnostic serology of severe acute respiratory syndrome-CoV-2 infection performed during the inclusion visit Regarding follow-up visits, only seropositive patients will be called for sampling, for serological follow-up at 3 months then 6 months.
223737701|NCT03863223|DRUG|Pyrotinib, Trastuzumab, Docetaxel|Pyrotinib 400mg orally daily until progressive disease
223737702|NCT03863223|DRUG|Placebo, Trastuzumab, Docetaxel|Placebo 400mg orally daily until progressive disease
223406396|NCT06362538|OTHER|Intima-media thickness (IMT)|Bmode ultrasonography
223406397|NCT06362538|BIOLOGICAL|Blood sampling|Measurement of parameters for defining cardiovascular risk and biomarkers.
223406398|NCT06362538|BIOLOGICAL|Stool Sample Culture Test|Evaluation of Gut Microbiota
223406399|NCT02923323|DEVICE|MRI including DTI , EEG, CGMS|Will be connected to continuous simultaneous systems
223406400|NCT02923323|BEHAVIORAL|Neurocognitive tests|Will perform multiple tests of neurocognitive functions after lunch
223737703|NCT02573727|DRUG|Nor adrenaline + albumin|
223737704|NCT02573727|DRUG|Terlipressin + albumin|
223737705|NCT00789451|PROCEDURE|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
224023375|NCT05800015|DRUG|Pemetrexed|IV Infusion, Q3W
224023376|NCT05800015|DRUG|Paclitaxel|IV Infusion, Q3W
224132758|NCT00169117|BEHAVIORAL|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
224132759|NCT02483104|DRUG|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
223406401|NCT02530723|OTHER|power training|Resistance training machines with CAM devices will be used for training.
223406402|NCT01890681|BEHAVIORAL|Baby NAP SACC|
223406403|NCT01890681|BEHAVIORAL|Back to Sleep|
224023377|NCT05800015|DRUG|Carboplatin|IV Infusion, Q3W
224023378|NCT05800015|DRUG|Cisplatin|IV infusion, Q3W
224023379|NCT05800015|DRUG|Placebo|IV infusion, Q3W
224132760|NCT02483104|DRUG|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
224132761|NCT02483104|DRUG|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
223406404|NCT01372995|DRUG|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
223406405|NCT01372995|DRUG|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
223406406|NCT01372995|OTHER|Inactive substance|Inactive substance given enterally for 5 days.
223406407|NCT00004990|DRUG|Dexamethasone|
223406408|NCT01661335|DRUG|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
223556439|NCT04714827|BIOLOGICAL|KQ-2003 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and BCMA，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion KQ-2003 CAR-T cells .
223556440|NCT04052750|BEHAVIORAL|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
223556441|NCT03617601|DIAGNOSTIC_TEST|MET|Testing of the metabolic equivalent of task before aortic procedure
224132762|NCT01728753|DRUG|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
224132763|NCT01728753|DRUG|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
224132764|NCT01728753|DRUG|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
223556442|NCT00652314|DEVICE|Thrombi-Gel|Applicaton of Hemostatic product during surgery
223556443|NCT01558596|PROCEDURE|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
223556444|NCT01558596|PROCEDURE|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
224132765|NCT01728753|DRUG|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
223556445|NCT04202068|DRUG|Ceftriaxone sodium and Sulbactam Sodium for injection|Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
223737706|NCT01494480|PROCEDURE|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
223737707|NCT06463743|DRUG|metformin|metformin
223737708|NCT06463743|DRUG|Placebo|Placebo
223737709|NCT03375801|OTHER|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
223737710|NCT05962320|OTHER|Education and counselling|Education and counselling of patients and their parents
223406409|NCT01661335|DRUG|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
223406410|NCT06297018|BEHAVIORAL|Bioenergy application|Bioenergy application: This group includes liver transplant recipients and recipients who underwent intervention. Depression, anxiety and stress levels are measured in the pre-test. Bioenergy is then applied. As a post-test, depression, anxiety and stress levels are measured again.
223737711|NCT05962320|OTHER|Avoiding the use of nasogastric catheters, drains and urinary catheters|Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible
223737712|NCT05962320|OTHER|Stimulation of intestinal motility in the postoperative period|Stimulation of intestinal motility in the postoperative period
223737713|NCT05962320|OTHER|Initiation of oral intake in the early postoperative period|Initiation of oral intake in the early postoperative period
223737714|NCT05962320|OTHER|Early removal of the patient by reducing postoperative IV fluid infusion|Early removal of the patient by reducing postoperative IV fluid infusion
223737715|NCT05962320|OTHER|Initiation of early mobilization of the patient in the postoperative period|Initiation of early mobilization of the patient in the postoperative period
223737716|NCT05962320|OTHER|Reducing opioid use and ensuring pain management|Reducing opioid use and ensuring pain management
223737717|NCT05962320|OTHER|Implement nausea and vomiting prophylaxis|Implement nausea and vomiting prophylaxis
223737718|NCT05962320|OTHER|Management of thirsty|Management of thirsty
223737719|NCT05962320|OTHER|Management of fear and stress|Use of recommended non-pharmacological interventions in the management of fear and stress
223737720|NCT04731259|DRUG|ATR-04|ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.
223737721|NCT04731259|OTHER|Placebo|Placebo
223737722|NCT03241355|DIETARY_SUPPLEMENT|prebiotic inulin-type fructan|
224132766|NCT00798655|DRUG|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
223406411|NCT04122742|PROCEDURE|skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
223406412|NCT04122742|OTHER|Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
223406413|NCT04122742|OTHER|Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
223406414|NCT04122742|OTHER|Functional involvement of identified epigenetic alterations|Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
223406415|NCT04122742|BIOLOGICAL|Culture of lymphoblastoid line from blood sample|Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
223406416|NCT04557215|DRUG|Rifaximin|Rifaximin is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
223406417|NCT04557215|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a clinically approved mucolytic agent.
223406418|NCT04557215|DRUG|Placebo|An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied.
223406419|NCT03123393|DRUG|TAK-659|TAK-659 Tablets
223406420|NCT01846364|DIETARY_SUPPLEMENT|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
223406421|NCT05863260|DRUG|Treatment Group|Treatment Group
223406422|NCT03289026|DRUG|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
223406423|NCT01215591|PROCEDURE|Gradual weaning from Nasal CPAP in preterm neonates|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
223406424|NCT00558701|DEVICE|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
223406425|NCT00558701|DEVICE|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
223406426|NCT01496001|PROCEDURE|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
223406427|NCT01496001|OTHER|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
223406428|NCT01631539|DEVICE|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
223406429|NCT01631539|DRUG|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
223737723|NCT03241355|DIETARY_SUPPLEMENT|Placebo maltodextrin|
223737724|NCT05317533|PROCEDURE|cardiac catheterization via distal radial artery|cardiac catheterization via distal radial artery
223406430|NCT01631539|DRUG|5 FU|every 2 weeks IV
224132767|NCT00798655|DRUG|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
223406431|NCT01631539|DRUG|Irinotecan|every 4 weeks chemoembolization
223406432|NCT00205023|PROCEDURE|Sonohysterography|SHG during surgery for endometrial cancer.
223406433|NCT00255463|DRUG|Anastrazole|
223406434|NCT00255463|DRUG|Gefitinib|
223556446|NCT01014572|BEHAVIORAL|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
223556447|NCT01014572|DRUG|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
223556448|NCT01014572|BEHAVIORAL|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
223556449|NCT00000401|DRUG|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
223556450|NCT00644072|DRUG|SNX-5422|
223556451|NCT05383781|OTHER|Hip and Knee focused exercises|Exercises which improves muscle strength, ROM
223406435|NCT01230086|DEVICE|ICD Implantation without DFT testing|Implantation
223406436|NCT01230086|DEVICE|Upper limit of vulnerability testing|Upper limit of vulnerability testing
223406437|NCT01230086|DEVICE|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
223406438|NCT00427648|DRUG|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
223406439|NCT00427648|DRUG|placebo|normal saline
223406440|NCT04009525|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
223406441|NCT04009525|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
223556452|NCT05383781|OTHER|Short foot exercise|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
223556453|NCT00162214|DRUG|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
223556454|NCT02534012|DRUG|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
223556455|NCT02534012|DRUG|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
223406442|NCT04009525|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
223406443|NCT04009525|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
223406444|NCT04009525|DRUG|cyclosporine A|cyclosporine A
223406445|NCT04009525|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
223406446|NCT04009525|DRUG|Tacrolimus|Tacrolimus
223406447|NCT04009525|DRUG|Methotrexate|Methotrexate
223406448|NCT06535334|DRUG|Chemotherapy|Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
223406449|NCT05576935|BEHAVIORAL|Stroop task|The task is partitioned in 4 blocks of 360 stimuli and each word will be presented on screen in 34 point font for 1000 ms with an inter-stimulus interval based on their performance on the Stroop max test. This max test will be performed during the familiarization trial, and is divided in blocks of 96 stimuli. After each block, the accuracy (ACC) will be calculated. When ACC \> 85%, the difficulty of the Stroop task will be increased by decreasing the stimulus presentation time (SPT). If ACC \< 85%, this block will be considered as an 'error' and the subject must redo the block without changing the SPT. The first block will have a SPT of 1500 ms. When the required ACC is achieved, the SPT will decrease in the following order: 1100, 900, 800,… to determine the individualized cognitive load. When the subject makes 3 errors in a row, or 5 errors during the whole trial, the trial will end. The SPT of the last block will be considered as the maximum capacity of that individual.
223406450|NCT05576935|BEHAVIORAL|Documentary|In order to avoid under- and over-arousal, participants will have the opportunity to choose between several documentaries. The participants will also receive a list of the available documentaries (based on selections from Netflix and Disney+) after the familiarization trial so that the trial can go as smoothly as possible.
223406451|NCT03677284|OTHER|Time assistive products|The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.
223406452|NCT03677284|OTHER|Information brochure|The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
223406453|NCT02536079|DRUG|NeuroAiD|
223406454|NCT00105079|DRUG|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
223406455|NCT00105079|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
223406456|NCT00105079|DRUG|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
223406457|NCT00105079|DRUG|Ritonavir|100 mg po bid
223406458|NCT04445038|DRUG|610|Recombinant anti-IL-5 Humanized Monoclonal Antibody
223406459|NCT04445038|DRUG|Placebo|Placebo
223406460|NCT05914493|OTHER|The effect of posture on cognitive function in early adolescence athletes|"Posture evaluation:~The form of Corbin et al. will be applied.~Evaluation of cognitive functions:~Basically, the Stroop test will be used, which evaluates the concentration and maintenance of attention depending on time and the task given."
223406461|NCT05844293|DRUG|FXI-GalNAc-siRNA|FXI-GalNAc-siRNA solution for injection
223406462|NCT05844293|OTHER|Placebo|Saline
223406463|NCT03415971|PROCEDURE|EMG befor denture treatment|
223406464|NCT03415971|PROCEDURE|EMG in a month after termination of treatment|
223556456|NCT02534012|PROCEDURE|Major abdominal surgery|
223556457|NCT05723692|BIOLOGICAL|ALTB-268|monoclonal antibody
223556458|NCT05723692|OTHER|Placebo|formulation buffer
223556459|NCT04635254|OTHER|Halophites-based cream 24 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
223556460|NCT04635254|OTHER|Halophites-based cream 48 hours|The concentration of active aqueous extract will be in the range of 2% to 30% (v/v) by cold emulsification. A 2 gram amount of Halophytes-based cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
223556461|NCT04635254|OTHER|Vehicle cream 24 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
223556462|NCT04635254|OTHER|Vehicle cream 48 hours|A 2 gram amount of vehicle cream will be applied under occlusion (TegaDerm tape) in a 4x4 cm squared area.
223556463|NCT04635254|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
223556464|NCT04635254|OTHER|Cowhage|The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
223556465|NCT03097523|DEVICE|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
223556466|NCT04299152|COMBINATION_PRODUCT|Stem Cell Educator-Treated Mononuclear Cells Apheresis|"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the educated autologous immune cells to the patient's circulation."
223556467|NCT00428935|BIOLOGICAL|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
223556468|NCT04538118|BEHAVIORAL|Shoulder disability|"Shoulder disability was evaluated with Patient-specific functional scale, the disabilities of the shoulder, arm and hand questionnaire, and the upper extremity functional index.~First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
223556469|NCT04538118|DEVICE|Shoulder Range of Motion|"Shoulder range of motion was evaluated with universal goniometer. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
223556470|NCT04538118|BEHAVIORAL|Pain Intensity|"Pain intensity was evaluated with Numeric Pain Rating Scale. First assessment was applied when patients came to physical therapy clinic at first.~Second assessment was repeated after 6 weeks."
223556471|NCT01453972|BEHAVIORAL|Long distanse moderate training|Moderate exercise
223556472|NCT01453972|BEHAVIORAL|Long interval training|High-intensity exercise, long duration
223556473|NCT01453972|BEHAVIORAL|Short interval training|High intensity exercise, short duration
224023380|NCT05292352|BEHAVIORAL|LFSD|"Assessment of child's usual diet to assess sugar intake in relation to the total usual diet.~Consultation with a nutritionist to help families identify foods high in sugar. Removal of foods and drinks high in free sugar from the home.~Counseling using motivational interviewing, patient-centered goal setting to help parents and participating youth identify barriers to compliance with the intervention. Provision of a study provided LFSD with sufficient quantity to meet the needs and adapted to meet the preferences of the entire household for the first 4 weeks. Facilitated grocery shopping trips every 3 months during year 1."
223406465|NCT03415971|PROCEDURE|EMG in a 3 months after termination of treatment|
223556474|NCT00595881|DEVICE|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
223556475|NCT05327075|OTHER|questionnaire|it is in the form of questionnaire and scoring tool
223556476|NCT02177721|BIOLOGICAL|Sample Collection|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for lethal factor (LF) levels."
223737725|NCT02896751|DEVICE|3D printed NIV mask|use of 3D printed mask
223737726|NCT02962804|DRUG|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
223737727|NCT02962804|RADIATION|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
224023381|NCT05267613|DRUG|Nexium 20mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
224023382|NCT05267613|DRUG|Nexium 10mg|Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
224132768|NCT00798655|RADIATION|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
223556477|NCT05535504|DEVICE|Low-frequency rTMS (experimental)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / Location: motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: tangential to scalp
223556478|NCT05535504|DEVICE|Low-frequency rTMS (sham comparator)|Frequency: Low-frequency (1Hz) rTMS / Intensity: 100% of resting motor threshold / motor hotspot of the contralesional primary motor cortex (the first dorsal interosseous muscle) / Number of total stimuli : 1800 ; Coil orientation: vertical to scalp
223406466|NCT05618678|BEHAVIORAL|DIGNITY|DIGNITY is a multi-component, multi-level intervention that guides shared decision-making in nursing homes to support person-centered dementia care. Based in theory, this intervention targets nursing home staff attitudes and behaviors around assessing and judging whether to engage in risk situations to support resident preferences for everyday living and care despite cognitive decline due to dementia. It includes a protocol manual, baseline training on how to implement the DIGNITY strategy, and six ECHO sessions to help frontline staff negotiate intrinsic and cultural factors in preference situations that carry a risk to residents' health and safety.
223556479|NCT01479764|DRUG|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
224023383|NCT05433181|DRUG|ACE2 Chewing Gum|The IP is formulated as an oral plant powder, which is packaged into a chewing gum. No specific excipient, buffer, salt or pH is required. CTB-ACE2, with efficient binding to both GM1 and ACE2 receptors, effectively blocks binding of the spike protein and viral entry into human cells. Oral epithelial cells are enriched with both receptors. In addition, ACE2 directly binds to the spike protein and inactivates SARS-CoV-2 virus. Therefore, CTB-ACE2 chewing gum is being evaluated for impact on entry and transmission of SARS-CoV-2.
223406467|NCT05618678|BEHAVIORAL|Infection Control|This is an attention control intervention with similar dose of educational content and attention from interventionist. It includes distribution of links to the CDC Infection Control Practice Guidelines for nursing homes, a baseline training on infection control practices for frontline workers, and six ECHO coaching sessions.
223406468|NCT06175078|DEVICE|Ultrasound Imaging 3D and Spectroscopy|Ultrasound imaging and spectroscopy will consist of collecting three dimensional data. Regions of interest in each of the tumour images and in the adjacent normal tissue will be selected for analysis.
223406469|NCT01255345|OTHER|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
223406470|NCT05300711|PROCEDURE|Bilateral salpingectomy|Removal of both fallopian tubes.
223406471|NCT05300711|PROCEDURE|Colorectal surgery|Colorectal surgery as indicated by attending surgeon.
223406472|NCT00584493|DRUG|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
223406473|NCT02028260|DRUG|Modafinil|200 mg daily
223406474|NCT02028260|DRUG|Placebo|similar appearing inert tablet
223406475|NCT01332760|OTHER|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
223406476|NCT01332760|OTHER|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
223406477|NCT02185326|DRUG|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
223406478|NCT03058562|DRUG|ABX-1431|ABX-1431, capsules, 40 mg in the fasting state
223406479|NCT03058562|DRUG|Placebo Comparator|Matching Placebo
223406480|NCT03058562|DRUG|ABX-1431|ABX-1431, capsules, 20 mg with a high fat meal
223406481|NCT03809780|DRUG|Lenalidomide|-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
223406482|NCT03809780|DRUG|Dexamethasone|-high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
223406483|NCT01421680|DIETARY_SUPPLEMENT|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
223406484|NCT03576963|DRUG|Guadecitabine|Given SC
223556480|NCT01479764|DRUG|Neostigmine|neostigmine, per usual practice
223556481|NCT01479764|DRUG|Glycopyrrolate|glycopyrrolate per usual practice
223406485|NCT03576963|BIOLOGICAL|Nivolumab|Given IV
223406486|NCT00336401|DRUG|Sevoflurane or Propofol|
223406487|NCT03569930|DRUG|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
223556482|NCT02916069|DEVICE|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
223556483|NCT02916069|DEVICE|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
223556484|NCT02916069|DEVICE|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
224023384|NCT05433181|OTHER|Placebo Chewing Gum|Chewing gum containing wild-type lyophilized plant cells manufactured to match the IP.
224023385|NCT05123482|DRUG|AZD8205|AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.
224023386|NCT05123482|DRUG|AZD8205 and AZD2936 (Rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
224023387|NCT05123482|DRUG|AZD8205 and AZD5305 (saruparib)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
224132769|NCT03119844|OTHER|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
223406488|NCT03569930|DRUG|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
223406489|NCT03569930|BEHAVIORAL|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
223406490|NCT02356939|DEVICE|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
223406491|NCT02356939|PROCEDURE|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
223556485|NCT05034809|DRUG|Melatonin 20 MG|Melatonin, also known as N-acetyl-5-methoxytryptamine will be the main intervention given to participating patients of this study. This study will use a dose of 20mg/day using the commercially available 5mg/tablet20-21. If a patient cannot be tolerate swallowing the whole tablet, it will be crushed and mixed with milk. According to the study done by Shah et al. there was no degradation in the active component of melatonin when mixed with milk or food as a medium for drug delivery.
223556486|NCT04889248|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|"Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks.~Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends.~The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax."
223556487|NCT04170088|DRUG|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
223556488|NCT04170088|DRUG|0.9% Normal Saline|Normal saline used for comparision of efficacy of tranexamic acid
223556489|NCT05813184|DRUG|Antibiotics|Any antibiotic therapy administered \> 7 days
223556490|NCT03800537|DEVICE|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
223556491|NCT01814865|DRUG|Abiraterone Acetate|1000 mg PO OD x 2 weeks
223556492|NCT01814865|DRUG|Prednisone|5 mg PO OD x 2 weeks
224132770|NCT03119844|OTHER|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
224132771|NCT03119844|OTHER|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
223556493|NCT01814865|DRUG|Aromatase Inhibitor|1 mg PO OD x 2 weeks
223556494|NCT00254150|PROCEDURE|Increase oxygen extraction rate|
223556495|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-in technique|This method consists of inserting the needle with the stylet-in, then only remove the stylet once the desired depth is achieved and CSF flow is expected. If no CSF comes back, the stylet is replaced before continuing to advance the needle until the subarachnoid space is entered. This is the technique generally used in our emergency department and will serve as the control treatment group.
223556496|NCT05009173|PROCEDURE|Lumbar puncture using the stylet-out technique|This method consists of inserting the needle through the epidermis and the dermis, which is estimated as a 0.5 to 1 cm length in children, then remove the stylet before progressing through the other structures until the subarachnoid space is entered. This approach will be used in the experimental technique group.
223556497|NCT00260832|DRUG|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m\^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
223556498|NCT00260832|DRUG|Dacogen (decitabine) only|20mg/m\^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
223556499|NCT00996879|DRUG|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
223556500|NCT00996879|DRUG|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
223556501|NCT00784888|OTHER|Aromatase inhibitors|non-interventional study
223556502|NCT01032603|PROCEDURE|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
223556503|NCT01032603|PROCEDURE|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
223556504|NCT03098433|DRUG|Liothyronine|Single dose
223556505|NCT03098433|DRUG|Levothyroxine|Active comparator
223556506|NCT03098433|DRUG|Placebos|Placebo
223556507|NCT04315727|GENETIC|WGS Diagnostic Blood take for genetic diagnostic.|Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
223556508|NCT04315727|GENETIC|Hair collection|Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
223556509|NCT01104545|DRUG|MK-3614|
223556510|NCT01104545|DRUG|Comparator: Placebo|
223556511|NCT04695470|DRUG|Fruquintinib and Sintilimab|"fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w"
223556512|NCT02562300|DRUG|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
223556513|NCT02562300|DRUG|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
223556514|NCT02057640|DRUG|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
223556515|NCT02057640|DRUG|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
223556516|NCT02057640|DRUG|MLN9708|4mg on day 1, 8, 15, 28
223556517|NCT03585764|DRUG|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
223556518|NCT03585764|DEVICE|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
223556519|NCT04307069|DRUG|Oxytocin|The drug wil be adminisrate for augmentation of labor at admission.
223556520|NCT00862758|DRUG|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
223556521|NCT03687294|DEVICE|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
223556522|NCT02746588|OTHER|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
223556523|NCT01550406|DEVICE|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
223556524|NCT01550406|DEVICE|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
223556525|NCT03953248|DRUG|L-Carnitine|
223556526|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
223556527|NCT02911298|DRUG|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
223556528|NCT03280849|OTHER|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
223556529|NCT04834193|PROCEDURE|Endoscopic ultrasound-guided fine-needle biopsy|Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)
224132772|NCT00343291|BIOLOGICAL|Cetuximab|Administered intravenously
223556530|NCT05216718|PROCEDURE|Mini-flap|Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
223556531|NCT05216718|PROCEDURE|Conventional flap|Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
223556532|NCT01563705|PROCEDURE|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
223556533|NCT01563705|PROCEDURE|Manual dexterity assessment|Purdue pegboard test
223556534|NCT02574767|BEHAVIORAL|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
223556535|NCT02574767|DIETARY_SUPPLEMENT|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
223556536|NCT02574767|BEHAVIORAL|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
223556537|NCT02574767|DIETARY_SUPPLEMENT|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
223556538|NCT03640507|DRUG|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
223556539|NCT03640507|DRUG|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
223556540|NCT03640507|DRUG|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
223556541|NCT04823286|OTHER|Virtual reality health platform during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis. The game will also aim at providing nutritional advice, and improving psychological wellbeing and cognitive function.
224023388|NCT05123482|DRUG|AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)|"AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors."
224132773|NCT00343291|BIOLOGICAL|Bevacizumab|Administered intravenously
224132774|NCT00343291|DRUG|Paclitaxel|Administered intravenously
223406492|NCT03369886|DIAGNOSTIC_TEST|Optical Coherence Tomography Angiography (OCTA)|The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
223406493|NCT02431286|DRUG|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
223406494|NCT02431286|DRUG|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
224023389|NCT05563415|BEHAVIORAL|Medicare AWV Practice Redesign Toolkit|Electronic health record-based tools coupled with practice redesign strategies and approaches
224023390|NCT05611021|BEHAVIORAL|Exercise|Three conditions will be tested: Walking, arm-cranking and control condition.
224023391|NCT06338995|DRUG|LY3650150|Administered SC.
223406495|NCT02431286|DRUG|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
223406496|NCT04244955|OTHER|Semi-directive interviews|The interviews, carried out by the child psychiatrist, will be semi-directive and short (15 to 30 minutes) one-on-one with the child or adolescent so that the presence of the parents does not influence the responses. The CPTS-RI index, which has 20 questions, will be filled, as well as other questions to understand what is problematic for the child.
223406497|NCT00376155|DRUG|sulfadoxine /pyrimethamine plus amodiaquine|
223406498|NCT05990712|DIETARY_SUPPLEMENT|Omega-3|Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.
223406499|NCT05990712|DRUG|Trehalose|Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
223406500|NCT05990712|DRUG|Zocular Eyelid System Treatment|A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
223406501|NCT05990712|OTHER|Blephadex cleansing eyelid wipes|Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
223556542|NCT05121298|DRUG|upadacitinib 15mg/day|Patients will receive upadacitinib 15mg/day and continue to receive same doses of MTX until 24 weeks. If patients achieve a European League Against Rheumatism (EULAR) moderate response or a Disease Activity Score 28 (DAS28-CRP) ≤3.2 at 12 weeks, and a DAS28-CRP of \<2.6 at 24 weeks, they will discontinue MTX, and continue upadacitinib until 48 weeks.
223406502|NCT01117038|DRUG|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
223406503|NCT01117038|DRUG|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
223406504|NCT02079350|DRUG|%6 HES and %4 Gelofusine|
223406505|NCT05486195|DRUG|SDI-118|SDI-118 Powder in Capsule
223556543|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using bupivacaine|while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of 0.25% bupivacaine with adrenaline 1:400,000 will be administered in increments bilaterally.
224023392|NCT06338995|DRUG|Placebo|Administered SC.
224023393|NCT06338995|DRUG|Standard therapy for INCS|Administered as intranasal spray.
224023394|NCT01241136|PROCEDURE|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
224023395|NCT01241136|PROCEDURE|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
224023396|NCT03496584|OTHER|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
224023397|NCT03496584|OTHER|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
224023398|NCT05723198|DRUG|Baricitinib|Administered orally
224023399|NCT05723198|DRUG|Placebo|Administered orally
224023400|NCT02444741|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
224023401|NCT02444741|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224023402|NCT02444741|OTHER|Laboratory Biomarker Analysis|Correlative studies
224023403|NCT02444741|BIOLOGICAL|Pembrolizumab|Given IV
224023404|NCT02444741|RADIATION|Proton Beam Radiation Therapy|Undergo PBRT
224023405|NCT02444741|RADIATION|Radiation Therapy|Undergo low dose radiation therapy
223406506|NCT05486195|DRUG|Placebo|Matching Placebo
223406507|NCT00289419|DRUG|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
223406508|NCT00289419|DRUG|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
224023406|NCT02444741|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224023407|NCT05550818|OTHER|High Ultra Processed Food Diet|Participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
224023408|NCT05550818|OTHER|No Ultra Processed Food Diet|Participants will be provided and consume a diet containing no UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, and overall diet quality, for 2 weeks.
223406509|NCT05666635|BIOLOGICAL|LTC004|"LTC004 Phase I:Participants will be allocated to one of the following dose groups: 3, 15, 45, 90, 180，270,360 and 450 ug/kg, and receive a treatment of LTC004 followed by 21 days of dose limited toxicity (DLT) observation period.~Phase Ib indication exploration~Other Name: LTC004 for Injection"
223406510|NCT04614935|BEHAVIORAL|Action Plan|See arm description.
223406511|NCT03194633|DRUG|Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Nifedipine GITS 60 mg (once per day)
223406512|NCT05643469|OTHER|Self-determination theory-based intervention plus instant messaging|subjects will receive brief interventions using the AWARD model and they will be allowed to select their own quit schedules (quit immediately, or quit progressively) with the ultimate goal of complete cessation. Follow-up booster intervention with WhatsApp/WeChat messages to help them to adhere to their schedules and independent 1-minute videos will be delivered.
223406513|NCT05643469|OTHER|AWARD model|Subjects will receive a brief intervention using the AWARD model and all of them will advise to quit immediately. Only general health advice via WhatsApp/WeChat will be delivered.
223406514|NCT01609296|DEVICE|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
223406515|NCT04189315|DRUG|asfotase alfa|Asfotase alfa is administered subcutaneously.
223556544|NCT05774249|PROCEDURE|Ultrasound guided pecto-intercostal Fascial Plane Block using normal saline|Sham Block will be done while Patients in supine decubitus position,parasternal area will be scanned using high frequency ultrasound linear probe .After identification of ribs with intercostal spaces in between ;the fourth intercostal space will be approached via 10 cm block needle targeting the plane between pectoralis major and external intercostal muscle under ultrasound guidance after which 20 mL of normal saline 0.9 % will be administered bilaterally.
224023409|NCT04563078|DEVICE|Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of active Transcranial Magnetic Stimulation (TMS). TMS is a noninvasive treatment that uses magnetic fields to induce a small electric current in specific brain regions.
224023410|NCT04563078|PROCEDURE|Sham Transcranial Magnetic Stimulation (TMS)|10-day treatment (2 per day with 10 minute break, 20 sessions in total) of sham control.
224023411|NCT06457009|COMBINATION_PRODUCT|Multi-component Intervention Package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for asthma;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for undiagnosed asthma patients;~7. To actively include individuals whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
224023412|NCT04448964|DRUG|JNJ-70033093|JNJ-70033093 will be administered orally as per assigned treatment sequence.
224023413|NCT05519475|DRUG|ALN-HSD|Administered by subcutaneous injection (SC)
224023414|NCT05519475|DRUG|Placebo|Administered by SC injection
224023415|NCT03586453|DRUG|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~* Osimertinib: Oral, Daily 28 day cycle.~* Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~* Tumor biopsy between C4 and C8 and at disease progression"
224023416|NCT05189769|BEHAVIORAL|CP no REACT|Coping Power no REACT
224023417|NCT05189769|BEHAVIORAL|CP+/No REACT|CP+ and no REACT
224132775|NCT00343291|DRUG|Carboplatin|Administered intravenously
224132776|NCT03754062|DRUG|Placebo - Cap|Administration of Placebo by pill.
223406516|NCT01870011|DRUG|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
223406517|NCT01870011|DRUG|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
223406518|NCT00879905|DRUG|HSP990|
223406519|NCT00872911|DIETARY_SUPPLEMENT|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
223406520|NCT00872911|DRUG|Exercise|progressive exercise training
223406521|NCT00386360|DRUG|Placebo comparator|oral weekly for one year
223406522|NCT00386360|DRUG|risedronate|35 mg risedronate, once a week for one year
223406523|NCT00937027|DRUG|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
223406524|NCT00297440|BEHAVIORAL|Cognitive-behavioral treatment|
223406525|NCT00297440|BEHAVIORAL|Exercise|
223406526|NCT01155180|DRUG|Leptin|Hormone - daily self injections for 6 months
223556545|NCT00489320|DEVICE|Cypher Stent|
223406527|NCT01155180|DRUG|Placebo|Placebo
223406528|NCT02908165|DRUG|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
223406529|NCT02908165|DRUG|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
223406530|NCT05517148|DEVICE|Therapeutic VR|Treatment module categories included: (1) Mindfulness-based stress reduction training: an audio conducting practice with breathing-based biofeedback training in immersive and interactive environments to support self-regulation and relaxation.
223406531|NCT02230904|DRUG|Rotigotine (Test product PR 2.3.1)|"* Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal"
223406532|NCT02230904|DRUG|Rotigotine (Reference product PR 2.1.1)|"* Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal"
223406533|NCT03964857|OTHER|Refined olive oil (ROO)|Consumption of chicken dishes made with ROO for a period of 8 weeks
223406534|NCT03964857|OTHER|Blended Oil 1 (BO1)|Consumption of chicken dishes made with BO1 for a period of 8 weeks
223406535|NCT03964857|OTHER|Blended Oil 2 (BO2)|Consumption of chicken dishes made with BO2 for a period of 8 weeks
223406536|NCT06445712|BEHAVIORAL|Parental Support Cold Pressor Task|Child will submerge their hand in cold water alone and holding the hand of a parent.
223556546|NCT02993822|DRUG|Orvepitant Maleate|Tablet, once daily, oral
223556547|NCT02993822|DRUG|Placebo|Tablet, once daily, oral
223556548|NCT04667598|DRUG|Modified Wenxin Decoction|Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
223556549|NCT06326359|PROCEDURE|autologous stromal vascular fraction|autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
223556550|NCT01924039|BEHAVIORAL|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
223556551|NCT01924039|OTHER|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
223556552|NCT00670618|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
223556553|NCT00670618|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
223406537|NCT05252572|BIOLOGICAL|CLL1 CAR T-cells|Drug: CLL1 CAR T-cells Each subject receive CLL1 CAR T-cells by intravenous infusion Other Name: CLL1 CAR T-cells injection
223556554|NCT00670618|DEVICE|Fluoride (Elmex Medical Gel)|Fluoride
223556555|NCT02040350|DRUG|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
223556556|NCT05525130|DIETARY_SUPPLEMENT|Food supplement|FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
223406538|NCT01961739|DRUG|2% lidocaine|Topical application, twice per day for 15 consecutive days
223556557|NCT05525130|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
223556558|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
223556559|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
223556560|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
223556561|NCT01541904|DRUG|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
223556562|NCT01541904|DRUG|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
224023418|NCT05189769|BEHAVIORAL|CP and REACT|Coping Power traditional and REACT
224023419|NCT05189769|BEHAVIORAL|CP+ and REACT|CP+ and REACT
224023420|NCT04428008|DRUG|Thymalfasin|Synthetic 28 amino acid peptide
224132777|NCT03754062|DRUG|L-dopa|Administration of L-dopa by pill.
223406539|NCT01961739|DRUG|placebo|topical application, twice per day for 15 consecutive days
223406540|NCT03458481|DRUG|SOF|400 mg tablet administered orally once daily
223406541|NCT03458481|DRUG|DAG181|Capsule administered orally once daily
223556563|NCT03702569|DIAGNOSTIC_TEST|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
223556564|NCT05535023|DRUG|SAR444245|Given by vein (IV)
223556565|NCT05535023|DRUG|Cemiplimab|Given by vein (IV)
223556566|NCT03874741|DRUG|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
223556567|NCT04463186|OTHER|Muscle Static Stretching|Static stretching for 2 minutes (SS2), static stretching for 4 minutes (SS4), and static stretching for 8 minutes (SS8). Each static stretching (SS) trial involved varied repetitions of 30-seconds self-stretches and 20-seconds relax periods.
223556568|NCT05183516|BIOLOGICAL|tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
223556569|NCT05734911|DRUG|Niraparib|We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
224132778|NCT03754062|DRUG|Haloperidol|Administration of Haloperidol by pill.
223737728|NCT05342259|PROCEDURE|Caudal nerve block /neuroaxial|"Technique of the caudal block The patient was placed in lateral decubitus position for blind caudal epidural block. A line was drawn to connect the bilateral posterior superior iliac crests and used as one side of an equilateral triangle; then the location of the sacral hiatus was approximated by palpating the sacral cornua as 2 bony prominences, the sacral hiatus was identified as a dimple in between. A needle was inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone was contacted.~A subjective feeling of loss of resistance suggests piercing the sacral ligament.The whoosh test, performed by auscultation at the thoracolumbar region with a stethoscope while injecting 2 mL of air, Palpating for subcutaneous bulging on rapid injection of 5 mL air or saline had a positive predictive value of 83% and a negative predictive value of 44%."
223737729|NCT05342259|PROCEDURE|Dorsal penile nerve block|"Technique of Dorsal penile nerve block:~Under aseptic technique and under ultrasound guidance. A 'hockey-stick' probe was used, covered by transparent sterile dressing. The probe was placed vertically over the pubic symphysis and the base of the penile shaft. With adjustment of the probe, a sagittal view of the penile shaft was produced. Scarpa's fascia was seen as a hyperechoic line superficial to the penile shaft. Under real-time guidance, the needle was inserted and advanced until its tip laid deep to Scarpa's fascia (i.e., within the subpubic space), where local anesthetic was deposited. The local anesthetic solution injected was 0.5% bupivacaine in a recommended volume. (2 ml up to 3 years and an additional 1 ml for each3 years up to maximum 6 ml)."
223737730|NCT05342259|PROCEDURE|Combined caudal and dorsal penile nerve block|Combined techniques of caudal and dorsal penile nerve block
223737731|NCT05969288|OTHER|Behavioral survey|"Behavioral survey by administering a short self-administered questionnaire (read more in the Detailed description section)."
224023421|NCT05261633|DEVICE|Diffusion Weighted Magnetic Resonance Imaging|Diffusion-weighted (DW)-MRI has a unique ability to probe tissue microstructure without the need for ionizing radiation or intravenous contrast agents. DW-MRI of the abdomen is utilized in detection, staging, and treatment surveillance of malignancies, and has shown great promise in various other applications, including for the assessment of fibrosis in the liver, pancreas, kidneys, and other organs.
224023422|NCT05394519|DRUG|Cagrilintide|Cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
224023423|NCT05394519|DRUG|Semaglutide|Semaglutide administered subcutaneously (s.c., under the skin) once-weekly
224023424|NCT05394519|DRUG|Placebo cagrilintide|Placebo cagrilintide administered subcutaneously (s.c., under the skin) once-weekly
224023425|NCT05394519|DRUG|Placebo semaglutide|Placebo semaglutide administered subcutaneously (s.c., under the skin) once-weekly
224023426|NCT05001880|BIOLOGICAL|Atezolizumab|Given IV
224023427|NCT05001880|BIOLOGICAL|Bevacizumab|Given IV
224023428|NCT05001880|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
223406542|NCT04090671|DIAGNOSTIC_TEST|Multidimensional Dyspnea Profile|The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
223406543|NCT00921531|DRUG|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
223406544|NCT00921531|DRUG|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
223556570|NCT04971239|DRUG|topical methotrexate micoemulsion|The selected microemulsion composition consists of 40% Jojoba oil, 45% Tween-80 and Span-85 at a ratio of 3:1 as surfactant and co surfactant, respectively and 15% water. The chosen concentration was based on preliminary studies conducted which delineated that these ratios provided the best skin deposition based on factorial skin modelling.The prepared microemulsions contains 0.1% methotrexate
223556571|NCT04971239|DEVICE|Excimer light|the excimer laser will be done twice weekly for a total treatment course of 12 weeks.
223556572|NCT04971239|DEVICE|Narrow band ultraviolet B|the Narrow band ultraviolet B will be done twice weekly for a total treatment course of 12 weeks.
223556573|NCT01221753|DRUG|docetaxel|
223556574|NCT01221753|DRUG|cisplatin|Given intravenously on day 1 of each cycle
223556575|NCT01221753|DRUG|5-FU|
223556576|NCT01221753|RADIATION|IMRT|
223556577|NCT01221753|DRUG|cetuximab|
223556578|NCT01221753|DRUG|carboplatin|
223556579|NCT04309851|DIAGNOSTIC_TEST|deep learning|the deep learning method is a field of study involving artificial neural networks and similar machine learning algorithms with many hidden layers.
223556580|NCT04249297|DRUG|Duphaston® (Dydrogesteron)|No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
223556581|NCT04183504|BEHAVIORAL|Brief parenting intervention|Coaching session on positive parenting practices and promoting child development
223406545|NCT00093314|DRUG|HuMax-CD20|
223406546|NCT05787717|OTHER|Parental presence|The parent is encouraged to stay close to their child and are given ample room on one side of the OR table for this purpose
223406547|NCT01464424|DRUG|Travoprost 0.004% ophthalmic solution|
223406548|NCT01464424|DRUG|Bimatoprost 0.01% ophthalmic solution|
223406549|NCT02069041|BIOLOGICAL|Ramucirumab|Administered IV.
223406550|NCT02069041|DRUG|FOLFOX4|Administered IV.
223556582|NCT00617058|DRUG|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
223556583|NCT00617058|BEHAVIORAL|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
224023429|NCT05001880|DRUG|Carboplatin|Given IV
224023430|NCT05001880|PROCEDURE|Computed Tomography|Undergo CT scan
224023431|NCT05001880|PROCEDURE|Cytoreductive Surgery|Undergo surgery
224023432|NCT05001880|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
224023433|NCT05001880|DRUG|Pemetrexed|Given IV
224023434|NCT05001880|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223406551|NCT00264719|DRUG|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
223406552|NCT00264719|DRUG|placebo|placebo 10 mg
223406553|NCT04981002|OTHER|Telemedicine Consultation with self orthopedic exam|Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.
223406554|NCT04981002|OTHER|Face-to-face Consultation|Direct face-to-face evaluation (without telemedicine consultation before).
223406555|NCT00152802|BIOLOGICAL|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
223406556|NCT00152802|BIOLOGICAL|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
223556584|NCT01628354|DRUG|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of \>5 letters or increase in retinal thickness of \>100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
223556585|NCT03071315|OTHER|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
224023435|NCT05195489|OTHER|Family Connectors|The Family Connectors Program is a manualized program that uses a time-limited parent-to parent (i.e. peer parent) support and education program delivered by phone to families of youth with serious mental health difficulties, assisting family members in becoming fully engaged with provider teams who coordinate and provide care. Family Connectors is delivered weekly by phone over the course of between three and six months.
224023436|NCT01695941|DRUG|Alisertib|Given PO
224023437|NCT01695941|DRUG|Bortezomib|Given SC
223556586|NCT03071315|OTHER|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
223556587|NCT00371215|BIOLOGICAL|rThrombin|1000 U/mL applied topically
223556588|NCT01939977|DRUG|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
223556589|NCT01939977|DRUG|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
223556590|NCT02810769|DIETARY_SUPPLEMENT|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
223556591|NCT02810769|DIETARY_SUPPLEMENT|Control|Sugar matched control containing berry flavouring and no phytochemicals
223556592|NCT02810769|DIETARY_SUPPLEMENT|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
223556593|NCT04217811|OTHER|No intervention|No intervention
224023438|NCT01695941|OTHER|Laboratory Biomarker Analysis|Correlative studies
224023439|NCT01695941|BIOLOGICAL|Rituximab|Given IV
224023440|NCT03282396|DRUG|Ibrutinib|Given PO
224023441|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
223406557|NCT01797887|BEHAVIORAL|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
223406558|NCT04023032|BEHAVIORAL|multicomponent cognitive intervention|"The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework."
223406559|NCT05296083|DIETARY_SUPPLEMENT|G3P-01|G3P-01 is a food-grade pectic product derived from squash.
223406560|NCT04386330|BEHAVIORAL|Distance-delivered NET|One-on-one intervention delivered by a paraprofessional; 12 weekly videoconference sessions at 90 minutes.
223406561|NCT03669926|RADIATION|Digital Breast Tomosynthesis+synthetic mammography|Two-view tomosynthesis performed with GE Senographe Pristina.
223406562|NCT01775059|DEVICE|Integrated sensor and infusion set.|
223406563|NCT00230659|OTHER|Blood sample to be taken.|Blood sample to be taken.
223406564|NCT01069042|DRUG|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
223406565|NCT06307132|OTHER|Aximus capsules（test）|Aximus capsules test preparation
224023442|NCT04537936|BEHAVIORAL|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
224023443|NCT04537936|BEHAVIORAL|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
224023444|NCT04537936|BEHAVIORAL|Pre-assessment questionnaire|Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
223406566|NCT06307132|DRUG|Aximus capsules（reference）|Aximus capsules reference preparation
223406567|NCT01511978|DRUG|Continuous 3,4-DAP|Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
223406568|NCT01511978|DRUG|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
224023445|NCT05810181|OTHER|Interview|"The following three groups of stakeholders will be interviewed to assess the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases:~(1) patients and families of children with rare genetic diseases who have received gene therapy (to assess their perspectives and understand their informational needs around participating in a clinical trial using gene therapy), (2) patients and families of children with rare genetic diseases who were offered but have decided against receiving gene therapy or ultimately did not qualify for a trial (to elicit feedback and to evaluate whether their informational needs and communication expectations about participating in a clinical trial using gene therapy were met), and (3) healthcare workers who provide care to patients receiving gene therapy (to assess their perspective regarding patient/family needs for gene therapy education and communication)."
223556594|NCT06128889|BEHAVIORAL|Supporting Transition and Resilience to Clinical Nursing Education (STRONG) Program|The STRONG program adopts an asynchronous online learning approach and will be delivered over one week by a trained counsellor, and a nurse researcher. Students will attend an online self-paced program. The program will comprise of topics such as: (1) Resilience and protective factors, (2) introduction to clinical nursing education, (3) experiences of clinical attachments, and (4) stress, physical wellbeing and diet materials. Students will have access to online materials (e.g., short videos), have opportunities to discuss (e.g., forum) and infographics. Overall, the program will be delivered over in one week lasting six hours.
223556595|NCT02083341|DEVICE|Lelo® Siri vibrator|external vibration device
223556596|NCT02083341|DEVICE|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
223556597|NCT02959853|DRUG|Anastrazole|
223556598|NCT02959853|BEHAVIORAL|weight loss|
224023446|NCT03198182|DRUG|Placebo|Specified dose on specified days
224023447|NCT03198182|DRUG|BMS-986036|Specified dose on specified days
224023448|NCT04482062|DEVICE|Edwards EVOQUE System|Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT
224132779|NCT05138874|BEHAVIORAL|Trending Feedback|Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.
223406569|NCT02187198|DRUG|Buprenorphine|
223556599|NCT06036602|BIOLOGICAL|cAD3-Sudan Ebolavirus Vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.
223556600|NCT06036602|OTHER|Placebo|0.9% NaCl solution for injection.
223556601|NCT05129280|DRUG|RO7444973|RO7444973 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective cohort.
223556602|NCT05129280|DRUG|Tocilizumab|Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
223556603|NCT01976546|DEVICE|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
223556604|NCT01253148|DEVICE|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
223556605|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff."
223556606|NCT03982108|PROCEDURE|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
223556607|NCT00197418|DRUG|rabeprazole, amoxicillin, clarithromycin, metronidazole|
224023449|NCT04482062|DRUG|Optimal Medical Therapy|Optimal Medical Therapy
224132780|NCT05138874|BEHAVIORAL|Benchmark Peer Comparison Feedback|Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.
224132781|NCT05138874|BEHAVIORAL|Private Commitment|Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.
224132782|NCT05138874|BEHAVIORAL|Public Commitment|Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
224138838|NCT01076842|DRUG|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
224138839|NCT01076842|DRUG|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
224023450|NCT05828069|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
223556608|NCT06045858|DRUG|Anticoagulation Agents|anticoagulation in peritoneal dialysis patients with non valvular atrial fibrillation during one year
223556609|NCT01672281|OTHER|vibrox- vs. resistance training|Comparison between two exercise interventions
224023451|NCT05828069|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224132783|NCT03720821|BEHAVIORAL|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
224023452|NCT05828069|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224132784|NCT00960934|DRUG|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
224132785|NCT00960934|DRUG|Placebo|Dose-matched oral placebo to MK-5442
224023453|NCT05828069|PROCEDURE|Computed Tomography|Undergo CT
224023454|NCT05828069|PROCEDURE|Echocardiography Test|Undergo ECHO
224132786|NCT00960934|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
224132787|NCT00960934|DIETARY_SUPPLEMENT|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
224132788|NCT05852678|OTHER|cohort|The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
224132789|NCT04958421|DEVICE|PiCSO Impulse System|After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
224132790|NCT02363270|PROCEDURE|Ketamine|IV Push or or IV Drip
224132791|NCT02311309|OTHER|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration \>8 g/dL.
223406570|NCT06444776|DIAGNOSTIC_TEST|Repetitive (semi-)objective and subjective taste, smell, and saliva analysis|"Study participants will undergo repetitive assessments of their taste, smell and saliva, using quality of life questionnaires, taste strips, sniffin sticks, and analysis of salivary function and composition.~Assessments will be done before treatment, in the 4th week (+/- 1 week) and last week of radiation therapy (+/- 1 week), and at 6 months (+/- 1 months) and 1 and 2 years post-therapy (+/- 3 months).~At the minimum, participants are expected to complete the assessments at baseline and 1 year after the end of radiation therapy. Assessments at all other time points are strongly encouraged but will be optional."
223406571|NCT01532518|DRUG|Nepadutant|Nepadutant oral solution
223406572|NCT04040140|OTHER|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
223406573|NCT06294639|DRUG|Esketamine|esketamine will be given intravenously
223406574|NCT00407238|DEVICE|Multi-purpose solutions (polyquaternium-1 and PHMB)|
223406575|NCT02074423|DIETARY_SUPPLEMENT|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
223406576|NCT02074423|DIETARY_SUPPLEMENT|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
223406577|NCT01575834|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
223406578|NCT01575834|DRUG|Placebo|Administered by subcutaneous injection once a month (QM)
223406579|NCT01575834|DRUG|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
223406580|NCT02609971|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
223406581|NCT04754828|OTHER|Assigned to a rounding style|Team rounded on new admissions either in hallway or at the bedside
223556610|NCT04182399|DRUG|Zonisamide Capsules|anti-epileptic drug that recently used as add on therapy of wearing off and fluctuation complications of dopaminergic drugs in PD patients
224023455|NCT05828069|PROCEDURE|FDG-Positron Emission Tomography and Computed Tomography Scan|Undergo FDG-PET imaging
224023456|NCT05828069|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224023457|NCT05828069|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224023458|NCT05828069|DRUG|Tovorafenib|Given PO
224023459|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Notched Noise Therapy|Notched Noise Therapy involves presenting wide-band sound with the tinnitus frequency region notched out, referred to as notched noise, or notch therapy. This procedure may distribute lateral inhibition into the notched frequency region, suppressing tinnitus neural activity believed to be occurring there. This type of therapy is provided through a sound file that is streamed through hearing aids.
224023460|NCT04661995|COMBINATION_PRODUCT|Hearing Aid and Broadband Noise|"Broadband Noise, or white noise, is a common tinnitus sound therapy treatment option. It is also commonly used as a masker noise for individuals with tinnitus that like to enrich their environment with sound."
224132792|NCT02311309|OTHER|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
224132793|NCT04388098|OTHER|Diagnosis of caries experience and periodontal health|
224132794|NCT01523314|DRUG|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
224023461|NCT04661995|DEVICE|Hearing Aid|A-O groups will use ear-level, self-contained devices (hearing aids) that (1) are capable of streaming shapeable broadband noise between 1-10 kHz; (2) allow for normal conversation; and (3) are comfortable, easy to use, and discrete. These criteria describe a behind-the-ear hearing aid with the capability of streaming custom sounds. Hearing aids are used to provide amplification to those with hearing loss and are fit by licensed audiologists. Sometimes, hearing aids can provide benefit to those with bothersome tinnitus.
224023462|NCT06835608|OTHER|Schroth Exercise Group|The study group will receive electrotherapy treatment (hot pack, ultrasound, tens) to the neck area for 30 minutes in each session. After electrotherapy treatment, kyphotic posture correction exercises will be applied with the help of proprioceptive and extroceptive stimuli in the sagittal plane with mirror control and specific corrective breathing. In the exercise program, exercise practices will be performed in specific positions in supine, prone, sitting and standing. The exercise program will be planned for approximately 40 minutes in each session. A total of 20 sessions of electrotherapy and exercise will be performed for 4 weeks. At the end of the 4th week, after the electrotherapy sessions are completed, exercise applications will continue for the other 4 weeks by the physiotherapist who performs the exercise 3 days a week.
224023463|NCT06835608|OTHER|Postural Exercises Group|Patients to be included in the control group will receive electrotherapy treatment (ultrasound, tens, hotpack) to the neck area for 30 minutes in each session. After the electrotherapy treatment, posture corrective exercises will be applied. Corrective exercise program for posture will consist of deep neck flexor muscle strengthening exercises, lower and middle trapezius strengthening, neck isometric exercises. All strengthening exercises will be given 3 sets of 10 repetitions per day, each repetition for 10 seconds. Stretching exercises will be given to the shortened upper trapezius and pectoralis major muscles. Stretching exercises will be given 2 sets of 5 repetitions per day, with each repetition lasting 20 seconds. In the first 4 weeks, a total of 20 sessions of electrotherapy and exercise will be performed in corrective exercises for posture. At the end of the 4th week, exercise applications will continue for the other 4 weeks 3 days a week.
224023464|NCT05783817|DRUG|3,4-Methyl enedioxy methamphetamine|MDMA (3,4 methylenedioxymethamphetamine) is a synthetic, psychoactive drug that is chemically similar to the stimulant methamphetamine.
224023465|NCT05783817|DRUG|Methamphetamine|Methamphetamine is a stimulant that affects the central nervous system. This is used as a control in the study.
223556611|NCT05522582|DRUG|Methotrexate tablets|Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
223556612|NCT05522582|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
223556613|NCT05522582|RADIATION|Radiotherapy|6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
223556614|NCT02994472|RADIATION|Gastric emptying scintigraphy using 99mTc-DTPA|
224023466|NCT05783817|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy with exposure and response prevention performed by therapist team.
224023467|NCT06557226|OTHER|oral and nutritional examination|Participants will receive a comprehensive oral examination, nutritional examination and will fill an oral health related quality of life questionnaire.
224023468|NCT03244384|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224023469|NCT03244384|OTHER|Clinical Observation|Undergo observation
224023470|NCT03244384|PROCEDURE|Computed Tomography|Undergo a CT scan
224023471|NCT03244384|PROCEDURE|CT Urography|Undergo a CT urography
224023472|NCT03244384|PROCEDURE|Cystoscopy|Undergo a cystoscopy
224023473|NCT03244384|PROCEDURE|Magnetic Resonance Imaging|Undergo a MRI
224023474|NCT03244384|BIOLOGICAL|Pembrolizumab|Given IV
224023475|NCT03244384|OTHER|Pharmacological Study|Correlative studies
223556615|NCT03305796|RADIATION|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
223556616|NCT04685005|DIETARY_SUPPLEMENT|"Wake Up"|The current composition of the WakeUp® beverage consists of herbal extracts of guarana, green tea, elderberry and Fruit-up
224023476|NCT03244384|OTHER|Quality-of-Life Assessment|Ancillary studies
224023477|NCT03244384|OTHER|Questionnaire Administration|Ancillary studies
223556617|NCT04685005|DIETARY_SUPPLEMENT|Caffeine|Caffeine
223556618|NCT04552288|DRUG|Benralizumab|All eligible patients will receive a benralizumab dose of 30 mg SC administered by a healthcare provider once every 4 weeks for the first 3 doses, followed by once every 8 weeks for 3 additional doses.
223556619|NCT05285644|DRUG|0.003% AR-15512 ophthalmic solution|Administered via topical ocular instillation
223556620|NCT05285644|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
223556621|NCT00786968|DRUG|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
223556622|NCT03001193|DRUG|DF 01|
223556623|NCT03001193|DRUG|Oxytocin|
223556624|NCT03001193|DRUG|Placebo|
224023478|NCT01416415|OTHER|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
224023479|NCT01416415|OTHER|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
224023480|NCT05269810|DRUG|SA001 Low dose|3 tablets b.i.d for 8 weeks
224023481|NCT05269810|DRUG|SA001 Mid dose|3 tablets b.i.d for 8 weeks
223556625|NCT04532294|DRUG|BGB DXP593|Administered intravenously (IV) as specified in the treatment arm
223556626|NCT04532294|DRUG|Placebo|Placebo to match BGB-DXP593
223556627|NCT04295759|DRUG|INCB7839|INCB7839 dosing will begin at 120 mg/m2/dose BID which is equivalent to the adult RP2D (200 mg PO BID) based on a typical adult size of 1.67m2. The INCB7839 dose may be decreased to 80 mg/m2/dose BID if the staring dose is not tolerable. 28 consecutive days (4 weeks) will constitute one course. Patients may continue to receive INCB7839 for 26 courses (approximately 2 years).
223556628|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 0.76 g|
223556629|NCT02244372|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.15 g|
223556630|NCT02244372|DIETARY_SUPPLEMENT|Placebo|
223406582|NCT00940615|OTHER|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
223406583|NCT00940615|OTHER|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
223406584|NCT02249728|DRUG|IV PBT2 microtracer and oral PBT2 single dose|
223556631|NCT05054491|BEHAVIORAL|Group Antenatal Care|Group ANC is an integrated approach that incorporates physical assessment, education and skill development, and peer support and takes a broader, more holistic, woman-centered approach to traditional antenatal care
223556632|NCT00156104|DRUG|Asenapine|5 mg BID
223556633|NCT00156104|DRUG|Asenapine|10 mg BID
223556634|NCT00156104|DRUG|Haloperidol|4 mg BID
223556635|NCT00156104|OTHER|Placebo arm|
223556636|NCT06433154|PROCEDURE|Arthroscopic surgery|Arthroscopic treatment (lysis and lavage) of internal derangement of the temporomandibular joint.
223556637|NCT01696981|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
223556638|NCT01696981|PROCEDURE|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
223556639|NCT02354261|DRUG|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
224023482|NCT05269810|DRUG|SA001 High dose|3 tablets b.i.d for 8 weeks
223406585|NCT02249728|DRUG|oral 14C-PBT2|
223556640|NCT03899233|DEVICE|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
224023483|NCT05269810|DRUG|Placebo|3 tablets b.i.d for 8 weeks
224023484|NCT01206543|OTHER|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
223406586|NCT02155283|DEVICE|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
223406587|NCT00470717|PROCEDURE|Weekly telephone call|Details of feeding and health/sickness will be obtained
223406588|NCT00857090|DRUG|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
223406589|NCT00857090|DRUG|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
223406590|NCT03542942|OTHER|treatment with EXIT-target volume|exclusion of the unaffected part of the uterus out of the treatment field
223406591|NCT04424420|DRUG|Paracetamol|Paracetamol oral tablet
223406592|NCT04424420|DRUG|Ibuprofen|Ibuprofen oral tablet
223406593|NCT04424420|DRUG|Placebo oral tablet|Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
223406594|NCT05990179|OTHER|Genome sequencing-based newborn screening|Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
223406595|NCT02282813|DRUG|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
223406596|NCT02282813|DRUG|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
223406597|NCT02282813|DRUG|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
223406598|NCT02282813|DRUG|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
223406599|NCT02921984|DRUG|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
223406600|NCT02921984|RADIATION|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
223406601|NCT02921984|DRUG|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
223406602|NCT02921984|DRUG|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
223406603|NCT02778009|RADIATION|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
223406604|NCT02778009|OTHER|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
223556641|NCT03899233|DRUG|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
223556642|NCT02473094|DRUG|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
223556643|NCT02473094|DRUG|Metformin|Metformin up to 2500mg/d
223556644|NCT02473094|RADIATION|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
223556645|NCT02473094|DRUG|Placebo|Placebo up to 2500mg/d
223556646|NCT00876096|OTHER|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
223556647|NCT02284815|DIETARY_SUPPLEMENT|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
223556648|NCT02299141|DRUG|Nintedanib|
224023485|NCT00185679|DEVICE|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:~1. Computer-controlled instrument;~2. Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~3. Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~4. Wash buffer"
224023486|NCT00133887|DRUG|rapamycin|3 to 5 mg/day
224023487|NCT00133887|DRUG|ciclosporine|Blood residual level \< or = to 125 ng/ml
224023488|NCT00133887|DRUG|tacrolimus|Blood residual level \< or = to 8 ng/ml
224023489|NCT06964776|DRUG|LY4268989|Administered orally
224023490|NCT06964776|DRUG|Placebo|Administered placebo
224023491|NCT06964776|DRUG|Midazolam|Administered orally
224023492|NCT06964776|DRUG|Midazolam|Administered intravenously (IV)
223556649|NCT05152524|DEVICE|Tigertriever 13|patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
223556650|NCT05662540|DEVICE|Positron Emission Tomography/Magnetic Resonance (PET/MR)|18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.
224023493|NCT02609854|DEVICE|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
224023494|NCT02609854|DEVICE|Sham Device|Inactive ultrasound device
223406605|NCT02778009|OTHER|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
223406606|NCT02778009|OTHER|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
223406607|NCT06577194|DRUG|Sintilimab + IL-2 Combined with CAPOX|Sintilimab + IL-2 Combined with Capox
223406608|NCT06577194|RADIATION|Short-course radiotherapy|Short-course radiotherapy+IL-2
223406609|NCT03858998|OTHER|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
223406610|NCT03858998|OTHER|Control|Current routine HIV care in Tanzania.
224023495|NCT03730857|DRUG|Olanzapine|olanzapine tablet
224023496|NCT03730857|DRUG|risperidone|risperidone tablet
224023497|NCT03730857|DRUG|Paliperidone|paliperidone tablet
224023498|NCT06225934|BEHAVIORAL|Exercise and home program to increase lateral flexion and rotation angles|Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
224023499|NCT06959277|DEVICE|Walkasins|Walkasins® is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
224023500|NCT06959277|OTHER|Fall Prevention Training|"Participants will watch 6 Steps to Prevent a Fall, a short (2 minute) educational video from the National Council on Aging, which describes simple steps to reduce fall risk. To improve their access to the education provided, participants will also receive three handouts, produced by the Center for Disease Control and Prevention (CDC) STEADI initiative (Stopping Elderly Accidents, Deaths, and Injuries), to review after the study visit. The STEADI Initiative is a coordinated approach for healthcare providers to implement the American and British Geriatrics Societies' Clinical Practice Guideline for fall prevention (https://www.cdc.gov/steadi/index.html)."
224023503|NCT01588834|PROCEDURE|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
224023504|NCT04812548|DRUG|sabatolimab|Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days
224023505|NCT04812548|DRUG|azacitidine|A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).
224023506|NCT04812548|DRUG|venetoclax|Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
223406611|NCT01152879|DIETARY_SUPPLEMENT|Home Parenteral Nutrition|Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
223406612|NCT03135054|DRUG|Quizartinib|Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
223406613|NCT03135054|DRUG|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
223406614|NCT01034436|DIETARY_SUPPLEMENT|fatty acid quality and overweight|Duration 12 weeks
223406615|NCT06684093|DEVICE|Back squat with Blood flow restriction machine|The blood flow restriction (BFR) machine is a specialized device designed to safely apply controlled pressure to the proximal limbs during exercise. It typically consists of adjustable cuffs or bands that are placed around the upper arms or thighs, which are connected to a pressure monitoring system. The device enables practitioners to restrict venous blood flow while allowing arterial blood flow to the working muscles. This method enhances the effects of low-intensity resistance training by promoting muscle hypertrophy and strength gains, similar to those achieved through high-intensity training. The BFR machine is commonly used in rehabilitation settings and athletic training programs to optimize performance and recovery while minimizing the risk of injury.
223406616|NCT06684093|BEHAVIORAL|Back squats|Back squats without any blood flow restriction
223406617|NCT02847091|DRUG|Ipragliflozin|Oral administration, 50mg once daily
224132795|NCT01523314|OTHER|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
224132796|NCT01479959|DEVICE|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
224132797|NCT05610358|DEVICE|smartphone application|In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
224023507|NCT01945541|DEVICE|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
223406618|NCT02847091|DRUG|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
223406619|NCT06494397|DRUG|VHX-896 and iloperidone|oral tablet
223406620|NCT06494397|DRUG|Iloperidone and VHX-896|oral tablet
223406621|NCT00434174|DRUG|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
223556651|NCT05278845|DRUG|SLC-391|SLC-391 is an AXL inhibitor
223556652|NCT02020798|OTHER|Dietary Intervention|
223556653|NCT06513390|DEVICE|Exoskeleton of default mode|Default mode: A standard control system offering a conventional assistive function of Exo-H3.
223406622|NCT00434174|DRUG|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
223406623|NCT06683404|DEVICE|Electrochemotherapy (ECT)|Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.
223556654|NCT06513390|DEVICE|Exoskeleton of Intelligent mode|Intelligent mode: The adaptive CPG-based control system developed by our researchers from Exo-H3.
224023508|NCT05014087|DRUG|Intravenous digoxin|"Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial.~Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing.~Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed."
223556655|NCT00802620|PROCEDURE|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
223556656|NCT03335150|BEHAVIORAL|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
223556657|NCT03335150|BEHAVIORAL|Supportive Care|Support Group for persons with PD-MCI
223556658|NCT03690986|BIOLOGICAL|VX15/2503|Given IV
224023509|NCT04871100|BEHAVIORAL|Unified Protocol- Alcohol|Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.
224023510|NCT04871100|BEHAVIORAL|Usual care|referrals to VA care for SUD and anxiety
223556659|NCT03690986|BIOLOGICAL|Ipilimumab|Given IV
223556660|NCT03690986|BIOLOGICAL|Nivolumab|Given IV
223406624|NCT06683404|DRUG|Bleomycin|Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane
223556661|NCT03838211|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
223556662|NCT03838211|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
224023511|NCT06788756|DRUG|Placebo in combination with Cytarabine Injection|placebo (0.9% Sodium Chloride Injection, i.e., the diluent for L-Annamycin for Injection) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
224023512|NCT06788756|DRUG|Liposomal Annamycin Injection in combination with Cytarabine Injection|190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
223556663|NCT04648488|OTHER|Experimental early mobilisation|early activ assisted exercises treatment
223556664|NCT04648488|OTHER|Aktive comparator standrad treatmnet|standard treatment with a plaster 3 weeks and then active assisted exercises
223556665|NCT01551654|DEVICE|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
223556666|NCT02097719|DRUG|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
223556667|NCT02097719|DRUG|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
223556668|NCT02097719|DRUG|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
223556669|NCT02097719|DRUG|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
223556670|NCT05086900|OTHER|Non-interventional Cross-sectional Patient Reported Outcome Measure Development|Development of Patient Reported Outcome Measure
224023513|NCT06788756|DRUG|Liposomal Annamycin Injection in combination with Cytarabine Injection|230 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.
224023514|NCT06788756|DRUG|Liposomal Annamycin for Injection in combination with Cytarabine Injection.|optimal dosage regimen (as determined in Part A) of L Annamycin for Injection (190 mg/m2/day or 230 mg/m2/day) for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days (i.e., the same as Treatment Arm 2 or 3, respectively, of Part A).
224023515|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
223406625|NCT01175096|DRUG|RAD001 (everolimus, Afinitor®)|"RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days."
223406626|NCT03442608|PROCEDURE|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
223406627|NCT06154980|PROCEDURE|Preoperative Ultrasound TLIP|TLIP will be performed in preop with 20cc of 0.2% ropivacaine administered bilaterally, 40cc total. Blocks will be performed under ultrasound guidance with an in-plane technique.
223406628|NCT06154980|PROCEDURE|Intraoperative TLIP|TLIP will be performed intraoperatively with 20cc of 0.2% ropivacaine bilaterally, 40cc total. Blocks under direct surgical visualization.
223406629|NCT00426166|DEVICE|Low Level Laser Therapy|7500 megawatts with a 980 nm treatment beam every 48 hours for two weeks beginning at suture removal.
223406630|NCT03366480|DRUG|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
223406631|NCT05330221|BEHAVIORAL|PAL2|Community health worked based intervention to mitigate psychosocial and life circumstance barriers to optimize health promotion coupled with high blood pressure and lifestyle disease state education Other Names: Pragmatic personalized, adaptable approach to lifestyle and life circumstance
223406632|NCT05330221|DRUG|PHARM-PAL2|"All intervention arm participants will be referred to our study pharmacist who will prescribe a antihypertensive medication as per standard of care medical treatment algorithm to achieve BP control.~Per AHA recommended guidelines, participants with an indication of diabetes mellitus (DM) and/or CKD will be started on SGLT2 inhibitor within the first month of starting the study intervention."
223406633|NCT02437773|BEHAVIORAL|Cognitive Behavioral Therapy - Adolescents|"A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
223406634|NCT02437773|BEHAVIORAL|Stress Management Therapy - Adolescents|An active control therapy with minimal effects on OCD symptoms.
223556671|NCT02000024|BEHAVIORAL|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
223556672|NCT02000024|BEHAVIORAL|National Diabetes Education Program|
223406635|NCT02437773|BEHAVIORAL|Optional CBT - Adolescents|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
223406636|NCT02437773|BEHAVIORAL|Cognitive Behavioral Therapy - Adults|"A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
223406637|NCT02437773|BEHAVIORAL|Stress Management Therapy - Adults|An active control therapy with minimal effects on OCD symptoms.
223406638|NCT02437773|BEHAVIORAL|Optional CBT - Adults|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
223556673|NCT04622501|PROCEDURE|posterior spinal decompression and posterior spinal instrumented fusion|posterior spinal decompression and posterior spinal instrumented fusion performed on a patient with Spinal Epidural Lipomatosis
224023516|NCT01003574|BEHAVIORAL|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
223406639|NCT02437773|OTHER|fMRI only - Healthy Control Adults|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
223406640|NCT02437773|OTHER|fMRI only - Healthy Control Adolescents|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
223406641|NCT00799890|DRUG|Sunphenon EGCG|200-800mg (1-4 capsules)
224132798|NCT03689413|DRUG|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
224132799|NCT03489993|DIAGNOSTIC_TEST|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
223406642|NCT00799890|DRUG|Placebo|1-4 capsules
223406643|NCT05035290|DEVICE|Negative pressure ventilation|Negative pressure ventilation - cuirass will be applied on the patient´s ches and abdomen immediately after extubation
223406644|NCT03266146|DRUG|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
223556674|NCT03102515|DRUG|USG-TAP block|
223556675|NCT03102515|DRUG|CIC|
223556676|NCT06277856|BEHAVIORAL|Peer interaction/control|This study was planned as a randomised controlled study with a two-group pretest and posttest design.
224132800|NCT03489993|DIAGNOSTIC_TEST|FGF23 and klotho|Measured using ELISA's.
224132801|NCT05254613|DRUG|ALXN1830|ALXN1830 will be administered as SC infusion(s).
224132802|NCT05254613|DRUG|Placebo|Placebo will be administered as SC infusion(s).
224132803|NCT06324279|DEVICE|Transvaginal ultrasound|Transvaginal ultrasound will be used to see the presence of cervical sliding sign
224132804|NCT06324279|DRUG|Misoprostol 200mcg Tab|Induction of labor by misoprostol
223406645|NCT03266146|DRUG|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
223406646|NCT05788172|OTHER|Iron isotope dilution|Menstrual blood loss will be determined using the iron isotope dilution technique and compared to the amount determined via the alkaline hematin method.
223406647|NCT05788172|OTHER|Alkaline hematin method|Menstrual blood loss will be determined using the alkaline hematin method and compared to the amount determined via the iron isotope dilution technique.
223556677|NCT04822896|BEHAVIORAL|Physical Exercise|"The videos will be prepared by the researchers and will be watched by the physical exercise group, which includes exercises such as shifting the jaw to the side, pushing the tongue forward, jaw opening, sliding the jaw with the tongue, opening the chin with the tongue, opening the chin by pressing the tongue against the palate and shifting the chin with the person's own resistance. Then they will be asked to do the exercises physically. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
223406648|NCT00305019|DRUG|clevudine|
223556678|NCT04822896|BEHAVIORAL|Kinesthetic Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as kinesthetic imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
223556679|NCT04822896|BEHAVIORAL|Visual Motor Imagery Exercises|"Seven exercises designated as jaw shifting, tongue pushing forward, jaw opening, jaw shifting with tongue, jaw opening with tongue, jaw shifting by pressing the tongue on the palate, and chin shifting with one's own resistance, the videos prepared by the researchers and containing these exercises Once viewed, it will be applied as visual imagery. Each exercise will be applied as 2 sets x 10 repetitions. There will be a 30-second break between sets."
223556680|NCT03737955|DRUG|Gemtuzumab Ozogamicin|Receive IV
223556681|NCT03737955|OTHER|Quality-of-Life Assessment|Ancillary studies
223556682|NCT02792309|BEHAVIORAL|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
224023517|NCT06349070|BEHAVIORAL|Low Touch - Text Messaging Implementation Strategy|The low touch strategy is designed as a tool to distill and organize the most important information from the Starting Early Program (StEP) original evidenced-based intervention curriculum. Video links are sent to pregnant subjects via automated SMS messaging. Subjects will receive videos (20 videos total) at least weekly lasting 17 to 31 weeks and the duration is based upon the gestational age at enrollment into the study. Subjects will also receive SMS messages in between videos at least weekly to keep them engaged and reinforce the video content delivered. The StEP curriculum is guideline concordant and includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management, enhance prenatal breastfeeding support, and build social support. The StEP curriculum was adapted into brief videos (\<5 minutes), and an additional module on Sleep Health was added.
223406649|NCT03563430|OTHER|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
223406650|NCT03563430|OTHER|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
223406651|NCT03563430|OTHER|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
223406652|NCT02446067|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
223556683|NCT05060016|DRUG|Tarlatamab|Intravenous (IV) infusion
223556684|NCT04635371|DEVICE|Non-invasive Monitoring|Wearable, wireless, non-invasive chest-patch devices will be attached to the patients following recruitment and aigning an informed consent form, and from that moment on, vitals will be collected automatically and analyzed retrospectively.
223556685|NCT04312477|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
223556686|NCT01896830|BIOLOGICAL|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
223556687|NCT01896830|BIOLOGICAL|0.9% normal saline|0.5 mL, intramuscular
224132805|NCT05097248|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
224132806|NCT05097248|DRUG|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
223556688|NCT01162252|BEHAVIORAL|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
223737732|NCT03620136|DRUG|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
224023518|NCT06349070|BEHAVIORAL|High Touch - Community Health Worker (CHW) Implementation Strategy|The curriculum will be delivered by CHWs. Each subject will be asked to participate in 1-hour live sessions with a CHW. During the sessions, videos are interspersed with open-ended questions and pauses to discuss these open-ended questions. This results in an interactive session that employs principles of active learning. The curriculum includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management during pregnancy, enhance prenatal breastfeeding support, and build social support and are anchored by the same brief videos developed for the low touch strategy.
224297835|NCT03946254|OTHER|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
224297836|NCT00673933|DRUG|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
224297837|NCT02463305|DRUG|Creatine monohydrate|21 grams creatine monohydrate total per day
224297838|NCT02463305|OTHER|Placebo|7 grams of dextrose dissolved in 500mL water, taken three times daily
224297839|NCT05709483|DRUG|Aspirin|Platelet assays including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, Thromboxana A2 levels- will be measured at baseline and 1 hour after administration of single-dose enteric-coated 81 mg aspirin
224297840|NCT04915014|PROCEDURE|sleeve gastrectomy with transit bipartition (SG +TB)|In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.
224297841|NCT04915014|PROCEDURE|Roux-en-Y gastric bypass (RYGB)|A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
224297842|NCT02494102|DRUG|Modafinil|Atypical Psychomotor stimulant
224297843|NCT02494102|DRUG|Placebo|
224297844|NCT03760614|DRUG|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
224297845|NCT03760614|DRUG|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
224297846|NCT06690008|PROCEDURE|Experimental group|SDF application
224297847|NCT05777824|COMBINATION_PRODUCT|anti-PD-1 or PD-L1 antibody|immunotherapy maintenance with anti-PD-1 or PD-L1 antibody every three weeks for 13 cycles after radiotherapy
223406653|NCT04037787|PROCEDURE|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
223556689|NCT01162252|BEHAVIORAL|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
223556690|NCT05052944|DEVICE|Cochlear implantation|Patients who receive cochlear implant for single-sided deafness
223556691|NCT06388746|OTHER|BRIX3000®|A gel that when applied to the tooth completely removes carious tissues in a chemo mechanical way without rotary instruments. It contains an enzyme that has bactericidal, bacteriostatic and anti-inflammatory properties and proteolytic properties that help soften and break down decayed tissue without destroying the underlying healthy collagen fibers.
224297848|NCT05777824|RADIATION|postoperative radiaotherapy|postoperative radiotherapy (60Gy or 50Gy)
223556692|NCT06388746|OTHER|Riva Star Aqua, SDI Limited, Australia|A solution that contains 44,800 ppm F and 253,870 ppm Ag. It acts as a fluoride storage for the acid challenges, while inhibites demineralization of hydroxyapatite crystals and preserves collagen from degradation in demineralized tissues.
223556693|NCT04601532|DEVICE|Catasyn™ Advanced Technology Hydrogel and SynePure™ Wound Cleanser|Catasyn™ Advanced Technology Hydrogel is a wound hydrogel that provides a moist wound environment. A moist wound environment is supportive to wound healing. SynePure™ Wound Cleanser is a non-cytotoxic wound cleanser for the removal of foreign material from epidermal and dermal wounds, burns, cuts, abrasions and minor irritations of the skin.
223556694|NCT04601532|DRUG|Silver Sulfadiazine|Silver sulfadiazine, a sulfa drug, is used to prevent and treat infections in burn wounds.
223406654|NCT04022538|PROCEDURE|Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~* The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
223406655|NCT04022538|PROCEDURE|Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~* The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~* The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~* Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
223406656|NCT05000164|DEVICE|Bausch + Lomb Ultra® Multifocal for Astigmatism|Study Lens
223406657|NCT04275011|OTHER|Progressive Resistance and Impact Exercise|Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (\~80% 1RM) or 6 (\~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.
223406658|NCT04275011|OTHER|Static Balance and Postural Exercise|Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
223406659|NCT02458144|PROCEDURE|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
223406660|NCT02422446|DRUG|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
223406661|NCT04467567|OTHER|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after Lutathera® treatment (at 24h, 96h and 168h after the infusion of Lutathera®) on the conventional camera and on the VERITON-CT camera
223406662|NCT00722774|BIOLOGICAL|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
223406663|NCT04316104|BEHAVIORAL|CuidaTXT|Culturally tailored text messages including dementia education, problem-solving skills training, social network support, care management and referral to community resources.
223406664|NCT00999609|BIOLOGICAL|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
223406665|NCT06509438|DEVICE|Embella (Deoxycholic acid, produced by Espad Pharmed Co.)|2 milliliters of Embella injectable solution containing 20 milligrams of deoxycholic acid
223406666|NCT05851560|DRUG|Oxidized regenerated cellulose(ORC)|Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
223406667|NCT05851560|DRUG|Hyaluronic acid(HA)|Hyaluronic acid(HA)
223556695|NCT02339844|DRUG|Aripiprazole|6 weeks of individual doses of aripiprazole
223556696|NCT06414135|BIOLOGICAL|Relma-cel|All participants will receive Relma-cel once at different dose levels: 25×10\^6 CAR+ T cells、50×10\^6 CAR+ T cells、75×10\^6 CAR+ T cells
223556697|NCT02269553|DEVICE|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
223556698|NCT02269553|DEVICE|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
223556699|NCT02991495|BIOLOGICAL|Stamaril, Sanofi Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
223556700|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Bio-Manguinhos|"1. Full dose~2. Fractional dose: one fifth (1/5)"
223556701|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|"1. Full dose~2. Fractional dose: one fifth (1/5)"
223556702|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
223556703|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
224023519|NCT04953104|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223556704|NCT02991495|BIOLOGICAL|Yellow fever vaccine, Chumakov Institute|"1. Full dose~2. Fractional dose: one fifth (1/5)"
223556705|NCT03069833|DIAGNOSTIC_TEST|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
224023520|NCT04953104|BIOLOGICAL|Nivolumab|Given IV
224023521|NCT04953104|DRUG|Relatlimab|Given IV
224023522|NCT06790966|COMBINATION_PRODUCT|Combination Treatment of PDS0101 and Pembrolizumab|"* Pembrolizumab (IV) every 3 weeks for up to 35 Cycles~* PDS0101 (SC) during Cycles 1, 2, 3, 4, and 12"
224023523|NCT06790966|DRUG|Pembrolizumab Monotherapy|Pembrolizumab (IV) every 3 weeks for up to 35 cycles.
224297849|NCT01678651|PROCEDURE|Stimulation with human FSH|Human FSH
224297850|NCT01678651|PROCEDURE|Stimulation with recombinant FSH|Recombinant FSH
223406668|NCT06342375|OTHER|Outbound phone call|Participants will receive either a live or pre-recorded outbound phone call
224023524|NCT04786574|DRUG|Tolvaptan (OPC-41061)|Tolvaptan suspension will be administered orally or via nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 2 years.
224023525|NCT00336752|PROCEDURE|non operative treatment|non operative treatment -casting for 6 weeks
223406669|NCT05863195|BIOLOGICAL|Bevacizumab|Given IV
223556706|NCT02296710|PROCEDURE|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
223556707|NCT06814301|DIAGNOSTIC_TEST|Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV|A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with Letermovir
223556708|NCT06814301|DIAGNOSTIC_TEST|Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV|A first determination will be made pre-HCT, followed by subsequent determinations at +30, +60, +90, +120, +150, +180, and +200 days post-HCT, as well as at the end of prophylaxis with LTV
224023526|NCT00336752|PROCEDURE|operative treatment of ankle fractures|operative treatment of ankle fractures
224132807|NCT05097248|DRUG|Losartan|Losartan will be orally administered at 50 mg for three days and increased to 100 mg if tolerated until the whole course of chemotherapy; if not tolerated, it will be maintained at 50 mg until the whole course of chemotherapy
224132808|NCT00884052|DRUG|Low dose levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
224132809|NCT00884052|DRUG|High dose levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
224132810|NCT00839423|DRUG|Placebo|capsules, daily, orally
224132811|NCT00839423|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
224132812|NCT00839423|DRUG|Venlafaxine XL|capsules, daily, orally
224132813|NCT03569306|DEVICE|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
224132814|NCT03569306|DEVICE|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
224132815|NCT03831815|DRUG|Cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
224132816|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
224132817|NCT00975429|DRUG|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
224132818|NCT04303793|DEVICE|Percutaneous PDA closure|transcatheter patent ductus arteriosus closure
224023527|NCT04840589|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
224023528|NCT04840589|PROCEDURE|Biopsy Procedure|Undergo a biopsy
224023529|NCT04840589|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224138840|NCT01076842|DEVICE|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
224138841|NCT01076842|DEVICE|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
223406670|NCT05863195|BIOLOGICAL|Cetuximab|Given IV
223406671|NCT05863195|PROCEDURE|Computed Tomography|Undergo SPECT/CT and/or CT
223406672|NCT05863195|DRUG|Floxuridine|Given via HAI pump
223406673|NCT05863195|DRUG|Fluorouracil|Given IV
223406674|NCT05863195|PROCEDURE|Implantation|Undergo surgery to place the HAI pump
223406675|NCT05863195|PROCEDURE|Intrahepatic Infusion Procedure|Undergo HAI
223406676|NCT05863195|DRUG|Irinotecan|Given IV
223406677|NCT05863195|DRUG|Leucovorin|Given IV
223406678|NCT05863195|DRUG|Oxaliplatin|Given IV
223406679|NCT05863195|BIOLOGICAL|Panitumumab|Given IV
223406680|NCT05863195|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223406681|NCT03331796|DEVICE|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
223556709|NCT04116437|DRUG|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily or 320mg once daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
223556710|NCT01114087|DRUG|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
223556711|NCT04859101|OTHER|Gum|2 minutes of gum chewing prior to procedure
223556712|NCT04859101|OTHER|Control|2 swallows prior to procedure
224023530|NCT04840589|PROCEDURE|Computed Tomography|Undergo a CT scan
223406682|NCT03331796|DEVICE|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
223406683|NCT03331796|DEVICE|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
223406684|NCT00726193|DEVICE|OsteoGen|OsteoGen Implatable stimulator
223406685|NCT03228888|OTHER|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
223406686|NCT06199284|DEVICE|Atalante exoskeleton|The gait training program using Atalante exoskeleton consisted of 3 sessions per week for 6 weeks. For each participant, the assistance of the exoskeleton can be specifically adjusted and can be set symmetrically or asymmetrically bases on his capabilities.
223406687|NCT01753570|DRUG|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
223406688|NCT01753570|DRUG|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
223406689|NCT01753570|DRUG|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
223406690|NCT01753570|DRUG|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
223406691|NCT01753570|DRUG|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
223406692|NCT02841761|DRUG|Midalozam|Syrup for oral use
223406693|NCT02841761|DRUG|Aprocitentan|Capsules for oral use
223406694|NCT04744025|DEVICE|Microfluidics chamber|Unwashed sperm will be placed into the inlet chamber of the microfluidics device. The most motile sperm will swim to the outlet chamber, and these sperms will be used for intracytoplasmic sperm injection (ICSI) into the eggs.
223556713|NCT04185077|DRUG|Bivalirudin|Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
223556714|NCT04185077|DRUG|Heparin|a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
223737733|NCT03620136|DRUG|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
223737734|NCT06330805|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
223737735|NCT06330805|OTHER|Contrast Agent|Given IV
224138842|NCT02702427|BIOLOGICAL|virus-specific T-Cells|infusion
224138843|NCT03176797|DIAGNOSTIC_TEST|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
224138844|NCT05799443|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
223406695|NCT04744025|OTHER|Density Gradient Centrifugation|Sperm will be washed and centrifuged according to standard protocol, and these washed sperm will be used for ICSI.
223406696|NCT01000155|DRUG|vorinostat|
223406697|NCT03303235|DRUG|Methylergonovine|IV vs IM
223406698|NCT03193684|DRUG|Empagliflozin 25 MG|subjects will receive daily dose of 25mg of empagliflozin for 3 months
223406699|NCT03193684|DRUG|Control|Placebo
223406700|NCT00537849|DEVICE|Sonablate 500(SB-500)|
223406701|NCT06263933|OTHER|Insight Scale|Before the patient was in DIPEM or control group and after the patient is involved in DIPEM or control group
223406702|NCT06263933|OTHER|Semi-directional interviews|"In the end of the intervention. In the end of DIPEM Or in the end of control group.~This intervention will be held after one month of hospitalization."
223406703|NCT06263933|OTHER|routine care|routine care
223406704|NCT06263933|OTHER|session of mutual assistance with a mediator psychologist|session of mutual assistance with a mediator psychologist
223406705|NCT02052024|DRUG|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
223406706|NCT02052024|DRUG|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
223406707|NCT03569410|BEHAVIORAL|increased protein intake via natural foods|Patients had to eat 1.4g/kg/day of natural protein.
223556715|NCT01489865|DRUG|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
223737736|NCT06330805|DRUG|Leuprolide|Given injection
224023531|NCT04840589|BIOLOGICAL|Ipilimumab|Given IV
224023532|NCT04840589|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224023533|NCT04840589|BIOLOGICAL|Nivolumab|Given IV
224023534|NCT04840589|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
224023535|NCT04840589|PROCEDURE|X-Ray Imaging|Undergo x-ray
224023536|NCT06506344|BEHAVIORAL|5S Trial|Participants will receive caring contacts/recruitment outreach, suicide risk screening, suicide safety planning, and, if indicated, connection to healthcare services, resources and the CLASP virtual outreach intervention.
223737737|NCT06330805|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223737738|NCT06330805|OTHER|Physical Performance Testing|Undergo functional fitness tests
223737739|NCT06330805|DRUG|Relugolix|Given PO
223737740|NCT00003010|DRUG|marimastat|
223737741|NCT04267133|DIAGNOSTIC_TEST|Facial video of detection of cardiac disease|This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).
224132819|NCT04348656|BIOLOGICAL|Convalescent plasma|Patients will receive 500 mL of convalescent plasma (from one single-donor unit of 500 mL or 2 units of 250 mL from 1-2 donations) collected by apheresis from donors who have recovered from COVID-19 and frozen (1 year expiration date from date of collection). The plasma unit will be thawed as per standard blood bank procedures and infused into the patient slowly over 4 hours. When administering 2 units of 250 mL, the 2nd unit will be administered after the first, and no longer than 12 hours later. The patient will be monitored for adverse events as per each site's policies.
223406708|NCT03569410|BEHAVIORAL|increase protein intake via protein supplements|Patients ate enough protein supplements in addition to their regular diet to reach eat 1.4g/kg/day of protein intake.
224132820|NCT06352099|DIETARY_SUPPLEMENT|Dietary supplement with micronised diosmin, hesperidin and herbal extracts|Taking a dietary supplement with micronised diosmin, hesperidin and plant extracts 1 or 2 sticks per day, as per the study design.
224132821|NCT01935362|DIETARY_SUPPLEMENT|Citrus supplement|
223406709|NCT03480490|DIAGNOSTIC_TEST|Pleural fluid C-reactive protein|"C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.~The pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.~Pleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.~c-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.~Pleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion."
223406710|NCT00720213|DEVICE|Respironics BiPAP autoSV2|Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
224132822|NCT01935362|DIETARY_SUPPLEMENT|Placebo|
224132823|NCT03248245|OTHER|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
224132824|NCT03248245|OTHER|TAU|Ordinary practices related to interprofessional team collaboration
223406711|NCT00720213|DEVICE|Respironics BiPAP autoSV3|Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
223406712|NCT05410665|PROCEDURE|Standard treatments for sepsis|Standard treatments for others
223556716|NCT04780802|PROCEDURE|The balloon catheter is placed at the various arterial feeders of the tumor|use of a balloon catheter for providing balloon occlusion, in addition to the standard microcatheter for drug delivery, both catheters are to be placed in parallel through a single guide catheter. Only one arterial puncture wound is involved. The inflated balloon provides temporary occlusion of all arterial tumor feeders except for the one which is selectively catheterized with a microcatheter for delivery of the therapeutic agent. The therapeutic agent consists of Lipiodol mixed with a chemotherapeutic drug, it is delivered through the microcatheter under fluoroscopic control.
223556717|NCT06658938|DRUG|Blinatumomab|"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"
223556718|NCT06658860|PROCEDURE|Modified Socket Shield Technique|The modified socket shield technique involves partial retention of the buccal aspect of the tooth root during extraction to preserve the surrounding alveolar bone and soft tissue. This technique is used to optimize the condition for delayed implant placement by preventing resorption of the alveolar ridge.
223556719|NCT06658860|PROCEDURE|Conventional Tooth Extraction|Conventional tooth extraction involves the complete removal of the tooth without the use of the socket shield technique. This arm served as the control group, with alveolar ridge changes observed and compared with those in the experimental arm over time.
223556720|NCT06662396|DRUG|MK-6552|Oral Gelatin Coated Capsule
223556721|NCT06662396|DRUG|Diltiazem|Oral Extended-Release Capsule
223556722|NCT06661863|PROCEDURE|alveolar ridge preservation with bioactive glass|Bioactive glass grafted into alveolar preservation.
223737742|NCT06555848|DEVICE|CERAMENT G|CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.
223737743|NCT05407480|OTHER|Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome
223737744|NCT06133413|DEVICE|Body Comp Pro connected scale (Withings manufacturer)|Use once a week
223737745|NCT06133413|OTHER|Alert generation by remote plateform|Alert will be generated from weight regain \> 5% of baseline weight
223737746|NCT04423484|OTHER|Data collection|Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
224132825|NCT05764356|GENETIC|Detection of genotype and RNA profile in platelet and white blood cell|Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing
223406713|NCT02462798|OTHER|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
223406714|NCT02462798|OTHER|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
224132826|NCT05764356|OTHER|Indicators test related to coagulation function|Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.
223406715|NCT02092298|DRUG|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
223406716|NCT02092298|DRUG|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
223406717|NCT02092298|DRUG|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
223406718|NCT00620945|DRUG|Phenoxybenzamine|"Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~* For patients with obstructing lesions on systemic side:~  * 0.25 mg/kg dose in the bypass circuit~ * None intravenous~* For patients without obstructing left sided lesions:~  * 0.5 mg/kg in the bypass circuit~ * 0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~* 0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~* 0.3 mg/kg P.O. every 8 hours for next 24 hours~* 0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~* Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
223556723|NCT06661863|PROCEDURE|alveolar ridge preservation with autologous bone|Autologous bone graft in alveolar ridge preservation.
223406719|NCT01808066|DEVICE|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
223406720|NCT00920439|BIOLOGICAL|PoliorixTM|Single dose, intramuscular administration.
223556724|NCT06661811|DRUG|CAR-T|CAR-T cells
223556725|NCT06661200|DEVICE|SMC signal recording|SMC recording involves collecting vibrations from the thorax using an antenna equipped with piezoelectric crystals. Subjects face the machine or stand with their backs to the machine, shirtless. Acquisitions last around ten seconds.
223556726|NCT06660966|PROCEDURE|M TAPA block|Grup M: The patients who underwent M-TAPA block were placed in the supine position. The right upper quadrant of the abdomen was cleaned with antiseptic solution. For the block procedure, 20-30 ml of 0.25% bupivacaine, 22G 8.5 cm stimuplex needle and 10-14 Hz high frequency USG were prepared for the procedure. The USG probe was determined in the costochondral area at the mid-clavicular line, and the internal and transversus abdominis muscles were determined. The needle was advanced with the in plane technique from cephalad to caudal, passing through the skin, subcutaneous, external and internal oblique muscles, respectively, and then over the transversus abdominis fascia. After the target was confirmed with 2 ml of saline, 0.3 mg / kg bupivacaine (20-30 ml) was administered.
223556727|NCT06660966|PROCEDURE|ESP block group|"In Group E, patients who were to undergo ESP block were placed in the lateral position with the right side up. The T8-T10 dorsal region was cleaned appropriately with antiseptic solution. For the block procedure, 20-30cc %0.25 bupivacaine, 22G 8.5cm stimuplex needle and 10-14Hz high frequency USG were prepared for the procedure.~The USG probe is first determined in the sagittal direction, the spinous process of the T10 thoracic vertebra is then followed 1-2 cm above the transverse process, with the in plane technique, the skin, subcutaneous tissue and erector spina muscle are passed, the needle is touched to the transverse process and the target is confirmed with 2cc saline, then 20-30 cc (0.5 mg / kg bupivacaine) of local anesthetic is administered and the procedure is terminated."
223556728|NCT06658639|DEVICE|Ultrasound lipolysis|Ultrasound lipolysis uses a Luvitra device to emit low-frequency ultrasound pulsed waves. The abdominal area is divided into two sections and the patient is placed in a comfortable supine lying position. The cavitation head is applied slowly to each segment in small circular movements. The treatment lasts 30 minutes on each side, with each session lasting 60 minutes. The same abdominal area is treated every two weeks for three months. The procedure involves cleaning the skin with alcohol cotton.
223556729|NCT06658639|DEVICE|Cryolipolysis|The study utilized Lipocool, a cryolipolysis apparatus from Korea, with a thermoelectric cooling element. Participants were treated with thermal coupling gel on their abdomen, and the tissue was drawn into the applicator with a moderate vacuum. The device was used for 40-50 minutes, with energy extraction controlled by sensors. The system stopped cold exposure and the clinician released the vacuum. Participants underwent cryolipolysis sessions every 2 weeks for 3 months.
223556730|NCT06658639|OTHER|Low Caloric Diet|A low-calorie diet is a structured plan that restricts daily caloric intake, often used for weight loss. It involves consuming 1,200 to 1,500 calories daily, creating a calorie deficit. However, it requires discipline and safety. The diet is low in fat (20-25%), high in complex carbohydrates (60%), and sufficient in protein (25-50%).
223556731|NCT06661499|OTHER|establish an artificial neural network model|to establish an artificial neural network model for pathogen diagnosis in ICU pneumonia
223737747|NCT05700981|DIAGNOSTIC_TEST|colon capsule endoscopy|Patient allocated for the intervention arm will have a CCE using the PillCam Colon 2 (Medtronic, Minneapolis, Minnesota, USA). Upon inclusion and allocation to the intervention arm patients are contacted by a dedicated CCE nurse. The course of the CCE procedure and preparations are explained thoroughly. In case of additional questions patients can contact the nurses by telephone during office hours (Monday-Friday, 8am-3pm). Before the CCE participants will have to undergo a bowel preparation procedure. The bowel preparation kit will be distributed by mail and is to be completed at home, beginning 72 hours before the CCE. The kit contains polyethylene glycol (PEG) sachets (Movicol, Norgine Danmark A/S, Herlev, Denmark), PEG solutions (MoviPrep, Norgine Danmark A/S, Herlev Denmark) and instructions on how to properly perform the preparation procedures.
224132827|NCT05764356|OTHER|Indicators test related to platelet function|Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.
224132828|NCT00757770|BIOLOGICAL|Rotarix|Two oral doses.
224132829|NCT00757770|BIOLOGICAL|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
223737748|NCT06413797|BEHAVIORAL|FDA warnings + Image|For six days (days 2-7) participants will be contacted and asked to complete a daily survey. As part of the survey, participants will view FDA-proposed LCC warnings with images at 30% size on a cigarillo package. Participants will be contacted each day to be invited to complete the survey for that day of the study protocol.
224023537|NCT02783664|OTHER|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
224132830|NCT02529293|DRUG|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
224132831|NCT02529293|DRUG|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
224132832|NCT03831802|DEVICE|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
224132833|NCT03831802|DEVICE|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
224132834|NCT04966195|RADIATION|stereotactic body raiotherapy|stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
224138845|NCT05799443|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days.
223406721|NCT04997330|DEVICE|Active rTMS|Bilateral high frequency (20Hz) rTMS will be delivered (over dorsolateral prefrontal cortex), at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive days on working day, 1500 pulses/session, 110% of motor threshold determined, 30 trains, 50 pulses per train and 15s inter train. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
223406722|NCT04997330|DEVICE|Sham rTMS|Sham rTMS will be delivered (over dorsolateral prefrontal cortex) , at two daily sessions (left side on the morning and right side on the afternoon), 10 consecutive working days. A session will typically last around 10 minutes. Alcohol cues consisted of a selection of 60 alcohol-related pictures (beverage, drinking-related behaviors, alcohol-related cues) from the Geneva Appetitive alcohol Pictures will be presented during each rTMS session.
223406723|NCT02266784|BEHAVIORAL|Contingency Management (CM)|
223406724|NCT02266784|DRUG|Transdermal nicotine skin patches (i.e. Habitrol)|
223406725|NCT02266784|OTHER|Supportive Counseling|
223406726|NCT04418557|DIAGNOSTIC_TEST|RT-PCR and antibody testing|Testing of amniotic fluid, cord blood, amnion and chorion, umbilical cord, vaginal mucous, maternal and neonatal sera, neonatal throat swab, and breast milk.
223406727|NCT01252095|DRUG|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
223406728|NCT01420068|DRUG|SPP100|
223406729|NCT04570839|DRUG|COM701 in combination with BMS-986207 and nivolumab.|Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
223406730|NCT03088202|OTHER|Educational program|E-learning lectures, group exercises, skills training
223406731|NCT03088202|OTHER|Standardized care pathways|Pathways for systematic follow-up
223406732|NCT03088202|OTHER|Early palliative care|Compulsory referral to palliative care at inclusion
223406733|NCT01935141|PROCEDURE|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
223406734|NCT01935141|DEVICE|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
223406735|NCT01935141|DRUG|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
223406736|NCT05060536|PROCEDURE|Removal of infrapatellar fat pad|"There is no agreed protocol for retaining or excising the infrapatellar fat pad with many surgeons routinely completely removing the fat pad to improve view of the proximal tibia while others opt to retain or minimally excise the tissue.~We are aware of no risks involved in performing this procedure and current practice of many orthopaedic surgeons is either to routinely remove or routinely retain the infrapatellar fat pad when performing total knee arthroplasty.~The potential benefits are that we will understand better whether removing or retaining this tissue does have a role in influencing outcomes after total knee replacement surgery. The results will be disseminated to the wider orthopaedic community to inform practice with the aim or improving outcomes from total knee arthroplasty."
223406737|NCT05060536|PROCEDURE|No removal of infrapatellar fat pad|Retaining the infrapatellar fat pad during total knee replacement- no surgical removal.
223406738|NCT00180882|DRUG|rituximab|
223406739|NCT03034980|OTHER|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
223406740|NCT03469700|OTHER|general anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
224023538|NCT05945602|OTHER|Neurophysiologic Biomarker Assessments|Non-invasive electroencephalography will be recorded to derive neurophysiologic biomarkers.
224132835|NCT03072719|DRUG|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
223406741|NCT03469700|OTHER|Paravertebral block|Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
223406742|NCT03469700|OTHER|Placebo PVB|Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
223406743|NCT02554682|BEHAVIORAL|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.
223406744|NCT02554682|BEHAVIORAL|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
223556732|NCT06660797|OTHER|Group1: A matching gutta-percha master cones will be used in up and down motion 2mm amplitude at a frequency of 100 strokes during approximately 1 min in each prepared canal.|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by matching gutta percha master cone , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
223556733|NCT06660797|OTHER|Group2: XP-endo Finisher activation: The XP-endo Finisher instrument will be used in continuous rotation for 1 mintute|The first microbial sample (S1) will be taken from the root canal immediately after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by XP-endo Finisher used in continuous rotation for 1 minute , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
223556734|NCT06660797|OTHER|Group 3:EasyClean system activation : EC instrument coupled to the countrangle handpiece and operated with a micromotor at approximately 20,000 rotations per minute in continuous rotation.|after access cavity preparation and before chemomechanical preparation.Samples will be subjected to bacterial viable count using blood agar. After complete chemomechanical preparation, a second microbial samble (S2) will be taken and managed the same way as S1.After irrigation activation protocol by EasyClean system activation , S3 will be collected from each root canal and managed as S1, S2 to evaluate effect of activation techniques on microbial reduction ,canals will be dried with a matching paper point then 1 mL of Iohexol (omnipaque) contrast media will be injected 2mL shorter than WL and activated by a matching gutta percha master cone , a digital radiographic image will be obtained for each tooth with the same angulation as that for WL and then the distance between WL and maximum irrigant penetration will be measured and recorded using SIDEXIS-XG software.
223556735|NCT06078527|DEVICE|Cheung-Bearelly Aesthesiometer|The Cheung-Bearelly Aesthesiometer will be used to deliver a range of calibrated stimuli through the channeled flexible laryngoscope to assess sensation of the laryngopharynx.
223737749|NCT06413797|BEHAVIORAL|FDA Warnings Text-Only|Participants will receive messages including images in 30% size.
224132836|NCT03072719|DRUG|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
223406745|NCT02554682|BEHAVIORAL|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
223406746|NCT03137641|OTHER|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
223556736|NCT06078527|PROCEDURE|Transnasal Laryngoscopy|A procedure to examine your larynx (voice box)
223556737|NCT06078527|OTHER|Questionnaires|Patient-reported health and behavioral outcomes measures will be administered
223737750|NCT06413797|BEHAVIORAL|Surgeon General Text-Only Warnings|Participants will receive messages including Surgeon General Text-only Warnings.
223737751|NCT03348345|BEHAVIORAL|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
223737752|NCT06183398|OTHER|Skin prick test|Specific skin prick tests for 6 raw food: peach, apple, sesame, carrot, lemon and orange
223737753|NCT02913547|DEVICE|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
224023539|NCT06300385|DEVICE|Electromyostimulation|Electromyostimulation (EMS), a low-frequency current, will be used for electrical stimulation of the wrist flexor muscle group. Stimulation frequency will be applied as 25 Hertz. Care will be taken to ensure that the current intensity does not cause pain in the patient. The size of the EMS electrodes is 2 cm2 and they will be placed in the form of 4 electrodes on the wrist flexor muscles (inner wrist area) with a distance of 1 cm between them. Each strengthening session will be 15 minutes for 6 weeks, 3 days a week, for a total of 18 sessions. EMS application will be carried out together with strengthening exercises. Laica MD6078 branded device belonging to the researchers will be used.
224132837|NCT00279968|DEVICE|ICD|
223737754|NCT03914040|OTHER|IPSE program|"1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
223737755|NCT02773927|DRUG|Metformin|Metformin in tablet presentation of 500 mg
223737756|NCT02773927|DIETARY_SUPPLEMENT|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
223737757|NCT02773927|OTHER|Placebo of agave inulin|Calcinated magnesia powder
223737758|NCT02773927|OTHER|Metformin placebo|Calcinated magnesia tablet
223737759|NCT05171283|OTHER|Oats or Oat Fibre|Interventions that contain whole grain oats or oat beta-glucan.
224023540|NCT06300385|OTHER|Strengthening exercises|All participants will do resistance exercises for strengthening, 3 sessions per week for 6 weeks. Each movement will be performed in 3 sets and 12 repetitions according to the planned intensity. Wrist curl, reverse wrist curl movements (with 10kg dumbbells) and power web flex grip movements will be applied simultaneously with EMS application. The program will last 15 minutes in total.
224023541|NCT05273853|PROCEDURE|Partial Adenoidectomy|Partial removal of adenoid
224023542|NCT02146651|DRUG|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
224023543|NCT02146651|DRUG|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
224023544|NCT02146651|DRUG|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
224023545|NCT02146651|DRUG|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
224132838|NCT05337527|DIETARY_SUPPLEMENT|beetroot juice|Acute effects of beetroot juice or placebo juice ingestion
224132839|NCT04115046|DEVICE|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
224132840|NCT04115046|DEVICE|FibroScan|manufactured by Echosens
223406747|NCT00758290|DRUG|Triclosan/Fluoride|Brush twice daily for 3 weeks
223406748|NCT00758290|DRUG|Fluoride/triclosan|Brush daily for 3 weeks
223406749|NCT04505657|DRUG|celecoxib plus lidocaine|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
223737760|NCT00372931|DRUG|AL-37807|
223737761|NCT00939276|DRUG|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
223737762|NCT00939276|DRUG|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
223737763|NCT01354847|DEVICE|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
223737764|NCT00343200|DRUG|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
224023546|NCT03882034|DRUG|Pegvisomant|A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer's recommendations. Adjustment of the dose will occur as per protocol.
224023547|NCT03184870|DRUG|BMS-813160|Specified dose on specified days
224023548|NCT03184870|BIOLOGICAL|Nivolumab|Specified dose on specified days
224023549|NCT03184870|DRUG|Nab-paclitaxel|Specified dose on specified days
224023550|NCT03184870|DRUG|Gemcitabine|Specified dose on specified days
224023551|NCT03184870|DRUG|5-fluorouracil (5-FU)|Specified dose on specified days
224023552|NCT03184870|DRUG|Leucovorin|Specified dose on specified days
224023553|NCT03184870|DRUG|Irinotecan|Specified dose on specified days
224023554|NCT06127407|DRUG|Ivosidenib 500mg|Provided as tablets, taken orally as two 250mg tablets once daily.
224023555|NCT06127407|DRUG|Placebo|Provided as tablets, taken orally once daily.
224023556|NCT05564117|DRUG|Semaglutide|Semaglutide tablets orally once daily for 64 weeks.
224132841|NCT04115046|DEVICE|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
223406750|NCT04505657|DRUG|Celecoxib|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
223406751|NCT04505657|DRUG|lidocaine|placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
223406752|NCT03225469|BEHAVIORAL|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
224023557|NCT05564117|DRUG|Placebo semaglutide|Semaglutide placebo-matching tablets orally once daily for 64 weeks.
224023558|NCT04743310|DRUG|tozuleristide|tozuleristide 24 or 36 mg administered intravenously 1-24 hours prior to surgery
224023559|NCT04743310|DEVICE|Canvas imaging system|imaging device attached to surgical microscope
224138846|NCT05799443|DRUG|cetuximab|cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days.
224138847|NCT05799443|RADIATION|SBRT|8-10Gy×5F，QOD
224138848|NCT03364426|OTHER|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
224138849|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
224023560|NCT04743310|PROCEDURE|Surgical resection of tumor|Standard of care surgical resection of tumor
223406753|NCT00884117|DRUG|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
223406754|NCT04948502|DEVICE|SaExten vena cava filter system|Subjects will undergo intervention, be implanted with a SaExten filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
223406755|NCT04948502|DEVICE|Denali inferior vena cava filter|Subjects will undergo intervention, be implanted with a Denali filter. The filter will be retrieved within 90 days or indwelled permanently, depending on the existence of thrombosis and the evaluation of the physician.
223406756|NCT04593485|DRUG|Camrelizumab for injection|Carrelizumab will be administered at a fixed dose
223406757|NCT01699373|PROCEDURE|Ultrasound scan|Pre-procedural ultrasound scan was performed
223406758|NCT01822730|DRUG|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
223406759|NCT01822730|DRUG|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
223406760|NCT04863001|DRUG|Antiarrhythmic drug|all classes of antiarrhythmic drugs used in pediatrics cardiology unit assiut university
223406761|NCT04698044|DIAGNOSTIC_TEST|Hospital Anxiety Depression Scale|HADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnessesHADS is a self-report questionnaire designed to screen the symptoms of anxiety and depression in individuals with medical diseases other than psychiatric illnesses The 4-point Likert type scale, which consists of 14 items, has 2 subscales. Each of the HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) subscales has 7 items. The score given for each question varies between 0 and 3. A high score indicates a high level of anxiety and depression. The responses given to the questions are given certain scores, and as a result, a score of 0-7 refers to a normal level, 8-10 to a level at the limit and 11 and above to a high level (abnormal level).
223406762|NCT00497523|DRUG|Beclomethasone dipropionate|
223406763|NCT00497523|DRUG|Beclomethasone dipropionate/Salbutamol combination|
223406764|NCT00497523|DRUG|Salbutamol|
223406765|NCT04830969|DRUG|Chlorhexidine gluconate oral rinse|Paroex® is a non-alcohol chlorhexidine preparation. Participants are to use 15 mL morning and evening for 3 months. With use of chlorhexidine, there is risk of reversible staining of teeth and the possibility of some alteration in taste. There is increased likeliness of staining in smokers, coffee drinkers and those who are susceptible to teeth staining in general. The cleaning of the front teeth is provided at the 3-month visit and helps to reduce any staining that may occur. If there is any alteration in taste, it should go away when use of chlorhexidine stops.
223406766|NCT04830969|PROCEDURE|Scaling & Root Planing|SRP is standard treatment of periodontitis. It involves using a scaler to remover subgingival plaque and other debris in the space between teeth and gums.
223556738|NCT05978674|BEHAVIORAL|rocking bed group|Babies assigned to the intervention group first will be placed on a rocking bed after routine care such as feeding and diaper changes and when the newborn is stable. A rocking attempt will be applied to the baby placed in the rocking bed for 30 minutes. After 30 minutes, the baby will not be lifted from the bed and will lie in bed for 90 minutes. After a period of two hours in total, the babies will be cared for and fed. Then, babies will be quota and control group measurements will be made.
224023561|NCT02978144|DRUG|AxV-128/Tc|Study drug 99mTc-Annexin V-128 (AxV-128/Tc) is administered intravenously prior to SPECT/CT imaging.
224023562|NCT04396236|DRUG|Lasmiditan|Administered orally
223406767|NCT04830969|DEVICE|Soft Picks|Soft Picks are a rubber interdental bristle cleaner. Participants are to use Soft Picks morning and evening for all 12 months of the study. They may cause some bleeding of the gums at first usage, but the bleeding should lessen and stop as use is continued (as gums heal). Soft-Picks are a readily available consumer product sold in supermarkets and drug stores.
223406768|NCT06041451|DRUG|Intravenous Immunoglobulins, Human|patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
223406769|NCT06041451|DRUG|Methylprednisolone 500 MG Injection|patients were treated with methylprednisolone
223406770|NCT03529513|DIAGNOSTIC_TEST|Medibio Depression Diagnostic Aid|The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
223406771|NCT03529513|DIAGNOSTIC_TEST|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
223556739|NCT01821066|DRUG|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
223556740|NCT01821066|DRUG|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
223556741|NCT01821066|DRUG|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
223556742|NCT01821066|DRUG|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
223556743|NCT02106572|DRUG|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
224023563|NCT04396236|DRUG|Placebo|Administered orally
224023564|NCT04396574|DRUG|Lasmiditan|Administered orally
224023565|NCT03786783|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
224023566|NCT03786783|DRUG|Carboplatin|Given IV
224023567|NCT03786783|DRUG|Cisplatin|Given IV
224023568|NCT03786783|DRUG|Cyclophosphamide|Given IV
224023569|NCT03786783|DRUG|Dexrazoxane|Given IV
224023570|NCT03786783|BIOLOGICAL|Dinutuximab|Given IV
224023571|NCT03786783|DRUG|Doxorubicin|Given IV
224023572|NCT03786783|DRUG|Etoposide|Given IV
224023573|NCT03786783|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224023574|NCT03786783|DRUG|Isotretinoin|Given PO
224023575|NCT03786783|DRUG|Melphalan|Given IV
224023576|NCT03786783|BIOLOGICAL|Sargramostim|Given SC
224023577|NCT03786783|DRUG|Thiotepa|Given IV
224023578|NCT03786783|DRUG|Topotecan|Given IV
224023579|NCT03786783|DRUG|Vincristine|Given IV
224023580|NCT06439277|DRUG|Tirzepatide|Administered SC
224023581|NCT06439277|DRUG|Placebo|Administered SC
224023582|NCT04587128|DRUG|Panitumumab|Epidermal growth factor receptor inhibitor, anti-neoplastic
224023583|NCT04587128|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor, anti-neoplastic
224023584|NCT04587128|DRUG|Irinotecan|anti-neoplastic, chemotherapy drug
223406772|NCT03529513|DIAGNOSTIC_TEST|Hamilton Rating Scale for Depression - 17 Item|The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
223406773|NCT00290953|DRUG|SR48692|
223406774|NCT06509633|OTHER|Pain Neuroscience education and standard rehabilitation regime|Median nerve gliding exercises, wrist and forearm muscle stretches, wrist mobilizations and finger joint mobilizations
223406775|NCT06509633|OTHER|standard Rehabilitation regime|standard Rehabilitation regime
223406776|NCT05799833|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)|4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.
223406777|NCT01004497|DRUG|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
223406778|NCT01004497|DRUG|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
223406779|NCT01004497|DRUG|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 \& 11
223406780|NCT01004497|DRUG|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 \& 11
223406781|NCT01004497|DRUG|Dexamethasone|40 mg/day, IV push, days 1-4 \& days 11-14
224023585|NCT04587128|DRUG|FOLFIRI Protocol|folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab
224023586|NCT04587128|DRUG|Bevacizumab|Bevacizumab (or biosimilar) may be administered with FOLFIRI per treating MD discretion and will be given per institutional standard (5 mg/kg intravenously day 1 and day 15 of 28 day cycle)
224023587|NCT03036488|BIOLOGICAL|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
224138850|NCT01981967|BIOLOGICAL|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
223406782|NCT01004497|DRUG|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
223406783|NCT01004497|DRUG|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
223406784|NCT06577974|DRUG|Combined contraceptive pills (Yasmin)|medical pretreatment prior to ICSI
223737765|NCT00343200|DRUG|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
223406785|NCT03171805|DRUG|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
223406786|NCT01677468|PROCEDURE|Intermediate embolization|TACE with substasis using gelfoam
223406787|NCT01677468|PROCEDURE|Complete embolization|TACE with complete embolization using gelfoam
223737766|NCT05009940|DEVICE|Graduated compression stockings|Both GraduSOX and Sigvaris are graduated compression stockings. These exert the greatest degree of of compression at the ankle, and the level of compression gradually decreases up the garment.
223406788|NCT05574218|PROCEDURE|Glycine air powder|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with glycine powder air-polishing.
223406789|NCT05574218|PROCEDURE|Rubber cup polishing|Every 3 months, ultrasonic instrumentation was carried out with an specific implant tip coated with Polyether Ether Ketone (PEEK), activated subgingivally and circumferentially around the implant. Then, the implants were treated with rubber cup and a polishing paste.
223406790|NCT02473939|DRUG|VR942 delivered via a Vectura Dry Powder Inhaler|
223406791|NCT02473939|DRUG|Placebo delivered via a Vectura Dry Powder Inhaler|
223737767|NCT03667560|PROCEDURE|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
223737768|NCT03667560|PROCEDURE|FlexHD|Patient will be implanted with FlexHD.
224023588|NCT03036488|DRUG|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
224023589|NCT03036488|DRUG|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
224023590|NCT03036488|DRUG|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
224023591|NCT03036488|DRUG|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
224023592|NCT03036488|DRUG|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
224023593|NCT03036488|DRUG|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
224023594|NCT03036488|BIOLOGICAL|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
224023595|NCT05062369|DEVICE|TaskFlow Transcranial Electrical Stimulation device|The TaskFlow Transcranial Electrical Stimulation device (TaskFlow-TES) is a custom brain stimulation device developed in-house at the University of Minnesota. Each tDCS intervention will last 20 minutes of either (i) 10 active (2-mA) or (ii) 5 active and 5 sham transcranial direct current stimulation (tDCS) over the course of 10 treatment sessions.
223406792|NCT03464188|BEHAVIORAL|Project Cornerstone|"Project Cornerstone basic elements are:~1. The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~2. 6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~3. Regular caregiver distress thermometer screening and problem support and self-care coaching.~4. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death."
224132842|NCT02218814|PROCEDURE|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
223737769|NCT02350881|DEVICE|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
224132843|NCT02218814|PROCEDURE|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
224132844|NCT05094999|DEVICE|Proprioceptive stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the intervention group will receive proprioceptive stimulations set to create illusions of movement.
224132845|NCT05094999|DEVICE|Sham stimulations|Vibration treatment will last eight weeks for each patient, with 4 sessions per week, 30 minutes per session. Subjects of the control group will receive sham stimulations.
223406793|NCT04856007|DRUG|Dapagliflozin/metformin XR FDC 5/500 mg|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
223406794|NCT04856007|DRUG|Dapagliflozin/metformin XR FDC 10/1000 mg|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
223406795|NCT04856007|DRUG|Dapagliflozin 5 mg + Metformin 500 mg XR|In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.
223406796|NCT04856007|DRUG|Dapagliflozin 10 mg + Metformin 1000 mg XR|In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
224132846|NCT00882999|DRUG|LY2127399|Administered via Injection
224132847|NCT00882999|DRUG|Placebo|Administered via Injection
223406797|NCT03107390|OTHER|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
223406798|NCT05160623|DRUG|Povidone-Iodine 1 % Topical Solution|Povidone-Iodine 1 % topical solution on a makeup remover pad, used to clean the lids and lashes once daily
223406799|NCT05160623|DRUG|Eyelid cleansing wipes|EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
223737770|NCT04516590|OTHER||There was no intervention in this observational study
223737771|NCT05350033|DEVICE|tDCS - tDCS|active-tDCS administered during 10 sessions, in Phase 1 and Phase 2
224132848|NCT01863407|DRUG|DAM|composed of dexamethasone, allantoin and metronidazole
224132849|NCT01863407|DRUG|Normal Saline|Normal Saline 250ml
224132850|NCT06371651|DIETARY_SUPPLEMENT|Supplement|Dietary supplement containing creatine and guanidinoacetic acid
224132851|NCT06371651|DIETARY_SUPPLEMENT|Placebo|Inert substance
224132852|NCT02413619|PROCEDURE|Vitrectomy|Vitrectomy
224132853|NCT02413619|PROCEDURE|Cataract surgery|Cataract surgery
224132854|NCT02413619|PROCEDURE|Combined surgery|Combined vitrectomy and cataract surgery at the same time
224132855|NCT03817567|DRUG|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
224132856|NCT06187116|OTHER|Physiotherapist consultation|The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.
224023596|NCT05062369|BEHAVIORAL|Executive Function Focused Cognitive Training|Working memory focused training occurs on a computer and consists of a variety of exercises selected to (i) place demands on the executive and storage functions of working memory (ii) adapt to challenge the participant's current ability level, (iii) provide ongoing feedback, and (iv) present novel stimuli across verbal, visual and spatial modalities. Training tasks are developed in-house. Tasks for each participant are delivered from and responses, audio, and video are stored on the HST server. The aim of using multiple tasks that require executive functions is to engage brain network functional connectivity in a number of different ways to promote generalization. Investigators will monitor each participant's training and customize the intervention to balance challenge and engagement. In addition, pre- and post-intervention, participants will perform 4-minute versions of a word and a spatial 3-back task identical across all weeks (but differing from the assessment versions).
224023597|NCT05064280|DRUG|Pembrolizumab|Given by IV (200 mg IV D1 Q3W)
224023598|NCT05064280|DRUG|Lenvatinib|Given by PO (20 mg PO QD)
223406800|NCT05376774|OTHER|Admitted to intensive care units|Admitted to intensive care units
223737772|NCT05350033|DEVICE|tDCS - Sham|active-tDCS administered during 5 sessions, in Phase 1
224023599|NCT01269190|PROCEDURE|High-Resolution Microendoscopy|Undergo evaluation of oral lesions using a high-resolution microendoscope
224023600|NCT01269190|PROCEDURE|Multispectral Imaging|Undergo evaluation of oral cavity using a widefield multispectral imaging
224023601|NCT01269190|DRUG|Proflavine|Proflavine) used to stain the mouth tissue after initial imaging.
224023602|NCT03819088|DIETARY_SUPPLEMENT|Zinc|Given PO
224023603|NCT04363801|DRUG|DKN-01 300mg|Administered by IV infusion
224023604|NCT04363801|DRUG|DKN-01 600mg|Administered by IV infusion
223737773|NCT05350033|DEVICE|Sham - tDCS|active-tDCS administered during 5 sessions, in Phase 2
223406803|NCT03546491|DRUG|Preventive Gel|0.4% Stannous Fluoride
223406804|NCT03546491|DRUG|Marketed Control|0.243% Sodium Fluoride
223406805|NCT06575556|DIAGNOSTIC_TEST|Cardiac CT and MRI|"• Cardiac MRI Protocol~The cardiac MRI protocol will include cine imaging, aortic flow, and 3D navigator of the aorta. These sequences will be performed to assess aortic root dimensions, including aortic root, sinuses of Valsalva, and sinotubular junction and ascending aorta diameters.~• CT Aortography Protocol:~The CT aortography protocol will include non-contrast and contrast-enhanced CT imaging. The non-contrast images will be used for calcium scoring, while the contrast-enhanced images will be used to assess aortic root dimensions"
223406806|NCT02284061|OTHER|physical activities adapted to children|
223406807|NCT04106804|DRUG|Abatacept 125 MG/ML|Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months
223406808|NCT04700917|BEHAVIORAL|Cognitive Behavioural Therapy|Internet-Based CBT
223406809|NCT02798380|DRUG|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
223556744|NCT02106572|DRUG|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
223556745|NCT06842381|OTHER|Telerehabilitation Program|A support system for the treatment of cervical pain based on Web technologies will be used, accredited as a health website. This system has a structure based on 4 sections: database treatment, database user profiles, recommendations, and feedback/biofeedback procedures. This system allows the registration and introduction of a subject, and modification of a treatment with electroanalgesia and exercises, according to the symptomatic evolution of the pain. It is based on an initial patient assessment system.
223556746|NCT06842381|OTHER|Face to Face Program|Electroanalgesia therapy and the McKenzie exercise protocol will be applied by six therapists with more than 10 years of experience in both procedures. This program will be developed in the Health Sciences clinical units of the Universities of Almeria, Granada and Malaga.
223556747|NCT06659484|DIAGNOSTIC_TEST|Assessment|"Evaluation carried out during a day hospital at T0 (initial assessment) and T3 (after the exercise program at around 3 months) including:~1. Clinical assessment by a geriatrician~   * Medical history; systematic search for symptomatic elements (asthenia, anorexia, weight loss); research into antecedents (chronic pathologies, etc.), treatments, lifestyle, eating habits, sedentary lifestyle,~  * Complete clinical examination: particularly of the musculoskeletal system, morphological data (weight and height, calf circumference), analysis of risk of falls,~  * Current medical treatments~  * Autonomy for basic activities (ADL), instrumental activities of daily living (IADL), visual disorders, hearing impairment, etc.~  * Assessment of comorbidities (Charlson score)~  * Screening for sarcopenia (using the SARC-F questionnaire),~  * An inventory of falls and their traumatic consequences,~  * Assessment of frailty status using FRIED criteria,~2. Nutritional assessment :~   * nutritional status will also be asses"
223556748|NCT06659484|OTHER|Multicomponent exercise program|"After inclusion in the protocol, participants with mobility disability risk factors are assigned to specialized and experienced kinesiologists at the end of the medical consultation.~Patients will be invited to take part in group-based exercise sessions, in small groups of no more than 10 patients, under the supervision of a kinesiologist. There will be 20 sessions over 10 weeks, at a rate of 2 sessions per week, each lasting one hour. The Multicomponent exercise program included progressive resistance and balance training."
223406810|NCT00054431|DRUG|imatinib mesylate|Given orally
223406811|NCT00054431|DRUG|decitabine|Given IV
223406812|NCT00054431|OTHER|laboratory biomarker analysis|Correlative studies
223556749|NCT06659484|OTHER|Follow-up at T3 + 6 months and T3 + 12 months|"Follow-up at T3 + 6 months :~\- After the T3 visit, patients will either be redirected to independent practice (booklet) or to relay structures. At T3 + 6 months (6 months after the 3-month visit), the kinesiologists will call each patient to assess their compliance with the program, any difficulties encountered, any falls (and their severity and consequences), fear of falling, their level of ADL/IADL autonomy, level of PA practice (RAPA), presence of frailty appreciation (FRIED), whether or not they have entered an institution.~Follow-up at T3 + 12 months :~At T3+12 months (12 months after the 3-month visit), patients will be seen again by the kinesiologists to make a final assessment of their physical and functional conditions, with measurements (Handgrip, SPPB, TUG, gait parameters, leg strength) and questionnaires (SarQol and FES-I).~Patients will only be seen again by the kinesilogists, as this is mainly a check-up and final advice visit, to continue the exercises performed since."
223556750|NCT03823287|DRUG|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
223737774|NCT05350033|DEVICE|Sham - Sham|sham-tDCS administered during 10 sessions, in Phase 1 and Phase 2
223737775|NCT06058767|DIAGNOSTIC_TEST|Otoacoustic Emissions Testing|An OAE (Otoacoustic Emissions) test is a non-invasive, quick, and commonly used hearing screening method. It is a non-behavioral test to access the function of the cochlea, which is the inner ear's sensory organ responsible for detecting sound.
223737776|NCT06058767|DIAGNOSTIC_TEST|Pure Tone Audiometry|The PTA testing is a hearing screening method used to assess an individual's ability to hear pure tones at different frequencies and at different sound levels. It is a behavioral test in which a child is conditioned to perform a play-based task upon hearing sounds at multiple frequencies.
223737777|NCT05338892|OTHER|Non-Interventional|No study treatment will be administered on this study.
223737778|NCT01631877|DRUG|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
223737779|NCT01631877|OTHER|placebo|injection placebo will be given for 5 days along with placebo tablets
223737780|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
223737781|NCT02937649|PROCEDURE|Laparoscopic sleeve gastrectomy using standard care bougie|After gastric mobilization, the standard care bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient is blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
223406813|NCT05836350|DRUG|4.8 g/m^2/day NaPB|12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
223406814|NCT05836350|DRUG|4.8 g/m^2/day placebo|12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
224023605|NCT04363801|DRUG|DKN-01 400mg|Administered by IV infusion
224023606|NCT04363801|DRUG|Tislelizumab 200mg|Administered by IV infusion
224023607|NCT04363801|DRUG|Tislelizumab 400mg|Administered by IV infusion
223556751|NCT03823287|DRUG|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
223556752|NCT03823287|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
223556753|NCT02282072|DEVICE|Deep brain stimulation：PINS Stimulation System|
223556754|NCT06658925|DRUG|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.|Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation.
223556755|NCT01847612|PROCEDURE|indocyanine green fluorescent cholangiography|
223556756|NCT01847612|DRUG|methylene blue|
223556757|NCT07020650|PROCEDURE|Socket preservation|After tooth extraction, the socket will be filled with a collagen plug and bone graft.
223556758|NCT07035015|OTHER|VR UGRA|The simulator applied principles of cognitive task analysis, which is a method aimed at describing the knowledge, cognitive process, and goal structures experts rely upon while performing a complex procedure
223406815|NCT05209568|DIETARY_SUPPLEMENT|Gluten Powder|Single oral dose of gluten powder
223556759|NCT07035015|OTHER|Mannequin-based simulation|The hybrid simulator will consist of a 3G mannequin and a gel-based part-task trainer.
224023608|NCT04363801|DRUG|Oxaliplatin|Administered by IV infusion
224023609|NCT04363801|DRUG|Capecitabine 1000mg/ m2 twice daily (BID)|Administered orally
224023610|NCT04363801|DRUG|Leucovorin Calcium|Administered by IV infusion
224023611|NCT04363801|DRUG|Fluorouracil|Administered by IV infusion
224023612|NCT01285843|PROCEDURE|Anterior Minimally Invasive Approach (AMIS)|
223406816|NCT02170220|DRUG|Vortioxetine|Vortioxetine tablets
223556760|NCT07033442|DRUG|Sevoflurane (Volatile Anesthetic)|Inhalational anesthetic used for maintenance of anesthesia. Administered at 2-3% concentration in a 40% oxygen-air mixture to maintain BIS values between 40-60.
223556761|NCT07033442|DRUG|Propofol 1%|Intravenous hypnotic agent used for induction (2-3 mg/kg) and maintenance (50-150 μg/kg/min) of anesthesia. Titrated to maintain BIS values between 40-60.
223556762|NCT07033442|DRUG|Remifentanil 2 MG|Short-acting opioid used for induction and maintenance of anesthesia at a dose of 1 μg/kg IV (induction) and 0.05-0.25 μg/kg/min (maintenance).
224138851|NCT02238496|PROCEDURE|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
224138852|NCT02238496|DRUG|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
223406817|NCT04964050|DRUG|Capozide|Capozide will be administered as per the treatment sequence.
223406818|NCT04964050|DRUG|ACE-Hemmer-Ratiopharm|ACE-Hemmer-Ratiopharm will be administered as per the treatment sequence.
223406819|NCT01636271|DRUG|darapladib|darapladib enteric coated tablets 160 mg
223406820|NCT01636271|DRUG|placebo|placebo
223406821|NCT02771847|BEHAVIORAL|survey|anonym survey is given to people
223406822|NCT01495650|BEHAVIORAL|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
223406823|NCT01153815|DRUG|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
223556763|NCT07033442|DRUG|Rocuronium 50 mg/5 ml|Neuromuscular blocker administered IV at 0.6-1.2 mg/kg for induction and 0.15 mg/kg for maintenance of muscle relaxation during surgery.
223556764|NCT07033442|DRUG|Lidocaine %2 ampoule|Administered intravenously at 1-1.5 mg/kg before anesthesia induction to reduce injection pain and facilitate induction.
223556765|NCT07033442|DRUG|Thiopental 500 mg vial for injection|Intravenous anesthetic agent used for induction of anesthesia at 4-6 mg/kg.
224138853|NCT02238496|DRUG|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
224023613|NCT06336603|DRUG|Winlevi (clascoterone) 1% & Adapalene 0.3% gel|Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD)
223406824|NCT01153815|DRUG|placebo|placebo
223406825|NCT03977870|OTHER|vital status determination|consultation of national registries
223406826|NCT01786993|DEVICE|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
223406827|NCT01786993|DEVICE|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
223406828|NCT05845632|OTHER|Treatment|Patients were treated with surgery, radiotherapy or surgery with postoperative radiotherapy.
223406829|NCT00521105|OTHER|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
223406830|NCT00941486|DRUG|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.
223406831|NCT00941486|DRUG|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
223406832|NCT00000668|DRUG|Ganciclovir|
223406833|NCT01672502|BEHAVIORAL|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
223406834|NCT01672502|OTHER|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
223406835|NCT01672502|OTHER|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
223406836|NCT03274388|PROCEDURE|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
223406837|NCT03274388|PROCEDURE|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
223406838|NCT02533440|PROCEDURE|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
223556766|NCT07033442|DRUG|Neostigmine 0,5 mg/ml ampoule|Administered IV at 0.04 mg/kg for reversal of neuromuscular blockade at the end of the procedure.
223556767|NCT07033442|DRUG|Atropine Sulphate 0.5mg/ml ampoule|Administered intravenously (0.4 mg per 1 mg neostigmine) to counteract muscarinic effects during neuromuscular blockade reversal; also 0.5 mg IV in cases of intraoperative bradycardia (HR \< 45 bpm).
223556768|NCT07033442|DRUG|Ephedrine Hydrochloride 0,05 mg/ml ampoule|Used intravenously at 0.1 mg/kg to manage intraoperative hypotension unresponsive to fluid and anesthetic dose adjustment.
223556769|NCT07033442|PROCEDURE|CO₂ Pneumoperitoneum|Creation of pneumoperitoneum with CO₂ insufflation for robotic prostatectomy; monitoring and recording of intra-abdominal pressures.
223556770|NCT07033442|DEVICE|Bispectral index (BIS) Monitoring|Monitoring of depth of anesthesia using bispectral index values; frontal placement preoperatively and throughout surgery. BIS maintained between 40-60.
223556771|NCT07033442|PROCEDURE|intraocular pressure measurement|Measurement of intraocular pressure (IOP) in both eyes at multiple intraoperative and postoperative time points (T0-T9).
223556772|NCT07033442|PROCEDURE|intraarterial cannulation and pressure measurement|Invasive arterial blood pressure measurement and blood gas measurements via an 18G catheter inserted into the radial artery
223556773|NCT07033442|PROCEDURE|Mechanical Ventilation|Ventilation initiated after intubation with volume-controlled settings (TV 6-8 ml/kg, RR 12, FiO₂ 50%), adjusted to maintain ETCO₂ between 30-36 mmHg.
223556774|NCT07033442|PROCEDURE|Peripheral Intravenous Cannulation|All participants received peripheral intravenous cannulation using 18-20 G IV cannulas placed on the dorsum of the hand before anesthesia induction.
223556775|NCT07033442|DRUG|Crystalloid solutions|Participants received calculated maintenance fluids with crystalloids through intravenous infusion prior to and during surgery.
224023620|NCT06364748|DEVICE|Cellular enabled blood pressure cuff|Smart cuff
224023621|NCT06364748|DEVICE|Standard of Care Cuff|Standard blood pressure cuff
223737782|NCT05270655|OTHER|Cognitive-behavioural intervention|Participants in the experimental group will receive five sessions of cognitive-behavioural intervention. Each session will be conducted face-to-face for 30-35 minutes a week and supplemented by home-based practices. The first session is an introductory to cognitive-behavioural intervention, the second session includes identifying, evaluating and challenging maladaptive thoughts, beliefs and behaviour, the third session includes behavioural activation, the fourth session is deep breathing, and the last session includes treatment evaluation and relapse prevention. The interventions will be delivered before chemotherapy sessions to avoid fatigue and to increase the patient's engagement with the interventions. To establish a strong therapeutic alliance and enhance intervention delivery and family support, parents will be invited to attend the introduction of the first session and the summary of each session (the last five minutes).
223737783|NCT01900327|RADIATION|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
223737784|NCT01900327|DRUG|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
223737785|NCT01900327|PROCEDURE|Surgery|Upfront pancreato-duodenectomy
223737786|NCT01900327|DRUG|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
223737787|NCT06207006|BEHAVIORAL|eConquerFear-HK|The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
223737788|NCT06207006|BEHAVIORAL|Basic Cancer Care|Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
223737789|NCT03832621|DRUG|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
223406839|NCT02533440|PROCEDURE|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
223556776|NCT07033442|PROCEDURE|Endotracheal Intubation|After induction of anesthesia and neuromuscular blockade, endotracheal intubation was performed using standard technique in all participants.
223556777|NCT07033442|PROCEDURE|American Society of Anesthesiologists (ASA) Standard Monitors|Routine ASA monitoring, including noninvasive blood pressure, ECG (D2 derivation), End-tidal carbon dioxide (ETCO₂) and Peripheral Oxygen Saturation (SpO₂), was performed in all patients, starting from the preoperative period and continuing throughout the surgery.
223556778|NCT07033442|PROCEDURE|Ventilatory Pressure and Compliance Monitoring|Throughout the procedure, the following lung mechanics were continuously measured: PEEP, peak airway pressure (PEAK), mean airway pressure (Pmean), plateau pressure (Pplato), and dynamic compliance.
223556779|NCT07034209|DRUG|Plonmarlimab|Subjects receive Plonmarlimab 6 mg/kg or 10 mg/kg, administered intravenously, once weekly for 8 weeks.
223556780|NCT00964483|BEHAVIORAL|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
223737790|NCT03832621|DRUG|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
223737791|NCT03832621|DRUG|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
223737792|NCT00757302|DEVICE|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
223737793|NCT00775970|BEHAVIORAL|walking activity|
223737794|NCT04008030|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223737795|NCT04008030|DRUG|Oxaliplatin|Specified dose on specified days
223737796|NCT04008030|DRUG|Leucovorin|Specified dose on specified days
223737797|NCT04008030|DRUG|Fluorouracil|Specified dose on specified days
224023622|NCT06084780|PROCEDURE|Intestinal, Multivisceral or Modified Multivisceral Transplantation|"Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:~* Isolated small bowel transplant (SBT): transplantation of the donor small intestine~* Modified multivisceral tran I lant (MMVT): transplantation of the donor pancreas and small intestine, with or without stomach~* Multivisceral transplant (MVT): transplantation of the donor pancreas, small intestine, and liver, with or without stomach"
224023623|NCT06084780|DRUG|Alemtuzumab|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1.
223556781|NCT00964483|BEHAVIORAL|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
223737798|NCT04008030|DRUG|Irinotecan|Specified dose on specified days
223737799|NCT04008030|DRUG|Bevacizumab|Specified dose on specified days
223737800|NCT04008030|DRUG|Cetuximab|Specified dose on specified days
223737801|NCT04008030|BIOLOGICAL|Nivolumab|Specified dose on specified days
223737802|NCT05826899|OTHER|54Fe SO4|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe
223737803|NCT05826899|OTHER|57Fe Oat-1|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe
223737804|NCT05826899|OTHER|58Fe Oat-2|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.
224023624|NCT06084780|DRUG|Tacrolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid.
224023625|NCT06084780|DRUG|Sirolimus|A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od.
224023626|NCT06678672|BEHAVIORAL|Contingency Management (CM)|The participants will receive and be trained to use a CO monitor and iCO app to upload videos to verify smoking abstinence at a minimum of once per day, 5 times per week, over 5 weeks. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through remote CO monitoring. They will receive clinician feedback at the time of each CO reading, following the established VA CM protocol developed in the earlier phase of the project. Each CO reading during the weeks 2-5 will also be accompanied with a brief (5-minute) telephone or video feedback CM counseling session from the study clinician.
224138854|NCT03477617|OTHER|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study's algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
223406840|NCT04983472|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be taken during supine, normal sitting and dyspnea reduction positions. Individuals with chronic obstructive pulmonary disease will be asked to perform normal breathing, pursed lip breathing, and breathing control during these positions. Respiratory muscle activation measurement of individuals will be taken during different breathing patterns in each position. Respiratory functions will be evaluated with pulmonary function test, respiratory muscle strength, intraoral pressure measurement device, respiratory muscle activation with surface electromyographic device, health status disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
224138855|NCT03477617|COMBINATION_PRODUCT|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
223406841|NCT01890122|DRUG|Alogliptin|Alogliptin tablets
223406842|NCT01890122|DRUG|Metformin HCl|Metformin HCl capsules
223406843|NCT01890122|DRUG|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
223406844|NCT01890122|DRUG|Alogliptin Placebo|Alogliptin placebo-matching tablets
223406845|NCT01890122|DRUG|Metformin Placebo|Metformin placebo-matching capsules
223406846|NCT01890122|DRUG|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
223406847|NCT02482688|BEHAVIORAL|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
223556782|NCT02065843|DRUG|Mulungu|500 mg/single dose/1 hour before dental surgery
223556783|NCT02065843|DRUG|Placebo|500 mg/single dose/1 hour before dental surgery
223556784|NCT02065843|DRUG|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
223556785|NCT02065843|DRUG|midazolam|15 mg/single dose/1 hour before dental surgery
223556786|NCT06914245|DIAGNOSTIC_TEST|Electronic bowel diary|This bowel diary will be available on the smartphone in the form of an application.
223556787|NCT06914245|DIAGNOSTIC_TEST|Faecal Incontinence Quality of Life questionnaire (FIQL)|This questionnaire will be available online.
223556788|NCT06914245|DIAGNOSTIC_TEST|EuroQoL 5 dimensions, 5 levels (EQ-5D-5L)|This questionnaire will be available online.
223556789|NCT00006003|DRUG|semaxanib|Given IV
223556790|NCT00006003|OTHER|laboratory biomarker analysis|Correlative studies
223556791|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) Online|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of an online family dyadic skills training and in-person core behavioral weight loss sessions.
223556792|NCT05981508|BEHAVIORAL|Together, Eating and Activity, Matter Plus (TEAM+) In-Person|TEAM+ is a 3-month, family enhanced behavioral weight loss (BWL) intervention designed for Black adults consisting of in-person family dyadic skills training and core behavioral weight loss sessions.
223556793|NCT02744612|DRUG|Brentuximab Vedotin|Given IV
223556794|NCT02744612|DRUG|Ibrutinib|Given PO
223556795|NCT06482203|OTHER|Trunk Extensor Endurance training & Scapular mobilization|"Trunk Extensor Endurance Training Level 1:Prone shoulder extension or prone shoulder raises Level 2: Prone back extension Level 3: Prone Ys or Y raises Level 4:Super man pose Level 5:Super man or prone cobra~(The given position should be hold for 10 seconds and performs 25 repetitions with 3 sec rests in between the efforts)~Scapular Mobilization:~Intervention program includes, supero-inferior, medio-lateral along with circumduction movements).~3 sets of 10-15 repetitions of each of the supero-inferior ,medio-lateral, and circumduction movements Between each session, there was a10 or 30-second break. The length of rests was adjusted depending on the patient's endurance"
223556796|NCT06786780|COMBINATION_PRODUCT|Drug: Cisplatin|Organoids were constructed prior to simultaneous radiochemical therapy
223556797|NCT04956731|OTHER|Pharmacist Provision of Medication Abortion|Pharmacists providing start to finish medication abortions
223556798|NCT05215808|DRUG|RBN-3143|Oral Administration of tablets
223556799|NCT02712983|DRUG|TIP|TIP dose regimen
223556800|NCT02712983|DRUG|TIP and placebo|TIP and inhaled placebo dose regimen
223556801|NCT02712983|DRUG|Placebo|Inhaled placebo dose regimen
223556802|NCT00628472|DRUG|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
223556803|NCT04235816|DRUG|Azithromycin|Administration of azithromycin during the first 15 months of life through the Expanded Program on Immunisation
223556804|NCT04235816|DRUG|Placebo|Administration of placebo during the first 15 months of life through the Expanded Program on Immunisation
223406848|NCT04295408|PROCEDURE|Pericapsular nerve group block with saline solution|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the saline solution was injected in 5-mL increments while observing for adequate fluid spread in this plane.a total volune of 40 ml saline solution was injected.
223406849|NCT04295408|PROCEDURE|Pericapsular nerve group block with ropivacaine|A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 100-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, local anesthetic was injected in 5-mL increments while observing for adequate fluid spread in this plane. a 2 mg.kg-1Ropivacaine in 40 ml of saline was injected
224132857|NCT06187116|OTHER|Orthopaedic surgeon consultation|The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
224132858|NCT03408652|DRUG|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
224132859|NCT06102252|DRUG|Paclitaxel/epirubcin/carboplatin|adjuvant treatment in endometrial carcinoma
224132860|NCT06102252|DRUG|Paclitaxel/carboplatin|Dose dense paclitaxel/carboplatin
223406850|NCT02894372|DEVICE|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
224132861|NCT04973033|DRUG|Tofacitinib|patients enrolled were prescribed tofacitinib 5mg twice a day orally.
224132862|NCT03470649|DRUG|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
224132863|NCT06555614|OTHER|Acellular Dermal Matrix(ADM)|A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
223556805|NCT05225233|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 seconds ramp up/ramp down at the beginning of the session)
223556806|NCT05225233|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
223556807|NCT04732130|BEHAVIORAL|Time-Restricted Feeding|Participants are instructed to limit food intake to maximum 8 hours per day.
223556808|NCT04732130|BEHAVIORAL|Alternate Day Fasting|Participants are instructed to fast every other day.
223556809|NCT01945216|DRUG|Alogliptin|Alogliptin tablets
223556810|NCT03381365|DEVICE|CuraSeal Percutaneous Intraluminal Closure System|
223556811|NCT01956630|BIOLOGICAL|Genetically modified DCs plus CIK cells|
223556812|NCT01956630|BIOLOGICAL|Donor leukocyte infusions (DLI)|
223556813|NCT01373684|DRUG|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
223556814|NCT01373684|DRUG|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
223556815|NCT03054805|DRUG|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight \> 30 kg
223556816|NCT03054805|DRUG|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight \> 30 kg
223556817|NCT06833931|DRUG|IV infusion|IV infusion
223556818|NCT06833931|OTHER|Placebo|IV infusion
223556819|NCT02965963|DRUG|Dopamine|
223556820|NCT02965963|DRUG|Metoclopramide|
223556821|NCT02965963|DRUG|Placebos|
223556822|NCT02965963|OTHER|Rest|
223556823|NCT02965963|OTHER|Exercise - 60%|60% of VO2max
223556824|NCT02965963|OTHER|Exercise - 85%|85% of VO2max
223556825|NCT05360966|DRUG|0.003% AR-15512 ophthalmic solution|Administered via topical ocular instillation
223556826|NCT05360966|DRUG|AR-15512 vehicle ophthalmic solution|Inactive ingredients administered via topical ocular instillation
223556827|NCT01808638|DRUG|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
223556828|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
223556829|NCT01808638|DRUG|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
223556830|NCT06360900|DEVICE|taVNS|Electrical transcutaneous auricular vagus nerve stimulation
223556831|NCT06360900|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
223556832|NCT06360900|BEHAVIORAL|Education Control|Education of FD condition
224132864|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
224132865|NCT00723411|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
224132866|NCT00723411|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
224023627|NCT06678672|BEHAVIORAL|Treatment as Usual (TAU)|Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (SFVAHCS), i.e., referral to Tobacco Cessation Clinic and the VA Telequit Quitline. The SFVAHCS Tobacco Cessation Clinic is a consult service that calls patients proactively 3 times to offer 1:1 behavioral counseling for smoking cessation. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for up to 5 sessions per NCI Quitline guidelines. The smoker initiates the first call, and subsequent calls will be proactively made by Quitline staff.
224023628|NCT06580912|DRUG|Krill oil|4 grams of krill oil per day
224132867|NCT02912728|BEHAVIORAL|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
224132868|NCT02912728|DEVICE|Standard CGM|use of CGM alone to assess CGM adherence
223406851|NCT02894372|DEVICE|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
223406852|NCT02555228|DRUG|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
223556833|NCT06360900|DEVICE|Sham taVNS|Sham (no current) transcutaneous auricular vagus nerve stimulation
223556834|NCT05396014|BEHAVIORAL|Enhanced Self-Care (ESC)|The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
223556835|NCT05396014|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
223556836|NCT05396014|BEHAVIORAL|Evidence-Based Exercise and Manual Therapy (EBEM)|Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
223556837|NCT05396014|DRUG|Duloxetine|Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
223556838|NCT06963905|DRUG|Relatlimab FDC + Nivolumab|Relatlimab: 360 IV Q3W (Dose level 1) and 120mg IV Q3W (Dose level -1) Nivolumab: 360mg IV Q3W
223556839|NCT06963905|DRUG|Sacituzumab Govitecan (SG)|10 mg/kg IV D1 \& D8 every 21-day cycles (Dose level 1); 7.5 mg/kg IV D1 \& D8 every 21-day cycles (Dose level -1); 5 mg/kg IV D1 \& D8 every 21-day cycles 21-day cycles (Dose level -2)
223556840|NCT06963905|DRUG|Nivolumab|360mg IV Q3W
223556841|NCT03367962|DRUG|[18F]F-Ara-G|the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
223556842|NCT04591639|DRUG|Dapagliflozin 10 milligrams [Farxiga]|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
223556843|NCT04591639|DRUG|Placebo|Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo.
224023629|NCT06580912|DIETARY_SUPPLEMENT|Mixed vegetable oil|4 grams of mixed vegetable oil per day
224132869|NCT02082145|DEVICE|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
224138856|NCT02087384|BIOLOGICAL|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
224138857|NCT02087384|DRUG|Placebo|injection of 0.9% saline
223406853|NCT02555228|OTHER|Water|5mls of water is given at least 30 minutes before the gastroscopy.
223406854|NCT05386459|DRUG|Interferon Gamma|injection form
223406855|NCT02045069|DRUG|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
223406856|NCT02045069|DRUG|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
223406857|NCT02045069|DRUG|Placebo|Placebo once daily for 3 days
223556844|NCT03062280|DRUG|Hydrocortisone|Modified release hydrocortisone
223737805|NCT05826899|OTHER|54 FeSO4 + Acai puree with honey|4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
224023630|NCT05650229|DRUG|KL1333|Twice daily
224023631|NCT05650229|DRUG|Placebo|Twice daily
224138858|NCT04807543|DRUG|17-hydroxyprogesterone caproate|intramuscular injection weekly
224138859|NCT04807543|DRUG|Castor Oil|intramuscular injection weekly
224138860|NCT05912855|DEVICE|qNOX|Non
224138861|NCT02149056|BEHAVIORAL|observation|
224138862|NCT02149056|OTHER|Impaired Glucose Tolerance|Impaired Glucose Tolerance
223406858|NCT04796532|OTHER|Home based HIIT|"Intervention will consist in a 16-week exercise program with HIIT with a frequency of 3 days/week. The Home-HIIT group participants will attend HIIT workout sessions supervised by a specialised instructor via a videoconference application. Every HIIT workout session will have a 10 minutes' warm-up, followed by an 8/12/16/20 minutes of HIIT (stages of physical adaptation every 4 weeks) training and 5 minutes' cool-down. Tabata method will be used with eight sets of 20 seconds of exercise bouts separated by 10 seconds rest, in 2 to 5 blocks. The intervention will have four stages of physical adaptation.~This group will have a follow-up period of 16 weeks."
223737806|NCT05826899|OTHER|57Fe Oat-1 + Acai puree with honey|4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.
224297851|NCT01473550|BEHAVIORAL|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
224297852|NCT04365179|DRUG|Nerofe|"Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1."
223737807|NCT05826899|OTHER|58Fe Oat-2 + Acai puree with honey|4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey
223556845|NCT04894877|PROCEDURE|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
223556846|NCT04894877|PROCEDURE|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
223556847|NCT04894877|PROCEDURE|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
223556848|NCT04894877|BEHAVIORAL|Lifestyle|diet, physical activity, smoking cessation
223556849|NCT04894877|DRUG|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
223556850|NCT05815550|DRUG|PPI|Use of PPI defined as PPI mentioned in the safety report
223556851|NCT04991870|BIOLOGICAL|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given CB-NK-TGF-betaR2-/NR3C1- intratumorally
223556852|NCT04991870|PROCEDURE|Resection|Undergo surgical resection
223737808|NCT03163615|DRUG|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
223737809|NCT03163615|DRUG|Placebo oral capsule|4 capsules, po, from admission up to 84 days
223737810|NCT04631029|BIOLOGICAL|Atezolizumab|Given IV
223737811|NCT04631029|DRUG|Carboplatin|Given IV
224023632|NCT03323944|BIOLOGICAL|huCART-meso cells|Intravenous administration or local delivery of lentiviral transduced huCART-meso cells.
224023633|NCT06635057|DRUG|Tirzepatide|Administered SC
224023634|NCT04747626|DEVICE|B-SAFER|Simplified hybrid frozen elephant trunk repair will be performed by utilizing B-SAFER technique which involves a physician modified endovascular stentgraft to treat the proximal aorta in subjects with aortic disease involving multiple segments.
224023635|NCT03060460|DIAGNOSTIC_TEST|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
224023636|NCT02924116|DEVICE|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
224297853|NCT04932941|DRUG|MP1032|Hard gelatin capsules for oral administration.
223556853|NCT03300141|OTHER|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
223556854|NCT03300141|OTHER|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
223556855|NCT03300141|OTHER|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
223737812|NCT04631029|DRUG|Entinostat|Given PO
223737813|NCT04631029|DRUG|Etoposide|Given IV
223737814|NCT05158114|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223737815|NCT04730830|OTHER|Questionnaire|Patients completing emergence assessment questionnaires at the time of the first dressing placement, as well as at the scheduled weekly placement. As part of a planned repair, the emergence will be assessed at most once a week, preferably at the beginning of the week by the patient. In any other case of dressing change, an emergence assessment will be requested.
223737816|NCT06132893|DRUG|BHV-7000|BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily
223737817|NCT06132893|DRUG|BHV-7000|BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
223737818|NCT06132893|DRUG|Placebo|Matching placebo taken once daily
223737819|NCT05706077|DEVICE|active tDCS|The electrode will measure 5x5 cm and a current of 2mA will be applied for 20 minutes. The current density will be 0.08mA/cm². tDCS will be applied three times a week for 20 minutes over four weeks.
224023637|NCT00166426|DRUG|Exisulind|
224023638|NCT04776148|DRUG|pembrolizumab|IV infusion
224023639|NCT04776148|DRUG|lenvatinib|oral capsule
224023640|NCT04776148|DRUG|regorafenib|oral tablet
224023641|NCT04776148|DRUG|TAS-102 (trifluridine and tipiracil)|oral tablet
224023642|NCT02563522|GENETIC|Engensis (VM202)|gene therapy
224023643|NCT02563522|DRUG|Placebo|Standard of care plus placebo
223737820|NCT05706077|DEVICE|sham tDCS|The electrode will measure 5x5 cm. The sham-type current will show a rising ramp where the initial 30 seconds will be real current with the same parameter as the active group. After this time, the current will be automatically stopped by the device. tDCS will be applied three times a week for 20 minutes over four weeks.
223737821|NCT05706077|OTHER|real Physical Therapy|Manual maneuvers and therapeutic exercises will be performed for 30 minutes, three times a week over four weeks.
223737822|NCT05706077|OTHER|placebo Physical Therapy|The placebo Physical Therapy will be applied for 30 minutes, three times a week over four weeks. The initial 20 minutes will be used for the application of simulated ultrasound bilaterally in the middle portion of the upper trapezius muscle. In the final 10 minutes, the researcher will place the palms of the hand under the occipital region without applying any force or movement with the participant in the supine position.
223406859|NCT04796532|OTHER|Traditional HIIT|"Intervention will consist in a 16-week exercise program with HIIT with a frequency of 3 days/week. The Traditional HIIT group participants will attend a group HIIT workout sessions supervised by a specialised instructor in a sport facility. Every HIIT workout session will have a 10 minutes' warm-up, followed by an 8/12/16/20 minutes of HIIT (stages of physical adaptation every 4 weeks) training and 5 minutes' cool-down. Tabata method will be used with eight sets of 20 seconds of exercise bouts separated by 10 seconds rest, in 2 to 5 blocks. The intervention will have four stages of physical adaptation.~This group will have a follow-up period of 16 weeks."
223406860|NCT04287075|PROCEDURE|Surgical Management of Neuroma|Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
223406861|NCT03547375|DRUG|Apatinib|Apatinib 500mg/d po,28 days as one cycle
223406862|NCT02545959|DRUG|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
223406863|NCT02545959|DRUG|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
223737823|NCT05945875|DRUG|Panitumumab-IRDye800|Given by IV
223737824|NCT05945875|OTHER|Indium In 111 Panitumumab|Given by IV
224023644|NCT06060873|OTHER|Clinical Stage I Disease|Patients undergo blood sample collection during screening and throughout the study. Based on results, patients will undergo a primary RPLND surgery or standard surveillance. Surveillance will follow until year 5.
224297854|NCT04932941|DRUG|Placebo|Placebo capsules matched to MP1032 for oral administration.
223406864|NCT02545959|DRUG|Rituximab IV|Blood infusion of rituximab (375mg/m2)
223406865|NCT00971438|PROCEDURE|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
223406866|NCT02691052|OTHER|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
223406867|NCT02706431|PROCEDURE|Hyperventilation|
223406868|NCT01737632|BEHAVIORAL|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
223406869|NCT01737632|BEHAVIORAL|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
223737825|NCT05945875|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Single Photon Emission Computed Tomography
223737826|NCT05945875|PROCEDURE|Computed Tomography|Undergo Computed Tomography
223737827|NCT05945875|PROCEDURE|Resection|Undergo standard of care surgical resection
224023645|NCT06060873|OTHER|Clinical Stage I with relapse, CSII Disease|Patients undergo blood sample collection during screening and throughout the study. Based on results, patients will undergo a primary RPLND surgery or reassessment and then surveillance will follow until year 5.
224023646|NCT04810078|BIOLOGICAL|Nivolumab and rHuPH20|Specified dose on specified days
224023647|NCT04810078|BIOLOGICAL|Nivolumab|Specified dose on specified days
223406870|NCT00813384|DRUG|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
223406871|NCT06670079|BEHAVIORAL|Prolonged exposure therapy + incentives for therapy session attendance|Prolonged exposure therapy plus incentives for therapy session attendance
223406872|NCT06485102|PROCEDURE|Carotid Surgery in patients with symptomatic or asymptomatic stenosis|Carotid Surgery in patients with symptomatic or asymptomatic stenosis
223406873|NCT02768480|OTHER|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
223737828|NCT05945875|PROCEDURE|Fluorescence Imaging|Undergo standard of care fluorescence imaging
223737829|NCT06294067|DIETARY_SUPPLEMENT|docosahexaenoic acid (DHA)|72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks.
223737830|NCT06294067|DIETARY_SUPPLEMENT|soybean oil placebo|72 healthy participants will be divided into 6 groups and receive varying amounts of DHA (0mg, 100mg, 200mg, 400mg, 800mg and 1000mg) over the course of 8 weeks. The 0mg group will receive only placebos.
223737831|NCT05407441|DRUG|Tazemetostat|oral, twice daily, dosage per protocol
224023648|NCT05768139|DRUG|STX-478|STX-478 is a mutant-selective PI3Kα inhibitor
224023649|NCT05768139|DRUG|Fulvestrant|Fulvestrant
224023650|NCT05768139|DRUG|Ribociclib|Ribociclib
224023651|NCT05768139|DRUG|Palbociclib|Palbociclib
223737832|NCT05407441|DRUG|Nivolumab|IV, dosage and schedule per protocol
223737833|NCT05407441|DRUG|Ipilimumab|IV, dosage and schedule per protocol
223737834|NCT04931095|DRUG|Cannabis|Cannabis will be orally ingested via a brownie
224023652|NCT05768139|DRUG|Letrozole|Letrozole
224023653|NCT05768139|DRUG|Anastrozole|Anastrozole
224023654|NCT05768139|DRUG|Exemestane|Exemestane
224023655|NCT05633667|DRUG|Zimberelimab (ZIM)|Administered intravenously
223737835|NCT04931095|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
223406874|NCT02768480|OTHER|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
223406875|NCT03364660|DEVICE|Acute epidural stimulation for cardiovascular stability|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord. Participants received mapping for cardiovascular stability.
223406876|NCT03364660|DEVICE|Long Term Epidural Stimulation for Cardiovascular Stability|Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily.
223406877|NCT03364660|DEVICE|Participants undergo approximately 4 months of epidural stimulation for voluntary movement.|Participants undergo approximately 4 months of epidural stimulation for voluntary movement 4-7 days weekly.
223406878|NCT03364660|DEVICE|Long Term Epidural Stimulation for Cardiovascular Stability plus Stand Training|Participants undergo approximately 4 months of epidural stimulation for cardiovascular stability, daily. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
223406879|NCT03364660|DEVICE|Participants undergo approximately 4 months of epidural stimulation for voluntary movement plus stand training.|Participants undergo approximately 4 months of epidural stimulation for voluntary movement, 4-7 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly. Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame with epidural stimulation for standing up to 5 days weekly.
223406880|NCT01934582|DRUG|UT-15C SR|
223406881|NCT01934582|DRUG|treprostinil diethanolamine|Open label study drug.
223406882|NCT06509958|DRUG|HR18034|HR18034
223556856|NCT06679192|DEVICE|Milled thickness varied soft upper surface, based on plantar pressure measurement|"This custom made shoe insole is milled, with a thickness varied soft upper surface ranging from 0-6mm in thickness. The base of the insole is 45 shore Ethylene-vinyl acetate (EVA).~This intervention makes the insole from an individual foot scan, a plantar pressure measurement from the individual and the shoe model to mill a finished custom made shoe insole with a soft upper surface. It is difficult in clinical practice of making shoe inserts to create a thickness varied soft upper with different zones all over the insole. Furthermore, a soft upper requires a physical positive model to be made of the foot and staff must spend time to grind the insole to an acceptable shape. A milled version would be more effective since it require no physical foot model, little to no work grinding the insole and enables the use of thickness-variations. It also enables the use of data-based insole-manufacturing, such as data from plantar pressure measurements."
223556857|NCT06679192|DEVICE|3mm soft upper surface|This intervention has a 3mm soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
223556858|NCT06679192|DEVICE|No soft upper surface|This intervention has a no soft layer on the insole, milled with a 45 shore base of the custom made insole. This is one of the most commonly used designs in clinical practice.
223556859|NCT05642455|GENETIC|Afamitresgene autoleucel|Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \<40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells/kg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion
223556860|NCT06349954|PROCEDURE|single-session ERCP|directly endoscopic stone extraction
223556861|NCT06349954|PROCEDURE|two-session ERCP|early endoscopic drainage followed by endoscopic stone extraction
223556862|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, intraoperative stage|Trocar layout is recorded by photo or diagram. The video of conventional or robot-assisted laparoscopy and intraoperative laparoscopic ultrasound images (where applicable) are recorded by the surgeon and anonymized. Depth measurements of internal structures (tumors, cysts, vascular network, anatomical landmarks) are taken using identifiable points on the surface of the liver for tumour resection.
223556863|NCT06044909|PROCEDURE|Minimal invasive hepatectomy, postoperative stage|The registration of imaging data in conventional or robot-assisted laparoscopy is performed by the scientific team using the developed registration algorithm. The data obtained from the clinical intervention will help improve the registration algorithm.
223556864|NCT06044909|OTHER|Preoperative data collection|Patient code (anonymised) + inclusion number, repeated on each page. Anonymised CT or MRI scan and date of scan. Type of cancer, planned surgery and approach (robotic or laparoscopic). Patient's age. Patient's surgical history. Toxic habits: tobacco, alcohol. Healthy liver, liver disease, cirrhosis. Anticoagulant and antiaggregant treatment.
223556865|NCT06044909|OTHER|Intraoperative data collection|Endoscope calibration. Intraoperative surgical and ultrasound images. Measurements for tumor's size and tumor's distances from liver surface and vascular vascular structures.
223556866|NCT06044909|OTHER|Postoperative data collection|Definitive anatomical pathology with the measurement of resection margins.
223556867|NCT01894854|PROCEDURE|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
223556868|NCT04953806|BEHAVIORAL|Step-CBT|Participants will complete Step-CBT, an integrative 8-week physical activity and cognitive behavioral therapy (CBT) intervention, delivered by a licensed clinical psychologist. Sessions will take place once per week for 60 minutes using VA Video Connect. Each session will include core components 1) Reviewing physical activity goals, prescribing new step count goal, and problem-solving barriers and 2) The weekly CBT intervention module.
223556869|NCT05011006|DIAGNOSTIC_TEST|NT3 blood draw|blood draw
223556870|NCT06788561|DEVICE|Transauricular Nerve Stimulation|Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
223556871|NCT06788561|DEVICE|s-taVNS|Hua Tuo brand SDZ-IIB electronic acupuncture therapy device and specially designed ear clips.
223556872|NCT05006937|PROCEDURE|Dusting|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
223556873|NCT05006937|PROCEDURE|Basket extraction|Basket extraction is when a small wire basket is used to remove stone fragments.
224023656|NCT05633667|DRUG|Domvanalimab (DOM)|Administered intravenously
223406883|NCT06509958|DRUG|Ropivacaine Hydrochloride Injection|Ropivacaine Hydrochloride Injection
223406884|NCT03866252|DRUG|LSD|LSD administration per os
223406885|NCT06123637|BEHAVIORAL|Analgesia nociception index-guided anesthesia|Maintaining the blood pressure based on analgesia nociception index of \>50 value
223737836|NCT03378544|BEHAVIORAL|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
223737837|NCT04393103|DRUG|Intralipid, 20% Intravenous Emulsion|"Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart."
223406886|NCT06123637|BEHAVIORAL|Standard anesthesia|Maintaining the blood pressure based on anesthesiologist's decision
223406887|NCT06684821|PROCEDURE|Racz catheter|Patients will undergo epidural neuroplasty using Racz catheter during lumber fixation.
223406888|NCT06684821|PROCEDURE|Classic lumber fixation|Patients will undergo classic lumber fixation.
223406889|NCT02518061|OTHER|No intervention|This is a retrospective study
223556874|NCT02891148|DRUG|BI 690517|
223556875|NCT05929703|BEHAVIORAL|HELP|This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.
224023657|NCT05633667|DRUG|Sacituzumab govitecan-hziy (SG)|Administered intravenously
224023658|NCT05633667|DRUG|Etrumadenant (ETRUMA)|Administered orally
224023659|NCT05633667|DRUG|Carboplatin|Administered intravenously
224023660|NCT05633667|DRUG|Cisplatin|Administered intravenously
224023661|NCT05633667|DRUG|Pemetrexed|Administered intravenously
224023662|NCT05633667|DRUG|Paclitaxel|Administered intravenously
224023663|NCT05633667|DRUG|Nab-paclitaxel|Administered intravenously
224023664|NCT05633667|DRUG|Docetaxel|Administered intravenously
224023665|NCT05633667|DRUG|Nivolumab|Administered intravenously
224023666|NCT02071134|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
224023667|NCT01775072|GENETIC|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, \& others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection \& research biopsies."
224023668|NCT01775072|GENETIC|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list).~Part D: Germline Profiling for Individuals at Elevated Cancer Risk"
224023669|NCT06403436|DRUG|TT125-802|TT125-802 administered orally
224297855|NCT03637335|COMBINATION_PRODUCT|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
223406890|NCT01270568|OTHER|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
223406891|NCT01270568|BEHAVIORAL|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
223406892|NCT01270568|BEHAVIORAL|Recollection|Subjects record daily events on a weekly basis for 8 weeks
223406893|NCT04931732|BIOLOGICAL|ctDNA analysis|ctDNA analysis of patients with suspected primary glioma tumors and in patients with suspected recurrence.
223406894|NCT02198170|DRUG|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
223406895|NCT02198170|DRUG|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
223406896|NCT04699474|DEVICE|Leg ergometer|Leg cycling in bed using motorized ergometer
223406897|NCT00569972|DRUG|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
223406898|NCT00569972|DRUG|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
223556876|NCT05929703|BEHAVIORAL|FAM-HELP|Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.
223556877|NCT06839131|DRUG|SPH9788|SPH9788 tablets administered orally
223556878|NCT06839131|DRUG|Placebo|Matching placebo administered orally
223556879|NCT04299308|BEHAVIORAL|Aerobic Exercise|Participants will exercise for 15 minutes based on heart rate range. The study team will employ a stationary bike to maintain control over workload
224023670|NCT03972254|BEHAVIORAL|Modified Interaction Guidance|The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
224023671|NCT06323577|PROCEDURE|Restricted kinematic alignment|TKA using restricted kinematic alignment under robotic assisted surgery (MAKO).
223406899|NCT00569972|DRUG|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
223406900|NCT00569972|DRUG|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
223556880|NCT06069362|OTHER|Manual physiotherapy and neurodynamic exercises|"* Cervical passive mobilisation techniques and techniques of the anatomical structures surrounding the nerve. These techniques aim to open the nerve root foramen. They are gentle traction techniques and contralateral lateral glide mobilisation techniques. Interface techniques for scalenes will also be included.~* Home exercises for cervical mobility and neurodynamic sliders of the upper extremity: Patients will be taught progressive upper extremity neurodynamic sliders, starting with gentle movement and progressing to exercises involving more movement based on the patient's irritability."
224023672|NCT06323577|PROCEDURE|Mechanical alignment|TKA using mechanical alignment under robotic assisted surgery (MAKO).
224023673|NCT06355193|DRUG|Langenlianqiao|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
223406901|NCT00569972|DRUG|Placebo|Matched oral placebo for weeks 2-7.
223406902|NCT05374031|OTHER|descriptive study|descriptive study
223406903|NCT02731430|DRUG|intrathecal morphine|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
223406904|NCT02731430|DRUG|intrathecal saline|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
223406905|NCT06874647|OTHER|AI-generated report for reference|The Janus-Pro-CXR group has the AI-generated report for reference and can make changes to the AI-generated report. Another group completes the report independently.
223406906|NCT01347723|OTHER|scrambler therapy|Undergo scrambler therapy
223406907|NCT01347723|OTHER|questionnaire administration|Ancillary studies
223406908|NCT01347723|PROCEDURE|management of therapy complications|Undergo scrambler therapy
223406909|NCT00379418|DRUG|Abciximab|
223406910|NCT02120118|RADIATION|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
223406911|NCT02120118|OTHER|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
223406912|NCT02120118|DRUG|Cisplatin|30mg/m2
223406913|NCT02120118|DRUG|Taxotere|20mg/m2
223406914|NCT06577012|PROCEDURE|Small incision lenticule extraction|Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (XJ, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
223406915|NCT01174381|BEHAVIORAL|lifestyle modification|Lifestyle modification for six months
223406916|NCT05689346|DEVICE|high tone power therapy|high tone power therapy
223406917|NCT05689346|OTHER|traditional physical therapy exercises|traditional physical therapy exercises for improving balance
223406918|NCT02174510|DRUG|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
223406919|NCT02174510|DRUG|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
223406920|NCT02174510|DRUG|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
224023674|NCT06355193|DRUG|LianhuaQingWen|The data of patients with COVID-19 mild disease treated in our Hospital from November to December 2022 were collected, and the patients were divided into 100 cases of langenlianqiao(LGLQ) treatment group, 100 cases of LianhuaQingWen(LHQW) treatment group, and 53 cases of placebo control group according to the treatments they received, and the proportion of occurrence of major clinical symptoms, the time of symptom disappearance, and the number of days in hospitalization, and the duration of infection were compared among the three groups.
224023675|NCT06355193|OTHER|placebo control group|placebo control group
224023676|NCT02930356|OTHER|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
224297856|NCT03637335|COMBINATION_PRODUCT|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
223406921|NCT02174510|DRUG|placebo|
223406922|NCT01069601|BIOLOGICAL|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
223406923|NCT03077815|OTHER|Systematically intermittent arm exercise|While holding a rubber ball for 5 minutes a day, together with strappy elastic compression arm veinElastic bandages defined for using this research provides of standard bandages, according to research personnel Guide, reached hand elbow near heart end 4 (2\~6) cm at of arm local pressure strong 50 mm-Hg (+/-10 mm-Hg) (about equivalent to provides pressure strong 6.67 thousand PA (kPa), also about equivalent to 0.97 PSI (pound per square inch)), to reached 5 minutes arm movement Shi short reduced vein return, promotion pathway vein extended of effect
223737838|NCT04393103|DRUG|Intravenous Atropine Sulfate|Atropine will be administered to ALL PATIENTS in Group A and group B by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till complete atropinization. Following this, an infusion of 10-20% of the atropinizing dose was given every hour.
223406924|NCT06733181|OTHER|REMINDER intervention|The REMINDER intervention includes 20 face-to-face group sessions, each approximately 60 to 75 minutes, held twice a week over ten weeks. This program aims to optimize memory, attention, executive function, and emotional regulation while promoting lifestyle habits that protect the aging brain. The sessions include brain health education, cognitive exercises, compensatory memory strategies, training for managing personally relevant goals (with goal setting), and stress management techniques (compassion-based therapies, relaxation methods, and mindfulness). As for the structure of the sessions, each starts with a mindfulness exercise and concludes with a review of the homework assignments. Every session includes a psychoeducation component focused on a specific topic, a time for sharing and reflection, and a practical activity.
223406925|NCT00953654|OTHER|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
223406926|NCT00953654|OTHER|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
223406927|NCT02746250|DRUG|Amitriptyline|The investigator recruits patients who have already discussed and agreed to the amitriptyline treatment with their physician. The patients start the treatment after the investigator have measured them once.
223406928|NCT01709487|PROCEDURE|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
223406929|NCT02940262|RADIATION|Gallium Ga 68 Gozetotide|Given IV
223406930|NCT02940262|OTHER|Laboratory Biomarker Analysis|Correlative studies
223406931|NCT02940262|PROCEDURE|Positron Emission Tomography|Undergo PET imaging
223406932|NCT01124994|PROCEDURE|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
223556881|NCT05258890|OTHER|Social Network Group Counseling|Researchers will identify the influential network members based on their network position, driving distance from the patient, speaking frequency, and whether they have high blood pressure. The index patient and social network members will meet with the study nurse on weeks 2, 6, and 12 after initial enrollment. The study nurse will begin the social network counseling session in which she will provide counseling on teamwork and blood pressure control. The teamwork specific topics will include how networks can work together as a team, communication tips for engaging with one another, spreading positive messages, and establishing the roles and responsibilities of each network team member. The blood pressure control specific topics will include the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. Patient and social network members will receive text messages every week in the weeks between sessions.
223556882|NCT05258890|OTHER|Individual Counseling|The index patient will meet individually with the study nurse on weeks 2, 6, and 12 after initial enrollment. The nurse will provide counseling on the basics of blood pressure, taking and adjusting medications, monitoring blood pressure, reducing salt, and being physically active. The patient will receive text messages every week in the weeks between sessions.
223737839|NCT03729804|DRUG|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
223406933|NCT01875146|OTHER|4x4 min HIT|Conventional 4x4 min high-intensity interval training
223406934|NCT01875146|OTHER|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
223406935|NCT01875146|OTHER|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
223556883|NCT06366789|DRUG|ZE46-0134|oral capsules QD
223556884|NCT06119971|DEVICE|ACUPRESSURE|Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
223737840|NCT03729804|DRUG|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
223406936|NCT01875146|OTHER|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
223406937|NCT01030302|DRUG|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
223406938|NCT05577533|BEHAVIORAL|O-Kidia game battery|Children will be playing on a series of games with a touch screen tablet while video and digit trajectories data will be collected from this mobile device to analyze eye-, face-, sound-recognition.
223406939|NCT05577533|BEHAVIORAL|O-Brain|Electrical recordings and measurements - A mobile EEG headset will be used during the visit - 30 min
223406940|NCT03852654|DRUG|18F-DCFPyL|"Subjects with biopsy proven prostate cancer, no prior local therapy, and:~PSA ≥ 10 ng/dl, or Gleason Sum ≥ 4+3, or clinical stage ≥cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan."
223406941|NCT04933344|OTHER|patients having had BJI or PJI treated with daptomycin|patients having had BJI or PJI treated with daptomycin who developped an adverse event : eosinophilic pneumonia and/or elevation of CPK
223406942|NCT02570464|PROCEDURE|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
223406943|NCT02570464|BIOLOGICAL|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
223556885|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose1|A topical drop of BRM424 ophthalmic solution.
223737841|NCT03729804|DRUG|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
223737842|NCT03729804|DRUG|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
223406944|NCT05509387|DEVICE|transcranial direct current stimulation and naming training|Participants will receive mild stimulation or no stimulation along with naming training
223737843|NCT05247177|DRUG|dexmedetomidine, ketamine co-administration with sevoflurane for general anesthesia|co-administration of sevoflurane, iv. dexmedetomidine and iv. ketamine to maintain a predefined EEG density spectrum array pattern for general anesthesia
223406945|NCT05232760|DEVICE|Supera™ Peripheral Stent System|The device will be employed for treatment of juxta-anastomotic stenosis in failing AV fistula after previous percutaneous angioplasty procedures
223406946|NCT01334229|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
223556886|NCT05927428|DRUG|BRM424 Ophthalmic Solution - Dose2|A topical drop of BRM424 ophthalmic solution.
223556887|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
223556888|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
223556889|NCT05671757|BIOLOGICAL|Daratumumab|Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
223556890|NCT04935697|DEVICE|nVNS|3x daily treatment of nVNS + SOC
223556891|NCT04935697|OTHER|SOC|Standard of care patient management.
223556892|NCT04493424|DRUG|Spesolimab|Spesolimab
223556893|NCT05077982|DIAGNOSTIC_TEST|Spirometry|Spirometry to assess lung function
223556894|NCT05077982|DIAGNOSTIC_TEST|6-minute walk|Exercise tolerance
223556895|NCT01910324|BEHAVIORAL|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
223556896|NCT01910324|BEHAVIORAL|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
223556897|NCT02469987|DRUG|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
223556898|NCT02469987|DRUG|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
223556899|NCT02469987|DRUG|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
223737844|NCT05247177|DRUG|Conventional general anesthesia by administration of sevoflurane alone|Administration of sevoflurane alone to maintain anesthesia with a bispectral index between 40-60
223406947|NCT01334229|DRUG|Placebo|Placebo for 6 weeks
223406948|NCT05089591|DEVICE|Intense Pulsed Light therapy|The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.
223406949|NCT05089591|DEVICE|Sham Treatment|The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
223737845|NCT00401141|PROCEDURE|Blood samples|
223737846|NCT04425434|OTHER|OBSERVATIONAL|We will look at the outcome of the the children treated to see if the survival is improved when these therapeutic measures are followed.
223737847|NCT06962215|OTHER|Paramedic training|"Nurses and care assistants at the centers randomized to the with training arm will undergo a day-and-a-half of training to help them support patients diagnosed with brain tumors. Training consists of half a day of theory, followed by a day of simulation."
223737848|NCT05996523|BIOLOGICAL|PRGN-2009|PRGN-2009 5x10\^11 viral particles (VP) subcutaneously (SC) approximately two weeks apart
223406950|NCT05049395|DEVICE|High Flow Nasal Cannula oxygen (HFNO)|The AIRVO2 is set at 30L/min, FiO2 100%, and 37℃ before anesthesia induction，and then 60L/min until the end of the procedure of sedated hysteroscopy.
223406951|NCT05049395|DEVICE|Regular oxygen|The patients are administered oxygen of 3L-6L/min until the end of the hysteroscopy operation.
223556900|NCT04314024|DRUG|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
223556901|NCT00039780|DRUG|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
223556902|NCT00039780|DRUG|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
223737849|NCT05996523|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenously (IV) concurrently with the first vaccine dose
223737850|NCT05445778|DRUG|Mirvetuximab soravtansine plus Bevacizumab|Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks
223737851|NCT05445778|DRUG|Bevacizumab|Participants will receive Bevacizumab 15mg/kg every 3 weeks
223737852|NCT01304966|PROCEDURE|biopsy|excisional biopsy
224023677|NCT02930356|OTHER|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
223406952|NCT05751213|OTHER|knack technique.|"It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)"
223737853|NCT06558279|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
223737854|NCT06558279|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
223737855|NCT06162221|DRUG|RMC-6291|Oral tablet
223737856|NCT06162221|DRUG|RMC-6236|Oral tablet
223406953|NCT05751213|OTHER|pelvic floor muscle exercises|It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
223406954|NCT02627313|DEVICE|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
223406955|NCT01868802|DRUG|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
223406956|NCT01868802|DRUG|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
223737857|NCT06162221|DRUG|Pembrolizumab|IV Infusion
223737858|NCT06162221|DRUG|Cisplatin|IV Infusion
223406957|NCT00894621|DRUG|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
223406958|NCT00894621|DRUG|Placebo|
223406959|NCT00153179|DRUG|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
223556903|NCT04309370|DEVICE|20 Hz rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS modulates cortical activation depending on the stimulation parameters used. Physiological studies have provided evidence that suggests that high-frequency (HF) rTMS produces an increase in local cortical excitability. Studies have also demonstrated that rTMS may increase or decrease functional connectivity between separate but related cortical structures, utilizing high and low frequency stimulation, respectively.
223737859|NCT06162221|DRUG|Carboplatin|IV Infusion
223737860|NCT06162221|DRUG|Pemetrexed|IV infusion
223737861|NCT06162221|DRUG|RMC-9805|Oral Tablet
223737862|NCT05891483|DRUG|SHR-1905 Injection|SHR-1905 Injection
224023678|NCT02877979|DRUG|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
224023679|NCT02877979|DRUG|Placebo|
224023680|NCT04169711|DRUG|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
224023681|NCT00824161|DRUG|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
223406960|NCT00153179|DRUG|placebo|matching placebo
223406961|NCT05265338|DRUG|KC1036|60mg QD
223406962|NCT04099745|DEVICE|CGM|Continuous Glucose Monitoring System
223406963|NCT04099745|DEVICE|FGM|Flash glucose monitoring System
224023682|NCT02125708|DEVICE|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
223406964|NCT04939298|DEVICE|Ultrasound|Ultrasound evaluation of the variation of thickness of abdominal muscles after 7 days of mechanical ventilation.
223406965|NCT00262197|BEHAVIORAL|Customized Physician Intervention|
223406966|NCT00262197|BEHAVIORAL|Customized Patient Intervention|
223406967|NCT04495829|DEVICE|Phorcides Analytical Engine|Surgery planning using the Phorcides analytical engine.
223556904|NCT00559455|DRUG|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
223556905|NCT00559455|DRUG|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
223737863|NCT05891483|DRUG|SHR-1905 Placebo Injection|SHR-1905 Placebo Injection
223737864|NCT00870896|DRUG|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
223737865|NCT04467879|DEVICE|Zona Plus Device|Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
223737866|NCT04467879|DEVICE|Control Device|Zona Plus control sham device, with a nominal weaker grip
224023683|NCT04575506|OTHER|Multidisciplinary intervention program|The intervention program includes an educational program promoting healthy dietary habits and physical activity (nutritionist and exercise physiologist) (2 times/month, for children and parents), and supervised home-based exercise (from 3 to 5 times/week, 38-44 min) program for 12-weeks.
223406968|NCT03433573|DEVICE|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.
223406969|NCT01445782|DRUG|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
223406970|NCT01445782|DRUG|Placebo|Multiple dose, oral inhalation (nebuliser solution)
223406971|NCT03807544|DEVICE|TENS|Transcutaneous electrical nerve stimulation
223406972|NCT05442229|OTHER|establish a new Chinese children's speech and language norm|1063 normally developing children and 96 abnormally developing children will be retrospectively enrolled from the medical records of stratified, randomly selected centers. A total of 4137 children with normal development and 448 children with abnormal development aged from 2 to 6 years old will be selected from 11 hospitals in China by multi-center, stratified, unequal proportion random sampling and face-to-face survey. Children's speech and language development was assessed by the Speech and Language Development Scale for children aged 2 to 6, compiled by the Linguistics and Language Research Centre of the Education University of Hong Kong.
223406973|NCT00691730|OTHER|laboratory biomarker analysis|Only sample collection, no other intervention - Correlative studies
223406974|NCT04021888|OTHER|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
223556906|NCT00559455|DRUG|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
223556907|NCT02805751|DEVICE|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
223556908|NCT02805751|OTHER|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
223556909|NCT02805751|OTHER|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
223556910|NCT03117868|OTHER|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
223556911|NCT03409705|DIETARY_SUPPLEMENT|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
223556912|NCT03409705|DIETARY_SUPPLEMENT|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
223556913|NCT02079116|OTHER|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 60 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
223556914|NCT02079116|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
224023684|NCT04874415|BEHAVIORAL|1RLD|1RLD=One text per day, ramped goal, loss incentive, daily goal time period
224023685|NCT04874415|BEHAVIORAL|1RLW|1RLW=One text per day, ramped goal, loss incentive, weekly goal time period.
223406975|NCT04061174|OTHER|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
223406976|NCT04061174|OTHER|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
223406977|NCT05173155|PROCEDURE|surgical approach|Comparison of short-term outcomes (patient mobility, quality of life, function, pain, and safety parameters) for the direct anterior approach and Lateral approach for hemiarthroplasty for patients who have experienced a femoral-neck hip fracture.
223406978|NCT02641743|DIETARY_SUPPLEMENT|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (\>50%)
223406979|NCT02641743|DIETARY_SUPPLEMENT|standard balanced formula|
223556915|NCT04837703|DRUG|Eltrombopag|Eltrombopag should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cation (e.g. aluminum, calcium, iron, magnesium, selenium and zinc). Eltrombopag may be taken with food containing little (\< 50 mg) or preferably no calcium.
223556916|NCT05644665|DRUG|Ozanimod|Specified dose on specified days
223556917|NCT05644665|DRUG|Placebo|Specified dose on specified days
223556918|NCT00093197|DRUG|KAI-9803 for Injection|0.05 mg
223556919|NCT00093197|DRUG|KAI-9803 for Injection|0.5 mg
223556920|NCT00093197|DRUG|KAI-9803 for Injection|1.25 mg
223556921|NCT00093197|DRUG|KAI-9803 for Injection|5 mg
223556922|NCT00093197|DRUG|Placebo|
223556923|NCT05247957|BIOLOGICAL|CAR-NK cells|NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
224023686|NCT04874415|BEHAVIORAL|1RGD|1RGD=One text per day, ramped goal, gain incentive, daily goal time period.
224023687|NCT04874415|BEHAVIORAL|1RGW|One text per day, ramped goal, gain incentive, weekly goal time period.
224023688|NCT04874415|BEHAVIORAL|2RLD|Two texts per day, ramped goal, loss incentive, daily goal time period.
224023689|NCT04874415|BEHAVIORAL|2RLW|Two texts per day, ramped goal, loss incentive, weekly goal time period.
224023690|NCT04874415|BEHAVIORAL|2RGD|Two texts per day, ramped goal, gain incentive, daily goal time period.
224023691|NCT04874415|BEHAVIORAL|2RGW|Two texts per day, ramped goal, gain incentive, weekly goal time period.
224023692|NCT04874415|BEHAVIORAL|1FLD|One text per day, fixed goal, loss incentive, daily weekly goal time period.
223406980|NCT02100462|DRUG|Chlorthalidone 12.5 mg|
223406981|NCT02100462|DRUG|Hydrochlorothiazide 25 mg|
223406982|NCT02100462|DRUG|Aspirin 81 mg|
223406983|NCT02003404|DEVICE|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
223406984|NCT02003404|DEVICE|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
223406985|NCT06035965|OTHER|Epilepsy Surgery Satisfaction Questionnaire (ESSQ-19)|19 items assessing post-surgery satisfaction.
223406986|NCT06035965|OTHER|Quality of Life in Epilepsy Inventory (QOLIE-31)|31 items to assess different dimensions of quality of life
223406987|NCT06035965|OTHER|Generalized Anxiety Disorder 7 (GAD7)|7 items, rated from 0 to 3, to detect anxiety disorders.
223406988|NCT06035965|OTHER|Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)|to screen for depressive disorders
223406989|NCT06035965|OTHER|Evaluation of Changes in Daily Life after Epilepsy Surgery (EVOCQUE)|self-questionnaire developed by the Toulouse epileptology team in 2023 for patients who have undergone epilepsy surgery. It aims to collect the feelings of patients concerning the changes induced by surgery in their daily life according to a 7-point Likert scale.
223406990|NCT04753008|DRUG|Dopamine administration|Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
223556924|NCT01321944|OTHER|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
223406991|NCT05051852|OTHER|Follow up|Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
223556925|NCT05143749|OTHER|video tutorial|get video tutorial
223556926|NCT05557851|COMBINATION_PRODUCT|Minnelide|Stressing the patient's pancreatic cancer by giving the anti super-enhancer Minnelide to increase endoplasmic reticulum (ER) stress and improve the progression-free survival (PFS) when patients are treated with standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.
223556927|NCT00964665|DRUG|albinterferon alfa-2b|
223737867|NCT04164615|DRUG|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
224023693|NCT04874415|BEHAVIORAL|1FLW|One text per day, fixed goal, loss incentive, weekly goal time period.
224023694|NCT04874415|BEHAVIORAL|1FGD|One text per day, fixed goal, gain incentive, daily goal time period.
224023695|NCT04874415|BEHAVIORAL|1FGW|One text per day, fixed goal, gain incentive, weekly goal time period.
224023696|NCT04874415|BEHAVIORAL|2FLD|Two texts per day, fixed goal, loss incentive, daily goal time period.
223406992|NCT02712554|DRUG|CL-108|7.5 mg/325 mg/12.5 mg tablet
223406993|NCT02712554|DRUG|M366|7.5 mg/325 mg tablet
223406994|NCT02712554|DRUG|Placebo|
223406995|NCT01095276|DRUG|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
223406996|NCT01095276|DRUG|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
223406997|NCT03649568|OTHER|Pork|1 oz lean pork
223406998|NCT03649568|OTHER|Egg|1 large whole egg
223406999|NCT03649568|OTHER|Black beans|0.5 cups cooked black beans
223407000|NCT03649568|OTHER|Almonds|1 oz almonds
223407001|NCT06411964|DIETARY_SUPPLEMENT|Prebiotic|Commercially available supplement (Bimuno)
223407002|NCT06411964|DIETARY_SUPPLEMENT|Placebo control|maltodextrin control supplement
223407003|NCT04145154|OTHER|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
223407004|NCT00979654|DRUG|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
223556928|NCT00964665|DRUG|albinterferon alfa-2b|
223556929|NCT00964665|DRUG|albinterferon alfa-2b|
223556930|NCT00964665|DRUG|albinterferon alfa-2b|
223556931|NCT00964665|DRUG|Pegasys®|
223556932|NCT00516893|BIOLOGICAL|BG00002-E (natalizumab high titer)|
223556933|NCT00284557|BEHAVIORAL|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
223556934|NCT01791049|DRUG|TD-1607|
223556935|NCT01791049|DRUG|Placebo|
223556936|NCT03440736|DRUG|Secukinumab|Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)
224023697|NCT04874415|BEHAVIORAL|2FLW|Two texts per day, fixed goal, loss incentive, weekly goal time period.
224023698|NCT04874415|BEHAVIORAL|2FGD|Two texts per day, fixed goal, gain incentive, daily goal time period.
223407005|NCT01395147|DRUG|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
223407006|NCT02045342|OTHER|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
223407007|NCT02045342|OTHER|Placebo|Ingest 500ml of placebo prior to metabolic measures.
223407008|NCT05962723|PROCEDURE|EUS|EUS examination and cystic fluid will be aspirated for analysis, including cystic fluid Glucose, CEA, amylase. Morey's biopsy will be done in the cases feasible for biopsy.
223407009|NCT01129557|DRUG|Aliskiren|
223407010|NCT01129557|DRUG|Valsartan|
224023699|NCT04874415|BEHAVIORAL|2FGW|Two texts per day, fixed goal, gain incentive, weekly goal time period.
223407011|NCT01446302|DIETARY_SUPPLEMENT|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
223407012|NCT00669669|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
223407013|NCT00669669|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
224023700|NCT05208905|DEVICE|Esprit BTK Device|Participants will receive Esprit BTK Device
224023701|NCT06568042|DRUG|LY3848575|Administered SC
223407014|NCT00669669|DRUG|Carmustine|Given IV
223407015|NCT00669669|BIOLOGICAL|Filgrastim|Given SC
223407016|NCT00669669|PROCEDURE|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
223407017|NCT00669669|RADIATION|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
223407018|NCT00669669|OTHER|Laboratory Biomarker Analysis|Correlative studies
223407019|NCT00669669|DRUG|O6-Benzylguanine|Given IV
223407020|NCT00669669|DRUG|Plerixafor|Given SC
223737868|NCT04164615|DRUG|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30\~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
223737869|NCT00003901|OTHER|immunohistochemistry staining method|
223407021|NCT00669669|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
223407022|NCT00669669|DRUG|Temozolomide|Given PO
223407023|NCT02935127|PROCEDURE|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
223407024|NCT02935127|PROCEDURE|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
223407025|NCT07170930|OTHER|Friendly Match-Play Exposure: extended vs. limited|This research explores the multidimensional physiological and biochemical responses to differing volumes of friendly match-play (i.e., extended vs. limited) during the late pre-season phase in soccer players.
223737870|NCT00003901|PROCEDURE|biopsy|
223407026|NCT07174739|DEVICE|Quantum Molecular Resonance (QMR) Treatment|Quantum Molecular Resonance (QMR) treatment will be administered using the Rexon-Eye® device (Resono Ophthalmic, Sandrigo, Italy) according to the protocol recommended by the manufacturer. The device features a contact electrode embedded in a mask worn over the participant's closed eyes, and it delivers stimulation to the epidermis of the closed eyelids, extending up to the lid border with an intensity setting of 4-5 on a scale of 0-10. The treatment is non-invasive and painless.
223407027|NCT07175376|OTHER|Supportive Care|Geriatric assessment (GA) -guided supportive care and weekly Patient Reported Outcomes (PRO) symptom assessment
223737871|NCT00003901|PROCEDURE|surgery|
223737872|NCT03134482|PROCEDURE|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
224023702|NCT06568042|DRUG|Placebo|Administered SC
224023703|NCT05734105|DRUG|Ripretinib|50 mg tablets
224023704|NCT05734105|DRUG|Sunitinib|12.5 mg tablets
223737873|NCT03134482|PROCEDURE|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
223737874|NCT00144209|DRUG|pramipexole|
223737875|NCT00144209|DRUG|levodopa in combination with benserazide|
224023705|NCT00004468|DRUG|calcitriol|
224023706|NCT01312857|DRUG|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
224023707|NCT01312857|DRUG|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
224023708|NCT00411853|DRUG|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
224023709|NCT06373367|OTHER|Illustration based application|Illustrations regarding the cause, risks, and warning signs of preeclampsia
224023710|NCT06373367|OTHER|Text based application|Standard preeclampsia discharge instructions
224023711|NCT00003849|BIOLOGICAL|rituximab|
224023712|NCT02551406|DEVICE|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
224023713|NCT01524601|DRUG|Rosuvastatin|20 mg rosuvastatin for 4 weeks
224023714|NCT04100668|DEVICE|Sensifree's Alpha sensor|RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
224023715|NCT04100668|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
223407028|NCT06081218|OTHER|activity test|Over 2 weeks, participants have to do a maximal progressive exercise and a 30 min constant exercise at 50% of maximal aerobic power
223407029|NCT06194240|BEHAVIORAL|DiabACT|E-program proposed to diabetic patients based on ACT therapy.
223407030|NCT04385082|DRUG|Active Cannabis|Smoked cannabis with THC
223407031|NCT04385082|DRUG|Placebo Cannabis|Placebo smoked cannabis (no THC)
223407032|NCT03158064|DRUG|Durvalumab|1500 mg by IV
223407033|NCT03158064|DRUG|Tremelimumab|"75 mg by IV~\*300mg"
223407034|NCT04978168|BEHAVIORAL|Core Intervention|Staff are provided with a core set of implementation strategies to facilitate interorganizational linkages between probation agencies and local community treatment providers.
223407035|NCT04978168|BEHAVIORAL|Peer Support Specialists (PSS)|Participants randomized to PSS will meet with a PSS for 6 months. Contact scheduled is flexible and based on the participant's needs and wants, plus written guidance for PSS-participant interactions.
223407036|NCT04978168|BEHAVIORAL|Treatment as Usual (TAU)|Participants randomized to TAU will receive the services that will be offered at the time the Core Implementation intervention is completed.
223407037|NCT05301114|BEHAVIORAL|Community Health Worker support|Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
223407038|NCT05940168|BEHAVIORAL|I-Navigator ACT|The intervention is an internet-delivered ten module Acceptance and Commitment Therapy treatment program for stressed and distressed parents of children with disabilities. The contents of the program is mostly text based, but also includes videos, mindfulness exercises and written exercises, as well as homework between modules.
223407039|NCT05940168|BEHAVIORAL|Navigator ACT group|The intervention is a five session Acceptance and Commitment Therapy group treatment for stressed and distressed parents of children with disabilities. All five sessions have different themes and are held by two group leaders. Sessions are around two and a half hours long. Homework is given between sessions.
223407040|NCT06794086|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy (SBRT) is a highly precise form of external beam radiation therapy used to treat tumors in various parts of the body. Enrolled patients will initiate SBRT treatment within 2 weeks after the first course of chemotherapy. Intensity-modulated radiation therapy (IMRT) will be used, with the gross tumor volume (GTV) receiving a dose of 8-12 Gy in 5 fractions, resulting in a total dose of 40-60 Gy. The biologically effective dose (BED) is equivalent to 72-132 Gy. The treatment will be administered from Monday to Friday.
223407041|NCT06794086|DRUG|PD-1 Monoclonal Antibody|PD-1 monoclonal antibody is a type of immunotherapy drug designed to treat various cancers by targeting the programmed death receptor-1 (PD-1) pathway.The PD-1 monoclonal antibody used in this study is sintilimab at a dose of 200 mg, administered via intravenous infusion on Day 1. Participants will be considered eligible only if they have completed four or more cycles of PD-1 monoclonal antibody treatment both before and after SBRT.
223407042|NCT06794086|DRUG|Chemotherapy|Chemotherapy regimens based on fluorouracil (5-FU), such as CAPOX with a 3-week cycle or mFOLFOX6/FOLFIRI/FOLFOXIRI with a 2-week cycle, may be combined with targeted therapy. During chemotherapy or chemoradiotherapy, optimal supportive care will be provided.
223407043|NCT06067906|OTHER|Hypocaloric diet|Hypocaloric diet
223407044|NCT06067906|OTHER|Dissociated diet|Dissociated diet
223407045|NCT05676606|DEVICE|Remote 1-minute single-lead electrocardiogram (ECG) monitoring in cancer patients after the first polychemotherapy cycle.|Recording of the ECG using smart-phone at rest, 15 minutes before registering ECG patient should not smoke,having tea, coffee, alcohol. During the ECG recording hands should be fixed to avoid poor quality. Patient sitting on a char with tow hands fixed on a table holding electrocardiograph with index fingers placed at the ECG electrode (left) and at the photoplethysmograph sensor(right).ECG signals are recorded from the fingers using first standard ECG lead. After registration, all ECG and photoplethysmography data will be sent to the server. The data will be automatically compared with a standard for data quality, after that the data will be sent to cardiologist. If quality will be not sufficient, the data will be deleted and the doctor will contact the patient to solve the quality issue. Thereafter, the parameters will be carried out by cardiologist, on the basis of which value of ECG monitoring will be estimated.
223407046|NCT01068678|DRUG|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
223407047|NCT01068678|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
223407048|NCT00840567|PROCEDURE|Skin biopsy|
223407049|NCT00840567|PROCEDURE|Blood draw & sample|
223407050|NCT04080388|DIAGNOSTIC_TEST|Lung Impedance Device|The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
223407051|NCT04080388|DRUG|Anti-congestive treatment|Continuation of in-hospital anti-congestive treatment
223407052|NCT04170738|DRUG|Adderall|3 weeks of Adderall
223407053|NCT02901210|PROCEDURE|Modified delorme procedure|
223407054|NCT02514798|OTHER|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
223556937|NCT03440736|BEHAVIORAL|Life-style intervention|A structured program to guide weight loss and increased physical activity
223556938|NCT03723720|DEVICE|Colonoscopy|Endoscopic examination of large bowel
223556939|NCT00438126|BEHAVIORAL|A lifestyle educational program|
223737876|NCT05064410|BEHAVIORAL|Educational Intervention|The colorectal cancer (CRC) educational activities will include the use of NCI CRC resources and materials, including a PowerPoint presentation, and CRC educational models and displays. The CRC education will be delivered in Spanish and English, and will consist of pre and post knowledge assessments including screening and behavioral intention questions. The educational intervention will take approximately 45 minutes-1 hour.
223737877|NCT03486795|DEVICE|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
223737878|NCT03486795|DEVICE|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
223737879|NCT03486795|DEVICE|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
223737880|NCT02813564|BEHAVIORAL|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
223737881|NCT00262808|BIOLOGICAL|sargramostim|
223407055|NCT02514798|OTHER|Respiratory Inductance Plethysmography (RIP) system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
223556940|NCT03307603|RADIATION|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
223556941|NCT03307603|DRUG|Phase Ib - nivolumab|240 mg intravenously
223556942|NCT03307603|DRUG|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
223556943|NCT06447623|DRUG|Apatinib|Apatinib is a kind of TKI inhibitor.
223556944|NCT06447623|DRUG|CDK4/6 Inhibitor|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
223556945|NCT06447623|DRUG|Aromatase inhibitor and Fulvestrant|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
223556946|NCT00467545|DRUG|telbivudine|
223556947|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZFR00|IOL replaces the natural lens removed during cataract surgery.
223556948|NCT03372434|DEVICE|Investigational Intraocular Lens Device #1: Model ZYR00|IOL replaces the natural lens removed during cataract surgery.
223556949|NCT03372434|DEVICE|TECNIS Multifocal Intraocular Lens: Model ZLB00|IOL replaces the natural lens removed during cataract surgery.
223556950|NCT06425887|DIAGNOSTIC_TEST|Smart watch|not interventional
223737882|NCT00262808|DRUG|fluorouracil|
223737883|NCT00262808|DRUG|leucovorin calcium|
223737884|NCT00262808|DRUG|oxaliplatin|
223737885|NCT00262808|PROCEDURE|adjuvant therapy|
223737886|NCT00262808|PROCEDURE|conventional surgery|
223556951|NCT04585542|DRUG|Polyethylene Glycol 3350|Nonspecific laxative comparison group.
223556952|NCT04585542|DRUG|Sodium Polystyrene Sulfonate Oral Suspension [SPS]|Potassium binder to treat hyperkalemia.
223556953|NCT04585542|DRUG|Patiromer|Potassium binder to treat hyperkalemia.
223556954|NCT04585542|DRUG|Sodium zirconium cyclosilicate|Potassium binder to treat hyperkalemia.
223556955|NCT06087991|BEHAVIORAL|Implementation of the BINDeR-Tx service model|ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.
223556956|NCT05844618|DRUG|Triamcinolone Acetonide (Aristocort® C)|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
223556957|NCT05844618|DRUG|Vehicle|On Day 1, Day 2, and Day 3, subjects will receive 2 applications of 3 mg/cm2 on the same lesional area, at an interval of approximately 12 ± 2 hours.
223556958|NCT06519773|PROCEDURE|Modified periosteal inhibition|"After local anathesia, a traumatic extraction of the hopeless tooth will be made trying as much as possible to preserve the labial plate of bone and overlying soft tissue.~* Once the tooth is extracted, the socket is gently debrided and irrigated using sterile saline solution. Then the dental implant is placed in the best prosthetic driven position, following the guidelines for immediate implants using prefabricated computer guided surgical template.~* After accurate implant placement, a full-thickness flap will be elevated at mesial and distal papilla making a buccal envelope. A soft bone lamina will be trimmed and hydrated in sterile saline solution for 30 s to soften it; it should be 1-2 mm larger and deeper than the vestibular bone. Then the jumping gap between the dental implant and the buccal plate of bone will be filled using either collagen sponge or xenograft."
223737887|NCT00262808|PROCEDURE|neoadjuvant therapy|
224023716|NCT04100668|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
224023717|NCT04882995|DIETARY_SUPPLEMENT|Psyillium fiber|Participants receive 7 days of psyllium fiber dietary supplement prior to scheduled surgery
224023718|NCT05074420|DRUG|Baricitinib|Given Orally
224023719|NCT00014131|BIOLOGICAL|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
224023720|NCT00580242|DRUG|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
224023721|NCT00580242|DRUG|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
224023722|NCT00580242|DRUG|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
224023723|NCT00580242|DRUG|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
224023724|NCT05333679|DEVICE|UTRA|Collect urine on intervention participants and screen for presence of TFV.
223407056|NCT02514798|OTHER|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
224023725|NCT05333679|BEHAVIORAL|UTRA feedback|Feedback will be provided to the participant based on the UTRA results on their adherence with provision of standard adherence counseling.
224023726|NCT00240045|DRUG|Midodrine, albumin, octreotide LAR|
224023727|NCT00240045|DRUG|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
224023728|NCT02572882|DIETARY_SUPPLEMENT|p-inulin|12 week self-administered treatment phase
223407057|NCT02514798|DEVICE|High-flow humidified nasal oxygen delivery system|
223407058|NCT02514798|DEVICE|CPAP (Positive Control)|
223407059|NCT06167837|DRUG|Metoclopramide Sulfone|Metoclopramide 10mg+NSS 10 ml IV 30-60 minutes before EGD
223407060|NCT06167837|DRUG|Normal Saline 10 mL Injection|Normal saline 10 ml IV 30-60 minutes before EGD
223407061|NCT03441802|OTHER|High quality extra virgin olive oil|Cases and controls were given 40 g/die high quality extra virgin olive oil
223407062|NCT00579579|BEHAVIORAL|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
223407063|NCT03236961|DRUG|Ertapenem|I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
223407064|NCT03236961|DRUG|Moxifloxacin|P.o. moxifloxacin 400 mg x1 for 7 days
223407065|NCT03055338|DRUG|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
223407066|NCT03055338|DRUG|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
223407067|NCT03055338|DRUG|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
223407068|NCT03055338|DRUG|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
223407069|NCT00975611|DRUG|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
223407070|NCT00975611|DRUG|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
223407071|NCT00975611|DRUG|Placebo|tablets BID, for 4 weeks
223407072|NCT04173780|DRUG|Atropine 0.01%|1 drop per day in both eyes for 1 year
223407073|NCT04173780|DRUG|Placebo|1 drop per day in both eyes for 1 year
223407074|NCT03058705|DRUG|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
223407075|NCT03058705|DEVICE|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
223407076|NCT02056015|DRUG|[68Ga]MLN6907|IV Administration of \[68Ga\]MLN6907 on Day 1
223407077|NCT00294372|DRUG|BILR 355 BS|
223407078|NCT00294372|DRUG|Placebo|
223407079|NCT06570148|OTHER|semi-directed interview or focus group|Participants will be recruited using purposive sampling with maximum variation. If they meet the inclusion criteria, they will be invited to take part in an online interview or focus group, lasting between 40 minutes and 1.5 hours. During the Zoom interview or focus group, they will be asked to answer several pre-defined open-ended questions based on an interview grid co-constructed with the co-investigators, including a patient partner and parent partners. They will be asked to answer closed socio-demographic questions at the end of the interview or focus group. The Zoom meeting will be recorded (audio) and then transcribed into anonymized written form.
223407080|NCT06661226|OTHER|Accleration drills|14 participants will be in experimental group A, giving them acceleration drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
224023729|NCT04443101|OTHER|different types of intracular lens|different types of intracular lens
224023730|NCT04371198|OTHER|Biopsy|Tissue biopsy
224023731|NCT05835154|BEHAVIORAL|Assessment|Complete checklist
224023732|NCT05835154|OTHER|Questionnaire Administration|Complete questionnaires
224023733|NCT05835154|OTHER|Interview|Undergo semi-structured feedback interview
224023734|NCT05835154|OTHER|Electronic Health Record Review|Review of medical records
224023735|NCT04025112|DEVICE|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
224023736|NCT04025112|OTHER|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
223407081|NCT06661226|OTHER|Change in Direction Drills|14 participants will be in experimental group B, giving them Change in direction drill protocol for six weeks. Measure all values before giving them protocol and after protocol.
224023737|NCT01179425|OTHER|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
224023738|NCT00050037|PROCEDURE|CBT|
224023739|NCT01137968|DRUG|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
224023740|NCT01137968|DRUG|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
223407082|NCT01682226|DEVICE|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
223407083|NCT01682226|DEVICE|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
223556959|NCT05935878|DEVICE|Cementless Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. Cementless components have a hydroxy-appatite coating to facilitate bone ingrowth. The cementless femoral component also has a smaller second peg, located anteriorly to the larger central peg that is also present of the cemented femoral component.
224132870|NCT06175962|BEHAVIORAL|TRAINING AND EXERCISE|"Menopause health training will take place in 2 sessions each week and will be completed in 4 sessions. Each session duration is 45 minutes. Baduanjin exercise training will take place in 2 sessions per week, each session lasting 30 minutes. It will be completed in 8 sessions in total. Relaxing music will be played during the Baduanjin exercise and relaxation will be encouraged. During the Baduanjin exercise, proper posture, conscious breathing and focus of the mind will be prioritized. While the movements are being implemented, their symbolic meanings will be explained to the participants. Women will be asked to perform baduanji 3 times a week for 8 weeks.~During this process, reminder messages will be sent to women via WhatsApp."
224132871|NCT03598569|OTHER|dyspnea|dyspnea assessment
224132872|NCT06248905|OTHER|Rehabilitation program based on the strengthening of gluteal muscles|Physiotherapy program (8 weeks)
224132873|NCT06248905|OTHER|Extracorporeal shock wave therapy|Focused shock wave therapy (3 weeks)
224132874|NCT02387372|DRUG|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~* Participants with CLCR \> 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~* Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
223407084|NCT01682226|BIOLOGICAL|Haploidentical donor CD34+ cells|CB grafts will consist of two CB units 4-6/6 HLA-matched to the patient to augment graft cell dose and additional T-cell depleted PBSC from a haplo-identical donor.
223407085|NCT05709028|DRUG|Fosfomycin|"Fosfomycin trometamol is a white crystalline powder which is very soluble in water. The granules are mixed with 90ml of cool water for the constitution to dissolve and will be administered soon after reconstitution. Each 30ml will contain 1g fosfomycin base.~* Children ≥ 6 months to \<1 year old will be administered 30ml (=1g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥ 1 to 11 years will be administered 60ml (=2g fosfomycin base) of dissolved solution and the remainder discarded for each dose.~* Children ≥12 and \<18 years will be administered the entire 90ml solution (= 3g fosfomycin base) for each dose."
223556960|NCT05935878|DEVICE|Cemented Oxford Unicompartmental Knee Arthroplasty|All patients will undergo the same surgical approach. 0.8mm diameter tantalum marker balls will be placed in the tibia and femur in all cases. All cemented components will be secured using the same cement.
223556961|NCT05924165|DRUG|5mg Oxycodone, Q6 PRN|Oxycodone is an opioid that is used to relieve moderate to severe pain.
223556962|NCT05924165|DRUG|10mg Ketorolac, Q6 PRN|Ketorolac is an NSAID used to relieve moderately severe pain.
223556963|NCT03350126|DRUG|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
224023741|NCT04754477|DEVICE|Active Osseointegrated Steady-State Implant System (OSI)|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
224023742|NCT04342793|DRUG|Placebo oral tablet|Placebo
224023743|NCT04342793|DRUG|ALS-L1023 1,200mg|ALS-L1023
224023744|NCT04342793|DRUG|ALS-L1023 1,800mg|ALS-L1023
224132875|NCT02387372|DRUG|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
224132876|NCT04133805|DIETARY_SUPPLEMENT|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
224132877|NCT02252237|BIOLOGICAL|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at following visits. Buccal cell collection swab
224132878|NCT04875949|PROCEDURE|Immunoabsorption/plasmapheresis procedure|
224132879|NCT00937560|DRUG|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
223556964|NCT03350126|DRUG|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
224132880|NCT00937560|DRUG|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
223407086|NCT05709028|DRUG|Standard of care antibiotics|Standard of care antibiotics will be chosen by the treating clinician according to institutional prescribing practices, local antibiograms and medication availability.
224132881|NCT00937560|DRUG|Carboplatin|Carboplatin was supplied locally in commercial batches.
224132882|NCT05912309|BEHAVIORAL|Time Restricted Eating (TRE)|Participants will be required to reduce their eating time window to ≤ 8 hours/day. Women can choose when to begin eating, but the last meal should be completed before or at 20:00 hours (concentrating the eating window towards the active phase confers higher cardiometabolic health benefits). Our preliminary results suggest that this eating window is feasible and safe. Participants will receive dietary advice regarding the daily amount of high quality protein and meal-specific protein quantities. All the participants will attend a lifestyle education program based on Mediterranean diet and WHO physical activity recommendations every two weeks.
224138863|NCT04228120|BEHAVIORAL|self-regulation programme|The programme consisted of one 20-to-30-minute, face-to-face individual education session related to self-regulation and problem-solving processes that was performed in accordance with the patient's plan. Furthermore, eight 15- to 20-minute telephone follow-up counselling sessions were delivered twice per week for four weeks.
223407087|NCT06960681|DIAGNOSTIC_TEST|External validity of the SFA score|Testing the external validity of the SFA score for the detection of in adult emergency departments
223407088|NCT03458832|DIAGNOSTIC_TEST|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
223407089|NCT03458832|DEVICE|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
223407090|NCT05007431|OTHER|Questionnaires|Data collection will be carried out by hetero-questionnaire carried out in the presence of the questioned.
223407091|NCT06331546|DIETARY_SUPPLEMENT|Low-oxalate diet|4 days of fixed eucaloric diet with low oxalate (\<60 mg/day), normal calcium content (600-1000 mg/day)
223407092|NCT06331546|DIETARY_SUPPLEMENT|High-oxalate diet|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium content (600-1000 mg/day)
223407093|NCT06331546|OTHER|soluble oxalate gut absorption test|Oral ingestion of 13C2-oxalate and sucralose.
223407094|NCT00655408|DRUG|elemental iron|Iron supplementation.
223407095|NCT02037178|OTHER|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
223407096|NCT02037178|OTHER|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
223407097|NCT02159053|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
223407098|NCT02159053|BIOLOGICAL|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
223407099|NCT02159053|BIOLOGICAL|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
223407100|NCT02143505|DRUG|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
223407101|NCT06035367|DEVICE|Non-invasive continuous monitoring device to record photoacoustic signal|"Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.~A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal."
223407102|NCT04105296|DEVICE|EKSO+ES|6 months of exoskeleton training with epidural stimulation.
223407103|NCT05598450|DEVICE|rTMS and MEG for auditory hallucinations via self controlled clinical trials|"a 4 weeks, weekly 345（23min\*3times\*5day） minutes, 1Hz, 100%RMT-rTMS protocol~Detail precedure:~Before intervention, each patient was scheduled to collect three magnetoencephalogram data sessions. Apply MEG technology to calculate possible locations and determine three intervention targets. Pseudo stimulation in the first week, 5-day intervention, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. Evaluate the scale after the first week of pseudo stimulation. Week 2-4 real stimulation, intervention 5 days a week, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. After the end of the fourth week, evaluate the scale. And follow-up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th days after the intervention."
223407104|NCT01135381|BEHAVIORAL|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
223407105|NCT04625881|DIETARY_SUPPLEMENT|Apple derived fiber|This is a combination of soluble and insoluble fiber
223407106|NCT05997069|OTHER|Posterior-anterior vertebral mobilizations followed by Prone press-up exercise|"Posterior-anterior vertebral mobilizations of the lumbar spine are achieved by applying a force on to a spinous process in a posteroanterior direction (Back to front).~Prone press-up exercise is started in the prone position (lying on stomach) on a flat surface. Participant keeps hands underneath the shoulders then press up his or her upper body while trying to keep the hips on the floor."
223556965|NCT05959447|DRUG|Camlipixant|Camlipixant will be administered
223556966|NCT05959447|DRUG|Dabigatran etexilate|Dabigatran etexilate will be administered
223556967|NCT05959447|DRUG|Gemfibrozil|Gemfibrozil will be administered.
223556968|NCT05049772|BEHAVIORAL|Telerehabilitation-based motor imagery training|10 weeks of motor imagery training and stabilization exercises.
223556969|NCT05049772|BEHAVIORAL|Stabilization exercises group|10 weeks of stabilization exercises.
223556970|NCT05278039|BEHAVIORAL|Respiratory-Swallow Phase Training|Participants will complete 6 respiratory-swallow phase training sessions that will last approximately one hour.
223556971|NCT05278039|OTHER|Swallow Practice|"Participants will complete 6 swallow practice sessions that will last approximately one hour."
223407107|NCT05997069|OTHER|Conventional physiotherapy|Traditionally used physiotherapy for the treatment of nonspecific low back pain (thermotherapy and general stretching exercises)
223407108|NCT06573450|OTHER|questionnaire survey|subjects fill out questionnaires
223407109|NCT06684249|PROCEDURE|Nerve Block Injections|This intervention involves the administration of supratrochlear and greater occipital nerve block injections. The injections consist of a mixture of local anesthetics and corticosteroids, designed to reduce the frequency and severity of migraine episodes. The procedure will be repeated every 12 weeks for a total duration of 6 months to assess the long-term efficacy and safety in managing chronic migraine.
223407110|NCT06684249|DRUG|Botulinum Toxin A|Participants in this arm will receive Botulinum toxin A injections as per the PREEMPT protocol tailored for chronic migraine treatment. The treatment involves multiple injections around the head and neck regions, administered every 12 weeks over a 6-month period. This standard approach aims to reduce migraine frequency through neuromodulation of pain pathways.
223407111|NCT05362617|DRUG|FOLFIRI|FOLFIRI as first line chemotherapy versus mFOLFOX6 after adjuvant chemotherapy
223407112|NCT00204919|DRUG|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
223407113|NCT00204919|DRUG|placebo|once-monthly placebo capsules
223556972|NCT05642234|PROCEDURE|Epidural Ultrasonography|In this study, we measured the intervertebral distance and skin-epidural distance with the help of ultrasonography in the thoracic and lumbar regions in sitting and rider positions.
223556973|NCT06429072|BEHAVIORAL|Mindfulness training|• I-MASS begins with one introductory telephone call by a mindfulness coach within 1 week of the patient scheduling surgery to introduce the participant to the Pattern Health app, discuss the benefits of combining mindfulness and acupuncture, discuss how to access the Healthwise educational content, and lead a brief (\~10 min) mindfulness exercise, as desired. Thereafter, participants will complete 4 self-directed mindfulness modules through the Pattern Health app (1 prior to surgery, 3 following surgery). Each mindfulness module is anticipated to last one week and includes a short (4-5 min) introductory video, daily sessions comprised of a 6-8 min guided mediation, and interactive suggestions for how to apply mindfulness within a daily routine (\~10-12 min total per daily session).
223556974|NCT06429072|OTHER|Acupuncture|This arm also includes up to 8 total acupuncture treatments (1 prior to surgery and up to 7 treatments in the 12 weeks after surgery). Auricular acupuncture will be the preferred form of acupuncture used. This technique involves inserting tiny needles in specific areas of the outer ear to target points believed to influence pain. If participants are unable to tolerate auricular acupuncture, they will have the option to receive peripheral acupuncture.
223556975|NCT06429072|BEHAVIORAL|Enhanced education|• The program consists of education prior to and after surgery for all participants. All of the educational material is delivered via the Pattern Health App. All educational content is from the Healthwise.net Duke Health Library (https://www.healthwise.net/dukehealth/Content) and is carefully selected with input by surgeons to be delivered during the appropriate phase of recovery. Education is in the form of short reading materials or videos, all designed to help safely and effectively recover from surgery. Educational topics include learning how to lift and sit when experiencing pain, proper precautions following surgery, how to ease back into daily activities following surgery, and ways to self-manage pain.
223556976|NCT06245005|DEVICE|Brain exercise gameplay on a portable electronic device|Feasibility is defined as a 70% completion rate for at least 3 of the six brain exercise games in study participants from which a 'first gameplay score' can be determined. Investigators will also assess level of satisfaction with the brain exercise intervention and barriers to playing in the busy preoperative clinical settings as evaluated by a patient-centered questionnaire (Discharge Survey).
223556977|NCT05756920|DRUG|ABL301|SAD: Participants will receive a single dose of ABL301 IV infusion, MAD: Participants will receive multiple doses of ABL301 IV infusion
223556978|NCT05756920|DRUG|Placebo|SAD: single Placebo IV infusion, MAD: multiple Placebo IV infusion
223556979|NCT00107432|DRUG|sorafenib tosylate|Given orally
223556980|NCT00107432|OTHER|laboratory biomarker analysis|Correlative studies
223556981|NCT03665766|DRUG|Cycloserine,Tacrolimus|
223556982|NCT04053855|BIOLOGICAL|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
223556983|NCT06254092|PROCEDURE|tourniquet binding of cervical|The procedure will be performed by surgeons with rich experience in clinical work
223737888|NCT02637752|BEHAVIORAL|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
223737889|NCT04458909|DRUG|Carboplatin|Given IV
223407114|NCT04509336|DRUG|Orphenadrine|100 mg twice daily
223407115|NCT04509336|DRUG|Baclofen|initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
223407116|NCT00457002|DRUG|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
223407117|NCT00457002|DRUG|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
223407118|NCT01149564|DRUG|iv ibuprofen|
223407119|NCT01149564|DRUG|oral ibuprofen|
223407120|NCT05776264|BEHAVIORAL|Music Condition|During one of the sessions, participants will listen to music while walking on the treadmill for 10 minutes.
223407121|NCT05776264|BEHAVIORAL|Podcast Condition|During one of the sessions, participant will listen to a podcast for 10 minutes while walking on the treadmill.
223407122|NCT00249340|BEHAVIORAL|Weight Watchers|
223407123|NCT00249340|BEHAVIORAL|brief behavioral weight loss treatment|
223556984|NCT01255839|DEVICE|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
223556985|NCT01255839|DRUG|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
223556986|NCT01140594|PROCEDURE|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
223556987|NCT01140594|PROCEDURE|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
223407124|NCT00249340|BEHAVIORAL|brief behavioral + Weight Watchers combined treatment|
224023745|NCT05049954|OTHER|Calorie-Restricted Healthy Ketogenic Diet|Participants in the experimental group will be advised on a Calorie-restricted Healthy Ketogenic Diet via 7 workshops. Participants will also be advised to monitor their urinary ketones to track compliance.
224023746|NCT05049954|OTHER|Calorie-Restricted Low Fat Diet|Participants will be advised on Calorie-restricted Low Fat diet via 7 workshops.
223407125|NCT05270616|PROCEDURE|robotic surgery|minimally invasive surgery using the Davinci robotic system
223407126|NCT05270616|PROCEDURE|uniport surgery|VATS minimally invasive surgery under the uniportal status
223407127|NCT05270616|PROCEDURE|multiple- port surgery|VATS minimally invasive surgery under the multiple- port status
223556988|NCT06300749|OTHER|Chiropractic Cervical Manipulation|"In the chiropractic cervical manipulation group, the patient was placed in the supine position. The therapist moved to the patient's head, identified the C5-C6 segment by palpation, and manually performed spinal manipulation from the right side using the cervical rotary break/index push technique since the dominant side of the patients was the right extremity. In the cervical rotary break/index thrust technique, the lateral aspect of the practitioner's index finger was placed in contact with the posterior aspect of the participant's C5 facet joint, and a rotational thrust was performed between the C5-C6 vertebrae."
223556989|NCT06300749|OTHER|Sham Technique Practice|The sham technique can be defined as a technique that does not have any therapeutic effect and is preferred to determine whether the efficacy of another technique is superior. The patient was placed in the supine position. The therapist moved to the patient's head, and the C5-C6 segment localized in the lower cervical region was detected by palpation. The C5-C6 segment was positioned to perform chiropractic cervical manipulation and waited for 30 seconds without any pushing force.
223556990|NCT06223971|DRUG|[11C]CPPC Injection|"A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]"
223556991|NCT06223971|DRUG|[11C]CPPC Injection|"A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.~Other Name: \[5-cyano-N-(4-(4-\[11C\]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide\]"
223556992|NCT05031338|DEVICE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
223556993|NCT05031338|PROCEDURE|Carpal Tunnel Release|Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
223556994|NCT01544101|OTHER|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
223556995|NCT01544101|DIETARY_SUPPLEMENT|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
223556996|NCT04435301|DEVICE|DC-Stimulator, NeuroConn, Germany|Neurostimulation device
223556997|NCT03154515|DRUG|Ingavirin|
224023747|NCT01590017|DRUG|cisplatin|
224023748|NCT01590017|RADIATION|external beam radiation therapy|
224023749|NCT01347762|DRUG|Nabilone|nabilone titrated to 1 mg by mouth twice daily
224023750|NCT01347762|DRUG|Placebo|one placebo capsule by mouth twice daily
223407128|NCT04539184|OTHER|Motion Style Acupuncture Treatment (MSAT)|MSAT required a part of the patient's body to move passively or actively while acupuncture needles are retained.
223556998|NCT03154515|DRUG|Placebo|
223556999|NCT02492191|DEVICE|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
223407129|NCT04539184|OTHER|Acupuncture|General acupuncture
223407130|NCT06524869|DIAGNOSTIC_TEST|Isokinetic neuromuscular assessment|All sports patients who had a muscle evaluation in addition to functional testing at 6-12 months after ACLR since March 2024
223407131|NCT05464966|DRUG|Glucose insulin potassium|After induction of anaesthesia,cardiac systolic-diastolic function was first measured by TEE, GIK solution was continuously pumped until the end of the procedure at a dose of 30 mU/kg/h of insulin, 0.12 g/kg/h of glucose and 0.06 mmol/kg/h of potassium chloride
223407132|NCT02283268|BIOLOGICAL|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
223557000|NCT02181491|OTHER|[11C]-P943|
223557001|NCT03694769|OTHER|Semi-structured interview|One-hour interview with researcher
223557002|NCT03694769|OTHER|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
223557003|NCT05421169|DIAGNOSTIC_TEST|diastolic hyperemia-free ratio (DFR)|diastolic hyperemia-free ratio uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure
223557004|NCT00025064|BIOLOGICAL|bleomycin sulfate|
224023751|NCT02899013|OTHER|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
224023752|NCT00000577|DRUG|Albuterol|
224023753|NCT00000577|DRUG|Colchicine|
224023754|NCT00000577|DRUG|Adrenal Cortex Hormones|
224023755|NCT00000577|DRUG|Adrenergic-Beta Agonists|
224023756|NCT00657670|DEVICE|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
223407133|NCT00454246|DRUG|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
223407134|NCT00454246|DRUG|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
224297857|NCT00896324|BEHAVIORAL|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
224297858|NCT00896324|BEHAVIORAL|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
224023757|NCT00657670|DEVICE|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
224023758|NCT06069674|DIAGNOSTIC_TEST|Serum dosage of GFAP and UCH-L1|blood test execution as per usual care in the ED
223407135|NCT00454246|DRUG|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
223407136|NCT02185118|DRUG|oxygen|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
223407137|NCT02185118|DRUG|Sevoflurane|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
223407138|NCT02185118|DRUG|Isoflurane|"1. Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~2. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
223407139|NCT06237738|BEHAVIORAL|Stress Ball Use|The intervention in this study involves the use of stress balls provided to participants in the intervention group. These are specially designed medium-firm silicone balls intended for squeezing with the hand opposite the one receiving cannulation during hemodialysis sessions. The primary objective of this intervention is to offer a simple, non-pharmacological method to potentially alleviate the pain associated with the cannulation process. Participants are instructed to use the stress ball for a period of three minutes before the start of cannulation. This activity is hypothesized to focus the participant's attention and possibly reduce the perception of pain, contributing to a more comfortable and less distressing cannulation experience.
223407140|NCT05563779|OTHER|Volume Control mode|Volume Control mode for mechanical ventilation
223557005|NCT00025064|DRUG|chlorambucil|
224023759|NCT02255266|DRUG|liraglutide|No treatment given.
224023760|NCT06463925|OTHER|acneic participants group|Application of Effaclar Duo+M to the face and trunk twice daily (morning and evening) after washing with the cleansing gel.
223557006|NCT00025064|DRUG|cisplatin|
223557007|NCT00025064|DRUG|dacarbazine|
223557008|NCT00025064|DRUG|doxorubicin hydrochloride|
223557009|NCT00025064|DRUG|etoposide|
223557010|NCT00025064|DRUG|ifosfamide|
224297859|NCT00896324|BEHAVIORAL|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
223557011|NCT00025064|DRUG|melphalan|
223557012|NCT00025064|DRUG|prednisolone|
223557013|NCT00025064|DRUG|procarbazine hydrochloride|
223557014|NCT00025064|DRUG|vinblastine sulfate|
223557015|NCT00025064|DRUG|vincristine sulfate|
223557016|NCT00025064|PROCEDURE|peripheral blood stem cell transplantation|
223557017|NCT00025064|RADIATION|radiation therapy|
223557018|NCT04520152|DEVICE|FreeFlowMedical Lung Tensioning Device|Bronchoscopic lung tensioning device implantation
223557019|NCT00301262|DRUG|Viagra (Sildenafil citrate)|
223557020|NCT02524236|DRUG|Botox injection in the prostate|transrectal access of prostatic injection
223557021|NCT00368745|DRUG|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
223737890|NCT04458909|DRUG|Cisplatin|Given IV
223737891|NCT04458909|DRUG|Gemcitabine|Given IV
224132883|NCT05912309|BEHAVIORAL|Exercise|Sport sciences specialists will design, supervise and monitor the concurrent exercise intervention following the 2020 WHO recommendations. The program will be tailored to the participant's ability and health, and will be focused on a gradual increase to levels that are safe. Resistance training: 3 times/week designed to manage, attenuate and even prevent the loss of skeletal muscle tissue and function. The exercise sessions will be scheduled within or immediately after their eating window in order to maximize muscular muscle protein synthesis. Morning and afternoon training schedules will be offered to participants.
224297860|NCT04177641|DIAGNOSTIC_TEST|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
224297861|NCT04177641|DIAGNOSTIC_TEST|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
224297862|NCT00892788|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
223407141|NCT05563779|OTHER|Pressure Control mode|Pressure Control mode for mechanical ventilation
223407142|NCT05563779|OTHER|Adaptive Pressure Control mode|Adaptive Pressure Control mode for mechanical ventilation
223407143|NCT03555318|OTHER|Ambulatory visit|All patients will have an ambulatory visit with the cardiologist.
223407144|NCT03555318|OTHER|Combined ambulatory visit|Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
223407145|NCT03555318|OTHER|Geriatric intervention|After the geriatric assessment, measures to improve frailty will be started.
223407146|NCT02084043|DRUG|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
223407147|NCT02084043|DRUG|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
223407148|NCT01594736|DRUG|ORSIRO|due randomization ORSIRO will be implanted
223407149|NCT01594736|DEVICE|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
223407150|NCT04384575|DIAGNOSTIC_TEST|blind spots|missed part during map the entire stomach through endoscopy
223407151|NCT02497560|DIETARY_SUPPLEMENT|proprietary formula|
223407152|NCT02030340|PROCEDURE|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
223407153|NCT03417557|DEVICE|Comfilcon A lens (test)|contact lens
223407154|NCT03417557|DEVICE|Omafilcon B lens (control)|contact lens
223407155|NCT04963322|OTHER|extracorporeal membrane oxygenation therapy|Extracorporeal membrane oxygenation for the management of severe refractory heart and lung dysfunction
223407156|NCT02075216|PROCEDURE|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
223407157|NCT02075216|BIOLOGICAL|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
223407158|NCT05677256|BIOLOGICAL|nOPV2|Vaccination
223407159|NCT01692925|DRUG|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
223407160|NCT01692925|DRUG|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
223407161|NCT04506463|DRUG|MM-II dose I|Intra-articular injection
223407162|NCT04506463|DRUG|MM-II dose II|Intra-articular injection
223407163|NCT04506463|DRUG|MM-II dose III|Intra-articular injection
223407164|NCT04506463|DRUG|Placebo|Intra-articular injection
223407165|NCT04506463|DRUG|Placebo|Intra-articular injection
223407166|NCT04506463|DRUG|Placebo|Intra-articular injection
223557022|NCT00368745|DRUG|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
223557023|NCT00395824|PROCEDURE|anticoagulation procedure|
223557024|NCT04547634|OTHER|Therapeutic Exercise and Education|The intervention will consist of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualized based on the evaluations of muscular strength and endurance. Sessions lasted 1 hour, carried out twice a week, for 12 weeks. This intervention will be complemented by nutritional education.
223557025|NCT02348034|DEVICE|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
223557026|NCT03079934|DEVICE|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
223557027|NCT04413656|OTHER|ablation|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ).
223557028|NCT04413656|OTHER|surgery|Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery, after surgery 1month, 3month).
223407167|NCT01475708|DRUG|Doxycycline|100 mg PO bid, 14 days
223407168|NCT05593081|GENETIC|HLA|Distinguish based on clinical features
223407169|NCT03428503|DRUG|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb\_UK) intravenous (IV) was given 100patients
224023761|NCT00407212|DRUG|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
223407170|NCT03428503|DRUG|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
223407171|NCT02854956|BEHAVIORAL|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :~* The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~* The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~* The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~* The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~* The Nisonger child behavior rating form which allow to assess the behavior disorders~* Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~* Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
223407172|NCT03303456|OTHER|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
223407173|NCT02359487|BEHAVIORAL|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
223407174|NCT02359487|BEHAVIORAL|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
223737892|NCT04458909|BIOLOGICAL|Nivolumab|Given IV
224023762|NCT03064386|PROCEDURE|Plate fixation|internal fixation with the plate
224023763|NCT03064386|PROCEDURE|Screw fixation|internal fixation with the screw
224132884|NCT05912309|BEHAVIORAL|Caloric Restriction|Individualised intensive behavioural intervention weight loss program including CR, exercise training and lifestyle education designed according to the current guidelines. CR will be tailored to participants (objectively assessed). Diet will provide 600 kcal/day less than the individual energy requirements based on measured resting energy expenditure (indirect calorimetry) and multiplied by an activity factor obtained by accelerometry. Experienced nutritionists will design personalized and balanced CR diet, and will train the participants through the food exchange system to follow the treatment. In those cases in which the CR compromised a protein intake of at least 1.2 g/kg/day, the macronutrient percentage distribution will be modified prioritizing achieving this minimum protein intake.
224132885|NCT03435172|DEVICE|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
223407175|NCT02528006|DEVICE|Type 2 Thyroplasty using Titanium Bridges|
224023764|NCT04600232|DIAGNOSTIC_TEST|Alere TB-LAM|Subjects also undergo clinical evaluation including CT, sputum smear, Gene Xpert and mycobacterial culture.
223407176|NCT00003118|DRUG|cisplatin|
223407177|NCT00003118|DRUG|fluorouracil|
223407178|NCT00003118|PROCEDURE|surgical procedure|
223407179|NCT00003118|RADIATION|radiation therapy|
223407180|NCT01702285|DRUG|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
223407181|NCT00707681|DRUG|MS-20|4 ml/vial
224023765|NCT03235284|OTHER|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
224023766|NCT03235284|OTHER|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
224023767|NCT03235284|OTHER|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
224023768|NCT03428737|PROCEDURE|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
224297863|NCT00892788|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
223407182|NCT00707681|DRUG|Placebo|4ml/vial
223737893|NCT04458909|OTHER|Questionnaire Administration|Ancillary studies
223737894|NCT06798831|BIOLOGICAL|Pertussis containing vaccine|Recombinant acellular pertussis (aP) vaccine (containing 5 µg of geneticallydetoxified pertussis toxin (PTgen),
223737895|NCT03119194|DRUG|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
223407183|NCT01085630|DRUG|pemetrexed disodium|Given IV
223407184|NCT01085630|OTHER|clinical observation|
223407185|NCT00032149|BIOLOGICAL|bleomycin sulfate|
223407186|NCT00032149|BIOLOGICAL|filgrastim|
223407187|NCT00032149|DRUG|cyclophosphamide|
223407188|NCT00032149|DRUG|etoposide|
223407189|NCT00032149|DRUG|mitoxantrone hydrochloride|
223407190|NCT00032149|DRUG|prednisolone|
223407191|NCT00032149|DRUG|vincristine sulfate|
223407192|NCT03643601|OTHER|Non-Interventional|Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
223557029|NCT02305589|DRUG|Sugammadex|Muscle relax reversing agent
223557030|NCT01882556|DRUG|onabotulinumtoxinA|
223557031|NCT01882556|DRUG|Placebo|
223407193|NCT05977660|DIAGNOSTIC_TEST|Cumberland ankle instability tool for diagnose to determine ankle instability and its severity|CAIT is a Patient-reported measures of outcome (PROM) and it is very simple, reliable, and valid measurement tool that is used without comparing with the contralateral ankle, which consists of 9 questions and is scored between 0 and 30, developed by Hiller and her colleagues in 2006 to measure the severity of functional ankle instability. Low scores of the participants indicate poor ankle stability, while high scores indicate good ankle stability.
223407194|NCT06146465|OTHER|speciality|Not
223407195|NCT01357499|DEVICE|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
223407196|NCT01357499|DEVICE|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
223557032|NCT02876237|OTHER|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
223557033|NCT02876237|RADIATION|Radiotherapy|standard radiotherapy
223557034|NCT06125925|PROCEDURE|Radiofrequency catheter ablation (RFCA)|Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.
223557035|NCT06125925|DRUG|Medical Therapy|AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.
224132886|NCT00848549|DRUG|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
223407197|NCT01017874|DRUG|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
223407198|NCT01017874|DRUG|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
223407199|NCT01017874|DRUG|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
223407200|NCT01017874|DRUG|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
223407201|NCT04025060|BEHAVIORAL|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
223407202|NCT04025060|BEHAVIORAL|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
223557036|NCT00070876|BEHAVIORAL|Mental health communication skills training|
223557037|NCT02251834|BEHAVIORAL|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
224138864|NCT02852148|DEVICE|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
223407203|NCT04025060|BEHAVIORAL|Regular soda|Subjects are asked to consume regular soda daily for two weeks
223407204|NCT05519826|DEVICE|Vascular surgery|"POLYMAILLE® EXTRA THIN vascular prostheses are indicated for replacement or bypass of arteries presenting aneurysm or obliterative arterial disease. Their indication is restricted to abdominal and peripheral surgery not crossing the knee flexion crease.~Abdominal vascular surgery includes aorto-iliac and/or aorto-femoral vascular repair, i.e. graft implantation with proximal anastomosis to abdominal aorta (supra and/or infra-renal).~Peripheral vascular surgery includes peripheral arteries repair, i.e. graft implantation with no aortic anastomosis, and/or extra-anatomic vascular repair such as axillo-femoral and/or crossover bypass (femoro-femoral and/or ilio-femoral) and/or femoro-popliteal bypass above the knee."
223407205|NCT02055924|DRUG|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
223407206|NCT02439060|OTHER|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
223407207|NCT02894645|DRUG|Prednisolone|Oral
223407208|NCT02894645|DRUG|Dexamethasone|Oral
223407209|NCT02894645|DRUG|L-Asparaginase|Intramuscular injection
223407210|NCT02894645|DRUG|Vincristine|Intravenous
224023769|NCT03428737|PROCEDURE|Pressure support ventilation|use of a pressure support level identical during the night to the pressure support level at the end of the day.
224023770|NCT02640885|DEVICE|Foley's cather ballon|
224023771|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
224023772|NCT00503659|PROCEDURE|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
223407211|NCT02894645|DRUG|Methotrexate|Intrathecal/ Intravenous/ Oral
223407212|NCT02894645|DRUG|Daunorubicin|Intravenous
224023773|NCT06585774|DRUG|INCA034176|IV infusion
224023774|NCT06585774|DRUG|Placebo|IV infusion
224138865|NCT01376713|BIOLOGICAL|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
223407213|NCT02894645|DRUG|Doxorubicin|Intravenous
223407214|NCT02894645|DRUG|Cyclophosphamide|Intravenous
223407215|NCT02894645|DRUG|Cytarabine|Intravenous/ Subcutaneous injection
223407216|NCT02894645|DRUG|6-Mercaptopurine|Oral
223407217|NCT02894645|DRUG|Thioguanine|Oral
223407218|NCT02894645|DRUG|Fludarabine|Intravenous
223407219|NCT02894645|DRUG|Imatinib|Oral (For BCR-ABL ALL only)
223407220|NCT06367504|DIETARY_SUPPLEMENT|DBMF|Once a day daily 30 minutes before lunch
223407221|NCT06367504|DIETARY_SUPPLEMENT|Placebo|Once a day daily 30 minutes before lunch
223407222|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
223407223|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
223407224|NCT00865228|DRUG|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
223407225|NCT00865228|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
223407226|NCT03004651|OTHER|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
223407227|NCT03004651|OTHER|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
223407228|NCT01702623|DRUG|Oxcarbazepine|
223557038|NCT02251834|OTHER|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
223557039|NCT03239951|DEVICE|iTind|temporary implant
223557040|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
223557041|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
223557042|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
223557043|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
223557044|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
223557045|NCT00987441|DRUG|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
223557046|NCT00178165|PROCEDURE|Skill Training Condition - problem solving training|
223557047|NCT00178165|PROCEDURE|REACH for TLC (Telephone Linked Computer) system|
223557048|NCT02720380|OTHER|Buteyko|Intervention will be held twice a week during 3 weeks.
223557049|NCT02720380|OTHER|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
223557050|NCT00368381|DRUG|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
223557051|NCT02687685|OTHER|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
223557052|NCT02687685|OTHER|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
223557053|NCT04717297|BEHAVIORAL|Medication Management Remote Intervention|First, the study pharmacist reviews the older adult's medication for potentially inappropriate medications. The pharmacist collaborates with the prescribing physician(s) to deprescribe as indicated. The pharmacist educates the older adult and OT on any changes that were made. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT provides training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered remotely.
223557054|NCT04717297|BEHAVIORAL|Waitlist Control|A trained research assistant will complete two attention control visits in the homes of participants. Visit will consist of semi-structured interview exploring the participant's life history.
224023775|NCT06585774|DRUG|Corticosteroids|Oral/IV Infusion
223737896|NCT00774618|DEVICE|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
223737897|NCT05615012|DRUG|BMS-986322|Specified dose on specified days
223737898|NCT05615012|DRUG|Rosuvastatin|Specified dose on specified days
223737899|NCT05615012|DRUG|Metformin|Specified dose on specified days
224023776|NCT03513874|DRUG|Metformin|Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
223407229|NCT04028050|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.
223737900|NCT05615012|DIETARY_SUPPLEMENT|Glucose|Specified dose on specified days
224023777|NCT03513874|DRUG|Insulin|Patients will continue insulin therapy following physicians' instructions.
224023778|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
224023779|NCT01589666|DRUG|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
224023780|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
224023781|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
224023782|NCT01589666|BIOLOGICAL|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
224023783|NCT02467218|OTHER|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
224023784|NCT04370977|DRUG|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
224132887|NCT00848549|DRUG|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
224132888|NCT00005050|DRUG|ethynyluracil|
224132889|NCT00005050|DRUG|fluorouracil|
224132890|NCT00005050|DRUG|oxaliplatin|
224132891|NCT05740449|DRUG|Decitabine|intravenous
224132892|NCT05740449|DRUG|Venetoclax|oral
223407230|NCT04028050|DRUG|Carboplatin|Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.
223407231|NCT04028050|DRUG|Etoposide|Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
223407232|NCT06133608|OTHER|MOBILIZATION TRAINING|"Things to consider in the hospital in the early period after surgery: The first day in the hospital after surgery, the importance of the abduction pillow and early mobilization,~* Exercises performed in bed in the early period after surgery: Exercises such as ankle pump, ankle rotation, bed-supported knee bending, hip contraction, opening exercise, thigh exercise, straight leg raise,~* Early standing up: Activities such as sitting in bed or on a chair, standing up with the help of a walker, walking,~* Exercises performed while standing: Exercises such as lifting the knee, opening the leg to the side,~* Daily living activities: It will provide information on regulating ADLs such as bathing, dressing, using the toilet, getting into and driving the car, going up and down stairs, eating, sleeping, doing housework, sexual life, and information about the safety precautions that should be taken at home."
223407233|NCT06576999|DEVICE|Sensor-based Balance Training|10 sessions of sensor-based balance training with exergaming feedback. For this training an adaptive integrated audio-visual feedback system composed of five IMUs and a force platform connected wirelessly to a computer has been used. The training protocol include exercises of balance control, encompassing a total of five distinct exercises: i) Latero-lateral load shifting while seated; ii) Load shifting while standing: latero-lateral and antero-posterior, to simulate the balance control performed during the day; iii) Load control during sit-to-stand; iv) Gait swing and loading phase response: to stimulate a correct load shifting during the swing and stance phase; v) Latero-lateral load shifting with knee flexion.
223407234|NCT06576999|OTHER|Usual Balance Trainging|10 sessions of usual balance training. The training includes: gait control exercises, weight shifting, and relies on both stable surfaces (i.e., steps) and unstable surfaces (i.e., oscillating platforms and various-sized fitballs). The protocol encompassed the application of stabilization techniques and the reaching of targets with the upper limb during upright position emulating the activity of daily living.
223407235|NCT01925430|DEVICE|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
223407236|NCT01925430|DEVICE|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
223407237|NCT04029025|PROCEDURE|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
223407238|NCT04029025|PROCEDURE|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
223407239|NCT04029025|PROCEDURE|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
223407240|NCT01346696|DEVICE|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
223407241|NCT05350618|OTHER|Ultrasound evaluation|A single transperineal ultrasound assessment session
224023785|NCT04370977|DRUG|Winthrop™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
224023786|NCT04599400|OTHER|There is no intervention in our study|There is no intervention in our study
224023787|NCT03539341|BEHAVIORAL|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
224132893|NCT05740449|DRUG|Navitoclax|oral
224132894|NCT05740449|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
224138866|NCT01376713|BIOLOGICAL|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
223407242|NCT05233553|OTHER|control of liver enzymes|follow-up with clinical and laboratory measurements
223407243|NCT00878943|DRUG|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
223407244|NCT01854190|DEVICE|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
223407245|NCT02737488|BEHAVIORAL|Trauma Systems Therapy (TST)|Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
223407246|NCT02737488|BEHAVIORAL|Treatment as Usual (TAU)|"Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency."
223407247|NCT04083885|OTHER|Virtual Reality|Participants will be provided with a virtual reality training program, personalized with respect to their abilities, endurance, needs and treatment goals. They will be trained to use the program and it will be installed in their home or provided at their long-term care facility. Participants will be suggested to perform VR 3-5 times a week for 8 weeks. Sessions will be 20-30 minutes long, depending on tolerance.
223407248|NCT04236492|PROCEDURE|Fresh osteochondral allografting|Transplantation of a fresh osteochondral allograft in the knee
223407249|NCT02006589|DRUG|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
223407250|NCT02006589|DRUG|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
223557055|NCT04717297|BEHAVIORAL|Medication Management In-Person Intervention|Participants in the waitlist control will be offered the medication management intervention to be completed in person. If they consent, the study pharmacist will review their medication for potentially inappropriate medications. The pharmacist will collaborate with the prescribing physician(s) to deprescribe any inappropriate medication as indicated. The pharmacist will educate the older adult and OT on any changes. The OT and older adult will develop a plan to reduce risk factors and improve medication management. Participants will receive tailored compensatory strategies and supports to remediate extrinsic risk factors and modify the home environment to improve medication adherence. The OT will provide training and active practice of the compensatory strategies and supports in the home in an effective and safe manner. All components of the intervention will be delivered in person.
223557056|NCT01771692|OTHER|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
223557057|NCT01771692|OTHER|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
223737901|NCT05615012|DRUG|Methotrexate|Specified dose on specified days
223737902|NCT05615012|DRUG|Leucovorin|Specified dose on specified days
223737903|NCT01078012|BEHAVIORAL|Trained counselling|
223737904|NCT02417688|DEVICE|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
224023788|NCT03539341|OTHER|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
224138867|NCT00916370|DEVICE|Core size Xience Prime|Core size includes a range of stent sizes.
224138868|NCT00916370|DEVICE|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
224138869|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
223737905|NCT04197089|DRUG|Vitamin D|First dose of 10.000 IU Vitamin D at baseline visit for all patients; stratification of treatment (10.000 or 50.000 IU Vitamin D) depending base 25(OH)Vitamin D levels. Treatment weekly during 4 weeks before scheduled cystectomy
223737906|NCT06377228|BIOLOGICAL|TAK-007|TAK-007 IV infusion.
223737907|NCT06377228|DRUG|Chemotherapy Agents|Fludarabine and cyclophosphamide IV infusion.
223737908|NCT00329654|PROCEDURE|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
223737909|NCT03190161|BEHAVIORAL|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
224023789|NCT06287775|BIOLOGICAL|Atezolizumab|Given IV
224023790|NCT06287775|PROCEDURE|Biopsy Procedure|Undergo optional tumor biopsy
223737910|NCT06378541|BEHAVIORAL|Virtual Hope Box Enhanced Facilitation|The VHB-EF intervention has two phases: (1) The in-person inpatient phase involves a single, one-on-one, 60-minute session delivered by the study interventionist prior to hospital discharge. During this session, the interventionist will obtain access to the participant's personal phone and assist them in downloading the VHB app. The interventionist will provide education about the app and personalized behavioral practice for each component of the app. They will also address strategies to enhance app use. In addition, participants will receive a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. (2) The remote-delivery phase builds on the work begun in the hospital via 2 follow-up phone contacts within 14 days following discharge, during which the study interventionist will monitor risk, review/revise VHB content, and support app use and outpatient treatment engagement.
223737911|NCT06378541|BEHAVIORAL|Enhanced Usual Care|The EUC condition will involve a one-on-one, 30-minute session delivered prior to hospital discharge, during which the study interventionist will review a list of Veteran mental health resources, community services, Veteran service organizations, and other Veteran social support services available to Veterans in the area. The EUC session will remain focused only on reviewing the standardized list of Veteran and community services; no counseling will be provided, and the list provided by the study interventionist does not include non-services (i.e., does not list any smartphone applications, including the VHB app).
223737912|NCT04240925|DEVICE|NIMV with sigh breaths|Sigh breaths: Maximal Inspiratory pressure (IPAPmax) increased of at least 25% ( ≥ 125%) with a frequency of at least 1/200 breaths. The sigh breaths will be delivered as part of the standard NIMV protocol
223737913|NCT04240925|DEVICE|Standard NIMV|Will be treated by standard NIMV with no sigh
223737914|NCT02902640|DRUG|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
223737915|NCT02902640|DRUG|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
223737916|NCT02902640|DRUG|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
223737917|NCT05754528|DRUG|Standard of care administration of Endocrine therapy|Standard daily dosing of endocrine therapy. Defined as taking endocrine therapy every day from the start.
224023791|NCT06287775|PROCEDURE|Biospecimen Collection|Undergo blood and urine sample collection
224132895|NCT06361264|COMBINATION_PRODUCT|Karanahan|During the preparatory stage, a tumor sample from participant is harvested intraoperatively. The primary culture is obtained from this tumor tissue sample. Repair cycle time is estimated, and the day when tumor cells are synchronized at the cell cycle G2/M phase is identified. The schedule of administering cyclophosphamide and DNAmix complex composite preparation is calculated according to the resulting time points. According to the elaborated regimen, the participant receives 4 intravenous cyclophosphamide injections at the dose of 300 mg/m2 in combination with 4 injections of 1-12 mg of DNAmix administered into prominent tumor nidi and lymph depots. The participant receives from 2 to 6 courses of therapy. The interval between courses is 21 days.
223737918|NCT05754528|DRUG|Dose-frequency escalation administration of Endocrine therapy|Endocrine therapy dose-frequency escalation. Defined as taking endocrine therapy every other day for 1 month and then daily.
224132896|NCT04136080|OTHER|vasopressors|control the mean arterial pressure with vasopressors
223737919|NCT00006337|DRUG|KW-6002|
223737920|NCT00006337|DRUG|IV Levodopa|
224023792|NCT06287775|PROCEDURE|Computed Tomography|Undergo CT scan
224023793|NCT06287775|BIOLOGICAL|Durvalumab|Given IV
224023794|NCT06287775|PROCEDURE|Echocardiography Test|Undergo ECHO
224023795|NCT06287775|DRUG|Iadademstat|Given PO
224023796|NCT06287775|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224023797|NCT06287775|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224023798|NCT03674437|BEHAVIORAL|Traditional Neurocognitive Assessments|Traditional Neurocognitive Assessments given with pen and paper
224023799|NCT03674437|BEHAVIORAL|Online Cognitive Battery (Cogsuite)|Cognition (Cogsuite) for a battery that consists of seven measurements.
224023800|NCT00521547|PROCEDURE|Electroacupuncture|
224023801|NCT00402038|DRUG|SC Methylnaltrexone|Dose 1
224023802|NCT00402038|DRUG|SC Placebo|
224132897|NCT00039442|DRUG|Capecitabine|Given orally
224132898|NCT00039442|OTHER|Laboratory Biomarker Analysis|Correlative studies
224132899|NCT01911299|DIETARY_SUPPLEMENT|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
224132900|NCT01911299|DIETARY_SUPPLEMENT|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
224132901|NCT03508141|DRUG|Fibrinogen Concentrate|Experimental
224132902|NCT03508141|DRUG|Cryoprecipitate|Comparator
224132903|NCT01013168|PROCEDURE|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
224132904|NCT00544011|BIOLOGICAL|bevacizumab|
224132905|NCT00544011|DRUG|capecitabine|
224132906|NCT00544011|DRUG|fluorouracil|
224132907|NCT00544011|DRUG|irinotecan hydrochloride|
224023803|NCT03575754|DEVICE|Percutaneous Ultrasound Gastrostomy|A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
223407251|NCT01610089|OTHER|stable isotope infusion|"Control subjects: \[15N2-ureido\] arginine (0.69 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of \[15N2-ureido\] arginine (0.69 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,\[15N2-ureido\] arginine (4.14 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of \[15N2-ureido\] arginine (4.14 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr)."
223407252|NCT02810366|OTHER|Physician versus Computer Coded Verbal Autopsy|Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
223407253|NCT00932048|DRUG|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
223407254|NCT04477148|DEVICE|endotracheal intubation|patients were intubated with 3 different blades
224023804|NCT05681858|DIAGNOSTIC_TEST|CT coronary angiography and [12N] NH3 PET-MR|Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
224023805|NCT01382706|DRUG|docetaxel|Given IV
224023806|NCT01382706|DRUG|lapatinib ditosylate|Given PO
224023807|NCT01382706|OTHER|immunohistochemistry staining method|Correlative studies
224132908|NCT00544011|OTHER|diagnostic laboratory biomarker analysis|
224132909|NCT01842841|DRUG|velaglucerase alfa|15-60 U/kg, EOW
224132910|NCT01418053|DRUG|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
224132911|NCT01418053|DRUG|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
223557058|NCT03300154|BEHAVIORAL|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
223557059|NCT03300154|BEHAVIORAL|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
223557060|NCT01436656|DRUG|LGX818|
223557061|NCT02102685|PROCEDURE|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
223557062|NCT02102685|PROCEDURE|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
223557063|NCT04667676|DEVICE|acupoint TENS|TENS was applied bilaterally on acupoint Ex-B1, 4Hz frequency, and 200 μs pulse width and intensity was set at the best highest tolerable intensity by the patient sensitivity without a sensation of discomfort for 45 minutes, three times/week for four weeks
223557064|NCT02636504|DEVICE|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
223557065|NCT04729972|COMBINATION_PRODUCT|NT-501 CNTF implant|Single implantation of CNTF-secreting NT-501 device into fellow (untreated) eye
223557066|NCT02535013|DEVICE|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
223557067|NCT00241176|DRUG|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
223557068|NCT02321917|DEVICE|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
223557069|NCT00576628|DRUG|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
224023808|NCT01382706|GENETIC|fluorescence in situ hybridization|Correlative studies
224023809|NCT01382706|OTHER|laboratory biomarker analysis|Correlative studies
224132912|NCT05963048|DRUG|Rituximab|IV infusion 1000 mg
224132913|NCT05963048|DRUG|IL6 inhibitor|6 mg/kg I V infusion monthly
224023810|NCT05559099|DRUG|Tecovirimat Oral Capsule|"200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)"
224023811|NCT05559099|DRUG|Placebo|Capsules to match tecovirimat
224023812|NCT06514898|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|"After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.~up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment)"
224023813|NCT06514898|BIOLOGICAL|TTRNA-xALT|All participants will receive a single infusion of T-cells.
224023814|NCT06514898|DRUG|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #5, #7 and #9.
224023815|NCT06514898|BIOLOGICAL|autologous HSCs|All participants will receive a single intravenous infusion of autologous HSCs.
224023816|NCT06514898|DRUG|Pembrolizumab|Participants will receive PD-1 blockade IV starting with ACT continuing for up to 2 years as long as tolerable and without disease progression.
224023817|NCT04018092|DEVICE|Active NIR-PBM|Near infrared light was delivered to the head using two MedX Rehab Console systems (MedX Health, 1116). Each MedX console included a control unit and 3 superluminous light emitting diode (LED) clusters. Each LED cluster (3MedX MCT502) consisted of 52 near infrared diodes and 9 visible red diodes. The 9 red diodes were deactivated. The energy delivered by each cluster was 1 joule \[J\]/cm2 in 45 sec at treatment wavelength of 870 nm per each 20 min. The LED cluster has an irradiance of 22.2 mW/cm2, treats an area of 22.48 cm2, with an energy density of 26.64/cm2 per cluster (total energy of 599J/cluster). During each session, the 6 clusters were arrayed on the scalp in 2 configurations, 20 minutes per array. Each configuration targeted 6 transcranial sites, guided by the 10-20 system, for a total of 12 sites during the 40-min session. Total energy delivered was 599J/cluster X 12 sites = 7188J. Intranasal stimulation was delivered using..
224023818|NCT04018092|DEVICE|Sham NIR-PBM|The MedX sham and Vielight interventions device are identical in all respects to the active device, except that the MedX console and diode clusters were modified to NOT deliver NIR light when turned on. The sham MedX devices were modified to deliver 'warmth', similar to that of the active devices. As with the active condition, a total of six sham interventions were given over a 12-week period, following the identical procedures described in the active condition
224132914|NCT04629898|BEHAVIORAL|multi-task in the real world and virtual reality video sport games|This was a 2-staged intervention study. The 1st stage intervention uses multitasks in the real world including stepping exercise, ball-kicking activity and bean-bag tossing activity. The 2nd stage intervention used video sport games conveyed by Xbox Kinect. Tennis and golf games were selected.
224023819|NCT05254743|DRUG|Pirtobrutinib|Administered orally.
224023820|NCT05254743|DRUG|Ibrutinib|Administered orally.
224023821|NCT01624805|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224023822|NCT01624805|DRUG|Cyclosporine|Given PO
224023823|NCT01624805|BIOLOGICAL|Filgrastim|Given SC
224132915|NCT02094053|DRUG|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
224132916|NCT02094053|DRUG|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
224132917|NCT02094053|DRUG|Placebo|placebo (oral) once daily, for 24 weeks
223557070|NCT03871309|DEVICE|Tigertriever|Mechanical Thrombectomy
223557071|NCT06057597|PROCEDURE|Laparoscopic OAGB|It is a gastric bypass surgery with a unique gastro-jejunal anastomosis, a long (11-14cm) and narrow (3-4cm) gastric pouch will be created by applying one horizontal 45-mm stapler at the angle of lesser curvature, just above the left branch of the crow's foot, and then four to five vertical 60-mm staple cartridges will be placed upwards to the angle of His, and calibrated along a 32-Fr bougie. Sectioning of the greater omentum into a bivalve will be performed. The jejunum will be measured using pre-measured strip and amounted antecolically at 150 cm from the ligament of Treitz. An end-to-side anastomosis will be performed with the gastric pouch, using a 45-mm linear stapler and an anterior running suture to close gastro-enterotomy.
223557072|NCT06057597|PROCEDURE|Laparoscopic RYGB|A small gastric pouch (30cc) will be created using a linear stapler. The alimentary limb will be moved up into an antecolic position after an epiploic transection so as to perform the gastro-jujunal anastomosis. The gastro-jejunostomy will be performed manually or using a linear or circular stapler. An alimentary limb of 150 cm and a biliary limb of 50cm will be measured (using premeasured strip) in order to perform the latero-lateral jejuno-jejunal anastomosis using a linear stapler. All mesenteric defects (Petersen's space and mesenteric defect) will be closed with a non-absorbable running suture
224023824|NCT01624805|DRUG|Methylprednisolone|Given IV or PO
224023825|NCT01624805|BIOLOGICAL|Pegfilgrastim|Given SC
224023826|NCT04251052|PROCEDURE|Bilateral Salpingectomy|Undergo bilateral salpingectomy
224023827|NCT04251052|PROCEDURE|Bilateral Salpingectomy with Oophorectomy|Undergo bilateral salpingo-oophorectomy
224132918|NCT01902953|DRUG|Lymphoseek and VBD Sln dissection|See detailed description of study design
224132919|NCT06205225|BEHAVIORAL|Text4HF|Behavioral text messages about heart failure self-care
224132920|NCT06205225|BEHAVIORAL|MyApps|consumer mobile health apps and devices for heart failure self-care
224132921|NCT06205225|BEHAVIORAL|MyApps & Text4HF|Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care
224138870|NCT00501215|BEHAVIORAL|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
223557073|NCT01934712|DRUG|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
223557074|NCT01934712|DRUG|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
223407255|NCT00937274|OTHER|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
223407256|NCT00937274|OTHER|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
223407257|NCT00937274|OTHER|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
223737921|NCT02049307|DRUG|Losartan 100mg daily|
223737922|NCT02049307|DRUG|Matching placebo|
223737923|NCT03087526|GENETIC|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
223407258|NCT01706341|DRUG|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
223557075|NCT03206970|DRUG|Zanubrutinib|Administered as specified in the treatment arm.
223557076|NCT01762384|PROCEDURE|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
223557077|NCT01762384|PROCEDURE|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
223557078|NCT01762384|DEVICE|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
223557079|NCT03702959|DRUG|Betamethasone|Corticosteroids
223557080|NCT03379948|DIAGNOSTIC_TEST|blood culture|blood culture to diagnose blood stream infection
223557081|NCT06553118|PROCEDURE|Total knee arthroplasty|Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
223557082|NCT02516982|OTHER|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
223737924|NCT03063658|DRUG|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
223737925|NCT03063658|DRUG|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
223737926|NCT02550366|DRUG|MRI Contrast|MRI Contrast
223737927|NCT04215978|DRUG|BGB-A445|Administered as specified in the treatment arm
223737928|NCT04215978|DRUG|tislelizumab|Administered as specified in the treatment arm
223737929|NCT05357274|DIAGNOSTIC_TEST|Diagnostic testing|Data will be uploaded to a server where algorithms will be deployed that incorporate features related to treatment use and variables of airflow will allocate the care pathway into one of the 4 pathways. Treatment will be directed by this using a validated automated decision support system
223737930|NCT02289976|PROCEDURE|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
224023828|NCT04251052|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224138871|NCT00501215|PROCEDURE|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
223407259|NCT01706341|DRUG|acetate Ringer's solution containing no glucose|
223407260|NCT01706341|DRUG|acetate Ringer's solution containing 1% glucose|
223407261|NCT03946319|DIAGNOSTIC_TEST|Introspect Health|Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
223407262|NCT02348918|DRUG|Luminate 1.0mg|
223407263|NCT02348918|DRUG|Luminate 2.0mg|
223407264|NCT02348918|DRUG|Luminate 3.0mg|
223407265|NCT02348918|DRUG|Avastin|
223407266|NCT02348918|DRUG|Luminate 0.5mg|
223407267|NCT04545008|DRUG|Famotidine|Oral Famotidine
223407268|NCT04545008|DRUG|N-Acetyl cysteine|Oral N-Acetyl Cysteine
223407269|NCT00506415|DRUG|Rivastigmine 5 cm^2|5 cm\^2 transdermal patch
223407270|NCT00506415|DRUG|Rivastigmine 10 cm^2|10 cm\^2 transdermal patch.
223407271|NCT00506415|DRUG|Rivastigmine 15 cm^2|15 cm\^2 transdermal patch.
223407272|NCT00506415|DRUG|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm\^2.
223557083|NCT02516982|OTHER|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
223557084|NCT02516982|OTHER|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
223557085|NCT02516982|OTHER|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
223557086|NCT04136548|DRUG|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
223557087|NCT04136548|OTHER|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
223557088|NCT05139719|DRUG|HEC585 dose A|taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage
223557089|NCT05139719|DRUG|HEC585 dose B|taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage
224023829|NCT04251052|PROCEDURE|Magnetic Resonance Imaging|Undergo pelvic MRI
224023830|NCT04251052|OTHER|Quality-of-Life Assessment|Ancillary studies
224023831|NCT04251052|OTHER|Questionnaire Administration|Ancillary studies
224023832|NCT04251052|PROCEDURE|Transvaginal Ultrasound|Undergo transvaginal ultrasound
224023833|NCT04251052|PROCEDURE|Ultrasound Imaging|Undergo pelvic ultrasound
224023834|NCT04302272|DEVICE|Spiration Valve System (SVS)|Spiration Valves are one-way endobronchial valves indicated for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The Spiration Valve is loaded in the deployment catheter, then passed through the channel of a flexible bronchoscope and deployed at the intended target location. The SVS device is designed to relieve the symptoms of shortness of breath and hyperinflation associated with severe emphysema without surgery.
223407273|NCT00506415|DRUG|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm\^2.
223557090|NCT05139719|DRUG|Placebo|taking Placebo orally once daily, up to 24 weeks in main stage
223737931|NCT00197730|DRUG|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
223737932|NCT00197730|DRUG|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
223737933|NCT03731520|DIAGNOSTIC_TEST|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
223737934|NCT04729569|PROCEDURE|Feather edge finish line preparation|Tooth preparation with feather edge finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
223737935|NCT04729569|PROCEDURE|Deep chamfer finish line preparation|Tooth preparation with deep chamfer finish line will be done to posterior teeth to receive all ceramic full coverage zirconia crowns.
223557091|NCT04030546|DRUG|Ivabradine|Ivabradine capsule
223557092|NCT04005469|DRUG|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
223557093|NCT01756573|DRUG|Dexamthsone|
223557094|NCT01756573|DRUG|Bupivacaine|
223557095|NCT04894838|PROCEDURE|Distal gastric bypass|Distal gastric bypass, revisonal surgery after failed RYGB
223557096|NCT01863069|DRUG|Interferon beta 1a|
224023835|NCT06962280|DRUG|Tirzepatide|Administered SC
223557097|NCT01863069|DRUG|(IM) AVONEX®|
224023836|NCT06962280|DRUG|Placebo|Administered SC
224023837|NCT06961344|DRUG|zagociguat 15mg|once daily oral tablets
224023838|NCT06961630|DRUG|Rivaroxaban|Rivaroxaban 2.5mg will be orally administered twice daily for 6 months.
223557098|NCT01707680|OTHER|SOC|Patient are given standard of care
223557099|NCT01312805|OTHER|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
223557100|NCT01312805|OTHER|CHICA Control|This is CHICA without the asthma module, and was used as a control
224023839|NCT06961630|DRUG|Atorvastatin|Atorvastatin 80mg will be orally administered daily for 6 months.
224023840|NCT05218499|DRUG|Brigimadlin|Brigimadlin taken orally on day 1 of each 21-day cycle (q3w).
224023841|NCT05218499|DRUG|Doxorubicin|Intravenous infusion of 75 milligram per square meter (mg/m2) on Day 1 of each 21-day cycle (q3w) until a maximum cumulative dose of 450 mg/m2 (approximately 6 cycles).
224023842|NCT04055090|GENETIC|Long-Term Follow-Up of Patients who Received Engensis (VM202)|No study drug is administered in this study. Patients who received Engensis (VM202) in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
224023843|NCT04055090|DRUG|Long-Term Follow-Up of Patients who Received Placebo|No study drug is administered in this study. Patients who received Placebo in the previous trial (VMDN-003) will remain blinded and were evaluated in this trial for long-term safety and efficacy.
223407274|NCT05428683|DRUG|intra-vitreal triamcinolone-moxifloxacin injection after cataract surgery as a prophylactic measures against post-operative endophthalmitis|At the end of surgery, 4mg triamcinolone acetonide and 0.2mg moxifloxacin from 0.5 moxifloxacin preservative-free eye drop) were injected once inferotemporally 3.5 mm posterior to the limbus via pars plana into the vitreous cavity by using 30 G needle.
223407275|NCT04578457|DEVICE|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
223407276|NCT04578457|DEVICE|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
223557101|NCT00861172|PROCEDURE|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
224023844|NCT05595642|DRUG|Astegolimab|Participants will receive SC astegolimab Q2W or Q4W
224023845|NCT05595642|DRUG|Placebo|Participants will receive SC placebo Q2W
223407277|NCT04578457|DEVICE|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
224023846|NCT05514444|BIOLOGICAL|MK-4464|MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.
224023847|NCT05514444|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg administered as an IV infusion every three weeks.
224023848|NCT05514444|DRUG|89Zr-MK-4464|89ZR-MK-4464 administered as an IV infusion on C1D1.
224023849|NCT06042569|DRUG|Cyclophosphamide|Given IV
224023850|NCT06042569|DRUG|Docetaxel|Given IV
223407278|NCT04578457|DEVICE|Hearing Aid with NR(3)|Each participant will be fitted with a third noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1) and NR(2).
224023851|NCT06042569|OTHER|Medical Chart Review|Ancillary studies
224023852|NCT06042569|OTHER|Questionnaire Administration|Ancillary studies
224023853|NCT05820087|DEVICE|HistoSonics Edison System|Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
224023854|NCT06644768|DRUG|valemetostat tosylate|Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
224132922|NCT06205225|BEHAVIORAL|Enhanced Usual Care|Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
223407279|NCT03950830|DRUG|Disulfiram|Disulfiram 400mg daily, continuously
223407280|NCT04674215|BEHAVIORAL|Turning in Bed|Preoperative Turning in Bed Training
223407281|NCT04674215|BEHAVIORAL|Mobilization|Preoperative Mobilization Training
223407282|NCT04674215|OTHER|information|Routine Clinical Care
223407283|NCT03062930|BEHAVIORAL|Track 1|Training of non-paretic arm followed by sham condition
224023855|NCT06644768|DRUG|pembrolizumab|One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
224023856|NCT04883762|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Undergo FMT via colonoscopy.
224132923|NCT00305643|DRUG|Capecitabine|Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
223407284|NCT03062930|BEHAVIORAL|Track 2|Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
223407285|NCT01742130|DRUG|sodium bicarbonate solution|
223407286|NCT01742130|DRUG|Isotonic saline|
223407287|NCT06577740|OTHER|Otago Exercise|Group-based otago exercises were performed for 4 weeks. They were also given a brochure containing otago exercises twice a week and applied individually and followed remotely. They were asked to walk normally for 30 minutes twice a week. They then entered a 4-week washout period.
223407288|NCT06577740|OTHER|Dual Task Focused Otago Exercise|After a 4-week washout period, face-to-face group-based and dual-task focused otago exercises were applied once a week for 4 weeks. Participants were given a brochure containing otago exercises including dual-task exercises twice a week and applied individually and monitored remotely. They were asked to walk normally for 30 minutes twice a week.
223407289|NCT00410540|DRUG|OROS hydromorphone HCL ; Morphine sulfate|
223407290|NCT06577844|OTHER|video support|video support provided to the patient before surgery
223407291|NCT03039504|DIETARY_SUPPLEMENT|Potensa, a succinate-based dietary supplement|Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
223407292|NCT03039504|DIETARY_SUPPLEMENT|Placebo|Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
223407293|NCT06526481|PROCEDURE|Endoscopic Transsphenoidal pituitary surgery : Double Nasoseptal Flap Technique|"Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~-On one side full sized nasoseptal flap will be elevated and a smaller sized nasoseptal flap will be elevated on the other side."
223407294|NCT06526481|PROCEDURE|Endoscopic Transsphenoidal pituitary surgery : Rescue Flap Technique|"Patients with with symptomatic pituitary macroadenoma and tumor size ≥ 2 cm will have transsphenoidal endoscopic excision of pituitary adenoma.~\- A horizontal incision will be performed in the nasal septum in a posterior to anterior direction starting from the sphenoid ostium to a point opposite anterior end of the middle turbinate ( approximately up to one half of septum)."
223407295|NCT00717912|OTHER|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
223407296|NCT00717912|OTHER|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
223407297|NCT00717912|OTHER|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
223557102|NCT02788032|OTHER|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
223557103|NCT02508584|BIOLOGICAL|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
223557104|NCT04925219|BEHAVIORAL|Remotely supervised exercise programme|Electronic walking log Fortnightly video/telephone calls with physiotherapist
223557105|NCT04925219|BEHAVIORAL|Self-directed exercise|Electronic walking log and instructions to exercise 4 times per week.
223557106|NCT01804049|DRUG|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
223557107|NCT01804049|DRUG|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
223557108|NCT06035406|DRUG|Retagliptin Phosphate Tablet|Retagliptin Phosphate Tablet;100mg
223557109|NCT01055938|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
223557110|NCT06318247|PROCEDURE|site preservation|Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
223557111|NCT03707990|DRUG|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
223557112|NCT03707990|DRUG|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
223557113|NCT03707990|DRUG|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
223557114|NCT02173639|DRUG|BI 1356/metformin|fixed dose combination tablet
224023857|NCT06434571|BEHAVIORAL|Telehealth cognitive behavioral therapy for insomnia (tCBT-I)|"The general sessions outlines are as follows with each session:~Session 1: determine treatment plan, set up sleep schedule and stimulus control, discuss strategies for how to stay awake to prescribed hour and what to do if wake up in middle of night, sleep hygiene education Session 2: continue upward titration of total sleep time, review sleep hygiene; introduce diaphragmatic breathing Session 3: continue upward titration of total sleep time, introduce mindfulness Session 4: continue upward titration of total sleep time, introduce progressive muscle relaxation Session 5: continue upward titration of total sleep time, discuss negative sleep beliefs Session 6: assess global treatment gains, discuss relapse prevention"
223407298|NCT02007681|BEHAVIORAL|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
223407299|NCT03525223|PROCEDURE|Change of dialysate [Na+]|Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
223407300|NCT05284786|DEVICE|nerve ultrasonography|Ultrasonography of different nerves was performed using a high frequency 18 MHz probe (esaote Ultrasound systems). Each nerve was scanned in axial plane, and the cross-sectional area (CSA) was measured at standardized anatomical points, in brief: median nerve in upper arm, elbow, forearm; ulnar nerve in upper arm and forearm; tibial nerve in popliteal and ankle; peroneal nerve in popliteal fossa, sural nerve in the calf and the vagus nerve.
223407301|NCT01051596|DRUG|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
223407302|NCT01051596|DRUG|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
223557115|NCT02173639|DRUG|BI 1356|
223557116|NCT02173639|DRUG|Metformin|
223557117|NCT02966288|DRUG|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
223557118|NCT02966288|DRUG|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
224023858|NCT06434571|BEHAVIORAL|Web-based cognitive behavioral therapy for insomnia (wCBT-I)|Participants receive a daily e-mail reminder to access the program and to complete a sleep log for the prior night's sleep. After completing the sleep log, the daily lesson is made available. Each participant will be provided with a unique password to access the online program.
223407303|NCT01999816|BEHAVIORAL|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
223407304|NCT04711590|OTHER|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
223407305|NCT01411150|DRUG|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
223407306|NCT03248999|DIAGNOSTIC_TEST|rectal swab|stool samples by rectal swab
223557119|NCT03758131|BEHAVIORAL|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
223557120|NCT03758131|BEHAVIORAL|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
223557121|NCT03758131|OTHER|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
223407307|NCT02514499|OTHER|Questionnaires|
223557122|NCT06106009|DRUG|PF-07976016|Oral solution, oral suspension or solid oral formulation(s)
223557123|NCT06106009|DRUG|Placebo|Oral solution, oral suspension or solid oral formulation(s)
223557124|NCT06106009|DRUG|Midazolam|Midazolam oral solution
223557125|NCT03213132|BEHAVIORAL|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
223557126|NCT03213132|BEHAVIORAL|Patient Education|Educational website containing information on insomnia
223557127|NCT02680938|DRUG|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~\- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
223557128|NCT02680938|DRUG|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~\- The two groups will be compared in the following terms:~1. The duration of the third stage of labor by stopwatch.~2. Hemoglobin (Hb) difference before and 12 h after delivery.~3. The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
223557129|NCT03621904|DRUG|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
223557130|NCT02924441|OTHER|Lidocaine|Applied to breast skin
223557131|NCT02924441|OTHER|Calming Music|Played during mammography
224132924|NCT00305643|DRUG|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
223407308|NCT05658770|BEHAVIORAL|5 days/ week|"The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1.~The exercises to be carried out in phase 1 are:~Supervised Aerobic Training intervention (AT): Perform 50 minutes/day, 3 days/week, totalling 150 min/week at moderate intensity, as recommended by WHO, in a range of 65-75% HRMax.~Supervised Aerobic Training plus Resistance Training intervention (AT+RT): Perform 50 minutes/day, 3 days/week, starting with 50% of 1-repetition maximum (1-RM) and follow a progression of increasing loads up to 75% of 1-RM for optimal gains in strength and insulin action.~Supervised High Intensive Interval Training intervention (HIIT): To be considered high intensive the heart rate needs to be above ≥85%. Perform 25 minutes/day, 3 days/week, totalling 75 min/week at a vigorous intensity, as recommended by WHO."
223557132|NCT02924441|OTHER|No Music|No music played during mammography
224023859|NCT06434571|BEHAVIORAL|Treatment as usual (TAU)|They will be encouraged to avoid starting any new treatment for their sleep unless recommended by their physician. They will be offered access to the web-based CBT-I program following the 6-month reassessment to complete if they wish.
224023860|NCT03952585|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224023861|NCT03952585|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224023862|NCT03952585|DRUG|Cisplatin|Given IV
223407309|NCT05658770|BEHAVIORAL|3 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
223407310|NCT05658770|BEHAVIORAL|2 days/ week|The type of exercise to be performed will be the one that has shown the greatest benefits for MAGE control in phase 1. The exercises to be carried out in phase 1 are the same as described in the first intervention.
223557133|NCT03588806|DRUG|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
223557134|NCT06497283|PROCEDURE|Binaural sound|Binaural sound: Binaural sound will be applied.
223557135|NCT01951989|DRUG|Imiglucérase (drug) pharmacokinetics|
223557136|NCT03089333|DRUG|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
223557137|NCT03089333|DRUG|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
223557138|NCT05206188|BEHAVIORAL|Mastering the World of Work (MWW)|Mastering the World of Work (MWW) is a 29-session individual intervention comprised of 7 modules each covered in 4 sessions, and a wrap-up session. Participants in the randomized clinical trial will be offered to meet on a weekly basis with the MWW clinician assigned to work with them.
223557139|NCT00815568|DRUG|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7\~D-2) Busulfan (3.2mg/kg, iv, D-6\~D-3) Total body irradiation (200cGy/day, D-2,-1)
223557140|NCT06637306|DRUG|Dupilumab|Dupilumab 600mg subcutaneous initial loading dose, 300mg for subsequent doses; administered every 3 weeks for 4 cycles. Immunotherapy drug FDA approved to treat patients with eczema, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Investigational/not yet FDA approved to treat patients with breast cancer.
223557141|NCT06637306|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenous every 3 weeks for 4 cycles and one 400mg intravenous dose one week following completion of chemotherapy. Cancer immunotherapy drug FDA approved for the treatment of high-risk, early-stage, triple-negative breast cancer (TNBC).
223557142|NCT06637306|DRUG|Paclitaxel|Paclitaxel 80mg/m2 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
223557143|NCT06637306|DRUG|Carboplatin|Carboplatin AUC 1.5 intravenous weekly for 12 weeks. Chemotherapy FDA-approved for the treatment of patients with breast cancer.
223557144|NCT04840485|DRUG|SHR-1314|SHR-1314 high dose
223557145|NCT04840485|DRUG|SHR-1314|SHR-1314 low-dose
223557146|NCT04840485|DRUG|Placebo|Placebo
223557147|NCT04287309|OTHER|CAR-T cells|CD19 targeted CAR-T treatment
223557148|NCT05749991|DEVICE|Dryshield|"DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)"
223557149|NCT05749991|DEVICE|Cotton roll isolation|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
223557150|NCT01031589|DRUG|TMC278 (Rilpivirine) LA; Placebo|
224023863|NCT03952585|PROCEDURE|Computed Tomography|Undergo CT
224023864|NCT03952585|OTHER|Fludeoxyglucose F-18|Receive FDG
223557151|NCT04707118|DRUG|cisplatin+Nab-paclitaxel+GEM|Laparoscopic exploration + thermal perfusion cisplatin 40 mg/m2, Postoperative exploration D1, 8 Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 after the second thermal perfusion 4 weeks plan, 6 cycles
223557152|NCT04707118|DRUG|Nab-paclitaxel+GEM|Nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, D1, 8, 15 4 weeks plan, 6 cycles
223557153|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. suturing the nasal conformer in the cleft side
224023865|NCT03952585|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
224023866|NCT03952585|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224023867|NCT03952585|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224023868|NCT03952585|BIOLOGICAL|Nivolumab|Given IV
224023869|NCT03952585|PROCEDURE|Positron Emission Tomography|Undergo PET
224023870|NCT03952585|OTHER|Quality-of-Life Assessment|Ancillary studies
224023871|NCT03952585|OTHER|Questionnaire Administration|Ancillary studies
224023872|NCT06370884|DRUG|IMT|a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
224297864|NCT06483087|BEHAVIORAL|Animated Education Program|Eight minutes animated vedio; presented individually to children in their rooms. The vedio explains specific aspectsof the cardiac cathetrization procedure.
223737936|NCT05276245|BEHAVIORAL|Structured Protocol of Nature Contact|This structured protocol was a 10-day nature-based program with high level of nature engagement and involvement of multiple sensory processes. The program was held in lunch breaks between 12:00 noon and 2:00 p.m. Each session consisted of 30 minutes in the Eco Garden of The Education University of Hong Kong. Activities of this program included walking, ecological photography, sketching butterflies, planting vegetables, drinking herbal tea, observing birds, and taking a nap in nature. Each activity corresponded to specific sensory pathways. For example, butterfly sketching is focused on the use of visual sense, whereas drinking herbal tea involved sense of taste, smell, and touch. Trainers with master's degrees in environmental education and rich experience in guiding ecological tours provided instructions and guidance to participants during the activities. Participants were also asked to pay attention to their surroundings and focus on their five senses during participation.
223737937|NCT04184531|OTHER|Medical Data Collect|It is a retrospective clinical study and we will collect only the medical data registered in our hospital software
223737938|NCT01524848|DRUG|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
223737939|NCT00073359|BEHAVIORAL|Cognitive Behavioral Therapy|
223737940|NCT00204854|BEHAVIORAL|telephone counseling|
223407311|NCT01818271|BEHAVIORAL|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
223737941|NCT00336713|DRUG|Saredutant (SR48968C)|oral administration (capsules)
223737942|NCT00336713|DRUG|Placebo|oral administration (capsules)
224297865|NCT04254640|DRUG|Cladribine Injection|Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
223407312|NCT01818271|BEHAVIORAL|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~* Advanced dynamic tasks, including stepping and other transitional tasks to treadmill \& over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~* Treadmill walking exercise program."
223407313|NCT00510211|DRUG|olanzapine|
223407314|NCT04529629|OTHER|surgery or drug|pheochromocytoma and adrenocortical carcinoma need surgery and primary aldosteronism need drug according to the genetic results
223407315|NCT02522364|DEVICE|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
223407316|NCT02522364|OTHER|Standard|Clinical and intermittent electrocardiographic follow-up of patients
223407317|NCT03903991|OTHER|Temperature recording|Tympanic and oesophageal temperatures will be recorded during the procedure
223407318|NCT05860192|DEVICE|Virtual Reality|Use of this virtual reality headset to deliver a single mindfulness session
223557154|NCT06637488|PROCEDURE|cleft lip repair using fisher technique|Disinfection of the field using Betadine , marking for the incision lines on the lip and vermilion on skin and mucosa , doing incisions as described by Fisher sub anatomic unit repair in 2005 , suturing using vicryl and prolene sutures. No nasal conformers used in this group
223557155|NCT00550810|DRUG|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
223557156|NCT01142778|DRUG|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
223557157|NCT01142778|DRUG|Docetaxel|Docetaxel at a dose of 100 mg/m\^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
223557158|NCT01142778|DRUG|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
223557159|NCT01142778|PROCEDURE|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
223557160|NCT01142778|RADIATION|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
223557161|NCT01142778|DRUG|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
223557162|NCT02384473|PROCEDURE|Real-Time CEUS|Undergo real-time CEUS
223557163|NCT02384473|PROCEDURE|SWE|Undergo SWE
223557164|NCT02384473|DRUG|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
223557165|NCT02384473|DEVICE|Philips Shear Wave Elastography|Type of equipment used for SWE
223557166|NCT05221632|DEVICE|Accelerated transcranial magnetic stimulation with real coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation.
223557167|NCT05221632|DEVICE|Transcranial magnetic stimulation with real coil|The stimulation mode of TMS is 1-Hz repetitive Transcranial magnetic stimulation .
223557168|NCT05221632|DEVICE|Transcranial magnetic stimulation with sham coil|The stimulation mode of TMS is accelerated continue theta-burst stimulation, but without active stimulation.
223557169|NCT01357538|DRUG|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
223557170|NCT01357538|DRUG|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
223557171|NCT05340712|DIETARY_SUPPLEMENT|new infant formula|New formula containing a prebiotic and a mix of probiotics, randomly assigned to infants during a 2-month period and allocated to all infants during the optional open-label follow-up period of 2 months.
223557172|NCT05340712|DIETARY_SUPPLEMENT|Standard formula|Standard infant formula containing no prebiotic nor probiotic, randomly assigned to infants during a 2-month period followed by an optional open-label follow-up period of 2 months with the new infant formula
223557173|NCT03249909|DEVICE|Exufiber Ag+|gelling fibre dressing with silver
223557174|NCT03249909|DEVICE|Exufiber|gelling fibre without silver
223557175|NCT03249909|DEVICE|Aquacel Ag Extra|gelling fibre with silver
223737943|NCT02937519|DEVICE|Chrono-chemotherapy pump:Melodie|
223737944|NCT02937519|DEVICE|Routine intravenous drip|
223407319|NCT05860192|OTHER|application for mindfulness|Application used to realize mindfulness in virtual reality
223407320|NCT04633967|DRUG|Alemtuzumab Injection|"This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed"
223557176|NCT03438279|OTHER|Non-Interventional|Non-Interventional
223557177|NCT01243372|GENETIC|mutation analysis|
223737945|NCT02937519|DRUG|induction Chrono-chemotherapy|
223557178|NCT01243372|OTHER|laboratory biomarker analysis|
223557179|NCT05286658|BEHAVIORAL|MEG/EEG|"The participant will sit still while their head is slid into the helmet-shaped bottom of the MEG device. The MEG contains sensors that passively detect weak magnetic fields outside the head produced by brain activity. The computer records the brain's electrical activity on the screen as wavy lines. The investigators will also ask you to wear sensors to capture eye-blinks (electrooculogram) and heartbeats (electrocardiogram) to facilitate removal from the MEG signal during analysis.~Participant will sit in front of a projector screen and be asked to put on a pair of headphones. Participant will be shown real words or nonsense words to read, the investigators may play sounds through headphones for the participant to repeat. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete."
223557180|NCT05286658|BEHAVIORAL|MRI|An MRI is a test that uses a magnetic field and pulses of radio wave energy to make pictures of organs and structures inside the body. The participant will be able to hear and speak to the research staff at all times during the MRI procedures. The MRI test will take about 15 minutes.
223737946|NCT02937519|DRUG|induction Routine-chemotherapy|
223737947|NCT02937519|DRUG|cisplatin chrono-chemotherapy|
223737948|NCT02937519|DRUG|cisplatin routine-chemotherapy|
223737949|NCT02937519|RADIATION|intensity-modulated radiation therapy|
223737950|NCT03888872|DEVICE|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
223737951|NCT03888872|OTHER|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~1. Wobble board training:~2. Active range of motion exercises (AROM):~3. Gentle manual stretching exercises for both UL \& LL:~4. Graduated gait training:"
223737952|NCT00527943|DRUG|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
223737953|NCT00527943|DRUG|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
223737954|NCT01447810|OTHER|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
223737955|NCT05954624|DRUG|Digoxin|oral
223737956|NCT05954624|DRUG|Rosuvastatin|oral
223737957|NCT05954624|DRUG|ZSP1273|oral
223737958|NCT05954624|DRUG|Itraconazole|oral
223737959|NCT05954624|DRUG|Probenecid|oral
223737960|NCT02345967|DEVICE|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
223737961|NCT03096327|DRUG|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
223737962|NCT03096327|DRUG|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
223737963|NCT04245384|OTHER|Internet-based dietetic treatment with video calls|The dietitian meets the patient through video calls, no physical meetings
223737964|NCT04245384|OTHER|Traditional dietetic treatment|The dietitian meets the patient through physical meetings
223737965|NCT00213915|DRUG|12 g of L-arginine glutamate during 6 weeks twice a day|
223737966|NCT04523233|DIAGNOSTIC_TEST|Amniocentesis|Amniocentesis is a procedure in which amniotic fluid is removed from the uterus for testing or treatment.
223737967|NCT00035464|DRUG|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
223737968|NCT00035464|DRUG|Placebo|placebo tablets, twice a day for 6 months
223737969|NCT00177528|DRUG|venlafaxine-XR|
223737970|NCT02794662|PROCEDURE|Oxygen Environment|FiO2 delivered by servo-controlled incubator
223737971|NCT02794662|PROCEDURE|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
223737972|NCT04655755|DRUG|Decitabine and Cedazuridine|Given PO
224297866|NCT04254640|DRUG|Aclarubicin|aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
224297867|NCT04254640|DRUG|G-CSF|G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
223737973|NCT04655755|DRUG|Venetoclax|Given PO
223737974|NCT02020005|OTHER|Non-flavored 2mg nicotine gum|
223737975|NCT02020005|OTHER|Non-flavored 4mg nicotine gum|
223737976|NCT02020005|OTHER|Mint-flavored 2mg nicotine gum|
223737977|NCT02020005|OTHER|Mint-flavored 4mg nicotine gum|
223737978|NCT02020005|OTHER|Non-flavored nicotine inhaler|
223737979|NCT02020005|OTHER|Mint-flavored nicotine ihaler|
223557181|NCT05286658|BEHAVIORAL|Speaking Tasks|The participant may be asked to perform some of the tasks from MEG again, this time outside of the scanner. As before, the participant may see real words or nonsense words to read, and the investigators may play sounds through headphones and ask the participant to repeat them. Participant speech will be recorded by a microphone. The investigators may ask the participant to identify what they heard by pressing a button on a button-box. These tasks are expected to take about one hour to complete.
223557182|NCT02995161|DRUG|BAY987521|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-106)
223557183|NCT02995161|DRUG|SPF control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
224023878|NCT04616183|DRUG|Abemaciclib|Given PO
224023879|NCT04616183|BIOLOGICAL|Cetuximab|Given IV
224023880|NCT04616183|DRUG|ERK1/2 Inhibitor LY3214996|Given PO
224023881|NCT05180045|BEHAVIORAL|LINKED-BP Program|The intervention arm will include training on HBPM, Sphygmo BP telemonitoring app, and CHW visits for education and counseling on lifestyle modification. Patients will be trained to measure their BP in the morning and evening for 7 days. Patients enter data using Bluetooth device transmission or manual entry. Guidance is provided on accurate BP measurement. The app stores and securely relays data to the cloud. The primary care provider and CHW will be able to visualize the remotely transmitted data via the clinician portal. Other components of usual care at the practices may include dietary counseling, on-site clinical pharmacists, social workers, case managers as needed for BP follow up, and assistance with medications and appointments as needed. The intervention period for each study participant is 12 months.
224023882|NCT06020014|DRUG|AZD4604|AZD4604
224023883|NCT06020014|OTHER|Placebo|Placebo
224023884|NCT04572841|DRUG|SAR441344|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
223557184|NCT01035463|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
223557185|NCT01035463|DRUG|Carmustine|Given IV
223557186|NCT01035463|DRUG|Cytarabine|Given IV
223557187|NCT01035463|DRUG|Etoposide|Given IV
223557188|NCT01035463|DRUG|Lenalidomide|Given PO
223557189|NCT01035463|DRUG|Melphalan|Given IV
223557190|NCT01035463|BIOLOGICAL|Rituximab|Given IV
224023885|NCT04572841|DRUG|Placebo|"Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous"
224023886|NCT05300022|OTHER|TeKnO T1D: Parents|app-delivered curriculum to provide psychoeducational education surrounding diabetes technology use
224023887|NCT02183051|DRUG|Meloxicam 7.5 mg|
224023888|NCT02183051|DRUG|Meloxicam 3.75 mg|
224023889|NCT02183051|DRUG|Meloxicam 1.875 mg|
224023890|NCT02183051|DRUG|Ibuprofen 200 mg|
224023891|NCT02183051|DRUG|Placebo|
224023892|NCT02183051|DRUG|Meloxicam 15 mg|
224023893|NCT02183051|DRUG|Ibuprofen 400 mg|
224023894|NCT00509678|DRUG|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
224023895|NCT06799533|DRUG|PF-08046031|Given into the vein (IV; intravenous)
223557191|NCT04924101|BIOLOGICAL|Pembrolizumab|IV infusion
223557192|NCT04924101|BIOLOGICAL|MK-4830|IV infusion
223557193|NCT04924101|BIOLOGICAL|Boserolimab|IV infusion
223557194|NCT04924101|DRUG|Lenvatinib|Oral capsule
223557195|NCT04924101|DRUG|Etoposide|IV infusion
223557196|NCT04924101|DRUG|Cisplatin|IV infusion
223557197|NCT04924101|DRUG|Carboplatin|IV infusion
223557198|NCT01092780|DRUG|MK-7288|one or two 10 mg capsules, orally, single dose
223557199|NCT01092780|DRUG|Placebo to MK-7288|one or two capsules, orally, single dose
223557200|NCT01092780|DRUG|Modafinil|two 100 mg tablets, orally, single dose
223557201|NCT01092780|DRUG|Placebo to modafinil|two 100 mg tablets, orally, single dose
223557202|NCT01412450|DEVICE|nitinol stent|implantation of one Protégé EverFlex stent
223557203|NCT03220932|PROCEDURE|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
224023896|NCT06119581|DRUG|LY3537982|Administered orally.
224023897|NCT06119581|DRUG|Pembrolizumab|Administered IV.
224023898|NCT06119581|DRUG|Placebo|Administered orally.
224023899|NCT06119581|DRUG|Cisplatin|Administered IV.
224023900|NCT06119581|DRUG|Carboplatin|Administered IV.
224023901|NCT06119581|DRUG|Pemetrexed|Administered IV.
224023902|NCT04090255|PROCEDURE|Renal puncture|The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcn
224023903|NCT05136196|PROCEDURE|Biopsy Procedure|Undergo tumor biopsies
224023904|NCT05136196|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224023905|NCT05136196|DRUG|Cabozantinib S-malate|Given PO
224023906|NCT05136196|PROCEDURE|Computed Tomography|Undergo CT scans
224023907|NCT05136196|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scans
224023908|NCT05136196|BIOLOGICAL|Nivolumab|Given IV
224023909|NCT06469242|DEVICE|Serafilcon A multifocal contact lenses|Investigational multifocal soft contact lenses
224023910|NCT06469242|DEVICE|Senofilcon A multifocal contact lenses|Commercially available multifocal soft contact lenses
224023911|NCT06469242|DEVICE|CLEAR CARE® Cleaning & Disinfecting Solution|Hydrogen peroxide-based contact lens cleaning and disinfection system
224023912|NCT05337514|BEHAVIORAL|Enhanced Engagement|EngAGE will allow care partners send older adults encouragement which will be read aloud to the older adult through the EngAGE app.
223407321|NCT05333601|BEHAVIORAL|eSCCIP|The Electronic Surviving Cancer Competently Intervention Program (eSCCIP) is an innovative eHealth intervention that combines cognitive behavioral and family systems therapy to provide parents and caregivers of children with cancer (PCCC) with evidence-based coping skills and psychosocial support focused on the family unit. eSCCIP has three 30-minute, self-directed, online modules which feature a unique mix of original video content and interactive activities, supplemented by three telehealth follow-up sessions. eSCCIP aims to reduce acute distress and symptoms of post-traumatic stress while increasing positive coping self-appraisal and use of cognitive coping skills.
223407322|NCT03627663|BEHAVIORAL|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
223407323|NCT03563963|DRUG|Ropivacaine 0.5% Injectable Solution|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
223407324|NCT03563963|DRUG|Lidocaine 2% Preservative-Free Injectable Solution|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
223407325|NCT03563963|OTHER|Air|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
223407326|NCT05131217|OTHER|Acute bout of Continuous Moderate Intensity Exercise|In this experimental intervention subjects will cycle continuously at moderate intensity (VO2 corresponding to lactate threshold) until a 200 kcal equivalent energy expenditure is reached.
223407327|NCT05131217|OTHER|Acute bout of High Intensity Interval Training|In this experimental invention subjects will alternate between 1 minute of high intensity cycling (watts corresponding to 85% VO2peak) and 1 minute of low intensity cycling (watts corresponding to 35-40% VO2peak) until a 200 kcal equivalent energy expenditure is reached.
223407328|NCT05131217|OTHER|Control|In this intervention placebo, subjects will lay down on a flat, soft surface for 30 minutes in a dimly light room. They will not be allowed to use any electronic devices or read during this time to avoid potentially influencing continuous data recording.
223557204|NCT03220932|DRUG|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
223557205|NCT01250184|OTHER|Physical therapy|Twelve sessions (3 per week)
223557206|NCT01250184|DRUG|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
223557207|NCT01250184|OTHER|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
223557208|NCT04528017|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
223557209|NCT04528017|DEVICE|Somofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
223557210|NCT04654611|DRUG|preservative free tafluprost 0.0015%|preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
223557211|NCT00178074|BEHAVIORAL|total sleep deprivation|
224023913|NCT05337514|BEHAVIORAL|Standard Engagement|Care partners can encourage their older adult partner using traditional / existing communication mechanisms.
224023914|NCT05041101|DRUG|Eribulin Mesylate|Given IV
224023915|NCT05041101|DRUG|Grapiprant|Given PO
224023916|NCT06369571|DRUG|Atorvastatin 10mg|Atorvastatin 10mg daily by mouth
224023917|NCT06369571|OTHER|Modification of dietary fat composition|Replace 10% of saturated fat intake with polyunsaturated fat
224023918|NCT01205152|BIOLOGICAL|asfotase alfa|
223557212|NCT00178074|PROCEDURE|PET imaging|
223557213|NCT02604602|OTHER|blood exam|laboratory test
224023919|NCT05726630|DRUG|Divozilimab|anti CD20 monoclonal antibody
224023920|NCT05726630|DRUG|Placebo|Placebo
224023921|NCT02491099|DRUG|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
224023922|NCT06613360|DRUG|CLN-978|Specified dose on specified days
224023923|NCT03701308|PROCEDURE|Biospecimen Collection|Undergo blood collection
224023924|NCT03701308|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspirate
224023925|NCT03701308|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224023926|NCT03701308|DRUG|Cytarabine|Given IV
224023927|NCT03701308|DRUG|Daunorubicin|Given IV
223557214|NCT01714037|DRUG|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
223557215|NCT01714037|DRUG|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
224023928|NCT03701308|PROCEDURE|Echocardiography Test|Undergo ECHO
224023929|NCT03701308|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224023930|NCT03701308|DRUG|Uproleselan|Given IV
224023931|NCT04286191|COMBINATION_PRODUCT|Operant Conditioning|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
224023932|NCT04286191|COMBINATION_PRODUCT|Control Group|This is the control intervention, or the non-conditioning group. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the tibialis anterior (TA), the muscle that lifts your toes and foot.
224023933|NCT06647524|DRUG|THC|Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)
223407329|NCT03023917|PROCEDURE|umbilical cord milking|Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
223407330|NCT03023917|PROCEDURE|umbilical cord clamping immediately|umbilical cord was cut immediately after birth
223557216|NCT01714037|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
223557217|NCT01714037|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
223557218|NCT01714037|DRUG|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
223737980|NCT01908361|BEHAVIORAL|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
223557219|NCT05541406|BEHAVIORAL|Proud & Empowered|Proud \& Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
223557220|NCT01825148|OTHER|radiolabeled Exendin|
224023934|NCT06647524|DRUG|Placebo|Participants will be administered identical plant material from which all THC has been removed by solvent extraction.
224023935|NCT04924543|OTHER|Online self-learning training module|Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
224023936|NCT04924543|OTHER|Refresher training|Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
224023937|NCT05997420|BEHAVIORAL|STAR Program|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 90 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 90 days following their discharge and then will be transitioned back to the next appropriate care location.
224132925|NCT00305643|PROCEDURE|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
224132926|NCT00305643|DRUG|Placebo|Oral placebo twice daily on days 1-21
224132927|NCT05086185|DIAGNOSTIC_TEST|Kalemic Response to Orange Juice|100% pulp-free orange juice
224132928|NCT05086185|DIETARY_SUPPLEMENT|Kalemic Response to Orange Juice with Fiber|100% pulp-free orange juice with psyllium-based fiber added
223407331|NCT06574932|BEHAVIORAL|Multi-Strategic Approach|The experimental group will be engaged in multi-strategy approaches including screen time and sanity challenges, weekly screen-free days, screen time reduction goals, screen time tracking, structured daily routines, parental involvement, and monitoring, family media plans, alternative engagements, and promotion of offline social interactions.
223407332|NCT03538288|DEVICE|rTMS|rTMS will be applied at 10 Hz to the DLPFC
223407333|NCT00749073|DEVICE|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
223407334|NCT01701440|DEVICE|Biofusionary Bebe|
223557221|NCT05111431|DRUG|Dexmedetomidine Hydrochloride Nasal Spray|"In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray."
223557222|NCT05111431|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation|"In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
223557223|NCT06281652|OTHER|Go classes|Classes of board games (Go), performed in groups of 6-10 subjects, once a week
224297868|NCT04254640|DRUG|cytarabine|cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.
224297869|NCT04732988|DRUG|HSG4112|Once-daily oral administration
223407335|NCT03307772|DIETARY_SUPPLEMENT|Probiotics|
223407336|NCT03307772|DIETARY_SUPPLEMENT|Prebiotics|
223407337|NCT03307772|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|
223407338|NCT03307772|DIETARY_SUPPLEMENT|Placebo|
223407339|NCT06344195|DRUG|Valacyclovir 500 mg|Valtrex 2g immediate dose followed by 500mg 2 times daily for 3 days along with the analgesic (SOS, if needed) for 6 days
223407340|NCT06344195|DRUG|Naproxen Sodium 550mg|550mg (as needed, SOS) for 6 days
223557224|NCT06281652|OTHER|Chess classes|Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
223557225|NCT06075134|PROCEDURE|Botox injection|Botox injection
223557226|NCT06075134|DEVICE|EMG|Quantitative Electromyography
223557227|NCT06075134|DRUG|Zinc Supplement|To increase efficacy of Botox
223557228|NCT05151692|DRUG|Nipocalimab|Nipocalimab will be administered as an IV infusion.
223557229|NCT05616546|BIOLOGICAL|Influenza Vaccine|The vaccine used in this study will be a licensed seasonal inactivated influenza vaccine for intramuscular injection that is approved by the FDA. Enrolled subjects will receive licensed seasonal inactivated influenza vaccine (administered as a part of the study).
223557230|NCT04903574|BEHAVIORAL|NEAT!2 sedentary behavior app|This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
223557231|NCT04903574|OTHER|Pregnancy smartphone app|This is a commercially available general pregnancy smartphone app
223407341|NCT04994210|DRUG|Sintilimab|"1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects."
223407342|NCT04994210|DRUG|Chidamide|"1. To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of newly diagnosed ENKTCL patients~2. To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of newly diagnosed ENKTCL patients.~3. Exploring biomarkers that may have predictive effects."
223407343|NCT03189095|BEHAVIORAL|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
224138872|NCT00501215|BEHAVIORAL|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
223407344|NCT05206006|OTHER|routine care|The choice of the initial antibiotic regimen will be let to the discretion of the emergency physician
223557232|NCT01959178|DEVICE|LD127025 MF|At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
223557233|NCT01959178|DEVICE|Air Optix Aqua MF|At Visit 1, one-half of the subjects will be randomized to receive the control soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the investigational soft contact lens.
223557234|NCT04424459|DRUG|opioid withdrawal|The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.
224138873|NCT01344837|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223557235|NCT00158249|DRUG|citicoline|2 gm/day, 8 weeks treatment
223557236|NCT00158249|DRUG|placebo|matched for physical appearance
223557238|NCT05583318|OTHER|Data collection|Data from hematological malignancy registries
223557239|NCT05583318|OTHER|Questionnaires|"9 questionnaires were sent out:~1. QLQ-C30 and SF-12 Quality of Life Questionnaire.~2. Oral quality of life questionnaire QLQ-OH15~3. Sexuality questionnaire SHQ-C22~4. Anxiety and depression questionnaire HADS,~5. Rosenberg Self-Esteem Questionnaire~6. RNLI Reintegration to Normal Life Questionnaire~7. Social Support Questionnaire SSQ6,~8. Socio-economic status questionnaire EPICES,~9. Complementary questionnaire collecting data on socio-professional status."
223557240|NCT05103605|DRUG|Osimertinib|Single arm treated by osimertinib
223557241|NCT06477393|OTHER|Regular rehababilitation|Subjects of the experimental and control groups will receive routine procedures applied in the resort sanatorium: physiotherapy (28-32), occupational therapy (12-18), dry hydromassage (7-8), psychotherapy or audiovisual relaxation (3-4), social worker's visit ( 1-2), physiotherapy (magnetotherapy, ultrasound therapy (8-9).
223557242|NCT06477393|OTHER|Heat procedures|"The bath is filled with 200 litres of warm tap water at 36-38°C. The participant lies in the prepared bath, ensuring the chest area remains uncovered. While in the bath, the participant performs gentle movements. The procedure lasts 12-15 minutes. Air is pumped into the water to increase the oxygen saturation in the bath environment.~A prepared gel pack will be placed in another bag and heated to 50-55°C. The heated pack will be delivered to the treatment area using pumps. For applications, the gel pack is used at 40-42°C. Temperature of the gel pack can range between 38-43°C."
223557243|NCT06477393|OTHER|Healing mud application|"Therapeutic mud applications: peat brought from the quarry is sifted, ground, and mixed with natural mineralisation of 20-22g/l with mineral water in a ratio of at least 4:1 until the consistency of thick sour cream. The prepared peat mud is heated to 50-55 degrees. The heated mud is fed to the place where the procedures are performed with the help of pumps. Mud mass at 40-42 degrees is used for applications. A mud temperature range of 38-43 degrees is possible.~Before the procedure, it is recommended not to eat, go to the toilet, or take a warm shower. A polyethene film is laid on a special heated couch, and a 2-4 cm thick layer of mud is poured into the area of the hands and feet, covered with a blanket. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel, and rests. Peloids are not reused."
223557244|NCT06477393|OTHER|Mineral water bath|The pearl bath is prepared by a physical method. The bath is filled with 200 l of warm 36-38 C mineral water, the subject lies in the prepared bath, leaving the heart area open, while lying in the bath he performs light movements. The duration of the procedure is 12-15 minutes. Air is blown into the water, which increases oxygen saturation in the bath environment. Before the procedure, it is recommended not to eat, go to the toilet, take a warm shower. After the procedure, the subject takes a warm, lukewarm shower, wipes himself with a soft towel and rests. Mineral waters are not reused.
223557245|NCT05822804|DEVICE|Vascular Closure Device (Tonbridge)|Hemostasis treatment for femoral artery puncture with Vascular Closure Device (Tonbridge).
224138874|NCT01344837|OTHER|Immunohistochemistry Staining Method|Correlative studies
224138875|NCT01344837|OTHER|Medical Chart Review|Correlative studies
224138876|NCT01344837|GENETIC|Microarray Analysis|Correlative studies
224297870|NCT04732988|DRUG|Placebo|Once-daily oral administration
223407345|NCT05206006|OTHER|Computerized Decision support app (CDSA)|Implementation of an Computerized Decision support app (CDSA) : physician will use this app to help him in the antibiotic choice. This app is an interactive algorithm based on international guidelines that takes into account patients' medical history and characteristics. Secondly, the application is also designed to propose an algorithm of antibiotic revaluation at day 3 for hospitalized patients, depending on patient clinical course, and biological and microbiological results. The revaluation suggests antimicrobial modification (escalation or de-escalation) or discontinuation and stopping rules with recommended duration of therapy also based on international guidelines.
223407346|NCT02409199|DRUG|Docetaxel|
223407347|NCT02409199|DRUG|apatinib|
224297871|NCT06289829|DRUG|remifentanil of the assigned dose|Ambu Auragain will be inserted after general anesthesia is induced with remimazolam and remifentanil. Each patient will be assigned with a certain dose of remifentanil, according to whether the previous patient's LMA insertion process was successful or not.
224297872|NCT06289829|DEVICE|Ambu Auragain for airway management|Ambu Auragain, a type of laryngeal mask airway, will be inserted into every patient after general anesthesia has been induced.
223407348|NCT02391415|BIOLOGICAL|VPM1002|Tuberculosis vaccine
223407349|NCT02391415|BIOLOGICAL|BCG|commercially available live vaccine BCG
224023938|NCT05997420|BEHAVIORAL|Usual Care|Hospitals and their patients will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
224023939|NCT04759911|OTHER|Quality-of-Life Assessment|Ancillary studies
224023940|NCT04759911|OTHER|Questionnaire Administration|Ancillary studies
224023941|NCT04759911|DRUG|Selpercatinib|Given PO
223407350|NCT02391415|BIOLOGICAL|VPM1002(Hyg+)|Tuberculosis vaccine
223407351|NCT06378593|DRUG|3HP-2827|3HP-2827 will be administered orally once daily in 28-day cycles.
223407352|NCT06236789|DRUG|Ifosfamide/mesna|Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression
223407353|NCT04262089|DRUG|Pembrolizumab (Keytruda)|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 2 administrations per patient, integrated into standard-of-care protocol prior to surgery. Based on the well-established time lines, the interval between diagnosis and standard of care hysterectomy is sufficient to treat patients with two cycles of pembrolizumab without interfering with standard of care.
223407354|NCT01599260|OTHER|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
223407355|NCT01075165|OTHER|silicone spray|application of silicone spray to predefined area qd 12 weeks
223557246|NCT05822804|DEVICE|EXOSEAL Vascular Closure Device (Codis Corporation)|Hemostasis treatment for femoral artery puncture with EXOSEAL Vascular Closure Device (Codis Corporation).
223557247|NCT06479083|OTHER|New Intervention form including|The central element of the new form of care is the implementation of a tele medical evaluation and coordination function, which controls individualized treatment processes within the network. The individualized evaluation and coordination of treatment paths is carried out within the already existing Parkinson's network RheinMain+ by a non-physician medical specialist (APN) specially trained for the indication Parkinson's disease.
223557248|NCT06479083|OTHER|Standard treatment|The standard treatment which all compulsory insured patients get.
223557249|NCT05689671|DRUG|Atezolizumab|1200 mg i.v. q3w
224023942|NCT04759911|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
224023943|NCT06056297|DRUG|Mavorixafor|Mavorixafor will be administered per schedule specified in the arm description.
224023944|NCT06056297|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
224023945|NCT02802254|BEHAVIORAL|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
224023946|NCT02802254|DEVICE|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
224023947|NCT00249002|DRUG|ABI-007|
224023948|NCT02667197|OTHER|Algorithm to determine overdose from opioid abuse|
224023949|NCT04049799|OTHER|Medically-supervised withdrawal|6-8 day withdrawal with buprenorphine/naloxone
224023950|NCT04049799|OTHER|Opioid agonist treatment|Induction and maintenance with buprenorphine/naloxone
224023951|NCT04049799|BEHAVIORAL|Comprehensive clinical care|Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
224023952|NCT05730062|DRUG|Oxycodone Hydrochloride|Oxycodone 10 mg IR
223407356|NCT01075165|OTHER|saline spray|application of saline spray to predefined area qd 12 weeks
223557250|NCT05689671|DRUG|Nab paclitaxel|100 mg/m² i.v. qw
223557251|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
223557252|NCT05689671|DRUG|Pembrolizumab|200 mg i.v. q3w
223557253|NCT05689671|DRUG|Cisplatin|75 mg/m² i.v. q3w
223557254|NCT05689671|DRUG|Carboplatin|AUC 5-6 i.v. q3w
223557255|NCT05689671|DRUG|Pemetrexed|500 mg/m² i.v. q3w
223557256|NCT06403098|DEVICE|External Nasal Dilator Strip|Participants will wear an extra strength Breathe Right nasal strip overnight.
223557257|NCT06269185|DRUG|Infliximab|Infliximab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
223557258|NCT06269185|DRUG|Adalimumab|Adalimumab is an antiinflammatory drug (anti-TNF therapy) commonly used in treatment of ulcerative colitis
224023953|NCT05730062|DRUG|Placebo|placebo comparator
224023954|NCT03768583|OTHER|Group TSM ICT sneakers|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
224023955|NCT03768583|OTHER|Group TSM ICT barefoot|Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
224023956|NCT03768583|OTHER|Group TSM health sneaker|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
224297873|NCT04134026|DRUG|HIF-PHI|Drug will be dosed orally three times a week.
223407357|NCT05245526|DEVICE|STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS|Reprocessed noninvasive pulse oximeter sensors.
223407358|NCT05831501|PROCEDURE|Trans abdominis plane block|Ultrasound guided infiltration of local anaesthetic bupivacaine via 22G Quincke needle between internal oblique and trans abdominis muscle layers in abdominal wall.
223407359|NCT03153904|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
223407360|NCT03153904|OTHER|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
223407361|NCT05208463|BEHAVIORAL|Joint Academy|Digitally deliverd exercise and education first line treatment for hip and knee osteoarthritis
223407362|NCT06090825|OTHER|Observational study|Observational study
223407363|NCT04351919|DRUG|Hydroxychloroquine|400mg per day during 10 days
223407364|NCT04351919|DRUG|Azithromycin|500 mg per day during 5 days
223407365|NCT03754335|PROCEDURE|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
223407366|NCT01569971|OTHER|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
223407367|NCT02387671|BEHAVIORAL|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
223407368|NCT02387671|BEHAVIORAL|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
223407369|NCT02387671|BEHAVIORAL|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
223407370|NCT02387671|BEHAVIORAL|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue \& dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
223407371|NCT05792033|OTHER|Prospective registry|Prospective registry of patients with primary diagnosis of T1 urinary bladder cancer
223557259|NCT04670523|PROCEDURE|Early postoperative day 0 (POD 0) chest tube removal.|Chest tube removal is a standard bedside intervention after lung resections. Its time point is normally defined according a traditional standard airleak threshold. Traditionally, in our department this threshold will be respected not earlier than 1 day after the operation. The patients of the study group are getting their chest tube removed according to our current airleak protocol (Flow \<20 mL/ min on digital suction device) but already in the operating room after wound closure (POD 0). If airleak is persisting than chest tube removal will be performed according to the traditional protocol not earlier than on postoperative day 1 (POD 1).
223557260|NCT04670523|PROCEDURE|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).|Chest tube removal according to traditional standard protocol not earlier than on postoperative day 1 (POD 1).
223737981|NCT01908361|BEHAVIORAL|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
224023957|NCT03768583|OTHER|Group TSM health barefoot|Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
223557261|NCT04771299|DRUG|Cariprazine|Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
223557262|NCT04771299|OTHER|Placebo|Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
223407372|NCT00418860|DRUG|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
223407373|NCT02053766|DRUG|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
223407374|NCT02053766|DRUG|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
223407375|NCT02053766|DRUG|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
223407376|NCT04411901|DRUG|Cholecalciferol (vitaminD3)|Theraputic vitamin D3 for CF and non CF bronchiectasis children
223407377|NCT05487001|PROCEDURE|dexamethasone group|"1\) Arm l (dexamethasone group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 188 ml + dexamethasone 10 mg (2 ml))~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
223407378|NCT05487001|PROCEDURE|sham group|"2\) Arm ll (sham group) Ultrasound-guided femoral nerve block with 1% lidocaine 15 ml after the end of surgery Postoperative femoral nerve patient controlled analgesia~* Total volume 250 ml (0.375% ropivacaine 60 ml + normal saline 190 ml~* Basal rate 4 mL/hr, Bolus volume 2 mL, Lock-out time 15 min"
223407379|NCT04791722|BEHAVIORAL|Adaptive Intervention|The investigators will conduct an adaptive intervention using six key implementation strategies identified in earlier research on the experiences of public housing authorities adopting a smoke-free housing policy: resident engagement, smoking cessation support, smoker compliance strategies, smoke-free policy enforcement, staff training and community partnership development. The implementation approach will be tailored for each property by varying the order and intensity of smoke-free policy implementation approaches. The design will determine the optimal plan for utilizing the six implementation strategies by learning from the challenges and successes of other properties (previous waves) and providing support to property managers to refine an implementation plan.
223407380|NCT03510039|BEHAVIORAL|Early device / Follow up|"Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call"
223407381|NCT03510039|OTHER|Usual care|"Group Before : usual care by nurses"
223407382|NCT04027530|DRUG|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
223407383|NCT03955822|OTHER|Phone survey|Phone Survey in order to evaluate adverse effect of the permanently implanted birth control device for women (Essure) will be proposed to wmen Treated between 2002 and 2017 with Essure.
223407384|NCT04409223|DRUG|Famitinib capsules|Oral KIT/PDGFRA kinase inhibitor
223407385|NCT04409223|DRUG|Sunitinib Capsules|Oral receptor tyrosine kinase (RTK) inhibitor
224023958|NCT04504604|DIAGNOSTIC_TEST|FoundationOne CDx and FoundationOne Liquid CDx|Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
224023959|NCT04877288|BIOLOGICAL|Belatacept|Specified dose on specified days
223407386|NCT05497310|DRUG|Arsenic trioxide|Patients will receive ATO 0.3mg/kg/day for days 1-5 (5 doses) and then 0.25 mg/kg/day every other day twice a week for the next 3 weeks (6 doses).
223407387|NCT05497310|DRUG|all-trans retinoic acid|Patients will receive ATRA 25/mg/m2/day for 28 continuous days without interruption.
223407388|NCT01343810|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
223407389|NCT01343810|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
223407390|NCT05737381|OTHER|Differential oxygen tension|By culturing the embryos in a differential O2 set-up, changing the O2 tension from reduced (5% O2) to ultralow (2% O2) from day 3 to day 5 of embryo development in vitro, we mimic the physiological differential changes in O2 as the embryo migrate from the oviduct to the uterus and develops in vivo.
223407391|NCT00113581|DRUG|EMD 72000 (matuzumab) + ECX|
223407392|NCT02414243|OTHER|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
224023960|NCT04877288|DRUG|Tacrolimus|Specified dose on specified days
224023961|NCT04877288|DRUG|Cyclosporine A|Specified dose on specified days
224023962|NCT04877288|DRUG|Mycophenolate Mofetil|Specified dose on specified days
224023963|NCT04877288|DRUG|Enteric Coated Mycophenolate Sodium|Specified dose on specified days
224023964|NCT04877288|DRUG|Corticosteroids|Specified dose on Specified days
224138877|NCT01344837|OTHER|Study of Socioeconomic and Demographic Variables|Correlative studies
224023965|NCT05271292|DRUG|Chiauranib|"Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period~Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles"
224023966|NCT04494256|DRUG|BIIB105|Administered as specified in the treatment arm.
223407393|NCT02414243|OTHER|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
224023967|NCT04494256|DRUG|Placebo|Administered as specified in the treatment arm.
224023968|NCT02625727|OTHER|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
224023969|NCT02625727|OTHER|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
224023970|NCT05712122|PROCEDURE|stellate block|stellate blockade effect on Ventricular arrytmia
224023971|NCT04647643|DRUG|Paclitaxel|Paclitaxel to treat peripheral arterial disease
224023972|NCT05293951|DEVICE|Mirror Strengthening Device|"Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
224023973|NCT05293951|DEVICE|Mirror Therapy|"Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions."
224023974|NCT03226951|DEVICE|Subthreshold 532nm laser|Subthershold 532nm laser
224023975|NCT00484731|PROCEDURE|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
224023976|NCT00484731|PROCEDURE|Infiltration with Bupivacaine|
224023977|NCT01684332|OTHER|Strawberry Jam|
223407394|NCT01489436|PROCEDURE|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
223407395|NCT01489436|PROCEDURE|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
223407396|NCT01297517|DRUG|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
223407397|NCT01297517|DRUG|Brinzolamide ophthalmic suspension, 1%|
223407398|NCT01297517|DRUG|Brimonidine tartrate ophthalmic solution, 0.2%|
223407399|NCT05817149|PROCEDURE|Blood samples|Blood samples
223407400|NCT04714879|OTHER|Device: anodal tDCS|anodal current modulated by an oscillatory component including a fixed (0,75 Hz) versus individually adapted so-tDCS frequency with three different stimulation durations (5 min, 2 min, 30 sec)
223407401|NCT04714879|OTHER|Device: no stimulation|sham stimulation
223407402|NCT04415164|DRUG|Xueshuantong lyophilized powder|Xueshuantong lyophilized powder (500mg), diluted with 250 ml of 0.9% sodium chloride injection, IV (in the vein), once a day, continue for 10 days.
223407403|NCT04415164|DRUG|Placebo|Xueshuantong lyophilized powder Placebo. The usage of placebo is the same as that in the experimental group.
223407404|NCT04415164|OTHER|Guidelines-based standard care|Guidelines-based standard care for acute ischemic stroke
223407405|NCT02637206|DRUG|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
223407406|NCT02637206|DRUG|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
223407407|NCT02637206|DRUG|Empty Patch|Empty patches without any ingredients will be used as negative control.
223407408|NCT02156037|BEHAVIORAL|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
224023978|NCT00986674|BIOLOGICAL|cixutumumab|Given IV
224023979|NCT00986674|DRUG|carboplatin|Given IV
224023980|NCT00986674|DRUG|paclitaxel|Given IV
224023981|NCT00986674|BIOLOGICAL|cetuximab|Given IV
224023982|NCT00632437|PROCEDURE|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
224023983|NCT02709213|DIAGNOSTIC_TEST|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
224023984|NCT02128542|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
224023985|NCT02128542|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224023986|NCT06451250|OTHER|Adult Day Service use for family member with dementia|Self-collection of salivary biomarkers 4 times daily for 5 days, two of those days the family member with dementia has to use adult day services
224138878|NCT01344837|GENETIC|Western Blotting|Correlative studies
224138879|NCT01892618|DRUG|Prevenar 13|13-valent pneumococcal conjugated vaccine
224138880|NCT01892618|DRUG|Pneumovax|23-valent pneumococcal polysaccharide vaccine
224023987|NCT03999021|DRUG|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
224023988|NCT04893109|DRUG|trastuzumab-emtansine|intravenous infusion
224023989|NCT04893109|DRUG|Trastuzumab SC|Muscular injection
223407409|NCT02156037|BEHAVIORAL|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
223407410|NCT05360147|DRUG|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
223557263|NCT04135807|COMBINATION_PRODUCT|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
223407411|NCT05360147|DRUG|Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides|oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
223407412|NCT04806711|DEVICE|Menicon Z Night|Menicon Z Night orthokeratology contact lenses were used to assess their efficacy in reducing myopia progression in children
223407413|NCT04806711|DEVICE|Control|Distance, single-vision glasses were used as a control
223407414|NCT02677571|PROCEDURE|Paravertebral Thoracic block|
223557264|NCT04058561|DEVICE|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
224023990|NCT04893109|DRUG|Paclitaxel|intravenous infusion
224023991|NCT05394337|DRUG|Atezolizumab|Given by vein (IV)
224023992|NCT05394337|DRUG|Tiragolumab|Given by vein (IV)
224023993|NCT05421598|DRUG|Amlitelimab|Injection solution Subcutaneous injection
224023994|NCT05421598|DRUG|Placebo|Injection solution Subcutaneous injection
223407415|NCT02677571|PROCEDURE|Pectorals nerve block|
223407416|NCT02677571|DRUG|Levobupivacaine 0.25%|
223407417|NCT02677571|DRUG|Morphine|
223407418|NCT02928653|DIETARY_SUPPLEMENT|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
223407419|NCT00775229|DRUG|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
223407420|NCT00775229|DRUG|Placebo|pill, by mouth, daily
223407421|NCT03742362|DEVICE|MRI scans of distal radius|MRI scans to monitor the fat fraction in the bone marrow of the distal radius
223407422|NCT02604992|DRUG|Treatment A|Dronabinol oral solution, under fed conditions
223407423|NCT02604992|DRUG|Treatment B|Dronabinol oral capsule, under fed conditions
223407424|NCT02604992|DRUG|Treatment C|Dronabinol oral capsule, under fasted conditions
223407425|NCT02754804|DEVICE|Biomechanic parameters|recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
223407426|NCT06325735|DIAGNOSTIC_TEST|None intervention|None intervention, observational study
223407427|NCT00628212|DRUG|Teneligliptin 10mg|
223407428|NCT00628212|DRUG|Teneligliptin 20 mg|
223557265|NCT06401694|OTHER|Home-delivered meals|Delivery of prepared meals compliant with Older Americans Act nutrition programs guidelines
223557266|NCT06401694|OTHER|Wellness check and socialization visit|At-home delivery with opportunity for driver observation and interaction
223557267|NCT06401694|BEHAVIORAL|Community Health Worker calls|Calls from a certified Community Health Worker (CHW) to assess needs, identify gaps in care and resources, and then support health and resource coordination
223557268|NCT06401694|OTHER|Supplemental grocery bag|Monthly delivery of a grocery bag containing a variety of nutritionally balanced foods and educational materials
224023995|NCT04481204|DRUG|Cisplatin|Given IV
224023996|NCT04481204|DRUG|Fluorouracil|Given IV
224023997|NCT04481204|DRUG|Gemcitabine|Given IV
223407429|NCT00628212|DRUG|Teneligliptin 40 mg|
223407430|NCT00628212|DRUG|Placebo|
223407431|NCT06001710|DEVICE|Needleless jet injector|Device consist of injection pen, ampule and activator.
223407432|NCT02511938|OTHER|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
223407433|NCT02511938|OTHER|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
223407434|NCT05527535|DIAGNOSTIC_TEST|Diabetic retinopathy screening by artificial intelligence|Screening diabetic patients' eyes with AI through digital health platform
223407435|NCT05527535|DIAGNOSTIC_TEST|Diabetic retinopathy screening by healthcare personnel|Screening diabetic patients' eyes by conventional method (healthcare personnel)
224023998|NCT04481204|DRUG|Irinotecan|Given IV
224023999|NCT04481204|DRUG|Leucovorin|Given IV
224024000|NCT04481204|DRUG|Nab-paclitaxel|Given IV
224024001|NCT04481204|DRUG|Oxaliplatin|Given IV
224024002|NCT04481204|RADIATION|Radiation Therapy|Undergo RT
224138881|NCT05120999|DEVICE|Train of four measurement|Use of either TetraGraph or TOFScan to measure the neuromuscular blockade
224138882|NCT03898869|DIAGNOSTIC_TEST|Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization
223407436|NCT01852149|DEVICE|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
223407437|NCT03792399|BEHAVIORAL|feedback counseling|Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
223407438|NCT03390972|DRUG|Placebo|Placebo (NaCl 0.9%) TCI infusion
224024003|NCT05852145|DRUG|Stevioside|"250 ml of natural water added with 0.1 gr. of stevioside should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
224024004|NCT05852145|DRUG|Sucrose|"250 ml of natural water added with 25 gr of sucrose should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
224024005|NCT05852145|OTHER|Natural water|"250 ml of natural water should be drunk~* Salivary pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Dental biofilm pH will be analyzed at 0,5,10,15,30,45 and 60 minutes later~* Streptococcus mutans and Strepcotoccus sobrinus proliferation in dental biofilm ( PCR copies) will be analyzed at 0 and 120 minutes later~* The relative abundance of Streptococcus mutans and Streptococcus sobrinus in dental biofilm will be analyzed using Amplicon Sequence Variant at 0 and 120 minutes later"
224297874|NCT04134026|DRUG|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
224297875|NCT03421041|DRUG|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
223407439|NCT03390972|DRUG|Dexmedetomidine|Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
223407440|NCT05282992|DIETARY_SUPPLEMENT|Native type II collagen|1 capsule/day
223407441|NCT05282992|DIETARY_SUPPLEMENT|Placebo|1 capsule/day
223407442|NCT00616148|DRUG|YKP3089|Oral dosage form
223407443|NCT00616148|DRUG|Placebo|
223407444|NCT05978050|DRUG|nimotuzumab plus paclitaxel|Nimotuzumab injection: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
223557269|NCT06248164|OTHER|No intervention|We will not carry out any type of intervention, just observe the behaviors and health parameters of parents and children.
223557270|NCT05764720|RADIATION|Daily Adaptive External Beam Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
223557271|NCT05014646|DRUG|Cholestyramine|Given PO
223557272|NCT05014646|DRUG|Leflunomide|Given PO
223557273|NCT03943901|DRUG|Rituximab|Rituximab is a monoclonal antibody
223557274|NCT03943901|DRUG|Cyclophosphamide|Chemotherapy drug, alkylating agent
223557275|NCT03943901|DRUG|Doxorubicin|Chemotherapy drug, anthracycline antibiotic
223557276|NCT03943901|DRUG|Vincristine|Chemotherapy drug, plant alkaloid
223557277|NCT03943901|DRUG|Prednisone|Steroid, anti-inflammatory
223557278|NCT03943901|BIOLOGICAL|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier
223557279|NCT05646446|BEHAVIORAL|REACH Program|The REACH program addresses alcohol use, sexual assault risk, and experiences relating to harm among bisexual women.
223557280|NCT06546202|OTHER|No Drug|This is an non-interventional, observational study. No drug was administered during this study.
224297876|NCT03336957|PROCEDURE|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
224297877|NCT00449319|PROCEDURE|Identification of appropriate therapies according to risks factors|
224297878|NCT00449319|DRUG|Daunorubicine|
224297879|NCT00449319|PROCEDURE|Transplant|
224297880|NCT01286389|OTHER|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
223407445|NCT05978050|DRUG|placebo plus paclitaxel|placebo: 50mg/10ml/stick Paclitaxel: 30mg/5ml/stick
223407446|NCT04203446|OTHER|Assessment of correctness of inhaling technique|Assessment of correctness of inhaling technique in patients with asthma or COPD
223407447|NCT01994434|PROCEDURE|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
223557281|NCT03393897|OTHER|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
223557282|NCT03393897|OTHER|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
223557283|NCT06348615|DEVICE|Anti-cellulite cream-gel Medical Device (DEFBODY)|one bottle of 400 ml, twice a day
223557284|NCT05908981|OTHER|sandalwood aromatherapy (Santalum album)|Aromatherapy is a relaxation therapy media that uses aromatic essence extracts from plant parts. Aromatherapy is used to treat and improve physical and psychological health
223557285|NCT05656222|DRUG|VIA combination treatment|a 90-minute intravenous infusion of irinotecan at a dose of 50 mg/m2/d for 5 days every 3 weeks, vincristine given at a dose of 1.4 mg/m2 (maximum 2 mg) on days 1 and 8, and oral administration of Anlotinib once daily on days 1-14 within a 21-day cycle.
223557286|NCT05132179|DRUG|Dakins Full Strength Solution, 0.5% Topical Solution, HOCl solution|Dakin´s solution is a 50/50 mixture of 1% sodiumhypochlorite and 2% sodiumhydrocarbonate, the mixture is a 0,5% chlorine solution. Dakin´s solution is not used in Sweden on wound. Dakin´s solution is only used in dental care in Sweden.
223557287|NCT05369598|DEVICE|Post-operative ABF followed by fitting according to clinical standard|Cochlear implant will be fitted first with anatomy-based fitting for 6 months and followed by default fitting for 2 months.
224024006|NCT03639753|BEHAVIORAL|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience + safe driving eLearning Modules
224024007|NCT03639753|OTHER|Usual Practice|Standard care for teens who get licensed in the state of PA
224024008|NCT06510374|DRUG|Nadofaragene Firadenovec|Vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification.
224024009|NCT03958474|DRUG|Oxycodone|Participants receive oxycodone or placebo.
223407448|NCT03197038|BEHAVIORAL|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
223557288|NCT05369598|DEVICE|Fitting according to clinical standard followed by post-operative ABF|Cochlear implant will be fitted first with default fitting for 6 months and followed by anatomy-based fitting for 2 months.
224024010|NCT03958474|DRUG|Remifentanil|Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
224024011|NCT06395948|DRUG|APG777|APG777 subcutaneous injection
224024012|NCT06395948|DRUG|Placebo|Matching placebo subcutaneous injection
223557289|NCT01059487|OTHER|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
224024013|NCT06297603|DRUG|Retatrutide|Administered SC
224024014|NCT06297603|DRUG|Placebo|Administered SC
224024015|NCT02513303|DRUG|Sirolimus|A single dose of sirolimus delivered locally
224024016|NCT02513303|PROCEDURE|AV Fistula Surgery|AV Fistula Surgery
224132929|NCT04087343|BEHAVIORAL|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
224132930|NCT04087343|BEHAVIORAL|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
224024017|NCT02513303|DEVICE|Sirolimus-eluting Collagen Implant (SeCI)|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
224024018|NCT06149286|DRUG|Odronextamab|Administered by intravenous (IV) infusion
224024019|NCT06149286|DRUG|Lenalidomide|Administered orally (PO)
224024020|NCT06149286|DRUG|Rituximab|Administered by IV infusion, or subcutaneously (SC)
224132931|NCT04980976|DEVICE|Blind insertion technique|Transesophageal echocardiography probe will be inserted using a conventional blind insertion technique.
223407449|NCT03197038|BEHAVIORAL|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
223407450|NCT04393519|DEVICE|TIPS procedure|Implantation of TIPS for portal hypertension
223557290|NCT05270941|PROCEDURE|COMPARISON OF PLATELET-RICH FIBRIN PREPARED WITH TITANIUM AND SUBEPITHELIAL CONNECTIVE TISSUE GRAFT|In the study, 118 maxillary bilateral multiple Miller Class I gingival recessions in 20 patients were treated. The gingival recessions were randomly treated with either T-PRF (58 teeth) or SCTG (60 teeth) using the modified coronally positioned flap technique. Gingival index, plaque index, probing pocket depth, gingival thickness, recession height, recession width, keratinized gingival width, and open root surface area were measured and recorded at baseline and at the 6th month. Postoperative pain levels were evaluated using the VAS (Visual Analogue Scale), and healing status was evaluated using the wound healing index. The pre- and post-treatment results of both treatment groups and the differences between the groups were evaluated and compared.
223557291|NCT03402594|DEVICE|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
224024021|NCT05599945|DRUG|NNC0581-0001|Participants will receive up to six single dose levels of subcutaneous NNC0581-0001 in a sequential manner with the dose increasing between cohorts.
224024022|NCT05599945|DRUG|Placebo (NNC0581-0001)|Participants will receive single dose of subcutaneous injection of placebo matched to NNC0581-0001.
224024023|NCT04023110|DRUG|Carvedilol|Individually dosed carvedilol
224024024|NCT04160052|DRUG|Azacitidine|Given SC or IV
224024025|NCT04160052|DRUG|Venetoclax|Given PO
224024026|NCT03482297|DEVICE|automated abdominal binder|The binder automatically inflates every time the participant stands up to apply a compression level of about 40 mmHg. Participants will wear the device throughout the active/sham study day.
224024027|NCT03482297|DEVICE|Sham binder|The binder automatically inflates every time the participant stands up to apply a compression level of about 5 mmHg. Participants will wear the device throughout the active/sham study day.
224132932|NCT04980976|DEVICE|C-MAC videolaryngoscope insertion technique|Transesophageal echocardiography probe will be inserted using a C-MAC videolaryngoscope insertion technique
224132933|NCT02974387|DRUG|Fluorometholone(FML)|
224132934|NCT02974387|DRUG|Loteprednol (Lotemax)|
224132935|NCT00541138|DRUG|carboplatin|CBDCA AUC=3
224024028|NCT03482297|DRUG|Placebo|Oral placebo will be given three times a day on the baseline day (placebo)
223407451|NCT02958735|OTHER|Exercise Challenge|Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
224024029|NCT03482297|DRUG|Midodrine|A midodrine pill 10mg will be given three times a day on the standard of care study day
224132936|NCT00541138|DRUG|tamoxifen citrate|Tamoxifen 100mg bid
224132937|NCT00541138|DRUG|topotecan hydrochloride|Topotecan 0.75 g/m2/d
224132938|NCT00541138|OTHER|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
224132939|NCT03398122|PROCEDURE|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
224132940|NCT03398122|DRUG|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
223407452|NCT00771719|DRUG|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
224132941|NCT02106455|DRUG|Sodium risedronate|Sodium risedronate tablets
224132942|NCT02382341|DEVICE|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
224132943|NCT00718289|OTHER|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
224132944|NCT00718289|OTHER|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate \[3.0 mmol/L in A and 0.3 in C\], citrate \[0 mmol/L in A and 0.8 in C\]
224132945|NCT02756975|DEVICE|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
224132946|NCT02756975|DEVICE|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
224132947|NCT06490198|DRUG|OBI-833/OBI-821|"OBI-833 is a glycoconjugate that consists of Globo H, a unique tumor-associated carbohydrate antigen (TACA), covalently linked to cross-reacting material 197 (CRM197), an inactive and nontoxic form of diphtheria toxin (DT) acting as the carrier protein.~OBI-821 is a saponin-based adjuvant derived from the bark of the Quillaja saponaria Molina tree. It is a purified saponin adjuvant structurally similar to adjuvant QS-21. The OBI-833/OBI-821 combination represents a carbohydrate-conjugate vaccine combined with an immune adjuvant, intended to serve as an active cancer immunotherapy."
224132948|NCT01293149|DRUG|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
224132949|NCT01293149|DRUG|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
224132950|NCT03102216|DIAGNOSTIC_TEST|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
224132951|NCT03102216|DIAGNOSTIC_TEST|CBC|Complete Blood Count
223407453|NCT03882983|DRUG|Antria Cell Preparation Process|"Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~* Stromal Vascular Fraction~* Adiployx Biological/Vaccine:"
223407454|NCT00167583|DRUG|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
223557292|NCT03402594|DEVICE|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
223557293|NCT01732029|OTHER|Normobaric hypoxia chamber|
223557294|NCT01264692|DRUG|ACT-280778|10 mg once daily for 28 ± 2 days
223557295|NCT01264692|DRUG|Placebo|Placebo oral capsules matching ACT-280778
223557296|NCT01264692|DRUG|Amlodipine|10 mg once daily for 28 ± 2 days
223557297|NCT00851552|BIOLOGICAL|rituximab|Given IV
224024030|NCT05882877|DRUG|Rocatinlimab|Subcutaneous (SC) injection
224024031|NCT05882877|OTHER|Placebo|SC injection
224132952|NCT03102216|DIAGNOSTIC_TEST|ECG|ElectroCardioGram
224132953|NCT03102216|DIAGNOSTIC_TEST|Lodox|Low dose x-ray
224132954|NCT04159077|DRUG|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
224132955|NCT04159077|DRUG|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
224132956|NCT00095368|DRUG|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
224132957|NCT02531464|OTHER|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
223557298|NCT00851552|DRUG|bortezomib|Given IV
223557299|NCT00851552|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223557300|NCT00851552|GENETIC|gene expression analysis|Correlative Study
223557301|NCT00851552|GENETIC|polymerase chain reaction|Correlative Study
223557302|NCT00851552|GENETIC|polymorphism analysis|Correlative Study
223557303|NCT00851552|GENETIC|proteomic profiling|Correlative Study
224024032|NCT05515341|DEVICE|Commercially Approved Interventional Medical Device/Therapy for Chronic Pain|Commercially Approved Interventional Medical Device/Therapy
224024033|NCT06295588|DRUG|Fucoidan extracted from F. Vesiculosus|4 g daily
224024034|NCT06295588|DRUG|Fucoidan extracted from U. Pinnatifida|4 g daily
224132958|NCT04906408|DEVICE|Prevena|Incisions will be dressed with closed incisional negative pressure wound therapy
224132959|NCT04906408|DEVICE|Prineo|Incisions will be dressed with Prineo
224132960|NCT04906408|DRUG|Traditional|Incisions will be dressed with bacitracin/xeroform
224132961|NCT05188612|COMBINATION_PRODUCT|Observational (registry)|Observational (Patient Registry)
224132962|NCT02318732|BEHAVIORAL|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
223737982|NCT01908361|BEHAVIORAL|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
223737983|NCT06188507|DRUG|GSK4347859|GSK4347859 will be administered
223737984|NCT06188507|DRUG|Placebo|Placebo will be administered
223737985|NCT02373020|OTHER|colonoscopic biopsies|
223407455|NCT00167583|DRUG|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
223407456|NCT02523183|DRUG|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
223407457|NCT04740398|DRUG|CBP-1008|CBP-1008 for injection; IV infusion; Infusion for 90 minutes
223407458|NCT03268226|DRUG|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
223557304|NCT00851552|OTHER|flow cytometry|Correlative Study
223557305|NCT00851552|OTHER|laboratory biomarker analysis|Correlative Study
223737986|NCT06200077|PROCEDURE|Modified Ridge-Splitting|Unlike the conventional ridge-splitting where bone grafting is done in the same visit after ridge splitting, modified ridge splitting involves splitting the ridge only at the first visit, then bone grafting is done either alone afterwards in the second visit (Modified 3-Staged Ridge-Splitting Group) and dental implants will be placed in the third visit, or, as in the Modified 2-Staged Ridge-Splitting Group, bone grafting and dental implants placement will be done in the second visit.
223737987|NCT06801574|OTHER|Erector Spinae Plane Block|After the surgical team places the final suture, while the patient is in the prone position, an ultrasound-guided ESP (Erector Spinae Plane) block will be administered bilaterally using a block needle. A total of 40 mL of 0.25% bupivacaine will be injected.
223407459|NCT01214291|DRUG|Toremifene|Toremifene 80mg daily
223407460|NCT00789373|DRUG|Pemetrexed|Induction therapy: 500 mg/m\^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
223407461|NCT00789373|DRUG|Cisplatin|Induction therapy: Cisplatin: 75 mg/m\^2, IV, on Day 1 of each 21-day cycle for 4 cycles
223407462|NCT00789373|DRUG|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
223407463|NCT00789373|DRUG|Pemetrexed|Maintenance therapy: 500 mg/m\^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
223557306|NCT03718806|DRUG|Zoliflodacin|oral suspension; oral administration
223737988|NCT06801574|OTHER|infiltration|Before the surgical team closes the incision, local infiltration with 40 mL of 0.25% bupivacaine will be performed at the surgical site.
223737989|NCT06676579|DRUG|Avacopan|Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.
223557307|NCT03718806|OTHER|high calorie, high fat breakfast|fasted/fed conditions
223557308|NCT00038090|DRUG|Thalidomide|100 mg capsules by mouth daily each evening
223557309|NCT00038090|DRUG|Dexamethasone|20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
223557310|NCT05689450|OTHER|Data collection: Amikacin concentration|Blood samples for the measurement of the concentration and calculation of the AUC of amikacin are collected 60 min (+/-30 min) and 8 h (+/-1 h) after the beginning of amikacin infusion. The blood collection after the start of the amikacin infusion will be repeated during every subsequent amikacin administration, but max. during 3 consecutive days.
223557311|NCT02777203|DEVICE|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag. This study is a pilot study with one arm (all patients will use the new EcoSac400 ECO-T bag.
223557312|NCT03075280|PROCEDURE|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
223557313|NCT04416334|DRUG|Colchicine plus symptomatic treatment (paracetamol)|Colchicine plus symptomatic treatment (paracetamol).
223737990|NCT06676579|DRUG|Prednisone|0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months
223737991|NCT06676579|DRUG|Methylprednisolone (drug)|Methylprednisolone 1g intravenous on day +1
223737992|NCT06676579|DRUG|Prednisolone|Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
224024035|NCT06244485|DRUG|Valemetostat tosylate|Administered orally once daily
224024036|NCT06244485|DRUG|T-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle
224024037|NCT06244485|DRUG|Dato-DXd|One IV infusion Q3W on Day 1 of each 21-day cycle.
224024038|NCT05307237|DEVICE|Dexcom G6 Continous Glucose Monitoring Management|CGM data will be transmitted from the bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by the remote monitoring team) and (2) Clinical Optimization (via CLARITY, by which a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub.
224132963|NCT05173844|OTHER|SleepFix mobile application|Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
224132964|NCT06583876|DEVICE|Coriofix System|Treatment of functional mitral regurgitation by reducing the mitral valve annular area through ablation of the posterior annulus.
223557314|NCT04416334|DRUG|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)|Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
223557315|NCT02819986|BEHAVIORAL|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
223557316|NCT00000696|DRUG|Interferon alfa-2a|
223557317|NCT00000696|DRUG|Zidovudine|
224024039|NCT05307237|DEVICE|Usual Care - Blinded Continuous Glucose Monitoring Management|CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring.
224024040|NCT05019703|BIOLOGICAL|Atezolizumab|Given IV
223407464|NCT00789373|OTHER|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
223407465|NCT00142831|DRUG|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
223407466|NCT04573049|DRUG|Levosimendan|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.
223407467|NCT04573049|OTHER|Placebo|On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.
223557318|NCT05192928|DEVICE|Ripple Health Smart Pill Cap|The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
223557319|NCT02498054|BEHAVIORAL|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
224024041|NCT05019703|DRUG|Cabozantinib|Given PO
224024042|NCT05538130|DRUG|PF-07799544|Tablet
224024043|NCT05538130|DRUG|PF-07799933|Tablet
223407468|NCT00080756|BIOLOGICAL|therapeutic estradiol|0.35mg/100ul per day as a nasal spray
223407469|NCT00080756|DRUG|deslorelin|1mg/100ul per day as a nasal spray
223407470|NCT00080756|DRUG|therapeutic testosterone|0.275mg/100ul per day as a nasal spray
223407471|NCT00080756|PROCEDURE|therapeutic conventional surgery|Undergo risk reduction mastectomy
223407472|NCT00080756|OTHER|active surveillance|Undergo continued surveillance
223407473|NCT00080756|PROCEDURE|quality-of-life assessment|Ancillary studies
223407474|NCT00080756|OTHER|laboratory biomarker analysis|Correlative studies
223407475|NCT00546377|BIOLOGICAL|filgrastim|
223407476|NCT00546377|BIOLOGICAL|pegfilgrastim|
223407477|NCT00546377|BIOLOGICAL|rituximab|
223407478|NCT00546377|BIOLOGICAL|sargramostim|
223407479|NCT00546377|DRUG|cyclophosphamide|
223407480|NCT00546377|DRUG|mitoxantrone hydrochloride|
223407481|NCT00546377|DRUG|pentostatin|
223407482|NCT00546377|GENETIC|fluorescence in situ hybridization|
223407483|NCT00546377|GENETIC|gene rearrangement analysis|
223407484|NCT00546377|GENETIC|polymerase chain reaction|
223407485|NCT00546377|GENETIC|protein expression analysis|
223407486|NCT00546377|OTHER|flow cytometry|
223407487|NCT00546377|PROCEDURE|biopsy|
223557320|NCT01270880|DRUG|Hsp90 inhibitor STA-9090|Given IV
224024044|NCT05538130|DRUG|encorafenib|Capsule
224132965|NCT02000141|PROCEDURE|Endoscopic Mucosal Resection|
224132966|NCT04786951|BEHAVIORAL|Attentional Bias Modification Training|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions and five sessions of Attentional Bias Modification Training.
224132967|NCT04786951|BEHAVIORAL|VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions
223407488|NCT03321968|BIOLOGICAL|Quadrivalent VLP Influenza Vaccine|Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine
223407489|NCT05071625|PROCEDURE|percutaneous vertebroplasty|percutaneous vertebroplasty under combined CT/fluoroscopy guidance for non-union after posterior fixation performed for a traumatic non-neurologic thoraco-lumbar vertebral fracture.
223407490|NCT05258266|DRUG|ZX-101A|Q.D., oral dosing
223407491|NCT04332081|DEVICE|hyperbaric oxygen therapy (HBOT)|The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without airbreaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medial unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient.
223557321|NCT01270880|OTHER|laboratory biomarker analysis|Correlative studies
223407492|NCT03805035|DEVICE|electroacupuncture|Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
223407493|NCT03805035|DRUG|antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
223407494|NCT03805035|DRUG|antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
223407495|NCT03805035|DEVICE|acupuncture|Minimal needling at ST36 and GB34
223407496|NCT02307422|GENETIC|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
223407497|NCT00225524|DRUG|Effexor XR|
223407498|NCT00002924|OTHER|mutation analysis|
223407499|NCT03667885|DIAGNOSTIC_TEST|Blood sample|basic blood sample
223557322|NCT01270880|GENETIC|polymerase chain reaction|Correlative studies
223557323|NCT01270880|OTHER|enzyme-linked immunosorbent assay|Correlative studies
223407500|NCT03667885|DIAGNOSTIC_TEST|urine sample|basic urine sample
223557324|NCT01270880|GENETIC|RNA analysis|Correlative studies
224024047|NCT04128501|DRUG|Azacitidine|Given SC
224024048|NCT04128501|DRUG|Venetoclax|Given PO
224024049|NCT06338462|DEVICE|Chatbot|The chatbot is a WhatsApp-based, artificial-intelligence powered customer service agent adapted for TB outreach. The objective of the Chatbot is to facilitate information gathering, education, and support throughout TB contact evaluation, ensuring accessible assistance on-demand during and after contact tracing procedures. It operates in a secure data environment that includes end-to-end encryption and has been reviewed and approved by the data protection team within the information technology unit at the Cali Secretariat of Public Health (SoPH) for the study purposes.
224024050|NCT06338462|DIAGNOSTIC_TEST|Oral testing|Oral testing involves collection of a saliva sample or use of a nylon swab to collect material from the tongue and oral mucosa that is then tested with a molecular test for Mycobacterium tuberculosis
224024051|NCT05784246|DRUG|Mirikizumab IV|Administered IV
224024052|NCT05784246|DRUG|Mirikizumab SC|Administered SC
224024053|NCT02286687|OTHER|Laboratory Biomarker Analysis|Correlative studies
224024054|NCT02286687|OTHER|Pharmacological Study|Correlative studies
224024055|NCT02286687|DRUG|Talazoparib|Given PO
224024056|NCT05508789|DRUG|Donanemab|Administered IV
224024057|NCT05508789|DRUG|Placebo|Administered IV
224024058|NCT06413706|DRUG|Abemaciclib|Administered orally
224024059|NCT06413706|DRUG|Temozolomide|Administered orally or IV
224024060|NCT05207878|OTHER|STEGA-MRI|Precision drawing task (movement assessment)
224024061|NCT05605899|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
223407501|NCT03667885|DIAGNOSTIC_TEST|Multi planar MRI|T1 (with reduced affinity for fatty tissue) +/- contrast, diffusion weighted sequences and wash in/wash out
223407502|NCT02679417|BEHAVIORAL|exercise|12 weeks of aerobic or resistant exercise
223407503|NCT00232739|DEVICE|CYPHER Sirolimus-eluting Coronary Stent|2.25 Cypher Sirolimus-eluting Coronary Stent
223407504|NCT03061825|DEVICE|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
223407505|NCT02744430|DRUG|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
223557325|NCT01270880|OTHER|spectrophotometry|Correlative studies
223557326|NCT01270880|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
223557327|NCT01270880|GENETIC|gene expression analysis|Correlative studies
223557328|NCT02386787|DEVICE|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
223557329|NCT00423982|DRUG|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
223557330|NCT00423982|DRUG|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
224024062|NCT05605899|DRUG|Cyclophosphamide|Administered intravenously
223557331|NCT01474005|DEVICE|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
223557332|NCT05739006|DRUG|BCD-201|up to 8 treatment cycles
223557333|NCT05739006|DRUG|Keytruda|up to 8 treatment cycles
223557334|NCT00182078|DRUG|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
223557335|NCT00182078|DRUG|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
223557336|NCT01098188|DRUG|LFB-R603|intravenous administration, dose-escalation study
224024063|NCT05605899|DRUG|Fludarabine|Administered intravenously
224024064|NCT05605899|DRUG|Etoposide|Administered intravenously
224024065|NCT05605899|DRUG|Rituximab|Administered intravenously
224024066|NCT05605899|DRUG|Doxorubicin|Administered intravenously
224024067|NCT05605899|DRUG|Vincristine|Administered intravenously
224024068|NCT05605899|DRUG|Prednisone|Administered orally
224024069|NCT03816332|BIOLOGICAL|Ipilimumab|Given IV
224024070|NCT03816332|BIOLOGICAL|Nivolumab|Given IV
224024071|NCT03816332|DRUG|Prednisone|Given PO
224024072|NCT03816332|DRUG|Tacrolimus|Given PO
224024073|NCT04689828|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
224024074|NCT04689828|DRUG|68Ga-PSMA-11|single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 185 MBq (3 - 5 mCi).
224024075|NCT04689828|DRUG|ARDT|administered orally on a continuous basis, as per package insert and guidelines
224024076|NCT03304639|BIOLOGICAL|Pembrolizumab|Given IV
223407506|NCT02744430|OTHER|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus \>5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
223407507|NCT05943236|DEVICE|Radiographic assessment of the medial-distal tibial angle|A long ankle view will be generated within a standard radiographic assessment and the medial-distal tibial angle will be assessed.
223557337|NCT01890590|DEVICE|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
223557338|NCT01679678|DEVICE|PolyHeal 2|PolyHeal is a sterile medical device
223557339|NCT01679678|DEVICE|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
223557340|NCT01606176|DRUG|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
223557341|NCT01606176|DRUG|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
223557342|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
223557343|NCT01153711|DRUG|BI 1744|10 mcg solution for oral inhalation
223557344|NCT01153711|DRUG|Ketoconazole|400 mg tablet
223557345|NCT01153711|DRUG|Ketoconazole|400 mg tablet
223557346|NCT03222362|OTHER|Surgery|
223557347|NCT01832493|DEVICE|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
223557348|NCT04075890|DEVICE|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
223557349|NCT01538355|OTHER|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
223557350|NCT01538355|OTHER|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
224024077|NCT03304639|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224024078|NCT03546374|PROCEDURE|Surgical Ablation|In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
224024079|NCT03546374|DEVICE|Cardioblate and Cryoflex hand held devices|The Cardioblate hand held devices consist of the Cardioblate iRF and Cryo surgical ablation devices.
224024080|NCT04318678|DRUG|CD123-CAR T|To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.
224024081|NCT04318678|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
224024082|NCT04318678|DRUG|Fludarabine|Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis
224024083|NCT04318678|DRUG|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide
224024084|NCT04318678|DRUG|Rituximab|Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of B-lymphocytes
224024085|NCT05182125|BIOLOGICAL|AdC6-HIVgp140|"The product is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.3 mL for AdC6-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC6-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the Investigator's Brochure (IB)."
223557351|NCT01538355|OTHER|Control diet|Patients stay on their regular diet.
223557352|NCT05242068|DEVICE|Veinlite|Use of vein imaging device for visualization of veins during peripheral IV placement
223557353|NCT05242068|OTHER|Standard care|Patients received standard intravenous catheterization.
223557354|NCT05891080|DRUG|Toripalimab|Specified dose on specified days.
223557355|NCT05891080|DRUG|JS004|Specified dose on specified days.
223557356|NCT05891080|DRUG|Pemetrexed|Specified dose on specified days.
223557357|NCT05891080|DRUG|Nab-paclitaxel|Specified dose on specified days.
223557358|NCT05891080|DRUG|Carboplatin|Specified dose on specified days.
223557359|NCT05891080|PROCEDURE|Surgery|Patients with resectable tumor after neoadjuvant therapy will be treated with surgery.
223557360|NCT03122808|DIAGNOSTIC_TEST|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
223557361|NCT03122808|DIAGNOSTIC_TEST|Partogram Analysis|Analysis of slope of partogram
223557362|NCT03138460|OTHER|standard medications crossed over to cannabis|
223557363|NCT01732510|DRUG|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
223557364|NCT01732510|DRUG|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
223557365|NCT03176862|DIAGNOSTIC_TEST|cardiac magnetic resonance scan|An MRI scan of the heart
223557366|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
223557367|NCT03176862|DIAGNOSTIC_TEST|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
223557368|NCT03176862|DIAGNOSTIC_TEST|12-lead ECG|Can be done immediately by the bedside.
223557369|NCT03176862|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
224024086|NCT05182125|BIOLOGICAL|AdC7-HIVgp140|"The products is diluted in 2.5% Glycerol/25 mM NaCl/20 mM TRIS \[tris(hydroxymethyl)aminomethane\], pH 8.0 formulation buffer to a concentration of 1.2 x 10\^11 vp/mL and filled at 0.6 mL for AdC7-HIVgp140 into a 2 mL Type 1 glass vial and stoppered with a gray chlorobutyl rubber stopper. The product is clear to slightly cloudy liquid, essentially free of visible particles.~AdC7-HIVgp140 should be stored at ≤ -65°C prior to use/preparation.~The study product is described in further detail in the IB."
224024087|NCT05182125|BIOLOGICAL|CH505TF gp120|"CH505TF gp120 is formulated in 20 mM sodium phosphate, 150 mM NaCl, 0.02% polysorbate 80 (PS80), pH 6.5, supplied as a frozen liquid in 2 mL glass vials. Each 2 mL vial contains 0.75 mL of formulated gp120 at a concentration of 0.8 mg/mL and is stored at ≤ -65°C.~The study product is described in further detail in the IB."
224024088|NCT05182125|BIOLOGICAL|GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])|The GLA-SE adjuvant will be provided as vials containing 20 mcg/mL GLA in a 4% oil-in-water emulsion. Each sterile, single use vial contains 0.4 mL of product. Product appears as a milky-white liquid. GLA-SE must be stored at 2° to 8°C and must not be frozen. The study product is described in further detail within the IB.
224132968|NCT04786951|BEHAVIORAL|Cognitive-behavioral therapy|Usual cognitive-behavioral treatment (CBT) sessions.
224132969|NCT04804891|BIOLOGICAL|Cell Therapy|Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
224132970|NCT00312299|DEVICE|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
224132971|NCT00312299|DEVICE|Round edge PMMA IOL|Round edge PMMA IOL
223407508|NCT00463047|DRUG|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
223407509|NCT03283787|DEVICE|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
224024089|NCT05182125|BIOLOGICAL|Placebo|Placebo will be Sodium Chloride for Injection, 0.9%, will be used as the placebo. It must be stored as recommended by the manufacturer.
224132972|NCT00312299|DEVICE|Acrysof IOL|Acrysof IOL
224132973|NCT00312299|DEVICE|square Edge PMMA IOL|Square edge PMMA intra ocular lens
224132974|NCT00312299|DEVICE|Square Edge PMMA IOL|Square Edge PMMA IOL lens
224132975|NCT06311136|BEHAVIORAL|Valence-Specific Ecological Momentary Intervention|The ecological momentary intervention is designed to enhance participants ability to select and effectively implement emotion regulation strategies fitting to the valence of their current emotions. Specifically, the intervention instructs participants to use the strategy of savoring to amplify their positive emotions, fostering an appreciation for the present moment. Conversely, for the attenuation of negative emotions, the intervention advocates to use the strategy of reappraisal, encouraging participants to reinterpret adverse situations in a more positive or neutral way, thus reducing their emotional impact. This targeted approach ensures that the emotion regulation strategies are not only effective but also contextually appropriate.
224132976|NCT04352322|DIETARY_SUPPLEMENT|A+HA(tm)|oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin
224132977|NCT04352322|DIETARY_SUPPLEMENT|Placebo|oral solution with no active ingredients
224132978|NCT00187239|DEVICE|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
224132979|NCT04393636|OTHER|Digital cardiac Counseling|"* Screening for reduced physical fitness and digital counseling.~* Screening for smoking and digital counseling.~* Screening for malnutrition and obesity and digital counseling.~* Screening for anxiety and depression and digital counseling.~* Screening for elevated pulmonary risk score and digital counseling."
224132980|NCT01576016|DEVICE|Accent MRI system (lead safety)|Patients implanted with an Accent MRI system
224132981|NCT01576016|DEVICE|Accent MRI system (with MRI scan)|Patients implanted with an Accent MRI system will receive an MRI scan
224132982|NCT02191709|DRUG|Dextromethorphan syrup|
224132983|NCT02191709|DRUG|Dextromethorphan soft pastilles|
223407510|NCT03283787|DEVICE|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
223407511|NCT03283787|DEVICE|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
223407512|NCT01735721|PROCEDURE|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
223557370|NCT03176862|BIOLOGICAL|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
223557371|NCT02963168|DRUG|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
223557372|NCT03302884|OTHER|biological sampling|Tumor and blood samples
223557373|NCT01178944|OTHER|Laboratory Biomarker Analysis|Correlative studies
223557374|NCT01178944|DRUG|Oxaliplatin|Given IV
224138883|NCT04669314|PROCEDURE|Liver resection or enucleation for liver hemangioma|Operations in which the hemangioma is selectively removed from the liver parenchyma border are named enucleation, and the operations in which the hemangioma is removed anatomically or non-anatomically with some liver parenchyma surrounding it are named liver resection
224138884|NCT01604304|PROCEDURE|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
224138885|NCT01604304|PROCEDURE|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
224024090|NCT05203965|DRUG|Mavoglurant (AFQ056)|Two 100mg tablets of Mavoglurant will be administered on the morning of one of the two experimental days by a RN or the physician investigator.
224024091|NCT05203965|DRUG|Placebo|Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
224024092|NCT06502691|OTHER|Best Practice|Receive of standard care
224024093|NCT06502691|PROCEDURE|Biopsy of Breast|Undergo breast biopsy
224024094|NCT06502691|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
224024095|NCT06502691|OTHER|Electronic Health Record Review|Ancillary studies
224024096|NCT06502691|OTHER|Fludeoxyglucose F-18|Given FDG
224024097|NCT06502691|RADIATION|Fluorine F 18 Fluorthanatrace|Given IV
224132984|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224132985|NCT00689819|BEHAVIORAL|Exercise|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224138886|NCT05339243|OTHER|ES 1|Two capsules orally once daily after breakfast for 84 days
224138887|NCT05339243|OTHER|HT ES1|Two capsules orally once daily after breakfast for 84 days
224138888|NCT05339243|OTHER|Placebo|Two capsules orally once daily after breakfast for 84 days
223407513|NCT02861807|DEVICE|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
223407514|NCT03020992|DRUG|Certolizumab Pegol|"* pharmaceutical form: solution for infusion in prefilled syringe~* concentration: 200 mg/mL~* route of administration: subcutaneous"
223407515|NCT02915731|DIETARY_SUPPLEMENT|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
223407516|NCT01006122|DRUG|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
223407517|NCT01006122|DRUG|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
223407518|NCT02560922|BEHAVIORAL|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
223407519|NCT02949596|BEHAVIORAL|Quality of life and quality of sexual life questionnaires|
223407520|NCT05519917|DRUG|Afatinib|Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.
223407521|NCT04227223|DIAGNOSTIC_TEST|biochemical measurements|TOC,TAC, and BDNF measurements are performed using ImAnOx , PerOx and BDNF tests (Immundiagnostik, Germany)
223407522|NCT03493854|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
224024098|NCT06502691|DRUG|Immune Checkpoint Inhibitor|Receive ICI treatment
224024099|NCT06502691|DRUG|Poly (ADP-Ribose) Polymerase Inhibitor|Receive PARP inhibitor treatment
224024100|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo \[18F\]FTT PET
224024101|NCT06502691|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
224024102|NCT05827016|DRUG|Iberdomide|Specified dose on specified days
224024103|NCT05827016|DRUG|Lenalidomide|Specified dose on specified days
224024104|NCT05473507|DIAGNOSTIC_TEST|Digital Dermoscopy|Digital Dermoscopy will be performed every 3 months.
224024105|NCT05473507|DIAGNOSTIC_TEST|Reflectance confocal microscopy (RCM)|Reflectance confocal microscopy (RCM) will be performed every 3 months.
224024106|NCT05473507|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical coherence tomography (OCT) will be performed every 3 months.
224024107|NCT05473507|DIAGNOSTIC_TEST|Dermtech tape-stripping|Dermtech tape-stripping for genetic analysiswill be performed every 6 months.
223407523|NCT03493854|DRUG|Doxorubicin|Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
223407524|NCT03493854|DRUG|Docetaxel|As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
223407525|NCT03493854|DRUG|Paclitaxel|As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
223407526|NCT03493854|DRUG|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
223557375|NCT01178944|DRUG|Pralatrexate|Given IV
223557376|NCT00640809|DRUG|Celecoxib|200 mg oral capsule twice daily for 2 weeks
223557377|NCT00640809|OTHER|Placebo|Matched placebo for 2 weeks
223557378|NCT00640809|DRUG|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
223557379|NCT03445377|DEVICE|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
223407527|NCT03493854|DRUG|FDC of Pertuzumab and Trastuzumab SC|The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
223407528|NCT03493854|DRUG|Trastuzumab IV|Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
223407529|NCT03493854|DRUG|Trastuzumab SC|After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
223407530|NCT03493854|PROCEDURE|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
223407531|NCT03493854|RADIATION|Post-operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
223407532|NCT03493854|DRUG|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
223407533|NCT04439942|OTHER|cardiac magnetic resonance imaging (MRI)|Cardiac MRI is a mandatory examination for Hypertrophic cardiomyopathy patients as it provides important information about the presence of fibrosis which is also directly associated with sudden cardiac death.
223407534|NCT05008432|DIAGNOSTIC_TEST|Home sleep apnea testing|Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
223407535|NCT01501539|PROCEDURE|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
223557380|NCT03445377|DEVICE|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
223557381|NCT00799630|DIETARY_SUPPLEMENT|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
223557382|NCT04701606|DRUG|Artecom® (pyronaridine-artesunate)|"\* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)"
224024108|NCT05473507|DIAGNOSTIC_TEST|Total Skin Examinations|Total Skin Examinations will be performed every 12 months.
223557383|NCT04701606|DRUG|Placebo|"\* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)"
224024112|NCT05536349|DRUG|Pirtobrutinib|Given by PO
224024113|NCT05536349|DRUG|Obinutuzumab|Given by (IV) vein
224024114|NCT05536349|DRUG|Venetoclax|Given by PO
224024115|NCT05536349|DRUG|Valacyclovir|Given by PO
224024116|NCT05536349|DRUG|Allopurinol|Given by PO
224024117|NCT06025578|DRUG|BMS-986278|Specified dose on specified days
224024118|NCT06025578|DRUG|BMS-986278 Placebo|Specified dose on specified days
224024119|NCT06966453|DRUG|Disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks.
224024120|NCT06211504|DEVICE|ProStop, sinus tarsi implant (STI)|Insertion of a sinus tarsi implant (ProStop from Arthrex) in sinus tarsi
224024121|NCT06211504|PROCEDURE|Conventional surgery|MDCO - medial displacement calcaneal osteotomy FDL transfer - flexor digitorum longus tendon transfer to the navicular bone Spring ligament repair - reconstruction of the spring ligament Strayer's procedure - gastrocnemius recession (if necessary) Cotton osteotomy - medial cuneiform opening wedge osteotomy (if necessary)
224024122|NCT05983133|DRUG|PF-08046052|Given into the vein (IV; intravenously)
224024123|NCT05050136|DRUG|Volixibat|Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
224024124|NCT05050136|DRUG|Placebo|Capsules matched to study drug without the active pharmaceutical ingredient
224024125|NCT04088396|DRUG|Baricitinib|Administered orally
224132986|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224132987|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224138889|NCT03311490|DEVICE|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
223407536|NCT01501539|PROCEDURE|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
223407537|NCT01864902|BIOLOGICAL|CART33 cells|genetically modified lymphocyte therapy
223407538|NCT01864902|BIOLOGICAL|anti-CD33 CART|
223407539|NCT01864902|BIOLOGICAL|anti-CD33 CAR T cells|
223407540|NCT02094352|DRUG|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
223407541|NCT02094352|DRUG|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
223557384|NCT06549166|OTHER|Experimental: VR and exercise|Participants will perform a 20-minute exercise program consisting of neck joint mobility exercises, neck and scapulothoracic muscle strengthening exercises, and stretching exercises. Then, for the next 20 minutes, they will engage in active neck movements using the Oculus Quest2 headset with the Ocean Rift game.
223557385|NCT06549166|OTHER|Sham Comparator: exercise|The control group will perform a 40-minute same neck exercises.
223557386|NCT03070860|RADIATION|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
223557387|NCT00404378|DRUG|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
224024126|NCT04088396|DRUG|Tocilizumab|Administered SC
224024127|NCT05559359|DRUG|Lebrikizumab|Administered SC
224024128|NCT05559359|DRUG|Placebo|Placebo given SC
223407542|NCT02094352|DRUG|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
223407543|NCT02094352|DRUG|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
223407544|NCT00739661|DRUG|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
223407545|NCT00739661|DRUG|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
223407546|NCT04168723|DRUG|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
223557388|NCT00404378|DRUG|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
223557389|NCT00404378|DRUG|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
223557390|NCT05090163|OTHER|PREP Plus|Group based exercise in addition to PREP exercises
223557391|NCT05090163|OTHER|PREP|Group based exercise
224024129|NCT05559359|DRUG|Topical Corticosteroid (TCS)|TCS administered
224024130|NCT06065462|DRUG|Dostarlimab|Given by vein (IV)
224024131|NCT06065462|DRUG|LB-100|GIven by vein (IV)
224024132|NCT06657768|DRUG|LY4006895|Administered IV
224024133|NCT06657768|DRUG|Placebo|Administered IV
224024134|NCT06566170|DRUG|Donanemab|Administered IV
224024135|NCT06566170|DRUG|Usual Care|Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
224024136|NCT04668300|BIOLOGICAL|Durvalumab|Given IV
224024137|NCT04668300|BIOLOGICAL|Oleclumab|Given IV
223407547|NCT04168723|DRUG|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
223407548|NCT04168723|DRUG|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
223407549|NCT04168723|DRUG|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
223407550|NCT02691949|DRUG|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
223407551|NCT03066713|OTHER|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
223407552|NCT03066713|OTHER|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
223407553|NCT03066713|OTHER|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
223407554|NCT03066713|OTHER|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
223407555|NCT06574646|DEVICE|LAL+|LAL+ IOL allows for refractive error (both sphere and cylinder) enhancements post-IOL implantation by exposing the IOL to ultraviolet (UV) light through a series of noninvasive treatments with a Light Delivery Device.
223407556|NCT06574646|DEVICE|Clareon Vivity Toric IOL|Clareon Vivity Toric IOL utilizes an extended depth of focus (EDOF) design, which incorporates nondiffractive wavefront shaping (X-WAVE) technology.
223407557|NCT02761421|OTHER|observation study|observation study
223407558|NCT04504188|DEVICE|Heart Rate Monitor Enhanced Treatment Optimization|Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.
224132988|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
223407559|NCT00529308|DEVICE|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
223407560|NCT00529308|DEVICE|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
223407561|NCT01725581|PROCEDURE|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
223407562|NCT06197438|DRUG|Tislelizumab|Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.
223407563|NCT06197438|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
223407564|NCT06197438|DRUG|Levo-Leucovorin|Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
223407565|NCT06197438|DRUG|5-fluorouracil|5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
223407566|NCT06197438|DRUG|Irinotecan Hydrochloride|Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.
223407567|NCT06197438|DRUG|Paclitaxel|Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.
223407568|NCT05905523|OTHER|Assessing prewriting skills in children|"In this study, your child will be asked to do the following things:~1. Play a drawing game on a tablet~2. Copy shapes using a pencil in a paper booklet~3. Write some letters and cut paper with scissors You will complete surveys and answer questions about your child's development"
223407569|NCT00937469|BEHAVIORAL|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
223557392|NCT04087941|BIOLOGICAL|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
223557393|NCT05456997|PROCEDURE|Muscle biopsy|Patients will have muscle biopsies taken at time of surgery under general anaesthetic. Open biopsies from the operation field (abdominal wall) will be taken by the surgical team without extending or making new skin incisions. Briefly, muscle samples (approximately 0.5cm3) are excised and haemostasis secured. The muscle biopsies will be snap frozen and stored at -80°C for the analysis of pathways relevant to muscle homeostasis using biochemical and molecular techniques.
223557394|NCT06053151|BEHAVIORAL|exercise counselling|. The experimental group will receive the cloud platform integration model for exercise consultation intervention for two phases continue 24 weeks to promote exercise behavior during pregnancy. The goal of the first phase was to start regular exercise, and the goal of the second phase was to continue regular exercise.
223557395|NCT01262560|DRUG|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
223557396|NCT01262560|DRUG|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
223407570|NCT00937469|OTHER|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
223407571|NCT03485742|OTHER|No intervention|No intervention. Collection of data on statin eligibility in patients admitted with MI
223407572|NCT06159751|OTHER|serum albumin level|serum albumin level in gonarthrosis
223407573|NCT05846490|DEVICE|CPAP|Continuous positive airway pressure + anti-hypertensive treatment intensification (if necessary)
223407574|NCT05846490|DRUG|Usual care|Anti-hypertensive treatment intensification (if necessary)
223407575|NCT03365635|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]|Same as described in arm description
223407576|NCT05475990|DRUG|Hydroxyethyl starch|10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223407577|NCT05475990|DRUG|Crystalloid|10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223407578|NCT05343364|DRUG|Vonoprazan|Oral Tablet
223407579|NCT04351113|DIETARY_SUPPLEMENT|MITO-AO|Participants will receive 160 mg with breakfast on day 1 of bed rest and 40 mg with breakfast on days 2-5.
223407580|NCT04351113|DIETARY_SUPPLEMENT|PB-125|Participants will receive 100 mg on days 1-5 of bed rest.
224132989|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224138890|NCT00610376|BEHAVIORAL|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
223407581|NCT04351113|OTHER|Placebo|Participants will receive Placebo on days 1-5 of bed rest.
223407582|NCT04351113|OTHER|Passive Leg Movement (PLM)|Participants will be tested for passive leg movement on baseline day 1, bed rest day 1, and post bed rest.
223407583|NCT04351113|OTHER|Plantar flexion|Participants will undergo plantar flexion on baseline day 2, pre bed rest, and post bed rest.
223407584|NCT04351113|OTHER|Isometric knee extensor test|Participants will undergo isometric knee extension on baseline day 2, pre bed rest, and post bed rest.
223407585|NCT04351113|OTHER|Bed rest|Participants will undergo 5 days bed rest after 5 day baseline assessments
223407586|NCT04076163|OTHER|serious game|a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
223407587|NCT02358239|PROCEDURE|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
223407588|NCT00947921|PROCEDURE|Plasty|Restrictive Annuloplasty
223407589|NCT00947921|PROCEDURE|Prosthesis|Valve replacement
223407590|NCT01868906|DRUG|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
223407591|NCT01868906|PROCEDURE|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
223407592|NCT01868906|DEVICE|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
223407593|NCT01868906|PROCEDURE|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
223407594|NCT01868906|RADIATION|Radiotherapy|Standard radiation therapy
223407595|NCT01868906|DRUG|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
223407596|NCT05854004|DIAGNOSTIC_TEST|Therapeutic Ultrasound|Therapeutic Ultrasound to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
223407597|NCT05854004|DIAGNOSTIC_TEST|Myofascial Release Technique|Myofascial Release Technique to Release Trigger Points to Increase Range of Motion and Pain Relief in Upper Trapezius Tightness
223407598|NCT04785872|OTHER|Education|NEUMAN SYSTEMS MODEL BASED NURSING APPROACH
223407599|NCT03588143|DEVICE|Electrical stimulation|Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
223407600|NCT02105987|DRUG|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
223407601|NCT02105987|DRUG|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
223407602|NCT05058079|BEHAVIORAL|Intraoperative Hand Held|Intraoperative hand holding
223407603|NCT02531048|DEVICE|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
223407604|NCT02531048|DEVICE|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
223407605|NCT02531048|DEVICE|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
223407606|NCT02531048|DEVICE|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
224132990|NCT00689819|BEHAVIORAL|Weight Loss|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224132991|NCT00689819|BEHAVIORAL|Low Sodium Diet|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
223407607|NCT03856411|DRUG|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
223407608|NCT06443528|DIAGNOSTIC_TEST|lung ultrasound|All enrolled infants underwent LUS examination performed by two ultrasound physicians. Monitoring included a complete lung scan in the first 24 hours of life (T0) and at day 3 (T1). All neonates underwent weekly ultrasound examinations until 36 weeks postmenstrual age (T2, T3…), so that the T2 scan was carried out at the end of the first week of life. LUS was performed according to a standardized protocol \[13\] when the neonate was in a quiet state, during routine clinical care to minimise discomfort. All ultrasound images and videos were digitally recorded, anonymised, and reviewed by a senior independent ultrasonographer blinded to patients' clinical information. Each lung was divided into three regions according to the anterior and posterior axillary lines and the mammary line. The regions were the upper-anterior, lower-anterior, and latera regions.
223407609|NCT02350283|DEVICE|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
223407610|NCT00204906|DIETARY_SUPPLEMENT|vitamin D supplementation|
223407611|NCT00001000|DRUG|Ampligen|
223557397|NCT01262560|DRUG|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
223557398|NCT03213938|DEVICE|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
223557399|NCT03213938|DEVICE|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
223557400|NCT02665663|DEVICE|medical device|
223557401|NCT03987802|DRUG|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
223737993|NCT06058169|DEVICE|Sub Acute Whole Body Vibration Training|Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
224132992|NCT00689819|BEHAVIORAL|Smoking Cessation|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224132993|NCT00689819|DRUG|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
224132994|NCT02488551|DEVICE|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
223407612|NCT04991441|DIETARY_SUPPLEMENT|Controlled Dietary Sodium Restriction|Participants will be provided with 2 meals and snacks daily, for 30 days (days 1-30) and 1 meal and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg \& 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (\<2,000g/day) and will be ordered and delivered through momsmeals.com
223407613|NCT04991441|DIETARY_SUPPLEMENT|Control Diet & Controlled Dietary Sodium Restriction|Participants will follow a Observational Control Diet (CON) diet (Months 1-5) followed by an Controlled Dietary Sodium Restriction (INT) diet (Months 6-7).
223407614|NCT05754905|OTHER|Magnetic resonance examination|the two groups are underwent magnetic resonance examination including enhanced 3D-WATSc sequence
223407615|NCT00968747|BEHAVIORAL|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
223407616|NCT00968747|BEHAVIORAL|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
223407617|NCT00968747|BEHAVIORAL|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
223407618|NCT00968747|DIETARY_SUPPLEMENT|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
223407619|NCT05801705|DRUG|Aromatase inhibitor|Aromatase inhibitor includes Arimidex, Aromasin, Femara.
223407620|NCT05801705|PROCEDURE|ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist)|Gonadotropin-releasing hormone agonist includes Buserelin, Goserelin, Leuprorelin, Nafarelin, Triptorelin
223407621|NCT05801705|DRUG|Tamoxifen|tamoxifen,10mg, bid
223407622|NCT05801705|DRUG|toremifene|toremifene, 60 mg, qd
223407623|NCT00660517|DRUG|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
223407624|NCT00660517|DRUG|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
223407625|NCT00660517|DRUG|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
223407626|NCT00660517|DRUG|placebo|placebo nasal spray one spray per nostril two times a day
223737994|NCT01496313|DRUG|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
224132995|NCT02488551|OTHER|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
224132996|NCT01390116|DIETARY_SUPPLEMENT|Aged garlic extract|2 aged garlic extract capsules taken twice daily
224132997|NCT01390116|DIETARY_SUPPLEMENT|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
224132998|NCT05405296|DEVICE|Truenat™ MTB Plus/COVID-19|Truenat™ MTB Plus/COVID-19is a disposable, room temperature stable, chip-based Real Time duplex PCR test, along with freeze dried PCR reagents provided in microtube for performing Real Time PCR for infectious disease and runs on the Truelab® Real Time micro-PCR Analyzer.
224132999|NCT05999474|DRUG|Topical tioconazole|Laser
223407627|NCT03507868|PROCEDURE|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.
223407628|NCT01244438|DRUG|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
223407629|NCT02268916|BEHAVIORAL|Counseling|OT led counseling
223407630|NCT02268916|BEHAVIORAL|Usual education|At the end of the study, will receive OT-led counseling
223557402|NCT04368494|BEHAVIORAL|12-week home based exercise|Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
223557403|NCT03026231|BIOLOGICAL|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
224133000|NCT06029712|DRUG|Heart failure polypill|Copackaging of heart failure medications (beta blocker, SGLT2i, MRA, and ACE/ARB/ARNI) in an overencapsulated polypill. Individual tablets will be hand-packed into a single capsule at the level of the pharmacy. Specific medications and doses will be individualized to the participant.
224133001|NCT06029712|DRUG|Control Rx|GDMT delivered as individual tablets
224133002|NCT05962996|DEVICE|Pupillometry|Measurement of pain levels by pupillometry during the insertion of a deep venous catheter
224133003|NCT03637192|OTHER|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
223407631|NCT02418949|DRUG|Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
223407632|NCT02418949|DRUG|Placebo for Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
223407633|NCT02418949|OTHER|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
224024138|NCT05053230|BEHAVIORAL|IM@Home|Participants in the IM@Home group will receive a 12-week virtual, synchronous, mind-body and fitness program. The Classes will be conducted via Zoom video conferencing platform. Patients will choose from a variety of weekly classes, occurring one to four times per week. An Integrative Medicine Service (IMS) clinical therapist (e.g., licensed dance therapist, certified yoga instructor, nurse specialist/physical trainer) with specific expertise in the oncology setting will lead each session. Activities range from more movement-based (fitness, yoga, dance therapy, or tai chi) to meditative-based classes (meditation, guided meditation, or music therapy). All clinicians will provide an overview of the session, 25 to 40 minutes of content, and five minutes for feedback and discussion. Each class lasts 30 to 45 minutes with optional audio or video participant participation and group chat.
224024139|NCT05053230|BEHAVIORAL|Enhanced usual care|Patients in the enhanced usual care will receive usual care. In addition, once enrolling into the trial, they will be given a handout to encourage them to visit the MSK's multimedia page on the Integrative Medicine website to access pre-recorded, on-demand meditation audio or video recordings for meditation, guided imagery, and relaxation.
224024140|NCT05669833|DRUG|Guselkumab|Guselkumab (GUS) subcutaneous injection
223407634|NCT02418949|OTHER|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
223407635|NCT00655993|DRUG|simvastatin|40 mg po daily
223407636|NCT03926117|BIOLOGICAL|Ziltivekimab|human IgG1k anti-human IL-6 monoclonal antibody
223407637|NCT03972748|DRUG|Itraconazole 200 mg|Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
223407638|NCT01265862|PROCEDURE|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
223407639|NCT01265862|PROCEDURE|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
223407640|NCT03468491|OTHER|combined training|The whole intervention period will last for 6 weeks, 2 visits per week, 1 hour per visit in the Research Building Room 630 of National Yang Ming University. All programs will be under the supervision of a physiotherapist with 2-year experience individually. 1. Hallux valgus correction: 1.1 Joint alignment correction (Grade II joint mobilization, 10 times/set, 3 sets/visit) - 1st MTP joint distraction - Proximal talofibular joint anteroposterior glide - (Grade III joint mobilization if any restriction being found) 1.2 Biomechanical taping (using Dynamic taping, 1 time/ visit, keep the taping for 2 days minimum) 1.3 Foot intrinsic muscle strengthening (10 times/set for each exercise, 3 sets/visit): - Short foot exercise - Toespread out exercise - Heel-rise exercises 2. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 2.1 Single lunge 2.2 Stepping down 2.3 Vertical squat 2.4 Vertical jumping
223407641|NCT03468491|OTHER|Proximal training|1\. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 1.1 Single lunge 1.2 Stepping down 1.3 Vertical squat 1.4 Vertical jumping All exercises will first start on firm surface without additional resistance/weight. Later, settings will be gradually shifted into on firm surface with resisted band from random direction, on a cushion with/ without resisted band, on a BOSU balance trainer. Progression are made every 2 weeks ideally, while adjustments may be taken into concern due to individual differences.
223407642|NCT00140387|BIOLOGICAL|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
223407643|NCT03918824|OTHER|Data extraction from medical files|Data extraction from medical files
223407644|NCT03981250|BEHAVIORAL|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
223407645|NCT01978132|PROCEDURE|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
223407646|NCT05953935|DEVICE|OKTO|Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz
223407647|NCT05953935|DEVICE|Standard clinical procedures|standard clinical procedures
223407648|NCT00291070|DRUG|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
223557404|NCT03026231|DRUG|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
223557405|NCT01339819|DRUG|Dabigatran|Patients assigned to this group will receive Dabigatran
223557406|NCT01339819|DRUG|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
223557407|NCT01594723|DRUG|120 mg LY2784544|Administered orally
223737995|NCT01496313|DRUG|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) \[OR 300 reduced to 200mg/day if dose was increased at unblinding.\] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
224024141|NCT05669833|DRUG|Golimumab|Golimumab (GOL) subcutaneous injection
224024142|NCT03198650|DRUG|Acalabrutinib|Acalabrutinib
224024143|NCT03198650|DRUG|Obinutuzumab|Obinutuzumab
224024144|NCT05849103|OTHER|Blood Pressure Control Targets|This intervention specifies the goal blood pressure as less than 150/100 versus less than 140/90
224024145|NCT05849103|OTHER|Hypertension Management|This intervention specifies whether the participant has hypertension management through their obstetric clinician or through a single nurse navigator who provides feedback and modifies hypertension treatment based on blood pressure values submitted by the participant.
224024146|NCT06972472|DRUG|Orforglipron|Administered orally
224024147|NCT06972472|DRUG|Placebo|Administered orally
224024148|NCT06972459|DRUG|Orforglipron|Administered orally
224024149|NCT06972459|DRUG|Placebo|Administered orally
224024150|NCT06450873|DRUG|Coriolus Versicolor Extract|Dietary Supplement Given PO
224024151|NCT06450873|OTHER|Questionnaire Administration|Ancillary studies
224024152|NCT01787487|DRUG|Azacitidine|Given SC or IV
224133004|NCT03637192|OTHER|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
224133005|NCT03709810|COMBINATION_PRODUCT|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
224133006|NCT03709810|OTHER|No Adhesive|No adhesive will be applied.
224133007|NCT03065504|DIETARY_SUPPLEMENT|Turmeric|
224133008|NCT03065504|DIETARY_SUPPLEMENT|Turmeric-containing combination tablet|
224133009|NCT03065504|DIETARY_SUPPLEMENT|Placebo tablets|
223407649|NCT05017792|BIOLOGICAL|Astrazenica vaccine|COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
223557408|NCT05511610|PROCEDURE|Sevoflurane uptake and supply|"Phase sevo 1)~* Moment 1 (M1): from OTI until end-tidal sevoflurane (etSEVO%) exceeds ettSEVO% by 10%. Deliver of sevoflurane to the system (SEVOdel) carried out by completely opening sevoflurane vaporizer (8%).~* M2) once etSEVO% surpass ettSEVO% by 10%: turn off sevoflurane vaporizer and observe the progressive fall etSEVO%. When etSEVO% approaches ettSEVO% (0.1-0.2 points above ettSEVO%), the investigators will turn on the sevoflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of sevoflurane.~Phase sevo 2) Objective: to maintain etSEVO% = ettSEVO% ±5% When the etSEVO% increases above the mentioned levels \>\> reduce SEVOdel by 0.25-0.5%.~When the etSEVO% decreases below the mentioned levels\>\> increase SEVOdel by 0.25-0.5%."
224133010|NCT05238467|OTHER|COVID antibody titers in the blood|COVID antibody titers will be quantitatively assessed at baseline, 8 weeks and approximately 6, 9, and 12 months from date of study enrollment. Titers will be compared to levels in 25 age matched adult participants with no prior history of cancer or prior history of non-metastatic solid cancer invasive cancer treated with a curative intent,.and in 25 age matched cancer participants who are on non-immunosuppressive treatments as defined below.
224133011|NCT02426060|DRUG|Imrecoxib|
224133012|NCT02426060|DRUG|Warfarin|
224133013|NCT02191423|DRUG|Oxytocin|administered pre-fMRI assessment
224133014|NCT02191423|DRUG|placebo|administered pre-fMRI assessment
224133015|NCT02191423|BEHAVIORAL|Dyadic psychotherapy|
224133016|NCT02667860|PROCEDURE|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
224133017|NCT02667860|PROCEDURE|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
224133018|NCT02667860|DEVICE|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
224133019|NCT02667860|DEVICE|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
224133020|NCT02239770|DRUG|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
224133021|NCT02239770|DRUG|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
224133022|NCT05649618|BIOLOGICAL|Tumor Infiltrating Lymphocytes|On day 0 patients will be intravenous infusion of TILs
224133023|NCT05649618|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen
224133024|NCT05649618|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
224133025|NCT05649618|DRUG|IL-2|Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance.
223407650|NCT05513482|DIAGNOSTIC_TEST|Tissue Doppler Imaging|With tissue Doppler ultrasonography (TDI), the maximum contraction rate of the diaphragm, maximum relaxation rate, and integral against time will be examined.
224133026|NCT04886999|BEHAVIORAL|Exploratory study on patient's perception of Asthma symptoms|To assess the perception of symptoms and the psychopharmacological aspects in patients with moderate to severe asthma comparing two inhalers of CHF1535 100/6 µg pMDI
224133027|NCT02520518|DRUG|Dapagliflozin|
223407651|NCT05513482|DIAGNOSTIC_TEST|M Mode Imaging|Diaphragm displacement during inspiration and expiration will be measured with M mode imaging
224133028|NCT02520518|DRUG|Placebo|
224133029|NCT02520518|BEHAVIORAL|Weight maintenance|
224133030|NCT02520518|BEHAVIORAL|Ad libitum dietary intake|
224133031|NCT02520518|BEHAVIORAL|Dietary restriction|
224133032|NCT05487053|PROCEDURE|Single-shot adductor canal block|Postoperative analgesia in this group will be carried out by a single-shot bolus of 20 ml Ropivacaine 0.5% in the region of the middle third of the adductor canal.
224133033|NCT05487053|PROCEDURE|Continuous femoral nerve block|Postoperative analgesia in this group will be carried out by continuous infusion of local anesthetics through a catheter installed to the femoral nerve in the area of the femoral triangle. Ropivacaine 0.2% solution will be used for postoperative analgesia. Local anesthetic infusion rate is 4 ml/h to 10 ml/h.
224133034|NCT00104078|DRUG|MYO-029|
224297881|NCT01286389|BEHAVIORAL|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
223407652|NCT04733066|DRUG|Teduglutide|Intervention group consists of patients, who receive teduglutide within routine medical care
223407653|NCT02705365|OTHER|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
223407654|NCT02705365|OTHER|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
223407655|NCT03138213|PROCEDURE|Total laparoscopic pancreaticoduodenectomy|Total laparoscopic pancreaticoduodenectomy
223407656|NCT03138213|PROCEDURE|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
223557409|NCT05511610|PROCEDURE|Washout phase|The investigators will close the sevoflurane vaporizer and will start the administration of Propofol in intravenous perfusion; the investigators will then open the FGF sequentially at 2\>5\>10 liters per minute (LPM), until the etSEVO% is \<0.2 MAC.
223557410|NCT05511610|PROCEDURE|Desflurane uptake and supply|"Phase desflu 1)~* Moment 1 (M1): from the end of Washout phase until end-tidal desflurane (etDESFLU%) exceeds ettDESFLU% by 10%. Deliver of desflurane to the system (DESFLUdel) carried out by completely opening the desflurane vaporizer (18%).~* M2) once etDESFLU% surpass ettDESFLU% by 20%: turn off the desflurane vaporizer and observe the progressive fall etDESFLU%. When etDESFLU% approaches ettDESFLU% (0.8-1.2 points above ettDESFLU%), the investigators will turn on the desflurane vaporizer following the MAAS method to ensure stability in inspired and expired concentrations of desflurane.~Phase desflu 2) Objective: to maintain etDESFLU% = ettDESFLU% ±5% When the etDESFLU% increases above the mentioned levels \>\> reduce DESFLUdel by 0.25-0.5%.~When the etDESFLU% decreases below the mentioned levels\>\> increase DESFLUdel by 0.25-0.5%."
223557411|NCT05511610|PROCEDURE|Final phase|"From the end of Phase desflu 2 until the end of the intervention. Maintenance of anesthesia with desflurane following the principles of MAAS Method.~Between 15-20 minutes before the end of the intervention, the investigators will stop the administration of desflurane, registering the time until the reaching etDESFLU% \< 0.2 MAC."
223557412|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection|Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
223557413|NCT04837885|PROCEDURE|Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection|intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)
223557414|NCT04837885|DRUG|LUTATHERA® by intra-arterial hepatic (IAH) injection|One treatment dose of LUTATHERA® by IAH injection. The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations
223557415|NCT04837885|PROCEDURE|Scan|Scans after completion of LUTATHERA® treatment injection
223557416|NCT06632587|PROCEDURE|Early cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Early cranioplasty is defined as being performed within 8 weeks following the decompressive hemicraniectomy.
223557417|NCT06632587|PROCEDURE|Standard-of-care cranioplasty|Cranioplasty is the surgical procedure to restore the skull after a decompressive hemicraniectomy. The latter procedure is employed as a life-saving measure to relieve intracranial pressure in patients with acute cranial injuries. Standard-of-care cranioplasty is defined as being performed after 3 months following the decompressive hemicraniectomy.
223557418|NCT05596461|DEVICE|Transcranial magnetic stimulation|Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.
224024153|NCT01787487|OTHER|Laboratory Biomarker Analysis|Correlative studies
224024154|NCT01787487|DRUG|Ruxolitinib Phosphate|Given PO
224024155|NCT05884320|DRUG|Sacituzumab Govitecan|Given by IV (vein)
224024156|NCT02928185|BEHAVIORAL|semi-structured interviews|
224024157|NCT04569747|COMBINATION_PRODUCT|Pertuzumab+TRASTUZUMAB|Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
224024158|NCT04569747|DRUG|ADJUVANT ENDOCRINE THERAPY|Oral, daily per cycle
224024159|NCT00120588|DRUG|magnesium|
224024160|NCT05444049|DEVICE|NEURESCUE device|The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.
224024161|NCT06648473|DIAGNOSTIC_TEST|MRI Scan|Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
224024162|NCT06573294|DRUG|GEN1057|Intravenous (IV) infusion
224024163|NCT06573294|DRUG|Premedication|IV infusion/orally by mouth.
224024164|NCT05720624|DRUG|Anhydrous Enol-oxaloacetate|Given PO
224024165|NCT05720624|OTHER|Best Practice|Receive standard of care therapy
224024166|NCT05720624|PROCEDURE|Biospecimen Collection|Undergo collection of CSF and blood
224024167|NCT05720624|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRS imaging
224024168|NCT05720624|OTHER|Questionnaire Administration|Ancillary studies
224024169|NCT04488055|BEHAVIORAL|Crisis Line Facilitation (CLF)|CLF is a motivational interviewing-based intervention
224024170|NCT04488055|BEHAVIORAL|Enhanced Usual Care (EUC)|In addition to receiving the brochure, EUC condition participants will meet with a therapist (in-person or remotely) for approximately 15 minutes for a descriptive overview of the brochure.
223407657|NCT04526288|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
223407658|NCT04526288|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
223407659|NCT01315938|DRUG|Abatacept Active Treatment|Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
223407660|NCT01315938|DRUG|Abatacept Delayed-Onset Treatment|Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
224024171|NCT03937154|DRUG|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
224024172|NCT03937154|DRUG|Placebo|Placebo comparator
224024173|NCT05385497|OTHER|Aerobic Exercise|Participants will perform a 30-minute exercise protocol (5 minutes warm-up and cool-down each and 20 minutes moderate intensity exercise) on a StepOne™ recumbent stepper
224024174|NCT05385497|DEVICE|Virtual Reality|Participants will interact with the virtual environment and view the gaming environment on a flat-screen TV placed in front of them at a suitable distance. The participants will play four games (50 repetitions/game divided into three blocks with 1-2 minutes rest between blocks), with the order of the games randomized in every session.
224024175|NCT03464097|DRUG|Ozanimod|Specified dose on specified days
224024176|NCT03464097|OTHER|Placebo|Specified dose on specified days
224133035|NCT02175771|DRUG|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
224133036|NCT02175771|DRUG|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
223407661|NCT03894826|DRUG|Vorinostat 100 MG|Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
223737996|NCT03798223|PROCEDURE|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
223737997|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
224024177|NCT06464926|DEVICE|Enterra Therapy System|"The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card).~The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options."
224024178|NCT06422884|DRUG|ENV-101|oral tablet, dosed once a day
224024179|NCT06422884|DRUG|Placebo|oral tablet, dosed once a day
224024180|NCT02392572|DRUG|Akt/ERK Inhibitor ONC201|Given PO
224133037|NCT02175771|DRUG|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
223407662|NCT00605631|DEVICE|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
223407663|NCT00086138|DRUG|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
223407664|NCT00086138|DRUG|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
223407665|NCT05079542|PROCEDURE|Timepoint of Implant placement of Bonelevel tapered implants|Implant surgery on different time points
223407666|NCT05079542|COMBINATION_PRODUCT|Material for tooth restoration - Lithiumdisilicate glass ceramic or zirconia|Tooth restoration with a certain material
223737998|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
223737999|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
223738000|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
224024181|NCT02392572|DRUG|Venetoclax|Given PO
224024182|NCT00351520|DRUG|Miltefose|
224024183|NCT06976801|DEVICE|Intramedullary tibial Nail|Subjects will receive the micromotion MicroMotion Intramedullary tibial Nail
224024184|NCT06976801|DEVICE|Intermedullary nail|The non-micromotion intermedullary nail
224024185|NCT04549532|BEHAVIORAL|Targeted Multidomain|Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.
224024186|NCT04549532|BEHAVIORAL|Behavioral Management|1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
223738001|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
223407667|NCT02407613|DEVICE|Philips Sonalleve MR-HIFU Breast Tumor Therapy System|Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
223407668|NCT03690843|OTHER|Test Battery|All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
223407669|NCT02684097|DRUG|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
223407670|NCT02684097|DRUG|Placebo|Matching placebo given every two weeks for 24 weeks
223407671|NCT04856306|OTHER|Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure|See previous descriptions
223407672|NCT04856306|DRUG|Elagolix Oral Product|See group 3 description
223407673|NCT06111378|DIETARY_SUPPLEMENT|fish oil|fish oil
223407674|NCT06111378|DIETARY_SUPPLEMENT|linseed oil|linseed oil
223407675|NCT06111378|DIETARY_SUPPLEMENT|walnut oil|walnut oil
223407676|NCT00460811|DRUG|Linaclotide Acetate|Oral, once daily
223407677|NCT00460811|DRUG|Matching placebo|Oral, once daily
223407678|NCT01902745|BEHAVIORAL|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
224297882|NCT03285789|OTHER|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
223407679|NCT01373502|DEVICE|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
223407680|NCT01373502|DEVICE|Taxus Liberté Stent|Taxus Liberté Coronary Stent
223407681|NCT04338841|OTHER|HOME-CoV rule implementation|"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.~Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments."
223407682|NCT02748356|DRUG|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
223407683|NCT01602861|DRUG|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (\>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
223407684|NCT01602861|DRUG|placebo|
223407685|NCT06575231|DIAGNOSTIC_TEST|in-vitro|responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.
223407686|NCT01888055|DEVICE|transcranial direct current stimulation|
223407687|NCT01888055|DEVICE|sham stimulation|
223407688|NCT00664573|BIOLOGICAL|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
223407689|NCT06128902|OTHER|tele health|home based exercise and telenursing
223407690|NCT04521179|DRUG|KN026 combination|30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046
223407691|NCT06237569|DRUG|Application of ketamine and midazolam or ketamine alone to patients undergoing cesarean section under spinal anesthesia|"A single dose of 0.5 mg/kg IV diluted to 5 ml with 0.9% saline was planned to be administered simultaneously to the Ketamine Group (GROUP 1), ketamine and midazolam within 5 minutes after the newborn umbilical cord was clamped (Group 2). After midazolam 0.03 mg/kg is given, a single dose IV bolus of 0.5 mg/kg diluted to 5 ml with 0.9% saline will be administered.~Patients experience dizziness, hallucinations, nausea, headache, vomiting, diplopia and blurred vision, the time until the first analgesic request; Depression parameters will be evaluated with the Edinburgh Postpartum Depression Scale (EPDS) in all patients before cesarean section and at the 1st, 2nd and 4th weeks after birth."
223407692|NCT05031195|OTHER|1st tertile, 2nd tertile, 3rd tertile|Patients will be divided into 3 groups according to the preoperative NLR value.
223407693|NCT06576154|DRUG|Cefazolin 1000 MG|"* Medication: Cefazolin~* Dosage: 1 gram~* Administration Timing: A single dose will be administered preoperatively."
223407694|NCT04902638|PROCEDURE|Intraarticular injection of dexamethasone|Intraarticular injection of dexamethasone
223738002|NCT03762148|DIETARY_SUPPLEMENT|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
223407695|NCT00237458|DRUG|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years"
223738003|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
223738004|NCT03762148|DIETARY_SUPPLEMENT|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
223738005|NCT03762148|DIETARY_SUPPLEMENT|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
223738006|NCT06073171|BIOLOGICAL|Blood sample|7.5 mL will be sampled on EDTA tube for each patient
223407696|NCT05161052|DEVICE|Corvis ST (dynamic Scheimpflug technology)|"* Measurement of corneal stiffness parameters { Deformation Amlitude (DAR1), Integrated radius, Stress parameter (SP A1), Stress strain index (SSI) and Corvis biomechanical index (CBI) } in keratoconic corneas before and after 3 and 6 months CXL using Corvis ST.~* Measurement of demarcation line depth using anterior segment OCT and correlate between corneal stiffness following CXL and demarcation line depth"
223407697|NCT00952068|DRUG|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
223557419|NCT05596461|DEVICE|Transcranial direct current stimulation|Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
223557420|NCT04238481|DRUG|Pudexacianinium chloride|Intravenous
223557421|NCT02901587|DRUG|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
223407698|NCT04430556|DRUG|Sertraline|Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.
223407699|NCT05183165|OTHER|Patients with Wilson's disease declaring pregnancy,|Blood and urine biological assessment Dietary assessment
223557422|NCT02901587|DRUG|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
223557423|NCT02901587|DRUG|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
223557424|NCT04050072|OTHER|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
223557425|NCT04050072|OTHER|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
223557426|NCT04050072|OTHER|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
223557427|NCT01636336|OTHER|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
223557428|NCT01636336|OTHER|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
223557429|NCT03244709|DRUG|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
223557430|NCT02270528|BEHAVIORAL|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (\~5 minutes)
223557431|NCT02270528|BEHAVIORAL|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
224133038|NCT02175771|DRUG|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
223407700|NCT03038568|DIAGNOSTIC_TEST|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
223557432|NCT03815149|DEVICE|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
223738007|NCT06073171|BIOLOGICAL|Cutaneous biopsy|4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients
223738008|NCT06073171|GENETIC|High troughput sequencing of human's exome|Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
224133039|NCT02175771|DRUG|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
224133040|NCT04096326|DRUG|AGN-151586|AGN-151586 solution for injection.
224133041|NCT04096326|DRUG|Placebo|Placebo solution for injection.
224138891|NCT00610376|BEHAVIORAL|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
224138892|NCT04476355|OTHER|Select and Tailor implementation interventions|Based on previously adapted guidelines and the assessment of innovation, adopters and practice environment for barriers and supports, the interventions mainly include patients education, practioners education and system changes.
223738009|NCT00242957|BEHAVIORAL|Intervention with Microfinance for AIDS and Gender Equity|
223407701|NCT05334524|OTHER|kinesiotaping with combined chain exercises|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises"
223738010|NCT01540656|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
223407702|NCT05334524|OTHER|kinesiotaping|"3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension"
223407703|NCT05870371|BEHAVIORAL|Feldenkrais Awareness Through Movement technique|10 group sessions, 50 minutes each, over a period of five weeks, which will include the application of the Feldenkrais Awareness Through Movement technique
223738011|NCT00694655|BIOLOGICAL|Yellow Fever Vaccine|Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
223738012|NCT00694655|PROCEDURE|Leukapheresis|In leukapheresis blood is drawn and then the white blood cells are separated from the blood sample in a laboratory procedure. Once the white blood cells are returned the blood is returned back to the bloodstream of the participant who provided the sample.
223738013|NCT00694655|PROCEDURE|Fine-needle aspiration (FNA)|In fine-needle aspiration a cell sample is collected using a needle and syringe. Fine-needle aspiration is typically used as a minimally invasive method of sample collection used to confirm a diagnosis.
223738014|NCT03994692|DEVICE|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
223738015|NCT03994692|PROCEDURE|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
223738016|NCT01050257|DRUG|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
223738017|NCT01050257|DRUG|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
224024187|NCT05491538|BEHAVIORAL|Social Cognition and Interaction Training-Work Edition (SCIT-WE)|Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
224024188|NCT05445843|DRUG|JDQ443|JDQ443 per os (PO) 200 mg twice a day continuously
224024189|NCT04469270|BIOLOGICAL|Engensis|Intramuscular injections
224024190|NCT04469270|OTHER|Placebo|Intramuscular injections
224024191|NCT05817812|DRUG|Efanesoctocog alfa|Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
224024192|NCT06299111|DRUG|REGN9933|Intravenous (IV) single dose administered
224024193|NCT06299111|DRUG|REGN7508|IV single dose administered
224024194|NCT06299111|DRUG|Placebo|IV single dose administered
224024195|NCT06438562|OTHER|Unfortified bouillon plus vitamin A in oil|Participants consume unfortified bouillon with vitamin A oil
224024196|NCT06438562|OTHER|Bouillon fortified with vitamin A #1 plus unfortified oil|Participants consume vitamin A #1 fortified bouillon plus unfortified oil
224024197|NCT06438562|OTHER|Bouillon fortified with vitamin A #2 plus unfortified oil|Participants consume vitamin A #2 fortified bouillon plus unfortified oil
224138893|NCT01317615|DRUG|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
224138894|NCT01317615|DRUG|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
223407704|NCT05870371|BEHAVIORAL|Acupuncture|10 sessions, two per week, of 25 minutes acupuncture each, which will include the insertion of a sterile disposable needle into standardized local, regional, and systematic or general acupuncture points that modify pain behavior in area of Cervical Spine.
223407705|NCT05870371|BEHAVIORAL|Stretching|10 sessions, two per week, of 15 minutes stretching each, which will include lateral flexion and counterrotation of the head performed for the upper part of the trapezius and the anterior scalene, lateral flexion and corresponding rotation for the levator scapulae, and flexion for the extensors of the Cervical Spine. The following muscles will be applied: upper trapezius, levator scapulae, scalenes, extensors of the Cervical Spine (splenoid, spinous, semispinalis, longus cephalic and cervical, iliocostalis cervical, multifidus and subscapularis), and sternocleidomastoid.
223407706|NCT03027141|BEHAVIORAL|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
223407707|NCT00020787|BIOLOGICAL|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
224024198|NCT05107219|PROCEDURE|Biopsy|Undergo biopsy
224024199|NCT05107219|PROCEDURE|Biospecimen Collection|Undergo collection of luminal fluid
224024200|NCT05107219|PROCEDURE|Esophagogastroduodenoscopy|Undergo EGD
224024201|NCT05107219|DRUG|Linaclotide|Given PO
224024202|NCT05107219|DRUG|Plecanatide|Given PO
224024203|NCT05519085|DRUG|mezigdomide|Specified dose on specified days
223407708|NCT00020787|DRUG|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
223557433|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
223557434|NCT00673231|DRUG|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
223557435|NCT00673231|DRUG|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
223557436|NCT00673231|DRUG|Placebo|Placebo
223557437|NCT00673231|DRUG|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
223738018|NCT06493266|BEHAVIORAL|neurolinguistic programmino|In this randomized controlled study, the group of patients with an indication for colposcopy in the Gynecological Oncology Department of Şanlıurfa Training and Research Hospital, Department of Gynecology and Obstetrics, will be divided into two groups and NLP training will be given before colposcopy in a double-blind manner, and after colposcopy, VAS (visual pain scale), fear of pain scale will be given. 3, evaluation will be made using the pain catastrophizing scale. NLP training will be given for approximately 20 minutes, and the group that will not receive NLP training will remain silent for 20 minutes. The results will be compared.
223738019|NCT00002130|DRUG|Vesnarinone|
223738020|NCT01618552|BEHAVIORAL|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
224024204|NCT05519085|DRUG|Pomalidomide|Specified dose on specified days
224024205|NCT05519085|DRUG|Bortezomib|Specified dose on specified days
224024206|NCT05519085|DRUG|Dexamethasone|Specified dose on specified days
224297883|NCT03285789|OTHER|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
224297884|NCT03582280|DRUG|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
223557438|NCT00673231|DRUG|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
223557439|NCT01279291|BIOLOGICAL|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
223557440|NCT01279291|DRUG|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
223557441|NCT01279291|DRUG|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
223557442|NCT01279291|DRUG|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
223557443|NCT02952313|DEVICE|Nasal Implant|
223557444|NCT06170190|BIOLOGICAL|IBI133|"IBI133:~The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the course of the study. Q3W"
223738021|NCT01618552|OTHER|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
223738022|NCT00584558|PROCEDURE|Catheter Ablation|Catheter Ablation of arrhythmias
224024207|NCT05270057|DRUG|Etoposide|Dose level -2=50 mg/m\^2; dose level -1=50 mg/m\^2; dose level 1=50 mg/m\^2; dose level 2=60 mg/m\^2; dose level 3=72 mg/m\^2; dose level 4=86.4 mg/m\^2; dose level 5=103.7 mg/m\^2; dose level 6=124.4 mg/m\^2; dose level 7=149.3 mg/m\^2
224024208|NCT05270057|DRUG|Doxorubicin|Dose level -2=10 mg/m\^2; dose level -1; dose level -1=10 mg/m\^2; dose level 1=10 mg/m\^2; dose level 2=12 mg/m\^2; dose level 3=14.4 mg/m\^17.3 mg/m\^2; dose level 4=17.3 mg/m\^2; dose level 5=20.7 mg/m\^2; dose level 6=24.8 mg/m\^2; dose level 7=29.8 mg/m\^2.
224024209|NCT05270057|DRUG|Cyclophosphamide|Dose level -2=480 mg/m\^2; dose -1=600 mg/m\^2; dose level 1=750 mg/m\^2; level 2=900 mg/m\^2; level 3=1080 mg/m\^2; level 4=1296 mg/m\^2; level 5=1555 mg/m\^2; level 6=1866 mg/m\^2; level 7=2239 mg/m\^2.
224024210|NCT05270057|DRUG|Rituximab|Level -2 through level 7: 375 mg/m\^2
224024211|NCT05270057|DRUG|Vincristine|Level -2 through level 7: 0.4 mg/m\^2/day
224297885|NCT02441244|DRUG|Visbiome|Visbiome probiotic
223407709|NCT00020787|DRUG|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
223407710|NCT03608033|BIOLOGICAL|OMS721|Biological: OMS721
223407711|NCT03608033|OTHER|Vehicle (D5W or saline)|5% Dextrose in water or normal saline solution
223557445|NCT03828097|DIETARY_SUPPLEMENT|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
223557446|NCT03828097|DIETARY_SUPPLEMENT|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
224024212|NCT05270057|DRUG|Prednisone|Level -2 through level 7: 60 mg/m\^2/twice daily (BID)
224024213|NCT05270057|DRUG|Loncastuximab Tesirine 0.075 mg/kg by IV|Cohort 1: 0.075 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
224024214|NCT05270057|DRUG|Loncastuximab tesirine 0.12 mg/kg by IV|Cohort 2: 0.12 mg/kg by IV. The dose-expansion phase will use the maximum-tolerated dose.
224297886|NCT02441244|OTHER|Placebo|Placebo
223407712|NCT03228979|OTHER|Structured Semi-Interactive Stroke Prevention Package|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
223407713|NCT04918017|DRUG|Treatment based on subtypes: Esomeprazole or Itopride|"Esomeprazole 40mg OD for EPS and Itopride 50mg TDS for PDS~In overlapped EPS/ PDS: treat with Itopride 50mg TDS first and then add Esomeprazole 40mg OD (if partially responded- assessed at week 4) or treat with Itopride 50mg TDS first and then change to Esomeprazole 40mg OD (if not responded- assessed at week 4)"
223407714|NCT04918017|DRUG|Treatment with proton pump inhibitor regardless of subtype: Esomeprazole|Esomeprazole 40mg OD
223557447|NCT06517069|OTHER|TEAS|Bilateral Neiguan point (PC6), Zusanli point (ST36) and Sanyinjiao point (SP6) were selected. Use Huatuo electronic needle therapy device, Sulodine electric stimulation hand circle TEAS, Huatuo electronic needle therapy device parameter setting: Density wave, 2/10Hz, current intensity from weak to strong, until the patient can tolerate the maximum intensity (acid, numbness, distension, pain) is appropriate, after the Sulodine brand electrical stimulation bracelet is turned on, gradually increase the stimulation intensity, until the patient can tolerate the maximum intensity is appropriate, stimulation for 30min until anesthesia induction
224024215|NCT05270057|DRUG|Loncastuximab tesirine 0.15 mg/kg by IV|Cohort 3: 0.15 mg/kg by IV The dose-expansion phase will use the maximum-tolerated dose.
223557448|NCT06517069|DRUG|Oxycodone|Oxycodone 0.1mg/kg was injected intravenously 5 minutes before anesthesia induction
223557449|NCT03594747|DRUG|Tislelizumab|Administered intravenously as described
223557450|NCT03594747|DRUG|Paclitaxel|Administered intravenously as described
224024216|NCT03607552|DEVICE|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
224024217|NCT03607552|DEVICE|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
223407715|NCT06320184|DIAGNOSTIC_TEST|Artificial Intelligence risk model|Combining blood-based biomarkers, radiologic parameters, clinical features, and AI tools to create a robust model to predict lung cancer risk.
223557451|NCT03594747|DRUG|Nab-paclitaxel|Administered intravenously as described
224024218|NCT04576455|DRUG|Giredestrant|Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
224024219|NCT04576455|DRUG|Fulvestrant or an Aromatase Inhibitor (Physician Choice)|Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
223407716|NCT02147834|DRUG|Ranolazine|"Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
224024220|NCT04576455|DRUG|LHRH Agonist|Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
224024221|NCT06211764|DRUG|TAR-200|Participants will receive TAR-200 intravesically.
223407717|NCT02147834|DRUG|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks"
223407718|NCT05214651|PROCEDURE|novel double row|The large - massive rotator cuff tears in in this group will be treated using a novel double row repairing techniques.
223407719|NCT05214651|PROCEDURE|suture bridge double row|The large - massive rotator cuff tears in in this group will be treated using a suture bridge double row repairing techniques.
224024222|NCT06211764|DRUG|Mitomycin C|Participants will receive MMC intravesically.
223557452|NCT03594747|DRUG|Carboplatin|Administered intravenously as described
223557453|NCT02315248|RADIATION|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
223557454|NCT06649253|OTHER|Sampling bone tissue and blood|Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
223557455|NCT06031285|DRUG|Sintilimab|sintilimab (200 mg intravenous infusion), a bevacizumab biosimilar (15 mg/kg intravenous infusion), and TACE-HAIC (c-TACE, FOLFOX-based HAIC).
223557456|NCT00412295|DEVICE|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
223557457|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
223557458|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
223557459|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
223557460|NCT03669757|DRUG|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
223557461|NCT03669757|DRUG|LEO 134310 vehicle|Active substance: none
223557462|NCT03669757|DRUG|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
223738023|NCT04882527|DEVICE|Non-invasive brain stimulation|Stimulation will be applied once per subject with one mA for 20 minutes over either the left inferior frontal lobe, the right inferior frontal lobe or the right superior parietal lobe.
223738024|NCT04882527|DEVICE|Sham stimulation|The electrode positions and the attachment procedures correspond to those of real tDCS but the electrical current will only be ramped up to 1 mA and switched off completely after 30 s of stimulation.
224024223|NCT06211764|DRUG|Gemcitabine|Participants will receive gemcitabine intravesically.
224024224|NCT06689085|COMBINATION_PRODUCT|Testosterone enanthate|XYOSTED 50mg, XYOSTED 75 mg, XYOSTED 100 mg
224024225|NCT02186847|RADIATION|Radiation Therapy|Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).
224297887|NCT00002006|DRUG|Zidovudine|
224297888|NCT00002006|DRUG|Sargramostim|
223557463|NCT02644369|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
224024226|NCT02186847|DRUG|Carboplatin|2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.
224024227|NCT02186847|DRUG|Metformin|Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),
224138895|NCT01317615|DRUG|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
224138896|NCT02859493|DEVICE|Saccharomyces cerevisiae|
224138897|NCT02859493|DEVICE|Placebo|
223557464|NCT03657784|DRUG|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
223557465|NCT01557101|PROCEDURE|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
223557466|NCT01557101|PROCEDURE|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
223557467|NCT02082080|OTHER|Education|
223557468|NCT02082080|OTHER|Social support|
223557469|NCT02095873|DIETARY_SUPPLEMENT|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
223557470|NCT02095873|DIETARY_SUPPLEMENT|Placebo|Mannitol, 108 mg
223557471|NCT01633840|OTHER|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
223557472|NCT01633840|OTHER|Elemental E028|Elemental E028 with no added food allergens
223557473|NCT04304053|DRUG|Treatment and prophylaxis|"Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7."
223557474|NCT04304053|OTHER|Standard Public Health measures|Isolation of patient and contact tracing as per national guidelines.
223557475|NCT00792740|DRUG|ITF2357|ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
224024228|NCT02186847|DRUG|Paclitaxel|50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
224024229|NCT06808984|DRUG|BMS-986368|Specified dose on specified days
223557476|NCT00792740|OTHER|Placebo|Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
223557477|NCT05658250|DEVICE|CRE8 polymer-free Amphilimus-eluting stent, Cre8 evo stent|Percutaneous coronary intervention using a Cre8 stent, Cre8 evo stent for long lesions
223557478|NCT05792007|PROCEDURE|Biological sampling in patients|blood and bone marrow samples from patients with Acute Leulemia.
223557479|NCT05792007|PROCEDURE|Biological sampling in control patients|blood and bone marrow samples from children undergoing orthopedic surgery exposing the bone marrow.(osteotomy of the pelvis).
224024230|NCT06808984|DRUG|Placebo|Specified dose on specified days
223557480|NCT01328028|OTHER|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
223557481|NCT01328028|OTHER|Data collection|Log sheet
223557482|NCT00703846|DRUG|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
223557483|NCT04062864|DEVICE|Pupil size|Measures the diameter of pupil before and after painful stimuli
223557484|NCT00136695|DRUG|anastrozole|1 mg QD
223557485|NCT04635709|DEVICE|biofeedback training and interferential therapy|compare the effect of applying both types of devices on the pelvic floor muscles
223557486|NCT02337101|OTHER|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
224024231|NCT07103018|DRUG|KTX-2001|Participants will receive escalating doses of KTX-2001 monotherapy
224024232|NCT07103018|DRUG|KTX-2001 + Darolutamide (NUBEQA®)|Participants will receive escalating doses of KTX-2001, in combination with the oral androgen receptor (AR) pathway inhibitor (ARPI), darolutamide (NUBEQA®)
224024233|NCT04101539|DEVICE|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
224024234|NCT04101539|DEVICE|Standard PVI|Standard PVI for AF.
224024235|NCT06312579|BEHAVIORAL|12-week home based exercise|Consistent with current physical activity recommendations for older adults, participants randomized in this arm will be prescribed 5 days/week of exercise, with seated cycling exercise performed on 3 days a week (Monday, Wednesday and Friday), and strength/balance exercise performed 2 days a week (Tuesday and Thursday).
224024236|NCT06312579|BEHAVIORAL|12-week standard of care|Participants in this group will be provided with guidance on the current standard of care. This includes guidance that these patients should slowly increase ambulation with appropriately fitted footwear.
224024237|NCT06653153|DRUG|Remternetug|Administered SC
224024238|NCT06653153|DRUG|Placebo|Administered SC
224024239|NCT06976697|DEVICE|Transcranial direct current stimulation|In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.
224024240|NCT06976697|DEVICE|Sham transcranial direct current stimulation|Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.
223557487|NCT02337101|BEHAVIORAL|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
223557488|NCT02613663|PROCEDURE|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
223557489|NCT02613663|PROCEDURE|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
223557490|NCT03968029|PROCEDURE|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
223557491|NCT03968029|PROCEDURE|suturing meniscal|meniscal tear sutured
224024241|NCT06513065|DRUG|Mitomycin c|"Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy."
224024242|NCT06502379|DRUG|AZD8965|AZD8965 will be administered orally.
224024243|NCT06502379|OTHER|Placebo|Placebo will be administered orally.
224133042|NCT01800279|OTHER|Physiotherapy Protocol|"Kinesitherapy~* Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~* Tongue in the palate for all applied exercises.~* Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
224024244|NCT05383274|COMBINATION_PRODUCT|Optilume Urethral DCB|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
224024245|NCT06842667|BEHAVIORAL|Papageno video|"The intervention will be a video (14 min 13 sec in length) of a series of clips from the Papageno interviews developed during the pilot phase of this project. The decision to combine the videos and shorten the total length of the video was based on the feedback we received during the acceptability and feasibility phase of this study. Interviewees were asked questions about a time in their life when they came close to suicide but found non-suicide alternatives (their Papageno story)."
224133043|NCT01800279|OTHER|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~* Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~* Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~* Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
224297889|NCT03352375|DEVICE|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
224297890|NCT03352375|DEVICE|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
224297891|NCT03721731|DEVICE|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
223557492|NCT01138696|OTHER|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
223557493|NCT01138696|OTHER|RX|X-rays and clinical investigation of the knee 20 years after surgery
223557494|NCT03873298|DRUG|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
224297892|NCT03944681|DRUG|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
224297893|NCT03442959|OTHER|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
224297894|NCT01366443|PROCEDURE|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
224297895|NCT01366443|PROCEDURE|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
224297896|NCT01366443|PROCEDURE|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
224297897|NCT05684471|PROCEDURE|Ultrasound Guided Suprainguinal Fascia iliaca Block|Patients in this group will be administered SFIB with 50 mL of local anesthetic solution (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
224297898|NCT05684471|PROCEDURE|Ultrasound Guided Anterior Quadratus Lumborum Block|Patients in this group will be administered anterior QLB with 40 mL of local anesthetic (Bupivacaine %0.25) under ultrasound guidance after the surgery is completed.
224297899|NCT00321594|DRUG|belinostat|Given IV
224297900|NCT03478228|OTHER|Multi-Sensory Training|
224297901|NCT05388240|OTHER|Education via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources."
224297902|NCT05388240|OTHER|Education and Exercise via a Mobile App|"This group will have access to Education and Resources tab that includes customary information given at a pre-op appointment plus some additional related education and resources. The app will also be used to help guide participants through an eight-week shoulder exercise program, together with physical therapy remote support."
224297903|NCT06225557|OTHER|ERAS community recommendation|Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section
223557495|NCT03612063|DEVICE|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
223557496|NCT03612063|DEVICE|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
223557497|NCT03612063|DEVICE|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
223738025|NCT01236937|DEVICE|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
223738026|NCT00116051|DEVICE|Acetabular implant, Monoblock cup|
223738027|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
223738028|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
224024246|NCT06842667|BEHAVIORAL|Control video|The control condition will involve viewing a mental health education video (12 min 14 sec in length) created by our team. It is a simple informational video, aimed at psychoeducation about suicide and safety promotion. It includes a list of mental health and crisis resources. Both videos are interview-style.
224024247|NCT03319849|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
224024248|NCT03319849|PROCEDURE|Sham|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
224024249|NCT06814132|DRUG|MK-5684|Oral tablet
224024250|NCT06814132|DRUG|Prednisone|Oral tablet
224024251|NCT06814132|DRUG|Fludrocortisone acetate|Oral tablet
224024252|NCT01195285|PROCEDURE|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
223557498|NCT03612063|DEVICE|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
223557499|NCT03612063|DEVICE|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
223738029|NCT04442022|DRUG|Selinexor (combination therapy)|Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
223738030|NCT04442022|DRUG|Placebo matching for Selinexor (combination therapy)|Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral
224024253|NCT01195285|PROCEDURE|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
224133044|NCT00194025|DRUG|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
223738031|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)
223738032|NCT04442022|DRUG|Rituximab (combination therapy)|Dose: 375 mg/m\^2 on Day 1; Route of administration: IV
223738033|NCT04442022|DRUG|Gemcitabine (combination therapy)|Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV
223738034|NCT04442022|DRUG|Dexamethasone (combination therapy)|Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV
224024254|NCT06814496|DRUG|Tarlatamab|Tarlatamab will be administered at a step-up dose of 1mg on Cycle 1 Day 1 and then 10 mg on Cycle 1 Day 8 and Cycle 1 Day 15 and every 2 weeks thereafter. For cycle 2 onwards, tarlatamab infusion will occur every 2 weeks on days 1 and 15 of each cycle.
224024255|NCT06814496|RADIATION|Concurrent Radiation Therapy|Standard of care RT can begin as early as Cycle 1 Day 16 and as late as Cycle 2 Day 28, assuming there is no ongoing CRS (extracranial)/ICANS (cranial).
224024256|NCT06814496|RADIATION|Sequential Radiation therapy|Standard of care radiation therapy can occur prior to Cycle 1 Day 1 (if radiation treatment is completed \<7 days prior to the start of tarlatamab) or be interdigitated with tarlatamab with a 7-day washout between RT and infusion, with RT to begin as early as Cycle 1 Day 22 and as late as cycle 2 Day 28, assuming no ongoing CRS (extracranial)/ICANS (cranial).
223738035|NCT04442022|DRUG|Cisplatin (combination therapy)|Dose: 75 mg/m\^2 on Day 1; Route of administration: IV
223407720|NCT05791097|DRUG|Ociperlimab|Ociperlimab is a monoclonal antibody formulated for intravenous infusion. 900 mg of ociperlimab will be administered on Day 1 of each 21-day cycle
223557500|NCT03612063|DEVICE|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~1. At rest~2. 4 mph~3. 5 mph~4. 6 mph~5. 7 mph~6. 8 mph~7. 9 mph~8. Post-exercise 1 minute~9. Post exercise 2 minutes"
223557501|NCT02782351|BIOLOGICAL|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
223557502|NCT02485639|BIOLOGICAL|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants received vaccine intramuscularly (IM) on Day 0.
223557503|NCT02015481|DRUG|Cabaletta|
223557504|NCT04236050|DRUG|Rocuronium|Rocuronium administered in continuous infusion or multiple bolus doses
223738036|NCT04442022|DRUG|Selinexor (continuous therapy)|Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral
224024257|NCT02254278|DRUG|Cisplatin|40 mg/m2 IV (intravenously) weekly for 6 weeks
224133045|NCT00004418|DRUG|glyceryl trierucate/glyceryl trioleate|Administration of glyceryl trierucate/glyceryl trioleate
224133046|NCT05877651|BIOLOGICAL|MASCT-I injection|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
224133047|NCT05782296|DEVICE|TrueLabor|Non invasive monitoring device
223407721|NCT05791097|DRUG|Placebo|Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
223407722|NCT05791097|DRUG|Tislelizumab|Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle
223557505|NCT04538300|DIAGNOSTIC_TEST|Abramowitz Emesis Score|Postoperative vomiting was evaluated by Abramowitz emesis score in recovery room.
223557506|NCT04538300|DIAGNOSTIC_TEST|Degree of nausea|Degree of postoperative nausea was evaluated.
223557507|NCT04538300|DIAGNOSTIC_TEST|Observer's Assessment of Alertness/Sedation Scale|Patients' sufficient wakefulness was evaluated by Observer's Assessment of Alertness/Sedation scale in the recovery unit.
223557508|NCT04538300|DIAGNOSTIC_TEST|Patient Satisfaction|Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
223557509|NCT04538300|DIAGNOSTIC_TEST|Surgeon Satisfaction|Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)
223557510|NCT04538300|OTHER|Chewing Peppermint gum|Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
224133048|NCT04654000|PROCEDURE|Rheopheresis procedure|rheopheresis is performed using an automated monitor (Plasauto, company HemaT) in a double-filtration cascade. Plasma purify from of high molecular weight proteins
224133049|NCT04654000|PROCEDURE|Sham-apheresis|Sham-apheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient.
223557511|NCT04437550|OTHER|Exercise|high intensity exercise = 15 x 60 s sprints at 85% velocity of VO2max (vVO2max) with 60 s walking at 20% vVO2max or moderate intensity exercise = walking at 60% vVO2max
223557512|NCT01320852|OTHER|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
223738037|NCT04442022|DRUG|Placebo matching for Selinexor (continuous therapy)|Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral
223738038|NCT05986916|DIAGNOSTIC_TEST|Liverscope® exam|Participants will undergo a LiverScope® examination to measure liver proton density fat fraction (PDFF, primary) and T1 and T2 values (exploratory).
224133050|NCT03587480|PROCEDURE|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
224133051|NCT03587480|PROCEDURE|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
224133052|NCT04667806|BEHAVIORAL|Questionnaires|Use questionnaires ( SF36 questionnaire (generic score) and St Georges's questionnaire (specific score))
223407723|NCT05791097|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of pembrolizumab will be administered on Day 1 of each 21-day cycle
223407724|NCT05791097|DRUG|Carboplatin|Carboplatin is a chemotherapy agent formulated for intravenous infusion. Carboplatin will be administered (AUC 6 mg/mL\*min) on Day 1 of each 21-day cycle
223407725|NCT05791097|DRUG|Cisplatin|Cisplatin is a chemotherapy agent formulated for intravenous infusion. Cisplatin will be administered (75 mg/m\^2) on Day 1 of each 21-day cycle
223407726|NCT05791097|DRUG|Pemetrexed|Pemetrexed is a chemotherapy agent formulated for intravenous infusion. Pemetrexed will be administered (500 mg/m\^2) on Day 1 of each 21-day cycle
223407727|NCT05791097|DRUG|Paclitaxel|Paclitaxel is a chemotherapy agent formulated for intravenous infusion. Paclitaxel will be administered (200 mg/m\^2) on Day 1 of each 21-day cycle
223738039|NCT05986916|DIAGNOSTIC_TEST|MR exam|Participants will undergo an advanced MR examination to measure liver PDFF, T1, T2, and liver stiffness values.
223738040|NCT05986916|DIAGNOSTIC_TEST|FibroScan® exam (optional)|Participants may undergo a FibroScan® exam (optional) to evaluate liver fat and liver stiffness.
223738041|NCT05986916|OTHER|Blood draw|Participants will undergo a blood draw (approximately 10 mL) for measurement of CBC, platelets, and complete metabolic panel with transaminases.
224024258|NCT02254278|RADIATION|IMRT 6 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy
224024259|NCT02254278|RADIATION|IMRT 5 weeks|Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy
224024260|NCT02852070|PROCEDURE|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
224024261|NCT02852070|PROCEDURE|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
223407728|NCT05791097|DRUG|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent formulated for intravenous infusion. Nab-paclitaxel will be administered (100 mg/m\^2) on Day 1, 8 and 15 of each 21-day cycle
223407729|NCT05315037|OTHER|Resistance Training|"Bench press: Exercise performed with participant lying supine with hands in prone position. Barbell is lowered vertically from fully extended elbow position to sternum, then returned to starting position. Barbell will be weighted with plates dependent on their strength and workout demands.~Deadlift: Consists of gripping bar while in a squat position. Extension of ankles, knees, and hips while gripping the bar brings the weight up until joints are locked completing the exercise concentric portion. The eccentric lowering of the weight follows and consists of flexion of joints.~Seated overhead press machine: This multi-joint exercise, deltoid and trapezius are the prime movers and triceps are secondary movers, with hands on the grips and a position allowing back and buttocks to be completely supported. They push against a load vertically until glenohumeral joint fully extends, then load is returned to starting position and process continues until all repetitions desired are achieved"
223407730|NCT03023215|PROCEDURE|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
223407731|NCT03023215|PROCEDURE|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
223407732|NCT03023215|BEHAVIORAL|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
223407733|NCT03023215|PROCEDURE|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
224024262|NCT03045068|BIOLOGICAL|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~1. Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~2. Subsequent platelet transfusion continued till completion via central venous access to the patient"
224024263|NCT03045068|BIOLOGICAL|FFP and Cryoprecipitate|"1. 1 unit of cryoprecipitate administered during MUF and or after MUF as needed~2. FFP transfusion 10ml/kg during MUF and or after MUF as needed"
223407734|NCT03920839|DRUG|Retifanlimab|INCMGA00012 administered intravenously every 3 weeks.
223407735|NCT03920839|DRUG|Gemcitabine|Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
223407736|NCT03920839|DRUG|Cisplatin|Cisplatin administered intravenously on Day 1 of 21-day cycles.
223407737|NCT03920839|DRUG|Pemetrexed|Pemetrexed administered intravenously on Day 1 of 21-day cycles.
224024264|NCT03045068|BIOLOGICAL|PRBC and cell saver Transfusion|1\. Transfuse for target Hematocrit \> 40 in neonates with SV physiology; Transfuse for Hematocrit\> 33 for 2-Ventricle physiology
223407738|NCT03920839|DRUG|Carboplatin|Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
223407739|NCT03920839|DRUG|Paclitaxel|Paclitaxel administered intravenously on Day 1 of 21-day cycles.
223407740|NCT06545539|OTHER|Fall Preparedness Exercise Class|The class will be held bi-weekly at two different locations. To ensure consistency across groups, the instructor(s) will adhere to a standardized class outline. Exercise modifications will be provided as necessary to adjust the intensity, ensuring all participants can follow the program.
223407741|NCT01123811|DRUG|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
223407742|NCT02841839|DRUG|Stannous Fluoride|
223407743|NCT05018182|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery
223407744|NCT05018182|DRUG|Irinotecan|Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection
223407745|NCT05018182|DRUG|Folinic Acid|Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection
223407746|NCT05018182|DRUG|5FU|5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
223407747|NCT05018182|DRUG|Capecitabine|Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
223407748|NCT04119869|OTHER|iaya|The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.
223407749|NCT00475488|PROCEDURE|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
223407750|NCT03585023|DIAGNOSTIC_TEST|Spontaneous miscarriage|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
223407751|NCT03585023|DIAGNOSTIC_TEST|Voluntary pregnancy interruption|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
224024265|NCT03045068|BIOLOGICAL|Factor Concentrate (Bebulin)|1\. Based on clinical bleeding and achievement of hemostasis
224024266|NCT06662539|DRUG|Petrelintide|Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
224024267|NCT06662539|DRUG|Placebo|Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
223407752|NCT01873846|DEVICE|Silicone Hydrogel Contact Lens|
223407753|NCT02062450|DEVICE|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
223557513|NCT01480583|DRUG|GRN1005|550 mg/m2 IV every 3 weeks
223557514|NCT01480583|DRUG|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
223557515|NCT01480583|DRUG|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
224024268|NCT06654037|DRUG|Abemaciclib|Given PO
224024269|NCT06654037|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224024270|NCT06654037|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224024271|NCT06654037|DRUG|Fluorouracil|Given IV
224024272|NCT06654037|PROCEDURE|Radiologic Imaging Procedure|Undergo radiologic imaging
224024273|NCT06458153|BEHAVIORAL|Neural responses to speech functional localizer|Measuring speech-related brain activity using fMRI during a speech listening task.
224024274|NCT06458153|BEHAVIORAL|Neural responses to silent articulation|Measuring speech-related brain activity using fMRI during a silent articulation task.
224024275|NCT06458153|BEHAVIORAL|Neural responses to self vs. externally generated speech|Measuring speech-related brain activity using fMRI during self-generated vs. externally-generated speech.
223407754|NCT02062450|DEVICE|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
223407755|NCT01221519|DRUG|AZD1656|3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
223407756|NCT02726009|DRUG|Degarelix|
223407757|NCT05419219|DEVICE|the multi-domain Tai Chi Digital therapy Software Application|regular Tai Chi exercise, 40 Hz gamma sound stimulation and 18 BPM breath control exercise
223407758|NCT00046137|DRUG|teriparatide|
223407759|NCT00046137|DRUG|raloxifene|
223557516|NCT01788397|BEHAVIORAL|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
223557517|NCT04653090|DIAGNOSTIC_TEST|Xray|Hip AP Xray
223557518|NCT02511795|DRUG|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
223557519|NCT02511795|DRUG|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
223557520|NCT02072252|BEHAVIORAL|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
223557521|NCT00712686|DRUG|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
223557522|NCT00712686|DRUG|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
223557523|NCT03500016|OTHER|High intensity interval training|See under arm description.
223557524|NCT02434549|DRUG|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
223557525|NCT02434549|DRUG|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
223557526|NCT06419556|PROCEDURE|Cervical Plexus Block|"The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt."
223557527|NCT05719857|PROCEDURE|Hepatic vein pressure gradient measurement|HVPG will be performed after light conscious sedation and with noninvasive vital sign monitoring. The right jugular vein will be catheterized with ultrasound assistance and after local anesthesia. Then a venous introducer will be placed and a balloon-tipped catheter will be advanced under fluoroscopic control into the right hepatic vein. Free hepatic pressure will be obtained with the balloon deflated, keeping the catheter tip in the right hepatic vein. Then, wedged venous pressure will be measured by inflating the balloon with 2 ml of air. At this moment, complete occlusion of the catheterized hepatic vein can be confirmed by injecting iodinated contrast and observing its retention. The presence of veno-venous communications can be detected during the test. To calculate the gradient, we perform the simple difference between the two measurements. Measurements will be performed in triplicate and the average used as the final value.
224024276|NCT06458153|BEHAVIORAL|Event-related potentials for speech|Measuring electroencephalography (EEG) based evoked potentials for self vs. externally generated speech
223557528|NCT05719857|PROCEDURE|Ultrasound-guided percutaneous liver biopsy|Percutaneous liver biopsy will be performed with the aid of US to choose the best site for the procedure, minimizing the incidence of complications. With the patient in dorsal decubitus, venous analgesia with fentanyl 25-50 mcg will be performed. After marking the appropriate site, skin asepsis and antisepsis will be performed with Chlorhexidine® and topical anesthesia with 1% lidocaine. Then, the liver will be punctured using a 14G semi-automatic tru-cut single-use liver biopsy needle. The recovered material will be stored in a 50 ml flask with 10% formaldehyde. Patients will remain at rest supervised for 4 hours, with hourly measurement of blood pressure (BP), heart rate (HR) and assessment of symptoms (abdominal pain, nausea, etc.). In the absence of any complications, patients will be discharged from the hospital.
223557529|NCT05719857|DIAGNOSTIC_TEST|Multiparametric Abdominal Magnetic Resonance with Elastography|The evaluation of the abdomen by MRI, with special interest to the liver and spleen, will be performed in a Siemens 3.0T Magnetom Prisma MR system. In addition to the routine protocol without contrast administration, MR elastography will be performed to assess liver stiffness and spleen stiffness. Data processing will be carried out at a Syngovia workstation.
223407760|NCT00046137|DRUG|placebo|
223407761|NCT04524793|OTHER|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
223407762|NCT04524793|OTHER|Physical examinations|GSV/SSV/AASV reflux, CEAP Classification (Clinical, Aetiological, Anatomical and Pathophysiology), Venous Clinical Severity Score (VCSS) and duplex ultrasound
223407763|NCT04486937|DRUG|S410914 tablet|S410914 tablet
223407764|NCT05643703|PROCEDURE|Suture method|One-layered Suture: Single layer intermittent suture; Two-layered Suture:Single layer intermittent suture plus U type reinforcement stitching
223557530|NCT04259437|OTHER|High Protein, Energy Dense Nutritional Supplement|Ready to drink oral supplement
223407765|NCT06577909|DRUG|Prednisone|Prednisone po, 20mg per day for 4 weeks, if response (Plt 30-100×100\^g/L), gradually taper to the maintenance dose of 5-10mg per day until 6 weeks after delivery; if not response, gradually taper to withdrawal.
223407766|NCT06577909|DRUG|IVIg|IVIg 400mg/kg (≤20g for the total dose) per day for 5 days, and repeated in the case of lack of response by day 14
223407767|NCT00239265|DRUG|Tamuslosin|
223407768|NCT02856932|OTHER|Conventional high viscosity glass ionomer|Dental restorative material
223407769|NCT02856932|OTHER|Glass ionomer with glass hybrid technology|Dental restorative material
223407770|NCT02104674|DRUG|lebrikizumab|Given SC on Days 1, 29, and 57
223407771|NCT02104674|DRUG|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
223407772|NCT02104674|OTHER|placebo|SC injection given on Days 1, 29, and 57
223557531|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
223557532|NCT03115203|OTHER|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
223557533|NCT05320354|DIAGNOSTIC_TEST|Microbial ID test|In addition to the standard of care procedure for patients suspected for a periprosthetic joint infection, the MID-test will be performed using the residual synovial fluid. Individual test results of the MID-test are not reported back to the participating sites in order to not interfere with the sites' standard of care approach.
223557534|NCT00252031|BEHAVIORAL|Dialectical Behavioral Therapy|
223557535|NCT02566785|OTHER|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
223557536|NCT05199636|OTHER|Dragon fruit product|Frozen dragon fruit based beverage
223557537|NCT02720055|OTHER|Psychological workbook|
223557538|NCT02720055|OTHER|Basic information workbook|Basic rehabilitation information that represents current practice.
223557539|NCT03073317|DIAGNOSTIC_TEST|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
223557540|NCT03423446|DRUG|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
223557541|NCT02441153|OTHER|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
223557542|NCT03101488|DRUG|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
223557543|NCT00444483|BEHAVIORAL|Structured diabetes teaching and treatment program|
223557544|NCT04818216|DRUG|Placebo|Placebo capsule containing inert ingredient
223557545|NCT04818216|DRUG|Nicotinamide riboside|250 mg Nicotinamide riboside capsules
223557546|NCT01642498|DEVICE|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
223557547|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
223557548|NCT02558036|OTHER|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
223557549|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
223557550|NCT02558036|OTHER|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
223557551|NCT05083208|DRUG|Parsaclisib|"Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years."
223557552|NCT05083208|DRUG|Chidamide|"Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments."
223557553|NCT06981390|DRUG|Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy
223557554|NCT06981390|DRUG|Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy
223738042|NCT05986916|OTHER|Body measurements|Participants will have their height, weight, waist circumference, and hip circumference measured.
223738043|NCT05986916|OTHER|Questionnaires|Participants will be asked to fill out questionnaires to collect information about their alcohol consumption, history of cigarette smoking, presence of diabetes, and history of liver disease and medications
224297904|NCT06225557|OTHER|Traditional postoperative care|Usual anesthesia and analgesia in elective cesarean section.
224297905|NCT02394730|DRUG|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
224297906|NCT02394730|DRUG|Placebo|Sugar pill taken orally once daily for 12 weeks
224297907|NCT05115591|DIAGNOSTIC_TEST|Spinal Ultrasound|Spinal Ultrasound is performed by an observer who records ultrasound characteristics of the intervertebral space chosen by the anesthetist who will practice spinal anesthesia
224297908|NCT05115591|PROCEDURE|Spinal Anesthesia|Spinal anesthesia is performed by an anesthetist after the observer recorded ultrasound characteristics of the intervertebral space chosen by the anesthetist, who is blinded to the ultrasound evaluation.
224297909|NCT06490120|OTHER|sampling method|feasibility outcomes will be compared between the 3 groups
223407773|NCT04227431|OTHER|Insulin degludec|Participants have been treated with Tresiba® (insulin degludec) for at least 20 weeks before entering the study. The study will be based on data already recorded in participants' medical records for approximately the last year and no new tests or procedures are required as part of the study.
223407774|NCT02591160|PROCEDURE|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
223407775|NCT04712162|OTHER|Other|Compare time to awakening and quality of recovery after general anesthesia between two groups.
223407776|NCT04154254|DIAGNOSTIC_TEST|PET/MR|The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
223557555|NCT06981390|DRUG|Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)|Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy
223557556|NCT06981143|BEHAVIORAL|Quantitative study|A validated questionnaire will be used to investigate the knowledge and perceptions of physical activity and exercise of specialists and residents in Pathological Oncology
224024277|NCT06458153|BEHAVIORAL|Neural responses to induced speech errors|Measuring speech-related brain activity using fMRI during conditions that induce auditory speech errors.
223557557|NCT04212013|DRUG|Ibrutinib|Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
224024278|NCT06458153|BEHAVIORAL|Neural responses to sensory-motor adaptation|Measuring brain activity using fMRI during a learning task with sustained altered auditory feedback.
224024279|NCT06458153|BEHAVIORAL|Speech production behaviors|Behavioral measurements of speech during reading passages and words
223557558|NCT04212013|DRUG|Rituximab|Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
224024280|NCT06458153|BEHAVIORAL|Auditory acuity testing|Measurements of auditory acuity during listening tasks.
224024281|NCT06458153|BEHAVIORAL|Neural responses to learning a non-speech auditory motor behavior|Mapping of brain areas using fMRI during learning of non-speech sound-evoking movements.
224133053|NCT04115618|RADIATION|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
224133054|NCT03134313|DEVICE|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
224133055|NCT05913284|DRUG|Methadone|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
223407777|NCT02056210|DRUG|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
223407778|NCT03721796|OTHER|Audio recording of initial consultation and debriefing interviews.|Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.
223557559|NCT04212013|OTHER|Placebo|Placebo capsules will be similarly dosed at 4 capsules daily.
223557560|NCT06602310|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application. Telematic non-face-to-face preoperative assessment.
223557561|NCT05517486|DRUG|GTX-101|Bupivacaine HCl metered spray
223557562|NCT05517486|DRUG|Bupivacaine HCl subcutaneous injection|Bupivacaine HCl, 50 mg/10 mL
223557563|NCT02783547|DRUG|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
223557564|NCT06661135|PROCEDURE|TLPD total laparoscopic pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the laparoscopy
223557565|NCT06661135|PROCEDURE|OPD open pancreaticoduodenectomy|It includes removal of the pancreatic or duodenal tumors using the open technique
223557566|NCT06659185|DIETARY_SUPPLEMENT|Exercise|The effects of placobo mouth rinsing on softball batting performance
224024282|NCT06665165|DRUG|AMX0114|Antisense oligonucleotides (ASOs) are a type of medicine that treats diseases by intercepting the mRNA messages sent within the cell, resulting in fewer specific proteins being made. AMX0114 is an ASO that targets the mRNA messenger that instructs the body to create a protein called calpain-2. Calpain-2 has been linked to the degeneration and death of neurons in many neurological diseases, including people living with sporadic ALS. AMX0114 is designed to reduce the levels of calpain-2, with the goal of slowing down the process that leads to neuron injury and death.
224024283|NCT06665165|OTHER|Placebo|Placebo
224024284|NCT05774197|BEHAVIORAL|Cognitive Behavioral Therapy for pain|Patient participating in this study will have survey assessments at baseline, 4 weeks (end of 4-week intervention period), and 6 weeks (end of 2-week post intervention period) assessing patient reported concerns, quality of life outcomes and usability of STAMP+CBT app. During this time, Patient will receive algorithm-based advice in response to their daily pain and mood surveys. These patients will be introduced to the extensive multi-media library of educational content covering medication support (e.g. using short and long-acting opioids, managing side effects, opioid safety); pain psychology (e.g. pain perception, pain and the stress response); health behaviors and pain (e.g. sleep hygiene); and skills training (e.g. activity pacing/ relaxation recordings).
224024285|NCT04186364|BEHAVIORAL|Assigned Ambassador|If assigned to the intervention group, participants will be assigned a medical student ambassador on arrival to the Emergency Department. A brief discussion may take place to review the child's history and survey results, and a copy of the survey will be placed near the patient's bedside for healthcare personnel to review. The student ambassador will accompany the child and their family through key points of their visit and will be expected to make accommodations for the child as determined by the accommodation survey results. The family will be required to allow the ambassador to stay throughout the ED visit.
224024286|NCT06608290|PROCEDURE|parasternal block|Administration of parasternal block with ropivacaine, bilaterally at the sternum before the start of surgery.
224024287|NCT06608290|DIAGNOSTIC_TEST|Lactate serum level|Blood samples were taken to identify serum lactate levels greater than 2 mmol/l and those that remained below this limit.
224024288|NCT03095677|OTHER|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
224024289|NCT03095677|OTHER|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
224024290|NCT06599606|DIAGNOSTIC_TEST|Ultrasonographic Assessment|A researcher will perform all ultrasonographic measurements using the ESAOTE My Lab 70 model ultrasound device with a 4-13 MHz linear probe. System settings will be kept constant throughout each study, and all images will be obtained using this single ultrasound device. Only the depth will be adjusted to optimally assess the relevant muscle. The muscle thickness measurement protocol with ultrasound includes four muscles on the dominant side of each child: two proximal upper and lower extremity muscles (biceps brachii/brachialis and quadriceps) and two distal upper and lower extremity muscles (forearm flexors and tibialis anterior). In the assessment of muscle echogenicity, images will be transferred to ImageJ software to calculate luminance ratios (LR).
223407779|NCT06055517|RADIATION|Pulsed low dose-rate radiotherapy (pLDRT)|Radiation treatment will be carried out with high-energy photons (6MV) using intensity modulated radiation therapy (IMRT) or volumetric arc radiation therapy (VMAT). The daily dose is 2 Gy, divided into 10 subfractions of 0.2 Gy spaced by 3 minutes. The cumulative dose will be individualized for each patient and can range from a minimum of 40 Gy to a maximum of 60 Gy.
223407780|NCT04597177|RADIATION|ST-IMRT SW-IMRT|
223407781|NCT06322641|OTHER|No treatment given|No treatment given
223407782|NCT05046262|DRUG|Calcium chloride|Calcium electroporation
223407783|NCT03308097|BEHAVIORAL|PrEP Mobile Messaging Intervention|See group description
223407784|NCT03308097|BEHAVIORAL|Enhanced Standard of Care|See group description
223557567|NCT06658327|OTHER|Dynamic stretching|Group A will receive 2\*10 repetitions of dynamic stretching of hamstrings and calf muscles in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
223557568|NCT06658327|OTHER|Static stretching|Group B will receive 2\*10 repetitions of static stretching of hamstrings and quads in standing position after application of hot pack (standard size which had been stored in a hydro collator tank of 74.5-80°C for 30 minutes) with 6-8 layers of towel was applied on lower extremity for 10 minutes. The subjects will be asked to stand upright with their feet parallel and facing forward with hands holding onto something. Each treatment session will last for 30 minutes. The protocol will be repeated every day for 5 days from the first day of treatment.
223557569|NCT06659913|BEHAVIORAL|Exercise training|Session 1: Consist of high intensity interval training performed on spinning bikes. An exercise physiologist will supervise the participants to perform a light 10 min warm-up, followed by 4 min working periods (intervals) interspersed by 3 min active breaks. The intensity should be 85-95% of estimated peak heart rate, corresponding to approximately 16 on the Borg scale (17). There will be a maximum of 10 participants in each group, depending on how many patients who are recruited for each of the two inclusion periods.I In addition, participants are encouraged to participate in the physical education at school and encouraged to perform exercise during the weekend, either with their family or friends.
223557570|NCT06662318|DRUG|Fentanyl Citrate|Fentanyl was given as a bolus of 1 µg/kg injected followed by a fentanyl infusion of 0.4 µg/kg/h. Fentanyl infusion was continued as Postoperative analgesia for 24 hours in a dose of 0.3 µg/kg/h.
223557571|NCT06662318|DRUG|Dexmedetomidine|Dexmedetomidine was given as a loading dose of 0.6 µg/kg, which was diluted to a total volume of 10 cc of normal saline and injected before induction of anesthesia over 10 minutes. Then, a DXM infusion prepared to provide 0.2-0.7 µg/kg/h was started Intraoperative; Postoperative DXM infusion was provided in a dose of 0.15 µg/kg/h for 24-h.
223557572|NCT06662318|DRUG|Lidocaine Hydrochloride|Lidocaine hydrochloride was provided as 2 mg/kg slowly IV before induction of anesthesia and as an IV infusion at a rate of 3 mg/kg/h. Postoprative lidocaine infusion at a dose of 1.5 mg/kg/h was administered for 24 Postoprative hours.
223557573|NCT05202262|DRUG|BFF MDI 320/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg
223557574|NCT05202262|DRUG|BFF MDI 160/9.6 μg|Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
223557575|NCT05202262|DRUG|BD MDI 320 μg|Budesonide MDI (BD MDI), 320 μg
223407785|NCT02035371|DRUG|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
223407786|NCT02035371|DRUG|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
223407787|NCT04153461|PROCEDURE|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
223407788|NCT04153461|PROCEDURE|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
223407789|NCT06569199|DEVICE|Functional Bracing|Premade fabricated braces in three sizes (small, medium and large) that have been designed for the pediatric age group between 0-5 years old will be stocked at the Alberta Children's Hospital. Braces will be applied to participants in the emergency department. As these braces are designed to allow for positional adjustments, if deemed necessary adjustments will be made by the attending orthopaedic surgeon at subsequent follow-up visit(s).
223407790|NCT06569199|DEVICE|Hip Spica Cast|The current standard of care for diaphyseal pediatric hip fractures in children aged 6 months to 5 years old is hip spica casting. A hip spica is a hard cast that covers a child's body from the chest down to their knees or ankles allowing for fracture immobilization to promote healing. Application of the spica cast occurs in the operating room and requires a general anaesthetic. Caring for a child in a hip spica cast presents significant challenges for caregivers due to the cast's cumbersome size and restricted mobility which makes routine caregiver activities like daily hygiene, toileting, transportation and skin surveillance difficult. Inadequate maintenance of the spica cast may result in skin complications, necessitating extra visits for cast adjustments, or potentially requiring revision casting in the operating room.
223407791|NCT03019237|DRUG|anti-IgE|intranasal anti-IgE
223407792|NCT03019237|OTHER|intranasal allergen|intranasal allergen
223407793|NCT03019237|OTHER|intranasal saline|intranasal placebo
223407794|NCT03907761|PROCEDURE|Hydrodissection|high velocity stream of normal saline is given to the dissection area by help of 10 ml syringe
223407795|NCT03926832|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea Syndrome (OSAS) management when moderate-to-severe. Subjects with OSA will be trained in the use of CPAP and will be instructed to use it every night for 3 months. These subjects will then return for a post-treatment completion of questionnaires (ESS and FAS) and compliance analysis.
223407796|NCT02907177|DRUG|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
223407797|NCT02907177|OTHER|Placebo|One tablet of matching placebo administered orally once daily in the morning
223407798|NCT06443957|DRUG|Intranasal normal saline|The patient was given 1ml of normal saline intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
223557576|NCT05202262|DRUG|Open-label Symbicort TBH 320/9 μg|Open-label Symbicort Turbuhaler 320/9 μg
223557577|NCT05909176|BEHAVIORAL|GYN Residency Training|The combined care model will be implemented and during months 5-14.
223557578|NCT05909176|BEHAVIORAL|Social Media Campaign|The social media campaign will be implemented along with the combined care model in months 15-18.
223557579|NCT06992713|DRUG|H1710 for Injection|Injection.
223557580|NCT06868641|BEHAVIORAL|TAIL-PrEP|The TAIL-PrEP intervention is comprised of two components: (1) monthly cab-LA monitoring with specimens self-collected by patient and mailed to a lab for processing; and (2) monthly HIV prevention coaching with personalized cab-LA feedback.
223557581|NCT07011173|DEVICE|Exotendon assistance|Assistive devices with distinct assistance dynamics
223557582|NCT07011173|DEVICE|End-effector assistance|Finger will be moved by the actuators connected to the fingertip
223557583|NCT02747459|BEHAVIORAL|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
223557584|NCT07028528|DIETARY_SUPPLEMENT|Levagen+|Participants will take 1 capsule twice daily with water after food. Each capsule will contain: A175mg containing 150 mg of palmitoylethanolamide (PEA). Total daily dose of 350mg Levagen+ containing 300 mg PEA
223557585|NCT07028528|OTHER|Placebo|Participants will take 1 capsule twice daily with water after food. Each capsule will contain microcrystalline cellulose \[MCC\]
223557586|NCT07033507|DIAGNOSTIC_TEST|MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions|Compare MRI diffusion coefficient and micro-calcifications to Kaiser Score in evaluation of BI-RADS 4 breast lesions
223557587|NCT07034300|DRUG|Lidocaine (drug)|40 ml of 0.5% lidocaine
223557588|NCT07034300|DRUG|Dexmedetomidine|Dexmedetomidine (0.5 μg/kg)
223557589|NCT05506982|DRUG|Psilocybin|Given PO
223557590|NCT05506982|BEHAVIORAL|Psychotherapy|supportive care
223557591|NCT05506982|OTHER|Quality-of-Life Assessment|Ancillary studies
223557592|NCT05506982|OTHER|Questionnaire Administration|Ancillary studies
223557593|NCT07036419|DRUG|Remimazolam Tosilate for injection|Remimazolam Tosilate for injection.
223557594|NCT07036419|DRUG|Propofol Injection|Propofol injection.
223557595|NCT07032779|OTHER|simulation|the students in the intervention group will have the Tag Team Patient Safety Simulation application. The students in the simulation group will be divided into 2 groups and each group will have the Tag Team Patient Safety Simulation application with the same scenario. The students in the labeling group will be included in the scenario as the scenario progresses. It will start with 4 students at the beginning, but with labeling, 7-8 students in each group will take the role of the actors, and the other students will take the role of the audience.
223557596|NCT07034833|BEHAVIORAL|Ventriloquist Puppet Interaction|children allocated to the Ventriloquist Puppet group were introduced to a Ventriloquist Puppet inside the clinic and were allowed to play, talk, and interact with the puppet for 5-10 minutes.
223557597|NCT07039955|BEHAVIORAL|Daily Chlorhexidine Bathing|Daily bathing using no-rinse, 4% chlorhexidine gluconate (CHG)-impregnated washcloths will be implemented in ICUs assigned to the intervention group. The purpose is to reduce CPE colonization and infection by maintaining effective residual CHG skin concentrations. Bathing will be performed by trained nursing staff following standardized protocols.
223557598|NCT07039955|BEHAVIORAL|Antimicrobial and PPI Stewardship Program|A targeted stewardship program will be implemented to reduce unnecessary carbapenem use and inappropriate proton pump inhibitor (PPI) prescriptions. The program includes audit and feedback, education of ICU physicians, and monthly monitoring of antimicrobial and PPI usage. Stewardship activities will be uniformly applied across both intervention and control ICUs.
224024299|NCT05615545|PROCEDURE|Cryoablation|Cryoablation of selected tumor lesions
224024300|NCT06809400|DRUG|LY4006896|Administered intravenously (IV)
224297910|NCT05512520|COMBINATION_PRODUCT|Intensity-modulated radiotherapy concurrent with capecitabine|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 45 to 50.4Gy in 25 to 28 fractions, concurrently with 2 cycles of capecitabine tablets (825mg/m2) for two weeks.
224297911|NCT06346002|BEHAVIORAL|Mindfulness-based intervention|The MBI program implemented comprised ten weekly sessions. Please refer to the arm/group descriptions for further details.
224297912|NCT02384850|DRUG|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
223407799|NCT06443957|DRUG|Intranasal insulin-20U|The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
223407800|NCT06443957|DRUG|Intranasal insulin-40U|The patient was given 1ml of 40U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
223407801|NCT04311333|DIAGNOSTIC_TEST|Endostomal three-dimensional ultrasonography|Examination with rectal probe enclosed by water-filled balloon. Rectal mode. Dynamic examination in different positions with and without increased intra-abdominal pressure.
223407802|NCT04311333|DIAGNOSTIC_TEST|Computerized tomography of the abdomen|"Supine position, without increased intra-abdominal pressure. Experienced radiologist interprets the examination.~If adequate examination has already been performed within the last 10 months, these images will be used and the patient will thus not undergo computerized tomography within the study."
223407803|NCT04311333|DIAGNOSTIC_TEST|Clinical examination|Patients will be clinically examined with inspection and palpation in supine and erect position with and without increased intra-abdominal pressure.
223407804|NCT04311333|DIAGNOSTIC_TEST|Evaluation at laparotomy/laparoscopy|During laparotomy or laparoscopy, inspection and/or palpation of the stoma at the abdominal wall orifice is performed.
223407805|NCT01453088|DRUG|Melphalan|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
223407806|NCT01453088|DRUG|Bortezomib|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
223407807|NCT06621914|DEVICE|BFR 80|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 80% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
223407808|NCT06621914|DEVICE|BFR40|The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to 40% of limb occlusion pressure during lower limb strengthening exercises. These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum.
223407809|NCT02355392|OTHER|Telemedical home blood pressure measurements|
223407810|NCT00731354|DEVICE|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
223407811|NCT00731354|DEVICE|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
223407812|NCT06555003|DRUG|Drug-Eluting Embolic Bead|A minimum of 2 sessions of DEBIRI treatment and 2-4 cycles of systemic chemotherapy are administered (based on tumor size, bilobar or unilobar involvement of the liver, treatment response rate, treatment tolerance, occurrence of side effects, and liver function). Prior to performing DEBIRI, initial angiography is done via the femoral or axillary artery to determine the anatomy of the right and left hepatic arteries as well as the arteries supplying the tumor. Subsequently, a vial of irinotecan (100 mg) eluted with a vial of beads(hepaSphere 25mg) is injected into the blood vessels feeding the tumor. The intervention will be repeated to deliver 200 mg of irinotecan intravascularly to the liver mass. A 14-day interval between the procedures is established to minimize side effects. Targeted therapy administration for each treatment group based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status as explained in control arm.
223738044|NCT04849806|DIAGNOSTIC_TEST|Assessments of the sympathetic nerve activity axis|"For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .~Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed."
224024301|NCT06809400|DRUG|Placebo|Administered IV
224024302|NCT06431477|DRUG|telmisartan|QD, PO
224024303|NCT06431477|DRUG|Losartan|QD, PO
224024304|NCT03935321|DRUG|NG-101|6 intrathecal bolus injections, each of 45mg
224024305|NCT03935321|DRUG|Placebos|6 intrathecal bolus injections, each of 45mg
224024306|NCT06609135|DEVICE|Sentec LuMon Device (EIT system)|Sentec EIT belts will be placed on infants up to once daily from consent through NICU discharge.
224297913|NCT02384850|DRUG|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
224297914|NCT02384850|DRUG|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
224297915|NCT02384850|DRUG|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
224024307|NCT06609135|DEVICE|Sentec Digital Monitoring System (transcutaneous CO2 monitor)|Sentec transcutaneous CO2 monitors will be placed on infants concurrently with EIT belts.
223557599|NCT07039955|BEHAVIORAL|Standard Bathing|Patients in ICUs assigned to the control group will receive standard daily bathing without the use of chlorhexidine. No CHG-containing products will be applied. This represents usual care in the participating hospitals.
224024308|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group.
224024309|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
224024310|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group
224024311|NCT06610071|DRUG|ICG administration|The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group.
224024312|NCT06610188|DIETARY_SUPPLEMENT|Prebiotic group|products containing a total of 9.2 g (4.6 g twice a day) inulin/oligofructose (50/50) mixture (prebiotic group) that individuals should consume daily were delivered to individuals in identical opaque bags.
224024313|NCT06610188|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|products containing a total of 9.2 g (4.6 g twice a day) maltodextrin (placebo group) that individuals should consume daily were delivered to individuals in identical opaque bags.
224024314|NCT06611215|DIETARY_SUPPLEMENT|Treatment|Prebiotic 1 - Stick pack of combination 1 of two polysaccharides mixed with a glass of water each morning
224024315|NCT06611215|DIETARY_SUPPLEMENT|Placebo|Placebo 1 - stick pack of maltodextrin 1 mixed with a glass of water each morning
224024316|NCT06611215|DIETARY_SUPPLEMENT|Treatment|Prebiotic 2 - Stick pack of combination 2 of two polysaccharides mixed with a glass of water each morning
224024317|NCT06611215|DIETARY_SUPPLEMENT|Placebo|Placebo 2 - stick pack of maltodextrin 2 mixed with a glass of water each morning
224024318|NCT06609941|OTHER|Alternative nostril breathing|Patients in this group will receive alternative nostril breathing along with pharmacological management. For alternative nostirl breathing patient will be advised to inhale slowly (4sec) and deeply through left nostril.Then hold breath for 2-3 sec. Release right nostril and use right ring finger to close left nostril. Exhale slowly (6sec) and completely through right nostril. Inhale slowly (4sec) and deeply through right nostril. Then hold breath for 2-3sec. Release left nostril and use right thumb to close right nostril. Exhale slowly (6sec) and completely through left nostril. Repeat the cycle.
224024319|NCT06609941|DRUG|Pharmacological therapy|"Participants in this group will only be provided with standard pharmacological management for 4 weeks as prescribed by a pulmonologist. For example:~Salbutamol inhaler (Short acting bronchodilator) Saltra inhaler (Selective long acting β2 adrenoceptor agonist) Tiotropium (Anticholinergic) Combivir (Nucleoside analogue - reverse transcriptase inhibitor) etc.~Week 01 and week 02:~Patients will receive medication prescribed by pulmonologist.~Week 03 and week 04:~Patients will receive medication prescribed by pulmonologist."
224024320|NCT06609785|BEHAVIORAL|Exercise|The volunteers successively completed both high intensity interval training (HIIT)and continuous aerobic training (CAT) under the supervision of a professional coach, and the interval between each type of exercise was 7 days. Each training session was initiated with a brief 2-minute standardized warm-up, followed by 20 minutes of cycling consisting of periods of 2 minutes at 80-95% maximal heart rate (HRmax) separated by 2 minutes of active recovery for the HIIT group or 20 minutes of cycling at 60-80% of HRmax for the CAT group.
224133056|NCT05913284|DRUG|Morphine|The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes
224133057|NCT00823849|DRUG|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
224133058|NCT00823849|DRUG|Probucol|250 mg Bid, PO after breakfast and dinner.
224133059|NCT00823849|DRUG|Cilostazol+Probucol|
224133060|NCT00823849|OTHER|Control Group|Routine treatment
224133061|NCT05373706|BEHAVIORAL|Alcohol Cue Reactivity Personalized Feedback Intervention|This online brief intervention provides personalized feedback using EMA data focused on alcohol cue reactivity to reduce alcohol misuse among young adults.
224133062|NCT04729491|DRUG|Dutasteride 0.5 mg|Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
224133063|NCT04729491|DRUG|Azithromycin|Azithromycin 500mg/day for 05 days
224133064|NCT04729491|DRUG|Nitazoxanide|500mg twice daily for 06 days
224297916|NCT01673698|DEVICE|ReShape Duo balloon|
223557600|NCT07071116|OTHER|Communication skills training|See Detailed Description
223557601|NCT07071116|OTHER|Communication skills training-Facilitator|See Detailed Description
223557602|NCT04750486|DEVICE|Sequential compression devices|Two lower limb intermittent compression devices to be placed on the mid-calf of each leg.
223557603|NCT02453750|DRUG|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls \>10%, the previous step will be repeated.
223557604|NCT02453750|DRUG|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
223557605|NCT04531956|OTHER|Diagnostic decision aid s-decided|The intervention will consist of implementing a patient decision aid (PtDA) in general practice. The patient decision aid will be developed in line with the systematic development process specified by the International Patient Decision Aids Standards (IPDAS)
223557606|NCT03320967|DIAGNOSTIC_TEST|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
223407813|NCT06555003|DRUG|Chemotherapy drug|Control group will receive 2-4 cycles of systemic chemotherapy based on functional status of the patient, adverse event rate and treatment tolerance, tumor size and characteristics. Targeted therapy administration for each treatment group in based on oncologist's decision and will be tailored to the tumor characteristics and the patient's clinical status (e.g., administration of Pembrolizumab for patients with high rosatellite instability (MSI-H) or Bevacizumab for tumors harboring KRAS mutations). Due to the targeted nature of these therapies, they can not be administered to all participants of the trial, while It is not ethically justifiable to withhold targeted therapies from patients who are candidates for these treatments based on their tumor characteristics and deprive them of potentially life-extending options.
224024321|NCT06609993|DRUG|intravenous rescue opioid analgesia using fentanyl|intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline
223407814|NCT02012322|DIETARY_SUPPLEMENT|Coenzyme Q10|100mg/day for three months
224024322|NCT06609993|DRUG|intravenous rescue atropine administration|atropine (Atropinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 0,5mg/kg of will be administered intravenously when heart rate \< 50
224024323|NCT06609993|DRUG|intravenous rescue urapidil administration|urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP \> 110 mmHg or SAP \> 200 mmHg
224024324|NCT06609993|DRUG|intravenous rescue ephedrine administration|ephedrine (Ephedrinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 10 mg will be administered intravenously when DAP \< 50 mmHg or MAP \< 65 mmHg
224024325|NCT06609993|BIOLOGICAL|concentrate of red blood cells|concentrate of red blood cells will be transfused when concentration of haemoglobin \< 10g%
224024326|NCT06609993|BIOLOGICAL|red blood cells autotransfusion|red blood cells from the operation site will be retransfused using cell saver
224024327|NCT06609993|DRUG|primary treatment of postoperative nausea and vomiting (PONV)|dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
224024328|NCT06609993|DRUG|secondary treatment of postoperative nausea and vomiting (PONV)|Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
224024329|NCT06609993|DRUG|intraopertative fluid challenge (IFC)|3 mililitre of synthetic colloid will be transfused intravenously per each sudden blood loss of 1 mililitre
224024330|NCT06609993|DRUG|postoperative rescue opioid analgesia using morphine|postoperative rescue opioid analgesia will be administered intravenously using 2 miligrams of morphine ((Morfini Sulfas WZF, 20mg/ml, solutio pro iniectione, Polfa Warszawa, Poland)every 10 minutes until postoperative pain perception using NPRS scale will decrease below 4 (NPRS; 0 meant no pain and 10 meant the worst pain imaginable)
224133065|NCT04729491|DRUG|Placebo|Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.
224133066|NCT01657448|DRUG|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
224297917|NCT01673698|OTHER|Diet counseling|
223407815|NCT02012322|DIETARY_SUPPLEMENT|Coenzyme Q10|300mg/day for three months
223407816|NCT02012322|DIETARY_SUPPLEMENT|Placebo|Three month period
223407817|NCT01862926|DRUG|Rituximab|
223407818|NCT01862926|DRUG|Cyclophosphamide|
223407819|NCT06875440|DRUG|CHX mouthwash|A total of 84 individuals diagnosed with gingivitis were selected for this study. These participants were randomly assigned to two different groups. The purpose of the study was to measure the periodontal parameters of the two molars adjacent to the mandible using a periodontal probe. All of the patients received scaling and root planing (SRP) as part of their treatment. However, the treatment groups differed in terms of the supplements they received. Group A was given a twice-daily dose of CHX, while Group B received a daily dose of Green tea. In addition to this, 2 ml of unstimulated saliva was collected from each patient both before and after 2 months. The purpose of collecting the saliva samples was to evaluate the total Neutrophil level and determine if there were any changes over time.
223407820|NCT04301011|BIOLOGICAL|TBio-6517|Engineered Oncolytic Vaccinia Virus
223407821|NCT04301011|BIOLOGICAL|Pembrolizumab|Immune checkpoint inhibitor.
223557607|NCT01627626|DRUG|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
223557608|NCT01627626|DRUG|saline|0.9% saline solution
223557609|NCT04952428|BEHAVIORAL|"Re-examination visit (today visit)"|"Re-examination visit (today visit) A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.~The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe SONDA PA\_ON (Orange Dental®, Aspachstr, Biberach, Germany) to determine their periodontal and peri-implant status. Clinical and radiographic examination will be performed. Moreover, signs as presence of suppuration, bleeding, redness, probing depth must be recorded at 6 sites per implant applying. As well, a specific survey about tobacco habits including modification of Fagestrom \& Richmond test will be conducted."
223557610|NCT00691457|DEVICE|Opti-Free contact lens solution|Solution
223557611|NCT00691457|DEVICE|ReNu Multiplus contact lens solution|Solution
223557612|NCT00691457|DEVICE|Clear Care contact lens solution|Solution
223557613|NCT01170273|DIETARY_SUPPLEMENT|vitamin D|cholecalciferol
223557614|NCT01170273|DIETARY_SUPPLEMENT|placebo|placebo tablet
223557615|NCT00334737|DRUG|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
223557616|NCT00334737|DRUG|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
223557617|NCT00334737|DRUG|sham injection|sham injection other names: not applicable
223557618|NCT00583752|BIOLOGICAL|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
223557619|NCT05107063|DRUG|Pravastatin|Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.
223407822|NCT03408938|DEVICE|of Masimo Radical-7¿ Pulse CO-Oximeter|"The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm"
224024331|NCT06859294|DRUG|LY3541860|Administered IV
224024332|NCT06989866|DRUG|Bupivacaine|Bupivicaine injection post operatively
224024333|NCT06989866|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline injected to control group
224024334|NCT06990555|OTHER|Neutral White Cast|This intervention consists of receiving a cast of neutral white color.
223407823|NCT01487395|DRUG|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
223407824|NCT01487395|DRUG|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
223407825|NCT01931436|DRUG|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
223407826|NCT01603693|DEVICE|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
224024335|NCT06990555|OTHER|Color Wrapped Cast|This intervention consists of receiving a cast of color that is the choice of the participant.
224024336|NCT06990555|OTHER|Cast with Cast Art|This intervention consists of receiving a cast with art at the request of the participant, to include drawing, multiple colors, glitter, and any artwork.
223557620|NCT05958953|PROCEDURE|Induction of Labor IoL|Center-specific IOL protocols, based on international guidelines, will be used.
223557621|NCT02316353|BIOLOGICAL|C1-esterase inhibitor|
223557622|NCT07080502|OTHER|Application for the creation of a questionnaire on alterations in vaginal penetration|"Development of domains and items:~Through the judgment of 10 experts, the set of items of each domain will be identified.~Development of the scale:~A pilot will be carried out to guarantee the viability and feasibility of what was created in the previous stage; The questionnaire will be applied to 30. participants.~Evaluation of the scale:~At this stage, the Questionnaire will be applied to a larger sample: 10 participants for each item create. In the same way as the previous stage, the Female Sexual Function Index will be applied together with the created questionnaire."
224024337|NCT00801489|DRUG|Cytarabine|Given IV
224024338|NCT00801489|DRUG|Decitabine|Given IV
224024339|NCT00801489|BIOLOGICAL|Filgrastim-sndz|Given SC
223557623|NCT07081464|OTHER|MRI, EEG, Pupillometry|Comparison of P300 wave amplitude, pupillometric responses, functional and structural brain connectivity, socio-adaptive function, cardiac autonomic balance between two phenotypic severity groups of young patients with Ondine Syndrome.
223557624|NCT07081321|BEHAVIORAL|Lithotomy position|Participants in the lithotomy decubitus position group were in the lithotomy position at the second stage of labor of delivery.
223738045|NCT04849806|DIAGNOSTIC_TEST|OSA severity|OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture
224024340|NCT00801489|DRUG|Fludarabine Phosphate|Given IV
224024341|NCT00801489|DRUG|Gemtuzumab Ozogamicin|Given IV
224133067|NCT01657448|DRUG|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
224133068|NCT05151328|DRUG|Plecanatide|Plecanatide or Placebo; Route of Plecanatide/placebo administration: tablet; dosage: 3mg, dosage form oral; Frequency of administration: QD
224133069|NCT00498108|DRUG|Rotigotine|
224133070|NCT00853333|DRUG|dexmedetomidine|
223557625|NCT07081321|BEHAVIORAL|Lateral Position|Participants in the lateral position group were in the lateral position at the second stage of labor of delivery.
223557626|NCT07081321|BEHAVIORAL|Upright Position|Participants in the upright position group were in the upright position at the second stage of labor of delivery.
223557627|NCT07079501|OTHER|Test Eye Cream (Formula# 899675 44A)|A white cream formulated as eye cream (Formula# 899675 44A) provided by L'Oréal R\&I China. Participants will apply 1ml of the product on the full face and neck twice daily for 8 weeks. The aim is to evaluate its efficacy on facial wrinkles, eye bags, dark circles, and other skin aging signs in healthy Chinese women.
224024342|NCT00801489|DRUG|Idarubicin|Given IV
224024343|NCT00801489|OTHER|Laboratory Biomarker Analysis|Correlative studies
224024344|NCT06208631|BEHAVIORAL|Gait retraining|Changing muscle coordination while walking
224024345|NCT06609772|OTHER|Individualised Pain Education|Individualised Pain Education
224024346|NCT06995924|OTHER|Educational Intervention|Complete self-directed interactive education
224024347|NCT06995924|OTHER|Electronic Health Record Review|Ancillary studies
224024348|NCT06995924|OTHER|Internet-Based Intervention|Receive access to CTAC
224024349|NCT06995924|BEHAVIORAL|Patient Navigation|Receive patient navigation services
224024350|NCT06995924|OTHER|Survey Administration|Ancillary studies
224024351|NCT06864026|DRUG|Tirzepatide|Administered SC
224024352|NCT06607185|DRUG|LY4066434.|Administered orally.
224024353|NCT06607185|DRUG|Cetuximab|Administered intravenously.
224024354|NCT06607185|DRUG|Nab paclitaxel|Administered intravenously.
224024355|NCT06607185|DRUG|Gemcitabine|Administered intravenously.
224024356|NCT06607185|DRUG|Oxaliplatin|Administered intravenously.
224024357|NCT06607185|DRUG|Leucovorin|Administered intravenously.
224024358|NCT06607185|DRUG|Irinotecan|Administered intravenously.
224024359|NCT06607185|DRUG|5Fluorouracil|Administered intravenously.
224133071|NCT00853333|DRUG|midazolam|
223407827|NCT01603693|DEVICE|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
224024360|NCT06607185|DRUG|Carboplatin|Administered intravenously.
224024361|NCT06607185|DRUG|Cisplatin|Administered intravenously.
224024362|NCT06607185|DRUG|Pemetrexed|Administered intravenously.
224024363|NCT06607185|DRUG|Pembrolizumab|Administered intravenously.
224024364|NCT07000045|DEVICE|Intravascular lithotripsy|Intravascular lithotripsy device used for calcium modification in coronary lesions, using either operator-determined or maximum pulsed numbers for lesion preparation prior to stenting.
224024365|NCT07000045|DEVICE|Rotational atherectomy|Rotational atherectomy device used to debulk calcified nodules before IVL and stent implantation.
224024366|NCT06676592|DIAGNOSTIC_TEST|Preoperative imaging|Preoperative imaging will be performed as part of the standard of care. Imaging data from US, CT, MRI, and/or PET performed for routine care will be used for this study.
224024367|NCT06676592|DIAGNOSTIC_TEST|3D framework|3D images of surface landmarks will be acquired by use of US and the Scaniverse app before surgery, in conjunction with the participant's standard-of-care US or US-guided biopsy procedure
224024368|NCT02677480|DIETARY_SUPPLEMENT|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
224024369|NCT02677480|DIETARY_SUPPLEMENT|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
224133072|NCT00853333|DRUG|propofol|
224133073|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with investigational device
224133074|NCT05316337|DEVICE|Electrocardiogram recording|ECG recording with reference device
224133075|NCT00917306|DRUG|PEP005 Gel|0.05% two day treatment
224133076|NCT01614236|DRUG|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
224133077|NCT01614236|DRUG|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
224133078|NCT04770987|OTHER|lateral neck flexor endurance test|Individuals will maintain the head in a neutral position off the ground in sidelying for as long as possible.
224138898|NCT01380444|PROCEDURE|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
223407828|NCT03111940|PROCEDURE|Optimisation of the result of intracoronary stenting according to specific algorithm|
223407829|NCT01800747|OTHER|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
223407830|NCT02696343|DEVICE|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
223407831|NCT02696343|DEVICE|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
223407832|NCT03308890|DRUG|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
223407833|NCT03308890|DRUG|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
223407834|NCT05775887|BIOLOGICAL|UQSC2 Vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373. The Study will be unblinded after Day 29, to enable subjects who received the investigational vaccine (UQSC2 vaccine) to seek vaccination with a TGA (Therapeutic Goods Administration) approved COVID-19 booster vaccine if indicated by public health authorities.
223407835|NCT05775887|BIOLOGICAL|NVX-CoV2373 vaccine|Subjects will be assigned to treatment group (UQSC2 or NVX-CoV2373) via randomisation. Each treatment group will receive a single dose of either UQSC2 or NVX-CoV2373
223407836|NCT05581277|BEHAVIORAL|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-individual format.
223407837|NCT01461694|DEVICE|Intense Pulsed Light (IPL)|Half Face Treated with IPL
223407838|NCT01461694|DEVICE|Alexandrite Laser|Half face treated with Alexandrite Laser
223407839|NCT01628731|DRUG|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
223407840|NCT01628731|DRUG|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
224024370|NCT06857942|DRUG|Tirzepatide|Administered SC
224024371|NCT02871258|DEVICE|The MetaNeb® System|
224024372|NCT07006792|DRUG|Lebrikizumab|Administered SC
224024373|NCT05502367|DRUG|ABI-2280 Vaginal Tablet/Insert|Vaginal Tablet
224024374|NCT07012148|DEVICE|UNEEG SubQ device|Subjects will be implanted with the UNEEG SubQ device in the neurosurgical operating suite under general anesthesia. Electrodes will be placed over the temporal lobe of the hemisphere established as the origin of seizures by previous EEG monitoring. Only one UNEEG device will be placed, and only the seizure onset hemisphere will be covered.
224024375|NCT01122160|DRUG|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
224024376|NCT01122160|DRUG|placebo|Placebo with berries (blackberries + strawberries)
224024377|NCT07011745|DRUG|Xanomeline/Trospium Chloride Capsule|Specified dose on specified days
224024378|NCT07011745|DRUG|Xanomeline Enteric Capsule|Specified dose on specified days
224024379|NCT07011745|DRUG|Placebo|Specified dose on specified days
224024380|NCT07011576|DRUG|fruquintinib|Participants will receive oral fruquintinib, with or without food, for the first 21 days of each 28-day cycle.
224138899|NCT01380444|PROCEDURE|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
224024381|NCT07011576|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|Participants will receive FOLFIRI once every 2 weeks on day 1 of every 28-day cycle (twice in each cycle). The FOLFIRI regimen consists of irinotecan given 180 mg/m2 intravenous infusion (IV), leucovorin 400 mg/m2 (or 200 mg/m2 levoleucovorin) IV, followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus injection and 5-FU continuous IV infusion of 2400 mg/m2 over 46 to 48 hours.
224024382|NCT03727438|BEHAVIORAL|Tele-Self CBTI|The Tele-Self CBTI intervention is comprised of two treatment components: 1) self-directed treatment via weekly readings from a treatment manual, and 2) weekly telephone-based nurse support contacts across a 8 week intervention period. Participants have 8 weeks to complete 6 study-related phone calls
224024383|NCT03727438|OTHER|Health Education Control|The Health Education Control condition is comprised of two components: 1) weekly reading from a health education manual, and 2) weekly telephone-based nurse support contacts across a 8 week period. At the end of the study, participants in the Health Education arm will be offered assistance for their sleep complaints, as needed, through the Durham Behavioral Sleep Medicine clinic.
224024384|NCT07015697|DRUG|Trastuzumab Deruxtecan|"Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE.~Expansion Part: Trastuzumab Deruxtecan will be administered at RDE."
224133079|NCT05280431|DEVICE|AGREE exoskeleton|"Upper limb exoskeleton with four actuated degrees of freedom (shoulder horizontal adduction/abduction, shoulder flexion/extension, humeral rotation, elbow flexion/extension), and one passive degree of freedom (wrist pronation/supination), implementing different rehabilitative strategies.~The intervention consists of the execution of different exercises with the affected arm supported by the AGREE device. The subject is actively involved in the exercises and the system provides different kinds of assistance that can be tailored according to the patient's status.~The following exercises can be performed:~* anterior reaching (in a plane or in the space)~* lateral elevation of the arm~* hand to mouth movements with or without an object in the hand~* moving objects (on a plane or in the space)~* exergames.~A subset of exercises is defined based on the patient's capability."
224133080|NCT05280431|DEVICE|FEXO exoskeleton|After patient's preparation (tDCS and FES) the FEXO assessment is conducted. The subject performs FEXO assessment games. This stage is also used to calibrate the reach and grasp movement intention EEG patterns. The movement is recorded using internal kinematic sensors; therefore, these measures can be extracted for both reaching and lifting movements. Trunk forward bending is measured to avoid compensatory movements when doing reaching assessment. The clinician then reviews the plan for today's session: game selection, number of repetitions and assistance levels. The patient gets ready to play the games and the clinician starts the first activity of the active stage of FEXO therapy. The patient plays the game and sees his own results. The clinician monitors patient activity, assistance levels, effort and signs of discomfort. The patient plays the next game and sees his own results, and the clinician checks the patient's progress with the results overview.
224133081|NCT05280431|OTHER|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~* Upper limb passive motion~* Occupational therapy exercises~* Constraint-induced movement therapy~* Upper limb active movement (reaching, grasping, elevation, spatial orientation)~* Repetitive task training"
224133082|NCT01449201|DRUG|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
223738046|NCT04849806|DIAGNOSTIC_TEST|Determination of PH and right HF severity|(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography
223738047|NCT04849806|DIAGNOSTIC_TEST|Comprehensive lung function and inspiratory muscle function testing.|Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.
224024385|NCT07023614|DRUG|Ninerafaxstat 200mg MR|Ninerafaxstat 200mg Modified Release tablet administered BID
224133083|NCT03734367|BEHAVIORAL|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
224133084|NCT01366066|DEVICE|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
224297918|NCT01673698|OTHER|Exercise counseling|
224297919|NCT00507546|DRUG|Ramelteon|8 mg nightly
224024386|NCT07023614|DRUG|Placebo|Matching placebo tablet administered BID
224024387|NCT04647253|DEVICE|AGENT DCB|Drug coated PTCA balloon catheter
223738048|NCT04849806|DIAGNOSTIC_TEST|Assessment of systemic inflammation|Based on blood samples taken.
223738049|NCT00278109|DRUG|cyclophosphamide|chemotherapy
223738050|NCT00278109|DRUG|Doxorubicin|doxorubicin
223738051|NCT00278109|RADIATION|radiation|radiation
223738052|NCT02090517|DEVICE|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
223738053|NCT02090517|DEVICE|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
223738054|NCT02090517|DEVICE|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
224024388|NCT04647253|DEVICE|PTCA balloon catheter|PTCA balloon catheter
224024389|NCT05301140|DEVICE|Vivistim System|VNS Paired with rehabilitation movements
224024390|NCT04300556|DRUG|Farletuzumab ecteribulin|Farletuzumab ecteribulin intravenous infusion.
224024391|NCT04300556|DRUG|Prednisone|Prednisone administered orally.
224024392|NCT04300556|DRUG|Prednisolone|Prednisolone administered orally.
224024393|NCT04300556|DRUG|Dexamethasone|Dexamethasone administered orally.
224024394|NCT04300556|DRUG|Lenvatinib|Lenvatinib administered orally.
223557628|NCT07081750|BEHAVIORAL|Dyadic tailored home-based activity program intervention|"1. During hospitalization, caregivers receive health education on managing behavioral and psychological symptoms of dementia. Patient-caregiver dyads participate in structured ward activities to assess activity preferences and capabilities, forming the basis for co-developing individualized home activity plans with training for caregivers.~2. A customized home activity kit is provided at discharge.~3. Post-discharge, a 12-week tailored home intervention is implemented, using a patient-centered model with caregiver support. Caregivers record participation and behavioral responses, which inform dynamic adjustments to activity content, difficulty, and methods."
223557629|NCT07081750|OTHER|Routine care|Participants will receive routine care consisting of standard hospitalization treatment, basic caregiver education on behavioral and psychological symptoms of dementia (BPSD), routine discharge instructions (including general home activity recommendations without personalized intervention assessment, planning or implementation), and routine post-discharge follow-up for 12 weeks.
224024395|NCT07035093|DRUG|Retatrutide|Administered SC
224024396|NCT07035093|DRUG|Placebo|Administered SC
224024397|NCT06721013|DRUG|Pirtobrutinib|Administered orally
224024398|NCT06721013|DRUG|Placebo|Administered orally
223557630|NCT07080840|BEHAVIORAL|Nursing education A+1|Dietary education once
224024399|NCT06883838|BEHAVIORAL|Survivorship care delivery intervention|"Guided by the Practical, Robust Implementation and Sustainability Model (PRISM), the intervention includes three evidence-based components:~1. Training: This will include provider-to-provider tele-mentoring using Enhancing Community Health Outcomes (ECHO).~2. Tracking: This includes systematically assessing cancer history and monitoring survivors' care to plan and organize subsequent care.~3. Coordinating care for cancer survivors. Each clinic leader will designate a staff member (or members) as the care coordinator champion after exploring current clinic staff, skills, and capacity of various staff roles."
224024400|NCT06717672|DRUG|Lidocaine 2% without vessel constrictor|"1. \_Lidocaine 2% provides rapid and effective local anesthesia for minor surgical procedures, such as biopsies, excisions, and suturing.~2. \_Pain relief\_: Lidocaine 2% has been shown to provide significant pain relief in patients with acute pain, such as post-operative pain, trauma, and burns.~3. \_Reducing pain intensity\_: Lidocaine 2% has been shown to reduce pain intensity by 30-50% in various clinical studies."
224024401|NCT06717672|DRUG|Normal Saline|Normal saline used is an iv fluid given for fluid replacement
223557631|NCT07080840|BEHAVIORAL|Nursing education A+2|Dietary education twice
224024402|NCT07043452|DRUG|Blinded Study Medication - Condition 1|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
224133085|NCT02985268|DEVICE|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus \[degenerative MR\] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
223557632|NCT07080840|BEHAVIORAL|Nursing education A+3|Dietary education three times
223557633|NCT07080840|BEHAVIORAL|Nursing education B+1|Medication education once
224133086|NCT02985268|DRUG|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
224133087|NCT02985268|DEVICE|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
224133088|NCT04709302|BIOLOGICAL|COVID-19|Patients diagnosed with a COVID-19 infection
224133089|NCT04709302|BIOLOGICAL|HIV|Patients diagnosed HIV-positive
224133090|NCT04709302|DRUG|ART|Patients on ART
224133091|NCT02172079|OTHER|Real mobilization-with-movement (MWM)|
223557634|NCT07080840|BEHAVIORAL|Nursing education B+2|Medication education twice
223557635|NCT07080840|BEHAVIORAL|Nursing education B+3|Medication education three times
223557636|NCT07080840|BEHAVIORAL|Nursing education AB+1|Combined dietary and medication education once
223557637|NCT07080840|BEHAVIORAL|Nursing education AB+2|Combined dietary and medication education twice
223557638|NCT07080840|BEHAVIORAL|Nursing education AB+3|Combined dietary and medication education three times
223557639|NCT07080658|DRUG|[14C]-WPV01|Single oral dose of 600 mg \[14C\]-WPV01
223557640|NCT07081529|DEVICE|Direct Restoration with Microhybrid Composite|Direct Class I restorations were placed in molar teeth using a microhybrid universal composite (Aelite All-Purpose Body, Bisco) and an adhesive system according to the manufacturer's instructions.
223557641|NCT07081529|DEVICE|Indirect Restoration with Reinforced Microfill Composite|Indirect Class I restorations were fabricated using a reinforced microfill composite system (Tescera Indirect Composite System Body, Bisco) in the laboratory and cemented into molar teeth using resin cement.
224133092|NCT02172079|OTHER|Sham mobilization-with-movement (MWM)|
224133093|NCT03628508|OTHER|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
224133094|NCT00429377|DRUG|tacrolimus|
224133095|NCT02402218|OTHER|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
224133096|NCT02402218|OTHER|Usual care plus incentives|Participants are given incentives after completing treatment goals.
223407841|NCT00509951|BEHAVIORAL|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
223557642|NCT07081126|DRUG|Daratumumab (Subcutaneously)|Kidney transplant recipients with late ABMR and de novo DSA treated with daratumumab (1800mg subcutaneous, weekly x 4, then monthly x 6).
223557643|NCT07081126|OTHER|control group|Kidney transplant recipients with late ABMR and de novo DSA treated with standard therapies (IVIG, plasmapheresis, rituximab, etc.) prior to the start of the daratumumab study.
223557644|NCT02147197|DRUG|Ulipristal acetate (UPA)|UPA tablet
223738055|NCT02090517|PROCEDURE|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
223738056|NCT00149123|DRUG|hydrocortisone 200 mg/day|
224133097|NCT02402218|OTHER|Usual Care|Participants receive standard of care in the clinic from their health care team.
224133098|NCT03614091|PROCEDURE|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
224133099|NCT03614091|PROCEDURE|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
224133100|NCT03417180|DRUG|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
224133101|NCT03417180|DEVICE|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
224133102|NCT01661400|DRUG|Metronomic Cyclophosphamide|
224133103|NCT01661400|DRUG|Thalidomide|
224133104|NCT05146232|OTHER|induction of anesthesia|induction of anesthesia during gastric sleeve surgery
223557645|NCT02147197|DRUG|Placebo|Matching placebo tablet.
223557646|NCT05377489|DRUG|RTX-GRT7039|RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
223557647|NCT01762774|DRUG|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
223557648|NCT01762774|DRUG|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
223557649|NCT06895603|DEVICE|Philips Advanced Monitoring Cuff (AMC)|The Philips AMC is a Class II (USA) and Class IIb (EU) medical device that is a non-invasive, semirigid disposable upper arm cuff with an integrated pneumatic actuator enabling hydraulic coupling of tissue pressure waveforms from the upper arm tissue.
223557650|NCT01800331|BEHAVIORAL|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
223407842|NCT00509951|BEHAVIORAL|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
223407843|NCT04578873|DRUG|QPX7831|capsule
223407844|NCT04578873|DRUG|placebo comparator|oral matched placebo capsule
223407845|NCT03452670|BEHAVIORAL|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
223557651|NCT06951464|DRUG|BL-B01D1|BL-B01D1 (2.2 or 2.5mg/kg) to be administered on Day 1 and Day 8 of every 3-week cycle for 2 cycles.
223557652|NCT06951464|DRUG|Almonertinib|Almonertinib 100mg QD
223407846|NCT03452670|OTHER|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
223407847|NCT05514015|DRUG|rituximab combined with corticosteroids|"Induction therapy:~Rituximab intravenous infusion of 1g, d1, d15, combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d), once a day, after 8 weeks of treatment, reduce by 5mg every 4 weeks until 0.25mg/kg, this dose was maintained for 8 weeks, and then reduced by 2.5mg every 4 weeks, until 5-10mg is maintained, and the total course of treatment was about one year or so;"
223407848|NCT05514015|DRUG|rituximab|Control group (treated with Rituximab monotherapy treatment) :Rituximab intravenous infusion of 1g, d1, d15
223407849|NCT02188147|DEVICE|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
223407850|NCT01022476|DRUG|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
223407851|NCT02473172|DEVICE|Pressure Support ventilation|Assisted mechanical ventilation
223407852|NCT02473172|DEVICE|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
223557653|NCT06853990|DEVICE|twiist insulin delivery system|twiist system includes a novel insulin pump, a CGM sensor and the DEKA Loop algorithm
223557654|NCT04664972|DRUG|Docetaxel +doxorubicin+ cyclophosphamide|The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
223557655|NCT04664972|DRUG|Docetaxel +Cisplatin|The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
223557656|NCT05381428|DRUG|Indomethacin suppository|Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.
223557657|NCT05381428|COMBINATION_PRODUCT|Indomethacin suppository and high-flow lactated ringer infusion combination|Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
223738057|NCT02580357|PROCEDURE|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
223738058|NCT02580357|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
223738059|NCT04563741|BEHAVIORAL|MOVE!+UP|behavioral weight management intervention developed for Veterans with PTSD
223738060|NCT04563741|BEHAVIORAL|MOVE!|standard VA weight management intervention
223738061|NCT04238351|DEVICE|Transnasal humidified rapid insufflation ventilator exchange|applying 40L of oxygen for 1min and afte that increase oxygen flow up to 70L for 1 min.
223407853|NCT06438614|DRUG|HITS|Four doses of hu3F8, five doses each of irinotecan and temozolomide and five doses of GM-CSF. Irinotecan 50mg/m2/day IV will be administered from day 1-5concurrently with temozolomide 150mg/m2/day orally. Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11
223738062|NCT04238351|DEVICE|Conventional face mask|applying oxygen using usual face mask
223738063|NCT03770650|PROCEDURE|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
223738064|NCT02064166|DRUG|Intranasal Insulin|"1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks."
223738065|NCT05173649|OTHER|Calisthenic Training|"Calisthenic Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Abductor-Adductor leg raise~2. Alternate toe touch~3. Knee Bend~4. Prone leg extension~5. Forward Lunges~6. Toe Raise/ Calf raise Progressive training include following exercises.~1\. Leg Lifts 2. Jack Twists 3. Side Lunges 4. Short bridge 5. Calf Raise with weight."
223738066|NCT05173649|OTHER|Neuromuscular Training|"Neuromuscular Training Performed thrice a week after baseline assessment Standard Physical therapy treatment along with following exercises.~1. Up and down step exercise in posterior and lateral directions.~2. Walking in anterior and posterior~3. Directions with eyes opened and eyes closed.~4. Walking in lateral direction with eyes opened and eyes closed.~5. Standing on one extremity~6. Inclination in anterior and lateral direction with eyes opened and closed. Progressive training includes following exercises.~1\. Up and down on Bosu exercise. 2. Plantar flexion on minitrampoline. 3. Standing on one extremity on Bosu. 4. Standing on one extremity on minitrampoline"
223738067|NCT00598663|DEVICE|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
224024403|NCT07043452|DRUG|Blinded Study Medication - Condition 2|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
224133105|NCT05146232|OTHER|maintainance of anesthesia|maintainance of anesthesia during gastric sleeve surgery either opioid free or opioid based
224133106|NCT05146232|OTHER|monitoring|electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.
224133107|NCT05146232|OTHER|First postoperative analgesia|IV acetaminophen will be administered every 6 h
223407854|NCT06438614|DRUG|Naxitamab + GM-CSF cycles|Patients that achieve CR after 2 or 4 cycles of HITS will move on to 5 cycles of Naxitamab + GM-CSF cycles.
223407855|NCT06438614|DRUG|NICE|Patients that do not have an objective response (CR/PR) will receive NICE within 3 weeks from last dose. Each cycle of NICE consists of four doses of hu3F8, five doses of GM-CSF, one dose of carboplatin, and 3 doses each of ifosfamide and etoposide (table 2). Hu3F8 2.25mg/kg IV will be administered on days 2, 4, 9and 11. GM-CSF 250mcg/m2/day SC will be administered on days 7-11. Ifosfamide 1.5 gr/m2/day IV will be administered from day 1-3 concurrently with etoposide 100 mg/m2/day IV. Carboplatin 400 mg/m2/day IV will be administered on day 1
223407856|NCT00160849|DRUG|Lopinavir/r|
223407857|NCT00616213|BIOLOGICAL|filgrastim|filgrastim will be administered at a standard dose and schedule
223407858|NCT00616213|DRUG|PR104|PR104 is administered intravenously once every 21 days
223407859|NCT00616213|OTHER|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
223407860|NCT03125252|OTHER|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~* thirst~* noise~* pain and well-being~* sleep~* isolation"
223407861|NCT03125252|OTHER|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:~* Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~* Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~* Use of reference antipsychotic pharmacological means"
223407862|NCT05550233|DEVICE|drug-coated balloon|drug-coated balloon in big de novo coronary disease
223738068|NCT00598663|DEVICE|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
223738069|NCT05093296|DRUG|Oxytocin nasal spray|24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
223738070|NCT05093296|DRUG|Naltrexone Pill|All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
223738071|NCT05093296|DRUG|Placebo|Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
223738072|NCT01909037|DIETARY_SUPPLEMENT|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
224133108|NCT05146232|OTHER|Second postoperative analgesia|50 mg IV dexketoprofen every 8 h for the first 48 h.
224133109|NCT05723549|DRUG|HCP1803-3|Take it once per period
224133110|NCT05723549|DRUG|RLD2002|Take it once per period
224024404|NCT07043452|DRUG|Blinded Study Medication - Condition 3|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
223407863|NCT01537042|DRUG|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
223407864|NCT01537042|DRUG|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
223407865|NCT03911232|DRUG|sugammadex|standard general anesthesia protocol with sugammadex
223557658|NCT04545723|DEVICE|FibriCheck|FibriCheck is a smartphone application that measures hearth rhythm using the phone's built-in camera. It is able to detect aberrant rhythms, such as atrial fibrillation.
223557659|NCT04628169|OTHER|no intervention applied|no intervention applied
223557660|NCT02189720|DRUG|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphate given based on Investigator assessment of optimal neuromuscular benefit. In adult patients \> 16 years of age, Doses ranged from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day and in pediatric patients age \< 16 years the maximum daily dose was 60 mg/day. No single dose to exceed 20 mg."
223557661|NCT06501638|DRUG|Memantine Hydrochloride 10 MG|Take Memantine Hydrochloride for intervention First week, 5mg(half the tablet), p.o.，bid. Second to Sixth week, 10mg(one tablet), p.o., bid
223557662|NCT06501638|DRUG|Placebo|Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
223557663|NCT06349460|BEHAVIORAL|FoodSteps behavioral intervention|Behavioral intervention that targets binge eating and weight-related behaviors. Each week, users are recommended or assigned one of five targets, set a relevant goal, and track their progress. If a target is recommended, the user can choose to select that target or a different target.
223557664|NCT06534541|BEHAVIORAL|Attentional bias to food cues|Measurement of the amount of attention given to food cues
223557665|NCT03179982|BEHAVIORAL|Safe South Africa|"Core components of the Safe South Africa intervention include the following:~* Theory driven, best-evidence intervention approaches to adolescent HIV prevention~* Linkages between HIV and IPV~* Victim Empathy~* Healthy Norms Regarding Masculinity~* Bystander Intervention Skills"
223557666|NCT04230811|DIAGNOSTIC_TEST|Corneal impression membrane (Millicell Cell Culture Insert, 12mm, hydrophilic PTFE 0.4µm (PICM01250))|Application of corneal membrane to the cornea for 3-5 seconds, after anaesthesia
223557667|NCT05963204|COMBINATION_PRODUCT|Sculptra and Alastin Restorative Skin Complex|Biostimulator and cosmetics
223557668|NCT05963204|COMBINATION_PRODUCT|Sculptra and CeraVe Daily Moisturizing Lotion|Biostimulator and cosmetics
223557669|NCT05609877|DRUG|Isotonic saline|Isotonic saline will be administered intravenously instead of pre-procedure analgesia.
223557670|NCT05609877|PROCEDURE|Less Invasive Surfactant Administration (LISA)|All infants will be treated with the Less Invasive Surfactant Administration (LISA) procedure
223557671|NCT05609877|DRUG|Fentanyl|Fentanyl 0.5-1.0 mcg/kg will be administered intravenously as pre-procedure analgesia
223557672|NCT05609877|BEHAVIORAL|Non-pharmacological standard operating procedure|All infants will receive the same non-pharmacological standard operating procedure.
223557673|NCT05098574|DRUG|Yaz|Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
223557674|NCT05098574|DRUG|Placebo|Appearance, packaging, and labeling of placebo will be matched to their active counterpart.
223557675|NCT06781931|DEVICE|DG1 Spectacle Lens|DG1 spectacle lens, daily wear for 36 months
223557676|NCT06781931|DEVICE|Single Vision Spectacle Lens|Single vision spectacle lens, daily wear for 36 months
223557677|NCT01527305|DRUG|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
223557678|NCT06506903|DEVICE|Medtronic Avalus Ultra|Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
223557679|NCT06298214|BEHAVIORAL|Her Health Program|Addition of a community health worker navigator to assist subject in navigating their health in the first year postpartum.
223557680|NCT03797625|DRUG|Irinotecan|60mg/m2，D1，8
223557681|NCT03797625|DRUG|DDP|60mg/m2，D1
223557682|NCT03797625|DRUG|Endostar|15mg/d，d1-d7 civ
223557683|NCT02128906|DRUG|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
223557684|NCT02128906|RADIATION|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
223557685|NCT02128906|DRUG|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
223557686|NCT02128906|DRUG|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
223557687|NCT04148482|OTHER|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
223557688|NCT05318534|DRUG|GL-0719|Administration route: intravenous infusion and subcutaneous injection
223557689|NCT05318534|DRUG|Placebo|Administration route: intravenous infusion and subcutaneous injection
223738073|NCT01669447|BIOLOGICAL|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
223738074|NCT06244316|DRUG|rhNGF concentration 1|Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
224024405|NCT07043452|DRUG|Blinded Study Medication - Condition 4|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
224024406|NCT07043452|DRUG|Blinded Study Medication - Condition 5|Participants will receive a double-blinded oral study medication as part of the participant's experimental sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, the medications are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study). Participants may receive a study drug that contains a prescription stimulant, a prescription cannabinoid (related to the active ingredient in cannabis or marijuana), a benzodiazepine (e.g., anti- anxiety medication), an opioid (e.g., a pain medication), a sleep medication, and/or an over-the-counter medication. The study is deeply blinded so that participants are not aware of possible drug conditions in the study and indication of the study drug names in the clinicaltrials.gov record would comprise the blind of the study. Detailed drug condition information will be added upon completion of study.
223738075|NCT06244316|DRUG|rhNGF concentration 2|Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
224024407|NCT07043452|DRUG|Placebo|Double blind administration of placebo.
224024408|NCT06712563|DRUG|Budesonide/glycopyrrolate/formoterol fumarate|Budesonide/glycopyrrolate/formoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist
224024409|NCT06728202|PROCEDURE|A Horizontal Ridge Augmentation in Atrophic Maxillary Ridge|Aiming to enhance bone volume (Quantity) in horizontal maxillary bone defects and density (Quality) , providing a viable solution for implant stability and long-term success.
224024410|NCT06727760|BEHAVIORAL|massage|"The mothers in the massage group applied colic massage according to the Educational Colic Massage Checklist twice a day for 15-20 minutes each time for three weeks, when the baby was calm and during colic attacks."
224024411|NCT06727760|BEHAVIORAL|kangroo care|"The mothers in the kangaroo care group applied kangaroo care according to the Educational Kangaroo Care Checklist twice a day for three weeks for 15-20 minutes each time when the baby was calm and during colic attacks."
224024412|NCT06727487|BEHAVIORAL|Basic recommendations|Daily basis activity counseling by WHO recommendations
224024413|NCT06727487|BEHAVIORAL|Physical exercise|A complete program of active physical exercise of medium and high intensity
224024414|NCT06727487|BEHAVIORAL|Nutritional advice|A complete program of nutritional counseling
223407866|NCT05908877|OTHER|History and Clinical evaluation|"HISTORY and CLINICAL EVALUATION and recording of the following parameters:~* Gestational Age~* Birth Weight~* Gender~* Weaning habits~* Anthropometric indices: actual age; actual weight; actual height; body mass index BMI (kg/m2) + percentile; waist circumference; age for height; weight for height; height for age; height standard deviation score (SDS)~* Vital parameters: heart rate (beats/min); respiratory rate (breaths/min); blood pressure (mmHg)~* Adipose tissue~* Subcutaneous fat tissue distribution~* Acanthosis Nigricans~* Stretch marks (striae)~* Tanner Puberty Stage"
224024415|NCT06727487|BEHAVIORAL|Psycho-oncological support|A program related with a patient Psycho-oncological follow-up
224024416|NCT06729593|BIOLOGICAL|Remdesivir|Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
223557690|NCT06375421|BEHAVIORAL|MEMI (Memory Ecological Momentary Intervention) Spaced Retrieval|Participants complete their initial learning session, and the subsequent retrieval sessions are spaced out over the course of the week (two short retrieval sessions each day) using MEMI. Then, they complete a 15-minute test for their memory of all of the trained items at the end of the week.
223557691|NCT06375421|BEHAVIORAL|Blocked Retrieval|Participants will complete their initial learning session on the target words, then immediately receive all of the exposures to each of the items in a single block. They do not complete any more retrieval sessions until one week later, when they complete a 15-minute test for their memory of all of the trained items.
223738076|NCT06244316|DRUG|Vehicle (Placebo solution)|Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
223738077|NCT06084611|DEVICE|Provox Life|Compliant use of Provox Life HMEs
223738078|NCT03171987|DRUG|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
223738079|NCT03171987|DRUG|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
223738080|NCT03362281|DRUG|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
223738081|NCT03362281|DRUG|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
224024417|NCT06729593|BIOLOGICAL|Remdesivir Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
223407867|NCT05908877|DIAGNOSTIC_TEST|Biological evaluation of the metabolic syndrome and components|"LABORATORY INVESTIGATIONS will include:~* Lipid Profile: total cholesterol (mmol/L); LDL - cholesterol (mmol/L); HDL - cholesterol (mmol/L); triglycerides (mmol/L)~* Glucose - Insulin Profile: HbA1c (%); serum glucose (mmol/L); insulinemia (µUI/mL); HOMA Index~* Liver Function: alanine aminotransferase (ALT or TGP) (U/L); gamma glutamyl transferase (GGT) (U/L)~* Cardio-Vascular Risk - Inflammation - Oxidative Stress: ultrasensitive C-reactive protein (ng/mL); leptin (ng/mL); adiponectin (ng/mL); serum selenium (μg/L); glutathione peroxidase (GPx) (U/L)"
223407868|NCT05908877|DIAGNOSTIC_TEST|Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage|"ULTRASOUND EVALUATION by:~* Carotid Intima-Media Thickness (cIMT) Measurement using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a high frequency linear array probe (5-13 MHz) and a semi-automated software (Auto IMT+), according to the Mannheim Consensus~* Measurements of Visceral-to-Subcutaneous-Fat Ratio using B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) with a 7.5 (12) MHz linear transducer for subcutaneous fat and a 3.5 MHz convex transducer for visceral fat measurement~* Ultrasound Quantification of Hepatic Steatosis: assessed with B-Mode ultrasound (Samsung Medison UGEO H60 Ultrasound System, Samsung Medison CO., LTD., Seoul Korea) using 3.5 MHz convex transducer; increased liver echogenicity, blurring of vascular margins and increased acoustic attenuation are the parameters considered in the quantification of hepatic steatosis"
223557692|NCT04161092|PROCEDURE|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
223557693|NCT04161092|OTHER|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
223557694|NCT05926544|BEHAVIORAL|Standard implementation webinar and online training|"The one-hour webinar (either live or pre-recorded) will include updated information about the COVID-19 virus, variant nomenclature, booster eligibility, mechanisms of action, and outcomes.~The 30-minute online training addresses how to communicate about COVID-19 vaccinations, presents a 5-step process for initiating conversations, includes example verbiage about how to address specific concerns, and has example videos that show how to implement the 5-step process with vaccine hesitant patients."
224024418|NCT06729593|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
224024419|NCT06881784|DRUG|daraxonrasib|oral tablets
224024420|NCT06881784|DRUG|docetaxel|intravenous (IV) infusion
224024421|NCT06722027|BEHAVIORAL|Compassion Centered Spiritual Health Team Intervention (CCSH-TI)|"Delivered to healthcare teams by spiritual health clinicians proficient in group facilitation. It is composed of 4 sessions delivered every other week and lasting 60 minutes each.~CCSH-TI sessions teach participants to attune to their interpersonal relationships; acknowledge and allow difficult emotions; and access compassion. It also provides psychoeducation about skillful coping strategies. Each session consists of didactic material about team norms and safety, a feeling check-in, facilitated group discussions about social connection and professional team building, and meditations to promote mindfulness, to cultivate a feeling of being nurtured, and to access compassion for self and others. CCSH-TI is delivered to healthcare teams by spiritual health clinicians proficient in group facilitation."
223557695|NCT05926544|BEHAVIORAL|Virtual facilitation|This intervention involves a 30-minute virtual facilitation site visit and 8 30-minute virtual facilitator coaching sessions. The virtual site visit over Zoom will establish the personnel and workflows at each pharmacy and allow the facilitator to establish rapport. Weekly Zoom calls will allow the virtual facilitator to work with a participant to review overall implementation challenges associated with approaching patients, delivering the intervention, and documenting results. Lastly, either the facilitator or the participant can request and schedule a Zoom call to go over any pressing implementation issue in need of rapid attention (e.g., technical difficulties with the website).
223557696|NCT04823858|PROCEDURE|Lumbar Interbody Fusion|The TLIF/PLIF system includes a TLIF/PLIF interbody cage and a pedicle screw system (4 screws with 2 rods). Any FDA cleared TLIF/PLIF interbody cage and pedicle screw system is acceptable for this study (with the exception of PEEK rods) as long as it is implanted per the package insert. No subjects implanted with an off-label use of a device are permitted for this study.
223557697|NCT05722197|BEHAVIORAL|Crisis Response Planning and Lethal Means Safety Counseling|Crisis Response Planning is an efficacious, one-session intervention that increases positive affect, decreases negative affect and psychiatric hospitalizations, and reduces suicide attempts by 76% among Servicemembers
223557698|NCT03522246|DRUG|Rucaparib|Oral rucaparib will be administered twice daily
223557699|NCT03522246|DRUG|Nivolumab|IV nivolumab will be administered once every 4 weeks
224024422|NCT06722027|BEHAVIORAL|Treatment as Usual|TAU refers to the current buffet of wellness and professional development activities that are available to employees at the Winship Cancer Institute.
223557700|NCT03522246|DRUG|Placebo Oral Tablet|Placebo tablets will be administered twice daily
223557701|NCT03522246|DRUG|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
223738082|NCT03362281|DRUG|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
223738083|NCT03362281|DRUG|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
223738084|NCT04519645|DRUG|Lacosamide intravenous|Study participants will receive lacosamide (LCM) as an intravenous (iv) infusion during the Treatment Period.
223738085|NCT04519645|DRUG|Lacosamide oral|Study participants may receive lacosamide (LCM) as an oral solution during the Extension Period.
224024423|NCT06885177|DEVICE|Experimental|Participants will receive treatment with Abbott's Coronary IVL System followed by stenting.
224024424|NCT07046923|DRUG|LY4175408|IV infusion
224024425|NCT06728163|OTHER|written education group|group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.
224133111|NCT05723549|DRUG|HCP1904-1|Take it once per period
224133112|NCT01855542|OTHER|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
224133113|NCT01855542|OTHER|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
224024426|NCT06728163|OTHER|VR educational material + breathing relaxation with verbal instruction|group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. Verbal instructions for breathing are provided for about 3 minutes and 3 seconds.
224024427|NCT06728163|OTHER|VR educational material + breathing relaxation with music intervention|group will receive standard preoperative guidelines as common educational materials. The VR-based educational materials and relaxation videos will utilize custom video content developed by Film Factory. The educational content involves a visual guide, where the patient, using a VR headset, is walked through the process of entering the operating room while listening to an explanation from the operating surgeon, which takes approximately 3 minutes. The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion.
224024428|NCT06728163|OTHER|written educational material + breathing relaxation with music intervention.|"group will receive standard preoperative guidelines as common educational materials. A written notice related to surgery that was previously used in the ward is provided.~The relaxation intervention, which provides instructions for calming the breath, lasts about 4 minutes and 32 seconds. After the intervention, an audio file in the form of a QR code will be provided, allowing participants to listen to it repeatedly at their discretion."
224024429|NCT06729606|BIOLOGICAL|Aviptadil|Administered by IV infusion over 12 hours per day for 3 days. The Day 1 infusion rate is 50 pmol/kg/hr, the Day 2 infusion rate is 100 pmol/kg/hr, and the Day 3 infusion rate is 150 pmol/kg/hr.
224024430|NCT06729606|BIOLOGICAL|Aviptadil Placebo|Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
224024431|NCT06729606|DRUG|Corticosteroid|In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
224024432|NCT06729177|BEHAVIORAL|Strategic and Interactive Signing Instruction|Evidence-based instructional methods, grounded in cognitive, sociocultural, and linguistic theories, are applied to interventions that support sign language development in deaf children.
223738086|NCT04519645|OTHER|Active Comparator|Active Comparator treatment will be chosen and dosed based on StOC (per local practice and treatment guidelines).
223738087|NCT05627011|BEHAVIORAL|Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)|EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
223738088|NCT05356494|OTHER|Postural drainage|(Group A will be treated with postural drainage)
223738089|NCT05356494|OTHER|Positive expiratory pressure|(Group B will be treated with positive expiratory pressure technique).
223738090|NCT04648969|DRUG|kisspeptin 112-121|20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
223738091|NCT04648969|DRUG|GnRH|1 intravenous dose of GnRH
223738092|NCT06311214|PROCEDURE|Biopsy Procedure|Undergo biopsy
223738093|NCT06311214|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224024433|NCT06729619|DRUG|The concentration of anti-infective drugs in blood and cerebrospinal fluid will be determined.|Blood and cerebrospinal fluid concentrations of anti-infective drugs such as vancomycin, meropenem, linezolid, cefoperazone sulbactam and ceftazidime ababactam will be monitored after the drug reaches a steady state.
224024434|NCT06728345|DRUG|Rimegepant|Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks
223407869|NCT05908877|OTHER|Nutritional assessment|"NUTRITION CONSULT Initial consult will include: food habits survey aiming at identifying the nutritional factors that led to an increased Body Mass Index (BMI) and recommendations At reevaluations the food diary of the patients will be evaluated and recommendations will be adapted accordingly.~The final visit will include evaluation of the food diary looking to identify the factors that have or have not helped to normalize BMI in order to recommend a long-term healthy lifestyle."
223407870|NCT05908877|BEHAVIORAL|Psychological evaluation of the impact of obesity/overweight|"PSYCHOLOGICAL ASSESSMENT by:~Evaluation of pediatric health-related quality of life will be assessed with Pediatric Quality of Life Inventory (PedsQL). The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life.~Another questionnaire that will be used is the the Rosenberg Self-Esteem Scale. It is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree. A higher score means higher self-esteem.~Drawing in children is a communicative tool, many times more than reading or language. It can measure the image of the self and the image of the others and is representative of the unconscious.~Questionnaires and drawing interpretation will be done at the initial presentation and at every control visit."
223407871|NCT01969773|DRUG|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
223738094|NCT06311214|PROCEDURE|Computed Tomography|Undergo CT
223738095|NCT06311214|PROCEDURE|Echocardiography Test|Undergo ECHO
224024435|NCT06726148|DRUG|ECI830|Experimental
224024436|NCT06726148|DRUG|ribociclib|Approved medication
224024437|NCT06726148|DRUG|fulvestrant|Approved medication
224024438|NCT06891443|DRUG|sepofarsen|RNA antisense oligonucleotide for intravitreal injection
224024439|NCT06891443|OTHER|Placebo IVT|Placebo with identical appearance to sepofarsen
223738096|NCT06311214|OTHER|Electronic Health Record Review|Undergo review of SOC RNA testing results
223738097|NCT06311214|DRUG|Enfortumab Vedotin|Given IV
223738098|NCT06311214|OTHER|Immunohistochemistry Staining Method|Undergo IHC assay
224024440|NCT04873232|BIOLOGICAL|Engensis|Injections with Engensis in study VMDN-003-2
224024441|NCT04873232|OTHER|Placebo|Injections with Placebo in study VMDN-003-2
224024442|NCT06723834|OTHER|Psychiatric Service Dog|Partnership with a trained service dog for PTSD.
224024443|NCT06723834|BEHAVIORAL|Prolonged Exposure Therapy|12 weeks of Prolonged Exposure once per week.
224024444|NCT06745323|DRUG|Tarlatamab|Tarlatamab will be administered by IV infusion.
224024445|NCT06787612|DRUG|Ubamatamab|Administered per the protocol
224024446|NCT06787612|DRUG|Bevacizumab|Administered per the protocol
223407872|NCT01969773|DRUG|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
223407873|NCT02925962|OTHER|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
223407874|NCT02925962|OTHER|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
224024447|NCT06787612|DRUG|Cemiplimab|Administered per the protocol
224024448|NCT06787612|DRUG|Fianlimab|Administered per the protocol
224133114|NCT03651193|DIAGNOSTIC_TEST|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
224024449|NCT06787612|DRUG|PLD|Administered per the protocol
224024450|NCT06787612|DRUG|Sarilumab|Prophylaxis administered per the protocol
224024451|NCT06795009|DRUG|Zanzalintinib|Taken by mouth.
224024452|NCT06795009|DRUG|Paclitaxel|175 mg\^m2 intravenous over 3 hours.
224024453|NCT06747858|BIOLOGICAL|ARCT-032|CFTR mRNA formulated in lipid nanoparticles
224024454|NCT05336383|DRUG|Radiation Therapy|Given by Infusion
224024455|NCT07060495|DEVICE|RADA16 hydrogel|Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.
224024456|NCT07060261|PROCEDURE|Transoral robotic surgery+MRI|During the standard of care MRI, there will be an added T2 and T2 SPACE sequences. These sequences are estimated to take an additional 6 minutes, with no added risk to the patient.
224024457|NCT06764485|DRUG|BMS-986365|Specified dose on specified days
224024458|NCT06764485|DRUG|Enzalutamide|Specified dose on specified days
223407875|NCT03055676|OTHER|Early drain removal|Removing drain(s) on postoperative day 3
223407876|NCT03055676|OTHER|Late drain removal|Removing drain(s) on postoperative day 5 or later
224024459|NCT06764485|DRUG|Abiraterone|Specified dose on specified days
224024460|NCT06764485|DRUG|Docetaxel|Specified dose on specified days
224024461|NCT06764485|DRUG|Predinsone/Prednisolone|Specified dose on specified days
224024462|NCT06758401|DRUG|Sigvotatug Vedotin|MMAE-Antibody Drug Conjugate targeting Integrin Beta-6
224024463|NCT06758401|DRUG|Pembrolizumab|Anti-PD-(L)1
224024464|NCT07063238|DRUG|MK-8527|Oral administration
224024465|NCT07063238|DRUG|Moxifloxacin|Oral administration
223407877|NCT01734005|DIETARY_SUPPLEMENT|Red Ginseng|Red Ginseng (1.4g/day)
224024466|NCT07063238|DRUG|Placebo|Oral administration
224024467|NCT05014074|OTHER|Theater/Pilot Testing|Participants will take part in a theater/pilot testing in order to receive adequate feedback and make substantive change in the intervention
224133115|NCT05304871|DRUG|Cefazolin|infusion
223407878|NCT01734005|DIETARY_SUPPLEMENT|Placebo|Placebo (1.4g/day)
223407879|NCT06940947|PROCEDURE|eFTR|endoscopic full thickness resection
223407880|NCT06940947|PROCEDURE|Surgery|standard-of-care surgery
223407881|NCT06364891|OTHER|VMMC NEXUS Digital application|A handheld digital application which supports segmentation of potential VMMC Clients
223407882|NCT06139575|DRUG|Lutetium Lu 177 JH020002 Injection|Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
223407883|NCT05976997|DRUG|Duvelisib, Chidamide|Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
223407884|NCT01608802|OTHER|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
223407885|NCT01608802|OTHER|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
223407886|NCT00004828|DRUG|liothyronine I 131|
223407887|NCT01808781|OTHER|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
223407888|NCT01808781|OTHER|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
223407889|NCT01534039|DEVICE|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
223407890|NCT01534039|DEVICE|FormaFlex|Hollister skin barrier for ostomy patients
224133116|NCT05304871|OTHER|saline|infusion
224133117|NCT01300897|PROCEDURE|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
224133118|NCT01300897|PROCEDURE|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
223407891|NCT05601115|PROCEDURE|Robot assisted therapy|In addition to the conventional treatment for 60 minutes in the RYT group, it was planned to perform robotic rehabilitation with a hand-finger robot \[Amadeo (Tyromotion, Graz, Austria)\] for 30 minutes, accompanied by a physiotherapist who is trained in the field of robotic rehabilitation and has at least 5 years of experience
223407892|NCT05601115|PROCEDURE|Conventional Therapy Group|An exercise program consisting of 45 minutes of range of motion exercises, strengthening exercises, balance exercises and neurophysiological exercises (Brunstroom exercises) and 15 minutes of NMES was planned, accompanied by a physiotherapist experienced for at least 5 years in stroke rehabilitation, in the conventional therapy group.
224024468|NCT07065721|DEVICE|Continuous glucose monitor|Participants will wear a continuous glucose monitoring sensor for 30 days. They will also wear a FitBit wrist watch to be able to track their physical activity and they will complete weekly surveys to report diabetes self-management behaviors. After the 30 days, they will participate in a qualitative interview to respond to questions about their experiences.
223407893|NCT02608983|DIETARY_SUPPLEMENT|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
224024469|NCT07065552|DRUG|Tirzepatide|Tirzepatide will be administered once weekly, subcutaneously, and patients will be taught how to administer this drug at home. Patients will be started on a dose of 5 mg tirzepatide weekly for four weeks prior to surgical staging. .
223407894|NCT02608983|DIETARY_SUPPLEMENT|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
223407895|NCT02608983|DIETARY_SUPPLEMENT|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
223407896|NCT03530592|DEVICE|Seated Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
223407897|NCT05234736|DRUG|CBL-514|CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)
223407898|NCT00787982|DEVICE|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
223407899|NCT01625819|BEHAVIORAL|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
223407900|NCT01625819|BEHAVIORAL|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
223407901|NCT01625819|BEHAVIORAL|Health Education|32 1-hour bi-weekly group sessions of health education
223407902|NCT00915408|DRUG|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
223407903|NCT00915408|DRUG|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
223407904|NCT00915408|DRUG|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
223557702|NCT06194604|DEVICE|Instrument-assisted soft tissue mobilization|Instrumented soft tissue mobilization is a type of manual therapy method.Istrumented soft tissue mobilization aims to reduce fascial limitations by increasing circulation. Increases in localized blood flow and soft tissue realignment promote muscle function, increased normal joint movement, and decreased pain.
223557703|NCT06194604|OTHER|Routine rehabilitation programe|Routine rehabilitation programe consisting of stretching and strengthening exercises will be applied.
223557704|NCT04683029|DRUG|Guselkumab Dose 1|Guselkumab Dose 1 will be administered intravenously.
223557705|NCT04683029|DRUG|Guselkumab Dose 2|Guselkumab Dose 2 will be administered subcutaneously.
223557706|NCT04683029|DRUG|Placebo|Placebo will be administered intravenously or subcutaneously.
223557707|NCT06027255|DIAGNOSTIC_TEST|IL-6|"Compare IL-6 level , as a marker of inflammation in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae."
224024470|NCT05437510|BIOLOGICAL|Nirsevimab|Pharmaceutical Form: Solution for Injection Route of Administration: Intramuscular
224133119|NCT01300897|PROCEDURE|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
224133120|NCT02742077|DEVICE|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
224133121|NCT01952197|OTHER|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
224297920|NCT00507546|DRUG|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
223557708|NCT06027255|DIAGNOSTIC_TEST|cytokines (IL-17, and IFN-ɣ)|"Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae"
223557709|NCT06027255|BEHAVIORAL|Compass 31|Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
223557710|NCT06438120|BEHAVIORAL|Chatbot-based positive psychology intervention|Eight positive psychology exercises will be delivered, including positive introduction, personal strengths, using strengths, three good things, gratitude, hope and optimism, active/constructive responding, and savoring.
223557711|NCT06830889|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
223557712|NCT06830889|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
223557713|NCT00686985|DRUG|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
223557714|NCT00814580|DRUG|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
223407905|NCT02128854|BEHAVIORAL|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
223407906|NCT02151851|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/ml~* Route of administration: Subcutaneous injection"
223557715|NCT00814580|DRUG|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
223557716|NCT02739763|BIOLOGICAL|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
223557717|NCT02482428|DRUG|Investigational Treatment|Applied twice daily for up to 12 weeks
223557718|NCT02482428|DRUG|Aldara|Applied 3 times a week for 16 weeks
223557719|NCT05658627|OTHER|active release technique|Hamstring active release technique-
223557720|NCT05658627|OTHER|conventional therapy|ultrasound therapy - stretching Exercise - Strengthening Exercise -
223557721|NCT02431780|DEVICE|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
223557722|NCT01824654|OTHER|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
223557723|NCT01824654|OTHER|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
223557724|NCT00945347|DRUG|Miglustat|Nasal instillation of miglustat
223557725|NCT00945347|DRUG|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
223557726|NCT03278717|DRUG|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
223557727|NCT03278717|DRUG|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
223557728|NCT02782052|DRUG|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
223557729|NCT02782052|DRUG|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
223557730|NCT02782052|DRUG|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~* Placebo (P; sterile 0.9% sodium chloride solution)~* Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~* Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
223557731|NCT06562166|RADIATION|online adaptive radiotherapy|Patients in ART group received daily online adaptive radiotherapy with a prescription dose of 50.4Gy/28f.
223738099|NCT06311214|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223738100|NCT06311214|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223407907|NCT02151851|DRUG|Methotrexate|"* Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral"
223407908|NCT02151851|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringes~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection"
223407909|NCT01663961|DRUG|YM178 OCAS|oral
223557732|NCT04451564|BEHAVIORAL|Mindfulness oriented recovery enhancement|8- week psychological program based on mindfulness techniques
223557733|NCT06326450|BEHAVIORAL|Augmented Reality simulation|Augmented simulation of medical crisis scenarios
223557734|NCT06326450|BEHAVIORAL|In Person simulation|In Person simulation of medical crisis scenarios
223557735|NCT03563742|DRUG|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
223557736|NCT03563742|DRUG|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
223557737|NCT03451981|PROCEDURE|mechanical instrumentation|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned
223557738|NCT03451981|PROCEDURE|Er:YAG laser|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
223557739|NCT03451981|PROCEDURE|Air Powder|mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments (titanium curettes) and the implant surface will be cleaned. Furthermore, an Air-Powder treatment will be provided on the implant surface.
223557740|NCT06472141|OTHER|Cervical stabilization exercises|Cervical Stabilization Exercises will be performed 3 days a week for 8 weeks.
223738101|NCT06311214|BIOLOGICAL|Sacituzumab Govitecan|Given IV
223738102|NCT06311214|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223738103|NCT04268849|DRUG|Ferumoxytol|Ferumoxytol (30 mg/mL) intravenous injection in single use vials.
223738104|NCT04268849|DRUG|Saline|Placebo for Ferumoxytol
223738105|NCT04268849|DRUG|Ferrous sulfate tablets|ferrous sulfate tablets containing 60 mg elemental iron
223738106|NCT04268849|DRUG|Vitamin C|Placebo: Vitamin C, 250 mg, given in the same bottle as the oral iron
223407910|NCT01663961|DRUG|Digoxin|oral
223407911|NCT00229996|DRUG|Oral Contraceptive|
223407912|NCT00229996|DRUG|Depot-Leuprolide/Norethindrone|
223407913|NCT03824795|DRUG|MGB-BP-3|MGB-BP-3
223407914|NCT03032042|DRUG|Azithromycin|
223407915|NCT03032042|DRUG|Albendazole|
223407916|NCT03032042|DRUG|Delayed treatment|Albendazole+Azithromycin
223407917|NCT06329349|OTHER|Exercise|12 weeks, 3 times a week of progressive endurance aerobic exercise (150 to 400kcal AEE per session)
223407918|NCT06329349|OTHER|Combined Exercise + Diet|12 weeks, 25% caloric reduction, based on PMID: 37069434
223407919|NCT01540487|DRUG|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
223407920|NCT01540487|DRUG|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
223557741|NCT06472141|OTHER|Standard treatment (Education + home exercises)|Individuals will be informed about TMJ disorders, parafunctional activities (chewing gum, nail/pen biting, etc.) and recommendations. In addition, Rocabado exercises will be given as a home program.
223557742|NCT04904471|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.
223557743|NCT04904471|OTHER|Placebo control|Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.
223407921|NCT05174832|DRUG|Cisplatin|75 mg/m2 IV days 1 of each 21-day cycle
223407922|NCT05174832|DRUG|Nab-paclitaxel|125 mg/m2 IV days 1 and 8 of each 21-day cycle
223407923|NCT05174832|DRUG|Pembrolizumab|200 mg IV every 21 days
223557744|NCT05887492|DRUG|TNG260|CoREST inhibitor, administered orally
223557745|NCT05887492|DRUG|Pembrolizumab|Pembrolizumab, an anti-PD-1 antibody, administered intravenously
223557746|NCT06523010|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
223557747|NCT06523010|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
223557748|NCT06059612|PROCEDURE|injection|steroid injection into superior cluneal nerve
223557749|NCT03026296|BEHAVIORAL|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
223557750|NCT03608241|DRUG|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
223557751|NCT03608241|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
223557752|NCT03241680|DIAGNOSTIC_TEST|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
223738107|NCT05011084|DEVICE|Game Ready Cryotherapy with Compression Group|Instead of using the traditional ice-pack cryotherapy (without compression), patients randomized into this group will use the Game Ready device, which uses cryotherapy with compression, during their post-operative treatment care.
223738108|NCT05011084|OTHER|Control Cryotherapy Group|Patients randomized to the control group will use the standard of care, which is using traditional cryotherapy (i.e., an ice pack without compression)
223407924|NCT05174832|DRUG|Olaparib|300 mg PO BID
223407925|NCT05025644|DRUG|Pre and post-CPB Drug: Dobutamine Hydrochloride|"* Pre-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) until a PG ≥ 50mmHg is achieved (DBT peak dose). The DBT peak dose (DBT-pd) will be recorded.~* Post-CPB provocation test at the DBT-pd achieved preoperatively."
223407926|NCT05025644|DRUG|Post-CPB Drug: Dobutamine Hydrochloride|"* Pre-CPB no intervention will be required.~* Post-CPB provocation test with DBT stress test will be started (starting at 5 mcg/kg/min, increasing every 3 min, to 10, 15 and 20 mcg/kg/min) or until postoperative provocable PG is \>16 mmHg."
223407927|NCT05163457|OTHER|Data collection|frailty evaluation
223407928|NCT01256164|DEVICE|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
223407929|NCT01256164|DEVICE|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
223557753|NCT00459875|DRUG|sunitinib malate|
223557754|NCT01210248|OTHER|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
223557755|NCT03898297|RADIATION|[18F]FPEB|Radiotracer: \[18F\]FPEB
223557756|NCT03898297|RADIATION|[11C]APP311|Radiotracer: \[11C\]APP311, \[11C\]UCB-J
223557757|NCT03735628|DRUG|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
223557758|NCT03735628|DRUG|Nivolumab|Nivolumab: concentrate for solution for infusion
223557759|NCT00504517|OTHER|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
223557760|NCT04509518|OTHER|Exercise therapy program plus TENS therapy|All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
224133122|NCT05769842|DRUG|propofol|Propofol was mainly used in the intervention group during anesthesia extubation. Propofol was given a small amount of times about 1\~2mg/kg before extubation when the patient recovered spontaneously.
224133123|NCT05769842|DRUG|normal saline|Same dose as propofol.
223407930|NCT06137859|BEHAVIORAL|Weekly-based functional fitness training|Participants will receive a 12-week duration of functional fitness training in daycare centers, which will be implemented twice a week. The 60-minute per session training series will be delivered and guided by qualified elderly health and fitness instructors, who will be provided with a workshop before this intervention. The workshop will be designed and delivered by the research team. The first session will focus on the physical literacy of older adults and the second session will focus on how to lead functional fitness training under the FITT principle for older adults. The main goal of functional training is to improve the range of joint motion, increase muscle strength and flexibility, and boost blood circulation safely. Therefore, symmetry training together with cardiovascular training is the core of the training program. Examples of the main training activities include cardio-full-body exercises, upper-body exercises, lower-body exercises and sensory integrative training.
223407931|NCT06137859|BEHAVIORAL|Mastering Physical Literacy Class|"A 30-minute MPLC program will be conducted by experienced elderly health and fitness instructors after WBFFT. This MPLC program aims to enhance the knowledge and understanding of physical literacy. Referring to the newly developed consensus statement, the MPLC includes the following five domains related to the relationship with movement and physical activity throughout life:~i) Why physical literacy matters - improves health, well-being and quality of life.~ii) Understanding physical literacy - value, enjoy and engage in physical activity for life.~iii) Everyone's physical literacy is different - their individual needs and experiences of movement and physical activity.~iv) Building physical literacy - think, feel, move and connect with others. v) How experience affects physical literacy - people, places and spaces around us."
223557761|NCT02180256|PROCEDURE|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
223557762|NCT06513546|DRUG|PLL001 or placebo daily subcutaneous injections|PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
223557763|NCT00335283|DRUG|Lansoprazole Tablet|40 mg bid x 16 weeks
223557764|NCT00335283|PROCEDURE|PH and impedence testing|24 hour ph monitoring
223557765|NCT00335283|PROCEDURE|manometry|done prior to pH probe to measure length of esophagus
223557766|NCT00335283|DRUG|lansoprazole|40mg bid
223557767|NCT00335283|DRUG|placebo|one tablet bid
223557768|NCT03536481|DRUG|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
223557769|NCT03536481|DRUG|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
223557770|NCT03203577|PROCEDURE|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
223557771|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
223557772|NCT04601207|DRUG|Cannabis Preparation|Dosed as a single oral dose
223557773|NCT02290782|RADIATION|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
223557774|NCT01406938|DRUG|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
223557775|NCT01406938|DRUG|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
223557776|NCT00000805|DRUG|Ganciclovir|
223557777|NCT03230890|DEVICE|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
223557778|NCT03778749|DIAGNOSTIC_TEST|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
223557779|NCT02156206|BEHAVIORAL|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
223557780|NCT04182477|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Neuro-cognitive test evaluating general mental status and performance
223557781|NCT05733234|DEVICE|Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia|Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface
223557782|NCT05733234|DRUG|Mechanical Treatment|Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
223738109|NCT03053076|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
223738110|NCT03053076|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
223738111|NCT00315198|DEVICE|Eye Patch|2 hours daily patching
223738112|NCT00315198|PROCEDURE|Near activities|near visual activities while patching
223738113|NCT00315198|PROCEDURE|Distance activities|distance visual activities while patching
223738114|NCT01621620|DRUG|Yohimbine|
223738115|NCT06208228|DEVICE|Kinesiotaping|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
223738116|NCT01569490|BEHAVIORAL|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
223738117|NCT01569490|BEHAVIORAL|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
223738118|NCT00510133|BIOLOGICAL|GRNVAC1|Autologous dendritic cell vaccine
224024471|NCT07070830|DEVICE|Active Comparator: Omnipod M System with lower starting dose|Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitoring system
224024472|NCT07070830|DEVICE|Active Comparator: Omnipod M System with higher starting dose|Omnipod M Automated Insulin Delivery System with Dexcom G6 continuous glucose monitoring system
224024473|NCT07065240|DRUG|SPT-300|A prodrug of allopregnanolone, a small molecule drug
224024474|NCT07065240|DRUG|Placebo|Placebo for SPT-300
224024475|NCT06897488|RADIATION|Adjuvant Radiotherapy|Participants will receive treatment following Lumpectomy
224024476|NCT06779630|DEVICE|Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System|Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
223738119|NCT00204607|BIOLOGICAL|mRNA|
223738120|NCT00204607|DRUG|GM-CSF s.c.|
223738121|NCT06355791|DEVICE|Minuteman G5 Device|The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
223738122|NCT04998201|DRUG|ARO-APOC3|ARO-APOC3 Injection
223738123|NCT04998201|DRUG|Placebo|Sterile Normal Saline (0.9% NaCl)
223738124|NCT04300855|DRUG|Sunphenon|The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months
223738125|NCT04300855|DRUG|Placebo|Matching placebo
223738126|NCT03822247|PROCEDURE|Multidisciplinary Recovery Program|"Preoperative care:~* Patient's education~* Providing respiratory training~* Assessment of nutritional status~* Application of compression stockings~* Thromboembolism prophylaxis by low molecular weighted heparin~* Induction of hemodynamic support 12 hours before the surgery~* Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~* Maintaining normothermia~* Multimodal prevention of postoperative nausea and vomiting~* Use of spinal anesthesia~* Prevention of excessive blood loss~* Local anesthetic infiltration~Postoperative care:~* Active pain control~* Early mobilization~* Early onset of oral nutrition~* Early delirium detection~* Application of compression stockings"
223738127|NCT02998333|PROCEDURE|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
223738128|NCT00719121|DRUG|Talarozole|Topical Application (20 mg)
223738129|NCT00719121|DRUG|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
223738130|NCT06622629|OTHER|Nature based Therapy (NbT): Planned therapeutic techniques performed in natural settings and based on nature-human active participation and connection|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application App, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
223738131|NCT06622629|OTHER|Nature based Therapy (NbT)|"The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application MyCap app, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life.~The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy)."
223738132|NCT03742037|DRUG|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
223738133|NCT03742037|DRUG|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
223738134|NCT03742037|DRUG|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
224024477|NCT06897748|DRUG|Placebo|Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study
224024478|NCT06897748|DRUG|Tozorakimab|Administered subcutaneously tozorakimab and placebo throughout the study
224024479|NCT06597734|DRUG|Olutasidenib|Given by PO
224024488|NCT07076121|DRUG|BMS-986504|Specified dose on specified days
224024489|NCT07076121|DRUG|Gemcitabine|Specified dose on specified days
223407932|NCT06137859|BEHAVIORAL|Daily based reflective writing|At the end of the baseline stage of this study, each participant of the intervention group will receive a template notebook for daily-based reflective writing. The required columns consist of the daily diet, physical activity, mood and sleep quality. Participants will be required to write down their behavior in this notebook daily. In each week's functional training course, there will be a life-sharing session, where the participants will be reminded to bring their notebooks and share their daily activities with others. They will receive feedback, advice and encouragement from the instructor and each other. The notebook will be collected during the last week of the intervention.
223407933|NCT06137859|BEHAVIORAL|Buddy Peers Support Group|Peer-support groups with buddy members will be arranged in each daycare center. Three pairs of buddies and hence about 6 participants will be formed per group. A total of 6 buddy pairs and 2 groups will be formed per daycare center. Buddy peers will encourage each other to do functional exercises regularly or to perform functional exercises together. The time and place for the practice will be decided among buddy members. A member in each group will be nominated as the leader to assist in the liaison and coordination of group activities. The group will perform weekly group-based functional exercises, and the time and place for the practice will be decided among group members. The group will be encouraged to hold monthly gatherings with their fitness instructor in order to strengthen social support.
223407934|NCT04981808|DEVICE|Telemonitoring|Telemonitoring of CGM and insulin pen data
223407935|NCT05422378|DRUG|STP705|STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
223738135|NCT03742037|DRUG|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
223407936|NCT01356303|DRUG|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
223407937|NCT03503370|DRUG|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
223407938|NCT03503370|DRUG|Placebo|Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
223407939|NCT04232917|DRUG|2LPAPI®|Treatment
223407940|NCT04232917|DRUG|Placebo|Placebo
223407941|NCT04353544|OTHER|delayed cord clamping|delayed cord clamping
223407942|NCT03773172|DRUG|MEDI6012|MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
223407943|NCT03773172|DRUG|Placebo|The placebo will mimic the active treatment.
223407944|NCT06482788|DRUG|Adebrelimab (anti-PD-L1) + XELOX|"Adebrelimab: 1200mg, i.v., each infusion lasts 30-60 minutes and is administered on the first day of each cycle (3 weeks).~Capecitabine: 1000mg/m2 , bid, orally, from day 1 to day 14 of each cycle (3 weeks).~Oxaliplatin: 130mg/m2, i.v., each infusion is administered on the first day of each cycle (3 weeks)."
223407945|NCT04292262|OTHER|Observational|Observational
223407946|NCT06581341|DEVICE|Repetitive Transcranial Magnetic Stimulation and Percutaneous Tibial Nerve Stimulation|"Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.~Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used."
223407947|NCT06581341|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS): rTMS is a non-invasive procedure that uses a magnetic coil placed on the scalp to deliver magnetic pulses to the motor cortex, with the aim of improving bladder function by modulating brain activity associated with bladder control. The MagRex magnetic stimulator with an 8-shaped coil will be used at a frequency of 10 Hz, delivering 2000 pulses per session (6 seconds on, 24 seconds rest protocol) at 90% of the motor threshold. The treatment will consist of 3 sessions per week over a period of 4 weeks.
223407948|NCT06581341|DEVICE|Percutaneous Tibial Nerve Stimulation|Percutaneous Tibial Nerve Stimulation (PTNM): PTNM involves the use of electrical stimulation applied to the posterior tibial nerve to enhance bladder function by modulating neural pathways. A needle will be placed 5-6 cm proximal to the tibial malleolus, with the following parameters: 200 μs pulse duration, 20 Hz frequency, 30 minutes per session, 3 times per week for 12 weeks. The Neurotrac Pelvitone device will be used.
223407949|NCT05154175|DEVICE|Ottobock helmet|Patients treated in current practice
223407950|NCT02974686|DRUG|Everolimus|
223407951|NCT02974686|DRUG|Mycophenolic Acid|
224024490|NCT07076121|DRUG|Nab-paclitaxel|Specified dose on specified days
224024491|NCT07076121|DRUG|Placebo|Specified dose on specified days
224024492|NCT06633016|DRUG|ABX-002|ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
224024493|NCT06633016|OTHER|Placebo|Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
224024494|NCT04339738|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224024495|NCT04339738|DRUG|Cabozantinib S-malate|Given PO
224024496|NCT04339738|PROCEDURE|Computed Tomography|Undergo CT, spiral CT
224024497|NCT04339738|PROCEDURE|FDG-Positron Emission Tomography|Undergo FDG-PET
224024498|NCT04339738|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224024499|NCT04339738|BIOLOGICAL|Nivolumab|Given IV
223407952|NCT02862665|DRUG|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
223407953|NCT02862665|DRUG|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
224024500|NCT04339738|DRUG|Paclitaxel|Given IV
224138900|NCT02969850|DIETARY_SUPPLEMENT|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
223407954|NCT01977755|DRUG|danegaptide|
223738136|NCT03742037|DRUG|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
223738137|NCT03742037|DRUG|cenerimod 2 mg (ex-4 mg)|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
223738138|NCT01914744|DRUG|Entecavir|entecavir 0.5 mg/day PO
223738139|NCT01914744|DRUG|Lamivudine|lamivudine 100 mg/day PO
223738140|NCT02577211|DIETARY_SUPPLEMENT|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
223407955|NCT01977755|DRUG|Placebo|
223407956|NCT06377813|OTHER|Mode-Kinetic Chain Exercise With Core Stability Exercises|the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
223407957|NCT06377813|OTHER|Mode-Kinetic Chain Exercise|the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
223407958|NCT02114424|DEVICE|Positional vibrator belt|Belt with vibarator to avoid sleep supine
223407959|NCT06139471|BEHAVIORAL|Virtual Reality-Enhanced Gagne's Instructional Model|Virtual Reality-Enhanced Gagne's Instructional Model
223407960|NCT04228679|DEVICE|Erbium laser|Erbium laser device
223407961|NCT04228679|DEVICE|Sham Laser|Sham laser device
223407962|NCT03367182|DRUG|Weekly paclitaxel|Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
223407963|NCT03367182|DRUG|Topotecan|Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
223407964|NCT03367182|DRUG|Pegylated liposomal doxorubicin|Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks
223407965|NCT03367182|DRUG|Bevacizumab|Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
223407966|NCT00298272|BIOLOGICAL|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
223407967|NCT00298272|DRUG|Placebo|Participants will receive placebo on Day 1 and Day 15
223407968|NCT00298272|DRUG|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
223407969|NCT00298272|DRUG|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
223407970|NCT00298272|DRUG|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
223738141|NCT02577211|DIETARY_SUPPLEMENT|Normocaloric enteral nutrition|25 kcal/kg of body weight
223738142|NCT01143454|DEVICE|NSR IDE-MRI: Research pulse sequences|NSR IDE-MRI: Research pulse sequences, Device Manufacturer NIH. Research pulse sequences are customized pulse sequences and analysis software developed by NIH scientists.
223738143|NCT03460483|OTHER|Genetic Counseling|Undergo genetic counseling
223738144|NCT03460483|OTHER|Genetic Testing|Undergo genetic testing
223738145|NCT03460483|OTHER|Laboratory Biomarker Analysis|Correlative studies
223738146|NCT03460483|PROCEDURE|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
223738147|NCT05390879|OTHER|Meditation|After the circuit, a 6 minutes long meditation auto-guided video.
223738148|NCT05390879|OTHER|Control|After the circuit, a 6 minutes long emotionally neutral video.
223738149|NCT04574167|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
223738150|NCT04574167|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
224024501|NCT04339738|OTHER|Quality-of-Life Assessment|Ancillary studies
224024502|NCT04339738|OTHER|Questionnaire Administration|Ancillary studies
224024503|NCT06928454|BEHAVIORAL|Text messages over 8 weeks|Learn about ADRD/Prepare as a care partner/Care for yourself/Get support
224024504|NCT06349473|DRUG|SR604|SR604 will be administered as SC injection.
224024505|NCT06349473|DRUG|Placebo|Placebo will be administered as single SC injection.
224024506|NCT05041309|BIOLOGICAL|Axicabtagene Ciloleucel|No investigational product will be administered
224024507|NCT05041309|BIOLOGICAL|Brexucabtagene Autoleucel|No investigational product will be administered
224024508|NCT05041309|BIOLOGICAL|Anitocabtagene autleucel|No investigational product will be administered
224024509|NCT05041309|BIOLOGICAL|KITE-753|No investigational product will be administered
224024510|NCT05041309|BIOLOGICAL|KITE-197|No investigational product will be administered
224024511|NCT05041309|BIOLOGICAL|KITE-363|No investigational product will be administered
224024512|NCT06447662|DRUG|PF-07934040|panKRAS inhibitor
224024513|NCT06447662|COMBINATION_PRODUCT|Gemcitabine|Chemotherapy (antimetabolite)
224024514|NCT06447662|COMBINATION_PRODUCT|Nab-paclitaxel|Taxane-type Chemotherapy
224024515|NCT06447662|COMBINATION_PRODUCT|Cetuximab|Monoclonal Antibody (EGFR Inhibitor)
224138901|NCT02969850|OTHER|Placebo|Subjects in this group will receive a placebo.
223407971|NCT00298272|DRUG|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
223407972|NCT00298272|DIETARY_SUPPLEMENT|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
223407973|NCT03522012|DRUG|Tocilizumab|Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
223407974|NCT02503124|BEHAVIORAL|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
223407975|NCT02503124|DEVICE|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
223407976|NCT02503124|OTHER|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
223557783|NCT02926027|DRUG|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
223557784|NCT02926027|DRUG|placebo|placebo
223557785|NCT02377752|BIOLOGICAL|Olaratumab|Administered IV
223557786|NCT02377752|DRUG|Doxorubicin|Administered IV
223557787|NCT01951586|DRUG|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
223557788|NCT01951586|DRUG|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
223557789|NCT01951586|DRUG|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
223557790|NCT01951586|DRUG|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
223557791|NCT01951586|DRUG|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
223557792|NCT01558492|DRUG|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
223557793|NCT01558492|DRUG|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
223557794|NCT05379218|DEVICE|Remote Ischemic Conditioning|"Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected."
223557795|NCT04023370|DEVICE|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
223557796|NCT00328887|GENETIC|CD40 Gene Transfer|gene transfer, intratumoral administration
223557797|NCT03060915|DEVICE|Polysomnography|Patient's undergo a polysomnography
223738151|NCT06853288|BEHAVIORAL|Diet containing 80% ultra processed foods|Very high ultra-processed food diet where 80% of calories are coming from ultra processed food
223407977|NCT02503124|OTHER|Informative meeting|A short sleep hygiene consultation.
223407978|NCT02503124|DRUG|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
223407979|NCT04168112|DRUG|Dextenza|Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
223407980|NCT04168112|DRUG|Prednisolone Acetate|post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
223407981|NCT01598064|DIETARY_SUPPLEMENT|GK#10|GK#10, 1 pack tid
223407982|NCT01598064|DRUG|Placebo|Placebo 1 pack tid po
223407983|NCT05587595|OTHER|questionnaires & data collection|questionnaires
223407984|NCT04939233|DEVICE|Exoskeleton glove|A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
223407985|NCT02225639|DRUG|PRC-063 25 mg|Oral 25 mg capsule - active
223407986|NCT02225639|DRUG|Placebo|Oral placebo capsule
223407987|NCT02225639|DRUG|PRC-063 35 mg|Oral 35 mg capsule - active
223407988|NCT02225639|DRUG|PRC-063 45 mg|Oral 45 mg capsule - active
223407989|NCT02225639|DRUG|PRC-063 55 mg|Oral 55 mg capsule - active
223407990|NCT02225639|DRUG|PRC-063 70 mg|Oral 70 mg capsule - active
223407991|NCT02225639|DRUG|PRC-063 85 mg|Oral 85 mg capsule - active
223407992|NCT02225639|DRUG|PRC-063 100 mg|Oral 100 mg capsule - active
223557798|NCT03060915|DEVICE|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
223557799|NCT00878254|BIOLOGICAL|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4.
223557800|NCT00878254|DRUG|Rituximab|Rituximab 375 mg/m\^2 intravenously (IV) on Day 1 for 4 Cycles during induction therapy. Participants achieving complete remission will then receive Rituximab maintenance therapy every 6 months for up to three years.
223557801|NCT00878254|DRUG|Cyclophosphamide|Cyclophosphamide 800 mg/m\^2 IV on Day 1 and 200 mg/m\^2 IV on Days 2 through 5 of Cycles 1 and 3.
224133124|NCT03023644|BEHAVIORAL|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
224133125|NCT05145504|DIAGNOSTIC_TEST|Evaluation of IL-6 biomarkers in synovial fluid|Evaluation of IL-6 biomarkers in synovial fluid in obese and normal weight patients with gonarthrosis
223407993|NCT02984865|DRUG|Sulfentanyl|
223407994|NCT02984865|DRUG|Nalbuphine|
223407995|NCT02984865|DRUG|flubiprofen axetil|
223407996|NCT02984865|PROCEDURE|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
223407997|NCT03379766|DEVICE|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
223407998|NCT03379766|DEVICE|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
223407999|NCT02575326|OTHER|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
223408000|NCT02575326|BEHAVIORAL|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
223408001|NCT01636193|BIOLOGICAL|Oral Rotarix®|2 doses administered orally.
223408002|NCT01636193|OTHER|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
223408003|NCT01063426|DRUG|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
223408004|NCT01063426|DRUG|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
223408005|NCT04860973|DEVICE|Weighted blankets|Weighted blankets given to patient for 7 days/nights
223738152|NCT06853288|BEHAVIORAL|Diet containing 20% ultra processed foods|Low ultra processed food diet where 20% of the calories are coming from ultra processed food
224133126|NCT01951014|OTHER|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
224133127|NCT02274584|GENETIC|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
223408006|NCT05061940|DIAGNOSTIC_TEST|Tumor Profiling|Testing TAA and HPV expression. HLA typing.
223408007|NCT04431349|DRUG|Ticagrelor 180mg|Patient received loading dose of ticagrelor for coronary angiography within 2 days prior to OPCAB or CABG.
223408008|NCT04431349|DRUG|Clopidogrel 75mg|Patient received loading dose of clopidogrel for coronary angiography within 2 days prior to OPCAB or CABG.
223408009|NCT04353713|DIETARY_SUPPLEMENT|40% Dextrose Gel|Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
223408010|NCT04353713|DIETARY_SUPPLEMENT|2% carboxymethylcellulose gel|placebo
223408011|NCT03871751|BEHAVIORAL|Safe and Sound Protocol|The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
223408012|NCT04258644|DRUG|Camrelizumab+Apatinib+Paclitaxel-albumin+S-1|Combination therapy of 4 drugs, 21 days for one cycle.
223408013|NCT05253573|DRUG|Nicotine patch|Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.
223408014|NCT05253573|BEHAVIORAL|Self-help materials (to support smoking cessation)|"Our team has translated and validated the World Health Organization's A guide for tobacco users to quit into Lao language for use as the self-help material in this study."
223408015|NCT05253573|BEHAVIORAL|Smartphone-based automated treatment for smoking cessation|The automated treatment(AT) include text messages, images, and videos. The AT content is designed to tap the theoretical mechanisms described in the Phase-Based Model (PBM). That is, treatment content is designed to increase motivation, self-efficacy, use of coping skills, and social support, while reducing nicotine withdrawal symptoms and stress. The AT will begin immediately after enrollment and continue for a 12-week period. The AT approach allows for several levels of personalization for each participant, including tailoring to participants' specific health conditions, individual cessation phases, and participants' self-efficacy level or smoking status in the past week.
223408016|NCT04159857|PROCEDURE|Fetal head extraction technique during the cesarean section|see above for the description about one-hand and two-hand fetal head extraction technique
223408017|NCT03492723|DIETARY_SUPPLEMENT|Aged Garlic Extract|NR
223408018|NCT06246240|OTHER|Chewing gum with vitamin C|Will chew vitamin C gum as soon as nausea begins
223408019|NCT03740087|OTHER|Omnivorous diet|Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.
223408020|NCT03740087|OTHER|Vegan diet|Used as a baseline for miRNA levels in blood
223408021|NCT03738670|PROCEDURE|Percutaneous RFA|Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
224133128|NCT01280890|BEHAVIORAL|Staff training using VIPS|Staff training using the VIPS framework
224133129|NCT01280890|BEHAVIORAL|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
224133130|NCT01280890|BEHAVIORAL|Control group|Filmed traditional Lectures will be given to care staff
223408022|NCT06573606|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
223408023|NCT05250570|BEHAVIORAL|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|This psychosocial treatment intervention uses a combination of interoceptive exposure therapy and elements of acceptance and commitment therapy (ACT) to assist individuals in tolerating benzodiazepine withdrawal symptoms and teaching skills to prevent relapse to benzodiazepine use. It will also provide psychoeducation about benzodiazepine use in OAT. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
223408024|NCT05250570|BEHAVIORAL|Relaxation Therapy|The relaxation therapy control condition involves psychoeducation about benzodiazepine use in OAT and progressive muscle-relaxation training. Both intervention and control arms will receive identical benzodiazepine discontinuation taper protocols.
223408025|NCT01835795|DEVICE|Swiss DolorClast® CLASSIC applicator|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
223557802|NCT00878254|DRUG|Cytarabine|Cytarabine (AraC) 2 grams/m\^2 IV on Days 1 and 2 of Cycles 2 and 4.
223557803|NCT00878254|DRUG|Doxorubicin|Doxorubicin 45 mg/m\^2 IV bolus on Day 1 of Cycles 1 and 3.
223557804|NCT00878254|DRUG|Etoposide|Etoposide (VP16) 60 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
223557805|NCT00878254|DRUG|Ifosfamide|Ifosfamide 1.5 grams/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
223557806|NCT00878254|DRUG|Leucovorin|Leucovorin 100 mg/m\^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m\^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is \< 0.1 µmol/L during Cycles 1 and 3.
223557807|NCT00878254|DRUG|Mesna|Mesna 360 mg/m\^2 IV on Days 1 through 5 of Cycles 2 and 4.
223557808|NCT00878254|DRUG|Methotrexate|Methotrexate (MTX) 1,200 mg/m\^2 in 250 mL with Dextrose 5% in water (D5W) IV over 1 hour, followed by Methotrexate 3,000 mg/m\^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3.
223557809|NCT00878254|DRUG|Vincristine|Vincristine 1.5 mg/m\^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3.
223557810|NCT04819087|BEHAVIORAL|Questionnaires and Rehabilitation Programs|Questionnaires and Rehabilitation Programs
223557811|NCT06837077|DRUG|SHR-1209 single-site subcutaneous injection|SHR-1209 single-site subcutaneous injection.
223557812|NCT06837077|DRUG|SHR-1209 multiple-site subcutaneous injections|SHR-1209 multiple-site subcutaneous injections.
223557813|NCT03879928|DRUG|Single ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
223557814|NCT03879928|DRUG|Multiple ascending doses of FM101|The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
223557815|NCT03879928|DRUG|Food effects of FM101|The study drug (FM101) will be administered orally under fasted condition and fed condition.
223557816|NCT01496053|DIETARY_SUPPLEMENT|AndoSan|AndoSan 30 ml x 2 for 21 days
223557817|NCT01496053|DIETARY_SUPPLEMENT|Sugar Extract|Sham comparator
223557818|NCT05120895|DRUG|Mevalotin|Oral tablets (starting dose 5 mg)
223557819|NCT06849765|BEHAVIORAL|Rehabilitation|The rehabilitation program will utilize the MORA app to create individualized interventions based on each patient's physical capabilities.
223557820|NCT04748328|PROCEDURE|ACL Reconstruction surgery and Rehabilitation Treatment|ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
223557821|NCT03872778|DRUG|[177Lu]-NeoB|\[177Lu\]-NeoB peptide receptor radionuclide therapy: 370 MBq/mL (10 mCi/mL), solution for infusion
223557822|NCT03872778|DRUG|[68Ga]-NeoB|\[68Ga\]-NeoB radioactive diagnostic agent: 50 µg, kit for radiopharmaceutical preparation
223557823|NCT03872778|DRUG|LCZ696|dose strength 49/51 mg, film-coated tablets for oral use
223557824|NCT00140296|BEHAVIORAL|Contraceptive counseling|
223557825|NCT02944708|DRUG|Conventional chemotherapy|
224024516|NCT06447662|COMBINATION_PRODUCT|Fluorouracil|"Part of FOLFOX chemotherapy regimen~cytotoxic chemotherapy (antimetabolite and pyrimidine analog)"
224024517|NCT06447662|COMBINATION_PRODUCT|Oxaliplatin|"Part of FOLFOX Chemotherapy Regimen~platinum based compound (alkylating agent)"
224024518|NCT06447662|COMBINATION_PRODUCT|Leucovorin|"Part of FOLFOX chemotherapy regimen~Folic Acid Analog"
223557826|NCT02944708|DRUG|Maintenance chemotherapy 1|
223557827|NCT02944708|DRUG|Maintenance chemotherapy 2|
223557828|NCT06471699|DEVICE|Continous Glucose Monitoring|The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
223557829|NCT06471699|OTHER|Self monitoring blood glucose|Capillary testing as in standard procedure
223557830|NCT05690347|BEHAVIORAL|Back At work After Surgery (BAAS)|see protocol
223557831|NCT03797963|DEVICE|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
223557832|NCT03797963|DEVICE|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
223557833|NCT01207609|PROCEDURE|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
223557834|NCT01719458|DRUG|(S,S)-[11C]MRB|PET radioligand
223557835|NCT06071663|PROCEDURE|Single and two visits pulpectomy|Comparison of clinical and radiographic outcome of Single and two visits pulpectomy
224024519|NCT06447662|COMBINATION_PRODUCT|Bevacizumab|VEG-F inhibitor
224024520|NCT06447662|COMBINATION_PRODUCT|Pembrolizumab|immune checkpoint inhibitor (PD-1 inhibitor)
224024521|NCT06447662|COMBINATION_PRODUCT|pemetrexed|"Can be used in Platinum-based Chemotherapy regimen~Antimetabolite"
224024522|NCT06447662|COMBINATION_PRODUCT|Cisplatin|"Can be used as part of Platinum-based chemotherapy regimen~Platinum-based antineoplastic (alkylating agent)"
223738153|NCT02759419|DRUG|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
223408026|NCT01835795|DEVICE|Swiss DolorClast® CLASSIC placebo applicator|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
223408027|NCT06328556|DRUG|botulinum toxin type A|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use.
223738154|NCT03313908|PROCEDURE|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
223738155|NCT03587961|DRUG|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
224024523|NCT06447662|COMBINATION_PRODUCT|Paclitaxel|"Can be used in Platinum-based chemotherapy regimen~Taxane"
224024524|NCT06447662|COMBINATION_PRODUCT|Carboplatin|"Can be used as part of a platinum-based chemotherapy regimen~platinum containing compound (alkylating agent)"
224024525|NCT06890598|DRUG|Olomorasib|Administered orally.
224024526|NCT06890598|DRUG|Pembrolizumab|Administered intravenously (IV).
224024527|NCT06890598|DRUG|Durvalumab|Administered IV.
224024528|NCT06890598|DRUG|Placebo|Administered orally.
224024529|NCT06585410|DRUG|Cemiplimab|Administered per protocol
224024530|NCT06585410|PROCEDURE|Standard of care|Primary surgery
224133131|NCT04032743|OTHER|ICU treatment|any treatment available by ICU
223408028|NCT06328556|PROCEDURE|Injection|Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
223408029|NCT04694599|DEVICE|Low flow oxygen|Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
223408030|NCT01436370|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
223408031|NCT01436370|BIOLOGICAL|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
223408032|NCT05445414|DEVICE|"SteWARdS Antibiotic Defense app"|"The SteWARdS Antibiotic Defense app is an evidence-based serious game app developed by the study team. The app uses gamification theories to increase user engagement and to deliver bite-sized information to participants. For example, players will learn about the uses of antibiotics through the messages delivered through the game and the cost of tackling antibiotic-resistant infections through purchasing an expensive antibiotic with the virtual currency earned from the games."
223408033|NCT01232413|DRUG|Placebo|Oral
223408034|NCT01232413|DRUG|ASP1941|Oral
223408035|NCT01232413|DRUG|Moxifloxacin|Oral
223408036|NCT04180514|DIAGNOSTIC_TEST|intradialytic hypotension episode|Intradialytic hypotension episode under regular hemodialysis
223408037|NCT03246308|RADIATION|Phototherapy|Taking blood sample.
223408038|NCT02395848|DRUG|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
223408039|NCT02774330|OTHER|Policy|This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
223408040|NCT03558763|DEVICE|Telemonitoring|During the telemonitoring treatment period the subjects will register; vital functions (blood pressure, heart rate, weight, SpO2) twice a week, physical movement daily by using a fitness device, have video calls with a nurse weekly the first 4 weeks and thereafter every fourth week the last 5 months. Twice a week (± 2 days) questionnaires (CAT and MRC) should be filled out at home.
223408041|NCT03558763|OTHER|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
223408042|NCT03829826|BIOLOGICAL|HyQvia|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
223408043|NCT03030560|DRUG|Lidocaine|patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
223408044|NCT03030560|DRUG|0.9% Sodium-chloride|patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
223408045|NCT05978544|DRUG|Itolizumab|Patients to be treated with Itolizumab.
223408046|NCT02276560|DRUG|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
223408047|NCT02276560|DRUG|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
223408048|NCT02276560|DRUG|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
223408049|NCT01024140|DRUG|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
223408050|NCT05053022|DEVICE|Skinpen Precision System|Subjects will receive a total of 8-12 treatments with the Skinpen Precision system targeting their Vitiligo lesions.
223408051|NCT02610374|OTHER|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
224024531|NCT06058520|DRUG|Fecal Microbiota - lyophilized|Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
223738156|NCT02985307|BEHAVIORAL|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
224024532|NCT06058520|DRUG|Placebo drug|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
224024533|NCT05581004|DRUG|RO7502175|RO7502175 will be administered as per the schedules specified in the respective arms.
224024534|NCT05581004|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedules specified in the respective arms.
224024535|NCT05581004|DRUG|Pembrolizumab|Pembrolizumab will be administered as per the schedules specified in the respective arms.
224024536|NCT05701917|DEVICE|ClotTriever System|Mechanical thrombectomy
224133132|NCT00807846|DRUG|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
224133133|NCT00807846|DRUG|Naproxen|Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
224297921|NCT04235452|DIAGNOSTIC_TEST|Somatosensory evoked potential|"Stimulation of the right and left median nerves for each subject were carried out with electrical square wave pulses of 0.2 ms duration applied at a rate of 5 HZ. with cathode proximally. The intensity of the stimulus was adjusted to produce minimal twitches of the thumb (1-2 cm thumb movement). Five hundred (500) stimuli were delivered. The recording electrode picked up the responses. They were then summated and averaged.~The final evoked potential was then displayed on the screen. When two reproducible SEPs responses were obtained the data was accepted for analysis. The graph was printed out on paper, for the purpose of simplification only one response was printed out."
223408052|NCT02610374|OTHER|Western-type Diet|A diet higher in fats and lower in carbohydrates
223408053|NCT02469935|PROCEDURE|ultrasound|surgeon-performed ultrasound
223408054|NCT04044066|BIOLOGICAL|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
223408055|NCT05704374|DIAGNOSTIC_TEST|sympathetic stimulation maneuver (mental arithmetic test, cold pressure test)|Mental arithmetic calculation and cold pressure increase sympathetic tone. For the mental arithmetic task, the subject is asked to mentally subtract a two-digit number from a four-digit number and respond within 5 seconds. This arithmetic calculation is repeated for different numbers. This test is continued for three minutes. For the cold pressure test, subjects are asked to immerse their right hand in 2-4 degrees cold water up to the elbow and hold it in the water for three minutes. The mental arithmetic task and cold stress test will be applied simultaneously.
224024537|NCT05701917|DRUG|Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.|Anticoagulants are a group of medications that decrease your blood's ability to clot.
223408056|NCT05704374|DRUG|Pregabalin 150mg|In the second phase of the experiment, 150 mg (single dose) of pregabalin will be given to FMS patients to reduce sympathetic activity and evaluate its effect on T- and H-reflexes.
223408057|NCT03629938|OTHER|evaluation|evaluation and classification of medial longitudinal arch height of foot in adults
224024538|NCT06747468|DRUG|Avexitide|Avexitide (also known as exendin 9-39), a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, is a 31-amino acid peptide with a free amino group at the N-terminus and an amidated C-terminus. By binding to the GLP-1 receptor, avexitide inhibits GLP-1 receptor signaling, thereby reducing GLP-1 receptor-mediated insulin secretion
224133134|NCT04615962|DRUG|Hydrocortisone Acetate 1% Cream|Hydrocortisone Acetate is the synthetic acetate ester form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties.
224133135|NCT04615962|DRUG|Mometasone Furoate|Mometasone is a medium-strength corticosteroid.
224133136|NCT04615962|DRUG|SNG100|A combination of low potency steroid and skin barrier repair agent
223408058|NCT02600468|DRUG|Orencia|
223408059|NCT00616343|DRUG|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
223408060|NCT03373084|OTHER|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
223408061|NCT03373084|OTHER|ultrasound|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
223738157|NCT02985307|BEHAVIORAL|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
223738158|NCT01270711|DRUG|Study Drug|non interventional study - usage as per usual care
223738159|NCT02941445|DRUG|sitagliptin and metformin|
224024539|NCT06747468|OTHER|Placebo|Matching placebo comparator
224024540|NCT03454828|DIETARY_SUPPLEMENT|obese carbohydrate diet|The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
224133137|NCT03126929|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
224133138|NCT04152525|OTHER|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
224297922|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Amino Acid daily for 13 days|A 30 mg zinc amino acid supplement is taken p.o. in the fasted state for 13 days.
224024541|NCT03454828|DIETARY_SUPPLEMENT|lean carbohydrate diet|The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and \<10% of total kcals in the form of sugar).
224024542|NCT07075705|PROCEDURE|Biopsy of Prostate|Undergo standard of care prostate biopsy
224024543|NCT07075705|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224133139|NCT01081873|DRUG|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
224133140|NCT05745896|OTHER|Telemedicine appointment|Three online appointments for pregnancy monitoring at prenatal care.
223408062|NCT03373084|OTHER|Self-questionnaire|Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
223408063|NCT06482190|DRUG|RSN0402 Part 1|Participants will receive single ascending doses of 2mg, 4mg, 8mg, 12 mg, and 16mg of RSN0402 or placebo on Day 1 for Cohort 1 to 5. Cohort 2(4mg) will also a single dose of 150 mg nintedanib soft capsule will be administered orally after at least 7-days washout period.
223408064|NCT06482190|DRUG|RSN0402 Part 2|Participants will receive multiple ascending doses of 4mg ,8mg,12mg ,16mg of RSN0402 or placebo administered once daily from Day 1 to Day 7 for Cohort 6 to 9.
223408065|NCT06482190|DRUG|Placebo|Participants will receive matching placebo across Part 1 and Part 2 of the study.
223408066|NCT02809079|DRUG|Mycophenolate mofetil|Mycophenolate mofetil 500mg Bid
223408067|NCT02809079|DRUG|Prednisone|prednisone 10mg Qd
223408068|NCT02126579|BIOLOGICAL|Peptide Vaccine (LPV7) + Tetanus peptide|1.5 mL administered half intradermally and half subcutaneously.
223408069|NCT02126579|OTHER|PolyICLC|1 mL administered half intradermally and half subcutaneously
223408070|NCT02126579|OTHER|Resiquimod|500 mg applied to vaccine site after vaccine administration
223408071|NCT02126579|OTHER|IFA|2 mL administered half intradermally and half subcutaneously
223408072|NCT02295046|DRUG|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
223408073|NCT00911469|DRUG|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
223408074|NCT00911469|DRUG|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
223408075|NCT04664023|PROCEDURE|Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection.|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
223408076|NCT04664023|PROCEDURE|Blood collection at 1st injection of vaccine against COVID-19, at at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers|40mL blood sample will be collected at each blood collection for immunologic, enzymatic and metabolic biomarker analysis
223408077|NCT00935402|BEHAVIORAL|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
224024544|NCT07075705|PROCEDURE|Micro-ultrasound Imaging|Undergo transperineal micro-ultrasound imaging
224024545|NCT07075705|PROCEDURE|Micro-ultrasound Imaging|Undergo transrectal micro-ultrasound imaging
224024546|NCT04620382|DRUG|Midodrine|Midodrine 5-10 mg, single oral dose
224024547|NCT04620382|DRUG|Placebo pill|single oral dose
224024548|NCT04620382|DEVICE|Abdominal compression|abdominal compression up to 40 mmHg during head-up tilt
223738160|NCT02941445|DRUG|Metformin|
224024549|NCT04620382|DEVICE|sham compression|Sham abdominal compression during head-up tilt
224024550|NCT07078461|DEVICE|1927-nm Thulium Laser therapy|The investigators will use the LaseMD LEO Laser System (1927-nm Thulium laser) to create controlled, localized microscopic treatment zones (MTZs) of thermal injury to treatment area (unilateral upper arm). The investigators will utilize the random mode using the C1 tip (spot size 200 micrometers), which involves irradiation of the entire upper arm until diffuse erythema and edema appear. Additionally, the investigators may use the C5 tip (350 micrometers spot size) for focused treatment, up to five passes, until coagulation becomes evident. The maximum fluence for all C1 tip is 3-60 J/cm2 and 1-20 J/cm2 for C5 tips. The maximum pulse energy is 20 J with a pulse duration of 20 ms.
224133141|NCT05745896|OTHER|Face-to-face appointment|Six to nine face-to-face appointments for pregnancy monitoring at prenatal care.
224133142|NCT03340792|DEVICE|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
224133143|NCT03011840|OTHER|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
224133144|NCT05224401|DRUG|Pivmecillinam and amoxicillin/clavulanic acid|1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.
224133145|NCT05224401|DRUG|Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility|Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.
224133146|NCT00441558|DRUG|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
223408078|NCT00981214|DRUG|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
223408079|NCT03324555|DRUG|ORIC-101|Oral suspension
223408080|NCT00675012|DRUG|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
223408081|NCT00675012|DRUG|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
223408082|NCT00675012|DRUG|capecitabine|orally 825 mg/sqm 2qDx14
223408083|NCT04229095|DRUG|Suvorexant 20 mg|Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit
223738161|NCT01689701|DIETARY_SUPPLEMENT|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
224024551|NCT05972291|DIETARY_SUPPLEMENT|Oral Glutamine|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
224024552|NCT05972291|OTHER|Control Arm|You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
224133147|NCT04426123|DRUG|Botulinum toxin type A|Intramuscular injection with Botulinum toxin type A in m.masseter and m.temporalis.
224133148|NCT04426123|OTHER|saline solution|Intramuscular injection with NaCl in m.masseter and m.temporalis.
224133149|NCT02580916|OTHER|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
224133150|NCT02491073|OTHER|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
223408084|NCT04229095|DRUG|Placebo oral tablet|Single-dose administration of placebo given on an inpatient clinical research unit
223408085|NCT03574272|OTHER|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
223408086|NCT06144216|OTHER|CLOE Outreach Intervention|The CLOE outreach intervention is a community-led, strengths-based, and trauma-informed program to support self-identifying women and youth who experience interpersonal and structural gender-based violence. Outreach services are designed to mitigate the effects of gender-based violence, build trusting relationships with service providers, and improve safety, well-being and engagement with health and social care.
223408087|NCT02371317|BEHAVIORAL|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
223408088|NCT02371317|BEHAVIORAL|Stress Management Education|Patients are randomized to an intervention
223408089|NCT02371317|OTHER|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
223408090|NCT02056041|PROCEDURE|Hepatectomy|
223408091|NCT05322941|DRUG|AEF0117|AEF0117 (1.0, 0.3, and 0.1 mg) capsules
223408092|NCT05322941|DRUG|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
223408093|NCT03079141|DRUG|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
223408094|NCT03079141|OTHER|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
223408095|NCT01780038|BEHAVIORAL|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
223408096|NCT01780038|BEHAVIORAL|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
223408097|NCT06462950|BEHAVIORAL|Do men and women differ in their reactions to the experimental conditions.|Do men and women differ in their reactions to the experimental conditions.
223408098|NCT04601519|OTHER|Cross-sectional observational study|Online questionnaire on the impact of type 1 diabetes on sleep quality
223408099|NCT05349110|DEVICE|Computer-aided diagnosis (CADx) systems|"* AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~* CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan)."
223408100|NCT01415817|OTHER|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
223408101|NCT00563641|OTHER|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
223408102|NCT00563641|OTHER|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
223738162|NCT01689701|DIETARY_SUPPLEMENT|Placebo|Placebo(1.3g/d)
223408103|NCT02529449|DRUG|Placebo|Oral
223408104|NCT02529449|DRUG|ASP1941|Oral
223408105|NCT01237041|DRUG|Niacin First|Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day
223738163|NCT05360576|DRUG|LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)|To prevent pregnancy
224024553|NCT01087294|PROCEDURE|Allogeneic stem cell transplant|Allogeneic stem cell transplant
223738164|NCT05360576|DRUG|NuvaRing Vaginal Ring|To prevent pregnancy
223408106|NCT01237041|DRUG|Placebo First|Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day
224024554|NCT01087294|BIOLOGICAL|Anti-CD19-chimeric-antigen-receptor-transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR. The cells are cultured in media containing IL-21, IL-7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
224024555|NCT01087294|PROCEDURE|Leukapheresis|Donors will undergo leukapheresis
224024556|NCT07090499|DRUG|PF-08046876|Intravenous administration
223408107|NCT01237041|DRUG|Dose-Establishing Study 1 Niacin 250mg|Niacin 250 mg po three times at 2 hour intervals on an inpatient day
223408108|NCT01237041|DRUG|Dose-Establishing Study 1 Niacin 500mg|Niacin 500 mg po three times at 2 hour intervals on an inpatient day
223408109|NCT01237041|DRUG|Dose-Establishing Study 2 Niacin 500mg|Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
223557836|NCT02455804|DEVICE|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
223557837|NCT04560816|DRUG|ALXN1840|ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
223557838|NCT04560816|DRUG|Placebo|Placebo will be administered orally.
223557839|NCT04560816|DRUG|Moxifloxacin|Moxifloxacin (400 milligrams) will be administered orally.
223557840|NCT00780767|DEVICE|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
223557841|NCT05570656|DEVICE|XSENS-Awinda|"The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day."
223557842|NCT02029456|DRUG|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
223557843|NCT02277691|DRUG|TAK-536TCH tablet|TAK-536TCH tablets
223557844|NCT02277691|DRUG|TAK-536CCB tablet|TAK-536CCB tablets
223557845|NCT02277691|DRUG|HCTZ 12.5 mg tablet|HCTZ tablets
223557846|NCT04416152|PROCEDURE|Pelvic reconstruction surgery|Pelvic reconstruction surgeries, such as anterior/posterior colporrhaphy, sacrospinous ligament fixation, transvaginal mesh repair and sacrocolpopexy.
223557847|NCT05739396|OTHER|core stabilization|The treatment session lasted one hour with short breaks of around 10 minutes and will be conducted three times per week for twelve successive weeks
223557848|NCT05314543|OTHER|Hypoxia|Subjects will be subjected to mild hypoxia simulating an altitude of 1750 m (normobaric hypoxia). Hypoxia decreases oxygen supply to tissue and limit exercise capacity. For this, the subjects will inhale a gas mixture depleted in oxygen (enriched in nitrogen). The barometric pressure at 1500 m being 621 mmHg, PIO2 at this altitude (PIO2 = (621 - 47) x 21%) is 120.5 mmHg. For sea level altitude where the barometric pressure is 760 mmHg, the hypoxic gas mixture should contain (x = 120.5 / (760 - 47)) 16.8% O2. Thus, by inhaling a gas mixture that is oxygen-depleted from 21 to 16.8%, subjects (will simulate the altitude of 1750 and) will experience the equivalent of a 20% reduction in oxygen supply.
223557849|NCT03560102|DEVICE|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
223557850|NCT03863379|DIAGNOSTIC_TEST|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
223738165|NCT04925037|BEHAVIORAL|self-questionnaire to patients undergoing SpAax follow-up|On the occasion of a single visit in consultation or hospitalization, an anonymous self-questionnaire will be distributed to patients undergoing SpAax follow-up
223738166|NCT04235231|DEVICE|Bed tilting|15° lateral tilt, original product brand name LINET Eleganza 5
223738167|NCT04235231|OTHER|Body positioning|Manual positioning of body by nurse: left side, back, right side, using positioning pillows
223738168|NCT05116930|DRUG|Neostigmine|IV infusion 20 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
223738169|NCT05116930|DRUG|Glycopyrrolate|IV infusion 4 μg/kg over 10 minutes repeated every 8 hours for a maximum of 3 doses
224024557|NCT07093541|DRUG|ecopipam HCl ~2mg/kg/day|Daily oral tablet taken every evening before bedtime.
223408110|NCT06189144|OTHER|Emollient cream treatment|Rilastil Difesa Sterile cream
223738170|NCT03253250|DRUG|ETV；TDF；ADV|NAs
223738171|NCT03253250|DRUG|Peginterferon Alfa-2a|peginterferon
223738172|NCT01948453|DIETARY_SUPPLEMENT|Garlic|Garlic tablet in adjunct to medical treatment
224024558|NCT02133053|OTHER|Medical Device, drug-like|Ectoin Allergy Nasal Spray
224024559|NCT02133053|DRUG|Beclomethasone|Beclomethasone nasal spray
223408111|NCT06189144|OTHER|no treatment|no treatment
223408112|NCT04333095|DRUG|Liposomal bupivacaine|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
223408113|NCT04333095|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
223408114|NCT02430649|PROCEDURE|Irreversible electroporation (IRE)|
223408115|NCT02430649|DEVICE|NanoKnife|
223408116|NCT02355938|DRUG|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
224024560|NCT00517777|DEVICE|continuous positive airway pressure ventilation|nighttime
224024561|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
224024562|NCT00517777|BEHAVIORAL|dietary and life style recommendations|
224024563|NCT04169737|DRUG|Acalabrutinib|Given PO
223408117|NCT02355938|DRUG|Placebo|1 dose of placebo every 6 hours x 2 doses
224024564|NCT04169737|BIOLOGICAL|Obinutuzumab|Given IV
223408118|NCT02355938|DRUG|Vancomycin|Vancomycin 125 mg every 6 hours
223408119|NCT05457218|DIETARY_SUPPLEMENT|Whey protein|The participant will consume a supplemental dose of whey protein (0.25 g/kg body weight)
223408120|NCT05457218|DIETARY_SUPPLEMENT|IPC80|The participant will consume a supplemental dose of IPC80 (0.25 g/kg body weight)
223408121|NCT05457218|DIETARY_SUPPLEMENT|Whole Buffalo Powder|The participant will consume a supplemental dose of Whole Buffalo Powder (0.25 g/kg body weight)
223408122|NCT04176419|DRUG|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
223408123|NCT04176419|DRUG|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
223408124|NCT04176419|DRUG|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
223408125|NCT04176419|DRUG|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
223408126|NCT04176419|DRUG|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
223408127|NCT04176419|DRUG|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
223408128|NCT04176419|DRUG|Gabapentin|600 mg orally at time of check in to the preoperative unit
223408129|NCT04176419|DRUG|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
223408130|NCT04176419|DRUG|Celecoxib|200 mg orally at time of check in to the preoperative unit
223408131|NCT04176419|DRUG|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
223408132|NCT05924191|DEVICE|Photobiomodulation|Intra-oral irradiations wll be performed with a low intensity Laser device at 4 anatomical points, with a wavelength of 660 nm. The extraoral FBM will be applied with 1 cluster (20cm2) with a wavelength of 630nm. Subsequently, the same region will be irradiated with the same cluster, using the 4 LEDs with a wavelength of 850 nm 1 hour before performing the surgery.
223408133|NCT05924191|DRUG|Placebo Corticosteroid|Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
223408134|NCT05924191|DEVICE|Simulation Photobiomodulation|The irradiation simulations will be practiced in the same anatomical points described in the experimental group. This protocol will be carried out 1 hour before the surgical procedure (Baseline). The Laser device will be disconnected and its beep sound will be recorded and run on simulating the irradiation.
223408135|NCT05924191|DRUG|Corticosteroid|The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
223408136|NCT02609607|DRUG|Bisacodyl|Rectal suppository
223408137|NCT02609607|OTHER|Placebo|Rectal suppository
223408138|NCT06327529|OTHER|SER 118|Bean High in Phytic Acid and High in Inhibitory Polyphenols
223408139|NCT06327529|OTHER|LMP 1001|Bean Low in Phytic Acid and High in Inhibitory Polyphenols
223408140|NCT06327529|OTHER|LPA 586|Bean Low in Phytic Acid and Low in Inhibitory Polyphenols
223408141|NCT06327529|OTHER|KAT B1|Bean High in Phytic Acid and Low in Inhibitory Polyphenols
223408142|NCT01317095|DEVICE|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
223408143|NCT01761604|DEVICE|Nasal ganglion block for TN|
223408144|NCT06022315|COMBINATION_PRODUCT|caloric restrction high carbohydrate low fat diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
223408145|NCT06022315|COMBINATION_PRODUCT|caloric restrction high fat low carbohydrate diet with exercise training program|"Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week."
223408146|NCT03168711|DRUG|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
223408147|NCT03168711|DRUG|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
223408148|NCT01010412|DEVICE|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
223408149|NCT01010412|DEVICE|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
223408150|NCT06142487|OTHER|Silk Pillowcase|100% Mulberry Silk Pillowcase
223408151|NCT06142487|OTHER|Cotton Pillowcase|100% Cotton Pillowcase
223738173|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
224024565|NCT04169737|DRUG|Venetoclax|Given PO
224024566|NCT06284486|DRUG|Venetoclax|Given by PO
224024567|NCT06284486|DRUG|Revumenib|Given by PO
224024568|NCT04931654|DRUG|AZD7789|anti-PD-1 and anti-TIM-3 bispecific antibody
223738174|NCT02388204|PROCEDURE|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
223738175|NCT00388271|DRUG|Alfuzosin (Xatral)|standard treatment plus alfuzosin
223738176|NCT00388271|DRUG|standard treatment|standard treatment
223738177|NCT03107754|DRUG|Lidocaine|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
224024569|NCT04832659|BEHAVIORAL|CEASE|The CEASE intervention is considered the accepted standard of care according to national treatment guidelines. Parents of a child scheduled to be seen at a participating pediatric practice will be provided with a brief intake survey. Office staff and clinicians will be trained how to utilize the intake survey system and how to provide evidence-based cessation assistance to parents who smoke. The brief intake survey will conduct screening to identify household smoking. The CEASE system will provide (1) Automatic documentation of smoking cessation services requested; (2) Automatically generated prescription for nicotine replacement therapy for parents who smoke (unless they opt out of receiving the prescription); (3) Automated enrollment in the state's free tobacco Quitline and the SmokeFreeTXT program, a text message program offered by the National Cancer Institute.
224133151|NCT02274324|DIETARY_SUPPLEMENT|different diets|3 different diets: A\\B\\C
224297923|NCT06348056|DIETARY_SUPPLEMENT|30 mg Zn Gluconate daily for 13 days|A 30 mg zinc gluconate supplement is taken p.o. in the fasted state for 13 days.
223408152|NCT03254745|OTHER|Pharmacist led pharmaceutical care|The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
223557851|NCT02767089|DRUG|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
223557852|NCT02767089|DRUG|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
223557853|NCT06792760|OTHER|Physiotherapy|The intervention will consist of 10 individual physiotherapy sessions delivered by a single physiotherapist trained in FMD. The physiotherapy programme will include education, movement retraining and a self-management plan.
223557854|NCT06792760|OTHER|Specific Breathing Techniques|The intervention will include education and training in specific breathing techniques, which will be exercised by the patient as a self-management plan for over 5-10 minutes daily.
223557855|NCT00441142|DRUG|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
223557856|NCT00441142|DRUG|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
223557857|NCT00441142|RADIATION|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
223557858|NCT01140997|DRUG|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
223557859|NCT01140997|DRUG|Peginterferon alfa-2a|sc, qw, for 48 weeks.
223557860|NCT06394479|OTHER|Outcome after bariatric surgery in patient with T1D|Retrospective evaluation of clinical data
223557861|NCT05523167|BIOLOGICAL|EFG PH20 SC|Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
223557862|NCT05523167|OTHER|PBO|Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
223738178|NCT03107754|DRUG|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
223738179|NCT04756791|PROCEDURE|SAPB|local anesthetic is injected between the serratus anterior and latissimus dorsi muscles.
223738180|NCT04756791|PROCEDURE|Local Injection Anesthesia|Anesthesia is injected directly into the tissue that is will be numbing.
223738181|NCT04918264|DRUG|Fluoropyrimidine treatment (5-FU or capecitabine) and dosage|In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
223738182|NCT04918264|OTHER|Uracil dosage|For each patient, uracil concentration will be evaluate and patients will be compared based on 16 ng/mL as threshold.
223738183|NCT04918264|BEHAVIORAL|Overall survival|For each group of patient, on 16 ng/mL as threshold for uracil concentration, overall survival will be compared betwen the two groups of patients (Uracil \<16 vs Uracil ≥16).
223738184|NCT00734903|BEHAVIORAL|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
223557863|NCT00000886|BIOLOGICAL|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
223738185|NCT00734903|BEHAVIORAL|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
223738186|NCT06391151|OTHER|exposure: OSA resulting from chronic tonsillitis|exposure: OSA resulting from chronic tonsillitis
223738187|NCT03259204|DEVICE|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
223738188|NCT02516215|OTHER|No intervention|
223738189|NCT01953120|DRUG|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
223408153|NCT06578026|BEHAVIORAL|Resilience Builder Program|The Resilience Builder Program® group therapy will meet for one class period once a week during the semester (12 sessions). The group aims to improve resilience skills: areas such as the ability to control emotions and behavior, social skills and interactions with peers, problem-solving skills, ability to be flexible in different situations, self-esteem, and optimistic thinking. The groups involve the group leader presenting a new topic and skill, the students discussing this topic and developing strategies associated with the skill, the students practicing the skill while getting feedback from the group leader, and a period focused on self-control strategies. A letter reviewing each session will be sent home to the parent/guardian each week. Also, each child will be asked to do an assignment between weekly sessions to help him/her practice new skills.
223408154|NCT05361577|DEVICE|Exoplulse Mollii suit|Exopulse Mollii suits consists of a body Garments (Jacket and Pants) and a control unit. The body Garments (Jacket and Pants) is a suit with 58 embedded electrodes that can stimulate 40 groups of muscles, conductive wires and connectors to a detachable control unit, whose intended purpose is to transmit electric pulses from the control unit to key nerves and corresponding muscle groups throughout the body. The control unit is a battery powered electrical device which sends low intensity electric pulses through connectors to the Body Garments which in turn transmits the pulses from the connectors to key nerves and corresponding muscle groups throughout the body.
223408155|NCT05361577|DEVICE|Exopulse Mollii suit (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
223408156|NCT02529046|DIETARY_SUPPLEMENT|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
223557864|NCT04098419|BEHAVIORAL|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
223557865|NCT06455566|DEVICE|Leadless pacemaker implantation through right internal jugular vein|Leadless pacemaker implantation through right internal jugular vein
223557866|NCT01597765|DRUG|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
223557867|NCT01597765|DRUG|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
223557868|NCT03670654|OTHER|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
223557869|NCT03670654|OTHER|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
223557870|NCT03455933|OTHER|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
223557871|NCT03455933|OTHER|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
223557872|NCT03455933|OTHER|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
223557873|NCT00431522|DRUG|Valproic acid, sodium salt|
224138902|NCT02969850|DIETARY_SUPPLEMENT|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
223408157|NCT02529046|BEHAVIORAL|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
223408158|NCT03408769|OTHER|Medical questionnaire|"* Brief Index of Sexual Functioning for Women questionnaire~* Quality of life questionnaire (EORTC QLQ-BR23)~* Partnership questionnaire (partnerschaftsfragebogen; PFB)~* Short interview about their sexual intimacy"
223408159|NCT01450215|DRUG|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
223557874|NCT05105581|BEHAVIORAL|Quality of life scale|"1. To assess the quality of life of patient~2. To assess the degree of OCD"
223557875|NCT03294044|BEHAVIORAL|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
223557876|NCT03294044|BEHAVIORAL|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
223408160|NCT01202578|DEVICE|tympanostomy tube|tympanostomy tube delivery system
223738190|NCT04300114|DRUG|Fluzoparib|Fluzoparib capsules po. 150 mg twice daily
223738191|NCT04300114|DRUG|Placebo|Placebo capsules po. twice daily
224133152|NCT00175084|BEHAVIORAL|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
224133153|NCT02681380|OTHER|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
224133154|NCT02681380|OTHER|Control group|No session will be planned for the participants.
223408161|NCT00184717|DRUG|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
223408162|NCT00184717|DRUG|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
223408163|NCT04831853|OTHER|nasopharyngeal swabbing procedure (self swabbing first)|Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
223408164|NCT04831853|OTHER|nasopharyngeal swabbing procedure (conventionnal swabbing first)|patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
223408165|NCT02209051|OTHER|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
223408166|NCT02209051|OTHER|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
223408167|NCT05566899|PROCEDURE|esophagogastroduodenoscopy (EGD)|"After colonoscopy, the patient will undergo the EGD at which time biopsy specimens will be obtained.~Participants will also be provided with a home stool collection kit which they can bring to the endoscopy visit or mail back. Satisfaction questions will be administered 3-7 days after EGD-SC"
223408168|NCT04843917|DIAGNOSTIC_TEST|Immunoglobulin G detection|Detection of immunoglobulin G against Spike Receptor Binding Domain against severe acute respiratory syndrome coronavirus 2
223408169|NCT02877004|DEVICE|3 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks
223408170|NCT02877004|DEVICE|2 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks
223408171|NCT02877004|DEVICE|1 Low-Level Laser Therapy Treatment Weekly|Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
223408172|NCT01671228|OTHER|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
223408173|NCT01671228|OTHER|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
223408174|NCT01671228|OTHER|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
223408175|NCT02633293|DRUG|Inhaled Treprostinil|Inhaled treprostinil up to 15 breaths (90 mcg) four times daily
223408176|NCT03104140|DRUG|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
223408177|NCT03104140|DRUG|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
223408178|NCT00238472|DRUG|nateglinide|
223408179|NCT01212237|PROCEDURE|fMRI Evaluation|Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
223408180|NCT00778817|BIOLOGICAL|IMC-A12|Given IV
223408181|NCT00778817|DRUG|mitotane|Given orally
223408182|NCT03357523|DEVICE|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
223408183|NCT03357523|DEVICE|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
223408184|NCT03357523|DEVICE|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
223408185|NCT03357523|DEVICE|Heating bag|Applying a standard 10X13 \[cm\] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
223408186|NCT00192231|BIOLOGICAL|CAIV-T|
223408187|NCT03719469|DIETARY_SUPPLEMENT|Green tea group|
223408188|NCT02838732|DIETARY_SUPPLEMENT|L-carnitine supplementation (500 mg per tablet per day, purchased from GNC company)|
223408189|NCT02356588|DRUG|Sufentanil Tablet 30 mcg|
223408190|NCT02356588|DRUG|Placebo Tablet|
223408191|NCT04410107|DIAGNOSTIC_TEST|Lung Function tests|Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
223408192|NCT04410107|DIAGNOSTIC_TEST|Exercise capacity|6-minute walk test (6MWT distance)
223408193|NCT04410107|DIAGNOSTIC_TEST|Exercise physiology|Cardiopulmonary exercise test (CPET)
223738192|NCT03760211|BEHAVIORAL|Multilevel Gaming Adherence Intervention|Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages
223738193|NCT03760211|BEHAVIORAL|Treatment as Usual +|Combination of electronic medication monitoring device and non-HIV related mobile gaming application
223408194|NCT04410107|DIAGNOSTIC_TEST|Health-related quality of life|Short-Form Health Survey Questionnaire (SF-36)
223408195|NCT04410107|DIAGNOSTIC_TEST|Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening|"1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD)."
223408196|NCT01418378|DEVICE|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
223557877|NCT04952753|DRUG|NIS793|Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.
223557878|NCT04952753|DRUG|Bevacizumab|Bevacizumab will be administered IV
223738194|NCT03234192|PROCEDURE|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
223738195|NCT03234192|PROCEDURE|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
223738196|NCT03234192|PROCEDURE|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
223738197|NCT00277290|DRUG|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
223738198|NCT01857232|DRUG|Ondansetron|5HT3-antagonist
223738199|NCT01857232|DRUG|Placebo|Comparator
223557879|NCT04952753|DRUG|Modified FOLFOX6|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]
223557880|NCT04952753|DRUG|FOLFIRI|5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]
223738200|NCT01857232|DRUG|Dexamethasone|Corticosteroid
223738201|NCT01857232|DRUG|Fosaprepitant|NK1 antagonist
223738202|NCT01857232|DRUG|APD403 IV|Amisulpride IV 20 mg
223738203|NCT01857232|DRUG|APD403 oral|Amisulpride oral 10, 20 or 40 mg
223738204|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
223557881|NCT04952753|DRUG|Tislelizumab|Investigational drug tislelizumab will be administered intravenously (IV).
224133155|NCT06065267|DRUG|sequential|amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
223408197|NCT01418378|DEVICE|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
223408198|NCT01659827|OTHER|Marcaine|Injection of 2cc of Marcaine
223557882|NCT06169943|OTHER|mHealth social support program|This is a 3-month program comprises mobile app, group discussion, individual telephone contact, and reminders.
223557883|NCT06169943|OTHER|Control|The same mobile app as the intervention group but with limited function.
223557884|NCT01242839|DEVICE|CACICOL20|CACICOL20 is a solution of dextran \& poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
223557885|NCT01242839|DEVICE|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
223557886|NCT04952597|DRUG|Ociperlimab|Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle
223557887|NCT04952597|DRUG|Tislelizumab|Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle
223738205|NCT01316120|OTHER|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
223738206|NCT00243581|BEHAVIORAL|Dean Ornish Heart Disease Reversing Program|
223738207|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed QD
223738208|NCT01190878|DRUG|ISV-303|0.075% of bromfenac in DuraSite dosed BID
223738209|NCT01190878|DRUG|DuraSite Vehicle|Vehicle dosed BID
223738210|NCT01190878|DRUG|Xibrom™|0.09% bromfenac dosed BID
224133156|NCT06065267|DRUG|Levofloxacin 500Mg Oral Tablet|Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
224133157|NCT00924976|BEHAVIORAL|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
224297924|NCT00804817|BEHAVIORAL|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
223408199|NCT01659827|OTHER|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
223408200|NCT01659827|OTHER|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
223408201|NCT01659827|OTHER|Saline|Injection of 1.25cc of Saline
223738211|NCT03352206|DRUG|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
224133158|NCT03738566|DEVICE|Esophageal self-dilation therapy|Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.
224133159|NCT03738566|PROCEDURE|Endoscopic therapy with esophageal dilation|A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
223408202|NCT03538730|BEHAVIORAL|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
223408203|NCT03866681|DRUG|sirolimus|The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
223408204|NCT02838823|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
223408205|NCT01641458|OTHER|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G\>A, c.1679T\>G, HapB3/c.1129-5923C\>G and c.2846A\>T).
223408206|NCT01641458|OTHER|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
223408207|NCT05020158|OTHER|Family Talk Intervention|A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
223408208|NCT00722358|DRUG|BMS-650032|"Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg"
223408209|NCT00722358|DRUG|Placebo|"Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo"
223408210|NCT01790984|OTHER|High sugar low starch diet|
223408211|NCT01790984|OTHER|Low sugar high starch diet|
223408212|NCT02597504|OTHER|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
223408213|NCT02597504|DEVICE|Quick Test|Quick Test, computerized test will be administered to all subjects.
223408214|NCT04303689|DRUG|Colchicine Tablets|patients with essential hypertension are randomized to receive either 3 weeks of colchicine
223408215|NCT04303689|DRUG|Placebo|patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
223408216|NCT00383760|DRUG|eribulin mesylate|Given IV
223408217|NCT00004872|BIOLOGICAL|recombinant human endostatin|
223408218|NCT03839004|BEHAVIORAL|Integrated approach to pregnancy|Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
223408219|NCT04021030|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention consists of 8, one-hour individual therapy sessions delivered over the course of 2 to 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.
223408220|NCT05519930|OTHER|hereditary high risk pancreatic cancer|Data collection trial for hereditary high risk pancreatic cancer patients.
223408221|NCT02711696|BEHAVIORAL|GCED, Gluten Contamination Elimination Diet|"A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED)."
223408222|NCT01063738|DIETARY_SUPPLEMENT|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
223408223|NCT01063738|OTHER|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
223408224|NCT01063738|OTHER|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
223408225|NCT01063738|DIETARY_SUPPLEMENT|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
223408226|NCT05522998|DRUG|Ciprofol|Ciprofol (0.4-0.5mg/kg) for anesthesia induction
223408227|NCT05522998|DRUG|Propofol|propofol(2-2.5mg/kg) for anesthesia induction
223408228|NCT06134310|PROCEDURE|Fascial Distortion Model|The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
223738212|NCT03352206|DRUG|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
223408229|NCT06134310|PROCEDURE|Core Stabilization Training|Week 1st (1 x 10 reps): Supine deep cervical activation, supine deep lumbar activation, prone deep cervical activation, prone deep lumbar activation, supine combined deep cervical and lumbar activation, and prone combined deep cervical and lumbar activation; Week 2nd (1 x 10 reps): Arm openings, hundreds 1, one leg stretch 1, double leg stretch 1, shoulder bridge, breaststroke, leg pull prone prep 1; Week 3rd (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 2, shoulder bridge, breaststroke, leg pull prone prep 2; Week 4th (1 x 10 reps): Arm openings, hundreds 2, one leg stretch 2, double leg stretch 3, shoulder bridge, breaststroke, leg pull prone prep 2; Week 5th to 8th (with Resistance Band; 1 x 10 reps): Arm openings, shoulder bridge, swan dive, scapula isolations, plough, biceps curl, roll up, roll up with biceps, roll up with rowing, seated spine twist, swimming in kneeling, one leg kick in kneeling and diamond press in standing
223408230|NCT06134310|PROCEDURE|Rocabado's 6x6 Exercises|Resting position of the tongue, rotational control of temporomandibular joint, rhythmic stabilization, axial extension of the neck, shoulder posture, and stabilized head flexion
223408231|NCT06134310|BEHAVIORAL|Patient Education|Participants are instructed to perform some behaviors while avoiding others based on the etiology of temporomandibular disorders.
223408232|NCT04757025|DEVICE|Electrical Impedance Tomography|In 27 patients ventilation will be guided with an Electrical Impedance Tomography system
223738213|NCT01122836|OTHER|Massage|Therapeutic Massage
223738214|NCT05918692|DRUG|BMF-500|Investigational Product
223738215|NCT00989014|DRUG|CD07805/47|0.5% Topical Gel
223738216|NCT00989014|DRUG|CD07805/47|0.18% Topical Gel
223738217|NCT00989014|DRUG|CD07805/47|0.07% Topical Gel
224024570|NCT04832659|BEHAVIORAL|CEASE + BIO|Children randomized to the CEASE + BIO group will have leftover blood from an already collected blood sample that was taken for a clinically indicated blood draw analyzed for cotinine. Parents of children in the CEASE +BIO group will receive a report of biomarker results followed by proactive outreach from a BIO counselor. The BIO counselor will explain the laboratory results and refer all parents in the household who smoke to tobacco treatment through the parent's primary care provider and/or the state quitline. The BIO counselor will troubleshoot any barriers to obtaining nicotine replacement therapy that may have been prescribed as part of the CEASE protocol and will promote strict smoke-free and vape-free home and car policies. BIO counselors will conduct a maximum of 6 calls per enrolled smoker.
224133160|NCT05525767|DRUG|Bevacizumab|All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
223408233|NCT04757025|DEVICE|Peripheral arterial Saturation|The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
223408234|NCT02829320|DRUG|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
223408235|NCT02829320|DRUG|Iron|Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
223408236|NCT01051791|DRUG|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
223557888|NCT04952597|DRUG|Concurrent Chemoradiotherapy|"Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles.~Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles~Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)"
223557889|NCT04077671|BIOLOGICAL|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
223557890|NCT01265563|DRUG|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
223557891|NCT01265563|DRUG|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
223557892|NCT01265563|DRUG|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
223738218|NCT00989014|DRUG|CD07805/47 placebo|Vehicle Topical Gel
224133161|NCT03323918|OTHER|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
223408237|NCT01691560|DRUG|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
223557893|NCT01265563|DRUG|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
223738219|NCT00120770|DRUG|Cellulose Sulfate Vaginal Gel (Microbicide)|
223738220|NCT01949168|DRUG|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
224133162|NCT03323918|OTHER|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
224133163|NCT00218036|DRUG|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
223557894|NCT01265563|DRUG|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
223557895|NCT00167141|DRUG|injection of hormonal male contraceptive|testosterone injections 4 times
223557896|NCT05563311|OTHER|Exercise on High-intensity interval training|3 times a week, for 8 weeks
223738221|NCT01949168|DRUG|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
223738222|NCT01949168|DRUG|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
224024571|NCT04493138|DRUG|Azacitidine|Given SC or IV
224024572|NCT04493138|DRUG|Quizartinib|Given PO
224024573|NCT06436027|DIAGNOSTIC_TEST|Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling|Targeted molecular profiling will be performed on formalin-fixed paraffin-embedded (FFPE) endomyocardial biopsies using the NanoString nCounter technology. A consortium-approved consensual targeted panel including 770 genes, developed by the Banff Molecular Diagnostics Working Group (MDWG) will be used.
223408238|NCT01691560|DRUG|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
224133164|NCT00218036|DRUG|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
223408239|NCT01691560|DRUG|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
223408240|NCT01691560|DRUG|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
223408241|NCT01588769|BIOLOGICAL|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
223408242|NCT01789112|OTHER|Blood sample|Taking of blood sample
223408243|NCT01292512|OTHER|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
223408244|NCT02752243|DRUG|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
223408245|NCT05390333|BEHAVIORAL|Self-Care Sampler for Family Carer Partners|The 6-week Self-Care Sampler for Family Caregivers program was created to provide a variety of evidence-based self-care practices that improve the mental and physical health of caregivers by relieving stress. Sessions will take place once a week for 90 minutes, each starting with a centering exercise and focusing on a new form of self-care. The first 30 minutes will be used for a support group and the last 60 minutes will be for a self-care practice. Self-care practices that will be offered throughout the 6 weeks include mindfulness, mindful drawing, exercise, and health prevention and promotion.
223408246|NCT02569970|DRUG|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
223408247|NCT02569970|DRUG|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
223408248|NCT00114075|PROCEDURE|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
223408249|NCT00114075|PROCEDURE|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
223557897|NCT05731817|OTHER|Observational study|N/A - observational study.
223557898|NCT06393270|DIAGNOSTIC_TEST|Modified US Public Health Service (USPHS) criteria|Dental caries classification system
223557899|NCT05358522|OTHER|Opioid Prescribing Report Cards|"Initial comparison: Clinicians will receive an initial peer comparison feedback report by email in which their post-operative opioid prescribing for patients undergoing their top 3 procedures is compared to the guideline recommended doses and the mean prescribing doses by other University of Pennsylvania Health System (UPHS) prescribers for each of those 3 procedures since the start of the baseline period.~Furthermore, in an attached report, for each of the 3 procedures, the mean patient reported ability to manage pain one week at home after the procedure will be displayed for those who received guideline compliant dosages of opioids relative to those who received higher than guideline recommended amounts.~Monthly comparison: On a monthly basis clinicians will get a report providing similar peer comparison feedback as above but with a monthly trend line of their performance since the start of the intervention."
223557900|NCT04998318|DEVICE|Pocket Colposcope|Both arms will receive treatment in order to prevent cervical cancer. However, the intervention using the pocket colposcope device will be used on half the enrolled subjects.
223557901|NCT04998318|PROCEDURE|Standard of Care Colposcopy|VIA and VILI as previously described,
223557902|NCT05402163|DEVICE|Adaptive DBS|aDBS vs cDBS
223557903|NCT05402163|DEVICE|Continuous DBS|aDBS vs cDBS
223557904|NCT03515135|BEHAVIORAL|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
223557905|NCT03102047|DRUG|durvalumab|Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
223557906|NCT01885884|BEHAVIORAL|Embedded Supportive Care|
223557907|NCT06302426|DRUG|INI-4001|INI-4001 is a small molecule TLR7/8 agonist being developed as a standalone treatment for the induction of anti-tumour immune responses and sensitization to immune checkpoint inhibitor (ICI) therapy.
223557908|NCT06302426|COMBINATION_PRODUCT|Nivolumab|During both Phase Ia and Phase Ib, patients may meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) may transition to combination therapy.
223557909|NCT06302426|COMBINATION_PRODUCT|Pembrolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
223557910|NCT06302426|COMBINATION_PRODUCT|Cemiplimab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
223557911|NCT06302426|COMBINATION_PRODUCT|Avelumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
223557912|NCT06302426|COMBINATION_PRODUCT|Atezolizumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
224133165|NCT00218036|DRUG|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
223408250|NCT01081769|DRUG|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
223408251|NCT01081769|DRUG|oral antipsychotics|daily treatment according to local label for maximally 24 months
223408252|NCT01733940|DEVICE|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
223408253|NCT01733940|DEVICE|Application of a dressing without clorhexidine gluconate|
223408254|NCT03230058|DRUG|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
223408255|NCT06131814|OTHER|2 groups|up 5 times repetition twice a week in first 4 week and then progress to 10 times repetition twice a week from 5-8th week of session
223408256|NCT00507455|DRUG|solifenacin succinate|Solifenacin succinate tablets
223408257|NCT00507455|DRUG|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
223408258|NCT00507455|DRUG|Placebo to solifenacin|
223408259|NCT00507455|DRUG|Placebo to tamsulosin|
223408260|NCT01633723|DRUG|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
223408261|NCT01633723|DRUG|Placebo of DA-6886|DA-6886 placebo
223408262|NCT00090714|GENETIC|pVGI.1(VEGF2)|
223738223|NCT01847157|DEVICE|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
223408263|NCT01509313|DEVICE|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
223408264|NCT01509313|DEVICE|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
223408265|NCT04303806|DRUG|rosuvastatin|receive rosuvastatin orally once daily.
223408266|NCT05109533|OTHER|Lactobacillus rhamnosus BMX 54, Lactobacillus reuteri RC-14, Lactobacillus rhamnosus GR-1|Probiotics implementation
223557913|NCT06302426|COMBINATION_PRODUCT|Durvalumab|During both Phase Ia and Phase Ib, patients meeting required criteria (at the discretion of the PI in consultation with the study Sponsor) transition to combination therapy.
223557914|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|25 μg p.o.
223557915|NCT05883540|DRUG|Lysergic Acid Diethylamide Tartrate|100 or 200 μg p.o.
223408267|NCT04440215|OTHER|Telerehabilitation and team meetings and team care plans|A mix of home or rehabilitation center visits and telerehabilitation will be planned by the rehabilitation team for a maximum of 16 weeks. Moreover, for each participant enrolled, a multidisciplinary meeting will be organised. The patient/family will participate in the meeting and the decision making process using the telerehabilitation platform. The team will generate an interprofessional individualized treatment plan, aiming for an interprofessional shared decision making process.
223408268|NCT04440215|OTHER|Usual care|Rehabilitation teams will be instructed to provide care as they have been doing previously. Currently, this translates into no telerehabilitation, and interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals.
223408269|NCT03803007|DRUG|Intravenous ACT017 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
223557916|NCT04277325|BEHAVIORAL|Emotionally Focused Therapy|Emotionally Focused Couples Therapy (EFT) is an empirically supported, attachment-based model of couples therapy that combines experiential, systems, and attachment theories with the goal of fostering the development of safe contact, accessibility, and responsiveness in both partners.
223557917|NCT04908865|DRUG|Belimumab|Belimumab will be administered.
223557918|NCT04908865|DRUG|Standard therapy|Standard therapy will be continued.
223557919|NCT06127836|PROCEDURE|ICG guided sentinel lymph node biopsy|The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.
223557920|NCT03764566|BEHAVIORAL|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
223557921|NCT05318469|DRUG|Ivermectin|Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
223557922|NCT05318469|DRUG|Balstilmab|Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
223408270|NCT03803007|OTHER|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
223408271|NCT00501410|DRUG|5-FU|2400 mg/m\^2 by vein over 46 Hours On Days 1 \& 2.
223408272|NCT00501410|DRUG|Cetuximab|Initial Dose = 400 mg/m\^2 by vein, then 250 mg/m\^2 Weekly On Days 1 \& 8
223408273|NCT00501410|DRUG|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
223408274|NCT00501410|DRUG|Leucovorin|400 mg/m\^2 by vein on day 1.
223557923|NCT05318469|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle
224133166|NCT00218036|DRUG|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
224133167|NCT00218036|DRUG|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
223408275|NCT00501410|DRUG|Oxaliplatin|85 mg/m\^2 by vein on day 1.
223408276|NCT01737710|BIOLOGICAL|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
223408277|NCT01737710|BIOLOGICAL|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
223408278|NCT01360242|PROCEDURE|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
223408279|NCT01360242|PROCEDURE|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
223408280|NCT04120649|PROCEDURE|hysterectomy|total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
223408281|NCT03178188|DEVICE|Pulsed-dye Laser|595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval
223408282|NCT03178188|DEVICE|Sham|Cryogen spray with the setting of dynamic cooling device 30/20
223408283|NCT04160234|OTHER|web-based questionnaires|Patients will be asked to complete web-based questionnaires on a tablet computer
223408284|NCT03945955|DIETARY_SUPPLEMENT|Melatonin|Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
223408285|NCT03945955|OTHER|Placebo|Placebo
223408286|NCT04707677|DEVICE|Titanium and ceramic dental Implants|Two types of implant placement and follow-up to compare the esthetic, clinical and radiographic parameters between them.
223408287|NCT05347576|DRUG|CKD-393(2)|QD, PO
223408288|NCT05347576|DRUG|CKD-501, D759, D150, D029|QD, PO
223408289|NCT03363776|BIOLOGICAL|BMS-986277|Specified dose on specified days
223408290|NCT03363776|BIOLOGICAL|Nivolumab|Specified dose on specified days
223408291|NCT00968643|RADIATION|radiation therapy|Given in multiple fractions or as a single fraction
223408292|NCT06352008|DRUG|Anlotinib|12mg once a day, taken orally before breakfast for 2 consecutive weeks and stopped for 1 week. Without special circumstances, it is recommended to take at a fixed time every day; If there is a missing dose during the administration, confirm that the time before the next administration is less than 12 hours, no more refilling. The maximum duration of drug use is tentatively 1 year.
223408293|NCT04974996|DRUG|Loncastuximab tesirine|Intravenous (IV) infusion
223557924|NCT01380197|DRUG|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
223557925|NCT01380197|DRUG|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
223557926|NCT02141399|DRUG|ALKS 5461|Sublingual tablet, taken daily
223557927|NCT01003236|DRUG|placebo|140 mg placebo tablets, 3 times per day for 3 months
223557928|NCT01003236|DRUG|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
223408294|NCT04974996|DRUG|Prednisone|Orally via tablet or capsule
223408295|NCT04974996|DRUG|Rituximab|Intravenous (IV) infusion
223557929|NCT01632475|BIOLOGICAL|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
223557930|NCT05730335|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
223557931|NCT03260374|DEVICE|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
223557932|NCT03260374|DEVICE|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
223557933|NCT03260374|DEVICE|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
223557934|NCT06640517|DRUG|Netakimab|netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks
223557935|NCT06640517|DRUG|Placebo|placebo will be administered subcutaneously at a scheme masking netakimab treatment
223557936|NCT06640517|DRUG|Adalimumab|adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks
223557937|NCT03926741|DRUG|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
223557938|NCT01296711|BIOLOGICAL|CDP6038 (olokizumab)|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
223408296|NCT04974996|DRUG|Cyclophosphamide|Intravenous (IV) infusion
223408297|NCT04974996|DRUG|Doxorubicin|Intravenous (IV) infusion
223408298|NCT04974996|DRUG|Vincristine|Intravenous (IV) infusion
223408299|NCT03157271|OTHER|Intramuscular Dry Needling|Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.
223408300|NCT00861393|BEHAVIORAL|CBT|12 Session CBT group
223408301|NCT00861393|BEHAVIORAL|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
223408302|NCT00926471|BEHAVIORAL|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
223408303|NCT01875757|DRUG|Vitamin D3|
223408304|NCT01875757|DRUG|Placebo|
223738224|NCT01847157|DRUG|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
223738225|NCT01847157|DRUG|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
223738226|NCT01847157|OTHER|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
224133168|NCT06282900|OTHER|University students|A cross-sectional study (Level IV evidence) will be conducted at the university (Acibadem University, Turkey). All students at the university will be invited to respond to a self-administered online survey. The survey will be prepared via Google Forms.
224133169|NCT03029416|RADIATION|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
223408305|NCT06253364|DRUG|PD-1 monoclonal antibody and lenvatinib|"Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months."
223408306|NCT03124589|BEHAVIORAL|Online Gambling Internet Intervention|CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
223408307|NCT05865496|DRUG|611|611 subcutaneous (SC) injection.
223408308|NCT05865496|DRUG|Placebo|Placebo subcutaneous (SC) injection.
223408309|NCT05047705|BEHAVIORAL|Distress Tolerance Skills Training|Individuals with TS will receive distress tolerance skill training. Therapeutic skill training will consist of 4 weekly 1-hour sessions. Skill training will occur either in-person or remotely via videoconferencing software. Sessions will focus on building participants' distress tolerance skills with strategies drawn from third-wave CBT.
223408310|NCT03383640|OTHER|Active exercises|Active flexion movements every waking hour of the replanted digits
223408311|NCT03356639|DRUG|ASP6981|Oral
223557939|NCT06264089|PROCEDURE|Preservation Rhinoplasty Nasal Valve Angle and Area|The same group of patients who underwent Preservation Rhinoplasty will be followed and the nasal valve angles before and after surgery will be compared.
223557940|NCT06157632|PROCEDURE|Thyriodectomy|Thyroidectomy
223557941|NCT00949923|DIETARY_SUPPLEMENT|tea capsule|3 tea capsules daily for 3 weeks
223557942|NCT03468751|DRUG|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
223557943|NCT00883168|DRUG|Placebo|Placebo
223408312|NCT03356639|DRUG|Placebo|Oral
223408313|NCT02737969|DEVICE|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
223408314|NCT00663390|DRUG|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
223408315|NCT01632293|BEHAVIORAL|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
223408316|NCT03543748|DEVICE|Transcranial Magnetic Stimulation|A total of 2000 trains will be delivered successively. The pulses will be delivered at 80% of motor thresholds.
223557944|NCT00883168|DRUG|azelastineHcl|azelastine hydrochloride 548 mg
223557945|NCT00883168|DRUG|fluticasone propionate|fluticasone propionate 200 mcg
223557946|NCT00883168|DRUG|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
223557947|NCT00262886|BIOLOGICAL|anti-thymocyte globulin|
223557948|NCT00262886|BIOLOGICAL|graft-versus-tumor induction therapy|
223557949|NCT00262886|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223557950|NCT00262886|DRUG|cyclophosphamide|
223557951|NCT00262886|DRUG|fludarabine phosphate|
223557952|NCT00262886|DRUG|mycophenolate mofetil|
223408317|NCT03543748|DEVICE|Sham Transcranial Magnetic Stimulation|The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
223408318|NCT03416205|DEVICE|Erbao electric knife|Erbao electric knife is used to cut the Duodenal sphincter
223408319|NCT03416205|DEVICE|Three-cavity incision knife|Three-cavity incision knife is used to cut the Duodenal sphincter
223408320|NCT03416205|DEVICE|Columnar expansion balloon|Columnar expansion balloon is used to expand the the Duodenal sphincter
223408321|NCT02484846|BEHAVIORAL|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
223408322|NCT05928507|DIAGNOSTIC_TEST|Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections|"The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.~Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information."
223557953|NCT00262886|DRUG|tacrolimus|
223557954|NCT00262886|PROCEDURE|allogeneic bone marrow transplantation|
223557955|NCT00262886|PROCEDURE|peripheral blood stem cell transplantation|
223557956|NCT05047029|PROCEDURE|Transjugular intrahepatic portosystemic shunt implantation|Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)
223557957|NCT05047029|DIAGNOSTIC_TEST|Magnetic resonance imaging|Multiparametric cardiac and hepatic magnetic resonance imaging
223557958|NCT02078180|DRUG|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
223557959|NCT02022761|DRUG|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
223557960|NCT00946764|DRUG|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
223557961|NCT00946764|DRUG|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
223557962|NCT00182052|DRUG|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
223557963|NCT00182052|OTHER|Placebo|Given orally twice daily.
223557964|NCT03704480|DRUG|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
223557965|NCT03704480|DRUG|Tremelimumab|300mg by IV infusion on D1 at cycle 1 only
223557966|NCT06125236|OTHER|Visit at D90|Visits at 90±7 days after stroke onset were conducted by trained and blinded investigators, with face-to-face, telephone call or Internet access.
223557967|NCT01202019|OTHER|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
223557968|NCT00849355|DRUG|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
224133170|NCT01606592|BEHAVIORAL|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
223557969|NCT03926923|OTHER|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
223408323|NCT06261307|BEHAVIORAL|Music intervention|Group intervention focusing on musical activities
223408324|NCT06261307|BEHAVIORAL|Circus intervention|Group intervention focusing on acrobatics and circus activities
223557970|NCT05411822|DEVICE|Lighting Intervention Blue light|Custom made lighting fixture that will deliver the blue lighting intervention. Blue light (λmax = 451 nm) on axis and off axis.
223557971|NCT05411822|DEVICE|Lighting Intervention Green light|Custom made lighting fixture that will deliver the green lighting intervention. Green light (λmax = 522 nm) on and off axis
223557972|NCT05411822|OTHER|Dim-light control condition|(\< 5 lux at the eye) for 30 min
223557973|NCT03352141|DEVICE|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
223557974|NCT04715568|DRUG|Losartan|50 mg tablets taken orally
223557975|NCT04715568|DRUG|Placebo|Tablets taken orally
223557976|NCT06212063|BEHAVIORAL|Cadet Health|Integrated physical and mental optimization training program used as tool for young individuals readying themselves to join the military
223557977|NCT01864148|DRUG|BIIB033|
223557978|NCT01864148|OTHER|Placebo|
223557979|NCT01864148|DRUG|Avonex|
223557980|NCT05657080|DEVICE|Cytosponge-TFF3|Cytosponge is a less invasive procedure than endoscopy and consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Five minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter can be retrieved by pulling on the string. Upon retrieval the Cytosponge scrapes against the surface of the top of the stomach and oesophagus and collect epithelial cells. The Cytosponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests. Trefoil Factor 3 (TFF3) is a protein that is expressed in intestinal type epithelia of the gastrointestinal tract. TFF3 is the best biomarker, which can be coupled to the Cytosponge to diagnose intestinal metaplasia.
223557981|NCT06516146|BEHAVIORAL|Exercise|The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months
223408325|NCT01257334|DRUG|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
223408326|NCT02312323|DEVICE|Definitive 65 HPT contact lenses|
224024574|NCT06391502|BEHAVIORAL|Multi-component Exercise Intervention Program|"The Vivifrail program (http://vivifrail.com) is a home-based exercise program that focuses on personalized multi-component exercise prescriptions based on an elderly person's functional abilities, including resistance/strength, balance, flexibility, and cardiovascular endurance exercise (i.e., walking).~During hospitalization, patients who meet the criteria of sodium intake will be screened, and then divided into groups according to the method of randomized controlled trial. The experimental group will carry out corresponding exercise plan according to the results of SPPB."
223408327|NCT02312323|DEVICE|Definitive 65 contact lenses|
223408328|NCT02405546|OTHER|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
224024575|NCT04436939|DEVICE|Dental implant|Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
224024576|NCT05334745|OTHER|Alvogyl|application of Alvogyl in the palatal wound with stent versus hyaluronic acid application
224024577|NCT00259584|BEHAVIORAL|Management and Outcome of SVCO|
224024578|NCT03916289|OTHER|No intervention would be taken|No intervention would be taken. Patients enrolled would be managed by this tiered diagnosis and treatment system and receive standard treatment according to clinical guidelines of osteoporosis.
224133171|NCT01606592|BEHAVIORAL|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
223408329|NCT02405546|OTHER|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
223408330|NCT00410813|DRUG|dasatinib|given orally
223408331|NCT00271063|DRUG|Liposomal Annamycin|3-day IV infusion
223408332|NCT03474185|BEHAVIORAL|Taking Charge of your Heart Health patient education classes|"Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management"
223408333|NCT06575023|PROCEDURE|Tamponade of lower uterine segment in management of placenta accreta spectrum cases|To compare the efficacy of lower uterine tamponade and partial lower myometrial resection in the management of intraoperative bleeding in cases with placenta accreta spectrum
223408334|NCT06575023|PROCEDURE|partial myometrial resection of lower uterine segment in management of placenta accreta spectrum cases|tamponade vs partial myomertial resection of lower uterine segment in managment of placenta accreta spectrum cases
223408335|NCT04657588|DEVICE|Navina anal insert|The Navina anal device is a single-use, pre-lubricated, liquid-filled rectal insert with a plastic applicator. The insert is filled with liquid mineral oil. The primary advantage of this new instrument is the fact that the liquid-filled insert will move and adapt as the fluid is transferred throughout the device making it easy to insert/remove and comfortable to wear. The design is intended to adjust to the contours of the individual anatomy to prevent leakage.
223408336|NCT04657588|OTHER|Care as usual|Care as usual means participants are to continue their usual treatment for FI, like they would if they would not have participated in this study.
223408337|NCT03600402|OTHER|Experimental|6 sessions of ankle manual therapy
223408338|NCT03600402|OTHER|Control|6 sessions of placebo intervention
223408339|NCT02533245|OTHER|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
223408340|NCT02533245|OTHER|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
223408341|NCT02533245|OTHER|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
223557982|NCT06516146|BEHAVIORAL|Meditation|"The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention."
223557983|NCT06516146|BEHAVIORAL|Diet|The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
223557984|NCT04728360|DRUG|BAT2206|45 mg/0.5 mL
223557985|NCT04728360|DRUG|Stelara (EU-sourced)|45 mg/0.5 mL
223557986|NCT01437579|PROCEDURE|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
223557987|NCT01437579|PROCEDURE|cystoscopy|cystoscopy under general anesthesia
223557988|NCT02798224|BEHAVIORAL|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
223557989|NCT02798224|BEHAVIORAL|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
223557990|NCT02027311|DRUG|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
223557991|NCT02027311|DRUG|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
223557992|NCT02027311|DRUG|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders \> 80 years old were administered 25mg iv bolus.
223557993|NCT06478316|PROCEDURE|Intracervical block|local injection of lidocain to the cervix
223557994|NCT05364970|COMBINATION_PRODUCT|VR_Training_1PP|Immersive VR scenario of physical training with avatar embodiment
223738227|NCT01847157|DEVICE|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
224024579|NCT00250679|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
224024580|NCT00250679|DRUG|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
224024581|NCT00250679|DRUG|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
224133172|NCT01606592|OTHER|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
224133173|NCT03126539|DRUG|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
223408342|NCT04237064|DIAGNOSTIC_TEST|Photoacoustic imaging|Photoacoustic imaging
223408343|NCT00812981|BIOLOGICAL|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
223557995|NCT05364970|COMBINATION_PRODUCT|VR_Training_3PP|Immersive VR scenario of physical training without avatar embodiment
223408344|NCT00812981|BIOLOGICAL|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
223557996|NCT01825512|DRUG|Deferiprone|Deferiprone 80 mg/mL oral solution
223557997|NCT01825512|DRUG|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
223557998|NCT06061263|OTHER|follow up|collecttion of clinicopathological data from a prespectively collected databse, including survival data.
223738228|NCT00969150|DRUG|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
223738229|NCT00969150|DRUG|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
223738230|NCT03059498|PROCEDURE|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
223738231|NCT03059498|PROCEDURE|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
223408345|NCT01391208|DRUG|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
223408346|NCT02758938|OTHER|Urologic biofeedback software|All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
223408347|NCT05349981|DEVICE|Phonak Lyric self-replacement procedure|The self-replacement procedure is an experimental procedure in which the Lyric user replaces the Lyric devices independently at every other device replacement, using dedicated candidacy, training, and management procedures, conducted by and at the discretion of his/her hearing care provider (HCP).
223408348|NCT02199795|DEVICE|Contralaterally Controlled Neuromuscular Electrical Stimulation|
223557999|NCT02466425|DRUG|SHP465|12.5mg and 25mg capsules (one capsule daily)
223558000|NCT02466425|DRUG|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
223558001|NCT04444986|DRUG|FAVIR 200 MG FT|FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.
223738232|NCT03059498|DRUG|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
223738233|NCT02525341|OTHER|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
224024582|NCT00250679|DRUG|Placebo|Placebo nebule or placebo aerolizer
224024583|NCT00187967|DEVICE|pumps used for cardiopulmonary bypass|
224024584|NCT06226818|OTHER|completion of scales and questionnaires|"Patient questionnaires Abuse assessment Screen, Evaluation of the PCL-5 score, Measurement of insomnia severity indexes (ISI), quality of life scores (WHOQOL-BREF), anxiety and depression using the HAD scale (Hospital Anxiety and Depression), self-esteem score using the Rosenberg scale, feeling of security and well-being using five-point Likert scales.~Questionnaire on daily and occasional smoking, alcohol consumption using the Alcohol Use Disorders Identification Test-Concise (AUDIT-C), cannabis dependence using the Cannabis Abuse Screening Test (CAST) and use of other psychoactive substances."
224024585|NCT01093521|DRUG|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
224024586|NCT01093521|DRUG|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
224133174|NCT03126539|RADIATION|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera ultraviolet B (UVB) light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
224133175|NCT03126539|PROCEDURE|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
224133176|NCT03864263|OTHER||
224133177|NCT03352414|DRUG|Alvimopan|alvimopan pill
223408349|NCT02199795|DEVICE|Cyclic Neuromuscular Electrical Stimulation|
223408350|NCT05088174|DRUG|Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule|"Drug:~Hetrombopag Olamine Tablet Ciclosporin Soft Capsule"
223408351|NCT04861350|OTHER|motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will mentally simulate each exercise with video 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
224024587|NCT03211910|DEVICE|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
224024588|NCT03211910|OTHER|Standard Care of Treatment|Standard Care of Treatment
224024589|NCT05337735|DRUG|XmAb20717|Given by vein (IV)
224024590|NCT00448279|DRUG|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
224024591|NCT00448279|DRUG|Chemotherapy|Schedule and dose at the investigator's discretion
224024592|NCT02179320|PROCEDURE|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
224024593|NCT02179320|DEVICE|acupuncture needle 0,25 x 40mm|
224024594|NCT02584582|DRUG|Liraglutide|
224024595|NCT02584582|DRUG|Exenatide|
224024596|NCT02584582|PROCEDURE|Liquid meal test|
224024597|NCT02584582|OTHER|No drug (Baseline day)|
223408352|NCT04861350|OTHER|physical training|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, the subjects will physically perform each exercise with supervision of investigator 10 times for a set, 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
223408353|NCT04861350|OTHER|combine physical training and motor imagery with action observation|Standing clamshell exercise with elastic band, sliding, and Romanian deadlift exercise will be instructed to the subjects with video, and they will practice each exercise for 3 times in physical to familiarize with the program. Then, each exercises will be mentally simulated with video for a set and physically performed with supervision of investigator for 2 sets, 10 times for each set and 3 sets totally. With 2 min interval between each sets, it will take approximately 8 minutes to finish each movement. It will also take 3 min for resting between each program.
223408354|NCT00182455|DRUG|Topiramate|25 - 400 mg/day x 12 weeks
223558002|NCT04444986|DRUG|AVIGAN 200 mg FT|AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
223558003|NCT04698564|DRUG|Hyperpolarized 13C-Pyruvate|"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."
224024598|NCT03907410|OTHER|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
224024599|NCT03907410|OTHER|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
224024600|NCT02985320|BIOLOGICAL|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
224024601|NCT02985320|BIOLOGICAL|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
224024602|NCT02985320|BIOLOGICAL|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
224024603|NCT02985320|BIOLOGICAL|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
223408355|NCT00182455|DRUG|Placebo|25 - 400 mg/day x 12 weeks
224024604|NCT02985320|BIOLOGICAL|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
224024605|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
224024606|NCT02985320|BIOLOGICAL|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
224024607|NCT02972866|DRUG|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
224024608|NCT01593306|DRUG|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
224024609|NCT01593306|DRUG|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
224024610|NCT06186570|BEHAVIORAL|Online-Based Self-Help Intervention|See the description above.
224024611|NCT02500849|GENETIC|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
224133178|NCT03352414|DRUG|Placebo|placebo pill
224133179|NCT02632110|DRUG|ALA|20% ALA applied to face prior to light treatment
224024612|NCT03718533|DRUG|Eltrombopag|Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration
224024613|NCT02116101|DIETARY_SUPPLEMENT|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
224024614|NCT02116101|DIETARY_SUPPLEMENT|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
224024615|NCT03728322|BIOLOGICAL|iHSCs treatment group|iHSCs intravenous injection
224024616|NCT02530203|DEVICE|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
224024617|NCT02530203|DEVICE|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
224024618|NCT00135759|DRUG|Naltrexone|low dose naltrexone in addition to daily methadone taper
224024619|NCT00135759|DRUG|Placebo comparator|1 capsule/day for 6 days
224024620|NCT00135759|DRUG|naltrexone|0.125 mg capsule/day for 6 days
224024621|NCT00135759|DRUG|naltrexone|0.250 mg capsule/day for 6 days
224024622|NCT04498455|DIETARY_SUPPLEMENT|Prebiotin|Fructo-oligosaccharide dietary supplement powder
224024623|NCT05922995|DRUG|Tasimelteon|20 mg capsules taken on a nightly basis
224024624|NCT00781287|DRUG|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
224024625|NCT00781287|DRUG|Raltegravir|400 mg BID PO
223558006|NCT00657137|DRUG|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
224024626|NCT05754333|DRUG|pudexacianinium chloride|Intravenous
224024627|NCT00549783|BIOLOGICAL|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
223558007|NCT00657137|DRUG|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
224024628|NCT00549783|BIOLOGICAL|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
224024629|NCT04574050|OTHER|SELF-BREATHE|A self -guided, internet -based intervention for patients with chronic breathlessness
223408356|NCT02488343|BEHAVIORAL|Behavioral Intervention|Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
223408357|NCT05121311|DIAGNOSTIC_TEST|NeoprediX B1 algorithm|Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm
223408358|NCT00279461|DRUG|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
223408359|NCT00279461|DRUG|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
223408360|NCT04408339|OTHER|No Intervention|No Intervention
223408361|NCT02541357|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
223408362|NCT02541357|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
223558008|NCT01760499|DRUG|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
224024630|NCT00728611|BIOLOGICAL|PRGF|intra auricular injection 6mg
224024631|NCT00728611|DRUG|hyaluronic acid|20 mg / 2 ml
223408363|NCT00468351|PROCEDURE|Intravitreal Injection of 1,5 mg of bevacizumab|
223558009|NCT01760499|PROCEDURE|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
223558010|NCT02414945|DRUG|Cyclophosphamide|
223558011|NCT02414945|DRUG|Fludarabine|
223558012|NCT02414945|BIOLOGICAL|Autologous tumor infiltrating lymphocytes (TILs)|
223558013|NCT02414945|BIOLOGICAL|Interleukin-2|
224024632|NCT00728611|DRUG|placebo|physiological water 3cc + lidocain 3cc
224024633|NCT02344563|DRUG|Meropem|
224024634|NCT02344563|DRUG|Mepem|
224133180|NCT02632110|DRUG|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
223408364|NCT00468351|PROCEDURE|Intravitreal injection of 4 mg of Triamcinolone acetonide|
223408365|NCT01707966|DRUG|Orteronel|
223408366|NCT01707966|DRUG|Placebo|
223408367|NCT02818946|DEVICE|MRI|Detection of cancer by MRI for pathologic nipple discharge
223408368|NCT02932774|DRUG|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
223408369|NCT02932774|DRUG|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
223408370|NCT02932774|OTHER|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
223408371|NCT05748743|PROCEDURE|glove changing|Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
223558014|NCT05068323|DIAGNOSTIC_TEST|Digital electroencephalography (EEG) for an hour (16 channels)|Digital electroencephalography (EEG) for an hour (16 channels)
223558015|NCT03456349|DRUG|HTL0018318|HTL0018318
223558016|NCT03456349|DRUG|Placebo|Placebo
223738234|NCT02525341|OTHER|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
223738235|NCT02525341|OTHER|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
224024635|NCT05293210|DRUG|Dexamethasone|"A daily dose of dexamethasone 20 mg intravenous for 3 days, followed by a daily dose of dexamethasone 6 mg intravenous or oral for 7 days.~Dexamethasone 6 mg orally or intravenously for 10 days (with the possibility of escalation to doses of 20 mg daily of oral or intravenous dexamethasone for 3 days if clinical criteria of respiratory distress develop despite treatment with doses of dexamethasone 6 mg daily)."
224024636|NCT00000301|DRUG|Amantadine|
224024637|NCT04984525|DRUG|SYNB1934|SYNB1934 is formulated as a nonsterile solution intended for oral administration
223738236|NCT02872467|DRUG|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
223738237|NCT02872467|OTHER|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
224024638|NCT04984525|DRUG|SYNB1618|SYNB1618 is formulated as a nonsterile solution intended for oral administration
224024639|NCT04942834|DRUG|Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone|Class I or III antiarrhythmic drug, including sotalol
224024640|NCT04942834|DEVICE|cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation using Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters (23mm and 28mm)
224024641|NCT00945126|OTHER|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
224024642|NCT03785171|PROCEDURE|surgical revascularization|Indirect revascularization procedure
224133181|NCT02632110|DEVICE|IBL 10 mW|10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds
224133182|NCT02632110|PROCEDURE|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
224133183|NCT02632110|DEVICE|IBL 20 mW|10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds
223408372|NCT03028207|PROCEDURE|Medical tests|During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
223408373|NCT03028207|OTHER|Questionnaire|During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
223408374|NCT04279431|DEVICE|EEG Recording|EEG recording acquired on BrainScope One device.
223408375|NCT04279431|OTHER|Neurocognitive Tests|Cognitive performance tests performed on BrainScope One device.
223408376|NCT04279431|OTHER|Clinician Evaluation|Clinician evaluation performed as part of standard of care at the clinical site.
223408377|NCT04279431|OTHER|22-item CSI|Self assessed 22-item Concussion Symptom Inventory (CSI).
223408378|NCT01268670|DRUG|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
223408379|NCT01268670|DRUG|Oxycodone|Subjects will receive topical LET and oral oxycodone.
223408380|NCT01268670|OTHER|Placebo|Subjects will receive topical LET and oral placebo.
223408381|NCT01791894|DRUG|arsenic trioxide|Given IV
223408382|NCT02699346|DEVICE|HS-1000 recording|
223408383|NCT02291042|DRUG|B+O Suppository|
223408384|NCT03146806|DRUG|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
223408385|NCT03678610|OTHER|Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A|Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
223558017|NCT05657938|DEVICE|Wearable Device|The wearable device used in this study is an FDA 510(k) cleared Class II medical device designed to collect medical grade, clinical quality biometric, physiological and other electronic clinician outcome assessments data in a clinical trial setting. The system processes raw data into recognizable clinical metrics including vital signs, activity and posture classifications, surface electromyography (sEMG), and sleep metrics. The sensors are multi-modal, multilocation, rechargeable and reusable.
223558018|NCT05657938|OTHER|Duchenne Video Assessment (DVA)|The DVA is a standardized tool that documents and assesses compensatory movement strategies as a marker of quality of movement.
223558019|NCT00435227|BIOLOGICAL|Motavizumab|A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
224024643|NCT00562705|BEHAVIORAL|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
224133184|NCT01266655|DRUG|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
224024644|NCT00562705|BEHAVIORAL|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
224024645|NCT02289612|OTHER|Yellow Mustard Gum Fibre|
224024646|NCT02289612|OTHER|Soluble Flaxseed Gum Fibre|
224024647|NCT02289612|OTHER|Fenugreek Gum Fibre|
224024648|NCT02744378|DRUG|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
224024649|NCT02744378|DRUG|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
224024650|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
224133185|NCT01266655|DRUG|Placebo|Placebo
224133186|NCT03699787|OTHER|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
224133187|NCT00846079|DEVICE|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
224133188|NCT03645408|DRUG|Exenatide|Subject received an injection of 5 mcg of immediate release exenatide.
224024651|NCT00520325|DRUG|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
224133189|NCT03645408|OTHER|Sham injection|Subjects received a sham injection with no study drug.
224133190|NCT04970771|BEHAVIORAL|Solving Wellness platform|Interactive wellness resources available include a wide range of curated content and resources including fitness and yoga classes, cooking classes, webinars on sleep and various mental health topics including resilience, stress management, relationships and mindfulness, and resources including e-books, videos and guided meditations. Online discussion groups will foster awareness for specific issues and allow casual discussion. A curated collection of links to additional resources including the Solving Healthcare podcast will also be provided.
224133191|NCT00516269|DRUG|Methylphenidate|18 mg by mouth daily for 2 weeks
224133192|NCT00516269|DRUG|Placebo|Capsule by mouth daily for 2 weeks
223408386|NCT01159041|BEHAVIORAL|Family Focused Treatment (FFT)|FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
223408387|NCT01159041|BEHAVIORAL|Individual Treatment (IP)|The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
223408388|NCT05399784|BEHAVIORAL|Early postpartum visit|The early postpartum visit will be an in-person visit with a medical provider at 14-21 days postpartum.
223408389|NCT05399784|BEHAVIORAL|Standard postpartum visit|The standard postpartum visit will occur at 35 to 56 days postpartum.
223408390|NCT05468905|OTHER|None of intervention|None of intervention
223408391|NCT00996125|BIOLOGICAL|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
223408392|NCT00996125|OTHER|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
223408393|NCT00922064|PROCEDURE|ECT|ECT series consisting of 6 to 14 ECTs
223558020|NCT00435227|OTHER|Placebo|A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.
223558021|NCT03231917|PROCEDURE|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
223558022|NCT03231917|PROCEDURE|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
223558023|NCT00664339|BIOLOGICAL|Flu Vaccine|Single dose of Flu vaccine by year (1)
224024652|NCT00000837|BIOLOGICAL|Varicella Virus Vaccine (Live)|
224024653|NCT00108654|DRUG|VRC-HIVADV014-00-VP|
224024654|NCT06402331|DRUG|FPI-2265|"Investigational treatment FPI2265 is a PSMA ligand radiolabelled with 225Ac.~Other Names:~225Ac-PSMA-I\&T"
224024655|NCT03085615|OTHER|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
224024656|NCT04754308|DIAGNOSTIC_TEST|Spirometry|The method of examination, Spirometry, is non-invasive (i.e. not an intervention that involves penetration into the body by means of incisions or injections.). It is a routine examination and there are no risks, adverse reactions, or discomforts associated with the examination.
224024657|NCT05109754|DEVICE|BiPAP EFL|Non-invasive ventilation using a novel ventilatory mode targeting expiratory flow limitation in COPD
224024658|NCT05629403|OTHER|observe|no intervention
224024659|NCT02825030|DRUG|Coppertone (BAY 987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation-SR15-78\_Y73-167).
224024660|NCT02570932|BIOLOGICAL|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
223408394|NCT03545685|OTHER|specific memory and attention realtime training|The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
223408395|NCT03279757|DRUG|AHES 5 minutes|Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
223408396|NCT03279757|DRUG|AHES 15 minutes|Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
223408397|NCT03279757|DRUG|AHES 25 minutes|Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
223408398|NCT03279757|DRUG|LTC 5 minutes|Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
224024661|NCT02905136|OTHER|Fundamental research|serum, whole blood, cerebrospinal fluid
224024662|NCT00833131|RADIATION|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
224024663|NCT00833131|RADIATION|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
224024664|NCT05159869|BEHAVIORAL|User-Led Meaningful Activity Plan|The User-Led Meaningful Activity Plan integrates persons with dementia as partners in the co-construction of an intervention involving personally meaningful activity. Activities are graded to correspond with disease progression. For example, (1) an individual who is/was a researcher may continue to maintain a job, conduct research, and even publish papers in the early stages of dementia. (2) As the dementia progresses, he or she may be able to continue to run analyses and read/access literature in his or her field. (3) In the moderate stages of dementia, this participant may read his or her existing publications or go to museums showcasing research of interest. As the disease approaches the severe stage, the participant may read very basic books about his or her former profession. (4) In the severe stages of dementia, this study participant may watch videos related to the former profession, e.g., British Broadcasting Corporation (BBC) or National Geographic.
224024665|NCT01358487|BEHAVIORAL|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
223408399|NCT03279757|DRUG|LTC 15 minutes|Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
223408400|NCT03279757|DRUG|LTC 25 minutes|Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
224133193|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
224133194|NCT00563004|DIETARY_SUPPLEMENT|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
224133195|NCT01907594|DRUG|D-cycloserine|
224133196|NCT01907594|DRUG|Nicotine Replacement Therapy (patch)|
224133197|NCT01907594|BEHAVIORAL|Smoking Cue Exposure|
224133198|NCT01907594|BEHAVIORAL|Progressive Muscle Relaxation|
224133199|NCT01907594|DRUG|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
224133200|NCT05067062|DIETARY_SUPPLEMENT|New Zealand blackcurrant extract|Capsules taken daily or intermittent
223408401|NCT03279757|DEVICE|fractional CO2 laser, 50 mJ, 5% density|Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
223408402|NCT04331067|DRUG|Paclitaxel|-Given standard of care
223408403|NCT04331067|DRUG|Carboplatin|-Given standard of care
223408404|NCT04331067|BIOLOGICAL|Nivolumab|-Given standard of care
223408405|NCT04331067|BIOLOGICAL|Cabiralizumab|-Will be provided by Bristol Myers Squibb
223408406|NCT04331067|PROCEDURE|Tumor biopsy|-Baseline, week 5, surgery, and at time of relapse (optional)
223408407|NCT04331067|PROCEDURE|Bone marrow|-Time of port placement (baseline), time of surgery, and time of recurrence (optional)
223408408|NCT04331067|PROCEDURE|Blood draw|-Baseline, week 5, prior to surgery , post-surgery follow-up (typically 3-4 weeks post-surgery), and disease progression (optional)
223408409|NCT02627664|OTHER|observational study|natural history of non dopaminergic signs
223558024|NCT00664339|OTHER|Conventional medical therapy for heart failure|According with the international guidelines
223558025|NCT05013346|OTHER|No intervention needed|No intervention required. Not a clinical trial
223558026|NCT06079281|DRUG|ALXN1850|ALXN1850 will be administered via subcutaneous (SC) injection.
223558027|NCT06079281|DRUG|Placebo|Placebo will be administered via SC injection.
224024666|NCT01358487|BEHAVIORAL|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
224024667|NCT05025046|DIAGNOSTIC_TEST|Thyroscan|To evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nudules with abnormal ultrasound features.
224133201|NCT05213468|DEVICE|PainDrainerTM|Self management digital tool for chronic pain
223408410|NCT01657721|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
223738238|NCT03352830|BEHAVIORAL|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
223738239|NCT03352830|OTHER|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
223408411|NCT02203721|DEVICE|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
223558028|NCT06026072|OTHER|CLAD-V SCORE|the CLAD-V score is measured by the doctor during the emergency take care. After 7 days the patient will be call back to compare the prediction of CLAD-V score and the reality of surgical intervention or no.
223558029|NCT00150215|DRUG|PF-00184562|
223738240|NCT01901198|BIOLOGICAL|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
224024668|NCT00669526|BEHAVIORAL|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
224024669|NCT00669526|BEHAVIORAL|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
224133202|NCT02786589|BIOLOGICAL|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
224133203|NCT01731301|DRUG|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
223408412|NCT02203721|DEVICE|TECNIS Monofocal IOL, Model ZCB00|
223408413|NCT02830503|PROCEDURE|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
223408414|NCT02189005|DIETARY_SUPPLEMENT|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
223408415|NCT02189005|DIETARY_SUPPLEMENT|Placebo|
223558030|NCT00150215|DRUG|Olanzapine|
223558031|NCT01721486|DRUG|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
223738241|NCT01901198|BIOLOGICAL|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
223738242|NCT02573857|DRUG|DSM265|Oral suspension from bulk powder
223738243|NCT02573857|DRUG|OZ439|Oral suspension from powder in a bottle
223738244|NCT05062681|DRUG|Dexamethasone|Patients will receive dexamethasone 8 mg q12hours
224024670|NCT00671944|OTHER|Low protein diet|Low protein diet for 6.5 weeks
224024671|NCT00006165|BEHAVIORAL|'Ohana (Family) Support Lifestyle Intervention|
224024672|NCT03465098|OTHER|Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT|The patients will receive 2 PET/CT , first exam with standard diet preceded by 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
224133204|NCT01731301|DRUG|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
224133205|NCT01731301|DRUG|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
223558032|NCT01721486|DRUG|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
223558033|NCT00582712|DRUG|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
223558034|NCT04211792|DEVICE|Icare Tonometer|Icare tonometers are a new class of rebound tonometers for IOP measurements. The Icare series of tonometers are hand-held tonometers, which are easy to operate and generally do not require topical anaesthesia for IOP measurements.
223558035|NCT04492748|COMBINATION_PRODUCT|Collagen and platelet rich plasma (PRP)|Ultrasound guided injections
223558036|NCT04492748|COMBINATION_PRODUCT|Collagen|Ultrasound guided injections
223558037|NCT04492748|COMBINATION_PRODUCT|Platelet rich plasma (PRP)|Ultrasound guided injections
223408416|NCT00243126|BEHAVIORAL|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
223408417|NCT04408170|DIAGNOSTIC_TEST|Point-of-care test for SARS-CoV-2|Throat and nose swabs and/or saliva samples and/or whole blood and/or finger stick samples may be taken to be tested on Point-of-care tests for SARS-CoV-2
223558038|NCT05052463|OTHER|electrolyte imbalance analysis|ın this retrospective study we aimed to evaluate the relationship between the ıcu prognosis and the electrolyte imbalance
223558039|NCT02173483|PROCEDURE|Quadriceps graft|
223558040|NCT00684710|DRUG|PAZ-417|
223558041|NCT00684710|DRUG|Placebo|
223558042|NCT01151384|DRUG|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
223558043|NCT03245411|BEHAVIORAL|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
223558044|NCT06129461|BEHAVIORAL|Single-session acceptance-based online workshop targeting food cravings as predictors of loss of control and binge eating in pregnancy|Participants in the intervention will learn acceptance-based strategies for reducing the adverse impact of food cravings on eating behaviors. Unlike control-based strategies, acceptance-based strategies do not attempt to change the content or frequency of thoughts; rather, they foster willingness to acknowledge and experience uncontrollable thoughts, urges, and emotions as what they are - nothing more, nothing less. Acceptance-based approaches have demonstrated efficacy in reducing the adverse impact of food cravings on eating behaviors in non-pregnant samples.
223558045|NCT05268692|DRUG|GS|drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
223558046|NCT05268692|DRUG|GnP|"drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.~nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle."
223558047|NCT02346227|DRUG|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
223558048|NCT02346227|DRUG|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
223558049|NCT06301776|DRUG|Ticagrelor|To compare the safety and efficacy of different DAPT duration combined with ticagrelor monotherapy.
223558050|NCT03708315|DRUG|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
223558051|NCT03708315|DRUG|Placebos|Placebo
223558052|NCT05064501|DIAGNOSTIC_TEST|spirometry|Lung function test: pre and post bronchodilator spirometry
223558053|NCT05064501|OTHER|Asthma control test|Asthma control test
223558054|NCT02688829|DEVICE|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
223558055|NCT05174546|DIAGNOSTIC_TEST|T2 magnetic resonance|Samples for assessment by the T2MR will be collected once daily in occasion of any consecutive febrile episode during neutropenia when blood cultures are ordered as per standard of care. T2 magnetic resonance will be run according to manufacturer's instructions
223558056|NCT02758600|OTHER|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
223558057|NCT03356353|DRUG|Sildenafil Citrate|20 mg tablets
223558058|NCT03496064|OTHER|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
223738245|NCT05062681|DRUG|Methylprednisolone|Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
223738246|NCT00999791|DRUG|Bevacizumab|
223408418|NCT06589219|DRUG|CMR316|CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort
223408419|NCT06589219|DRUG|Placebo|Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
223408420|NCT02972879|PROCEDURE|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
223408421|NCT02972879|PROCEDURE|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~* LASER 904nm~* P: 1.5W/cm²~* 30mV/cm²~* Area 2 cm²~* 1 Joule por ponto ( in the A1 pulley)"
223408422|NCT02972879|PROCEDURE|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
223558059|NCT00615693|DRUG|AEB071|
223558060|NCT01901289|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
223558061|NCT05970341|BEHAVIORAL|1. Welcome package|"At the end of the baseline data collection visit at the clinic, the Research Staff will hand the participant a welcome packet that includes:~* educational and motivational written materials (about such topics as CKD and healthy eating for early CKD stages)~* a collection of recipes featuring kidney-friendly vegetables"
223738247|NCT00999791|DRUG|Diclofenac|
224024673|NCT06156618|DIETARY_SUPPLEMENT|Nitrate|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of nitrate supplement on healthy control and people with dental erosion (PwDE). This study aims to explore the effect of nitrate supplement on oral microbiome in WMS and SP and its impact on blood pressure and arterial stiffness in healthy controls and PwDE.
224024674|NCT01853137|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
224024675|NCT04248231|OTHER|CINSARC signature|CINSARC molecular signature analysis
224024676|NCT00647725|PROCEDURE|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
224024677|NCT00647725|PROCEDURE|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
223408423|NCT02972879|PROCEDURE|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
223408424|NCT02441738|PROCEDURE|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
223408425|NCT02441738|PROCEDURE|Catheter Ablation|The procedure will be performed following standard of care guidelines.
223408426|NCT04749485|DRUG|HX008|Patients will receive HX008 3mg/kg by intravenous (IV) infusion on Day 1, every 3 weeks (Q3W), till progressed disease or withdrawal.
223408427|NCT05024188|DRUG|Antibiotics|Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
223408428|NCT05024188|OTHER|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation is the process of transferring stool from a healthy donor to another.
223408429|NCT05024188|OTHER|Cellules Pills|7 days of cellules placebo pills.
223408430|NCT05024188|OTHER|Agarose Capsules|Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
223408431|NCT05002231|DRUG|Losmapimod 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fasted conditions.
223408432|NCT05002231|DRUG|Losmapimod two 7.5 mg oral tablets|Subjects will receive two losmapimod 7.5 mg tablets by mouth under fasted conditions.
223558062|NCT05970341|BEHAVIORAL|2. Welcome information (phone or text)|"Those allocated to the intervention arm will receive a welcome call from the Program Staff to provide further details and expectations about the program (such as delivery details and schedule).~Those allocated to the control arm will receive an SMS text that informs them of their arm allocation, what to expect and a phone number to call for questions."
223558063|NCT05970341|BEHAVIORAL|3. Produce delivery + Recipes customized to produce|"* Content: Bags with kidney-friendly produce will include 2 vegetables sufficient for 2 meals for 4 people, 1 type of fruit, and 1 dried fruit. The total cost is estimated at USD 20, excluding delivery, for prices in June 2022.~* Delivery: Bags will be delivered to the participant's preferred location (e.g. home or work) and period of the day (e.g., morning, evening).~* Recipes: SMS texts will precede each delivery to share an URL to recipes customized to the items being delivered, and to inform of an upcoming produce bag, its content.~* Frequency:~  1. Weeks 1-2 (2 weeks): No bags delivered.~ 2. Weeks 3-10 (8 weeks): Delivered weekly, for a total of 8 bags.~ 3. Weeks 11-18 (8 weeks): Delivered every two weeks, for a total of 4 bags.~ 4. Weeks 19-26 (8 weeks): No bags delivered."
223558064|NCT05970341|BEHAVIORAL|4. E-gift cards to a grocery store of choice|"Five (5) e-gift cards to a major local grocery retailer chosen by the participant (from 3 options) at the following frequency:~1. Weeks 1-6: No e-gift card.~2. Week 7: One card of USD 30.00 value.~3. Week 11 \& 15: One card of USD 40.00, for a total of USD 80.00.~4. Week 19 \& 23: One card of USD 60.00, for a total of USD 120.00."
223738248|NCT05230225|BEHAVIORAL|Physician Notification Letter|Receiving the electronic Physician Notification Letter to highlight echocardiography results that are consistent with or may be consistent with severe AS and to be reminded of ACC/AHA Clinical Practice Guideline recommendations regarding the management of severe AS.
223738249|NCT00816231|BEHAVIORAL|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
224024678|NCT00257062|DRUG|Levofloxacin|
224024679|NCT04822831|BEHAVIORAL|45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The experimental group was given 45 degree Semi-sitting 2 hrs and upper-limb exercise training 10 mins once a day, and this intervention kept 4 weeks.
224024680|NCT04822831|BEHAVIORAL|no 45 Degree Semi-recumbent Position With Upper Limb Exercise Training|The control group was with usual treatment.
223408433|NCT05002231|DRUG|Losmapimod one 15 mg oral tablet|Subjects will receive one losmapimod 15 mg tablet by mouth under fed conditions.
223408434|NCT04178460|DRUG|Niraparib combined with MGD013|"The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation)."
223408435|NCT05392205|DIAGNOSTIC_TEST|18F-FDG|Each subject receives a single intravenous injection of 18F-FDG and 68Ga-FAP-2286, and undergo PET/CT imaging within the specified time. A part of participants will also undergo additional 68Ga-FAPI-46 PET/CT for comparison.
223408436|NCT02191774|PROCEDURE|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
223408437|NCT06576700|BIOLOGICAL|Grape Seed Extracts|2 capsules/day for 8 weeks
223408438|NCT02353546|BEHAVIORAL|CALM|
223408439|NCT05284318|DRUG|Antibiotics treatment|After receiving intravenous antibiotics treatment for 2 weeks, and clinician determines whether to continue with any antibiotics.
224024681|NCT01037244|DRUG|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
224024682|NCT01037244|DRUG|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
224024683|NCT04833699|OTHER|rubber water bag|bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
224024684|NCT03966807|BEHAVIORAL|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
224024685|NCT03966807|BEHAVIORAL|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
224024686|NCT04269330|PROCEDURE|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.|Comparison of normal and small size mesh in open inguinal hernia repair: Multicenter Prospective Randomized Controlled Trial.
223558065|NCT05970341|BEHAVIORAL|5. Personalized practical & emotional support through a dedicated health partner|"* Each participant is assigned a program staff (dedicated health partner) who call them briefly (15 min or so) over the phone for empathy-based support on the participant's health journey, and practical suggestions for shopping and food preparation.~* The Health Partner will share periodically via SMS text a curated list of evidence-based, trustworthy online educational resources.~* Health partners are not trained to answer medical or health-related questions and will not provide medical guidance or advice of any kind. For such questions, they will encourage participants to contact the clinic or physician.~* Frequency:~  1. Weeks 1-2 (2 weeks): No calls.~ 2. Weeks 3-7 (4 weeks): 2 calls a week, for a total of 8 calls.~ 3. Weeks 8-26 (18 weeks): 1 call every 2 weeks, for a total of 10. But during weeks 7, 11, and 19, participants will be given the choice to keep at 1x/week or decrease to 1x every 4 weeks."
223558066|NCT01813058|DRUG|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
223558067|NCT01813058|DRUG|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described."
223558068|NCT04493970|OTHER|High School Students Survey|To assess retention, effectiveness and factors impacting comprehension of cardiopulmonary resuscitation (CPR) training among high school students.
223558069|NCT05612893|OTHER|pathogen|"The patients were divided into groups according to the pathogen(bacteria or virus).~The influenza upper respiratory tract infection cohort will be grouped mainly according to age."
223558070|NCT00395486|DRUG|Rosuvastatin|10mg
223558071|NCT00395486|DRUG|Atorvastatin|10mg
223558072|NCT01145001|BEHAVIORAL|Cognitive Behavioural Therapy|Weekly CBT for all subjects
223558073|NCT01145001|BEHAVIORAL|Contingency Management|incentives given for abstinence based on urine analysis
223558074|NCT01145001|DRUG|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
223558075|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
223558076|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
223558077|NCT00713778|PROCEDURE|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
223558078|NCT05347680|DEVICE|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
223558079|NCT05347680|DEVICE|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
223558080|NCT00361231|DRUG|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
223558081|NCT00361231|DRUG|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
224024687|NCT03728556|BIOLOGICAL|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
223558082|NCT00361231|DRUG|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
223558083|NCT01668446|DRUG|Sildenafil|sildenafil tablets(50 mg) daily
223558084|NCT01668446|DRUG|estradiol valerat|
223558085|NCT04839068|DEVICE|covid 19 on pregnancy outcomes|covid 19 on pregnancy outcomes and sex ratio at birth
223558086|NCT03158740|BEHAVIORAL|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
223558087|NCT03158740|BEHAVIORAL|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
223558088|NCT03601065|OTHER|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
223558089|NCT01545791|DRUG|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
223558090|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
223558091|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
223558092|NCT01205932|DRUG|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
223558093|NCT01205932|DRUG|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
224024688|NCT03728556|BIOLOGICAL|CS1001 placebo|Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
223738250|NCT00816231|OTHER|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
223738251|NCT00816231|OTHER|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
224024689|NCT01207297|DRUG|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
224024690|NCT01207297|DRUG|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
224024691|NCT04141969|DIETARY_SUPPLEMENT|RLP|RLP nutraceutical
224024692|NCT04141969|OTHER|Placebo|Inert brown powder
223408440|NCT03355131|BEHAVIORAL|Adapted NASA's Mission X program|8 Weeks Adapted National Aeronautics and Space Administration's (NASA's) Mission X (MX) program
223408441|NCT02568293|OTHER|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
223408442|NCT02568293|OTHER|Saline|Saline is used as a control.
223408443|NCT00327873|OTHER|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
223408444|NCT00327873|OTHER|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
223408445|NCT05979012|BEHAVIORAL|MIndfulness Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.It is up to them if they want to listen to the daily recordings."
223408446|NCT05979012|BEHAVIORAL|Listening to Jazz|"All groups will complete a baseline and 4-week follow-up survey.~Participants in Jazz Group 1 and Jazz Group 2 will engage in daily listening 4-week intervention.They will have access to electronic audio recordings, with the order of listening labeled for each day. The recordings will increase gradually throughout the study, starting with about 10 minutes each day in the first week and reaching 30 minutes each day in the final week. The schedule is as follows: Week 1= 10 minutes, Week 2= 15 minutes, Week 3= 20 minutes Week 4= 30 minutes. It is up to them if they want to listen to the daily recordings."
223408447|NCT03692234|DIETARY_SUPPLEMENT|125 mg L-homoarginine|capsules for oral supplementation
223408448|NCT03692234|OTHER|placebo|capsules for oral supplementation
223408449|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; low dose
223408450|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; middle dose
223408451|NCT06672172|DRUG|HRS-7535 tablet|HRS-7535 tablet; high dose
223408452|NCT06672172|DRUG|HRS-7535 placebo tablet|HRS-7535 placebo tablet
223558094|NCT04736290|OTHER|NLR|Calculation of NLR
223558095|NCT04736290|OTHER|PLR|Calculation of PLR
223558096|NCT00800527|DRUG|Gabapentin|Gabapentin 800 mg one a day up to 30 day
223558097|NCT00800527|DRUG|Diclofenac|Diclofenac 75 mg one a day up to 30 day
223558098|NCT05555641|DRUG|Nafamostat Mesylate|ECMO patients were given continuous anticoagulation with nafamostat mesylate, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
223558099|NCT05555641|DRUG|Unfractionated Heparin|ECMO patients were given continuous anticoagulation with unfractionated heparin, coagulation function was monitored every 6 hours, and APTT was maintained at 1-1.75 times the upper limit of normal detection until reaching the study endpoints, including 14 days after enrollment, 24 hours after withdrawal from ECMO, or any switch to ECMO mode during ECMO treatment.
223558100|NCT01814397|DRUG|Anastrozole|1 mg orally daily
223558101|NCT01814397|DRUG|exemestane|25 mg orally daily
223558102|NCT01814397|DRUG|letrozole|2.5 mg orally daily
223558104|NCT00313144|DRUG|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
223558105|NCT06176794|DRUG|Immediate release torsemide 20mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
223558106|NCT06176794|DRUG|Extended release torsemide 24mg tablet|Subjects will receive approximately one week of daily immediate release 20mg torsemide (plus daily placebo of 24mg extended release torsemide) and one week of daily extended release 24mg torsemide (plus daily placebo of 20mg immediate release torsemide) with no gap in between. Subjects will be randomly assigned to immediate-release torsemide-first arm versus extended-release torsemide-first arm and at the end of the initial one-week period, they will be switched to the other intervention. Subjects will consume only the provided meals with standardized amount of sodium content throughout the study period.
223558107|NCT04973202|OTHER|Stay for alcohol detoxification|Stay for alcohol detoxification : routine care.
223558108|NCT00143624|DRUG|Rosiglitazone maleate|See Detailed Description.
223558109|NCT00143624|DRUG|Placebo|See detailed description.
223558110|NCT02177331|DRUG|Lacidipine|
223738252|NCT06046456|OTHER|Prenatal Affective CogntiiveTraining|A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
223738253|NCT06018259|PROCEDURE|healthy volunteers blood sampling|One blood sample will be taken from healthy volunteers in order to isolate PBMC and to assess the effect of the lipid of interest on them PBMC will be activated in vitro (e.g. using LPS or PHA) in the presence or absence of the lipid of interest.
223738254|NCT05821868|DEVICE|Dosivent|Dosivent® inhalation chamber is designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
223738255|NCT05821868|DEVICE|Aerochamber Plus Flow Vu|Aerochamber Plus Flow Vu® inhalation chamber is also designed to optimize the delivery of inhaled bronchodilators and corticosteroids in the treatment of respiratory diseases
223738256|NCT00129493|BEHAVIORAL|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
223738257|NCT05517889|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography is a non-invasive scanner which generates real-time in-vivo images of the skin and its adnexal structures. Images are generated by light-interferometry.
223738258|NCT01665066|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
223738259|NCT01665066|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
223738260|NCT01665066|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
223738261|NCT01665066|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
223738262|NCT01665066|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
223738263|NCT01338831|DRUG|LFA102|
223738264|NCT02793102|OTHER|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
223408453|NCT05006287|DRUG|Non-vitamin K oral anticoagulants (NOACs)|"NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated."
223408454|NCT05006287|DRUG|Warfarin|"Warfarin Group (Comparator):~Patients randomized to the warfarin group will receive warfarin titrated to achieve a target International Normalized Ratio (INR) of 2.5 (range 2.0 to 3.0). Warfarin will be started as early as post-operative day 1 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until INR is 2.0 or above."
223408455|NCT01368601|PROCEDURE|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
223408456|NCT06399380|OTHER|Manual mobilization of the carpal bones.|The mobilization of the carpal bones will be done in the following way: patient in supine position, with elbow flexion of approximately 90º, so that the forearm and wrist are almost vertical. The examiner positions the thumb on the dorsal aspect of the scaphoid and trapezius, and the index finger on the dorsal aspect of the piriformis and hamate. Next, a manual ventral force is applied until the resistance of the wrist tissues is felt for 30 seconds. The technique will be repeated 5 times, with a 10-second rest between each application.
223738265|NCT02793102|OTHER|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
223738266|NCT02793102|OTHER|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
223738267|NCT05814887|DEVICE|ReLink|Medical device
223738268|NCT03256539|BEHAVIORAL|Sleep intervention|Behavioral sleep intervention program
223738269|NCT03256539|BEHAVIORAL|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
223738270|NCT00902369|DRUG|AK106-001616|Part1: Dose escalation Part2: Dose expansion
223738271|NCT00902369|DRUG|Placebo|
223738272|NCT00902369|DRUG|Active comparator|
223738273|NCT04859881|OTHER|No intervention|No intervention
223738274|NCT01026792|DRUG|Temsirolimus|Given IV
224024693|NCT05748496|BEHAVIORAL|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training|Brief behavioral sleep therapy, sleep hygiene education and mindfulness training using breathing exercises and Yoga Nidra
223408457|NCT06399380|OTHER|Placebo|A technique will be performed that will have no effect; the hands will be placed at a point that will not be the carpal tunnel, such as the forearm.
223408458|NCT00408642|BEHAVIORAL|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
223738275|NCT01026792|OTHER|Laboratory Biomarker Analysis|Correlative studies
224024694|NCT01411215|DRUG|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
224024695|NCT04333927|DRUG|Chemotherapy|Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
224024696|NCT04333927|OTHER|Observation|Patients in observation group will not receive any anti-cancer therapy.
223738276|NCT00309842|BIOLOGICAL|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
223738277|NCT00309842|DRUG|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
223738278|NCT00309842|DRUG|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \> 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
223738279|NCT00309842|DRUG|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
223738280|NCT00309842|DRUG|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
223738281|NCT00309842|PROCEDURE|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
223738282|NCT00309842|RADIATION|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
223738283|NCT00423150|DRUG|Temozolomide|Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
223408459|NCT00408642|BEHAVIORAL|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
223408460|NCT00580151|DRUG|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
223408461|NCT00580151|DRUG|placebo|1 dose every 6 hours
223558111|NCT05446038|BEHAVIORAL|Multi-Family Guided Self-Help FBT|Previous research has shown that Family-Based Treatment (FBT) is an effective treatment for Anorexia. We hope to learn whether an adaptation of Family-Based Treatment (FBT), called online Multi-Family Guided Self-Help FBT, is feasible and acceptable for families of young people with Anorexia. The 'Self-Help' aspect of the treatment consists of a series of educational videos for parents about how to help their child with Anorexia, which parents watch on an online platform. The 'Multifamily' and 'Guided' aspects of the treatment consists of weekly meetings by Zoom for a group of parents of young people with Anorexia, with a facilitator present to guide a group discussion around whether parents feel they understood the content of the videos and whether the content is helpful.
223558112|NCT01591954|DEVICE|Video Augmentation|Assessment of value of video-based navigation system
223558113|NCT01323088|OTHER|Control|Standard care control (no exercise)
223558114|NCT01323088|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
223738284|NCT04082325|DRUG|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
223738285|NCT04082325|DRUG|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
224024697|NCT04333927|PROCEDURE|Immunotherapy|Camrelizumab 200mg intravenously every 3 weeks until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal.
223408462|NCT00708461|BEHAVIORAL|weight gain prevention|"1. Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~2. Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~3. Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~4. Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices."
223408463|NCT01786161|DRUG|Vancomycin continuous infusion|Vancomycin 24 hour intravenous continuous infusion
223408464|NCT01786161|DRUG|Vancomycin intermittent dosing interval|Vancomycin intravenous infusion at rate 1000mg/hr
223408465|NCT02514720|OTHER|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
223408466|NCT04865263|DEVICE|Digital Pain-Management Tool|Self management digital tool for chronic pain
223408467|NCT00745342|BEHAVIORAL|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
223408468|NCT00363233|DRUG|flax lignans|
223558115|NCT01323088|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
223558116|NCT04142138|OTHER|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
223558117|NCT01849692|DRUG|ESBA1008 solution|Intravitreal injection or infusion
223558118|NCT01849692|DRUG|Ranibizumab|Intravitreal injection
223558119|NCT00856596|DRUG|Sertaconazole nitrate cream 2%|Once a day topical cream
223738286|NCT04082325|DRUG|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
223738287|NCT04082325|DRUG|Placebo|Placebo to Lu AF88434 oral solution, single dose
223738288|NCT04018950|DRUG|ETX2514|intravenous infusion
223738289|NCT04018950|DRUG|14C-ETX2514|intravenous infusion
223738290|NCT02051946|DEVICE|Retroject Device|
223738291|NCT02051946|DRUG|ethacrynic acid injection|
224024698|NCT04333927|RADIATION|Radiotherapy|45 Gy to regional lymph nodes and 54 to 59.4 Gy to preoperative tumor bed.
224024699|NCT00848926|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
223738292|NCT02051946|DRUG|balanced salt solution|
223408469|NCT01796392|DEVICE|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
223738293|NCT02316041|PROCEDURE|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
223738294|NCT02316041|DEVICE|ReLEx® (SMILE)|
223738295|NCT03510520|DEVICE|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
223738296|NCT03510520|DEVICE|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
223738297|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.1 μg|solution for intradermal injection, 0.1 µg / 0.1 mL
223738298|NCT05398562|DIAGNOSTIC_TEST|Mycobacterial recombinant allergens 0.2 μg|solution for intradermal injection, 0.2 µg / 0.1 mL
224297925|NCT00804817|BEHAVIORAL|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
223738299|NCT05398562|DIAGNOSTIC_TEST|Placebo|solution for intradermal injection
223738300|NCT02919501|DRUG|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
223738301|NCT02919501|OTHER|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
223738302|NCT02919501|DRUG|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
223738303|NCT03204305|DRUG|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
223738304|NCT03204305|DRUG|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
223738305|NCT05105061|DRUG|Ketamine (Ketalar)|0.5 mg/kg of body weight
223738306|NCT05105061|DRUG|Placebo|IM injection of matching placebo
223738307|NCT03793582|DIAGNOSTIC_TEST|ApneaLink Type III portable sleep study|Type III portable sleep study
223738308|NCT01979809|BEHAVIORAL|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
223738309|NCT01571414|DRUG|PA-824|200-mg tablets once a day
223738310|NCT01571414|DRUG|Efavirenz (EFV)|600-mg tablets once a day
223738311|NCT01571414|DRUG|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
224297926|NCT04683419|DEVICE|Modified Thoracoscopic pleural Cryobiopsy|"Thoracoscopic pleural biopsy will be taken with a modified technique raising of the parietal pleura by injection of saline, adrenaline and xylocaine, then taking the biopsy via a cryoprobe"
224297927|NCT00578981|BEHAVIORAL|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
223738312|NCT01571414|DRUG|Rifampin (RIF)|300-mg capsules once a day
223738313|NCT01947920|DRUG|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
223738314|NCT01947920|DRUG|Placebo|Size-matching capsules containing an appropriate inactive excipient
223738315|NCT04178499|DIAGNOSTIC_TEST|cytokine analysis|analysis of intraocular cytokines
223738316|NCT03282942|OTHER|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~* Squatting~* Leg press~* Knee Extension~* Knee Flexion~* Supine Challenge~* High Pull~* Elbow flexion~* Extension of elbows~* Development~* Abdominal"
223738317|NCT03282942|OTHER|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
223738318|NCT05196009|BEHAVIORAL|mHealth peer navigation and social support|Peer navigation, asynchronous support via SMS, Motivational Interviewing, virtual social support group focused on mental health and substance use, linkage and follow-up
224297928|NCT02497118|DRUG|Endostatin|Endostatin,7.5mg/m\^2,intravenous, d1-14;
224297929|NCT02497118|DRUG|Vinorelbine|vinorelbine,25mg/m\^2,intravenous, d1, d8;
224297930|NCT02497118|DRUG|Cisplatin|Cisplatin，75mg/m\^2 intravenous,divide into d1-3
223408470|NCT01796392|OTHER|Optimal Medical Management|This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
223408471|NCT06174103|DEVICE|BiVACOR TAH System|The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
223408472|NCT04000139|DRUG|Standardized anthocyanin-rich extract|3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
223558120|NCT06452641|OTHER|Jones technique|Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
223558121|NCT06452641|OTHER|Cross-friction massage|Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
223558122|NCT00796731|DRUG|SAR3419|administered by intravenous infusion
223558123|NCT01420913|DRUG|Pregabalin|Pregabalin 300mg a day
223558124|NCT02548481|OTHER|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
223558125|NCT04636840|DEVICE|Space From Body and Eating Concerns- Teen|Mobile application with coaching component
223558126|NCT06423456|DRUG|Lidocaine IV|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
223558127|NCT06423456|DRUG|Saline|Pain measurement will be performed using a visual analog scale (VAS) for postoperative pain after the operation. At the same time, patients' intraoperative analgesic use, postoperative nausea-vomiting and antiemetic use will be recorded.
223558128|NCT00744380|DRUG|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
223558129|NCT00744380|DRUG|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
223558130|NCT01329653|BEHAVIORAL|aerobic training|12 weeks of aerobic training, 4X/week
223558131|NCT01329653|BEHAVIORAL|Wait list|wait list control condition
223558132|NCT01207076|BIOLOGICAL|90Y-AHN-12|"The intervention consists of two parts.~1. The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~   * Dose escalation of nonradiolabeled AHN-12:~   Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~2. Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~   * the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
223558133|NCT00153140|DRUG|polyethyleneglycol3350|
223558134|NCT01932372|DRUG|Tofacitinib (Xeljanz)|5 mg Tablet BID
223558135|NCT01932372|DRUG|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
223558136|NCT05070351|DRUG|PPI deprescribing|Patients currently on a proton pump inhibitor (PPI) undergoing transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized to receive instructions to stop taking their PPI.
223558137|NCT01917929|DEVICE|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
223558138|NCT04106219|DRUG|LY3295668 Erbumine|Administered orally.
223558139|NCT04106219|DRUG|Topotecan|Administered IV.
223558140|NCT04106219|DRUG|Cyclophosphamide|Administered IV.
223558141|NCT03266744|DIAGNOSTIC_TEST|Computerised Tomography|
223558142|NCT03266744|DIAGNOSTIC_TEST|Whole Body Magnetic Resonance Imaging|
223558143|NCT03266744|DIAGNOSTIC_TEST|Bone scan|
223558144|NCT03114111|DRUG|aminolevulinic acid (ALA)|
223558145|NCT03114111|DRUG|Placebo|
223558146|NCT00740753|DEVICE|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
223558147|NCT02738541|DRUG|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
223558148|NCT02738541|DRUG|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
223558149|NCT04061824|DRUG|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
224024700|NCT04878653|DEVICE|BACtrack S80 Breathalyzer|The breathalyzer, BACtrack S80 Breathalyzer, will be calibrated per manufacturer's recommendations before each reading will be taken. Participants will administer the breathalyzer test on themselves. They will be instructed on how to hold and blow into the breathalyzer machine.
223408473|NCT04000139|DRUG|Placebo|3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
223558150|NCT04061824|DRUG|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
223558151|NCT03890900|OTHER|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
223558152|NCT02951403|PROCEDURE|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
223558153|NCT02951403|OTHER|Conservative treatment|Physiotherapy protocol is introduced to patients.
223558154|NCT01185951|DRUG|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
223558155|NCT01185951|DEVICE|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
223558156|NCT01185951|DRUG|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
223558157|NCT01185951|BEHAVIORAL|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
223558158|NCT01185951|BEHAVIORAL|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
223558159|NCT01185951|BEHAVIORAL|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
223558160|NCT00332085|DRUG|Chromium Picolinate|
223558161|NCT00302354|DRUG|OROS methylphenidate HCl|
223558162|NCT00302354|DRUG|SODAS methylphenidate HCl|
223558163|NCT00648388|DRUG|Cilostazol Tablets 100 mg|100mg, single dose fasting
223558164|NCT00648388|DRUG|Pletal® Tablets 100 mg|100 single dose fasting
223558165|NCT02748044|DEVICE|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
223558166|NCT00741897|DRUG|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
223558167|NCT03367923|OTHER|Communication Intervention|Receive email/text
223558168|NCT03367923|OTHER|Counseling|Undergo exercise counseling
223558169|NCT03367923|OTHER|Fitbit tracker|Wear Fitbit tracker
223558170|NCT03367923|OTHER|Quality-of-Life Assessment|Ancillary studies
223558171|NCT03367923|OTHER|Questionnaire Administration|Ancillary studies
223558172|NCT03367923|BEHAVIORAL|Telephone-Based Intervention|Receive phone call
223558173|NCT03440151|PROCEDURE|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
223558174|NCT03440151|PROCEDURE|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
223558175|NCT05882045|DRUG|Retatrutide|Administered SC
223558176|NCT05882045|DRUG|Placebo|Administered SC
223558177|NCT06539754|BEHAVIORAL|Music|Participants will have bone conducting headphones available to listen to the music of their choice from premade Spotify playlists.
223558178|NCT04734860|BIOLOGICAL|COVI-AMG|COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
223558179|NCT04734860|DRUG|Placebo|Diluent solution
223558180|NCT01396590|DRUG|Perampanel|6 x 2 mg perampanel once per day
223558181|NCT01396590|DRUG|Perampanel|12 mg perampanel once per day
223558182|NCT04406207|OTHER|Demonstration of T cell responses|"Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients.~The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest."
223558183|NCT00500461|DRUG|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
223558184|NCT05748509|OTHER|Surface EMG activations|We will try to find out which of the exercises such as pressing the back back, waist extension on the balance ball, lumbar extension in the active prone position, Superman exercises have better lumbar extensor muscle activations. Muscle activations of individuals will be evaluated using superficial EMG. An 8-channel EMG Noraxon MiniDTS system (Noraxon, USA, Inc, Scottsdale, AZ) will be used to measure signals from the muscles.
223558185|NCT01310946|OTHER|Database|Database
223558186|NCT02551380|DRUG|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
223558187|NCT02551380|OTHER|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
223558188|NCT03028415|DEVICE|AMPLEX|A bone graft substitute
223558189|NCT03028415|PROCEDURE|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
223558190|NCT00706108|BEHAVIORAL|Observational study|Observational (descriptive) study of technical and non-technical performance
223558191|NCT02907216|BIOLOGICAL|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
223558192|NCT02907216|BIOLOGICAL|Rotarix|Two doses administered orally
223558193|NCT01925040|DEVICE|Placement of restoration|Placement of restorations
223558194|NCT02241733|BEHAVIORAL|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
223558195|NCT02241733|BEHAVIORAL|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
223558196|NCT06009991|DRUG|Remimazolam besylate|"Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need)."
223558197|NCT06009991|DRUG|Propofol|"Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance"
223408474|NCT05182060|BEHAVIORAL|Transition Intervention|"We will implement a bundle of care transition safety strategies with the assistance of home care coordinators at the study site and corresponding home health provider teams (nurses, rehabilitation therapists).~Home care coordinators will approach patients at the study site being referred for home health and provide resources to assist them with preparing for their transition home. These resources include a link to a video about home health services, a caregiver assessment, a care task role assignment sheet, and a shopping list. The study team will contact the older adult and caregiver by telephone within 48 hours of the home visit to confirm eligibility, explain the study, obtain consent for participation, and ask them to complete the the Hospital-to-Home Health Transition Quality Index (H3TQ) over the phone. Home health providers in the home will also complete the H3TQ."
223408475|NCT04912908|OTHER|Images taken during knee replacement surgery|Images taken during knee replacement surgery will be compared to CT-Scan that was performed before surgery
223408476|NCT01225250|DEVICE|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
223558198|NCT06971978|OTHER|Online decision support platform to support evidence-based heat health risk assessment and extreme heat event preparedness planning|The intervention group will receive facilitated engagement with Chart. Chart is an online decision support platform designed to support evidence-based risk assessment and planning for extreme heat risk mitigation. Chart has a risk assessment platform that provides estimates of heat-health risks at a census tract level under various hazard conditions. It also has a decision support platform that links drivers of risk in a given location with information about potential risk reduction activities and includes information useful to policymakers regarding intervention efficacy, timing, and cost. Facilitated engagement includes an initial introduction to the platform, real-time questions and answers, and focused discussion regarding priority interventions and planning and implementation needs. This engagement comprises about five hours of time that can be provided over the course of a couple weeks or several months, depending on the needs of the health department.
223558199|NCT06971978|OTHER|Heat and health risk assessment and preparedness information|Study participants in the control group will be provided with a package of information supportive of heat-health vulnerability and risk assessment and planning for risk reduction activities through built environment hazard mitigation and public health programming. This package will include an annotated list of online resources, including those available on Heat.gov and the CDC website, and a selected set of review papers on heat-health vulnerability, heat-health risk assessment, heat hazard mitigation through built environment strategies, and heat action planning and preparedness.
223558200|NCT06055309|DRUG|Cannabis (up to three doses)|a dose of cannabis will be baked into brownies
223558201|NCT05079347|DIAGNOSTIC_TEST|HIV rapid test|Using a rapid test to assess a patient's HIV status
223558202|NCT05107011|DRUG|LBL-015 for Injections|Initial dose - MTD ; Q2W ; intravenous infusion
223558203|NCT06384131|DRUG|ABI-4334|10 mg or 50 mg tablets for oral administration
223558204|NCT06384131|DRUG|Placebo|10 mg or 50 mg tablets for oral administration
223558205|NCT04555577|DRUG|Peposertib|Given PO
223558206|NCT04555577|RADIATION|Radiation Therapy|Undergo radiation therapy
223558207|NCT04555577|PROCEDURE|Resection|Undergo surgical resection
223558208|NCT04555577|DRUG|Temozolomide|Given PO
223558209|NCT06040684|DIAGNOSTIC_TEST|Level of antibodies|The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.
223558210|NCT04296188|PROCEDURE|serratus anterior plane block|ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
223558211|NCT04296188|PROCEDURE|erector spina plane block|ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
223558212|NCT02778542|BEHAVIORAL|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
223558213|NCT02778542|BEHAVIORAL|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
223558214|NCT06563466|OTHER|The experimental intervention PEGASUS|See arm description.
223558215|NCT06563466|OTHER|Treatment as usual|See arm description
223558216|NCT05275478|DRUG|TNG908|TNG908, a selective PRMT5 inhibitor, will be administered orally
223558217|NCT03168737|PROCEDURE|Computed Tomography|Undergo PET-CT scan
223558218|NCT03168737|RADIATION|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
223558219|NCT03168737|PROCEDURE|Positron Emission Tomography|Undergo PET-CT scan
223558220|NCT05838950|OTHER|high-intensity interval training intervention|Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
223558221|NCT04394416|DRUG|Imatinib|Therapeutic
223558222|NCT04394416|DRUG|Placebo oral tablet|Placebo
223558223|NCT06093880|DEVICE|monofocal intraocular lens|monofocal aspheric hydrophilic-hydrophobic intraocular lens
223558224|NCT05893225|DRUG|Metformin Hydrochloride 850 mg Oral Tablet|Metformin Hydrochloride oral tablets 850 mg t.i.d. or b.i.d.
223558225|NCT05893225|DRUG|Placebo|Placebo matching Metformin Hydrochloride oral tablets t.i.d. or b.i.d.
223558226|NCT05788432|DEVICE|Sequent Please Neo|Patients in whom treatment with (Sequent Please Neo) has been attempted
223558227|NCT04255849|BIOLOGICAL|9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)|Gardasil-9 HPV vaccine
223558228|NCT04255849|OTHER|Saline Placebo|Saline Placebo
223558229|NCT05779241|DRUG|LYN-005|Risperidone long-acting oral capsule
223558230|NCT05779241|DRUG|Risperidone|Risperidone immediate release (IR) oral tablets
223558231|NCT06224140|PROCEDURE|Heparin Anticoagulation|Conventional dialysis with heparin as anticoagulant treatment
223558232|NCT06224140|PROCEDURE|Regional Anticoagulation Procedure (RAP)|Dialysis without heparin as anticoagulant but based on the use of a calcium-free dialysis bath. Calcium is then restored by reinjection of a 10% calcium chloride solution.
223558233|NCT00295009|DEVICE|ProDisc|Total disc replacement with ProDisc
224297931|NCT01851018|RADIATION|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
223408477|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
224297932|NCT01851018|RADIATION|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
223408478|NCT01225250|PROCEDURE|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
223408479|NCT02134431|DEVICE|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
223408480|NCT03517540|DRUG|Tropifexor (LJN452)|Comparison with monotherapy and different combination doses
223408481|NCT03517540|DRUG|Cenicriviroc (CVC)|Comparison with monotherapy and different combination doses
224297933|NCT04798118|PROCEDURE|toilet bronchoscope|Toilet bronchoscopy will be done by infuse normal saline or N-Acetylcysteine with a syringe, observing the flow of saline at the distal tip of the bronchoscope then suction intra bronchial visible secretions during the procedure and also suction of specific lobe guided by radiological finding in the patient A chest X-ray will be routinely performed prior and after the procedure, HRCT is mandatory when chest x-ray not clearly defining the collapse monitoring of heart rate, oxygen saturation, ventilator parameters, and arterial blood pressure will be done
224297934|NCT00448136|DRUG|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
224297935|NCT00448136|DRUG|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
224297936|NCT00448136|DRUG|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
224297937|NCT00448136|DRUG|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
224297938|NCT03784521|DEVICE|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
224297939|NCT03784521|DEVICE|Standard care|Patients are treated with standard intravenous solutions and vascular access management
224297940|NCT01099059|DRUG|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for \<30 Kg and 150 mg/day for \>30 Kg)
224297941|NCT01099059|DRUG|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)
224297942|NCT05060432|DRUG|EOS-448|Anti-TIGIT monoclonal antibody
223408482|NCT04242810|DEVICE|rTMS|TMS will be applied over task-based target at an intensity up of 130% rMT. The optimal coil placement during stimulation will be guided using the BrainSight neuronavigation system.
223408483|NCT04242810|DEVICE|Sham rTMS|An electrical sham coil that produces the same auditory and somatosensory stimulations, without a significant magnetic field, will be used as an active control.
223408484|NCT04242810|PROCEDURE|MRI scan|Participants will undergo an MRI scan directly after rTMS stimulation that will last less than 120 minutes. During the scan, subjects will encode and retrieve object pictures.
223408485|NCT04653038|DRUG|MGD013|A fixed dose of MGD013 600mg IV Q2W will be administered to subjects
223408486|NCT02473627|DRUG|DS-1971a|200mg tablet
223408487|NCT02473627|DRUG|midazolam hydrochloride|2.5mg oromucosal liquid
223408488|NCT02473627|DRUG|Omeprazole|20mg gastro-resistant capsule
223408489|NCT02473627|DRUG|Pioglitazone hydrochloride|15mg tablet
223408490|NCT02473627|DRUG|Buproprion|150mg Prolonged release tablet
223408491|NCT02473627|DRUG|Tolbutamide|500mg tablet
223408492|NCT00413582|DRUG|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
223408493|NCT00413582|DRUG|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are \> 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of \> 4/10 throughout the duration of PCA use.
223408494|NCT04691362|DRUG|Tranexamic Acid Oral Product|Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration
223408495|NCT04691362|DRUG|Tranexamic acid injection|Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration
224024701|NCT05130853|BEHAVIORAL|Social Skills and Neurocognitive Individualized Training (SoCIAL)|"SoCIAL is composed of two modules:~1. Social Cognition Training The Emotions recognition training will train the subject's ability in discriminating between different emotional states through photos and videos. The Theory of Mind (ToM) training will help subjects discriminate between emotional expressions in social contexts and understand other people's mental state with videos that display actors expressing several emotional states. More details in Palumbo et al., 2017.~2. Narrative Enhancement Training The narrative enhancement training consists in story-telling exercises focused on improving the subject's capacity to comprehend his/her emotional experience."
224024702|NCT05130853|OTHER|Treatmment-as-usual|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study. TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
224024703|NCT04621591|DEVICE|Saneso 360° gastroscope|Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.
224024704|NCT01553123|DRUG|Ulipristal Acetate|once daily, oral
224024705|NCT01553123|DRUG|Iron|once daily, dried ferrous sulfate
223408496|NCT02248844|BIOLOGICAL|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
223408497|NCT01779440|BEHAVIORAL|Electronic Decision Support System|
223408498|NCT01842230|DRUG|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"* Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~* over the period I \& II(cross-over)"
223408499|NCT01842230|DRUG|Telmisartan 80mg and S-amlodipine 5mg|"* Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~* over the period I \& II(cross-over)"
223408500|NCT01205269|DRUG|AZD8683, 50 mcg|Dry powder for inhalation, single dose
223408501|NCT01205269|DRUG|Placebo|Dry powder for inhalation, single dose
223408502|NCT01205269|DRUG|AZD8683, 200 mcg|Dry powder for inhalation, single dose
223558234|NCT00295009|PROCEDURE|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
223558235|NCT00767663|DRUG|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
223558236|NCT00767663|DRUG|placebo|placebo twice daily, minimal three days pretreatment
223558237|NCT03254706|OTHER|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
223558238|NCT03254706|OTHER|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
223558239|NCT03254706|OTHER|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
223558240|NCT03254706|OTHER|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
223558241|NCT02740062|DEVICE|NIBS system for evaluation and non invasive current stimulation|
223558242|NCT02091531|DRUG|MLN0128|
223558243|NCT06375473|DRUG|Irinotecan liposome II combination therapy regimen|Irinotecan liposome II combination therapy regimen
223558244|NCT03533439|DIAGNOSTIC_TEST|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
223558245|NCT05361720|DRUG|Cabozantinib|Given PO
223558246|NCT05361720|BIOLOGICAL|Ipilimumab|Given IV
223558247|NCT05361720|BIOLOGICAL|Nivolumab|Given IV
223558248|NCT00945529|DRUG|inhaled nitric oxide (iNO)|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
224024706|NCT00454129|PROCEDURE|cholangiography via double-balloon enteroscopy|
224024707|NCT00454129|PROCEDURE|MR cholangiography|
224024708|NCT06147284|BEHAVIORAL|Preventive interventions|Parallel randomized controlled trial
224024709|NCT06254768|DEVICE|Continuous glucose monitor|its a device used to measure glucose from interstitial fluids and provides feedback regarding the same every 5 minutes.
224024710|NCT05232994|DRUG|Esomeprazole 20mg|Combination 2 g of oral extended release metformin, Esomeprazole 20mg daily until delivery.
224024711|NCT03080831|DRUG|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
223408503|NCT01545167|GENETIC|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
223408504|NCT02192463|DRUG|NVP ER 300 mg (KCR 20%) Medium Release|
223408505|NCT02192463|DRUG|NVP ER 300 mg (KCR 25%) Medium Release|
223408506|NCT02192463|DRUG|NVP ER 300 mg (KCR 30%) Slow Release|
223408507|NCT02192463|DRUG|NVP ER 400 mg (KCR 25%) Medium Release|
223408508|NCT02192463|DRUG|NVP ER 300 mg (KCR 40%) Slow Release|
223408509|NCT02192463|DRUG|NVP ER 300 mg (ECR 20%) Fast Release|
223408510|NCT02192463|DRUG|NVP ER 400 mg (KCR 20%) Medium Release|
223558249|NCT06146751|DRUG|Superparamagnetic Iron Oxide Nanoparticles|Patients will receive a novel ferumoxytol-enhanced cardiac magnetic resonance imaging.
223558250|NCT00418704|DRUG|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
223558251|NCT00418704|DRUG|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
223558252|NCT02199093|OTHER|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
224024712|NCT03080831|DRUG|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
223408511|NCT02192463|DRUG|NVP ER 400 mg (KCR 30%) Slow Release|
223408512|NCT02192463|DRUG|NVP ER 400 mg (KCR 40%) Slow Release|
223408513|NCT02192463|DRUG|NVP ER 400 mg (ECR 20%) Fast Release|
223408514|NCT02192463|DRUG|Nevirapine immediate release (IR) 200 mg|
223408515|NCT04131660|DEVICE|AVAPS-AE mode during NIV|NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) \* Size (m) \* 23).
223408516|NCT04131660|DEVICE|S/T mode during NIV|"NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support."
223408517|NCT04667923|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the tidal volume, peak inspiratory flow, inspiratory time, respiratory rate and the pressure gap during triggering on NIV and plateau pressure on mechanical ventilation
223408518|NCT04667923|DIAGNOSTIC_TEST|Respiratory muscles ultrasound|Measurement of the diaphragm thickening fraction, assessment of the contraction of scalene and sternocleidomastoid muscles
223408519|NCT04667923|DIAGNOSTIC_TEST|Electro impedance tomography|Measurement of the lung impedance changes in 4 quadrants, measurement of regional ventilation delay in 4 quadrants
223408520|NCT04667923|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension
223408521|NCT04667923|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
223408522|NCT04667923|DIAGNOSTIC_TEST|Quasistatic pressure-volume curve|Quasistatic pressure-volume curve
223408523|NCT01408303|DRUG|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
223408524|NCT01408303|DRUG|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
223408525|NCT01408303|DRUG|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
223408526|NCT01207687|BIOLOGICAL|bevacizumab|Given IV
223408527|NCT01207687|OTHER|laboratory biomarker analysis|Correlative studies
223408528|NCT01207687|PROCEDURE|quality-of-life assessment|Ancillary studies
223408529|NCT02280837|OTHER|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
223408530|NCT00006105|DRUG|amifostine trihydrate|
223408531|NCT00006105|DRUG|cisplatin|
223408532|NCT00006105|DRUG|gemcitabine hydrochloride|
224024713|NCT04525872|OTHER|Full parenteral nutrition light protection of the bag, tubing and lipids|Each infant enrolled in this study will receive full PN light protection including the PN bag, lipids and tubing.
224024714|NCT00945308|DRUG|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
224024715|NCT00945308|DRUG|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
224024716|NCT04025580|BIOLOGICAL|Flucelvax|Seasonal influenza vaccine
224024717|NCT04025580|BIOLOGICAL|Fluvirin|Seasonal influenza vaccine
224024718|NCT04025580|BIOLOGICAL|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
224024719|NCT05127629|PROCEDURE|Immediate implant placement|After tooth extraction, a dental implant is placed immediately.
224024720|NCT05127629|PROCEDURE|Guided bone regeneration|After implant placement, the gap between implant and the buccal bone wall is filled with Bio-oss collagen.
223408533|NCT00006105|PROCEDURE|adjuvant therapy|
223408534|NCT05258305|DEVICE|AuraGen 1-2-3 with AuraClens|Autologous fat transfer (AFT) is a minimally invasive medical procedure that includes aspirating adipose tissue from one part of the body, and washing, filtering and re-injecting the processed fat tissue into a different part of the body with the primary purpose of adding volume. The AuraGen 1-2-3 with AuraClens is a lipoaspirate wash system designed to be used in the operating room in conjunction with a user-provided liposuction cannular, a vacuum source, and waste canister.
223408535|NCT00765505|BEHAVIORAL|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
223408536|NCT00765505|BEHAVIORAL|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
223408537|NCT01129427|DRUG|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
223558253|NCT02199093|OTHER|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
224297943|NCT05060432|DRUG|pembrolizumab|Anti-PD-1 monoclonal antibody
223408538|NCT01129427|DRUG|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
223408539|NCT01129427|DRUG|Pantoprazole|"Pharmaceutical form: delayed-release tablet~Route of administration: oral"
223408540|NCT00333827|DRUG|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
223408541|NCT00333827|PROCEDURE|cell|stem cell
223408542|NCT02685176|DEVICE|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
223408543|NCT02685176|OTHER|No heat|No active heating provided post cooling
223408544|NCT03776266|PROCEDURE|No intervention is required due to retrospective observational study|Red blood cell transfusion on or after percutaneous coronary intervention
223408545|NCT04491825|DIAGNOSTIC_TEST|Skin suction blistering and skin biopsies|Skin suction blistering and skin biopsies will be used for the identification of potential proteomic biomarkers that can distinguish MF from eczema, psoriasis and healthy control skin.
223408546|NCT01486446|DRUG|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
223408547|NCT01486446|DRUG|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
224024721|NCT05127629|PROCEDURE|Wound closure with gelatin sponge|After guided bone regeneration, patient in the control group receive gelatin sponge for wound closure.
223408548|NCT04368546|DRUG|Sunitinib|
223558254|NCT06024551|OTHER|Telerehabilitation|Patients in this arm will be given telerehabilitation three times a week, for four weeks.
223558255|NCT06024551|OTHER|home exercise program|Patients in this arm will receive home exercise program for four weeks
223558256|NCT01063062|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
223558257|NCT01063062|DRUG|Methotrexate|methotrexate as per standard of care in clinical practice.
223558258|NCT03935178|DIAGNOSTIC_TEST|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
223558259|NCT03042429|DRUG|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
223558260|NCT03042429|DRUG|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
223558261|NCT03009162|DRUG|Lasmiditan|200 mg, single oral tablet
223558262|NCT06512779|OTHER|Control Group|sleep hygiene education
223558263|NCT06512779|PROCEDURE|Surgical Intervention|Surgical Intervention includes uvulopalatopharyngoplasty (UPPP) and transoral robotic surgery (TORS). UPPP involves the removal of the uvula and tonsils, while TORS consists of the removal of the uvula, tonsils, and adipose tissue at the base of the tongue.
223558264|NCT06512779|OTHER|Oropharyngeal Training (face-to-face)|Participants will attend face-to-face oropharyngeal training sessions with a therapist in the lab, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
223558265|NCT06512779|OTHER|Oropharyngeal Training (telerehabilitation)|Participants will attend online oropharyngeal training (telerehabilitation) sessions with a therapist, each lasting 45-60 minutes, 1-2 times per week, over a 12-week intervention period.
223558266|NCT06512779|DEVICE|Continuous Positive Airway Pressure|Participants will use Continuous Positive Airway Pressure (CPAP) throughout the intervention period.
224024722|NCT05127629|PROCEDURE|Wound closure with collagen matrix|After guided bone regeneration, patient in the control group receive collagen matrix (Mucograft Seal) for wound closure.
224024723|NCT03488433|DEVICE|Abduction brace|Donjoy Ultrasling IV
224297944|NCT05060432|DRUG|inupadenant|A2A receptor antagonist
224297945|NCT05060432|DRUG|Dostarlimab|Anti-PD-1 monoclonal antibody
224297946|NCT05060432|DRUG|SOC chemotherapies|SOC chemotherapies in 1L mNSCLC
224297947|NCT02384252|OTHER|functional tissu atrial analysis|
224297948|NCT04810442|OTHER|Nap|45-minute nap between scanning procedures
224297949|NCT02013375|PROCEDURE|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
224297950|NCT02013375|DRUG|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
224297951|NCT02013375|RADIATION|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
224297952|NCT02013375|DRUG|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
224297953|NCT02013375|DRUG|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
224297954|NCT06094452|OTHER|Computerized Cognitive Training|Participants in intervention group will receive a multidomain, adaptive computerized cognitive training program (www.66nao.com) and will be required to complete at least 30 minutes of training per day (3 cycle of 5 2-min tasks), 5 days a week for 24 weeks. Multidomain coverage paradigms include working memory, calculation, processing speed, attention, executive function, and short-term and long-term memory.
224297955|NCT06094452|OTHER|Treatment As Usual|Patients in control group will receive TAU for 24 weeks, which includes (1) regular medication management from the Memory Clinic, if applicable; (2) basic health education at each follow-up (face to face) and twice per month on the internet .
224297956|NCT05226559|PROCEDURE|Multimodal Physical therapy approach plus usual care|HVLA spinal manipulation, mobilization, soft tissue treatment, therapeutic exercise, education, plus standard pharmacological treatment.
224297957|NCT05226559|DRUG|Usual care|Standard pharmacological treatment alone.
224297958|NCT06425770|PROCEDURE|indirect digital impression and 3D printed cast|the provisional restoration will be scanned with intraoral scanner extraorally, based on which a virtual model will be created, from which a 3D printed cast will be created with manually fabricated gingival mask based on the provisional restoration
224024724|NCT03488433|DEVICE|Antirotation sling|Donjoy shoulder immobilizer
224024725|NCT01362257|DRUG|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
224024726|NCT01362257|DRUG|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
224024727|NCT02995954|DRUG|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
224024728|NCT04507126|BIOLOGICAL|Bacillus Calmette-Guerin (BCG)|Vaccine
224024729|NCT04011618|DRUG|Ellagic Acid / Pomegranate Extract|Polyphenol, ellagitannin, it is found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with 90% ellagic acid, 500 mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
224024730|NCT04011618|DRUG|Placebo oral capsule|Calcined magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
224024731|NCT03343457|BEHAVIORAL|Cognitive therapy|
224024732|NCT03650257|BIOLOGICAL|gp96|25 mcg IH
223408549|NCT03856125|OTHER|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~* Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~* TENS Frequency - 2 Hz~* TENS Pulse width - 250 microseconds~* Duration - 30 minutes.~* TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~* Administration - One per week"
223408550|NCT03856125|OTHER|Sham PENS plus exercise|"The technique will be performed on the radial nerve, the places of the needle's. The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~* Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle.~* Needle wil be placed at the at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's.~The current will not be working, and the needles will be placed during 30 minutes.~\- Administration - One per week"
223408551|NCT00523848|DRUG|bortezomib|IV
223408552|NCT00523848|DRUG|pegylated liposomal doxorubicin hydrochloride|IV
223408553|NCT00523848|DRUG|thalidomide|Oral
223408554|NCT01801865|DEVICE|GE OPTIMA MR430s with HDX/GE Electronics|
223408555|NCT05063422|DRUG|polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose|3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges
223408556|NCT05066425|DIETARY_SUPPLEMENT|Soluble Corn Fiber|Participants will be asked to consume a packet of 22g Soluble Corn Fiber/day for 4 weeks
223408557|NCT05066425|DIETARY_SUPPLEMENT|Maltodextrin|Participants will be asked to consume a packet of 22g Maltodextrin/day for 4 weeks
223408558|NCT01367886|DRUG|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
223408559|NCT01938092|DRUG|Diazepam|
223408560|NCT01938092|DRUG|Placebo|
223408561|NCT04939831|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
223408562|NCT04939831|OTHER|Total Abdominal Radical Hysterectomy|Radical hysterectomy with bilateral pelvic lymph node dissection is performed as standard type C RH by Q-M classification, including cardinal ligaments divided at pelvic sidewall and uterosacral ligaments divided at near the sacral origin and the upper 1/4 to 1/3 of the vagina.
223408563|NCT03729167|PROCEDURE|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
223408564|NCT02536092|DEVICE|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
223408565|NCT01006304|DRUG|JNJ-39439335, Placebo|
223558267|NCT03137680|BEHAVIORAL|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
223558268|NCT01790646|OTHER|intubation|intubation using Glidescope videolaryngoscope
223408566|NCT00574704|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
223408567|NCT00574704|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
223408568|NCT00574704|DRUG|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
223408569|NCT00574704|DRUG|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
223408570|NCT00985504|DRUG|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
223408571|NCT00985504|DRUG|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
223408572|NCT02174692|OTHER|Exercise|"One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 mins rest between sets"
223408573|NCT01884246|BEHAVIORAL|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
223408574|NCT01884246|OTHER|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
223408575|NCT05237167|PROCEDURE|Shoulder reduction|This is standard of care and only measure as a time component outcome in the study
223408576|NCT06370169|DEVICE|Endoscopic ultrasound placement of Coil and glue|The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue
223408577|NCT00371410|PROCEDURE|vitrectomy|
223408578|NCT00371410|DRUG|intravitreal triamcinolone acetonide|
223408579|NCT00371410|PROCEDURE|macular focal laser photocoagulation|
223558269|NCT03818906|PROCEDURE|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
223558270|NCT03818906|PROCEDURE|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
224024733|NCT03650257|DRUG|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
223408580|NCT03711786|OTHER|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
223408581|NCT03711786|OTHER|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
223558271|NCT03818906|PROCEDURE|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
223558272|NCT03818906|PROCEDURE|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
223558273|NCT03349138|DEVICE|Conventional Therapy|
224133206|NCT03862690|DRUG|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
224133207|NCT05006898|COMBINATION_PRODUCT|PBO to control presbyopia symptoms|Low dose PBO to control presbyopia symptoms
223558274|NCT03349138|DEVICE|Robotic Glove|
223558275|NCT03349138|DEVICE|Electrical Stimulation|
223558276|NCT03685903|DEVICE|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
223558277|NCT02620033|BEHAVIORAL|Yoga therapy|
223558278|NCT03877614|OTHER|ASCVD risk score|ASCVD score\< 10% will be in the control or low-risk group
223558279|NCT01546233|BEHAVIORAL|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
223558280|NCT01546233|BEHAVIORAL|standard education|standard education before and after chemotherapy
223558281|NCT06139614|BEHAVIORAL|PERSIST|PERSIST is adapted from empirically validated treatment of negative affect and low positive emotion. Skills Training 1 includes content across 4 sessions on 1) understanding emotions, 2) present-moment emotional awareness, 3) cognitive flexibility, and 4) countering avoidant and emotion-driven responses. Skills Training 2 includes content across 4 sessions on a) translating values to action, b) lower barriers to action, c) countering avoidance, and d) maintaining actions that support personal resilience. The classes will occur every other Wednesday, resulting in a 16-week intervention period.
223558282|NCT01457404|BEHAVIORAL|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
223558283|NCT01457404|BEHAVIORAL|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
223558284|NCT02263196|OTHER|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
223558285|NCT02263196|OTHER|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
223558286|NCT02748499|OTHER|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
223558287|NCT02748499|OTHER|Control|Participants maintain their daily acitvities.
223558288|NCT04392674|DEVICE|the new tissue containment system|using the new tissue containment system during Laparoscopic myomectomy morcellation
223558289|NCT04307368|OTHER|FODMAP diet|8 weeks of diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP)
223558290|NCT04307368|OTHER|Elimination-rotational diet|During the patient's first visit an IgG antibody titration test against specific nutrients will be performed to determine food hypersensitivity. Based on the results of the obtained food panels, patients will be offered an elimination-rotational diet for a period of 8 weeks.
223558291|NCT04307368|OTHER|Classic diet|8 weeks of classic diet treatment (recommended by the gastroenterologist who supervises them).
223558292|NCT05744778|OTHER|Dry needling|In addition to the physical therapy and exercise program, the dry needling group will consist of patients who have had 3 sessions of dry needling applied to the trigger points in the trapezius muscle, 5 days apart.
223558293|NCT05744778|OTHER|Physical therapy and rehabilitation|The physical therapy and rehabilitation group will consist of patients who will be applied the same exercise program together with the same physical therapy applications (superficial heat (infrared lamp), transcutaneous electrical nerve stimulation (TENS) and therapeutic ultrasound (TUS)) 5 sessions per week for 3 weeks.
223558294|NCT06553105|DIAGNOSTIC_TEST|ct scan|use ct scan for diagnosis fistula
223558295|NCT05007418|BIOLOGICAL|STI-1492|Anti-CD38 A2 KOKI DAR T cells
224133208|NCT04435145|BEHAVIORAL|Sugar-sweetened beverage warning label|A sugar-sweetened beverage warning label appropriate for the college-aged population was developed and applied to beverage stations at one large campus dining hall
223558296|NCT03860831|DRUG|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
223558297|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
223558298|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
223558299|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
223558300|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
224133209|NCT01079962|DRUG|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
224024734|NCT03650257|RADIATION|radiotherapy|Stupp regimen of radiotherapy
224133210|NCT01079962|DRUG|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
223558301|NCT00396786|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
223558302|NCT00396786|DRUG|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
223558303|NCT02216916|DRUG|HM781-36B|
223558304|NCT02620800|DRUG|5FU|5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump
223558305|NCT02620800|DRUG|nab-paclitaxel|nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
223558306|NCT02620800|DRUG|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
223558307|NCT02620800|DRUG|calcium leucovorin|calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15
223558308|NCT02620800|DRUG|oxaliplatin|oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
223558309|NCT00269750|DRUG|OROS® oxybutynin or Ditropan®|
223558310|NCT02597452|DEVICE|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
223558311|NCT03375645|DRUG|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
223558312|NCT01774669|DEVICE|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
223558313|NCT01774669|OTHER|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
224133211|NCT01754220|DRUG|Montelukast|Montelukast is a leukotriene receptor antagonist
224133212|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation|Aerogen Solo
224133213|NCT04840992|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
223558314|NCT01555970|DRUG|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
224133214|NCT04840992|BIOLOGICAL|Placebo for Inhalation|Aerogen Solo
224133215|NCT04840992|BIOLOGICAL|Placebo|Intramuscular administration
224133216|NCT01072539|DRUG|tigecycline|As prescribed by physician in usual clinical practice
224133217|NCT00134225|DEVICE|Muscle Pattern Recognition (MPR)|
223558315|NCT01555970|DRUG|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
223558316|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises and Physical Activity Counseling|Scoliosis specific corrective exercises and physical activity counseling
223558317|NCT05454800|OTHER|Scoliosis Specific Corrective Exercises|Only scoliosis specific corrective exercises
223558318|NCT06340724|DRUG|Vonoprazan|20 mg tablet twice daily
223558319|NCT06340724|DRUG|Amoxicillin|1 g tablet three times daily
223558320|NCT06340724|DRUG|Banxiaxiexin decotion|100 ml liquid-medicine twice daily
223558321|NCT05492227|DIAGNOSTIC_TEST|Left-overs|Totally nasal swab leftovers were stored from the biobank of Hospital Puerta del Hierro. The coded specimens were kept at -80°C and analyzed using the SARS-CoV-2 NAD Kit. Previously these specimens were analyzed using the gold-standard RT-PCR.
223558322|NCT04848467|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine (CVnCoV)|Two intramuscular injections administered 28 days apart at a dose level of 12 μg mRNA.
223558323|NCT04848467|BIOLOGICAL|Quadrivalent influenza vaccine (QIV)|One intramuscular injection as 0.5 mL. Each 0.5 mL dose will contain 15 μg haemagglutinin (HA) from each of the four influenza strains.
223558324|NCT04848467|OTHER|Placebo|One intramuscular injection as normal saline \[0.9% NaCl\].
223558325|NCT00924014|DRUG|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
223558326|NCT00924014|DRUG|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
223558327|NCT00924014|DRUG|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
223558328|NCT05827328|OTHER|Observation|Observe the 30-day mortality and 30-day morbidity.
224024735|NCT02924064|DRUG|Teneligliptin 20mg|
224024736|NCT02924064|DRUG|Placebo|
224024737|NCT02924064|DRUG|Metformin ≥ 1000 mg|
224024738|NCT05721820|PROCEDURE|TAVR|Transcatheter aortic valve replacement
224024739|NCT03759951|BEHAVIORAL|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
224133218|NCT01331239|DRUG|LCI699|Osilodrostat 1 mg and 5 mg capsules, was prepared by Novartis and supplied to the Investigator. The capsule formulation of osilodrostat was later changed to tablets and this change was implemented in the study with Protocol amendment 6. Osilodrostat was open labeled 1 mg, 5 mg, 10 mg and 20 mg tablets.
224297959|NCT06425770|PROCEDURE|direct digital impression|the emergence profile will be directly scanned with intraoral scanner at 0, 2, 10, and 20 minutes after removing the provisional restoration
223558329|NCT01533337|PROCEDURE|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
223558330|NCT03545087|DRUG|Lanabecestat|Administered orally
223558331|NCT03545087|DRUG|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
223558332|NCT02523092|DRUG|Acthar gel|Acthar gel given IM or SQ as per package insert
223738319|NCT00762242|PROCEDURE|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
223738320|NCT02278588|DRUG|Rasagiline|
223738321|NCT02045797|DRUG|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
223738322|NCT02045797|DRUG|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
223738323|NCT01264978|DEVICE|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
223738324|NCT01134978|BEHAVIORAL|Practice Order|"Blocked order - predictable~Random order - unpredictable"
223738325|NCT00776347|DRUG|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
223738326|NCT00776347|DRUG|Donepezil|
223738327|NCT00735787|BIOLOGICAL|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
223738328|NCT00735787|BIOLOGICAL|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
223738329|NCT02493673|DEVICE|Continuous positive airway pressure device|(ResMed Spirit S8)
223738330|NCT03251508|DRUG|Peanut OIT|Participants will be given increasing doses of the peanut flour as peanut oral immunotherapy (OIT) with increasing doses every 2 weeks over a period of 3 months up to a 300 mg target dose. This 300 mg peanut OIT maintenance dose is then continued daily for 3 months. Participants will then introduce dietary peanut of approximately 300 mg of peanut protein and continue daily ingestion for an additional 6 months.
224133219|NCT00850018|PROCEDURE|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
224133220|NCT00850018|BEHAVIORAL|Usual care|Participants will receive usual care for the treatment of SCD.
223408582|NCT00762814|DEVICE|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
223408583|NCT01057316|DEVICE|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
223408584|NCT01057316|DEVICE|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
223738331|NCT00101907|DRUG|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
223738332|NCT00101907|BIOLOGICAL|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
224133221|NCT00207766|DRUG|infliximab or placebo|
224133222|NCT02577250|DRUG|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
223408585|NCT01057316|DEVICE|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
223408586|NCT01982617|OTHER|Motivational Interviewing|
223738333|NCT00101907|DRUG|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
223738334|NCT00101907|DRUG|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
223738335|NCT04062838|DRUG|Dextrose 50|As above
223738336|NCT05883930|OTHER|'Let's Move' program|"Students will complete data collection forms as part of the program. According to International Physical Activity Questionnaire (IPAQ), those who are low in activity and inactive will be assigned to the appropriate intervention program based on their sedentary lifestyle stage.~Students will enter the module system prepared according to the five different stages of change \[not thinking (1), thinking (2), preparing (3), acting (4), continuing (5)\] of sedentary living.~There are 12 different initiatives for each phase/module of the program. Summary and reinforcing questions are asked at the end of each trial. If participants do not answer the questions, they cannot continue with the next week's initiative.~Participants' daily step counts with the smart wristband are recorded in the program.~Daily alerts/reinforcement messages related to that week's initiative will be sent during all phases."
224133223|NCT00348582|DRUG|Ketorolac, Nepafenac|
224133224|NCT00946530|DEVICE|Bright light|Participants uses bright light
224133225|NCT00946530|DEVICE|Control|Participants uses dim light
223558333|NCT02094209|DEVICE|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
223558334|NCT04027595|PROCEDURE|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
223558335|NCT00943098|DRUG|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
223558336|NCT00943098|DRUG|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
223558337|NCT02689414|PROCEDURE|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
223738337|NCT05883930|OTHER|no intervention|No intervention will be applied to the control group.
224024740|NCT03759951|BEHAVIORAL|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
224024741|NCT03759951|BEHAVIORAL|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
224024742|NCT03759951|BEHAVIORAL|Control|No training will be performed during a 1-year period. Participation only in measurements.
224133226|NCT05685641|DIAGNOSTIC_TEST|Histoplasma Urine Antigen Lateral Flow Antigen test|Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
224133227|NCT05685641|DIAGNOSTIC_TEST|Cryptococcal Lateral Flow Antigen test|Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
224133228|NCT05685641|DIAGNOSTIC_TEST|Tuberculosis-lipoarabinomannan Lateral Flow Antigen test|Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
224133229|NCT05212155|BEHAVIORAL|family-based behavioral treatment (FBT)|Individual and group treatment of parent/child dyads to improve dietary choices, minimize sedentary behaviors, increase physical activity levels, and identify social support environments that reinforce healthy lifestyle choices.
223408587|NCT01982617|OTHER|Psychoeducation|
223558338|NCT02689414|PROCEDURE|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
223408588|NCT00004208|DRUG|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
223408589|NCT00004208|BEHAVIORAL|Supportive care|Patients randomized to this arm will be treated as outpatients.
223408590|NCT04993716|OTHER|observational|Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
223408591|NCT02972619|OTHER|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
223558339|NCT01510990|DRUG|Gefitinib|gefitinib 250mg/day daily
223558340|NCT05073484|DRUG|BAT6021|Ⅳ infusions
223558341|NCT05073484|DRUG|BAT1308|Ⅳ infusions
223558342|NCT02052115|BEHAVIORAL|12 month exercise and weight loss intervention|
223558343|NCT02400606|OTHER|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
223408592|NCT02688543|PROCEDURE|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
223408593|NCT02688543|RADIATION|radiofrequency ablation|
223408594|NCT02688543|DEVICE|ultrasound|
223408595|NCT02566213|OTHER|Parabolic flight|
223408596|NCT02566213|OTHER|Motor skills measurements|"* the kinematics measurements of the right hand with a motion analysis system;~* the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~* the measurement of position of the moved object with an inductive position encoder."
223408597|NCT02553018|DRUG|Methotrexate|
223558344|NCT02400606|OTHER|Solving VP cases|See above
223558345|NCT05908994|OTHER|Examination|Exmainations including imaging, neurophysiological, kinetic and kinematic measurmetns. Behavioral assessments
223558346|NCT00348101|DRUG|Combined therapy with enoximone and esmolol|
223558347|NCT02547246|DEVICE|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
223558348|NCT02547246|DEVICE|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
223558349|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
223738338|NCT04111679|OTHER|Music|Participant selected music, applied using noise cancelling headphones
223408598|NCT03836690|BIOLOGICAL|CD62L- Tem|Donor memory T cells that have been depleted of CD62L+
223408599|NCT00466245|DRUG|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
223408600|NCT00466245|DRUG|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
223738339|NCT01566461|DEVICE|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
223408601|NCT03379727|DRUG|Midostaurin|Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.
223558350|NCT02177734|BIOLOGICAL|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
223408602|NCT03379727|DRUG|Cytarabine|Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion
223558351|NCT02177734|BIOLOGICAL|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
223558352|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor."
223558353|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor."
223738340|NCT01566461|DEVICE|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
223738341|NCT05270954|BIOLOGICAL|Betuvax-CoV-2|Vaccine: Betuvax-CoV-2 intramuscular injection solution (0.5 ml)
223738342|NCT05270954|DRUG|Placebo|Placebo: a 0.9% NaCl intramuscular injection solution (0.5 ml)
223738343|NCT03279692|DRUG|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
223738344|NCT04167683|OTHER|No intervention|No intervention
223738345|NCT06596148|OTHER|Access to Shingrix dashboard|The investigators will build and grant access to a clinical dashboard that exists behind the VA firewall. The dashboard will identify Veterans from each VA facility who are receiving immunosuppressants (prescribed via the VA). The dashboard will also provide information about the number of Shingrix vaccines each patient has received (which have been documented within the VA electronic health record). VA clinicians will have access to view information about patients based on their VA electronic health record permissions.
224133230|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 0 and 4
223738346|NCT05986019|DEVICE|transcranial focused ultrasound (tFUS)|Transcranial focused ultrasound (tFUS) is a promising new technology that is both noninvasive and may be focally applied to deep brain targets. tFUS utilizes transducers which contain piezoelectric elements to produce pulses of ultrasonic waves that summate deep in the brain. Transcranial focused ultrasound (tFUS) uses a single transducer fixed in a head-worn apparatus on the scalp to produce ultrasonic waves deep into the brain.
224133231|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
224133232|NCT01008995|DRUG|placebo|Subcutaneous injection at Week 12
224133233|NCT01008995|DRUG|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
224133234|NCT03446937|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
224133235|NCT03446937|DRUG|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
224133236|NCT03446937|DRUG|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
224133237|NCT02062528|DIETARY_SUPPLEMENT|omega-3 fatty acids|highly dosed in EPA
224133238|NCT02062528|DIETARY_SUPPLEMENT|placebo|
224133239|NCT06053827|OTHER|Frozen embryo transfer|A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy
224133240|NCT00080366|DRUG|1-Octanol|
224133241|NCT01679080|DRUG|Zoledronic acid|antiresorptive and calcium and vitamin D
224133242|NCT01679080|DRUG|Teriparatide|anabolic and calcium and vitamin D
224133243|NCT01679080|OTHER|No active treatment|Calcium and vitamin D
224133244|NCT02856269|DIETARY_SUPPLEMENT|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
224297960|NCT06425770|PROCEDURE|conventional impresion and cast|conventional impression with elastomer (silicon), from which a high-precision epoxi-resin cast with gingival mask will be created
223738347|NCT06007560|OTHER|Exercise|Aerobe cycling training consisting of 12-weeks of HR-controlled training at 50-60% of VO2max (maximal oxygen uptake) for 1 hour, for 2 times (week: 1-6) to 3 times (week: 7-12) per week
223738348|NCT05448066|DIAGNOSTIC_TEST|Component resolved diagnosis|Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
223558354|NCT04385316|DIAGNOSTIC_TEST|DNA extraction of samples and high-throughput sequencing of small panels|"DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor."
223558355|NCT00625391|DRUG|Placebo|500 mg medicinal starch pills daily
223738349|NCT05448066|DIAGNOSTIC_TEST|Standard diagnosis|Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
223738350|NCT05776667|RADIATION|Hypofractionated Radiation Therapy|"Participants will receive preoperative 5-day HFRT (30Gy/5fx once daily over consecutive weekdays) followed by standard of care wide local excision 2-6 weeks later."
223738351|NCT05436951|BEHAVIORAL|Brief on-shift nap|The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.
223408603|NCT03379727|DRUG|anthracycline ((daunorubicin or idarubicin): Induction Phase only|daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
223408604|NCT00715273|DRUG|Atorvastatin|10 to 80 mg of atorvastatin each day
223738352|NCT05459116|DEVICE|Placement of nasogastric balloon|A nasogastric balloon catheter will be inserted after inclusion. This will be a NutriVent (Sidam S.R.L., Mirandola, Italy) for patients \>40kg, and a SmartCath Esophageal pressure catheter (Vyaire/Carefusion) for patients \<40kg. This placement is similar to a standard nasogastric tube placement, which is a common procedure in an ICU. Potential minor side effects include a nosebleed, sore throat and erosion of the nose where the tube is anchored. All patients will receive this intervention. When the esophageal catheter becomes displaced or is accidentally removed during the study period, it will be replaced.
223558356|NCT00625391|DRUG|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
223738353|NCT05785000|OTHER|Physical exercise programme as an add-on|Consists of an individually tailored bike exercise program guided by symptoms, pulse rate and patient specific judgement of exertion monitored also by BORG RPE and VAS and progressively increasing time and level of resistance below symptom provocation
223738354|NCT05785000|OTHER|Control patients receiving usual care|No exercise intervention
223738355|NCT01896440|DRUG|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
223738356|NCT02176330|OTHER|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
223738357|NCT02176330|OTHER|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
223738358|NCT05151146|DRUG|ANJ900|Metformin hydrochloride delayed-release tablets
223738359|NCT05151146|DRUG|Metformin IR|metformin hydrochloride
223738360|NCT02104700|DRUG|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
224024743|NCT00220753|DEVICE|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
224024744|NCT02953171|OTHER|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
224024745|NCT02953171|DIETARY_SUPPLEMENT|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
223408605|NCT00715273|DRUG|Niacin|2000 mg of niacin each day
223408606|NCT00715273|DRUG|Colesevelam|3.8 g of colesevelam each day
223408607|NCT00715273|DRUG|Placebo Niacin|Placebo niacin each day
223408608|NCT00715273|DRUG|Placebo Colesevelam|Placebo colesevelam each day
223408609|NCT06270576|DRUG|Lipopolysaccharides|LPS aka endotoxin is a component of bacterial cell walls and is ubiquitous in the environment. It is found in pet dander, house dust and environmental dusts and has been heavily studied in asthma.
223408610|NCT03726827|OTHER|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
223558357|NCT00625391|DRUG|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
223558358|NCT00625391|DRUG|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
223558359|NCT05415254|DRUG|Calcitriol|Calcitriol supplementation orally
223558360|NCT03869567|DEVICE|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
223558361|NCT00248911|BEHAVIORAL|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
223558362|NCT01505036|OTHER|SMARTCARE service|U-Healthcare service
223738361|NCT06151795|DIAGNOSTIC_TEST|XTR006|Single dose intravenous injection of XTR006. Serial whole-body PET scan will be obtain after injection, blood and urine collection after injection for the assessment of pharmacokinetics.
223408611|NCT02481089|OTHER|validation group|
223408612|NCT00170027|DEVICE|Magnetocardiograph|
223738362|NCT01384968|DIETARY_SUPPLEMENT|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
223738363|NCT03847454|COMBINATION_PRODUCT|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
224024746|NCT02953171|OTHER|Pasteurized sauerkraut|Sauerkraut without live bacteria.
223408613|NCT00712192|PROCEDURE|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
223408614|NCT01837264|DEVICE|Magellan®|
223408615|NCT00651833|DRUG|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
223408616|NCT02367651|DRUG|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
223408617|NCT02367651|DRUG|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
223558363|NCT02553551|DRUG|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
223558364|NCT02553551|DRUG|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
223558365|NCT03303053|DRUG|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
223558366|NCT03303053|DRUG|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
223558367|NCT03303053|DRUG|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
223558368|NCT06166342|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
223558369|NCT06166342|DIETARY_SUPPLEMENT|TCI153 probiotic sachet|Consume 1 sachet daily
223408618|NCT01076673|BIOLOGICAL|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
223408619|NCT01076673|DRUG|Hyaluronic Acid|Hyaluronic acid injections
223408620|NCT00697905|DRUG|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
223408621|NCT00697905|DRUG|Carboplatin|Intravenous following Gemcitabine infusion on day 1
223558370|NCT06657599|PROCEDURE|Major Abdominal Surgery|Patients with ASA I-IV, over 18 years of age, undergoing major abdominal surgery, have gynecological and GIS tumor, expected to stay in postoperative care unit for more than 24 hours.
223558371|NCT03599778|DRUG|Apatinib|XELOX + apatinib's MTD
223558372|NCT06652412|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
223558373|NCT06652412|OTHER|data prospectively collected|in cohort 2, external control from real word, data of patients with the same baseline characteristics from the same period and the same institute will be prospectively collected.
223558374|NCT06652412|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
223558375|NCT06652412|DRUG|Sintilimab|200 mg q3w
223558376|NCT06652412|DRUG|Fluorouracil|5-Fluorouracil or capecitabine
223738364|NCT03847454|OTHER|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
223738365|NCT01017614|DRUG|Monofer|"* administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~* administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
223738366|NCT01017614|DRUG|Iron Sulphate|200 mg daily
223738367|NCT00000901|DRUG|Indinavir sulfate|
223738368|NCT00000901|DRUG|Lamivudine|
223738369|NCT00000901|DRUG|Stavudine|
223738370|NCT01851564|DEVICE|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
224024747|NCT02953171|OTHER|Placebo capsule|Capsules without probiotics
224024748|NCT06109675|BEHAVIORAL|Nutrition Education|All mothers in this group will be given 3 nutrition education sessions including detailed informations on Nutrition Therapy in Cystic Fibrosis. In addition to the education sessions, an informational booklet and a high-energy sample recipe booklet will be given.
224024749|NCT06262685|OTHER|Preemptive pharmacogenetic atorvastatin dose based on CPIC guidelines|"Atorvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
224024750|NCT06262685|OTHER|Preemptive pharmacogenetic simvastatin dose based on CPIC guidelines|"Simvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
223408622|NCT00697905|DRUG|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
223408623|NCT00697905|DRUG|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
223408624|NCT02972905|DRUG|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
223408625|NCT02972905|DRUG|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
223408626|NCT04356547|DEVICE|Fiberoptic intubation with laryngeal mask AuraGain|Participants should perform an fiberoptic tracheal intubation through the AuraGain laryngeal mask, in a pediatric simulator.
223558377|NCT06652412|DRUG|Raltitrexed|Raltitrexed
223558378|NCT06652412|DRUG|Oxaliplatin|Oxaliplatin
223558379|NCT06652412|DRUG|Irinotecan (CPT-11)|irinotecan
223558380|NCT00249587|DRUG|Methadone|dosed to effect, every six hours
223558381|NCT03226847|PROCEDURE|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
223558382|NCT00395499|DRUG|Risperidone|
223738371|NCT01851564|OTHER|Standard Therapy|Standard Medical and Endoscopic Therapy
223738372|NCT03284164|DRUG|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
224138903|NCT05830513|DEVICE|Virtual Reality|Women will be randomly allocated to undergo OPU either with the use of virutal reality (group A) or the control group with standard treatment, without analgesia(group B). The participants of group A will wear the Oculus Quest 2 and will be surrounded by a virtual world. They will see objects flying towards themselves. They will be able to interact with the virtual world by hand controllers and can try to catch the objects.
224138904|NCT06553443|DEVICE|Angioplasty of all peripheral AVF stenosis|All peripheral AVF stenosis are to be treated with the same type of balloon depending on allocation
224138905|NCT02913352|PROCEDURE|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
223408627|NCT04356547|DEVICE|Fiberoptic intubation without laryngeal mask|Participants should perform an fiberoptic tracheal intubation without laryngeal mask, in a pediatric simulator.
223408628|NCT04031846|DRUG|Rotarix™|Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
223408629|NCT04031846|DRUG|Infanrix™ hexa|Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
223408630|NCT04031846|DRUG|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevenar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
223408631|NCT04031846|DRUG|Prevenar 13™|13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
223738373|NCT01401868|DRUG|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
223738374|NCT03202797|OTHER|audiometric tests|tone and speech audiometry
223738375|NCT03202797|OTHER|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
223738376|NCT03202797|OTHER|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
223408632|NCT05695612|OTHER|Novaloc Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Novaloc attachments. The proper Novaloc abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
223558383|NCT04303104|OTHER|GeneXpert Edge|Screening intervention: novel diagnostic for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected and performed at point-of-contact in a mobile van
223558384|NCT04303104|OTHER|GeneXpert Ultra|Screening intervention: novel diagnostic test for Active Case Finding (GeneXpert MTB/RIF) for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
223558385|NCT03939962|DRUG|SHR1210 combined with FOLFOX|"1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
223558386|NCT06661070|DEVICE|Electrolysis Percutaneous Therapeutic (EPTE)|EPTE device (Ionclinics, Valencia, Spain)
223558387|NCT06661070|OTHER|Dry Needling|A dry needle with size 0.30 × 40 (Agupunt, Barcelona, Spain)
223738377|NCT00221598|PROCEDURE|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
223738378|NCT05343975|PROCEDURE|biopsy with audio-guided Meditation|biopsy with audio-guided Meditation
223738379|NCT03635710|DEVICE|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
223738380|NCT03849859|DEVICE|Single plastic stent|Deployment of single plastic stent
223738381|NCT03849859|DEVICE|Multiple plastic stents|Deployment of multiple plastic stents
223738382|NCT01725334|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
223738383|NCT01058109|OTHER|calcium-rich diet|dietary calcium intake of 1500 mg/d
223738384|NCT01058109|OTHER|Calcium rich diet|dietary intake of 1500 mg/d from food
223738385|NCT05462821|DEVICE|Eye Patch|adhesive patch to cover eye
223738386|NCT06668064|DRUG|EYP-1901|Intravitreal Injection
223738387|NCT06668064|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
223408633|NCT05695612|OTHER|Locator Attachment|Each patient will receive two inclined implants placed in the mandibular canine region bilaterally using the flapless surgical technique. Patients will receive mandibular overdentures with Locator attachments. The proper Locator abutments will be selected and screwed on the implants according to the prosthetic platform and the tissue height. The metal housings will be connected to the existing mandibular overdenture by pick-up technique.
223738388|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
223738389|NCT06662188|GENETIC|JAG201|Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9-miniSHANK3)
223738390|NCT04233554|BEHAVIORAL|Patient Priorities Care|Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
223738391|NCT05521542|DEVICE|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter|SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter is a Drug-Coated Balloon to treat de novo lesions in patients with symptomatic stable angina, unstable angina, or NSTEMI
223738392|NCT06605300|DRUG|Intranasal Oxytocin (IN-OXT)|Subject assigned to receive intranasal administration of oxytocin (24 IU).
224024751|NCT06262685|OTHER|Preemptive pharmacogenetic pitavastatin dose based on CPIC guidelines|"Pitavastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
223408634|NCT00012376|DRUG|bryostatin 1|Given IV
223408635|NCT00012376|BIOLOGICAL|sargramostim|Given subcutaneously
224024752|NCT06262685|OTHER|Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines|"Rosuvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
223408636|NCT00012376|OTHER|laboratory biomarker analysis|Correlative studies
223408637|NCT00012376|OTHER|pharmacological study|Correlative studies
223408638|NCT02229760|DRUG|Tipranavir capsules|
223408639|NCT02229760|DRUG|Ritonavir capsules|
223408640|NCT04104503|DRUG|Lu AF11167|Lu AF11167 - 2 mg modified release tablets (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
224138906|NCT02913352|PROCEDURE|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
223408641|NCT04104503|DRUG|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
224138907|NCT00438399|DRUG|C. propionate - Corticosteroid 1|Twice daily application
224138908|NCT00438399|DRUG|C. propionate- Corticosteroid 2|Twice daily application
223408642|NCT04104503|DRUG|Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release tablet (reference formulation)|Single oral dose
223408643|NCT04723927|OTHER|Older adults|The data for motor function and gait pattern analysis was obtained.
223408644|NCT04632082|BEHAVIORAL|Telepsychoeducation with personalized videos|1 session with a psychologist plus 1 video a week for 4 weeks chosen based on symptom presentation
223408645|NCT04632082|BEHAVIORAL|Telepsychoeducation without personalized videos|1 session with a psychologist focused on reassurance and aspects of the outbreak
223408646|NCT02180529|DRUG|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
223408647|NCT02180529|DRUG|Placebo|
223408648|NCT03313557|DRUG|Wee-1 kinase inhibitor AZD1775|Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
223408649|NCT00786760|OTHER|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
223738393|NCT06605300|DRUG|Intranasal Vasopressin (AVP)|Subjects assigned to receive intranasal administration of vasopressin (20 IU).
223738394|NCT06605300|DRUG|Intranasal Placebo|Subjects assigned to receive intranasal administration of placebo.
223738395|NCT06588504|DRUG|Dasiglucagon|Participants will receive s.c. injection of dasiglucagon.
223738396|NCT06588504|DRUG|Glucagon|Participants will receive i.m. injection of glucagon.
223738397|NCT06215586|DRUG|Tovinontrine (CRD-750|Tablets administered orally
223738398|NCT06215586|DRUG|Placebo|Tablets administered orally
224024753|NCT06262685|OTHER|Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines|"Pravastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
224024754|NCT06262685|OTHER|Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines|"Lovastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
223408650|NCT00786760|OTHER|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
224024755|NCT06262685|OTHER|Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines|"Fluvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/"
223408651|NCT03809754|PROCEDURE|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
223408652|NCT03809754|PROCEDURE|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
223408653|NCT00772876|DRUG|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
223408654|NCT00042159|DEVICE|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
223408655|NCT00674960|RADIATION|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
223408656|NCT06491173|DEVICE|InfraScanner 2500™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
223408657|NCT04007120|DRUG|RVT-1601|Inhaled RVT-1601 administered once daily over two days
223408658|NCT06521697|DRUG|Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture|Multimodal analgesia using dexmedetomidine-ketamine-lidocaine mixture vs placebo normal saline
223408659|NCT06521697|DEVICE|Minimal flow sevoflurane|Minimal flow sevoflurane anesthesia (0.5 L/min) vs low flow sevoflurane (1 L/min)
223408660|NCT06868654|DRUG|Belantamab mafodotin|Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate
223408661|NCT06868654|DRUG|Daratumumab|Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody
223408662|NCT06868654|DRUG|Bortezomib|Proteasome Inhibitor
223408663|NCT06868654|DRUG|Dexamethasone|Synthetic glucocorticoid with anti-tumor activity
223408664|NCT04138498|DRUG|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
223408665|NCT04138498|DRUG|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
223408666|NCT04138498|DRUG|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
223408667|NCT04138498|DRUG|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
223408668|NCT05306691|DRUG|Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).|Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.
223408669|NCT06928493|OTHER|oral examination|"The pre-examination behaviors and attitudes of the children included in the study were measured by an independent dentist (Ş.Y.İ) using the Frankl Behavior Rating Scale (FS). Following this, the children were randomly divided into two groups PCC and CCC . The oral examination of PCC group was done in an isolated dental environment with white overalls, an FFP3 mask, and a visor. The oral examination of CCC group was done in normal dental environment with a standard white coat and surgical mask.After that, patients were asked to draw themselves or the pediatric dentist who performed the examination. A child psychiatrist (B.A.S.) and a pediatric dentist (R.D) with an internationally valid Child Drawing Analysis training certificate evaluated the children's drawings independently."
223408670|NCT01777282|DRUG|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
223408671|NCT01777282|DRUG|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
223408672|NCT01777282|DRUG|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
223408673|NCT01777282|DRUG|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
223408674|NCT01777282|DRUG|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
223738399|NCT06665672|DEVICE|Wrist worn vibro-acoustic device|The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.
223738400|NCT01239706|DRUG|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
223738401|NCT06860477|DRUG|Tislelizumab|Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle.
224024756|NCT06262685|OTHER|Standard of Care (SoC) dosing of atorvastatin|Subject allocated to this arm will receive the atorvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
223738402|NCT06860477|DRUG|Lenvatinib|Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily
223738403|NCT06860477|PROCEDURE|cryoablation|Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone. Lenvatinib plus Tislelizumab will be administered 1-3 days after cryoablation.
224024757|NCT06262685|OTHER|Standard of Care (SoC) dosing of simvastatin|Subject allocated to this arm will receive the simvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
224024758|NCT06262685|OTHER|Standard of Care (SoC) dosing of pitavastatin|Subject allocated to this arm will receive the pitavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
224024759|NCT06262685|OTHER|Standard of Care (SoC) dosing of rosuvastatin|Subject allocated to this arm will receive the rosuvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
223408675|NCT01777282|DRUG|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
223738404|NCT06860477|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|FOLFOX chemotherapy was administered intravenously every 2 weeks for a maximum of 12 cycles (oxaliplatin 85 mg/m², leucovorin, 400 mg/m2, fluorouracil 400 mg/m² \[bolus\], and fluorouracil 2400 mg/m² as a 46-h continuous intravenous infusion
223408676|NCT03990467|BIOLOGICAL|Plasma dosage of amikacin, piperacillin and tazobactam|Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam
223408677|NCT03953976|RADIATION|Intensity modulated radiation therapy (IMRT)|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
223408678|NCT06914934|DIETARY_SUPPLEMENT|High-dose resveratrol 500 mg/day|High-dose resveratrol 500 mg/day (preferably a high-bioavailability formulation, e.g., trans-resveratrol with piperine or liposomal).
223408679|NCT06914934|OTHER|Placebo|Placebo capsules, identical in appearance and schedule.
223408680|NCT06313398|BIOLOGICAL|Biotin-labeled red blood cells|Cellular Product (patient's own red blood cells washed in Biotin and infused back to patient)
223408681|NCT01131455|BIOLOGICAL|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
223408682|NCT00764660|DRUG|SCH 900435|tablets
223408683|NCT00764660|DRUG|Placebo|tablets
223408684|NCT06919055|OTHER|PCG auditory stimulation|PCG auditory stimulation during mental stress
223408685|NCT06919055|OTHER|MHR stimulation|MHR auditory stimulation during mental stress
223408686|NCT06919055|OTHER|Control-no treatment|no stimulation during mental stress
224024760|NCT06262685|OTHER|Standard of Care (SoC) dosing of prasavastatin|Subject allocated to this arm will receive the prasavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
224024761|NCT06262685|OTHER|Standard of Care (SoC) dosing of lovastatin|Subject allocated to this arm will receive the lovastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
224138909|NCT00438399|DRUG|C. propionate -Corticosteroid 3|Twice daily application
224138910|NCT00438399|DRUG|Corticosteroid 1- C. propionate|Twice daily application
224138911|NCT00438399|DRUG|Corticosteroid 2 - C. propionate|Twice daily application
224138912|NCT00438399|DRUG|Corticosteroid 3 - C. propionate|Twice daily application
223738405|NCT07001020|BEHAVIORAL|Technology-based Intervention|Technology-based intervention co-developed by a community board.
223738406|NCT06995378|BEHAVIORAL|Lab Result Communication Tool|A behavioral intervention delivered through a personalized EHR-integrated lab result communication tool designed to improve emotional and cognitive responses to lab results among adults aged 65+. The tool applies behavioral science principles such as risk personalization, simplified messaging, and visual framing to reduce patient anxiety, enhance understanding, and support informed decision-making.
223738407|NCT07132684|DRUG|Daunorubicin/Idarubicin|Daunorubicin/Idarubicin is used in Induction Therapy and Maintenance Therapy.
223738408|NCT07132684|DRUG|Cytarabine|Cytarabine is used in Induction Therapy, Consolidation Therapy and Maintenance Therapy.
223738409|NCT07132684|DRUG|Azacitidine|Azacitidine is used in VA regimen
223738410|NCT07132684|DRUG|Venetoclax|Venetoclax is used in VA regimen
223738411|NCT04678011|PROCEDURE|Personalized surveillance and intervention protocol|This study uses one arm. Participants will undergo endoscopic surveillance with intervals between 6 months and 2 years, depending on severity of polyposis and performed endoscopic interventions.
223738412|NCT03782636|DRUG|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
223738413|NCT03782636|OTHER|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
223408687|NCT06922123|BEHAVIORAL|Tactile stimulation|Patients will undergo a resting-state EEG and fNIRS recording, followed by the administration of the SECONDs scale. Tactile stimulation will then be performed on eight areas of the body (internal and external forearms, palms and backs of the hands on both sides) using six different stimuli categorized as pleasant, neutral, or unpleasant. Stimuli will be applied manually in randomized blocks. EEG and fNIRS data will be recorded before, during, and after stimulation. Behavioural responses will be evaluated through video analysis by independent raters. The session will last approximately 90 minutes.
223408688|NCT06922123|DEVICE|Neurophysiological Monitoring with SedLine|SedLine is a non-invasive neurophysiological monitoring device used to record the brain's electrical activity (EEG) through frontal electrodes. In this study, SedLine is employed to measure resting-state and stimulus-evoked cortical responses in patients with disorders of consciousness (DoC), in combination with functional near-infrared spectroscopy (fNIRS). The EEG signals are used to assess changes in neural activity before, during, and after tactile stimulation with various affective valences (pleasant, neutral, unpleasant). This combined multimodal approach enhances the understanding of sensory processing and cortical reactivity in patients with impaired consciousness.
223408689|NCT05354869|DEVICE|Urostym|electric pelvic floor muscle stimulator
223408690|NCT05354869|BEHAVIORAL|Standard care|patient education on home exercises and stretching
223408691|NCT05963633|BEHAVIORAL|Episodic Future Thinking (EFT)|The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
223408692|NCT05963633|BEHAVIORAL|Episodic Recent Thinking (ERT)|In the episodic recent thinking (ERT) condition, the participant will instead describe in vivid details events that have occurred in the recent past.
223738414|NCT06688344|OTHER|fESWT|fESWT will be applied for 1 session between weeks 4-9. The device will be set to low intensity at 0.20 mJ/mm2 - 4 Hz, 500 pulses will be applied from the tibiofemoral interval to the center of the tibiofemoral joint, and 1000 pulses will be applied to the soft tissues around the patella.
223738415|NCT06688344|OTHER|Conventional Physiotherapy|"Participants will be included in the traditional physiotherapy program for the first 9 weeks, and exercise progression will be provided in the form of weekly checks in the 10-12 week period. Between the 12-24th weeks, the exercise program will continue with face-to-face follow-up twice a month.~The traditional physiotherapy program to be applied in the first 9-week period will be as follows :~Week 1 Weight Transfer as Tolerable, NMES, Elevation, Cold Application, Ankle Pumping Exercises, Heel Slide Exercises, Isometric Quadriceps Exercises, Straight Leg Raise Exercises, Extension Brace~Week 2-3 Weight Transfer, Gait Training, NMES, Heel Slide Exercises, Straight Leg Raise, Quadriceps and Adductor Isometric Exercises, Extension Brace, Bicycle, Hip Abduction-Adduction Exercises~Week 4-8. week Mini Squat, Leg Press, Soft Ground Walking, Neuromuscular Training on Balance Board, Functional Strengthening with Elastic Band, Stair Climbing Up and Down"
223738416|NCT06688344|OTHER|shamfESWT|Participants in the control group will receive sham fESWT once a week in weeks 4-9. Participants will be prepared in the same way as the fESWT procedure, but the application will be done with a sham device.
223738417|NCT07050173|DRUG|Gamma-glutamylcysteine (GGC)|400mg tablet orally (two times) per day.
223738418|NCT07049029|BEHAVIORAL|PREP-Y|The intervention is a series of behavioral health/psychoeducational modules that the participant will learn from. Participants will use the information discussed and overall impact on physical activity engagement, chronic pain management, and quality of life will be measured
223738419|NCT06736431|BEHAVIORAL|Text-based resource referral platform with diabetes educational materials|Text-based resource referral platform with diabetes educational materials
223738420|NCT06737341|DRUG|Bupivacaine Liposomes(BL)|20ml of bupivacaine liposomes (266mg) + 10 ml of bupivacaine 0.75% hydrochloride + 20ml saline for ultrasound guided CMB.
224024762|NCT06262685|OTHER|Standard of Care (SoC) dosing of fluvastatin|Subject allocated to this arm will receive the fluvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
224138913|NCT03374748|OTHER|N/A - observational study|N/A - observational study
223408693|NCT04089579|BIOLOGICAL|Cord Tissue Mesenchymal Stromal Cells|Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
223558388|NCT04621240|BEHAVIORAL|Online SMART & Stress Solutions|1\. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
223558389|NCT05894889|BIOLOGICAL|Pembrolizumab 200 mg IV infusion|"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
223408694|NCT04089579|OTHER|Placebo Infusion|Placebo comparative infusion
223558390|NCT06290505|DRUG|Durvalumab|"Durvalumab will be supplied by AstraZeneca as a 500 mg vial concentrate for solution for infusion. The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0 and density of 1.054 g/mL. The label-claim volume is 10 mL.~Durvalumab is a sterile, clear to opalescent, colorless to slightly yellow solution, free from visible particles.~Investigational product vials are stored at 2°C to 8°C and must not be frozen. Investigational product must be kept in original packaging until use to prevent prolonged light exposure."
223558391|NCT02686632|BEHAVIORAL|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
223558392|NCT03206918|DRUG|Zanubrutinib|Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
223738421|NCT06737341|DRUG|Bupivacaine(B)|10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block
224024763|NCT03866304|DEVICE|Device: S2 Picosecond laser|Each subject will receive up to 16 laser treatments.
224138914|NCT00231244|DEVICE|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
224133245|NCT06179550|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with NGT according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223408695|NCT05992337|DIAGNOSTIC_TEST|Blood sampling|Blood sample collection for mRNA determination
223408696|NCT05992337|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for detection of ventricular dysfunction
223408697|NCT05992337|DIAGNOSTIC_TEST|Cardio MRI|MRI for early detection of myocardial impairment caused by chemotherapy
223408698|NCT05992337|DIAGNOSTIC_TEST|24-hours monitoring of ECG|Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity
223408699|NCT05992337|DIAGNOSTIC_TEST|24 hours monitoring of BP|Diagnostic test for detection of hypertension as a consequence of cardiotoxicity
224024764|NCT03501641|OTHER|image-based virtual reality learning|The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
224024765|NCT03501641|OTHER|video-based learning|voice of the staffs and standard patients.
223408700|NCT06931704|DRUG|Elranatamab|"Each injection may be up to 2 mL in volume; however, if the maximum volume allowed per institution's policy is lower than 2 mL, the number of injections may be increased to accommodate this difference in volume and ensure the correct dose is delivered. Elranatamab should be administered to the abdomen, with preference given to the lower quadrants when possible.~Each participant may receive study intervention for a maximum of 24 cycles."
223408701|NCT06931704|DRUG|Daratumumab|1800 mg will be administrated every cycles
223408702|NCT06931704|DRUG|Lenalidomide|Daily administarted during 21 days, at each cycle
223408703|NCT06940765|DEVICE|GID SVF-2 Device System|The GID SVF-2 device is indicated for use for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue.
223408704|NCT06940076|DRUG|gayo arabica coffee skin extract cream|Assessment of glagou scale, skin analyzer, corneometer, and tewameter was done before and after the treatment . The subject will receive directions on how to use the cream before the study starts. The cream was used 2 times daily (7.40 AM and 1.00 PM) for 8 weeks.
223408705|NCT06941168|PROCEDURE|Robotic Total Gastrectomy and Laparoscopic Total Gastrectomy|"RTG:Robotic total gastrectomy with D2 lymphadenectomy performed using the Da Vinci Surgical System, following the Japanese Gastric Cancer Treatment Guidelines.~LTG:Laparoscopic total gastrectomy with D2 lymphadenectomy performed by experienced surgeons following standardized procedures, based on the Japanese Gastric Cancer Treatment Guidelines."
223408706|NCT06941207|BEHAVIORAL|virtual reality video viewing group|The caregivers, the first group in the experimental group, will be shown a total of 8 sessions of virtual reality-based videos (nature, forest walks and city tours, etc.) for an average of 30 minutes, twice a week for 4 weeks.
223408707|NCT06941207|BEHAVIORAL|benson relaxation exercise group|The second group in the experimental group, the caregivers, will have a total of 8 sessions of Benson relaxation exercises for 20-25 minutes, twice a week for 4 weeks.
223408708|NCT06940661|DRUG|Obinutuzumab|"Patient will receive 1000 milligrams intravenous (IV) infusion on week 0, week 2, week 24 and week 26.~Patients will receive the same standardized glucocorticoid tapering schedule (prescribe as a standard of care management and considered as auxiliary medicinal product)~Premedication for obinutuzumab infusion related reactions (considered as auxiliary medicinal products) :~* 100 mg methylpredinisolone~* 1000 mg paracetamol~* 5 mg dexchlorpheniramine"
224024766|NCT00038909|DRUG|BDDrFVII|
224024767|NCT04264078|BIOLOGICAL|CD7 UCAR-T cells|Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
224024768|NCT04264078|DRUG|Fludarabine|30mg/m\^2 per day for 6 days
224024769|NCT04264078|DRUG|Cytoxan|600mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
224024770|NCT04264078|DRUG|Melphalan|50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
224024771|NCT02832154|OTHER|Internet-Based Intervention|Complete online PA program
224024772|NCT02832154|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224024773|NCT02832154|OTHER|Questionnaire Administration|Ancillary studies
224024774|NCT04989465|BIOLOGICAL|Investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection
224138915|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
224138916|NCT02472119|DIETARY_SUPPLEMENT|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
224138917|NCT02472119|DIETARY_SUPPLEMENT|Gluten-free diet|gluten-free diet
224024775|NCT04989465|BIOLOGICAL|Control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd. 25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0·5 mL of light disodium phenol phosphate, sodium hydrogen phosphate and sodium chloride per injection
224024776|NCT01507818|DEVICE|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0\>
224024777|NCT01507818|DEVICE|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
224024778|NCT00075647|DRUG|temsirolimus|Given IV
224024779|NCT00075647|OTHER|laboratory biomarker analysis|Correlative studies
223738422|NCT06740526|DRUG|Sibeprenlimab|"Sibeprelimab SC (Period 1)~Sibeprelimab SC (Period 2)"
223738423|NCT07053423|DRUG|Dupilumab|Pharmaceutical form:Solution for injection-Route of administration:SC injection
223738424|NCT07053423|DRUG|Placebo|Pharmaceutical form:Solution for injection-Route of administration:SC injection
223738425|NCT04727047|DEVICE|neuromuscular electrical stimulation|All subjects will receive standard rehabilitation for Achilles tendon repair. In addition, neuromuscular electrical stimulation will be applied to the calf muscles of the injured leg. The stimulation volume, the electrode placement and the intensity of the stimulation will be selected based on the mechanical strength of healing Achilles tendon. The intervention will be applied for 6 weeks after repair.
223738426|NCT03676218|OTHER|Elderly cancer patients|No intervention: Panel of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
223738427|NCT06758011|DEVICE|ivWatch|Patients wear ivWatch device at time of already scheduled chemotherapy on study.
224133246|NCT06179550|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with IOE according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm (Appendix). However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224133247|NCT01255046|DRUG|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
224133248|NCT01255046|DRUG|STA-1|300mg/tab, 2 tab/tid for 72 weeks
224133249|NCT01255046|DRUG|placebo|2 tab/tid for 72 weeks
224133250|NCT01389622|OTHER|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
224133251|NCT01389622|OTHER|acupuncture|random points + digital pressure
224133252|NCT00325286|DRUG|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
223408709|NCT06940583|OTHER|VR|Participants will view a relaxing virtual environment (e.g. nature landscapes, lightly animated themes) for 5 minutes prior to the colposcopy procedure and during the colposcopy wearing a VR headset.
223408710|NCT06940583|OTHER|Podcast|Participants will listen to a podcast of relaxing or informative content for 5 minutes before and 5 minutes during colposcopy. The content will be selected according to individual preferences (e.g. storytelling, humorous content or educational content).
223408711|NCT06941285|OTHER|Data collection|Data collection
223408712|NCT06940687|BEHAVIORAL|Pre-recorded Music Session|A pre-recorded concert session
223408713|NCT06940687|BEHAVIORAL|Live Music Session|A 45-minute live music performance
224133253|NCT00115804|DRUG|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
224133254|NCT06376266|COMBINATION_PRODUCT|nutritional supplements|a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
224133255|NCT02226042|BEHAVIORAL|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
224138918|NCT02568124|DRUG|Tranexamic Acid|
223408714|NCT02511418|DRUG|Simvastatin|
223408715|NCT06939998|PROCEDURE|FOBIET|"an endotracheal tube (ET) is initially inserted into the nasal cavity, and then a flexible fiberoptic bronchoscope is introduced through it. The endotracheal tube will be connected to a catheter mount by which the investigator can deliver oxygenation. When using a nasal endotracheal tube, the tip is lubricated with 2% lignocaine jelly before being inserted into the nasal cavity and pushed up and down to allow the jelly to spread. The fiberoptic bronchoscope descends through the endotracheal tube after being inserted into the nasal passage as a nasal airway in the direction of the vocal cords until they can be seen.~After identifying the vocal cords, 2 ml of 2% lidocaine will be sprayed over the supraglottic area using the bronchoscope's working channel. An additional 2 ml of 2% lidocaine will then be sprayed directly onto the vocal cords, after which the tip of an endotracheal (ET) tube will be carefully inserted into them."
223738428|NCT07063303|OTHER|Intermittent feeding|"Feeding Frequency: Enteral nutrition will be provided every 4 to 6 hours via nasogastric tube.~Feeding Volume: Each session will deliver 240 to 720 mL of enteral formula. Feeding Duration: Each feeding session will last approximately 20 to 60 minutes."
223738429|NCT07063303|OTHER|Continuous feeding|"Feeding Frequency: Enteral nutrition will be administered continuously for 20 hours per day via nasogastric tube.~Feeding Volume: The total daily volume will be divided evenly over the 20-hour infusion period, based on individual nutritional requirements.~Feeding Duration: Each 24-hour cycle includes 20 hours of continuous feeding followed by a 4-hour rest period."
223738430|NCT06898515|DEVICE|Reprieve System|The Reprieve System is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
224138919|NCT02568124|DRUG|Placebo|
224138920|NCT02207595|DRUG|UCB5857|"* Active Substance: UCB5857~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
224138921|NCT02207595|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Capsule~* Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~* Route of Administration: Oral Use"
223408716|NCT06939998|PROCEDURE|CFOBI|a 5.0-mm flexible fiberoptic bronchoscope (Pentax) will be loaded with an endotracheal tube of the proper size (7.5 for male and 7.0 for female patients). The bronchoscope tip will then be introduced into the nasal cavity, and the vocal cords will be detected.
224024780|NCT01616056|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Wear bandage lenses
223738431|NCT06898515|DRUG|furosemide infusion|Participants randomized to ODT will be treated with guided diuretic titration, as recommended in the ESC guidelines on diuretic therapy
223738432|NCT06648382|BEHAVIORAL|Self-directed psychotherapy program for premenstrual disorders|The intervention consists of receiving 11 videos that are 10-15 minutes in length along with a workbook containing homework exercises. Participants are instructed to watch the videos over the course of two menstrual cycles: the first 6 during the first cycle and the last 5 during the second cycle. Each module focuses on a different skill inspired by cognitive behavioral therapy and dialectical behavior therapy.
224024781|NCT01616056|OTHER|questionnaire administration|Ancillary studies
224024782|NCT01616056|PROCEDURE|optical coherence tomography|Optional ancillary studies
223408717|NCT03103152|DRUG|High dose Aspirin & Vitamin D|Aspirin 1 x 300mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
224024783|NCT02447367|DRUG|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
223408718|NCT03103152|DRUG|High dose Aspirin, Vitamin D placebo|Aspirin 1 x 300mg tablet daily \& Vitamin D placebo (8 drops).
223558393|NCT06659653|DRUG|PRG2302|Dose group 1: with a dosage of 0.5x10\^6 (cells/kg) per dose Dose group 2: with a dosage of 1.0x10\^6 (cells/kg) per dose Dose group 3: with a dosage of 2.0x10\^6 (cells/kg) per dose
224024784|NCT02447367|DRUG|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
224024785|NCT06347406|OTHER|Blood flow restriction combined with physiotherapy and education|Blood flow restriction Physiotherapy exercises Education
224138922|NCT01970514|DEVICE|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
223558394|NCT00292201|DRUG|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
223558395|NCT06658561|PROCEDURE|cold snare polypectomy|Place the special cold snare in the normal mucosa 1-2mm away from the polyp edge. Tighten the snare at a constant speed and gently lift it up and then excision.
223558396|NCT06658561|PROCEDURE|hot snare polypectomy|According to evaluation of the polyps, directly place the snare on the edge of the polyp including a clear margin of normal tissue (1-2 mm) or after submucosal injection. Tighten the snare at a constant speed and gently lift it up.Use the electrocoagulation and electroscission mode, power on for several seconds until the polyp is cut off.
224024786|NCT00873314|BEHAVIORAL|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
224024787|NCT00873314|BEHAVIORAL|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
224024788|NCT01249274|DRUG|Progesterone|100mgs progesterone twice daily
223408719|NCT03103152|DRUG|Low dose Aspirin , Vitamin D|Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
223558397|NCT06991348|DRUG|Tegoprazan|Tegoprazan 50 mg daily for 28 days
223738433|NCT04735666|DEVICE|TauroPace™|TauroPace™ is intended to be used as a disinfecting solution during any CIED related surgery procedure or handling of any uncoated or silicon-, epoxy- or polyurethane-coated CIED (including its components, e.g., leads) made of titan or stainless steel in any adult patient requiring or carrying a CIED.
223738434|NCT04219891|DEVICE|WaveLight EX500 excimer laser system with InnovEyes sightmap|FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the WaveLight EX500 software will be upgraded to include the InnovEyes treatment.
223738435|NCT04219891|PROCEDURE|LASIK|Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system and data obtained from the InnovEyes sightmap.
224024789|NCT01249274|OTHER|Placebo|Matched placebo pills to be taken twice daily
224024790|NCT01725542|DRUG|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
224024791|NCT00138671|DRUG|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
224024792|NCT00138671|DRUG|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
224024793|NCT05941767|DRUG|Dexmedetomidine nebulization|The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.
224024794|NCT05941767|DRUG|Lidocaine nebulization|The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.
224138923|NCT05913141|OTHER|Drug screen with PDO/PDO-TIL/PDOTS|Drug screen with patient-derived organoids, patient-derived organoids-tumor-infiltrating lymphocyte coculture system, or patient-derived organotypic tissue spheroids.
223408720|NCT03103152|DRUG|Low dose Aspirin, Vitamin D placebo|Aspirin 1 x 100mg tablet daily \& Vitamin D placebo 8 drops daily.
223408721|NCT03103152|DRUG|Aspirin Placebo, Vitamin D|Aspirin 1 x 300mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
223408722|NCT03103152|DRUG|Aspirin placebo, Vitamin D placebo|Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
223558398|NCT06991348|DRUG|Pantoprazole|Pantoprazole 40 mg daily for 28 days
223558399|NCT03512808|DRUG|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
223738436|NCT04219891|DEVICE|InnovEyes sightmap|Non-contact ophthalmic diagnostic device that captures images of the eye and collects ocular data preoperatively to generate a patient-specific ablation profile for refractive correction surgery
223738437|NCT06910046|DIAGNOSTIC_TEST|CLE and ssRAB-guided cryobiopsy|All procedures are performed under general anesthesia with endotracheal intubation and mechanical ventilation. A conventional flexible bronchoscope is used to examine the subject's airway and clear the secretion. After the registration procedure is completed, the catheter of the ssRAB system is navigated to the target lesion. Cone beam computed tomography (CBCT) is used to confirm whether the target lesion has been reached. After that, an appropriate CLE probe is inserted. Right before CLE imaging, 2.5 ml of 10% fluorescein sodium is administered intravenously. CLE is then used to examine the target lesion. Based on real-time CLE imaging, the optimal biopsy location is identified and localized on the fluoroscopy. After CLE imaging, the CLE probe is retracted, followed by cryobiopsy at the same location under fluoroscopy guidance. Rapid on-site evaluation is available during the procedure to assess sample adequacy.
223738438|NCT05636098|DEVICE|Masimo Rainbow Sensors|Noninvasive pulse oximeter sensor
223738439|NCT05933629|BEHAVIORAL|Online EmReg|A Web-based group intervention to improve emotion regulation in individuals with traumatic brain injury (TBI). Online EmReg is a 3-hour on-demand training workshop
223738440|NCT05933629|BEHAVIORAL|Consultation Sessions|3 months of bi-weekly consultation sessions
223738441|NCT06913023|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3mg for 4 weeks.
223738442|NCT06913023|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7mg for 4 weeks.
223738443|NCT06913023|DRUG|Semaglutide 14 MG [Rybelsus]|Semaglutide 14mg for 16 weeks.
223738444|NCT06913023|DRUG|Placebo Oral Tablet|Placebo tablet
224024795|NCT05941767|DRUG|Dexmedetomidine IV|The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
223738445|NCT06914232|COMBINATION_PRODUCT|Warm Compress|The intervention involves perioperative Warm compress therapy administered to the participants in the intervention group before and after cataract surgery for 3 seesions per week for 6 weeks. The therapy aims to enhance tear film stability and alleviate symptoms of dry eye by delivering warm compress to the meibomian glands to restore their function. Participants will undergo a session of warm compress therapy prior to surgery and another one following the surgery.
223738446|NCT06914232|DIAGNOSTIC_TEST|Standard Care|The control group will receive standard care, which includes artificial tears or other conventional methods for dry eye management for 3 sessions per week for 6 weeks. , but they will not receive Warm Compress therapy.
223738447|NCT06914531|OTHER|Questionnaire comprehension test|Participants will complete a standardized questionnaire assessing social cognition, adapted for cochlear-implanted children aged 3 to 6 years. The assessment includes the Item Scale and the Test of Emotions Comprehension adapted and mixed together. The questionnaire evaluates children's ability to understand emotions, social interactions, and cognitive perspective-taking. Each child will complete the test in a single session lasting approximately 20 minutes, under the supervision of a trained investigator, with an orthophonist and a parent present
223738448|NCT06913413|COMBINATION_PRODUCT|core stabilization exercise|Will receive 8 week core stabilization exercise 3 session per week which include 10 min warm up and 10 min cool down (walking ) 6 sets of movements co contraction of abdominal muscles (Abdominal hollowing) ,bridging ,dead bug ,plank with 50,000 IU of vitamin D weekly
223738449|NCT06913413|DIAGNOSTIC_TEST|stabilization exercise|stabilization exercise 3 session per week which include 10 min warm and 10 min cool down (walking ) sham medicine, 6 sets of movements co contraction of abdominal muscles (Abdominal hollowing) ,bridging ,dead bug and plank
223738450|NCT06913179|BIOLOGICAL|All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission following CAR-T infusion will subsequently undergo allo-HSCT|All enrolled patients will first receive CAR-T cell therapy. Patients who achieve complete remission (CR) following CAR-T infusion will subsequently undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) based on clinical assessment. The entire treatment process will be standardized and closely monitored, with follow-up evaluations focusing on adverse events, engraftment success, relapse risk, and overall survival.
224024796|NCT05941767|DRUG|Lidocaine IV|The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
224024797|NCT02706912|BEHAVIORAL|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
224024798|NCT06367673|BIOLOGICAL|iPSC-NK cells|iPSC-NK cells
224024799|NCT04503343|OTHER|non-drug intervention|mindfulness training, relaxation training, or electrical cerebellar stimulation
223408723|NCT05311059|PROCEDURE|Laparoscopic ovarian drilling|Drilling needle was introduced and connected by monopolar current, held against ovarian surface for 4 seconds using a power of 40 watt, 4 puncture was done in each ovary with putting into consideration that the puncture must be not superficial and it must go deep through the main substance of the ovary
223408724|NCT03899792|DRUG|LOXO-292|Oral LOXO-292
223408725|NCT05412550|BEHAVIORAL|Exercise self-management|Six walking exercise self-management telehealth sessions will focus on behavior change techniques and personalized action plans. Peer support groups will be held every three months, and will be focused on supporting participants in attaining sustained exercise. Text message prompts will focus on encouraging exercise and health self-management.
223408726|NCT05412550|BEHAVIORAL|Attention control|The six individual telehealth sessions, six peer-group sessions, and text message prompts will focus on general health education. No prompts for exercise or health self-management will be given.
223408727|NCT06775340|DRUG|RSS0343 Tabella|RSS0343 tablets, oral;
224024800|NCT01049971|DEVICE|wound protector|after minilaparotomy, the wound protector is applied
224024801|NCT01049971|DEVICE|no wound protector|use of woven drape instead of wound protector
224024802|NCT00264927|DRUG|SR121463B|
224024803|NCT05898256|DRUG|Cadonilimab|10mg/kg administered intravenously (IV)
223408728|NCT05675930|DEVICE|Photobiomodulation Therapy|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days
223558400|NCT03512808|DRUG|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
223558401|NCT06992843|OTHER|Goal-directed care bundle for neuroprotection|"Reducing lactate (Lac) to \<2 mmol/L within 24 hours.Maintaining systolic arterial pressure at 120-140 mmHg.~Elevating the head-of-bed to 30 degrees. Maintaining body temperature ≤37.7°C. Maintaining PaO₂ at 70-100 mmHg. Maintaining PaCO₂ at 35-45 mmHg. Maintaining blood glucose at 7.8-10.0 mmol/L. Maintaining serum sodium level at 140-150 mmol/L. If any management parameter falls outside the target range, immediate correction is required within 24 hours of enrollment and must be sustained for 72 hours. Given the dynamic nature of some targets (e.g., mean arterial pressure, body temperature), a degree of flexibility is permitted in achieving these goals. Patients are considered to have successfully implemented the neuroprotection bundle if the achievement rate of individual targets is ≥80% and all targets are met. The medications(antipyretics, vasopressor agents) is acceptable to achieve these targets."
223558402|NCT06992843|OTHER|Usual Care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
223558403|NCT04601038|DRUG|CORT108297|120mg of a selective glucocorticoid receptor antagonist, taken as 2 tablets daily for 2 weeks
223558404|NCT04601038|DRUG|Placebo|Placebo taken as 2 tablets daily for 2 weeks
223558405|NCT04926636|BEHAVIORAL|Health and Wellness Coaching|An enhanced mobile application that allows for participation in health coaching features. Participants will be assigned to a health coach and will have coaching sessions scheduled.
223558406|NCT05396846|BEHAVIORAL|Eating Plan 1|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
224024804|NCT05898256|DRUG|Gemcitabine|1 g/m2, administered as an IV infusion within 30 minutes
224024805|NCT05898256|DRUG|Cisplatin|80 mg/m2, administered as an IV infusion over 4 hours
224024806|NCT02418273|DRUG|denosumab|These subjects will receive two doses of denosumab.
223408729|NCT05675930|OTHER|Placebo sham device|Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
223558407|NCT05396846|BEHAVIORAL|Eating Plan 2|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
223558408|NCT05396846|BEHAVIORAL|Eating Plan 3|The goal is to follow a preventive style of eating that is thought to lower the risk of colorectal cancers.
223558409|NCT01526941|DRUG|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
223558410|NCT01526941|DRUG|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
223558411|NCT06072833|BEHAVIORAL|Patient Financial Education / Navigation|The investigator anticipates that this will include a baseline financial assessment and educational content, likely using a virtual platform. Participants will be connected with a PAF case manager. There will be monthly follow-ups to the participant for 6-months to address any financial concerns through additional counseling/navigation.
223558412|NCT07028957|PROCEDURE|Group A; Low volume local anesthetic in Ultrasound guided combined Supraclavicular and Interscalene block for Upper limb surgery|Group A; will receive ultrasound guided combined Supraclavicular Block (SCB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%) and Interscalene Block (ISB) with 7-10 ml (3.5-5 ml bupivacaine 0.5% plus 3.5-5 ml lidocaine 2%).
223558413|NCT07028957|PROCEDURE|Group B; High volume local anesthetics (30-40ml) ultrasound guided combined Supraclavicular Block (SCB) and Interscalene Block (ISB)|Group B; High volume local anesthetics in ultrasound guided combined Supraclavicular Block (SCB) with 15-20 ml (7.5-10ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%) and Interscalene Block (ISB) with 15-20 ml (7.5-10 ml bupivacaine 0.5% plus 7.5-10 ml lidocaine 2%).
223558414|NCT06880055|DIAGNOSTIC_TEST|Shield Blood Test for colo-rectal cancer Screening|Shield Blood Test for colo-rectal cancer Screening
223738451|NCT06912620|DIETARY_SUPPLEMENT|Soy-based RUTF|This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids
223738452|NCT06912620|DIETARY_SUPPLEMENT|Soy-maize-sorghum-based RUTF|This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids
223738453|NCT06912620|DIETARY_SUPPLEMENT|Standard RUTF|This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients
223738454|NCT06913634|DRUG|Luspatercept (ACE-536)|Luspatercept (ACE-536)
223738455|NCT06914583|DEVICE|Sodium Hyaluronate|Sodium Hyaluronate 32 mg/ml
223738456|NCT06914804|DEVICE|Stomasense|A smart device worn alongside stoma pouch systems which detects onset of a leak.
223738457|NCT02697695|OTHER|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
223738458|NCT00433849|DRUG|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
223738459|NCT00433849|DRUG|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25\~400μg(i.v./p.o.)/4weeks for 40 weeks
224024807|NCT01952054|DRUG|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
224024808|NCT04213430|OTHER|diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
224024809|NCT00002060|DRUG|Inosine pranobex|
224024810|NCT02585479|DRUG|Pirarubicin|"1. Pirarubicin 30mg/m2 intravenously~2. Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
224024811|NCT02585479|DRUG|Oxaliplatin|"1. Oxaliplatin 100 mg/m2 intravenously~2. Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
224024812|NCT02585479|DRUG|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
224024813|NCT02585479|DEVICE|Gelfoam|Hepatic artery embolization with Gelfoam.
224297961|NCT02860442|BEHAVIORAL|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
224297962|NCT02860442|OTHER|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
224297963|NCT06456437|DEVICE|Post-conditioning Balloon dilation and contraction|The balloon was filled at a pressure of no more than 4 atm at the original occlusion of the vessel to block blood flow for 2 minutes (confirmed by angiography), and then contracted to reperfuse the blood flow for 2 minutes, and the above steps were repeated 4 times to complete the in situ ischaemic post-acclimatisation intervention.
224297964|NCT02654171|DRUG|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
224297965|NCT02654171|DRUG|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
224297966|NCT04216615|BEHAVIORAL|preoperative anxiety|patients who are anxious
224297967|NCT02219971|DRUG|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
224297968|NCT05289128|DEVICE|Experimental group|10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
223408730|NCT05368493|OTHER|MRI task|Task fMRI (Simon) \[ Time Frame: Children will undergo MRI scans when they are 6-11 years of age. \] Children will also complete a task, which will allow exploratory analyses of the functionality of attention-related neural circuits. The Simon fMRI task is a non-verbal task equivalent to the Stroop that tests sustained attention and inhibitory control and discriminates children with and without ADHD. Exploratory fMRI time-series data for each participant will be modeled using a general linear model with 3 predictors: congruent correct, incongruent correct, and incorrect. Contrast images for each participant (e.g., incongruent-minus-congruent) will be generated and entered into a group-level random-effects model. Analyses are exploratory, and will focus on frontal lobe activity during each type of trial.
223408731|NCT06019845|DEVICE|MAGiC™|Robotic magnetic radiofrequency (RF) ablation catheter
223408732|NCT03208166|DEVICE|Doctormate|Ischemic conditioning device
223408733|NCT03208166|OTHER|Usual Care|Standard medical care
223408734|NCT03668119|BIOLOGICAL|Nivolumab|Specified dose on specified days
223408735|NCT03668119|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223408736|NCT02252393|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RARC with IUD
223558415|NCT07033780|DEVICE|Spaced iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left dorsolateral prefrontal cortex (DLPFC) to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity. TMS-EEG will be performed to measure changes in brain plasticity throughout the trial. An EEG cap will be placed on the participant's head, and the electrodes on the cap will be filled with saline gel using a dull syringe.~During the intervention, the study team will conduct a baseline TMS-EEG measurement consisting of single TMS pulses. Participants will then complete iTBS-s (experimental study intervention), which will be delivered to the left DLPFC. Following iTBS-s, post-iTBS TMS-EEG measurements will be obtained consisting of 3 TMS trains delivered to the left DLPFC (Post-0, Post-20, and Post-60 minutes)."
223738460|NCT00290914|DRUG|Vilazodone|
223738461|NCT07206485|DEVICE|vibro-acoustic therapy|Vibroacoustic therapy (VAT) is a type of sound therapy that involves passing low frequency sine wave vibrations into the body via a device with embedded speakers
223408737|NCT02252393|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RARC with EUD
223738462|NCT07206485|DEVICE|Motion Guidance Laser|Motion Guidance Laser is a tool used to improve the curative progression by leading to excessive participation of the subject, helping to facilitate motor skills, postural stability
223408738|NCT02252393|OTHER|intraoperative complication management/prevention|Undergo RARC with IUD
223408739|NCT02252393|OTHER|intraoperative complication management/prevention|Undergo RARC with EUD
223408740|NCT02252393|OTHER|quality-of-life assessment|Ancillary studies
223408741|NCT05355051|DRUG|Azacytidine|Given by Vein (IV)
223408742|NCT05355051|DRUG|Pembrolizumab|Given by Vein (IV)
223738463|NCT07206485|OTHER|selected physical therapy exercises program|"1. Passive Prolonged Stretching and positioning~2. Range of motion exercises for both upeer limb and lower limb~3. Balance exercises static and dynamic"
224297969|NCT05289128|DEVICE|Sham Control|10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity.The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
224297970|NCT02287493|OTHER|Pharmacokinetic Analysis|
224297971|NCT00324311|DRUG|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
223408743|NCT05977335|DIAGNOSTIC_TEST|Autonomic Function Testing|Autonomic Function Testing (AFT) includes Valsalva Manoever, Deep Breathing Test, and Head-up Tilt Table Testing.
223408744|NCT04973930|BEHAVIORAL|Interpersonal Psychotherapy|Time-limited, affect-focused, empirically supported psychotherapy
223408745|NCT04973930|DRUG|Venlafaxine HCl ER|FDA-approved antidepressant medications
224024814|NCT05664386|DRUG|propofol|propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
224024815|NCT05664386|DRUG|ciprofol|Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
224297972|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
223408746|NCT05336227|BEHAVIORAL|Virtual Reality Exergaming|The VR intervention will include home-based exercise using the Oculus Quest, a heart rate monitor (Polar OH1), BP cuff, and mobile application. The games will include rhythmic movements to music and sport/recreation activities that elicit high energy expenditure. Participants will be instructed to reach 150 minutes per week of moderate-exercise in week 1 and maintain this volume across the 12-week intervention. The intervention will include behavioral, physical education coaching through videoconference, which we refer to as Tele-PE. Tele-PE will aim to enhance adherence, provide basic exercise knowledge, and increase mastery playing the games. Calls will last 15 minutes, and be provided weekly in month 1, bi-weekly in month 2, and one call at the end of month 3.
223738464|NCT07205328|DRUG|MT200605|MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.
223738465|NCT07205328|DRUG|MT200605|MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.
223738466|NCT07205328|DRUG|MT200605|MT200605 is an agonist of the receptor tyrosine kinase B (TrkB) and can enhances ATP synthesis in the mitochondria of the striatum and bolsters antioxidant and free radical-scavenging capabilities.
224024816|NCT02742636|DEVICE|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
224024817|NCT01100034|DRUG|Etanercept|Expected duration of 24 weeks as one course
224024818|NCT01382420|PROCEDURE|surgery|adrenalectomy
224024819|NCT00547131|DRUG|temozolomide|
224133256|NCT04234815|BEHAVIORAL|CETA Short Session (CSS)|CETA Short Session (CSS) is a brief, low-intensity psychosocial intervention incorporating foundational components of the Common Elements Treatment Approach (CETA). CETA is an 8-12 session, transdiagnostic psychotherapy for common mental disorders. CSS was designed to serve as both a prevention/support approach for a broader range of needs, as well as an engagement/outreach strategy to identify and refer individuals to treatment. CSS is delivered in a group format over approximately two hours and consists of: 1) Psychoeducation: instruction about the brain and brain functioning, including normalization of psychological responses to stress and a brief self-assessment; 2) Safety: screening and referral for individuals identified as at risk of harm to self or others; and 3) Cognitive coping: based on the cognitive triangle, participants practice identifying an unhelpful thought changing it to a more helpful alternative, and examining how these thoughts impact feelings and behaviors.
224133257|NCT04234815|BEHAVIORAL|Psychoeducation and Safety|This intervention is the same as CSS with the exception that the cognitive coping skill training is removed.
224133258|NCT02294721|DEVICE|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
224133259|NCT02294721|DEVICE|The CPREazy|feedback device-1
224133260|NCT02294721|DEVICE|TrueCPR|feedback device -2
224133261|NCT02294721|DEVICE|The CPR PRO APP|feedback device -3
224024820|NCT00547131|OTHER|laboratory biomarker analysis|
224024821|NCT00547131|OTHER|liquid chromatography|
224133262|NCT02294721|DEVICE|The CardioPump|feedback device- 4
224133263|NCT01300611|DRUG|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
224133264|NCT01300611|DRUG|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
224024822|NCT00547131|OTHER|mass spectrometry|
224024823|NCT00547131|OTHER|pharmacological study|
224133265|NCT02683915|PROCEDURE|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
224133266|NCT01132989|DRUG|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and \< 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
224133267|NCT06866028|DEVICE|Real-time fNIRS neurofeedback from Turbo-Satori|Activity in the target brain region measured by fNIRS in real-time will undergo processing on Turbo-Satori (BrainVoyager; Maastricht, Netherlands) to infer changes in oxygenated blood activity in the target brain region and relayed to the task program for visual feedback.
224133268|NCT06866028|DEVICE|Yoked sham feedback from Turbo-Satori|Previous data acquired from another individual in the experimental group will be loaded into Turbo-Satori (BrainVoyager; Maastricht, Netherlands) software for preprocessing in real-time and relayed to the task program for visual feedback.
224133269|NCT06626139|DRUG|Psilocybin|Healthy participants will receive up to 25 mg psilocybin.
224297973|NCT03090997|DIETARY_SUPPLEMENT|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
224297974|NCT03090997|DIETARY_SUPPLEMENT|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
224297975|NCT04901013|OTHER|Affinity|Affinity is an aseptically processed, hypothermically stored fresh allograft with viable cells, growth factors/cytokines, and extracellular matrix (ECM).
224297976|NCT02775136|DEVICE|HS-1000 recording|
223408747|NCT04850989|DEVICE|Pico Goblin VR headset|We worked with Limbix to tailor content on a Pico Goblin VR headset by creating two exposure therapy themes (general social skills training/dinner party or job interview) based on CBT principles and literature. The Pico Goblin VR headset projected a 5.5-inch diagonal screen size (depth: 139.7 mm; height: 122mm; width: 68mm) with 2560 x 1440-pixel resolution, 3 degrees of freedom, 92° field of view, a refresh rate of 70Hz, and 54-71mm interpupillary distance (Kyoto, 2017). It was chosen because displays of the pre-recorded VRE videos could be smoothly operated wirelessly with a tablet that showed the selected scenes in real-time. Further, the headset could be conveniently switched on and off, and dovetailed the participant's head motion. These scenes were filmed with a 360° stereoscopic camera, each lasting between 1.5 to 10 min.
224297977|NCT00770536|DRUG|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
223408748|NCT03466684|OTHER|BIA-guided fluid resuscitation protocol|"In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA."
223558416|NCT07033780|DEVICE|Compressed iTBS|"Intermittent Theta-Burst Stimulation (iTBS) is a form of non-invasive brain stimulation that uses magnetic pulses applied to the scalp using a coil. iTBS will be used to stimulate the left dorsolateral prefrontal cortex (DLPFC) to enhance long-term potentiation (LTP)-like activity, a physiological mechanism associated with brain plasticity. TMS-EEG will be performed to measure changes in brain plasticity throughout the trial. An EEG cap will be placed on the participant's head, and the electrodes on the cap will be filled with saline gel using a dull syringe.~During the intervention, the study team will conduct a baseline TMS-EEG measurement consisting of single TMS pulses. Participants will then complete iTBS-c (active comparator), which will be delivered to the left DLPFC. Following iTBS-c, post-iTBS TMS-EEG measurements will be obtained consisting of 3 TMS trains delivered to the left DLPFC (Post-0, Post-20, and Post-60 minutes)."
223558417|NCT07033000|DIETARY_SUPPLEMENT|Placebo|Placebo
223558418|NCT07033000|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing blend of Digestive Enzymes, Dandelion, Ginger \& Fennel Extracts
223558419|NCT07033546|BEHAVIORAL|Toy bracelets|The intervention involves the use of colorful, child-friendly toy bracelets worn by children during procedures requiring physical restraint in the pediatric intensive care unit. These bracelets are designed to offer a sense of familiarity, distraction, and emotional comfort during potentially distressing experiences. Unlike standard care, which involves restraint without any therapeutic distraction tools, the toy bracelets serve as a non-pharmacological, low-cost, and easily applicable intervention aimed at reducing emotional distress. The intervention is distinguished by its simplicity, immediate usability, and focus on integrating play-based elements into clinical care to address the psychological needs of hospitalized children.
223558420|NCT07033923|DIAGNOSTIC_TEST|Brain magnetic resonance imaging (MRI) with structural (anatomical) and functional sequences (optional)|Brain MRI with structural (anatomical) and functional sequences (without contrast injection) will be collected. The cognitive tests will be carried out during the recording of the functional MRI (optional) in order to highlight the neural correlates of mood variations.
223558421|NCT07033923|BEHAVIORAL|Computerized cognitive tests|"Cognitive tests can be administered during the recording of a functional MRI, in order to highlight the neural correlates of mood variations.~Cognitive data from a computerized experimental psychology experiment: this test involves different tests on a computer or tablet, including a test evaluating the minimal variations in the subject's mood and motivational state during the task, as well as its decision-making abilities."
223558422|NCT07033923|DEVICE|Daily longitudinal monitoring by mobile MOODELING application|Daily longitudinal monitoring by mobile MOODELING application (mood, energy, events) with self-monitoring tools (calendar, mood curve) at home. Follow-up duration on the application: 12 months
223558423|NCT07033390|OTHER|survey|validity and reliability study of MOS
223558424|NCT06879041|DRUG|AZD2287|AZD2287 is administered through intravenous injection.
223558425|NCT06879041|DRUG|AZD2275|AZD2275 is administered through intravenous infusion.
223558426|NCT06879041|DRUG|AZD2284|AZD2284 is administered through intravenous injection.
223558427|NCT07033754|DIETARY_SUPPLEMENT|Propionibacterium freudenreichii P.UF1|one capsule once a day with/beforebreakfast for 120 days
223558428|NCT07033754|DIETARY_SUPPLEMENT|Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia|one capsule once a day with/beforebreakfast for 120 days
223558429|NCT07034508|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
223558430|NCT07034508|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
223558431|NCT07034508|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm
223558432|NCT07034508|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
223558433|NCT07034508|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223558434|NCT06086392|DRUG|Placebo|administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
223558435|NCT06086392|DRUG|0.1mg/kg Dexamethasone|administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the supraclavicular brachial plexus block
223558436|NCT06086392|DRUG|0.05mg/kg Dexamethasone|administration of 0.5ml/kg of 0,2% ropivacaine with 0.05mg/kg Dexamethasone for the supraclavicular brachial plexus block
223738467|NCT07205328|DRUG|Placebo|The placebo does not contain any active ingredients.
223738468|NCT07205848|OTHER|No intervention|No intervention
224024824|NCT00547131|PROCEDURE|conventional surgery|
224024825|NCT00547131|RADIATION|stereotactic radiosurgery|
224297978|NCT00770536|DRUG|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
224297979|NCT00770536|DRUG|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
224297980|NCT00770536|DRUG|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
223408749|NCT03466684|OTHER|Traditional fluid resuscitation protocol|Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
223408750|NCT05042661|DEVICE|acupuncture-like transcutaneous electrical nerve stimulation|The intervention group performed Al-TENS therapy 3 times a week for at least 20 minutes each time for 4 consecutive weeks. The second, fourth, and eighth week after the intervention.
223408751|NCT04682717|DEVICE|perfusion index monitoring for postinduction hypotension|Hemodynamic parameters will be recorded at 1-min intervals till 10 min after intubation. Hypotension will be defined as a drop in SBP to \<30% of baseline or absolute MAP \<60 mmHg. MAP \<55 mmHg (severe hypotension) will be treated immediately by rapid intravenous fluid administration (10 ml/kg) and ephedrine sulphate 6 mg IV boluses. Bradycardia will be defined as HR \<50 bpm or decrease by more than 30% below baseline value, whichever will be lower and will be treated with atropine 0.6 mg IV boluses. The incidence of hypotension will be calculated in 2 sets - 5 min after induction of anesthesia (effect of induction agent) and first 15 min after induction (effect of induction process and endotracheal intubation).
223408752|NCT00684411|DRUG|Imatinib mesylate|
223408753|NCT00044070|DRUG|YM872 (zonampanel)|
223408754|NCT01344824|BIOLOGICAL|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
223408755|NCT01344824|DRUG|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
223408756|NCT01344824|DRUG|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
223408757|NCT01344824|DRUG|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
223408758|NCT00780130|OTHER|No Intervention|male \& female college students ages 20 to 50, asymptomatic normals
223408759|NCT06321406|DEVICE|NMES (neuromuscular electrical stimulation)|With this application, swallowing muscles are stimulated and muscle strength increases.
223408760|NCT06321406|BEHAVIORAL|Exercise|Traditional Conservative swallowing treatment
223408761|NCT00409487|DEVICE|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
224297981|NCT03510182|DEVICE|transcranial direct current stimulation|
223408762|NCT00409487|DRUG|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
223408763|NCT02273063|DEVICE|Transcranial Magnetic Stimulation (TMS)|Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
223408764|NCT00114439|DRUG|Lithium carbonate|
223408765|NCT03324386|BEHAVIORAL|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
223408766|NCT03324386|BEHAVIORAL|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
224024826|NCT04572087|OTHER|Behavioral training and verum stimulation|Cognitive control training and verum tDCS
223408767|NCT03324386|BEHAVIORAL|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
223408768|NCT03324386|OTHER|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
223408769|NCT04490512|BIOLOGICAL|FluBHPVE6E7|Multiple subcutaneous, intradermal or intramuscular administrations
223408770|NCT04274010|DIAGNOSTIC_TEST|PillCamTM Crohn's capsule|Capsule endoscopy for small and large bowel to assess Crohn's disease activity.
223408771|NCT04274010|DIAGNOSTIC_TEST|Magnetic resonance enterography|MRI scan of small bowel to assess small bowel Crohn's disease activity.
223408772|NCT04274010|PROCEDURE|Ileo-colonoscopy|Endoscopic procedure to assess Crohn's disease activity in colon and terminal ileum.
223408773|NCT00901108|PROCEDURE|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
223408774|NCT00901108|PROCEDURE|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
223408775|NCT04955314|OTHER|PA vertebral mobilization|A PA mobilization is a technique in which one vertebra slides over another due to a force applied with the hands of the physiotherapist
224024827|NCT04572087|OTHER|Behavioral training and sham stimulation|Cognitive control training and sham tDCS
223408776|NCT00109655|BIOLOGICAL|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
223408777|NCT06445803|BIOLOGICAL|KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）|"CD19/CD22 cells will be infused on Day1 after induction chemotherapy regimen.~Lymphodepleting chemotherapy:3 days of IV chemotherapy with fludarabine and cyclophosphamide.~Fludarabine 30 mg/m2/day IV x 4 days (days -5 through -3) Cyclophosphamide 500 mg/m2/day IV x 2 days (days -5 and-3)"
223408778|NCT00125749|BIOLOGICAL|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
223408779|NCT01762436|DRUG|bisoprolol|
223408780|NCT01762436|DRUG|atenolol|
223408781|NCT04048213|OTHER|questionnaire|questionnaire send to the parents
224024828|NCT05868174|DIAGNOSTIC_TEST|89Zr-TLX250|Single IV administration followed by 89Zr-DFO-girentuximab PET/CT (or PET/MRI) scan at screening and approximately 8-10 weeks (±1 week) after Cycle 3 Day 1, as well as at the end of treatment visit (if feasible). The PET/CT should be obtained within 4-7 days after 89Zr-TLX250 administration
224024829|NCT05868174|COMBINATION_PRODUCT|177Lu-TLX250 and Peposertib|"Dose escalation and de-escalation for the determination of the Maximum tolerated combination/ Recommended phase 2 dose.~All subjects will receive 177Lu-TLX250 intravenously on day 1 and Peposertib BID on days 4-21 of each 84-day cycle."
223738469|NCT07206173|OTHER|The Londrina Activites of Daily Living Protocol|The Londrina Activites of Daily Living Protocol is a performance-based test protocol that objectively evaluates ADL. The participant was instructed to perform the tasks at the stations at the same speed they would typically do at home. The protocol consists of five stations with different tasks consisting of arranging objects, walking with weights, organizing objects, organizing clothes and walking.
223738470|NCT07205822|DRUG|Dato-DXd|All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants ≥ 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. Continued treatment with the same study drug post-progression may be allowed, based on prior discussion with sponsor/sponsor representative/study physician on a case-by-case basis following written investigator's confirmation of continuing clinical benefit to the patient post progression. The study is anticipated to enrol for an 18-month period, and DCO is expected to occur approximately 6 months after the last participant has been dosed.
223408782|NCT05125848|DEVICE|CM-1500|The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
223738471|NCT07207057|DRUG|Placebo|An over-encapsulated placebo capsule taken once daily to match the treatment arms following a 5-week titration phase.
223738472|NCT07207057|DRUG|Telmisartan|"Over-encapsulated telmisartan 40mg per day for 36 months (plus their usual SoC) following a 5-week titration phase.~Titration phase for telmisartan: Week 1-3: one 20 mg capsule per day; Week 4-5: one 40 mg capsule per day"
223738473|NCT07207057|DRUG|Terazosin (Hytrin)|"Over-encapsulated terazosin 5mg per day for 36 months (plus their usual SoC) following a 5-week titration phase.~Titration phase for terazosin: Week 1: one 1 mg capsule per day; Week 2: one 2 mg capsule per day; Week 3: one 3 mg capsule per day; Week 4: one 4 mg capsule per day; Week 5: one 5 mg capsule per day"
223738474|NCT07205458|BEHAVIORAL|IMB Model Web-Based Breastfeeding Education Program|A structured, model-based online education program designed to increase fathers' knowledge about breastfeeding through interactive lessons, videos, and resources. Fathers will be informed about breastfeeding during the postpartum period. The breastfeeding knowledge test will be completed two weeks after baseline data collection, and motivational interviews will be planned according to fathers' needs.
223738475|NCT07205458|BEHAVIORAL|Motivational interview sessions, Breastfeeding self efficiay,Behavioral Skills|Motivational interview sessions aimed to strengthen fathers' motivation for breastfeeding and improve supportive behaviors. These sessions will begin between postpartum days 13-17 after the information phase is complete. The number of sessions will be based on fathers' needs (minimum of two and up to four). Each session's duration will follow the Turkish Ministry of Health's Postpartum Care Guide (2018). The second session will occur between postpartum days 21-30. After the motivational interviews are completed, fathers will have received information and motivation according to the Information-Motivation-Behavioral Skills (IMB) Model. Education and interview sessions will continue until postpartum day 42, shaped according to fathers' needs. At the end of all trainings, fathers are expected to have developed the skills to support mothers during breastfeeding and to have gained self-efficacy in the breastfeeding process
223738476|NCT05713032|PROCEDURE|Pulsed radiofrequency on lumbar dorsal root ganglion|voltage of pulsed radiofrequency on DRG
223738477|NCT04958785|DRUG|Magrolimab|Administered intravenously
223408783|NCT06451536|DIAGNOSTIC_TEST|Ga-68 FAPI PET/CT|imaging of FAP expression of tumor before immunotherapy
223408784|NCT05203796|DEVICE|Transcutaneous pulsed electrical stimulation (NuEyne 02)|Arm 1: Experimental: Experimental group: Dry eye disease patients (n=12) Device: Pulse Electrical Stimulation Pulse Electrical Stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
223738478|NCT04958785|DRUG|Nab-Paclitaxel|Administered intravenously
223738479|NCT04958785|DRUG|Paclitaxel|Administered intravenously
224133270|NCT06626139|BEHAVIORAL|Context 1|Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
223408785|NCT05203796|DEVICE|Sham stimulation|Arm 2: Sham Comparator: Comparison group: Dry eye disease patients (n=12) Device: Sham stimulation Sham stimulation: Patients wear our clinical trial device 30mins once a day for 4 weeks.
223408786|NCT03255161|BEHAVIORAL|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
223408787|NCT03743805|DRUG|Flumazenil|0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg
223408788|NCT03743805|DRUG|Naloxone|0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
223408789|NCT01295671|BEHAVIORAL|Provision of beverages|Home delivery of specified beverage type
223738480|NCT04958785|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223738481|NCT04867837|DRUG|Octaplex|Four-factor prothrombin complex concentrate (4F-PCC)
223738482|NCT06114992|DEVICE|Servo-n HFOV modes|Treatment with high frequency oscillatory ventilation with Servo-n device in accordance to Standard of Care
223738483|NCT04752137|DRUG|Indocyanine green|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
224133271|NCT06626139|BEHAVIORAL|Context 2|Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
223408790|NCT01372293|DRUG|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
223408791|NCT04181528|DEVICE|Total knee arthroplasty implant|In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
223408792|NCT04152811|BEHAVIORAL|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
223408793|NCT04152811|OTHER|Usual Diabetes Care|Usual Diabetes Care
223408794|NCT06127693|DRUG|Tetravalent Influenza Vaccine|All participants will receive the tetravalent influenza vaccine
223408795|NCT06127693|BEHAVIORAL|High-frequency electrical stimulation|All participants will receive High-frequency electrical stimulation
223408796|NCT01501461|PROCEDURE|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
224024830|NCT04606043|PROCEDURE|Sandblasting|Sandblasting will be applied onto the vestibular surfaces of the teeth before applying the etchant.
223408797|NCT06326398|OTHER|Stoma Care|Nursing students practice stoma care with low and high fidelity simulation
223408798|NCT01112488|OTHER|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
223408799|NCT05209815|BEHAVIORAL|Questionnaire|Questionnaire
223408800|NCT03205956|DRUG|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
223408801|NCT00058656|PROCEDURE|Infusion of Activated & Expanded Autologous T Cells|
223408802|NCT02975388|DRUG|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
223408803|NCT01551914|DEVICE|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
223408804|NCT01551914|DEVICE|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
223408805|NCT01311765|OTHER|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
224024831|NCT04606043|PROCEDURE|Acid Etching|Only acid etching will be applied onto the vestibular surfaces of the teeth before rebonding
224024832|NCT03760705|OTHER|Data Collection|"1. Collection of data as detailed below:~   1. Clinical data collected by SCDB~  2. Clinical, administrative, pharmacy, financial data collected by each participating hospital~  3. Administrative data collected by MOH~2. Data will be extracted and anonymized on a secure healthcare analytics platform~3. Collaboration with the MOH for collection of administrative and financial data~4. Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~5. Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data."
224024833|NCT01831856|DRUG|1g of F373280|Oral administration, one capsule each evening with dinner.
224024834|NCT01831856|DRUG|Placebo|Oral administration, one capsule each evening with dinner.
224024835|NCT01832233|PROCEDURE|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
224024836|NCT01873222|DEVICE|OFDI-guided PCI & IVUS|"* Assessment by IVUS at post-PCI~* Assessment by OFDI at a 8-month follow-up"
224133272|NCT06626139|DRUG|Placebo|Healthy participants will receive an inactive placebo.
223408806|NCT06287476|OTHER|Acute exercise bout on visit 2 and 3|1\) a 5-minute warm-up, 2) 4 minutes at 60% of the maximal workload (determined on Study Day 1), 3) 2 minutes active break at 15 watt, 4) 4 minutes at maximal workload.
223408807|NCT00794248|DRUG|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
223408808|NCT00794248|DRUG|fexofenadine|Allegra 180 mg daily x 7 days
223408809|NCT02058537|DRUG|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
223408810|NCT03253549|DEVICE|SMArTVIEW|Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
224024837|NCT01873222|DEVICE|IVUS-guided PCI & OFDI|"* Assessment by OFDI at post-PCI~* Assessment by OFDI at a 8-month follow-up"
224024838|NCT01284660|DIETARY_SUPPLEMENT|DHA|DHA ingested orally by heavy smokers
224133273|NCT03166436|PROCEDURE|Radiofrequency ablation|radiofrequency ablation
224133274|NCT03166436|PROCEDURE|Biliary stenting|biliary stenting
224133275|NCT05092971|DEVICE|Shock or startle device|Shock and startle devices were used as aversive stimulus (shock and startle)
223408811|NCT01561326|BEHAVIORAL|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
224133276|NCT03216551|DIAGNOSTIC_TEST|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
223738484|NCT04752137|DEVICE|SPY-PHI|The SPY PHI and its dye Indocyanine Green dye (ICG) is a non-invasive device that is connected to a light source tower that is already available in the hospital in the operating room under Gynecology and Obstetrics Equipment. This is a special light source lamp that allows to test for vascularity in the soft tissues intraoperatively. Previous research in animal models proved the concept that the increased vascularity in tumors can be used to use this device to improve intraoperative assessment of tumor margins during resection. Our study will help to establish a correlation between activity with the dye and histological findings. This information has the potential to help sarcoma patients by avoiding staged surgeries, decreasing hospitalization times, and decreasing the likelihood of local recurrence by improving margin quality.
223738485|NCT06380517|DEVICE|Luminopia|dichoptic movies/shows shown through a virtual reality headset
224297982|NCT00463320|DRUG|Pazopanib eye drops and Allergen Refresh Plus eye drops|
223738486|NCT06380517|OTHER|Eye Patch|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye
223738487|NCT01698203|DRUG|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
223738488|NCT01698203|DRUG|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
223408812|NCT01561326|BEHAVIORAL|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
223408813|NCT01561326|BEHAVIORAL|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
223558437|NCT06883903|OTHER|day-night cycle application|In this group, colostrum delivered to the unit within the first 5 days of life was administered by the nurse every three hours for 14 days. In order to create a day/night cycle, a white incubator cover was used routinely in the unit during the day (between 08.00-20.00 hours) and a dark colored incubator cover was used at night (between 20.00-08.00 hours).
223558438|NCT06883903|OTHER|routine practice|"In this group, colostrum delivered to the unit within the first 5 days of life was administered every three hours for 14 days by the nurse.~is the group whose covers are used."
223558439|NCT05767047|DRUG|Apremilast|Oral tablets or liquid suspension
223558440|NCT07053046|OTHER|Standard engagement approach|"Large group meetings led by PRECIDENTD PIs; composed of \~20 sites (with \~25 site investigators and \~40 study staff). PRECIDENTD PIs will share updates and facilitate discussion around any problems.~Problem identification and steps toward solution occur sequentially. A problem is identified in the data (e.g., slow recruitment), then brought to the Stakeholder Advisory Council (SAC) for advisement, then back to site investigators and study staff to implement recommended changes, the PIs look at data to see if changes improved the problem. PIs and the Stakeholder Engagement Core broker information and relationships with SAC partners."
223558441|NCT07053046|OTHER|Agile methods engagement approach|"Small group meetings led by a coordinator trained in agile methods; composed of \~4 sites each (representing 4-6 investigators and 6-10 study staff), plus 2-3 Stakeholder Advisory Council (SAC) patient partners. Meetings will focus on problem-solving around specific topics and apply agile tools and principles.~Sites in each small group will review process data together and each site will identify a specific topic (recruitment, retention, medication adherence) to focus on improving over the next month. Research partners at sites and patient partners will contribute to discussion and reflection on barriers, challenges, successes, and facilitators. Steps toward solutions occur on a rapid timeframe, iteratively using data as a guidepost."
223558442|NCT07058922|DIAGNOSTIC_TEST|evaluation of systemic microvascular reactivity|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging.
224024839|NCT01284660|DIETARY_SUPPLEMENT|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
224024840|NCT01498653|DRUG|GW685698/GW642444|ICS/LABA
224024841|NCT01498653|DRUG|CCI18781|ICS
223408814|NCT01584986|BIOLOGICAL|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
224024842|NCT05208866|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
224024843|NCT05895565|DRUG|PMG1015|Including 3 dose levels: level 1, level 2 and level 3
224024844|NCT05895565|DRUG|PMG1015 placebo|Including 2 dose levels corresponding to PMG1015 level 1 and level 2, with no placebo group set for PMG1015 level 3
224297983|NCT04407494|BIOLOGICAL|Reporting of anosmia, ageusia and other clinical symptoms|Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA
224297984|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
223408815|NCT00641030|DRUG|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
223408816|NCT00641030|DRUG|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
223408817|NCT00641030|GENETIC|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
223408818|NCT00641030|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
223408819|NCT00641030|OTHER|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
224024845|NCT01442818|DRUG|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
224024846|NCT01442818|DRUG|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
223408820|NCT00641030|OTHER|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
223408821|NCT00641030|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
223408822|NCT05901441|DRUG|Hydromorphone|For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone
223408823|NCT05901441|DRUG|Sufentanil|For those in SF group: they will be administered with 40 ug/ml sufentanil
223408824|NCT05901441|DRUG|Ropivacaine|0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
223408825|NCT02892539|RADIATION|Coronary Angiography|
223408826|NCT05478460|OTHER|Hookwire localization|Patients were performed CT -guided hook wire localization(20G×120mm, PAJUNK medizintechnologie, Geisingen in Germany). patients were placed on a CT table in a suitable position(supine, prone, lateral) to obtain the shortest needle insertion route for their initial CT scan. Local anesthesia of the skin and planned puncture tract was performed using 10ml Lidocaine 1%. Next, the needle was inserted into or near the pulmonary nodule.
223408827|NCT02893150|BEHAVIORAL|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
223408828|NCT02893150|BEHAVIORAL|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
223408829|NCT02893150|BEHAVIORAL|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems\[47\]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
223558443|NCT07058922|DIAGNOSTIC_TEST|ABPM|Ambulatory blood pressure measuring: systolic, diastolic and mean arterial pressures
223558444|NCT07058922|DIETARY_SUPPLEMENT|beetroot supplement|A powdered beetroot extract supplement containing 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.
223738489|NCT01698203|DRUG|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
224024847|NCT01561209|DRUG|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
223558445|NCT06774131|DRUG|UGN-104|UGN-104 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-104 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the UUT.
223558446|NCT07066397|BIOLOGICAL|ARM011|ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process
223558447|NCT07066397|DRUG|Fludarabine|Administered prior to infusion of ARM011
223558448|NCT07066397|DRUG|Cyclophosphamide|Administered prior to infusion of ARM011
223558449|NCT06875388|OTHER|Task specific Training|Group A will receive a basic protocol of 40 minutes involving 10 minutes of warm up 10 10 mins of task-specific training 10 mins of leg strength exercises and 10 mins of cool-down exercises.
223558450|NCT06875388|OTHER|Specific Yoga Poses|For group B, a series of yoga poses will be applied. Each training session consists of a 10-minute warm-up, 20 minutes of yoga exercises, and a 10-minute cool-down.
223738490|NCT06833086|PROCEDURE|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
224024848|NCT01561209|DRUG|Placebo|"Placebo pill~1 before bedtime"
224024849|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.
224024850|NCT05602831|OTHER|detect HPV and genetic variants|Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.
224024851|NCT03459274|DEVICE|VR-Biofeedback|The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
223738491|NCT06833086|PROCEDURE|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
223738492|NCT06284473|DRUG|Ketamine|Ketamine is an N-methyl-D aspartate receptor agonist
224024852|NCT05050253|DEVICE|Super-oxidized solution (SOS)|Peritoneal lavage with super-oxidized solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
223738493|NCT06284473|OTHER|Saline|Intranasal saline flushes pollen, dust, and other debris from nasal passages. It also removes excess mucus and adds moisture
224024853|NCT05050253|DEVICE|Ringer's solution|Peritoneal lavage with Ringer's solution in patients undergoing emergency abdominal surgery for secondary peritonitis.
223738494|NCT05316662|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
223738495|NCT05564936|DEVICE|ME&MG mobile application|ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.
224024854|NCT06311604|DRUG|Isoflurane|"Inclusions will have 4 phases according to gradual increased doses of isoflurane:~Phase 1: Inclusion of 3 patients with 0.3 MAC isoflurane. In the absence of an increase of ICP \> 20% from baseline, inhaled sedation is maintained for 24 hours until the primary endpoint is assessed. If there one patient who does not tolerate this threshold, three additional patients will be included in this phase. A maximum of one treatment failure (see definition below) is tolerated in the phase 1~Phase 2: Inclusion of 3 additional patients with isoflurane dosage of 0.5 MAC under the same conditions as phase 1.~Phase 3: Inclusion of 3 additional patients with isoflurane dosage of 0.7 MAC under the same conditions as phases 1 and 2.~Phase 4: Inclusion of 12-15 additional patients will be included at the 0.7 MAC dose, to have 18 patients exposed to 0.7 MAC isoflurane."
223408830|NCT02366637|DRUG|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
223738496|NCT05226455|DRUG|venetoclax + azacitidine +/- donor lymphocyte infusion|Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)
223738497|NCT03026712|DEVICE|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
223738498|NCT03026712|DEVICE|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
223738499|NCT02958839|PROCEDURE|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
223738500|NCT04551846|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral feeding will be administered to the PICU patients
224024855|NCT02279069|DEVICE|4-roll canne|
223738501|NCT04551846|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
224024856|NCT02601664|PROCEDURE|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
224024857|NCT02601664|PROCEDURE|Conventional PCI|Conventional PCI
224133277|NCT06260072|DRUG|magnesium and riboflavin supplement|Five capsules considered one dose of the intervention (one 400 mg magnesium capsule and four 100 mg riboflavin capsules)
223408831|NCT02366637|DRUG|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
223408832|NCT04859400|DIETARY_SUPPLEMENT|Whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB)|The whey protein supplement high in leucine and β-hydroxy-β-methylbutyrate (HMB) is ingested once daily, preferably either in the evening before going to bed or within two hours after having finished exercising.
223738502|NCT03274687|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223738503|NCT03274687|OTHER|Laboratory Biomarker Analysis|Correlative studies
224024858|NCT02070588|DEVICE|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
224024859|NCT02424513|RADIATION|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
224024860|NCT00052182|BIOLOGICAL|EP HIV-1090|
224024861|NCT02972125|DRUG|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
224024862|NCT02972125|DRUG|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
224024863|NCT00298090|DEVICE|StO2 monitoring|placement of the StO2 device/ external noninvasive
224024864|NCT03572322|OTHER|Focus Group|Focus Group
224024865|NCT03572322|OTHER|Interviews|Interviews
224133278|NCT05549141|OTHER|treadmill gait training with gait facilitators|6 sessions of 30 minutes each of treadmill gait training with functional electrical stimulation as a gait facilitator
223408833|NCT04859400|BEHAVIORAL|Standardized nutritional program|During at least two personal counseling meetings with a dietician, the patient's diet is assessed and individual nutritional interventions - based on the personal needs and individual preferences of the patient - are developed. The overall goal is to optimize protein an energy intake.
223408834|NCT04859400|BEHAVIORAL|Standardized exercise program|In at least two personal counseling meetings with a physiotherapist, the patient's individual training plan is compiled and agreed upon (mainly including strength, endurance and balance exercises). The patient then exercises at home and records the trainings with the app.
223738504|NCT03274687|OTHER|Quality-of-Life Assessment|Ancillary studies
223738505|NCT03274687|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
223738506|NCT01024296|DEVICE|Port Close|Device for applying loop suture to close surgical site
223408835|NCT06191952|DIAGNOSTIC_TEST|Cognigram|Cognigram (previously known as the Cogstate Brief Battery) is a brief, computer-administered cognitive test battery requiring about 20-25 minutes for administration, consisting of four cognitive tasks to measure psychomotor function, attention, working memory, and learning and memory. Eisai owns the commercial rights for Cognigram and has kindly agreed to offer the required licenses for the present project free of charge. Digital cognitive testing will take place in the respective social and care centers on a tablet which is not connected to the internet. Testing will be performed pseudonymized and data from the cognitive tests will be downloaded regularly by the study team and added to the database at LMU hospital.
223558451|NCT06875388|OTHER|Tasl specific Training with perturbation|GGroup C will be 40 minutes involving 10 minutes of warm-up 10 minutes of task-specific training involving perturbation 10 mins of leg strength exercises involving perturbation and 10 mins of cool-down exercises.
224024866|NCT05402748|OTHER|placenta-MSCs derived exosomes|Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
224024867|NCT03840226|DRUG|Placebo Oral Tablet|Placebo tablets
223558452|NCT06875388|OTHER|Specific yoga poses with perturbation|Group D training session consists of a 10-minute warm-up, 20 minutes of yoga exercises with perturbation, and a 10-minute cool-down
224024868|NCT03840226|DRUG|Magnesium Oxide|Magnesium tablets
224024869|NCT03444753|DRUG|BMS-986299|Specified dose on specified day
224024870|NCT03444753|BIOLOGICAL|Nivolumab|Specified dose on specified day
224024871|NCT03444753|BIOLOGICAL|Ipilimumab|Specified dose on specified day
224024872|NCT03316625|DIAGNOSTIC_TEST|Bone densitometry measurement|Bone Densitometry and measurement of body composition
224024873|NCT00972205|DRUG|paclitaxel|Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
224024874|NCT00972205|DRUG|CBT-1(Registered Trademark)|CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
224024875|NCT00972205|RADIATION|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
224024876|NCT02216357|DRUG|Ifetroban, Oral Capsule|
224024877|NCT02216357|DRUG|Placebo, Oral Capsule|
224024878|NCT00354458|DRUG|rolofylline|rolofylline 30 mg IV QD; 3 days
224024879|NCT00354458|DRUG|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
224133279|NCT05549141|OTHER|treadmill gait training not-associated with gait facilitators|6 sessions of 30 minutes each of treadmill gait training
224133280|NCT06108323|BEHAVIORAL|Theapeutic exercise plus action observation training|Participants make an observation of actions related to the training they are going to perform. Subsequently, they perform the therapeutic exercise session.
224133281|NCT06108323|BEHAVIORAL|Therapeutic exercise plus sham observation training|Participants make a sham observation. Subsequently, they perform the therapeutic exercise session.
224133282|NCT03571620|DRUG|Q301 Cream|1.0% or 1.4% Q301 Cream
224133283|NCT03571620|DRUG|Vehicle|Vehicle Control
224133284|NCT00798213|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
224133285|NCT00798213|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
224133286|NCT06693063|OTHER|Data collection|Some data will be collected for all patients included: medical and family history, chest pain data and medical care data
224133287|NCT06692257|BEHAVIORAL|Observation|To perform a comparative analysis of orofacial functions with an emphasis on breathing and chewing patterns in individuals with and without MIH.
224133288|NCT04255550|DIAGNOSTIC_TEST|Esophageal doppler|It is a prospective observational clinical study to correlate hemodynamic monitoring between non-invasive Electrical Cardiometry and minimally invasive Esophageal Doppler during major abdominal surgery.
223558453|NCT03641807|OTHER|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
223558454|NCT03641807|OTHER|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
223558455|NCT07080359|DRUG|Isavuconazole treatment|Administer isavuconazole as follows: Loading dose: 200 mg every 8 hours (q8h) for three times, Maintenance dose: 200 mg once daily (qd)
223558456|NCT07081334|BIOLOGICAL|PV-001|9-valent vaccine containing antigens for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
223558457|NCT07081334|BIOLOGICAL|PEV-001|PEV-001 is a formulation of the PV-001 vaccine that excludes the HPV antigens and contains only aluminum phosphate.
223558458|NCT07079618|DRUG|SGC001|In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug SGC001 should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.
223558459|NCT07079618|DRUG|Placebo|In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug placebo should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.
224024880|NCT02550717|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
224024881|NCT02550717|DRUG|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
224024882|NCT05235321|DEVICE|Standard GAT|Standard Goldmann Applanation Tonometry (GAT): this is the standard method for IOP measurement in clinical practice
224024883|NCT05235321|DEVICE|Fixed force GAT|An investigational device similar to standard GAT
224024884|NCT05235321|DEVICE|Upright applanating prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device
224024885|NCT05235321|DEVICE|Supine Applanating Prototype|An investigational device, prism used in standard and fixed-force GAT is attached to a portable device performed in the supine position
224024886|NCT02853357|OTHER|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
224024887|NCT02853357|OTHER|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
224024888|NCT02853357|OTHER|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
224024889|NCT02682641|DRUG|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
224024890|NCT02682641|DRUG|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
224024891|NCT00836095|DEVICE|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
224133289|NCT06892938|DIAGNOSTIC_TEST|Atrial Fibrillation Identification|Identification of atrial fibrillation by device.
224133290|NCT06898762|OTHER|characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.|characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.
224133291|NCT06897761|DEVICE|Interactive Digital Respiratory Game|With the development of technology and digitalization, Digital Respiratory Games (DRG) offer an alternative solution. DRGs, with their difficulty levels, provide a platform for progression, offering a fun and engaging experience that enhances patient adherence to therapy through storytelling and user interaction. The absence of a locally made DRG in Turkey, despite the chronic respiratory diseases impact, has led to the need for an interactive DRG with personalized features. The developed interactive DRG and device will be Turkey first interactive DRG example, designed to respond to different respiratory maneuvers. The developed DRG and device will detect the lung volume and flow rates and allow for the real-time execution of maneuvers within the Active Cycle of Breathing Techniques (ACBT) in a playful environment.
224133292|NCT06897761|OTHER|home-based exercise training|Patients in the home-based exercise training group will be asked to perform the active breathing techniques cycle, which is an airway clearance technique, twice a day, 7 days a week, for 20 minutes each, for 8 weeks and to follow the program that includes physical activity recommendations. Patients who use mucolytic and/or nebulized drugs such as hypertonic saline or mannitol will be instructed to perform nebulization before performing the active breathing techniques cycle.
224133293|NCT06898372|DRUG|JAK Inhibitor|The retrospective analysis will examine the effects of Janus Kinase 1/2 (JAK1/2) inhibitors, such as Baricitinib and Ruxolitinib, on neurological symptoms and brain MRI.
223408836|NCT06191952|DIAGNOSTIC_TEST|Subjective cognitive decline questionnaire (SCD-Q)|The SCD-Q is a validated questionnaire assessing the presence of subjective cognitive deterioration in abilities such as memory, attention, language, and executive function. The scale includes 24 dichotomous questions (yes/no), evaluating decline in daily life during the last two years. The SCD-Q score ranges from 0 to 24, with higher scores indicating greater perceived cognitive change (cut-off classified as SCD equal or greater as 7).
223408837|NCT06191952|DIAGNOSTIC_TEST|blood-based biomarkers|Blood plasma and serum samples will be collected by the project staff according to standard operating procedures used at LMU Munich and subsequently processed and measured at the Department of Psychiatry and Psychotherapy to quantify the blood-based biomarkers for AD using Elecsys immunoassays running on a Cobas e402 analyzer. All test results (including the respective cut-off measurements for normal vs abnormal) will be forwarded directly to the participants' GPs. No further explanations and instructions will be provided to avoid any unwanted bias, and participants will only be informed about their results by their doctors. Roche has kindly offered to provide blood biomarker assays free of charge for the present project.
223738507|NCT05096416|DEVICE|The three-dimensional (3D) printed hemodialysis vascular model|The three-dimensional (3D) printed hemodialysis vascular model will be used as a guide map to cannulate the patients for hemodialysis and to minimize the risk of vascular access complications
223738508|NCT06957535|BEHAVIORAL|Navigation|Navigation is provision of 1:1 support from a Diné peer-navigator
224138924|NCT02693795|OTHER|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
223738509|NCT06957535|BEHAVIORAL|TEAM|TEAM encompasses culturally tailored mammography education modules
223738510|NCT04992572|DRUG|Propofol Injection|25mg Propofol administered by injection
223408838|NCT06191952|DIAGNOSTIC_TEST|ki:elements digital speech biomarker for cognition (ki:e SB-C)|The ki:elements digital speech biomarker for cognition (ki:e SB-C) can be collected remotely in fully automated telephone visits, taking 15 minutes to complete based on three specific assessments measuring learning and memory, processing speed, executive function, and language capabilities. The ki:e SB-C uses artificial intelligence and automatic speech analysis to process and transcribe speech, followed by an extraction of relevant features, combined into four subdomain and one global cognition score.
223738511|NCT04992572|DRUG|Lidocaine Hydrochloride, Injectable|Licocaine administered locally via injection.
224024892|NCT00836095|DEVICE|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
224024893|NCT01306487|PROCEDURE|Vitrectomy|Macular hole surgery
224024894|NCT05373589|OTHER|conventional ventilation, group C|In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.
224024895|NCT05373589|OTHER|pressure support, group PS|In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
224024896|NCT04409886|BIOLOGICAL|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
224024897|NCT05525611|DRUG|Cabergoline 0.5 MG|Cabergoline 0.5 mg once a week in 12 weeks
224024898|NCT05525611|OTHER|Placebo|Placebo once a week in 12 weeks
224024899|NCT03046784|OTHER|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
224024900|NCT04255069|DRUG|Placebo|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
224024901|NCT04255069|DRUG|Dose 1 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
224024902|NCT04255069|DRUG|Dose 2 JKB-122|A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
224024903|NCT04015856|BEHAVIORAL|Full TP intervention|CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups-including adolescent girls, adolescent boys, parents/community members, community leaders-around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
224024904|NCT04015856|BEHAVIORAL|Light TP intervention|The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
224024905|NCT04105309|BEHAVIORAL|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
224024906|NCT04105309|BEHAVIORAL|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
224024907|NCT04105309|BEHAVIORAL|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
224024908|NCT04105309|BEHAVIORAL|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
223738512|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Perception Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Perception Training: Visual Sweeps; Mind's Eye; Hawk Eye; and Divided Attention. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
224024909|NCT04795882|BIOLOGICAL|BCMA CAR T cells|Infusion with ATIMP: BCMA CAR T-cells
224024910|NCT04795882|BIOLOGICAL|BCMA/CD19 CAR T cells|Infusion with ATIMP: BCMA/CD19 CAR T-cells
224024911|NCT05516550|DRUG|Treamid|Participants will receive Treamid 25 mg once a day daily during 4 weeks
224024912|NCT05516550|DRUG|Treamid twice a day|Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
224024913|NCT05516550|DRUG|Treamid once a day|Participants will receive Treamid 50 mg in the morning daily during 4 weeks
224024914|NCT05516550|DRUG|Placebo|Participants will receive Placebo in the morning and in the evening daily during 4 weeks
224138925|NCT02693795|OTHER|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
224024915|NCT01849822|DEVICE|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
224024916|NCT00882427|OTHER|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
224024917|NCT04495803|OTHER|Cognitive Behavioural Group Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population. Additional strategies for COVID-19 specific worry content have been included.
224133294|NCT06898008|OTHER|Assessment of socio-demographic, anthropometric, psychometric and clinical characteristics|age, sex and place of residence, socioeconomic level, education, anthropometric data, first-degree family history, screen time, physical activity time, sleep time, comorbidity, drug treatments, education, total IQ, results of Epworth, CDI, ISI, ADHD, CONNERS, SCSC, Horne and Ostberg questionnaires, hearing aids, referring professional, melatonin dosage, ferritinemia, etiology of sleepiness
224133295|NCT04689750|DIAGNOSTIC_TEST|Next generation sequencing|"Genetic profile of donors will be collected at the time of PBSC or BM stem cell donation. Genetic profile of recipients will be collected at 1-month, 6-month, 12-month post-HSCT and at time of relapse or occurrence of leukaemia.~Gene mutations and pathogenic gene fusion will be determined in the peripheral blood and/or marrow samples by next-generation sequencing (NGS) using a myeloid-gene panel and nanopore long-read sequencing."
224133296|NCT04260022|DRUG|Ascentage Pharma HQP1351 bioavailable inhibitor|HQP1351 taken by mouth every other day
224133297|NCT04260022|DRUG|Blinatumomab|Administered in all patients as a continuous IV infusion at the dosage of 28μg daily (9μg daily for Cycle 1 Day 1 to Day 7).
224133298|NCT01877382|DRUG|Milademetan|DS-3032b will be administered as an oral capsule. It will be supplied in 5, 20, 80, and/or 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
223408839|NCT04893447|BEHAVIORAL|SPI+|Suicide prevention hotline follow-up specialists will call participants to (1) conduct a brief suicide risk assessment; (2) review and discuss the participant's connection and support plan or safety plan; and (3) provide referrals to social services or other support with treatment engagement, if indicated. Participants will receive at least one and optional additional phone calls, generally delivered according to the following schedule: days 3, 7, 14, 30, 60, 90. Modifications may be made to the schedule due to weekends, holidays, or participant availability, and additional calls may be scheduled as desired by the participant. The follow-up will stop once the participant is successfully engaged in outpatient treatment or does not desire further follow-up support.
224133299|NCT01877382|DRUG|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5, 20, 80, and/or 200 mg. An alternate combination of 30 and/or 100 mg capsules of milademetan may be utilized.
224133300|NCT00649467|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
224133301|NCT00649467|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
224133302|NCT06831344|DRUG|Vonoprazan ODT-1 or ODT-2 without Water|Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
224133303|NCT06831344|DRUG|Vonoprazan ODT-1 or ODT-2 with Water|Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
224133304|NCT06831344|DRUG|Vonoprazan (Reference)|Vonoprazan will be administered orally as a tablet
224133305|NCT02020031|DRUG|Vancomycin|
224133306|NCT05006521|DRUG|KN-002|KN-002 dry powder inhaler
224133307|NCT02397603|DRUG|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
224133308|NCT02397603|DRUG|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
224133309|NCT02210104|DRUG|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
224133310|NCT02210104|DRUG|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
224133311|NCT02210104|BIOLOGICAL|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.
224133312|NCT05517356|PROCEDURE|Tailored management strategies|"Our basic surgical strategies for the central repair operations for ATAAD are as follows. As arterial lines for cardiopulmonary bypass, side branches of the axillary and femoral arteries were used. Circulatory arrest was established when the nasopharyngeal temperature reached 25°C. Anterograde selective cerebral perfusion was performed through the right axillary artery, and the brain was perfused at approximately 5 mL/kg/min. The extent of aortic replacement was determined according to the extent of dissection involvement.~For malperfused patients with symptom onset within 6 hours, the immediate central repair was performed followed by repeat CTA postoperatively, and endovascular reperfusion was applied if the malperfusion persisted. While for patients with symptom onset beyond 6 hours, delayed central repair were performed after the organ functions improved."
224133313|NCT04282070|DRUG|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
224133314|NCT04282070|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
224133315|NCT04282070|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
224133316|NCT04282070|DRUG|Albumin Paclitaxel|Maximum 6 cycles for combined therapy.
224133317|NCT04084938|PROCEDURE|Prostate operation or prostate artery embolization|As described above.
224133318|NCT05331950|OTHER|Office Workers|Office Workers which will be observed/exposed with different task and different factors
224133319|NCT00316381|PROCEDURE|Autologous bone marrow-derived stem cells|
224138926|NCT02935114|DRUG|37% Carbamide Peroxide|"* no Gingival dam protection (as manufacturer´s instruction)~* 37% Carbamide Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
223408840|NCT04893447|BEHAVIORAL|SP+CC (Caring Contacts)|SP+CC follow-up includes one phone conversation with a suicide prevention hotline follow-up specialist and a series of personalized caring messages sent over the course of 12 months via text or email (based on participant preference). Caring contacts will generally be sent according to the following schedule: 3 in the first week, 6 weekly, 6 bi-weekly, 4 monthly; 2 bi-monthly, and one each for the participant's birthday, Thanksgiving, Christmas, and New Year's (total of 25 over 12 months). Slight variation in the schedule is allowed. There is no expectation that participants respond to the text messages; if they do, follow-up specialists reply to any incoming texts. Replies are individually-tailored and caring.
224024918|NCT04620811|DRUG|lirentelimab|Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8
224024919|NCT02775799|OTHER|Registration|Registration according to approved data sets
224024920|NCT01078675|DRUG|rosuvastatin calcium|5 mg, oral, once daily, 24 months
224024921|NCT01078675|DRUG|rosuvastatin calcium|10 mg, oral, once daily, 24 months
224024922|NCT01078675|DRUG|rosuvastatin calcium|20 mg, oral, once daily, 24 months
224024923|NCT04208009|BEHAVIORAL|Advance care planning animated videos|Four advance care planning videos: 1) Description of ACP; 2) Explanation of the importance of engaging in ACP now; 3) Communicating wishes to one's loved ones and family members; and 4) Communicating wishes to one's doctor.
224024924|NCT01765465|DRUG|Rowachol|
224024925|NCT01765465|DRUG|Placebo|
224024926|NCT00779051|DRUG|Zolpidem 10mg tablets|
224024927|NCT03714204|BEHAVIORAL|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
224024928|NCT00874341|OTHER|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
224024929|NCT05127538|DIAGNOSTIC_TEST|Gait analysis|Gait analysis Zebris Rehawalk (Zebris Medical GmbH, Germany) computerized gait evaluation system is used to assess the kinetic and kinematic analysis of the gait. The system consists of a treadmill and a computer. For gait assessment, patients walk at their preferred comfortable walking speed.
224024930|NCT05127538|DIAGNOSTIC_TEST|Balance Assessment|Static and dynamic balance Static and dynamic balance and stability limit values are evaluated with the E-LINK FP3 Force Plate (Biometrics Ltd, United Kingdom) system. The device consists of a computer and a platform on which individuals can place their feet. For static balance measurement, individuals are asked to place their feet on the marked places on the platform and hold an object on the computer screen at a fixed point for 30 seconds without support from their hands. For dynamic balance, individuals need to follow a moving object on the computer screen for 30 seconds by putting their body weight forward, backward, and sideways with their feet.
224024931|NCT03929315|BEHAVIORAL|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
224024932|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Feasibility|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
224133320|NCT03534063|GENETIC|CYP2D6-guided opioid therapy|Using a standardized consult note, recommendations were made to avoid tramadol, hydrocodone, codeine, and oxycodone in PMs, IMs, and UMs and to use an alternative opioid (e.g. morphine, hydromorphone) or non-opioid (e.g. NSAID). Consideration of tramadol as the first-line opioid will be recommended for NMs.
223408841|NCT02965001|DRUG|68Ga-NOTA-AE105|The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
223408842|NCT01512004|DRUG|Propiverine Hydrochloride|drug of oral capsule
223408843|NCT01512004|DRUG|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
223408844|NCT04471688|DIAGNOSTIC_TEST|infectious disease screening|Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
223558460|NCT00119028|PROCEDURE|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
223558461|NCT05571644|DRUG|mFOLFOXIRI + Cadonilimab|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
224133321|NCT05875558|PROCEDURE|M-TACE|Lipiodol combined with microspheres
224133322|NCT04923620|DRUG|cetuximab+mFOLFOX6|cetuximab 500mg/m2 d1 Oxaliplatin 85mg/m2 d1 Calcium Folinate 400mg/m2 d1 5-fluorouridine 400mg/m2 d1 5-fluorouridine 2400mg/m2 46h q2w, 6 cycles
224133323|NCT04923620|RADIATION|short-course radiotherapy|25Gy/5Fx short-course radiotherapy between the forth and the fifth cycle of cetuximab+mFOLFOX6
224133324|NCT03853512|DRUG|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
224133325|NCT03853512|OTHER|Semisolid vaseline|Product is applied to the other side of the inguinal region.
223408845|NCT05999201|OTHER|craniocervical neural mobilization|the patients will receive The craniocervical neural mobilization in the form of passive craniocervical flexion in which An anterior rotation of the head will be done which stimulates the meninges.To increase mechanical stress in the nervous system, patients will be asked to do a descent and retropulsion of the shoulders while gradually extending both elbows. in addition to Passive lateral cervical sliding and Craniocervical flexion with mouth opening.The neural mobilization should be mild, progressive, and slow. The protocol lasted 15 minutes and also the patients will receive selected physiotherapy program
224024933|NCT04159350|DEVICE|Rectal Expulsion Device (RED) - Validation|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their LEFT side and RED is gently inserted into the rectum. The patient then attempts to expel RED while remaining on their side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
224024934|NCT06057194|DRUG|Letermovir 240 mg Oral Tablet|Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
223408846|NCT05999201|OTHER|selected physiotherapy program|the patients will receive selected physiotherapy program in the form of Suboccibital muscles inhibition suboccipital inhibition technique (SIT), from supine lying position, the therapist will sit at the patient's head head with the elbows rested on the surface of the table. Then, the therapist will place both hands behind the head of the patient with the palms facing upwards, the fingers flexed, and the finger pads positioned on the posterior arch of the atlas to allow the occiput to rest in the palm of the hands. the patients will receive also trigger point release technique in the form of An ischemic compression for sternocleidomastoid muscle, temporal muscle, upper trapezius muscle and splines muscles
224024935|NCT01744795|OTHER|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
224133326|NCT04676542|OTHER|Exercise|One hour of a beginning martial art class ,and a one hour walk at 4.0 mph pace.
224133327|NCT02320968|OTHER|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
224133328|NCT06304675|OTHER|no intervention|no intervention
224133329|NCT00383578|DRUG|Vildagliptin 100 mg qd|
224133330|NCT00383578|DRUG|Metformin 1500 mg daily|
224133331|NCT02485548|DRUG|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
224133332|NCT02485548|DRUG|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
224133333|NCT02485548|DRUG|Cisplatin|All patients will receive concurrent cisplatin.
224133334|NCT02485548|RADIATION|IMRT|All patients will receive IMRT
224133335|NCT00089271|DRUG|alvespimycin hydrochloride|Given IV
224133336|NCT00089271|OTHER|laboratory biomarker analysis|Correlative studies
224133337|NCT00714298|OTHER|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
224133338|NCT05275296|DEVICE|Intracranial stent for wide-necked aneurysms|Intracranial stent for wide-necked aneurysms
224133339|NCT03516955|DRUG|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
224133340|NCT00605722|DRUG|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
224133341|NCT00605722|DRUG|erlotinib (Tarceva)|150 mg orally (po) daily.
224133342|NCT03300219|BEHAVIORAL|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
224133343|NCT03909932|OTHER|Observational study : no intervention|Observational study : only exporting data
224133344|NCT00210080|DRUG|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
224133345|NCT02530606|PROCEDURE|Photoacoustic Imaging|Undergo PAI
224133346|NCT01155297|BEHAVIORAL|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
224133347|NCT01155297|BEHAVIORAL|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
224133348|NCT02156232|PROCEDURE|TIPS|TIPS is performed with a standard technique. TIPS revision will be planned if any evidence of shunt dysfunction is observed.
224138927|NCT02935114|DRUG|35% hydrogen Peroxide|"* Gingival dam protection (as manufacturer´s instruction)~* 35% Hydrogen Peroxide application (2 sessions of 45 minutes)~* Tooth sensitivity (Verbal and visual scale) and color evaluation"
224138928|NCT04254783|DRUG|Risankizumab|Intravenous (IV) infusion
224024936|NCT02341027|DEVICE|Jadelle|within 5 days of delivery and before discharge from hospital
223408847|NCT05446701|DIAGNOSTIC_TEST|serum level of FAM19A5|Detection of serum level of FAM19A5 of patients and controls by using ELISA technique.
224024937|NCT02341027|DEVICE|Jadelle|6-8 weeks (42-56 days) postpartum
224024938|NCT05435768|DRUG|Denosumab|Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days
223408848|NCT02861105|DRUG|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
223408849|NCT02861105|OTHER|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
223408850|NCT03136237|DRUG|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
223408851|NCT03136237|DRUG|Digoxin|Day 1 of Cohort 1
223408852|NCT03136237|DRUG|BCX7353 + digoxin|Day 19 of Cohort 1
223558462|NCT05571644|DRUG|mFOLFOX6|mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycels before surgery
224133349|NCT02156232|PROCEDURE|SPSS embolization|Embolization of SPSS will be conducted via the same jugular vein before TIPS implantation. The major procedures included (a) angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b) embolization of SPSS with coils of varying diameters or Amplatzer Vascular Plug, which resulted in the SPSS disappearing at postembolization angiography.
224133350|NCT01042613|PROCEDURE|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
224133351|NCT01042613|PROCEDURE|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
224133352|NCT01313364|DEVICE|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
224133353|NCT00143975|DRUG|Cytarabine|3 g/m2 bid. i.v day 1-3
224133354|NCT00143975|DRUG|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
224133355|NCT00143975|DRUG|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
224133356|NCT00143975|DRUG|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
224133357|NCT00845546|DRUG|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
224133358|NCT01240512|DRUG|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
224133359|NCT04762407|DRUG|HGP1910|Take it once per period.
224133360|NCT04762407|DRUG|HGP1909|Take it once per period.
223408853|NCT03136237|DRUG|Rosuvastatin|Day 1 of Cohort 2
223408854|NCT03136237|DRUG|rosuvastatin + BCX7353|Day 15 of Cohort 1
223408855|NCT03136237|DRUG|Cyclosporine + BCX7353|Day 14 of Cohort 3
224133361|NCT04762407|DRUG|HCP1903|Take it once per period.
224138929|NCT04254783|DRUG|Cytochrome P450 (CYP) Substrates|Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
223408856|NCT02110303|DRUG|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
223408857|NCT02110303|DRUG|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
223408858|NCT00651261|DRUG|cytarabine|Given IV
223408859|NCT00651261|DRUG|daunorubicin|Given IV
223408860|NCT00651261|DRUG|midostaurin|Given orally
223408861|NCT00651261|OTHER|placebo|Given orally
223408862|NCT00651261|DRUG|dexamethasone acetate|ocular medication administration
223558463|NCT05571644|DRUG|mFOLFOXIRI|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles before surgery
224024939|NCT01574378|DEVICE|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
224024940|NCT01574378|DEVICE|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
223408863|NCT01609010|DRUG|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
223408864|NCT01609010|DRUG|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
223408865|NCT06210113|BEHAVIORAL|Mindfulness-based Stress Reduction|An 8-week Mindfulness-based stress reduction training programme
224024941|NCT05142488|BIOLOGICAL|Covid -19 (recombinante) vaccine|Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
224024942|NCT00419510|BEHAVIORAL|Culturally Tailored Genetic Counseling|
224024943|NCT01759368|DEVICE|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
224024944|NCT01191268|DRUG|Insulin Glargine|
224024945|NCT01191268|DRUG|LY2189265|
224024946|NCT01191268|DRUG|Insulin Lispro|
224024947|NCT03112564|OTHER|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
224024948|NCT03112564|DRUG|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
224024949|NCT01222026|DRUG|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
224024950|NCT01222026|DRUG|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
224024951|NCT00700973|BEHAVIORAL|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
224024952|NCT00700973|OTHER|Usual care|Substance use disorder usual care
224024953|NCT03218345|PROCEDURE|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
224024954|NCT03558373|DRUG|Immunosuppressive|Immunosuppressive therapies
224024955|NCT02294227|BIOLOGICAL|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
224024956|NCT02294227|OTHER|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
224024957|NCT02145247|DRUG|hCG|"3\. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4\. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
224024958|NCT00888004|DRUG|AFQ056|
224024959|NCT00888004|DRUG|Placebo|
224024960|NCT01177579|DIETARY_SUPPLEMENT|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
224024961|NCT01768637|DRUG|Aspirin|Aspirin 81 mg by mouth daily
224024962|NCT01768637|DRUG|Clopidogrel|Clopidogrel 75 mg by mouth once daily
224024963|NCT00126373|DRUG|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
224024964|NCT00899548|GENETIC|DNA methylation analysis|laboratory analysis
224024965|NCT00899548|GENETIC|microarray analysis|laboratory analysis
224024966|NCT00899548|GENETIC|polymerase chain reaction|laboratory analysis
224024967|NCT00899548|OTHER|laboratory biomarker analysis|laboratory analysis
224024968|NCT02561065|BEHAVIORAL|Lifestyle intervention|"1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
224024969|NCT04690868|DRUG|AD-213-A|1 tablet administered before the breakfast during 5 days
224024970|NCT04690868|DRUG|AD-2131|1 tablet administered before the breakfast during 5 days
224024971|NCT00511472|DRUG|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
224024972|NCT00511472|DRUG|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
224024973|NCT00511472|DRUG|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
224024974|NCT02709096|DRUG|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
224024975|NCT02709096|DRUG|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
223408866|NCT00471341|DRUG|Celecoxib|
224024976|NCT02515877|RADIATION|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
223408867|NCT00471341|DRUG|placebo|
224024977|NCT02515877|DRUG|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
224024978|NCT02515877|DRUG|Carboplatin|AUC= 2,5 (Calvert formula)
223408868|NCT03095144|DEVICE|Spinal anesthesia|Pyloromyotomy under spinal anesthesia
224024979|NCT01091077|DIETARY_SUPPLEMENT|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
224024980|NCT05880849|DRUG|Choline|Eight 275mg capsules taken orally twice daily (4 capsules with breakfast \& 4 capsules with dinner) x 180 days
224024981|NCT02387905|PROCEDURE|Management of Therapy Complications|Undergo vertebral body cement augmentation
224024982|NCT02387905|OTHER|Quality-of-Life Assessment|Ancillary studies
224024983|NCT02387905|OTHER|Questionnaire Administration|Ancillary studies
224024984|NCT02387905|RADIATION|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
224024985|NCT04176848|DRUG|CFI-400945|CFI-400945 32 mg: Cycle 1: Days 1-7, then Days 15-21; Cycle 2 on: orally once daily
224024986|NCT04176848|DRUG|Durvalumab|Cycle 2 on: Durvalumab 1500mg IV on Day 1 (28 day cycles)
224024987|NCT05279742|DRUG|MANP|Single subcutaneous injection 5 µg/Kg
223408869|NCT03095144|DEVICE|General anesthesia|Pyloromyotomy under general anesthesia
223408870|NCT00687271|DRUG|MK-6213|MK-6213 160 mg for 4 weeks.
223408871|NCT00687271|DRUG|Atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
223408872|NCT00687271|DRUG|Placebo for MK-6312 160 mg|
223408873|NCT00687271|DRUG|Placebo for Atorvastatin 20 mg|
223408874|NCT00299338|DRUG|SP01A|
223408875|NCT01134107|DRUG|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
223408876|NCT01134107|DRUG|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
224024988|NCT05279742|DRUG|Sacubitril/Valsartan|Oral single dose 97/103 mg
224024989|NCT05279742|DRUG|Oral Placebo|Oral single dose that contains no active ingredient
224024990|NCT05279742|DRUG|Injection Placebo|Single subcutaneous injection that contains no active ingredient
224024991|NCT03520686|DRUG|NAI + Pembrolizumab|"This intervention combines Nogapendekin alfa inbakicept (NAI), an immunostimulatory protein complex, with pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of NSCLC in Cohort A of QUILT-2.023.~Nogapendekin Alfa Inbakicept (NAI): A soluble complex consisting of two protein subunits of a human IL-15 variant bound with high affinity to a dimeric human IL-15Ra sushi domain/human IgG1 Fc fusion protein (inbakicept), serving as an immunostimulatory agent.~Dose: 15 µg/kg Route of Administration: Subcutaneously (SC)~Pembrolizumab: A humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing T-cell mediated immune responses against cancer cells.~Dose: 200 mg Route of Administration: Intravenously (IV)"
224024992|NCT03520686|DRUG|NAI + Nivolumab + Ipilimumab|"Nogapendekin Alfa Inbakicept (NAI): A soluble complex consisting of two protein subunits of a human IL-15 variant bound with high affinity to a dimeric human IL-15Ra sushi domain/human IgG1 Fc fusion protein (inbakicept), serving as an immunostimulatory agent.~Dose: 15 µg/kg Route of Administration: Subcutaneously (SC)~Nivolumab: A PD-1 blocking antibody that enhances T-cell activity against cancer cells.~Dose: 3 mg/kg Route of Administration: Intravenously (IV) Schedule: Days 1, 15, and 29 every 6 weeks~Ipilimumab: A CTLA-4 blocking antibody that promotes T-cell activation and anti-tumor immunity.~Dose: 1 mg/kg Route of Administration: Intravenously (IV) Schedule: Day 1 every 6 weeks"
224024993|NCT03520686|DRUG|Pembrolizumab|"Drug: Pembrolizumab~The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
224024994|NCT03520686|DRUG|NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel|"This intervention combines Nogapendekin alfa inbakicept (NAI), pembrolizumab (an anti-PD-1 immune checkpoint inhibitor), carboplatin (a platinum-based chemotherapy drug), and either nab-paclitaxel or paclitaxel (taxane chemotherapies) for the treatment of squamous NSCLC in Cohort B of the QUILT-2.023 trial.~Detailed Components:~Nogapendekin Alfa Inbakicept (NAI): An immunostimulatory protein complex.~Dose: 15 µg/kg Route of Administration: Subcutaneously (SC) Schedule: Day 1 every 3 weeks~Pembrolizumab: A PD-1 blocking antibody.~Dose: 200 mg Route of Administration: Intravenously (IV) Schedule: Day 1 every 3 weeks~Carboplatin: A platinum-based chemotherapy drug.~Dose: AUC 6 IV Route of Administration: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles only (Induction phase)~Nab-paclitaxel or Paclitaxel: Taxane chemotherapy drugs. The investigator chooses which one to use"
224024995|NCT03520686|DRUG|Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice)|"This intervention combines pembrolizumab, a PD-1 inhibitor, with carboplatin, and either nab-paclitaxel or paclitaxel (investigator's choice), for the treatment of squamous NSCLC in the control arm of the QUILT-2.023 trial for cohort B.~Detailed Components:~Pembrolizumab: A PD-1 blocking antibody.~Dose: 200 mg Route of Administration: Intravenously (IV) Schedule: Day 1, every 3 weeks Carboplatin: Chemotherapy agent.~Dose: AUC 6 IV Route of Administration: Intravenously (IV) Schedule: Day 1, every 3 weeks for 4 cycles only (Induction phase)~Nab-paclitaxel or Paclitaxel: Chemotherapy agents. The investigator chooses which one to use.~Nab-paclitaxel Dose: 100 mg/m²~Route of Administration: Intravenously (IV) Schedule: Day 1 and Days 8 and 15, every 3 weeks for 4 cycles (Induction phase)~Paclitaxel Dose: 200 mg/m²~Route of Administration: Intravenously (IV) Schedule: Day 1, every 3 weeks for 4 cycles (Induction phase)"
224024996|NCT03520686|DRUG|Cisplatin/carboplatin and pemetrexed plus pembrolizumab.|"Brief Description: Chemoimmunotherapy regimen to treat nonsquamous NSCLC in the experimental or control groups of Cohort C in the QUILT-2.023 study.~Detailed Components:~Cisplatin or Carboplatin:~Cisplatin Dosing: 75 mg/m2, intravenously Route: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase) OR~Carboplatin: Dosing at AUC 6 IV, intravenously Route: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase)~Pemetrexed:~Dosing at 500 mg/m2, intravenously Route: Intravenously (IV) Schedule: Day 1 every 3 weeks~Pembrolizumab:~Dosing at 200 mg Route: Intravenously (IV) Schedule: Day 1 every 3 weeks"
224133362|NCT04874467|PROCEDURE|Supportive periodontal therapy|"A complete professional prophylaxis session will be performed, which includes ultrasound debridement, scaling with curettes and dental polishing with a rubber cup. On the other hand, in implants affected by mucositis, supra and sub-gingival debridement will be performed using a combination of ultrasound with a titanium tip and titanium curettes.~All patients will receive personalized hygiene instructions. Patients will be instructed to brush their implants twice daily using the modified Bass technique with a medium-hard manual toothbrush and low-abrasive toothpaste. In addition, they will be taught to use specific interproximal brushes. If access with an interdental brush is not possible, flossing will be indicated. Oral hygiene instructions will be reviewed at each visit."
224133363|NCT02712177|BIOLOGICAL|4CMenb|
224133364|NCT02712177|BIOLOGICAL|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
224133365|NCT02712177|BIOLOGICAL|conjugated pneumococcal vaccine|
224133366|NCT02712177|BIOLOGICAL|MMRV|
224133367|NCT06355401|DRUG|Tamoxifen 20mg|maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT
224133368|NCT00828334|DEVICE|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
223408877|NCT01542489|DRUG|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
223408878|NCT01542489|DRUG|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
223408879|NCT01542489|DRUG|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
223408880|NCT04012593|BEHAVIORAL|Diary|
223408881|NCT02463851|DEVICE|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
223408882|NCT02463851|DEVICE|Contact Force single-tip ablation catheter|
224024997|NCT03520686|DRUG|Cisplatin/carboplatin and pemetrexed plus atezolizumab.|"This is a chemoimmunotherapy regimen to treat nonsquamous NSCLC in the experimental or control groups of Cohort C in the QUILT-2.023 study~Detailed Components:~Cisplatin or Carboplatin: Chemotherapy agents, the Investigator's choice between one or the other.~Cisplatin Dosing: 75 mg/m2, intravenously Route: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase) Carboplatin Dosing at AUC 6 IV Route: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase)~Pemetrexed:~Dosing at 500 mg/m2, intravenously Route: Intravenously (IV) Schedule: Day 1 every 3 weeks~Atezolizumab:~Dosing at 1200 mg Route: Intravenously (IV) Schedule: Day 1 every 3 weeks"
224024998|NCT03520686|DRUG|Carboplatin and paclitaxel plus atezolizumab and bevacizumab.|"This regimen combines chemotherapy agents with checkpoint and VEGF inhibitors to treat nonsquamous NSCLC in experimental and control groups of Cohort C in QUILT-2.023 trial.~Detailed Components:~Carboplatin:~Dosing at AUC 6 IV Route: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase)~Paclitaxel:~Dosing at 175 or 200 mg/m², intravenously (Investigator's Choice) Route: Intravenously (IV) Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase)~Atezolizumab:~Dosing at 1200 mg, intravenously Route: Intravenously (IV) Schedule: Day 1 every 3 weeks~Bevacizumab:~Dosing at 15mg/kg Route: Intravenously (IV) Schedule: Day 1 every 3 weeks"
224024999|NCT03520686|DRUG|Carboplatin and nab-paclitaxel plus atezolizumab.|"This regimen combines chemotherapy agents with a checkpoint inhibitor to treat nonsquamous NSCLC in experimental and control groups of Cohort C in QUILT-2.023 trial.~Detailed Components:~Carboplatin: Chemotherapy agent.~Dosing at AUC 6 IV~Route: Intravenously (IV)~Schedule: Day 1 every 3 weeks for 4 cycles (Induction Phase)~Nab-paclitaxel: Chemotherapy agent.~Dosing at 100 mg/m², intravenously~Route: Intravenously (IV)~Schedule: Days 1, 8, and 15 every 3 weeks for 4 cycles (Induction Phase)~Atezolizumab: Immunotherapy drug.~Dosing at 1200 mg~Route: Intravenously (IV)~Schedule: Day 1 every 3 weeks"
224025000|NCT03520686|DRUG|NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel|"This intervention combines Nogapendekin alfa inbakicept (NAI) with the checkpoint inhibitors nivolumab and ipilimumab, carboplatin (a chemotherapy agent), and nab-paclitaxel, and is being explored in NSCLC patients of Cohort D in the QUILT-2.023 trial.~Detailed Components:~Nogapendekin alfa inbakicept (NAI): Immunomodulatory agent. Dose: 1.2 mg Route of Administration: Subcutaneously (SC) Schedule: Days 1, 15, and 29 of each 6-week cycle~Nivolumab: Checkpoint inhibitor. Dose: 360 mg Route of Administration: Intravenously (IV) Schedule: Days 1 and 22 of each cycle~Ipilimumab: Checkpoint inhibitor. Dose: 1 mg/kg Route of Administration: Intravenously (IV) Schedule: Day 1 of each cycle~Carboplatin: Chemotherapy agent. Dose: AUC 6 Route of Administration: Intravenously (IV) Schedule: Days 1 and 22 (Cycle 1 only)~Nab-paclitaxel: Chemotherapy agent. Dose: 100 mg/m2 Route of Administration: Intravenously (IV) Schedule: Days 1, 8, 15, 22, 29, and 36 (Cycle 1 only)"
224025001|NCT05018208|OTHER|Computer-Assisted Intervention|Use smartphone app
224025002|NCT05018208|PROCEDURE|Patient Monitoring|Wear Biofourmis wearable device(s)
224025003|NCT05018208|OTHER|Questionnaire Administration|Complete questionnaires
224025004|NCT04517851|BIOLOGICAL|Elotuzumab|Given IV
224025005|NCT04517851|OTHER|Questionnaire Administration|Ancillary studies
224025006|NCT04774393|DRUG|Decitabine and Cedazuridine|Given PO
224025007|NCT04774393|DRUG|Enasidenib|Given PO
224025008|NCT04774393|DRUG|Ivosidenib|Given PO
224025009|NCT04774393|DRUG|Venetoclax|Given PO
224025010|NCT05056844|PROCEDURE|Contrast Enhanced Digital Mammography|Undergo CESM
224025011|NCT05056844|PROCEDURE|Digital Tomosynthesis Mammography|Undergo DBT
224025012|NCT05056844|DRUG|Iodinated Contrast Agent|Given iodine-based contrast agent IV
224025013|NCT05056844|OTHER|Questionnaire Administration|Ancillary studies
224025014|NCT02427464|BIOLOGICAL|Engensis (VM202)|gene therapy
224025015|NCT02427464|OTHER|placebo|
224025016|NCT04009044|DRUG|Afimoxifene|Apply topically
224025017|NCT04009044|PROCEDURE|Core Biopsy|Undergo core needle biopsy
224133369|NCT04972734|BIOLOGICAL|premature newborns developing a NEC|weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC
224025018|NCT04009044|OTHER|Questionnaire Administration|Ancillary studies
224025019|NCT05345171|GENETIC|DTX301|non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector
224025020|NCT05345171|OTHER|Placebo|normal saline infusion
223558464|NCT05571644|DRUG|mFOLFOXIRI+AK104+fruquintinib|Cadonilimab（AK104）6mg/kg, intravenous d for 60 minutes, followed by mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) every 2 weeks for 6 cycles, and fruquintinib (3mg Qd, D1-21, Q4W for 3 months) before surgery
224025021|NCT05345171|DRUG|Oral Corticosteroids|Participants who receive DTX301 solution will receive oral corticosteroids.
224025022|NCT05345171|DRUG|Placebo for oral corticosteroids|Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
224025023|NCT05345171|DRUG|Sodium Acetate|A tracer for the Ureagenesis Rate Test (URT)
224025024|NCT03432286|DRUG|Galcanezumab|Administered SQ
224025025|NCT03432286|DRUG|Placebo|Administered SQ
224025026|NCT02954874|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224025027|NCT02954874|OTHER|Laboratory Biomarker Analysis|Correlative studies
224025028|NCT02954874|OTHER|Patient Observation|Undergo standard monitoring
224025029|NCT02954874|BIOLOGICAL|Pembrolizumab|Given IV
224025030|NCT02954874|OTHER|Quality-of-Life Assessment|Ancillary studies
224025031|NCT02954874|OTHER|Questionnaire Administration|Ancillary studies
224025032|NCT02954874|RADIATION|Radiation Therapy|Undergo radiation therapy
224025033|NCT05614739|DRUG|LOXO-435|Oral
224025034|NCT05614739|DRUG|Pembrolizumab|IV
224025035|NCT05614739|DRUG|enfortumab vedotin|IV
224025037|NCT06438640|BEHAVIORAL|My Anesthesia Choice-HF Model|Brief clinician training on shared decision making, paired with provision of a 1-page tabular format conversation aid listing answers to frequently asked questions regarding common anesthesia options for hip fracture surgery (spinal anesthesia; general anesthesia)
224025038|NCT06383390|DRUG|Retatrutide|Administered SC
224133370|NCT04972734|BIOLOGICAL|premature newborns without NEC|weekly Blood sample and daily Stools sample during 12 weeks
223558465|NCT07079709|BEHAVIORAL|Workfocused CBT|In WCBT, the central idea is that CBT techniques can be applied in a work context with the aim of achieving both usual treatment goals related to symptoms and RTW. To ensure positive effects at both symptomatic and functional levels, a work perspective must be fully integrated into the intervention to optimize the treatment effect which demands collaboration with the sick leave prescribing doctor and the patient's employer. The protocol is based on principles of increasing return-to-work self-efficacy (RTW-SE). Work-specific components, such as work anamnesis, adjusting the difficulty of work tasks, and developing a return-to-work plan that includes recommendations for workplace accommodations, are integrated into all treatment sessions.
223558466|NCT07079709|OTHER|Standard Care (in control arm)|Standard Care is defined as care by the sick leave prescribing physician and the rehab coordinator. Other interventions such as psychological treatment, physiotherapy etc. may also be included in this arm.
224025039|NCT06383390|DRUG|Placebo|Administered SC
224025040|NCT06207188|OTHER|Non-Interventional Study|Non-interventional study
224025041|NCT04164225|BEHAVIORAL|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
224025042|NCT04164225|BEHAVIORAL|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
224025043|NCT06128070|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224025044|NCT06128070|PROCEDURE|Chest Computed Tomography|Undergo chest CT
224025045|NCT06128070|PROCEDURE|Echocardiography|Undergo ECHO
224025046|NCT06128070|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
224025047|NCT06128070|DRUG|Methotrexate|Given IV
224025048|NCT06128070|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224025049|NCT06128070|DRUG|Ruxolitinib Phosphate|Given PO
224025050|NCT06128070|DRUG|Tacrolimus|Given IV
224025051|NCT06424327|OTHER|Patient-Reported Outcomes Measurement Information System|Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
224025052|NCT06403852|COMBINATION_PRODUCT|Functional Magnetic Resonance Imaging (fMRI) with propofol|Three 16-min sessions in wakeful baseline, light sedation, and recovery will be conducted (Fig. 2). Light sedation will be achieved by IV infusion of propofol to achieve effect-site concentrations of 1.0 μg/ml. Infusion rate will be manually controlled. An initial bolus dose (525 µg/kg) and subsequent infusion rate (82 µg/kg/min) for each participant
224025053|NCT04789681|DRUG|Canakinumab|Given SC
224025054|NCT04789681|OTHER|Quality-of-Life Assessment|Ancillary studies
224025055|NCT05142189|BIOLOGICAL|BNT116|Intravenous injection
224025056|NCT05142189|BIOLOGICAL|Cemiplimab|Intravenous infusion
224025057|NCT05142189|DRUG|Docetaxel|Intravenous infusion
223558467|NCT06456008|OTHER|Standard of care|Standard of care
224025058|NCT05142189|DRUG|Carboplatin|Intravenous infusion
224025059|NCT05142189|DRUG|Paclitaxel|Intravenous infusion
224025060|NCT05142189|BIOLOGICAL|BNT316|Intravenous infusion
224025061|NCT05142189|BIOLOGICAL|anti-B7-H3 antibody conjugated to topoisomerase I inhibitor|Intravenous infusion
224025062|NCT05142189|BIOLOGICAL|anti-HER3 antibody conjugated to topoisomerase I inhibitor|Intravenous infusion
224025063|NCT05142189|BIOLOGICAL|Bispecific antibody for PD-L1 and VEGF-A|Intravenous infusion
224133371|NCT03520439|DRUG|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
224025064|NCT05509777|DRUG|Mirikizumab|Administered IV or SC
224025065|NCT01908777|OTHER|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
224025066|NCT06305728|DIAGNOSTIC_TEST|89Zr-DFO-HuMab-5B1 immunoPET|Participants who choose to will undergo immunoPET before surgery.
224025067|NCT06305728|DIAGNOSTIC_TEST|HP MRI|Participants who choose to will undergo HP MRI before surgery.
224025068|NCT06305728|COMBINATION_PRODUCT|Blood assay|Will be drawn within 6 weeks of surgery and annually as post operative care
224025069|NCT04947527|DRUG|Test varnish|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
224025070|NCT04947527|DRUG|Placebo|A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
224025071|NCT06598371|DRUG|Cyclophosphamide|Given by IV
224025072|NCT06598371|DRUG|Fludarabine|Given by IV
224025073|NCT06598371|DRUG|KSQ-004EX|Given by IV
224025074|NCT06598371|DRUG|Interleukin-2|Given by IV
224133372|NCT03520439|DRUG|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
224133373|NCT05747755|BEHAVIORAL|ADEPT Program|Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
223408883|NCT03551171|DRUG|ZL-2306 (niraparib)|"About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose."
223408884|NCT00280280|DRUG|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
223408885|NCT05354856|DRUG|Indocyanine green|A bolus of ICG (0.2 mg/kg body weight) will be injected intravenously and flushed with 5 mL of saline. Gastric perfusion will subsequently be assessed along specific regions of interest (ROI) with q-ICG (quantitative perfusion assessments with ICG) to obtain baseline perfusion values.
223408886|NCT02618603|DRUG|Botulinum toxin A|
223408887|NCT02618603|DRUG|Triamcinolone Acetonide|
223408888|NCT02760823|DRUG|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
223558468|NCT01766804|DIETARY_SUPPLEMENT|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
223558469|NCT01766804|DIETARY_SUPPLEMENT|placebo|
223558470|NCT05285761|BEHAVIORAL|Provision of extended information on the conduct of complementary feeding|"Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.~In addition to the paper brochure and the generic information, parents in the intervention group will also receive the new recommendations relating to CF through an educational device (in the form of a smartphone application). This app will deliver information and very short videos illustrating various aspects of responsive feeding during CF and taking up the themes of the paper brochure. These 106 messages will be delivered regularly from the 3rd months until the 36th months of the child."
223738513|NCT05538832|DEVICE|BrainHQ Computerized Cognitive Training - Visual Cognitive Control Training Paradigm|The Cognitive Training is a program consisting of the follow set of exercises developed by Posit Science Corporation (BrainHQ) which is to be evaluated for Visual Cognitive Control Training: Mind Bender; Divided Attention; Card Shark; and Freeze Frame. Participants use a standard web browser on a broadband connected computer and go to the study web site. Participants perform multiple trials over the course of a session, with auditory/visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each assigned session, the difficulty of the next session is updated to ensure that each participant is appropriately challenged.
224025075|NCT06345729|DRUG|MK-1084|Oral tablets
224025076|NCT06345729|OTHER|Placebo|Oral tablets
224025077|NCT06345729|BIOLOGICAL|Pembrolizumab|IV infusion
224025078|NCT05031897|DRUG|Fludarabine|Given IV
224133374|NCT05940727|OTHER|Habitual macroalgae consumption|The participant have a habitual macroalgae consumption at baseline.
224025079|NCT05031897|RADIATION|Total-Body Irradiation|Undergo TBI
224025080|NCT05031897|PROCEDURE|Donor Lymphocyte Infusion|Undergo DLI
224133375|NCT05940727|OTHER|No macroalgae consumption|The participants exclude any macroalgae products from their diet
224133376|NCT00590915|DRUG|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
223408889|NCT02760823|DRUG|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
223408890|NCT03161743|PROCEDURE|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
223408891|NCT01951534|BEHAVIORAL|Breast Reconstruction Decisional Aid (BRDA)|
223408892|NCT01951534|BEHAVIORAL|Usual Care|
224025081|NCT05031897|DRUG|Cyclophosphamide|Given IV
223408893|NCT00126347|PROCEDURE|supplementation with betaine, serine, and folic acid|
223408894|NCT01656135|OTHER|Blood drawing for immune monitoring and questionnaires|
224025082|NCT05031897|DRUG|Tacrolimus|Given IV
224025083|NCT05031897|DRUG|Mycophenolate Mofetil|Given IV
224025084|NCT05031897|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
224025085|NCT05031897|DRUG|Melphalan|Given IV
224025086|NCT05031897|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/ biopsy
224025087|NCT05031897|PROCEDURE|Diagnostic Imaging|Undergo diagnostic imaging
224025088|NCT05031897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224025089|NCT05962385|DEVICE|Brain state while receiving TMS|Brain state whilst receiving TMS - cognitive control or perceptual. Repeated measures design, so all participants receive the same procedures.
224133377|NCT06482554|DRUG|Lumateperone 42 mg|Standard treatment with lumateperone
224133378|NCT06482554|DRUG|Risperidone 2 mg|Standard treatment with other antipsychotic drugs
223408895|NCT02314260|OTHER|bishop score calculation|Assessment of bishop score by vaginal examination
223408896|NCT02314260|OTHER|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
223408897|NCT02314260|OTHER|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
224133379|NCT01626352|DRUG|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.
224133380|NCT01626352|DRUG|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
224297985|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
223408898|NCT02314260|PROCEDURE|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
224025090|NCT03355976|DRUG|Nivolumab|240mg flat dose every 2 weeks
224025091|NCT03355976|DRUG|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
224025092|NCT04817761|DRUG|Calaspargase pegol (S95015)|"Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2."
224025093|NCT06450392|DRUG|Tranexamic acid injection|100 mg/mL (manufactured concentration) local TXA injection in the orbit
224025094|NCT06450392|DRUG|Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)|1g IV TXA
224025095|NCT06450392|DRUG|normal saline - injection|0.9% Normal Saline injection in the orbit
224025096|NCT06450392|DRUG|normal saline - intravenous|0.9% IV Normal Saline
224025097|NCT05321368|BEHAVIORAL|LINKED-HEARTS Program|The intervention arm will include training on home blood pressure monitoring, Sphygmo blood pressure telemonitoring app, Community Health Worker visit for education, counseling on lifestyles modification and Pharmacist to collaborate with other providers to optimize pharmacologic therapy to improve hypertension outcomes and with payors to ensure consistent access to drug therapy.
224025098|NCT03164564|DRUG|Oral CAB|CAB 30 mg tablet
224025099|NCT03164564|DRUG|Oral TDF/FTC|TDF/FTC 300 mg/200 mg fixed dose combination tablet
224025100|NCT03164564|DRUG|Placebo for oral CAB|Placebo tablets
224025101|NCT03164564|DRUG|Placebo for oral TDF/FTC|Placebo tablets
224025102|NCT03164564|DRUG|CAB LA|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
223408899|NCT06649968|DEVICE|DESC-Glove (active)|Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, receiving vibratory stimuli that are synchronized with the exercises being performed.
223408900|NCT06649968|DEVICE|DESC-Glove (sham)|Rehabilitation treatment for the upper limb using the DESC-Glove device. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20-minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. During each session, patients will wear the DESC-Glove on the affected hand, but will not receive any vibratory stimuli.
223738514|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|single dose of 1 × 10(7) cells intrathecally
224025103|NCT03164564|DRUG|Placebo for CAB LA|Administered as one 3 mL intramuscular injection in the gluteal muscle
224025104|NCT05296304|DRUG|Bexarotene|Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
224025105|NCT05296304|RADIATION|Total Skin Electron Beam (TSEB)|At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).
224025106|NCT05186077|OTHER|Magnetic Resonance Imaging|Imaging data for research purposes (high-resolution T1 structural and DWI MRI) will be acquired
224133381|NCT04068064|PROCEDURE|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days."
223738515|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 5 × 10(7) cells intrathecally each 1 month (±4 days) apart
223738516|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|2 doses of 1 × 10(8) cells intrathecally each 1 month apart
223738517|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
223738518|NCT02315027|BIOLOGICAL|Autologous Mesenchymal Stem Cells|Ten doses of 2.5 x 10(7) (±20%) cells intrathecally six months (±1 month) apart
224025107|NCT05186077|OTHER|Psychiatric testing|Subjects will be evaluated using psychiatric assessments
224025108|NCT05186077|OTHER|Eye-Tracking|Eye-tracking assessments will be done to biases toward positive and negative stimuli including images of neutral, fearful/threatening, sad, and happy.
224025109|NCT05186077|OTHER|Neuropsychology Evaluation|The neuropsychology evaluation will measure verbal learning/memory, attention/working memory, psychomotor speed, verbal fluency/processing speed, and executive function
224025110|NCT06292013|DRUG|Lepodisiran Sodium|Administered SC
224025111|NCT06292013|DRUG|Placebo|Administered SC
224025112|NCT02000089|DRUG|Secretin|inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
224025113|NCT02000089|DIAGNOSTIC_TEST|MRI|MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
223408901|NCT06649968|OTHER|Traditional rehabilitation|Traditional rehabilitation treatment for the upper limb. The protocol includes 8 exercises, each lasting 2 to 3 minutes. The treatment is conducted daily under the supervision of a therapist and consists of two 20- minute sessions per day, with a 10-minute break in between for neuro-muscular and attentional recovery. The treatment is performed three times a week, totaling 24 sessions over a 4-week period. The DESC- Glove will not be used during this treatment.
223738519|NCT06710145|BEHAVIORAL|Combat Attention Training|The Combat Attention App is a response-time based mechanized preventive intervention designed to train combat soldiers' attention toward threats before combat exposure in order to reduce the risk for combat-related post-trauma symptoms. In light of the results of controlled studies that proved the efficacy of this preventive intervention, the Israel Defense Forces (IDF) decided at the beginning of the Iron Swords War (October 7th, 2023) to implement an internet-based App of the intervention, and soldiers and combat reservists were invited to train on the Combat Attention App.
224025114|NCT02000089|OTHER|Tumor marker gene test with CA19-9|A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
224025115|NCT05735184|DRUG|Ziftomenib|Oral Administration
224025116|NCT05735184|DRUG|Venetoclax|Oral Administration
224025117|NCT05735184|DRUG|Azacitidine|Subcutaneous or Intravenous Administration
224133382|NCT04068064|PROCEDURE|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
224133383|NCT03424889|DRUG|Xylometazoline|Nasal administration of Xylometazoline
224133384|NCT03424889|DRUG|Saline|Nasal administration of 0.9% Saline
224133385|NCT00111917|DRUG|Infliximab|anti-TNF
223738520|NCT03554083|DRUG|Atezolizumab|Given IV
223408902|NCT02521142|OTHER|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
223408903|NCT02521142|OTHER|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
223408904|NCT02521142|OTHER|OCT|non-invasive imaging of retinal and choroidal structures.
223408905|NCT02521142|OTHER|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
223738521|NCT03554083|DRUG|Cobimetinib|Given PO
223738522|NCT03554083|BIOLOGICAL|Tiragolumab|Given IV
223738523|NCT03554083|DRUG|Vemurafenib|Given PO
223738524|NCT03055000|BIOLOGICAL|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
224133386|NCT00111917|OTHER|Placebo|Placebo infusion
224133387|NCT05250830|DEVICE|TrueRelief device|TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.
223408906|NCT06476912|OTHER|weight-shifting exercise|lateral weight-shifting balance training and VNS
223738525|NCT03055000|BIOLOGICAL|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
223738526|NCT03055000|OTHER|Placebo|WFI (0.5mL) on Day 0 and Day 21
224025118|NCT05735184|DRUG|Daunorubicin|Intravenous Administration
224025119|NCT05735184|DRUG|Cytarabine|Intravenous Administration
224025120|NCT05735184|DRUG|Quizartinib|Oral Administration
224025121|NCT05496374|DRUG|Placebo|Placebo-matching capsules was administered orally.
224025122|NCT05496374|DRUG|SPR720 500 mg|SPR720 500 mg (250 mg × 2 capsules) was administered orally.
224025123|NCT05496374|DRUG|SPR720 1000 mg|SPR720 500 mg (250 mg × 4 capsules) was administered orally.
224025124|NCT00673010|RADIATION|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
224025125|NCT05514054|DRUG|Imlunestrant|Administered orally.
224025126|NCT05514054|DRUG|Tamoxifen|Administered per local approved label.
224025127|NCT05514054|DRUG|Anastrozole|Administered per local approved label.
224025128|NCT05514054|DRUG|Letrozole|Administered per local approved label.
224025129|NCT05514054|DRUG|Exemestane|Administered per local approved label.
224025130|NCT02849223|DEVICE|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
224025131|NCT02849223|DEVICE|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
224133388|NCT05250830|DEVICE|Sham TrueRelief device|The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
224025132|NCT05663515|DRUG|Exenatide|All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs.
224025133|NCT05663515|DRUG|Non-GLP-1 RA based glucose lowering drugs|Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period.
223408907|NCT06407765|OTHER|Dual task training|Dual task training incorporates both cognitive and motor tasks. Tasks like walking and asking the patient to point towards objects, collect start from the objects hanging above the patient and asking the patient to name the objects shown to him/her. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
223408908|NCT06407765|OTHER|Dual task training with backward walking|This group will get both dual task training and backward walking. For dual task training same protocol as active comparator is followed. For backward walking; the patient is firstly asked to walk backward with complete physiotherapist assistance. Secondly, the patient is asked to walk for 15 m through the treatment room's hallway while holding a safety bar with the hand on the unaffected side. Third, without using a safety bar, the participants were urged to walk freely. Lastly, the participants tried to walk backwards at a reasonable pace while progressively increasing their distance travelled and speed. This treatment will be given for 4 weeks, 4 times a week for 40 minutes. Each task is done for 7 minutes with a 3 minutes break in between.
223408909|NCT01644292|OTHER|EPIC WheelS|EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
223408910|NCT05525403|OTHER|Knee Extension Exercise|Participants will be seated in a Steel Flex machine with weight equal to 50% of their 1 repetition maximum added to the machine. Participants will extend the dominant knee until the assigned fatigue level.
223408911|NCT05525403|OTHER|Quiet Rest|Participants will sit quietly for two minutes, three times.
223408912|NCT05797961|BEHAVIORAL|HIV self-testing with online supervision|A pilot study to assess the feasibility of HIV self-testing with online supervision
223408913|NCT05797961|OTHER|Control|venue-based HIV testing
223408914|NCT02780726|DRUG|roxadustat|Oral
223408915|NCT00858533|BEHAVIORAL|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
223408916|NCT03250754|DEVICE|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
223408917|NCT02463929|DRUG|Diphenhydramine|Intravenous Injection
223408918|NCT02463929|DRUG|normal saline|Intravenous Injection
224025140|NCT06994845|DRUG|iptacopan|Cohort 1 (12 to \< 18 years of age): Iptacopan 200 mg b.i.d.(twice daily) Cohort 2 (2 to \< 12 years old): Dosing tbd
224025141|NCT04837547|BIOLOGICAL|Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)|There will be two immunotherapy products manufactured and administered to subjects enrolled on this trial. The first product will be autologous dendritic cells (DCs) loaded with total tumor messenger ribonucleic acid (mRNA) (TTRNA) derived from malignant tumors. The second product will be autologous T lymphocytes stimulated ex vivo against TTRNA antigens for autologous transfer (TTRNA-xALT). DCs are professional antigen-presenting cells critical for the initiation of B and T-cell responses in vivo.
224025142|NCT06752668|DRUG|ORX750|ORX750 capsule.
224025143|NCT06752668|DRUG|Placebo|ORX750 matching placebo capsule.
224025144|NCT05370521|DRUG|Tildacerfont|Oral tablet formulation taken once daily.
224025145|NCT05370521|DRUG|Placebo|Non-active dosage form taken once daily.
224025146|NCT05940272|BEHAVIORAL|Hematolo-GIST Training|Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
224025147|NCT05940272|BEHAVIORAL|Participants Appointment|Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
224025148|NCT06870487|DRUG|PF-08046032|PF-08046032 will be administered intravenously (IV) infusion.
224025149|NCT06870487|DRUG|Sasanlimab|Sasanlimab will be administered as subcutaneous (SC) injection.
224025150|NCT04015141|DRUG|Perampanel Oral Suspension|Perampanel oral suspension.
224025151|NCT04015141|DRUG|Perampanel Tablet|Perampanel tablet.
224025152|NCT07027462|DIETARY_SUPPLEMENT|Mushroom blend|A mushroom blend that is targeted to improve gastrointestinal symptoms.
224025153|NCT07027462|OTHER|Placebo|Placebo product.
224025154|NCT07027514|DRUG|tolododekin alfa|Participants will receive tolododekin alfa as an intratumoral injection every 3 weeks (Q3W).
224025155|NCT07027514|DRUG|Cetrelimab|Participants will receive cetrelimab Q3W.
224025156|NCT06000449|BEHAVIORAL|Center M|Digital mental health platform. Screening and prevention activities will be provided through the Center M platform, telehealth group mindfulness sessions, and digitally delivered home practice materials.
224025157|NCT06000449|BEHAVIORAL|Treatment as Usual|Paper screening and PD handout.
224025158|NCT05025800|DRUG|CD47 Antagonist ALX148|Given IV
224025159|NCT05025800|DRUG|Lenalidomide|Given PO
224025160|NCT05025800|BIOLOGICAL|Rituximab|Given IV
224025161|NCT07037433|DRUG|Maridebart Cafraglutide|Maridebart cafraglutide will be administered SC.
224025162|NCT07037433|DRUG|Placebo|Placebo will be administered SC.
224025163|NCT06884748|DRUG|Ursodiol 500 MG|Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.
223408919|NCT02463929|DRUG|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
224133389|NCT06375980|OTHER|Intraoperative Mechanical Ventilation Strategies|The intervention involves the management of mechanical ventilation during major abdominal surgery. This includes the adjustment of ventilation parameters such as tidal volume, respiratory rate, peak pressure, positive end-expiratory pressure (PEEP), and inspiratory flow rate. The aim is to optimize ventilation strategies to reduce the risk of postoperative pulmonary complications
223408920|NCT02463929|DRUG|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
223408921|NCT02463929|DRUG|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
224025164|NCT07090122|PROCEDURE|Radiofrequency ablation and bone augmentation with radiotherapy|employs radiofrequency-generated heat to eradicate cancer cells, followed by the application of a bone-stabilizing agent
224025165|NCT07090122|PROCEDURE|Radiotherapy alone|High-energy radiation
224025166|NCT07096843|DRUG|budoprutug|Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183
224025167|NCT06911502|DRUG|Golcadomide|Specified dose on specified days
224025168|NCT06911502|DRUG|Rituximab|Specified dose on specified days
224025169|NCT06911502|DRUG|Lenalidomide|Specified dose on specified days
224025170|NCT06911502|DRUG|Cyclophosphamide|Specified dose on specified days
224025171|NCT06911502|DRUG|Doxorubicin|Specified dose on specified days
224025172|NCT06911502|DRUG|Vincristine|Specified dose on specified days
224025173|NCT06911502|DRUG|Prednisone/Prednisolone|Specified dose on specified days
224025174|NCT06911502|DRUG|Bendamustine|Specified dose on specified days
224025175|NCT03522142|DRUG|INCB081776|INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
224133390|NCT00748085|DEVICE|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
224133391|NCT02842112|OTHER|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
224133392|NCT02943265|OTHER|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
224133393|NCT00000993|DRUG|Zidovudine|
224138930|NCT03215654|OTHER|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
223408922|NCT06682845|OTHER|Collection of data in patients' medical files|"* Demographic data~* Health data: body mass index, weight, tobacco consumption, history of hyperglycemia/ diabetes mellitus, Eastern Cooperative Oncology Group (ECOG) status, glomerular filtration rate, hemoglobin rate~* Cancer-related data: date of diagnosis, tumoral site, tumor histology type, histology grade, date of first metastases involvement, presence of visceral metastases, presence of liver metastases, presence of lymph node-only metastases~* Treatment-related data: previous line of treatment, co-treatment with anti-PD1, enfortumab vedotin (EV) treatment start date, EV treatment end date, EV posology, presence of EV reduction of dose or increased interval between perfusions, number of EV cycles~* Adverse events (AE)-related data: occurrence of cutaneous AE, grade of cutaneous AE, date of cutaneous AE, type of cutaneous AE, management of cutaneous AE, discontinuation of EV treatment, rechallenge of EV treatment~* Outcomes data: best overall response rate"
223408923|NCT01704690|DRUG|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
223408924|NCT01704690|DRUG|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
224025176|NCT03522142|DRUG|INCMGA00012|INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
224025177|NCT05959629|DEVICE|Waterlase Express™, BIOLASE®|Er,Cr:YSGG laser 2780nm (Waterlase Express™, BIOLASE®) with 300μm tip (EdgePro #3) will be placed into the mid-root of the canal. The tip will be activated and slowly withdrawn to the orifice (1-2mm/sec) following the manufacturer settings (energy 15 Millijoule (mJ), repetition rate 50 Hertz (Hz), 0% air, 0% water).
224025178|NCT05959629|OTHER|Sodium Hypochlorite|Root canals will be instrumented up to size 30/0.04 taper using 1.5cc of 3% NaOCl in between files.
224025179|NCT07092033|DEVICE|Bimodal Neuromodulation|The device is a non-invasive stimulation device that consists of a controller that connects to headphones for sound delivery to the ears and connects to a mouth component that provides gentle electrical stimulation to the tongue surface. The sound is currently configured according to a tinnitus person's audiogram (i.e., hearing threshold profile for different sound frequencies) during device fitting. Individuals are recommended to use the device for 60 minutes daily (two 30-minute sessions consecutively or at different times of the day) for at least 12 weeks.
224025180|NCT07098260|BEHAVIORAL|DECIDE for MOM Provider Training|Participants will take an asynchronous online DECIDE for MOM provider training (approximately 3hours). DECIDE stands for Decide the problem; Explore the questions; Closed or open-ended questions; Identify the who, why, or how of the problem; Direct questions to your health care professional; Enjoy a shared solution. The 5 modules will cover shared decision-making, perspective-taking, patient activation, attributional errors, and being a responsive provider to perinatal individuals.
224025181|NCT03573401|COMBINATION_PRODUCT|Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
224025182|NCT03573401|COMBINATION_PRODUCT|Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
223408925|NCT01704690|DRUG|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
224025183|NCT06890611|DRUG|Bimagrumab|Administered SC
224025184|NCT06890611|DRUG|Tirzepatide|Administered SC
224025185|NCT06890611|DRUG|Bimagrumab + Tirzepatide Coformulation|Administered SC
224025186|NCT03722407|DRUG|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
224025187|NCT05115513|DRUG|Medium THC|Marijuana flower with medium THC
224025188|NCT05115513|DRUG|Placebo THC|Marijuana flower with no THC
224025189|NCT06914895|DRUG|Tirzepatide|Administered SC
224025190|NCT06914895|DRUG|Placebo|Administered SC
224025191|NCT05531565|DRUG|Litifilimab|Administered as specified in the treatment arm.
224025192|NCT05531565|DRUG|Placebo|Administered as specified in the treatment arm.
224025193|NCT06828471|BEHAVIORAL|Social Cognition Training|Neuroplasticity-based social cognition training that targets a range of social cognition skills, including visual and vocal affect perception, social cue perception, theory of mind, self-referential style, and empathy
224025194|NCT05540782|BEHAVIORAL|PROMIS-SF v2.0 -Cognitive Function 8a|Patient-Reported Outcomes (PROs)
224025195|NCT03987386|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224025196|NCT03987386|OTHER|Quality-of-Life Assessment|Ancillary studies
224025197|NCT03987386|OTHER|Questionnaire Administration|Ancillary studies
223408926|NCT05164484|DEVICE|Transpulmonary thermodilution|Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
224025198|NCT03987386|RADIATION|Radiation Therapy|Undergo conventional radiation therapy
224025199|NCT06916065|DRUG|Eloralintide and Tirzepatide|Administered SC
224025200|NCT06916065|DRUG|Eloralintide|Administered SC
224025201|NCT07114601|DRUG|LY4257496|Administered IV
224025202|NCT07114601|DRUG|Standard of Care Anticancer Therapies|Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib
224025203|NCT06912633|BIOLOGICAL|human retinal progenitor cells|Single intravitreal injection of 8.8 million retinal progenitor cells (RPCs)
224025204|NCT06912633|OTHER|Mock injection|Pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection. Subjects randomized to the sham control group will undergo identical preparation as the active treatment group immediately prior to treatment, including application of anesthetics.
224138931|NCT00379197|DRUG|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
224025205|NCT06921759|DRUG|Lebrikizumab|Administered SC
224025206|NCT06921759|DRUG|Placebo|Administered SC
224025207|NCT07115030|BEHAVIORAL|PCT+2HOPE|"Each PCT+ group follows the same structure and starts with the group setting an agenda. Clients identify issues to work on using these steps: 1) Identify an issue and if/how it relates to their PTSD or substance use, 2) Brainstorm ideas that may help, 3) Evaluate how useful each idea is, and 4) Choose a plan. Clients are encouraged to implement and evaluate the effectiveness of the plan and share the outcome at their next group. At the end of the group, clients process their experiences of the discussion.~HOPE is a flexible, module-based individual treatment where the ordering and emphasis of each module are determined by client priorities. HOPE is trauma-focused; clients relate their current symptoms to their experience of IPV, but do not process traumatic memories. Modules focus on 1) Establishing safety, providing information and skills that enhance empowerment, 2) Cognitive behavioral therapy skills, and 3) Improving relationships and establishing healthy boundaries."
224025208|NCT06931626|DRUG|NMS-03305293|Route of administration: Oral
224025209|NCT06931626|DRUG|Temozolomide|Route of administration: Oral Commercially available Temozolomide
224025210|NCT05691023|DEVICE|Vivistim System|Paired VNS during rehabilitation, facilitated by a rehab therapist in the subject's home (at-home treatment)
224025211|NCT06937086|DRUG|Mirikizumab|Administered IV
224025212|NCT06937086|DRUG|Mirikizumab|Administered SC
224025213|NCT06937086|DRUG|Tirzepatide|Administered SC
224025214|NCT06937086|DRUG|Placebo|Administered SC
224025215|NCT06937099|DRUG|Mirikizumab|Administered IV
224025216|NCT06937099|DRUG|Mirikizumab|Administered SC
224025217|NCT06937099|DRUG|Tirzepatide|Administered SC
223408927|NCT06149364|BEHAVIORAL|ISKE|"The intervention will consist of an e-health software Programme that we have named Istumisen Keskeyttäminen (ISKE) will be installed on the desktop of participants.~Functionality of the software: the primary purpose of the software is to remind users (basically office-based workers) to take a break on a regular basis (recommended time 30 minutes).~At the end of the workday, the software provides information on the number of breaks taken and how long each lasted. The user will also have access to such information.~What happens during the prompted break: once the software prompts the user to take a break, she/he can click the Continue button to proceed with the break. The software will include activities that are suggested for the user to do during break. After the break, the record of the time (duration of the break, and when the break was taken) can be taken."
223408928|NCT06684184|DRUG|Blinatumomab|The initial dose is 9 µ g, administered intravenously continuously for 5 days, with a total dose of 38.5 µ g. After stopping the medication for one week, the patient received a second infusion of Blinatumomab for a total of 5 days, with a total dose of 38.5 µ g.
223738527|NCT04734652|COMBINATION_PRODUCT|Biktarvy®|"Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose."
224025218|NCT06937099|DRUG|Placebo|Administered SC
224025219|NCT06941974|BEHAVIORAL|Patient Navigation Program|PATH navigation is an antenatal patient navigator program designed to reduce barriers to care, enhance access, improve self-efficacy and knowledge, and improve multiple perinatal health outcomes. PATH navigation is a flexible, multi-pronged, patient-centered program with the capacity to evolve with patient needs and preferences. Early in pregnancy, navigators will establish themselves as a non-medical resource and will introduce PATH as a program designed to help inform, support, and connect patients during pregnancy. Navigators will review screen and address supportive and adverse non-medical needs, facilitate communication, perform logistical support, provide advocacy and bridge communication with clinical teams, and perform health education. Navigation services will be tailored to individual medical, psychosocial, or logistical complexity.
224025220|NCT06945419|DRUG|LY4086940|Administered orally
224025221|NCT06945419|DRUG|Placebo|Administered orally
224025222|NCT07145723|OTHER|Earkick app|"Participants will have a baseline visit followed by an 8-week home monitoring period (HMP) using the Earkick app.~The Earkick app will interact with a mental health chatbot. Participants will complete online surveys at the midpoint (4 weeks) and end (8 weeks) of the HMP. Participants will choose one mental health-related topic to focus on from weeks 1-4 and one physical health-related topic to focus on from weeks 5-8.~Additionally, participants will have a post-HMP interview over Zoom."
224025223|NCT03382457|DEVICE|Transcatheter Tricuspid Valve Repair|Repair of the tricuspid valve through a transcatheter approach
224025224|NCT06948422|DRUG|Orforglipron|Administered orally.
224025225|NCT06948422|DRUG|Placebo|Administered orally.
224025226|NCT06954337|OTHER|Usual practice pattern (UPP)|Patient follows usual practice pattern for routine care
224025227|NCT06954337|OTHER|Experimental: Enhanced Telehealth (ET)|Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications
224025228|NCT06948435|DRUG|Orforglipron|Administered orally
224133394|NCT03294668|BEHAVIORAL|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
224025229|NCT06948435|DRUG|Placebo|placebo administered.
224025230|NCT06952530|DRUG|Orforglipron|Administered orally
224025231|NCT06952530|DRUG|Placebo|placebo administered
224025232|NCT07144280|DRUG|PF-08046054|"Antibody Drug Conjugate~Participants will receive PF-08046054, administered as an IV infusion."
224025233|NCT07144280|DRUG|Docetaxel monotherapy|Participants will receive Docetaxel, administered as an IV infusion.
224025234|NCT07145112|PROCEDURE|Laser interstitial thermal therapy|MRI guided laser
224025235|NCT07145112|DRUG|Lomustine|Given orally (PO)
224025236|NCT07148414|DRUG|SPY002-072|Experimental
224025237|NCT07148414|DRUG|Placebo|Matching Placebo
224025238|NCT05711485|OTHER|Whole blood transfusion|Whole blood is sourced from the Zambia National Blood Transfusion Service.
224025239|NCT03862430|DRUG|NanO2TM|0.1 mL/kg NanO2 infusion
224025240|NCT03862430|DRUG|Placebo Saline Infusion|Saline Infusion
224025241|NCT07157774|DRUG|Muvalaplin|Administered orally
224025242|NCT07157774|DRUG|Placebo|Administered orally
224025243|NCT07161661|PROCEDURE|Usual VA Care|The usual treatment provided by PM\&R clinicians for CLBP
224025244|NCT07161661|PROCEDURE|Osteopathic manipulative treatment|Between your first visit (baseline) and 12 weeks, participants will receive up to 4 usual care visits plus OMT.
224025245|NCT06253715|DRUG|Isoniazid|Once daily weight-based dose
224025246|NCT06253715|DRUG|Rifampin|Once daily weight-based dose
224025247|NCT06253715|DRUG|Pyrazinamide|Once daily weight-based dose
224025248|NCT06253715|DRUG|Ethambutol|Once daily weight-based dose
224025249|NCT06253715|DRUG|Rifapentine|Once daily weight-based dose
224025250|NCT06253715|DRUG|Moxifloxacin|Once daily weight-based dose
224025251|NCT07165028|DRUG|Tirzepatide|Administered SC
224025252|NCT07165028|DRUG|Retatrutide|Administered SC
224025253|NCT07165028|DRUG|Placebo|Administered SC
223408929|NCT00695292|DRUG|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
223408930|NCT00695292|DRUG|Carboplatin|carboplatin AUC=4 on Day 1
224025254|NCT07172516|DRUG|Azetukalner|Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
224025255|NCT07172516|DRUG|Placebo|Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
224025256|NCT07173049|BEHAVIORAL|AAC Speech supplementation|The speech supplementation intervention involves learning to point to pictures, words, or letters on a communication board while simultaneously producing speech. Children will spend up to 30 minutes learning to use the strategy in one- on-one interaction with a speech therapist and demonstrate mastery by using the strategy successfully on a series of test stimuli.
224025257|NCT07176416|DEVICE|Veritas Vision System|Veritas Vision System
224025258|NCT07176273|BEHAVIORAL|Modular Cognitive Processing Therapy|"CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of stuck points in thinking that interfere with recovery and (b) using Socratic questioning and a series of Contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need. Modular CPT contains the same core elements of CPT, but content is repackaged into modules instead of sessions so that clinicians can select and dose treatment elements according to patient need."
224025259|NCT07176273|BEHAVIORAL|Modular Prolonged Exposure Therapy|PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. Modular PE is comprised of the same elements of standard PE, but clinicians select and dose modules (i.e., imaginal exposure, in vivo exposure) based on individual patient need.
224025260|NCT07176273|BEHAVIORAL|Step Down Treatment|Self-managed treatment will involve receiving a self-help version of the remaining treatment materials and ongoing use of the intervention companion app (CPT Coach or PE Coach).
224025261|NCT07176273|BEHAVIORAL|Digital Interventions|The prompt will be a text message delivered through VA-approved technology (e.g., PETALS).
224025262|NCT07176273|BEHAVIORAL|Cognitive Processing Therapy (CPT)|"CPT is a first-line treatment for PTSD that includes the following core elements: (a) identification of stuck points in thinking that interfere with recovery and (b) using Socratic questioning and a series of progressive worksheets to examine stuck points, develop balanced beliefs, and facilitate the experience of natural emotions."
224025263|NCT07176273|BEHAVIORAL|Prolonged Exposure (PE)|PE is a first-line treatment for PTSD that includes the following core elements: (a) in vivo exposure and (b) imaginal exposure to the trauma memory. In imaginal exposure, participants repeatedly, systematically approach their trauma memory and related thoughts and feelings. In in vivo exposure, participants repeatedly, systematically approach objectively safe people, places, objects, and situations that they avoid because these stimuli remind them of their trauma.
224025264|NCT07190807|DEVICE|Boston Scientific WaveWriter Alpha™ SCS Systems|Time Varied Pulse (TVP)-SCS settings
224025265|NCT03660826|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224025266|NCT03660826|PROCEDURE|Bone Marrow Aspirate|Undergo bone marrow aspiration and biopsy
224025267|NCT03660826|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224025268|NCT03660826|DRUG|Capivasertib|Given PO
224025269|NCT03660826|DRUG|Cediranib Maleate|Given PO
224025270|NCT03660826|PROCEDURE|Computed Tomography|Undergo CT scan
224025271|NCT03660826|BIOLOGICAL|Durvalumab|Given IV
224133395|NCT03294668|OTHER|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
224133396|NCT02853006|BIOLOGICAL|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
224133397|NCT02853006|PROCEDURE|Biopsy|
224133398|NCT02853006|PROCEDURE|Excised tissues|
223408931|NCT00695292|DRUG|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
223408932|NCT04793009|DEVICE|funnel-shaped, intraperitoneal mesh placement|Implantation of a prophylactic, 3D funnel-shaped, intraperitoneal, non-absorbable and synthetic mesh (Dyna Mesh IPST 2x15x15 cm™ and 3x16x16 cm™, FEG Textiltechnik, Aachen, Germany,)
223408933|NCT03092765|DRUG|E6011|Intravenous administration
223408934|NCT03092765|DRUG|Placebo|Intravenous administration
223408935|NCT01333904|DRUG|PUR118|inhaled
223408936|NCT02362672|DRUG|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
223408937|NCT02362672|DRUG|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
224025272|NCT03660826|PROCEDURE|Echocardiography Test|Undergo Echo
223408938|NCT04439968|OTHER|Clinical algorithm|In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
223408939|NCT00998075|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
223408940|NCT00998075|DRUG|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
224025273|NCT03660826|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224025274|NCT03660826|DRUG|Olaparib|Given PO
224133399|NCT01354041|BEHAVIORAL|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
224133400|NCT05754697|OTHER|Instrument assisted soft tissue mobilization in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
224133401|NCT05754697|OTHER|Positional release technique in addition to traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
224133402|NCT05754697|OTHER|Traditional treatment|The treatment protocol will be two sessions will be given per week for 4 weeks.
224133403|NCT02338492|DEVICE|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
224025275|NCT07188467|BEHAVIORAL|Digitized SH+|Digitized SH+ is a group-based, stress management program (adapted from the original Self-Help Plus intervention developed by the World Health Organization), that utilizes animated videos and group discussions to teach participants skills such as Grounding, Unhooking (from difficult thoughts), Being Kind (to self and others), Identifying Values, and Making Room for Difficult Thoughts and Feelings.
224025276|NCT06507930|OTHER|Telehealth Hospice Visits|Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
223408941|NCT00998075|DRUG|ASA|Tablet, oral, single dose
224025277|NCT07203534|OTHER|Standard of Care|Standard of care for a bone marrow biopsy/bone marrow aspiration includes routine site-specific lidocaine anesthetic.
224025278|NCT07203534|OTHER|Virtual Reality intervention|Participants will wear the VR headset (Quest 3 by Meta) during your bone marrow procedure.
224025279|NCT07202884|DRUG|Orforglipron|Administered orally
224025280|NCT07202884|DRUG|Placebo|Administered orally
224025281|NCT07209189|DRUG|Toripalimab + Chemotherapy|"Toripalimab is the study drug and will be given via IV in all arms except Rad+/-Chem : Adjuvant radiation or chemoradiotherapy"
223408942|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
224025282|NCT07209189|DRUG|Toripalimab|Study drug
223408943|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
223408944|NCT00254800|DRUG|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
223408945|NCT04494061|PROCEDURE|blood collection|Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.
224025283|NCT07209189|RADIATION|Chemoradiotherapy or radiation|In the adjuvant phase, either radiation or chemoradiotherapy is used for treatment
223408946|NCT06665048|DRUG|Oxycodone HCl|Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
223408947|NCT05483686|BEHAVIORAL|Shine|This tailored, multifaceted mobile intervention aims to improve HIV-related outcomes and increase gender affirmation among African American transgender women. Potential users will opt-in by texting from their own mobile phone and, once registered, will be enrolled into a program that will be theory-based, targeted, tailored, and personalized. Users will receive three main types of texts: informational, motivational, and skill-building. Finally, the program will include three web-based video components: scripted vignettes, unscripted peer narratives, and educational instruction. By developing an intervention using a technology that is part of the everyday lives of most African Americans, the aim is to reduce HIV disparities. The proposed intervention can be used by clinics and community-based organizations that serve transgender women.
223408948|NCT05483686|BEHAVIORAL|Control|A playlist of CDC-developed videos designed to provide information on HIV for transgender women
223408949|NCT01543178|DRUG|open-label rifaximin|550 mg three times a day (open-label)
223408950|NCT01543178|DRUG|double-blind placebo|3 times a day (double-blind)
223408951|NCT01543178|DRUG|double-blind rifaximin|550 mg three times a day (double-blind)
223408952|NCT04150978|OTHER|High Protein Polymeric Formula|Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions
224025284|NCT07203378|OTHER|Whole-body resistance training and aerobic exercise|A 12-week individualized, home-based, unsupervised, whole-body resistance training and aerobic exercise routine will be provided to each study participant.
224025285|NCT07206121|DEVICE|Radiofrequency ablation alone|Demonstrate the accuracy of the device to produce 1 cm depth of ablation around the tumor bed, as evaluated by post-ablation deep shave margins.
224025286|NCT07206121|DEVICE|Radiofrequency ablation Electrosurgical Device|SIRA-1000 an radiofrequency ablation device, is designed to fit the post-lumpectomy cavity to provide uniform ablation.
224025287|NCT07209085|DEVICE|FastWave Artero™ Peripheral IVL System|The FastWave Artero™ Peripheral IVL System includes a generator and a balloon-based catheter designed to treat calcified blockages in peripheral arteries. During a single endovascular index procedure, the catheter is positioned within the target femoropopliteal artery and inflated at low pressure. The device emits short bursts of pulsatile sonic pressure waves that fracture calcium deposits, improving vessel flexibility and allowing dilation at low balloon pressures to restore blood flow. Multiple inflations may be performed as needed. Adjunctive angioplasty or stenting may be used at the investigator's discretion.
224025288|NCT07211997|DEVICE|FebriDx|Bacterial/Non-Bacterial Point-of-Care Assay that detects the presence of MxA and CRP in fingerstick blood
224133404|NCT01071096|DRUG|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
223408953|NCT04150978|OTHER|Oligomeric Formula|Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions
223408954|NCT04150978|DRUG|5% Dextrose|500 ml of 5% Dextrose administered to a peripheral vein.
224025289|NCT07214701|DRUG|Ketamine (0.5 mg/kg)|Intravenous infusion of ketamine 0.5 mg/kg over 10 minutes before spinal injection, diluted in 50 ml 0.9% NaCl Saline
224025290|NCT07214701|DRUG|Dexmedetomidine|Intravenous infusion of dexmedetomidine 0.25 μg/kg over 10 minutes before spinal injection, diluted in 50 ml 0.9% NaCl Saline
224025291|NCT07213765|DRUG|Contezolid|contezolid 800mg po q12h\*6m
224025292|NCT07213765|DRUG|Azithromycin|azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*6m
224025293|NCT07213765|DRUG|Azithromycin|azithromycin 500mg po tiw (250mg po tiw for BW under 50kg)\*12m
224025294|NCT07213765|DRUG|Ethambutol (E)|ethambutol 25mg/kg po tiw\*6m
224025295|NCT07213765|DRUG|Ethambutol (E)|ethambutol 25mg/kg po tiw\*12m
223408955|NCT06046495|DRUG|PLB1004|PLB1004 will be orally self-administered by the patient as a mono-therapy.
223408956|NCT04587869|BEHAVIORAL|CBT Coping Intervention|A cognitive behavior therapy group intervention that addresses coping with discrimination and medical mistrust among Black sexual minority men (SMM).
223408957|NCT03351608|DRUG|Sugammadex 2 mg/kg|For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
223408958|NCT03351608|DRUG|Sugammadex 4 mg/kg|For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
223408959|NCT03351608|DRUG|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
223408960|NCT03351608|DRUG|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
223408961|NCT00000115|DRUG|Acetazolamide|
223408962|NCT00933907|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks
223408963|NCT03230578|OTHER|Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
223408964|NCT04400383|DRUG|AB011 Injection|"Stage 1 Single treatment: AB011 Injection with dose escalation of 1mg/kg up to 40mg/kg, as well as dose expansion with recommended dose level from dose escalation.~Stage 2 Combo Treatment: AB011 combine XELOX( GC) or Gem/nab-P (PC) Injection with dose escalation of 10mg/kg up to 30mg/kg, as well as dose expansion with recommended dose level from dose escalation."
223408965|NCT02727478|OTHER|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
223408966|NCT01077778|PROCEDURE|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
223408967|NCT02334878|BIOLOGICAL|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
223408968|NCT02334878|PROCEDURE|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40\*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra \& through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted \& the remaining tape cut off at the level of the skin.
223408969|NCT01408511|DRUG|Mapracorat|Application of the investigational product on the affected skin areas
223408970|NCT05961956|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention.
223408971|NCT05031312|PROCEDURE|inferior oblique weakening|inferior oblique myectomy versus inferior oblique anterior nasal transposition in superior oblique palsy treatment
223408972|NCT00808210|DRUG|Infliximab|Intravenous repeating dose
224025296|NCT07213765|DRUG|Rifampicin (R)|rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*6m
224025297|NCT07213765|DRUG|Rifampicin (R)|rifampicin 600mg po tiw (450mg po tiw for BW under 50kg)\*12m
224025298|NCT07213804|DRUG|LY4170156|Administered IV
223408973|NCT00808210|DRUG|Methotrexate|Oral or parenteral repeating dose
223408974|NCT00808210|DRUG|Methylprednisolone|Intravenous repeating dose
223408975|NCT00808210|DRUG|Ocrelizumab|Intravenous repeating dose
223408976|NCT00808210|DRUG|Placebo|Intravenous repeating dose
223408977|NCT03816020|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside capsules 250mg x 2 BID
223408978|NCT03816020|OTHER|Placebo|Placebo capsules BID
223408979|NCT04651933|GENETIC|Homologous recombination deficiency model|A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
223408980|NCT00337701|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
223738528|NCT04734652|COMBINATION_PRODUCT|TLD- fixed-drug combination single tablet|Standard of care Dolutegravir-based regimen
224025299|NCT07213804|DRUG|Paclitaxel|Administered IV
224025300|NCT07213804|DRUG|Topotecan|Administered IV
224025301|NCT07213804|DRUG|Gemcitabine|Administered IV
224025302|NCT07213804|DRUG|Pegylated liposomal doxorubicin|Administered IV
224025303|NCT07213804|DRUG|MIRV|Administered IV
224025304|NCT07213804|DRUG|Bevacizumab|Administered IV
224025305|NCT07213804|DRUG|Carboplatin|Administered IV
224025306|NCT07214480|BEHAVIORAL|Motor-based speech treatment|Speech Motor Chaining (Preston, Leece \& Storto, 2019) will be used to guide structured practice and random practice on speech sounds. A web-based platform (chaining.syr.edu) will be used to guide aspects of the treatment (feedback type, feedback frequency, stimulus complexity, variability). Treatment will occur in 10 minute sessions via teletherapy.
224025307|NCT07214662|DRUG|GDC-0587|Participants will receive GDC-0587 orally as per the schedule in the protocol.
224025308|NCT07214662|DRUG|Giredestrant|Participants will receive Giredestrant orally as per the schedule in the protocol.
224025309|NCT07214662|DRUG|Omeprazole|Participants will receive Omeprazole orally as per the schedule in the protocol.
224133405|NCT01071096|DRUG|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
224025312|NCT07214129|DRUG|Nebulized nitroglycerin|Nebulized nitroglycerin as vaso-reactive agen in pulmonary arterial hypertension
224025313|NCT07214363|DEVICE|Irreversible Electroporation Ablation Generator|The irreversible electroporation ablation system (Irreversible Electroporation Ablation Generator) used in this study delivers an ablation field with a voltage of 3,000 volts. It received U.S. Food and Drug Administration (FDA) approval in 2023 but has not yet been introduced in Taiwan. This study will target participants with malignant liver tumors who are unsuitable for surgical resection but are eligible for local ablation therapy, specifically those with tumors located adjacent to the inferior vena cava, hepatic veins, or within 1 cm of the main trunks of both portal veins. A total of 20 participants will undergo ablation treatment under intubation and general anesthesia. Postoperative monitoring will focus on potential complications, and participants will be followed for four months to assess complete tumor ablation and intrahepatic recurrence, in order to verify the clinical feasibility and advantages of this system.
224025314|NCT07213648|BEHAVIORAL|MindTrails-Movement|CBM-I training app with active CBM-I training condition
224025315|NCT07213648|OTHER|Waitlist Control|Version of MindTrails-Movement app including surveys and list of support resources but without active CBM-I training component
224025316|NCT07213531|DIAGNOSTIC_TEST|Medical imaging analysis via artificial intelligence algorithms|Development of AI algorithms based on pre-procedural imaging annotations and clinical informations to predict the transcatheter procedural outcomes
224025317|NCT07214935|DRUG|Placebo matched to M2951|Participants will receive single oral dose of placebo matched to M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
224025318|NCT07214935|DRUG|Moxifloxacin|Participants will receive single oral dose of moxifloxacin in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
224025319|NCT07214935|DRUG|M2951 Low Dose|Participants will receive single oral low dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
224133406|NCT05265143|OTHER|bolus/intermittant feeding|sequential randomization
224133407|NCT02003729|DEVICE|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
224133408|NCT05429229|DRUG|VisuXL®|It consists of a preservative-free eye drop composed of 100 mg cross-linked hyaluronic acid, 100 mg coenzyme Q10, 500 mg vitamin E TPGS (D-alpha-tocopheryl polyethylene glycol succinate), one drop is applied in each eye every 4 hours for a month.
224133409|NCT05429229|DRUG|Lagricel PF®|It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.
224133410|NCT05429229|DRUG|Humylub PF®|It consists of eye drops without preservatives composed of 0.1% sodium hyaluronate and 0.18% chondroitin sulfate, one drop is applied to each eye every 4 hours for a month.
224133411|NCT05871229|DEVICE|Lumoral Treatment|Photodynamic antibacterial dual-light device with a marker substance
224133412|NCT05871229|OTHER|Standard treatment for peri-implantitis|Standard treatment for peri-implantitis as per international, national and clinic guidelines
224133413|NCT05435144|DIETARY_SUPPLEMENT|Elderberry|European black elderberry extract
224133414|NCT05435144|OTHER|Placebo|Inactive placebo
224133415|NCT04030780|DIETARY_SUPPLEMENT|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
224133416|NCT04030780|OTHER|Placebo|similar capsules administered twice daily
223408981|NCT00337701|DRUG|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
223408982|NCT04178902|DRUG|ABBV-467|Intravenous (IV) Infusion
224025320|NCT07214935|DRUG|M2951 High Dose|Participants will receive single oral high dose of M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
224025321|NCT07213960|DRUG|APL2|Complement (C3) Inhibitor
223408983|NCT04752956|OTHER|"Total nasal symptom score (TNSS)"|TNSS contains 4 parameters in assessing the severity of allergic rhinitis: nasal congestion, runny nose, nasal itching, and sneezing. Each symptom is scored out of 4 points, from 0 to 3. 0, none- there are no complaints 1- mild- any symptom that exists but is not particularly annoying; 2, moderate, - any annoying symptom but does not interfere with daily activities or sleep; 3, severe - any symptom preventing daily activities or disturbing during sleeping. The total score is calculated by summing all the scores of 4 fields, which vary ranges from 0 to 15 .In our study, all patients will be instructed to record their TNSS symptom scores on their diary cards each morning before taking the drug. Patients will be graded on baseline TNSS parameters compared to 4 weeks before starting treatment.
224025322|NCT07213960|OTHER|Placebo|Sterile solution of equal volume to active arm
224025323|NCT07214402|OTHER|dietary counselling|12-week antioxidant diet, including increased consumption of antioxidant-rich foods such as ≥5 servings/day vegetables, ≥2 servings/day fruit, ≥8 ½ servings/day wholegrains and 3-4 servings/week lean meat
224133417|NCT04959253|COMBINATION_PRODUCT|Psilocybin assisted therapy|A package of psychological therapy and a single dosing session of psilocybin.
224133418|NCT04959253|COMBINATION_PRODUCT|Placebo assisted therapy|A package of psychological therapy and a single dosing session of placebo.
224133419|NCT04003077|DEVICE|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm\^2; power density, 300mW/cm\^2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm\^2.
224138932|NCT00379197|PROCEDURE|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-\[18F\]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
223408984|NCT04752956|BEHAVIORAL|"Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ)"|"PRQLQ, is a self-administered, disease-specific questionnaire, evaluating physical, emotional, and social status of individuals with AR. It contains 23 items in 5 domains: nose symptoms (RS), eye symptoms (ES), practical problems (PF), activity limitation (RL) and other symptoms (OS). One score is given to each domain. 7-point scale (from 0, not problematic; to 6, very problematic). The overall score is derived from the average score of all items (20). In our study, the Turkish validated form of PRQLQ was used~Patients will be asked to answer PRQLQ questions at the end of each week during treatment. At the end of the treatment, an average of 4 weeks will be taken as the PRQLQ score. Basal PRQLQ questions will be evaluated by the participants based on 4 weeks prior to treatment."
223408985|NCT04752956|DIAGNOSTIC_TEST|Nasal cytology|In anterior rhinoscopy, nasal cytology will be scraped off the middle part of the lower turbinate with the help of a small sterile cotton swab. The cellular material obtained will be fixed by air drying on a glass slide and then stained by the May-Grünwald-Giemsa method. Preparations that do not contain respiratory epithelium or contain less than 10 epithelium at high magnification will be excluded from the study. A percentage of cells per 100 cells will be reported. NECs (nasal eosinophilic count) will be evaluated according to the quantitative classification of Gelardi et al. An experienced cytologist who is blind to the study groups will perform this test. Eosinophil percentages in nasal smears of all patients will be evaluated before and after the treatment.
223408986|NCT04752956|DIAGNOSTIC_TEST|anterior rhinomanometry|Children's right, left and total nasal airway resistance (NAR) and nasal airflow (NAF) will be measured with active anterior rhinomanometry ZAN 100 USB Rhinomanometry (Longmont, Colo., USA). In the evaluation, the NAR- pressure difference / air flow (R = P / V) formula will be used at a constant 150 Pascal prescribed by the European Rinomanometry Standardization Committee in 1984. After the patient is rested for 20 minutes, measurements will be made at 20-22 ° C and the nasal secretion will be cleared. NAR and NAF values of the participants will be measured before starting treatment and 4 weeks after treatment.
223408987|NCT03877068|DEVICE|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.
223408988|NCT03877068|DIAGNOSTIC_TEST|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
223408989|NCT01757093|DEVICE|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
223408990|NCT01757093|DEVICE|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
223408991|NCT05440045|DRUG|6MW3211|6MW3211 injection, 30mg/kg, Q2W
223408992|NCT01699672|OTHER|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
223408993|NCT04888793|DIAGNOSTIC_TEST|Serologic immune response evaluation|Detection of total and neutralizing antibodies against SARS-CoV-2
223408994|NCT02093780|BEHAVIORAL|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
223408995|NCT02093780|BEHAVIORAL|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
223408996|NCT06088680|DEVICE|Glycar Pericardial Patch|Glycar Bovine pericardial patch with AldeCaptm Technology (aka SJM with EnCaptm technology)
223408997|NCT00640120|DEVICE|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
223408998|NCT03915301|PROCEDURE|Satisfaction assessed by the VAS [followed by its scale information in the Description]|Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10
224133420|NCT00941954|BEHAVIORAL|Structured Education|The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
223738529|NCT03566667|DRUG|Metoprolol|Betablocker
223738530|NCT03566667|DRUG|Standard care|Standard care
223738531|NCT05619211|BEHAVIORAL|Sprint-Intensity Interval Training with Telecoaching|Maximal intensity exercises that use the arms.
223738532|NCT02592291|DEVICE|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
223738533|NCT02050282|OTHER|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
223738534|NCT00253474|BIOLOGICAL|PEG-interferon alfa-2a|
223738535|NCT03341832|DRUG|NVP-1203|oral dose for 7 days
223738536|NCT03341832|DRUG|NVP-1203-R|oral dose for 7 days
224133421|NCT00941954|BEHAVIORAL|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
224133422|NCT05524870|OTHER|Mobilization|Movement with mobilization plus exercise
224133423|NCT01453569|DRUG|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
224133424|NCT01453569|DRUG|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
224133425|NCT01453569|DRUG|Placebo|simulant of sodium oligo-mannurarate capsule
223738537|NCT03341832|DRUG|NVP-1203 placebo|oral dose for 7 days
223738538|NCT03341832|DRUG|NVP-1203-R placebo|oral dose for 7 days
224133426|NCT01085058|DRUG|lenograstim|
224133427|NCT05835245|PROCEDURE|Cryoablation|Cryoablation is performed under US or CT guidance per Investigator decision.
224133428|NCT05835245|DRUG|Sintilimab|a PD-1 immune check inhibitor
224133429|NCT05835245|DRUG|Lenvatinib|Lenvatinib capsules
224133430|NCT05570045|DIETARY_SUPPLEMENT|Colos Gain|"Dietary Supplement: Colos Gain Colos Gain is a nutrient product made by VITADAIRY Dairy Joint Stock Company.~Condition: Powder~Color: White to light yellow~Scent: The fresh scent of milk, gracious sugary smell.~Date of use: 24 months from the manufactured date.~Direction: Mix 5 spoons of Colos Gain (equal to 45 grams) with 180 ml of warm water (50˚C) which provides 210kcal (The energy density reaches 1kal/ml). Consume 2-3 glasses per day or follow the directions from the medical supervisors.~The product should consume less than 1 hour. Do not let the child eat the leftovers of the previous meal.~Preserve: Store in a clean, dry place, and keep away from direct sunlight. Opened can or package must be closed and used up within 3 weeks."
224133431|NCT02961686|RADIATION|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
224133432|NCT03916471|DEVICE|Solyx™ SIS System|Single-incision sling system
223408999|NCT04723446|DRUG|Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate|Corsodyl® Alcohol-free is a clear to slightly opalescent oromucosal solution with an odour of peppermint that contains 0.2% w/v chlorhexidine digluconate which is an antimicrobial preparation for external use. It is effective against a wide range of Gram negative and Gram positive vegetative bacteria, yeasts, dermatophyte fungi and lipophilic viruses. It is active against a wide range of important oral pathogens and is therefore effective in the treatment of many common oral conditions.
224025324|NCT07213596|BEHAVIORAL|VR Exposure Therapy|"Virtual Reality Exposure Therapy (VRET) is a form of psychotherapy that uses immersive virtual environments to simulate trauma-related stimuli in a controlled and safe setting, allowing individuals to gradually confront and process distressing memories or triggers.~VRET is grounded in prolonged exposure (PE) therapy, a well-established treatment for PTSD and anxiety disorders.~In this study, VRET is delivered in 5 weekly sessions, each lasting approximately 50 minutes, using a customized VR system.~Sessions are tailored based on participant group (e.g., COVID-19 survivor vs. healthcare worker).~Each session includes psychoeducation, exposure to individualized trauma-related virtual scenes, and guided emotional processing.~The system incorporates eye-tracking, breathing exercises, and real-time subjective distress scaling (SUDs) to monitor engagement and safety."
224133433|NCT03916471|DEVICE|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
224133434|NCT03921138|OTHER|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
224133435|NCT02373241|DRUG|Losartan|Standard dosing
224133436|NCT02373241|DRUG|Losartan|Experimental dosing
224133437|NCT03719326|DRUG|Etrumadenant|Etrumadenant is an A2aR and A2bR antagonist for oral use
224133438|NCT03719326|DRUG|IPI-549|IPI-549 is a phosphoinositide-3-kinase-gamma inhibitor for oral use
224133439|NCT03719326|DRUG|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous (IV) use
224025325|NCT07213596|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Face-to-face CBT with exposure elements, targeting trauma-related symptoms. Administered in 5 weekly sessions.
224025326|NCT07213596|BEHAVIORAL|Supportive Psychotherapy|Therapist-led supportive therapy (TAU), focusing on empathy, validation, and emotional support without structured exposure.
224133440|NCT03719326|DRUG|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor for intravenous (IV) use
224133441|NCT00451750|DRUG|Cortisol|20 mg for 3 times
224133442|NCT06169371|DRUG|Abemaciclib|Week 1 50mg orally BID
224133443|NCT06169371|DRUG|Abemaciclib|Week 2 100mg orally BID
224133444|NCT06169371|DRUG|Abemaciclib|Week 3+ 150mg orally BID
224133445|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
224133446|NCT03421964|BEHAVIORAL|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
224133447|NCT03993964|DRUG|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
224133448|NCT00703833|DRUG|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
224133449|NCT00703833|DRUG|Placebo (unspecified)|matching placebo
224133450|NCT00229203|DRUG|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
224133451|NCT00377533|DEVICE|wheelchair rear anti-tip device|assistive device
224133452|NCT03607838|DRUG|SI-6603|SI-6603 will be injected into an intervertebral disc.
224133453|NCT03607838|DRUG|Sham injection|The injection will be performed without needle placement into an intervertebral disc.
224133454|NCT04023513|OTHER|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
223738539|NCT01930851|PROCEDURE|Gastric bypass operation|
223738540|NCT06783660|DEVICE|Peptide-loaded collagen sponge and collagen gel complex|A piece of peptide-loaded collagen sponge (Regenomer®) and collagen gel complex
223738541|NCT06783660|DEVICE|Collagen sponge|Type 1 Collagen sponge (Regenomer)
224025327|NCT07213518|DEVICE|High Velocity Nasal Insufflation|COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity Nasal Insufflation
224025328|NCT07213518|DEVICE|Continuous Positive Airway Pressure|COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous Positive Airway Pressure
223738542|NCT04272528|OTHER|uniform care|The leader develops training plan and trains nurses, who provide uniform care and education to patients according to the training.
224025329|NCT07214337|DEVICE|Digital Inhaler Attachment|This intervention is the attachment of a digital device to provide patient with coaching for optimal inhaler use and technique, as well as monitoring of patient use of inhaler to patient and health care team. Patient will continue to use inhalers prescribed as per usual care for management of COPD.
224025330|NCT07214220|PROCEDURE|Endovascular Intracranial aneurysm treatment|Endovascular Intracranial aneurysm treatment using devices such as coils, flow diverters, etc. The treatment will include devices that are all FDA approved.
224025331|NCT07214220|DEVICE|nOCT imaging|During the aneurysm treatment and during the subsequent follow-up, nOCT imaging will be performed.
224025332|NCT07213752|DEVICE|Diode Laser Application in Deep Periodontal Pockets|A 940 nm indium-gallium-aluminum-phosphate diode laser (Ezlase, Biolase, USA) with a 400 μm fiber was used in contact mode at 1.5 W, pulse 20/20 ms, 20 s/cm², power density 1.061 W/cm², and 15 J/cm² energy in deep periodontal pockets.
224025333|NCT07213752|PROCEDURE|Professional Mechanical Plaque Removal|Professional mechanical removal of supragingival plaque and calculus
224025334|NCT07213752|PROCEDURE|Scaling and Root Planing|Subgingival scaling and root planing
224025335|NCT07213830|BIOLOGICAL|IPN01203|Study intervention will be provided in a vial.
224025336|NCT07214597|DEVICE|VoiceLove mobile phone application|Access to VoiceLove app to facilitate secure, real-time communication between family members and NICU patients.
224025337|NCT07214324|OTHER|Collection of biological material|"For MGUS, SMM and MM patients, biological material (bone marrow aspirate, bone marrow biopsy, peripheral blood) consists exclusively of left-over samples obtained during routine diagnostic procedures and clinical practice management of their disease.~For healthy volunteers, biological material includes waste bone tissue obtained during orthopedic surgery (endo- or arthro-prosthesis) and peripheral blood collected for research purposes.~Both cohort of patient will be asked to donate gingival crevicular fluid (GCF) (this is a non-invasive procedure with no associated risks)."
224025338|NCT07213726|DEVICE|Delfi Personalized Tourniquet System|Bilateral proximal thigh bands that will be applied and inflated to a pressure of 80% of occlusive pressure as determined by the automated tourniquet before exercise. A standard exercise session would not include any blood occlusion.
224025339|NCT07214948|DEVICE|INGA Catheter|"Insertion of the INGA balloon catheter (medical device) through the cervical canal into the uterus is performed for labor induction. During a vaginal examination, the Investigator inserts the catheter so that the balloon tip lies between the amniotic membranes and the internal cervical os. The balloon is filled with 50-75 ml of sterile saline (NaCl) and secured to the upper thigh to maintain gentle traction. The catheter remains in place for up to 24 hours or until spontaneous expulsion. If not expelled, it is removed after 24 hours.~After expulsion or removal, cervical status and Bishop score are assessed. If Bishop ≥ 6, amniotomy and/or oxytocin induction are initiated within one hour. If Bishop \< 6, further management follows"
224025340|NCT07214948|DEVICE|Currently used single balloon catheter|Insertion of a balloon catheter through the cervical canal into the uterus for induction of labor.
224025341|NCT07214740|DRUG|APL-2, Pegcetacoplan|Complement (C3) Inhibitor
224025342|NCT07214142|DRUG|PD-1|patients will receive short-course chemotherapy and concurrent PD-1
224025343|NCT07214441|BEHAVIORAL|Breathe Easier+|Breathe Easier+ includes guided instruction using a digital manual, a walking program, RT training sessions, a weekly telephone coaching call, daily text messages, and assessments at three time points.
224133455|NCT04023513|OTHER|Control, no intervention|No Intervention, control
223738543|NCT04272528|OTHER|conventional care|Nurses carry out the routine care procedures.
223738544|NCT01769040|DRUG|Rifaximin|550 mg two times daily for 28 days
223738545|NCT01769040|DRUG|placebo|
223738546|NCT01299623|BEHAVIORAL|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
223738547|NCT00484237|DRUG|etanercept|
224025344|NCT07214649|BIOLOGICAL|Organoid-guided treatment|Engrafment of the Cholangiocyte Organoids in the common bile duct with leakage
224025345|NCT07214415|DRUG|Hyperbaric Oxygen Therapy|"Each HBOT session is scheduled for approximately 95 minutes. The session will begin with a descent of up to 15 minutes (longer if needed for comfort/safety) to a pressure of 2.0 ATA, followed by 30 minutes of breathing 100% oxygen. At the midpoint, there will be a 5-minute air break from oxygen, after which subjects resume breathing 100% oxygen for another 30 minutes. Finally, the session will conclude with an ascent of up to 15 minutes (longer if needed for comfort/safety) back to 1.0 ATA.~All sessions are delivered under direct medical supervision with standardized safety protocols. Once approved after medical and behavioral screening, participants complete a battery of cognitive, mental health, and quality of life assessments at baseline (pre-) and after completing the therapy (post-). This arm is distinct from any sham or control interventions because all participants receive the active HBOT treatment."
224133456|NCT04023513|OTHER|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
224133457|NCT04023513|OTHER|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
224133458|NCT01266434|DRUG|Simvastatin|10 mg once daily for 8 weeks
224133459|NCT01266434|DRUG|B1-6-12|1 tablet once daily for 8 weeks
224133460|NCT05629533|DEVICE|SimpleSense|The study is observational only. No interventions will be triggered by the SimpleSense device
223409000|NCT04723446|DRUG|Colgate Peroxyl® -1.5% Hydrogen peroxide|Peroxyl mouthwash is a clear aqua-blue liquid oromucosal solution which 100ml of solution contains 1.5g of Hydrogen peroxide (as 30% Hydrogen Peroxide solution). It is an oral antiseptic cleanser for external use. The principal action is brought about by contact of hydrogen peroxide with peroxidases and catalases present in tissues and saliva, which causes the rapid release of oxygen. This provides mechanical cleansing which flushes out mouth debris and helps in the treatment of oral irritations. This mouthwash is used as a cleanser in the symptomatic relief of minor mouth and gum irritations.
223409001|NCT04723446|OTHER|Oral-B® Gum & Enamel Care -Cetylpyridinium chloride|The Oral-B® Gum \& Enamel Care mouthwash is an oromucosal solution containing Cetylpyridinium chloride (CPC) and used as an adjunct to oral hygiene.
223409002|NCT04723446|OTHER|No rinsing|No rinsing
223409003|NCT02851121|OTHER|Sensorial stimulations|
223409004|NCT02851121|OTHER|Experimental protocols|
224025346|NCT07214103|DRUG|• Sivelestat intravenous infusion|"* Intervention: Sivelestat 0.20 mg/kg/h via continuous intravenous infusion (IVSE) for 72 hours~* Anticoagulation: Unfractionated heparin (UFH) at a minimum dose of 100 IU/24h (or higher if required)"
224025347|NCT07214103|DRUG|NaCl intravenous infusion|"* Intervention: NaCl 0.9% (normal saline) via continuous intravenous infusion (IVSE) at the same rate as the experimental group for 72 hours~* Anticoagulation: Unfractionated heparin (UFH) at a minimum dose of 100 IU/24h (or higher if required)"
224025348|NCT07214454|DEVICE|Transcranial direct current stimulation (Nettle device) 2mA stimulation for 20 minutes per day|The Nettle device, manufactured by Samphire Neuroscience, contains four electrodes, two of which provide stimulation to the primary motor cortex (M1), and two stimulate the dorsolateral prefrontal cortex (DLPFC). A treatment session consists of 2mA stimulation for 20 minutes per day. Nettle is a Class IIa medical device which has a CE mark and is currently marketed for use in dysmenorrhoea and the mood component of premenstrual syndrome.
224025349|NCT07214233|BEHAVIORAL|Treatment as Usual|Behavioral health services consisting of x, y, and z
224025350|NCT07214233|BEHAVIORAL|Peer Support Services (PSS)|Behavioral health services (treatment as usual) along with referral to and utilization of Peer Support Specialist services
224025351|NCT07214077|BEHAVIORAL|Harmonized Healing App|A smartphone-driven music-based intervention designed to support daily or as-needed use of personalized music to manage and alleviate pain exacerbations.
224025352|NCT07214077|BEHAVIORAL|Psychoeducation|Educational materials on drivers of chronic pain in the context of HIV and strategies for pain management.
224025353|NCT07214259|BEHAVIORAL|Online Sober Active Community|Participants will have access to an online sober active community that they can use to augment their recovery process.
224025354|NCT07214259|BEHAVIORAL|Recovery coach|Participants will work with a recovery coach including having weekly phone calls with that recovery coach.
224025355|NCT07213570|DRUG|standard second line treatment, at discretion of the investigator|Combination treatment may include: 5FU/LFA, capecitabine, oxaliplatin, irinotecan, bevacizumab, aflibercept
224025356|NCT07213570|DRUG|Regorafenib (BAY73-4506)|"Regorafenib will be administered following a dose-escalation strategy: starting dose 80 mg/day orally with weekly escalation, per 40 mg increment up to 160 mg/day regorafenib); if no significant drug-related adverse events occurred for 21 days of a 28-day cycle. The following cycle will be administered at highest tolerated dose from cycle 1 (up to 160 mg), as per current guidelines and clinical practice.~Treatment will continue until disease progression, unacceptable toxic effects, motivated decision to stop the treatment by the treating physician, or refusal or withdrawal of consent by the patient.~Every cycle will be administered every 28 days (four weeks) +/- 3 days."
224025358|NCT07214870|DRUG|NNC4005-001|NNC4005-0001 will be given as a single ascending dose via subcutaneous route
224025359|NCT07214870|DRUG|Placebo|Placebo matched to NNC4005-0001 will be given via subcutaneous route
224133461|NCT04929340|OTHER|Probiotic bacteria|The children are randomly allocated to a test or a control group with aid of computer-generated numbers at the time of consent. After the treatment, children in the test group are given 5 drops per day containing probiotic bacteria (Lactobacillus reuteri Protectis DSM 17938, Biogaia AB, Sweden) before bedtime. One dose consists of a minimum of 100 million live bacteria. Children in control group are given 5 drops per day (containing no bacteria).
224025360|NCT07214519|BEHAVIORAL|TA Intervention|Technical assistance (TA) intervention designed to support PSH agencies in sustainably implementing evidence-based practices to reduce tenant overdose and improve tenant health more broadly.
224025361|NCT07214779|DRUG|INCB123667|Oral; tablet
223409005|NCT02851121|BEHAVIORAL|Emotional protocols|
223409006|NCT02851121|OTHER|Protocol with a spatial dimension|
224133462|NCT04929340|OTHER|Placebo|Children in control group are given 5 drops per day (containing no bacteria).
223409007|NCT00571142|PROCEDURE|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
223409008|NCT00571142|PROCEDURE|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
223409009|NCT04483830|DRUG|Sulodexide|an oral dose of 2 capsules each day for 21 days
223409010|NCT04483830|DRUG|Placebo|an oral dose of 2 capsules each day for 21 days
223409011|NCT00702767|DRUG|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
223409012|NCT04743544|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
223409013|NCT01987089|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
223409014|NCT05888363|OTHER|No Intervention|Difference in outcomes in patients with rectal foreign bodies removed in the emergency department or in the operating room.
223409015|NCT04390490|DEVICE|Graphene quantum dots combined with Si nanowire photoelectrochemical immunosensor|Graphene quantum dots combined with Si nanowire is a new method of photoelectrochemical immunosensor
223409016|NCT01591135|DRUG|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
223409017|NCT01591135|DRUG|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
223409018|NCT01591135|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
223409019|NCT01591135|RADIATION|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
223558471|NCT05285761|BEHAVIORAL|Provision of current official information on complementary feeding|Parents will receive the paper brochure (new communication support developed by Santé publique France (the French Public Health Agency)), which is the current official information on complementary feeding (CF) in France. Parents will also receive generic information contained in the health record and in connection with the general development. These 48 messages will be delivered regularly by a smartphone application from the 3rd months until the 36th months of the child.
223558472|NCT06838351|BEHAVIORAL|Guided Drawing Intervention|The guided drawing activity is a 20 minute session which integrates mindfulness and drawing elements. Participants were given a pencil and blank paper to use while they watched a pre-recorded video guiding them through a mindfulness and drawing activity. In the pre-recorded video, participants are instructed to draw elements of nature from exemplar photographs (e.g., leaves, twigs). The activity incorporates drawing with aspects of mindfulness meditation (i.e., being non-judgmental of thoughts and behaviors, focusing on breathing, and embodiment).
223558473|NCT06838351|BEHAVIORAL|Free Drawing Control|Participants are instructed to draw freely for about 20 minutes.
223558474|NCT06838351|BEHAVIORAL|Basic Control|Participants are instructed to complete simple paper and pencil activities (e.g., mazes, connect the dots) for about 20 minutes.
224025362|NCT07214779|DRUG|Investigator's choice of chemotherapy|The investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:
224025363|NCT07213674|DRUG|Xaluritamig|Xaluritamig will be administered IV.
224025364|NCT07213674|DRUG|Abiraterone acetate|Abiraterone acetate will be administered orally.
223558475|NCT07080723|OTHER|Algorithm guided treatment (AGT)|"AGTs consist of strategies (which treatments to use), tactics (how to implement each treatment) and treatment steps (in what order to implement the different treatments). Furthermore, AGTs also define critical decision points during the treatment at which the effects of a certain treatment are assessed and based on this assessment recommend specific treatment revisions according to preset if-then rules. This is most often done by implementing measurement-based care."
223558476|NCT07080723|OTHER|Treatment as usual (TAU)|TAU includes the standard clinical care for patients with TRD as determined by a senior consultant.
223558477|NCT06948006|DRUG|AZD4144|Participants will receive AZD4144 orally.
223558478|NCT06948006|DRUG|Omeprazole|Participants will receive omeprazole orally.
224025365|NCT07213674|DRUG|Docetaxel|Docetaxel will be administered IV.
224025366|NCT07213674|DRUG|Cabazitaxel|Cabazitaxel will be administered IV.
224025367|NCT07214194|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|Non-invasive vagus nerve stimulation will be delivered with a well-validated device. taVNS delivers stimulation on the left ear, with the placement of the stimulating electrode differing between the active and sham conditions. Stimulation will occur during each learning trial (total of 30 trials per phase).
224025368|NCT07214506|OTHER|HPV Self-collection|The individual will receive both verbal instruction on self-collection from trained health educators in the MHU as well as adapted educational materials on HPV self-collection and information about follow-up care in the case of abnormal results. Individuals will be provided with a safe and private space in the Mobile Health Unit to self-collect.
224025369|NCT07214506|OTHER|Usual Care|Usual care, will involve reminders about overdue Cervical Cancer screening and support with scheduling clinic appointments for screening, arranging for transportation, and addressing other barriers to attendance
224025370|NCT07213869|DEVICE|Transcranial alternating current stimulation (tACS)|Alpha tACS daily, in repeated sessions delivered during three 2-week stimulation periods, alternating with three 2-week no-stimulation (baseline) periods, for a total duration of approximately three months
224025371|NCT07214051|BEHAVIORAL|Cancer Screening Information|The intervention group (n=250) received educational materials that included: screening center details, and reminders related to cancer screening. Two follow-up calls, at four-week intervals each, assessed screening status for all participants.
224025372|NCT07212868|DRUG|REMD-477 versus Placebo|Placebo versus glucagon receptor antagonist using a human monoclonal antibody with a high level of antagonistic effect against human glucagon receptor.
224025373|NCT07212868|OTHER|Exogenous glucagon versus saline infusion|The effect of increased glucagon concentrations in plasma on glucose metabolism during glucose clamp will be studied.
224025374|NCT07214246|OTHER|No Interventions|No interventions for participants
224025375|NCT07214532|DEVICE|ctDNA-Guided Treatment Strategy|Circulating tumor DNA testing using Signatera Genome assay is performed every 3 months for up to 4 years to guide timing of CDK4/6 inhibitor initiation. Participants with positive ctDNA results initiate CDK4/6 inhibitor therapy (ribociclib or abemaciclib) plus standard endocrine therapy for a minimum of 2 years. Participants with negative ctDNA results continue endocrine therapy alone with ongoing surveillance. CDK4/6 inhibitor selection and endocrine therapy regimen per the physician's choice following standard-of-care guidelines.
224025376|NCT07214545|DEVICE|Trigeminal Nerve Stimulation|This intervention is expected to have an effect following a treatment period of 6 weeks.
224025377|NCT07214545|DEVICE|Sham Trigeminal Nerve Stimulation|This intervention is NOT expected to have an effect following a treatment period of 6 weeks.
224025378|NCT07214922|DRUG|Treatment A|Participants will receive single dose of Treatment A in treatment period 1, 2, 3 or 4 under fasted conditions.
224025379|NCT07214922|DRUG|Treatment B|Participants will receive single dose of Treatment B in treatment period 1, 2, 3 or 4 under fasted conditions.
224025380|NCT07214922|DRUG|Treatment C|Participants will receive single dose of Treatment C in treatment period 1, 2, 3 or 4 under fasted conditions.
223409020|NCT03150719|DRUG|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
223409021|NCT03150719|DRUG|Ivacaftor|IVA 150 mg tablet.
223409022|NCT03150719|DRUG|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
224025381|NCT07214922|DRUG|Treatment D|Participants will receive single dose of Treatment D in treatment period 1, 2, 3 or 4 under fasted conditions.
224025382|NCT07213635|DRUG|Bupivacaine-epinephrine|Participants randomized to this experimental arm will receive a paracervical block with 10 mL 0.5% bupivacaine with epinephrine before their vaginal hysterectomy and prolapse repair
224025383|NCT07213635|DRUG|Normal saline|Participants randomized to this experimental arm will receive a placebo paracervical injection with 10 mL 0.5% normal saline before their vaginal hysterectomy and prolapse repair
224025384|NCT07214961|DRUG|AB001|Pb-212 PSMA targeted alpha radioligand therapy
224025385|NCT07213908|BEHAVIORAL|TS-C-STEP|Cognitive behavioral sleep intervention.
224025386|NCT07213908|BEHAVIORAL|Sleep Health Education (SHE)|Health Education
224025387|NCT07213856|BEHAVIORAL|Dietitian-Guided Nutritional Intervention|Participants receive a diet plan and nutritional counseling provided by a registered dietitian, based on a standardized protocol aligned with the Dietary Reference Intakes (DRIs) and adapted for the management of Parkinson's disease and constipation. The intervention includes follow-ups with the dietitian over a 3-month period.
224025388|NCT07214818|DRUG|Dapagliflozin|Dapagliflozin 10 mg PO once daily for 6 months
224025389|NCT07214818|DRUG|Empagliflozin|Empagliflozin 10 mg PO once daily for 6 month
224025390|NCT07214818|OTHER|Standard Therapy|immunosuppressive therapy and renoprotective agents for 6 months
224025391|NCT07214714|DRUG|Fentanyl (IV)|Patients will receive Fentanyl loading dose of 1 µg/kg over 10 minutes, followed by an infusion of 0.5-1 µg/kg/h.
224025392|NCT07214714|DRUG|Dexmedetomidine|Patients will receive Dexmedetomidine loading dose of 0.5 µg/kg over 10 minutes, followed by an infusion of 0.3-0.9 µg/kg/h.
224133463|NCT02411201|DRUG|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
224133464|NCT01260467|DRUG|memantine|10 milligrams orally twice a day
224133465|NCT06093763|PROCEDURE|Group without bone grafting|Open wedge corrective osteotomy and plate fixation without bone grafting.
223409023|NCT03150719|DRUG|Placebo|Placebo matched to IVA tablet.
223409024|NCT00932308|DIETARY_SUPPLEMENT|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
223409025|NCT00932308|DIETARY_SUPPLEMENT|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
224025393|NCT07213817|BIOLOGICAL|IPN60300|IPN60300 will be administered at assigned dose level.
224133466|NCT06093763|PROCEDURE|Group with bone grafting|Open wedge corrective osteotomy and plate fixation with harvesting and using bone from the iliac crest.
224133467|NCT03935087|DIAGNOSTIC_TEST|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
223409026|NCT00640757|DIETARY_SUPPLEMENT|Methionine deficient diet|Hominex with a low protein diet
223409027|NCT00640757|DIETARY_SUPPLEMENT|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
223409028|NCT06214663|OTHER|0.9 NaCl solution|Saline injections will be administered over the sacral area (both posterior iliac spines and 2 cm downward and medial), and this technique was described by Lytzen et al in 1989 and later standardized. The results will be compared between the three groups.
223409029|NCT04742400|DRUG|tolebrutinib 60mg|60 mg orally
223409030|NCT04742400|DRUG|tolebrutinib 120mg|120 mg orally
223409031|NCT02480673|DIETARY_SUPPLEMENT|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
223409032|NCT02480673|DIETARY_SUPPLEMENT|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
223409033|NCT02480673|BEHAVIORAL|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
223558479|NCT06950177|BIOLOGICAL|CoV-RBD-scNP-001 and 3M-052-AF|All subjects will receive the investigational vaccine CoV-RBD-scNP-001 adjuvanted with 3M-052-AF.
223558480|NCT05878951|DRUG|OnabotulinumtoxinA|Intra-detrusor OnabotulinumtoxinA is commonly known as botox
223558481|NCT00483366|DRUG|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~1. 500 mg/m2 bid~2. 600 mg/m2 bid~3. 600 mg/m2 bid~4. 725 mg/m2 bid~5. 725 mg/m2 bid~6. 850 mg/m2 bid~7. 850 mg/m2 bid"
223558482|NCT00483366|DRUG|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~1. 550 mg/m2~2. 550 mg/m2~3. 675 mg/m2~4. 675 mg/m2~5. 825 mg/m2~6. 825 mg/m2~7. 1000 mg/m2"
223558483|NCT00483366|DRUG|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~1. 400 mg/d~2. 400 mg/d~3. 400 mg/d~4. 400 mg/d~5. 400 mg/d~6. 400 mg/d~7. 400 mg/d"
223558484|NCT00483366|GENETIC|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
223558485|NCT00483366|GENETIC|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
223558486|NCT00483366|GENETIC|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
223558487|NCT03753685|DRUG|X-396(Ensartinib) Capsule|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
224025394|NCT07214844|DEVICE|Iovera Medial Branch Cryoneurolysis|"The iovera group will receive fluoroscopic guided medial branch cryoneurolysis with the subject in the prone position under asepsis:~* Investigator injects 1% lidocaine at the treatment site using a 25-gauge, 3/4 -inch needle to numb the skin and tissue around the facet joint~* Introducer needle is inserted through the skin wheal to the target medial branch nerve below the junction of the superior articular and transverse process~* The introducer needle is positioned, and an x-ray image is taken to confirm the needle's position~* With the desired introducer needle position confirmed, the iovera Smart Tip is guided through the introducer needle and the handpiece is secured to the Smart Tip. The start/stop button on the iovera° handpiece is then pressed to start the cycle.~* After the cycle is complete, Smart Tip can be removed and next treatment cycle can commence ensuring an overlap of the ice ball~* The needle is removed, and light compression is applied with gauze"
223409034|NCT01997476|PROCEDURE|Combined EUS, e-PFT and sEUS Testing|"advantage of combined EUS, ePFT \& sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
223409035|NCT01812460|OTHER|Intervention-training-group|As descriped in Arm Description
223409036|NCT05879289|DIETARY_SUPPLEMENT|A power supplement|A dietary supplement containing vitamins and collagen
223409037|NCT00571740|BIOLOGICAL|bevacizumab|Given IV
223409038|NCT00571740|BIOLOGICAL|cetuximab|Given IV
223558488|NCT05579509|DRUG|Midazolam and Fentanyl|Prior to the start of the nerve block, patients in Arm 1 will receive titrated pharmacological sedation with IV midazolam with a goal of achieving moderate sedation. If pain is felt despite subcutaneous lidocaine, IV fentanyl may be administered with a goal of achieving moderate sedation with analgesia.
223558489|NCT05579509|BEHAVIORAL|Educational Reassurance|Patients in the nonpharmacologic group will receive intraprocedural education and reassurance without pharmacologic sedation. They will have the option to receive more pharmacologic sedation at any point during the nerve block (cross-over to titrated sedation group).
223558490|NCT04153175|COMBINATION_PRODUCT|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
223558491|NCT04153175|COMBINATION_PRODUCT|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
223558492|NCT01045148|RADIATION|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
224133468|NCT03169452|DEVICE|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
224133469|NCT04622787|OTHER|Knowledge translation|"A. Healthcare Providers Observational Study - measure of the effectiveness of the International Guidelines training courses (face to face and online) delivered to medical professionals (involves all clinical partners).~The International Guidelines training courses on the evidence-based principles of Early Detection (ED), Early surveillance (ES), and Early intervention (EI) will be delivered to healthcare providers.~Face-to-face professional trainings will be set up at each Consortium partner location. E-learning platform will allow for training and follow-up resources will be available to clinicians in all languages that are spoken/written in the locations of the Consortium partners.~Clinicians will be assessed on their knowledge and standard clinical practices in survey format before trainings and after the trainings."
224133470|NCT03777371|OTHER|Anti HIV Seropositive Pregnant Women|
223409039|NCT00571740|DRUG|fluorouracil|Given IV
223409040|NCT00571740|DRUG|leucovorin calcium|Given IV
223409041|NCT00571740|DRUG|oxaliplatin|Given IV
223409042|NCT04200989|BIOLOGICAL|Peanut allergen|Intralymphatic immunotherapy injections.
223409043|NCT05944848|DRUG|1 mg CL-197 capsules|Single oral dose of 1 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
223409044|NCT05944848|DRUG|10 mg CL-197 capsules or CL-197 placebo|Single oral dose of 10 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
223409045|NCT05944848|DRUG|30 mg CL-197 capsules or CL-197 placebo|Single oral dose of 30 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
223409046|NCT05944848|DRUG|60 mg CL-197 capsules or CL-197 placebo|Single oral dose of 60 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
223409047|NCT05944848|DRUG|100 mg CL-197 capsules or CL-197 placebo|Single oral dose of 100 mg CL-197 capsules or CL-197 placebo administered following ≥10 hour fast
223409048|NCT06242548|OTHER|physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic)|"organisation of 4 physical activity outings in the mountains at a level already practised by the subjects, while maintaining their usual diet (normoglucidic or ketogenic).~During each of of the 4 physical activity outings, collection of capillary blood samples (blood sugar, ketone levels), non-invasive biometric data (weight, oxygen saturation by transcutaneous sensor), and questionnaires (BORG scale, food consumption before/during/after exercise)."
223558493|NCT01045148|RADIATION|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
223558494|NCT00230061|BIOLOGICAL|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
223558495|NCT04489147|DRUG|Metformin|metformin 850 mg orally twice daily along the cycle of ICSI
223558496|NCT03112512|DEVICE|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
223558497|NCT03112512|DEVICE|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
224133471|NCT02982304|DEVICE|Deep Brain Stimulation|Deep Brain Stimulation Electrode
224133472|NCT05851508|DRUG|Methylprednisolon|Intratympanal injection with Methylprednisolon 62.5 mg/ ml
224133473|NCT05851508|DRUG|Placebo|Intratympanal injection with saline, natriumchloride 0.9%
223558498|NCT06489158|DIAGNOSTIC_TEST|Detect VOCs in exhaled gas|The exhaled gas of the patients should be collected within one week before surgery and be tested within 24 hours after enrollment. Then receive treatment according to the existing diagnosis and treatment process.
223558499|NCT03090646|OTHER|Financial Incentive|Up to three gift cards to a major online retailer.
224025395|NCT07214844|PROCEDURE|Radiofrequency ablation (RFA)|"Subjects will receive a fluoroscopic guided RFA medial branch block in the prone position under asepsis:~* The Right L4, L5, S1 articular pillars are identified with fluoroscopy at each level and the target points are located~* A skin wheal is formed using 5mL 1% Lidocaine and 5mL 0.25% Bupivacaine~* A 20-gauge, 10cm needle with a 10mm active tip is inserted using a 15-degree oblique view and a 15-degree caudad angle onto the waist of each pillar at each level~* Anterior-posterior and oblique neuroforamen views confirm positioning~* Stimulation is performed and recorded to confirm proper needle placement~* A mixture of 3mL of 0.25% Bupivacaine and 2mL of 1% Lidocaine is divided and injected at each level~* A lesion is then performed at each level at 80 degrees centigrade for 60 seconds~* The needles are removed, and bandages applied to the puncture sites~* The same procedure is carried out on the opposite side"
224025396|NCT07214038|OTHER|toothpaste|toothpaste with stain removing abilities
223409049|NCT04816617|BEHAVIORAL|Aerobic exercise intervention|The whole exercise lasts for 12 months, consisted of 6-month supervised exercise and 6-month maintenance period. It is moderate -intensity exercise (60-80% Maximum heart rate), each time last for 30 mins (plus 10-minutes for warm-up and cool-down), 3-4 times a week, for the first six months, which will be supervised in person by physical educators and/or physical professionals. In the maintenance period, participants are asked to exercise at the same intensity and frequency, but will not be supervised in person by physical educators/professionals. They will receive reminder on a weekly basis and their physical activities be recorded by accelerometer. Types of exercise will be chosen according to individual school's facility and feasibility, including jogging, fast walking, badminton, running, football etc.
224025397|NCT07214831|BEHAVIORAL|Large language model-based chatbot brief alcohol intervention session|The intervention is a large language model-based chatbot designed to delivered brief alcohol interventions using motivational interviewing-consistent strategies. The chatbot session will last approximately 45 minutes and will include a decisional balance exercise, feedback on drinking patterns, normative beliefs about drinking, alcohol-related consequences, goal setting, and harm-reduction strategies.
224025398|NCT07214493|DEVICE|Taleo Adjust|The Taelo Adjust foot is a energy staorage and return (ESR) prosthetic foot on which is mounted an hydraulic ankle joint allowing an adjustable heel hight for 0 to 7 cm.
224133474|NCT04834973|DRUG|tigilanol tiglate|"Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours."
224133475|NCT04834973|DRUG|pembrolizumab|"Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy."
224133476|NCT03364608|DRUG|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
223409050|NCT04816617|BEHAVIORAL|Psycho-education|It consists of 6 sections of psycho-education, with topics covering mood regulations and mental well-being. Approximately 1 section in every two months.
223409051|NCT05922566|COMBINATION_PRODUCT|fMRI + Mukbang videos|Specific video program + fMRI will be allocated to the participants in this group. The specific video program includes control videos without food information, eating and food images without sound, chewing and swallowing sound without images, and Interactive content in Mukbang. Participants will undergo structural image scans, resting state scans, and task state scans. The task-fMRI will be performed while watching Mukbang to explore the activation of brain functional areas.
223409052|NCT04608396|DRUG|AXS-05|AXS-05 taken daily for up to 52 weeks, until relapse.
223409053|NCT04608396|DRUG|Placebo|Placebo taken daily for up to 52 weeks, until relapse.
224133477|NCT03364608|DRUG|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
223409054|NCT05010538|DRUG|Sarecycline|60 mg sarecycline tablets will be given for subjects with a body weight of 33 to 54 kg, 100 mg sarecycline tablets will be given for subjects with a body weight of 55 to 84 kg, and 150 mg tablets will be given for subjects with a body weight between 85 and 136 kg.
223409055|NCT04103125|DEVICE|Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.|The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
223409056|NCT05967013|COMBINATION_PRODUCT|Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.|"All injections with ZENEO® injector will be performed in the thigh. Due to MRI performance constraints, injection sites will be identified on the same thigh/leg at each treatment period: first leg on treatment period 1, opposite leg on treatment period 2.~At each treatment period, two injection sites will be identified spaced 8 to 15 cm apart. The 2 injections should be performed on the same leg at each treatment period.~In total, 2 injections will be performed per treatment period, and subjects will receive 4 injections during the study :~* 2 injections on bare skin: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector.~* 2 injections through clothing: 1 with GAMMA configuration of ZENEO® injector \& 1 with GAMMA-Low configuration ZENEO® injector."
223409057|NCT01450306|DRUG|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
223409058|NCT01450306|BEHAVIORAL|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
223409059|NCT01450306|DRUG|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
223409060|NCT03784742|OTHER|Nitrate rich beetroot juice|James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).
223409061|NCT03784742|OTHER|Placebo beetroot juice|James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
224025399|NCT07214493|DEVICE|The usual participant's foot|The usual foot of the participant is an Energy Storage and Return (ESR) prosthetic foot (no heel height adjustement)
224025400|NCT07214064|DRUG|RIC regimen|Venetoclax (Venclyxto®): 400 mg abs./d day -8 to -2, Fludarabine 30 mg/m2 BSA day -6 to day -2, Treosulfan 10 g/m2 BSA day -4 to day -2
224025401|NCT07214688|DRUG|Fludarabine|Patients will receive fludarabine administered at the dose of 30 mg/m2 intravenously daily on Days -6 to -2
224025402|NCT07214688|RADIATION|Intermediate-dose Total Body Irradiation (TBI)|Patients will receive intermediate-dose total body irradiation (TBI) administered at the dose of 800 cGy in 4 total fractions, 2 fractions per day on Days -2 to -1
224133478|NCT03364608|OTHER|Placebo MDI|Placebo MDI (2 actuations)
224133479|NCT03364608|DRUG|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
224133480|NCT03364608|DRUG|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
224133481|NCT00410501|DRUG|Indacaterol (QAB149)|
223409062|NCT03239249|OTHER|IKO-model|A systematic model for drop-out prevention.
223409063|NCT03239249|OTHER|Treatment as usual|Schools randomized to control group (22) work as previously with school dropout
224025403|NCT07214688|DRUG|Post-transplant Cyclophosphamide (PTCy)|Patients will receive post-transplant cyclophosphamide (PTCy) administered at the dose of 40 mg/kg intravenously on Days +3 to +4.
224025404|NCT07214688|DRUG|Tacrolimus|Patients will receive tacrolimus administered at a dose adjusted to maintain trough levels between 5-15 ng/mL orally starting on Days +5.
224025405|NCT07214688|DRUG|Mycophenolate mofetil (MMF)|Patients will receive mycophenolate mofetil (MMF) administered at the standard dose of 15 mg/kg orally three times daily starting on Day +5 to Day +35 or per institutional guidelines.
224025406|NCT07215000|DRUG|Golytely|large volume liquid prep.
224025407|NCT07215000|DRUG|Sulfave|SUFLAVE is a split-dose (2-day) regimen. A total of 2 bottles are required for complete preparation for colonoscopy. You will take 2 bottles of liquid in two separate doses. One dose of SUFLAVE is equal to one bottle plus one flavor enhancing packet.
224133482|NCT01442740|PROCEDURE|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
224133483|NCT03730883|PROCEDURE|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
224133484|NCT03730883|PROCEDURE|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
223409064|NCT03403140|DRUG|Etanercept|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
223409065|NCT05644626|DRUG|BGB-B167|Intravenous administration
223409066|NCT05644626|DRUG|Tislelizumab|Intravenous administration
223409067|NCT01976962|RADIATION|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
223409068|NCT04439474|DRUG|Vitamin D3|For up to 8 days, 50,000 units of vitamin D3 are given daily to patients in the first group so that the serum level of vitamin D reaches above 30 g / ml.
223409069|NCT04439474|DRUG|Routine treatment|In this group, patients receive their usual medications and treatments
223409070|NCT01041157|OTHER|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
223558500|NCT03911323|OTHER|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
224025408|NCT07215000|DRUG|Sutab|SUTAB comes in a kit that contains two medication bottles and a cup for water. Each bottle contains 12 tablets (pills). You'll take 12 pills (one bottle) with water from the cup the night before your exam. Later that evening, drink two more cups of water. Fill the cup to the line each time. Then, six hours before your exam, repeat all three of those steps.
224025409|NCT07214467|DEVICE|Deep Brain Stimulation|An individualized aDBS protocol will be used to examine therapeutic effect.
224025410|NCT07213700|OTHER|None, this is a non-interventional observational study|None applicable
224025411|NCT07213557|DRUG|standard nivolumab and oxaliplatin- based chemotherapy|"Nivolumab will be administered as 30 minutes intravenous infusion at the dosage of 360 mg every 3 weeks or 240 mg every 2 weeks as flat dose followed by investigator's choice of oxaliplatin-based chemotherapy regimen:~* XELOX (oxaliplatin 130 mg/m2 on day 1 and capecitabine 1,000 mg/m2 orally twice daily on days 1- 14 administered every 3 weeks) or~* mFOLFOX6 (oxaliplatin 85 mg/m2 on day 1 followed by lederfolin 200 mg m2 on day 1, fluorouracil 400 mg m2 on day 1 and 2,400 mg m2 continuous infusion over 46 hours every 2 weeks)"
224133485|NCT03071549|DRUG|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
224133486|NCT03071549|DRUG|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
224133487|NCT04799236|DRUG|Group 1: Miltefosine|Miltefosine 50 mg pill will be administered po every 8 hours with food, during 28 days
223409071|NCT00288626|DRUG|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
223409072|NCT00288626|DRUG|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
223409073|NCT00288626|PROCEDURE|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
223409074|NCT02821026|PROCEDURE|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
223409075|NCT02821026|DRUG|Anti-Thymocyte Globulin|
223409076|NCT02821026|DRUG|Mycophenolate mofetil|
223409077|NCT02821026|DRUG|Tacrolimus|
223409078|NCT02821026|DRUG|Etanercept|
223409079|NCT02821026|DRUG|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
223409080|NCT02108548|DRUG|ASP7657|oral
224133488|NCT04799236|DRUG|Group 2: Pentavalent Antimony|will be administered by IV infusion diluted in 150 ml of DWD5% over 20 minutes
224133489|NCT04799236|DRUG|Group 3: Liposomal amphotericin B|3 amps (150 mg) will be administered by IV infusion iver 2 hours every other day for a total of 15 doses.
223409081|NCT02108548|DRUG|Placebo|oral
224025412|NCT07213557|DRUG|simvastatin in combination with standard nivolumab and oxaliplatin-based chemotherapy|"Nivolumab will be administered as 30 minutes intravenous infusion at the dosage of 360 mg every 3 weeks or 240 mg every 2 weeks as flat dose followed by investigator's choice of oxaliplatin-based chemotherapy regimen:~* XELOX (oxaliplatin 130 mg/m2 on day 1 and capecitabine 1,000 mg/m2 orally twice daily on days 1- 14 administered every 3 weeks) or~* mFOLFOX6 (oxaliplatin 85 mg/m2 on day 1 followed by lederfolin 200 mg m2 on day 1, fluorouracil 400 mg m2 on day 1 and 2,400 mg m2 continuous infusion over 46 hours every 2 weeks)~* SIM will be administered per os daily at a fixed dosage of 40 mg that represents the recommended dose as cholesterol lowering agents."
224025413|NCT07213895|DRUG|Empagliflozin/Linagliptin/Metformin HCL|One Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg extended release film-coated tablet
224025414|NCT07213895|DRUG|Trijardy® XR Extended release film coated tablets|One Trijardy® 25mg/5mg/1000mg Extended Release Tablets
224025415|NCT07210268|DEVICE|TI-NDBS|In the active TI-NDBS condition, participants receive transcranial stimulation for 60 minutes through scalp electrodes using temporal interference (TI). Two electrode sets deliver high-frequency alternating currents (e.g., 2000 Hz and 2020 Hz), generating a 20 Hz beat frequency at depth to stimulate targeted brain regions. Stimulation is delivered in six 10-minute blocks with 30-second ramp-up and ramp-down periods to minimize discomfort. Electrode configurations differ by group to target either the nucleus accumbens or anterior insula, based on finite element modeling. The maximum current is up to 2 mA per electrode, and no single region receives more than 2 mA.
224025416|NCT07210268|DEVICE|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
224025417|NCT07214766|DRUG|Trastuzumab|Trastuzumab will be administered to participants as a solution for injection.
224025418|NCT07214883|OTHER|No Interventions|No intervention for participants.
224025419|NCT07213492|BEHAVIORAL|Group-Based Psychoeducation|Participants attend a six-session, group-based psychoeducation program delivered over 8 weeks. Sessions focus on improving insight into bipolar disorder, relapse prevention, lifestyle strategies (e.g., sleep, nutrition, substance use), and digital literacy. The aim is to enhance understanding of illness and support long-term functioning.
224025420|NCT07213492|BEHAVIORAL|Peer Support|Trained peer support workers provide biweekly sessions over 6 months to participants. The sessions are based on the CANMAT/ISBD Patient and Family Guide and include emotional support, psychoeducation, and shared experience. Each participant receives up to 12 sessions aimed at improving engagement and understanding of illness.
224025421|NCT07213492|BEHAVIORAL|Personalized Support for Community Healthcare Provider|The research team provides two personalized support sessions over 6 months to each participant's healthcare provider (e.g., family doctor or psychiatrist). Support includes treatment recommendations based on the CANMAT/ISBD 2018 Guidelines and training on the C-IMPACT BD web-based clinical decision support tool.
224025422|NCT07213791|DRUG|LY4337713|Administered IV.
224025423|NCT07214116|BEHAVIORAL|Educational Video|The educational video will last 5 minutes and is designed to inform participants about the onychocryptosis surgical procedure. The principal investigator will clearly and accessibly explain what the surgery involves, the steps to follow, and what participants can expect before, during, and after the procedure.
224025424|NCT07214116|DEVICE|Virtual Reality|Participants will use Meta Quest 3 VR glasses during the onychocryptosis surgery. The device features adjustable straps, interpupillary distance settings, and built-in headphones with spatial sound, allowing immersive visualization and audio tailored to patient preferences. Disposable masks will be used for hygiene. The immersive content will be a 360-degree video of a relaxing walk through a forest accompanied by gentle music, starting 5 minutes before the procedure. Patients may remove the glasses or stop the VR experience at any time if desired.
224025425|NCT07214116|BEHAVIORAL|Music Therapy|Participants will wear over-ear headphones with disposable covers and noise-cancellation (Bose® QuietComfort 25) connected to an Apple® iPod. Music will start 5 minutes before the ingrown toenail surgery and continue throughout the procedure. Only instrumental classical music, royalty-free and from Musopen.org, will be played in a 1-hour playlist. The same playlist will be used for all participants. Participants can adjust the volume at any time. Music will be temporarily paused if communication with the patient is needed and resumed afterward.
224025426|NCT07214675|DEVICE|HistoSonics Edison System|The HistoSonics Edison System is intended for the non-invasive mechanical destruction of prostate tissue for the treatment of BPH using histotripsy, a non-thermal, mechanical process of focused ultrasound.
224025427|NCT07214428|DIETARY_SUPPLEMENT|freeze-dried table grape powder|48g freeze-dried table grape powder/day for 4 weeks
224025428|NCT07214428|DIETARY_SUPPLEMENT|Placebo|48g placebo/day for 4 weeks
223558501|NCT06239480|DRUG|QTORIN 3.9% Rapamycin Anhydrous Gel|QTORIN 3.9% Rapamycin Anhydrous Gel
223409082|NCT02108548|DRUG|naproxen|oral
223409083|NCT01506401|DEVICE|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
223409084|NCT01506401|PROCEDURE|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure \< or = 35cmH20; Prescribed PEEP/FiO2 chart
223409085|NCT06303401|OTHER|SI joint thrust manipulation|"experimental group given the thrust manipulation along with heating pad. 3 sessions per week will be given for 4 weeks. The pain measure by using NPRS, functional status and disability through ODI will be evaluated.~after every 3 sessions."
223558502|NCT03057041|DRUG|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
223558503|NCT03057041|DRUG|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
223409086|NCT06303401|OTHER|pelvic stabilization exercises|Heating pad for 10- 15 mints Pelvic stabilization exercises include Bridging (3 sets x 10 reps with 10 secs hold) Pelvic Tilt exercise(3 sets x 10 reps with 10 secs hold) Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold) clamshell Exercise (3 sets x 10 reps with 10 secs hold) .3 sessions per week will be given for 4 weeks. The pain using NPRS , functional status and disability will be evaluated by using ODI after every 3 sessions.
223738548|NCT06427824|OTHER|Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery)|An educational program designed by geriatricians, surgeons, anesthesiologists and palliative care physicians to help people with bladder cancer who plan to receive a cystectomy learn strategies to improve their mobility, medication management, mental clarity/delirium and how they document important side effects or health issues after surgery.
223409087|NCT01020630|DRUG|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
224025429|NCT07214298|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224025430|NCT07214298|PROCEDURE|Biospecimen Collection|Undergo ascites, pleural fluid and blood sample collection
224025431|NCT07214298|PROCEDURE|Computed Tomography|Undergo CT
224025432|NCT07214298|DRUG|Fluorouracil|Given IV
223409088|NCT01020630|DRUG|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
224025433|NCT07214298|DRUG|Irinotecan|Given IV
224025434|NCT07214298|DRUG|Leucovorin Calcium|Given IV
224025435|NCT07214298|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224025436|NCT07214298|DRUG|Oxaliplatin|Given IV
224025437|NCT07214298|DRUG|Pegcetacoplan|Given IV and SC
224025438|NCT07214987|DRUG|Toripalimab-tpzi|Toripalimab-tpzi is a humanized IgG4 monoclonal antibody specific against human PD-1.
224025439|NCT07214987|DRUG|Cisplatin|Cisplatin is an injectable chemotherapy agent classified as a platinum-based alkylating agent.
224025440|NCT07214987|DRUG|Docetaxel|Docetaxel is a taxane chemotherapy agent.
224025441|NCT07214753|BIOLOGICAL|benralizumab|30mg s.c. as per SmPC
224025442|NCT07214623|DEVICE|Neuro endovascular embolic coil|i-ED COIL, Kaneka Corporation
224025443|NCT07214389|BEHAVIORAL|Quality Measures (Audit and Feedback)|Clinic-level reports/dashboards providing case-mix-adjusted retention and outcome measures with benchmarks and peer comparisons, derived from EHR and Medicaid claims; delivered periodically to guide quality improvement.
224025444|NCT07214389|BEHAVIORAL|Quality Improvement (QI) Toolkit|A self-guided QI toolkit for OTPs with step-by-step change packages, PDSA templates, training materials, and case examples to improve retention. Provided together with the quality measures in Arms 1-2; designed for use without external facilitation.
224025445|NCT07214389|BEHAVIORAL|External QI Facilitation|Structured facilitation based on the NIATx model. Facilitators provide training, coaching, and feedback to an OTP change team, using the measures and toolkit to guide retention-focused QI.
223409089|NCT02690818|BEHAVIORAL|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
223409090|NCT04646343|OTHER|administration of F-CISS and F-PWES pre version|the CISS questionnaire is a 6 items questionnaire, the PWES is a 3 items questionnaire. Only 10 minutes are required to fulfilled the questionnaires.
223409091|NCT04646343|OTHER|administration of definitive version of F-CISS and F-PWES plus F-DASH, F-HFS and F-SF 36|The administration will required 25 minutes
223409092|NCT06224556|COMBINATION_PRODUCT|Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program|"Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed."
223409093|NCT05042999|DEVICE|Oculus Go Virtual Reality Goggles|Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
223409094|NCT00840957|BIOLOGICAL|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
223409095|NCT05664022|PROCEDURE|Global postural reeducation|"The GPR involves a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles, and enhancing the contraction of antagonist's muscles, thus avoiding postural asymmetry.~The GPR method includes eight therapeutic postures, lying, sitting or standing, to be held for 15/20 minutes each. Postures can be variously combined during sessions. Postures are chosen on the basis of some parameters, such as the amount of pain, load capacity and age of the patient, and muscle chains to be stretched. to increase the standardization of treatment, it will be proposed only 2 or 3 postures."
223409096|NCT02192996|DIETARY_SUPPLEMENT|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
223409097|NCT02819037|PROCEDURE|gas chromatography|
223409098|NCT02819037|PROCEDURE|Stool analysis for detection of malabsorption|
223409099|NCT00245128|DRUG|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
223409100|NCT05009693|OTHER|White Light Application|White Light Therapy
224025446|NCT07213583|DRUG|ALXN2220|Participants will receive ALXN2220 via IV infusion.
224025447|NCT07214012|OTHER|Joint contraceptive and couple communication education|"Joint Comprehensive Contraceptive Education~a. Visual and written description of all currently available contraceptives with explanation of pros and cons~Couple constructive communication education~1. Specific couple contraceptive conversation examples.~2. Interactive worksheet to help with joint desired contraceptive decision-making and making a consistent use plan"
224025448|NCT07214012|OTHER|Couple communication consultation with Interventionist to increase partner engagement and improve communication|"1. Couples will bring their completed workbook to reference during the meeting and assess fidelity~2. Reinforce couple contraceptive communication skills. Address any challenges couple has with skill implementation~3. Review desired contraceptive method \& consistent use plan~4. Use motivational interviewing techniques to help couple agree on contraceptive plan"
224025449|NCT07214012|OTHER|Check-ins to support continued partner support & communication|"1. Review progress toward couple contraceptive communication skills and use of agreed contraceptive method~2. Assess factors promoting successful contraceptive use and communication skills~3. Address barriers to consistent contraceptive use and communication skill implementation via shared problem-solving"
224025450|NCT07214012|OTHER|Check-ins to support continued partner support & communication|"1. Review progress toward couple contraceptive communication skills and use of agreed contraceptive method~2. Assess factors promoting successful contraceptive use and communication skills~3. Address barriers to consistent contraceptive use and communication skill implementation via shared problem-solving"
224025451|NCT07214272|DEVICE|Fraxel® FTX Laser System|"The Fraxel Laser System has two fiber-laser sources that are contained in a single Console. The Console is electrically connected to the facility power source. Laser energy produced by the unit is delivered to the tissue through the Handpiece, which is connected to the Console by the Handpiece Cable. Treatments are delivered through removable, disposable Treatment Tips which attach to the Handpiece. A Treatment Key is required to activate treatments and is inserted into the port on the side of the Touchscreen.~The system includes two lasers with wavelengths of 1550 nm and 1927 nm. The two-wavelength option allows for targeted treatment of different tissue depths, and the wavelength can be selected through the Console Touchscreen. Interchangeable Tips allow for treatment of both small and large areas."
223409101|NCT01585051|DRUG|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
224025452|NCT07213973|DRUG|Povorcitinib|Oral; Tablet
223409102|NCT01585051|DRUG|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
224025453|NCT07213778|DRUG|REGN7508|Administered per the protocol
224025454|NCT07213778|DRUG|Acetylsalicylic Acid (ASA)|Administered per the protocol
224025455|NCT07213778|DRUG|Placebo|Administered per the protocol
224025456|NCT07214974|BEHAVIORAL|Structured wellness care|Participants engage in structured wellness programs, including cognitive training exercises (e.g., memory games, problem-solving tasks) and lifestyle counseling focused on diet, physical exercise, sleep hygiene, and stress management. Sham elements may be included for blinding consistency.
224025457|NCT07214974|DEVICE|Wearable brain-computer interface devices|Participants use an active non-invasive brain-computer interface (BCI) device for neurofeedback training, designed to enhance cognitive function through real-time brain activity monitoring and modulation. Sham (non-functional) devices are provided to other arms for blinding.
224025458|NCT07214974|BIOLOGICAL|Stem Cell Therapy - Experimental|Participants receive administration of autologous or allogeneic stem cells through intravenous or targeted delivery methods aimed at neuroregeneration. Placebo saline infusions are used in other arms to preserve blinding.
224025459|NCT07214974|OTHER|Control - Placebo Comparator|Participants receive no active treatment. To maintain blinding, they undergo placebo procedures, such as saline infusions mimicking stem cell therapy or sham (non-functional) devices simulating BCI therapy.
224025460|NCT07213882|DRUG|DT-7012|This study use the Bayesian one-stage time-to-event continual reassessment method (TITE-CRM) design for dose finding phase I clinical trials, using an empirical dose-toxicity model with linear weights. A maximum total of 30 patients with CTCL, given 4 candidate dose levels (0.3; 1.0; 3.0; 10.0 mg/kg) will be dose-assigned starting from 1mg/kg dose level, in cohorts of 1 patient and including safety rules notably to ensure staggered accrual.
224025461|NCT07214636|BEHAVIORAL|Structured Pre-Sleep Exercise|Participants in this group will undergo a new program structured around exercises typically used individually or in combination in the literature, at pre-sleep times. Individuals will complete a program consisting of 5-minute breathing, 10-minute aerobic, 5-minute strengthening, and 10-minute oropharyngeal exercises, three times a week for 12 weeks, for a total of 36 sessions. Two-minute rest breaks will be provided between exercises. The exercises will be presented to users weekly as a video/training sheet prepared by the therapist. Individuals in this group will be monitored and tracked through the system to be developed. This group will only have access to this video/training sheet information in the user panel opened in the system. The system will remind users of the exercises as an exercise program, without gamification, and will provide instant data flow.
224025462|NCT07214636|BEHAVIORAL|ApneaTheraPlay (ATP)|Participants will exercise individually at pre-sleep times, three days a week, for 12 weeks, using a digital video-based game exercise system developed by researchers, for a total of 36 sessions. Access to the exercise program will be provided via a web system, and all time spent in the system and reactions will be recorded in a report. The ApneaTheraPlay system will implement programs consisting of breathing (5 minutes), aerobic (10 minutes), strengthening (5 minutes), and oropharyngeal exercises (10 minutes) in a predetermined progression.
224025463|NCT07214025|DRUG|Safety and efficacy of Romiplostim in Treatment of chronic ITP in children|Children diagnosed with chronic immune thrombocytopenia (ITP) will receive Romiplostim, a thrombopoietin receptor agonist administered as a once-weekly subcutaneous injection. The initial dose will be 1 µg/kg, with subsequent dose adjustments (up to a maximum of 10 µg/kg weekly) based on platelet response, in order to maintain platelet counts ≥50 × 10⁹/L while minimizing the risk of bleeding. Treatment duration will be determined according to study protocol, and patients will be monitored regularly for efficacy (platelet count response, bleeding events) and safety (adverse events, laboratory parameters).
224025464|NCT07213505|OTHER|Testing new front-end features|New front-end features (i,e, the Focused Beamformer which nhances directional hearing and the AI Mode Medium (utilizes artificial intelligence for optimized sound processing) will be compared to the approved beamformer and AI mode) in a within subject design. Subjects will be fitted with a MED-EL SONNET 3 audio processor.
223409103|NCT01462760|DEVICE|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
223409104|NCT01462760|DEVICE|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
223409105|NCT03155464|PROCEDURE|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
223409106|NCT03155464|DRUG|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
223409107|NCT01566266|DRUG|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
223409108|NCT01566266|DRUG|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
224133490|NCT05441137|BEHAVIORAL|Ride-On Cars Training with Different Postures|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual-effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
224025465|NCT07214090|BEHAVIORAL|Transparent Augmented Reality with Real-World Video Feed Overlay (RVAT)|This intervention uses a transparent augmented virtual reality headset equipped with forward-facing cameras that capture the patient's real-world environment in real time. Transparent virtual and augmented reality overlays computer-generated elements (e.g., visual cues, guidance, or interactive content) onto the live view of the physical environment. This approach maintains a strong anchoring in reality while providing therapeutic visual enhancements, tailored in real-time to the patient's responses. Sessions last 10 minutes and are delivered in a controlled clinical environment, supervised by trained staff.
224025466|NCT07214090|BEHAVIORAL|Passive Multisensory Virtual Reality Immersion via Head-Mounted Display (RVEP)|This intervention involves the use of a head-mounted display to immerse the patient in a fully computer-generated virtual environment. The virtual reality passive exposure is designed to distract patients from painful or anxiety-inducing sensations by engaging multiple sensory modalities (visual, auditory, and occasionally tactile). Patients are exposed to relaxing or engaging scenarios, such as natural landscapes or calm immersive scenes, without requiring interaction. Sessions last 10 minutes and are delivered in a controlled clinical environment, supervised by trained staff.
224025467|NCT07214311|DRUG|PLG0206|PLG0206 Solution
224025468|NCT07214311|DRUG|Placebo|Placebo
224025469|NCT07213622|PROCEDURE|Smartglasses|Wearing smart glasses while performing a nerve block
224025470|NCT07213999|DEVICE|Novel neural recorder|The neural recorder does not suffer saturation from stimulation artifacts, allowing circuits to record neural signals with higher precision.
224025471|NCT07214909|OTHER|Ingesting coffee without creamer|Ingesting coffee without creamer and evaluating gastric emptying with gastric ultrasound at different time points.
224025472|NCT07214909|OTHER|Ingesting coffee with creamer|Ingesting coffee with creamer and evaluating gastric emptying with gastric ultrasound at different time points.
224025473|NCT07213544|DRUG|Remimazolam besylate|Remimazolam
224025474|NCT07213544|DRUG|Propofol|Propofol
224025475|NCT07213479|BEHAVIORAL|Isometric Exercise and Lifestyle Change Advice|"The intervention consists of two distinct phases:~• Intensive Phase (12 weeks) - a structured, high-support period involving three weekly supervised isometric exercise sessions and lifestyle change advice. The supervised exercise programme will consist of 4 × 2-minute bouts of wall squat exercise, with 2-minute rest periods between bouts. Participant squat height position will be based on individual calculations determined at baseline. Target rate of perceived exertion (RPE) for each bout will be:~* Bout 1: RPE 4 (target range: 3.5-4.5)~* Bout 2: RPE 5.5 (target range: 5-6)~* Bout 3: RPE 7 (target range: 6.5-7.5)~* Bout 4: RPE 8.5 (target range: 8-9) If the RPE falls outside the target zone for a given bout, participants will adjust their squat height accordingly.~Lifestyle change advice will be given in booklet form in accordance with current NICE guidelines for hypertension.~• Maintenance Phase (12-24 weeks) - focus on sustaining exercise and lifestyle behaviour changes"
224133491|NCT05441137|BEHAVIORAL|Conventional Therapy|The other independent OT will be responsible for providing conventional therapy based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general propose of the training is to facilitate the developmental scales and improve mobility, socialization and upper limb use in functional tasks.
224133492|NCT01438749|DRUG|Placebo|Single dose
224133493|NCT01438749|DRUG|RO4917838|Single doses (3 dose levels)
223409109|NCT00768703|DEVICE|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
223409110|NCT01631643|DEVICE|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
223409111|NCT02368223|DEVICE|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
223409112|NCT03885895|DRUG|Tranexamic Acid Injectable Product|Ampoules used for intradermal injection
223409113|NCT03885895|DEVICE|Q switched KTP (532nm)|LASER
224025476|NCT07213479|BEHAVIORAL|Lifestyle Change Advice|Lifestyle change advice given as per current standard care for hypertension
224025477|NCT07213739|DEVICE|CLP and pulsation|"As an alternative to manual repositioning, advanced air mattress systems have been introduced to periodically relieve support pressures.~A number of measurements have been used to examine the performance of support surfaces. As an example, interface pressure measurements between the individual and the support surface have been extensively used in both lab-based and clinical studies . We are now investigation the functions to reduce pressure in our new Caylis mattress"
224025478|NCT07214727|DRUG|ALN-5288|ALN-5288 will be administered IT.
224025479|NCT07214727|DRUG|Placebo|Placebo will be administered IT.
224025480|NCT07214558|OTHER|Routine Clinical Anesthesia Practice|Patients undergoing total knee arthroplasty will receive either spinal or general anesthesia as determined by routine clinical practice and the attending anesthesiologist's decision. Investigators will not influence the choice of anesthesia method.
224133494|NCT01438749|DRUG|diazepam|Single dose
223738549|NCT06427824|OTHER|Geriatric Service/ Discharge Planning|A geriatric team will meet with participants after surgery to help them reinforce the strategies they learned in the education video sessions. As part of a geriatric service, this team will also help participants plan/coordinate their discharge from the hospital after surgery.
223409114|NCT03561714|BEHAVIORAL|Cardometabolic Team Intervention|The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
223409115|NCT01168414|DRUG|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
223409116|NCT01168414|DRUG|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
224025481|NCT07214376|DEVICE|Pulmonary Artery Denervation (PADN)|"In patients randomized to Intervention, a Contrast pulmonary artery (PA) angiography will be performed to identify the pulmonary artery bifurcation and measure the PA diameter. Once the anatomy is deemed suitable, a radiofrequency ablation catheter will be introduced into the ostium of the left PA and the distal bifurcation of the main PA. The catheter will be maneuvered within the PA to deliver energy circumferentially, ensuring tight electrode contact with the endovascular surface. Approximately three ablations will be performed at a target temperature of 50 °C (range 45-55 °C) for 120 seconds each at both the left PA ostium and the distal main PA bifurcation.~All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)"
224025482|NCT07214376|DEVICE|Sham procedure control|In patients randomized to a placebo-procedure, a script will be followed for approximately 20 minutes to simulate the PADN procedure. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)
224025483|NCT07214181|DRUG|Topical amitriptyline 1% gel|Patients diagnosed with burning mouth syndrome received topical amitriptyline 1% gel applied intraorally. The gel was instructed to be placed on the oral mucosa (tongue and/or other symptomatic areas) two times per day for several weeks, without swallowing. Treatment was provided as part of routine clinical care. This retrospective study collected data on pain intensity, patient global impression of improvement, and adverse events to evaluate the real-world effectiveness and tolerability of this topical formulation.
224025484|NCT07213466|BEHAVIORAL|Group Therapy Program|a 12-week group therapy program centered around weight loss and healthy eating.
224025485|NCT07213466|DRUG|semaglutide|Brand name: Wegovy
223409117|NCT00540150|BIOLOGICAL|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
223409118|NCT02019264|DRUG|Lorcaserin hydrochloride|APD356 10 mg twice daily
224025486|NCT07213466|DRUG|Phentermine-Topiramate|Brand name: Qsymia
224025487|NCT07213466|DRUG|naltrexone and bupropion (combination)|Brand name: Contrave
224025488|NCT07213609|DRUG|GSK5460025|GSK5460025 will be administered
224025489|NCT07214207|DRUG|Suvorexant 10 mg|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment, mid-treatment, and post-treatment lab visits. Suvorexant (SUV) will be placed in opaque capsules with dextrose filler. Following the pre-treatment visit, participants will receive a labeled blister pack with 28 pills and be instructed to take one pill orally about 30 minutes prior to sleep time each night for 4 weeks. Participants will be provided education about common side effects. At the end of the 4-weeks, participants will return to the lab to complete a mid-treatment lab visit, receive a second labeled blister pack, and will be instructed to continue taking one pill orally about 30 minutes prior to sleep time each night for 4-weeks. Participants will return to complete a post-treatment lab visit. Participants will complete daily surveys to monitor side effects throughout the 8-week medication trial.
224025490|NCT07214207|OTHER|Placebo|This study is a double-blind study. Participants will complete an initial screening visit and pre-treatment, mid-treatment, and post-treatment lab visits. The placebo pill will be identical in appearance to suvorexant but will contain only dextrose. Following the pre-treatment visit, participants will receive a labeled blister pack with 28 pills and be instructed to take one pill orally about 30 minutes prior to sleep time each night for 4-weeks. Participants will be provided education about common side effects. At the end of the 4-weeks, participants will return to the lab to complete a mid-treatment lab visit, receive a second labeled blister pack, and will be instructed to continue taking one pill orally about 30 minutes prior to sleep time each night for 4-weeks. Participants will return to complete a post-treatment lab visit. Participants will complete daily surveys to monitor side effects throughout the 8-week medication trial.
224025491|NCT07213843|OTHER|INF® Therapy|INF® therapy is a manual technique designed to improve neural circulation by using a series of manual holds administered by a trained practitioner,
224025492|NCT07213843|OTHER|NVIf|NVIf is a dietary intervention that uses a patented ultrasound technology to assess vascular responses to food allergens
224025493|NCT07214571|DRUG|S-337395|S-337395 will be administered per schedule specified in the arm description.
224025494|NCT07214571|DRUG|Placebo|Placebo matched to S-337395 will be administered per schedule specified in the arm description.
224025495|NCT07213661|DEVICE|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Bi-annual topical application of 38% silver diamine solution to new ICDAS lesions code 3-6. Advantage Arrest, Elevate Oral Care, West Palm Beach FL
224025496|NCT07213661|DEVICE|"A typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride Varnish (FV)"|GC Fuji (for ART) and FluoriMax Varnish. Atraumatic Restoration Treatment (ART) to new ICDAS lesions code 3-6, followed by bi-annual topical fluoride varnish (FV) to all teeth.
224025497|NCT05317936|DRUG|Pirtobrutinib|Given by PO
224025498|NCT05317936|DRUG|Venetoclax|GIven by PO
224025499|NCT05549752|DRUG|Flecainide Injectable Solution|Intravenous Flecainide at a dose of 2.0mg/kg (maximum dose: 150mg) in 100ml D/W 5% for 10 minutes.
223409119|NCT02019264|DRUG|Placebo|Placebo twice daily
223558504|NCT03604588|DIAGNOSTIC_TEST|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
224025500|NCT05549752|DRUG|Amiodarone Injectable Solution|Intravenous Amiodarone at a dose of 5.0-7.0 mg/kg for 1 hour, and maintenance dose of 50mg/h (maximum dose: 1000mg) for up to 24 hours.
224025501|NCT05406752|DRUG|paracetamol Uniflash (125 mg/ 1.25 mL)|Oromucosal solution (125 mg/ 1.25 mL) for buccal route
224025502|NCT03362047|DRUG|Riciguat Group|Patients will be administered 12 weeks Riciguat
224025503|NCT03362047|DRUG|Macitentan Group|Patients will be administered 12 weeks Macitentan
224025504|NCT00390585|DRUG|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
224025505|NCT00390585|DRUG|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
224025506|NCT01932567|OTHER|Physiotherapy|
224025507|NCT01932567|PROCEDURE|Electrical impedance tomography|
224025508|NCT05968547|OTHER|Driving assessment in glaucoma patient|One group of patient will be given questionnaire while the other group will respond to a questionnaire while the other group will have vision assessment. Patients could participate in both groups.
224025509|NCT05432778|DRUG|Letermovir Pill|Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
224025510|NCT05397184|BIOLOGICAL|Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)|Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
224025511|NCT05539274|DIAGNOSTIC_TEST|human papilloma virus testing and genotyping in cervical cancer cases|an observational analytical prospective cross-sectional study was managed from July 2019 to July 2022 on 70 cervical cancer patients collected from gyne-oncology unit in Shatby obstetrics and gynecology university hospital of Alexandria medical school after taking a written consent and following approval by Alexandria medical school institutional ethics committee. All patients were subjected to full history taking as age, gravidity, parity, contraceptive history, medical disease, detailed marital history and smoking. Collection of the sample from all cases of the study for human papilloma virus testing and genotyping was done after diagnostic workup and before treatment of the study cases at any time in post-menopausal women and at mid cycles period in premenopausal women by cervical smear using PAP spatula and endocervical brush.
223558505|NCT05925413|DRUG|Cadonilimab+TACE|Cadonilimab: 15mg/kg Q3W Day1 Select the best TACE treatment strategy. Traditional TACE (cTACE) or DEB-TACE can be selected. TACE treatment can be continued as needed based on disease control. The combination of cadonilimab is given 3 to 7 days after the first TACE treatment, and the subsequent administration of cardonilizumab is given once every 3 weeks, if the time overlaps with TACE treatment, it is generally administered 3 to 7 days after TACE treatment. Treatment was discontinued until intolerable toxicity, death, withdrawal of informed consent, initiation of a new antitumor therapy, or other reason specified in the protocol, whichever occurs first. Patients in this study received cadonilimab for up to 24 months.
224025512|NCT00552877|DEVICE|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
224025513|NCT01351103|DRUG|LGK974|
224025514|NCT01351103|BIOLOGICAL|PDR001|
224025515|NCT04450160|DRUG|Anhydrous Enol-Oxaloacetate (AEO)|Oral supplementation with AEO along with the Standard of Care (Temozolomide)
224025516|NCT04450160|OTHER|Standard of Care|Standard of Care Temozolomide
224025517|NCT00358553|DRUG|Insulin|
224025518|NCT04604548|DRUG|Oral administration of 100 mg KH176 twice daily|Drug: KH176
224025519|NCT01793220|OTHER|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
224025520|NCT00823056|DIETARY_SUPPLEMENT|probiotics|placebo
224025521|NCT00823056|DIETARY_SUPPLEMENT|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
224025522|NCT01833715|DRUG|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
224025523|NCT01833715|DRUG|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
224025524|NCT01833715|DRUG|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
224025525|NCT05833633|DIAGNOSTIC_TEST|MUSCLE MAGNETIC RESONANCE IMAGING (MRI)|To assess longitudinally at baseline and 1 year later changes on muscle MRI, genetic test, functional motor and respiratory assessments in the DMD group with different type of small mutations and the DMD group with non sense mutations treated with Atarulen in order to better define natural history of these patients. .
224025526|NCT00752310|DRUG|Darunavir|
224025527|NCT01836653|DRUG|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224025528|NCT01836653|DRUG|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224025529|NCT01836653|DRUG|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224025530|NCT01836653|DRUG|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224025531|NCT01836653|DRUG|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224025532|NCT01836653|DRUG|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
224025533|NCT02303522|OTHER|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
224025534|NCT04153123|DRUG|Epinephrine|
224025535|NCT06954116|DRUG|Iparomlimab and Tuvonralimab (QL1706)|"Neoadjuvant phase: A single cycle of Iparomlimab and Tuvonralimab (7.5 mg/kg) will be administered within 1 week prior to surgery.~Adjuvant phase: Six cycles of Iparomlimab and Tuvonralimab (7.5 mg/kg, Q3W) will be initiated starting at 2 weeks postoperatively."
224025536|NCT06954116|PROCEDURE|Partial hepatectomy|Will be performed at an appropriate interval following neoadjuvant therapy initiation.
223409120|NCT02682303|DEVICE|Elastic Bandage (Idealplast C®)|"Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish"
224025537|NCT03454698|OTHER|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
224025538|NCT02216617|DRUG|Taxotere, Cisplatin, Afatinib|
223409121|NCT02682303|DEVICE|Pretape cramer® (non standarized tape)|"Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group."
223409122|NCT00089687|DRUG|GBR 12909|
223409123|NCT05244070|DRUG|BMS-986403|Specified dose on specified days
223409124|NCT05244070|DRUG|Fludarabine|Specified dose on specified days
223409125|NCT05244070|DRUG|Cyclophosphamide|Specified dose on specified days
223409126|NCT01317888|DRUG|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
224025539|NCT06085911|BEHAVIORAL|One day course|a physical one-day course at the Covid rehabilitation clinic. During these six hours, general information about rehabilitation principals will be given. Theory about three 15 focus areas of importance will be presented; daily routine, importance of being active and cognitive training. They will meet others with similar problems and will be given an opportunity to exchange experience. 8-10 patients will participate in the group.
224025540|NCT06085911|BEHAVIORAL|Individual follow-ups|the patient will meet a therapist in a physical consultation at the Covid rehabilitation clinic lasting for 1.5 hours. Together they will in detail map out symptoms and impairment of function in the patient's life. Together the patient and the therapist will create plan to address these problems consisting of tailored home-based exercises within the three focus areas. Tree follow-up consultations will be given.
224025541|NCT05648526|DRUG|ACTH4-10Pro8-Gly9-Pro10|ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
224025542|NCT05648526|DRUG|Ketamine|negative-positive control (ketamine 40 mg/kg BW subcutaneously)
224025543|NCT04680494|OTHER|moderate intensity physical exercise|
224025544|NCT04680494|OTHER|high intensity physical exercise|
224025545|NCT04680494|OTHER|rest|
224025546|NCT01807013|PROCEDURE|ultrasound, liver elastometry, minilaparoscopy|"* conventional high-end ultrasound technique,~* small access laparoscopy with fine laparoscopes~* Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
224025547|NCT00911079|PROCEDURE|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
224025548|NCT00911079|RADIATION|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
224025549|NCT04993612|DIAGNOSTIC_TEST|Blood gas analysis|"Two blood samples will be drawn from the wedge position, behind the inflated balloon, during the right heart catheterization, and blood gas analyses will be performed. First sample will be drawn directly after inflating the ballon, and the second one 2 minutes later."
224025550|NCT01776801|OTHER|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
224025551|NCT02725346|PROCEDURE|Acromioplasty with planning|
224025552|NCT02725346|PROCEDURE|Acromioplasty without planning|
224025553|NCT01969318|DRUG|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
224025554|NCT01969318|DRUG|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
223409127|NCT03306628|OTHER|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
223409128|NCT03786328|BEHAVIORAL|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
223409129|NCT03786328|BEHAVIORAL|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
223409130|NCT05494944|PROCEDURE|ThuLEP|Minimal invasive prostate intervention
223409131|NCT02087540|DRUG|Telmisartan 80mg|
223409132|NCT02087540|DRUG|Rosuvastatin 20mg|
224025555|NCT01969318|DRUG|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
224025556|NCT02782689|DEVICE|Kit Biflex|Two-layer reusable compression system
224025557|NCT02782689|DEVICE|Profore|Four-layer compression system
224025558|NCT03882411|BEHAVIORAL|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. In addition to education, providers will receive a patient preference report in real time with options for coordination of care
224133495|NCT06534814|DIAGNOSTIC_TEST|AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM)|The AI-Driven Identification Model for Gastric Cancer Lymph Node Metastasis (AID-GLNM) intervention involves the development and application of an advanced artificial intelligence (AI) system specifically designed to enhance the identification and characterization of lymph node metastasis in patients diagnosed with gastric cancer.
224133496|NCT04866303|DIAGNOSTIC_TEST|Home-based SARS-CoV-2 test kit|A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
224133497|NCT03668691|DEVICE|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
224133498|NCT06553183|PROCEDURE|immersive virtual reality|Exercise based on virtual reality video games. Immersive type will be used.
224133499|NCT06553183|PROCEDURE|traditional physicaltherapy|pneumatic compression, exercise and skin care
224133500|NCT04377594|PROCEDURE|Radio frequency ablation|Two different radio frequency ablation procedures
224133501|NCT03195855|OTHER|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
224133502|NCT00783211|DRUG|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
223409133|NCT02087540|DRUG|Rosuvastatin 10mg|
224133503|NCT00783211|DRUG|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
223409134|NCT02087540|DRUG|Placebo(for Telmisartan 80mg)|
223558506|NCT06292754|PROCEDURE|magnesium pin in additional to the suture anchor|magnesium pin in additional to the suture anchor used routinely in clinical practice
224025559|NCT03938545|DRUG|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
224025560|NCT03938545|OTHER|Placebo (Administered via subcutaneous injection)|Placebo
224025561|NCT04061447|DRUG|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
224025562|NCT04061447|DRUG|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
224133504|NCT00783211|DRUG|placebo|placebo, once daily for 15 days
224133505|NCT05120960|DRUG|tepotinib|Given by PO
223409135|NCT02087540|DRUG|Placebo(for Rosuvastatin 20mg)|
223409136|NCT02087540|DRUG|Placebo(for Rosuvastatin 10mg)|
224133506|NCT05120960|DRUG|tepotinib plus osimertinib|Given by PO
224133507|NCT00923234|DRUG|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
224133508|NCT00923234|DRUG|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
224133509|NCT03077126|OTHER|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
223409137|NCT05617157|OTHER|Stair stepping|stepping up and down 32 stairs for 1 minute
223409138|NCT01226966|DRUG|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
223409139|NCT05284331|OTHER|addition of two follow-up visits post infection|"Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection"
223558507|NCT06292754|PROCEDURE|routine suture anchor|routine suture anchor for the treatment-as-usual
223738550|NCT06427824|OTHER|Questionnaires|These questionnaires will ask about the participants' mobility, frailty, quality of life and additional health/risk factors before and after surgery.
223409140|NCT06049563|DIAGNOSTIC_TEST|Diagnostic MRI|MRI scan of the upper abdomen performed with the low-field 0.4T MRI system.
224025563|NCT04768387|DIETARY_SUPPLEMENT|Personalized microbiome diet|The personalized nutrition model estimates the optimal micronutrient compositions for a required microbiome modulation. In this study, we computed the microbiome modulation needed for an IBS case, based on the IBS-indices generated by the machine learning models. According to that, the baseline microbiome compositions are perturbed randomly with a small probability p. Perturbed profiles are accepted with a probability proportional to the decrease in the IBS-index as suggested by Metropolis sampling. This Monte-Carlo random walk in the microbiome composition space is expected to meet a low IBS-index microbiome composition nearby the baseline microbiome composition of the patient with a minimal modulation. The personalized nutrition model, then, estimates the optimized nutritional composition needed for this individual, expecting to drive the IBS-index to lower values.
224025564|NCT01725048|DRUG|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
223409141|NCT04267809|DRUG|Metformin Hydrochloride|Metformin 500mg tablets are registered and licensed in Singapore. For the study, we will be sourcing the Metformin tablets from Singapore General Hospital Formulary.
224025565|NCT01725048|DRUG|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
224025566|NCT01060540|GENETIC|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
224025567|NCT01060540|BEHAVIORAL|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
223409142|NCT04267809|DRUG|Calcium and Vitamin D|Calcium and Vitamin D tablets are registered and licensed in Singapore. For the study, we will be sourcing the Calcium and Vitamin D tablets from Singapore General Hospital Formulary.
223409143|NCT03660111|DIAGNOSTIC_TEST|spirometry|only measurement of spirometry
224025568|NCT01060540|BEHAVIORAL|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
224025569|NCT04288765|DRUG|Daratumumab Only Product in Parenteral Dose Form|"Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21~Daratumumab:~Cycles 1-2: weekly Cycles 3-4: every two weeks Cycles 5-8: every month Dexamethasone: 40 mg weekly"
224025570|NCT04985890|BIOLOGICAL|UB-421|10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy
224025571|NCT04985890|OTHER|UB-421+chidamide|10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.
224025572|NCT05234229|OTHER|Survey|Collection of immunization status by questionnaire
224025573|NCT02304796|BEHAVIORAL|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
224025574|NCT02304796|BEHAVIORAL|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
224025575|NCT02082236|DRUG|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
224025576|NCT02082236|DRUG|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
224025577|NCT02082236|DRUG|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
224025578|NCT02082236|DRUG|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
224025579|NCT05023603|DIAGNOSTIC_TEST|self-report questionnaire|Individual subject factors included and self-report questionnaires will be collected through an interview process.
224025580|NCT00098852|DRUG|rosiglitazone maleate|
224025581|NCT00735020|BIOLOGICAL|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
224025582|NCT00735020|BIOLOGICAL|Influenza Vaccine|1 dose of Influenza Vaccine
224025583|NCT06090877|DEVICE|US and shear wave elstography|using B mode US to assess ulnar nerve echogenicity, measuring its cross sectional area and assess any other anatomical abnormalites Measuring ulnar nerve stiffness using shear wave elastography All measurements done at the cubital tunnel, 2 cm proximal and distal to it compare findings with electrodiagnostic studies and intra operative findings
224133510|NCT03077126|DEVICE|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
224133511|NCT03077126|DIAGNOSTIC_TEST|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
224133512|NCT03077126|PROCEDURE|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
223409144|NCT06578689|BEHAVIORAL|Education|The control group received standard care, while the intervention group received standard care supplemented with formal educational session followed by ongoing education on foot care using mobile health by a clinical pharmacist.
223409145|NCT04848051|BEHAVIORAL|CRC screening reminder|Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening
223409146|NCT04848051|BEHAVIORAL|CRC Reminder & Short message|Participants randomized to the CRC Reminder \& short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening
224133513|NCT00064129|BIOLOGICAL|Ipilimumab|Given IV
223738551|NCT04975334|DRUG|Naloxone|One bolus of naloxone
223738552|NCT06690775|DRUG|TORL-1-23|2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.
224133514|NCT00064129|OTHER|Laboratory Biomarker Analysis|Correlative studies
224025584|NCT02647320|DRUG|Sitagliptin 100 mg|Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration
224133515|NCT00064129|OTHER|Pharmacological Study|Correlative studies
224297986|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
223409147|NCT04848051|BEHAVIORAL|CRC Reminder and Navigation Program|Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance
223409148|NCT04848051|BEHAVIORAL|CRC Reminder & CRC education|Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
223409149|NCT03637062|DRUG|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
223409150|NCT03637062|DEVICE|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
223409151|NCT03067532|PROCEDURE|existed simulation system user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
223409152|NCT03067532|PROCEDURE|home made simulator user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
223409153|NCT03942471|BEHAVIORAL|Mindfulness Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a well-defined and systematic patient-centered educational approach which provides training in mindfulness meditation to teach adolescents with Type 1 diabetes to take better care of themselves and live healthier and more adaptive lives by learning to become more connected to the present moment through the use of breath and training for awareness of the moment.
223409154|NCT01137149|BEHAVIORAL|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
223409155|NCT01137149|BEHAVIORAL|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
223409156|NCT06240936|OTHER|Active Cycle of breathing|Active Cycle of Breathing Techniques will be given to group A. In Active cycle of breathing exercises, breathing control, thoracic expansion and forced expiration technique will be applied. 3-4 sets of exercise ,10-15 mint, 4 times per week for 4 weeks.
224133516|NCT00064129|BIOLOGICAL|Sargramostim|Given SC
223409157|NCT06240936|OTHER|Active Cycle of breathing with Acapella|"Acapella device will be used along active cycle of breathing techniques to group B. 3-4 sets ,10 mints foe acapella training ,15 -20 munts ,4 times per week for 4 weeks.~This technique is active form of therapy in which patient uses its own energy on request to aid in treatment."
223409158|NCT02914613|DRUG|SF0166 Topical Ophthalmic Solution|
223738553|NCT06690775|DRUG|TORL-1-23|3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
223738554|NCT06690775|DRUG|TORL-1-23|3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
223738555|NCT06690775|DRUG|Pegfilgrastim (drug)|6.0 mg subcutaneous injection on Day 4 of each cycle.
224133517|NCT01053845|OTHER|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
223738556|NCT02940301|DRUG|Ibrutinib|Given PO
224133518|NCT02697084|OTHER|anal cancer|Anal cancer patients with TEP TDM
224133519|NCT01724125|OTHER|personal electronic medical record|
224133520|NCT03209635|DIETARY_SUPPLEMENT|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
224025585|NCT02647320|DRUG|DS-8500a 25mg|DS-8500a 25mg tablet for oral administration
224025586|NCT02647320|DRUG|Placebo Tablet|Placebo matching DS-8500a tablet for oral administration
224025587|NCT02647320|DRUG|Placebo Capsule|Placebo matching sitagliptin over-capsule for oral administration
224297987|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
224025588|NCT00160784|PROCEDURE|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
224025589|NCT00160784|PROCEDURE|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
224025590|NCT00160784|OTHER|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
224025591|NCT02941250|DEVICE|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
224025592|NCT02049151|DRUG|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
223409159|NCT03495479|DRUG|OMN54|Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
223409160|NCT03693183|DRUG|Ketorolac/HPMC|0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
223409161|NCT03693183|DRUG|HPMC|0.80% Hydroxypropyl Methylcellulose solution 4 times per day for 2 days
223409162|NCT03693183|DRUG|Vehicle|Vehicle
223409163|NCT02461966|OTHER|Aflatoxin|Evaluation of Aflatoxin level
223409164|NCT03819712|PROCEDURE|Collection of blood samples|23 mL of blood will be collected during the inclusion visit
223409165|NCT03819712|OTHER|Collection of fecal samples|Fecal sample self-collected after the inclusion visit
223409166|NCT03819712|OTHER|Collection of urine samples|10 mL of urine will be collected during the inclusion visit
224025593|NCT02049151|DRUG|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
224025594|NCT02049151|DRUG|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
224025595|NCT02049151|DRUG|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent \[%\] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
224025596|NCT03572478|DRUG|Rucaparib|600 mg taken by mouth twice daily.
224025597|NCT03572478|DRUG|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
224025598|NCT00596427|DRUG|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
224025599|NCT00596427|DRUG|Placebo|Placebo tablets: 3 tablets twice per day
224025600|NCT04728412|DEVICE|High Flow Oxygen Therapy (HFOT)|HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
224025601|NCT00003998|DRUG|carboplatin|
224025602|NCT00003998|DRUG|docetaxel|
224025603|NCT00003998|DRUG|paclitaxel|
224025604|NCT00003998|PROCEDURE|surgical procedure|
224025605|NCT00320541|DRUG|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
224025606|NCT00320541|DRUG|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
224025607|NCT00320541|DRUG|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
223409167|NCT03819712|OTHER|Collection of vaginal swaps|Sample of vaginal microbiota collected during the inclusion visit
224025608|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
224025609|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
223409168|NCT03718208|DIETARY_SUPPLEMENT|Paediatric Formula|Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.
223409169|NCT03316651|DRUG|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
223409170|NCT06119815|DIAGNOSTIC_TEST|CO2 GAP|"CO2 gap will be measured by insertion of radial arterial cannula and internal jugular C.V.P~* I.V.C collapsibility will be measured by abdominal us at the subcostal area and the IVC diameters will be measured in M-mode coupled to 2D mode 3 cm before the IVC joined the right atrium to ensure that IVC diameter measurements are accurate and that the inter- and intra-observer variability of IVC can be minimized. The IVC collapsibility index (IVCCI) will be calculated as follows: (maximum diameter on expiration (IVC max) - minimum diameter on inspiration (IVC min).~* Echocardiography for all patients to asses cardiac index in a parasternal (2D) view. The aortic diameter (AoD) will be measured at the aortic valve annulus. The aortic area (AA) will be calculated using the formula: AA = π × (AoD2/ 4). We measured the aortic blood flow using pulsed"
223409171|NCT01168778|BEHAVIORAL|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
224025610|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
224025611|NCT00284817|DRUG|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
224025612|NCT00284817|DRUG|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
224025613|NCT04706767|DRUG|Co-administration Lidocaine and Dexmedetomidine|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.
224025614|NCT04706767|DRUG|Dexmedetomidine infusion|Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.
224025615|NCT04706767|DRUG|Lidocaine infusion|Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.
224025616|NCT04706767|DRUG|Saline infusion|Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.
224025617|NCT02608593|PROCEDURE|Strattice|Implant based reconstruction with strattice cover of part or all of implant
224025618|NCT04293445|DIAGNOSTIC_TEST|spirometry, FOT, Induced sputum, bloods, nasal brushes, nasal lavage, skin prick, throat swab|At the point of baseline visit, exacerbation and annual visit, the above tests will be performed to allow comparison of a participants profile before and during an exacerbation
224025619|NCT03294746|OTHER|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
224025620|NCT03294746|OTHER|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan\* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
224025621|NCT02401360|DRUG|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
224025622|NCT02401360|DRUG|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
224025623|NCT01605292|PROCEDURE|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
224025624|NCT01605292|PROCEDURE|Palpation|Manual palpation for localizing radial artery for inserting needle.
224025625|NCT03057977|DRUG|Empagliflozin|once daily
224025626|NCT03057977|DRUG|Placebo|once daily
224025627|NCT02112331|OTHER|Raw human milk|
224025628|NCT02112331|OTHER|Pasteurized human milk|
224025629|NCT02112331|OTHER|Pasteurized-homogenized human milk|
224025630|NCT02112331|OTHER|Gastric samples|
224025631|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
224025632|NCT03553368|DIAGNOSTIC_TEST|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
224025633|NCT03553368|DIAGNOSTIC_TEST|MR|MRI data will be acquired without the use of any device as a reference.
224025634|NCT03553368|DIAGNOSTIC_TEST|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
224025635|NCT03553368|DIAGNOSTIC_TEST|CPAP-MR|MRI data will be acquired with the use of CPAP.
224025636|NCT01650246|DRUG|lesinurad|Tablets, 400 mg QD
224025637|NCT01730794|OTHER|NAVA ventilation|Neurally adjusted ventilatory assist
224025638|NCT01730794|OTHER|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
224133521|NCT03209635|DIETARY_SUPPLEMENT|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10\^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
224133522|NCT00228306|BEHAVIORAL|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
224025639|NCT04947423|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel or Placebo
224025640|NCT04947423|DRUG|Placebo|Subjects will self-administer DPI-386 Nasal Gel or Placebo
224025641|NCT05003817|DEVICE|Percutaneous left ventricular unloading|Percutaneous left ventricular unloading involves the placement of a mechanical pump which draws blood from the left ventricle and returns it into the aorta at flow rates approaching native cardiac output.
224025642|NCT05510752|BEHAVIORAL|Cognitive Behavioural Group Therapy|CBGT is a 6-week group that meets weekly for 2-hours per week, where participants learn cognitive and behavioural techniques to enhance coping skills for their everyday anxieties.
224025643|NCT05510752|BEHAVIORAL|Psychoeducation|Psychoeducation is the most common non-pharmacological treatment for perinatal distress, where participants learn about healthy infant milestones and how to implement self-care in their daily lives, which in turn reduces distress during the perinatal period.
224025644|NCT01459419|DRUG|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
224025645|NCT01459419|DRUG|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
224133523|NCT02857335|BEHAVIORAL|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
224133524|NCT01353937|DRUG|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
224133525|NCT02983630|OTHER|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
223558508|NCT05077995|DEVICE|Polar M200|Participants will have to wear the activity monitors (AP and Polar M200) for at least 7 days. Minutes spent in each activity type will be summed to a total day score. Participants will be instructed to do their regular daily life activities without limitation, but to note their main activity categories in an activity diary, with a main focus on cycling and participation in structured exercise.
223738557|NCT02940301|OTHER|Laboratory Biomarker Analysis|Correlative studies
224133526|NCT02546674|DRUG|Nilotinib|A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.
224025646|NCT02831803|DIETARY_SUPPLEMENT|Walnuts|28 gm/day in single-serve package
224025647|NCT02831803|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
224025648|NCT01011426|DRUG|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
224025649|NCT01011426|DRUG|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
224025650|NCT02539537|DRUG|Gemcitabine|
224025651|NCT02539537|DRUG|Folinic Acid|
224025652|NCT02539537|DRUG|5-Fluoro-uracil|
224025653|NCT02539537|DRUG|Oxaliplatin|
224025654|NCT02539537|DRUG|Irinotecan|
224025655|NCT02539537|DRUG|L-folinic|
224133527|NCT03147274|BEHAVIORAL|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
224133528|NCT04657952|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block will be performed by a transnasal approach. Few drops of lidocaine 2% will be instilled into both anterior nares. Then a cotton-tipped applicator soaked in 4% lignocaine \& adrenaline (1 to 200000 will be passed through both the nares and the end of the applicator tip will be positioned just superior to the middle turbinate and anterior to the pterygopalatine fossa and sphenopalatine ganglion for 5 min with the patient in the supine position.
224133529|NCT04657952|DRUG|Medical Treatment|Patients will receive paracetamol 1 gm 6 hours daily intravenously for a day. If adequate pain relief will not be achieved, intravenous diclofenac 75 mg twice daily will be added.
224133530|NCT01518426|DEVICE|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
224025656|NCT04249596|DRUG|Tianeptine Sodium|At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
224025657|NCT06137014|DRUG|Fortified Oral Rehydration Therapy|Oral rehydration solution with reduced glucose and added amino acids.
224025658|NCT06137014|DIETARY_SUPPLEMENT|Standard of Care Oral Rehydration Therapy|Glucose-based oral rehydration therapy according to World Health Organization guidelines.
224025659|NCT06432894|COMBINATION_PRODUCT|Analgesia Nociception Index, remimazolam|"The purpose of this study is to determine the validity of ANI in patients undergoing surgery with remifentanil and remimazolam.~During this study, remimazolam infusion rate is determined by the pharmacopoeia.~Remifentanil infusion rate is determined based on the patient's vital signs, systemic status and pain levels. And remifentanil is administrated via targeted infusion control using the Minto model.~ANI scores, vital signs, remifentanil infusion rate are collected at predetermined time points according to the protocol from the start to the end of the surgery."
224025660|NCT04124393|PROCEDURE|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
224025661|NCT02669511|DRUG|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
224133531|NCT02656758|BEHAVIORAL|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
224133532|NCT05678192|DRUG|oral menopausal hormone therapy|Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
224297988|NCT01319773|DRUG|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
223409172|NCT05456178|OTHER|Electrostatic wipe|"The main objective will be to study the feasibility of the quantification of domestic fungal exposure with electrostatic wipe. The interval of environmental fungal exposure quantification values measured by conventional mycology and by NGS will be established, with analysis of the correlation between the quantification obtained by the two techniques.~For this, an electrostatic wipe will be deposited in the living room and another one in the bedroom for 12 weeks. The wipes will be analyzed by the mycology laboratory of the Croix Rousse hospital."
223409173|NCT06171087|DRUG|Domperidon|oral
224025662|NCT03960307|OTHER|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
224133533|NCT05678192|DRUG|transdermal menopausal hormone therapy|Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
224133534|NCT00000875|DRUG|Indinavir sulfate|
224133535|NCT00000875|DRUG|Diphenhydramine hydrochloride|
224133536|NCT00000875|DRUG|Lymphocytes, Activated|
224133537|NCT00000875|DRUG|Lamivudine|
224133538|NCT00000875|DRUG|Zidovudine|
224133539|NCT00000875|DRUG|Acetaminophen|
224133540|NCT00000875|DRUG|Aldesleukin|
224133541|NCT00580944|PROCEDURE|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
224297989|NCT03898713|DIAGNOSTIC_TEST|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
224297990|NCT02185313|OTHER|visual stimulus to follow|
224297991|NCT00063414|DRUG|Alicaforsen|
223409174|NCT06171087|DRUG|Placebo|oral tablet
223558509|NCT03304054|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
223558510|NCT03304054|DRUG|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
223558511|NCT05246839|BEHAVIORAL|Brief Video|Videos about colorectal cancer screening.
223558512|NCT05246839|BEHAVIORAL|Brief Video Plus|Videos about colorectal cancer screening and modalities.
223558513|NCT03556228|DRUG|VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)|Taken orally once daily
223738558|NCT02940301|BIOLOGICAL|Nivolumab|Given IV
224025663|NCT02913235|PROCEDURE|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
224025664|NCT04675021|DRUG|AZD6094 (Savolitinib) film coated tablets 600 mg|AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
224025665|NCT04675021|DRUG|[14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)|14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
224025666|NCT04675021|DRUG|[14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)|14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
224025667|NCT00953407|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224025668|NCT00953407|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224025669|NCT00953407|DEVICE|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224025670|NCT00953407|DEVICE|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224025671|NCT00953407|DEVICE|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224025672|NCT02268474|DEVICE|532nm KTP Laser vs 595nm Pulse Dye Laser|Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
224025673|NCT04267783|DIAGNOSTIC_TEST|Shear wave elastography|Investigate the feasibility of use of shear-wave elastography of the uterus during the third stage of labour and following placental delivery in order to predict uterine atony .
224025674|NCT03742284|DEVICE|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
224025675|NCT04454177|DEVICE|HUAWEI watch|HUAWEI Watch will be assigned to patients within 24 hours before TAVR. HUAWEI Watch GT series can continuously monitor and record multiple biometric parameters heart rate, step counts, sleep cycles and can detect and record the pulse oxygen saturation, as well as analyze QRS complexes and P waves after triggering.
224025676|NCT03435497|BEHAVIORAL|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
224025677|NCT02050230|BIOLOGICAL|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
224025678|NCT04265313|OTHER|Measurement of Quality of Life|Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
224025679|NCT05943223|DRUG|Piperacillin/tazobactam|Post-operative piperacillin/tazobactam 100 mg/kg IV q8h (to a maximum of 4.5 g IV q8h)
224025680|NCT05943223|DRUG|Normal saline|Post-operative normal saline 50 mL once daily
224297992|NCT05834166|OTHER|Upper back strengthening and Postural correction|The treatment protocol will involve upper back strengthening exercises and postural correction exercises 3 times a week for 10 to 15 minutes. Upper back strengthening will involve exercises with light-to-moderate load of free weights (body weight or resistance bands) or with a stability ball. Postural correction will involve maintaining the correct posture.
223738559|NCT03674242|DRUG|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
223738560|NCT03674242|DRUG|Gemcitabine|IV infusion 1000 mg/m2
223738561|NCT03674242|DRUG|Carboplatin|IV infusion AUC2
224025681|NCT05943223|DRUG|CefTRIAXone Injection|Post-operative ceftriaxone 50 mg/kg IV once daily (to a maximum of 2 g IV once daily)
224025682|NCT05943223|DRUG|Metronidazole Injection|Post-operative metronidazole 10 mg/kg IV q8h (to a maximum of 500 mg IV q8h)
224025683|NCT06124872|OTHER|Survey questionnaire|Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported
224025684|NCT06124872|OTHER|Key informant interview|Semi-structured interview with selected key informants
224025685|NCT01719926|DRUG|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
224025686|NCT04685850|OTHER|sequela evaluation|clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance
224025687|NCT05199220|OTHER|Questionnaire|Participant must complete a questionnaire about injury during crossfit practice
224025688|NCT04121195|DRUG|Dose escalation|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
224025689|NCT04662762|OTHER|Nursing intervention programme|educational information
224025690|NCT01466634|PROCEDURE|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
224025691|NCT05374161|BEHAVIORAL|Acceptance and Commitment Therapy|The ACT-based intervention will be delivered in a group format. Due to the COVID-19 pandemic and given that breast cancer patients are considered a vulnerable population, the intervention will be administered online through a GDPR compliant platform. The six, weekly, 90-minute treatment sessions (total of 9 hours) will be conducted in groups of approximately 8-10 participants and one therapist.
224297993|NCT05935566|OTHER|health questionnaire|Telephone interview with patient to verify medical history, including tonsillectomy and adenoidectomy.
224297994|NCT05161650|DIETARY_SUPPLEMENT|Ketone monoester (3-OHB)|Commercially available ketone supplement
224025692|NCT05374161|OTHER|Waitlist Control Group|Participants randomized to the WL condition will be asked to continue receiving the services they receive from anti-cancer associations (receiving care from nurses, or/and support from social workers, or/and physiotherapy or/and individual psychological support from licensed psychologists just like the women in the experimental condition).
224025693|NCT03933930|OTHER|Lactate-directed therapy|If the lactate level elevates, we transfuse pRBC to increase Hct\>30%. If Hct \>30%, dopamine infusion starts.
224025694|NCT03933930|OTHER|Goal-directed therapy|If SVV\>15%, transfuse lactate ringer/normal saline alternatively to keep SVV\<15%.
224025695|NCT02795429|DRUG|Spartalizumab|Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
224025696|NCT02795429|DRUG|Capmatinib|Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
224025697|NCT05782452|PROCEDURE|Ophthalmic examination|Facial photographs of the participants were obtained at the time of enrolment. Pre- and post-operative anterior eye segment photographs were obtained under diffuse, direct focal and retro illumination. Clinical data, including basic information, family history, and comprehensive pre- and post-operative ophthalmic examination findings, were recorded.
224025698|NCT05782452|GENETIC|Whole-exome sequencing|Performing whole-exome sequencing and bioinformatics analysis.
224025699|NCT00701779|DRUG|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
224025700|NCT03432715|BEHAVIORAL|Student Wellness Champions|"Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy."
224025701|NCT03432715|BEHAVIORAL|Teacher Wellness Champions|"Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes."
224025702|NCT04700722|DIAGNOSTIC_TEST|Skin Biopsy|Test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein, define sensitivity and specificity of skin biopsy detection of phosphorylated α-synuclein deposition for the diagnosis of synucleinopathies and to differentiate between the synucleinopathies by quantitative measurement of phosphorylated α-synuclein with skin biopsies.
224138933|NCT06099691|BEHAVIORAL|Qualitative Interviews|Participants will take part in one 90-minute interview (or two 45-minute interviews if preferred). The interview will have two sections. The first section will include discussion of what matters to participants. The second section will introduce PROMs which may be pertinent to measuring what matters. The participants will be helped to reflect on their relevance and usefulness to them.
223409175|NCT04476693|OTHER|Breakfast consumption|"Consumption of breakfast: The breakfast provided was designed based on the characteristics of an ideal breakfast outlined in Giovannini et al., (2008). The breakfast provided in the present study will include the following: all-bran cereals (Kellogg's), semi-skimmed milk (Tesco), Royal Gala Apple (Tesco) and Orange Juice from Concentrate (Tesco) containing the amount of carbohydrates usually consumed at breakfast in the UK (Reeves et al., 2013). The portion for each participant will contain 0.06 g of carbohydrate per kcal of measured RMR. As the portion size (20% of daily calorie intake) will be calculated based on individual RMR , no leftovers will be allowed."
223409176|NCT04476693|OTHER|Breakfast Omission|Omission of breakfast. Participants will consume water within 15 min, the individual volume of which will be calculated based on the liquid content of the breakfast \[milk (ml)+ orange juice (ml)\].
223409177|NCT03245528|DRUG|LJPC-501|angiotensin II
224025703|NCT02530853|OTHER|Laser acupuncture|Laser acupuncture
224025704|NCT02411500|DRUG|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
224025705|NCT00362453|BEHAVIORAL|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
224138934|NCT03490357|PROCEDURE|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
224138935|NCT03490357|PROCEDURE|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
224297995|NCT05161650|DIETARY_SUPPLEMENT|Placebo drink|Isocaloric placebo
223409178|NCT06564298|DRUG|Sintilimab|Sintilimab 200mg iv.gtt d1, every 21 days
223409179|NCT06564298|DRUG|Ramucirumab|Ramucirumab 10mg/kg iv.gtt d1, every 21 days
223409180|NCT06564298|DRUG|SOX/XELOX|SOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and S-1 40mg/m2 po bid d1-14, every 21 days XELOX: Oxaliplatin 130mg/m2 iv.gtt d1, every 21 days and Capecitabine 1000mg/m2 po bid d1-14, every 21 days
223409181|NCT01579786|PROCEDURE|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
223409182|NCT01964222|BEHAVIORAL|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
223738562|NCT06155500|BIOLOGICAL|OTQ923|There is no treatment allocation. Patients administered were OTQ923 while enrolled on the treatment protocol CADPT03A12101 (NCT04443907)
223738563|NCT06102304|DEVICE|Focused Extracorpeal Shock wave|Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus.
224133542|NCT06373172|OTHER|virtual simulation-based education program|"We used vSim® for Nursing - Nursing Medical-Surgical as the virtual simulation-based education program. Four modules were included: (a) acute myocardial infarction, (b) diabetes mellitus, (c) transfusion, and (4) asthma. Each module learning sessions was conducted based on scenarios, which consisted of five steps: Suggested reading, Pre-simulation quiz, vSim, Post-simulation quiz, and Guide reflection questions. For each module, the intervention was performed for two hours. The participants attended four module learning sessions and received eight hours of training. Debriefing using guided reflection questions were completed in the form of a team reflection, followed by an instructor-learner discussion and feedback for 20 minutes of each module."
224297996|NCT05662735|DEVICE|Mesh repair|Augmentation of hiatal hernia repair with TiMESH® reinforcement
223409183|NCT03883230|DIAGNOSTIC_TEST|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
223558514|NCT03947164|OTHER|biopsy|"For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination."
223558515|NCT04937400|OTHER|Daily screening for delirium|Each child will be screened twice daily for delirium throughout the transplant hospitalization
223558516|NCT04261400|BEHAVIORAL|MAMAACT|Improved communication regarding warning signs of pregnancy complications
223558517|NCT02954406|DRUG|TAK-659|TAK-659 immediate release tablet
224025706|NCT03187340|BEHAVIORAL|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
223409184|NCT06363331|BEHAVIORAL|Emotional Training|Emotional Training Therapy following the programme in the computer
223409185|NCT01972243|OTHER|no intervention|
223409186|NCT05684861|DRUG|Isotretinoin|systemic isotretinoin was given to all 90 patients , dose was prescribed according to weight for 3 months
223409187|NCT05684861|DIAGNOSTIC_TEST|ELISA Assays of Serum TWEAK.|: From each subject, 5mL of blood was collected into vacutainers before and after treatment with isotretinoin. The blood samples were centrifuged at 3000g for 10 min at a temperature of 4°C, then . Quantitative determinations for serum TWEAK were achieved using the corresponding commercially available ELISA kit supplied by the AssayMax
223558518|NCT02954406|DRUG|Bendamustine|Bendamustine intravenous infusion
223738564|NCT06102304|DEVICE|Sham Extracorpeal shock wave|(EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.
223558519|NCT02954406|DRUG|Rituximab|Rituximab intravenous infusion
224025707|NCT03187340|BEHAVIORAL|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
224025708|NCT04398420|DEVICE|TVERP|Transurethral Vapor Enucleation Resection of the prostate
224025709|NCT04398420|DEVICE|TURis|Transurethral Vapor Enucleation Resection of the prostate
224025710|NCT04398420|DEVICE|HoLEP|Transurethral Vapor Enucleation Resection of the prostate
224025711|NCT05624294|DRUG|CS0159|Tablets administered orally
224025712|NCT05624294|DRUG|Placebo|Tablets administered orally
224025713|NCT01640054|DRUG|Fostamatinib|Fostamatinib 100mg once daily
223558520|NCT02954406|DRUG|Gemcitabine|Gemcitabine intravenous infusion
223558521|NCT02954406|DRUG|Lenalidomide|Lenalidomide capsule
224025714|NCT00165087|DRUG|asparaginase (E. Coli)|
224025715|NCT00165087|DRUG|asparaginase (Erwina)|
224025716|NCT00165087|DRUG|dexrazoxane|
223558522|NCT02954406|DRUG|Ibrutinib|Ibrutinib capsule
223558523|NCT06597266|DEVICE|Smart template - designed prosthetic check socket|Evidence-generated trial prosthetic sockets are designed automatically by performing machine learning analysis of past socket designs that were produced by expert clinicians, the participant's residual limb size and shape descriptors and patient descriptors
223558524|NCT06597266|DEVICE|Clinician-designed prosthetic check socket|Active comparator prosthetic sockets are designed by expert prosthetists, bespoke to the participant, in a computer aided design environment (CAD)
223558525|NCT03162510|DRUG|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
223558526|NCT03162510|DRUG|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
223558527|NCT03162510|DRUG|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
223558528|NCT03162510|DRUG|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
224025717|NCT00165087|DRUG|doxorubicin|
224025718|NCT00165087|PROCEDURE|cranial radiation (once daily fractionation)|
224025719|NCT00165087|PROCEDURE|cranial radiation (twice-daily fractionation)|
224025720|NCT00165087|PROCEDURE|Intrathecal chemotherapy without radiation|
224025721|NCT04740008|DRUG|Low Nicotine Content Cigarettes|Low Nicotine Content Cigarettes 0.4 mg/g nicotine; 9 mg tar Other Name: Reduced Nicotine Content Cigarettes
224025722|NCT04740008|OTHER|Control message|Participants will read control message
224025723|NCT04740008|OTHER|Test message|Participants will read test message
224025724|NCT00029172|OTHER|case management|
224025725|NCT05220254|BEHAVIORAL|MindCotine's VR app|The MindCotine program would be a 6-week intervention to help users utilize mindfulness based skills, and involves virtual exposure therapy.
224025726|NCT04248985|OTHER|Pre-Imaging - an ultrasound technique of acquiring images|Technique involves finding low quality images of the heart during CPR prior to pausing CPR to acquire high quality images once CPR is paused.
224133543|NCT02665364|BIOLOGICAL|IFNα-Kinoid|
224297997|NCT05662735|PROCEDURE|Suture repair|Primary laparoscopic repair of the hiatal hernia using non-absorbable sutures
224025727|NCT02839837|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
224025728|NCT02839837|DEVICE|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
224025729|NCT04923854|OTHER|No intervention|No intervention
224025730|NCT00061451|DRUG|Pemetrexed|
224025731|NCT00061451|DRUG|Gemcitabine|
224025732|NCT03125525|DEVICE|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
224025733|NCT03345134|DRUG|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
224025734|NCT04950088|OTHER|Hand-held video game device|
224133544|NCT02665364|OTHER|Placebo|
224133545|NCT02665364|OTHER|ISA 51 VG|
224133546|NCT03888391|DEVICE|Active TNS|
224133547|NCT03736954|BEHAVIORAL|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
224133548|NCT06179615|OTHER|surface hardness test for denture teeth|surface hardness test of denture teeth at insertion then after 6 months of use
224133549|NCT06179615|OTHER|wear resistance of denture teeth measurement|2D, Vertical wear, 3D Volumetric wear were measured for denture teeth
224133550|NCT00423735|DRUG|Dasatinib|Given PO
224133551|NCT00423735|OTHER|Pharmacological Study|Correlative studies
224133552|NCT05839431|BEHAVIORAL|Virtual Reality for Youth Phobias|The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
224133553|NCT02040818|DRUG|tigecycline, N-acetylcysteine, heparin combination|
224133554|NCT02040818|DEVICE|guide-wire exchange|
223409188|NCT05711251|OTHER|Physical Activity in Health Promotion|During the term, the participants in the study group took lessons on many subjects, from the benefits of physical activity to suggestions to increase physical activity at work and in daily life.
223409189|NCT05930626|OTHER|Biomarkers of acrylamide, glycidol, POPs, PFAS|These are food contaminants (acrylamide, glycidol) and environmental pollutants (POPs, PFAS). Assess the associations between biomarkers of acrylamide and glycidol exposure and disease outcomes in a case-cohort study based on two prospective cohorts with biobanks. The investigators also aim to assess the exposure-affected OMICS signatures and molecular pathways underlying disease development (specifically cardiovascular diseases such as myocardial infarction and stroke and cancer such as breast-, endometrial and colorectal cancer) for these exposures along with POPs and PFAS using a prospective cohort study utilizing and integrating various 'OMICs' technologies.
223409190|NCT06461936|DRUG|Sintilimab|Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
223409191|NCT06461936|DRUG|Lenvatinib|Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.
223409192|NCT00942890|DEVICE|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
223558529|NCT02831738|DIETARY_SUPPLEMENT|Polydextrose|Polydextrose 12 g
223558530|NCT02831738|DIETARY_SUPPLEMENT|Control Treatment|no polydextrose
224133555|NCT00446485|DRUG|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
224133556|NCT00446485|DRUG|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
224133557|NCT00446485|DRUG|placebo|placebo during 6 months
224133558|NCT00654784|DRUG|idebenone|idebenone 450 mg/day (150 mg three times a day)
224133559|NCT00654784|DRUG|placebo|
223558531|NCT03392389|BIOLOGICAL|mRNA-1653|Escalating dose levels
223558532|NCT03392389|OTHER|Placebo|Saline
223558533|NCT00137137|PROCEDURE|Placement of the mini-screw|
224133560|NCT04996472|BEHAVIORAL|Sensitivity to phonological rules: Adults|Assess whether adults are sensitive to different phonological patterns that are predicted to align with development of morphosyntax or the lexicon.
224133561|NCT04996472|BEHAVIORAL|Sensitivity to semantic category cues: Adults|Assess whether adults show improved learning of OR or family resemblance rules when a semantic category cue is used.
224133562|NCT02864940|DEVICE|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
224133563|NCT02864940|DEVICE|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
224133564|NCT02581111|DRUG|Naloxone|Naloxone 8-mg IV bolus
224133565|NCT02581111|DRUG|Normal saline|
224133566|NCT01722487|DRUG|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
224138936|NCT05235217|DRUG|Test product (T) 40 mg Hard Gelatin Capsules|Hard Gelatin Capsules products containing 40 mg Esomeprazole
224025735|NCT05694104|OTHER|Malnutrition|For the diagnosis of malnutrition, we adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
224025736|NCT01557283|OTHER|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
224025737|NCT04962802|BEHAVIORAL|Manhood 2.0|Manhood 2.0 engages young men in questioning, challenging, and transforming harmful gender norms, with the goal of reducing intimate partner and sexual violence and unintended teen pregnancy. Manhood 2.0 is a male-only group-level intervention, based on social cognitive theory, social norm theory, theory of gender and power, and the theory of reasoned action. Activities include group discussion, role playing, knowledge sharing, and skill-building; their purpose is to challenge young men to think critically about social expectations and restrictive norms, engage in dialogue about these gender norms, and then assess the way rigid norms affect their attitudes and behaviors toward key issues, including intimate relationships, gender-based violence, substance abuse, sexually transmitted infections, and early pregnancy. Sessions are two hours long and occur once a week for seven weeks.
224025738|NCT04962802|BEHAVIORAL|Post-High School Readiness|Post-High School Readiness program helps young men prepare for life after high school. This includes helping them prepare resumes, learning how to apply to jobs or colleges, providing interview prep, and other life skills. It is a male-only group-level program that includes discussion, feedback, knowledge sharing, and skill-building; their purpose is to prepare young men for life after high school. Sessions are two hours long and occur once a week for seven weeks.
224025739|NCT03644251|OTHER|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
224025740|NCT05156632|BIOLOGICAL|Medium-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection.
224025741|NCT05156632|BIOLOGICAL|High-dosage COVID-19 Vaccine,Inactivated|The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
224025742|NCT05156632|BIOLOGICAL|Placebo-comparator group|The composition is aluminium hydroxide with no antigen ,0 SU/0.5 mL,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
224025743|NCT04820777|OTHER|perturbation training|external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
224025744|NCT04820777|OTHER|Conventional' balance training|Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
224025745|NCT03645057|DRUG|Crisaborole|This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
224025746|NCT03645057|DRUG|Tacrolimus 0.03% Ointment|This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
224133567|NCT01722487|DRUG|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
224133568|NCT01450046|DRUG|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
224133569|NCT00469404|DRUG|Buprenorphine|
224133570|NCT00568880|DRUG|bortezomib|bortezomib 1.0-1.3mg/m2 IV
224133571|NCT00568880|DRUG|hydroxychloroquine|hydroxychloroquine 200 mg pill
224133572|NCT00579501|DRUG|Trabectedin|Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
224133573|NCT00579501|DRUG|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
224133574|NCT01549743|DRUG|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
223409193|NCT00942890|BEHAVIORAL|TMARP standard of care|The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
223409194|NCT03451591|DRUG|Isosorbide Mononitrate XL (ISMN)|Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
223409195|NCT03451591|DRUG|Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models.
223558534|NCT05402176|OTHER|Whole Lung Lavage|Whole Lung Lavage (WLL) is performed as standard of care. Outcome following WLL is observed.
224133575|NCT01549743|DRUG|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
224133576|NCT01549743|DRUG|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
224133577|NCT04818814|BEHAVIORAL|Mindfulness Meditation App|Listening to audio-guided meditation sessions using a mobile app.
223409196|NCT03451591|DRUG|ISMN XL and Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models. Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
223409197|NCT03451591|OTHER|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol administered for the entire duration of the study.
224025747|NCT04980508|DIAGNOSTIC_TEST|corpus cavernosum electromyography|Cc-EMG was performed by using the cc-EMG module of Ellipse 4 device (Andromeda, Germany), which comprises of a 2-channel electromyography amplifier with a row sampling rate of 16 kHz, filtered sampling rate of 166.67 Hz and a band width of 0.5-30 Hz with the speed of the thermo-writer paper set at 5 mm/s. Measurements of the electrical activity of the corpus cavernosum (EACC) were done for 10 minutes using coaxial needle electrodes during the flaccid state and after intracavernous papaverine (60 mg) injection.
224025748|NCT01873495|DRUG|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
224025749|NCT05486546|PROCEDURE|Contoura with Phorcides|Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
224025750|NCT05486546|DEVICE|WaveLight Wavefront Optimized|Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
224025751|NCT02366377|DRUG|SHR3824|
224025752|NCT02366377|DRUG|Placebo|
224025753|NCT02366377|DRUG|Metformin|
224025754|NCT01206777|DRUG|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
224025755|NCT01315223|OTHER|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
224025756|NCT01416688|PROCEDURE|assessment of therapy complications|Will be given by questionnaire
224025757|NCT01416688|PROCEDURE|psychosocial assessment and care|Will be given by questionnaire
224025758|NCT01416688|PROCEDURE|quality-of-life assessment|Will be given by questionnaire
224025759|NCT00002023|DRUG|Zidovudine|
224025760|NCT02601196|DRUG|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle."
224025761|NCT03175965|DEVICE|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
224025762|NCT02080221|DRUG|FOLFOXA|
224025763|NCT02047643|DEVICE|Computer algorithm to initiate pump suspension|If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
223409198|NCT01022320|PROCEDURE|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
223409199|NCT03928587|DIETARY_SUPPLEMENT|2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.|One lozenge once daily for 12 months
223409200|NCT03928587|DIETARY_SUPPLEMENT|Placebo|Placebo once daily for 12 months
223409201|NCT06299384|OTHER|LyssnCrisis|LyssnCrisis is an AI-based coding and feedback tool for implementation in crisis counseling settings, training counselors (call-takers) in suicide risk assessment skills.
223409202|NCT00006483|BIOLOGICAL|sargramostim|
224025764|NCT00923533|DRUG|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
224025765|NCT00923533|DRUG|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
224025766|NCT01432717|BIOLOGICAL|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
224025767|NCT01432717|OTHER|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
224025768|NCT05874115|OTHER|liquid biopsy|liquid biopsy
224025769|NCT04187053|PROCEDURE|Conventional mechanical therapy|Both experimental and sham arms will receive the Conventional mechanical therapy
224025770|NCT04187053|DRUG|Saline|Sham group will receive saline as a sham for methylene blue
224025771|NCT04187053|DRUG|Methylene Blue|Experimental arm will receive methylene blue
224025772|NCT04187053|DEVICE|Light emitting laser|Experimental arm will receive Light emitting laser
224025773|NCT04187053|DEVICE|Non-light emitting laser|Sham group will receive Non-light emitting laser
224025774|NCT05390983|PROCEDURE|Carotid endarterectomy with stent removal|Standard carotid endarterectomy will be extended with the stent removal
224025775|NCT06283004|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
224025776|NCT06283004|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
224025777|NCT06283004|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
224025778|NCT04032626|DRUG|Lenalidomide 10 mg|Lenalid
224025779|NCT04032626|DRUG|Placebo|Placebo
224025780|NCT03082742|DRUG|Hydrochlorothiazide|
224025781|NCT03082742|DRUG|Furosemide|
224025782|NCT02445001|PROCEDURE|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
224025783|NCT00675090|DRUG|GSK239512|GSK239512 oral tablets once a day
224025784|NCT00675090|DRUG|Placebo|Placebo tablets to match once a day
224025785|NCT00699894|DRUG|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
224025786|NCT00699894|DRUG|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
223409203|NCT03728348|DIAGNOSTIC_TEST|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
223409204|NCT03728348|PROCEDURE|Colonoscopy|Subjects will undergo a screening colonoscopy.
224025787|NCT04684602|BIOLOGICAL|PrimePro™/ PrimeMSK™|Injection via condition specific route of administration.
224025788|NCT00081042|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
224025789|NCT04125030|OTHER|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
224025790|NCT01648881|RADIATION|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
224025791|NCT03561012|BEHAVIORAL|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
224025792|NCT03561012|OTHER|Control Condition|Standard of care
224025793|NCT00858884|OTHER|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
224025794|NCT00295594|DRUG|tacrolimus|Immunosuppression
224025795|NCT00842985|DRUG|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
224025796|NCT06067568|DRUG|Lutikizumab Dose A|Injection; subcutaneous (SC)
224025797|NCT06067568|DRUG|Lutikizumab Dose B|Injection; subcutaneous (SC)
224025798|NCT01548560|DRUG|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
224025799|NCT01548560|DRUG|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
224025800|NCT01742611|DRUG|ASP1585|oral
224025801|NCT04895683|BEHAVIORAL|Text message content|Behavioural science-informed text messages aimed at improving COVID-19 vaccination uptake.
224133578|NCT04818814|BEHAVIORAL|Engagement and Distraction App|Listening to engaging and distracting videos of interest to the participant using a mobile app.
224133579|NCT03191006|DEVICE|MEI BIN insoles|insoles
224133580|NCT01370057|DEVICE|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
224133581|NCT03364673|OTHER|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
224133582|NCT03364673|OTHER|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
223409205|NCT00573274|DEVICE|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
223409206|NCT02811146|DEVICE|Bilevel Positive Pressure Airway|Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
223409207|NCT02811146|OTHER|Heart rehabilitation|Heart rehabilitation, for 12 weeks, 3 times a week
223409208|NCT04971135|DRUG|SAN711|SAN711 liquid formulation
223409209|NCT04971135|OTHER|Placebo|Matching placebo
223409210|NCT01644708|BEHAVIORAL|Self empowerment|"1\. Group meeting, introducing the method and the assessment tools~1. Self-empowerment,~2. Handing over the journal,~3. Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
223409211|NCT00890370|PROCEDURE|Airway clearance technique|
223409212|NCT05383365|OTHER|Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise|"The treatment includes Suboccipital MFR in the supine position.The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences.The therapist will develop a line of tension through the suboccipital tissues by supinating the forearms and pulling apart two hands from each other;Then, for the second level in the first position of hands,pressure is applied to the anterior and superior direction.The pressure is held and increased until the therapist feels the decrease of muscle tone.These techniques last 10 minutes.~Another intervention in this group is the sham DNF exercise with a Pressure Biofeedback Unit(PBU).Considering that minimum detective change with PBU is 15 mmHg; After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg,the participant will increase the pressure to 12 mmHg by nodding action."
224025802|NCT01147237|DEVICE|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
224025803|NCT02995577|OTHER|Feeding tolerant|
224025804|NCT02995577|OTHER|Feeding intolerant|
224025805|NCT02995577|OTHER|Necrotizing enterocolitis|
224025806|NCT05237661|DIETARY_SUPPLEMENT|Moon Balance|Moon Balance is a blend of 6 food ingredients
224025807|NCT05342909|OTHER|5x a week BFR training group|This group will perform the two exercises 5x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
224025808|NCT05342909|OTHER|2x a week BFR training group|This group will perform the two exercises 2x a week with blood flow restriction, set to 80% of limb occlusion pressure, applied to the dominant thigh.
224025809|NCT01765166|BEHAVIORAL|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
224025810|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 25 mg/kg on day +3 and +4
224025811|NCT05780554|DRUG|Cyclophosphamide|Post transplant cyclophosphamide 50 mg/kg on day +3 and +4
224025812|NCT01224795|DRUG|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to \< 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
224133583|NCT02232087|DRUG|Salmeterol|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
224025813|NCT01224795|DRUG|Placebo Comparator|Placebo Peramivir, administered intravenously.
224025814|NCT03166826|OTHER|Modified Apgar Scoring System|Modified APGAR scoring system
224025815|NCT04532138|DEVICE|VS-CMAC Rigid Fiberoptic Stylet|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.
224025816|NCT04532138|DEVICE|C-MAC Video laryngoscope awake intubation|patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
224025817|NCT03355170|COMBINATION_PRODUCT|Lansoprazole/Domperidone|Experimental
224025818|NCT03355170|DRUG|Lansoprazole|Active comparator
224133584|NCT02232087|DRUG|fluticasone propionate|A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
224133585|NCT02446353|DRUG|Apetrol ES / Megace|Sequences of administered drugs
223409213|NCT05383365|OTHER|Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)|"The treatments include the DNF exercise with a PBU. The treatment is performed in the supine position and the airbag is placed under the occiput bone and is inflated to a base pressure of 20 mmHg. The participant will increase and hold the pressure to a special point by nodding action. The exercise is repeated for 3 sets, in each set 2 mm Hg is added to the pressure. The pressure will be increased from 22 to 32 mm Hg during 4-week of treatment, and each goal is held for 10 seconds and repeated 10 times. There will be 5 sec of rest between each repetition and 2 min of rest between each set.~Another intervention in this group is sham MFR. The therapist's hands will be placed only inferior to the occipital bone and a superficial touch is applied without any upward or lateral pressure. sham treatment in this group, like the opposite group, lasts 10 minutes."
223409214|NCT06665321|BEHAVIORAL|Internet-based psychodynamic therapy (IPDT)|The intervention is 9 week long with weekly modules that the participants work with while receiving weekly support from an assigned therapist.
223409215|NCT03346681|DRUG|N-acetyl cysteine|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
223409216|NCT04922255|DEVICE|Reusable Underwear|Reusable Underwear are similarly available for purchase online and are absorbent underwear for bladder leak protection
223409217|NCT04922255|DEVICE|Disposable urethral support|The disposable urethral support is a tampon-like device that is available over the counter to help women with urinary incontinence (UI)
223409218|NCT04922255|BEHAVIORAL|Pelvic floor physical therapy|Experienced pelvic health physical therapists (at University of Pittsburgh) will complete two visits one week apart.
223409219|NCT00683124|DRUG|Losartan and nebivolol|"Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations"
223409220|NCT00683124|DRUG|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
224025819|NCT03765320|PROCEDURE|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
224025820|NCT03765320|PROCEDURE|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
224025821|NCT01549054|DRUG|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
224025822|NCT01549054|DRUG|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
224025823|NCT01549054|DRUG|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
224025824|NCT01549054|DRUG|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
224133586|NCT06296433|OTHER|VR rehabilitation|VR software application containing education, exergames, therapeutic exercises and relaxation sections.
224133587|NCT06296433|OTHER|VR video application|VR software application that plays 2D nature videos
224138937|NCT05235217|DRUG|Reference product (R) 40 mg Hard Gelatin Capsules|Reference product (R) 40 mg Hard Gelatin Capsules
224138938|NCT01451034|PROCEDURE|WHYX cancer group|WHYX cancer diagnosed by pathologic report
224025825|NCT03794167|DRUG|Busulfan|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
224025826|NCT03794167|DRUG|Cyclophosphamide|cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
224025827|NCT03794167|DRUG|Etoposide|etoposide 400mg/m2 day i.v. on days -5 and -4
224025828|NCT03794167|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on days -3 and -2
224025829|NCT00622349|DRUG|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
224025830|NCT00622349|DRUG|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
224025831|NCT00622349|DRUG|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
224025832|NCT05638997|OTHER|Instrument assisted manipulation + Core exercises|The effect of Instrument assisted manipulation on chronic non-spesific low back pain
224025833|NCT05638997|OTHER|Mulligan mobilization with movement + Core exercises|The effect of Mulligan mobilization with movement on chronic non-spesific low back pain
224025834|NCT05638997|OTHER|Core exercises|The effect of core exercises on chronic non-spesific low back pain
224025835|NCT02850367|DIETARY_SUPPLEMENT|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
224025836|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
224025837|NCT02850367|DIETARY_SUPPLEMENT|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
223409221|NCT00683124|DRUG|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
223409222|NCT02677922|DRUG|AG-120|Specified dose on specified days
223409223|NCT02677922|DRUG|Azacitidine|Specified dose on specified days
223409224|NCT02677922|DRUG|AG-221|Specified dose on specified days
223409225|NCT05283135|DRUG|risankizumab|Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.
223409226|NCT05310071|DRUG|Aducanumab|Administered as specified in the treatment arm.
223409227|NCT05310071|DRUG|Placebo|Administered as specified in the treatment arm.
223409228|NCT00439985|BEHAVIORAL|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
223409229|NCT01012726|PROCEDURE|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
223409230|NCT03261414|PROCEDURE|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
223409231|NCT03261414|PROCEDURE|usual care|Standard care before induction of anesthesia
224025838|NCT02850367|DIETARY_SUPPLEMENT|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
224025839|NCT02850367|BIOLOGICAL|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
224025840|NCT02850367|BIOLOGICAL|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
224025841|NCT06453785|DEVICE|Promaxo portable MRI|"The Promaxo portable MRI is an FDA cleared MRI device for MR-guided procedures. It uses a novel truly open MRI with an unobstructed field of view and central aperture for robotic guided intervention and has a limited footprint allowing it to be places in a standard operating theatre or large clinic room. The strength of magnet is also low enough that special precautions and equipment are not to take biopsies."
223409232|NCT03752034|OTHER|Muscle Fiber Fragments (MFFs)|During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
223409233|NCT00266292|BEHAVIORAL|Fish oil (Bio-Marine, Pharma Nord)|
223409234|NCT00266292|BEHAVIORAL|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
223409235|NCT06576336|PROCEDURE|laparoscopic adrenalectomy|laparoscopic adrenalectomy
223409236|NCT05816629|DIAGNOSTIC_TEST|Multiparameter ultrasound based-AI|Multiparameter ultrasound based-AI for the diagnosis of thyroid nodules
223409237|NCT02570789|DRUG|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
223409238|NCT02001311|DRUG|Chlorhexidine gluconate|
224025842|NCT01166867|DEVICE|Photo-plethysmography monitoring|monitoring vital sign in infant
224025843|NCT01562457|DRUG|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
224025844|NCT01000636|PROCEDURE|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
224025845|NCT01734174|PROCEDURE|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
224025846|NCT01734174|PROCEDURE|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
224025847|NCT01734174|PROCEDURE|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
224025848|NCT02936167|BIOLOGICAL|Ringer Lactate|
223409239|NCT04205643|BIOLOGICAL|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
223409240|NCT04205643|OTHER|Placebo SC|Subcutaneous injection of Placebo SC
223409241|NCT01788826|PROCEDURE|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
223409242|NCT01788826|PROCEDURE|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
223409243|NCT03337087|DRUG|Fluorouracil|Given IV
223409244|NCT03337087|DRUG|Irinotecan Sucrosofate|Given IV
223409245|NCT03337087|OTHER|Laboratory Biomarker Analysis|Correlative studies
223409246|NCT03337087|DRUG|Leucovorin Calcium|Given IV
223409247|NCT03337087|DRUG|Rucaparib|Given PO
223409248|NCT05877118|BEHAVIORAL|Enhanced Overdose Education (EOE)|"EOE was adapted by Co-I Dr. Monique Miley at HHC's premier addiction hospital-The Rushford Center. It follows the guidelines set by Co-PI Jonathan Craig Allen when working with opioid patients reluctant to obtain naloxone:~* Express confidence in naloxone~* Provide a clear statement about suitability (You are an excellent candidate for naloxone)~* Begin discussion using presumptive language (You must be ready for an overdose)"
223409249|NCT05877118|BEHAVIORAL|Standard education|Written instructions that accompany a kit prescription in many EDs throughout the country.
223409250|NCT02707484|DRUG|Thalidomide (100mg)|Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
223409251|NCT02707484|DRUG|Thalidomide (50mg)|Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
223558535|NCT00782171|DEVICE|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
223409252|NCT02707484|DRUG|placebo|Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
223558536|NCT00005636|DRUG|cisplatin|
224025849|NCT02936167|BIOLOGICAL|Plasmalyte|
224025850|NCT03258164|BIOLOGICAL|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
224025851|NCT03258164|BIOLOGICAL|Standard Lipofilling|Non-ASC enriched fat grafts
223409253|NCT04249102|DEVICE|Guardian Connect, Medtronic|Guardian Connect is real-time continuous glucose sensor systems which provide glucose information updated every 5 minutes
223409254|NCT04249102|DEVICE|Abbott Diabetes Care|Abbott Diabetes Care is a Flash Glucose Monitoring system that provides up to 8 hours of retrospective continuous glucose monitoring data to users when the monitor is waved in proximity with the sensor.
223409255|NCT02231567|OTHER|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
224025852|NCT04509115|DRUG|Short-acting opioid prescription for acute pain|Patients not currently using opioids who receive a new short-acting opioid prescription as part of routine care for acute pain will be recruited and followed prospectively for 180 days.
224025853|NCT04457167|DEVICE|Robot-assisted|robot-assisted surgery
224025854|NCT04457167|PROCEDURE|Not robot-assisted surgery|Not robot-assisted surgery
224138939|NCT02370017|BIOLOGICAL|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
224138940|NCT02365584|DRUG|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
223409256|NCT02231567|OTHER|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
223409257|NCT01871844|DRUG|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
223409258|NCT01871844|DRUG|octreotide 50 mcg tid|
223409259|NCT01871844|DRUG|Placebo|
223409260|NCT05847374|DEVICE|Polysomnography|Sleep architecture will be recorded using portable PSG (Prodigy) from 24:00 to 8:00. Pulse oximetry (SpO2) and heart rate were recorded continuously during the PSG. Simultaneously, the waveforms from the ventilator were recorded using Bettercare (R) system.
223558537|NCT00005636|DRUG|pemetrexed disodium|
223558538|NCT04618042|DRUG|FX06|FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
223558539|NCT04618042|DRUG|Placebo of FX06|Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
223558540|NCT05440669|BEHAVIORAL|white noise|white noise will reduce pain and stress in nasal cpap application
223558541|NCT00002955|DRUG|fluorouracil|
223558542|NCT00002955|DRUG|leucovorin calcium|
223558543|NCT00002955|DRUG|trimetrexate glucuronate|
223558544|NCT06762613|COMBINATION_PRODUCT|Generative AI Based Puncture Surgery Navigation System|Participants will receive percutaneous lung puncture under the guidance of GPS.
224138941|NCT01557218|OTHER|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
224138942|NCT01557218|OTHER|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
224138943|NCT01557218|OTHER|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
224138944|NCT01557218|OTHER|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
224138945|NCT01557218|OTHER|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
224025855|NCT02701348|OTHER|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
223409261|NCT02921724|DEVICE|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~1. Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~2. Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
223409262|NCT00018187|DRUG|Bupropion|
223409263|NCT00018187|DRUG|Mecamylamine|
223409264|NCT00018187|DRUG|Nicotine Patch|
223409265|NCT05905315|DRUG|Paclitaxel and Carboplatin|Paclitaxel 175 mg/m2, followed by carboplatin 5 area under the curve (AUC). This will be administered in a 3-weekly scheme.
223409266|NCT05905315|COMBINATION_PRODUCT|Chemoradiation|According to standard treatment.
223409267|NCT00865878|DRUG|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
223409268|NCT00865878|OTHER|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
223409269|NCT03549728|DRUG|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
224025856|NCT02701348|DRUG|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
224025857|NCT02701348|PROCEDURE|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
224025858|NCT02701348|OTHER|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
224133588|NCT06261099|OTHER|control + working group|Upper extremity positioning, overhead activity training, reaching activities, weight transfer exercises, proprioceptive exercises, and daily living activities training will be applied to this group using the telerehabilitation method, which was applied to in 5 sessions per week for 6 weeks.
224133589|NCT03025217|BEHAVIORAL|Total Lifestyle Coaching (TLC)|
224133590|NCT01897181|DEVICE|Hearing aids|Using hearing aids for 12 months
224133591|NCT04585217|PROCEDURE|Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)|"Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality."
223409270|NCT03549728|PROCEDURE|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
223409271|NCT03515811|DEVICE|Signia™ Stapling System|Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
223409272|NCT06349226|OTHER|cell isolation from intervertebral disc tissue and biomarker investigation|metabolomic, cellular and molecular analysis on intervertebral disc derived cells and investigation of tissue neuroinflammatory and pain-related biomarkers
223409273|NCT05107492|DRUG|450mg|following a single subcutaneous dose of PF-06480605 450 mg
223558545|NCT06762613|DEVICE|Cone beam CT|Participants will receive percutaneous lung puncture under the guidance of cone beam CT.
224025859|NCT03451162|DRUG|DHES0815A|DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
224025860|NCT01882933|DRUG|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
224133592|NCT00620971|DRUG|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
224133593|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
224133594|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
224133595|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
224133596|NCT00620971|DRUG|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
224133597|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
223409274|NCT05107492|DRUG|150mg|following a single subcutaneous dose of PF-06480605 150 mg
223409275|NCT05107492|DRUG|Placebo|following a single subcutaneous dose of placebo
223409276|NCT03428243|DEVICE|truSculpt|Device comparison of Circumference measurement at Baseline vs 18 months post treatment
223558546|NCT02310854|PROCEDURE|ACL Repair|augmented suture of acute ACL rupture (\<3 weeks after injury)
224133598|NCT00620971|DRUG|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
223558547|NCT02310854|PROCEDURE|ACL reconstruction|reconstruction hamstring autograft
224133599|NCT00620971|DRUG|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
223558548|NCT06007677|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous injection.
224025861|NCT01882933|PROCEDURE|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
223409277|NCT04339062|DRUG|Cemiplimab|Cemiplimab: via IV, flat predetermined dosage every 21 days.
224025862|NCT02598817|OTHER|Standard Infant Formula|Standard Infant Formula containing High Sn-2
224025863|NCT06027164|DEVICE|Portable Ultrasound System|EchoNous KOSMOS
224025864|NCT04088773|DIAGNOSTIC_TEST|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
224025865|NCT04088773|DIAGNOSTIC_TEST|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
224025866|NCT04088773|DIAGNOSTIC_TEST|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
224025867|NCT03305731|BEHAVIORAL|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
224025868|NCT03658668|DEVICE|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (\<4 mA) to induce changes in cortical excitability.
223409278|NCT04339062|DRUG|Everolimus|Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
223409279|NCT04339062|DRUG|Sirolimus|Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab
223409280|NCT04339062|DRUG|Prednisone|40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab
223409281|NCT02748642|DRUG|BITS7201A|BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
223409282|NCT02748642|DRUG|Placebo|Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
223409283|NCT03117153|OTHER|DA-5502 liquid toothpaste|6 weeks study, brush three times daily, liquid toothpaste
223409284|NCT03117153|OTHER|placebo|same flavor solution, brush three times daily
223409285|NCT04407182|DIETARY_SUPPLEMENT|Viusid and Asbrip|"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.~Treatment duration: 21 days."
223409286|NCT01514981|DRUG|AMG 761|Single dose of AMG 761 on study day 1.
223409287|NCT01514981|DRUG|Placebo|Single dose of placebo on study day 1.
223409288|NCT06388460|OTHER|Asthma Link|Providers enroll patients to receive school-supervised asthma therapy and an asthma educational workbook
223409289|NCT06388460|OTHER|Enhanced Usual Care|Providers enroll patients to receive an asthma educational workbook
223558549|NCT06735872|PROCEDURE|Non invasive ventilation (NIV)|"This group will receive a unique 10-minute session of non invasive ventilation with standard parameters directly on the CT table. The treatment will be delivered via a naso-buccal mask.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety."
223558550|NCT06735872|PROCEDURE|High flow oxygen therapy (HFO)|"This group will receive a unique 10-minute session of high flow oxygen directly on the CT table. The treatment will be delivered via a nasal cannula.~Prior to treatment, each participant will have a planned standard care chest CT.~During the session, a senior intensivist watching for participant's comfort and safety."
223558551|NCT04829825|DIAGNOSTIC_TEST|18F-GP1 PET/MR|Patients will receive 1-3 18F-GP1 PET/MR
223558552|NCT04874220|DEVICE|Deep Brain Stimulation|Deep brain stimulation will be used
224025869|NCT03658668|DEVICE|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
223409290|NCT02523755|DRUG|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
223409291|NCT02523755|DRUG|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
223558553|NCT02383888|DRUG|BI 425809|
223558554|NCT02383888|DRUG|BI 425809|
223558555|NCT02383888|DRUG|Placebo|
223558556|NCT02383888|DRUG|BI 425809|
223558557|NCT03793426|BIOLOGICAL|Fibryga|Human plasma-derived fibrinogen concentrate
223558558|NCT04545164|DIAGNOSTIC_TEST|CAD4TB|CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
223558559|NCT04545164|DIAGNOSTIC_TEST|FujiLAM|Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
223558560|NCT05765604|BIOLOGICAL|Recombinant COVID-19 variant vaccine(Sf9 cell)|IM
223558561|NCT05765604|BIOLOGICAL|Recombinant COVID-19 vaccine(CHO cell)|IM
224025870|NCT03658668|OTHER|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
224025871|NCT01532726|DRUG|ESL|ESL 400/800/1200 mg tablets once daily
224133600|NCT00620971|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
224133601|NCT01165593|OTHER|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
224133602|NCT04069156|DEVICE|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
224133603|NCT04069156|DRUG|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
224133604|NCT04069156|DRUG|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
224133605|NCT04875338|DRUG|plate-rich plasma|1ml prp (plate-rich plasma to be prepared with the blood taken from the patient on the day of injection), , while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
223409292|NCT04710654|OTHER|connective tissue manipulation|Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
223409293|NCT04710654|OTHER|Interferential current stimulation (100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 100 Hz frequency three days a week, for four weeks.
223558562|NCT05532722|DRUG|ABC008|Given subcutaneous injection
223558563|NCT04812028|DRUG|Magnesium sulfate|Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
224025872|NCT05353673|DRUG|Sitagliptin|Oral Sitagliptin (100mg/m2 daily) for 12 weeks. DPP4 inhibitors have anti-inflammatory, immunomodulatory, and hematopoietic effects in addition to their glycemic regulatory effects. In vivo experiments found that endogenous DPP-4 inhibits megakaryopoiesis, and knockout or inhibition of DPP4 in vivo can enhance the recovery of hematopoietic function after stress. The loss of DPP-4 activity in DPP-4-/-mice mice resulted in an expansion of the megakaryocyte progenitor population in vivo, the recovery time of platelets was shorter than in normal mice after platelet depletion with anti-mouse CD41 antibody. Compared with ordinary mice, the number of platelets increased, which provides a theoretical basis for the use of DPP-4 inhibitors in patients with ITP, and has potential clinical significance.
224025873|NCT05353673|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
224025874|NCT04631172|OTHER|Coronavirus Anxiety Scale , COVID-19 Phobia Scale|Using two questionnaire completed in face-to-face interviews Participants were asked the Coronavirus Anxiety Scale (CAS), and the COVID-19 Phobia Scale (C19P-S).
224025875|NCT06279065|DIAGNOSTIC_TEST|Analysis of blood and microbiome samples (stool, oral lavage)|Analysis of blood and microbiome samples (stool, oral lavage) especially composition of the gut microbiome and potential interaction with immune cells
224025876|NCT06389253|OTHER|Histological Analysis|For the study, a minimal part of the periarticular tissue, specifically the sinus tarsi juxta-articular fatty tissue, that is normally dissected and discarded during the surgical operation of insertion and removal of the calcaneo-stop screw, will be analyzed
224025877|NCT03522480|DEVICE|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
224025878|NCT03522480|OTHER|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
224025879|NCT00648817|DRUG|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
224025880|NCT00648817|DRUG|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
224025881|NCT02871310|DIETARY_SUPPLEMENT|IQP-AS-118|1 tablet in the morning
224025882|NCT02871310|DIETARY_SUPPLEMENT|Placebo|1 tablet in the morning
223738565|NCT01329640|DEVICE|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
223738566|NCT00488163|DRUG|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
224025883|NCT04564651|OTHER|platelet transfusion|when the ADP inhibition \>70%, give one unit platelet tansfusion
224025884|NCT03418948|DEVICE|CC followed by EC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
224025885|NCT03418948|DEVICE|EC followed by CC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
224025886|NCT03418948|DEVICE|2x EC|EC = endocuff assisted colonoscopy
224025887|NCT03418948|DEVICE|2x CC|CC = conventional colonoscopy
224025888|NCT02051270|OTHER|Descriptive study|More than 65 years old elders
224025889|NCT04756960|DRUG|CHF6001|4 inhalations of CHF6001 800 µg/20 mg NEXThaler® dry-powder inhaler (DPI), (total dose of 3200µg) co-administered with an intravenous microdose (18.5µg (18.5 kBq)) of \[14\^C\]-labelled CHF6001
224025890|NCT03672656|DEVICE|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
224025891|NCT03672656|DEVICE|conventional laser|conventional laser multiple-session treatment
224025892|NCT02720614|RADIATION|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
224025893|NCT06502873|PROCEDURE|biological samples collection|Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
224025894|NCT06084156|DRUG|HSK7653|Part 1: Day 1 to Day 4, not take; Part 2: Day 6 - Take HSK7653 35 mg; HSK7653 25 mg on day 13, day 20, day 27, and day 34; Part 3: Day 41 - Take HSK7653 25 mg
224025895|NCT06084156|DRUG|Metformin|Part 1: Day 1 to Day 4, 1000mg BID; Part 2: Not take; Part 3: Day 38- day 47, 1000mg BID
224025896|NCT04646915|OTHER|Day surgery|Patients with CuRC who meet the standards will be assigned to day surgery center for surgery
224138946|NCT01557218|OTHER|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
224138947|NCT01557218|OTHER|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
224025897|NCT04524884|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
223558564|NCT02975167|OTHER|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
224025898|NCT04524884|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
224025899|NCT01708213|DEVICE|Aline HA|Implantable dermal filler
224025900|NCT03764956|OTHER|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
224025901|NCT03764956|OTHER|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
224025902|NCT01197859|DEVICE|Definitive Contact Lens|Daily wear contact lens
224025903|NCT01197859|DEVICE|Biofinity|Daily wear contact lens
224025904|NCT03354442|DEVICE|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
224025905|NCT04207866|OTHER|Teleconferencing|Use of video/audio stream to provide auditory training at a remote site.
224025906|NCT04207866|OTHER|Auditory training services|"Participants will engage in regular visits with a specialist to: 1) facilitate auditory training exercises; 2) work with the family/friends to encourage optimal communication strategies in the home; 3) evaluate and assess achievement of listening goals.~Auditory training assess/reviews skills associated with but not necessarily limited to: 1) developing strategies to repair communication breakdowns; 2) listening in quiet; 3) listening in noise; 4) listening to a degraded signal."
224133606|NCT04875338|DRUG|saline (0.9 NACI)|1 ml saline (0.9 NACI) while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
223409294|NCT04710654|OTHER|Interferential current stimulation (0-100 Hz frequency)|The four electrodes (superficial, self-adhesive, 5x9 cm rectangular) coming out of the two channels will be used. Two of the electrodes will be placed bilaterally at the level of the spinal segment, T9-L2, where the sympathetic fibers of the gastrointestinal tract are innervated, in the posterior region, and the other two will be placed anteriorly on the umbilicus lateral to the abdomen. The current will be applied at the sensory level, increasing to the extent that the patient feels the current effectively but does not reveal pain, discomfort and visible muscle contractions. The application will be made to the individuals at 0-100 Hz frequency three days a week, for four weeks.
224025907|NCT00816686|BIOLOGICAL|AGS-16M18|IV Infusion
224025908|NCT04428125|DIAGNOSTIC_TEST|Magnetic Resonance Scan of Thoracic outlet region|Both groups will undergo Magnetic Resonance Scan of cervicothoracobrachial region in order to study the anatomy of this region.
224025909|NCT04428125|DIAGNOSTIC_TEST|Duplex Ultrasound assessment of Upper limbs|Both groups will undergo Duplex Ultrasound assessment of Upper limbs, in order to study diameters and flow of the vascular system of the upper limbs.
224025910|NCT03609853|DRUG|Placebo|Placebo vapor (distilled water)
224025911|NCT03609853|DRUG|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
224025912|NCT00693316|DRUG|ORM-12741|Alternating panel single dose escalation.
224025913|NCT05355233|OTHER|bebo concept|techniques to remove urinary incontinence
224025914|NCT05355233|OTHER|diaphragmatic breathing|techniques to remove urinary incontinence
224025915|NCT05635539|DIETARY_SUPPLEMENT|"Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet"|calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
224025916|NCT05572268|DRUG|to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection|to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
224025917|NCT04964414|OTHER|Smell Retraining|Smell practice with household scented items
224025918|NCT04964414|DRUG|Budesonide|Nasal irrigation with liquid steroid
224138948|NCT01557218|OTHER|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
224138949|NCT01973452|DRUG|Dexmedetomidine|
224138950|NCT01973452|DRUG|Placebo|
224138951|NCT04371952|DRUG|Doxycycline|comparison of doxycycline 200 mg/day to placebo
223409295|NCT04710654|OTHER|behavioural therapy|"The behavioral therapy includes patient education (description of the disease, symptoms, risk factors, treatment, defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advices (diet, water consumption, fiber food, etc.), teaching effective defecation posture, timed toilet training, self-abdominal massage.~Constipation Behavioral Therapy Booklet will be prepared within the scope of behavioral therapy."
223409296|NCT04710654|OTHER|exercise program|"Exercise program consisting of physical activity, core stabilization exercises and pelvic floor muscle exercises.~Exercise Program Booklet will be prepared within the exercise training."
223409297|NCT02421705|OTHER|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
224138952|NCT04371952|DRUG|Placebo|Placebo : lactose, 380 mg/gélule
224133607|NCT04875338|DRUG|betametazon|1 ml betametazon while the patient is in the supine position, the affected elbow is 90 flexion and neutral rotation, The non-dominant thumb will be placed at the sensitive point in the lateral epicondyle. The injection will be applied to the point with a 23 g needle. After the injection, the subjects will be taught a stretching exercise of the joint extensors of the wrist and fingers. Subjects will be asked to do this exercise five times in one session, two sessions a day
224133608|NCT03689062|PROCEDURE|induction of labor|oxytocin intravenous drip
223409298|NCT03101631|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment (CGA)|"CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~* Nutritional Assessment: Mini Nutritional Assessment (MNA)~* Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~* Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~* Psychological status: Geriatric Depression Scale (GDS)~* Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~* Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~* Age~* Haemoglobin~* CrCl~* Presence of geriatric syndromes"
223409299|NCT04867226|DRUG|Colchicine 0.5 MG|participant will be given a Colchicine regimen in a dose of 0.5mg twice daily for 14 days or until symptoms subsides,those with low body weight and develop side effect like diarrhea and vomiting dose will be reduced and supportive treatment will be given .
224025919|NCT05821751|DIETARY_SUPPLEMENT|inulin|"Inulin will be given to enrolled patients according to manufacturer label indications.~ICIs (i.e. nivolumab and pembrolizumab) alone or in combination with chemotherapy, if clinically indicated, and their administration scheduling will be planned as per international and local guidelines."
224025920|NCT05821751|DRUG|Pembrolizumab|Pembrolizumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
224025921|NCT05821751|DRUG|Nivolumab|Nivolumab in monotherapy or in combination with chemotherapy (platinum + 5 FU) in standard clinical practice according to the international and local guidelines + inulin
224133609|NCT03689062|PROCEDURE|follow up|hospitalization and antibiotics
224133610|NCT01953536|DRUG|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
224133611|NCT01953536|DRUG|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m\^2.
224133612|NCT01953536|DRUG|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
224133613|NCT01953536|DRUG|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
224133614|NCT01953536|DRUG|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
224133615|NCT03864718|PROCEDURE|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
223409300|NCT04867226|DRUG|usual care treatment|control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.
223409301|NCT05372432|OTHER|Handgrip strengths measurements with Jamar-type hand dynamometer and, tip pinch strengths measurements with pinchmeter|The handgrip strength and tip pinch strength of the participants were measured using the Jamar-type hand dynamometer and pinch meter available in our clinic. The handgrip strengths were measured with shoulders in adduction and neutral rotation, elbows in 90 degrees flexion, and forearms and wrists in a neutral position, while the tip pinch strengths were measured by squeezing a pinch meter between the thumb and index finger. Participants took a deep breath and then applied gripping force with maximal force while exhaling. In the analysis, the average of the three measurements made with an interval of five minutes was taken as the basis for the analysis.
223558565|NCT02975167|OTHER|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
223558566|NCT02975167|PROCEDURE|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
223558567|NCT02975167|BEHAVIORAL|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
224133616|NCT04215523|DRUG|Dapagliflozin|Dapagliflozin dispensing claim for any dose is exposure
224133617|NCT04215523|DRUG|DPP-4 inhibitor|DPP4 inhibitor dispensing claim for any dose is reference
224133618|NCT01426607|DEVICE|AMO|
224133619|NCT01670409|RADIATION|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
224133620|NCT01670409|DRUG|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
224297998|NCT01378455|OTHER|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
223409302|NCT05372432|OTHER|The Nine Hole Peg Test|This test was used to evaluate the hand dexterity of the participants. This test consists of a square area and nine holes in this area, nine cylinders suitable for these holes, and a storage box. Participants quickly took the nine cylinders from the storage box and placed them in the holes, and after placing all the cylinders, they put the cylinders back in the storage box one by one. In the evaluation of the test, the time elapsed during these operations was measured in seconds with a chronometer, and shorter times were considered to indicate better hand dexterity.
224025922|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
223409303|NCT04812223|PROCEDURE|Delayed umbilical cord clamping|The umbilical cord will be clamped 60 seconds after the baby is born.
224025923|NCT00326404|DRUG|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
224025924|NCT01718353|DRUG|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
224025925|NCT01718353|DRUG|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
224025926|NCT01718353|DRUG|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
224025927|NCT00526032|PROCEDURE|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
224025928|NCT02940938|OTHER|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
224133621|NCT06160869|BEHAVIORAL|Acceptance and commitment therapy|"The psychoeducational intervention will consist of seven structured sessions aimed at introducing patients with primary psychosis to the principles and practices of Acceptance and Commitment Therapy (ACT). The primary focus of the intervention is to empower participants to effectively manage distressing thoughts and feelings while pursuing meaningful and valued life goals. Each session covers specific aspects of ACT.~Acceptance and commitment therapy will be adminitered in addition to treament as usual provided to patients."
224133622|NCT06160869|COMBINATION_PRODUCT|Treatment as usual|The treatment as usual (TAU) for all patients regardless of condition will consist of hospital treatment, including daily medication management sessions with a psychiatrist (e.g., antipsychotic and other medications as appropriate), community meetings, other group therapy, case management, occupational therapy, open air walks, discharge planning, physical examination, and other services (e.g., medical testing).
223409304|NCT04812223|PROCEDURE|Early umbilical cord clamping|The umbilical cord will be clamped 15 seconds after the baby is born.
223409305|NCT04812223|PROCEDURE|Milking of the umbilical cord|The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
223409306|NCT00662584|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
223409307|NCT03418688|DRUG|COR388|COR388 administered for 10 or 28 days.
223409308|NCT03418688|DRUG|Placebo|Placebo administered for 10 or 28 days.
223409309|NCT05999071|DIETARY_SUPPLEMENT|Coriandrum sativum seeds|Each group consisted of 50 students. In the C. sativum group, dried powdered seeds of C. sativum were administered, while in the control group, starch was provided as a placebo. Both the C. sativum and placebo capsules were identical in shape, color, and outer packaging to maintain the blinding of the participants.
223409310|NCT04398108|DRUG|Margetuximab Margetuximab-IV|Drug: Chosen Chemotherapy (Capecitabine) -Oral Capecitabine tablet Drug: Chosen Chemotherapy (Vinorelbine) Vinorelbine -IV Drug: Chosen Chemotherapy (Gemcitabine) Gemcitabine -IV
223409311|NCT05713890|OTHER|Home-based Action Observation Treatment with virtual-reality for upper limb rehabilitation|"Observation of a VR scenario depicting multiple repetitions of a specific upper limb motor task belonging to typical activities of daily living, followed by mental imagination of the action observed and then by the execution of the same task, using objects provided in a kit.~In each session, patients will watch 2 different videos and will perform the two corresponding actions. The time scheduled for observation, imagery and execution of each action will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes. New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
223409312|NCT05713890|OTHER|Home-based landscape observation with virtual-reality for upper limb rehabilitation|"Observation of virtually explorable landscapes followed by rest with eyes closed without focusing on any thought in particular and then execution of the same actions requested to VR-AOT-group. In each session, patients will explore 2 different landscapes and perform 2 different actions. The time scheduled for observation, rest and action execution will be of 5, 3, and 7 minutes, respectively, so that each session will last about 30 minutes.New actions, chosen from a dataset of 50 stimuli showing progressively increasing levels of difficulty, will be weekly administered on the basis of patient's degree of motor impairment, to involve different manual skills.~30 minutes sessions, 5 times a week for 3 consecutive weeks (15 sessions in total)."
223409313|NCT01629251|DEVICE|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
224025929|NCT00455325|DRUG|Placebo Comparator: First Intervention (3 weeks)|once daily placebo tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
224133623|NCT02596152|OTHER|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
223409314|NCT03147690|DRUG|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
223409315|NCT03771911|DEVICE|AED|Instructions provided by an AED
224025930|NCT00455325|DRUG|Active Comparator: Second Intervention (3 weeks)|Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
224025931|NCT00455325|DRUG|Active Comparator: Third Intervention (3 weeks)|Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
224025932|NCT00455325|DRUG|Active Comparator: Fourth Intervention (3 weeks)|Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
224025933|NCT04923841|OTHER|High intensity light box for bright light therapy and single vision spectacle lenses|High intensity light box for bright light therapy and single vision spectacle lenses
224025934|NCT04923841|OTHER|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses|High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses
224025935|NCT04923841|OTHER|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses|High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses
224025936|NCT04923841|OTHER|Atropine 0.01% eye drop and and single vision spectacle lenses|Atropine 0.01% eye drop and and single vision spectacle lenses
224025937|NCT02910661|OTHER|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last \~90 min. and be audio-recorded. An observer will take field notes.
223409316|NCT03771911|DEVICE|Telephone|Instructions provided by emergency Call Center (telephonically) with the help of an AED.
223409317|NCT03739086|PROCEDURE|erector spinae plane block|unilateral or bilateral or bilevel erector spinae plane block performance for postoperative pain or acute pain
223409318|NCT04521062|DEVICE|Dilapan S|Placement of Dilapan S
223409319|NCT05584033|DIAGNOSTIC_TEST|Mansora Arabic test battery for childhood apraxia of speech|Searching of apraxia of speech in children with Specific Language Impairment in able to better management of these cases.
223558568|NCT02975167|BEHAVIORAL|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
223558569|NCT02975167|PROCEDURE|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
224025938|NCT03937726|OTHER|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
224025939|NCT03937726|OTHER|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
224025940|NCT05281965|DRUG|Retinoic acid|Retinoic acid oral
224025941|NCT05031403|OTHER|Telerehabilitaton|Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.
224025942|NCT05031403|OTHER|Home Exercise|Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
224133624|NCT02596152|OTHER|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
224133625|NCT05133804|DRUG|Methylphenidate|Ritalin 10mg
224133626|NCT05133804|DRUG|Reboxetine|Reboxetine 4mg
224133627|NCT05133804|DRUG|Placebo|Placebo matched to Reboxetine
224133628|NCT05133804|DRUG|Placebo|Placebo matched to Ritalin
224133629|NCT02208024|RADIATION|Stereotactic Body Radiation Therapy|
224133630|NCT03957655|BIOLOGICAL|SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12
223409320|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 100 μg/mL
223409321|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 200 μg/mL
223409322|NCT00656825|DRUG|P144 cream|P144 cream will be given at a dose of 300 μg/mL
223409323|NCT00656825|DRUG|Placebo|Placebo will be randomly given to 4 subjects in each panel
224133631|NCT05126706|BEHAVIORAL|Digital lifestyle management|Digital lifestyle management for Weight Loss Control after Thyroidectomy
224133632|NCT06070116|DRUG|Ivermectin w/ Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg) plus Albendazole (ALB) (400 mg)
224133633|NCT06070116|DRUG|Ivermectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Ivermectin (IVM) (150 µg/kg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
223409324|NCT04120259|DRUG|Metformin Oral Tablet|A biguanide drug used as a first line therapy for Diabetes MellitusType 2
223409325|NCT04120259|DIETARY_SUPPLEMENT|Vinegar|A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.
223409326|NCT03388684|PROCEDURE|Conjoined twin separation surgery|This study included 4 case reports on conjoined twins (CT), 2 male and three female patients; 3 of them were parasitic and one was conjoined. We operated upon 2 parasitic and one conjoined. The 1st case died preoperatively.
223409327|NCT06571721|OTHER|Topical Product: Almond Oil|1-2 Drops of randomized topical product will be applied on entire face nightly.
223409328|NCT06571721|OTHER|Topical Product: Almond oil augmented with 0.5% Vitamin E|1-2 Drops of randomized topical product will be applied on entire face nightly.
223409329|NCT06571721|OTHER|Topical Product: 0.025% Tretinoin oil augmented with castor oil|1-2 Drops of randomized topical product will be applied on entire face nightly.
224025943|NCT01366495|BEHAVIORAL|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
223409330|NCT03389204|OTHER|PHYSICAL THERAPY|EXERCISES AND EDUCATION TO FOLLOWING AFTER DISCHARGE PHYSICAL TREATMENT
223409331|NCT02589639|DRUG|Empagliflozin|
223409332|NCT02589639|DRUG|Placebo|
223409333|NCT02589639|DRUG|Placebo|For blinding purposes
223409334|NCT05508048|BEHAVIORAL|The existential approach and logotherapy-based psychosocial support program|Existential Approach and Logotherapy Based Support Program, which raises awareness about the meaning and purpose of the individual's life, enables them to produce solutions to the sense of meaninglessness, anxiety, feeling of emptiness, and many other problems, and develops different perspectives.The content of the program is base on existential analysis and logotherapy. The program lasted for eight weeks, with the first and last session of the scale applications. Additional sessions were set for each session where the aims and objectives of the session could not achieve. A session lasting at least 50 minutes were held each week.
223558570|NCT04075292|DRUG|Acalabrutinib|acalabrutinib 100 mg twice daily orally
224025944|NCT00509587|DRUG|pazopanib hydrochloride|Given orally
224025945|NCT00509587|PROCEDURE|pharmacological study|Correlative studies
224025946|NCT00509587|PROCEDURE|laboratory biomarker analysis|Correlative studies
224025947|NCT02159196|DRUG|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
224025948|NCT02159196|DRUG|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
223409335|NCT00255866|BEHAVIORAL|Skills training for the care of dementia patients|
223409336|NCT03495531|DEVICE|Virtual Reality|Virtual Reality headset with calming scenery
223409337|NCT00703157|PROCEDURE|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
223409338|NCT00703157|PROCEDURE|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
223409339|NCT03085966|BIOLOGICAL|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
223409340|NCT05446857|DRUG|Glecaprevir / Pibrentasvir Pill|Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.
223409341|NCT04018846|PROCEDURE|Revascularization using a BIOPROTEC Graft|It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.
223409342|NCT00979316|DRUG|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
223409343|NCT00979316|DRUG|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
223409344|NCT00979316|DRUG|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
223409345|NCT00979316|DRUG|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
223558571|NCT04075292|DRUG|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
223558572|NCT04075292|DRUG|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
223558573|NCT06006702|DRUG|TYRA-300-B01|TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
223558574|NCT02516995|DEVICE|Functional magnetic resonance imaging|
223558575|NCT02516995|DEVICE|Ultrasound|
223558576|NCT05960578|DRUG|Apalutamide|Given PO
223558577|NCT05960578|PROCEDURE|Biopsy|Undergo tumor biopsy
224025949|NCT02159196|DRUG|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
224025950|NCT01839500|DRUG|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
224025951|NCT03275844|PROCEDURE|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
224025952|NCT02145689|BIOLOGICAL|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
224025953|NCT02326012|BEHAVIORAL|Emotion Regulation Individual Therapy for Adolescents|
223558578|NCT05960578|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223558579|NCT05960578|PROCEDURE|Computed Tomography|Undergo CT scan
223558580|NCT05960578|DRUG|Golimumab|Given SC
223558581|NCT05960578|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224025954|NCT03311334|DRUG|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
224025955|NCT03311334|DRUG|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
224025956|NCT03311334|DRUG|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 22 of the study.
224025957|NCT06165939|DRUG|Intra-articular corticosteroid injection|Ultrasound-guided intra-articular corticosteroid injection treatment in the shoulder joint (2 ml SHINCORT INJ 10 MG/ML + 2 ml 2% Xylocaine) is performed once for the patient at the first week.
224133634|NCT06070116|DRUG|Moxidectin + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg) plus Albendazole (ALB) (400 mg)
224025958|NCT06165939|DRUG|hydrodilation with 15% hypertonic dextrose|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is 15% hypertonic dextrose (6 ml 50% Dextrose + 2 ml 2% Xylocaine + 12 ml normal saline, totaling 20 ml).
224025959|NCT06165939|DRUG|hydrodilation with Normal saline|The second round of ultrasound-guided shoulder joint injection is performed at the fourth week during the follow-up period and the injectate is Normal saline (2 ml 2% Xylocaine + 18 ml normal saline, totaling 20 ml).
224025960|NCT02931799|BEHAVIORAL|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
224025961|NCT02931799|OTHER|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~* PRO-2 Scale for patients with Crohn's Disease~* 6-Point Mayo Score for patients with Ulcerative Colitis~* Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
224025962|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
224025963|NCT02931799|OTHER|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
224025964|NCT02931799|OTHER|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
224025965|NCT02745392|DRUG|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
224025966|NCT02745392|DRUG|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
224025967|NCT01306955|DRUG|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
224025968|NCT01306955|OTHER|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
224025969|NCT01691768|DRUG|1% tenofovir gel|"Participants will be randomized to receive 1% tenofovir gel through either:~* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~* The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."
224025970|NCT02830971|PROCEDURE|Doing Different ICU techniques and skills|
224133635|NCT06070116|DRUG|Moxidectin + Diethylcarbamazine + Albendazole|Participants will be given a dose of oral Moxidectin (Mox) (8 mg), Diethylcarbamazine (DEC) (6 mg/kg) and Albendazole (ALB) (400 mg)
223409346|NCT01567917|PROCEDURE|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~\- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
224025971|NCT03794687|PROCEDURE|Left heart catheterization|Catheterization via the distal radial artery
224025972|NCT00912691|DRUG|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
224025973|NCT04908462|DRUG|AL01211 or Placebo (Part A)|Five dose groups with doses ranging from 2mg to 60 mg
224133636|NCT03712332|BEHAVIORAL|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
224133637|NCT03475576|OTHER|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
224133638|NCT00229164|DEVICE|Transcutaneous Electric Nerve Stimulation (TENS)|
223409347|NCT06410677|DIAGNOSTIC_TEST|DNA Sequencing, RNA Sequencing|"High-coverage Whole-Exome Sequencing sequencing of DNA samples from ESCC was performed.~RNA expression was analyzed using the NanoString PanCancer Immuno-Oncology 360TM Panel that includes a set of more than 700 genes involved in the main biological pathways of human immunity. These experiments were performed by the Genomics platform of Institut Curie. Total RNAs were used as templates."
223409348|NCT04075071|BEHAVIORAL|Teacher-Child Interaction Training - Universal|Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
223409349|NCT06939959|DRUG|Artificial tear|commercially available artificial tears will be used consisting of same ingredients.
224025974|NCT04908462|DRUG|AL01211 or Placebo (Part B)|Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
224025975|NCT01959334|DRUG|Nasal Glucagon (NG)|
224025976|NCT01959334|DRUG|Glucagon IM|
224025977|NCT01620476|DRUG|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
224025978|NCT01620476|DRUG|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
224025979|NCT01620476|DRUG|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
224025980|NCT01620476|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
224025981|NCT00851448|DIETARY_SUPPLEMENT|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
224133639|NCT01405118|DRUG|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
223409350|NCT06939959|DRUG|insulin human|injection humulin will be used to make topical insulin drops
223409351|NCT03494634|DRUG|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
223409352|NCT02078245|OTHER|MRI|MRI
223409353|NCT03092778|PROCEDURE|Cryoablation|"A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.~The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn."
223409354|NCT00161005|PROCEDURE|PCI|Immediate transport to invasive center after thrombolysis
223409355|NCT02968173|DRUG|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
223409356|NCT02670525|GENETIC|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
223409357|NCT02125383|PROCEDURE|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
223558582|NCT05960578|PROCEDURE|PSMA PET Scan|Undergo PSMA PET
224025982|NCT06248385|DEVICE|2D ultrasound|2D TVUS
224025983|NCT00267904|OTHER|Coffee|Caffeinated coffee and decaffeinated coffee ingestion
224025984|NCT00267904|OTHER|Banana|Banana ingestion
224025985|NCT00267904|OTHER|Olives|Olives ingestion
224025986|NCT00267904|OTHER|Temp. manip.|Manipulate temperature at skin of the back
224133640|NCT04677621|OTHER|Nurse Telehealth|Subjects will receive nurse telehealth Mobile Decision Support System (MAP) DBS care
224133641|NCT04677621|OTHER|STANDARD DBS|Subjects will receive standard in-person clinic-based DBS care administered without the use of Mobile Decision Support System (MAP) DBS
224138953|NCT03548038|OTHER|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
224138954|NCT00349752|BIOLOGICAL|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
223558583|NCT05960578|PROCEDURE|Bone Scan|Undergo bone scan
224025987|NCT04238273|DIAGNOSTIC_TEST|Functional Echocardiography|Imaging studies to assess Hemodynamics of both groups on and off non invasive ventilation
223409358|NCT02125383|PROCEDURE|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
223409359|NCT00124501|BEHAVIORAL|Biofeedback-assisted relaxation training|10 sessions BART
223409360|NCT06305455|BIOLOGICAL|Escherichia coli ESBL|To evaluate the change in the resistance profile of infections of community origin caused by Escherichia coli, isolated from any culture material in patients admitted to the intensive care unit of a tertiary hospital.
223558584|NCT03724383|BEHAVIORAL|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
223558585|NCT03724383|BEHAVIORAL|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
223558586|NCT03724383|BEHAVIORAL|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
224025988|NCT02519400|DRUG|Amitriptyline|Single oral dosing
224025989|NCT06354231|DRUG|DV|2.0 mg/kg, intravenously administered every 2 weeks
224025990|NCT06354231|DRUG|Toripalimab|3.0mg/kg, intravenously administered every 2 weeks
224025991|NCT06354231|PROCEDURE|Laser surgery|Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy.
224025992|NCT02851485|DRUG|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
224025993|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
224025994|NCT02851485|DRUG|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
224025995|NCT00887432|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
224025996|NCT00887432|OTHER|Laboratory Biomarker Analysis|Correlative studies
224025997|NCT00887432|OTHER|Patient Observation|
224025998|NCT00887432|DRUG|Placebo Administration|Given PO
224025999|NCT00887432|OTHER|Quality-of-Life Assessment|Ancillary studies
224026000|NCT00887432|OTHER|Questionnaire Administration|Ancillary studies
223409361|NCT05823935|PROCEDURE|Bakay purse string|After developing the bladder flap, Vicryl polyglactin 910 sutures (Ethicon, Inc, Somerville, NJ) will be placed on the line between the cervicovaginal junction and the bladder starting at either 4 to 3 o'clock or 8 to 9 o'clock, as anchor sutures. Paying attention not to get closer than 1 cm to the bladder, the first suture will be passed from 4 o'clock to 3 o'clock and continued circumferentially in a full-thickness purse string fashion through 3, 1, 10, 8, 7, 5 o'clock completing a circle while including both uterosacral ligaments.
223409362|NCT05823935|PROCEDURE|Cuff closure via vaginal route group|After the uterus will be removed via vaginal route, vaginal cuff ends will be grasped via vaginal approach and sutured continuous locked sutures using Vicryl polyglactin 910 sutures in one layer.
223409363|NCT04689620|DEVICE|laser|treating the venous ulcer with laser
224026001|NCT03389906|OTHER|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
223409364|NCT00591565|DRUG|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
223409365|NCT02788409|OTHER|Not applicable for study|Provide external perspective on background second primary cancer incidence rates for REASSURE study.
223409366|NCT05468684|OTHER|no intervention|there are no interventions planned, we observe the patients in a cohort study which is named inception cohort study because we test participants before the condition develops.
223409367|NCT06574763|DRUG|RC48/Carboplatin|RC48, 2.5mg/kg, iv, Q3W Carboplatin, AUC 5, iv, D1, Q3W
223409368|NCT02588768|DEVICE|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
223558587|NCT03724383|OTHER|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
223558588|NCT03724383|OTHER|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
224026002|NCT04927182|OTHER|Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
224133642|NCT05075967|OTHER|Health Equity|This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks \[BTAN\]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
224133643|NCT05075967|BEHAVIORAL|Social Media Influencers|"In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of:~* HIV/sexually transmitted infections (STI) testing promotion~* PrEP (and general HIV prevention) awareness and promotion~* Definition and benefits of viral suppression.~Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events."
224297999|NCT01378455|OTHER|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
224298000|NCT04014855|DRUG|Iron Supplement|in iron deficiency anemia
223558589|NCT04308239|BEHAVIORAL|Reactive balance training|Participants were exposed to simulated trips and slips under safe, controlled conditions in order to practice their reactive response to these common balance perturbations.
223558590|NCT04308239|BEHAVIORAL|Otago Balance Training|Balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support).
223409369|NCT00937365|BEHAVIORAL|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
223409370|NCT00937365|PROCEDURE|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
223409371|NCT00937365|PROCEDURE|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
223409372|NCT02980068|DRUG|15N Nitrate|1,000 mg/11.8 mmol, oral, on day one, hour zero
223409373|NCT02980068|DRUG|14N Nitrate|1,000 mg/11.18 mmol, oral, on day hour, hour zero
223558591|NCT01443364|BIOLOGICAL|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
223409374|NCT03938350|BEHAVIORAL|Dialectical Behavior Therapy (DBT) Skills Training|Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation. The sessions will be delivered virtually via a HIPAA-compliant video platform.
223409375|NCT03935139|BIOLOGICAL|glucose measurement|Glucose values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
223409376|NCT03935139|BIOLOGICAL|lactacte measurement|Lactate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
224026003|NCT04927182|OTHER|Moderate Exercise Training (Age Group 2; 31 to 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
223409377|NCT03935139|BIOLOGICAL|pyruvate measurement|pyruvate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
224026004|NCT04927182|OTHER|Moderate Exercise Training (Age Group 3; Above 45 years)|Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
224026005|NCT06092619|OTHER|Vojta Therapy|The therapist applied pressure to defined zones on the body whilst positioned in prone, supine and side lying, where the stimulus leads to automatically and involuntarily complex movement.The parents were also instructed on at least one of the exercises from the first session, after the initial assessment. The home program was progressively increased and supervised until the three therapy positions were mastered, during weekly or fortnightly follow ups. The recommended dose was four times per day at home, in session no longer than 15-20 minutes; however, the daily frequency of each family due to different availability was also taken in account. The frequency of the dose was divided into 3 groups: families who could carry on therapy a) three times per day, b) four times per day, c) one or two times per day, d) less than seven times per week or therapy at the clinic
224026006|NCT06092619|OTHER|Conventional physiotherapy:|Conventional physiotherapy intervention included goal-directed functional training based on tasks. These motor skills will be performed in enhanced and adapted settings, but as similar as possible to the usual activities of daily living. Family and children participated in the goal setting, and the approach will focus on overcoming the limitations of the activities to reach these, instead of the modification of the movement patterns. This intervention is founded in motor learning and behavioral neuroscience, focusing on participation and activity acquisition.
224133644|NCT05075967|BEHAVIORAL|Intersectional Stigma Reduction|This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
223409378|NCT03935139|BIOLOGICAL|glycerol measurement|glycerol values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
223409379|NCT03935139|PROCEDURE|Bone free flap monitoring|Bone free flaps will be monitored with a microdialysis catheter directly positioned in bone tissue.
223409380|NCT03472430|DEVICE|Transcutaneous electrical nerve stimulation|The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
223409381|NCT03472430|DEVICE|TENS machine with electrodes not emitting any impulses.|TENS machine with electrodes not emitting any impulses.
223409382|NCT03808181|DEVICE|ChloraSolv|Weekly application of ChloraSolv for 6 weeks
223409383|NCT06710353|DRUG|Albumin solution|"A 20% albumin solution is administered over one hour starting from the induction of anesthesia, using the following formula:~(4.0-preoperative serum albumin (g/dL))×plasma volume (kg×0.65-0.8 dL)"
223409384|NCT06710353|DRUG|Crystalloid solutions|The same volume of crystalloid solution as the administered albumin is infused.
223409385|NCT01099618|DRUG|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
223409386|NCT01099618|DRUG|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
223409387|NCT01099618|DRUG|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
223409388|NCT05691582|DEVICE|GRAIL|"The subjects experiment GRAIL virtual reality for three days, during which they deal with 4 different activities.~In the first activity subjects are required to ask over the treadmill in a snow environment.~in the second they are required to stand over the moving platform in a simulation of a boat pitch.~in the third they have to walk over a bridge with a slope. in the fourth the subjects are required to try so interact with virtual reality and to ski between snowman.~if it is possible, on the last day a gait analysis is executed"
223409389|NCT03464331|BEHAVIORAL|Zero-time exercises|The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
224026007|NCT01055379|DRUG|Rasagiline|1 mg/day for 12 weeks; orally
224026008|NCT01055379|DRUG|Placebo|Once daily for 12 weeks; orally
224026009|NCT04945915|OTHER|blood sampling|There was no intervention because this reasearch is observational study.
223409390|NCT03464331|BEHAVIORAL|relaxation exercises and deep-breathing exercises|The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON\_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
223409391|NCT05547139|OTHER|Protocolized weaning of respiratory support|The protocolized weaning aims to keep babies on CPAP for a longer period of time and will measure how long it takes babies to wean to 2L nasal cannula support or come off all support (room air, RA).
223409392|NCT06107569|OTHER|Fecal microbiota transplant (Promicrobioma)|Fecal microbiota transplant with Promicrobioma (freeze-dried isolated microbiota)
223409393|NCT06107569|DRUG|Antibiotic|Antibiotics for Clostridioides infection (oral vancomycin) or association of intravenous metronidazol for severe cases.
224026010|NCT02927600|OTHER|Low GI Breakfast|Intake of low GI breakfast
224026011|NCT02927600|OTHER|High GI Breakfast|Intake of high GI breakfast
224026012|NCT02927600|OTHER|Low GI Dinner|Intake of Low GI dinner
224133645|NCT05075967|BEHAVIORAL|Peer Support|"Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains:~* HIV, PrEP, nPEP, other HIV prevention options and ART education~* Adherence to PrEP, ART and medical care~* HIV/STI testing~* New HIV diagnosis~* Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma)~* Self-care~* Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care~* Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)"
224133646|NCT05075967|OTHER|Standard-of-care|Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.
223409394|NCT05876806|DRUG|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis
223409395|NCT05876806|DRUG|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
223409396|NCT00161603|BEHAVIORAL|Semi-structured, open-ended interviews|
223409397|NCT01452243|DRUG|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
223409398|NCT00213109|DRUG|Miglitol|
223409399|NCT02254382|DEVICE|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
223409400|NCT04454255|BEHAVIORAL|FunSpeech|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
223409401|NCT04454255|BEHAVIORAL|Control|Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
223409402|NCT03564119|DRUG|S5G4T-1|Once a day topical cream
223409403|NCT03564119|DRUG|S5G4T-2|Once a day topical cream
223409404|NCT00508599|OTHER|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
223409405|NCT00634036|DRUG|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
223409406|NCT00634036|DRUG|placebo|matching placebo (inert tablet)
223409407|NCT01946828|DEVICE|FIM|Field Induced Mydriasis device
223409408|NCT02431611|BEHAVIORAL|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
223409409|NCT02431611|BEHAVIORAL|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
223409410|NCT02811965|OTHER|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
223409411|NCT02811965|OTHER|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
223409412|NCT02811965|DEVICE|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
223409413|NCT02811965|DEVICE|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
224026013|NCT02927600|OTHER|High GI Dinner|Intake of high GI dinner
224026014|NCT02701140|PROCEDURE|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
224026015|NCT02701140|PROCEDURE|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
224026016|NCT02701140|PROCEDURE|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
224026017|NCT02701140|PROCEDURE|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
224133647|NCT06269289|OTHER|web based education|Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
223409414|NCT02811965|DEVICE|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
223409415|NCT02811965|DEVICE|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
223409416|NCT04573322|DRUG|Trans Sodium Crocetinate|TSC, at the optimum safe and tolerable dose determined in the lead-in phase, administered via IV bolus every 6 hours for up to 15 days
224026018|NCT02701140|PROCEDURE|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
223409417|NCT04573322|DRUG|Normal saline|Normal Saline, in an equivalent volume by participant body weight, administered via IV bolus every 6 hours for up to 15 days
223409418|NCT03896022|DEVICE|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
223558592|NCT02643615|DEVICE|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
223558593|NCT02643615|DEVICE|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
223558594|NCT02643615|DRUG|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
224026019|NCT01515397|DRUG|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
224026020|NCT01515397|DRUG|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
224026021|NCT02853747|BEHAVIORAL|Physical Activity, 20-meter shuttle run|cross-sectional physical activity assessment and medical screeening
224026022|NCT04619901|OTHER|Semi-structured interviews|Exploring the psychological and social impact on parents of a palliative care decision concerning their child in the neonatal period
224026023|NCT04619901|OTHER|Questionnaire|Assessing the neuro-developmental evolution of children and understanding the determinants of the psychological and social impact of palliative care decisions on parents
224026024|NCT04619901|OTHER|following Scales|Scales : Hospital Anxiety and Depression, Intolerance to Uncertainty, and Brief COPE.
224026025|NCT04114630|DRUG|erenumab 70mg/mL|Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
224026026|NCT00638131|DRUG|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
224133648|NCT06269289|OTHER|Standard education brochure|The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.
224133649|NCT02004782|DRUG|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
223409419|NCT03896022|DEVICE|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
223409420|NCT03896022|DEVICE|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
223409421|NCT03207269|OTHER|Dietary|Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
223409422|NCT02438423|BIOLOGICAL|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
223409423|NCT02438423|OTHER|Placebo|
223409424|NCT01341275|BIOLOGICAL|hepatitis B vaccine|10 ug dose, one-time administration
223409425|NCT01341275|BIOLOGICAL|hepatitis B vaccine|20 ug dose, one-time administration
224026027|NCT00447304|DRUG|moxifloxacin|
224026028|NCT00447304|PROCEDURE|cholecystectomy|
224026029|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
224026030|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
224026031|NCT02865486|DIETARY_SUPPLEMENT|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
224133650|NCT02004782|DRUG|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
224133651|NCT04732819|BEHAVIORAL|High touch multi-pronged behavioral intervention|"In this intervention, facilities will work with our research team to accomplish the following:~1. Identify and engage a Facility Opinion Leader.~2. Employ Consenting Specialists to facilitate the clinical consent for vaccination process.~3. Engage well respected persons in the community who are willing to provide messages that promote trust in the vaccine and that will be distributed widely within a facility by email, website, text and/or social media.~4. Distribute buttons, T-shirts, and masks that promote awareness about vaccination (e.g., Ask me about the COVID-19 vaccine!) through facility leadership.~5. Acquire additional COVID-19 testing kits using funds provided by our research team."
223409426|NCT03253900|DEVICE|Stable rowing simulator|a standard stable/fixed rowing simulator
223409427|NCT03253900|DEVICE|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
223409428|NCT03253900|DEVICE|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
223409429|NCT02401152|OTHER|Sports drink 1|Sports drink with a specific source of CHO.
223409430|NCT02401152|OTHER|Sports drink 2|Sports drink with a specific source of CHO
223409431|NCT02401152|OTHER|Placebo|iso-caloric sports drink with maltodextrin as CHO source
223409432|NCT05503537|PROCEDURE|post-isometric relaxation technique|Post-isometric relaxation technique will be performed by asking the patient to contract his calf muscles using 20% of his strength. Maintain the contraction for 10 second with 15 second of rest time between each contractions. A total of 4 contractions will be performed.
224026032|NCT05347420|DIAGNOSTIC_TEST|The visual Neuropad test and the quantitative Neuropad test|The visual screening test includes whether the Neuropad test paper changes completely from blue to pink within 10 minutes (visual screening test a) and the time to complete color change (visual screening test b). the quantitative screening test using a handheld color scanner to scan the rate of color change, which estimated by the slope of the Neuropad color change per minute.
224133652|NCT01318473|DEVICE|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
223409433|NCT05503537|PROCEDURE|Static stretching|Static stretching will be performed by asking patient to perform dorsiflexion till the point of discomfort. The patient will hold the stretch for 15 second and 5 repetitions will be performed.
223409434|NCT05503537|PROCEDURE|Basic Cardiac Rehabilitation Protocol|Ankle pumps, leg slides, walking
223409435|NCT03858751|DRUG|Placebo oral capsule|Placebo capsule before bedtime
223409436|NCT03858751|DRUG|LTM1201AZ|LTM1201AZ oral capsule before sleep
223409437|NCT03858751|DRUG|LTM1201AT|LTM1201AT oral capsule before sleep
223558595|NCT02643615|DRUG|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
223558596|NCT05790798|OTHER|occupational therapy-based instrumental daily living activities intervention|Occupational therapy-based instrumental activities of daily living intervention were applied to 9 people with disabilities in the intervention group, with sessions consisting of 45 minutes twice a week (totally 8 weeks/16 sessions). While the activity intervention program was being created for the intervention group, the problem areas in the ADL and IADL determined by the evaluations made before the intervention were identified. Ten occupation kits including 2 ADLs (dressing and feeding nutrition), and 8 IADLs (laundry, meal preparation, light cleaning, paperwork, use of technology, lifting and carrying, fine motor and gross motor leisure groups) were used as interventions. Various materials (jar, shirt, spoon, teapot, play dough, stapler, plastic bag, sponge, etc.) were prepared to be used in each occupation kit and to simulate daily activities.
223558597|NCT05790798|OTHER|Quite recreation activity|For the control group, information about the scope, duration and requirements of the research was shared throughout the process. During this period, reading activities continued. The final evaluation of all participants was made at the end of the 8th week of the study and the study was completed.
224026033|NCT04406090|OTHER|Mechanical Trombectomy|Stent retriever for treatment of cerebral arterial occlusions
224026034|NCT02567500|BEHAVIORAL|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
224026035|NCT02567500|BEHAVIORAL|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~* The social cognitive marker (NEPSY II) : theory of mind and affect recognition~* The emotional marker:~  * Differential emotion scale IV (DES IV): emotional individual stability~ * Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~* Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~* Evaluation of diagnosis with DSM-IV criteria:~  * MINI-Kids~ * Psychosis section of Kiddie-SADS"
224026036|NCT01129466|DIETARY_SUPPLEMENT|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
224133653|NCT04804033|DRUG|BHV-3500 (zavegepant)|BHV-3500 (zavegepant) softgel capsule.
224133654|NCT04804033|DRUG|Placebo|Matching placebo softgel capsule.
224138955|NCT00349752|OTHER|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
224138956|NCT03136770|DIETARY_SUPPLEMENT|CK-30|Compound K 600 mg
223409438|NCT03858751|DRUG|LTM1201AG|LTM1201AG oral capsule before sleep
223409439|NCT03858751|DRUG|LTM1201AD|LTM1201AD oral capsule before sleep
223409440|NCT01195311|DRUG|INCB024360|INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
223409441|NCT00107861|DRUG|Ad.hIFN-β (BG00001, IDEC-201)|
223409442|NCT02245009|PROCEDURE|Cardioversion|
224138957|NCT03136770|DIETARY_SUPPLEMENT|Red ginseng extracts|Red ginseng extracts 2.94 g
223409443|NCT02939677|OTHER|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
223409444|NCT06511635|OTHER|Qualitative interview|Interview between participant and a researcher, in order to identity the determinants of participation in a clinical trial among participants in the CMVictory vaccine trial.
223409445|NCT06511635|OTHER|Quantitative questionnaire|Anonymous online survey using a 3-part questionnaire, studying knowledge of clinical research and the determinants of participation in a preventive vaccine study in a population of young women (aged 18-40).
223409446|NCT01136941|DRUG|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
223409447|NCT00718614|PROCEDURE|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
223409448|NCT00543881|DEVICE|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
224138958|NCT03052842|DRUG|C16G2 Strip|Antimicrobial Peptide
224138959|NCT03052842|OTHER|Placebo Strip|Placebo
223409449|NCT00543881|DEVICE|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
223409450|NCT03676608|BIOLOGICAL|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
223409451|NCT03676608|OTHER|Usual educational care|The WHO protocol for maternal lactation.
223409452|NCT03393923|OTHER|Application of the anterior wedge|Application of anterior wedge in tennis
223409453|NCT00677521|DRUG|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
223409454|NCT00134823|OTHER|weight based dosing decision support|weight based dosing decision support
223409455|NCT00564850|DRUG|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
223409456|NCT01493518|DRUG|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
223558598|NCT00561158|BEHAVIORAL|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~* Rate Your Plate: determining high fat foods~* Label Reading: reading food labels~* Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~* Recipe Modification: preparing old recipes in new ways to reduce fat~* Eating Out: order healthier fast foods~* Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~* Substituting fat-modified foods for high fat foods~* Avoiding fat as a seasoning or flavoring~* Avoiding fried foods~* Modifying meat~* Replacing high fat foods with fruits, vegetables, grains and breads"
223558599|NCT05598125|DEVICE|electronic cigarette (e-cigarette)|
224026037|NCT01129466|DIETARY_SUPPLEMENT|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
224026038|NCT04331223|OTHER|Observation|observational
224026039|NCT05418023|OTHER|Salivary Collection|Collection of saliva via swab for miRNA processing
224026040|NCT05418023|OTHER|Adaptive Assessment|Includes Vineland Adaptive Behavior Scale or equivalent
223409457|NCT03059043|DEVICE|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
223409458|NCT03059043|DEVICE|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
223409459|NCT04057742|DIAGNOSTIC_TEST|AlloSure ddcfDNA assay|2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
223409460|NCT04057742|DIAGNOSTIC_TEST|AlloMap assay|10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A, at transplant for Group B, and transplant and 3 months for Group C
223409461|NCT04057742|DIAGNOSTIC_TEST|Inflammatory Cytokines|10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months post-transplant for Group A
223409462|NCT04057742|DIAGNOSTIC_TEST|Immune Cell Phenotypes|Collection of up to 1 cup of urine for per participant each study visit
223409463|NCT01194232|DRUG|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
223409464|NCT01036282|BEHAVIORAL|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
223409465|NCT01036282|BEHAVIORAL|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
223409466|NCT03975673|PROCEDURE|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
223409467|NCT00314327|DRUG|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
223409468|NCT05691127|DIAGNOSTIC_TEST|Complete blood count (CBC), C reactive protein (CRP(., Chest x ray, ABG, Electrolytes, Random blood sugar, Creatinine|I will use these investigations in my study
223558600|NCT05598125|DEVICE|conventional tobacco cigarette|
224026041|NCT05418023|OTHER|Medical and Demographic questionnaire|Survey that collects basic medical and demographic information
224133655|NCT06177184|OTHER|Donor Human Milk - Nutritional Replacement|All DHM in North America is pasteurized and provided through certified milk banks regulated by the Human Milk Banking Association of North America. DHM for this study will be obtained from the NorthernStar Mothers Milk Bank (NMMB). The milk is pasteurized and rigorously tested according to Human Milk Banking Association of North America guidelines. In Canada, DHM is categorized as food or nutritional therapy and the milk bank is monitored and certified by the Canadian Food Inspection Agency. The product used for this study will be the same product that is provided to other hospital units (mainly the neonatal intensive care units) in Alberta and around Canada. The product will not be modified or tampered with in any way.
224133656|NCT05239949|OTHER|Hypopressive exercises|For hypopressive exercises, the patient will be instructed to inhale, then breathe to expand the ribcage, and then exhale completely. Hold the breath out before relaxing core and ribcage.
223409469|NCT02741076|DRUG|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
223409470|NCT02741076|DRUG|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
223558601|NCT03938766|DIAGNOSTIC_TEST|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
224133657|NCT05239949|OTHER|Pelvic floor exercises|For pelvic floor exercises, the patient is instructed to hold each contraction for 6 seconds.
223409471|NCT03105180|OTHER|A mixture of 2.7% sorbitol-0.54% mannitol solution|Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
223409472|NCT02040129|DEVICE|Acrysof Toric IOL|Lens implantation following cataract surgery
223409473|NCT06143280|OTHER|Data collection|Data collection using entries in the medical records of the respective patients (surgery reports, progress notes, consultation reports, imaging and pathology reports) who underwent surgery with the new dynamic technique for soft palate reconstruction.
223409474|NCT02920762|OTHER|on-interventional study - retrospective database review|
223409475|NCT01115244|DRUG|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
223409476|NCT06031740|PROCEDURE|Sclerotherapy with 1.5% polidocanol|"2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.~\- Group 2: Foam sclerotherapy."
223409477|NCT06031740|PROCEDURE|Foam sclerotherapy.|Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
223409478|NCT03778892|BEHAVIORAL|'Project Raincoat' Mobile Phone Application|Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
223409479|NCT01500382|DRUG|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
223409480|NCT01500382|DRUG|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
223409481|NCT01500382|OTHER|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
223409482|NCT01500382|OTHER|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
223409483|NCT01500382|DRUG|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
223409484|NCT03617380|OTHER|Usual Care|patients participating Usual Care discharge services
223409485|NCT03617380|OTHER|PharmD TOC|patients participating in a community pharmacy-based Transitions of Care Program (PHARMD-TOC)
223409486|NCT04423744|DRUG|BAY1817080|Film-coated tablet
223409487|NCT04423744|DRUG|Moxifloxacin|Film-coated tablet
224133658|NCT04917835|DEVICE|PLADUO(PX1000)|Three sessions of argon- and nitrogen- NTAPP treatment at 1-week interval. Two passes of argon-NTAPP treatment and two passes of nitrogen-NTAPP treatment were sequentially performed in each session. Argon plasma at a pulse energy of 0.8 J/pulse with a 12 msec of pulse duration and nitrogen-plasma at a pulse energy of 0.75 J/pulse delivered with a 7 ms of pulse duration.
224133659|NCT05974085|DRUG|Selinexor+RCHOP|XPO-1 inhibitor selinexor in combination with RCHOP
223409488|NCT04423744|DRUG|Placebo|Matched placebo as film-coated tablet
223409489|NCT06043505|OTHER|Echographic hemodynamic algorithm guiding fluid resuscitation|"Ultrasound Hemodynamic Algorithm (UHA):~1. st step: 1/ Assessment of left ventricular filling pressures by Mitral Doppler echocardiography (2) 2/ Pulmonary ultrasound on 4 anterior dials (3)~   E/Ea \>14 and/or E/A \>2~  * YES =\> No filling test =\> Bilateral anterior B lines on lung ultrasound =\> YES =\> Consider administration of diuretics~  * NO =\> Step 2~2. nd step: Assessment of filling response by dynamic maneuvers VTI (Velocity Time Integral) increase \>15% after passive leg raising (4) or Mini-fluid challenge (5,6) Or decision of a 250ml filling test~   * YES =\> consider 250ml bolus filling~  * NO =\> stop vascular filling~3. rd step if dynamic maneuvers in favor of a response to filling: 1/ Assessment of response to 250ml filling 2/ If no response to vascular filling: Pulmonary ultrasound on 4 anterior dials (3) Change from a pulmonary profile A to a pulmonary profile B~   * YES =\> depletion~  * NO =\> stop vascular filling"
223558602|NCT00361868|DRUG|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
224133660|NCT00209170|BEHAVIORAL|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
224133661|NCT00209170|DRUG|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
224133662|NCT00209170|DRUG|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
224298001|NCT02622451|BEHAVIORAL|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
224298002|NCT02622451|BEHAVIORAL|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
223409490|NCT00415727|DEVICE|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
223409491|NCT06831448|DEVICE|Prototype dressing|Five-layer foam dressing with polyurethane, cellulose, bicomponent, superabsorbent polymer, silicone adhesive, acrylic adhesive. LDPE. Size: 10cm x 10 cm. Topical application. Single use.
223558603|NCT00361868|DRUG|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
224133663|NCT06554470|DRUG|Systemic Methotrexate|Patients will receive systemic methotrexate (intramuscular; 50 mg/m2 body weight).
224133664|NCT06554470|DRUG|Local Methotrexate|Patients will receive local methotrexate (25 mg methotrexate as a fixed dose).
224133665|NCT04719169|DIAGNOSTIC_TEST|Dynamic MRI enema|Dynamic MRI enema
224026042|NCT05418023|OTHER|Autism Assessment|Includes Autism Diagnostic Observation Schedule (ADOS), Childhood Autism Rating Scale (CARS), Gilliam Autism Rating Scale (GARS), Autism Diagnostic Interview - Revised (ADIR) or an equivalent
223409492|NCT06831448|DEVICE|Marketed dressing 1|Five-layer foam dressing with polyurethane, polyethylene, cellulose, bicomponent, superabsorbent polymer, silicone adhesive, acrylic adhesive, polypropylene. Size: 12.9cm × 12.9cm. Topical application. Single use.
223409493|NCT06831448|DEVICE|Marketed dressing 2|Five-layer foam dressing with silicone, polyurethane, polyacrylate, cotton, viscose, polyester and polyolefin. Size: 10cm x 10 cm. Topical application. Single use.
223409494|NCT00485251|PROCEDURE|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
223409495|NCT00485251|PROCEDURE|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
223558604|NCT02479087|DRUG|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of \> 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
223558605|NCT02719964|OTHER|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
224026043|NCT05418023|OTHER|Intellectual Development Assessment|Includes Mullens Scales of Early Learning, Stanford Binet Intelligence Scales, Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Bayley Scales of Infant Development or an equivalent
223738567|NCT03889821|BEHAVIORAL|Parent-implemented Early Start Denver Model|The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.
224026044|NCT01393327|BEHAVIORAL|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
224026045|NCT04479631|DRUG|BRII-196|BRII-196 given intravenously
224026046|NCT04479631|DRUG|Placebo|Placebo given intravenously
224026047|NCT00291590|BEHAVIORAL|DHEP|
224026048|NCT04160767|DRUG|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
224026049|NCT04160767|BEHAVIORAL|Gluten free diet|Gluten free diet will be encouraged in both arms
224026050|NCT04160767|OTHER|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
224026051|NCT00351949|BIOLOGICAL|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
224026052|NCT01196273|OTHER|Comprehensive non invasive cardiovascular examination|"The examination includes:~* Anamnesis incl. admission form~* Physical examination~* Documentation of the medical therapy (incl. HAART)~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* 6 minute walk test~* Blood collection~* Questionnaire to quality of life and health economics"
224026053|NCT02277002|DEVICE|Cabin Air Filtration|
224026054|NCT02277002|OTHER|Placebo|No Cabin Air Filtration
224026055|NCT06036303|DEVICE|Nasr fascial closure device|Nasr fascial closure device is a novel device for fascial closure
224026056|NCT06036303|DEVICE|Berci Fascial Closure Device|Berci Fascial Closure Device is a known device for fascial closure
224026057|NCT00639353|DEVICE|senofilcon A toric soft contact lens|contact lens
224026058|NCT00639353|DEVICE|senofilcon A sphere soft contact lens|contact lens
223409496|NCT00485251|PROCEDURE|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
223409497|NCT00485251|PROCEDURE|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
224026059|NCT05971667|DRUG|tadalafil|tadalafil 10 mg one tablet daily
224026060|NCT05971667|DRUG|Sildenafil|sildenafil 20 mg two tablets daily
224026061|NCT05971667|DRUG|pentoxifylline|pentoxifylline 400 mg two tabs daily
224026062|NCT02838771|OTHER|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
224026063|NCT02838771|OTHER|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
224026064|NCT01904123|OTHER|Laboratory Biomarker Analysis|Correlative studies
224026065|NCT01904123|OTHER|Pharmacological Study|Correlative studies
224026066|NCT01904123|DRUG|STAT3 Inhibitor WP1066|Given PO
224026067|NCT03324191|DIETARY_SUPPLEMENT|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
224026068|NCT03324191|DIETARY_SUPPLEMENT|Tea beverage|Tea beverage
224133666|NCT04719169|DIAGNOSTIC_TEST|Fluoroscopic enema|Fluoroscopic enema
223409498|NCT02892773|DEVICE|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times per therapy session.~* Each I.S. therapy session will last about 15 minutes, 3 times per day.~* Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
223409499|NCT02892773|DEVICE|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated 3 times.~* Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~* Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
223409500|NCT05137782|OTHER|Specialty Palliative Care|Specialty palliative care, as opposed to primary palliative care.
223409501|NCT01193374|BEHAVIORAL|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
223409502|NCT01193374|BEHAVIORAL|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
223409503|NCT01193374|BEHAVIORAL|basic educational brochure|Booklet by ADA sent x 1.
223409504|NCT03640390|DRUG|Dexmedetomidine|This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.
223409505|NCT03640390|DRUG|Magnesium Sulphate|This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour
223409506|NCT03640390|DRUG|Normal saline|This group will receive normal saline infusion
223409507|NCT02134015|DRUG|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
223409508|NCT02134015|DRUG|Erlotinib|Oral erlotinib 150 mg/day
223409509|NCT02134015|DRUG|Placebo|Placebo infusion every 3 weeks
223409510|NCT06626230|DRUG|Curcuminoid Capsules|"500 mg curcuminoids from C3 Complex capsule. Curcuma longa (Turmeric), a constituent of the spice turmeric, is considered a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits Study participants will be instructed to insert the curcumin capsules gelatin intra-anally every day for a 14-day treatment period.~Escalating doses"
223409511|NCT04540419|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular administration
223409512|NCT04540419|BIOLOGICAL|Placebo|Intramuscular administration
223409513|NCT03697343|RADIATION|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
224026069|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
224026070|NCT03324191|DIETARY_SUPPLEMENT|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
224026071|NCT03324191|OTHER|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
224026072|NCT02596165|DEVICE|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
224026073|NCT04379726|BEHAVIORAL|therapeutic optimization|patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
224026074|NCT00561054|DRUG|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
224026075|NCT03772444|DIETARY_SUPPLEMENT|Beetroot juice|Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
224138960|NCT03280342|DRUG|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
224138961|NCT03280342|DRUG|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
224138962|NCT00523406|PROCEDURE|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
223409514|NCT03697343|RADIATION|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
223409515|NCT04378725|BEHAVIORAL|School-based smoking prevention and cessation program (The KOTAK program)|"Advance Intervention: Following the screening process, this intervention package was inclusive of group-briefing for the smokers in at least 3 subsequent sessions in one academic year. The content delivered by the dentist were based on the KOTAK guidebook consisted of 8 Modules.The modules were as follows:~1. Introduction: Identifying students who smoke~2. Cigarette and addiction~3. The danger of smoking and passive smokers~4. Advantages of smoke-free lifestyle and adolescent perception on smoking~5. Legal and religious perception of smoking~6. The benefits of smoking cessation~7. Preparation and how to stop smoking~8. Nicotine withdrawal symptom and relapse prevention~The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval."
223409516|NCT01507792|DRUG|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
223409517|NCT01507792|DRUG|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
223409518|NCT06575257|DRUG|Darolutamide|600 mg orally twice daily for 12 weeks before radical prostatectomy
223409519|NCT06575257|DRUG|Goserelin 3.6 mg|3.6 mg goserelin hypodermic once per 4 weeks
223409520|NCT00789841|DEVICE|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
223409521|NCT06576635|DRUG|Docetaxel|75 mg/m2 IV over 1-hour Day 1 of each 21-day cycle
223409522|NCT06576635|DRUG|Paclitaxel|135 mg/m2 IV over 3 hours Day 1 of each 21-day cycle
223409523|NCT06576635|DRUG|Gemcitabine|"1000 mg/m2 or 1250 mg/m2 IV over 30 min Days 1, 8, and 15 of each 28-day cycle or Days 1 and 8 of each 21-day cycle 28 days (1000mg/m2 cohort)~21 days (1250mg/m2 cohort)"
223409524|NCT06576635|DRUG|Pemetrexed|500 mg/m2 IV over 10 minutes Day 1 of each 21-day cycle
223409525|NCT06576635|DRUG|Vinorelbine|30 mg/m2 IV through a weekly injection over 6-19 minutes Days 1, 8, and 15 of each 21-day cycle
223409526|NCT00347958|BIOLOGICAL|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
223409527|NCT00754234|BEHAVIORAL|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
223409528|NCT06255756|BEHAVIORAL|Routine rehabilitation training|"Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week."
223409529|NCT06255756|BEHAVIORAL|Swallowing rehabilitation training|"Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced."
223558606|NCT02719964|OTHER|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
223558607|NCT02719964|OTHER|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
223558608|NCT00559845|DRUG|5-fluorouracil|600 milligrams per meter squared (mg/m\^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
223558609|NCT00559845|DRUG|Epidoxorubicin|90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
223558610|NCT00559845|DRUG|Cyclophosphamide|600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
223558611|NCT00559845|DRUG|Paclitaxel|Paclitaxel was administered at 80 mg/m\^2 i.v. over 1 hour weekly for 12 weeks.
223558612|NCT00559845|BIOLOGICAL|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
223558613|NCT04904276|DRUG|Fostamatinib|Fostamatinib disodium
223558614|NCT01097265|DRUG|capecitabine|
223558615|NCT01097265|DRUG|oxaliplatin|
224026076|NCT03772444|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
223558616|NCT01097265|OTHER|active surveillance|
224026077|NCT03772444|DIETARY_SUPPLEMENT|Water|Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
224026078|NCT03715439|DEVICE|Dental implant|A single dental implant was inserted 3 months after tooth extraction
224026079|NCT00454441|DRUG|MF101|
224026080|NCT04781387|DRUG|CRS3123|Study drug dosed PO BID for a total of 10 days
224026081|NCT04781387|DRUG|Active Comparator|Active comparator dosed PO QID for 10 days
224026082|NCT01890304|OTHER|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
224026083|NCT02084745|PROCEDURE|Boston keratoprosthesis type 1|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
224026084|NCT02084745|PROCEDURE|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
224026085|NCT05822167|OTHER|High Protein Meal at Cold Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Cold meal will be served at 25 degree C and below."
223558617|NCT01097265|OTHER|laboratory biomarker analysis|
223558618|NCT01097265|PROCEDURE|adjuvant therapy|
224026086|NCT05822167|OTHER|High Protein Meal at Warm Temperarute|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
224026087|NCT05822167|OTHER|High Protein Meal at Hot Temperature|"High Protein Meal providing 500kcal with 60% energy from protein, 30% fat, 10% carbohydrate.~Meal will be served at hot temperature i.e., 60 degree C and above."
224026088|NCT05822167|OTHER|High Carbohydrate Meal at Cold Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Cold meal will be served at 25 degree C and below."
224026089|NCT05822167|OTHER|High Carbohydrate Meal at Warm Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C."
223558619|NCT01097265|PROCEDURE|lymph node mapping|
223558620|NCT01097265|PROCEDURE|sentinel lymph node biopsy|
223409530|NCT06255756|PROCEDURE|Acupuncture therapy|"The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula)."
223409531|NCT02693470|DRUG|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
223409532|NCT01941849|DRUG|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
223409533|NCT01941849|RADIATION|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
224026090|NCT05822167|OTHER|High Carbohydrate Meal at Hot Temperature|"High carbohydrate meal providing 500 kcal with 65% of energy from carbohydrates, 25% from proteins and 10% from fats.~Meal will be served at hot temperature i.e., 60 degree C and above."
224026091|NCT05822167|OTHER|High Fat Meal at Cold Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Cold meal will be served at 25 degree C and below.
224026092|NCT05822167|OTHER|High Fat Meal at Warm Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at warm temperature i.e., between 40 degree C and 60 degree C.
224026093|NCT05822167|OTHER|High Fat Meal at Hot Temperature|High fat meal will contain 60% fat, 30% protein, 10% carbohydrate. Meal will be served at hot temperature i.e., 60 degree C and above.
224026094|NCT05296720|BEHAVIORAL|Tactile stimulation|Participants are asked to react as fast as possible to a tactile stimulation
224133667|NCT02310971|BIOLOGICAL|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
223409534|NCT02504242|DEVICE|Inject BMP|
223409535|NCT02504242|PROCEDURE|Locally Harvested Bone|
223409536|NCT00001680|DRUG|Thalidomide|
223409537|NCT01242670|BIOLOGICAL|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
223409538|NCT03567395|DIETARY_SUPPLEMENT|Melatonin|Melatonin (5 mg sublingual tablet) administered for 3 days
223409539|NCT03567395|DIETARY_SUPPLEMENT|Honey|Raw Honey (1.5 tablespoons) administered for 3 days
223558621|NCT03680781|DEVICE|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device."
224026095|NCT02245906|DIETARY_SUPPLEMENT|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
224026096|NCT02245906|DIETARY_SUPPLEMENT|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
223558622|NCT03086408|DEVICE|THRIVE|active nasal oxygen delivery system
223558623|NCT03086408|DEVICE|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
223558624|NCT01939522|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|
223558625|NCT05442723|PROCEDURE|On-Pump CABG|coronary artery grafting by using cardiopulmonary bypass machine
223558626|NCT05442723|PROCEDURE|Off-Pump CABG|coronary artery grafting by beating heart technique
224026097|NCT02245906|DIETARY_SUPPLEMENT|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
224026098|NCT00132847|BIOLOGICAL|German Cockroach Allergen extract|
224026099|NCT05560100|OTHER|Nominal Group Technique - 2 to 3 hour virtual meeting|Participants will be invited to a 2-3 online virtual online meeting with the goal of constructing and defining elements for producing a risk statement for dry needling that can be used for informed consent.
224133668|NCT04648423|DRUG|Sodium Oxybate|solution for oral administration
224133669|NCT04648423|DRUG|Placebo|solution for oral administration
224133670|NCT04958863|OTHER|Surgical mask|Use of a surgical mask during test
224133671|NCT04958863|OTHER|Polyester reusable mask|Use of a polyester reusable mask during test
223409540|NCT03304977|OTHER|questionnaire via smartphone|questionnaire via smartphone
223409541|NCT02318355|OTHER|normal saline|Crystalloid intravenous solution
223409542|NCT02318355|OTHER|lactated ringers|Crystalloid intravenous solution
223409543|NCT05243433|DEVICE|Laparoscopic surgery using the Maestro Platform|Laparoscopic cholecystectomy, laparoscopic hernia repair, laparoscopic appendectomy, laparoscopic bariatric surgery (gastric sleeve or gastric bypass), or laparoscopic colectomy performed using the Maestro Platform.
223409544|NCT02953210|DRUG|dexter ketamine|multimodal anesthesia without opioids ketamine as induction drug
223409545|NCT02953210|DRUG|Lidocaine Hydrochloride|continuous infusion intravenous
223409546|NCT02953210|DRUG|Fentanyl Hydrochloride|intravenous
223409547|NCT02953210|DRUG|Clonidine Hydrochloride|clonidine intravenous pre induction
223558627|NCT03367403|DRUG|Donanemab|Administered IV
224133672|NCT05589116|OTHER|Online Compassionate Imagery Intervention|The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
224026100|NCT05963529|OTHER|Humidity-ramp protocol|Participants are exposed to 42°C and 28% relative humidity for 70 minutes. Thereafter, humidity is increased 3% until an ambient humidity of 70% is achieved. The humidity at which esophageal temperature (and rectal temperature and heart rate) inflect is subsequently determined.
223409548|NCT02953210|DRUG|Midazolam Hydrochloride|premedication
223409549|NCT02953210|DRUG|Isoflurane Volatile Liquid|maintenance of general anesthesia
223409550|NCT02953210|DRUG|Rocuronium Injectable Solution|induction of general anesthesia
223409551|NCT02953210|DRUG|Propofol 1 % Injectable Suspension|induction of general anesthesia
223409552|NCT02953210|DRUG|Dexamethasone-21-Sulfobenzoate, Sodium Salt|at the end of the procedure 4mg IV
223409553|NCT02953210|DRUG|Ranitidine Hydrochloride|at the end of the procedure
223409554|NCT02953210|DRUG|Ondansetron Hydrochloride|at the end of the procedure
223409555|NCT02953210|DRUG|Ketorolac Injectable Solution|at the of the procedure
223409556|NCT02953210|DRUG|Bupivacaine Hydrochloride|at the end of the procedure for infiltration of trocar wounds
223409557|NCT06682689|DEVICE|transcutaneous vagus nerve stimulation|Two groups will use a tVNS stimulator for 12 weeks. Group 1 will apply active stimulation for up to 4 hours daily at a comfortable level for 6 weeks, while Group 2 will use it at the lowest intensity (0.1 mA). After 6 weeks (T2), the groups will switch. Participants will be instructed to use the device for at least 1 hour a day, with a recommendation of 4 hours, following guidelines and recent studies. The CE-certified tVNS® E device non-invasively stimulates the vagus nerve via the ear. It is approved for treating a.o.depression. Device parameters (intensity, pulse length, frequency) mimic invasive VNS techniques, ensuring safe and effective signal transmission. Stimulation will be applied to the left ear, with intensity adjusted to a tingling sensation, avoiding discomfort. The study follows an approved protocol, with low-intensity stimulation as a control. The device delivers biphasic impulses at 25 Hz, with 28 seconds ON and 32 seconds OFF, and is safe for extended use.
223409558|NCT02752113|DRUG|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
223409559|NCT02752113|DRUG|Metformin and Insulin sc|Metformin and Insulin sc
223409560|NCT00915018|DRUG|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
223409561|NCT00915018|DRUG|Trastuzumab|Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
224026101|NCT05963529|OTHER|Above-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% higher than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
224026102|NCT05963529|OTHER|Below-inflection fixed-condition exposure|After a 1 hour equilibrium at 42°C and 28% relative humidity, humidity will be increased 3% every 10 min until it is \~5% lower than the participants' individual esophageal temperature inflection point identified in the humidity ramp protocol. These conditions will be held constant for the remainder of the 9-hour exposure period (starting from the beginning of equilibrium). Tap water will be provided at regular intervals to limit dehydration.
224026103|NCT05963529|OTHER|Control fixed-condition exposure|Participants are exposed for 9-hours to 28°C with 35% relative humidity. Participant will be allowed to drink tap water ad libitum.
224026104|NCT01001559|DRUG|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
223409562|NCT00915018|DRUG|Paclitaxel|Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
223409563|NCT03258918|BEHAVIORAL|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
223409564|NCT00326716|DRUG|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
223409565|NCT03805568|DRUG|dexmedetomidine infusion group|dexmedetomidine as anaesthetic adjuvant
223409566|NCT03805568|DRUG|remifentanil infusion group|remifentanil as anaesthetic adjuvant
224026105|NCT01001559|DRUG|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
224026106|NCT01001559|DRUG|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
224026107|NCT01636960|BIOLOGICAL|PegIFN alfa-2b|
223409567|NCT06063070|DRUG|Fluzoparib Capsules|oral
223409568|NCT06063070|DRUG|Bevacizumab|Injectable solution
223409569|NCT00918411|DRUG|Ramosetron|oral
223558628|NCT03367403|DRUG|Placebo|Administered IV
223558629|NCT03367403|DRUG|LY3202626|Administered orally
224026108|NCT00312143|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
223409570|NCT00918411|DRUG|Placebo|oral
223409571|NCT01146093|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
223409572|NCT03159871|DEVICE|Stratafix suture|Stratafix barbed sutures during C-Sections.
223409573|NCT03159871|DEVICE|Vicryl suture|Standart Vicryl suture during C- Sections.
223558630|NCT00213941|DEVICE|Echocardiography|
224026109|NCT00172484|PROCEDURE|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
223409574|NCT05280626|DRUG|Sintilimab|After one cycle of standard R-CHOP chemotherapy, Group A uses Sintilimab with R-CHOP, with Sintilimab administered on day 10 post-chemotherapy, scheduled for 5 cycles. After 5 cycles CR patients in group A continue Sindilizumab treatment for 8 times, once every 21 days.
223409575|NCT05280626|DRUG|Rituximab|After one cycle of standard R-CHOP chemotherapy, Group B uses R-CHOP for 5 cycles. After 5 cycles, CR patients in group B are followed up for observation.
223409576|NCT03073031|DEVICE|Tablet: Samsung Galaxy Tab A|
223409577|NCT02657122|DRUG|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
224026110|NCT00172484|PROCEDURE|nursing program|To establish a systemic stroke prevention, education protocol
224026111|NCT00172484|PROCEDURE|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
224026112|NCT06342271|OTHER|Nordic walking training|Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.
224026113|NCT06342271|OTHER|Free Walking training|Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.
224026114|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution with epinephrine 1:100,000~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
224026115|NCT00482573|PROCEDURE|Dental local anesthesia|"* 2% lidocaine solution without vasoconstrictor~* infusion of 1,8 mL (one cartridge)~* Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
224026116|NCT02587468|DIETARY_SUPPLEMENT|Juice Plus+(R)|before-after comparison of plasma phenolics
224026117|NCT05029479|OTHER|Bonding in NCCLs|bonding agent which can resist moisture and has shorter decalcifying and curing time
224026118|NCT01209780|BIOLOGICAL|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
224026119|NCT01209780|BIOLOGICAL|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
224026120|NCT01209780|BIOLOGICAL|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children \<4 years.
224026121|NCT04510831|OTHER|Refined maize with extrinsic addition of labelled FeSO4|Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)
224026122|NCT04510831|OTHER|T.molitor native chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
224026123|NCT04510831|OTHER|T molitor reduced chitin|Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
224026124|NCT04354896|DRUG|Levothyroxin|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH 0.4 to 4.6 mU/L, no change to dose; TSH ≥4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
224026125|NCT04354896|DRUG|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
224026126|NCT03034629|BEHAVIORAL|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
224026127|NCT05552885|OTHER|Evaluation|The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
224026128|NCT06081517|BEHAVIORAL|Social Determinants of Health and toxicity questionnaires|Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.
223409578|NCT02657122|DRUG|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
223409579|NCT02657122|DRUG|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
223409580|NCT02657122|DRUG|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
223409581|NCT00886444|DRUG|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
223409582|NCT00781729|BEHAVIORAL|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
224133673|NCT00543569|DRUG|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
224026129|NCT05837494|DRUG|Intra-articular Ozone and corticosteroids|"patients will undergo one session a week for a total of four sessions of intra-articular knee injection with combination of 5ml (25 μg/ml) ozone injection + 2 ml lignocaine 2% + 2 ml Betamethasone sodium phosphate 4 mg.~Under aseptic precautions. A22-gauge needle was positioned inferior-laterally into the infera-patellar pouch, injection of 2 ml of 4 mg Betamethasone sodium phosphate, and 2 ml injection lignocaine 2% was injected slowly (over 1-2 minutes). The needle was left in space for the 5 ml (25 μg/ml) ozone injection. Patients were advised to avoid strenuous activity for 2-3 days following the intra-articular injection."
224026130|NCT05837494|DRUG|intra-articular PRGF Method|"Patients will undergoes two doses with 2 weeks interval by injection of already synthetic plasma rich in growth factors \[PRGF\] vial intra-articularly.~This vial is formed of lyophilized cake of platelet growth factors in a tightly sealed container stored at 2-8◦C which synthesized under complete aseptic technique by activation of platelets to release its growth factors and cytokines which help in knee cartilage regeneration and act as potent anti-inflammatory to reduce the pain.~Prior to usage, reconstitution of the product was done using 1 ml saline and 1 ml lignocaine 2% followed by gentle vial rubbing for 3 min then, the mixture was kept at ambient temperature for 5 min to ensure complete protein re-hydration."
224026131|NCT03463161|DRUG|Pembrolizumab|Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
224026132|NCT03463161|DRUG|Epacadostat|Epacadostat (100mg) taken by mouth twice a day.
224026133|NCT04639141|COMBINATION_PRODUCT|Synbiotic|Prebiotic + Probiotic
224026134|NCT04639141|BEHAVIORAL|Gut-directed Hypnotherapy|Psychotherapy sessions
224133674|NCT00543569|DRUG|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
224133675|NCT00543569|DRUG|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
224026135|NCT02637960|DRUG|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
224026136|NCT02637960|DRUG|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
224026137|NCT02560714|DEVICE|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
224026138|NCT00133146|BIOLOGICAL|Grass MATA MPL|
223409583|NCT00781729|BEHAVIORAL|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
223409584|NCT04134767|BEHAVIORAL|Health Linkage|Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
223409585|NCT04134767|BEHAVIORAL|Overdose Education|Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
223409586|NCT04028804|PROCEDURE|FDG PET|Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.
223558631|NCT02934841|DRUG|Conbercept|
224026139|NCT01542931|DRUG|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
224133676|NCT00543569|DRUG|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
224133677|NCT00543569|DRUG|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
224133678|NCT03097224|BEHAVIORAL|Prehabilitation|Four weeks of tele-supervised prehabilitation
224133679|NCT03194152|DIETARY_SUPPLEMENT|Peanut|Dietary Supplement: Peanut
224133680|NCT03194152|DIETARY_SUPPLEMENT|Control|Dietary Supplement: High carbohydrate snacks
223558632|NCT02934841|DRUG|sham|
223558633|NCT03704844|OTHER|non applicable|non applicable
223558634|NCT00194077|DRUG|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
223558635|NCT00194077|DRUG|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
224026140|NCT01844947|DRUG|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance \>60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
224133681|NCT04019275|BEHAVIORAL|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
224138963|NCT04504370|DRUG|GLP-1 receptor agonist|PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
224138964|NCT04504370|DRUG|Placebo|PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
224138965|NCT04640207|DEVICE|Facial skin treatment|Facial skin treatment using the Alma Hybrid system with a unique pattern that includes both ablative and non-ablative wavelengths
224138966|NCT01320111|DRUG|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
223409587|NCT04028804|PROCEDURE|FLT PET|The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
224026141|NCT01844947|DRUG|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
224026142|NCT00102609|DRUG|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
223409588|NCT05883657|DEVICE|Condition 1 : Prototypes (816-v1) every weeks|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
223409589|NCT05883657|DEVICE|Condition 2 : Prototypes (816-v1) every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
223409590|NCT03486080|DRUG|Dutogliptin Tartrate|Active treatment
223409591|NCT03486080|DRUG|Filgrastim Injectable Product|Active treatment
223409592|NCT03486080|DRUG|Placebos|placebo control
223409593|NCT06489470|PROCEDURE|Strokectomy/Necrosectomy|After obtaining CT-/MRT-perfusion, the infarcted area (e.g. infarct core) of malignant MCA-infarction is localized. By using the neuronavigation, surgical resection of necrotic tissue is performed in a non-eloquent area until the space occupying effect is released. At the end of the surgery, the bone flap is reinserted and fixated.
223409594|NCT00300885|DRUG|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
223409595|NCT00300885|DRUG|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily\] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
223409596|NCT00001409|DRUG|Interleukin-2|
223409597|NCT01019395|DRUG|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
223409598|NCT04373395|PROCEDURE|D-CLAG|Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor
224026143|NCT00102609|DRUG|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
224026144|NCT00102609|DRUG|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
224026145|NCT04234854|DIAGNOSTIC_TEST|Intravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent|IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
224026146|NCT04176146|BEHAVIORAL|Peer comparison and social norms messaging|This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
224026147|NCT05007808|DRUG|G001 Topical Gel|Non-steroidal anti-inflammatory drug for topical administration
224026148|NCT05007808|DRUG|Vehicle|Vehicle Gel for topical administration
224026149|NCT00005597|DRUG|temozolomide|200 mg/m\^2/day, PO, on Days 1-5 of each 28 day cycle.
224026150|NCT02621125|DIETARY_SUPPLEMENT|Fertilix|daily supplementation
224026151|NCT02621125|OTHER|Placebo|Placebo
224026152|NCT00728585|DRUG|Palifermin|Given IV
224026153|NCT00728585|OTHER|Placebo|Given IV
224026154|NCT02675504|OTHER|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
224026155|NCT00645047|BEHAVIORAL|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
224026156|NCT00645047|BEHAVIORAL|In-Person CBT|In-Person Provision Of Cognitive Therapy
224026157|NCT01304433|DRUG|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
224026158|NCT02107053|DIETARY_SUPPLEMENT|PJ|
224026159|NCT02107053|DRUG|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
224026160|NCT02687022|DEVICE|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
224026161|NCT02687022|DEVICE|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
224026162|NCT06254547|OTHER|Daily updated ranking on leaderboard|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service and view a daily updated leaderboard ranking.~Leaderboards will demonstrate participant's ranking in their respective group, participant's (anonymized) name, cumulative point total, total case amount, and current level. Participant ranking will be based on the cumulative point total. All groups will have continual access to their personal score.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
223409599|NCT05648942|DIAGNOSTIC_TEST|Anemia testing|Patients will undergo a point of care test to identify possible anemia
223409600|NCT04213066|DEVICE|Portable tablet|Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
224133682|NCT02020096|PROCEDURE|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
224133683|NCT02020096|PROCEDURE|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
223409601|NCT01985529|OTHER|Exercise|
223409602|NCT05473949|DRUG|Profofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|Use of 1% Propofol (Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
224026163|NCT06254547|OTHER|Daily motivational message|"The intervention will last for seven days. Participants will on day two through seven receive a group daily message using an internet-based messaging service encouraging training.~Participants will not receive further training encouragement to train in the app or interact with the research group beyond this, aside from technological aid."
224026164|NCT02574156|DRUG|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
224026165|NCT02146456|DRUG|Tranexamic Acid|
224026166|NCT00505284|DRUG|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
224133684|NCT03338517|OTHER|Helium Neon Laser|
224133685|NCT03150095|BEHAVIORAL|Health coaching|Patients will work with a health coach by telephone
224133686|NCT03259997|DIETARY_SUPPLEMENT|Probiotic supplement|Probiotic supplement
223409603|NCT05473949|DRUG|Ketofol for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients|use of Ketofol (1% Propofol + 5% Ketamine with a ratio 1/4) Indution dose: 0.75mg/kg Maintenance dose: 6-7mg/kg/h) for Sedation in Cholangiopancreatography for ASA III and ASA IV Patients
223409604|NCT02086149|BEHAVIORAL|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
223409605|NCT02086149|BEHAVIORAL|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
223409606|NCT04824326|BEHAVIORAL|PSAI-CA|"The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day."
223409607|NCT03382626|DEVICE|anodal tDCS|Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
223558636|NCT04967287|DEVICE|MyopiaX|MyopiaX treatment twice a day
224026167|NCT00505284|DRUG|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
224026168|NCT00505284|DRUG|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
224026169|NCT00505284|DRUG|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
224133687|NCT03259997|DIETARY_SUPPLEMENT|Placebo|Placebo
224133688|NCT01070602|PROCEDURE|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
224133689|NCT03169023|BEHAVIORAL|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
224133690|NCT03169023|BEHAVIORAL|Enhanced Usual Care Packets|-From the American Cancer Society Website
224133691|NCT03169023|OTHER|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
224133692|NCT03169023|OTHER|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
224133693|NCT03169023|OTHER|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
223409608|NCT03382626|DEVICE|Computer-assisted training|The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
223409609|NCT03382626|DEVICE|sham tDCS|Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
223409610|NCT00603902|DRUG|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
223409611|NCT00603902|DRUG|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
223409612|NCT00603902|DRUG|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
224026170|NCT00505284|DRUG|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
224026171|NCT00351130|DRUG|valsartan|
224026172|NCT00351130|DRUG|amlodipine|
224026173|NCT03601988|RADIATION|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
224026174|NCT03601988|DRUG|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
224026175|NCT03476213|PROCEDURE|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
224026176|NCT03476213|PROCEDURE|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
224026177|NCT02736305|DRUG|Regorafenib|Once a day for 21 days in a 28 days cycle
224026178|NCT03027492|OTHER|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
224026179|NCT00340691|DRUG|Doxycycline|
224026180|NCT01275131|DRUG|Insulin aspart|
224026181|NCT01275131|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
223409613|NCT02129413|DEVICE|Delta system|
223409614|NCT00444938|DEVICE|H1 -coil TMS device|
223409615|NCT01652768|OTHER|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
223409616|NCT01652768|OTHER|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~1. Introduce the palliative care team concept.~2. Provide contact information for the palliative care team given~3. Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~4. Offer community resources to patient and caregiver (Appendix B)~5. Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~6. Provide supportive care"
223409617|NCT01652768|OTHER|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~1. Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~2. Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~3. Provide supportive care."
223409618|NCT01652768|OTHER|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care"
223409619|NCT01652768|OTHER|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Administer Symptom Assessment Tool~3. Provide pain and/or symptom management intervention~4. Provide supportive care"
223409620|NCT01652768|OTHER|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Re-assess pain and/or symptom management issues and /or intervention~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care."
223409621|NCT01676935|DRUG|ABT-126|See arm description
223409622|NCT06325839|OTHER|HypnoBirthing training and oxytocin massage group|HypnoBirthing training and oxytocin massage were applied for a total of 12 hours for 4 weeks with the experimental group.
223409623|NCT00003113|BIOLOGICAL|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
223409624|NCT00003113|DRUG|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
223409625|NCT00003113|DRUG|etoposide|Etoposide is given on days 1-3.
223409626|NCT00003113|DRUG|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
224133694|NCT03169023|OTHER|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
224133695|NCT03169023|OTHER|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
224026182|NCT02202954|OTHER|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
224026183|NCT01134120|DRUG|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
224026184|NCT03031860|OTHER|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
224026185|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Aerobic Walking Exercise Training|"This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance."
224026186|NCT05344040|BEHAVIORAL|Remotely Delivered and Supported Stretching and Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
224026187|NCT00282204|BEHAVIORAL|antenatal hypnosis + audio compact disc on hypnosis|
224026188|NCT00282204|BEHAVIORAL|Audio compact disc on hypnosis|
224026189|NCT00731120|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
224026190|NCT00731120|DRUG|Placebo|Vortioxetine placebo-matching capsules
224026191|NCT00322673|DRUG|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
224026192|NCT02292654|DRUG|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
223409627|NCT00003113|DRUG|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
224026193|NCT03709420|DRUG|Placebo|Placebo capsule to match active drug
224026194|NCT03709420|DRUG|FOR-6219|FOR-6219 capsule
224026195|NCT02541760|DRUG|Monteleukast|4 ml monteleukast daily for one month
224026196|NCT02541760|DRUG|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
223409628|NCT00003113|RADIATION|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
223409629|NCT06580717|DRUG|enavogliflozin 0.3mg|"Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
223409630|NCT06580717|DRUG|enavogliflozin Placebo|"A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo."
223409631|NCT02889939|OTHER|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
223409632|NCT01180699|BIOLOGICAL|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
223409633|NCT02145442|DIETARY_SUPPLEMENT|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
223558637|NCT04967287|DEVICE|Myopia control spectacles|To be used all as prescribed
224026197|NCT02582567|OTHER|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
224026198|NCT02142660|PROCEDURE|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
223409634|NCT01033032|DRUG|Amrubicin|"Phase I: dose-escalating portion with the starting dose of amrubicin at 90mg/m\^2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m\^2; DL3 - 110mg/m\^2; and DL4 - 120mg/m\^2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
223409635|NCT02944552|DRUG|bicyclol tablet 25mg|Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
223409636|NCT02944552|DRUG|bicyclol tablet 50mg|Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
223558638|NCT00985608|DRUG|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
223558639|NCT00985608|DRUG|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
223558640|NCT04928885|BEHAVIORAL|Wits Workout Program|12 week, one hour per week multi-modal, interactive training.
224026199|NCT05202548|OTHER|Immuno-histochemical staining|blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
224026200|NCT01635400|DRUG|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
224026201|NCT02434939|DRUG|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
224026202|NCT02434939|DRUG|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
224026203|NCT05163587|COMBINATION_PRODUCT|low GI composite flour|low GI composite flour orally in chapati form (3times/day)
224026204|NCT04412915|OTHER|Labor induction|Labor induction with oxytocin or prostagladin
224026205|NCT04967534|BEHAVIORAL|WB-EMS|Simultaneous, individually adjustable stimulation of 12 muscle groups using an interval approach with a duty cycle of 6s impulse/4s rest, bipolar electric current (impulse -frequency 85Hz, -width 350μs, rectangular pattern) will be applied. After a 4-week conditioning period, 1.5x 20 min/week WB-EMS will be conducted for 12 weeks (total training duration 8 weeks). Easy to perform functional exercises focusing on balance, transfer ability, stepping, and lower extremity strength will be done during WB-EMS. Exercise intensity will be individually prescribed and adjusted by the rate of perceived exertion (RPE-Borg CR10 scale 4 (moderate) to 7 (hard)). WB-EMS will be fully supervised one-on-one.
224026206|NCT04967534|BEHAVIORAL|social contact control group|Psycho-social intervention with participants randomized to the control group receiving (if wanted) the same social contact time (20-30 minutes/week) as the WB-EMS group. Depending on personal preferences and Covid-19 restrictions this will be done by phone or in-person one-on-one. Health-related topics and/or general chatting will be offered.
224133696|NCT03169023|BEHAVIORAL|iOTA|-Washington University based intervention
223409637|NCT02944552|DRUG|polyene phosphatidylcholine capsule 456mg|Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
223409638|NCT02309411|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
223409639|NCT00904761|OTHER|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
223558641|NCT04928885|OTHER|Control Group that receives intervention after the study|The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
223558642|NCT04607174|OTHER|Pathologic group|"Voluntary Activation level will be determined according to the interpolate twitch technique (ITT).~During isometric contractions (knee at 40° flexion), three electric shocks (doublets) will be delivered. The first shock will be delivered at rest before contraction. The second one will be delivered 3-4 s after the beginning of the effort. The third one will be delivered at rest 2-3 s after the contraction has ended. Two isometric contractions will be performed, with a 3-minute break.~Then, 3 consecutive continuous passive motion (CPM) extension-flexions of the knee joint (range 105-0°), and 3 isokinetic concentric contractions (ISOK) will be performed. During both CPM and ISOK an electric shock will be delivered during each repetition. The instant of stimulation will be determined in a way allowing the twitch moments to peak at exactly 40° of knee flexion during extension. The same procedure will be administered first to the affected limb, and then to the non-affected limb."
224026207|NCT02391857|PROCEDURE|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
224026208|NCT01426763|BIOLOGICAL|CINRYZE with rHuPH20|
224026209|NCT04154176|OTHER|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
224026210|NCT02926976|DRUG|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
224026211|NCT02926976|DRUG|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
224133697|NCT00673478|DRUG|Tiotropium+Salmeterol|
224133698|NCT00673478|DRUG|Salmeterol|
223409640|NCT03656692|DRUG|Acthar Gel|Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
224133699|NCT00673478|DRUG|Tiotropium|
224133700|NCT03374384|OTHER|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
224133701|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume
224026212|NCT02926976|DRUG|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
224026213|NCT02926976|DEVICE|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
224026214|NCT02926976|DEVICE|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
223409641|NCT01478672|PROCEDURE|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
223409642|NCT00281177|BEHAVIORAL|Asthma Disparity Reduction Strategy|
223409643|NCT01017276|DRUG|ASP1585|oral
223738568|NCT03889821|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
223738569|NCT03459378|OTHER|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
224026215|NCT02926976|DEVICE|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
224026216|NCT03942809|DEVICE|Effectiveness|Effectiveness and Practicability in anesthetized patient under controlled conditions
224026217|NCT06423209|OTHER|Strength training program|Strength training program to be developed during 16 weeks. There will be 3 exercise sessions per week and those participants who perform at least 2 sessions during the program will be considered for the statistical analysis.
224026218|NCT06373029|OTHER|Ultrasound examination|The investigators made ultrasound examinations to the participants to test whether the model could improve their diagnostic accuracy
224026219|NCT02966951|BIOLOGICAL|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
224026220|NCT02652013|OTHER|cognitive evaluation|
224026221|NCT03821389|DEVICE|NIOD Frequencer|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
224026222|NCT00069238|BIOLOGICAL|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
224026223|NCT00069238|DRUG|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
224026224|NCT03039257|DIETARY_SUPPLEMENT|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
224026225|NCT02024763|BEHAVIORAL|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
224026226|NCT01190137|DIETARY_SUPPLEMENT|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
224026227|NCT03201705|DEVICE|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
224026228|NCT00729768|DRUG|basiliximab|2 intravenous doses
224026229|NCT00729768|DRUG|efalizumab|Subcutaneous repeating dose
223409644|NCT06085326|OTHER|Smart Checklist|The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
223409645|NCT06685705|DRUG|Magnesium Sulfate and Bupivacaine 0.125%|patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.
223409646|NCT06685705|DRUG|bupivacaine and Neostigmine|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally
223409647|NCT06685705|DRUG|fentanyl and bupivacaine|patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
224026230|NCT00729768|DRUG|mycophenolate mofetil|Oral repeating dose
224026231|NCT00729768|DRUG|corticosteroids|Repeating doses
224026232|NCT00729768|DRUG|cyclosporine|Oral repeating dose
224026233|NCT01001832|DRUG|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
224026234|NCT01001832|DRUG|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
223409648|NCT02693106|DIETARY_SUPPLEMENT|Control|Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.
223409649|NCT02693106|DIETARY_SUPPLEMENT|Leucine|Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.
224026235|NCT04129853|DEVICE|Cyberlegs Xleg|Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee
224133702|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume
224133703|NCT06142461|DRUG|Gardasil|Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume
223409650|NCT02693106|DIETARY_SUPPLEMENT|Butyrate -|Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.
223409651|NCT02693106|DIETARY_SUPPLEMENT|Butyrate +|Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.
223409652|NCT02693106|DIETARY_SUPPLEMENT|Octanoate -|Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.
223409653|NCT02693106|DIETARY_SUPPLEMENT|Octanoate +|Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.
223409654|NCT02693106|DIETARY_SUPPLEMENT|Carnitine|Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.
223409655|NCT02693106|DIETARY_SUPPLEMENT|Butter fraction|Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.
223409656|NCT04020692|BEHAVIORAL|EOPC Intervention|"The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization."
223409657|NCT03104049|DEVICE|Neuromuscular taping|"NMT applications:~1. rhomboid major muscle~2. muscles abdominals~3. spinal muscles~4. pectoralis major muscles~5. gastrocnemius muscle~6. upper trapezius muscle~7. anterior muscles of the neck"
223409658|NCT01564888|PROCEDURE|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
223409659|NCT03924401|DRUG|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
223409660|NCT05070949|BEHAVIORAL|Mindful Self-Compassion|Bi-weekly meeting will involve six lessons: What is Self-Compassion , Practicing Self-Compassion, Discovering your Compassionate Voice, Self-Compassion and Resilience , Self-Compassion and Burnout and Making it Count
223409661|NCT06483178|DEVICE|Attune knee implant|Attune cementless cruciate retaining rotating platform implant (DePuy Synthes) with a standard gap balancing cruciate sacrificing surgical technique
223409662|NCT06483178|DEVICE|Triathlon knee implant|Triathlon cementless condylar stabilised implant (Stryker) with a standard gap balancing cruciate sacrificing surgical technique
223558643|NCT06225518|BEHAVIORAL|Individualized physical activity management system|Participants will be provided with personalized exercise recommendations determined by a decision system by public health nursing and physiotherapy and rehabilitation experts via the mobile application. Targets will be determined for participants based on their completion of physical activity recommendations every day and every week in the mobile application. The initial program will be individually created based on the initial data collected and each participant's lifestyle, physical activity level and barriers to physical activity. Then, depending on the participants' ability to achieve their goals, the duration and intensity of the suggestions given will be individualized to a level that the person can complete.
223558644|NCT03470194|OTHER|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
223558645|NCT03470194|OTHER|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
223409663|NCT06176274|OTHER|Prehabilition program|this program includes nutrition, physical activity, medical optimization and psychological support interventions.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. it will be applied for 4 weeks before surgery. the first meeting is scheduled for 40 minutes. the program compliance process will be monitored by phone weekly. postoperative recovery and functional capacity measurements will be performed.
223409664|NCT03558425|DRUG|CKD-381|1 tablet administered before the breakfast during 7 days
224026236|NCT04094025|DRUG|dATS|d-Amphetamine Transdermal System
224026237|NCT01729325|BEHAVIORAL|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
224026238|NCT00001563|BIOLOGICAL|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
224026239|NCT00001563|BIOLOGICAL|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
224026240|NCT00001563|DRUG|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
224026241|NCT05350579|OTHER|Yogurt Intervention|"Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract."
224133704|NCT06142461|DEVICE|PharmaJet Stratis® Needle-Free Injection System|0.5mL dose injection
224133705|NCT06142461|DEVICE|PharmaJet Tropis® Needle-Free Injection System|0.1mL dose injection
224133706|NCT01869751|DRUG|Prucalopride|Treatment with prucalopride for slow-transit constipation
224133707|NCT02124707|DRUG|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
224133708|NCT02124707|DRUG|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
224026242|NCT05975957|DEVICE|Photomodulation Therapy with the Light-Aid system|Patients in the intervention group (FBM) will be submitted to 10 treatment sessions (twice a week/five weeks) with the Light-Aid system (Bright Photomedicine, SP, Brazil), operated in continuous mode, with 100 LEDs of 850nm wave per tip, with application time varying from 4 to 8 minutes. Irradiation parameters will be customized based on pain intensity, skin phototype and Body Mass Index (BMI).
223409665|NCT03558425|DRUG|D026|1 tablet administered before the breakfast during 7 days
224026243|NCT05975957|DEVICE|Control|Patients in the placebo group will undergo the same therapeutic protocol as the FBM group using a device with the same appearance as the Light-Aid System, but with inert light emission. In both groups, the treatment will be administered in contact with the skin over the knee, with the patient positioned in dorsal decubitus. The three tips of the device will be positioned horizontally over the anterior region of the knee with the central tip over the patella.
224133709|NCT02124707|DRUG|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
224133710|NCT00037635|DRUG|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
224133711|NCT00037635|DRUG|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
224133712|NCT01692353|OTHER|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
224133713|NCT04054843|DIAGNOSTIC_TEST|Afamin|Plasma maternal afamin levels
223409666|NCT00839800|DRUG|Symbicort Turbuhaler|160/4.5 µg
223409667|NCT00839800|DRUG|Terbutaline Turbuhaler|0.4 mg
223409668|NCT04687137|DRUG|TAK-743 300 mg|TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks
223409669|NCT01422564|DEVICE|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
223409670|NCT01422564|DEVICE|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
223409671|NCT00735969|DRUG|Peginterferon|
223409672|NCT00735969|DRUG|Ribavirin|
223558646|NCT04305769|DRUG|Alanyl-glutamine|The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.
224026244|NCT03080012|OTHER|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
224026245|NCT03080012|OTHER|Plasma/serum sampling|Simultaneously with saliva sampling.
224026246|NCT02453360|PROCEDURE|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
224133714|NCT03822871|DRUG|CTT1403|Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
224133715|NCT03822871|DRUG|CTT1057|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
224133716|NCT03822871|DRUG|68Ga-PSMA-11|Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
224133717|NCT03489135|DEVICE|ReVene Thrombectomy Catheter|Endovascular treatment of an acute iliofemoral DVT
224133718|NCT01088438|BEHAVIORAL|Contextualization workshop|A four-hour course on contextualization.
224133719|NCT03212846|OTHER|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
224133720|NCT02276716|DIETARY_SUPPLEMENT|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
224133721|NCT00511342|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
224133722|NCT00511342|DRUG|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
224133723|NCT00555048|BIOLOGICAL|alemtuzumab|
224133724|NCT00555048|DRUG|busulfan|
224133725|NCT00555048|DRUG|cyclophosphamide|
224133726|NCT00555048|DRUG|methotrexate|
224133727|NCT00555048|DRUG|tacrolimus|
224133728|NCT00555048|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224133729|NCT00555048|PROCEDURE|peripheral blood stem cell transplantation|
224133730|NCT04766138|DEVICE|Fecobionics|Fecobionics is a new device to be inserted through the anal canal into rectum for studying defecation
224138967|NCT01320111|DRUG|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
224026247|NCT02453360|DRUG|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
224026248|NCT03770559|PROCEDURE|Minimal Invasive RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery
224026249|NCT03770559|PROCEDURE|Open RAMPS|Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
223409673|NCT03925948|BEHAVIORAL|PLAN 4 Success-Diabetes|The study intervention-PLAN 4 Success-Diabetes-consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
223409674|NCT01372618|DRUG|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
223409675|NCT02801617|DRUG|PRO-067|1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
223409676|NCT02801617|DRUG|GAAP Ofteno®|1 drop QD during 30 days Active comparator, reference medication.
223409677|NCT03524417|BIOLOGICAL|Equine rabies immunoglobulin injection on day 7|The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
223409678|NCT01954056|DRUG|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
223409679|NCT01954056|DRUG|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
223409680|NCT03038542|BEHAVIORAL|Gain-framed text messages|
224026250|NCT02308826|BEHAVIORAL|Turtle Program|
224026251|NCT02308826|BEHAVIORAL|Cool Little Kids|
224026252|NCT04493190|PROCEDURE|Scapular control training|Participants in this group will learn how to maintain normal scapular position at first. Then they will progress to moving arm with good scapular control with mirror. Afterward, participants will undergo movements protocol which give different directions of arm movements while keeping scapula in a good alignment. They will also receive scapular-focused exercises. The difficulty of the movement protocol will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
224026253|NCT04493190|PROCEDURE|General exercise|Participants in this group will receive a general shoulder strengthening with theraband or dumbbell. Load will increase weekly. They will be trained three times per week for 6 weeks with an average duration of 30 min per session.
224026254|NCT04260425|OTHER|Serving of oatmeal made from low avenanthramides oats and water|One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
224026255|NCT04260425|OTHER|Serving of oatmeal made from high avenanthramides oats and water|One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
224133731|NCT03395275|BEHAVIORAL|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~1. Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~2. Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~3. Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
223409681|NCT03038542|BEHAVIORAL|Standard care text messages|
223409682|NCT01767766|DRUG|TGR-1202|TGR-1202 Daily Oral Dose
223409683|NCT06128772|OTHER|Battlefield Acupuncture|5 points of acupuncture treatment in each ear weekly for 8 weeks
223409684|NCT03956563|DEVICE|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
224026256|NCT06424626|DRUG|AK104+Axitinib|Subjects receive AK104 10mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
224026257|NCT06424626|DRUG|AK112+Axitinib|Subjects receive AK112 20mg/kg intravenously (IV) every 3-week cycle plus Axitinib until progression.
223558647|NCT04310436|BEHAVIORAL|Modifying saccades by looking down to naval.|Paragraphs from list Provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly down to their naval to reset the lateral tongue position.
223409685|NCT03956563|DEVICE|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
223409686|NCT00053196|BIOLOGICAL|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
224298003|NCT02945605|OTHER|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~1. Eye-Head coordination, gaze stability and convergence exercises~2. Sitting balance~3. Standing static balance (i.e. feet-in-place)~4. Dynamic balance (feet moving, but not walking)~5. Ambulation (gait exercises)~6. Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
224298004|NCT02945605|OTHER|Standard of Care|Standard care as directed by a physician.
224298005|NCT04232813|DRUG|Estradiol 10 MCG Vaginal Tablet [VAGIFEM]|To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
223409687|NCT00053196|BIOLOGICAL|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC\> 1000/uL for 3 consec days
223558648|NCT04310436|BEHAVIORAL|Modifying saccades by looking in air.|Paragraphs from list provided by Researcher. Participants to read out loud for 10 minutes twice per day for the five week period. On any word they anticipate / experience dysfluencies look quickly up to reset the lateral tongue position.
223558649|NCT06264999|DEVICE|Journey II CR|Implantation of Journey II CR Crucite Retaining Knee
223558650|NCT06264999|DEVICE|Journey II XR|Implantation of Journey II XR Bi Cruciate Retaining Knee
223738570|NCT05791045|PROCEDURE|single vs double|we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
224026258|NCT05884151|DRUG|Tranexamic acid|Group A 30 patients treated with Intradermal Tranexamic acid injection (4mg/ml) for preparation an insulin syringe was used with a volume of 1ml containing 0.04 ml of TXA and the reminder being normal saline to ensure 4mg preparation in each insulin syringe
224026259|NCT05884151|DRUG|Platelets rich plasma|Group B 30 patients prescribed with PRP (1ml) intra-dermally PRP was obtained manually by a two-step procedure using a centrifuge machine. First spin was performed at 1500 RPM for 10 minutes. Second spin was performed at 4000 RPM for 10 minutes. Thus, obtaining a two-part plasma. Upper two third was platelet poor plasma and was discarded. Lower one third was platelets rich plasma. Before injection applying 0.1 ml calcium chloride was added for each 1 ml of PRP to activate the platelets. PRP was injected 1 ml by using 30 G needle (insulin syringe) in each cm2 of melasma.
224026260|NCT04019548|DEVICE|Percutaneous Endoscopic Gastrotomy tube placement|placement of the PEG tube depends on arm
224026261|NCT04019548|DRUG|Cisplatin injection|"Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV"
224026262|NCT04019548|RADIATION|Radiotherapy|Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
224026263|NCT06172881|DEVICE|Investigational Contact Lens|A soft contact lens that will be worn only at the study visit.
224026264|NCT01658722|DRUG|Bapineuzumab|
224026265|NCT04793802|OTHER|PHYSIO|session of physiotherapy
224026266|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10\^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
224026267|NCT02251288|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
224026268|NCT02251288|DRUG|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
224026269|NCT02046824|DEVICE|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
224026270|NCT02046824|DEVICE|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
224298006|NCT04232813|DRUG|Promestriene Vaginal|To insert the cream the patient must use the applicator provided in the way explained in the prospectus.
224298007|NCT00057213|DRUG|Radafaxine|
224298008|NCT02702713|DIETARY_SUPPLEMENT|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
224298009|NCT02702713|DIETARY_SUPPLEMENT|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
224298010|NCT02702713|DIETARY_SUPPLEMENT|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
224298011|NCT02702713|DIETARY_SUPPLEMENT|Bakery placebo|Bakery placebo: Biscuits without enrichment
224298012|NCT02702713|DIETARY_SUPPLEMENT|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
224298013|NCT02702713|DIETARY_SUPPLEMENT|Egg placebo|Egg placebo: Frozen pancakes without enrichment
223409688|NCT00053196|DRUG|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
223409689|NCT00053196|DRUG|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
223409690|NCT00053196|DRUG|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants
223409691|NCT00053196|DRUG|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
223409692|NCT00053196|DRUG|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
224133732|NCT03395275|BEHAVIORAL|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
224026271|NCT02046824|DEVICE|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
224026272|NCT02046824|OTHER|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
224133733|NCT02797691|OTHER|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
223409693|NCT00053196|PROCEDURE|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
223409694|NCT00053196|DRUG|allopurinol|300 mg/day PO Days -8 thru -1
223738571|NCT01127308|DRUG|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin
224026273|NCT00208923|DRUG|Busulfan, Cyclophosphamide and Fludarabine|"* Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~* Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~* Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
224026274|NCT00219804|DRUG|tetrabenazine or placebo|
224026275|NCT02594826|BEHAVIORAL|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
224026276|NCT02594826|BEHAVIORAL|General health education control|General health and cancer education
224026277|NCT03438851|DEVICE|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
224026278|NCT02254525|DRUG|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
224133734|NCT02797691|OTHER|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
224133735|NCT03579524|PROCEDURE|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
224298014|NCT01475084|DEVICE|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
224298015|NCT02527018|DEVICE|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
223409695|NCT04939987|DRUG|Tramadol|Opioid Control Cohort (One treatment selected)
223409696|NCT04939987|DRUG|Gabapentin|Experimental Cohort (Multimodal Approach)
224298016|NCT05882279|OTHER|No Intervention|This is a non-interventional study.
224298017|NCT01250483|OTHER|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
223409697|NCT04939987|DRUG|Hydrocodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
223409698|NCT04939987|DRUG|Oxycodone-Acetaminophen|Opioid Control Cohort (One treatment selected)
223409699|NCT04939987|DRUG|Ketorolac|Experimental Cohort (Multimodal Approach)
223409700|NCT04939987|DRUG|Acetaminophen|Experimental Cohort (Multimodal Approach)
223409701|NCT04939987|DRUG|Ketorolac tromethamine|Experimental Cohort (Multimodal Approach)
223409702|NCT04939987|DRUG|Ketamine|Experimental Cohort (Multimodal Approach)
223409703|NCT06371235|OTHER|Pregiferon|This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier
223409704|NCT00204009|BEHAVIORAL|Disease Surveillance, Family Studies, Questionnaire Followup|
223409705|NCT03668444|BEHAVIORAL|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
223409706|NCT03668444|BEHAVIORAL|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
223409707|NCT00136929|DRUG|Thrombolytic therapy|
223738572|NCT04375488|OTHER|Resistance Exercise Training|60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week
223738573|NCT04375488|OTHER|Inspiratory Muscle Training|with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
223409708|NCT00136929|PROCEDURE|Percutaneous coronary intervention (PCI)|
223409709|NCT06110494|DRUG|Iron oxide nanoparticles treatment Ferumoxytol/H2O2|Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
224026279|NCT02254525|DRUG|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
224026280|NCT03986281|OTHER|Omron Wearable Device|Omron wearable device compared to arterial line readings
224026281|NCT03986281|OTHER|Standard Arterial Line|Omron wearable device compared to arterial line readings
224026282|NCT03985085|OTHER|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
224026283|NCT03557580|DRUG|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
224026284|NCT03557580|DRUG|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
224026285|NCT03557580|DRUG|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
224026286|NCT01575028|DRUG|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
224026287|NCT01575028|DRUG|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
224026288|NCT00552487|DRUG|synacthen|1 µg synacthen in the vein
224026289|NCT04015999|DIETARY_SUPPLEMENT|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
224026290|NCT04015999|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
224026291|NCT03026985|OTHER|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
224026292|NCT00557947|DEVICE|Suture|intradermal and topical suturing
224026293|NCT00557947|DEVICE|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
224026294|NCT03383926|PROCEDURE|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
224026295|NCT03383926|PROCEDURE|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
223409710|NCT06110494|DRUG|NaOCl|Participants receive a topical treatment through a root canal irrigation needle containing 3% NaOCl for 10 minutes contact time
223409711|NCT06110494|DRUG|NaCl|Participants receive a topical treatment through a root canal irrigation needle containing 0.89% NaCl for 10 minutes contact time
223409712|NCT06110494|DRUG|supplementary irrigation|"All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously"
223409713|NCT03929120|BIOLOGICAL|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)|Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
223409714|NCT05552248|DEVICE|LumbarBelt SOFT 300|15 patients will be included in this group and will used the medical device LumbarBelt SOFT 300 during sport practice (at least 2 sport sessions per week), for 12 weeks.
223409715|NCT05552248|OTHER|Control group LumbarBelt SOFT 300|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt SOFT 300), for at least 2 sport sessions per week during 12 weeks.
223409716|NCT05552248|DEVICE|LumbarBelt MID 500|15 patients will be included in this group and will used the medical device LumbarBelt MID 500 during sport practice (at least 2 sport sessions per week), for 12 weeks.
223409717|NCT05552248|OTHER|Control group LumbarBelt MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device LumbarBelt MID 500), for at least 2 sport sessions per week during 12 weeks.
223409718|NCT02289248|DRUG|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
223409719|NCT02289248|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
223409720|NCT03038867|DRUG|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
224026296|NCT02792751|DEVICE|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
224026297|NCT02792751|OTHER|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
224026298|NCT02535936|PROCEDURE|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
224026299|NCT04847193|OTHER|Dietary Intervention 1: Placebo|Participants receive a study drink supplemented with a placebo for 5 days
224026300|NCT04847193|OTHER|Dietary Intervention 2: Xanthohumol and Iso-alpha acids|Participants receive a study drink supplemented with xanthohumol, Iso-alpha acids or a combination of both for 5 days
224133736|NCT03579524|PROCEDURE|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
223409721|NCT03038867|DRUG|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
223409722|NCT00562172|DRUG|Insulin glargine|Once daily in the morning
223409723|NCT00562172|DRUG|Glimepiride|Once daily in the morning
224026301|NCT05599620|BEHAVIORAL|AWARE|AWARE addresses alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization.
224026302|NCT05599620|BEHAVIORAL|General Health Promotion|General Health Promotion is an attention and dose matched intervention with no overlapping components with AWARE.
224026303|NCT06728189|BIOLOGICAL|CAR-NKT Cells treatment|"Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells Lymphodepleting regimen, Cyclophosphamide 250mg/m2 IV on day -5 to -3 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of CAR-NKT on day 0.~Potential CGC738 doses:~Dose level 1: 5.0×106 CAR- NKT cells/m2; Dose level 2: 1.5×107 CAR- NKT cells/m2; Dose level 3: 4.5×107 CAR- NKT cells/m2;"
224026304|NCT06728475|DEVICE|virtual reality|"In Xbox, we will choose suitable games that aim to improve upper limb function like boxing, Darts, tennis, goalkeeping, basketball, disc throwing, balling, and volleyball.~The Kinect sensor has the advantage of auto adjustment of its camera according to the child's position and height that's to say the child can perform the game in sitting or standing according to their abilities.~They will receive 30 minutes of VR intervention in addition to the time required for the designed physical therapy program."
224026305|NCT06728475|OTHER|mirror therapy|Mirror Therapy A mirror of 30 × 20 inches was used for the MT, which was large enough to cover the entire affected limb while still allowing the reflection of the non-affected limb to be seen. The child was seated in a chair with the forearms resting on the table. In the mid-sagittal plane, the mirror box was positioned at an angle of 70° to 80° to the trunk. The affected limb was placed behind the mirror. The child was asked to perform the exercises bilaterally and symmetrically as much as possible. Even if the affected side did not move easily or fully, the child was advised to synchronize the motions with both hands and arms. The researcher constantly reminded the child to concentrate on the movement of the non-affected limb in front of the mirror, which helped to increase the mirror illusion
224133737|NCT05821621|OTHER|no intervention|observational study : there is no intervention
224133738|NCT05259267|BEHAVIORAL|Online Group Therapy for PTG|Online Group Therapy for PTG consists of eight sessions. Each sessions have specific themes. First session: psychoeducation, normalization of the experiences and emotions. Second session: emotion regulation skills. Third session: awareness of the negative thoughts that make patients worried, anxious, feared. Forth session: restructuring of the thoughts and practicing mindfulness technics. 5. session: practicing of self-disclosure skills 6. session: creating a breast cancer story with balancing losses and gains. 7. session: sharing of the effects of breast cancer on life and developing new life priorities 8. session: making life meaning and developing new life goals.
224133739|NCT05259267|BEHAVIORAL|Online Support Group|Online support groups also consist of eight sessions. 1. session: introducing the program and learning the expectancies 2. session: sharing what is known about breast cancer 3. session: risk and protective factors for breast cancer 4. session: sharing side effects of surgical operation and treatments 5. session: sharing the reactions of family, close friends 6. session: patient-doctor relationship and also sharing the challenges and facilitators of healthcare system 7. session: sharing the current position in the treatment and of what has been done for improvement 8. session: sharing the reliable information sources for breast cancer and close
224133740|NCT03198754|DEVICE|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
224133741|NCT03198754|DEVICE|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
224026306|NCT06728475|OTHER|virtual reality with mirror therapy|group C will receive combined effect of both techniques (virtual reality and mirror therapy)
224026307|NCT06727929|DIAGNOSTIC_TEST|Collection of gingival crevicular fluid, ELISA|GCF samples were collected at baseline and at the 6-8 -week follow-up appointment after non-surgical periodontal treatment . After removing the supragingival plaque from the interproximal surfaces with sterile curettes, these sample surfaces were isolated with cotton rolls and slightly air-dried to avoid contamination. Standardized paper strips were inserted 1 to 2 mm into the gingival sulcus and held for 30 seconds to collect GCF. Strips contaminated with blood or saliva were discarded and not evaluated. The paper strips were transferred to a precalibrated Periotron 8000 device to measure the fluid volume. Paper strips were placed in sterile Eppendorf tubes and stored at -80C, until laboratory analysis. The level of GCF Dkk-1 and sFRP5 levels was measured by ELISA using commercial kits.
224026308|NCT06727617|DRUG|Serplulimab|intravenous infusion of 300 mg, administered every 3 weeks as one cycle, on the first day of each cycle, with a maximum treatment duration of 2 years (up to 35 treatment cycles)
223409724|NCT00562172|DRUG|Metformin|At least 1000 mg/day
223409725|NCT05127317|DIAGNOSTIC_TEST|Mechanical power|"In our study, mechanical power (MP) will be calculated during mechanical ventilation in patients who will be operated under general anesthesia.~MP will be calculated with the simplified formula applied by Gattinoni et al. MPvcv: RR x Tv x (PIP-\[(Pplat-PEEP)/2\]) x 0.098(2) In pressure-controlled ventilation, the simplified MP formula of Becher et al. well be used.~MPpcv: RR x Tv x (ΔPinsp + PEEP) x 0.098 (11)~For MP calculated according to the weight of the patients; Indexed MP: MP /kg according to IBW. For the force applied to the lungs in each inspiration; Dynamic power (mJ/min): Vt x RR x \[(Pplato+ tPEEP)/2\]. For the driver power that provides the gas flow; Driving power (mJ/min): Vt x RR x \[ (Pplat - tPEEP) / 2\]. Calculating mechanical energy; Mechanical energy (mJ/kg): 0.098 x (V x kg ) x (PIP - \[(P plateau- PEEP) / 2\]) formulas were used"
223409726|NCT01599858|DRUG|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
224026309|NCT06727617|DRUG|Chemotherapy|"Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles."
224298018|NCT03606876|DRUG|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
223409727|NCT01599858|DRUG|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
223409728|NCT06205043|DEVICE|StimSearch programming algorithm software|This is an algorithm based method to program deep brain stimulation in patients of Parkinson's disease
224026310|NCT06727617|RADIATION|radiotherapy|Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.
224026311|NCT00564551|BEHAVIORAL|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
224026312|NCT00564551|BEHAVIORAL|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
224026313|NCT00171600|DRUG|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
224026314|NCT01528501|DRUG|Panobinostat (LBH589)|
224026315|NCT02383004|OTHER|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
224026316|NCT02058654|DRUG|Creatine|Creatine powder (5 g)
224026317|NCT02058654|DRUG|Placebo|Bulking agent powder (5 g)
224026318|NCT05717439|DIAGNOSTIC_TEST|CAPS-5-R|A semi-structured clinical interview to assess core PTSD symptoms for diagnosis and severity rating.
223409729|NCT06205043|DEVICE|Clinician based programming|This is Standard of Care programming performed for patients undergoing deep brain stimulation for Parkinson's disease
224026319|NCT05717439|DIAGNOSTIC_TEST|Senseye DT|Using a machine learning algorithm, Senseye DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
223409730|NCT03622684|BEHAVIORAL|Muscle relaxation according to Jacobson|
223409731|NCT00380133|DRUG|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
223409732|NCT00380133|DRUG|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
223409733|NCT00380133|DRUG|Placebo|Tablets matched to SB681323 or prednisolone
223409734|NCT01994941|DRUG|Clopidogrel|"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
224026320|NCT05374213|BEHAVIORAL|Mindfulness-Based Intervention|Mindfulness practices use a non-stigmatizing approach, combining secularized eastern meditative practices with western psychological advances to improve stress-management and self-care. Participants learn to generate less distress, engage more positively and fully in their lives and experiences, and respond more adaptively to challenges instead of reacting in automatic and unhelpful ways.
224026321|NCT05398744|OTHER|Group Exercise Program|At-home, aerobic group exercise program facilitated by exercise physiologist via video format, 3 times a week for 16 weeks.
224026322|NCT06110143|OTHER|Periodontal treatment|Periodontal treatment
224026323|NCT05568524|OTHER|BFRT|Low-load (30% 1RM) resistance exercise with blood flow restriction
224026324|NCT05568524|OTHER|Control|Moderate-to-high load (60%-80% 1RM) resistance exercise
224026325|NCT06227000|BEHAVIORAL|Living Longer and Stronger with SCI|Study staff will schedule a brief zoom training session with each person assigned to the intervention to ensure that they are able to download and use the Zoom platform. Once a weekly session day and time has been determined the 8-week LLS intervention program will begin. LLS group participants will participate in 2-hour weekly sessions co-facilitated by a study investigator and one of the study's senior advisors. Participants will be encouraged to set a health-oriented goal and complete weekly action plans. They will be provided with materials each week with health-related information and resources. Participants will also be asked to complete a short survey each week to rate the session. After completing the 8 sessions, a link to the post-test survey and some questions to evaluate the LLS program will be sent to the participants. Finally there will be follow up survey to be completed at 4 months post intervention.
224026326|NCT06227000|BEHAVIORAL|Control|Participants will be sent links to the three surveys at the same time as those assigned to the LLS group but they will not attend any of the zoom calls. They will be offered all study materials at the end of the study.
224026327|NCT04950322|DRUG|SHR-1701、CAPOX|SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
224026328|NCT04950322|DRUG|Placebo、CAPOX|Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
224026329|NCT05951933|OTHER|Strenghtening + TES|Strenghtening of rotator cuff and scapulothoracic muscles protocol with the incorporation of anodal transcranial direct stimulation (real if experimental or sham if control)
224026330|NCT03889743|DRUG|Dexamethasone treatment during 3 days|Dexamethasone 1,0 mg oral tablets. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
224133742|NCT00986310|DRUG|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
224133743|NCT00986310|DRUG|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
224133744|NCT00943982|DRUG|Interferon Gamma 1-b|
223409735|NCT01994941|DRUG|Ticagrelor|"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."
224133745|NCT03190096|PROCEDURE|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
224133746|NCT03090373|DEVICE|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
223409736|NCT02027454|DRUG|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
223409737|NCT02027454|DRUG|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
224026331|NCT03889743|DRUG|placebo treatment during 3 days|1,0 mg oral tablets. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
224026332|NCT05649852|OTHER|Socio-aesthetic care|Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
224133747|NCT04399512|PROCEDURE|Nonsurgical root canal treatment|Nonsurgical root canal treatment will be given
224133748|NCT02646267|DRUG|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
224298019|NCT03676699|DIAGNOSTIC_TEST|Ultrasound chest|Ultrasound detection of extravascular lung water
224298020|NCT00050232|DRUG|AVP-923|
223409738|NCT02027454|DRUG|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
223409739|NCT02733848|DRUG|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
223558651|NCT03286543|DEVICE|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
223558652|NCT06177262|BEHAVIORAL|cognitive behavioral therapy|Cognitive behavioral therapy for eating disorders.
223558653|NCT01822899|DRUG|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
224026333|NCT05649852|OTHER|Supportive care|Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
224026334|NCT06475183|DIETARY_SUPPLEMENT|Bouchard Belgian Dark Chocolate Probiotic Napolitains, containing bifidobacterium longum|Bouchard Belgian Dark Chocolate Probiotic Napolitains containing 10 billion CFUs of bifidobacterium longum daily for 6 weeks
224133749|NCT02646267|DRUG|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
224133750|NCT02646267|DRUG|dabigatran etexilate|110mg, twice a day, oral
224133751|NCT03943979|OTHER|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
224298021|NCT05533398|OTHER|Stress ball use|They were asked to use the ball for at least 10 minutes during the dialysis treatment and when they felt stressed or unwell at home/work. Patients with arteriovenous fistula or arteriovenous graft were instructed to use the stress ball with the other hand, where there was no vascular access.
224298022|NCT02757976|DEVICE|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave \> 7 mV, pacing threshold \< 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
224026335|NCT06286709|BIOLOGICAL|Faecal Microbiota Transplant|FMT is 50mL aliquots of filtered suspension of stool (0.6g/mL). FMT for administration via colonoscopy will be made up of 150g stool in 250mL (5 aliquots). FMT for administration via enema will be made up of 30g stool in 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
224026336|NCT06286709|OTHER|FMT Placebo|FMT Placebo is 50mL aliquots containing 0.9% w/v saline and glycerol in a ratio of 9 parts saline: 1 part glycerol v/v. FMT Placebo for administration via colonoscopy will be made up of 250mL (5 aliquots). FMT Placebo for administration via enema will be made up of 50mL (1 aliquot) made up to 100mL by the addition of 50mL normal saline
224026337|NCT04854980|OTHER|Blood Sample|Blood sample, 2- to 5 tea spoon full (between 10 to 25 mL approximately) between 43 to 96 days after first dose of the vaccine.
224026338|NCT04420936|BEHAVIORAL|MAINTAIN PRIME Lifestyle Coaching|Participants will receive two years patient support consisting of supportive coaching via EHR patient portal and tracking tools with EHR. Participants will also receive primary care physician (PCP) support with real time progress reports with counseling tips via EHR prior to visits, notification of weight changes greater or equal to 10 pounds, and annual PCP feedback.
223558654|NCT01822899|DRUG|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
224026339|NCT04420936|BEHAVIORAL|Control tracking|Participants will receive two years of patient support consisting of prevention updates via EHR patient portal and tracking tools within the EHR. Participants in this group will not receive primary care physician (PCP) support.
223558655|NCT01822899|DRUG|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
224026340|NCT02821741|DEVICE|The Twin Stim Plus, 3rd Edition|Mild transcutaneous electrical stimulation will be applied to the cymba conchae of the left ear on day 1 and the left earlobe on day 2 (or vice versa) using a commercially available TENS unit (transcutaneous electrical nerve stimulator) attached to a pair of silver electrodes.
224026341|NCT02821741|DEVICE|Medoc Pathway System|Device used to apply Thermal stimulation to both arms.
224026342|NCT06815445|PROCEDURE|None tourniquet|No tourniquet is used throughout the surgery.
224026343|NCT03220763|OTHER|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
223558656|NCT01822899|DRUG|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
223558657|NCT05332392|DEVICE|INVSENSOR00040|Noninvasive wearable health monitoring device
224026344|NCT03224351|DRUG|VX-659|Tablet for oral administration.
224026345|NCT03224351|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination tablet for oral administration.
224026346|NCT03224351|DRUG|IVA|Tablet for oral administration.
224026347|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/IVA)|Placebo matched to VX-659 and TEZ/IVA.
224026348|NCT03224351|DRUG|TEZ|Tablet for oral administration.
224026349|NCT03224351|DRUG|VX-561|Tablet for oral administration.
223558658|NCT06289426|OTHER|Yoga|The yoga program will consist of body awareness, meditation, poses, breathing practices, relaxation, and positive affirmations in Sanskrit and English.
224026350|NCT03224351|DRUG|Placebo (matched to VX-659/TEZ/VX-561)|Placebo matched to VX-659, TEZ and VX-561.
224026351|NCT01328717|DEVICE|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
224026352|NCT04321044|GENETIC|Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation|We attempt to idendtify predictors of blood pressure response to renal denervation by using a GWAS (Genome wide association study) approch.
224026353|NCT03701867|OTHER|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
224026354|NCT03440320|BEHAVIORAL|MY-SKILLS - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain
223558659|NCT02628405|DRUG|Carboplatin|Given IV
223558660|NCT02628405|DRUG|Etoposide|Given IV
223558661|NCT02628405|DRUG|Ifosfamide|Given IV
223558662|NCT02628405|OTHER|Laboratory Biomarker Analysis|Correlative studies
223558663|NCT02628405|DRUG|Lenalidomide|Given PO
223558664|NCT02628405|BIOLOGICAL|Rituximab|Given IV
223558665|NCT02782234|BEHAVIORAL|Contract management|
224026355|NCT03440320|BEHAVIORAL|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..
224026356|NCT01912456|BIOLOGICAL|Low-volume C1-esterase inhibitor|
224026357|NCT01912456|BIOLOGICAL|Higher-volume C1-esterase inhibitor|
224026358|NCT01912456|BIOLOGICAL|Low-volume placebo|
224026359|NCT01912456|BIOLOGICAL|Higher-volume placebo|
224026360|NCT01201343|DRUG|Interferon beta-1a|
224026361|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
224026362|NCT00914160|DRUG|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
224026363|NCT00914160|DRUG|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
224026364|NCT03883425|OTHER|interRAI-HC assessments|Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses
224138968|NCT06206278|DRUG|Infigratinib|Infigratinib is a selective ATP-competitive inhibitor of fibroblast growth factor receptor (FGFR) 1-3 that inhibits FGFR downstream signaling and proliferation in human cancer cell lines with FGFR genetic alterations, significantly inhibiting the growth of several types of cancers driven by FGFR amplification, fusion and mutation.
224138969|NCT02193815|DRUG|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
224138970|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 4% solution
224138971|NCT02193815|DRUG|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
224138972|NCT02193815|OTHER|Vehicle|Active ingredient-free vehicle to 2% Ointment
224026365|NCT05869630|OTHER|Exercise Programme|All patients were informed about knee OA, joint protection principles, and the exercise effects on knee OA before treatment. The exercises were supervised by a physiotherapist for 30 minutes twice a week and once a week as a home program. The exercise program consisted of a warm-up, strengthening knee extensors and lower extremity stretching exercises. Firstly, quadriceps isometric and adductor isometric (roll tightening) exercises, hamstring stretching, quadriceps stretching, and gastrocnemius stretching were applied. Then, hip flexion-extension-abduction-adduction, and knee extension while sitting were applied with exercise bands. Strengthening exercises were composed of three sets with 10 repetitions. Stretching exercises were performed 10 repetitions for 10 seconds.
224026366|NCT05869630|OTHER|Experiments|The total RNA was isolated from peripheral blood samples taken from patients and the control group by applying the protocol of the manufacturer (LucigenMasterPure™ Complete DNA and RNA Purification Kit, USA). The total RNA was isolated in three steps: Lysis stage of the whole blood samples, precipitation of nucleic acids and precipitation of total RNA. The purity and concentration of the isolated total RNA samples were measured with the spectrophotometer (Thermo Fischer) device. The samples were stored at -80°C until the next step. To determine the microRNA expression levels; firstly, conjugate DNA (cDNA) was synthesized from total RNA samples according to the manufacturer's protocol. Whether the desired region reproduced in the reaction and whether there were primer dimers were checked by adding a melting curve step. In addition, blood samples of 30 age-sex matched healthy volunteers were compared.
224026367|NCT00597298|DEVICE|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
224026368|NCT00597298|DEVICE|sham threshold|non-training physical activity
224026369|NCT02839642|DRUG|Rivastigmine|
224026370|NCT02839642|DRUG|Placebo|
224026371|NCT05077865|DRUG|MYMD-1|150 mg capsule
224026372|NCT05077865|DRUG|Placebo|Matching in appearance to MyMD-1 150mg capsule
224026373|NCT04478656|BIOLOGICAL|BBV121|BBV121 or Placebo are administered intramuscularly in deltoid region on Day 0 and 28
224026374|NCT00709696|DRUG|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
224026375|NCT00709696|DRUG|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
224026376|NCT00825617|DRUG|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
224026377|NCT04074863|PROCEDURE|Darrach|Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
224026378|NCT04074863|PROCEDURE|Prosthesis|Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
224026379|NCT00001962|DRUG|Daclizumab|Daclizumab, 1mg/kg, every 2 weeks for a total of 5 infusions.
224026380|NCT05224336|DRUG|Psilocybin|25mg oral psilocybin
224026381|NCT05224336|DRUG|Placebo Niacin|100mg oral niacin
224026382|NCT02648165|BEHAVIORAL|Attention Bias Modification|Computer based Attention Bias Modification
224026383|NCT02648165|BEHAVIORAL|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
224026384|NCT02648165|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
224026385|NCT00458887|PROCEDURE|management of therapy complications|Undergo hearing tests
224026386|NCT00194857|DRUG|erythropoietin, GCSF|
224026387|NCT02334774|PROCEDURE|Swallowing and Oral Care Program|An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
224026388|NCT01440374|DRUG|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
224026389|NCT01440374|DRUG|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
224026390|NCT03542513|DEVICE|Colli-Pee|Urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium).
224026391|NCT03542513|DEVICE|Qvintip|Vaginal self-samples will be collected with the Qvintip (Aprovix AB, Uppsala, Sweden).
224026392|NCT04201132|DEVICE|Carotid artery stenting with Neuroguard IEP System|Carotid artery stenting (treatment) with the Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection
224026393|NCT01341756|RADIATION|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
224026394|NCT01980654|DRUG|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
224026395|NCT01980654|DRUG|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
223409740|NCT02733848|OTHER|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
224138973|NCT02193815|DRUG|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
224138974|NCT02193815|DRUG|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
224138975|NCT00070980|PROCEDURE|Massage therapy|
223409741|NCT02733848|OTHER|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
224133752|NCT03943979|DEVICE|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
223409742|NCT05669417|DRUG|Magnesium sulfate|Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.
223409743|NCT03279822|OTHER|not any intervention|not any intervention
224026396|NCT05768256|BEHAVIORAL|Mindfulness-Based Cognitive-behavioral Therapy for Distress|Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.
224026397|NCT00895674|DRUG|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
224026398|NCT00760903|OTHER|Conventional MRI of the brain|
224026399|NCT00760903|OTHER|MR spectroscopy (MRS)|
224026400|NCT00760903|OTHER|MR Diffusion Tensor Imaging (DTI)|
224026401|NCT05288803|OTHER|Clinical decision support tool (CDS tool)|The investigators will integrate the CDS tool into clinical practice at each participating clinic after data collection for the Control cohort is complete. All physical therapists at the participating clinic locations will use the CDS tool to inform rehabilitation decision making for Veterans with total knee arthroplasty. The CDS tool will provide personalized information regarding each Veterans' recovery in addition to personalized visit utilization guidelines. Clinicians will use the CDS tool with Veterans at their initial postoperative visits and every 2weeks throughout their course of care thereafter.
224026402|NCT05730270|BEHAVIORAL|Stress reduction program 1|Participants will receive daily online lessons
224026403|NCT05730270|BEHAVIORAL|Stress reduction program 2|Participants will receive daily online lessons
223409744|NCT02719717|DEVICE|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
223409745|NCT02647190|DRUG|Erwinia Chrysanthemi asparaginase|
223409746|NCT05802524|DIAGNOSTIC_TEST|Neurowave Group|"Neurosensory stimulation will consist in the administration of pairs of stimuli consisting of emotionally significant images and sounds in the personal life history (two rare stimuli) alternating with neutral images and sounds devoid of emotional significance (two distracting stimuli"
223409747|NCT06969482|BEHAVIORAL|measuring knowledge level|The study group consists of 70 nurses, each consisting of 35 people. After the routine training of the hospital was given to the control and experimental groups, their consents were obtained and the pre-tests were completed, they were divided into experimental and control groups using simple randomization. The first group of nurses in the control group will not receive any intervention other than the routine training given by the hospital.
223558666|NCT02688699|PROCEDURE|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
224026404|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
224026405|NCT02593669|PROCEDURE|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
224026406|NCT02593669|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
224026407|NCT02593669|DRUG|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
224026408|NCT02513420|BEHAVIORAL|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
224026409|NCT02725957|DRUG|Trehalose for IV Infusion|
224026410|NCT02725957|DRUG|Saline 0.9% IV|
224026411|NCT03102554|GENETIC|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
224133753|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
224133754|NCT01604876|DEVICE|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
223409748|NCT06969482|OTHER|educational intervention|the effectiveness of training by making measurements after training and comparing them with pre-training results
223558667|NCT02840318|OTHER|Compassion Intervention|See arm description
223558668|NCT00575107|OTHER|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
224026412|NCT06258915|DRUG|Adalimumab|Adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously)
224026413|NCT06258915|DRUG|Mycophenolate Mofetil|2 g/day orally for 36 weeks
223409749|NCT03915587|DEVICE|CardioQ-EDM and CipherOx-CRI|A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
224026414|NCT02966392|DEVICE|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
224026415|NCT02673151|PROCEDURE|Computed Tomography (CT) scan|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
224026416|NCT02673151|DRUG|68Ga-PSMA-11|68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11), administered by intravenous (IV) injection.
224026417|NCT02673151|PROCEDURE|Positron Emission Tomography (PET)|PET/CT scan using 68gallium-labeled prostate-specific membrane antigen-11 (68-Ga-PSMA-11).
224026418|NCT01709747|DRUG|Hydromorphone Hydrochloride|Opioid for chronic pain
224026419|NCT01709747|DEVICE|Programmable Implantable pump|"Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone"
224026420|NCT00231153|DRUG|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
224138976|NCT01012505|OTHER|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
224138977|NCT03256474|OTHER|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
224138978|NCT03902782|PROCEDURE|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
223409750|NCT06968429|DRUG|NBP Softgel Capsules|take orally on an empty stomach；2 capsules 3/day
223409751|NCT06968429|DRUG|Placebo|take orally on an empty stomach；2 capsules 3/day
224026421|NCT00231153|DRUG|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
224026422|NCT04729998|DRUG|Rivaroxaban film-coated tablet 20 mg|Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 20 mg of rivaroxaban.
224026423|NCT04729998|DRUG|Xarelto® film-coated tablet 20 mg|Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 20 mg of rivaroxaban.
224026424|NCT05699135|DRUG|Avelumab first-line maintenance|Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
224026425|NCT02712229|BEHAVIORAL|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
224026426|NCT04487834|DRUG|Simethicone Solution|Oral daily treatment for four weeks
224026427|NCT04487834|DIETARY_SUPPLEMENT|Vivatlac Baby|Oral daily treatment for four weeks
224026428|NCT03538249|OTHER|Aerobic training|
224026429|NCT03538249|OTHER|Inspiratory muscle training|
224026430|NCT03538249|OTHER|Resistance Training|
224026431|NCT03538249|OTHER|Aerobic and Inspiratory training|
224026432|NCT03538249|OTHER|Combined|Aerobic, inspiratory and resistance training
224026433|NCT04150601|DEVICE|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
224026434|NCT04150601|DEVICE|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
224026435|NCT04150601|OTHER|Spontaneous Exhalation|A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
224026436|NCT05205057|OTHER|Saliva|Unstimulated whole saliva is collected
224138979|NCT03902782|PROCEDURE|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
224138980|NCT03902782|PROCEDURE|Sham ESP block|As described earlier
224138981|NCT03902782|PROCEDURE|Sham Intercostal block|As described earlier
224138982|NCT03902782|DRUG|Bupivacaine-epinephrine|As described earlier
224138983|NCT03902782|DRUG|Dexamethasone injection|As described earlier
224138984|NCT03902782|DRUG|Normal saline|As described earlier
224138985|NCT00804739|OTHER|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
224138986|NCT04668001|DEVICE|Near-Infrared Transcranial Photobiomodulation|tPBM-NIR involves the use of a device that administers near-infrared light over the scalp. The light activates target brain regions.
224026437|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
223409752|NCT06566872|DEVICE|ME-APDS|No Intervention
223409753|NCT06967623|DEVICE|diaphragm ultrasound|On the day of hospitalization or the first day of mechanical ventilation, the patient's position was elevated by 30°, and the high-frequency linear probe of the ultrasound was placed perpendicular to the skin in the cranio-caudal direction, and the diaphragm apposition zone, where the right anterior and middle axillary line corresponds to the 8th-10th intercostal space, was imaged and measurements were made with B mode.
223409754|NCT00119249|DRUG|sorafenib tosylate|Given orally
223409755|NCT00119249|OTHER|laboratory biomarker analysis|Correlative studies
223409756|NCT04699318|PROCEDURE|Group B|To release the pediatric hypospadias using Double Dartos Tubularized incised plate (TIP) Urethroplasty
223409757|NCT04699318|PROCEDURE|Group A|To release the pediatric hypospadias using Single Dartos Tubularized incised plate (TIP) Urethroplasty
224026438|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
223558669|NCT00575107|OTHER|Exercise|Standard training of leg extension
223558670|NCT04113356|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
223558671|NCT03919084|OTHER|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
224026439|NCT01177722|BIOLOGICAL|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
224138987|NCT04668001|DEVICE|Sham Transcranial Photobiomodulation|tPBM-Sham involves the use of an identical device to tPBM-NIR but does not administer near-infrared light. It mimics the sensation by applying heat but does not actually activate target regions of the brain
223409758|NCT05387096|OTHER|Definitive multi-faceted intervention consisting of several components|The definitive intervention will consist of the following components: structured history of medication (SHiM), Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) screening for PIMs and PPOs, drug-drug and drug-disease interactions screening, face-to-face consultation with attending hospital physicians to discuss PIMs, PPOs, interactions and other issues, pre-discharge medication review and adjustment, detailed medication adjustment discharge report to patients' general practitioners (GPs), post-discharge follow-up contact with patients' GPs and community pharmacists at 1 week, 1 month and 3-6 months post -discharge. The interventions will be applied by a trained physician or pharmacist.
223409759|NCT05387096|OTHER|Sham Intervention|Sham intervention in the form of the modified Medication Adherence Rating Scale (MARS) questionnaire in addition to standard care.
223409760|NCT02138487|OTHER|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
223409761|NCT02138487|OTHER|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
223409762|NCT01065337|BIOLOGICAL|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
223409763|NCT01065337|BIOLOGICAL|bone marrow stem cells (BMC)|bone marrow stem cells
223409764|NCT04585256|OTHER|Trendelenburg positioning|Women positioned in the trendelenburg position prior to external cephalic version
224026440|NCT01177722|BIOLOGICAL|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
224026441|NCT04023721|DRUG|Inarigivir soproxil|Inarigivir soproxil 200 mg tablets
224026442|NCT04023721|DRUG|Nucleoside/nucleotide (NUC) analogue inhibitors|Continuation of prestudy NUC therapy
224026443|NCT03234790|OTHER|Filtered Air Exposure|Exposure to Filtered air
224026444|NCT03234790|OTHER|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
224026445|NCT03656978|BEHAVIORAL|dynamic|Use the according methods in dynamic arm descriptions.
224026446|NCT03656978|BEHAVIORAL|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
224026447|NCT00433459|DRUG|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
224026448|NCT00433459|DRUG|dacarbazine|drug is used in first line treatment in combination (COPDAC)
224026449|NCT00433459|DRUG|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
224026450|NCT00433459|DRUG|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
224026451|NCT00433459|DRUG|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
224026452|NCT00433459|DRUG|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
224138988|NCT02193256|DRUG|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
224138989|NCT02193256|DRUG|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
224138990|NCT02193256|DRUG|Placebo|
224138991|NCT01927419|DRUG|Nivolumab|
224138992|NCT01927419|DRUG|Ipilimumab|
224138993|NCT01927419|DRUG|Placebo|Matching nivolumab
224138994|NCT03107455|DEVICE|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
223409765|NCT03084107|OTHER|Questionnaire|The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
224026453|NCT00433459|RADIATION|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
224026454|NCT00433459|RADIATION|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
224026455|NCT06175390|RADIATION|68Ga-FAPI-46 PET/CT|"Cohort A:~Tumor assessments by 18F-FDG PET/CT (per PERCIST v1.0) will be performed at: baseline, after the first 2 treatment cycles (between C2D15 and C3D1), and before surgery (after the last administration of neoadjuvant chemotherapy) Tumor assessment by 68Ga-FAPI-46 PET/CT will be performed at: baseline and before surgery (after the last administration of neoadjuvant chemotherapy).~Cohort B:~Tumor assessments by 18F-FDG PET/CT per PERCIST v1.0 will be performed at baseline, every 8 weeks (+/- 1 week) for the first 24 weeks, and every 12 weeks (+/- 1 week) thereafter until disease progression or treatment discontinuation, whichever is later.~Tumor assessments by 68Ga-FAPI-46 PET/CT will be performed at baseline and after the first 2 treatment cycles and will be synchronized with 18F-FDG PET/CT."
224026456|NCT06175390|BIOLOGICAL|Tumor samples analysis|"Patients will undergo a mandatory biopsy of the primary tumor at baseline, after the first 2 treatment cycles and during the surgery. A lymph node biopsy will be performed at baseline if feasible in cohort A, and and in case of disease progression for cohort B (if clinically feasible).~In addition to the usual morphological and immunohistochemical (ER, PR, HER2+, CPS score, PD-L1 status with SP142 …) analyses in the cohort A and cohort B , exploratory analyses will be performed."
224026457|NCT06175390|BIOLOGICAL|Blood samples analysis: Circulating Tumor DNA|Blood samples will be collected at baseline. In addition for cohort A at cycles 2 and 3, within 21 days before surgery, 10 to 21 days after surgery and at cycle 8 after surgery. In addition for cohort B after the first 2 treatment cycles and in case of disease progression (if clinically feasible).
224133755|NCT05630430|PROCEDURE|The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures|Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
224133756|NCT01613547|DRUG|Amoxicillin|80 mg/kg/day for 7 days
224133757|NCT01613547|DRUG|Placebo|7 days
224133758|NCT01767870|PROCEDURE|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
224133759|NCT01767870|PROCEDURE|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
224133760|NCT00311558|BIOLOGICAL|recombinant interferon alfa-2b|SSG x 5 week
224133761|NCT00311558|DRUG|sodium stibogluconate|SSG \& IFN
224026458|NCT06243393|DRUG|Sacituzumab Govitecan (SG)|Treatment with Sacituzumab Govitecan (SG)
223409766|NCT00826683|BIOLOGICAL|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
223409767|NCT02960711|DRUG|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
223409768|NCT02960711|DRUG|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
223409769|NCT04940793|DEVICE|POD FT|Cataract surgery
224026459|NCT06243393|DRUG|Physicians Choice (PhC).|Treatment according to oncologic guidelines.
224026460|NCT04557462|DRUG|LNP023|Capsule 200 mg (b.i.d.) taken orally twice a day
223409770|NCT01156961|DRUG|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
223409771|NCT01156961|DRUG|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
223409772|NCT00523471|PROCEDURE|Blood test|
223409773|NCT05746728|DRUG|Surufatinib|"Safety run-in phase: 200-250mg, QD, Q3W~Dose expansion phase: according to the dose determined in the safety run-in phase"
224026461|NCT00989131|DRUG|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
224133762|NCT00311558|DRUG|SSG & interferon|1 arm study with SSG \& interferon
224133763|NCT03477526|PROCEDURE|Pulmonary rehabilitation program|3 weeks, ...
224133764|NCT00103805|DRUG|levodopa|
224133765|NCT02979730|OTHER|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
224133766|NCT02979730|OTHER|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
224133767|NCT04247750|DRUG|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
224133768|NCT01100996|OTHER|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
224133769|NCT01100996|OTHER|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
224133770|NCT06522581|DRUG|Citicoline Sodium|one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth
223409774|NCT05746728|DRUG|Tislelizumab|200mg, d1, iv, Q3W
223409775|NCT05139771|DEVICE|THE ENDOART® IMPLANTATION (Artificial Endothelial layer)|Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
223409776|NCT06576609|DEVICE|INJEX [ Needle less anesthesia]|already described
224133771|NCT05662254|BEHAVIORAL|Personalized Behavioral Intervention|Behavioral lifestyle intervention assigned according to each participant's mood and lifestyle data patterns.
223409777|NCT06183385|OTHER|Saliva collection|Collection of 2 samples of 1.5 to 2mL of saliva by passive salivation in healthy volunteers
223409778|NCT06183385|OTHER|Vaginal secretion collection|Collection of vaginal secretions with 2 dry swabs in women
224026462|NCT00989131|DRUG|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
224026463|NCT05178667|DIETARY_SUPPLEMENT|High dose|Food supplements are consumed during 3 months by healthy volunteers.
224026464|NCT05178667|DIETARY_SUPPLEMENT|Low dose|Food supplements are consumed during 3 months by healthy volunteers.
224026465|NCT05178667|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 months by healthy volunteers.
224026466|NCT03836989|DEVICE|Electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. Useful for both Sensory and Subsensory
224026467|NCT02263937|PROCEDURE|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
224026468|NCT02263937|PROCEDURE|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
224026469|NCT01688414|PROCEDURE|photoacoustic imaging|Undergo PAI
224026470|NCT01688414|PROCEDURE|fluorescence imaging|Undergo fluorescence imaging
224026471|NCT01688414|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
224026472|NCT01602523|DRUG|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
224026473|NCT01602523|DRUG|Placebo|Placebo inhaler once daily 28 days
224026474|NCT04234425|BEHAVIORAL|Trauma-Informed Yoga|Trauma-Informed Yoga practice held within a high school weight training class
224026475|NCT04759664|DRUG|LUT014 Gel (Dose 1)|Topical gel
224026476|NCT04759664|DRUG|LUT014 Gel (Dose 2)|Topical gel
224026477|NCT04759664|DRUG|Placebo|LUT014 matching placebo topical gel
224026478|NCT03965611|PROCEDURE|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
224026479|NCT03965611|PROCEDURE|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
223409779|NCT06183385|OTHER|IP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry|"sample preparation and analysis :~* Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva.~* Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification~* LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode)~Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results.~Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method."
223409780|NCT02881515|OTHER|Low Sodium Diet|Ten days of low sodium diet
223409781|NCT02881515|OTHER|Medium Sodium Diet|Ten days of a medium sodium diet
223409782|NCT02881515|OTHER|High Sodium Diet|Ten days of a high sodium diet
223409783|NCT02416609|RADIATION|LDR|LDR will be delivered during each cycle of Gem-based doublets
223409784|NCT02416609|DRUG|Gem-based doublets|4 cycles of Gem-based doublets
223409785|NCT02416609|RADIATION|SBRT|SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
223409786|NCT04938180|BIOLOGICAL|AMB-05X|AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
223409787|NCT04120077|DIETARY_SUPPLEMENT|EyePromise DVS, EyePromise DVS plus EyePromise EZTears|Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
224026480|NCT03965611|PROCEDURE|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
224026481|NCT05209750|DIAGNOSTIC_TEST|FAPI PET/CT|This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
224026482|NCT05690100|DRUG|GeliO3|Anti-inflammatory Gel which has a beneficial role on wound healing
224026483|NCT05690100|DRUG|Gingi gel|Anti-inflammatory Gel which has a beneficial role on wound healing
224026484|NCT02258308|BEHAVIORAL|CHW intervention|Home education and support for asthma self management
224026485|NCT03998254|DRUG|V503|9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
224026486|NCT03998254|DRUG|Gardasil|qHPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine
224026487|NCT00622453|OTHER|Screening|Electrocardiography Blood Test
224026488|NCT03503253|DEVICE|Interlock-35 Fibered IDC Occlusion System|Use of detachable coil for LAA leak closure
224026489|NCT03503253|DEVICE|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
224026490|NCT03503253|DEVICE|Azur Peripheral Coil System|Use of detachable coil for LAA leak closure
224026491|NCT05112107|BEHAVIORAL|Culinary workshops|Approved ketogenic recipes will be applied in educational cooking workshops at the ketogenic diet clinic at Instituto da Criança HCFMUSP.
224026492|NCT03266354|PROCEDURE|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
224026493|NCT01621113|DRUG|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
224026494|NCT01621113|DRUG|Placebo|Placebo tablet, twice daily, for 10 weeks.
224026495|NCT03274960|COMBINATION_PRODUCT|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
224133772|NCT00670397|DRUG|HPPH|IV
224133773|NCT04510350|OTHER|Biomarkers analysis|Genetic analysis of regions of interest
223409788|NCT03616873|OTHER|Early Mobilization|The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
223409789|NCT04712448|DIAGNOSTIC_TEST|Anti-COVID test|No intervention is foreseen by the protocol
224026496|NCT00518791|OTHER|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
223409790|NCT01188330|BEHAVIORAL|WITH Comprehensive Geriatric assessment|"Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose"
223409791|NCT01188330|BEHAVIORAL|Conventional|no Comprehensive Geriatric assessment
223409792|NCT02582892|DRUG|Vit D|20 mg/day
224026497|NCT00518791|OTHER|Usual Care|No altered organisation of care
224026498|NCT05176535|DIETARY_SUPPLEMENT|FertyBiotic Balance|Lactobacillus rhamnosus BPL 205, Lactobacillus plantarum BPL207 and Lactobacillus crispatus BPL209
224133774|NCT02298478|BEHAVIORAL|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
224133775|NCT05449496|BEHAVIORAL|Dietary Education Curriculum|Curriculum of dietary education and group-based counseling to encourage whole-food plant-based eating
223409793|NCT04562246|DIAGNOSTIC_TEST|Serologic assays for antibodies to SARS-CoV-2|Beckman Coulter and Roche automated immunoassays
223409794|NCT04124601|RADIATION|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
224133776|NCT02690233|PROCEDURE|Elective Surgery|Elective laparoscopic inguinal hernia repair
224133777|NCT05434247|DEVICE|Needle choice|The type of needle use was the only intervention
223409795|NCT04124601|DRUG|Ipilimumab|Infusion
223409796|NCT04124601|DRUG|Nivolumab|Infusion
223409797|NCT02906501|PROCEDURE|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
223558672|NCT03919084|OTHER|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
224026499|NCT03823560|DEVICE|Celegyn®|Medical device Celegyn® presents itself as a cream.
224026500|NCT03823560|DEVICE|Matching placebo|IP placebo presents itself as a cream.
224026501|NCT04530409|DRUG|Early-Corticosteroids|early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
224026502|NCT01824160|DEVICE|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
224026503|NCT02435758|PROCEDURE|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
224026504|NCT00589082|DRUG|DaunoXome|
224026505|NCT00589082|DRUG|Daunorubicine|
224026506|NCT02946970|OTHER|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
224026507|NCT02946970|OTHER|Control|Intragastric administration of distilled water
224133778|NCT00932152|DRUG|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
224133779|NCT00932152|DRUG|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
224133780|NCT00932152|DRUG|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
224133781|NCT00932152|DRUG|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
224133782|NCT00421343|DRUG|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
224138995|NCT03488251|DRUG|MT-3724|MT-3724 will be administered.
223409798|NCT02906501|PROCEDURE|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
223409799|NCT04813068|OTHER|Semi-structured interview|Semi-structured interview to identify attitudes to re-irradiation in lung cancer
223409800|NCT04614025|BIOLOGICAL|PLX-PAD|PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
223409801|NCT00703586|DRUG|Maraviroc|"ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
223409802|NCT01921322|DEVICE|Pump|722 Paradigm Real-Time System
224026508|NCT03924739|BEHAVIORAL|Nurse-coordinated integrated care model for AF|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
224026509|NCT04999098|DRUG|Echinaforce Forte tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~the tablet contain additional excipients"
223409803|NCT01921322|OTHER|CGMS Gold|Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
223409804|NCT03612596|BEHAVIORAL|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
223409805|NCT03612596|BEHAVIORAL|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
223738576|NCT04674046|DEVICE|Nonoperative treatment|Patients where the ankle is evaluated as stable using arthroscopy will be treated with conservative treatment using a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
224133783|NCT00421343|DRUG|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
224133784|NCT00421343|BEHAVIORAL|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
224133785|NCT06516666|BEHAVIORAL|Music|"Participants went through four stages. In the rest stage, they were instructed to relax. In the neutral control stage, they watched an informative video about plastic injection molding. In the sadness induction stage, they viewed sad clips from either Hachi: A Dog's Tale or My Brother and Sister, with the order randomized across participants. In the music intervention stage, they listened to the cheerful Cuckoo Waltz. Each stage lasted for about 6 minutes.~The interventions for the two groups were exactly same.~PS: On the basis of the PHQ-9, this HAMD interview was conducted to further group the participants. So, following the experimental protocol, participants who scored ≥ 5 on the PHQ-9 measure underwent the HAMD interview, while the remaining individuals were simply interviewed about their feelings during the experiment."
224133786|NCT02537314|DRUG|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
224133787|NCT02537314|OTHER|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
224133788|NCT00121303|DRUG|cytarabine|
224133789|NCT00121303|DRUG|daunorubicin hydrochloride|
224133790|NCT00121303|DRUG|gemtuzumab ozogamicin|
224133791|NCT05137509|DEVICE|Computerized Tomography|Using Computerized Tomography for diagnosis COVID -19 patients
224133792|NCT06323915|DEVICE|intraocular lens implantation in cataract surgery|Implantation of intra ocular lenses in both patient's eyes in remplacement of the natural cataracted cristallin that has been removed from the patient's eye during the cataract surgery
224133793|NCT03305094|PROCEDURE|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
224133794|NCT02221180|DRUG|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
224133795|NCT02221180|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
224138996|NCT03488251|DRUG|Gemcitabine|Gemcitabine will be administered.
223409806|NCT03325816|DRUG|Nivolumab|Nivolumab is administered intravenously
223738577|NCT04674046|PROCEDURE|Operative treatment|Patients where the ankle is evaluated as unstable using arthroscopy will be operated on. Standard operative treatment is open reduction and internal fixation (ORIF) of the fracture using plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
223558673|NCT03919084|OTHER|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
223558674|NCT03919084|OTHER|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
223558675|NCT03919084|OTHER|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
223558676|NCT00296049|DRUG|daptomycin|
223558677|NCT00296049|DRUG|vancomycin|
223558678|NCT03444103|DRUG|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
223558679|NCT03444103|DRUG|Placebo / Clazakizumab|0.9% Saline
224026510|NCT04999098|DRUG|Echinaforce Chewable tablets|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 32 mg per tablet Dry weight content in 1 tablet: 5.9 mg~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)\* with an approx. dry plant equivalent of 1.8 mg per tablet Dry weight content in1 tablet: 0.3 mg~The tablets contain additional excipients"
224026511|NCT04999098|DRUG|Echinaforce tincture|"Tincture of fresh Echinacea purpurea (L) MOENCH: Herba rec. T. aerial part DER = 1:12-13 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)~Echinacea purpurea: (L) MOENCH: Radix rec. root part DER = 1:11-12 (Drug to extraction solvent ratio) extraction solvent = ethanol 65.1 % (V/V) = 57.3 % (m/m)"
224026512|NCT00344474|BEHAVIORAL|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
224026513|NCT03442985|DRUG|Palovarotene 2.5 mg|Subjects received a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
224026514|NCT03442985|DRUG|Palovarotene 5.0 mg|Subjects received a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
224026515|NCT03442985|OTHER|Placebo|Subjects received placebo, once daily, for up to 24 months.
224026516|NCT04196608|DRUG|Ceftolozane/tazobactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
223558680|NCT02008942|DRUG|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
223558681|NCT02008942|DRUG|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
224026517|NCT04196608|DRUG|imipenem- relebactam|Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria
224026518|NCT00271427|DRUG|L-Selenomethionine|
223558682|NCT00759876|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
223558683|NCT04792788|PROCEDURE|Weaning from mechanical ventilation|Cross over study: 3 periods of 40 minutes in ventilation mode (NAVA or PSV); to register ventilator traces and cardiopulmonary parameters during the last 10 minutes of each period.
223558684|NCT02514811|BEHAVIORAL|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
223558685|NCT00268944|BIOLOGICAL|Myozyme|20 mg/kg qow
223558686|NCT03636893|DRUG|FLOT Chemotherapy|5-FU+Leucovorin+Docetaxel+Oxaliplatin
223558687|NCT03636893|DRUG|SOX Chemotherapy|Oxaliplatin+Tegafur gimeracil oteracil potassium capsule (TGO)
223558688|NCT03087877|DEVICE|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
224026519|NCT01633983|DRUG|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
224026520|NCT01633983|DRUG|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
224026521|NCT00790608|DRUG|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
223558689|NCT00824252|BEHAVIORAL|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
223558690|NCT04808726|BEHAVIORAL|Teach Back Method|Effect of Breastfeeding Training on Breastfeeding Success Using The Teach Back Method: Randomized Controlled Study
223558691|NCT00570791|DEVICE|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
223558692|NCT00971581|DRUG|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
223558693|NCT00758069|DRUG|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
223558694|NCT00758069|DRUG|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
223558695|NCT00758069|DRUG|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
223558696|NCT03957668|DRUG|PEG 3350|PEG 3350 17 g once daily for 14 days
223558697|NCT03957668|DRUG|Lactulose|Lactulose 10 g once daily for 14 days
223409807|NCT03325816|RADIATION|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
223409808|NCT04994691|OTHER|No Message|No messages are sent
223409809|NCT04994691|OTHER|Standard message|2 MyChart reminders that child is overdue for well child check visit
223409810|NCT04994691|OTHER|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
223409811|NCT04359940|DIAGNOSTIC_TEST|Cardiac MRI|For clinical surveillance
223409812|NCT01154114|DRUG|darapladib|darapladib 40 mg oral dose
223409813|NCT06534099|OTHER|Control|Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.
223409814|NCT06534099|OTHER|Experimental|The Wuqinxi exercise regimen was conducted under the guidance of a professional Wuqinxi instructor, where the experimental group practiced the five animal forms of the exercise, which include the Tiger, Deer, Bear, Ape, and Bird forms. The exercise period was 24 weeks, with the first 4 weeks designated as the learning phase and weeks 5 to 24 as the consolidation and reinforcement phase. The frequency of exercise was three times per week, with each session lasting 70 minutes, including 10 minutes for warm-up and relaxation activities.
223558698|NCT01295840|DEVICE|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
223558699|NCT03818607|DRUG|ABP 959|intravenous infusion
223558700|NCT03818607|DRUG|Eculizumab|intravenous infusion
223558701|NCT02691910|DRUG|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
224026522|NCT01716117|DEVICE|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
224026523|NCT05779397|DEVICE|Masimo RAD-GT|Non-contact infrared thermometry device
224026524|NCT03794908|DEVICE|Light therapy A (Bright) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
223409815|NCT06207097|OTHER|physiotherapy techniques|Dry neeling: invasive physiotherapy technique where an acupuncture needle is used on painful points Elastic taping: physiotherapy technique where elastic bandage is used on the skin Exercise program: physical exercise prescription
223409816|NCT02573181|BIOLOGICAL|V114|V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.
223558702|NCT02691910|DRUG|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
224026525|NCT03794908|DEVICE|Light therapy B (Dim) via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
223558703|NCT02697760|RADIATION|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
223558704|NCT01761799|BEHAVIORAL|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
223558705|NCT00002134|DRUG|Ganciclovir|
224138997|NCT03488251|DRUG|Oxaliplatin|Oxaliplatin will be administered.
224138998|NCT00274157|BEHAVIORAL|Behavior|
223409817|NCT02573181|BIOLOGICAL|Prevnar 13™|Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
223409818|NCT03143985|DRUG|Vactosertib|Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). Vactosertib inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
223558706|NCT00006144|DRUG|Lopinavir/Ritonavir|
223558707|NCT00006144|DRUG|Emtricitabine|
223558708|NCT00006144|DRUG|Stavudine|
223558709|NCT05778864|DRUG|LY3473329|Administered orally.
223558710|NCT04027283|DIETARY_SUPPLEMENT|Erythritol|50g erythritol dissolved in 300mL tap water
223558711|NCT04027283|DIETARY_SUPPLEMENT|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
223558712|NCT04027283|DIETARY_SUPPLEMENT|D-allulose|25g D-allulose dissolved in 300mL tap water
223558713|NCT04027283|DIETARY_SUPPLEMENT|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
223558714|NCT04027283|DIETARY_SUPPLEMENT|Tap water|300mL tap water
223558715|NCT04027283|DIETARY_SUPPLEMENT|Tap water + lactisole|300mL tap water + lactisole (450ppm)
223409819|NCT03143985|DRUG|Pomalidomide|POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
223409820|NCT05057598|OTHER|Community-based participatory research on diet and lifestyle|"The intervention use a web site that contains a section to exchange information on recipes and on strategy to comply with the recommendations, and an agenda to inform on meetings, conferences, kitchen classes, walking groups, organised by the participant themselves. The investigators are developed specific recommendations for women with different characteristics. The investigators intend to improve the specificity of information with short questionnaires on portion size of relevant items using photographs or usual container in the kitchen and develop a health application for smartphone to facilitated a more efficient and timely exchange on information.~The participants will receive a free phone number for emergencies, active 2 hours a day for 5 days a week."
223409821|NCT02271152|PROCEDURE|FAST mapping and ablation|
224026526|NCT04531553|PROCEDURE|Thoracic epidural analgesia|Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).
224133796|NCT02221180|DRUG|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
224133797|NCT04729920|DEVICE|Mechanical insufflation/exsufflation device (MI-E)|download of device (MI-E) data and self-reported satisfaction with the device
224133798|NCT05738902|OTHER|Assessment of compliance to ERAS.|Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.
224133799|NCT01887028|DEVICE|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
224133800|NCT00463658|OTHER|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
224133801|NCT03007017|PROCEDURE|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
224133802|NCT03007017|PROCEDURE|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
223409822|NCT02271152|PROCEDURE|PVI|
223409823|NCT02251457|DRUG|Ranolazine|Ranexa is FDA approved for chronic angina
223409824|NCT03850496|DEVICE|Revitive IX Neuromuscular Stimulation Device|Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
223409825|NCT02846181|DRUG|[14C]-SK-1405|
223409826|NCT03731819|DIAGNOSTIC_TEST|Abbreviated PB MRI|Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
223409827|NCT02605343|OTHER|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
224026527|NCT04531553|PROCEDURE|ESPB with levobupivacaine and dexmedetomedine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.
224133803|NCT00790738|DRUG|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
224133804|NCT00790738|DRUG|placebo|placebo
223409828|NCT06576310|DEVICE|Mandibular Advancement Device|In this research, participation in the protocol seamlessly integrates into routine care at the Odontology Department of the University Hospital of Toulouse. The visits include the provision of the orthosis at 3 weeks (T1), with EMGs and digital occlusal analysis. The 6-week follow-up visit (T2) adjusts therapeutic propulsion, subjectively resolving symptoms related to OSAS. At the T0 visit, the researchers collect the polysomnographic monitoring before fitting the orthosis (carried out in the patient's reference sleep laboratory) to assess treatment efficiency. The end-of-research visit (6 months after T1) comprehensively collects data, including questionnaires on stress, anxiety, sleep quality and quantity, oral habits, temporo mandibular dysfunction pain, and quality of life. Moreover, the researchers collect the polysomnographic monitoring after 3 months fitting the orthosis (carried out in the same patient's reference sleep laboratory than before fitting the orthosis).
223409829|NCT03468114|BEHAVIORAL|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
223409830|NCT03468114|BEHAVIORAL|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
223409831|NCT01017770|DRUG|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
223409832|NCT01017770|DRUG|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing \> 35 kg.
223409833|NCT04396197|OTHER|Physiotherapy|Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
224026528|NCT04531553|PROCEDURE|ESPB with levobupivacaine|patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
224026529|NCT04637308|DRUG|Succinylated gelatin|"Succinylated gelatin (SG, Gelofusine; B. Braun, Crissier, Switzerland) is a clear, inexpensive, safe, colloidal plasma volume-expanding solution, weight-average molecular weight (MWw) 30 kDa."
224026530|NCT06450938|DEVICE|AI guidance for finding radiographic features|A secured website was made for the trial in which each student could log in using the assigned number. All the image datasets were uploaded to this website. The students will be randomly assigned to the experiment and control group. Both students were asked to segment the features associated with the quality of root canal treatment and predict the prognosis of treatment while the experiment group had access to AI guidance and the control group didn't.
223409834|NCT02308891|DRUG|lactated Ringer's solution (vigorous hydration arm)|"* Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
224026531|NCT00451100|DRUG|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
224026532|NCT00451100|DRUG|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
224026533|NCT03490526|DEVICE|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
223409835|NCT02308891|DRUG|lactated Ringer's solution (standard hydration arm)|\- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
223409836|NCT02308891|DEVICE|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
224026534|NCT03490526|DEVICE|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
224026535|NCT04629001|DIAGNOSTIC_TEST|Covid-19 PCR , IGM|test for Covid-19
224026536|NCT01386788|OTHER|There is no intervention planned (observational)|No intervention foreseen
224133805|NCT01204255|DRUG|lorazepam|Given topically
224133806|NCT01204255|DRUG|diphenhydramine hydrochloride|Given topically
224133807|NCT01204255|DRUG|haloperidol|Given topically
224133808|NCT01204255|OTHER|questionnaire administration|Ancillary studies
224133809|NCT01204255|OTHER|laboratory biomarker analysis|Correlative studies
223409837|NCT03350789|DEVICE|Real acupuncture|manual acupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 \& L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today
223409838|NCT03350789|DEVICE|Sham acupuncture|sham acupuncture without skin penetration(0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
223409839|NCT00044629|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|
223409840|NCT00044629|DRUG|zolpidem tartrate (Ambien)|
224133810|NCT06400563|DEVICE|MRg-NIRS|The trial tests the investigator designed and developed Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) imaging system for breast cancer detection. The wearable NIRS imaging system uses 8 flex circuit strips, each with six photo-detectors (PDs) and six source fibers, that are ready to attach to a breast radially by using an adhesive nipple cover and breast tape.
224133811|NCT06399640|DRUG|Eltanexor|Eltanexor will be taken by mouth
224133812|NCT06399640|DRUG|Venetoclax|Venetoclax will be taken by mouth
224133813|NCT06399640|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224133814|NCT06399640|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224133815|NCT01737567|OTHER|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
223409841|NCT00044629|DRUG|Placebo|
224133816|NCT01737567|OTHER|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
224026537|NCT03089151|BEHAVIORAL|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~1. A garden plot in a Denver Urban Garden~2. Seeds and plant starts~3. Introductory gardening workshop~4. Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
224026538|NCT01114061|DEVICE|Insupatch|Applying heat to the infusion site using the insupatch device
224026539|NCT00862355|DRUG|SPARC147609|IV infusion
224026540|NCT00862355|DRUG|Reference147609|IV infusion
224026541|NCT03249025|DRUG|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
224026542|NCT03249025|DRUG|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
224026543|NCT05535634|DIAGNOSTIC_TEST|Sound Ear Check|Hearing test, measurement of the input impedance of the middle-ear transmission system
224026544|NCT02153372|OTHER|BMC2012|
224026545|NCT00581815|DEVICE|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
224026546|NCT00581815|DEVICE|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
224026547|NCT04429997|PROCEDURE|Removal of fibrosynovial tissue|Remove of fibrosynovial tissue at the superior border of patella
224026548|NCT04429997|PROCEDURE|Non-removal of fibrosynovial tissue|Do not remove of fibrosynovial tissue at the superior border of patella
224026549|NCT02986334|DRUG|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
224133817|NCT02077387|BEHAVIORAL|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
223409842|NCT04715074|BEHAVIORAL|Interviews|We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.
223409843|NCT04715074|BEHAVIORAL|Pilot|Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
223409844|NCT02235844|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|
223409845|NCT03674112|DRUG|Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)|PH FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
223409846|NCT03674112|DRUG|Pertuzumab IV|Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
223409847|NCT03674112|DRUG|Trastuzumab IV|Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
223409848|NCT05537818|DEVICE|AVPI Device|"The AVPI device system consists of a small, hand-held, micro-pressure pulse generator device that is operated by a hand-held mobile smartphone (iPhone®) with a downloaded software application or app. The AVPI device is connected to an earpiece assembly that splits into two earbuds (right and left) that seat comfortably into each respective ear.~1. AVPI device for pressure regulation~2. Earpiece Assembly - a small, flexible, hollow tube that divides into right and left earpieces~3. Earbuds - replaceable, multiple sizes~4. Smartphone with the AVPI app"
223409849|NCT01263236|DRUG|LY2940094|Administered orally
223409850|NCT01263236|DRUG|Placebo|Administered orally
223558716|NCT00976287|PROCEDURE|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
223558717|NCT00976287|PROCEDURE|Conserved Therapy|Conserved Therapy
224133818|NCT02077387|BEHAVIORAL|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
223558718|NCT04333979|OTHER|Drainage|Using drain after operation
224026550|NCT02986334|DRUG|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
224026551|NCT02986334|DRUG|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
224133819|NCT04213287|DRUG|Dexketoprofen Trometamol|Drug: Dexketoprofen Trometamol oral tablet
224133820|NCT04213287|OTHER|spinal anesthesia|Drug: heavy bupivacaine 2,5 ml 0,5%
224133821|NCT04213287|OTHER|IPACK|Drug: bupivacaine 20 ml 0,025%
224133822|NCT04213287|OTHER|PAI|Drug: bupivacaine 30 ml 0,025%
224133823|NCT04213287|OTHER|Adductor canal block|Drug: bupivacaine 20 ml 0,025%
224138999|NCT00274157|BEHAVIORAL|diet control, smoking cessation, exercize|
224133824|NCT00666133|DEVICE|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
224133825|NCT04838106|OTHER|Not applicable as observational study|Not applicable as observational study.
224133826|NCT02214199|OTHER|Manipulative Therapy Techniques|
224133827|NCT02214199|OTHER|Home Exercises|
223409851|NCT02389387|OTHER|Intensive Intervention|I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
223409852|NCT02539433|PROCEDURE|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
224026552|NCT04265924|OTHER|fraction of inspired oxygen (FIO2)|The fraction of inspired oxygen (FIO2) is given accordingly (\>0.85 for the \>0.85 group, and \<0.7 for the \<0.7 group) to the patients during the surgery.
223409853|NCT03189693|OTHER|PVB|nerve stimulator-guided PVB will be performed at two levels
223558719|NCT00588237|DRUG|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
224026553|NCT00827801|BEHAVIORAL|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.
224026554|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
224026555|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
224026556|NCT04386707|BIOLOGICAL|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age|Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
224026557|NCT04386707|BIOLOGICAL|Three doses control wIPV at the schedule of 2,3,4 months of age|Three doses control wIPV at the schedule of 2,3,4 months of age
224026558|NCT04001985|OTHER|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
224026559|NCT04001985|OTHER|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
224026560|NCT00120406|DEVICE|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
224026561|NCT00120406|PROCEDURE|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
224026562|NCT06209671|BIOLOGICAL|INS19 CAR-T Cells|INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.
224026563|NCT06381050|DRUG|SHR-7631|The total dosage of SHR-7631 was calculated according to the weight weighing results of the subjects before each administration, and was administered by intravenous drip.
224026564|NCT00956514|DEVICE|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
224026565|NCT03703245|OTHER|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
224026566|NCT03703245|OTHER|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
224026567|NCT03542409|OTHER|MR Perfusion Scan|MR perfusion scan before and during surgery.
224026568|NCT03542409|OTHER|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
224026569|NCT03542409|OTHER|Standard of Care Intraoperative MRI|The standard of care intraoperative MRI sequences used routinely will be sufficient for these 10 new samples.
224026570|NCT00001457|DRUG|Lamivudine|
224026571|NCT04641039|PROCEDURE|Anterior lumbar disc annulus removal versus replacement|Owestry scale, SF12, Facet joint arthritis measured with Pathria scale, discal degeneration measured with Modic and Phirrmann scales
224026572|NCT05588687|BEHAVIORAL|Virtual reality|Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
224026573|NCT05588687|DEVICE|Tablet|Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
224133828|NCT00252122|DRUG|Ketamine|Ketamine. 0.2 mg/kg, intravenously
224026574|NCT03507660|OTHER|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
224026575|NCT02791373|DRUG|Vinorelbine|Mobilisation Chemotherapy
224026576|NCT02791373|DRUG|Gemcitabine|Mobilisation Chemotherapy
224026577|NCT06025162|DRUG|enoxaparin|dose of enoxaparin at 48 hours post-VTE prophylaxis initiation
224133829|NCT05553626|DEVICE|Left bundle branch pacing|Left bundle branch pacing by a single/dual chamber pacemaker or dual chamber ICD device through the pacing lead at left bundle branch region
223409854|NCT03189693|OTHER|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
223409855|NCT03189693|OTHER|GA|All patients will receive general anesthesia.
223409856|NCT03189693|OTHER|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
224026578|NCT04926220|DEVICE|Trans-esophageal Doppler monitoring|Trans-esophageal Doppler monitoring (CARDIOQ-ODM; Deltex Medical, Chichester, UK) for monitoring of cardiac output
224026579|NCT04926220|DEVICE|MostCareUP Haemodynamic Monitor|MostCareUp (Vytech, Padova, Italy) waveform analysis cardiac output monitor
224026580|NCT04926220|DEVICE|Argos Cardiac Output (CO) Monitor|Argos monitor (Retia Medical, Valhalla, NY, USA) for cardiac output monitoring
224026581|NCT00914264|DEVICE|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 \& 12 months
224026582|NCT00606567|OTHER|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
224026583|NCT03982615|DEVICE|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
224026584|NCT03982615|DEVICE|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
224026585|NCT00571831|PROCEDURE|intraocular lens implantation|Intraocular lens implantation
224026586|NCT01989767|BEHAVIORAL|control Rehabilitation as usual|Rehabilitation as usual
223409857|NCT02882360|DEVICE|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
223558720|NCT04661371|PROCEDURE|Laparoscopic cholecystectomy|"Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)"
224026587|NCT01989767|BEHAVIORAL|education|Education as add on to to rehabilitation as usual
224133830|NCT05553626|DEVICE|Bi-ventricular pacing|Bi-ventricular pacing by a CRT/CRTD device
224133831|NCT02981277|DRUG|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
224133832|NCT02981277|DRUG|Spray as you go|Lignocaine delivery using Spray as you go method
224133833|NCT03144323|BEHAVIORAL|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
224026588|NCT06524752|OTHER|The presence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
224026589|NCT06524752|OTHER|Non-existence of nausea and vomiting within 24 hours after surgery|This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
224133834|NCT04684914|BIOLOGICAL|HepTcell|Intramuscular injection
223409858|NCT02882360|OTHER|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
224026590|NCT03947437|BIOLOGICAL|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
224026591|NCT03947437|BIOLOGICAL|Placebo|Sterile normal saline for injection.
224026592|NCT06409520|DIAGNOSTIC_TEST|thyroid function tests|(TSH, free T4) The normal ranges of thyroid function tests were 0.40-4.99 mIU/L for TSH and 0.7-1.8 ng/dL for free T4. The same testing method will performed on all samples from all patients.
224026593|NCT06409520|DIAGNOSTIC_TEST|cardiac enzymes|troponine
224026594|NCT06409520|DIAGNOSTIC_TEST|ECG|Electrocardiogram
224026595|NCT01002365|OTHER|Oxygen delivery|
224026596|NCT01002365|OTHER|Oxygen administration|
224026597|NCT01326234|BEHAVIORAL|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
224026598|NCT01326234|BEHAVIORAL|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
223409859|NCT03711565|DEVICE|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
223558721|NCT03389412|DRUG|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
223558722|NCT03389412|DEVICE|Conditional alarm|Eight weeks of treatment.
224026599|NCT03127254|BEHAVIORAL|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
224133835|NCT04684914|DRUG|Placebo|Intramuscular injection
224133836|NCT06313437|DRUG|Revumenib|Menin inhibitor, 25 and 113 mg capsules, taken orally per protocol.
224133837|NCT06313437|DRUG|Midostaurin|Kinase inhibitor, capsule taken orally per protocol.
224133838|NCT06313437|DRUG|Cytarabine|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
224133839|NCT06313437|DRUG|Daunorubicin|Antineoplastic agent, via intravenous (into the vein) infusion per protocol.
224133840|NCT03410927|DRUG|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
223409860|NCT03711565|DEVICE|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
223409861|NCT02972684|DEVICE|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
223409862|NCT05198063|BIOLOGICAL|Recombinant novel coronavirus vaccine (CHO cells)|At 6 months after the basic immunization (window period ± 1 month), 1 dose of recombinant novel coronavirus vaccine (CHO cells) is vaccinated.
223409863|NCT02084108|OTHER|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
223409864|NCT00081224|DRUG|capecitabine|
223409865|NCT00081224|DRUG|celecoxib|
224026600|NCT03127254|BEHAVIORAL|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
224026601|NCT03127254|BEHAVIORAL|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
224026602|NCT03127254|BEHAVIORAL|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
224026603|NCT03127254|BEHAVIORAL|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
224026604|NCT02391454|DEVICE|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
224026605|NCT02391454|OTHER|Usual care|
223558723|NCT04457791|BEHAVIORAL|Personalized dietary advice|Via an self-developed website and algorithm, participants will receive digital personalized dietary advice to increase dietary fiber intake, aiming to reduce constipation complaints. The advice is personalized on phenotype (habitual diet, gender)
223558724|NCT02332993|DIETARY_SUPPLEMENT|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
223558725|NCT03712176|BEHAVIORAL|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
223558726|NCT03309254|OTHER|High Glycemic Index|High Glycemic Index Food
224026606|NCT01295034|DIETARY_SUPPLEMENT|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
224026607|NCT01295034|DRUG|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
224026608|NCT00903955|OTHER|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
224026609|NCT06456450|BIOLOGICAL|Biological Treatment for severe asthma patients|Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
223558727|NCT03309254|OTHER|Low Glycemic Index|Low Glycemic Index Food
224026610|NCT06426667|PROCEDURE|posterior tibial nerve radiofrequency|pulse radiofrequency at 45 V for 300 seconds at 42 degrees Celsius is applied to the posterior tibial nerve area. During the procedure, the temperature at the electrode tip is kept below 42°C. Following negative aspiration (in the absence of blood), 2 cc of 1% lidocaine + 4 mg dexamethasone is applied to the same area.
224026611|NCT06426667|PROCEDURE|plantar fasciitis radiofrequency|the spur area on the calcaneal bone is identified, and sensory and motor stimulations are applied using the RF cannula. If no sensory or motor response is elicited in the area, conventional radiofrequency at 45 V for 60 seconds at 80 degrees Celsius is applied to the spur area after confirming the placement of the RF cannula.
224026612|NCT06116955|DRUG|Midazolam and sufentanil|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with midazolam combined with sufentani.
224133841|NCT02566330|DEVICE|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
224133842|NCT03125655|DIAGNOSTIC_TEST|Inflammatory markers|
224133843|NCT01521234|BEHAVIORAL|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
224133844|NCT04253977|BEHAVIORAL|HEALTH-P2|The HEALTH-P2 curriculum includes evidence based lifestyle change strategies to prevent excess gestational weight gain and postpartum weight retention embedded within and delivered as part of home visits.
223409866|NCT00081224|RADIATION|radiation therapy|
223409867|NCT00081224|PROCEDURE|surgery|
223409868|NCT04942028|BEHAVIORAL|Exposure|Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
223409869|NCT04942028|BEHAVIORAL|Standardized education|Standardized routine care education for individuals suffering from distress related to somatic symptoms, primarily focusing on healthy lifestyle behaviors such as sleep, diet, and exercise
223558728|NCT01643265|DIETARY_SUPPLEMENT|Whey Milk Protein|20 grams of Whey Milk Protein
223738578|NCT04674046|BEHAVIORAL|Standardized education|All participants, regardless of group allocation, will receive education focusing on basic self- management. A physiotherapist will be responsible for the education. The intention will be to increase self-efficacy and encourage self-management. Participants will learn about crutch walking, cast or orthosis usage, loading principles, be advised to stay physically active within proper restrictions and how to rest and reduce pain and swelling of the ankle in the acute phase. Participants will also receive a standard information brochure about the condition, treatment and basic self-management.
224026613|NCT06116955|DRUG|Midazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with midazolam and sufentani combined with propofol.
224026614|NCT06116955|DRUG|Remazolam and sufentanil.|Patients undergoing bronchoscopic diagnosis and treatment under moderate sedation with remazolam combined with sufentani.
224026615|NCT06116955|DRUG|Remazolam, sufentanil and propofol|Patients undergoing bronchoscopic diagnosis and treatment under deep sedation with remazolam and sufentani combined with propofol.
224026616|NCT03982901|DIAGNOSTIC_TEST|Mental Stress Test|In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
224026617|NCT05127252|DIAGNOSTIC_TEST|Vaginal and rectal microbiome and metabolome|Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.
224026618|NCT04793659|DRUG|Oral Fasudil 90 mg/day|Oral tablet
224026619|NCT04793659|DRUG|Oral Fasudil 180 mg/day|Oral tablet
224026620|NCT04793659|DRUG|Oral Placebo|Oral tablet
224026621|NCT03748407|OTHER|Dosages of Thyroid parameters|Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
224026622|NCT00557934|OTHER|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
224133845|NCT04253977|BEHAVIORAL|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
224133846|NCT05971004|DEVICE|Arthrys (Collagen Peptide solution)|one injection of collagen peptide solution (Tiss'You, Republic of San Marino) at the site of the inflamed ligament attachment point
224026623|NCT04806542|BEHAVIORAL|TMR-group|A mindfulness-based 8 week program.
224133847|NCT05971004|DRUG|Depo medrol|one injection of depo-medrol at the site of inflamed ligament attachment point (femoral condyle), combined with oral slow-acting symptomatic drugs (glucosamine 1500mg, atrodar 50mg) for 3 consecutive months.
224026624|NCT04806542|BEHAVIORAL|Treatment as usual|Individual counselling.
224026625|NCT03917680|DIAGNOSTIC_TEST|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
224026626|NCT03917680|GENETIC|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
224026627|NCT03917680|DIAGNOSTIC_TEST|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
224133848|NCT04523441|OTHER|Focus group|Holding of a focus group by a sociologist
224133849|NCT04523441|OTHER|Semi-directive interview|Conducting a semi-directive interview by a sociologist after discharge from hospital
224133850|NCT00157937|DRUG|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
224133851|NCT00157937|DRUG|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
224133852|NCT06411119|DEVICE|Meta Oculus Quest 2™ Virtual Reality Exergaming|Participants utilised the Meta Oculus Quest 2™ Virtual Reality headset to play the Beat Saber game, which involves striking blocks in time to music using hand controllers. Gameplay was configured at a moderate difficulty level in 'no-fail' mode to encourage continuous activity across pre-selected songs, requiring participants to perform movements such as lateral steps, squats, and arm motions. Each session lasted for 20 minutes, including 30-second rest intervals between songs, to maximise physical activity and monitor heart rate, perceived exertion, and technology acceptance.
223409870|NCT04942028|BEHAVIORAL|Prolonged assessment|Patients are encouraged to keep a rudimentary symptom diary to track if and how their symptoms interact with mood and lifestyle behaviors
223409871|NCT06340841|BEHAVIORAL|Personal Incentives|The participant receives incentives directly if they complete an activity on a given day.
224026628|NCT02440451|DEVICE|Neurofeedback using BCI|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
224026629|NCT06185361|DRUG|Fluoxetine 20 MG|fluoxetine
224133853|NCT02987348|DRUG|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
224133854|NCT02987348|DRUG|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
223409872|NCT06340841|BEHAVIORAL|Personal Restorative Incentives|The participant receives incentives directly if they complete an activity on a given day. They are given an additional incentive to return to completing activities if they did not complete an activity on a prior day.
224026630|NCT06185361|DRUG|Desmopressin|desmopressin
223409873|NCT06340841|BEHAVIORAL|Charity Incentives|The participant earns compensation for charity if they complete an activity on a given day.
224026631|NCT01749605|DRUG|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
224026632|NCT01749605|DRUG|ciprofloxacin 250 mg BID x 3 days|
224026633|NCT00437580|DRUG|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
224133855|NCT02987348|DRUG|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
224133856|NCT05918874|OTHER|Descriptive questionnaire|Questionnaires were administered to calculate whether the children were obese or not, to determine their asthma control levels, to determine their physical activity levels and to determine their leisure time activities.
224133857|NCT00256087|DRUG|Probiotic Lactobacillus|
224133858|NCT00256087|OTHER|Lactose Powder|
224133859|NCT04289415|BEHAVIORAL|Individual Placement and Support|Employment specialist will work together with the participants in accordance to the method IPS in order to help the participant obtain competitive employment
224133860|NCT03432052|PROCEDURE|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
224133861|NCT00230529|DRUG|infliximab|
224133862|NCT01479374|DRUG|AL-4943A ophthalmic solution|
224133863|NCT01479374|DRUG|AL-4943A vehicle|Inactive ingredients used as placebo
224133864|NCT01479374|DRUG|Olopatadine hydrochloride ophthalmic solution, 0.2%|
224133865|NCT00091702|BIOLOGICAL|Cold-adapted live attenuated influenza vaccine (FluMist)|
224133866|NCT00091702|BIOLOGICAL|Inactivated influenza vaccine (IAIV)|
223409874|NCT06340841|BEHAVIORAL|Charity Restorative Incentives|The participant earns compensation for charity if they complete an activity on a given day. They are given an additional incentive for charity to return to completing activities if they did not complete an activity on a prior day.
223738579|NCT05011864|BEHAVIORAL|Behavioral Activation|In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
223738580|NCT05011864|BEHAVIORAL|Fall Prevention|Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
223738581|NCT05011864|OTHER|Telephone support|Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
224133867|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
223409875|NCT03453099|OTHER|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~1. An abbreviated version of the Caffeine Assessment Tool (CAT)~2. Sleep Questionnaire (SQ)~3. Surgical Fear Questionnaire (SFQ)~4. WHO Alcohol AUDIT Tool~5. WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
224026634|NCT00655291|DRUG|XP20B|
224026635|NCT00655291|DRUG|Placebo|
224026636|NCT03063112|DEVICE|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
224026637|NCT03063112|DRUG|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
224026638|NCT03063112|DEVICE|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
224026639|NCT03063112|DRUG|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
224026640|NCT04253067|DEVICE|Active fCO2 laser treatment|The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
224026641|NCT04253067|DEVICE|Sham fCO2 laser treatment|The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
224133868|NCT01606761|DRUG|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
224133869|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
224133870|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
224133871|NCT01606761|DRUG|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
224139000|NCT04153617|DIETARY_SUPPLEMENT|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
224139001|NCT04153617|DIETARY_SUPPLEMENT|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
224133872|NCT03616327|DEVICE|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
224133873|NCT05086289|DRUG|LY3526318|Administered orally
224026642|NCT02116985|DEVICE|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
223409876|NCT03453099|OTHER|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr postoperatively.
223409877|NCT04820699|OTHER|post isometric relaxation and muligan bent leg raise|6 week intervention
223409878|NCT04820699|OTHER|muligan bent leg raise|muligan bent leg raise
223409879|NCT02620176|DEVICE|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
223409880|NCT04116060|DIETARY_SUPPLEMENT|Dietary Nitrate|Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
223409881|NCT04116060|DIETARY_SUPPLEMENT|Control|Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
223409882|NCT04346667|DRUG|Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
223409883|NCT04346667|DRUG|Hydroxychloroquine Sulfate Loading Dose|Hydroxychloroquine administered as a loading dose only
223409884|NCT04346667|DRUG|Chloroquine|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2
223409885|NCT04346667|DRUG|Placebo|Standard of Care plus placebo
223409886|NCT05681325|DIETARY_SUPPLEMENT|green tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
223409887|NCT05681325|DIETARY_SUPPLEMENT|matcha tea|It will be given 2 cups / day for 30 days. To prepare each cup, a tea pack will be immersed into a cup of hot water.
223409888|NCT01905020|OTHER|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
223409889|NCT01905020|OTHER|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
223409890|NCT03121001|DRUG|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
223409891|NCT03121001|DRUG|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
223409892|NCT03121001|DRUG|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
223409893|NCT03121001|RADIATION|Total body irradiation|3 Gy on day -1
223409894|NCT03121001|PROCEDURE|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
223409895|NCT03121001|DRUG|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
223409896|NCT03121001|DRUG|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
223558729|NCT01643265|DIETARY_SUPPLEMENT|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
223558730|NCT02160665|DRUG|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G \& W Laboratories, Inc.)
223558731|NCT02160665|DRUG|Vehicle|Vehicle of Test product (G \& W Laboratories, Inc.)
224026643|NCT02116985|DEVICE|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
224026644|NCT05335954|DRUG|noradrenaline|noradrenaline
224026645|NCT01115660|BEHAVIORAL|stroke education|call by medication coach 2 weeks after hospital discharge
224026646|NCT01313637|DRUG|GSK573719/GW642444 125/25mcg|125/25mcg
224026647|NCT01313637|DRUG|GSK573719 125mcg|125mcg
224026648|NCT01313637|DRUG|GW642444 25mcg|25mcg
224026649|NCT01313637|DRUG|Placebo only|Placebo
224026650|NCT03692260|PROCEDURE|3D stent in Herbert screw insertion vs titanium plate|benefit of 3d template in fracture gap
224026651|NCT02441166|PROCEDURE|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
224026652|NCT00892684|DIETARY_SUPPLEMENT|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
224026653|NCT00892684|DIETARY_SUPPLEMENT|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
224026654|NCT03537287|DRUG|17 alpha hydroxyprogestrone caproate|250 mg of 17 alpha hydroxyprogestrone caproate weekly
224026655|NCT03537287|DRUG|Vaginal progesterone|200 mg of vaginal progesterone daily
224026656|NCT03537287|DRUG|Oral dydrogesterone|2 tablets of dydrogesterone daily
224026657|NCT04557111|DEVICE|remote monitoring|CIED monitoiring with remote monitoring device
224026658|NCT01840787|DEVICE|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
224026659|NCT01840787|DEVICE|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
224026660|NCT01840787|DEVICE|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
223409897|NCT04754386|BEHAVIORAL|Acceptability of OraQuick Advance© Rapid HIV-1/2 Antibody screening Oral fluid-based HIV test|The project offers HIV oral test kits to index parents/caregivers with children eligible for index testing services at facility settings to expand access to HIV testing and treatment services for children, and to ensure that all children who screen positive with an oral fluid-based HIV screening kit are linked to confirmatory testing, and newly diagnosed children are initiated on ART.
224026661|NCT00816348|DRUG|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
224026662|NCT02425709|DRUG|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
224026663|NCT02425709|DRUG|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
224026664|NCT02425709|DRUG|Placebo|Women will receive an oral placebo 1 hour before the procedure
223409898|NCT00832572|DRUG|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
224026665|NCT04152460|DEVICE|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
224133874|NCT05086289|DRUG|Placebo|Administered orally
224133875|NCT04777643|DRUG|Cannabidiol|Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.
223409899|NCT00832572|DRUG|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
223409900|NCT05193539|BEHAVIORAL|Augmented reality and virtual reality rehabilitation|"This group underwent augmented reality and virtual reality rehabilitation with 4 different systems.~The RAPAEL Smart Glove® is a wearable sensory system that contains a single 9-axis movement and position sensor with 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measures wrist movements, and 5 bending sensors that measure finger movements. The RAPAEL Smart Board® is a rehabilitation system used to improve arm function by practicing gravity-compensated movements. The RehabMaster® is a game-based Kinect sensor AR rehabilitation system which uses a 3D camera to digitize patient movements and quickly analyze their range of motion, speed, motion angle, and movement cycles. rehabilitation exercise using games to encourage active arm and trunk movements and promote successful rehabilitation. The COG-Trainer® is a VR system that uses a training device synchronized with the screen through simulation."
224133876|NCT04777643|OTHER|Placebo|Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.
223409901|NCT05193539|BEHAVIORAL|Conventional occupational therapy|The group underwent standard ocupational therapy, such as range of motion and strengthening exercises for the affected upper extremity, table-top activities, and training for activities of daily living.
223409902|NCT05903625|DIETARY_SUPPLEMENT|Control Group - Standard White Bread|Participants consume commercially available standard white bread, serving as the control intervention.
223409903|NCT05903625|DIETARY_SUPPLEMENT|Lysine Group - Lysine-Fortified Bread|Participants consume bread fortified with lysine, an essential amino acid, in a specified dosage, frequency, and duration.
223409904|NCT05903625|DIETARY_SUPPLEMENT|Phosphorus Group - Phosphorus-Fortified Bread|Participants consume bread fortified with phosphorus, an essential mineral, in a specified dosage, frequency, and duration
223558732|NCT02160665|DRUG|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
223558733|NCT04317521|DEVICE|Use of EKO Core and EKO Duo electronic stethoscopes|Listen to heart murmurs
223558734|NCT06134115|DIETARY_SUPPLEMENT|Lipocet® (food supplement)|1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
224026666|NCT04152460|OTHER|Grandioso x-tra|Nanohybrid Bulk Resin Composite
224026667|NCT02838147|DEVICE|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
224026668|NCT02838147|DEVICE|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
224026669|NCT06442436|DRUG|Nemtabrutinib|25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
224026670|NCT04218084|DRUG|Voxelotor|Participants are randomized 1:1 to receive voxelotor or placebo.
224026671|NCT04218084|DRUG|Placebo|Matching placebo.
224026672|NCT06962306|DRUG|Methadone hydrochloride|Initial dosing 0.2mg/kg, potential to escalate to 0.25mg/kg following interim analysis
224026673|NCT06962306|DRUG|Fentanyl/Hydromorphone|Per routine care
224026674|NCT05133778|DIETARY_SUPPLEMENT|Sweet orange and pomegranate extract|From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
224133877|NCT01996748|DRUG|DF277|Two administrations daily for 7 days
224133878|NCT01996748|DRUG|Placebo|Two administrations daily for 7 days
224139002|NCT04280887|DEVICE|MyPad|Ultrasound bed wetting alarm
224139003|NCT06342323|RADIATION|SBRT|the fiducial marker was implanted with 3D template assistance under CT guidance
223558735|NCT06134115|DIETARY_SUPPLEMENT|Lipocet Placebo|Lipocet Placebo matching to Lipocet
223558736|NCT05059301|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.
223558737|NCT02626429|DIETARY_SUPPLEMENT|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
223558738|NCT04494542|PROCEDURE|Sustained Low Efficiency Dialysis (SLED)|sustained low efficiency dialysis (SLED)
223558739|NCT04494542|PROCEDURE|Continuous Renal Replacement Therapy|Continuous Renal Replacement Therapy
223558740|NCT02428998|DIETARY_SUPPLEMENT|Korean Red Ginseng|
223558741|NCT02428998|DIETARY_SUPPLEMENT|Placebo|
224026675|NCT05133778|OTHER|Maltodextrin control|Supplementation with 760 mg maltodextrin
224026676|NCT06643143|DRUG|IkT-001Pro|IkT-001Pro
224026677|NCT06643143|DRUG|Placebo|Placebo
224026678|NCT05816122|DEVICE|MSCopilot® Detect mobile application|MSCopilot® Detect includes active tests for walking, cognition, dexterity and vision, and e-questionnaires related to fatigue and Multiple Sclerosis quality of life
224026679|NCT05580588|DRUG|SPH4336|400 mg SPH4336 PO QD
224026680|NCT04723420|OTHER|Steamroller technique|Following intravitreal gas injection, patient positioned face down for 4-6 hours and subsequently patient changes the position of the head so that the bubble is then placed directly over the retina break.
224026681|NCT04723420|OTHER|Direct technique|Following intravitreal gas injection, patient is immediately positioned so that the bubble is placed directly over the retina break.
224026682|NCT06062147|BEHAVIORAL|Teacher training|Training for teachers in the intervention arm in the learning process, SLLD and early warning signs, with an identification grid. Observation of identified pupils and implementation of educational and environmental adjustments.
224026683|NCT04912375|BEHAVIORAL|Priming intervention|The pilot RCT will ask participants to complete a simple word-searching exercise as a goal-priming of healthy eating and can be completed in 5 min.
224026684|NCT05093699|DEVICE|Butterfly iQ+ ultrasound probe|Diagnostic ultrasound probe on-market (FDA approved) capable of dual-plane viewing
224026685|NCT05093699|DEVICE|Ultrasound probe|Standard single-view ultrasound probe
224026686|NCT00211185|DRUG|Denileukin diftitox|Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.
224026687|NCT00211185|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
224026688|NCT00211185|DRUG|Doxorubicin|Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
224026689|NCT00211185|DRUG|Vincristine|Vincristine will be administered IV at a dosage of 1.4 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
223409905|NCT05903625|DIETARY_SUPPLEMENT|Lysine and Phosphorus Group - Double Fortified Bread|Double Fortified Bread: Participants consume bread fortified with both lysine and phosphorus in specified dosages, frequencies, and durations.
223409906|NCT00933621|PROCEDURE|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
223409907|NCT01704118|DEVICE|I-gel|Supraglottic airway device
224026690|NCT00211185|DRUG|Prednisone|Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.
223409908|NCT01704118|DEVICE|ProSeal Laryngeal mask|Supraglottic airway device
223409909|NCT00737906|PROCEDURE|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
223409910|NCT03356080|DRUG|Decitabine|Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
223409911|NCT03356080|DRUG|Cytarabine|cytarabine, iv,15mg/m2 q12h, Day1-Day10
224026691|NCT00211185|OTHER|Pegfilgrastim|Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm\^2) for 2 days post-nadir.
224026692|NCT00712673|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
224026693|NCT00712673|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
224026694|NCT00712673|DEVICE|Pen auto-injector|
224026695|NCT00712673|DRUG|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
223409912|NCT03356080|DRUG|All-transretinoic acid|All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
223409913|NCT03356080|DRUG|G-CSF|G-CSF 300ug,sc,Day 0 until CR is achieved
223409914|NCT04717531|DRUG|Pyrotinib|400mg, qd, po, day 1-21
223409915|NCT04717531|DRUG|Trastuzumab|6 mg/kg, day 1
224026696|NCT02729428|DEVICE|MRI|Participants will undergo an MRI scan
224026697|NCT05839496|OTHER|Cervical stabilization exercises|Patients learned the activation of deep cervical flexor and extensor muscles. Then, during the activity of deep cervical muscles, superficial cervical muscles and upper extremity muscles were also strengthened. Thus, it was aimed to strengthen all neck muscles and upper extremity muscles in different positions synchronously and to increase their endurance.
224026698|NCT04581096|OTHER|no intervention|just descriptive analysis of clinical data
224026699|NCT00969527|DIETARY_SUPPLEMENT|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
224026700|NCT00969527|DIETARY_SUPPLEMENT|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
224133879|NCT05071560|OTHER|Combined exercise training|"Before the intervention, these women will undergo an evaluation of cardiorespiratory fitness, functional fitness, psychological status and a physiatry assessment. A consent form is signed before the start.~The physical exercise intervention was planned based on the recommendations of the American College of Sports Medicine for cancer survivors (ACSM 2019), with two supervised combined training sessions (mobility, aerobic training, strength and flexibility training) planned, and one unsupervised aerobic training session per week, interspersed with at least one rest day in between, for 8 weeks. The intensity will be individualized and defined based on the initial assessment. The structure of the training plan was based on the FITT-VP principles (frequency, intensity, time, type, volume and progression) recommended by the ACSM (2019)."
223409916|NCT04717531|DRUG|Pertuzumab|420 mg, day 1
223409917|NCT04717531|DRUG|Docetaxel|100 mg/m2, day 1
223409918|NCT04717531|DRUG|Epirubicin|90mg/m2, day 1
223409919|NCT04717531|DRUG|Cyclophosphamide|600 mg/m2, day 1
223409920|NCT02049892|OTHER|Metal Ion Levels|
223409921|NCT06046781|OTHER|physical exercise|The patients were randomized into 5 groups as control group, walking at 2 weeks, walking at 4 weeks, waist exercise at 2 weeks, waist exercise at 4 weeks.
223409922|NCT00835224|DRUG|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
224133880|NCT02621879|PROCEDURE|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
224133881|NCT05407090|DIETARY_SUPPLEMENT|probiotic supplementation|Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.
224026701|NCT05470439|BEHAVIORAL|My Interprofessional Care team for Adherence and Research Engagement (MI-CARE)|MI-CARE is an innovative, tailored coordinated care intervention by pharmacist-community health worker (CHW) team derived from a previous research and a clinical pilot implementation. MI-CARE will identify and address individual, clinical, social-cultural and structural barriers to medication adherence and hypertension management. MI-CARE consists of an initial individualized needs assessment (Baseline). During Months 1-2, pharmacist-CHW team will deliver a tailored intervention including an individualized medication chart, preferred adherence aids, hypertension therapy optimization, tailored education based on medication beliefs, tools to combat social stressors, and referrals for structural barriers such as food insecurity, transportation and drug costs. Tailored family/care partner participation and telehealth visits will be provided when needed during this time. A booster visit to assess patient progress and reinforce intervention components will occur at Month 2.
224026702|NCT00471159|DRUG|docetaxel|
224026703|NCT00471159|DRUG|PF-3512676|
224026704|NCT01242358|DEVICE|Capnography|Capnographic monitoring
224026705|NCT01242358|DEVICE|Standard monitoring|Standard monitoring
224026706|NCT02274818|BEHAVIORAL|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~* No more than 80 hours of work per week (when averaged over 4 weeks)~* 1 day off in 7 (when averaged over 4 weeks)~* In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
224026707|NCT06483529|DIAGNOSTIC_TEST|compliance measurement|compliance can be measured by analyzing pressure volume curves generated through different methods
224133882|NCT05407090|DIETARY_SUPPLEMENT|placebo|Participants enrolled in the placebo group will receive a placebo instead of probiotics.
224133883|NCT05146583|PROCEDURE|Autologous bone marrow aspirate injected intradiscal after microdiscectomy|Harvested from SI-joint, 2-5ml BMA is injected in the discectomy defect.
224133884|NCT05146583|PROCEDURE|Discectomy only|Transflaval discectomy with or without the use of a microtube (according to surgeons' preference).
224133885|NCT06102642|BIOLOGICAL|Combining free gingival graft with frenotomy procedure|The aim of the study is to evaluate the usage of free gingival graft combined with frenotomy in order to measure the gain in the width of keratinized gingiva, relapse, mucosal healing and postoperative pain.
224133886|NCT01562366|DEVICE|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
224133887|NCT01562366|PROCEDURE|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
224133888|NCT01220986|PROCEDURE|Liver biopsy|0, 30, 60, 90 min post inflow-division
223409923|NCT00835224|DRUG|Midodrine|To treat low blood pressure.
223409924|NCT00835224|DRUG|Placebo|A pill with an inactive substance that looks like the study drug.
223409925|NCT02097238|DRUG|Eribulin Mesylate|Given IV
223409926|NCT02097238|OTHER|Pharmacological Study|Correlative studies
223409927|NCT06334328|BEHAVIORAL|Virtual reality based mindful movement therapy|VR-MMT combines VR games, multisensory and cognitive stimulation, hand-eye and full body coordination, creative processes, expressive movement, mindfulness practice, and social connectedness.
223409928|NCT05628428|OTHER|Exercise to strengthen neck area.|An exercise protocol will be carried out through educational videos. There will be a total of four videos which will pose exercises for two weeks each. These exercises will be done twice a week. A reminder will be sent by email on the days that they must be carried out.
224133889|NCT03150108|DRUG|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
224133890|NCT03150108|DRUG|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
224133891|NCT03150108|DRUG|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
224133892|NCT04222933|DEVICE|Motorized cryotherapy|application of motorized cryotherapy after ACL reconstruction
224133893|NCT04222933|DEVICE|Classical cryotherapy|application of an ice bag
224133894|NCT05923489|DIAGNOSTIC_TEST|Routine Angiography Follow-up|Patients in the RAF group will have routine angiography follow-up at 12 months after revascularization.
224133895|NCT05923489|DIAGNOSTIC_TEST|Routine Clinical Follow-up|Patients in the RCF group will have routine clinical follow-up at 12 months after revascularization, and the physician will decide whether further invasive testing is needed.
224133896|NCT05804006|OTHER|Conventional physiotherapy followed by HIIT-REC program|The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
223409929|NCT05628428|OTHER|Information|Information will be provided on neck pain and how exercise is able to help prevent it.
223409930|NCT03064698|OTHER|Post-partum Doppler ultrasound|Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
223409931|NCT05832853|BEHAVIORAL|Wu Qin Xi exercise|The training schedule for Wu Qin Xi consisted of two phases: the first phase lasted for eight weeks, while the second phase lasted for 16 weeks. In the first phase, Wu Qin Xi group was given twice repetitions of the intervention. The second phase consisted of three repetitions of the Wu Qin Xi group. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
224133897|NCT01341379|DRUG|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
224133898|NCT03293277|DRUG|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
224133899|NCT03293277|DRUG|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
224133900|NCT03293277|DRUG|Intranasal Placebo|Intranasal Placebo
224133901|NCT03293277|DRUG|Intravenous Placebo|Intravenous Placebo
223409932|NCT05832853|BEHAVIORAL|Wu Qin Xi, resistance training and endurance training|During the first 8 weeks, the training consists of learning and consolidating the movements of the Wu Qin Xi. In the second 16 weeks, participants perform a full set of movement exercises. Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and two sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 15 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
224026708|NCT01947985|DRUG|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
224026709|NCT01947985|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
224026710|NCT04136665|OTHER|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
224026711|NCT03603028|DEVICE|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
224026712|NCT03806387|DRUG|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
224026713|NCT04638595|OTHER|Observation|This project seeks to recruit 25 male and 25 female typically developing children between the ages of 3 and 18 years of age. Non-invasive measurements of movement patterns will be collected during common activities of daily living over a single data collection session.
224026714|NCT04151797|OTHER|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~* Data collection on comorbidities, medication and laboratory results.~* A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~* A detailed feedback to the geriatrician.~* A written report addressed to the attending physician"
224026715|NCT00081107|DRUG|epothilone D|
224026716|NCT04819984|DEVICE|TCM5 device (Radiometer) for PtC02 continuous measurement|Evaluation of PtC02 variation as a reflect of PaC02 during 30 minutes of weaning proof for mechanical ventilation (spontaneous ventilation on T-piece)
224026717|NCT02717572|RADIATION|Fludeoxyglucose F 18|
223409933|NCT05832853|BEHAVIORAL|Resistance training and endurance training|Each resistance training session contained two lower-body exercises (seated calf raises and hip abduction) and three upper-body exercises (lateral pull downs, biceps curls, and triceps push downs) and three sets for each exercise. Endurance training is performed by continuous walking on an undisturbed indoor track for 30 min. Participants warmed up for 20 min prior to the intervention and cooled down for 10 min at the end.
224026718|NCT02717572|DEVICE|Positron Emission Tomography|
224026719|NCT02717572|DEVICE|Computerized Tomography|
223409934|NCT01106911|DEVICE|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
224026720|NCT02717572|DEVICE|Magnetic Resonance Imaging|
224026721|NCT05898243|PROCEDURE|Reduction|An Rx will be performed before and after the reduction of the dislocation. After that, the neurovascular state will be checked and also if there is some associated injury.
224026722|NCT01990209|DRUG|Orteronel|
224026723|NCT04398407|BEHAVIORAL|Coaching and Advancement for Peer Providers (CAPP)|The CAPP intervention will combine executive coaching approaches and techniques with the specific needs and environmental demands of individuals working as PSS. A person who has been a PSS and trainer of PSS nationally has developed the CAPP intervention using the expertise of Center staff, the Harvard Institute of Coaching (IOC) and our Peer Advisory Group. Individuals randomized to the experimental condition will receive 16 individual coaching sessions tailored to the specific job stressors they are experiencing. CAPP is designed to address the following issues: role confusion, lack of clarity about job tasks, conflict with other providers, burnout, lack of organizational commitment and job satisfaction.
224026724|NCT01576250|OTHER|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
224026725|NCT00879866|BIOLOGICAL|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
224026726|NCT04395027|DEVICE|atrial septal defect closure|The iatrogenic septal defect will be closed in the usual manner
224133902|NCT06317857|OTHER|Centio Forte|A new Alkasite material has been introduced with superior strength and bioactive ion release where it is considered the new alternative to amalgam.
224133903|NCT01368159|DEVICE|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
224133904|NCT01975935|DRUG|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
223409935|NCT00505960|BEHAVIORAL|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
223738582|NCT05561881|OTHER|popliteal artery and the capsule of the posterior knee (IPACK) block|ultra-sound visualization of the popliteal artery and posterior surface of the distal femur then the image of the femoral condyles and popliteal artery will be obtained. A needle with a tip length of 100 mm will be inserted in a medial to the lateral plane parallel to the femur in the middle area between the popliteal artery and femur,20 ml local anesthetic solution will be given into this space with adequate and equal distribution of anesthetic agent
224026727|NCT03048799|DEVICE|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
224026728|NCT01468831|DRUG|Minocycline|100 mg of minocycline in a pink opaque capsule
224026729|NCT01468831|OTHER|Placebo|Pill with inactive ingredients in a pink opaque capsule
224026730|NCT01468831|DRUG|Bevacizumab|1.25 mg bevacizumab injection
224026731|NCT05540054|OTHER|Inspiratory muscle training|Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
224026732|NCT05540054|OTHER|Standard pulmonary rehabilitation programme|The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
224026733|NCT02764294|OTHER|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
224026734|NCT02764294|OTHER|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
224026735|NCT02764294|OTHER|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
224133905|NCT01975935|DRUG|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
224133906|NCT02082314|PROCEDURE|RFA Vertebroplasty|
224026736|NCT01405586|DRUG|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
224133907|NCT05111496|RADIATION|Gafchromic film|Before the X-ray radiation, a Gafchromic film will be placed on the patient's back at the start of the operation
223409936|NCT05393869|OTHER|Health communications|Participants are assigned to view health communications with risk and efficacy statements.
223409937|NCT05140746|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Baseline 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans before NAC followed by abdomen 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT scans after one cycle of NAC treatment or before surgery.
223558742|NCT01469143|DRUG|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
223558743|NCT01469143|DRUG|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
224026737|NCT01405586|DRUG|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
224026738|NCT01405586|DRUG|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
224026739|NCT01131234|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
224026740|NCT01131234|DRUG|Cediranib Maleate|Given PO
224026741|NCT01131234|OTHER|Pharmacological Study|Correlative studies
224026742|NCT01131234|OTHER|Laboratory Biomarker Analysis|Correlative studies
224026743|NCT02801968|PROCEDURE|Tap block|
224026744|NCT02801968|OTHER|intravenous analgesia|
224026745|NCT04168853|DIAGNOSTIC_TEST|vascular reactivity of internal thoracic arteries|"1. Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~2. Blood sampling and biochemical analysis"
224026746|NCT06044974|DEVICE|Nd-YAG Fotona|four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
224026747|NCT06044974|DRUG|Epidermal Growth Factor|"Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle"
224026748|NCT04537182|PROCEDURE|Lung volume reduction surgery|Lung volume reduction by surgery
224026749|NCT04537182|PROCEDURE|Bronchoscopic lung volume reduction with valves|Lung volume reduction with endobronchial valves.
224026750|NCT00241605|DRUG|rosiglitazone/metformin|
224133908|NCT00307060|DRUG|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
224133909|NCT00307060|DRUG|losartan / Duration of Treatment: 6 weeks|
224133910|NCT02388061|DRUG|Tenecteplase|
224133911|NCT02388061|DRUG|Tissue Plasminogen Activator|
224133912|NCT00102453|DRUG|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
224133913|NCT03698604|PROCEDURE|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
224133914|NCT02358330|OTHER|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
224133915|NCT03599141|BEHAVIORAL|Trust-building Self-management Together|Trust building plus depression self-management
224133916|NCT03599141|BEHAVIORAL|Depression Management|Traditional depression self-management
224133917|NCT05103319|OTHER|Data collection for statistical analysis to identify patterns of treatment response/ non-response|All data are restricted from the patient physical and electronic record of the Pain Management-Unit of the University Hospital Basel. No external data sources will be used. Records will be screened from 2012- May 2021. Variables collected are e.g. demography, medical diagnosis, psychological diagnosis, infusion therapy, medication, pain.
223409938|NCT04641325|OTHER|Exercise Intervention Group|Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 8 weeks all patients will return for re-assessment.
223409939|NCT01814696|DEVICE|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
223409940|NCT03232879|BEHAVIORAL|Motor Imagery|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
223409941|NCT03232879|BEHAVIORAL|Action Observation|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
223409942|NCT03523364|DEVICE|dental restorations|partial or complete ceramic restorations bonded to dental tissues after WAB and total etching or after total etching
224026751|NCT03634020|DEVICE|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
224026752|NCT05103293|DIAGNOSTIC_TEST|patient-derived tumor-like cell clusters drug sensitivity test|Intervention Description：Neoadjuvant therapy regimen of patients in the PTC group is guided by PTC drug sensitivity results. After operation, adjuvant targeted therapy for pCR patients is based on original treatment, adjuvant targeted therapy for non-pCR patients is based on a secondary PTC drug sensitivity results.
224026753|NCT06418828|OTHER|return to work|Ask patients if they are going back to work
224026754|NCT00027495|DIETARY_SUPPLEMENT|curcumin|
224026755|NCT04439682|OTHER|Aerobic exercise|Aerobic exercise will be performed to all participants for a single session. Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor (Polar FT 100, China) will be used to follow subjects' heart rate during aerobic exercise.
224026756|NCT04312321|DEVICE|Mandatory phone call consultation|Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
224026757|NCT04312321|DEVICE|Mandatory audiovisual consultation|Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
224026758|NCT00624143|DRUG|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC \>1000/MM3 or development of fungal infection
224026759|NCT02212210|DRUG|Methylprednisolone|
224026760|NCT02212210|DRUG|Normal saline|
224026761|NCT02934425|OTHER|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
224026762|NCT02934425|OTHER|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
224026763|NCT05491304|DRUG|Dexamethasone|Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
224026764|NCT05491304|DRUG|Etoposide|Used in severe group combined with etoposide.
224026765|NCT05491304|DRUG|Ruxolitinib|Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
224026766|NCT03784560|OTHER|The Psychomotor Vigilance Task (PVT)|PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.
224133918|NCT05670964|DEVICE|Connecting valve system|UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter
223409943|NCT02146196|DEVICE|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
223409944|NCT02146196|DEVICE|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
223409945|NCT02084732|DRUG|Sorafenib|drug
224298023|NCT02757976|DEVICE|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
223409946|NCT02315404|PROCEDURE|CAP|CAP fitted to the end of the endoscope
223409947|NCT01421823|DRUG|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
223409948|NCT01421823|DRUG|Placebo|2 weeks local treatment with placebo ointment
223409949|NCT04920201|OTHER|Over-ground walking without GEMS-H|Over-ground walking without GEMS-H (30 min per session, at least 3 times per weeks, total 10 sessions)
223409950|NCT04920201|DEVICE|Over-ground walking with GEMS-H with resist mode|Over-ground walking with GEMS-H with resist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
223409951|NCT04920201|DEVICE|Stair ascent with GEMS-H with assist mode|Stair ascent with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
223409952|NCT04920201|DEVICE|Incline walking with GEMS-H with assist mode|Incline walking with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
223409953|NCT02995174|DEVICE|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
223409954|NCT02995174|DEVICE|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
223409955|NCT04468568|DRUG|Atosiban|Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.
223409956|NCT04468568|DRUG|Terbutaline|Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.
223409957|NCT06181188|DRUG|Ketamine|Patients will receive a combination of ketamine and midazolam for conscious sedation
223738583|NCT05561881|OTHER|genicular nerves block|ultra-sound transducer placed parallel to the femur shaft and the epicondyle will be identified, the superomedial superolateral and inferomedial genicular arteries, which follow a similar route with each genicular nerve will be visualized close to the periosteal areas, A20G needle with a tip length of 50mm will be directed in the plane of the US probe in the long axis view. After confirming placing of the needle next to each genicular artery a total amount of 20 ml local anesthetic in equal increments at multiple sites.
223738584|NCT02508493|OTHER|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
223738585|NCT02508493|OTHER|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~* Digit Symbol Substitution Test (DSST)~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~* Variant of Choice Reaction Time (CRT)~* Variant of the One-back working memory tool"
223738586|NCT05276492|DRUG|Abiraterone Oral Tablet|Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.
223738587|NCT05276492|DRUG|Prednisone tablet|Prednisone is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
223738588|NCT05276492|OTHER|Drug Dairy/Log|A drug dairy/log that will the study team will give for you to document information about the study drugs and meals you take during the study.
223738589|NCT05276492|DRUG|Low-fat meal|"A low-fat meal that will be taken with abiraterone. If you have questions about what is considered a low-fat meal during the study, ask the study doctor or research staff."
223738590|NCT04830527|BEHAVIORAL|EMA prompting for patients|"EMA prompting will consist of the delivery of the PHQ-4 and PANAS questionnaires, as well as basic identification, therapy motivations and expectations, location, current activity and social interactions.~These prompts will be presented to patients during a 7 day period, 5 times per day."
223409958|NCT06181188|DRUG|Midazolam|Patients will receive 1mg of midazolam regardless of which arm they are in and my be given 1mg doses for added sedation as needed every 3-5 minutes
223409959|NCT06181188|DRUG|Fentanyl|Patients randomized to the midazolam and fentanyl arm will receive 25mcg incremental doses for procedural sedation
223409960|NCT05864079|DIAGNOSTIC_TEST|Platelet count|Platelet count in study groups
223409961|NCT05864079|DIAGNOSTIC_TEST|Developmental endothelial locus-1 (DEL-1)|Serum DEL-1 in study groups
224133919|NCT05670964|DEVICE|Central haemodialysis Venous Catheter|Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
224133920|NCT01165021|DRUG|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
224133921|NCT01165021|DRUG|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
224133922|NCT01165021|DRUG|Folic Acid|Administered orally.
224133923|NCT01165021|DRUG|Vitamin B12|Administered Intramuscular injection.
224133924|NCT01165021|DRUG|Dexamethasone|Administered orally.
224133925|NCT05275153|OTHER|Home based cognitive rehabilitation program|The home based cognitive rehabilitation program intervention was conducted for 30 minutes each time, 3 times a week for 8 weeks, a total of 24 times.
224133926|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG|"EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.~Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.)."
224133927|NCT05913427|DRUG|Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo|EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
224133928|NCT03192982|DEVICE|A-V impulse 6000 Series|foot pad and pump
223409962|NCT05864079|DIAGNOSTIC_TEST|soluble P-selectin (sP-sel)|Serum sP-sel in study groups
223409963|NCT02597439|DRUG|Omega-3 fatty acids|
223558744|NCT01241188|BIOLOGICAL|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
224026767|NCT03784560|OTHER|Epworth Sleepiness Scale|"Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score."
223409964|NCT02597439|OTHER|Placebo|
224026768|NCT03784560|OTHER|Karolinska sleeping scale|"The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (\<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off"
224298024|NCT04078880|DIETARY_SUPPLEMENT|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
224298025|NCT04037930|BEHAVIORAL|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
223409965|NCT04565197|BIOLOGICAL|convalescent plasma|"Transfuse 2 aliquots of plasma (200 mL x 2) per patient.~* Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min)~* Transfuse second aliquot at same rate 2 hours after completion of first aliquot"
223409966|NCT01644799|DRUG|idelalisib|oral
223409967|NCT01644799|DRUG|lenalidomide|oral
223409968|NCT06180096|DRUG|Riociguat film coated tablets|1 tablet of 2.5 mg Riociguat
223409969|NCT06180096|DRUG|Adempas Filmtabletten|1 tablet of 2.5 mg Riociguat
223409970|NCT00954941|DRUG|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
223409971|NCT00954941|DRUG|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
223409972|NCT04709146|DIAGNOSTIC_TEST|Audio-Vestibular evaluation|Diagnostic evulation with audiometry, Tympanography, SVV, VHIT, VNG.
223409973|NCT05524168|RADIATION|SBRT|SBRT for metastatic lesions
223409974|NCT05524168|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.
223409975|NCT05524168|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
223409976|NCT05524168|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
223409977|NCT06574971|DEVICE|Low intensity focused ultrasound using the NeurGear Zenbud|The NeurGear Zenbud is a wearable earbud that delivers low intensity focused ultrasound to the auricular branch of the vagus nerve
223409978|NCT05567653|DIETARY_SUPPLEMENT|Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 (Sanprobi Stress)|3-month, multi-strain probiotic supplementation (one a day, 3 x 10⁹ CFU)
223409979|NCT05567653|DIETARY_SUPPLEMENT|Starch (placebo)|3-month placebo
223409980|NCT03656653|BEHAVIORAL|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
223409981|NCT00001504|DRUG|9-cis-Retinoic Acid|
223409982|NCT03755557|DRUG|Rhinocort|Application of a nasal spray
223409983|NCT03755557|DRUG|Budesolv|Application of a nasal spray
223409984|NCT03755557|OTHER|Placebo|Application of a nasal spray
223409985|NCT05424510|DRUG|Ringer's Lactate|500 ml of Ringer's Lactate
223409986|NCT05424510|OTHER|IV line|Placing of an IV line before surgery
223409987|NCT02158013|OTHER|Levorag Emulgel|
223409988|NCT02158013|DRUG|Diltiazem|
223409989|NCT01564108|DRUG|Ranibizumab|Series of intravitreal injections of Ranibizumab
223409990|NCT03552055|OTHER|Non-interventional Study|no interventions in this study, just specimen collection
223409991|NCT02730403|OTHER|Treatment As Usual|
223409992|NCT06682403|BEHAVIORAL|Received cable lock as default|Participants will receive a cable lock as the default safety device option after filling out the survey. If the participant took a cable lock during their hospital visit and noted this in the survey, they will not be shipped a cable lock. If participants did not take a cable lock and noted this in the survey, they will be shipped a cable lock.
223409993|NCT06682403|BEHAVIORAL|Choice between cable lock or lock box|Participant will have the option to select a lock box or cable lock shipped to their address after filling out the study survey.
223409994|NCT02266797|DRUG|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
223409995|NCT02266797|OTHER|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
223409996|NCT02693145|OTHER|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
223558745|NCT01241188|BIOLOGICAL|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
223558746|NCT01228136|DRUG|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
223558747|NCT01228136|OTHER|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
223558748|NCT05114707|DRUG|camrelizumab|Camrelizumab was administrated with 200mg each time, every three weeks for a total of 11 cycles since the first day of induction chemotherapy.
223558749|NCT01444625|OTHER|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
223558750|NCT01444625|OTHER|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
223558751|NCT04078958|DIETARY_SUPPLEMENT|Salmon fishmeal|Salmon fishmeal with high protein content
223558752|NCT04078958|DIETARY_SUPPLEMENT|Whey|Whey with high protein content
223558753|NCT02924246|BIOLOGICAL|cholera vaccination|Oral cholera vaccination on day 0 and day 14
223558754|NCT02924246|OTHER|raw milk|raw milk
224133929|NCT03192982|DEVICE|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
224133930|NCT01419665|BIOLOGICAL|GP2013|Type: Biological/Vaccine
224133931|NCT01419665|BIOLOGICAL|rituximab|Type: Biological/Vaccine
224133932|NCT06473337|DIAGNOSTIC_TEST|Blood sample|Serum blood sample for Vitamin D testing
224133933|NCT04834882|OTHER|Data collection (|online survey
223558755|NCT02924246|OTHER|pasteurized milk|pasteurized milk
223558756|NCT02924246|OTHER|UHT milk|UHT milk
223558757|NCT02342691|DRUG|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
223558758|NCT02342691|DRUG|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
223558759|NCT02931513|OTHER|Blood samples|
223558760|NCT02931513|DEVICE|Fibroscan|
223558761|NCT02931513|OTHER|Questionnaires|
223558762|NCT02931513|BIOLOGICAL|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
223558763|NCT05872542|DRUG|Silver Diamine Fluoride (SDF)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.
223558764|NCT05872542|OTHER|Glass Ionomer Restoration (GI)|Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.
223558765|NCT05872542|OTHER|Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)|Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
223558766|NCT00733070|DEVICE|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
223558767|NCT00434447|DRUG|Zoledronic acid|
223558768|NCT03179930|DRUG|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
223558769|NCT03179930|DRUG|Pembrolizumab|pembrolizumab 200 mg IV on D1
223558770|NCT01164891|DRUG|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
223558771|NCT05051670|PROCEDURE|da vinc SP gastrectomy|radical subtotal gastrectomy performed by da vinci SP
223558772|NCT00610350|DRUG|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
223558773|NCT00610350|DRUG|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
223738591|NCT04830527|BEHAVIORAL|PDF Reports for therapists|After the patients' EMA data is collected, a previously designed R script will summarize and transform the data into a brief and graphic report for therapists in the experimental arm of the study. These reports are intended to provide detailed information about the patients' mood, anxiety levels, positive and negative affects, as well as crossed data such as mood according to location, anxiety according to activity, etc.
224133934|NCT05169645|OTHER|Physical activity monitoring - Symptom monitoring|"This is an observational study. There is no intervention outside the collection of data from participants. Consenting participants in the study will be provided with a Fitbit activity tracker and asked to wear it for a period of three months.~The Fitbit measures:~* Physical activity using daily step count~* Additional physical activity entries~* Heart rate~* Sleep quality~* Calories burned~* Food log~Participants will be asked to download an app onto their smart phone entitled Athena CX. This app is designed to capture:~* Urticaria symptomatology using the urticaria control test~* Symptoms of depression using 2 items from the PHQ 9~* Symptoms of anxiety using two items from the GAD~* Short form self-compassion scale"
224133935|NCT02583945|PROCEDURE|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
224133936|NCT02934776|DEVICE|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
224133937|NCT02302794|PROCEDURE|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
223558774|NCT02214888|DRUG|BIRB 796 BS, low dose|
223558775|NCT02214888|DRUG|BIRB 796 BS, high dose|
223558776|NCT02214888|DRUG|Placebo|
224133938|NCT02302794|PROCEDURE|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
223409997|NCT00694473|DEVICE|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
223409998|NCT06138262|OTHER|Health promotion of education pre-conception nutritional preparation|Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
223409999|NCT01391858|DRUG|lyrica|150mg of pregabalin/placebo
223410000|NCT03004638|DRUG|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
223410001|NCT03004638|DRUG|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
223410002|NCT03004638|DRUG|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
223410003|NCT03004638|DRUG|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
223410004|NCT03004638|DRUG|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
223410005|NCT03004638|DRUG|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
223410006|NCT04435418|DRUG|Apixaban|The decision to treat with apixaban and the timing of initiation will be at the attending physicians' discretion, independent of enrolment in EASSE.
223410007|NCT02162537|DRUG|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
223558777|NCT05947175|BIOLOGICAL|Vertebral bone marrow (vBMA) clot|The clotted vBMA will be obtained from vertebral bone marrow aspirate.The vBMA clot contain mesenchymal stem cells (MSCs), growth factors, platelet and osteogenic and anti-inflammatory mediators.
223558778|NCT05947175|OTHER|Bone allograft chips|Bone allograft chips will be obtained from Musculoskeletal Tissue Bank at IRCCS Istituto Ortopedico Rizzoli.
224026769|NCT03784560|OTHER|Trail making test|Most variants of this test, which was apparently introduced in 1938 by Partington (Partington \& Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
224026770|NCT04869943|DRUG|Enobosarm|Oral Enobosarm 9mg per day
224026771|NCT04869943|DRUG|Exemestane|Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
224026772|NCT02838693|PROCEDURE|Not applicable. This is an observational study.|Not applicable. This is an observational study.
224026773|NCT01768117|BIOLOGICAL|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
224026774|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses with Molded Mark|
224026775|NCT02939170|DEVICE|Delefilcon A Multifocal Contact Lenses|
224026776|NCT06127056|DEVICE|High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
224133939|NCT00093080|DRUG|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
224133940|NCT05320458|OTHER|Pulmonary Rehabilitation|1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
223410008|NCT02162537|DRUG|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
223410009|NCT02162537|DRUG|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
223410010|NCT02162537|RADIATION|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
223410011|NCT05653479|DRUG|UPB-101|UPB-101 Subcutaneous injection
223410012|NCT00663416|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
223410013|NCT00663416|DRUG|Saline placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
223558779|NCT02765113|PROCEDURE|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
223558780|NCT02765113|PROCEDURE|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
224133941|NCT01229488|DEVICE|Intervention|Project was withdrawn before starting. There were no interventions
224133942|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic, Polyphenol-rich Extracts|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract~Once a day"
223558781|NCT00073736|DRUG|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
223558782|NCT00073736|DRUG|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
223558783|NCT00073736|DRUG|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
223558784|NCT00073736|DRUG|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
223558785|NCT00073736|DRUG|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
223558786|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
223558787|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
223410014|NCT02327871|DEVICE|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
223410015|NCT01901458|DEVICE|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
223410016|NCT01901458|DEVICE|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
223410017|NCT05317039|OTHER|silica-calcium phosphate nanocomposite SCPC|Patients will be treated with the buccal plate repositioning technique and grafted with SCPC then the grafted defect will be covered with a platelet-rich fibrin membrane.
224026777|NCT06127056|DEVICE|sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)|In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.
223410018|NCT05317039|OTHER|freezed dried bone|Patients will be treated with the buccal plate repositioning technique and grafted using DFDBA. then the grafted defect will be covered with a platelet-rich fibrin membrane.
223410019|NCT04634344|DRUG|DZD2269|A single dose of DZD2269 starting at 5 mg will be given on Cycle 0 and then followed by a wash-out period. Multiple doses of DZD2269 at the same dose level will be given once daily after the wash-out period.
223410020|NCT03432637|PROCEDURE|spontaneous ventilation|thoracoscopic lobectomy under spontaneous ventilation
223410021|NCT03432637|PROCEDURE|intubated anesthesia with single-lung mechanical ventilation|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
223410022|NCT00984542|DRUG|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
223410023|NCT01088763|DRUG|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
224026778|NCT05612165|DEVICE|Transcranial Direct Current Stimulation(tDCS)|The tDCS intervention was conducted for 20 minutes(2000μA) each time, 5 times a week for 2 weeks, a total of 10 times.
224026779|NCT05612165|DEVICE|Sham Transcranial Direct Current Stimulation(sham tDCS)|The sham tDCS intervention was conducted for 20 minutes(0μA) each time, 5 times a week for 2 weeks, a total of 10 times.
224026780|NCT00539890|DRUG|Technosphere Insulin|
224026781|NCT05337852|OTHER|Emotional Freedom Technique|"To the pregnant women in the experimental group; Emotional freedom technique was applied online with the researcher twice a week. The release protocol of EFT was taught to the participants and it was applied between the interviews made by the researcher. Whether the participant did the application or not was confirmed by phone and a homework schedule was used for smooth follow-up.~* PUQE, PRAQ-2 tests will be applied before the intervention,~* SUE and PUQE will be applied before and after each session,~* After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2."
224026782|NCT02681133|OTHER|Epidemiological study Survey|
224026783|NCT03842254|DRUG|Erythropoietin|Subcutaneous injection of erythropoietin 10,000 units
224026784|NCT01580969|DRUG|Bevacizumab|Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.
223410024|NCT01088763|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223410025|NCT01088763|OTHER|pharmacological study|Correlative studies
223410026|NCT01088763|DRUG|dexamethasone|Given IV
223410027|NCT01156181|PROCEDURE|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
224026785|NCT01580969|DRUG|Minocycline|Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
224026786|NCT01580969|RADIATION|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
224133943|NCT05990764|DIETARY_SUPPLEMENT|Probiotic, Prebiotic|"probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum)~Once a day"
224133944|NCT05990764|OTHER|Placebo|"placebo~Once a day"
224133945|NCT01982604|DRUG|TI-Inhalation Powder A|Inhaled Insulin
224133946|NCT01982604|DRUG|TI-Inhalation Powder B|Inhaled Insulin
224133947|NCT06006858|BIOLOGICAL|Moderna COVID-19 Vaccine|Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.
223410028|NCT01156181|PROCEDURE|control|Embryo transfer without any intervention
223410029|NCT05881564|OTHER|blood use for priming cardiopulmonary bypass circuit|one arm will have the cardiopulmonary bypass circuit primed with blood
223410030|NCT05881564|OTHER|clear prime for cardiopulmonary bypass|this arm will not have bypass circuit primed with blood
223410031|NCT00116974|PROCEDURE|Scaling and root planing|Scaling and root planing
223410032|NCT04132323|PROCEDURE|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
223410033|NCT05898828|DRUG|Nivolumab|Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.
223410034|NCT05898828|DRUG|Entinostat|Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.
223410035|NCT05898828|BIOLOGICAL|Montanide(R) ISA-51 VG Adjuvant|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
224026787|NCT03523429|DRUG|blinatumomab|Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
224026788|NCT01538927|DRUG|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
224026789|NCT01538927|DRUG|Suture|Black silk 000
224026790|NCT04432246|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
224133948|NCT01540916|OTHER|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
223558788|NCT00387569|BIOLOGICAL|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
223558789|NCT02881931|BEHAVIORAL|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
223558790|NCT03915574|DEVICE|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
223558791|NCT03915574|DEVICE|Standard Epidural|Control group - standard epidural (no dural puncture)
223558792|NCT01749124|DEVICE|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
223558793|NCT05722938|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days
223558794|NCT05722938|DRUG|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days
223558795|NCT05549297|DRUG|Tebentafusp|Soluble gp100-specific T cell receptor with anti-CD3 scFV
223558796|NCT05549297|DRUG|Tebentafusp with Pembrolizumab|Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab
224026791|NCT01248091|PROCEDURE|Nitroprusside Gel|10 cc nitroprusside gel
224026792|NCT01248091|PROCEDURE|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
224026793|NCT01014260|DRUG|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
224026794|NCT01014260|DRUG|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
224026795|NCT02803892|DRUG|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
224026796|NCT02803892|DRUG|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
224133949|NCT01540916|OTHER|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
224133950|NCT03502252|BEHAVIORAL|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
223558797|NCT05549297|DRUG|Investigators Choice|Investigators choice of therapy
223558798|NCT02502292|BEHAVIORAL|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
223558799|NCT04332536|OTHER|Exercise with and without Codeine|This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
223558800|NCT06643377|DRUG|Enlicitide|Oral tablet
224026797|NCT02803892|DRUG|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
224026798|NCT02803892|DRUG|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
224026799|NCT04076748|DRUG|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
224026800|NCT04076748|DRUG|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
224139004|NCT03111264|BEHAVIORAL|CHAMP|"The CHAMP only group intervention is based on Food Friends \& Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
223410036|NCT05898828|BIOLOGICAL|H1299 Cell Lysates|H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
224133951|NCT02410707|DRUG|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
223410037|NCT01422889|DEVICE|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
223410038|NCT01672554|DRUG|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
223410039|NCT02119403|OTHER|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
223410040|NCT06266195|DIAGNOSTIC_TEST|sierological test|sierological test: circulant vescicles
223410041|NCT01049256|OTHER|carbon dioxide|sinusoidal carbon dioxide administration
223410042|NCT03039764|DEVICE|Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
223410043|NCT05643742|BIOLOGICAL|CTX112|CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
223410044|NCT05099497|OTHER|Using Practice Facilitators to Support Physicians|Utilize practice facilitators to empower family physicians to contact those who remain unvaccinated have better access to the COVID-19 vaccine.
223410045|NCT02293512|BEHAVIORAL|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
223410046|NCT02293512|BEHAVIORAL|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
223410047|NCT02293512|BEHAVIORAL|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
223410048|NCT04245748|DRUG|Escitalopram|Escitalopram, a SSRI, commercially known as LexaproTM, is commonly prescribed for anxiety disorders and is FDA-approved for acute and maintenance treatment of MDD and GAD.
224133952|NCT02410707|DRUG|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
223410049|NCT04245748|DRUG|Duloxetine|Duloxetine, a SNRI, commercially known as CymbaltaTM, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.
223410050|NCT04950348|DEVICE|Personalized TKA prosthesis|TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy
223410051|NCT04950348|DEVICE|Zimmer NexGen prostheses|Commercial products used on a large scale
223410052|NCT05333302|BIOLOGICAL|CD19 CAR-T-cells|One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.
223410053|NCT05333302|DRUG|Tocilizumab|Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
223410054|NCT00488644|DRUG|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
223410055|NCT00488644|DRUG|Liothyronine|15 mcg PO Daily for 8 Weeks
223410056|NCT03221816|DRUG|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
224133953|NCT02410707|DRUG|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
224133954|NCT01160952|DRUG|itraconazole|the two groups are defined by different treatment duration
224133955|NCT04926194|BIOLOGICAL|Decidual stromal cells (DSC)|DSCs are isolated from donated human placenta and have been shown to have anti-inflammatory effects.
224133956|NCT03798912|COMBINATION_PRODUCT|RaniPill capsule containing octreotide|Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
223410057|NCT03221816|DRUG|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
223410058|NCT05356520|PROCEDURE|Endoscopy Ivor-lewis|Endoscopy Ivor-lewis
223410059|NCT05356520|PROCEDURE|Laparoscopic transabdominal enlarged gastrectomy|Laparoscopic transabdominal enlarged gastrectomy
224133957|NCT01260766|DEVICE|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
224133958|NCT01260766|DEVICE|Placebo Patch|same as active patch
224133959|NCT06266273|OTHER|No intervention|No intervention
223410060|NCT05349656|PROCEDURE|TQL block|Ultrasonography-guided quadratus lumborum block (QLB) where we will infiltrate local anesthetic solution adjacent to the anterolateral aspect of the quadratus lumborum muscle
223410061|NCT05349656|PROCEDURE|PENG block|Ultrasound-guided local anesthetic infiltration will be injected in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly
223410062|NCT02977572|DEVICE|Non-Invasive Ventilation|In arm description
223410063|NCT02977572|DEVICE|Continuous Positive AirwayPressure CPAP|In arm description
223410064|NCT06142994|DIETARY_SUPPLEMENT|Atusin CAP|This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.
223410065|NCT06142994|DIETARY_SUPPLEMENT|Placebo|The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
223410066|NCT04750265|DEVICE|Robotic assisted early mobilization|Robotic assisted early mobilization Robotic assisted early mobilization started within 72 hours of ICU admission.
223410067|NCT03957473|DEVICE|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
223410068|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily
223410069|NCT01197534|DRUG|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
223410070|NCT01197534|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
224026801|NCT05125263|OTHER|kinesiotaping group|"Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
224133960|NCT00626912|PROCEDURE|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
224133961|NCT03185455|OTHER|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
224133962|NCT02088684|DRUG|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
224133963|NCT02088684|DRUG|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
224133964|NCT02088684|DRUG|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
224133965|NCT02088684|DRUG|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
224139005|NCT03111264|BEHAVIORAL|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
224139006|NCT02379390|DRUG|Cabazitaxel XRP6258|
223410071|NCT01741987|OTHER|Optive ®|instilation of 1 drop each eye 4 times per day
223410072|NCT01741987|OTHER|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
223410073|NCT05630287|DRUG|[14C]-Selpercatinib|Administered as an oral solution
223410074|NCT05630287|DRUG|Selpercatinib|Administered orally
223410075|NCT05630287|DRUG|[14C]-Selpercatinib|Administered intravenously
223410076|NCT02783495|BEHAVIORAL|Device: iPad|All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
223558801|NCT03674073|BIOLOGICAL|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
223558802|NCT03674073|PROCEDURE|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
223558803|NCT04293926|OTHER|Exercise|Resistance exercise program for 8 weeks, 3 times a week, with a 60 min session duration.
223558804|NCT04548934|DEVICE|Personal protective equipment (PPE)|Wearing of PPE (FFP3 mask, gloves, eye protection, long-sleeved gown)
223558805|NCT04548934|DEVICE|No Personal protective equipment (PPE)|Standard CPR without wearing PPE
224139007|NCT02379390|DRUG|Ezalutamide|
224139008|NCT02379390|DRUG|Abiraterone acetate|
224139009|NCT02379390|DRUG|Prednisone|
223410077|NCT01322243|OTHER|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
223410078|NCT03919552|DRUG|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
223410079|NCT03919552|DRUG|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
223410080|NCT03919552|RADIATION|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
223410081|NCT03919552|RADIATION|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
224026802|NCT05125263|OTHER|mulligan taping group|"Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)"
224026803|NCT00815685|DRUG|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
223410082|NCT03490552|PROCEDURE|mechanical thrombectomy|Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.
223410083|NCT05696990|OTHER|3/7 Resistance Training Method|3/7 Resistance Training Method
224026804|NCT03143816|DRUG|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
224026805|NCT02656160|DRUG|Placebo|Placebo 3 hrs before sleep
224026806|NCT02656160|DRUG|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
224026807|NCT02778711|DRUG|secukinumab|anti-IL-17
224026808|NCT00473135|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU
224026809|NCT00473135|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
224026810|NCT01508715|OTHER|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
224026811|NCT04320797|DIAGNOSTIC_TEST|Flow cytometry analysis of urine samples|"Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326"
224026812|NCT02076178|DRUG|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
224026813|NCT02076178|DRUG|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
224026814|NCT02076178|DRUG|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
224026815|NCT02076178|DRUG|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
224026816|NCT02400294|OTHER|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
224026817|NCT04112121|BEHAVIORAL|Meeting with a Chaplain coupled with Biblical Readings|
224026818|NCT06065969|RADIATION|Photobiomodulation|660 nm and 100 mW, directing the light beam towards the radial artery region, for 10 minutes per session.
224026819|NCT04300686|BIOLOGICAL|Tocilizumab|"The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead."
224026820|NCT04300686|BIOLOGICAL|Adalimumab|"The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint).~After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead."
223410084|NCT05696990|OTHER|3X9 Resistance Training Method|3X9 Resistance Training Method
223410085|NCT04439877|BEHAVIORAL|Peri-implant disease diagnosis|Diagnosis of peri-implant disease
223410086|NCT03622060|DRUG|Nitroglycerin|200 microgram intraarterial nicardipine and 500 microgram nitroglycerin administered before sheath removal
223410087|NCT03527589|DEVICE|Prostate artery embolization|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
223558806|NCT04122911|DRUG|Temozolomide|pharmacological
223410088|NCT02683928|BIOLOGICAL|GBR 830|
223410089|NCT02683928|BIOLOGICAL|Placebo|
223410090|NCT03686059|DRUG|Omega 3|daily intake of 250 mg
223410091|NCT03686059|DEVICE|punctal plug|punctal plug will be inserted in inferior punctum
223558807|NCT00439543|DRUG|Iloprost inhalation|
223558808|NCT03663504|OTHER|No Preparation|No preparation before surgery
223558809|NCT03663504|DRUG|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
223410092|NCT00723502|DRUG|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
223410093|NCT00723502|DRUG|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
223410094|NCT02824055|DRUG|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
224026821|NCT02700763|OTHER|[18F]dabrafenib molecular imaging|A \[18F\]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
223410095|NCT02824055|DRUG|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
223410096|NCT03723850|DEVICE|Active tDCS|The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
223410097|NCT03723850|DEVICE|Sham tDCS|The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
223410098|NCT01749475|DRUG|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
223410099|NCT01749475|OTHER|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
223410100|NCT02146937|DRUG|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
224026822|NCT02805608|DRUG|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
224026823|NCT02805608|DRUG|Injection of 18F-FDG|One injection intravenously of 18F-FDG
223410101|NCT03393325|OTHER|Observation of treatment with Tadalafil-Delivra|Tadalafil 2% in a Delivra base (Transdermal Application)
223410102|NCT01014169|BEHAVIORAL|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
224026824|NCT02805608|DEVICE|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
224026825|NCT02805608|DEVICE|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
224026826|NCT05751772|OTHER|Patient therapeutic education|"The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes:~1. Targeted education on patient needs related to heart failure, heart failure medications and self-care;~2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan;~3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care)."
224026827|NCT05760391|RADIATION|Radiotherapy|IMRT or SABR for patients with ESCC.
224026828|NCT02011087|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
224026829|NCT05031663|DIETARY_SUPPLEMENT|Almond group|Participants in the Almond group will receive 15% of their daily energy intake in the form of almonds as a snack
224026830|NCT05031663|DIETARY_SUPPLEMENT|Control Group|Participants in the control group will receive an isocaloric carbohydrate based commercial snack (pretzel)
224026831|NCT00125502|BIOLOGICAL|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
223410103|NCT00033722|DIETARY_SUPPLEMENT|folic acid|
223410104|NCT00033722|DRUG|lometrexol|
223410105|NCT04063553|OTHER|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
223410106|NCT04063553|OTHER|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
223410107|NCT05827133|OTHER|No intervention|No intervention
223410108|NCT02596555|DRUG|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
223410109|NCT00357799|DEVICE|VeinViewer|Using the VeinViewer, IV attempts will be made
223410110|NCT04722705|DEVICE|fractional Er:YAG laser|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed 2,940 nm Er:YAG fractional laser. (long pulse mode, 1500mJ, 2Hz, 2 pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
223410111|NCT04722705|DEVICE|Intense pulse light|"At baseline, three lesions were randomized. Topical anesthetic cream was applied to the scar 30 minutes before laser treatment.~The same dermatologist performed IPL. (irridation energy: 12.5J/cm2, pulse duration: 10ms, 1pass) The face was cooled after treatment with gauze soaked in ice water. The laser treatment was conducted total three sessions, immediately at suture removal, 4 weeks after suture removal and 8 weeks after suture removal. The evaluation of scar site was conducted 3 months later after last treatment."
224026832|NCT00125502|DRUG|MF59 adjuvant|Oil-in-water emulsion
224026833|NCT00125502|DRUG|Placebo|Normal saline solution
224026834|NCT04467528|DEVICE|Electroacupuncture|"Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days"
224026835|NCT04467528|DRUG|Conventional drug therapy|"Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial"
224026836|NCT05887817|DRUG|Finerenone|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
224026837|NCT05887817|DRUG|Placebo|Study participants will be instructed to take either finerenone or placebo orally once daily (preferably at approximately the same time every during the morning). For study participants with baseline eGFR less than 60mL/min/1.73 m2, the starting dose will be 10mg/day of finerenone (equivalent to 10mg/day in the placebo group), followed by 20 mg/day (equivalent to 20mg/day in the placebo group) approximately 4 weeks after the first dose, in accordance with the latest package insert. The dose should be increased to 20mg/day (equivalent to 20mg/day in the placebo group) in principle after 4 weeks from the start of the first dose, in accordance with the latest package insert. Study participants with a baseline eGFR of 60 mL/min/1.73m2 or higher will receive 20mg/day of finerenone (equivalent to 20mg/day in the placebo group) as the starting dose.
224026838|NCT06150898|PROCEDURE|Prospective data and sample collection|Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire
224026839|NCT06150898|DRUG|Ketorolac 10 Mg Oral Tablet|Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery
224026840|NCT06150898|DRUG|Pregabalin 75mg|Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery
224026841|NCT06150898|DRUG|Omeprazole 20mg Capsule|Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery
224026842|NCT01045408|DIETARY_SUPPLEMENT|Berry extract|Berry extract for weeks
224026843|NCT04598568|DEVICE|balanSys UNI|Implantation of a balanSys UNI knee prosthesis implanted with a spacer block surgical technique
224026844|NCT05125484|OTHER|experimental Bowen Technique|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
224026845|NCT05125484|OTHER|Experimental Myofacial release technique|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
224026846|NCT00710021|DRUG|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
224026847|NCT00710021|DRUG|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
224026848|NCT05988359|PROCEDURE|Caries treatment with a dental turbine|G1 (n=30) conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
224133966|NCT04752579|OTHER|Pilates exercise program|"The program will be individually supervised and will be conducted twice a week at the physiotherapy center.~• Slow execution of 7-10 repetitions of the following Pilates exercises: Pelvic Curl, Pilates Single Legs Lifts \& Leg Change, Twist Supine Pilates exercise, Chest Lifts Pilates Exercise, Chest Lift with Rotation Pilates exercise, 100's Prep Pilates Exercise, Single Leg Stretch Pilates Exercise, Front Support Pilates Exercise and Basic Back Extension Pilates Exercise. After the 6th week, while the person will be familiar with the basic exercises of the Pilates method the following exercises will be added: Leg Pull Front, Side Bend Pilates Exercise, Sphinx - Abdominal Lift Pilates Exercise, Shoulder Bridge Prep Pilates and Shoulder Bridge Pilates Exercise. Each session will be completed with breathing exercises and stretching exercises of the torso and lower limbs for 5 minutes."
224133967|NCT02473159|DRUG|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
223410112|NCT02593097|DRUG|Metformin|Metformin 500mg twice daily
223410113|NCT02593097|DRUG|Matching Placebo|Matching Placebo twice daily
223410114|NCT05316961|DEVICE|Active PEMF|PEMF 1.5mT, 10Hz, 10 minutes
223410115|NCT05316961|DEVICE|Sham PEMF|PEMF 0mT, 0Hz, 10 minutes
223410116|NCT05316961|OTHER|Eccentric exercise|Eccentric exercise, 10 repetitions, 3 sets
223410117|NCT01413126|DIETARY_SUPPLEMENT|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
223410118|NCT04195204|DRUG|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia and once daily for 7 days after surgery.
223410119|NCT04195204|DRUG|Placebos|Investigators administrated intravenously saline solution as a placebo
223410120|NCT02295969|DRUG|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
223410121|NCT05433532|DRUG|Azacitidine|Azacitidine: 75mg/m2 qd, d1-d7, subcutaneous injection
224026849|NCT05988359|PROCEDURE|Caries treatment with Er:YAG laser|G2 (test, n=30) group, a conventional high-volume evacuator (Monoart® Euronda, Vicenza, Italy) was used to remove aerosols during caries treatment.
223410122|NCT05433532|DRUG|Venetoclax|Venetoclax: 100mg d1, 200mg d2, 300mg d3, 400mg d4-d14 or 21, oral (Adjusted according to the peripheral blood BCR/ABL1 results on day 14)
223410123|NCT05433532|DRUG|Flumatinib|Flumatinib: 600mg qd, d4-d21, oral
223410124|NCT03702335|BEHAVIORAL|Dietary Counselling|Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
223410125|NCT06369454|DRUG|Ritlecitinib|Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg) with 153Sm2O3
223558810|NCT03273452|DRUG|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
223558811|NCT01723293|BEHAVIORAL|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
223558812|NCT03542656|DRUG|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
224026850|NCT05277220|DEVICE|Thermal Camera Thermo Malin TC|"Thermo Malin TC thermal camera (also called HIKVISION TP 31B portable thermal camera). Manufacturer of the researched product is HIKVISION.~This thermal camera is equipped with a thermal detector with a resolution of 160 x 120 elements or an infrared resolution of 19,200 pixels.~Thermal sensitivity of the Thermo Malin TC thermal imager is 40 milliKelvin (0.04 °C), with a spatial resolution of 5.48 mrad and a field of view of 37.2 x 50 °. Temperature accuracy at one point varies by +/- 0.5 °C. This thermal imager has four color palettes to highlight the desired elements.~This camera is specially designed for measuring body temperature in a temperature range from +30 to + 45 °C.~As part of the research, the thermal camera will enable the acquisition and recording of thermographic images at three times of study. These images are then transferred to the operating software for the Thermo Malin Series to process, analyze and make changes to elements of thermographic images."
224026851|NCT03581825|DEVICE|senofilcon A Multifocal|JJVC Investigational Multifocal Contact Lens
224026852|NCT03581825|DEVICE|senofilcon A Sphere|ACUVUE OASYS 2-WEEK with HYDRACLEAR PLUS
224133968|NCT05602259|DIAGNOSTIC_TEST|induced sputum|After premedication with 400 μg inhaled salbutamol, sputum will be induced by inhalation of hypertonic (NaCl 3%) or isotonic (NaCl 0.9%) saline combined according to the FEV-1 value (\> or ≤ than 65% predicted). Saline will be combined with additional salbutamol delivered by an ultrasonic nebulizer (Ultra-Neb 2000; Devilbiss, Somerset, PA, USA) with an output set at 0.9 ml/min. Each subject will inhale the aerosol for three consecutive periods of 5 min for a total of 15 min. For safety reasons, FEV-1 will be monitored throughout the induction and will be stopped if FEV-1 would fall by more than 20% from baseline.
223410126|NCT03074058|DRUG|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID
224026853|NCT03581825|DEVICE|etafilcon A Multifocal|1-Day Acuvue Moist Brand Multifocal Contact Lens
224026854|NCT03581825|DEVICE|etafilcon A Sphere|1-Day Acuvue Moist Brand Contact Lens
224026855|NCT02508246|DRUG|Cisplatin|Given IV
224026856|NCT02508246|DRUG|Docetaxel|Given IV
224026857|NCT02508246|OTHER|Laboratory Biomarker Analysis|Correlative studies
224026858|NCT02508246|OTHER|Pharmacological Study|Correlative studies
224026859|NCT02508246|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224026860|NCT02508246|DRUG|WEE1 Inhibitor AZD1775|Given PO
224026861|NCT04465747|OTHER|Publications|Reviewing published evidence
224026862|NCT01124032|DRUG|methylphenidate|a capsule containing 20 mg
223410127|NCT03074058|DRUG|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
223410128|NCT06610097|OTHER|Nutritional Counseling|The nutritional intervention for the treatment group -- personalized counseling on increasing fiber intake and maintaining adequate caloric intake during treatment -- will be administered as (1) a 60-minute initial telehealth consultation within the first week of study enrollment, and (2) up to two 30-minute follow-ups throughout the study, ideally the first follow-up within 6 weeks of study enrollment. These sessions will be led by a registered dietitian using cultural awareness and symptom assessment.
223410129|NCT02671838|BEHAVIORAL|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
223410130|NCT06286683|DEVICE|lung ultrasound|Used to diagnose and monitor pulmonary aeration in the context of prolonged decubitus disorders (atelectasis) via the lung ultrasound score (LUS).
223410131|NCT06286683|DEVICE|Transcranial Doppler|Non-invasive, bedside method of measuring cerebral blood flow.
223410132|NCT06286683|DEVICE|near-infrared spectroscopy (NIRS)|Non-invasive, bedside method of cerebral oximetry that requires no advanced expertise.
223410133|NCT06286683|DEVICE|clinical examination|clinical examination
223558813|NCT00606034|DRUG|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
223558814|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
223558815|NCT00946608|DRUG|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
224026863|NCT03444350|DEVICE|Gaseous ozone|SRP plus gaseous ozone
224026864|NCT03444350|DEVICE|SRP plus placebo|only SRP
224026865|NCT00515632|DRUG|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
224026866|NCT02633579|DRUG|erythromycin lactobionate|intravenous administration of erythromycin
224026867|NCT02633579|DRUG|Atropine|intravenous administration of atropine
224026868|NCT02633579|DRUG|Erythromycin with atropine|intravenous administration of erythromycin with saline
224026869|NCT02633579|DRUG|Saline|intravenous administration of saline
224026870|NCT03812393|DRUG|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
223410134|NCT00816998|PROCEDURE|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
223558816|NCT00946608|DRUG|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
224026871|NCT03366623|BEHAVIORAL|Hospital clown|Presence of the hospital clown
224133969|NCT05602259|DIAGNOSTIC_TEST|lung biopsy|As per standard practice, biopsies will be taken from the primary tumour site or from a metastatic site.
224133970|NCT05602259|DIAGNOSTIC_TEST|bronchoalveolar lavage|When available, the remaining material from a patient's bronchoalveolar lavage will be collected.
224133971|NCT05602259|DIAGNOSTIC_TEST|blood draw|As per standard practice, blood will be drawn from patients before and during treatment. Data on white blood cells will be collected.
224133972|NCT05250271|OTHER|15 g dextrose|15 g dextrose tablets
224026872|NCT03366623|BEHAVIORAL|No hospital clown intervention|Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
224026873|NCT00832234|DRUG|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
224026874|NCT00511901|DRUG|placebo|
224026875|NCT00511901|DRUG|epoetin alpha|
223410135|NCT00816998|PROCEDURE|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
223410136|NCT02522884|DEVICE|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
223558817|NCT04027803|BIOLOGICAL|BCD-148|single intravenous infusion of BCD-148 (900 mg)
224026876|NCT00511901|DRUG|Niferex|
224026877|NCT00003890|DRUG|MG 98|
224026878|NCT02447172|DRUG|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
224026879|NCT02447172|OTHER|Placebo|Matching placebo sponge
224133973|NCT05250271|OTHER|5 g dextrose|5 g dextrose tablets
224133974|NCT05250271|OTHER|Protein bar|5 g carbohydrates + 10 g protein
224133975|NCT00952237|DRUG|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
223558818|NCT04027803|BIOLOGICAL|Soliris|single intravenous infusion of Soliris (900 mg)
223558819|NCT03116802|DRUG|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
223558820|NCT02227082|RADIATION|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
224026880|NCT04705207|PROCEDURE|reflexology massage|the patient receive only foot reflexology massage
224133976|NCT00952237|DRUG|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
224133977|NCT01778088|DRUG|I-131-CLR1404 Injection|
224133978|NCT06156111|DEVICE|Transepithelial abutment group|Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm
223410137|NCT05063279|OTHER|Progressive resistance training|Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
223410138|NCT05657561|OTHER|early mobilization|Mobilization training was given to the intervention group.
223410139|NCT03970005|BEHAVIORAL|Step-Based Care Model|Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
223558821|NCT02227082|DRUG|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
223558822|NCT06267937|PROCEDURE|Access to surgery|access to surgery after hip fracture
223558823|NCT06267937|OTHER|type of intitution|public or private health care facility
224026881|NCT04705207|PROCEDURE|sham massage|the patient receive only foot traditional massage
224026882|NCT06203015|DIAGNOSTIC_TEST|The Cambridge Neuropsychological Test Automated Battery.|to determine cognitive dysfunction
224026883|NCT06203015|DIAGNOSTIC_TEST|Venous blood samples|to measure levels of cytokines, endotoxin, and genetic markers.
224026884|NCT06203015|DIAGNOSTIC_TEST|brain MRI|to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations
224026885|NCT06203015|DIAGNOSTIC_TEST|the Montgomery-Åsberg Depression Rating Scale|to measure severity of depressive symptoms
224026886|NCT06203015|OTHER|questionnaire prepared by the researchers|collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
224026887|NCT01165931|DRUG|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
224026888|NCT05471830|DRUG|Apixaban|No drug will be provided to participants. Patients follow routine clinical practice/administration.
224026889|NCT00032526|DRUG|Corticosteroids|
224026890|NCT00032526|BEHAVIORAL|Classical conditioning to corticosteroid|
224026891|NCT00485498|DRUG|Olanzapine Hydrochloride|
224026892|NCT00485498|DRUG|Risperidone|
224026893|NCT01864954|BEHAVIORAL|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
224026894|NCT00541398|BEHAVIORAL|Implementation of guideline|Outreach visits with interactive education for health staff
224026895|NCT00300521|GENETIC|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
224026896|NCT03006731|BEHAVIORAL|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
224026897|NCT03006731|BEHAVIORAL|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
224026898|NCT02757027|DRUG|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
224026899|NCT02757027|DRUG|Intravenous HES|HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
224133979|NCT06156111|DEVICE|Direct to implant group|It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
224133980|NCT00123851|DRUG|Tarceva (OSI-774)|
223410140|NCT01521520|DRUG|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
224026900|NCT06060015|DRUG|5mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 5mg
224026901|NCT06060015|DRUG|10mg bupivacaine|Anesthetic technique, the patient receives subarachnoid hyperbaric bupivacaine at a dose of 10 mg
224026902|NCT03991702|DIAGNOSTIC_TEST|diagnostic test|The overall motor function of the patient will be assessed using the Medical Research Council (MRC) scale and Palmar dynamometer strength
224026903|NCT05420285|DRUG|Dapagliflozin|Dapagliflozin (Forxiga) is a very potent selective and reversible inhibitor of SGLT2.
224026904|NCT04308161|DRUG|vitamin D oral gel|vitamin D is a fat soluble vitamin which has important calcemic roles in the body regarding bone homeostasis and calcium/phosphorus balance. Recently, the non-calcemic roles of vitamin D as anti-inflammatory, anti-oxidant and immuno-regulatory functions have been widely reported.So, we tried to use it for prevention of radiation induced oral mucositis
224026905|NCT04308161|DRUG|Miconazole Topical Gel|topical anti fungal agent
224026906|NCT04308161|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
224026907|NCT04308161|DRUG|Oracure gel|Topical analgesic gel
224026908|NCT04308161|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
224026909|NCT04646954|DIAGNOSTIC_TEST|Host DNA methylation testing|Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample
224026910|NCT04646954|DIAGNOSTIC_TEST|Cervical cytology and/or high-risk human papillomavirus assays|Cervical cytology and/or high-risk human papillomavirus assays
224026911|NCT03689660|OTHER|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
224026912|NCT03689660|OTHER|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
224133981|NCT00123851|DRUG|Capecitabine|
224133982|NCT00123851|DRUG|Oxaliplatin|
223558824|NCT05200611|DIAGNOSTIC_TEST|Fecal Immunochemical Test|Participants with positive fecal immunochemical test results were further examined by colonoscopy.
224026913|NCT03689660|OTHER|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
224133983|NCT05140005|DIAGNOSTIC_TEST|GlowTest COVID-19 Antigen Home Test|diagnostic testing for Covid 19
224133984|NCT02998554|DRUG|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
224133985|NCT02998554|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
224133986|NCT04931316|OTHER|antiglaucoma|use antiglaucoma in ocular hypertension
224133987|NCT05399238|DEVICE|The objective is to measure the temperature of the lingual dorsum|Subjects will make one visit to our clinic with burning mouth syndrome and control healthy . They will be asked to acclimate to room temperature for at least 20 minutes. Subjects are requested not to consume hot drinks or food for at least an hour before imaging and not to use any skin preparations.
223410141|NCT02630251|DRUG|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
223410142|NCT04063293|BIOLOGICAL|Platelet Rich Plasma|PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
223410143|NCT06136273|BEHAVIORAL|Treatment measures and intervention strategies|To conduct observational process improvement and hypothesis-deriving studies related to penetrating traumatic injuries using data from the Methodist trauma registry and open source data repositories.
223410144|NCT03692286|COMBINATION_PRODUCT|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
223558825|NCT00770497|DRUG|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
224026914|NCT01561404|DRUG|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
224026915|NCT04421183|DIAGNOSTIC_TEST|draw blood|draw blood from the all of patients
224026916|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
224026917|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
224026918|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
224133988|NCT05241015|OTHER|Control Group|Treatment protocol; It will be applied to improve posture, strengthen muscles, eliminate shortness, increase flexibility, balance/coordination, sit up/stand up and in-bed mobilization, and improve gait. Before taking the treatment, a general evaluation will be made and as a result of this evaluation, muscle shortness, loss of strength, postural disorders and the activities and positions they have the most difficulty in daily life will be determined. Treatment programs will be shaped according to the problems determined in line with the evaluations made.
223410145|NCT03692286|DRUG|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
223558826|NCT00770497|DRUG|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
224026919|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
224026920|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
224133989|NCT05241015|OTHER|Exercises Group|In addition to the standard physiotherapy program, sensorimotor training including the cervical region will be given to the this group. Deep cervical flexor and extensor muscles, which provide stability in the cervical region, will be trained. A Pressure Biofeedback Device will be used to train the deep cervical flexors. Both positional and kinesthetic sensory training will be provided by maintaining the stability of the cervical region by means of the laser kit that provides visual feedback.Additionally, oculomotor exercises will be given.
224133990|NCT01121159|PROCEDURE|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
224133991|NCT04095988|PROCEDURE|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
224133992|NCT04095988|PROCEDURE|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
224133993|NCT00043875|DRUG|lamotrigine|
224133994|NCT03367065|RADIATION|Dynamic contrast enhanced computerised tomography|
223410146|NCT03692286|DRUG|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
223410147|NCT03273101|DEVICE|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
224133995|NCT05298696|DRUG|Cilostazol|Cilostazol 100 mg twice daily
224133996|NCT05298696|DRUG|Placebo|Placebo twice daily
223410148|NCT03273101|OTHER|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
223558827|NCT00770497|DRUG|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
223558828|NCT00820859|BEHAVIORAL|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
223558829|NCT00820859|BEHAVIORAL|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
223410149|NCT03481972|DRUG|Doxycycline and tauroursodeoxycholic acid|doxycicline and tauroursodeoxycholic acid
223410150|NCT03481972|DRUG|Standard of care|Standard of care
223410151|NCT01863667|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
223410152|NCT01863667|DRUG|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
223410153|NCT01863667|DRUG|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
223410154|NCT01863667|DRUG|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
223410155|NCT02539940|DEVICE|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
223410156|NCT03236467|BEHAVIORAL|Progressive Exercise Training|Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
223410157|NCT05949346|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
224026921|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
223410158|NCT05949346|BEHAVIORAL|School services for families of children with Dyslexia|Selected school personnel will deliver services as usual for the control group.
224026922|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
224026923|NCT01572753|DRUG|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
223410159|NCT02687568|OTHER|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
223410160|NCT03627546|OTHER|Rapid Treatment strategy|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during 12 weeks of provided sofusbuvir/velpatasvir treatment."
223558830|NCT01612286|DRUG|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle \*4cycles
224026924|NCT00547820|OTHER|placebo|
224026925|NCT00547820|DEVICE|Urinary sensor|
224026926|NCT00557648|BEHAVIORAL|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
224026927|NCT00557648|BEHAVIORAL|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
224026928|NCT03588286|PROCEDURE|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting \> 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL\<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
224026929|NCT03588286|OTHER|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
224026930|NCT03588286|PROCEDURE|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) \<30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
224026931|NCT02750280|DEVICE|MatriStem® [Urinary Bladder Matrix (UBM)]|Porcine derived urinary bladder extracellular matrix
224026932|NCT02750280|DEVICE|Mepilex® [Silicone foam dressing]|primary wound dressing
224133997|NCT05941858|BEHAVIORAL|Smoking Cessation Intervention|Receive smoking cessation resource document
224133998|NCT05941858|PROCEDURE|Carbon Monoxide Measurement|Undergo CO test
224133999|NCT05941858|OTHER|Internet-Based Intervention|Receive access to WaQi/Tai Chi program
224134000|NCT05941858|OTHER|Survey Administration|Ancillary studies
224134001|NCT05941858|OTHER|Tai Chi|Practice Tai Chi
224134002|NCT06217536|DRUG|Lurbinectedin|Given intravenously (IV)
223410161|NCT03627546|OTHER|Usual Care (facilitated referral)|articipants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then followed separately. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
224134003|NCT06217536|RADIATION|Radiotherapy|Conventionally fractionated radiotherapy or external beam radiation
224134004|NCT06217536|PROCEDURE|Non-investigational surgery|Non-investigational surgical procedure on tumor tissue
224134005|NCT03900754|DRUG|Oxytocin|Intranasal administration of oxytocin
224026933|NCT02963740|BEHAVIORAL|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
224026934|NCT02963740|BEHAVIORAL|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
224026935|NCT02963740|BEHAVIORAL|Group Phone Calls|Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
223410162|NCT01992172|DRUG|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
223410163|NCT01992172|OTHER|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
223410164|NCT03045263|BEHAVIORAL|Pivotal Response Treatment|Behavioral intervention for autism
223558831|NCT06291012|DRUG|Quick response: Amoxicillin for 3 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
223558832|NCT06291012|DRUG|Delayed response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days"
223558833|NCT06291012|DRUG|Quick response: Amoxicillin for 5 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)"
223558834|NCT06291012|DRUG|Delayed response: Amoxicillin for 7 days|"Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days"
224026936|NCT02963740|BEHAVIORAL|Diet|Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
224026937|NCT00432146|DRUG|lugol's solution|
224026938|NCT00518466|DRUG|topiramate|25 mg modified-release capsules
224026939|NCT00518466|DRUG|phentermine|7.5 mg immediate-release capsules
224026940|NCT00518466|DRUG|topiramate|100 and 25 mg immediate-release tablets
224026941|NCT00518466|DRUG|phentermine|37.5 and 7.5 mg immediate-release tablets
224026942|NCT04463173|DRUG|Anaprazole|single dose, oral administration 30 minutes after breakfast with high fat food.
224134006|NCT03900754|DRUG|Placebo|Placebo
224134007|NCT02098460|DRUG|Atorvastatin, Probucol, Cilostazol|
224026943|NCT04463173|DRUG|Anaprazole|single dose, oral administration before breakfast.
224026944|NCT05557227|OTHER|1-hour cycling|60 % VO2 max
224134008|NCT03484000|BEHAVIORAL|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
224134009|NCT01752842|DRUG|Fenofibrate|
224026945|NCT02534987|OTHER|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
224026946|NCT03301896|DRUG|LHC165|LHC165 intratumoral injection
224026947|NCT03301896|BIOLOGICAL|PDR001|PDR001 infusion
224026948|NCT05066737|PROCEDURE|lateral suspension via V-NOTES surgery|pop-q, pisq-12 assesment of patients with pelvic organ prolapse before and 6 or 12 month after lateral suspension surgery performed via V-NOTES technique.
223410165|NCT05330117|PROCEDURE|TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
224026949|NCT00506987|DRUG|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
224134010|NCT01752842|DRUG|Placebo for fenofibrate|
224134011|NCT04169334|BEHAVIORAL|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
224134012|NCT06203496|DIAGNOSTIC_TEST|Blood sample|Blood sample
224134013|NCT01683071|DRUG|Placebo|Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
224134014|NCT01683071|DRUG|EXPAREL 67 mg|5 mL EXPAREL expanded with 15 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
224026950|NCT00506987|DRUG|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
224026951|NCT02325479|DRUG|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
224026952|NCT02325479|DRUG|tissue culture media|intrauterine administration after oocyte pickup as placebo
224026953|NCT00309296|BEHAVIORAL|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
224026954|NCT01781507|DRUG|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
224026955|NCT01781507|DRUG|Placebo|This placebo ( sugar pill) will provide the negative control for this study
224026956|NCT06161168|DEVICE|Bootle Blast Play Phase (B)|"Bootle Blast will be trialed for 14 weeks in the homes of 60 young people (6 to 17 years) with any motor condition that could be addressed by the Bootle Blast system, regardless of their diagnosis. The investigators will assess feasibility (e.g. independent home setup, ability to set/meet self-directed play time goals), enablers/barriers to use, and perceived value.~During the 8-week intervention phase (B), children will have Bootle Blast at home and play it according to their family-directed playtime goals. Weekly logs of therapy activities and problems encountered while playing will be collected through survey links. Additionally, families will record a video of their child performing the tasks associated with their COPM goals on a weekly basis. After the 8-week intervention (B) phase, participants will enter a second 3-week baseline (A) phase, during which they'll be asked to stop playing Bootle Blast, and the game will be programmatically locked to prevent further play."
224026957|NCT05381610|DEVICE|Peristeen|The Peristeen system will be handled by Coloplast trained personnel. The investigator and a trained nurse will participate in all the investigation related procedures. The nurse is trained in the handling of the investi-gational product as well as this is described in detail in the Instruction for Use (IFU). Subjects (and their caregivers, if appropriate) will also be trained on the use of Peristeen prior to independent use at home.
224026958|NCT00190411|DRUG|celiprolol|celiprolol
224026959|NCT00190411|DRUG|Control|Untreated controls excluding betablockers
224026960|NCT04830423|PROCEDURE|Medical ozone injection|Patients in the ozone (O2-O3) injection group will be given intraarticular and periarticular knee injections 3 times as the first dose of 10 μg / ml, the second dose is 15 μg / ml, and the third dose is 20 μg / ml, each session in a volume of 10 ml. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
224026961|NCT04830423|PROCEDURE|steroid injection group|In the steroid injection group, 1 ml of betamethasone (6 mg / ml) will be injected once intraarticular knee injection. Patients will be evaluated according to the study criteria at the beginning, 4 and 12 weeks later by a blinded investigator.
224026962|NCT03466801|DRUG|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
223410166|NCT05330117|PROCEDURE|Control TENS|"This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (procedure typically will take from 5-15 minutes). The TENS units have pre-program settings improving convenience, reproducibility and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject."
223410167|NCT03288155|DIETARY_SUPPLEMENT|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
224026963|NCT03466801|DRUG|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight \>60kg ,500mg/d\<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
224026964|NCT05247554|DRUG|Hydroxychloroquine + low-dose prednisone|Hydroxychloroquine, tablets, 400mg/day for 6 months combined with Prednisone, 20mg/day for 1 month, then 10mg/day for 20 weeks (ie up to M6). The cumulative doses of prednisone during the 6 months of the study will be 1820mg
224026965|NCT05247554|DRUG|Prednisone|"prednisone, tablets, 40mg/day for 4 weeks, then 30mg/day for 2 weeks, then 20mg/day for 2 weeks, then 15mg/day for 2 weeks, then 10mg/day for 14 weeks (i.e. up to 6 months ).~The cumulative doses of prednisone during the 6 months of the study will be 2870mg "
224026966|NCT04633551|DIETARY_SUPPLEMENT|Anti-inflammatory supplement|commercially available combination of curcumin, quercitin, resveratrol, and green tea
224026967|NCT04386811|DRUG|Calcitriol|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
224134015|NCT01683071|DRUG|EXPAREL 133 mg|10 mL EXPAREL expanded with 10 mL normal saline as single-injection femoral nerve block prior to total knee arthroplasty
224134016|NCT01683071|DRUG|EXPAREL 266 mg|20 mL EXPAREL as single-injection femoral nerve block prior to total knee arthroplasty
224134017|NCT03121183|DEVICE|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
224134018|NCT03121183|BEHAVIORAL|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
224134019|NCT01625598|PROCEDURE|Photography of the retina|Every subject will undergo photography of the retina in both eyes
224134020|NCT01625598|PROCEDURE|Retinal photography|"Device~Subjects will have photography of both eyes"
224134021|NCT01073696|DRUG|granisetron IV|IV
224134022|NCT01073696|DRUG|granisetron patch|patch
223410168|NCT03231163|OTHER|No Music|Participants lie supine on a table while no music is played.
223410169|NCT03231163|OTHER|Relaxing Classical Music|Participants lie supine on a table while classical music is played.
223410170|NCT03231163|OTHER|Self-Selected Relaxing Music|Participants lie supine on a table while self-selected relaxing music is played.
223410171|NCT05804214|OTHER|Dairy and plant based infant formula feeding|Parents have already decided to feed their infant with the product (a dairy and plant based infant formula) daily, starting within the first 4 months of life, continuing for at least 2 months
223410172|NCT00184886|DRUG|Methotrexate 15 mg/week for 12 weeks|
223410173|NCT06208917|DRUG|Ondansetron (Oral soluble film OR injections) ,Dexamethasone|Participants will randomly assigned 1:1 to receive treatment (Oral soluble film of Ondansetron plus dexamethasone OR Ondansetron injections plus dexamethasone).
223558835|NCT01872195|OTHER|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
223558836|NCT04810013|PROCEDURE|non-invasive measurement of cerebral autoregulation|Non-invasive measurement of the cerebral autoregulation in the postoperative period in 80 neonates and infants with complex congenital heart disease undergoing cardiopulmonary bypass surgery. A continuous, moving Pearson's correlation coefficient will be calculated between the arterial pressure and near-infrared spectroscopy signals and displayed continuously during surgery using a laptop computer and the ICM+ software (Cambridge Enterprise).
223558837|NCT04826107|DRUG|DP303c treatment|DP303c injection, every 3 weeks.
223558838|NCT04826107|DRUG|DP303c treatment（second-line of HER2-positive）|DP303c injection, every 3 weeks.
224026968|NCT04386811|OTHER|Placebo|A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
224026969|NCT05488015|OTHER|Global Postural Re-education (GPR)|GPR intervention lasted 8 weeks. Each week the postures had to be performed on 4 or 5 days.
224134023|NCT00975702|PROCEDURE|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
223410174|NCT02822014|OTHER|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
223410175|NCT03450317|DRUG|Aspirin 80mg|No treatment
223410176|NCT02935712|DRUG|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
223410177|NCT02935712|DRUG|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
223410178|NCT02935712|DRUG|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
223410179|NCT00615550|DRUG|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
223410180|NCT00615550|DRUG|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
223558839|NCT04826107|DRUG|DP303c treatment （third-line of HER2-positive）|DP303c injection, every 3 weeks.
223558840|NCT04826107|DRUG|DP303c treatment（≥second-line of HER2 low expressing）|DP303c injection, every 3 weeks.
223558841|NCT04826107|DRUG|DP303c + PD-1/PD-L1 treatment|DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.
223558842|NCT00994201|OTHER|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
223558843|NCT04222634|OTHER|Radiotherapy (SBRT) and/or surgery (metastasectomy)|Metastasis-directed therapy (surgery and/or radiotherapy) as treatment for oligoprogressive lesions
223558844|NCT06174454|OTHER|Respiratory Pediatric Physiotherapy|Prolonged slow expiration Tracheal pumping Controlled expiratory flow exercises Forced expiration technique
223558845|NCT06174454|OTHER|Control Group|Will be subject to muscle compressions of the upper limbs. Both groups will receive the usual treatment for pneumonia prescribed by their treating doctor.
224026970|NCT05488015|OTHER|Lifestyle habits|No change in lifestyle habits during the 8-week trial.
224026971|NCT00556387|DRUG|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
224134024|NCT04527354|DRUG|Treamid|Participants will receive Treamid 50 mg once a day during 4 weeks
223410181|NCT03971396|OTHER|Physiotherapists working in intensive care|Physiotherapists working in intensive care will be reached by mail or telephone. Physiotherapists will be asked to complete the prepared questionnaire.
223410182|NCT02640664|DRUG|Ranibizumab|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
223410183|NCT04902027|DRUG|Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)|All subjects will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
223410184|NCT04255576|DIETARY_SUPPLEMENT|Dietary Supplement: Calcium/Vitamin D|All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia.
223410185|NCT03631680|PROCEDURE|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
223410186|NCT04124731|DRUG|sintilimab plus anlotinib|Sintilimab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21
223410187|NCT04124731|DRUG|Chemotherapy|"1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total."
223410188|NCT02763930|OTHER|Control diet|
223410189|NCT02763930|OTHER|Milk diet|
223410190|NCT02763930|OTHER|GABA-rich cheese diet|
223410191|NCT02965573|BIOLOGICAL|ARGX-113|
223410192|NCT02965573|DRUG|Placebo|
223410193|NCT05179889|DRUG|mFOLFIRINOX|"Irinotecan 150 mg/m2 IV day 1, oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 48 hours) continuous infusion\] 12 cycles per 2 weeks~mFOLFOX 6 \[Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 week"
223410194|NCT05179889|DRUG|mFOLFOX 6|Oxaliplatin 85 mg/m2 IV day 1, Leucovorin 400 (or levoleucovorin 200) mg/m2 IV day 1, 5-FU 400 mg/m2 IV bolus day 1, 5-FU 1200 mg/m2/d IV x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion, 12 cycles per 2 weeks
223410195|NCT06155344|OTHER|Food Frequency Questionnaire|We will obtain a global index of vegetalization of the diet (the Plant based Diet Index: PDI) from data obtained using semi-quantitative questionnaires on food frequency (Food Frequency Questionnaire (FFQ)) validated on the national ELFE cohort (French Longitudinal Study from Childhood (https://www.elfe-france.fr)) and completed by women in the 1st trimester of pregnancy (T1) and at delivery.
223410196|NCT06155344|OTHER|Collection of 4 mL maternal blood|One tube collection of 4 mL maternal blood in the first trimester and at delivery.
223410197|NCT05595967|BEHAVIORAL|Health education intervention|Both the two session contains modules focusing on heath related knowledge and pelvic floor muscle exercise. Both two session will be delivered by primary healthcare women workers in small groups (about 20 women per group). The local healthcare workers are responsible for making appointment with each participant through group activities. Each participant will receive a healthy calendar practice to record the number of exercises per day which will be supervised by primary healthcare workers. All healthcare workers are required to attend a full-day workshop organized base on the scheme and teaching materials developed by our research team. The contents of the workshop include: (1) introduction of pelvic floor dysfunction; (2) risk factors and prevention of pelvic floor dysfunction; (3) kegel movement; (4) methods of dealing with severe illness; (5) a standard procedure of group activities or one-on-one activities; (6) skills needed for the delivery of health education intervention.
223410198|NCT06033027|DEVICE|Carbonhand|During this phase, participants use the Carbonhand soft-robotic glove system in daily life for 6 weeks to support the performance of daily activities with their affected hand in the home environment. The participants are free to choose for which activities, when and for how long they use the Carbonhand. However, it is recommended to use the Carbonhand at least 180 minutes a week during the most common ADL, such as household activities, dressing/undressing, eating/drinking/cooking, and/or leisure activities.
223410199|NCT03654612|DRUG|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
223410200|NCT02964481|GENETIC|Whole exome sequencing|DNA sequencing of protein coding sections of all genes
223410201|NCT00315458|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
223410202|NCT00315458|DRUG|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
223410203|NCT02382575|DRUG|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
223410204|NCT02382575|DRUG|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
223410205|NCT03809975|OTHER|Multidisciplinary Community Program|"Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 \< BMI \<32.5; Psychology: PEG \> 4 or PHQ-4 \> 5 or PAM level \< 3"
223410206|NCT03809975|OTHER|Current model of care|No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
223410207|NCT04717752|DRUG|Ovidrel|recombinant human chorionic gonadotropin for injection
223410208|NCT04717752|DRUG|Troprilin|triptorelin acetate injection
223558846|NCT04339933|DIAGNOSTIC_TEST|FGFR test|Detection of FGFR gene mutations in the tumor tissue and urine of patients
223558847|NCT00660413|DEVICE|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
223558848|NCT01611688|DRUG|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
223558849|NCT01611688|DRUG|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
223558850|NCT01611688|DRUG|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
223558851|NCT06358664|PROCEDURE|Pars plana vitrectomy|Standard pars plana vitrectomy will be performed
223558852|NCT03197714|DRUG|OPB-111077|"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"
224134025|NCT04527354|DRUG|Placebo|Participants will receive Placebo once a day during 4 weeks
223410209|NCT06280859|BEHAVIORAL|Hoosier Sport|Hoosier Sport is a sport-based youth development intervention. The intervention targets physical activity levels, exercise and nutrition knowledge, and leadership skills. The intervention is delivered in person twice a week (Tue/Thu) during PE class. Each class lasts 45-minutes, and covers sport skills, and then a brief lecture and activity on exercise/nutrition/leadership skills. Additionally, once a week Hoosier Sport is delivered virtually (via Zoom) during home room for 20-minutes. This involves activities to allow the students to be active during the school-day.
223410210|NCT00987337|DRUG|Filibuvir|300 mg BID
223410211|NCT00987337|DRUG|Filibuvir|600 mg BID
223410212|NCT00987337|DRUG|Placebo|BID
223410213|NCT01807754|PROCEDURE|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
223410214|NCT01807754|PROCEDURE|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
223410215|NCT05159947|DRUG|SPT-07A injection|20mg (2), dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
223410216|NCT05159947|OTHER|placebo|2 Injection simulants, dissolved in 250ml of normal saline, and injected intravenously for 90±20min, twice a day, and administered for 7 days.
223410217|NCT01294241|DRUG|Oleogel-S10|1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
223410218|NCT01294241|DEVICE|Mepilex® soft silicone faced polyurethane foam dressing|Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
223410219|NCT02109627|DRUG|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
223410220|NCT02109627|DRUG|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
223410221|NCT03011827|OTHER|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
223410222|NCT02571673|BEHAVIORAL|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
223410223|NCT04432766|DRUG|BAT2020|After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
223410224|NCT01047566|DRUG|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
224134026|NCT06717282|BEHAVIORAL|visual rehabilitation for ophthalmic compliance|contextual, behavioral, and cognitive-based program for ophthalmic compliance
224134027|NCT06717282|BEHAVIORAL|Using contextual, behavioral, and cognitive-based stragegies to develop training programs|"Key Features of the Intervention:~1. Contextual Adaptation: Participants practice ophthalmic examination procedures in a simulated clinical environment to familiarize themselves with real-world conditions.~2. Behavioral Strategies: Positive reinforcement, such as rewards (snacks, toys, or videos), is used to encourage participation and cooperation during sessions.~3. Cognitive Support: Animated materials and interactive exercises are employed to teach the concepts required for visual tests, with take-home tasks for generalization.~4. Individualized Goals: Individualized training plans and objectives are established collaboratively with caregivers based on participants' cognitive and behavioral profiles.~Duration and Frequency:~Six sessions, each lasting one hour, are conducted biweekly, with flexibility based on caregiver availability."
223410225|NCT01047566|DRUG|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
223410226|NCT02276248|RADIATION|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
223410227|NCT02276248|DRUG|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
223410228|NCT00802048|DRUG|Local anesthetic (Ropivacaine)|Local anesthetic infusion
223410229|NCT00802048|DRUG|Saline|Saline serum infusion
223410230|NCT00086619|DRUG|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
223410231|NCT00489918|DRUG|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
223410232|NCT00489918|DRUG|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
224298026|NCT06357663|OTHER|Mindfulness practice with Calligraphy|The unique style of Art Meditation where mindfulness (heightened awareness) is achieved by combination of movement and focus on Chinese Tao Calligraphy while chanting a mantra. The practitioners repeatedly trace the lines of Tao calligraphy with fingers and chant the mantra. This enables them to achieve deep concentration, while maintaining fully alert state. The practice can be done in sitting or standing, depending on the health status and age.
223410233|NCT02748213|DRUG|Xeloda|Participants will receive oral Xeloda, 950 mg/m\^2 twice a day on Days 1 to 14 of each 21-day cycle.
223410234|NCT02748213|DRUG|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m\^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m\^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
223410235|NCT02748213|DRUG|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
223558853|NCT06010758|DRUG|Listerine Experimental Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Experimental Mouthwash twice a day, morning and night.
223558854|NCT06010758|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
224026972|NCT00556387|DRUG|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
224026973|NCT00088686|DRUG|Capsaicin (Intramucosal Injection)|
224026974|NCT01937156|DRUG|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
224026975|NCT01937156|DRUG|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
224026976|NCT00529958|PROCEDURE|Patellar Tendon|Patellar Tendon autograft
224026977|NCT00529958|PROCEDURE|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
224026978|NCT00529958|PROCEDURE|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
224026979|NCT04464785|DEVICE|CentriMag Circulatory Support System|The CentriMag Circulatory Suppose System is indicated for providing support for up to 30 days for one or both ventricles of the heart to treat post-cardiotomy patients who fail-to-wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.
224026980|NCT06102980|DEVICE|Transparietal ultrasound (US)-based shear wave elastography (SWE) attenuation measurement|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
223410236|NCT00987818|OTHER|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
223410237|NCT04273113|OTHER|Difficulties in Emotional Regulation Scale, Five Facet Mindfulness Questionnaire, Becks Depression and Becks Anxiety|Patients asked to complete these 4 questionnaires pre, during and post biofeedback training
223410238|NCT04273113|BEHAVIORAL|HRV Biofeedback (Healing Rhythms)|Sensors placed on fingers to capture heart rate and skin temperature
223410239|NCT00224861|BEHAVIORAL|Self-Management|
223410240|NCT00224861|BEHAVIORAL|Adherence|
223410241|NCT03051451|DRUG|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
223558855|NCT06010758|DRUG|Listerine Total Care Zero|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash twice a day, morning and night.
223558856|NCT06010758|OTHER|Listerine Cool Mint Zero|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash twice a day, morning and night.
224026981|NCT06102980|DEVICE|Transparietal ultrasound (US)-based shear wave elastography (SWE) stiffness measurement|The operator will be blinded to any clinical record. Before US-SWE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using an Aloka Arietta 850 (Olympus America, PA, USA), each patient must be supine. Upon breath-hold at the end of expiration, ten measurements will be obtained with the probe placed in the area of the right hepatic lobe through an intercostal space.
224026982|NCT06102980|DEVICE|Vibration-controlled transient elastography (VCTE) attenuation measurement|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
224026983|NCT06102980|DEVICE|Vibration-controlled transient elastography (VCTE) stiffness measurement|The operator will be blinded to any clinical record. Before VCTE, the patient must be fasted for a minimum of 4 hours and must remain alcohol-free for 7 days. Using the FibroScan® Compact 530 (Echosens, Paris, France), each patient must be supine with the right arm in abduction and the ipsilateral hand resting under the head. Upon breath-hold at the end of expiration, ten measurements will be obtained with the M-probe placed in the area of the right hepatic lobe through an intercostal space. Transition to an extra large probe will be based on a VCTE automatic probe selection tool prompt.
224298027|NCT00001253|BEHAVIORAL|cognitive tests and scales|
223558857|NCT02043106|OTHER|plantar vibration|
223558858|NCT02930382|OTHER|Baroreflex assessment|
223558859|NCT05243524|OTHER|Maveropepimut-S|SC injection on days 7, 28, then q8w
223558860|NCT05243524|DRUG|Cyclophosphamide 50mg|PO BID, one week on, one week off
223558861|NCT05720689|OTHER|using relaxing music|music diffusion during dental care under MEOPA
223558862|NCT05720689|OTHER|No relaxing music|dental care under MEOPA without music
223558863|NCT05131867|DRUG|nimodipine|(60 mg/4 hours) orally or via nasogastric tube
223558864|NCT05131867|DRUG|Oral Nimodipine and milrinone|Oral Nimodipine then after the diagnosis of vasospasm is confirmed, start milrinone bolus
223410242|NCT03051451|DRUG|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
223410243|NCT03051451|DRUG|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
223410244|NCT03454061|OTHER|physical activity|Physical education program (PEP) of 16-week length
223410245|NCT04003883|DEVICE|Holter ECG|A Holter ECG will be recorderd during shifts
223410246|NCT00913263|DRUG|2-hydroxyflutamide (2-HOF) [Liproca Depot]|Ready made paste including 600 mg 2-HOF for injection as a single dose
223410247|NCT00913263|DRUG|2-Hydroxyflutamide|The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
223410248|NCT04637503|BIOLOGICAL|GD2, PSMA and CD276 CAR-T cells|infusion, for 1x10\^6\~1x10\^7 cells/kg via IV
223410249|NCT05087511|OTHER|motor and sensory development assessment|Peabody Motor Development Scale 2 was used to evaluate motor development and Dunn's Sensory Profile was used to evaluate sensory processing.
223410250|NCT03373877|DRUG|PU-H71|PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
223410251|NCT03373877|DRUG|Ruxolitinib|Dosing will be in accordance with current package insert and dose subject was on during study entry.
223410252|NCT05383430|DIAGNOSTIC_TEST|: Conners rating scale-Stanford-Binet Intelligence Scales- stuttering severity index third edition (SSI-3) .|Questionaire tests for ADHD -IQ-Stuttering severity assessment
223410253|NCT05122182|DRUG|Candesartan Cilexetil|Angiotensin Receptor Blocker (ARB)
223410254|NCT05122182|DRUG|Repagermanium|C-C chemokine receptor type 2 (CCR2) antagonist
223410255|NCT05122182|DRUG|Candesartan Placebo|Angiotensin Receptor Blocker (ARB) placebo
223410256|NCT05122182|DRUG|Repagermanium Placebo|C-C chemokine receptor type 2 (CCR2) antagonist placebo
223410257|NCT02914782|OTHER|Observational Study|
223410258|NCT03484962|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
223410259|NCT03484962|PROCEDURE|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
223410260|NCT06265129|DIAGNOSTIC_TEST|Complete blood picture (done in the morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)|morning after the night of monitored sleep by PSG. With stress on red blood cell indices (RBC count, MCV, MCH, RDW)
223558865|NCT04283214|OTHER|Cardiopulmonary Resuscitation|Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
223558866|NCT00060801|DRUG|BIIL 283 BS (Amelubent)|
223558867|NCT05366621|DRUG|Anti-osteoporosis medications|Medication exposure was defined as the usage of osteoporosis medications approved by the Taiwan Food and Drug Administration (TFDA), including alendronate, risedronate, ibandronate, zoledronic acid, denosumab, raloxifene, bazedoxifene, calcitonin, and teriparatide, but excluded patients using the osteoporosis medication for cancer-related treatments (such as high dosing frequency of zoledronic acid or denosumab).
223410261|NCT05202197|OTHER|Smart cupboard|Development of a memory task with the help of a smart cupboard
223558868|NCT03091517|BEHAVIORAL|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
223558869|NCT05800925|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
223410262|NCT03063060|OTHER|vitamin D levels and Calcium levels examination|observational
223410263|NCT03199560|DRUG|Tc 99m tilmanocept|lymphatic mapping agent
223410264|NCT03199560|DRUG|Tc 99m filtered sulfur colloid|lymphatic mapping agent
223410265|NCT05385263|DRUG|Nivolumab Injection [Opdivo]|Nivolumab ( 3mg/kg IV) on day +5. If CAR-T expansion\<100 cells/microL on day +7 one additional dose of nivolumab (3mg/kg IV) will be given on day +19
223410266|NCT01209520|DRUG|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
223410267|NCT01209520|DRUG|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
223410268|NCT01209520|DRUG|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
223410269|NCT01209520|DRUG|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
223558870|NCT03571009|DEVICE|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
224298028|NCT02553278|DEVICE|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
224298029|NCT02553278|DEVICE|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
223410270|NCT01209520|PROCEDURE|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
223410271|NCT01209520|PROCEDURE|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
223410272|NCT01209520|DRUG|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
223410273|NCT01209520|DRUG|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
223558871|NCT04573699|DEVICE|CNT-HF|A modified CNT, will be delivered as a pacing sequence able to acutely influence sympathetic tone.
223558872|NCT01907308|DRUG|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
223558873|NCT01907308|DRUG|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
224026984|NCT06102980|DEVICE|Endoscopic ultrasound (EUS)-guided shear wave elastography (SWE) stiffness measurement|"EUS-SWE will be performed by an experienced endoscopist, blinded to clinical records. The expert will use the ArrietaTM 850 EUS console (Fujifilm, Tokyo, Japan) using a linear ultrasound video gastroscope EUS-J10 (Pentax Medical, Hoya Corp, Japan). Both lobes will be evaluated. The transducer will be positioned in the gastric window to visualize right liver segment number five and left liver segment two or three. The elastogram region of interest (ROI) will be placed within the liver tissue at a distance ≥10 mm beneath the hepatic capsule in an area free of vessels and artefacts. A 10-mm circular ROI will be placed within the elastogram at a depth of 4-5 cm from the skin, and a minimum of ten successful kilopascal measurements will be obtained.~In the first stage of this research, the EUS-SWE measurement will be limited to the estimation of liver fibrosis only. Currently, available EUS-SWE equipment does not allow the estimation of the attenuation."
224026985|NCT02761161|DRUG|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
224026986|NCT02761161|BEHAVIORAL|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
224026987|NCT03316300|COMBINATION_PRODUCT|NT-501|"Each NT-501 implant consisted of hCNTF-secreting NTC-201-6A.02 cells encapsulated within supportive matrices and surrounded by a semipermeable polymer membrane.~The NTC-201-6A cells continuously secrete CNTF from the NT-501 implant into the vitreous cavity. Implanted by a qualified Health Care Professional."
224026988|NCT03316300|PROCEDURE|Sham Procedure|The sham surgery involved a superficial conjunctival incision performed under local anesthetic and closure with a single suture.
224134028|NCT06889714|DEVICE|ultrasonography|Right thigh length (between the right femur greater trochanter and patella) was measured and recorded while the patients were lying supine. A linear transducer (Philips Affiniti 50, Philips Medical Systems, Seattle, WA, United States) was used for ultrasonographic measurements. The rectus femoris (RF) and vastus intermedius (VI) were visualized with the feather-touch technique after a generous amount of ultrasound gel was sprayed in the center of the right thigh, and the thickness of the muscles was determined and recorded using ultrasonography software. After these measurements, the rectus femoris-to-thigh length ratio (RF/B), vastus intermedius-to-thigh length ratio (VI/B), and total muscle thickness-to-thigh length ratio (T/B) were calculated and recorded.
224298030|NCT01334710|DRUG|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
224298031|NCT00979381|BIOLOGICAL|influenza vaccine|influenza vaccination
224298032|NCT01558297|BEHAVIORAL|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
224298033|NCT01558297|BEHAVIORAL|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
223410274|NCT01209520|DRUG|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
223410275|NCT02116127|DEVICE|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
223410276|NCT02116127|DEVICE|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
223410277|NCT01630187|DRUG|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
223558874|NCT04113707|BEHAVIORAL|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
223558875|NCT04233307|DIAGNOSTIC_TEST|Telethermographic images|Infrared digital thermography photographs of fracture wound and contralateral limb before and after propofol infusion.
223558876|NCT01126268|DRUG|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
223558877|NCT05949255|DIETARY_SUPPLEMENT|Probiotic|10 subject will receive a probiotic daily for 12 weeks.
223558878|NCT05949255|DIETARY_SUPPLEMENT|Placebo|10 subjects will receive a placebo daily for 12 weeks.
223558879|NCT03960411|DRUG|Doxycycline 100Mg Capsule|Doxycycline capsule
223558880|NCT03960411|DRUG|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
223738592|NCT02150174|BEHAVIORAL|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
223738593|NCT00314405|DRUG|Methylene blue (1%)|
223738594|NCT00314405|DRUG|Rhenium sulfure|
223738595|NCT00314405|PROCEDURE|Surgical procedure|
224298034|NCT01558297|BEHAVIORAL|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
224298035|NCT03074747|DIAGNOSTIC_TEST|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
223410278|NCT01630187|DRUG|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
224026989|NCT05094557|BEHAVIORAL|Experimental Group 1: Body swapping VR intervention + psychoeducational video + Treatment As usual|The patient will be embodied in his/her own avatar and will maintain a conversation with a counsellor's avatar of his/her choice. Once the experiment starts, the patient, embodied in his/her own body, will start describing his/her problem in terms of subjective experiences of being obese in daily life. Then, he/she will be body swapped to the counsellor's body and try to respond to the problem just manifested by the patient. The crucial aspect here is that the patient, from the counsellor's viewpoint, will see a representation of his/her real body when looking at the patient's avatar speaking and moving. Therefore, the patient will have the opportunity to see himself/herself in first person (1PP) and second person (2PP) perspectives.
223410279|NCT01200147|OTHER|study withdrawn no details|
224026990|NCT05094557|BEHAVIORAL|Experimental Group 2: VR intervention without body swapping + psychoeducational video + Treatment As usual|"Participants from the Experimental Group 2 will be embodied in their own body and will participate in pre-established discourse provided by the chosen counsellor, who will ask about the perceived barriers for engagement with a healthier lifestyle and will give practical recommendations about how to achieve a healthier and happier life, in terms of healthy eating and physical activity. No body swapping will take place for this group. Participants will also continue receiving Treatment As usual plus a Psychoeducational video with useful information about how to engage with a healthier lifestyle."
224026991|NCT05094557|BEHAVIORAL|Control Group: Psychoeducational video + Treatment As usual|Participants from the Control Group will receive their Treatment As Usual plus a Psychoeducational video. Treatment as usual will consist of regular medical, nutritional and/or psychiatric follow-ups with the obesity specialists of the Vall d´ Hebron University Hospital and standard routine tests. These visits aim to provide practical recommendations about how to achieve a gradual weight loss and engage more with physical exercise.
223410280|NCT06578260|BEHAVIORAL|Peer support groups with a solution-focused approach|To investigate the effectiveness of a support group intervention using a solution-focused approach among school children in 5th-7th grade in southeastern Norway
223410281|NCT01035294|BEHAVIORAL|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
223410282|NCT01035294|BEHAVIORAL|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
223410283|NCT00961350|DRUG|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
223410284|NCT00961350|DRUG|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
223410285|NCT06537427|OTHER|Data collection|"The data to be collected are the following:~* Demographic data: gender and age of the patient at diagnosis of SCI;~* Drug assumption and drug abuse at the time of SCI;~* A complete assessment of patients' comorbidities;~* Complete neurological examination on admission and at 6-8 months follow-up according to ASIA protocol;~* Neuro-radiological data: spinal CT and MRI performed within 48 hours of admission to document the type, level and extent of the lesion of the spine and the spinal cord;~* CSF pressure, chemical and biological markers;~* Serum chemical and biological markers;~* Data coming from surgical procedure: type of decompression, type of stabilization, extension of the stabilization, surgical approach, staged surgery, timing of surgery, length of surgery, eventual intraoperative, postoperative or long-term surgical-related complications \[13\];~* Data on hospitalization: length of stay, hospital-acquired infections, any adverse event occurred during hospitalisation."
223410286|NCT05435729|DRUG|DSP-9632P 27.5 mg|Single dose of DSP-9632P 27.5 mg
223410287|NCT05435729|DRUG|DSP-9632P 82.5 mg|Single dose of DSP-9632P 82.5 mg
223410288|NCT05435729|DRUG|Placebo|Placebo for DSP-9632P
223410289|NCT05435729|DRUG|DSP-9632P 55.0 mg|Multiple dose of DSP-9632P 55.0 mg
224026992|NCT02092688|DEVICE|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
224026993|NCT03914729|PROCEDURE|Primary Closure|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.
224026994|NCT03914729|PROCEDURE|Gluteus Maximus Fascia Plasty Flap|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
224026995|NCT00061152|DRUG|Capsaicin Dermal Patch|
223558881|NCT05666934|DEVICE|Augmented Reality Storybook|The AR system was developed using a Vuforia Engine Package for Unity (PTC Inc, San Diego, CA), which enabled to create an application for children to view a storybook in their own homes. The children and caregivers could view eight scenarios (receiving a praise, broken toys, waiting in line at the playground, getting a vaccination, waiting for watching a video, hitting someone in an accident, grabbing a toy, understanding another person's feelings) and learn strategies for emotional events reflected in the tablet (Figure 1). This AR application supports a tablet size of 10.4 inches and is equipped with a Samsung Galaxy Tab A7.
223558882|NCT03395691|PROCEDURE|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
223558883|NCT03395691|PROCEDURE|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
224026996|NCT04918446|OTHER|T-POSE|Tablet based education and videos on opioid safety, use, and storage/disposal of the drug.
224026997|NCT04918446|OTHER|Usual Care|Printed instruction sheets on prescribed opioid.
224026998|NCT05538559|OTHER|Chemomechanical caries removal by Carie-Care|caries in primary teeth will be removed using Carie-Care™ the chemomechanical agent.
224026999|NCT05538559|OTHER|Mechanical caries removal by Atraumatic Restorative Technique|caries in primary teeth will be removed using the mechanical caries removal by ART method.
224027000|NCT00096343|DRUG|carboplatin|
224027001|NCT00096343|DRUG|paclitaxel|
224027002|NCT00001573|DRUG|SU101|
224027003|NCT02465853|DRUG|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
224027004|NCT02465853|DRUG|Physiological saline solution|Injection 0.9% Physiological saline solution\<1.0 ml
224134029|NCT05745402|BEHAVIORAL|Mobility Checkup for older adults|The Mobility Checkup (MC) for older adults is a 45-minute preventative physical therapy visit designed to maintain mobility during aging. It has two parts, measurement (25 minutes) and education (20 minutes). The 5 standardized measures of physical performance in the MC are Walking speed, single leg stance time (balance), Five rep sit to stand (muscular endurance, transitions), 6-meter walk test (general endurance), and Timed up from floor test (transitions). Participants are provided education structured into 4 elements. 1. They are told their performance scores 2. They are shown how their performance scores on each of the measures compare to age and sex-referenced normative values 3. They are provided information about what their performance predicts about their health 4. They are referred to an appropriate provider if there was a health or safety concern during their MC or they are educated to follow the recommendations for physical activity that are recommended by the CDC.
224134030|NCT00002340|DRUG|Atovaquone|
224134031|NCT00002340|DRUG|Pentamidine isethionate|
224134032|NCT06898216|DEVICE|Steerable FANS|This device is designed for flexible ureteroscopy procedures in patients with lower pole renal stones ≤2 cm. It features an active deflection mechanism that enables independent adjustment to enhance access into the lower pole calyx. The description focuses solely on the device and does not include procedural details already provided in the arm description.
224027005|NCT02465853|OTHER|physical therapy and occupational therapy|rehabilitation
224027006|NCT04876872|OTHER|no intervention|no intervention
224027007|NCT05670873|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation given to the left dorsolateral prefrontal cortex
224027008|NCT02877966|DIETARY_SUPPLEMENT|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
224027009|NCT02877966|OTHER|Placebo|
224134033|NCT06898216|DEVICE|Conventional FANS|This device is intended for use in flexible ureteroscopy for lower pole renal stone management. It relies on passive deflection provided by the flexible ureteroscope for navigation into the lower pole calyx. The description is limited to the device characteristics without duplicating procedural details from the arm description.
224134034|NCT03120780|DRUG|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
223738596|NCT00314405|PROCEDURE|Anatomo-pathologic procedure|
224027010|NCT02877914|OTHER|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
224027011|NCT00079066|BIOLOGICAL|cetuximab|
224027012|NCT00079066|PROCEDURE|quality-of-life assessment|
224027013|NCT05846347|DRUG|GC012F injection|Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) once by intravenous infusion on Day 0.
224134035|NCT03120780|DRUG|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
224027014|NCT04701892|OTHER|Indicators of central sensitisation|Indicators of central sensitisation, assessed by the Central Sensitization Inventory
224027015|NCT02857166|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
224027016|NCT01315353|PROCEDURE|Cervical Cryotherapy|Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
224027017|NCT01315353|PROCEDURE|Loop Electrosurgical Excision Procedure (LEEP)|Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
224027018|NCT03567434|OTHER|Alcohol vs. Placebo|Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
224027019|NCT05042232|OTHER|SARS-CoV-2 Positive|Participants who have tested positive for SARS-CoV-2, both with and without symptoms
224027020|NCT05042232|OTHER|SARS-CoV-2 Negative|Participants who have tested negative for SARS-CoV-2
224027021|NCT06043752|DRUG|Remsima|The patient will be given one Injection of REMSIMA 120 mg subcutaneously at week 0, 1, 2, 3, 4 and then every 2 weeks i.e., at 6, 8, 10 and 14 weeks. If the weight of the patient is \>80 kg, 2 injections will be given.
224027022|NCT00758277|DRUG|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
224027023|NCT00758277|DRUG|Placebo|Sugar Pill
224027024|NCT00159692|DRUG|Amlodipine|
223410290|NCT05435729|DRUG|Levodopa formulation|Single dose of Levodopa formulation
223410291|NCT05654376|BEHAVIORAL|Art therapy|"Participant's creativity is stimulated by visual arts materials and various art therapy techniques, in relation to 6 topics: self-care, stress management, flourishing caregiving, challenging caregiving, loss and grief, and sense of professional meaning.~The strategy consists of stimulating an observant and symbolic gaze, facilitating visual expression, promoting communication about what it has been expressed, and gather learning from the multidimensional impact of the creative art process (sensations, emotions, cognitions and spiritual experiences)."
223410292|NCT04825691|DIAGNOSTIC_TEST|Immunohistochemistry of prostate biopsy|Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions
224027025|NCT04491266|DIETARY_SUPPLEMENT|FBA|N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.
223410293|NCT02678065|DEVICE|InPact Admiral DEB|
223410294|NCT06578676|DRUG|Empagliflozin 25 MG|PO, QD
224027026|NCT04491266|DIETARY_SUPPLEMENT|placebo|maltodextrins
224027027|NCT00617253|DRUG|recombinant interleukin-21|3 mcg/kg, s.c. injection
224027028|NCT00617253|DRUG|sunitinib|Hard gelatine capsules, 12.5 mg
224027029|NCT00617253|DRUG|recombinant interleukin-21|10 mcg/kg, s.c. injection
224027030|NCT00617253|DRUG|recombinant interleukin-21|30 mcg/kg, s.c. injection
224027031|NCT00617253|DRUG|recombinant interleukin-21|100 mcg/kg, s.c. injection
224027032|NCT04193124|DIAGNOSTIC_TEST|transcranial doppler.|Daily monitoring of transcranial doppler until the disappearance of the intracranial vasosparm
224134036|NCT06111053|OTHER|ENDS|Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
224134037|NCT06111053|OTHER|CI|Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
224134038|NCT06111053|OTHER|No ENDS|Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.
224134039|NCT06111053|OTHER|NI|Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
224134040|NCT05265845|BEHAVIORAL|Intervention|The intervention aims to support infant feeding decisions and teach responsive feeding strategies.
224134041|NCT05265845|BEHAVIORAL|Text4Baby|Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
224134042|NCT00202631|DEVICE|Surface Functional Electrical Stimulation|
224134043|NCT04211155|OTHER|Questionnaires|The participant will complete questionnaires, including ones on pubertal development and quality of relations with parents and friends.
223410295|NCT06578676|DRUG|Ezetimibe/Rosuvastatin 10/10mg|PO, QD
223410296|NCT06578676|DRUG|Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg|PO, QD
223410297|NCT03924180|DIETARY_SUPPLEMENT|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
223410298|NCT01574365|DRUG|RTA 402|
223410299|NCT00466362|BEHAVIORAL|The Evje Model|Lifestyle intervention
223410300|NCT04019782|DRUG|Collagen-PVP|Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)
223410301|NCT04019782|DEVICE|Hylan G-F 20|Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)
223410302|NCT03952273|COMBINATION_PRODUCT|PCI with BioMatrix Alpha™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
223410303|NCT03952273|COMBINATION_PRODUCT|PCI with Combo™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
223410304|NCT04663633|OTHER|Core stability training|Functional Rhythmic Core Stability exercises performed by the experimental group. 30 minutes insert included in the Gymnasts regular training.
223410305|NCT05399940|DIAGNOSTIC_TEST|Serum PSA,Delta Neutrophil Index(DNI),WBC|Urine culture, prostate volume
223410306|NCT06594146|BIOLOGICAL|CM313 injection|CM313
223410307|NCT06594146|OTHER|placebo|placebo
224027033|NCT02720367|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
224027034|NCT04397341|DRUG|docetaxel, cisplatin, fluorouracil|Biweekly Induction regimen with Docetaxel, Cisplatin and Fluorouracil
224027035|NCT01607112|BIOLOGICAL|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
224027036|NCT02881957|DRUG|Cholecalciferol|
224027037|NCT02881957|OTHER|Placebo|Oral syrup placebo
224027038|NCT05742022|DRUG|"Phospholipovit"|500 mg orally 2 times a day, for 12 weeks
224027039|NCT05742022|DRUG|Placebo|500 mg orally 2 times a day, for 12 weeks
224027040|NCT04485858|DEVICE|CorNeat KPro|CorNeat KPro will be implanted into the subject's eye where the optic component snaps into the patient's trephined cornea and is sutured to the eye wall using 3 non-degradable sutures and the skirt component is placed under the conjunctiva
224027041|NCT04041011|DRUG|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
224027042|NCT04041011|DRUG|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
224027043|NCT04041011|DRUG|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
224027044|NCT04848493|BIOLOGICAL|COVID-19 vaccines|This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
224027045|NCT04317807|DRUG|Levetiracetam Pill|Levetiracetam is an anticonvulsant that is frequently used to treat epilepsy in children and adults due to its superior tolerability, ease of use and excellent safety profile. It is rapidly absorbed and rapidly crosses the blood-brain barrier. Levetiracetam does not affect metabolism of antipsychotic drugs and may normalize hippocampal hyperactivity by decreasing excessive glutamatergic and dopaminergic transmission, thereby making it an ideal agent to test the hypothesis that reducing excessive hippocampal activity may enhance treatment of early psychosis and prevent antipsychotic toxicity. Levetiracetam will be administered in 500 mg capsules twice a day.
224027046|NCT04317807|OTHER|Placebo|The placebo pill (sugar pill) will look just like the levetiracetam pill but does not contain levetiracetam. Placebo will be taken along with optimal antipsychotic medication selected by either the outpatient provider or the hospital staff responsible for the participant's care. Participants will be instructed to take the placebo pill twice daily for 12 weeks.
224027047|NCT04518605|DIETARY_SUPPLEMENT|Low protein breakfast|Low protein yoghurt containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.
224027048|NCT04518605|DIETARY_SUPPLEMENT|High protein breakfast|High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.
224027049|NCT04518605|OTHER|Exercise training|Participants will be asked to participate in organized exercise training 3 times per week.
224027050|NCT05281159|BEHAVIORAL|Risk Information|This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
224027051|NCT05281159|BEHAVIORAL|Risk Information + Action|This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
224027052|NCT03705832|DRUG|Ginger Extract|2gm Capsule of Ginger extract
224027053|NCT03705832|DRUG|Placebo|Matching Placebo
224027054|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
224027055|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
224134044|NCT04211155|OTHER|MRI|Within 2 weeks of the first study visit, the participant will return to the University where they will undergo MRI.
224134045|NCT01968187|DRUG|FE 992097|"Each spray pump actuation delivered a 50 μL volume of solution that contained 1.6 mg carbetocin (FE 992097); each dose consisted of 3 spray pump actuations in each nostril that delivered a total of 9.6 mg carbetocin.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days."
224134046|NCT01968187|DRUG|Placebo|"Each spray pump actuation delivered a 50 μL volume of sterile sodium chloride solution 0.9%; each dose consisted of 3 spray pump actuations in each nostril.~Parents were instructed to administer 3 intranasal spray actuations in each nostril 3 times daily before meals for 14 days."
223410308|NCT06303089|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, characteristics of smoking sheet, tobacco-related knowledge, perceptions of tobacco harm. Smokers will be asked the history of smoking cessation sheet, the Fagerstrom Test of Nicotine Dependence, Smoking Self-efficacy Questionnaire, Cigarette Withdrawal Scale, Intention to Quit Smoking sheet, Motivation to Quit Smoking sheet, Alcohol Use Disorders Identification Test, and International Physical Activity Questionnaire.
223558884|NCT02664649|DRUG|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~\- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily"
223558885|NCT02664649|DRUG|Standard of care|VKA or Antiplatelet therapy
223558886|NCT03293849|OTHER|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
224027056|NCT00762736|DRUG|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
224134047|NCT06897865|OTHER|survey|SURVEY
224134048|NCT06898840|OTHER|Fruit drink|Commercially available fruit drinks or smoothies
224134049|NCT06897891|COMBINATION_PRODUCT|Acupuncture combined with core stability training|All patients were given routine health education guidance and core stability training. Acupuncture group combined with core stability training
224134050|NCT06897891|COMBINATION_PRODUCT|Dragon Tank joint core stability training|All patients were given routine health education guidance and core stability training. Huolong Tank group adopts Huolongcan combined core stability training
224134051|NCT06898827|PROCEDURE|IVR using the Morpheus Programme|Patients in the intervention group will receive 20 mins of immersive therapy during cardiac rehabilitation
224134052|NCT06898827|PROCEDURE|Cardiac Rehabilitation control group|Cardiac rehabilitation but no IVR
224134053|NCT06899139|OTHER|Orthokeratology Lens Wear|"Orthokeratology Lens Wear~Intervention Type:~Device~Description:~Participants will wear gas-permeable orthokeratology (OK) lenses overnight for a minimum of 8 hours per night. Lenses are designed to reshape the cornea temporarily to reduce refractive error and slow axial elongation. This intervention is administered to both the experimental and control groups."
223738597|NCT05835453|OTHER|Whitening|Two syringes of 10% carbamide peroxide bleaching gel will be provided for use with each type of tray. Volunteers will be instructed to use the whitening gel once a day for 2 hours, for 3 days per week with each retainer, completing a total of 4 weeks of whitening procedure.
224027057|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
223410309|NCT06909734|BEHAVIORAL|Trauma-Informed Motivational Interviewing|"Trauma-Informed Motivational Interviewing: Core Principles~TIMI integrates two evidence-based approaches: Trauma-Informed Care (TIC) and Motivational Interviewing (MI). TIC emphasises understanding and acknowledging the impact of trauma on individuals' behaviours and emotional well-being. MI, a client-centred approach, fosters intrinsic motivation for change by exploring ambivalence and strengthening personal autonomy."
223410310|NCT02042755|DEVICE|trifocal intraocular lens|Standard cataract surgery
223410311|NCT00550745|BIOLOGICAL|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
223410312|NCT00550745|BIOLOGICAL|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
223410313|NCT06940726|OTHER|Quality of Life questionnaires|Subjects will complete a number of self-questionnaires on subjects such as attention span, anxiety levels and sleep quality.
223410314|NCT06940726|OTHER|Hearing tests|listening to sounds on headphones and repeating words
223410315|NCT06940726|BEHAVIORAL|Auditory prediction task|listening to sounds and assessing auditory perception
223410316|NCT06940726|BEHAVIORAL|Attention task|assessment of reaction time to visual or auditory cues
223410317|NCT06940544|DIAGNOSTIC_TEST|Stepwise Multimodal Home-Based HF Screening|The Stepwise Multimodal Home-Based HF Screening intervention involves a targeted community outreach program to identify undiagnosed heart failure (HF) in high-risk individuals. Participants randomized to the intervention arm (ACTIVE) are asked to self-collect dried blood spots for NTproBNP analysis. Those with elevated NTproBNP (≥125 pg/ml) in the dried blood spots are summoned to the study clinic and undergo confirmatory point-of-care NTproBNP testing and an AI-enabled echocardiogram, with the aim to confirm or rule out heart failure.
223410318|NCT06941467|DRUG|Timolol Maleate Solution|Timolol 0.5% solution. The number of drops delivered will be based on the initial wound size and will remain constant for the duration of the study period or until the wound is fully re-epithelialized which will be determined by the PI either by photo or in person visit.
223410319|NCT06941467|OTHER|Standard of Care|Vaseline
223410320|NCT06939621|BEHAVIORAL|VR-based physical activity with motivational stimuli|"Participants will undergo four weekly supervised VR-based training sessions, each lasting approximately 35 minutes, over four weeks. Each session includes:~1. VR Warm-Up: Activities adapted from NVIDIA VR Fun House on SteamVR, involving repetitive movements through mini-games like throwing objects, archery, and sword handling.~2. Aerobic and Balance Exercises: Walking in place within a virtual natural environment, incorporating stretching steps and one-leg balance tasks.~3. Lower-Body Training: VR-based exercises such as Balloon Game for hip flexibility (popping balloons with foot movements), Cave Game for squatting motions, and sit-to-stand activities.~4. Upper-Body Training: VR exercises involving racket-based ball hitting and reaching activities at varied distances.~Participants received motivational messages from a virtual coach designed to enhance the three psychological needs outlined in Self-Determination Theory: competence, autonomy, and relatedness."
223410321|NCT06939621|BEHAVIORAL|VR-based physical activity without motivational stimuli|"Participants will undergo four weekly supervised VR-based training sessions, each lasting approximately 35 minutes, over four weeks. Each session includes:~1. VR Warm-Up: Activities adapted from NVIDIA VR Fun House on SteamVR, involving repetitive movements through mini-games like throwing objects, archery, and sword handling.~2. Aerobic and Balance Exercises: Walking in place within a virtual natural environment, incorporating stretching steps and one-leg balance tasks.~3. Lower-Body Training: VR-based exercises such as Balloon Game for hip flexibility (popping balloons with foot movements), Cave Game for squatting motions, and sit-to-stand activities.~4. Upper-Body Training: VR exercises involving racket-based ball hitting and reaching activities at varied distances.~In this condition, instead of motivational stimuli, participants received neutral information regarding the activity (e.g., This exercise is good for your legs )."
223410322|NCT06939621|BEHAVIORAL|Standard Physical Activity with motivational stimuli|"Participants will engage in four individual training sessions, supervised by a trainer, scheduled once per week for a total duration of four weeks. Each session will last approximately 35 minutes and include: 5 minutes of warm-up and stretching, 10 minutes of aerobic and balance exercises (walking in place, heel raises, knee lifts, leg curls), 10 minutes of lower-body exercises (squats), and 10 minutes of upper-body exercises (shoulder abduction 180°, shoulder flexion 180°, shoulder external rotation 90°, bending 35°, trunk extensions 80°).~Participants received motivational messages from a real coach designed to enhance the three psychological needs outlined in Self-Determination Theory: competence, autonomy, and relatedness."
223410323|NCT06939621|BEHAVIORAL|Standard Physical Activity without motivational stimuli|"Participants will engage in four individual training sessions, supervised by a trainer, scheduled once per week for a total duration of four weeks. Each session will last approximately 35 minutes and include: 5 minutes of warm-up and stretching, 10 minutes of aerobic and balance exercises (walking in place, heel raises, knee lifts, leg curls), 10 minutes of lower-body exercises (squats), and 10 minutes of upper-body exercises (shoulder abduction 180°, shoulder flexion 180°, shoulder external rotation 90°, bending 35°, trunk extensions 80°). In this condition, instead of motivational stimuli, participants received neutral information regarding the activity (e.g., This exercise is good for your legs )."
223410324|NCT06940089|BEHAVIORAL|Attention Intervention using a customized BCI decoder|"During the offline phase of the intervention, participants will perform an attentional task while intracranial brain activity is recorded. Data from this session will be used to train a personalized decoder capable of classifying attentional engagement.~During the training phase, participants will receive real-time visual feedback contingent on their brain activity when attentional engagement is detected. This closed-loop feedback aims to reinforce successful attention and enhance performance over repeated sessions."
223738598|NCT05488457|DRUG|deuterated oxytocin (d5OT)|Subjects will receive a 1 IU bolus of deuterated oxytocin (d5OT) intraoperatively during their nonemergent cesarean delivery.
223738599|NCT04746235|DRUG|Decitabine and Cedazuridine|Given PO
223738600|NCT04746235|DRUG|Venetoclax|Given PO
223738601|NCT00594997|BEHAVIORAL|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
223410325|NCT06940089|BEHAVIORAL|Attention Intervention without using a customized BCI decoder|"During the offline phase, participants will perform an attentional task while intracranial brain activity is recorded. A personalized decoder will be created for each participant but will not be used during the training phase sessions.~During the training phase, participants will receive visual feedback while performing attentional tasks; however, the feedback will not be contingent on their brain activity. Instead, feedback will be non-contingent and unrelated to actual attentional engagement. This group is not expected to experience improvements in attentional performance through the training sessions."
223410326|NCT06939517|DEVICE|SeaBand|Drug-free, reusable Acupressure elastic wristbands applied to bilateral wrists for nausea relief
223410327|NCT06939699|BEHAVIORAL|Social Media-Based Education|This intervention includes daily delivery of 56 infographic/video-based educational materials over 8 weeks via WhatsApp or Instagram. The content focuses on awareness of breast, cervical, and colorectal cancer screenings, healthy lifestyle behaviors, and digital health literacy. The materials are developed based on the Socio-Ecological Model.
223410328|NCT06939699|BEHAVIORAL|Standard Online Education|Participants receive two 40-minute online educational sessions one week apart via Microsoft Teams/Zoom. The content includes cancer screening awareness (breast, cervical, colorectal), preventive strategies, and the use of digital health tools such as e-Nabız and MHRS.
223410329|NCT06941220|OTHER|mulligan group|SNAG technique was applied from a sitting position on the edge of the table while both feet were on a foot rest. A specialized Mulligan belt was used around the patient's waist and therapist's hips. The mobilizing force was applied parallel to the facet joint plane (cephalic direction) and over the spinous processes of the respective symptomatic spinal levels. The patients were asked to lean forward as much as possible during application of the mobilizing force and then return to the starting position while the therapist maintained his mobilizing force until the end. plus traditional therapy
223410330|NCT06941220|OTHER|Maitland mobilization|"The subjects were placed in the prone position on a plinth with their hands beside them, and the therapist stood on the subject's side, the ulnar surface of the hand (between pisiform and hamate) was placed over the hypomobile spinous process. The second hand was placed on top of the first to enhance its force. With the therapist's elbows slightly bent and shoulders exactly above the spinous process, an oscillatory movement of the vertebra was executed by applying a posterior-anterior force to the hypomobile or painful spinous process.~Grade III mobilization was applied four times, each with 60 s of oscillation and 20 s of rest in between them (2 or 3 oscillations per second) plus traditional therapy"
223410331|NCT06941220|OTHER|traditional therapy|the patients will receive traditional therapy in the form of passive stretching, strengthening, and lumbar stabilization exercises
223410332|NCT06537362|DEVICE|Mouthpiece with cheek-holder|A cheek support integrated into the mouthpiece is used for the measures
223410333|NCT02056184|DRUG|Adalimumab|
223410334|NCT04092868|OTHER|Blood samples PK/ PD protamine|PK/ PD protamine
223558887|NCT02169024|BEHAVIORAL|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
224027058|NCT00762736|DRUG|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
223410335|NCT06939530|PROCEDURE|Hydrodilatation (20 ml)|"First, an SSNB will be performed with 4 ml of 0.25% anesthetic + 0.5 ml of corticosteroid in the suprascapular notch.~After 15 minutes of the SSNB, ultrasound-guided HD will begin. To do this, the patient will be placed in a lateral decubitus position on the unaffected arm. The arm to be treated will be positioned at the patient's side without forcing its extension. The joint cavity will then be approached posteriorly, introducing a spinal needle in the ultrasound plane between the humeral cortex and the labrum. The joint cavity will then be confirmed by introducing physiological saline solution and observing its reflux by pushing the plunger. Subsequently, 5 ml of 0.25% anesthetic + 0.5 ml of corticosteroid will be introduced, and the corresponding volume will be completed with saline solution, this case 20 ml."
223558888|NCT02169024|OTHER|Standard individual prenatal care|Standard of care- individual prenatal care
223558889|NCT01562522|OTHER|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
223558890|NCT05440591|DRUG|Dapagliflozin|Dapagliflozin 10mg tablets
223558891|NCT05440591|DRUG|MetFORMIN 500 Mg Oral Tablet|Metformin 500 mg tablets twice daily
223558892|NCT05440591|DRUG|Dapagliflozin / metFORMIN Pill|Combination pill
223558893|NCT01988662|PROCEDURE|Neovascular Age-related Macular Degeneration|Blood measurement
223558894|NCT02543177|PROCEDURE|coronary angiography|
223558895|NCT02543177|PROCEDURE|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
224027059|NCT00762736|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
223558896|NCT02543177|PROCEDURE|prior kidney irrigation|
224027060|NCT01050790|DRUG|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
224027061|NCT04241601|DRUG|Interleukin-2 [IL-2]|Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
224027062|NCT04241601|OTHER|Placebo Dextrose 5% solution|Placebo Comparator: Dextrose 5% solution
223410336|NCT06939530|PROCEDURE|Hydrodilatation (40 ml)|"First, an SSNB will be performed with 4 ml of 0.25% anesthetic + 0.5 ml of corticosteroid in the suprascapular notch.~After 15 minutes of the SSNB, ultrasound-guided HD will begin. To do this, the patient will be placed in a lateral decubitus position on the unaffected arm. The arm to be treated will be positioned at the patient's side without forcing its extension. The joint cavity will then be approached posteriorly, introducing a spinal needle in the ultrasound plane between the humeral cortex and the labrum. The joint cavity will then be confirmed by introducing physiological saline solution and observing its reflux by pushing the plunger. Subsequently, 5 ml of 0.25% anesthetic + 0.5 ml of corticosteroid will be introduced, and the corresponding volume will be completed with saline solution, this case 40 ml."
224027063|NCT02785471|BEHAVIORAL|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
224027064|NCT02785471|BEHAVIORAL|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
224027065|NCT01880528|DRUG|lisinopril|Given PO
224134054|NCT06899139|DEVICE|Repeated Low-Level Red-Light Therapy Intervention Type: Device Description: Participants in the experimental group will receive repeated low-level red-light (R.L.R.L.) therapy twice daily using a no|"Description:~Participants in the experimental group will receive repeated low-level red-light (R.L.R.L.) therapy twice daily using a non-invasive light-emitting device. Each session will last no more than 3 minutes, with a minimum interval of 4 hours between sessions. The therapy is administered under parental supervision and aims to enhance myopia control in conjunction with orthokeratology."
224134055|NCT05803889|OTHER|Cardiac evaluation|In order to obtain information on the body composition of the patients, a body composition measurement will be performed. A resting cardiac echocardiography will be performed to record myocardial deformations in a non-vulnerable way. A non-invasive evaluation of arterial function will be performed by ultrasound on the femoral artery during a standardized passive movement of the leg. An assessment of myocardial deformations will also be performed under submaximal exercise conditions (at a target heart rate of 120 beats per minute, low to moderate exercise intensity). All of these measurements will be performed during evaluation 1 and reproduced in the same way during the 4 other sessions planned during (evaluation 2, 3 and 4) and after the treatment (evaluation 5).
224134056|NCT05803889|OTHER|Cardiac evaluation|The same measurements as the EC + Tax group will be performed but only once, at the end of the treatment.
223410337|NCT06940024|DEVICE|VSP Group|Digital surgical splints were generated using Dolphin software and a Form 3D printer
223410338|NCT06939543|BEHAVIORAL|empathy|physicians' awareness of their health status, empathy towards patients
223410339|NCT00454688|DRUG|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
223410340|NCT00454688|DRUG|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
223410341|NCT00617890|BIOLOGICAL|robatumumab|Robatumumab IV every two weeks until disease progression.
223410342|NCT04357665|PROCEDURE|Bilateral TAPP Repair|laparoscopic transabdominal preperitoneal repair using 2 separate meshes fixed by laparoscopic tackers
223410343|NCT04357665|PROCEDURE|Open PP Repair|Open pre-peritoneal repair using single mesh fixed by sutures
223410344|NCT04357665|PROCEDURE|Bilateral Lichtenstein Repair|Bilateral Lichtenstein Repair using 2 separate meshes fixed by sutures
223410345|NCT03266315|BIOLOGICAL|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
223410346|NCT03266315|OTHER|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
223410347|NCT06045325|DIAGNOSTIC_TEST|Orbscan II|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
223410348|NCT06045325|DIAGNOSTIC_TEST|IOL Master 700|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
223410349|NCT06045325|DIAGNOSTIC_TEST|IOL Master 500|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
223410350|NCT06045325|DIAGNOSTIC_TEST|Atlas 9000|Diagnostic assessment to measure white-to-white.
223410351|NCT06045325|DIAGNOSTIC_TEST|Lenstar 900|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
223410352|NCT06045325|DIAGNOSTIC_TEST|Pentacam|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
223410353|NCT06045325|DIAGNOSTIC_TEST|iTrace|Diagnostic assessment to measure white-to-white and corneal thickness.
223410354|NCT06045325|DIAGNOSTIC_TEST|Argos|Diagnostic assessment to measure anterior chamber depth, white-to-white, and corneal thickness.
223410355|NCT06045325|DIAGNOSTIC_TEST|Manual caliper measurement|Manual diagnostic assessment to measure white-to-white.
223410356|NCT02640950|DEVICE|NeuroStar TMS|Transcranial Magnetic Stimulation
223410357|NCT05066204|OTHER|Sequence of teaching-/learningmethod|see: arm/group descriptions
223410358|NCT01431690|DRUG|warfarin|A single 25 mg dose of warfarin
223410359|NCT01431690|DRUG|omefas|4 x 1 g capsule dose of Epanova®
223410360|NCT01431690|DRUG|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
224027066|NCT01880528|DRUG|placebo|Given PO
224027067|NCT05722574|BEHAVIORAL|Romantic Competence Intervention|Online, 30-minute self-administered relationship competence program for youth ages 16-20
224027068|NCT05722574|BEHAVIORAL|Information Only Control Condition|Online, 30-minute self-administered relationship education activity for youth ages 16-20
224027069|NCT01018303|DIETARY_SUPPLEMENT|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
224134057|NCT06898138|DEVICE|Brain Interchange System|The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research. It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously. In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain. It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
224298036|NCT03231319|PROCEDURE|Fascia iliaca compartment block with IV-PCA|1\. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
224298037|NCT03231319|PROCEDURE|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"1. Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~2. Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
224134058|NCT06898801|OTHER|Just-in-time video training|"A Just-in-time educational video was designed and produced by the investigating team. Content of the video includes;~* Environmental set up and patient positioning~* Equipment preparation including stylet insertion~* Description of internal anatomy of airway~* Suggested instructional language for supervisors~* Example footage of an intubation~* Tips and common pitfalls~* Guidance for intubation assistant on how to perform cricoid pressure"
224134059|NCT07084103|BEHAVIORAL|Psychosocial Support Intervention|Participants in the intervention arm will receive a structured psychosocial support program designed for women diagnosed with fetal anomaly. The program includes individual counseling sessions, stress management techniques, emotional support, and educational materials addressing coping strategies and mental well-being. The intervention will be delivered by trained healthcare professionals over sessions during the prenatal period.
224134060|NCT07082699|OTHER|antegrade enema|Introduce saline at a flow rate of 40 ml/minute through the distal end of the ileostomy. The initial enema volume is approximately 500 ml, with a maximum of 1000 ml. Perform twice weekly for one month.
224134061|NCT07082699|OTHER|retrograde enema|Introduce saline at a flow rate of 40 ml/minute through the anus. The initial enema volume is approximately 500 ml, with a maximum of 1000 ml. Perform twice weekly for one month.
224298038|NCT03231319|PROCEDURE|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
224298039|NCT06881498|PROCEDURE|acute normovolemic hemodilution|The ANH was conducted with more than 8 ml/kg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g/dL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.
224298040|NCT05301530|DRUG|Faceptor|NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.
224298041|NCT05301530|DRUG|Herceptin|Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.
224298042|NCT05301530|DRUG|Docetaxel|The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
224298043|NCT05473819|DRUG|Buffered Local Anesthesia|"Buffered local anesthesia will be administered after being previously prepared just before the injection time.~Buffering Local Anesthetic Solutions Using 8.4% Sodium Bicarbonate in a 19:1 Ratio: Using the REMOVE AND REPLACE hand buffering method~-Under sterile conditions, 0.09 mL of local anesthetic solution will be removed from the cartridge using a 0.5 mL syringe with a 28- gauge, 0.5-inch needle (Kendall Monoject Insulin Syringe \[Tyco Healthcare, tyco.com\] lot number 027501). Using a separate unused syringe, 0.09 mL of the commercially available 8.4% sodium bicarbonate will be removed from the 50 mL vial and immediately injected into the local anesthetic cartridge. The cartridge will be inverted 5 times to mix the solution, and no precipitation will be present."
223410361|NCT05126069|DEVICE|Ab interno gelatin microstent|Ab interno gelatin microstent
223410362|NCT05126069|PROCEDURE|Trabeculectomy|Trabeculectomy
223410363|NCT01304511|DRUG|Orgalutran|
223410364|NCT00904358|DIAGNOSTIC_TEST|cross sectional area|
223410365|NCT00044018|DRUG|CDC-501|
223410366|NCT05809232|OTHER|CARES-guided Group|Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
224134063|NCT07083336|OTHER|CMNT diet|Hypocaloric CMNT diet plan: A diet plan with intermittent use of enriched traditional-Chinese-medicinal-foods CMNT diet
223410367|NCT04244552|BIOLOGICAL|ATRC-101|ATRC-101 is an engineered, fully-human IgG1 antibody derived from a naturally-occurring human antibody.
223410368|NCT04244552|BIOLOGICAL|Pembrolizumab|Pembrolizumab (Keytruda®) is a humanized immunoglobulin G4 monoclonal antibody with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
223558897|NCT05723965|OTHER|As training material for deep learning model.|Using labeled images as training materials for artificial intelligence to develop object detecting model.
224027070|NCT02373943|OTHER|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
224027071|NCT02373943|OTHER|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
224027072|NCT02373943|OTHER|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
224027073|NCT01439360|BIOLOGICAL|Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Intramuscular injection
224027074|NCT01439360|BIOLOGICAL|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
223410369|NCT04244552|DRUG|Pegylated liposomal doxorubicin (PLD)|Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
224298044|NCT05473819|DRUG|Conventional Unbuffered Local Anesthesia|The control group will receive the unbuffered conventional anaesthetic solution
223410370|NCT00154284|DRUG|Everolimus (Certican)|
223410371|NCT00154284|DRUG|Cyclosporine (Neoral)|
223410372|NCT00154284|DRUG|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
223410373|NCT00154284|DRUG|Basiliximab (Simulect)|
223558898|NCT05723965|OTHER|As materials for external validation for the buildup model.|Using the external validation set to evaluate prediction rate and survival outcome.
223558899|NCT04887610|PROCEDURE|Ischemic preconditioning|Four 5-minute cycles of 200 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
224027075|NCT01439360|BIOLOGICAL|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
224027076|NCT01439360|BIOLOGICAL|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
224027077|NCT01439360|BIOLOGICAL|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
224027078|NCT06043167|DIAGNOSTIC_TEST|The predictive value russian rendition the FOUR score.|"It is planned to include at least 200 adult OAR patients and all those transferred to the rehabilitation department for evaluation.~To maintain accounting documentation, an individual registration card is offered for registration. The paper version of the IRC records the age of the patient, the diagnosis according to the International Classification of diseases of the tenth revision (ICD-10), the day of hospital stay and ICU. The level of consciousness is assessed according to the unified interdisciplinary scale of disorders of consciousness, Glasgow Coma Scale (GCS), Full Outline of Unresponsiveness (FOUR) and Richmond Agitation-Sedation Scale (RASS). After each inspection, the data is entered into the electronic version of the IRC."
224027079|NCT01825733|DRUG|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
224027080|NCT01825733|DRUG|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
223410374|NCT03023618|DEVICE|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
223410375|NCT04917003|OTHER|RIC plus EDAS|Patients who are allocated into RIC group will undergo EDAS surgery combined 3-month RIC treatment. The opposite operation will be performed at 3 months after the first operation.
224027081|NCT00484458|DEVICE|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
224027082|NCT00484458|DEVICE|Total Disc Replacement|Total disc
224027083|NCT00345293|BIOLOGICAL|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
224027084|NCT05209763|PROCEDURE|More intensive rehabilitation|Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.
224027085|NCT05209763|DIETARY_SUPPLEMENT|More intensive nutrition|"in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses"
223410376|NCT04917003|OTHER|EDAS|Patients who are allocated into the control group will accept EDAS surgery twice. The second operation will be performed at 3 months after the first operation.
223558900|NCT04887610|PROCEDURE|Ischemic preconditioning control|Four 5-minute cycles of 20 mmHg cuff inflation of the brachial artery, each separated by 5-minutes deflated recovery (i.e. 40 minutes total time)
223558901|NCT04887610|DIETARY_SUPPLEMENT|Low fat meal|Meal containing 1006 calories, 1 g fat, 0.2 g saturated fat, 0 g trans fat, 20 mg cholesterol, 191 g carbohydrates, 60 g protein, 1560 mg sodium
224027086|NCT00297336|DRUG|Topiramate|80 patients with diagnosed with migraine
224027087|NCT06598449|DRUG|fenfluramine|Clear, cherry flavored oral solution
224027088|NCT06598722|DRUG|BCL-2 inhibitors combined with the HyperCVAD regimen|BCL-2 inhibitors combined with the HyperCVAD regimen for newly diagnosed adult T-ALL/LBL
224298045|NCT00016276|DRUG|dexrazoxane hydrochloride|Given IV
224298046|NCT00016276|DRUG|doxorubicin hydrochloride|Given IV
224298047|NCT00016276|DRUG|cyclophosphamide|Given IV
224298048|NCT00016276|DRUG|paclitaxel|Given IV
224298049|NCT00016276|BIOLOGICAL|trastuzumab|Given IV
224298050|NCT00016276|PROCEDURE|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
224298051|NCT00016276|RADIATION|radiation therapy|Undergo radiation therapy
224298052|NCT00016276|DRUG|tamoxifen citrate|Given orally
224027089|NCT06598722|OTHER|Propensity score matching historical data|Propensity score matching was conducted with historical data (matching factors included age, gender, initial LDH levels, and the presence or absence of a large mediastinal mass at diagnosis) to compare the advantages and disadvantages of the experimental regimen with previous induction treatment protocols.
224027090|NCT06605495|COMBINATION_PRODUCT|fumigation with Chinese medicine|Eye fumigation with the Eyesight Eye Therapy,10 minutes once daily for 6 weeks.
224027091|NCT06605495|DRUG|Oral herbal medicine|Patients were identified into the appropriate group according to the individual evidence profile, and the herbal formula under the corresponding evidence profile was taken orally as one dose of 150 ml of water twice a day for 6 weeks.
224027092|NCT06605495|DRUG|Modern Western Medicine|Referring to the Chinese Expert Consensus on Dry Eye: Treatment (2020), this course of treatment totaled 6 weeks.
224027093|NCT03271554|DRUG|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
224027094|NCT05203068|DIAGNOSTIC_TEST|Recombinant tuberculosis allergen (RTA)|Single intradermal application of 0.2 µg/0.1 mL RTA (CFP10-ESAT6) in the middle of the forearm
224027095|NCT02368678|PROCEDURE|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
224134064|NCT07084532|OTHER|Chewing gum|Dry mouth was diagnosed in the initial assessment of diabetic individuals assigned to the intervention group. Following the assessment, they were asked to chew gum for 15 minutes before each main meal for seven days. Dry mouth was re-evaluated with the Xerostomia Scale seven days later.
224134065|NCT07084532|OTHER|Standart therapy group|The control group was informed about the study. They were then assessed for dry mouth. They were asked to follow their standard treatment. They were warned not to chew gum. A day later, dry mouth was assessed again without any treatment.
224134066|NCT07078643|PROCEDURE|Superior Hypogastric Plexus Block (SHPB)|Laparoscopic superior hypogastric plexus block with bupivacaine and lidocaine injection near sacral promontory.
224134067|NCT07078643|PROCEDURE|Erector Spinae Plane Block (ESPB)|Erector spinae plane block with ultrasound-guided injection of bupivacaine and lidocaine at T10 level.
224134068|NCT07084662|DRUG|Xinlikang capsules|Xinlikang capsules after meals, 5 capsules each time, 3 times a day for 12 weeks
224134069|NCT07084662|DRUG|mimic capsules|mimic capsules, 5 capsules each time after meals, 3 times a day for 12 weeks.
224134070|NCT06929754|OTHER|Lip bumper|Lip bumper appliance will be given as intervention to Lip bumper group
224134071|NCT06930326|OTHER|intradermal exosome|The solution was drawn into five 1 mL tuberculin syringes, each fitted to a 30-gauge short needle. Intradermal injections of 0.05 to 0.1 mL per site were administered at approximately 1 cm apart, delivering a total volume of 5 mL per session.
224134072|NCT06930326|OTHER|0.9 % NaCl|The solution was drawn into five 1 mL tuberculin syringes, each fitted to a 30-gauge short needle. Intradermal injections of 0.05 to 0.1 mL per site were administered at approximately 1 cm apart, delivering a total volume of 5 mL per session.
223558902|NCT04887610|DIETARY_SUPPLEMENT|High fat meal|Meal containing 1030 calories, 62 g fat, 23 g saturated fat, 0.5 g trans fat, 445 mg cholesterol, 76 g carbohydrates, 41 g protein, 2080 mg sodium.
224134073|NCT00052169|DRUG|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
223558903|NCT02079831|BEHAVIORAL|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
223558904|NCT02079831|BEHAVIORAL|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
224027096|NCT02368678|PROCEDURE|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
224027097|NCT04541498|OTHER|Impact of air pollution and climate changes|To assess the short- and long- term impact of air pollution and climate changes
224134074|NCT04552535|DRUG|Second line (2L) afatinib|Afatinib
224027098|NCT05396677|DRUG|Acetaminophen|2 x 500 mg acetaminophen (one time)
224027099|NCT05396677|OTHER|Placebo|2 x 500 mg microcrystalline cellulose (one time)
224027100|NCT01428232|OTHER|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
224134075|NCT04552535|DRUG|Second line chemotherapy|Chemotherapy
224134076|NCT05050721|OTHER|CT imaging|clinical, radiological and biochemical parameters associated with disease progression
224134077|NCT06929247|PROCEDURE|Pulpotomy using Neoputty Mineral Trioxide Aggregate|Pulpotomy (Test Group): Removal of coronal pulp followed by Neoputty MTA placement and restoration.
224134078|NCT06929247|PROCEDURE|single visit pulpectomy using metapex|pulpectomy: removal of radicular pulp followed by metapex placement and final restoration
224134079|NCT02808533|DRUG|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
223558905|NCT02079831|BEHAVIORAL|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
223558906|NCT05452031|BEHAVIORAL|Care2Sleep|A multicomponent behavioral sleep program, consisting of sleep hygiene, stimulus control, sleep compression, pleasurable activity, daily walking, and light exposure.
223410377|NCT01090349|DEVICE|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
223410378|NCT01090349|DEVICE|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
223410379|NCT03487627|BEHAVIORAL|Electronic and Care Support Manager Contact|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3 months after discharge. The electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
223410380|NCT03487627|BEHAVIORAL|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the electronic and CSM intervention.
223410381|NCT00566020|DRUG|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
223410382|NCT04959981|DRUG|ERAS-007|Administered orally
223410383|NCT04959981|DRUG|ERAS-601|Administered orally
223410384|NCT04959981|DRUG|Osimertinib|Administered orally
223410385|NCT04959981|DRUG|Sotorasib|Administered orally
223410386|NCT00010010|DRUG|exemestane|
223410387|NCT00010010|DRUG|goserelin acetate|
223410388|NCT02786875|OTHER|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI\<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).
223558907|NCT05452031|BEHAVIORAL|Sleep Education|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
223558908|NCT03503591|DEVICE|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
223558909|NCT01113008|PROCEDURE|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
223558910|NCT01113008|PROCEDURE|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
223558911|NCT01278121|DIETARY_SUPPLEMENT|Diet A|3 days, 6 meals a day
223558912|NCT01278121|DIETARY_SUPPLEMENT|Diet B|10 days, 6 meals a day
223738602|NCT00594997|BEHAVIORAL|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
223738603|NCT01730157|BIOLOGICAL|ipilimumab|Given IV
223738604|NCT01730157|RADIATION|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
223738605|NCT01730157|OTHER|laboratory biomarker analysis|Correlative studies
223738606|NCT00301444|DEVICE|mirror-box treatment|
223738607|NCT00301444|BEHAVIORAL|Mental visualization|
224027101|NCT01428232|OTHER|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
223738608|NCT02834104|DEVICE|RMI|
223738609|NCT02834104|OTHER|myocardial biopsy|
224027102|NCT06419998|PROCEDURE|Group A: Pure transanal endorectal pull-through (TAERPT)|Patients of Group A will be treated totally by pure transanal endorectal pull-through without the assistance of laparoscopy
224027103|NCT06419998|PROCEDURE|Group B: Laparoscopic-assistance endorectal pull-through (LAERPT)|Patients of Group B will be treated transanal endorectal pull-through but with the assistance of laparoscopy
223410389|NCT02786875|OTHER|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, \<7% SFA).
223410390|NCT02786875|BEHAVIORAL|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
223410391|NCT02786875|BEHAVIORAL|Basic physical activity|General recommendations for physical activity
223410392|NCT02786875|DRUG|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
223738610|NCT02834104|BIOLOGICAL|blood sample|
223738611|NCT00245206|DRUG|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
223738612|NCT00245206|DRUG|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
224027104|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
224027105|NCT00790816|DRUG|Lapatinib|Lapatinib monotherapy
223410393|NCT02786875|DRUG|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
223738613|NCT00245206|DRUG|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
223738614|NCT00816075|DRUG|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
224134080|NCT02808533|OTHER|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
223410394|NCT04397016|BEHAVIORAL|Option Grid Decision Aid|-A table with side-by-side comparisons of treatment options organized as responses to patients' frequently asked questions
223410395|NCT05189990|DIAGNOSTIC_TEST|Electrical impedance tomography|Fatty liver patients will be recruited from the Department of Medicine at Queen Mary Hospital. Gender- and age- matched control subjects will be publicly recruited. Subjects will undergo the EIT-liver scan and FibroScan®. Selected subgroups will also undergo MRI-PDFF scan. The performance characteristics of the device and with respect to Fibroscan/ MRI-PDFF for liver fat quantification will be assessed.
224134081|NCT04095286|DRUG|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
223410396|NCT01722825|DRUG|LY2157299|Administered orally.
223410397|NCT02582242|DRUG|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
223410398|NCT05182710|BEHAVIORAL|Stress Inoculation Training|"The SIT programme/intervention will involve~1. 30 minute educational phase of preparatory information to allow participants to conceptualise the types of stressors they are likely to face and the role of stress on performance~2. 30 minutes of skills acquisition which will involve discussion of and teaching participants techniques to reduce stress in simulated resuscitation events~3. Inoculation through the application of acquired skills in 1-2 resuscitation scenarios"
223410399|NCT05182710|BEHAVIORAL|Alternative Training|"1. 30 minutes of teaching on management of a drowning patient (in order that both control and intervention perceive they have had teaching of the same length as the other group)~2. 1-2 resuscitation simulation events (same scenario and tasks as in the intervention group)"
223410400|NCT05330819|OTHER|Non-interventional|Blood thrombogenicity in patients with previous history of myocardial infarction will be studied using Badimon perfusion chamber, SEM and TEG.
223410401|NCT02101736|DRUG|Cabozantinib|This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 24 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, for Cohort A, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. For Cohort B, the criteria that subjects who do not achieve 15% reduction by 8 cycles are considered treatment failure and taken off study was eliminated. Subjects will be carefully monitored for toxicities associated with cabozantinib.
223410402|NCT00942591|DRUG|Interferon beta 1b|
223410403|NCT00942591|DRUG|Atorvastatin|
223410404|NCT05048381|DIAGNOSTIC_TEST|Next Generation Sequencing|Next Generation Sequencing of sweat and whole blood samples for non-coding miRNAs to define biomarkers that enable to differentiate between patients with active tuberculosis, a differential diagnostic disease and healthy individuals.
223410405|NCT00459290|DRUG|mifepristone|
223410406|NCT05532852|DRUG|standard-of-care plus Paxlovid|standard-of-care plus Paxlovid
224134082|NCT04095286|DRUG|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
223558913|NCT04654624|DRUG|SDF|Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
223738615|NCT02763852|DRUG|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
224134083|NCT06392256|PROCEDURE|Non surgical therapy|Non-surgical submarginal instrumentation using titanium curettes with saline irrigation will be done once in the treatment session.
224134084|NCT06392256|PROCEDURE|Free gingival Grafting|In the PM-NS-FGG group, soft tissue augmentation using a free gingival graft will be performed.
223738616|NCT02763852|DRUG|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
224134085|NCT02310633|BEHAVIORAL|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
224134086|NCT02310633|BEHAVIORAL|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
223410407|NCT05532852|DRUG|standard-of-care|standard-of-care
223410408|NCT04520750|DRUG|PTX-022|Safety and Efficacy of PTX-022 in the Treatment of Adults with Pachyonychia Congenita
223410409|NCT06683300|DRUG|DAPT for 3 months after vertebral artery stenting|After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
223410410|NCT02228733|DRUG|KBP-5074|Comparisons of different doses of study drug
223410411|NCT04731090|DRUG|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.|IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
223410412|NCT04731090|OTHER|Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths|Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
223410413|NCT01598493|DEVICE|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
223410414|NCT01598493|DRUG|Flamazine|Silver sulfadiazine cream
223410415|NCT03648320|OTHER|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
223410416|NCT02321657|OTHER|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
223558914|NCT04654624|DRUG|ART|Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
223558915|NCT02086487|DRUG|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)"
223558916|NCT01904474|OTHER|Next.Step - e-therapeutic intervention program|
224027106|NCT00790816|DRUG|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
224027107|NCT06729853|DRUG|SAP-001|a single oral dose of SAP-001
224027108|NCT06729203|DEVICE|Ultrasound cavitation|Ultrasound Fat Cavitation (USFC) is the method in handling obesity, especially in destroying fat and shaping a particular part of the body. As one of the non-surgical correction methods, USFC is preferred at decreasing the risk of complications due to obesity.
224027109|NCT06729203|OTHER|Exercise|The female will stand on the cushioned tread and grasp by her both hands the two arms of the treadmill. Treadmill will adjust to apply moderate intensity training. It was used for 30 minutes divided into five-minutes warming up, twenty-minutes active exercise and five-minutes cooling down and it was used twice a week for twelve weeks.
224027110|NCT06728943|PROCEDURE|ureteral dilatation|Direct semi-rigid ureteroscopy will initially be attempted without endodilatation (KARL STORZ, 43 cm, 6°, 7 Fr.). On failure to advance the semi-rigid ureteroscope through the ureter, intra-ureteric instillation of 20 ml of aminophylline (250 mg/10 mL) through ureteric stent and another trial to pass the same scope will be done after 10 minutes of intra-ureteral aminophylline instillation.
224134087|NCT02310633|BEHAVIORAL|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
224134088|NCT04848454|DRUG|Camrelizumab with vinorelbine and cisplatin|Camrelizumab: 200mg iv., every 3 weeks(one cycle), for 1 year(17cycles in total); Vinorelbine: 25mg/m2 day 1, 8 iv. or 60-80 mg/m2 or. day1, 8, every 3 weeks(one cycle), for 6 cycles; Cisplatin: 75mg/m2 (divided into 2 days), every 3 weeks(onr cycle), for 6 cycles.
223558917|NCT01904474|OTHER|Standard treatment protocol|
223558918|NCT06451692|OTHER|Clinical pharmacist|The clinical pharmacist calls the patients' GP 90 days after discharge for follow-up
223558919|NCT02907983|DRUG|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
224134089|NCT04092816|BEHAVIORAL|FAMILY Intervention|The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
224298053|NCT00016276|OTHER|laboratory biomarker analysis|Correlative studies
224298054|NCT01696136|DEVICE|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
223410417|NCT02321657|OTHER|Toys, books and games|Games, books and toys used to distract
223410418|NCT00392340|BIOLOGICAL|filgrastim|
223410419|NCT00392340|DRUG|doxorubicin hydrochloride|
223738617|NCT02763852|DRUG|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
223738618|NCT05703399|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
224027111|NCT06729281|DEVICE|kinesio tape|The application of kinesio tape is a relatively new method, first developed in 1973 by Kenzo Kase in Japan, also known as elastic bandage, which has become popular in the last 10 years following announcements at major events such as the Olympic Games.
224027112|NCT06728969|DEVICE|MT1 Auditory startle response patterns analysis algorithm|Objective measurements of attention and inhibition.
224027113|NCT06728969|DEVICE|T.O.V.A. Continuous Performance Test|Objective measurements of attention and inhibitory control.
224027114|NCT02721173|DRUG|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
224027115|NCT02721173|DRUG|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
224298055|NCT06716879|DRUG|Donzakimig|Drug: Donzakimig Pharmaceutical form: Subcutaneous solution
223410420|NCT00392340|DRUG|topotecan hydrochloride|
223410421|NCT00392340|DRUG|vincristine sulfate|
223410422|NCT00725153|DEVICE|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
223410423|NCT00725153|DEVICE|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
223410424|NCT01580605|DRUG|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
223410425|NCT02792712|DRUG|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
224027116|NCT06727591|PROCEDURE|Split Bone Block Technique|An intraoral crestal incision with/out vertical arms was performed on alveolar ridge using blade no.15. After flap reflection, patroning the defect to help guide the area to be grafted from the donor site. At the chin area (donor site) unicortical cuts will be made at least 5 mm inferior to root tips, 5 mm superior to inferior border of mandible and 5 mm away from the mental foramen. The graft was luxated and split into two bone shells each 1 \~ 2 mm in thickness using disc. The bone shells and the donor site were scrapped for autogenous graft particles. Decortication of the recipient site. The graft was stabilised into the recipient site using two or more self tapping titanium screws placed midway corono-apical in the bone shell following the ridge contour. The autogenous particles were packed into the space between the split bone block and the ridge. Collagen sponge was used to cover the donor site. After 4 months the site was approached for implant placement using crestal incision
224027117|NCT06729411|DEVICE|Minimal Offloading dressing|Metatarsal minimal offloading dressings (MODs) are standard offloading devices that are gaining attention. MODs offload a specific ulcerated area and could reduce variability when applying the device onto the skin. MODs are new predesigned devices that do not require any further adaptation or clinician skills and can be directly applied to an ulcerated metatarsal head using a non-irritating adhesive.
223410426|NCT02792712|DRUG|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
223410427|NCT06409481|DRUG|Antineoplastic Agents|small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
224027118|NCT06729411|DEVICE|Felted foam|The felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.
224027119|NCT06728371|DRUG|Methadone|0.2mg/kg intravenous methadone given at induction
224027120|NCT06728371|DRUG|Morphine|0.2mg/kg intravenous morphine given at induction
224027121|NCT04415983|DRUG|Nitazoxanide|Nitazoxanide twice daily
224027122|NCT04415983|DRUG|Clarithromycin|Klacid twice daily
224027123|NCT04415983|DRUG|Metronidazole|Metronidazole twice daily
223410428|NCT03742518|DRUG|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
224027124|NCT04415983|DRUG|Proton pump inhibitor|Omeprazoe twice daily
224027125|NCT00904046|DRUG|Pioglitazone|30 mg orally daily for 6 months
224027126|NCT00904046|DRUG|Placebo|Placebo taken orally once a day for 6 months.
223410429|NCT03742518|DRUG|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
223410430|NCT03742518|DRUG|Topical vehicle solution|Vehicle solution application will be performed by the individual subject at approximately the same time each day.
223410431|NCT04557579|PROCEDURE|Clear corneal phacoemulsification and IOL implantation|Clear corneal phacoemulsification and IOL implantation were performed by 2 surgeons (Chao-Kai Chang and Hung-Yuan Lin) by using an identical technique to minimize differences in surgically induced aberrations between groups. The surgical process involved topical anesthesia, a 3-step clear corneal incision (2.75 mm) at 180° (temporal in both eyes), a 5.0-mm continuous curvilinear capsulorhexis, phacoemulsification using the stop-and-chop technique, IOL implantation with an injector, IOL centration, and a sutureless incision. The study IOL models include EDOF Symfony IOL (AMO, Santa Ana, CA, USA), bifocal Restor +2.5D IOL (Alcon, Fort Worth, TX, USA), and monofocal Sensar AR40e IOL (AMO, Santa Ana, CA, USA).
224027127|NCT03503058|BIOLOGICAL|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
224027128|NCT03503058|BIOLOGICAL|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|"Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis~Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on PfSPZ-CVac Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of PfSPZ Challenge."
224027129|NCT03503058|OTHER|Normal Saline|0.9% Sodium chloride
223410432|NCT02124200|DEVICE|EGO/CE4, 9mg nicotine|
223738619|NCT05703399|OTHER|Questionnaire Administration|Complete questionnaire
223738620|NCT06466278|DRUG|Icosapent ethyl|2dd2
223738621|NCT06466278|DRUG|Placebo|2dd2
224134090|NCT01124201|OTHER|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
224134091|NCT02307539|PROCEDURE|Psychosocial Assessment and Care|Undergo PCPI
224134092|NCT02307539|OTHER|Palliative Therapy|Undergo PCPI
224134093|NCT02307539|OTHER|Quality-of-Life Assessment|Undergo QOL assessment
224134094|NCT02307539|OTHER|Questionnaire Administration|Undergo questionnaire administration
224134095|NCT04982510|DEVICE|complete denture|3D printed complete denture
224134096|NCT04377334|BIOLOGICAL|MSC|infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells
224134097|NCT05025735|DRUG|Dapagliflozin 10Mg Tab|"Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib."
224134098|NCT01374763|DRUG|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
223410433|NCT04399018|OTHER|Diagnostic Test: Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection.~Blood sample will be stained according to the manufacturers' recommendations with a lyophilized cocktail (LyotubeTM ready-to-use, BD Bioscience).~At least 10,000 neutrophils will be acquired on a 3-laser, 8-color BD FACSCanto-II TM flow cytometer (BD Biosciences, San José, CA).~Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
224027130|NCT03503058|DRUG|Chloroquine chemoprophylaxis alone|"Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS."
224027131|NCT00061529|DRUG|Brimonidine Tartrate Ophthalmic Solution|
224027132|NCT01422226|DRUG|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
223410434|NCT03070600|OTHER|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
223410435|NCT03070600|OTHER|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~1. Risk Score \>6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~2. participant declines partner self-tests regardless of partner HIV status, and/or~3. their partner declines self-testing or tests positive."
223410436|NCT05729789|BEHAVIORAL|Group Written Exposure Therapy|Group Written Exposure Therapy (GWET) is a brief cognitive behavioural therapy for PTSD aimed at allowing patients to process their traumatic experiences in a safe environment. GWET will consist of 6 group sessions (1 orientation session and 5 weekly group sessions). Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
223410437|NCT04005404|DRUG|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
223558920|NCT02907983|DRUG|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
223558921|NCT06423495|DEVICE|low-intensity laser treatment|The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.
224027133|NCT01422226|OTHER|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
224027134|NCT05916573|DRUG|HSK16149|single oral adminiatration, 20mg
224027135|NCT04674670|DRUG|Bromocriptine Mesylate Capsules|Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
224027136|NCT04674670|DRUG|Amisulpride 400 MG|Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
224134099|NCT01374763|DRUG|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
224134100|NCT01734980|PROCEDURE|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
224134101|NCT02115113|DRUG|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
224027137|NCT04674670|DRUG|Placebo|Healthy controls and fibromyalgia patients will be administered a placebo as for comparison with the effects of bromocriptine (healthy controls and patients) and amisulpride (healthy controls only) on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
224027138|NCT02961296|OTHER|No intervention|No intervention will be needed.
224027139|NCT02037841|OTHER|Nursing-driven clinical pathway for management of inpatient asthma|
224027140|NCT06963801|BEHAVIORAL|Moms2B|An established group-based pregnancy program focusing on improving nutrition, social, and medical support.
224134102|NCT02115113|DRUG|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
224134103|NCT04389398|DEVICE|pocket compression fixation belt|Pocket compression fixation belt to is used to compress the postoperative wounds of CIEDS patients, and its effect of preventing hematoma is evaluated.
224134104|NCT01011036|DRUG|clobazam|test substance
224134105|NCT01011036|DRUG|clonazepam|positive control
224134106|NCT01011036|DRUG|tolterodine|active placebo
224134107|NCT04824417|DRUG|Itraconazole 200 mg|Control
224027141|NCT06963801|BEHAVIORAL|DBT-P|An emotional skills group where emotion regulation skills are taught in the context of the pregnancy and expected life with an infant.
223410438|NCT04005404|DRUG|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
223410439|NCT04005404|DRUG|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
223410440|NCT02176655|DRUG|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
223410441|NCT02176655|DRUG|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
223410442|NCT06012396|BEHAVIORAL|Stoke complex exercise program|"1. warm-up(5min) flexibility exercise - neck, triceps brachii, biceps brachii, forearm, back, quadriceps, biceps femoris, ankle~2. main exercise(40min) aerobic exercise(20min)- use stepper, treadmill, high intensity HRR60%, RPE 11\~14 low intensity HRR30%, RPE 9\~11 repeated interval training strength and balance exercises(20min)- program1. upper(shoulder press, chest press, biceps curl), lower(hip flexion, knee extension), Core(plank exercise, sit up) program2. upper(seated back row, triceps extension), lower(hip extension, hip abduction, knee flexion, Core(superman exercise, bridge exercise) repeated ever other day program1, program2 clean-up(5min) - same as warm-up"
223410443|NCT06162949|DRUG|Vonoprazan|an acid suppressor therapy that inhibits the H+, K+-ATPase enzyme system in a potassium-competitive manner.
223410444|NCT06162949|DRUG|Amoxicillin|An antibiotic of penicillins antibiotic group
223410445|NCT06162949|DRUG|Clarithromycin|An antibiotic of macrolide group
223410446|NCT06162949|DRUG|Esomeprazole|An acid suppressor therapy that blocks the proton pump.
223558922|NCT02542033|OTHER|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
224027142|NCT00873353|DRUG|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
224027143|NCT03270904|DEVICE|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
224027144|NCT04856644|DRUG|4-month rifapentine-based regimen|8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin
224027145|NCT06434376|BIOLOGICAL|Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology|Blood samples were collected for MRD detection within one month (week 3) after colorectal cancer surgery, and MRD-positive patients were selected for routine chemotherapy (course of 6 months). Blood and tumor tissue samples of enrolled patients were collected, and relevant clinical data were recorded. The whole exon and expression profile of surgical tumor tissue samples were sequenced, neoantigens were analyzed, and immunomodulators were prepared. After the preparation of individualized immunomodulators, combined treatment was performed simultaneously with chemotherapy. During the treatment process, patients' response to treatment and survival were observed, and tumor load, ctDNA changes, imaging and other indicators before and after treatment were compared. To evaluate the efficacy of immunotherapy.
224027146|NCT01438684|DRUG|RPh201|400 microliter s.c. twice a week for 3 months
224027147|NCT01438684|DRUG|Saline|400 microliter Saline solution s.c. twice a week for 3 months
223410447|NCT02233387|OTHER|injection with [18F] HX4 and PET imaging|"A standard clinical \[18F\]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline \[18F\]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) \[18F\]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of \[18F\]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i"
223410448|NCT02659007|OTHER|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
223410449|NCT02309476|DEVICE|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
223410450|NCT02309476|DEVICE|PASCAL Laser, Green Laser 1|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
223410451|NCT02309476|DEVICE|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
223410452|NCT02309476|DEVICE|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
224027148|NCT00213291|DRUG|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
224134108|NCT04824417|DRUG|Voriconazole 200mg|Comparator
224134109|NCT01967524|DRUG|botulinum toxin A + ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
224134110|NCT01967524|DRUG|Ropivacaïne|"D0 :~* Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~* QDSA (Saint-Antoine pain questionnaire)~* QCD (Pain Questionnaire)~* MPI (Multidimensional Pain Inventory)~* Beck scale~* HAD (Hospital Anxiety and Depression scale)~* SF36 (Short Form 36)~* injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
224134111|NCT00148850|DRUG|Pioglitazone|
224134112|NCT00109304|BIOLOGICAL|VEE 3526|
224134113|NCT01208701|DRUG|Atorvastatin|Zarator, 80 mg pr day for 5 days
224134114|NCT01208701|DRUG|Unikalk|1 tablet Unikalk pr day for 5 days
224134115|NCT01512147|OTHER|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
224134116|NCT04083898|BIOLOGICAL|Isatuximab|Isatuximab will be administered on a 28-day cycle
224134117|NCT04083898|DRUG|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
224134118|NCT04083898|DRUG|Prednisone|Prednisone will be administered on a 28-day cycle as follows
224134119|NCT04470128|DRUG|Stage I: HSK21542 0.5 μg/kg|intravenous injection
224134120|NCT04470128|DRUG|Stage I: HSK21542 1 μg/kg|intravenous injection
224134121|NCT04470128|DRUG|HSK21542 0.5 μg/kg|intravenous injection
224134122|NCT04470128|DRUG|HSK21542 1 μg/kg|intravenous injection
224027149|NCT03141008|OTHER|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
224134123|NCT04470128|DRUG|HSK21542 2 μg/kg|intravenous injection
224027150|NCT00491777|DEVICE|Noninvasive Hemodynamic Patient Monitor|
224027151|NCT04677868|DRUG|Methotrexate|Methylprednisolone 1 mg/kg/day MTX (10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II;
224134124|NCT04470128|DRUG|Placebo|intravenous injection
224134125|NCT00609453|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
224134126|NCT00247260|DEVICE|32P BioSilicon|
224027152|NCT05391477|DEVICE|GI-Genius artificial intelligence|The software allows for the real-time characterization of framed polyps during a colonoscopy classifying them on adenoma or non-adenoma.
224134127|NCT02395653|DRUG|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
224134128|NCT00040014|DRUG|exemestane|
224134129|NCT02469532|DEVICE|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
224134130|NCT02469532|DEVICE|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
224134131|NCT01757756|DRUG|Pf-05175157|200-mg administered twice daily for 14 days
224134132|NCT01757756|DRUG|placebo|placebo administered twice daily for 14 days
224134133|NCT01757756|DRUG|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
224298056|NCT06716879|DRUG|Placebo|Drug: Placebo Pharmaceutical form: Subcutaneous solution
223410453|NCT02309476|DEVICE|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
223410454|NCT02309476|DEVICE|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
224027153|NCT00425984|PROCEDURE|Adult male circumcision|
224027154|NCT01786174|DRUG|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
224027155|NCT01786174|OTHER|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
224027156|NCT02315352|DRUG|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
224027157|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
224027158|NCT02315352|DRUG|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
224134134|NCT00234819|DRUG|Bazedoxifene/Conjugated Estrogen|
224134135|NCT02453438|OTHER|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
224134136|NCT00483158|DRUG|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
224134137|NCT03736629|DRUG|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
224134138|NCT03736629|DRUG|Placebo|Placebo
224027159|NCT02315352|DRUG|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
224027160|NCT02315352|DRUG|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
224027161|NCT04712331|OTHER|Graduated abdominal strengthening exercises|"Graduated abdominal strengthening exercises~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors)."
224027162|NCT04712331|DEVICE|The Russian current stimulation|The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation.
224134139|NCT06293677|DRUG|Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 40 mg/kg q6 h eGFR 150-199 : 30 mg/kg q4h eGFR 200-299 : 40 mg/kg q4h eGFR \&amp;gt;/= 300 : 40 mg/kg q4h~Piperacillin-tazobatam dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR 120-149 : 150 mg/kg q6 h eGFR 150-199 : 120 mg/kg q4h eGFR 200-299 : 150 mg/kg q4h eGFR \&amp;gt;/= 300 : 180 mg/kg q4h~The maximum doses for the antibiotic prescription before the first drug monitoring will be 2gr of MER every 4 hours and 4gr of PIP every 4 hours.~The duration of infusion will be set to 2 h."
223410455|NCT05022940|OTHER|Usual gold-standard multidisciplinary rehabilitation for TBI|In individual and group interventions within a holistic interdisciplinary rehabilitation program focusing on resumption of daily activities and social roles. Interventions could include physiotherapy or physical training, occupational therapy, speech therapy, and neuropsychology/psychology, which aimed at reducing the impacts of cognitive difficulties in daily life by using self-guided and environmental strategies.
223410456|NCT00746889|DRUG|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
223410457|NCT00746889|DRUG|saline|Single intraarticular injection of 1 ml of 0.9% saline
223410458|NCT00326274|DRUG|Helioblock® SX Cream|
224027163|NCT04712331|OTHER|Combination Product: Graduated abdominal strengthening exercises and the Russian current stimulation|"Graduated abdominal strengthening exercises and the Russian current stimulation~In this study the following equipments will be used to achieve treatment approaches:~Exercise mat and inflatable Swiss ball 55 cm \& 65 cm diameter. Wall bar, wedges, elastic tubing (Thera-band) with resistance ranges from light to very heavy (yellow, red, blue, green, and gray colors).~The Russian current is used for enhancing muscle; the muscular fiber by the electric stimulation."
224027164|NCT03569657|BEHAVIORAL|A positive psychology workshop|Group workshop
224027165|NCT02634957|BEHAVIORAL|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
224027166|NCT01008293|DRUG|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
224027167|NCT01008293|DRUG|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
224027168|NCT04162613|OTHER|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
224027169|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
224027170|NCT03815032|DEVICE|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
224027171|NCT00515320|DRUG|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
224027172|NCT00515320|DRUG|Placebo|Oral dispersible tablet placebo
224134140|NCT06293677|DRUG|Standard dosages of piperacillin-tazobactam or meropenem|"Meropenem dosages according to eGFR \[mL/min/1.73 m²\] :~eGFR\> 50 : 40mg/kg q8h eGFR 25-49 : 40mg/kg q12h eGFR 15-24 : 20mg/kg q12h~Piperacillin-tazobactam :~eGFR \>50 : 100mg/kg q6h eGFR 20-49 : 50mg/kg q6h eGFR 15-29 : 50 mg/kg q8h"
224134141|NCT03522194|DRUG|Sevoflurane|Anesthesia maintenance with Sevoflurane
224134142|NCT03522194|DRUG|Propofol|Anesthesia maintenance with Propofol
224027173|NCT02867293|PROCEDURE|ultrasound guided ascitic fluid drainage|
224027174|NCT02867293|PROCEDURE|operative drainage of ascites through small skin incision after induction of anesthesia|
223410459|NCT03095326|DIETARY_SUPPLEMENT|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
224027175|NCT02867293|DEVICE|ultrasound|
224027176|NCT00211497|DRUG|MBI 226 Acne Solutions|
223410460|NCT03095326|DRUG|Sucrose|Placebo of sucrose syrup
223410461|NCT03095326|BIOLOGICAL|PCV Vaccine|Pneumococcal conjugate vaccine
223410462|NCT03095326|BIOLOGICAL|PPV Vaccine|Pneumococcal polysaccharide vaccine
223410463|NCT06272539|PROCEDURE|Exercise|The exercise The exercise will be adapted according to the phases based on the results already published, limiting in each phase the degrees of flexion and extension of the spine in order to avoid the risk of electrode migration.
224027177|NCT05276609|DRUG|HS-20093 (Phase Ia: Dose escalation)|Intravenous (IV) administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
224027178|NCT05276609|DRUG|HS-20093 (Phase Ib: Dose expansion)|IV administration of HS-20093 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
224027179|NCT06132126|DRUG|LY3938577|Administered SC.
224027180|NCT06132126|DRUG|Placebo|Administered SC.
224027181|NCT06132126|DRUG|Insulin degludec|Administered SC.
224027182|NCT04389736|BEHAVIORAL|Sitting|Participants sat in a chair with back, arms and legs supported.
224027183|NCT04389736|BEHAVIORAL|Standing|Participants were asked to stand with arms supported and feet spaced approximately 15 cm apart. If needed, adjustment of standing posture was allowed during standing trial to prevent orthostatic hypotension.
224027184|NCT04389736|BEHAVIORAL|Self-selected maximal intensity of neuromuscular electrical stimulation|Small electrodes placed (5\*5 cm) on the lower limb of both legs. The instruction for NMES intensity was that the maximal intensity participants were be able to withstand for 2 hours whilst imagining sitting at home watching TV without feeling discomfort.
224027185|NCT01778660|OTHER|Type of Counselling (Mnemonic)|
224027186|NCT01778660|OTHER|Standard|
224134143|NCT00003809|BIOLOGICAL|cetuximab|
224134144|NCT00003809|DRUG|cisplatin|
224134145|NCT03700788|DRUG|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
223410464|NCT06272539|PROCEDURE|Spinal Cord Stimulation|Spinal cord stimulation (SCS) involves an implantable pulse generator with the potential for enhanced therapeutic success through stimulation algorithms and parameters (28). Spinal cord stimulation (SCS) targeting distal areas, such as the dorsal root ganglion, may offer greater anatomical specificity in therapy
223410465|NCT06573463|DEVICE|Prefabricated band and loop|Prefabricated space maintainer requires only one visit as it fits into the patient's mouth at the clinic without needing the dental lab. It comes in a kit with different band sizes.
223558923|NCT02542033|OTHER|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
223558924|NCT04052789|OTHER|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
224134146|NCT03700788|DRUG|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
224134147|NCT02345824|DRUG|Ribociclib|CDK4/6 INHIBITOR
224027187|NCT02042612|DRUG|Sedation with sevoflurane during 48-hr in ICU|
223410466|NCT06573463|DEVICE|Conventional Band and loop|Conventional band and loop is the most widely used space maintainer, It shows high success rate and good patient compliance, but needs more than one visit due to the laboratory work.
223410467|NCT00002202|DRUG|Indinavir sulfate|
223410468|NCT00002202|DRUG|Amprenavir|
223410469|NCT02182115|DRUG|antiseptic bundle|"1. Chlorhexidine gluconate liquid soap for bathing daily.~2. Chlorhexidine gluconate mouthrinse to use twice daily.~3. Nasal mupirocin to apply twice daily."
223410470|NCT02182115|DRUG|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
223410471|NCT01464593|DRUG|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
223410472|NCT01464593|OTHER|5% Dextrose Solution|Single 30 minute intravenous infusion
223410473|NCT01464593|DRUG|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
224027188|NCT00077220|DRUG|carboplatin|
224027189|NCT00077220|DRUG|paclitaxel|
224027190|NCT00077220|PROCEDURE|adjuvant therapy|
224027191|NCT00077220|RADIATION|radiation therapy|
224027192|NCT03714932|DIAGNOSTIC_TEST|3shape ortho analyzer software|Arch analysis , manual analysis , digital analysis , Mixed dentition , Tanaka and Johnston
224134148|NCT00296725|DRUG|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day \*All increases only if tolerated.
224134149|NCT00296725|DRUG|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. \*All increases only if tolerated.
224134150|NCT02622724|DRUG|Interferon beta-1a|Investigational drug
224027193|NCT02296970|PROCEDURE|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
224027194|NCT04281004|BIOLOGICAL|Amniotic Fluid (AFED)|One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days
224027195|NCT04281004|OTHER|Saline Solution|One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
224027196|NCT03628898|DEVICE|INVSENSOR00025|Noninvasive pulse oximeter sensor
224027197|NCT02137720|BEHAVIORAL|Telephonic Diabetes Self-Management Support|
224027198|NCT02137720|OTHER|Educational Print Materials|
224134151|NCT02622724|DRUG|Placebo|Placebo for investigational drug
224134152|NCT05098548|PROCEDURE|angioplasty|using a balloon to stretch open a narrowed or blocked artery. However, most modern angioplasty procedures also involve inserting a short wire-mesh tube, called a stent, into the artery during the procedure. The stent is left in place permanently to allow blood to flow more freely .
224134153|NCT04367025|DRUG|Camrelizumab|Camrelizumab: 200mg,iv drip for 1h,d1,q3w
224134154|NCT04367025|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;
224134155|NCT04367025|DRUG|S1|S-1:40\~60mg Bid, d1\~14, q3w;
223410474|NCT02148978|DRUG|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
223410475|NCT04319263|DRUG|induction regimen of intravesical BCG|intravesical instillation of 6 weekly doses of BCG
223410476|NCT05688839|DRUG|Jaktinib hydrochloride tablets|2 doses per day, 100mg Jaktinib
223410477|NCT05688839|DRUG|placebo|2 doses per day, placebo
223410478|NCT06485050|COMBINATION_PRODUCT|Photodynamic therapy|"Application of red laser-photodynamic therapy using Rapid Podia Laser diode® (MEDENCY). The following protocol will be followed: 1) mechanical debridement of the nail, 2) disinfection of the nail with alcohol, 3) application of topical photosensitiser (Toluidine blue gel) for 5 minutes with the area covered, 5) application of 635 nm diode laser for 10 minutes.~Daily application of ciclopirox 8% with ethyl acetate, ethanol (96%), ketosteryl alcohol, hydroxypropyl chitosan and purified water."
223558925|NCT00712036|BEHAVIORAL|Interim|Methadone maintenance with emergency counseling only for up to 4 months
223558926|NCT00712036|BEHAVIORAL|Comprehensive|Methadone treatment with counseling as usual
223558927|NCT00712036|BEHAVIORAL|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
224027199|NCT05149430|OTHER|Observational Quality of life and functional capacity|Observational Quality of life and functional capacity
224027200|NCT00450060|DEVICE|lumbar puncture with Quincke-design needles|
224027201|NCT00450060|DEVICE|lumbar puncture with Sprotte-design needles|
224027202|NCT04040816|DRUG|SAP-001|SAP-001 or placebo treatment in a 4:1 randomization ratio
224027203|NCT00793000|DRUG|PF-04287881|75 mg oral dose (prepared solution) given once
224027204|NCT00793000|DRUG|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
224027205|NCT00793000|DRUG|PF-04287881|150 mg oral dose (prepared solution) given once
224027206|NCT00793000|DRUG|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
224027207|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
224134156|NCT04745286|DRUG|S-ketamine|Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Agent preparation method of S-ketamine group (Group S): Draw the dosage of S-ketamine 0.25mg ·kg -1 and dilute it with normal saline to 5ml in opaque 5-ml syringes.
224027208|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
224027209|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
224027210|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
224027211|NCT00793000|DRUG|PF-04287881|1000 mg oral dose (prepared solution) given once
224027212|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
224134157|NCT04745286|DRUG|normal saline group|"Patients will receive the label-covered trial agent covered by the label after premedication 5 min before induction. Normal saline group (Group N): 5ml of normal saline, labeled as study agents."
224134158|NCT05734326|DEVICE|Ultrasound elastography|ultrasound elastography (USE) is emerging as a promising additional tool to discern malignant thyroid nodules, allowing increased diagnostic accuracy, Due to its ability to assess stiffness as an indicator of malignancy, USE has recently become an additional tool for thyroid nodule differentiation, in combination with conventional US and FNA \[18\].
224134159|NCT05478330|DRUG|Flutamide 1% gel|Group A: Flutamide-treated patients: Consisted of 25 patients with acne vulgaris treated with 1% Flutamide topical gel on the face two times per day for a duration of 8 weeks.
223410479|NCT04596410|RADIATION|LLLT applied every other day|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied every other day
223410480|NCT04596410|RADIATION|LLLT applied daily|Low-level laser therapy (LLLT) protocol combining red and infrared wavelengths applied daily
223410481|NCT02888041|DRUG|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
223410482|NCT02888041|DRUG|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
223410483|NCT05540847|PROCEDURE|Interfascial Injection|Interfascial Injection on Ultrasound-guided Obturator Nerve Block
223410484|NCT05540847|PROCEDURE|Subpectineal Injection|Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
223410485|NCT04277364|DIETARY_SUPPLEMENT|phosphatidic acid supplementation|The total daily doses will be distributed in 3 individual doses: in the group that will ingest 750mg per day, the individual doses will be 250mg, while in the group that will ingest 375mg per day, the individual doses will be 125mg. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
223558928|NCT01734954|PROCEDURE|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
224027213|NCT00793000|DRUG|PF-04287881|1250 mg oral dose (prepared solution) given once
224027214|NCT00793000|DRUG|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
224027215|NCT00793000|DRUG|PF-04287881|1500 mg oral dose (prepared solution) given once
224027216|NCT00793000|DRUG|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
224027217|NCT00793000|DRUG|PF-04287881|300 mg oral dose (prepared solution) given once
224027218|NCT00793000|DRUG|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
224027219|NCT00793000|DRUG|PF-04287881|750 mg oral dose (prepared solution) given once
224027220|NCT00793000|DRUG|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
224027221|NCT00793000|DRUG|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
224027222|NCT00793000|DRUG|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
223410486|NCT04277364|OTHER|Placebo (corn starch supplementation)|Three individual doses of corn starch will be consumed per day. The capsules should be consumed at breakfast, 30 minutes before each training session (or at lunch, on days when there is no training) and at dinner.
223558929|NCT01734954|PROCEDURE|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
223558930|NCT01734954|DRUG|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
223558931|NCT01734954|DEVICE|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
223558932|NCT01734954|DEVICE|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
223558933|NCT01734954|DRUG|supplemental oxygen|supplemental oxygen during the block and/or during surgery
223558934|NCT01734954|DRUG|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
224027223|NCT04648735|OTHER|driving evaluation and practice|"The participants completed the actual driving with a licensed driving instructor on the passenger side in the car and with a dual-control, automatic-transmission car.~Each participant completed three runs of the same route. The first twos were practices to familiarize themselves with the course. The driving instructor graded them on the third run. Each trial took about 10 minutes. The participants were scored according to governmental driver test guidelines. Scoring on individual driving maneuver is weighted. Depending on the type of error, 8, 16 or 32 points were deducted from 100, for example, 32 points for getting too close to pedestrian lane, running a red light or railroad crossing, and 8 points for stopping in S-curve forward and backward. 70 or above is considered as a pass. The occupational therapists in the backseat recorded driving behaviors, including whether the driver checked rear and side mirrors, excessive sweating, distractibility, number of adjustments, etc."
224027224|NCT00831831|BEHAVIORAL|Safety planning|See detailed description
224027225|NCT02041741|BEHAVIORAL|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
223558935|NCT01734954|DRUG|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
223558936|NCT01734954|PROCEDURE|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
223558937|NCT05010200|BIOLOGICAL|PGV-001|personalized genomic peptide vaccine
223558938|NCT05010200|BIOLOGICAL|Poly-ICLC|immune modulator
223558939|NCT05010200|BIOLOGICAL|CDX-301|soluble recombinant human protein to work on stem cell
223558940|NCT00930917|DEVICE|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
223558941|NCT00930917|DEVICE|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
224027226|NCT02041741|BEHAVIORAL|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
224027227|NCT01143974|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
224027228|NCT01217957|DRUG|Ixazomib|Ixazomib capsules
224027229|NCT01217957|DRUG|Lenalidomide|Lenalidomide capsules
224027230|NCT01217957|DRUG|Dexamethasone|Dexamethasone tablets
224027231|NCT05631431|DIETARY_SUPPLEMENT|Curalin|Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals
224134160|NCT05478330|DRUG|topical gel without flutamide|Group B: Consisted of 25 patients with acne vulgaris treated with topical gel with the same component as the other group, except for flutamide, on the face twice per day for a duration of 8 weeks.
223410487|NCT04277364|OTHER|Strength training|All participants will be submitted to a 8-week strength training program, with 3 training sessions per week, totaling 24 training sessions.
223558942|NCT00930917|OTHER|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
224027232|NCT04166890|DRUG|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
224027233|NCT00500162|BEHAVIORAL|Tri-Luma Maintenance regimen|
224134161|NCT00487084|DRUG|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
224134162|NCT00487084|DRUG|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
224134163|NCT00487084|DRUG|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
224134164|NCT02997384|OTHER|Information|information of women about their risk of breast cancer and the screening methods recommended for them
223410488|NCT05369338|DEVICE|Low Level Light Therapy|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
224027234|NCT05040477|OTHER|Muscle energy Technique|"Muscle Energy technique was used to increase the strength of weak muscles,relaxation of tightened muscles in result mobilizes the restricted joint segments.MET's group received 3-5 repetition of post isometric relaxation (PIR).~Treatment through Facet Joint Mobilization based on 3 sets of 15 repetitions of unilateral poster-anterior glide (UPA) using initially grade I \& II mobilizations followed by grade III of mitland glides on selected tender segments and 5 repetitions of extension sustained natural apophyseal glides (SNAGs) on hypo mobile segments.~Conventional therapy comprising of stretching and isometric strengthening exercises in combination with TENS and heat therapy."
223410489|NCT05369338|DEVICE|Sham Controll|"The application of LLL is applied for 12 minutes using Repuls 7 (Repuls Lichtmedizintechnik GmbH, Vienna). This is a class IIb medical device. It applies pulsed red light of a frequency of 640nm. The intensity is 175 mWcm-2, which corresponds to a power density of 4,100 mW. The pulse frequency is set to 2.5 hz.~The device is positioned 7cm from the skin using a distance ring. The sham treatment is performed with the same device and the same distance ring without activating it."
223410490|NCT01760031|OTHER|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
223410491|NCT01155934|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
223410492|NCT02801513|BEHAVIORAL|Brief Mindfulness Training|Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
224027235|NCT03448120|PROCEDURE|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
224134165|NCT02199106|DEVICE|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
223410493|NCT02801513|BEHAVIORAL|Resting Control Training|Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
223410494|NCT02403479|DRUG|Silver Colloid|Topical silver colloid will be administered for 6 weeks. This will either occur before topical saline nasal spray. Participants are randomized as to the order of sprays. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
223410495|NCT02403479|OTHER|Saline|Topical saline will be administered for 6 weeks. This will occur before the topical silver colloidal nasal spray. Participants are randomized as to the order of sprays.
223410496|NCT02671799|DEVICE|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
223410497|NCT06967012|DRUG|Oral Zonisamide Therapy|Zonisamide tablets are administered orally with the following dosage schedule: Weeks 1-2: 2 mg/kg/day, Weeks 3-4: 4 mg/kg/day, Weeks 5-6: 6 mg/kg/day. After the initial six weeks, the dosage is adjusted based on the patient's condition, with weekly increments of 1 mg/kg/day. The maintenance dose ranges from 4 to 6 mg/kg/day, administered in 1-2 divided doses daily. For children weighing ≥50 kg, the adult dosage should be used.
224027236|NCT03448120|PROCEDURE|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
223410498|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
224134166|NCT02199106|DEVICE|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
224298057|NCT06181747|DEVICE|a serious mobile device-based game prototype (Save the Muse Home)|The cognitive impairment corresponding to the symptoms, which we are interested in, focuses on executive inhibition, motor inhibition, sustained attention, selective attention, working memory, and planning ability. The training content will be presented in different scenarios as effective training components. The story line of the warrior breakthrough runs through the whole game, each level is adapted according to the functional damage areas of different patients, and each level involves reward and punishment mechanisms to keep the interest of the players, the difficulty gradient of each level is kept moderate, and the game includes design elements such as space, time, object attributes, actions, rules, skills, and probabilities, etc., which ultimately completes Save the Muse Home, a serious game for the treatment of ADHD.
224298058|NCT00375492|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
223410499|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
224027237|NCT02482870|DEVICE|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
224134167|NCT04583111|DRUG|Domperidone|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
223410500|NCT02203461|DRUG|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
223410501|NCT00274612|DRUG|Telmisartan|
223410502|NCT00274612|DRUG|Ramipril|
223410503|NCT03782012|BEHAVIORAL|Supported|Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
224027238|NCT02482870|DEVICE|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
224027239|NCT01620255|DRUG|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
224027240|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
224134168|NCT04583111|DRUG|sulpiride|Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.
224134169|NCT05425875|PROCEDURE|Bronchoalveolar lavage using wall mount suction|BAL will be performed using wall mount suction with a pressure \<100 mmHg
224134170|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction|A 50-mL syringe will be used to apply suction through the working channel of a bronchoscope
223410504|NCT03907748|OTHER|Music Intervention|After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).
223410505|NCT03907748|OTHER|Reading Intervention|After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
223410506|NCT04633512|DEVICE|ActivSight|Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
223410507|NCT02391012|BIOLOGICAL|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
224027241|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
224027242|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
224027243|NCT01620255|DRUG|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
224027244|NCT03077360|BEHAVIORAL|Lifestyle|Lifestyle changes to lose weight or become more fit
224027245|NCT04357860|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 200 mg
224027246|NCT04357860|DRUG|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment up to 14 days plus Sarilumab 400 mg
224027247|NCT04357860|DRUG|Best available treatment|Best available treatment up to 14 days
224027248|NCT03478150|OTHER|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol
224027249|NCT03478150|DEVICE|laser diode|The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
224027250|NCT02151422|BEHAVIORAL|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
223410508|NCT04429100|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|One novel MRI sequence, i.e. the quantitative imaging of macromolecular proton fraction (MPF), will be introduced into this study. MPF is defined as the relative amount of protons associated with macromolecules involved in magnetization exchange with free water protons. This parameter is independent of the pool model used for quantification and the pulse sequences used for data acquisition. Recent studies have found a strong association between MPF and collagen content in the fibrotic liver, indicating MPF is a potential biomarker of early-stage liver fibrosis.
224027251|NCT05302388|DRUG|SIBP-R002|SIBP-R002: injection; strength: 1, 2, 4, 8 or 12 mg; dose escalation and the first group is 1mg (intravenous infusion, 5 groups, the first group consisted of four people, and the other groups consisted of eight).
224027252|NCT05302388|DRUG|Dexamethasone or Methyl prednisolone|Intravenous infusion, 5mg or 1\~2mg/kg. These were administered within 30 minutes prior to infusion of the experimental drug.
224134171|NCT05425875|PROCEDURE|Bronchoalveolar lavage using manual suction with rubber tubing|A 50-mL syringe with an attached rubber tubing will be used to apply suction through the working channel of a bronchoscope
224134172|NCT02230878|DRUG|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
224134173|NCT02230878|DRUG|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
224134174|NCT02230878|DRUG|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
224134175|NCT02230878|DRUG|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
224134176|NCT02230878|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
224134177|NCT00356863|BEHAVIORAL|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
224134178|NCT01850862|OTHER|Collective group exercise program in patients with KOA|
224134179|NCT01850862|OTHER|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
224298059|NCT00375492|DRUG|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
223410509|NCT05390775|BEHAVIORAL|Written Exposure Therapy (WISE)|WISE consists of five weekly sessions. At session one, the therapist will provide psychoeducation about PTSD, rationale for the proposed intervention, and then instructions for writing about their traumatic experience during each session. Psychoeducation and treatment rationale are scripted to ensure consistency. The participant will be instructed to write about the same trauma memory (their recent MVC) during each session. They will be asked to look back at the event and write for 30 minutes about the details of the event including what they saw, heard, felt, smelled, etc. without regard for spelling or grammar. The participant will self-report SUDs levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
223738622|NCT05023889|DRUG|patisiran|"Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days)."
223738623|NCT05641831|PROCEDURE|Biospecimen Collection|Undergo peripheral blood collection
223738624|NCT05641831|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy and aspiration
224027253|NCT05302388|DRUG|Diphenhydramine|10mg, intramuscular injection.These were administered within 30 minutes prior to infusion of the experimental drug.
224027254|NCT05302388|DRUG|Placebo|The same volume of placebo as SIBP-R002: injection; strength: the same volume of placebo as SIBP-R002 of 1, 2, 4, 8 or 12 mg (intravenous infusion, 5 groups, the first group consisted of one people, and the other groups consisted of two). The rule and dose of placebo were the same as SIBP-R002.
224027255|NCT03165929|DRUG|Flurbiprofen|oral flurbiprofen spray
224027256|NCT03165929|DRUG|placebo|oral placebo spray
224027257|NCT03702556|DEVICE|MRI scan|7.0 tesla functional MRI scan
224027258|NCT02086266|OTHER|PILATES|
224027259|NCT02086266|OTHER|PFMT and AES|
224134180|NCT01602926|PROCEDURE|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
224134181|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
224027260|NCT04725825|OTHER|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
224027261|NCT04725825|OTHER|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
224027262|NCT00861263|DEVICE|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
224027263|NCT02640820|DRUG|Sensitizing DPCP Ointment|Sensitization
224027264|NCT02640820|DRUG|Treatment DPCP Ointment|Treatment
224027265|NCT01486771|DRUG|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
224027266|NCT00047203|DRUG|alvocidib|Given IV
224027267|NCT00286520|PROCEDURE|Transanal irrigation with Peristeen Anal Irrigation|
224027268|NCT05998356|DEVICE|Balloon Eustachian Tuboplasty (BET) under general anesthesia.|Subjects will undergo general anesthesia with intubation. After retraction of the inferior turbinate using Naphazoline, the balloon will be inserted under optical control through the pharyngeal ostium of the Eustachian tube and inflated two times at a pressure of 10 bars as instructed by the manufacturer.
224134182|NCT01602926|PROCEDURE|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
224134183|NCT01161082|DRUG|REGN727(SAR236553)|subcutaneous
224134184|NCT02814864|DRUG|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale\>2) will receive Mesenchymal Stromal Cell (MSC) injections
224134185|NCT02462733|BEHAVIORAL|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
224134186|NCT02462733|BEHAVIORAL|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
224134187|NCT01954472|BEHAVIORAL|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
223410510|NCT05390775|BEHAVIORAL|Non-emotional Writing|Following randomization, the first session for the control writing condition will be conducted as follows, which is detailed in a structured manual for therapists. The therapist will read instructions for writing about non-emotional topics. The participant will be instructed to describe what they did yesterday from the time they woke up until the time they went to bed, as objectively as possible, without regard for spelling or grammar. The therapist will then leave the participant with a written version of the instructions for 30 minutes while the participant writes. As discussed, the participant will self-report Subjective Unites of Distress Scale (SUDS) levels to the therapist at the beginning and end of each session. After 30 minutes, the therapist will ask the participant to stop writing, review the experience of writing and discuss as needed, and conclude the session. Therapists will collect the written narrative described above.
224134188|NCT01954472|BEHAVIORAL|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
223410511|NCT00005606|BIOLOGICAL|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
223410512|NCT00005606|BIOLOGICAL|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
223410513|NCT04988932|DRUG|Inhaled nitric oxide|Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
223410514|NCT06512285|DIAGNOSTIC_TEST|Continuous Pulse Oximetry|The patient will wear a continuous pulse oximeter after their adenotonsillectomy surgery until the following morning. This will record continuous pulse oximetry data to allow for analysis of any desaturations in the first night following the surgery. This study is observational only and this data will not be used to impact any treatment
223410515|NCT01981707|DEVICE|F-Choline-PET|
223410516|NCT02476578|OTHER|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
223410517|NCT00497393|BEHAVIORAL|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
224027269|NCT05998356|DEVICE|Insertion of catheter for probing and flushing the Eustachian tube under general anesthesia|Participants in the control group will benefit from the insertion of a dedicated catheter, TubaClean, into the Eustachian tube during 2 minutes with gentle washing with saline solution, and then the catheter will be removed. This type of device is used to wash the Eustachian tube lumina during ear surgery. Thus, the procedure in the control group will be very close to the BET, except that no dilation will be performed. No Eustachian tube dilation will occur in this control group since the diameter of the catheter itself is not large enough to cause dilation. Eustachian tube catheterization is not per se a treatment of ETD but just of mucosal plugs, and the investigators expect no effect of this catheter insertion on the outcomes of the study. At the end of the procedure, subjects will have nasal dressings similar to the BET procedure to ensure the blinding of the study.
224027270|NCT04209699|DRUG|BMS-986165|Single dose
224134189|NCT03170479|DIETARY_SUPPLEMENT|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
224134190|NCT03170479|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
223738625|NCT05641831|DRUG|Canakinumab|Given SC
223738626|NCT05641831|PROCEDURE|Chest Radiography|Undergo chest x-ray
223738627|NCT05641831|PROCEDURE|Echocardiography|Undergo ECHO
223738628|NCT05641831|DRUG|Placebo Administration|Given SC
223738629|NCT05641831|OTHER|Quality-of-Life Assessment|Ancillary studies
223738630|NCT06119529|DRUG|LY3872386|Administered IV.
223738631|NCT06119529|DRUG|Prednisone|Administered orally.
223738632|NCT06119529|DRUG|Placebo|Administered IV.
223738633|NCT04933942|DRUG|Lomustine|Oral administration of Lomustine
223738634|NCT04933942|DRUG|Romiplostim|Subcutaneous administration of Romiplostim
224027271|NCT04209699|DRUG|Famotidine|Single dose
224027272|NCT00674869|OTHER|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
224134191|NCT00697658|DRUG|Paliperidone ER|6 mg tablet once daily, variable treatment length.
224027273|NCT05863312|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
224027274|NCT05863312|PROCEDURE|Pars plana vitrectomy with scleral buckle|In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
224027275|NCT05863312|OTHER|Sulfur hexafluoride gas tamponade|At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
224027276|NCT05863312|OTHER|Perfluoropropane gas|At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
224027277|NCT06270433|DRUG|Toludesvenlafaxine hydrochloride sustained-release tablets|80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks
224027278|NCT06270433|DRUG|Desvenlafaxine succinate sustained-release tablets|50 mg orally once daily dosing for 8 weeks
224027279|NCT05280587|DEVICE|Technological Rehabilitation|Specific rehabilitation for balance disorder using the robotic platform
224027280|NCT03607539|DRUG|Sintilimab|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
224027281|NCT03607539|DRUG|Pemetrexed|500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.
224027282|NCT03607539|DRUG|Platinum|Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
224027283|NCT03607539|DRUG|Placebos|10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
224027284|NCT02489513|DRUG|[14C]-AG-120|Labeled investigational drug
224027285|NCT04642768|DIETARY_SUPPLEMENT|KetoneAid Ketone Ester|Commercially available ketone supplement
224027286|NCT04642768|DIETARY_SUPPLEMENT|Maltodextrin|Commercially available maltodextrin supplement
224027287|NCT01324115|DRUG|NG-nitro-L-arginine|
224134192|NCT03311399|OTHER|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
224134193|NCT03311399|OTHER|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
224134194|NCT00333619|BEHAVIORAL|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
224027288|NCT01324115|OTHER|laboratory biomarker analysis|
223738635|NCT02547467|OTHER|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
224027289|NCT01324115|OTHER|pharmacological study|
224027290|NCT01324115|PROCEDURE|computed tomography|
224027291|NCT01324115|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
224027292|NCT04256603|DRUG|Gabapentin|Timing of gabapentin initiation
224027293|NCT04256603|OTHER|No gabapentin|No gabapentin
224027294|NCT00988195|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
224027295|NCT00988195|DRUG|Doxorubicin|Weeks 13-24 (once every 3 weeks)
224027296|NCT00269347|PROCEDURE|Chiropractic Spinal Manipulation|
224027297|NCT00269347|PROCEDURE|Exercise|
224027298|NCT00269347|BEHAVIORAL|Self-care|
224134195|NCT00333619|BEHAVIORAL|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
224134196|NCT02640144|DRUG|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
224134197|NCT02640144|DRUG|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
224134198|NCT02031822|PROCEDURE|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
224134199|NCT04311801|DIAGNOSTIC_TEST|Optical Coherence Tomography|Every patient underwent OCT examination before and after surgery.
224134200|NCT03294928|OTHER|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
224134201|NCT02658344|BIOLOGICAL|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection
223738636|NCT01230801|BIOLOGICAL|BMN 701|GILT-tagged recombinant human GAA
224134202|NCT02658344|DRUG|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
223738637|NCT01122706|OTHER|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
223410518|NCT05136105|BEHAVIORAL|Preventive Narrative Exposure Therapy (PreNET) family intervention|"Sessions: (1) Participants are invited to narrate the event in detail, in line with the protocol of the trauma-focused intervention NET. Furthermore, participants and caregiver(s) will receive a brief psychoeducation about expected symptoms and supportive behaviour in the aftermath of sexual violence.~(2) Two weeks after session 1, the second session focuses on caregiver only and their emotions. The narration of the event is read to the caregiver(s). Caregiver(s) receive assistance regulating their emotions. They receive psychoeducation on how to support their child.~(3) Two weeks after the second session, the children assisted by their caregivers lay a chronological lifeline of their most important life experiences. The chronology and the context of the traumatic events is reinforced. The narration of the sexual abuse is read again to the child and the caregiver(s). The caregiver(s) are encouraged to support emotionally their child during the renarration."
224027299|NCT06444685|OTHER|Exercise and cognitive training interventino|Exercise and cognitive training based on Table tennis and Tabletop games.
224027300|NCT03682549|DIAGNOSTIC_TEST|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
224027301|NCT04017728|DEVICE|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
224134203|NCT03493867|DEVICE|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
223410519|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.1 Usage|Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
223410520|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.2 Usage|Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
223410521|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 1.3 Usage|Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
223410522|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 1|Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
223558943|NCT03949452|OTHER|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
223558944|NCT03949452|OTHER|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
223558945|NCT02534025|PROCEDURE|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
223558946|NCT04678037|BEHAVIORAL|PROs assessment using sickle cell disease mobile app (SCD-app)|A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
223558947|NCT00070928|DRUG|valerian|
223558948|NCT04652206|DRUG|SCO-101|Oral tablets with a strength of 50 mg or 150 mg according to dose level (cohort). Administered for 6 consequtive days in a bi-weekly schedule in each treatment cycle. Treatment until disease progression.
224027302|NCT04017728|DEVICE|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
224027303|NCT04620226|OTHER|Quality Improvement|Rapid Point-of-Care testing will provide participants with a HCV antibody and RNA result within 2 hours. If the participant is HCV RNA+, they will receive an inpatient consultation from a liver specialist prior to discharge. We hypothesize that this model will minimize losses in the continuum-of-care and improve linkages to care.
224027304|NCT02463643|DRUG|Z-215 10mg|Z-215 10mg, capsules
224027305|NCT02463643|DRUG|Z-215 20mg|Z-215 20mg, capsules
224134204|NCT03209440|BEHAVIORAL|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
224134205|NCT03209440|BEHAVIORAL|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
223558949|NCT04652206|DRUG|Gemcitabine|Used according to marketing authorisation
223558950|NCT04652206|DRUG|Nab paclitaxel|Used according to marketing authorisation
224027306|NCT02463643|DRUG|Z-215 Placebo|Z-215 placebo-matching capsules
224027307|NCT02463643|DRUG|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
224027308|NCT02463643|DRUG|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
224027309|NCT04005053|DRUG|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
224027310|NCT04005053|DRUG|Placebo oral tablet|Placebo
224027311|NCT05385133|PROCEDURE|Computer guided condylar position|post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates
223410523|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 2|Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
223558951|NCT00842153|DRUG|Clobetasol propionate foam|Topical Clobetasol propionate foam
223558952|NCT00842153|DRUG|Vehicle foam|Vehicle foam does not include the active drug.
224027312|NCT05385133|PROCEDURE|Manual condylar position|post-osteotomy condylar position was performed using the conventional manual method
224027313|NCT06397729|BEHAVIORAL|Wait-List Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
224027314|NCT06397729|BEHAVIORAL|PREVENT Tool|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help the care team link patients to resources in their community. PREVENT follows up with patients electronically and communicates progress on behavior change to the care team.
224027315|NCT04397003|BIOLOGICAL|Neoantigen DNA vaccine|All study injections will be given intramuscularly using an integrated electroporation device (TDS-IM system, PapiVax Biotech). At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
224027316|NCT04397003|DRUG|Durvalumab|-Supplied by AstraZeneca
224027317|NCT04397003|DEVICE|TDS-IM v2.0 Device|-Integrated electroporation administration system
224027318|NCT04397003|PROCEDURE|Peripheral blood draws|-Pre-treatment, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Vaccine Day 1, Vaccine Day 29, Vaccine Day 85, Vaccine Day 141, on even numbers of cycles for durvalumab for one year following completion of vaccine
224027319|NCT05268614|RADIATION|Radiation therapy|"Participants will receive either 70 gray (Gy), 60 Gy, or 50 Gy of radiation based on the following criteria:~70 Gy: Pretreatment level of plasma circulating free HPV DNA (cfHPV DNA) ≤ 12 copies/mL~60 Gy: Tumor tissue positive for HPV subtype other than 16 OR Pretreatment level of cfHPV DNA 13-99 copies/mL OR Pretreatment level of cfHPV DNA ≥ 100 copies/mL AND \<95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy~50 Gy: Tumor tissue positive for HPV subtype 16, pretreatment level of cfHPV DNA ≥ 100 copies/mL, AND ≥ 95% decrease in the level cfHPV DNA by the end of week 4 of radiation therapy"
224027320|NCT05268614|DRUG|Cisplatin|"All participants will receive 40 mg/m2 of cisplatin intravenously over 60 minutes weekly during radiation therapy.~If cisplatin is not recommended by the treating medical oncologist or is not tolerated, it is permissible to switch to an alternative chemotherapy regimen per institutional practice, but chemotherapy should not be discontinued unless mandated by the patient's condition."
224027321|NCT05066308|DRUG|CBD|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (\>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
224027322|NCT05066308|OTHER|Placebo|Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
224134206|NCT03209440|BEHAVIORAL|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
224134207|NCT04273126|BEHAVIORAL|Adapted Family Resilience Intervention|The program consists of approximately 8-10 modules lasting approximately one hour. Sessions focus on psychoeducation and key resilience skills.
223410524|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 2.1 Usage|Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
223410525|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 3|Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
223410526|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 3.1 Usage|Participants will use their Radicle Calm Active Study Product 3.1 as directed for a period of 6 weeks.
223410527|NCT05837910|DIETARY_SUPPLEMENT|Placebo Control Form 4|Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
223410528|NCT05837910|DIETARY_SUPPLEMENT|Calm Active Study Product 4.1 Usage|Participants will use their Radicle Calm Active Study Product 4.1 as directed for a period of 6 weeks.
223558953|NCT00002540|OTHER|Laboratory Biomarker Analysis|Correlative studies
223558954|NCT00002540|PROCEDURE|Medical Examination Assessment|Undergo DRE
223558955|NCT00002540|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
223410529|NCT00003563|RADIATION|WBRT|3 GY of WBRT daily for a total of 10 days
223410530|NCT00003563|DRUG|MGd|5.0 mg /kg MGd plus WBRT
223410531|NCT03433196|DRUG|HS-25 and Atorvastatin|HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
223738638|NCT05628649|BEHAVIORAL|Teaching Kitchen Collaborative Curriculum|"Participants in the intervention arm will first attend 16 weeks of intensive 2-hour classes covering hands-on cooking skills, dietary recommendations (as described within the Harvard Healthy Eating Plate), mindfulness and stress reduction skills, activity and movement techniques, and tools for behavior change. Next, they will attend monthly booster classes for 8 months, with a final assessment for the sustainability of outcomes at 18 months. Sessions will be taught by a combination of a chef educator, dietitian, health coach, or medical doctor.~The study will consist of 2 cohorts of individuals from 4 teaching kitchen program institutions. Each institution will run one-two cycles of the program with each cycle including both a treatment and control group. Each individual cohort will consist of a maximum of 80 individuals; with 40 block-randomized to the intervention and 40 in the control group receiving normal standard of care (followed by their PCP)."
224027323|NCT05252923|DRUG|Sulodexide|Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
224027324|NCT05768841|BEHAVIORAL|mental health issues|survey on mental health issues in endurance athletes
224027325|NCT03726957|BEHAVIORAL|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
224027326|NCT05296408|BEHAVIORAL|motor learning based therapy|Motor learning based therapy will include functional task/task component training and will be employed to practice hand-to-mouth, forward reach, grasp-release, and object manipulation. Training will include high repetition both in the clinic and during home exercise practice. Tasks will be decomposed into component parts and practiced in this manner with the goal of returning to full task performance as skill develops Training will be tailored to each individual subject's capability and progressed according to a motor control hierarchy to ensure adequate challenge. Training is always started at the appropriate level of challenge for an individual to ensure adequate challenge is delivered whether the individual is higher or lower functioning.
224027327|NCT05296408|BEHAVIORAL|MyoPro|The MyoPro supports motor learning-based training by reinforcing coordinated movement practice, allowing for finely incrementalized training progression, and encouraging high repetition of movement. Importantly, the device assists the user to move the paretic limb in a manner they may otherwise be unable to do. This further motivates the user to continue attempts to move the paretic limb. When a user attempts to volitionally contract a weak muscle, sensors embedded within the MyoPro detect the EMG signal, which triggers activation of a motor within the device. The motor assists the user to complete the desired movement (e.g. opening of the hand).Subjects experience real-time biofeedback through their ability to sense and see movement of the target joint(s) and via their interface with the software on a computer that provides visual feedback of the EMG level of the contracting muscle
224027328|NCT05296408|BEHAVIORAL|Home Exercise Program|Every subject will be assigned an individualized HEP. Therapy staff will create written handouts for the user to follow. The HEP will include photographs of the study participant performing his/her exercises/functional tasks along with written instructions. Each individual will have their own personalized HEP that will be created during their study participation and will be dispensed only to them. The HEP will reinforce in-clinic therapy. The HEP will be progressed regularly, and individuals will log practice time. The HEP for M+ML will include practice with and without the MyoPro; the HEP for ML-alone will include practice without MyoPro. Each HEP session will require approximately 90 minutes to complete.
224027329|NCT00501514|DRUG|Growth hormone|
224027330|NCT02077595|DEVICE|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
224027331|NCT01092000|BEHAVIORAL|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
224027332|NCT01092000|OTHER|Education|Monthly exercise tips handout.
224027333|NCT06051916|OTHER|residual urine|The study includes two group, A and B. Se previously
224027334|NCT00184821|PROCEDURE|Ischemic preconditioning|
224027335|NCT00184821|PROCEDURE|Forearm ischemic exercise|
224027336|NCT00184821|PROCEDURE|Annexin A5 scintigraphy|
224027337|NCT00184821|DRUG|Diazoxide|
224027338|NCT00184821|DRUG|glibenclamide|
224027339|NCT00184821|DRUG|adenosine|
224134208|NCT00743457|DEVICE|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
224134209|NCT00394238|PROCEDURE|Ultrasonographic imaging|
224134210|NCT03101059|PROCEDURE|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
224134211|NCT01864824|DRUG|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
224027340|NCT04065152|DRUG|Talimogene laherparepvec|Talimogene laherparepvec
224027341|NCT01556893|DEVICE|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
224027342|NCT00003193|DRUG|amifostine trihydrate|
224027343|NCT00003193|DRUG|paclitaxel|
224027344|NCT00003193|PROCEDURE|conventional surgery|
224027345|NCT00003193|RADIATION|radiation therapy|
224027346|NCT06311955|RADIATION|Carbon ion radiotherapy|The patients will receive 72GyE per 18 fractions of carbon ion radiotherapy. Patients with thymus cancer should be combined with platinum-based regimen (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin; paclitaxel combined with cisplatin or cisplatin / carboplatin / loplatin / nedaplatin; docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles. The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was local relapse-free survival, overall survival and cause-specific survival.
224027347|NCT06311955|OTHER|combined with platinum-based regimen|combined with platinum-based regimen
224134212|NCT01864824|DRUG|Placebo|Placebo
224134213|NCT01807195|OTHER|contrast medium usage|
224134214|NCT00390247|DRUG|thalidomide|
224134215|NCT03333330|DRUG|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
224027348|NCT00221247|PROCEDURE|Acupuncture|acupuncture
224027349|NCT01400555|DRUG|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
224027350|NCT01400555|DRUG|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
224027351|NCT01400555|DRUG|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
224027352|NCT01400555|DRUG|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
224027353|NCT05171101|OTHER|MAVEN|The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
224027354|NCT06648733|OTHER|Structured pharmaceutical discharge management|These patients will receive structured pharmaceutical discharge management from inpatient to outpatient care.
224027355|NCT01155375|DRUG|Ferumoxytol|Experimental: Ferumoxytol
224027356|NCT01155375|DRUG|Oral Iron|Active Comparator: Oral iron
224027357|NCT01653184|DIETARY_SUPPLEMENT|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
224027358|NCT01166321|RADIATION|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
224027359|NCT02719678|OTHER|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
224027360|NCT00388453|DEVICE|Dx-pH Probe|24 hour ph monitoring
224027361|NCT00388453|PROCEDURE|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
224027362|NCT05417633|PROCEDURE|intraocular lens - RayOne EMV (Rayner Surgical GmbH,Berlin, Deutschland)|Inducing different values of monovision
224027363|NCT00005652|DRUG|rituximab|
224027364|NCT05239351|DEVICE|Jalucomplex|Device: Jalucomplex Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
224027365|NCT00762970|DEVICE|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
224134216|NCT06048926|DRUG|Carrelizumab|200 mg/time, iv, Q3W
224134217|NCT06048926|DRUG|Paclitaxel injection|50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
224134218|NCT06048926|DRUG|Cisplatin|25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
224027366|NCT00762970|DEVICE|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
224027367|NCT00762970|DEVICE|Control Lens|Spectacle Lenses.
224027368|NCT01480674|DRUG|Trastuzumab|
224027369|NCT03133325|DEVICE|GP0045|Hyaluronic acid gel
224027370|NCT03133325|DEVICE|Restylane Lyft Lidocaine|Hyaluronic acid gel
224027371|NCT02689596|DRUG|Oxytocin|
224027372|NCT02689596|OTHER|Placebo|
224027373|NCT03818204|DEVICE|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
224027374|NCT00887250|DRUG|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
224027375|NCT00887250|DRUG|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
224027376|NCT00887250|DRUG|Comparator: Placebo|Placebo to Losartan
224027377|NCT06499714|OTHER|Exposure to 3600 m|Participants will travel to and stay for 2 days at an altitude of 3600 m.
224027378|NCT06239272|PROCEDURE|Surgical resection|Low, Intermediate and High-risk Surgery to remove tumor (standard of care)
224027379|NCT06239272|RADIATION|Proton beam radiation therapy|Low, Intermediate and High-risk Radiation therapy is considered standard of care for patients with NRSTS who have positive tumor margins. However, the dose that will be given in this study is higher than what is usually given, therefore, the dose of radiation in this study is research. Radiation will start about 3 to 6 weeks after your surgery, depending on how quickly you recover from surgery. Radiation will be given daily (Monday through Friday) for about 5 to 6 weeks.
223410532|NCT03433196|DRUG|Atorvastatin|Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
224027380|NCT06239272|DRUG|Pazopanib|Intermediate and High-risk By mouth, either by tablet or a liquid suspension, 7 doses, days 1 to 7
224027381|NCT06239272|DRUG|Ifosfamide|Intermediate and High-risk Ifosfamide is a structural analogue of cyclophosphamide. Into the vein (IV) over about 3 hours, 3 doses, days 1, 2, and 3
224027382|NCT06239272|DRUG|Doxorubicin|Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
224027383|NCT06239272|DRUG|Selinexor|"High-risk Dosage and route of administration: Selinexor tablets for oral administration should be taken at approximately the same time each day without regards to meals.~Selinexor is a selective inhibitor of nuclear export (SINE). Selinexor specifically blocks XPO1-mediated nuclear export by forming a slowly reversible covalent bond with the nuclear export protein XPO1 By mouth, either by tablet or a liquid suspension, 1 dose and day 3"
224027384|NCT03864146|BEHAVIORAL|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
224134219|NCT06048926|RADIATION|Concurrent chemoradiotherapy|Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
224298060|NCT01937247|PROCEDURE|Patients will be inducted in the induction room|The patients will be inducted in the induction room
224027385|NCT01497600|DRUG|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
224027386|NCT01497600|DRUG|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
224027387|NCT03542461|DRUG|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
224027388|NCT03542461|OTHER|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
224027389|NCT00001718|DEVICE|Electropalatography|
224027390|NCT02536807|DRUG|Hyaluronan|HA gel injection
224027391|NCT00549809|PROCEDURE|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
224027392|NCT05158582|OTHER|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|"The modified exercise program group will perform following exercises:~Resisted static Squats SLER Banded rows SL Banded Jumps Resisted explosive reverse lunges 5hurdle Jumps Elevated single leg Swiss ball Bosu Banded Stars RLE Barbell lunge Static shoulder Abd.with banded leg Add Ant.Banded static squat with medball press Bosu banded superman Sit ups"
224134220|NCT02572895|DIETARY_SUPPLEMENT|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
224134221|NCT02690207|BIOLOGICAL|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
223410533|NCT05251896|PROCEDURE|Plasma-free procedure|Use albumin solution, lactated Ringer's solution, normal saline as replacement fluid
223410534|NCT01906216|DRUG|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
223410535|NCT01906216|PROCEDURE|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
223410536|NCT00640913|PROCEDURE|Reversal of defunctioning stoma|Reversal of defunctioning stoma
223558956|NCT05903898|DEVICE|AI software StrokeSens (Circle NVI)|Computed tomography (CT) and computed tomography angiography (CTA) imaging studies acquired upon admission will be assessed by the AI software StrokeSENS (Circle NVI). StrokeSENS is CE marked and available for clinical diagnostic purposes in the EU and UK.The software will be a decision support tool in addition to standard radiological services available in all primary stroke centers in Northern Norway where image interpretation is done by a radiologist or resident in radiology. The software can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the Alberta Stroke Program Early CT Score (ASPECTS) and occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (MCA). Output to radiologists will be automated ASPECT scoring, automated search for LVO or MeVO.
223558957|NCT05221840|DRUG|Durvalumab|Durvalumab IV (intravenous infusion)
224027393|NCT05158582|OTHER|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercise program group will perform the same exercises as they doing for their low back pain.
224027394|NCT00114413|DRUG|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
224027395|NCT00114413|PROCEDURE|eNO measurement|measured by Aerocrine® NIOX device
224027396|NCT03616041|DEVICE|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
223410537|NCT06041360|DIAGNOSTIC_TEST|Pure tone audiometry PTA ,Speech audiometry ,Otoacoustic emission,Auditory evoked potentials including (ABR).|Neurological tests for diagnosis of peripheral neuropathy
223558958|NCT05221840|DRUG|Oleclumab|Oleclumab IV (intravenous infusion)
223558959|NCT05221840|DRUG|Monalizumab|Monalizumab IV (intravenous infusion)
223558960|NCT05221840|OTHER|Placebo|Placebo IV (intravenous infusion)
223558961|NCT06471491|OTHER|Driving pressure-guided positive end-expiratory pressure|Driving pressure-guided positive end-expiratory pressure during the surgical procedure
223558962|NCT06189963|BIOLOGICAL|SNK01|SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug
223558963|NCT06189963|OTHER|Placebo|Sodium Lactate Hartmann's Solution
223410538|NCT05753020|BEHAVIORAL|CKM Jumpstart Tool|The CKM JumpStart Tool is a 1-page handout that describes the values of a patient and words that a providers can try with the patient to explore the patient' values more and to provide a values-based introduction to CKM. The values described in the CKM JumpStart Tool is based on a patient's response to a single validated question that we will ask the patient at T1, if they had to choose, do they value care directed at longevity or comfort. Using the patient's answer to the values question, study staff will generate a CKM JumpStart Tool prior to their upcoming clinic visit with their nephrologist. Study staff will inform the patient that their response to the values question will be shared with their provider prior to their next clinic visit and that their providers might bring up their values and treatment options for kidney disease, if the situation permits. We will share the CKM Jumpstart Tool with their provider and provide instruction on how to use the Tool.
223410539|NCT01019694|DRUG|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
223410540|NCT01019694|DRUG|Combivent Respimat 20/100 mcg|Open label randomized parallel
223410541|NCT01019694|DRUG|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
223410542|NCT01831076|DRUG|Exemestane|Given PO
223410543|NCT01831076|DRUG|Exemestane and tamoxifen|exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
223410544|NCT03297320|OTHER|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
223410545|NCT00795002|DRUG|alvocidib|Given IV
223410546|NCT00795002|DRUG|mitoxantrone hydrochloride|Given IV
223410547|NCT00795002|DRUG|cytarabine|Given IV
223410548|NCT00795002|OTHER|pharmacological study|Correlative studies
223558964|NCT05312697|BIOLOGICAL|Setrusumab|A fully human anti-sclerostin monoclonal antibody (mAb)
223558965|NCT06482671|DRUG|Rikkunshi-to|Kampo medicine (Herbal). ikkunshito is composed of the following eight herbal medicines: extracts of Atractylodes lancea Rhizome, Ginseng, Pinellia tuber, Poria sclerotium, Jujube, Citrus unshiu Peel, Glycyrrhiza, and Ginger. Among these, the extracts of the Atractylodes lancea Rhizome, Ginseng, Poria sclerotium, Pinellia tuber, Citrus unshiu Peel, and Glycyrrhiza
223558966|NCT06482671|OTHER|Placebo|inactive drug, The matching placebo contains Corn Starch (vehicle), Lactose Hydrate (vehicle), Dextrin (vehicle), Magnesium Stearate (lubricant), FD\&C Blue No.1 Aluminum Lake (coloring agent), FD\&C Yellow No.5 Aluminum Lake (coloring agent), and Red Ferric Oxide (coloring agent).
223558967|NCT04869007|DEVICE|hysterosonography|Isthmocele mesured by hysterosonography before ART procedure
223558968|NCT06424743|OTHER|exercise|exercise programs with different volumes
223558969|NCT05241691|DEVICE|Guided Growth Plate System Plus|The implant is thought as one of the surgical options to perform epiphysiodesis and hemiepiphysiodesis minimally invasive, that is without recourse to a corrective osteotomy.
223558970|NCT04445519|DRUG|NCX 470 0.065% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
223558971|NCT04445519|DRUG|Latanoprost 0.005% (initial phase of trial)|Latanoprost Ophthalmic Solution, 0.005%
223558972|NCT04445519|DRUG|NCX 470 0.1% (initial phase of trial)|NCX 470 Ophthalmic Solution, 0.1%
223558973|NCT04445519|DRUG|NCX 470 0.1% (remainder of trial)|NCX 470 Ophthalmic Solution, 0.1%
223558974|NCT04445519|DRUG|Latanoprost 0.005% (remainder of trial)|Latanoprost Ophthalmic Solution, 0.005%
223558975|NCT04254562|BEHAVIORAL|Weekly Meetings with a Supported Employment/Supported Education Specialist|Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.
224027397|NCT05605574|BEHAVIORAL|Advance Care Planning conversations|In the first conversation, patients and caregivers are guided through conversations using a modified version of the Serious Illness Conversation Guide, which explores understanding of the AYA's illness and treatment plan, information preferences, goals, sources of support, fears and worries, and goals of care. In the second conversation, participants are introduced to and encouraged to complete portions of the advance care planning document, Voicing My CHOiCES. Participants are guided through a discussion of this experience and may share their perceptions of each other's preferences for care. In the third conversation, participants may discuss previous conversations or other new Advance Care Planning topics. At the end of each conversation, a summary of the conversation will be documented in the electronic medical record and the investigator will communicate directly any information requested by the patient or caregiver to be shared with specific members of the patient's care team.
224027398|NCT02170792|DRUG|BIBR 1048 MS|Low, medium or high dose
224027399|NCT02170792|DRUG|Ranitidine|150mg
224027400|NCT05785702|DEVICE|The anti-wandering system|During the testing period, the system will promptly notify care staff if a participant enters unauthorized areas. A care staff will then go to that area and search for the participant. After the participant is found, care staff will reset the system, and then return the participant to a safe place.
224134222|NCT01002053|PROCEDURE|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
224134223|NCT00484965|PROCEDURE|Coronary stenting|
223410549|NCT00795002|OTHER|laboratory biomarker analysis|Correlative studies
223410550|NCT05352464|OTHER|cervical traction with EMG biofeedback|"Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position.~Ask the patient to assume sitting position on a comfortable chair. Place surface electrodes of EMG biofeedback at the level of C5-6 Para spinal muscles to pick up the activity of the muscles and convert it to vis-ual and auditory impulses produced from the device. Tell the patient to try to relax the tension of the neck muscles as much as he can by lowering the visual and auditory impulses from the device"
223410551|NCT05352464|OTHER|cervical traction and conventional physical therapy|Continuous traction for 15-20 minutes in sitting position on average at an angle of 15-25 degrees of cervical flexion or in the most pain-free position
223410552|NCT03864679|OTHER|Exercise|Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
224027401|NCT03718078|DEVICE|Confocal Laser Endomicroscopy|"The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~1. Ex vivo study~   \- Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~2. In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins"
224027402|NCT00495287|DRUG|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
224027403|NCT04876677|DRUG|Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium|Two inhalations bid: 4 inhalations; total daily dose of 400/24/50 μg BDP/FF/GB
223558976|NCT04254562|BEHAVIORAL|Focused Skill and Strategy Training (FSST)|Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.
224027404|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
224027405|NCT03711851|BEHAVIORAL|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
224027406|NCT03711851|OTHER|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
224027407|NCT01933113|DEVICE|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
224027408|NCT00348231|DRUG|dual-action insulin analog|
224027409|NCT04499274|DRUG|0 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 nl) using ondansetron
224027410|NCT04499274|DRUG|0.2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (0.2 ul) using ondansetron
224027411|NCT04499274|DRUG|2 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (2 ul) using ondansetron
224027412|NCT04499274|DRUG|20 ul of ondansetron|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were added with different doses (20 ul) using ondansetron
224134224|NCT05674201|COMBINATION_PRODUCT|Propofol-Dexmedetomidine|Propofol-Dexmedetomidine AND Propofol-Remifentanil
224134225|NCT06041646|DRUG|Sublingual film containing Igalmi|Sublingual film containing 180 µg of Igalmi (dexmedetomidine)
224134226|NCT02637024|RADIATION|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
224027413|NCT00744185|DRUG|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
224027414|NCT00744185|DRUG|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
224027415|NCT05627713|OTHER|Blood sample collection|Blood sample collection between inclusion and 12 months after inclusion
224027416|NCT05627713|OTHER|urine sample collection|urine sample collection at inclusion
224027417|NCT05116293|DRUG|Midazolam oral solution|Oral syrup
224134227|NCT02637024|RADIATION|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
224134228|NCT05283863|DEVICE|High-frequency stimulation|Patients in this group will receive sub-threshold high-frequency (aka 1200Hz) spinal cord stimulation for 2 weeks.
224134229|NCT05283863|DEVICE|Sham Stimulation|Patients in this group will receive receive sham spinal cord stimulation (aka no stimulation) for 2 weeks.
224134230|NCT00517335|PROCEDURE|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
223558977|NCT04254562|BEHAVIORAL|Enhanced Services as Usual|One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
223558978|NCT05001984|DRUG|Alirocumab|Alirocumab 75mg subcutaneously every 2 weeks for a total of 26 weeks.
223558979|NCT05785286|OTHER|BPH 3-item questionnaire|BPH 3-item questionnaire. The questionnaire consists of only three items. A raw score ranging from 0 to 5 is assigned to each of the items, giving a final total score varying from 0 (no symptom) to 15 (very symptomatic).
224027418|NCT05116293|DRUG|Digoxin Oral Tablet|Oral tablet
224027419|NCT05116293|DRUG|Acetaminophen Oral Tablet|Oral tablet
224027420|NCT00879762|BIOLOGICAL|MVA Smallpox Vaccine|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
224027421|NCT00879762|OTHER|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
224027422|NCT04981366|DIETARY_SUPPLEMENT|Protein supplement|40g of whey protein in the breakfast;
224027423|NCT04981366|DIETARY_SUPPLEMENT|isocaloric supplement|42g of isocaloric supplement in the breakfast;
224027424|NCT02086123|PROCEDURE|Epidural Analgesia|Bupivacaine + Fentanyl
224134231|NCT00801853|DRUG|Aerovant|Aerovant 1mg bid (dry powder)
224027425|NCT02086123|PROCEDURE|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
224027426|NCT04664439|DIAGNOSTIC_TEST|CT-FFR|CCTA examination will be performed by qualified medical imaging technicians, and patients will be scanned with 256rows of CT, according to standard operating norms. The coronary artery physiological function evaluation software(Keya Medical Technology, Beijing, China)will be configured in the core laboratory in advance, and the relevant imaging analysts will be trained. The core laboratory will receive the CCTA inspection data and evaluate the CCTA image quality. According to the standard operation flow of the software specification, the CT-FFR analysis will be carried out on the images that meet the requirements, and the CT-FFR value of the lesions will be measured.
224134232|NCT00801853|DRUG|Aerovant|Aerovant 3mg bid (dry powder)
224134233|NCT00801853|DRUG|Aerovant|Aerovant 10mg bid (dry powder)
224134234|NCT00801853|OTHER|placebo|placebo control (dry powder)
224027427|NCT05316194|OTHER|Digital treatment for hip and knee osteoarthritis|"The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program."
224027428|NCT05847725|OTHER|Elastic bandaging|"The bandages were wrapped circularly along the extremity from the toes to the groin, drawing an 8 at the ankle with a 50% overlap rate, starting with 80% tension and decreasing the pressure proximally."
224027429|NCT05847725|OTHER|Short stretch bandaging|Short tension bandage application was started on postoperative day 1 following the removal of the drains. According to the width of the extremity, using short tension bandages of 6, 8 and 10 cm width, starting from the sole of the foot, the first layer was wrapped circularly with 50% overlapping rate, 80% tension, and wrapped from the sole of the foot to the groin.
224027430|NCT05847725|OTHER|Kinesio taping|Kinesio taping was applied in the form of a fan by cutting into 4 longitudinal pieces using the lymphatic correction technique with 15-20% tension, starting from the periphery of the inguinal lymph nodes on the medial, anterior and lateral of the leg, following the removal of the drains from the 1st post-op day.
224027431|NCT03800641|DRUG|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
224027432|NCT02569554|DRUG|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
224027433|NCT02569554|DRUG|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
224027434|NCT02686905|DIETARY_SUPPLEMENT|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
224027435|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
224027436|NCT02686905|DIETARY_SUPPLEMENT|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
224027437|NCT02686905|DIETARY_SUPPLEMENT|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
224134235|NCT03768531|DRUG|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
224134236|NCT03768531|DRUG|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
224027438|NCT02686905|DIETARY_SUPPLEMENT|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
224027439|NCT02686905|DIETARY_SUPPLEMENT|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
224027440|NCT04242563|OTHER|VIRTUAL REALITY|Patient equipped with virtual reality in transfer room
224027441|NCT00225693|DEVICE|drug eluting coronary stent|
224027442|NCT01809223|DRUG|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
224027443|NCT01809223|DRUG|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
224027444|NCT01809223|OTHER|sham injection|sham intravitreal injection per month, fixed injection
224027445|NCT00881608|DRUG|Placebo|Placebo, 1 capsule daily for five days
224134237|NCT01216592|OTHER|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
224134238|NCT02241044|DEVICE|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
224134239|NCT02241044|DEVICE|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
224134240|NCT02797704|DRUG|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
224027446|NCT00881608|DRUG|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
224027447|NCT01771328|DRUG|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
224027448|NCT01771328|DRUG|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
224027449|NCT03214094|DRUG|Vonoprazan|Vonoprazan tablets
224027450|NCT02322138|OTHER|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
223410553|NCT05202067|BEHAVIORAL|pharmaceutical education|The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
223410554|NCT04065984|DEVICE|Microstim 2v2 Stimulator|Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
223410555|NCT04244084|DRUG|MMH-407|Oral use.
223410556|NCT04244084|DRUG|Placebo|Oral use.
223410557|NCT00026494|DRUG|temozolomide|
224027451|NCT02322138|OTHER|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
224027452|NCT02322138|OTHER|Reference Group|Breast fed ad libitum
224027453|NCT02711111|DEVICE|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
224027454|NCT02711111|DEVICE|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
224027455|NCT00598143|BEHAVIORAL|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
224027456|NCT00598143|BEHAVIORAL|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
224027457|NCT03385070|DIAGNOSTIC_TEST|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
224027458|NCT00913354|DEVICE|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
224027459|NCT00913354|DEVICE|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
224027460|NCT00315432|DRUG|Pegylated Interferon and Ribavirin|
224027461|NCT02583087|PROCEDURE|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
224027462|NCT01274585|DEVICE|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
224027463|NCT01274585|DEVICE|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
224134241|NCT01064193|PROCEDURE|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~* Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~* Insert carefully the pipelle de Cornier® in the uterus through the cervix.~* Withdraw the piston to create a negative pression~* Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~* Withdraw the pipelle de Cornier® when filled with tissue~* Reinsert internal piston to deposit sample in cup filled with a fixative."
224134242|NCT01064193|PROCEDURE|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
224134243|NCT04825145|OTHER|Pregnancy|Pregnancies complicated by preeclampsia
224298061|NCT01937247|PROCEDURE|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
223410558|NCT00026494|DRUG|vinorelbine tartrate|
223410559|NCT01052194|DRUG|Placebo|tablet, placebo b.i.d. for 12 weeks
223410560|NCT01052194|DRUG|VX-509|tablets, 25mg b.i.d. for 12 weeks
223410561|NCT01052194|DRUG|VX-509|tablet, 50 mg b.i.d. for 12 weeks
223410562|NCT01052194|DRUG|VX-509|tablet, 100 mg b.i.d. for 12 weeks
223410563|NCT01052194|DRUG|VX-509|tablet, 150 mg b.i.d. for 12 weeks
223410564|NCT00943540|DRUG|raltegravir QD|Raltegravir 800mg QD
223410565|NCT00943540|DRUG|atazanavir|atazanavir
223410566|NCT00943540|DRUG|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
223410567|NCT02949440|PROCEDURE|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
223558980|NCT01345929|DRUG|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
223558981|NCT01345929|DRUG|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
223558982|NCT03396497|DRUG|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
223558983|NCT03396497|DRUG|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
223558984|NCT02456753|DEVICE|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
223558985|NCT02151903|DRUG|DI-Leu16-IL2|DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
223558986|NCT02412189|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
223558987|NCT02412189|DRUG|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
223410568|NCT02949440|PROCEDURE|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
223410569|NCT02890576|OTHER|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
223558988|NCT06299163|BIOLOGICAL|NM32-2668|Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody
224027464|NCT03177278|DRUG|[14C]-plazomicin|single intravenous dose
224027465|NCT02013505|OTHER|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
224027466|NCT02715531|DRUG|5-FU|5-FU (400 mg/m\^2) will be administered as an IV bolus, followed by 2400 mg/m\^2 by continuous IV infusion over 46 (± 1) hours, q2w.
224027467|NCT02715531|DRUG|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
224027468|NCT02715531|DRUG|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
224027469|NCT02715531|DRUG|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
224027470|NCT02715531|DRUG|Leucovorin|Leucovorin 200 mg/m\^2 L-isomer form or 400 mg/m\^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
224027471|NCT02715531|DRUG|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m\^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
224134244|NCT04061681|BEHAVIORAL|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
224134245|NCT04044209|DRUG|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
223410570|NCT00529620|DRUG|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
223558989|NCT01547351|OTHER|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
223558990|NCT00004573|DRUG|ganciclovir|
224027472|NCT02715531|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2 will be administered IV over 120 (± 5) minutes q2w.
223410571|NCT00529620|DRUG|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
223410572|NCT00529620|DRUG|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
223558991|NCT06626529|BEHAVIORAL|Guided mindfulness meditation|Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.
223558992|NCT06626529|BEHAVIORAL|Scenery video|Watching a ten-minute video of calming music and images
223558993|NCT00505973|DRUG|SCA-136|
223558994|NCT02018536|DRUG|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
223558995|NCT02018536|DRUG|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
224027473|NCT02715531|DRUG|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m\^2) twice daily on Days 1-4 of a 21-day cycle.
224027474|NCT02715531|DRUG|Cisplatin|Cisplatin will be administered as 80 mg/m\^2 IV over 120 minutes q3w (Group E2).
224027475|NCT02723409|PROCEDURE|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
224027476|NCT02723409|PROCEDURE|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
224134246|NCT04044209|DRUG|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
224134247|NCT03712345|DRUG|IFX-1 low dose|Single IV infusions of IFX-1
224134248|NCT03712345|DRUG|IFX-1 high dose|Single IV infusions of IFX-1
224134249|NCT03712345|DRUG|Placebo|Placebo
224027477|NCT02723409|PROCEDURE|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
224027478|NCT02723409|PROCEDURE|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
224027479|NCT02723409|PROCEDURE|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
224027480|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
224027481|NCT00679653|DRUG|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
224027482|NCT00679653|DRUG|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
224027483|NCT00679653|DRUG|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
224027484|NCT00679653|DRUG|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
223410573|NCT03324620|OTHER|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
224027485|NCT04308772|BEHAVIORAL|Web-based Physiotherapy|Participants will receive an exercise programme, based on those patients usually get in the form of an exercise leaflet, delivered via a web-based physio website (www.giraffehealth.com). Participants will be asked to complete their exercise programme as prescribed (at least once each day) and to fill out an online exercise diary which the physiotherapist can see remotely from the clinical site.
224027486|NCT00795951|BIOLOGICAL|T.R.U.E. Test|48 hour application of 28 allergens and negative control
224027487|NCT00353379|DRUG|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
224027488|NCT00353379|DRUG|Placebo|Participants will take placebo for 6 weeks.
224027489|NCT00186771|DEVICE|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
224027490|NCT00186771|DEVICE|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
224027491|NCT02277405|DEVICE|Shikani Optical Stylet|Optical intubation
223410574|NCT04941612|DEVICE|Activa IM-Nail|PLGA bioabsorbable intramedullary nail
223410575|NCT06130514|DEVICE|Ultrasound|Ultrasound-guided stellate ganglion block with 1% mepivacaine 5 mL
223410576|NCT06130514|DEVICE|Fluoroscopy|Fluoroscopic-guided thoracic sympathetic ganglion block with 1% mepivacaine 3 mL
224027492|NCT02277405|DEVICE|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
224027493|NCT03126708|DRUG|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
224027494|NCT03126708|DRUG|cisplatin plus paclitaxel|Chemotherapy
223410577|NCT03185195|DRUG|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
223410578|NCT03185195|DRUG|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
223410579|NCT03185195|DRUG|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
223410580|NCT04160039|DEVICE|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
223558996|NCT02018536|DRUG|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
223558997|NCT02018536|DRUG|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
224027495|NCT01832441|OTHER|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
224027496|NCT02088749|BEHAVIORAL|lifestyle intervention for obesity|
224134250|NCT04600050|OTHER|usual care and exercise education|Provide exercise training materials after the education of exercise and health to enable home-based exercise
223410581|NCT01684423|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
223410582|NCT01684423|DRUG|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
223410583|NCT01684423|DRUG|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
223410584|NCT05822323|OTHER|BTX-A|Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
223410585|NCT05822323|PROCEDURE|free gingival graft|The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
223410586|NCT05458999|OTHER|Virtual reality headset during percutaneous coronary intervention|Virtual reality glasses during percutaneous coronary intervention
223558998|NCT02018536|DRUG|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
224027497|NCT05877287|OTHER|mindfulness-based stress reduction program|The FTSA program will be carried out once a week for 60 minutes, for 8 weeks, in a total of 8 sessions. The program will be conducted in face-to-face groups. Sessions will be held in a suitable area in the practice area. In each 60-minute session, it is planned to be 20 minutes of narration on the subject of the session, accompanied by a power point presentation, and the remaining 40 minutes of exercise, meditation practices and sharing experiences.
224027498|NCT04293315|BEHAVIORAL|Improvement Cycles|"This is a multi-component intervention following the Institute for Healthcare Improvement (IHI)'s Collaborative Model for Achieving Breakthrough Improvement by implementing plan-do-study-act (PDSA) improvement cycles. The investigators will conduct 8 participative learning sessions for the primary care team. These sessions will be aimed at identifying opportunities for improvement oriented to the design and application of innovative approaches based on best practices."
224027499|NCT00377247|BIOLOGICAL|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
224027500|NCT00690820|DRUG|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
224027501|NCT00690820|DRUG|Placebo Comparator|Placebo
224027502|NCT00629330|BEHAVIORAL|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
224298062|NCT01937247|DRUG|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
223410587|NCT04890197|DIETARY_SUPPLEMENT|tahini|48 grams tahini
223410588|NCT04890197|OTHER|control|no intervention
224027503|NCT04581668|OTHER|Neurally adjusted ventilatory assist first|Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode
224027504|NCT04581668|OTHER|Conventional ventilation first|Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist
224027505|NCT00585377|DRUG|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
224027506|NCT03422354|PROCEDURE|Ultrasound guided PVB with General Aneasthesia|An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
224027507|NCT03422354|DEVICE|Ultrasound|Ultrasound
224027508|NCT03422354|DRUG|Paravertebral block|Patients will receive single shot L1-L2 PVB before undergoing GA
224027509|NCT03422354|DRUG|General Aneasthesia|General Aneasthesia
224027510|NCT01383772|PROCEDURE|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
224027511|NCT01312012|DRUG|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level \> 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
224027512|NCT03752918|DRUG|MDMA|A single dose of 1.5mg/kg will be administered once orally.
224027513|NCT03752918|DRUG|Niacin|A single dose of 250mg will be administered once orally.
224027514|NCT00846391|DRUG|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
224027515|NCT00846391|DRUG|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
224027516|NCT00846391|DRUG|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
224027517|NCT01509131|DRUG|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
224027518|NCT01509131|DRUG|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
223410589|NCT01455597|DRUG|WC3011 Estradiol Vaginal Cream|WC3011 estradiol vaginal cream, 3 times a week for 40 weeks.
223410590|NCT00441129|DEVICE|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
223410591|NCT00441129|DEVICE|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
223558999|NCT02018536|DRUG|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
223559000|NCT02018536|DRUG|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
224027519|NCT00251420|PROCEDURE|writing about disease|writing about physical or emotional consequences of pulmonary disease
224027520|NCT02652273|DRUG|Abatacept|Abatacept 125mg/ml
224134251|NCT04600050|OTHER|Eccentric exercise|Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
224134252|NCT02765633|DRUG|Cangrelor|
224134253|NCT02640066|OTHER|acupuncture|
223410592|NCT00405431|DRUG|Restasis|1 drop in study eye twice a day X 6 months
223410593|NCT00405431|DRUG|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
223410594|NCT03358069|DIAGNOSTIC_TEST|Emergence agitation scale|Emergence agitation scale: PAED scale \> 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
223410595|NCT04632069|COMBINATION_PRODUCT|N acetyl cysteine + vagus nerve stimulation|NAC x 14 days, taVNS x 10 days
223559001|NCT05335304|OTHER|intervention group 1|Kinesio taping The intervention of this experimental study is therapeutic taping (kinesio tape) on the respiratory muscles of the participants.
223559002|NCT05335304|OTHER|intervention group 2|Rigid taping The intervention of this experimental study is therapeutic taping (rigid tape) on the respiratory muscles of the participants.
223559003|NCT05335304|OTHER|intervention group 3|Thoracic Mobilization The intervention of this experimental study is active-passive Thoracic mobilization techniques on the on the upper, middle or lower parts of the chest of the participants
223559004|NCT05335304|OTHER|intervention group 4|Core Stabilization The intervention of this experimental study is Core Stabilization exercises to the trunk muscles of the participants.
224027521|NCT02442323|BEHAVIORAL|Walking Intervention|12-week walking program
224027522|NCT00913120|DRUG|YM150|oral
224027523|NCT00913120|DRUG|Placebo|oral
224027524|NCT00913120|DRUG|Enoxaparin|injection
224027525|NCT00122915|DEVICE|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
224134254|NCT02585999|DEVICE|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
224134255|NCT00485589|DRUG|Methotrexate|Oral repeating dose
224134256|NCT00485589|DRUG|Ocrelizumab|Intravenous repeating dose
224027526|NCT00635856|DRUG|Gefitinib|Iressa
224027527|NCT00648830|PROCEDURE|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
223410596|NCT01156623|PROCEDURE|EBUS-TBNA|All included patients received TBNA for lymph node study via a flexible ultrasonic bronchoscope with a linear scanning probe on the tip (BF-UC206F-OL8, Olympus). The curved-probe scanned parallel to the insertion direction of bronchoscope, and the obtained images were linked to the ultrasound scanner (EU-2000C, Olympus) incorporated with Doppler-flow imaging. Each lymph node greater than 5mm in short axis measured by cursors was selected for subsequent TBNA with a 22-gauge (NA-201SX-4022, Olympus) needle in a condition of real-time EBUS guidance. A cytology examination was sent for pathologist blinded for the clinical history and image result of patients. When a tissue core was obtained by TBNA, the specimen was also sent for pathology study.
223410597|NCT03421210|DRUG|Nicotine patch|Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
223410598|NCT02443714|DEVICE|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
223410599|NCT02443714|DEVICE|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
224027528|NCT00648830|DRUG|Clarithromycin|single-dose 250 mg immediate-release oral tablets
224027529|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
224027530|NCT00449553|DRUG|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
224027531|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
224027532|NCT00449553|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
224027533|NCT02475902|BEHAVIORAL|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
224027534|NCT02475902|BEHAVIORAL|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
224027535|NCT00104559|BEHAVIORAL|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
224027536|NCT00104559|BEHAVIORAL|Standard paper consent form|Standard paper consent form
223410600|NCT00534781|DEVICE|plasma microdebrider|Coblation of the Achilles
223410601|NCT00534781|PROCEDURE|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
223410602|NCT03325634|OTHER|Laboratory Biomarker Analysis|Correlative studies
224027537|NCT03339570|PROCEDURE|Orthopedic treatment for a proximal humeral fracture|Orthopedic treatment consisting in inmobilization of the arm in a sling for the first three weeks, followed by physical therapy.
224134257|NCT00485589|DRUG|Placebo|Intravenous repeating dose
224134258|NCT02104999|DEVICE|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
223410603|NCT03325634|OTHER|Quality-of-Life Assessment|Ancillary studies
223410604|NCT03325634|OTHER|Questionnaire Administration|Ancillary studies
223410605|NCT03325634|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223410606|NCT03412734|DRUG|Chlorhexidine|Chlorhexidine preparation solutions
223410607|NCT03412734|DRUG|Iodine|Iodine-based preparation solutions
223410608|NCT04851990|OTHER|To Better Days Large Patch|Large patch containing vitamin D \& Dextrose for transdermal absorption
223559005|NCT05335304|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation respiratory rehabilitation, stretching exercises, posture correction exercises
223559006|NCT01667497|DRUG|Fampridine SR|
223559007|NCT01667497|DRUG|Placebo|
223559008|NCT02606123|DRUG|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
224027538|NCT05748691|DIAGNOSTIC_TEST|Clinical implementation of hs-cTnT|To investigate the clinical impact on the transition from a hs-cTnI assay to a hs-cTnT assay in consecutive patients presenting to the Emergency Department or Acute Medical Unit with suspected acute coronary syndrome.
224027539|NCT00722930|DRUG|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
224027540|NCT05310487|BIOLOGICAL|162|The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
224027541|NCT05310487|OTHER|Placebo|an intervention that appearance is the same as 162, but contains no active ingredients
224027542|NCT04616976|BIOLOGICAL|convalescent plasma|convalescent plasma was get from the patients who recovery from COVID-19
224027543|NCT04634825|BIOLOGICAL|Enoblituzumab|Anti-B7-H3 antibody
224027544|NCT04634825|BIOLOGICAL|Retifanlimab|Anti-PD-1 antibody
224027545|NCT04634825|BIOLOGICAL|Tebotelimab|PD-1 X LAG-3 bispecific DART molecule
224027546|NCT02688283|OTHER|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
224027547|NCT05087485|OTHER|education|digital education in skin cancer diagnostics
224027548|NCT05624385|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Tremor-Related Subjects
224027549|NCT00286078|DEVICE|Precision|Implantable neurostimulator
224134259|NCT00249639|BEHAVIORAL|Contingency management|Rewards valued $1-$100
224134260|NCT00003856|DRUG|temoporfin|
224298063|NCT01937247|PROCEDURE|STANDARD PROCESS|standard process
224298064|NCT01663727|DRUG|Bevacizumab [Avastin]|Intravenous repeating dose
224298065|NCT01663727|DRUG|Paclitaxel|Intravenous repeating dose
223410609|NCT04851990|OTHER|To Better Days Small Patch|Small patch containing vitamin D \& Dextrose for transdermal absorption
223410610|NCT02467790|DRUG|PEX168|PEX 168: 200µg,Subcutaneous,one time.
223410611|NCT04679532|OTHER|Gx sweat patch|Adhesive-backed flexible epidermal wearable regional sweat patch to collect and analyze sweat via microfluidics and colorimetric assay
224027550|NCT00521560|DRUG|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
224027551|NCT05199974|PROCEDURE|Midline abdominal closure|Abdominal Closure in Emergency Midline Laparotomy
224027552|NCT00293631|DRUG|Lornoxicam 8 mg|
224027553|NCT00293631|DRUG|Lornoxicam 16 mg|
223410612|NCT04679532|OTHER|Reference sweat patch|Adhesive Tegaderm with absorbent pad regional sweat patch to collect sweat, followed by standard benchtop gravimetry and ion chromatography methods to analyze sweat
223410613|NCT05732337|DEVICE|Poxclin Coolmousse|cooling mousse for application in the skin
223410614|NCT04870385|BEHAVIORAL|5-week prevention program|Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
223410615|NCT04870385|BEHAVIORAL|Control|Control group waitlisted to receive prevention program after completion of final data collection.
223410616|NCT00812383|DEVICE|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
223410617|NCT04604171|BEHAVIORAL|Action Observation Training|Action Observation Training (AOT) is composed, according to Franceschini et al. (2012), by 20 different videos of daily activities (actions) carried out with the upper limbs. Patients underwent only one task per day for 20 sessions, starting from the easiest. Each action (unimanual or bimanual) is observed from a first-person perspective. Actors in the videos are young non-disabled people, either men or women. Patients are asked to carefully observe the videos, in order to prepare themselves to imitate the presented actions, while the therapist consistently holds the patient's attention with verbal feedback. At the end of each sequence, the therapist prompts the patient to perform the same movement with the paretic upper limb over a time period of 2 minutes, providing verbal instructions or help, if needed. Each session lasts about 30 minutes (3 min of sequence observation and 2 min of action performance for 3 motor sequences repeated twice).
223410618|NCT04604171|BEHAVIORAL|Task Oriented Training|In Task Oriented Training patients performed functional activities with the upper limbs, using the same objects for AOT, in both unimanual and bimanual modalities, without watching the video beforehand. The therapist just provided for verbal instructions and feedback, avoiding demonstrative or imitative indications. The therapist could passively support the movement if patients were completely unable to perform the actions. When necessary, the therapists could also actively facilitate the upper limb movement if patients were unable to correctly perform the actions. Based on the patient's level of motor ability and progress, the levels of movement and task difficulty could be adjusted accordingly. Patients underwent one task per day for 20 sessions. Each session lasted about 30 minutes.
223410619|NCT04604171|BEHAVIORAL|Conventional Treatment|Conventional treatment consists of a range of different patient-tailored interventions, selected by the therapist on the basis of the functional level of the patient. Treatment sessions include training for transfers, mobility, walking up and down steps, balance tasks and tailored functional tasks for the upper limbs (unimanual and bimanual). Moreover, it is also provided for joint and soft tissue mobilization, specific sensory stimulation, exercises to increase strength, both for lower and upper limbs. Each session lasted about 60 minutes.
223410620|NCT00984893|DRUG|zoledronic acid|
223410621|NCT00984893|DRUG|Any oral bisphosphonates marketed in Canada|
223410622|NCT04747886|BEHAVIORAL|WW Only|WW is a structured behavioral weight management program that focuses on diet, physical activity and mindset skills. The dietary approach is based on creating an energy deficit diet to produce weight loss while also being attentive to the quality of the calories. Specifically, the WW program assigns SmartPoints values to foods based on calories, sugar, saturated fat and protein. In addition, particular foods are assigned a points value of zero (0) to encourage a healthier eating pattern (e.g. fruits, vegetables, non-fat yogurt, fish).
223410623|NCT04747886|BEHAVIORAL|WW + PolyRules!|In addition to WW, participants will be asked to engage in daily cognitive training using the PolyRules! app for three months. They will be instructed to start with 20-min of daily cognitive training and to progressively increase their training time to 30-min.
223410624|NCT05901935|DRUG|DP303c|DP303c injection, 3.0 mg/kg, Q3W.
223410625|NCT05901935|DRUG|Trastuzumab|IV, 6 mg/kg, D1, Q3W
224027554|NCT00293631|DRUG|Ketorolac 30 mg|
224027555|NCT00293631|DRUG|Placebo|
224027556|NCT02745743|DRUG|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
224027557|NCT03401541|DRUG|Calcifediol|One capsule of 900 micrograms of 25(OH)D
224027558|NCT03401541|DRUG|Calciferol|One capsule of 900 micrograms of Vitamin D
224027559|NCT02009995|BEHAVIORAL|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
224298066|NCT01663727|DRUG|Placebo|Intravenous repeating dose
223410626|NCT05901935|DRUG|Vinorelbine Tartrate|IV, 25 mg/m\^2，D1、D8，Q3W
223410627|NCT05901935|DRUG|Capecitabine tablets|PO 1000 mg/m\^2, bid, D1-D14, Q3W
223410628|NCT03259464|DRUG|BI 685509|3 sequential dose groups
223410629|NCT03259464|DRUG|Placebo|3 sequential dose groups
224298067|NCT06898437|DRUG|177Lu-LNC1004 Injection|Intravenous administration: a single dose of 80 mCi per Cycle
224298068|NCT04339751|DRUG|Vorinostat|Administration of Vorinostat
224298069|NCT01513564|DRUG|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
223738639|NCT04208204|OTHER|somatocognitive physiotherapy|Somatocognitive physiotherapy (SCT) is a multimodal physical therapy approach that has been developed in an attempt at alleviating the burden of longstanding pain. The main foci of SCT include: (1) bodily exercises and techniques increasing body awareness, ability to relax and control muscle tension in different situations; (2) education about the vulvodynia and factors influencing pain experience; (3) coping with emotions and thoughts related to bodily experiences; and (4) structured homework assignments promoting application of the learned techniques in daily situation and gradual exposure to activities associated with pain. An important goal of SCT is to facilitate integration of new bodily habits into the patient's daily activities. The most important learning process thus occurs in the space between the treatment sessions. The therapeutic techniques are to be rehearsed in everyday situations.
224027560|NCT02009995|BEHAVIORAL|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
224027561|NCT02152657|OTHER|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
224027562|NCT04112901|DEVICE|Microprocessor-controlled knee joints|Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).
224027563|NCT04112901|DEVICE|Non-microprocessor-controlled knee joints|Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
224027564|NCT04175002|DRUG|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
224027565|NCT02388646|OTHER|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
224027566|NCT02388646|DEVICE|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
224027567|NCT02388646|OTHER|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
224027568|NCT01728532|DEVICE|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
224027569|NCT01728532|DEVICE|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
224027570|NCT01462838|BIOLOGICAL|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
224027571|NCT01530022|DRUG|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
224027572|NCT01530022|DRUG|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
224027573|NCT02953366|DRUG|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
224027574|NCT02953366|DRUG|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
224134261|NCT01922778|PROCEDURE|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
224134262|NCT04633057|DRUG|TJ101|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site, investigator evaluate effectiveness and safety.
224134263|NCT04633057|DRUG|NordiFlex|TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive Recombinant Human Somatropin Injection 0.034 mg/kg once a day, until 52 weeks back site, investigator evaluate effectiveness and safety.
223410630|NCT05082675|PROCEDURE|HLA Matched allogeneic transplant|
223410631|NCT06368271|DIETARY_SUPPLEMENT|Lipidomics|Health beneficial effects of medium-chain fatty acids
223738640|NCT05216731|PROCEDURE|Femoro-popliteal bypass|Under general or local anesthesia: Use of the best vascular substitute (inverted saphenous vein or vascular prosthesis).
224027575|NCT02977208|PROCEDURE|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
223410632|NCT00410332|DRUG|Traumeel S|homeopathic remedy
223410633|NCT00410332|DRUG|Placebo|placebo drug, identical in size, form and taste as treatment remedy
223410634|NCT04156711|PROCEDURE|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
223410635|NCT00017082|DRUG|oxaliplatin|
223410636|NCT00169611|DRUG|methylphenidate|
223410637|NCT05137444|BIOLOGICAL|LYB001|The investigational vaccine, with its antigen consisting of receptor-binding domain (RBD) from SARS-CoV-2 and virus-like particle (VLP) vector, adjuvanted with aluminum hydroxide.
224027576|NCT02977208|PROCEDURE|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
224027577|NCT02977208|PROCEDURE|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms
224027578|NCT02977208|DRUG|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
224027579|NCT01266135|DRUG|QAX576|QAX576 10 mg/kg intravenous infusion
223410638|NCT05137444|BIOLOGICAL|Placebo|Aluminum hydroxide
223410639|NCT04771221|DIAGNOSTIC_TEST|pH metry|The collection of mucus from the laryngopharynx to determine the acid-base values through pH-metry.
223410640|NCT04771221|DIAGNOSTIC_TEST|Filling out the questionnaire|Completion of the questionnaire index of reflux symptoms. An analysis of the results of the effectiveness of this method in patients with complaints of sore throat, coughing, burning sensation in the throat, cough, frequent sore throat, difficulty swallowing, lump in the throat, feeling of a foreign body in the throat, voice change, heartburn, belching will be carried out. Evaluation results range from 0 to 5, where 0 is an indicator of no problem, and 5 is an indicator of a serious problem
224027580|NCT01266135|DRUG|Placebo|Placebo to QAX576 intravenous infusion
224027581|NCT03514212|BEHAVIORAL|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
224027582|NCT06164509|DRUG|Alphintern® , tablet, Amoun, Egypt|Medications will be taken three times daily for 7 days postoperative, after that all cases will be reexamined regarding healing rate, adverse effect and failure rate of medical treatment.
224027583|NCT00153361|BEHAVIORAL|Discussion Group|
224027584|NCT00153361|BEHAVIORAL|Video Discussion Group|
223410641|NCT04771221|DEVICE|Endoscopic laryngoscopy|Video laryngoscopy and assessment of the presence / severity of the symptoms. Evaluation results range from 0 to 4, where 0 is an indicator of no problem, and 4 is an indicator of a serious problem
223559009|NCT03772795|OTHER|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
224027585|NCT03776019|DEVICE|AVWF device|The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
224027586|NCT03844542|DEVICE|Therapeutic plasma exchange|Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
224027587|NCT05604638|DRUG|Tenecteplase plus Tirofiban|Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
224027588|NCT05604638|DRUG|Tenecteplase plus Placebo|Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min
223410642|NCT04771221|DEVICE|Acoustic voice analysis|acoustic analysis of the voice was performed in singers with voice disorders before and after treatment using program of the Lingwaves
223410643|NCT04483960|DRUG|(Arm Closed) Nafamostat Mesilate|Nafamostat continuous IV infusion for 7 days or until day of hospital discharge at a dose of 0.2mg/kg/hour. No adjustment in dose is needed for renal impairment, including for renal dialysis. The daily dose of nafamostat should be administered in 500 mL (rate of infusion 20.8 mL/hour) of normal saline. Normal saline is recommended (due to the tendency for patients with COVID-19 towards hyponatraemia) but not mandated, and 5% dextrose would be acceptable if felt clinically appropriate.
223559010|NCT03772795|OTHER|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
223738641|NCT05216731|PROCEDURE|Endovascular procedure|Under general anesthesia, local anesthesia or sedation: Performing a balloon angioplasty completed by preferred stent deployment or drug-coated balloon angioplasty.
223738642|NCT05826886|BEHAVIORAL|Emotional Writing|Participants complete four 20-minute sessions of emotional writing (at home) on four consecutive days. Instructions are provided online before each writing session.
224027589|NCT01360060|DRUG|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
224027590|NCT02045966|DRUG|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
224027591|NCT02045966|DRUG|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
224027592|NCT02045966|DRUG|BMS-791325|
224027593|NCT02652143|DEVICE|AneVivo (Medical device for in vivo culture of embryos)|
224027594|NCT02652143|OTHER|comparator for embryo culture in vitro|
224027595|NCT01696838|OTHER|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
224027596|NCT01696838|OTHER|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
224027597|NCT03109145|OTHER|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
224027598|NCT05979454|DIAGNOSTIC_TEST|Krebs von den Lungen-6 (KL6)|KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
224027599|NCT03407560|DEVICE|SintLife|"Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage."
224027600|NCT06006689|DRUG|Qishen Yiqi Dripping Pills placebo 3 bags|Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
224134264|NCT01954069|DEVICE|Semi-quantitative pregnancy test|
224134265|NCT00066118|DEVICE|Dental amalgam restorations|
224134266|NCT02637440|PROCEDURE|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
224027601|NCT06006689|DRUG|Low dose Qishen Yiqi Dripping Pills 3 bags|Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
224027602|NCT06006689|DRUG|High dose Qishen Yiqi Dripping Pills 3 bags|High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
224134267|NCT02637440|PROCEDURE|Angio guided PCI|Patients receive PCI without FFR measurement
224134268|NCT01369849|DRUG|Akt Inhibitor MK2206|Given PO
224134269|NCT01369849|DRUG|Bendamustine Hydrochloride|Given IV
224134270|NCT01369849|OTHER|Laboratory Biomarker Analysis|Correlative studies
223410644|NCT04483960|DRUG|(Arm Closed) Enoxaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Enoxaparin will be 1mg/kg q12h or 1.5mg/kg q24h."
223410645|NCT04483960|DRUG|(Arm Closed) Dalteparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Dalteparin will be 100IU/kg q12h or 200IU/kg q24h."
223410646|NCT04483960|DRUG|(Arm Closed) Tinzaparin|"Patients will be administered either a standard dose, intermediate dose or therapeutic anticoagulation of low molecular weight heparin (depending on assigned arm), choice of agent according to availability and local practice at the participating site.~The maximum dose of Tinzaparin will be 175IU/kg q24h (not available within Australia)."
223410647|NCT04483960|BIOLOGICAL|(Arm Never Opened) Hyperimmune globulin|2 doses of 30mL (3x10mL vials) of COVID-19 Hyper-Immunoglobulin (Human) given over 2 days within 48 hours of randomisation. Three vials will have approximately 10500 AU of neutralising antibodies, equivalent to approximately 200mL of convalescent plasma
223559011|NCT06552546|DRUG|Icodextrin|Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
223559012|NCT05725226|DEVICE|Double J Stent 6Fr x 26cms|Surgery will be performed by expert Urologist.
223559013|NCT05725226|DEVICE|Double J Stent 4Fr x26cms|Surgery will be performed by expert Urologist.
224134271|NCT01369849|BIOLOGICAL|Rituximab|Given IV
224134272|NCT02262884|DEVICE|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
224134273|NCT02262884|DEVICE|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
224134274|NCT03687138|OTHER|24h urin sample|The samples will analyzed by proteomic techniques
223410648|NCT04483960|DRUG|Nirmatrelvir-Ritonavir|The dose of nirmatrelvir-ritonavir is dependent on renal function. Participants will receive 100mg BD of Ritonavir and either 150mg BD (if eGFR 30-59 mL/min/1.73m2) or 300mg BD (eGFR = 60 mL/min/1.73m2) of Nirmatrelvir. Investigators are advised to consider withholding treatment if participant's eGFR \< 30 mL/min/1.73m2.
223559014|NCT04231682|DRUG|Denosumab Injection|Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.
223559015|NCT04231682|DRUG|Placebos|Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
223738643|NCT02176681|DRUG|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
223738644|NCT02176681|DRUG|Insulin|Insulin
223738645|NCT02799212|DRUG|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
224027603|NCT04703231|DIAGNOSTIC_TEST|measurement of macular thickness, corneal thickness and lens opacities|The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
224027604|NCT05998473|DIAGNOSTIC_TEST|Dynamic stability measurement|The subject is asked to walk 8 meters 3 times: at free speed, at fast speed, and with large steps.
224027605|NCT03453320|DRUG|Albumin solution|Infusion rate and effects
224027606|NCT03286257|BEHAVIORAL|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
224134275|NCT03377244|BEHAVIORAL|HBHS|Faith based diabetes curriculum that teaches participants to connect faith and health plus church-level policy changes that encourages participants to engage in healthy behaviors.
224134276|NCT03377244|BEHAVIORAL|HBHS Policy|Church-level policy changes that encourages participants to engage in healthy behaviors.
224134277|NCT03377244|BEHAVIORAL|WORD DPP|Faith based diabetes curriculum that teaches participants to connect faith and health.
224134278|NCT00756886|DRUG|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
223738646|NCT02799212|DRUG|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
224134279|NCT00756886|DRUG|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
224134280|NCT00174785|DRUG|dronedarone (SR33589)|oral administration (tablets)
224134281|NCT00174785|DRUG|placebo|oral administration (tablets)
224134282|NCT01314976|DRUG|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
224027607|NCT01337115|PROCEDURE|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
224027608|NCT01337115|PROCEDURE|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
224027609|NCT05259020|COMBINATION_PRODUCT|ID140009|Combination Product: ID140009 Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg/ Amlodipine 10mg/ Valsartan 160mg
224027610|NCT05259020|COMBINATION_PRODUCT|ID1803+ID1805|(Amlodipine 10mg/Valsartan 160mg)+(Ezetibmibe 10mg/ Rosuvastatin Ca 20.8mg)
224027611|NCT05528029|DEVICE|Leadless Pacemaker (Micra)|Micra leadless pacemaker is implanted in the right ventricle via femoral vein. The Micra introducer/dilator assembled system is inserted over a stiff guidewire in the right atrium. After the removal of the guidewire and the dilator, the delivery system is advanced into the introducer and the Micra is placed under fluoroscopy guidance, preferably in the septal region of the right ventricle.
224027612|NCT02269332|OTHER|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
224027613|NCT03369990|DRUG|Botulinum toxin type A|Botulinum toxin type A(DWP450)
224027614|NCT03369990|DRUG|Placebos|Normal Saline
224027615|NCT05367232|DRUG|ICP-033 tablet|Administered orally, once a day, 28 days per cycle
224027616|NCT00226837|DRUG|Nitrous oxide|nitrous oxide by inhalation during induction
224027617|NCT01130233|PROCEDURE|robotic assisted rectal resection|robotic assisted rectal resection
224027618|NCT01130233|PROCEDURE|laparoscopic rectal resection|laparoscopic rectal resection
224027619|NCT02920619|DEVICE|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
224027620|NCT00610467|DEVICE|Disease Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
224027621|NCT00610467|DEVICE|Control Group|Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
224027622|NCT02684253|DRUG|Nivolumab|
224027623|NCT02684253|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|
224027624|NCT06024395|BEHAVIORAL|Dental FearLess|Dental FearLess is a self-administered CBT-based mobile app that takes approximately 1 hour to complete.
224027625|NCT02670031|OTHER|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
224027626|NCT02670031|OTHER|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
224027627|NCT02670031|OTHER|Electrocardiogram|To examine specific function of the heart.
224134283|NCT01314976|DRUG|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
224027628|NCT02670031|DEVICE|Ambulatory Blood Pressure Monitoring|A 24-hour test.
223410649|NCT04483960|DRUG|Remdesivir|The dose of intravenous remdesivir is 200 mg on day 1 followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first. Remdesivir will be administered as an intravenous infusion via a central or peripheral venous catheter over a 30-120 minute period, as per local practice.
224027629|NCT02670031|OTHER|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
224027630|NCT03626519|OTHER|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
224027631|NCT03626519|OTHER|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
224027632|NCT00044031|BIOLOGICAL|G17DT Immunogen|
224027633|NCT00551460|DRUG|arsenic trioxide|
224027634|NCT00551460|DRUG|gemtuzumab ozogamicin|
224027635|NCT00551460|DRUG|mercaptopurine|
224027636|NCT00551460|DRUG|methotrexate|
224027637|NCT00551460|DRUG|tretinoin|
224027638|NCT03151096|DIETARY_SUPPLEMENT|Riboflavin|one pill of Riboflavin will be taken orally with water
224027639|NCT03151096|DIETARY_SUPPLEMENT|Placebo|one pill of placebo will be taken orally with water
224027640|NCT05699954|DIAGNOSTIC_TEST|Presence of Blink impression features for cancer in colorectal polyps|"1. 20 LNPCPs will be collected from the UZ Ghent database (all LNPCPs, ICF present).~2. A survey will be made where participant endoscopist will be informed about the study. They will here be asked for electronic consent.~3. The survey asks for demographics of the participant endosopists (experience, country where they work).~4. The last part of the survey is where the 20 images of the LNPCPs are shown. After evere image 4 questions are asked. Is this a colorectal polyp? (Yes/No)~   * Is your Blink (first) Impression that this polyp contains cancer? (Yes/No)~  * If yes, why do you think that? (Free comment box)~  * What treatment would you recommend for this polyp? (piecemeal endoscopic mucosal resection/endoscopic submucosal disection/surgery)~5. Study will be closed after 2 weeks.~6. Data analysis"
224134284|NCT00274768|DRUG|capecitabine|A total of 115 cycles of therapy were administered and five patients did not complete cycle 1. The median number of cycles initiated was four (range 1-16).
224134285|NCT00120289|DRUG|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
224134286|NCT00120289|DRUG|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
224134287|NCT02285712|DEVICE|Vascular ultrasound system|
224134288|NCT03214926|DEVICE|Moving Through Glass intervention|
224134289|NCT03619291|OTHER|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
223410650|NCT04062201|DRUG|Bedaquiline Oral Tablet|Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - \>50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
223410651|NCT04062201|DRUG|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
224027641|NCT00519038|OTHER|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
223559016|NCT02340858|DEVICE|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
223559017|NCT03768089|DRUG|Placebo (matched to VX-121 suspension)|Placebo matched to VX-121 suspension for oral administration.
224027642|NCT00519038|OTHER|Usual Care|Usual care is the current practice actually performed in the hospital
224027643|NCT00640887|DRUG|rifabutin in combination with efavirenz|"Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
224027644|NCT00640887|DRUG|rifabutin in combination with nevirapine|"IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
224027645|NCT00640887|DRUG|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
224027646|NCT03074760|DIAGNOSTIC_TEST|Adenovirus|Diagnostic test for the presence of the adenovirus in the population groups
224027647|NCT03074760|DIAGNOSTIC_TEST|Rotavirus|Diagnostic test for the presence of the Rotavirus in the population groups
224027648|NCT03074760|DIAGNOSTIC_TEST|H. pylori|Diagnostic test for the presence of H. pylori infection in the population groups
224027649|NCT03226210|DRUG|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
224027650|NCT01687530|PROCEDURE|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
224027651|NCT02012114|OTHER|Cysteamine bitartrate|No intervention
224027652|NCT01745848|DRUG|Roflumilast|
224027653|NCT00776126|DEVICE|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
224027654|NCT02026310|DRUG|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
224134290|NCT03619291|OTHER|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
224134291|NCT03619291|OTHER|control|physical inactivity, reading sports science literature, total duration 15 minutes
224134292|NCT01932931|DIETARY_SUPPLEMENT|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
223410652|NCT04062201|DRUG|Delamanid in Oral Dosage Form|Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - \>50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
223410653|NCT04062201|DRUG|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
223559018|NCT03768089|DRUG|VX-121 (Suspension)|Suspension for oral administration.
223559019|NCT03768089|DRUG|TEZ/IVA|Fixed-dose combination tablet for oral administration.
223559020|NCT03768089|DRUG|IVA|Tablet for oral administration.
223559021|NCT03768089|DRUG|Placebo (matched to TEZ/IVA)|Placebo matched to TEZ/IVA for oral administration.
223559022|NCT03768089|DRUG|Placebo (matched to IVA)|Placebo matched to IVA for oral administration.
223559023|NCT03768089|DRUG|VX-121 (Tablet)|Tablet for oral administration.
223559024|NCT03768089|DRUG|Placebo (matched to VX-121 tablet)|Placebo matched to VX-121 tablet for oral administration.
223559025|NCT01780337|DRUG|Oxytocin|Intranasal dose of 20 IU oxytocin
223559026|NCT01780337|OTHER|Saline|Intranasal dose of saline
224027655|NCT02026310|DRUG|glargine and metformin|
224027656|NCT00679627|DRUG|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
224027657|NCT00679627|DRUG|Placebo|Matching placebo
224027658|NCT02731794|DEVICE|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
224027659|NCT02731794|PROCEDURE|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
224027660|NCT00396500|DRUG|Albendazole (400 mg) and/or Vitamin a|
224027661|NCT00448123|DRUG|Tamsulosin|Study Drug
224027662|NCT00448123|DRUG|Placebo|Placebo
223410654|NCT04062201|DRUG|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
223410655|NCT04062201|DRUG|Isoniazid Oral Product|Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group \>50kg: 600mg daily
223410656|NCT04062201|DRUG|Ethambutol Oral Product|Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group \>50kg: 1200mg daily
224027663|NCT00419666|DRUG|Calcitriol 3mcg/g|Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
224027664|NCT02027623|BEHAVIORAL|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
224027665|NCT02027623|BEHAVIORAL|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
224027666|NCT03991104|DRUG|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
224027667|NCT03991104|DRUG|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
224027668|NCT03991104|RADIATION|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
224027669|NCT06305377|DEVICE|Tandem Control IQ|Use of Tandem control IQ in a group of diabetic adolescents in not good glicaemic control
224027670|NCT00454766|BEHAVIORAL|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
224027671|NCT00645541|PROCEDURE|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
224027672|NCT02504944|DRUG|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
223410657|NCT04062201|DRUG|Pyrazinamide Oral Product|Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group \>50kg: 2000mg daily
223410658|NCT04062201|DRUG|Linezolid Oral Tablet|Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - \>50kg: 600mg daily
223410659|NCT04062201|DRUG|Clofazimine Oral Product|Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - \>50kg: 100mg daily
223410660|NCT04062201|DRUG|Levofloxacin Oral Tablet|Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group \>50kg:1000mg daily
223410661|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
223410662|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
223410663|NCT01602367|DRUG|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
223410664|NCT01602367|DRUG|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
223410665|NCT02183038|DRUG|Meloxicam low|
223559027|NCT05072860|DRUG|Topical tranexamic acid|temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
223559028|NCT05072860|OTHER|: normal saline|temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
223410666|NCT02183038|DRUG|Meloxicam high|
223410667|NCT02183038|DRUG|Naproxen sodium|
223410668|NCT02183038|DRUG|Meloxicam placebo low|
223559029|NCT06361394|OTHER|mindfulness course|"The experimental group will enroll in the elective course named Mindfulness and Happiness, which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course."
223410669|NCT02183038|DRUG|Meloxicam placebo high|
223410670|NCT02183038|DRUG|Naproxen sodium placebo|
223410671|NCT01210846|DRUG|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
223410672|NCT04952025|DIAGNOSTIC_TEST|Diagnostic criteria|Diagnostic criteria of ALS
223410673|NCT04586816|COMBINATION_PRODUCT|1% red maple leaf extract in cream base|1% red maple leaf extract is combined in a cream base
223410674|NCT04586816|COMBINATION_PRODUCT|5% red maple leaf extract|5% red maple leaf extract is combined in a cream base
223410675|NCT04586816|COMBINATION_PRODUCT|vehicle|vehicle cream base only
223410676|NCT05875896|PROCEDURE|Total wrist fusion|Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
224027673|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences baseline|Additional Liver Multiscan sequences at baseline besides standard care MRI liver /MRCP prior to ERCP.
224027674|NCT05359497|DEVICE|MRCP+ analysis baseline|Post processing tool (Software) for quantifying MRCP images after MRCP is performed. Patient involvement is not necessary during this procedure.
223559030|NCT02427139|DEVICE|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
223559031|NCT03319459|DRUG|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
223559032|NCT03319459|DRUG|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
223738647|NCT06216977|OTHER|Clear Liquids|Participants will not take anything by mouth after midnight the day before surgery but will be given 12 ounce clear liquid (Sugar-free Gatorade) at bedside at the pre-operative holding area
223410677|NCT02118116|OTHER|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
223410678|NCT02322112|OTHER|Microcrystalline Cellulose Supplementation|Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
224027675|NCT05359497|DEVICE|Liver Multiscan analysis baseline|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences at baseline are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
224027676|NCT05359497|DIAGNOSTIC_TEST|MRI liver with MRCP|An extra MRI liver with contrast and MRCP is performed 8 weeks after the ERCP following standard care protocol
224027677|NCT05359497|DIAGNOSTIC_TEST|Liver Multiscan sequences follow-up|Additional Liver Multiscan sequences are performed at 8 weeks after ERCP.
224027678|NCT05359497|DEVICE|MRCP+ analysis follow up|Post processing tool (Software) for quantifying MRCP images after the MRCP from follow up is performed. Patient involvement is not necessary during this procedure.
224027679|NCT05359497|DEVICE|Liver Multiscan analysis follow up|Post processing tool (Software) for determining the corrected T1 time after the additional LMS sequences from the follow up scan are performed. This cT1 reflects the activity of inflammation/fibrosis of the liver. Patient involvement is not necessary during this procedure.
224027680|NCT04305938|DIAGNOSTIC_TEST|Minimally invasive and non-invasive blood analyte measurement|Rapid point-of-care minimally invasive blood analyzer consisting of a spectrometer and a computer loaded with Kaligia software that controls the data acquisition and signal processing to interpret blood analyte measurement.
224027681|NCT02707237|OTHER|Verbal counseling|Verbal counseling done by physician
224027682|NCT02707237|OTHER|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
224027683|NCT04553198|BEHAVIORAL|Backward Locomotion Treadmill Training (BLTT)|9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
224134293|NCT00651612|DRUG|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
223410679|NCT02322112|OTHER|Acacia Gum Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
223738648|NCT06216977|OTHER|Standard of Care|Participants will not take anything my mouth after midnight day before surgery
223738649|NCT05145491|PROCEDURE|Immediate Vitrectomy|Surgery to remove epiretinal membrane (ERM). Vitrectomy will be performed on eyes within 1 month of randomization
223738650|NCT05145491|PROCEDURE|Deferred Vitrectomy|"Vitrectomy may be performed only if at least one of the following criteria is met:~1. Decrease in visual acuity ≥10 letters from baseline at a single visit presumed to be from ERM~2. Decrease in visual acuity ≥5 letters from baseline at two consecutive visits presumed to be from ERM~   a. Visits must be at least one month apart~3. Participant actively requests surgery due to worsening symptoms~4. Complication requires prompt surgical intervention (e.g., macular hole, retinal detachment, non-clearing vitreous hemorrhage)"
223738651|NCT02446457|OTHER|Laboratory Biomarker Analysis|Correlative studies
223738652|NCT02446457|DRUG|Lenalidomide|Given PO
223738653|NCT02446457|BIOLOGICAL|Pembrolizumab|Given IV
223738654|NCT02446457|BIOLOGICAL|Rituximab|Given IV
224027684|NCT01886378|DRUG|UX007|
224027685|NCT03369561|DIAGNOSTIC_TEST|Serum urea and creatinine and the calculated e GFR|The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
224027686|NCT03975205|DRUG|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
224027687|NCT03168386|PROCEDURE|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
223410680|NCT02322112|OTHER|Resistant Starch Type 4 Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
223410681|NCT06428123|BEHAVIORAL|Mirror Therapy on present Lower Limb|Patients will be seated close to a table on which a mirror will placed vertically. The normal (i.e., no amputated limb) will be placed in front of the mirror and made to perform movements of the different joints while the patient looking into the mirror.
223410682|NCT06428123|DIAGNOSTIC_TEST|Mental Imagery on present Lower Limb|"Mental imagery technique in which patients will be instructed to concentrate on sensations from each area of the body, including the phantom limb. Patients will be advised to imagine comfortable, thorough movement and sensation in the phantom limb, such that they could stretch away the pain, and finally to allow the limb to rest in a comfortable position. The actual therapy of moving and feeling the limb will lasted for 5 minutes. Patients will be asked to perform 40 minutes of meditation and imagery exercises."
223410683|NCT03090958|BEHAVIORAL|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
224027688|NCT05632445|DRUG|Apixaban vs. DAPT|Apixaban vs DAPT after LAAO
224027689|NCT02019043|OTHER|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
224027690|NCT02088918|DRUG|Nateglinide|
224134294|NCT00651612|DRUG|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
224134295|NCT05551338|OTHER|Serious games|The training protocol will entail using a tablet-based program that includes 6 serious games. Patients will be asked to use the program twice a week for 3 months. The serious games that will be used in this study were developed to challenge short-term memory and selective attention in six different games. Each of the six games comprise 20 different stages of varying difficulty, where stage 1 is the easiest and stage 20 is the most difficult.
224134296|NCT01944969|DRUG|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
223559033|NCT03319459|DRUG|Trastuzumab|HER2/neu receptor inhibitor
223559034|NCT02241655|DEVICE|a pragmatic EEG-guided anesthetic protocol|
224027691|NCT02088918|DRUG|Nateglinide/Metformin|
224027692|NCT02088918|DRUG|Metformin|
224027693|NCT03646201|BEHAVIORAL|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
224027694|NCT01210066|DRUG|Fentanyl|IV fentanyl 1mcg/kg
223559035|NCT04815512|DIAGNOSTIC_TEST|Liver function tests.|serum alanine amino transferase (ALT), aspartate amino transferase (AST), albumin (ALB), alkaline Phosphatase (ALP), total bilirubin.
223559036|NCT04815512|DIAGNOSTIC_TEST|kidney function tests|creatinine , urea and serum uric acid will be analysed in the serum.
223559037|NCT05770089|OTHER|Adapted Physical Activity (APA)|A 8-weeks program of APA (2x1hour per week) via videoconferencing composed of resistance training and yoga.
223559038|NCT00027144|BIOLOGICAL|Heat Shock Protein 70 HSP70|
223559039|NCT00733733|DRUG|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
223559040|NCT00256464|BEHAVIORAL|Multi-component Yoga Intervention|
223559041|NCT05906680|PROCEDURE|Additional biopsies collection|We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.
224134297|NCT02560831|BEHAVIORAL|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
224134298|NCT02560831|BEHAVIORAL|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
224134299|NCT05089344|DRUG|Growth Hormone|growth hormone
224134300|NCT05089344|DRUG|Clomiphene citrate daily and recombinant FSH (Gonal-F®)|Clomiphene citrate daily and recombinant FSH (Gonal-F®)
224134301|NCT03279302|DRUG|Glepaglutide|Solution for injection
224134302|NCT03411707|DIAGNOSTIC_TEST|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
224134303|NCT04203563|BEHAVIORAL|Strong People Strength Training|A community-based progressive strength training program
224134304|NCT05781971|DIETARY_SUPPLEMENT|high protein|Patients in high-protein group will be given a target protein amount of 2.0 g/kg/d. Standard enteral nutrition is the first choice,the remaining target value will be met by intravenous amino acid infusion.
224134305|NCT05781971|BEHAVIORAL|rehabilitation|In this trial, the investigator will provide early rehabilitation treatment such as respiratory training, bicycle training, and medium frequency electrical stimulation to patients.
224134306|NCT05781971|DIETARY_SUPPLEMENT|standard protein|The investigator set a protein target of 1.2 g/Kg/d for the standard protein group, which will be supplied enterally or parenterally.
224134307|NCT00961337|BIOLOGICAL|Trivalent inactivated influenza vaccine|one dose
223410684|NCT02541513|DRUG|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
223410685|NCT03581058|DRUG|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
223559042|NCT03030352|BEHAVIORAL|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
224027695|NCT01210066|OTHER|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
224027696|NCT01210066|OTHER|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
224027697|NCT01079741|BIOLOGICAL|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
223410686|NCT06143241|DEVICE|Threshold IMT|Threshold is used in respiratory muscle training in the form of resistance loading.
223410687|NCT06143241|DRUG|Antiepileptic medication|They will continue their antiepileptic medication prescribed by their doctor.
223559043|NCT05746091|PROCEDURE|wrist arthroscopy|Arthroscopic Partial Trapeziectomy with Hematoma Distraction in Basal Thumb Arthritis
223559044|NCT05141175|DEVICE|Hypertension medication algorithm|The algorithm is configured to align medication choices based on the hemodynamic findings from the ICG readings. This decision support tool was created so as to organize these medications based on their mechanism of action and is consistent with the evidence-based treatment of hypertension.
223559045|NCT05141175|DEVICE|Impedance Cardiography|The ICG system provides a printed report that indicates whether a person's hemodynamic state is predominantly one that is vasoconstricted, hyperdynamic, or mixed
223559046|NCT04961346|DEVICE|Ultrapro® mesh|large-pore, lightweight polypropylene mesh
223559047|NCT04961346|DEVICE|Premilene® mesh|small-pore, heavyweight polypropylene mesh
224027698|NCT04182594|DRUG|Degarelix|Treatment will start with two injections of 120 mg each followed by maintenance of a single injection of 80 mg administered every 28 days
224027699|NCT04182594|DRUG|GnRH agonist|GnRH agonist at the discretion of the treating Urologist/Oncologist for 1 year
224027700|NCT00446992|DRUG|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
224027701|NCT05171023|DEVICE|ROTEM and standard coagulation tests|ROTEM and standard coagulation tests assessment
224027702|NCT02590809|DRUG|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
224027703|NCT02590809|DRUG|Placebo|Placebo will be given for 30 days
224027704|NCT02590809|OTHER|Walk distance test|Walk distance test during 6 minutes
224027705|NCT02590809|OTHER|Exercise echocardiography|
224027706|NCT03341208|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
224027707|NCT01443715|BEHAVIORAL|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
224134308|NCT04759014|OTHER|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life|The effect of using two different prosthetic feet on functional capacity, pain severity, satisfaction level and quality of life
223410688|NCT05312463|DRUG|Tongjiang granule|Tongjiang granules, 1 bag / time, 3 times / day.
223410689|NCT05312463|DRUG|Tongjiang granule simulant|Tongjiang granule simulant,1 bag / time, 3 times / day.
223559048|NCT06023121|DIAGNOSTIC_TEST|Measurement of levels of an exosome-based liquid biopsy signature|Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
223559049|NCT02526953|DRUG|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
224027708|NCT01443715|BEHAVIORAL|Treatment as Usual|Standard treatment in the community
224027709|NCT05311891|DIAGNOSTIC_TEST|RT PCR|Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
224027710|NCT05807737|DEVICE|Ultrasound scanning with artificial intelligence|Three residents who are eligible to perform ultrasound-guided regional anesthesia will scan volunteers in random order with artificial intelligence software (Nerveblox) fed by an FDA-cleared ultrasound device.
224027711|NCT00947674|DEVICE|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
224134309|NCT03501745|BEHAVIORAL|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
224134310|NCT03948308|BIOLOGICAL|blood sample|blood sample before, during and after infection treatment
224134311|NCT01490762|DRUG|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
224134312|NCT01490762|DRUG|Regular Human Insulin|Subcutaneous injection
224027712|NCT06227078|DEVICE|Kinesiotaping|"Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results."
224027713|NCT03635307|OTHER|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
223559050|NCT02526953|DRUG|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
223559051|NCT02526953|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
223559052|NCT02526953|DRUG|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
223738655|NCT05070065|DEVICE|Cognitive remedy intervention with virtual reality (CEREBRUM)|Cognitive Remedial method Virtual Reality (CEREBRUM)
224027714|NCT00414713|PROCEDURE|red blood cell transfusion|red blood cell transfusion
224027715|NCT02472769|DRUG|IBP-9414|
224027716|NCT02472769|DRUG|Placebo|Sterile water
224027717|NCT00037128|DRUG|GL701|
224027718|NCT03143660|BEHAVIORAL|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
224027719|NCT03143660|BEHAVIORAL|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
224027720|NCT03905954|OTHER|Usual care|For this cross sectional survey, participants will be receiving usual care according to there health care systems
224027721|NCT05217654|DRUG|Dapagliflozin 10mg|Daily orally administration of 10mg dapagliflozin
224027722|NCT05217654|DRUG|Placebo|Daily orally administration of 10mg dapagliflozin-placebo
224027723|NCT05106829|OTHER|Physical therapy program with treadmill training without using of ankle weights.|The physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill without ankle weights.
224027724|NCT05106829|OTHER|Physical therapy program with treadmill training with using of ankle weights.|he physical therapy program include manual standing on the mat, manual standing on the mat with step forward and step backward, kneeling and half kneeling on the mat, changing position exercises from prone to standing and from supine to standing, equilibrium, protective and righting reactions using balance board and medical ball, balance training exercise from standing on the mat, strengthening exercises for weak dorsiflexors, stooping and recovery exercising from standing position, squatting to standing exercise, gait training in different directions and, stretching exercises for tight muscles (e.g: hip flexors, hamstrings and calf muscles in lower limb and for wrist flexors, pronators and elbow flexors in upper limb) + gait training on treadmill with ankle weights.
224027725|NCT04681027|DRUG|Oxymorphone hydrochloride (HCl)|Opioid
224134313|NCT04512469|DEVICE|Low molecular weight mesh|Following liver implantation, the subcostal incision will be closed using a running fascial closure with absorbable 1-0 Polydioxanone (PDS) suture and staples, with the treatment group also receiving a mesh.
224134314|NCT03038659|DEVICE|Penile Duplex|Measuring intima media thickness
224134315|NCT00418964|PROCEDURE|Single bundle hamstring|Single bundle hamstring
224134316|NCT00418964|PROCEDURE|Double bundle hamstring|Double bundle hamstring
223559053|NCT02526953|DRUG|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
223559054|NCT02526953|RADIATION|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
223559055|NCT04583215|DEVICE|Paired Associative Stimulation (PAS)|On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
223559056|NCT05491096|OTHER|Proprioceptive Neuromuscular Training|Proprioceptive exercises will be divided into three components. The first component will be comprised of standing on Foam with eyes open and eyes closed and passing any object from one subject to the other for 10 minutes. The second component consists of activity that will be performed in groups of two. Throwing and catching a ball will be performed while standing on foam for additional10 minutes. The third component, throwing and catching a ball, will be performed on trampoline to further challenge the balance system. After each set of 10-minute exercise, the subjects will be given two-minute resting periods. In the end, 10 minutes will be given for cooling down in which deep breathing exercises and static back extensor stretching exercises will be performed to avoid fatigue and to bring the heart rate back to the normal resting level.
223738656|NCT04263948|DEVICE|Picado system internet platform and connected objects|The system will monitor the circadian rhythms, physical activity, sleep, symptoms and body weight of patients with advanced pancreatic cancer during one week before (baseline) and six weeks after the 1st course of standard mFOLFIRINOX. The reach of preset thresholds for several parameters that are automatically computed will trigger alerts toward approved health professionals, and their responses will be traced.
224027726|NCT00188175|RADIATION|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
224027727|NCT02169453|DRUG|BIA 9-1067|OPC, Opicapone
224027728|NCT02169453|DRUG|Placebo|PLC, Placebo
224027729|NCT02169453|DRUG|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
224027730|NCT01999270|DRUG|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
224027731|NCT01999270|DRUG|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
224134317|NCT00418964|PROCEDURE|Bone patellar tendon bone|Bone patellar tendon bone
224134318|NCT05511675|DEVICE|cold application|ISO-BALL
224134319|NCT01044680|DIETARY_SUPPLEMENT|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
223410690|NCT03738436|OTHER|Physical therapy traditional neuromuscular training, NMT|The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
223410691|NCT03738436|OTHER|Physical therapy modified visual feedback, MVF|traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
224134320|NCT01044680|DIETARY_SUPPLEMENT|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
224134321|NCT04284943|PROCEDURE|Long limb Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
224134322|NCT04284943|PROCEDURE|Conventional Roux-en-Y reconstruction after subtotal gastrectomy|The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).
224134323|NCT04284943|PROCEDURE|Billroth II reconstruction after subtotal gastrectomy|The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
223410692|NCT00000918|DRUG|Indinavir sulfate|
223410693|NCT00000918|DRUG|Lamivudine/Zidovudine|
223410694|NCT00000918|DRUG|Ritonavir|
223410695|NCT00000918|DRUG|Amprenavir|
223410696|NCT00000918|DRUG|Efavirenz|
223410697|NCT00000918|DRUG|Saquinavir|
223410698|NCT00000918|DRUG|Lamivudine|
223410699|NCT00000918|DRUG|Stavudine|
224134324|NCT05516693|OTHER|Myofacial muscle training protocol.|Muscle training for orofacial motricity stimulation
223410700|NCT00000918|DRUG|Zidovudine|
223410701|NCT00000918|DRUG|Didanosine|
223410702|NCT01417741|DEVICE|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
223410703|NCT00098436|DRUG|laromustine|
223410704|NCT00098436|DRUG|temozolomide|
223410705|NCT04664036|DIAGNOSTIC_TEST|ultrasound|ultrasound to check for NAFLD according to Saverymuttu criteria
223410706|NCT04664036|DIAGNOSTIC_TEST|elastography|elastography to compare liver stiffness indices
223410707|NCT04664036|DIAGNOSTIC_TEST|controlled attenuation parameter (CAP)|CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis
223738657|NCT02282670|DRUG|DA-5204|
224027732|NCT01999270|DEVICE|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
224027733|NCT03200015|DRUG|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
224027734|NCT06372678|BIOLOGICAL|CM326|CM326 injection
224027735|NCT06372678|DRUG|Placebo|Placebo
223410708|NCT04664036|DIAGNOSTIC_TEST|FLI|the FLI is a score panel designed to screen for NAFLD
223410709|NCT04664036|DIAGNOSTIC_TEST|FIB-4|the FIB-4 is a score panel designed to screen for significant fibrosis
223410710|NCT04664036|DIAGNOSTIC_TEST|NFS|the NFS is a score panel designed to screen for significant fibrosis
223410711|NCT03777436|DRUG|Apremilast|Oral
223410712|NCT03777436|OTHER|Placebo|Oral
223410713|NCT03080064|BEHAVIORAL|Health Coach Intervention|Please see arm description.
223410714|NCT00676364|DRUG|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
223738658|NCT02282670|DRUG|Stillen tab.|
224027736|NCT04866446|DEVICE|endotracheal intubation and laringeal mask airway insertion|endotracheal intubation and laringeal mask airway insertion on the airway manikin with different devices
224134325|NCT02367534|PROCEDURE|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
224134326|NCT05102149|DRUG|PB-201|PB-201: 100 mg each time, orally in the morning and evening respectively;
224134327|NCT05102149|DRUG|Vildagliptin|Vildagliptin: 50 mg each time, orally in the morning and evening respectively;
224134328|NCT05102149|DRUG|PB-201 matched placebo|PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;
224134329|NCT05102149|DRUG|Vildagliptin matched placebo|One tablet each time, orally in the morning and evening respectively;
223410715|NCT00676364|DRUG|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
224027737|NCT02210234|DIETARY_SUPPLEMENT|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
224027738|NCT02210234|DIETARY_SUPPLEMENT|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
224027739|NCT01743625|DRUG|COV155|COV155 tablets
224027740|NCT01743625|DRUG|placebo|
224027741|NCT03021954|BIOLOGICAL|Platelet Rich Plasma|Platelet rich plasma is an autologous blood with high amount of platelet. It produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
224027742|NCT00004252|DRUG|fluorouracil|
224027743|NCT00004252|DRUG|leucovorin calcium|
224027744|NCT00004252|DRUG|semaxanib|
224027745|NCT00000198|DRUG|Piracetam|
224027746|NCT02791945|BEHAVIORAL|Medical Management Counseling|Brief alcohol counseling
224027747|NCT02791945|DRUG|N-acetylcysteine|Experimental supplement
224027748|NCT02791945|DRUG|Placebo|Placebo comparator
224027749|NCT01346436|PROCEDURE|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
224027750|NCT05063825|BEHAVIORAL|Simple cognitive task intervention|"A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes."
223410716|NCT05209464|DEVICE|Tele-Tai Chi|Study participants will follow a 12-week simplified Tele-Tai-Chi (TC) program delivered via an application installed on a tablet. The intervention emphasizes essential TC movements that are easily comprehensible and can be performed repetitively in a flowing manner. The protocol includes up to six core TC movements based on the traditional Cheng Man-Ch'ing's Yang-style short form. Additionally, a set of traditional TC warm-up exercises that focus on loosening the physical body, incorporating mindfulness and imagery into movement, promoting overall relaxation, and coordinating breathing awareness are included. Chairs are used in the protocol for a subset of seated warm-up exercises, as well as for stability and rest as needed. Participants will be asked to practice the protocol (45-60 min) at home for at least 3 days a week for 12 weeks. The TC program will also include 2 or more live instructional sessions via Zoom with a TC instructor.
223738659|NCT04067557|DIAGNOSTIC_TEST|molecuar test of BV|diagnosis of BV
224027751|NCT05063825|BEHAVIORAL|Attention placebo|A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
224134330|NCT05402098|PROCEDURE|Endodontic treatment using traditional access|Endodontic treatment will be carried out following complete removal of pulp chamber roof and achieving straight line access
223738660|NCT06245291|DRUG|Imdusiran|subcutaneous injection
223738661|NCT06245291|DRUG|Durvalumab|intravenous injection
223738662|NCT05435079|DEVICE|high-flow oxygen therapy device for tracheotomized patients|From the output end of the automatic pressure-adjustable oxygen flow meter, connect the oxygen suction tube, Venturi, Fisher \& Paykel MR850 heated humidifier, RT308 breathing tube with humidification tank, closed sputum suction tube and tracheostomy tube), Adjust the MR850 to invasive automatic transmission, the temperature sensor automatically adjusts and maintains the gas temperature at the inlet of the tracheostomy tube at 37°C according to the feedback temperature, and adjusts the oxygen therapy device according to the gas outflow from the exhalation port of the patient's inspiratory phase. The gas flow rate is 40-60L/min. According to the monitored pulse oxygen saturation (SpO 2 ), the concentration of the venturi valve and the corresponding oxygen flow rate are adjusted to maintain the SpO 2 between 94% and 100%.
223738663|NCT02383316|OTHER|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
224027752|NCT03061630|DRUG|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
224027753|NCT03061630|DRUG|Cisplatin|D1: CISPLATIN 60G/M2
224027754|NCT01090622|DRUG|XPF-001|Oral capsule
224027755|NCT01090622|DRUG|Placebo|Oral capsule
224027756|NCT01071525|DRUG|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant
224027757|NCT02722733|DRUG|G-CSF (filgrastim)|
224134331|NCT05402098|PROCEDURE|Endodontic treatment using conservative access|Endodontic treatment will be carried out following partial removal of pulp chamber roof, extended only to the extent which helps to locate all the orifices with no efforts will be made to achieve straight line access
223410717|NCT06578403|DEVICE|external microneedling|external micro\_needling
224027758|NCT02722733|DRUG|Cytosine arabinoside with G-CSF (filgrastim)|
224027759|NCT02430688|PROCEDURE|Irreversible electroporation (IRE)|
224027760|NCT02430688|DEVICE|NanoKnife|
224027761|NCT00526487|DEVICE|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
224027762|NCT00526487|DEVICE|Endovascular Repair|Endovascular Repair
224027763|NCT01171105|DRUG|AZD5213|oral solution, multiple ascending doses
224027764|NCT01171105|DRUG|Placebo to AZD5213|
224027765|NCT05537688|BEHAVIORAL|Identification of Graphic Markers|"The study consists of a single physical visit to the research team's site.~Participants will take a graphic task included in a validated test for language impairment in adults and older adults (DTLA). This test with writing data has a maximum completion time of 15 minutes. Diagnostic data will be collected from the patient's chart, frailty data and socio-demographic data will be collected by self-questionnaires.~Participants will be evaluated by the principal investigator or his or her representatives from the research team."
224027766|NCT02718937|DRUG|BTA-C585 oral capsule|
224027767|NCT02718937|DRUG|Matching placebo capsules|
224027768|NCT01911065|BIOLOGICAL|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
224027769|NCT01535950|DRUG|LFG316|
224027770|NCT01535950|DRUG|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
223410718|NCT06578403|OTHER|minimally invasive non- surgical periodontal therapy|minimally invasive non- surgical periodontal therapy
223410719|NCT06578403|DEVICE|internal micro_needling|internal micro\_ needling
223410720|NCT00903708|DRUG|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
223410721|NCT00447343|PROCEDURE|Decompressive cervical spine surgery|"Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery~Healthy volunteers will ONLY undergo two scans 6 months apart."
223410722|NCT00447343|PROCEDURE|fMRI and MRS scan|A scan pre-op and 6 months post-op.
223410723|NCT03636802|OTHER|Questionnaire BPI|Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
223410724|NCT01342770|OTHER|Laboratory Biomarker Analysis|Correlative studies
223410725|NCT01342770|DRUG|Pioglitazone Hydrochloride|Given PO
223559057|NCT05491096|OTHER|Conventional Physical Therapy|Conventional treatment protocolconsists of a structured exercise protocol Each training session consisted of three parts, the first part included the main movements (warming up 10 minutes plus 5 minutes stretching exercises), the second part consisted of specific movements (exercises with theraband and physioball, 20 minutes), and the third part composed of cool down exercises (10 minutes).(22)Experimental treatment protocolwill be proprioceptive training program. PTP will be based on earlier studies, and will be carried out for eight weeks, with two 60-minute sessions per week. It will start with 10 minutes of Warm-up activities when the subjects will be advised to do light manual stretches and to step up and down on foam to get their body warmed up to have improve muscular flexibility. This will be followed by 30 minutes of proprioceptive exercises targeting lower extremities.
223559058|NCT00265837|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
223559059|NCT00265837|PROCEDURE|allogeneic bone marrow transplantation|
223410726|NCT01342770|OTHER|Quality-of-Life Assessment|Ancillary studies
223410727|NCT02782559|DRUG|Sildenafil|
223410728|NCT02782559|DRUG|Placebo|Color and size matched to active drug (sildenafil)
223410729|NCT03821259|OTHER|Psychological measures|Participants will be asked to provide basic demographic information and to complete five measures, screening for cognitive impermanent and measuring PTSD symptoms, lifetime trauma exposure, emotion regulation and group identification.
223410730|NCT02316600|DEVICE|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
223410731|NCT02877875|BEHAVIORAL|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
223559060|NCT00265837|PROCEDURE|in vitro-treated bone marrow transplantation|
223738664|NCT06508593|DIAGNOSTIC_TEST|Serum metabolic profile|Venous serum samples were analyzed for serum metabolic profiles using liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) non targeted metabolomics techniques
223738665|NCT05428488|DRUG|Abatacept (W12-W48)|"The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study."
224027771|NCT04660266|DIAGNOSTIC_TEST|Liver Ultrasound|liver ultrasound examination, including gray-scale and seven Doppler examination
224027772|NCT00549614|DRUG|acipimox|capsule, 250 mg, 4 times daily for 28 days
224027773|NCT00549614|DRUG|placebo|capsule, 250 mg, 4 times daily for 28 days
223410732|NCT02877875|OTHER|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
223410733|NCT02877875|BEHAVIORAL|Treatment as usual|Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
223410734|NCT02169375|OTHER|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
223410735|NCT00552370|DRUG|Lantus®|
223410736|NCT00869999|DRUG|Everolimus|Taken orally once daily in the morning
223410737|NCT00869999|DRUG|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
223410738|NCT01146899|OTHER|Provider Alert|Provider influenza vaccine alert
223559061|NCT04788485|DRUG|Diosmectite|use of diosmectite as a food thickener in neonates in with gastroesophageal reflux in noenates
223559062|NCT06310941|DEVICE|Mechanical insufflation-exsufflation|Combined use of mechanical insufflation-exsufflation with nebulized hypertonic saline in intubated patients with nosocomial respiratory tract infection
223410739|NCT03788993|OTHER|Blue-depleted evening light condition|"A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin."
223410740|NCT03788993|OTHER|Normal light condition|"The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h."
223410741|NCT02127411|BEHAVIORAL|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
223559063|NCT06310941|OTHER|Standard of Care|systemic antibiotic therapy and catheter suctioning of secretions as recommended by guidelines
223559064|NCT06310941|OTHER|Hypertonic saline with hyaluronic acid|Commercially available combination of 7% hypertonic saline with 0.1% hyaluronic acid given as nebulization during the MI-E session
223559065|NCT02972346|DRUG|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
223559066|NCT04601259|COMBINATION_PRODUCT|Orkla Corn Plaster with salicylic acid|Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
224027774|NCT02343055|OTHER|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
224027775|NCT02866110|BEHAVIORAL|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
224027776|NCT02866110|DEVICE|MRI|Echo-planar Imaging of brain BOLD signal
224027777|NCT03933527|BEHAVIORAL|making staining beverage rinse during in-office tooth bleaching|the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
224027778|NCT00160238|DRUG|Betahistine 24 mg bid (Betaserc)|
224027779|NCT00194519|DRUG|Generic acyclovir|400 mg twice-daily oral
224027780|NCT00194519|DRUG|Placebo|twice-daily oral
224027781|NCT03791671|OTHER|individual balance training|One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
224027782|NCT03791671|OTHER|group balance training|Like the individual balance training
223559067|NCT04601259|DEVICE|Orkla Corn Protector|Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
223559068|NCT04811755|BEHAVIORAL|Surgical timing from ED admission to surgery|the impact of delay of time between patient admission to ED and surgery for source control on 90-d mortality and postoperative outcomes in patients with gastrointestinal perforation with or without septic shock
223559069|NCT04528550|BIOLOGICAL|Autologous bone marrow-derived mononuclear cells|Intrathecal transplantation of autologous bone marrow-derived mononuclear cells through lumbar injection.
223559070|NCT04528550|DRUG|Placebo|Included patients will receive the same amount of saline through lumbar injection.
223559071|NCT05171374|DRUG|Dabrafenib|Observational stusy. No intervention is planned
223738666|NCT05428488|DRUG|TNF Inhibitor (W12-W48)|In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
223738667|NCT05428488|DRUG|TNF Inhibitor (W0-W12)|All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
223559072|NCT05171374|DRUG|Trametinib|Observational stusy. No intervention is planned
223738668|NCT06435819|OTHER|Embodied Conversational Agent (ECA)|A computer-animated character that can explain a medical illustration to laypersons.
224027783|NCT05918172|DEVICE|endotracheal cuff pressure manual measurement|The cuff pressure of the tracheal tube will be monitored every 8 hours in the manual group using a portable manometer. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients. Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices. The application period will continue from the day of intubation to extubation or a maximum of 14 days. Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit.
224027784|NCT05918172|DEVICE|endotracheal cuff pressure automatic measurement|"The cuff pressure of the tracheal tube will be monitored continuously using a pneumatic device in the automatic group. The target endotracheal tube cuff pressure will be 20 cm H2O during the follow-up of patients.~Before starting to work, PICU nurses will be given training in recognizing and preventing VAP and using cuff pressure measuring devices.~The application period will continue from the day of intubation to extubation or a maximum of 14 days Study data forms will be filled out by PICU nurses and monitored by physicians. The research group will periodically observe PICU personnel to verify adherence to the protocol. While patients are mechanically ventilated, VIP findings will be routinely screened at each daily visit."
224134332|NCT05108610|OTHER|Shi-style manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
224134333|NCT05108610|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
224134334|NCT00941889|DRUG|Saline|0.5 ml
224134335|NCT00941889|DRUG|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
223410742|NCT02236871|BEHAVIORAL|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
224027785|NCT05163171|OTHER|questionnaire|questionnaire for conjugal violence prevalence
224027786|NCT01088828|OTHER|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
224027787|NCT06583720|PROCEDURE|Oral hygiene at home|Participant will be taught on how to correctly brush their teeth, use dental floss and scrape their tongues at home.
224027788|NCT06583720|PROCEDURE|aPDT|A weekly aPDT session will be performed for a period of 30 days, with the photosensitizer (PS) annatto manipulated at a concentration of 20% (Fórmula e Ação®). 2 ml (quantity measured with a pipette) will be applied to the middle third and dorsum of the tongue for 2 minutes for incubation (pre-irradiation time). The excess will be removed with a suction device in order to keep the surface moist with the PS itself. Six points will be irradiated with a distance of 1 cm between them, considering the light scattering halo; the LED will be positioned at a distance from the tongue so as to form a 2 cm halo at each point. The device will be previously calibrated with a wavelength of 395-480 nm, for 20 seconds per point, energy of 9.6 J.
224027789|NCT06583720|DIETARY_SUPPLEMENT|Probiotics|Probiotic lozenges containing Streptococcus salivarius K12 (BLIS K12®) (OralBiotic; Master Products, Fort Lauderdale, Florida, United States) will be used. Each patient will receive 60 lozenges, which should be allowed to dissolve slowly and completely in the mouth. Patients are instructed to use the lozenges twice a day for a period of 30 days.
224027790|NCT03732560|OTHER|Non-Interventional|Non-Interventional
224027791|NCT00444171|PROCEDURE|insulin infusion rate controled by computer algorithm|
223410743|NCT02236871|BEHAVIORAL|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
223410744|NCT02186860|BIOLOGICAL|CAR-T cells|Given IV
224027792|NCT00444171|PROCEDURE|insulin infusion rate guided by in-house glucose management protocol|
224027793|NCT01536015|DRUG|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
224027794|NCT01536015|DRUG|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
223410745|NCT04439448|RADIATION|dual-energy X-ray absorptiometry (DEXA) scan|Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass
223410746|NCT04439448|OTHER|Carotid and branchial artery ultrasound|Ultrasound to assess carotid plaque and brachial artery flow mediated dilation
223410747|NCT04439448|DIAGNOSTIC_TEST|2-hour oral glucose tolerace test|Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min
224134336|NCT04020094|COMBINATION_PRODUCT|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
223410748|NCT04439448|DIAGNOSTIC_TEST|Blood collection|Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells
223410749|NCT05847465|OTHER|Bike stress test|This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).
223410750|NCT05847465|OTHER|Heat Tolerance Test|"The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test."
223410751|NCT05847465|OTHER|Heat nociception test|"This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded."
223559073|NCT00177294|DRUG|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
223559074|NCT00177294|BEHAVIORAL|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
223559075|NCT00177294|BEHAVIORAL|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
224027795|NCT00042406|DRUG|HuMax-CD4|HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
224027796|NCT00042406|DRUG|Placebo|Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.
224027797|NCT00042406|DRUG|Humax-CD4|HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
223410752|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
223410753|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
223410754|NCT01057966|DIETARY_SUPPLEMENT|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
223410755|NCT05143346|DEVICE|Intubation|Using video stylet and video laryngoscope in difficult intubation in patients with trauma or suspected to be have difficult intubation.
223410756|NCT04997668|DEVICE|SOLTIVE Thulium Fiber Laser|Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.
223410757|NCT04997668|DEVICE|Ho:YAG Laser|Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
223410758|NCT03200769|DEVICE|CPAP active|CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg
223410759|NCT03200769|DEVICE|CPAP placebo|CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
223738669|NCT04735016|DEVICE|DiamondTemp™ Ablation System|A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
224027798|NCT04788381|DRUG|Bevacizumab|Enrolled patients may be eligibled if bevacizumab was discontinued within 6 weeks prior to unexpected operation.
223738670|NCT05104476|DRUG|Lu AF82422|Solution for infusion
223738671|NCT05104476|DRUG|Placebo|Solution for infusion
223738672|NCT05984888|BEHAVIORAL|MIND Diet Intervention Group|Participants will receive individually tailored nutrition counseling on adopting the MIND diet pattern from a registered dietitian nutritionist (RDN) for a total of 8 sessions spanning 12 weeks. After completing the counseling sessions participants will be followed up 6 months later to collect additional questionnaires and assessments.
224027799|NCT03028038|DRUG|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
224027800|NCT03028038|DRUG|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
224027801|NCT03598088|DEVICE|Ovaprene|non-hormonal contraceptive ring
224027802|NCT03613987|DEVICE|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
224134337|NCT05628025|OTHER|Organ phantom of prostate|Participants will operate on a 3D printed model of the prostate.
224134338|NCT02535832|DRUG|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
224134339|NCT02535832|DRUG|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
224134340|NCT00246948|PROCEDURE|Active conservative treatment of sciatica|
224134341|NCT01236742|DEVICE|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
224134342|NCT01236742|DEVICE|single-vision glasses|daily wear of spectacle glasses to correct vision
224134343|NCT04342039|DRUG|Budesonide Nasal|budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline
224134344|NCT04342039|OTHER|Placebo|2 sprays each nostril daily on days as indicated in the timeline
224134345|NCT03517683|OTHER|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
224134346|NCT03517683|OTHER|High speed|speed of intrathecal injection will be 1ml in 5 seconds
223410760|NCT04132869|BEHAVIORAL|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
223410761|NCT00026117|DRUG|BenFin|
223410762|NCT00026117|OTHER|placebo|
223410763|NCT04398303|BIOLOGICAL|ACT-20-MSC|1 million cells / kg body weight in 100 ml in conditioned media
223410764|NCT04398303|BIOLOGICAL|ACT-20-CM|100 ml of conditioned media only
223410765|NCT04398303|BIOLOGICAL|Placebo|100 ml of MEM-α
224027803|NCT03343847|BIOLOGICAL|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
224027804|NCT03343847|OTHER|Placebo|Placebo Comparator
224027805|NCT01668667|DRUG|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
224027806|NCT01668667|DRUG|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
224027807|NCT01668667|DRUG|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
224134347|NCT04969497|DRUG|"Treatment A: M207 3.8 mg MiniMac"|"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
224134348|NCT04969497|DRUG|"Treatment B: M207 3.8 mg MACAP"|"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
224134349|NCT04969497|DRUG|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0|Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
224134350|NCT05515822|DRUG|Oxycodone Hydrochloride|The doses were calculated according to the ideal body weight. Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
223410766|NCT00774514|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
224027808|NCT01668667|DRUG|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
224027809|NCT01582685|BEHAVIORAL|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
224027810|NCT04961723|DIAGNOSTIC_TEST|(OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
224027811|NCT06268769|DRUG|Tacrolimus Pill|Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
224027812|NCT06268769|DRUG|Tacrolimus capsule|Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
224027813|NCT02867878|DRUG|Adenosine|
224027814|NCT02867878|DRUG|Saline solution|
224027815|NCT04838600|DEVICE|ChloraSolv|Debridement with ChloraSolv until the wound is visually assessed as clean.
224027816|NCT03113903|BEHAVIORAL|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
224027817|NCT06106620|DIETARY_SUPPLEMENT|Placebo|Placebo drink consisting of 12 oz of flavor-matched water.
223410767|NCT05961943|BEHAVIORAL|RESPONSE-2-PAD|The RESPONSE-2-PAD program will undergo evaluation through a pilot study includes 50 patients living with peripheral arterial disease. Participants will take part in an initial assessment which will measure their sedentary time/physical activity using activPAL and their six-minute walking distance. They will then take part in a 12-week tailored, coaching-based intervention delivered remotely. The intervention involves the use of an activity tracker (sedentary reminder) and an online structured education program coupled with coaching calls that review sedentary time and activity goals weekly. At 12-weeks all participants will be invited to a follow up assessment. Participants will also be invited to take part in a semi-structured interview to explore their views and opinions of the program and its acceptability. At six months all patients will be invited for a final follow-up measurements.
223410768|NCT04510623|OTHER|ARBs and/or ACE inhibitors|This is an observational study only.
223410769|NCT04510623|OTHER|Usual Care|This is an observational study only.
223410770|NCT02215395|DRUG|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
224027818|NCT06106620|DIETARY_SUPPLEMENT|Safety Shot|Safety Shot consisting of a 12 oz drink containing vitamins, mineral, and botanical extracts.
224027819|NCT04488718|OTHER|EnergieShake® Junior Powder Complete|Oral Nutritional Supplement
224027820|NCT02096315|DRUG|POL7080|Intravenous infusion
224027821|NCT00477321|DRUG|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
224134351|NCT05515822|DRUG|Dezocine|Dezocine was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
224134352|NCT05515822|DRUG|Esketamine and Oxycodone|Esketamine was administered 5min before skin incision, and Oxycodone was administered within 30min before the end of surgery. The parameters of patient controlled intravenous analgesia (PCIA) pump were set as continuous volume: 0ml, PCA: 6ml, lock time: 5min, extreme limit: 30ml, and connect with peripheral venous access at the beginning of skin suture.
223410771|NCT03231995|BIOLOGICAL|Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.|"Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)"
223410772|NCT02528110|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
223410773|NCT02528110|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
224027822|NCT02652923|DRUG|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
224027823|NCT00662233|DRUG|cyclophosphamide|
224027824|NCT00662233|DRUG|doxorubicin hydrochloride|
224027825|NCT00662233|DRUG|etoposide|
224027826|NCT00662233|DRUG|ifosfamide|
224027827|NCT00662233|DRUG|vincristine sulfate|
224027828|NCT00662233|PROCEDURE|adjuvant therapy|
224027829|NCT00662233|PROCEDURE|neoadjuvant therapy|
224027830|NCT00662233|PROCEDURE|therapeutic conventional surgery|
224027831|NCT00662233|RADIATION|brachytherapy|
224027832|NCT00662233|RADIATION|intraoperative radiation therapy|
224027833|NCT00662233|RADIATION|radiation therapy|
224027834|NCT00681785|DRUG|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
224027835|NCT03343301|BIOLOGICAL|Bemarituzumab|Administered by intravenous infusion over approximately 30 minutes
224027836|NCT03343301|DRUG|Modified FOLFOX6|"Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours."
224134353|NCT05521932|OTHER|endometrium collected|endometrium tissue collected following adhesiolysis surgery
224027837|NCT00307502|DRUG|Nevirapine|tablets 200 mg, 400 mg/day
223410774|NCT02528110|OTHER|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
223410775|NCT02528110|OTHER|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
223410776|NCT05434195|DIETARY_SUPPLEMENT|Arcofolin® 5-Methyltetrahydrofolate|5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck \& Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.
223410777|NCT05434195|DIETARY_SUPPLEMENT|Arcofolin® Placebo|The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.
223410778|NCT04478695|DRUG|AMG 330|Continuous intravenous (IV) infusion.
223738673|NCT05984888|BEHAVIORAL|General Health Curriculum (GHC) Group|Participants will meet with trained study staff for 8 sessions spanning 12 weeks covering content on non-diet related health topics. After these sessions, participants will be followed up 6 months later to collect additional questionnaires and assessments. Once 6-month follow-up has been completed, participants will be offered to receive the MIND diet intervention offered in the MIND Diet Intervention Group.
223738674|NCT06367751|DIAGNOSTIC_TEST|ctDNA measurement|Blood samples are collected as part of standard of care and ctDNA measurements will be performed on these samples.
223738675|NCT02653001|OTHER|Stool sample collection|Collection of complete stool sample
223738676|NCT06497569|BEHAVIORAL|Dietitian Consultation|"Participants will meet with a dietitian who will provide individualized nutrition counseling and dietary goals for calorie and protein intake.~Bi-weekly, 30-minute dietitian telehealth visits will be conducted via ZOOM videoconferencing at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention."
223738677|NCT06497569|BEHAVIORAL|Survey|"Surveys will be conducted using the PG-SGA short form19-21 and a brief symptom assessment tool that captures additional nutrition-impact symptoms not captured by the PG-SGA (e.g., swallowing difficulty) measured by the FACT Esophageal and Gastric Cancer scales and the FAACT anorexia/cachexia scales 22,23 through REDCap.~Surveys are completed at the pre-intervention baseline visit and monthly during the intervention period prior to the dietitian visits (up to 90 days), and at the 4 and 6 month timepoints post-intervention."
224027838|NCT00307502|DRUG|Efavirenz|tablets 600 mg, 600 mg/day
224027839|NCT00307502|DRUG|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
224027840|NCT00307502|DRUG|Nelfinavir|tablets 250 mg, 2500 mg/day
224027841|NCT00307502|DRUG|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
224027842|NCT00307502|DRUG|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
224027843|NCT00307502|DRUG|Atazanavir|capsules 200 mg, 400 mg/day
224027844|NCT00307502|DRUG|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
224027845|NCT00307502|DRUG|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
224027846|NCT00307502|DRUG|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
223410779|NCT04478695|DRUG|Pembrolizumab|Intravenous (IV) infusion.
223410780|NCT03525938|PROCEDURE|TAP block|Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
223410781|NCT05622838|DIAGNOSTIC_TEST|Alpha1 -Antitrypsin level|measuring alpha1 -antitrypsin level in pregnant women
223410782|NCT05800938|DRUG|Isosorbid mononitrate|Imdur tablets were given twice daily for 4 weeks
223410783|NCT05800938|DRUG|Placebo|Placebo tablets were given twice daily for 4 weeks
223410784|NCT02158325|PROCEDURE|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0\~3.9, 4.0\~5.0, 5.1\~6.0 mm in diameter)
223410785|NCT01191125|OTHER|medical food with AN777|Two(220 mL)servings every day for six months
223410786|NCT01191125|OTHER|oral nutritional formula|Two (220 mL) servings daily for six months
223410787|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
223410788|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
223410789|NCT02099617|PROCEDURE|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
223410790|NCT01544842|DRUG|0.1 % tacrolimus ointment|applied topically to oral mucosa
223410791|NCT01544842|DRUG|0.1 % triamcinolone paste|applied topically to oral mucosa
223410792|NCT01544842|DRUG|Orabase paste|applied topically to oral mucosa
223410793|NCT00644917|DRUG|Xenaderm|20mg under Finn chambers
223410794|NCT00644917|DRUG|Placebo|20mg under Finn chambers
223410795|NCT01872117|OTHER|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
224027847|NCT00307502|DRUG|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
224134354|NCT02938585|DRUG|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
224134355|NCT02938585|DRUG|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
223410796|NCT01872117|OTHER|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
224134356|NCT03427905|PROCEDURE|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
223410797|NCT01136356|DRUG|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
223410798|NCT01136356|DRUG|morphine|parenteral morphine may be administered multiple times each day
223410799|NCT05330156|PROCEDURE|Transurethral resection of the prostate|\- After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
223410800|NCT05330156|PROCEDURE|transurethral enucleation of prostate|After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
223410801|NCT00758485|DRUG|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
223410802|NCT00758485|DRUG|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
223410803|NCT00402688|DRUG|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
223410804|NCT00402688|DRUG|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
223410805|NCT00402688|DRUG|levofloxacin|500mg tablet once daily for 4 weeks.
223410806|NCT01453270|DEVICE|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
223410807|NCT01453270|OTHER|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
223410808|NCT00220688|DEVICE|Acupressure Wristbands|
223410809|NCT05320315|DEVICE|Foto Ultra ISDIN® Solar Allergy Fusion Fluid|The tested MD is a very high protection sunscreen
223410810|NCT00221871|DRUG|Different dosages of Ketamine|
223410811|NCT05259462|BEHAVIORAL|Intervention|Participants will utilize low-cost, consumer available head-mounted displays to meet with peers and coaches online. The program will last 4 weeks and include 2 x 1-hour sessions per week of supervised peer-to-peer gaming. The coaches will utilize behavioral change and mindfulness techniques to promote autonomy, competence, and relatedness through a respectful, cohesive, and positive atmosphere. These strategies will be framed by the Self-Determination Theory and learned from the National Center on Health, Physical Activity, and Disability (NCHPAD) mindfulness coaching workshops. Some of the mindfulness-based strategies will include guided breathing focused exercises, body scanning, meditation, and acceptance of social anxiety and shyness
223410812|NCT02347774|DRUG|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
223410813|NCT02347774|DRUG|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
223410814|NCT02347774|DRUG|Placebo eFlow (CS) nebulizer|Placebo BID eFlow (R) Closed System (CS) nebulizer
223559076|NCT04277481|OTHER|10 minute cold pack|10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
223559077|NCT04277481|OTHER|12 minute cold pack|12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
223410815|NCT03839862|DRUG|TNF-inhibition|Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
223410816|NCT03269630|OTHER|No intervention. Biospecimen collection only|Biospecimen collection
223410817|NCT04973969|OTHER|Decapeptyl|diagnosis of predictio value
223410818|NCT04758468|BEHAVIORAL|Telerehabilitation-based pelvic floor muscle training|"Telerehabilitation-based pelvic floor muscle training group will individually receive telerehabilitation-based pelvic floor muscle training under the guidance of a physiotherapist 2 sessions per week for 8 weeks. Participants will do their exercises themselves 2 times on the days where sessions are held with a physiotherapist. Participants will continue to exercise 3 times a day in the remaining days.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
223410819|NCT04758468|BEHAVIORAL|Home-based pelvic floor muscle training|"The home-based pelvic floor muscle training group will do their individual exercises 3 times a day for 8 weeks.~Both intervention groups will follow the same pelvic floor muscle training protocol for 8 weeks."
223410820|NCT00921557|DRUG|Alendronate|Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
223410821|NCT00921557|DRUG|Placebo|Oral tablet taken once weekly
223559078|NCT04277481|OTHER|15 minute cold pack|15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
223559079|NCT04277481|OTHER|20 minute cold pack|20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
223559080|NCT03981107|OTHER|Chest Compression Only CPR (CO-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions only~The instructions from the dispatcher in interventional arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions only~* Push hard on the chest with a pace of 100/minute without interruptions for rescue breathing."
224134357|NCT03427905|PROCEDURE|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
224134358|NCT02511951|PROCEDURE|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
224027848|NCT05012891|OTHER|OneStep Smartphone Application|"OneStep technology is a smartphone application (app) utilizing smartphone sensors to provide ongoing gait diagnostics. The eligible study participants will be asked to download and install the app on their own smartphones and carry the smartphone in their front pants pocket at all times.~The app will collect the required gait parameters but, will not present them (or any summary thereof) to the study participants or their physiotherapists, in order not to influence the rehabilitation plan."
224027849|NCT04877730|DEVICE|Fully Closed Loop (FCL)|Closed loop without a meal anticipation module without announced carbohydrate
224027850|NCT04877730|DEVICE|Fully Closed Loop with meal anticipation module (FCL+)|Closed loop with a meal anticipation module and without announced carbohydrate
224027851|NCT04877730|DEVICE|Hybrid Closed Loop (HCL)|Closed loop without a meal anticipation module with announced carbohydrate
224027852|NCT02866136|DRUG|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
223410822|NCT00921557|DIETARY_SUPPLEMENT|Calcium carbonate/vitamin D|Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
223410823|NCT00656292|DRUG|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
223410824|NCT00656292|DRUG|Placebo|1 pill po/NG every day x 6 days
223410825|NCT05393648|DEVICE|Accelerated Theta Burst Stimulation|Cool B65- A/P - active side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
223559081|NCT03981107|OTHER|Standard CPR (S-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a ration of 30:2~The Instructions from the dispatcher in the control arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions and rescue breathing~* Push hard on the chest 30 times and give 2 rescue breaths. The pace of the compressions should be 100/minute."
223559082|NCT05094063|OTHER|patient education by mobile application|Training will be given to the patients in the experimental group.
223559083|NCT06479291|DRUG|Hydroxychloroquine Oral Tablet|Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
224027853|NCT02866136|DRUG|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
224027854|NCT02866136|DRUG|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
224027855|NCT02866136|DRUG|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
224027856|NCT02866136|DEVICE|Laser (local treatment)|
224134359|NCT00288834|BEHAVIORAL|dysphagia rehabilitation|
224134360|NCT03277144|DEVICE|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
224134361|NCT03277144|OTHER|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
224134362|NCT00213980|DRUG|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
223410826|NCT05393648|DEVICE|Sham accelerated Theta Burst Stimulation|Cool-B65 A/P - sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
223410827|NCT00846248|DIETARY_SUPPLEMENT|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
223410828|NCT00846248|DIETARY_SUPPLEMENT|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
223410829|NCT03259425|DRUG|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then participant will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
223410830|NCT03259425|DRUG|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
223559084|NCT06479291|DRUG|Eltrombopag|Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
224027857|NCT02866136|DEVICE|cryoapplication (local treatment)|
224027858|NCT02866136|RADIATION|I125 radioactive plaques (local treatment)|
224027859|NCT02866136|DRUG|intravitreal Melphalan (local treatment)|
224027860|NCT00405691|DEVICE|"TOPS System - Total Posterior Arthroplasty Implant"|
224027861|NCT03516929|DIAGNOSTIC_TEST|carotid duplex, both LL arterial duplex|assessment of carotid stenosis and lower limb peripheral ischemia.
224027862|NCT01992393|BEHAVIORAL|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
224027863|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
224027864|NCT01457547|BIOLOGICAL|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
224027865|NCT03243877|OTHER|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
224027866|NCT02790268|PROCEDURE|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
224134363|NCT06390254|OTHER|Resilience-Enhancing Nursing Suppor|The resilience-building nursing intervention in this study is a multifaceted approach aimed at enhancing the psychological well-being and coping abilities of community-dwelling older adults. Unlike standard care, which typically focuses on symptom management, this intervention emphasizes proactive strategies to promote resilience and improve overall quality of life.
224027867|NCT02870335|OTHER|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
224027868|NCT02870335|OTHER|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
224027869|NCT01013597|DRUG|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
224027870|NCT02731573|DRUG|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
224027871|NCT02731573|PROCEDURE|Open heart surgery|Subject will undergo open heart surgery according to standard of care
224027872|NCT00862628|DRUG|Rebamipide|100mg tid, 4 or 8 weeks
224027873|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
224027874|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
224027875|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
224027876|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
224134364|NCT04058262|OTHER|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
224134365|NCT04058262|OTHER|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
224134366|NCT04058262|OTHER|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
224134367|NCT04058262|OTHER|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
224134368|NCT04698213|DRUG|Axitinib Oral Tablet|"Axitinib is an orally bioavailable tyrosine kinase inhibitor currently approved in EU for treatment of patients affected by metastatic renal cell carcinoma (mRCC) progressed after another anti VEGFR-tyrosine kinase inhibitor (TKI).~Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect."
224298070|NCT01513564|DRUG|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
223410831|NCT02882581|RADIATION|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
223410832|NCT05835037|DRUG|Zinc Gluconate 30 MG|Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year
223410833|NCT05835037|DRUG|Placebo|Participants will take one placebo tablet per day for 1 year
223410834|NCT05184595|OTHER|Carfilzomib delivered in OH only|Patients receive the whole treatment en OH.
223410835|NCT05184595|OTHER|Carfilzomib delivered in OH and HaH combined|Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
223410836|NCT03267134|DEVICE|Hydrus Microstent|Device implanted into the Schlemm's canal of the eye for the purpose of providing a natural outflow pathway for aqueous humor. The Hydrus Microstent is intended for lifetime use of the glaucoma patient.
223410837|NCT03267134|PROCEDURE|Ophthalmic surgery|Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia
223410838|NCT04112043|BEHAVIORAL|Walking Exercise|Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
223410839|NCT04112043|DRUG|Nicotinamide Riboside (NR)|Participants randomized to this intervention will receive 1,000 mg/day of NR.
224298071|NCT06821191|DRUG|clopidogrel 75 mg|Clopidogrel 75 mg od for 30 ± 5 days
223410840|NCT04157296|BEHAVIORAL|Cognitive behavioral therapy (CBT)|The CBT intervention will consist of 12 weekly 60 minute sessions of the manualized therapy, adapted from the Coping Cat program, for the treatment of pediatric anxiety disorders.
223559085|NCT02053922|DRUG|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
224027877|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
224027878|NCT00427895|BIOLOGICAL|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
224027879|NCT00427895|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
224298072|NCT06821191|DRUG|Prasugrel 5 mg|Prasugrel 5 mg od for 30 ± 5 days
223738678|NCT06497569|BEHAVIORAL|Fitbit Data Collection|Participants will log food intake while sharing their data with a dietitian during the 30-minute dietitian telehealth visits at the pre-intervention baseline visit, monthly during the intervention period (up to 90 days) and at the 4 and 6 month timepoints post-intervention.
224027880|NCT03070951|DRUG|OBE2109|OBE2109 100mg tablets for oral administration once daily
224027881|NCT03070951|DRUG|Placebo to match OBE2109|Placebo to match OBE2109 100mg tablets for oral administration once daily
224027882|NCT03070951|DRUG|Placebo to match Add-back|Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
224027883|NCT03070951|DRUG|Add-back|Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
224027884|NCT03747198|DIETARY_SUPPLEMENT|methylsulfonylmethane|Subjects will be given 2 g/day methylsulfonylmethane.
224027885|NCT03747198|OTHER|Placebo|Subjects will be given 2 g/day placebo (rice flour).
224027886|NCT04206579|DRUG|10% Dextrose|A mixture of 150 cc dextrose 10% in oral formulation
224027887|NCT04206579|DRUG|Natrium Dextrose|A mixture of 150 cc dextrose 10% + 20 cc sodium in oral formulation
224027888|NCT00911287|DRUG|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
224027889|NCT03163485|DEVICE|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
224027890|NCT03163485|DEVICE|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
224027891|NCT05802641|RADIATION|SBRT|Participants with early lung cancer receive single fraction (30Gy/1f) or multiple fractions of SBRT（36Gy/3f).
224027892|NCT02855970|OTHER|completion of a quality of life questionnaire|
224027893|NCT04581954|DRUG|Ruxolitinib|Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action.
224027894|NCT04581954|DRUG|Fostamatinib|Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
224027895|NCT04581954|OTHER|Standard of care|Standard of care treatment as per site-level policies and guidelines.
224027896|NCT01729143|OTHER|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
224027897|NCT05687526|BIOLOGICAL|Telitacicept|"12-17 years old: Telitacicept 2.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks.~5-11years old: Telitacicept 3.0-3.5 mg/kg (with a maximum dose of 160 mg) subcutaneously once a week plus SOC for 12 weeks."
224027898|NCT05593237|DEVICE|High Frequency rTMS|Stimulation provided at 10 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (3,000 pulses/session)
224027899|NCT05593237|DEVICE|Low Frequency rTMS|Stimulation provided at 1 Hz over target brain regions in thirty trains consisting of 10 seconds of stimulation alternating with 50 seconds of rest (300 pulses/session)
224027900|NCT05137353|BEHAVIORAL|Music Training (RitMoZ Training)|This training is inspired by intervention concepts followed in SUVAG Polyclinic in Zagreb, Croatia and Kodaly pedagogy in Hungary. RitMoZ Training programme consists of 6 main activities: matching activity, nursery rhymes, rhythmic stimulations, music shapes, music writing and music reading. The training focuses on the perceptual overlap between language and music, embodiment and entrainment. The aim of the training is to improve characteristic features of reading disorders such as phonological awareness, perception of rhythm, phonological working memory and perception of speech sounds.
224027901|NCT05137353|BEHAVIORAL|Spelling Training|This training consists of activities which focus on practicing spelling words in a computer task; the aim is to train orthographic processing which is suggested to improve phonological awareness and phonological working memory.
224027902|NCT06041048|DRUG|Modafinil|Single dose (200 mg) of medication versus placebo given to healthy control subjects
224027903|NCT05322850|BIOLOGICAL|Orca-Q|All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
223410841|NCT04157296|BEHAVIORAL|computerized cognitive training (CCT)|CCT intervention will consist of approximately 30 minutes of CCT games prior to each CBT session, to engage cognitive control capacity prior to receipt of CBT. The CCT games will be designed to target focused attention, response inhibition, working memory and multiple simultaneous attention to constitute a general executive function training, and activate neural systems associated with executive function/cognitive control. Difficulty of the games will be titrated individually and by session to avoid boredom and progressively activate the functional systems underlying cognitive control.
223410842|NCT00018941|BIOLOGICAL|aldesleukin|
223410843|NCT00212342|DRUG|Norethisterone,Ethinylestradiol|
223410844|NCT00212342|DRUG|Sugar pill|
224027904|NCT03868488|BEHAVIORAL|Imagery tasks|All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
224027905|NCT03058029|DEVICE|Gelesis200|Subject would take Gelesis200 capsules 2 times per day.
224027906|NCT03058029|DEVICE|Placebo|Subject would take placebo capsules 2 times per day.
224027907|NCT00879112|DRUG|MB07811|Oral
224027908|NCT00879112|DRUG|Placebo|Oral
224027909|NCT06658366|DIAGNOSTIC_TEST|impression of the teeth|Only conventional and digital impressions (comparable with taking videography) are taken of the patients teeth.
223410845|NCT05252208|OTHER|Stretching exercise|Stretching (30-45 minutes, 5 days per week, 6 months)
223738679|NCT06497569|BEHAVIORAL|Referral to Dietitian|Usual Care condition referral to a dietitian based on physician discretion.
224027910|NCT04501211|DRUG|Granisetron|transdermal sancuso patch
224027911|NCT03944473|DRUG|Sugammadex|Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
224027912|NCT03944473|DRUG|Neostigmine|Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
224027913|NCT05591222|DRUG|Placebo|Placebo will be administered subcutaneously as two injections for each dose.
224027914|NCT05591222|DRUG|Daxdilimab|Daxdilimab will be administered subcutaneously as two injections for each dose.
223410846|NCT05252208|OTHER|Walking exercise|Walking (30-45 minutes, 5 days per week, 6 months)
224027915|NCT06589960|COMBINATION_PRODUCT|Health education and physical exercise|"Nine face to face sessions and group discussion health education sessions. An Educational booklet was prepared and distributed to all attendants.~Lab results were discussed individually with each participant.~Rheumatologist and physiotherapist also provided messages.~The exercise program targeted and strengthened the muscles around the knee especially quadriceps muscle, stretching the muscles of lower limbs, and stretching and increasing the range of motion of front and back lower limb muscles (quadriceps muscle, hamstring muscle, gluteus muscle and calf muscles).~Phone calls to follow up the participants and maximize their adherence to the health education program. WhatsApp groups was created, and messages were distributed to summarize the content of the booklet and the exercises videos.~Final reassessment to assess the effect of health education and lifestyle modification was carried out with participants who continued till the end of the study."
224027916|NCT01659788|DIETARY_SUPPLEMENT|Coenzyme Q10 concomitant treatment|
224027917|NCT01659788|DIETARY_SUPPLEMENT|Placebo|
224027918|NCT00249054|DEVICE|ASR hip prosthesis|Implantation of resurfacing prosthesis
224027919|NCT00249054|DEVICE|ReCap hip prosthesis|Implantation of resurfacing prosthesis
224027920|NCT06611254|DEVICE|Contrast enhanced ultrasound imaging (CEUS) and post processing with ULM|CEUS is a contrast based ultrasound technique and ULM (Ultrasound Localization Microscopy) is a post-processing bioinformatical method to quantify microvascular architecture and perfusion dynamics.
224027921|NCT06609733|DEVICE|Twin block|The TB group used a single appliance continuously, with appropriate reduction of occlusal surface height by 1 mm when clinically indicated. Both groups had follow-up appointments every 6 weeks.
224027922|NCT06609733|DEVICE|Clear aligner with mandibular function|The MA group underwent stepwise mandibular forward movement with clear aligners (Invisalign, Align Inc, CA, USA) worn for 22 hours/day and replaced every 7 days.
224027923|NCT06609967|PROCEDURE|application of PRF|PRF will be randomly administered into one group of patients undergoing any extractions group A (Right after the extraction) Group B will be a control group in which extraction sockets will be left to heal with the natural blood clot. Consenting patients will be assigned into groups randomly and not informed which group they were placed into. The PRF will be administered obtained from a tube of 10 ml blood and no material will be placed in the control group. The progress of healing and post-operative complications will be tracked over a period of 7 days with patients being called for follow-up on days 3, 5 and 7
224027924|NCT06609967|PROCEDURE|application of conventional surgicel|it will be a control group in which extraction sockets will be left to heal with the natural blood clot.
224027925|NCT06610058|OTHER|Instrument Assisted Soft Tissue Mobilization first Control second|Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.
224027926|NCT06610058|OTHER|Control first Instrument Assisted Soft Tissue Mobilization second|This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
224027927|NCT06610305|DRUG|Transdermal estradiol|0.1 mg/day delivered via weekly patch
224027928|NCT06610305|DRUG|Progesterone|100 mg twice daily (200 mg/day total) administered via oral capsule
224027929|NCT06610305|DRUG|Transdermal placebo patch|Once weekly via transdermal patch
223410847|NCT05630261|BEHAVIORAL|Self-help CBT-I|The intervention will cover the following topics: (a) physiological linkage between the brain and stress, (b) sleep hygiene, (c) stimulus control, (d) sleep restriction, (e) cognitive restructuring, and (f) positive psychology. Each weekly session will be divided into 6-8 chapters. Chapters are supported by short videos and interactive games. Homework activities will be assigned after each session.
224027930|NCT06610305|DRUG|placebo capsule|Twice daily via oral capsule
224027931|NCT06610734|DRUG|Adebrelimab|Adebrelimab combined with chemotherapy synchronous LDRT
224027932|NCT06610734|DRUG|Chemotherapy|Chemotherapy
224298073|NCT06616298|OTHER|Assessing and Listening to Individual Goals and Needs (ALIGN)|Assessing and Listening to Individual Goals and Needs (ALIGN). ALIGN utilizes the skills of palliative care social workers (PCSWs) trained in family and systems-level theory to address changing preferences for care, family distress, and to facilitate communication across care transitions to improve care aligned with preferences. A patient navigator supports the patient/caregiver and social worker dynamic by helping patients access care and resources. The intervention is implemented virtually in community SNFs and follows patients for 45 days after SNF discharge to reflect real-world patient flow.
223410848|NCT05630261|BEHAVIORAL|Self-help CBT-D|The intervention will cover the following topics: (a) physiological linkage between the brain and stress, (b) emotion management, (c) cognitive restructuring, (d) behavioral activation, and (e) positive psychology. Each weekly session will be divided into 6-8 chapters. Some chapters are supported by short videos and e-worksheets. Homework activities will be assigned after each session, which include weekly record of emotions or between-session practice.
223559086|NCT02053922|DRUG|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . \[Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada\] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
224027933|NCT06610734|RADIATION|low dose radiotherapy|low dose radiotherapy
224027934|NCT06609447|DIETARY_SUPPLEMENT|VSL#3|VSL#3 450 billion CFU/sachet
224027935|NCT06609447|DIETARY_SUPPLEMENT|Placebo|Placebo sachets with maltose, cornstarch and dioxide
224027936|NCT06609447|DRUG|Vedolizumab|Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
224027937|NCT06609759|DRUG|Standard chemotherapy regimen|In terms of postoperative adjuvant treatment, treatment is based on the guideline standard treatment plan, which can be adjusted according to the doctor's experience.
224027938|NCT06609551|DRUG|6-month adjuvant chemotherapy with 5-FU monotherapy|6 months of adjuvant chemotherapy with 5-FU monotherapy. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
223410849|NCT05251961|PROCEDURE|operative deformity correction|"* The participants will be subjected to surgical correction using growing rods as a novel technique for their long bone deformities.~* Procedure will be done under anaesethia~* Osteotomy , fracture reduction , deformity correction will be done , then introduction of the growing rod"
223410850|NCT06188871|DRUG|Dupilumab|Two injections of 300mg dupilumab, subcutaneous 14 days apart
223410851|NCT00542009|DRUG|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
223559087|NCT02053922|DRUG|Misoprostol|Misoprostol (200 mcg Tablet) \[Misotac, Sigma Pharmaceutical Industries, SAE, Egypt\] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
224027939|NCT06609551|DRUG|XELOX intensive treatment group|XELOX intensive treatment group. The follow-up strategy for the four groups of subjects will be the same, including but not limited to chest plain or enhanced CT, abdominal/pelvic enhanced CT, and detection of the tumor marker carcinoembryonic antigen (CEA), until disease progression occurs. All patients will undergo peripheral blood ctDNA-MRD testing again six months after surgery.
224027940|NCT06609954|OTHER|Reduced Exertion High Intensity Training (REHIT)|Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform training sessions on a cycle ergometer. Each session will consist of a 3-minute warm-up period followed by two 20-second all-out sprints interspersed with 3 minutes of slow pedaling for recovery. Total of 18 sessions of REHIT will be performed thrice a week on alternate days by the participants for consecutive 6 weeks.
224027941|NCT06609954|OTHER|High Intensity Interval Training (HIIT)|Patients in this group will be provided with a caloric restriction plan by a nutritionist that will be followed throughout the training duration. Week 1 will be baseline fitness level and familiarization week. Participant will perform a 5 min warm-up exercises then do cycling or treadmill running for 20 min at 40%-60% of HRR and then will conclude with 5 min cool down exercises. From week 2 to 6 participants will be instructed to perform a warm up of 5 min, then 4 bouts of 4 min of HIIT will be performed at 80%-95% of HRR separated by 3-min active recovery periods of moderate intensity cycling at 60%-70% of the HRR followed by 5 min cool down exercises. Pre and post session vitals will be noted. Total of 18 sessions of either HIIT will be performed thrice a week on alternate days by the participants for consecutive 6 weeks.
224134369|NCT04698213|DRUG|Avelumab|Avelumab is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity.
224134370|NCT04169724|BEHAVIORAL|Calm Meditation|10 minutes per day of meditation via the Calm app.
224134371|NCT02256332|DIETARY_SUPPLEMENT|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
224134372|NCT02256332|DIETARY_SUPPLEMENT|High dose plant based ingredient|Reference food with high dose of plant based ingredient
224134373|NCT02256332|DIETARY_SUPPLEMENT|Reference food format|Reference food without plant-based ingredient
224134374|NCT02005848|BIOLOGICAL|Alpha-1 Antitrypsin|
224134375|NCT02005848|OTHER|Placebo|Placebo
223410852|NCT00542009|DRUG|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
223559088|NCT01421238|BEHAVIORAL|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
223559089|NCT03709069|DIETARY_SUPPLEMENT|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
224134376|NCT00228254|DRUG|Zinc (12.5 mg/day)|
223410853|NCT00542009|DRUG|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
223410854|NCT00542009|DRUG|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
223410855|NCT00542009|DRUG|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
223410856|NCT04284098|OTHER|General anesthesia (GA).|Patients received standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
223410857|NCT04284098|OTHER|PECS block using bupivacaine .|The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%, after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
224027942|NCT06609382|OTHER|Patients had a higher left ventricular mass index or not （the exact value is determined by the cut-off value for the clinical outcomes)|Patients were grouped by the cutoff value of left ventricular mass index (LVMI) for all cause death, and the Maximally Selected Rank Statistics method was used to determine the optimal cutoff point of LVMI for death.
224027943|NCT06610149|DIETARY_SUPPLEMENT|Probiotic mixture|8 weeks treatment with Probiotic mixture
224027944|NCT01111747|PROCEDURE|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
224134377|NCT00228254|DRUG|vitamin A 10,000 IU per week|
224134378|NCT04424355|DIAGNOSTIC_TEST|Chest MRI|Patients referred by the primary care physician with suspected pneumonia
224298074|NCT01232491|DRUG|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
224298075|NCT01232491|DIETARY_SUPPLEMENT|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
223410858|NCT04284098|OTHER|PECS block using bupivacaine and dexmedetomidine|D group:The patients undergo an ultrasound-guided PECS I using 10 ml bupivacaine 0.25% and PECS II using 20 ml bupivacaine 0.25%+dexmedetomidine (1µg/kg) after 10-minutes observation the patients receive standard GA including fentanyl as intraoperative analgesic and morphine as postoperative analgesic in the first 24 hours.
223410859|NCT02012361|PROCEDURE|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
223410860|NCT02012361|PROCEDURE|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
223410861|NCT02012361|PROCEDURE|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
223410862|NCT02962453|DEVICE|Morning walk|gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
223410863|NCT02962453|DEVICE|Ground Walker|gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
223410864|NCT01398969|BIOLOGICAL|Fresh FMT|Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
223410865|NCT01398969|BIOLOGICAL|Frozen-and-Thawed FMT|Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
223410866|NCT02892110|DRUG|Varenicline|2 mg daily
223410867|NCT02892110|DRUG|Placebo|2 mg daily
223410868|NCT03303313|DRUG|Cemdisiran|Subcutaneous (sc) injection of Cemdisiran
223410869|NCT03799640|OTHER|Standard Yoga|Yoga using standard poses and linear movements
223410870|NCT03799640|OTHER|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
223738680|NCT06497569|BEHAVIORAL|Social Determinants of Health Survey (SDOH)|"Participants will complete a SDOH Survey that captures individual-level factors (insurance type, preferred language, educational attainment, annual household income, digital health literacy, financial toxicity, and self-reported barriers to care \[e.g., transportation\]) and structural-level factors (neighborhood disadvantage, rural residence).~Digital health literacy will be measured using the validated eHEALS scale, an 8-item measure assessing confidence with finding, evaluating, and applying electronic information to inform health decision-making (score ≤ 30 indicates low literacy)."
223738681|NCT05557877|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224027945|NCT01111747|PROCEDURE|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
224027946|NCT02390245|OTHER|Free Eye Screenings|This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
224027947|NCT02390245|OTHER|Enhanced Intervention|This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
224027948|NCT02390245|OTHER|Usual Care|This group will receive ophthalmic referral.
224134379|NCT05905211|OTHER|Observational Tests|The Berg Balance Scale was used to evaluate the balance levels, the Timed Up and Go Test was used to evaluate the functional mobility levels, and the Functional Independence Scale was used to evaluate the activities of daily living. The World Health Organization Quality of Life Instrument-Older Adults Module (WHOQOL-OLD) was used to evaluate the quality of life, the Fear of COVID-19 Scale was used to evaluate the COVID-19 fear levels, the Geriatric Depression Scale was used to evaluate the symptoms of depression.
223738682|NCT05557877|DRUG|Low-Dose Aspirin|Given PO
223738683|NCT05557877|OTHER|Questionnaire Administration|Ancillary studies
223738684|NCT05557877|PROCEDURE|Biopsy|Undergo breast biopsy
224134380|NCT00734773|BIOLOGICAL|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
224134381|NCT00734773|DRUG|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
223738685|NCT06191978|DRUG|ASTX727|Given by PO
223738686|NCT06191978|DRUG|Venetoclax|Given by PO
223738687|NCT05626712|BIOLOGICAL|CELZ-201 Administration|Participants in this group will receive a single dose of CELZ-201, in addition to standard of care for Type 1 Diabetes treatment. Perinatal tissue derived cells will be administered at a dose of 1x10\^6 cells/kg via an intra-arterial infusion into the dorsal pancreatic artery.
223738688|NCT05626712|OTHER|Control Group|Enhanced standard of care for Type 1 Diabetes treatment only.
224134382|NCT00734773|DRUG|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
223410871|NCT03799640|OTHER|Educational Control|Lectures on health and fitness
223410872|NCT06574490|PROCEDURE|Myofunctional therapy (+)|A series of myofunctional exercises performed in 10-20 sessions over 6 months
223738689|NCT05683756|BEHAVIORAL|Brief Parent Behavioral Intervention|PBI administered in pediatric primary care by an embedded therapist.
223410873|NCT06574490|PROCEDURE|Myofunctional therapy (-)|NO exercises; A series of myofunctional exercises performed in 10-20 sessions over 6 months is delayed by 1 year
223410874|NCT00356148|DRUG|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
223738690|NCT05683756|BEHAVIORAL|Sleep-Focused Parent Behavioral Intervention|SF-PBI administered in pediatric primary care by an embedded therapist.
224027949|NCT02574754|DRUG|warfarin|warfarin 10 mg PO x 1
223410875|NCT00826397|PROCEDURE|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
223559090|NCT04887168|BEHAVIORAL|Survive & Thrive|Psychoeducational Intervention: Survive \& Thrive (Ferguson, 2008; Mahoney et al, 2018). A total of 10 manualised sessions of approximately 1.5 hour duration are offered. Individual sessions run using an educational format and in an informal setting, with a strong emphasis on avoiding individual disclosures. Groups will be delivered utilising a multi-disciplinary work force consisting of mental health staff in a ratio of 2 per group. Groups will consist of a maximum of 8-10 participants
223559091|NCT05270148|OTHER|HIIT|12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
224027950|NCT06610292|OTHER|Pharmacist-led medication reconciliation services|"Upon admission, information about patients Best Possible Medication History (BPMH) was extracted. Information on current medications, both regular and as-needed, was also recorded. All data were cross-referenced with the electronic records and verified through patients or caregivers interviews to create a comprehensive medication list.~Then, comparison was conducted between standard care medication list and Pharmacist-led medication reconciliation list to identify any possible medication discrepancies. Also, during hospital stay and upon discharge emerging medication discrepancies were assessed and resolved.~Moreover, the impacts on healthcare resources utilization within 30 days post-discharge was measured. This includes evaluating hospital re-admissions, emergency department visits, and the occurrence of any adverse drug events (ADEs)."
223410876|NCT00826397|PROCEDURE|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
223410877|NCT02329171|DRUG|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
223559092|NCT05270148|OTHER|Fat Max|12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer. MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
223559093|NCT05803161|DRUG|Congrong Runtong oral liquid|"Congrong Runtong oral liquid：component total glycosides of Cistanche extracted and refined from the traditional Chinese medicine Cistanche deserticola"
224027951|NCT06610123|DIETARY_SUPPLEMENT|Caffeine and Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
224027952|NCT06610123|DIETARY_SUPPLEMENT|Placebo and Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
224027953|NCT06623344|OTHER|Magnetic Resonance Imaging with or without Contrast|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
224027954|NCT05553522|COMBINATION_PRODUCT|Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine|"SRS and oral tucatinib for 2 wk, followed by oral tucatinib, oral capecitabine, and intravenous (IV) trastuzumab maintenance during 21-d cycles until tumor progression, participant withdrawal, a severe adverse event deemed related to the study drug, or the treating physician discontinues the drug. There are three dosing levels of tucatinib (Dose Level 0, Dose Level -1, or Dose Level -2) using a dose de-escalation scheme. Dosing of capectabine (1000 mg/m2 BID Days 1-14) and trastuzumab (6 mg/kg once per 21 days; 8 mg/kg initial loading dose) per cycle will remain the same regardless of tucatinib dosing.~Dose Level 0: 300 mg twice a day (BID) continuously for 2 wk post SRS, then 300 mg BID continuously per cycle.~Dose Level -1: 250 mg twice a day (BID) continuously for 2 wk post SRS, then 250 mg BID continuously per cycle.~Dose Level -2: 200 mg twice a day (BID) continuously for 2 wk post SRS, then 200 mg BID continuously per cycle."
224027955|NCT02485054|OTHER|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
224027956|NCT04417322|OTHER|observation of serum A.actinomycetemcomitans levels|Analysis of serum A.actinomycetemcomitans levels
224027957|NCT06729827|DEVICE|Hypotension prediction Index - HPI|"Patients in the HPI group, in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA) with ClearSight non-invasive hemodynamic monitoring and with the HPI software enabled.~The patients will be treated with a bolus of norepinephrine 5 mcg each time that HPI is 85 or higher."
224027958|NCT03722147|BIOLOGICAL|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
224027959|NCT02788903|OTHER|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
224027960|NCT03095430|DEVICE|Monitoring|Monitoring
224027961|NCT06305156|DIAGNOSTIC_TEST|Bone Mineral Density quantification|"In the first visit, participants receive clinically indicated CT scan, where bone mineral density will be derived.~In a second, study related visit, participants will receive a DXA scan for bone mineral quantifications."
224027962|NCT04531150|DRUG|INV-101|Subjects will be randomized to receive INV-101 tablets
224027963|NCT04531150|DRUG|Placebo|Subjects will be randomized to receive placebo tablets
224027964|NCT06023407|OTHER|Water Immersion Heat Therapy|10-weeks of 3 days per week in 1 of the 2 arms
224027965|NCT02193191|DRUG|Plerixafor|
224027966|NCT05950022|PROCEDURE|Endoscopic tenotomy surgery of the iliopsoas tendon|The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
224134383|NCT00734773|DRUG|Motexafin gadolinium|"* Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~* For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~* During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
224134384|NCT00734773|DRUG|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
224134385|NCT00734773|DRUG|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
224134386|NCT00734773|RADIATION|Radiation therapy|Given at weeks 11 through 16.
224134387|NCT05491057|DRUG|Neratinib|Neratinib standard dose 240 mg once daily for 1 year
224027967|NCT02673905|OTHER|Tissue Engineered Product|Implantation of tissue engineered products
224027968|NCT05357781|DIAGNOSTIC_TEST|Laboratory test|Frequency of fatigue (defined as Fatigue Scala for Motor and Cognitive Function (FSMC) total ≥ 43 points) in MS patients with IgG-deficiency
224027969|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus collagen|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
224027970|NCT04621383|DIETARY_SUPPLEMENT|Whey protein plus maltodextrin|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 17 weeks. At the beginning of the experiment, two weeks and at the end three weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16), magnetic ressonance imaging (weeks 2 and 17) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
224134388|NCT04343079|DIAGNOSTIC_TEST|PET CT|measurement of surgical margins during lumpectomy
224134389|NCT05233449|DEVICE|NoL monitor|NoL monitor : non invasive, adhesive digital device
223410878|NCT02329171|PROCEDURE|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
223559094|NCT05803161|DRUG|Placental Congrong Runtong oral liquid|Placental Congrong Runtong oral liquid
223559095|NCT02018523|DRUG|Lenalidomide|lenalidomide 10mg/day orally until disease progression
224134390|NCT05233449|PROCEDURE|Stimulation|Stimulation : 100 Hertz, 5 seconds, 10-30-60 milliamps, inner forearm
224134391|NCT02370355|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood samples
224134392|NCT02370355|OTHER|Laboratory Biomarker Analysis|Correlative studies
224134393|NCT06105424|PROCEDURE|Lung Permeability Assessment|A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
224134394|NCT02351258|DEVICE|70% Isopropyl alcohol embedded caps|Protective cap on central lines
224134395|NCT02351258|OTHER|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~1. Daily assessment whether central line is needed~2. Central line Site Care~3. Central line Hub/Cap/Tubing Care"
224134396|NCT00285974|DEVICE|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
224134397|NCT00698789|DRUG|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
223410879|NCT04067167|OTHER|WB-EMS (Sham-intervention)|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
223559096|NCT01545869|PROCEDURE|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
223559097|NCT02068677|OTHER|Sympathetic response|Sympathetic response will be defined as change in heart rate by \>10 bpm and change in BP \<10mmHg.
223559098|NCT02068677|OTHER|no sympathetic response|no Sympathetic response will be defined as change in heart rate by \<10 bpm and change in BP \<10mmHg.
224134398|NCT00698789|DRUG|INCB019602|20 mg in AM with placebo administration in PM
224134399|NCT00698789|DRUG|INCB019602|5 mg in PM with placebo administration in AM
224134400|NCT00698789|DRUG|INCB019602|20 mg in PM with placebo administration in AM
223410880|NCT04067167|OTHER|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
224134401|NCT00698789|DRUG|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
224134402|NCT00698789|DRUG|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
224134403|NCT00698789|DRUG|Metformin|Stable dose metformin monotherapy
224134404|NCT00510328|DEVICE|Whole Body Vibration|
224027971|NCT06458218|COMBINATION_PRODUCT|Multi-component Interventions|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, EmoEase, for individuals with mental health issues among high-risk COPD population(very familiar with intelligent mobile phone);~3. NicQuit, digital health intervention to smokers;~4. Health education to smokers and individuals with mental health issues;~5. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~6. To actively include individuals whose blood pressure and glucose are higher than the normal value into the National Essential Public Health Service in China;~7. A CBT-based health education to the BMI abnormal;~8. Pay-for-performance incentives to medical workers."
223410881|NCT04067167|OTHER|Free WB-EMS|"Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~* patients perform simple exercises during the stimulation period following a video tutorial~* time-effort per session: \~20 min~* 2 training sessions per week"
223410882|NCT04067167|OTHER|Flexi band resistance training|"Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~* patients perform resistance exercises using flexi bands~* flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~* time-effort per session: \~20 min~* 2 training sessions per week"
223410883|NCT02087488|OTHER|auricular acupuncture(AA)|"Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.~Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.~Treatment frequency: every 3 days.~Duration: 4 weeks."
223410884|NCT02087488|OTHER|placebo AA|"Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).~Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.~Treatment frequency: every 3 days.~Duration: 4 weeks."
224027972|NCT03145792|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
224027973|NCT03145792|BEHAVIORAL|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
224027974|NCT00733928|DEVICE|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
224027975|NCT00733928|DEVICE|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
224027976|NCT06785103|BEHAVIORAL|Risk assessment messaging|"Participants who are randomized to the HIV risk assessment arm will receive a brief video message at their baseline visit, containing information related to HIV risk assessment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the HIV risk assessment content category."
224027977|NCT06785103|BEHAVIORAL|U=U messaging|"Participants who are randomized to the U=U arm will receive a brief video message at their baseline visit, containing information related to U=U core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the U=U content category."
224027978|NCT06785103|BEHAVIORAL|Healthy Living messaging|"Participants who are randomized to the Healthy Living arm will receive a brief video message at their baseline visit, containing information related to Healthy Living core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Healthy Living content category."
223559099|NCT03719963|DEVICE|Cochlear implant|Cochlear implant for hearing process by surgical intervention
223559100|NCT01648244|OTHER|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
224027979|NCT06785103|BEHAVIORAL|Community benefits messaging|"Participants who are randomized to the Community benefits arm will receive a brief video message at their baseline visit, containing information related to Community Benefits core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Community Benefits content category."
224027980|NCT06785103|BEHAVIORAL|Fresh start effect|"Participants who are randomized to the Fresh start effect arm will receive a brief video message at their baseline visit, containing information related to Fresh Start core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Fresh start effect content category."
224134405|NCT03939806|DRUG|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
224134406|NCT03939806|DRUG|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
224134407|NCT01163253|DRUG|CP-690,550|5 mg oral BID
223559101|NCT01308255|DRUG|Infliximab|"Prior to week 26~* Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~* Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~* Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
223559102|NCT01308255|DRUG|Methylprednisolone|Steroid
224027981|NCT06785103|BEHAVIORAL|Education-based messaging (#1)|"Participants who are randomized to the Education-based #1 arm will receive a brief video message at their baseline visit, containing information related to HIV education core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based #1 content category."
224027982|NCT06785103|BEHAVIORAL|Education-based #2 messaging (gamification)|"Participants who are randomized to the Education-based #2 arm will receive a brief video message at their baseline visit, containing information related to HIV education/gamification core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Education-based/gamification content category."
224027983|NCT06785103|BEHAVIORAL|Default appointment messaging|"Participants who are randomized to the Default appointment arm will receive a brief video message at their baseline visit, containing information related to Default Appointment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Default Appointment content category."
224134408|NCT01163253|DRUG|CP-690,550|10 mg oral BID
224134409|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
224134410|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
224134411|NCT04163406|DIETARY_SUPPLEMENT|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
224134412|NCT01699620|PROCEDURE|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
224027984|NCT06785103|BEHAVIORAL|Reserved for you messaging|"Participants who are randomized to the Reserved for you arm will receive a brief video message at their baseline visit, containing information related to the Reserved for you core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Reserved for you content category."
224134413|NCT02492997|DEVICE|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
224134414|NCT02492997|OTHER|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
224134415|NCT03670394|DIAGNOSTIC_TEST|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
223410885|NCT02087488|DRUG|Eszopiclone|"Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks."
223410886|NCT02484456|DRUG|AV 101 (4-Chlorokynurenine)|L-4-chlorokynurenine (4-Cl-KYN) was developed as a prodrug that is rapidly converted in vivo to its active metabolite 7-chlorokynurenic acid (7-Cl-KYNA), a well-characterized N-Methyl-D-aspartate receptor (NMDAR) antagonist at the glycine site.
223410887|NCT02484456|OTHER|Placebo Comparator|Placebo
223410888|NCT00910533|DRUG|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
224134416|NCT02892565|OTHER|Blood sample|
223410889|NCT04593511|DRUG|LY03009 F1|a single dose of LY03009 F1
223410890|NCT04593511|DRUG|LY03009 F2|a single dose of LY03009 F2
224134417|NCT02393118|DEVICE|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
224134418|NCT05209412|DEVICE|Lepu Paclitaxel coated balloon|Paclitaxel is the pharmacologically active substance for anti-neointima. The active drug coating is located on the surface of the balloon, which contains 1.5 μg Paclitaxel per 1 mm2.
224134419|NCT05209412|DEVICE|Resolute Integrity Zotarolimus eluting stents|The device consists of a balloon-expandable intracoronary drug-eluting stent pre-mounted on the MicroTrac Rapid Exchange stent delivery system. Drug eluting stent is composed of metal stent, primer and drug coating. The Stent is manufactured from a cobalt alloy (MP35N). The strut thickness is 88.9 μm and the length elements is 0.9 mm. The drug coating consists of the zotarolimus and BioLinx polymer (C10/C19/PVP) system. A coating of polymers loaded with zotarolimus in a formulation applied to the entire surface of the stent at a dose of approximately 1.6 µg/mm2 which results in a maximum nominal drug content of 380 µg on the largest stent (4.0 x 38 mm).
224134420|NCT05209412|DRUG|Aspirin|Aspirin is required for 3 months be a part of the dual antiplatelet therapy (DAPT) after PCI.
224134421|NCT05209412|DRUG|Ticagrelor|Ticagrelor is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI.
224134422|NCT05209412|DRUG|Clopidogrel|Clopidogrel is required for 12 months to be a part of the dual antiplatelet therapy (DAPT) after PCI when Ticagrelor is unfeasible or contradicted.
224134423|NCT01397552|DRUG|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
224134424|NCT01397552|DRUG|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
224134425|NCT04251689|DRUG|Mannitol|Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
224134426|NCT04251689|DRUG|Placebo|0.9% normal saline 100 ml
224134427|NCT03934892|DIAGNOSTIC_TEST|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
224134428|NCT00110318|PROCEDURE|Manual therapy and therapeutic exercise|
224134429|NCT00110318|PROCEDURE|Corticosteroid injections|
223410891|NCT04593511|DRUG|LY03009 F3|a single dose of LY03009 F3
223410892|NCT04593511|DRUG|LY03009 F4|a single dose of LY03009 F4
223410893|NCT00813254|BEHAVIORAL|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
223410894|NCT01996254|DEVICE|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
224134430|NCT02521688|PROCEDURE|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
224027985|NCT06785103|BEHAVIORAL|Social norms messaging|"Participants who are randomized to the Social norms arm will receive a brief video message at their baseline visit, containing information related to Social Norms core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Social Norms content category."
224027986|NCT06785103|BEHAVIORAL|Empowerment messaging|"Participants who are randomized to the Empowerment/goal setting arm will receive a brief video message at their baseline visit, containing information related to Empowerment core concepts and encouraging them to return for a repeat HIV test. They will also receive brief SMS follow-up messages at 8 and 11 week after baseline reminding them about HIV retesting and re-emphasizing concepts from the Empowerment content category."
224027987|NCT04041583|DEVICE|Cervical Interfacet Spacers|The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis \[2\]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion \[2\].
224134431|NCT00987922|DEVICE|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
224134432|NCT02848339|DRUG|aspirin|aspirin desensitization
223410895|NCT02023411|DRUG|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneous every day at 8-9 pm
224134433|NCT05851339|OTHER|SF- 36 Questionnaire|applicants will fill health related quality of life SF-36 Questionnaire after PCNL or RIRS
224298076|NCT06928857|DEVICE|EMG-based FES rehabilitation|Each subject will receive 15 individual rehabilitation sessions, each lasting 60 minutes, conducted 3 to 5 times per week over a period of 5 to 3 weeks, depending on the weekly frequency. Each participant will perform task-oriented exercises while using the FitFES device.
224298077|NCT06928857|OTHER|Traditional rehabilitation|Each subject will receive 15 individual rehabilitation sessions, each lasting 60 minutes, conducted 3 to 5 times per week over a period of 5 to 3 weeks, depending on the weekly frequency. Each participant will perform task-oriented exercises.
223410896|NCT02023411|OTHER|Placebo|Placebo
223410897|NCT05334953|DEVICE|ESWT|"Group 1 (n = 17) will be given two times a week, total 5 sessions of ESWT + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
223410898|NCT05334953|DEVICE|Phonophoresis|"Group 2 ( n=17) will be given five times a week total 10 sessions of diclofenac phonophoresis + home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
223410899|NCT05334953|DEVICE|Ultrasound|"Group 3 (n=17) will be given five times a week total 10 sessions of ultrasound therapy+ home exercise program~Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises"
223410900|NCT05334953|OTHER|Control group|Other: Home Workout Program Patients will be given eccentric exercises and stretching exercises
223559103|NCT01308255|DRUG|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
223559104|NCT01308255|DIETARY_SUPPLEMENT|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
223559105|NCT03528876|DRUG|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
224027988|NCT04634929|PROCEDURE|bariatric surgery|bariatric surgery
224134434|NCT02070406|DRUG|cyclophosphamide|Given IV
223559106|NCT01964495|DRUG|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
224027989|NCT04634929|DIETARY_SUPPLEMENT|conservative diet|conservative diet
224027990|NCT01972711|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
224027991|NCT01972711|DRUG|Amisulpride|Amisulpride as a single oral dose of 400 mg
224027992|NCT01972711|DRUG|Placebo|single oral dose placebo
224027993|NCT05695937|DIETARY_SUPPLEMENT|phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
224027994|NCT05695937|DIETARY_SUPPLEMENT|krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
224027995|NCT05695937|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol
224027996|NCT05695937|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil
224134435|NCT02070406|DRUG|fludarabine phosphate|Given IV
224134436|NCT02070406|BIOLOGICAL|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
224134437|NCT02070406|BIOLOGICAL|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
223559107|NCT01964495|DRUG|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
223559108|NCT01964495|DRUG|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
224134438|NCT02070406|BIOLOGICAL|aldesleukin|Given SC
224027997|NCT00235547|BEHAVIORAL|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
223410901|NCT01637454|DRUG|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
224027998|NCT03584568|BEHAVIORAL|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
224027999|NCT03584568|OTHER|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
224028000|NCT00894153|DRUG|chemotherapy plus p53|chemotherapy plus p53
224028001|NCT00894153|DRUG|chemotherapy|chemotherapy
224028002|NCT00894153|RADIATION|radiotherapy|radiotherapy
224028003|NCT02778256|DEVICE|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
224028004|NCT02778256|DEVICE|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
224028005|NCT06015178|OTHER|Intelligent Language Model|Subjects must use the intelligent language model to complete the retrieval and protocol design execution of an interdisciplinary task, in addition to Google search, literature search and book query.
223559109|NCT02929199|OTHER|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
224028006|NCT06015178|OTHER|control|Subjects can only use Google search, literature retrieval and book query, and cannot use any AI-driven conversational natural language processing tools to complete the retrieval and protocol design execution of an interdisciplinary task.
224134439|NCT02070406|RADIATION|fludeoxyglucose F 18|Correlative studies
224134440|NCT02070406|PROCEDURE|positron emission tomography|Correlative studies
223410902|NCT01637454|DRUG|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
223410903|NCT03348930|DRUG|Tolcapone 200 MG|All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
223559110|NCT02929199|OTHER|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
223559111|NCT03614741|DRUG|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
223559112|NCT03614741|DRUG|Tinzaparin bolus|4500 IU bolus of Tinzaparin
223559113|NCT03760198|DRUG|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
223559114|NCT03760198|OTHER|Placebo|normal saline is injected intradermally to each axilla
223559115|NCT05302973|OTHER|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
223559116|NCT05302973|OTHER|Aerobic exercise|30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
224134441|NCT02070406|OTHER|laboratory biomarker analysis|Correlative studies
223410904|NCT02755467|DEVICE|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
223410905|NCT02091089|DEVICE|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
223738691|NCT06445530|BEHAVIORAL|MFeast ENHANCED|Intervention group will initially receive prepared MTF (low carbohydrate, low-fat meals, which have been shown to improve glycemia in people with prediabetes) delivered by MFeast (10 meals weekly); Tailored Medical Nutrition Therapy (MNT) delivered by dieticians from MFeast via monthly phone calls and focused on only: ↓sugar-sweetened beverages and ↑fruit and vegetable consumption; Lactation snack bundles to boost milk supply + structural support for breastfeeding/pumping via lactation consultants and pumping supply subsidization; culturally-adapted seasoning bundles; and dependent meal boxes for children in the household (i.e., will include 10 developmentally appropriate snack and small meal bundles, for up to 24 weeks. At postpartum week 8 participants will be offered a transition from prepared medically tailored meals to Instacart fresh food delivery (via study team-crafted virtual grocery store) for 16 more weeks.
224134442|NCT04185441|DRUG|Tanzânia association|Tanzânia association capsule
224134443|NCT04185441|DRUG|Omnic Ocas|Tamsulosin 0,4 mg
224134444|NCT04185441|OTHER|Omnic Ocas placebo|Tamsulosin placebo
224134445|NCT04185441|OTHER|Tanzânia association placebo|EMS association placebo
224134446|NCT02877355|DRUG|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
224134447|NCT01367301|DRUG|paclitaxel|Given IV
224134448|NCT01367301|DRUG|carboplatin|Given IV
223410906|NCT01231451|DRUG|DMPA|All subjects will take DMPA
223410907|NCT00746148|OTHER|Reflexology|10 weekly sessions of 45 minutes each
223559117|NCT00080834|DRUG|DJ-927|
223559118|NCT06349265|DRUG|Carpal Tunnel Hydrodissection with %5 dextrose in water injection|Under the inplane ulnar approach, 3ml injectate was injected to hydrodissect the median nerve from the flexor retinaculum, and the residual 2ml injectate was then injected to hydrodissect the inferior median nerve away from the flexor tendons.
223559119|NCT02258568|BEHAVIORAL|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
224134449|NCT01367301|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
224028007|NCT04929548|DRUG|Pyrotinib Maleate Tablets|Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.
224028008|NCT03278951|BEHAVIORAL|Video Conferencing Group|
224028009|NCT03278951|BEHAVIORAL|In Person Group|
224028010|NCT00427336|DRUG|Fludarabine|30 mg/m\^2 by vein daily over 30 minutes
224134450|NCT01367301|RADIATION|brachytherapy|Undergo HDR brachytherapy
224134451|NCT01367301|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
223410908|NCT04955405|OTHER|The seven visit telemedicine protocol|The transition of care team (pharmacist, advanced practice provider, social worker) will conduct an initial visit as a team with the patient using the telemedicine platform. During the visit, the team will assess the clinical, social, and pharmaceutical needs of the patient. The transition of care team will then meet to discuss the specific needs of the patient and to develop a care plan for the next 6 telemedicine visits. Either the social worker or the advanced practice provider will conduct the next 6 visits. The pharmacist will provide medication counseling as needed and recommended by the entire care team. The next 3 visits will occur weekly, the following 2 visits will occur biweekly, and the remaining 1 visit will occur at some point during the third month.
223410909|NCT06385574|OTHER|Virtual reality therapy|Conventional hand therapy
223410910|NCT01767246|OTHER|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
223410911|NCT01767246|OTHER|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
223410912|NCT04826081|OTHER|data collection|data collection
223410913|NCT05003804|BIOLOGICAL|STMC-103H|STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
223410914|NCT05003804|BIOLOGICAL|Placebo|Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
223410915|NCT03930355|OTHER|Blood transfusion|Patients who received blood transfusion in the perioperative period
223410916|NCT03930355|OTHER|Control|Patients who did not receive blood transfusion in the perioperative period
223410917|NCT05430750|DRUG|Nitrous oxide|In conventional nitrous oxide carrier group 2% Sevoflurane in O2-N2O (60 % FiO2) @3L/min will be delivered to achieve MAC 0.5.
223559120|NCT04249492|DEVICE|IOL implantation experimental (Isopure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
223559121|NCT04249492|DEVICE|IOL implantation active comparator (Micropure 1.2.3.)|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
223559122|NCT01582516|BIOLOGICAL|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
223559123|NCT01364454|OTHER|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
223738692|NCT06445530|BEHAVIORAL|MFeast Usual Care|"Those assigned to the MFeast Usual Care group will receive prepared MTF delivered by MFeast and as needed MNT from 1 to 24 weeks postpartum."
223738693|NCT05870111|DRUG|Citicoline (cytidine diphosphate-choline)|2000mg/day citicoline, administered orally, for 4 weeks
224134452|NCT01367301|OTHER|laboratory biomarker analysis|Correlative studies
223738694|NCT05870111|DRUG|Placebo oral capsule|placebo capsule daily for 4 weeks, matched in appearance to citicoline to preserve double-blind, administered orally
224134453|NCT02598466|DRUG|Abatacept|
224134454|NCT01628094|DRUG|RO5024048|
224028011|NCT00427336|DRUG|Cyclophosphamide|300 mg/m\^2 by vein daily over 2 hours
224028012|NCT00427336|DRUG|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
224028013|NCT00465725|DRUG|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
224028014|NCT01625572|PROCEDURE|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
224028015|NCT01625572|PROCEDURE|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
224028016|NCT00922103|PROCEDURE|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
224134455|NCT01628094|DRUG|RO5190591|
224134456|NCT01628094|DRUG|RO5466731|
224134457|NCT01628094|DRUG|ribavirin [Copegus]|
224134458|NCT01628094|DRUG|ritonavir|
224134459|NCT02504268|DRUG|Abatacept|
224134460|NCT02504268|DRUG|Methotrexate|
224134461|NCT02504268|OTHER|Abatacept Placebo|
224134462|NCT02504268|OTHER|Methotrexate Placebo|
224134463|NCT01672437|OTHER|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
224134464|NCT00692510|DRUG|AZD3480|Capsule, oral, dose once daily, 7 days
224134465|NCT00692510|DRUG|Placebo|Capsule, oral, dose once daily, 7 days
224134466|NCT00692510|DRUG|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
224134467|NCT05143762|DRUG|paracetamol|patients will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day)
224134468|NCT05143762|DRUG|Dexamethasone|patients will receive dexamethasone 0.5mg/kg IV.
224134469|NCT05143762|DRUG|normal Saline|patients will receive placebo 10 ml normal saline IV.
224134470|NCT03379012|DRUG|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
224134471|NCT01254513|DRUG|Docetaxel every 3 weeks + Prednisone|"* Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously"
224028017|NCT00922103|PROCEDURE|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
224028018|NCT03717948|OTHER|BFR Exercise|Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
223410918|NCT05430750|DRUG|Nitrous oxide|In streamed-in nitrous oxide carrier group 2% Sevoflurane in O2 -Air (60 % FiO2) will be delivered @3.0L/min to achieve a MAC of 0.5. Then, the FGF will be decreased to 1.0 L (low flow) and N2O will be 'streamed-in' @ 40 %.
223410919|NCT05430750|DRUG|Sevoflurane|Ventilation will be initiated with 2% sevoflurane in all the groups
223410920|NCT02435537|DRUG|Dexmedetomidine (Precedex)|intrathecal administration
223410921|NCT02435537|DRUG|Bupivacaine|intrathecal 10 mg bupivacaine
223410922|NCT02435537|DRUG|Morphine|intrathecal 0.5mg morphine
223410923|NCT04947007|DRUG|Bupivacaine hydrogen chloride (HCl) 0.025 % in 15+15 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 15 ml +15 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
223410924|NCT04947007|DRUG|Bupivacaine HCl 0.025 % in 10+10 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 10 ml +10 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
223410925|NCT04947007|DRUG|Bupivacaine HCl 0.025 % in 5+5 ML Injection|In this group, US guided suprascapulary and axillary block will be performed with 5 ml +5 ml 0.025% bupivacaine for each block site using a 22 gauge 10 mm block needle.
223559124|NCT01139203|DRUG|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
223559125|NCT00982046|DEVICE|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
223559126|NCT00982046|DEVICE|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
224028019|NCT03717948|OTHER|CTL Exercise|Participants will exercise on a recumbent bike placed on flat ground (CTL).
223410926|NCT04947007|DRUG|Isotonic solution|In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
223559127|NCT00982046|DEVICE|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
223559128|NCT00982046|DEVICE|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
223559129|NCT00982046|DEVICE|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
223559130|NCT00982046|DEVICE|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
223559131|NCT05533307|DIAGNOSTIC_TEST|observational analysis of mediolateral episiotomy with arizona sexuel function scoring after 3 months of normal vaginal birth|ASEX (ARİZONA SEXUEL FONCTİON SCORİNG) TEST
224028020|NCT01419457|DRUG|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
224028021|NCT01419457|DRUG|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
224028022|NCT01419457|DRUG|Favipiravir|800 mg Single Dose
224028023|NCT02579174|DEVICE|Medacta GMK Sphere|
224028024|NCT02215538|DRUG|OROS methylphenidate|
224134472|NCT01254513|DRUG|Docetaxel weekly+ Prednisone|"* Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously"
224134473|NCT00893048|DRUG|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
224134474|NCT00893048|DRUG|Placebo Oral Tablet|Placebo
223410927|NCT01580670|DRUG|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
223410928|NCT02097745|DRUG|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
223410929|NCT02097745|DRUG|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
223410930|NCT00425750|DRUG|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
223410931|NCT00425750|DRUG|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
223410932|NCT00425750|OTHER|laboratory biomarker analysis|Tissue and blood collection.
223410933|NCT00425750|OTHER|pharmacological study|Blood collection.
223410934|NCT00027066|DRUG|Active Aspirin|325mg tablet daily
223410935|NCT00027066|DRUG|Active Warfarin|2mg scored tablet daily
223410936|NCT00027066|DRUG|Aspirin placebo|325mg aspirin placebo pill
223410937|NCT00027066|DRUG|Warfarin placebo|2mg scored placebo tablet
223559132|NCT04268121|DRUG|Neoadjuvant treatment|4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide followed by surgery or chemoradiotherapy
223559133|NCT04268121|DRUG|Adjuvant treatment|Surgery (before study entry) followed by 4 cycles of platinum-based chemotherapy (carboplatin or cisplatin) plus etoposide
224028025|NCT02215538|DRUG|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
224028026|NCT00984425|DRUG|Lapatinib and Sorafenib|Comparison of different dosages of two drug
224028027|NCT00655486|DRUG|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
224028028|NCT01057498|DRUG|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
224028029|NCT01057498|DRUG|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
224028030|NCT06008886|BEHAVIORAL|Vegan diet|Normocaloric diet based solely on foods of plant sources.
223410938|NCT03594981|BIOLOGICAL|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
223410939|NCT05472272|OTHER|Formula diet|Participants will receive a low-calorie (815-835 kcal/day; approximately 43% carbohydrate, 29% protein, and 29% fat) formula diet product for 12 weeks, followed by a gradual food reintroduction phase combined with physical activity support for 12 weeks.
224028031|NCT06008886|BEHAVIORAL|Mediterranean diet|Diet with a predominance of plant foods fruits, vegetables, whole grains, nuts and legumes); moderate to low consumption of fish, white meat, low-fat dairy and eggs; and very low consumption of red and processed meats, butter, full-fat dairy and sweets.
223410940|NCT05472272|OTHER|Food-based diet|Participants will receive a low-calorie (815-835 kcal/day; 45-50% carbohydrate, 20-30% protein, and 20-30% fat) food-based diet created by dietitians for 12 weeks. After 12 weeks, participants will increase energy intake gradually and be encouraged to increase daily physical activity to maintain weight loss for another 12 weeks.
224028032|NCT05536609|PROCEDURE|Epineural suture|2 or three sutures
223410941|NCT02861222|DRUG|Doxorubicin|
223410942|NCT04804423|DRUG|38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)|38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
223410943|NCT04804423|DRUG|Sodium fluoride varnish (generic name; Duraphat®)|22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
223559134|NCT00253773|DRUG|acetominophen, sulfer amino acids; cysteine and methionine|
223559135|NCT02443116|BIOLOGICAL|NGM282|
223559136|NCT02443116|OTHER|Placebo|
223559137|NCT05144893|BEHAVIORAL|Virtual Mindfullness-Based Intervention|Virtual administration of the social support components of an adapted 4-week Mindfulness Based Cognitive Therapy for Postpartum Depression (MBCT-PD) intervention. Each session includes a review of assigned online mindfulness practice and barriers to practice, other homework if also assigned, psychoeducation, and mindfulness practices relevant to the session's theme.
224028033|NCT05536609|PROCEDURE|Non-operative treatment|The injured finger is protected in a plaster cast
223559138|NCT00330408|BEHAVIORAL|GP training|
223559139|NCT03393936|BIOLOGICAL|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
223559140|NCT03393936|BIOLOGICAL|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
223559141|NCT04168008|BEHAVIORAL|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
223559142|NCT04168008|BEHAVIORAL|WISH Parenting|The educational sessions will focus on parenting and baby care.
223559143|NCT04637776|OTHER|Hospitalization|Hospitalization for any reason
223559144|NCT04069468|DEVICE|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
223559145|NCT05046067|PROCEDURE|Computed Tomography|Undergo CT
223559146|NCT05046067|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery per standard of care
224028034|NCT05467254|BIOLOGICAL|CLL1+CD33 CAR-T|CLL1+CD33 CAR-T is a new type CAR-T cells therapy for patients with acute myeloid leukemia.
224028035|NCT02136420|DRUG|Promethazine|Subject receives promethazine
224028036|NCT02136420|BEHAVIORAL|Hyper gravity training|Subject receives hypergravity training before testing
224028037|NCT02136420|DRUG|Placebo|Placebo
224028038|NCT02136420|BEHAVIORAL|No hypergravity training|Subjects do not receive normal Earth gravity
224028039|NCT06510647|OTHER|Hormonal Therapy Agent|"With an endometriosis diagnosis in which hormonal therapy is indicated, patients who satisfy inclusion and exclusion criteria will be administered scientifically validated questionnaires at the time of the visit (time 0): Endometriosis Health Profile-30 and the Short Form Health Survey SF-12.~The second evaluation will be conducted 6 months later (time 1) along with a gynecological examination and gynecological ultrasound, and the same two questionnaires will be administered. Patients will be defined as non-responsive to medical therapy if their Endometriosis Health Profile 30 scores are equal to or higher at the time 1 visit compared to the enrollment visit at time 0.~Patients will then be re-evaluated 12 months (time 2) after the first visit with the same criteria, and the two questionnaires will be administered once more. Similarly, patients with EHP-30 scores equal to or higher than the previous control at time 1 will be defined as non-responsive to medical therapy."
224028040|NCT06235892|DRUG|TACROLIMUS|TACROLIMUS 2-3.5 ng/ml
223410944|NCT01757184|DRUG|Sebelipase Alfa|IV infusions of sebelipase alfa
223410945|NCT01757184|DRUG|Placebo|IV infusions of matched placebo
223410946|NCT05460351|DIETARY_SUPPLEMENT|BRJ+Nitrate|Participants in this group drank a 70 mL bottle of Beet It Sport drink with nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
223410947|NCT05460351|DIETARY_SUPPLEMENT|Control|Participants in this group drank a 70 mL bottle of Beet It Sport drink without nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
223410948|NCT03350646|OTHER|Volume of medium during embryo transfer|
223410949|NCT04644302|DIAGNOSTIC_TEST|microcirculation recording|non-invasive recording of sublingual microcirculation and blood sampling together with regular withdraws
223410950|NCT01666158|BEHAVIORAL|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
224028041|NCT04864106|DEVICE|Endoscopic Examination|Endoscopic airway grading using a rigid 75-degree angle laryngoscope.
224028042|NCT05885828|OTHER|White bread|After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
224028043|NCT05885828|OTHER|Whole wheat bread|After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
224028044|NCT05885828|BEHAVIORAL|Plant-based diet|After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.
224028045|NCT05885828|OTHER|Conventional diabetic diet|Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.
224028046|NCT05885828|OTHER|Follow-up visit every 1-2 years|Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.
224028047|NCT06101667|DRUG|Best medical management|Best medical management included assessment of vital signs and neurological deficits,airway protection respiratory support,circulation;blood pressure monitoring;nutritional support;complication control;symptomatic treatment;laboratory and imaging examinations;etiological analysis and evaluation; anti platelet（e.g. aspirin,adenosine diphosphate (ADP) receptor inhibitors,Adenosine reuptake inhibitors,Glycoprotein platelet inhibitors）；anticoagulation(e.g. warfarin, rivaroxaban,dabigatran,apixaban,edoxaban)；lipid lowering(e.g. Statins,Fibrates）；control of blood pressure(e.g. Thiazide diuretics,Potassium-sparing,Loop diuretic,Beta-blockers,Angiotensin II receptor blockers,Calcium channel blockers,Alpha blockers,Central alpha-2 receptor agonists);control of blood glucose(e.g. SULFONYLUREAS (SFUs),GLINIDES,BIGUANIDES,ALPHA-GLUCOSIDASE INHIBITORS: STARCH BLOCKERS,THIAZOLIDINEDIONES,GLP-1 ANALOGS,DPP-4 INHIBITORS,SGLT2 inhibitors); control of other risk factors
224028048|NCT06101667|PROCEDURE|Endovascular treatment|The strategies that were used for endovascular treatment included :stent retrievers (e.g., Solitaire® \[Medtronic, USA\], Trevo® \[Stryker, USA\], EMBOTRAP® \[Johnson \& Johnson, USA\], Captor® \[HeartCare, China\] and other stent-retriever systems) thromboaspiration (e.g., Penumbra® \[Penumbra, USA\], Afentta® \[HeMo, China\] and other aspiration systems)) balloon angioplasty (e.g., Gateway® \[Stryker, USA\], Neuro RX® \[SinoMed, China\], FocuStar® \[HeMo, China\] and other intracranial balloon catheter systems) stent deployment (e.g., Wingspan® \[Stryker, USA\], Apollo® \[MircoPort, China\], Enterprise® \[Johnson \& Johnson, USA\], Neuroform EZ® \[Stryker, USA\] and other Intracranial stent systems)) intraarterial thrombolysis (with alteplase or urokinase) combinations of above approaches that were left to the discretion of the treating team
224028049|NCT06130306|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 45 minutes targeted the pudendal nerve, thrice weekly for a minimum of 8 weeks. The treatment plan remains ongoing until the patient opts to discontinue voluntarily.
224134475|NCT02548572|DEVICE|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
224134476|NCT00126178|BIOLOGICAL|HSPPC-96|
224134477|NCT02296437|OTHER|Transcranial direct current stimulation combined with cognitive training|
224134478|NCT04114513|DIETARY_SUPPLEMENT|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
223410951|NCT01902641|DRUG|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
223410952|NCT01902641|DRUG|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
224134479|NCT04114513|DIETARY_SUPPLEMENT|Inulin|BENEO-Orafti, white powder 5 weeks intervention
223410953|NCT01902641|DRUG|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
224134480|NCT04114513|DIETARY_SUPPLEMENT|Pectin|BANG \& BONSOMER GROUP OY, white powder 5 weeks intervention
224134481|NCT04114513|DIETARY_SUPPLEMENT|Beta-glucan|Tate \& Lyle, white powder 5 weeks intervention
224134482|NCT04114513|DIETARY_SUPPLEMENT|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
223410954|NCT01984632|PROCEDURE|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
223410955|NCT01984632|PROCEDURE|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
223410956|NCT00554515|DRUG|HD IL2|
223410957|NCT04454983|DEVICE|Lipiflow Thermal Pulsation System|The LipiFlow Console provides the user interface and control elements of the system, including all software, algorithms and control elements. The Activator, a single-use sterile device, delivers automated therapeutic energies to each meibomian gland. Its contoured design vaults the cornea and protects the eye allowing a maximum therapeutic temperature of 43 degrees Celsius to reach glands from the inner eyelid. Insulation protects the cornea from exceeding a safe 39.5 degrees Celsius, while a pressure feedback loop sends pulsed sequences to expel blockages. Force equalization protects the globe from pressure transmission by focusing energy only on the eyelid. Delivered through the LipiFlow Activator, Vectored Thermal Pulse™ technology applies a combination of heat and pressure to the inner eyelid to safely remove gland obstructions and stagnant gland content. Therapeutic motion provides proximal-to-distal peristalsis to clear gland contents.
223559147|NCT06249061|DIETARY_SUPPLEMENT|oral sodium bicarbonate|Those in the oral sodium bicarbonate intervention group will be encouraged to sip a solution of 1 imperial teaspoon (\~5g) of sodium bicarbonate dissolved into 250ml of water throughout labour with other drinks. If the first solution is fully consumed, a second solution will be prepared and offered. Thus, each participant can receive a maximum dose of 2 imperial teaspoons (\~10g) of sodium bicarbonate.
224134483|NCT02503774|DRUG|Oleclumab|Participants will receive IV infusion of oleclumab as stated in arms' description.
224134484|NCT02503774|DRUG|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arms' description.
224298078|NCT06927726|DRUG|4% Articaine HCL With 1:100,000 Epinephrine|"Preoperative clinically and radiographic examination will be performed for each patient. Local maxillary infiltration anesthesia adjacent to the tooth with extraction will be the anesthetic method used throughout by a vestibular (1.5 ml) and a palatal injection (0.3 ml). The following agents will be applied for anesthetization: Septanest 4% Articaine HCL With 1:100,000 Epinephrine. The injections and the extractions will be performed by certified dentists of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Tanta University.~Dental extraction will be performed after full anesthesia, tested with a probe on the buccal mucosa, palatal mucosa, and the tooth itself each minute after injection, and after subjective symptoms of numbness by the patient."
223410958|NCT04454983|DEVICE|iLux System|The iLux™ System is used to apply localized heat and pressure to a patient's eyelids. The system consists of a handheld instrument coupled to a single-use, sterile disposable component that is positioned to bridge the eyelid. The iLux device allows view of the eyelid through a magnifier, then warms the eyelid to 40 to 42˚C, then force-limited compression is applied manually to express the melted meibum from obstructed glands. Warming is accomplished using light energy emitted from LEDs in the Instrument. The LEDs are located behind a clear window on the open end of the Shroud. Two wavelengths of light are used: lime-green (568 nm) and near-infrared (850 nm). A mechanism in the Instrument allows the operator to apply pressure to the eyelid by controlling the movement of the Outer Pad using finger pressure applied to the Compression Control button. The force applied to the Compression Control is measured by a sensor in this mechanism.
223559148|NCT06387290|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative therapeutic approach.
223559149|NCT06387290|BEHAVIORAL|Patient-Centered Chronic Pain Management Visits|Participant will meet with their primary care provider for patient-centered care and shared decision making while discussing their chronic pain management strategy (e.g., opioid analgesics).
223559150|NCT06368739|BEHAVIORAL|Nurture program|"1. Nurture Monthly Packages: Sent every four weeks until the member reaches the end of pregnancy (delivery or other reasons, e.g., miscarriage), with a maximum of eight packages. Each package includes:~   * A US$40 gift card (2 x $20 each) to a grocery store.~  * A healthy eating information sheet selected from Brighter Bites project (https://brighterbites.org/).~  * A set of three recipes.~  * Nutrition-related Frequently Asked Questions (included in four out of the eight packages).~2. Two 30-Minute Nutritional Consultations over the phone: Designed by a Registered Dietitian Nutritionist (RDN) who trained a bilingual nutrition specialist to deliver the consultations. Topics revolved around healthy eating during pregnancy, such as food choices, portion sizes, budget-friendly shopping, food safety, and food preparation. No nutrition therapy advice to manage diseases was provided."
223559151|NCT06368739|OTHER|Regular benefits|Includes regular healthcare services offered as part of the health plan coverage with Medicaid/CHIP.
223559152|NCT06305806|DRUG|Ivabradine|Participants will receive ivabradine for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).
223559153|NCT06305806|DRUG|Ivabradine Placebo|"The control (placebo) oral tablets will be similar to the study drug, ivabradine.~The control packaging matches the packaging.~Participants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months)."
223559154|NCT06305806|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
224134485|NCT00956215|DRUG|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
224134486|NCT00956215|DRUG|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
224134487|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing, externally chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the subgoal chosen by the study coordinator. Subgoals will gradually increase from the participant's baseline adherence up to 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
224134488|NCT05378607|BEHAVIORAL|End of year 1 adherence prize drawing|Participants will have a chance to participate in a prize drawing at the end of year 1 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on reaching 90% in the three months preceding the end of year 1.
224134489|NCT05378607|BEHAVIORAL|SMS motivational messages + reminder of prize drawing|Participants will receive weekly motivational messages with a reminder of their upcoming prize drawing throughout year 1 of the study.
224298079|NCT06927726|DRUG|3% plain mepivacaine HCL|"Preoperative clinically and radiographic examination will be performed for each patient. Local maxillary infiltration anesthesia adjacent to the tooth with extraction will be the anesthetic method used throughout by a vestibular (1.5 ml) and a palatal injection (0.3 ml). The following agents will be applied for anesthetization: Scandonest 3% plain mepivacaine HCL (Septodont, Manufactured By Novocol Pharmaceuticals of Canada). The injections and the extractions will be performed by certified dentists of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Tanta University.~Dental extraction will be performed after full anesthesia, tested with a probe on the buccal mucosa, palatal mucosa, and the tooth itself each minute after injection, and after subjective symptoms of numbness by the patient."
223410959|NCT05899283|DEVICE|OCI-HF160|OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
223410960|NCT05899283|DEVICE|FX800HDF|FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
223410961|NCT03658161|BEHAVIORAL|Communicating About Sexual Concerns and Dysfunction Effectively|The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
223410962|NCT03240289|BEHAVIORAL|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
223410963|NCT02085629|BIOLOGICAL|Donor M reg (Mreg_UKR)|"Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description)."
223410964|NCT06576778|PROCEDURE|PROVSIONALIZATION|glass fiber composite as a temporary framework followed by PEKKTON definitive framework.
223559155|NCT06305806|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
223559156|NCT00651014|DRUG|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
223559157|NCT00651014|DRUG|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
223410965|NCT04693208|DEVICE|Laser therapy|Laser treatment parameters will be two combined wavelength (660 and 970 nm), 3.2 Watt peak power, 320 milliWatt/cm2, 36.8 Joule/cm2 fluency, and 50% frequency, for a total time of 3 minutes for each site
223559158|NCT02655757|DRUG|Sitagliptin|5 mg, 1 tablet per day for 12 months
223559159|NCT02655757|DRUG|Placebo|Placebo,1 tablet per day for 12 months
223738695|NCT05799287|BIOLOGICAL|Telitacicept|Subcutaneous injection
223738696|NCT05799287|DRUG|Placebo|Placebo to Telitacicept
224134490|NCT05378607|BEHAVIORAL|Year 2 re-allocation based on year 1 performance|In Year 2 of the study, participants who have reached 90% by the end of year 1 will no longer be given sub-goals and instead will be eligible for prize drawings if they maintain the fixed level of 90% or higher. Those who have not reached 90% by the end of year 1 will be allocated to the intervention group that showed the highest effectiveness in year 1.
224134491|NCT05378607|BEHAVIORAL|End of Year 2 viral suppression prize drawing|Participants will have a chance to participate in a prize drawing at the end of Year 2 with larger prize amounts of up to 20,000 Ugandan Shillings (approximately $6), where eligibility is based on achieving viral suppression by the end of Year 2.
223410966|NCT00485199|PROCEDURE|Pneumatic Retinopexy|
223410967|NCT00485199|PROCEDURE|Vitrectomy with Gas|
223410968|NCT01509417|OTHER|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
223410969|NCT01509417|OTHER|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
223410970|NCT03877601|DRUG|Bevacizumab-IRDye800CW|Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
223559160|NCT03742479|DEVICE|Restylane® Silk|Injectable Hyaluronic Acid (HA)
223559161|NCT06245486|DIETARY_SUPPLEMENT|Crispact®|Contains 20 Bld CFU/Stick of probiotic Lactobacillus crispatus M247
223559162|NCT06245486|DIETARY_SUPPLEMENT|Placebo|Placebo
223559163|NCT00066599|DRUG|voriconazole|
223559164|NCT02336685|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
223559165|NCT02336685|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
223559166|NCT02336685|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
223559167|NCT02336685|DRUG|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
223559168|NCT02224287|PROCEDURE|Technologist control of fluoroscopy|Technologist control of fluoroscopy
223559169|NCT02224287|PROCEDURE|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
223738697|NCT06441006|DRUG|Bedaquiline|Frequency: daily Route of administration: oral
223738698|NCT06441006|DRUG|Linezolid|Frequency: daily Route of administration: oral
223738699|NCT06441006|DRUG|Pretomanid|Frequency: daily Route of administration: oral
223738700|NCT06441006|DRUG|Moxifloxacin|Frequency: daily Route of administration: oral
224134492|NCT05378607|BEHAVIORAL|Incentivization based on gradually increasing self-chosen adherence goals|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000, or 10,000 Ugandan Shillings if adherence matches or exceeds the self-chosen subgoal. While self-chosen, subgoals are subject to a minimum threshold determined by baseline adherence working towards 90% adherence. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
224134493|NCT05378607|BEHAVIORAL|Incentivization based on a fixed adherence goal|Wisepill data on adherence will be collected remotely. Every three months, participants have a chance to participate in a prize drawing for an airtime reward of 500, 5,000 or 10,000 Ugandan Shillings if adherence matches or exceeds the fixed adherence goal of 90%. Prize drawings can be done during regularly scheduled clinic visits if the participant has a visit corresponding to the 3-month mark or remotely via SMS text message.
224134494|NCT05378607|BEHAVIORAL|SMS motivational messages|The control group will also receive weekly motivational messages but without the reminder of the upcoming prize drawing.
224134495|NCT05746884|PROCEDURE|duodenal mucosectomy|Standard resection technique will be performed for duodenal mucosectomy, as well as the usual hemostasis at the discretion of the operator.
224134496|NCT05746884|PROCEDURE|ampullectomy|Standard resection technique will be performed for ampullectomy, as well as the usual hemostasis at the discretion of the operator.
224134497|NCT00307515|DRUG|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
224134498|NCT00307515|DEVICE|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
224134499|NCT00836680|DEVICE|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
223410971|NCT03877601|DIAGNOSTIC_TEST|Fluorescence endoscopy|Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
224134500|NCT00308438|DRUG|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
224134501|NCT03866863|OTHER|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight \< 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight \< 10th centile combined with umbilical artery pulsatility index \> 95th centile or breakage of growth.
223410972|NCT04571645|DRUG|Dociparstat|Dociparstat is a glycosaminoglycan derived from porcine heparin.
223410973|NCT04571645|OTHER|Control|0.9% Normal Saline
223410974|NCT04357067|DEVICE|Lingual brackets|A type of bracket that applied lingual surface of teeth.
223410975|NCT04357067|DEVICE|Labial brackets|A type of bracket that applied labial surface of teeth.
223410976|NCT03691987|BIOLOGICAL|Preprocessed thawed donor FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
223410977|NCT03691987|BIOLOGICAL|Preprocessed thawed autologous FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
223410978|NCT06030323|OTHER|No intervention|This is not an interventional study. The study is classified as 'pre-clinical device development or performance testing'. The purpose of the study is to develop and validate the AI models using data collected from people affected by stroke in a hospital environment, to test the accuracy of the optimised models, and to ascertain patient preference for sensor location.
223410979|NCT05961306|DIAGNOSTIC_TEST|SCID 5|"SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone."
223559170|NCT06967337|BEHAVIORAL|Microsteps|Microsteps (behavioral nudges) are a series of short, written messages that were developed by the Thrive Global Wellbeing and Behavior Change Platform, based in the US. The Microsteps messages deliver step-wise, small health behavioral nudges that align with research on behavior change strategies. The behavioral nudges focus on health behaviors that could be useful adjunct interventions for GLP-1RA users, (improved food choices, exercise, sleep and stress management).
223738701|NCT06441006|DRUG|Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelines|The local SOC regimen consistent with preferred regimen(s) in international guidelines. In most cases this will be 24 weeks of bedaquiline, pretomanid, linezolid, and moxifloxacin (6BPaLM). Doses and durations of each component may change based on the latest international guidelines and the local SOC.
223738702|NCT06088121|DEVICE|ATNC MDD-V1 (Real TMS + Real Cog)|Synchronized TMS and cognitive stimulation to 6 brain areas.
223738703|NCT06088121|DEVICE|ATNC MDD-V1 (Sham TMS + Real Cog)|Sham device, has the same appearance and sound as the real device, combined with real cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
223738704|NCT06088121|DEVICE|ATNC BN-V1|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
224134502|NCT00025532|OTHER|iodine I 131 monoclonal antibody CC49-deltaCH2|
224134503|NCT02130427|DIAGNOSTIC_TEST|CT scan|Weekly 3D/4D CT scan
224134504|NCT00258427|BIOLOGICAL|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
224134505|NCT00258427|BIOLOGICAL|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10\^9/L)
224134506|NCT00258427|DRUG|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if \<4 years old)
224134507|NCT00258427|DRUG|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
224134508|NCT00258427|DRUG|fludarabine phosphate|35 mg/m\^2 intravenously (IV) on Days -5 through -2.
224134509|NCT00258427|DRUG|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
223410980|NCT05587504|OTHER|E-cigarette with sweetness type 1 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1."
224134510|NCT00258427|BIOLOGICAL|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
224134511|NCT04010786|DRUG|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
223410981|NCT05587504|OTHER|E-cigarette with sweetness type 1 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2."
223410982|NCT05587504|OTHER|E-cigarette with sweetness type 2 and pronation level 1|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1."
223410983|NCT05587504|OTHER|E-cigarette with sweetness type 2 and pronation level 2|"An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2."
223410984|NCT04700241|DIETARY_SUPPLEMENT|Potassium nitrate|Acute intervention (5.5 hours)
223410985|NCT04700241|DIETARY_SUPPLEMENT|Placebo|Acute intervention (5.5 hours)
224028050|NCT06130306|PROCEDURE|pelvic floor muscle training combined with transanal electrical stimulation|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system \[AM1000B; Shenzhen Creative Industry Co. Ltd, China\]) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB 4, Electronic Concept Lignon Innovation, France)) at a current intensity of \< 60 mA (as high as possible to get a PFM contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients also conducted 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks. If the patient is willing, the treatment plan can continue until the patient voluntarily decides to stop.
224028051|NCT06050577|DRUG|oral Semaglutide/Rybelsus|Weeks 1-4: 3 mg of oral semaglutide once daily. Weeks 5-52: 7 mg of semaglutide once daily as maintenance dose. Dose may be increased to 14 mg of semaglutide once daily as maintenance dose after 2 months if glucose levels are out of range.
224134512|NCT04010786|DRUG|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
224134513|NCT00409201|DRUG|reboxetine adjuvant therapy|
224134514|NCT02346500|DEVICE|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
224134515|NCT01175967|OTHER|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
224134516|NCT01175967|OTHER|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
224134517|NCT01175967|OTHER|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
224134518|NCT01175967|OTHER|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
224134519|NCT05096871|GENETIC|Genotyping by Real Time PCR|"3 mL of blood will be withdrawn by venipuncture in EDTA tube. DNA extraction will be done after centrifugation and used for genotyping assay of ( BDNF ) gene with the Real- time polymerase chain reaction.~BDNF level in serum will also be analyzed by Sandwich enzyme linked immunosorbant assay kit ( ELISA)."
224134520|NCT01389648|OTHER|Pre Operative|Pre operative chest physiotherapy treatment
224134521|NCT00862849|DRUG|Insulin Lispro|
223738705|NCT06088121|DEVICE|ATNC BN-V2|The navigation system is used to determine the exact brain location to be stimulated (coordinates for the stimulation point).
224134522|NCT00862849|DRUG|Regular Human Insulin|
224134523|NCT00862849|DRUG|rHuPH20|
224134524|NCT01621672|DRUG|Revlimid|10 mg/day in the morning same time each day
223410986|NCT06768944|DRUG|Psilocybin 25 mg|The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the high-dose (25mg)
223410987|NCT06768944|DRUG|Psilocybin 1 mg|The drug product (DP) PEX010 is a capsule for oral administration and is manufactured with DS PYEX (12.5-14.0% psilocybin), excipients, and HPMC capsules. The product is manufactured in two product strengths, and this represents the low-dose (1mg)
223410988|NCT06768944|DRUG|Metyrapone 750 mg|metyrapone 750mg capsules, which will be administered in 2 doses
224028052|NCT06050577|DRUG|Placebo|Weeks 1-4: 3 mg of oral placebo once daily. Weeks 5-52: 7 mg of placebo once daily as maintenance dose. Dose may be increased to 14 mg of placebo once daily as maintenance dose after 2 months if glucose levels are out of range.
224028053|NCT04426461|BEHAVIORAL|Behavioral Activation|Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
224028054|NCT04426461|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
223410989|NCT06768944|DRUG|Placebo|inactive placebo
223410990|NCT03725488|OTHER|Questionnaire|"students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants."
224028055|NCT04426461|BEHAVIORAL|Supportive therapy|Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
224028056|NCT06384911|BEHAVIORAL|Financial Incentives Program|Adolescent participants will receive financial incentives for meeting diabetes self-management and clinical outcome goals.
224028057|NCT01210261|DEVICE|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
224028058|NCT01210261|DEVICE|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
224028059|NCT02768870|DEVICE|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
224028060|NCT03105622|BEHAVIORAL|TV and music|Watching TV or listening to music while running on a treadmill
224028061|NCT04388397|PROCEDURE|Arteriovenous Grafts|Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
224028062|NCT05033873|OTHER|Universal Exercise Unit Therapy (UEU)|Standing, walk standing, half standing, kneel standing, half kneel standing, quadruped position, three point quadruped , alternative quadruped , transitions, walking all these will be done in Universal Exercise Unit with a standardized protocol regimen.
224134525|NCT04941352|BEHAVIORAL|6-session Interpersonal Relations Theory-based Motivational Interviews and 3 month follow-up.|6-session Interpersonal Relations Theory-based Motivational Interviews were applied to the individuals in the study group. All sessions were conducted face-to-face in the form of individual interviews. Each interview lasted an average of 30-40 minutes. With this intervention, it was aimed to increase treatment cooperation and motivation in individuals with schizophrenia, to increase insight, to improve adherence to treatment, daily living skills and social functionality.Study data were collected using a personal information form, the Functional Remission of General Schizophrenia Scale (FROGS) and the Scale for Assessing the Three Components of Insight (SAI). The data were analyzed on the basis of pre-intervention, post-intervention and 3 months after the intervention.
224134526|NCT02506296|DRUG|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
224134527|NCT02506296|DEVICE|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
223410991|NCT05989061|DEVICE|PEEK customized healing abutment|Guided delayed implant and a customized PEEK healing abutment placed simultaneously with implant surgery
223410992|NCT05989061|DEVICE|Titanium customized healing abutment|Guided delayed implant and a customized Titanium healing abutment placed simultaneously with implant surgery
224134528|NCT01238315|BIOLOGICAL|HuCNS-SC|Surgery to implant human CNS stem cells
223410993|NCT00379717|DRUG|Cisplatinum|
223410994|NCT00379717|DRUG|Docetaxel|
223410995|NCT00379717|DEVICE|Tomotherapy|
223559171|NCT06967337|BEHAVIORAL|Storytelling video|The storytelling video is a short, 2D animated, wordless storytelling video, of 2:21 minutes duration. The humorous, animated story features a minion-like character who, with the help of their dog, learns to adopt better health behaviors after experiencing an episode of burnout. The video mirrors the written Microsteps messages, conveying them through comical demonstration, rather than through instructional language. The animated characters are free of cultural identifiers, with the intention of increasing the accessibility of the video by overcoming barriers associated with culture, education, language and literacy. The video is intended to underscore and complement the written Microsteps messages, enhance their durability and boost hope and happiness in viewers.
224298080|NCT06927388|DEVICE|freeform myopia control spectacles|The open ring freeform myopia control spectacle lens designs incorporate positively powered cylindrical annular refractive elements (CARE) on the back surface with a superiorly positioned opening in each CARE. The CARE provides an effective optical myopic defocus signal for myopia control and the ring opening facilitates a defocus free zone to aid a smoother visual free transition from downgaze through to upgaze (far) vision for the wearer. The OR designs provide a difference in area and strength of myopia defocus by altering design parameters i.e. zone widths and zone powers. The OR2 and OR3 designs have wider zones and/or higher zone powers than OR1.
224298081|NCT06927388|DEVICE|Commercial myopia control spectacle lens (CML)|Myoless freeform peripheral plus myopia control spectacle lens by IOT
223410996|NCT04917159|BEHAVIORAL|ACT (Acceptance and Commitment Therapy) plus brief CHF education|The participants will identify their values and clarify their alternative behavior, exploring their thoughts and feelings, and finding ways to meet their own and their family member's needs. The rational bond between the patient and his/her family caregiver will be emphasized. In addtion, the contents of brief CHF education are based on the latest national clinical practice guideline for CHF, including symptoms monitoring, medication adherence, fluid and salt restriction, smoking cessation, alcohol consumption, and physical activity maintenance.
223410997|NCT04917159|BEHAVIORAL|HE (Health Education)|The educational contents are based on the latest national clinical practice guideline for CHF. Besides the basic information on CHF education provided in intervention group, the contents of CHF education also include definition of CHF, epidemiology, diagnosis, comorbidity, and CHF treatment. ACT components are not covered.
224028063|NCT05033873|OTHER|Sling Exercise Therapt (SET)|"1. The patient's bilateral knee joints/feet will be suspended by a rope belt, and then the patient's pelvis will be elevated and maintained in supine or lateral position, adding flexion and extension training to lower limb if permitted.~2. In supine or lateral position, with patient's head, trunk and pelvis fixed, the therapist will use appropriate elastic bands to assist patient's limbs to do passive-power assisted-power resistance training in all directions (bending, stretch, outreach, and adduction).~3. The patient's chest and abdomen will be suspended by a wide elastic band, positioned him-self in the prone position with the fulcrum of bilateral elbows and knees, and then the torso swayed in all directions, therapists could assist~4. Target elbow and wrist will be suspended, according to the patient's ability to do passive/active open and close chain movement"
224028064|NCT05033873|OTHER|Routine Physical Therapy / Control Group|"Control group will receive routine physiotherapy with duration one hour including~* Active and passive joint movement~* Muscle strength training~* Bridging exercises~* Balance training in sitting and standing positions, according to the patients' functional state.~* Weight bearing exercises on affected Limbs"
224028065|NCT03401229|BIOLOGICAL|Benralizumab 30 mg SC + Mometasone Furoate|"Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
224028066|NCT03401229|BIOLOGICAL|Matching placebo SC + Mometasone Furoate|"Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
223410998|NCT02299622|GENETIC|Genetic test|Next-generation sequencing (AmpliSeq) \& fusion analysis
223410999|NCT05772377|DRUG|Hydrochloride anlotinib|Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 10 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 8mg will be taken.
223559172|NCT06967337|BEHAVIORAL|Instructional Video|The Instructional Video is a short 2:27min video demonstrating the microsteps and presenting additional information about the rationale for adopting them. The video features an educator who explains these points in a didactic format, and a second educator who demonstrates performing a microstep (stretching at a desk).
223559173|NCT05817422|BIOLOGICAL|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.
223559174|NCT05817422|OTHER|Placebo|0.9% NaCl solution for injection.
223559175|NCT01908491|DEVICE|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
224028067|NCT02963610|DRUG|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
223411000|NCT05772377|DRUG|cis Platinum/carboplatin|Concurrent chemotherapy with cisplatin at 75mg/m2 during radiotherapy will be the most preferred regimen. For patients who cannot tolerate the toxicity of cisplatin, 75 mg/m2 nedaplatin will be used as an alternative drug.
223738706|NCT06295731|DRUG|INBRX-106|INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
223411001|NCT05772377|RADIATION|External beam radiotherapy and brachytherapy|Radiation will be given by external beam of 40Gy total dose and 3D-brachytherapy of 30Gy/2.5F. Duration of radiotherapy will be no more than 5 weeks
223411002|NCT00348777|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
223738707|NCT06295731|DRUG|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
223411003|NCT00348777|DRUG|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
224028068|NCT02963610|DRUG|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
224028069|NCT04801810|OTHER|Normobaric hypoxia|Low oxygen exposure to mimic \~8500 feet elevation (experimental).
224028070|NCT04801810|OTHER|Normobaric normoxia|Normal oxygen exposure to mimic sea level conditions (sham comparator).
224028071|NCT01947972|DIETARY_SUPPLEMENT|Tailored protein fortification|4-4.5g of protein/kg/d
224028072|NCT02088437|OTHER|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
224028073|NCT02088437|OTHER|Usual Care|once daily physiotherapy whilst acute hospital inpatient
224028074|NCT03141385|OTHER|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
224028075|NCT03141385|OTHER|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
224028076|NCT06004947|DRUG|CCX168|Administered orally.
224028077|NCT06004947|DRUG|Midazolam|Administered orally.
223411004|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
223411005|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
223411006|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
223411007|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
223411008|NCT00729664|BIOLOGICAL|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
223411009|NCT03507634|DRUG|Opioid free Anesthesia dexmedetomidine and lidocaine|Opioid free anesthesia with dexmedetomidine and lidocaine
223411010|NCT03507634|DRUG|Opioid based anesthesia Fentanyl and Remifentanyl|Opioid based anesthesia with Fentanyl and Remifentanyl
223411011|NCT04403230|PROCEDURE|Retreatment of teeth prepared without finish line|Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
223411012|NCT01276756|DRUG|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
223738708|NCT05201547|DRUG|Carboplatin-Paclitaxel|Chemotherapy will be administered by intravenous infusion. Carboplatin AUC 5-6 + Pacltaxel 175 mg/m² every 3 weeks. Total duration of treatment: 6 cycles
223738709|NCT05201547|DRUG|Dostarlimab|Dostarlimab will be administered through a 30-minute infusion at a dose of 500 mg Q3W from Cycle 1 through Cycle 4 and at a dose of 1,000 mg Q6W thereafter, beginning at Cycle 5 Day 1 up to a maximum of 2 years.
224028078|NCT06004947|DRUG|Celecoxib|Administered orally.
224028079|NCT06004947|DRUG|Itraconazole|Administered orally.
224028080|NCT06004947|DRUG|Rifampicin|Administered orally.
224028081|NCT05718310|DRUG|Nitroglycerin|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
224028082|NCT05718310|DRUG|Saline|25 migraine patients without aura of both genders are randomized to receive a 20-minutes infusion of NTG and/or sterile saline on two days, with at least one week in between
224028083|NCT06340399|DIETARY_SUPPLEMENT|BCAA|patients administering BCAA
224028084|NCT06340399|OTHER|patient not administered BCAA|patients not administered BCAA
224028085|NCT04384185|OTHER|Exercise protocol|"Exercises:~* Pelvic tilt.~* brinding.~* cuadruped arm/leg raise.~* Abdominal strengthening exercises.~* Low-back muscles stretching.~* The side bridge.~* Side leg separation"
224028086|NCT04384185|OTHER|Manual therapy|"1. Functional diaphragm balancing technique: gentle vertical pressure was applied for 5 minutes at the diaphragm level.~2. Muscle fiber stretching technique: a cranial traction was performed from the lower edge of the costal arches during the inspiratory breathing phase, for more than 10 respiratory cycles.~3. Phrenic-center inhibition technique (Figure 3C): the soft tissue was pumped during the expiratory phase by gently and simultaneously using both hands to create pressure in cranial and caudal direction, for more than 10 respiratory cycles."
224028087|NCT00565474|DRUG|Fluvastatin|Graft vasculopathy
224028088|NCT04693494|OTHER|Training program|Training program consisting in 4 sessions with information about milestones to achieve and advices for motor development. Triptychs and short videos containing the main points containing the main points.
224028089|NCT01774110|OTHER|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
224028090|NCT04580966|BEHAVIORAL|Inquiry Based Stress Reduction (IBSR) workshop|The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
224028091|NCT03680404|DRUG|Control (Phenylephrine)|This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
224028092|NCT03680404|DRUG|Phenylephrine + Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
224028093|NCT03680404|DRUG|Phenylephrine + Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
224028094|NCT03680404|DRUG|Phenylephrine + Tempol|This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
224134529|NCT05346913|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy(ICBT)|ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
223411013|NCT01276756|DRUG|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
224134530|NCT01951235|DRUG|Imeglimin|
224134531|NCT01951235|DRUG|Placebo|
224134532|NCT02700100|DEVICE|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~* Tetralogy of Fallot~* Truncus Arteriosus~* Pulmonary Atresia~* Transposition of Great Arteries with Ventricular Septal Defect (VSD)~* Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
224134533|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
224134534|NCT01339949|DEVICE|IRay|low voltage external beam radiosurgery
224134535|NCT06357260|DRUG|Pregabalin and Carbamazepine|Carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need
224134536|NCT06357260|DRUG|Carbamazepine|Carbamazepine with dose of Carbazmaepine being titrated as per patients's need
224134537|NCT04753242|OTHER|Online survey questionnaire|Self-developed questionnaire based on relevant literature, own experience and consultation with participating professional societies. The survey contains 25 questions on structural and process variables regarding psychosocial care structures that psychosocial C\&L services have established in acute hospitals in the context of the COVID-19 pandemic, the implementation and use of COVID-19-related services for patients, relatives and staff, special challenges, as well as needs and wishes for the future. Thereby the survey is aiming at the creation of a data basis for improving the structural and process quality of psychosocial care services through psychosocial C\&L services in the context of pandemics, especially the COVID-19 pandemic.
223411014|NCT01276756|DRUG|Ribavirin|Ribavirin (\> 75kg:1200 mg, \<75kg:1000mg daily)48 weeks
223411015|NCT01877642|DRUG|Lorazepam 1 mg IM|Lorazepam 1 mg intramuscular
223411016|NCT01877642|DRUG|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg
223411017|NCT01877642|DRUG|Inhaled Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
223411018|NCT01877642|DRUG|Placebo IM|intramuscular placebo to mimic lorazepam 1 mg IM
224134538|NCT01268423|PROCEDURE|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
224134539|NCT01268423|PROCEDURE|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
224134540|NCT00123916|DRUG|Benznidazole|Daily po Benznidazole or placebo (weight based) during 40 - 80 days (depending on body weight)
224134541|NCT00123916|DRUG|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 - 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
224134542|NCT01593501|DIETARY_SUPPLEMENT|vitamin D3|pharmaceutical grade D3
224134543|NCT03117062|OTHER|occlusal reduction|relief of occlusion following endodontic treatment
224134544|NCT06531070|DIETARY_SUPPLEMENT|Nitrate|"A four-day supplementation period, separated by one week including a 3-day washout period between conditions will be applied before conducting strength and endurance assessments~Days 1 to 3 the randomly assigned supplement (N, NC, or PLA) will be ingested 2 hr before a standard low-volume training session including 3 sets of 8 to 10 reps of squat and deadlift using a very light load (e.g., own body mass) and flexibility exercises following by 5 min of running at self-paced intensity rated as light (12) with the rating of perceived exertion Borg Scale.~Day 4: the assigned supplement will be ingested 2.5 h before the assessments~Assessment of strength and endurance will be conducted"
224134545|NCT05729425|DEVICE|Ultrasound Microvessel Imaging|Undergo microvessel ultrasound imaging
223411019|NCT05215977|DRUG|MW031|"The active ingredient of MW031 is a recombinant human anti-RANKL monoclonal antibody ,subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
223411020|NCT05215977|DRUG|Placebo|"subcutaneous injection of 60 mg (1.0 mL)every 6 months for a maximum of 2 consecutive doses throughout the trial.~Dietary Supplement: Elemental Calcium Oral, at least1000 mg Dietary Supplement: Vitamin D Oral, 400 IU"
223411021|NCT04554901|DIETARY_SUPPLEMENT|Cocoa|2-week, once-daily 70%, 50g cocoa bar manufactured by The UWI Cocoa Research Institute (14 bars)
223411022|NCT00838656|DRUG|carboplatin|Given IV in one of two schedules
223411023|NCT00838656|DRUG|gemcitabine hydrochloride|Given IV in one of two schedules
224028095|NCT03656237|OTHER|Usual Training|Training in a classroom setting of health care providers
224028096|NCT03656237|OTHER|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
224028097|NCT00029497|PROCEDURE|Acupuncture|
224028098|NCT00029497|DRUG|Amitriptyline|
223411024|NCT00838656|DRUG|paclitaxel|Given IV in one of two schedules
223411025|NCT01957098|DIETARY_SUPPLEMENT|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
223411026|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 4% D-xylose|
223411027|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 8% D-xylose|
223411028|NCT01957098|DIETARY_SUPPLEMENT|Active comparator: 8% L-arabinose|
223559176|NCT01908491|DEVICE|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
224028099|NCT06270927|DIAGNOSTIC_TEST|MRI|neuroimaging using MRI scanner
224028100|NCT06270927|DIAGNOSTIC_TEST|CT|neuroimaging using CT scanner
224028101|NCT05617911|DEVICE|Blood Flow Restriction Cuff|Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
224134546|NCT03653403|DRUG|IDP-126 Gel|Component A
224134547|NCT03653403|DRUG|Control Gel|gel
224134548|NCT04790266|DIAGNOSTIC_TEST|Cardiac MRI|cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled
223411029|NCT06510543|DIETARY_SUPPLEMENT|Goal-directed EN therapy|The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.
223411030|NCT06510543|DIETARY_SUPPLEMENT|Conventional EN therapy|The participants will be administered the conventional nutritional therapy according to the Chinese expert consensus on perioperative nutritional support in enhanced recovery after surgery (2019 edition).
223411031|NCT05906615|DRUG|Lidocaine IV|Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
223411032|NCT01359332|PROCEDURE|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
224028102|NCT05617911|PROCEDURE|Sham and standard of Care Therapy|SoC PT + non-inflated BFR cuff
223411033|NCT02218437|DRUG|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
223411034|NCT05287035|DRUG|Dexamethasone injection|Dexamethasone will be injected at the dosage recommended by the FDA.
223411035|NCT05287035|OTHER|Saline injection|Saline will be injected for the placebo arm of the study.
223411036|NCT03216122|PROCEDURE|Conventional/Delayed Loading|
223559177|NCT01605604|BEHAVIORAL|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
224028103|NCT00640016|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
224028104|NCT00640016|BIOLOGICAL|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
224134549|NCT02815176|OTHER|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
223411037|NCT03216122|PROCEDURE|Immediate Loading|
223411038|NCT02527733|DRUG|Ranibizumab|
223411039|NCT02527733|DRUG|Ranibizumab and laser|
224028105|NCT00640016|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
224028106|NCT00640016|OTHER|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
224028107|NCT01122862|DRUG|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
224028108|NCT01122862|OTHER|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
224028109|NCT01122862|OTHER|Sterile water|Sterile water
224028110|NCT01222273|DIETARY_SUPPLEMENT|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
224028111|NCT06154486|DRUG|semaglutide use|patient using semaglutide for at least 7 days
224028112|NCT04376853|DEVICE|Apple Watch Series 5|Digital monitoring via Apple Watch
224028113|NCT05621031|DEVICE|Whole body Vibration|Whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform, set at these parameters: frequency 30 Hz; amplitude: 2 mm; 1 min activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
224028114|NCT05621031|OTHER|Habitual Therapy|Physical therapy will be administered to all study subjects. Experimental group will perform their session the same day that the experimental intervention.
223559178|NCT02285023|OTHER|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
223559179|NCT00736749|PROCEDURE|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
223559180|NCT00736749|OTHER|Questionnaire Administration|"Complete patient response form, Health Status Update Form (called the Keep in Touch form), and Quality of Life Questionnaire (PROMIS)"
223559181|NCT03192293|DRUG|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
223559182|NCT05738967|BEHAVIORAL|Transdiagnostic cognitive behavioral therapy (CBT)|Adolescent-caregiver dyads will will participate in CBT focused on exposure therapy and behavioral activation. It will also include flexible incorporation of emotion-focused coping and adaptations for autism.
223559183|NCT05738967|BEHAVIORAL|Treatment as usual|Adolescent-caregiver dyads will participate in coordinated referrals to the community. They may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
223559184|NCT05118165|DIETARY_SUPPLEMENT|Dietary supplement with protein|Will be included protein supplements in the preoperative diet.
224028115|NCT05621031|DEVICE|Placebo whole body vibration|Placebo whole body vibration will be administered with a vibration platform (Power Plate Move). Subjects will do several exercises (squats and steps) whilst on the platform. The platform will only be working for 3 seconds (parameters: frequency 30 Hz; amplitude: 2 mm) and after 3 seconds, the vibration will stop. Same as experimental group, there will be 1 min placebo activation; 1 min rest, 5 activations. 15 sessions will be carried out (2/week).
224028116|NCT01551160|OTHER|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
224028117|NCT01844245|PROCEDURE|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
224028118|NCT04316182|DRUG|Cabozantinib|Cabozantinib 60 mg/day. Cabozantinib dose will be modified upon development of adverse events.
224028119|NCT01821716|BIOLOGICAL|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
224028120|NCT02699983|BEHAVIORAL|Behavioral Dietary Intervention|Use SparkPeople web-based program
224028121|NCT02699983|BEHAVIORAL|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
224028122|NCT02699983|DEVICE|Activity Monitoring Device|Wear Fitbit activity monitoring device
224028123|NCT05908604|OTHER|Robot for madication management|The effect of a robot in medication management for older people's home care
224028124|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the ERA test will be provided to participants and their gynecologists for the personalized embryo transfer.
224028125|NCT04687670|DIAGNOSTIC_TEST|ERA|Before the randomization, Endometrial Fluid (EF) and Endometrial Biopsy (EB) samples will be collected from all participants. EF will be obtained by aspiration immediately prior to the EB after around 120 hours of progesterone (P) impregnation following the standard HRT cycle. The results of the diagnosis will not be disclosed with the patients randomized into this arm nor with their gynecologists.
224028126|NCT00003263|BIOLOGICAL|recombinant interferon alfa|vaccine
224028127|NCT00003263|DRUG|cisplatin|
224028128|NCT00003263|PROCEDURE|surgical procedure|
224028129|NCT00003263|RADIATION|radiation therapy|
224028130|NCT04395430|BEHAVIORAL|Usual Care|"Participants will receive standard care which consist of the following:~* a lifestyle counseling visit~* educational materials~* goal-setting by a healthcare professional, and~* information about general weight management resources.~* weighing scale and measuring tape with instructions to use~* fitness tracker"
224028131|NCT04395430|BEHAVIORAL|online KKH Sports Singapore Program with Usual Care|"Participants will receive standard care and basic sports equipment and cooking materials for the online programme.~The online programme will be available up to 4 days per week (Weekdays evenings and Weekends mornings or early afternoons) and all household family members are invited to participate. The majority of the programming will be run by trained research coordinator and volunteers from KKH and Sports Singapore coaches. A regular rotation of comprehensive programming is provided, which includes online fitness, cooking, nutrition, and peer support classes. Every session includes up to 60 minutes of exercise and/or active play, and each session has an additional special 'theme.' For example, one to two sessions per week includes nutrition related programming (e.g., cooking classes), parent specific activities (e.g., a yoga class), peer support sessions (e.g., small group discussions around issues such as weight stigmatization), and fitness classes (e.g., soccer classes)."
224028132|NCT00338533|DEVICE|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
224028133|NCT04579133|DRUG|Olaparib|300 mg BID OR 200 mg BID (if glomerular filtration rate \[GFR\] 31 to 50 mL/min)
224028134|NCT04579133|DRUG|Durvalumab|Durvalumab 1500 mg IV
223411040|NCT04143698|DEVICE|endoscopic retrograde cholangiopancreatography|The duodenoscope will be passed to the duodenum in the standard fashion. Once the papilla has been identified in the duodenum, cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure. If cannulation is considered difficult, advanced cannulation techniques can be used per standard of care at the discretion of the individual endoscopist. The types of accessories used will be left to the discretion of the individual endoscopist and will be dependent on procedure indication and personal preference. Cross-over to the alternate duodenoscope type can be performed at any time if the desired technical maneuver cannot be performed with the designated duodenoscope.
223411041|NCT05463380|OTHER|standard of care|The patient will be treated following the satndard of care in the participating units
223411042|NCT04097054|PROCEDURE|Augmented preoperative planning|The study investigates the impact of augmented preoperative planning on OR time variance in complex and rare visceral surgical procedures.
223411043|NCT03751839|DIAGNOSTIC_TEST|Biochemical Tests|The investigators will perform blood tests in every participant.
223411044|NCT03751839|DIAGNOSTIC_TEST|Osteodensitometry|The investigators will perform an osteodensitometry in every participant.
223411045|NCT03751839|DIAGNOSTIC_TEST|Clinical Tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
223411046|NCT03751839|DIAGNOSTIC_TEST|HR-QCT|The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
223411047|NCT03751839|DIAGNOSTIC_TEST|HR-pQCT|The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
223411048|NCT00748462|DEVICE|Fractional CO2 Laser|"the treatment settings:~1. Pulse duration : 5 to 7ms depending on skin reaction~2. Spot Density: 49 MTZ/cm2 (Low density)~3. Power: 15 W = (75 - 105) mJ/MTZ"
223411049|NCT02285101|BIOLOGICAL|PEG-BCT-100|
223738710|NCT04966117|BEHAVIORAL|Risk-Guided DMP|"Patients will be assigned a cardiac nurse to help manage their heart condition who will:~1. develop a care plan and communicate with the patients' General Practitioner (GP) and cardiologist about management, particularly medications to help control risk factors.~2. provide health coaching at pre-specified times over 12 months via telehealth (phone or video call) to ensure that patient's take their medications as prescribed and to give health education and guidance on lifestyle changes.~3. facilitate cardiac rehabilitation via a smart phone or tablet app (called SmartCR). This app monitors health and physical activity, has prompted tasks to do and delivers education via video, audio and written articles. The information from this app can be used by the cardiac nurse during telehealth follow-up.~4. invite participation to a supervised 6-week group exercise program which will require using our on-site gym."
223411050|NCT04958213|DRUG|Dextrose prolotherapy injection|15% dextrose prolotherapy injection into the knee and 15% dextrose prolotherapy injection will be applied to the painful adhesions of the ligaments around the knee.
223411051|NCT04958213|COMBINATION_PRODUCT|conventional physical therapy|4 weeks (20 sessions) physical therapy (Hotpack, TENS and Ultrasound) and home exercise program (isometric and isotonic exercises).
223411052|NCT01496950|DEVICE|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
223411053|NCT01496950|DEVICE|Placebo|10Hz placebo rTMS delivered to the vertex
223559185|NCT01749657|DEVICE|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
223559186|NCT03401944|DRUG|TPN|
223559187|NCT03401944|OTHER|Control|
223559188|NCT05803863|DRUG|Myatro|myopia control with 0.01% atropine drops
223559189|NCT05803863|DRUG|Myatro XL|myopia control with 0.05% atropine drops
223559190|NCT01892150|OTHER|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
224028135|NCT04259073|DRUG|Pregabalin 150mg|two capsules, one is placebo, the other correspond to pregabalin 150 mg ingested orally one hour before cesarean section
224028136|NCT04259073|DRUG|Placebos|two capsules filled with sugar ingested orally one hour before cesarean section
223411054|NCT02446210|DEVICE|Magstim 200|Transcranial Magnetic Stimulation
223411055|NCT02446210|DEVICE|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
223411056|NCT05102682|OTHER|Balance exercise program using exoskeleton device|Exercise program focused on strengthening core body muscles and balance supported by Rex exoskeleton device
223411057|NCT01021462|PROCEDURE|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
223411058|NCT06576713|DIAGNOSTIC_TEST|Combiner whole genome and RNA sequencing|High-throughput DNA and RNA sequencing
223411059|NCT00040274|DRUG|DPC 817|
223411060|NCT00631046|DIETARY_SUPPLEMENT|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
223411061|NCT00631046|DIETARY_SUPPLEMENT|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
223411062|NCT05954390|DIETARY_SUPPLEMENT|Undenatured beta-glucan solution|The active comparator is a solution containing undenatured beta-glucans
223411063|NCT05954390|OTHER|Placebo|The placebo comparator is the same solution as the active therapy except it does not contain any undenatured beta-glucans
223411064|NCT05649761|DRUG|QL1604 injection|Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
223411065|NCT01236469|PROCEDURE|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
223411066|NCT06257654|DEVICE|REZUM|The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.
223411067|NCT01554527|PROCEDURE|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
223411068|NCT01554527|OTHER|No CPAP treatment|Children randomized to the comparison group will receive routine care
223559191|NCT02406573|DEVICE|Crest® Sensi-Stop™ Strips|
223559192|NCT07000136|DRUG|AZD0780|Participants will receive daily oral dose of AZD0780
223559193|NCT07000136|DRUG|Placebo|Participants will receive daily oral dose of placebo
223411069|NCT05630573|BIOLOGICAL|TNM001|intramuscular injection
223411070|NCT05630573|BIOLOGICAL|Placebo|intramuscular injection
224028137|NCT04259073|DRUG|Pregabalin 300mg|two capsules of pregabalin 150 mg ingested orally one hour before cesarean section
224028138|NCT00544388|DRUG|levocetirizine dihydrochloride|
223411071|NCT00755027|DRUG|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
223411072|NCT05415176|DIETARY_SUPPLEMENT|Taurine supplementation|Participants will receive 3g of taurine to be supplemented in the morning in single-dose capsules. The intervention will last 16 weeks.
223411073|NCT05415176|OTHER|Pshysical exercise|Participants will perform a multicomponent type workout that explores strength, aerobic and balance capacities with load progression every 15 days. The sessions will last 60 minutes each, being held three times a week with a day of rest in between. The intervention will last 16 weeks
223411074|NCT05415176|OTHER|Placebo control|The participants will receive a supplementation capsule containing placebo in the morning in single-dose capsules. The intervention will last 16 weeks.
223411075|NCT02284776|BEHAVIORAL|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
223411076|NCT04229862|PROCEDURE|Laryngeal mask airway insertion|Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
224028139|NCT03800459|BEHAVIORAL|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
224028140|NCT02566265|BIOLOGICAL|Fluzone High Dose Vaccine|
224028141|NCT02566265|BIOLOGICAL|Standard of care/Placebo|
224028142|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
224028143|NCT01287065|DRUG|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
224028144|NCT01287065|DRUG|Placebo AM|Inhalation powder
224028145|NCT01287065|DRUG|Placebo PM|Inhalation powder
224028146|NCT00108147|PROCEDURE|Circuit Training|
224028147|NCT00108147|PROCEDURE|Cardiac Rehabilitation|
224028148|NCT00108147|PROCEDURE|Flexibility and toning|
224028149|NCT05916118|OTHER|Aerobic Exercise|Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which may be divided in up to three, ten-minute bouts of exercise.
224028150|NCT06193460|DEVICE|low-level laser therapy|photobiomodulation mode of diode laser (low-level laser therapy).
224028151|NCT02875977|OTHER|Educational video|A 4-minute educational video describing PFPT
224028152|NCT02875977|OTHER|Educational handout|A 2-page educational handout describing PFPT
224028153|NCT00259987|DRUG|Lapatinib (GW572016) oral tablets|
224028154|NCT05318079|BEHAVIORAL|Virtual Reality Gaming|Peer-to-peer gaming.
224028155|NCT05049486|RADIATION|CT scan|Patients will undergone a pelvic CT scan.
224028156|NCT03904355|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
224028157|NCT03904355|DRUG|human chorionic gonadotropin|HCG triggering of ovulation
224028158|NCT03904355|PROCEDURE|Ovum pick up|34 to 36 hours after oocyte retrieval
223411077|NCT02345980|DRUG|Sildenafil|
223411078|NCT02345980|DRUG|Placebo|
223738711|NCT04966117|BEHAVIORAL|Usual Care|Usual care patients will receive standard cardiology care as scheduled that includes adherence to guideline-based care (medications and physical activity), education (self-care), a treatment plan to manage co-morbidities, early post-discharge follow-up/support and routine preventative care.
223738712|NCT04557956|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224028159|NCT03904355|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
224028160|NCT02699112|OTHER|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
224028161|NCT01362660|OTHER|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
224028162|NCT01270087|DRUG|Adalimumab|40 mg IV every 14 days
224028163|NCT01718782|DEVICE|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
224028164|NCT01718782|DEVICE|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
224028165|NCT05010187|BEHAVIORAL|Behavioral: Motivational Interview (MI)|Single-session, brief motivational interview.
224028166|NCT05010187|BEHAVIORAL|Behavioral: Health Coaching (HC)|Single-session health coaching.
224028167|NCT05902923|PROCEDURE|endovascular intervention|endovascular intervention
224028168|NCT02796820|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
224028169|NCT05591482|PROCEDURE|mesh repair|mesh repair of diaphragmatic hernia
224028170|NCT04367532|OTHER|Foam rolling|Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.
223411079|NCT01707160|DRUG|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
224028171|NCT04367532|OTHER|Tissue flossing|A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
224028172|NCT03834987|OTHER|Neurodevelopmental Assessment|Developmental assessment at baseline and longitudinally as measured by age and ability-appropriate scales, including: the Mullen Scales of Early Learning, the Peabody Scales of Motor Development, the Vineland 3, and Beery Visual Motor Integration
223411080|NCT01707160|DRUG|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
224028173|NCT03770637|DRUG|Glucagon RTU|Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
224028174|NCT03770637|OTHER|Placebo|The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
224028175|NCT03377426|DRUG|LYS228|LYS228 IV infusion
224028176|NCT03377426|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
224028177|NCT00098384|DRUG|rifaximin|
224028178|NCT01216033|DRUG|111-In-ABY-025|Intravenous injection of the agent
224028179|NCT00841880|DRUG|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
224028180|NCT00841880|DRUG|Ramipril|10 mg once a day
224028181|NCT00841880|DRUG|Ramipril|5mg once a day
224028182|NCT03130010|DRUG|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
224028183|NCT02931825|BEHAVIORAL|Reminder letter|"The letter will consist in several parts:~* Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~* Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~* Request information if they've done their follow-up or if we have incorrect information~* Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
224028184|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
223411081|NCT01052480|BIOLOGICAL|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
223411082|NCT01052480|DRUG|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
223411083|NCT04535492|BEHAVIORAL|Decision Making Support Tool|Primary care practices randomized in a stepped wedge cluster design will implement a newly developed predictive model and analytic tool to improve shared decision-making for patients.
223411084|NCT00529373|DRUG|Odanacatib|50 mg tablet orally once weekly (OW)
223411085|NCT00529373|DRUG|Placebo for Odanacatib|50 mg tablet orally OW
223411086|NCT00529373|DIETARY_SUPPLEMENT|Vitamin D3|5600 IU orally OW
223411087|NCT00529373|DIETARY_SUPPLEMENT|Calcium carbonate|If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
223411088|NCT01094574|DRUG|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
223411089|NCT01094574|DRUG|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
224028185|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
224028186|NCT01259726|OTHER|Placebo|10 mL placebo once daily for 14 days
224028187|NCT01259726|BIOLOGICAL|VP20621|VP20621 as oral liquid once daily for 14 days
224028188|NCT02076217|DRUG|Copper T-380 IUD|
224028189|NCT02076217|DRUG|LNG IUD|
224028190|NCT02076217|DEVICE|Contraceptive implant Nexplanon|
224028191|NCT02076217|DRUG|Depo-Provera|
224028192|NCT02587429|BEHAVIORAL|Patient education|
224028193|NCT00180921|DRUG|Imatinib|
224028194|NCT00244231|DRUG|Nidadd|
224028195|NCT01586000|DRUG|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
224028196|NCT01586000|DRUG|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
224028197|NCT01586000|DRUG|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
224028198|NCT05494060|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
224028199|NCT05494060|DRUG|Penpulimab Injection|Penpulimab Injection 100mg per bottle, 200mg IV Day 1, cycled every 21 days
224028200|NCT05494060|DRUG|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
224028201|NCT00634660|DRUG|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
224028202|NCT01679353|DRUG|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
224028203|NCT01679353|DRUG|normal saline 0.5ml|
224028204|NCT05226026|BEHAVIORAL|NiteCAPP HELPS|4 weeks of NiteCAPP (a digital version of CBT-I recently developed at Mizzou)
224028205|NCT05226026|OTHER|Tapered Withdrawal|Gradual tapered withdrawal following CDC guidelines, with additional check-ins and motivational interviewing with a therapist.
223411090|NCT01094574|DRUG|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
223411091|NCT05364866|DRUG|Antiarrhythmic drug Therapy|Propafenone, Sotalol and Amiodarone
224028206|NCT04097366|DIAGNOSTIC_TEST|ABUS|Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.
224028207|NCT04097366|DIAGNOSTIC_TEST|CEM|A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.
224028208|NCT04097366|DIAGNOSTIC_TEST|ABB-MRI|ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
224028209|NCT01886820|DRUG|[18F]NAV4694|
224028210|NCT02069210|OTHER|Blood transfusion|Intraoperative blood transfusion
224028211|NCT00009620|DRUG|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
224028212|NCT00009620|DRUG|Saline|Infusion of normal sal
224028213|NCT00095069|DRUG|MK0928, gaboxadol / Duration of Treatment - 1 year|
224028214|NCT00095069|DRUG|Comparator: placebo / Duration of Treatment -1 year|
223411092|NCT05364866|DEVICE|cryoballoon ablation|Medtronic Arctic Front Advance™ Cardiac CryoAblation Catheters including 23mm and 28mm.
223411093|NCT03898791|DRUG|LY3295668 Erbumine|oral capsules
223411094|NCT01707173|BEHAVIORAL|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
223411095|NCT01707173|BEHAVIORAL|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
223411096|NCT00613769|DRUG|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
223559194|NCT07001618|DRUG|MaaT033 capsule|MaaT033 capsule will be taken orally once a day for a week before every Cemiplimab cycle for the first 6 months of treatment.
223559195|NCT07001618|DRUG|Cemiplimab|CB will be administered 350 mg IV over 30 minutes every 21 days up to 2 years
224028215|NCT01847118|DRUG|Sevacizumab|
224028216|NCT05277129|OTHER|Analysis of post-stroke immune responses|Analysis of immune responses in peripheral blood
224028217|NCT03134157|DRUG|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
224028218|NCT03134157|DRUG|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
224028219|NCT03134157|DRUG|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
224028220|NCT02673957|OTHER|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
224028221|NCT03595605|BEHAVIORAL|Ambulation|This group will be encouraged twice daily to ambulate
224028222|NCT03595605|OTHER|Standard of Care|Care as usual at inpatient NYU Langone
224028223|NCT06017141|PROCEDURE|Biospecimen Collection|Undergo blood and tissue sample collection
224028224|NCT06017141|OTHER|Electronic Health Record Review|Ancillary studies
224134550|NCT05528874|DIETARY_SUPPLEMENT|Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes|Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.
224134551|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 4 before recipe 5|"After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner."
223411097|NCT00613769|DRUG|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
223411098|NCT01768377|DRUG|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
223411099|NCT01768377|DRUG|Fentanyl|Fentanyl 2 microgram/Kg BW IV
223411100|NCT01768377|DRUG|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
223559196|NCT07001618|DRUG|Cisplatin|75mg/m2 at day 1 (d1) every 21 days (q21)
223559197|NCT07001618|DRUG|Carboplatine|Area Under the Curve (AUC) 5-6 at d1 q21
223559198|NCT07001618|DRUG|Pemetrexed (Alimta)|500mg/m2 at day 1 (d1) q21
223559199|NCT07001618|DRUG|Bevacizumab|10mg/kg at d1 and day 15 (d15) every 28 days (q28)
223559200|NCT07001618|DRUG|Paclitaxel|175mg/m2 at d1 q21 or 80 mg/m2 at d1, day 8 (d8), day 15 q28
224028225|NCT06017141|DRUG|Fentanyl Citrate|Given via injection
224028226|NCT06017141|DRUG|Propofol|Given IV
224028227|NCT06017141|OTHER|Questionnaire Administration|Ancillary studies
224028228|NCT06017141|DRUG|Sevoflurane|Given via inhalation
224028229|NCT06017141|PROCEDURE|Surgical Procedure|Undergo SOC surgery
224028230|NCT06200064|OTHER|Self-stretching exercise group|Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
223411101|NCT05953051|PROCEDURE|ACL reconstruction with bone/PrP-composite|"During standard ACL reconstruction, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well."
223411102|NCT05953051|PROCEDURE|ACL reconstruction (Standard)|Standard ACL reconstruction with Semitendinosus alone or plus gracilis, femoral fixation via extracortical fixation by adjustable loop device, tibial fixation via a bio-interference screw or adjustable device
223411103|NCT02499848|DRUG|PRX302|Single prostate cancer lesion injected with PRX302.
223411104|NCT04166474|DRUG|Dolutegravir|Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.
223411105|NCT05182684|DEVICE|Vital Patch(TriBell Lab)|"Electrocardiograms were recorded using VP-100 for more than six hours and transmitted to a central data server located in Seoul National University Hospital.~The data on a central server was confirmed and evaluated."
223411106|NCT04207606|BEHAVIORAL|Post Epidural Steroid Injection Follow-up|All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
224028231|NCT06200064|OTHER|Post-isometric relaxation exercise group|"The investigators used one of the autogenic inhibition techniques - post-isometric relaxation (PIR), known as the muscle contraction-relaxation technique, during which, the subject is lying on his back, he is asked to press his head in the specified direction (50% of the subject's maximum pressure force). to the resistance provided by the therapist. During the press, resistance was provided for 10 seconds and followed by a passive stretch of the muscle in the opposite direction of movement. A total of 5 repetitions are performed for each muscle with a 5-second break. All movements are performed without causing pain of more than moderate intensity."
224028232|NCT06135077|OTHER|T-PRF alone|T-PRF is the material to be tested in this study as an alternative to classical bone graft
224028233|NCT06135077|OTHER|T-PRF/Xenograft|One part of T-PRF will be divided into minute pieces to be mixed with xenograft
224028234|NCT04040400|RADIATION|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
224028235|NCT05785234|DRUG|sufentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 0.5 ng·ml-1 of sufentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 0.2 - 0.6 ng·ml-1 of sufentanil.
224028236|NCT05785234|DRUG|remifentanil-remimazolam group|Induction of general anesthesia with 6mg·kg-1·h-1 of remimazolam combined with 4 ng·ml-1 of remifentanil. Maintenance of general anesthesia with 1-2mg·kg-1·h-1 of remimazolam combined with 2-6 ng·ml-1 of remifentanil.
224028237|NCT00460174|BIOLOGICAL|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
224028238|NCT00460174|DRUG|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
224134552|NCT05528874|DIETARY_SUPPLEMENT|Crossover: Recipe 5 before recipe 4|Same as previous group, but starting with recipe 5
223411107|NCT01226082|DEVICE|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
223411108|NCT05084027|COMBINATION_PRODUCT|venetoclax combining with fludarabine and melphalan|Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
224028239|NCT00460174|PROCEDURE|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
224028240|NCT00460174|RADIATION|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
224028241|NCT02959450|DIETARY_SUPPLEMENT|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
224028242|NCT00399230|DRUG|Optive|
224028243|NCT01548157|DRUG|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
224028244|NCT00027781|DRUG|sabarubicin|
223411109|NCT02034929|DEVICE|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
223411110|NCT02034929|DEVICE|Standard colonoscopy|Standard colonoscopy
223411111|NCT05610397|DEVICE|STALIF®|STALIF® C, or M, Ti or FLX
223559201|NCT07001618|DRUG|gemcitabine|1250 or 1000 mg/m2 d1, d8 q21
223559202|NCT07001618|DRUG|Docetaxel|75 mg/m2 d1 q21 or 33mg/mq d1, d8 q21 q21
223559203|NCT07001618|DRUG|Vinorelbine i.v. 25 mg/m²|25-30 mg/m2 d1, d8 q21
223559204|NCT07001618|DRUG|Vinorelbine oral|30 mg/50 mg per os 3 days per week (metronomic)
223559205|NCT06808451|DEVICE|DNA PCR|Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.
223559206|NCT06808451|DIAGNOSTIC_TEST|Urine Culture|Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.
223738713|NCT04557956|PROCEDURE|Computed Tomography|Undergo CT scan
224134553|NCT04888234|DRUG|Ru-Yi-Jin-Huang Powder|Ru-Yi-Jin-Huang Powder is the most common TCM topical drug for skin diseases. It is often used to treat skin ulcers, sprain of joint with swelling, and other inflammatory diseases.
224134554|NCT01202721|DRUG|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
224134555|NCT01202721|DRUG|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
224134556|NCT05640674|DRUG|Ibuprofen|Non-opioid
224134557|NCT05640674|DRUG|Hydrocodone/acetaminophen|Opioid
224134558|NCT05640674|DRUG|Acetaminophen|Non-opioid
224134559|NCT02626845|DRUG|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
224134560|NCT02626845|OTHER|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
223411112|NCT00269373|PROCEDURE|PET-CT|no drugs included
224028245|NCT04540848|DRUG|Group A (Exparel plus supraclavicular block)|"Patients will receive 20 cc (266 mg) of Exparel injected in the distal radius area and a supraclavicular block in the recovery room.The supraclavicular blocks will be ultrasound guided and consist of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
224134561|NCT00551538|DRUG|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
224134562|NCT00551538|DRUG|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
223559207|NCT06611163|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter
224028246|NCT04540848|DRUG|Group B (Bupivacaine HCL plus supraclavicular block)|"Patients will receive 20 cc of Bupivacaine 0.25% (50mg) in the distal radius area.In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
224134563|NCT00974051|DRUG|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
224134564|NCT00974051|OTHER|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
224134565|NCT00974051|OTHER|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
224134566|NCT00261248|BIOLOGICAL|Immunization with inactivated bacteria|
224134567|NCT01403701|BEHAVIORAL|Physical therapy|pelvic floor physical therapy
224134568|NCT05360355|PROCEDURE|total face reconstruction surgery and intraoperative indocyanine green angiography|Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
224134569|NCT06409091|DEVICE|Medium weight or Heavy weight mesh|Patients received a hernia repair with one of the two groups
224134570|NCT01650818|OTHER|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
224134571|NCT01650818|OTHER|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
223411113|NCT04073927|DIETARY_SUPPLEMENT|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
223411114|NCT04102267|DRUG|Bupivacaine liposome injectable suspension|Liposomal bupivacaine 266 mg via injection
223411115|NCT04102267|DRUG|Bupivacaine HCl without epinephrine via continuous infusion|Bupivacaine HCl 300 mg via continuous infusion
223411116|NCT04471194|DIAGNOSTIC_TEST|Self-sampling HPV test|Tests for human papillomavirus from cervical cell sample
223411117|NCT04471194|DIAGNOSTIC_TEST|Fecal occult blood test|Tests for human hemoglobin from blood in fecal samples
223559208|NCT06611163|DRUG|Placebo|Placebo SC injection at Day 1 and Week 4
223559209|NCT06681818|OTHER|carbon monoxide measurement via smokerlyzer|participants in this study will provide breath samples for carbon monoxide measurements pre and post liver resection
223559210|NCT07002996|BEHAVIORAL|SMIP|Participants will undergo a 3-month-long regimen of 60 minutes spatial memory training sessions held twice a week, consisting of a series of computerized virtual reality tasks.
223738714|NCT04557956|DRUG|Dabrafenib Mesylate|Given PO
223738715|NCT04557956|PROCEDURE|Echocardiography Test|Undergo ECHO
223738716|NCT04557956|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223738717|NCT04557956|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223738718|NCT04557956|DRUG|Tazemetostat Hydrobromide|Given PO
223738719|NCT04557956|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
224134572|NCT00089479|DRUG|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
224134573|NCT00089479|DRUG|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
224134574|NCT00089479|DRUG|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
224134575|NCT06410599|DRUG|Ketamine|Two ketamine hydrochloride (Ketamin Inresa 2 ml) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Ketamine hydrochloride (Ketamin Inresa 2 ml) is applied continuously over a time span of 40 minutes with a subanesthetic dosage of 0.5 mg per kg body weight.
224134576|NCT06410599|DRUG|Placebo|Two times placebo (Isotone E NaCL 0.9 %) infusions (interval 2-3 days) per week for three weeks, 6 infusions in total. Placebo is applied continuously over a time span of 40 minutes.
224134577|NCT06410599|BEHAVIORAL|CBASP|In addition to standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements, patients in the CBASP conditions receive one CBASP group session (50 min) per week for 12 weeks. The single sessions (one 50 min and one 25 min per week) contents are CBASP-specific.
224134578|NCT06410599|BEHAVIORAL|TAU|Standard ward psychotherapeutic program (group and single sessions) with cognitive behavioural, sociotherapeutic, occupational therapy and physiotherapeutic elements.
223559211|NCT07002996|OTHER|No intervention|Control participants will not receive spatial memory intervention training. They will watch documentaries and then complete multiple choice quizzes on its content to ensure they are paying attention. The placebo condition will match the experimental condition in terms of duration and visit frequency.
223411118|NCT02123589|DRUG|Deep sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
223411119|NCT02123589|DRUG|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
223411120|NCT02123589|DRUG|Light sedation(midazolam and fentanyl )|0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
223411121|NCT00894270|PROCEDURE|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
223411122|NCT00894270|PROCEDURE|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
223411123|NCT00894270|DEVICE|Novofine needle|Novofine 5mm needle
223411124|NCT00757042|DRUG|Tezepelumab|Administered by subcutaneous or intravenous injection
223411125|NCT00757042|DRUG|Placebo|Matching placebo administered by subcutaneous or intravenous injection.
223411126|NCT02508077|DRUG|Fluorouracil|Given IV
223411127|NCT02508077|DRUG|Irinotecan Hydrochloride|Given IV
223411128|NCT02508077|OTHER|Laboratory Biomarker Analysis|Correlative studies
223411129|NCT02508077|DRUG|Leucovorin Calcium|Given PO
223411130|NCT02508077|BIOLOGICAL|Panitumumab|Given IV
223559212|NCT06872489|BIOLOGICAL|SL-28.|Allogeneic, non-HLA matched, Leucocyte-Tells-based therapy
223738720|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Maintenance Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.
223411131|NCT02915705|BIOLOGICAL|burosumab|solution for subcutaneous (SC) injection
224028247|NCT04540848|DRUG|Group C(supraclavicular block only)|"In the recovery room the patient will be given the supraclavicular block which will be ultrasound guided and consisting of 20 cc of Bupivacaine HCl 0.25% .Anesthesiologist performing the block will be instructed to surround the brachial plexus with the local anesthetic, taking special care to inject in the corner pocket."
224028248|NCT02148419|OTHER|no intervention|
224028249|NCT00050388|GENETIC|Allovectin-7®|
224028250|NCT03909217|PROCEDURE|TECAS Procedure|"Location:~1. Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~2. Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
224028251|NCT03909217|DRUG|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
224028252|NCT03909217|DRUG|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
224028253|NCT04578574|OTHER|Bodily Illusions (BI) Procedure|Each sessions will consists of two types of illusions that are 15 min each, the rubber hand illusion (RHI) and the walking illusion (WI) that involve both arms and legs.
224134579|NCT01547468|PROCEDURE|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
223411132|NCT02915705|DRUG|Oral Phosphate Supplement|oral tablet; oral solution; oral powder
223411133|NCT02915705|DRUG|active vitamin D|tablet, oral solution
223411134|NCT04881864|BEHAVIORAL|Tele-Enhance Fitness|Livestream, instructor-led tele-exercise classes, involving balance, endurance, and strength training
223411135|NCT00002205|DRUG|Abacavir sulfate|
223411136|NCT00002205|DRUG|Amprenavir|
223411137|NCT00263705|DRUG|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
223411138|NCT00263705|DRUG|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
223411139|NCT06134427|OTHER|basic combat training (investigator did not design the intervention)|12 weeks basic combat training is 12 weeks is a compulsory program for all cadets accepted in republic indonesia defense university
223411140|NCT01039727|OTHER|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
223411141|NCT01039727|OTHER|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
223411142|NCT01870973|PROCEDURE|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
223738721|NCT06568549|DRUG|Mycophenolate Mofetil (MMF) Withdrawal Group|Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
223411143|NCT01870973|PROCEDURE|no root canal treatment, anesthesia, pain medications, and antibiotic|
223559213|NCT07019389|OTHER|Turkish Version of the Scale of Food Allergy Anxiety (SOFAA)|Participants will complete the Turkish-translated versions of the Scale of Food Allergy Anxiety (SOFAA). Children will complete the SOFAA-C; their parents will complete the SOFAA-P. The study aims to evaluate the reliability and validity of the translated scales through internal consistency, factor analysis, and test-retest reliability methods.
223738722|NCT02597699|DRUG|Remifentanil + Lidocaïne|
223738723|NCT02597699|DRUG|Sufentanil + Lidocaïne|
223738724|NCT06015711|DRUG|Maxigesic administration|Preoperative Maxigesic IV administration
224028254|NCT04578574|DEVICE|Transcranial direct electrical stimulation (tDCS)|Each sessions will consists of electrical current delivered from a battery-driven, constant current stimulator using saline-soaked surface sponge electrodes. One electrode will be placed on your scalp on the right side and the other electrode over the left eye on your forehead. A weak current will be applied for 30 min at the same time as the BI.
223411144|NCT04668079|OTHER|Modified cross body stretch|"Athlete was in side lying positioned. trunk was moved posteriorly 200 to 300 and shoulder is raised to 900 and semi flex both knees. Athlete was ask to passively pull the humerus across the body into horizontal adduction with the opposite hand.~5 reps once daily 3 sets for 4 weeks was given"
223411145|NCT04668079|OTHER|Modified sleeper stretch|"Athlete was in side lying positioned on the involved side, trunk was rolled posteriorly 200 to 300 and shoulder is raised to 900 and elbow is flexed to 900 and semiflex both knees. athlete was ask to perform internal rotation passively by using the opposite arm.~5 reps once daily 3 sets for 4 weeks was given"
223411146|NCT06574542|DIAGNOSTIC_TEST|Push enteroscopy (PE)|All patients enrolled in this study underwent evaluation using push enteroscopy (PE)
223411147|NCT06574542|DIAGNOSTIC_TEST|Colonoscopy|After push enteroscopy (PE), all patients subsequently underwent a colonoscopy on the same day or the next day. However, if a culprit lesion was identified during PE and the patient was considered at risk for undergoing colonoscopy, the colonoscopy was not performed and was presumed to be negative.
223411148|NCT01031511|BEHAVIORAL|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
223411149|NCT01031511|OTHER|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
223411150|NCT00150488|DEVICE|Uracyst|2% weekly for 6 weeks, monthly for 4 months
223411151|NCT01266291|DRUG|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
223411152|NCT02173665|DRUG|BI 1356 BS - Powder in bottle (PIB)|
223411153|NCT02173665|DRUG|BI 1356 BS - Tablet|
223411154|NCT02173665|DRUG|Placebo|
223411155|NCT04059029|PROCEDURE|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
223411156|NCT03291431|DEVICE|Intermittent theta burst transcranial magnetic stimulation|20 iTBS sessions (active or sham) administered over the course of 2 weeks
223411157|NCT03177460|BIOLOGICAL|Daratumumab|Given IV
223411158|NCT03177460|DRUG|FMS Inhibitor JNJ-40346527|Given PO
223411159|NCT03177460|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
223411160|NCT01348620|DEVICE|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson \& Johnson Medical Spa)
223411161|NCT01348620|PROCEDURE|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
223411162|NCT05944497|PROCEDURE|Interscalene brachial plexus block|Using a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).
223411163|NCT00481351|DRUG|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
223411164|NCT00481351|DRUG|ezetimibe|ezetimiba 10mg once a day
223411165|NCT00481351|DRUG|simvastatin 20mg|simvastatin 20mg once a day
223411166|NCT00481351|DRUG|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
223411167|NCT01427647|PROCEDURE|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
223411168|NCT05697172|OTHER|Low-intensity focused ultrasound|80-second stimulus with an estimated tissue ISSPA=2.26 W/cm2, with (sham) or without (verum) interposition of Sorbothane film
224028255|NCT04578574|OTHER|Sham Transcranial Direct Electrical Stimulation (tDCS)|Each session of the Sham tDCS will be applied for 30 min at the same time as the BI.
224028256|NCT02529813|DRUG|Cyclophosphamide|Given IV
224028257|NCT02529813|DRUG|Fludarabine Phosphate|Given IV
224028258|NCT02529813|OTHER|Laboratory Biomarker Analysis|Correlative studies
224028259|NCT02529813|BIOLOGICAL|Tisagenlecleucel|Given IV
224028260|NCT03421431|DRUG|EDP-305 Dose 1|Two tablets daily for 12 weeks
224028261|NCT03421431|DRUG|EDP-305 Dose 2|Two tablets daily for 12 weeks
224134580|NCT01547468|PROCEDURE|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
224134581|NCT01094717|DRUG|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
223411169|NCT00180609|DEVICE|Automatic threshold test in Insignia Pacemakers from Guidant|
224028262|NCT03421431|DRUG|Placebo|Two tablets daily for 12 weeks
224028263|NCT01581151|DRUG|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
224134582|NCT01094717|DEVICE|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
224134583|NCT01094717|DRUG|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
224134584|NCT01094717|DEVICE|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
224134585|NCT00126399|DRUG|doxycycline|
223411170|NCT06257823|OTHER|No intervention|No intervention
223411171|NCT00808912|DRUG|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
223411172|NCT00808912|OTHER|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
223411173|NCT00994383|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
223411174|NCT06922162|BEHAVIORAL|Tickle stimulation|"Patients will be subjected to tickling:~they will be tickled bilaterally in three areas, the soles of the feet, the armpits, and the ribs-plus a control area, the forehead. The stimulation will be manual and performed by rubbing the targeted body part while opening and closing the fingers in pairs in an arched motion. Additionally, patients will also undergo a neutral stimulation (in the same body areas), which consists of simply touching the area without inducing tickling."
224028264|NCT01581151|DRUG|Monthly Ranibizumab|30 days between treatments
223411175|NCT06922162|DEVICE|Neurophysiological Monitoring with SedLine|SedLine is a portable, non-invasive EEG monitoring device used to record electrical brain activity through frontal electrodes. In the TICKLING-DOC study, SedLine is used to assess cortical responses in patients with disorders of consciousness (DoC) during manual tactile stimulation, specifically tickling, and neutral touch. The EEG data are recorded before, during, and after stimulation to detect neural reactivity and possible correlations with behavioral responses. The goal is to investigate whether tickle-evoked EEG activity reflects residual consciousness and contributes to diagnostic and rehabilitative strategies. SedLine allows continuous monitoring in a bedside setting, offering safe, real-time assessment of brain function.
223411176|NCT04577560|GENETIC|First polar body biopsy in MII oocytes|Since PBs are by-products of the meiotic division of the oocyte and are not required for fertilization and subsequent embryo development, they can be removed to assess exclusively maternal chromosomal information without harming the embryo integrity. As previously described, PB biopsy does not impact the morphokinetic parameters of the embryo development and can be safely applied without the risk of impairing the reproductive potential of the embryo.
223411177|NCT04577560|GENETIC|PGT-A blastocyst|preimplantation genetic screening for aneuploidies
223411178|NCT01419392|DRUG|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
223411179|NCT01419392|DRUG|matching placebo|orally, 4 times per day for 21 days
223411180|NCT06939673|DEVICE|Acellular Porcine-Derived Wound Matrix|This intervention is a sterile, acellular, three-dimensional biologic scaffold derived from porcine liver tissue using a proprietary perfusion decellularization and drying process. It retains the native extracellular matrix structure and supports tissue granulation and healing in complex wounds. Miro3D is applied topically to the debrided wound bed and rehydrated prior to use. It is indicated for use in a range of chronic and complex wounds, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and surgical dehiscence. In this study, it is administered in an outpatient setting alongside standard of care treatments.
223411181|NCT06940557|DRUG|Bionerv|alpha lipoic acid; 300mg, methylcobalamin; 500mcg, vitamin B1; 39mg and vitamin B6; 8mg, 2 tablets once daily
223411182|NCT06940557|DRUG|Placebo|maltodextrin, microcrystalline cellulose, tricalcium phosphate, silicon gioxide, magnesium stearate 2 tablets once daily
223411183|NCT06055205|OTHER|PAC-plan|The participants will be asked to complete electronic questionnaires at baseline, and at 6 weeks and 52 weeks after discharge from the hospital. The completion of these questionnaires will take place during the 6-week follow-up appointment at the hospital (a standard follow-up for all patients undergoing surgery at the Division of Orthopedic Surgery, Oslo University Hospital, Norway). Additionally, participants will be invited for a phone-based follow-up appointment with the study coordinator 52 weeks after discharge. The participants will receive the questionnaires electronically via SMS or email. If electronic options are not feasible, data can be collected through paper questionnaires sent by mail. Data will not be directly obtained from general practitioners.
223411184|NCT02835625|RADIATION|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
223559214|NCT07021040|DIAGNOSTIC_TEST|olfactory testing|"Patients will undergo smell testing, using the Smell Identification Test (Sensonics), a validated widely-used 40-item scratch-and-sniff style psychophysical test to determine olfactory function."
223559215|NCT07021040|OTHER|Odor stimulation|"subset of patients will be asked to sniff a specific odor for about an hour, using commercially available odor pens (Sniffin' Sticks or Sensonics). These odor pens are widely used for olfactory training therapy, a treatment designed to help people with some forms of smell loss; they are also used in psychophysical olfactory testing."
223738725|NCT03755895|OTHER|formal hypnosis|patients will have brachytherapy detachment under Kalinox and formal hypnosis
223738726|NCT03755895|DRUG|Kalinox|patients will have brachytherapy detachment under Kalinox
223738727|NCT05100069|DRUG|Brigatinib|Brigatinib Tablets
224028265|NCT06450431|OTHER|SF-36 questionnaire French version and PAS.fr questionnaire|Patients will receive both the SF-36 questionnaire (control generic questionnaire for QoL evaluation validated in French language) and the PAS.fr questionnaire at the designated time (before surgery, 6, 12 or 36 months after surgery) during the consultation, or by mail. For concurrent validation of the PAS.fr questionnaire, a second questionnaire will be sent to the patients 2-4 weeks thereafter.
224028266|NCT04923152|DRUG|moderate statin dose|5 mg rosuvastatin per day
224028267|NCT04923152|DRUG|high dose statin|40 mg rosuvastatin per day
224028268|NCT01980550|DRUG|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
224028269|NCT02053987|OTHER|Intensive rehabilitation in the home.|
224028270|NCT02522455|OTHER|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
224028271|NCT02522455|OTHER|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
223411185|NCT02835625|RADIATION|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
223411186|NCT00594867|DRUG|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
223559216|NCT07021040|PROCEDURE|Olfactory biopsy|Biopsy involves a simple cytology brush technique of the lining of the nose in a region called the olfactory cleft, using a nasal endoscope, and can be done in clinic or in the operating room at the time of a nasal surgery. Topical oxymetazoline and tetracaine spray is applied to the nasal cavity, a rigid nasal endoscopy (0-degree 4 mm endoscope, Karl Storz) is performed to visualize the olfactory cleft, and a small nasal cytology brush biopsy (Hobbs Medical)is performed by swabbing and rotating brush gently in the olfactory cleft. Cytology sample is placed into a buffer (Hibernate-E, Thermo Fisher)on ice for transport to the research lab.
223559217|NCT07020923|DRUG|Atacicept|Drug: Atacicept
223559218|NCT05812924|BIOLOGICAL|Platelet-rich plasma (PRP)|0.1-0.2 mL injections of platelet-rich plasma (PRP) will be injected to the vulvovaginal area. The injections will be placed every 5mm and at an angle of 60° into the mucosa and lamina propria of the posterior wall of the vagina.
223559219|NCT06689007|OTHER|Implementation Intervention|The intervention employs four established implementation strategies according to the Expert Recommendations for Implementing Change: conduct educational meetings, provide ongoing consultation, provide technical assistance, and change physical structure and equipment. The first component is a six-week online course led by the PI that combines weekly pre-recorded lectures, hands-on activities, group mentoring sessions and a reflective assignment. The second component of the intervention is ensuring access to the equipment needed for FES. The third component of the intervention is access to the FES Toolkit.
223559220|NCT07019571|DEVICE|Wireless Multichannel Transcranial Current Stimulator (tDCS)|tDCS will be delivered for 13 minutes (active) or only at the beginning and end of the 13 minute period (sham) using Neuroelectrics Instrument Controller software and a battery-driven Starstim 8-channel transcranial direct current stimulator with 1cm2 ceramic electrodes and SIGNAGEL conductive saline gel.
223559221|NCT07019571|BEHAVIORAL|Cue exposure|Participants will undergo three, twenty-second trials of exposure to individualized cues at the top of the established urge hierarchy, previously determined to precede picking or biting behaviors before and after tDCS.
223559222|NCT07019571|BEHAVIORAL|Boredom induction|Participants will be left in the testing room without access to a cellphone or reading materials for 2 different 6 minute periods.
223559223|NCT07030010|OTHER|Breakfast meal challenge with tonic drink|High-carbohydrate containing breakfast meal with the addition of the tonic drink
223559224|NCT07030010|OTHER|Breakfast meal challenge with placebo drink|High-carbohydrate containing breakfast meal with the addition of the placebo drink
223559225|NCT07026695|DEVICE|transcutaenous vagal nerve stimulation|Low level Stimulation of the Auricular Branch of the Vagal Nerve at the tragus
224028272|NCT04626492|DIAGNOSTIC_TEST|Quantitative MRI imaging|Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence
224134586|NCT03529136|BIOLOGICAL|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
224134587|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
224134588|NCT01124448|BIOLOGICAL|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
223738728|NCT05466786|OTHER|Standard Management|Standard Management
223559226|NCT07026695|DEVICE|Sham transcutaenous vagal nerve stimulation|Sham treatment
223738729|NCT06848478|BEHAVIORAL|Exercise Intervention|In addition to the standard of care, participants engage in exercise coaching and a 12-week exercise program, encompassing three 60-minute supervised sessions per week.
224028273|NCT02548260|DEVICE|Syndactyly without compression|three week relative immobilization by syndactyly
224028274|NCT02548260|DEVICE|Syndactyly with compression|three week relative immobilization by syndactyly and compression
224028275|NCT02548260|DEVICE|Rigid splint without compression|three week rigid immobilization by splint
224028276|NCT02548260|DEVICE|Rigid splint with compression|three week rigid immobilization by splint and compression
224134589|NCT00950079|DRUG|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
223411187|NCT00594867|DRUG|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
223411188|NCT00594867|DRUG|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
223411189|NCT03850483|DRUG|PF-06700841|PF-06700841 topical cream
223411190|NCT03850483|DRUG|Vehicle (Placebo)|Vehicle topical cream
223411191|NCT04343040|DIETARY_SUPPLEMENT|carbohydrate supplement (Preload™)|carbohydrate supplement (Preload™) will be administered 4-hours prior to bariatric surgery (experimental treatment) Preload™ is a neutral-tasting carbohydrate loading drink mix specifically designed for use before elective surgery. Preload is presented in 50g pre-measured sachets which when added to water (400ml) produces a solution with low osmolality.
223411192|NCT04343040|PROCEDURE|6 hours of preoperative fasting|Standard of care. In this group, patients continue the standard of care treatment before surgery with fasting recommended 6 hours before surgery.
224134590|NCT00950079|DRUG|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
224134591|NCT04429685|DRUG|Ketamine|Low dose ketamine - Ketalar (Racemic Ketamine Hydrochloride) Saline - Isotonic/Normal Saline
224134592|NCT04429685|DRUG|Saline (placebo)|Saline (placebo)
224028277|NCT00141726|DRUG|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
223411193|NCT02609815|DRUG|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
223411194|NCT02609815|DRUG|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
223411195|NCT03801005|BIOLOGICAL|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
223411196|NCT02828774|OTHER|there will be no intervention.|this study is observational, procedure are done in vitro and on animal models.
223411197|NCT01882959|OTHER|Radiofrequncy Denervation|
223411198|NCT05377944|DRUG|BAT2306|150 mg/1 ml/injection (2 injections/visit)
223411199|NCT05377944|DRUG|EU-approved Cosentyx|150 mg/1 ml/injection (2 injections/visit)
223411200|NCT04883983|DRUG|Open Label Placebo|Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
223411201|NCT04883983|DRUG|Patient medication as standardly prescribed|Pain medication will be prescribed per standard treatment for initial prescription. On request for additional pain medication, pain medication will be prescribed as per the standard protocol. Pain assessment surveys will be used at 2, 6, and 12 week followups.
223411202|NCT05124288|OTHER|Observations on Relapsed AML Allogeneic Transplanted patients|This is not an interventional clinical study. This is a retrospective/prospective observational study on Relapsed AML Allogenic Transplanted patients. Additional samples will be collected during the standard practice.
223559227|NCT07029503|DRUG|Eplerenone|"Participants will receive eplerenone 25 mg once daily or every other day, based on baseline potassium levels, eGFR, systolic blood pressure, and concomitant use of weak or moderate CYP3A4 inhibitors.~The study will implement a safety protocol with predefined procedures for managing significant hyperkalemia, worsening renal function, and hypotension. These will include temporary or permanent dose reduction or discontinuation of eplerenone, and, if necessary, administration of the potassium binder sodium zirconium cyclosilicate (SZC, Lokelma®)."
223738730|NCT06848478|BEHAVIORAL|Nutritional Intervention|In addition to the standard of care, participants receive dietary coaching and engage in a 12-week daily dietary program enriched with a blend of fruits and vegetables.
224028278|NCT00828841|DRUG|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
224028279|NCT00828841|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
224028280|NCT00828841|DRUG|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
224028281|NCT00828841|DRUG|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
224028282|NCT00828841|DRUG|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
224028283|NCT04147650|DRUG|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
224028284|NCT04147650|DRUG|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
224028285|NCT04147650|DRUG|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
224028286|NCT04147650|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
224028287|NCT02108587|DEVICE|optical coherence tomography|Undergo optical coherence tomography
224028288|NCT03015818|OTHER|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
224028289|NCT01188213|DIETARY_SUPPLEMENT|Methylsulfonylmethane (MSM)|
224028290|NCT05179720|OTHER|puncture stent-assisted transperineal prostate biopsy|Patients in the experimental group used a puncture stent to assist transperineal prostate biopsy
224028291|NCT04415463|DEVICE|Multisegmented fully covered self-expandable metal stent|Esophageal FC-SEMS
224028292|NCT03281837|DEVICE|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
224028293|NCT03281837|OTHER|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
224028294|NCT01734408|BIOLOGICAL|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
223411203|NCT04161248|DRUG|Venetoclax|"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
223411204|NCT04161248|DRUG|Rituximab Injection|375 mg/m2 - Day 1, cycle 1.
223411205|NCT04161248|DRUG|Rituximab SC|1400 mg fixed dose - Day 1, cycle 2 and 3
223411206|NCT04161248|DRUG|Gemcitabine|1000 mg/m2 - Day 1 to day 8
223411207|NCT04161248|DRUG|Dexamethasone|40 mg daily - Day 1 to day 4
223411208|NCT04161248|DRUG|Cisplatin|75mg/m2 - Day 1
224028295|NCT01734408|BIOLOGICAL|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
224028296|NCT01734408|BIOLOGICAL|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
224028297|NCT01734408|BIOLOGICAL|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
224028298|NCT01734408|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo
224028299|NCT02203292|BEHAVIORAL|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb \< 9.0 g/dL
223411209|NCT04161248|DRUG|Glofitamab|Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP
223411210|NCT04161248|DRUG|Tafasitamab|Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15)
223411211|NCT06776016|DIETARY_SUPPLEMENT|Butyrate|Agent: The dietary supplement contains tributyrin, a pro-drug of butyrate. Method: Participants receive the supplement orally at a dose of 20 ml, 2-3 times daily, 12 weeks.
223738731|NCT06016517|DRUG|Etanercept|50 mg subcutaneously weekly
223738732|NCT06016517|DRUG|Adalimumab|40 mg subcutaneously every 2 weeks
224028300|NCT02203292|BEHAVIORAL|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb \< 7.0 g/dL
224028301|NCT01354808|DRUG|Dual Anti-Platelet Therapy (DAPT)|"* Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
224028302|NCT01354808|DRUG|Triple Anti-Platelet Therapy (TAPT)|"* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
224028303|NCT03741933|DRUG|Apremilast 30mg|Apremilast 30 mg tablet
224028304|NCT05222763|BEHAVIORAL|Web-assisted patient education intervention designed according to the self-regulation model|Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
224028305|NCT05222763|BEHAVIORAL|The website where the mastectomy patients handbook|The site where the patient booklet is available as pdf
224028306|NCT00473681|BEHAVIORAL|Self-Help Intervention Program-High Blood Pressure|
224028307|NCT04371653|DRUG|PRIM-DJ2727|administration orally
224028308|NCT04371653|DRUG|Placebo|administration orally placebo
224028309|NCT03958786|OTHER|Simplified Geriatric Evaluation|"* Questionnaires~* Self assessment questionnaires~* Mobility and balance tests"
224028310|NCT03958786|OTHER|Sampling|\- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
224028311|NCT04138797|PROCEDURE|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
224134593|NCT02882763|OTHER|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
223411212|NCT06122610|DEVICE|Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)|SPECT/CT will be performed after first cycle of Lutathera® treatment
223411213|NCT06122610|DEVICE|Photon Emission Tomography / CT (PET/CT)|PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment
224028312|NCT04138797|DEVICE|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
224028313|NCT02880033|DRUG|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
224028314|NCT02880033|DRUG|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
224028315|NCT00153517|DRUG|oral versus vaginal metronidazole|
224028316|NCT04487574|DRUG|XC221|Participants will receive XC221 100 mg 2 times a day during 14 days
223411214|NCT06122610|DRUG|64Cu-Dotatate|Standard of care administration of radioactive drug for PET/CT
223411215|NCT06122610|DRUG|177Lu-Dotatate|Standard of care administration of radioactive drug for PET/CT and SPECT/CT
223411216|NCT03548779|BEHAVIORAL|Pre-visit prep|Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.
223411217|NCT03548779|DIAGNOSTIC_TEST|usual care + exome seq|Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
223411218|NCT05294055|DRUG|Etoposide|Etoposide 1.5-1.8g/m2, single dose
223411219|NCT05294055|DRUG|Cyclophosphamide|Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
223411220|NCT05294055|DRUG|Mecapegfilgrastim, day 2|Mecapegfilgrastim 12mg SC, on day 2 after chemotherapy
223411221|NCT05294055|DRUG|Mecapegfilgrastim, day 5|Mecapegfilgrastim 12mg SC, on day 5 after chemotherapy
223411222|NCT06786195|OTHER|Whole-body vibration and Jumping|The subjects were first asked to jump in place 20 times, as if they were jumping rope. Then, whole-body vibration was applied. While the participants stood upright on the whole-body vibration device, low-amplitude (1.2 mm) vibrations were applied at eight different frequencies (25, 27, 29, 31, 33, 35, 37, 39 Hz), each lasting for 10 seconds, with a 5-second rest period in between. The Achilles tendon will be percussed 10 times with an electronic reflex hammer.
224028317|NCT04487574|DRUG|Placebo|Participants will receive Placebo 2 times a day during 14 days
224028318|NCT03445351|OTHER|Aerobic, resistance and concorrent.|All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
224028319|NCT02590263|RADIATION|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
224028320|NCT02590263|DRUG|Temozolomide|Temozolomide will be administered per label.
224028321|NCT02590263|DRUG|ABT-414|ABT-414 will be administered by intravenous infusion
224028322|NCT00010712|DRUG|Black Cohosh|
224028323|NCT00002646|DRUG|fenretinide|
224028324|NCT00002646|DRUG|tamoxifen citrate|
224028325|NCT02354313|DRUG|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
224028326|NCT04731766|BEHAVIORAL|Citrine 5 % sodium fluoride|Citrine varnish is a 5% sodium fluoride varnish, It was developed to prolong the contact between the tooth surface and fluoride to increase the resistance against caries attack and manage tooth hypersensitivity; the active ingredient of fluoride varnish is mostly 5% sodium fluoride.
224028327|NCT04731766|BEHAVIORAL|concocted nano-silver fluoride|Nano-silver fluoride (NSF) is a solution which has been introduced as an experimental formulation in which it's stability for three years has been proved by Santos et al. The laboratory synthesis of concocted NSF was carried out in a nano-technology center; Several trials were done until we have reached a successful end product.
224028328|NCT01790126|DRUG|ARN-509|
224028329|NCT01790126|DRUG|LHRH Agonist|
224028330|NCT03639233|BEHAVIORAL|YESS!|Web based self-management education
224028331|NCT04027322|DRUG|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
224134594|NCT05528224|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"OCD patients will take part in four structured online lessons for 6 weeks. Lesson one: Psychological Health Education, including the knowledge about OCD, SUDs and other related information.~Lesson two: Exposure and Response Prevention (ERP), including the knowledge about ERP, exposure item list and other related information.~Lesson three: Practice of Exposure and Response Prevention. Patients are asked to perform ERP practice based on what they have learned previously: practice at least once a day, a day about one hour all together. On this basis, in the main study, patients with severe obsessive and compulsive symptoms(Y-BOCS≥24) will be provided with extra therapist-guided ICBT: twice a week, about an hour one time. While in the pilot study, non-responders at week 3(YBOCS score reduction rate\<25%) will be provided with extra therapist-guided ICBT.~Lesson four: Practice retrospection and relapse prevention."
224134595|NCT05528224|OTHER|Cognitive Behavioral Group Therapy (CBGT)|OCD patients will be asked to come to Shanghai Mental Health Center to take part in the offline CBT group. Each group will be treated for 6 weeks, twice a week for 2 hours each time. The treatment was supervised by an experienced CBGT therapist. The structure of the course basically corresponds with the SC-ICBT group.
224134596|NCT05528224|DRUG|conventional medical treatment (TAU)|"In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs) approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram. The second-generation atypical antipsychotics may also be combined as a potentiator if the patient requires.~The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual."
224134597|NCT00718666|BIOLOGICAL|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
224134598|NCT04779671|BEHAVIORAL|VR cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~They will receive one immersive leisure-based VR cognitive training for 30 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training."
224134599|NCT04779671|BEHAVIORAL|Traditional cognitive training|"All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program."
224134600|NCT00516425|BIOLOGICAL|pegfilgrastim|
224134601|NCT00516425|DRUG|cyclophosphamide|
224134602|NCT00516425|DRUG|doxorubicin hydrochloride|
224134603|NCT00516425|DRUG|epirubicin hydrochloride|
224134604|NCT00516425|GENETIC|proteomic profiling|
224134605|NCT00516425|OTHER|diagnostic laboratory biomarker analysis|
224134606|NCT00516425|OTHER|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
224028332|NCT04027322|DRUG|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
224028333|NCT04027322|DRUG|Normal saline|Placebo for the control group.
224028334|NCT01128738|DRUG|GSK1358820|Onabotulinum toxin type A
224028335|NCT01128738|DRUG|Placebo|Placebo
224028336|NCT06406556|COMBINATION_PRODUCT|Pegaspargase combined with concurrent radiotherapy.|Patients receive CCRT (radiation 50 Gy and two cycles of pegaspargase 2500 unit/m2 every 3 weeks). 4 courses of pegaspargase were performed after CCRT.
224134607|NCT00516425|OTHER|pharmacological study|
224134608|NCT00516425|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
224134609|NCT00516425|PROCEDURE|adjuvant therapy|
223559228|NCT07034326|OTHER|Electroacupuncture combined with immunotherapy|Connect the electroacupuncture therapy instrument, select the density wave 2 Hz/100 Hz, the current intensity should be tolerated by the patient, leave the needle for 20 min.Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
223559229|NCT07034326|DRUG|Zilongjin tablet combined with immunotherapy|Take Zilongjin tablets orally, 4 tablets each time, 3 times a day.Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
223559230|NCT07034326|DRUG|Immunotherapy|Immunotherapy including but not limited to pabolizumab and attilizumab were repeated every 21 days for treatment weeks.The period is 1 year, and maintenance treatment can be carried out in accordance with the drug instructions and guidelines.
223559231|NCT07034729|BEHAVIORAL|training to develop emotional intelligence skills|2 hours in a week, 6 week training
224028337|NCT01178671|DRUG|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
224028338|NCT01178671|DRUG|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
224028339|NCT01178671|OTHER|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
224028340|NCT02435966|DEVICE|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
224028341|NCT02435966|DEVICE|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
224028342|NCT02435966|OTHER|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
224028343|NCT00573885|DRUG|defined green tea catechin extract|Given orally
224028344|NCT00573885|OTHER|placebo|Given orally
224028345|NCT04742322|DIETARY_SUPPLEMENT|Bifidobacterium Lactis CCT7858|Probiotic B Lactis
224028346|NCT04742322|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin
224028347|NCT00490009|DRUG|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~* Platelet count of 150,000/mm³ = 75 cGy~* Platelet count ≥ 100,000/mm³ but \< 150,000/mm³ = 65 cGy"
224028348|NCT00490009|DRUG|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
224028349|NCT00490009|DRUG|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
224028350|NCT00490009|DRUG|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
224028351|NCT02827253|DEVICE|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
224028352|NCT06064513|OTHER|verbal empathy training|Empathy training will be given to nurses in the control group using face-to-face interview technique. In this training, the researcher will explain verbally what empathy is and how to make an empathetic approach to sick individuals. The training will be given to nurses twice, one week apart, at their own time.
224028353|NCT06064513|OTHER|video based empathy training|Nurses in the video group will be shown a video recording about empathy. Nurses will be allowed to watch the training video twice, with an interval of one week. After the empathy training is completed, the evaluation phase will begin. For this purpose, 2 weeks and 4 weeks after the end of the last training, nurses in both study groups will be asked to fill out the Integrative Nursing Competency Scale and Empathy Level Determination Scale. In the study, a comparison of nurses' pre-test and post-test answers will be made to evaluate the effectiveness of video-based education.
224028354|NCT05472948|DRUG|Surufatinib|Surufatinib will be given 200/250 mg po. qd.
223559232|NCT07034690|OTHER|Educational Material|Health Education Intervention delivered via clinic visits (every 4 months) and virtual sessions (between each clinic visit)
223559233|NCT07034690|OTHER|Standard of care|Standard of care
223559234|NCT07033234|DRUG|HS-20118|HS-20118
223559235|NCT07034170|BEHAVIORAL|Enhanced Rehabilitation Program|Participants in the intervention group receive an enhanced rehabilitation program, including muscular electrical stimulation, guided active rehabilitation sessions, and structured physical engagement during periods of consciousness. The intervention is designed to promote functional improvement in post-cardiac arrest patients.
224028355|NCT05472948|DRUG|Sintilimab|Sintilimab administered IV at a dose of 200mg every 3 weeks.
223559236|NCT07042386|BEHAVIORAL|CROWN Intervention|"CROWN Intervention includes:~1. Private BP screenings in salon Heart Health Stations by trained Heart Health Stylists~2. Free Omron home BP monitor paired with a mobile app for twice-daily telemonitoring~3. In-depth coaching sessions + monthly check-ins with a community health worker~4. Bi-weekly medication review and adherence support by a clinical pharmacist~5. Digital social-needs screening (AHC HRSN) with referral to community resources"
223738733|NCT06016517|DRUG|Upadacitinib|15 mg orally once daily with subcutaneous placebo injection every 2 weeks
224028356|NCT05472948|DRUG|Capecitabine|Capecitabine will be given 2 weeks on/1 week off (1000 mg/m2 BID po.)
224028357|NCT02652962|DEVICE|Gelesis200|3 capsules each containing 0.70 g
224028358|NCT02652962|OTHER|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
224028359|NCT01917513|DEVICE|G-EYE™ colonoscopy|G-EYE™ colonoscopy
224028360|NCT01917513|DEVICE|Standard Colonoscopy|Standard Colonoscopy
224028361|NCT03084224|GENETIC|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
224028362|NCT02253303|OTHER|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
224028363|NCT04998734|DIAGNOSTIC_TEST|ASI-SR|Psychometric properties of ASI-SR
224028364|NCT01211197|DRUG|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
224028365|NCT01211197|DRUG|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
224028366|NCT01211197|DRUG|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
224028367|NCT00070863|BEHAVIORAL|Individual Cognitive Behavioral Therapy|
224028368|NCT02302690|BIOLOGICAL|Blood sample for immunology|
224028369|NCT06200298|PROCEDURE|Erector spinae plane block with naropeine [3,75 mg/mL]|"Erector spinae plane block Procedure:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the ESPB group, a long-acting local anaesthetic: ropivacaine 3.75 mg/mL, 30 mL.~* Repetition of the gesture for the transverse controlateral process"
224028370|NCT06200298|PROCEDURE|ESPB with saline 0,9%|"Procedure for the Erector spinae plane block Procedure by NaCl 0.9%:~* Ultrasound scan with protective sleeve and sterile gel. Research of the thoracic spine process between T8 (for thoracic arthrodesis) and T12 (for lumbar arthrodesis)~* Once the thorny process is identified, horizontal shift to the transverse process.~* When the transverse process is spotted, sagittal rotation of the ultrasound probe~* Skin puncture with an 80 mm hyperechogenic needle in the plane of the ultrasound probe. The needle will be placed in contact with the transverse process~* Injection, after aspiration, of the solution prepared blindly by the anesthesiologist performing the procedure. For the control group: saline isotonic serum 30 mL.~Repetition of the gesture for the transverse controlateral process"
224028371|NCT03898115|BEHAVIORAL|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
224028372|NCT02702973|OTHER|Observe the fundus characteristics after therapy.|
224028373|NCT02678013|PROCEDURE|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
224028374|NCT02678013|PROCEDURE|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
224028375|NCT05131620|PROCEDURE|Virtual Reality|It is planned that VR glasses are put on 5-10 minutes before the procedure and continued throughout the procedure, and the total monitoring time will continue for 30 minutes.
224298082|NCT06926907|BEHAVIORAL|The Teacher Education and Classroom Habits (T.E.A.C.H.) Program|The T.E.A.C.H. Program utilized essential constructs of the Social Cognitive Theory to deliver virtual nutrition education to Montessori teachers over a 6-week period. The intervention consisted of four program components: 1. An interactive online nutrition education platform with 6 modules was developed using a WordPress website. Each module contained 5 topics including adult nutrition, child nutrition, classroom food practices, cultural practices, and teacher-parent communication. Teachers were provided login information via email containing a unique identifier to be used as their username and were prompted to complete one module per week for 6 weeks; 2. Live weekly virtual education sessions were held via Zoom to supplement and reinforce the online learning experience; 3. A Montessori-based nutrition curriculum with 6 weekly lessons to utilize in the classroom was provided to each participant; 4. Educational handouts to be disseminated to parents.
224028376|NCT05131620|PROCEDURE|Acupressure|Acupressure will be applied 10 minutes before catheter extraction after CAG.
224028377|NCT00913666|DRUG|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
224028378|NCT03133520|DEVICE|High flow oxygen therapy|High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
224298083|NCT06928909|OTHER|Intensity-adapted pediatric acute myeloid treatment guidelines|This is an observational study evaluating the current standard of care AML therapy in Malawi. The therapy guideline used is an adaptation of the International Society of Paediatric Oncology (SIOP) guidelines for pediatric AML in resource-constrained centers published by the International Society of Paediatric Oncology (SIOP). It is currently the standard of care in Malawi for all patients with AML. Receipt of this therapy guideline is independent of participation in research.
224298084|NCT06927687|BIOLOGICAL|ZG005 for Injection|Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks.
224298085|NCT06928207|COMBINATION_PRODUCT|Provide the diagnostic (RDT) for free to clients suspected of having malaria and provide a subsidized ACT to only those testing positive|To promote the use of the recommended first line drug, we implement a conditional subsidy. The retail provider is given the malaria diagnostic for free and is instructed to test clients suspected of having malaria. Only if the test is positive, the provider is instructed to provide the ACT at a low cost.
224298086|NCT06928779|DRUG|Dazucorilant|Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration
224298087|NCT06926933|DRUG|Eligard® 45 mg|45 mg of leuprolide acetate
224028379|NCT04351022|BIOLOGICAL|CART-38|Split intravenous infusion of CART-38 cells \[dose escalating infusion of (5-20)x10\^6 CART-38 cells/kg\].
224028380|NCT02170935|DRUG|BIBR 1048 capsule|
224028381|NCT03416998|OTHER|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
224028382|NCT03252951|BEHAVIORAL|Eccentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
224028383|NCT03252951|BEHAVIORAL|Concentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
223559237|NCT07042386|BEHAVIORAL|Enhanced Usual Care|"Enhanced Usual Care include:~1. Private BP screenings in salon Heart Health Stations by Heart Health Stylists~2. Printed cardiovascular health brochures~3. Free home blood pressure monitor (no app integration)~4. Standard referrals to social and health services"
224028384|NCT03252951|BEHAVIORAL|Isometric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
223411223|NCT06778096|BEHAVIORAL|Postnatal anxiety and depression iCBTprogram|The overarching goal of this stand-alone program is to introduce women to CBT skills to help manage symptoms of anxiety and depression, such as psychoeducation, cognitive restructuring and problem solving, behavioural activation, graded exposure and relapse prevention. Each lesson is accompanied by practical homework and resources (e.g., medication during breastfeeding, attachment and bonding, information for entourage, sleep, self-care, intrusive thought, problem solving), and is built to be easily generalizable to a broad range of women. The three lessons must be completed within a 6-week period, with up to two weeks to complete each lesson. Participants will be notified of new lessons available via email and text message reminders. There is a 5-day lockout between lessons stopping the participants to complete the next session once a session is completed to ensure that the sessions are completed over multiple weeks to allow for revision and practice.
224028385|NCT03252951|BEHAVIORAL|Biofeedback|Standard of Care Biofeedback Training
224028386|NCT05822453|DRUG|Gemcitabine|Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle
223411224|NCT00589654|OTHER|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
223411225|NCT06532500|BEHAVIORAL|CBT-MyOWL|12-sessions of CBT-MyOWL
223411226|NCT06532500|BEHAVIORAL|CBT-as-usual|12-sessions of CBT using Mind Over Mood or Anxiety Phobia
223411227|NCT06959563|BIOLOGICAL|9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use|By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
223411228|NCT04458545|BIOLOGICAL|Oxy(Gly)4-sKLH vaccine - Low Dose|Oxy(Gly)4-sKLH vaccine - Low Dose
223411229|NCT04458545|BIOLOGICAL|Oxy(Gly)4-sKLH vaccine - High Dose|Oxy(Gly)4-sKLH vaccine - high dose
223411230|NCT04458545|BIOLOGICAL|Placebo Oxy(Gly)4-sKLH vaccine|Oxy(Gly)4-sKLH vaccine - Placebo
223411231|NCT05467930|OTHER|Survey|Survey completion by the participant to collect information about health and social experience
224028387|NCT05822453|DRUG|S1|S1 (60 mg/day if body surface area \< 1.25 m2, 80 mg/day if body surface area = 1.25\~1.50 m2) will be administered by PO on Day 1 \~ 14 of each 21-day cycle
224028388|NCT05822453|DRUG|Tislelizumab|Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle
224028389|NCT05436080|DEVICE|U/S|Epididymal Ultrasongraphic Findings by Scrotal U/S
224028390|NCT06494527|DRUG|RG002C0106|RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
224028391|NCT00489892|DRUG|Modafinil|
224028392|NCT02838485|OTHER|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
224028393|NCT02838485|OTHER|Imagery|The subject will be asked to imagine performing hand movements.
224028394|NCT06078280|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
224028395|NCT02752321|DEVICE|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
224028396|NCT04911556|DIETARY_SUPPLEMENT|Bifidobacterium longum|types of intestinal flora
224028397|NCT04911556|DIETARY_SUPPLEMENT|A placebo made of starch|placebo
224028398|NCT03539783|DIAGNOSTIC_TEST|Respiratory epithelial cell brushing|At specified time points, nasal brushings will be performed to obtain RNA.
224028399|NCT02767375|DRUG|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 \& 2 , IA，q4-6 Weeks
224028400|NCT02767375|PROCEDURE|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
223411232|NCT05467930|OTHER|Medical History Review|Review of the participant's medical history at New York Presbyterian/Columbia University Irving Medical Center
224028401|NCT00272922|DEVICE|hernia repair|
223411233|NCT05467930|OTHER|Sample Collection|Collection of nasal and blood samples
223411234|NCT05047965|PROCEDURE|Dixon MRI|Undergo Dixon MRI
224028402|NCT04465760|DRUG|Xisomab 3G3|Given IV or via catheter
224028403|NCT02066285|DRUG|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
223411235|NCT05047965|PROCEDURE|Magnetic Resonance Imaging|Undergo standard MRI
223411236|NCT04722315|DIETARY_SUPPLEMENT|Modified Atkins diet|12 weeks of modified Atkins diet
223411237|NCT04540900|BIOLOGICAL|KB301|non-integrating HSV-1 vector expressing human type III collagen
223411238|NCT04540900|OTHER|Placebo|sterile isotonic saline
223411239|NCT06188364|OTHER|Standard of Care|The usual Transition Supports and Services (USS) that prepare care partners of persons with TBI for post-rehabilitation discharge, so the the delivery of traditional CHW outreach services such as finding health, community and social determinants referrals, problem-solving, and connecting care partners to long-term supports/services
223411240|NCT06188364|OTHER|Experimental|"Novel aspects of the CHW experimental intervention for TBI care partners include:~1. CHW services begin prior to inpatient rehabilitation discharge;~2. care partners get timely, useful health management materials;~3. encounters focus on unlimited, brief, situation-focused calls to help care partners assess and resolve pressing concerns; and~4. long-term support capacity for care partners is built by establishing a reliable referral network of medical, community, and social services that become foundational resources beyond study completion."
224028404|NCT00151151|BEHAVIORAL|Computer-Assisted Motivational Intervention|
224028405|NCT00151151|BEHAVIORAL|Didactic Educational Counseling|
224134610|NCT06576102|OTHER|Persisting SARS-CoV-2 infection|Prevalence of persisting SARS-CoV-2 infection among immunocompromised patients defined as the persistence or the recurrence of symptoms and signs (fever, dyspnea, hypoxemia, changes on chest-X ray or CT scan) and positive SARS-CoV-2 PCR ≥ 21 days after the time 0 (day of the first test positive for SARS-CoV-2 infection)
223411241|NCT05398302|PROCEDURE|Image Guided Biopsy|Undergo image-guided biopsy
223411242|NCT00990392|DRUG|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
223411243|NCT00990392|OTHER|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
223411244|NCT05893147|OTHER|De-escalation VS No De-escalation|"No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result)~De-escalation group: switched to narrower spectrum antibiotic."
223411245|NCT05893147|OTHER|Oral beta-lactams VS non beta-lactams|"Beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole.~Non beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime."
223411246|NCT05893147|OTHER|Central vascular catheter retention VS Central vascular catheter replacement|"Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 72 hours from blood culture finalization~Central vascular catheter retention: the catheter will not be changed and will be retained until it is no longer needed."
224028406|NCT06299085|OTHER|50 adult patients suffering from severe or morbid obesity, male and female, candidates for bariatric surgery.|"50 adult patients suffering from severe or morbid obesity (BMI ≥ 35 kg/m2 in the presence of comorbidities and BMI ≥ 40 kg/m2, respectively), male and female, candidates for bariatric surgery (Sleeve Gastrectomy and Roux-en-Y Gastric Bypass).~Two timepoints: T0 (pre-hospitalization) and T1 (follow-up 12 months +/- 1 month).~Expected assessments at T0 and T1:~* Blood chemistry tests to monitor metabolic markers involved in dietary and metabolic changes.~* Bone densitometry for body composition analysis (DEXA).~* Analysis of pre-intervention walking and the ability to recover motor activity after bariatric surgery using gait analysis."
224028407|NCT06081582|DRUG|Toripalimab|"This study was conducted on 30 patients with initially unresectable locally advanced head and neck squamous cell carcinoma who underwent two cycles of PD-1 antibody (trepril monoclonal antibody) combined with fluorouracil, cisplatin, and cetuximab conversion therapy. The feasibility of radical surgery should be evaluated before surgical treatment.Three patients were enrolled in the safe induction period before the study began.~The dosage of medication used is as follows:~Toripalimab: 240mg, Day1, Q3W~Cisplatin: 25mg/m2, Day1-3, Q3W（every 3 weeks）~5-FU: 1000mg/m2, Day1-3, Q3W~Cetuximab Day 1, 8, 15, Q3W, 400 mg/m2 initial dose; Afterwards, 250 mg/m2 per week"
224134611|NCT03326830|DEVICE|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).
223411247|NCT05893147|OTHER|Cephalosporin VS Carbapenem for low risk AmpC organisms|"Cephalosporin (ceftriaxone) at standard doses~Carbapenem (like Meropenem, Ertapenem etc) at standard doses"
223738734|NCT06016517|DRUG|Tocilizumab|162 mg administered SQ every 2 weeks
224134612|NCT03326830|DEVICE|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
224134613|NCT01652248|PROCEDURE|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
224134614|NCT01467908|DEVICE|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
224134615|NCT01580592|DRUG|Omalizumab|150mg, s.c., every 4 weeks
224134616|NCT01580592|DRUG|Omalizumab|300mg, s.c., every 4 weeks
224134617|NCT01580592|DRUG|Placebo|Placebo, s.c., every 4 weeks
224134618|NCT00783341|DRUG|GAP-134|
224134619|NCT00783341|DRUG|placebo|
224134620|NCT03591679|DRUG|Oxytocin|20 units by slow intravenous drip injection
224134621|NCT03591679|PROCEDURE|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
224134622|NCT04043338|DRUG|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
224134623|NCT04043338|DRUG|Placebo|Placebo supplied as matching capsules or tablets
224134624|NCT01205672|DRUG|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
224134625|NCT04619121|DEVICE|NIR-tPBM|The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
224134626|NCT04619121|DEVICE|Sham device|The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
224134627|NCT00564954|DRUG|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
224134628|NCT00564954|DRUG|Placebo|orally once a day for 7 days
224134629|NCT03471767|DRUG|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
224134630|NCT03471767|DRUG|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
224134631|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
224134632|NCT03815487|DEVICE|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
224298088|NCT01427166|OTHER|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
223411248|NCT05893147|OTHER|Routine follow-up blood culture VS No routine follow-up blood culture|"Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria.~No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria"
223411249|NCT04855435|DRUG|MBS8(1V270)|The investigational medicinal product will be administered IV by infusion. Subjects will be treated in cycles.
224028408|NCT04778956|DRUG|Toripalimab|Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); Toripalimab should be completed for 2 cycles at 1-2 weeks before surgery, and continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
224028409|NCT04778956|PROCEDURE|salvage surgery|Endoscopic nasopharyngectomy is used for recurrent nasopharyngeal tumor and selective neck dissection for recurrent regional lymph node.
224028410|NCT03997617|DIAGNOSTIC_TEST|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
224028411|NCT01808482|DRUG|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
224028412|NCT01808482|DRUG|Part A: matching placebo|Matching placebo
224028413|NCT01808482|DRUG|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
224028414|NCT01808482|DRUG|Part B: matching placebo|Matching placebo
224028415|NCT01808482|DRUG|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
224028416|NCT01105754|BEHAVIORAL|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
224028417|NCT00721669|DRUG|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
224028418|NCT04343638|DEVICE|conventional nociception control|While Intraoperative opioid will be administered by conventional clinical practice in control arm.
224028419|NCT04343638|DEVICE|ANI monitor guided nociception control|The intraoperative opioid will be administered by maintaining the 4-minute moving average of ANI ≥50 in ANI-monitor guided nociception control arm.
224028420|NCT03128008|DRUG|Carboplatin|Single arm non randomized open label study. Subjects will receive standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
223411250|NCT06466382|OTHER|Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling|The intervention studied is a treatment recommendation by a specialized molecular tumorboard (mTB). This recommendation is based on an MSR which is created by TP, i.e., molecular analysis of clinical specimens, obtained from the individual participant. TP, a technology platform of several precision-cancer profiling domains, combines and rates the most efficient drugs/ experimental treatments for an individual ovarian cancer patient independent of standard of care. The usability in clinical practice of this recommendation will be tested. It should support the clinical decision of the treating oncologists and patients to choose the best possible therapy for the individual patient.
223411251|NCT06466382|DRUG|Carboplatin / Paclitaxel Chemotherapy|2 cycles of chemotherapy with carboplatin AUC5 3-weekly and paclitaxel 175 mg/m2 3-weekly or carboplatin AUC2 weekly and Paclitaxel 60-80mg/m2 weekly
223411252|NCT04432831|DRUG|Faricimab|Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
223411253|NCT04432831|OTHER|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
223411254|NCT03731585|BEHAVIORAL|Behavioral Intervention|Participate in psychological sessions
223411255|NCT03731585|OTHER|Educational Intervention|Participate in educational sessions
223738735|NCT06059820|OTHER|rehabilitation treatment|3-month immobilization period, hyperextension braces for specific fractures, therapeutic exercises, and gradual activity restoration.
224028421|NCT03128008|DRUG|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
224028422|NCT03128008|RADIATION|Daily hyperfractionated radiation therapy|All subjects will receive 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
224298089|NCT01081314|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
223411256|NCT03731585|OTHER|Questionnaire Administration|Ancillary studies
223411257|NCT03731585|PROCEDURE|Support Group Therapy|Participate in group sessions
223411258|NCT06052033|PROCEDURE|CO2|CO2 laser treatment is a surgical procedure that employs a high-powered carbon dioxide laser beam to precisely ablate cervical lesions. The laser is applied with a depth of 7-10mm and a width of 3-5mm beyond the lesion area in a single session. This intervention aims to address persistent low-grade cervical lesions associated with high-risk HPV infection.
223411259|NCT06962566|BEHAVIORAL|Morning exercise|Participants performed a 45-minute treadmill brisk walking in the morning between 08:00 to 11:00 AM.
223738736|NCT06059820|PROCEDURE|Spine fusion|Pedicle screw fixation or fusion; anterior plate fusion
223411260|NCT06962566|BEHAVIORAL|Evening exercise|Participants performed a 45-minute treadmill brisk walking in the evening between 18:00 to 21:00 PM.
223411261|NCT05769218|BEHAVIORAL|CHORUS+|The CHORUS+ intervention will include a baseline interview with a peer recovery coach to encourage uptake of HIV PrEP (pre-exposure prophylaxis) and medications for opioid use disorder (MOUD) through motivational interviewing (MI). Participants will also be offered HIV self-testing on the day of recruitment, HIV PrEP (if they are HIV negative) and MOUD. Participants will then receive peer coaching for 6 months to increase adherence to PrEP and or MOUD.
223411262|NCT05769218|OTHER|Standard of care|Normal protocols for care of participants who inject opioids will be followed.
223411263|NCT04699123|DRUG|NC318 800 mg|NC318 will be given intravenously (IV) weekly for 8 doses and then every 2 weeks for patients receiving combination therapy treatment or weekly for patient receiving NC318 in monotherapy.
223411264|NCT04699123|DRUG|NC318 400 mg|NC318 will be given intravenously (IV) every 2 weeks.
223411265|NCT04699123|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be given IV every 3 weeks
223411266|NCT06491927|GENETIC|No Intervention|Observational study
223411267|NCT06307925|DRUG|HC010|HC010 Q2W/28d intravenous infusion
223411268|NCT06117293|DEVICE|Mosaic|1550 Fractional Laser System
223411269|NCT00004787|DRUG|filgrastim|
223411270|NCT06684054|DRUG|docetaxel, anthracycline, cyclophosphamide|"1. Participants were required to receive 6 cycles of TEC/TAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.~2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.~3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study."
223411271|NCT01756794|PROCEDURE|Liver transplantation|
223411272|NCT05567744|OTHER|Registry|Registry
223411273|NCT03089268|PROCEDURE|Colonoscopy|A colonoscopy will be performed to all individuals.
223411274|NCT03089268|PROCEDURE|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
223411275|NCT03089268|GENETIC|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
223411276|NCT04191369|DIAGNOSTIC_TEST|Esophagogastroduodenoscopy|Esophogagastroduodenoscopy for the evaluation of esophageal varices, gastric varices and hypertensive gastropathy. Portal pressure gradient will be evaluated via interventional radiology as gold standard.
223411277|NCT04191369|DIAGNOSTIC_TEST|Endoscopic ultrasound|"Endoscopic ultrasound evaluation for the presence of esophageal varices, peri and para-esophageal collateral veins, gastric varices, portal hypertensive gastropathy, azygos vein diameter, blood flow and BFVI.~Portal pressure gradient will be evaluated via interventional radiology as gold standard."
223411278|NCT06621030|DEVICE|MIB Breath Analyzer|Going through visit-specific blood glucose excursions by the administration of glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC IMS and the MIBs (investigational devices). Going through visit-specific blood glucose excursions by consuming a standardized meal, monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices) Imitating the glucose excursion from the meal excursion by infusing glucose and insulin (clamp), monitoring physiological processes, and measuring reference blood glucose values and VOC measurements in the breath using a GC-IMS and the MIBs (investigational devices).
223411279|NCT05246189|OTHER|Telephone Call|"Eligible subjects will be pre-selected by the study investigators on the basis of the medical file. A letter of information about the study will be sent to all the pre-selected eligible patients, with the exception of patients who have expressed an objection to the processing of their data for research purposes during their treatment.~The investigators will contact eligible patients by telephone approximately 2 weeks after the mailing of the information letter. During this telephone call, the investigator will answer any questions the patient may have about the study and will collect the patient's non-objection to participate in the study and their responses to the questionnaire."
223559238|NCT07045649|DIAGNOSTIC_TEST|1-minute sit-to-stand test|The 1-minute sit-to-stand test will be assessed upon discharge from the Cardiac Intensive Care Unit. It may be assessed up to 48 hours after discharge from the unit. It will be performed on a standardized 46.0 cm chair without armrests, placed against the wall. Participants will be seated in the chair, without support, with their knees and hips at 90° flexion, with their feet parallel to the floor and their arms crossed over their chest. Participants will be instructed to stand up and sit down as quickly as possible without using their arms for 1 minute and will be instructed to stop whenever they wish. However, they must return as quickly as possible, since the goal is to complete as many repetitions as possible in 1 minute. Vital signs and dyspnea and leg fatigue will be assessed using the Modified Borg Scale before and after the test. A repetition will be identified as standing up completely straight and returning to the sitting position.
224028423|NCT05782426|DRUG|paclitaxel polymeric micelles for injection|Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles. If patient assessment is of clinical benefit, maintenance therapy with sindilizumab plus paclitaxel polymeric micelles for injection(≤230mg/m\^2) can be continued based on investor's evaluation and patient's own choice until disease progression (PD), unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified conditions for discontinuation of treatment, whichever comes first.
224028424|NCT00406653|DRUG|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
224028425|NCT00406653|DRUG|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
224028426|NCT00406653|DRUG|abatacept|"\~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
224028427|NCT00818649|DRUG|bortezomib|1.3mg/m\^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
224028428|NCT00818649|DRUG|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
224028429|NCT02926144|DEVICE|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
223411280|NCT03714334|DRUG|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
223411281|NCT04973176|DEVICE|Standard Bougie|Standard Bougie for endotracheal intubation
223559239|NCT07048860|OTHER|ICOPE intense intervention|The ICOPE-intense intervention (45 hours centre-based (in-group and in-person) multidomain intervention, everyday home-based lifestyle improvement, and weekly individual phone/video call for support)
223559240|NCT07048860|DIETARY_SUPPLEMENT|Ketone Ester (KE) supplementation|12.5g once a day of KE for week 1, and 25g once a day of KE supplementation week 2 to week 8.
224028430|NCT02926144|DEVICE|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
224028431|NCT03169322|PROCEDURE|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
224028432|NCT03513588|DRUG|Placebo|tablet, 0 mg, 14 days, every 12 hours
224028433|NCT03513588|DRUG|PF-06865571|tablet, 50 mg, 14 days, every 12 hours
224028434|NCT03513588|DRUG|PF-06865571|tablet, 300 mg, 14 days, every 12 hours
224028435|NCT05955313|DRUG|Naltrexone Hydrochloride|treatment of vulvodynia
224028436|NCT06367010|COMBINATION_PRODUCT|Iodine-125 brachytherapy combine with Anlotinib|Iodine-125 brachytherapy combine with Anlotinib
224028437|NCT00685633|DRUG|bicalutamide|Given orally
224028438|NCT00685633|DRUG|enzastaurin hydrochloride|Given orally
224028439|NCT04210869|DIETARY_SUPPLEMENT|Mixed Nuts|Study volunteers will receive daily 60 g of mixed nuts (15 g walnut, 15 g cashew, 15 g hazelnut, 15 g pistachio) for 16 weeks.
224028440|NCT03435757|PROCEDURE|OFD+IMP+CPS|open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
224028441|NCT03435757|PROCEDURE|OFD+IMP|open flap debridement (OFD) and intramarrow penetration (IMP)
224134633|NCT00657852|DRUG|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
224134634|NCT00657852|DRUG|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
224134635|NCT05371990|OTHER|Determination of Eating habits|Questionnaire
224134636|NCT00678587|DRUG|Eltrombopag|75 mg, once daily, oral
224134637|NCT00678587|DRUG|Placebo|placebo, once daily, oral
224134638|NCT01747278|DRUG|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
224134639|NCT00003539|BIOLOGICAL|trastuzumab|
224134640|NCT00003539|DRUG|paclitaxel|
223411282|NCT04973176|DEVICE|Flexi-tip Bougie (P3 Medical Bristol,UK)|Flexi-tip Bougie for endotracheal intubation
223559241|NCT07048860|DIETARY_SUPPLEMENT|Placebo|2.5 g of nonketogenic canola oil
223559242|NCT07048860|DIETARY_SUPPLEMENT|Vitamin D3|2 sprays (i.e. 2000 iu) per day in the morning for 60 days
223559243|NCT07048860|DIETARY_SUPPLEMENT|OMega 3|1000 mg: 1 table per day in the morning during 60 days
224028442|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
224028443|NCT00940108|BIOLOGICAL|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
224028444|NCT01768520|DRUG|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg"
224134641|NCT01952730|BIOLOGICAL|GVAX|
223411283|NCT00373620|DRUG|paclitaxel|
223411284|NCT00652626|DRUG|azacitidine|
223411285|NCT06466525|DRUG|LBT-3627|Synthetic peptide
223411286|NCT06466525|DRUG|Placebo|Vehicle
223559244|NCT07048860|DIETARY_SUPPLEMENT|vitamin B9|5 mg cp: 1 tablet morning and 1 tablet evening for 60 days
223559245|NCT07048860|DIETARY_SUPPLEMENT|Vitamin B12|250 microgram: 1 tablet per day in the morning for 30 days, then 1 tablet every 10 days for 30 days
223559246|NCT07048860|DIETARY_SUPPLEMENT|Leucin-rich whey|In case of Sarcopenia or low protein intake (\<1.2 g/kg/day), Oral Nutritional Supplementation enriched in essential amino acid (leucin)
223559247|NCT07048860|OTHER|ICOPE Step 1|usual ICOPE Step 1
223411287|NCT04189783|DRUG|Liposomal Bupivacaine|Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity
224028445|NCT01768520|DRUG|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
224028446|NCT01768520|DRUG|Placebo|"1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg"
224028447|NCT03931031|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
224134642|NCT03703830|DEVICE|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
224134643|NCT03703830|OTHER|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
224134644|NCT03703830|DEVICE|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
224134645|NCT03703830|DEVICE|Cerebello-spinal direct current stimulation|Cerebello-spinal transcranial direct current stimulation (csDCS) will be applied during 25 minutes at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11)
224134646|NCT03703830|DEVICE|Sham cerebello-spinal direct current stimulation|Sham cerebello-spinal direct current stimulation (csDCS sham) will be applied during 30 seconds at 2 mA of intensity. The anode was placed on the scalp over the cerebellum area (1 cm below the inion) and the cathode over the spinal lumbar enlargement (2 cm under T11). However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
224298090|NCT01081314|BEHAVIORAL|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
223411288|NCT04189783|DRUG|Quadratus Lumborum Block|"Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (RESQU block) on day 4 after surgery"
223411289|NCT04189783|OTHER|Questionnaire Administration|Ancillary studies
223411290|NCT00317785|DRUG|cyclophosphamide|
223411291|NCT00317785|DRUG|cyclosporine|
223411292|NCT00317785|DRUG|methotrexate|
223411293|NCT00317785|DRUG|mycophenolate mofetil|
223411294|NCT00317785|DRUG|sirolimus|
223411295|NCT00317785|DRUG|tacrolimus|
223411296|NCT00317785|OTHER|pharmacological study|
223411297|NCT00317785|PROCEDURE|allogeneic bone marrow transplantation|
223411298|NCT00317785|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224028448|NCT04842097|BEHAVIORAL|Mindfulness-based stress reduction|An online mindfulness-based stress reduction intervention will be administered in a group format of maximum 15 participants, once a week for 120 minutes for 8 weeks by an experienced therapist trained in MBSR. Sessions will include sitting and lying meditation, hatha yoga and a body scan where attention is sequentially focused on different parts of the body. Individual autonomous practice between 30-45 minutes, 6 times / week will also be recommended. To support individual autonomous practice, a daily diary and two guided videos (around 35 minutes/each) were created.
224028449|NCT05889481|GENETIC|cytogenetic analysis on tumour tissue|Array-CGH methods on oligonucleotide platforms from Agilent Technologies were used. Tumour DNA from MU samples was extracted using the Gentra Pure Gene commercial kit (QIAGEN), as per clinical practice. Once extracted, the quantity and purity of the DNA obtained were evaluated. All samples deemed suitable for quality were processed following the protocol indicated by Agilent Technologies. The data obtained were analysed using Cytogenomics software. These analyses will allow a genotypic characterisation of the tumour to be obtained.
224028450|NCT05889481|BIOLOGICAL|Digital Pathology|Digital Pathology is an emerging discipline that enables quantitative analysis of digital images using highly standardised approaches. It will allow quantitative measurements of the interactions between immune cells and characterise their relative spatial distribution. In addition, it will be able to generate further information that will allow in-depth study of the tumour microenvironment of uveal melanoma
224028451|NCT02075541|BIOLOGICAL|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224028452|NCT02075541|DRUG|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224028453|NCT03149718|BEHAVIORAL|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
224028454|NCT03149718|BEHAVIORAL|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
224134647|NCT05564286|DRUG|Fosaprepitant|In fosaprepitant group, patients would receive fosaprepitant combined with tropisetron plus dexamethasone to prevent chemoradiotherapy-induced nausea and vomitting while the control group would only be given tropisetron and dexamethasone .
224134648|NCT05564286|DRUG|tropisetron|All patients received tropisetron 5mg on day 1.
223559248|NCT03529617|OTHER|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
224134649|NCT05564286|DRUG|Dexamethasone|.All patients received dexamethasone 5mg infusion on day 1 and oral dexamethasone 3.75 mg once a day on day 2-3.
224134650|NCT06502756|DEVICE|SOBER, mobile Application providing digital CBT|SOBER is a software application (Android) that delivers cognitive behavioral therapy (CBT) in a structured and interactive manner. It analyzes patterns in participants\&#39; lifestyles to identify problematic behaviors related to their alcohol consumption. By providing tailored guidance and support, the app aims to help individuals make sustainable changes, ultimately reducing hazardous drinking. This approach combines the principles of CBT with the convenience and accessibility of digital technology, offering a personalized experience to support the reduction of alcohol consumption.
224134651|NCT02076321|DRUG|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
223411299|NCT00317785|PROCEDURE|peripheral blood stem cell transplantation|
223411300|NCT00317785|RADIATION|total-body irradiation|
223411301|NCT06578494|DEVICE|Ultrasound|Ultrasound-guided peripheral intravenous catheter insertion
223411302|NCT02764281|DRUG|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."
223411303|NCT02764281|PROCEDURE|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
223411304|NCT01623310|DRUG|Fluticasone Propionate|Using Optinose Exhalation Delivery System
223411305|NCT02291666|DRUG|CRCHUM-MT cocktail|
223559249|NCT07081503|DRUG|ADX-626|siRNA duplex oligonucleotide
223559250|NCT07081503|DRUG|Placebo|Saline
223411306|NCT02898597|BEHAVIORAL|Cognitive Behavioral Therapy|Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
223411307|NCT02673931|DRUG|Byetta (Lilly, Exenatide)|See description of arms
223411308|NCT02673931|DRUG|Conoxia (AGA, oxygen)|See description arms
223411309|NCT02673931|DRUG|20% Human Albumin|
223411310|NCT02530125|OTHER|Laboratory Biomarker Analysis|Correlative studies
223411311|NCT02530125|BIOLOGICAL|Pidilizumab|Given IV
223411312|NCT03747523|DRUG|Ergocalciferol|Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
223411313|NCT03171038|OTHER|Telemonitoring|
223411314|NCT03303690|PROCEDURE|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
223411315|NCT03961321|RADIATION|stereotactic mr guided adaptive radiotherapy|Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing (SIS) of the urethra with a dose of 32.5 Gy in 5 fractions (6.5 Gy per fraction).
223411316|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
223411317|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
223411318|NCT01568034|DRUG|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
223411319|NCT01568034|DRUG|Placebo|single-dose
223411320|NCT01568034|DRUG|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
223411321|NCT01568034|DRUG|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
223411322|NCT02499367|DRUG|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
223411323|NCT02499367|RADIATION|Radiation therapy|20 Gy to metastatic lesion
223411324|NCT02499367|DRUG|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
223411325|NCT02499367|DRUG|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
223411326|NCT02499367|DRUG|Cisplatin|40 mg/m2, weekly for 2 weeks
223411327|NCT03937895|BIOLOGICAL|'SMT-NK' Inj (allogeneic Natural Killer cell)|In 120 mL, 3x10\^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
223411328|NCT03937895|DRUG|Pembrolizumab Injection [Keytruda]|Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
223411329|NCT02589132|OTHER|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
224028455|NCT06443554|PROCEDURE|Health Management Intervention Program|This study implemented a 12-week eye health management intervention program based on the Protection Motivation Theory (PMT). The intervention included eye health interventions conducted twice weekly at community health service locations.During the health management process, specialist doctors from higher-level comprehensive hospitals provided professional guidance, while community general practitioners took on a leading role. They provided personalized eye health management for patients under the guidance of the PMT theory. The intervention content included group education, individual guidance, experience sharing meetings, and traditional Chinese medicine appropriate technology, among other aspects.
224028456|NCT06443554|PROCEDURE|Standard Treatment|Each week, patients were subjected to standard treatment and follow-up procedures, including basic interventions, medication, and routine follow-up via phone or WeChat, during which general conditions were assessed.
224028457|NCT04697303|OTHER|anorectal function test|anorectal function test
224134652|NCT02076321|DRUG|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
224134653|NCT05622383|OTHER|aromatherapy|aromatherapy,
223411330|NCT04411511|OTHER|Exposure to the Dutch measures due to the Covid-19 pandemic.|Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
223411331|NCT04836273|DRUG|Dasiglucagon|Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
223411332|NCT04836273|DEVICE|HyoPen|multi-dose reusable pen injector
223559251|NCT07080801|DRUG|RAG-21|Intrathecal bolus administration of RAG-21 will be initiated at a dose of 120 mg, prepared with a dedicated solvent into a 10 mL sterile aqueous solution. Dosing will occur every 2 weeks, with the dose escalating to 180 mg after 3 administrations. Subsequently, the dosing interval will be extended to every 4 weeks. The investigator will then select an optimal dose from the completed dose cohorts or continue dose escalation until the maximum tolerated dose (MTD) is reached, with a predefined maximum dose of 210 mg. For continued treatment, the investigator-determined optimal dose will be administered as a fixed dose every 4 weeks, with a total treatment duration of 6 months (8 administrations).
224028458|NCT04388774|DRUG|Ketamine|A single 40-minute intravenous infusion
223411333|NCT04836273|DRUG|Placebo|Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
223411334|NCT06098339|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
223411335|NCT06098339|DEVICE|Lens B (lotrafilcon B)|Daily wear for one month
223559252|NCT07080892|PROCEDURE|distal iPACK|● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.
224028459|NCT00594360|BEHAVIORAL|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
224028460|NCT04421521|PROCEDURE|Acupuncture|Acupuncture with disposable needles will be implemented
224134654|NCT05622383|OTHER|music concert|music concert
224134655|NCT05622383|OTHER|aromatherapy and music concert,|aromatherapy and music concert,
223411336|NCT00013338|PROCEDURE|Ambulation Training|
223411337|NCT05366348|OTHER|Recreational activity|Horse-back riding
223411338|NCT02445157|OTHER|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
223411339|NCT02915757|DEVICE|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
223559253|NCT07080892|PROCEDURE|proximal iPACK|● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
223559254|NCT07081035|DRUG|Warfarin (low-intensity anticoagulation)|"Low-intensity INR group (Experimental):~Participants will receive anticoagulation therapy with warfarin, aiming for a reduced INR range of 1.5-2.0, which is lower than the current standard recommendation. Warfarin dosing will be regularly adjusted based on INR monitoring throughout the 6-month study period."
223411340|NCT03916549|DEVICE|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
223411341|NCT03867136|DRUG|PZA sensitivity guided ultra-short all Oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
223411342|NCT03867136|DRUG|Standardized Shorter Regimen|Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
223411343|NCT04121130|DEVICE|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
223411344|NCT04121130|DEVICE|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
223411345|NCT05624021|OTHER|Scapular functional training|The scapular functional training consists of press up and push up plus. Press up was done in sitting position on the training bench, feet on the floor with straight arm and the palms on the edge of the bench fingers pointing forward and then lift off and dip down just in front of the seat by moving the shoulder girdle. Progression is done by placing weight on the thigh. Push-up plus exercise started from a push up position on the hand, feet or knees and keeping the torso rigid by bracing the abdominals followed by protracting the scapula as high as possible. Progression is done moving from knees to the feet or adding resistance on the upper back. The training continued for three sessions per week for four weeks.
223411346|NCT05624021|OTHER|Cervical isometric exercises|The isometric neck exercises taught to all the participants to perform in neutral sitting positions at home thrice a day for 15-days continuously. The sequences of exercises were shoulder circling in clockwise and anticlockwise direction, scapular retraction with cervical retraction, neck flexion, extension, either side of lateral bending/flexion, left and right rotation. Each exercise follows a set of 10 repetition of maximum voluntary contraction with a progressive hold time of 3, 5, 7, and 10 seconds depending on the severity of pain and tolerance of the participants.
223411347|NCT05624021|OTHER|Moist heating|A hydrocollator moist heat packs was applied over back of the neck in supine position to receive optimal heating. It was given for 20 minutes/day, five-day a week for four-week.
223411348|NCT02492984|DRUG|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
223411349|NCT04128046|PROCEDURE|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
223411350|NCT04128046|PROCEDURE|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
223411351|NCT05939869|OTHER|Medical and Clinical History|Retrospective and prospective analysis of patients data will be done.
223411352|NCT02782117|DEVICE|Luminopia One|Luminopia One is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
223411353|NCT04042389|BEHAVIORAL|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
223411354|NCT04042389|BEHAVIORAL|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
223411355|NCT04042389|BEHAVIORAL|Control|No messages sent.
223411356|NCT04550689|DEVICE|Bone graft|Bone grafts produced by Straumann LLC
223411357|NCT01971775|DEVICE|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
223559255|NCT07081035|DRUG|Warfarin (standard anticoagulation)|"Standard INR group (Active Comparator):~Participants will receive anticoagulation therapy with warfarin, maintaining an INR within the standard therapeutic range of 2.0-3.0. Warfarin dosing adjustments will be made regularly according to standard clinical practice and INR monitoring throughout the 6-month study period."
224028461|NCT01190982|DRUG|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
224028462|NCT00722852|DRUG|ketoprofen in Diractin®|100 mg (b.i.d.)
224028463|NCT00722852|DRUG|Placebo|100 mg (b.i.d.)
224028464|NCT00849277|DRUG|Lactobacillus casei Shirota|
224028465|NCT05466773|BEHAVIORAL|Hemodialysis eating index (HDEI) base education intervention|The investigators have developed the educational materials for patients, in order to improve the dialysis outcomes. The interventions will be delivered to patients and nurses in hospital based hemodialysis centers.
224028466|NCT00008489|DRUG|Didanosine|
224028467|NCT04305080|OTHER|Anodic oxidation|Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid \& Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.
224028468|NCT04305080|OTHER|Untreated abutment|Abutment will be left untreated with its gray color.
224028469|NCT01203748|PROCEDURE|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
224028470|NCT01203748|PROCEDURE|PVI|Pulmonary vein antrum isolation
224298091|NCT06710457|OTHER|ESP|Patients will receive an erector spinae plane (ESP) block in addition to standard medical treatment to prevent PONV and postoperative pain.
224298092|NCT06710457|OTHER|No ESP|Patients will receive standard medical treatment to prevent PONV and postoperative pain.
224134656|NCT04767633|DRUG|split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing|The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
224134657|NCT00305253|DEVICE|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
224134658|NCT02136199|OTHER|Active Implementation of ShareEBM Toolkit|
223411358|NCT01971775|DEVICE|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
224028471|NCT01203748|PROCEDURE|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
224134659|NCT02136199|OTHER|Passive Dissemination of Share EBM|
224298093|NCT03077529|DIETARY_SUPPLEMENT|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
224298094|NCT03077529|DIETARY_SUPPLEMENT|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
224298095|NCT06927518|OTHER|Receptive language intervention by using the total communication|Receptive language intervention using Total Communication (TC) for children with autism can be highly effective. Total Communication involves using a combination of communication methods to support language comprehension and expression. It recognizes that individuals with autism often benefit from multi-modal communication rather than relying solely on spoken language.
224298096|NCT03974412|DIAGNOSTIC_TEST|Head Up Tilt Table (HUT)|"Participant randomized to open-label diagnostic strategy. Results and all follow-up care to be in the hands of treating cardiologist as this is a pragmatic study.~the early HUT \[protocol: supine pre-tilt phase 5 min, un-medicated HUT to 70 degrees for 20 minutes; if response negative then 400 μg of sublingual nitroglycerin and continued 70 degree tilt for 20 minutes\]"
223411359|NCT00243295|DRUG|rhBMP-2/CPM|
223411360|NCT02792894|BEHAVIORAL|Family networks program|Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
224028472|NCT03139357|OTHER|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
224134660|NCT00240552|DRUG|fosamprenavir|
224134661|NCT00240552|DRUG|Telzir®|
224134662|NCT02393573|DRUG|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
224134663|NCT02393573|DRUG|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
224134664|NCT02800473|DEVICE|Strorz (commercial)|
224298097|NCT03974412|DEVICE|Implantable Loop Recorder|ILR is a small subcutaneously implanted device, lasting up to 3 years, that records heart rhythms, and which may be either auto-triggered or patientactivated.
224298098|NCT06702033|RADIATION|Radiation therapy|IMRT or IMPT
224298099|NCT06702033|DRUG|Cisplatin|Dose of 100 mg/m\^2 IVPB over 60 minutes
223411361|NCT05284448|DRUG|pentoxifylline (Trental SR®)|400 mg three times daily
223411362|NCT02258438|BEHAVIORAL|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
223411363|NCT02258438|BEHAVIORAL|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
223559256|NCT07080463|PROCEDURE|vasculens and cta|using vasculens and cta for one group and cta for the second group (control)
224028473|NCT04169230|DRUG|Citalopram|Single dose administration of citalopram (20mg)
224028474|NCT04169230|DRUG|Placebo oral tablet|Single dose administration lactose placebo tablet
224028475|NCT05458557|DIAGNOSTIC_TEST|Rapid Antigen Testing|Community testing for SARS-COV-2 using rapid Antigen test
224028476|NCT02275494|PROCEDURE|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
224134665|NCT02800473|DEVICE|CyPaM2 (experimental)|
224134666|NCT01785810|DRUG|Maraviroc 300 mg|Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
224134667|NCT02819115|BIOLOGICAL|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
224134668|NCT02923752|DEVICE|MRI|Contrast-enhanced MRI
224134669|NCT01750632|PROCEDURE|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
224298100|NCT06702033|PROCEDURE|Surgery|Standard of care
224298101|NCT03801421|PROCEDURE|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
224298102|NCT03801421|PROCEDURE|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
223411364|NCT02258438|BEHAVIORAL|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
223411365|NCT06621290|OTHER|Semi-structured interviews|Semi-structured interviews on ED-patients experiences of frailty assessment with the CFS
223411366|NCT02390102|DRUG|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
223559257|NCT07080489|DEVICE|Active high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/F4|Participants receive anodal HD-tDCS targeting the left or right DLPFC (F3/F4).
224028477|NCT01142596|DRUG|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
224028478|NCT01142596|DRUG|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
224028479|NCT01314820|OTHER|normal saline injection|20 cc normal saline injection into knee joint
223559258|NCT07080489|DEVICE|Sham high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/F4|Participants receive sham HD-tDCS targeting the left or right DLPFC (F3/F4). The device mimics the sensation of stimulation without delivering active current.
223559259|NCT07080489|DEVICE|Active high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/ kathodal F4|Participants receive anodal HD-tDCS targeting the left DLPFC (F3) and cathodal stimulation targeting the right DLPFC (F4).
223559260|NCT07080489|DEVICE|Sham high-definition transcranial direct current stimulation (HD-tDCS) - anodal F3/ kathodal F4|Participants receive sham HD-tDCS targeting the left DLPFC (F3) and right DLPFC (F4). The device mimics the sensation of stimulation without delivering active current.
223559261|NCT07081230|COMBINATION_PRODUCT|SRP with hyaluronic acid|patients will receive hyaluronic acid mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement
223559262|NCT07081230|COMBINATION_PRODUCT|SRP + Injectable Platelet-Rich Fibrin|patients will receive Albumin gel mixed with concentrated growth factors injected into the periodontal pocket after mechanical debridement
224028480|NCT01314820|OTHER|sham injection|no saline injection
224028481|NCT01520493|OTHER|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
224028482|NCT01518933|DRUG|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
224028483|NCT01518933|DRUG|Saline|Placebo
224028484|NCT05514782|OTHER|Cleansing Lotion|Facial cleansing lotion to be used by study participants (morning and evening, 2x daily).
224028485|NCT05514782|OTHER|Facial Moisturizer|Anti-aging facial moisturizer to be used by study participants after anti-aging daily serum before sunscreen.
224028486|NCT05514782|OTHER|Sunscreen SPF 40+|"Sunscreen to be applied after application of the facial moisturizer in the morning. Participants were asked to reapply every 2 hours.~Per FDA this intervention is an Over the counter"
224028487|NCT02388867|PROCEDURE|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
224028488|NCT02388867|PROCEDURE|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
224028489|NCT00045513|DRUG|7-hydroxystaurosporine|
224028490|NCT00045513|DRUG|fludarabine phosphate|
224028491|NCT05344781|OTHER|Questionnaire|Questionnaire regarding relationship and sexual satisfaction
224028492|NCT04600193|OTHER|Diet containing organic phosphate|The patients will be receiving a 5 days diet containing organic phosphate
224028493|NCT04600193|OTHER|Diet containing inorganic phosphate|The patients will be receiving a 5 days diet containing inorganic phosphate
224028494|NCT01248546|PROCEDURE|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
224028495|NCT00652210|OTHER|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
224028496|NCT04535804|DRUG|Aspirin/placebo|By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
223411367|NCT02390102|DRUG|Placebo|Saline solution 0.9%
223411368|NCT05500339|OTHER|M-health App|Pregnant women receive the App designed for the support of the first 1000 days of life
223411369|NCT05500339|OTHER|Standard care|Pregnant women receive standard supportive and educational methods.
223411370|NCT03840395|DEVICE|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
223411371|NCT05172817|DRUG|Advixa (Adalimumab)|Injection Advixa(Adalimumab) 40 mg/ 0.4 ml will be administered subcutaneously to the participants by trained medical personnel. Single dose for phase 2 and biweekly for 3 months for phase 3.
223411372|NCT02776436|DRUG|Dexamethasone|Dose of prophylactic dexamethasone will be reduced for all patients
223411373|NCT02776436|DRUG|Prednisone|standard prednisone 5 mg bid for patients with prostate cancer
224028497|NCT04320394|DIAGNOSTIC_TEST|QuantiFERON Monitor®|The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
224298103|NCT02716350|DIETARY_SUPPLEMENT|B-GOS|comparison versus placebo
224298104|NCT02716350|DIETARY_SUPPLEMENT|Maltodextrin|placebo
224028498|NCT06108960|OTHER|Proprioceptive neuromuscular facilitation|Group A (Proprioceptive neuromuscular facilitation.) will be treated with Proprioceptive neuromuscular facilitation, before applying exercise, Hot pack will be applied for 15 minutes. (8 weeks, 4 sessions per week) The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
224028499|NCT06108960|OTHER|Pelvic stabilization exercises|"Group B (Pelvic stabilization exercises) will be treated with Pelvic Stabilization Exercise, before applying exercise we will apply Hot pack for 15minutes (8 weeks, 3 sessions per week).~All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first be taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks."
224028500|NCT01213160|DRUG|AZD4547|film coated tablet, PO, twice daily
224028501|NCT03050255|OTHER|Medical air|
224028502|NCT03050255|OTHER|Oxygen (2Liter/min)|
224028503|NCT03050255|OTHER|Oxygen (4Liter/min)|
224028504|NCT00956748|DRUG|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
224028505|NCT00956748|DRUG|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
224028506|NCT01907360|DRUG|HLD200 (methylphenidate hydrochloride)|
224028507|NCT05955287|BEHAVIORAL|Telemonitoring|Text messages of encouragement will be sent to patients and partners. No more than 2 messages will be sent per week to prevent respondent fatigue.
223411374|NCT06642142|PROCEDURE|ESP block|"The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure.~Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored."
223411375|NCT00931437|DIETARY_SUPPLEMENT|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
223411376|NCT04821180|PROCEDURE|Three and four-part proximal humeral fractures' treatment|Open Reduction and Internal Fixation with angle stable plate PHILOS versus RSA (Reverse Shoulder Arthroplasty
223411377|NCT06339944|OTHER|sensory motor training|in this group 17 participants will receive conventional therapy and then followed by kinesthetic exercises. 3 sessions per week includes 10 repetitions with 3sets.
223411378|NCT06339944|OTHER|kinesthetic exercises|in this group 17 participants will receive conventional therapy and then followed by kinesthetic exercises. 3 sessions per week includes 10 repetitions with 3sets.
223411379|NCT02498444|DRUG|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
223411380|NCT01224093|DRUG|Chemotherapy|as prescribed
223411381|NCT01224093|DRUG|rituximab [MabThera/Rituxan]|as prescribed
223411382|NCT05950893|PROCEDURE|pressure support level|Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Downward PS level titration was performed from 20 cmH2O to 2 cmH2O at a 2cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O.Inspiratory effort is measured as pressure generated by inspiratory muscles using esophageal pressure monitoring.
223559263|NCT07080827|BEHAVIORAL|TTM-Based Online Psychoeducation Program|A 5-week structured psychoeducation program based on the Transtheoretical Model (TTM), delivered via WhatsApp. Educational content was tailored to the participant's stage of change and included videos, texts, and interactive materials to promote treatment adherence in individuals with psychosis.
224028508|NCT05955287|BEHAVIORAL|Peer Based|Patients and partners will attend OSA virtual support groups led by an African American patient with long-standing OSA and their bed partner. Peer-motivator couples will be trained and certified as competent prior to interacting with study participants. They will share their experiences with managing OSA including coping strategies to maximize CPAP adherence.
224028509|NCT05955287|BEHAVIORAL|CPAP Education|Patients with OSA and their bed partners will participate in two 1-hour video support groups at 2 weeks and 2 months ran by patients with OSA and their bed partners
224028510|NCT05955287|BEHAVIORAL|Usual Care|Participants will receive OSA education and CPAP training from providers trained in OSA management.
224028511|NCT05576194|DEVICE|TauroPace|All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
224028512|NCT05576194|DEVICE|Hydrogen Peroxide|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
224028513|NCT05576194|DRUG|Taurolidine|All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
224028514|NCT03573726|OTHER|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
223411383|NCT06383234|PROCEDURE|LG-TAP block with local anesthetic|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Ropivacaine 0.5% on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
223559264|NCT07080827|BEHAVIORAL|Standard Face-to-Face Psychoeducation Program|A 3-week conventional psychoeducation program delivered face-to-face at the Community Mental Health Center. The program focused on general treatment adherence without utilizing the Transtheoretical Model and included verbal education, printed materials, and discussions.
223559265|NCT07080827|OTHER|TTM-Based Online Psychoeducation Program|The intervention was provided after a 3-month delay following initial observation. Participants received the same 5-week online psychoeducation program as the main intervention group
223559266|NCT07079527|DEVICE|Manual Positive End Expiratory Pressure (PEEP) Therapy|Participants in this group receive Manual Positive End Expiratory Pressure (PEEP) therapy. The intervention is delivered using a tight-fitting mask that applies positive pressure at the end of expiration, helping to keep the alveoli open, enhance oxygenation, and prevent airway collapse. The therapy is administered according to a structured protocol over a 4-week period, aiming to reduce breathlessness, improve lung function, and support ventilation. Along with PEEP, participants also receive baseline Active Cycle of Breathing Techniques (ACBTs) for airway clearance and breathing control.
223559267|NCT07079527|DEVICE|Non-Invasive CPAP Therapy|Participants in this group receive Non-Invasive Continuous Positive Airway Pressure (CPAP) therapy. CPAP provides a constant level of positive pressure throughout the entire breathing cycle using a non-invasive ventilator and a full-face or nasal mask. This therapy improves gas exchange, reduces the work of breathing, and eases symptoms such as dyspnea. Like Group A, CPAP therapy is delivered following a standardized protocol for 4 weeks, and participants also perform baseline ACBTs to support respiratory function.
224028515|NCT02647567|OTHER|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
223411384|NCT06383234|PROCEDURE|LG-TAP block with saline solution|The laparoscopic guided TAP Block was performed by surgeon at the beginning of surgery, injecting 15 ml of Saline solution (NaCl 0.9%) on each side, using an atraumatic needle (10/15 cm length, 20 Gauge diameter) close to the anterior axillary line, between the iliac crest and the subcostal margin. Correct needle tip positioning between the transverse muscle of the abdomen and the internal oblique was verified through laparoscopic guidance.
223559268|NCT07081776|DEVICE|OptiNIV|"Patients assigned to the OptiNIV group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with an optimized mask (OptiNIV) and in the second session they will receive NIV with a traditional oronasal mask (Visairo). The study will follow a crossover design, meaning each patient will undergo both sessions, In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours."
223559269|NCT07081776|DEVICE|Visairo|"Patients assigned to the Visairo group will be submitted to two consecutive 60-minute sessions. In the first session, they will receive NIV with a traditional oronasal mask (Visairo) and in the second session they will receive NIV with an optimized mask (OptiNIV). The study will follow a crossover design, meaning each patient will undergo both sessions. In both sessions, NIV will be delivered using the same ventilator (ASTRAL 150 - ResMed Europe). Ventilator settings will be set to ensure the most effective ventilation and the best comfort for each patient. However, these settings must remain unchanged during the two sessions. A 30-minute washout period is planned between the sessions, during which patients will receive traditional oxygen therapy through a Venturi mask. The 30 min wash-out periodod can be extended until PtCO₂ returns within ±2 mmHg of baseline or until 60 minutes have passed. The maximum total treatment time for each patient will be approximately 3 hours."
224028516|NCT02647567|OTHER|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
224028517|NCT00398645|DRUG|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
224028518|NCT05399420|DIAGNOSTIC_TEST|Blood sampling|One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes
224134670|NCT03140995|BEHAVIORAL|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
224134671|NCT04289246|DEVICE|Medication Ambient Display (MAD)|"MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken."
224134672|NCT03429816|PROCEDURE|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
224134673|NCT02310139|PROCEDURE|Colonoscopy|
223411385|NCT06383234|PROCEDURE|Port site infiltration|Prior the surgical incision, an infiltration of the laparoscopic access using a total of 10 ml Ropivacaine 0.5% was performed by surgeon
224028519|NCT03329560|BIOLOGICAL|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
223411386|NCT00717834|BIOLOGICAL|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
223411387|NCT04566003|DRUG|[18F]GTP1|Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.
224028520|NCT01822288|DRUG|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
224028521|NCT01822288|DRUG|Estradiol & medroxyprogesterone acetate|Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
224028522|NCT02636179|OTHER|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
224028523|NCT05331963|OTHER|Kinesio Taping|Kinesio tape is designed in a specific way that it mimics the human skin nature. It more or less has the same width as the epidermis layer and can be stretched upto 40% of its resting length.Clinically, kinesio tape (KT) is used both alone and with other physiotherapeutic interventions, mainly for the pain control, to reduce inflammation, and to improve functional activity in patients with shoulder pain
224028524|NCT01173406|BEHAVIORAL|CPAP education|Standard CPAP education plus an session and one telephone follow up
224028525|NCT00585195|DRUG|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
224134674|NCT04050098|DRUG|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
224134675|NCT04050098|DRUG|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
224134676|NCT02379754|DRUG|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
224134677|NCT05624684|DIAGNOSTIC_TEST|Multiplex respiratory PCR|The BIOFIRE® FILMARRAY® Pneumonia plus Panel
224134678|NCT04081597|DRUG|Star-101|Administered orally
224134679|NCT04081597|DRUG|Placebo|Administered orally
223411388|NCT04566003|DRUG|[18F]PI-2620|Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.
224028526|NCT00585195|DRUG|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
224028527|NCT00585195|DRUG|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
224028528|NCT02006953|PROCEDURE|Bolus feeding schedule following gastrostomy tube placement|
224134680|NCT01019486|DRUG|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
224134681|NCT01019486|DRUG|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
224134682|NCT03440853|BEHAVIORAL|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
224134683|NCT03440853|OTHER|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
224134684|NCT03226132|BEHAVIORAL|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
223411389|NCT04566003|DRUG|[18F]MK-6240|Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
223411390|NCT02797457|PROCEDURE|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
223411391|NCT02797457|PROCEDURE|Prosthetic forehands|Prosthetic forehands
224028529|NCT02006953|PROCEDURE|Continuous chimney feeds following gastrostomy tube placement|
224028530|NCT01523925|BEHAVIORAL|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
224134685|NCT03226132|BEHAVIORAL|Repeated Contact|Repeated Contact
224134686|NCT01351402|PROCEDURE|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
224134687|NCT04021394|DIAGNOSTIC_TEST|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
224134688|NCT04021394|DIAGNOSTIC_TEST|Parsortix CTC platform|EMT-independent platform
224134689|NCT02705508|DRUG|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
224134690|NCT02705508|DRUG|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
224134691|NCT02705508|DRUG|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
224298105|NCT00885014|BEHAVIORAL|CBT|Telephone cognitive-behavioral therapy
223411392|NCT02027545|BEHAVIORAL|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
223411393|NCT02027545|BEHAVIORAL|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
224028531|NCT01523925|BEHAVIORAL|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
224028532|NCT01523925|BEHAVIORAL|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
224028533|NCT01523925|BEHAVIORAL|Functional electrical stimulation|
224028534|NCT03322072|DEVICE|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
224028535|NCT02796560|DRUG|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
224028536|NCT02796560|DRUG|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
224028537|NCT05146687|OTHER|Aflibercept|intravitreal injection
224028538|NCT05146687|OTHER|Ranibizumab|intravitreal injection
224028539|NCT05146687|OTHER|Bevacizumab|intravitreal injection
224028540|NCT02533570|DRUG|Brentuximab vedotin|
224028541|NCT02533570|DRUG|Placebo|
224028542|NCT03995667|OTHER|Questionnaire Administration|Ancillary studies
224028543|NCT03995667|DEVICE|Tumor Treating Fields Therapy|Optune-Tumor Treating Fields (TTFields). Transducer arrays affixed to scalp, worn continuously.
224134692|NCT02705508|RADIATION|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
224134693|NCT00003450|BIOLOGICAL|Ad5CMV-p53 gene|
224134694|NCT05843110|OTHER|Decision-making process|Retrospective evaluation using scales, questionnaires and a semi-structured interview
224134695|NCT03633227|DRUG|Obeticholic Acid (OCA)|OCA will be administered per dose and schedule specified in the arm description.
223411394|NCT02027545|BEHAVIORAL|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
223411395|NCT02027545|BEHAVIORAL|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
223411396|NCT03777592|PROCEDURE|erector spinae plane block|local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
223411397|NCT04713839|OTHER|no intervention|We didn't have an intervention program, we used two questionnaires to evaluate participants.
224028544|NCT03020654|OTHER|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
224134696|NCT03633227|DRUG|Placebo|OCA matching placebo will be administered per the schedule specified in the arm description.
224134697|NCT01276665|PROCEDURE|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
224134698|NCT01276665|PROCEDURE|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
224134699|NCT03965832|DEVICE|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
224134700|NCT03965832|DEVICE|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
224134701|NCT01419483|DIETARY_SUPPLEMENT|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
224134702|NCT00348634|DRUG|Tegaserod|
224134703|NCT04419285|BEHAVIORAL|Locomotion task|The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
224298106|NCT00885014|BEHAVIORAL|EAP|Employees Assistance Program
224028545|NCT03020654|OTHER|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
223411398|NCT04037163|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
223411399|NCT06389903|BEHAVIORAL|assessment|post-surgery behavioral assessment using scales
223411400|NCT04998617|OTHER|Toothpaste with curcumin|Subjects will be given toothpaste to be used during this study with 0.5% curcumin
223411401|NCT04998617|OTHER|Toothpaste without curcumin|Subjects will be given toothpaste to be used during this study without curcumin
223411402|NCT05359419|COMBINATION_PRODUCT|aminolevulinic acid hydrochloride gel, 10%|10% ALA with Red Light
223411403|NCT05359419|COMBINATION_PRODUCT|aminolevulinic acid HCl topical solution, 20%|20% ALA with Blue Light
223411404|NCT02453334|DRUG|Injectafer|
223411405|NCT02453334|OTHER|Normal Saline|
223411406|NCT02772172|DEVICE|Surgical Template|
223411407|NCT03710473|DIAGNOSTIC_TEST|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
223559270|NCT07081048|OTHER|Buzzy®.Group|The ice pack, which has been removed from the deep freezer in advance, should be left at room temperature for 10 minutes, and the hole in the ice pack should be placed on the hook behind the Buzzy® will be placed on the lateral side of the left heel and activated for 30 seconds. After 30 seconds, Buzzy® will be pulled up 1 centimetre (cm), and the heel will be punctured with a sterile lancet to collect blood on the Guthrie card. After the heel blood collection procedure, Buzzy® will be pulled back to the punctured heel area and left for another 30 seconds.
223559271|NCT07081048|OTHER|ShotBlocker Group|"ShotBlocker will be placed on the designated area for collecting the baby's heel blood. After ensuring that the protrusions of the ShotBlocker are in contact, pressure will be applied for 20 seconds.~The heel will be punctured with a sterile lancet in the area designed for applying the ShotBlocker, and the ShotBlocker will be removed from the area. The blood collected will be collected on Guthrie paper."
224028546|NCT05132283|DEVICE|3D Slicer|Navigational device used during surgery to locate abnormal lymph nodes.
223411408|NCT00693498|BIOLOGICAL|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
223411409|NCT00693498|BIOLOGICAL|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
223411410|NCT02452632|DRUG|ASP1941|oral
223411411|NCT02452632|DRUG|Placebo|oral
223411412|NCT04128969|DIETARY_SUPPLEMENT|CS+|Oral carnitine supplementation
223411413|NCT04128969|DIETARY_SUPPLEMENT|CS-|Placebo
223411414|NCT00950443|DEVICE|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
223411415|NCT00950443|DEVICE|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
224028547|NCT05132283|DEVICE|Monaco|Navigational device used during surgery to locate abnormal lymph nodes.
223411416|NCT06960603|OTHER|Full pulpotomy|First: Cutting the coronal pulp tissue to the level of the root canal orifices. Second: Followed by taking samples of the pulpal blood Third: Placement of calcium silicate material capping over the pulp
223411417|NCT06622876|DIAGNOSTIC_TEST|Computed tomography exam of the chest|Computed tomography exam of the chest done for other indications other than pulmonary emboli, in which incidental pulmonary embolism was detected.
223411418|NCT02594553|BEHAVIORAL|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
223411419|NCT03357068|PROCEDURE|Control|Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
223411420|NCT03357068|PROCEDURE|Acid|Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
223411421|NCT06393309|DRUG|Levetiracetam|Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam
223411422|NCT06393309|DRUG|Sodium valproate|Patients with idiopathic generalized epilepsy who were under treatment with valproate
223411423|NCT02617160|DEVICE|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
223559272|NCT07079891|OTHER|MINS|MINS
223559273|NCT07081919|PROCEDURE|femtosecond laser-assisted arcuate keratotomy (FSAK) combined with standard cataract surgery|"1. 5-year follow-up assessing stability of astigmatism correction. Most FSAK studies track ≤2 years. This addresses critical evidence gaps in durability~2. Combines topographic data with patient-reported visual function (VF-14/QoV questionnaires at all visits. Links anatomical changes to real-world visual experiences"
223559274|NCT07081113|OTHER|Cyriax Mobilization|Deep transverse friction massage applied to the wrist and forearm muscles, 3 sessions/week for 4 weeks, along with TENS and hot packs.
224028548|NCT05969054|DRUG|Lacosamide 100 mg|Subjects who were randomly divided into group A took lacosamide for 6 months during treatment (initial dose was 50mg bid, maintained for one week and then increased to 100mg bid and maintained at this dose)
224134704|NCT04419285|BEHAVIORAL|Posturology task SOT (Sensory Organization Test)|The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
224134705|NCT04419285|BEHAVIORAL|The quality of life questionnaire|Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
223411424|NCT02617160|OTHER|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
223411425|NCT04090060|BEHAVIORAL|Practice Self-/Companion Exams|300 men and 50 couples will be randomized and encouraged to practice anal exams at home before Visit 2. Practice results will be elicited by staff. They will return for Visit 2 (six months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam at home, they will record the results. At the clinic, they will have a Digital Anal Rectal Exam (DARE) by a clinician who will give the subject his results.
224028549|NCT05969054|DRUG|Levetiracetam 250mg|Subjects randomly divided into group B took levetiracetam for 6 months during treatment (initial dose was 250mg bid, maintained for one week and then increased to 500mg bid and maintained at this dose).
224028550|NCT01594008|OTHER|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
223411426|NCT04090060|BEHAVIORAL|Control Arm|300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (six months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam at home, and record the results. At the clinic, they will receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
223411427|NCT01508091|BEHAVIORAL|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
223411428|NCT01508091|BEHAVIORAL|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
223411429|NCT04722068|OTHER|Kinetics test|Subjects will participate in two study visits to evaluate lipoprotein kinetics before and after administration of evinacumab.
223411430|NCT02074358|DRUG|Apixaban|
223411431|NCT02074358|DRUG|Cofact (4-Factor PCC)|
223411432|NCT02074358|DRUG|Beriplex P/N (4-Factor PCC)|
223411433|NCT02074358|DRUG|Placebo (Saline solution)|
223411434|NCT00108017|DRUG|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
224028551|NCT01594008|OTHER|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
224134706|NCT05683652|DEVICE|TRAINING BOOKLET|Cancer patients in the intervention group, who will receive immunotherapy for the first time, will be given face-to-face training with the prepared training booklet and followed up by phone. Patients who received immunotherapy after the 1st, 2nd and 3rd cycles, respectively, will be called by phone. The researcher's phone number will be given to the intervention group patients and they will be told that they can call 24/7 if they experience any symptoms. The telephone interview form created by the researcher will be used during the monitoring by telephone.
224134707|NCT01655823|DRUG|Placebo|Sham treatment acting as control arm
224134708|NCT01655823|DRUG|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
223411435|NCT00108017|DRUG|Comparator: timolol maleate|
223411436|NCT00108017|DRUG|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
223411437|NCT00108017|DRUG|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
223411438|NCT03950414|BIOLOGICAL|CMV specific T-cells|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~* Low Dose Tier - Viral-Specific T cell infusion 5 x10\^3 cells/kg body weight(BW)~* Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10\^4 cells/kg BW~* High Dose Tier - Viral-Specific T cell infusion 2.5 x10\^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection."
223559275|NCT07081113|OTHER|Muscle Energy Technique (MET)|Isometric contractions performed against therapist resistance to improve range of motion and reduce pain, 3 sessions/week for 4 weeks.
223559276|NCT07079852|DRUG|Placebo|This is an inactive control condition.
224028552|NCT01594008|OTHER|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
224028553|NCT01828788|DRUG|Ropivacaine|
224028554|NCT01828788|DRUG|placebo|
224028555|NCT02913534|RADIATION|whole brain radiotherapy|
224028556|NCT00515983|BIOLOGICAL|DC/Apo-Nec|
224028557|NCT02601651|DRUG|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
224028558|NCT02601651|DRUG|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
224028559|NCT04886453|DRUG|Balanced general anesthesia without morphine|Balanced general anesthesia without morphine
224028560|NCT04886453|DRUG|Standard general anesthesia balanced with morphine|Standard general anesthesia balanced with morphine
224028561|NCT04886453|OTHER|Data collection|Data collection
224028562|NCT04886453|OTHER|Assessment of pain|visual analog scale
224134709|NCT04539249|DRUG|Magnesium sulphate|"1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
224134710|NCT04539249|DRUG|Pentazocine|"Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section."
224028563|NCT04886453|OTHER|Recovery quality score|QoR15 questionnaire
224028564|NCT04978142|DEVICE|transcranial Direct Current Stimulation (tDCS)|Non-invasive neuromodulation employing a direct current, applied using a DC STIMULATOR PLUS manufactured by NeuroConn Technology by NeuroCare. This is a micro-processor-controlled constant current source. It meets the highest safety standards thanks to (hardware- and software-based) multistage monitoring of the current path. By continuously monitoring electrode impedance it can detect insufficient contact with the skin and automatically terminate stimulation. This is a reliable method of avoiding any injury to the patient.
224028565|NCT00046397|DRUG|Modified Vaccinia Virus Ankara TBC-M|
224028566|NCT03679806|OTHER|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
224028567|NCT03679806|OTHER|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
224028568|NCT00348023|DRUG|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
224028569|NCT05004571|DRUG|EQU-001|EQU-001 in 10 and 20 mg capsules
224028570|NCT05004571|DRUG|Placebo|Matched placebo
224028571|NCT00000201|DRUG|Selegiline|
224028572|NCT02632032|DRUG|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice"
224028573|NCT00226343|DRUG|Depakote-ER|
224028574|NCT05765162|BEHAVIORAL|Patient reported ourcomes|Full screening for the perioperative periode
224028575|NCT03408561|OTHER|Internet-Based Intervention|Receive message via Twitter
224028576|NCT03408561|OTHER|Survey Administration|Ancillary studies
224028577|NCT00437541|DEVICE|Insulation retrofitted into house|
223559277|NCT07079852|DRUG|Psilocybin 15mg|This is a moderate psychoactive dose.
224028578|NCT04007341|DRUG|Dexmedetomidine|The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
224028579|NCT00287703|DEVICE|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
224028580|NCT00287703|DEVICE|Pulsating Electro-Magnetic Fields sham|sham PEMF
224028581|NCT00820196|DRUG|Nexagon®|
224028582|NCT00820196|DRUG|Nexagon® vehicle|
224028583|NCT04002401|BIOLOGICAL|Axicabtagene Ciloleucel|A single infusion of CAR-transduced autologous T cells administered intravenously
224028584|NCT04002401|DRUG|Rituximab|Administered intravenously
223411439|NCT03337113|OTHER|Working Memory Training|The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
223411440|NCT03337113|OTHER|Sham Working Memory Training|In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
224028585|NCT04002401|DRUG|Fludarabine|Administered according to package insert
224028586|NCT04002401|DRUG|Cyclophosphamide|Administered according to package insert
224028587|NCT00423930|BIOLOGICAL|bevacizumab|
224028588|NCT00423930|DRUG|cisplatin|
224028589|NCT00423930|PROCEDURE|conventional surgery|
224028590|NCT00423930|RADIATION|intensity-modulated radiation therapy|
224028591|NCT04642872|OTHER|Infant BIT|Not use of unaffected hand containment. Both hand are use to improve the bimanual coordination
224028592|NCT04642872|OTHER|Infant CIMT/BIT|Use unaffected hand containment in part of the intervention and then, both hands in bimanual activities without containment.
224028593|NCT04642872|OTHER|Conventional therapy|Following the usual therapy in the baby.
224028594|NCT04642872|OTHER|infant cimt|use of unaffected hand containment to improve the use of affected hand with unimanual activities
224028595|NCT00155935|PROCEDURE|venous puncture|
224028596|NCT06390878|OTHER|Biodiversity|In rewilding kindergartens, the yards are modified with biological elements, i.e., vegetation and plantation will be added to the yards.
224028597|NCT06390878|OTHER|Playground equipment|Playground equipment that increase the physical activity of children will be added to the kindergarten yards.
224028598|NCT06397677|GENETIC|Research Testing Performed (Laboratory)|Blood collection (DNA, RNA)
224028599|NCT06397677|DIAGNOSTIC_TEST|Information Collected as Standard of Care|High Resolution CT Scan (Chest), Pulmonary Function Testing (PFT), 6-Minute Walk Test (6MWT)
224028600|NCT06397677|OTHER|Research Testing Performed|Blood collection (non-genetic), Buccal Swab, Rheumatologic Assessment, Pulmonary Assessment, Questionnaires
224028601|NCT00623701|BIOLOGICAL|Allerslit forte|sublingual placebo preparation, daily
224028602|NCT00623701|BIOLOGICAL|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
224028603|NCT03696823|PROCEDURE|laparoscopic cholecystectomy|treatment of chronic calcular cholecystitis laparoscopically
224134711|NCT04798885|BEHAVIORAL|GAIN 2.0|1\) three structured group sessions of two hours duration performed jointly by a neuropsychologist, an occupational therapist and a physiotherapist. Relatives are also invited. 2) Up to five weekly semi-structured individual sessions of 30 min. duration with an allocated therapist
224134712|NCT02462304|PROCEDURE|End-Point-Management grid laser|
224028604|NCT04598503|OTHER|full history and clinical examination|For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) \[10\]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
223411441|NCT03337113|DEVICE|repetitive Transcranial Magnetic Stimulation|"The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application."
223411442|NCT03337113|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.
223411443|NCT01164579|DRUG|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
223411444|NCT01164579|DRUG|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
223411445|NCT01164579|DRUG|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
223411446|NCT06534853|OTHER|Post Facilitation Stretch|"The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times."
223411447|NCT06534853|OTHER|Reciprocal Inhibition|"The patient is placed in the lateral decubitus position with the affected side up and a Dutchman's roll or pillow under the iliac crest. Positioned at the edge of the table, the patient's inferior leg is flexed with the foot at the table's edge. The patient grasps the headpiece of the table with the superior hand, allowing the superior leg to drop off the back of the table.The therapist stands behind the patient, providing support to prevent posterior pelvic rotation with their thigh behind the pelvis. The cephalad hand grasps the top of the iliac crest and applies a caudad force, while the caudad hand gently guides the affected leg without generating force.The patient hikes the hip against the resistance from the therapist's cephalad hand, creating an isometric contraction for 5-10 seconds. The patient then relaxes, followed by a rapid stretch held for 10 seconds until the next barrier is reached. This procedure is repeated 3-5 times."
223411448|NCT06534853|OTHER|Conventional Physical Therapy|"A comprehensive therapeutic regimen that includes a 10-minute session of hot pack therapy specifically targeted at the low back region. In addition to this, participants will receive trigger point release therapy to alleviate muscle tension.The treatment plan also incorporates a tailored exercise protocol designed to enhance back health and strength. This protocol includes:~1. Back isometric exercises~2. Bridging exercises~3. Cat and camel stretches~4. Prone press-ups~5. Abductor strengthening exercises"
223411449|NCT02927951|DRUG|Pregabalin|150mg bid
223411450|NCT02927951|DRUG|Placebo|150mg bid
223411451|NCT02165917|PROCEDURE|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
223411452|NCT02165917|PROCEDURE|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
223411453|NCT06092788|DRUG|NTP42:KVA4 Capsule|Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule
223411454|NCT06092788|DRUG|NTP42:KVA4 Liquid|Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid
224028605|NCT05628168|OTHER|Neurodynamic Mobilization Techniques|The slider neurodynamic technique for the median nerve is conducted.Tensioner neurodynamic technique for the tibial nerve is conducted.
224028606|NCT05628168|OTHER|Selected Physical Therapy Program|The participants only received a selected therapy program similar to the NMG with no change in duration.
224028607|NCT00080093|BEHAVIORAL|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
224028608|NCT00080093|BEHAVIORAL|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
224028609|NCT01637181|PROCEDURE|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
223411455|NCT00433394|PROCEDURE|cancer prevention intervention|
223411456|NCT00433394|PROCEDURE|educational intervention|
224028610|NCT02461329|DRUG|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
223411457|NCT03681548|DRUG|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
223411458|NCT02535767|DRUG|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
223411459|NCT01602211|OTHER|Internet-Based Intervention|Receive full access to INSPIRE
224134713|NCT02462304|DRUG|ranibizumab|
223411460|NCT01602211|OTHER|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
223411461|NCT01602211|OTHER|Medical Chart Review|Ancillary studies
223411462|NCT01602211|OTHER|Quality-of-Life Assessment|Ancillary studies
223411463|NCT01602211|OTHER|Questionnaire Administration|Ancillary studies
223411464|NCT00302328|PROCEDURE|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
223411465|NCT04267679|DRUG|Cannabidiol|25 mg full-spectrum CBD soft gel capsules
223411466|NCT04335851|OTHER|Video based aerobic exercise|"During social isolation induced by COVID-19, physically inactive people will do exercise in company with aerobic exercises named videoswalk at home which made by American Heart Association. 3 days a week in total 4 weeks. Each sessions will last approximately 30-40 minutes."
223411467|NCT02464163|BIOLOGICAL|Panblok|Intramuscular injection
223411468|NCT02464163|BIOLOGICAL|rHA adjuvant|Intramuscular injection
223411469|NCT05992142|DRUG|5-ASA|Assessment of the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, who report to be in clinical remission during a routine follow-up visit
223411470|NCT05732571|OTHER|Breathing techniques over 12 sessions / 6 weeks inc yoga|as above
223411471|NCT00406341|DRUG|Difluprednate Ophthalmic Emulsion|
223411472|NCT01601119|DRUG|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
223411473|NCT01601119|OTHER|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
223411474|NCT01535521|DEVICE|Sleep Position Trainer (SPT)|
223411475|NCT03347305|BEHAVIORAL|automated DP|Energy expenditure measurement
223411476|NCT03347305|BEHAVIORAL|Calorimetric chamber|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
223411477|NCT03491462|DRUG|Arimoclomol|2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
223411478|NCT03491462|DRUG|Placebo|2 matched placebo capsules taken 3 times daily
223411479|NCT01800929|DEVICE|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
224028611|NCT02461329|DRUG|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
224028612|NCT00372645|DIETARY_SUPPLEMENT|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
224028613|NCT00372645|DIETARY_SUPPLEMENT|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
224028614|NCT00372645|DRUG|Placebo|Placebo
224028615|NCT00372645|OTHER|Folate rich foods|200 µg folate per day from folate-rich foods
224028616|NCT01622114|OTHER|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
223411480|NCT02645474|PROCEDURE|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
223411481|NCT02645474|PROCEDURE|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
223411482|NCT02645474|DRUG|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
223411483|NCT02262520|DRUG|Apixaban|
223411484|NCT02262520|DRUG|Digoxin|
224028617|NCT02659800|OTHER|Laboratory Biomarker Analysis|Correlative studies
224028618|NCT02659800|BIOLOGICAL|NT-I7|Given IM
224028619|NCT02659800|OTHER|Placebo|Given IM
224134714|NCT02462304|DRUG|Bevacizumab|
223411485|NCT03084120|OTHER|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
223411486|NCT03084120|OTHER|Retrieval of umbilical cord blood.|-During childbirth
223411487|NCT03084120|OTHER|Retrieval of placenta.|-During childbirth
223411488|NCT03084120|OTHER|Collection of newborn's and mother's lock of hair.|-During childbirth
223411489|NCT03084120|OTHER|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
223411490|NCT03084120|OTHER|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
223411491|NCT02309762|DRUG|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
223411492|NCT02309762|DRUG|Placebo|Solution containing no active ingredients
223411493|NCT03371862|DRUG|Liraglutide Pen Injector [Victoza]|Pilot study of liraglutide in patients with short bowel.
223411494|NCT01591057|DIETARY_SUPPLEMENT|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
223411495|NCT01591057|DIETARY_SUPPLEMENT|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
223411496|NCT01591057|DIETARY_SUPPLEMENT|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
224028620|NCT02217579|DIETARY_SUPPLEMENT|Protein|A food containing 5 grams/serving of supplemental protein.
224028621|NCT02217579|DIETARY_SUPPLEMENT|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
224028622|NCT02217579|DIETARY_SUPPLEMENT|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
224028623|NCT02217579|DIETARY_SUPPLEMENT|Control|An isocaloric food not containing the test protein and fiber.
224028624|NCT06297759|OTHER|Questionnaire|Sense of Competence in Dementia Care Staff (SCIDS) Scale
224028625|NCT02938091|OTHER|High-fat diet|Typical Western diet
224028626|NCT02938091|OTHER|Low-fat diet|Traditional Caribbean Hispanic diet
224028627|NCT02369640|PROCEDURE|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
224028628|NCT00143676|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
224028629|NCT00143676|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
224028630|NCT00143676|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
224028631|NCT03306017|OTHER|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
224028632|NCT00002291|DRUG|Pentamidine isethionate|
224028633|NCT01459900|PROCEDURE|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
224028634|NCT01459900|PROCEDURE|Renal angiography|Renal angiography by femoral access.
224028635|NCT05867563|DRUG|TQB2103 for injection|TQB2103 for injection is an antibody-drug conjugate targeting CLDN18.2. The drug structure mainly includes anti-humanized CLDN 18.2 antibody, linker and cytotoxic DDDXD, with Drug antibody Ratio (DAR) of 8.
224134715|NCT05300100|BEHAVIORAL|sensorimotor activities|"The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~* Trial 1 : Straightening: passage from sitting to sitting.~* Trial 2 : Movement with difficulty of balance: heel-toe walking~* Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~* Trial 4 : Move to a target, 5 m away~* Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~* Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. ."
224134716|NCT00187837|PROCEDURE|SW|Stepwise removal of carious tissue in 2 stages
224134717|NCT00187837|PROCEDURE|DCE|one complete excavation
224134718|NCT04799405|DEVICE|tDCS|"Daily sessions (28 daily sessions): The device will be used to apply 30 minutes of tDCS to the participant with MDD's scalp in each of 28 daily sessions.~Thereafter, participants with MDD will undergo a taper phase of an additional 9 sessions of tDCS applied in progressively decreasing frequency until day #60 of the study as follows:~1. First taper phase: three 30 minutes tDCS sessions applied every other day;~2. Second taper phase: three 30 minutes tDCS sessions applied one every third day;~3. Third and final taper phase: three final 30 minutes tDCS sessions applied one every fourth day."
224134719|NCT05430451|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
224134720|NCT05430451|BEHAVIORAL|Referral card|The content consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information, and strong supporting messages or slogans.
224134721|NCT05430451|BEHAVIORAL|Self-help smoking cessation booklet|The contents include information about the benefits of quitting, smoking and diseases, methods to quit, how to handle withdrawal symptoms, declaration of quitting, etc.
224134722|NCT05430451|BEHAVIORAL|Simple physical exercise training|The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises, and c) resistance exercises. Participants will receive handgrips and elastic bands, and trained smoking cessation ambassadors will demonstrate and encourage the use of handgrip and elastic bands onsite with an instruction leaflet.
224134723|NCT05430451|BEHAVIORAL|Simple physical exercises with instant messaging support|During the 3-month instant messaging support, smoking cessation counselors will deliver regular messages to encourage the practices of simple physical exercise, provide strategies for managing craving and withdrawal symptoms, and provide information on smoking-related knowledge and available smoking cessation services. Our trained smoking cessation counselors will also provide real-time support upon participants' inquiries.
224134724|NCT05430451|BEHAVIORAL|SMS|SMS on follow-up survey reminders
224134725|NCT04612062|DRUG|CEE321|CEE321 administered to all subjects
224134726|NCT04975971|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
224134727|NCT03483506|DRUG|BI 1467335|Film-coated tablet
224134728|NCT03483506|DRUG|BI 1467335 (C-14) intravenous solution|Intravenous solution
224134729|NCT02849912|OTHER|questionnaire|
224134730|NCT05381376|DIAGNOSTIC_TEST|Hysteroscopy|Hysteroscopy for CSGE, AFS, and endometrial receptivity assessment
224134731|NCT05381376|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography for Uterus size and endometrial thickness
224134732|NCT00002157|DRUG|Thalidomide|
224134733|NCT04496596|DRUG|Suramin|Suramin is administered via IV infusion as a single dose of 3 mg/kg
224134734|NCT04496596|DRUG|Placebo|Placebo
223559278|NCT07080736|BEHAVIORAL|E-learning|"The training consists of an e-learning module created on the RISE - Articulate platform, and is based on previously developed e-learning modules (SP-reflex) and physical training aimed at other target groups, but was adapted to the specific context of detention.~This specific training will consist of sensitising information, theoretical knowledge, as well as some concrete tools and tips for suicide prevention within detention. Relevant examples and cases will be discussed. The following topics, among others, will be discussed:~* How common is suicide?~* What myths exist about suicide?~* Why do people contemplate suicide?~* What is the process from suicidal thoughts to suicide?~* How do I recognise signs of suicidal thoughts?~* What can I do if I notice signs?~* What if someone attempts suicide or a suicide occurs?~* How do I take care of myself?"
223411497|NCT05560269|BEHAVIORAL|Verbal coaching vs. Constraint based coaching|"* 15 repetitions of kettlebell swings using verbal cues and physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues and physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using verbal cues to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using verbal cues to combine both parts of the movement → 30 seconds to 1 minute rest interval~* 15 repetitions of kettlebell swings using physical constraints to teach the second part of the movement → 30 seconds to 1 minute rest interval→ 15 repetitions of kettlebell swings using physical constraints to combine both parts of the movement → 30 seconds to 1 minute rest interval"
223411498|NCT00649922|BIOLOGICAL|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
223411499|NCT00649922|BIOLOGICAL|placebo|2 injections Day 1, 1 injection Days 15 and 29
223411500|NCT00649922|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
223411501|NCT02407925|BEHAVIORAL|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
223411502|NCT03596112|OTHER|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
223411503|NCT03596112|OTHER|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
223411504|NCT00601939|BEHAVIORAL|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
223559279|NCT07080437|DRUG|Immunotherapy Therapy|"Patients will receive concurrent chemoradiotherapy (CCRT) combined with immunotherapy. The treatment includes:~Radiotherapy: Individualized radiotherapy targeting the tumor. Concurrent Chemotherapy: Platinum-based doublet chemotherapy (e.g., cisplatin + fluorouracil or S-1) administered during radiotherapy.~Immunotherapy: PD-1 inhibitor (e.g., tislelizumab) used to enhance the immune response against cancer cells.~The treatment will be tailored to each patient's condition, with regular follow-up assessments every 3 months for up to 2 years to monitor efficacy and safety."
223559280|NCT07081685|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|robot-guided high-frequency rTMS treatment (10hz - 5 sessions) of the primary motor cortex
223559281|NCT07081685|DEVICE|sham repetitive Magnetic Transcranial Stimulation (rTMS)|sham robot-guided high-frequency rTMS treatment (10hz - 5 sessions) of the primary motor cortex
223559282|NCT07079696|DRUG|ATRA|"Treatment Phase (Duration: 18 months) Intervention: ATRA oral administration using a stepwise titration protocol (detailed below). Patients may discontinue treatment if intolerable adverse events occur; post-withdrawal symptom exacerbation is monitored.~\*Titration Protocol\*~Treatment Cycle (C): 3 weeks per cycle. Dose escalation follows:~Cycle Dosage Duration C1.1 15 mg/m²/day 2 weeks on / 1 week off C1.2 20 mg/m²/day 2 weeks on / 1 week off C1.3 25 mg/m²/day 2 weeks on / 1 week off Blinded Assessments: primary endpoints: ADOS-2 SA score, CARS, SRS, ATEC, Gesell, and Sensory Motor (SM) scales.~Biomarker/Diagnostic tests: blood tests (CBC, liver/kidney function, vitamin panels, ATRA levels, hepatitis markers), neuroimaging (cranial fMRI), neurophysiology (EEG, audiometry), skeletal imaging (limb long-bone radiographs, growth monitoring), and biobanking: 1 blood tube for proteomics (baseline, 6/12/18 months). Repeat all assessments at 6, 12, and 18 months after ATRA treatment."
224028636|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
224028637|NCT01175954|DRUG|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
224134735|NCT02010216|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
224134736|NCT06553196|BEHAVIORAL|MATAspire Web-app|Substance misuse prevention education and adaptive coping skills
224134737|NCT01717664|DRUG|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
224134738|NCT01999413|DRUG|OMEGAVEN|AML Study treatment induction phase
223411505|NCT00601939|BEHAVIORAL|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
223411506|NCT03244930|DRUG|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
223411507|NCT05648422|DIETARY_SUPPLEMENT|Probiotics|Saccharomyces Boulardii 200 mg every 12 hours for 6 days at week 1, 5 and 9
223411508|NCT05648422|DIETARY_SUPPLEMENT|NSS Nutritional Support System|Nutritional Support System consists in NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, glycine, tryptophan, and inuline) every 12 hours for 12 weeks.
223411509|NCT05648422|DRUG|Deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days
224134739|NCT01999413|DRUG|Daunorubicin|AML Study treatment induction phase
224134740|NCT01999413|DRUG|Cytarabine|AML Study treatment induction phase
223411510|NCT05648422|OTHER|Specific diet|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of smoothies at breakfast and dinner, high consumption of fish, five meals during the day, 70% of meals eaten during the day will consist on vegetables, fruits, roots, cereals, and legumes. Red meat, gluten, lactose, junk food, sugar, salt, fast food free.
223411511|NCT05648422|OTHER|Conventional diet (WHO)|This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of general nutricional recommendations.
223411512|NCT01288196|DRUG|Placebo IV|A single 30-minute IV infusion of placebo
223411513|NCT01288196|DRUG|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
223559283|NCT00258908|BIOLOGICAL|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
223559284|NCT07080541|OTHER|Physical literacy and life satisfaction|Participants in the technology experimental group will engage in physical activity in nature while being exposed to information pills on physical literacy and the importance of physical activity in health to improve quality of life and life satisfaction via social media
223559285|NCT07080541|OTHER|Analogic information|Participants in the analogic experimental group will engage in physical activity in nature while being exposed to information pills on physical literacy and the importance of physical activity in health to improve quality of life and life satisfaction via paper sheets.
223559286|NCT07079943|OTHER|Self-questionnaire : satisfaction and quality of life|Patient satisfaction and quality of life outcomes assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
223559287|NCT07079943|OTHER|Self-reported questionnaire : educational or professional|Patient educational or professional outcomes, assessed through standardized self-reported questionnaires completed day of inclusion (6 months after the pediatric-to-adult rheumatology transition consultation realized in the context of programm CAPADJA or not. )
224028638|NCT05028907|DRUG|5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
224028639|NCT05028907|DRUG|sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months|The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
224028640|NCT02793076|OTHER|Bollywood Dance|8 week Bollywood Dance Program
224028641|NCT06308848|DIETARY_SUPPLEMENT|Microbiota-Directed Food|MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.
224028642|NCT06308848|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|RUTF is standard ready-to-use therapeutic food for SAM children aged 6 months and above.
224298107|NCT05565339|DEVICE|PMEIs|"To evaluate audiological outcomes post-operatively, the air-bone gap (ABG) was assessed.~To evaluate safety of the devices, adverse events were collected.A post-operative minimum and maximum follow-up period was not defined. The mean of the post-operative follow-up period of all patients was calculated. To assess whether implantation of PMEI affected residual hearing pre- and post-operative bone conduction thresholds were evaluated."
223411514|NCT01288196|DRUG|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
223411515|NCT01288196|DRUG|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
223411516|NCT01288196|DRUG|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
223411517|NCT01288196|DRUG|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
223411518|NCT03068195|PROCEDURE|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
223411519|NCT03068195|PROCEDURE|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
223411520|NCT04828018|OTHER|Coffee Morning|Coffee mornings (a maximum of n=2) will be held to raise awareness of the project and to promote participant recruitment. These will be held remotely via video conference if Covid-19 restrictions prevent in-person attendance by the researcher.
223411521|NCT04828018|OTHER|Recruitment Leaflets|Recruitment leaflets will be hand-delivered to all In-Pensioner residents at Royal Hospital Chelsea. Leaflets will be delivered internally by Royal Hospital Chelsea internal mail-room
223411522|NCT04828018|OTHER|Consent Form completion|All participants will be asked to complete Consent Forms before engaging in the study. The researcher will be available to answer any questions via phone calls if required.
223411523|NCT04828018|OTHER|Participant Information Sheet|All participants will receive Information Sheets which they will read in their own rooms (or elsewhere for Key Staff). The researcher will be available to answer any questions via phone calls if required.
223559288|NCT07079917|PROCEDURE|subperiosteal tunneling for horizontal alveolar ridge augmentation|subperiosteal dissection through horizontal incision only
223559289|NCT07079917|PROCEDURE|conventional alveolar ridge augmentation|horizontal alveolar ridge augmentation through trapezoidal flap
224028643|NCT00218660|DRUG|Naltrexone|150mg/day Naltrexone
224028644|NCT00218660|BEHAVIORAL|BRENDA|Psychosocial Treatment
224028645|NCT00218660|BEHAVIORAL|CBT|Cognitive Behavioral Therapy
224028646|NCT00218660|DRUG|Placebo|
224028647|NCT00416143|PROCEDURE|bed rest|
224028648|NCT00416143|DRUG|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
224028649|NCT05602389|OTHER|VL-G-A57|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
224028650|NCT05602389|OTHER|VL-G-E12|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
224028651|NCT05602389|OTHER|Placebo|Dose: 700mg daily Route: Oral Regimen: 2 capsules in the morning with food and 2 capsules in the evening with food Duration: 60 days
224028652|NCT02706132|BIOLOGICAL|Mesenchymal Stem Cells(MSCs)|Six doses of 1\*10\^6/kg body weight MSCs are given, intravenously.
224028653|NCT04667182|OTHER|Meal-Tagging App and Web-based Portal:|Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.
224028654|NCT04667182|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 18 weeks.
224028655|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish sauce|
224028656|NCT01724073|DIETARY_SUPPLEMENT|Leafy vegetable-fish/liver sauce|
224028657|NCT01724073|DIETARY_SUPPLEMENT|Misola|
224028658|NCT01365832|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
224028659|NCT02638480|DEVICE|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
224028660|NCT03242720|PROCEDURE|Cardiac Ablation for Atrial Fibrillation|Ablation of arrhythmia focus in the heart for atrial fibrillation
224028661|NCT04244838|DIAGNOSTIC_TEST|Gait Analysis|The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
224028662|NCT02486744|DRUG|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
224298108|NCT06929065|PROCEDURE|HIFU vs Cryoablation|HIFU vs cryoablation
224298109|NCT06927323|OTHER|Otago exercise program|The Otago Exercise Program is composed of strength training and balance training. Strength training consisted of flexion and extension exercises of the knee, ankle, and toe joints, as well as hip opening exercises to strengthen the sides of the pelvis. Balance training consisted of walking backwards, walking in a figure of eight, heel-toe walking, standing on one leg, walking on the heels, walking on the toes, heel-toe walking backwards, standing up from a sitting position, and walking up stairs. Otago exercise program will be performed with action observation train will be instructed to watch a video on a 22-inch screen positioned 1 meter away from them, while comfortably seated in a chair with armrests. They are not allowed to follow along or engage in any movement while watching the video.
224298110|NCT06928532|BEHAVIORAL|Seated TC|3-month seated Tai Chi training (24 sessions in total) given to Parkinson's disease patients
224298111|NCT06927531|OTHER|sacral massage|During labor, pregnant women will be given effleurage (stroking) and vibration (vibration) techniques to the sacral region in a comfortable position during contractions, once an hour for a maximum of 10 minutes.
224298112|NCT06927531|OTHER|pilates ball|During labor, pregnant women will be given pelvic oscillation movements (a full rotation of the hips, going right/left, coming forward and backward, lightly bouncing on a ball while holding onto the headboard) once an hour during the active phase of labor.
224028663|NCT01380015|OTHER|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
224028664|NCT01380015|OTHER|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
224028665|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
224028666|NCT01613560|DRUG|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
224028667|NCT01613560|DRUG|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
224028668|NCT02656823|DEVICE|ANKYLOS C/X implant A 6.6|Treatment with six (6) 6.6 mm implants and a bridge to restore chewing function of an edentulous maxilla.
224028669|NCT00136981|DRUG|torcetrapib/atorvastatin|
224028670|NCT00136981|DRUG|atorvastatin|
224028671|NCT02482077|DRUG|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
224028672|NCT02482077|DRUG|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
224028673|NCT02482077|DRUG|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
224028674|NCT02105584|DEVICE|Implantation of LAA closure device|
224028675|NCT03661203|BEHAVIORAL|Focus group|Focus group for qualitative group only
224028676|NCT03661203|BEHAVIORAL|Individual interview|Individual interview for qualitative group only
224028677|NCT03661203|BEHAVIORAL|online self questionnaire|online self questionnaire
224028678|NCT03661203|BEHAVIORAL|self questionnaire|online self questionnaire following focus group or individual interview For qualitative group only
224028679|NCT00353769|PROCEDURE|Hair Apposition Technique|
224028680|NCT00822523|DRUG|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
224028681|NCT00822523|DRUG|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
224028682|NCT00822523|DRUG|Saline|Single Dose, Intramuscular into right EDB muscle
224028683|NCT04924842|OTHER|Review of medical file|Review of medical patient file, including patient tracing, brief summary of the disease course, barrier gestures, social distancing.
224028684|NCT04924842|OTHER|Phone call interview|less than 15 minutes phone call
223411524|NCT04828018|OTHER|New In-Pensioner Resident Information Pack|New In-Pensioner resident information packs will be distributed by a member of RHC staff as part of their 'arrivals' process and six months after residency at RHC. The researcher will be available to answer any questions via phone calls if required.
223411525|NCT04828018|OTHER|Key Staff Interviews|Key Staff interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
223411526|NCT04828018|OTHER|In-Pensioner Resident Interviews|In-Pensioner resident interviews will take place with the Researcher in a private space at Royal Hospital Chelsea. If Covid-19 restrictions are in place, 'online' interviews will take place using a digital platform such as 'Skype', 'Teams' or 'Zoom'.
223411527|NCT04828018|OTHER|ICECAP-A Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
223411528|NCT04828018|OTHER|WHOQOL-BREF Quality of Life Questionnaire|New In-Pensioner residents and In-Pensioner residents taking part in the Qualitative Interviews will be asked to complete n=2 QoL questionnaires. New In-Pensioners will be asked to complete their QoL measures when the individual takes up residence at Royal Hospital Chelsea, the second six months later. In-Pensioner residents taking part in the interviews will be asked to complete the questionnaire at the start of the interview.
223411529|NCT01050582|DRUG|Risperidone|As per local prescribing practices
223411530|NCT01050582|DRUG|Other atypical antipsychotic drugs|As per local prescribing practices
223411531|NCT04676269|BIOLOGICAL|Amnion only|Patients endometrium will be transplanted with amnion only (without seeded cells)
223411532|NCT04676269|BIOLOGICAL|Amnion - endometrium cells|Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
223411533|NCT04676269|BIOLOGICAL|Amnion - amnion epithelial cells|Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
223411534|NCT04676269|BIOLOGICAL|Amnion-EnSC-AESC|Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
223411535|NCT06499038|PROCEDURE|Total Hip Arthroplasty|Surgery for total hip replacement
223411536|NCT05484999|OTHER|Meals|12 weeks of medically tailored meals
223411537|NCT05484999|OTHER|Meals + Social Support|12 weeks of medically tailored meals and12 weeks of social media based support
223411538|NCT05484999|OTHER|Control|Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
223411539|NCT00000945|DRUG|Cidofovir|
223411540|NCT00000945|DRUG|Probenecid|
223411541|NCT04162431|DIAGNOSTIC_TEST|spectroscopic measurement|measurement of the tissue with spectroscopy
223411542|NCT04162431|DIAGNOSTIC_TEST|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
223411543|NCT04162431|DIAGNOSTIC_TEST|histopathology and cytology|Histopathology and cytology will be performed on the samples
223411544|NCT04042623|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
223411545|NCT01519219|RADIATION|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
223411546|NCT00624936|DRUG|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
224028685|NCT06027593|BEHAVIORAL|Mixed methods intervention|"Investigators will implement the intervention at the completion of the rapid user-centered design process and consultation with CDC collaborators.~During the rapid user-centered design process, the team will engage key stakeholders to create and optimize feedback reports that will fit the prescribing context, and determine appropriate implementation supports that will be needed to accompany the introduction of the feedback reports to each setting.~Following the initial awareness-building activities, investigators will circulate the antibiotic prescribing feedback reports. After the first 3 months (approximately) of report dissemination, the team will assess the feasibility and acceptability of the reports and implementation activities by administering a brief survey to prescribers and also conducting interviews with them. No direct identifiers will be collected."
224028686|NCT02513719|DEVICE|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
224028687|NCT01009580|DRUG|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
224028688|NCT01009580|DRUG|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
224028689|NCT01000285|DRUG|Bortezomib|
224028690|NCT01000285|DRUG|Etoposide|
224028691|NCT01000285|DRUG|Vincristine|
224028692|NCT01000285|DRUG|Doxorubicin|
224028693|NCT01000285|DRUG|Prednisone|
224028694|NCT01000285|DRUG|Cyclophosphamide|
224028695|NCT01000285|DRUG|Raltegravir|
224028696|NCT05584787|PROCEDURE|Soractelite Echolaser Transperineal focal laser ablation|US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
224028697|NCT05677152|DRUG|Intravenous Infusion of Aclasta®|Intravenous Infusion of Aclasta® (Verum) or physiological saline solution 0.9% (Placebo)
223411547|NCT00624936|DRUG|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
224028698|NCT02714387|OTHER|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
224028699|NCT00361660|BEHAVIORAL|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
224134741|NCT02000713|OTHER|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
224134742|NCT02000713|OTHER|Clinical Exam|Brief neurological exam will be performed.
223411548|NCT00423332|DRUG|Cediranib|45 mg oral tablet
223411549|NCT00423332|DRUG|Cediranib Placebo|oral tablet
223411550|NCT00719485|OTHER|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
223411551|NCT02304861|PROCEDURE|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
223411552|NCT02304861|PROCEDURE|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
223411553|NCT02682693|DRUG|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
223411554|NCT02682693|DRUG|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
223411555|NCT02682693|DRUG|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
223411556|NCT02682693|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
223411557|NCT02682693|DRUG|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
223411558|NCT02682693|DRUG|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
223411559|NCT02682693|DRUG|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
223411560|NCT03431831|BEHAVIORAL|Intervention Control|diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
223411561|NCT03431831|BEHAVIORAL|Counselling|Usual care as listed in comparator intervention plus motivational interviewing to identify areas of barriers and how to overcome them, to help patient set achievable food, physical activity and beverage goals for themselves weekly and monthly. To identify whether knowledge or confidence counseling is more important for each participant and follow up with them. To help them learn self-management techniques for overeating.
223411562|NCT03431831|DRUG|Contrave|In addition to usual care as described in the comparator intervention, these participants will be prescribed Contrave and raised to the therapeutic dosage within one month. They will be monitored closely for side effects and meds adjusted accordingly.
223559290|NCT07081724|BEHAVIORAL|Online Parent Training in Early Behavioral Intervention (OPT-In-Early)|"the Online Parent Training in Early Behavioral Intervention (OPT-In-Early; Dai et al., 2018, 2021,2022) is a self-directed online resource for caregivers of children with autism or high likelihood of autism. The OPT-In-Early program includes 14 modules (6 mandatory, 8 optional) comprising text and video demonstrations to teach caregivers effective methods for improving their children's language, social, and adaptive skills (e.g., using utensils, toilet training), and reducing their children's disruptive behavior. Parents are taught how to facilitate joint attention, imitation, pretend play, language, sharing, emotional engagement, social play, and self-help skills such as feeding and dressing in their child using behavioral principles (e.g. prompting, shaping and fading) during play and naturalistic daily routines. The optional modules cover such topics as picky eating and toilet training."
224028700|NCT00361660|BEHAVIORAL|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
224028701|NCT04558749|OTHER|State-trait anxiety inventory scale|This scale is composed of two parts, part one measures anxiety traits and part two measures anxiety state. Each part comprises 20 statements. This scale is a (4) point scale, with a score ranging a minimum of 20 grades to a maximum of 80 grades.
224028702|NCT04558749|OTHER|Edinburgh Postnatal Depression Scale (EDPS)|The EPDS is a self-report measure that focuses on the cognitive symptoms of depression. It excludes somatic items that might generate false positives both during pregnancy and after childbirth.7 The EPDS consists of 10 items, each scored 0-3 points, with a potential scale score of 0-30.
223411563|NCT03431831|DRUG|Contrave and Counseling|This group of participants will receive a combination of all the above interventions including diet/physical activity prescription, motivational interviewing and Contrave.
224028703|NCT06382454|DEVICE|Assist-On Arm Robot Group|30 minutes of individualized trunk, lower extremity and upper extremity exercises; the other 30 minutes will be treated with the robotic system. In the robot-assisted treatment, a total of 12 movements will be used, including the movement patterns that patients have the most difficulty in daily life and two movement patterns used in the Proprioceptive Neuromuscular Facilitation approach. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
224028704|NCT06382454|OTHER|Control Group|For 30 minutes, exercises including trunk, lower extremity and upper extremity exercises specific to the individual will be practiced, while the movement patterns to be used in the robotic system will be practiced in the other 30 minutes with the physiotherapist. Individual-specific rehabilitation program; individual-specific trunk, lower extremity and upper extremity exercises to be applied in both groups will consist of the following exercises according to the needs of the patients, and the degree of difficulty will be planned according to the needs of the patients. All patients will be treated for 8 weeks, 3 days a week, 60 minutes a day.
224028705|NCT04248660|OTHER|uterine artery doppler measurement|"The effect of delivery type on changes in uterine blood flow will be investigated.~Doppler results groups will be defined according to the effect of deviations in uterine blood flow on neonatal and perinatal results."
224028706|NCT01468129|OTHER|Cell Saver|
224028707|NCT00907790|BEHAVIORAL|Usual Care (Control Group)|
224028708|NCT00907790|BEHAVIORAL|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
224028709|NCT04987437|DEVICE|Friendly short stem|Total Hip Arthroplasty with Friendly Short stem
224028710|NCT01201733|OTHER|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
224134743|NCT06081998|OTHER|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
224134744|NCT06081998|OTHER|Cowhage|25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
224134745|NCT04915677|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Subepithelial connective tissue graft will be harvested and inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
224134746|NCT04915677|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix|After local anesthesia a mesio-distal crestal incision will be performed reaching the alveolar bone. Split thickness dissection performed both buccal and palatal. Xenogenic volume stable collagen matrix will be inserted beneath the mucoperiosteal flap and stretched buccally and lingually using a modified horizontal mattress suture. The flap margins at the crest will be adapted using single interrupted sutures in order to achieve a primary closure of the flap.
224134747|NCT03407196|DRUG|Forxiga|Oral antidiabetics
224134748|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
224134749|NCT03910998|DRUG|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
223411564|NCT00885664|DRUG|Truvada (tenofovir/emtricitabine)|Tenofovir/emtricitabine fixed dose combination once daily
223411565|NCT00885664|DRUG|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
223411566|NCT00685399|DRUG|AIN457|AIN457 subcutaneous dose
223411567|NCT00685399|DRUG|AIN 457|AIN457 low dose (i.v)
223411568|NCT00685399|DRUG|AIN457|AIN457 high dose (i.v)
223411569|NCT01311076|DRUG|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
223411570|NCT01311076|DRUG|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
223411571|NCT01311076|DRUG|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
223411572|NCT01311076|DRUG|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
223411573|NCT02374268|BEHAVIORAL|Exercise program alone|
223559291|NCT07081217|DIAGNOSTIC_TEST|Intravenous Radiocaine|Intravenous injection of Radiocaine
223559292|NCT07081061|OTHER|BetterHelp|Use program as needed for 16 weeks
224028711|NCT01201733|OTHER|Ultrasound therapy and hot pack|
223411574|NCT02374268|DIETARY_SUPPLEMENT|Combined exercise program and nutrition supplement|
223411575|NCT02374268|OTHER|Waitlist control group|
223411576|NCT04891146|OTHER|Systemic inflammatory immmune index|Systemic Inflammatory Immune index calculated from platelet, neutrophil and lymphocyte count
223411577|NCT00256386|DEVICE|Electronic Medical Record (EMR) to clinician's in-basket|
223411578|NCT00256386|DEVICE|Automated Voice Message (AVM) reminder to patient's phone|
223411579|NCT00256386|PROCEDURE|Pharmacy Team phone call-letter followup|
224028712|NCT02087709|OTHER|Low-calorie diet|
224028713|NCT02880540|DRUG|Fentanyl|
224028714|NCT02880540|DRUG|Morphine|
224028715|NCT02880540|DRUG|Dexmedetomidine|
223411580|NCT01228890|BEHAVIORAL|CATCH-IT|"The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent \[14 modules\] and parent \[5 modules\] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT Tracker will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits)."
223411581|NCT01228890|BEHAVIORAL|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education \[psycho-education described below\], provider training \[described in Case Finding and Recruitment\], active monitoring and referral \[case management, discussed under assessments\], physician and nurse education and routine contact with PCP \[study design rationale\]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
224028716|NCT00760773|DRUG|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
224028717|NCT00760773|DRUG|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
224028718|NCT00760773|DRUG|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
224028719|NCT05060068|DRUG|S-ketamine (low dose)|Patients in the low-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 2 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
224028720|NCT05060068|DRUG|Placebo|Patients in the placebo group will receive a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline until 30 min prior to the end of the surgery.
224028721|NCT05060068|DRUG|S-ketamine (high dose)|Patients in the high-dose ketamine group will receive a bolus of 0.5 mg/kg S-ketamine in saline, followed by continuous infusion of 4 μg/kg/min S-ketamine in saline until 30 min prior to the end of the surgery.
224028722|NCT04710160|DRUG|Novel fast-setting calcium silicate cement (Protooth)|In form of power and liquid to be mixed together to form a paste.
224028723|NCT01516593|DRUG|Induction Phase|"* dd -2 to 1: Methylprednisolone~* dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~* dd 2, Rituximab~* dd 7, Methotrexate~* dd 14, Rituximab~* dd 15, Etoposide~* dd 21, Methotrexate~* dd 29, Rituximab and Doxorubicin~* dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~1. pts in CR: consolidation phase followed by bulky site irradiation~2. pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~3. pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
224028724|NCT01516593|DRUG|Consolidation Phase (on day +50)|"* dd 1-2: cytarabine twice a day~* dd 3 and 11: rituximab~* dd 11-13: leukapheresis for PBPC collection."
224028725|NCT01516593|DRUG|Intensification phase|"1. One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~2. CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~3. AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
224028726|NCT01516593|DRUG|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
224028727|NCT01516593|RADIATION|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
224028728|NCT04810754|DRUG|Daratumumab Injection|1800 mg per injection; 8 consecutive injections once a week; subcutaneous application in abdomen
223411582|NCT01863199|DRUG|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
223411583|NCT01863199|DRUG|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
223411584|NCT01863199|DRUG|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
223411585|NCT04058093|BEHAVIORAL|Functional Training Program|"Functional training program (FTP) include:~1. Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~2. Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students."
223411586|NCT06044415|DRUG|JWH018|A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants
223411587|NCT06044415|OTHER|non-active control (no substance)|Participants will inhale from a vaporizer with an empty chamber.
223411588|NCT02218047|DRUG|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
224028729|NCT02132013|BEHAVIORAL|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
223411589|NCT02218047|DRUG|Best available therapy (BAT)|Best available therapy as selected by the investigator
223411590|NCT01308827|PROCEDURE|Blood culture|A baseline blood culture will be obtained in all participants
223411591|NCT01308827|PROCEDURE|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
223411592|NCT06495476|DRUG|Ginkgo biloba extract 50 dropping pills|Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.
223411593|NCT06495476|DRUG|Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant|"Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance.~Size: 10 mg analog ingredient/pill."
223411594|NCT00927862|GENETIC|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
223559293|NCT07080333|BIOLOGICAL|biopsy|After verifying the patient's identity, obtaining their informed consent and confirming that there are no immediate contraindications to performing biopsies (haemorrhagic and infectious), the patient will be prepared for RTUV, which will be performed by cystoscopy under anaesthesia in the operating theatre.
223559294|NCT02815657|DRUG|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
223559295|NCT02815657|DRUG|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
223559296|NCT04261725|GENETIC|EGFR mutation|Searching the EGFR mutation in pulmonary biopsy
223559297|NCT00960791|DEVICE|AZD1656|Oral single dose
224028730|NCT00193999|DEVICE|Placement of nasogastric tube|
224028731|NCT00611312|BEHAVIORAL|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
224028732|NCT04395898|PROCEDURE|pancreaticoduodenectomy|Whipple's procedure
224028733|NCT02568865|OTHER|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
224028734|NCT02568865|OTHER|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
224028735|NCT02568865|OTHER|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
224028736|NCT02568865|OTHER|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
224028737|NCT04816331|OTHER|Medical records and clinical measurements|"Medical records and clinical measurements: Detailed antenatal, birth, resuscitation, oxygen requirements throughout inpatient stay and detailed neonatal intensive care management will be collected. Therapeutic Hypothermia treatment including initiation, duration and clinical examination, and investigations such as scans. In addition, clinical data will include medication, neurological (paediatric developmental psychologist assessment and Bayley Scales of Infant and Toddler Development) and multiorgan examination.~Questionnaires for caregivers to assess social-emotional and adaptive domains.~Tissue samples analysis and processing: Samples of blood, urine and saliva will be used for laboratory testing.~Biomarker correlation with Multiorgan outcomes using statistical analysis: Data collected from medical records, clinical measurements, questionnaires, and tissue processing will be analysed using SPSS software for statistical analysis and modelling."
224134750|NCT06033339|OTHER|Blood sampling|Collection of 10 ml of blood on EDTA tubes per patient. Once collected, the blood tubes will be transported within 24 hours to the IRB (Biotherapy Research Institute) of Montpellier University Hospital, where the monocytes will be isolated by magnetic sorting on the basis of expression of surface marker CD14+, after a preliminary step of Ficoll. Monocytes will then be frozen in nitrogen at -196°C until use (biobank).Gain-of-function experiments will then be performed on monocytes by transfecting them with the microRNA of interest or control. The expression of the pyrin protein and its phosphorylation rate will be evaluated after induction by immunoprecipitation experiments followed by western blot. The activity of the pyrin inflammasome will also be studied by looking at pyroptosis and toxicity rate using LDH test. All these experiments will be carried out in the absence and in the presence of the microRNA in order to study its role in the pathophysiology of FMF.
224134751|NCT06516939|DRUG|bFGF|Half-face randomized control
223411595|NCT00927862|GENETIC|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
223559298|NCT07081789|BEHAVIORAL|Music Listening|Participants will listen to a 24 min 54 sec music track for 4 days (starting 3 days before menstruation).
223559299|NCT07081789|BEHAVIORAL|Puzzle Activity|Participants will do puzzles for the same duration and timing.
224028738|NCT04179162|DRUG|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
224028739|NCT04179162|DRUG|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
224028740|NCT05269355|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm description.
224028741|NCT05269355|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm description.
224028742|NCT05269355|OTHER|Placebo|Placebo will be administered as per the schedule specified in the arm description.
224028743|NCT05958654|BEHAVIORAL|Detection of Elder mistreatment Through Emergency Care Technicians-Revised for Primary Care (DETECT-RPC) screening tool|"DETECT is an elder mistreatment (EM) screening tool created for medics in the Fort Worth Texas area to use when responding to the homes of older adults, enabling them to screen for signs of elder mistreatment. DETECT-RPC is the adapted version of this tool designed specifically for use by home-based primary care (HBPC) clinicians.~The DETECT-RPC tool is designed to:~1. Be brief and easy to use.~2. Focus on the clinician's direct observations of the older adult and their physical and social environment.~3. Provide clear guidance on reporting suspected EM.~4. Integrate seamlessly into existing procedures and medical charting systems."
224028744|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
224028745|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose A|Administration of Dose A of ACI-24.060
224028746|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose B|Administration of Dose B of ACI-24.060
224028747|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose C|Administration of Dose C of ACI-24.060
224028748|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose D|Administration of Dose D of ACI-24.060
224028749|NCT05462106|BIOLOGICAL|Placebo|Administration of Placebo
224028750|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose X|Administration of Dose X of ACI-24.060. Dose X will be a dose already tested in Study Part 1
224028751|NCT05462106|BIOLOGICAL|ACI-24.060 at Dose Y|Administration of Dose Y of ACI-24.060
223411596|NCT00927862|OTHER|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients \>=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
223411597|NCT00820248|BIOLOGICAL|panitumumab|Given IV
223411598|NCT00820248|DRUG|cisplatin|Given IV
223411599|NCT00820248|RADIATION|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
224028752|NCT03409627|BIOLOGICAL|INXN-4001|Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
224028753|NCT01315496|DRUG|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
224028754|NCT00081497|BIOLOGICAL|agalsidase beta|1.0 mg/kg every 2 weeks
224028755|NCT06854861|DRUG|Lyumjev 100 UNT/ML Injectable Solution|0.1 unit insulin Lyumjev /kg body weight is injected subcutaneously
224028756|NCT06854861|DRUG|Premixed Lyumjev|A solution of 5 ng glucagon /Unit Lyumjev is injcetd subcutaneously. 0.1 unit insulin / kg body weight is used.
224028757|NCT06082908|DIAGNOSTIC_TEST|Diagnostic test|Subjective and objective measurement will be performed in older adults.
224028758|NCT00134433|GENETIC|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
224028759|NCT00134433|DRUG|oral L-arginine supplementation (at a dose of 6 g/day)|
224028760|NCT05067465|DIETARY_SUPPLEMENT|Selected food groups|"Food groups~1. Milk and dairy products~2. Whole-grain products (rich in soluble fibers)~3. Sausage and processed meat (pork)~4. Meat-free sausage and meat alternatives (based on egg, soy)"
224028761|NCT06606483|DRUG|MDR-001|Oral administration of small molecule MDR-001 tablets
224028762|NCT06606483|DRUG|Placebo|Administered orally placebo
223411600|NCT00820248|RADIATION|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
223411601|NCT00820248|RADIATION|intensity-modulated radiation therapy|Patients undergo radiotherapy
223411602|NCT05167630|OTHER|prognostic marker|prognostic marker
223411603|NCT04306965|DRUG|Apremilast|30 mg twice daily (BID)
223411604|NCT02020538|OTHER|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
223411605|NCT02020538|OTHER|High-chloride perioperative intravenous fluid strategy|
223411606|NCT00641602|DRUG|Esomeprazole|40mg once daily
224028763|NCT00210977|DRUG|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
224028764|NCT00002331|DRUG|Ethambutol hydrochloride|
224028765|NCT00002331|DRUG|Clarithromycin|
224028766|NCT00002331|DRUG|Clofazimine|
224028767|NCT06609746|DIETARY_SUPPLEMENT|Thyme extract|Three Gastrolit capsules daily with a low FODMAP diet for 8 weeks
224028768|NCT06609746|OTHER|Placebo|Placebo capsules daily with a low FODMAP diet for 8 weeks
224028769|NCT06674915|DRUG|HRS-5965 capsules|Oral 50 mg.
224028770|NCT00959647|DRUG|Vismodegib|Vismodegib was supplied in capsules.
224028771|NCT00959647|DRUG|FOLFOX|FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.
223411607|NCT00641602|DRUG|Lansoprazole|30mg once daily
223411608|NCT06574841|OTHER|Blood Flow Restriction training|BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.
223411609|NCT02237196|BIOLOGICAL|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
223411610|NCT02237196|BIOLOGICAL|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
223411611|NCT02237196|BIOLOGICAL|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
223559300|NCT07079774|DEVICE|Transverse Bone Transport System|"This is a prospective, international, multicentre, observational post-market clinical follow-up (PMCF) study. Adult subjects will be treated according to the manufacturer's Instructions for Use, with follow-up extending to 12 months post-device removal. Participating sites include centres in the US, Europe, the UK, and South Africa.~Subjects will be followed using a phased framework:~T0: Index Surgery (baseline data, operative details, ulcer status) T1: End of Distraction (device parameters, adverse events, ulcer status) T2: End of Compression (similar to T1) T3: Device Removal (confirmation of union, ulcer status)~Post-removal visits:~F3: 3 months F6: 6 months F12: 12 months"
223559301|NCT07079657|PROCEDURE|Thulium laser + growth factor serum + LED|3 sessions at intervals of 6 weeks
224028772|NCT00959647|DRUG|FOLFIRI|FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.
224028773|NCT00959647|DRUG|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
223559302|NCT07079657|PROCEDURE|Thulium laser + growth factor serum|3 sessions at intervals of 6 weeks
223559303|NCT07079657|PROCEDURE|Thulium laser|3 sessions at intervals of 6 weeks
224028774|NCT03824639|BEHAVIORAL|Structured exercise|Exercise instruction and encouragement
223411612|NCT02237196|BIOLOGICAL|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
223411613|NCT01522378|DRUG|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
223411614|NCT02166398|DRUG|UI15AML055MT|tab, PO
223411615|NCT02166398|DRUG|Amosartan 5/50|tab, PO
223411616|NCT04441528|DRUG|Lid wipes containing terpinen-4-ol and sodium hyaluronate|Lid wipes will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
223411617|NCT04441528|DRUG|Baby shampoo|Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
223411618|NCT04830371|BIOLOGICAL|EuTCV (Vi-CRM Typhoid conjugate vaccine)|Single dose, Intramuscular administration
223411619|NCT04830371|BIOLOGICAL|Typbar-TCV|Single dose, Intramuscular administration
223411620|NCT02049905|DRUG|Aldoxorubicin|
223411621|NCT02049905|DRUG|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
223559304|NCT07080918|PROCEDURE|Irrigation|Irrigation procedures were performed with needles of different designs, each 30 G, for three different groups
223559305|NCT07080606|BEHAVIORAL|Brief exposure therapy and exercise|Treatment provided in this study includes an open label brief imaginal exposure therapy for Post Traumatic Stress Disorder (PTSD) and moderate intensity aerobic exercise (i.e., 70-75% max heart rate). Participants all receive 30 minutes of psychotherapy and 25 minutes of exercise.
223559306|NCT07079462|COMBINATION_PRODUCT|Radiotherapy followed by chemotherapy|"Radiotherapy: Low-dose radiotherapy to the abdominal cavity region, 5-10 Gy/5 fractions. For visible local lesions, large fraction radiotherapy is administered, 15-30 Gy/5 fractions, once daily.~Immunotherapy: One week after the completion of radiotherapy, cadonilimab, 6 mg/kg, is administered every two weeks."
224028775|NCT03824639|BEHAVIORAL|Health Education|Provision of general information about a variety of health topics
224028776|NCT01079338|OTHER|caffeine|
224028777|NCT01340196|DRUG|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
224028778|NCT03279133|DRUG|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
224028779|NCT05622617|DRUG|no intervention|no intervention
224028780|NCT04567290|DRUG|Chewed ticagrelor|Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
223411622|NCT01488383|DRUG|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
223411623|NCT01488383|DRUG|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
223411624|NCT05445505|DEVICE|intermittent theta burst stimulation|iTBS is a new form of excitatory rTMS treatment that is less time-consuming and more effective than traditional rTMS in a single treatment session.
223411625|NCT05445505|DEVICE|sham iTBS|The pseudo-stimulation device looks and sounds the same as the iTBS device
223411626|NCT01750697|DRUG|Rituximab|Participants will receive rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
223411627|NCT03980145|DEVICE|G-EO System (Reha Technology AG: Olten, Switzerland)|Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
223411628|NCT03980145|OTHER|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
224028781|NCT04567290|DRUG|Swallowed ticagrelor|Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
224028782|NCT05474599|OTHER|conventional physical therapy|TENS
223411629|NCT02511145|OTHER|occlusive bandage|
223411630|NCT02511145|DEVICE|ablative fractional CO2 laser pretreatment|
223411631|NCT02511145|DEVICE|Microneedles pretreatment|
223411632|NCT02511145|DRUG|METVIXIA Cream|
223411633|NCT04791189|OTHER|questionnaire|questionnaire to survey the needs of adolescents with juvenile idiopathic arthritis and the views of their parents in the area of sexual health.
224028783|NCT05474599|OTHER|Dry cupping therapy|Experimental group was given Dry cupping therapy along with TENS.
224028784|NCT00108212|BEHAVIORAL|Diet|
224028785|NCT00329342|BEHAVIORAL|Occupational ergonomic training|Adequate postural habits in activities of daily living
224028786|NCT03660553|DRUG|Insulin Glargine|0.40 units/kg body weight
224028787|NCT03660553|DRUG|Insulin Glargine|0.20 units/kg body weight
224028788|NCT03660553|DRUG|Insulin Aspart|0.20 units/kg body weight
224028789|NCT03660553|DRUG|Insulin Lispro|0.20 units/kg body weight
224028790|NCT00171704|DRUG|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
224028791|NCT00171704|DRUG|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
224028792|NCT05255367|COMBINATION_PRODUCT|(poly)phenols rich foods|"Prior to start the intervention (initial time of the study) the volunteers will follow their habitual diet during 30 days as a control period, and then they will start with the intervention period (baseline) following their habitual diet supplemented with (poly)phenol rich products during 60 days (after intervention).~At the beginning of the study (initial time), at the beginning of the intervention (baseline) and at the end of the intervention (after the intervention) with rich (poly)phenols foods, biological samples (blood, urine and feces) and anthropometric measurements will be taken. In addition, the participants will record the food intake weekly with a 24 h dietary-recall form."
224028793|NCT02253108|DEVICE|Everolimus eluting bioresorbable polymer stent|
224134752|NCT06516939|DRUG|Bovine Basic Gel|Bovine Basic Gel
224134753|NCT00997048|PROCEDURE|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
224134754|NCT00997048|PROCEDURE|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
223411634|NCT00532389|DRUG|LBH589|
223411635|NCT03317730|DRUG|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
224028794|NCT02253108|DEVICE|Biolimus eluting bioresorbable polymer stent|
224028795|NCT03336151|BEHAVIORAL|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
224028796|NCT02586922|DEVICE|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
223411636|NCT06196255|DRUG|anti-FcRL5 CAR-T|anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.
223411637|NCT06577038|DEVICE|PCI with use of IVL|Use of IVL for the treatment of calcific coronary artery lesions at operator's discretion
224028797|NCT04773496|DIAGNOSTIC_TEST|instrumental description of the subject's center of gravity (COG) sway|qualitative and quantitative analysis of the balance function through the description of the center of gravity (COG) sway
224134755|NCT04610034|BEHAVIORAL|"Resilient Caregivers"|"Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program."
224134756|NCT04610034|OTHER|Care as usual|The control arm will receive usual care, which implies no systematic support.
224134757|NCT01656681|DIETARY_SUPPLEMENT|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
224134758|NCT01656681|DIETARY_SUPPLEMENT|Placebo|Placebo tablet
224134759|NCT05580055|DIAGNOSTIC_TEST|Affinity|Blood Analyser
223411638|NCT00595855|PROCEDURE|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5\_FU supplementation and argon laser suturelysis
224028798|NCT04335240|OTHER|Premature family music therapy intervention to support parenting, attachment bond and preterm development|We have structured an integrated psychological and music therapeutic protocol that aims to limit or overcome neonatal long-term developmental morbidities, promote parenting and attachment bond in preterm infants.
224028799|NCT03295994|PROCEDURE|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
224028800|NCT03295994|PROCEDURE|Non-Operative|Physical therapy (without surgery).
224028801|NCT02749630|DRUG|Placebo|Matching placebo to UTTR1147A administered intravenously
224028802|NCT02749630|DRUG|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
224028803|NCT03296891|OTHER|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
224028804|NCT04897451|OTHER|Questionnaire|EQ5D-5L questionnaire self-reported 3 months after delivery
224028805|NCT04058613|DRUG|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
224028806|NCT04058613|OTHER|placebo|placebo
224028807|NCT06177249|BIOLOGICAL|Control vaccine|A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
224134760|NCT00896987|DRUG|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg\~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
224134761|NCT00896987|DRUG|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg\~600 mg) and maintenance for 40 weeks (600 mg)
223411639|NCT00595855|PROCEDURE|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
223411640|NCT03518762|PROCEDURE|Sustained lung inflation (SLI)|SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
223411641|NCT03518762|PROCEDURE|Continuous positive airway pressure (CPAP)|CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
223559307|NCT07079462|DRUG|Chemotherapy (control)|Standard second-line treatment regimen: (XELOX/FOLFOX or XELIRI/FOLFIRI + bevacizumab/ cetuximab)
224028808|NCT06177249|BIOLOGICAL|Experimental vaccine|A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
224028809|NCT01907802|DRUG|Dabrafenib|Given PO
224028810|NCT01907802|OTHER|Laboratory Biomarker Analysis|Correlative studies
224028811|NCT01907802|OTHER|Pharmacogenomic Study|Correlative studies
224028812|NCT01907802|OTHER|Pharmacological Study|Correlative studies
224028813|NCT00915304|BEHAVIORAL|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.~Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
224028814|NCT00223522|DEVICE|MEMS caps|
224028815|NCT05780411|OTHER|questionnaire|The symptom related checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire, Distress thermometer
224028816|NCT00205491|DRUG|Venlafaxine|
224028817|NCT03225495|PROCEDURE|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
224028818|NCT03225495|PROCEDURE|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
224028819|NCT04412629|DRUG|Cabozantinib|Cabozantinib should be taken on an empty stomach (at least 1 hour before or 2 hours after eating) at the same time every day.
224134762|NCT01727050|DEVICE|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
224134763|NCT01727050|DEVICE|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
224134764|NCT02641366|DEVICE|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
224134765|NCT02641366|PROCEDURE|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
224134766|NCT02641366|PROCEDURE|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
223411642|NCT04681820|DRUG|Flumatinib|Flumatinib mesylate tablets 600mg qd for 24 months
224028820|NCT04412629|PROCEDURE|Blood for plasma biomarkers|Baseline, cycle 1 day 8, cycle 1 day 15, and day 1 of every cycle thereafter
224134767|NCT02136121|DEVICE|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
223559308|NCT07080749|OTHER|Vagal nerve stimulation through deep exhalation exercise|Deep Exhalation Treatment: Participants will receive a set of standard balloons to use for deep exhalation. They will sit in a comfortable position, take a deep breath in and blow their breath continuously out into the balloon. They repeat the deep exhalation process for a total of 4 consecutive breaths. They perform this breathing exercise once every hour during waking hours each day.
223559309|NCT07080749|OTHER|Vagal nerve stimulation through ear electrical stimulation|Ear Electrical Stimulation Treatment: Participants will receive a small electrical stimulator and electrode set to be applied to their left ear. The investigators will train the participants to use the device safely and effectively. Once they are comfortable with the procedure, they will perform the procedure at home for 20 minutes twice daily.
224028821|NCT04412629|PROCEDURE|Tissue biopsy|Baseline, before start of cycle 2, and time of progression
224028822|NCT03171077|OTHER|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
224028823|NCT03171077|OTHER|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
224028824|NCT03171077|OTHER|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
224028825|NCT00893282|DEVICE|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
224028826|NCT00893282|DEVICE|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
224028827|NCT03956537|DEVICE|NEO Pedicle Screw System™|The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
224028828|NCT03956537|DEVICE|Neo Cage System™|Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
224028829|NCT04262947|DEVICE|Near Infrared Vein Imaging|Use of NI vein imaging device for visualization of veins during peripheral IV placement
224028830|NCT04262947|OTHER|Conventional IV placement|IV placement utilizing conventional methods
224028831|NCT00816400|DRUG|MEDI-575|MEDI-575 as an IV infusion
224028832|NCT01319188|DRUG|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
224028833|NCT01319188|PROCEDURE|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
224028834|NCT01319188|OTHER|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
224028835|NCT04127890|DIETARY_SUPPLEMENT|ELO Water|oxygen-enriched water
223411643|NCT04681820|DRUG|Nilotinib|Nilotinib Capsules 400mg bid for 24 months
224028836|NCT04127890|DIETARY_SUPPLEMENT|Placebo drinking water|bottled drinking water
223411644|NCT02653144|DRUG|Ropivacaine|local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
223411645|NCT02653144|DRUG|Dexmedetomidine|local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
223411646|NCT02653144|DRUG|Dexamethasone|local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
223411647|NCT00744965|DRUG|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
223411648|NCT00744965|DRUG|Placebo|Sham dose adjustments of the placebo will be made.
223559310|NCT07080749|OTHER|No intervention (observational study)|The no intervention group will not receive treatment immediately after their baseline assessments, they will be scheduled for another visit after two weeks, then a new set of baseline measurements will be recorded as the post intervention data.
224028837|NCT02672215|BEHAVIORAL|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
224028838|NCT02672215|BEHAVIORAL|generic advice|general, non-tailored web-based generic advice with tips
224028839|NCT03207685|DEVICE|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
223411649|NCT00611572|DRUG|iomazenil|Given as IV infusion
223559311|NCT03515733|DRUG|PF-04995274|PF-04995274 tablets
224028840|NCT05925179|PROCEDURE|Surgical crown lengthening|Surgical clinical crown lengthening with bone excision
224028841|NCT05925179|DRUG|Augmentin|Pre-operative antibiotic prophylaxis (2 g Augmentin)
224028842|NCT00428623|PROCEDURE|wound dressing|
224028843|NCT05946278|OTHER|Sample collection for gene expression|This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
224028844|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
224028845|NCT00081770|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
224028846|NCT00081770|DRUG|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
224028847|NCT00081770|BIOLOGICAL|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
224028848|NCT00081770|DRUG|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
224028849|NCT01399333|DIETARY_SUPPLEMENT|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
224028850|NCT01399333|DIETARY_SUPPLEMENT|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
224028851|NCT01399333|DIETARY_SUPPLEMENT|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
223411650|NCT00611572|DRUG|iomazenil|saline IV infusion
223411651|NCT04724538|RADIATION|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
223411652|NCT04724538|DRUG|99mTc-pertechnetate aerosol|99mTc-pertechnetate is 99mTc-labeled carbon ultrafine aerosol
223411653|NCT00000412|DRUG|Alendronate|
223411654|NCT00000412|DRUG|Calcitriol|
223411655|NCT00000412|DRUG|Placebo Alendronate|
223411656|NCT00000412|DRUG|Placebo Calcitriol|
223559312|NCT03515733|DRUG|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
223559313|NCT03648177|BEHAVIORAL|IPGT|Behavioral Intervention for Patients with Chronic Pain
223559314|NCT03648177|BEHAVIORAL|Treatment as Usual|Standard Care
223559315|NCT06473077|PROCEDURE|ETT beyond C7 level|Endotracheal cuff is placed deeper beyond C7 level, but above carina
224028852|NCT03408054|DRUG|Oxytocin|Oxytocin 10-5M solution
224028853|NCT03408054|DRUG|Nitroglycerin|Nitroglycerin 25-1000mcg
224028854|NCT00191867|DRUG|Teriparatide|
224028855|NCT02552641|OTHER|Food effect|
224028856|NCT02552641|DRUG|Esomeprazole|
224028857|NCT02552641|DRUG|Amoxicillin|
224028858|NCT02552641|DRUG|Clarythromycin|
224028859|NCT00247585|DRUG|Ethanol (Bourbon or Vodka)|
224028860|NCT05125666|OTHER|Dual Task Training (Motor + Cognitive)|Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.
224028861|NCT05125666|OTHER|Traditional Regular Exercise|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
224028862|NCT06498505|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
224028863|NCT06498505|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
223411657|NCT03107585|PROCEDURE|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
224028864|NCT00601419|DRUG|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
224028865|NCT06178926|DRUG|Propofol|Propofol was IV infused 1.0-1.5mg/Kg and then maintenance at 1.0-2.0mg/Kg/h
224028866|NCT06178926|DRUG|Ciprofol|Ciprofol was IV infused 0.2- 0.3mg/Kg and then maintenance at 0.2-0.3mg/Kg/h
224028867|NCT04897672|OTHER|Observational study|Observational study
224028868|NCT01614197|DRUG|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
224028869|NCT01614197|DRUG|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
224134768|NCT02029508|PROCEDURE|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
224134769|NCT02029508|PROCEDURE|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
224134770|NCT02029508|PROCEDURE|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
224134771|NCT03262532|OTHER|Web-base simulator|Training manipulation of TEE using a Web-based simulator
223411658|NCT03547011|PROCEDURE|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
224028870|NCT01614197|DRUG|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
224028871|NCT01614197|DRUG|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~* Age 1 - 1.99 give 8 mg of methotrexate~* Age 2 - 2.99 give10 mg of methotrexate~* Age 3 - 8.99 give 12 mg of methotrexate~* Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
224028872|NCT01614197|DRUG|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age"
224134772|NCT03262532|OTHER|No web-base simulator|Training manipulation of TEE with out a web-base simulator
224134773|NCT00233259|BEHAVIORAL|Mediterranean Diet|Mediterranean dietary program
224134774|NCT00233259|BEHAVIORAL|Physical Activity|Physical activity program
224134775|NCT00233259|BEHAVIORAL|Stress Management|Stress management program
224134776|NCT00233259|BEHAVIORAL|Social Support|Social support
224134777|NCT00233259|BEHAVIORAL|Smoking Cessation|Smoking cessation program
223411659|NCT03547011|PROCEDURE|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
223411660|NCT01562782|OTHER|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
223411661|NCT03532386|PROCEDURE|ICSI|ICSI for both couples
223411662|NCT04720924|DEVICE|Computer-aided Real-time Automatic Quality-control System|EGD automatic quality-control system(AQCS),developed based on deep convolutional neural network (DCNN) models,could facilitate real-time detection of upper gastrointestinal lesions, assess inspection completeness and mucosal visibility, and calculate time of EGD procedure.
223411663|NCT06258499|COMBINATION_PRODUCT|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is manually placed into the joint fusion space during fusion surgery.
224028873|NCT01614197|DRUG|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients \>9 years of age"
224028874|NCT00948142|DRUG|CEM-102|600 mg BID oral tablets for 10-14 days
224028875|NCT00948142|DRUG|Linezolid|600 mg BID oral tablets
224028876|NCT00948142|DRUG|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
224028877|NCT01896154|DIETARY_SUPPLEMENT|NPS|Comparison of multiple dietary non-digestible polysaccharides
224028878|NCT05545657|BEHAVIORAL|Cognitive assessments|Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).
224028879|NCT05545657|OTHER|Simultaneous EEG-fMRI scan|EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.
224134778|NCT00233259|OTHER|Control group|Usual Diabetes Care Control group
224134779|NCT01368393|PROCEDURE|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
224134780|NCT01368393|PROCEDURE|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
224298113|NCT06928441|DEVICE|Transcutaneous Pulsed Electrical Stimulation (Device: WL-2103A)|The Transcutaneous Electrical Nerve Stimulator (TENS) creates electrical impulses from a 9VDC-battery whose continuous intensity rate can be controlled by the user. The alligator clip with 2 electrodes is placed on the tragus part of the ear (shown to be 45% innervated via auricular vagus nerve) to stimulate the vagus nerve with an adjustable peak intensity (0-80mA), a frequency of 2 - 250Hz and a pulse width of 30-260 µsec. The vagus nerve contains a mixture of different types of nerve fibres, which are organized into bundles (fascicles). The fibres vary in diameter and conduction velocity, with A-type fibres the largest and fastest and C-type fibres the smallest and slowest, with B-type fibres intermediate. During nerve stimulation, fibres are activated in order of size from the largest (A-type) to the smallest (C-type). It has been suggested that A-type fibres are mainly activated during the stimulation via auricular vagus nerve.
224298114|NCT06927063|DIAGNOSTIC_TEST|blood-based protein biomarker assessments|Assessment of multiple blood-based biomarkers of different cellular origin and inflammatory mediators
224298115|NCT06927063|DIAGNOSTIC_TEST|blood-based metabolomic/lipidomic biomarker assessments|Assessment of multiple blood-based TBI-related metabolomic and lipidomic biomarkers
224298116|NCT06927063|DIAGNOSTIC_TEST|Diffusion-weighted magnetic resonance imaging (brain)|Diffusion-weighted magnetic resonance imaging
223411664|NCT05174299|DEVICE|magnetic stimulation|For Experimental Arm, active magnetic stimulation on motor cortex followed by active magnetic stimulation on spinal cord, patients underwent ten sessions of double active magnetic stimulation with low frequency repetitive transcranial magnetic stimulation (rTMS) over the bilateral primary motor cortex of the lower leg followed by low frequency repetitive magnetic stimulation over the spinal cord. For Active Comparator Arm, active magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord. For Sham Comparator Arm, sham magnetic stimulation on motor cortex followed by sham magnetic stimulation on spinal cord.
223411665|NCT03537976|OTHER|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
223411666|NCT05794776|DEVICE|BurstDR stimulation|BurstDR spinal cord stimulation
223411667|NCT05794776|DEVICE|Tonic stimulation|Tonic spinal cord stimulation
223411668|NCT05794776|DEVICE|No stimulation|Stimulator is switched off
223559316|NCT06924918|OTHER|Scalp Acupuncture Treatment|"Acupoint Selection:~Baihui (GV20), Sishencong (EX-HN1), Frontal Midline Line (MS1), Vertex Midline Line (MS5), Lateral Line 1 of Vertex (MS7), Shenting (GV24), Yintang (EX-HN3), Shuaigu (GB8)~Acupuncture Manipulation:~Needles with a diameter of 0.18-0.35 mm and length of 13-25 mm are selected. After routine disinfection of the acupoint skin, the practitioner holds the micro-needle and quickly inserts it into the subcutaneous tissue at an insertion angle of 15°-30°, primarily using superficial horizontal insertion. The insertion depth is maintained at 15-20 mm, adjusted according to the child's head circumference, body size, and body mass. Needles are retained for 30 minutes.~Course of treatment:~2 times a week for 12 weeks"
224028880|NCT05545657|OTHER|Multimodal magnetic resonance imaging|3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.
224028881|NCT05545657|OTHER|Peripheral blood neuropathology biomarkers assay|Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.
224028882|NCT05657717|DRUG|Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey|After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.
224134781|NCT01250093|DEVICE|acupuncture|
224134782|NCT00946777|OTHER|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
224134783|NCT01914705|PROCEDURE|Landmark Procedure|Using Landmarks to guide SCVC placement
224134784|NCT01914705|PROCEDURE|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
223411669|NCT01985191|DRUG|SAR405838|"Pharmaceutical form:capsule~Route of administration: oral"
223411670|NCT01985191|DRUG|Pimasertib|"Pharmaceutical form: capsule~Route of administration: oral"
223411671|NCT03661931|DIAGNOSTIC_TEST|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
224028883|NCT05637385|BEHAVIORAL|Training of perception and oculo-motor control|Behavioral training of eye movements and perception
224028884|NCT02245672|DRUG|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
224028885|NCT02245672|DRUG|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
224028886|NCT02245672|DRUG|Placebo|Placebo administered via the CRC749 and Diskus devices
224028887|NCT00003657|BIOLOGICAL|filgrastim|
224028888|NCT00003657|DRUG|Amifostine|
224028889|NCT00003657|DRUG|Carboplatin|
224028890|NCT00003657|DRUG|Etoposide|
224028891|NCT00003657|DRUG|Ifosfamide|
224028892|NCT00003657|PROCEDURE|peripheral blood stem cell transplantation|
224028893|NCT03740594|BEHAVIORAL|KMC|Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
224028894|NCT02980237|OTHER|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
224028895|NCT02980237|OTHER|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
224028896|NCT06475443|DRUG|pyrotinib plus capecitabine|oral
224028897|NCT00153504|BEHAVIORAL|Housing and Health Study housing rental assistance|
224028898|NCT00153504|BEHAVIORAL|Standard local practice housing assistance|
224028899|NCT02580695|BIOLOGICAL|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
224028900|NCT02580695|DRUG|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
224028901|NCT02947776|BEHAVIORAL|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
224028902|NCT02947776|BEHAVIORAL|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
224028903|NCT00971932|DRUG|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.
224028904|NCT00971932|DRUG|Cisplatin/Carboplatin|Subjects will receive 100 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 \[AUC5\]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
223411672|NCT06303557|DRUG|Preoperative Erector Spinae Plane Block|Erector spinae plane block will be performed bilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, and when the patient is placed in the prone position.
223411673|NCT06303557|DRUG|Postoperative Erector Spinae Plane Block|Erector spinae plane block will be performed unilaterally, under US guidance, after the surgical operation, under general anesthesia, and when the patient is placed in the prone position.
223411674|NCT03313466|BEHAVIORAL|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
223411675|NCT03313466|BEHAVIORAL|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
223411676|NCT05648201|DRUG|Doravirine 100Mg Tab|1 single dose of 100mg taken orally
223411677|NCT05648201|DRUG|Raltegravir 600Mg Tab|1 single dose of 1200mg taken orally
223411678|NCT05648201|DRUG|Biktarvy 50/200/25 Tab|1 single dose of 50/200/25 taken orally
224028905|NCT00971932|DRUG|5-Fluorouracil|Subjects will receive 1000 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
224028906|NCT00889317|DEVICE|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
224134785|NCT02426554|DIETARY_SUPPLEMENT|DDU-supplement|DDU: Vitamin D, DHA, Uridine
224134786|NCT02426554|DIETARY_SUPPLEMENT|Placebo supplement|
223411679|NCT05896904|DIAGNOSTIC_TEST|Echocardiography|Echocardiography
223411680|NCT02097563|BEHAVIORAL|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
223411681|NCT02097563|BEHAVIORAL|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
224028907|NCT05363423|PROCEDURE|Draf III procedure with lateral pedicled nasoseptal flaps applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre. Type 1 flaps consisted of mucosa over the lateral nasal wall, and type 2 flaps consisted of the aforementioned mucosa and corresponding septal mucosa. After Draf III procedure, type 1 flaps were used to cover the bare bone of the ipsilateral frontal process and part of the ipsilateral anterior frontal table, which also constituted the bare bone area of the Draf II procedure. Type 2 flaps were used to cover for the bare bone of the ipsilateral frontal process and bilateral anterior or posterior frontal table."
224028908|NCT05363423|PROCEDURE|Draf III procedure without any flap applied|"The standard Draf III procedure was performed as described by Gross and Wormald using an outside-in technique. The cranial portion of the nasal septum was removed, and the frontal process of the maxilla and frontal beak were carefully abraded, resulting in the frontal T. Distinct to the procedure of Gross and Wormald, the frontal T was then lowered to the first branch of the anterior ethmoidal artery instead of the first olfactory fibre."
224028909|NCT02451241|OTHER|acupuncture|electroacupuncture
224028910|NCT01749020|OTHER|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
224028911|NCT01749020|OTHER|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
224028912|NCT01894633|DRUG|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
224028913|NCT01894633|RADIATION|Total brain radiotherapy|30 Gy in 10 daily fractions from Monday to Friday
224028914|NCT02301598|PROCEDURE|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
224028915|NCT01305525|DEVICE|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
224028916|NCT01097785|DRUG|Simvastatin|40 mg, P.O.,daily for 30 days
224028917|NCT01097785|DRUG|Placebo|1 capsule daily for 30 days
224028918|NCT04334733|OTHER|Cartoon group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process.
224028919|NCT04334733|OTHER|Kaleidoscope group|The children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
224028920|NCT04334733|OTHER|Cartoon+Kaleidoscope group|The children in the groups were distracted by watching cartoon 5 minutes before echocardiography process and then the children in the groups were distracted by kaleidoscope during echocardiography, until the process was over.
224028921|NCT06108037|BEHAVIORAL|Generative AI for electronic communication and disclosure|We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
224028922|NCT05807607|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
224298117|NCT06927063|DIAGNOSTIC_TEST|Structural magnetic resonance imaging (brain)|Structural magnetic resonance imaging
224298118|NCT06927063|DIAGNOSTIC_TEST|PET imaging (brain)|Positron emission tomography imaging
223411682|NCT02739425|DEVICE|Sentimag Device|The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
223411683|NCT05878002|DEVICE|polysomnography|Sleep study through polysomnographic examination
223411684|NCT04450082|PROCEDURE|One anastomosis gastric bypass|The linear stapler divides the stomach horizontally at the junction of the corpus and antrum at the level of crow's foot. In cases where the pre-operative study has shown the presence of the gastric fundus, if possible the fundus was dissected and a long, narrow gastric pouch was designed starting from beyond the crow's foot to just lateral the angle of His over a 42-Fr orogastric tube. Gastrojejunostomy was then performed between 200-220 cm distally to the ligament of Treitz using a 45-mm.
223411685|NCT03711682|DIETARY_SUPPLEMENT|Cinnamon|Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
223411686|NCT03711682|DIETARY_SUPPLEMENT|Wheat Flour|Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
223411687|NCT04691843|DRUG|Iron Sulfate|Early, high dose, iron supplementation
223411688|NCT04219124|DRUG|IMP oral tablet|Dapagliflozin 10 MG
223411689|NCT04219124|DRUG|Placebo oral tablet|Matching placebo tablets
223411690|NCT00863343|BIOLOGICAL|Public Health Notification|For any H5 positive results, notification of the result to the site's local public health authorities.
223411691|NCT04195243|DRUG|Dapagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
223411692|NCT04195243|DRUG|Empagliflozin Pill|The patient will take one pill, every 24 hr, during 7 days
223411693|NCT04195243|DRUG|Placebo pill|The patient will take one pill, every 24 hr, during 7 days
224298119|NCT06927063|PROCEDURE|Standard colonoscopy with pinch biopsies|Standard colonoscopy including pinch biopsies from the bowel wall at several levels (terminal ileum, ascending colon, transverse colon, descending colon, and rectosigmoideum) for histology, microbiome analysis and metabolomics
224028923|NCT05807607|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation|SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
224028924|NCT05807607|PROCEDURE|Change according to the scale of the PainDetect questionnaire|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
224028925|NCT01386060|OTHER|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
224028926|NCT03940053|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
224028927|NCT03005860|DRUG|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
224028928|NCT03005860|DRUG|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
224028929|NCT03005860|DRUG|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
224028930|NCT03005860|DRUG|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
224028931|NCT00499356|DEVICE|pressure reducing insole|
224028932|NCT00499356|DEVICE|GlideSoft®|
224028933|NCT01765192|DRUG|Roflumilast|Roflumilast was supplied in tablets.
224028934|NCT01765192|DRUG|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
224028935|NCT01765192|DRUG|Montelukast|Montelukast was supplied in tablets.
224028936|NCT03194815|DRUG|Intravenous immunoglobulin|This is a blood product containing antibodies from thousands of healthy donors.
224028937|NCT03194815|DRUG|Placebo|This is the control, or sham, treatment
224028938|NCT03194815|DRUG|Rituximab|Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
224028939|NCT05140525|DRUG|Macitentan Tablets|10 mg oral once daily
224028940|NCT05140525|DRUG|Riociguat|1 mg to 2.5mg oral three times daily
223559317|NCT06924918|OTHER|Tuina Treatment Group|"Prescription:~Spleen Meridian (Pi Jing), Small Heavenly Heart (Xiao Tianxin), Five Finger Joints (Wu Zhi Jie), Internal Bagua (Nei Bagua), Hand Yin-Yang (Shou Yin Yang), Upper Three Passes (Shang San Guan), Gushing Spring (Yongquan, KI-1), Leg Three Miles (Zusanli, ST-36) Manipulation Techniques~Pushing/Kneading the Spleen Meridian (Tonifying Pi Jing):~Tapping Small Heavenly Heart (Xiao Tianxin):~Kneading the Five Finger Joints (Wu Zhi Jie):~Moving the Internal Bagua (Nei Bagua):~Separating Yin and Yang (Separating Shou Yin Yang):~Pushing Up the Upper Three Passes (Pushing San Guan):~Kneading Gushing Spring (Yongquan, KI-1):~Kneading Leg Three Miles (Zusanli, ST-36):~2 times a week for 12 weeks"
223559318|NCT04147377|BEHAVIORAL|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
223559319|NCT05269225|OTHER|Organic diet|Organically produced foods.
223559320|NCT05269225|OTHER|Conventional diet|Conventionally produced foods.
224028941|NCT05140525|DEVICE|balloon pulmonary angioplasty|on hemodynamics and RV function (including advanced assessments of RV-PA coupling
224028942|NCT02285426|DEVICE|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality \[visual scale adapted from Herth 2009 and Zaric 2013\] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
224028943|NCT05032768|RADIATION|post-operative radiotherapy|Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
224028944|NCT01322048|DRUG|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
224028945|NCT01322048|DRUG|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
224028946|NCT04033848|PROCEDURE|Arthroscopic assisted ankle fracture treatment|Any complex ankle fracture, as discriped above, will be treated arthroscopically and will be prospectively followed-up using well validated PROMs
224028947|NCT05407922|PROCEDURE|Laparoscopy vs Non-laparoscopy approach|Pregnant women who will undergo a laparoscopic or open surgical exploration of the abdomen
224028948|NCT04220125|DRUG|Ketamine Group|Ketamine intravenous administration 0.5 mg/kg over 40 minutes.
224028949|NCT04220125|DRUG|Midazolam injection|Midazolam intravenous administration 0.045 mg/kg IV over 40 minutes.
224298120|NCT06927063|DIAGNOSTIC_TEST|Fecal microbiome assessments|Fecal microbiome assessments (DNA)
224298121|NCT06928363|DRUG|KY-0301|KY-0301 is an antibody-drug conjugate (ADC) targeting both EGFR and c-Met, developed independently by Novatim Immune Therapeutics (Zhejiang) Co., Ltd
224298122|NCT02646449|DRUG|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
224298123|NCT02646449|DRUG|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
223411694|NCT04551274|BEHAVIORAL|Music Therapy|Music Therapy interventions involve the use of live music (performed or created by the therapist and/or patient), and a process that includes patient-specific assessment, treatment, and evaluation
223411695|NCT04049162|DIETARY_SUPPLEMENT|Blueberry Plus Exercise (BB-EX)|Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
223411696|NCT04049162|DIETARY_SUPPLEMENT|Blueberry Placebo Plus Exercise (P-EX)|Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
223411697|NCT01421225|DEVICE|Closed-loop Insulin Pump therapy|Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
223411698|NCT01421225|DEVICE|Standard Insulin Pump Therapy|Subjects insulin doses followed their usual home routine.
223411699|NCT04155216|BEHAVIORAL|Relaxation and guided imagery program|Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
223411700|NCT04398589|DRUG|Dexmedetomidine injection|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
223411701|NCT04398589|DRUG|Saline injection|We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
224134787|NCT03247205|BEHAVIORAL|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
224134788|NCT06425783|PROCEDURE|Warmed Blood Transfusion|"The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K."
223411702|NCT03618173|DRUG|Dexamethasone|IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
224028950|NCT02797353|OTHER|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
224028951|NCT06445309|OTHER|Sensory test of functional plant-based drink|Once the volunteers have been recruited, a telephone interview lasting less than 10 minutes will be carried out where what the study consists of will be explained as well as the information sheet for the participant will be read to them so that they understand what the study consists of. study. Once the necessary questions have been asked according to the inclusion criteria, if the participant enters the study, data such as name, surname, age, gender, smoker, consumer of vegetable drinks, pathologies and contact information will be collected. If the participant does not enter the study, their personal data will no longer be collected and they will be informed that according to the exclusion criteria they can no longer participate in the study. Once these data are obtained, it will be randomized using the EXCEL program.
224028952|NCT00084578|DRUG|celecoxib|
224028953|NCT00084578|DRUG|rosiglitazone maleate|
224028954|NCT00084578|PROCEDURE|conventional surgery|
224028955|NCT00084578|PROCEDURE|neoadjuvant therapy|
224028956|NCT00519961|DEVICE|Elecsys®proBNP|
224134789|NCT02467647|DRUG|Thalidomide|
223411703|NCT03618173|DRUG|Placebos|IV saline serum at the dose of 0,2mL/kg maximum 8mL
224134790|NCT02467647|DRUG|HLJDT|
224134791|NCT00006054|DRUG|anti-thymocyte globulin|
224134792|NCT00006054|DRUG|busulfan|
224134793|NCT00006054|DRUG|cyclophosphamide|
224134794|NCT00006054|DRUG|cyclosporine|
224134795|NCT00006054|DRUG|etoposide|
223411704|NCT00911612|DRUG|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
223411705|NCT00911612|DRUG|Placebo|Inert capsule matching the study drug, given twice daily
223411706|NCT02049814|DRUG|Metformin|Metformin tablets
223411707|NCT02049814|DRUG|Voglibose|Voglibose tablets
224134796|NCT00006054|DRUG|methotrexate|
224134797|NCT00006054|DRUG|methylprednisolone|
223411708|NCT02049814|DRUG|Acarbose|Acarbose tablets
223411709|NCT00786981|OTHER|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
223411710|NCT00786981|OTHER|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
223411711|NCT05354778|DRUG|Hydrocortisone|Corticosteroid
223411712|NCT05354778|DRUG|Placebo|Normal saline only
223411713|NCT00832611|DEVICE|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
223411714|NCT06389305|DRUG|peripheral blood lymphocytes|autologous or allogeneic peripheral blood lymphocytes
224134798|NCT00006054|DRUG|prednisone|
224134799|NCT00006054|PROCEDURE|Allogeneic Bone Marrow Transplantation|
224028957|NCT03258333|PROCEDURE|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
223411715|NCT06389305|DRUG|CIK cell|autologous or allogeneic cytokine-induced killer (CIK) cells
223411716|NCT02292953|OTHER|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
224134800|NCT01934192|DRUG|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
224134801|NCT01934192|DRUG|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
224134802|NCT01934192|DRUG|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
223411717|NCT00532753|BEHAVIORAL|Community Empowerment|
223411718|NCT05969769|OTHER|Thoracic Sustained Natural Apophyseal Glides|Sustained Natural Apophyseal Glides 3 sets of 10 reps with 1 min rest btw sets.
223411719|NCT05969769|OTHER|Muscle Energy Techniques|Short wave diathermy for 10 to 15 mins Muscle Energy Techniques of following muscles will be performed, Hip flexors muscles, Quadrates lamborum muscles, Erector spinae muscles, Piriformis muscles, PFS technique of METs Isometric hold 5-7 sec, Stretching 15 sec, Rest 30 sec.
223411720|NCT04758364|OTHER|measurement of gait speed|Cross sectional, cohort
224028958|NCT04694898|BEHAVIORAL|Standard programme|The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron \& folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.
224134803|NCT01934192|DRUG|Placebo IV|Placebo will be administered IV every 6 hours
224134804|NCT01760824|DRUG|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
224134805|NCT01760824|DRUG|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
224134806|NCT05249816|BIOLOGICAL|NVX-CoV2373|A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant
224134807|NCT05249816|BIOLOGICAL|BBIBP-CorV vaccine|BBIBP-CorV vaccine administered per manufacturer instructions.
224134808|NCT03714035|OTHER|no intervention|no intervention
223411721|NCT04138472|DRUG|dexmedetomidine|intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
223411722|NCT04138472|DRUG|fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
223411723|NCT04138472|DRUG|lidocaine|intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
223411724|NCT01091857|BEHAVIORAL|STRIDE|
223559321|NCT04085653|DRUG|alpelisib|"Alpelisib will be provided as 50 mg, 125mg and 200 mg film coated tablets as individual patient supply, and will be dosed on a flat scale of mg/day not to be adjusted to body weight or surface area.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a maximum starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
224028959|NCT04694898|BEHAVIORAL|SURE intervention|"The SURE package includes: 1) promoting diversified agriculture; 2) promoting infant and young child feeding practices; 3) women empowerment in decision making related to agriculture, food and health; and 4) enhanced food security and Water, Sanitation and Hygiene (WASH) practices."
224028960|NCT01924351|RADIATION|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
224134809|NCT00347763|PROCEDURE|10% permethrin in water applied as low volume spray|
224134810|NCT04208763|DRUG|Imipenem|Inj Imipenem 1gm i.v. TDS
224298124|NCT00586482|DRUG|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
223411725|NCT06141174|OTHER|disease outcome ( mortality and length of stay )|insertion of intercostal tube to drain pleural collection
223559322|NCT03452033|DRUG|H-1337 Placebo|H-1337 Placebo Vehicle
223559323|NCT03452033|DRUG|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
223559324|NCT03452033|DRUG|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
223559325|NCT03452033|DRUG|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
223559326|NCT05012007|OTHER|Reminder Phone|Standard reminder via phone (audiocare)
223559327|NCT05012007|OTHER|Reminder Text|reminder via text (VEText)
223559328|NCT04511871|BIOLOGICAL|CCT303-406|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT303-406. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single dose of CCT303-406 via intravenous injection.
223559329|NCT02784119|PROCEDURE|temporary porto-caval shunt|temporary porto-caval shunt
224028961|NCT03282487|DRUG|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
224028962|NCT00281333|BEHAVIORAL|"Karate exercises and strengthening exercises"|
224134811|NCT04208763|DRUG|Tigecycline|Inj Tigecycline 100mg stat f/b 50mg i.v. OD
224134812|NCT04208763|DRUG|GMCSF|Inj GM-CSF 500mcg s.c. OD
224134813|NCT04208763|DRUG|Colistin|Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
224134814|NCT01189435|DRUG|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
224298125|NCT00586482|DRUG|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
223411726|NCT04777786|OTHER|Physical Therapy|Individualized physical therapy treatments will be provided based on impairments identified during assessments. Treatment may include but is not limited to the following: passive, assisted and active ROM, manual therapy, soft tissue massage, myofascial release, therapeutic activities and exercise and patient education. Treatment duration and frequency will be specific to each patient, providing personalized care. This type of intervention is considered a pragmatic approach, which will allow for generalization of the results due to the similarity with clinical practice.71 Pilot data indicates women will receive physical therapy intervention 1-2x/week for 3-6 weeks beginning \~4 weeks after surgery (x̄=10 visits).
224028963|NCT02918123|BIOLOGICAL|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
224028964|NCT04344600|DRUG|Peginterferon lambda alfa-1a subcutaneous injection|Peginterferon lambda-1a 180 micrograms by subcutaneous injection
224134815|NCT02787434|OTHER|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
224134816|NCT02118610|DRUG|L-tetrahydropalmatine (30mg)|Active comparator
224134817|NCT02118610|DRUG|Sugar pill|Placebo
223411727|NCT00214786|BIOLOGICAL|Islet cell transplantation|Allogenic islet transplantation
223411728|NCT02993250|DRUG|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
223411729|NCT02993250|DRUG|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
223411730|NCT02993250|DRUG|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
223411731|NCT06574958|BIOLOGICAL|CD38/CS1 injection|"Dosage form and specification: injection, 40mL/ dose, according to the number of positive cells 1×106/kg Properties: Colorless or slightly light white clear liquid Prescription composition: CD38/CS1 CAR T cells, 2.5% human blood albumin, 0.9% sodium chloride injection.~Administration mode: intravenous injection Storage condition: 2-8℃ for 8h Mechanism of action :38WP as a dual-target CAR T cell therapy, compared with single-target CAR T cell therapy, its advantage is that it can reduce antigen escape of tumor cells."
223411732|NCT05582408|DEVICE|Measures of Standard Noise Reduction NR1|Each participant will be fitted with the Standard Noise Reduction (NR1)
224134818|NCT03627910|DIETARY_SUPPLEMENT|symbiotic|Feed supplementation
224134819|NCT03627910|DIETARY_SUPPLEMENT|zinc and arginine|Feed supplementation
224134820|NCT04989010|DRUG|89Zr-NY005|89Zr-NY005 injection followed by 89Zr-NY005 PET scan
224134821|NCT05689658|BEHAVIORAL|Brazilian Diabetes Prevention Program|A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity
224134822|NCT05689658|BEHAVIORAL|Diet|Hypocaloric diet prescription
224134823|NCT05328921|DRUG|Antihypertensive Agents|Patients with narrow angle glaucoma and on systemic antihypertensive drugs.
224134824|NCT05328921|DRUG|Antihistaminics|Patients with narrow angle glaucoma and on systemic antihistaminic drugs.
223411733|NCT05582408|DEVICE|Measures of Noise Reduction Principle NR2|Each participant will be fitted with the novel Noise Reduction principle NR2 on the same hearing aid
224028965|NCT04344600|OTHER|Saline|Saline subcutaneous injection
224028966|NCT00846339|DRUG|Bupropion|bupropion
224028967|NCT04261335|BIOLOGICAL|CL2020 cells|1.5 million or 15 million cells, IV on day 5 to 14 of birth
224028968|NCT00036686|DIETARY_SUPPLEMENT|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
224028969|NCT00036686|OTHER|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
224134825|NCT05277649|OTHER|Exercise programme|Performing a programme of warm-up and stretching exercises for the cervico-mandibular region aimed at improving mobility and muscle condition.
224134826|NCT01641549|PROCEDURE|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
224134827|NCT01641549|DRUG|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
224134828|NCT01605591|PROCEDURE|the DLT bending to the right|bending the bronchial lumen of DLT 60\~90 degrees in the same side with the tracheal lumen
224134829|NCT01605591|PROCEDURE|the DLT bending to the left|bending the bronchial lumen of DLT 60\~90 degree opposed to the tracheal lumen
224134830|NCT02952326|PROCEDURE|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
224134831|NCT02952326|PROCEDURE|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
224298126|NCT00586482|BEHAVIORAL|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
223411734|NCT05582408|DEVICE|Measure of Noise Reduction Principle NR3|Each participant will be fitted with the novel Noise Reduction principle NR3 on the same hearing aid
223411735|NCT02571842|DRUG|Intravenous Rituximab|\- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
223411736|NCT02571842|DRUG|ACEI/ARB and corticosteroids|"* ACEI or ARB will be prescribed as high as tolerable dose.~* Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
224028970|NCT03459144|DRUG|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
224028971|NCT03459144|DRUG|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
224028972|NCT04854369|DRUG|68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit|The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.
224028973|NCT00837551|DRUG|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
224028974|NCT00876694|DRUG|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
224028975|NCT00876694|DRUG|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
224028976|NCT02773875|DEVICE|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
224028977|NCT00288509|BIOLOGICAL|Botulinum toxin type A|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety \& efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
224028978|NCT03506282|OTHER|Running while listening to a traffic audio track|While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
224028979|NCT03506282|OTHER|Running with music at moderate volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB)."
224028980|NCT03506282|OTHER|Running with music at moderate-to-high volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB)."
223411737|NCT02566642|OTHER|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
223411738|NCT01888445|DRUG|roxadustat|oral
223411739|NCT01888445|DRUG|darbepoetin alfa|iv
223411740|NCT01250574|OTHER|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
224134832|NCT05775744|OTHER|Tight postpartum blood pressure control|The standard of care for patients with pregnancy induced hypertension is to start antihypertensive therapy if blood pressures are consistently over 150/100 mm Hg. There is no established standard of care for titrating blood pressure medication in the postpartum period for those with chronic hypertension and the approach to these patients varies by institution. The intervention in this study will be to start antihypertensive medications at a lower blood pressure cutoff, which is commonly used in the non-pregnant patient population to more tightly control blood pressure. Remote patient monitoring may be considered standard of care. The blood pressure targets chosen for this study are considered to be standard of care for non-pregnant people.
223411741|NCT01250574|OTHER|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
223411742|NCT01416974|DRUG|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
223411743|NCT01416974|BIOLOGICAL|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
223411744|NCT02037191|DRUG|Methotrexate|"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
223411745|NCT02037191|DRUG|Placebo|"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
223411746|NCT05871944|OTHER|KAlternborn Joint Mobilization|This is a join mobilization technique to reduce the joint stiffness and help in improving joint range of motion
224134833|NCT06521957|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
223411747|NCT05871944|OTHER|Post stretch Facilitation Technique|This is a PNF techniques used to relax the muscles and help in getting more free range of restricted joint
223411748|NCT03172923|DEVICE|sliding hip screw|fixation of the fracture with a sliding hip screw
223411749|NCT03172923|DEVICE|intramedullary nial|fixation of the fracture with an intramedullary nail
223411750|NCT02527434|BIOLOGICAL|Tremelimumab monotherapy|IV infusion
223411751|NCT02527434|BIOLOGICAL|MEDI4736 monotherapy|IV infusion
223411752|NCT02527434|BIOLOGICAL|MEDI4736 + tremelimumab combination therapy|IV infusion
223411753|NCT00713258|DRUG|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
223411754|NCT00713258|DRUG|Alendronate|70 mg alendronate weekly
223411755|NCT02897219|DRUG|ipragliflozin|Oral administration once daily
223411756|NCT02897219|DRUG|Placebo|Oral administration once daily
223411757|NCT02897219|OTHER|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
223411758|NCT01832558|DRUG|Eplerenone|
223411759|NCT01832558|DRUG|Placebo|
223411760|NCT01322490|BIOLOGICAL|PROSTVAC-V|
223411761|NCT01322490|BIOLOGICAL|PROSTVAC-F|
223411762|NCT01322490|DRUG|GM-CSF|
223411763|NCT01322490|OTHER|GM-CSF Placebo|
223411764|NCT01322490|BIOLOGICAL|Placebo|PROSTVAC V/F Placebo
223411765|NCT05654870|DRUG|Valbenazine|Oral treatment
223411766|NCT05654870|DRUG|Placebo|Placebo matching valbenazine
223411767|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
223411768|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
224028981|NCT04559880|DRUG|Tranexamic Acid Injection [Cyklokapron]|Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
224028982|NCT01535014|DRUG|Dietressa|Comparison of different dosages (frequency) of drug
224134834|NCT04200716|BEHAVIORAL|Moderate intensity continuous training - session|Moderate exercise continuous exercise 30 minuts session
224134835|NCT04200716|BEHAVIORAL|High intensity interval training - session|The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
224134836|NCT00832546|DRUG|Placebo|
224134837|NCT00832546|DRUG|Oral NGX426 (Powder in solution)|
224134838|NCT01473810|BIOLOGICAL|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
224134839|NCT01473810|BIOLOGICAL|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
224134840|NCT01473810|BIOLOGICAL|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
224134841|NCT01473810|BIOLOGICAL|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
224134842|NCT02408055|DRUG|TA-8995|
224134843|NCT02831075|BIOLOGICAL|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
224134844|NCT02831075|BIOLOGICAL|saline|
224134845|NCT04691752|OTHER|Audit|Audit from clinical records
224134846|NCT03817255|OTHER|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
224134847|NCT03817255|OTHER|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
224134848|NCT04423614|OTHER|Inspiratory Muscle Training|Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
224134849|NCT04423614|OTHER|Relaxation Breathing|Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
224134850|NCT02223455|OTHER|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
224134851|NCT01948284|PROCEDURE|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
224134852|NCT01948284|PROCEDURE|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
224134853|NCT01948284|DEVICE|Suction Unit|
223411769|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program|Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
223411770|NCT04852068|BIOLOGICAL|Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program|Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
223411771|NCT00014430|BIOLOGICAL|trastuzumab|"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.~The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation-functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."
224028983|NCT01535014|DRUG|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
224028984|NCT01209845|DRUG|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
224028985|NCT04350216|DRUG|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|"The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study."
224134854|NCT01477190|DRUG|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.
224134855|NCT01477190|DRUG|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
224134856|NCT04901403|OTHER|Education|Parents will be provided with information about Earned Income Tax Credits and budgeting
224134857|NCT04901403|OTHER|Home visiting|Parents as Teachers home visiting program
224134858|NCT01155648|DEVICE|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
224134859|NCT01155648|DEVICE|Chest wall compression for ten minutes in chest|
224134860|NCT06555237|DRUG|Trametinib tablet|Trametynib orally once daily in 0,025mg/kg dose
224134861|NCT06555237|DRUG|Standard therapy|Disopiramide and Beta blockers orally
224134862|NCT02399839|DRUG|lomitapide|As prescribed by Physician.
224134863|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
224134864|NCT01374815|OTHER|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
223411772|NCT00014430|DRUG|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
224028986|NCT04549337|BEHAVIORAL|Exercise training|"Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity."
224028987|NCT05741151|DIAGNOSTIC_TEST|PET-Neck Parkinsonian patients|Brain and neck PET-CT scan with 68Ga-PSMA to detect metabolism in the Superior Cervical Ganglion of both sides.
224028988|NCT05427721|DRUG|Thymol|200 mg each 8 hours for 90 days
223411773|NCT05339633|DRUG|[14C]-D-0502|Drug: \[14C\]-D-0502 and D-0502
223411774|NCT06139900|OTHER|Assessment|No intervention will be applied to the participants. Postural stability will be evaluated in the virtual reality environment and real environment.
223411775|NCT01431716|DRUG|EFI/ACT-385781A|
224028989|NCT04322942|DIAGNOSTIC_TEST|Monocyte Distribution Width|Monocyte Distribution Width as part of the CBC result.
224028990|NCT02844881|DRUG|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
224028991|NCT02844881|BIOLOGICAL|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
224028992|NCT02349451|BIOLOGICAL|adalimumab|
224028993|NCT02349451|BIOLOGICAL|ABT-122|
224028994|NCT04494581|OTHER|questionnaire|Questionnaire survey
224028995|NCT03643120|OTHER|Qualitative interview|Explorative study of gender dysphoria.
224028996|NCT01103635|BIOLOGICAL|CD40 agonist monoclonal antibody CP-870,893|Given IV
224028997|NCT01103635|BIOLOGICAL|tremelimumab|Given IV
224028998|NCT01103635|OTHER|laboratory biomarker analysis|Correlative studies
224028999|NCT02907931|OTHER|Point of Care Ultrasound|
224029000|NCT05023395|DRUG|MEE-HU Medicus|This investigational medicinal product (MEE-HU Medicus) is a patented mixture of amino acids and pentose sugar. The mixture according to the invention in particular is suitable as medicine for resistance-breaking of antibiotic resistances of pathogens, in particular for resistance-breaking of multiple antibiotic resistances, a method for decreasing bacterial resistance to antibiotics.
224029001|NCT05023395|OTHER|Placebo|Placebo
224029002|NCT02301650|DRUG|Lamivudine|mothers use Lamivudine in late pregnancy
224029003|NCT02301650|DRUG|Telbivudine|mothers use Telbivudine in late pregnancy
224029004|NCT02301650|DRUG|Tenofovir|mothers use Tenofovir in late pregnancy
224029005|NCT02673203|DEVICE|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
224029006|NCT02673203|BEHAVIORAL|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
224029007|NCT01097239|DEVICE|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
224029008|NCT01268722|DEVICE|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
224029009|NCT01268722|DEVICE|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
224134865|NCT03386656|DRUG|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
224134866|NCT03386656|OTHER|Saline Solution|Placebo
224134867|NCT05844800|PROCEDURE|Nuss repair of Pectus Excavatum|The Nuss procedure is a minimally-invasive repair technique of PE (MIRPE), whereby one to three curved metal bars are inserted behind the sternum to correct the shape of the anterior chest wall. The bars are left in situ for three years and then removed.
224134868|NCT05844800|DRUG|Epidural anesthesia|The Nuss procedure of pectus excavatum repair surgery is performed under general anesthesia. Epidural anesthesia, with a constant infusion of 0.25% bupivacaine, was routinely used and was maintained in the early postoperative period.
223411776|NCT02648139|DRUG|Dentifrice|3x/day for 7 days.
223411777|NCT02655822|DRUG|Ciforadenant|100 mg orally twice daily for the first 14 days of each 28-day cycle.
223411778|NCT02655822|DRUG|Ciforadenant|100 mg orally twice daily for 28 days of each 28-day cycle.
223411779|NCT02655822|DRUG|Ciforadenant|200 mg orally once daily for the first 14 days of each 28-day cycle.
223411780|NCT02655822|DRUG|Ciforadenant + atezolizumab|Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
223411781|NCT02655822|DRUG|Ciforadenant|Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
224134869|NCT06495307|DRUG|rhPRG4|Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
224134870|NCT03468699|COMBINATION_PRODUCT|Autologous BMMC transplantation|Stem cell transplantation
224134871|NCT05678985|BEHAVIORAL|Choose to Move|As described under study arm description.
224029010|NCT01756612|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
224029011|NCT02386709|DEVICE|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
224029012|NCT04223869|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
224029013|NCT05116046|BIOLOGICAL|Recifercept|Recifercept
224029014|NCT05737186|DRUG|SGLT-2 inhibitor|dapagliflozin
224029015|NCT02602054|PROCEDURE|Surgical treatment|Standard left thoracotomy
224029016|NCT02602054|DRUG|Control group|"\- Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~\- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days"
224029017|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cell) group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
224029018|NCT04646590|BIOLOGICAL|Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper arm of 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells) placebo.
224029019|NCT00424866|DRUG|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
224029020|NCT00424866|DRUG|Placebo|Vehicle: 0 µg/kg
224029021|NCT00429312|BIOLOGICAL|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
224029022|NCT05751291|DRUG|Bupivacaine Hydrochloride|"Pericapsular Nerve Group (PENG) Block: 20 mL of 0.25% bupivacaine will be injected in increments while observing for an adequate fluid spread in this plane. Fascia Iliaca Compartment (FIC) Block: 20 mL of 0.25% bupivacaine will be injected until it spreads.~laterally toward the iliac spine and medially toward the femoral nerve."
224029023|NCT02683941|DRUG|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
224029024|NCT02683941|DRUG|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
224029025|NCT02683941|DRUG|Best Supportive Care|Best Supportive Care is best available therapy at the choice of the investigator
224029026|NCT03242551|DRUG|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
224029027|NCT05843513|OTHER|Monitoring (observational study)|The relationship between dental wear and the behaviour of the participants will be analysed.
224029028|NCT02623153|DRUG|Oxaliplatin|oxaliplatin 130 mg/m2
224029029|NCT02623153|DRUG|capecitabine|capecitabine of 1000 mg/m2
224029030|NCT02623153|DRUG|S1|S1 of 40 mg/m2
224029031|NCT02623153|DRUG|Docetaxel|docetaxel 40 mg/m2
224029032|NCT04459065|DRUG|IRDye800CW-nimotuzumab|50 mg of IRDye800CW-nimotuzumab will be infused intravenously over a period of 30 minutes. Lung cancer resection surgery will be done at different time points post infusion
224029033|NCT06186453|BEHAVIORAL|Father-Preterm Newborn Bonding Program|B-PreBAP will be applied to the fathers in the intervention group. B-PreBAP application will consist of two stages. The first stage will be passive participation and the second stage will be active participation. B-PreBAP will be applied to fathers for a total of two weeks (Heo \& Oh, 2019). In order to prevent interaction between the fathers in the intervention group and the fathers in the control group, the intervention will not be carried out during the routine visiting and information hours of the NICU (13:30-14:30 on Mondays, Wednesdays and Fridays). In the first two interviews, NICU introduction and B-PreBAP education about preterm newborns will be given. In the last three interviews, fathers will be involved in one-to-one practices with their preterm newborns.
224029034|NCT00261846|DRUG|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
224134872|NCT06118567|DRUG|Nitrous oxide|Nitrous oxide gas.
224029035|NCT04980937|PROCEDURE|Microsurgical reconstruction of peroneal nerve with or w/o nerve grafts.|
224029036|NCT03807674|PROCEDURE|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
224029037|NCT03630341|DRUG|Clomiphene Citrate 50mg|oral 50 mg tablets
224029038|NCT03630341|DRUG|L-carnitine|1000 mg oral tablet
224029039|NCT03630341|DRUG|Placebo Oral Tablet|oral tablets identical to L-carnitine
224134873|NCT06118567|DRUG|Room Air|Room Air
224134874|NCT03095521|DRUG|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
224134875|NCT03095521|DRUG|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
224029040|NCT04334434|OTHER|Telerehabilitation|15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist
223411782|NCT04217096|DRUG|Paclitaxel liposome|Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic
223411783|NCT04217096|DRUG|S-1|Patients receive S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；\>1.50m\^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
224298127|NCT02932228|OTHER|ImPACT|"The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
223411784|NCT03249012|OTHER|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
223411785|NCT03249012|OTHER|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
223411786|NCT05306912|BIOLOGICAL|Blood samples|Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
223411787|NCT02549326|DIETARY_SUPPLEMENT|vitamin D|
223411788|NCT02549326|DIETARY_SUPPLEMENT|Placebo|
223411789|NCT00862004|PROCEDURE|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
223411790|NCT00542399|DRUG|Levemir (insulin detemir)|Levemir once a day
223411791|NCT00542399|DRUG|Levemir twice a day|Levemir twice a day
224298128|NCT06128720|DEVICE|Hyperbaric Oxygen|Participant will undergo 60 minutes of Hyperbaric oxygen at 1.5ATA while breathing 100% oxygen
224298129|NCT06128720|DEVICE|Sham Hyperbaric Oxygen|Participant will undergo 60 minutes of Sham Hyperbaric Oxygen at atmospheric pressure while breathing room air.
223411792|NCT05280938|BEHAVIORAL|MAAP|Women randomized to the MAAP intervention will complete an 8 week (2hr/wk) hybrid adapted Kabat-Zinn's MBSR.(Kabat-Zinn, 1990) MAAP intervention includes activities related to spirituality, self-empowerment, interdependence, and story-telling, which are salient to AAW.(Watson-Singleton et al., 2019) Women will receive practice links and a program work book (5th grade level) containing objectives and weekly MAAP activities/. Individual weekly home practice is expected. Type and minutes of home practice will be recorded in weekly logs. Program attendance, type, amount of practice, and changes in mindfulness (Five Facet Mindfulness Questionnaire) will be included in data analysis.
223559330|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
223559331|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM SMOG|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
224029041|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Oil|The study foresees the intake of 2 capsules per day during 84 days
224029042|NCT06048354|DIETARY_SUPPLEMENT|Wheat Polar Lipid Complex Powder|The study foresees the intake of 2 capsules per day during 84 days
224029043|NCT06048354|DIETARY_SUPPLEMENT|Placebo|The study foresees the intake of 2 capsules per day during 84 days
224029044|NCT05032079|PROCEDURE|cryoablation|single probe ultrasound guided cryoablation
224029045|NCT01228708|OTHER|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
224029046|NCT01660126|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
224029047|NCT01660126|DRUG|Placebo|
224029048|NCT00078611|DRUG|natalizumab|
224029049|NCT03049176|DRUG|PrEP (Truvada)|oral, daily Truvada for HIV-negative participants
224029050|NCT03049176|DRUG|Antiretrovirals|oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant
224298130|NCT06112184|OTHER|SK-M11/3A1 Digital health program|Digital Health program with participants using an autoinjector delivered via the Sidekick mobile application (app)
224029051|NCT03049176|PROCEDURE|Semen washing|collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination
224029052|NCT03049176|PROCEDURE|Artificial vaginal insemination|collection of semen from an HIV-negative man, followed by intravaginal insemination
224298131|NCT06169657|DEVICE|Body-weight-supported treadmill training (BWSTT)|Walking on a treadmill in a harness with body weight support as needed
224298132|NCT06169657|DEVICE|EksoNR exoskeleton gait training|Walking in the EksoNR exoskeleton
223411793|NCT05280938|BEHAVIORAL|Educational Program|"The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects."
223411794|NCT06198153|OTHER|Stationary Cycling|In addition to the conventional physical therapy, children in this group will receive 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks.
223411795|NCT06198153|OTHER|Progressive Functional Training|In addition to the conventional physical therapy, the training will follow a 6-week progressive functional training program for lower extremities. These exercises will include sit-to-stand exercise, lateral/forward step-up exercise (i.e. climbing a stair or stepping up onto a kerb), and half-knee rise exercise (i.e. rising from the ground). All exercises will be performed in 1-3 sets of 10-15 repetitions, with a 90 second rest in between the sets. Each exercise will be performed within 10-15 minutes. Training session will be given 3 times a week. During the training, intensity will be progressively increased by increasing the repetitions
224029053|NCT04932668|OTHER|Feasibility and Impact of Home-based Electrical Stimulation Program|"Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion."
224029054|NCT02286778|DIETARY_SUPPLEMENT|Acetogenins|Acetogenins BID for 12 months
224029055|NCT02286778|DIETARY_SUPPLEMENT|Placebo|
224029056|NCT03650478|DEVICE|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
223411796|NCT00568061|DRUG|Nitric Oxide|Nitric oxide for inhalation
223411797|NCT00568061|DRUG|Placebo|Nitrogen gas (placebo) for inhalation
223411798|NCT00857987|DRUG|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
223411799|NCT00857987|OTHER|Placebo|Vehicle
223411800|NCT05043207|DIAGNOSTIC_TEST|uAud|Patients will receive hearing aid treatment based on an audiometry obtained with an user-operated automated audiometry procedure
223411801|NCT05043207|DIAGNOSTIC_TEST|Traditional audiometry|Patients will receive hearing aid treatment based on an audiometry obtained with an traditional audiometry procedure
224029057|NCT03650478|DEVICE|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
224029058|NCT02922309|BEHAVIORAL|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
224029059|NCT02922309|BEHAVIORAL|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
224029060|NCT02749240|OTHER|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
224029061|NCT00343252|DRUG|teriparatide|20 ug/day, subcutaneous, 18 months
224029062|NCT00343252|DRUG|risedronate|35 mg/once weekly, oral, 18 months
224029063|NCT00343252|DRUG|placebo|once weekly, oral, 18 months
224029064|NCT00343252|DRUG|placebo|daily, subcutaneous, 18 months
223411802|NCT03656497|OTHER|Observational|No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia
223411803|NCT05027451|DRUG|IXT-m200|Anti-methamphetamine chimeric monoclonal antibody (mAb)
223411804|NCT05027451|OTHER|Placebo|Normal saline
223411805|NCT01896128|DRUG|Armodafinil|
223411806|NCT01896128|DRUG|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
224029065|NCT00572390|DRUG|oestrogen|Cyclic oestrogen substitution therapy
224029066|NCT00459160|PROCEDURE|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
224029067|NCT03742167|OTHER|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
224029068|NCT00988871|DEVICE|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
224029069|NCT03453931|DRUG|Corticosteroid injection|Intravenous high dose corticosteroids
224029070|NCT01740323|DRUG|Placebo|daily placebo for 6 weeks
224029071|NCT01740323|DRUG|Curcumin|500 mg BID
224029072|NCT02274194|DEVICE|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
223411807|NCT02307279|DEVICE|Gelesis100|
223411808|NCT02307279|DEVICE|placebo|
223411809|NCT01692379|DEVICE|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
223411810|NCT01692379|OTHER|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
223411811|NCT00003620|DRUG|alvocidib|Given IV
223411812|NCT00003620|OTHER|laboratory biomarker analysis|Correlative studies
223411813|NCT02173002|OTHER|myIBDcoach|
223411814|NCT02173002|OTHER|Standard care|
223411815|NCT02390921|DRUG|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
223411816|NCT02390921|DRUG|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
223411817|NCT04514874|OTHER|Questionnaire|Self-questionnaire about socio-demographical status, health status and lifestyle habits during and following the COVID-19 pandemic.
223411818|NCT06685263|BEHAVIORAL|Group 1|The development group comprises 385 individuals. Following the data collection phase of the development group, the independent risk factors for the onset of delirium will be identified through statistical analysis. A delirium prediction model will then be constructed using the identified risk factors.
223411819|NCT06685263|BEHAVIORAL|Group 2|The validation group comprises 385 individuals. The delirium prediction model created using the data from the development group will be validated by testing the data from the validation group. This will enable the evaluation of the model's fit and calibration in predicting delirium.
223411820|NCT04974060|DRUG|Remifentanil Injection|Dilute 2mg Remifentanil with normal saline to 50 ml (40ug/ml) and continuously intravenous infused at the doses of 0.02, 0.04, 0.06, and 0.08 μg/kg/min for each lasting 30 minutes.
223411821|NCT06029413|PROCEDURE|myo + fascial injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as well as for fascial layers as described.
223411822|NCT06029413|PROCEDURE|traditional trigger point injection|10 cc 0.5 % lidocain solution injection for intermuscular hypersensitive nodule as described.
223411823|NCT06464718|DRUG|Fortibone|Participants were given daily sachet containing 5g of Bio active collagen peptides (Fortibone). Electrolyte mix containing 500 mg calcium as calcium lactate, 4 MCg calcitriol and selenised yeast rich in vitamin D3 (400IU) (Colabone®, Vivapharm SA).
223411824|NCT06464718|DRUG|Chewable Tablet|calcium compound containing 25 g calcium carbonate (500mg elemental calcium) and vitamin D3 400IU taken daily
223411825|NCT06620172|PROCEDURE|CT-guided Radiofrequency Thermocoagulation (RFT)|Participants in this group will undergo CT-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure involves real-time CT imaging to guide the placement of the needle and monitor the process.
223411826|NCT06620172|PROCEDURE|Fluoroscopy-guided Radiofrequency Thermocoagulation (RFT)|Participants in this group will undergo fluoroscopy-guided trigeminal ganglion radiofrequency thermocoagulation (RFT). The procedure utilizes fluoroscopic imaging for needle placement and monitoring.
223411827|NCT05146518|BEHAVIORAL|Supportive and Dignified Maternity Care|"The core components of intervention would include: capacity-building of a typical maternity team comprising clinical staff (gynaecologists, doctors, nurses) and support staff (ward boys/porters and maids); collaborative care, a team-driven approach, led by gynaecologists (ward in-charge), attempts to integrate care and behaviour practices of staff according to the principles of measurement-guided care-plans, quality improvement and accountability, with a focus on meeting SDMC needs; staff and patient feedback: a complaints register will be maintained by designated staff; and brief exit interviews will elicit, and record, the degree to which care has been supportive and respectful; Accountability and governance (performance review): reports of non-respectful care will be discussed, and remedial actions decided, in periodic meetings.~Note: Since it is a behavioural intervention being administered at health system level so LSHTM has exempted this study to have a sponsor."
223411828|NCT05741801|OTHER|interviews|observations of healthcare professionals working in hospitals (outreach/sepsis team), one-on-one interviews with healthcare professionals, and focus groups or interviews with ex-patients/family members.
223411829|NCT01677572|DRUG|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
223411830|NCT01677572|DRUG|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
223411831|NCT01999699|BIOLOGICAL|HEPLISAV|
223411832|NCT03445546|DIAGNOSTIC_TEST|diagnostic test of platelet function|Light transmittance aggregometry and VerifyNow
223559332|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
224029073|NCT02274194|DEVICE|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
224029074|NCT05286697|DIAGNOSTIC_TEST|measuring optic nerve diameter|During the measurement of the optic nerve diameter, a layer of sterile water-soluble gel will be applied on the closed eyelid with a linear 10-5 MHz ultrasound probe.
224029075|NCT06486038|DIAGNOSTIC_TEST|MRI standard and qMRI|Non-contrast cervical spine MRI including morphological and quantitative MRI sequences on a 3 Tesla scanner. MRI examination includes conventional and experimental sequences
224029076|NCT06486038|OTHER|MEPs and SSEPs|Neurophysiological examination by motor and somatosensorial evocked potential using transcranial magnetic stimulation and electrical stimulation to the peripheral nerve
224029077|NCT06486038|OTHER|Neuromotor assessment|Upper and Lower limb assessment: Purdue Pegboard Test (PTT), Box and Block test (BBT), Nine Hole Peg Test (NHPT), gait analysis and 30 seconds sit to stand test (30CST)
223411833|NCT03058250|OTHER|Transesophageal echocardiography|
223411834|NCT02693002|DRUG|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
223411835|NCT02693002|DRUG|Placebo|inactive ingredient
223411836|NCT04594070|DRUG|Ferrous sulfate|Iron supplementation
223411837|NCT00708214|DRUG|BIBW 2992|BIBW 2992 at high and medium dosages
223411838|NCT00708214|DRUG|BIBW 2992|BIBW 2992 at high and medium dosages
224134876|NCT05239559|DEVICE|Bubble CPAP oxygen delivery device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the nasopharynx of the baby. An underwater tube (expiratory arm) that acts as a blow off valve is interposed between the oxygen source and the baby. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the baby. The constant bubbling of gas through the blow off mechanism delivers the bubbling CPAP effect. Oxygen may be delivered by nasal prongs inserted into the nostril of child.~The system has three components:~1. Continuous gas flow into the circuit: The gas flow rate required to generate CPAP is usually 5-10 L/min.~2. A nasal interface connecting the child's airway with the circuit:~3. An expiratory arm with the distal end submerged in water to generate end-expiratory pressure.~The source of oxygen will be either an oxygen concentrator or cylinder, central distribution through pipelines."
223411839|NCT00708214|DRUG|Letrozole|Letrozole at standard dosage
223411840|NCT00708214|DRUG|Letrozole|Letrozole at standard dosage
223411841|NCT00557544|DRUG|metoclopramide|metoclopramide 0,15 mg/kg
223411842|NCT00557544|DRUG|placebo|placebo per os
223411843|NCT00557544|DRUG|ketoprofen|ketoprofen 1 mg/Kg
223411844|NCT06682221|DIETARY_SUPPLEMENT|Whey protein supplementation.|Protein supplementation will be provided through isolated whey protein, commonly known as whey protein isolate, which was generously donated by the Heroes Science Institute (HSI), as stated in the attached declaration. This whey protein isolate, with a vanilla flavor, is packaged in 25-gram sachets, each providing a total of 20 grams of protein per dose/sachet.
223411845|NCT06682221|BEHAVIORAL|Resistance training|The resistance training protocol in the study included seven exercises: high pull, leg extension, leg curl, bicep curl, triceps pushdown, lateral raise, and machine bench press, taking about 60 minutes per session. The first week focused on familiarizing participants with the exercises to ensure proper execution before intensive training began. Training occurred three times a week for 12 weeks, with each exercise performed in 3 sets of 8 to 12 repetitions and rest periods of 1 to 2 minutes. The load was progressively increased by 2% to 10% weekly, based on participants\&#39; ability to complete repetitions with full range of motion. Assessments were conducted before training and 24 hours after the final session to evaluate the effects on physical and functional parameters.
223411846|NCT06682221|OTHER|Group Control|The control group will not participate in any of the interventions proposed in the study, meaning it will not receive supplementation or undergo resistance training, serving as a reference to compare the results of the other intervention groups.
223411847|NCT06299358|OTHER|Foot massage|Infants in the foot massage group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts.
223411848|NCT06299358|OTHER|Mother heart sound|The sound recorded by the researcher under appropriate conditions will be played to the babies in the maternal heart sound group from an appropriate distance. The sound will be played a total of four times, on two consecutive days of the week, just before the baby's restlessness begins and for half an hour.
223411849|NCT06299358|OTHER|Foot massage and maternal heart sound|Infants in the foot massage and maternal heart sound group will receive foot massage by the researcher on two consecutive days of the week for a total of four times. The massage will be performed in accordance with the specified application steps for 10 minutes just before the baby's restlessness starts. From the beginning of the massage, the pre-recorded maternal heart sound will be played to the infant for 30 minutes from an appropriate distance.
223411850|NCT01163968|BEHAVIORAL|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
223559333|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating SMOG - 5th Grade Level|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
223411851|NCT00650247|DRUG|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
223559334|NCT04500171|BEHAVIORAL|Colocare Instruction Video: Modified SAM + CAM -Superior rating|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
224029078|NCT06486038|PROCEDURE|Anterior cervical discectomy and fusion|If applicable: Anterior cervical discectomy and fusion surgery using PEEK or modern carbon fiber material
224029079|NCT05709795|PROCEDURE|Confluent areas|Use of omnipolar technology to guide CTI ablation in sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
224029080|NCT05709795|PROCEDURE|Wave Speed|Use of omnipolar technology to guide CTI ablation in sites with low wave speed. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of high voltage sites. If not successful then CTI line (gold standard)
224134877|NCT03675438|OTHER|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
223411852|NCT00650247|DRUG|Imitrex® Tablets 100 mg|100mg, single dose fed
224134878|NCT05989490|OTHER|Static stretching|The participants are assigned to four bouts of static stretching of the right knee flexors with a 20-second rest period between bouts 20 to the point of discomfort and to the point of pain.
224298133|NCT06169657|DEVICE|Overground gait training|Walking overground in a harness with body weight support as needed
224298134|NCT04520932|PROCEDURE|Radiofrequency ablation|RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.
223559335|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
223559336|NCT04500171|BEHAVIORAL|CDC Colorectal cancer screening for life brochure: SAM + CAM Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
223559337|NCT04500171|BEHAVIORAL|Colocare Instruction Sheet: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
223559338|NCT04500171|BEHAVIORAL|CDC Colorectal Cancer Screening for Life Brochure: SAM + CAM - Superior rating Cloze Procedure|Suitability and Comprehensibility Assessment of Materials (SAM + CAM). The SAM + CAM is comprised of 22 evaluation items within the 6 original categories. The SMOG is a readability assessment tool that uses a formula to calculate grade levels by the number of sentences, total number of words in the sentences, and the number of polysyllabic words
223559339|NCT06955416|DRUG|Reamberin|Infusion of study drug REAMBERIN®, solution for infusion 1.5%, in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
223559340|NCT06955416|DRUG|Placebo|Infusion of 0,9% normal saline in a volume of 750-1500 ml per day (in accordance with the optimal dose established in stage 1), for 2 days or until resolution of DKA, whatever occurs earlier.
223738737|NCT06963086|BEHAVIORAL|Eating disorder prevention program (the Body Project)|The Body Project is an eating disorder prevention program for girls and young women aged 15-22 years old. The program will be delivered in groups of 6-10 youth by peer mentors, and in two formats: in-person and virtual. We are assessing two versions of the program - a 6-session version (6 weekly 45-minute sessions) and a 2-session version (2 weekly 2-hour sessions). Participants will be divided into 4 cohorts: high school in-person, university in-person, high school-aged (15-18 years) virtual, and university-aged (19-22 years) virtual. The high school in-person groups will do the 6-session version, and the university in-person groups as well as all virtual groups will do 2 weekly 2-hour sessions. Both versions cover similar content, and use a scripted intervention manual.
223738738|NCT04727723|DRUG|Lutathera®|Treatment with Lutathera® will be independent from participation in this observational study and must not be initiated for the purpose of participating in this study. The decision to treat patients with Lutathera® will occur before patients are enrolled in the study.
224029081|NCT05709795|PROCEDURE|Voltage|Use of omnipolar technology to guide CTI ablation in sites with high voltage. If not successful then ablation of sites with both low wave speed and high voltage. If not successful then ablation of low wave speed sites. If not successful then CTI line (gold standard)
224029082|NCT05709795|PROCEDURE|CTI line|Do not use omnipolar information. CTI line performance
224029083|NCT00200460|DRUG|Nebivolol|
224029084|NCT05300360|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase enzyme deficiency test
223559341|NCT04469920|DRUG|Saroglitazar Magnesium 2 mg|1 tablet, single dose at Day 1
224029085|NCT06168552|DIAGNOSTIC_TEST|Injection of fluorescent developer (anti-EGFR-IR800CW)|The patient underwent Da Vinci robot or fluorescent laparoscopy-assisted radical resection of pancreatic cancer, and anti-EGFR antibody-IR800CW imaging agent was injected in the day before surgery, and fluorescence detection was performed
224134879|NCT02822404|DIETARY_SUPPLEMENT|Urinary and blood sample for Cystatine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
224134880|NCT01691352|PROCEDURE|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
224134881|NCT01691352|PROCEDURE|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
224298135|NCT06253052|BEHAVIORAL|Additional pre-OP-visit|OP-schedule is closely monitored and patients will be visited to support and encourage them in drinking clear fluids.
223738739|NCT04342026|OTHER|Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors|Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)
223738740|NCT06641726|OTHER|Not applicable- observational study|This is non-interventional, cross-sectional observational study and thus there is no intervention.
224029086|NCT00520169|DRUG|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
223559342|NCT04469920|DRUG|Saroglitazar Magnesium 4 mg|1 tablet, single dose at Day 1
224029087|NCT05166980|DIETARY_SUPPLEMENT|Mutiply-fortified salt|Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine
224029088|NCT05166980|DIETARY_SUPPLEMENT|Iodized salt|Salt fortified with iodine
223411853|NCT05294692|BEHAVIORAL|Financial Health Incentives|Caterpillar Health (Caterpillar Health Inc., Leeds, UK) is a multi-component healthy living app that includes financial incentive (points redeemable for consumer goods like movies or gym passes) and was made available to Leeds, UK residents on the Apple iTunes/App Store and Google Play app stores on August 8, 2022. The app was later made available to all of the UK as of October 3, 2022. The app uses the smartphone's in-built accelerometer and/or is integrated with Apple Health and Google Fit to promote physical activity through step tracking. To offer a variety of popular incentives, Caterpillar Health formed partnerships with two major UK based companies, Vue Cinema and Hussle (a gym network system), allowing users to redeem points for free movie and gym passes. Additionally, the company collaborated with a UK health agency (Active Leeds via Leeds City Council) to assist in the development and approval of educational health quiz content.
223411854|NCT04591886|BEHAVIORAL|mind. body. voice.|The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
224029089|NCT01054846|OTHER|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
224029090|NCT01054846|OTHER|Bicycle helmet education only|As described under the respective arm
224029091|NCT03436108|DIAGNOSTIC_TEST|Measurement of Bisphenol in urine|to see level of this material in blood of women
224134882|NCT01536119|BEHAVIORAL|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
223411855|NCT02239731|DRUG|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
223411856|NCT03966300|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
224134883|NCT06678347|BEHAVIORAL|Leadership for recovery|The intervention will be delivered as a group-based programme (6 sessions) to the managers of the included employees. The programme includes educative and reflective parts as well as various strategies promoting both managers' own recovery and the recovery of employees.
224134884|NCT03266666|BEHAVIORAL|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
223559343|NCT05714618|DIAGNOSTIC_TEST|Gadolinium-enhanced cardiac MRI|Cardiac magnetic resonance imaging (MRI) with a protocol designed to measure myocardial inflammation and fibrosis.
223559344|NCT05714618|DIAGNOSTIC_TEST|B Natriuretic Peptide|Measurement of B Natriuretic Peptide on patients' blood samples at 10 and 60+/-15 days.
224029092|NCT01852474|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
224029093|NCT03457363|DEVICE|DTM will be add above NC|After oxygenation by classical nasal cannula, the DTM will be place above NC
224029094|NCT02982915|BIOLOGICAL|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
224029095|NCT02982915|BIOLOGICAL|Fluzone High Dose Vaccine|Intramuscular injection
224029096|NCT00350896|DEVICE|Thumb orthoses|
224029097|NCT04107376|DIAGNOSTIC_TEST|Retroviewing endoscopy|The colon is inspected with a new retroviewing endoscope
224029098|NCT03872570|DRUG|Phenylephrine|intravenous administration
224029099|NCT03872570|DRUG|Norepinephrine|intravenous administration
224029100|NCT01489410|DRUG|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
224134885|NCT03266666|OTHER|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
224134886|NCT00470652|DEVICE|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was \>4/10. After a 10-day test period, the post-intervention data collection started.
224134887|NCT05986032|DIAGNOSTIC_TEST|Respiratory Oscillometry|Measurement of respiratory system reactance by respiratory oscillometry
223411857|NCT03916237|OTHER|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
223411858|NCT03916237|OTHER|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
223411859|NCT03916237|OTHER|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
223411860|NCT03916237|OTHER|Regular School Based Health Asthma Care|Regular care in the School Health Program
223559345|NCT05714618|DIAGNOSTIC_TEST|Systemic inflammatory markers|Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 10 and 60+/-15 days.
223559346|NCT05539950|OTHER|Cardiopulmonary rehabilitation|Cardiopulmonary rehabilitation helps patients maximize functional potential due to progressive deconditioning or acute decompensation following an acute medical event. This intervention is medically supervised and individualized according to their results of the cardiopulmonary Exercise Testing (CPET).
223559347|NCT05539950|OTHER|Health education|Individualized exercise prescription will be given according to their results of the cardiopulmonary Exercise Testing (CPET). Recommendations for lifestyle modification will also be given.
223559348|NCT03045406|DRUG|Apixaban|Tablets
223559349|NCT03045406|DRUG|Dalteparin|Injections
223411861|NCT01628900|OTHER|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
223411862|NCT01628900|OTHER|Care management|Hospital vs home
223411863|NCT00002659|DRUG|cisplatin-e therapeutic implant|
223411864|NCT01580852|PROCEDURE|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
223411865|NCT01580852|PROCEDURE|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
223411866|NCT04245436|DRUG|Duloxetine|Encapsulated duloxetine 30 mg, 60 mg; once-daily
223411867|NCT04245436|DRUG|Escitalopram|Encapsulated escitalopram 5 mg, 10 mg, 15 mg, 20 mg; once-daily
223411868|NCT06498856|OTHER|Isotonic saline infusion|Volume expansion with one liter of isotonic saline intravenously over two hours.
223411869|NCT01847586|PROCEDURE|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
223411870|NCT01847586|PROCEDURE|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
223411871|NCT00608777|DRUG|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
223411872|NCT01760135|DIETARY_SUPPLEMENT|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
223411873|NCT01760135|DIETARY_SUPPLEMENT|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
224029101|NCT01489410|DRUG|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
224029102|NCT05397860|PROCEDURE|Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes|Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
224029103|NCT00253994|PROCEDURE|Acupuncture|
223411874|NCT05882825|OTHER|Dry Needling Therapy Knowledge and Awareness Questionnaire|Dry Needling Therapy Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
223411875|NCT04194463|OTHER|ChemoFit exercise prehabilitation intervention|Exercise intervention consists of walking monitored by wearing a pedometer device. After a baseline measurement of participant's walking activity is done, increase in step count from baseline step count is prescribed. This increase in step count is achieved by walking or jogging at moderate intensity for a target of 30 minutes per day, each day. Participants are also encouraged to perform other physical if they wish and are able to. Patients are regularly contacted by a member of the research team on a weekly basis and given an option to maintain or to increase their step count further. The same approach is used after each week of the intervention. Strengthening exercises will form a further part of the exercise intervention. They are performed every day, 7 days a week. Patients are supplied with resistance bands with handles. They are educated on how to perform two repetitions of 5 simple exercises, each for 1 minute duration.
224029104|NCT02441712|DEVICE|PENS|
224134888|NCT06184269|DRUG|BR1017-1|One tablet administered alone
224134889|NCT06184269|DRUG|BR1017-1A|One tablet administered alone
224134890|NCT06184269|DRUG|BR1017-1B|One tablet administered alone
224134891|NCT01810042|DRUG|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
224134892|NCT02306187|DRUG|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
224134893|NCT06689059|OTHER|Multimodal Data Integration and Multi-Task Learning|This study utilizes a multimodal data integration and multi-task learning approach to predict perioperative events after hip replacement surgery. By combining various data types, including demographics, surgical details, medical history, and lab results, the model enhances prediction accuracy for outcomes like AKI, blood transfusion needs, and ICU transfers. The use of ensemble learning algorithms such as CatBoost optimizes the platform's performance, offering a unique method for clinical decision support.
224134894|NCT04304755|DRUG|Zoledronic Acid 5 MG in 5 ML Injection|Zoledronic acid
224134895|NCT04304755|DRUG|Placebos|NaCl 0.9%
224134896|NCT06693414|OTHER|Tailored health promotion education|14 weeks tailored education
224134897|NCT06693414|OTHER|Routine nursing education|14 weeks nursing education
224134898|NCT06691334|DEVICE|PRP injection|Active comparator: PRP 3 cycles of platelet-rich plasma injection treatment in 4 weeks intervals. Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under the urethra. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
223411876|NCT00365404|BEHAVIORAL|Diet and exercise promotion|
223411877|NCT01994148|PROCEDURE|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
223411878|NCT01342523|OTHER|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
223411879|NCT01342523|OTHER|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
223411880|NCT01342523|OTHER|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
223411881|NCT01342523|OTHER|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
223411882|NCT01342523|OTHER|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
224029105|NCT02446886|DRUG|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
224029106|NCT01919710|DRUG|rHSA/GCSF|for treatment of neutropenia
224029107|NCT00928447|DRUG|rHuPH20|0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
224029108|NCT00928447|DRUG|Placebo|0.25 mL ID syringe push bolus injection of placebo control
224029109|NCT05291767|OTHER|Diet|participants will consume a high fat (intervention) or high carbohydrate (control) meal.
224029110|NCT05291767|BEHAVIORAL|Exercise|participants will exercise with medium intensity under supervision for 30 minutes (intervention) or rest (control) after consuming the meal.
224029111|NCT01610011|DIETARY_SUPPLEMENT|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
224029112|NCT04766931|DRUG|FB2001|Subjects will be administered with FB2001 by intravenous (IV) infusion
224029113|NCT04766931|DRUG|FB2001 Placebo|Subjects will be administered with FB2001 placebo by intravenous (IV) infusion
224029114|NCT01259284|DRUG|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
223411883|NCT01342523|OTHER|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
223411884|NCT01342523|OTHER|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
224134899|NCT06691334|DEVICE|Hifu procedure and PRP injection|Procedure: PRP injection of 2ml platelet-rich plasma from centrifuged for 5 min patient's blood under urethra.And intravaginal Hifu in4 weeks intervals. Cycle patient will examined and asked to fill daily micturition plan International consolation on incontinence questionnaire-urinary incontinence short form (ICIQ UI SF), urogenital distress inventory (UDI-6), incontinence impact questionnaire (11Q-7) and over active bladder symptoms scores (OABSS).
224134900|NCT06692465|DRUG|GT20029 Tincture|5mg (0.5%) and 10mg (1%) one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
224134901|NCT06692465|DRUG|GT20029 matching placebo|5mg (0.5%) and 10mg (1%) matching placebo one single dose per day (QD) treatment over 12 weeks period; 5mg (0.5%) and 10mg (1%) matching placebo twice per week (BIW) treatment, on every Monday and Thursday over 12 weeks period
224134902|NCT06693466|OTHER|Facial expression block|Data will be collected to assess the facial expression, body movements and vocalization of (non-) painful heat stimuli. The experiment includes individually tailored and randomly administered painful (perceived as moderate pain) and non-painful heat stimuli.
224134903|NCT06693466|OTHER|Conditioned pain modulation block|The conditioned pain modulation will be tested according to internationally agreed standards and includes a painful phasic heat (test stimulus) and a painful tonic cold stimulus (conditioning stimulus).
224134904|NCT06693466|OTHER|Pain facilitation block|Pain facilitation will be assessed by using painful mechanical pinprick stimuli. The magnitude of pain experienced after a single mechanical pinprick stimulus is compared to that of a train of 10 pinprick stimuli of the same force.
224134905|NCT06696820|DRUG|PCSK9 inhibitors combined with atorvastatin/rosuvastatin|A single subcutaneous injection of 420 mg Iroceliumab upon admission, along with a standard dose of 20 mg Atorvastatin or 10 mg Rosuvastatin
224134906|NCT06696820|DRUG|Atorvastatin/Rosuvastatin|Conventional Atorvastatin 20 mg / Rosuvastatin 10 mg
223411885|NCT02360241|DEVICE|Robot|Use of the robot to locate the fictional needle
223411886|NCT00792051|BIOLOGICAL|Inactivated influenza vaccine|0.5ml intramuscular single dose
223411887|NCT00792051|BIOLOGICAL|Saline|0.5ml intramuscular, one dose
223411888|NCT02931344|DIETARY_SUPPLEMENT|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
223411889|NCT06155955|DRUG|"Emicizumab, HEMLIBRA®"|low dose
224029115|NCT01259284|DIETARY_SUPPLEMENT|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
224029116|NCT01259284|OTHER|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
224029117|NCT05139433|BEHAVIORAL|Telepsychotherapy|"5 weekly psychotherapy sessions that will cover the following contents: psychoeducation on stress responses, family communication, relaxation and mindful techniques, emotion recognition, management of irritability, behavioral activation and cognitive restructuring. The sessions will be implemented via the internet by a trained psychologist. Participants will also have access to the psychoeducational videos described at intervention 2"
223411890|NCT05300581|OTHER|OPAT for PWID|Observational: Patients with a history of injection opioid use will receive home OPAT while also receiving substance use disorder care including medications for opioid use disorder and multidisciplinary health coach and case management support.
223411891|NCT05067608|BIOLOGICAL|Control arm receiving normal (never before frozen) platelets as per current clinical practice|Liquid platelets arm (control) and may receive multiple platelet transfusions per thrombocytopenic cycle.
223411892|NCT05067608|BIOLOGICAL|Treatment arm receiving cryopreserved platelets|Cryopreserved platelets arm (treatment) and may receive multiple platelet transfusions per thrombocytopenic cycle.
223411893|NCT00556946|DRUG|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
223411894|NCT06574711|OTHER|Sacha inchi oil yogurt|Sacha inchi oil was incorporated into a nonfat yogurt acting as a source of linolenic acid
223411895|NCT06574711|OTHER|Hybrid palm oil yogurt|Interspecific hybrid palm oil was incorporated into a nonfat yogurt as a source of bioactive compounds
223411896|NCT06574711|OTHER|Control yogurt|Conventional full-fat yogurt
223411897|NCT04856267|DEVICE|"LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)"|Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
223411898|NCT02929589|DRUG|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
223411899|NCT02929589|DRUG|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
224029118|NCT05139433|BEHAVIORAL|Psychoeducational Videos|15 educational videos to be watched by the families. There will be one video about psychoeducation on stress responses, one about family communication, four about mindfulness and relaxation techniques, two about emotion recognition, one about management of irritability, one about behavioral activation, three about healthy routines, one about cognitive restructuring, and one about management of anxiety crisis.
224029119|NCT05889065|PROCEDURE|Conventional Physical Therapy|"group A will receive conventional physical therapy including~10~ultrasound(1.5w/cm2~,3 MHz continuous type, duration 10 minutes),hot packs (on affected region of shoulder for 10 minutes),shoulder ROM, stretching exercises, and joint mobilization five times per week for two weeks with 40 minutes duration of each session. Maitland mobilization will be given in supine position.~· After giving glenohumeral joint distraction, caudal, dorsal, and ventral glides will be given at a rate of 2-3 oscillation/second for 1 to 2 minutes to patients. Grade I or II rhythmic oscillations will be applied in free range."
224029120|NCT05889065|PROCEDURE|PNF techniques|In this group 20 repetitions of diagonal scapular pattern (anterior elevation and posterior depression, posterior elevation and anterior depression) with 20 seconds rest period will be given to subjects. PNF techniques of rhythmic initiation and repeated contractions will be used in all patterns, applied for 40 minutes.
224134907|NCT02773238|PROCEDURE|Computed Tomography|Undergo FDG PET/CT
223411900|NCT02929589|DRUG|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
224134908|NCT02773238|PROCEDURE|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
224134909|NCT02773238|RADIATION|Fludeoxyglucose F-18|Undergo FDG PET/CT
223411901|NCT02929589|DRUG|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
223411902|NCT02332057|DRUG|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
224029121|NCT02667717|BEHAVIORAL|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
224029122|NCT02667717|BEHAVIORAL|Usual care|Patients will have the usual care as an intervention.
224029123|NCT00613262|OTHER|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
224134910|NCT02773238|OTHER|Laboratory Biomarker Analysis|Correlative studies
224134911|NCT02773238|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT
224134912|NCT02773238|RADIATION|Radiation Therapy|Undergo functional avoidance radiation therapy
224134913|NCT02773238|PROCEDURE|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
224134914|NCT02773238|RADIATION|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
224134915|NCT02773238|RADIATION|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
224134916|NCT07027228|OTHER|Using virtual reality glasses or listening to music|Donors in the intervention group will be randomly assigned and shown relaxing nature images through virtual reality glasses.
224134917|NCT07027228|OTHER|Using listening to music|Donors in the intervention group will be randomly assigned and will listen to relaxing music.
224134918|NCT06693297|DEVICE|Immediate loading of early placed implants|Implants with active thread design will be used. The implants placed will be randomly allocated into either immediate loading or conventional loading group.
224134919|NCT06693297|DEVICE|Conventional loading of early placed implants|Definitive loading of early placed implants upon successful osteointegration (after 8 weks)
224134920|NCT02487901|DEVICE|ultrasonic osteotome|making gutter with ultrasonic osteotome
224134921|NCT02487901|DEVICE|drill|making gutter with drill
224134922|NCT05085028|DRUG|Pembrolizumab 25 MG/ML [Keytruda]|Pembrolizumab to be given at 400mg intravenous over 5 different frequencies
224134923|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
224134924|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
223411903|NCT02332057|DRUG|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
223411904|NCT06478472|DRUG|Orelabrutinib in combination with rituximab|"Induction Phase:~Orelabrutinib + rituximab for a total of 6 cycles of 28 days each Obrutinib (O) 150mg oral d1-28 Rituximab (R) 375mg/m2 IV d0~Maintenance phase:~Orelabrutinib 150mg po qd 24 cycles of 28 days each"
224298136|NCT06253052|BEHAVIORAL|Liberal fasting regime|Patients may drink up to 200 ml clear fluids between 2 h prior to the surgery and the call to operation room.
224134925|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
223411905|NCT06120426|PROCEDURE|total en bloc spondylectomy|Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.
223411906|NCT02772926|DIETARY_SUPPLEMENT|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
223411907|NCT02772926|DIETARY_SUPPLEMENT|Placebo|Placebo 900 mg per day
223559350|NCT03100539|OTHER|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
223559351|NCT03100539|OTHER|Care ally assisted massage|CA-M consisted of in-person training for veteran/care-ally dyads to learn a standardized 30-minue massage routine, instructional DVD, and printed treatment manual. Participants were to complete three care ally-assisted massage sessions weekly for 12-weeks.
223559352|NCT02551094|DRUG|colchicine|0.5 mg tablet taken once a day
223559353|NCT02551094|DRUG|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
223559354|NCT04309890|OTHER|Arabic version of the Overactive Bladder Symptom Score Questionnaire|All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily
223559355|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
223559356|NCT00778297|BIOLOGICAL|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
223559357|NCT00809835|DRUG|Galantamine|Daily 8 mg galantamine capsule
223559358|NCT00809835|BEHAVIORAL|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
223559359|NCT05838625|DEVICE|Digital Therapeutic|A prescription digital therapeutic in the form of a smartphone app.
224134926|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
223559360|NCT05100017|DRUG|Methocarbamol|Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
223559361|NCT05100017|DRUG|Oxybutynin|Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
223559362|NCT05767398|DRUG|Zanubrutinib|Administered as a tablet or capsule
223559363|NCT06500013|BEHAVIORAL|Self-designed messages|Messages designed by participants
223559364|NCT06500013|BEHAVIORAL|Standardized messages|Messages designed by researchers based on behavioral change theories
224134927|NCT00555828|GENETIC|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
224134928|NCT00555828|PROCEDURE|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
223559367|NCT05659719|OTHER|Recifercept|Patients received recifercept intervention in the phase 2 clinical trial
223559368|NCT03679546|DRUG|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
224134929|NCT06355557|OTHER|AI enabled ultrasound system for self-directed learning|use of the AI enabled ultrasound system for self-directed learning
224134930|NCT06355557|OTHER|Simulator for self-directed learning|use of the simulator for self-directed learning
224134931|NCT06355557|OTHER|traditional with human instructors|Medical students who are randomised to this arm
224134932|NCT05719051|DRUG|Albumin infusion|Albumin infusion was administrated according to the standard clinical practice
224134933|NCT02560493|BEHAVIORAL|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
224134934|NCT02526719|PROCEDURE|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
224134935|NCT02670460|DEVICE|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
223559369|NCT03679546|DRUG|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
223559370|NCT05126030|DEVICE|Topaz TTVR System|Transcatheter tricuspid heart valve replacement
223559371|NCT04270149|BIOLOGICAL|ESR1 peptide vaccine|ESR1 peptides plus Montanide and GM-CSF
224134936|NCT05668468|DIETARY_SUPPLEMENT|Bifidobacterium adolescentis IVS-1 capsule|Daily Bifidobacterium adolescentis IVS-1 capsule containing up to 6x10 ninth cfu per capsule or daily cellulose capsule
224134937|NCT05668468|OTHER|Placebo cellulose capsule|Daily cellulose capsule
223411908|NCT03478566|DEVICE|Transcutaneous CO2 monitoring|The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
223411909|NCT01461486|DEVICE|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
223411910|NCT01461486|DEVICE|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
223411911|NCT02343939|DRUG|Entospletinib|Tablet(s) administered orally every 12 hours
223411912|NCT02343939|DRUG|Daunorubicin|60 mg/m\^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
223411913|NCT02343939|DRUG|Cytarabine|100 mg/m\^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
223411914|NCT02343939|DRUG|Decitabine|20 mg/m\^2 administered intravenously
223411915|NCT02343939|DRUG|Azacitidine|75 mg/m\^2 administered intravenously or subcutaneously
223559372|NCT02756962|DRUG|Cytarabine|
223559373|NCT02756962|PROCEDURE|Allogeneic stem cell transplant|
223559374|NCT02756962|PROCEDURE|Bone marrow aspiration|"* Baseline~* Approximately 30 days after cytotoxic induction therapy~* End of treatment"
223559375|NCT02756962|PROCEDURE|Punch skin biopsy|"* The first will be obtained with the initial blood and bone marrow collections, whenever possible.~* The second will be obtained at the time of re-biopsy to confirm remission."
223559376|NCT02756962|DEVICE|ClinSeq|Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
223559377|NCT04829643|DIAGNOSTIC_TEST|PET/MRI|A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
223559378|NCT01628029|OTHER|Counseling|Undergo CBT
223559379|NCT01628029|DRUG|Methylphenidate Hydrochloride|Given PO
223559380|NCT01628029|PROCEDURE|Phototherapy|Undergo light therapy
224134938|NCT04205578|DRUG|dl-3-n-butylphthalide (NBP)|25 mg of NBP in 100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
224134939|NCT04205578|DRUG|Normal Saline 0.9% Infusion Solution|100 mL of normal saline was administered intravenously since the day of extracranial-to-intracranial bypass surgery and continued twice daily for 14 postoperative days.
224134940|NCT02319096|OTHER|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
224134941|NCT04307836|DEVICE|Renal Denervation|Renal Denervation: DENEX system
224134942|NCT01891760|DEVICE|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
224134943|NCT01891760|DEVICE|Profore|Four-layer compression bandaging therapy.
224134944|NCT05204511|OTHER|endurance training|endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 30-60 minutes per session
224134945|NCT05204511|OTHER|concurrent training|combination of endurance training of low to moderate intensity on a bicycle ergometer, crosstrainer or treadmill performed for 20-40 minutes per session and resistance training of moderate intensity performing 2-3 sets of leg press, leg curls, chest press and seated horizontal rows
224134946|NCT04290481|OTHER|oxygen saturation and perfusion index screening|Oxygen saturation and perfusion index values that are measured by pulse oximeter is used for screening critical congenital heart disease.
224134947|NCT00280150|BIOLOGICAL|bevacizumab|Given IV
224134948|NCT00280150|DRUG|carboplatin|Given IV
224134949|NCT00280150|DRUG|erlotinib hydrochloride|Given orally
224134950|NCT00280150|DRUG|paclitaxel|Given IV
224134951|NCT00280150|RADIATION|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
224134952|NCT03303040|OTHER|Electrical stimulation of hemidiaphragm|Electrical impulses
224134953|NCT02607332|DRUG|Paclitaxel|
224134954|NCT00020566|BIOLOGICAL|dactinomycin|Given IV
224134955|NCT00020566|DRUG|busulfan|Given orally and IV
224134956|NCT00020566|DRUG|doxorubicin hydrochloride|Given IV
224134957|NCT00020566|DRUG|etoposide|Given IV
224134958|NCT00020566|DRUG|ifosfamide|Given IV
224134959|NCT00020566|DRUG|melphalan|Given orally and IV
224134960|NCT00020566|DRUG|vincristine sulfate|Given IV
224134961|NCT00020566|PROCEDURE|autologous hematopoietic stem cell transplantation|Given IV
224134962|NCT00020566|PROCEDURE|conventional surgery|Given to patients deemed to require it
224134963|NCT00020566|RADIATION|radiation therapy|Given to patients deemed to require it
224134964|NCT02915107|DEVICE|BioFreedom|PCI with BioFreedom
224134965|NCT02915107|DEVICE|Orsiro|PCI with BioFreedom
224134966|NCT02477293|DRUG|Hyeonggaeyeongyo-tang|
224134967|NCT00556192|DRUG|rituximab|"1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
224134968|NCT00474162|DRUG|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
224134969|NCT00474162|DRUG|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
224134970|NCT02534194|OTHER|Image acquisition|Images of baby's face (including ear) and feet
224029124|NCT02202668|DEVICE|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
224029125|NCT05268874|OTHER|Clavipectoral block|Clavipectoral block will be performed with patients in the supine position. The probe will be placed on the anterior border of the medial third (or on the proximal or distal end, according to the localization of the fracture) of the clavicle. A 22-gauge, 50 mm block needle will be inserted in a caudal to cephalic direction, the periosteum of the clavicle and the surrounding fascia will be visualized, 30 ml of 0.25% bupivacaine will be injected between these two layers. The local anesthetic spread to medial and lateral third of the clavicle will be seen.
224029126|NCT03448133|DEVICE|Magstim rTMS|The device is made in London,UK
224029127|NCT01638117|OTHER|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
224029128|NCT01638117|DRUG|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
224029129|NCT01638117|DRUG|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
224029130|NCT01638117|DRUG|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
224029131|NCT01638117|OTHER|Saline|Saline, Daily for up to 21 days
224029132|NCT01638117|OTHER|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
224029133|NCT02858349|BEHAVIORAL|No intervention|No intervention
224134971|NCT02312076|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
224134972|NCT05577091|GENETIC|Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.|"Intratumoral or intraventricular administration via Ommaya reservoir.~Dose level 0: 1×10\^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients.~Dose level 1: 1×10\^8/ 5×10\^6 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the dose should be reduced to 5×10\^6 cells.~In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and the subsequent doses will be administered weekly.~Dose level 2: 5×10\^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4 patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side effects could have occurred in the 1×10\^7cells dose, the researcher would re-determine the dosage of the multidose clinical exploration study."
224134973|NCT01590862|DEVICE|Deep Brain Stimulator|Medtronic Deep Brain Stimulation device turned on and off
224134974|NCT02334670|DRUG|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
224134975|NCT03560635|BEHAVIORAL|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
224134976|NCT03699449|DRUG|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
224134977|NCT03699449|DRUG|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
224134978|NCT03699449|DRUG|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
224029134|NCT02858349|BEHAVIORAL|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
224029135|NCT03353558|DEVICE|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
224029136|NCT05933187|DRUG|Treatment A: Emraclidine 30mg IR tablets (reference)|IR oral tablets
224029137|NCT05933187|DRUG|Treatment B: Emraclidine 30mg IR test tablets 1|IR oral tablets
223559381|NCT01628029|OTHER|Placebo Administration|Given PO
224029138|NCT05933187|DRUG|Treatment C: Emraclidine 30mg IR test tablets 2|IR oral tablets
223559382|NCT01628029|OTHER|Quality-of-Life Assessment|Ancillary studies
223559383|NCT01628029|PROCEDURE|Sham Intervention|Undergo sham light therapy
223559384|NCT01628029|DRUG|Therapeutic Melatonin|Given PO
224029139|NCT05933187|DRUG|Treatment D: Emraclidine 30mg IR test tablets 3|IR oral tablets
224029140|NCT02536703|DEVICE|Lotus Valve System|Lotus Valve System
223411916|NCT04553822|OTHER|Assisted autogenous drainage group (DAA)|DAA, is used when the patient is not able to perform this technique autonomously and is assisted by the physiotherapist. Its greatest utility is in infants and preschoolers. The technique consists of positioning the patient in a supine position with the head slightly elevated on the supporting plane and then placing both hands around the rib cage and applying bimanual expiratory compression on both hemithoraxes. The physiotherapist must ensure that the child takes 2 to 3 controlled breaths, close to the residual level, with the objective that the expiratory flow displaces the secretions, located distally, towards the central airways.
223559385|NCT06282471|BEHAVIORAL|Expressive Writing and Problem-Solving Therapy (EW+PST)|Participants will undergo a 6-week self-guided EW+PST. Participants will be provided with 6 printed journals (one for each week of the study) and instructed to write at least 2 entries per week.
223559386|NCT02417662|RADIATION|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
223738741|NCT04974086|OTHER|Sexually transmitted infection (STI) testing clinical decision support (CDS) tool|The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
223738742|NCT00001437|DRUG|pentoxifylline|
223738743|NCT04265053|DRUG|Indomethacin 25 MG/50 MG|Indomethacin is a nonsteroidal anti-inflammatory drug commonly used to reduce fever, pain, stiffness, and swelling from inflammation. It prevents the production of prostaglandins, endogenous signaling molecules known to cause symptoms from inflammation. Indomethacin is used to test COX as a potential mechanism explaining sex differences in CBF control. Indomethacin usage is IND exempt.
223738744|NCT04265053|DRUG|Placebo - Lactose|Participants will be screened for lactose intolerance. Total dosing will be calculated to match the mg needed for the indomethacin study visit. Placebo usage is IND exempt.
223738745|NCT04265053|DRUG|Ganirelix Acetate|"Gonadotropin-Releasing Hormone (GnRH) antagonist ganirelix acetate as a model to isolate estrogen and testosterone effects on the cerebrovascular system. Participants receive daily injections of ganirelix for 12-14 days for Aim 3 studies only. This will be overseen by clinical endocrinologists.~Both males and females receive this treatment in Aim 3."
223738746|NCT04265053|DRUG|Testosterone Transdermal Product|In Aim 3, males receive this for 7-9 days of the ganirelix treatment.
224029141|NCT05394376|OTHER|Level of noise and environment (public vs private) while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the level of noise in their environment changes and whether they are in a public or private setting prior to each set of measurements.
224029142|NCT01971203|DRUG|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
224029143|NCT01971203|BEHAVIORAL|CBT|16 weeks of treatment
223411917|NCT04553822|OTHER|Group prolonged slow expiration (ELPr)|Passive expiratory aid technique applied to the baby by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
223411918|NCT04553822|OTHER|Control group (CG)|Nebulization with 4 ml Muconeb® 3% hypertonic serum, for 8 minutes in a Philips® vibrating mesh nebulizer. Once the nebulization is finished, you will wait 30 minutes in a closed room.
223559387|NCT02417662|OTHER|Non-investigational SACT|There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
223738747|NCT04265053|DRUG|Estradiol Topical|In Aim 3, females receive this for 7-9 days of the ganirelix treatment.
223738748|NCT04265053|DRUG|Antacid|Participants will be given a dose of over-the-counter antacid to combat the gastrointestinal distress expected from Indomethacin. Participants will be given a dose of over-the-counter antacid during the placebo visit to mimic the indomethacin study visit. Antacid is IND exempt.
223738749|NCT03935633|DRUG|CN128 Tablets|Iron chelator， oral tablets
223738750|NCT05051475|PROCEDURE|Endoscopic radiofrequency ablation|Endoscopic ablation technique for Barrett's epithelium
223738751|NCT05051475|PROCEDURE|Endoscopic hybrid argon plasma coagulation|Endoscopic ablation technique for Barrett's epithelium
223738752|NCT04124406|DEVICE|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
223738753|NCT02680821|PROCEDURE|ALL reconstruction (Anterolateral ligament)|
223738754|NCT02680821|PROCEDURE|ACL revision (Anterior cruciate ligament )|
224029144|NCT00860613|OTHER|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
224029145|NCT05368051|COMBINATION_PRODUCT|long course radiotherapy + capecitabine + PD-1 monoclonal antibody|long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations in patients with locally advanced rectal cancer
224029146|NCT05395910|DRUG|Paclitaxel|This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
224029147|NCT03353350|DRUG|efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224029148|NCT03353350|DRUG|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224029149|NCT00373815|DRUG|Everolimus|
223411919|NCT03187730|BEHAVIORAL|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
223411920|NCT03187730|BEHAVIORAL|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
223411921|NCT03187730|DRUG|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
223411922|NCT05102357|PROCEDURE|Conservative Treatment (splint)|splint 6 weeks
223411923|NCT04589377|BEHAVIORAL|Mindfulness Training|Training is focused on learning the principle of RAIN (recognize, accept, investigate, non-identify) in the context of physics learning.
224029150|NCT01566656|DRUG|total lymphoid irradiation and anti-thymocyte globulin|"* TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
223411924|NCT04668248|OTHER|Simulation|"The simulation will consist of a one-time, short immersive simulation session at the STRATUS Center for Medical Education at BWH. The session will be conducted for up to one intern at the same time, in accordance with social distancing practices at BWH. This simulation session will consist of one short, hands-on scenario of simulated patient experiences with expert facilitators in the simulated hospital rooms to help providers identify when they are in the hot state and their reactions, and work on improving communication skills, differential diagnoses, and alternative therapeutic options. These scenarios are intended to simulate both in-person and virtual interactions that are common in the inpatient setting. During these trainings, we will use behavioral principles like time pressure and increasing cognitive load to simulate a hot state environment. After the scenarios, the facilitator will perform a debriefing session for the interns."
224029151|NCT05427903|PROCEDURE|Cryotherapy|Ice packs application for 5 minutes after IANB injection
224029152|NCT05427903|PROCEDURE|Buccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine|Buccal infiltration after IANB
224029153|NCT01690364|OTHER|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
224029154|NCT01690364|OTHER|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
224029155|NCT04950725|BEHAVIORAL|Strength RMT|2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit
224029156|NCT04950725|BEHAVIORAL|Strength RMT and nasal breathing|2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
224029157|NCT04950725|BEHAVIORAL|Endurance RMT|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit
224029158|NCT04950725|BEHAVIORAL|Endurance RMT and nasal breathing|15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
224029159|NCT04950725|BEHAVIORAL|Low dose RMT|10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
223411925|NCT04668248|OTHER|Online educational training|Providers assigned to the control arm will receive online educational training about other poorly-prescribed medications, including albumin, transfusion, and blood product repletion guidelines. This information will be in the form of electronically-delivered links to information already housed and available at BWH, including reviewing BWH guidelines and literature about transfusion reactions. The interns will be asked to answer several clinical questions about optimal prescribing. Albumin and related products are also high-risk medications often overprescribed on twilight shifts.
223411926|NCT05962333|BIOLOGICAL|Intra-arterial delivery of autologous MABs|three times intra-arterial administration of autologous mesoangioblasts in biceps brachii of the left arm at 4-6 week interval
224029160|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
224029161|NCT00807235|DRUG|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
224134979|NCT03699449|DRUG|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
224134980|NCT03699449|DRUG|durvalumab + tremelimumab + paclitaxel treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + Tremelimumab (300mg i.v. once) + non-platinum-based standard of care chemotherapy (weekly paclitaxel up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 60mg/m2 (day 1,8,15 every 4 weeks)"
224134981|NCT03699449|DRUG|durvalumab +chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 24 months) + non-platinum-based standard of care chemotherapy (paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
224134982|NCT03162055|DRUG|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
223411927|NCT02089373|PROCEDURE|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
223411928|NCT02089373|PROCEDURE|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
223411929|NCT00669097|DRUG|TKI258|
223411930|NCT00708383|OTHER|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
223411931|NCT00708383|OTHER|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
223559388|NCT01673906|DRUG|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
224134983|NCT03162055|DRUG|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
223559389|NCT03423030|DRUG|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
223559390|NCT03423030|DRUG|Placebo|matching placebo supplied as powder for oral solution
224029162|NCT00795613|DRUG|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN\>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
224134984|NCT03852914|DEVICE|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
224134985|NCT00606814|DRUG|IPI-504, docetaxel|"1. IPI-504 administered IV at a dose of 300mg/m2~2. Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
223411932|NCT04084951|BIOLOGICAL|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of peripheral blood mononuclear cells (PBMCs) manufactured with immunogenic epitopes of HPV16
223411933|NCT04084951|DRUG|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
223411934|NCT04084951|DRUG|Ipilimumab|cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
223411935|NCT04084951|DRUG|Nivolumab|programmed cell death 1 (PD-1) blocking antibody
223411936|NCT03735277|BIOLOGICAL|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10\^8 total nucleated cells with a minimum of 1.25 × 10\^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
223559391|NCT03423030|DRUG|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
223559392|NCT01681186|DRUG|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
223559393|NCT01681186|DRUG|LY2940680 Tablet (Test)|Administered orally as a tablet
223559394|NCT01681186|DRUG|Lansoprazole|Administered orally as a capsule
223559395|NCT01681186|DRUG|Placebo Capsule(s)|Administered orally as a capsule(s)
224134986|NCT04417114|DRUG|Rosuvastatin|Statin
224134987|NCT04248400|OTHER|Tai Chi training|A 24 weeks Tai Chi training with three 1-hour section per week
224134988|NCT04248400|OTHER|Conventional exercise|A 24 weeks conventional exercise training with three 1-hour section per week
224134989|NCT06027073|BIOLOGICAL|omalizumab|adding omalizumab to anti asthmatic therapy
224134990|NCT03450525|OTHER|No intervention|No intervention
223559396|NCT05818540|DEVICE|Eclipse novel CPAP mask|Participants will wear the mask for 6 hours a night for 60 days.
223411937|NCT02585947|DRUG|Tenofovir|Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
223559397|NCT05818540|DEVICE|ResMed P-10 mask|Participants will wear the mask for 6 hours a night for 60 days.
223559398|NCT05160415|DRUG|Sevasemten|Daily oral dose of 10 mg daily until Visit 8 (Day 57), followed by 15 mg daily until Visit 13 (Month 6), followed by 20 mg until Visit 21 (Month 15), followed by 10 mg daily to Visit 27 (Month 24).
223559399|NCT00148993|BIOLOGICAL|Tumor Cell Vaccine|
223559400|NCT03106441|DEVICE|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
223559401|NCT03106441|DEVICE|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
223411938|NCT04595045|DRUG|Botulinum toxin type A infiltrations|Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice
223411939|NCT00306020|DRUG|topical morphine|
223411940|NCT01760174|DRUG|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
223411941|NCT01760174|DRUG|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
223411942|NCT04620447|OTHER|Intelligent Virtual Reality Therapy System (IVRTS)|The approach of the Novel Intelligent Software interface approaches follows the basic premise that human beings think in terms of images rather than words. While the existing modes of treatment for phobias rely mainly on talk therapies and counseling; This novel intelligent software treatment methodology deals with the development of VR programs integrated with hardware for simulating various phobia-inducing situations, followed by novel automated integrated most effective psychotherapy; altering these images to reduce the anxiety experienced. Our treatment package includes a VR device integrated with easily comprehensible voice commands, along with a user manual and easy user interface, thereby reducing the effort of training required for operating the device. The framework is a combination of the therapy methodologies with VR, motion sensors and biofeedback.
223411943|NCT05442502|PROCEDURE|The overlap guiding tube(OGT) method|The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.
223411944|NCT05442502|PROCEDURE|The conventional overlap method|After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
223411945|NCT06578572|BIOLOGICAL|R21Matrix M|A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly over 3 months (one dose per month over 3 months (May, June, and July 2024) plus a booster dose in June 2025.
223411946|NCT01708382|DEVICE|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223411947|NCT01920412|DEVICE|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
223411948|NCT03745846|BIOLOGICAL|Composite Gel Containing Black Raspberry|Composite Gel Containing Black Raspberry 3,000/preparation
223411949|NCT03745846|BIOLOGICAL|placebo|Composite Gel Containing Black Raspberry-placebo
223411950|NCT00504712|DRUG|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
223411951|NCT00504712|DRUG|saline|Saline injection every two weeks
223411952|NCT01061112|DRUG|Flurbiprofen Control - Flurbiprofen Only|A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
223411953|NCT01061112|DRUG|Flurbiprofen Inhibition - Flurbiprofen & Fluconazole|A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
223559402|NCT05483712|DEVICE|Brass Mesh Bolus|During a standard-of-care 15 fraction radiotherapy treatment, a brass mesh bolus will be used for a single fraction. Small in-vivo dosimeters will be used for three treatment fractions to measure and compare skin doses for quantification purposes.
223559403|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
223559404|NCT01293344|OTHER|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
224029163|NCT00795613|DRUG|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
223411954|NCT01061112|DRUG|Ketoprofen Control - Ketoprofen Only|A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
223411955|NCT01061112|DRUG|Ketoprofen Inhibition - Ketoprofen & Fluconazole|A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
223411956|NCT01061112|DRUG|Tolbutamide Control - Tolbutamide Only|A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
223559405|NCT04193111|DIAGNOSTIC_TEST|TMD pain screener|The danish TMD pain screener is given to all participants
224029164|NCT05566314|DIETARY_SUPPLEMENT|Amunizer|12 oz. herbal, probiotic and antioxidant herbal beverage
224029165|NCT05566314|OTHER|Placebo|12 oz. flavored beverage
224298137|NCT04082429|DRUG|Concizumab|When patients are randomised/allocated to concizumab prophylaxis, they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week (Wk) 0) (arm 2, 3 and 4) or visit 9a (Wk 24) (arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (Wk 6) or 9a.3 (Wk 30) and will be based on the concizumab exposure level measured at the previous visit 4a (Wk 6) or 9a.2 (Wk 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual replacement therapy until visit 9a (week 24; end of main part). In the extension part, patients in arm 1 will receive daily concizumab subcutaneous injections.
224298138|NCT02664545|DEVICE|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
224298139|NCT02664545|PROCEDURE|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
224298140|NCT05395715|PROCEDURE|Electrical stimulation|Patients with cubital tunnel syndrome will receive either surgery and sham stimulation, or conditioning electrical stimulation 7 days prior to surgery
224298141|NCT06437600|PROCEDURE|Immediate angioplasty|See arm/group descriptions.
224298142|NCT06421701|DRUG|anti-CD19 CAR-NK cells|Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning. Anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6.
224298143|NCT04905290|DEVICE|Left ventricular coronary sinus (BiV) configuration|For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay. Patients with a defibrillator will receive two additional delays LV precedes default by 30ms and LV precedes default by 60ms.
224298144|NCT04905290|DEVICE|Conduction system pacing-only configuration|Conduction System Pacing (CSP) of the left bundle branch. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, and default - 60ms AV delay.
224298145|NCT04905290|DEVICE|Conduction System Pacing Optimized Therapy (CSPOT) configuration|A combination of Left Ventricle pacing and Conduction System Pacing of the left bundle branch. During the acute protocol, the eight delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay, CSP precedes default by 30ms, LV precedes default by 30ms and LV precedes default by 60ms.
224298146|NCT04476862|DRUG|Cerliponase Alfa|Commercially available product provided to patient by participating clinic site.
224298147|NCT04476862|DEVICE|Administration Kit|Commercially available administration kit provided to the patient by participating clinic site.
224298148|NCT04502758|DEVICE|MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field properties on the active site are identical to that of the standard Cool-B70 coil, cleared for iTBS treatment.
223411957|NCT01061112|DRUG|Tolbutamide Inhibition - Tolbutamide & Fluconazole|A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
223411958|NCT00813072|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
223411959|NCT00813072|DRUG|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
223411960|NCT00813072|DRUG|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
223411961|NCT01303172|BIOLOGICAL|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL) will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
223411962|NCT01303172|DRUG|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
223411963|NCT03131843|DRUG|Alcohol|Alcohol cleansing swab/wipe
223411964|NCT03131843|DRUG|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
223411965|NCT02359955|DEVICE|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
223411966|NCT02359955|DEVICE|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
223559406|NCT03916536|PROCEDURE|Holmium Laser|Holmium laser enucleation of large sized prostate
224029166|NCT03545776|OTHER|Critical Care EEG Course|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG"
224029167|NCT05226754|DRUG|Diacerein|After enrolment, patients will be randomized (n=20 group A) to receive diacerein capsules 50 mg every 12 hours for 10 days.
224029168|NCT05226754|DRUG|placebo capsules|After enrolment, patients will be randomized (n=20 group A) to receive placebo capsules (lactose and magnesium stearate) every 12 hours for 10 days.
224029169|NCT00219622|DRUG|tofimilast|
224029170|NCT02379481|DIETARY_SUPPLEMENT|NS 550mg|
224029171|NCT02379481|DIETARY_SUPPLEMENT|NS 1100mg|
224029172|NCT02379481|DIETARY_SUPPLEMENT|placebo|
224029173|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot|Acute supplementation with 140 ml Beet It Sport Shots, James White Ltd, containing \~400mg dietary nitrate
224134991|NCT06197048|BEHAVIORAL|Nutritional counseling|"The intervention group will recieve 30 x 2 minutes with nutritonal counseling seperatet by a 15 minutes break. The participants will receive individually tailored guidance based on the information recieved at baseline measurments.~The couseling will be based on the Norwegian goverments dietary advices and the recommendation from the Directorate of Health for the prevention of cardiovascular diseases."
224029174|NCT05514821|DIETARY_SUPPLEMENT|Beet It Sport Shot Placebo|Acute supplementation with 140 ml Beet It Sport Shots Placebo, James White Ltd, in which the nitrate has been removed via an ion exchange resin, containing \~ 0 mg dietary nitrate
224029175|NCT05715853|OTHER|QSant|QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
224029176|NCT02564939|DRUG|ramelteon|double-blind RCT
224029177|NCT02564939|DRUG|Placebo|double-blind RCT
224029178|NCT00025103|BIOLOGICAL|dactinomycin|
224029179|NCT00025103|DRUG|carboplatin|
224029180|NCT00025103|DRUG|cyclophosphamide|
224029181|NCT00025103|DRUG|doxorubicin hydrochloride|
224134992|NCT02581865|DRUG|NBI-98854|
224134993|NCT02581865|DRUG|Placebo|
224134994|NCT00855257|DRUG|Acid Nicotinique|
224029182|NCT00025103|DRUG|etoposide|
224029183|NCT00025103|DRUG|melphalan|
224029184|NCT00025103|DRUG|vincristine sulfate|
224029185|NCT00025103|PROCEDURE|autologous bone marrow transplantation|
224029186|NCT00025103|PROCEDURE|conventional surgery|
224029187|NCT00025103|PROCEDURE|peripheral blood stem cell transplantation|
224134995|NCT00855257|DRUG|Placebo|
224134996|NCT02493322|DRUG|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
224134997|NCT02493322|DRUG|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
224134998|NCT02493322|DRUG|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
224134999|NCT03480958|DEVICE|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
223411967|NCT04852419|DRUG|ZN-c5|ZN-c5
223411968|NCT03326570|BEHAVIORAL|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
223411969|NCT00991237|OTHER|Pulsed Radiofrequency|Pulsed Radiofrequency
223411970|NCT00128232|DRUG|Octreotide LAR|
223411971|NCT05189652|OTHER|Myofascial Release and Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises - Reach forward with sitting and hamstring (3 reps\*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (1 set of 30 seconds will be applied with a rolling period of 2-4 seconds).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied). Foam Roller massage will apply to thoracolumbar posterior chain (2 sets of 30 seconds will be applied to each area with a rolling period of 2-4 seconds)."
224029188|NCT00025103|RADIATION|radiation therapy|
224029189|NCT01183078|PROCEDURE|free-hand|Free-hand technique utilizes x-rays to find screw holes.
224029190|NCT01183078|PROCEDURE|Wand technique|Wand technique is utilized to find screw holes.
224029191|NCT01012713|DRUG|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
224029192|NCT01012713|DRUG|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
224029193|NCT01012713|PROCEDURE|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
224029194|NCT02389114|OTHER|Soy Protein|Soy protein is commonly consumed in Asian diet.
224135000|NCT03480958|OTHER|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
224135001|NCT03480958|OTHER|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
224135002|NCT01993615|PROCEDURE|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
224135003|NCT01993615|PROCEDURE|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
224135004|NCT06138327|DRUG|BMN 255|Oral Capsule
224135005|NCT06138327|DRUG|Placebo|Oral Capsule
223559407|NCT03916536|PROCEDURE|Thulium Laser|Thulium laser enucleation of large sized prostate
224029195|NCT02389114|OTHER|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
224029196|NCT00410397|PROCEDURE|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
224029197|NCT00410397|PROCEDURE|Sham Manipulation|Neutral positional, gentle palpation
224029198|NCT00985153|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
224029199|NCT00985153|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
224029200|NCT00985153|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
224029201|NCT04271787|OTHER|questionnaire|Questionnaire
224135006|NCT03018912|OTHER|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?"
224135007|NCT02581358|OTHER|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
224135008|NCT03532581|OTHER|Indocyanine Green Solution|Given Subcutaneous injection
224135009|NCT03532581|PROCEDURE|Lymphangiography|Undergo lymphangiography
224135010|NCT00111579|BIOLOGICAL|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
224135011|NCT00111579|OTHER|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
224135012|NCT03508661|OTHER|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
224135013|NCT01807260|PROCEDURE|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
224135014|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
223559408|NCT03916536|PROCEDURE|Bipolar diathermy|Bipolar enucleation of large sized prostate
223559409|NCT02582814|DRUG|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
223559410|NCT02582814|DRUG|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
224029202|NCT01283698|DRUG|Experimental: LAS 41004 dosage 1|dosage 1, once daily
224029203|NCT01283698|DRUG|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
224029204|NCT01283698|DRUG|Experimental: LAS 41004 dosage 3|dosage 3, once daily
224029205|NCT01283698|DRUG|Placebo Comparator: placebo|once daily
224029206|NCT01283698|DRUG|Reference|Active Comparator,once daily
224029207|NCT05021094|DRUG|Kuntai Capsule|The instructions is pointed that each Kuntai capsule is 0.5g and the usage of Kuntai capsule is oral taking 4 capsules each time, 3 times a day, and 4 weeks is a course of treatment. The patients will taking 3 courses of treatment in this study.
224135015|NCT03317574|DRUG|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
224135016|NCT02155361|DRUG|Topical Citrullus colocynthis fruit oil (1%)|
224135017|NCT02155361|DRUG|Topical vehicle oil|
224135018|NCT05126745|DEVICE|color flow Doppler ultrasonography|Doppler ultrasonography
224135019|NCT06057636|BEHAVIORAL|Self-Administered Hypnosis|Participants will choose from one of three 20-minute prerecorded hypnosis audio files. Practices using the recordings will be documented on the hypnosis practice log.
224135020|NCT06057636|BEHAVIORAL|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recording for 6 weeks and will be encouraged to practice daily. Practices using the recordings will be documented on the hypnosis practice log.
224135021|NCT00799929|OTHER|in vitro fertilization (IVF/ICSI)|
224135022|NCT03661450|DIAGNOSTIC_TEST|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
224135023|NCT02664207|PROCEDURE|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
224135024|NCT05357326|DRUG|Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
223559411|NCT03530995|DRUG|Belumosudil|Development candidate
223559412|NCT03530995|DRUG|Itraconazole|Perpetrator drug
223559413|NCT03530995|DRUG|Rabeprazole|Perpetrator drug
223559414|NCT03530995|DRUG|Rifampicin|Perpetrator drug
223559415|NCT03530995|DRUG|Omeprazole|Perpetrator drug
223411972|NCT05189652|OTHER|Exercise Group|"The exercise program will be applied 3 days a week for 4 weeks. Participants will warm up by walking for 5 minutes before exercise. Stretching exercises- Reach forward with sitting and hamstring (3 reps\*30 sec).~First 2 weeks:~Squat exercise (3 sets of 10 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (30 seconds).~Star Excursion balance training (2 rounds to be applied).~Last 2 weeks:~Squat exercise (3 sets of 15 reps). Standing on one leg with knee flexed and hip-knee flexed at 90 degrees (40 seconds).~Star Excursion balance training (3 rounds to be applied)."
223411973|NCT02619357|DEVICE|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
223411974|NCT02619357|DEVICE|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
223411975|NCT02619357|DEVICE|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
223411976|NCT02619357|DEVICE|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
223411977|NCT02619357|DEVICE|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
223411978|NCT02619357|OTHER|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
223411979|NCT02619357|OTHER|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
223411980|NCT02619357|OTHER|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
223411981|NCT04952805|DRUG|MAD0004J08|MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
223411982|NCT04952805|OTHER|Placebo|Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
223411983|NCT00462709|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
223411984|NCT00204698|DRUG|Aciphex|20 mg of aciphex taken twice daily
223411985|NCT01736345|GENETIC|Genetic Providers|Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
223411986|NCT01736345|OTHER|Visual Aids|Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
223411987|NCT01736345|OTHER|Post-Disclosure Asessments|Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
223411988|NCT01736345|OTHER|In-person Clinical Follow-Up|Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
223738755|NCT06771635|OTHER|concurrent|"The concurrent training program is divided into three types of training: endurance, cardiovascular and neuromotor.~Resistance training sessions were performed in a circuit format with \>30 rest periods between exercises. The volume of work ranged from 8 to 12 repetitions at 60% of the estimated 1 maximum repetition (RM).~The cardiovascular work time per session ranged from 25-50 min depending on the intensity of the exercise and the intensity was regulated according to the maximum heart rate (FHR) estimated for each subject between 60-75%~The neuromotor training intensity of the sessions was low. The participants wore a heart rate monitor and were instructed not to exceed 60% of their HRF"
223738756|NCT06771635|BEHAVIORAL|Health Education Session|Single formative session on healthy lifestyle and nutrition provided to both groups. Control group received only this session without concurrent training.
224029208|NCT05021094|DRUG|Femoston|The estrogen and progesterone sequential regimen was adopted. The Femoston was contain estradiol tablets and estradiol didroxyprogesterone tablets. Red tablets (estradiol, 2 mg/d) were taken in the first 14 days, and gray tablets (estradiol, 2 mg/d, dydrogesterone,10 mg/d) were taken in the last 14 days. 28 days was a course of treatment, and three courses of treatment were taken. The patients will taking 3 courses of treatment in this study.
224029209|NCT00505869|BEHAVIORAL|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
224029210|NCT00505869|BEHAVIORAL|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
224029211|NCT00505869|BEHAVIORAL|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
224029212|NCT00865969|DRUG|Belinostat|
224135025|NCT05357326|DEVICE|Orthokeratology|wear orthokeratology at night while sleeping
223738757|NCT06474676|DRUG|Cyclophosphamide|Given by IV
224135026|NCT05357326|DRUG|Atropine Sulfate 0.04% Eye Drop|use one drop into subconjunctiva
224135027|NCT00310388|DRUG|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
224135028|NCT01864798|DRUG|Denosumab|
224135029|NCT01587573|OTHER|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
224029213|NCT04219397|OTHER|Medication take back|Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.
224029214|NCT04219397|OTHER|Medication home disposal|Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
224029215|NCT03370471|BEHAVIORAL|Retrieval Practice + Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
224029216|NCT03370471|BEHAVIORAL|Retrieval Practice + Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)
224029217|NCT03370471|BEHAVIORAL|Study Only + Moderate Intensity Exercise|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
224029218|NCT03370471|BEHAVIORAL|Study Only + Gentle Stretching|Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)
224029219|NCT04005417|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
224029220|NCT04005417|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
224029221|NCT04005417|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
224029222|NCT03968393|DRUG|Non-vitamin K oral anticoagulant (NOAC)|Participants randomized to the intervention arm will be prescribed one of the following NOACs for the duration of follow-up: edoxaban 60 mg daily (dose reduction to 30 mg, if applicable), apixaban 5 mg twice daily (dose reduction to 2.5 mg, if applicable), dabigatran 110 mg twice daily, or rivaroxaban 20 mg daily (dose reduction to 15 mg, if applicable). The choice of NOAC will be left up to the participant's prescribing physician.
224029223|NCT01520298|DRUG|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
224135030|NCT03341897|PROCEDURE|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
223411989|NCT01736345|OTHER|6 Month and 12 Month Assessments|At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
223411990|NCT04471857|BEHAVIORAL|Hypnosis|
223411991|NCT01448330|DRUG|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
223411992|NCT05646264|DRUG|Agomelatine|Agomepratine is added to a second-generation antipsychotic drug (olanzapine, aripiprazole, risperidone, etc.)
223411993|NCT04468347|DRUG|Flortaucipir F18|IV injection, 240 megabecquerel (MBq) (6.5 mCi)
224029224|NCT01520298|DRUG|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
224029225|NCT03275753|OTHER|Visual Function Tests|All subjects will undergo a battery of visual function tests
224029226|NCT03253874|BEHAVIORAL|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
223411994|NCT04468347|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
223411995|NCT02139202|BEHAVIORAL|Social Influence|
223411996|NCT02139202|BEHAVIORAL|Electronic Pill Bottles|
223411997|NCT02139202|BEHAVIORAL|Financial Incentives|
223411998|NCT00521638|BIOLOGICAL|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
223738758|NCT06474676|DRUG|T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy|Given by IV
224029227|NCT02225951|DIETARY_SUPPLEMENT|Nutritional product|
224029228|NCT02225951|OTHER|Standard breakfast according to ADA recommendations|
224029229|NCT01765179|DRUG|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
224029230|NCT02608281|DEVICE|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
224029231|NCT00435890|BEHAVIORAL|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
224029232|NCT05147883|BEHAVIORAL|Exercise|Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
224029233|NCT02491268|DRUG|Cilostazol|
224029234|NCT02491268|DRUG|Placebo|
224029235|NCT01498029|PROCEDURE|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
224029236|NCT01498029|DEVICE|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
224029237|NCT06008327|DRUG|Topical 15% Trichloroacetic acid|Recently trichloroacetic acid (TCA), a superficial chemical exfoliative agent has shown efficacy in treating acanthosis nigricans. Data from this would help in establishing it as a treatment of choice thereby lead to reduction in cost and benefit the patient both financially and psychologically.
224029238|NCT04757350|OTHER|Observational research, not applicable|Observational research, not applicable
224029239|NCT00392327|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224029240|NCT00392327|DRUG|Carboplatin|Given IV
224029241|NCT00392327|DRUG|Cisplatin|Given IV
223411999|NCT03442686|BEHAVIORAL|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
223412000|NCT00003441|DRUG|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
223412001|NCT02791919|DRUG|Cytarabine|Given IV or IT
223412002|NCT02791919|BIOLOGICAL|Filgrastim|Given IV or SC
223412003|NCT02791919|DRUG|Fludarabine Phosphate|Given IV
223412004|NCT02791919|OTHER|Laboratory Biomarker Analysis|Correlative studies
224029242|NCT00392327|DRUG|Cyclophosphamide|Given IV
224029243|NCT00392327|BIOLOGICAL|Filgrastim|Given IV or SC
224029244|NCT00392327|DRUG|Isotretinoin|Given PO
224029245|NCT00392327|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224029246|NCT00392327|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224029247|NCT00392327|OTHER|Quality-of-Life Assessment|Ancillary studies
223412005|NCT02791919|OTHER|Pharmacological Study|Correlative studies
224029248|NCT00392327|RADIATION|Radiation Therapy|Undergo radiation therapy
224029249|NCT00392327|DRUG|Vincristine Sulfate|Given IV
224029250|NCT01414504|BIOLOGICAL|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
223412006|NCT02791919|DRUG|WEE1 Inhibitor AZD1775|Given PO
223412007|NCT01624571|DRUG|LD02GIFRO|comparison of different dosages of drug
223412008|NCT01710202|DRUG|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
224029251|NCT01414504|BIOLOGICAL|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
224029252|NCT01414504|BIOLOGICAL|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
224029253|NCT01414504|BIOLOGICAL|Control|control, 0.1mL Pneumovax at 3-5yrs
224029254|NCT04508023|DRUG|Rivaroxaban|Participants will receive rivaroxaban 10 mg tablet orally once daily.
224029255|NCT04508023|OTHER|Placebo|Participants will receive matching placebo tablet orally once daily.
224029256|NCT04508023|OTHER|Standard of Care (SOC)|SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
224029257|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
224029258|NCT01401192|DRUG|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 \& cisplatin 70mg/m2 D1 every 3 weeks
224029259|NCT01401192|DRUG|pemetrexed plus cisplatin|pemetrexed 500mg/m2 \& cisplatin 70mg/m2 every 3 weeks
224029260|NCT01401192|DRUG|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 \& cisplatin 70mg/m2 D1 every 3 weeks
224029261|NCT00437736|DRUG|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
224029262|NCT01330173|DRUG|Vismodegib|Given PO
224029263|NCT01330173|OTHER|Pharmacological Study|Correlative studies
223412009|NCT01307904|OTHER|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
223412010|NCT01307904|OTHER|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
223412011|NCT04398004|DRUG|Clarithromycin|Treatment with 500 mg Clarithromycin orally twice daily for seven days
223412012|NCT03583580|RADIATION|Accelerated Partial Breast Irradiation|Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
223412013|NCT05705739|PROCEDURE|retrolaminar block|curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
223412014|NCT05705739|PROCEDURE|ESPB|curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
223412015|NCT00665431|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
223412016|NCT00665431|DRUG|celebrex|200 mg celecoxib qd
223412017|NCT00665431|OTHER|Placebo|sugar pill bid
223412018|NCT00665431|DRUG|Rescue Antacid|Antacid Tablets
223412019|NCT00513383|DRUG|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
223412020|NCT00513383|DRUG|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
223412021|NCT00513383|DRUG|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
223412022|NCT00513383|RADIATION|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
223412023|NCT00513383|DRUG|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
223412024|NCT00513383|DRUG|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
223412025|NCT00513383|DRUG|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
223559416|NCT03978052|DIETARY_SUPPLEMENT|EGCG|"FontUp capsules (100 mg of EGCG each)~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
223559417|NCT03978052|DIETARY_SUPPLEMENT|Placebo EGCG|"Placebo FontUp (same appearance as active).~12 months, three to five capsules per day (participant's weight ≤ 50kg: 3 capsules/day; weight \>50kg: 5 capsules/day."
223559418|NCT03978052|OTHER|Healthy lifestyle recommendations|Personalized advice on diet, physical activity, cognitive training, and social stimulation activities.
223559419|NCT03978052|OTHER|Multimodal lifestyle intervention|"* Dietary intervention: personalized dietary recommendations based on MedDiet, 9 individual counseling sessions.~* Physical activity intervention: Guided gymnasium (aerobic, strength, and balance activities). Minimum one class/week the first 6months, and two classes/week from month 7 to 12). Achieve a physically active lifestyle (10,000 steps/day; individuals living with disability 8,500 steps/day). Achieve moderate physical exercise in older adults (150 to 210 minutes/week or 90 to 150 minutes depending on medical history.~* Cognitive training: NeuronUP, 3/week, 30 min sessions~* Psychoeducation: ten 90-minute sessions~* Social stimulation activities: ten to twelve 90-to-120-minute sessions."
223559420|NCT04158726|BEHAVIORAL|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
223559421|NCT02058511|DRUG|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
223412026|NCT05536232|BEHAVIORAL|Low carbohydrate diet|Low carbohydrate diet under 75 g per day
223559422|NCT02058511|PROCEDURE|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
223559423|NCT03784131|DRUG|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
223559424|NCT05678816|DEVICE|BREATHER|respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
223559425|NCT05678816|OTHER|physiotherapy prgramme for rehabilitation of stroke patients|"physiotherapy prgramme for rehabilitation of stroke patients which include:~* Passive stretching exercise, strengthening exercise.~* Postural control and balance exercise from different positions as quadruped, kneeling, sitting and standing.~* Gait training."
223738759|NCT04596644|DRUG|Active Cannabis|6.58% THC + \<0.01% CBD cannabis (in one cigarette)
223412027|NCT03119350|OTHER|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
223412028|NCT05738057|DRUG|Camrelizumab|200mg on day1 of every 3 weeks, starting on day1 of cycle1
223412029|NCT05738057|DRUG|Gemcitabine Injection|1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
223412030|NCT05738057|DRUG|Cisplatin injection|25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1
223412031|NCT05738057|DRUG|Cisplatin-Eluting Beads|used for D-TACE
223412032|NCT05738057|PROCEDURE|D-TACE|TACE with Cisplatin-Eluting Beads (with Cis 30mg). More TACE can be done if clinically necessary.
223412033|NCT02060838|PROCEDURE|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
223412034|NCT05169801|DRUG|BP102, paclitaxel, carboplatin|BP102, paclitaxel, carboplatin
223412035|NCT05169801|DRUG|Avastin®, paclitaxel, carboplatin|Avastin®, paclitaxel, carboplatin
223412036|NCT01583140|BEHAVIORAL|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
223412037|NCT01583140|BEHAVIORAL|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
223412038|NCT06427746|PROCEDURE|Standard|Basic ambulance personnel are trained in the application of the CPSS scale in suspected stroke. The CPSS scale is a tool used to quickly assess stroke severity in pre-hospital settings. It is a three-point scale that takes into account the patient's level of consciousness, facial droop, and arm weakness. If a patient with suspected stroke meets certain criteria, they will be coded as having a suspected stroke by the SOREU. These criteria include having one item in three of the CPSS scale, being of adult age, and being independent at home.
224029264|NCT01330173|OTHER|Laboratory Biomarker Analysis|Correlative studies
224029265|NCT03037164|DEVICE|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
224029266|NCT03037164|DEVICE|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
224029267|NCT00253877|OTHER|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
224029268|NCT02466633|OTHER|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
223412039|NCT06427746|PROCEDURE|Video call|Among the tools already available to improve evaluation of patients rescued in the field, SOREU has video calls between the dispatch room physician and the rescuer in the field. Thus, the rescuer in the field will perform the CPSS during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room, potentially increasing the ability to identify a stroke.
223412040|NCT06427746|PROCEDURE|Video call + LARIO|LARIO scale's effectiveness in identifying patients with ischemic stroke caused by a large vessel occlusion in the anterior cerebral circulation. The anterior cerebral circulation supplies blood to the front and upper parts of the brain. Occlusion of a large vessel in this area can lead to a severe stroke. Rescuer in the field will perform the CPSS and the LARIO during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room.
223412041|NCT02279875|DRUG|Linezolid|
223412042|NCT02279875|DRUG|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
223412043|NCT04387565|OTHER|magnesium and vanadium measurements and compare|Magnesium and vanadium will be measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).
223412044|NCT02220738|DRUG|ABT-957|ABT-957 administered twice-daily for 7 days
223412045|NCT02220738|OTHER|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
223412046|NCT05520073|DIETARY_SUPPLEMENT|Lactobacillus plantarum|Lactobacillus product 1 pack daily
223412047|NCT05520073|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C tablet 1 pack daily
223412048|NCT01669863|DEVICE|ECMO|Use of veno-venous ECMO in non-intubated patients with ARDS
223412049|NCT01669863|PROCEDURE|ECMO in non-intubated patients|Use of veno-venous ECMO in non-intubated patients with ARDS
224029269|NCT00116727|DRUG|ENBREL®|50 mg/wk SC
224029270|NCT06324565|DIAGNOSTIC_TEST|D-Dimer test|All patients in whom preoperative diagnostics have not been able to exclude a surgical pathology and who are candidates for diagnostic-therapeutic surgery will be referred for minimally invasive abdominal exploration in the real suspicion of ovarian torsion. During the pre-operative phase, blood exams will be performed including coagulation which will be integrated with the D-dimer values. In addition, as usual, the clinical examination of the patients will be performed integrated with the various diagnostic image tools generally used in this category of patients (abdomen ultrasound +/- magnetic resonance in urgency).
224029271|NCT05611437|OTHER|Ultrafast ultrasonography|Ultrasonography of the neck, patient in supine position, neck hyper-extended. Three different scanning planes containing several landmarks. Carried out in the 12h prior extubation.
224029272|NCT05329545|DRUG|Upifitimab rilsodotin|Upifitimab rilsodotin will be administered once every four weeks until completion, disease progression, unacceptable toxicity, voluntary discontinuation, or death (approximately up to 18 months).
224029273|NCT05329545|OTHER|Placebo|Placebo controlled arm.
224029274|NCT06328803|BEHAVIORAL|Rehabilitation training|Including 1) Basic treatment, including corresponding control of risk factors and education on healthy lifestyles. 2)Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.
224029275|NCT06328803|BEHAVIORAL|Active Breathing Exercises|Active breathing exercises aim to enhance the strength and flexibility of respiratory muscles through a series of exercises, improving breathing patterns and increasing respiratory efficiency. The following are common components of active breathing exercises: 1) Deep Breathing. 2) Chest Expansion. 3) Diaphragmatic Breathing. 4) Coughing Techniques. 5) Expiratory Resistance Training. 6) Gradual Increase in Activity.
224029276|NCT02259907|DRUG|KUC 7483 CL|
223412050|NCT00075205|DRUG|SR141716 (Rimonabant)|
223412051|NCT06578754|OTHER|This is an non-interventional study|Only blood samples will be required in this study. It is noninterventional.
223412052|NCT06358547|DIAGNOSTIC_TEST|PGT-A|PGT-A is a technique that allows for the prediction of embryo ploidy status through analysis of a trophectoderm biopsy conducted prior to embryo transfer.
223412053|NCT04931277|PROCEDURE|cataract surgery|stepped surgery in the form of primary phacoemulsification and secondary posterior chamber intraocular lens (PCIOL) implantation in patients with uveitis.
223412054|NCT04181476|DRUG|Sunscreening Agents|Four different sunscreens
223738760|NCT04596644|DRUG|Placebo Cannabis|\<0.01% THC:CBD cannabis.
224029277|NCT02259907|DRUG|Placebo|
224029278|NCT02259907|OTHER|High fat meal|
224029279|NCT05208671|OTHER|NOURISH Food Box|Selection of healthy groceries designed to reduce chronic inflammation and improve insulin resistance with healthy cooking/self-care curriculum
224029280|NCT03599973|OTHER|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
224029281|NCT03022279|PROCEDURE|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
224029282|NCT03022279|PROCEDURE|local wound infiltration|local anesthesia provided at the surgical site utilizing 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
223412055|NCT02189031|DEVICE|Tactor array|
223412056|NCT02189031|DEVICE|Bypass Tactor|
223412057|NCT06416774|DRUG|68Ga-HX01 Injection(0.05mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
223412058|NCT06416774|DRUG|68Ga-HX01 Injection(0.1mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
223412059|NCT06416774|DRUG|68Ga-HX01 Injection(0.07mCi/kg)|"The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments."
223412060|NCT03881189|DEVICE|SUNEKOS® 200|The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
223412061|NCT05629780|DRUG|Resuscitation fluid|Cristalloid fluids given as a resuscitational intervention
223412062|NCT06524362|BEHAVIORAL|Pelvic Floor Physiotherapy (PFR)|"Intervention: Participants will undergo a structured pelvic floor physiotherapy program for three months.~The program includes:~Eight Personal Sessions: Each session lasts 45 minutes.~Frequency:~Once a week for the first month (four sessions). Biweekly for the next two months (four sessions). Home Exercises: Participants will be guided on pelvic floor exercises to be performed at home throughout the three months."
223412063|NCT06524362|BEHAVIORAL|Conventional group|"Patients completing three months post-low anterior resection (LAR) for rectal cancer or six weeks post-diversion ileostomy closure following LAR will be recruited to Conventional group after randomization.~Recruited subjects in the conventional group recieves usual care following low anterior resection such as fluid intake, fiber intake, diet, toilet posture, life style advice etc"
223412064|NCT02588794|DEVICE|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
223559426|NCT04204694|OTHER|3-time blood sampling for septic shock patients|15 mL blood are sampled at day1, day 3 and day 7, from the arterial catheter inserted for all patients with septic shock
223559427|NCT04204694|OTHER|Only one blood sampling for controls patients|15 mL blood are sampled from a blood donation
223559428|NCT01000012|DEVICE|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
223559429|NCT01000012|DEVICE|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
223738761|NCT06660368|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|Filgrastim/G-CSF 300 mcg/day for 6 days beginning 24 hours prior to multiagent chemotherapy (days 0-5), cladribine 5 mg/m2 given intravenously over 2 hours for 5 consecutive days (days 1-5), cytarabine given IV over 4 hours for 5 consecutive days (days 1-5) beginning 2 hours after the completion of cladribine, and mitoxantrone 16 mg/m2 given intravenously over 30 minutes for 3 days (days 1-3) after completion of cytarabine.
224029283|NCT00005082|PROCEDURE|biopsy|
224029284|NCT00005082|PROCEDURE|magnetic resonance imaging|
224029285|NCT00182299|PROCEDURE|porcine small intestine submucosa (SIS)|
224029286|NCT04951401|OTHER|lipid profile|lipid profile
224029287|NCT04951401|OTHER|ECG|ECG
224029288|NCT01198353|DRUG|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
224029289|NCT04419883|DEVICE|McMurray Enhanced Airway|Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
224029290|NCT01685671|DRUG|NESP 60μg|Administrated NESP 60μg once subcutaneously
224029291|NCT01685671|DRUG|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
224029292|NCT05131568|DEVICE|Layered thermal insulation system|No other intervention
224029293|NCT05011773|DEVICE|Deep brain stimulation|Electrical pulses from implanted generator that has already been implanted for therapeutic reasons
223412065|NCT04417855|DIAGNOSTIC_TEST|G-Walk|"Every individual will be examined with a non-invasive G-Walk device which is a sensor mounted on a belt and fasten on individuals' lumbar spine region during two test activities: Timed up and go and 6-meter walk tests. Data collection will include kinematic parameters. Oswestry Disability Index (ODI) score will also be collected."
223412066|NCT02630173|PROCEDURE|Scaling and root planing|Scaling and root planing was done in both the groups
223412067|NCT02630173|OTHER|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
223412068|NCT05353751|BEHAVIORAL|Kind Minds Program|"The KMP intervention uses an online mindfulness phone based program. During the 9-week program, Community Health Worker (CHW) Kindness Coaches will meet weekly for 30 minutes via Zoom with either a) the caregiver and adolescent (in separate meetings), or b) the adolescent only to review and complete a new session using the online mindfulness program. Participants will be prompted to complete mindfulness activities between sessions by notifications, conducive to their school and work schedules. Weekly content and meditations/activities focus on mindfulness skills of present moment awareness, nonjudgment, compassion, and gratitude."
223412069|NCT05262361|BEHAVIORAL|Office-based Vergence and Accommodative Therapy|Office-based Vergence and Accommodative Therapy has four phases which start with gross vergence and accommodation. Disparity vergence is isolated using instruments such as vectograms and accommodation is isolated using near far charts and accommodative rock. The final phase includes the integration of vergence and accommodation to increase range and visual comfort which performing activities close to the person.
224139010|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS)|TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders. Although tDCS is not currently FDA-approved it is considered a non-significant-risk therapy with no record of serious adverse effects.
223412070|NCT06050356|BIOLOGICAL|H107e|Participants will receive two i.m. injections of 20 µg unadjuvanted H107e on Day 1 and Day 29
223412071|NCT06050356|BIOLOGICAL|CAF®10b|Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29
223559430|NCT05486325|DEVICE|Endolumik Gastric Calibration Tube (EGCT)|"Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia."
223559431|NCT04327427|OTHER|Aspirin|Outcome Analysis of Aspirin in liver transplantation
223412072|NCT06050356|BIOLOGICAL|H107e/CAF®10b - low adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (low adjuvant dose) on Day 1 and Day 29
223412073|NCT06050356|BIOLOGICAL|H107e/CAF®10b - full adjuvant dose|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
223412074|NCT06050356|BIOLOGICAL|Low dose intranasal H107e|Participants will receive one i.n. administration of 15 µg H107e (low dose intranasal H107e) on Day 85
223412075|NCT06050356|BIOLOGICAL|Full dose intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 85
223412076|NCT06050356|BIOLOGICAL|H107e/CAF®10b|Participants will receive two i.m. injections of 20 µg H107e/CAF®10b (full adjuvant dose) on Day 1 and Day 29
223412077|NCT06050356|BIOLOGICAL|i.m. placebo|Participants will receive two i.m. injections of placebo on Day 1 and Day 29
223412078|NCT06050356|BIOLOGICAL|BCG|Participants will receive one i.d. injection of BCG on Day 1
223412079|NCT06050356|BIOLOGICAL|i.d. placebo|Participants will receive one i.d. injection of placebo on Day 1
223412080|NCT06050356|BIOLOGICAL|Intranasal H107e|Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
223412081|NCT05582980|DEVICE|HD-tDCS|See detail in arm/group descriptions regarding the intervention.
223559432|NCT03517839|OTHER|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
223559433|NCT05869058|DIAGNOSTIC_TEST|a deep convolutional neural network|a deep convolutional neural network developed for detection and assessing the perfusion of parathyroid gland during endoscopic thyroidectomy
223559434|NCT06331286|DRUG|dulaglutide injection|0.75mg Subcutaneous injection once a week for 24 weeks
223559435|NCT02483923|DRUG|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
223559436|NCT02483923|DRUG|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
223559437|NCT01379248|DEVICE|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
223412082|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral tablet.
224029294|NCT02624310|DRUG|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
224029295|NCT02624310|DRUG|Placebo|
224029296|NCT00178126|DEVICE|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
224029297|NCT00178126|DEVICE|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
224029298|NCT02895451|BEHAVIORAL|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
224029299|NCT02988622|DEVICE|Fraxel Laser|One half of the scar is treated with Fraxel Laser
224029300|NCT02988622|DEVICE|CO2 Laser|One half of the scar is treated with CO2 Laser.
224029301|NCT04579601|PROCEDURE|ERAS program|We designed our centre's ERAS program through different measures during the preoperative, intraoperative and postoperative period. This program incluided received comprehensive multidisciplinary information, daily goals and expected discharge date, explained the expansión exercises, the video-assisted thoracoscopic surgery (VATS) under general anaesthesia combined with regional techniques, leaving only one chest tube at the end of the surgery, maintain normothermia, extubation after the end of the surgery, and early removal of the urinary catheter. From the time of extubation, the patients began oral tolerance and respiratory physiotherapy exercises. Also, the patients were allowed to walk around early.
224029302|NCT02036879|DRUG|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
224029303|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 1|Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
224029304|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Placebo Control 2|Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
224135031|NCT04453696|BEHAVIORAL|Assessment scales-the Spielberger's State-Trait Anxiety Inventory, Modified Dental Anxiety Scale and a visual analog scale.|"STAI-S, like kinetic energy, refers to a palpable reaction or process taking place at a given time and level of intensity. STAI-T, like potential energy, refers to individual differences in reactions. Both of STAI-S and STAI-T scales includes 20 questions. For each question, the scores range from 1 (almost never) to 4 (almost always) points. For both scales, the sum of the scores ranges from 20 to 80. A score between 36 and 41 refers to a mean anxiety level, with values greater than 41 classified as a high level of anxiety.~The MDAS consists of 5 questions that measure anxiety at different stages of dental treatment. The options range from 1 (not anxious) to 5 (very anxious) for each question. The sum of the scores varies from 5 to 25; values between 19 and 25 indicate a high level of dental anxiety.~The VAS scale was included in the present study to determine how anxious the patients felt according to their own thoughts. Scores range from 0 (no anxiety) to 10 (extreme anxiety)."
224135032|NCT04302103|BIOLOGICAL|RC18 160mg|subcutaneous injection
224135033|NCT04302103|BIOLOGICAL|RC18 240 mg|subcutaneous injection
224135034|NCT05831618|OTHER|Interactive Visuo-Vestibular training|Dynamic motor activitites aimed to enhance the visuo-vestibular interaction and the sensorial reweighting will be performed for the Interactive Visuo-Vestibular training group.
224135035|NCT05831618|OTHER|Vestibular rehabilitation training|Dynamic motor activitites aimed to enhance vestibular reflexes will be performed for the vestibular rehabilitation group
224135036|NCT03677817|DRUG|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
224135037|NCT03677817|DRUG|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
224135038|NCT03072641|DIETARY_SUPPLEMENT|ProBion Clinica|
224135039|NCT03657914|PROCEDURE|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
223559438|NCT00728208|DRUG|GSK372475|1.5mg for 28 days
223559439|NCT04981639|PROCEDURE|IVPCA|Intravenous patient controlled analgesia will be performed.
223559440|NCT04981639|PROCEDURE|TAP|Transversus abdominis plane block will be performed.
223559441|NCT04981639|PROCEDURE|IMS|Intramuscular electrical stimulation will be performed.
223559442|NCT05864430|OTHER|Face-to-face Training Group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
223738762|NCT06660368|DRUG|Venetoclax|Venetoclax will be administered orally, once daily, with food.
223738763|NCT02026895|GENETIC|Genetic blood sample|
224029305|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 1.1|Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
224029306|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.1|Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
224029307|NCT05589948|DIETARY_SUPPLEMENT|Radicle Calm Study Active Product 2.2|Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
224029308|NCT01687907|BEHAVIORAL|Music|
223412083|NCT04271488|DRUG|Tasurgratinib|Tasurgratinib oral capsule.
223412084|NCT06047366|DRUG|Sodium bicarbonate|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
223412085|NCT06047366|DRUG|Lidocaine w/ epi|Septodont's standard formulation of 2% lidocaine with epinephrine
223412086|NCT06047366|DRUG|Articaine w/ epi|Septodont's standard formulation of 4% articaine with epinephrine
223412087|NCT06047366|DRUG|Mepivacaine plain|Septodont's standard formulation of 3% mepivacaine
223412088|NCT06570941|DRUG|Chylobinoid Topical Cream|The topical cream is applied to the effected area to reduce or eliminate the symptoms of restless leg syndrome
223412089|NCT03483961|BIOLOGICAL|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
223412090|NCT03483961|BIOLOGICAL|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
223412091|NCT03483961|BIOLOGICAL|Placebo|Placebo is vaccine diluent alone
223412092|NCT06288841|DRUG|Ropivacaine injection|Ultrasound-guided bilateral QLB2 was performed using Ropivacaine injection prior to anesthesia induction
223412093|NCT06288841|DRUG|Bupivacaine liposome|Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
224029309|NCT02637570|DIETARY_SUPPLEMENT|Hibiscus tea|
224029310|NCT02637570|DIETARY_SUPPLEMENT|green tea|
224029311|NCT02637570|DIETARY_SUPPLEMENT|placebo (dextrose)|
224029312|NCT04578782|DRUG|OnabotulinumtoxinA|BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
224029313|NCT06020118|BIOLOGICAL|Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)|Influenza vaccination and mRNA COVID-19 booster will be given at Visit 1.
224135040|NCT01850745|OTHER|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
224135041|NCT05798169|OTHER|Resistance training|Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
224135042|NCT02287012|OTHER|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
224135043|NCT03192527|DRUG|KN015|experimental drug
223412094|NCT05869461|BEHAVIORAL|KP Specific Wellness Sessions|The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.
223412095|NCT05869461|BEHAVIORAL|Peer Navigation|Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
223412096|NCT02430519|PROCEDURE|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
223412097|NCT02430519|PROCEDURE|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
223412098|NCT02430519|DEVICE|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
223559443|NCT05864430|OTHER|DataMatrix supported Face-to-face training group|Students will follow the lesson with the QR code given simultaneously with the training given during the education process. The training will be held in such a way that the students will be given the opportunity to ask questions and will end with 10 minutes of time to be given to the questions of the students.
223412099|NCT02430519|DEVICE|autologous platelet-rich fibrin|
223412100|NCT00356603|DRUG|Sumatriptan Succinate|Sumatriptan Succinate
223412101|NCT02400918|OTHER|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
224029314|NCT06020118|BIOLOGICAL|Sequential Vaccination (Influenza vaccine then mRNA COVID booster)|Influenza vaccine will be given at Visit 1 and mRNA COVID booster will be given at Visit 2.
224029315|NCT06020118|BIOLOGICAL|Sequential Vaccination (mRNA COVID booster then Influenza vaccine)|mRNA COVID booster will be given at Visit 1 and Influenza vaccine will be given at Visit 2.
224029316|NCT00311727|BIOLOGICAL|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
224029317|NCT03562247|OTHER|Usual Care of IPF|standard of care given to patients with IPF
224029318|NCT03562247|OTHER|Telenursing|scheduled phone calls with the patient and care giver
224135044|NCT03192527|DRUG|Placebo|Comparator.
224135045|NCT03192527|DRUG|Triptorelin|The drug is used for down-regulation of endogenous FSH.
224135046|NCT03129581|BEHAVIORAL|Dietary Counseling|Counseling to only eat during a restricted amount of time.
224135047|NCT00798694|DRUG|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
224135048|NCT00798694|DRUG|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
223412102|NCT03661619|PROCEDURE|Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
223412103|NCT03661619|PROCEDURE|Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
223412104|NCT01234870|DRUG|Gadolinium|
223412105|NCT01234870|DRUG|Adenosine|
223412106|NCT00531115|DRUG|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
223412107|NCT03298958|DRUG|Rapamycin|Subject will be randomized to one of the 2 arms
223412108|NCT03298958|DRUG|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
224029319|NCT03562247|OTHER|Telenursing and Remote Monitoring|scheduled phone calls and home monitoring of physiologic parameters
224029320|NCT01204398|DRUG|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
224029321|NCT04281446|DEVICE|Photobiomodulation|Application of light at specific wavelength for interaction with biological tissue
223412109|NCT02802124|RADIATION|carbon-ion radiotherapy for tumor away from GI|
224029322|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
224029323|NCT00983931|DRUG|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
224029324|NCT00983931|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
224029325|NCT02843477|DEVICE|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure \< 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
224029326|NCT02847351|DIETARY_SUPPLEMENT|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
224029327|NCT00544362|BIOLOGICAL|cetuximab|
223412110|NCT02802124|RADIATION|carbon-ion radiotherapy for tumor adjacent to GI|
223412111|NCT00728468|DRUG|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
223412112|NCT04947774|RADIATION|Prophylactic Cranial Irradiation|The extensive-stage SCLC patients will receive prophylactic cranial irradiation ±immunotherapy after standard first-line chemotherapy combined with immunotherapy, until disease progression or death
223412113|NCT01010529|OTHER|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
223412114|NCT06215950|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically
223412115|NCT06215950|BIOLOGICAL|CD70 CAR-T cells|After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
223738764|NCT05030428|DRUG|Inclisiran sodium 300 mg|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
224029328|NCT00544362|DRUG|cisplatin|
224029329|NCT00544362|DRUG|fluorouracil|
224029330|NCT00544362|PROCEDURE|conventional surgery|
224029331|NCT04009850|OTHER|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
224029332|NCT04009850|OTHER|E-cigarette Flavor|Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
224135049|NCT05117229|DEVICE|MetaWear Sensor|Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
224135050|NCT01774344|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
224135051|NCT01774344|DRUG|Placebo|Placebo tablets matching in appearance
223412116|NCT01597570|DEVICE|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
223412117|NCT04088175|OTHER|JUUL ENDS - Virginia Tobacco 5% nicotine strength|JUUL ENDS - Virginia Tobacco 5% nicotine strength
223412118|NCT04088175|OTHER|JUUL ENDS - Virginia Tobacco 3% nicotine strength|JUUL ENDS - Virginia Tobacco 3% nicotine strength
223412119|NCT04088175|OTHER|JUUL ENDS - Menthol 5% nicotine strength|JUUL ENDS - Menthol 5% nicotine strength
223412120|NCT04088175|OTHER|JUUL ENDS - Menthol 3% nicotine strength|JUUL ENDS - Menthol 3% nicotine strength
223412121|NCT04088175|OTHER|JUUL ENDS - Mint 5% nicotine strength|JUUL ENDS - Mint 5% nicotine strength
223412122|NCT04088175|OTHER|JUUL ENDS - Mint 3% nicotine strength|JUUL ENDS - Mint 3% nicotine strength
223412123|NCT04088175|OTHER|JUUL ENDS - Mango 5% nicotine strength|JUUL ENDS - Mango 5% nicotine strength
223412124|NCT04088175|OTHER|JUUL ENDS - Mango 3% nicotine strength|JUUL ENDS - Mango 3% nicotine strength
223412125|NCT01262287|DRUG|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
223412126|NCT01262287|DRUG|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
223412127|NCT02954133|DEVICE|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
223412128|NCT02954133|DEVICE|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
223412129|NCT02954133|DEVICE|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
223412130|NCT02954133|DEVICE|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
223412131|NCT00932373|DRUG|trastuzumab-MCC-DM1|Intravenous escalating dose
223412132|NCT01637922|DRUG|BI 201335|BI 201335 for 9 days
223412133|NCT01637922|DRUG|BI 201335|BI 201335 for 9 days
223412134|NCT01223625|DRUG|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
223412135|NCT01223625|DRUG|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
223412136|NCT05769075|DRUG|TY-2136b|"Drug: TY-2136b PO, QD or BID~Escalation stage: 7 increased dose cohorts from low dose to MTD (from 40mg QD to 420mg QD)"
223412137|NCT05769075|DRUG|TY-2136b|"Expansion stage: 4 distinct cohorts~The dose for the Expansion stage will be determined based on results from the Escalation stage"
223412138|NCT01842984|BEHAVIORAL|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
223412139|NCT01497925|DRUG|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
223412140|NCT05680246|DEVICE|DHOPE-PRO|Prolonged DHOPE preservation \>4 hours
223412141|NCT01423396|OTHER|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
223412142|NCT01423396|OTHER|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
223412143|NCT03258541|DEVICE|TraceIT®|This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.
223412144|NCT03258541|RADIATION|Volumetric Arc Therapy (VMAT)|VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.
223412145|NCT03258541|PROCEDURE|Surgery|Low anterior resection of the rectum: 8-10 weeks post-radiotherapy
223412146|NCT01356043|DRUG|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
224029333|NCT01558011|DRUG|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
223738765|NCT05030428|DRUG|Placebo|Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
223738766|NCT06536166|DRUG|Ruxolitinib|IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
224029334|NCT01281969|DRUG|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
223412147|NCT01356043|DRUG|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
223412148|NCT02509507|DRUG|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10\^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 \& 2, up to 8mL in Cohorts 3 \& 4 of the Group A \& Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10\^6 PFU/mL to the 2nd dose at 10\^7 or 10\^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 \& 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10\^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10\^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 \[dated 26 October 2021\], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.
223412149|NCT02509507|DRUG|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
223412150|NCT00869102|DRUG|GLP-1|intravenous, 124,5 pmol/kg body weight
223412151|NCT00857675|DRUG|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
223412152|NCT00857675|DRUG|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
224029335|NCT01281969|DRUG|Placebo|Normal saline, IV (in the vein), over 2 days
224029336|NCT04688073|BEHAVIORAL|Exercise|Running
224029337|NCT04688073|BEHAVIORAL|Rest|sit and rest
224135052|NCT00258089|DRUG|Levofloxacin|
224135053|NCT05618496|DEVICE|Sodium Hyaluronate Lyophilizate|Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.
223412153|NCT00857675|DRUG|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
223412154|NCT00287040|BEHAVIORAL|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
223412155|NCT00758901|DEVICE|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
223412156|NCT00302848|DRUG|Drospirenone|
223412157|NCT00302848|DRUG|Levonorgestrel|
223412158|NCT00302848|DRUG|Other progestin containing oral contraceptive|
223412159|NCT05684991|DIETARY_SUPPLEMENT|KMS-66 Ashwagandha 300mg|One capsule is taken by mouth twice daily with water
223412160|NCT05684991|DIETARY_SUPPLEMENT|placebo capsule|One capsule is taken by mouth twice daily with water
223412161|NCT02647957|PROCEDURE|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
223412162|NCT05663112|PROCEDURE|Sentinel lymph node biopsy|Sentinel lymph node biopsy will be performed.
223412163|NCT05663112|PROCEDURE|Breast massage|Breast massage will be performed for a duration of 5 minutes.
223412164|NCT05663112|PROCEDURE|Blue dye injection|Isosulfan blue dye will be injected in the subareolar region of the breast
223412165|NCT00093912|DRUG|clevidipine|
223412166|NCT00093912|DRUG|sodium nitroprusside|
223412167|NCT00384618|DRUG|pravastatin|
223412168|NCT00384618|DRUG|vitamin E|
223412169|NCT02221336|DEVICE|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
223412170|NCT02221336|DEVICE|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
223412171|NCT04220788|OTHER|Enhanced pharmacist service|Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated
223738767|NCT06536166|DRUG|Placebo|IBM patients treated by placebo, twice a day, during 12 months.
224029338|NCT01088373|DRUG|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
224029339|NCT06158685|OTHER|Study Group|"Treatment: Hyperextension exercises as described by McKenzie (in addition to the conventional physiotherapy program)~McKenzie Hyperextension Exercises:~* Exercises:~  1. Prone position, arms by the side, deep breath, relax back muscles, holding for 2-3 minutes.~ 2. Prone position, raise trunk by raising head above forearms, elbows at shoulder level, maintaining for 2-3 minutes (10 repetitions).~ 3. Prone position, hands at elbow level, straighten elbows, raise the upper body from the floor and backwards as far as pain permits, holding for 2-3 seconds (10 repetitions).~ 4. Standing with feet shoulder-width apart, hands on waist, leaning backwards as far as possible from the lumbar region without bending knees, holding for 2-3 seconds (10 repetitions).~     Additional Information:~* Researcher Consistency: All treatments and evaluations were performed by the same researcher.~Frequency: 5 days a week Duration: 3 consecutive weeks"
224135054|NCT00611897|DRUG|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
224135055|NCT00611897|DRUG|placebo and ketamine|placebo N-acetylcysteine
224135056|NCT05508438|DEVICE|Transfemoral mitral-valve repair|Transfemoral mitral-valve repair
224135057|NCT04995328|OTHER|Radiation Care Gel|The investigational medical product of this study is a hydrogel, Radiation Care® gel which increases moisturizing and it can be applied to the target areas including skin folds and creases.
224135058|NCT01023412|DIETARY_SUPPLEMENT|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
223412172|NCT04220788|OTHER|Usual care|Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
223412173|NCT00938769|OTHER|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
223412174|NCT00938769|OTHER|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
223738770|NCT05456425|DRUG|CBT-001|CBT-001 eye drop
223738771|NCT05456425|DRUG|Vehicle|Formulation without drug
223412175|NCT02464592|PROCEDURE|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
223412176|NCT02268292|BEHAVIORAL|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
223559444|NCT05864430|OTHER|Online training group|The training will take approximately 3 hours. The training will be done interactively, allowing students to talk to each other and ask questions, and will end with 10 minutes of time for students' questions.
223412177|NCT02386267|DRUG|L-leucine|L-leucine pills per os for 6 months
224029340|NCT06158685|OTHER|Control Group|"Treatment: Conventional physiotherapy program~* Components:~  * Hot pack was applied to the lumbar region for 20 minutes~ * Ultrasound (ITO device) at 1 MHz and 1.5 W/cm2 for 5 minutes~ * Transcutaneous Electrical Nerve Stimulation (TENS) at 50-100 Hz for 20 minutes~ * Researcher Consistency: All treatments and evaluations for both groups were performed by the same researcher.~* Session Duration: An average of 45 minutes per session~* Frequency: 5 days a week~* Duration: 3 consecutive weeks~* Total Sessions: 15"
224029341|NCT00628264|DRUG|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
224029342|NCT00628264|DRUG|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
224135059|NCT02488096|DEVICE|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
224135060|NCT02488096|DEVICE|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy \~ 1 week after the MRI."
224135061|NCT00674830|BEHAVIORAL|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
224135062|NCT00674830|BEHAVIORAL|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
224135063|NCT00674830|BEHAVIORAL|placebo|usual care
223412178|NCT02360969|OTHER|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS \<50 Deep anesthesia and muscle relaxation: BIS \<50 and TOF 0/4"
223412179|NCT04850417|DRUG|Beta blocker, aspirin, clopidogrel|Pragmatic design. Beta-blockers and Antiplatelets drugs selected by the investigators. Asprin and Clopidogrel recomended for patients allocated to prologed DAPT. Aspirin Alone recomended for patients allocated to short antiplatelet therapy
223412180|NCT02779010|BEHAVIORAL|Hand washing with soap and Health education|Health education on key environmental variables and hand washing with soap
223412181|NCT02510664|BEHAVIORAL|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
223412182|NCT01757002|BEHAVIORAL|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
223412183|NCT01757002|BEHAVIORAL|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
223412184|NCT00474071|DRUG|Remifentanil|See Detailed Description.
223412185|NCT04394780|PROCEDURE|cooling|First, patients underwent peritoneal dialysis (PD) at 37 C (standard temperature) and then patients underwent PD cooling. After each PD session, the patient had a CT scan for the study team to study myocardial perfusion at rest and after introduction of a pharmacological stressor.
223412186|NCT05600231|OTHER|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
223559445|NCT06076252|PROCEDURE|Modified Blumgart Anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
224029343|NCT02675127|DRUG|Daktavira|1 tablet contains 60 mg Daclatasvir
223412187|NCT05600231|OTHER|LISTERINE COOL MINT ZERO Alcohol Mouthwash|Participants will use LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 second after brushing teeth twice daily.
223412188|NCT05600231|OTHER|Reach Unflavored Waxed Dental Floss|Participants after brushing for 1 timed minute, will rinse mouth with water and Floss once a day.
223412189|NCT05600231|OTHER|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
223738772|NCT03909815|DEVICE|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
223412190|NCT02021344|BEHAVIORAL|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
224029344|NCT02675127|DRUG|Daklinza|1 tablet contains 60 mg Daclatasvir
224029345|NCT03743467|DIAGNOSTIC_TEST|Clinical evaluation of vision and eye tests|"* VFQ-25 Questionnaire~* BCVA~* Contrast sensitivity~* Color sensitivity examination (Ishihara test 38 plates)~* Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~* Slit lamp examination~* Shirmer test, Break up time test~* Corneal pachymetry (optical pachymetry)~* IOP~* Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer"
224029346|NCT05981599|OTHER|There is no intervention|There is no intervention. Only retrieving clinical, biological and epidemiological data from patient files
223412191|NCT03097757|RADIATION|Ultrasound - guided fracture reduction|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
223412192|NCT03097757|PROCEDURE|Standard of care fracture reduction|Closed reduction of a fractured bone.
223412193|NCT02259374|PROCEDURE|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
223412194|NCT02259374|PROCEDURE|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
223412195|NCT02237469|RADIATION|Prone and supine simulation|Treatment planning in the two positions.
223412196|NCT05111912|DRUG|XW003|XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003). All eligible participants assigned to the XW003 study groups should aim to reach the respective final target dose of XW003 at 1.2 mg, 1.8 mg, or 2.4 mg once weekly.
223412197|NCT05111912|DRUG|Saxenda|If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).
223412198|NCT05455541|DIAGNOSTIC_TEST|AI augmented POCUS examination|Internists will perform POCUS studies as they consider appropriate for patient management. Interpretation of the POCUS exams will be aided by machine learning based analysis of the videos.
223412199|NCT00004043|DIETARY_SUPPLEMENT|calcitriol|
223412200|NCT00317187|BIOLOGICAL|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
223412201|NCT00317187|BIOLOGICAL|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
223412202|NCT05418933|OTHER|Family workshop|Family workshops for 5 courses, with 6-7 families in one course. The workshops were 2 hours per session, one time per week, for a total of 6 weeks.
223559446|NCT06076252|PROCEDURE|conventional Blumgart anastomosis in LPD|This study is a clinical study designed by parallel control, the test group is LPD patients with modified Blumgart anastomosis and the control group is LPD patients with conventional Blumgart anastomosis
223559447|NCT00168636|DRUG|Vitamin A|
223559448|NCT01772524|BIOLOGICAL|ALD403|
223559449|NCT01772524|DRUG|Placebo|
223559450|NCT05348356|DRUG|Nirogacestat|nirogacestat oral tablet
223559451|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
223559452|NCT01538979|BIOLOGICAL|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
223559453|NCT01538979|BIOLOGICAL|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
223738773|NCT03909815|DEVICE|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
224029347|NCT04307251|DEVICE|Navio™ Robotics-assisted Surgical System, LEGION Total Knee System|Robotic TKA uses computer software to convert anatomical information into a virtual patient-specific 3D reconstruction of the knee joint.The surgeon uses this virtual model to plan optimal bone resection, implant positioning, bone coverage, and limb alignment based on the patient's unique anatomy.
224029348|NCT04307251|DEVICE|Conventional, LEGION Total Knee System|Total Knee Arthroplasty (TKA) is a widespread orthopaedic procedure for restoring functionality and minimizing pain due to end stage osteoarthritis. Conventional TKA, well-accepted as the standard of care, is performed with manual instrumentation guided by intramedullary or extramedullary alignment rods, as well as rotational guides that are not patient-specific.
224029349|NCT04618445|BEHAVIORAL|some risk factors that might be correlated with TMD|Fonesca questionnaire
223412203|NCT06363344|OTHER|Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999)|An advanced practice nurse who is a member of the PICU team monitors patients by questionnaires at 1 and 3 months. Depending on the anomalies detected, whether at the somatic, psychological, emotional or social level, the nurse refers to competent specialists and collaborators and continues monitoring of the family as needed.
224029350|NCT03525431|DIAGNOSTIC_TEST|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
224029351|NCT02767713|DRUG|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
224029352|NCT02767713|OTHER|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
224135064|NCT06230835|BEHAVIORAL|Intervention Group|Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
224298149|NCT04502758|DEVICE|Sham MagVenture TMS Therapy System w/Theta Burst Stimulation|During each session continuous theta burst stimulation (cTBS) in which 1800 pulses are delivered continuously over 120 seconds to the right dorsolateral prefrontal cortex (RDPFC) is administered first, followed by iTBS in which 1800 pulses are delivered in 2 second bursts, repeated every 10 seconds for 570 seconds (1800 pulses) to the left dorsolateral prefrontal cortex (LDPFC). The device consists of a magnetic stimulator, MagPro X100 and a magnetic coil used for MT determination, C-B70 and a treatment coil, the Cool-B70 A/P coil. The A/P version of the coil, contains both an active site (A) and a sham (P) site. The magnetic field on the sham site is significantly reduced, and is less than 5% of that of the active site.
224298150|NCT06204887|PROCEDURE|Manual dynamic activation|The root canals were filled with irrigation solutions. A main gutta percha cone was positioned 1 mm shorter than the working length and 2 mm coronal-apical direction movement was performed at a rate of 100 strokes per minute during 60 s.
223412204|NCT02110758|OTHER|Pilot of Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track \& coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track \& coordinate care, and measure and improve performance.
223412205|NCT02604043|OTHER|pH monitoring|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
223412206|NCT02604043|OTHER|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
223412207|NCT00680095|DRUG|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
223412208|NCT00680095|DRUG|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
223738774|NCT06171152|DRUG|Liraglutide Pen Injector [Saxenda]|A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
223412209|NCT00680095|DRUG|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
223559454|NCT03833986|OTHER|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
223559455|NCT03010774|BEHAVIORAL|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
223738775|NCT06171152|OTHER|Medication Diary|Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
223738776|NCT05130190|DEVICE|RF Treatment|ProVu treatment probe will be energized and RF energy delivered in a pre-programmed, controlled method based on the predetermined size of the affected tissue.
223738777|NCT06548230|DRUG|Nadunolimab|Give by IV
223738778|NCT06548230|DRUG|Azacitidine|Given by IV
224029353|NCT02668484|DEVICE|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
224029354|NCT02668484|DEVICE|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
224029355|NCT01564628|DEVICE|CADScor1|Acoustic recording
224029356|NCT01735851|DRUG|Thoracic epidural analgesia|
224029357|NCT01735851|PROCEDURE|Bilateral Paravertebral block|
224029358|NCT05610332|DRUG|Camrelizumab|Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.
223412210|NCT00680095|OTHER|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
223412211|NCT00680095|OTHER|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
223412212|NCT01097889|DIETARY_SUPPLEMENT|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
223412213|NCT01097889|DIETARY_SUPPLEMENT|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|"Peanut-based fortified supplement~One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein"
223412214|NCT00618644|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
223412215|NCT00090025|DRUG|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
223412216|NCT00090025|DRUG|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
223412217|NCT01851122|DIETARY_SUPPLEMENT|L-theanine capsule|L-theanine 250mg capsule
223412218|NCT01851122|DIETARY_SUPPLEMENT|Placebo capsule|
223412219|NCT02215200|DRUG|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
223412220|NCT02215200|DRUG|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
223412221|NCT02215200|DRUG|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
223412222|NCT02215200|DRUG|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
223559456|NCT03010774|BEHAVIORAL|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
223559457|NCT00408382|DRUG|atorvastatin, Lipitor|
223559458|NCT00789594|BEHAVIORAL|laboratory monitoring alerts|laboratory monitoring alerts
223738779|NCT06548230|DRUG|Venetoclax|Given by mouth (PO
223738780|NCT04682652|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
223738781|NCT04447755|DRUG|Lenvatinib|Lenvatinib capsules administered orally at 14 mg/m\^2 QD
223738782|NCT05712720|DRUG|Experimental: Group 1 - 50mg RZ402|RZ402 50 mg oral tablet, once daily for 3 months
224029359|NCT05610332|DRUG|Albumin Taxol|Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle
223738783|NCT05712720|DRUG|Experimental: Group 2 - 200mg RZ402|RZ402 200mg oral tablet, once daily for 3 months
223738784|NCT05712720|DRUG|Experimental: Group 3 - 400mg RZ402|RZ402 400mg oral tablet, once daily for 3 months
224029360|NCT05610332|DRUG|FLOT scheme|"Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1,~4 cycles before and after operation, q2w"
224029361|NCT01442831|DRUG|Human ADME|Oral single dose
223412223|NCT03497104|OTHER|Surplus blood tests|Surplus blood donation
223412224|NCT04858646|OTHER|Experimental( Group A ): Aerobic exercises|Subjects in A group was treated with different types of aerobic exercises such as 10 minute walking, 10 minute trampoline exercise and 10 minutes ball throwing activities
223412225|NCT04858646|OTHER|Conventional( Group B): Conventional Physical therapy|The group B was treated with conventional therapy. Conventional treatment protocol passive ROM and stretching passive ROM for 15 minutes and stretching for 15 minutes.Treatment duration for both groups will be 30 minutes. Each subject received total30sessions of the treatment, with 5 treatment sessions per week for 6 weeks
223412226|NCT05482113|DRUG|Liposomal bupivacaine|Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
223412227|NCT05482113|DRUG|Bupivacaine Hcl 0.25% Inj|Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
223559459|NCT00789594|BEHAVIORAL|Result management module|Result management module
223559460|NCT03673085|DRUG|CN128|CN128
223559461|NCT03673085|OTHER|placebo|The tablets without CN128
223559462|NCT05658848|OTHER|Collaborative infertility counseling|Collaborative infertility counseling for coping stratigies and marital satisfaction
223559463|NCT04689490|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|Only diagnostic tests
223559464|NCT00801723|DRUG|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
223559465|NCT00801723|DRUG|Placebo Tablet|Placebo Tablet once daily.
223559466|NCT04458441|OTHER|warm group/cold group|sequential randomization
223559467|NCT00995397|DRUG|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
223412228|NCT01694160|DRUG|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
223559468|NCT00995397|DRUG|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
223738785|NCT05712720|OTHER|Placebo: Group 4 - Placebo|Placebo oral tablet, once daily for 3 months
223738786|NCT06963671|BEHAVIORAL|Blood Flow Restriction|The treatment group will receive standard rehabilitation as a home program plus low-load resistance training with BFR application while at the hand therapy clinic for their appointments
224029362|NCT04625998|BEHAVIORAL|Enhanced CATCH Elementary School Program|Enhanced CATCH Elementary School Program is a Coordinated School Health Program that includes the CATCH Coordination Guide.
224029363|NCT04625998|BEHAVIORAL|CATCH Early Childhood (CEC)|Implementation of the CATCH Early Childhood coordinated nutrition and physical activity program for Early Care and Education (ECE) centers.
224029364|NCT02299492|OTHER|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
224029365|NCT05231031|BEHAVIORAL|Aerobic exercise|continuous aerobic exercise on a treadmill
224029366|NCT05231031|BEHAVIORAL|breathing exercise|continuous aerobic exercise plus breathing exercise (Mindfulness)
223412229|NCT02183883|DRUG|Afatinib|"40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade \> 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg."
224029367|NCT05231031|BEHAVIORAL|Relaxation training|continuous aerobic exercise plus relaxation training
224029368|NCT03956485|OTHER|Type of center|Tertiary versus non-tertiary
223412230|NCT00435708|BEHAVIORAL|5 portions fruit and vegetables/day|Participants consume \> = 5 portions fruit and veg per day
223412231|NCT03713060|DIAGNOSTIC_TEST|Mixed meal test|All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
223412232|NCT02170974|DRUG|BIBR 1048 MS polymorph II|
223412233|NCT02170974|DRUG|BIBR 1048 MS polymorph I|
223412234|NCT01859169|PROCEDURE|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
223412235|NCT01543035|DRUG|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
223412236|NCT00912743|DRUG|olaparib|400 mg po bid continuously
223412237|NCT01615406|DRUG|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
223412238|NCT00694083|DRUG|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
223412239|NCT00570193|DRUG|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
223412240|NCT00570193|DRUG|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol
223412241|NCT03447561|BEHAVIORAL|Anticipatory + consummatory food reward|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
223412242|NCT03447561|BEHAVIORAL|Consummatory food reward|Exposure to consummatory food reward (drinking sips of chocolate milkshake).
223412243|NCT06110702|BEHAVIORAL|EMDR|Eye movement Desensitization and Reprocessing (as described in the 8-phases protocol), administered both online or in presence.
224029369|NCT02422862|OTHER|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
224029370|NCT04621773|PROCEDURE|Preimplantation Genetic Screening(exposure)|Preimplantation genetic screening (PGS) was developed in the late 1980s as an alternative to prenatal diagnosis for couples at risk of transmitting a genetic or chromosomal abnormality to their children. In embryos created through in vitro fertilisation (IVF), cells are biopsied and analysed using genetic tests such as polymerase chain reaction and fluorescent in situ hybridisation (FISH).
223412244|NCT03291184|DEVICE|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
224029371|NCT00434473|DRUG|A-001|A-001
223412245|NCT02973503|DRUG|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
223412246|NCT05852275|OTHER|Olive-oil|Participants will add to their usual diet a daily intake of 30 mL of an olive oil rich in polyphenols for 3-months (100 days)
223412247|NCT02384746|DRUG|Fulvestrant|500 mg intramuscular every 28 days
223412248|NCT02384746|DRUG|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
223412249|NCT00208169|DRUG|Aripiprazole|
223412250|NCT00862823|DRUG|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
223412251|NCT00862823|DRUG|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
223738787|NCT06550128|DRUG|AHB-137|AHB-137 injection will be administered subcutaneously.
223738788|NCT06550128|DRUG|AHB-137 and Placebo|AHB-137and placebo will be administered subcutaneously.
224029372|NCT00434473|OTHER|Placebo|Placebo
224029373|NCT01201265|DRUG|Bevacizumab|15 mg/kg iv every 3 weeks
224298151|NCT06204887|PROCEDURE|Passive ultrasonic activation|A non-cutting ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) coupled to an ultrasonic device (DTE S6 Led, Guilin Woodpecker Co., Guilin, Guangxi, China) (mode: E, setting: 6) was used according to the manufacturer's recommendations.
223738789|NCT06550128|DRUG|AHB-137 (16weeks)|AHB-137 injection will be administered subcutaneously.
223738790|NCT04962867|DRUG|E7090|140 mg of E7090 is orally administered once daily.
224029374|NCT01201265|DRUG|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
223412252|NCT00747019|BEHAVIORAL|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
223412253|NCT00747019|BEHAVIORAL|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
223412254|NCT03132844|OTHER|Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.
223412255|NCT01586923|BIOLOGICAL|RBC transfusion|RBC transfusion of different storage age
224029375|NCT01201265|DRUG|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
223412256|NCT01137058|DEVICE|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
223412257|NCT01137058|DEVICE|SMBG group|Glucose control with self monitoring of blood glucose.
224029376|NCT04640077|OTHER|No Intervention|No intervention
223412258|NCT05751980|BEHAVIORAL|Med Wise Rx|The program consists of two 120-minute classes led by trained community site-based facilitators, designed to help older adults communicate more effectively with their pharmacists.
223412259|NCT05055960|DIAGNOSTIC_TEST|Stroke simulation and machine learning|Using simulation and machine learning approaches to classify the source of embolic stroke.
223412260|NCT02177526|DEVICE|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
223412261|NCT04869774|DEVICE|How2Trak mobile application|Patients will undergo virtual monitoring of their incision and symptoms using the How2Trak application(app). Using the app, patients will be asked to answer a series of questions and photograph their surgical incision on post-operative day 3, 5, 7, 10, 20, and 30. Patient responses and photographs entered into the app will be reviewed within 72 hours by a trained Nurse Specialized in Wound, Ostomy and Continence. If a concern is identified the nurse will contact the patient to arrange a virtual visit using the how2trak app or notify the surgeon team (including colorectal surgeons and physician residents) in accordance with clinical discretion.
223559469|NCT03401658|DEVICE|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
223559470|NCT01986231|DRUG|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
223559471|NCT02882789|DRUG|LCB01-0371|Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
224029377|NCT04640077|DRUG|donanemab|Administered IV
224029378|NCT02119845|DEVICE|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
224029379|NCT01257425|DRUG|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
224029380|NCT02844647|OTHER|Hyperpolarized Pyruvate (13C)|MRI contrast agent
224029381|NCT00304525|DRUG|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
223412262|NCT00846001|PROCEDURE|Coronary artery bypass grafting|Standard coronary surgry according guidelines
223559472|NCT02882789|DRUG|LCB01-0371 400mg|Cohort 2: Crossover designed administration
223738791|NCT03204370|DRUG|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
223738792|NCT06099457|BEHAVIORAL|SIB-Time web-application tool|Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
223738793|NCT02260271|OTHER|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
224029382|NCT00680680|DRUG|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
224029383|NCT01498367|PROCEDURE|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
224029384|NCT01374373|BIOLOGICAL|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
224029385|NCT05314920|BEHAVIORAL|Transdiagnostic cognitive-behavioral therapy (TD-CBT)|Transdiagnostic cognitive-behavioral therapy (TD-CBT)
224029386|NCT05314920|BEHAVIORAL|Bernstein and Borkovec progressive muscle relaxation (PMR)|Bernstein and Borkovec progressive muscle relaxation (PMR)
224029387|NCT04925973|DRUG|Tofacitinib 10 MG [Xeljanz]|Tofacitinib 10mg PO BID
224029388|NCT03576170|OTHER|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
224029389|NCT00467168|BEHAVIORAL|Diet|
224135065|NCT03768141|PROCEDURE|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
223412263|NCT00846001|DEVICE|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
223412264|NCT06094725|DRUG|Relacorilant|Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration
223412265|NCT04042714|DRUG|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
223412266|NCT01371110|DRUG|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
223412267|NCT01371110|DRUG|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
223412268|NCT02994225|DRUG|Indocyanine Green|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
223412269|NCT02342158|PROCEDURE|biopsy or surgical sampling|
223412270|NCT02342158|OTHER|blood sampling|
223412271|NCT03753464|PROCEDURE|Gingival biopsy and blood sample collection|Gingival and blood samples will be collected.
223412272|NCT03710863|DRUG|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
223412273|NCT03991962|DRUG|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
224029390|NCT02682745|DRUG|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
224029391|NCT02682745|DRUG|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
224029392|NCT00513643|DRUG|insulin aspart|6, 12, 24 U s.c.
224029393|NCT00513643|DRUG|human regular insulin|6, 12 and 24 IU sc
224029394|NCT05636722|BEHAVIORAL|Unguided web-based intervention|An online unguided intervention based on Cognitive Behavioural Therapy and elements of Dialectical Behaviour Therapy, Problem Solving Therapy, and Mindfulness Based Cognitive Therapy. The intervention consists of 6 modules with each a theoretical part, a weekly assignment and (optional and mandatory) exercises. Participants are advised to complete one module weekly. The original intervention was adapted to students (language, addition of podcasts, examples that were more suited to their lives).
224029395|NCT01182194|DRUG|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
224029396|NCT01182194|DRUG|YAZ®|3 mg/0.02 mg Tablets
224029397|NCT04262817|DRUG|Nicotine form|participants will receive 36mg/ml nicotine salt and freebase nicotine
224029398|NCT04262817|OTHER|E-cigarette experimental flavor|Participants will receive menthol and tobacco flavored e-cigarettes
224029399|NCT02756273|DEVICE|bridge device|
224029400|NCT02756273|DEVICE|no bridge device|
224029401|NCT04992182|BIOLOGICAL|Placebo|0.3 mL IM saline solution
224029402|NCT04992182|BIOLOGICAL|Inactivated vaccine booster|0.5 mL IM
224029403|NCT04992182|BIOLOGICAL|mRNA vaccine booster|0.3 mL IM
224029404|NCT04992182|DRUG|Viral vector vaccine booster|0.5 mL IM
224298152|NCT06204887|PROCEDURE|Laser activation|A 2940 nm Er:YAG-laser device (Lightwalker, Fotona, Ljubljana, Slovenia), equipped with a handpiece (H14, Fotona) holding a 8.5 mm long and 600 µm diameter-tapered fiber tip (SWEEPS 600, Fotona) was used for irrigation activation. The device was set to AutoSWEEPS mode with two ultrashort micropulse durations (25 μs) continuously varying at 0.3 W, 20 mJ, 15 Hz settings. The air and water sprays were turned off.
223412274|NCT03991962|RADIATION|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
223412275|NCT06578169|DRUG|Hormonal Therapy Agent|Women initiating either Hormonal Contraceptives or Hormone replacement therapy in menopause
224029405|NCT01998087|BEHAVIORAL|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
224029406|NCT00368992|BIOLOGICAL|cetuximab|Given IV
224029407|NCT00368992|DRUG|paclitaxel|Given IV
224029408|NCT00368992|BIOLOGICAL|bevacizumab|Given IV
224029409|NCT00201721|DRUG|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
224029410|NCT00201721|DRUG|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
224029411|NCT00201721|DRUG|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
224029412|NCT02902874|OTHER|Blood sample|
224029413|NCT02377804|OTHER|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
224298153|NCT02673879|OTHER|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
223412276|NCT01932710|PROCEDURE|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
224029414|NCT02377804|OTHER|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
224029415|NCT02377804|DEVICE|stainless steel needles (0.3mm x 50mm)|
224029416|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
224029417|NCT04018599|DRUG|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
224135066|NCT05848050|PROCEDURE|biological samples (blood test and lumbar puncture)|"On the day of excision of the cerebral metastasis, additional biological samples (blood test and lumbar puncture) will be taken in the operating room.~A biological sample of the tumor tissue (brain metastases of a solid cancer with contrast uptake of at least 1 cm accessible to surgical excision) will also be taken and preserved by freezing, in accordance with current practice and after obtaining their written agreement. .~Biological samples (liquid biopsies and tumour) from patients who have explicitly expressed their consent will be kept after the end of the research as part of a biobank in order to be able to carry out any additional analyses."
224135067|NCT00861861|DRUG|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
224135068|NCT00861861|DRUG|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
224135069|NCT01143168|BIOLOGICAL|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
223412277|NCT01560312|DEVICE|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
224029418|NCT01685164|OTHER|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
224029419|NCT05620368|BEHAVIORAL|Mindfulness and Compassionate Living Course (MCLC)|"The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments."
224029420|NCT05620368|BEHAVIORAL|Usual care intervention|"If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week)."
224029421|NCT00646633|PROCEDURE|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
224029422|NCT02668185|DRUG|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
224029423|NCT02668185|DRUG|Placebo|Placebo
224135070|NCT00734734|BIOLOGICAL|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
224135071|NCT02815241|DRUG|BAY987517|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
224029424|NCT03172676|DRUG|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
224135072|NCT05176431|DEVICE|ESWT (wave type: focused)|Extracorporeal Shock Wave Therapy, device: Electronica, Pagani, Italy
223412278|NCT00708812|DRUG|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
223738794|NCT05574439|BEHAVIORAL|TCOC treatment|The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
224029425|NCT03172676|DRUG|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
224029426|NCT03172676|DRUG|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
224135073|NCT05176431|DEVICE|ESWT (wave type: radial)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
224135074|NCT05176431|DEVICE|ESWT (wave type: sham)|Extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
224298154|NCT02673879|OTHER|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
223412279|NCT00708812|DRUG|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
223412280|NCT03593824|PROCEDURE|bilateral cataract removal surgery for dense cataract|Participants were born with dense bilateral cataracts (extreme adversity) will undergo surgery for bilateral cataract removal at an early age, mostly around 3 months of age.
223412281|NCT03593824|PROCEDURE|bilateral cataract removal surgery for non-dense nuclear cataract|Participants were born with non-dense and nuclear bilateral cataracts (watered-down adversity) will undergo cataract removal surgery bilaterally in a compromised timing, mostly around one year old.
224029427|NCT04497454|OTHER|EIT-Group|A mechanical ventilation strategy with the main goal to maintain DP \< 16 cmH2O
223412282|NCT00966524|PROCEDURE|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
223412283|NCT03781635|DRUG|bolus of intravenous ketamine|low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
223412284|NCT03781635|DRUG|continuous infusion of intravenous ketamine|An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
223412285|NCT02766803|DRUG|Simvastatin and micronized trans-resveratrol|
223559473|NCT05340387|OTHER|Balance Resistance Aerobic Cognitive exercises (BRACE)|Study will be conducted after the approval of Ethical review board. The BRACE exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. Week 1-3 : Balance: Romberg, tandom standing, single leg stance Resistance: chair rise Aerobic exercises: 6mint walk Cognitive: count reverse from 50 Week 4-6: Balance: Sit to stand, functional reach, Tug Test Resistance: stair climbing Aerobic Exercises: Marching in space Cognitive: Remember 5 words, spell backward, remember 5 animals Week 7-9: Balance: Perturbation, throwing a ball, kicking a ball Resistance: Floor transfer, squatting Aerobic Exercises: Cycling Cognitive: Count even number from 1-50, calculation, addition, subtraction, multiplication division Week 10-12: Balance: Combination of All Resistance: Combination of All Aerobic Exercises: 6 minutes' walk test, marching steps, cycling Cognitive: Combination of all
223412286|NCT00172328|BIOLOGICAL|Hepatitis B vaccine|
223559474|NCT05340387|OTHER|Otago's Protocol|"Study will be conducted after the approval of Ethical review board. The Otago's exercise training would be perform in 4 times a week for 12 weeks, lasting approximately 40-50 minutes each time. WEEK 1-3: Warm up: March, head movement, neck movement, back extension, trunk movement, ankle movements Strength: Front knee strengthening, Back knee strengthening, Side hip strengthening, Calf raises, Toe raises (10 repetitions each) Balance: Knee bends, Backwards walking, Walking and turning around, Sideways walking, Tandem stance (heel toe stand), Tandem walk (heel toe walk), One leg stand, Heel walking, Toe walk, Heel toe walking backwards, Sit to stand, Stair walking. (10 repetitions each) Flexibility: calf stretch, back of thigh stretch Hold for 10 to 15 seconds and repeat on other leg.~Walk: 5 or 10 minutes' walk~This protocol will be followed for 12 weeks with increased repetitions after every 3 week."
223559475|NCT04206254|BIOLOGICAL|gp96|heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.
223559476|NCT00623233|DRUG|Gemcitabine|Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
223559477|NCT00623233|DRUG|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
223559478|NCT03379857|OTHER|Drug urinal test|Non Applicable
224029428|NCT04497454|OTHER|ARDSNet|Low PEEP-FiO2 table ARDS Network ventilation protocol
224029429|NCT01168323|BEHAVIORAL|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
224029430|NCT04444544|OTHER|High Risk Abdominal Surgery|Pancreatectomy, Esophagectomy, Gastrectomy and Hepatectomy
224029431|NCT03087019|RADIATION|Radiation|Standard use of radiation is administered
224029432|NCT03087019|DRUG|Pembrolizumab|Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
224029433|NCT05129553|DEVICE|Béa Applicator and Béa Cervical Cap Device|Single-use of the investigational device
224029434|NCT00976612|DRUG|Nilotinib|Nilotinib 400mg bid daily
224029435|NCT01372098|BEHAVIORAL|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
224029436|NCT05955794|OTHER|voice recordings|"Experimental treatment/procedure:~The first recording will be made in the laboratory. The lab will have sound insulation (the sound-to-noise ratio of the room should be at least 30dB) to record the voice samples. Similar to the recordings made in the lab, parents/caregivers will be instructed on how to collect voice recordings at home several times during the day using a smartphone. Parents/caregivers will be asked to note down the patient's emotional state during each recording in a predefined protocol.~All patients will undergo paediatric, morphological, neurocognitive and behavioural assessment, hearing and ENT evaluation, perceptual and acoustic voice analysis.~Perceptual assessment will be done blind.The vowel recordings will be analysed by two software tools: Biovoice \[1\] and Praat \[2\]."
224135075|NCT01735617|DRUG|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
223412287|NCT00776295|BIOLOGICAL|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes|Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
223412288|NCT02714595|DRUG|Cefiderocol|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days, or 2 g every 6 hours for participants with creatinine clearance \>120 mL/min.
223412289|NCT02714595|DRUG|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
223412290|NCT01327170|PROCEDURE|Subthreshold diode micropulse laser|
223412291|NCT02295592|PROCEDURE|TSTstarr+|"TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
223412292|NCT02295592|PROCEDURE|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
223412293|NCT00217373|BIOLOGICAL|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
223412294|NCT00217373|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given SC
223412295|NCT00217373|BIOLOGICAL|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
223412296|NCT00217373|BIOLOGICAL|Sargramostim|Given SC
223559479|NCT01751906|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
223559480|NCT01751906|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
223559481|NCT04771923|DRUG|Tranexamic acid|Topical instillation of tranexamic acid up to 3x. If bleeding is not controlled patients crossover to adrenaline.
223559482|NCT04771923|DRUG|Adrenaline|Topical instillation of adrenaline up to 3x. If bleeding is not controlled patients crossover to tranexamic acid.
223559483|NCT04985409|BEHAVIORAL|Feedback|The system uses Sonifi health (TV content and visualizations) and Fitabase (3rd party server to process Fitbit data and export to Sonifi). The system utilizes the patient's TVs to engage the patient and multidisciplinary team in monitoring ambulation status.
223738795|NCT05574439|DRUG|Semaglutide 3 mg/ml|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
224029437|NCT02373410|PROCEDURE|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
224029438|NCT02373410|PROCEDURE|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
224029439|NCT02373410|PROCEDURE|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
223412297|NCT06501391|DRUG|PD-L1/PD-1 inhibitor and chemotherapy|Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.
223412298|NCT06501391|RADIATION|SRT or WBRT|Stable brain metastases (BM) patients in this arm will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
223412299|NCT01398618|DRUG|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
223412300|NCT06451419|OTHER|Tests on non motor symptoms|Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.
223412301|NCT00089063|BIOLOGICAL|tyrosinase peptide|Given SC
223412302|NCT00089063|BIOLOGICAL|gp100 antigen|Given SC
224029440|NCT02373410|PROCEDURE|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
224029441|NCT02373410|DRUG|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
224029442|NCT02373410|DRUG|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
224029443|NCT02373410|DRUG|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
224029444|NCT02373410|DRUG|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
224029445|NCT04412291|DRUG|Anakinra Prefilled Syringe|A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
223412303|NCT00089063|BIOLOGICAL|MART-1 antigen|Given SC
223412304|NCT00089063|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
223412305|NCT00089063|DRUG|Montanide ISA 51 VG|Given SC
223412306|NCT00089063|BIOLOGICAL|sargramostim|Given SC
223412307|NCT00089063|OTHER|laboratory biomarker analysis|Correlative studies
223412308|NCT00331669|PROCEDURE|deep brain stimulation|high frequency stimulation
223412309|NCT02701530|BEHAVIORAL|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
223412310|NCT04446455|OTHER|InVEST: Increased Velocity Exercise Specific to Task|Functional Power Training
223412311|NCT04446455|OTHER|TAPAT: Tonic and Phasic Alertness Training|Computerized cognitive training.
223412312|NCT02423343|DRUG|Galunisertib|Administered orally
223412313|NCT02423343|DRUG|Nivolumab|Administered IV
223412314|NCT00177242|DRUG|Gefitinib|
223412315|NCT01180751|RADIATION|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
223412316|NCT02208193|BEHAVIORAL|Cognitive and psycho-behavioral effects of an artistic dimension|
223412317|NCT01948440|BEHAVIORAL|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
224029446|NCT04412291|DRUG|Tocilizumab Prefilled Syringe|8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
224029447|NCT04412291|DRUG|Standard-of-care treatment|"SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)"
224029448|NCT01240031|OTHER|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~* Thorough sensory and nutrition assessment (questionnaire).~* Nutrition plan adjusted daily according to the assessment.~* Serving appetising, energy- and protein-dense meals, snacks and drinks."
223412318|NCT03737500|DEVICE|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
223412319|NCT03737500|DEVICE|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
223559484|NCT05771636|BEHAVIORAL|Mental Imagery|"Mental Imagery consists of imagining a situation in the most vivid way possible, including all sensory modalities (visual image, sensations, smells, sounds, emotions). It can be used to act as a motivational amplifier, by pre-experimenting a situation in imagination.~The best possible self imagery consists of imagining the best version possible of one's self , after accomplishing all their major life goals, in a future where everything turned out the best way possible. What does this best version of you do, in terms of actions, on an everyday basis ? The planned imagery exercise consists of rehearsing an activity in a mental way, before actually doing it. It can help to visualize the outcome of this activity and benefits it can provide to the participant before actually getting it done."
223559485|NCT05771636|BEHAVIORAL|Control condition (activity planification)|The participant identifies 4 activities that he plans to do in the course of the next 2 weeks.
223559486|NCT02569372|BIOLOGICAL|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
223559487|NCT03484156|DEVICE|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
223559488|NCT01110330|DRUG|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
223559489|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
224029449|NCT01240031|OTHER|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
223412320|NCT00892671|OTHER|Simulation|simulation of airway management and vascular access
223412321|NCT05403853|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
223412322|NCT05403853|DIAGNOSTIC_TEST|Fingerstick|Capillary Blood Draw
223412323|NCT02865499|DRUG|acarbose|acarbose treatment with meals
223412324|NCT02996123|OTHER|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
223412325|NCT05534919|DRUG|Nefecon|Nefecon is taken orally as capsules once daily for 9 months.
223412326|NCT04449302|PROCEDURE|Immediate molar implant with customized healing abutment|"Patients will receive an immediate implant with customized healing abutment~1. Atraumatic extraction without flap elevation using periotomes and elevators then sectioning of the roots will be performed to preserve the interseptal bone.~2. The drilling will be performed starting from the pilot drill in the interseptal bone to the twisting drills according to the manufacturer's instructions to the selected implant size. The implant is to be placed immediately then the insertion torque will be measured using a torque wrench. In order to place the customized healing abutment, the insertion torque should be more than 25 ncm.~3. The gap distance will be filled by xenograft, a plastic abutment will be screwed in place then a flowable composie resin will be applied around into small amounts and cured to take the soft tissue contour then finishing and polishing of the customized healing abutment will be done."
223412327|NCT06197230|OTHER|Drawing Intervention|"The primary sections of Drawing Intervention will be the art-making and art-sharing sections. During the art-making segment, the group leader will guide the participants through a paper-warming exercise before assigning them a specific subject to draw freely for 20-30 minutes. The leader will then ask participants to talk about the meaning of their artwork, encouraging them to explore their emotions regarding the theme and their drawing. This procedure will be implemented in each segment of the intervention (6 sessions)."
223412328|NCT03606928|DRUG|docetaxel, oxaliplatin, 5-FU, leucovorin|This is a single-arm study with all patients receiving mFLOT chemotherapy.
223412329|NCT00438607|DRUG|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
223412330|NCT00438607|DRUG|Placebo|Matched placebo for MTD or MTD-1
223412331|NCT06666816|OTHER|inapplicable|inapplicable
223412332|NCT05946317|PROCEDURE|Lingual nerve function assessed after removal of mandibular third molar with lingual split technique|The lingual split technique is based on using chisel and hammer in bone removing. After the buccal and lingual flaps are raised and retracted. Two buccal bone cutting with horizontal cutting up between them are performed, The disto-lingual bone fragment is fractured inward by placing the cutting edge of the chisel at 45 degrees with the surface of the bone and directed towards the lower second premolar of the opposite side. By maintaining the cutting edge of the chisel parallel to the external oblique ridge, a few light taps with the mallet will separate the lingual plate from the rest of the alveolar bone. And it released from soft tissues, buccally force is applied to roll the whole tooth lingually. The neurological function of the lingual nerve was assessed after the demise of local anesthesia, then the location of the disorder and taste function and healing time are determined by sensory neurological tests on a graphic map that divides the tongue into sextants.
223412333|NCT03779750|DIAGNOSTIC_TEST|s.creatinine|All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
223412334|NCT06684834|OTHER|5:2 carbohydrate restriction|Carbohydrate ingestion restricted to \<8% of energy intake on 2 self-selected consecutive days each week over 28-30 days. Ad libitum dietary amount, type and pattern followed on the remaining 5 days each week.
223559490|NCT01110330|DRUG|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
223559491|NCT02557100|DRUG|Abatacept|
223559492|NCT02557100|DRUG|Adalimumab|
223559493|NCT02557100|DRUG|Methotrexate|
223738796|NCT05574439|DRUG|Placebo (Semaglutide 3 mg/ml)|Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
223738797|NCT01347697|PROCEDURE|Reconstruction with an acellular porcine dermal collagen implant (biological mesh)|Reconstruction of floor of lesser pelvis with an acellular porcine dermal collagen implant (biological mesh) after extended excision of rectum including levator muscles in advanced low rectal cancer.
223738798|NCT01347697|PROCEDURE|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
224029450|NCT01070030|DRUG|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
224029451|NCT03707197|BEHAVIORAL|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
224029452|NCT02644486|DRUG|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
224029453|NCT02644486|DRUG|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
224135076|NCT06554028|DRUG|chemotherapy TP regimen combined with Tislelizumab|"Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~•Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Other Names:~Docetaxel Cisplatin Paclitaxel"
223412335|NCT06684834|OTHER|Early time-restricted carbohydrate intake|Carbohydrate intake restricted to \<8% of energy intake after 4pm each day for 28 days. Ad libitum dietary amount, type and pattern followed before 4pm.
223412336|NCT02905981|DRUG|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
223412337|NCT02905981|DRUG|Shohl's solution|Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
224029454|NCT02644486|DRUG|Irbesartan|Irbesartan 300mg/d
223559494|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|10 ml extrafascial interscalene brachial plexus block
223559495|NCT04726280|DRUG|Ropivacaine 0.75% Injectable Solution|20 ml extrafascial interscalene brachial plexus block
223559496|NCT00529347|DEVICE|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
223559497|NCT00938821|PROCEDURE|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
223559498|NCT03038607|DRUG|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
223559499|NCT03195348|OTHER|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
223559500|NCT05191888|DRUG|Vonoprazan and Amoxicillin|14-day vonoprazan high-dose two-in-one therapy
223559501|NCT05191888|DRUG|Vonoprazan, Amoxicillin and Clarithromycin|14-day vonoprazan triple therapy
224135077|NCT02344407|BIOLOGICAL|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
223412338|NCT02905981|DRUG|Triferic|Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
223412339|NCT02113098|OTHER|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
224029455|NCT04340323|OTHER|Pelvic Floor Muscle Training (PFMT)|The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).
224029456|NCT03728777|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
224029457|NCT01058408|RADIATION|Intensity modulated radiotherapy|Administered daily 5 days per week
224029458|NCT01058408|DRUG|RAD001|Taken orally once a day
223412340|NCT02113098|OTHER|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
223559502|NCT05191888|DRUG|Rabeprazole, Amoxicillin, Clarithromycin and Metronidazole|14th Rabeprazole reverse mixed therapy
223559503|NCT00442442|DEVICE|mosquito coils|mosquito coil / night mosquito coil \& LLIN / night
224029459|NCT01058408|DRUG|cisplatin|Administered intravenously once a week
224029460|NCT04017676|OTHER|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
224029461|NCT02279394|DRUG|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 \& 15 Cycles 3-8
224029462|NCT02279394|DRUG|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
224029463|NCT02279394|DRUG|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
224029464|NCT05998538|PROCEDURE|Knee Replacement|Total vs Partial Knee Replacement
224029465|NCT05003440|DRUG|NNC0385-0434|Participants will get 1 tablet (oral use) of NNC0385-0434 per day for 10 days in either 15, 40 or 100 mg
224029466|NCT05003440|DRUG|Placebo|Participants will get 1 tablet (oral use) of placebo per day for 10 days
224029467|NCT01895283|BEHAVIORAL|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
224029468|NCT03829293|DEVICE|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher\&Paykel, New-Zealand)
224135078|NCT02344407|BIOLOGICAL|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
224135079|NCT02344407|BIOLOGICAL|Placebo|
224135080|NCT00213252|DRUG|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
224135081|NCT00213252|DRUG|Prednisolone|Six daily doses of oral prednisolone
223412341|NCT01910545|DRUG|OTS167IV|
223412342|NCT03660189|OTHER|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
223412343|NCT02051140|DIETARY_SUPPLEMENT|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
223412344|NCT02051140|DIETARY_SUPPLEMENT|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
223412345|NCT03761030|DRUG|L-DOPA|We will be using generic sinemet 25/100 tablets in this study.
223412346|NCT03761030|DRUG|Placebo Oral Tablet|25/100 placebo tablets
223559504|NCT00442442|DEVICE|LLIN|Sleep under LLIN every night
223559505|NCT00616811|DRUG|vildagliptin|
223559506|NCT00616811|DRUG|Sitagliptin|
223559507|NCT05645978|DEVICE|Pacemaker insertion|Patients who underwent pacemaker insertion between January 2015 and December 2020
223559508|NCT06457776|PROCEDURE|Dental management|The oral conditions of the included patients will be evaluated at baseline. When indicated, dental extractions will be performed before the beginning of Antiresorptive Therapy. Patients will then receive a six-months intervals follow-up, during which primary and secondary prevention of dental diseases will be performed.
223559509|NCT01460875|BIOLOGICAL|recombinant interferon alfa-2b|Given SC
223559510|NCT01460875|OTHER|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
223559511|NCT00368680|DEVICE|Early Bubble CPAP|
223559512|NCT04644276|DEVICE|Mask with Mask Adhesive/Arm 1|Patients will be randomized to Arm1 if they receive the mask adhesive and mask on the first study night then the mask without the mask adhesive on the second study night.
223559513|NCT04644276|DEVICE|Mask without Mask Adhesive / Arm 2|Patients will be randomized to Arm 2 if they receive the mask without mask adhesive on the first study night then the mask adhesive with the mask on the second study night.
223559514|NCT06163950|OTHER|Fatigability assessment|An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
224135082|NCT06473493|DRUG|Alverine|180 mg/day (1 capsule orally, 3 times a day), taken continuously for 24 weeks
224135083|NCT04032171|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
223412347|NCT04274244|DRUG|Cross-Linked Hyaluronate Gel Prefilled Syringe 30 MG/3ML|"Regenerative periodontal therapy + Cross-linked hyaluronic acid 1.8%:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Hyadent BG® 1,8% filling the bone defect from the bottom upwards in the test group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks."
223412348|NCT04274244|DRUG|Enamel Matrix Proteins (Active comparator group)|"Regenerative periodontal therapy + Enamel matrix proteins:~* The modified minimal invasive surgical technique, described by Cortellini 2011, will be used to raise the interdental papilla over the bone defect.~* Measurement of bone defect with a 0.5mm periodontal probe (PCP-UNC 15, Hu-Friedy Manufacturing, Illinois, USA) to characterize the defect anatomy.~* Inflammatory tissue will be debrided and the root carefully planed using Gracey curettes.~* The site will be washed with physiologic sterile solution, dried and the root wil be conditioned with 24% Ethylenediamine tetraacetic acid (EDTA) for two minutes, then the defect area will be carefully rinsed with sterile saline to remove any residual EDTA.~* Application of Emdogain® filling the bone defect from the bottom upwards in the active comparator group.~* Single internal modified mattress suture (5/0 Vicryl, Ethicon).~* Sutures will be removed after two weeks."
223412349|NCT01860040|DRUG|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
224029469|NCT00723021|DRUG|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
224029470|NCT00723021|DRUG|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
224029471|NCT00723021|DRUG|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
224029472|NCT00723021|DRUG|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
224029473|NCT00723021|DRUG|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
224029474|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
224029475|NCT01502020|DRUG|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
224029476|NCT01502020|DRUG|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
224029477|NCT02673840|DRUG|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
224029478|NCT02673840|DRUG|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
224029479|NCT00348855|OTHER|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
224029480|NCT00348855|BEHAVIORAL|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
224029481|NCT00348855|BEHAVIORAL|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
223412350|NCT01860040|DRUG|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
223412351|NCT01860040|DRUG|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
223412352|NCT05896566|DRUG|Giredestrant|Giredestrant: 30 mg daily, PO from day 1 until the day of re-biopsy/surgery.
224029482|NCT00348855|BEHAVIORAL|Stop Smoking|Minimal intervention
224029483|NCT00348855|BEHAVIORAL|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
224029484|NCT00348855|OTHER|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
224029485|NCT02667977|OTHER|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
224029486|NCT02667977|OTHER|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
224029487|NCT02388685|OTHER|Exercise|Home exercise therapy
224029488|NCT02622958|DRUG|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
224029489|NCT02622958|OTHER|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~* Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~* Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
223412353|NCT05896566|DRUG|Triptorelin|Triptorelin: 3.75 mg IM on day 1. Note: If re-biopsy/surgery cannot be done on day 29 (±3 days) from the first injection, then a second dose of triptorelin should be given on day 29 (±3 days).
223412354|NCT05896566|DRUG|Anastrozole|Anastrozole: 1 mg daily, PO from day 1 until the day of re-biopsy/surgery.
223412355|NCT00863148|DRUG|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
224135084|NCT04032171|DRUG|Avonex®|Participants received avonex® IM injection once a week.
224135085|NCT04032171|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to avonex® once a week.
224135086|NCT04032171|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
224135087|NCT03147339|OTHER|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
224135088|NCT02822534|DRUG|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
224135089|NCT00992784|BIOLOGICAL|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
224298155|NCT03344978|OTHER|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
224298156|NCT03344978|OTHER|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
224298157|NCT04325152|DEVICE|FCSEMS plus Clip|After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
223412356|NCT01931995|DEVICE|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
223412357|NCT01931995|PROCEDURE|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
223559515|NCT05464771|PROCEDURE|Surgery for hip and knee replacement|Elective inpatient surgery for hip and knee replacement
223559516|NCT00640380|OTHER|Nerve stimulation|CPVB with NS
224135090|NCT00992784|BIOLOGICAL|FluarixTM|Single dose, intramuscular injection
224135091|NCT02428530|OTHER|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
224135092|NCT04228692|PROCEDURE|Self-catheterization only|Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.
224135093|NCT04228692|DEVICE|Posterior tibial nerve stimulation + self-catheterization|"Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary."
224135094|NCT02570763|DEVICE|Active tDCS stimulation|
223559517|NCT00640380|OTHER|Loss of resistance to air|CPVB with LOR
223559518|NCT05635396|DEVICE|Wearable, non invasive sensor for seizure detection|The device consists of a chest strap and an electronics module that attaches to the strap. The device stores and transmits vital sign data including ECG, heart rate, respiration rate, body orientation and activity. This sensor will be worn every day (on a 24 hours basis) excepted during weekends for up to 4 weeks.
224029490|NCT01676181|PROCEDURE|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
224029491|NCT01676181|PROCEDURE|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
224029492|NCT02953860|DRUG|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
224135095|NCT02570763|DEVICE|Sham tDCS stimulation|
224135096|NCT05415046|PROCEDURE|Sacral ESPB|Erector spinae plane block performed with 0,25% bupivacaine (1 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
224135097|NCT01231360|OTHER|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
224135098|NCT01231360|OTHER|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
224298158|NCT04325152|DEVICE|FCSEMS|FCSEMS was released as the same as mentioned above. No fixating method was used.
224298159|NCT00997139|DRUG|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
224298160|NCT00787579|DEVICE|Bifocal spectacles|+1.50D bifocal spectacles
224298161|NCT00787579|DEVICE|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
224298162|NCT00313443|PROCEDURE|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
223412358|NCT06968949|BEHAVIORAL|Unadapted Brief Intervention for School Clinicians (BRISC; BR-O)|BRISC is a four-session, individual engagement, assessment, brief intervention and triage strategy for youth age 13-18. BRISC provides a research-based approach to improving structure, efficiency, and effectiveness of school mental health via five elements: (1) Stepped care/tiered structure; (2) Culturally-informed engagement and motivation strategies;(3) Systematic problem-solving framework; (4) Modularized common elements approach; and (5) Structured assessment and monitoring.BRISC is hypothesized to operate on specific mechanisms that influence improvements in efficiency and clinical outcomes.
223412359|NCT06968949|BEHAVIORAL|Brief Intervention for School Clinicians (BRISC) with Implementation Strategies Adapted for School-Employed Practitioners (BR-A)|BR-A is a version of the Brief Intervention for School Clinicians with implementation strategies (IS) adapted for delivery by in the education sector by school-employed practitioners. Although IS modifications will be determined by Study 1 activities, we anticipate that BR-A may include changes to training pacing or format (e.g., asynchronous e-learning modules and videos); adaptations to format/content of consultation; and/ or addition of other ISs to enhance skills development (e.g., development of a learning collaborative) and/or overcome organizational or system barriers (e.g., educational outreach, changes to regulations). Core components of BRISC will be retained in the BR-A condition.
223412360|NCT01700075|DRUG|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
223412361|NCT01700075|DIETARY_SUPPLEMENT|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
223412362|NCT05896501|DEVICE|Fractional Flow Reserve|Functional assessement of anatomical stenosis of coronary artery
224135099|NCT03861546|BEHAVIORAL|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
223412363|NCT05011786|PROCEDURE|hernia repair/ligation of the hernial sac|the inguinal hernia sac is ligated using sutures at the level of internal ring throught an inguinal incision in the open group and using laparoscopic instruments in the laparoscopic group
223412364|NCT02347215|OTHER|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
223412365|NCT02347215|PROCEDURE|Stress imaging|Stress imaging
223412366|NCT02074969|DEVICE|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
223412367|NCT02074969|DEVICE|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
223412368|NCT04685460|OTHER|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images|customized 3D-printed bolus fabricated based on reconstruction of computed tomography (CT) images were used in this study.
223559519|NCT05354609|OTHER|MR-enterography|All patients will undergo a simplified MR-enterography, which includes four sequences, without bowel cleansing or injection. On the same day, the standard MR-enterography will be performed as in clinical practice, after ingestion of the usual oral preparation.
224298163|NCT06360068|DRUG|Sulfasalazine Tablets|All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.
223559520|NCT03090516|DRUG|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
223559521|NCT03090516|DRUG|Donepezil|Arm A：Aricept 5mg/day
224298164|NCT03017118|DIETARY_SUPPLEMENT|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
224298165|NCT03017118|OTHER|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
224298166|NCT01651143|DRUG|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
224298167|NCT01651143|DRUG|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
224298168|NCT04097171|OTHER|Diet|Participants will consume each diet for 14 days in a crossover design.
223412369|NCT01577212|RADIATION|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
223412370|NCT00014495|BIOLOGICAL|filgrastim|
223559522|NCT03090516|DRUG|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
223559523|NCT03625947|OTHER|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
223559524|NCT01289288|BEHAVIORAL|Mailed printed materials and in-office training|"1. Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~2. Two sessions of in-office training with two standardized patients"
224298169|NCT05253365|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
223559525|NCT05895331|DIAGNOSTIC_TEST|Thiol/Disulphide Homeostasis|An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
224029493|NCT05341596|PROCEDURE|repeat endotracheal intubation|repeat endotracheal intubation in the PACU after planned extubation of the initial endotracheal intubation for general anesthesia or combined general anesthesia other than that performed in the operating room
224029494|NCT03327337|PROCEDURE|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
224029495|NCT00770341|DRUG|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
224029496|NCT00770341|DRUG|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
224029497|NCT00770341|DRUG|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
224029498|NCT00603720|DRUG|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
224029499|NCT00603720|DRUG|L-Arginine|aids in nitric oxide production
224029500|NCT00603720|DRUG|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
224029501|NCT03876860|DEVICE|Silicone Dilator|Addition of silicone band to standard vaginal dilator
224029502|NCT03876860|DEVICE|Standard Dilator|Standard vaginal dilator
224029503|NCT04375020|DRUG|GABA|GABA nutritional supplement 750mg per day for 6 months
224029504|NCT06066450|DEVICE|Genoss® DES system, Genoss® Osfit system|This is a drug-eluting stent used to improve the diameter of the coronary artery in patients with symptomatic ischemic heart disease, with de novo lesions in the native coronary artery, where the reference vessel diameter ranges from 2.25mm to 5.00mm.
224298170|NCT00968760|PROCEDURE|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
223412371|NCT00014495|DRUG|cytarabine|
223412372|NCT00014495|RADIATION|bismuth Bi213 monoclonal antibody M195|
223412373|NCT01357317|OTHER|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
223412374|NCT01357317|OTHER|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
223412375|NCT01357317|DRUG|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
224029505|NCT00960531|BIOLOGICAL|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
224029506|NCT00960531|BIOLOGICAL|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
224029507|NCT00960531|BIOLOGICAL|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
223412376|NCT02598232|DEVICE|1,414nm Nd:YAG Laser System|It has high absorption coefficient in water and a short pulse width.
224029508|NCT01455857|DRUG|ITCA 650|ITCA 650 is exenatide in DUROS
224029509|NCT01455857|OTHER|ITCA placebo|Formulation in DUROS (no exenatide)
224029510|NCT03753620|DEVICE|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
224029511|NCT03753620|DEVICE|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
224029512|NCT00637923|DRUG|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
224029513|NCT00637923|DRUG|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
224029514|NCT00637923|BIOLOGICAL|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
223412377|NCT02921685|DRUG|Monalizumab|Four dose levels will be tested.
223412378|NCT01401764|OTHER|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
223559526|NCT03454399|PROCEDURE|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
224029515|NCT00637923|DRUG|Ribavirin|Weight-based ribavirin for 48 weeks.
224029516|NCT00000550|BEHAVIORAL|health education|
224029517|NCT03422588|PROCEDURE|Laparoscopic right colectomy|Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
224029518|NCT05321888|OTHER|Mechanical Ventilation|Standard Protocol
224029519|NCT05321888|OTHER|Mechanical Ventilation with Postural drainage|This Group will be treated by postural drainage and mechanical ventilation for two consecutive days
224029520|NCT02709824|DRUG|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
224298171|NCT00968760|PROCEDURE|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
224298172|NCT00968760|PROCEDURE|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
224298173|NCT00968760|DRUG|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
224029521|NCT02709824|DRUG|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
224029522|NCT04538456|OTHER|questionnaire and optional interview|Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.
224029523|NCT03634514|DRUG|Recombinant human growth hormone - Biomatrop|The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
224029524|NCT03634514|DRUG|Recombinant human growth hormone - Hormotrop|The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
224029525|NCT00883051|DRUG|Lasmiditan|Oral application of one dose of either 50 mg lasmiditan,100 mg lasmiditan, 200 mg lasmiditan, 400 mg lasmiditan or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
224029526|NCT00883051|DRUG|Placebo|Placebo
224029527|NCT01335451|DRUG|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
224029528|NCT01335451|DRUG|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
224135100|NCT04654091|PROCEDURE|Cryoteraphy with liquid nitrogen|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of cryotherapy with liquid nitrogen will be carried out using CryoPen b® (HO Equipment, Hhislenghien-Belgium). To analyze the homogeneous application in all the patients in the study, perform 2 applications of 15 seconds per session, with an interval of 30 seconds between each application, such and as manufacturers recommend. The number of sessions in which the product is applied will be a maximum of 5, following the procedure of previous studies."
224135101|NCT04654091|PROCEDURE|Nitric-zinc complex|"Weekly, at each visit, before applying the treatment, a debridement of the hyperkeratotic tissue covering the wart will be performed with a scalpel handle of number 3 and a scalpel blade of number 15, and then the treatment will be applied.~Subsequently, the application of nitric acid-zinc complex with Verrutop® (Isdin, Barcelona-Spain) will be carried out. The preparation is applied by making small touches with the applicators included in the product.~The number of sessions in which the product is applied will be a maximum of 5, following the recommendations of the manufacturers in the product data sheet."
224135102|NCT04561921|DRUG|Magnesium sulfate|patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
224298174|NCT00968760|DRUG|Carmustine|300 mg/m\^2 IV over 1 hour on Day -6
224298175|NCT00968760|DRUG|Etoposide|200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2
224298176|NCT00968760|DRUG|Cytarabine|200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.
224298177|NCT00968760|DRUG|Melphalan|140 mg/m\^2 IV over 30 minutes on Day -1
223412379|NCT04350125|BIOLOGICAL|Autologous Platelet Rich Plasma|One 4-5mL platelet rich plasma injection administered to each side of the intracavernosal space on the right and left side of the corpus cavernosum at the base of the penis, every two weeks for 6 weeks.
223412380|NCT01045187|RADIATION|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
223412381|NCT01045187|RADIATION|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
223559527|NCT05409053|PROCEDURE|open reduction|the displaced fractures will be treated with open reduction so as to achieve the near anatomical alignment
223559528|NCT05409053|PROCEDURE|Closed reduction|the non displaced fractures will be treated with closed reduction and percutaneous pinning
223559529|NCT05409053|OTHER|Conservative management|the non displaced fractures will be treated with closed reduction and castor slab
223559530|NCT03723330|DIETARY_SUPPLEMENT|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
224029529|NCT01408615|DRUG|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
224029530|NCT01696669|DRUG|Chemotherapy|"* Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8."
224029531|NCT01696669|PROCEDURE|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
224029532|NCT01696669|RADIATION|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response \<90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
224135103|NCT04561921|DRUG|Mepivacaine-Levonordefrin Hydrochloride|patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
224298178|NCT03561441|DRUG|Tailored aggressive hydration|"1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
224029533|NCT02011373|PROCEDURE|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
223412382|NCT05531630|DEVICE|Nasal rinsing with saline 0.9%|"Nasal irrigations with saline (NaCl 0.9%) are considered golden standard in the treatment of chronic rhinosinusitis. Sachets consisting of mixtures for saline solutions, produced by DOS Medical®, consist of 1.875g sodium chloride and 0.625g sodium bicarbonate (figure 5). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the saline solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device and has a CE-label (CNK number 3309028)."
223412383|NCT05531630|DEVICE|Nasal rinsing with Xylitol|"Xylitol is a sugar-alcohol that is already implemented in the treatment of patients with (difficult-to-treat) chronic rhinosinusitis. Some (pilot) studies have already showed a positive effect in CRS patients without cystic fibrosis. Xylitol nasal rinsing salt, produced by DOS Medical®, is a mixture of 4g Xylitol, 1.875g sodium chloride, 0.625g sodium bicarbonate and 0,03g mint (Figure 3). The content of the sachet has to be dissolved in 250mL heated water (lukewarm drinking water, max 37°C) in a NasoFree® nasal irrigator (Figure 4). Afterwards, the solution has to be mixed according to the instructions, the temperature has to be tested on the palm or forearm and afterwards, the product can be used. The patient will be asked to rinse their nose with the Xylitol solution, once daily, for six weeks.~The sachet with rinsing salt is considered to be a class I medical device, has a CE-label (CNK number 3309036) and is already commercially available in Belgium and The Netherlands."
223412384|NCT01780519|DRUG|lorazepam|single dose of 1 mg lorazepam
223412385|NCT00403481|DRUG|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
224029534|NCT05812833|BEHAVIORAL|Education|Pregnant women will be given online baby care training
224029535|NCT05167305|OTHER|This is an observational study|This is an observational study
224029536|NCT02337751|DRUG|TVP-1012 1mg|TVP-1012 1mg Tablets
224029537|NCT02618642|RADIATION|Irradiations of the biceps brachii muscle with PILER light. The participants were randomized into 4 groups: group v - no filter/ group x - red filter/ group y - blue filter/ group z - placebo.|"Biceps brachii examination was carried out before (examination 1) and after (examination 2) a series of 10 PILER light treatments. It included a traditional electrodiagnostic examination and the assessment of the pressure pain threshold (PPT).~The electrodiagnostic examination of the muscle was performed using the unipolar stimulation method from the direct motor point. The passive electrode (6 cm x 6 cm) was attached to the side of the distal part of the forearm, and the distal edge of the electrode was adjacent to the proximal edge of the ulnar styloid process. The examination was performed with a Multitronic MT3 electrotherapy apparatus set.~PPT at the direct motor point was determined using an algometer (Algometer commander TM ITECH Medical Industries). A head with a rubber jacket with a surface area of 0.5 cm2 was used to cause pressure pain. Pressure was exerted until the participant reported pain, at which time the force (lbs) marked by the algometer was recorded."
224029538|NCT04026659|OTHER|Multi-modal exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
224029539|NCT02711969|DRUG|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
224029540|NCT02434068|OTHER|CT|followup
224029541|NCT03373201|DRUG|Tasimelteon|Oral capsule
224029542|NCT03373201|DRUG|Placebo|Oral capsule
224029543|NCT05727345|PROCEDURE|Interscalene brachial plexus block|Preoperative ultrasound-guided interscalene brachial plexus block application
224029544|NCT05727345|PROCEDURE|Shoulder anterior capsular block|Preoperative ultrasound-guided shoulder anterior capsular(SHAC) block application
224029545|NCT00832182|DRUG|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
224029546|NCT00832182|DRUG|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
224029547|NCT01513577|OTHER|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
224029548|NCT01513577|OTHER|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
224029549|NCT05810454|DEVICE|iPACES (interactive Physical and Cognitive Exercise System)|"iPACES involves a pedal-to-play neuro-exergame in which physical and mental exercise are combined in an interactive way. In this condition a person will pedal to control forward motion in a tablet-based game, such as when pedaling along a virtual path and steering to different assigned errand locations."
223412386|NCT00403481|DRUG|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
223412387|NCT01537926|DRUG|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
223412388|NCT01537926|DRUG|Placebo|sugar pill manufactured to minic NAC 600mg capsule
223412389|NCT04571905|DEVICE|Osteosynthesis with resorbable Material|Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
223412390|NCT05553990|OTHER|intestinal flora disturbance|To observe the clinical prognosis of stroke patients complicated with tumor after enterobacterial disorder
223412391|NCT05988177|DRUG|Carrimycin tablets|Carrimycin tablets are administered 400mg a day orally for 7 days.
224029550|NCT05810454|DEVICE|PACE (Physical and Cognitive Exercise)|"PACE involves a pedal-while-play experience in which physical and mental exercise are combined in a simultaneous, but not fully interactive way. In this condition a person will pedal while also separately steering in a tablet-based game, such as when pedaling while automatically progressing along a virtual path to different assigned errand locations."
224029551|NCT02391779|DIETARY_SUPPLEMENT|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
224029552|NCT02391779|BEHAVIORAL|Walking training|30-60 minutes walking training, 5 days/week.
224298179|NCT03561441|DRUG|Tailored standard hydration|"1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
223412392|NCT05974878|OTHER|Exercise|"* Joints targeted by exercise; bilateral wrist, metacarpophalangeal, proximal and distal interphalangeal joints, elbow and shoulder joints.~* The muscles targeted by the exercises; lumbricals, iinterosseals, thenar and hypothenar muscles, forearm flexors, forearm extensors, forearm supinators and pronators, elbow flexors and extensors, and shoulder girdle muscles.~* Content of the exercises; There will be warm-up exercises, pinch grip, full grip, nerve and tendon gliding exercises, exercises that improve proprioception, functional exercises, strengthening exercises and stretching exercises."
223412393|NCT05974878|OTHER|Conventional Physiotherapy|For control group there will be aerobic exercise recommendation and resistive exercises focused on upper extremity.
223412394|NCT03028688|DEVICE|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
223412395|NCT03941054|OTHER|Pressure Release|Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
223412396|NCT02175511|DEVICE|Cloud-based home BP monitoring|"a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network."
223412397|NCT06070142|PROCEDURE|TEP Group|Inguinal hernia surgery will be performed with the TEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
223412398|NCT06070142|PROCEDURE|eTEP Group|Inguinal hernia surgery will be performed with the eTEP method and the 15x12x10 cm polyprolene patch used in this surgery will be marked with small metallic clips from the lateral, superomedial and inferomedial sides.
223559531|NCT03723330|OTHER|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
224029553|NCT02391779|BEHAVIORAL|Flexibility training|5 days/week; e.g. stretching training at home
224029554|NCT02391779|DIETARY_SUPPLEMENT|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
224029555|NCT02391779|BEHAVIORAL|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
224029556|NCT01006473|OTHER|Exercise training|
224029557|NCT01910181|DRUG|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
223559532|NCT00499512|BEHAVIORAL|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
224029558|NCT02070224|OTHER|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
224029559|NCT02070224|OTHER|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
224029560|NCT05663437|OTHER|Core stabilization exercises|6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.
224029561|NCT05663437|OTHER|Core stabilization exercises + neural mobilization technique|"6 core stabilization exercises including: dead bug, side lying, prone, bird dog, bridging, planks (1x10 reps for 15-30 secs each exercise) 3 alternative days a week, for 4 weeks.~Neural mobilization technique (SLR intervention for first 2 weeks and slider intervention for last 2 weeks)."
224029562|NCT02842320|OTHER|biological samples|bone marrow and blood
224029563|NCT05397834|DRUG|Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|2 inhalations of Test and Reference product in each study period
224029564|NCT05397834|DRUG|FLOVENT DISKUS|2 inhalations of Test and Reference product in each study period
224029565|NCT00408252|OTHER|biopsies|No intervention, only biopsy for translational project
223412399|NCT00149344|RADIATION|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
223412400|NCT02464943|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
224029566|NCT00408252|DRUG|SU011248|no intervention
223412401|NCT03278223|DEVICE|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
224135104|NCT02035982|DRUG|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
223412402|NCT03278223|DEVICE|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
223412403|NCT03496896|OTHER|TARGET|The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
223412404|NCT04429789|BEHAVIORAL|Active-Alert Hypnosis|Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
224029567|NCT01350310|PROCEDURE|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
224029568|NCT01350310|PROCEDURE|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
224029569|NCT01350310|PROCEDURE|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage \>6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
224029570|NCT00285220|PROCEDURE|Laparoscopic Truncal Vagotomy|
224029571|NCT02174042|DRUG|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
224029572|NCT00665912|PROCEDURE|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
224029573|NCT00665912|PROCEDURE|Standard post-lobectomy wound care|Standard post-lobectomy wound care
224029574|NCT04672226|DIETARY_SUPPLEMENT|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
224298180|NCT03075319|PROCEDURE|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
224298181|NCT03075319|PROCEDURE|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
224298182|NCT03667079|OTHER|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
223412405|NCT04429789|BEHAVIORAL|Traditional Hypnosis|Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
224029575|NCT02662101|DEVICE|Exsalt SD7, Exsalt T7 Wound Dressing|
224135105|NCT02035982|DRUG|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
224135106|NCT05186766|DEVICE|Video-Assisted Operating Room Introduce Program|Video demonstration about operation room
224135107|NCT03453021|DRUG|Mepolizumab|
224135108|NCT00398957|DRUG|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
223412406|NCT02099110|DRUG|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
224135109|NCT02795546|DRUG|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
224135110|NCT02795546|BIOLOGICAL|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
224135111|NCT01363713|DRUG|DE-114 ophthalmic solution|
224135112|NCT03173586|OTHER|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
224135113|NCT02051725|OTHER|Active life-style intervention|
224135114|NCT03798249|OTHER|Gluten|Tereos
224135115|NCT03798249|OTHER|Placebo|Nestlé Health Science
224135116|NCT00399594|PROCEDURE|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
224135117|NCT00399594|PROCEDURE|B|LV lead placement in standard (lateral / posterolateral) position.
224135118|NCT01102218|DRUG|Erythropoietin|Standard of Care
224135119|NCT01102218|DRUG|Erythropoietin|Standard of Care
224135120|NCT01102218|DRUG|Pentoxifylline|400 mg qd po for 6 months
224135121|NCT00803543|DRUG|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
224135122|NCT00803543|DRUG|Placebo|Dosage: Two tablets once a day for 24 weeks
224298183|NCT03667079|OTHER|Mass deworming only|Delivery of mass deworming to people only
224298184|NCT03667079|OTHER|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
224298185|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Legacy lidstock|CONTROL
224029576|NCT07020208|BEHAVIORAL|Transition Shock skills|"* Assign experienced nurse mentors to new graduates.~* Conduct weekly one-on-one meetings for the first three months, then biweekly for ongoing support.~* Discuss challenges, successes, and strategies for coping with difficult situations.~* Provide case study reviews where mentors guide mentees through real-world nursing scenarios.~  * Skills Applied: interpersonal communication. 2. Peer Support Groups~ * Content:~* Establish weekly or biweekly group discussions where nurses share challenges and coping strategies.~* Use reflective journaling prompts to encourage discussion.~* Introduce role-playing exercises for dealing with complex patients, staff conflicts, and ethical dilemmas."
223412407|NCT02099110|DRUG|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
223559533|NCT04399863|BEHAVIORAL|ETOILE therapeutic education|ETOILE is a patient education program, in accordance with French recommendations, which offers to patients and caregivers the opportunity to follow a customized educational training on their disease. Better quality of life and enhanced autonomy are the aim of this program.
224135123|NCT03299738|BIOLOGICAL|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg
224135124|NCT03747744|OTHER|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
224135125|NCT02930369|PROCEDURE|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
224135126|NCT05603507|OTHER|inspiratory muscle training|training done with a pressure threshold-loading device
224135127|NCT05603507|OTHER|pulmonary rehabilitation|Circuit training of aerobic and resistive exercise
224135128|NCT02297113|DEVICE|Macintosh blade|conventional endotracheal intubation
224135129|NCT02297113|DEVICE|C-MAC videolaryngoscope|
223412408|NCT02099110|DRUG|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
223412409|NCT02099110|DRUG|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
223412410|NCT02099110|DRUG|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
223412411|NCT02099110|DRUG|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
223412412|NCT02099110|DRUG|Metformin >= 1500 mg/day|Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
223412413|NCT02099110|BIOLOGICAL|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
223412414|NCT02099110|DRUG|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
223412415|NCT02064816|DRUG|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
223412416|NCT02064816|DRUG|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
223412417|NCT00735813|DEVICE|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
223412418|NCT00735813|DEVICE|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
223412419|NCT04129957|PROCEDURE|Placement of dental implants|All the included patients underwent the placement of at least one implant in either upper jaw, or lower jaw, or both.
223559534|NCT04590430|DRUG|HFB30132A|Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
223559535|NCT04590430|OTHER|Placebo|Participants randomized to placebo will receive the same volume of solution as participants on active treatment.
223559536|NCT02903225|BEHAVIORAL|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
223559537|NCT01557257|DRUG|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
224135130|NCT05046678|DIAGNOSTIC_TEST|Control|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and nonsmokers if they had no previous history of smoking
224135131|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontally healthy|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
224135132|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and nonsmokers if they had no previous history of smoking
224135133|NCT05046678|DIAGNOSTIC_TEST|Smokers with gingivitis|without attachment and alveolar bone loss who had gingival inflammation, PD ≤ 3 mm and BOP \> 30% in the full mouth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
224135134|NCT05046678|DIAGNOSTIC_TEST|Non-smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and nonsmokers if they had no previous history of smoking
224135135|NCT05046678|DIAGNOSTIC_TEST|Smokers with periodontitis|interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth and smokers if they had smoked ≥10 cigarettes/day for ≥5 years
224298186|NCT05713552|DEVICE|Acuvue Oasys 1 Day for Astigmatism with Amcor laminated lidstock|TEST
224298187|NCT04835649|OTHER|Exercise|Both groups will receive exercise-based training
224298188|NCT03421158|BEHAVIORAL|breastfeeding|Newborns were breastfed during the procedure
223559538|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
223559539|NCT01557257|DRUG|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
223559540|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
223559541|NCT01557257|DRUG|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
224029577|NCT06704334|OTHER|Median nerve electrical stimulation treatment|Median nerve electrical stimulation is an electrical stimulation therapy in which the electrode is placed at the median nerve point 2cm above the carpal wrinkles on the palmar surface of the wrist joint. Generally, the right median nerve is used for electrical stimulation. Electrical stimulation improves cognitive function by stimulating neurons in the brain and improving information transmission between neurons. When electrical current stimulates the brain, it can increase the activity level of neurons and promote the signal transmission between neurons. Its mechanism of action includes the regulation of neurotransmitter acetylcholine, thereby enhancing cognitive function.
224029578|NCT06704334|DRUG|Huperzine A injection|intramuscular
224029579|NCT06704334|DRUG|Ginkgo leaf dropping pill|oral
224029580|NCT01215422|PROCEDURE|timed intubation|timed intubation
224029581|NCT04925206|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion following myeloablative conditioning with busulfan.
224029582|NCT01816854|DEVICE|Stenting|
224029583|NCT01875172|DRUG|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
224029584|NCT01875172|DRUG|placebo|
223559542|NCT01557257|DRUG|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
224029585|NCT01875172|BEHAVIORAL|smoking cessation counseling|
224029586|NCT03330457|BIOLOGICAL|Andexanet alfa (bolus)|fXa inhibitor antidote
224029587|NCT03330457|DRUG|Betrixaban 80 mg PO QD|fXa inhibitor
224029588|NCT03330457|BIOLOGICAL|Andexanet alfa (infusion IV)|fXa inhibitor antidote
224135136|NCT05398276|BEHAVIORAL|Behavioral Exposure For Introceptive Tolerance|BE-FIT will consist of a 6-session one-on one program with a clinician that are approximately 45 minutes delivered, over the course of 3 weeks (twice/week). Sessions will coincide with scheduled cardiac rehabilitation sessions at RWJ Cardiac Rehabilitation Program. The elements of BE-FIT are (1) psychoeducation about avoidance/anxiety and values clarification and committed action for exercise and lifestyle PA; (2) graded, repeated exposure to bodily sensations and exercise to build tolerance of discomfort; (3) fading safety behaviors and elimination of exercise avoidance behaviors to promote tolerance of uncertainty and reduce catastrophizing; and (4) use of Fitbit activity tracker to facilitate physical activity monitoring and provide physical activity feedback and goal-setting.
224298189|NCT03421158|DIETARY_SUPPLEMENT|oral sucrose|Newborns were given oral sucrose during the procedure
224298190|NCT03421158|BEHAVIORAL|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
223559543|NCT01667224|DIETARY_SUPPLEMENT|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
223559544|NCT01667224|DIETARY_SUPPLEMENT|Placebo|Amount and calorie of placebo are same with Actiponin.
223559545|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system with bone cement.
223559546|NCT05377450|DEVICE|Engage Partial Knee|Unicompartmental knee arthroplasty utilizing the Engage Partial Knee system without bone cement.
224029589|NCT04142450|DEVICE|CoolSculpting® System|Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
224029590|NCT02262143|DRUG|Rosuvastatin|Rosuvastatin 10 mg, qd, po
224029591|NCT02262143|DRUG|Fenofibrate|Fenofibrate 160mg, qd, po
223559547|NCT01222091|DRUG|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
223559548|NCT01222091|DRUG|Placebo to Match Propranolol|
223559549|NCT01222091|DRUG|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
224029592|NCT01767207|OTHER|mental disorders|mental disorders
224029593|NCT01767207|BEHAVIORAL|screening for mental disorders|screening for mental disorders
224029594|NCT00474669|DRUG|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
224029595|NCT00480584|DRUG|gemcitabine|Levels 1 through 4: 1000 mg/m\^2
224029596|NCT00480584|DRUG|capecitabine|Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2
224029597|NCT00480584|DRUG|erlotinib|Levels 1 through 4: 100 mg
224029598|NCT05579158|BEHAVIORAL|Mobile application and wearable device|Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
224029599|NCT05579158|BEHAVIORAL|Time-restricted eating|Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
224029600|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
224029601|NCT00695617|DRUG|trisodiumcitrate|trisodiumcitrate 1.035 M
224029602|NCT01177605|OTHER|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
224029603|NCT05545605|DRUG|Sodium oligomannate|Patients with acute ischemic stroke were recruited, and after signing informed consent, those who met the inclusion/exclusion criteria were randomly assigned in a 1:1 ratio to receive treatment in the trial group (receiving sodium oligomannate)
224029604|NCT05545605|DRUG|Placebo capsule|the control group (receiving placebo capsule) for 24 weeks.
223412420|NCT04781283|DEVICE|measurement of endothelial cell density by specular microscopy|"During this first appointment (T0), in addition to the usual treatment, measurement of the endothelial cell density by specular microscopy will be carried out on the affected eye (basal cell density). To overcome the variability linked to the machine, three consecutive measurements will be taken; the average of the three measurements will be used.~As part of his post-operative follow-up, the patient will be reviewed at one month, one year, two years, three years, four years and five years after the operation. During these consultations and as part of the research, a new determination of the cell density (3 consecutive measurements) by specular microscopy of the operated eye and an evaluation of the position of the XEN implant will be carried out each time. ® by OCT scan for patients having undergone this surgery."
223412421|NCT06149611|DRUG|[14C] TQB3616|TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.
223412422|NCT01435304|DEVICE|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
224029605|NCT03450798|DEVICE|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
224029606|NCT03450798|DEVICE|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
224029607|NCT02544217|DRUG|KH176|
224029608|NCT02544217|DRUG|placebo|
224029609|NCT00861835|OTHER|ROSE|rapid on-site evaluation by cytopathology
224029610|NCT05844514|DIAGNOSTIC_TEST|Breath test|Patients must be fasted for a minimum of 4-6 hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.
224029611|NCT05171439|DRUG|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
224029612|NCT00647673|DRUG|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
224029613|NCT00647673|DRUG|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
224029614|NCT02883283|PROCEDURE|Epidural loading dose|Labor epidural analgesia loading dose
224029615|NCT02883283|DEVICE|Epidural catheter|Epidural loading dose via epidural catheter
224029616|NCT02883283|DEVICE|Epidural needle|Epidural loading dose via epidural needle
224135137|NCT05398276|BEHAVIORAL|Health Education Control|HEC is a time-matched control intervention that will be administered on the same delivery schedule as BE-FIT. The intervention content includes: (1) educational information about health topics relevant to healthy aging, and (2) Use of the Fitbit activity watch for PA monitoring. The 6 topics introduced in the HEC include: nutrition, sleep, brain health, emotional health, living with chronic conditions, how to be a smart patient. The health information will be conveyed through lectures and handouts. The goal of sessions will be to provide education, particularly as it relates to healthy aging. Patients will be given the same Fitbit as in the BE-FIT but will not be given PA goals.
224135138|NCT01658579|DRUG|HOE901-U300 (new formulation of insulin glargine)|
224135139|NCT01658579|DRUG|Lantus (insulin glargine)|
224135140|NCT02040883|DRUG|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
224135141|NCT02040883|DRUG|Tandospirone|Tandospirone，30mg per day
223412423|NCT06211686|OTHER|Protein powder and Resistance exercise|"1. Protein powder supplementation 25-30 g/day~2. Resistance exercise 2 time/week"
223412424|NCT06578325|OTHER|Thai dance meditation|Thai dance meditation training program will be based on aerobic Thai dance exercise combined with Buddhist meditation. The participants will perform aerobic Thai dance meditation while concentrated on hand movements through counting the numbers 1 2 3 4 5 6 7 1 on the 1st round and continuing on the 2nd round, counting as 1 2 3 4 5 6 7 2…. Repeat for 8 rounds. Thai dance meditation will be conducted at mild to moderate intensity (40-60% heart rate reserve) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (50-60% heart rate reserve). In both phases the training will be performed foe 50 minutes, 3 times per week.
223412425|NCT06578325|OTHER|No intervention|No intervention
223412426|NCT06237530|BEHAVIORAL|Visceral body scan (VBS)|The VBS consisted of a mindfulness exercise designed to bring awareness to visceral sensations in the cardiac, respiratory, gastrointestinal, and urinary systems. These physiological systems were chosen because most of the paradigms developed in the literature to assess interoception focus on them (Khalsa et al., and they are widely recognized in the literature as interoceptive senses (Nord \& Garfinkel, 2022)
223559550|NCT00395187|PROCEDURE|Photodynamic Therapy|
223559551|NCT01280058|DRUG|Carboplatin|Given IV
223559552|NCT01280058|OTHER|Laboratory Biomarker Analysis|Correlative studies
224029617|NCT02598752|OTHER|Symptom-limited cardiopulmonary exercise test (CPET)|
224029618|NCT02598752|OTHER|Resting assessment of cardiac function by echocardiography|
224029619|NCT02598752|OTHER|Post-exercise assessment of cardiac function by echocardiography|
224029620|NCT02598752|OTHER|Pulmonary function|
223559553|NCT01280058|DRUG|Paclitaxel|Given IV
223559554|NCT01280058|BIOLOGICAL|Wild-type Reovirus|Given IV
223559555|NCT02839187|RADIATION|Neuroimaging|AV45-positron emission tomography
224029621|NCT02598752|BEHAVIORAL|Patient-reported outcomes questionnaire|
224135142|NCT01410266|OTHER|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
224298191|NCT03421158|BEHAVIORAL|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
224029622|NCT01744951|BEHAVIORAL|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
224029623|NCT02422056|DRUG|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
224029624|NCT02422056|DRUG|Saline|Infusion of saline in the same rate used for the intervention group
224029625|NCT04335812|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
224029626|NCT02065141|OTHER|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
224029627|NCT02113241|DRUG|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
224029628|NCT02113241|DRUG|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
224029629|NCT06328426|DIETARY_SUPPLEMENT|Vitamin D|The dose of Vitamin D will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
224029630|NCT06328426|DIETARY_SUPPLEMENT|Omega-3|The dose of omega-3 will be 1000 mg /day taken orally. The duration of the intervention will be 4 months.
224029631|NCT06328426|DRUG|Metformin|The dose of metformin will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
224029632|NCT06328426|DIETARY_SUPPLEMENT|Placebo|The duration of the intervention will be 4 months.
224029633|NCT02818088|BEHAVIORAL|n-Back (Cognitive Training)|
224029634|NCT04847960|DIETARY_SUPPLEMENT|BioGaia Probiotic Lozenges|BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
224029635|NCT04174079|DRUG|chemotherapy|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
224029636|NCT02090374|OTHER|Poly ICLC|Dose escalation: 10ug, 100ug, 500ug Highest dose: 1000ug
224029637|NCT02090374|OTHER|Poly I:C|Single dose: 500ug
224029638|NCT02090374|OTHER|R848|High dose: 10ug Low dose: 1-2ug
224029639|NCT02090374|OTHER|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
224029640|NCT02090374|OTHER|Vitamin D|4000U orally
224029641|NCT02090374|OTHER|Tuberculin|Tuberculin PPD
224029642|NCT00216697|DRUG|bortezomib|
224029643|NCT02901041|DRUG|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
224029644|NCT02901041|BEHAVIORAL|Take Control|"Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic"
224029645|NCT02901041|DRUG|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
224029646|NCT01249937|DRUG|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
224029647|NCT01249937|DRUG|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
223412427|NCT06237530|BEHAVIORAL|Somatosensory body scan (SBS)|The SBS consisted of a mindfulness exercise designed to bring awareness to tactile (e.g., itching) and musculoskeletal (e.g. g., tension) sensations in different parts of the body, namely, the head and neck, back, arms, and legs. Body scan exercises typically focus on these types of bodily cues (in addition to breathing) (Williams, 2010).
223412428|NCT06237530|BEHAVIORAL|External control meditation (ECM)|The ECM consisted of a mindfulness exercise designed to bring awareness to external stimuli, including sounds and visual properties of the environment.
223412429|NCT01307592|BIOLOGICAL|rituximab|
224029648|NCT00337519|PROCEDURE|allogeneic stem cell transplantation|see detailed description
224029649|NCT00337519|DRUG|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
224029650|NCT03890419|DEVICE|Green light|Green light exposure
224029651|NCT03890419|DEVICE|Clear light|Full spectrum light exposure
224029652|NCT03890419|DEVICE|Blue Light|Blue light exposure
224029653|NCT04744051|DRUG|50 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 50 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
224029654|NCT04744051|DRUG|150 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 150 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
224135143|NCT03702530|BIOLOGICAL|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
224029655|NCT04744051|DRUG|300 Adipose Derived Stem Cell Infusion|Each participant in this arm will receive a single dose of 300 million cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour.
224029656|NCT04744051|DRUG|Placebo Infusion|Each participant in this arm will receive a single dose of placebo. Upon completion of the study each placebo participant will with be given the option to be treated with their cultured adipose derived stem cells derived from their own adipose (fat) tissue via infusion therapy delivery over the course of one hour. Dosage for the crossover will be determined by the PI following review of data collected from the other arms of the study.
224029657|NCT00975507|BIOLOGICAL|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
224135144|NCT03702530|OTHER|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
224135145|NCT03702530|BIOLOGICAL|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
224135146|NCT00183950|DRUG|Noscapine|
224135147|NCT01889654|OTHER|Venous blood sampling|
224135148|NCT04460417|BEHAVIORAL|Enhanced Care|The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
224135149|NCT04460417|BEHAVIORAL|TAU|"Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking."
224298192|NCT00821873|OTHER|CR Plug|CR Plug will be placed in the harvest site
224135150|NCT02299063|DRUG|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
224135151|NCT02299063|DRUG|0.9% NaCl|
223412430|NCT01307592|DRUG|gemcitabine hydrochloride|
223412431|NCT01307592|DRUG|lenalidomide|
223412432|NCT01307592|DRUG|oxaliplatin|
223412433|NCT05099185|BIOLOGICAL|Water-soluble vitamins and trace elements measures|We would like to measure water-soluble vitamins (B1, B6, B9, B12, C) and trace elements (zinc, selenium) in blood and dialysate for the patients treated by online post-dilution hemodiafiltration patients. There measures on blood are done systematically during the half-yearly report of our patients in our hemodialysis center. Only results are collect for the study.
223412434|NCT02641418|OTHER|Supervised exercise programme|supervised exercise programme
223412435|NCT00934336|OTHER|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
224029658|NCT00975507|BIOLOGICAL|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
224029659|NCT00975507|BIOLOGICAL|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
224029660|NCT00975507|BIOLOGICAL|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
224029661|NCT01659619|DRUG|Erythromycin|125mg in normal saline single use infusion for 5 min.
224135152|NCT01362686|DRUG|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
224298193|NCT06084962|BIOLOGICAL|DeepTag-GPRC5D Targeted CAR T-cells|Each subject receive DeepTag-GPRC5DTargeted CAR T-cells by intravenous infusion
224029662|NCT03243045|PROCEDURE|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
224029663|NCT04047238|OTHER|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~* Welcome to the patient and reality orientation therapy (7 minutes)~* Conducting the main activity of reminiscence (40 minutes)~* Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
224029664|NCT00493545|BIOLOGICAL|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
224029665|NCT03404765|BEHAVIORAL|Tai Chi|
224029666|NCT06441188|DIAGNOSTIC_TEST|Thin layer conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin layer of conventional ultrasound coupling gel.
224298194|NCT06214169|DRUG|Cisatracurium Besylate|Addition of cisatracurium to plain lignocaine for IVRA.
224298195|NCT06214169|DRUG|Lignocaine|Plain Lignocaine for IVRA
224298196|NCT02453776|DRUG|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
224298197|NCT00754403|DRUG|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
224298198|NCT00754403|DRUG|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
224135153|NCT01362686|DRUG|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
223412436|NCT00934336|OTHER|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
224029667|NCT06441188|DIAGNOSTIC_TEST|Thick layer of conventional ultrasound coupling gel|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick layer of conventional ultrasound coupling gel.
224029668|NCT06441188|DIAGNOSTIC_TEST|Thin conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thin conventional ultrasound coupling gel pad.
224135154|NCT01362686|DRUG|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
223412437|NCT05750602|DIETARY_SUPPLEMENT|LIMICOL|Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
223412438|NCT05750602|DIETARY_SUPPLEMENT|PLACEBO|Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
223412439|NCT01959464|DRUG|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
223412440|NCT01959464|DRUG|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
224135155|NCT03096223|DRUG|KHK4083|IV administration
224135156|NCT02566941|DEVICE|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
224135157|NCT02108951|DRUG|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
224135158|NCT02176395|DRUG|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
224135159|NCT02176395|PROCEDURE|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
224135160|NCT02176395|DRUG|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
224135161|NCT02002806|OTHER|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
224135162|NCT02002806|OTHER|Placebo Injection|
224135163|NCT02763878|PROCEDURE|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
224135164|NCT02763878|PROCEDURE|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
224135165|NCT03650686|OTHER|Food weighing (gold standard)|Method which consists in weighing precisely the main dish at the beginning and then end of meal using a SOEHNLE scale (+/- 1g).
224135166|NCT03650686|OTHER|Automated photographic method (method to be evaluated)|The nursing staff will position the tray for automatic picture taking before and after the meal. Taking a photograph of the entire tray will allow the patient's identity to be identified by his meal card which will then be coded for analysis and the plate will be targeted at the time of the nutritional analysis by the software. This method will automatically provide the percentage of each main dish food consumed using an advanced image processing algorithm and an optimized artificial intelligence system that will recognize the food before and after consumption. Automatic processing and transfer will enable food intake to be collected.
224135167|NCT03650686|OTHER|Semi-quantitative method (routine method)|Staff will indicate whether 1, ¾, ½, ¼ or 0 (corresponding to 100%, 75%, 50% 25% or 0) of the food in the main course has been consumed.
224135168|NCT00895518|BEHAVIORAL|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
224135169|NCT03806179|DRUG|10 MBq/kg Betalutin|10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
224135170|NCT03806179|DRUG|15 MBq/kg Betalutin|15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
224135171|NCT02310828|DRUG|Acetium|Capsule for oral administration contains L-cysteine 100mg
224135172|NCT02310828|DRUG|Placebo|A placebo capsule matching Acetium for oral administration.
224135173|NCT01769417|DRUG|Placebo|Placebo
223412441|NCT04341805|PROCEDURE|PrevOmega|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of AGHO depending on the randomization performed.
223412442|NCT04341805|PROCEDURE|Physiological saline|The intervention consisted of placing a prosthesis at the umbilical trocar level with subsequent application of SSF depending on the randomization performed.
223412443|NCT01732458|DRUG|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
223412444|NCT01732458|DRUG|Placebo to Aprepitant|
223412445|NCT01732458|DRUG|Ondansetron|Administered IV at a dose of 4 mg for participants \>40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants \<1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
223412446|NCT01732458|DRUG|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
223412447|NCT00002435|DRUG|Thymic Humoral Factor|
224029669|NCT06441188|DIAGNOSTIC_TEST|Thick conventional ultrasound coupling gel pad|The GE Logiq E10 ultrasound scanner and the ML6-15 linear probe will be used to collect B-mode images of the nipple-areolar complex following routine clinical imaging practice, using a thick conventional ultrasound coupling gel pad.
224029670|NCT00194766|DRUG|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
224029671|NCT06024681|OTHER|Faecal microbiota transplant|Capsulised faecal microbiota transplant prepared from rationally selected donor, based upon donor metabolomic charateristics
224029672|NCT03249714|DRUG|Ofatumumab|Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
224029673|NCT03249714|DRUG|Matching placebo of ofatumumab|Matching placebo in pre-filled syringes
224029674|NCT04877795|DIAGNOSTIC_TEST|Blood sampling|Blood will be sampled from enrolled patients and analyzed for levels of troponin, copeptin and heart-type fatty acid binding protein (HFABP).
224029675|NCT02882113|DRUG|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
224029676|NCT05512754|DRUG|Ibuprofen 400 mg|400 mg tablet
224135174|NCT01769417|DRUG|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
224135175|NCT01987167|DRUG|ACTHAR|Injectable Gel
224135176|NCT00116857|DRUG|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
224135177|NCT00116857|DRUG|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
224135178|NCT02375633|DRUG|DW-330SR2|
224135179|NCT02375633|DRUG|Pelubiprofen|
224298199|NCT05842421|DEVICE|optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography|each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
223412448|NCT00002435|DRUG|Zidovudine|
224029677|NCT05804760|DIAGNOSTIC_TEST|Measurement of implant parameters|"1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption."
224029678|NCT01996813|DEVICE|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
224029679|NCT00605644|DRUG|MOA-728|Oral Capsules
224029680|NCT00605644|DRUG|Placebo|Placebo
224029681|NCT03497754|DEVICE|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
224029682|NCT00219453|DEVICE|Jet Injector with Protector Cap (HSI-500)|
224029683|NCT03376945|DRUG|trail cohort|"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
224029684|NCT03376945|DRUG|control cohort|"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
224135180|NCT03998475|BEHAVIORAL|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
224135181|NCT04507477|BIOLOGICAL|Rituximab|For EBV seropositive lungs meant for an EBV seronegative recipient, one dose of rituximab (500mg) will be added to the EVLP perfusate and be allowed to circulate for 3-4 hours.
224135182|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
224135183|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
224135184|NCT00608530|BEHAVIORAL|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
224135185|NCT00608530|BEHAVIORAL|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
224135186|NCT04217889|OTHER|Questionnaire|Short questionnaire that can be completed during the usual consultation.
224298200|NCT02161250|DIETARY_SUPPLEMENT|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
224298201|NCT02161250|DIETARY_SUPPLEMENT|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
223559556|NCT01505673|DRUG|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
223559557|NCT01505673|DRUG|Saline|Placebo injection of 1.8mg saline once daily for 6-months
224029685|NCT05273216|DIAGNOSTIC_TEST|Transcranial Duplex Sonography|Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.
224029686|NCT05273216|DIAGNOSTIC_TEST|Brain MRI|The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
224029687|NCT05273216|DIAGNOSTIC_TEST|Blood biomarkers|"Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz."
224029688|NCT06016309|OTHER|There is no intervention.|There is no intervention.
224029689|NCT04805190|BEHAVIORAL|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
224029690|NCT04805190|BEHAVIORAL|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
224029691|NCT01306097|DRUG|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
224029692|NCT00379743|BEHAVIORAL|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
224029693|NCT00379743|BEHAVIORAL|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
224135187|NCT05383729|OTHER|learning-curve-based training modality|It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
224135188|NCT05383729|OTHER|fixed-training-time training modality|It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
224135189|NCT01434888|DRUG|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
224135190|NCT01434888|DRUG|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
224135191|NCT01434888|DRUG|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
224135192|NCT01357915|PROCEDURE|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
223412449|NCT05517668|DRUG|Intravenous infusion of N-acetylcysteine|If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.
224135193|NCT01357915|BIOLOGICAL|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
224135194|NCT00220766|DRUG|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
224135195|NCT00220766|DRUG|Dextrose, 5% in Water|
224135196|NCT02671942|DRUG|Roflumilast|
224135197|NCT02671942|DRUG|Placebo|
224135198|NCT00239772|BEHAVIORAL|Cognitive Processing Therapy|
224135199|NCT00239772|BEHAVIORAL|Prolonged Exposure Therapy|
224135200|NCT02841787|BEHAVIORAL|iCBT for late life depression|
224135201|NCT00607958|DRUG|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
224135202|NCT06418776|OTHER|Intensive therapy|Intensive chemotherapy courses (MEC, FLAG, FLAG-Ida, FLAG-Mito)
224135203|NCT06418776|OTHER|Low intensity therapy|Low intensity therapy (Aza+Ven, Dac+Ven, LDARA-C+Ven)
224135204|NCT01763268|BIOLOGICAL|Trivivac vaccine|Trivalent MMR vaccine
224135205|NCT00207103|DRUG|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
224135206|NCT00207103|DRUG|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
224029694|NCT02679131|DRUG|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
224029695|NCT02866084|DEVICE|Device|"The following parameters will be set for active treatments using the CVS Device:~* A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~* The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
223412450|NCT05517668|DRUG|Intravenous infusion of Fomepizole (4-MP)|If randomized to fomepizole, the proposed infusion schedule for fomepizole closely mirrors the dosing outlined in the medication's package insert. Specifically, the Antizol (fomepizole) doses (bags) #1-5 allocated for the study will precisely adhere to the manufacturer's recommendations from the package insert. This entails an initial loading dose of 15 mg/kg followed by four subsequent doses of 10 mg/kg. The dose of fomepizole will not be adjusted based on age, presence of liver injury or renal insufficiency.
223412451|NCT00880113|PROCEDURE|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
223412452|NCT03146949|DEVICE|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
223412453|NCT03146949|DEVICE|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
223412454|NCT03280602|PROCEDURE|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
223412455|NCT03280602|PROCEDURE|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
223412456|NCT02638584|DRUG|Ilaprazole|Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast
223412457|NCT02638584|DRUG|Rabeprazole|Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
223559558|NCT05985993|DEVICE|low-intensity transcranial ultrasound stimulation (TUS)|The rTUS was administered using an immersion-type focused ultrasound transducer (V391-SU, Olympus NDT, Waltham, USA). Low-intensity transcranial ultrasound stimulation on the target. Duration:20 days (workdays for four consecutive weeks).
224029696|NCT03092895|BIOLOGICAL|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
224029697|NCT03092895|DRUG|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
224029698|NCT03092895|DRUG|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
224029699|NCT03092895|DRUG|GEMOX|Subjects receive GEMOX treatment every 2 weeks
224029700|NCT01112306|DRUG|ACT-293987|Tablets, twice daily
223559559|NCT04225052|DRUG|YHP1903|YHP1903 Tab. 1mg
224029701|NCT02216643|PROCEDURE|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire FR® and/or thromboaspiration with Penumbra System® versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
224029702|NCT02216643|DEVICE|Stentriever Solitaire FR® or Penumbra System®|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
223412458|NCT00800995|DIETARY_SUPPLEMENT|SOD|
223412459|NCT00800995|DIETARY_SUPPLEMENT|Sham|
223412460|NCT05411783|PROCEDURE|Low tie of IMV|The IMV will be tie under the left colic vein
223412461|NCT02660567|PROCEDURE|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
223412462|NCT00994461|DRUG|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
223412463|NCT00994461|DRUG|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
223412464|NCT00994461|DRUG|Placebo|Placebo tablet three times a day with meal for 2 weeks
224029703|NCT05085223|OTHER|Daily urine collection for biochemical analysis|For every patient in ICU, a daily morning urine sample will be collected from the already collected urine via catheter.
223412465|NCT01368705|DIETARY_SUPPLEMENT|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
223412466|NCT01368705|DIETARY_SUPPLEMENT|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
223412467|NCT01368705|DIETARY_SUPPLEMENT|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
223412468|NCT05271149|OTHER|Routine Physical Therapy|Routine physical therapy and orthosis
223412469|NCT03193372|DRUG|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
223412470|NCT02639650|DRUG|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
223412471|NCT02639650|DRUG|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
223412472|NCT02639650|DRUG|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
223559560|NCT04225052|DRUG|Champix|Comparator Champix Tab. 1mg
223559561|NCT04301479|DRUG|hydrocortisone sodium succinate|Steroid group will receive 200 mg of hydrocortisone diluted in 120 mL of saline at an infusion rate of 5mL/hr for 3 days or shock reversal
223559562|NCT04301479|DRUG|Saline|Control group will receive 120 mL of saline solution at a rate of 5mL/hr for 3 days or shock reversal
223559563|NCT04220242|OTHER|Video recordings with analysis thereafter applied|Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis
224029704|NCT05085223|OTHER|Subanalysis for comparison of 24hour urine collection versus spot-check measurements|For a subgroup of 30 sedated patients, 24 hour urine collection will be collected. In addition, every 2 hours a 10ml urine sample will be collected.
224029705|NCT00056485|BEHAVIORAL|Pleasant Events-Based Behavioral Intervention|
224029706|NCT04446533|DRUG|Hydrogen Peroxide and Hyaluronic acid filming formulation|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
224029707|NCT04446533|DRUG|Chlorhexidine 0.2%|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
224029708|NCT04446533|DRUG|Placebo|"Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth)."
224029709|NCT00852046|DRUG|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
224029710|NCT03008707|PROCEDURE|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
224029711|NCT01074671|DEVICE|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
224029712|NCT00180570|DEVICE|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
224029713|NCT03832634|DIAGNOSTIC_TEST|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
224029714|NCT01208493|OTHER|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
224029715|NCT01208493|OTHER|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
224029716|NCT05166460|DEVICE|Kidney cooling device|renal cooling device designed to maintain renal hypothermia at or below 5ºC for 60 minutes.
224029717|NCT04146415|DIAGNOSTIC_TEST|Spect scan with mTc99-PYP|. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
224029718|NCT05831930|DRUG|Nituozumab|Nituozumab injection 200mg, administered once a week on the first day, with a duration of at least 60 minutes for a total of 7 times
224029719|NCT02767401|DEVICE|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
224029720|NCT02767401|DRUG|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
224029721|NCT00430443|DRUG|Liposomal Annamycin|3-day IV infusion
224135207|NCT00207103|DRUG|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
224135208|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
224029722|NCT01942720|DEVICE|Capsule endoscopy and Ileocolonoscopy tests|
224029723|NCT04588623|DIETARY_SUPPLEMENT|Omnibiotic Stress Repair (OBSR)|OBSR is given orally once daily (3g) for 3 months
224029724|NCT04588623|OTHER|Placebo|Placebo is given orally once daily (3g) for 3 months
224029725|NCT00790764|BIOLOGICAL|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
224029726|NCT00790764|OTHER|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
224029727|NCT01267877|OTHER|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
224135209|NCT00207103|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
224135210|NCT00207103|DRUG|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
224135211|NCT01043354|BEHAVIORAL|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
224135212|NCT01043354|BEHAVIORAL|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
224135213|NCT01043354|BEHAVIORAL|attention placebo intervention|6 monthly counseling sessions about general health topics
223412473|NCT02639650|DRUG|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
223412474|NCT02639650|DRUG|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
223412475|NCT02639650|DRUG|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
223412476|NCT02639650|DRUG|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
223412477|NCT02639650|DRUG|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
223412478|NCT00461773|DRUG|Letrozole|Letrozole 2.5 mg po qd
224029728|NCT01267877|OTHER|read favorable article prior to answering questions|"read A Backlash of Mistrust"
224029729|NCT02438319|OTHER|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
224029730|NCT02438319|OTHER|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
224029731|NCT01607554|DRUG|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
224029732|NCT03525899|PROCEDURE|Pars plana vitrectomy|Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
224029733|NCT05722132|BEHAVIORAL|One cycle|Message Design Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
224029734|NCT05722132|BEHAVIORAL|4 cycles|Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program.
224135214|NCT05525338|DRUG|Alectinib|In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
224135215|NCT01205555|DEVICE|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (\<8 IU\\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\\L) the insemination will be the next day."
223412479|NCT00461773|DRUG|Bevacizumab|bevacizumab 10 mg/kg IV
223412480|NCT05538364|BIOLOGICAL|platelet rich plasma injection|Platelet rich plasma will be injected to the epidural space under light sedation using target-controlled infusion of propofol to an effect site concentration of between 0.5 to 1.5mcg/ml.
223412481|NCT05960916|PROCEDURE|Densah® burs|Osseodensification is a non-excavating implant site preparation technique, it creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects.
223412482|NCT05960916|PROCEDURE|Conventional Burs|Conventional burs is the gold standard that used to prepare the osteotomy site by drilling of the bone and creating a bed for implant placement, it is used according to the manufacturer instructions.
223412483|NCT01377350|DEVICE|"Pneumedicares monitoring system."|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
224029735|NCT05722132|BEHAVIORAL|5 Dollar Incentive|"Participants will receive 3 messages per cycle that contain information on how to enroll in a cessation program. The introductory message will mention that participants will receive $5 if they enroll in the program or that they should look out for messages with a $ sign at the beginning that will provide an incentive if they respond."
224029736|NCT05722132|BEHAVIORAL|Raffle Incentive|"The incentive message (indicated with a leading $ sign) will invite participants to respond, and participants that do so will be included in a random drawing depending on the condition. The incentive message for the opportunity to win will contain a link to a website that provides full details of the timing of the drawing, the chances of winning, and when notification of winners will be made."
223412484|NCT01377350|DEVICE|"Pneumedicares monitoring system"|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
223412485|NCT04429568|OTHER|Smoked Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.
223559564|NCT04220242|OTHER|Examination of microsections of tissue excised for the purposes of cancer resection|Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution
223559565|NCT04220242|OTHER|Cancer organoid development and testing|Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer
223559566|NCT06959862|DEVICE|Transcatheter Aortic Valve Implantation/Replacement|The device is placed in patients heart at the level of aortic valve through a transfemoral access from femoral groin as indicated in device IFU
224029737|NCT02695641|DRUG|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
224029738|NCT02695641|DRUG|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
224135216|NCT04836455|BEHAVIORAL|The FDA's The REal Cost vaping prevention ads - Health harms theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about the health harms of vaping will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
224135217|NCT04836455|BEHAVIORAL|The FDA's The Real Cost vaping prevention ads - Addiction theme|Three vaping prevention video ads from the FDA's The Real Cost prevention campaign about vaping addiction will be shown to participants at week 0, 1, and 2. Ads will be shown in a random order.
224135218|NCT04836455|BEHAVIORAL|Neutral vaping ads|Three neutral (i.e., purely informational and without graphics) vaping video ads developed by the Investigators will be shown to participants at weeks 0, 1, and 2. Ads will be shown in a random order.
224298202|NCT02149290|DEVICE|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
224298203|NCT03548649|DEVICE|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
224298204|NCT02835781|OTHER|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
224298205|NCT01995266|DRUG|Asunaprevir|
224298206|NCT01995266|DRUG|Daclatasvir|
224135219|NCT04811248|OTHER|telephone call for parents of patients|telephone call for parents of patients aged 6 years old
224135220|NCT01986634|PROCEDURE|Laser Treatment|Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
224135221|NCT00580177|PROCEDURE|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
224135222|NCT00580177|PROCEDURE|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
224298207|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given intravenously only once at dose of 10 mg
224135223|NCT00580177|PROCEDURE|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
224135224|NCT03029650|DRUG|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
224135225|NCT03029650|DRUG|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
224135226|NCT04698590|DEVICE|Wavefront Guided Scleral Lenses|Custom wavefront guided, higher order aberration correcting scleral lenses
224135227|NCT04698590|DEVICE|Traditional Scleral Lenses|Traditional scleral lenses
224135228|NCT01875367|DRUG|Trastuzumab Injectable Solution|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
224135229|NCT01875367|DRUG|Trastuzumab Injectable Product|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
224135230|NCT01875367|DRUG|Trastuzumab Injection|Powder for concentrate for solution for infusion. 1 cycle
224135231|NCT00473837|DRUG|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
224298208|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
224298209|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
224298210|NCT00788294|BIOLOGICAL|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
223412486|NCT04429568|OTHER|Vaped Cannabis|Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.
224298211|NCT04414761|DRUG|Progesterone|oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger
224298212|NCT04414761|DRUG|GnRH Antagonist|GnRH antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
224029739|NCT04174144|PROCEDURE|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
224029740|NCT00882453|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
223412487|NCT04429568|OTHER|Tobacco Cigarette|Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.
223412488|NCT03625375|OTHER|Exercise|Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
224029741|NCT03726814|BIOLOGICAL|EPC treatment group|Brain injection EPC
224029742|NCT03952806|DRUG|Verdiperstat|300mg 2 oral tablets, twice daily
224029743|NCT03952806|DRUG|Placebo|Matching placebo
224029744|NCT01601483|DRUG|MC-1101|1% Ophthalmic Solution TID
224029745|NCT01601483|DRUG|MC-1101 Vehicle|Ophthalmic solution, TID
223412489|NCT00638222|OTHER|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
223412490|NCT00092625|DRUG|MK0653, ezetimibe|
223412491|NCT00092625|DRUG|Comparator: ezetimibe, placebo|
224029746|NCT03072277|DIETARY_SUPPLEMENT|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
224029747|NCT03072277|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
224029748|NCT00655863|DRUG|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
224029749|NCT00655863|DRUG|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
224029750|NCT00655863|DRUG|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
224029751|NCT00683176|DRUG|Choline Fenofibrate|135 mg
224029752|NCT00683176|DRUG|Placebo|Placebo
224029753|NCT02557321|DRUG|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
224029754|NCT02557321|DRUG|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
224029755|NCT04286568|BEHAVIORAL|WOW Intervention|Health education and coaching, health care navigation,
224029756|NCT06401460|OTHER|Yannianjiuzhuan method combined with reverse breathing training|"Timing of Operations~1. Reverse Abdominal Breathing: Performed from 9:00 AM to 11:00 AM and from 7:00 PM to 9:00 PM daily, one inhalation and one exhalation constituting one cycle, with 30 cycles per training session, twice a day, over a period of ten days.~2. Yannian Jiuzhuan Method: Conducted daily from 7:00 AM to 9:00 AM and from 9:00 PM to 11:00 PM, twice a day, for a duration of ten days."
224029757|NCT02827357|OTHER|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
224029758|NCT01138007|DRUG|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
224029759|NCT01138007|DRUG|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
224029760|NCT02897401|BIOLOGICAL|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
224029761|NCT02897401|BIOLOGICAL|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
224029762|NCT02897401|BIOLOGICAL|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
224029763|NCT02897401|BEHAVIORAL|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
224029764|NCT02897401|PROCEDURE|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
224029765|NCT04930224|DIAGNOSTIC_TEST|The effect of GPER-1 on the formation of diabetic retinopathy|Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models
224029766|NCT00096057|BIOLOGICAL|monoclonal antibody HuHMFG1|
224029767|NCT05911841|DRUG|LY3454738|Administered SC
223412492|NCT00478803|PROCEDURE|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
224029768|NCT05911841|DRUG|Placebo|Administered SC
224029769|NCT05541211|OTHER|Coeliac plexus neurolysis|Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).
223412493|NCT00478803|DEVICE|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
224029770|NCT05541211|OTHER|Splanchnic nerve neurolysis|Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
224029771|NCT01240083|DEVICE|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
224029772|NCT01240083|DEVICE|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
224029773|NCT01240083|DEVICE|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
224029774|NCT06582719|DEVICE|GPT-based counseling|AI-based counseling provided to the patient, accessible on their smartphone device at the time of Gestational Diabetes diagnosis
224029775|NCT06582719|OTHER|Nutritional Counseling|Standard Nutritional Counselling provided by a registered dietician at the time of Gestational Diabetes diagnosis
223412494|NCT02887248|DRUG|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
223412495|NCT02887248|DRUG|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
223559567|NCT05464914|DRUG|CEO Pack|is a eugenol-free, surgical dressing and periodontal pack that has no burning sensation, no unpleasant taste or odor, and offers proven protection to surgical sites. This product promotes cleanliness and healing. Plastic and cohesive, ropes of any length or thickness can be formed. The smooth texture allows this product to adapt closely to the teeth and tissue in order to protect the wound. It sets with resilient, non-brittle hardness.
223559568|NCT05433441|PROCEDURE|ESPark Intervention|The treatment will include 15 sessions (1 session per week). An initial assessment will be carried out during the first session in order to determine the objectives and the personalized follow-up.
224029776|NCT05996783|DEVICE|Colli-Pee Small Volumes|Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
224029777|NCT05996783|DEVICE|Evalyn Brush|Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.
224029778|NCT03825484|DRUG|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
224029779|NCT06412393|DIETARY_SUPPLEMENT|Black tomato extract powder|take 2 packets per day for 8 weeks
224029780|NCT06412393|DIETARY_SUPPLEMENT|Placebo powder|take 2 packets per day for 8 weeks
224029781|NCT05613452|RADIATION|Carbon ion beam radiotherapy|Patients receive carbon ion radiotherapy of 12GyE per fraction, totally 4 fractions. Patients with tumors ≥4cm should receive at least 4 cycles of platinum-based doublet chemotherapy.
224029782|NCT06644898|OTHER|Level walking training|For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.
224029783|NCT06644898|OTHER|Downhill walking training|For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.
224029784|NCT06644898|OTHER|Uphill walking training|For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
224029785|NCT06337838|DRUG|Desmopressin Injectable Solution|Intravenous desmopressin, 20 mcg, single dose administration.
224135232|NCT00473837|DRUG|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
223559569|NCT06554886|DEVICE|Cryoneurolysis|Cryoneurolysis
223559570|NCT06836245|OTHER|Measure the patient's body temperature intraoperatively using instruments|"1. Core Body Temperature Measurement:~   Nasopharyngeal Temperature Probe: Insert the probe into the patient's nasal cavity to measure the temperature of the nasopharynx.~   Esophageal Probe: Insert the probe through the esophagus to measure the temperature of the lower esophagus.~   Bladder Temperature Probe: Insert the probe into the bladder to measure the temperature of the urine.~   Tympanic Temperature Probe: Place the probe in the ear canal to measure the temperature near the tympanic membrane.~2. Peripheral Body Temperature Measurement:~Axillary: Place the thermometer under the armpit, suitable for routine temperature monitoring, but may not be as accurate as core temperature measurement.~Oral: Place the thermometer under the tongue, suitable for conscious and cooperative patients.~Rectal: Insert the thermometer into the rectum to provide an accurate temperature measurement, but may not be suitable for all patients, especially those with rectal diseases or immunosuppressed conditions."
223559571|NCT05849675|DRUG|Pitolisant 17.8 MG [Wakix]|Single dose pitoliosant (36mg)
223559572|NCT05849675|DRUG|Placebo|Single dose placebo
224135233|NCT00720421|DRUG|AZD7325|AZD7325 10 mg oral 2 capsules
224135234|NCT00720421|DRUG|AZD7325|AZD7325 1 mg oral 2 capsules
223412496|NCT00119717|DEVICE|NeuroFlo™ catheter|45 minute treatment
224029786|NCT06337838|DRUG|Tranexamic Acid Injectable Product|Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
224029787|NCT06337838|OTHER|Placebo|Intravenous 0.9% saline solution
224029788|NCT05998850|BEHAVIORAL|Community Health Worker Support with Resources|6-months of hands-on tailored support spanning the domains of social support, advocacy and navigation to achieve their action plans.
224029789|NCT06186726|RADIATION|carbon ion radiotherapy|The patients received 72GyE/18 doses of carbon ion radiotherapy.
224029790|NCT06801860|BEHAVIORAL|Very brief smoking cessation advice|All participants will receive very brief smoking cessation advice (guided by the AWARD model, assess, warning, refer, and do-it-again) with a smoking cessation information booklet onsite at baseline.
224029791|NCT06801860|BEHAVIORAL|Chewing gum|Participants in the intervention group will receive 1-2 packs of chewing gum over a 1-week intervention period.
224135235|NCT00720421|DRUG|AZD7325|AZD7325 Placebo oral 2 capsules
224135236|NCT00720421|DRUG|Lorazepam|Lorazepam 1 mg oral 2 tablets
224135237|NCT00720421|DRUG|Lorazepam|Lorazepam Placebo oral 2 tablets
224135238|NCT05900011|BEHAVIORAL|Quality of life questionnaire|Measurement of the quality of life of patients with eosinophilic esophagitis by the PedsQL questionnaire eosinophilic esophagitis module
223412497|NCT00119717|OTHER|Control|ASA Guidelines
223412498|NCT00329537|DRUG|Sargramostim (Leukine)|Self-subcutaneous injection
223412499|NCT00329537|DRUG|Placebo|Self-subcutaneous injection
223412500|NCT02557581|OTHER|No training|
223412501|NCT02557581|OTHER|Endurance training|
223412502|NCT02557581|OTHER|Resistance Training|
224029792|NCT06801860|BEHAVIORAL|Chewing gum usage leaflet|A leaflet of usage tips for chewing gum, including 1) the potential benefits of chewing gum, 2) suitable usage time and dosage, and 3) the proper disposal of used gum.
223412503|NCT02557581|DRUG|Terbutaline|
223412504|NCT02557581|DRUG|Clenbuterol|
223412505|NCT02557581|DRUG|Placebo|
223412506|NCT00184132|PROCEDURE|Psychiatric intensive care unit in Norwegian home style|
224029793|NCT04661878|BEHAVIORAL|Social Support|The app will provide opportunities for participants to interact with each other as well as trained peer mentors to receive and provide social support.
224029794|NCT04661878|BEHAVIORAL|Informational Resources|The app will provide opportunities for participants to review HIV-related health information in engaging formats (e.g., activities, multi-media resources, and answer to users' health questions)
223412507|NCT00184132|PROCEDURE|Psychiatric intensive care unit sparsely furnished and not decorated|
223412508|NCT03798470|BEHAVIORAL|Peer Addiction Counseling|After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
224029795|NCT04661878|BEHAVIORAL|Self-Monitoring and habit formation|The app will provide opportunities for participants to track their treatment adherence and schedule tailored reminders.
223412509|NCT03688308|PROCEDURE|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
223412510|NCT03688308|PROCEDURE|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
223412511|NCT05577988|OTHER|single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.|"* Individuals without genetic loss of function to metabolize clopidogrel: stop DAPT and switch to a single antiplatelet therapy by clopidogrel.~* Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.~* Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin."
223412512|NCT06198491|BEHAVIORAL|Misbeliefs about HPV training|Intervention trainings mentioned false beliefs before or after the current knowledge
224029796|NCT04661878|BEHAVIORAL|Goal setting and action planning|The app will provide opportunities for participants to identify goals, select action items, and receive tailored feedback on the action plan.
224029797|NCT04560036|DIAGNOSTIC_TEST|FAZA PET/MRI scan|FAZA PET/MRI scan before and after the standard of care chemotherapy
224029798|NCT06251453|DRUG|SGLT2 inhibitor|Dapagliflozin Empagliflzoin
223412513|NCT04601077|DRUG|Nitric Oxide lozenges, 30 mg|Nitric Oxide lozenge, 30 mg twice a day for 30 days
223412514|NCT04601077|DRUG|Placebo|Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
223412515|NCT03798509|DRUG|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
223412516|NCT06279546|DIAGNOSTIC_TEST|Detection of structures|Pre-recorded videos, cropped according to the different windows (mediastinal, gastric, duodenal) will be analyzed by the AIWorks-EUS model and endoscopists on different times for recognition of the different normal anatomical structures.
224029799|NCT06634459|DEVICE|Reia System|Reia pessary
224029800|NCT06634459|DEVICE|Standard of Care Pessary|Gellhorn pessary or ring with/without support without knob pessary
224029801|NCT03867175|RADIATION|Stereotactic Body Radiation Therapy|Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)
224029802|NCT03867175|BIOLOGICAL|Pembrolizumab|Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
224029803|NCT04328337|DRUG|Intralipid, 20% Intravenous Emulsion|Infusion of Intralipid 20%
224029804|NCT04328337|DRUG|Placebos|saline 30 ml/hr for 12 hours through an IV
224029805|NCT05403138|DRUG|Daratumumab|Induction Phase: (8mg/kg) via intravenous (IV) evey 2 weeks for two cycles. Maintenance Phase: (4mg/kg) IV every 4 weeks.
224029806|NCT05403138|DRUG|Placebo|Induction Phase: matching placebo (8mg/kg) via intravenous (IV) every 2 weeks for two cycles; Maintenance Phase: matching placebo (4mg/kg) IV every 4 weeks.
223412517|NCT01873404|DRUG|BG00010|As specified in the treatment arm
223412518|NCT01873404|DRUG|Placebo|As specified in the treatment arm
223412519|NCT04804826|PROCEDURE|Pelvic Reconstructive Surgery|Pelvic Reconstructive Surgery including total vaginal hysterectomy
223412520|NCT02420561|BEHAVIORAL|Motivational Interviewing|"* One in-person motivational interviewing session intervention that lasts for 45-minutes~* Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
224029807|NCT04828486|DRUG|Futibatinib|Given PO
224029808|NCT04828486|BIOLOGICAL|Pembrolizumab|Given IV
224029809|NCT04828486|OTHER|Quality-of-Life Assessment|Ancillary studies
224029810|NCT03144999|BIOLOGICAL|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
224029811|NCT06215573|DIETARY_SUPPLEMENT|Melatonin|5mg melatonin supplement, once daily, from Ritual BioSeries
224029812|NCT06215573|DIETARY_SUPPLEMENT|Placebo supplement|Placebo supplement, once daily, from Ritual BioSeries
223412521|NCT02420561|BEHAVIORAL|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
223412522|NCT03759587|DRUG|Niraparib|Niraparib capsule
223412523|NCT01657825|DRUG|Isavuconazole|oral
224029813|NCT05469399|OTHER|Experimental Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). After these applications, the students will be given a theoretical course on the admission of the patient to the clinic after the operation. After the theoretical lesson, a link for the virtual reality game application consisting of three different cases will be sent to the students for them to play on the phone and computer. Students will play this game application for a week. After the game application process, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
223412524|NCT01657825|DRUG|Warfarin|oral
224029814|NCT05469399|OTHER|Control Group|"Students will be given a knowledge test and an objective structured clinical exam for skill assessment (Initial knowledge and skill assessment). No application will be made to the students for one week. One week later, students will be given a knowledge test, an objective structured clinical exam for skill assessment (final knowledge and skill assessment)."
224029815|NCT05103228|DRUG|Follitropin Alfa|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
224029816|NCT05103228|DRUG|Follitropin delta|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
223412525|NCT04933552|OTHER|Siponimod|Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod, that have started before inclusion of the patient into the study will be enrolled.
223412526|NCT03871205|BIOLOGICAL|Neoantigen loaded DC vaccine|Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
223412527|NCT05932537|PROCEDURE|Preoperative visualization techniques|describe techniques for pre-operative visualization of subcutaneous contraceptive implants
224029817|NCT05103228|DRUG|human menopausal gonadotropin|lower dose gonadotropin (follitropin alpha/ follitropin delta + hpHMG) vs. higher dose stimulation (Follitropin alpha/delta + hpHMG)
224029818|NCT06330779|OTHER|Trauma-adapted yoga|"Trauma-adapted-yoga (TAY) classes The classes, which span eight weeks with a once-a-week frequency, each last approximately 45-50 minutes. These small group classes are structured in a semi-circle arrangement to create a sense of security and empowerment for the participants. The teaching approach is trauma-sensitive, characterized by its inviting nature, provision of choices when facing challenges (A-B choices), and direction toward tangible physical sensations to enhance interoceptive awareness. Each yoga session follows a structured sequence of activities designed to promote participants' well-being and physiological awareness.~Online TAY classes After eight weeks, adolescents in the yoga group can continue their practice online. Exclusive to previous in-person participants, they'll receive a link for recorded classes and they will have the possibility to contact their health care contact any time."
224029819|NCT06311968|RADIATION|Proton radiotherapy|Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
223412528|NCT02858804|DRUG|Etoposide|50 mg/m2, IV d1-4
224029820|NCT06311968|OTHER|combined platinum based chemotherapy|combined platinum based chemotherapy
223412529|NCT02858804|DRUG|Doxorubicin|10 mg/m2, IV, d1-4
223412530|NCT02858804|DRUG|Dexamethasone|30 mg/d, d1-5
223412531|NCT02858804|DRUG|Vincristine|0.4 mg/m2, IV, d1-4
223412532|NCT02858804|DRUG|Cyclophosphamide|750 mg/m2 ,d5
223412533|NCT02858804|DRUG|Cytarabine|2g/m2, q12h, d1
223412534|NCT02858804|DRUG|Cisplatin|100mg/ m2,IV, d1
223412535|NCT02858804|DRUG|Rituximab|375 mg/m2 IV, d1
223412536|NCT02858804|DRUG|Thalidomide|50-150mg/d, po, d1-28
223412537|NCT02858804|DRUG|Prednisone|0.5mg/Kg, po, qod
223412538|NCT03864757|DEVICE|thyroplasty implant|Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.
223412539|NCT04443946|DRUG|Propofol|5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
223412540|NCT04443946|DRUG|1% Sevoflurane|add 1% end-tidal sevoflurane 20 minutes after endotracheal intubation.
223412541|NCT04443946|DRUG|1% Sevoflurane continue|1% sevoflurane continued to maintain anesthesia after endotracheal intubation.
223412542|NCT04443946|DRUG|Sufentanil|0.01 μ g kg-1 min-1 sufentanil were pumped continuously at maintain phase
223412543|NCT04443946|DRUG|2% Sevoflurane|2% sevoflurane continued to maintain anesthesia after endotracheal intubation.
223412544|NCT04443946|DRUG|Propofol half|2.5 mg kg-1 h-1 propofol was pumped continuously after endotracheal intubation.
223412545|NCT02024074|OTHER|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
223412546|NCT05800561|DIAGNOSTIC_TEST|Hepatic venous-portal gradient (HVPG) measurement|preoperative evaluation of Hepatic venous-portal gradient (HVPG) and ICG-retention test
223412547|NCT04337905|DEVICE|ADHD-VR diagnosis tool|"Since that time and in accordance with the application area, several definitions have been formulated: for example, Fuchs and Bishop (1992) defined VR as real-time interactive graphics with 3D models, combined with a display technology that gives the user the immersion in the model world and direct manipulation; Gigante (1993) described VR as The illusion of participation in a synthetic environment rather than external observation of such an environment. VR relies on a 3D, stereoscopic head-tracker displays, hand/body tracking and binaural sound. VR is an immersive, multi-sensory experience; and Virtual reality refers to immersive, interactive, multi-sensory, viewer-centered, 3D computer generated environments and the combination of technologies required building environments."
223559573|NCT01346943|DEVICE|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
224029821|NCT02416804|DRUG|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -\> 10 μg/hr -\> 15 (5+10) μg/hr -\> 20 μg/hr
224029822|NCT02416804|DRUG|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -\> 200 mg/d -\> 250 mg/d -\> 300 mg/d
223412548|NCT04744194|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
223412549|NCT04744194|OTHER|Assisted nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 - 3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps.
223412550|NCT01056237|DRUG|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
223412551|NCT01056237|DRUG|Azathioprine|1.0-2.0mg/kg/d
223412552|NCT06061120|DEVICE|Recording of an extended high-resolution ECG|Recording of an extended high-resolution ECG
223412553|NCT04967482|PROCEDURE|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.
223412554|NCT04967482|PROCEDURE|Conventional transarterial chemoembolization (cTACE)|The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
223412555|NCT02746978|OTHER|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
224029823|NCT04442737|DRUG|D/C/F/TAF FDC|A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
224029824|NCT04442737|DRUG|TAF/FTC FDC|TAF/FTC ARV regimen will be administered once daily.
224029825|NCT04442737|DRUG|INI Based Regimen|The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
224029826|NCT00744523|DEVICE|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
224029827|NCT02904486|BEHAVIORAL|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
224029828|NCT06257524|OTHER|Education and training|Pediatric resource toolkits availability via TREKK for Kids Ongoing interactions, and intensive training and education sessions
224135239|NCT05418062|BEHAVIORAL|Acceptance and commitment therapy (ACT)|8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
224135240|NCT01045772|DRUG|rilonacept|160mg of rilonacept 1x/week
224135241|NCT05059548|OTHER|Video-Assisted Thoracoscopic Surgery|patients receive Video-Assisted Thoracoscopic Surgery under general anesthesia
224135242|NCT02145091|DRUG|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
224135243|NCT02145091|DRUG|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
224135244|NCT02145091|DRUG|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
224135245|NCT02145091|DRUG|Placebo|An oral placebo (lactose pill).
224135246|NCT02237157|DRUG|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
224135247|NCT03623126|OTHER|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
224135248|NCT04711876|BIOLOGICAL|Cytokine level in blood and CSF|Measure of cytokine level
224135249|NCT02019394|DRUG|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
224135250|NCT02456376|PROCEDURE|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
224135251|NCT02456376|PROCEDURE|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
224135252|NCT03312712|RADIATION|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
224135253|NCT03312712|OTHER|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
224135254|NCT03312712|OTHER|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
224135255|NCT03312712|DIAGNOSTIC_TEST|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
224135256|NCT05609123|DIAGNOSTIC_TEST|Endothelial glycocalyx damage assessment|Degradation products of endothelial glycocalyx will be assessed in the blood and urine.
224029829|NCT04869423|BEHAVIORAL|Dog-Assisted Therapy|During seven weeks patients will assist one time per week (1 hour). The therapy will be conducted by an expert psychologist. The intervention will consist of 7 weeks conducted once a week (50 minutes each session). It will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to say goodbye to the dogs.
224135257|NCT02951988|DRUG|Rapastinel|Rapastinel pre-filled syringes for IV injections.
224135258|NCT02951988|DRUG|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
224135259|NCT04615689|OTHER|The collection of feces|When the infants will be diagnosed with urinary tract infection, feces will be collected. Feces will be collected from healthy infants with informed consent.
224299131|NCT02836626|PROCEDURE|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
223412556|NCT02746978|OTHER|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
223412557|NCT00006351|DRUG|gemcitabine hydrochloride|
224029830|NCT03107104|DEVICE|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
224029831|NCT03107104|DEVICE|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
223412558|NCT00006351|DRUG|lonafarnib|
223412559|NCT06382246|OTHER|Exercise snacks|Bodyweight-style exercise snacks lasting 1-minute each performed with vigorous effort 4 times per day on two consecutive days.
223412560|NCT06577545|BEHAVIORAL|Behavioural Lifestyle (BL)|24-week behavioural lifestyle intervention
223412561|NCT04881695|OTHER|Questionary patients|"The patients will answer 1 questionnaire consisting of 5 parts :~* General (demographic information)~* Desire for a child~* Hospital Anxiety and Depression scale~* Sexual life~* Additional questions regarding medical care"
224029832|NCT03054480|DEVICE|Fractional Micro-Needle Radiofrequency|
224029833|NCT03054480|DRUG|Botulinum toxin type A|
224029834|NCT05333224|OTHER|Telerehabilitation|Family-centered, goal-oriented early physiotherapy approaches will be applied.
223412562|NCT04881695|OTHER|Questionary controls|"Witnesses will complete 1 survey containing 4 parts:~* General (demographic information)~* Desire to have a child~* Hospital Anxiety and Depression scale~* Sexual life"
223412563|NCT02145260|DRUG|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
223412564|NCT02145260|DRUG|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
223412565|NCT02550379|BEHAVIORAL|Intervention|Emotion Recognition Training
223412566|NCT02550379|OTHER|Placebo|Placebo Training
223412567|NCT01214967|BEHAVIORAL|Problem Solving Education|psycho-educational intervention
223412568|NCT01702220|BEHAVIORAL|CBT|6-12 sessions of CBT in person or over the phone
224029835|NCT05333224|OTHER|Home-based|Family-centered, goal-oriented early physiotherapy approaches will be applied.
224029836|NCT06798363|DRUG|propranolol|different dose
224029837|NCT04822285|BEHAVIORAL|Psychological Triaging Intervention|The PTI intervention followed the path of RAPID Psychological First Aid model of John Hopkins University (Everly\& Lating 2012). The content of the PTI represents a simple structure that is revolved around five core phases including (R: establishing rapport and reflective listening, A: assessment, P: prioritization, I: intervention and D: disposition\& follow up).
224029838|NCT04822285|BEHAVIORAL|Routine psychological support|For the comparison group, the researchers provided them with routine psychological support that mainly revolved around enhancing their self-compassion, practicing mindfulness exercises, keeping them socially connected with their family and peers. Moreover, adopt a healthy lifestyle such as; engage in physical activity, eating a well-balanced diet, and sleeping well.
224029839|NCT00063154|DRUG|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
224029840|NCT01669876|DIETARY_SUPPLEMENT|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
224029841|NCT01669876|DIETARY_SUPPLEMENT|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
224029842|NCT03272425|DRUG|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
224029843|NCT03272425|DRUG|lesinurad 200 mg|Comparator 1
224029844|NCT03272425|DRUG|allopurinol 300 mg|Comparator 2
224029845|NCT01978262|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
224029846|NCT06120348|DEVICE|Charge-Balanced, Symmetric Nerve Stimulation|Charge-Balanced, Symmetric Nerve Stimulation device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
224029847|NCT06120348|DEVICE|Sham Stimulation|Sham device 30 mins once a day for 4weeks(28days) and twice a week from the 5weeks to the 12 weeks.
224029848|NCT02742623|DRUG|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
224135260|NCT03053596|DEVICE|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
224029849|NCT00196404|DRUG|DR-3001a|4mg daily vaginally
224029850|NCT00196404|DRUG|DR-3001b|6 mg vaginally daily
224029851|NCT00196404|OTHER|Placebo|Administered vaginally to match experimental arms
224029852|NCT02038439|BEHAVIORAL|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
224029853|NCT02038439|BEHAVIORAL|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
224029854|NCT02038439|BEHAVIORAL|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
224029855|NCT04571866|OTHER|Beta-glucan bread|Beta-glucan is a dietary fiber with beneficial health effects, both on cholesterol levels and potentially blood glucose levels.
224029856|NCT02290522|PROCEDURE|Tumor biopsy|Biopsy of lesion for molecular characterization
224029857|NCT03136328|DRUG|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
224029858|NCT04740892|OTHER|Wash IP|Parent participant will bathe the child participant with the investigational wash at least 3 times per week, but no more than once daily, for 4 weeks.
224029859|NCT04740892|OTHER|Cream IP|Parent participant will apply the investigational cream on their child participant twice daily for 4 weeks.
224029860|NCT00490880|DRUG|gemcitabine|
224029861|NCT00490880|DRUG|cisplatin|
224029862|NCT00490880|PROCEDURE|radical cystectomy|
224029863|NCT00490880|PROCEDURE|radiotherapy|
224029864|NCT00325039|PROCEDURE|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
223412569|NCT01702220|OTHER|ECC|6 biweekly sessions of ECC over the telephone
223412570|NCT04167098|OTHER|PRP injection|0.5 ml Platelet-rich Plasma around A1 tendon sheath
224029865|NCT00325039|PROCEDURE|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
223412571|NCT04167098|OTHER|Corticosteroid injection|0.5 ml methylprednisolone around A1 tendon sheath
223412572|NCT04167098|OTHER|Placebo injection|0.5 ml 0.9% saline around A1 tendon sheath
223412573|NCT02502682|DRUG|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
223412574|NCT05312762|DEVICE|MaxioCel|Microfiber wound dressing
223412575|NCT05312762|DEVICE|AquaCel Extra|Hydrofiber dressing
223412576|NCT00253825|DEVICE|mCIMT combined with or without eye patching|
223412577|NCT05235893|PROCEDURE|Reflexology|Reflexology was applied to soles of the babies in the second study group during 5-7 minutes, three minutes before the painful procedure was started by a physiotherapist, certificated in reflexology.
223412578|NCT05235893|PROCEDURE|Sucrose %24|The newborns who were given one ml of a single-use 24% concentration of sucrose solution in the form of ready to use preparations
223412579|NCT05235893|PROCEDURE|Kangaroo care|The newborns who were placed on the mother's lap for 3-5 minutes before the painful intervention and kangaroo care was applied
223412580|NCT05235893|PROCEDURE|Music|"Newborns who were exposed to the recorded Deep Sleep track from Bedtime Mozart: Classical Lullabies for Babies music"
223412581|NCT06080399|OTHER|Continuous subcutaneous apomorphine infusion (CSAI)|the CSAI proposed in the usual healthcare pathway of each PD patients included
223412582|NCT00300560|DRUG|Colistin|
223412583|NCT02256124|DRUG|Lamotrigine|
223412584|NCT02256124|DRUG|Placebo|
224029866|NCT00480246|DRUG|BL 1020|
224029867|NCT00480246|DRUG|Perphenazine|
224135261|NCT00041613|GENETIC|INGN 201|
223412585|NCT01463189|BEHAVIORAL|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
223412586|NCT00454363|OTHER|Laboratory Biomarker Analysis|Correlative studies
224029868|NCT02639468|DEVICE|Stroke Volume estimation using electrical impedance tomography|
224029869|NCT00418925|DRUG|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
223412587|NCT00454363|DRUG|Pazopanib Hydrochloride|Given PO
223412588|NCT00454363|OTHER|Pharmacological Study|Correlative studies
223412589|NCT05069220|DRUG|18F-MFBG|Patients with neuroendocrine malignancies receive 2-4 MBq/kg of 18F-MFBG intravenously followed by PET/CT after 60min of injection.
223412590|NCT05069220|DRUG|68Ga-Dotatate|Patients with malignant PPGL and NB receive intravenously 68Ga-Dotatate followed by PET/CT after 40min of injection.
223412591|NCT00548301|DRUG|cyclosporine|
223412592|NCT06382701|OTHER|aromatherapy|Patients in the intervention group; ten minutes before the needle is inserted into the arterio-venous fistula, clove oil will be applied by the interviewer as a spray between 0.5-1 ml, depending on the length of the patient's fistula. Patients in the placebo group; 10 minutes before the needle is inserted into the arterio-venous fistula, 0.5-1 ml of aromatic cloves, which do not contain active ingredients and dissolved in pure water, will be applied as a spray by the interviewer, depending on the length of the patient's fistula.
223412593|NCT06382701|OTHER|placebo|This is the group in which 0.5-1 ml of aromatic clove, which does not contain active ingredients and is dissolved in pure water, is applied as a spray to the arterio-venous fistula area, depending on the length of the fistula, ten minutes before needle cannulation in all hemodialysis sessions for four weeks in individuals receiving standard hemodialysis treatment.
223412594|NCT05664360|OTHER|Age (young versus older)|Age
223412595|NCT05871762|OTHER|Registry study, no specific intervention|Registry study, no specific intervention
223412596|NCT00570063|DRUG|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
223412597|NCT00570063|DRUG|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
224029870|NCT01009203|DRUG|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
224029871|NCT01009203|DRUG|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
224029872|NCT06475573|DIETARY_SUPPLEMENT|dietary fiber probiotic beverages|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021). Carbohydrates were to account for 55%-60% and fat for 25%-30% of total daily energy intake. Participants in experimental group consumed two 35g sachets of fermented dietary fiber probiotic solid beverages daily, replacing part of the staple food for lunch and dinner."
224029873|NCT06475573|OTHER|whole grain porridge|"The intervention period lasted for 8 weeks. During this time, Participants received dietary guidance from researchers. The target energy intake was based on the limited energy diet model recommended in the Chinese Guidelines for Medical Nutrition Therapy of Overweight/Obesity (2021).Participants in control group consumed two 35g sachets of convenient whole grain porridge daily, replacing part of the staple food for lunch and dinner."
224029874|NCT03749603|DEVICE|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
223412598|NCT03082859|BEHAVIORAL|Exercise|This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
223412599|NCT05988827|DEVICE|NGenuity|Cataract surgery performed under microscope using NGenuity
223412600|NCT06156995|DEVICE|Deep Acupuncture at Zhongliao Point to Stimulate Sacral Nerve|Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.
223412601|NCT06156995|DRUG|Oral Mosapride Tablets|Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
223412602|NCT00697463|DRUG|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
224029875|NCT02974088|DEVICE|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
224029876|NCT02974088|DEVICE|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
224029877|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
224029878|NCT00892723|DRUG|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
224029879|NCT00892723|DRUG|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
224029880|NCT00426153|DRUG|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
224029881|NCT00426153|DRUG|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
224029882|NCT00150969|DIETARY_SUPPLEMENT|vitamin K1 (phylloquinone)|
224029883|NCT00150969|DIETARY_SUPPLEMENT|placebo|1 pill daily
224029884|NCT05253495|DRUG|DOC Group B|Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1
224029885|NCT05253495|DRUG|Pv-COMRAD 1 and 2 Group B|polatuzumab vedotin x1; dexamethasone x 5; vincristine x1, cyclophosphamide x 3; doxorubicin x1; methotrexate x; rituximab 2x; ITT x1
224029886|NCT05253495|DRUG|Pv-R-CYM 1 and 2 Group B|polatuzumab vedotin x 1; methotrexate x 1; rituximab x 1; cytarabine x 5;
224029887|NCT05253495|DRUG|DOC Group C|cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
224029888|NCT05253495|DRUG|MAD CPR 1 and 2|methotrexate x 1; dexamethasone x 5; polatuzumab Vedotin x 1, cyclophosphamide x 3; doxorubicin x 1; rituximab x2; IT triples x 2 in induction 1, IT triples x 2 in induction 2
224029889|NCT05253495|DRUG|Pv-R CYVE 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4;
224029890|NCT05253495|DRUG|Pv-R CYVE-MTX 1 and 2|Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
224029891|NCT05253495|DRUG|MAD CP|dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
224135262|NCT03448718|DRUG|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of \> 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
224135263|NCT00603980|DRUG|Inhaled placebo + oral placebo|Inhaled Staccato placebo + oral placebo
224135264|NCT00603980|DRUG|Inhaled alprazolam 0.5 mg|Inhaled Staccato alprazolam 0.5 mg + oral placebo
224135265|NCT00603980|DRUG|Inhaled alprazolam 1 mg|Inhaled Staccato alprazolam 1 mg + oral placebo
224135266|NCT00603980|DRUG|Inhaled alprazolam 2 mg|Inhaled Staccato alprazolam 2 mg + oral placebo
224135267|NCT00603980|DRUG|Oral alprazolam 1 mg|Oral alprazolam 1 mg + Inhaled placebo
224029892|NCT05253495|DRUG|Pv-Cytarabine/etoposide|polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
224029893|NCT05253495|DRUG|AD CP|polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
224135268|NCT00603980|DRUG|Oral alprazolam 2 mg|Oral alprazolam 2 mg + Inhaled placebo
223412603|NCT05191290|DRUG|unfractionated heparin|standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
223412604|NCT05191290|DRUG|Sodium Citrate|8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
223412605|NCT05444452|DEVICE|Implanatation of Genoss DES sirolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
223412606|NCT05444452|DEVICE|Implanatation of Xience DES everolimus-eluting coronary system|Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
223412607|NCT03307252|DRUG|Digoxin|Tablet
224029894|NCT05253495|DRUG|Bv-AVD-R 1 and 2: COHORT IIa|brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2
224029895|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; vinblastine x2; dacarbazine x 2; rituximab x 2;
224029896|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-4 SER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; rituximab x 2;
224029897|NCT05253495|DRUG|Bv-AVD-R|Brentuximab vedotin x2; doxorubicin x2; vinblastine x 2; dacarbazine x 2; rituximab x2;
224029898|NCT05253495|DRUG|Bv-NVD-R, Cycle 1-4 RER|brentuximab vedotin x 2; nivolumab x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
224029899|NCT05253495|DRUG|Bv-NAVD-R, Cycle 1-2|brentuximab vedotin x 2; nivolumab x 2; doxorubicin x 2; vinblastine x 2; dacarbazine x 2; rituximab x 2;
224029900|NCT05253495|RADIATION|Involved Site Radiation Therapy|21 Gy in 14 fractions of 1.50 Gy per day. The treatment will be given 5 days per week. All fields shall be treated once each day. The total elapsed treatment time will be 2.8 weeks (14 sessions) for each field.
224029901|NCT04579627|BEHAVIORAL|Questionnaire|A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
224029902|NCT00615836|DRUG|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
224029903|NCT06646445|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg via a 30-minute IV infusion q3w on Day 1 of each 21-day cycle; 8 cycles ± 9 additional cycles (17 cycles in total).
224029904|NCT06646445|PROCEDURE|Watch-and-wait approach|"Watch-and-wait strategy:~* TAP-CT scan At months 3 and 6 during 8 cycles of treatment, at months 9 and 12, and during additional 9 cycles of treatment if performed, and every 3 months thereafter for up to 2 years,~* Colonoscopy with biopsies at months 3, 6, 9, 12, and 24."
224029905|NCT06646445|PROCEDURE|Surgery|Standard of care surgery performed with a maximal delay of 21 days (3 weeks) from randomization.
224135269|NCT00603980|DRUG|Oral alprazolam 4 m|Oral alprazolam 4 mg + Inhaled placebo
224135270|NCT00603980|DRUG|Oral alprazolam 2 mg qualifying session|Qualifying session (2 mg oral alprazolam)
224135271|NCT00603980|DRUG|Oral placebo qualifying session|Qualifying control session (oral placebo)
224135272|NCT03986346|DEVICE|pulsed dye laser|The scar will receive PDL 585 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
224135273|NCT03986346|OTHER|standardized care|the scar will receive standardized care such as scar massage.
224135274|NCT01957826|OTHER|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
224135275|NCT01957826|OTHER|placebo intervention|placebo administration
224029906|NCT06646445|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy (5-fluorouracil/capecitabine ± oxaliplatin 3 months to 6 months) according to the current guidelines, at the investigator's discretion.
224029907|NCT02962544|PROCEDURE|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
224029908|NCT02962544|PROCEDURE|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
224029909|NCT02962544|DEVICE|Visumax device|
224029910|NCT02962544|DEVICE|FS 200 device|
224029911|NCT03993821|DRUG|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
224029912|NCT05138367|PROCEDURE|transplantation of human UCA-PSCs or WJ-MSCs into ovaries of POF patients|After vaginal sterilization, TVUS-guided transplantation was performed by the senior-level medical physician B Wang), using a SIEMENS ACUSON ANTANES premium edition system (SIEMENS AG Healthcae Sector, Erlangen, Germany), equipped with a 6-10 MHz probe. The solution (a total number of 2×10\^7cells, 1×10\^7 /400 μL for unilateral ovarian injection) was injected into the ovary by using 21G PTC needles (Hakko Medical Co, Japan) under TVUS guiance. Each patent received up to three transplantations.
224029913|NCT04433273|DEVICE|Electrical vestibular nerve stimulation|Electrical vestibular nerve stimulation using a headset device
224135276|NCT06208982|DIAGNOSTIC_TEST|Colonoscopy images and videos|A CADx system in real-time characterization of colonic ulcer diseases was constructed using artificial intelligence to extract endoscopic features from the training set. Subsequently, the performance of the CADx system was preliminarily tested through the validation set.
224135277|NCT04946136|OTHER|Gait modification|Individualized gait modifications guided by real-time visual feedback of knee load
224135278|NCT02434627|DRUG|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
223412608|NCT03307252|DRUG|Furosemide|Oral solution
223412609|NCT03307252|DRUG|Metformin|Oral solution
223412610|NCT03307252|DRUG|Rosuvastatin|Film-coated tablet
223412611|NCT03307252|DRUG|Verapamil|Film-coated tablet
223412612|NCT03307252|DRUG|Rifampin|Film-coated tablet
224029914|NCT04700332|DRUG|DCFPyL PET/CT|Prostate Membrane Specific Antigen-specific imaging
224029915|NCT04835077|OTHER|aerobic exercise|Structured aerobic exercises (Each session will consist of 50 minutes and will be divided into three parts: 5 minutes of warm-up exercises, 40 minutes of aerobic exercises, 5 minutes of cool down exercises) will be taught in the first session.
224029916|NCT04835077|OTHER|postural stabilization exercises|Structured postural stabilization exercises (strengthening exercises, balance-coordination exercises, flexibility exercises) will be taught in the first session.
224135279|NCT02683525|DRUG|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
223412613|NCT03307252|DRUG|Cimetidine|Tablet
223412614|NCT03307252|DRUG|Probenecid|Tablet
223412615|NCT03482453|DRUG|TAK-788|TAK-788 capsules.
223412616|NCT03482453|DRUG|Placebo|TAK-788 placebo-matching capsules.
223412617|NCT03482453|DRUG|TAK-788|TAK-788 DiC.
223412618|NCT03444662|DIETARY_SUPPLEMENT|Placebo supplement|Cellulose and Sunflower oil
223412619|NCT03444662|DIETARY_SUPPLEMENT|Citicoline and Omega-3 supplement|Citicoline and Omega-3
223412620|NCT03444662|DIETARY_SUPPLEMENT|Omega-3 supplement|Cellulose and Omega-3
223412621|NCT00624429|DRUG|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
223412622|NCT02568189|DEVICE|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
223412623|NCT03166722|OTHER|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
223412624|NCT03166722|DEVICE|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
223412625|NCT02246400|BEHAVIORAL|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
223412626|NCT03119870|OTHER|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
223412627|NCT03119870|OTHER|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
223412628|NCT03119870|OTHER|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
223412629|NCT01735461|DIETARY_SUPPLEMENT|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
224029917|NCT04641871|DRUG|Sym021|IV infusion over 30 minutes on day 1 and 15 of each cycle.
224029918|NCT04641871|DRUG|Sym022|IV infusion over 30 minutes on day 1 and 15 of each cycle.
224029919|NCT04641871|DRUG|Sym023|IV infusion over 30 minutes on day 1 and 15 of each cycle.
224029920|NCT04641871|DRUG|Irinotecan Hydrochloride|IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
224029921|NCT00509808|DEVICE|Electrostimulation|"1. 1st month GN wearing (activated or sham mode)~2. 2nd month wearing (opposite mode)~3. 3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~4. 6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~5. 9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
224029922|NCT02703493|RADIATION|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
224029923|NCT05614154|OTHER|hypochlorous active substance|Poviodin iyot
224029924|NCT05111054|OTHER|Resistance Exercise|Acute leg-based resistance exercise bout (3 sets performed to volitional failure on leg extension and leg curl machines)
224029925|NCT01545323|GENETIC|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
224029926|NCT04854668|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)；
224029927|NCT04854668|DRUG|Bevacizumab|Bevacizumab 7.5mg/kg, intravenous drip, on Day 1
224029928|NCT04854668|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, intravenous drip, on Day 1；
224029929|NCT04854668|DRUG|Capecitabine|Capecitabine 850mg/m2 administrated orally twice daily from Day 1-14.
224029930|NCT03046693|DRUG|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
224135280|NCT06117800|OTHER|TeamSTEPPS|Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
224029931|NCT03046693|DRUG|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
224135281|NCT01660087|DEVICE|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
224135282|NCT03476785|BEHAVIORAL|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
224135283|NCT03476785|BEHAVIORAL|Yoga|Subjects will perform strength and flexibility exercises.
224135284|NCT01064024|DRUG|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
224135285|NCT01064024|DRUG|Placebo|Tablets, every 8 hours for 48 hours
224135286|NCT04265586|BEHAVIORAL|Education|"Sleep hygiene education is either face-to-face appointment or video-meeting with trained nurse."
224135287|NCT04265586|BEHAVIORAL|Web-based Cognitive Behavioural Therapy (iCBT)|iCBT is a web-based programme (7-16 weeks) designed to treat the symptoms of insomnia.
224135288|NCT02114567|OTHER|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
223412630|NCT01161511|BIOLOGICAL|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
223412631|NCT03139474|DRUG|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
224029932|NCT01313689|DRUG|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
224029933|NCT01313689|DRUG|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
224029934|NCT05172349|BIOLOGICAL|LV-Visio-AMTRIX|Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
224135289|NCT06377800|OTHER|navicular mobilization along conventional therapy.|"In the prone position, when the foot is stabilized by a towel underneath, navicular mobilization is administered. The therapist's fixing hand wraps the calcaneus, grasps the talus bone, and fixes it.~By placing the thumb on the plantar surface of the foot and pushing with the thumb of the other hand in a dorsal direction, navicular mobilization is provided.~This dorsal glide will be given with 2 sets of 5 minutes. Each session will be of 30 minutes."
223412632|NCT03139474|DRUG|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach \> 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
224029935|NCT01657851|DRUG|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
223412633|NCT02157376|DRUG|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
223412634|NCT02157376|DRUG|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
223412635|NCT02824120|OTHER|Comedy|patients will watch comedy film
223412636|NCT02824120|OTHER|Documentary|patients will watch a documentary film
223412637|NCT02885220|OTHER|Conventional Program|No scheduled intermediate weight loss goals provided to patient
223412638|NCT02885220|OTHER|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
224029936|NCT01657851|DRUG|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
224029937|NCT01657851|DRUG|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
224029938|NCT00687973|DRUG|Valsartan/amlodipine 80/5 mg tablets|
224029939|NCT00687973|DRUG|Amlodipine 5 mg capsules|
224029940|NCT00687973|DRUG|Amlodipine 10 mg capsules|
224135290|NCT06377800|OTHER|conventional therapy|ultrasound therapy at 1.5 w/cm2 for 7 minutes in continuous mode at a 3MHz frequency. Stretching targets the medial arch and surrounding muscles like calf and tibialis posterior with exercises such as arch lift, heel raise, towel pickup, and toe lift. Additionally, strengthening exercises for intrinsic foot muscles like standing toe curls and towel toe curls are included. Ice pack application for 10 minutes follows
223412639|NCT04306731|DIETARY_SUPPLEMENT|Nanotechnology Structured water Magnalife|Nanotechnology Structured water Magnalife is drinking water that has been modified using nanotechnology to change the structuring of water molecules
223412640|NCT04306731|DRUG|Trimethoprim|Antibiotic
224135291|NCT00158548|DRUG|SP, chloroquine, amodiaquine, primaquine, artesunate|
224135292|NCT01912430|BEHAVIORAL|ICC (Integrated Care Coaching) Intervention Group|
224135293|NCT01627067|DRUG|Everolimus|10 mg by mouth once daily.
224135294|NCT01627067|DRUG|Exemestane|25 mg by mouth once daily.
224135295|NCT01627067|DRUG|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
224135296|NCT04972344|DIAGNOSTIC_TEST|Ionized magnesium|Assessment of ionized magnesium level
223412641|NCT04306731|DIETARY_SUPPLEMENT|Ordinary bottled drinking water|Placebo
224029941|NCT00687973|DRUG|Atenolol 50 mg tablets|
224029942|NCT00687973|DRUG|Atenolol 100 mg tablets|
224029943|NCT00512460|DRUG|RTA 744|4.8 mg/m\^2 by vein Over 2 Hours On Days 1-3.
224029944|NCT00219648|DRUG|PEP03|
224029945|NCT01959022|DRUG|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
224029946|NCT05150951|BEHAVIORAL|Novel Exploration|Exploration of a novel 3D-environment in virtual reality.
223412642|NCT01074268|DRUG|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
223412643|NCT01074268|DRUG|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
223412644|NCT01074268|DRUG|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
223412645|NCT00966992|DRUG|Zoledronic acid|
223412646|NCT03006601|OTHER|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
223412647|NCT01598844|DEVICE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
223412648|NCT03726372|DRUG|Rocuronium|rocuronium is a neuromuscular blocking agent with a duration of 40 minutes
223412649|NCT03726372|OTHER|continuous infusion|rocuronium is continuously infused
223412650|NCT03726372|OTHER|intermittent injection|rocuronium is intermittently given
223412651|NCT00880412|DRUG|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
224029947|NCT05150951|BEHAVIORAL|Threat conditioning|Session 1. Threat conditioning to two different (CS+, CS-) virtual reality contexts (i.e rooms). One of these is paired with a mild electric shock. The context paired with the electric shock (CS+) is counterbalanced across participants. Participants are instructed that they may receive electrical shocks during the procedure.
224029948|NCT05150951|BEHAVIORAL|Extinction|Session 2. Participants are repeatedly exposed to the both contexts from session 1 (CS+, CS-), but no shocks are delivered.
224029949|NCT05150951|BEHAVIORAL|Reinstatement|Session 3. Participants are again repeatedly exposed to both contexts from session 1 (CS+, CS-), after a few shocks delivered in a neutral context.
224029950|NCT05150951|BEHAVIORAL|Visual attention control task|Session 2. A visual attention task used as a control task instead of novel exploration.
224029951|NCT01656382|DRUG|ABLC|
224029952|NCT01007448|DRUG|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
223412652|NCT00880412|DRUG|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
223412653|NCT01298804|BEHAVIORAL|Problem Solving Education and Activated Referral to Care|"The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time."
223412654|NCT03858972|DRUG|Tesetaxel|Tesetaxel plus reduced dose of capecitabine
223412655|NCT03858972|DRUG|Capecitabine|Reduced dose of capecitabine
224029953|NCT04327492|DIAGNOSTIC_TEST|Biomarker - FGF 23; troponin I; PCR - high sensitivity; BNP|peak wave velocity; gray weale plaque classification
224029954|NCT02816242|OTHER|concept map teaching|teaching anatomy using concept map to improve critical thinking
224029955|NCT02816242|OTHER|traditional teaching|teaching anatomy using lecture
224029956|NCT02770573|OTHER|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
224135297|NCT01633996|PROCEDURE|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
224135298|NCT00537550|DRUG|Vincristine|Steroids pre-treatment
224135299|NCT00537550|DRUG|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
224135300|NCT01849835|PROCEDURE|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
224135301|NCT01849835|PROCEDURE|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
224135302|NCT01700517|OTHER|Spinal anesthesia|spinal anesthesia
224135303|NCT01700517|OTHER|Femoral nerve block|Femoral nerve block
224135304|NCT01700517|OTHER|sciatic nerves block|sciatic nerves block
224135305|NCT04062851|OTHER|No Gastric residual volume monitoring|Gastric residual volumes will not be monitored
224135306|NCT02215993|DRUG|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
224135307|NCT02215993|DRUG|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
223412656|NCT05457686|OTHER|kinesio tape|According to this, the proximal part of the band is located close to the lymph node. In our study, as stated in the literature, the proximal part of the tape will be adhered to the fibular head area next to the lymph nodes without applying any stretching. Then 5-10% stretching is applied and the distal part is adhered. 2 separate tapes are applied so that the strips cross each other
223412657|NCT05457686|OTHER|Sham taping|In the same procedure and time as kinesiotaping, inelastic tape will be used instead of kinesiotape.
223412658|NCT05457686|OTHER|Exercise|Routine exercise and physiotherapy program applied after knee arthroplasty surgery will be applied
223412659|NCT01578239|DRUG|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment was given to the participants until the end of study for symptom control purpose, unless the participant progressed or died.~In the active comparator arm, 60 mg Octreotide LAR treatment was given to the participants every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died."
224135308|NCT05056454|BEHAVIORAL|Online therapy with coaching within STAND|"Participants with moderate depressive symptoms on the CAT-MH (and no current suicidality) will meet with a trained coach, and receive access to online course materials from one of 2 lesson platforms - ThisWayUp's MUMentum course or UCLA DGC's ParentMood course. The efficacy of each online course will be compared for equivalency.~Participants are encouraged to practice their lesson homework for at least one week before meeting with their coach and starting the next lesson."
223412660|NCT01578239|DRUG|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.
224029957|NCT02770573|OTHER|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
224029958|NCT02770573|OTHER|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
224029959|NCT02224976|BEHAVIORAL|Intensified Training|Volunteers will increase exercise training by 30% from baseline
224029960|NCT04231942|DEVICE|Graduated Compression Stocking: continuous using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
224029961|NCT04231942|DEVICE|Graduated Compression Stocking: intermittent using|Class 1 (RAL-GZ 387 standard: 18-21 mm Hg at the ankle level) below-knee graduated compression stockings
224029962|NCT06195254|RADIATION|Stereotactic body radiotherapy (SBRT)|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions.
224029963|NCT06195254|DRUG|PD-1 blocking antibody|All the patients first received SBRT with the dose of 25Gy up to 50Gy in five fractions and then received the treatment of PD-1 blockers including pembrolizumab (200 mg every 3 weeks), carelizumab (200 mg every 3 weeks), tislelizumab (200 mg every 3 weeks), sintilimab (200 mg every 3 weeks), zimberelimab (240 mg every 3 weeks) until the tumor progressed or the side effects became intolerable.
224135309|NCT05056454|BEHAVIORAL|Clinical care within STAND|Participants with severe depressive symptoms or significant suicidality on the CAT-MH will be allocated to access clinical care, which entails weekly psychotherapy sessions and psychiatric care, when needed or appropriate. While clinical care will be available for the entire 6-month duration of the treatment component of the study, participants will be informed that on average therapy is completed within 13 sessions. The schedule of psychiatric care will be determined by the provider.
224029964|NCT06398977|DRUG|Dapagliflozin|Dapagliflozin10MG, PO once daily
223412661|NCT02302417|PROCEDURE|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
223412662|NCT02302417|OTHER|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
223412663|NCT02629939|BEHAVIORAL|course for learning CPR|
223412664|NCT04518241|BEHAVIORAL|MI sessions|"Three counseling sessions lasting less than 60 minutes each to identify goals, factors that promote or impede goals, and increase readiness for ART with high adherence"
224029965|NCT06266715|DRUG|ATP Group|Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
224029966|NCT06266715|DRUG|Placebo Group|Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
224029967|NCT02121834|DRUG|LY3050258|
224029968|NCT02121834|DRUG|Placebo|
224029969|NCT02991131|DRUG|Tedizolid (Sivextro, BAY1192631)|Antibiotic
224029970|NCT02991131|DRUG|Linezolid|Antibiotic
224135310|NCT05056454|OTHER|Perinatal Psychiatric Care|Perinatal psychiatric care involves medication management and supportive therapy for up to six months, with referrals to relevant community resources by the final visit.
224135311|NCT02504476|DRUG|AMG 581|Active drug
224135312|NCT02504476|DRUG|Placebo|Placebo
224135313|NCT02504476|DRUG|Midazolam|Interaction
224029971|NCT04918667|COMBINATION_PRODUCT|Berberine incorporated in gamma cyclodextrin|Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin
224029972|NCT04918667|DIETARY_SUPPLEMENT|Berberine|Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
224135314|NCT00926796|DRUG|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
224135315|NCT00926796|DRUG|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
224135316|NCT00926796|DRUG|Gemifloxacin|One 320 mg tablet administered orally.
224135317|NCT05414708|BEHAVIORAL|Art Therapy|During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
224135318|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler|
224135319|NCT02162485|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
224135320|NCT02162485|DRUG|Seretide Diskus|
224135321|NCT02162485|DRUG|Seretide Diskus with charcoal|
224135322|NCT01628016|BEHAVIORAL|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
224135323|NCT02801162|DEVICE|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
224135324|NCT02801162|DEVICE|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
224135325|NCT01341652|BIOLOGICAL|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
224135326|NCT01341652|BIOLOGICAL|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
223412665|NCT04518241|BEHAVIORAL|TMQQ|Weekly text messages with health information as well as motivational messages. Two days later a true/false quiz question is sent. Participants earn 4 points for answering correctly, 2 points for answering incorrectly, and 0 points for not answering. Participants earn $1 for each point. Messages are sent over 21 weeks.
223412666|NCT04518241|BEHAVIORAL|Type of compensation|Participants who achieve HIV viral suppression at 21 weeks will receive either fixed compensation of $275 or be entered into a lottery where they have a 3/10 chance of winning $500, and a 7/10 chance of winning $175. Those who do not achieve HIV viral suppression receive a $50 participant incentive.
224029973|NCT05130242|PROCEDURE|Cement-augmented Pedicle Screws (CPS)|Patients who received surgical treatment with CPS for osteoporotic fractures in the thoracic or lumbar spine
224029974|NCT05130242|PROCEDURE|Hybrid Construct (HC)|Patients who received surgical treatment with HC consisting of pedicle screws and additional hooks for osteoporotic fractures in the thoracic or lumbar spine
224029975|NCT03676231|DRUG|SGM-1019|Active
224029976|NCT03676231|DRUG|Placebo|Inactive
224029977|NCT05169320|DEVICE|Subcutaneous implantable loop recorder (ILR) implantation|All patients will undergo subcutaneous implantable loop recorder (ILR) implantation to quantify AF burden 1 month before the ablation procedure and at least 1 year after the ablation procedure.
224029978|NCT05169320|PROCEDURE|Mapping and catheter ablation|Driver regions will be identified during persistent AF using a conventional electroanatomical mapping system, multielectrode mapping catheters, and leading-driver maps generated by novel single-signal algorithms based on an automatic and accurate analysis of the instantaneous amplitude and frequency modulations displayed by atrial signals (iAM and iFM, respectively). Such maps enable the location of the spatiotemporally stable regions that drive persistent AF (leading drivers). Leading-driver regions that can be reasonably targeted/isolated with catheter ablation without high-risk of complications upon radiofrequency delivery will be targeted for ablation.
224135327|NCT06263634|OTHER|Hand exercises|30-45 minutes of home exercises consisting of stretching, mobility and strengthening
223412667|NCT05494710|OTHER|Bleomycin electrosclerotherapy treatment|The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
223412668|NCT01731119|DRUG|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
223412669|NCT03000010|DEVICE|Incisional Wound Vac|
224029979|NCT05169320|PROCEDURE|Minimally invasive surgical ablation via thoracoscopy|"This procedure will be performed only in those patients whose leading-driver maps in the previous mapping and catheter ablation procedure fulfill the following requirements:~1. Extensive atrial remodeling who will not likely get any benefit from catheter-based ablation due to too large atrial leading driver areas (≥10-15% of atrial surface), or~2. Leading drivers located at regions with high-risk of complications upon radiofrequency delivery (e.g. left and right atrial appendages, coronary sinus, in the vicinity \[≤5 mm\] of the cardiac specific conduction system).~In such patients, the leading-driver regions not completely targeted or not targeted at all in the previous index mapping and catheter ablation procedure, will be specifically ablated/isolated by minimally invasive surgical ablation techniques via thoracoscopy."
224135328|NCT02260102|DRUG|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
224135329|NCT02460757|OTHER|Laryngoscopy|Observation of glottic width in different arms
224135330|NCT00632463|BIOLOGICAL|RI-001|Dose 1
224135331|NCT00632463|BIOLOGICAL|RI-001|Dose 2
224298213|NCT03957330|BEHAVIORAL|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
224298214|NCT03074253|DIAGNOSTIC_TEST|Echocardiography|Patients are undergoing echocardiography
223412670|NCT03000010|OTHER|Standard Bandage|
223412671|NCT03828721|OTHER|Rx for Success Smartphone Application|"The Rx for Success (RS) mobile application (app) was developed by the non-profit, Children, Inc. The app is designed to be informational and motivational with both video and cueing content. The app uses a View It, Cue It, Do It model that allows parents to quickly download the smartphone app, view brief videos of age-indexed, research-based language enrichment practices; and regulate a push notification cueing program. Videos embedded in the RS app provide a summary of dialogic reading tailored for the child's age, and suggestions for encouraging verbal interactivity and social-emotional engagement through dialogic reading. Key behaviors reinforced by the app include discussing the story before reading to build interest and enthusiasm, followed by interactive reading modeled by specific types of verbal/behavioral prompts for the parent to make and responses to what the child says or does."
223412672|NCT03828721|OTHER|Control - screen time reduction|Control families will receive a new, specially designed children's book regarding limiting screen-based media use and encouraging healthy/active alternatives (Baby Unplugged: Play, Hutton/Jones, blue manatee press), which lists American Academy of Pediatrics screen time recommendations on the back cover.
223412673|NCT02347813|DRUG|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
223412674|NCT01017536|BIOLOGICAL|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
223412675|NCT01017536|BIOLOGICAL|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
223559574|NCT04457206|BEHAVIORAL|SCI Group and one-on-one services through student led occupational therapy clinic|The Collaborative Community Clinic (CCC) students collaborate with Dr. Walker to conduct the spinal cord injury/disease (SCI/D) Health and Participation Program, which consists of a combination of groups and one-on-one OT sessions serving persons with spinal cord injury and disease who are un- or under-insured. The program includes a pre-assessment session, four groups, optional individual sessions and a post-survey. Group topics include bowel/bladder management, community mobility, advocacy, transportation, promoting intimacy, adaptive parenting and finding resources. Students are involved in recruiting participants, co-leading group sessions, treatment planning and implementation for individual sessions, and development of topic-specific materials.
224029980|NCT00570050|DRUG|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
224135332|NCT00632463|BIOLOGICAL|RI-001|Placebo
224135333|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
224135334|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
224135335|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
224029981|NCT00570050|DRUG|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
224029982|NCT03155256|PROCEDURE|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
224029983|NCT03155256|PROCEDURE|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
224029984|NCT05639335|OTHER|No Character Control|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing no characters.
223412676|NCT00899119|PROCEDURE|leukapheresis|
223412677|NCT03131752|BEHAVIORAL|Elastic Resistance Intervention in Exacerbated Patients|The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
223412678|NCT01385137|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given orally
223412679|NCT01385137|OTHER|placebo|Given orally
224029985|NCT05639335|OTHER|Experimental Characters|Participants will view images of three breakfast cereals (Frosted Flakes, Apple Jacks, Froot Loops) containing their respective brand characters (e.g., Tony the Tiger) and a licensed character recently featured on these cereal brands (e.g., Buzz Lightyear).
224029986|NCT06099847|DEVICE|Sham TENS Stimulation|Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.
224029987|NCT06099847|DEVICE|Sacral TENS Stimulation|Sacral TENS stimulation have been applied to directly the skin of sacral area.
224029988|NCT01005433|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
224029989|NCT01005433|DRUG|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
224029990|NCT05031208|DIAGNOSTIC_TEST|Memory task|Word recognition task
224135336|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
224135337|NCT00586924|DRUG|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
224135338|NCT00586924|DRUG|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
224135339|NCT01609803|OTHER|laboratory biomarker analysis|Correlative studies
224135340|NCT02074579|DRUG|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
223412680|NCT01159405|RADIATION|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg \& 20 mg of GP will be injected
224135341|NCT02074579|DRUG|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
224135342|NCT02315937|PROCEDURE|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
223412681|NCT02837731|DEVICE|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
224135343|NCT06553534|OTHER|SAMURAI PICU Bundle|"The proposed multifaceted SAMURAI PICU Bundle is an intervention with the following core elements: 1) PICU Warning Tool: an automated clinical decision support (CDS) tool to provide a non-interruptive interprofessional predictive alert, 2) twice daily safety huddles with unit leadership, and 3) bedside assessment including the care team and patient's family to complete and display a bedside mitigation plan to prevent deterioration. This intervention combines the automated accurate prediction of the PICU Warning Tool with the use of provider intuition or a gut feeling from huddles to improve decision making at the bedside. Peripheral elements and possible adaptations will be suggested during Aim 1 and additional peripheral elements may be added by local sites after discussion with the PI through a user-centered design approach."
224298215|NCT03074253|DIAGNOSTIC_TEST|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
224298216|NCT03074253|DIAGNOSTIC_TEST|computed tomography|Patients are undergoing computed tomography
224298217|NCT03074253|DIAGNOSTIC_TEST|blood withdrawl|Peripheral blood samples are being collected from all patients
223412682|NCT03573973|OTHER|Improved product placement of fresh fruit and vegetables|The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.
223412683|NCT03573973|OTHER|Sham comparator|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
224298218|NCT01850186|DEVICE|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
223412684|NCT04323163|BEHAVIORAL|Physical Activity|3 sessions per week, 60 minutes per session for 6 months
223412685|NCT01779843|DRUG|Cytarabine|
223412686|NCT01779843|DRUG|Idarubicin|
223412687|NCT01779843|DRUG|Alisertib|
223412688|NCT04841395|DIAGNOSTIC_TEST|Intravaginal ejaculatory latency time (IELT), Arabic Index of Premature Ejaculation (AIPE), Morningness-Eveningness Questionnaire (MEQ)|Self-estimated intravaginal ejaculatory latency time IELT is defined as the time between the onset of vaginal intromission and the onset of intravaginal ejaculation. In the present research, self-estimated IELT duration was obtained as a result of interviews with the participants. Moreover, Arabic Index of Premature Ejaculation (AIPE), International Index of Erectile Function (IIEF-5), Pittsburgh Sleep Quality Index (PSQI) and Morningness-Eveningness Questionnaire (MEQ) were administered to all participants.
223412689|NCT01352195|BEHAVIORAL|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
223412690|NCT06479538|OTHER|Post isometric relaxation|17 participants will be in experimental group A giving them Post isometric relaxation of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
223412691|NCT06479538|OTHER|Post facilitation stretching|17 participants will be in experimental group A giving them Post facilitation stretching of Quadratus lumborum for four weeks, measuring all values before giving them protocol and after protocol.
223412692|NCT01119859|DRUG|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
223412693|NCT01119859|DRUG|Adalimumab|
224029991|NCT05695625|OTHER|Spinal anesthesia + bilateral erector spine plane block|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
224029992|NCT05695625|OTHER|Spinal anesthesia|"Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered."
224029993|NCT00888446|BIOLOGICAL|tgAAC09|
224029994|NCT00888446|BIOLOGICAL|tgAAC09|
224029995|NCT00888446|BIOLOGICAL|tgAAC09|
224029996|NCT00888446|OTHER|Formulation buffer|Sterile isotonic buffered salt solution
224029997|NCT01731509|OTHER|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
224029998|NCT02261051|OTHER|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
224029999|NCT02490202|DRUG|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
224030000|NCT02490202|DRUG|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
224030001|NCT00096720|DRUG|levodopa|
224030002|NCT00096720|DRUG|Mirapex (pramipexole)|
224030003|NCT00096720|PROCEDURE|[123I]ß-CIT and SPECT imaging|
224030004|NCT03203720|BEHAVIORAL|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
223412694|NCT01119859|DRUG|Placebo to tocilizumab|
223412695|NCT01119859|DRUG|Placebo to adalimumab|
224030005|NCT03378505|BEHAVIORAL|Mobile App|Purposeful Living Mobile App JOOL to be used daily
224030006|NCT03378505|BEHAVIORAL|Reflection|Bi-weekly online reflection question
224030007|NCT02414581|DRUG|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
224030008|NCT02414581|DRUG|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
224030009|NCT02414581|DRUG|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
224030010|NCT01603186|DRUG|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
224030011|NCT01603186|DRUG|Quetiapine Fumarate|25 mg tablet once a day
224030012|NCT02083484|BIOLOGICAL|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
224298219|NCT01850186|DRUG|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
223412696|NCT02789774|PROCEDURE|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
223412697|NCT02789774|PROCEDURE|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
223412698|NCT02263430|DEVICE|Deep Brain Stimulation|
223412699|NCT05337280|DEVICE|Imagio OA/US|Imagio optoacoustic/ultrasound
223412700|NCT01916096|DEVICE|Delica Device|
223412701|NCT03550495|BEHAVIORAL|psychiatry involvement|See arm description.
223412702|NCT04121559|BEHAVIORAL|School Interventions|"1. Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~2. Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~3. Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~4. Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~5. Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing."
223412703|NCT04121559|BEHAVIORAL|Community Interventions|"1. Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~2. Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing."
223412704|NCT04121559|BEHAVIORAL|School System Interventions|"1. Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~2. Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office."
223412705|NCT04745533|DIAGNOSTIC_TEST|Antigen detection test|To compare the results of the antigen detection test against the polymerase chain reaction in the study of contacts of COVID-19 patients during quarantine.
223412706|NCT04200651|DRUG|Dexamethasone Ophthalmic Insert|DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
224030013|NCT05831813|BEHAVIORAL|Goal-Based Cognitive Behavioural Intervention|A goal-based cognitive behavioural intervention in a group format that addresses negative social cognitions and focuses on social approach processes
224030014|NCT02077569|DRUG|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
224030015|NCT01947192|PROCEDURE|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
224030016|NCT01947192|PROCEDURE|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
224030017|NCT04246567|PROCEDURE|Mean Blood Pressure (MBP)|Mean blood pressure (MBP) for patients 50-65 mmHg
224030018|NCT04246567|DRUG|Add to 0.5 mcg / kg fentanyl.|When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
224030019|NCT01589354|PROCEDURE|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
224030020|NCT01589354|PROCEDURE|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
224030021|NCT01589354|DEVICE|Ultrasound guided technique|The block will be performed under U/S guidance
224030022|NCT01589354|DRUG|Ropivacaine|20ml of 0.375% Ropivacaine
224298220|NCT03996148|DRUG|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
223412707|NCT04200651|DRUG|Prednisolone Acetate 1% Oph Susp|Prednisolone acetate 1% eye drops are used 2-4 times daily for 30 days as the current standard of care for treating inflammation and eye pain after cataract surgery. Prednisolone, like dexamethasone, is a steroid. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.
224030023|NCT01589354|DRUG|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
224030024|NCT03975595|BEHAVIORAL|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
224030025|NCT03975595|BEHAVIORAL|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
224030026|NCT04743154|OTHER|In-hospital nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure during index admission.
224030027|NCT04743154|OTHER|After-discharge nonculprit-lesions percutaneous coronary intervention (PCI)|To perform percutaneous coronary intervention of non-culprit vessels in a staged procedure after hospital discharge.
224030028|NCT02577757|DEVICE|MRI|MRI
224030029|NCT02976454|BEHAVIORAL|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
224030030|NCT02976454|BEHAVIORAL|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
224030031|NCT02875093|DRUG|ADI-PEG 20|Investigational Medicine
224030032|NCT02875093|DRUG|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
224030033|NCT01704820|PROCEDURE|Retroflexion in the right colon|
224030034|NCT00609882|OTHER|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
224298221|NCT03996148|DRUG|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
224298222|NCT03996148|DRUG|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
223412708|NCT00588133|DRUG|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = \>6.6: reduce infusion to 1.5 mg/kg/hr"
223412709|NCT00588133|DRUG|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
224030035|NCT00609882|OTHER|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
223412710|NCT02869347|DRUG|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
223412711|NCT02869347|DRUG|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
223412712|NCT04530188|DRUG|Sevoflurane|Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)
223412713|NCT04530188|DRUG|Propofol|Intravenous sedation with propofol, as already used in our ICU
223412714|NCT05899777|OTHER|Yizhi Baduanjin|Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
223412715|NCT00105547|DRUG|MPC-7869|oral 800 mg BID
223412716|NCT00105547|DRUG|MPC-7869|Oral BID dosing
224030036|NCT03421093|PROCEDURE|Surgeries|Surgeries or surgeries plus adjuvant therapies
224030037|NCT02019927|DEVICE|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
223412717|NCT00104780|BIOLOGICAL|EP-2101|
223412718|NCT00104780|BIOLOGICAL|incomplete Freund's adjuvant|
224030038|NCT02019927|DEVICE|Sham|Sham
224030039|NCT00705354|DRUG|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
224030040|NCT00705354|PROCEDURE|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
224030041|NCT03524300|PROCEDURE|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
223412719|NCT05148676|OTHER|Residual Symptoms and the Quality of Life in Individuals Recovered from COVID-19 Infection: A Survey from Pakistan|An anonymous online survey was administrated in Pakistan from November 2020 to April 2021 in COVID-19 survivors. The questionnaire used the 12-Item Short Form Health Survey (SF-12) to assess mental and physical QoL. Multivariate linear regression was used to explore factors associated with mental and physical QoL scores.
223559575|NCT04136093|OTHER|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
224030042|NCT03524300|PROCEDURE|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
224030043|NCT00246402|DRUG|Acipimox|
223559576|NCT04136093|OTHER|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
224030044|NCT06176339|DRUG|Pentoxifylline Oral Tablet|Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
224030045|NCT06176339|DRUG|Placebo|Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
224030046|NCT00371046|PROCEDURE|Transvaginal ultrasound cervical length|
224030047|NCT00371046|PROCEDURE|Cervicovaginal fetal fibronectin|
224030048|NCT03741647|DIAGNOSTIC_TEST|sleep study and blood sample|full night polysomnographic study and blood sample to detect some genetic issues
224030049|NCT02317081|DEVICE|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
223412720|NCT04663529|OTHER|contact lens|daily disposable soft contact lens
223412721|NCT00616265|DEVICE|CPAP|Pressure device on airway to maintain it open
223412722|NCT02644954|DRUG|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
223412723|NCT02644954|DRUG|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
223412724|NCT02644954|DRUG|Topical Coal tar|Topical coal tar to be applied once daily
223412725|NCT02644954|DRUG|Topical calcipotriol|Topical calcipotriol to be applied once daily
224030050|NCT00705835|BIOLOGICAL|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
224135344|NCT05742672|OTHER|ABDOMINAL MASSAGE APPLICATION|"* Experiment group twice a day in the morning and evening and 30 minutes after the feeding meal, for 15 minutes. For a period of time, effusion, petrissage, vibration massage movements will be applied by the researcher in accordance with the procedure (Abdominal Massage Application Directive). The application will continue for 7 days.- On the 3rd day (short term), 5th day (mid term) and 7th day (long term) to the massaged experimental group, the Constipation Severity Scale (CQS) and the Constipation Quality of Life Scale (QQQL) will be administered to determine the effect.~* Day 7 Rome Ш Constipation Diagnostic Criteria (Annex: 2) will be applied again and the patient's constipation status will be evaluated for the last time.~* Routine treatment and care practices in the clinic will continue."
224298223|NCT01740635|DEVICE|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
224298224|NCT02216513|DRUG|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
224030051|NCT02546895|OTHER|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
224030052|NCT05488574|OTHER|Deep breathing with Yoga positioning|Deep breathing with yoga positioning 10min in morning, 1 minute noon, and 1 minute evening (diner)
223559577|NCT04136093|OTHER|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
224030053|NCT05041855|BEHAVIORAL|The Healthy Living Program/La Vida Saludable|A whole-family group childhood obesity intervention delivered at community recreation centers
224030054|NCT05041855|BEHAVIORAL|Recommended Treatment of Obesity in Primary Care|A healthy lifestyle counseling protocol that enhances usual primary care
224030055|NCT04716530|OTHER|No intervention is associated with the study.|No intervention is associated with the study.
224030056|NCT02373553|OTHER|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
224030057|NCT02373553|OTHER|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
224030058|NCT00977054|DRUG|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
224030059|NCT00977054|DRUG|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight \< 75 kg, 1,000 mg/day; body weight loss \>= 75 kg, 1,200 mg/day)
224030060|NCT04371861|DEVICE|Peripheral Artery Treatment|Peripheral lesions may be treated by any standard of care methods of treatment.
223559578|NCT05107635|DEVICE|AtriCure Commercially Available Devices|Epicardial and endocardial hybrid ablation procedure used to treat the IST or POTS using AtriCure commercially available devices.
223559579|NCT02465788|DEVICE|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
223559580|NCT04646746|DIETARY_SUPPLEMENT|100% wheat|100 g of bread backed with 100% wheat
224030061|NCT01173198|DEVICE|WAVEFRONT Optimized LASIK|30 patients
224030062|NCT01173198|DEVICE|WAVEFRONT GUIDED LASIK|30 patients
224030063|NCT01354171|DEVICE|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
224030064|NCT02917278|DIETARY_SUPPLEMENT|Meals|High Protein renal-specific meals
224030065|NCT03549312|DRUG|Genvoya|"Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48."
224030066|NCT03549312|DRUG|Epclusa|"HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96."
224135345|NCT06187844|PROCEDURE|Inguinal exploration|Inguinal exploration will be done for all the included patients.
224298225|NCT02216513|DRUG|placebo|normal saline IV for 4 hours for 5 consecutive days
223559581|NCT04646746|DIETARY_SUPPLEMENT|50% nude barley and 50% wheat|100 g of bread backed with 50% nude barley and 50% wheat
223559582|NCT04646746|DIETARY_SUPPLEMENT|75% nude barley and 25% wheat|100 g of bread backed with 75% of nude barley and 25% wheat
223559583|NCT04646746|DIETARY_SUPPLEMENT|50% gene-modified high-amylose barley and 50% wheat|100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
224135346|NCT06187844|PROCEDURE|Laparoscopy|All patients will have abdominal laparoscopy first to assess the location of the impalpable testis, the inguinal canal and the cord structures.
223412726|NCT04133701|BEHAVIORAL|Time-Restricted Feeding|After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
223412727|NCT02263560|BEHAVIORAL|Kinematic measurements|
223412728|NCT00975182|DRUG|GDC-0941|Oral repeating dose
223412729|NCT00975182|DRUG|erlotinib HCl|Oral repeating dose
223412730|NCT01394731|DRUG|Acetaminophen|
223559584|NCT03159676|RADIATION|Proton beam|Proton beam
223559585|NCT01918605|DEVICE|Diluted spacer|
223559586|NCT01918605|DEVICE|Non-diluted spacer|
223559587|NCT02964884|DRUG|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
224030067|NCT03549312|DRUG|Biktarvy|"Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96."
224030068|NCT04270630|BEHAVIORAL|Shared Decision Aid|The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
224030069|NCT02238522|DRUG|ZEN003365|
224030070|NCT04727853|DRUG|irinotecan liposome injection|Drug: irinotecan liposome injection
224030071|NCT02231853|BIOLOGICAL|MVST|MVST Infusion
224135347|NCT02069496|BIOLOGICAL|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
224135348|NCT04167306|DRUG|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
224135349|NCT04167306|DRUG|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
224135350|NCT04167306|OTHER|Placebo for varenicline|Capsules for oral use
224135351|NCT04167306|OTHER|Placebo for bupropion|Capsules for oral use
224135352|NCT00129350|PROCEDURE|Pulmonary rehabilitation programme|
223412731|NCT01394731|DRUG|Meperidine|
223412732|NCT03055780|DEVICE|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
223412733|NCT06283329|DIAGNOSTIC_TEST|vocal cords echography|Ultrasound assessments of the amplitude of the vocal cords movement were performed on a sagittal median section of the arytenoid cartilages with a 30° inclination using a Golf Head ultrasound probe at 3 different time points: before induction (T0), after extubation (T1), in recovery room 30 minutes after extubation(T2). We have defined H0, H1 and H2, the maximum course of the vocal cords measured respectively at T0, T1 and T2
223412734|NCT02174263|BIOLOGICAL|tocilizumab|Given IV
223412735|NCT02174263|OTHER|laboratory biomarker analysis|Correlative studies
224135353|NCT05688579|DRUG|Mineralocorticoid Receptor Antagonists(MRAs)|Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
223412736|NCT02174263|OTHER|quality-of-life assessment|Ancillary studies
223412737|NCT02369965|DRUG|albuvirtide|albuvirtide 320mg administered intravenously once a week
223412738|NCT02369965|DRUG|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
223412739|NCT02369965|DRUG|tenofovir|tenofovir 300mg administered orally once daily
223412740|NCT02369965|DRUG|lamivudine|lamivudine 300mg administered orally once daily
223412741|NCT05832684|DRUG|ZVS101e|ZVS101e contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human wild type CYP4V2 gene.
223559588|NCT02964884|BEHAVIORAL|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
223559589|NCT02964884|DRUG|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
223559590|NCT02964884|BEHAVIORAL|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
223559591|NCT01332591|PROCEDURE|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
223559592|NCT05503095|GENETIC|Genetic analysis for PCSK9 polymorphisms|Determination of PCSK9 gene polymorphism and serum PCSK9 concentration
223559593|NCT01781793|OTHER|Room air|Humidified room air (21% oxygen) will be inspired
224135354|NCT05688579|OTHER|Blank control|Participants will be treated with the original antihypertensive drugs for 48 months.
223559594|NCT01781793|OTHER|Hyperoxia|60% oxygen will be inspired
223559595|NCT05594225|BEHAVIORAL|Virtual Neuromuscular/Dual-Task Training|The vNDTT strategy incorporates lower body strength exercises with landing stabilization focus. Exercises will begin after the initial study visit and last for 8 weeks.
223559596|NCT01574820|DRUG|placebo tablet|placebo tablet for 6 months
223559597|NCT01574820|DRUG|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
224135355|NCT03060603|DRUG|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
224135356|NCT04186000|BIOLOGICAL|Ad26.ZEBOV vaccine|The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
224298226|NCT02802449|DRUG|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 \[also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3\] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
223412742|NCT03404037|DIAGNOSTIC_TEST|serum endostatin level|"An oral (metoprolol 20 mg) was given to the patients with heart rates \> 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R\&D Systems, Minneapolis, Minnesota, USA"
224030072|NCT02231853|BIOLOGICAL|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
224030073|NCT00506233|BEHAVIORAL|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
224030074|NCT05620251|DIAGNOSTIC_TEST|Blood test|Assessment of humoral immune response
224030075|NCT00158899|DRUG|GW501516 oral tablets|
224030076|NCT05694572|DEVICE|Implantation of a CIED|Implantation of a CIED
224135357|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
224135358|NCT04013438|DRUG|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
224298227|NCT02802449|DRUG|Placebo|
224298228|NCT01375153|DRUG|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
224298229|NCT01375153|DRUG|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
224298230|NCT06337253|DRUG|Sulfadoxine/pyrimethamine plus amodiaquine|Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.
224298231|NCT03183648|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
224030077|NCT05647850|OTHER|No intervention|No intervention
224298232|NCT00003224|BIOLOGICAL|QS21|vaccine adjuvant
223412743|NCT02946554|BIOLOGICAL|HepaStem|
223412744|NCT03225105|DRUG|M3541|Participants received M3541 orally once per fraction day (FD) for two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as M3541 holidays).
223412745|NCT03225105|RADIATION|Palliative Radiotherapy (RT)|Participants received RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Friday, with Saturday and Sunday as RT holidays).
223412746|NCT02922751|OTHER|Liver Stiffness Measurement (LSM)|LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
224030078|NCT01285050|DRUG|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
224030079|NCT01285050|DRUG|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
224030080|NCT01285050|DRUG|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
224030081|NCT04318951|BEHAVIORAL|Intensive communicative-pragmatic social interaction.|"ILAT requires individuals with aphasia to engage in social interaction. Groups of three patients and a therapist are seated around a table and provided with picture cards showing different objects (e.g., bottle). Each card has a duplicate that is owned by one of the other players. The goal is to obtain this duplicate from a fellow player by requesting the depicted object (e.g., Give me the \[…\]). If the duplicate is available, the addressee hands over the corresponding card to the person who initiated the request sequence. If the duplicate is not available, the addressee rejects the request. In the event of misunderstandings, the players ask clarifying questions. Throughout the training, participants use formulaic expressions to indicate whether a request is accepted (Here you are, Thank you, You're welcome), rejected (I'm sorry, No problem, Too bad) or unclear (Pardon me?). Treatment duration will be four weeks."
224030082|NCT04318951|BEHAVIORAL|Standard care.|Depending on the participants' diagnoses and needs, standard care will include: occupational therapy (2-3 hours of weekly practice), physiotherapy (3 hours of weekly practice), and speech-language therapy (2-3 hours of weekly practice with non-communicative, impairment-specific exercises). Standard care will be delivered in accordance with state-of-the-art procedures in rehabilitation centers certified in Germany. Treatment duration will be four weeks.
224030083|NCT00767273|PROCEDURE|PET Scan|
223412747|NCT05661474|DRUG|Fitostimoline ® hydrogel group|Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
223412748|NCT05661474|DRUG|Saline gauze group|Treatment of DFUs with saline gauze every day for 12 weeks.
223412749|NCT05238727|DRUG|1.8 ml mepivacaine hydrochloride|1.8 ml mepivacaine IANB
223412750|NCT05238727|DRUG|3.6 ml mepivacaine hydrochloride|3.6 ml mepivacaine IANB
223412751|NCT05238727|DRUG|1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI|1.8 ml mepivacaine IANB plus 1.8 ml articaine BI
223412752|NCT01772173|OTHER|Vessel measurements|Measurement of retinal vessels
223412753|NCT01925729|BIOLOGICAL|ragweed|ragweed arm only
223412754|NCT01925729|BIOLOGICAL|histamine|histamine arm only
223412755|NCT01925729|DRUG|pseudoephedrine|pseudoephedrine arm only
224030084|NCT00767273|DRUG|FLT|
224030085|NCT00767273|DRUG|FDG|
224030086|NCT03030703|DIETARY_SUPPLEMENT|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
224030087|NCT04051788|OTHER|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
224135359|NCT00127062|OTHER|Oxford street|2 h walk around Oxford street
223412756|NCT01925729|DRUG|Oxymetazoline|oxymetazoline arm only
223412757|NCT04527692|OTHER|Questionnaire|semi-structured interviews on the quality of life
223412758|NCT05498129|OTHER|School meal|School lunch was comprised of rice, ghee and beef
224030088|NCT04051788|OTHER|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
224030089|NCT05891912|OTHER|Technological devices intervention (use of tablet and big screen with games oriented to training physical and cognitive function)|"The treatment will be performed in 30 min sessions, twice a week during 12 weeks. the weekly sessions will include the following games:~* 1 session per week: 15min small TABLET and 15min LIGHTS game.~* 1 session per week: 15min TABLE TABLET and 15min game of VINTAGE."
224135360|NCT00127062|OTHER|Hyde park|2 h walk around Hyde park
223412759|NCT05498129|OTHER|School meal plus micronutrient powder|School lunch plus micronutrient powder
224135361|NCT00840944|DRUG|somatropin|somatropin 0.050 mg/kg/day
223412760|NCT05498129|OTHER|No school meal|No school meal
223412761|NCT03093194|OTHER|vaginal preparation before CS with Septal soap and septol.|vaginal preparation before CS with Septal soap and septol.
223412762|NCT03093194|OTHER|No vaginal preparation before CS with Septal soap and septol.|No vaginal preparation before CS with Septal soap and septol.
223412763|NCT01889329|DIETARY_SUPPLEMENT|RUTF-1|Made from local food ingredients
223412764|NCT01889329|DIETARY_SUPPLEMENT|RUTF-2|Made from local food ingredients
223412765|NCT01889329|DIETARY_SUPPLEMENT|Plumpynut|Commercially made from peanut paste
223412766|NCT00252291|DRUG|Aridol|
223412767|NCT00252291|DRUG|Methacholine|
223412768|NCT00252291|PROCEDURE|Exercise challenge|
223412769|NCT02320305|BIOLOGICAL|MART-1 Antigen|Given IM
223412770|NCT02320305|DRUG|TLR4 Agonist GLA-SE|Given IM
223412771|NCT02320305|OTHER|Laboratory Biomarker Analysis|Correlative studies
223412772|NCT02913677|DIETARY_SUPPLEMENT|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
223412773|NCT01820598|DEVICE|Multisite NMES training during 6 weeks|
223412774|NCT06450327|OTHER|This is a cross-sectional observational study|There will be no intervention in the study.
223412775|NCT05060276|BIOLOGICAL|STI-3258|Intravenous infusion of STI-3258 will be given (one infusion every three weeks).
223412776|NCT01171027|PROCEDURE|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
224030090|NCT02367365|OTHER|No Intervention|No intervention
224030091|NCT02367365|OTHER|No Intervention|No intervention
224030092|NCT06161935|OTHER|no intervention|no intervention, it is a retrospective study .
224030093|NCT03954795|PROCEDURE|TAP|Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
224030094|NCT03954795|PROCEDURE|OSTAP|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
224030095|NCT00343135|DRUG|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
224135362|NCT00840944|DRUG|triptorelin|triptorelin 3.75 mg each month
224135363|NCT03132480|OTHER|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
224135364|NCT05596968|DRUG|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
224135365|NCT06244940|DIAGNOSTIC_TEST|Whole Genome Sequencing (WGC) from subject samples|Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
223412777|NCT01171027|PROCEDURE|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
223412778|NCT02887976|DRUG|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
223412779|NCT02887976|DRUG|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
223412780|NCT03278327|PROCEDURE|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
223412781|NCT03278327|DEVICE|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
223412782|NCT04050852|DRUG|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
224030096|NCT06130748|DEVICE|Hybrid Hyrax|these patents will be treated using Two mini-screws supported hybrid hyrax
223412783|NCT02011633|DRUG|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
223412784|NCT02011633|DRUG|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
223412785|NCT02011633|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
223412786|NCT00634361|DRUG|ethyl-eicosapentaenoic acid|2 mg per day
223412787|NCT02354677|OTHER|In vitro experiments on bronchial epithelial cells|
223412788|NCT00874627|OTHER|Milk|sublingual administration of milk
223559598|NCT06196658|DRUG|anti-EX02 CAR T cells|"Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg"
223559599|NCT05392673|OTHER|KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)|Artificial liver scavenges inflammatory factors.
223559600|NCT04882878|OTHER|Placebo|Placebo will be administered intravenously.
223559601|NCT04882878|DRUG|Nipocalimab|Nipocalimab dose 1 and dose 2 will be administered intravenously.
223559602|NCT04882878|DRUG|Standard-of-care treatment|Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
223559603|NCT01780246|DRUG|nusinersen|Administered by intrathecal (IT) injection
224030097|NCT00297570|DRUG|Pegylated Interferon and Imatinib|
224030098|NCT01423253|DRUG|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
224030099|NCT06101433|DIETARY_SUPPLEMENT|Soy isoflavone|the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
224030100|NCT06101433|OTHER|Placebo|the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
224030101|NCT00470145|DRUG|SB-568859|
224030102|NCT05448781|DRUG|Endostatin|Eligible patients with advanced NSCLC were treated with endostatin combined with Tirelizumab and platinum-containing two-drug chemotherapy.26 cases of non-squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Pemetrexed+Carboplatin. and 12 cases of squamous cell carcinoma were treated with endostatin combined with Tirelizumab and Paclitaxel/Albumin paclitaxel+Carboplatin,The maintenance treatment phase was continuous treatment with Endu combined with Tirelizumab
224030103|NCT00701077|DRUG|3,4-Di-amino-Pyridine|a single 20 mg dosing
224030104|NCT00701077|DRUG|placebo|placebo
224030105|NCT03519165|DEVICE|EV1000(FloTrac System 4.0)|
224030106|NCT01519466|DEVICE|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
224030107|NCT01519466|DEVICE|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
224030108|NCT00307125|DRUG|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
224030109|NCT00307125|DRUG|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
223412789|NCT00874627|OTHER|Milk|placebo
223412790|NCT02550782|DRUG|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
223412791|NCT02550782|DRUG|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
223412792|NCT04215627|DEVICE|non-invasive monitoring|Comparing the PiCCO monitor to the non-invasive BB-613PW device in hemodynamically unstable critically ill patients in the ICU
223412793|NCT04273529|DRUG|thalidomide|100mg，po，qn，for 14 days.
224030110|NCT02844049|DEVICE|Deep Brain Stimulation|surgical procedure
224030111|NCT02007889|DRUG|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
223412794|NCT04273529|DRUG|placebo|100mg，po，qn，for 14 days.
223412795|NCT00874874|DRUG|sorafenib tosylate|
223412796|NCT01106560|PROCEDURE|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
223412797|NCT01106560|PROCEDURE|Standard postero-lateral approach|
223412798|NCT05504980|PROCEDURE|Repositioning|Patients in the intervention group will be given 30 degrees right lateral, supine, and 30 degrees left lateral positions, 1 hour apart, respectively.
223412799|NCT03771560|DRUG|folinic acid|subject will take folinic acid daily for 12 weeks
223412800|NCT03111680|OTHER|environmental intervention|a multi component environmental intervention
223412801|NCT01095562|DRUG|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
223412802|NCT01095562|DRUG|Placebo|Placebo
223412803|NCT02744729|DRUG|99mTc-3PRGD2|For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
223412804|NCT03917446|DRUG|Propofol bolus|Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
223412805|NCT01653821|PROCEDURE|Carotid body excision|
223412806|NCT02499211|OTHER|Intervention stores|"In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them."
223412807|NCT04124211|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
223412808|NCT02887183|DRUG|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
223412809|NCT01182051|BEHAVIORAL|CBT or relaxation training|8 weeks of CBT or relaxation training.
223412810|NCT05586347|DRUG|Nicardipine|Nicardipine 0.2-0.5μg/(kg·min) was infused at the beginning of CPB.
223412811|NCT05586347|OTHER|normal saline|It has the same capacity as group N。
224030112|NCT01279096|DRUG|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
224030113|NCT00051363|DEVICE|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
224030114|NCT00051363|DEVICE|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
224030115|NCT03545009|DIETARY_SUPPLEMENT|Sodium Nitrate|70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
223412812|NCT04412109|PROCEDURE|thoracic epidural catheterization|thoracic epidural catheterization for postoperative pain control
223412813|NCT02063477|DIETARY_SUPPLEMENT|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
223412814|NCT02063477|DIETARY_SUPPLEMENT|Oligopin®|"Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~\- TOTAL POLYPHENOL CONTENT \> 96~1. MONOMERS + PHENOLIC ACIDS 30~2. DIMERS \>15~3. OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) \> 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule"
224030116|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice no Nitrate|70ml Concentrated Beetroot Juice with nitrate removed
224030117|NCT03545009|DIETARY_SUPPLEMENT|Beetroot Juice|70ml Concentrated Beetroot Juice
224030118|NCT02831205|DEVICE|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
224030119|NCT02831205|DEVICE|everolimus-eluting cobalt-chromium (Xience) stent|
224030120|NCT06085651|PROCEDURE|Selective thoracolumbar fusion (STLF) surgery|Selective thoracolumbar fusion (STLF) surgery, is an established corrective surgical technique for spinal deformities with excellent outcomes over time
224030121|NCT02154789|DRUG|polidocanol|
224135366|NCT01513226|OTHER|Cycled light|lights on at daytime, lights off at nighttime
224135367|NCT03205826|OTHER|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
224135368|NCT02562248|OTHER|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
223412815|NCT05822076|PROCEDURE|Paravertebral block (ropivacaine) left|Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
223412816|NCT05822076|PROCEDURE|Paravertebral block (ropivacaine) right|Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. 0.5% Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients
224030122|NCT02154789|PROCEDURE|infra-red coagulation|
224030123|NCT02154789|PROCEDURE|cryotherapy|
224135369|NCT02562248|OTHER|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
224135370|NCT00383422|DRUG|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
224135371|NCT00383422|DRUG|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
224298233|NCT00003224|BIOLOGICAL|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
224298234|NCT00003224|BIOLOGICAL|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
223412817|NCT02746965|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
223412818|NCT02746965|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
223412819|NCT02746965|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
223559604|NCT02434653|OTHER|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
223559605|NCT02434653|OTHER|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
224030124|NCT04669977|DIETARY_SUPPLEMENT|Mulberry juice|One bottle (600ml/bottle) of sanitized mulberry juice would be sent to participants of the auxiliary group with instructions to consume 50ml of juice diluted with drinking water at room temperature. Also, a reminder of the next clinical visit is attached. They are expected to finish the mulberry juice in 10 to 11days instead of 12 days.
224030125|NCT04258527|DRUG|Pemigatinib|Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
224030126|NCT04158596|DEVICE|Vibration Therapy|SDX-3101 is used for drug-free treatment of CRSsNP in adults.
224030127|NCT01975454|DRUG|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
224030128|NCT01975454|DRUG|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
224030129|NCT04370457|OTHER|Administration of the MyPal ePRO system|Patients will be asked to complete self-report questionnaires at baseline, and every month for the first six months and at 12-month follow-up
224030130|NCT04311060|DIAGNOSTIC_TEST|Molecular panel|"* Detection of CBF rearrangements using PCR: CBFB-MYH11 \[inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22).~* NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT"
224030131|NCT01210079|DRUG|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
224030132|NCT01210079|DRUG|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
224030133|NCT04646512|DIETARY_SUPPLEMENT|Taurine group and exercise and placebo group and exercise|Both groups supplemented with taurine and / or placebo will perform physical training.
224135372|NCT04048525|PROCEDURE|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
224135373|NCT04048525|PROCEDURE|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
224135374|NCT06484439|DRUG|Ketorolac|10 mg PO q 6h scheduled
224135375|NCT06484439|DRUG|Oxycodone|5 mg PO PRN
223412820|NCT01277627|DRUG|Nevirapine|nevirapine: 400 mg a day.
223412821|NCT01277627|DRUG|efavirenz, protease inhibitors|efavirenz: 600 mg a day
223559606|NCT02363972|DEVICE|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
223559607|NCT02314156|DRUG|Telapristone Acetate|Given transdermally
223559608|NCT02314156|OTHER|Placebo|Given PO
223559609|NCT02314156|DRUG|Telapristone Acetate|Given PO
223559610|NCT02314156|OTHER|Placebo|Given transdermally
223559611|NCT02314156|OTHER|Laboratory Biomarker Analysis|Correlative studies
223559612|NCT02314156|OTHER|Questionnaire Administration|Ancillary studies
223559613|NCT06351774|BEHAVIORAL|Physical therapy|Physical therapy for the treatment of chronic low back pain, as directed by a licensed Physical Therapist. The Healthy Minds Innovations (HMI) program is an app-based learning platform developed through the University of Wisconsin-Madison Center for Healthy Minds. The HMI app includes foundational meditation practices and short podcast-style lessons based on the science of wellbeing to cultivate mindfulness, positive relationships, and insight into the nature of the self.
223559614|NCT04342949|BEHAVIORAL|quality of life|To observe the difference of quality of life
224030134|NCT04646512|OTHER|Physical training with Deep Water Running|There will be a physical training for eight weeks.
224030135|NCT00147823|DEVICE|Vitoss Alone|Synthetic bone graft material
224030136|NCT00147823|DEVICE|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
224030137|NCT00979433|DEVICE|Bubble CPAP|Bubble CPAP will be delivered using Fischer \& Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
224030138|NCT00979433|DEVICE|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
224030139|NCT06233721|OTHER|Online education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as oral anticoagulant (OAC) medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
224030140|NCT06233721|OTHER|Face-to-face education|Education content was prepared by the researchers by reviewing the literature. Education content included topics such as OAC medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
224030141|NCT04256382|OTHER|dementia pain care education|Participants are educated about dementia pain care.
224030142|NCT04256382|OTHER|dementia care education|Participants are educated about dementia pain care.
224030143|NCT00367120|DRUG|Azithromycin Extended Release|
224135376|NCT06484439|DRUG|Acetaminophen|650 mg q 6h scheduled
224135377|NCT06484439|DRUG|Ibuprofen|600 mg PO scheduled q6h
224135378|NCT06484439|DRUG|Hydrocodone|5 mg hydrocodone PO PRN q6h
224135379|NCT02520622|BEHAVIORAL|Digital photographs loaded onto a mobile device|
224135380|NCT02520622|BEHAVIORAL|Skin exam reminders|
224135381|NCT02520622|BEHAVIORAL|Social support network|
224135382|NCT01269372|DEVICE|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
223412822|NCT01031680|DRUG|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
223412823|NCT01031680|DRUG|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
223412824|NCT04044040|BEHAVIORAL|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
223559615|NCT02317601|DRUG|methylprednisolone sodium succinate|Single dose Intravenous
223559616|NCT02317601|DRUG|placebo saline|
224030144|NCT00367120|DRUG|Amoxicillin/Clavulanate|
224030145|NCT02426879|PROCEDURE|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
224030146|NCT01032382|DRUG|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
224030147|NCT01032382|DRUG|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
224030148|NCT02211144|DRUG|BIBR 796 BS|
224030149|NCT02211144|DRUG|Placebo|
224030150|NCT00412971|DRUG|Hexvix|Single installation, TURB
224135383|NCT01269372|DEVICE|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
223412825|NCT06178211|DRUG|Immunotherapy: Adebrelimab|Adebrelimab 1200mg Q3W
223412826|NCT06178211|DRUG|chemotherapy: carboplatin plus nab-paclitaxel|carboplatin plus nab-paclitaxel
223559617|NCT02382731|BEHAVIORAL|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
224030151|NCT00412971|OTHER|Standard white light cystoscopy|
224030152|NCT04746443|OTHER|NOT APPLICABLE (NA)|THE INTERVENTION GROUP IS NOT APPLICABLE TO THE CURRENT STUDY DESIGN
224135384|NCT01463904|PROCEDURE|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
224135385|NCT05054673|OTHER|universal adhesive|PALFIQUE universal adhesive
224135386|NCT05054673|OTHER|universal adhesive|3M™ ESPE™ single bond Universal Adhesive
224135387|NCT03798444|RADIATION|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
224135388|NCT03798444|RADIATION|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
223559618|NCT02382731|BEHAVIORAL|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
223559619|NCT02250794|DRUG|metformin and sitagliptin|metformin 750 mg PO twice daily
224030153|NCT00002566|DRUG|carboplatin|
224030154|NCT00002566|DRUG|cisplatin|
224030155|NCT00002566|DRUG|cyclophosphamide|
224030156|NCT00002566|DRUG|etoposide|
224030157|NCT00002566|DRUG|ifosfamide|
224030158|NCT00002566|DRUG|vinblastine sulfate|
224030159|NCT00002566|PROCEDURE|autologous bone marrow transplantation|
223412827|NCT03515005|BEHAVIORAL|Lay Health Advisor|Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
224030160|NCT00002566|PROCEDURE|conventional surgery|
224030161|NCT00002566|PROCEDURE|peripheral blood stem cell transplantation|
224030162|NCT02963181|DRUG|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
224030163|NCT02963181|DRUG|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
224030164|NCT00028743|DRUG|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
224030165|NCT00028743|DRUG|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
224030166|NCT00028743|DRUG|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
224030167|NCT00028743|DRUG|topotecan hydrochloride|"4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
224030168|NCT06236282|DEVICE|ArtiSential®|Articulated laparoscopic device made by Livsmed Co, South Korea.
224030169|NCT04572412|RADIATION|Low dose Radiotherapy|"External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved."
223412828|NCT01812954|DRUG|Methotrexate|
223412829|NCT01812954|DRUG|Cyclosporins|
223412830|NCT01812954|DRUG|fumaric acid|
223412831|NCT01812954|DRUG|Acitretin|
223412832|NCT01812954|DRUG|Infliximab|
223559620|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin glargine given once daily
224030170|NCT04722926|OTHER|PJI|patients having had a PJI managed at the CRIOAc Lyon, with or without relapse
224030171|NCT05863858|DRUG|Sequential Regimen: Levofloxacin 500 mg BID, Amoxicillin 1 gm BID, omeprazole 20 mg BID for first five days followed by Levofloxacin 500 mgBID, Tinidazole 500 mg BID, Omeprazole 20 mg BID|The eradication rate of H. Pylori with levofloxacin-based sequential therapy
224030172|NCT05863858|DRUG|Triple Regimen: Moxifloxacin 400mg OD, Amoxicillin 1 gm BID, Omeprazole 20mgBID|The eradication rate of H. Pylori with moxifloxacin-based triple therapy
224030173|NCT01504750|PROCEDURE|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
224030174|NCT05263479|DRUG|HS-20089 (Phase Ia：Dose escalation )|Participants will receive HS-20089 in 21 day dosing cycles. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
224030175|NCT05263479|DRUG|HS-20089 (Phase Ib: Dose expansion)|IV administration of HS-20089 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
224030176|NCT05803655|OTHER|36-hour duration between ovulation triggering and oocyte pick-up procedure|36-hour duration between ovulation triggering and oocyte pick-up procedure
224030177|NCT05803655|OTHER|38-hour duration between ovulation triggering and oocyte pick-up procedure|38-hour duration between ovulation triggering and oocyte pick-up procedure
224135389|NCT04146467|DEVICE|Renuvion APR Device|The Renuvion APR Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Renuvion APR Handpiece has a non-extendable electrode to generate helium plasma.
224135390|NCT02902744|DRUG|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
224135391|NCT02202096|OTHER|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
224135392|NCT02202096|OTHER|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
224135393|NCT02202096|OTHER|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
224135394|NCT02202096|OTHER|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
224135395|NCT02202096|OTHER|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
223559621|NCT02250794|DRUG|metformin and sitagliptin|sitagliptin 100 mg PO once daily
224135396|NCT02202096|OTHER|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
223412833|NCT01812954|DRUG|etanercept|
223412834|NCT01812954|DRUG|Adalimumab|
223412835|NCT01812954|DRUG|Ustekinumab|
223412836|NCT00047073|DRUG|Rapamycin|"Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same."
223412837|NCT00047073|PROCEDURE|Surgery|Surgical resection.
223559622|NCT02250794|DRUG|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
224030178|NCT03939091|DIAGNOSTIC_TEST|Ultrasonography|Renal Ultrasonography
224030179|NCT01098136|OTHER|Chiropractic|Manual treatment of musculoskeletal complaints
224030180|NCT01098136|OTHER|Conventional medical intervention|Medical, physiotherapy
224030181|NCT01098136|OTHER|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
224030182|NCT02540057|PROCEDURE|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
224030183|NCT02540057|PROCEDURE|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
224135397|NCT02202096|OTHER|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
224135398|NCT02202096|OTHER|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
224135399|NCT02202096|OTHER|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
224135400|NCT02202096|OTHER|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
224135401|NCT02202096|OTHER|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
224135402|NCT02163304|OTHER|Sucrose|
224135403|NCT02163304|OTHER|Artificial Sweetner|
224135404|NCT02163304|OTHER|Tasteless Solution|
224135405|NCT01114958|DRUG|Cisplatin, Thiosulfate|Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
224135406|NCT03689504|DIETARY_SUPPLEMENT|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
224135407|NCT03689504|BEHAVIORAL|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
223412838|NCT00047073|PROCEDURE|Supportive Care|"Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented."
223412839|NCT01905527|OTHER|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
223559623|NCT06510179|OTHER|Toothbrushing|Patients brush their teeth using the technique instructed to them using the toothbrush provided.
224030184|NCT02571049|DRUG|DFN-11|Sumatriptan 3 mg versus 6 mg
224030185|NCT02319577|DRUG|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
224030186|NCT02319577|DRUG|Gefitinib|EGFR tyrosine kinase inhibitor
224030187|NCT02954068|DRUG|IV Oxytocin + IM placebo|
224030188|NCT02954068|DRUG|IM Oxytocin + IV placebo|
224030189|NCT00137124|DRUG|L-Arginine|oral administration of L-arginine for 4 weeks
224030190|NCT01055262|DEVICE|Heatwrap 1|8 hours continuous topically-applied heat
224030191|NCT00290043|DRUG|Insulin glulisine|
224030192|NCT06270472|PROCEDURE|hernioplasty|"The polysome repair was carried out as described by pelisse . In the case of a lateral hernia, the spermatic cord was mobilised and the cremasteric fibers were separated (in men). The hernia sac was dissected from the cord structures and reduced in the preperitoneal space through the internal ring. A dissection gauze was inserted through the internal ring to create the preperitoneal space. The medial border of the internal ring and the epigastric vessels were lifted with a refractor and blunt digital dissection was carried out in the preperitoneal space in all directions. A pocket was created to allow a complete expansion of the mesh. The conventional mesh was introduced with blunt forceps and, after the gauze has been removed, positioned in the preperitoneal space .~In the case of a medial hernia, the preperitoneal space was reached by incising the transversalis fascia around the base of the sac. Completion of the repair is the same as the lateral hernia procedure."
224030193|NCT02072447|DRUG|YH4808 PO and [14C]-YH4808 IV|
224135408|NCT03689504|BEHAVIORAL|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
224135409|NCT06185218|OTHER|Intravesical Botulinum Toxin|Botulinum Toxin injections will be made into the bladder.
224135410|NCT05557955|OTHER|Breathing test|Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
224135411|NCT04103255|OTHER|High frequency and intensive prevention program|This study is a 4 week non-randomized controlled trial (RCT)
224135412|NCT02537379|DRUG|SOF|SOF 400 mg tablets administered orally once daily
223412840|NCT01905527|OTHER|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
223412841|NCT01905527|OTHER|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
224030194|NCT03500250|OTHER|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
224030195|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
224030196|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
224030197|NCT04188691|BIOLOGICAL|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）|Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
223412842|NCT06355076|PROCEDURE|New urethral reconstruction|This kind of reconstruction suture has larger area, higher firmness, better fixation of the position of broken end and prolongation of functional length.
223412843|NCT01030289|DEVICE|real tDCS|transcranial direct current stimulation
223412844|NCT01030289|DEVICE|sham tDCS|transcranial direct current stimulation
224030198|NCT04188691|BIOLOGICAL|Normal saline|Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
224030199|NCT04188691|BIOLOGICAL|Aluminum adjuvant|Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
224030200|NCT05969925|DIAGNOSTIC_TEST|new biomarkers for heart failure|assess efficacy of new biomarkers for heart failure
224030201|NCT02182557|DRUG|WAL 801 CL Dry Syrup|
224030202|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup|
224030203|NCT02182557|DRUG|WAL 801 CL Dry Syrup placebo|
224030204|NCT02182557|DRUG|Ketotifen Fumarate Dry Syrup placebo|
223412845|NCT04620837|DRUG|Tislelizumab|Tislelizumab：200mg Q3W IV. There will be no dose reduction for Tislelizumab ， if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
224030205|NCT01757808|DRUG|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
224030206|NCT01757808|DRUG|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
223412846|NCT04620837|DRUG|Anlotinib hydrochloride|Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.
223412847|NCT06125652|DRUG|anti Tim-3/CD123 CAR-T cell therapy|Enrolled patients will receive prespecified dose of autologous CAR-T cells.
223412848|NCT01521832|DRUG|SEN0014196|5 mg single oral dose
223412849|NCT01521832|DRUG|SEN0014196|25 mg single oral dose
223412850|NCT01521832|DRUG|SEN0014196|75 mg single oral dose
223412851|NCT01521832|DRUG|SEN0014196|150 mg single oral dose
223412852|NCT01521832|DRUG|SEN0014196|300 mg single oral dose
223412853|NCT01521832|DRUG|SEN0014196|600 mg single oral dose
223412854|NCT01521832|DRUG|SEN0014196|300 mg single oral dose (females)
223412855|NCT01521832|DRUG|SEN0014196|100 mg multiple oral dose
223412856|NCT01521832|DRUG|SEN0014196|300 mg multiple oral dose
223412857|NCT01521832|DRUG|SEN0014196|100 mg BID multiple oral dose
223412858|NCT01521832|DRUG|SEN0014196|100 mg BID multiple oral dose (females)
224030207|NCT00561951|DRUG|fesoterodine fumarate|8mg tablets OD for 12 weeks
224030208|NCT00561951|DRUG|Placebo|Corresponding placebo tablets OD for 12 weeks
224030209|NCT00561951|DRUG|fesoterodine fumarate|4mg tablets OD for 12 weeks
224030210|NCT00546130|DRUG|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
224030211|NCT00546130|DRUG|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
224030212|NCT00546130|DRUG|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
224030213|NCT02949505|BEHAVIORAL|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
224030214|NCT04157140|DRUG|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
224030215|NCT04157140|DEVICE|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
224030216|NCT05101616|DRUG|camrelizumab+chemotherapy|camrelizumab 200mg，ivdrip，q3w； albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
224030217|NCT05101616|DRUG|Chemotherapy|albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w； oxaliplatine 85mg/m2、ivdrip，d1，q3w； S-1 40 mg/m2，po, bid，d1\~d14，q3w. 3 cycles.
224135413|NCT02537379|DRUG|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
224135414|NCT03179514|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
224135415|NCT03179514|DRUG|Lipid Regulating Drugs|Mainly including statins
224135416|NCT03179514|DRUG|Coronary Vasodilator|Mainly including nitrates
224135417|NCT03179514|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
224135418|NCT03731364|DRUG|CA-008|5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)
224135419|NCT03731364|DRUG|Placebo|Placebo
223412859|NCT03649932|DIETARY_SUPPLEMENT|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
223412860|NCT02757833|OTHER|A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.|Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
223412861|NCT03319238|OTHER|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
223412862|NCT02976740|RADIATION|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
223412863|NCT02976740|DRUG|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
223412864|NCT02976740|DRUG|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
223412865|NCT04858776|COMBINATION_PRODUCT|Perivascular dexamethasone|Dexamethasone delivery around target vein segment(s)
223412866|NCT04858776|COMBINATION_PRODUCT|Perivascular sham|Saline delivery around target vein segment(s)
223412867|NCT01095380|OTHER|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
223412868|NCT05944744|DRUG|Adenosylcobalamin|The drug contains Cobamamide / Adenosylcobalamin with dose of 3000 mg.
223412869|NCT05944744|DRUG|Placebo|The drug doesn't contain any properties or substances for treatment.
223412870|NCT03525275|DEVICE|Battlefield Acupuncture|Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols
223412871|NCT03525275|PROCEDURE|Post-surgical shoulder protocol|Surgery specific post-surgical physical therapy protocol
223412872|NCT00789945|OTHER|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
223412873|NCT00789945|OTHER|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
223412874|NCT02934698|DRUG|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
223412875|NCT02654977|DRUG|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
223412876|NCT04454047|PROCEDURE|Extracapsular arthroscopy|Extracapsular arthroscopy method was used to treat refractory tennis elbow
223412877|NCT01921101|BEHAVIORAL|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
223559624|NCT03002324|BEHAVIORAL|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
223559625|NCT03002324|BEHAVIORAL|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
224030218|NCT01329965|DRUG|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
224030219|NCT01941134|DRUG|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
224135420|NCT03670914|DIAGNOSTIC_TEST|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
224135421|NCT00340314|PROCEDURE|Circumferential Pulmonary Vein Ablation|
224135422|NCT00340314|DRUG|Antiarrhythmic Drug Therapy|
224135423|NCT05829616|DRUG|QLS12004|Subjects will be treated with different dose groups of QLS12004 according to the frequency and periodicity of administration as specified in the protocol, until disease progression or unacceptable toxicity.
224135424|NCT03780556|DRUG|Lornoxicam and mepridine|compare the effect of each to control pain
224135425|NCT04284956|PROCEDURE|Proximal and distal segment of saphenous vein harvested by No-Touch technique|two longitudinal incisions are made on the thigh and shank from unilateral lower limb (for harvesting of proximal segment of saphenous vein, incision is started from about 3 or 4cms inferolateral to the pubic tubercle and then extended downward). As previous reported. the adventitia and perivascular tissue are carefully kept intact to avoid damage. Then a margin of about 5 mm from both sides of the vein is created to include the fat pedicle using electrocautery, and all visible side branches are ligated with 4-0 silk or by metal clipping (branches are divided at the pedicle margin rather than the vein trunk). The saphenous vein is then separated from its bed using scissors and electrocautery, together with surrounding tissue.
224298235|NCT00003224|BIOLOGICAL|p946/tet-p|This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)
224298236|NCT00003224|BIOLOGICAL|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
224298237|NCT02337023|RADIATION|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
223412878|NCT01921101|OTHER|control|participants will receive standard care for nutrition received from hospital admission to discharge
223412879|NCT02311127|DEVICE|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
223412880|NCT02311127|DEVICE|StatLock|Device secures PICC however, device has to be changed weekly
224030220|NCT05830578|DEVICE|ASUS Blood Pressure Monitor/Oximeter/ECG Monitor|"The ASUS Blood Pressure Monitor/Oximeter/ECG Monitor analyzes data collected by the integrated electrical sensors on a ASUS Vivowatch to generate an ECG waveform similar to a Lead I, calculate average heart rate, and provide a rhythm classification to the user for a given 30 second session. When a user opens the ECG App while wearing the ASUS VivoWatch on one wrist and places the finger of the opposite hand on the digital crown, they are completing the circuit across the heart which begins a recording session.~Once the recording session is complete, the ECG App performs signal processing, feature extraction and rhythm classification to generate a session result."
223412881|NCT01483027|DEVICE|TheraSphere|yttrium 90 microspheres
223412882|NCT04453449|DRUG|Midazolam|Midazolam given as a sedative during diagnostic lumbar medial branch block
223412883|NCT00815542|DEVICE|double balloon catheter|cervical ripening using double balloon catheter
223412884|NCT00815542|DRUG|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
223412885|NCT02367846|DRUG|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
223412886|NCT02367846|DRUG|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
224135426|NCT06281886|DRUG|Induction Immunotherapy-Toripalimab|Toripalimab 240mg iv. drip, Q3W, 2 cycles
224135427|NCT06281886|DRUG|Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin|Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.
224135428|NCT06281886|RADIATION|Radiotherapy|Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.
224135429|NCT06281886|DRUG|Apatinib|Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.
224135430|NCT06281886|DRUG|Capecitabine|Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
224135431|NCT02626572|DRUG|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
224298238|NCT03986138|DRUG|gadopiclenol|Single intravenous bolus injection
224298239|NCT03986138|DRUG|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
224298240|NCT06231264|DEVICE|transcutaneous electrical acustimulation at treatment sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
224298241|NCT06231264|DEVICE|transcutaneous electrical acustimulation at sham sites|A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
224030221|NCT02852473|OTHER|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
224030222|NCT02997371|DRUG|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
224030223|NCT02997371|DRUG|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
224135432|NCT02626572|DRUG|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
224135433|NCT02626572|DRUG|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
223412887|NCT06483191|BEHAVIORAL|Acceptance and Commitment Therapy|A half-day pre-operative virtual ACT group workshop, booster post-operative ACT text messages once a week for 6 weeks and a telephone follow-up with a physiotherapist at 6-8 weeks (all in addition to standard care).
223412888|NCT05295693|DEVICE|Correlation of the Quantra with the TEG|"The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB.~The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device."
223412889|NCT05817539|PROCEDURE|Fluid balance negativation|"During the RRT, UFnet will be settled on 2ml/kg/h and adapted to hemodynamic tolerance and tissue perfusion .~When the patient's baseline body weight is reached the UF net will be settled to maintain it.~In case of failure of the fluid balance negativation after 24h, UFnet will be settled on 3ml/kg/h. Then when the baseline body weight is reached UFnet will be settled on 0.5 et 1ml/kg/h or if necessary adapted to 1,5ml/kg/h to maintain it~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min) or tissue hypoperfusion, UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min and without tissue hypoperfusion."
223412890|NCT05817539|PROCEDURE|Body weight Stabilization|"During the RRT, UFnet will be settled between 0 et 1 ml/kg/h and adapted in case of weight stabilization failure or hemodynamic intolerance.~In case of weight stabilisation failure ( variation \>3% after 24h), the UF net can be increased to 1,5 ml/kg/h, as long as high intakes require UFnette at 1.5mL/kg/h to stabilize water balance, with daily reassessment.~In case of hemodynamic intolerance (NADN \> 0,5 µg/kg/min), UF net will be stopped during 6 hours and restarted if NADN \< 0,5 µg/kg/min."
223412891|NCT06144125|BIOLOGICAL|fresh frozen plasma|transfusion of fresh frozen plasma
223412892|NCT06144125|BIOLOGICAL|prothrombin complex concentrate|prothrombin complex concentrate administration
223412893|NCT01364688|DRUG|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
223412894|NCT01364688|DRUG|no drug|no drug
223412895|NCT06337890|PROCEDURE|Zero contrast FEVAR|Use of automated CO2 angiographies with Fusion Imaging for zero contrast FEVAR
223412896|NCT00129688|DRUG|cloxacillin and amikacin (once or twice daily dosage)|
223412897|NCT04807309|DRUG|Danazol Pill|Danazol 200 mg orally twice a day
223412898|NCT04807309|DRUG|Placebo|Placebo twice a day
224030224|NCT02728882|BIOLOGICAL|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
224030225|NCT01581541|DRUG|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
224030226|NCT06493331|OTHER|Talking Circle|"step 1 A round seating area is created with chairs. Questions addressing students' perspectives on therapeutic communication styles, the difficulties and conveniences in their communication, and the problems they experience.~step 2 An object that indicates the talking order will be determined (ball). This object will pass from hand to hand and determine the order of speaking.~A conversation is started and the students are asked about their thoughts and experiences regarding communication with the pediatric patient and their family with questions prepared by the researchers.~step 3 The student who does not want to talk can say 1 pass. In the next round, he is encouraged to speak.~When the sharing is completed, the experiences of the participants will be shared and group comments will be received."
224135434|NCT02626572|DRUG|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
223412899|NCT02857400|OTHER|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
223412900|NCT02857400|OTHER|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
223412901|NCT01470963|OTHER|Implementation of referral template|Implementation of referral template at the GP office
223412902|NCT05314322|PROCEDURE|Deep brain stimulation with high frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
224030227|NCT00001023|DRUG|Clarithromycin|
224030228|NCT00001023|DRUG|Azithromycin|
224135435|NCT00504335|DRUG|BIO 300 Capsules|
224135436|NCT04887103|OTHER|Hot water application|Pregnant women will apply hot water to their legs before going to sleep for a week.
224135437|NCT02357849|DRUG|Aripiprazole|see arm description
224135438|NCT02357849|DRUG|Fluoxetine|see arm description
224135439|NCT02771249|DRUG|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
223412903|NCT05314322|PROCEDURE|Deep brain stimulation with low frequency|Deep brain stimulation implanted at the patients' Substantia Nigra
223412904|NCT00185263|GENETIC|AdF5FGF-4 vs. Placebo|Intracoronary infusion
223412905|NCT03928899|PROCEDURE|New procedure|An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.
224030229|NCT00001023|DRUG|Rifabutin|
224030230|NCT02306382|PROCEDURE|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
224030231|NCT02306382|DEVICE|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
224030232|NCT02373254|DRUG|Ibuprofen|Ibuprofen 400 mg and 800 mg
224030233|NCT02373254|DRUG|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
224030234|NCT01596621|DRUG|Bendamustine hydrochloride|Bendamustine will be be administered per dose and schedule specified in the arm description.
224030235|NCT03846141|OTHER|Placebo|Inhalation of room air for 20 min per day during 7 days
224030236|NCT03846141|OTHER|Hydrogen|Inhalation of 4% hydrogen for 20 min per day during 7 days
224030237|NCT03868605|DEVICE|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
224030238|NCT03868605|DEVICE|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
224030239|NCT04329832|DRUG|Hydroxychloroquine|Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 4 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate)\<50ml/min). For patients \< 45kg, doses will be halved. For patients with GFR\<50ml/min, the final dose of hydroxychloroquine will not be administered. If the patient has already received hydroxychloroquine prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
224030240|NCT04329832|DRUG|Azithromycin|Patients in the azithromycin arm will receive azithromycin 500 mg on day 1 plus 250 mg daily on days 2-5 (may be administered intravenously per clinician preference). If the patient has already received azithromycin prior to randomization (no more than 2 days), the prior doses will count toward the 5-day total.
224030241|NCT02521467|BIOLOGICAL|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
224030242|NCT02521467|OTHER|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
224135440|NCT02771249|DRUG|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
223412906|NCT03691207|DRUG|AL101|"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously"
223559626|NCT03002324|BEHAVIORAL|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
224030243|NCT01990118|DRUG|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
224030244|NCT01990118|DRUG|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
224030245|NCT06107725|DRUG|Minocycline|Minocycline 200 mg every 24 hours for five days to be initiated within 24hr of stroke onset.
224030246|NCT04359004|OTHER|Vagus Nerve Stimulation (VNS)|Vagus Nerve Stimulation (VNS) will be performed percutaneously through the internal jugular vein during the patient's routine VT ablation procedure. The nerve will be stimulated using standard pacing systems used for clinical purposes. A series of stimulation frequencies and pulse widths will be used to define optimal effects and 'dosing'. Activation recovery interval (ARI) will be measured from the unipolar electrograms. In addition, heart rate and blood pressure responses will be continuously recorded.
224030247|NCT03295110|OTHER|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
224135441|NCT02771249|DRUG|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
224135442|NCT02771249|DIETARY_SUPPLEMENT|Pyridoxine|
224135443|NCT01758666|DRUG|Methotrexate,Calcium folinate|
224135444|NCT03354819|BEHAVIORAL|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
224135445|NCT03354819|BEHAVIORAL|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction"
224135446|NCT04619875|OTHER|KB5|KB5, a novel glycan, is a Kaleido laboratory code for KB174
224135447|NCT04619875|OTHER|SG1|SG1 is a novel glycan
224135448|NCT04619875|OTHER|Lactulose|Lactulose is a synthetic dissacharide
223412907|NCT04056533|BIOLOGICAL|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
223412908|NCT02881489|OTHER|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
223412909|NCT04392375|DRUG|Nifedipine 30 MG|Nifedipine XL is a long-acting medication used to lower blood pressure. The investigators want to learn whether women who receive the study drug will experience fewer severe-range blood pressure readings, and therefore need fewer intravenous (IV) medications to safely lower blood pressure.
223412910|NCT04392375|DRUG|Placebos|At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
224030248|NCT03295110|OTHER|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
224030249|NCT04498065|BIOLOGICAL|Biological data|Biological data
224030250|NCT04498065|OTHER|Clinical data|Clinical data
224030251|NCT05148143|DRUG|Raltitrexed combined with oxaplatin|Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
224135449|NCT04070352|DRUG|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
223412911|NCT00220428|BIOLOGICAL|T-Cell Vaccination|
224030252|NCT04283331|DRUG|Proparacaine Ophthalmic|Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
224030253|NCT03969147|DEVICE|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
224030254|NCT03969147|DEVICE|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
224030255|NCT03969147|DEVICE|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
223412912|NCT04146493|DIAGNOSTIC_TEST|Blood samples for Heparin-binding protein measurement|Blood samples before and after given heparin
223412913|NCT00747370|PROCEDURE|movement of midurethra, bladder neck, cervix and rectum|
223412914|NCT00798668|DIETARY_SUPPLEMENT|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
223412915|NCT00798668|DIETARY_SUPPLEMENT|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
223412916|NCT05108350|DRUG|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment T1 followed by 7 days washout and then receive treatment R1+R.
223412917|NCT05108350|DRUG|T1: FDC 5/500 mg; R1+R: SHR3824 5 mg + Metformin 500 mg XR|SHR3824 5 mg + Metformin 500 mg XR In cohort 1 (low dose strength), subjects will receive treatment R1+R followed by 7 days washout and then receive treatment T1.
223412918|NCT05108350|DRUG|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment T2 followed by 7 days washout and then receive treatment R2+R.
223412919|NCT05108350|DRUG|T2: FDC 5/1000 mg; R2+R: SHR3824 5 mg + two Metformin 500 mg XR|SHR3824 5 mg + Metformin 1000 mg XR In cohort 2 (high dose strength), subjects will receive treatment R2+R followed by 7 days washout and then receive treatment T2.
223412920|NCT04112602|OTHER|Sputum|Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
223412921|NCT04112602|OTHER|Tracheal aspiration|Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
223412922|NCT02926729|DEVICE|nonlinear microscopy imaging of excised surgical margins|Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
223412923|NCT02926729|PROCEDURE|standard lumpectomy without nonlinear microscopy imaging|Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
223412924|NCT00116818|DRUG|GW685698X aqueous nasal spray|
223412925|NCT02982681|DRUG|Platelet rich fibrin|In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
223412926|NCT02982681|DRUG|Bioactive Glass|The control site were packed with the bioactive glass graft alone
223412927|NCT03317314|DIAGNOSTIC_TEST|Lung Biopsy during LVAD Implantation|Lung Biopsy during LVAD Implantation
223412928|NCT01288937|DRUG|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
223412929|NCT01288937|DRUG|Placebo|Patients will be randomly assigned to placebo for 9 weeks (including a 1 week dose titration period), matching the schedule of the study drug.
223412930|NCT02695966|PROCEDURE|Whipples Surgery|Whipples Surgery
223412931|NCT04242472|BEHAVIORAL|SMS-based Mobile Health intervention|Nutritional related SMS text message mobile health intervention will be provided to Tuberculosis patients.
223412932|NCT02149979|DEVICE|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
224030256|NCT02341859|DEVICE|stenfilcon A|contact lens
224030257|NCT02341859|DEVICE|delefilcon A|contact lens
224030258|NCT02341859|DEVICE|narafilcon A|contact lens
224030259|NCT02237313|BEHAVIORAL|psychological support and therapeutic education program|
223412933|NCT02490371|DEVICE|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
223412934|NCT02490371|BEHAVIORAL|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
223412935|NCT02323542|OTHER|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
223412936|NCT05623540|DRUG|Bisphosphonates, Combinations|
223412937|NCT04059614|PROCEDURE|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
223412938|NCT03219814|OTHER|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
224030260|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
224030261|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Healthy Children|Healthy children will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
224030262|NCT04845633|OTHER|Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 week by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
224030263|NCT04845633|OTHER|Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Children with Down Syndrome|Children with Down syndrome will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
224030264|NCT00556920|DRUG|COREG CR|
224030265|NCT05198908|OTHER|VR group|"Women in this group will wear virtual reality glasses (15-20 minutes) until the episiotomy repair begins and ends. At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
224135450|NCT06197932|OTHER|Routine exercise and running training|impact of a 4-week running training program on physical performance variables in a control group comprising 15 participants. The control group exclusively underwent running training, and measurements were taken for variables such as the strength of the big toe of both right and left feet using a hip and toe dynamometer (measured in kilograms). Additionally, assessments included vertical jump height and horizontal jump distance (both measured in centimeters), balance using the Y-balance test, and agility via the T-test. All measurements were conducted with standardized equipment, both before and after the training period. se physical performance indicators.
224298242|NCT03286010|BEHAVIORAL|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
223412939|NCT03219814|OTHER|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
223412940|NCT00610155|DRUG|Placebo|BID
223412941|NCT00610155|DRUG|Pregabalin|Dose 75 mg titrated to 150 mg, bid
223412942|NCT00610155|DRUG|Tramadol SR|Dose 50mg titrated to 200 mg, bid
223412943|NCT06966921|DEVICE|CES|Currently, most CES intervention studies are applied to the general public, and a few studies focus on athletic performance. There are no related studies on residents of psychiatric nursing homes, nor are there any research designs for improving cognitive impairment. Therefore, this study explores the use of CES programs to improve the cognition, anxiety, depression, and other conditions of residents of psychiatric care homes, with the goal of improving their quality of life.
223412944|NCT06578858|BEHAVIORAL|Application of questionnaires|Application of SOC-13 and BRS questionnaires in patients after gastric cancer surgery
223412945|NCT01488136|DRUG|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
223412946|NCT01488136|DRUG|Placebo|Lactose Ph capsules (Placebo)
223412947|NCT06968559|DRUG|Dexamethasone|Dexamethasone 0.2 mg/kg of ideal body weight (IBW) IV (at a maximum of 20 mg per day) will be blindly infused from day 1 to day 5;
223412948|NCT06968559|DRUG|Placebo|Placebo: one IV administration per day from day 1 to day 5.
223412949|NCT06314113|DIETARY_SUPPLEMENT|Epigallocatechin Gallate|Oral treatment with Epigallocatechin Gallate 200 mg per day
223412950|NCT01251419|OTHER|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
223412951|NCT01718535|DEVICE|Spartan FRX CYP2C19 Test System|
223412952|NCT03293979|DIAGNOSTIC_TEST|Test A i Flu A&B implemented in emergency service|Test A i Flu A\&B implemented in emergency service
223412953|NCT01605552|BEHAVIORAL|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
223412954|NCT01605552|OTHER|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
223412955|NCT06302556|DIAGNOSTIC_TEST|Immune checkpoints analysis|The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.
223412956|NCT06302556|DIAGNOSTIC_TEST|Gene expression analysis|Immune cells will be purified from bronchoalveolar lavage; total RNA will be purified and subjected to gene expression analysis by Quantigene multiplex 80-plex Assay, which allows to evaluate simultaneously the follow mRNA targets: CCL2, CCL3, CCL5, CXCL10, CSF2, CSF3, IL1A, IL1B, IL1RN, IL6, IL6R, IL8, IL10, IL12B, IL17A, IL18, IL22, IL28A, TNF, TNFRSF4, IFNA2, IFNB1, IFNG, IFI16, IFITM1, IFITM3, MX1, TLR3, TLR4, TLR7, TLR8, NOD1, NOD2, CASP1, NLRP3, PYCARD, CD44, CLEC4M, CD209, ITGA4, ITGB7, CH25H, ABCA1, HMGCS1, NR1H3, ACAT1, PDCD1, PTGS2, CD274, CD69, MPO, HAVCR2, TAP1, ERAP1, ERAP2, AGTR2, AGTR1, PPARG, CRP, IL7, IL12A, ACE2, ELOVL6, CD38, NOS2
223559627|NCT03002324|BEHAVIORAL|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
223559628|NCT03002324|BEHAVIORAL|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
223559629|NCT06479512|DEVICE|ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index|Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
224030266|NCT05198908|OTHER|Skin to skin group|"For women in this group, a warm sterile operating room towel will be placed on the newborn until the episiotomy repair begins and ends, so that her naked body remains on the mother's chest.At the same time, the hospital protocol will be applied to this group.~Before episiotomy repair, each woman is given superficial perineal anesthesia with a 4 ml ampoule of Jetocaine (ADEKA®, lidocaine HCl 40 mg/2 mL, epinephrine 0.025 mg/2 mL). This dose is repeated if necessary."
224030267|NCT04229251|BEHAVIORAL|Online Mindfulness-based Intervention|The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.
224030268|NCT04229251|BEHAVIORAL|Online Introductory Psychology Program|The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
224030269|NCT01789125|DRUG|Nicotine Patch|
224030270|NCT01789125|BEHAVIORAL|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
223412957|NCT00589615|BEHAVIORAL|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
223559630|NCT02131090|DEVICE|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
223559631|NCT02131090|DEVICE|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
223559632|NCT02131090|DEVICE|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
223559633|NCT02088879|BEHAVIORAL|chest compression with kneeling position|
224030271|NCT01789125|BEHAVIORAL|Education-Supportive Psychotherapy|
223559634|NCT02088879|BEHAVIORAL|chest compression with standing position|
223559635|NCT02752633|DRUG|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
224030272|NCT06168188|DRUG|Neulasta® (pegfilgrastim)|Intravitreal injection of Neulasta® (pegfilgrastim) after TON
224030273|NCT03555474|PROCEDURE|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
224030274|NCT03555474|PROCEDURE|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
223412958|NCT06048861|DEVICE|KForce Sens|The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.
223412959|NCT06048861|DEVICE|Baseline Electrıgoniometer|The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
223412960|NCT05726071|DEVICE|Holter|24 hour electrocardiography
223412961|NCT04482361|DIAGNOSTIC_TEST|Presence of specific anti-SARS-CoV-2 antibodies|Presence of specific anti-SARS-CoV-2 antibodies
223559636|NCT02752633|DRUG|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
223559637|NCT02846389|OTHER|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
223559638|NCT03781895|DRUG|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
224030275|NCT03555474|PROCEDURE|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
224030276|NCT04729764|DRUG|GP681 Tablet|Designed as 5 dose groups (20mg, 40mg, 60mg, 80mg, 120mg), the starting dose group (20mg) 8 subjects (including 2 placebo), each other 10 subjects (including Placebo (2 cases), male and female.
224030277|NCT00654342|PROCEDURE|Intraoperative injection (in vivo)|Intraoperative injection
224030278|NCT00654342|PROCEDURE|Postoperative injection (ex vivo)|postoperative injection
224030279|NCT04065178|BEHAVIORAL|Level of activity|"Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way."
224030280|NCT04613349|OTHER|MRI|"All patients included will benefit from the two methods of evaluating the anatomical relationships between the facial nerve and the parotid tumor:~1. New medical imaging technique evaluated: high-resolution 3 Tesla parotid MRI with specific sequences and gadolinium injection;~2. Gold standard: Intraoperative examination."
224030281|NCT00164645|BEHAVIORAL|Problem Solving intervention|
224030282|NCT03154073|BEHAVIORAL|Moderate Intensity Exercise Training (MOD)|For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.
224030283|NCT03154073|BEHAVIORAL|Vigorous Intensity Exercise Training (VIG)|The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
224030284|NCT04007185|PROCEDURE|Maximal, safe resection of brain tumour|Standard surgical resection as part of routine care
223412962|NCT04747353|DEVICE|Catheter ablation procedure with heart 3D model|Device: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets
223412963|NCT03962777|OTHER|chlorhexidine|patients used chx moutrinses for four days
224030285|NCT04598204|DRUG|Treatment with oral rapmycin|To treat the enrolled patients with oral rapamycin with an initial dosage of 0.8mg/m2, once daily for children under 3 years old and twice daily (every 12 hours) for those above 3 years, and adjust the dosage to target a trough concentration of rapamycin in plasma as 10-15ng/ml （OR 15-20ng/ml if the efficacy of treatment is not satisfactory）. One course lasts for 12weeks and no more than 4 course is given.
224030286|NCT03878251|DEVICE|Quantitative attention evaluation criteria in intellectual disability|Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
224298243|NCT04619095|DIETARY_SUPPLEMENT|Psyllium|See the information already included in the arm descriptions.
223412964|NCT03962777|OTHER|oil pulling|patients used oil pulling for four days
223412965|NCT04291183|BEHAVIORAL|horticultural therapy|Flowers and vegetables will be planted with the elderly. Growth of plants planted with the elderly will be observed and maintained
223412966|NCT04774367|DEVICE|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
223559639|NCT05030610|BEHAVIORAL|BeatIt-ASD|BeatIt-ASD, designed to be implemented with autistic individuals, is an adaptation of BeatIt. The intervention aims to improve mood and decrease depressive symptoms through an increase in meaningful engagement in recreational, domestic, and social/leisure activities.
223559640|NCT01334216|OTHER|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
223559641|NCT01334216|OTHER|CHICA Placebo|This was CHICA without the study module.
223559642|NCT04425967|RADIATION|pre-operative radiotherapy|pre-operative radiotherapy
224298244|NCT04619095|DIETARY_SUPPLEMENT|Placebo|See the information already included in the arm descriptions.
223412967|NCT04774367|DEVICE|Order of forceps : First large capacity biopsy forceps and second standard biopsy forceps|Order of forceps : First standard biopsy forceps and second large capacity biopsy forceps
223412968|NCT05369065|COMBINATION_PRODUCT|Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
223412969|NCT05369065|DIAGNOSTIC_TEST|Arterial Angiography Only|Arterial Angiography Only without Intervention
223412970|NCT05369065|COMBINATION_PRODUCT|Single Arm non-Randomized Ablation Treatment|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
223412971|NCT02547792|BIOLOGICAL|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
224030287|NCT03753672|DIAGNOSTIC_TEST|preload responsiveness|We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%
224030288|NCT04256434|DRUG|Dinalbuphine sebacate|150 mg Dinalbuphine sebacate
224030289|NCT04256434|DRUG|Nalbuphine HCl|20 mg Nalbuphine
224030290|NCT04811209|OTHER|1.Baseline Measurements Before Surgery|"* Baseline demographic data~* Baseline physiological variables (blood pressure, heart rate, respiratory rate, oxygen saturation)~* Baseline investigations (hemoglobin, coagulation profile, serum electrolytes) if appropriate.~* Preoperative pain state using NRS (0-10)~* Preoperative functional state using the QoR-15 questionnaire~* Pain expectation - patients will be asked preoperatively with the question In a scale from 0 to 10 (where 0 = no pain and 10 = worst pain imaginable), what do you consider is an acceptable pain score for your first (and second) day after surgery?... Two weeks after surgery?~* Pain castastrophizing scale"
224030291|NCT04811209|OTHER|2.Intraoperative Anesthetic Management|All study patients will be managed per routine clinical practice and institutional standard for the performed surgery.
224030292|NCT04811209|OTHER|3.Postoperative Analgesic Management|"postoperative pain will be managed on the ward using a multimodal analgesic regimen as appropriate. This includes:~1. acetaminophen 650 - 1,000 mg given orally every 6 hours around the clock~2. NSAIDs e.g., celecoxib or other agents given orally around the clock per clinical guideline; omit if contraindicated or per surgeon's preference~3. Opioids e.g., hydromorphone 1-2 mg or oxycodone 15-30 mg given orally every 1-2 hours as required by the patient per standard nurse administered analgesic protocol.~4. In the event of severe pain refractory to the above treatments, the patient will be offered IV opioid e.g., intermittent doses of 0.2-0.4 mg hydromorphone IV every 10 minutes until pain becomes tolerable"
224030293|NCT04811209|OTHER|4.Postoperative NRS Pain Assessment|Pain assessment using NRS pain scores (0 = no pain and 10 = worst possible pain) will be performed by an independent research staff, starting immediately in the PACU and serially over the first 48 hours after surgery or until hospital discharge.
224030294|NCT04811209|OTHER|5.Postoperative Global Rating Scale (GRS) Pain Assessment|Also, the degree of pain relief after treatment is assessed using a subjective 15-point Global Rating Scale (GRS) as mentioned above (Background). This is performed at the same time of each NRS assessment and a minimum of twice daily
224030295|NCT04811209|OTHER|6.Postoperative Patient Acceptable Symptom State (PASS) Assessment for Pain|"During each NRS pain assessment before or after an analgesic intervention on POD 0, 1 and 2, the patient will also be asked this question- In your opinion, do you consider your current pain state satisfactory after your operation? Patients giving a positive response are considered having an acceptable pain state. The PASS is the 75th centile for the pain NRS score in those with a satisfactory pain state."
224030296|NCT04811209|OTHER|7.Postoperative Quality of Recovery Assessment|The quality of recovery 15 questionnaire (QoR-15) to measure the dimension of quality of recovery will be administered once in the morning of POD 1 and POD 2. The MCID and PASS for QoR are determined in the same way as for NRS score. The final MCID value will be average of 4 values, 1 generated by the anchor based method and 3 generated by the distribution based method. The PASS for QoR is the 75th centile of the QoR-15 score in those patients who rated their recovery as good.
224030297|NCT04811209|OTHER|8.Other Postoperative Assessments|Additionally, opioid related adverse effects e.g., nausea, vomiting, itchiness, constipation, sedation (RASS + Ramsay)/ and respiratory depression will be assessed daily.
224030298|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography|"All the intensivists performing the TTE in the involved centers fulfill the criteria of the American Society of Echocardiography and of the European Society of Intensive Care.~Medicine to be considered as experts in critical care echocardiography. Each center performs the TTE evaluation by means of the ultrasound device available in the unit equipped with the tissue Doppler imaging program and a phased array transducer of 2.5 MHz and doppler signals is recorded along with the electrocardiogram.~For the purpose of this study, the following TTE parameters are recorded from the apical 4-chamber view during each set of measurements:"
223412972|NCT02547792|BIOLOGICAL|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
223412973|NCT02547792|OTHER|Placebo Tablets|Enteric coated tablet for oral delivery
223412974|NCT02041663|BIOLOGICAL|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
223412975|NCT02008695|BEHAVIORAL|adult microfinance|"Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households"
223412976|NCT02008695|BEHAVIORAL|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
223412977|NCT02008695|BEHAVIORAL|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
223412978|NCT00224068|DRUG|Sodium ferric gluconate, ferrous sulfate, standard of care|
223412979|NCT03005496|DRUG|Zinc|included in intervention arm
223412980|NCT03005496|DRUG|Nifedipine|included in intervention and control arm
223412981|NCT03005496|DRUG|Beta Carotene|included in intervention arm
223412982|NCT03005496|DRUG|Vitamin D3|included in intervention arm
223412983|NCT03005496|DRUG|Dexamethasone|included in intervention and control arm
224135451|NCT06197932|OTHER|Big Toe Strengthening Exercise|impact of a 4-week intervention involving toe-strengthening exercises and concurrent running training on 15 participants. Pre-assessment measurements included big toe strength, vertical and horizontal jump heights, Y-balance for balance, and T-tests for agility. Following pre-assessment, participants followed a structured toe-strengthening protocol, performing 15 repetitions in three sets twice a day for three weeks. Post-intervention measurements, using the same units and instruments, aim to reveal the effects of the intervention on specified physical variables. This research provides insights into the potential benefits of combining toe-strengthening exercises with running training for enhanced physical performance.
224135452|NCT00100633|DRUG|CpG7909 oligodeoxynucleotides (ODN)|
224135453|NCT00100633|BIOLOGICAL|Hepatitis B virus vaccine|
224135454|NCT05072717|PROCEDURE|Perfusion with Indocyanine green|Infusion of Indocyanine green to determine perfusion in meniscal tear tissue.
224135455|NCT03057457|DEVICE|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
224135456|NCT03641209|DRUG|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
224135457|NCT03641209|OTHER|Placebo|Half physiological saline solution as the non-active placebo solution
224135458|NCT00135486|BIOLOGICAL|MenC-TT|
223412984|NCT00845221|DRUG|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
223412985|NCT04607564|OTHER|Ntombi Vimbela! intervention|Ntombi Vimbela! constitutes a series of ten workshops running for a total 35 hours. The intervention is designed to raise awareness about sexual rights, violence against women and girls and its drivers; sensitise about gender inequality and build more gender equitable beliefs; sensitise about sexual assault; equip participants with skills to assess and act in situations where there is a high risk of sexual assault; build resilience and skills to withstand social and material pressures in college or university ; enable utilisation of health, psycho-social services and access to justice for survivors; enhance communication skills and building healthy sexual relationships; promote mental health and coping and build empathy towards survivors.
224030299|NCT04584203|PROCEDURE|Spontaneuos breathing trial|The Spontaneous Breathing Trial will be performed accordingly to the clinical practice of the involved centers (a total support - including positive end-expiratory pressure plus pressure support equal or lower to 8 cmH20)
224030300|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_1|Echocardiography performed within 24h from patient's admission - not optional
224030301|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_2|Echocardiography performed within 12h from patient's spontaneous breathing trial - not optional
224135459|NCT00135486|BIOLOGICAL|Hib-MenC-TT|
224135460|NCT02711215|DIAGNOSTIC_TEST|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
224135461|NCT02711215|DRUG|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
224135462|NCT02711215|DRUG|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
224135463|NCT02711215|DRUG|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
224135464|NCT04508673|OTHER|GH provocation tst|All patients underwent insulin-induced hypoglycaemia stimulation test also called insulin tolerance test (ITT), considered the 'gold standard' test for GHD diagnosis. Following insulin administration by venipuncture (1UI/mL), levels of hGH and glucose were monitored on serum and fluoride tube plasma, respectively, at intervals of 0, 30, 45, 60 and 90 minutes (T0, T30, T45, T60 and T90).
224298245|NCT03213730|OTHER|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
223412986|NCT02337608|DRUG|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
223412987|NCT02337608|DRUG|Placebo|placebo daily dosing in the morning daily for 12 weeks
224030302|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_3|Echocardiography performed at 60 +/- 12h from patient's admission - optional
223412988|NCT01541332|DRUG|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
223412989|NCT01541332|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
223559643|NCT05962242|RADIATION|Radiation Therapy|External Beam Radiation to Head and Neck
224030303|NCT04584203|DIAGNOSTIC_TEST|Bedside Echocardiography_4|Echocardiography performed 24h after patient's estubation - optional
224030304|NCT04428827|PROCEDURE|Unilateral adrenalectomy in patients with unilateral disease|Unilateral adrenalectomy in patients with unilateral disease
224030305|NCT05172427|BEHAVIORAL|14 days of EMI|Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.
224135465|NCT01600768|DRUG|Beta-Lactams|infusion time: 30 mins or 1 hr
224135466|NCT01600768|DRUG|Beta-Lactams|infusion time 4 hrs
224135467|NCT01597427|DRUG|Clonidine|Administration of 2 μg/kg of intravenous clonidine
223412990|NCT01541332|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
223412991|NCT00183859|DRUG|irinotecan|Intraperitoneal Irinotecan given every three weeks
223412992|NCT05185037|DEVICE|Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)|The purpose of this study is to compare measurements of NIBP taken by the study device and measurements taken by the current FDA-approved algorithm included in Rev. N.0 software for the IntelliVue patient monitors during motion artifact in patients undergoing caesarian section deliveries under epidural anesthesia
223412993|NCT00002875|BIOLOGICAL|filgrastim|
223559644|NCT03483779|DRUG|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
223559645|NCT03483779|DRUG|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
223412994|NCT00002875|DRUG|cisplatin|
223559646|NCT02180919|DEVICE|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
223559647|NCT00433966|DRUG|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
223559648|NCT00433966|DRUG|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
223559649|NCT00433966|DEVICE|Bare metal stent|Uncoated bare metal stent
223559650|NCT00433966|DEVICE|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
223738799|NCT04600414|OTHER|Collaborative Care for Mental Health Symptoms|CoCM is based on six key principles: 1) evidence-based, 2) measurement-based, 3) team-based, 4) population-based, 5) patient-centered, and 6) accountable. CoCM supports the delivery of evidence-based pharmacological and psychosocial treatments. CoCM is measurement-based with screening and monitoring of patient-reported outcomes over time to assess treatment response and facilitate treatment adjustments. CoCM is team-based led by a primary care provider with support from a care manager in consultation with a psychiatrist who provides treatment recommendations for patients who are not responding. CoCM is population-based whereby a registry is used to monitor treatment engagement and facilitate the identification of patients falling through the cracks. CoCM is patient-centered with proactive outreach to engage and activate patients. Collaborative care is accountable with continuous quality improvement to meet clinic performance benchmarks.
223738800|NCT04600414|OTHER|Collaborative Care for Opioid Use Disorder and Mental Health Symptoms|"Pharmacologic treatment of OUD will rely mainly on transmucosal buprenorphine/naloxone prescribed by primary care providers with DATA 2000 waivers. Measurement-based care and treat to target are fundamental principles of CoCM and will be incorporated into the intervention. Care managers will ask four yes/no questions about: 1) opioid withdrawal symptoms, 2) illicit opioid craving, 3) illicit opioid use, 4) medication side effects. If necessary, consulting psychiatrists will then recommend a change to the treatment plan to the primary care provider. In the case of buprenorphine/naloxone, options for changing the treatment plan include: 1) increasing the dosage (max dose 32mg), 2) augmenting with clonidine, 3) switching to injectable buprenorphine, and/or 4) intensifying psychosocial interventions. If the patient is experiencing medication side effects, but not opioid withdrawal symptoms or illicit opioid craving, consideration will be given to lowering the medication dosage."
223738801|NCT06472830|OTHER|Non-Interventional Study|Non-interventional study
224030306|NCT05172427|BEHAVIORAL|Uncertainty reappraisal training|CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
224030307|NCT00334854|DRUG|doxorubicin hydrochloride|
223412995|NCT00002875|DRUG|cyclophosphamide|
223412996|NCT00002875|DRUG|lomustine|
223412997|NCT00002875|DRUG|mesna|
223412998|NCT00002875|DRUG|vincristine sulfate|
223412999|NCT00002875|RADIATION|low-LET electron therapy|
223413000|NCT00002875|RADIATION|low-LET photon therapy|
223413001|NCT01245959|DRUG|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
223413002|NCT01245959|RADIATION|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
223413003|NCT00985387|DRUG|Solifenacin|oral
223413004|NCT02739009|DRUG|MOR106 single ascending doses, intravenous|
223413005|NCT02739009|DRUG|Placebo single ascending doses, intravenous|
223413006|NCT02739009|DRUG|MOR106 multiple ascending doses, intravenous|
224030308|NCT00334854|DRUG|ifosfamide|
224030309|NCT00334854|PROCEDURE|adjuvant therapy|
224030310|NCT00334854|PROCEDURE|conventional surgery|
224030311|NCT00334854|PROCEDURE|neoadjuvant therapy|
224030312|NCT00334854|RADIATION|radiation therapy|
224030313|NCT01439152|DRUG|BAY94-9343|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
224030314|NCT01439152|DRUG|BAY94-9343 (Expansion)|BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
223559651|NCT05265234|DRUG|Dupilumab|IL-4 antagonist to improve moderate-severe atopic dermatitis
223559652|NCT05265234|DEVICE|Optical Coherence Tomography|OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.
224030315|NCT01439152|DRUG|BAY94-9343 (1.8 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
223413007|NCT02739009|DRUG|Placebo multiple intravenous administrations|
223413008|NCT00648115|OTHER|Basic Vocational Services|Vocational services
223413009|NCT00648115|OTHER|Self-Study|Veteran receives self-study resources
223413010|NCT00648115|OTHER|Group Program|Veteran participates in group vocational program
223413011|NCT05453188|DEVICE|Experimental|Pre- and post-intervention measurement of quality of life, self-perceived fatigue and blood lactic acid concentration after each Nordic Walking session.
223413012|NCT05453188|GENETIC|Control|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine genetic profile and allele frequencies of patients with persistent COVID and association by Total Genotype Score (TGS) with fatigue status.
223413013|NCT00182611|DRUG|cisplatin|
223413014|NCT00182611|DRUG|tegafur-gimeracil-oteracil potassium|
223413015|NCT00182611|PROCEDURE|adjuvant therapy|
223413016|NCT00182611|PROCEDURE|conventional surgery|
224030316|NCT01439152|DRUG|BAY94-9343 (2.2 mg/kg)|BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
224030317|NCT00421707|DRUG|GW876008|
224030318|NCT00421707|OTHER|Placebo|
224030319|NCT01546350|GENETIC|PGD|array CGH after blastocyst biopsy
224030320|NCT01546350|PROCEDURE|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
224030321|NCT03261700|BEHAVIORAL|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
224135468|NCT01597427|DRUG|Placebo|Injection of placebo solution.
224135469|NCT00389740|DRUG|MK0217, /Duration of Treatment : 12 Months|
224135470|NCT00389740|DRUG|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
224135471|NCT00058734|BIOLOGICAL|Dendritic Cells Pulsed with HIV antigens|
224135472|NCT03745196|DRUG|PC945|Study drug under investigation
224135473|NCT03745196|DRUG|Placebo|Placebo control
224135474|NCT02515617|DEVICE|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
223413017|NCT00182611|PROCEDURE|neoadjuvant therapy|
223413018|NCT05958628|OTHER|Conventional physiotherapy|"The treatment program was designed in line with the patients' compliance, functional capacities and rehabilitation goals as neurodevelopmental therapy based on the ability to adapt to change, reorganization and healing in the brain by focusing on neuroplasticity from neurodevelopmental treatment approaches; Proprioceptive neuromuscular facilitation techniques to increase selective and voluntary movement; functional exercises to increase motor control skills, stretching exercises for spasticity and neuromuscular electrical stimulation.~The control group received conventional physiotherapy exercises for 45 minutes and neuromuscular electrical stimulation for 15 minutes."
224135475|NCT02515617|DEVICE|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
223413019|NCT05958628|OTHER|Robotic Hand Exoskeleton System|In the treatment applications with the robotic hand exoskeleton system, which is designed to accelerate the healing process of patients in need of hand rehabilitation, to gain motor skills, to provide strength training and to increase participation in treatment, the patient will be asked to allow the system to move the hand at adjusted angles for 10 minutes and to accompany this movement. In the applications, while the patient is sitting comfortably and safely, the patient will be asked to place the stroke-affected hand into the system. The hand of patients who may have difficulty due to the functional status of the upper extremity and the severity of spasticity will be placed with the help of the physiotherapist. The physiotherapist will be with the patient throughout the application.
223413020|NCT04806893|DRUG|lerodalcibep|300 mg subcutaneous injection every month (Q4W)
224030322|NCT03261700|OTHER|Information and referral condition|Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
224030323|NCT05225194|OTHER|COVID-19|SARS-CoV-2 infection
224030324|NCT05225194|OTHER|ARDS|Acute respiratory distress syndrome
224030325|NCT00046254|DRUG|Zoledronic Acid|
224135476|NCT05439694|DRUG|Tranexamic acid|have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)
224135477|NCT04378920|DRUG|LEAF-4L6715|LEAF-4L6715
224135478|NCT00511524|DRUG|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
223413021|NCT04806893|OTHER|Placebo|matching subcutaneous injection every month (Q4W)
223413022|NCT06104254|OTHER|education|we will give an education to experimental group about pain and pain management.
223413023|NCT00439283|DRUG|infliximab|
223413024|NCT00439283|DRUG|methotrexate|
223413025|NCT05697354|PROCEDURE|Cognitive rehabilitation using interactive tablet|the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
223559653|NCT05265234|DEVICE|Reflectance confocal microscopy|RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.
224135479|NCT00511524|DRUG|[carbonyl-^11C]GW842166|\[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
223413026|NCT05697354|PROCEDURE|Cognitive rehabilitation using smartphone App Medico Amico|the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
223413027|NCT03601598|DRUG|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
223413028|NCT03601598|DRUG|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
223413029|NCT01871129|DRUG|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
223413030|NCT01871129|OTHER|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
223413031|NCT03018080|DRUG|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
223413032|NCT03018080|DRUG|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
223413033|NCT00643474|DEVICE|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
223413034|NCT00643474|DEVICE|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
223413035|NCT04713631|DRUG|Artesunate|Artesunate is approved for the treatment of malaria and is on the World Health Organization list of Essential Medicines. Artesunate has a hemisuccinate group which confers substantial water-solubility and high oral bioavailability and therefore a convenient oral route of administration. Artesunate has a good safety and tolerability profile, having been used to treat millions of adults and children globally.
223413036|NCT04713631|DRUG|Curcumin|Curcumin has been used in Indian cuisine and traditional medicine for centuries. It has low solubility in aqueous solution and yields low serum levels following oral administration. In the setting of inflammatory bowel disease where the required site of action is the bowel, systemic absorption may be less relevant. Curcumin and its reduced metabolites undergo conjugation in the liver. Curcumin has a half life of 6-7 hours. It has been found to be safe at oral doses of 2 gm and 3 gm a day in patients with ulcerative colitis, for up to 1 year. In a dose titration study conducted in children with inflammatory bowel disease 2 gm twice daily of curcumin was well tolerated
223413037|NCT04713631|DRUG|Placebo A|Artesunate looking placebo
223413038|NCT04713631|DRUG|Placebo C|Curcumin looking placebo
223413039|NCT05952869|DRUG|Enlicitide Decanoate|Oral tablet
223413040|NCT05952869|DRUG|Placebo|Placebo
224030326|NCT05261048|OTHER|Pelvic Proprioceptive neuromuscular facilitation in addition to Conventional Physical Therapy|"The experimental group received both conventional and Pelvic PNF for 30 minutes each, once in a day, 4 days per week. The experimental group will be given anterior elevation-Posterior depression pattern with the techniques of Rhythmic initiation, Slow reversal and Stabilizing reversal. These techniques will be given on affected side for total 30 minutes with 15 minutes of pelvic PNF in one session with rest periods in between. Participants will be positioned into side lying with both hip flexion 1000 and knee flexion 450, neck supported by a pillow with flexion of 300. Hand placement for anterior elevation over the crest of the ilium one hand overlaps other for posterior depression heel of the one hand hold with other hand on the ischial tuberosity.~Pull up and Push down command will be given along with the techniques of rhythmic initiation, slow reversal and stabilizing reversal."
224030327|NCT05261048|OTHER|Conventional Physical Therapy|"Conventional physiotherapy will be asked to perform truncal exercises in spine and sitting position for total 30 minutes including rest periods in between, once in a day for 4 days per week.~Exercises in supine position included (pelvic bridging, unilateral pelvic bridging, upper trunk rotation (clasped hand), lower trunk rotation (crook lying) with 3 repetitions for each exercise.~In sitting position, exercises included flexion and extension of lower trunk, rotation of upper and lower trunk, forward and lateral reach with 3 repetitions for each exercise."
224030328|NCT03411447|OTHER|Parenteral nutrition|
224030329|NCT03411447|OTHER|Enteral nutrition|
224030330|NCT04331496|OTHER|Hypertonic solution|Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
224030331|NCT04331496|OTHER|Physiological solution|Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
224030332|NCT01629602|PROCEDURE|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
224135480|NCT05291949|DEVICE|ATLASense RAPHAEL PolyMonitor|All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.
224135481|NCT04839770|DEVICE|Axonpen system|"The Axonpen™ system, containing the Axonpen and the Axonmonitor, has been cleared for the illumination and visualization of intracranial tissue and fluids and the controlled aspiration of tissue and/or fluid during surgery of the ventricular system or cerebrum.~The Axonpen is a neuroendoscope integrated with suction (sourced from hospital vacuum) and irrigation (sourced from third-party saline infusion bag) functions. The Axonmonitor is used for view and storage of the endoscopic image. The Axonpen™ system is intended to optimize the procedure of minimally invasive neurosurgery for early ICH evacuation."
223413041|NCT00740792|DRUG|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
223413042|NCT00740792|DRUG|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
224030333|NCT02876198|DEVICE|Gonioscopy|Study of the trabecular structure by gonioscopy
224135482|NCT01621152|OTHER|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
224135483|NCT01621152|OTHER|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
224030334|NCT03302351|DRUG|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
224030335|NCT03302351|DRUG|ketamine|31 patients will receive intravenous ketamine 0.4 mg/kg.
224298246|NCT03213730|OTHER|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
224298247|NCT04032158|DRUG|Evobrutinib|Participants received evobrutinib twice daily (BID).
224298248|NCT04032158|DRUG|Avonex®|Participants received avonex® IM injection once a week.
223413043|NCT00740792|DRUG|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
223413044|NCT00740792|DRUG|placebo|placebo one spray per nostril BID
224030336|NCT03302351|DRUG|Dexmetedomidine+Ketamine|33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
224030337|NCT03990831|DIAGNOSTIC_TEST|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
224030338|NCT05717231|BEHAVIORAL|laughter yoga|laughter yoga
224030339|NCT00126893|DRUG|CC-401|
224030340|NCT04185454|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daily intake of Jarlsberg cheese
224030341|NCT01723254|BIOLOGICAL|IGE-1|Intramuscular, multiple dose
224030342|NCT01723254|BIOLOGICAL|IGE-2|Intramuscular, multiple dose
224298249|NCT04032158|DRUG|Avonex® matched Placebo|Participants received IM injection of placebo matched to Avonex® once a week.
224298250|NCT04032158|DRUG|Evobrutinib matched Placebo|Participants received placebo matched to evobrutinib twice a day.
224298251|NCT01772264|DRUG|PF-05089771|titration from 150mg BID to 450mg BID
224298252|NCT01772264|DRUG|Placebo|matched placebo
224298253|NCT03214341|RADIATION|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
224298254|NCT03384017|OTHER|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
224298255|NCT03262727|DRUG|BMS-986165|Oral administration of specified dose on specified days
224298256|NCT03262727|DRUG|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
223413045|NCT02458248|BEHAVIORAL|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
223559654|NCT03981757|DEVICE|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
224030343|NCT01723254|BIOLOGICAL|Saline|Saline (0.9% sodium chloride)
224030344|NCT01074216|DRUG|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
224030345|NCT05848687|DRUG|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
224030346|NCT05848687|DRUG|Mitoxantrone|Given IV
224030347|NCT05848687|DRUG|PEG asparaginase|Given IV
224030348|NCT05848687|DRUG|Bortezomib|Given IV
224030349|NCT05848687|DRUG|Vorinostat|Taken PO or NG
224030350|NCT05848687|DRUG|Mercaptopurine|Given PO or NG.
224030351|NCT05848687|DRUG|Methotrexate|Given IV, IM or PO
224030352|NCT05848687|DRUG|Blinatumomab|Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction
224030353|NCT05848687|DRUG|Ziftomenib|3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
224135484|NCT01770873|BEHAVIORAL|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
224135485|NCT06224881|DRUG|Ascorbic acid|2 gm every 8hrs for 4 days
224135486|NCT02278289|DEVICE|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
224135487|NCT02278289|PROCEDURE|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
224298257|NCT04129320|BIOLOGICAL|enoblituzumab|anti-B7-H3 antibody
224298258|NCT04129320|BIOLOGICAL|MGA012|anti-PD-1 antibody
224298259|NCT04129320|BIOLOGICAL|MGD013|PD-1 X LAG-3 bispecific DART protein
223413046|NCT03207048|DEVICE|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
223413047|NCT03207048|DEVICE|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
223413048|NCT03900169|GENETIC|Genetic|Lipid profile
223413049|NCT05533268|OTHER|Mental training|Mental training (guided mindfulness meditation by Jon Kabat-Zinn for 20 minutes, 3 times per week.
223413050|NCT05533268|OTHER|Physical training|Physical training (continuous moderate-intensity training at 40-60% of participants' heart rate reserve for 20 minutes excluding warm-up/cool-down, 3 times per week.
223413051|NCT05533268|OTHER|Mental & physical training|Mental and physical training (combination of mindfulness mediation for 20-minutes, 3 times per week and continuous moderate-intensity training for 20 minutes, 3 times per week.
223559655|NCT03668496|DRUG|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
224030354|NCT05260515|BEHAVIORAL|Staying Sharp intervention|"In the Staying Sharp online program, participants have the opportunity to select which health pillars they are most interested in improving (Be social, Engage your brain, Manage stress, Ongoing exercise, Restorative sleep, and Eat right). After selecting the health pillars, participants can set plans and goals. There are designated activities in each health pillar for participants to complete, including watch videos, read articles, or play games. Participants will follow a step-by-step guide to achieve these goals. The website tracks the status of these goals.~Participants will use Staying Sharp program for 4 months. Research staff will call participants to encourage participants to use the program. Right after the completion of the 4-month program, we will send out a survey to understand user experiences. We will follow participants for another 4 months. After 4 months follow-up, an exit study survey will be conducted either via videoconferences or in-person visits."
224030355|NCT05088018|OTHER|Cannabigerol|Cannabigerol is a non-psychoactive cannabinoid obtained from the cannabis plant.
224030356|NCT05088018|OTHER|Placebo|A placebo form of the same swallowable tablet with no cannabigerol
224030357|NCT03451760|DRUG|Feru-guard 100M|Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
224030358|NCT03451760|OTHER|Feru-guard 100M Placebo|In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
224030359|NCT02976701|DRUG|DLBS1033|
224030360|NCT02976701|DRUG|Placebo|
224030361|NCT02976701|DRUG|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
224135488|NCT05542329|DEVICE|Monitoring by Tele-Medecine|Monitoring by Tele-Medecine
224135489|NCT04434820|DEVICE|External negative pressure dressing system (Yuwell 7E-A portable suction unit)|A portable suction unit that will deliver 125 mm Hg of continuous pressure to the dressing and will remove exudates into a disposable canister for 4 days.
224135490|NCT01982773|BEHAVIORAL|Virtual Hope Box Smartphone App|Smartphone app
224135491|NCT01982773|BEHAVIORAL|Enhanced Treatment as Usual|Printed materials
224135492|NCT01029886|DRUG|exenatide once weekly|subcutaneous injection, 2mg, once weekly
224298260|NCT02072824|DRUG|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
224298261|NCT02072824|DRUG|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
223413052|NCT05533268|OTHER|DASH diet|DASH diet ( (more vegetables, fruits and low-fat dairy foods and moderate amounts of whole grains, fish, poultry and nuts; and less than 3 grams of sodium daily) for 6-weeks.
223413053|NCT04769518|PROCEDURE|Advanced Recovery Room Care (ARRC)|High acuity care
223559656|NCT03668496|DRUG|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
224298262|NCT02072824|DRUG|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
223559657|NCT01491789|DEVICE|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
223559658|NCT02982434|DRUG|Pharmaceutical composition containing botulinum toxin|
223559659|NCT02982434|DRUG|0.9% normal saline|
223559660|NCT02982434|PROCEDURE|Coronary artery bypass grafting|
223559661|NCT00853242|DRUG|Placebo|
224135493|NCT01029886|DRUG|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
224135494|NCT05415540|OTHER|Questionnaires|Subjects included in the study will answer questionnaires
224135495|NCT02388022|DEVICE|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
224135496|NCT01952457|DEVICE|Zilver PTX|
224135497|NCT01952457|DEVICE|prosthetic bypass|
224135498|NCT03294681|DEVICE|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
224135499|NCT03936517|DRUG|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
224135500|NCT03936517|DRUG|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
224135501|NCT04922619|DEVICE|tonotopy based fitting then default fitting|Cochlear implant with default fitting then tonotopy based fitting
223413054|NCT01709682|DRUG|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
223559662|NCT00853242|DRUG|Genz-644470|
224030362|NCT03866707|OTHER|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
224135502|NCT04922619|DEVICE|default fitting then tonotopy based fitting|Cochlear implant with tonotopy based fitting then default fitting
224030363|NCT03866707|OTHER|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
224030364|NCT03866707|OTHER|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
224135503|NCT00093860|DRUG|Propranolol|
224135504|NCT01218789|DRUG|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
224135505|NCT01778127|BEHAVIORAL|Activity Monitor|Measurement of physical activity.
224135506|NCT01778127|BEHAVIORAL|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
224135507|NCT01778127|BEHAVIORAL|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
224135508|NCT00668304|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
224135509|NCT01348425|DEVICE|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
224135510|NCT01348425|DEVICE|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
224298263|NCT03084367|DIAGNOSTIC_TEST|iFR pullback|iFR pullback assessment post angiographically successful PCI
223413055|NCT01709682|PROCEDURE|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
223413056|NCT01709682|PROCEDURE|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
223559663|NCT00853242|DRUG|Sevelamer carbonate|
224135511|NCT00007904|BIOLOGICAL|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC \> 10,000/uL x1 day after the nadir cycles 1-3.
224135512|NCT00007904|DRUG|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
224135513|NCT00007904|DRUG|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
224135514|NCT00007904|DRUG|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
224135515|NCT00007904|DRUG|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
224135516|NCT00007904|PROCEDURE|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
224135517|NCT00007904|RADIATION|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
224298264|NCT03413137|PROCEDURE|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
224298265|NCT03413137|PROCEDURE|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
223413057|NCT03195621|DEVICE|Stent implantation|Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
223559664|NCT05850130|OTHER|Acupuncture intervention|"6 weeks of acupuncture once a week. The acupuncture intervention will consist of weekly session administered over a period of 6 weeks (± 4 days). A two-way verum acupuncture treatment protocol will employ 8 selected acupoints.~After week 7, patients included in Arm A may receive an optional 6 weeks of acupuncture. This option of acupuncture continuation will be left to the patient choice in agreement with a physician acupuncturist."
223559665|NCT05850130|OTHER|No acupuncture|The patient in the Arm B will not receive acupuncture treatment for a period of 6 weeks after randomization (weeks 1-6) and during the following weeks 8-13 (acupuncture intervention) if its NRS score is \<4/10 at week 7. If the patient' NRS score is ≥ 4/10 at week 7, the patient in control Arm B will receive the same acupuncture intervention that the patient in the Arm A (6 weeks).
223559666|NCT00597623|OTHER|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
223559667|NCT00597623|OTHER|Placebo|syringes under cutaneous vol = 8 ml
223413058|NCT05518240|DEVICE|Stent Retrievers|Procedure: Embotrap device
223559668|NCT03497975|DRUG|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
223559669|NCT03497975|DRUG|Placebo Tablets|Placebo matching NAL ER with no active substance
224030365|NCT04364009|DRUG|Anakinra plus oSOC|"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"
224030366|NCT04364009|DRUG|oSOC|Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.
224030367|NCT03795597|DRUG|Carfilzomib|Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
224030368|NCT03795597|DRUG|Busulfan IV|Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
224030369|NCT03795597|DRUG|Melphalan IV|Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
224135518|NCT04347317|PROCEDURE|Low Intensity IMT|"The control group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 30% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
224135519|NCT04347317|PROCEDURE|High Intensity IMT|"The experimental group will get a supervised IMT with Threshold IMT device, once a day, 5 days a week for a maximum of 28 days or until the participant is weaned successfully. In each session the participant will do 5 sets of 6 repetitions with 2 minutes of rest between sets. The initial training load will be adjusted to 60% of the MIP and will be increased by 10% of the initial MIP weekly.~The patient will be placed in a semi-incorporated position (head of the bed elevated 45º). The ICU physiotherapist will check before training that the cuff of the tracheal tube is correctly swollen to avoid air leaks during the training. The ICU physiotherapist will disconnect the mechanical ventilation during the IMT and will provide supplemental oxygen when required. However, between series the participant will be returned to ventilator support. Patients will be instructed to do a whole expiration and immediately inspire as forceful as possible until reaching the total lung capacity."
224135520|NCT04915924|DEVICE|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Advanced heart failure patients will be implanted with the HM3 LVAS
223413059|NCT05518240|DEVICE|Stent Retriever|Procedure: Solitaire device
224030370|NCT01822236|OTHER|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
224030371|NCT01822236|OTHER|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
224030372|NCT03080428|DIAGNOSTIC_TEST|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
224030373|NCT05631977|OTHER|Point of care ultrasound cardiac examination|The study intervention consists of a POCUS cardiac examination by site approved personal using an FDA cleared US scanner. Usual care of study participants will not be impacted.
224030374|NCT06078839|DRUG|Nafamostat mesilate|Nafamostat mesilate treatment group was dissolved with 5% glucose at the dosage of 2.0mg/kg/ day to a total of 50ml(Maximum concentration 10mg/ml)
224030375|NCT06078839|DRUG|5% glucose|Add 50ml of 5% glucose into a 50ml syringe
224030376|NCT00916825|BEHAVIORAL|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
223413060|NCT01605240|DRUG|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
224030377|NCT00697723|PROCEDURE|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
224030378|NCT02265367|DRUG|Levomilnacipran|
223413061|NCT01605240|DRUG|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
223413062|NCT00248742|BEHAVIORAL|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
223413063|NCT03397498|BEHAVIORAL|CogniFit™|The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.
223559670|NCT05495243|DRUG|ARINA-1|ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)
223559671|NCT05495243|DRUG|Placebo|Isotonic saline (0.9%)
223559672|NCT01208883|OTHER|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment \[18F\]FDG-PET for treatment adaptation
223559673|NCT06322745|PROCEDURE|Suture renorrhaphy only for hemostasis of the tumor bed in laparoscopic partial nephrectomy|Suture renorrhaphy will be used in 2 layers; medullary and cortical, with Vicry 2/0 or 3/0 and secured with V-lock. Early unclamping will be done after hemostasis of the medullary layer. Renorrhaphy of the cortical layer will be continued after that.
224030379|NCT02265367|DRUG|Placebo|
224030380|NCT02889003|DRUG|Pioglitazone + TKI|
224030381|NCT01847053|OTHER|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
224030382|NCT01847053|OTHER|Oatmeal|Oatmeal control, around 70g; without cinnamon
223559674|NCT06322745|PROCEDURE|Thulium beam coagulation and suture renorrhaphy for hemostasis of the tumor bed in laparoscopic partial nephrectomy|A 2-μm continuous thulium laser with 365 μm laser fiber at 30-40 W will be used for coagulation of the tumor bed. Large vessels that may not be completely sealed with thulium beam will be closed by V-lock to achieve safe and stable hemostasis. Early unclamping will be done after hemostasis of the tumor bed. Suture renorrhaphy will be used in 1 layer to approximate the renal parenchyma.
224030383|NCT06187285|DRUG|Empagliflozin 25 MG|Patient will get Empagliflozin 25
224030384|NCT06187285|DRUG|Sitagliptin 100mg|Patient will get Sitagliptin 100 mg
224030385|NCT07019545|DRUG|Belantamab Mafodotin|Belantamab mafodotin is administered intravenously (IV) at a dose of 1.9 mg/kg on Day 1 of every other 28-day cycle for the first two administrations and then 1.9 mg/kg on Day 1 of every third 28-day cycle.
224030386|NCT07019545|DRUG|Dexamethasone|Dexamethasone is administered IV or per OS (PO) at a dose of 40 mg/day on days 1, 2, 3, 4 and 15, 16, 17, 18 of every 28-day cycle for the first two cycles in participants \<75 years; at 20 mg/day on days 1, 2, 3, 4 and 15, 16, 17, 18 of every 28-day cycle for the first two cycles in participants ≥75 years.
224030387|NCT06693609|DRUG|EMP-01|EMP-01 capsules
224030388|NCT06693609|DRUG|EMP-01 Placebo|EMP-01 placebo capsules
224030389|NCT04223856|DRUG|Enfortumab vedotin|Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
224030390|NCT04223856|DRUG|Pembrolizumab|IV infusion on Day 1 of every 3-week cycle
224030391|NCT04223856|DRUG|Cisplatin|administered as IV infusion on Day 1 of each 3-week cycle
224030392|NCT04223856|DRUG|Carboplatin|Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
224030393|NCT04223856|DRUG|Gemcitabine|IV infusion on Days 1 and 8 of every 3 week cycle
224030394|NCT04687228|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
224030395|NCT04687228|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
224030396|NCT07020793|PROCEDURE|green subthreshold laser therapy|The intervention consists of green subthreshold laser therapy delivered using the Norlase µSec™ Technology, a novel microsecond-pulsed laser platform specifically designed for retinal treatments.
224030397|NCT05869526|DIETARY_SUPPLEMENT|Fish oil|EPA rich fish oil
224030398|NCT05869526|DIETARY_SUPPLEMENT|Kril oil|Superba Krill Oil
224030399|NCT05869526|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
224030400|NCT03226275|DRUG|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
224030401|NCT03226275|DRUG|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
223559675|NCT03590626|DRUG|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
223738802|NCT03081260|OTHER|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
223738803|NCT03081260|OTHER|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
223738804|NCT05322577|DRUG|Bemarituzumab|Intravenous (IV) infusion
224030402|NCT03226275|DRUG|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
224030403|NCT02139787|OTHER|Radio Story|
224030404|NCT02139787|OTHER|Control -listened to a brochure|
224030405|NCT07019597|DEVICE|Non-invasive neuromodulation NESA(NNG)|NESA is a non-invasive monitoring device, which emits low frequency (1.3-14.28 Hz, depending on the programme), low intensity (0.1-0.9 mA), low voltage (±3 V) ultra low currents, and therefore imperceptible to the patient. It is based on neuromodulation of the autonomic nervous system.
224030406|NCT07019597|DEVICE|Non-invasive Neuromodulation Posterior Tibial (NTPG)|NTPG is an electrotherapy using a device called NEUROTRAC MYOPLUS PRO (brand name) to perform non-invasive TENS-type electrotherapy with biphasic currents.
224030407|NCT03337451|DRUG|OPN-305|Patients will receive study drug every 4 weeks
224030408|NCT01708122|DRUG|Fentanyl|100 mcg in 1 mL intranasal spray
224030409|NCT01708122|DRUG|saline|Sodium Chloride 0.9% intranasal spray
224030410|NCT05175651|BEHAVIORAL|Genetic risk assessment|A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
224030411|NCT04547153|DRUG|5-fluorouracil|200mg/square metre/day civ D1-D21
224030412|NCT04547153|DRUG|Docetaxel|25mg/square metre ivdrip D1, D8, D15
224030413|NCT06096896|PROCEDURE|MWA|Microwave ablation (MWA) was performed under EOB-MRI guidance in patients with confirmed or suspected eHCC.
223559676|NCT01651065|BEHAVIORAL|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
224030414|NCT00294554|DRUG|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
224030415|NCT00294554|DRUG|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
224030416|NCT05817760|PROCEDURE|Z-scrotoplasty|Z shape incision of the penoscrotal web and closure
224030417|NCT05817760|PROCEDURE|Heineke-Mikulicz scrotoplasty|Transverse incision of the penoscrotal web with vertical closure
224030418|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
224030419|NCT00494858|BEHAVIORAL|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
224030420|NCT00710281|RADIATION|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:"
224135521|NCT05280041|BEHAVIORAL|SOLENA - Online self-help program for older adults who lost the partner|SOLENA follows the most relevant CBT elements of interventions for prolonged grief: 1) Exposure, e.g., telling the story of the loss; 2) cognitive reappraisal or restructuring of individual dysfunctional thoughts associated with the loss; 3) integration and restoration including self-care and social reengagement; and 4) behavioural activation. SOLENA's content is provided through a conversational virtual agent, Sol, who guides the user through the Study section the CBT intervention itself. In 10 study modules that address either the acceptance of the loss or the restoration and adaptation to a new life, SOLENA includes 1) readings, i.e., texts based about grief related topics that provide the background and rational for the module; and 2) exercises to encourage mourners to actively reflect on their grief and apply their new knowledge to their daily life and to practise the new routines regularly. SOLENA also provides users with the Notebook, Activities, and My Support sections.
224135522|NCT03430817|DRUG|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
224135523|NCT03430817|DRUG|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
224135524|NCT03722784|DEVICE|Invigor A (test)|silicone hydrogel lens
223559677|NCT01651065|BEHAVIORAL|Control|
224030421|NCT00219713|DRUG|nitrous oxide and oxygen|
224030422|NCT02909270|DEVICE|Mediclore|to apply mediclore fully around thyroid gland
224030423|NCT04788576|DIAGNOSTIC_TEST|Invasive physiologic evaluation (fractional flow reserve, coronary flow reserve, index of microcirculatory resistance)|In case of heart failure with preserved ejection fraction confirmed by HFA-PEFF scoring system without functionally significant coronary artery disease, coronary angiography with invasive physiologic evaluation including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance will be performed to evaluate the distribution and clinical implication of coronary microvascular dysfunction.
224030424|NCT02822170|OTHER|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
224030425|NCT03516851|PROCEDURE|Precision bypass group|With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
224135525|NCT03722784|DEVICE|Invigor B (control)|silicone hydrogel lens
224135526|NCT01963208|DRUG|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
224135527|NCT01963208|DRUG|Placebo|placebo
224135528|NCT01336556|PROCEDURE|Oral appliance|Anterior mandibular repositioner: used for two months
224135529|NCT06600178|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10mg oral
224135530|NCT06600178|DRUG|Placebo|Placebo tablet given to subject vs. active drug.
224135531|NCT00497016|DRUG|atorvastatin 80 mg|
224135532|NCT02675153|DRUG|Rapamycin|Participants with gastrointestinal strictures were treated with rapamycin 2mg daily at least six months.
224135533|NCT00448916|DRUG|Pregabalin|Orally-administered pregabalin
224135534|NCT00332800|DRUG|Nutritional Supplementation|
224135535|NCT06348407|DRUG|IgE monoclonal antibody|omalizumab
224135536|NCT00808730|PROCEDURE|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
223413064|NCT03397498|BEHAVIORAL|Control-games|The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
223413065|NCT03674346|OTHER|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~* The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~* The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~* The time of return. It is time that allows the patient to regain his classic state of consciousness."
223559678|NCT05422495|BEHAVIORAL|training with Cycléo device (COTTOS ®),|8 weeks of training
223559679|NCT05422495|OTHER|non intervention|non intervention
223559680|NCT06314373|DRUG|HSK39775 Monotherapy|HSK39775 will be administered orally once daily
224030426|NCT00462865|DRUG|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
224030427|NCT05446688|DRUG|6MW3211|6MW3211 injection, 45mg/kg, Q2W
224030428|NCT04592861|RADIATION|carbon ion RT|daily carbon ion radiotherapy
224030429|NCT04592861|DRUG|Chemotherapy drug|Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
224030430|NCT00863863|DRUG|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
224030431|NCT00863863|DRUG|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
224030432|NCT05477381|DIAGNOSTIC_TEST|Measurement of cervical stiffness by Pregnolia Device|"The Pregnolia® System is designed to provide information about the mechanical properties of the cervical tissue by assessing the CSI (Cervical Stiffness Index) through a probe that will create a weak vacuum to retract tissue. The Pregnolia® System is designed with the purpose to provide an alternative diagnostic marker to identify women at risk of spontaneous PTB.~The Pregnolia® System is a CE-marked device developed for quantitative assessment of softening of the uterine cervix.~The Pregnolia® System will be applied within its intended use."
224030433|NCT04886310|DIAGNOSTIC_TEST|Peabody Developmental Motor Scale II (PDMS-2)|is composed of six subtests (reflex, stationary, locomotion, object manipulation, grasping, and visual-motor integration) that measure inter-related abilities in early motor development. It was designed to assess gross and fine motor skills in children from birth through 5 years of age.
223559681|NCT04961528|DRUG|Tranexamic Acid 500 MG|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days"
224030434|NCT01438021|OTHER|pharmacological study|Correlative studies
224030435|NCT01438021|DRUG|methotrexate|Given intraventricularly
224030436|NCT02864381|DRUG|Andecaliximab|800 mg administered via IV infusion
224030437|NCT02864381|DRUG|Nivolumab|3 mg/kg administered via IV infusion
224030438|NCT00152139|PROCEDURE|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
224030439|NCT00152139|DRUG|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
224030440|NCT04507061|DRUG|runcaciguat|Titrated dose of active dose 1, dose 2, dose 3, dose 4 of runcaciguat will be administered orally once a day.
224030441|NCT04507061|OTHER|Placebo|Sham-titrated dose of matching placebo will be administered orally once a day.
224030442|NCT02245126|DRUG|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
224030443|NCT02245126|DRUG|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
224030444|NCT05995639|PROCEDURE|Dry Needling|Dry needling is an evidence-based therapeutic procedure used primarily in musculoskeletal rehabilitation. It involves inserting thin needles into specific trigger points in muscles, tendons, or fascia, aiming to alleviate pain and improve musculoskeletal function. Unlike acupuncture, dry needling focuses on resolving myofascial pain and dysfunction by directly targeting trigger points, often identified through palpation and anatomical understanding. Academic exploration of dry needling delves into its physiological mechanisms, clinical effectiveness, and potential integration into comprehensive treatment strategies.
224030445|NCT05995639|PROCEDURE|Ozone Injection|Intramuscular ozone injection is a therapeutic intervention utilized within the context of musculoskeletal care, particularly for individuals grappling with conditions such as myofascial pain syndrome and related neuromuscular issues. This technique involves the controlled introduction of ozone gas, a chemically reactive form of oxygen, directly into targeted muscle tissue through an injection. This intramuscular administration is guided by precise anatomical knowledge and is designed to harness the potential therapeutic benefits of ozone's reactive properties.
224030446|NCT05871255|OTHER|Zantogin® Gel|Zantogin® Gel (ZG) is a multicomponent vaginal lubricant endowed with lenitive and anti-inflammatory properties, developed as class II medical device for the treatment of VVA.
224030447|NCT01992042|DRUG|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
224030448|NCT01992042|DRUG|Pimonidazole|
224030449|NCT01769235|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
223413066|NCT03674346|OTHER|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
223413067|NCT04543149|DIAGNOSTIC_TEST|Flow cytometric immunophenotyping|To evaluate T cell subsets and monocyte
223413068|NCT01583309|PROCEDURE|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
223413069|NCT01583309|PROCEDURE|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
223413070|NCT05654961|OTHER|Use of telemedicine|Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
223413071|NCT00600912|DRUG|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
223413072|NCT00600912|DRUG|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
223413073|NCT05235412|OTHER|Not applicable: Observational study without any interventions.|Exposures of interest: Maternal diet and lifestyle, demographics, anthropometrics, infant's health outcomes
223413074|NCT00775801|DEVICE|FLD|Artificial lumbar disc
223413075|NCT00775801|DEVICE|Control|Artificial lumbar disc
223413076|NCT05708872|BEHAVIORAL|Autohypnosis|Patients in the study group will receive a voice recording with hypnotic instructions with a suggestion to improve the psychophysical state.
223413077|NCT05708872|BEHAVIORAL|Relaxing music|Patients in the control group will receive a recording with relaxing music
223413078|NCT01848912|DEVICE|Zephyr Biopatch Device|
223413079|NCT05894941|OTHER|Corrective Exercises|A total of 6 evidence-based exercises and stretches namely; Upper trapezius stretch, Sternocleidomastoid stretch, pectoral stretch; Chin tuck exercise, YTWL exercise, and resisted/isometric neck extension exercise will be prescribed to the exercise group while the postural education group will follow the guidelines provided by National Institutes of Health (NIH) for using computers and other sources. The control group will receive no intervention.
223413080|NCT05894941|OTHER|Postural Education|Postural guidelines for doing daily activity especially sitting for prolonged periods and using electronic devices like computers and other electronic devices.
223413081|NCT04893616|OTHER|Integration of vaccination services into delivery services|The purpose of the work is to integrate readily available birth dose vaccinations (Oral Polio and the Tuberculosis vaccine) currently given in a separate clinic into the maternity delivery services through improved training, checklist, and job aides.
223413082|NCT01672541|BEHAVIORAL|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
224030450|NCT01769235|DRUG|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
224030451|NCT01769235|DRUG|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
224030452|NCT04292002|BEHAVIORAL|Test@Work|Offer of a general health check including opt-in sexual health consultation and HIV testing, weight/height, Body Mass Index (BMI), blood pressure, mental health screen. Provision of tailored health advice and a resource pack with information and signposting.
224030453|NCT00007917|DRUG|alvocidib|
224030454|NCT00007917|DRUG|gemcitabine hydrochloride|
224030455|NCT05172167|DIAGNOSTIC_TEST|Levels of IgG and IgM SARS-CoV-2 antibodies blood test.|0,1,2 months
224030456|NCT05172167|DIAGNOSTIC_TEST|RT-PCR SARS-CoV-2 nasopharyngeal swab|0,1,2 months
224030457|NCT06292650|DRUG|ZM-02-L|rAAV-PsCatCh2.0 intravitreal injection of low dose
224030458|NCT06292650|DRUG|ZM-02-H|rAAV-PsCatCh2.0 intravitreal injection of high dose
224030459|NCT06292650|PROCEDURE|ZM-02-S|sham intravitreal injection of ZM-02 (not actual injection)
224030460|NCT01727622|DRUG|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
224030461|NCT01727622|OTHER|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
224030462|NCT01727622|PROCEDURE|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
224030463|NCT05398016|BEHAVIORAL|low-intensity intervention for anxiety|Brief (6-8 weekly 30-min sessions) delivery of a structured behavioral treatment for mild-to-moderate anxiety. Treatment will be based on principles of cognitive behavioral therapy (CBT).
224030464|NCT02736773|OTHER|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
224030465|NCT02377791|GENETIC|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5\*1/\*1 vs CYP3A5\*1/\*3 or CYP3A5\*3/\*3
223413083|NCT01672541|BEHAVIORAL|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
223413084|NCT01268618|DIETARY_SUPPLEMENT|Probiotic|"2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:~1. Lactobacillus acidophilus NAS, 30 billion CFU~2. Bifidobacterium bifidum Malyoth, 120 billion CFU~3. Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU"
223413085|NCT01268618|DIETARY_SUPPLEMENT|Placebo|2 capsules, 3x/day placebo capsules
223738805|NCT05322577|DRUG|CAPOX|CAPOX administered as a combination of oxaliplatin as an IV infusion and capecitabine orally as tablets.
224135537|NCT02787330|BEHAVIORAL|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
224135538|NCT02787330|BEHAVIORAL|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
224135539|NCT00001251|DRUG|Mafosfamide|
224135540|NCT01890070|DIETARY_SUPPLEMENT|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
224135541|NCT01890070|DIETARY_SUPPLEMENT|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
223413086|NCT03770754|PROCEDURE|Clean and shape Control group|"For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol"
223413087|NCT03770754|PROCEDURE|Cleand and shape Group 1|For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol
224135542|NCT01890070|DIETARY_SUPPLEMENT|Red wine|Italian Organic Red Wine
224135543|NCT01890070|DIETARY_SUPPLEMENT|Olive Oil|Italian Organic Olive Oil
223413088|NCT03770754|PROCEDURE|Clean and shape Group 2|"For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered"
223413089|NCT04867642|DRUG|UCB0022|Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.
223413090|NCT04867642|OTHER|Placebo|Study participants will receive placebo comparator in a pre-specified sequence during the Treatment Period of Part A, B and C.
223413091|NCT00249132|DRUG|risperidone|
224030466|NCT05165147|OTHER|no intervention|no intervention
224135544|NCT01890070|DIETARY_SUPPLEMENT|Wild mixed greens|Italian organic wild mixed greens
224135545|NCT01890070|DIETARY_SUPPLEMENT|Chestnut|Italian Organic Chestnut
224135546|NCT01890070|OTHER|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
224135547|NCT04597619|OTHER|Novel Nonopioid Pathway|The novel nonopioid pathway consists of preoperative counseling, postoperative standardized orders and standard of care adjunctive and analgesic medications, specialized discharge instructions and written patient instructions regarding medications and activity.
224135548|NCT04914741|DRUG|Rituximab|Rituximab 375 mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
224135549|NCT04914741|DRUG|Cyclophosphamide|Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
224298266|NCT03863093|DEVICE|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
224298267|NCT03863093|DEVICE|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
224298268|NCT03251274|OTHER|machine bathing|machine bathing 20-min duration at evening
223413092|NCT01779128|PROCEDURE|PET-CT|
223413093|NCT01779128|PROCEDURE|MR-PET|
223413094|NCT02362802|DEVICE|Implantable Cardioverter Defibrillator|
223413095|NCT00179660|DRUG|Lenalidomide|Capsules for oral administration.
223413096|NCT03039530|BEHAVIORAL|Group Cognitive Behavioral Therapy|9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
223413097|NCT03039530|BEHAVIORAL|Postnatal Care As Usual|Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
223413098|NCT01521286|OTHER|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
223413099|NCT03935425|DEVICE|FitMi Plus|A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
223413100|NCT03935425|DEVICE|FitMi Basic|A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
223413101|NCT06093516|DEVICE|Tinted Lenses|Tinted coloured lenses with UV protection within spectacle frames with the intension to help reduce the symptoms of Visual stress.
223413102|NCT02035449|DEVICE|McGrath MAC|McGrath MAC is a videolaryngoscope
224030467|NCT02752646|DRUG|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
224030468|NCT02752646|DRUG|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
224030469|NCT03651986|DIAGNOSTIC_TEST|ctDNA methylation analysis by NGS|A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)
224135550|NCT04914741|DRUG|Doxorubicin|Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
224135551|NCT04914741|DRUG|Vincristine|Vincristine 1.4mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
224135552|NCT04914741|DRUG|Prednisolone|Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
224135553|NCT04914741|DRUG|Glofitamab|Glofitamab will be administered by IV infusion as per the schedule specified in the respective arm
224135554|NCT04914741|DRUG|Polatuzumab vedotin|Polatuzumab 1.8mg/kg administered by IV infusion on Day 1 of every 21-day cycle
224135555|NCT04015414|DRUG|Varenicline|191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
224298269|NCT03251274|OTHER|traditional bathing|traditional bathing
224298270|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
223413103|NCT02220036|DIETARY_SUPPLEMENT|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
223413104|NCT02196441|DRUG|2% tetracaine local anaesthetic drops|topical anaesthetic drops
224030470|NCT01146054|DEVICE|CyberKnife based stereotactic radiotherapy|"1. Initial orthogonal images will be obtained to confirm location of fiducial seeds.~2. Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~3. Quality assurance will be performed as per standard practice at each participating institution."
224030471|NCT01146054|DRUG|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
224030472|NCT01146054|DRUG|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
224030473|NCT03439176|OTHER|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
224030474|NCT03439176|OTHER|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
224030475|NCT03439176|OTHER|PL4|This strip contains a new adhesive
224030476|NCT03439176|OTHER|PL16-L|This strip contains a new adhesive
224030477|NCT02237651|DEVICE|topical anesthesia multi-use device|
224030478|NCT02237651|DEVICE|topical anesthesia Intranasal Mucosal Atomization|
224030479|NCT02397811|DIETARY_SUPPLEMENT|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
224030480|NCT02397811|DIETARY_SUPPLEMENT|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
224135556|NCT04015414|DRUG|Cytisine|185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
224298271|NCT00650442|DRUG|Estradiol Transdermal System Placebo - Current Adhesive|single application
224298272|NCT02290275|DIETARY_SUPPLEMENT|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
224298273|NCT02290275|OTHER|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
224298274|NCT02290275|DIETARY_SUPPLEMENT|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
224298275|NCT05211999|BEHAVIORAL|Precede-Proceed Model Based Simulation Experience|The program was created on the basis of the PRECEDE-PROCEED Model.The program consists of eight phases. It will be carried out with theoretical training and simulation experience in the experimental group. In the control group, theoretical training will be given. Results will be followed.
224030481|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
224030482|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
224030483|NCT02397811|DIETARY_SUPPLEMENT|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
224030484|NCT02397811|DIETARY_SUPPLEMENT|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
224030485|NCT04643509|DEVICE|Niccomo|Niccomo monitoring added to pulmonary arterial catheter monitoring
224030486|NCT05810272|BEHAVIORAL|Metabolic Trial|Participants will undergo a metabolic trial to assess for their anabolic response to a protein-carbohydrate meal.
224030487|NCT05810272|BEHAVIORAL|15 sit-to-stands with calf raises|Participants (n=10; 5F/5M) will be randomized to perform 15 sit-to-stands with calf raises every 30 minutes for the 4 hour duration between muscle biopsies
224030488|NCT03906435|BEHAVIORAL|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
224030489|NCT06082583|DEVICE|Remote Ischemic Conditioning|Remote ischemic conditioning conducted by an electric auto-control device will be performed twice a day for 14 days, each session including 5-min ischemia and 5-min reperfusion.
224030490|NCT06082583|DRUG|Tibetan Medicine (Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills, Qiwei Tiexue Pill)|Comprehensively Tibetan medicine for 28 days, including Shiliu Jianwei Powder, Ershiwuwei Yuganzi Pills and Qiwei Tiexue Pill, dosage of which are 1.5g daily.
224030491|NCT04385420|DRUG|ATR-002 MEK Inhibitor|Drug ATR-002 administered as film-coated tablet via oral route
224135557|NCT04359082|DIETARY_SUPPLEMENT|CocoaVia supplement|CocoaVia is a dietary supplement that has concentrated bioflavanols of 225 mg flavanols per pill along with 30 mg theobromine and 10 mg caffeine
224298276|NCT05211999|BEHAVIORAL|Control Group|No intervention in control group just theoretical education was done for them.
224135558|NCT04359082|OTHER|Placebo Pill|Placebo pill has no bioflavanols with 30 mg theobromine and 10 mg caffeine
223413105|NCT02196441|DRUG|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
223413106|NCT05416021|DRUG|dapivirine|dapivirine vaginal ring
223413107|NCT02035202|BEHAVIORAL|CBT2go|CBT administered using mobile intervention.
223413108|NCT02035202|DEVICE|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
223413109|NCT01531621|OTHER|Biomarker sampling|Blood samples every 8-12 weeks
223413110|NCT00178685|BEHAVIORAL|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
223413111|NCT00690677|DRUG|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
223413112|NCT03223415|OTHER|Detection and isolation of C. difficile carriers|"Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward."
223738806|NCT05322577|DRUG|SOX|SOX administered as a combination of oxaliplatin as an IV infusion and S-1 orally.
223738807|NCT05322577|DRUG|Nivolumab|IV infusion.
223413113|NCT01835873|OTHER|Lactated Ringer's|
223413114|NCT01835873|OTHER|HES 130/0.42|Balanced colloid solution
223413115|NCT04210401|OTHER|Duodenoscope Culture|Culture of reusable duodenoscopes following each use.
223413116|NCT05121701|DEVICE|Videolaryngoscope|C-MAC PM-Karl Storz
224030492|NCT04385420|DRUG|Placebo oral tablet|Placebo film-coated tablet administered via oral route
223413117|NCT05121701|DEVICE|Macintosh Laryngoscope|Laryngoscope
223413118|NCT00004063|BIOLOGICAL|recombinant interferon alfa|
223413119|NCT00004063|DRUG|cisplatin|
223413120|NCT00004063|DRUG|gemcitabine hydrochloride|
223413121|NCT00004063|PROCEDURE|hyperthermia treatment|
223413122|NCT01566539|DRUG|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
223413123|NCT01566539|DRUG|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
223413124|NCT01566539|DRUG|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
223413125|NCT01566539|DRUG|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
223413126|NCT01566539|DRUG|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
223413127|NCT01811810|RADIATION|Radiation therapy (XRT)|
224030493|NCT05781776|OTHER|Otago exercises and core strengthening|"Otago exercise program consisted of strengthening and balance exercises. The strengthening exercises focus on major lower limb muscles. Progression of exercises was done by increasing the duration and then intensity.~Balance exercises involved knee bends, backward walking, walking, and turning around, sideways walking, tandem stance (heel to toe), tandem walk (heal to toe walk), one leg stand, heel walking, toe walk, heel to toe walking backward, sit to stand and stair walking. Balance exercises progressed with varying levels of support depending on their balance and confidence. The individuals repeated each exercise 10 times."
223413128|NCT01811810|OTHER|Androgen Deprivation Therapy (ADT)|
223413129|NCT01811810|OTHER|Chemotherapy|
224135559|NCT01290120|DRUG|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
224135560|NCT00607438|DRUG|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
224135561|NCT00607438|DRUG|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
223413130|NCT01097590|DEVICE|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
223413131|NCT01097590|DEVICE|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
223738808|NCT05392946|DRUG|Bortezomib|Given SC
223738809|NCT05392946|BIOLOGICAL|Daratumumab|Given SC
223738810|NCT05392946|DRUG|Dexamethasone|Given PO
223738811|NCT05392946|DRUG|Iberdomide|Given PO
223738812|NCT05963698|DEVICE|WATCHMAN device|Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
223738813|NCT05740566|DRUG|Tarlatamab|Tarlatamab will be administered as an IV infusion.
223738814|NCT05740566|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SOC.
223738815|NCT05740566|DRUG|Topotecan|Topotecan will be administered per local SOC.
223738816|NCT05740566|DRUG|Amrubicin|Amrubicin will be administered per local SOC.
224135562|NCT00383214|DRUG|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
224135563|NCT00383214|OTHER|Placebo|Intravenous
224030494|NCT05781776|OTHER|Gaze stability exercises and core strengthening|"The exercise protocol in Gaze Stability exercises included adaptation exercises and substitution exercises. In adaptation exercises, individuals performed rapid, active head rotations while watched a visual target with the target remaining stationary. Substitution exercises, individual performed eye-head movements between targets with the goal of seeing clearly during the task. That target moved in the opposite direction of head movement.~Adaptation exercises included: Horizontal and vertical (stationary target) viewing exercises done with a near target, sitting. Horizontal and vertical (stationary target) viewing exercises done with near and far targets (6-10 feet), sitting. Horizontal and vertical (stationary target) viewing exercises were done with near and far targets, standing."
224135564|NCT01388582|DEVICE|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
224298277|NCT00841906|DEVICE|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
223413132|NCT00181285|DEVICE|High Frequency Chest Wall Oscillator|High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
223413133|NCT02382497|DEVICE|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
223413134|NCT02382497|DEVICE|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
223413135|NCT02382497|DEVICE|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
223413136|NCT02382497|DEVICE|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
223413137|NCT05037045|DRUG|GLP-1 receptor agonist|GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
223413138|NCT04414020|DRUG|Progesteron|intramusculer progesterone
223413139|NCT05387369|DRUG|Paxlovid|The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
223738817|NCT06522906|BEHAVIORAL|Muscle Strengthening|Patients will be offered five video consultations (30-45 minutes each) with a physical therapist over 3 months. The physical therapist will prescribe an exercise program individualized to the OA patient that will include strengthening exercises (2 quadriceps, 1 hip/gluteal, 1 hamstrings/gluteal, 1 calf, and 1 other) to be performed at home 3x/week.
224030495|NCT05401279|DRUG|Tislelizumab|Tislelizumab 200mg will be administered on Day 1 of each 21 day cycle for 8 21-day cycles.
224030496|NCT05401279|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 will be administered on Days 1 and 8 for four to six 21-day cycles.
224030497|NCT05401279|DRUG|Cisplatin|Cisplatin 70mg\^m2 will be administered on Day 1 for four to six 21-day cycles.
224030498|NCT01619150|DRUG|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
224030499|NCT01619150|DRUG|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
224030500|NCT01956500|DIETARY_SUPPLEMENT|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
224030501|NCT01956500|DIETARY_SUPPLEMENT|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
224135565|NCT01388582|DEVICE|Implanon|60 mcg/day contraceptive implant
224135566|NCT01388582|DRUG|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
224135567|NCT01388582|DEVICE|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
224135568|NCT01388582|DEVICE|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
224135569|NCT03707158|BEHAVIORAL|Therapist-Led CBT (telehealth, office-based, or hybrid)|Participants receiving therapist-led CBT will participate in therapist-led (telehealth or office-based) CBT treatment for up to 20 weeks. Weekly therapist-led treatment sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
223413140|NCT06534489|PROCEDURE|neoadjuvant immuno-chemotherapy and surgery|After enrolled, patients should receive neo-adjuvant immuno-chemotherapy and a re-evaluation will be performed after treatment to decide surgery strategy.
224030502|NCT02682472|OTHER|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
224298278|NCT00841906|DEVICE|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
224298279|NCT06492200|OTHER|Psyllium husks|Patients in the intervention group will receive nutritional counseling and will be asked to take 10g (one tablespoon) of ground psyllium husks daily to significantly increase the fiber content of their diet.
223413141|NCT04607694|RADIATION|Proton radiotherapy|Proton radiotherapy
224030503|NCT06428136|DIAGNOSTIC_TEST|Clamshell exercises with Electrical Muscle Stimulation (CT + EMS)|"Side-lying clamshells: 3 sets of 10 repetitions per leg, 3 times per week Hip abduction with theraband: 3 sets of 10 repetitions per leg, 3 times per week Bridge with hip abduction: 3 sets of 10 repetitions per leg, 3 times per week~Electrical muscle stimulation:~Applied to the gluteus medius and minimus muscles for 20 minutes per session, 3 times per week Frequency and intensity adjusted to individual tolerance"
224030504|NCT06428136|OTHER|Conservative Treatment (CT)|Stretching: Iliotibial band stretch: 30-second hold, 3 repetitions per leg, 2 times per day Quadriceps stretch: 30-second hold, 3 repetitions per leg, 2 times per day Hamstring stretch: 30-second hold, 3 repetitions per leg, 2 times per day
224030505|NCT06845150|OTHER|Dual-task training|Combined simultaneous physical and cognitive training in an immersive environment
224030506|NCT06845150|OTHER|Single task training|Sequential cognitive and then physical training
224030507|NCT04258488|DRUG|Rivaroxaban Oral Tablet|For 12months, Rivaroxaban oral tablet 20mg once daily For renal disorder subjects\_creatinine clearance 15-49 mL/min, 15mg once daily
223738818|NCT06522906|BEHAVIORAL|General Physical Activity|The general program will consist of four 60-minute live video consultations conducted by a promotora. The first three sessions will be conducted every 2 weeks, with a booster session occurring one month later. The promotora will help dyads set achievable personalized physical activity goals.
224030508|NCT04258488|DRUG|Vitamin K antagonist(warfarin)|For 12months, keep the international normalized ratio (INR) 1.7-3.0
224030509|NCT06555588|BEHAVIORAL|ENGAGE|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is based on an integration of Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) approaches for managing symptoms of pain, fatigue, and distress. Participants are trained in behavioral symptom management skills (e.g., activity pacing, mindfulness) with an emphasis on engaging in highly valued activities.
224030510|NCT06555588|BEHAVIORAL|Supportive Care|This intervention is delivered by trained therapists over four, 45-60 minute, manualized telehealth sessions. The session content is designed to provide participants with education, support, and resources for a range of issues relevant to those with advanced cancer (e.g., education on symptoms, body image concerns, and financial concerns).
224030511|NCT03840486|DEVICE|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
224135570|NCT03707158|BEHAVIORAL|Guided Online CBT|Participants receiving guided online CBT will complete an online, self-paced, standardized and digitalized CBT program for up to 20 weeks with 8 modules, with adjunctive therapist phone support for supportive accountability. The self-administered treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
223738819|NCT06522906|BEHAVIORAL|Education|Administered by a promotora, treatment will include 4 live video educational sessions about OA
224030512|NCT03840486|DEVICE|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 40% FiO2 for 3 minutes, 70% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
223738820|NCT04615013|DRUG|Capecitabine|Not applicable to this study
223738821|NCT04615013|DRUG|Carboplatin|Not applicable to this study
224030513|NCT03840486|DEVICE|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
224030514|NCT03840486|DRUG|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
224030515|NCT03840486|DRUG|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 40% FiO2, 70% FiO2 or 100% FiO2 for 3 minutes each.
224030516|NCT06447142|OTHER|Open kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, open kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
224135571|NCT06434103|DRUG|SHR-A1921；Adebrelimab；SHR-8068；carboplatin|SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
224135572|NCT04152005|OTHER|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
224135573|NCT06874374|DEVICE|Closed-loop tACS|Individual alpha tACS
224135574|NCT06874374|DEVICE|Sham Comparator|Sham stimulation
224135575|NCT03577912|PROCEDURE|TAP block administered by Surgery|TAP block administered by Surgery
224135576|NCT03577912|PROCEDURE|TAP block administered by Anesthesia|TAP block administered by Anesthesia
223413142|NCT04607694|RADIATION|Photon radiotherapy|Photon radiotherapy
223413143|NCT00267969|DRUG|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
224135577|NCT05522712|DEVICE|Acapella user|"The exercise session will include three sets of deep breaths. Each set will include 10 repetitions which were fol¬lowed by 30 to 60 seconds pause in between. Patients will be instructed to perform slow maximal inspiration, while expiration was done through acapella in a prolonged manner to minimize airway closure and alveolar collapse. In the Acapella device, resistance was increased continuously on each successive day. The technique will be applied for 15 minutes.~Components of Acapella® treatment will include :~* Breathing control~* 10 breaths through the Acapella® device~* Inhaling up to approximately three - quarter maximum breathing capacity~* 2-3 second breath hold~* Active exhalation to Functional residual capacity but not too forcefully (3-4 second)~* The patient did 2-3 huffs at the end of the session, Cough or forced expiration in a set cycle."
224030517|NCT06447142|OTHER|Closed kinetic chain strengthening exercise|A web-based 8-week exercise program consisting of stretching exercises, closed kinetic chain strengthening exercises, and functional exercises for the knee and hip will be performed.
224135578|NCT05522712|DEVICE|Incentive spirometer user|"1. Sit upright in a chair or in bed. Hold the incentive spirometer at eye level, hold a pillow to help splint or brace the incision to decrease pain at incision.~2. Put the mouthpiece in mouth and close lips tightly around it. Slowly breathe out (exhale) completely.~3. Breathe in (inhale) slowly through mouth as deeply as possible. As taking the breath, the ball will rise.~4. Try to get the ball as high as possible.~5. When getting it, hold breath for 10 seconds, or as long as possible.~6. Then, breathe out slowly through mouth. Then, Rest for a 30-60 seconds.~7. Repeat 10 times. Try to get the ball to the same level or higher with each breath.~8. repeat 10 times for 3 sets."
224030518|NCT01806129|OTHER|Standard practice related to reproductive heath|Patients undergo usual standard practice related to reproductive health.
224030519|NCT01806129|OTHER|Training modules, algorithm, referral development|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
224030520|NCT06063564|BEHAVIORAL|PREVENT|PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
224030521|NCT06063564|BEHAVIORAL|Wait-list Control|Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool.
224030522|NCT05350631|OTHER|OnKO-Tips&Tricks digital phone application|Using daily OnKO-Tips\&Tricks digital phone application
224135579|NCT05522712|PROCEDURE|Control|This group is a control group will not receive new intervention just traditional chest physiotherapy and mobilization
224135580|NCT01208038|DRUG|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
224135581|NCT05998954|PROCEDURE|transmuscular quadratus lumborum and modified erector spinae plane (QLESP) block|Fifteen ml of 0.375% ropivacaine was administered between the erector spinae muscle and the transverse process. Fifteen ml of 0.375% ropivacaine was subsequently given between the quadratus lumborum and the psoas major muscles.
223413144|NCT00267969|DRUG|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
223413145|NCT04822792|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection test
223413146|NCT01309360|DRUG|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
223413147|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
223413148|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
223413149|NCT01309360|DRUG|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
223413150|NCT00004863|DRUG|GEM 231|
223738822|NCT04615013|DRUG|Docetaxel|Not applicable to this study
223738823|NCT04615013|DRUG|Fluorouracil|Not applicable to this study
224135582|NCT05998954|PROCEDURE|suprainguinal fascia iliaca block|Thirty ml of 0.375% ropivacaine will be injected cranial to the inguinal ligament between the fascia iliaca and the iliopsoas muscle.
224135583|NCT04850703|DEVICE|Transcranial Radom Noise Stimulation|tRNS against Dapoxetine in LPE patients
223413151|NCT00004863|DRUG|paclitaxel|
223413152|NCT05355584|OTHER|Cryotherapy application|The temperature sense test was applied on the dominant side shoulder of the participants against the risk of sensory loss or decreased sensation. In order to test cold intolerance, a cold pack was placed on the forearm of the individuals. After waiting 2-3 minutes, the region was evaluated. Individuals meeting the inclusion criteria were assigned to the groups according to the randomization list created by the computer. Then, the participants' shoulder isometric muscle strength, shoulder flexibility, shoulder endurance and shoulder balance was evaluated. Except for shoulder endurance, all measurements were repeated three times, with a 30-second rest period between each repetition. A 2-3-minute rest period was given after each test. Then, the cold pack was wrapped in a thin and wet cloth on the shoulders of the participants. The treated area was checked every 5 minutes and the participants were asked to say when they felt any unusual symptoms.
223738824|NCT04615013|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given IT or IN
224030523|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Manioc powder (placebo) 60 g/day
224030524|NCT00502021|DIETARY_SUPPLEMENT|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
224030525|NCT00502021|DIETARY_SUPPLEMENT|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
224030526|NCT00502021|DIETARY_SUPPLEMENT|Placebo|Safflower oil 30 ml/day
224030527|NCT02777723|DRUG|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
224030528|NCT02777723|DRUG|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
224030529|NCT01139021|BIOLOGICAL|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
223413153|NCT04762979|DRUG|Alpelisib|Alpelisib 300mg, PO, days 1-28 of each cycle.
224030530|NCT00917605|OTHER|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
224030531|NCT02361138|DRUG|SHR3824|
224030532|NCT02361138|DRUG|Placebo|
224030533|NCT01115751|DRUG|LY2780301|"Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression."
224030534|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight sleep and morning wake|Overnight period and morning period device measurements
224030535|NCT06222385|DIAGNOSTIC_TEST|Device measurements during overnight wake and morning sleep|Overnight period and morning period device measurements
224030536|NCT03558360|DIAGNOSTIC_TEST|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
224030537|NCT06056167|DRUG|Degludec insulin|"Enrolled patients will be initiated on regular insulin sliding scale (ISS) every 6 hours, administrated subcutaneously at 0600, 1200, 1800 and 2400 in patients who are nil per os and on intravenous fluid or parenteral nutrition or continuous tube feeding, according to King Faisal Specialist Hospital \& Research Center (KFSH\&RC) protocol.~Patients with two capillary point of care glucose levels of \> 10 mmol/L (180 mg/dl) will be initiated on insulin degludec at dose of 0.2 units/ kg.~Dose adjustments will be carried out on daily basis based on blood glucose levels following a written protocol."
224030538|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 80mg|The patient received one treatment of RC18 80mg in the test group
224030539|NCT04235933|BIOLOGICAL|Tai Ai(RC18) 160mg|The patient received one treatment of RC18 160mg in the test group
224030540|NCT04235933|BIOLOGICAL|RC18 240mg|The patient received one treatment of RC18 240mg in the test group
224030541|NCT04354844|BEHAVIORAL|questionnaire|questionnaire
224030542|NCT04692415|DRUG|Degludec|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
224030543|NCT04692415|DRUG|Glargine U300|treatment of DM and it's affect on Glycaemic Variability, Oxidative Stress, Arterial Stiffness and the Lipid Profiles
224030544|NCT00935194|DRUG|oseltamivir|75mg,bid,for 5 days
224135584|NCT04850703|DRUG|Take Dapoxetine|Dapoxetine against tRNS in LPE patients
224135585|NCT04850703|COMBINATION_PRODUCT|Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants|Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
224135586|NCT04850703|DIAGNOSTIC_TEST|Compare LPE EEG endophenotype between participants and healthy controls|Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
224298280|NCT03962582|DEVICE|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
223413154|NCT04762979|DRUG|Fulvestrant|Fulvestrant 500mg, IM, once monthly
223413155|NCT04762979|DRUG|Aromatase inhibitor|Aromatase Inhibitor, administered per standard of care
223413156|NCT01120015|DRUG|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
223413157|NCT02713360|BEHAVIORAL|Cognitive Therapy|
223413158|NCT05405946|BEHAVIORAL|Computerized Cognitive Remediation Therapy|"Sessions of 45 minutes will be developed 2 times a week, for 4-5 months (performing a total of 40 sessions). The sessions will be led by an experienced clinician with psychotic patients, and trained for the management of CCRT. Each intervention session will be individualized according to the results of the evaluation tests and the computerized program itself will adapt the difficulty of the tasks according to the performance of each patient.~The cognitive remediation NeuroPersonalTrainer platform includes two rehabilitation modules: the cognition module that includes attention, memory and executive functions with different levels of complexity and the Social Cognition module which allows working on different aspects of emotional processing, theory of mind and cognitive biases through 43 tasks based on multiple multimedia materials."
223413159|NCT05405946|OTHER|Treatment as Usual|Patients receiving TAU include psychoeducation about the disorder, psychiatric visits, and follow-up and review of drug treatment. In addition, they make individual visits with psychology, nursing and / or social work. In all cases, patients are treated in outpatient clinics.
223413160|NCT05540912|DRUG|D064+D701|Reference
223413161|NCT05540912|DRUG|CKD-828 Formulation 1|Test 1
223738825|NCT04615013|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224030545|NCT00935194|OTHER|blank|no antiviral therapy
224030546|NCT00935194|DRUG|chinese medicinal herbs|200ml,p.o,qid,for 5 days
224030547|NCT00935194|DRUG|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
224030548|NCT03588728|OTHER|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
224135587|NCT02170805|DRUG|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
224135588|NCT02170805|DRUG|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
224135589|NCT02170805|DRUG|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
224135590|NCT02170805|DRUG|Pantoprazole|Pantoprazole 40 mg
224135591|NCT03260205|DRUG|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
223413162|NCT05540912|DRUG|CKD-828 Formulation 2|Test 2
223413163|NCT05569668|DRUG|Paclitaxel- and platinum-based chemotherapy|Neoadjuvant Chemotherapy
224135592|NCT03260205|DRUG|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
224135593|NCT03260205|DRUG|SPD489|SPD489
223413164|NCT03773250|BEHAVIORAL|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
224135594|NCT06898086|DEVICE|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation using the CE-certified Myval™ transcatheter heart valve series
224135595|NCT06899269|DEVICE|robotic resection with Da Vinci Xi|robotic resection with Da Vinci Xi
224135596|NCT06897540|DEVICE|Upper endoscopy|View mucosa of esophagus with upper endoscope
223413165|NCT03140410|OTHER|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
223413166|NCT05923138|DIETARY_SUPPLEMENT|MULTIDOMAIN NUTRITIONAL INTERVENTION: DIET, EXERCISE AND NUTRITIONAL SUPPLEMENTS|"Nutritional intervention (diet, dietetic recommendations and/or supplements). Participants will receive specific recommendations about diet, energetic dietetic supplementation, oral nutritional supplements, exercise... The Nutrition Team (formed by cardiologists, dieticians, nurses...) will closely monitor patients with periodic visits and reassessment of nutritional status and compliance with recommendations."
223413167|NCT05923138|DIETARY_SUPPLEMENT|CONTROL|Standard treatment (usual recommendations in patients with heart failure)
223413168|NCT05454644|OTHER|Person-Centred Prescription Model|"Step 1: Identify patients with advanced chronic condition and limited life expectancy.~Step 2: Interview with patients or closes caregiver.~Step 3: Medication Review~The clinical pharmacist conduct a structured medication review based on the medication appropriateness index (MAI):~* Indication/effectiveness: Product information, STOPPFrail (Screening Tool of Older Persons' Prescriptions in Frail adults with limited life expectancy) criteria and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.~* Dosage adjustment: Product Information and Lexi-Comp's Geriatric Dosage Handbook.~* Correct and practical directions: Medication Regimen Complexity Index (MRCI).~* Drug-drug interactions: Bot Plus/Beers Criteria and drug burden index (DBI), which measures dose-dependent anticholinergic and sedative loads.~* Drug-disease interactions: Beers Criteria.~* Duplication, duration and cost-effectiveness: Product information.~Step 4: Treatment Plan"
223413169|NCT06967350|OTHER|CARE & AIDET communication mode|The new communication mode, which incorporates fundamental communication principles (AIDET) and service recovery strategies (CARE)
223413170|NCT06967350|OTHER|CARE communication mode|CARE (C: connect, A: apologize, R: repair, E: exceed) is a standard service recovery communication mode in medical services.
223559682|NCT04961528|DRUG|Terlipressin|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days"
223413171|NCT06967350|OTHER|AIDET communication mode|AIDET is a nurse-patient communication mode that contains essential communication principles. Each letter represents a step for communication: Acknowledge, Introduce, Duration, Explanation, and Thank. It describes in detail the application and characteristics of the primary language in communication, logical and procedural.
223413172|NCT04104763|BEHAVIORAL|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
223738826|NCT04615013|DRUG|Leucovorin|Not applicable to this study
224135597|NCT06898567|OTHER|Right Lateral Position|Participants rested for 10 minutes in a fully seated position, leaning their backs on a chair, without crossing their legs and placing their feet parallel to the floor. During this time, the arm to be measured was kept at heart level.
224135598|NCT06898567|OTHER|Left Lateral Position|Left Lateral Position
224135599|NCT06898567|OTHER|Semi Fowler Position (45° Fowler)|Semi Fowler Position (45° Fowler)
224135600|NCT06897995|OTHER|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|Participants in the exercise groups were trained five times a week for six weeks. The regimen began with a 5-min warm-up and ended with a 5-min cool-down, both at 40% of heart rate reserved (HRR). The circuit training participants were trained for three bouts of 10-min moderate-intensity exercise (60% of HRR) with 1-min rest intervals at a stationary ergometer, a rowing machine, and an elliptical trainer, respectively. The cycling training group was trained on an ergometer for three bouts of 10-min cycling on a stationary ergometer.
224298281|NCT00903448|DRUG|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
223559683|NCT04961528|DRUG|Placebo|"Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient).~The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days."
223738827|NCT04615013|DRUG|Oxaliplatin|Not applicable to this study
223738828|NCT04615013|DRUG|Paclitaxel|Not applicable to this study
223738829|NCT06852872|OTHER|CRET Therapy|Diathermy therapy with a protocol to preheat the back extensor muscle
223738830|NCT06852872|OTHER|ILEX training|Isolated lumbar Extension Training
223738831|NCT06852872|OTHER|CRET therapy sham|Diathermy therapy withouth any radiofrequency as a sham intervention
224135601|NCT06897917|DRUG|Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets|"1. Calculate the total opioid dosage administered to the patient in the previous 24 hours and convert it to an equivalent dose of oxycodone/naloxone sustained-release tablets(Mimeixin).~2. Based on the principle of incremental dosing, calculate the total dosage to be administered on the day of enrollment, divide it into two portions, and administer one portion every 12 hours (q12h).~3. In case of breakthrough pain during treatment, administer an equivalent dose of immediate-release morphine or other medications equivalent to 10%-20% of the 24-hour background dosing for relief.~4. If the number of breakthrough pain events exceeds 2 in a day after dosing, adjust the dosage again based on the incremental dosing principle. Adjustments should be made every 1-2 days, with each adjustment increasing the dose by a gradient of 5 mg/2.5 mg or 10 mg/5 mg of oxycodone/naloxone sustained-release tablets, twice daily, and so on. The maximum daily dose of oxycodone should not exceed 160 mg."
223413173|NCT00216619|DRUG|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
223413174|NCT00216619|DRUG|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
224030549|NCT03588728|BEHAVIORAL|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
224030550|NCT00455338|BEHAVIORAL|Meal Composition|
224030551|NCT01917019|DRUG|Placebo|matching placebo tablets
224030552|NCT01917019|DRUG|BIIB041 (fampridine)|fampridine prolonged-release tablets
224030553|NCT02497625|BEHAVIORAL|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
224030554|NCT02497625|BEHAVIORAL|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
224030555|NCT02497625|OTHER|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
224030556|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 600 mg, IV infusion for 1 hour on Day 1.
224030557|NCT05614895|DRUG|RO7223280|Participants will receive RO7223280, 400 mg, IV infusion for 1 hour on Day 1.
224030558|NCT02027701|BIOLOGICAL|IgPro20|
224030559|NCT00005825|DRUG|cisplatin|
224030560|NCT00005825|DRUG|mitomycin C|
224030561|NCT00005825|DRUG|tretinoin|
224030562|NCT00005825|DRUG|vinorelbine tartrate|
224030563|NCT00302419|DRUG|intracoronary infusion,|streptokinase, 250,000 units
224030564|NCT00302419|PROCEDURE|primary percutaneous coronary angioplasty|
224135602|NCT06898164|OTHER|This study does not involve any interventions|This study does not involve any interventions
223413175|NCT04399213|PROCEDURE|50 µg Histamine|Skin prick through 50 µg/5 µL histamine diHCl
223413176|NCT04399213|PROCEDURE|15 µg Histamine|Skin prick through 15 µg/5 µL histamine diHCl
223413177|NCT04399213|PROCEDURE|5 µg Histamine|Skin prick through 5 µg/5 µL histamine diHCl
224030565|NCT02982187|DEVICE|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
223413178|NCT04399213|PROCEDURE|Placebo (saline)|Skin prick through 5 µL saline (0.9% NaCl)
224030566|NCT02982187|DEVICE|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
223413179|NCT00204464|PROCEDURE|Exercise|
223413180|NCT05589688|DRUG|Acyclovir|Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
224030567|NCT02982187|DEVICE|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
224030568|NCT02982187|DEVICE|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
224030569|NCT02982187|OTHER|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
223413181|NCT05575778|DIAGNOSTIC_TEST|computed tomographic perfusion|The recruited patients would complete both pre- and post-operative computed tomographic perfusion
223413182|NCT06682897|BEHAVIORAL|Tai Chi training|60 minutes each session, three sessions per week, lasting 4 weeks for undertaking.
223738832|NCT06560762|DRUG|STM01|Neonatal mesenchymal stem cells (nMSCs),
224030570|NCT02982187|OTHER|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
224030571|NCT02982187|OTHER|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
224030572|NCT02982187|OTHER|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
224030573|NCT03392506|DEVICE|EBUS-TBNA-RTE|Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
224030574|NCT00189033|DRUG|psyllium fibre (dietary supplement)|
224030575|NCT00189033|DRUG|wheat bran (dietary supplement)|
224030576|NCT00189033|DRUG|rice wheat (placebo)|
224030577|NCT00165633|DRUG|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
224030578|NCT00165633|DRUG|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
224030579|NCT00165633|DRUG|Placebo|Placebo capsule, orally, three times a day, after meals.
224135603|NCT06897449|BEHAVIORAL|Positive psychological intervention|Each week consists of two modules, focusing on different techniques and methods from positive psychology, aimed at improving athletes' mental health and performance.
224135604|NCT06897449|OTHER|Introduction to Positive Psychology Poster|The poster serves as an introductory resource, summarizing key concepts of positive psychology in an accessible format.
224135605|NCT06898359|RADIATION|Radioimmunotherapy|SCRT (a total of 25 Gy in 5 days) followed by sintilimab (3mg/kg intravenous drip on day 1; every 3-week cycle for two cycles)
224298282|NCT00903448|DRUG|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
223413183|NCT04541953|OTHER|Telerehabilitation Therapy|Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises and stretching.
223413184|NCT04541953|OTHER|In-person Rehabilitation Therapy|Range of motion exercises and stretching
223413185|NCT03128177|DIETARY_SUPPLEMENT|Dietary sodium|High (6 g) versus low (1.5 g) sodium diet
223413186|NCT01053663|DRUG|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
223413187|NCT04871204|DRUG|Octreotide Injection|10 mg Sandostatin LAR intramuscular injection
223413188|NCT04374123|DIAGNOSTIC_TEST|Serological screening for IgG and IgM antibodies against COVID-19|Serum evaluation for IgG and IgM antibodies against COVID-19 in patients in the endoscopy unit during the COVID 19 pandemic
223413189|NCT01544387|OTHER|Bed Rest|"* Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~* Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~* Subjects may have limited bathroom privileges"
223559684|NCT03558269|BIOLOGICAL|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
223559685|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
223559686|NCT04026009|BIOLOGICAL|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 or 3 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval. The third dose will be administered approximately 15 months after the second dose."
223413190|NCT01544387|OTHER|Activity|"* Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~* Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
223413191|NCT05758610|DRUG|ETH-155008|"ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal."
223413192|NCT03533114|DRUG|JZP-258|Participants randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
223413193|NCT03533114|DRUG|Placebo Oral Solution|Participants randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
223413194|NCT05618938|OTHER|Rocabado's approach|"Group A will be treated with Rocabado's approach. Rocabado' approach will be comprised of six exercises.~1. Rest position of the tongue~2. Control of TMJ rotation~3. Rhythmic stabilization technique~4. Axial extension of the neck The patients will receive Rocabado's approach consisting 6 repetitions six times a day thrice per week for four weeks"
223413195|NCT05618938|OTHER|Kraus exercises|"Group B will be treated with Kraus exercises. Kraus exercises will be comprised of eight exercise programs.~1. Tongue position at rest~2. Teeth apart: the patient will be educated to maintain the teeth apart can be therapeutic, which facilitates the resting tongue position~3. Nasal-diaphragmatic breathing~4. Tongue up and wiggle~5. Strengthening~6. Touch and bite: Proprioceptive re-education: Lateral deviation The patients will receive Kraus exercises with the frequency of 2 sets and 10 repetitions twice a day three times per week for four weeks"
223413196|NCT02237612|PROCEDURE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
223413197|NCT02237612|OTHER|laboratory biomarker analysis|Correlative studies
223559687|NCT04026009|DRUG|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
223559688|NCT01413906|DRUG|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
223559689|NCT03289663|DRUG|synergistic combination of insecticides|third generation insecticide -treated bednets
224135606|NCT06898021|DIAGNOSTIC_TEST|3DStent|Coronary interventions will be performed according to the standard of care, which includes IVUS guidance. In patients undergoing stent implantation, a 3DStent image acquisition will be done followed by IVUS.
224135607|NCT02362308|OTHER|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
224135608|NCT02362308|DRUG|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
223559690|NCT03289663|DRUG|Pyrethroids|Conventional insecticide
223559691|NCT05727007|DIAGNOSTIC_TEST|MRI in colon cancer|The MRI protocol will include the following imaging series: T1 and T2 in axial and coronal plane before the administration of intravenous contrast, diffuse weight imaging in axial plane and T1 after the administration of intravenous contrast
223559692|NCT05727007|DIAGNOSTIC_TEST|CT in colon cancer|The CT scan protocol will include the following: per os and intravenous administration of contrast, axial slices of 0.3mm thickness and reconstruction per 1mm, multi-planar reformation and three-dimensional volume rendering
223559693|NCT03978741|DEVICE|Yōni.Fit Test Device|The Yōni.Fit Test Device is a silicone pessary.
224135609|NCT05301322|BIOLOGICAL|RSVpreF Vaccine|RSV Vaccine
224135610|NCT05301322|OTHER|Placebo|Placebo
224135611|NCT05301322|BIOLOGICAL|Seasonal Inactivated Influenza Vaccine|SIIV
224135612|NCT03059563|DRUG|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
223413198|NCT02423395|DRUG|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
223413199|NCT02423395|DRUG|Placebo|calcium in muscle cramps in cirrhotic patients
223413200|NCT01862250|DRUG|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~* 10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~* 20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~* HR ≤70/min, sustained for ≥30 min after administration"
223413201|NCT03455101|OTHER|There is no intervention.|There is no intervention.
223413202|NCT06576557|OTHER|KNEE-DEeP intervention- Knowledge translation and exercise for early degenerative knee pain|The intervention for health care professionals (GPs and physiotherapists) will consist of training and education. The two-hour educational workshop for GPs will focus on diagnosis and management of patients with early degenerative knee pain, and enhancing communication skills. Training for physiotherapists will focus on delivery of a 'best practice' session. The patient participant intervention will consist of an 'enhanced consultation' delivered by the GP. This will involve a physical exam, key educational messages, written information and a treatment plan. Patients will receive a single session of physiotherapy within 2 weeks of referral from their GP. This 'best practice' session will focus on self-management skills, targeted patient education, goal setting, action planning and exercise prescription.
223413203|NCT04408742|OTHER|pain|"Lower abdominal and low back pain was questioned. Pain intensity was evaluated with a 0 to 10 cm visual analog scale (VAS): 0 indicated no pain and 10 indicated the worst imaginable pain \[18\]. Pain that developed during the activity was also questioned and stated as pain+ activity. A higher score indicates a more severe pain."
223413204|NCT04408742|OTHER|fatigue|"Fatigue was assessed by the Fatigue Severity Scale (FSS). This is a 9-item questionnaire that assesses the effect of fatigue on daily living. Each item is a statement on fatigue that the subject rates from 1 completely disagree to 7 completely agree. A score of 4 or higher generally indicates severe fatigue."
223413205|NCT04408742|OTHER|anxiety|"The Spielberger State Trait Anxiety Inventory (STAI) was used to evaluate levels of anxiety. The state part of the STAI is a 20-item self-report inventory designed to measure state anxiety (current feelings of apprehension, worry, etc.). The STAI state scale is scored on four levels of anxiety intensity from 1 not at all to 4 very much and with a total score between 20 and 80. A higher total score indicates a more severe anxiety level."
223413206|NCT04408742|OTHER|position sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
223413207|NCT04408742|OTHER|balance|The Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used to measure limits of stability. The participants were asked to position themselves in a comfortable position on the platform and their foot position coordinate was recorded. The participants were asked to complete as quickly as possible the directional tasks displayed on a screen, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s. A total score was recorded. The higher the total score, the better the ability of the subjects to transfer the center of gravity.
223559694|NCT03978741|DEVICE|Yōni.Fit Comparator Device|The Yōni.Fit Comparator Device is a silicone pessary with a different configuration.
224030580|NCT05975151|DRUG|Pseudomonas aeruginosa|A total of 63 subjects with intermediate and high risk NMIBC who were scheduled for transurethral resection of bladder tumor (TURBT) from March 2023 in three centers were enrolled in this study. The enrolled patients received submucosal injection of 1U of Pseudomonas aeruginosa injection and bladder irrigation with chemotherapy drugs (gemcitabine, mitomycin C, epirubicin or pirarubicin) immediately after TURBT. After urine was cleared, a sterile urinary catheter was placed, and 10U of Pseudomonas aeruginosa injection and 40ml of normal saline were injected. The perfusion solution was kept for 1 hour, and the position was changed every 20 minutes. The treatment was given once within 24 hours after operation, then once a week for 12 weeks, and then once a month for 12 months in total. Patients were followed up every 3 months after surgery. The last follow-up was completed in February 2025
224030581|NCT00388557|DRUG|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
224030582|NCT01694355|DRUG|Vitamin D|
224030583|NCT04793152|DRUG|Vancomycin|Administration as outlined
224030584|NCT04747782|OTHER|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.|no interventions performed. Just collecting data, blood samples and post-mortem biopsies.
224030585|NCT02019589|DRUG|Progesterone|
224030586|NCT02019589|DRUG|Placebo|
224030587|NCT02894112|DIETARY_SUPPLEMENT|non-fat milk|1 serving of non-fat fluid milk
224030588|NCT02894112|DIETARY_SUPPLEMENT|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
224030589|NCT02894112|DIETARY_SUPPLEMENT|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
224135613|NCT03059563|OTHER|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
224135614|NCT01345097|DEVICE|Total Hip Arthroplasty|Total Hip Arthroplasty
224298283|NCT02113553|DRUG|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
224298284|NCT00453557|DRUG|rhGH|
224298285|NCT01739296|OTHER|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
224298286|NCT01739296|OTHER|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
224298287|NCT03632317|DRUG|Panobinostat|30 mg/m\^2
223413208|NCT04408742|OTHER|dual task performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
223413209|NCT04835090|OTHER|screening test|using three screening tools
223413210|NCT02016105|DRUG|GP2017 Adalimumab|
224030590|NCT04681547|PROCEDURE|Genicular nerve Block|"After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves."
224030591|NCT04681547|PROCEDURE|Local Infiltration Analgesia|100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
224030592|NCT01702597|DEVICE|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
224135615|NCT06897553|BEHAVIORAL|ACT-based group therapy|"ACT-based group therapy based on the manual Living Well with Neurological Conditions published by Hill et al. (2017; NHS Fundation Trust; available: https://goo.gl/aX6qB5). The manual was translated into German and adapted by shortening sessions, simplifying language and adapting exercises based on clinical experience. The publication of the feasibility study for the adapted manual is currently in preparation. The group therapy includes eight weekly sessions with a duration of 100 minutes each. Three to six individuals participate in a group. The therapy is delivered by at least one licensed psychotherapists. A co-therapist might be included based on individual needs of the group members."
224135616|NCT05917457|OTHER|balance coordination and strengthening training|"The 25 individuals who met the inclusion criteria were divided into 2 groups, including 13 in the study group and 12 in the control group.~Study group: Low vision children were given balance, coordination training and general strengthening training with sandbags for 70 minutes 3 days a week (5-minute warm-up phase, 20-minute balance training, 20-minute coordination training, 20-minute strengthening training and 5-minute cooling phase) for 8 weeks."
224135617|NCT06816420|OTHER|Cold Application|The effects of local cold application on pain and vital signs during port catheter needle insertion will be studied in this group.
224135618|NCT06892652|OTHER|Supportive care measures|shared decision making with patients and families to receive specialist palliative care
224298288|NCT03632317|DRUG|Everolimus|3.0 mg/m\^2
223413211|NCT02016105|DRUG|Humira ® Adalimumab|
223413212|NCT04874662|DIETARY_SUPPLEMENT|NAM/B6|Single daily dose administration will take place from Day 0 (V1) to Day 8 (V4) around 8 am after an overnight fast from the subsequent evening at 9 pm.
223413213|NCT00411242|DRUG|agomelatine|
223413214|NCT00411242|DRUG|placebo|
223413215|NCT01216956|DRUG|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
223413216|NCT03995589|OTHER|Walking|Technology-guided semi-supervised walking therapy
223413217|NCT03995589|OTHER|Control|Go Home and Walk advice
223413218|NCT06260410|DIAGNOSTIC_TEST|Blood draw for ctDNA and circulating tumor cell collection.|During routine blood sample collection, additional blood will be drawn for analysis of ctDNA and to collect Circulating Tumor Cells.
223413219|NCT00305955|DEVICE|Spectacles|optimal spectacle correction
223413220|NCT01579838|DRUG|Eculizumab|PNH and or atypical TTP classical protocols
223413221|NCT04681911|DRUG|Inetetamab|Inetetamab: 8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
223559695|NCT04550520|DIAGNOSTIC_TEST|Glucagon|Glucagon with the empirical formula of C153H225N43O49S, and a molecular weight of 3483 g/mol, is a single-chain polypeptide containing 29 amino acid residues. Glucagon is provided in a single dose vial as powder. One container contains 1 mg of glucagon which results in a concentration of 1 mg/ml after dissolution in a volume of 1 ml (Glucagen NovoNordisk (Hypokit)). The currently used standard dose regimen is 1 mg of glucagon in adults. The solution for subcutaneous injection will be prepared by the study personnel according to the attached package leaflet.
223559696|NCT04550520|DIAGNOSTIC_TEST|Placebo|As placebo 1 ml sodium chloride (NaCl) 0.9% to inject subcutaneous is used. It has the same optical appearance as glucagon.
224030593|NCT01702597|OTHER|Physiotherapy|Patients will receive a standardized physical therapy.
224030594|NCT03252054|DIAGNOSTIC_TEST|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
224030595|NCT00592085|BEHAVIORAL|Questionnaires|Participants will use a computer to complete a series of questionnaires.
224030596|NCT00592085|BEHAVIORAL|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
224298289|NCT00206765|DRUG|Risperidone|
224135619|NCT06898697|DRUG|Epidural fentanyl|Fentanyl will be injected in the epidural space by the surgeon one or two levels above the surgical site.
224135620|NCT06898697|DRUG|epidural midazolam|midazolam will be injected in the epidural space by the surgeon one or two levels above the surgical site.
223413222|NCT04681911|DRUG|Pyrotinib|Pyrotinib: 400mg, oral, every day.
223413223|NCT04681911|DRUG|Capecitabine|Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
223413224|NCT04681911|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2, D1, D8, 3-week cycle
224030597|NCT00592085|BEHAVIORAL|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
224030598|NCT04140383|PROCEDURE|Cataract Surgery|Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
224030599|NCT00887679|DRUG|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
224030600|NCT02573454|BEHAVIORAL|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
224030601|NCT01347346|GENETIC|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
224030602|NCT00555542|DRUG|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
224030603|NCT02168842|DRUG|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
224135621|NCT02471664|DEVICE|Mitral Loop Cerclage Annuloplasty|
224135622|NCT01369316|PROCEDURE|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
223413225|NCT04681911|DRUG|Vinorelbine|Vinorelbine, 25-30 mg/m2, D1, D8, 3-week cycle
223413226|NCT04681911|DRUG|Carboplatin|Carboplatin, AUC = 6, 3-week cycle
223413227|NCT04681911|DRUG|Albumin paclitaxel|Albumin paclitaxel, 100 mg/m2, weekly
223413228|NCT04681911|DRUG|Eribulin|Eribulin, 1.4 mg/m2, D1, D8, 3-week cycle
223413229|NCT02690298|DEVICE|ExSpiron|Non-Invasive respiratory volume monitoring
223413230|NCT05784324|OTHER|No intervention|No intervention
224030604|NCT02168842|DRUG|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
224135623|NCT01369316|PROCEDURE|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
224135624|NCT02678988|DEVICE|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter \[mg/mL\]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
224135625|NCT02678988|DEVICE|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
224135626|NCT02678988|DRUG|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
224135627|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation active stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of active rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
224135628|NCT06373445|DEVICE|repetitive transcranial magnetic stimulation sham stimulation|This study was conducted on 20 eligible fibromyalgia patients with sleep disorders. They were randomized to have 20 sessions of sham rTMS (1 Hz, 120% of resting motor threshold with total 1200 pules /session) over the right dorsolateral prefrontal area (DLPFC) for 5 sessions/week for 4 weeks.
224298290|NCT00206765|DRUG|Paroxetine|
224298291|NCT04340817|DIAGNOSTIC_TEST|Proteomics|Mass-spectometry proteomics
223413231|NCT01937910|BEHAVIORAL|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
223413232|NCT04765995|DRUG|HZBio1 0.96mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
223413233|NCT04765995|DRUG|HZBio1 3mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
223413234|NCT04765995|DRUG|HZBio1 6mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
223413235|NCT04765995|DRUG|HZBio1 9mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
224135629|NCT04939077|BIOLOGICAL|Allogeneic Human Umbilical Cord Mesenchymal Stem Cells|In CABG with hUC-MSC treatment group, 1×10\^7 Human Umbilical Cord Mesenchymal Stem Cells were injected at the edge of the myocardial infarction area at 20 points at the same time in CABG
224135630|NCT03872583|OTHER|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
224135631|NCT03872583|OTHER|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
224030605|NCT04717284|OTHER|Self-compassion intervention (SCI)|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the SCI group will then be instructed to reflect on their recalled parenting event and prompted to think about and write about the event in a self-compassionate manner. The prompt is designed to induce on all of the three key elements of self-compassion described by Neff (2003a): self-kindness; common humanity; and mindfulness. The same instructions will be provided for follow-up period.
224030606|NCT04717284|OTHER|Control condition|All participants will be asked to recall a recent parenting event they feel ashamed of and type it into a text box provided. Participants in the control group will then be instructed to make notes about factual information of the event (e.g. time of day, who was there, the weather, etc.). During the two-week follow-up period, participants in the control group will not take part in any intervention as part of the trial.
224030607|NCT04332601|BEHAVIORAL|Fatigue Management Therapy|14 sessions of 1h CBT intervention
224030608|NCT04332601|OTHER|TAU (Treatment as usual)|No CBT intervention
224030609|NCT04873414|BIOLOGICAL|Convalescent plasma treatment|Convalescent Plasma collected from patients who recover from COVID-19 and have been discharged from the hospital for at least 14 days.
224030610|NCT04958850|OTHER|a cross-sectional survey|Collect the data of this year and compare it with that of ten years ago
224030611|NCT02558192|DIETARY_SUPPLEMENT|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
224030612|NCT02558192|DIETARY_SUPPLEMENT|PLACEBO|1 vials q12 for 15 days
224030613|NCT00210756|DRUG|epoetin alfa|
224030614|NCT00277108|DRUG|Escitalopram (Lexapro)|
224030615|NCT02685943|BEHAVIORAL|Psychotherapy|
224030616|NCT03333187|PROCEDURE|Allogeneic stem cell transplantation|
224030617|NCT03333187|DRUG|Ruxolitinib continuous therapy|
224030618|NCT02853721|OTHER|iPTH|iPTH assay six hours after surgery
224030619|NCT02853721|OTHER|no dosage of iPTH|Ca and P on postoperative day 1 and 2
224030620|NCT00157183|DEVICE|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
224030621|NCT00303641|DEVICE|Medtronic Resting Heart Bypass System|
224030622|NCT05592314|OTHER|No intervention|No intervention
224030623|NCT02159430|OTHER|Clinical and psychopathological assessment of HAE patients|
224030624|NCT01110876|DRUG|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
224030625|NCT01110876|DRUG|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
224030626|NCT01110876|DRUG|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
224030627|NCT02483182|DRUG|ZEP-3 ointment 1.0%|
224030628|NCT02483182|DRUG|Acyclovir cream 5%|
224030629|NCT06087016|OTHER|Urine vibrational analysis|Urine vibrational analysis
224030630|NCT05309343|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill, etc.
224030631|NCT04589754|DRUG|Sintilimab plus chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks; sintilimab (10ml; 100mg) was administered intravenously every 3 weeks.
224030632|NCT04589754|DRUG|Adriamycin-based chemotherapy|AI regimen chemotherapy (ADM 50 mg / m2, D1 + IFO 2.5 g / m2, D1-3, IV drip) was used for 3 weeks; CAV / IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg / m2 D1 + VCR 1.4mg/m2 D1 and regimen 2: IFO 1.5g/m2 D1-5 + VP-16 100mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.
224030633|NCT01026454|DRUG|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
224030634|NCT01026454|DRUG|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
224030635|NCT03090815|GENETIC|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
224030636|NCT00265421|PROCEDURE|Suture technique for perineal repair after delivery|
224030637|NCT02496520|BIOLOGICAL|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
224030638|NCT02496520|PROCEDURE|Surgery as needed by the patient´s tumor and stage|
224030639|NCT02496520|DRUG|Chemotherapy as needed by the patient´s tumor and stage|
224030640|NCT02496520|RADIATION|Radiation therapy as needed by the patient´s tumor and stage|
224030641|NCT02498470|PROCEDURE|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
224030642|NCT05441254|DRUG|Camrelizumab; Nab-paclitaxel; S-1|"Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment."
224135632|NCT02551133|DRUG|dexamethasone|1 hour before surgery
224298292|NCT04340817|DIAGNOSTIC_TEST|Transcriptomics|Next generation sequencing
224298293|NCT04340817|GENETIC|Genomics|Targeted genetics
224298294|NCT02212002|DRUG|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
224298295|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
223413236|NCT04765995|DRUG|HZBio1 12mg / kg|HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
223413237|NCT04765995|DRUG|Placebo|Matching placebo will be administered intramuscularly.
223413238|NCT01096719|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies
223413239|NCT01096719|BEHAVIORAL|Dietary Goal: Reduction in Energy Density of Dietary Intake|Consume low ED foods (ED \< 1.0) for at least 10 items consumed per day and limit high ED foods (ED \> 3.0) to two items consumed per day.
223413240|NCT01096719|BEHAVIORAL|Dietary Goal: Reduction of Energy Intake|Limit energy intake to 1200 to 1500 kcals/day and \< 30% kcals from fat.
223413241|NCT03864224|BEHAVIORAL|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
223413242|NCT04316429|OTHER|Egg included vegan phase|: Participants will meet with a registered dietitian and receive instructions to include 2 eggs per day for 6 weeks as part of their otherwise vegan diets. Participants will also receive instructions to preserve an isocaloric condition with the addition of 2 eggs in their diets. Counseling of the study participants will be based on the U.S. Department of Agriculture (USDA) healthy vegetarian meal plans, with modifications to exclude dairy products. \[21\] Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet (with the exception of including eggs) will also be provided.
223413243|NCT04316429|OTHER|Vegan Phase|The participants will consume a vegan diet for 6 weeks. The study dietitian will provide counseling and sample meal plans based on the USDA healthy vegetarian dietary pattern, with modifications to exclude eggs and dairy products. Additional resources (e.g., educational materials, recipes, etc.) for adopting and maintaining a vegan diet will also be provided.
223413244|NCT05641805|OTHER|PAQ-C (Physical activitiy questionare for children), MoCA (Montreal Cognitive Assessment), PBS (Pediatric Balance Scale), Modified Mini Mental State Examination, BMI (Body Mass Index)|"PAQ-C will use to evaluate physical activity level of participants. MoCA and Modified Mini Mental State Examination will use to evaluate cognitive functions of participants.~PBS will use to evaluate participants' balance responses."
223413245|NCT00514215|BIOLOGICAL|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
223413246|NCT00514215|OTHER|flow cytometry|Days 1 \& 32
223413247|NCT00514215|OTHER|immunoenzyme technique|Days 1 \& 32
223413248|NCT00514215|PROCEDURE|biopsy|CT guided biopsy on days 1 \& 32
223413249|NCT00514215|PROCEDURE|cryosurgery|Days 1 and 32
223413250|NCT03635515|DEVICE|Gentlewave|The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
223559697|NCT04823728|GENETIC|Autoimmune encephalitis and paraneoplastic neurological syndromes|"This is a non-interventional study involving biological samples (DNA). Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL)/NeuroBioTec (including tissue, cells or biological fluids) and genetic analysis for research purposes (e.g. involving genes related to the disease for which the patient was followed). Additionally, patients will be informed about the present study."
223413251|NCT03635515|PROCEDURE|Standard Endodontic Protocol|The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
223413252|NCT02148796|DRUG|Broncho-Vaxom (BV)|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma, Switzerland (OM stands for Omnia Medicamenta) Storage: Store in the original package
223413253|NCT02148796|OTHER|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
223413254|NCT02099890|DIETARY_SUPPLEMENT|Omega-3|
223413255|NCT02099890|DIETARY_SUPPLEMENT|Vegetation Protein Powder|
223413256|NCT02099890|DIETARY_SUPPLEMENT|InflanNox|
223413257|NCT02099890|DIETARY_SUPPLEMENT|Anti-oxidant Network|
224298296|NCT01425333|PROCEDURE|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
223413258|NCT02099890|DIETARY_SUPPLEMENT|Chlorella|
223559698|NCT04521946|DRUG|Etoposide|Given IV
223559699|NCT04521946|DRUG|Fludarabine Phosphate|Given IV
223559700|NCT04521946|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
223559701|NCT04521946|BIOLOGICAL|Lapine T-Lymphocyte Immune Globulin|Given IV
223559702|NCT04521946|DRUG|Melphalan|Given IV
223559703|NCT04521946|DRUG|Mycophenolate Mofetil|Given PO or IV
223559704|NCT04521946|DRUG|Tacrolimus|Given IV
223559705|NCT04521946|DRUG|Thiotepa|Given IV
224298297|NCT04111406|DRUG|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
223413259|NCT05783167|DIAGNOSTIC_TEST|Self-sampling for HPV infection|After informed consent has been provided, the woman will be asked to collect firstly a first-void urine sample using the Collipee device and secondly to collect a vaginal self-sample using the dry Evalyn® Brush device. Socioeconomic, demographic and clinical data will be collected in the Bissau HIV Cohort database and through study questionnaires to collect background information on risk factors for HPV persistence and development of cervical cancer (HIV genotype, immune status, parity). Questionnaires will collect additional information on the acceptance of cervical screening measures to better evaluate the feasibility of implementing self-collected screening among HIV infected women in Guinea-Bissau.
223413260|NCT06577402|DIETARY_SUPPLEMENT|nutritional support|nutritional support
224030643|NCT06189560|BEHAVIORAL|comprehensive rehabilitation|"All the participants were provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.) and pharmacological treatment (aspirin, statins, anticoagulants, etc.).~Regrading swallowing function training, both groups were given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, and the Mendelsohn maneuver, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
224030644|NCT06189560|DRUG|SGB|the observation group was given SGB once a day, with 10 sessions as a course of treatment and each side of the body for one course. All the materials included: 1) 1.5ml of 2% Lidocaine hydrochloride injection (1ml: 0.5mg), Vitamin B12 Injection 500ug (1ml: 0.5g), the 5 ml disposable syringe and the sterile disposable dental injection needles. The specific operation procedure was as follows\[16\]: The operator stood at the patient\&#39;s block side, and the patient was placed in the supine position, with the head leaning 45 degrees toward the contralateral side of the block side. After routine disinfection of the skin, a paratracheal approach was adopted, which was, 2.5cm above the sternoclavicular joint and 1.5cm outside the midline of the neck.
224030645|NCT06058260|OTHER|Pediatric Quality of Life Inventory (questionnaire) and The Stanford-Binet Intelligence Scale fifth edition|Quality of Life Assessment By Pediatric Quality of life Inventory. Cognitive Function Assessment By The Stanford-Binet Intelligence Scale fifth edition.
224030646|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
224030647|NCT00751842|DRUG|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
224030648|NCT00751842|DRUG|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
224135633|NCT06898931|BEHAVIORAL|Dialect Interpreting Training|The intervention group will receive a combination of offline and online language-switching training. The offline intervention will last for 2 months, with three training sessions per week, each lasting 1 hour. The training content will simulate the interpreting process, requiring participants to switch and convert rapidly and accurately between two dialects, covering multiple aspects including listening comprehension, oral expression, and information processing. The online intervention will last for 4 months, during which participants will regularly complete exercises through a language training app or website and upload their assignments.
224135634|NCT06755125|OTHER|Kinesio Taping|Patients in Group A was treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with kinesio taping. Kinesio tape was applied directly to the muscle with 50% stretching.During the treatment, kinesio tape will be applied to the patients twice a week, eight times in total.
224135635|NCT06755125|OTHER|Dry Needling|Patients in Group B was treated with a hot pack, TENS, simple piriformis stretch, and isometrics, along with dry needling.During the treatment, dry needling was applied to the patients twice a week, eight times in total.
224135636|NCT06701331|DRUG|Placebo|Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
223559706|NCT00832598|RADIATION|[18F]FACBC PET and [18F]FLT PET imaging|\[18F\]FACBC PET and \[18F\]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
224135637|NCT06701331|DRUG|Upadacitinib|Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
224135638|NCT06898034|OTHER|Ultrasound|Postpartum ultrasound exam
224135639|NCT01620632|PROCEDURE|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
224135640|NCT06898723|DRUG|Shenfu Injection|The treatment will utilize Ginseng and Aconite Injection, which primarily consists of Red Ginseng and Aconite
224135641|NCT06898268|DRUG|Metoclopramide|Patients were prescribed metoclopramide twice a day for one week.
224135642|NCT06898268|DRUG|Ondansetron|Patients were put on oral ondansetron in BD doses for one week.
224135643|NCT06899048|DIAGNOSTIC_TEST|residual neuromuscular block risk prediction score|it is a clinical tool designed to estimate the likelihood of residual neuromuxcular blockade in postoperative patients
223413261|NCT03646864|DRUG|ACT-541468|ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening.
223413262|NCT03646864|OTHER|Placebo|Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening.
223413263|NCT04002115|DRUG|Clofarabine|"Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total."
223413264|NCT04002115|DRUG|Fludarabine|Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
223413265|NCT04002115|DRUG|Busulfan|Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
223559707|NCT05647837|DIAGNOSTIC_TEST|lumper puncture|lumper puncture
223559708|NCT00586716|DRUG|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
223559709|NCT01500252|DEVICE|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
224030649|NCT03231930|DEVICE|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
223413266|NCT04002115|PROCEDURE|Total Body Irradiation (TBI)|TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
223413267|NCT04002115|DRUG|Cyclophosphamide|Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
223413268|NCT04002115|DRUG|Granulocyte Colony-Stimulating Factor|G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
223559710|NCT01500252|DEVICE|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
223559711|NCT03544489|BEHAVIORAL|E-ICD Intervention|Home walking 3 days/week x 12 weeks
223559712|NCT04833686|BEHAVIORAL|Mozart|Music composed by Mozart, a musical piece 24 minutes long.
223559713|NCT04833686|BEHAVIORAL|Instrumental music|Instrumental music , a musical piece 24 minutes long
223559714|NCT04833686|BEHAVIORAL|Silence|Silence, a piece 24 minutes long.
224030650|NCT03231930|DEVICE|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
224030651|NCT01315951|BIOLOGICAL|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
224030652|NCT03501160|OTHER|Face-to face semi-structured in-depth interview|Face-to face semi-structured in-depth interview will be arranged in order to explore the inappropriate social behavior and caregiver stress from caregivers. The interview will be guided by a semi-structured interview guide which specially designed for exploring clinical picture of inappropriate social and affectionate behavior and caregiving distress. The interview guide mainly consisted of specific questions and open-ended questions that encourage the subjects to talk freely in relevant topics during interview. Demographic data was also collected in the beginning of interview. Each interview will be conducted around 60 minutes until data saturated. The interview will be audio-taped with informed consent from subjects.
224030653|NCT01492465|DRUG|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
224030654|NCT00430261|DRUG|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
224030655|NCT02618031|PROCEDURE|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA (tissue plasminogen activator) directly at the site of the clot. The protocol calls for use of the Trevo stent retriever (Stryker Neurovascular) for the first pass of clot removal.
224030656|NCT02325167|BEHAVIORAL|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
224030657|NCT02325167|BEHAVIORAL|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
224030658|NCT05593679|DIAGNOSTIC_TEST|Tc-99m PYP Cardiac scan|Tc-99m PYP Cardiac scan
224030659|NCT00394953|DRUG|Darbepoetin alfa|As prescribed, iv.
224030660|NCT00394953|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
224030661|NCT03586687|DRUG|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
224030662|NCT02629289|DRUG|HSP-130|
224030663|NCT02629289|DRUG|US-approved Neulasta|
224030664|NCT02629289|DRUG|EU-approved Neulasta|
224030665|NCT05712733|OTHER|Microbiological and histopathological investigation of bile and gallbladder wall specimens.|Bile and gallbladder wall specimens will be taken from all patients included in the study. The material will be sent for microbiological and histopathological investigation.
224030666|NCT01769066|DRUG|Sequential Gefitinib With Pemetrexed/Platinum|
224030667|NCT01769066|DRUG|Pemetrexed/Platinum|
224030668|NCT03181451|DRUG|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
224030669|NCT01510522|DRUG|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month
224030670|NCT01510522|DRUG|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: \> 1.700mg/day for 6 month"
224030671|NCT00390182|DRUG|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study."
224030672|NCT00002184|DRUG|Nelfinavir mesylate|
224030673|NCT00002184|DRUG|Levocarnitine|
224030674|NCT00002184|DRUG|Adefovir dipivoxil|
223413269|NCT04002115|DRUG|Tacrolimus|Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
223413270|NCT04002115|DRUG|Cellcept|Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
223413271|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 1g|
223413272|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 5g|
223559715|NCT03115827|DRUG|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
223559716|NCT03115827|DRUG|Carbidopa|Carbidopa 200mg twice a day
223559717|NCT02600416|OTHER|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
224030675|NCT00002184|DRUG|Saquinavir|
224030676|NCT00002184|DRUG|Lamivudine|
224030677|NCT00002184|DRUG|Stavudine|
223413273|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 10g|
223413274|NCT02260336|DIETARY_SUPPLEMENT|Panax Notoginseng Powder 15g|
223413275|NCT02260336|DRUG|Celecoxib Capsule 400 mg daily|
223413276|NCT05724251|OTHER|healthy|no intervention
223413277|NCT05724251|OTHER|periodontitis|no intervention
223413278|NCT06574594|DRUG|Methotrexate|methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination
223413279|NCT06574594|DRUG|Methotrexate|methotrexate continuation group : keep methotrexate
223413280|NCT02713932|DEVICE|Transcatheter aortic valve implantation|
223413281|NCT00944242|DRUG|Sertraline|
223413282|NCT00944242|DRUG|Sertraline Hydrochloride|
223413283|NCT01392924|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
223413284|NCT01558557|OTHER|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
223413285|NCT04844749|DRUG|VERU-111|Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent
223413286|NCT04844749|DRUG|Enzalutamide, Abiraterone|Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer
223413287|NCT01506102|DEVICE|Thromboelastography|Thromboelastography during labor and after delivery
224030678|NCT00002184|DRUG|Zidovudine|
224030679|NCT06321549|OTHER|The reference point of minimally invasive mastectomy procedure conducted|November 2018 as a temporal reference point was predicated on the milestone of the medical center's inaugural minimally invasive mastectomy procedure conducted
224030680|NCT02335125|BEHAVIORAL|Motivational Interviewing|
223413288|NCT03806725|DIAGNOSTIC_TEST|Intravenous administration of iodinated contrast medium for coronary CT angiography|Administration of iodinated contrast medium for coronary CT angiography
223413289|NCT02420730|DRUG|AGN-232411|AGN-232411 topical ophthalmic solution
223413290|NCT02420730|DRUG|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
223413291|NCT01338402|DEVICE|Lotrafilcon B contact lens|Silicone hydrogel contact lens
224030681|NCT02335125|BEHAVIORAL|Cognitive Behavioral Therapy Elements|
224030682|NCT02335125|DRUG|Psychotropic Drugs|
224030683|NCT02335125|OTHER|Care Management|
224030684|NCT01937325|DRUG|ivacaftor|active arm
224030685|NCT01937325|DRUG|placebo|active arm
224030686|NCT03313453|DEVICE|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
224030687|NCT03313453|DEVICE|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
224030688|NCT06026085|OTHER|Skinceuticals skin care product(CE)|Skinceuticals skin care product(CE FERULIC)+routine sun protection
224030689|NCT06026085|OTHER|fraxel laser therapy|Fraxel DUAL 1550/1927 Laser System
223413292|NCT01338402|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
223413293|NCT01338402|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
223413294|NCT00900159|DRUG|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
223413295|NCT00900159|DRUG|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
224030690|NCT06026085|OTHER|0.9% normal saline|0.9% normal saline+routine sun protection
223413296|NCT02555787|DRUG|Tacrolimus|oral
223413297|NCT03443622|DRUG|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
223413298|NCT03550872|BEHAVIORAL|Physical Training|Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
223413299|NCT02580617|BIOLOGICAL|ALLO-ASC|Infusion for Crohn's disease
223413300|NCT04630236|DIAGNOSTIC_TEST|Ultrasound|Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
223413301|NCT04321356|DEVICE|Triathlon PCR TKA|Total Knee Arthroplasty System
223413302|NCT04321356|DEVICE|Triathlon PS TKA|Total Knee Arthroplasty System
223413303|NCT04321356|DEVICE|Persona PCR TKA|Total Knee Arthroplasty System
223413304|NCT04321356|DEVICE|Persona PS TKA|Total Knee Arthroplasty System
223413305|NCT01296945|OTHER|Kiosk|Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
224030691|NCT00308386|BEHAVIORAL|Nurse Case Management intervention|Intervention is meeting with nurse case managers
224030692|NCT04283721|OTHER|Educational video|Ten-minutes educational video on epidural/spinal analgesia benefits and side effects (sample video link: https://youtu.be/jAhoKhvcbP4). The informational video will be administered by co-investigators, who are anaesthesiologists. The video will be shown on an institutional iPad that will be thoroughly disinfected by the co-investigators before and after each use. Co-investigators will receive training on the disinfection process, and each disinfection will be documented on a logbook, dated and signed by the co-investigators.
224030693|NCT01165645|DRUG|lopinavir|Given orally
224030694|NCT01165645|DRUG|ritonavir|Given orally
224030695|NCT01165645|GENETIC|polymerase chain reaction|Correlative studies
224298298|NCT04111406|DRUG|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~1. insertion at mid-level of surgical insertion~2. insertion depth is 3-5 cm in space, not more than 5 cm~3. using benzoin tincture and transparent dressing to fix catheter~4. test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~5. After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
224298299|NCT00307606|DRUG|Solu-medrol 125 mg|
224030696|NCT01165645|OTHER|flow cytometry|Correlative studies
224030697|NCT01165645|OTHER|enzyme-linked immunosorbent assay|Correlative studies
224030698|NCT01165645|OTHER|laboratory biomarker analysis|Correlative studies
224030699|NCT04362410|BIOLOGICAL|Experimental: Tezepelumab|Tezepelumab single dose subcutaneously injection.
224030700|NCT04362410|OTHER|Placebo|Placebo single dose subcutaneously injection.
224030701|NCT03286322|OTHER|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
224030702|NCT03286322|OTHER|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
224030703|NCT06435130|OTHER|Dietary intervention with chokeberry juices|The first stage of the dietary intervention lasted 8 weeks. Study participants consumed 100 ml of chokeberry juice daily. Chokeberry juice came from ecological cultivation (Poland). Participants qualified for the study had specific biochemical parameters tested: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. Blood tests were performed in a certified external laboratory before and after 8 weeks of intervention. In addition, blood pressure and waist circumference were tested.
224030704|NCT06435130|OTHER|Dietary intervention with chokeberry juices and fibers|The second stage of the dietary intervention lasted 4 weeks. Study participants consumed 100 ml of chokeberry juice daily and 10 g chokeberry fiber daily (from ecological cultivation, Poland). Blood tests were performed in a certified external laboratory after 4 weeks of intervention. The following blood tests were performed: fasting glucose and insulin level, lipid profile (triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol), glycated hemoglobin, uric acid, C-reactive protein (CRP), creatinine, liver enzymes: alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamylotranspeptydase (GGTP), homocysteine and antioxidant potential. In addition, blood pressure and waist circumference were tested.
224135644|NCT06898554|OTHER|The structured balance training protocol|The structured balance training protocol consists of 7 exercises including balance and hop stabilization exercises for athletes with chronic ankle instability.
224135645|NCT06898645|DEVICE|navigated iTBS (Intermittent theta-burst stimulation) targeting the cerebellum|1,800 pulses per session for unilateral cerebellum, 50-minute intersession interval, 80% resting motor threshold, total 75600 pulse number.
224135646|NCT05902754|DIETARY_SUPPLEMENT|Generally Recognized as Safe - Sulforaphane|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of Sulforaphane a day with a meal for 28 days.
224135647|NCT05902754|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to maintain the same food ingestion habits as before the study and take 2 tablets of placebo a day with a meal for 28 days.
224135648|NCT06346028|DEVICE|Brainsway H4 deep rTMS coil and Brainsway stimulator system|"An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC."
224135649|NCT05022771|DRUG|PMG1015 Dose 1|Dose level 1 of PMG1015
224135650|NCT05022771|DRUG|PMG1015 Dose 2|Dose level 2 of PMG1015
224135651|NCT05022771|DRUG|PMG1015 Dose 3|Dose level 3 of PMG1015
224135652|NCT05022771|DRUG|PMG1015 Dose 4|Dose level 4 of PMG1015
224298300|NCT01816815|DRUG|BAY1002670|
224298301|NCT01816815|DRUG|Placebo|
224135653|NCT05022771|DRUG|PMG1015 Dose 5|Dose level 5 of PMG1015
224135654|NCT05022771|DRUG|PMG1015 Dose 6|Dose level 6 of PMG1015
224135655|NCT05022771|DRUG|Placebo|Placebo to match
224135656|NCT05022771|DRUG|PMG1015 Dose 7|Dose level 7 of PMG1015
224135657|NCT04611711|DRUG|decitabine＋ TQB2450 injection|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors."
224298302|NCT02667288|DRUG|A-101 Solution|
224298303|NCT02957188|OTHER|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
223738833|NCT02375113|DIETARY_SUPPLEMENT|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
223738834|NCT02766725|DRUG|preparation F12 sildenafil in situ gel|in situ vaginal gel
223738835|NCT02766725|DRUG|preparation F2 sildenafil in situ gel|in situ vaginal gel
223738836|NCT02766725|DRUG|placebo gel|vaginal gel
223738837|NCT01721382|DRUG|Sitagliptin|
223738838|NCT05729659|DIETARY_SUPPLEMENT|Sideritis Scardica (SidTea+) extract supplementation|1500 mg of Sideritis Scardica (SidTea+) extract per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
223738839|NCT05729659|DIETARY_SUPPLEMENT|Placebo supplementation|1500 mg of placebo per day, divided into 3 equal doses of 500 mg (every 8 hours) for a total duration of 1 month
223738840|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
223738841|NCT03772275|DIAGNOSTIC_TEST|New york Heart Association Class I|New york Heart Association Class I
224030705|NCT04328051|OTHER|Dental Implant Placement|Antibiotic prophylaxis will be done. After rinsing with 0.12 % chlorhexidine, patients will receive local anaesthesia. A crestal incision will be done and a mucoperiostic flap will be raised. As the commercial specifies, progressive diameter drills will be used under constant sterile saline irrigation to prepare the implant site. Once finished the drilling sequence, one investigator will open the opaque envelope to know which type of implant, depending on the connection, has to be placed by the surgeon. Dental implant will be placed crestally and depending if it has primary stability or not, it will be leaded submerged or non-submerged. The flap will be repositioned and sutured without tension with 4/0 polyamide. Postoperative instructions and medication will be prescribed and explained.
224030706|NCT03672422|DIAGNOSTIC_TEST|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
224030707|NCT03672422|BEHAVIORAL|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
224030708|NCT03672422|DIAGNOSTIC_TEST|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
224030709|NCT03672422|DIAGNOSTIC_TEST|Urine sample|50 ml of urine in collection container.
224030710|NCT05666388|PROCEDURE|Rescue stenting|Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
224030711|NCT06018181|DRUG|Shuxuetong Injection|According to clinical real treatment records
224030712|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
224030713|NCT02196714|DRUG|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
224030714|NCT02196714|DRUG|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
223413306|NCT01296945|OTHER|paper|Participants will receive a paper handout with nutrition educational information.
223413307|NCT01296945|OTHER|Kiosk PLUS paper|Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
223738842|NCT03196934|DRUG|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
223738843|NCT06095453|OTHER|Pain control regimens|Narcotics in cholecystectomy and hernia repairs
223738844|NCT04253145|DRUG|PM 01183|Lyophilisate for solution for infusion
223738845|NCT04253145|DRUG|Atezolizumab|Concentrate for solution for infusion
223738846|NCT01868685|DRUG|BYM338|BYM338
223738847|NCT01868685|DRUG|Placebo|Placebo
223738848|NCT05609240|DRUG|Cefuroxime|See arm/group description
223738849|NCT03403595|DRUG|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
223738850|NCT01347008|DRUG|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
223738851|NCT01347008|DRUG|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
223738852|NCT00776958|OTHER|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
223738853|NCT05102799|OTHER|No intervention|No intervention
223738854|NCT05901168|OTHER|Active Video Games Intervention|Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
223738855|NCT05901168|OTHER|Traditional Exercise Intervention|"Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes."
223738856|NCT01784640|DRUG|Hsp90 inhibitor AUY922|Given IV
224298304|NCT01196078|DRUG|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
223738857|NCT01784640|DRUG|pemetrexed disodium|Given IV
223738858|NCT01784640|OTHER|pharmacological study|Correlative studies
223738859|NCT01784640|OTHER|laboratory biomarker analysis|Correlative studies
223413308|NCT01296945|OTHER|Kiosk PLUS web|Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
223413309|NCT02115581|DRUG|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
223413310|NCT02115581|DRUG|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
224030715|NCT02196714|DRUG|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
224030716|NCT03275129|DIAGNOSTIC_TEST|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
224030717|NCT04003220|PROCEDURE|blood sample|The extra samples will be taken Blood sampling
224030718|NCT04003220|PROCEDURE|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
224030719|NCT00690833|DRUG|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
224030720|NCT05270174|OTHER|no intervention|no intervention
223413311|NCT03763825|BEHAVIORAL|Mini-AFTERc|Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
223413312|NCT06468345|BEHAVIORAL|acupressure|Application was made to CV12, ST25, SP6, HT7 and LI4 acupressure areas.
223413313|NCT06468345|BEHAVIORAL|Area different from acupressure area|Massage application to non-acupressure hand, foot and abdominal areas
224030721|NCT03865147|DRUG|Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)|Investigational Drug
224030722|NCT03865147|DRUG|EMLA cream|Active Comparator
224135658|NCT04611711|DRUG|decitabine＋ TQB2450 injection＋Anlotinib|"Real low-dose epigenetics drugs (decitabine) can reverse the resistance of PD-1 inhibitors by re-regulating the immune microenvironment.~TQB2450 is a humanized monoclonal antibody targeting PD-L1, which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, so as to restore the activity of T cells and thereby enhance the immune response, and has the potential to treat various types of tumors.~Anlotinib Hydrochloride is a multi-target receptor tyrosine kinase inhibitor with significant inhibitory activity against angiogenesis related kinases (VEGFR1/2/3, FGFR1/2/3, etc.) and other tumor cell proliferation-related kinases (PDGFR /, C-Kit, RET, etc.), which can play a dual role in anti-tumor angiogenesis and tumor growth inhibition. "
224135659|NCT00657631|BEHAVIORAL|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, \& Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl \& Wilson, 1999)."
224135660|NCT05149040|OTHER|"survey Intensive care of very elderly: What do they wish for themselves?"|self-administered mailed survey
224298305|NCT01196078|DRUG|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
224298306|NCT00700609|BEHAVIORAL|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
223413314|NCT02555150|DRUG|PRC-063|Oral extended-release capsule
223413315|NCT02555150|DRUG|lisdexamfetamine dimesylate|Oral capsule
223413316|NCT02555150|DRUG|Placebo|Oral placebo capsule
223738860|NCT05430737|RADIATION|stereotactic body radiotherapy|The radiation dose to the primary tumor was 40 or 45 Gy in five fractions according to the clinical determination of the radiologist. The dose to the positive lymph nodes and the prostate and seminal vesicles was 37.5Gy in five fraction. And internal iliac, external iliac, obturator, and presacral pelvic drainage regions received 25 Gy/5f, simultaneously. The treatment was delivered every other day. The volumetric modulated arc radiotherapy (VMAT) or intensity-modulated radiotherapy (IMRT) was used to complete treatment. Image-guided radiotherapy(IGRT) was performed for every treatment.
223738861|NCT00895323|OTHER|enzyme-linked immunosorbent assay|
223738862|NCT00895323|OTHER|pharmacological study|
223738863|NCT00895323|PROCEDURE|whole-body scintigraphy|
224030723|NCT03865147|DRUG|Post Operative Analgesia (Paracetamol, Ibuprofen)|Standard of Care
224030724|NCT02802098|DRUG|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
224030725|NCT02802098|DRUG|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
224030726|NCT03693456|OTHER|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
224030727|NCT01592864|DRUG|Stannous Fluoride|dentifice
224030728|NCT01592864|DRUG|Sodium Monofluorophosphate|dentifrice
224030729|NCT04151953|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
224030730|NCT02271425|DRUG|Evacetrapib Tablet|Oral administration
224030731|NCT02271425|DRUG|Evacetrapib Intravenous|Intravenous administration
224030732|NCT05737290|DEVICE|Clear aligners|Patients with mild anterior crowding will be treated with non-extraction treatment using clear aligners.
223413317|NCT01377922|DRUG|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
224030733|NCT05737290|DEVICE|Fixed appliances|Patients with mild anterior crowding will be treated with non-extraction treatment using fixed appliances.
224030734|NCT02171325|DRUG|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
224030735|NCT02660307|OTHER|PROGRESS group|
224030736|NCT05090748|DEVICE|Echocardiographic.|Echocardiographic test.
224030737|NCT04671134|OTHER|Biomimetic remineralizing agent|Self-assempling peptide
224030738|NCT04671134|OTHER|Resin Modified Glass Ionomer Varnish|Resin Modified Glass Ionomer Varnish
224030739|NCT04615767|DIETARY_SUPPLEMENT|D-chiro-inositol|as described previously
224030740|NCT00279773|DRUG|TKI258|
224030741|NCT04626895|DEVICE|Paxman Scalp Cooling Device|Paxman scalp cooling device
224030742|NCT04652167|DIAGNOSTIC_TEST|PCT|"Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration."
224030743|NCT04652167|DIAGNOSTIC_TEST|suPAR|Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
224030744|NCT04652167|DIAGNOSTIC_TEST|Standard care|Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
224030745|NCT01365143|PROCEDURE|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
224030746|NCT01365143|PROCEDURE|Open Radical Prostatectomy|Open radical prostatectomy
224030747|NCT01384422|DRUG|GLPG0634|
224135661|NCT06381414|BEHAVIORAL|Observation|"Identify the prevalence of early wear in primary dentition, using Childhood Early Oral Aging Syndrome (CEOAS) index.~The CEOAS index involves scores of 0 to 3 for the assessment of tooth wear and dental management, whereas scores of I, II and III are used concomitantly in cases of the presence of enamel defects."
224135662|NCT06068361|DIAGNOSTIC_TEST|EEG|32-electrode EEG (resting state, passive auditory and active visual task) + simultaneous recording with a 4 dry electrode EEG cap
224030748|NCT01185925|DRUG|Sildenafil|Sildenafil, 50 mg 3 times/day
224030749|NCT01185925|DRUG|Placebo|Placebo
224030750|NCT05792969|BEHAVIORAL|Functional measures and public health outcomes|"Questionnaires:~* Activities of daily living - ADL~* Barthel Index~* Instrumental activities of daily living- IADL~* Health Related Quality of Life - EQ-5D-5L~* Geriatric Depression Scale (GDS)~* State-Trait Anxiety Inventory - STAI-Y)~* Caregiver Burden Inventory questionnaire (CBI)"
224030751|NCT01056133|OTHER|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be\< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
224030752|NCT03008447|DRUG|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
224030753|NCT03008447|DRUG|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
224135663|NCT01196169|DRUG|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
224135664|NCT01196169|DRUG|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if \> one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of \< 50 ml/min. Patients with creatinine clearance of \< 50 ml/min will only receive one dose.
223738864|NCT00895323|RADIATION|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
224030754|NCT03008447|DRUG|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
224030755|NCT03008447|DRUG|PBO|Single dose of placebo administered within 5 minutes before bedtime.
224030756|NCT04189237|OTHER|Electroacupuncture|needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
224030757|NCT02425930|PROCEDURE|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
224030758|NCT02425930|DRUG|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA\>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
224030759|NCT00073112|DRUG|ABT-751|
224030760|NCT00200434|DRUG|Nebivolol|
224135665|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
224135666|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
224135667|NCT00808249|DRUG|AZD7325|2 tablets taken twice a day for 28 days
224135668|NCT00808249|DRUG|Placebo|2 tablets taken twice a day for 28 days
224135669|NCT04691063|DRUG|SHR-1316; Carboplatin; Etoposide；Radiotherapy|SHR-1316; Carboplatin; Etoposide；Radiotherapy（Part 1 and Part 2）
224135670|NCT04691063|DRUG|Palcebo; Carboplatin; Etoposide；Radiotherapy|Palcebo; Carboplatin; Etoposide；Radiotherapy（Part 2）
224135671|NCT00002058|DRUG|Clofazimine|
224135672|NCT03829332|BIOLOGICAL|Pembrolizumab|IV infusion
224135673|NCT03829332|DRUG|Lenvatinib|oral capsule
224135674|NCT03829332|DRUG|Placebo for lenvatinib|oral capsule
223413318|NCT01377922|DRUG|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
224135675|NCT05094830|PROCEDURE|Stomach Intestinal Pylorus-Sparing (SIPS) Procedure|The SIPS procedure will be performed as an investigational bariatric surgery. The SIPS procedure involves the creation of a standard sleeve gastrectomy over a 36-40 bougie. Division of the duodenum post-pylorus is performed, followed by the creation of a common channel 300 cm from the ileo-cecal valve. A hand-sewn anti-side duodenoileostomy is performed and the anastomosis tested for leaks through use of endoscopic insufflation and under water air leak test. Incisions are then closed in standard fashion. The SIPS procedure itself is not a separate surgery but rather a modification to the standard of care surgery.
223413319|NCT03250858|BEHAVIORAL|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
224030761|NCT02120716|BEHAVIORAL|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
224030762|NCT03458286|DEVICE|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
224030763|NCT00256451|DRUG|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
224030764|NCT00256451|DRUG|placebo|placebo pills
224030765|NCT00256451|OTHER|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
224030766|NCT00256451|OTHER|Sham alcohol|non-alcoholic placebo alcohol
224030767|NCT05659277|OTHER|Workplace Stress and Irregular shift hours|The physiological, psychological, and cognitive impacts that workplace stress and irregular shift hours have on first responders.
224030768|NCT01493648|DRUG|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
224030769|NCT01493648|DRUG|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
224135676|NCT04054349|OTHER|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
224135677|NCT05834764|DRUG|Pyrotinib|Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）
223413320|NCT03250858|BEHAVIORAL|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
223413321|NCT04793308|OTHER|Endodontic files|Engine-driven nickel titanium Ni-Ti instruments
223738865|NCT05699798|OTHER|Conservative Treatment (CT)|Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions.
224030770|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
224030771|NCT00550875|BIOLOGICAL|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
224030772|NCT00550875|BIOLOGICAL|placebo|Sublingual. 2 drops/daily 2 years
224030773|NCT04078165|DEVICE|Zero-Gravity|Free-floating, suspended personal radiation protection
224030774|NCT04078165|DEVICE|Conventional radiation protection|Standard lead shields and aprons
224135678|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
224135679|NCT00430521|BIOLOGICAL|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
224135680|NCT04065880|OTHER|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
224135681|NCT04065880|OTHER|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
224135682|NCT01448291|DRUG|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
224135683|NCT01996202|DRUG|Ipilumimab|
224135684|NCT01996202|RADIATION|Radiation|
223413322|NCT06035146|PROCEDURE|Mechanical energy monitoring|Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.
223413323|NCT06035146|PROCEDURE|Conventional mechanical ventilation|The conventional procedure of mechanical ventilation controlled according to the physician's decision.
223413324|NCT03231072|DEVICE|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
223413325|NCT02909712|DRUG|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
224030775|NCT04609059|DRUG|M201-A Injection|"Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
224135685|NCT02592603|DEVICE|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
224135686|NCT05756673|DRUG|Colgate Cavity Protection Toothpaste|Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
224135687|NCT05756673|DRUG|LISTERINE ZERO Alcohol Mouthwash COOL MINT|Participants will use LISTERINE ZERO Alcohol Mouthwash COOL MINT for 30 second after brushing teeth twice daily.
224030776|NCT04609059|DRUG|Placebo|"Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)"
224030777|NCT02803047|DRUG|Coppertone (BAY987516)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation number - SR15-61-Z15-034).
224030778|NCT02643836|DEVICE|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
224030779|NCT00118443|BEHAVIORAL|Question, Persuade, Refer (QPR) training|
224030780|NCT01504308|DEVICE|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
224030781|NCT01504308|DEVICE|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
224030782|NCT02687425|DRUG|Pioglitazone|15mg/day,po
224030783|NCT02687425|DRUG|imatinib mesylate|400mg/day,po
224030784|NCT05708625|DRUG|Intralesional Sodium stibogluconate|Sessions will be held once weekly for a maximum of 6 weeks
224030785|NCT05708625|PROCEDURE|Intralesional Cryotherapy|Intralesional Cryotherapy. Sessions will be held every two weeks
224030786|NCT05708625|DRUG|Intralesional Voriconazole|Weekly intralesional Voriconazole
224030787|NCT05708625|DRUG|Oral doxycycline|200 mg daily for 6 weeks or till complete cure
224030788|NCT00442299|DEVICE|Fractionated Plasma Separation and Adsorption (FPSA)|
224030789|NCT04782388|DRUG|Alprazolam|Study participants will receive Staccato alprazolam at prespecified time-point.
224030790|NCT04782388|OTHER|Placebo|Study participants will receive Staccato placebo at prespecified time-point.
224030791|NCT00326469|DRUG|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
224030792|NCT00458809|DRUG|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
224030793|NCT02369445|BEHAVIORAL|Moisture Pager Intervention for Toilet Training|
224030794|NCT02369445|BEHAVIORAL|Standard of Care|
224030795|NCT01326533|DRUG|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
223559718|NCT06403982|OTHER|Continuation of oxytocin after ELA|"The use of oxytocin will be continued after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor.~Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery."
224030796|NCT01326533|OTHER|Placebo|Thirteen weeks of oral placebo provided as capsules
224030797|NCT04071353|DRUG|Interferon|Interferon combined with ribavirin antiviral therapy
224030798|NCT04071353|DRUG|ribavirin|Interferon combined with ribavirin antiviral therapy
224030799|NCT04071353|DRUG|DAAs|DAAs antiviral treatment
224030800|NCT00477854|DRUG|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
224030801|NCT03878498|OTHER|therapeutic management|therapeutic management of anal fistula in Crohn Disease
224030802|NCT03373487|BEHAVIORAL|The cognitive rehabilitation program ReMind|Cognitive rehabilitation, i.e. psychoeducation, strategy training \& retraining
224030803|NCT04079803|DRUG|Placebo oral tablet|Oral placebo tablet
224030804|NCT04079803|DRUG|Simufilam 100 mg tablet|Simufilam 100 mg oral tablet
224030805|NCT04079803|DRUG|Simufilam 50 mg oral tablet|Simufilam 50 mg oral tablet
224030806|NCT02166866|OTHER|Quality of Life Questionairre and Education|
224030807|NCT00231387|DRUG|rosiglitazone|
224030808|NCT02600455|DRUG|Orencia|
224030809|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
224030810|NCT01321346|DRUG|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
224030811|NCT01321346|DRUG|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
224030812|NCT01279512|DRUG|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
224030813|NCT01279512|DRUG|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
224030814|NCT04792658|BEHAVIORAL|Detailed interview with personal demographic data|, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.
224030815|NCT04792658|BEHAVIORAL|Intelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)|the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence
223413326|NCT02909712|DRUG|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
223413327|NCT01417247|PROCEDURE|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
223413328|NCT03175705|BIOLOGICAL|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10\^7/m2 Loading Dose 2: 6x10\^7/m2 Loading Dose 3: 9x10\^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
223413329|NCT03175705|DRUG|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
223413330|NCT03175705|DRUG|Tegafur|Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.
223413331|NCT06565494|DRUG|midomafetamine (MDMA)-Assisted Therapy|This treatment consists 3 Preparation sessions followed by 3 Experimental sessions at 4-week intervals; after each Experimental session, 3 weekly Integration sessions will be conducted. For the first Experimental Session, the dose of MDMA is 80 mg; for the second and third Experimental Sessions, the dose of MDMA is 120 mg. For all three Experimental sessions, a supplemental dose of 50% of the initial dose will be available. The Preparation, Experimental, and Integration Sessions will involve psychotherapy developed specifically for this trial and population.
224030816|NCT04792658|BEHAVIORAL|The Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)|it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality
224030817|NCT04792658|BEHAVIORAL|the Hamilton Depression Rating Scale|it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54
224030818|NCT04792658|BEHAVIORAL|The Hamilton Anxiety Rating Scale|it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56
224030819|NCT04792658|BEHAVIORAL|The Minnesota Multiphasic Personality Inventory-2 (MMPI-2)|It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic
224030820|NCT01294683|DRUG|Simvastatin|
224030821|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
224030822|NCT01294683|DRUG|Extended Release (ER) niacin/laropiprant (N/LRPT)|
224030823|NCT01294683|DRUG|Placebo|
224030824|NCT02941133|OTHER|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
224030825|NCT02941133|OTHER|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
224030826|NCT00298909|BEHAVIORAL|physical exercise|physical exercise
224030827|NCT00298909|DRUG|niaspan (extended-release niacin)|niaspan (extended-release niacin)
224030828|NCT00298909|DRUG|niacin|niacin extended-release
224030829|NCT00298909|OTHER|control|control
224030830|NCT05591820|BEHAVIORAL|Brief behavioral parent training with optional booster sessions|A brief and individually-tailored behavioral parent training program that combines stimulus control and contingency management techniques to treat children's behavioral difficulties in three (bi)weekly sessions and optional booster sessions.
224030831|NCT05591820|BEHAVIORAL|Care as usual|The care that is usually provided by the clinical institutions to treat children's behavioral difficulties. There are no restrictions regarding type or duration of CAU (only the brief parent training will not be allowed) which may for example include psychoeducation, (long) parent training, child treatment (e.g., pharmacotherapy, cognitive behavioral therapy) or family therapy.
224030832|NCT01215500|RADIATION|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~1. 8 Gy/ fraction x 3 fractions = 24 Gy~2. 10 Gy/fraction x 3 fractions = 30 Gy~3. 12 Gy/fraction x 3 fractions = 36 Gy~4. 14 Gy/fraction x 3 fractions = 42 Gy~5. 16 Gy/fraction x 3 fractions = 48 Gy~6. 18 Gy/fraction x 3 fractions = 52 Gy~7. 20 Gy/fraction x 3 fractions = 60 Gy"
224030833|NCT01881750|BEHAVIORAL|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
224030834|NCT01881750|BEHAVIORAL|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
224135688|NCT05756673|DRUG|LISTERINE COOL MINT Antiseptic Mouthwash|Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.
224135689|NCT05756673|DEVICE|TePe Original Interdental Brush|Participants will use Interdental Brush according to their personalized mouth map once daily in the morning.
224135690|NCT00746031|DRUG|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
224135691|NCT00746031|DRUG|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
223413332|NCT02046590|DRUG|Propofol|
223413333|NCT02046590|OTHER|General anesthesia|
224135692|NCT02973464|DRUG|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
223413334|NCT06004921|DRUG|AB801|Administered as specified in the treatment arm
224135693|NCT02973464|DRUG|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
224135694|NCT02814357|OTHER|Control (market standard)|
224135695|NCT02814357|OTHER|wheat flour|
224135696|NCT02814357|OTHER|chickpea flour|
224135697|NCT02814357|OTHER|guar gum|
224135698|NCT02814357|OTHER|barley|
224135699|NCT04838925|DEVICE|Mobile Neurofeedback App|Neurofeedback intervention delivered via mobile app. Participants wear an EEG headset which is connected to a mobile app that delivers feedback about brainwave data indicating whether they are in a calm, relaxed state. Participants hear a lower/simple sound when they are below a target level and higher/richer sound when they approach or achieve their target.
223413335|NCT06004921|DRUG|Placebo|Administered as specified in the treatment arm
224030835|NCT00770237|BEHAVIORAL|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
224030836|NCT00770237|BEHAVIORAL|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
224030837|NCT00508248|DIETARY_SUPPLEMENT|omega 3 fatty acids|1g daily
224030838|NCT00508248|DIETARY_SUPPLEMENT|placebo|olive oil capsule
224030839|NCT00846456|BIOLOGICAL|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
224030840|NCT05223751|BEHAVIORAL|Meo Health Breathing and humming exercises|"The Intervention Group will receive training on the Meo Health breathing therapy, which will include:~* Being shown the Meo Health Breathing Therapy On-Boarding video~* Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application.~* Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach.~Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention.~A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group.~A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group."
224030841|NCT00984763|BIOLOGICAL|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
224030842|NCT01779687|DRUG|raltegravir|Raltegravir 400 mg BID for 7 days
224030843|NCT01779687|DRUG|Atorvastatin|Atorvastatin 20 mg QD for 7 days
224030844|NCT03379922|BEHAVIORAL|Stress balls|Squeezing stress balls while receiving ESWL treatment
224030845|NCT03379922|BEHAVIORAL|Headphones|Listening to music while receiving ESWL treatment
224030846|NCT01126151|BEHAVIORAL|parent handbook|parent handbook
224030847|NCT03708822|DRUG|Docetaxel and Cisplatin and Nimotuzumab|Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;
224030848|NCT02975024|DEVICE|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
224030849|NCT02975024|DEVICE|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
224030850|NCT02975024|DEVICE|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
224030851|NCT04990492|DIAGNOSTIC_TEST|Paper GAD 7|The paper based GAD 7 that is commonly accepted at clinics
224030852|NCT04990492|DIAGNOSTIC_TEST|Voice Administered GAD 7|This is the voice based GAD 7 that is administered through a Mirror device equipped with Amazon Alexa software.
224030853|NCT01134016|DRUG|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
224030854|NCT01626703|OTHER|Reminding call|
224030855|NCT04269005|OTHER|Implementation of the SCCM|Implementation of the SCCM includes a baseline survey, assessment of screening questions stage 1 (with consequence), screening questions stage 2 (with consequence) and if necessary psychosomatic-psychiatric consultation and liaison service including if applicable post hospital intervention and a follow-up survey in a distressed focus sample.
224030856|NCT05161832|BEHAVIORAL|Nocebo|Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.
224135700|NCT05641818|OTHER|Screening tool for vitamin D deficiency|(1) Determination of 25(OH) Vitamin D3 in human serum samples and (2) Question based screening tool with personal (age, gender,...), lifestyle (e.g. sun exposure, outdoor activity) and dietary factors that affect the status of vitamin D in the human body.
224135701|NCT06897709|PROCEDURE|Classic Approach in Laparoscopic Appendectomy|underwent laparoscopic appendectomy using the standard approach
224135702|NCT06897709|PROCEDURE|Stump first Approach in Laparoscopic Appendectomy|Stump first Approach in Laparoscopic Appendectomy
224030857|NCT05161832|BEHAVIORAL|Placebo|Placebo ultrasound with no diagnosis of injury.
224030858|NCT06244758|DRUG|Finerenone 20 MG Oral Tablet|The intervention is administered orally.
224030859|NCT06244758|DRUG|Placebo|The intervention is administered orally.
224030860|NCT01764113|BEHAVIORAL|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
224030861|NCT01764113|BEHAVIORAL|Standard dietary counselling|
224030862|NCT00537368|DRUG|CNTO 888|
224030863|NCT00530296|BEHAVIORAL|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
224030864|NCT00926211|DEVICE|ARTAS™ System|Hair harvest using a computer-assisted system
224030865|NCT00926211|PROCEDURE|Manual Hair Harvest|Hair harvesting via the manual technique
224030866|NCT02696772|OTHER|Energy intake|
224030867|NCT00298454|DRUG|Furosemide|
224030868|NCT02580396|DEVICE|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
223413336|NCT03348007|OTHER|Taking two kinds of mineral water|1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
223413337|NCT02269228|DRUG|Asasantin ER|
223413338|NCT02269228|DRUG|Placebo|
223413339|NCT04204109|OTHER|Interprofessional case-based learning|"The trial is an educational intervention where groups of healthcare professionals receive the same case-based learning: one group receives case-based learning with healthcare professionals of various professional backgrounds (experimental) versus another group receiving case-based learning with healthcare professionals exclusively of the same professional background (control).~The educational intervention consists of a case that is developed for the purpose of the intervention.~The participants in the experimental group will be randomised into six teams who will receive interprofessional case-based learning. The experimental group will be made up of healthcare professionals from various groups. The participants in the control group will be randomised in groups of one profession"
223413340|NCT03170362|OTHER|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
223413341|NCT04615403|DRUG|Travoprost|Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision
223413342|NCT01278004|DRUG|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
223413343|NCT01278004|DRUG|Placebo|Capsule
223413344|NCT01152749|DRUG|Nicotine|Single-dose of new NRT product
223413345|NCT01152749|DRUG|Nicotine Gum|Single-dose of marketed nicotine gum
223413346|NCT01662817|BEHAVIORAL|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
223413347|NCT01662817|BEHAVIORAL|Control|PCP manages depression in the usual way for six months
223413348|NCT00256269|DRUG|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
223413349|NCT00256269|DRUG|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
223413350|NCT06684561|DEVICE|PIS|"All subjects will be instructed to change the investigational infusion sets (PIS) every 246 hours (10 days \& 6 hours) or at set failure. Each subject is required to wear the CGM device continuously.~defined as any one of the following: After completing 2 sets, the subjects have an optional office visit to download pump and CGM data and will continue to additional two wears. At day 40 or after using 4 completed wears of infusion sets (Note: early infusion set failure with wear time of \<6 hours due to insertion failure will be reported, yet not accounted as completed wear), the patients will return to a visit, download pump and CGM data, and end the study.~if study 1 is successful, participants will enter study 2; , the same study designed will be performed on the current on-market Extended infusion set (EIS) for comparison of clinical performance with the PIS, using the same cohort of pump users"
223413351|NCT02116933|PROCEDURE|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
223738866|NCT05699798|OTHER|Instrument-assisted Soft Tissue Mobilization (IASTM)|"IASTM was performed only on the neck and upper back muscles on the aching side using the sweep technique on the origo and insertion lines. A total of 6 sessions were applied, two sessions per week for 3 weeks.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
223738867|NCT05699798|OTHER|Extracorporeal Shock Wave Therapy (ESWT)|"ESWT therapy was applied on the muscle with active trigger point, at 1.5-2.0 bar pressure, at 10 Hz frequency, 2000 beats in each session, twice a week, in total 6 sessions.~Conservative treatment (HP, US, TENS) was applied for 3 weeks, with 5 sessions per week, a total of 15 sessions."
223738868|NCT06340828|OTHER|Washing Microbiota Transplantation|Fecal samples from healthy adults were collected and underwent multiple centrifugations and filtrations to obtain a bacterial solution, which was then transplanted into the duodenum of patients via a nasogastric tube.
223738869|NCT02060604|DRUG|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
223413352|NCT02116933|PROCEDURE|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
223413353|NCT04835610|DEVICE|pvi|The Plethysmographic Variability Index (PVI) can be measured with both finger and forehead probes. Vasoconstriction may reduce the reliability of PVI measurements in pediatric surgical patients prone to hypothermia. The vascular structure of the forehead area is resistant to changes in vasomotor tonus. The aim of our study is to compare the efficacy of PVI values measured at the finger and forehead areas to predict fluid responsiveness in these patients.
223413354|NCT01109953|OTHER|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
223413355|NCT05921292|COMBINATION_PRODUCT|Omeza Products Used in Combination|"Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza® combination therapy which includes the use of the following products:~* Omeza® Lidocaine Lavage~* Omeza® Complete Matrix (OCM™)~* Omeza® Skin Protectant At each treatment (on days 0, 7, 14, 21; +/- 3 days each), the patient's intact skin around the wound/ulcer will be prepped with Omeza® Lidocaine Lavage. OCM™ will be applied directly to the wound/ulcer and Omeza® Skin Protectant will be applied to the periwound and surrounding intact skin. Treatments may be repeated during an optional 7 additional weeks (on days 28, 35, 42, 49, 56, 63, and 70; +/- 3 days each). Final assessment will be made at week 12."
223413356|NCT06449430|DRUG|Sedation with propofol|Sedation with propofol
223413357|NCT06449430|DRUG|Spinal analgesia with bupivacaine|Spinal analgesia with bupivacaine
223413358|NCT02567123|BEHAVIORAL|Experimental|
223738870|NCT02060604|DRUG|Ranibizumab|3 monthly ranibizumab, then as needed
223738871|NCT02733588|DRUG|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
223738872|NCT00233103|DRUG|Sertraline|Sertraline arm
223738873|NCT00233103|DRUG|Placebo|Placebo
223738874|NCT03807063|BIOLOGICAL|Rivogenlecleucel|Given IV
223738875|NCT03807063|DRUG|Rimiducid|Given IV
223413359|NCT03340454|OTHER|Test-and-treat EHR-CHW intervention|a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
223413360|NCT03340454|OTHER|Usual care of EHR-only intervention|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
223413361|NCT00466388|DRUG|Cevimeline|
223413362|NCT03682848|DRUG|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
223413363|NCT01464164|DRUG|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
224030869|NCT00625950|PROCEDURE|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
224030870|NCT02841930|OTHER|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
224030871|NCT04668586|DEVICE|Holmium:YAG laser machine|Ureteroscopy with Holmium:YAG laser lithotripsy
224030872|NCT04668586|DEVICE|Thulium Fiber laser machine|Ureteroscopy with Thulium Fiber laser lithotripsy
224030873|NCT03159741|OTHER|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
224030874|NCT03159741|OTHER|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
224030875|NCT03159741|OTHER|Placebo + GIP|Placebo and GIP are used as study tools.
224030876|NCT03159741|OTHER|Placebo + Saline|Placebo
224030877|NCT06243419|DEVICE|vein viewer|The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.
223413364|NCT01464164|DRUG|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
223413365|NCT02594982|OTHER|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
223413366|NCT02043444|RADIATION|FDG PET-CT|
223738876|NCT04387435|OTHER|A change or titration in the current or frequency settings of the VNS therapy system.|The study treatment involves changing the output current or frequency of the default device settings in a FDA approved device for VNS therapy. The proposed frequency changes in this study are within the FDA approved output current and frequency levels.
223738877|NCT05205733|OTHER|Mail-in semen analysis kit|Presumably an easier, convenient, and more comfortable way to provide a semen analysis with an in-home mail-in semen analysis kit
224030878|NCT06243419|DEVICE|virtual reality|The child watched the application by wearing virtual glasses during the PIC insertion
224030879|NCT06243419|DEVICE|vein viewer and virtual reality|"The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.~The child watched the application by wearing virtual glasses during the PIC insertion"
224030880|NCT03346941|DRUG|DAA treatment|Direct-acting antiviral-based treatment
224030881|NCT00330850|DRUG|PRO-513|
224030882|NCT02920931|DRUG|Tenofovir disoproxil|
224030883|NCT06513754|OTHER|Ozone|Ozone is a pollutant that forms as a result of nitrogen oxides or volatile organic compounds interacting with UV radiation. Ozone will be created via a generator in the lab
224030884|NCT06513754|BEHAVIORAL|Heavy Intensity|Heavy intensity exercise between the first and second ventilatory threshold for 45 minutes
224030885|NCT06513754|BEHAVIORAL|Moderate Intensity|Moderate intensity exercise below the first ventilatory threshold for approximately 75 minutes
224030886|NCT06513754|OTHER|Filtered Air|Exposure to filtered air (\<10 ppb ozone)
224030887|NCT01051700|DRUG|GW786034|Investigational product
224030888|NCT01051700|OTHER|Placebo|Placebo
224030889|NCT00606073|OTHER|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
224030890|NCT05956054|OTHER|needle type|straight or curved
224030891|NCT05169125|PROCEDURE|standard hemodialysis|patients who will undergo standard hemodialysis (dialysate sodium concentration 143 mmoL/L)
224030892|NCT05169125|PROCEDURE|lower dialysate sodium dialysis|patients who will undergo hemodialysis with lower dialysate sodium concentration (140 mmoL/L)
224030893|NCT02334033|OTHER|other|
224030894|NCT02823626|DRUG|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
224030895|NCT04197726|OTHER|sbeIIa/b white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
224030896|NCT04197726|OTHER|Control white bread|one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
224030897|NCT05453019|DEVICE|Cochlear Implant|The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
223413370|NCT00606385|PROCEDURE|Liver resection|Laparoscopic or Open hepatectomy
223413371|NCT01438398|PROCEDURE|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
223413372|NCT01438398|PROCEDURE|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
223413373|NCT00097825|DRUG|Zoledronic Acid|
223413374|NCT03618394|DIETARY_SUPPLEMENT|MCT/ω-3-PUFA|lipid emulsion
223413375|NCT03618394|DIETARY_SUPPLEMENT|Soybean Based|lipid emulsion
223559719|NCT06403982|OTHER|Discontinuation of oxytocin after ELA|The oxytocin pump will be changed to 0.9% sodium chloride solution pump after the administration of ELA. The vital signs (blood pressure, saturation, heart rate) and the Doppler velocities in the uterine arteries, umbilical artery and the fetal middle cerebral artery will be measured directly before the administration of ELA and then after 30, 60 and 120 minutes. After 2 hours the patients will be examined to assess the progress of labor. If no progress is detected due to the secondary weakening of uterus contractile function, the oxytocin will be reintroduced. Additionally, the velocities in the uterine arteries will be measured during the first day after the delivery.
223738878|NCT03855280|DRUG|APVO101|Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
223738879|NCT04993456|PROCEDURE|Caridac surgery|Cardiac surgery
223738880|NCT01508858|DRUG|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
223738881|NCT01508858|DRUG|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
223738882|NCT01508858|DRUG|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
224030898|NCT03438786|PROCEDURE|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
224135703|NCT05108805|PROCEDURE|Telemedicine Visit|A remote telemedicine visit with audio and video, using the internet with a nurse practitioner (NP) located elsewhere. The participant and NP will activate the telemedicine App in their electronic device. Family will obtain vital signs (BP, heart rate (HR), respiration rate (RR), SPO2) and provide NP with the information. NP will also review the previous vital signs. Review of system questions are asked, and the answers given by subject recorded. Neurological assessment done, and ICE score calculated.
223413376|NCT06568822|OTHER|Asessment|Data prepared by researchers regarding the general characteristics of older adults will be examined.
223413377|NCT06568822|OTHER|The Physical Activity Scale for the Elderly (PASE)|PASE will be used to assess the physical activity levels of older adults.
223413378|NCT06568822|OTHER|Turkish Version of the Satisfaction with Life Scale (T-SWLS)|T-SWLS will be used to assess life satisfaction of older adults.
223413379|NCT06568822|OTHER|Modified Morisky Scale (MMS)|MMS will be used to evaluate medication adherence in older adults.
223413380|NCT02724046|DRUG|Ciprofloxacin|Single-dose oral ciprofloxacin
223413381|NCT03093142|DEVICE|tDCS & neurofeedback|tDCs and neurofeedback
223413382|NCT03093142|DEVICE|neurofeedback|Neurofeedback
223413383|NCT03093142|DEVICE|sham neurofeedback|sham neurofeedback
223413384|NCT00375414|PROCEDURE|PEG-Gastropexy|
223413385|NCT05616195|OTHER|3D printed bone prosthesis replacement surgery|To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.
223413386|NCT03053752|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
223559720|NCT02965794|OTHER|Care pathways for colorectal cancer|development of a care pathway for this patient group
223559721|NCT06073912|PROCEDURE|Open sinus lifting|Sinus lateral window to graft the floor of the sinus using sinus red diamond stone
223559722|NCT06073912|PROCEDURE|Collecting blood sample|Blood sample is collected to harvest PRP and PRF
223559723|NCT06073912|PROCEDURE|Bone graft harvesting|Bone graft harvesting from the chin area
223738883|NCT01014650|DRUG|GLYX-13|single IV or SC dose
223738884|NCT01014650|DRUG|IV normal saline|Single IV dose of normal saline
223738885|NCT00004182|DRUG|irinotecan hydrochloride|
224135704|NCT05108805|PROCEDURE|Vital sign measurements|Participant and their family will record and measure vital signs using a wearable device and will place a call to the covering nurse practitioner to report the vital signs prior to reporting to the out patient visit.
224135705|NCT05108805|PROCEDURE|Out-Patient Clinic Visit|Physical exam and review of all available data
224135706|NCT05108805|PROCEDURE|Blood pressure and pulse oximeter|Participant and their family take their blood pressure and pulse oximeter
224135707|NCT05108805|BIOLOGICAL|Axicabtagene Ciloleucel|Axicabtagene Ciloleuce given by IV
224135708|NCT05108805|DRUG|Cyclophosphamide|Given IV
224135709|NCT05108805|DRUG|Fludarabine|Given IV
224135710|NCT05687695|OTHER|backward walking program|six weeks of backward walking program at self selected speed for 30 minutes 3 times per week
223413387|NCT01881477|PROCEDURE|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
223413388|NCT04736147|BIOLOGICAL|JNJ-64300535|JNJ-64300535 injection will be administered intramuscularly.
224030899|NCT03438786|PROCEDURE|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
224030900|NCT02934321|DIETARY_SUPPLEMENT|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
224030901|NCT02934321|DIETARY_SUPPLEMENT|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
224030902|NCT01301820|DRUG|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
224030903|NCT01301820|DRUG|Lenalidomide|lenalidomide 10mg/d (d1- d21)
224030904|NCT02437734|PROCEDURE|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
224030905|NCT06242054|DIAGNOSTIC_TEST|Motor Function Assessment System|Participants were instructed to extend their fingers and subsequently clench their fists to the maximum possible range of motion, in order to complete the evaluation of Motor Function Assessment System.
224135711|NCT05687695|OTHER|core training|six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
224135712|NCT06137521|PROCEDURE|Coronary angiography|
224135713|NCT00259220|DRUG|erythomycin|erythomycin
224135714|NCT00259220|PROCEDURE|gastric lavage alone|gastric lavage alone
224135715|NCT00259220|PROCEDURE|erythromycine and gastric lavage|erythromycine and gastric lavage
224135716|NCT05864443|PROCEDURE|Severe complications following emergency surgery|The respondents are limited to surgeons who had previously experienced severe complications following emergency surgery as chief surgeons.
224135717|NCT03180359|BIOLOGICAL|Recommended vaccine scheme according to French Vaccine Schedule 2015|"* BCG~* Measles mumps rubella (MMR)~* Varicella (chicken pox)~* Rotavirus~* Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~* Yellow Fever~* Diphteria tetanus poliomyelitis whopping cough (DTwP)~* Haemophilus influenzae type b~* Hepatitis B~* Meningococcus conjugate~* Pneumococcus~* Human papillomavirus~* Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
224135718|NCT05906641|DIETARY_SUPPLEMENT|High-protein diet|Protein intake will be increased to be 30% calories from protein with calcium caseinate.
224135719|NCT04752189|BEHAVIORAL|Enhanced Replicating Effective Programs (Enhanced REP)|Enhanced REP includes 1. a tailored MMH curriculum, 2. tailored training, and 3. ongoing provider consultation or facilitation to support implementation.
224135720|NCT04752189|BEHAVIORAL|Standard implementation|The standard implementation of the Michigan Model for Health is consistent with Standard REP and includes the curriculum materials, standard training, and as-needed technical assistance.
224135721|NCT03761719|OTHER|No intervention|No intervention
224135722|NCT03422133|OTHER|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
223413389|NCT00603473|DRUG|gabapentin|Orally administered gabapentin
223413390|NCT00852059|DRUG|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
223413391|NCT00852059|DRUG|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
223413392|NCT02278445|RADIATION|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
223413393|NCT02278445|DEVICE|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
223413394|NCT02590497|PROCEDURE|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
223413395|NCT02590497|DRUG|Gadolinium|Undergo gadolinium-enhanced MRI
224030906|NCT03003559|DEVICE|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
224030907|NCT01793363|PROCEDURE|Tracheotomy|
224030908|NCT05803616|DIAGNOSTIC_TEST|Liquid biopsy|ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
224030909|NCT02708017|PROCEDURE|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
224030910|NCT02708017|PROCEDURE|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
224030911|NCT02083666|DRUG|SOBI002|Test Product
224030912|NCT02083666|DRUG|Placebo|Reference product
224030913|NCT00221741|DRUG|Fresh Frozen Plasma (blood product)|
224030914|NCT02039960|DRUG|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
224030915|NCT02748720|OTHER|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
224030916|NCT06441721|DEVICE|Vitamin b12 measure|Measure vitamin b12 in serum and its impact on Haemodialysis patient
224135723|NCT04134325|BIOLOGICAL|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
223413396|NCT02590497|OTHER|Laboratory Biomarker Analysis|Tissue genetic analysis
223413397|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
224030917|NCT06257992|OTHER|Dry Needling|3 treatments of dry needling to inactivate all active trigger points found in patient's cervical muscles.
224030918|NCT06257992|OTHER|Stretch|3 treatments of stretch applied to all cervical muscles that present active trigger points in patient's cervical muscles.
224030919|NCT05735821|OTHER|Giving breastfeeding training|The control group will not be interfered with. Breastfeeding training will be given to the video and simulator group and the 3 groups will be compared.
224030920|NCT00657202|DRUG|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
224030921|NCT05386797|PROCEDURE|Geniculate Artery Embolization|The GAE procedure involves the use of an embolization agent to block blood flow to specific areas of the knee. Under sedo-analgesia, access to the target vessels is gained through the femoral or radial artery. GAE is performed with angiography to visualize blood vessels to assess the affected knee joint and ensure successful treatment.
224135724|NCT04134325|BIOLOGICAL|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks or 400 mg every six weeks as per standard of care after treatment with CD30.CAR T cells
223413398|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
223413399|NCT02590497|PROCEDURE|Magnetic Resonance Imaging|Undergo FLAIR sequence
223413400|NCT02590497|PROCEDURE|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
223413401|NCT05391347|OTHER|Orange oil aromatherapy|5 minutes before the invasive procedure, 3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process.
224298307|NCT04058574|DEVICE|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
223413402|NCT05204680|BEHAVIORAL|Aerobic Exercise|The participant will work with the physical therapist on an exercise regimen.
223413403|NCT02644668|DRUG|Placebo|Granules for oral suspension (placebo)
223413404|NCT02644668|DRUG|Reldesemtiv 150 mg|Granules for oral suspension, 18.7% reldesemtiv
223413405|NCT02644668|DRUG|Reldesemtiv 450 mg|Granules for oral suspension, 56.0% reldesemtiv
223413406|NCT04553601|DIAGNOSTIC_TEST|18F-FDG PET/CT and PET/CT-guide targeted biopsy in another group of participants|Each subject receive a single intravenous injection of 18F-FDG PET/CT and PET/CT-guide targeted biopsy within the specified time
223413407|NCT00691444|DIETARY_SUPPLEMENT|Melatonin|"Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
223413408|NCT00691444|DIETARY_SUPPLEMENT|Melatonin|"Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
223413409|NCT00691444|BIOLOGICAL|Melatonin|"Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
224030922|NCT02880631|DEVICE|BAROSTIM NEO™ System|
223413410|NCT04771286|DRUG|BI 1015550 (C-14)|BI 1015550 (C-14)
223413411|NCT02240212|DRUG|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
223559724|NCT06073912|PROCEDURE|Autogenous corticocancellous block graft|Simultaneous implant placement with sinus lifting and grafting using autogenous corticocancellous block, stabilized inside the sinus using clamp or screws that will be removed before closure
223559725|NCT06073912|PROCEDURE|Mineralized plasmatic matrix graft|Simultaneous implant placement with sinus lifting and grafting using mineralized plasmatic matrix that is formed using PRP of the patient mixed with particulate autogenous graft from the chin area
223559726|NCT06073912|DEVICE|Centrifuge|Centrifuge will be needed to get the PRP in the Comparator group and PRP in both groups
224030923|NCT02868866|BEHAVIORAL|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
224030924|NCT02870166|OTHER|blood sample|
224030925|NCT00177034|DRUG|Narrow Band UVB Treatment|
224030926|NCT02763787|DRUG|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
224030927|NCT02763787|DRUG|Placebo|Identical placebo
224135725|NCT05374551|OTHER|Transcranial magnetic stimulation|Transcranial magnetic stimulation will be used to stimulate brain activity in a brain region of experimental interest (lateral parietal cortex) and in a control brain region (vertex). All participants will experience both forms of stimulation, in separate sessions. Stimulation will be applied as a probe to understand the basic phenomenon of how brain processes support episodic memory.
224135726|NCT03003403|BEHAVIORAL|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
223413412|NCT02240212|DRUG|Paclitaxel|Paclitaxel sourced locally will be administered IV
223413413|NCT04846712|OTHER|Collect data of medical record|Collect data of medical record: initial physical examination, ultrasound (US), Magnetic Resonance Imaging (MRI), physical examination at 30 days, physical examination at 3 months, physical examination at 6 months and final examination at 12 months.
223413414|NCT03102996|DRUG|Nephrotrans|Sodium hydrogen carbonate, ATC-Code: A02AH
224030928|NCT01323634|DRUG|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
224298308|NCT01672944|OTHER|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
223413415|NCT03102996|OTHER|Placebo|Identical capsules without active substance.
223413416|NCT04347369|OTHER|other|clinical diagnosis
223413417|NCT03832764|DEVICE|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
223413418|NCT00733421|DRUG|etoricoxib|90 mg once daily
223413419|NCT00733421|DRUG|tramadol|100 mg twice daily
223413420|NCT06485921|OTHER|Ischemic compression|Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
223413421|NCT06485921|OTHER|Instrument assisted soft tissue mobilization Group|Participants will received a total of 12 treatment sessions over 6 weeks, with 2 sessions per week.
223559727|NCT06073912|DEVICE|ACM bur|Auto Chip Maker will be used to collect the autogenous particulate bone graft for the sticky bone graft
223559728|NCT05659017|GENETIC|Genetic analysis|The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
223559729|NCT06121076|OTHER|SDM-EBP training|A 20-hour tailored SDM combined with EBP training program consisting of a seven-hour lecture and a four-hour hands-on practice session.
223559730|NCT02191878|DRUG|TKM-080301|TKM-080301 intravenous infusion
223559731|NCT01312493|DRUG|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
223559732|NCT01312493|RADIATION|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
223559733|NCT01601756|DEVICE|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
223559734|NCT01601756|DEVICE|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
224030929|NCT01323634|DRUG|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
224030930|NCT05056987|DEVICE|Lehfilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
224030931|NCT05056987|DEVICE|Senofilcon A contact lenses|CE-marked spherical soft contact lenses worn according to to the product package insert/Instructions for Use
224030932|NCT05056987|DEVICE|AOSEPT PLUS with HydraGlyde|Hydrogen peroxide-based cleaning and disinfecting solution
224030933|NCT02035644|DRUG|Jinlida granules|
223559735|NCT00613002|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
223559736|NCT00613002|DRUG|placebo gel|once daily transdermal placebo gel
223559737|NCT04747054|DRUG|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
224030934|NCT02035644|DRUG|placebo granules|
224030935|NCT02294916|DEVICE|AWS|Video-laryngoscopy 1
224030936|NCT02294916|DEVICE|Intubrite|Video-laryngoscopy 2
224030937|NCT02294916|DEVICE|AirTraq|Optical-laryngoscopy
224030938|NCT02294916|DEVICE|MIL|Direct-laryngoscopy
224030939|NCT03466996|BEHAVIORAL|Intervention group|More frequent follow up with face to face interaction.
224030940|NCT03466996|BEHAVIORAL|Standard of care group|Transition goal setting during annual follow up.
224030941|NCT00004145|BIOLOGICAL|anti-thymocyte globulin|
224030942|NCT00004145|DRUG|cyclophosphamide|
224135727|NCT06302309|OTHER|Psychological intervention|The intervention consists of four sessions of a 'managing the mental state' intervention, of which the first and second session will take place in the home-setting of the patient; the two remaining sessions will take place remotely. The sessions include psychoeducation on what anxiety is and how stress and anxiety can influence FOG, identifying how people are allocating attention and engage in specific thought-processes (e.g. worrisome thoughts) during walking, and educating patients about 'managing the mental state' compensation strategies that involve ways to reduce anxiety or stress and will be specifically tailored to the individual patient.
224135728|NCT05083156|OTHER|Diet Change|Observation Cohort will be observed for treatment response to elimination of cow's milk
224030943|NCT00004145|DRUG|fludarabine phosphate|
224030944|NCT00004145|PROCEDURE|peripheral blood stem cell transplantation|
224030945|NCT04304573|DIAGNOSTIC_TEST|Total serum calcium blood test|Total serum calcium measurements will be done on the first postoperative day. Also ionized calcium, corrected total serum calcium for serum albumin with Payne's formula and PTH will be monitored.
224030946|NCT04497922|DEVICE|e-ink screen|A virtual display screen developed by e-ink that displays patient status, basic demographics, care team information, pending tests and anticipated disposition
224030947|NCT04497922|BEHAVIORAL|Treatment as usual|Treatment as usual in the emergency department with communication of testing results, imaging and disposition by the primary clinical emergency department team.
224030948|NCT00627211|PROCEDURE|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
224030949|NCT05532982|OTHER|Interviews and Surveys|Qualitative interviews and surveys
224030950|NCT02409368|DRUG|Nivolumab|
224030951|NCT04176302|DEVICE|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
224030952|NCT04176302|DIAGNOSTIC_TEST|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
224030953|NCT04176302|OTHER|Traditional clinical practice|The neurologists will receive the patient \& caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
224030954|NCT00186394|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
224030955|NCT03881618|PROCEDURE|electroacupuncture+auricular pressure,|electroacupuncture+auricular pressure for 20 minutes
224030956|NCT06349928|OTHER|Focus group or interview|Focus groups and qualitative interview will be conducted with dancers investigating thoughts, beliefs and behaviors related to injury. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
224030957|NCT05467423|DIETARY_SUPPLEMENT|Iron|4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
224030958|NCT04910789|PROCEDURE|transhiatal/transabdominal approach|Radical surgery should be finished via transhiatal/transabdominal approach
224030959|NCT04910789|PROCEDURE|thoracoabdominal approach|Radical surgery should be finished via thoracoabdominal approach
224135729|NCT02198651|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
224135730|NCT02198651|OTHER|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
224135731|NCT02595047|PROCEDURE|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
224135732|NCT04718584|DRUG|Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)|All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.
224135733|NCT03525457|PROCEDURE|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
224135734|NCT00000248|DRUG|Pergolide|
224135735|NCT04589962|OTHER|access axillary or brachial artery|access to the axillary or brachial artery during Transcatheter Aortic Valve Implantation (TAVI), Fenestrated/Branched-Endovascular Aortic Repair (F/BEVAR), chimney-EVAR (Ch-EVAR) or visceral side branches stenting
224135736|NCT02370940|OTHER|High phytate intake|
224135737|NCT02370940|OTHER|Low phytate intake|
224135738|NCT05020093|PROCEDURE|Injection molding|preheated bilk-fill composite, co-cured universal adhesive, David Clark cavity design
224135739|NCT05020093|PROCEDURE|Incremental packing|Incremental packing of conventional composite; pre-cured universal adhesive, non-beveled cavity design
224135740|NCT04438252|DIAGNOSTIC_TEST|ICDAS II|Index for caries detection
224135741|NCT04438252|DEVICE|CariScan Pro|Device for early caries detection
224135742|NCT04438252|RADIATION|Digital Radiograpgy|Device for digital x-ray imaging
224135743|NCT03379506|DRUG|EBR/GZR FDC Tablet|Participants who are 12 to \<18 years of age will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily by mouth.
224135744|NCT03379506|DRUG|Placebo|Placebo tablet matched to EBR/GZR FDC tablet.
224135745|NCT03379506|DRUG|Grazoprevir Oral Granules|Participants 3 to \<12 years of age take grazoprevir granules 0.5 mg by mouth in a soft food vehicle at a dose not to exceed 50 mg.
223413422|NCT06485921|OTHER|Exercise and workplace modifications|Participants will receive stretching and strengthening exercises for neck and scapular stabilizer muscles as a 6-week home program.
223413423|NCT03292666|DRUG|Oral Anticoagulant|Oral anticoagulants used to treat or prevent venous thromboembolism
223413424|NCT00251238|DRUG|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
223413425|NCT01494883|BEHAVIORAL|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
223559738|NCT04747054|RADIATION|Loco-regional radiotherapy|"Depending on the choice of radiotherapy timing:~* Before 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time between one week after the first administration of pembrolizumab and the first day of the 3rd cycle.~* After 3 cycles of pembrolizumab with or without chemotherapy : radiotherapy could start at any time after 3rd cycle (C3D1) and up to a maximum of 4 weeks after the 6th cycle of pembrolizumab.~Dose/fraction of radiotherapy: 54 Gy/18 fractions (recommended schedule) or 70Gy/33-35 fractions or other curative dose/fraction schedules with shorter duration and biologically equivalent dose of at least 60Gy at the discretion of local investigators, in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary. Other cycles of pembrolizumab will be administered during and after radiotherapy."
223413426|NCT04309383|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
223559739|NCT04747054|DRUG|Chemotherapy|"If the investigator decide to add chemotherapy with pembrolizumab, and depending on the radiotherapy timing:~* Start of radiotherapy planned before 3rd cycle: Chemotherapy could be delayed after the end of radiotherapy and start from cycle 3 or 4 of pembrolizumab. Administration of chemotherapy can be delayed in case of non resolved grade 3 or higher toxicity from radiotherapy.~* Radiotherapy planned after 3rd cycle: Chemotherapy should start at the same time of pembrolizumab.~Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles"
223559740|NCT05319600|BEHAVIORAL|Diabetes behavior change skills training|Behavior-change skills training will be provided through eight web-delivered content and activity sessions across the 12-week program. Sessions 1 through 4 will occur weekly and sessions 5 through 8 biweekly. Each session takes approximately 15-20 minutes for the adolescent to complete both content learning and related activities. These learning sessions focus on skills like problem solving and goal setting.
223559741|NCT05319600|BEHAVIORAL|Physical activity promotion program|The physical activity incentives program includes 12 weeks of personalized goals and incentives for increasing physically active minutes along with weekday text-based support. Active minutes, defined as minutes with moderate to vigorous physical activity, will be tracked via a Garmin fitness activity tracker.
223559742|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months and booster immunization at 18 months of age.
223559743|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax)|Performed primary immunization following a 0-1-2-month schedule at the aged from 3 to 5 months.
224030960|NCT01585987|BIOLOGICAL|Ipilimumab|
224030961|NCT01585987|OTHER|Best Supportive care (BSC)|
224030962|NCT03634696|OTHER|mPCL|Smart phone application to support palliative care among late-stage cancer patients
224030963|NCT03634696|OTHER|Usual Care|Usual care through OCRI palliative care clinic
224030964|NCT05686382|PROCEDURE|Continuous Wound Infusion|continuous local anesthetic infiltration of the wound
224030965|NCT05686382|PROCEDURE|TAP block|ultrasound guided injection of local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles
224030966|NCT02041520|DRUG|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
224030967|NCT02041520|OTHER|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
224135746|NCT03379506|DRUG|Elbasvir Oral Granules|Participants 3 to \<12 years of age take elbasvir oral granules 1 mg by mouth in a soft food vehicle at a dose not to exceed 100 mg.
224135747|NCT03227965|BIOLOGICAL|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
224135748|NCT00565656|DRUG|BEVACIZUMAB|Administration of Bevacizumab
224135749|NCT03006471|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
224135750|NCT03006471|DRUG|Placebo - Cap|one per day before breakfast during 12 weeks.
224135751|NCT02480894|DRUG|BMS-663068|BMS-663068
224298309|NCT01672944|OTHER|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
223413427|NCT04344483|DRUG|2% Lidocaine and 1:100,000 Adrenaline|Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
223413428|NCT04344483|DRUG|Normal saline|Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
223413429|NCT02313311|OTHER|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
223413430|NCT06217705|BEHAVIORAL|Project Calm|Project Calm is a \~30-minute self-guided digital intervention designed to teach children and adolescents empirically supported emotion regulation skills to facilitate self-calming when faced with intense negative emotions. Project Calm uses vignettes, interactive activities, and engaging graphics to teach youth calming skills.
224135752|NCT02480894|DRUG|Maraviroc|Maraviroc
224135753|NCT03309592|DRUG|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
224135754|NCT03309592|DRUG|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
224135755|NCT02871401|DRUG|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
224135756|NCT02871401|DRUG|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
224135757|NCT01120379|DEVICE|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
223413431|NCT04760431|DRUG|Trastuzumab|8 mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles, administered by IV infusion every week until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223413432|NCT04760431|DRUG|Taxanes|Docetaxel: 75 mg/m2, administered by IV infusion every 3 weeks Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks Paclitaxel Liposome: 135-175 mg/m2, administered by IV infusion every 3 weeks
223413433|NCT04760431|DRUG|Pertuzumab|840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
223413434|NCT04760431|DRUG|Tyrosine kinase inhibitor|Pyrotinib: 400mg po within 30 minutes after a meal, QD, every 3 weeks Neratinib: 240mg po QD, every 3 weeks Tucatinib: 300mg po Q12H
223413435|NCT00184327|BEHAVIORAL|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
223413436|NCT00184327|BEHAVIORAL|Diagnostic assessment - child and adolescent psychiatry|
223413437|NCT03747380|OTHER|inspiratory muscle program|pre-operative inspiratory muscular training program
223413438|NCT03377231|DEVICE|Stratamark®|Film-forming dressing for the prevention and treatment of stretch marks.
223413439|NCT04927780|DRUG|Leucovorin Calcium|IV
223413440|NCT04927780|DRUG|Fluorouracil|IV
223413441|NCT04927780|DRUG|Irinotecan Hydrochloride|IV
223413442|NCT04927780|DRUG|Oxaliplatin|IV
224030968|NCT05378230|DIETARY_SUPPLEMENT|Probiotic preparation of three Lactobacillus plantarum strains (CECT 7527, CECT 7528, CECT 7529)|"All subjects were submitted to 4 weeks intervention consisting on a dose-dependent regime of Lactobacillus plantarum AB-B (strains CECT 7527, CECT 7528, CECT 7529; AB-LIFE). Before starting the intervention period, all subjects were submitted to a 2-weeks run-in period. During the wash-in and intervention-periods, participants were instructed to maintain their habitual dietary habits and to continue their normal pattern of physical activity throughout the study period.~Treatments during the intervention period were: Week 1: 1 capsule/day taken during breakfast; Week 2: 2 capsules / day at- breakfast; Week 3: 2 capsules at breakfast and 1 at dinner; Week 4: 2capsules at breakfast and 2 capsules at dinner. Each capsule contains 1.2x10\^9 cfu (colony forming units) in a 1: 1: 1 ratio of the three strains."
224030969|NCT03482583|DRUG|Nicotine Replacement Therapy|Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
224135758|NCT04375241|OTHER|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device|Subjects with asymptomatic atrial fibrillation will be screened by using a Mobile ECG Device
224135759|NCT06047899|DIETARY_SUPPLEMENT|Luteolin|Luteolin extracted from Chrysanthemum Ramat 98% HPLC by Scyherb® food grade certified according to Safe Quality Foods (SQF) - Level 3 Comprehensive Food Safety and Quality Management System Certification by the Safe Quality Food Institute (SQFI).
224135760|NCT06047899|OTHER|Placebo|mannitol formulated for oral administration (capsules)
224135761|NCT04758598|DEVICE|Direct Selective Laser Trabeculoplasty (DSLT)|DSLT employs frequency-doubled, Q-switched Nd:YAG laser with a wavelength of 532 nm. During the procedure, a laser beam targets the trabecular meshwork (TM) - to improve intraocular fluid outflow. The laser beam is delivered in short nanosecond pulses and the selective cellular effect occurs at the pigmented cells of the TM. This increases the permeability of the TM endothelial cells and thereby increases outflow, resulting in reductions in IOP. In contrast to SLT, the DSLT treatment directs the laser beam directly through the sclera around the limbus without the need for a delivery device (gonioscope lens). Laser treatment lasts for about 2 seconds with about 120 laser shots delivered to the sclera around the limbus.
224298310|NCT04831372|PROCEDURE|Off Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table
224298311|NCT04831372|PROCEDURE|On Table Group|Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
224298312|NCT02182869|DRUG|Combivent® HFA inhalation aerosol|
224298313|NCT02182869|DRUG|Combivent® CFC inhalation aerosol|
223413443|NCT04927780|PROCEDURE|Resection|Open or minimally-invasive pancreatectomy.
223413444|NCT01063192|DRUG|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
223413445|NCT01063192|DRUG|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
223413446|NCT00373230|BEHAVIORAL|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
223413447|NCT02302469|DRUG|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
223413448|NCT05154045|OTHER|Experimental Formula|Diabetes-specific study formula
223413449|NCT05154045|OTHER|Test Meal|Instant oatmeal
223413450|NCT05308953|DRUG|NVG-291|NVG-291 is a drug injected under the skin (subcutaneous).
223413451|NCT05308953|OTHER|Placebo|Salt water is being used as a placebo and will be injected under the skin (subcutaneous).
223413452|NCT01579097|OTHER|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
223413453|NCT01579097|OTHER|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
223413454|NCT01616797|BEHAVIORAL|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
224298314|NCT04467268|BEHAVIORAL|Sleep extension|The sleep extension programme was designed around four alternative assumptions: 1) that among this group of habitual short sleepers, extending time in bed (TIB) would represent a significant behavioral change to established night-time and daytime routines; 2) that for practical purposes (accommodating personal, family and work schedules) extended time in bed is best anchored against typical rise-times; 3) that sleep onset may represent a particular challenge for those advancing habitual bed-times by over 1 hour each night; and 4) that in consenting to the trial, participants were motivated to make and sustain behavioral change.
223413455|NCT03830697|OTHER|Acupuncture intervention|Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui（DU20）, Zhongyu（RN12）, Tianshu （ST25）(bilateral), Guanyuan（RN4）, uterus (bilateral)（EX-CA1）, Dahe（KI12） (bilateral),Zusanli （ST36）(bilateral), Sanyinjiao（SP6） (bilateral), Taichong （LR3）(both sides).
223413456|NCT01456754|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
223413457|NCT01456754|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
223413458|NCT02461433|DEVICE|Prevena|Prevena Incision Management system
223413459|NCT02461433|DEVICE|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
223413460|NCT02547220|BIOLOGICAL|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre \[mL\] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
223413461|NCT02547220|DRUG|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
223413462|NCT05495282|OTHER|Microvideo|Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
223413463|NCT06575127|DRUG|FOLFOXIRI Protocol|as mentioned in Arm description
223559744|NCT06314659|BIOLOGICAL|Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax)|Performed booster immunization at 18 months of age.
223559745|NCT02497365|DRUG|Besifloxacin|
223559746|NCT02497365|DRUG|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
224030970|NCT03482583|OTHER|Referral to AHEC/Quitline|Participants will be referred to local AHEC/Quitline for treatment
224030971|NCT01386281|DRUG|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
224030972|NCT01280110|DRUG|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
224030973|NCT01280110|DRUG|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
224030974|NCT00551941|PROCEDURE|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
224030975|NCT00551941|PROCEDURE|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
224030976|NCT05521802|BIOLOGICAL|B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell|Autologous 2nd generation BCMA-directed CAR-T cells, single infusion intravenously
224030977|NCT01249989|BEHAVIORAL|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
224030978|NCT01249989|BEHAVIORAL|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
224030979|NCT01249989|BEHAVIORAL|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
224030980|NCT04840641|DRUG|Flucloxacillin|Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
223413464|NCT01523782|DRUG|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
223559747|NCT05584163|DEVICE|Extracorporeal shock waves|3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
223413465|NCT06119620|DEVICE|intermitted theta burst stimulation|Participants receive intermitted theta burst stimulation for 3-4 minutes before completing the N-back task.
223413466|NCT00660244|DRUG|anastrozole|Oral
223413467|NCT02253589|BEHAVIORAL|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
224030981|NCT00413972|DRUG|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
224030982|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
224030983|NCT00413972|DRUG|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
224030984|NCT00413972|DRUG|Placebo|Placebo once daily for a total of eight weeks
224030985|NCT01759407|DRUG|Ropivicaine|
224030986|NCT01759407|DRUG|Epinephrine|
224030987|NCT03197779|DRUG|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
224030988|NCT03197779|DRUG|Aspirin|Oral administration
224030989|NCT03197779|OTHER|Placebo|Oral administration
224135762|NCT04758598|DEVICE|Selective Laser Trabeculoplasty (SLT)|SLT employs frequency doubled Q switched Nd:YAG laser with a wavelength of 532 nm. It is delivered in short nano second pulses and the resulting selective effect to the pigmented cells of the TM, leaving the surrounding non-pigmented cells unaffected. This increases the permeability of the TM endothelial cells and can assist in increasing outflow and hence result in reductions in IOP. The procedure lasts approximately 10 minutes, with delivering 100 separate laser beams through a manually rotated mirrored lens (gonioscope), involving prolonged contact with the participant's eye. This treatment is applied on the cornea through a gonioscopic lens which is used to direct the laser beam to the desired location - the TM (360 degrees of treatment area).
224135763|NCT00254735|DRUG|quetiapine fumarate|
223413468|NCT03689829|DRUG|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
223559748|NCT00566410|DRUG|Dichloroacetate|Continuous daily oral dosage (bid).
223559749|NCT00323960|DRUG|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
223559750|NCT00323960|DRUG|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
224030990|NCT00807261|DRUG|Gemcitabine and Docetaxel|"Drug and schedule~* Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~* Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~* Treatment should be delayed if the ANC\<1,500/ mm3, or if the platelet count \<75,000/mm3 on the first day of the next cycle.~* Gemcitabine \& docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
224030991|NCT02143557|OTHER|Fat-Modified Breast Milk|
224030992|NCT02143557|OTHER|MCT formula|
224030993|NCT00486629|BEHAVIORAL|Exercise and dietary education|Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
223559751|NCT00323960|DRUG|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
224030994|NCT03268122|OTHER|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
224030995|NCT03268122|OTHER|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
224030996|NCT06266884|OTHER|Kangaroo care|Kangaroo care is a safe and effective method in which the baby is placed in an upright position on the parent's bare chest, wearing only a diaper and a hat, and the baby's needs for nutrition, warmth, love and trust are met and provides positive interaction between the parent and the baby.
224030997|NCT03737474|DRUG|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
224135764|NCT00254735|DRUG|SSRI/Clomipramine|
224135765|NCT00267371|DEVICE|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
223413469|NCT03689829|DRUG|Placebo|Corresponding placebo s.c. injections.
223413470|NCT03793205|DRUG|Long-acting G-CSF|Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
223413471|NCT03793205|DRUG|Short-acting G-CSF|Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
223413472|NCT06182111|PROCEDURE|Intraoperative morphine|Morphine dose = 0,1 mg mg/kg (maximum 10 mg) intravenous given 20 min after start of surgery
223413473|NCT03390751|OTHER|Data collection|The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
223413474|NCT03114605|BEHAVIORAL|Mindfulness-based Intervention|
223413475|NCT04299568|DEVICE|Anti gravity treadmill training|Lower Body Positive Pressure (LBPP) treadmill training for 15 minutes
223413476|NCT04299568|PROCEDURE|Physical Therapy|Heat Therapy in combination with Electro-therapy for 10 minutes, followed by tibio-femoral and patello-femoral joint mobilization
223413477|NCT03468660|BEHAVIORAL|Auditory training with feedback|Experimental group receives phoneme-level and sentence-level training with feedback
223413478|NCT03468660|BEHAVIORAL|Listening paradigm with no feedback|Active controls listen to acoustic stimuli with no feedback
223413479|NCT02200172|OTHER|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
223413480|NCT02200172|OTHER|Placebo|
223413481|NCT03459560|DRUG|PolyPill|After the baseline enrollment and excluding non-eligible participants, we randomized villages to Polypill and control arms. Follow-ups are scheduled for 1, 3, and 6 months after the initial enrollment in the Polypill arm and every six months thereafter. For the minimal care arm, the follow-ups are arranged every six months.
223413482|NCT00204776|DRUG|Capecitabine and Oxaliplatin|
223413483|NCT06352112|OTHER|Pelvic Floor Muscle Training|PFMT consisted of both slow voluntary contractions lasting 15 seconds each (5-s contraction, 5-s hold and 5-s relaxation) and fast voluntary contractions lasting 2-s each. A set of exercises included 10 slow and 10 fast voluntary contractions. During the first week, women performed five sets of exercises a day, and the exercises were continued for eight weeks by increasing five sets each week. The exercises were performed as home exercises.
223413484|NCT06352112|OTHER|Hypopressive Exercises|"HE program in which different placements of the upper and lower extremities were used in standing, sitting and supine positions, and the participants were asked to perform the exercises with a hypopressive maneuver to maintain apnea and rib cage expansion for approximately 10 seconds. Exercises were started with three repetitions a day, and then the number of repetitions was increased to five and/or 10, depending on the participant's tolerance. The exercises were performed as home exercises."
223413485|NCT00642564|OTHER|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
223413486|NCT05823233|OTHER|Cold application+Deep friction+Home exercise+Eccentric stretching|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. Simultaneously with the electrical stimulation of the affected arm, the patient will be asked to stretch for 5 seconds and rest for 5 seconds, and doing this 15 times will be considered 1 set. After 1 minute of rest, he will be asked to do this practice for 2 more sets, so 3 sets of 15 repetitions will be completed in total. A total of 12 sessions will be applied 3 days a week for 4 weeks. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
223413487|NCT05823233|OTHER|Cold application+Deep friction+Home exercise|In our study, deep friction massage will be performed by the researcher with the tip of the thumb, maintaining the pressure for 3-5 minutes in the posterior direction to the tenoosseous junction. The application will be performed 3 times a week for a total of 12 sessions for 4 weeks. After the deep friction massage, cold application will be made for 15 minutes. In our study, a home exercise program consisting of passive stretching and strengthening (concentric and eccentric) exercises will be applied.
223413488|NCT00550043|DRUG|INCB018424|
223413489|NCT00550043|DRUG|Placebo|
223413490|NCT05013320|DRUG|Glycopyrrolate + dexmedetomidine|Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.
223413491|NCT05013320|DRUG|Dexmedetomidine|Dexmedetomidine administration during the surgery.
223559752|NCT01604525|BEHAVIORAL|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
223559753|NCT01604525|BEHAVIORAL|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
223559754|NCT01604525|OTHER|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
223559755|NCT05327842|DEVICE|New training simulator|Participants receive training with new simulator
223559756|NCT05327842|DEVICE|Traditional simulator|Participants receive traditional training
223559757|NCT05558137|DRUG|Mivacurium|0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
223559758|NCT05595265|DIAGNOSTIC_TEST|immunohistochemical|Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.
223559759|NCT00961740|BEHAVIORAL|Cognitive Behavioural Therapy|See summary
223559760|NCT00961740|OTHER|Waitlist condition|See Summary
224135766|NCT00267371|DRUG|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
224135767|NCT00813618|DRUG|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
223413492|NCT04185220|DRUG|Recombinant human Interleukin-15 (rhIL-15)|Interleukin 15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation 3 + 3 system with a starting dose of 2 mcg/kg/day and a second dose level of 4 mcg/kg/day on days 1-5 of each of six cycles.
223413493|NCT04185220|BIOLOGICAL|Mogamulizumab|Mogamulizumab (intravenous (IV) over at least 1 hour) will be administered at a dose of 1 mg/kg on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle. Treatment will continue for a maximum of 6 cycles.
223413494|NCT01027520|OTHER|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
223413495|NCT01493674|DIETARY_SUPPLEMENT|folic acid|two 5-mg tablets of folic acid
223413496|NCT05032027|OTHER|probiotics|recieving probiotics at the first day of chemoradiotherapy daily
223413497|NCT02581280|OTHER|Residual blood|Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
223413498|NCT04145180|OTHER|Manual therapy|40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
224030998|NCT04291820|PROCEDURE|Intravenous induction and desflurane anaesthesia maintenance|Anaesthesia will be inducted with intravenous propofol + opioid and maintained with desflurane according to the BIS levels
223413499|NCT05510479|OTHER|Software as medical device|At home measurements of visual acuity through a mobile app
223413500|NCT05655364|OTHER|Mobile application|Breastfeeding Supportive Mobile Application
224030999|NCT04291820|PROCEDURE|Inhalation induction with sevoflurane and anaesthesia maintenance with sevoflurane|Anaesthesia will be inducted with sevoflurane and maintained with sevoflurane according to the BIS levels
224031000|NCT01704924|DEVICE|Prevena|Device will be applied at end of procedure over closed incision
224031001|NCT01704924|PROCEDURE|Standard of Care Dressing|Dressing applied as Standard of Care
223413501|NCT05453227|DRUG|Zinc|To test the effect of a novel zinc-containing vaginal topical on GSM/VVA symptoms.
223413502|NCT00937976|PROCEDURE|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
223413503|NCT00404391|DRUG|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
223413504|NCT00404391|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
223413505|NCT00404391|DRUG|Placebo|2 tablets every 12 hours
223413506|NCT02434146|DRUG|Topical Phenylephrine Solution|Given topically via spray
223413507|NCT02000960|DRUG|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
223413508|NCT04823273|BEHAVIORAL|General improvement|Changes to interface to be more intuitive.
223559761|NCT02120300|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally
224031002|NCT03617341|PROCEDURE|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
224031003|NCT01724853|PROCEDURE|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
224031004|NCT01724853|OTHER|Conservative|Injection
224031005|NCT02513745|DEVICE|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
224031006|NCT02513745|DEVICE|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
223413509|NCT04823273|BEHAVIORAL|In-line help text|General improvement + in-line help text
223413510|NCT04823273|BEHAVIORAL|Interruptive alert|General improvement + interruptive alert
223413511|NCT04492176|DEVICE|CO2 fractional laser（ACUPULSE,Lumenis）|gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times
223413512|NCT02257073|BEHAVIORAL|Cognitive-behavioral treatment|
223413513|NCT02257073|BEHAVIORAL|Waiting List|
223413514|NCT01763060|RADIATION|CT scan|
223413515|NCT01763060|BEHAVIORAL|Cognitive function|
223413516|NCT01763060|RADIATION|MRI|
223413517|NCT01983540|BIOLOGICAL|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
223413518|NCT01983540|BIOLOGICAL|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP\~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
223413519|NCT01983540|BIOLOGICAL|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP\~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
223413520|NCT03283657|BEHAVIORAL|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
223413521|NCT03283657|BEHAVIORAL|Usual care (UC)|Standard care with routine medical care.
223413522|NCT05103982|BEHAVIORAL|Coping with Infertility Program|6 10-minute videos with assigned homework
223413523|NCT05945940|OTHER|no intervention|no intervention
223559762|NCT02120300|DRUG|SOF|400 mg tablet administered orally once daily
223559763|NCT02120300|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223559764|NCT01375816|DRUG|FOLFIRI 1-Bevacizumab|
223559765|NCT01375816|DRUG|fluorouracil|
223559766|NCT01375816|DRUG|irinotecan hydrochloride|
223559767|NCT01375816|DRUG|leucovorin calcium|
223559768|NCT01375816|DRUG|liposome-encapsulated irinotecan hydrochloride PEP02|
223559769|NCT01375816|DRUG|Bevacizumab|
224031007|NCT04771468|DEVICE|MOSTCAREup Monitoring|The patients will be equipped with mini-invasive hemodynamic monitoring (the MOSTACAREup system). The MOSTCAREup obtains the hemodynamic data from either the same arterial femoral line used by the neuro-radiologist to perform the treatment or from a dedicated radial artery, as decided by the attending anesthetist to monitor and optimize arterial pressure (the decision to use the arterial line is at discretion of the attending anesthetist for clinical reasons and does not delay the procedure, which starts using always the femoral access).
224031008|NCT04771468|DEVICE|Ecocardiography|Echocardiography will be performed 1) soon after the end of the treatment (whenever possible, avoiding delays, before od during the treatment in the angiography room); 2) at day 1 after the procedure; 3) at day 3 after the procedure.
224031009|NCT02331251|DRUG|Pembrolizumab|
224031010|NCT02331251|DRUG|Gemcitabine|
224031011|NCT02331251|DRUG|Docetaxel|
224031012|NCT02331251|DRUG|Nab-paclitaxel|
224031013|NCT02331251|DRUG|Vinorelbine|
224031014|NCT02331251|DRUG|Irinotecan|
224031015|NCT02331251|DRUG|Liposomal Doxorubicin|
224031016|NCT02542774|OTHER|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
224031017|NCT02678247|DEVICE|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
224031018|NCT02678247|DEVICE|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
224031019|NCT01209143|DRUG|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
224031020|NCT01209143|DRUG|Rosiglitazone|Rosiglitazone was supplied in tablets.
224031021|NCT01209143|DRUG|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
224031022|NCT02737709|DRUG|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
224031023|NCT03013582|BIOLOGICAL|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
224031024|NCT03013582|PROCEDURE|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
224031025|NCT04289766|OTHER|Conventional Treatment|These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.
224031026|NCT04289766|OTHER|Focal Muscle Vibration (120Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
224031027|NCT04289766|OTHER|Focal Muscle Vibration (60Hz)|These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
224135768|NCT00813618|DRUG|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
224135769|NCT00813618|DRUG|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
224135770|NCT00438893|DIETARY_SUPPLEMENT|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
223559770|NCT06308601|OTHER|Laughter yoga|Laughter is an innate, most natural, sincere and universal response to humorous stimuli. Philosophically, it is explained by relief theory, conflict theory and superiority theory (Öztürk \& Tezel, 2021). The emergence of laughter yoga was made by Dr., an Indian medical doctor, in 1995. It was created by combining breathing exercises and unconditional laughter with the work of Madan Kataria and his wife Madhuri Kataria. In laughter yoga, the individual can laugh in a simulated way with the interaction of group members, without a funny situation, joke or joke. The body cannot distinguish between real and unreal laughter, and fake laughter begins to turn into real laughter (Kataria, 2011).
223559771|NCT01258556|DIETARY_SUPPLEMENT|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10\*9 cfu/ml daily for 30 days.
223559772|NCT01258556|DIETARY_SUPPLEMENT|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
224031028|NCT02038491|PROCEDURE|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
224031029|NCT01145755|DRUG|AZD2066|18 mg once daily
224031030|NCT01145755|DRUG|Placebo|
224031031|NCT01145755|DRUG|Duloxetine|60 mg once daily
224031032|NCT02740972|DRUG|NS-065/NCNP-01|
224031033|NCT02740972|DRUG|Placebo|
224031034|NCT01704638|DRUG|fluvoxamine|
224031035|NCT01704638|DRUG|Digoxin|
224031036|NCT06525961|DEVICE|iTEAR100 Neurostimulator|To apply an iTEAR100 Neurostimulator for the stimulation to the anterior ethmoidal nerve - which is located at the point between bony and fleshy tissue alongside the nose. Participants should apply stimulation to each side of the nose for 30 seconds, twice a day. It is recommended to apply once in the morning and once in the evening.
224031037|NCT02954965|BEHAVIORAL|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
224031038|NCT02954965|BEHAVIORAL|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
224031039|NCT01848951|DRUG|Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed. Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain institution's standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
224135771|NCT01113996|BEHAVIORAL|Protein supplementation and strength training|Protein supplementation and strength training
224135772|NCT01113996|DIETARY_SUPPLEMENT|Protein supplementation|Protein supplementation
224135773|NCT01252641|BIOLOGICAL|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
224135774|NCT02897869|DRUG|POL7080|7 doses of POL7080 alone over 2.5 days
224135775|NCT02897869|DRUG|Amikacin|3 doses of Amikacin alone over 2.5 days
224135776|NCT02897869|DRUG|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
224135777|NCT03036423|BEHAVIORAL|Online video education|
224135778|NCT03036423|BEHAVIORAL|Computerized mental exercises|
223413524|NCT03843489|DEVICE|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
224135779|NCT03235817|OTHER|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
223413525|NCT03843489|DEVICE|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
223413526|NCT04580940|DEVICE|SpyGlass™ Discover Digital System|Observational, prospective, registry study for the clinical utility of the SpyGlass Discover digital catheter during a PTCS procedure.
223413527|NCT03478644|DEVICE|Experimental Denture Wipe|Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.
223413528|NCT03478644|OTHER|Tap Water|Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
223413529|NCT02283684|PROCEDURE|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
223413530|NCT02283684|PROCEDURE|Bipolar TUVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
224031040|NCT01848951|DRUG|TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound. The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants (subcostal position x2 and lateral position x2)
224031041|NCT04407585|DIAGNOSTIC_TEST|Covid-19 swab PCR test|Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.
224031042|NCT04983641|OTHER|Pre-Visit Messages|"Patients in both experimental arms (E-mail and Digital Patient Portal MyChart) were sent pre-visit messages regarding PROMIS form completion via each respective modality at 1 week and also 3 days prior to their respective Orthopaedic clinic visits"
224031043|NCT03933774|DRUG|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
224031044|NCT03933774|DRUG|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
224031045|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Internal Sensations and Experiences)|The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
224031046|NCT04103385|BEHAVIORAL|RISE (Reconnecting to Individual Strength and Energy)|Aims to reduce life stressors and improve physical health
224031047|NCT03068065|DRUG|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
224031048|NCT03068065|DRUG|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
224031049|NCT03068065|DRUG|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L
224031050|NCT03078426|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
224031051|NCT03078426|OTHER|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
224031052|NCT05749289|DRUG|Al18F-octreotide|Al18F-octreotide I was injected into the patients before the PET/CT scans
224031053|NCT00352911|DRUG|VGX-410 (Mifepristone)|
224031054|NCT00352911|DRUG|Placebo for VGX-410 (Mifepristone)|
224031055|NCT05635981|OTHER|Clearfil Majesty ES-2 Resin Composit Application to Non-carious Cervical Lesions|A restorative treatment method that is applied to non-carious cervical lesions using composite resin restoration after adhesive material application.
223413531|NCT03640533|BEHAVIORAL|Nanit-Insights|Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
223413532|NCT00330993|DRUG|mifepristone, misoprostol|
223413533|NCT06576947|OTHER|Virtual reality|Participants receive virtual reality treatment, 8 weeks of treatment/ 2 times a week
223413534|NCT06576947|OTHER|Neuromodulation of the tibialis posterior nerve|Participants receive neuromodulation of the tibialis posterior nerve8 weeks of treatment/ 2 times a week/ 30 minutes
223413535|NCT06576947|OTHER|Pelvic floor muscle training|Participants receive pelvic floor muscle training 5 times a day for 9 weeks
224031056|NCT01775267|PROCEDURE|Associating liver partition and portal vein ligation for staged hepatectomy|
224031057|NCT01775267|PROCEDURE|Portal vein embolization or ligation|
224031058|NCT01827293|DRUG|Promethazine|
224031059|NCT01827293|DRUG|Lorazepam|
224135780|NCT03235817|DEVICE|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
224135781|NCT03235817|DEVICE|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
224135782|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
224135783|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
224135784|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
224135785|NCT00856258|DRUG|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
223413536|NCT05871047|DEVICE|tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application|Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.
223413537|NCT02913183|DRUG|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
223413538|NCT02913183|DRUG|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
224031060|NCT05358028|OTHER|Hand Arm Bimanual Intensive Technique including Lower Extremity (HABIT-IL)|"HABIT-ILE along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities.~Functional task as maintaining ADL:~i.Eating with spoon while standing ii. Combing hair while standing. iii. Counting cards while standing and putting them in box. Standing and walking I. standing with support of upper extremity II. walking with the help walkers III. walking on parallel bar playing activities: I. playing with cards while standings II. taking toys out of box and putting them in other box while standing III. grasping a fixed rod by hand and trying to maintain balance on physio stability ball"
224031061|NCT05358028|OTHER|Hand Arm bimanual intensive Technique (HABIT)|"HAIBT along with the conventional Bobath treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities HAIBT along with the conventional Bobth treatment will be performed for 30 days in the form of groups for 3 hours, children will be performing individual activities~Playing activities on table:~I. building towers with Lego blocks, II. Holding book by one hand and turning pages , III. Playing games with cards, IV. Drawing random impressions on paper, V. taking toys out of one box and placing them in other box one by one~Activities of daily living :~I. eating with spoon from bowel II. combing hair while sitting, III. opening of bottle cap for drinking water Age appropriate video games while sitting will be provided according to the ease of children"
224031062|NCT03717129|DRUG|Genvoya Oral dose|Single Genvoya oral dose directly observed
224031063|NCT03717129|DRUG|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
224135786|NCT00388258|DRUG|Alvimopan|
223413539|NCT03955705|DRUG|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
223413540|NCT03955705|DRUG|Normal saline|0.9% Sodium chloride (normal saline or NSS)
224135787|NCT03674658|DRUG|Propafenone|oral, TID
224135788|NCT02621619|DRUG|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
224135789|NCT02621619|DRUG|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
224135790|NCT05566288|DRUG|Cytisinicline|compressed film-coated tablet containing 3 mg cytisinicline
224135791|NCT05566288|DRUG|Placebo|Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
224135792|NCT05566288|DRUG|Moxifloxacin|400 mg tablets
224135793|NCT03663140|DIAGNOSTIC_TEST|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
224135794|NCT02911623|DEVICE|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
224135795|NCT06028425|DRUG|LOXO-783|Administered orally.
223413541|NCT01600027|PROCEDURE|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
223413542|NCT01600027|PROCEDURE|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
223413543|NCT02768727|DRUG|Xenon|drug given in concentrations of 0% to 60% over period of 2 hours
223413544|NCT02903940|DEVICE|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
223413545|NCT05219591|DEVICE|EPR|application of EPR technology during CPAP treatment
224135796|NCT03626740|OTHER|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
224135797|NCT03626740|OTHER|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
224135798|NCT01605344|DRUG|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
224135799|NCT01605344|DRUG|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
223413546|NCT02295826|DRUG|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
223413547|NCT02295826|DRUG|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
223413548|NCT03901820|DEVICE|Medication Interaction System of Dr App (SIMDA)|A module for the electronic clinical records allowing detection of the potential drug interactions
223413549|NCT00928291|OTHER|procalcitonin|plasma PCT measurement
224135800|NCT01911013|PROCEDURE|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
224135801|NCT01911013|DEVICE|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
224135802|NCT01911013|DEVICE|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
224135803|NCT02494388|PROCEDURE|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
223413550|NCT00928291|DRUG|antibiotic therapy|antibiotic therapy use
224135804|NCT06187623|OTHER|Clinic based exercise|"15 patients and their parents in the clinic-based group will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 3 days a week (24 sessions) with a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 4 days of the week."
223413551|NCT01029782|DRUG|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
223413552|NCT01029782|DRUG|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
223559773|NCT04607434|DRUG|Ocotillol Type Ginsenoside Derivatives|Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
224031064|NCT05423886|OTHER|Personalized screening invitation interval|Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
224031065|NCT03796260|DRUG|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
224031066|NCT03796260|DRUG|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
224031067|NCT05429333|OTHER|Artificial intelligence-assisted personalized diet|"The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings."
224031068|NCT01871753|OTHER|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
224031069|NCT03107897|OTHER|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
224031070|NCT01295177|DRUG|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
224135805|NCT06187623|OTHER|Home based exercise|"15 patients in the home-based group and their parents will be informed about the treatment program. Exercise training will be given to individuals by a physiotherapist trained in ISST- International Schroth 3-Dimensional Scoliosis Therapy.~Individuals in this group will be included in an exercise program 1 day a week (8 sessions) accompanied by a physiotherapist for 8 weeks. Each exercise session will last 50 minutes. Patients will be asked to do the given home exercises on the remaining 6 days of the week."
224135806|NCT03839017|DEVICE|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
223559774|NCT02283905|DRUG|amphotericin-B|continuously infused
224031071|NCT00753272|BIOLOGICAL|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
223559775|NCT02283905|DRUG|voriconazole|intravenously or orally administered
223559776|NCT05906485|BEHAVIORAL|fNIRS Neurofeedback-VR Training|In the fNIRS Neurofeedback-VR Training, we have designed a classroom scenario modeled and children are expected to learn how to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
223559777|NCT05906485|BEHAVIORAL|Computerized Cognitive Training|In the Computerized Cognitive Training, children will complete a range of tasks covering attention control and working memory using a conventional training programme, namely Cogmed.
224031072|NCT00753272|BIOLOGICAL|Fluarix TM|IM administration, two times one annual dose
224031073|NCT06046768|OTHER|Psychological care|Psychological consultations (interviews, scales), participation in a discussion group for parents in Visio via Zoom, a speech therapy assessment and possible complementary multidisciplinary consultations)
224031074|NCT00292877|DRUG|SB-240563 (Mepolizumab)|
224031075|NCT05900960|DIETARY_SUPPLEMENT|Tea|Orally administered. Decaffeinated tea, with no additives (sugar, honey, etc.)
224135807|NCT00374855|DRUG|PPAR alpha|
224135808|NCT00374855|DRUG|Hydrochlorothiazide|
224135809|NCT00374855|DRUG|Placebo|
224135810|NCT05194046|DRUG|JP-1366 20mg 1capsule|will be orally administered
224135811|NCT05194046|DRUG|Amoxicillin 500Mg Cap|Amoxicilin 500Mg 2 capsules will be orally administered
224135812|NCT05194046|DRUG|Clarithromycin 500Mg Tab|Amoxicilin 500Mg 1 tablet will be orally administered
224135813|NCT03264794|DRUG|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
223413553|NCT03894189|DRUG|Doxapram Hydrochloride|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
223559778|NCT00019968|DRUG|melphalan|
223559779|NCT00019968|DRUG|tumor necrosis factor|
223413554|NCT03894189|DRUG|Theophylline|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
223413555|NCT03963492|OTHER|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
224031076|NCT02866539|DRUG|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
224031077|NCT02866539|DRUG|Placebo|Similar looking inactive powder
224031078|NCT04734327|PROCEDURE|Orthokine periradicular injection|Ultrasound guided injections
224031079|NCT04734327|PROCEDURE|Orthokine epidural injection|Ultrasound guided injections
224031080|NCT02935933|DRUG|bupivicaine|Paravertebral block
224031081|NCT02935933|DRUG|morphine|
224031082|NCT02935933|DRUG|Dexmedetomidine|
224031083|NCT02890394|OTHER|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
224031084|NCT03993860|DIETARY_SUPPLEMENT|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
224031085|NCT03993860|DIETARY_SUPPLEMENT|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
224031086|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single ascending dose.
224031087|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a multiple ascending dose.
224135814|NCT03264794|DRUG|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
223413556|NCT00896792|OTHER|counseling intervention|
223413557|NCT00896792|OTHER|questionnaire administration|
223413558|NCT00896792|OTHER|survey administration|
223559780|NCT00810771|BEHAVIORAL|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
224135815|NCT03264794|DRUG|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
224135816|NCT01734096|OTHER|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
223413559|NCT00896792|PROCEDURE|end-of-life treatment/management|
223413560|NCT00896792|PROCEDURE|psychosocial assessment and care|
223413561|NCT02318446|DRUG|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
223413562|NCT02318446|DRUG|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
223413563|NCT01226784|BEHAVIORAL|Physcial activity|Strenght training Relaxation exercise
224031088|NCT05384262|DRUG|AZD0780|Subjects will receive AZD0780 orally as a single and multiple ascending dose.
224031089|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.
224031090|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.
223413564|NCT03321500|OTHER|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
223413565|NCT03321500|OTHER|Silicone-based soft liner|gold standard for denture relining material
224031091|NCT05384262|DRUG|Placebo|Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.
224031092|NCT05384262|DRUG|Rosuvastatin|Subjects will receive rosuvastatin orally.
224031093|NCT00606957|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
224031094|NCT04326504|OTHER|No intervention|This will be an observational study, no intervention will be performed
224031095|NCT00002997|PROCEDURE|cryosurgery|
224031096|NCT04760054|BEHAVIORAL|HUBOD|Participants in the intervention group will attend 5 separate training sessions instructing them in Hubod. The Hubod exercise is a partnered coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of the Hubod exercise by the end of their participation in this intervention.
224031097|NCT04760054|BEHAVIORAL|Active Comparator|Participants in the active comparator group will attend 5 separate training sessions. Each session will involve a 5 minute warmup of joint mobilization exercises and mild pedaling on the bicycle before the main effort of continuously using the bicycle for approximately 20 minutes. The session finishes with a 5 minute cooldown period and light stretch. Heartrate will be monitored regularly in order to prevent this exercise exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
224135817|NCT01734096|DRUG|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
224135818|NCT03550287|DIETARY_SUPPLEMENT|Experimental product|10 g/day
224135819|NCT03550287|DIETARY_SUPPLEMENT|Placebo product|10 g/day
224135820|NCT03286712|DRUG|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
223413566|NCT06224647|BEHAVIORAL|Mobile Transdiagnostic Emotion Regulation Intervention|"The intervention aims to provide a tailored and engaging way for users to manage and comprehend their emotional well-being.~It consist of 5 components:~1. Daily tracking of emotions~2. A suite of exercises placed in six categories facilitating adaptive emotion regulation skills (i.e., upregulation of positive effect, self-compassion, cognitive defusion and cognitive restructuring, mindfulness, breathing techniques),~3. A self-assessment module where users can complete surveys evaluating their states (e.g., wellbeing) and traits (e.g., perfectionistic tendencies),~4. A personal toolkit area (i.e., each exercise is represented by an object commonly found in a student's room. Users can collect objects of favoured exercises in the virtual ROOM, enabling them quick access to exercises they liked / found helpful),~5. A recommendation system linking users to the content based on their specific needs or preferences"
223413567|NCT03512054|PROCEDURE|Standardized 5-step weaning procedure|"Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver…) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation"
223413568|NCT00003853|DRUG|4'-iodo-4'-deoxydoxorubicin|
223413569|NCT04798053|BEHAVIORAL|Questionnaire|14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)
224031098|NCT04760054|BEHAVIORAL|Control Condition|Participants in this group will attend 5 separate training sessions. Each session will involve watching educational videos on martial arts techniques and training methods from a sedentary position. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
224031099|NCT04723186|DRUG|MT1002 for Injection|MT1002 will be initiated as close to the start of PCI as possible. MT1002 should be initiated during diagnostics angiography when indication for PCI is confirmed, provided the PCI is indicated right after the coronary angiography. PCI can start after MT1002 initiation as soon as ACT is confirmed to be ≥ 200 sec or within 30 min after MT1002 starts, whichever occurs first. MT1002 will be administered by an intravenous injection of 0.90 mg/kg, 1.2 mg/kg, or 0.6 mg/kg (depending on the dose selected for the cohort) prior to the PCI procedure, immediately followed by an IV infusion of 1.8 mg/kg/hour, 2.3 mg/kg/hour, or 1.2 mg/kg/hour (depending on the dose selected for the cohort) until completion of the procedure. At completion of PCI, subjects will be continued on IV MT1002 for 4 hours from infusion start.
224031100|NCT02924142|DEVICE|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
224031101|NCT00414687|DRUG|Ventavis (Iloprost, BAYQ6256)|
224031102|NCT03602456|OTHER|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
224031103|NCT01289171|DRUG|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
224031104|NCT00026208|DRUG|Vincristine|1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
223413570|NCT04798053|BIOLOGICAL|blood sample and salivary sample|10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.
223413571|NCT02067845|BEHAVIORAL|Adapted Many Men, Many Voices (3MV) group level intervention|"The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning."
223413572|NCT02067845|BEHAVIORAL|A group-based HIV/STI prevention intervention for women who have sex with women|
224031105|NCT00026208|DRUG|Cyclophosphamide|650 mg/m², on week 1 and 5
224031106|NCT00026208|DRUG|Doxorubicin|25 mg/m², on week 1, 3, 5, 7
224031107|NCT00026208|DRUG|Prednisone|40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
224031108|NCT00026208|DRUG|Bleomycin|5 u/m² intravenously (IV) on week 2, 4, 6, 8
224031109|NCT00026208|DRUG|Etoposide|60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
224031110|NCT00026208|RADIATION|Low-dose radiotherapy (RT)|20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
224031111|NCT03244735|OTHER|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
223413573|NCT06482398|DRUG|Sericin extract and turmeric extract cream|Apply the sample 2 times a day for 8 weeks
223413574|NCT06482398|DRUG|Triamcinolone acetonide 1% Cream|Apply the sample 2 times a day for 8 weeks
224031112|NCT00969410|BIOLOGICAL|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
224031113|NCT02846753|PROCEDURE|trans catheter heart valve replacement|trans catheter heart valve replacement
224031114|NCT00103051|DRUG|cisplatin|
224031115|NCT00103051|DRUG|gefitinib|
224031116|NCT00103051|DRUG|gemcitabine hydrochloride|
224031117|NCT00103051|PROCEDURE|conventional surgery|
223413575|NCT01538277|PROCEDURE|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
223413576|NCT01538277|OTHER|Standard ablation procedure|Standard ablation procedure
223413577|NCT00459277|DRUG|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
223413578|NCT05930054|DEVICE|skeletal anchorage and rapid palatal expansion|Eighteen patients were randomly divided into 2 groups through a free randomization program (Random Allocation Software 2.0). Baseline demographic characteristics were matched in both groups. All appliances were fabricated by the same technician in the orthodontic lab. All individuals were treated by a single practitioner.
223413579|NCT00687544|BIOLOGICAL|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
223413580|NCT00687544|DRUG|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is \<65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is \>85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
223413581|NCT05729360|DRUG|GamCoviMab|A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
223413582|NCT00917176|DEVICE|Occipital nerve stimulation|
223413583|NCT01788527|DEVICE|CGM|Real Time Continuous Glucose Monitoring
223413584|NCT02195869|DRUG|Ibrutinib|
223413585|NCT03915327|DRUG|Intravenous iron isomaltose anhydride|Enrolled subjects would receive intravenous iron isomaltose anhydride within 24 hours of the subject's inclusion.
223413586|NCT02402387|PROCEDURE|Neutral head position|
223413587|NCT02402387|PROCEDURE|Flexed head position|
223413588|NCT02402387|PROCEDURE|Extended head position|
223559781|NCT00810771|BEHAVIORAL|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
223559782|NCT06160687|PROCEDURE|PSV mode during NIV|NIV will be delivered using PSV mode of ventilation
223559783|NCT06160687|PROCEDURE|ASV intellisync|ASV intellisync mode will be used to deliver NIV
223559784|NCT04017819|DRUG|18F-C-SNAT4|Radiotracer- Dose 10 mCi
223559785|NCT04017819|DEVICE|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
223559786|NCT06573437|DEVICE|Vascular Stent - Vesto Endoprosthesis|Vascular Stent Implant - Vesto Endoprosthesis
224031118|NCT00103051|PROCEDURE|neoadjuvant therapy|
224031119|NCT02225353|DRUG|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
223559787|NCT04575545|DIAGNOSTIC_TEST|Serology test for COVID-19|ELISA test
223559788|NCT06414460|DRUG|ISM3412|ISM3412 will be administered orally once daily.
224031120|NCT02225353|DRUG|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
224031121|NCT02225353|DRUG|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
224031122|NCT02284451|OTHER|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
224031123|NCT00905112|OTHER|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
224031124|NCT00905112|OTHER|Standard OB Care|Receive standard obstetrical care
223559789|NCT05692518|DEVICE|MAGNET System, DI Bio-fragmentable|Anastomoses achieved by magnetic compression.
223559790|NCT03865589|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound shear wave elastography
224031125|NCT00790322|DRUG|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
224031126|NCT00790322|OTHER|Placebo|Solution for oral use
224031127|NCT04002609|OTHER|oxygen|oxygen supplementation during brronchoscopy
224031128|NCT03528863|BEHAVIORAL|Online Mindfulness Meditation|Receive web-based mindfulness meditation
224135821|NCT03082989|DEVICE|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
224135822|NCT03082989|OTHER|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
223413589|NCT02402387|PROCEDURE|Rotated head position|
223413590|NCT02402387|DEVICE|Air-Q SP Airway|
223413591|NCT00949559|DRUG|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
223413592|NCT05527275|DRUG|Mitoxantrone liposome combine with Chidamide|"Mitoxantrone Hydrochloride Liposome Injection： Grade 1: 14mg/ m2, D1; Grade 2: 17mg/ m2, D1; Grade 3: 20mg/ m2, D1; Chidamide：20mg twice a week (D1 and D4 or D2 and D5 or D3 and D6) Every 28 days for a cycle, a maximum of 6 cycles of treatment. Mitoxantrone Hydrochloride Liposome Injection RP2D was determined in the phase I trial, and the combination regimen will be used to in the phase II study, with a cycle of every 28 days and a maximum of 6 cycles of treatment.~Subsequently, maintenance treatment was performed: Chidamide, 20mg twice a week, for 1 year."
223413593|NCT00789698|DRUG|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
223413594|NCT00789698|DRUG|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
223413595|NCT02242682|OTHER|Child passenger safety video|
223413596|NCT03327727|DRUG|Investigational Agent: VL-2397|VL-2397
223413597|NCT03327727|DRUG|Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B|Voriconazole, Isavuconazole, or Liposomal amphotericin B
224031129|NCT03528863|OTHER|Questionnaire Administration|Ancillary studies
224031130|NCT04012229|GENETIC|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score \> or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
223559791|NCT04793204|DRUG|fezolinetant|oral
224031131|NCT05765669|PROCEDURE|Percutaneous screw fixation|Surgical intervention in the form of percutaneous screw fixation
224031132|NCT05765669|OTHER|Pain management|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
224031133|NCT05765669|OTHER|Physical therapy|Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
224031134|NCT04908111|BIOLOGICAL|ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
224031135|NCT04908111|BIOLOGICAL|MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
224031136|NCT04908111|COMBINATION_PRODUCT|Standard of care treatment|Patients will continue to receive SoC treatment (chemotherapy and checkpoint inhibitor).
224135823|NCT04520828|OTHER|postural repositioning|The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
224135824|NCT03933514|OTHER|Plaque control|Children were instructed about the hygiene procedures
224135825|NCT02790554|DEVICE|Moyo strap-on|Continous monitoring
224135826|NCT02790554|DEVICE|Hand-held Doppler|Intermittent monitoring
224135827|NCT01661166|DRUG|Fesoterodine|4 mg
224135828|NCT01661166|DRUG|Placebo oral tablet|Placebo
224135829|NCT00099788|DRUG|Ranolazine|IV to oral transition.
224135830|NCT00099788|DRUG|Placebo|IV to oral transition.
224135831|NCT02370498|BIOLOGICAL|pembrolizumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
224135832|NCT02370498|DRUG|paclitaxel|80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
224135833|NCT02590523|DRUG|Vancomycin|Intracameral vancomycin injection during cataract surgery
224135834|NCT02590523|DRUG|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
224135835|NCT02590523|DRUG|Placebo|Intracameral placebo injection with BSS during cataract surgery
223559792|NCT05035225|OTHER|Survey|Multiple Pharmacy Use Survey
223559793|NCT06338748|DEVICE|Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode|Dexcom G7 used in blinded mode
223559794|NCT04075591|DEVICE|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
224135836|NCT03497442|DRUG|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
224135837|NCT03497442|DRUG|Placebo Vehicle Gel|Vehicle Gel
224135838|NCT01313026|PROCEDURE|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
224135839|NCT04114500|DIAGNOSTIC_TEST|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
224135840|NCT00456729|DRUG|Metronidazole|
224135841|NCT00456729|PROCEDURE|Blood tests|
224135842|NCT05825209|DRUG|Food-Grown Magnesium|1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
224135843|NCT05825209|DRUG|Microcrystalline cellulose|1 daily dose of 2 capsules containing microcrystalline cellulose
224135844|NCT03768830|BEHAVIORAL|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
223413598|NCT02017431|OTHER|Allergen|Subject specific allergen is inhaled on day 1 of the triad
223413599|NCT02017431|OTHER|Saline|Saline is inhaled on day 1 of the triad
223413600|NCT02017431|OTHER|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
223413601|NCT00723762|PROCEDURE|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
223413602|NCT03123445|DRUG|Endostar|Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
223413603|NCT03123445|DRUG|Gemcitabine|Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
223413604|NCT03123445|DRUG|Cisplatin|Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
223413605|NCT02812069|DEVICE|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
223413606|NCT03456804|DRUG|ESK981|Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
223413607|NCT04862169|OTHER|educational intervention (SPARK)|"There are 3 modules with 11 chapters. These topics were considered as the most relevant topics for implementation of palliative care for PHC nurses. Also, topics were selected based on our previous literature review of the previous study on the content of PHC nurses training program.~The first module is the introduction. This consists of three chapters: introduction, support system and effective communication. Total reading time is estimated to be one hour. The second module is about the nursing approach in palliative care. It is estimated to be completed in around 2 hours and 15 minutes. The last module is about end of life care.~The participants are expected to access this module before the scheduled synchronous mode. Modules will be provided in the electronic version, so that participants are able to download and read them on their own devices. We are also providing video as trigger for case study discussion"
223413608|NCT04862169|OTHER|electronic version of the modules|electronic version of the modules
223413609|NCT01945840|PROCEDURE|Roux en Y Gastric Bypass Surgery|
223413610|NCT01945840|OTHER|Gut hormone infusion|
223413611|NCT01945840|OTHER|Placebo infusion|
223413612|NCT01945840|OTHER|Very low calorie diet|
223413613|NCT00736164|DIETARY_SUPPLEMENT|selenomethionine|Given orally
224031137|NCT04908111|BIOLOGICAL|MVA-NYESO (Route = IM injection, Dose = 1.5×10^8 pfu)|"Patients commence their SoC chemotherapy in combination with an immune checkpoint inhibitor in 3 weekly cycles. Patients are screened during the first 2 cycles of SoC treatment to confirm eligibility for the trial.~Patients who receive trial vaccines (safety run in stage, Arm A of the NSCLC randomisation cohort and Squamous Oesophageal Cancer Cohort) continue to receive their SoC treatment plus:~* First prime ChAdOx1-MAGEA3-NYESO vaccine on Cycle 3 Day 1 of SoC treatment.~* First boost MVA-MAGEA3 vaccine, and if applicable a first boost MVA-NYESO vaccine, 21 days later.~* For patients who have not progressed: second prime ChAdOx1-MAGAEA3-NYESO vaccine 15 weeks following first prime vaccine~* Second boost MVA-MAGAE3 vaccine, and if applicable a second boost MVA-NYESO vaccine, 21 days following second prime vaccine~Patients in Arm B of the NSCLC randomisation cohort will continue to receive their SoC treatment only throughout the trial (i.e. no trial vaccines)"
224135845|NCT04905199|PROCEDURE|Temporary transvenous cardiac pacing|Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
224135846|NCT05966844|BEHAVIORAL|Mindfluness and Virtual Reality|They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
223413614|NCT00736164|OTHER|placebo|Given orally
223413615|NCT04786860|PROCEDURE|CPR|Cardiopulmonary resuscitation performed on patients with in-hospital cardiac arrest
223413616|NCT04613921|OTHER|Observational Protocol|The cohorts will be followed for one year after LT transplantation except for group 3 (1-year follow-up after inclusion)
223413617|NCT04289155|DRUG|GX-I7|patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks
223413618|NCT06915610|OTHER|Invitation of all participants to CCS according to the standard of care (active comparator)|Invitation of all participants to CCS according to the standard of care
223559795|NCT04017650|BIOLOGICAL|Cetuximab|Given IV
223559796|NCT04017650|DRUG|Encorafenib|Given PO
223559797|NCT04017650|BIOLOGICAL|Nivolumab|Given IV
223559798|NCT03829969|BIOLOGICAL|Toripalimab|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
224135847|NCT00286390|PROCEDURE|Acupuncture|
223413619|NCT06915610|OTHER|Invitation of all participants to CCS through self-sampling|"A self-sampling kit mailed to the participants, with a prepaid envelope for returning them after sample collection. Participants may also return the kits by depositing them in a container that will be available in their Health Care Center.~The invitation for CCS through self-sampling is accompanied by written instructions, SMS reminders and navigation support (dedicated telephone line, WhatsApp, website)"
223413620|NCT06915610|OTHER|Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care|In a telephone contact, prompted by an SMS, participants will be given the opportunity to schedule CCS according to the standard of care or to ask for a self-sampling kit to be mailed to them. Depending on their choice, the procedure will be similar to what is described for arm SOC or for arm SS, as applicable
223413621|NCT06915610|OTHER|Invitation of all participants to CCS according to the standard of care, followed by invitation of those non-adherent to CCS through self-sampling|Participants not adhering to CCS after the first invitation (SOC) will be additionally invited for CCS screening through self-sampling (as in SS)
223413622|NCT06915610|OTHER|Invitation of all participants to CCS through self-sampling, followed by invitation of those non-adherent to CCS according to the standard of care|Participants not adhering to CCS after the first invitation for self-sampling (SS) will be additionally invited for CCS screening according to the standard of care (as in SOC)
223413623|NCT06915610|OTHER|Invitation of all participants to CCS, asking them to choose between self-sampling and the standard of care; this mode of invitation is repeated when participants do not adhere to the first invitation|Participants not adhering to CCS after a first invitation for screening through a method of their choice (CHOICE) will be invited again, also being given the opportunity to choose between the standard of care or self-sampling (as in the first CHOICE invitation). Depending on the participants' choice, the procedure will be similar to what is described for arm SOC or for arm SS, as applicable, both in the first and in the second CHOICE invitations
224135848|NCT00001940|DRUG|Voriconazole|
224135849|NCT06186635|OTHER|Traditional yoga|This group will practice traditional yoga for an average of 2 hours, preferably once a week, for 12 weeks.
223559799|NCT03450343|DRUG|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
223559800|NCT03450343|DRUG|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
223559801|NCT04777435|DIAGNOSTIC_TEST|Therapeutic orientation test for TMA|Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.
223559802|NCT06545929|DRUG|Sunobinop|1 tablet taken orally at bedtime
223559803|NCT06545929|DRUG|Placebo to match sunobinop|1 tablet taken orally at bedtime
223559804|NCT00394758|PROCEDURE|CO2 laser surgery|
223559805|NCT00394758|PROCEDURE|ultrasonic surgical aspiration|
224135850|NCT06186635|OTHER|AI-Assisted Yoga|This group will practice AI-assisted yoga for an average of 2 hours, preferably once a week, for 12 weeks.
224135851|NCT04441736|DEVICE|High flow nasal cannula|Device gives high flow oxygen comparable to non invasive ventilation and conventional oxygen therapy
224135852|NCT03096002|BEHAVIORAL|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
224135853|NCT05653297|DEVICE|Vacuum-Assisted Closure|NPWT (MEDWAY GROUP VAC) will be applied on post traumatic raw areas until the wound is ready for reconstruction, Then it will be applied over skin graft after coverage
224135854|NCT03184857|PROCEDURE|open maxillary sinus lifting|biopsy of the region 6 months later
223413624|NCT05272111|OTHER|DBM fasciatherapy+ conventional physical therapy|DBM fasciatherapy (3 sessions per day). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the fasciatherapy. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
223413625|NCT05272111|OTHER|fascial manipulation+ conventional physical therapy|Fascial manipulation (3 sessions per day). This technique involves the identification of specific, localized areas of the fascia with limited movements. Once it is identified, then a specific point on the fascia is targeted and through the appropriate manipulation of this precise part of the fascia, movement can be restored. + hot pack (10 min) + neck isometrics (neck flexion, extension, side bending) + neck stretches (neck flexors, extensors, side benders and rotation). A total of 45 min session three times a week on alternate days for three weeks
223413626|NCT04326361|PROCEDURE|Neonatal surgeries|Current practices of neonatal surgeries in India
223413627|NCT02745431|DRUG|Oxytocin|
224031138|NCT03674944|BEHAVIORAL|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).
224135855|NCT00439673|DRUG|5-Azacytidine|
224135856|NCT00439673|DRUG|Valproic Acid|
224135857|NCT00439673|DRUG|ATRA|
224135858|NCT05271396|OTHER|Clinical Assessment|The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
224135859|NCT02665923|OTHER|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
223413628|NCT02745431|DRUG|Placebo|
224135860|NCT02731807|DIETARY_SUPPLEMENT|Dose A: TA-65 24mg, powder|
224135861|NCT02731807|DIETARY_SUPPLEMENT|Dose B: TA-65, 8mg, powder|
224135862|NCT02731807|DIETARY_SUPPLEMENT|Dose C: TA-65 3.2mg, capsule|
224135863|NCT02731807|DIETARY_SUPPLEMENT|Dose D: TA-65 8mg, capsule|
224135864|NCT02731807|DIETARY_SUPPLEMENT|Dose E: TA-65 32mg, capsule|
224135865|NCT01089582|OTHER|No intervention|
224135866|NCT00375635|PROCEDURE|mFPSA treatment|
224135867|NCT04141215|BIOLOGICAL|BIOBank bone paste|BIOBank bone paste (PPT322)
223413631|NCT06940167|OTHER|Myofascial Release Group|myofascial release therapy combined with a home exercise program: Myofascial release techniques will be applied manually to the cervical and upper trapezius regions by a trained physiotherapist. The intervention will be administered three times per week for four weeks, totaling 12 sessions. In addition, participants will follow a standardized home exercise program designed to improve cervical mobility and reduce muscle tension.
223413632|NCT06940167|OTHER|Kinesiology Taping Group|kinesiology taping combined with a home exercise program : Kinesiology tape will be applied to the cervical region following a standardized taping protocol. The taping will be performed by a trained physiotherapist three times per week for four weeks, totaling 12 sessions. The tape will remain on the skin for 3-5 days per application.
223413633|NCT06940167|OTHER|Home Exercise Program (Control Group)|Home exercise program: The exercise program includes cervical mobility exercises, stretching, and strengthening exercises aimed at improving posture and reducing muscle tension. The intervention will be performed three times per week for four weeks, totaling 12 sessions.
223413634|NCT06939868|DIETARY_SUPPLEMENT|Shatavari Root Extract, oral capsule|"This intervention consists of a proprietary, standardized extract of Asparagus racemosus (Shatavari), formulated specifically for women's health and cognitive support. The supplement is provided in oral capsule form and standardized to a specific concentration of shatavarin IV, the primary active compound. Participants will take one capsule daily for 30 days.~This formulation, known as SheVari4™, is patent-pending and manufactured by Cepham, designed to address vasomotor symptoms (hot flashes) and other menopausal concerns. It is distinct from other Shatavari supplements in its standardization and use in a placebo-controlled, double-blind trial targeting postmenopausal women."
224135868|NCT04141215|BIOLOGICAL|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
224135869|NCT06152419|DEVICE|Questionnaire|Patients will be asked to complete questionnaires to evaluate the quality and the impact of the video and to assess the need for additional information.
224135870|NCT03453190|COMBINATION_PRODUCT|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
224135871|NCT05468723|DEVICE|Carecube Negative Pressure Isolation Chamber|Subjects will be tasked to stay within the Carecube Isolation Chamber for at least 4 hours and have 3 consecutive timepoints illustrating a plateau level for all participants parameters. Environmental data will be collected by physicians and nurses \[which may include physicians, physician assistants, Registered Nurses, Licensed Practical Nurses, medical technicians and emergency medical technicians (EMTs)\] . Additionally, atmospheric Oxygen, Carbon Dioxide, humidity, and room temperature will be monitored and recorded on an hourly basis. External to the room humidity and temperatures will also be recorded. The participant will be exposed to room temperature (° Fahrenheit) and humidity (RH%), ranging from 65°- 90° Fahrenheit and 30%-60% RH. Participants will also be asked to record on a questionnaire, in order to demonstrate that the Carecube Negative Pressure Isolation chamber is a safe and non-hostile environment for the patients that will be contained during normal operations.
224135872|NCT04772664|DIETARY_SUPPLEMENT|Multispecies-Probiotic|Participants in intervention group receive 2x3g of a multistrain probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus salivarius W24, Lactococcus lactis W19.
224135873|NCT04772664|DIETARY_SUPPLEMENT|Placebo Supplement|Participants in the placebo group receive 2x3 gram of a placebo supplement not containing probiotic strains.
224135874|NCT05474690|DRUG|Docetaxel + Carboplatin + Trastuzumab + Pertuzumab|"Subjects who met the inclusion conditions were randomly divided into TCbHP group and ECHP-THP group according to 1:1.~Stratified at randomization by the following factors: T, N, HER2 expression (HER2 protein 3+ vs HER2 protein 2+ but FISH+), and hormone receptor status (HR positive vs HR negative).~TCbHP regimen drug dose: docetaxel 75 mg/m2 + carboplatin (AUC=6) + trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg) + pertuzumab Antibiotics (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle."
224135875|NCT05474690|DRUG|(Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)|Dosage of ECHP-THP regimen: epirubicin 90mg/m2+cyclophosphamide 600mg/m2 followed by docetaxel 90mg/m2, trastuzumab (first loading dose 8 mg/kg, sequential maintenance dose 6 mg /kg) + Pertuzumab (the initial loading dose of 840 mg, and the sequential maintenance dose of 420 mg), every 21 days as a cycle.
224135876|NCT02108600|DRUG|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
224135877|NCT05124795|DRUG|IMU-935|IMU-935 capsules
224135878|NCT02425007|DEVICE|Incentive spirometry|
224135879|NCT05500924|OTHER|Intervention group|5 sets of functional activities each will be repeated for 3 times , while the therapist is performing mulligan mobilization techniques Sit to stand Squat Stand to sit Stairs stepping Bridging
224135880|NCT04915664|DEVICE|Pessary|Use of Pessary as treatment of POP
224031139|NCT03674944|BEHAVIORAL|Behavioral Weight Loss (BWL)|All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
224031140|NCT06565000|OTHER|AHA Not Instrumented then AHA Instrumented|First, the participant will undergo a performance assessment using the Assisting Hand Assessment test, following the standard protocol in the occupational therapy room. Subsequently, they will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Finally, a second round of assessment using the Assisting Hand Assessment will be conducted.
224135881|NCT03377010|OTHER|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
224135882|NCT03377010|OTHER|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
224135883|NCT04138030|PROCEDURE|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
224135884|NCT04138030|PROCEDURE|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
224299132|NCT02836626|PROCEDURE|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
223559806|NCT05372978|BEHAVIORAL|Cash transfer|Participants will receive a one-time unconditional cash transfer of $8,500.
224031141|NCT06565000|OTHER|AHA Instrumented then AHA Not Instrumented|"First, the participant will proceed to the motion analysis laboratory located across the hall, where an engineer will outfit them with motion capture markers. These markers comprise ultra-reflective spheres affixed to specific anatomical landmarks on their upper limbs using hypoallergenic tape. Afterward, the participant's functional capacity will be evaluated using the Melbourne Assessment. Then, will undergo a performance assessment using the Assisting Hand Assessment test.~Finally, they will go to the occupational therapy room where a second round of assessment using the Assisting Hand Assessment without markers will be conducted."
224031142|NCT05908045|OTHER|KAP Survey|This is a cross-sectional study that utilizes a KAP (knowledge, attitude, and practice) survey. This type of survey can be conducted on a representative sample of physical therapists who are currently involved in clinical practice. These types of surveys are useful for identifying gaps between what people know and how they act on that knowledge. There have been previous studies that have utilized KAP surveys when identifying knowledge, attitude, and practice behaviors of physical therapists.
224031143|NCT04357197|DEVICE|Closed-loop|The system will be tested to see if it can avoid hypotension
224031144|NCT04020354|BEHAVIORAL|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
224031145|NCT04020354|BEHAVIORAL|Usual Care|Usual customary care
224031146|NCT00834145|DEVICE|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
224031147|NCT02542111|DRUG|Bortezomib|Bortezomib IV
224031148|NCT02542111|DRUG|Gemcitabine|Gemcitabine IV
224031149|NCT02542111|DRUG|Dexamethasone|Dexamethasone IV
224031150|NCT02542111|DRUG|Cisplatin|Cisplatin IV
224031151|NCT03207100|COMBINATION_PRODUCT|Analgesia-first minimal sedation|Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
224031152|NCT03207100|COMBINATION_PRODUCT|Antihypertensive treatment|Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
224031153|NCT03604523|DEVICE|Dilation by Balloon|Esophageal dilation by balloon device.
224031154|NCT03604523|DEVICE|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
224031155|NCT03499197|DIAGNOSTIC_TEST|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
224031156|NCT02074163|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
224031157|NCT02074163|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
224031158|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031159|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031160|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031161|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031162|NCT02074163|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031163|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031164|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031165|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031166|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031167|NCT02074163|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
224031168|NCT02074163|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
224299133|NCT03707665|DIAGNOSTIC_TEST|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
224031169|NCT02074163|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
224135885|NCT02423434|OTHER|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
224135886|NCT05696171|PROCEDURE|Cochlear implant manual insertion|Manual insertion of the cochlear implant into the round window during the surgery
224135887|NCT05696171|PROCEDURE|Cochlear implant robotized insertion|Robotic insertion of the cochlear implant into the round window during the surgery
223413635|NCT06941246|PROCEDURE|Non Surgical Periodontal Treatment|the intervention includes Non Surgical Periodontal Therapy( scaling and root planning ),performed to reduce periodontal inflammation .Gingival Crevicular fluid samples will be collected before and after treatment to assess changes in prolactin hormone levels.
223413636|NCT06941246|DEVICE|paper points|we use paper point to collect GCF sample
223413637|NCT06941246|DEVICE|ELISA Kits|The samples are analyzed by ELISA kits to measure prolactin levels
223413638|NCT06941142|DRUG|Sirolimus (albumin - bound)|Dose escalation, intravenous infusion
223413639|NCT06941142|DRUG|Palbociclib tablet|The dosage is 125 mg, orally once a day. Taken continuously for three weeks followed by a one - week break, with a treatment cycle of four weeks
224135888|NCT04004533|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP)|At the time of each ERCP procedure, information on procedure indication, technical performance of the duodenoscope and adverse events will be collected using a newly designed duodenoscope assessment tool. The duodenoscope assessment tool was developed to measure the technical performance of the duodenoscopes based on three components: passage and positioning at the papilla, performing requisite technical maneuvers and technical features. Each performance component is graded on a scale ranging from 1 to 5 (1 for easy maneuverability, 5 for most difficult maneuverability). Duodenoscope assessment tool also captures data on procedural indications, cannulation success rates and adverse events.
223413640|NCT06941142|DRUG|Fulvestrant injection|The dosage is 500 mg, intramuscular injection. It is given on the 1st and 15th days of the first cycle, with a treatment cycle of four weeks. After that, it is administered once every four weeks.
223413641|NCT04672577|OTHER|Observational study|No intervention is planned
223413642|NCT06940791|DRUG|Tirabrutinib|Tirabrutinib (480 mg) taken orally daily at fasting condition
223413643|NCT06940791|DRUG|Placebo|Placebo taken orally daily at fasting condition
224031170|NCT05778877|DRUG|SEL-302|"SEL-302 Drug: MMA-101 (1.0E13 vg/kg)~Drug: SEL-110 (0.15 mg/kg or up to 0.3 mg/kg)~Other Names:~SEL-110.36, ImmTOR"
224135889|NCT00300651|BEHAVIORAL|Cognitive Behavioral Therapy|
224135890|NCT06063408|BEHAVIORAL|Cognitive Functional Therapy|"Cognitive functional therapy (CFT) is a novel intergraded behavioral approach for individualizing the management of spinal pain, targeting the bio-psycho-social factors of rehabilitation, and enabling the patient to self-manage the condition.~CFT lies within the broad spectrum of the biopsychosocial approach for the management of spinal pain. CFT uses a multidimensional clinical reasoning framework with aim to enable the clinician to identify modifiable components of the condition, evaluate patients' behavioral responses to pain, and compose and drive a tailored rehabilitation program mainly based on self-management. The intervention is comprised by the interplay on making sense of pain, exposure with control, and lifestyle change."
224135891|NCT06063408|BEHAVIORAL|Conventional Therapy|Each individual session involve a combination of pain management with electrotherapy, massage and relaxation techniques. Also include some posture exercise these will be targeted on body alignment to the neutral position, and strengthening the whole neck area. strengthening program will be include isometrics on all cervical movements with a band which progressively increase the resistance of the band by change it and process to exercise against the band resistant. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
224299134|NCT03377764|PROCEDURE|Landmark Technique Control group|Spinal Anesthetic
224299135|NCT03377764|PROCEDURE|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
223413644|NCT06941090|OTHER|sampling stool|Participants will receive a self-sampling stool kit with detailed instructions by mail to their home address. Samples will be mailed back by the participant to the treatment laboratory, which will determine the characteristics of their intestinal microbiota.
223413645|NCT04936750|OTHER|Analysis of body composition|The cross section of the third lumbar spine in the CT scan images of the patients was analyzed to obtain the parameters related to the body composition of the patients
223413646|NCT00664768|DIETARY_SUPPLEMENT|Neocate Infant|minimum of 8 fl. oz daily
223413647|NCT00664768|DIETARY_SUPPLEMENT|new Neocate|minimum of 8 fl oz daily
223413648|NCT05161260|BEHAVIORAL|Yoga Breathing|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Yoga Breathing group will practice a breathing exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their breathing activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
223559807|NCT04426149|DIETARY_SUPPLEMENT|trehalose|patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
224031171|NCT05258045|RADIATION|F18 FDG|Radioactive material
224031172|NCT01162317|OTHER|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
224031173|NCT01162317|OTHER|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
224031174|NCT05462886|DEVICE|Masimo INVSENSOR00057|Noninvasive wearable health monitoring device
224031175|NCT03711175|PROCEDURE|Subscapularis repair|Utilizing fiberwire, high tensile strength suture
224031176|NCT03711175|DEVICE|Shoulder implant|Reverse shoulder arthroplasty device
224031177|NCT06380855|PROCEDURE|Flexible colonoscope assisted hybrid transanal total mesorectal resection|Endoscopic pursestring suture (EPSS) was performed at the distance from 1cm to the inferior edge of the tumor by a double-channel flexible colonoscope. An endoloop was inserted through one channel. Meanwhile, the endoclips was inserted through the other channel one by one to fix the endoloop around the rectal wall. And then the endoloop was tightened slowly. After completing the routine lavage lumen, a full-thickness, circumferential dissection was performed by flexible colonoscope following taTME surgical principle until it converged with the laparoscopy group.
224031178|NCT06610708|OTHER|Cardiac Prehabilitation Program|Patients begin with a one-on-one assessment by a program cardiologist and a CR nurse, followed by a symptom-limited cardiopulmonary exercise test (CPET) to tailor their exercise regimen. The exercise program, based on the FITT (frequency, intensity, time, and type) principle, includes biweekly sessions either at home or at a commercial gym, with ongoing oversight by SJHC CRSP rehabilitation trainers. Additionally, participants have access to dietary counseling to optimize heart-healthy nutrition.
224031179|NCT06609564|DEVICE|inspiratory muscle training|Inspiratory muscle training with a pressure-adjustable device
224031180|NCT06609564|OTHER|Convantional chest physiotherapy|Chest physiotherapy
224031181|NCT07020000|DEVICE|Device: Nerve Cuff and Retractor System|Endoscopic Assisted Retropsoas (EARP) Nerve Cuff Electrode and an EARP Retractor system to safely monitor lumbar nerve root activity and function during standard interbody fusion surgeries.
224031182|NCT07019337|DRUG|Pyrotinib|400mg or 320mg qd
224135892|NCT04853524|DRUG|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
224135893|NCT04853524|DRUG|Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)|A combination of BIC, FTC and TAF will be administered orally.
224135894|NCT05181319|OTHER|occurrence of bronchopulmonary dysplasia|We observe the incidence of bronchopulmonary dysplasia
224135895|NCT02498756|BIOLOGICAL|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
224031183|NCT07019337|DRUG|Capecitabine|500mg tid
224031184|NCT07019454|DEVICE|Physician Modified Endografting|This is the only intervention in the study
224031185|NCT07019233|DEVICE|Real Time Pressure Controller|The purpose of the real-time pressure controller proposed in this experiment is to overcome the deficiencies of the existing technology and provide a pressure filling device for the prevention of chemotherapy-induced peripheral neuropathy that can accurately control the pressure, with the pressure decreasing in a sequential manner from the distal end (toes/fingers) to the proximal end (wrists, limbs). The application of this device is of great clinical significance to reduce the peripheral neurotoxicity of paclitaxel and to improve patients' drug compliance.
224031186|NCT07020299|DEVICE|Device : Digital electrical muscle stimulator is applied to induce diaphragm contraction.|TEDS group will be subjected to sessions of TEDS as follow : Digital electrical muscle stimulator (EV-906 Digital TENS/EMS made in TAIWAN) is applied to induce diaphragm contraction.
224031187|NCT07020416|DEVICE|Transcutaneous electrical acustimulation in automatic synchronization with breathing|This intervention will be carried out via the AutoSTEA device.
224031188|NCT07021014|DEVICE|NightWare|A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.
224031189|NCT07021014|DEVICE|Sham NightWare|NightWare decive will not deliver an intervention (i.e., no vibration)
224031190|NCT07019896|PROCEDURE|Minimal Vitrectomy Surgery|The epiretinal membrane is peeled directly through the intact vitreous. Limited localized vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling.
224031191|NCT07019896|PROCEDURE|Conventional Vitrectomy|Standard pars plana vitrectomy is performed with posterior vitreous detachment induction and core vitreous removal prior to epiretinal membrane peeling.
224135896|NCT02498756|DRUG|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
224135897|NCT00576251|DRUG|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
224135898|NCT00576251|DRUG|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
224135899|NCT00423618|RADIATION|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
224135900|NCT02432040|DRUG|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
224135901|NCT02432040|DRUG|Placebo|Placebo tablets, made to look like the interventional drug
224135902|NCT05682586|BIOLOGICAL|umbilical cord mesenchymal stem cells|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
224135903|NCT05682586|DRUG|paxlovid|Participants will receive standard dose of paxlovid therapy, which contains 300mg namatevir and 100mg litonavir twice a day for a total course of 5 days.
223413649|NCT05161260|BEHAVIORAL|Attention Control|"For the12 weeks, participants will be asked to use the mobile study app, completing 3, 10 minute exercises, 5 days a week. Participants in the Attention Control group will practice a mindfulness exercise guided by the mobile study application. The application will also send nudges and reminders throughout the day. Participants will engage with the research study app along with other participants in groups of 2-7 at their own convenience. Participants may practice their mindfulness activity with either a group of participants, through the video conferencing feature of the app, or on their own. The study instructor may join sessions on a random basis to ensure compliance with the technique and to clarify any questions participants may have."
223413650|NCT06577077|DRUG|Product CM9241GRU|01 tablet in the morning and 01 tablet in the evening for 14 days
224031192|NCT07019623|DEVICE|Rüsch® Balloon Catheter Ch. 24|"After cesarean delivery, patients in the intervention group receive the following intervention: The Rüsch® Balloon Catheter Ch. 24 will be inserted directly into the uterus before uterotomy closure.~After insertion of the catheter, the catheter balloon is filled with 60 - 80 ml of 0.9% saline solution and connected to the vacuum device whereby an intrauterine vacuum of -60 to a maximum of -70 kPa is applied once the uterotomy is closed. Once the catheter has been positioned, it is left in place for one hour as a prophylactic measure while a vacuum is applied.~The device will be removed by draining the liquid in the balloon, after 1 hour of vacuum-induced tamponade. The final decision for removal of the catheter in this study is made by the senior physician responsible for the woman."
224031193|NCT07019623|OTHER|Ultrasonography|The position of the balloon catheter as well as the condition of the uterine cavity are assessed immediately postoperatively using ultrasonography.
224031194|NCT07020884|DRUG|ZT002 Injection|Administered SC
224031195|NCT07020884|DRUG|ZT002 Placebo|Administered SC
224031196|NCT07019584|OTHER|Wai Ji Match Fun card games|Group intervention using game activities with Wai Ji Match Fun cards. A total of eight group sessions, which last for 60 minutes each, will be conducted once a week for a period of 8 weeks.
224031197|NCT07020364|DEVICE|A single working element for bipolar enucleation|"Device: A single working element compatible with both bipolar and laser modalities.~The bipolar energy will be used for cutting and coagulation during enucleation."
224031198|NCT07020364|DEVICE|A single working element for laser enucleation|"Device: A single working element compatible with both bipolar and laser modalities.~Thulium or Holmium laser will be employed for tissue dissection and hemostasis."
224031199|NCT04416191|OTHER|Limb immobilization|Participants will undergo a 2-week period of leg immobilization
224031200|NCT07019493|OTHER|No Intervention: Observational Cohort|Not applicable: Observational cohort study
224031201|NCT07020897|OTHER|Clinician-administered joint mobilization|Tibiofemoral arthrokinematic extension joint mobilization and multidirectional patellofemoral mobilization applied by a physical therapist.
224031202|NCT07020897|OTHER|Self-administered joint mobilization|Tibiofemoral arthrokinematic extension joint mobilization and multidirectional patellofemoral mobilization applied by the research participant.
224031203|NCT07020897|OTHER|Exercise-based physical therapy|In-clinic exercise-based physical therapy supervised by a physical therapist, with home exercises to be performed on days without a clinical visit.
224031204|NCT05938231|DEVICE|Gastric Bypass Stent System|Subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy. Following a 3-month treatment period, the device is removed, and subjects are followed for 6 months.
224031205|NCT05938231|BEHAVIORAL|Dietary Intervention|The patients in the trial group or in the control group,have 9-month dietary intervention in the syudy period.
224135904|NCT01552187|DRUG|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
224135905|NCT01552187|DRUG|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
223413651|NCT06577077|DRUG|Placebo|01 tablet in the morning and 01 tablet in the evening for 14 days
223413652|NCT06835465|DRUG|Divarasib|Divarasib will be administered as a single oral dose as specified for the respective period.
223413653|NCT06835465|DRUG|Rifampin|Rifampin will be administered QD on Days 1 to 7 and Days 9 to 13 and as a single oral dose on Day 8 as specified for the respective period.
223559808|NCT04130724|DIAGNOSTIC_TEST|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
223559809|NCT04130724|DIAGNOSTIC_TEST|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
223559810|NCT02191657|DRUG|Deferiprone|Oral iron chelator
223559811|NCT03415451|DEVICE|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
224031206|NCT06728852|DRUG|Administration of Vorolanib|This study utilizes Vorolanib, a novel angiogenesis inhibitor, as a monotherapy for advanced non-small cell lung cancer (NSCLC) patients who have failed at least two lines of systemic therapy. Vorolanib is administered orally at a dosage of 300 mg daily. The intervention focuses on its efficacy and safety as a third-line or beyond treatment, aiming to improve progression-free survival (PFS) and other clinical outcomes. Vorolanib targets VEGFR, PDGFR, and other tyrosine kinases, distinguishing it from other therapies by its enhanced anti-angiogenesis properties and tolerable safety profile in late-stage cancer treatment.
224031207|NCT05353933|OTHER|Thread embedding acupuncture|Thread embedding acupuncture (TEA) that use chromic catgut thread with 3/0 size with 1 centimeter long for each acupoint (TRUSTIGUT® (C), CPT Sutures Co., Ltd, Ho Chi Minh, Vietnam). Every 2 weeks in 4 weeks (twice), 13 acupoints will be embedded including Xiawan (CV-10), Zhongwan (CV-12), Shangwan (CV-13) and Zusanli (ST-36), Neiguan (PC-6), Geshu (BL-17), Ganshu (BL-18), Pishu (BL-20) in both sides of the body.
224031208|NCT05353933|DRUG|Pantoprazole 40mg|Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam) thirty minutes to one hour before the first meal once daily for 4 weeks.
224299136|NCT02933021|OTHER|Blood sample taken|
224299137|NCT02933021|OTHER|Answering a lifestyle questionnaire|
224031209|NCT06895122|PROCEDURE|High resistance training|Participants will perform the exercises at high speed, emphasizing explosive movements to maximize muscle power development.
224031210|NCT06895122|PROCEDURE|Multicomponent Training|Various exercise modalities are integrated, including aerobic training, mobility, strength, balance, and coordination exercises.
223413654|NCT06829771|DRUG|TQB2825 injection +R-CHOP regimen|"R-CHOP is a cancer treatment regimen that uses a combination of five drugs to treat non-Hodgkin lymphoma, e.g., Rituximab+Cyclophosphamide+Doxorubicin Hydrochloride+Vincristine+Prednisone (R-CHOP).~TQB2825 Injection: TQB2825 is a bispecific antibody targeting the cluster of differentiation 20 (CD20) receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T cells.~Rituximab: A monoclonal antibody that binds to the CD20 antigen on the surface of B cells.~Cyclophosphamide: An alkylating agent that inhibits the synthesis of DNA and proteins in cancer cells.~Doxorubicin Hydrochloride: An antineoplastic antibiotic that inhibits the synthesis of DNA and RNA.~Vincristine: A microtubule inhibitor that blocks the normal function of microtubules during cell division.~Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects.~TQB2825 injection + GemOx (Gemcitabine + Oxaliplatin)"
223413655|NCT06829771|DRUG|TQB2825 injection + GemOx|"TQB2825 Injection: TQB2825 is a bispecific antibody targeting the CD20 receptor on tumor cells and the CD3 receptor on T cells.~Gemcitabine: A nucleoside analog that inhibits DNA synthesis. Oxaliplatin: A platinum-based chemotherapy drug that forms cross-links with DNA, inhibiting DNA replication and transcription."
223413656|NCT06787196|DRUG|Dexamethasone|Dexamethasone, single-dose, 8 mg IV administered intraoperatively
223413657|NCT02331914|PROCEDURE|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
223413658|NCT02331914|PROCEDURE|Tumor biopsy|Tumor biopsy after disease progression
223413659|NCT04662905|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|ECAP-controlled, closed-loop SCS
223413660|NCT06953141|DIAGNOSTIC_TEST|Ultrasound|Transabdominal and transvaginal imaging will be performed to eligible women following gynecological surgery within 24 - 48 hours.
223413661|NCT06163469|DEVICE|Bladder instillation with Irrisept|9 months of bladder instillations (3 months of saline and 6 months of chlorohexidine gluconate)
224031211|NCT03442114|BEHAVIORAL|Hydroxyurea SDM Toolkit|Implementation tools and visit decision aids
224031212|NCT03442114|BEHAVIORAL|Clinician Pocket Guide|current hydroxyurea protocol and ASH pocket guide
224135906|NCT04042675|DIAGNOSTIC_TEST|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
224135907|NCT01434381|BIOLOGICAL|Pfs25-EPA/Alhydrogel|
224135908|NCT00920036|DEVICE|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
224135909|NCT02636348|DIETARY_SUPPLEMENT|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
224135910|NCT02636348|DIETARY_SUPPLEMENT|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
224299138|NCT02933021|OTHER|Follow-up phone call from researcher (two years after first visit)|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
224299139|NCT00467636|PROCEDURE|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
223559812|NCT02865954|DEVICE|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
224031213|NCT02903368|DRUG|Apalutamide|
224135911|NCT03342196|DRUG|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
224135912|NCT03342196|DRUG|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
223559813|NCT02059499|DRUG|imiquimod|Given intra-anally
223559814|NCT02059499|DRUG|fluorouracil|Given intra-anally
223559815|NCT02059499|OTHER|questionnaire administration|Ancillary studies
223559816|NCT02059499|OTHER|laboratory biomarker analysis|Correlative studies
224031214|NCT02903368|DRUG|Leuprolide|
224299140|NCT00467636|DRUG|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI \< 30 = 0.1 unit/kg. BMI \> 30 = 0.2 unit/kg)
224031215|NCT02903368|DRUG|Prednisone|
224299141|NCT02232490|BIOLOGICAL|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
224299142|NCT02232490|BIOLOGICAL|Placebo|
224031216|NCT02903368|DRUG|Abiraterone Acetate|
224031217|NCT06892210|DRUG|Methylprednisolone (drug)|ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
224031218|NCT06892210|DRUG|Hydrocortisone|ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
224031219|NCT06828172|BEHAVIORAL|Exercise|Two conditions will be tested: Arm-cranking and control condition.
224031220|NCT06888817|DRUG|Bevacizumab|Intravenous bevacizumab at a 600 mg flat dose every three weeks for four courses over 12 weeks
224031221|NCT06888817|DRUG|Dexamethasone|Daily oral dexamethasone followed by a protocol-based tapering dose over 12 weeks
224031222|NCT06805136|BEHAVIORAL|Community-based social interaction intervention|The intervention focuses on free or low-cost social interaction by offering community initiatives and activities, online spaces for interaction, and social events to young and working-age adults in London. Activities include but are not limited to social walks, bingo nights, board game afternoons and pub quizzes.
224031223|NCT06809270|BEHAVIORAL|Walking training intervention|Moderate intensity intermittent walking training for a period of 10 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is four times a week.
224031224|NCT06766162|OTHER|Virtual reality pain distraction|The intervention group in this study will undergo their EMR and ESD procedure with the addition of virtual reality (VR) as a supportive tool. Participants in this group will use a VR headset during the procedure, designed to provide an immersive experience that may help manage pain and anxiety. The use of VR will be integrated alongside the standard care protocol, including routine sedation and pain management practices VR headset is from DRVR, Rescope innovation which is registered as medical device in the UK.
224031225|NCT06766162|OTHER|Standard analgesia and sedation|Standard local protocol for analgesia and sedation, incorporating fentanyl and midazolam.
224031226|NCT00699452|DRUG|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
224031227|NCT00699452|DRUG|placebo|placebo
224031228|NCT02800226|DEVICE|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
224135913|NCT03342196|DRUG|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
224135914|NCT05607940|PROCEDURE|blood volume loss based blood transfusion|Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.
224031229|NCT02800226|DEVICE|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
224031230|NCT06411483|DEVICE|ObeEnd Band|The ObeEnd band provides electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
224031231|NCT06411483|OTHER|Placebo|The nonfunctional ObeEnd band does not provide electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
224031232|NCT04179331|OTHER|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
224135915|NCT05607940|PROCEDURE|hemoglobin concentration based blood transfusion|Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
224135916|NCT06022978|PROCEDURE|Submucosal Saline Injection|Inject 3-5 mL of saline into the submucosa within 10 minutes using a single-use 22G mucosal needle. The puncture point is located 0.5 cm from the edgeof the lesion, and the saline injection is stopped when the esophageal mucosa is elevated by approximately 1 cm.
224135917|NCT06022978|PROCEDURE|Blue laser Imaging and Magnifying Endoscopy|It is a new system for image-enhanced endoscopy using laser light. By clicking a button on the endoscope only , endoscopists can electronically stain and magnify the digestive tract lesions. This system can help endoscopists observe leisons more clearly and improve diagnosic accuracy.
224135918|NCT04715308|PROCEDURE|Urinary diversion|The formation of a stoma to divert urine to the skin because of the need to resect the bladder as part of surgery for advanced pelvic malignancy
224031233|NCT04179331|OTHER|Saline|Isotonic saline will serve as a placebo.
224031234|NCT00510250|DRUG|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
224031235|NCT00510250|DRUG|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
224031236|NCT00510250|PROCEDURE|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
224031237|NCT02705144|OTHER|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
224031238|NCT01800266|BEHAVIORAL|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
224135919|NCT00240188|PROCEDURE|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
224135920|NCT00240188|PROCEDURE|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
224135921|NCT04526756|PROCEDURE|Mechanical Thrombectomy|Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
224135922|NCT03013205|PROCEDURE|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
224135923|NCT03013205|PROCEDURE|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
224135924|NCT03013205|PROCEDURE|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
224135925|NCT03013205|PROCEDURE|Physiotherapy|
224135926|NCT04051151|BEHAVIORAL|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
224135927|NCT01147575|DIETARY_SUPPLEMENT|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
224135928|NCT01147575|DIETARY_SUPPLEMENT|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
224135929|NCT00247182|BEHAVIORAL|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
223413662|NCT05214859|BEHAVIORAL|The Dyadic Expressive Arts Group Therapy|This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
223559817|NCT06440200|BEHAVIORAL|group gamed-based activity|Participants in interventional group will play the active-type software with Switch game console which develops by Nintendo company. Team building, cooperation, cohesion, sense of belonging and sense of achieving will be emphasized.
223559818|NCT06653764|OTHER|Chest physiotherapy and aerobic exercise training|Chest Physiotherapy including Percussion, vibration and shaking; along with it aerobic exercises such as walking up and down stairs, bedside ambulation, step walking
223559819|NCT03645278|DRUG|SHR0532|Ascending dose oral adminstration
223559820|NCT03645278|DRUG|Placebo|Ascending dose oral administration
223559821|NCT05016310|DIETARY_SUPPLEMENT|High Dose Vitamin D|High dose vitamin D: Subjects will receive 50,000 IU vitamin D2 weekly x 16 weeks followed by 4,000 IU of vitamin D3 daily with a goal 25(OH)D level of ≥45 but ≤80 ng/mL.
223559822|NCT05016310|DIETARY_SUPPLEMENT|Standard of Care Vitamin D|Standard of Care Vitamin D: Vitamin D will be supplemented to 25(OH)D levels, with a goal 25(OH)D level of \>30 ng/mL according to Endocrine Society Practice Guidelines.
223559823|NCT01179269|DRUG|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
223559824|NCT02134561|BEHAVIORAL|psychological interview|
223559825|NCT02134561|RADIATION|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
223559826|NCT02134561|OTHER|cognitive tests|
223559827|NCT02134561|OTHER|neurological tests|
224031239|NCT02730988|BEHAVIORAL|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 \& 2 \& 1 Plan.
224031240|NCT00209456|DRUG|DatSCAN|
224031241|NCT02956512|DRUG|Dexibuprofen|Dexibuprofen 300mg
223413663|NCT03582774|OTHER|Best Practice|Undergo standard of care
223413664|NCT03582774|PROCEDURE|Computed Tomography|Undergo PET/CT
224135930|NCT00247182|BEHAVIORAL|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
223413665|NCT03582774|RADIATION|Gallium Ga 68-labeled PSMA-11|Given IV
223559828|NCT02224443|DRUG|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
223559829|NCT02224443|DRUG|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
223559830|NCT02224443|DRUG|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
223559831|NCT02224443|DRUG|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
223559832|NCT02224443|DRUG|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0%
223413666|NCT03582774|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223559833|NCT03144128|DIETARY_SUPPLEMENT|Vitamin D|5,000IU vitamin D given daily for 12 weeks
223559834|NCT03144128|DIETARY_SUPPLEMENT|Placebo|Placebo capsules given daily for 12 weeks
223559835|NCT01373255|PROCEDURE|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
223559836|NCT03989349|DRUG|Placebo|Placebo
223559837|NCT03989349|DRUG|Nemolizumab|Nemolizumab
223559838|NCT01266252|DRUG|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
223738886|NCT03818828|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
224031242|NCT01679795|DRUG|Tibolone|
224031243|NCT01679795|DRUG|Placebo|
224031244|NCT03520933|DIAGNOSTIC_TEST|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
223413667|NCT05859568|DEVICE|Pinna-located microphone|Sound processors using a pinna-located microphone
223413668|NCT05859568|DEVICE|Pinna-simulated microphone algorithm|Sound processors using a pinna-simulated algorithm
223413669|NCT06022848|PROCEDURE|occipital nerve stimulator|Quantitative sensory testing
224031245|NCT03520933|DIAGNOSTIC_TEST|niPGT-A|Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of vitrification. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
224031246|NCT02870569|DRUG|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
224031247|NCT02870569|DRUG|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
224031248|NCT02047292|DEVICE|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
224031249|NCT02047292|DEVICE|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
224031250|NCT02047292|DEVICE|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
224031251|NCT02579707|DRUG|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
224031252|NCT02382016|DRUG|Macitentan|Macitentan film-coated tablet 10 mg once daily.
223413670|NCT02636231|DRUG|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
223413671|NCT02636231|RADIATION|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
223413672|NCT05501470|DRUG|Probiotic|Probiotic
224031253|NCT02382016|OTHER|Placebo|Matching placebo tablet once daily.
223413673|NCT05501470|DRUG|Placebo|Placebo
223413674|NCT05501470|DEVICE|CapScan®|"The only non-standard sample collection instrument is the CapScan® device. The CapScan Collection Capsule (Capsule) is a non-invasive device that collects gastrointestinal samples along the GI tract that are then analyzed outside the body. Samples collected by the Capsule will be expressed, then undergo DNA sequencing and mass spectrometric analysis to determine the identity and function of the bacterial and host cells in the different regions of the GI tract and compared to similar analyses conducted on concomitantly collected stool samples."
223559839|NCT01127672|BIOLOGICAL|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
223559840|NCT01127672|DRUG|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
224031254|NCT00084266|DRUG|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
224031255|NCT00084266|DRUG|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
224031256|NCT03343951|OTHER|Examination|"Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~* diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~* if the patient needs a new appointment at the shoulder clinic~* if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS."
224135931|NCT00247182|BEHAVIORAL|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
224031257|NCT00730171|DRUG|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
223413675|NCT06386198|BEHAVIORAL|Health Advocate|The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
223413676|NCT04200443|DRUG|Cabozantinib|Given PO
223413677|NCT04200443|OTHER|Quality-of-Life Assessment|Ancillary studies
223413678|NCT04200443|OTHER|Questionnaire Administration|Ancillary studies
223413679|NCT04200443|DRUG|Temozolomide|Given PO
223413680|NCT04806386|DIETARY_SUPPLEMENT|Psyllium|Psyllium fiber powder baked into a bar is commonly used as a first line of treatment for patients with fecal incontinence.
223413681|NCT06195306|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224031258|NCT02221986|BEHAVIORAL|Interdisciplinary rehabilitation|
224031259|NCT03268733|DRUG|Folic Acid|Tablet 5 mg
224031260|NCT01729156|DRUG|Metformin|1000 mg metformin twice daily in 3 months
224031261|NCT01729156|DRUG|Placebo|2 tablets twice daily in 3 months
224135932|NCT03298191|DRUG|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
223413682|NCT06195306|PROCEDURE|Mammography|Undergo mammography
223413683|NCT06195306|DRUG|Omega-3-Acid Ethyl Esters|Given PO
223413684|NCT06195306|OTHER|Questionnaire Administration|Ancillary studies
223413685|NCT06195306|PROCEDURE|Random Periareolar Fine-Needle Aspiration|Undergo RPFNA
223413686|NCT06195306|DRUG|Tamoxifen|Given PO
223413687|NCT06292546|DRUG|Vonoprazan|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
223413688|NCT06292546|DRUG|Amoxicillin|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
224031262|NCT04548414|OTHER|No.|This is an observational study with no intervention.
224031263|NCT00659893|DRUG|PEP005 Topical gel|0.05%, two day dose
224031264|NCT05119426|BIOLOGICAL|Vi-TT|Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and \<16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
224031265|NCT02997488|DEVICE|Pentax Airwayscope|intubation using Pentax Airwayscope
224031266|NCT02997488|DEVICE|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
224031267|NCT04183972|PROCEDURE|ultrasound examination|the participants will be placed in the supine position, with head turned slightly away from the operating side and arms beside the body. The operator will identify right and left interscalene brachial plexuses by ultrasound equipment (Sonosite EDGE or GE LOGIQ e). Clear images and videos of brachial plexus will be captured and saved.
224031268|NCT03249077|BEHAVIORAL|Digital DPP|The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
224031269|NCT03249077|BEHAVIORAL|In-person DPP|The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
224031270|NCT03249077|OTHER|DPP not enrolled|Access to usual care services without restrictions.
224031271|NCT04603664|DIAGNOSTIC_TEST|serum NGAL and cystatin c|measuring serum NGAL and cystatin c on admission and after 48 hours in critically ill patients with covid 19 then compare results to serum creatinine and signs of acute kidney injury
223413689|NCT06292546|DRUG|Bacillus subtilis enteric-coated capsules|Group A: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days, followed by 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group B: vonoprazan 20 mg bid + amoxicillin 0.75 g qid+ 2 doses of bacillus subtilis enteric-coated capsules for 14 days. Group C: 2 doses of bacillus subtilis enteric-coated capsules for 14 days, followed by vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days. Group D: vonoprazan 20 mg bid + amoxicillin 0.75 g qid for 14 days.
223413690|NCT04624256|PROCEDURE|Discussion|Patients and physicians engage in discussion
223413691|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo conventional hypofractionated radiation therapy
223413692|NCT04624256|RADIATION|Hypofractionated Radiation Therapy|Undergo moderate hypofractionated radiation therapy
223413693|NCT04624256|OTHER|Laboratory Biomarker Analysis|Correlative studies
223413694|NCT04624256|OTHER|Quality-of-Life Assessment|Ancillary studies
223559841|NCT04469387|PROCEDURE|Limited decompressions at adjacent segment with asymptomatic pre-existing spinal canal stenosis|In terms of limited decompression at the adjacent segment, partial laminotomy, flavectomy, and bilateral medial facetectomies up to the pedicle will be performed. Complete laminectomy and destroy of posterior ligament complex will be avoided.
223559842|NCT04469387|PROCEDURE|Responsible segments fused|In terms of responsible segments fused, L4-5 and L5-S1 were fused using posterior lumbar interbody fusion (PLIF).
223559843|NCT03312790|DEVICE|Tasks|Augmented reality device Real condition
223559844|NCT03252041|DEVICE|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
223559845|NCT01352221|DRUG|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
224031272|NCT00528164|BEHAVIORAL|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
224031273|NCT03599557|BEHAVIORAL|STOP-HPV communication intervention|This intervention will be communication skills training.
223559846|NCT01352221|DRUG|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
224031274|NCT02952001|DRUG|4 mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
224031275|NCT02952001|DRUG|Sham procedure|This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
224031276|NCT02604225|DRUG|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
224031277|NCT02604225|DRUG|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
224031278|NCT03540472|DRUG|tacrolimus|On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
224031279|NCT02672709|DRUG|apixaban|
224031280|NCT00421200|DRUG|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
224031281|NCT00421200|DRUG|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
224031282|NCT00937833|PROCEDURE|Prostatectomy|
224031283|NCT00937833|DEVICE|Surgisis Male Sling|
224135933|NCT03298191|DRUG|Ritodrine|Those women will be given Ritodrine for tocolysis
224135934|NCT03298191|DRUG|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
224135935|NCT00671580|DRUG|PZ-601|750 mg
223559847|NCT02016716|DRUG|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
224031284|NCT03608267|DEVICE|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
224298315|NCT01916746|PROCEDURE|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
224031285|NCT06250348|OTHER|Non invasive measure of endogenous exhaled Nitric Oxyde in exhaled gaz, by a laser spectrometer|A sample of exhaled gases is taken from the expiratory part of the respirator circuit (same way as a capnometry measurement). A laser spectrometer continuously and non-invasively monitors online the concentrations of endogenous NO exhaled by patients.
224031286|NCT01707225|DRUG|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
224031287|NCT03399487|DRUG|LDK378(Ceritinib)|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days."
224031288|NCT04730544|DRUG|Nivolumab 480mg + Ipilimumab|Nivolumab 480 mg q4w + Ipilimumab 1 mg/kg q6w
224031289|NCT04730544|DRUG|Nivolumab 240 mg + Ipilimumab|induction phase : Nivolumab 240 mg q3w + Ipilimumab 1 mg/kg q3w and then maintenance : Nivolumab 480 mg q4w
224031290|NCT03278106|OTHER|Laboratory Biomarker Analysis|Correlative studies
224298316|NCT00127036|DRUG|XELOX|XELOX: Oxaliplatin 130 mg/m\^2 intravenously (IV); Capecitabine 825 mg/m\^2 by mouth (po)
224031291|NCT03278106|DRUG|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
224031292|NCT00207701|DRUG|infliximab|
224031293|NCT04910854|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks.
224135936|NCT00671580|DRUG|PZ-601|1000 mg
224135937|NCT00671580|DRUG|Standard of Care|as directed
224298317|NCT00127036|DRUG|XELIRI|XELIRI: Irinotecan 240 mg/m\^2 IV; Capecitabine 825 mg/m\^2 by mouth (po)
224298318|NCT00127036|DRUG|Bevacizumab|7.5 mg/kg intravenously (IV)
224135938|NCT02068131|DRUG|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
224135939|NCT02068131|DRUG|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
224135940|NCT01919905|DIETARY_SUPPLEMENT|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
224135941|NCT04245527|DEVICE|Joovv Infrared Light Device|Joovv is the leading manufacturer of personal, in-home red light therapy devices
224135942|NCT03574935|DRUG|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~1. Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~2. Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~3. Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
223559848|NCT02016716|DRUG|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
224031294|NCT06494202|OTHER|Innovative rehabilitation|Conventional rehabilitation program associated with innovative therapies.
224031295|NCT06494202|OTHER|Conventional rehabilitation program.|Conventional rehabilitation program
224031296|NCT05711966|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
224031297|NCT05711966|DEVICE|Less invasive surfactant administration (LISA)|SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
224031298|NCT02229045|DRUG|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
224135943|NCT03574935|DRUG|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
223413695|NCT04624256|OTHER|Questionnaire Administration|Ancillary studies
223413696|NCT04624256|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223413697|NCT06568055|OTHER|No Intervention|This is non-interventional study.
223413698|NCT06115720|OTHER|Video assisted consent|The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA. This video will aim to communicate the same information as that found in the traditional verbal consent, using an actor undergoing an anaesthetic to provide context.
223559849|NCT02016716|DRUG|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
223413699|NCT02625532|PROCEDURE|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
223413700|NCT02625532|PROCEDURE|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
224031299|NCT02229045|DRUG|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
224031300|NCT05381779|OTHER|Inspiratory Muscle Training Group|"Patients in the training group will receive inspiratory muscle training with the PowerBreathe® (inspiratory muscle training device) at 50% of the maximal inspiratory pressure.~Patients in the training group inspiratory muscle training will be given 2 sets of 15 minutes a day for a total of 30 minutes/per day or a single session for 30 minutes/week, 7 days/week for a total of 8 weeks.~Patients in the training group will be given respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week."
224135944|NCT01514188|DRUG|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
224135945|NCT01514188|DRUG|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
224135946|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 2% Twice a day|nasal spray
224135947|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 3% Twice a day|nasal spray
224135948|NCT01277341|DRUG|Bepotastine Besilate Nasal Spray 4% Twice a day|nasal spray
224298319|NCT05312242|DIETARY_SUPPLEMENT|United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) MMS|Introduction of UNIMMAP MMS along with novel counseling strategies to increase acceptability and adherence to prenatal supplementation
224298320|NCT05312242|DIETARY_SUPPLEMENT|Iron Folic Acid Supplement|Standard of Care Intervention
224298321|NCT00358293|DRUG|Tizanidine (sublingual or oral)|
224298322|NCT02133586|OTHER|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
223413701|NCT04817696|OTHER|Patients without chronic pain symptoms|Verbal score \< 3 at 3 months
223413702|NCT04817696|OTHER|Patients with chronic pain symptoms|Verbal score ≥ 3 at 3 months
223413703|NCT06316609|OTHER|Gestational Exposure to Emerging Contaminants (ECs)|Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation.
223559850|NCT02016716|DRUG|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
223559851|NCT02248649|BEHAVIORAL|Structured physical activity|Walking instruction and encouragement
223559852|NCT02248649|BEHAVIORAL|Health education|Provision of general information about a variety of health topics
223559853|NCT01912443|DRUG|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
223559854|NCT05851534|BEHAVIORAL|Preoperative optimisation program|Preoperative screening of all patients scheduled for pancreatic resection on (aerobic) fitness level, malnutrition risk, psychological resilience, haemoglobin, iron and HbA1c concentration, frailty, and alcohol and smoking behaviour. All patients are provided with a patient-tailored, multimodal prehabilitation program, in which these potentially (partly) modifiable factors are preoperatively addressed
224135949|NCT01277341|DRUG|Placebo Nasal Spray|nasal spray
224135950|NCT03026413|PROCEDURE|pulmonary vein antrum modification|
224135951|NCT05203276|DRUG|Envafolimab|300mg，SC，Q3W，d1
224135952|NCT05203276|DRUG|Endostar|210mg，CIV，Q3W，d1-3
224135953|NCT03590522|GENETIC|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
224135954|NCT02932332|OTHER|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
224135955|NCT02932332|OTHER|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
224135956|NCT02932332|OTHER|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
223559855|NCT01439971|BIOLOGICAL|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
224299143|NCT02893202|OTHER|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
223559856|NCT01439971|BIOLOGICAL|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
223559857|NCT01439971|BIOLOGICAL|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
223559858|NCT01439971|BIOLOGICAL|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
224135957|NCT02932332|OTHER|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
223413704|NCT06165510|DEVICE|Epicardial AF ablation using AtriCure EPi-Sense-AF Guided Coagulation System with Left Atrial Appendage Exclusion using the AtriCure LARIAT Suture Delivery Device.|2 stage procedure - minimally-invasive epicardial ablation with left atrial appendage exclusion using LARIAT procedure via a subxiphoid incision. This is then combined with endocardial radiofrequency catheter ablation in a separate staged procedure.
223413705|NCT06165510|PROCEDURE|Standard Endocardial Catheter Ablation|Standard percutaneous endocardial catheter ablation of atrial fibrillation
224031301|NCT05381779|OTHER|High Intensity Interval Training Group|"High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points."
223413706|NCT05149144|DIAGNOSTIC_TEST|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule
223413707|NCT05149144|BEHAVIORAL|audio signal dataset creation and validation; machine learning analysis, empirical evaluations|The project tests and adapts the technology developed at MIT for vocalization collection and labeling, and contributes to data gathering among Italian subjects (and their quality validation) in order to create a multi-cultural dataset and to enable cross-cultural studies and analyses. Next, the focus is placed on the analysis of harmonic features of the audio in the vocalizations of the dataset to identify recurring individual features and patterns corresponding to specific communications purposes or emotional states. Supervised and unsupervised machine learning approaches are developed and different machine learning algorithms will be compared to identify the most accurate ones for the project goal. Last, an exploratory evaluation of the vocalization-understanding machine learning model is conducted to test the usability and utility of the tool for vocalization interpretation.
223413708|NCT06495242|PROCEDURE|Direct pulp capping and partial pulpotomy|Two types of vital pulp therapy procedures
224031302|NCT05381779|OTHER|Control Group|Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
224031303|NCT00818389|DRUG|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
223413709|NCT05894018|DRUG|Fluzoparib|150mg, orally, bid
223413710|NCT05894018|PROCEDURE|Radioactive particle implantation|Radioactive iodine-125 seeds implantation
224031304|NCT00818389|DRUG|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
224031305|NCT00818389|DRUG|placebo|an inactive substance
224031306|NCT01494454|DEVICE|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
224031307|NCT01494454|DEVICE|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
223413711|NCT04755764|DRUG|Labetalol|Beta blocker
223413712|NCT04755764|DRUG|Atenolol|Beta blocker
224031308|NCT03548987|DRUG|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
224031309|NCT03548987|DRUG|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
224031310|NCT02945501|DEVICE|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
224031311|NCT02945501|DEVICE|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
224031312|NCT05826743|DEVICE|COLO BT™|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
224031313|NCT05826743|OTHER|Stoma Creation|Protective ileostomy
224031314|NCT02741583|OTHER|altitude rehabilitation program|altitude exposure
224031315|NCT02741583|OTHER|rehabilitation program|Rehabilitation at low altitude
224031316|NCT05541315|DRUG|JNJ-88260237|JNJ-88260237 will be administered orally.
224031317|NCT05541315|DRUG|Placebo|Matching placebo will be administered orally.
224031318|NCT03686267|OTHER|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
224031319|NCT03686267|OTHER|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
224031320|NCT03686267|OTHER|titanium abutment with no color masking|color masking methods are avoided in this arm
224031321|NCT04088864|DRUG|Fludarabine|Fludarabine is a purine antagonist antimetabolite
223413713|NCT04755764|DRUG|Nifedipine|Calcium channel blocker
223413714|NCT04881578|OTHER|continuous cardiac monitoring before and after transcatheter PFO closure|Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF
223559859|NCT01439971|BIOLOGICAL|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
223738887|NCT03818828|OTHER|Profore Compression Therapy|Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits
224031322|NCT04088864|DRUG|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative alkylating agent
224031323|NCT04088864|DRUG|Autologous CD22 CAR T|Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
223413715|NCT05497518|OTHER|Observational study - registry|The Study is a longitudinal observational cohort study that collaborates with health systems to obtain both electronic healthcare records (EHR) and patient-entered data. Eligible people with a diagnosis of chronic kidney disease at any stage, age 18 years and above, are identified through EHR data review, referral by a provider, or are recruited through the NKF's outreach campaign. Patients self-enroll into the online registry and share their experiences and health data through a secure portal where they can also find education, tips, and support. Research partners can view aggregate data through a collaboration portal.
223413716|NCT04556084|DRUG|Blinatumomab|"Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day"
223413717|NCT06963047|DIAGNOSTIC_TEST|Ultrasound|The purpose of the test is to diagnose and assess the amount of blood loss.
223413718|NCT06963047|OTHER|Standard care|Routine management
223413719|NCT06961279|DIETARY_SUPPLEMENT|Resveratrol|Administered orally once every 12 hours
223413720|NCT06961279|DIETARY_SUPPLEMENT|Placebo|Administered orally once every 12 hours
223413721|NCT04797611|DEVICE|TNM Device|Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive tvCVS device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
223413722|NCT03867409|BEHAVIORAL|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
223413723|NCT04901325|DRUG|Baricitinib|Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
223559860|NCT01037725|DRUG|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
223559861|NCT01037725|DRUG|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
223559862|NCT06525610|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|We will be assessing the use of weight-bearing CT, specifically its imaging, with RSA-like software, for analyzing fracture healing over time for a periprosthetic distal knee fracture.
223559863|NCT01905228|DRUG|CBL0137|"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
224031324|NCT02564874|OTHER|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
224031325|NCT04823221|DEVICE|Rezūm System|The basic principle of the Rezūm System is to deliver a controlled amount of sterile water vapor directly into the hyperplastic tissue in the transition zone of the prostate using a transurethral approach .The stored thermal energy in the vapor is transferred directly onto the cell membranes as the vapor condenses and releases the heat of condensation, causing cell death. Inaddition, this thermal energy transfer collapses the vasculature within the treatment zone, resulting in a bloodless procedure. During procedure the water vapor is created by a heating element in the Rezūm Delivery Device,Saline flush during vapor delivery protects and preserves the urethra.
224031326|NCT04281550|OTHER|Think Drink|The Think Drink Guide that had three interacting components. The 'policy' component was directed at the governance of the care home, whereas 'practice' components were directed at hydration procedures and processes, and 'educational' components that provided learning resources for care home staff to develop knowledge and understanding of hydration care. Think Drink was implemented through a short awareness-raising educational programme and accompanying information booklet detailing a range of practices (including organisational, system and individual practice) designed to encourage hydration.
224031327|NCT04835701|BEHAVIORAL|Music|Music may be played through a portable speaker in close proximity to the patient or through the patient's own headphones, if preferred. Music will be played at a low enough volume for subjects to hear standard anticipatory guidance during the procedure.
224135958|NCT05344976|BIOLOGICAL|MSLN STAR-T cells|Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
223559864|NCT06660927|DEVICE|liac Bifurcation Stent Graft System|to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
223559865|NCT06660706|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
223559866|NCT04410848|OTHER|To determine the diagnostic of Choledocholithiasis with symbolic regression model|To determine the diagnostic of Choledocholithiasis with symbolic regression model
223559867|NCT06659237|DIAGNOSTIC_TEST|16s rRNA or shotgun metagenomics|16s rRNA or shotgun metagenomics on oral and fecal samples
224135959|NCT04416126|BIOLOGICAL|ARCT-810|ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
224135960|NCT04416126|OTHER|Placebo|The placebo for this study is 0.9% sterile saline.
224135961|NCT03216317|BEHAVIORAL|Intervention Group|Isometric handgrip training consisting of four series
224298323|NCT02133586|OTHER|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
223559868|NCT04102124|DRUG|SHR3680|Tablet. Specifications of 80mg
223559869|NCT04102124|DRUG|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
223559870|NCT04102124|DRUG|SHR3680(Placebo)|Tablet. Specifications of 80mg
223559871|NCT04102124|DRUG|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
223413724|NCT06163820|DRUG|Bevacizumab|Bevacizumab is a humanised monoclonal antibody with molecular weight 167kD that inhibits all isoforms of the vascular endothelial growth factor (VEGF) and is produced from a Chinese hamster ovary mammalian system. It has high specificity for isoform-A and has a half-life of \~21 days.
224031328|NCT06795230|OTHER|Muscle strengthening (BFRT)|"The experimental group will perform a low-intensity strengthening program (20% 1RM) in combination with the BFRT system consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, performing 4 sets of 30/15/15/15 repetitions as usual in this type of interventions.~Once the first exercise has been completed, a rest of 3 - 4 minutes should be taken depending on the fatigue perceived by the patient. Subsequently, the other two exercises will be performed following the scheme already outlined.~Taking into account the scientific evidence concerning the safety and adverse effects linked to the BFRT system, it is determined that the pressure applied in the experimental protocol will be 60% of the TRP of each subject, following the recommendations that locate the effective pressure between 50 - 80% of the TRP of each subject."
223413725|NCT06163820|DRUG|Ipilimumab|Ipilimumab is an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Ipilimumab is a recombinant human immunoglobulin monoclonal antibody that binds CTLA4 and blocks the interaction between CD80/86 and CTLA4.
223413726|NCT06163820|DRUG|Nivolumab|Nivolumab ia an immune checkpoint inhibitor (ICI) that targets anti-tumour immunity. Nivolumab is a fully human monoclonal IgG4 antibody targeting PD-1 which demonstrates activity across a range of tumours.
223413727|NCT06163820|RADIATION|Hypofractionated stereotactic radiotherapy|Hypofractionated stereotactic radiotherapy (hSRT) will be delivered to previously untreated brain metastases in eligible participants. hSRT will be delivered to all symptomatic brain metastases, all brain metastases \>1 cm and all brain metastases located in eloquent areas of the brain. hSRT will be commenced after the first cycle of nivolumab plus ipilimumab and completed before the second cycle of nivolumab plus ipilimumab. hSRT should be commenced within 1 week from the planning MRI.
223413728|NCT05916144|BEHAVIORAL|Interaction-Based Early Education Program|The intervention program will be created based on the ETEÇOM model which is the Turkish adaptation of the Responsive Teaching Program developed in the United States. In this program, by improving the interactive behaviors of experts/educators or parents, the aim is for the child to acquire or develop 15 core behavior. Each session is planned to last between 60-90 minutes on average and will be conducted in a group format, consisting of 5 sessions, and can be conducted face-to-face or online.
223413729|NCT05872386|BEHAVIORAL|Buprenorphine uptake/retention via Telehealth|Bupe by the Book (BBB) randomly assigns unstably housed library patrons with opioid use disorder to a telehealth to receive buprenorphine (aka, Suboxone) treatment from Father Joe's Villages Health Center.
223413730|NCT05872386|BEHAVIORAL|Control group|unstably housed library patrons with opioid disorder are assigned randomly to a treatment as usual control group (in-person at the clinic)
223413731|NCT04509193|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)
223413732|NCT04509193|DRUG|Warfarin|Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
223413733|NCT03300505|DRUG|ARRx|Given intravenously (IV)
223413734|NCT03300505|DRUG|Enzalutamide|Given by mouth (PO)
223413735|NCT02905318|DRUG|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
224031329|NCT06795230|OTHER|Conventional physical therapy|The control group will perform a conventional muscle strengthening protocol consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, with a dumbbell at 70% of 1RM, performing a total of 4 sets of 8 - 12 repetitions each, avoiding muscle failure in each set.
224031330|NCT00830648|BIOLOGICAL|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
224031331|NCT04248270|DRUG|18F-PM-PBB3|All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
224031332|NCT03289377|BEHAVIORAL|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
224031333|NCT00602394|DRUG|Lithium|
223413736|NCT06240572|OTHER|no intervention|no intervention
223559872|NCT01221623|BIOLOGICAL|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
223559873|NCT01221623|BIOLOGICAL|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
223559874|NCT02279433|DRUG|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
223559875|NCT06991270|DEVICE|OMNI 3.0 Surgical System|Canaloplasty and trabeculotomy.
224031334|NCT00069316|DRUG|Omr-IgG-am|
224135962|NCT06471998|DRUG|Sodium Chloride injection|"Patients will receive a localized subcutaneous injection of 0.9% sodium chloride over 10 sessions (1 session per week), combined with standard treatment including stage I and II analgesics and physiotherapy in line with the recommendations of the French National Authority for Health.~At each session, 250ml to 500ml of physiological serum will be injected subcutaneously using a Meso-Kit-Perfuser\* or injection octopus positioned by the nurse according to the injection points defined by the investigating physician during the inclusion visit, with a dermographic tracer for surgical use."
224031335|NCT00756470|DRUG|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
223413737|NCT04254419|BIOLOGICAL|NK cells|"The universal donor TGFβi NK cells will be cryopreserved until they are delivered bedside for infusion. The trained staff will thaw the product by the bedside. The administration of the cells will be done via an Ommaya intra-cavitary/a programable ventriculoperitoneal (VP) shunt.~Once the infusion is ready for administration patients will be admitted to the infusion unit for monitoring. NK cells will be administered through the Ommaya/VP shunt in approximately 3 milliliters over approximately 2-5 minutes; followed by 1.5-2 milliliter preservative-free normal saline flush over approximately 1 minute."
223413738|NCT02822378|DIETARY_SUPPLEMENT|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
223413739|NCT02822378|DIETARY_SUPPLEMENT|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
223413740|NCT02822378|DIETARY_SUPPLEMENT|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
223413741|NCT00209963|DRUG|Gaboxadol|
223413742|NCT03756623|DRUG|Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
223413743|NCT03756623|DRUG|Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
223413744|NCT03756623|OTHER|Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
223738888|NCT03818828|OTHER|Cadexomer Iodine dressing|During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.
224031336|NCT00756470|DRUG|Paclitaxel|80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
224031337|NCT00756470|DRUG|5-Fluorouracil (5-FU)|500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
224031338|NCT00756470|DRUG|Epirubicin|75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
224031339|NCT00756470|DRUG|Cyclophosphamide|500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
224031340|NCT03434782|DRUG|In-office dental bleaching|The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
224031341|NCT03434782|DRUG|Low Level Laser Therapy|It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
224031342|NCT03434782|DRUG|5% potassium nitrate / 2% sodium fluoride gel|5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer's protocol.
224031343|NCT01006928|OTHER|Questionaire|Questionaire to mothers
224031344|NCT00820027|DRUG|Etoricoxib 90 mg|One 90 mg tablet once daily
224031345|NCT00820027|DRUG|Etoricoxib 120 mg|Two 60 mg tablets once daily
224031346|NCT00820027|DRUG|Ibuprofen 600 mg|One tablet three times daily
224031347|NCT00820027|DRUG|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
224031348|NCT00820027|DRUG|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
224031349|NCT00820027|DRUG|Matching Placebo for Ibuprofen|One tablet three times daily
224031350|NCT00820027|DRUG|Morphine|As needed via patient-controlled analgesia (PCA) device or as a bolus intravenous injection
224031351|NCT00820027|DRUG|Oxycodone|5 mg as needed
224031352|NCT04849936|DIAGNOSTIC_TEST|Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy|Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
224031353|NCT05300074|OTHER|Inspiratory Muscle Training|IMT is performed with an IMT Threshold flute that can be adjusted according to the MIP. The training resistance start at 60% MIP and is calculated weekly and end (if tolerated) at 80 % MIP.
224031354|NCT06001489|BEHAVIORAL|360-degree Virtual Reality Patient Tour|A 360-degree video that encompasses the entire clinical pathway. Patients are able to familiarize themselves with the hospital settings (nursery ward, operating room, intensive care unit).
224031355|NCT06001489|DIAGNOSTIC_TEST|State Trait Anxiety Inventory|Spielberger's State Trait Anxiety Inventory provides insight in the presence of anxiety.
224031356|NCT06001489|DIAGNOSTIC_TEST|Amsterdam Preoperative Anxiety and Information Scale|This validated questionnaire provides insight in the presence of anxiety. It also measures the need for information.
224031357|NCT05703867|DEVICE|Active microcurrent therapy|Non-invasive transpalpebral microcurrent therapy delivery to the upper and lower eyelids
224031358|NCT03285178|DRUG|IW-1701|Oral Tablet
224298324|NCT03233425|BEHAVIORAL|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
224298325|NCT04273581|DRUG|placebo|100mg/d，qn，for 14 days.
224031359|NCT03285178|DRUG|Placebo|Oral Tablet
224031360|NCT02376075|DRUG|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
224031361|NCT02376075|DRUG|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
224031362|NCT03292718|DEVICE|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
224031363|NCT01388790|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m\^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
224031364|NCT01388790|DRUG|Cisplatin|Cisplatin 60 mg/m\^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
224298326|NCT04273581|DRUG|Thalidomide|100mg/d，qn，for 14 days.
224298327|NCT00700323|DIETARY_SUPPLEMENT|PS-Omega3 conjugate supplementation|
224031365|NCT01388790|DRUG|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m\^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
223413745|NCT06339866|OTHER|The Effect of Two Different Video Interventions on Pain and Anxiety in Children with Adenotonsillectomy: A Randomized Controlled Study|The population of the study will be all patients who had adenotonsillectomy surgery between the ages of 6-12 in the Ear Nose and Throat Service of Zonguldak Bülent Ecevit University Hospital, and the sample will be all patients who had adenotonsillectomy surgery between the specified dates and who meet the inclusion criteria.
224031366|NCT01128894|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
224031367|NCT01128894|DRUG|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
223413746|NCT05669326|OTHER|NODDI TRACT|"Compared to their usual management, the participation of the patient in this study implies an additional visit during which an MRI examination without contrast injection will be performed, lasting approximately 40 minutes (including installation and deinstallation).~The operative time, surgical procedures and postoperative follow-up are not modified in this study."
223413747|NCT04152772|DEVICE|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
224031368|NCT04785235|PROCEDURE|Non-Surgical Periodontal Therapy|
224031369|NCT03758287|DRUG|CT053PTSA|
224135963|NCT02724774|BEHAVIORAL|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
224135964|NCT06130852|BEHAVIORAL|Behavioral Parent Training|10 thematic sessions aimed at changing the parent's view of their child by encouraging them to focus on appropriate behaviors. The sessions focus on specific themes such as positive attention, the principle of reinforcement, or even homework management.
224135965|NCT04533815|BEHAVIORAL|LOCK sleep intervention|Nursing home staff are trained to use a collaborative problem-solving approach to sleep quality improvement using front-line huddling
223413748|NCT02313493|BEHAVIORAL|Baby Triple P|
223413749|NCT01468194|OTHER|Breathing procedure 1|inhalation during one step, exhalation during the next step
223413750|NCT01468194|OTHER|Breathing procedure 2|inhalation and exhalation during one step
224031370|NCT03758287|DRUG|Gefitinib|
224031371|NCT02091050|OTHER|2D HDR planning|HDR planning using simple radiograph (2D)
224031372|NCT02091050|OTHER|3D HDR planning|HDR planning using computed tomography (3D)
224031373|NCT00334724|PROCEDURE|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
224031374|NCT00334724|PROCEDURE|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
224031375|NCT00755651|PROCEDURE|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
224135966|NCT06041295|BEHAVIORAL|on-the-job training of lung expansion therapy|on-the-job training of lung expansion therapy
224135967|NCT02130258|DEVICE|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
223413751|NCT03100968|PROCEDURE|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
223413752|NCT03100968|DEVICE|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
223413753|NCT02731651|PROCEDURE|open hysterectomy|Hysterectomy with laparotomy incision.
223413754|NCT02731651|PROCEDURE|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
223413755|NCT03025932|PROCEDURE|repair of giant hiatal hernia with mesh and anterior fundoplication|
223413756|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
223413757|NCT02664467|DEVICE|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
224031376|NCT01366287|DRUG|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
224031377|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
224031378|NCT01366287|DRUG|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
224031379|NCT02725099|DRUG|Chewing Ticagrelor|180 mg Chewing Ticagrelor
224031380|NCT02725099|DRUG|Oral Ticagrelor|180 mg oral Ticagrelor
224031381|NCT00195507|DRUG|Etanercept|
224031382|NCT00370409|PROCEDURE|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
224031383|NCT00973362|DEVICE|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
224135968|NCT02130258|PROCEDURE|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
223738889|NCT06327451|DRUG|Atorvastatin 20mg|Liptor is a capsule in the form of 20 mg, once daily.
224135969|NCT03914495|DIETARY_SUPPLEMENT|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
224135970|NCT03914495|DIETARY_SUPPLEMENT|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
224135971|NCT05600647|DEVICE|Electromagnetic Field therapy with an exercise program|"1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training"
224031384|NCT00973362|DEVICE|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
224031385|NCT03754413|DEVICE|experimental|Neuramis® Deep Lidocaine
224135972|NCT05600647|OTHER|exercise program|the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
224135973|NCT00488592|BIOLOGICAL|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
224135974|NCT00488592|BIOLOGICAL|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
224135975|NCT00488592|DRUG|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
224298328|NCT00700323|DIETARY_SUPPLEMENT|placebo|
224298329|NCT02159781|PROCEDURE|periodontal treatment - scaling and root planning|
223413758|NCT06619353|DIAGNOSTIC_TEST|Blood Sample|Patients' blood samples are tested at 1 month, and then annually for 3 years post-intervention to assess residual thrombotic, metabolic, and inflammatory risk.
223413759|NCT06619353|OTHER|DICOM Dataset|Patients' DICOM dataset is evaluated using artificial intelligence-based quantitative coronary analysis to assess a procedural risk.
223413760|NCT00343226|DRUG|Basiliximab|
223413761|NCT04441320|DEVICE|Coated metal ureteral stent(CMUS)|Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
223413762|NCT04441320|DEVICE|Double-J stent(DJS)|Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
223413763|NCT06280274|DRUG|Metformin|Metformin 500mg oral once daily for 7 days, increased to 1000mg (500mg twice daily) for another 7 days, taken in morning and evening with meals, for a total of 14 days of treatment prior to surgery. Continue dose on day of surgery and up to post operative day 2, or until time of discharge, whichever happens first.
223413764|NCT06280274|OTHER|Placebo|Placebo tablet
223413765|NCT04858490|DRUG|Diazepam|Symptom-triggered diazepam treatment: 10 or 20mg, at the clinician's discretion
223413766|NCT03494231|DRUG|HLX06|recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
223413767|NCT06665191|OTHER|No Intervention: Observational study for prevalence of dental wear and its association with quality of life|not applicable as it is an observational study testing the prevalence of dental wear in patients attending Cairo University
224031386|NCT03754413|DRUG|comparator|No-treatment
224031387|NCT02674789|BEHAVIORAL|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
223413768|NCT05173831|DRUG|Midomafetamine|Initial dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later
223413769|NCT05173831|BEHAVIORAL|Therapy|Manualized therapy performed by therapist team
223413770|NCT03056638|DRUG|Degarelix|Degarelix monthly for 6 months
223413771|NCT03056638|RADIATION|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
224031388|NCT05543486|DEVICE|Levitation 2 Tri-Compartment Offloader (TCO) knee brace|Spring Loaded Technology Levitation 2 Tri-Compartment Offloader (TCO) brace containing proprietary spring technology providing a knee extension assist.
224031389|NCT05543486|DEVICE|Knee sleeve|Neenca soft knee sleeve comprised of elastic air knit fabric with a silicone padded patella inset and flexible stays on the medial and lateral sides.
224031390|NCT00897416|OTHER|laboratory biomarker analysis|
224031391|NCT03480256|DRUG|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
224031392|NCT02843204|DRUG|Pembrolizumab|Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
224031393|NCT02843204|BIOLOGICAL|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
224031394|NCT01969825|BEHAVIORAL|Massage|
223413772|NCT01811641|OTHER|season, dietary intake|
223413773|NCT00468481|DRUG|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
224031395|NCT04196153|PROCEDURE|Pedicle screws instrumentation|The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.
224031396|NCT00959166|OTHER|PET scan|PET brain scan
224031397|NCT01412099|BEHAVIORAL|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
224031398|NCT01412099|BEHAVIORAL|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
224031399|NCT00931554|PROCEDURE|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
224031400|NCT06091761|OTHER|Auricular acupuncture|Auricular acupuncture is conducted weekly in eight weeks using patches, each with a square shape and a side length of 10 mm, along with sterilized needles measuring 0.25 x 1.3 mm. Five acupoints on one ear are selected, which included Shen-men (TF4), Stomach (CO4), Spleen (CO13), Endocrine (CO18), and Hunger point. The patch with the needle will remain in place for one week.
224031401|NCT06091761|OTHER|Thread embedding acupuncture|Thread embedding acupuncture is performed every two weeks in eight weeks using a single Polydioxaone thread. Needles has a gauge size of 29G, a shaft length of 38mm, and a thread length of 50mm, folded in half, and are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles with a gauge size of 30G, a shaft length of 25mm, and a thread length of 30mm, folded in half, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the thread being inserted into the body, the needle will be withdrawn immediately.
224031402|NCT06091761|OTHER|Sham Thread embedding acupuncture|Sham Thread embedding acupuncture is performed every two weeks in eight weeks. Needles without threads has a gauge size of 29G, and a shaft length of 38mm, are applied to ten acupoints, including Qihai (CV6), Shuifen (CV9), and Tianshu (ST25), Shuidao (ST28), Daheng (SP15), Siman (KI14) on both sides of the body. Needles without threads with a gauge size of 30G, and a shaft length of 25mm, are used for five acupoints, which included Zhongwan (CV12) and Zusanli (ST36), Pishu (BL20) on both sides of the body. After the needle being inserted into the body, it will be withdrawn immediately.
224031403|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
224031404|NCT00393328|DRUG|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
224031405|NCT05975801|OTHER|Dry Cupping Therapy|
224298330|NCT05717855|DIAGNOSTIC_TEST|Displaying optic chiasm for screening septooptic dysplasia|Displaying and measuring the width and length of the optic chiasm for screening septooptic dysplasia with ultrasound between 16-20 weeks of gestation
224298331|NCT04415736|OTHER|No intervention, observational study|
224298332|NCT04413136|BEHAVIORAL|Web-ORLA|
224298333|NCT04413136|BEHAVIORAL|Control|
223413774|NCT00468481|DRUG|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
223413775|NCT01451528|BIOLOGICAL|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
223413776|NCT00734162|DRUG|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
223413777|NCT00734162|DRUG|Placebo|TDF placebo tablet once daily
223413778|NCT04290715|OTHER|no intervention|no intervention
223413779|NCT02008474|BEHAVIORAL|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
223413780|NCT02008474|BEHAVIORAL|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
223413781|NCT02008474|BEHAVIORAL|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
223413782|NCT02008474|BEHAVIORAL|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
223413783|NCT04050878|DEVICE|Facial scanner (Bellus3D) to assess perioral alterations|Use of a digital caliper for conventional measurements and a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
223413784|NCT03831113|DRUG|Magnitude Group|Dose reductions will alternate between 1mg or 2 mg weekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
223413785|NCT03831113|DRUG|Frequency Group|Dose reductions of 2 mg will occur alternate between once weekly to biweekly until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
223413786|NCT01838564|OTHER|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
223413787|NCT01838564|OTHER|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
223738890|NCT01797601|DRUG|Human Insulin|160 U of insulin
224298334|NCT03516396|BEHAVIORAL|Training Plus|Training plus enhanced community development activities
223413788|NCT03484663|DEVICE|central venous catheter (small catheter drainage)|Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
223413789|NCT04017507|DEVICE|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
223413790|NCT04017507|DEVICE|Side-to-side electric toothbrush|Side-to-side electric toothbrush used twice daily
223413791|NCT04017507|DEVICE|Manual toothbrush|Manual toothbrush used twice daily
223413792|NCT03485807|BEHAVIORAL|Mindfulness Training (MT)|2 week SmartPhone-based mindfulness training
223413793|NCT03485807|BEHAVIORAL|Active Coping Training (CT)|2 week SmartPhone-based structurally equivalent coping training
223738891|NCT01797601|DRUG|Placebo|Insulin dilution medium without insulin
223413794|NCT02547415|OTHER|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~* Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~* Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
223559876|NCT05906134|PROCEDURE|Local intercostal nerve block|Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
223559877|NCT05906134|PROCEDURE|Cryo-analgesia and intercostal nerve block|The cryo-ablation will occur 2 cm from the sympathetic chain 2 intercostal spaces above and 2 intercostal spaces below the access incision. The patient will also receive a total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
223559878|NCT05906134|PROCEDURE|Serratus plane catheter blocks and intercostal nerve blocks|A total of 1.2 cc/kg of 0.25% Bupivacaine + epinephrine will be administered. A total of 20 cc of the weight-based calculation will be reserved for the serratus plane catheter. The remaining local anesthetic will be divided into two-thirds for the chest and one-third for the abdomen. Patients with serratus plane catheters will have an ongoing infusion of 0.2% ropivacaine at 8 ml per hour. The serratus plane catheters will also receive a bolus of 20 ml of 0.25% bupivacaine with epinephrine on POD #1, 2, 3, 4, and 5 by the pain service.
223559879|NCT05906134|PROCEDURE|Thoracic epidural catheter|"The pain service and thoracic surgery attending physician will assess if the patient's pain is not well-controlled using the pain modality they are randomized to. If additional pain control is needed, this will likely consist of a thoracic epidural catheter.~Any additional pain control will be added as an adjunct to the study arm and will be noted in the data set."
224031406|NCT05975801|OTHER|Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound|
224031407|NCT00975351|DIETARY_SUPPLEMENT|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
224031408|NCT03774251|BIOLOGICAL|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
224031409|NCT03774251|DEVICE|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
224031410|NCT01951781|OTHER|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
224031411|NCT05155241|BEHAVIORAL|online health promotion video|Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
224135976|NCT00488592|BIOLOGICAL|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
224135977|NCT05393076|DRUG|Linerixibat|Linerixibat dose and administration as per study intervention.
224135978|NCT05651217|DEVICE|disposable urinary catheter|The trial group was intervened with disposable sterile urinary catheter. The model of the trial group includes two chamber type (Fr8, Fr10, Fr12, Fr14, Fr16, Fr18, Fr20, Fr22, Fr24) and three chamber type (Fr16, Fr18, Fr20, Fr22, Fr24).
224135979|NCT05651217|DEVICE|super smooth antibacterial urinary catheter|the control group was intervened with ultra smooth antibacterial catheter. The control group models include single chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr), double chamber (6Fr, 8Fr, 10Fr, 12Fr, 14Fr, 16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr, 28Fr, 30Fr), and three chamber (16Fr, 18Fr, 20Fr, 22Fr, 24Fr, 26Fr)
224031412|NCT05155241|BEHAVIORAL|Control (same online health promotion video)|Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
224031413|NCT00524719|PROCEDURE|Open Reduction and Internal Fixation|Fixation with volar locked plate
224031414|NCT00524719|PROCEDURE|Non-Spanning External Fixation|Radio-radial external fixation
224031415|NCT00524719|PROCEDURE|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
224031416|NCT01837355|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|
224031417|NCT01837355|DIETARY_SUPPLEMENT|Placebo|
224135980|NCT00327548|BEHAVIORAL|guided imagery|
223413795|NCT03573557|DEVICE|Pink Pad|Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.
223413796|NCT03573557|DEVICE|Bean Bag|Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
224031418|NCT02311998|DRUG|Bosutinib|Given PO
224135981|NCT05475912|OTHER|Group A, excercises|Each group will receive treatment three times per week for 3 weeks total 7 sessions.
224135982|NCT04930211|DRUG|Dexamethasone-Lidocaine|Kambin's triangle approach in transforaminal epidural injection: Kambin's triangle is defined as a right triangle over the dorsolateral disc. The hypotenuse is the exiting nerve root, the base is the superior border of the caudal vertebra, and the height is the dura/traversing nerve root. it is possible to inject agents at the entrance and middle zone as the main areas of nerve entrapment by injecting at the retrodiscal area of the entrance zone, as proximal area of the targeted nerve root.
224135983|NCT00825955|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
224135984|NCT00825955|OTHER|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
223413797|NCT03573557|DEVICE|Gel Pad|Gel Pad used for patients in steep Trendelenburg position during surgery.
223413798|NCT03508726|DRUG|Ascorbate|"Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV"
223413799|NCT00924495|DEVICE|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
224031419|NCT02311998|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
224031420|NCT00769613|BIOLOGICAL|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
224031421|NCT00769613|BIOLOGICAL|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
224031422|NCT00769613|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224031423|NCT00769613|GENETIC|polymerase chain reaction|
224031424|NCT00769613|OTHER|flow cytometry|
224031425|NCT00769613|OTHER|immunological diagnostic method|
224031426|NCT00769613|OTHER|laboratory biomarker analysis|
224031427|NCT03241212|BEHAVIORAL|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
224031428|NCT01630434|DEVICE|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
224031429|NCT01630434|DEVICE|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
224031430|NCT06310057|DRUG|Tofacitinib|Tofacitinib (JAKi) is a targeted therapy option for patients with refractory ax-SpA.
224031431|NCT05203354|RADIATION|Narrowband Ultraviolet B|patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months
224031432|NCT05203354|DRUG|Acitretin|patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
224031433|NCT02766894|DEVICE|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
224135985|NCT00825955|PROCEDURE|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
224135986|NCT05895227|PROCEDURE|Oocyte retrieval|
224135987|NCT05903391|DEVICE|3D-Printed Finger Splints|The intervention is wearing a novel finger splint produced by a 3D-printer
223413800|NCT05321238|OTHER|High agency and immediate threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
223413801|NCT05321238|OTHER|High agency and distant threat|Participants were asked to make several decisions for the main character in the interactive digital narrative that related to drinking / turning down alcoholic drinks.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
223413802|NCT05321238|OTHER|Low agency and immediate threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from acute alcohol poisoning after ingesting too much alcohol in a short period of time.
223559880|NCT07001215|DEVICE|In the intervention group, patients will be treated with auto-adjusting APAP, providing variable pressures throughout the sleep hours.|AutoCPAP will be prescribed to patients undergoing bariatric surgery.
224031434|NCT05158998|DRUG|propofol infusion|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
224031435|NCT05158998|DRUG|sevoflurane inhalation|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
223559881|NCT07001215|DEVICE|CPAP|In the control group, patients will be treated with CPAP.
224031436|NCT00921960|OTHER|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
224031437|NCT03920709|OTHER|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
224031438|NCT00316134|PROCEDURE|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
224031439|NCT05140733|PROCEDURE|lumbar foraminal decompression|lumbar foraminal decompression with endoscopic instruments.
224031440|NCT05140733|PROCEDURE|Fusion surgery|Fusion surgery for patients with foraminal stenosis
224031441|NCT04855266|DRUG|Sucrose|5 mg/kg of intravenous iron sucrose (maximum dose of 200 mg). Iron sucrose will be diluted
224031442|NCT04855266|DRUG|Placebo|Normal saline (NaCl 0.9%) 5 mL/kg (maximum volume 210 mL)
224031443|NCT04855266|DIAGNOSTIC_TEST|Tilt Table Test|A table that adjusts the body position from horizontal to vertical to simulate standing up. Heart rate and blood pressure are monitored throughout the test.
224135988|NCT05903391|DEVICE|Conventional Finger Splints|This intervention is wearing a finger splint produced by a conventional method using thermoplastic material typically used in a clinical setting
224135989|NCT02210871|DRUG|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
224135990|NCT06250517|DEVICE|EVLP|The right lung will be perfused for 3h with EVLP
224135991|NCT06250517|DEVICE|Cold preservation|The left lung will be cold preserved as usual protocol
224135992|NCT00005096|DRUG|docetaxel|
224135993|NCT05943327|DRUG|Lu AG06474|Oral Solution
224135994|NCT05943327|DRUG|Placebo|Oral Solution
224135995|NCT05943327|DRUG|Lu AG06474|Capsule
223413803|NCT05321238|OTHER|Low agency and distant threat|Participants were asked to read a narrative in which the main character turns down alcoholic drinks at a party. The participants can not influence the decisions of the main character and only consume the narrative passively.The decisions made lead to a ending consistent with the decisions of the participant. In the story presented, a character dies from multiple organ failure after ingesting too much alcohol over a long period of time.
223413804|NCT04544202|DRUG|Dabrafenib and Trametinib|"The starting dose of the combination treatment will be administered as follows:~* Dabrafenib, 150 mg, twice daily (BID);~* Trametinib, 2.0 mg, once daily (QD)"
223413805|NCT04544202|DRUG|Dabrafenib|If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
223413806|NCT04544202|DRUG|Trametinib|If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
224135996|NCT06616766|DRUG|YH42946|YH42946
224135997|NCT02955654|BEHAVIORAL|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
224135998|NCT02955654|DRUG|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
223413807|NCT00765518|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
223413808|NCT00765518|OTHER|Standard of Care|Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
223413809|NCT00003446|DRUG|fluorouracil|
223413810|NCT00003446|DRUG|leucovorin calcium|
223413811|NCT00003446|DRUG|trimetrexate glucuronate|
223559882|NCT07003893|OTHER|Diaphragmatic Proprioceptive Neuromuscular Facilitation + Aerobic exercises|Control group will perform aerobic exercises only Experimental group will perform diaphragmatic proprioceptive neuromuscular facilitation in addition to aerobic exercises
223559883|NCT04066504|DRUG|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
223738892|NCT04170283|DRUG|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily (for a total daily dose of 320 mg), or the last dose level received in the BeiGene parent study.
224031444|NCT04359251|OTHER|Gas exchanges at different PEEP|Gas exchanges measurement at different PEEP
224135999|NCT02955654|BEHAVIORAL|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
224136000|NCT03253991|DEVICE|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
224136001|NCT05836818|OTHER|Question (Q)|Flu vaccine acceptance question: a question asked of participants about their willingness to accept a flu vaccine
224136002|NCT05836818|OTHER|Messaging (M)|Flu vaccine educational materials -videos and flyers containing flu vaccine educational information
224136003|NCT04702555|DRUG|VTS-K|An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
224136004|NCT03218423|DEVICE|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
224136005|NCT00918476|DRUG|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
224031445|NCT04359251|OTHER|lung mechanics at different PEEP|lung mechanics measurement at different PEEP
224031446|NCT04359251|OTHER|Hemodynamics changes at different PEEP|Hemodynamics changes measurement at different PEEP
224031447|NCT04905147|DRUG|Mosapride|Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
224031448|NCT04905147|DRUG|Placebo|Placebo drug 15 mg
224031449|NCT04089969|DIAGNOSTIC_TEST|CTA/FFRct|Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
224031450|NCT04089969|DIAGNOSTIC_TEST|SOC cardiovascular evaluation|Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
224031451|NCT06023277|BIOLOGICAL|ConvitVax|ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
224136006|NCT03551301|OTHER|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
224031452|NCT05221463|BEHAVIORAL|Video-assisted breastfeeding training|Breastfeeding training was given to the experimental group for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and routinely used by nurses in breast milk training in neonatal units. During the training, mothers were allowed to watch breast milk and breastfeeding training videos. On the third day after the training, feedback was received from the applications in the video regarding the knowledge and skills of the mother, and the mother's questions were answered.
224031453|NCT05221463|BEHAVIORAL|The hospital's routine general breastfeeding training|The control group was given the hospital's general breastfeeding training for 3 days by means of the training material prepared by the training nurse of the hospital about breast milk and breastfeeding and used routinely by nurses in breast milk training in neonatal units, and the questions of the mother were answered. The mothers in this group performed the routine breastfeeding process and no other interventions were made.
224031454|NCT04932538|OTHER|Kİnesio Taping|Kinesio Taping® (KT) is used for pediatric rehabilitation to reduce pain, facilitate or inhibit muscle activity, prevent injuries, reposition joints, aid the lymphatic system, support postural alignment, and improve proprioception
224031455|NCT01050348|DRUG|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
224031456|NCT01050348|DRUG|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
224031457|NCT01135706|OTHER|No Intervention|This study does not include an intervention but is observational in nature.
224031458|NCT03193489|OTHER|Follow-up|
224031459|NCT03193489|OTHER|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
224031460|NCT03193489|OTHER|Control Parkinson group|No treatment.
224031461|NCT04476056|OTHER|Intensified Nutritional Therapy|Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
224031462|NCT01862133|OTHER|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
224031463|NCT02645695|DEVICE|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
224031464|NCT02645695|DEVICE|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
224031465|NCT01578759|PROCEDURE|Salpingectomy|Removal of the fallopian tubes
224031466|NCT03675672|DRUG|Misoprostol Oral Tablet|Misoprostol 200mcg
224031467|NCT03675672|DRUG|Placebo Oral Tablet|Placebo Tablet
224031468|NCT02804178|DRUG|ATR-101|125-1000 mg twice per week
223413812|NCT03617614|BEHAVIORAL|Collaborative Care Model|"Trained care managers (CM) work collaboratively with patients, caregivers, and primary care providers to provide education, care navigation and behavioral activation. The latter includes a stepped psychotherapy intervention called ENGAGE, that focuses on reward exposure engagement in meaningful, rewarding activities for patients. Patients (home) visits are delivered over a period of 6 to 16 weeks. Progress is assessed with standardized measures for depression (PHQ-9), anxiety (GAD-7) and functioning (WHO-DAS). Furthermore, patients are presented by the CM at Systematic Case Review meetings where an integrated team of medical, psychiatric and allied health professionals work collaboratively to review the patient's goals and treatment to formulate a care plan and recommendations."
223413813|NCT03617614|BEHAVIORAL|Mood Consultation|A meeting with a psychiatrist to do assessment, provide education and make recommendations regarding the care of the patient for the Primary Care Provider.
224031469|NCT00529022|DRUG|Azacitidine|75 mg/m\^2 Subcutaneous Injection or by vein Daily for 5 Days.
224031470|NCT00529022|DRUG|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
224031471|NCT00529022|DRUG|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
224031472|NCT00874666|OTHER|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
224031473|NCT00874666|DIETARY_SUPPLEMENT|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
224031474|NCT01106404|DEVICE|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
224031475|NCT01723813|BIOLOGICAL|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
224031476|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
224031477|NCT01723813|BIOLOGICAL|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
224031478|NCT02004548|DRUG|Metatinib Tromethamine|
224031479|NCT02190669|OTHER|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
224031480|NCT03580772|DEVICE|Persona TKR|Persona® TKR (Zimmer Biomet)
224031481|NCT03580772|DEVICE|Attune TKR|Attune® TKR (Depuy synthes)
223413814|NCT06274073|PROCEDURE|Dorsal digital block|Dorsal regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedure mentioned are compared)
223413815|NCT06274073|PROCEDURE|Palmar digital block|Palmar regional digital block anesthesia (No drug or device is being investigated here; the two digital block procedures mentioned are compared)
223413816|NCT04134429|DEVICE|Everion|The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
224031482|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
224031483|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
223413817|NCT00741676|PROCEDURE|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3\~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
223413818|NCT00741676|PROCEDURE|open distal gastrectomy|Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
223413819|NCT03578796|DIAGNOSTIC_TEST|ECAS-N|assessing ALS-specific cognitive impairment
224031484|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
224031485|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
224031486|NCT00775450|BIOLOGICAL|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
224136007|NCT05930392|PROCEDURE|Gingival depigmentation using microsurgery|GINGIVAL DEPIGMENTATION USING MICROSURGICAL BLADE AND MAGNIFICATION LOUPES
223413820|NCT03578796|DIAGNOSTIC_TEST|MoCA|assessing cognitive impairment
223413821|NCT03578796|DIAGNOSTIC_TEST|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
223413822|NCT03578796|OTHER|Questionnaire|Questions related to work situation and car driving
223413823|NCT00465296|DRUG|rosiglitazone|
223413824|NCT00875108|DRUG|VIAject™|Subcutaneous injection 25 IU/mL
223413825|NCT01515865|DRUG|Midodrine HCl|dose at subject's current dose level
223413826|NCT01515865|DRUG|Placebo|single dose of matching placebo
223413827|NCT06158984|DEVICE|IPL|Intense pulse light (IPL) therapy is used for the treatment of drug-related dry eye in glaucoma patients.
223413828|NCT05170152|PROCEDURE|ultrasonography-guided injection|ultrasonography-guided injection
223413829|NCT05170152|PROCEDURE|pullae A1 release|ultrasonography-guided pullae A1 release
223413830|NCT04689373|DIAGNOSTIC_TEST|VAS Score|"The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain.~The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills."
224031487|NCT03099317|OTHER|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
224031488|NCT03099317|OTHER|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
224031489|NCT00939679|PROCEDURE|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
224136008|NCT05930392|PROCEDURE|Conventional surgical depigmentation|GINGIVAL DEPIGMENTATION USING CONVENTIONAL SURGICAL TECHNIQUE
224136009|NCT03977727|DRUG|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
224136010|NCT03977727|DRUG|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
224136011|NCT03977727|DEVICE|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
224031490|NCT00939679|DIETARY_SUPPLEMENT|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period."
224298335|NCT03516396|BEHAVIORAL|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
224298336|NCT03516396|BEHAVIORAL|No Inputs then Community development and training|No inputs for 24 months then add community development and training
224298337|NCT04763018|DEVICE|iTEAR100|Neurostimulation external nasal nerve to stimulate tear production
224298338|NCT02070302|DRUG|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
224298339|NCT02070302|DRUG|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
223413831|NCT04065971|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
224031491|NCT06224608|BIOLOGICAL|Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC)|"1.0ml/bottle, containing 2.5μg/ml low dose, 5μg/ml medium dose, and 10μg/ml high dose of active ingredient.~Take 0.1ml and inject it into the center of the front 1/3 of the palm side of the forearm by the Montessori method Single dose administration."
224136012|NCT04355312|DIAGNOSTIC_TEST|Use of Indocyanine Green in laparoscopic ovarian cystectomy|"During intraperitoneal cystectomy or Plasmajet destruction of the cyst, as a benign organic cyst requiring surgical treatment, peroperatively, at the end of the cystectomy procedure, injection by the anesthetist on a peripheral venous route of a bolus of Indocyanine green diluted 0.2mg / kg. Installation of the SPIES camera system (KARL STORZ GmbH \& Co.KG, Tuttlingen, Germany).~Evaluation of the degree of fluorescence at the location of cystectomy or destruction of the cyst.~A fluorescence score between 0 and 4 (on the model of a Likert scale) will be used for the evaluation of fluorescence.~A second reading of the Likert scale results will be carried out by a second inspector so that the score is as objective as possible. Then, second evaluation technique realized by the METAMORPH software, which will assign a raw and objective score according to the fluorescence visualized."
223413832|NCT04065971|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
223413833|NCT03836183|DIAGNOSTIC_TEST|Pleuropulmonary ultrasound with clinical examination|Pleuropulmonary ultrasound associate with a clinical examination
224136013|NCT02661607|PROCEDURE|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
224136014|NCT02661607|DEVICE|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
224136015|NCT02661607|PROCEDURE|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
223413834|NCT05331443|DIAGNOSTIC_TEST|Reactive hyperemia-peripheral arterial tonometry Index (RHI )|RHI was assessed by RH-PAT using the EndoPAT2000 system .
223413835|NCT04953689|BEHAVIORAL|Conscientiousness Coach|Participants will use the Conscientiousness Coach app to organize their goals and assist them in engaging in more conscientious behaviors. The participant will also be educated about Conscientiousness as it relates to healthy living and accomplishing life goals and values. Participants will receive brief phone calls during weeks 1, 2, 6, and 10 from the research assistant, tracking progress, answering queries, and return visits to the clinic/teleconference will be scheduled for further assistance during week 4 and week 8. These mid-study visits (or 'Booster Sessions') will last approximately 50 minutes and will involve a brief discussion of goal and value progress and app usage; at this in-person meeting/teleconference, similar questions and topics will be covered as in the bi-monthly phone calls. At week 12, there is a treatment termination visit with the principal investigator and research assistant.
223413836|NCT06557629|DIAGNOSTIC_TEST|Ultrasound assessment|Ultrasound assessment of gastric residual volume
223413837|NCT03520777|OTHER|Art Intervention|Type of artist intervention will be determined by the subject and the assigned artist.
223413838|NCT06968507|DRUG|Methylprednisolone (drug)|In our study, we use methylprednisolone as a oral treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days)
223413839|NCT06968507|DRUG|Dexamethasone|In our study we use dexamethasone 8mg/2ml form as intratympanic treatment every other day, totally 4 doses.
223413840|NCT06967207|OTHER|Not applicable- observational study|Not applicable- observational study
223413841|NCT06967532|DIAGNOSTIC_TEST|Blood test|Blood sampling
223413842|NCT01482637|OTHER|CAS|All clients will be asked to complete the CAS instrument.
224031492|NCT03651583|BEHAVIORAL|Kiko exercises-combines breathing and movement|
224031493|NCT05270785|OTHER|STAT-PC|STAT-PC is an adapted version of Suicidal Teens Accessing Treatment after an ED Visit (STAT-ED). It is a brief intervention based on motivational interviewing (MI) that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management (2-3 follow-up calls). The intervention will consist of an initial session with the youth focusing on accessing mental health care plus two case management calls. The interventionist will also be available to assist with referrals for connection to other services later during the study period as needed for up to two months. The intervention may include contact with the youth's mental health provider to make sure linkages are made.
224031494|NCT05270785|OTHER|YST-III|YST-III is an adapted version of Youth-Nominated Support Team for Suicidal Adolescents (YST-II). The intervention is a brief intervention developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation (SI). Participants will nominate 1-2 supportive adults (age 18 and older) from their lives who agree to provide ongoing contact and support for up to 2 months. YST-III will include an introductory session with the youth who will nominate their support persons plus referrals for mental health services. The support persons will receive training on how to best support their youth partner and then ongoing calls to support them in working with their youth partner for up to 2 months.
224031495|NCT00803829|OTHER|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
224136016|NCT06499545|OTHER|Pressure release|Release of pre-pressure at the latent trigger point of flexor digitorum brevis
224136017|NCT06499545|OTHER|Non emision Laser|Non emision laser in Flexor digitorum brevis latent trigger point
224136018|NCT00862966|OTHER|citrate|comparison of different catheter lock solutions
224136019|NCT00862966|OTHER|heparin|comparison of different lock solutions
224298340|NCT02979236|DEVICE|STENTYS Xposition S|
224298341|NCT05017259|DIETARY_SUPPLEMENT|calorie restriction diet|The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
224031496|NCT00931333|PROCEDURE|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
224031497|NCT00438347|BEHAVIORAL|Aerobic Exercise|One hour per day three times a week for one year
224031498|NCT00438347|BEHAVIORAL|Stretching and toning|One hour per day three times a week for one year
224031499|NCT01094379|PROCEDURE|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
224031500|NCT01094379|PROCEDURE|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
224031501|NCT05295680|DRUG|Hymecromone|Hymecromone 400 mg 3 times daily by mouth.
224031502|NCT04460014|BEHAVIORAL|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
224031503|NCT04460014|BEHAVIORAL|Attention Placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
224031504|NCT03820089|DIAGNOSTIC_TEST|Ultrasonography TP|TP us will be made to the included women
223413843|NCT06047678|BEHAVIORAL|Cardiovascular fitness|A randomized single-blind controlled trial tested the hypothesis that different variants of resistance training (antagonistic lower and upper body training, agonistic lower and upper body training, and aerobic training) have different effects on blood pressure (systolic and diastolic), aortic pulse wave velocity (PWVao), and augmentation index (Aix) values and compared subjects with normotension and hypertension during and after exercise session.
224031505|NCT03772353|DRUG|Dalpiciclib|Dalpiciclib (SHR6390) is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.
224031506|NCT03772353|DRUG|Pyrotinib|Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC)
224031507|NCT03772353|DRUG|Letrozole|Letrozole, a third-generation aromatase inhibitor, is the principal drug used in the treatment of postmenopausal patients with both early- and advanced-stage endocrine-responsive breast cancer (BC).
224031508|NCT03772353|DRUG|Fulvestrant|Fulvestrant is a selective oestrogen receptor (ER) degrader used in postmenopausal women with hormone receptor-positive advanced breast cancer
224136020|NCT03037658|OTHER|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
224031509|NCT04727879|PROCEDURE|Synovial membrane biopsy with puncture of synovial fluid|The biopsy of the shoulder bursae will be carried out thanks to a device Tru-cut (Tru-Cut Biopsy Needle), minimally invasive, introduced, as during an infiltration, within the bursa serosa.
224031510|NCT04727879|PROCEDURE|Joint fluid sampling|In case of associated peripheric arthritis, the patient will also be offered a sample of joint fluid during a cortisonic infiltration for analgesic purposes, performed as part of routine care.
224136021|NCT04190784|OTHER|Stretching exercises|Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
224136022|NCT04190784|OTHER|Placebo stretching|The therapist maintains the same manual contact without stretching force.
224031511|NCT04727879|PROCEDURE|Blood sample|A blood sample taken during routine care and unused will also be collected from patients and controls for immunoassays.
224031512|NCT00005074|DRUG|alvocidib|
224031513|NCT05528250|OTHER|Survey|International Physical Activity Questionnaire (IPAQ)-Short Form ,Anthropometric Measurements and Evaluation Body Weight and Height, Electromyogram (EMG), Digital Dynamometer measurement ,Static Balance Measurements ,Dynamic Balance Measurements ,Tecnobody Balance Measurement , Mini-Balance Evaluation (MiniBESTest) Systems Test ,Y Balance Test ,Flamingo Balance Test ,Modified Borg Scale.
224136023|NCT00374153|BEHAVIORAL|Feedback|Online personal feedback report
223413844|NCT01073605|DRUG|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
224031514|NCT05528250|DEVICE|Treadmill|Participants will sign a consent form approved by the ethics committee.Before data collection, height, weight, circumference measurements, leg length, thigh area subcutaneous fat measurement, heart rate, blood pressure and saturation values will be recorded. Before the muscle fatigue protocol, the muscle strength, balance assessment and fatigue of the participants will be evaluated. The muscle fatigue protocol will be done with a treadmill. At the end of the muscle fatigue protocol, the necessary evaluations will be made again and the participants will be rested.
224031515|NCT03552822|OTHER|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
224136024|NCT00374153|BEHAVIORAL|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
224136025|NCT00374153|BEHAVIORAL|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
223413845|NCT01073605|DRUG|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
223413846|NCT01073605|DRUG|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
223413847|NCT00001997|DRUG|Interleukin-2, Polyethylene Glycolated|
224031516|NCT06421896|BEHAVIORAL|motivational Enhancement Therapy|Motivational Enhancement Therapy (MET) is a systematic intervention that focuses on eliciting and strengthening a person's intrinsic motivation to change. MET is rooted in motivational interviewing principles, emphasizing empathy, autonomy, and the evocation of the patient's own motivations for change. The therapy typically involves several sessions where therapists help patients identify personal goals, explore ambivalence towards change, and develop actionable plans to achieve their desired outcomes.
224031517|NCT01749540|DRUG|luspatercept|subcutaneous injection
224031518|NCT02729103|DRUG|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
224031519|NCT02174796|PROCEDURE|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
224031520|NCT02174796|PROCEDURE|orthopedic treatment|orthopedic treatment by vacuum bell.
224136026|NCT05162950|DIAGNOSTIC_TEST|physical exercise as a standardized high intensity exercise test|High intensity exercise test, cycling, performed at the Karolinska University Hospital
224136027|NCT05162950|BEHAVIORAL|Stress vulnerability|Web based survey of validated psychological questionnaires measuring fatigue (MFS), exhaustion disorder (KEDS), anxiety (LSAS-SR, HADS), depression (HADS), and Karolinska sleep questionnaire
224136028|NCT06182813|OTHER|Beta auditory beats (Group A)|Beta auditory beats for 25 min and then perform alternate wall toss test.
224136029|NCT06182813|OTHER|white noise (Group B)|Involves participants receiving White noise for 25 min and then perform alternate wall toss test.
224136030|NCT03071536|DRUG|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
224136031|NCT02817815|DEVICE|Electrocardiogram (ECG)|
224136032|NCT02817815|BIOLOGICAL|Blood sampling from the cephalic vein|
224136033|NCT02817815|BIOLOGICAL|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
224136034|NCT02817815|BIOLOGICAL|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
223413848|NCT00001997|DRUG|Zidovudine|
223413849|NCT00001997|DRUG|Didanosine|
223413850|NCT00726973|DRUG|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness \>100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
223413851|NCT00726973|DRUG|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
223413852|NCT00806273|DEVICE|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
223413853|NCT00806273|DEVICE|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
223413854|NCT03052231|DEVICE|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
224136035|NCT02817815|PROCEDURE|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
223413855|NCT02417142|DRUG|Exenatide|Exenatide SQ 2mg/week for 24 weeks.
223413856|NCT02417142|DRUG|Placebo|Placebo SQ 1x/week for 24 weeks.
223413857|NCT00204217|DEVICE|endotracheal intubation|
223413858|NCT05230706|OTHER|Cephalic helmet|An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
223413859|NCT05353842|BEHAVIORAL|WOWii Program|Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
224031521|NCT03506893|DEVICE|Alphapump|"Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking"
224031522|NCT03506893|PROCEDURE|Ascites puncture|Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
224031523|NCT05755035|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
224031524|NCT05755035|BIOLOGICAL|HYQVIA|Participants will receive SC infusion of HYQVIA.
224031525|NCT01474499|DRUG|Glycerine|
224031526|NCT01474499|DRUG|Docusate sodium and sorbitol rectal solution|
224031527|NCT00181987|DRUG|methylphenidate HCl (Concerta)|
224136036|NCT02817815|BIOLOGICAL|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
224136037|NCT02986893|BEHAVIORAL|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
224136038|NCT02986893|BEHAVIORAL|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
224136039|NCT05506592|OTHER|dermatological product|cosmetic shampoo
224136040|NCT00621855|DRUG|placebo|matched placebo
224031528|NCT02263534|PROCEDURE|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
224031529|NCT02263534|PROCEDURE|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
224031530|NCT03935503|PROCEDURE|TEP|By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
224136041|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
224136042|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
224136043|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
224136044|NCT00621855|DRUG|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
224136045|NCT02953782|DRUG|Magrolimab|Administered intravenously
224031531|NCT03935503|PROCEDURE|Lichtenstein repair|"After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches."
224031532|NCT04409249|DIAGNOSTIC_TEST|imaging, blood tests|PCR and CT results, hemogram, urea, creatinine, AST, ALT, LDH, D-Dimer, ferritin, lipase, amylase, CRP, procalcitonin, albumin, total protein, coagulation tests-PT, APTT, Fibrinogen-, Troponin T, CK , electrolytes, blood gas, bilirubins
224031533|NCT06101823|BIOLOGICAL|OpSCF|Monoclonal Antibody
224031534|NCT06101823|BIOLOGICAL|Placebo|Formulation buffer without active agent
224031535|NCT06101823|BIOLOGICAL|OpSCF (Open Label Extension)|Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
224031536|NCT03154762|DEVICE|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
224031537|NCT03154762|DEVICE|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
224031538|NCT03984903|OTHER|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
224136046|NCT02953782|DRUG|Cetuximab|Administered intravenously
224136047|NCT04743700|PROCEDURE|Piezocision|Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.
224136048|NCT04743700|PROCEDURE|Micro-osteoperforations|Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP
224031539|NCT03984903|OTHER|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
224136049|NCT00323505|DRUG|Pegylated Interferon|
224136050|NCT00323505|DRUG|Interferon-alpha2a|
224136051|NCT03579953|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
224136052|NCT03579953|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
224031540|NCT03984903|OTHER|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
224136053|NCT01737840|DRUG|Pantoprazole|33 patients
224136054|NCT01737840|DRUG|Ranitidine|33 patients
224136055|NCT03972124|DRUG|CBD 100 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
223559884|NCT07029022|BEHAVIORAL|Mindfulness-Based Intervention (MBI)|This intervention consisted of three 90-minute in-person workshops delivered monthly over a three-month period. Content included psychoeducation, guided stretching, and focused-attention meditation. Participants were also encouraged to practice mindfulness at home for 10 minutes daily and to follow lifestyle guidance on diet and physical activity.
224031541|NCT03984903|OTHER|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
224031542|NCT01788267|OTHER|scan examination HR-pQCT|
224031543|NCT00447850|PROCEDURE|endometrial biopsy|
223413860|NCT05171842|BEHAVIORAL|Observe the prognosis after stent implantation|Observe the prognosis of patients after undergoing specific operations. Specific surgery: Use femoral artery or brachial artery to implant naked stent (stent with diameter ≤7mm, stents with \>7mm are not restricted) to restore the blood flow of the true lumen superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulant therapy should be performed for at least 1 day after surgery. Anticoagulant drugs are not restricted. After discharge from the hospital, the double antibody should be taken for 3 months, and the monoclonal antibody should be maintained for at least 1 year.
223413861|NCT05458401|DRUG|Trastuzumab deruxtecan|No drug will be administered during this study.
223413862|NCT06575101|PROCEDURE|Target Temperature Management Treatment|Target Temperature Management Treatment
223413863|NCT04366843|OTHER|chair massage|Chair massage was performed useing only traditional methods of Swedish massage were used, consisting of stroking (smooth, continuous movements to relax and calm the sympathetic nervous system), kneading (consisting of wringing, squeezing muscles, compressing pressure points for the relaxation of soft tissues, i.e. muscles, tendons, fascia), stretching combined with swaying and passive movements of the upper limbs (to mobilize the joints of the upper limbs) and final stroking combined with slapping and shaking percussion, vibration.
223559885|NCT00604318|DRUG|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
223559886|NCT03479541|BEHAVIORAL|Timing of Rehabilitation|Participants in the Earlier Physical Therapy group will start physical therapy within a week of enrollment and baseline testing. Participants allocated to the Later Physical Therapy group will wait 6 weeks after enrollment and baseline testing before starting physical therapy, and re-test on study outcomes before starting physical therapy. Both groups will see a physical therapist in person twice per week for 2 weeks and once per week for 4 weeks for a total of 8 sessions over 6 weeks. Each session will last 60 minutes and consist of cardiovascular, cervical spine, and vestibular therapy exercises (static and dynamic balance). Participants will perform daily home exercises for 30 minutes with similar subcategories from the in-person sessions. Both the in-person physical therapy and home exercises will be individualized and progressive at the discretion of the physical therapist depending on the performance of the participant.
223559887|NCT03479541|BEHAVIORAL|Biofeedback|Wearable sensors measure movement during the home exercise program for later feedback.
223559888|NCT07028346|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I) is a first-line, non-medication treatment for insomnia that helps individuals identify and change the thoughts and behaviors that contribute to their sleep problems.
224031544|NCT03838107|BEHAVIORAL|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
224031545|NCT00419783|DRUG|bilastine|20 mg tablets.
224031546|NCT00419783|DRUG|Bilastine|100 mg (5 tablets of 20 mg)
224031547|NCT00419783|DRUG|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
224031548|NCT00419783|DRUG|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
224031549|NCT00419783|DRUG|Placebo|Placebo tablets
224136056|NCT03972124|DRUG|CBD 200 mg OD|CBD oil - purified to \<1% THC in soft-gel capsules
224136057|NCT03972124|DRUG|Placebo|Soft-gel capsules containing placebo
224136058|NCT02678234|DRUG|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
224136059|NCT01006863|DRUG|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
224136060|NCT01006863|DRUG|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution \[group 1 (n=30)\], ephedrine 0.7 mg/mL \[group 2 (n=30)\], ephedrine 1 mg/mL \[group 3 (n=30)\] or ephedrine 1.5 mg/mL \[group 4 (n=30)\]or phenylephrine 15 mcg/mL \[group 5 (n=30)\]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
224298342|NCT01431911|DRUG|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
223559889|NCT07028346|BEHAVIORAL|Sleep Education|Sleep Education group comprises psychoeducation sessions on sleep hygiene.
223559890|NCT06877299|DRUG|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)|Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
223559891|NCT06875609|DIAGNOSTIC_TEST|Blood and Tissue Collection|Blood samples, and tissue samples will be collected from the participants, and used to determine whether circulating tumor DNA (ctDNA) testing can help monitor treatment in patients with CSCC, and to determine how ctDNA levels change in patients.
224031550|NCT04828083|DRUG|Lidocaine IV|Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
224031551|NCT04828083|DRUG|Saline IV|Intravenous saline of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
224031552|NCT04987892|DEVICE|UroLift System|Prostatic lift
224031553|NCT04987892|DRUG|Tamsulosin Hydrochloride|Tamsulosin HCl 0.4mg
224031554|NCT04777526|OTHER|Proprioception exercises|Exercises for recognition of thumb position and thumb force sense.
224031555|NCT04777526|OTHER|Joint protection program|Reeducation in the activities daily life
223413864|NCT04366843|OTHER|the exercise program|The original set of exercises was developed based on the knowledge and clinical experience of the authors of the study and based on EBP (Evidence Based Practice). The program consisted of 14 strengthening and stretching exercises involving the muscles of the trunk and limbs whose main goal was to mobilize the joints and strengthen the weakened muscles and relax overloaded muscle groups.
224031556|NCT04777526|OTHER|Thumb orthosis|Thumb night orthosis
224031557|NCT04777526|OTHER|Manual distraction|Manual distraction of CMC joint
224136061|NCT01006863|DRUG|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine \[group 5 (n=30)\] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
224136062|NCT00813514|GENETIC|VEGF genotyping|blood sample for gene analysis
224136063|NCT03791359|OTHER|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
223413865|NCT05494814|OTHER|Child Care Centers Served Meals Prepared by Central Kitchen|The child care centers who are served by the central kitchen will receive meals that include locally sourced fresh fruits and vegetables to serve their staff and children.
223413866|NCT00704600|DRUG|nelfinavir|"Phase I:~* take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 0: PET-CT~Phase II:~* take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~* day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~* day 7 biopsy~* day 7, 21 and week 15 :PET-CT + perfusion CT"
223559892|NCT07034391|DRUG|denosumab combined anti-PD-1 inhibitor with chemotherapy|120mg of denosumab，d1 in a 28-days cycle；200mg of anti-PD-1 inhibitor, d1 in a 21-days cycle；500mg/m2 of pemetrexed, d1 in a 21-days cycle; AUC4-5 of carboplatin, d1 in a 21-days cycle, for 4-6 cycle
223559893|NCT07034482|DRUG|Intralesional Triamcinolone 5 mg/ml|Solution containing 5 mg TAC was injected intralesionally, every week for 6 weeks or until the scar flattened, whichever occurred earlier. Not more than 2 ml of the solution was injected per session, using 27G needle pre-mounted on an insulin syringe.
223559894|NCT07034482|DRUG|Intralesional 5-fluorouracil|Solution containing 45 mg 5-FU was injected intralesionally, every week for 6 weeks or until the scar flattened, whichever occurred earlier. Not more than 2 ml of the solution was injected per session, using 27G needle pre-mounted on an insulin syringe.
223559895|NCT07034560|DRUG|Tranexamic Acid (TXA)|500 mg oral tranexamic acid (Transamin®), taken once daily at bedtime for 12 weeks.
223559896|NCT07034560|DRUG|melatonin (Circadin)|2 mg oral melatonin (Circadin®), taken once daily at bedtime for 12 weeks.
223559897|NCT07034560|DRUG|Placebo|Placebo capsule identical in appearance, taken once daily at bedtime for 12 weeks.
223559898|NCT07033650|OTHER|Bulk-fill composite (X-tra Fil)|Bulk fill resin composite
223559899|NCT07033650|OTHER|flowable Bulk-fill composite (X-tra Base)|flowable resin composite
224136064|NCT03105700|DEVICE|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
224136065|NCT04662242|DRUG|Selenium Supplement|Zelnite 400mcg/day in normal saline 100ml iv infusion for 7 days
224136066|NCT04662242|DRUG|normal saline|normal saline 100ml iv infusion for 7 days
224136067|NCT00403559|DRUG|Elidel|
224136068|NCT00403559|DRUG|Ketoconazole Cream|
223413867|NCT02506556|DRUG|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"
223413868|NCT02875613|DRUG|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
223413869|NCT04400851|DRUG|Sintilimab|Patients were enrolled by the design of phase I study standard. Sintilimab was divided into three dosage levels: 1 mg / kg, 3 mg / kg, and 10 mg / kg. The first level of sintilimab was followed by dose escalation
223559900|NCT07033650|DEVICE|compothixo oscillating packing|oscillating packing device
223559901|NCT07033767|DRUG|genistein|Participants will receive genistein treatment (10-15 mg/kg/day with a maximum dose of 1500mg/day) for 3 months. From the 3-month- to 6-month follow-up, participants will receive a dose of 20-25 mg/kg/day (with a maximum dose of 1500mg/day). According to participant preference, Genistein will be provided as a capsule (250mg per capsule). For participants that are unable to swallow the capsule the capsule may be opened and the powder from the capsule can be mixed with a beverage or food. Interim clinical evaluations will occur at 3 and 6 months to assess, tolerability, adherence and efficacy.. Post-treatment assessment after a 3-month washout will occur at 9 months to determine delayed adverse effects and persistence of beneficial effects after genistein discontinuation.
223738893|NCT04170283|DRUG|Tislelizumab|Patients in Australia who participated in a parent study that involved combination therapy of zanubrutinib and tislelizumab will receive tislelizumab at a dose of 200mg every 3 weeks..
223738894|NCT02968927|DRUG|Everolimus 0.5 MG|
224031558|NCT00414128|DRUG|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
224031559|NCT00414128|DRUG|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
224031560|NCT00932685|DRUG|Midazolam|Midazolam 0.5mg/kg
224031561|NCT00932685|DEVICE|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
224031562|NCT05644457|GENETIC|Circulating tumour DNA dynamics|Circulating tumour DNA (ctDNA) can be identified in patients with a wide variety of cancers and has been shown to allow early prediction of disease relapse after treatment with curative intent in HNSCC.
224031563|NCT05829590|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture bowel segment images and prompt abnormal lesions based on speech recognition and deep learning.
224031564|NCT01023854|PROCEDURE|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
224031565|NCT06498531|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
224031566|NCT06498531|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
223413870|NCT06459453|OTHER|Kaltenborn|Per participant was randomized to receive low grade Kaltenborn manual mobilization(grade I).Any tightening of the connective tissues surrounding the joint (grade II) or oscillations followed by additional stretching (grade III).Kaltenborm mobilization is performed for wrist flexion,extension,radial and ulnar deviation.The duration of intervention will be 4 weeks,3 sessions per week, a total of 12 sessions will be given to the study participants. Each session will be last for 30 minutes .Conventional physical therapy will be given to the participants along with kaltenborn.
223413871|NCT06459453|OTHER|Mulligan|Per participant gave concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Mulligan mobilization is performed for wrist flexion and extension(in the form of fist)MCP joint flexion and extension,Thumb IC joint flexion and extension, abduction and adduction of fingers, The duration of intervention will be 4weeks,3 sessions per week ,a total of 12 sessions will be given to the study participants .Each session will last for 30 minutes. Conventional physical therapy will be given to the participants along with conventional physiotherapy.
223559902|NCT07034040|BEHAVIORAL|SmaRTWork|The SmaRTWork app provides weekly individually tailored self-management plans by matching the participant's health information and sick leave status with targeted educational messages, physical activity advice, and exercise recommendations. In addition, participants with specific problems regarding i) work accommodations, ii) workplace conflicts, iii) large responsibilities as caregivers, iv) financial problems, or v) who do not think they will return to the old workplace are offered to be set in contact with a caseworker at the social insurance office. The intervention is given in addition to usual care.
224031567|NCT00576836|BIOLOGICAL|Cultured Thymus Tissue Implantation (CTTI)|Thymus tissue (from unrelated donor), thymus donor, and thymus donor's birth mother screened for safety. CTTI was done under general anesthesia. Cultured thymus tissue was implanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not \>18 grams/m2 body surface area (1.0 grams/kg body weight). At time of CTTI, skin biopsy was obtained to look for preexisting T cells. 2-3 months post-CTTI allograft biopsy was done to evaluate for thymopoiesis \& graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-CTTI, subjects followed by immune evaluations, using blood samples.
223559903|NCT07034651|PROCEDURE|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
223559904|NCT07032753|DEVICE|eOPRA|Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system for transhumeral amputees.
223559905|NCT07032753|DEVICE|OPRA|Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations
223559906|NCT07032753|DEVICE|eOPRA with sensory feedback|Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations with sensory feedback.
223559907|NCT07032753|DEVICE|eOPRA without sensory feedback|Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations without sensory feedback.
223559908|NCT07034937|OTHER|Combination of aerobic training (treadmill walking) and resistance training|Combination of aerobic training (treadmill walking) and resistance training using resistance bands for deltoid, biceps, triceps, and quadriceps muscles. Conducted twice weekly for 6 weeks (12 sessions). Tools include treadmill and theraband loop bands.
223559909|NCT07034235|PROCEDURE|Dentin Wet|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on wet dentin in the etch-and-rinse application strategy.
223738895|NCT02968927|DRUG|Auranofin 6 MG|
224031568|NCT00576836|OTHER|Cultured Thymus Tissue Implantation with Parathyroid Transplantation|Parental parathyroid donors screened for eligibility and safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most Human Leukocyte Antigens (HLA) alleles with thymus donor. Parathyroid harvest \& transplant preferably done at same time as CTTI. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of CTTI.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced \& placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
224031569|NCT03589092|GENETIC|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
224136069|NCT05924906|DRUG|NB002|Strength: 100 mg:5 mL solution in a single-use vial Administration: intravenous infusion
224298343|NCT01431911|DRUG|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
224031570|NCT02463188|BEHAVIORAL|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
224031571|NCT05815290|DRUG|Cadonilimab|Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles
224031572|NCT00991263|GENETIC|gene expression analysis|
224031573|NCT00991263|GENETIC|polymerase chain reaction|
224031574|NCT00991263|OTHER|laboratory biomarker analysis|
224136070|NCT04773899|DIAGNOSTIC_TEST|Procedure : Multimodal microvascular assessment at study inclusion|"* Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy."
224136071|NCT03637699|BEHAVIORAL|Positive Psychology|5-week positive psychology intervention
224136072|NCT02510170|OTHER|no intervention|
224031575|NCT01321359|DRUG|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
224031576|NCT02939547|DRUG|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
224031577|NCT01296347|DRUG|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
224136073|NCT01237106|OTHER|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
224031578|NCT02240693|DRUG|BI 409306|
224031579|NCT02240693|DRUG|Placebo|
223413872|NCT05969015|BEHAVIORAL|Prochaska and DiClemente transtheorical model|The Prochaska and DiClemente model will be combined to a self-management program in patients with T2DM within 18 months. They will be classified accordingly to their readiness for changing. A care provider will manage the group towards an optimal self-management, aiming to improve their glycemic control and other outcomes of relevance. We will conduct 1 session per week until the end of 12nd intervention month. After, the sections will be conducted each 2 weeks until the end of the trial. Healthcare professional will provide support to the care provider. The recommended processes to progress the patients will be used to trigger them accordingly to their stage, at the discretion of the care provider. We will also consider individualities and non-anticipated problems as a part of the process of behavior changing.
223413873|NCT04305457|DRUG|Nitric Oxide|Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the subject.
223559910|NCT07034235|PROCEDURE|Dentin Overwet|Composite resin restorations of non-carious cervical lesions will be performed with an adhesive on overwet dentin in the etch-and-rinse application strategy.
223559911|NCT07034235|DEVICE|Ambar Universal APS Plus; FGM|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive
223559912|NCT07034235|DEVICE|Prime&Bond Active; Dentsply Sirona|Composite resin restorations of non-carious cervical lesions will be performed with an universal adhesive
224031580|NCT02240693|DRUG|BI 409306|
223559913|NCT07034157|PROCEDURE|Percutaneous Coronary Intervention|Coronary stenting performed as part of routine care for patients with coronary artery stenosis.
224136074|NCT00432952|BEHAVIORAL|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
223559914|NCT07034157|PROCEDURE|Cerebrovascular Intervention (CAS ）|Patients with intervention-indicated head and neck artery stenosis will receive carotid artery stenting based on clinical evaluation.
223559915|NCT07034157|OTHER|No Intervention / Observation|Clinical observation or standard follow-up in patients without significant disease
224031581|NCT02240693|DRUG|Placebo|
224136075|NCT00516633|BEHAVIORAL|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
224136076|NCT03584854|DRUG|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
224136077|NCT03584854|DRUG|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
224136078|NCT00100724|BIOLOGICAL|rPA102|
223413874|NCT03462160|OTHER|Placebo control group|Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.
223738896|NCT02968927|DRUG|Vitamin D3|
223738897|NCT02968927|DRUG|CC-11050|
223738898|NCT02968927|DRUG|2HRbZE/4HRb|
224031582|NCT02240693|DRUG|Placebo|
224136079|NCT01253421|DRUG|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
224136080|NCT01253421|DRUG|placebo|single-dose placebo capsule
224136081|NCT04270994|DRUG|Misoprostol|
224031583|NCT02240693|DRUG|BI 409306|
224031584|NCT02240693|DRUG|BI 409306|
224031585|NCT02240693|DRUG|Placebo|
224031586|NCT02240693|DRUG|Placebo|
224031587|NCT02705560|OTHER|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
224031588|NCT02705560|OTHER|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
224031589|NCT02705560|OTHER|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
224031590|NCT05965661|OTHER|virtual reality upper limb hand training|The PD patients randomized in the experimental group will receive virtual reality upper limb hand training.
224031591|NCT05965661|OTHER|virtual reality control training|The PD patients randomized in the control group will receive virtual reality control training.
224031592|NCT01116882|PROCEDURE|PCI|
224031593|NCT03876782|DIAGNOSTIC_TEST|IOLMaster|IOL power calculation will be done with IOLMaster
224031594|NCT03876782|DIAGNOSTIC_TEST|Verion|IOL power calculation will be done with Verion
224031595|NCT02879422|GENETIC|genetic analysis|
224136082|NCT03553433|DRUG|Apremilast 30mg|Anti-psoriatic drug
223413875|NCT03462160|DIETARY_SUPPLEMENT|Probiotic experimental group|Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.
223413876|NCT02678169|DEVICE|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
224031596|NCT05227885|OTHER|questionnaire form|A questionnaire will be applied to all participants. A questionnaire form will be applied to collect data on demographic information, pain, disease activity, nutritional habits, physical activity status and physical functional status of the patients included in the study.
224136083|NCT03553433|DRUG|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
223413877|NCT02917291|DRUG|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)
223413878|NCT02917291|OTHER|Control group|(Ph 2) No treatment will be administered
223413879|NCT02917291|DRUG|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
223413880|NCT05214443|PROCEDURE|POEM + F|POEM would first be performed as per usual technique. Upon completion of the myotomy, a 2cm incision would be created over the adventitial layer at the level of gastro-esophageal junction (GEJ), allowing scope entry into the peritoneal cavity. The anterior part of the gastric fundus would be located, grasped with endoscopic forceps and pulled towards the esophageal myotomy site. The intended anterior fundus would then be anchored to the edge of the muscle at the GEJ, with the use of X-TackTM system. After confirming adequate hemostasis and secure anchorage of fundus to the esophagus, the mucosal entry site for the submucosal tunnel would be closed with endoscopic clips as per usual POEM technique.
223413881|NCT04054115|DRUG|Alprostadil 5 MCG Injection|During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
223413882|NCT01443585|DEVICE|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
223413883|NCT03443362|PROCEDURE|Punch Biopsy|A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
223559916|NCT07034846|OTHER|High-intensity intermittent IMT and Otago Exercises Group|Patients in the experimental group will perform 7 sets of high-intensity intermittent inspiratory muscle training (IMT) for eight weeks, one day a week face-to-face with the researcher and two days at home, for a total of three days, each set consisting of 2 minutes of loading and 1 minute of rest for a total of 21 minutes. The Otago exercise program will be conducted for eight weeks, two days a week home-based and one day face-to-face with the researcher. The Otago exercise program will be complemented with walking exercise every day of the week. The Otago exercise program is designed to be progressive. The protocol was created to increase the difficulty of training at four different levels and every 2 weeks. The Otago exercise program will be applied to both the experimental group and the control group in the same protocol.
223738899|NCT03642236|DRUG|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
223738900|NCT01498211|PROCEDURE|Biopsy|3 mm punch biopsy of the skin at the distal leg.
224031597|NCT01783041|DRUG|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
224031598|NCT01783041|DRUG|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
224031599|NCT04054752|BIOLOGICAL|Recombinant human IL-7-hyFc (NT-I7)|NT-I7 administered at escalating doses of 720, and 960g/kg to determine OBD of NT-I7
224031600|NCT04054752|BIOLOGICAL|Vaccine sequence 1|Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
224031601|NCT04054752|BIOLOGICAL|Vaccine sequence 2|Day 1 Immunization Pre-NT-I7: Hep A#1, Hep B#1 Day 64, Immunization Post-NT-I7:Td and Polio Day 106: no Vaccine 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1
224031602|NCT05634980|OTHER|FEES|Fiberoptic Endoscopic Evaluation of Swallowing (FEES) exam
224031603|NCT00971243|DRUG|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
224136084|NCT00127504|DRUG|Rifampin|
224136085|NCT00127504|DRUG|Azithromycin|
224136086|NCT00087737|DRUG|DVS-233 SR|
224136087|NCT00087737|DRUG|Venlafaxine ER|
224136088|NCT00740168|DRUG|bevacizumab treatment|single infusion 10 mg/kg
224136089|NCT04897282|DIAGNOSTIC_TEST|UCRI|Biomarker panel and algorithm
224136090|NCT05604469|DIAGNOSTIC_TEST|Isolation of skin microbiota|Isolation of skin microbiota including, Staphylococcus epidermidis, Propionibacterium acnes, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pyogenes and Candida.
223413884|NCT03443362|PROCEDURE|Blood sampling|Blood sampling
223413885|NCT04001296|BEHAVIORAL|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
223413886|NCT02910206|DRUG|Etomidate|etomidate is given intravenously
223413887|NCT02910206|DRUG|propofol|propofol is given intravenously
223413888|NCT02910206|DRUG|Sufentanil|sufentanil is given intravenously
223413889|NCT02910206|DRUG|Cisatracurium|Cisatracurium is given intravenously
223413890|NCT00291876|BIOLOGICAL|Havrix™|2 doses at 12 months interval
224031604|NCT00971243|DRUG|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
224031605|NCT00971243|DRUG|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
224031606|NCT00971243|DRUG|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
224031607|NCT00971243|DRUG|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
224031608|NCT02216474|OTHER|Transcranial direct current stimulation|
224031609|NCT02686060|DEVICE|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
224031610|NCT03728374|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
224031611|NCT01941797|BEHAVIORAL|interruption of oral hygiene|
224031612|NCT00517582|DRUG|HOE-140|Subcutaneous at time 0 and 6 hours
224031613|NCT00517582|OTHER|Placebo|Subcutaneous at time 0 and 6 hours
223413891|NCT06682663|BEHAVIORAL|Live Streaming Exercise|Participants try to achieve 150 minutes of moderate-vigorous training per week. The exercise program includes live streaming exercise by trained health professionals, including pregnancy-specific exercises, with professional pregnancy trainers to provide guidance and support when needed.
224031614|NCT04919239|BIOLOGICAL|RUTI®|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
224136091|NCT03092869|OTHER|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
224136092|NCT03092869|OTHER|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
224136093|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
223413892|NCT00239122|BEHAVIORAL|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
223413893|NCT05812235|PROCEDURE|esophagectomy|esophagectomy
223413894|NCT01680536|DRUG|maraviroc|
223413895|NCT00802035|DRUG|Baclofen IR|30 mg; single dose
223413896|NCT00802035|DRUG|Baclofen ER|30 mg; single dose
223559917|NCT07034846|OTHER|Sham IMT and Otago Exercises Group|Patients in the control group will perform 7 sets of sham inspiratory muscle training (IMT), consisting of 2 minutes of loading and 1 minute of rest in each set for a total of 21 minutes, one day a week face-to-face with the researcher and two days at home, for eight weeks. The Otago exercise program will be conducted for eight weeks, two days a week home-based and one day face-to-face with the researcher. The Otago exercise program will be complemented with walking exercise every day of the week. The Otago exercise program is designed to be progressive. The protocol was created to increase the difficulty of training at four different levels and every 2 weeks. The Otago exercise program will be applied to both the experimental group and the control group in the same protocol.
223559918|NCT07034287|OTHER|Telehealth physical therapy and pharmacy consultation|Telehealth physical therapy and pharmacy consultation at baseline emergency department visit.
223559919|NCT07033910|DEVICE|sepsis adsorption column|after the initiation of fluid and antibiotic therapy according to the Surviving Sepsis Campaign 2021 Guidelines, an additional routine sepsis adsorption column (Biosky® MG350) was used within 48-72 hours.
224136094|NCT01449682|DRUG|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
224136095|NCT02237976|BEHAVIORAL|Self-hypnosis|
224136096|NCT02237976|BEHAVIORAL|Routine practice|
224136097|NCT03218982|BEHAVIORAL|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
223413897|NCT02951208|DEVICE|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
223413898|NCT02951208|BEHAVIORAL|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
223413899|NCT02951208|DEVICE|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
223413900|NCT02951208|BEHAVIORAL|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
224031615|NCT04919239|BIOLOGICAL|Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
224031616|NCT02513888|DIETARY_SUPPLEMENT|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
224031617|NCT02513888|DIETARY_SUPPLEMENT|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
224031618|NCT00414284|DRUG|Increased dose of Kaletra|
224136098|NCT05346601|DRUG|Chiauranib|50mg po only once
223413901|NCT03083015|PROCEDURE|revascularization|a sterile sharp needle was used to irritate the apical tissue until bleeding occurred apically in the root canal space so as to create a biological scaffold for the regenerative process
224031619|NCT00001032|DRUG|Zidovudine|
224031620|NCT00001032|DRUG|Zalcitabine|
224031621|NCT04578613|DRUG|ICP-022|ICP-022 at a dose of 150mg, QD
224031622|NCT04578613|DRUG|Chlorambucil|0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
224031623|NCT04578613|DRUG|Rituximab|375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
224031624|NCT05918250|BIOLOGICAL|mRNA-2736|mRNA-2736 will be administered IV.
224031625|NCT00343954|DRUG|L-citrulline tablets, 1000 mg|
223413902|NCT03083015|PROCEDURE|Apexification|a 3-5 mm thickness of MTA using a hand plugger and was verified radiographically.
223413903|NCT05498844|BEHAVIORAL|Medical Nutrition Therapy (counselling)|Participants will receive nutrition counseling to enhance adherence to the principles of the Mediterranean diet and support the achievement of adequate levels of lipid control, blood pressure and weight.
224031626|NCT00742053|DEVICE|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
224031627|NCT00369304|DRUG|pharmacokinetic (how the body absorbs and eliminates) interaction|
224031628|NCT04879771|PROCEDURE|Receive gastrointestinal endoscopy|patients receive gastrointestinal endoscopy in the morning or afternoon
224031629|NCT06507202|DRUG|Remimazolam|General anesthesia is induced and maintained by continuous infusion of remimazolam and remifentanil, and recovered with flumazenil.
224031630|NCT06507202|DRUG|Propofol|General anesthesia is induced and maintained by continuous infusion of propofol and remifentanil.
224031631|NCT06323018|PROCEDURE|Remote Ischemic Preconditioning|4 cycles of 5 min pressure (produces an ischemia episode in subject's upper limb) with AutoRIC device (Starfish Medical, Canada)
224031632|NCT06323018|OTHER|SHAM|4 cycles of 5min light pressure (no ischemia produced) with AutoRIC device (Starfish Medical, Canada) to imitate the RIPC procedure
224031633|NCT02092220|DEVICE|Bionic Pancreas|
223413904|NCT02230020|DEVICE|Nasal High Flow|
224031634|NCT02092220|DEVICE|Insulin pump with or without CGM|
224031635|NCT02739360|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
224031636|NCT01583153|OTHER|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
224031637|NCT01583153|OTHER|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
224031638|NCT01683487|PROCEDURE|Observation|Observational study only, no intervention.
224031639|NCT01414374|DRUG|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
224031640|NCT01414374|DRUG|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
224031641|NCT05557058|DEVICE|Gore Glaucoma Device Implant (GORE GDI)|Unilateral implantation of one of two different configurations of the GORE GDI
224031642|NCT02127918|DRUG|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
224031643|NCT00687817|DRUG|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
224031644|NCT04589429|DRUG|Morphine 10 MG/ML|intrathecal morphine 300 micrograms
224031645|NCT04589429|DRUG|Nalbuphine Hydrochloride 10 MG/ML|intrathecal nalbuphine 2mg.
224031646|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
224136099|NCT01062594|OTHER|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
223413905|NCT02308540|BIOLOGICAL|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate \[alum\]) and preservative (thiomersal).
223413906|NCT02308540|BIOLOGICAL|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
223413907|NCT02308540|BIOLOGICAL|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
223559920|NCT07034872|OTHER|Control Group|Participants in the control group will receive two face-to-face physiotherapy sessions and one asynchronous video-based exercise training session per week for eight weeks. Following the baseline assessments, a conventional exercise program will be individually planned by the physiotherapist for each child. Each 60-minute session will include strengthening exercises for upper and lower extremity muscles, active and passive stretching exercises for spastic muscles, static and dynamic balance training in standing, and gait exercises.
223738901|NCT03852641|OTHER|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
224031647|NCT01193920|OTHER|Saline solution|Subjects received two injection of saline solution.
224031648|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
224031649|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
224031650|NCT01193920|BIOLOGICAL|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
224031651|NCT01193920|OTHER|saline solution|Subjects received one injection of saline solution.
224031652|NCT03844490|OTHER|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made."
223413908|NCT03734289|BEHAVIORAL|Caregiver Coaching|Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
223413909|NCT03997240|PROCEDURE|Chiropractic Applied Clinical Neuroscience|Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
223413910|NCT00259948|PROCEDURE|Aerobic exercise training|
223413911|NCT02412163|DEVICE|Ellipse IM HTO Nail|
224031653|NCT03844490|OTHER|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
224031654|NCT00913653|DRUG|LCZ696|
223413912|NCT02914704|DEVICE|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
224031655|NCT00437723|DRUG|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
223413913|NCT02571101|DRUG|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
223413914|NCT02571101|DRUG|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
223413915|NCT02571101|DRUG|Condencia|Contains chlomipramine HCl 15mg.
223413916|NCT02571101|DRUG|CDFR0812-Placebo|Placebo tablet of CDFR0812.
224031656|NCT00542529|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
224136100|NCT01062594|OTHER|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
224136101|NCT01062594|OTHER|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
224136102|NCT03227562|DRUG|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
224136103|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
224136104|NCT02753829|PROCEDURE|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
224136105|NCT02753829|OTHER|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
224136106|NCT02675894|DEVICE|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
223413917|NCT02571101|DRUG|Condencia-Placebo|Placebo tablet of Condencia
223413918|NCT04666701|DRUG|Escócia association|Escócia association tablet
223738902|NCT03946384|OTHER|data collection|data collection on the history of the disease, hemophilia
223738903|NCT00531817|DRUG|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
224031657|NCT02097641|BIOLOGICAL|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
224031658|NCT02097641|BIOLOGICAL|Plasma-Lyte A|Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
223413919|NCT04666701|OTHER|Placebo Ketorolac|Placebo Ketorolac tablet
223413920|NCT04666701|OTHER|Placebo Scopolamine|Placebo Scopolamine dragee
223413921|NCT04666701|DRUG|Ketorolac Tromethamine|Ketorolac tablet
223413922|NCT04666701|DRUG|Scopolamine|Scopolamine dragee
223413923|NCT04666701|OTHER|Placebo Escócia association|Placebo Escócia association tablet
223413924|NCT02595463|DRUG|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
223413925|NCT02595463|DRUG|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
223413926|NCT02285166|DRUG|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
223413927|NCT02285166|DRUG|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
224031659|NCT01231516|DRUG|GSK1349572|50mg once daily
224031660|NCT01231516|DRUG|Raltegravir|400mg twice daily
224031661|NCT01231516|DRUG|GSK1349572 Placebo|Inactive placebo tablet once daily
224031662|NCT01231516|DRUG|Raltegravir Placebo|Inactive placebo tablet twice daily
224031663|NCT01670123|BEHAVIORAL|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
224031664|NCT02105350|DRUG|MEK 162|
224031665|NCT02105350|DRUG|Gemcitabine|
224031666|NCT02105350|DRUG|Oxaliplatin|
224031667|NCT05507918|OTHER|Oral water and clear liquids|Measured oral intake of fluids prior to tonsillectomy
224136107|NCT02675894|DEVICE|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
223413928|NCT03766867|DRUG|Vortioxetine infusion 25 mg|1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
224031668|NCT04047589|BEHAVIORAL|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
224031669|NCT04047589|BEHAVIORAL|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
223413929|NCT03766867|DRUG|Vortioxetine tablets 10 mg/day|10 mg, tablets, oral administration once daily
223413930|NCT03766867|DRUG|Placebo infusion|concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
223413931|NCT03766867|DRUG|Placebo tablets|oral administration once daily
223738904|NCT00531817|DRUG|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
224031670|NCT01749449|OTHER|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
224136108|NCT02618980|OTHER|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
224136109|NCT03768791|OTHER|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
224136110|NCT03768791|OTHER|SCS is switched on|Spinal cord stimulator is on
224136111|NCT03711994|OTHER|Alkantis|cold therapy pack placed on the wound post operatively
224136112|NCT02649543|PROCEDURE|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
224136113|NCT02649543|PROCEDURE|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
224299144|NCT00333879|DEVICE|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
223413932|NCT03468686|DEVICE|Bilateral rTMS|The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.
223413933|NCT03468686|DEVICE|Sham rTMS|The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.
223738905|NCT00531817|DRUG|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
223738906|NCT03522974|DIETARY_SUPPLEMENT|Strawberry powder|Freeze dried strawberry powder
223413934|NCT03468686|DEVICE|Unilateral rTMS (High frequency)|The coil will locate on F3 in accordance with the 10-20 international system. Unilateral rTMS include stimulate the Left DLPFC at 10Hz for a 5seconds train of stimulation, 10 seconds inter-train interval, and a total of 75 pulse trains. .
223413935|NCT03857217|DEVICE|Extra-Corporeal Membrane Oxygenation|ECMO is implanted in cardiac surgery patients.
223738907|NCT03522974|DIETARY_SUPPLEMENT|Placebo powder|40 g/d placebo powder matched for taste and appearance
223413936|NCT04850430|PROCEDURE|Gastric venous reconstruction|Patients will be assigned to study after intraoperative evaluation of gastric venous drainage after coronary vein resection during TP, and the gastric venous outflow will be reconstructed after TP.
223413937|NCT06576024|BIOLOGICAL|2 doses of HAV|Participants will receive two doses of HAV with a 6-month interval
223738908|NCT01302587|DRUG|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
224031671|NCT00172107|DRUG|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
224031672|NCT00172107|DRUG|placebo|placebo powder for subcutaneous injection
224031673|NCT00172107|DRUG|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
224031674|NCT00172107|DRUG|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
224031675|NCT00409214|DRUG|LS11 (talaporfin sodium)|
224031676|NCT00409214|DEVICE|Light source (interstitial light emitting diodes)|
224031677|NCT00409214|PROCEDURE|Intraoperative placement of device in glioma|
224031678|NCT05053425|DRUG|Venetoclax|given po.
224031679|NCT05053425|DRUG|Azacitidine|given sc.
224031680|NCT05053425|DRUG|Cladribine|given ivgtt.
224031681|NCT05053425|DRUG|Cytarabine|given sc or ivgtt.
224031682|NCT05053425|DRUG|Idarubicin|given ivgtt.
224031683|NCT03170154|DEVICE|Clareon aspheric hydrophobic acrylic monofocal IOL|Ultraviolet-absorbing and blue light-filtering IOL composed of high refractive-index foldable and flexible acrylic material. IOLs are implantable medical devices intended for long term use over the lifetime of the cataract subject.
224031684|NCT02669420|PROCEDURE|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
224031685|NCT05609201|DIAGNOSTIC_TEST|HRCT Thorax|HRCT Thorax at 0, 6 and 12 months
224031686|NCT05609201|DEVICE|Glycocheck Endothelial Glycocalyx Assessment|Measure of EG degradation using GlycoCheck Microvascular Health Score at 0, 6 and 12 months
224031687|NCT05609201|DIAGNOSTIC_TEST|Blood biomarkers|Endothelial glycocalyx degradation blood biomarkers and angiogenesis markers at 0, 6 and 12 months
224031688|NCT05609201|DIAGNOSTIC_TEST|Peripheral leucocyte telomere length|HT-STELA (High-throughput single telomere length assessment) at 0, 6 and 12 months
224031689|NCT05609201|DIAGNOSTIC_TEST|Pulmonary function testing|Pulmonary Function Tests (Spirometry and Gas Transfer) and 6-minute walk distance at 0, 6 and 12 months
224031690|NCT05609201|DIAGNOSTIC_TEST|Patient reported outcome measures|Electronic collection of patient reported outcome measures
224031691|NCT06319456|DRUG|Lisaftoclax (APG-2575)|QD, oral administration, every 28 days for a dosing cycle.
224136114|NCT02649543|PROCEDURE|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
223413938|NCT06576024|BIOLOGICAL|At least one dose of HAV|Participants will receive the first dose of HAV and will receive the second dose with a 6 -month interval voluntarily.
224136115|NCT01316991|DIETARY_SUPPLEMENT|Chewing Gum|chewing gum will be provided
223413939|NCT02302638|OTHER|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
223413940|NCT05445635|DEVICE|Iriscope|The use of Iriscope to improve the diagnostic yield of bronchoscopy in the setting of peripheral lung nodules
223413941|NCT04387019|DIAGNOSTIC_TEST|blood sampling|blood sampling from peripheral vein
223413942|NCT02919319|DRUG|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
223413943|NCT02919319|DRUG|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
224031692|NCT06319456|DRUG|Acalabrutinib|BID, oral administration, every 28 days for a dosing cycle.
224031693|NCT06319456|DRUG|Fludarabine|Every 28 days for a treatment cycle, administration of 6 cycles.
224136116|NCT01316991|DIETARY_SUPPLEMENT|No Gum|no chewing gum will be provided
223413944|NCT02919319|DRUG|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
223413945|NCT02919319|DRUG|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
223413946|NCT02919319|DRUG|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
224031694|NCT06319456|DRUG|Cyclophosphamide，CTX|Every 28 days for a treatment cycle, administration of 6 cycles.
224031695|NCT06319456|DRUG|Rituximab|Every 28 days for a treatment cycle, administration of 6 cycles.
224031696|NCT06319456|DRUG|Chlorambucil|Every 28 days for a treatment cycle, administration of 6 cycles.
223413947|NCT02919319|DRUG|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
223413948|NCT03486158|DEVICE|CalproSmart™ system|Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
223413949|NCT00174564|DRUG|oxaliplatin|
224031697|NCT00359190|DRUG|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
224031698|NCT05393284|DRUG|OPL-0401 Dose 1|Pharmaceutical Form: Capsule; Route of Administration: Oral
224031699|NCT05393284|DRUG|Placebo|Pharmaceutical Form: Capsule; Route of Administration: Oral
224031700|NCT05266586|DRUG|Obicetrapib|tablets
224031701|NCT05266586|DRUG|Ezetimibe 10mg|capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
224031702|NCT05266586|OTHER|Obicetrapib placebo|tablets; no active ingredient
224136117|NCT03164226|DEVICE|Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain|To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
224136118|NCT01763281|DRUG|CRH|
224136119|NCT01763281|DRUG|Placebo|
224136120|NCT05881772|OTHER|Photobiomodulation|It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
224136121|NCT02779192|DRUG|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
223413950|NCT00443079|DRUG|IdB 1016 (Siliphos)|1 pill 3 times daily x 6 weeks
223413951|NCT00443079|DRUG|Matched placebo|1 pill 3 times daily x 6 weeks
223413952|NCT02619864|DRUG|AZD2014|
223413953|NCT05443763|OTHER|An interdisciplinary intensive therapy program|Children will receive physical, occupation, and/or speech therapy 1-3 hours/day each for 4-5 days/week x 4 weeks.
223413954|NCT02547142|OTHER|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
224031703|NCT05266586|OTHER|Ezetimibe placebo|capsules; no active ingredient
224031704|NCT02905760|DRUG|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
224031705|NCT02905760|DRUG|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
224031706|NCT02905760|DRUG|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
224031707|NCT02905760|DRUG|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
224136122|NCT02779192|DRUG|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
224136123|NCT02779192|DRUG|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
224136124|NCT05855317|OTHER|Blood sample|Additional blood samples will be taken on a catheter, used for standard care.
224031708|NCT06385756|DRUG|Amobarbital|Participants with gynecological laparoscopic surgery who met the trial inclusion criteria were randomly divided into 2 groups. After entering the room, peripheral intravenous infusion was opened and oxygen was absorbed by the mask for 5 L/min. Mean arterial pressure, heart rate and oxygen saturation were routinely monitored. After positioning, the amobarbital-propofol group was given amobarbital sodium 1 mg/kg 1 min before induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 1.5mg /kg for general anesthesia induction. The propofol group was given the same volume of normal saline 1 min before anesthesia induction, followed by Sufentanil 0.5ug /kg, cisatracurium 0.2mg /kg, penehyclidine hydrochloride 0.01mg /kg, propofol 2.5mg /kg.
224031709|NCT06385756|DRUG|Propofol|propofol
224031710|NCT04752878|DIAGNOSTIC_TEST|Ottawa sitting scale|The Ottawa Sitting Scale is a performance-based balance measurement consisting of 10 items that aims to evaluate the sitting balance in a comprehensive, specific, efficient and functional manner.
224031711|NCT03456271|OTHER||
224031712|NCT01117857|DRUG|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
224031713|NCT04793620|OTHER|TQL1055|Semisynthetic saponin adjuvant
224031714|NCT04793620|BIOLOGICAL|Acellular pertussis vaccine|Acellular pertussis vaccine
224031715|NCT04569383|BIOLOGICAL|MVA-SARS-2-S vaccinations (days 0 & 28)|Vaccination with MVA-SARS-2-S in two escalating dose regimens
224031716|NCT04569383|BIOLOGICAL|Comirnaty|Vaccination with Comirnaty (21 day interval)
224031717|NCT00633061|DRUG|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children \>2 months and 1.5 mg/kg every 12 hours for infants \<2 months. Duration of treatment is 6 weeks.
224031718|NCT05798611|DRUG|ART0380|Randomized patients will orally receive ART0380.
224031719|NCT03654313|BIOLOGICAL|MEDI6570|MEDI6570
224031720|NCT03654313|BIOLOGICAL|Placebo|Placebo
224031721|NCT03654313|BIOLOGICAL|Part B Placebo|Placebo
224031722|NCT06544902|OTHER|VR Stress Management|First Resort (FR) is an eight-week wellness program that comprises 22 modules, each lasting between 10 and 20 minutes, participants will complete modules weekly in person. Each module will teach participants about values-based goal setting/ behavioral activation, and cognitive restructuring.
224031723|NCT06544902|BEHAVIORAL|Education Control|Participants in this group will receive one-time educational material regarding stress. The participants can review the material remotely. American Heart Association (AHA) brochures and infographics regarding chronic stress and women's health, heart disease and mental health among black women, healthy for good sleep well, among other useful resources.
224031724|NCT06060392|DRUG|Semaglutide Pill|Patient will receive oral semaglutide
224031725|NCT06685575|PROCEDURE|Endoscopic Foraminotomy Surgery|Endoscopic Foraminotomy Surgery in Stable Lumbar Foraminal Stenosis
224031726|NCT06964191|COMBINATION_PRODUCT|PA5108 Ocular Implant low dose|The PA5108 Ocular Implant low dose is supplied preloaded into the needle of a single use administration device ready for use.
224031727|NCT06964191|COMBINATION_PRODUCT|PA5108 Ocular Implant, high dose|The PA5108 Ocular Implant high dose is supplied preloaded into the needle of a single use administration device ready for use.
224136125|NCT05691634|PROCEDURE|MRI|Patient with a tatoo will perform an MRI. The possible symptoms during the MRI or after MRI will then be described (duration, type,...).
224136126|NCT05691634|OTHER|Likert scale questionnaire|The patient will appreciate his feeling after MRI on a Likert scale (from 1 to 5)
224031728|NCT06964191|DRUG|Latanoprost 0.005% Ophthalmic Solution|Latanoprost eye drops at a concentration of 0.005%
224031729|NCT06404060|BEHAVIORAL|Personalized Cardiopulmonary Rehabilitation|"Participants in this group will complete 2-3 cardiopulmonary rehabilitation sessions per week, for 12 weeks, as tolerated. Rehabilitation sessions are provided by respiratory therapists, exercise physiologists, physical therapists, nurses, or others who have experience and training in either pulmonary or cardiac rehabilitation.~Rehabilitation sessions (adjusted based on the participant's baseline assessment, symptoms, and progress) last about 1 hour and include education, aerobic exercise, strength, and flexibility training."
224031730|NCT06404060|OTHER|Education|Participants in this group will receive two general education sessions at the start of the intervention with weekly phone/virtual follow-ups from site study staff.
224031731|NCT04206488|DRUG|JNJ-70033093|Participants will receive JNJ-70033093 orally.
224031732|NCT04206488|DRUG|Digoxin|Participants will receive digoxin orally.
224031733|NCT03123276|DRUG|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
224031734|NCT03123276|DRUG|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
224031735|NCT04559919|OTHER|Seizure status|We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
224136127|NCT01412658|DIETARY_SUPPLEMENT|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
223413955|NCT03110406|OTHER|whole-body vibration training|Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
223413956|NCT00205556|PROCEDURE|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
223413957|NCT00205556|PROCEDURE|low flux hemodialysis|standard treatment
223413958|NCT05038774|OTHER|Face to face Educational Training|"1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension."
224031736|NCT04559919|DIAGNOSTIC_TEST|Tests|We will collect results from imaging, electroencephalogram, and laboratory tests.
224031737|NCT04559919|OTHER|Epilepsy|We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.
224031738|NCT04559919|OTHER|Demographics and psychosocial|We will collect information on age, sex, date of death if applicable, marital status, education level, income type, driving status, employment, benefits, sick leave, number of household members.
224031739|NCT04559919|OTHER|Health care|We will collect information on received health care; visit dates, caregiver, dispensation dates of antiepileptic drugs
224031740|NCT05245097|DEVICE|Tango Belt|The Tango Belt is a patient-contacting electronic device made out of medical grade plastics and biocompatible fabrics worn around the waist. The Tango Belt contains a fall-in-progress detection algorithm which can detect a serious hip-impacting fall-in-progress using built-in sensors and deploy an automotive-grade cold-gas airbag to protect the hips from ground impact forces. When connected to Wi-Fi, the Tango Belt can send automated fall and impact alerts to caregivers and Healthcare Providers (HCPs) while recording motion and event data, which can then be analyzed for usage-based metrics viewable via a companion mobile app and/or desktop app. Alerts are sent in the form of short message service (SMS) texts and emails to alert recipients designated in the mobile or desktop Companion App. The Tango Belt can also detect non-serious hip-impacting or non-hip impacting falls in which the wearer may have incurred a minor injury (i.e., not a major hip injury) and/or may be unable to get up.
224031741|NCT05245097|OTHER|Standard of Care (SOC)|The standard of care (SOC) in the US for managing the fall risk of geriatric patients is the CDC's Stopping Elderly Accidents, Deaths, and Injuries (STEADI) initiative, which implements the America and British Geriatric Societies'' Clinical Practice Guidelines for fall risk management. The STEADI algorithm consists of tools and resources for healthcare providers for fall risk screening, assessment, and interventioniv,v. Screening and assessment includes identifying fall history and modifiable factors related to fall and fall injury risk (e.g. fear of falling, gait, strength, balance, medications, comorbidities, etc.); then interventions to reduce the fall and fall injury risk are applied based upon assessment findings, and can include physical therapy, medication adjustments, patient education, bed and chair alarms, bed rails, etc.
224031742|NCT04770493|DRUG|Lamotrigine|Participants will be randomized to lamotrigine (25 mg/day to 200 mg/day in two divided doses) for 9 weeks. A comparator group will receive placebo (sugar pills).
224031743|NCT04770493|DRUG|Placebo|Matching placebo (sugar pill)
224031744|NCT04931836|BEHAVIORAL|Physical Activity Intervention|Three walking sessions/week for a total of 8 weeks (24 total sessions) - Walking sessions will either take place on new commercial treadmills in the Epidemiology Clinical Research Center or remotely at or around a participant's home. Regardless of the walking location, walking sessions will be 30 min in duration during intervention weeks 1 through 4 and a minimum of 45 min each during intervention weeks 5 through 8.
224031745|NCT04700306|BEHAVIORAL|Sophrology|Patient must make 8 visits with interviews and questionnaires, including 7 visits with a session of sophrology.
224031746|NCT06529380|DEVICE|DBS ON|Electrical stimulation of the nucleus accumbens.
224031747|NCT06529380|DEVICE|DBS OFF|DBS will remain OFF (on at 0V).
224136128|NCT01412658|DIETARY_SUPPLEMENT|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
224136129|NCT06430112|DRUG|Liposomal Bupivacaine|After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).
224136130|NCT06430112|DRUG|Ropivacaine|Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
224136131|NCT05180110|DIAGNOSTIC_TEST|Venepuncture|Venous blood draw
224136132|NCT05180110|DIAGNOSTIC_TEST|Fingerstick|Capillary blood draw
224136133|NCT04863014|DRUG|evinacumab|Intravenous infusion every 4 weeks (Q4W)
224136134|NCT04863014|OTHER|Placebo|Intravenous infusion Q4W
224136135|NCT02602938|DRUG|Aspirin|Take aspirin (100mg) orally once a day for 2 months
224136136|NCT04301921|OTHER|Traditional punkcture site and No anticoagulation|Traditional punkcture site and No anticoagulation
224136137|NCT04301921|OTHER|Traditional punkcture site and ACT-guided anticoagulation|Traditional punkcture site and ACT-guided anticoagulation
224136138|NCT03464123|OTHER|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
224136139|NCT01889966|DRUG|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
224136140|NCT00632190|OTHER|fluorophotometry|
223413959|NCT05038774|OTHER|Printed Education Material|"1. Key points of current hypertension guidelines.~2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.~3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.~4. checklists to assist in the diagnosis of secondary hypertension.~5. Patient information leaflet about hypertension."
223413960|NCT00248365|BIOLOGICAL|Theralux extracorporeal photochemotherapy|
224136141|NCT00632190|PROCEDURE|colposcopic biopsy|
223413961|NCT00528489|BIOLOGICAL|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
223413962|NCT00528489|BIOLOGICAL|IL-12|Cytokine injection
223413963|NCT00528489|BIOLOGICAL|IL-15|Cytokine injection
224136142|NCT00632190|PROCEDURE|colposcopy|
223738909|NCT03181204|PROCEDURE|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
224136143|NCT00632190|PROCEDURE|light-scattering spectroscopy|
224299145|NCT01988506|DRUG|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
223413964|NCT02171312|DEVICE|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
224031748|NCT05404685|DEVICE|Low insufflation pressure (7mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 7 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
224031749|NCT05404685|DEVICE|Standard insufflation pressure (12mm Hg) for Robotic Assisted Partial Nephrectomy|"Use of insufflation pressure at 12 mm Hg. The groups will differ only with respect to the insufflation pressure level set on the AirSeal® system.~The level of pressure will be adjusted at the beginning of the surgery, after placement of the trocars, in accordance with the result of the randomization."
224031750|NCT02791737|BEHAVIORAL|Exercise Intervention|Complete individualized exercise program
224031751|NCT02791737|OTHER|Laboratory Biomarker Analysis|Correlative studies
224031752|NCT02791737|PROCEDURE|Physical Therapy|Complete individualized exercise program
224031753|NCT02791737|OTHER|Quality-of-Life Assessment|Ancillary studies
224031754|NCT02791737|OTHER|Questionnaire Administration|Ancillary studies
224031755|NCT06035874|DRUG|Bempedoic acid|Patient willl be randomized 1:1 in both the arms
224031756|NCT05042505|DRUG|Dapagliflozin 10Mg Tab|Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg
224031757|NCT05042505|DRUG|Sitagliptin 100mg|Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
224031758|NCT05844228|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
224031759|NCT05783375|OTHER|ADUNU program for delivery of RHD care services|The ADUNU program will be deployed by the Ugandan Ministry of Health and the involved District Health Offices to include echocardiography integrated into primary healthcare to screen for RHD and a registry-based care system to keep patients linked to care and prophylaxis.
224031760|NCT00692978|DRUG|Fluticasone Propionate_1.5|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
224031761|NCT00692978|DRUG|Fluticasone Propionate_3|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
224031762|NCT00692978|DRUG|Fluticasone Propionate_6|Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
224031763|NCT00692978|DRUG|FP From Active 250 ug MDI Inhaler|Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
223413965|NCT02171312|BEHAVIORAL|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
223413966|NCT05791539|PROCEDURE|Erector spinae plane block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
223413967|NCT05791539|PROCEDURE|erector spinae plane block + retrolaminar block|Patients will be divided into 2 groups group 1 will receive US-guided ESPB and group 2 will receive US-guided ESPB + US-guided Retrolaminar plain block before induction of GA.
223413968|NCT00691912|DRUG|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
223413969|NCT00691912|DRUG|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
224031764|NCT04540744|DRUG|FDC of macitentan/tadalafil (10 mg/20 mg)|FDC of macitentan/tadalafil (10 mg/20 mg) tablet will be administered orally as per assigned treatment sequence.
224031765|NCT04540744|DRUG|Macitentan 10 mg|Macitentan 10 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
224031766|NCT04540744|DRUG|Tadalafil 20 mg|Tadalafil 20 mg tablet will be administered orally as a free combination as per assigned treatment sequence.
224031767|NCT00607022|DEVICE|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
224031768|NCT02504515|OTHER|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
224031769|NCT02940821|OTHER|Toothbrushing|Mechanical plaque removal
224031770|NCT02940821|OTHER|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
224031771|NCT02940821|OTHER|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
224031772|NCT02940821|OTHER|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
224031773|NCT02940821|OTHER|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
224031774|NCT04842656|OTHER|Post isometric relaxation|Patients in group B will receive post isometric relaxation technique. Patient lying in supine position, with the treated leg is placed into flexion at the hip and knee, so that the foot rests on the table lateral to the contra lateral knee (the leg on the side to be treated is crossed over the other). Therapist places one hand on the contra lateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis (PIR MET). The starting position will be the 1st sign of resistance towards end range. Therapist Force will be same as patient's force. Initial effort is approximately 20% of patient's strength. Duration of contraction is 7-10 seconds with three repetitions
223413970|NCT06152146|DEVICE|Shockwave Therapy|Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)
223413971|NCT06152146|OTHER|SHAM shockwave therapy|Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
223413972|NCT00716014|DRUG|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
223413973|NCT00716014|DRUG|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
223413974|NCT04507386|BEHAVIORAL|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
223413975|NCT05218343|BEHAVIORAL|"EHR-based nudge interventions"|Change/introduction of default drug and frequency during electronic prescribing of high-risk drugs for a patient aged ≥65 years
223413976|NCT02649439|BIOLOGICAL|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopoxvirus
223413977|NCT02649439|BIOLOGICAL|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
223413978|NCT03017378|BIOLOGICAL|TB/FLU-01L|TB / FLU-01L (intranasal application)
223559921|NCT07034872|OTHER|Intervention Group|Following baseline assessments, a personalized 60-minute exercise program will be developed by the physiotherapist for each child in the intervention group, consisting of two face-to-face sessions and one asynchronous video-based session per week for eight weeks. Each session will include 30 minutes of multidimensional trunk-focused exercises-such as static and dynamic trunk control (e.g., reaching, rotational movements), scapular and pelvic mobilizations, isolated muscle training, proprioceptive activities, and core strengthening-followed by 30 minutes of conventional therapy, including upper and lower extremity strengthening, stretching for spastic muscles, balance training in standing, and gait exercises.
224031775|NCT04842656|OTHER|Active release technique alongwith conventional treatment|Patients in Group A will receive active release technique.ART will be applied with patient in prone lying, knee flexed at 90. The therapist will place his elbow tip on taut band of piriformisand direct pressure isapplied, patient is then asked to do internal rotation of hip, in order to achieve lengthening of the muscle. This will be repeated 5-7 times.
223413979|NCT03017378|BIOLOGICAL|TB/FLU-01L|TB/FLU-01L (sublingual application)
223413980|NCT01578473|DRUG|Vitamin D2|oral softgel 2000 IU once daily 9 months
223413981|NCT01578473|DRUG|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months"
223413982|NCT01578473|DRUG|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
223413983|NCT03884530|DRUG|Ticagrelor (Brilique) 90|Drug name Brilique 90 ml Drug form tablet
223738910|NCT03181204|PROCEDURE|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
223738911|NCT03181204|PROCEDURE|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
224031776|NCT02822638|OTHER|STEMI PATIENT Cohort|PCI
224136144|NCT04633473|BEHAVIORAL|SIB-Time Web-Application Tool|Parents used the dual-language SIBTime app to watch video stories about common sibling experiences, respond to question prompts, track connection routines, and listen to guided Acceptance and Commitment Therapy (ACT) exercises for parents. During the 4-week intervention period, parents used the app at their convenience.
224136145|NCT03166865|BIOLOGICAL|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10\~7 diluted on 5 mL of Platelet Rich Plasma
223413984|NCT03884530|DRUG|Aspirin 75mg|Drug name Aspirin 75 ml Drug form tablet
223413985|NCT05591976|OTHER|Exercise training program|16-week, structured exercise training program including resistance and aerobic exercise
223413986|NCT02451774|DRUG|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
223413987|NCT02451774|DRUG|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
223413988|NCT04141501|DRUG|Psilocybin|single dose of psilocybin (25mg). orally in form of a capsule
223413989|NCT04141501|DRUG|Placebo oral capsule|single dose of mannitol (100%)
223413990|NCT05756816|DEVICE|SurePulse VSP|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VSP placed on the volunteer.
223413991|NCT05756816|DEVICE|SurePulse VS|A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VS placed on the volunteer.
223413992|NCT00945035|DRUG|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
223413993|NCT00945035|DRUG|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
224031777|NCT00584597|DRUG|Saline|Saline Control
224031778|NCT00584597|DRUG|Traumeel S|Traumeel S 1 mL
224031779|NCT00584597|DRUG|Traumeel S|Traumeel S 2mL
224031780|NCT00584597|DRUG|Traumeel S|Traumeel S 3mL
224136146|NCT03166865|OTHER|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
224136147|NCT01824173|OTHER|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
224031781|NCT03511313|DEVICE|Renal denervation|After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
224031782|NCT03511313|DIAGNOSTIC_TEST|Renal angiography|A renal angiography according to standard procedure.
224031783|NCT04291599|DRUG|Ketorolac|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
224031784|NCT04291599|DRUG|Opioid|Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
224031785|NCT06567808|DRUG|Cefazolin|administration as outlined
224031786|NCT06567808|DRUG|Vancomycin|administered as outlined
224031787|NCT05363371|BEHAVIORAL|Minds and Mentors|Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
224031788|NCT05363371|BEHAVIORAL|Twelve Step Intervention Group|Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
224031789|NCT02769377|DEVICE|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
223413994|NCT06166446|DEVICE|subtractive technique|The milled denture teeth are then bonded into the milled recesses using a special PMMA bonding system.
223738912|NCT04857515|DEVICE|Clickotine®|Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.
224031790|NCT02769377|DEVICE|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
224031791|NCT04296253|GENETIC|SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor|blood sampling
224136148|NCT01824173|OTHER|Aerobic exercise|Moderate intensity for 45 minutes
224136149|NCT02421744|BEHAVIORAL|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
224136150|NCT02421744|BEHAVIORAL|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
224136151|NCT02683226|DRUG|Vipdomet|
223413995|NCT06166446|DEVICE|additive technique|The denture teeth were printed as one unit using the same method with tooth resin (DENTCA Denture Tooth, Shade A2).
223413996|NCT02888912|OTHER|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
223413997|NCT02888912|OTHER|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
223413998|NCT01958814|DRUG|Salbutamol|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
223413999|NCT01958814|DRUG|Placebo|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
223414000|NCT01063621|DRUG|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
223414001|NCT05865574|DRUG|BAT1706 Injection|1 vial/carton, 400 mg/16 mL/vial
224136152|NCT02683226|DRUG|Incresync|
223414002|NCT02896062|BEHAVIORAL|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
223738913|NCT03183375|DRUG|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
224031792|NCT01870232|PROCEDURE|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
224031793|NCT03120247|DRUG|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
224031794|NCT03120247|DRUG|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
224031795|NCT03120247|DRUG|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
224031796|NCT04532203|DRUG|CAR-T cells|Each subject receive CAR T-cells by intravenous infusion
224031797|NCT04532203|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
224031798|NCT06096987|OTHER|Electronic medical record portal videos|Teen to teen videos reviewing information about electronic medical record portals and information shared in electronic medical record portals.
224031799|NCT06096987|OTHER|General adolescent health videos|Teen to teen videos reviewing information about general adolescent health issues.
224031800|NCT03987178|BEHAVIORAL|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
224031801|NCT03987178|OTHER|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
224031802|NCT05425628|DEVICE|"NeoChord Transcatheter Mitral Repair System (or NeoChord System)"|"The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum."
224031803|NCT06053723|OTHER|Fonseca's Anamnestic Questionnaire|The questionnaire includes 10 questions about joint, head and neck pain, pain during masticatory activity, parafunctional habits, decreased joint motion, impaired occlusion and emotional stress.
223738914|NCT03338855|DRUG|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
224031804|NCT06053723|OTHER|Numeric Pain Scale|It is a simple, reliable and short-term method that is frequently used to measure pain intensity in the clinic.
224031805|NCT06053723|OTHER|Jaw Functionality Limitation Scale-20|"It includes a total of 20 items, with 0 indicating no limitation and 10 indicating severe limitation in each item, about the function of the TMJ during different activities, difficulty in chewing and jaw limitation."
224031806|NCT00627263|BEHAVIORAL|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
224031807|NCT01005459|DRUG|Tetracaine|Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
224031808|NCT01005459|DRUG|Bupivacaine|Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
224031809|NCT02280694|DRUG|Capecitabine|
224031810|NCT02280694|DRUG|Cyclophosphamide|
224031811|NCT02280694|DRUG|Methotrexate|
224031812|NCT02280694|DRUG|Celecoxib|
224136153|NCT06520319|DRUG|68Ga-MGS5|Each patient received a single intravenous injection of 68Ga-DOTATATE (2-4 mCi) and underwent PET/CT scanning 40-60 minutes after the injection. Or receive one intravenous injection of 68Ga-MGS5 and undergo two PET/CT scans at 1 and 2 hours post-injection, respectively.
224136154|NCT01156038|DEVICE|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
223414003|NCT03064815|DEVICE|Videocapsule endoscopy|"Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures."
223414004|NCT03064815|PROCEDURE|colonoscopy|Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
223414005|NCT03064815|DIAGNOSTIC_TEST|PROMETHEUS® IBD sgi Diagnostic™|This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
223414006|NCT03064815|DIAGNOSTIC_TEST|Fecal calprotectin|A stool test to measure inflammation in the gut.
224031813|NCT03998982|DRUG|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
224031814|NCT03998982|DRUG|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
224136155|NCT01948388|DRUG|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
223414007|NCT03961958|DRUG|Propofol reduction|Reduction of propofol target concentration
223414008|NCT04635995|BIOLOGICAL|LVGN7409|IV infusion once every 3 weeks (Q3W).
223414009|NCT05872555|DRUG|Psychiatric Drugs|Receiving any Antipsychotic, Benzodiazepine, antidepressant, mood stabilizer
223414010|NCT06097923|DRUG|Active fluid management with BIA monitoring|The participants in active fluid management with BIA monitoring arm received fluid supplementation targeting specific range of ECW ratio by BIA (0.390-0.406). If a patient with dehydrated status indicated by the ECW ratio was less than 0.390, a bolus infusion was performed using 250ml of crystalloid fluid (PlasmaLyte). If a patient with overhydrated status indicated by the ECW ratio was more than 0.406, 10mg of furosemide was administered. Changes in the ECW ratio were measured at one hour after initial intervention for fluid adjustment, and these processes continued until the ECW ratio was within the normal range (0.390-0.406).
223414011|NCT06097923|DRUG|Conventional fluid management without BIA monitoring|The participants in conventional fluid management without BIA monitoring arm underwent conventional fluid management without specific targets of ECW ratio by BIA.
223414012|NCT01600365|DRUG|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
223738915|NCT00151099|DRUG|high caloric drink with protein|
223738916|NCT00511667|DRUG|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
223738917|NCT00511667|DRUG|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
223738918|NCT04394104|OTHER|Survey|No intervention is being administered.
224136156|NCT04972487|DRUG|Tofersen|Administered as intrathecal bolus injection
224136157|NCT01959737|PROCEDURE|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
224136158|NCT05415852|DEVICE|Laser|Laser
224136159|NCT04757909|DIAGNOSTIC_TEST|Monthly Haemoglobinometry|"Monthly measurement of capillary hemoglobin with non-invasive techniques in primary health care.~Inclusion in a transfusion circuit with referral to a hospital day hospital if necessary."
224136160|NCT06273306|DEVICE|IMIDOC|Patient´s Mobile App for recording clinical data
224031815|NCT02730598|DEVICE|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to \~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
223414013|NCT01600365|DRUG|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
223414014|NCT00976976|DRUG|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
223414015|NCT01844648|DRUG|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
223414016|NCT01844648|DRUG|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
223414017|NCT01002430|BIOLOGICAL|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
223414018|NCT05924425|DRUG|Daridorexant 50 mg|Patients randomized in the experimental group will receive the treatment every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
224031816|NCT02730598|DEVICE|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
224031817|NCT04633486|DIAGNOSTIC_TEST|zoom-endoscopy|Endoscopic monitoring of intestinal transplant recipients is done with zoom-endoscopes for exact diagnostic of intestinal mucosa.
224136161|NCT03920826|DEVICE|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
223559922|NCT07034105|DIAGNOSTIC_TEST|Gait Analysis|"* Overground Walking: Stroke patients walk in a natural environment, collecting data on their gait parameters such as stride length, cadence, and gait speed.~* Treadmill: Patients walk on a treadmill at their comfortable pace, allowing for more control over their walking speed while measuring the same gait parameters as in overground walking.~* Body-Weight Supported Treadmill: Patients walk on a treadmill with a body-weight support system that reduces the load on the legs, enabling patients with more severe impairment to perform walking tasks safely while recording gait parameters."
223559923|NCT07033208|DEVICE|Feasibility to obtain thermal variance measurements using a wireless thermal capsule|A total of 10 healthy volunteers will be enrolled in this study all consented participants will receive the same intervention.
223559924|NCT07035938|OTHER|observational study|observational study
224031818|NCT02949804|BEHAVIORAL|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
224031819|NCT06095700|PROCEDURE|first rib resection|standard first rib resection
224031820|NCT06095700|PROCEDURE|First rib avulsion|As the active treatment, just instead of resectioning the first rib, we will do an avulsion of the first rib through the same incision
223414019|NCT05924425|DRUG|Placebo|Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
223414020|NCT05924425|PROCEDURE|Polysomnography|A full-night polysomnography recording with blood pressure and heart rate monitoring will be performed at night in the Sleep Laboratory from 11 p.m. to 7 a.m. at baseline (before the randomization) and at the end of each period (Period A/M1, Period B/M2). The recording procedure consists of an electroencephalogram, two electrooculograms, an electromyogram, an electrocardiogram, and a videographic recording. This examination is painless (the sensors are glued to the skin for the duration of the recording). The advantages of this video-polysomnography are based on the evaluation of sleep architecture, micro-arousals, respiratory events and nocturnal motor behavior.
223414021|NCT05924425|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, M1, M2
223414022|NCT05924425|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems will be performed at inclusion, M1, M2
223414023|NCT05924425|PROCEDURE|Actimetrics|Measurement of actimetrics for seven days in average (with a minimum of three nights required) prior to the inclusion visit, M1 visit and M2 visit.
223414024|NCT05924425|PROCEDURE|24-hour Ambulatory Blood Pressure Monitoring (ABPM|Evaluation of the 24-hour hemodynamic profile of a patient by multiple and regular blood pressure and heart rate measurements. The ABP will be monitored at inclusion, M1 and M2
223414025|NCT05924425|OTHER|Biomarker assay|Determination of AD biomarkers (Aβ42, Aβ40, Tau, P-Tau, neurofilament) and proinflammatory cytokines (TNFa, IL6) in serum and cerebrospinal fluid (CSF) and dosage of Orexin-A/hypocretin-1 in the CSF
223414026|NCT02578381|DEVICE|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
223559925|NCT06713798|DRUG|Atezolizumab 1200 mg IV|atezolizumab (intravenous 1200mg Q3W)
223559926|NCT06713798|DRUG|Tiragolumab 600 mg IV|Tiragolumab (intravenous 600mg Q3W)
223559927|NCT07034716|PROCEDURE|CORONARY BYPASS SURGERY USING CARDIOPULMONARY BYPASS|The study will be conducted on cardiac surgical patients who will undergo isolated elective CABG with nonpulsatile flow during cardiopulmonary bypass
223414027|NCT02578381|DEVICE|Validation of Boston Scientific pressure wire|
223414028|NCT04800887|DEVICE|TECNIS Eyhance intraocular lens|Cataract surgery and implantation with extended depth of focus intraocular lens
223414029|NCT04800887|DEVICE|Monofocal intraocular lens Tecnis ZCB00|Cataract surgery and implantation with monofocal intraocular lens
224031821|NCT00357851|DRUG|Aprotinin|
224031822|NCT05344729|DRUG|TQB3616 Capsule|It inhibits the proliferation of tumor cells by reducing the level of retinoblastoma protein (Rb) phosphorylation in cancer cells and blocking the progression of cells from G1 to S phase.
224031823|NCT03270423|DEVICE|PathMate2|To improve self-regulation of overweight adolescents and subsequently their weight status, we tested, whether a biofeedback relaxation exercise decreases stress and whether relaxation services as well as sensor data integration implemented in a novel Smartphone App supported intervention have effects on stress, physical activity and weight outcomes. During the intensive phase of 6 months, patients of the intervention group (IG) are equipped with a smartphone and a specially designed chat App with game character, which encourages them through a virtual coach to achieve daily activity, healty lifestyle or relaxation challenges and earn virtual rewards, to increase adherance to the health information system.
224031824|NCT03270423|DEVICE|PathMateS|Overweight or obese adolescents of the treatment as-usual group (CG) have monthly visits on site during the intensive phase. Counseling for physical activity, healthy eating and lifestyle as well as psychosocial wellbeing is provided by a pediatrician.
224031825|NCT05786495|OTHER|Early Discontinuation of Antibiotics|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be stopped after 72 hours of treatment and defervescence for 24 hours, irrespective of neutrophil count
224031826|NCT05786495|OTHER|Standard of Care|Antibacterial treatment (i.e piperacillin/tazobactam, ceftazidime, cefepime, meropenem, vancomycin, amikacin, tobramycin, ciprofloxacin) will be continued until resolution of neutropenia
224031827|NCT06176807|RADIATION|Venous Excess Ultrasound Score|"\-- The IVC diameter : Grade 0: \<5 mm with respiratory variation Grade I: 5-9 mm with respiratory variation Grade II: 10-19 mm with respiratory variation Grade III: \>20 mm with respiratory variation Grade IV: \>20 mm with minimal or no respiratory variation~\- Hepatic vein (HV) interrogation by pulsed wave Doppler identification and analysis of A, S, and D waves.~Grade 0: normal S \> D Grade I: S \< D with antegrade S Grade III: S flat or inverted or biphasic trace - Portal vein Doppler (PD)as follow: Grade 0: \<0.3 pulsatility index Grade I: 0.3-0.49 pulsatility index Grade III: 0.5-1.0 pulsatility index Pulsatility index is calculated as (Vmax - Vmin)/Vmax~\- VEXUS staging of venous congestion. (VEXUS ) Grade 0: IVC grade \<III, HD grade 0, PV grade 0 Grade I: IVC grade IV, but normal HV/PV pattern Grade II: IVC grade IV with mild flow pattern abnormalities in HV/PV Grade III: IVC grade IV with severe flow pattern abnormalities in HV/PV"
224031828|NCT03282240|BIOLOGICAL|QIV-HD|0.7 mL-dose was administered intramuscularly (IM) into the upper arm area.
224031829|NCT03282240|BIOLOGICAL|Licensed TIV-HD1|0.5 mL-dose was administered IM into the upper arm area.
224031830|NCT03282240|BIOLOGICAL|Investigational TIV-HD2|0.5 mL-dose was administered IM into the upper arm area.
224031831|NCT00369473|DRUG|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
224031832|NCT00369473|DRUG|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
224031833|NCT05427604|OTHER|Olive oil|ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
224031834|NCT05427604|OTHER|Olive Oil|ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
224031835|NCT05427604|OTHER|DHA oil|ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h
224031836|NCT05427604|OTHER|DHA oil|ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)
224031837|NCT02845843|DRUG|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
224031838|NCT02845843|DRUG|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
224031839|NCT01675479|DEVICE|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
224031840|NCT03254485|DRUG|IW-1973|Oral Tablet
224031841|NCT03254485|DRUG|Placebo Oral Tablet|Oral Tablet
223414030|NCT04913688|PROCEDURE|bedside ultrasound performed group|If deep vein thrombosis (DVT) is suspected among patients who visit the emergency department, an emergency physician performs bedside ultrasound of lower extremities to the patients agreed to participate in this study. The patients also are examined duplex ultrasound by radiologist.
223414031|NCT05326178|OTHER|General information about depression|"Before starting the intervention, the participants are told that they will be shown parts of a website about depression. The participants are instructed to carefully attend to the website (e.g., to read the text precisely, to hear attentively to the podcasts and to view carefully the videos and images on the website). The time window spent for the reception of each part of the website are fixed.~The participants will be shown parts of the website regarding general information about depression."
223414032|NCT06120088|DRUG|Bubpivacaine|Bupivacaine is a long-acting local anesthetic commonly used to provide pain relief by blocking nerve signals in a specific area. It's often utilized for various medical procedures and surgeries, offering prolonged numbing effects.
223414033|NCT06120088|DRUG|dexamethasone|Dexamethasone is a potent corticosteroid with anti-inflammatory properties. It's frequently employed as an adjunct in medical treatments to reduce inflammation and swelling, and in some cases, to prevent nausea and vomiting associated with certain medications or procedures.
224031842|NCT01225419|DRUG|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
223414034|NCT06120088|DRUG|fentanyl|Fentanyl is a powerful synthetic opioid pain reliever. It acts on the central nervous system to alleviate severe pain. Fentanyl is significantly potent and is used in medical settings for acute pain management, such as during surgeries or for chronic pain in cases where other opioids may not be as effective.
223414035|NCT00090493|BIOLOGICAL|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
224031843|NCT01767480|DEVICE|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
224031844|NCT01767480|BEHAVIORAL|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
224031845|NCT05569031|DRUG|Venlafaxine|patients with tramadol abuse will use venlafaxine for 10 days.
224031846|NCT05569031|DRUG|Lofexidine|patients with tramadol abuse will use lofixidine for 10 days.
224031847|NCT02910739|DRUG|MK-8931|MK-8931 40 mg
224031848|NCT02146326|BEHAVIORAL|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
224031849|NCT02146326|BEHAVIORAL|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
224031850|NCT00106418|DRUG|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
224031851|NCT06446544|PROCEDURE|VPFE monitoring with intraoperative alveolar recruitment maneuvers.|VPFE monitoring with intraoperative alveolar recruitment maneuvers.
224031852|NCT06446544|PROCEDURE|VPFE monitoring with intraoperative alveolar recruitment maneuvers.|VPFE monitoring with intraoperative alveolar recruitment maneuvers.
224031853|NCT04866251|DIAGNOSTIC_TEST|Gag reflex test; assessment of Mallampati Score|Testing of gag reflex Assessment of Mallampati Score
224031854|NCT02614456|DRUG|interferon-gamma and nivolumab|
224031855|NCT03813420|BEHAVIORAL|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
224031856|NCT03813420|BEHAVIORAL|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
224136162|NCT03920826|DEVICE|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
224136163|NCT01985009|DEVICE|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
224136164|NCT01836887|DIETARY_SUPPLEMENT|Very low polyphenol fruit based drink (control)|
224136165|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - low|
224136166|NCT01836887|DIETARY_SUPPLEMENT|Polyphenol-enriched fruit-based drink - high|
224299146|NCT06258759|BIOLOGICAL|autologous platelet-rich plasma supplement|the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
223414036|NCT00090493|BIOLOGICAL|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
223414037|NCT02071706|DEVICE|PET/MRI system|Enrolled subject undergoes PET/MR scan
224031857|NCT03813420|BEHAVIORAL|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
224031858|NCT01104116|RADIATION|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
224031859|NCT05922293|OTHER|blow bottle|When you blow through a tube into water in a bottle, the pressure in the airways increases. This opens up the passageways between bronchioles, allowing air to flow behind the mucus and push it into the larger airways. This way, it will be easy to remove the mucus by coughing or huffing.
224031860|NCT05922293|OTHER|percussion|"Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises.~* Do this for a total of 10 breaths,~* Perform two huffs, and~* Cough.~* Close their mouth around the tube and exhale slightly forcefully for 3 seconds to produce bubbles. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized"
224031861|NCT02584803|RADIATION|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~1. Patient Acceptability of procedure~2. Patient Comfort:~3. Ease of exam for the examiner"
224031862|NCT05907278|BEHAVIORAL|Advanced Cooking Education|"Participants attend the ACE Program for 12 weeks after school.~On one assigned day of the week, participants attend ACE virtually. The session will begin with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes).~On any day during the week, the students will make a dish using groceries they received (1 hour)."
224031863|NCT06124287|DIAGNOSTIC_TEST|MR Enterography (MRE)|MRI scan
224031864|NCT00227474|DRUG|recombinant modified vaccinia Ankara-5T4 vaccine|
224031865|NCT00227474|PROCEDURE|adjuvant therapy|
224031866|NCT00227474|PROCEDURE|recombinant viral vaccine therapy|
224031867|NCT01340651|DRUG|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
224031868|NCT01722110|DRUG|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
224031869|NCT01722110|DRUG|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
224031870|NCT04216901|DIAGNOSTIC_TEST|Endoscopists refer to AI for diagnosis|The AI will provide a pathological prediction of the lesion during colonoscopy.
224031871|NCT00565539|DRUG|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
224031872|NCT04754204|DEVICE|Arrhythmia Management System (AMS)|AMS records rhythm, heart rate, subject-reported symptoms, and multiple parameters that include respiration rate, activity and body posture.
224031873|NCT00125281|DRUG|S-adenosyl-methionine (SAMe) capsules|
223414038|NCT00179777|DIETARY_SUPPLEMENT|Hydrolysed infant formula|Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.
224031874|NCT00024986|DRUG|Tenofovir DF|
224031875|NCT03622619|OTHER|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
224031876|NCT03622619|OTHER|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
224031877|NCT03187574|DEVICE|Elevate Ant™|Surgery with Elevate Ant™
224031878|NCT03187574|DEVICE|Perigee™|Surgery with Perigee™
223414039|NCT00179777|DIETARY_SUPPLEMENT|Nonhydrolysed infant formula|Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.
223414040|NCT01214083|DRUG|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
223414041|NCT01214083|DRUG|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
223414042|NCT01214083|DRUG|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
223414043|NCT04289376|OTHER|Gaze tracking - no intervention|Monitor gaze as subjects watch a video
224031879|NCT03531944|OTHER|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
224031880|NCT03531944|OTHER|Usual care|Usual care with physician and as needed visit to the nurse
224031881|NCT03774966|PROCEDURE|Adductor Canal Block + Catheter & IPACK block|Adductor Canal Block + Catheter \& IPACK block
224136167|NCT05942157|OTHER|Therapeutic Drug Monitoring (TDM)|Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
223414044|NCT01908829|DRUG|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
224031882|NCT03774966|PROCEDURE|Adductor canal block + catheter|Adductor canal block + catheter
224031883|NCT04361942|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Intravenous injection of 1 million MSCs (MSV cells)/Kg suspended in 100 ml physiological saline solution.
224031884|NCT04361942|OTHER|Placebo|Intravenous injection of 100 ml physiological saline solution containing no cells
224031885|NCT02181387|DRUG|Acetaminophen|administered every 6 hours by mouth up to 4 doses
224031886|NCT02181387|DRUG|Placebo|
223414045|NCT01908829|DRUG|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
223414046|NCT01908829|DRUG|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
223414047|NCT01908829|DRUG|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
224031887|NCT05678751|DIAGNOSTIC_TEST|lower genital tract microorganisms detection using Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS)|Detection of pathogens and microorganisms in the lower genital tract of infertile and spontaneously pregnant women by a new MALDI-TOF MS-based technique
224031888|NCT02715791|BEHAVIORAL|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified."
224031889|NCT02715791|OTHER|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
224031890|NCT01406340|DRUG|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
224031891|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
224031892|NCT03990181|DIETARY_SUPPLEMENT|meal matrix & CS|Test meal consumed with the control supplement
224031893|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
224031894|NCT03990181|DIETARY_SUPPLEMENT|no-matrix & CS|Test drink consumed with the control supplement
224031895|NCT05321147|BIOLOGICAL|lacutamab|Patients will receive a fixed dose of 750mg as 1-hour IV infusion
224031896|NCT03073265|DEVICE|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
224031897|NCT03866161|DEVICE|Continuous positive airway pressure|Continuous positive airway pressure treatment
224031898|NCT05367115|OTHER|longitudinal observational study|longitudinal observational study
224031899|NCT02849288|DEVICE|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
224031900|NCT01822509|BIOLOGICAL|Ipilimumab|Given IV
224031901|NCT01822509|OTHER|Laboratory Biomarker Analysis|Correlative studies
224031902|NCT01822509|BIOLOGICAL|Nivolumab|Given IV
224031903|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Deflazacort|Subjects with duchenne muscular dystrophy undergoing drug therapy with Deflazacort
224031904|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group with Prednisone/Predisolone|Subjects with duchenne muscular dystrophy undergoing drug therapy with Prednisona/Predinisolone
224031905|NCT04740554|BEHAVIORAL|Duchenne Muscular Dystrophy group without Corticosteroids therapy|Control group with duchenne muscular dystrophy without the use of corticosteroid drug therapy.
224031906|NCT04740554|BEHAVIORAL|Control Group Typically Developing|Control group with tipical development.
224031907|NCT02823366|DRUG|Fenofibrate|
224031908|NCT02823366|DRUG|UDCA|
223414048|NCT01908829|DRUG|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
224031909|NCT05235230|DRUG|Test product (T) 25 mg Film Coated Tablets|Film Coated Tablets products containing 25 mg Quetiapine
224031910|NCT05235230|DRUG|Reference product (R) 25 mg Film Coated Tablets|Reference product (R) 25 mg Film Coated Tablets
224031911|NCT01696942|DRUG|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
224031912|NCT01696942|DRUG|Mesalamine|mesalamine 800 mg orally three times daily
224031913|NCT04039256|DEVICE|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
224031914|NCT00921596|PROCEDURE|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
224031915|NCT00265746|DRUG|Metformin|
224136168|NCT05341505|BEHAVIORAL|Emotion Regulation Intervention|We will administer a cognitive-behavioral treatment targeting emotion dysregulation, including mindfulness skills and other cognitive and behavioral emotion regulation skills.
224136169|NCT02727270|OTHER|No Intervention - Observational Study|No Intervention - Observational Study
224031916|NCT00265746|BEHAVIORAL|Lifestyle intervention - diet, physical activity|
224136170|NCT01260935|PROCEDURE|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
224136171|NCT01260935|PROCEDURE|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
224299147|NCT06258759|BIOLOGICAL|no autologous platelet-rich plasma supplement|the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
224299148|NCT03958123|DRUG|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
224136172|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
224136173|NCT00242385|BIOLOGICAL|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
224136174|NCT03089216|PROCEDURE|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
223738919|NCT01230268|OTHER|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
223738920|NCT01073982|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
224298344|NCT05389982|OTHER|mHealth (GetWell)|GetWell Loop utilizes an interactive health care application to allow patients to more actively participate in their care. We plan to work with GetWell to develop a custom build plan for kidney stone formers to achieve key aspects of stone prevention and provide patient education. This care plan will be developed using native capabilities within GetWell Loop.
224031917|NCT06370260|DEVICE|Hydrogen Carbamide/Peroxide Gel|"UNISEPT® ORAL GEL is an oral gel containing 10% w/v urea peroxide which releases 3.50% w/w hydrogen peroxide, glycerin, propylene glycol, carbopol, disodium EDTA, sodium saccharin, methyl salicylate, menthol, and water, serving as the active ingredient.~Participants should apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0., i.e. the day of the biopsy (see procedure in the detailed description). Consumption of liquid or solid foods should be avoided for at least thirty minutes following gel application.Participants are asked to maintain their usual oral hygiene routine.~UNISEPT® ORAL GEL is a Class IIa, CE-marked medical device made and distributed by Intermed S.A. and Ioulia And Irene Tseti Pharmaceutical Laboratories S.A."
224031918|NCT06370260|DEVICE|Placebo Gel|"Placebo gel is a similar (look-and-taste-alike) product to UNISEPT® ORAL GEL, made by the same manufacturer, without active ingredients, containing glycerin, propylene glycol, carbomer, menthol, sodium saccharin, methyl salicylate, triethanolamine.~Participants are called upon to apply the gel in exactly the same way as the experimental product, i.e apply the gel to the biopsy area and the corresponding sextant teeth three times daily, leaving it on for five minutes without rinsing, for a total of 14 days, beginning on day 0."
224298345|NCT05389982|OTHER|Standard Care|Office based pathway
224298346|NCT03219931|DRUG|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
224298347|NCT03219931|DRUG|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
223414049|NCT01908829|DRUG|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
223738921|NCT05748977|DRUG|SABA SAMA ICS Vs LABA LAMA ICs|Short acting agents,long acting agents ,ics
223738922|NCT05372328|OTHER|Position of arm while taking blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which their arm position changes prior to each set of measurements.
223738923|NCT00324324|DRUG|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
223738924|NCT00324324|DRUG|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
223738925|NCT04963933|DEVICE|Nautilus endovascular device|Patients will be treated with the Nautilus Endovascular device followed by treatment follow up for up to 6 months
223738926|NCT02025244|PROCEDURE|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
224031919|NCT05997498|PROCEDURE|mechanical cervical dilatation|mechanical cervical dilatation during elective cesarean section
224031920|NCT01668511|BIOLOGICAL|ABT-981|Injection
224031921|NCT01668511|BIOLOGICAL|Placebo|Placebo Injection
224031922|NCT03666936|OTHER|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
224031923|NCT01142856|BIOLOGICAL|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
224031924|NCT04031716|BEHAVIORAL|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
224031925|NCT03413735|OTHER|Green Tea Extract|Confections containing green tea extract that will be ingested daily for 4 weeks
224298348|NCT03275766|OTHER|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
224298349|NCT03275766|OTHER|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
224299149|NCT03958123|DRUG|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
224136175|NCT03089216|PROCEDURE|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
223414050|NCT01908829|DRUG|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
224031926|NCT03413735|OTHER|Placebo|Confections containing no green tea extract that will be ingested daily for 4 weeks
223559928|NCT07034716|PROCEDURE|cardiac surgical patients who will undergo isolated elective cardiopulmonary bypass|The study will be conducted on cardiac surgical patients who will undergo isolated elective CABG with pulsatile flow during cardiopulmonary bypass
224136176|NCT03089216|PROCEDURE|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
224136177|NCT03089216|PROCEDURE|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
224136178|NCT03089216|DRUG|8% arginine and calcium carbonate|using during all the treatment.
224136179|NCT03280641|DRUG|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
224136180|NCT03280641|DRUG|Warfarin Sodium|Target INR:1.6-3.0
224136181|NCT02260245|BEHAVIORAL|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
224136182|NCT02263482|OTHER|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
224136183|NCT02263482|OTHER|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
224136184|NCT02263482|OTHER|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
224136185|NCT02742350|DEVICE|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
224136186|NCT03365427|OTHER|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
224136187|NCT00001165|DRUG|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
224136188|NCT06254027|DEVICE|Forte|One application per day for a complete treatment period.
223414051|NCT01908829|DRUG|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
223414052|NCT04093011|PROCEDURE|Congenital Heart Disease Surgery|Patients with congenital heart disease will undergo congenital heart disease surgery.
223559929|NCT07034196|OTHER|Primary Care Treatment in lieu of Rheumatologist|RA patients will be randomized to receive their RA care via their established PCP who completed a structured training course in RA and who has monthly case review/consultation sessions with the rheumatology team in this study
223559930|NCT07033884|BEHAVIORAL|Peer Engagement and Exploration of Responsibility and Safety|PEERS involves a one-on-one session with a firearm-owning Veteran peer interventionist. The appointment will last between 15 minutes and one hour, and the modality (i.e., in-person or virtual) will be based on Veteran participant preference. Principal components of the PEERS session will include: 1) engaging - initiating conversation in a non-confrontational manner; 2) focusing - quickly concentrating the discussion on the topic of firearms and means safety; 3) evoking - reflecting the participants' reasons both for and against engaging in means safety, leveraging the participants' own rationale for change as a tool for increasing behavior change; and 4) planning - once a plan is agreed upon, this information is put into writing. Participants will also be provided the same psychoeducational materials provided to the participants in the active control condition.
224136189|NCT06254027|DEVICE|Active Cover Light|One application per day for a complete treatment period.
224136190|NCT06254027|DRUG|Loceryl|One application per week for a complete treatment period.
224136191|NCT05763160|DRUG|RZL-012|Ready to use drug product for injection into the subcutaneous fat
224136192|NCT06080776|DRUG|SH-1028 tablets|The initial dose of SH-1028 tablets is 200 mg once daily.
224136193|NCT06080776|DRUG|Placebo SH-1028 tablets|Placebo SH-1028 tablets.
224136194|NCT04547894|DRUG|ASC09F|ASC09F (300 mg ASC09 and 100 mg Ritonavir) one tablet at a time, once per day, up to 7 days.
224136195|NCT00706667|DRUG|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
224136196|NCT05753280|DRUG|Vitamin D|Patients take 800 mg vitamin D capsules daily during the whole treatment period
224136197|NCT00417976|DRUG|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
224136198|NCT00417976|DRUG|Bevacizumab|10 mg/kg every 2 weeks.
224136199|NCT00417976|DRUG|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
224136200|NCT04348591|BEHAVIORAL|Cognitive Restructuring|All participants will learn how to change their thinking in order to be less upset when confronted with stressors
223414053|NCT01481662|DEVICE|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
224136201|NCT04348591|DEVICE|neurostimulation|all participants will receive inhibitory, excitatory, and sham transcranial magnetic stimulation over different neural targets during the experimental session. The purpose of the neurostimulation is not treatment, but causal interference/enhancing of brain circuitry to identify candidate neural regions for future interventions
224136202|NCT00032968|DRUG|Buprenorphine/naloxone|
224136203|NCT00780169|DRUG|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~* sorafenib starting dose 400 mg/day~* irinotecan starting dose 80 mg/m2 on day 1"
224136204|NCT03858062|DEVICE|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
224136205|NCT03858062|DEVICE|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
224136206|NCT01022567|PROCEDURE|Appendicectomy|Standard appendicectomy
224136207|NCT01022567|DRUG|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
224031927|NCT02979483|OTHER|14-EISCP|"The 14-EISCP starts with the end of the first visit medical for patients who have symptoms suspicious of or confirmed symptomatic aPDAC (ECOG PS ≥ 2 and/or initially ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel):~The The 14-EISCP will include:~* Pain management,~* Nutritional management,~* Pathological examination and site of biopsy,~* Imaging,~* Endoscopy for diagnosis purpose or for biliary/duodenal stenting.~After the 14-EISCP, patients will receive best supportive care or chemotherapy according to their ECOG PS status:~* ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~* ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel Patients will be treated by: FOLFOX7 lightened"
224031928|NCT04790019|BEHAVIORAL|Low energy availability|Participants will be provided with food to eat every day and will not be permitted to consume any other calorie containing foods or beverages. This amount of energy contained within the food provided will be one third of that contained in the food provided in the control condition (45 kilo-calories per kilogram of fat-free mass per day) and will be standardized between and within participants for carbohydrate, protein and fat composition.
224031929|NCT04790019|BEHAVIORAL|High impact jumping|Participants will perform a brief session of high impact jumping every morning (10 maximum effort vertical counter-movement jumps, and 5 maximum effort lateral drop jumps in each direction) and a similar session of high impact jumping every evening (20 maximum effort vertical counter-movement jumps).
224031930|NCT03794570|DEVICE|Blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
224136208|NCT04078672|PROCEDURE|NOTAL-OCT V3.0|AMD and DR patients
224031931|NCT03794570|DEVICE|Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
224136209|NCT02998060|PROCEDURE|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
224031932|NCT01598311|DRUG|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
224031933|NCT01598311|DRUG|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
224031934|NCT01598311|DRUG|Placebo|Placebo size 00 opaque hard gelatin capsules.
224136210|NCT02998060|DEVICE|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
224136211|NCT02998060|DEVICE|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
224136212|NCT03371160|DEVICE|Nutriplace™ System|The Nutriseal™ Nutriplace™ System is an electromagnetic tracking system for feeding tube placement designed to aid qualified operators in the placement of the Nutriseal™ Enteral Feeding Tube™ into the stomach or small intestine.
224136213|NCT03177980|DRUG|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
224136214|NCT03177980|DRUG|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
224136215|NCT05272527|BEHAVIORAL|Transition to Motherhood Program|Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
224136216|NCT00991380|BEHAVIORAL|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
224136217|NCT00991380|BEHAVIORAL|Usual Care|Control
224136218|NCT01003080|DEVICE|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
224136219|NCT01003080|OTHER|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
224136220|NCT00143260|DRUG|Viagra (Sildenafil Citrate) 100 mg|
224136221|NCT04246580|PROCEDURE|Indocyanine green-guided systematic pelvic lymphadenectomy|Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
223414054|NCT02365389|DRUG|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
224136222|NCT01317667|BIOLOGICAL|RVEc|
224136223|NCT04482868|PROCEDURE|Percutaneous screw fixation through K-wire-assisted reduction and maintenance|Percutaneous screw fixation for acute scaphoid fractures through K-wire-assisted reduction and maintenance
224136224|NCT02104804|DRUG|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
224136225|NCT02104804|DRUG|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
224299150|NCT03958123|DRUG|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
224136226|NCT03509272|DEVICE|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
224031935|NCT05560347|OTHER|Hot water application|Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
224136227|NCT00603434|DRUG|OROS-MPH|18 mg bid on days 1 and 2
223738927|NCT02025244|PROCEDURE|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
223738928|NCT01297140|BEHAVIORAL|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
223738929|NCT01402674|DRUG|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
224031936|NCT00680784|DRUG|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
224031937|NCT00680784|OTHER|Placebo Patch|Placebo Patch
224136228|NCT00603434|DRUG|OROS-MPH|27mg bid on days 3 and 4
224298350|NCT03275766|OTHER|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
224031938|NCT06499727|DRUG|Acetazolamide|Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
224031939|NCT06499727|DRUG|Placebo|Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
224031940|NCT05972564|DRUG|Empagliflozin 25 MG|Empagliflozin is an FDA-approved SGLT2 inhibitor used for the treatment of type 2 diabetes, with off-label use for diabetic kidney disease and for heart failure with reduced ejection fraction even in those without diabetes.
224298351|NCT03275766|OTHER|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
223414055|NCT02365389|DRUG|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
224031941|NCT05972564|DRUG|Placebo|Placebo consists of gelatin capsules.
224031942|NCT00688103|DRUG|ETN Alone|etanercept (25 mg, twice/week, s.c.)
224136229|NCT00603434|DRUG|OROS-MPH|35 mg bid on days 5-9
224136230|NCT00354263|BIOLOGICAL|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
224136231|NCT00354263|BIOLOGICAL|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
224136232|NCT00394290|DEVICE|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
224136233|NCT02720016|BEHAVIORAL|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
223414056|NCT02637401|BEHAVIORAL|Dialectical Behaviour Therapy|
223414057|NCT05695014|OTHER|Teach Back Metod|teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
223414058|NCT04052243|DIAGNOSTIC_TEST|Invasive exercise testing|Invasive hemodynamic exercise testing
223414059|NCT05797935|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin was given at a dose of 10 mg/day in one group and its effect was observed on the pancreatic fat content
223414060|NCT03391570|DRUG|COX-2 inhibitor|Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
223414061|NCT03391570|DRUG|Placebo Oral Tablet|Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
223414062|NCT03391570|PROCEDURE|Preoperative peritoneal biopsy|Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
223414063|NCT03391570|PROCEDURE|Single-port laparoscopic surgery|Single-port laparoscopic surgery with CO2 gas
223414064|NCT03391570|PROCEDURE|Postoperative peritoneal biopsy|Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
223414065|NCT02792192|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
223414066|NCT02792192|BIOLOGICAL|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
223414067|NCT02247440|DRUG|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
224031943|NCT00688103|DRUG|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
224031944|NCT06820710|OTHER|Physical activity|Appropriate exercises for supervised small group sessions will be prescribed by a physiotherapist or expert in exercise science. Each session will last approximately 40 minutes, three times a week, and will be based on the international guidelines for physical exercise in the elderly population, and the VIVIFRAIL Multicomponent Physical Exercise Program to Prevent Frailty and the Risk of Falls. Accelerometers and other wearable sensors (smartwatches) will be used to monitor the physical activity performed.
224031945|NCT06820710|OTHER|Cognitive stimulation|Cognitive stimulation will be delivered by expert neuropsychologists twice a week (48 sessions in total) for approximately 30 minutes. Residents will be divided into small groups (3-5 people) of similar cognitive level, and the intervention will be delivered using a computerized tool (REmote stimulation for COgnitive DEcline (RECODE) developed by researchers at the University of Padova with the aim of stimulating different domains (i.e., attention, working memory, visual memory, language, orientation and executive functions) through exercises of increasing difficulty.
224031946|NCT06820710|OTHER|Nutritional Intervention|Participants in the intervention group will be advised to follow a Mediterranean diet and will also receive functional foods; in particular, they will be offered 80 g/day of sourdough bread fortified with vegetable matrix rich in polyphenols (e.g., olive leaves) and 100 g/day of probiotic artichokes on alternate days.
223414068|NCT06012890|OTHER|Automation of cardiac MRI acquisition|The intervention will consist of the automation of the cMRI examination.
223414069|NCT02002455|DEVICE|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
223414070|NCT06070181|DEVICE|Enamel matrix derivate|'Applying Enamel matrix derivate in the periodontal pockets after completing the non-surgical periodontal treatment
223414071|NCT06070181|PROCEDURE|Non-surgical periodontal treatment|No additional/adjunctive treatment with Emdogain
223414072|NCT02360150|RADIATION|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
223414073|NCT03088124|DRUG|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
223414074|NCT02320058|DRUG|Ipilimumab|
223414075|NCT02320058|DRUG|Nivolumab|
223414076|NCT00695279|PROCEDURE|Venipuncture|Blood draw
223414077|NCT06062121|DEVICE|Motor-cable-driven Rehabilitation Robotic System|Subjects will wear the motor-cable-driven system and receive 30 minutes (including preparation time) wrist and forearm robot-assisting exercise
223414078|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
223414079|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
224031947|NCT06820710|OTHER|Vaccinations|Participants in the intervention group will be offered to receive appropriate vaccinations according to the national vaccination calendar. Vaccine doses will be provided by the Department of Preventive Medicine, Vaccine Office, National Health Service, on prescription from the general practitioners.
223414080|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
223414081|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|2 doses 2 months apart
223414082|NCT01339923|BIOLOGICAL|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
223414083|NCT01339923|BIOLOGICAL|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
223414084|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
223414085|NCT01339923|BIOLOGICAL|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
223414086|NCT02809547|DEVICE|Dried Blood Spot device|
223414087|NCT05717049|DRUG|Theophylline Tablets|12 week oral treatment
223738930|NCT01392976|DRUG|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
223738931|NCT01392976|DRUG|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
223738932|NCT05589207|DIAGNOSTIC_TEST|Vascular wall invaded|Inferior vena cava vascular wall is invaded according to pathologic examination on the postoperative tumor thrombus/ vascular wall specimen.
223414088|NCT06078007|BEHAVIORAL|MyMoodCoach|The MyMoodCoach prevention intervention is an evidence-based online intervention based on cognitive-behavioral therapy principles such as behavioral activation, problem solving and challenging negative thoughts.
223414089|NCT02157285|BEHAVIORAL|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
223414092|NCT04762615|DIAGNOSTIC_TEST|AMH level measurement|AMH level measurement using ELISA test from blood samples
223414093|NCT05334485|DRUG|Pyridostigmine Bromide|Oral 60mg pyridostigmine bromide
223414094|NCT05334485|OTHER|Placebo|Oral starch placebo
223414095|NCT06683066|DRUG|Triprorelin for injection|Specification: Triprorelin for injection 3.75mg. Produced and supplied by Qilu Pharmaceutical Co.
223414096|NCT06683066|DRUG|Diphereline|Specification: Diphereline 3.75mg. Produced by Ipsen Pharma Biotech and supplied by Qilu Pharmaceutical Co.
223414097|NCT00729157|RADIATION|Fludeoxyglucose F-18|Correlative studies
223414098|NCT00729157|OTHER|Laboratory Biomarker Analysis|Correlative studies
223414099|NCT00729157|OTHER|Pharmacological Study|Correlative studies
223414100|NCT00729157|PROCEDURE|Positron Emission Tomography|Correlative studies
223414101|NCT00729157|BIOLOGICAL|Ziv-Aflibercept|Given IV
223414102|NCT02122705|DEVICE|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
223414103|NCT03646526|DRUG|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
223414104|NCT03646526|DRUG|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
223414105|NCT03997565|PROCEDURE|TKR|No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
223414106|NCT02478866|DRUG|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
223414107|NCT01895881|DRUG|Estradiol|
223414108|NCT01895881|DRUG|Placebo|
224031948|NCT06663137|DRUG|NDV01 intravesical controlled release formulation of gemcitabine and docetaxel|NDV01 is administered intravesically using a catheter.
223414109|NCT04703361|BIOLOGICAL|Placebo NaCl|Placebo
224031949|NCT06658548|OTHER|Isometric handgrip exercise training with resistance exercise|The subjects will perform 24 consecutive days, an isometric handgrip exercise at 30% Maximum Voluntary Contraction (M.V.C)continue the exercise protocol for another 48 consecutive days.
224031950|NCT06658548|OTHER|Resistance Exercise|The subjects will undergo outpatient training intervention during a period of 8 weeks will be using a hypertrophic maximum strength training method, which will divided into three phases: (1) muscle habituation training (2 weeks), (2) hypertrophic training I (5 weeks), and (3) hypertrophic training II, with intensified eccentric work (5 weeks).
224031951|NCT04980443|DIAGNOSTIC_TEST|CELTiC test|The CELTiC test is a blood-based test consisting of four mRNA markers and the risk factor age.
224031952|NCT06598605|BEHAVIORAL|Parental Reflective Functioning Workshop|Four online workshop sessions via Zoom will be based on psycho-educational knowledge concerning emotional regulation and specialized in autism. The group size will be up to 15 participants, with each session lasting an hour and a half, after which participants will be asked to complete a reflective journal.
224031953|NCT06610253|DIETARY_SUPPLEMENT|Protein|"Controlled, randomized, single-blind, parallel-group, prospective. Planned, parallel, randomized, single-blind, controlled clinical trial (RCT). Participants will be randomly assigned to one of four interventions: Whey Protein Concentrate - WPC, Pea Protein Isolate - PPI, Rice Protein ISOLATE - RPI, a combination of PPI and RPI to see if the intervention works together in synergy.~The experiment was scheduled for week 8. Each participant will consume 30g of a dedicated preparation every day for 8 weeks. The planned measurements will be performed three times - before the experiment begins, after 4 and 8 weeks."
224031954|NCT06610136|DIETARY_SUPPLEMENT|Caffeine plus Resistance training|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
224031955|NCT06610136|OTHER|Placebo + Resistance training|Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
224031956|NCT06610006|PROCEDURE|High Intensity Interval Training (HIIT)|High intensity interval training on treadmill with moderate intensity (40-60%HRR) in week 1 to achieve the baseline fitness level and from week 2 to 5 they will progress to high intensity with setting the lower target HR 40-60%HRR and upper target HR 80-85%HRR with 1:4 work to rest ratio followed by 5-7 min of cool-down period..A total of 15 sessions of high intensity interval training alone , for thrice a week on alternative days for 5 consecutive weeks will be given. Warm-up session consisting of stretching exercises prior to intervention and cool down session after intervention will also be done and vitals before and after the session will be taken.
224031957|NCT06610006|PROCEDURE|Isometric Wall Squat|For isometric wall squat, each training session will be composed of 4 × 2-min bouts of IWS followed by 2-min rest periods. In first week, participants will do squat training or there will be a protocol for selecting exercise intensity in which participants will be given 30-s to perform a wall squat to select a position that they predict would elicit an target RPE score by varying the squat height. Based on the final squat height and RPE score, after bout 4, participants will be given a starting squat height for training session 1 and will then be progressed in each week
223414110|NCT04703361|BIOLOGICAL|Niacin|B3 vitamin, Niacin
223414111|NCT04703361|BIOLOGICAL|Na-3-OHB|Na-3-OHB
223414112|NCT05328206|OTHER|Standard of care for intubated children|Patient ventilated through a cuffed endotracheal tube and having a cuff leak test prior extubation
223414113|NCT01077037|OTHER|Decision Aid|Chest pain choice decision aid
223414114|NCT03734328|PROCEDURE|connective tissue graft|"* anesthesia of the palatal mucosa~* subepithelial connective tissue graft harvesting~* suturing (5/0 silk suture)"
223414115|NCT03734328|PROCEDURE|connective tissue graft&PRF|"anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)"
223414116|NCT03734328|OTHER|connective tissue graft&PRF|"* taking blood from patient~* centrifuging blood~* obtain PRF"
223414117|NCT00127998|DRUG|chloroquine|
223414118|NCT00127998|DRUG|sulfadoxine-pyrimethamine|
223414119|NCT00127998|DRUG|amodiaquine|
223414120|NCT00127998|DRUG|amodiaquine+artesunate|
223414121|NCT00127998|DRUG|amodiaquine+sulfadoxine-pyrimethamine|
223414122|NCT00127998|DRUG|sulfadoxine-pyrimethamine+artesunate|
223414123|NCT00127998|DRUG|artemether-lumefantrine|
223414124|NCT00127998|DRUG|mefloquine|
223414125|NCT06574698|DRUG|Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy|Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy
223414126|NCT00531713|DRUG|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
223414127|NCT03335007|DRUG|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
223414128|NCT03335007|OTHER|Placebo|Placebo tablet given one hour before starting the root canal treatment
223414129|NCT05720715|DRUG|cyclosporine A 0.05% eye drops|"Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.~Group B: receive topical prednisolone with placebo eye drops (tear replacement).~The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months."
223414130|NCT05940376|DRUG|rapid acting insulin|Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2°C) and, was provided by the cornea specialist and was self-administered by patients at a dosage of 1 eye drop 4 times daily. Treatment continued until NK healed and then tapered accordingly. Patients would discontinue topical insulin if the condition did not improve or worsen within 4 weeks. Patients were followed up daily and slit-lamp photographs were captured with and without fluorescein corneal staining.
224031958|NCT02664727|BEHAVIORAL|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
224031959|NCT02664727|BEHAVIORAL|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
224031960|NCT05180669|OTHER|OARSCM Software Application|Access is granted to participants for 12 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
224031961|NCT05180669|OTHER|MyMAT Software Application|Access is granted to the MyMAT mobile application for 12 weeks which provides educational content regarding MOUD treatment.
224031962|NCT04715178|OTHER|No intervention- registry only|No intervention- registry only
224031963|NCT06996951|DIAGNOSTIC_TEST|:PULMONARY FUNCTION TEST|PATIENT WILL HAVE PULMONARY FUNCTION TESTING PERFORMED, MEASURING FEV1/FVC.
224031964|NCT06996951|DIAGNOSTIC_TEST|NASAL ENDOSCOPY|PATIENT WILL HAVE NASAL ENDOSCOPY TO RECORD LUND KENNEDY ENDOSCOPIC SCORE
224031965|NCT06996951|DIAGNOSTIC_TEST|LEUKOSORB FILTER PAPER APPLICATION TO NASAL CAVITY|LEUKOSORB FILTER PAPER STRIP WILL BE APPLIED INSIDE THE NOSTRIL TO SAMPLE NASAL MUCOUS TO OBTAIN IMMUNOGLOBULIN LEVELS TO MONITOR INFLAMMATION WITHIN THE NASAL MUCOUS
224031966|NCT06996951|BEHAVIORAL|SINONASAL OUTCOME TEST 22 QUESTIONNAIRE|PATIENT WILL COMPLETE THE SINONASAL OUTCOME TEST 22 QUESTIONNAIRE TO EVALUATE FOR SINONASAL SYMPTOMS DURING THE STUDY
224031967|NCT06996951|BEHAVIORAL|CYSTIC FIBROSIS QUESTIONNAIRE-REVISED|PATIENT WILL COMPLETE THE CYSTIC FIBROSIS QUESTIONNAIRE-REVISED TO EVALUATE FOR CYSTIC FIBROSIS RELATED SYMPTOMS DURING THE STUDY
224031968|NCT06996951|BEHAVIORAL|PATIENT HEALTH QUESTIONNAIRE-9|PATIENT WILL COMPLETE THE PATIENT HEALTH QUESTIONNAIRE-9 TO EVALUATE FOR QUALITY OF LIFE DURING THE STUDY
224031969|NCT06996951|DRUG|STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID|PATIENT WILL STOP USING NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID
224031970|NCT06991803|OTHER|root canal treatment and irrigation activation|After the teeth were isolated with a rubber dam, the endodontic access cavity was opened. Then, #10-15 K-type hand files were inserted into the canals, and after determining point 0.0 with the electronic apex locator, the working length was determined to be 0.5 mm shorter than this point and confirmed radiographically. When a discrepancy was observed, the apex locator was considered correct. The root canals were prepared with ProTaper Next up to 3 sizes larger than the initial diameter via a torque-controlled endodontic motor in 300 rpm/2-5.2 Ncm rotation mode. Between each file, the canals were irrigated with 5 ml of 2.5% NaOCl. In retreatment cases, after opening the access cavity under rubber dam isolation, the guta percha was removed with RT files, and the rest of the procedure was performed in the same manner as for primary root canal treatment.
224031971|NCT06609369|BEHAVIORAL|Experimental health intervention|Behavioral health intervention
224031972|NCT06609369|DRUG|Varenicline|Days 1-3: 0.5mg once daily, Days 4-7: 0.5mg twice daily; Days 8-56: 1.0mg twice daily.
224031973|NCT00322205|DRUG|zyban|
224031974|NCT06527794|BEHAVIORAL|RHYTHM (Remote Hypertension Tracking Help Management)|Home blood pressure telemonitoring with remote medication management by a centralized multidisciplinary team led by a pharmacist; and social support, lifestyle education and connection to community resources to address social needs, provided by a community health worker who is embedded with the centralized team and is tightly connected to community resources and partners
224031975|NCT06527794|BEHAVIORAL|Enhanced usual care (UC)|All participating sites will receive training on appropriate blood pressure measurement and education on guideline-based hypertension therapy. Additionally, participants in usual care will receive a standardized packet with evidence-based hypertension education material and a blood pressure monitor to complete blood pressure measurements at home.
224136234|NCT02720016|BEHAVIORAL|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
224031976|NCT06609720|PROCEDURE|(guided tissue regeneration)|Randomized clinical and radiographic trial
224031977|NCT01313117|DRUG|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
224031978|NCT00434915|DRUG|DHEA|
224031979|NCT07011628|OTHER|Same Day Discharge|Patients in the same day discharge arm will be discharged from the hospital within 6 hours of arriving to the recovery unit and without an overnight stay in the hospital.
223414131|NCT06666530|OTHER|Questionary|Three self-questionnaires, either completed independently or with assistance, will be administered at inclusion (between the first obstetric ultrasound and 28 weeks of amenorrhea), during the third trimester of pregnancy, and at 1 year postpartum
223738933|NCT00502177|BEHAVIORAL|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
223738934|NCT02716103|OTHER|blood collection|
223738935|NCT02716103|OTHER|bone marrow collection|
224136235|NCT02720016|BEHAVIORAL|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
224136236|NCT04793763|OTHER|traditional therapeutic exercises|group A will receive traditional exercises
224136237|NCT04793763|OTHER|traditional therapeutic exercises and McKenize technique|Group B will receive traditional therapeutic exercises and McKenize technique
224031980|NCT06614764|OTHER|AG (experimental Andiroba Gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the AG received application of the experimental desensitizing gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
224031981|NCT06614764|OTHER|KF2G (Potassium nitrate gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the dental elements of the KF2G received application of the potassium nitrate gel on the buccal surfaces of the central incisors, lateral incisors, canines and upper and lower premolars, with a rubber cup in an active way, for 10 minutes.
223414132|NCT03554148|OTHER|No intervention|This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
223414133|NCT02073448|DRUG|GK530G|
223414134|NCT02073448|DRUG|CD0271|
223414135|NCT02073448|DRUG|CD1579|
223414136|NCT06580301|DRUG|YK012|The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
223414137|NCT00327769|DRUG|Fulvestrant|250 mg intramuscular injection
224031982|NCT06614764|OTHER|PG (Placebo Gel)|Prior to bleaching treatment with 35% hydrogen peroxide, the PG group received the application of a placebo gel (without active ingredient), under the same conditions described for the experimental gel.
224031983|NCT01661478|OTHER|Training on motivational interviewing|
224031984|NCT01350453|BEHAVIORAL|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
224031985|NCT01350453|BEHAVIORAL|Standard Care|Participants will receive their usual care from their NHS provider.
224136238|NCT04793763|OTHER|traditional therapeutic exercises and deep neck flexor exercises|Group C receive traditional therapeutic exercises and deep neck flexor exercises
223414138|NCT00327769|DRUG|Anastrozole|1 mg tablet
223414139|NCT02141412|DRUG|dexmedetomidine 0.25 µg/kg IV|
224031986|NCT06459466|PROCEDURE|kinesiotherapy exercises with cervical mobilization|Kinesiotherapy Exercises includes Neck stretches , shoulder and upper back mobility, pectoral stretch, cervical isometrics, shoulder blade protraction and retraction
223414140|NCT02141412|DRUG|dexmedetomidine 0.5 µg/kg IV|
223414141|NCT02141412|DRUG|dexmedetomidine 1 µg/kg IV|
223414142|NCT02141412|DRUG|Placebo Comparator|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
223414143|NCT06341855|DIAGNOSTIC_TEST|MRD-ctDNA|ctDNA-MRD is a powerful biomarker, and ctDNA-MRD is a reliable predictive biomarker in EC.
223738936|NCT04183920|OTHER|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
224031987|NCT06459466|PROCEDURE|cervical Mobilization|This includes Cervical lateral glide mobilization
224136239|NCT05607017|DRUG|Losartan|Taken Orally
224136240|NCT05607017|RADIATION|Radiation Therapy|Photon Radiation Therapy
224136241|NCT02049749|BEHAVIORAL|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
223414144|NCT04015635|OTHER|None involved|NO intervention
223414145|NCT00436124|DRUG|oseltamivir [Tamiflu]|
223414146|NCT05730959|DEVICE|Sacral nerve modulation|Implant of nerve stimulator
224136242|NCT02942849|DRUG|r-hFSH|As per standard clinical practice
223414147|NCT03522714|DEVICE|Fluid Immersion Simulation System|Dolphin Fluid Immersion Simulation® System Mattress will be used
223414148|NCT03522714|DEVICE|Air Fluidized Bed System|Air Fluidized Bed (Clinitron) will be used.
223414149|NCT01430403|BIOLOGICAL|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) \[IU/mL\] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
223414150|NCT01430403|DRUG|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
223414151|NCT01430403|BIOLOGICAL|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
223414152|NCT01430403|BIOLOGICAL|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
223414153|NCT05018403|DRUG|Intravenous AON-D21|AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
223414154|NCT05018403|DRUG|Intravenous placebo|Isotonic glucose solution identical in appearance to AON-D21.
223738937|NCT04183920|OTHER|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
223738938|NCT04888156|OTHER|Unchanged treatment|Treatment is the same pre- and post self-tonometry
223738939|NCT04888156|OTHER|Changed treatment|Treatment is changed post self-tonometry
223738940|NCT02335099|DRUG|ticagrelor|ticagrelor 90 mg twice a day for 6 months
223738941|NCT02335099|DRUG|Placebo|1 pill twice a day for 6 months
223738942|NCT01312688|OTHER|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
223414155|NCT01540214|OTHER|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).~At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).~At time of surgery: additional cystoscopy."
224031988|NCT06684652|PROCEDURE|3TB+6SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. For each predefined mpMRI suspicious lesion, urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained sextant six-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
223414156|NCT00565877|OTHER|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
223559931|NCT07033884|OTHER|Active Control|"Veterans will receive no treatment and will not interact with peers. A no treatment control condition was selected due to the preventative nature of PEERS, as well as the early stage of evaluation for this intervention. However, given the varied recruitment outlets and subsequent lack of standardized usual care, as well as ethical concerns with not providing important resources to firearm owning Veterans, two informational handouts will be added to this control condition. Specifically, Veterans in this condition will be provided with an informational handout developed by the National Sports Shooting Foundation, which includes a variety of secure firearm storage options, as well as a handout listing national mental health and suicide prevention resources."
223559932|NCT07034079|DEVICE|complete dentures|"Participants were randomly allocated into two intervention sequences using a computer-generated randomization list. The two sequences were:~* Group A: Received maxillary complete denture with palatal rugae first, followed by a smooth polished palatal surface denture after a 2-month adaptation period.~* Group B: Received a smooth polished palatal surface denture first, followed by a rugae-enhanced denture after a 2-month adaptation period."
223559933|NCT07033702|DEVICE|Airway-Exchange Broncholaryngoscope (AEBLScope)|Airway Exchange Broncholaryngoscope (AEBLScope) - A modified disposable flexible bronchoscope designed to allow visualization during airway tube exchange procedures.
223559934|NCT07033143|DRUG|Adebrelimab+SOX|"Adebrelimab: 1200mg, intravenous drip, day 1, 21 days as one cycle, treatment duration is 1 year.~SOX: Eight cycles after the operation, intravenous infusion of oxaliplatin at 130 mg/m2. On the first day, oral administration of S-1 at 40-60 mg twice a day. From the first to the 14th day, 21 days constitute one cycle.~Enhanced CT examinations of the chest, abdomen and pelvis were conducted every 9-12 weeks in the first year of treatment. Then have a check-up every 24 weeks."
223559935|NCT07032519|BEHAVIORAL|Mindfulness Intervention|Participants will use the smartphone app daily for pain tracking and weekly to engage with mindfulness content and complete additional assessments.
223559936|NCT07032948|DEVICE|FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter、EasyStars™ High Density Mapping Catheter、Columbus™ 3D EP Navigation System|All patients were treated withFireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter、EasyStars™ High Density Mapping Catheter and Columbus™ 3D EP Navigation System for rapid arrhythmia.
223559937|NCT06883409|PROCEDURE|Interval Cytoreduction Surgery|"The procedure started with the cytoreduction of highest complexity (determined at the time of initial inspection), after which, if necessary, the patient underwent a complete hysterectomy, bilateral salpingo-oophorectomy, omentectomy, or partial peritonectomy and excision of any peritoneal implants present. The magnitude of the surgical procedures will be classified as:~1. Standard surgery: minimal hysterectomy, adnexectomy y omentectomy~2. Radical Surgery: included resection of the ovaries, of the rectouterine excavation (pouch of Douglas) and or the peritoneum between the bladder and uterus, hysterectomy, rectosigmoid colectomy, and complete omentectomy~3. Supra-radical Surgery: included other procedures such as splenectomy, diaphragm resection, or other intestinal resection."
223559938|NCT07032974|DEVICE|Franseen|Franseen needle
224031989|NCT06684652|PROCEDURE|3TB+12SB|The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Urologists firstly obtained three-core TB from the lesion within the mpMRI suspicious lesion. Then urologists obtained fore-zone 12-core SB. Each core was placed in an individual container and reported separately in accordance with the Ginsburg scheme. Histology was evaluated by senior uropathologists who were blinded to the imaging findings.
224031990|NCT07015632|OTHER|Performance of the Upper Limb, Brooke Scale, grip strength test|Thirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (PUL 2.0, Brooke Scale, grip strength), computer vision-based video analysis, and machine learning algorithms.
224031991|NCT03602261|DRUG|Calcifediol Oral Capsule|Capsule, weekly
224298352|NCT03828266|OTHER|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
224298353|NCT04613674|DRUG|Camrelizumab Plus Chemotherapy|camrelizumab+chemotherapy
224298354|NCT04613674|DRUG|placebo+chemotherapy|placebo+chemotherapy
224298355|NCT00270257|DRUG|Buprenorphine/Naloxone|Oral tablet
223559939|NCT07032974|DEVICE|Forward-bevel|Forward-bevel needle
224298356|NCT03018210|PROCEDURE|Surgical repair of the rotator cuff|
223559940|NCT07032974|DEVICE|Fork-tip|Fork-tip needle
223559941|NCT07043270|DRUG|Nab-paclitaxel + Gemcitabine|Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).
223559942|NCT07043270|DRUG|modified FOLFIRINOX (mFOLFIRINOX)|Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).
224298357|NCT02799238|BIOLOGICAL|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
223414157|NCT06683885|DRUG|Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone|"For non GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Obutinib, 150mg, QD, P.O.; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Obutinib maintain treatment for 6 months. Obutinib, 150mg, QD, P.O. After 6 cycles of initial treatment, the efficacy was evaluated.~For GCB type: Rituximab, 375mg/m2, QD, D1,8,15(the first cycle), d1(Starting from the second cycle), ivgtt; Compound Cyclophosphamide Tablets, 50mg:50mg BID, P.O.; Decitabine, 10mg, QD，D1-5, ivgtt; Prednisone, 60mg, QD D1-7, P.O. Every 21 days is a cycle, and the efficacy is evaluated every 2 cycles. Decitabine maintenance treatment for 4 cycles, 21 days per cycle. Decitabine, 10mg, QD，D1-5, ivgtt. Evaluate the efficacy after 6 cycles of treatment."
223414158|NCT03079011|DRUG|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
223414159|NCT03079011|DRUG|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
224031992|NCT03602261|DRUG|Placebo oral capsule|Capsule, weekly
224031993|NCT06690216|DIAGNOSTIC_TEST|PET/CT （[18F]AlF-NOTA-PCP2）|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
224031994|NCT06690216|DIAGNOSTIC_TEST|[18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors|This intervention involves the use of \[18F\]AlF-NOTA-PCP2, a radiopharmaceutical agent specifically designed for PET/CT imaging. Patients will receive an intravenous injection of \[18F\]AlF-NOTA-PCP2, followed by whole-body PET/CT scanning one hour later. The primary purpose of this intervention is to assess PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and esophageal cancer, before the initiation of treatment. This imaging technique offers a non-invasive, repeatable, and comprehensive method to monitor PD-L1 status, in contrast to traditional tissue biopsy, which is invasive and limited to a single time point.
224031995|NCT07019220|DRUG|Gemcitabine|Intravesical installation
224031996|NCT07019194|DRUG|Senaparib capsules(20mg)|Single oral dose of Senaparib administered under fasting condition, 1\*20mg capsules in first intervention period and then 2\*10mg capsules in second intervention period (after washout period: at least 5 days)
224031997|NCT07019194|DRUG|Senaparib capsules(10mg)|Single oral dose of Senaparib administered under fasting condition, 2\*10mg capsules in first intervention period and then 1\*20mg capsules in second intervention period (after washout period: at least 5 days)
224031998|NCT07020689|PROCEDURE|CABS|Following diagnosis, individuals with OHS were counseled on therapeutic options, including CPAP therapy, body weight reduction, or CABS. The final decision was made through a shared decision-making process. The CABS procedure was conducted under general anesthesia and integrated bariatric and multilevel airway surgery within a single operative session. This transdisciplinary approach aimed to address both sleep-disordered breathing and obesity-related ventilatory compromise. A general surgeon performed the bariatric procedure, while an otorhinolaryngologist conducted the airway surgery sequentially during the same operation. For the bariatric component, laparoscopic sleeve gastrectomy (LSG) was the primary procedure, while laparoscopic Roux-en-Y gastric bypass was reserved for individuals with significant gastroesophageal reflux or poorly controlled diabetes. Airway surgery encompassed interventions at the nasal, palatal, and lingual levels.
224031999|NCT07020767|PROCEDURE|Vestibular Socket Therapy (VST) Group|A minimally invasive vestibular incision technique for atraumatic tooth extraction, followed by immediate implant placement using BioHorizons implants. The socket is augmented with MegaOss™ allograft and covered with T-barrier™ collagen membrane, stabilized with membrane tacks. Soft tissue closure is achieved with 7/0 nylon sutures. Customized composite healing abutments are used, and zirconia crowns are delivered at 3 months.
224032000|NCT07020767|PROCEDURE|Flap Elevation Group|Traditional mucoperiosteal flap elevation with intrasulcular and vertical incisions, followed by atraumatic extraction and immediate implant placement using BioHorizons implants. The socket is grafted with MegaOss™ allograft, covered with T-barrier™ collagen membrane, and stabilized with tacks. The site is closed with 7/0 nylon sutures. Healing abutments and zirconia crowns are applied following the same timeline as the VST group.
224136243|NCT03740412|BEHAVIORAL|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
224136244|NCT03752606|BIOLOGICAL|TACHOSIL GROUP|
223414160|NCT03079011|DRUG|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
223559943|NCT07050654|DEVICE|Dual-task cycling|"Pairs of participants are formed, who will be the SocialBike players; these pairs consist of users from the same center. The two players are in the same room where two replicas of the SocialBike system are installed.~The participants can each view, on their own screen, the virtual scenario, either a park or a city environment. Movement within these VR environments is synchronized with the patient's actual pedaling speed, measured in revolutions per minute (RPM) from the cycle ergometer. Movement occurs along a predefined path. The participant's heart rate will always be monitored.~The therapist chooses the optimal ergometer workload, the type of exercise, and social/single-player mode. Each session (either single- or multi-player mode) lasts 10 minutes. The available exercise are: Find the intruder (go/no-go task); Prepare your Meal (spatial attention); Watch the road (working memory)."
223738943|NCT03249233|DEVICE|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
223414161|NCT05339711|OTHER|Robotic Pet Therapy/Robot Cat Group|"İn this study, the patients interacted with the robot cat Silver for 20 minutes during the hemodialysis session once a week for eight weeks (two months) under the supervision of the researcher."
223414162|NCT05339711|OTHER|Pet Therapy/Betta Fish Group|İn this study, two fish and the necessary materials (aquarium, fish food, plastic plant, aquarium stone, etc.) were given to the patients by the researcher to keep pets for eight weeks.
223414163|NCT03817008|PROCEDURE|Ascending aorta replacement with graft|Patient with planned Ascending aorta replacement with graft
223414164|NCT04564378|OTHER|This is an observational study. There is no therapeutic intervention.|This is an observational study. There is no therapeutic intervention.
223414165|NCT06321861|DIETARY_SUPPLEMENT|Caffeine|Participants will take one caffeine pill. The dose of caffeine will be calculated based on participants' body mass (3mg/kg body mass). Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.
223738944|NCT03249233|DEVICE|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
223738945|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
223738946|NCT05131074|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
223738947|NCT05523661|DRUG|Dasatinib plus anti-CD19/CD22 CAR-T cells|Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy
224032001|NCT07018882|DEVICE|Sullivan|Patients who are clinically eligible for cochlear implant surgery and can tolerate the surgery will be asked for their consent and then undergo the cochlear implant procedure. The outcome of the cochlear implant surgery will be evaluated through auditory performance assessments. Additionally, adverse effects will be monitored to assess the efficacy and safety of the cochlear implants on auditory function.
224032002|NCT07019467|OTHER|Bed Bath With Auditory Hypnosis|"In the bed bath protocol accompanied by audio suggestion, a 30-60 minute audio recording containing audio suggestions specific to the ICU patient will be prepared with the support of a specialist hypnotherapist. This audio recording will include the following messages: - The purpose of the bed bath, - Procedures to be performed during the bed bath, - The benefits of the bed bath, - Feeling safe during the bed bath, - Improvement in physiological parameters and comfort levels after the bed bath.~While it is noted that auditory suggestion typically lasts 30-60 minutes, even a 15-minute auditory suggestion has been reported to provide benefits."
224032003|NCT07019740|OTHER|CASE GROUP|SYMPATHETIC SKIN RESPONSE, CUTANEOUS QUIET PERIOD AND COMPASS-31 QUESTIONNAIRE EVALUATED
223738948|NCT02461225|DEVICE|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
224032004|NCT07021326|OTHER|there is no intervention|This is an observational, cross-sectional study with no intervention. Data were collected through a single body composition measurement without any treatment or manipulation. Biochemical, clinical and anthropometric data was collected directly from the patient's clinical records. No intervention was needed.
224032005|NCT07019012|DRUG|SGLT2i+Metformin+Cofrogliptin|The combination of SGLT2i+Metformin+Cofrogliptin
224032006|NCT07019012|DRUG|SGLT2i+Metformin+Linagliptin|The combination of SGLT2i+Metformin+Linagliptin
224032007|NCT07019181|DRUG|Tislelizumab|Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
224136245|NCT02038218|DRUG|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
223414166|NCT06321861|DIETARY_SUPPLEMENT|Placebo|Participants will take one pill with no caffeine in it. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
223414167|NCT06321861|OTHER|No substance|Participants will take no substance. They will just wait 60 minutes and then engage in the exercise protocol.
223414168|NCT06040970|DRUG|Sacituzumab|"Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg"
223414169|NCT06040970|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV
224032008|NCT07019181|DRUG|albumin-bound paclitaxel|albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks
224032009|NCT07019181|DRUG|Nedaplatin|Nedaplatin 80mg/m2，day 1 of every 3 weeks
224032010|NCT07021261|DRUG|Utidelone plus capecitabine|UTD2 50 mg/m²/day orally on Days 1-5, repeated every 21 days for 2 years; Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.
224136246|NCT04374110|OTHER|Clinical data|Clinical characteristics from medical records
223414170|NCT04228146|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|"Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes."
223414171|NCT04228146|OTHER|Waitlist Control|Delay access to the self-help CBT-I treatment.
223414172|NCT04448522|RADIATION|reduced dosage IMRT|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：63.6Gy/30Fr/2.12Gy; PTVnd：63.6Gy/30Fr/2.12Gy; PTV1：54Gy/30Fr/1.8Gy; PTV2：49.2Gy/30Fr/1.64Gy"
223414173|NCT04448522|RADIATION|conventional dosage IMRT|"1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx：69.96Gy/33Fr/2.12Gy; PTVnd：69.96Gy/33Fr/2.12Gy; PTV1：59.4Gy/33Fr/1.8Gy; PTV2：54Gy/33Fr/1.64Gy"
223414174|NCT02100995|BEHAVIORAL|Intervention Simultaneously Targeting Obesity and Pain|
223414175|NCT02100995|BEHAVIORAL|Weight Loss/Weight Self-Management|
223414176|NCT02100995|BEHAVIORAL|Chronic Pain Self-Management|
223414177|NCT04158102|DRUG|Bupivacaine liposome injectable suspension|Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
223559944|NCT06743425|OTHER|RAMP Reports|Participants will receive text-based requests for reports with embedded links to select radio button questionnaires directly on their mobile device. Questions include current inattention/hyperactivity symptoms, school performance, and any engagement in behavioral therapy. Inattention/hyperactivity symptom questions and scoring is taken directly from the publicly available Vanderbilt Rating Scales, which is a commonly used, guideline-recommended tool for both diagnosis and management of ADHD for use by parents and teachers.
223559945|NCT06743425|OTHER|Digital Education Handouts|The digital education handouts will be sent via email to the control group and will serve as an attention control. They will consist of information regarding a general pediatric health topic and will be emailed at intervals matching the RAMP requests in the intervention group.
223559946|NCT07052669|RADIATION|Hypofractionated Radiation Therapy|All patients will receive split-course hypofractionated radiotherapy. First course of radiotherapy: Total dose of 4000 cGy in 10 daily fractions (400 cGy per fraction) or 3000 cGy in 6 daily fractions (500 cGy per fraction). Three weeks after the completion of the first course of hypofractionated radiotherapy, tumor response and toxicity will be evaluated. For patients who achieve a partial response and without grade 2 or higher respiratory toxicity, a second course of radiotherapy will be planned for the residue disease at a total dose of 2000 \~2400 cGy in 5\~6 fractions (400 cGy per fraction). The interval between the two courses of radiotherapy will be 28 days.
224032011|NCT07021261|DRUG|Capecitabine|Capecitabine 1000 mg/m² twice daily on Days 1-14, repeated every 21 days for 8 cycles.
224032012|NCT07019428|PROCEDURE|Free gingival graft stabilized by Titanium fixation tacs|Free gingival graft stabilized by Titanium fixation tacs , in patients with inadequate keratinized gingiva
224032013|NCT07019428|PROCEDURE|Free gingival graft stabilized by sutures|Free gingival graft stabilized by sutures , in patients with inadequate keratinized gingiva
224136247|NCT00389103|BIOLOGICAL|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
223414178|NCT04168502|DRUG|Gemtuzumab Ozogamicin|Patients will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
223414179|NCT00971464|BEHAVIORAL|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
223414180|NCT00971464|DEVICE|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
223414181|NCT03604679|DRUG|SyB C-0501|Specified dose on specified days
223414182|NCT00266578|DRUG|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
223414183|NCT04481789|DRUG|MT-1186|Suspension
223414184|NCT04481789|DRUG|Rosuvastatin|Tablets
223414185|NCT04481789|DRUG|Sildenafil|Tablets
224032014|NCT07020182|OTHER|physical therapy program|Group A will performed a physical therapy program that completed two daily sessions till discharge from the hospital .Exercise training starts from randomisation until hospital discharge,and administered twice per day, seven times per week. The study will be start from day 1 of hospital admission till discharge from the hospital.The study duration will be 12 weeks
224136248|NCT04515043|DRUG|INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.|blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
224136249|NCT02213302|DRUG|placebo administration|
224136250|NCT02213302|DRUG|midazolam intravenous administration|
224136251|NCT04501679|DRUG|Nemolizumab|Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection.
224136252|NCT04501679|DRUG|Placebo|Participants received matching placebo as SC injection.
224136253|NCT05890287|DRUG|Chidamide|Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
224298358|NCT02799238|RADIATION|Radiotherapy|Radiotherapy 5 days/week for 6 weeks
223414186|NCT04481789|DRUG|Furosemide|Tablets
223559947|NCT07052669|RADIATION|Conventionally Fractionated Radiation Therapy|Patients in this group will receive a total dose of 6000- 6400 cGy in 30- 32 fractions, with 200 cGy per fraction.
223559948|NCT07052669|DRUG|Concurrent Chemotherapy|Paclitaxel plus platinum-based chemotherapy.
223559949|NCT07052669|DRUG|concurrent chemotherapy|Paclitaxel plus platinum-based chemotherapy or pemetrexed plus platinum-based chemotherapy.
224032015|NCT06697145|PROCEDURE|Cardioneuroablation|Ablation of parasympathetic ganglia of the heart
223414187|NCT04599348|DIETARY_SUPPLEMENT|HRG 80 Red Ginseng|A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.
224032016|NCT01389427|DRUG|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032017|NCT01389427|DRUG|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032018|NCT01389427|DRUG|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032019|NCT01389427|DRUG|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032020|NCT01389427|DRUG|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032021|NCT01389427|DRUG|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032022|NCT01389427|DRUG|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032023|NCT01389427|DRUG|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032024|NCT01389427|DRUG|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032025|NCT01389427|DRUG|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
223559950|NCT07052669|DRUG|Consolidative immunotherapy|Following the completion of chemoradiotherapy, PD-1/PD-L1 immune checkpoint inhibitor consolidation therapy will be administered for up to 12 months.
223414188|NCT05639816|PROCEDURE|Saline irrigation group|Normal saline irrigation of common bile duct after complete stone removal
224032026|NCT01389427|DRUG|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
223414189|NCT01757938|PROCEDURE|Shang Ring Guided Circumcision|
223414190|NCT01757938|PROCEDURE|Forceps Guided Circumcision|
223414191|NCT03566914|DRUG|Tadalafil 10 MG|Tadalafil 10 mg per oral once daily for 3 months
223414192|NCT03566914|OTHER|Placebo|TPlacebo tablet per oral once daily for 3 months
223414193|NCT01535508|DRUG|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
223414194|NCT05050123|BEHAVIORAL|iPhone Google Cardboard virtual reality meditation/relaxation app|Virtual reality meditation/relaxation app that has 6 scenes of 360° visual imagery with soothing music. The patient can spend about 15 minutes exploring the app.
223414195|NCT05050123|BEHAVIORAL|Standard relaxation training|"15 minute sessions of guided imagery using Mayo Clinic Patient Education CD-ROM Relaxation for Your Mind and Body"
223414196|NCT00978081|DRUG|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
224032027|NCT01389427|DRUG|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
224032028|NCT06829498|DRUG|BCAA|The three BCAAs will be combined together and dissolved in a flavored solution.
224032029|NCT06829498|OTHER|Placebo|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
224032030|NCT06112834|BIOLOGICAL|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
224032031|NCT02123433|BIOLOGICAL|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
224032032|NCT00285987|PROCEDURE|Reconstruction of the cruciate ligament|
224032033|NCT00948493|DRUG|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
224136254|NCT03282708|OTHER|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
223414197|NCT06441838|BEHAVIORAL|Surah Inshirah|The effects of Surah Al-Inshirah on patients' depression, anxiety, stress and mental well-being will be evaluated during hemodialysis in the experimental group.
223559951|NCT06749236|DRUG|test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension|Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).
224136255|NCT02862821|OTHER|HR-EEG|
224136256|NCT03365479|DRUG|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
223559952|NCT06749236|DRUG|reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension|Participants will receive a single dose of the reference formulation(R) ( two bags of 100 mg deuteriumremidvir hydrobromide for suspension).
223559953|NCT06899152|DIAGNOSTIC_TEST|HepQuant DuO|HepQuant DuO is a quantitative liver function test. It assesses cholate uptake, a liver specific function. Cholate is a naturally occurring substance that is cleared by the liver. Cholate uptake reflects the health of liver cells.
223559954|NCT06899152|OTHER|Multiparametric MRI Scans|Standard of care
223414198|NCT03152838|GENETIC|DNA methylation and Real-time Polymerase Chain Reaction Analysis|"Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes."
223414199|NCT03152838|DIAGNOSTIC_TEST|Gilliam Autism Rating Scale Arabic version|"An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt."
223414200|NCT03374917|DRUG|ABBV-951|powder for solution
223559955|NCT07066306|DRUG|Ketamine|In the ketamine group, 0.2 mg/kg of ketamine will be administered locally. This application will be performed twice: once during the Le Fort I osteotomy and once during the sagittal split osteotomy. After calculating the total dose, it will be equally divided and administered locally to both the maxilla and the mandible.
223559956|NCT07066306|DRUG|Articaine Hydrochloride + Epinephrine|A total of 4 ampoules of articaine hydrochloride will be used. Two ampoules will be administered prior to the incision during the Le Fort I osteotomy, and the remaining two ampoules will be used prior to the incision during the sagittal split osteotomy.
224032034|NCT03797079|PROCEDURE|ESP block|A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
224032035|NCT03797079|PROCEDURE|TEA|Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
224032036|NCT03797079|DEVICE|Catheter insertion|After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
224032037|NCT03797079|DRUG|Bupivacaine|After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
224032038|NCT00193687|DRUG|bifeprunox|
224032039|NCT06535867|DIAGNOSTIC_TEST|mHealth|The mobile health (mHealth) program will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers.
224032040|NCT04337515|DEVICE|CliniMacs®|CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
224032041|NCT05677893|DRUG|MBS-COV|MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.
224032042|NCT05677893|OTHER|Placebo|Normal saline
224032043|NCT00599976|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation
224032044|NCT03017274|OTHER|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
224032045|NCT05791760|BEHAVIORAL|Compassion-focused therapy (CFT) for complex PTSD|The group protocol includes 12 two-hour sessions. Each session begins and ends with a practical exercise (calming rhythmic breathing) and each session includes psychoeducation (conceptualization, self-compassion). At the end of the session, participants are asked to practice at home between sessions (1 hour per week). The protocol consisted of 3 parts; sessions 1-5 focused on compassion understanding, including psychoeducation on emotion regulation, self-compassion skills, and mindfulness skills. Sessions 6-8 focused on motivation to care, compassion from others, the compassionate self, and the relationship between the compassionate self and self-criticism. Sessions 9-12 focused on using compassion in daily life. The group has a maximum of nine participants and is given by three therapists. All therapists are pre-trained to apply the intervention.
224136257|NCT01977079|OTHER|procalcitonin|
224136258|NCT00186056|DRUG|Mifepristone|Glucocorticoid antagonist
224136259|NCT00186056|DRUG|Placebo Oral Tablet|Inactive placebo tab
224136260|NCT04286542|DIAGNOSTIC_TEST|Cold, dry air|Participants will be exposed to cold (\<-10°C, \<10% relative humidity), dry air for 15 minutes.
224136261|NCT04979832|DRUG|GM-CSF, fosfomycin and metronidazole|GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
224136262|NCT05444478|PROCEDURE|Microwave ablation|only microwave ablation for tumor
224136263|NCT05444478|DRUG|Lenvatinib|lenvatinib (80 mg for body no more than 60kg，120 mg for body weight \>60 kg)
224136264|NCT00978809|OTHER|Epley maneuver|
224136265|NCT00978809|OTHER|Semont maneuver|
224136266|NCT01032993|DIETARY_SUPPLEMENT|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
224136267|NCT01032993|OTHER|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
224136268|NCT05872594|DIAGNOSTIC_TEST|Online questionnaire|data will be collected remotely on the online platform Qualtrics
224136269|NCT00647868|DRUG|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
224298359|NCT02799238|DRUG|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
224032046|NCT00229411|BEHAVIORAL|simulation training|
224032047|NCT05328323|OTHER|questionnaire application|"Participants will be asked to fill in the Physical Activity and Social Support Scale (PASSS) adapted into Turkish. Evaluations of the participants will be made in the form of an online survey via Google Forms. Multidimensional Scale of Perceived Social Support and International Physical Activity Questionnaire will be used for construct validity of the scale, and SF-12 physical and mental component summary scores will be used for convergent and divergent validity. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
224032048|NCT03253926|DRUG|Lorcaserin|Lorcaserin 10mg BID
224032049|NCT03253926|DRUG|Placebo|Placebo capsule BID
224032050|NCT03253926|DRUG|Marijuana|Smoked marijuana cigarette
224032051|NCT01485354|DEVICE|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
224298360|NCT01630681|BEHAVIORAL|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
224299151|NCT03958123|DRUG|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
224299152|NCT03958123|DRUG|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
223414201|NCT05133089|DEVICE|ALV1 System|The ALV1 system is designed to create a controlled size interatrial shunt via a proprietary intra-cardiac catheter. There is no temporary or permanent implant used to create or maintain the interatrial shunt. The therapy is intended to be delivered in a single procedure administered under general anesthesia in a cardiac catheterization laboratory.
223414202|NCT04068129|DEVICE|photoscreen|Determine amblyopia risk factors
223414203|NCT00943150|DEVICE|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
223414204|NCT00943150|PROCEDURE|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
223414205|NCT01413750|DRUG|Carboplatin|Given IV
223414206|NCT01413750|OTHER|Laboratory Biomarker Analysis|Correlative studies
223414207|NCT01413750|DRUG|Paclitaxel|Given IV
223414208|NCT01413750|OTHER|Placebo Administration|Given PO
223414209|NCT01413750|DRUG|Vorinostat|Given PO
223414210|NCT03124407|DRUG|Capsaicin Topical Solution|Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
223414211|NCT03124407|OTHER|Drug product vehicle|This is the vehicle for the active treatment drug product, but without capsaicin
223559957|NCT06817707|OTHER|Evaluation of urinary dysfunction in patients with CANVAS|Urinary dysfunction will be evaluated with neurologic exam, interrogation, urinary dairy report, self-questionnaires, biologic analysis, Sudoscan and urological exams
224032052|NCT01882751|DEVICE|Conformis CR Total Knee Replacement|iTotal CR by Conformis
224032053|NCT01882751|DEVICE|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
224032054|NCT00050726|DRUG|Interleukin-2|
224032055|NCT01862302|DRUG|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
224032056|NCT01862302|DRUG|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
224032057|NCT02869776|BEHAVIORAL|Questionnaire|Behavioral questionnaires
224032058|NCT02869776|PROCEDURE|Rapid finger stick|HIV and HCV testing through rapid finger stick
224032059|NCT02869776|PROCEDURE|Venipuncture|HIV and HCV testing through venipuncture
224032060|NCT00906360|DRUG|sunitinib malate|Given orally or by percutaneous gastrostomy tube
224032061|NCT00906360|OTHER|pharmacological study|Correlative studies
224032062|NCT00906360|RADIATION|3-dimensional conformal radiation therapy|Undergo radiotherapy
224032063|NCT00906360|BIOLOGICAL|cetuximab|Given IV
224032064|NCT05452850|DIAGNOSTIC_TEST|Left and Right Ventricular Global Strain Imaging|Two-dimensional, color Doppler, spectral Doppler, and 3D digital echocardiographic image recordings will be taken from parasternal, apical, subcostal, and modified sections using a Philips Epiq CVx echocardiography device and X5-1 probe. Conventional parameters, additional parameters, and strain analyzes will be performed with speckle tracking echocardiography from these recordings.
224032065|NCT02016456|DEVICE|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
224032066|NCT02016456|DEVICE|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
224032067|NCT02101034|BIOLOGICAL|Cetuximab|
224032068|NCT02101034|DRUG|PD 0332991|
224032069|NCT02300909|PROCEDURE|Lumbar Decompression Surgery|Lumbar Decompression Surgery
224032070|NCT02300909|PROCEDURE|Microdiscectomy Surgery|Microdiscectomy Surgery
224032071|NCT02300909|OTHER|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
224032072|NCT01652950|BEHAVIORAL|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: \<150 fitness points per month - equivalent to \< 1 gym visit per month - no reward, up to Level 5, which was \>3000 fitness points/month - equivalent to \>20 gym visits/month."
224032073|NCT05988554|DIETARY_SUPPLEMENT|Placebo sachet|Consume 1 sachet daily
224032074|NCT05988554|DIETARY_SUPPLEMENT|Hibiscus sabdariffa extract and collagen products|Consume 1 sachet daily
224032075|NCT00747825|DRUG|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
224032076|NCT03142763|OTHER|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
224299153|NCT03958123|DRUG|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
224299154|NCT01400919|DEVICE|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
223414212|NCT05555524|OTHER|Baby oil|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool baby oil will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
223414213|NCT05555524|OTHER|Placebo|"Before each application~* Hand hygiene will be done~* Skin care will be done to the affected area and the area is thoroughly dried.~* Participants will wear a hospital gown and seated comfortably on their bed.~* Gentle massage with the cool distilled water will be applied on the itching area and is continued for 15-20 min.~* Message will be applied for three times a week before each hemodialysis session for 12 weeks"
223414214|NCT06968884|OTHER|Protocol based|"Preoperative administration of iron, b12 and folate if criteria is met. Medication to aid in smoking cessation is offered if patient uses tobacco. Nutritional supplements offered pre-operative is patient malnurished and preoperative drink offered to all.~Anaesthetic method adapted with increased use of epidural, blocks and local anaesthesia.~Administration on TXA and fluids according to protocol. Postoperative nutritional drink to increase protein intake. Early mobilisation to reduce risk of VTE."
223414215|NCT06968884|PROCEDURE|Control (Standard treatment)|"Preoperative bloods including haemoglobin to establish that surgery is safe. Transfusions given if clinically necessary, no other protocol for anaemia treatment other then available clinical guidelines.~Peri- and postoperative treatment given in accordance with best clinical practice, no additional protocol."
223414216|NCT06620640|DEVICE|Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.|Nigth stimulation
223414217|NCT05852717|PROCEDURE|AutoSCT OR CAR T-cell Therapy|Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP
223414218|NCT05852717|DRUG|GDP|Gemcitabine Cisplatin Dexamethasone
223414219|NCT05852717|DRUG|Epcoritamab|Epcoritamab
223414220|NCT06968936|DRUG|Sucrose Iron，subcutaneous recombinant human erythropoietin，intravenous vitamin C|Patients in the experimental group will receive a combination therapy consisting of intravenous sucrose iron (200 mg), subcutaneous recombinant human erythropoietin (150 IU/kg), and intravenous vitamin C (2 g), administered once daily for three consecutive days within the week prior to surgery.
223414221|NCT06968936|PROCEDURE|Routine perioperative management|Routine perioperative management based on clinical judgment, including observation, monitoring, and standard nursing practices.
223414222|NCT06968338|BIOLOGICAL|ARGX-213|Intravenous or subcutaneous administrations of ARGX-213
223414223|NCT06968338|OTHER|Placebo|Intravenous or subcutaneous administrations of placebo
223414224|NCT02279654|DRUG|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
223414225|NCT04502654|DEVICE|Actiwatch 2 (Philips Respironics, Murrysville, USA)|Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm\* 2.3 cm\* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
223414226|NCT00396656|DRUG|Atenolol|100 mg tablets orally once a day (od) in the morning.
224032077|NCT03142763|DIETARY_SUPPLEMENT|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
224032078|NCT02847741|OTHER|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
224032079|NCT03437018|OTHER|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
223414227|NCT00396656|DRUG|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
223414228|NCT00396656|DRUG|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
223414229|NCT05747326|DRUG|oral vinorelbine and capecitabine|The eligible patients were enrolled to receive oral metronomic vinorelbine 40 mg on day 1, day 3, day 5 every week (Monday, Wednesday, and Friday) and capecitabine 500mg three times daily (tid) after meals every 3 weeks. Until disease progression or unacceptable toxicity occurred, or the patient refused medication, vinorelbine and capecitabine were administered continuously without drug-free periods over 21-day cycles.
223414230|NCT03107039|BEHAVIORAL|Exercise|A 12 week resistance exercise curriculum
223414231|NCT03107039|BEHAVIORAL|Health Education|A 12 week health education curriculum
223414232|NCT00552643|DEVICE|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
223414233|NCT00552643|DEVICE|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
223559958|NCT07068191|COMBINATION_PRODUCT|"Dietary supplement Gepaktiv"|"Dietary supplement Gepaktiv 60 minutes before meals 2 capsules × 3 times/day"
224136270|NCT04086069|DEVICE|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
224136271|NCT00067314|DRUG|Edotecarin|
224136272|NCT02128282|DRUG|CX-4945|API powder-in-capsule in 200 mg strength.
224136273|NCT02128282|DRUG|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
224136274|NCT02128282|DRUG|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
224299155|NCT03340142|DEVICE|VIVO™|Diagnose the area of a PVC or VT onset
223414234|NCT00175149|DRUG|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
223414235|NCT05917184|OTHER|Telehealth|Two video telehealth visits will be conducted and recorded within 3 days of one another (+/- 1 day)
223414236|NCT02821754|DRUG|Durvalumab|Flat dose of 1500 mg every 4 weeks.
223559959|NCT07068191|DRUG|UDCA (Ursodeoxycholic acid)|UDCA 10-15 mg/kg/day
223559960|NCT07068191|DRUG|Ademetionine|Ademetionine 800-1600 mg/day.
224032080|NCT06323200|PROCEDURE|lymphaticovenous anastomosis|The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).
224032081|NCT04994327|OTHER|Beta-glucan bread|Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
224032082|NCT04600700|DEVICE|Clinical Decision support system (CDSS) for inotrope weaning|A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
224032083|NCT02827630|OTHER|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
224032084|NCT02827630|OTHER|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
224032085|NCT06248554|DRUG|PD-1 Inhibitors|Patients in the intervention group received post-operative adjuvant PD-1 inhibitor therapy, 240 mg intravenously every three weeks for nine cycles
224032086|NCT00247338|DRUG|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
224032087|NCT02787525|OTHER|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
224032088|NCT03081052|DRUG|iNO|Subject will receive inhaled Nitric Oxide in this intervention
224032089|NCT03081052|DRUG|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
223414237|NCT02821754|DRUG|Tremelimumab|Flat dose of 75 mg every 4 weeks for up to 4 doses.
223414238|NCT02821754|PROCEDURE|Trans-arterial Catheter Chemoembolization (TACE)|TACE will be performed on Day 36 (+/-96hrs).
223414239|NCT02821754|PROCEDURE|Radiofrequency Ablation (RFA)|RFA will be performed on Day 36 (+/-96hrs).
223414240|NCT02821754|PROCEDURE|Cryoablation|Cryoablation will be performed on Day 36 (+/-96hrs).
223414241|NCT05724680|OTHER|cognitive behavior therapy|Psycho-therapeutic intervention
223414242|NCT05693064|OTHER|wait-list|wait-list
223414243|NCT05693064|PROCEDURE|chiropractic adjustments|chiropractic adjustments
223414244|NCT02324504|DEVICE|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
223414245|NCT06575010|DRUG|Liposomal bupivacaine|20 mL Liposomal bupivacaine (Exparel) will be given in the shoulder block prior to surgery
223414246|NCT06575010|DRUG|Bupivacaine Hcl 0.5% Inj|0.75% bupivacaine will be given in the shoulder block prior to surgery
223414247|NCT06575010|DRUG|Dexamethasone|10 mg Dexamethasone will be given in the shoulder block prior to surgery
223414248|NCT04836013|DIETARY_SUPPLEMENT|combined Lactobacilli|1 oral stick per day for 30 days starting the day of antibiotic treatment
223414249|NCT04836013|OTHER|Placebo|1 oral stick per day for 30 days starting the day of antibiotic treatment
223414250|NCT04091789|DRUG|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
223414251|NCT01365078|DIETARY_SUPPLEMENT|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
223559961|NCT07071012|DRUG|Bupivacaine|Used for regional anesthesia during nephrectomy procedure (e.g., paravertebral or external oblique intercostal block)
223559962|NCT07071012|DRUG|morphine|Used for postoperative pain control via PCA device
223559963|NCT07071012|DRUG|paracetamol|Used as part of postoperative multimodal analgesia
223559964|NCT07071012|DRUG|Diclofenac|Administered for postoperative pain management
223559965|NCT06767098|OTHER|theraputic exercises for neck muscles and smartphone holder|strech and strength exercises for neck muscles. and using smartphone holder daily.
223559966|NCT06767098|OTHER|theraputic exercises for neck muscles|strech and strength exercises for neck muscles.
224032090|NCT01103245|DRUG|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
223414252|NCT01365078|DIETARY_SUPPLEMENT|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
223414253|NCT01826513|DEVICE|Standard AutoSet algorithm|An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
223414254|NCT01826513|DEVICE|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
223414255|NCT04074369|DIAGNOSTIC_TEST|CRISPR-based Test|CRISPR-based Test performed on sputum or BALF in TB suspects.
223414256|NCT05478161|DEVICE|(ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
223414257|NCT00435682|DRUG|Botox (Allergan Inc., US)|
223414258|NCT05542784|PROCEDURE|Modified LERV|"Patients routinely underwent LC. The ligature clamp clamps the distal end of the capsule tube. In this case, you need to perform two steps:~Laparoscopic operation: proximal incision, anterograde placement of guide wire into the duodenum. The catheter was removed and the balloon dilated. The balloon was released and removed when the ERCP was initiated for cannulation. After successful ERCP retrograde placement, the anterograde guide wire was pulled out and the gallbladder was removed.~ERCP procedure: After the anterograde guide wire was observed by duodenoscope, duodenal papilla was placed through a retrograde incision along the anterograde guide wire, and a retrograde cannula was inserted into the common bile duct. Remove stones by dragging them with a net basket or/and balloon. Angiography confirmed that there was no filling defect in the extrahepatic bile duct, and ENBD was indwelled."
223414259|NCT05743348|BEHAVIORAL|Telepsychotherapy|Remotely delivered psychotherapy sessions
223414260|NCT06353984|DIETARY_SUPPLEMENT|Minimeal product|Intervention product consisting of bioprocessed oats and chickpeas
223414261|NCT06353984|DIETARY_SUPPLEMENT|Reference product|Reference product mimicking available soups and fruit drinks
223414262|NCT03139578|DEVICE|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
223414263|NCT03139578|DEVICE|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
223414264|NCT03139578|DEVICE|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
224032091|NCT01103245|DRUG|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
224032092|NCT01103245|DRUG|Spironolactone (SPL 25)|spironolactone 25mg daily
224032093|NCT01103245|DRUG|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
224136275|NCT03497026|DEVICE|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
224299156|NCT01483053|DRUG|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
223414265|NCT03139578|DEVICE|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
223414266|NCT02602990|DEVICE|SQUID™|
223414267|NCT01474473|DEVICE|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
223414268|NCT01474473|DEVICE|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days"
223414269|NCT01718678|DRUG|Melatonin|it is kind of drug
223414270|NCT01718678|DRUG|Placebo|It is Placebo
224032094|NCT01103245|DRUG|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
224032095|NCT05184686|OTHER|noise expose|simulate noise expose environments
224032096|NCT05184686|OTHER|RF expose|simulate RF expose environments
224032097|NCT01409616|DRUG|darexaban|oral
224032098|NCT01409616|DRUG|darexaban (double dose)|oral
224032099|NCT01409616|DRUG|Acetyl Salicylic Acid|oral
224032100|NCT01409616|DRUG|clopidogrel|oral
224032101|NCT03675178|DRUG|Anerning particle|Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
223414271|NCT04504214|OTHER|Upper limb repeated multi-site tendon vibrations|Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
224032102|NCT03675178|DRUG|control group|Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
224032103|NCT05987722|OTHER|Enoxolone|The experimental group returned home after the operation and used glycyrrhetinic acid toothpaste three times a day for oral cleaning.After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
224136276|NCT02273557|DRUG|Asasantin ER (new formulation I - low)|
224136277|NCT02273557|DRUG|Asasantin ER (new formulation III - medium)|
224136278|NCT02273557|DRUG|Asasantin ER (new formulation II - high)|
224136279|NCT02273557|DRUG|Asasantin ER (present commercial formulation)|
224136280|NCT03998020|OTHER|scale of severity|assessment of the severity of the sleep disorders by scale
224136281|NCT03998020|GENETIC|blood sample|Genetical study, serum and sample
224136282|NCT04412382|DIAGNOSTIC_TEST|NETosis markers|"NETosis markers (Cf-DNA. MPO-DNA, Cit-H3) and the cytokines IL-6 and IL-1β will be analyzed from the subjects' plasma.~Spittle sample (or bronchoalveolar fluid if necessary for diagnostic-therapeutic purposes) will be collected and the detection of NETs at electron microscopy will be assessed."
223414272|NCT02312089|DRUG|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
223414273|NCT04216836|DIETARY_SUPPLEMENT|Magnesium oxide|Magnesium capsule
223414274|NCT04216836|DIETARY_SUPPLEMENT|Placebo|Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.
223414275|NCT03243032|DRUG|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
223414276|NCT03243032|DRUG|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
223414277|NCT03243032|DRUG|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
223414278|NCT03243032|DRUG|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
223414279|NCT02552069|DEVICE|Tritanium® cup|
223414280|NCT02477332|BIOLOGICAL|QGE031|
223414281|NCT02477332|BIOLOGICAL|Omalizumab|
223559967|NCT06222827|DRUG|Satralizumab Prefilled Syringe|Satralizumab is supplied as prefilled syringe with 1 millimeter of solution for subcutaneous injection corresponding to 120mg of satralizumab. During the first period (double blind period), satralizumab will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
224032104|NCT05987722|OTHER|Sensodyne|The Active Comparator group returned home after the operation and used glycyrrhetinic acid -free toothpaste(Sensodyne) three times a day for oral cleaning. After the operation, toothpaste was used three times a day to clean the mouth for 12 weeks . Clinical evaluation was using the patient-reported pain score, painkillers, wound healing index (complete epithelization and color matching score), periodontal pocket depth, gingiva index, plaque index and were recorded before operation and 1st, 2nd, 3rd, 4th, 8th, 12th week after surgery. The control group used ordinary toothpaste for oral cleaning, and the rest of the research time, measurement time and measurement results were the same as the experimental group. During the study period, we will continue to monitor whether there is any adverse reaction, and if any adverse reaction occurs, the trial will be stopped.
224032105|NCT00261313|DRUG|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
224032106|NCT00261313|DRUG|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
224032107|NCT00215878|DRUG|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
224032108|NCT00457184|PROCEDURE|Blood tests|
223414282|NCT02477332|OTHER|Placebo|
224032109|NCT04109196|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
224032110|NCT02214433|DRUG|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
224032111|NCT02214433|DRUG|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
224032112|NCT02214433|DRUG|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
224032113|NCT02214433|DRUG|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
224032114|NCT02214433|DRUG|Debio 1450 Capsule|Debio 1450 40 mg capsules
224032115|NCT02214433|DRUG|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
224032116|NCT02214433|DRUG|Pantoprazole|Pantoprazole 40 mg orally
224136283|NCT04469374|OTHER|Jumping exercise|Participants will be required to perform 10 maximal vertical jumps, with a 10-s rest interval between each jump, using an arm swing in countermovement style on three days per week. The jumps will be performed without shoes on a hard surface. The jumps will be preceded by a warm-up lasting approximately 3 min and consisting of mobilisation exercises for the legs and lower back. Jumping will be progressed over time and in accordance with individual needs.
223414283|NCT04024345|DIAGNOSTIC_TEST|Barratt Simplified Measure of Social Status (BSMSS)|Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
223414284|NCT04024345|DIAGNOSTIC_TEST|Global Assessment of Functioning scale (GAF)|Used to measure overall levels of functionality of an individual
223414285|NCT04024345|DIAGNOSTIC_TEST|General Self-Efficacy Scale (GSES)|Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
223414286|NCT04024345|DIAGNOSTIC_TEST|Perceived Stress Scale (PSS)|To assess the perceived stress
223414287|NCT04024345|DIAGNOSTIC_TEST|Coping Orientation to Problems Experienced (Brief COPE),|It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
223414288|NCT04024345|DIAGNOSTIC_TEST|Multidimensional Scale of Perceived Social Support (MSPSS)|to explore the subject's social support system
223414289|NCT02549287|BEHAVIORAL|SafeCare|An evidence-based home visiting program
223414290|NCT02549287|BEHAVIORAL|Supportive Case Management|Child welfare services as usual
223414291|NCT03793842|OTHER|Usual care|Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.
223414292|NCT03793842|DEVICE|PEEP titration by EIT|PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
223559968|NCT06222827|DRUG|Placebo Comparator|Placebo prefilled syringe is identical in composition to satralizumab, but does not contain the satralizumab active agent. It is identical in appearance and packaging to satralizumab. During the first period (double blind period), placebo will be administered at weeks 0, 2, 4 and every 4 weeks until week 48. During the second period (open label period), satralizumab will be administered at weeks 48, 50, 52 and every 4 weeks until week 96.
223559969|NCT00661726|DRUG|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
223414293|NCT03173664|DEVICE|KAMRA Inlay|Unilateral implantation of the KAMRA inlay in the corneal stroma.
223414294|NCT02442570|BIOLOGICAL|recombinant human alpha B-crystallin|intravenous injections
223414295|NCT02442570|OTHER|Placebo comparator|intravenous injection
223559970|NCT01900522|DRUG|ITI-214 Dose A|ITI-214 Dose A Oral Solution
223559971|NCT01900522|DRUG|ITI-214 Dose B|ITI-214 Oral Solution Dose B
224032117|NCT01101477|PROCEDURE|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~1. Patients become irritant and interfere procedures.~2. Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~1. Systolic blood pressure is less than 90mmHg;~2. Mean arterial blood pressure is less than 65mmHg;~3. Oxyhemoglobin saturation is less than 90 %~with any duration."
224032118|NCT02332109|DEVICE|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
224032119|NCT03597412|DRUG|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
224032120|NCT03597412|DRUG|Monorova|Rosuvastatin 20mg
224032121|NCT06236529|BEHAVIORAL|Health Behavior Change Counseling|A telephone-based intervention employing principles and practices of motivational interviewing.
224032122|NCT06236529|BEHAVIORAL|Self-management program|An evidence-based 6-week SMP led by a registered nurse. The SMP was based on the Arthritis Self-Management Program and the Chronic Disease Self-Management Program.
224032123|NCT04111432|BIOLOGICAL|Concomitant administration of EV71vaccine with EPI vaccines|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
224032124|NCT04111432|BIOLOGICAL|Single injection of EPI vaccine|The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
224032125|NCT04111432|BIOLOGICAL|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
224032126|NCT01121978|PROCEDURE|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
224032127|NCT05214196|DRUG|Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)|SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
224136284|NCT04469374|OTHER|Balance exercise (sham control)|Participants will be required to perform balance exercises. Participants will be required to balance on one leg for up to 60 seconds (2 x 60 s is equivalent in duration to the 10 jumps). This exercise will be progressed.
223414296|NCT06160115|DEVICE|Flow cytometry|"1. Profiling of NK cells using flow cytometry on peripheral blood and bone marrow aspirate samples.~2. Isolation and identification of pathogens causing BSI and bacterial drug susceptibility testing using VITEK compact fully automatic microbial identification instrument."
224136285|NCT06082648|DEVICE|Transcranial magnetic stimulation|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla.Stimulation group: Intermittentpulse transcranial magnetic stimulation (iTBS) will be performed with : the cluster consists of 3 pulses, the intra-cluster frequency is 50Hz, the intercluster frequency is 5Hz, the interval is 8.2s for every stimulus. There are 20 cycles and a total of 600 pulses. Each intervention time is 3min11s, and the stimulation intensity is set as 80% resting state motion threshold. The intervention will be performed once a day for 2 weeks.
223414297|NCT05131438|DRUG|sugemalimab|sugemalimab (Anti-PD-L1 antibody)
223414298|NCT06218940|DRUG|HY1272|Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
223414299|NCT00250952|DRUG|Botox Cosmetic™|
223414300|NCT06062589|RADIATION|Iodine-125 particle brachytherapy|All enrolled patients' relapsed or metastatic lesions underwent image-guided radiation I-125 particle implantation brachytherapy (single implantation, half-life of 60 days, 99% of total dose given after 90 days). The prescribed dose is above 130Gy. Technical process: positioning and preoperative planning design; Template reset and particle implantation under the guidance of image system; Rapid and real-time intraoperative optimization; Postoperative dose validation.
223414301|NCT06062589|DRUG|AK104|AK104 treatment (6mg/kg Q2W) starting within 1 week of particle implantation, for a total of 6 cycles or until disease progression, intolerable toxicity, investigator decision, withdrawal of informed consent, death, or other reasons as specified in the protocol.
223414302|NCT05389930|DRUG|THC-dominant cannabis|Smoked cannabis with 9.53% THC and 0.09% CBD
223414303|NCT05389930|DRUG|CBD-dominant cannabis|Smoked cannabis with 0.35% THC and 11.27% CBD
223559972|NCT01900522|DRUG|ITI-214 Dose C|ITI-214 Dose C Oral Solution
223559973|NCT01900522|DRUG|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
223559974|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
223559975|NCT01900522|DRUG|ITI-214 Dose E|ITI-214 Dose E Oral Solution
223559976|NCT01900522|DRUG|ITI-214 Dose F|ITI-214 Dose F Oral Solution
223559977|NCT01900522|DRUG|ITI-214 Dose G|ITI-214 Dose G Oral Solution
223559978|NCT01900522|DRUG|ITI-214 Dose H|ITI-214 Dose H Oral Solution
223559979|NCT01900522|DRUG|Placebo|ITI-214 Matching Placebo Oral Solution
223414304|NCT05389930|DRUG|Cannabis placebo|Smoked placebo cannabis plant material
223414305|NCT05389930|DRUG|Alcohol|Drink containing 0.3 g/kg of alcohol
223414306|NCT05389930|DRUG|Alcohol placebo|Placebo beverage contains only juice and a negligible trace of alcohol for masking
223414307|NCT00427921|BIOLOGICAL|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
223414308|NCT05796466|BEHAVIORAL|How-to talk so kids will listen and listen so kids will talk|The How-to Parenting Program focuses on how expectations, rules, and values are better communicated (vs. what rules ought to be). It includes skills related to the three components of authoritative parenting, namely affiliation, structure, and autonomy support. 1) Affiliation: Parents learn how to listen and respond to their children in a way that helps them feel accepted unconditionally. 2) Structure: Parents learn how to communicate expectations, give feedback, follow through, and use joint problem-solving in a factual, non-judgmental way. 3) Autonomy support: Parents learn how to validate emotions, encourage initiatives, and free children from roles. Finally, the How-to program can be endorsed by parents of various cultural backgrounds, as suggested by the large number (\> 30) of languages in which the material is translated. This advantage is crucial in ethnically diverse regions such as Canada.
223414309|NCT05796466|BEHAVIORAL|Nobody's Perfect|Nobody's Perfect is delivered in family resource centers across Canada to support parents of infants and preschoolers. Its focus is on developing parents' capacity to problem solve, providing child development information, and helping parents recognize their strengths and find their own positive ways to interact with their children. It thus does not teach specific parenting skills and does not suggest specific rules to put into practice in the home-environment.
223414310|NCT05383040|PROCEDURE|Percutaneous release|Percutaneous release of A1 pulley release will be performed in the well-managed operation theater set up, using an 18 gauge hypodermic needle, after preparation of the skin and injection of 1ml 2% plain lidocaine. The proper location of the pulley will be defined using surface landmarks in each digit after waiting a few minutes to allow the anesthetic to take effect the 18 gauge needle will be longitudinally moved to keep the level of the needle parallel with the tendon grating sensation will be elucidated confirming the cut of pulley until there is no grating sensation felt and improvement of symptoms. A sterile dressing will be placed.
223414311|NCT04229654|OTHER|Questionnaire|A written questionnaire was used to capture demographic data, obstetric history, knowledge, expectations, and perception of anomaly scans.
223414312|NCT01166438|DRUG|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
223414313|NCT01166438|DRUG|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
223414314|NCT01166438|DRUG|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
223414315|NCT01166438|DRUG|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
223414316|NCT05935397|DEVICE|percutaneous coronary intervention|patients with CAD undergoing PCI with second generation DES
223559980|NCT03486301|DRUG|BDB001 (EIK1001)|BDB001 (EIK1001) is an immunotherapy agent.
224032128|NCT05522933|OTHER|4 weekly musculoskeletal health promotion workshops with stretching and muscle-strengthening exercise|The modified online multidimensional musculoskeletal health promotion program will consist of 4 weekly workshops for 90-minute each for a group size of 8-12 participants. The topics of the workshop are: (1) exercise and health \& work; (2) prevention of musculoskeletal problems; (3) musculoskeletal health and traditional Chinese medicine; and (4) mental health and community resources. Each workshop will consist of stretching and muscle strengthening exercises (30 minutes), a health education topic (about 45 minutes), and a question-and-answer period (about 15 minutes).
223414317|NCT04618198|OTHER|Immediate anti-TB therapy|Study participants will receive immediate empiric anti-TB therapy
223414318|NCT04618198|OTHER|Sepsis-specific dose anti-TB therapy|Study participants will receive conventional WHO weight-based dose anti-TB therapy
223414319|NCT03719781|DIAGNOSTIC_TEST|standardized minimental testing|To diagnose postoperative cognitive dysfunction
223559981|NCT03486301|DRUG|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
224032129|NCT00432887|DRUG|caffeine administration|
224032130|NCT00501527|BIOLOGICAL|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
224032131|NCT00501527|OTHER|Placebo|Placebo 2 drops daily
224032132|NCT03635333|DRUG|Nicotine|Nicotine level (6 or 18 mg)
224032133|NCT03635333|DRUG|Flavor|Flavor of e-juice (tobacco, menthol, strawberry)
223559982|NCT05820139|PROCEDURE|Control Group|Patients will be randomized to a 200mL (control group)
223559983|NCT05820139|PROCEDURE|Test Group|Patients will be randomized to a cut-off of 150mL (test group)
223559984|NCT01673854|DRUG|Ipilimumab|
223559985|NCT01673854|BIOLOGICAL|Vemurafenib|
223559986|NCT00285155|DRUG|Bupropion|
223559987|NCT04222894|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
224136286|NCT06082648|DEVICE|Sham Transcranial magnetic stimulationt|The magnetic stimulator equipment is provided by the MagProX100 magnetic stimulator ( MagVenture, Lucernemarken, DK-3520 Farum, Denmark), with 8-shaped coil, a maximum stimulation frequency of 30Hz and a maximum stimulation intensity of 6 Tesla. Patients on the Sham stimulation group will be interfered with the stimulation coil perpendicular to the skull, so that they will hear the sound of machine without having therapeutic effects. The parameters will be the same as those in the stimulation group.
224136287|NCT01941524|DRUG|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
223414320|NCT06017297|DRUG|Durvalumab|Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles
223414321|NCT06017297|DRUG|Tremelimumab|A single dose of tremelimumab at 300mg IV is given on C1.
223559988|NCT04222894|OTHER|Control Diet|Participants will be asked to continue their usual diets for the 12-week study period.
224032134|NCT06491407|DIAGNOSTIC_TEST|Chewing and swallowing performance assessment and related factors|In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided.
223414322|NCT06017297|DRUG|Gemcitabine|Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.
223414323|NCT06017297|DRUG|Cisplatin|Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.
223559989|NCT06889090|DRUG|: two syringes of lidocaine 10 mg/mL will be prepared. A 10-mL syringe (induction syringe) will be given during the induction of anesthesia and A 50 mL syringe (infusion syringe) will be used as conti|: two syringes of lidocaine 10 mg/mL will be prepared. A 10-mL syringe (induction syringe) will be given during the induction of anesthesia and A 50 mL syringe (infusion syringe) will be used as continuous infusion.
223559990|NCT06889090|DRUG|A 10-mL syringe of 10 mcg/mL fentanyl (induction syringe) and a 50-mL syringe of saline (infusion syringe) will be prepared as placebo.|A 10-mL syringe of 10 mcg/mL fentanyl (induction syringe) and a 50-mL syringe of saline (infusion syringe) will be prepared as placebo.
223559991|NCT04911647|DEVICE|ERCP using plastic stent|Insertion of plastic stent (plastic stent with inner diameter 1.8mm or more) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
223559992|NCT04911647|DEVICE|ERCP using metal stent|Insertion of metal stent (full covered self-expandable metal stent) in the biliary obstruction will be performed using ERCP in the patients with the pancreatic cancer undergoing neoadjuvant therapy.
223559993|NCT01101958|DEVICE|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
223559994|NCT01101958|DEVICE|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
223559995|NCT05027347|DIAGNOSTIC_TEST|plasma circulating tumor DNA|A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
223559996|NCT01248572|DEVICE|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
224032135|NCT06450756|BEHAVIORAL|Couples arm|The Couples Arm aims to improve family planning (FP) utilization in pastoralist communities, addressing significant disparities in contraceptive use and unmet FP needs between pastoralist and agrarian communities in Ethiopia. Pastoralist areas face challenges such as low contraceptive usage, high unmet FP needs, and elevated rates of maternal and child morbidity and mortality. In 2016, only 9.1% of women in pastoralist areas used contraceptives, compared to a 41% prevalence rate in 2019 for the general population in Ethiopia. Reasons for non-use of contraceptives include lack of knowledge, unwillingness, negative perceptions, desire for many children due to child mortality concerns, and male dominance in FP decision-making. The study hypothesizes that engaging men and educating women about FP could enhance FP utilization, increase male involvement in family planning, and empower women.
224032136|NCT06450756|BEHAVIORAL|Male arm|This arm focused on promoting male involvement in family planning (FP) through comprehensive health education and video messages. Husbands were encouraged to become supportive partners and share FP information with their wives. Separate education sessions were held for men, recognizing their greater exposure to social activities and information in pastoralist contexts. Pastoralist wives typically rely on their husbands for information due to limited social access. Women in pastoral communities have significant informal power in family decisions, influenced by factors such as age, husband's status, sons' ages, eloquence, and wisdom. Reproductive health discussions are primarily between husband and wife. Education aimed to improve modern contraceptive use, overcoming common barriers like husband objection and religious influence on decision-making.
224032137|NCT00720941|DRUG|Pazopanib|800 mg administered once daily orally continuous dosing
224032138|NCT00720941|DRUG|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
224032139|NCT02870699|DEVICE|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
224032140|NCT02870699|DEVICE|Placebo excipient|film forming excipient solution
224136288|NCT01941524|DRUG|Beractant instillation|aEEG and NRs monitoring during beractant instillation
224136289|NCT05007249|PROCEDURE|Use of the Chalaxie pedagogical evaluation tool|Use of the Chalaxie pedagogical evaluation tool during two visits
224136290|NCT04110418|DRUG|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
224136291|NCT03543306|DRUG|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
223559997|NCT07081802|DRUG|Da Jian Zhong Tang (Zanthoxylum, Ginger, Ginseng, Maltose)|"Da Jian Zhong Tang (Zanthoxylum, Ginger, Ginseng, Maltose)was administered orally twice daily from preoperative day 3 to postoperative day 3. The decoction aims to warm the middle jiao and promote gastrointestinal recovery, with dose adjustments based on syndrome differentiation."
223559998|NCT07081802|PROCEDURE|Transcutaneous Electrical Acupoint Stimulation (TEAS)|TEAS was delivered at acupoints ST36/ST37 (10Hz continuous wave, 30min/session) once daily from intraoperative day to postoperative day 4. On surgery day, stimulation started 30min preoperatively for 1 hour. Intensity was adjusted to elicit deqi sensation.
223414324|NCT06017297|PROCEDURE|Surgical Resection|If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.
223414325|NCT06035640|OTHER|Interview|Participants will be engaged in a semi-structured interview.
223414326|NCT00347009|DRUG|adefovir dipivoxil|10mg once daily
223414327|NCT06575907|OTHER|no intervention|no intervention
224032141|NCT00604279|DRUG|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
223414328|NCT06091917|DIETARY_SUPPLEMENT|Betaine supplementation in infant formula|Infant formula will be supplemented with betaine to provide a final concentration of 100 µmol/L in the reconstituted milk. The intervention will last for 12 weeks.
223414329|NCT06091917|DIETARY_SUPPLEMENT|Regular infant formula|Regular (unmodified) infant formula . The intervention will last for 12 weeks.
223559999|NCT07081802|OTHER|ERAS|"Standardized ERAS protocol included: (1) Preoperative carbohydrate loading; (2) Intraoperative goal-directed fluid therapy; (3) Minimally invasive surgery; (4) Multimodal opioid-sparing analgesia; (5) Early oral feeding (semi-liquid diet at 6h post-op); (6) Early ambulation (first mobilization at 8h post-op). Implemented by a multidisciplinary team."
223560000|NCT07081802|OTHER|Multimodal Prehabilitation Program|(1) Exercise: Daily aerobic/resistance training (30min, 5×/week); (2) Nutrition: High-protein diet (1.5g/kg/day) + oral supplements if needed; (3) Psychological Support: Cognitive-behavioral therapy sessions (2×/week). Tailored to individual patient risk profiles.
223560001|NCT07079423|DRUG|Teclistamab (Tec)|Teclistamab will be administered via a subcutaneous injection
223560002|NCT07080372|DIAGNOSTIC_TEST|assesment|This study aims to assess the role of early arterial phase in detecting and differentiating hepatocellular carcinoma from dysplastic nodules in chronic liver disease patients.
223560003|NCT07079592|DIAGNOSTIC_TEST|AI-ECG Guidance|Participants undergo screening using the AI-ECG system. Those identified as high-risk for pulmonary hypertension receive echocardiography to confirm the diagnosis and guide subsequent management.
223560004|NCT07081867|PROCEDURE|Supra-inguinal Fascia Iliaca Block (SIFIB)|Ultrasound-guided injection of 40 mL of 0.25% bupivacaine between the iliacus muscle and fascia iliaca via a supra-inguinal approach, performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
224032142|NCT00604279|DRUG|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
224032143|NCT03972007|DEVICE|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
224032144|NCT00076492|DRUG|CoQ10|
224032145|NCT00076492|DRUG|GPI 1485|
224032146|NCT01179451|DEVICE|echocardiogram|echocardiogram
224032147|NCT00355056|OTHER|Sham Procedure|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure). Participants completing 1 year follow-up are eligible for PFO closure with the AMPLATZER PFO Occluder.
224032148|NCT00355056|DEVICE|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
224299157|NCT01483053|DRUG|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
223414330|NCT00006178|DRUG|Sirolimus|
223414331|NCT00006178|DRUG|Thymoglobulin|
223414332|NCT06252558|DIETARY_SUPPLEMENT|Symbiotic|One-a-day administration of a capsule supplement containing:15 billion CFU probiotic blend (Lactobacillus acidophilus La-14, Bifidobacterium longum BB536, Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus GG, Lactobacillus gasseri Lg-36) and 250mg of chicory root inulin.
224032149|NCT03348865|BEHAVIORAL|Fertility Life Counselling Aid (FeLiCiA)|The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
224032150|NCT03699436|OTHER|Electrotherapy with Galvanic Current|The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
224032151|NCT03699436|OTHER|Control without Electric Stimulation Therapy|The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
224299158|NCT02502773|DRUG|Hydroxethyl starch|
223414333|NCT06252558|DIETARY_SUPPLEMENT|Placebo|Daily fiber capsule containing microcrystalline cellulose
223414334|NCT04119297|OTHER|Routine care|"* Routine care was applied to the periorbital area by clinical nurses.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
223414335|NCT04119297|OTHER|Cold gel pack|"* Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
223414336|NCT04119297|DRUG|Heparinoids Topical Cream|"* Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale"
223560005|NCT07081867|PROCEDURE|Sacral Erector Spinae Plane Block (SESPB)|Ultrasound-guided injection of 40 mL of 0.25% bupivacaine into the fascial plane deep to the erector spinae muscle at the sacral level (S2), performed preoperatively for postoperative analgesia in patients undergoing hip fracture surgery under spinal anesthesia.
223414337|NCT01509560|DRUG|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
223560006|NCT07079358|BEHAVIORAL|Veterans Cardiac Rehabilitation Referral Program|"1. A CDS tool that identifies Veterans hospitalized with CR-eligible conditions and prompts physicians to refer them to CR.~2. Educational materials that explain to Veterans the benefits and importance of participating in CR.~3. Defined responsibilities for a facility-based CR referral coordinator who will support development and oversight of the referral process."
223560007|NCT07081763|DRUG|Baricitinib 2 MG|Administered orally at 2 mg QD from W0 to W10.
223560008|NCT07081763|DRUG|Sirolimus 2 MG|Administered orally at 2 mg QD from W0 to W10.
224032152|NCT02884427|DEVICE|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
224032153|NCT02884427|DEVICE|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
224032154|NCT02884427|DEVICE|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
224032155|NCT05802758|BEHAVIORAL|Psychopathy.comp and training in virtual reality (VR)|Psychopathy.comp is a CFT-based manualized program of 20 sessions a 60 min, on a weekly basis. During the CFT-intervention, partipants try out their new skills in a tailored VR setting (x5)
224032156|NCT00861224|OTHER|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
224032157|NCT01894373|DRUG|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
224136292|NCT04377061|DIAGNOSTIC_TEST|Evaluation of anemia|Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
224136293|NCT03713931|DIAGNOSTIC_TEST|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
224136294|NCT03939351|DIAGNOSTIC_TEST|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
223414338|NCT06256952|BEHAVIORAL|PIT paradigm|"The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value."
223414339|NCT06256952|BEHAVIORAL|social exclusion (Cyberball task)|Social exclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social exclusion, subjects will be systematically excluded by one co-player, and during social inclusion, ball tosses will be balanced between all three players.
223414340|NCT06256952|DIAGNOSTIC_TEST|Saliva samples|Assessing acute stress effects in AUD and HC subjects
223560009|NCT07081763|OTHER|Placebo of baricitinib 2 MG|Administered orally at 2 mg QD from W0 to W10.
223560010|NCT07081763|OTHER|Placebo of sirolimus 2 MG|Administered orally at 2 mg QD from W0 to W10.
223560011|NCT04362800|OTHER|MRI|MRI at baseline and J90
223560012|NCT04362800|OTHER|Electro-Encephalography-High Density|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
223560013|NCT04362800|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
224136295|NCT03832153|PROCEDURE|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
223560014|NCT04362800|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
224032158|NCT01894373|BIOLOGICAL|CIK|
224032159|NCT00901277|BEHAVIORAL|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
224032160|NCT00901277|BEHAVIORAL|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
224136296|NCT04202653|DRUG|ETV|entecavir 0.5 mg qd
224136297|NCT04202653|DRUG|TQ-A3334|TQ-A3334 po qw
224136298|NCT04202653|DRUG|TQ-B2450|TQ-B2450 q3w iv
224136299|NCT01968954|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
223414341|NCT06256952|DIAGNOSTIC_TEST|basic psychological assessment|"* Sociodemographics~* ASSIST~* Quantity Frequency: Alcohol, tobacco/e-cigarette, Cannabis \& other illegal drugs~* SCID: AUD criteria and tabak use disorder life time and last year \& acute depressive symptoms \& symptoms for Mania and psychotic disorder~* Edinburgh Handedness Inventory (EHI)~* Fagerström Test for Nicotine depend (FTND)~* Barratt Impulsiveness Scale - Kurzversion (BIS-15)~* Allgemeine Depressionsskala (ADS)~* State-Trait-Anxiety Inventory (STAI-T)~* Alcohol Use Disorders Identification Test (AUDIT)~* Cannabis Use Disorder Identification Test (CUDIT)~* CAS -A (Alkohol)~* Fragebogen zur Sozialen Unterstützung (F-SozU K-14)~* Oslo-3-Items-Social-Support Scale~* Social Skills Rating System (SSRS)~* Trier Inventory for chronic stress (TICS)~* Rejection Sensitivity Questionnaires (RSQ-9)~* Need to belong scale (NTBS)~* Fragebogen zu Gedanken und Gefühlen (FGG-14)~* Internationale Trauma Questionnaire (ITQ)~* Zahlen-Symbol-Test (DST)~* Wortschatztest (verbal intelligence)"
223414342|NCT06256952|DIAGNOSTIC_TEST|pre and post cyberball task|Positive and Negative Affect Schedule(PANAS)
223414343|NCT06256952|DIAGNOSTIC_TEST|VAS|subjective arousal, subjective stress, valence, perceived ostracisms/loneliness
223414344|NCT06256952|DIAGNOSTIC_TEST|after cyberball task|"* Need Threat Scale~* Manipulation check (VAS scale)"
223414345|NCT06256952|BEHAVIORAL|social inclusion (Cyberball task)|Social inclusion will be assessed using the cyberball paradigm: subjects will play an online game tossing a ball to each other with two more virtual co-players. Using a cover story, we make subjects believe that the co-players really exist and that they play a live online game. During social inclusion, ball tosses will be balanced between all three players.
223414346|NCT05573932|OTHER|Leaderboard|De-identified leaderboard showing average durations of exercises completed by all participants in leaderboard group.
223414347|NCT05573932|OTHER|Take-home packet|Take-home packet of exercises.
223414348|NCT02151305|DRUG|Propofol, remifentanil|
224032161|NCT00681746|DRUG|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
224032162|NCT00681746|DRUG|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
224032163|NCT03898947|PROCEDURE|Diagnostic hysteroscopy and targeted endometrial biopsy|Diagnostic hysteroscopy and targeted endometrial biopsy
224136300|NCT01968954|OTHER|Placebo|subcutaneous injection, every 2 weeks for 12 months
224136301|NCT03411265|OTHER|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
224136302|NCT01337063|OTHER|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
224136303|NCT04511026|DRUG|Lymphoseek|Radioactive diagnostic agent
224136304|NCT04511026|DEVICE|Single Photon Emission Computed Tomography (SPECT)|Imaging test
223414349|NCT02151305|DRUG|Sevoflurane|
223414350|NCT02924285|PROCEDURE|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
223414351|NCT02924285|DRUG|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
223414352|NCT01545037|DIETARY_SUPPLEMENT|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
224032164|NCT01489202|DEVICE|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
223414353|NCT01545037|OTHER|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
223414354|NCT03416426|DEVICE|Amplatzer® PFO occluder or Gore® Septal Occluder|The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
224032165|NCT01489202|DEVICE|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
224032166|NCT04099017|OTHER|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~1. Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~   Procedural detail:~   Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~2. Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~3. Kinesiotaping:"
224136305|NCT04511026|DRUG|Indocyanine Green (ICG)|Cyanine dye used in medical diagnostics manufactured by Akorn Inc.
224136306|NCT04511026|DEVICE|Neoprobe Gamma Detection System NPB11L(Model1102)|Neoprobe Gamma Detection System NPB11L(Model1102) made by Devicor Medical Products, Inc.
224136307|NCT00644254|PROCEDURE|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
224136308|NCT02385877|DRUG|[18F]4F-MHPG|IV injection of \[18F\]4F-MHPG
224136309|NCT02385877|DRUG|[18F]3F-PHPG|IV injection of \[18F\]3F-PHPG
223414355|NCT00179972|DEVICE|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
223414356|NCT02764372|BEHAVIORAL|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
223414357|NCT02764372|BEHAVIORAL|Exergames|Participants played exergames existent in the Wii game console
223414358|NCT02336568|DRUG|Oxytoine|In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
223414359|NCT02336568|DRUG|PLACEBO|In the first week 24 IU \* 2/day. in the 2nd \& 3rd 40 IU \* 2/day
223560015|NCT07080294|OTHER|extended platelet rich fibrin injection in pocket|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared. Then the liquid platelet-rich layer (liquid-PRF) including the buffy coat layer with accumulated platelets and leukocytes, will be collected in a separate syringe. The albumin gel and native liquid PRF will then be thoroughly mixed by utilizing a female-female luer lock connector. Now injectable e-PRF in final form is ready to be used.
223560016|NCT07080294|OTHER|albumin injection in pocket|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared.
223560017|NCT07080294|OTHER|scaling and root planing|removes plaque and calculus above and below the gumline using manual or ultrasonic instruments.
223738949|NCT02461225|DEVICE|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
224032167|NCT04099017|OTHER|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~   Procedural detail:~   i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~   Iv. lateral step up:~2. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~3. Kinesiotaping:"
224032168|NCT04099017|OTHER|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~1. Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~   Procedural detail:~   i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~2. Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
224032169|NCT00733993|DRUG|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
224299159|NCT03592576|DRUG|Navitoclax|Tablet, Oral
224299160|NCT03592576|DRUG|Venetoclax|Tablet, Oral
224299161|NCT03168594|DRUG|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
224299162|NCT03168594|DRUG|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
223414360|NCT01830868|DRUG|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
223414361|NCT01599533|OTHER|blood samples|
223414362|NCT02653781|BEHAVIORAL|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
223414363|NCT02653781|BEHAVIORAL|control group|The control group will have contents exposed solely from the dialogue-exhibition.
223414364|NCT02653781|BEHAVIORAL|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
223560018|NCT07080190|DRUG|Early N-Acetylcysteine|Patients received N-acetyl cysteine early (at admission) in the course of treatment of acute hair dye poisoning.
223560019|NCT07080190|DRUG|Late N-Acetylcysteine|Patients received the standard treatment of N-acetyl cysteine after starting organ affection in the course of treatment of acute hair dye poisoning.
223560020|NCT07081828|DEVICE|Surgery|Patients who undergo surgery utilising the Senhance Surgical System.
223560021|NCT07081698|OTHER|Infant walnut intake|The intervention group will receive walnuts at 10 g/day, and the control group will be advised to avoid walnuts/tree nuts during the intervention. The purpose of this research is to learn more about how walnuts as a first food in infants impact immunity and the development of bacteria living in your baby's gut.
223414365|NCT02653781|BEHAVIORAL|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
223414366|NCT02348645|PROCEDURE|Spinal fusion|
223414367|NCT02348645|PROCEDURE|Spinal decompression|
223414368|NCT02251418|DEVICE|Extracorporeal shockwave therapy|
223414369|NCT01972438|DRUG|ASEDs|Experimental Intervention
223414370|NCT01972438|DRUG|Saline|Control Intervention
223414371|NCT00274274|DRUG|insulin detemir|
223414372|NCT00274274|DRUG|insulin aspart|
223414373|NCT04955353|DIETARY_SUPPLEMENT|AVC-H2|A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
223414374|NCT04955353|DIETARY_SUPPLEMENT|Placebo|A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
223560022|NCT00322413|DRUG|Epoetin|
223560023|NCT07079540|DRUG|X842|X842 capsules
223560024|NCT07079540|DRUG|X842 Placebo|X842 placebo-matching capsules
224032170|NCT00733993|DRUG|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
224032171|NCT00733993|DRUG|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
224032172|NCT00733993|DRUG|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
224032173|NCT04201600|DEVICE|Continuous Glucose Monitoring System (CGMS)|Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
224032174|NCT01072877|DRUG|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
224032175|NCT01072877|DRUG|Placebo Vehicle|Placebo vehicle
224032176|NCT02782403|DRUG|Axitinib|Given PO
224032177|NCT02782403|DRUG|Bosutinib|Given PO
224032178|NCT02782403|OTHER|Laboratory Biomarker Analysis|Correlative studies
224032179|NCT05351853|DIETARY_SUPPLEMENT|Omnivore|This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
224032180|NCT05351853|DIETARY_SUPPLEMENT|Vegetarian|20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
224032181|NCT05351853|DIETARY_SUPPLEMENT|Vegan|20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
223414375|NCT02097329|DRUG|palbociclib commercial free base|125 mg oral capsule single dose
223414376|NCT02097329|DRUG|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
223414377|NCT02097329|DRUG|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
223414378|NCT02097329|DRUG|palbociclib commercial free base|125 mg oral capsule single dose
223414379|NCT02097329|DRUG|antacid|30 mL orally once (2h before palbociclib)
223414380|NCT02097329|DRUG|antacid|30 mL orally once (2h after palbociclib)
223414381|NCT01478776|DIETARY_SUPPLEMENT|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
223414382|NCT01478776|DIETARY_SUPPLEMENT|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
223414383|NCT01045382|BIOLOGICAL|Mesenchymal stem cells|Mesenchymal stem cell injection
223414384|NCT01045382|OTHER|Isotonic solution|Isotonic solution injection
223414385|NCT05129865|DRUG|LYT-300|A prodrug of allopregnanolone, a small molecule drug
223414386|NCT05129865|OTHER|Placebo|Placebo for LYT-300
223414387|NCT06349291|DIAGNOSTIC_TEST|Detection of venous thrombosis via US|Detection of venous thrombosis via US in patients after removal of central venous catheter
223414388|NCT00604591|DRUG|Tolcapone|200 mg by mouth three times a day
223414389|NCT00604591|DRUG|Placebo|200 mg by mouth three times a day
223414390|NCT05282537|BEHAVIORAL|In person academic activities|All participants will perform academic activities in person from March to December, 2022
223414391|NCT06535152|DEVICE|Lifelight|Lifelight is a artificial-intelligence software application that enables completely contactless spot measurements (i.e., one-off measurements without prior calibration) of PR and BP. Based on the science of remote photoplethysmography (rPPG), Lifelight works by detecting tiny changes in the colour of facial skin that occur every time the heart beats. All that is required to generate PR and BP measurements is that the software application is downloaded onto a computer device (e.g., smartphone or tablet) with a standard camera, and that the patient's face stays in the line of sight of the camera for up to 60 seconds.
223414392|NCT06535152|DEVICE|Manual sphygmomanometer|Blood Pressure Measurement
223414393|NCT01573832|OTHER|integrated client care group|receives integrated client care for wound treatment
223560025|NCT07079540|DRUG|Lansoprazole|Lansoprazole capsules
223560026|NCT07079540|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
223738950|NCT00484939|DRUG|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
224032182|NCT02804776|DRUG|Gefitinib|250mg oral daily for 4 weeks
224032183|NCT00133692|DRUG|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
224032184|NCT00133692|DRUG|Atenolol/HCTZ/Trandolapril|
224032185|NCT00031187|DRUG|SGN-15 (cBR96-doxorubicin immunoconjugate)|
224032186|NCT00031187|DRUG|Taxotere (docetaxel)|
224299163|NCT03002662|OTHER|colonoscopy|
223414394|NCT03162653|DRUG|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
223414395|NCT03162653|DRUG|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
223414396|NCT06383754|DEVICE|Clareon|Monofocal intraocular lens
223560027|NCT06363474|PROCEDURE|Decompressive Craniectomy|Patients allocated to this arm will undergo decompressive craniectomy, which involves the surgical removal of a section of the skull (bone flap). This procedure is performed to alleviate intracranial pressure (ICP) by providing additional space for the swollen brain to expand. The surgery will be performed by a single surgical team under general anesthesia. After the procedure, patients will be closely monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
223560028|NCT06363474|PROCEDURE|Cisternostomy|Patients allocated to this arm will undergo cisternostomy, a microsurgical technique used in neurosurgery. Cisternostomy involves the creation of an additional space for cerebrospinal fluid (CSF) circulation to alleviate brain edema and lower intracranial pressure (ICP). The surgery will be performed by the same surgical team under general anesthesia. Following the procedure, patients will be monitored for various parameters including duration on mechanical ventilation, duration of ICU stay, duration of hospital stay, and Glasgow Outcome Scale (GOS) at the time of discharge.
223560029|NCT02645565|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
223560030|NCT02645565|DRUG|Azathioprine|azathioprine will be given at 2 mg/kg.
223560031|NCT02645565|DRUG|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
223560032|NCT07079644|BIOLOGICAL|Nivolumab + Relatlimab|As per product label
223560033|NCT07079644|BIOLOGICAL|Nivolumab + Ipilimumab|As per product label
223560034|NCT07079644|BIOLOGICAL|Immunotherapy monotherapy|As per product label
224032187|NCT02952287|DEVICE|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
224032188|NCT00062894|DRUG|Iodine I 131 Tositumomab|
224032189|NCT02895438|DIETARY_SUPPLEMENT|gluten|
224032190|NCT00044915|DRUG|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
223414397|NCT06383754|DEVICE|Tecnis 1|Monofocal 1 Piece intraocular lens
223560035|NCT07079644|DRUG|BRAF/MEK inhibitors|As per product label
223560036|NCT06890988|OTHER|Care Navigator|"The Care Navigator will be added to the dental team as an added resource to:~1. Champion the use of the multicomponent HIV intervention in the dental clinic among clinic administrators, residents, dental hygienists, dental assistants, and other dental team staff.~2. Provide technical assistance~3. Provide logistical assistance ; and~4. Support dental team in educating patients about HIV prevention and treatment options"
223560037|NCT06890988|OTHER|Multicomponent HIV Service Package|"Multicomponent HIV Service Package consisting of:~1. Clinical Decision Support (CDS) within electronic medical record (EMR) system to help providers identify patients who would benefit from HIV screening or re-engagement in HIV care.~2. Point-of-care HIV testing in the dental clinic.~3. Patient and provider-facing educational materials to support providers in discussing HIV prevention options (for patients who test HIV negative) and treatment (for patients who test HIV positive or are out of HIV care) options."
223560038|NCT04061616|BEHAVIORAL|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
223738951|NCT00484939|DRUG|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
223738952|NCT02500784|DRUG|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
224032191|NCT00044915|DRUG|Placebo|All patients receive 1.25 mg of placebo
224299164|NCT03940794|OTHER|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
223414398|NCT04515654|OTHER|IDEAS (Identity Evolution and Sharing) Performance|60 minute webinar depicting first-hand stories of transgender and gender non-conforming individuals followed by expert panel/talk-back
223738953|NCT02500784|OTHER|Formoterol B (placebo)|2mL, BID inhaler for 12 months
223414399|NCT00511745|DRUG|Rabeprazol|As prescribed
223414400|NCT01186692|DEVICE|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
223414401|NCT01487122|RADIATION|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
223414402|NCT01487122|RADIATION|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
223414403|NCT01487122|PROCEDURE|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
223738954|NCT00230464|DRUG|LAF 237|
223738955|NCT06973187|DRUG|BGB-16673|BGB-16673 will be administered orally
223414404|NCT01803750|BEHAVIORAL|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
224032192|NCT04160338|DEVICE|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
224136310|NCT03374553|DEVICE|MINI DO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
223414405|NCT04153760|DRUG|Aspirin 81 mg|Aspirin 81 mg p.o. daily
223414406|NCT04153760|DRUG|Placebo|Placebo p.o. daily
223414407|NCT05421182|OTHER|Revised Impact of Event Scale|to measure the affect of routine life stress,everyday traumas and acute stress
223414408|NCT05421182|OTHER|Hospital Anxiety and Depression scale|to measure anxiety and depression
223414409|NCT05421182|OTHER|36-Item Short Form Survey|SF-36 is a set of generic, coherent, and easily administered quality-of-life measures.
223414410|NCT05421182|OTHER|satisfaction survey|satisfaction survey of the trusted person about the communication with ICU personal
223414411|NCT05421182|OTHER|semi-directed interview with trusted person on the general experience of the patient's medical evacuation|interview of the trusted person about the medical evacuation : evacuation announcement;organization of the medical evacuation,; concerns related to evacuations;reception and information by the center admitting the evacuated patient; arrangements of visit, patient repatriated
223414412|NCT05421182|OTHER|semi-directed interview with trusted person on the general experience of hospitalization in intensive care|interview of the trusted person about ICU hospitalization: reception in ICU; ICU organization; concerns related to ICU hospitalization, information and communication with ICU staff, arrangements of visit, context of ICU discharge
223414413|NCT04591366|OTHER|Barrier dressing|A barrier dressing will be applied either pre or post implant prior to a culture swab and closing the incision.
223738956|NCT06973187|DRUG|Pirtobrutinib|Pirtobrutinib will be administered orally
223738957|NCT04882228|DRUG|Entelon Tab.150mg|twice daily for 8 weeks
223738958|NCT04882228|DRUG|Venitol Tab.|twice daily for 8 weeks
223738959|NCT04882228|DRUG|Placebo of Venitol Tab.|twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
223738960|NCT04882228|DRUG|Placebo of Entelon Tab.150mg|twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
224032193|NCT00995020|PROCEDURE|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
224032194|NCT00995020|PROCEDURE|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
224032195|NCT04038593|OTHER|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
224032196|NCT04038593|DEVICE|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
224032197|NCT04131400|DIAGNOSTIC_TEST|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
224032198|NCT04279938|DRUG|Tinostamustinein|Tinostamustine80-120mg IV Q3W (dose to be determined in part 1) for 6 cycles
224032199|NCT04279938|DRUG|Pembrolizumab|Pembrolizumab 200mg IV Q3W until disease progression or unacceptable toxicities (max. 2 years)
224032200|NCT04279938|DRUG|Rituximab|Rituximab 375 mg/m2 IV Q3W for 6 cycles
224136311|NCT03374553|DEVICE|MINI SO636|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach.~For MINIject 636, there are 2 types of Delivery Tools available to implant and position the CS636 implant.~Both types of Delivery Tools are being studied in this amended study: Dual Operator Delivery Tool (DODT) and Single Operator Delivery Tool (SODT).~DODT is used in the first arm (cohort 1 - MINI DO636), SODT is used in the second arm (cohort 2 - MINI SO636)."
224136312|NCT05491694|DRUG|Toripalimab|Toripalimab 240mg
224136313|NCT05491694|DRUG|Epirubicin|90mg/m2，IVD，q3w
224136314|NCT05491694|PROCEDURE|High Intensity Focused Ultrasoun|HIFU treatment at lesion site
224136315|NCT05491694|DRUG|Cyclophosphamide|600mg/m2，IVD，q3w
224136316|NCT05491694|DRUG|Carboplatin|AUC 5，IVD，q3w
224136317|NCT05491694|DRUG|Nab-paclitaxel|260mg/m2，IVD，q3w
224136318|NCT03825094|DEVICE|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
223414414|NCT04463147|DEVICE|Needle-pilotTM device|The main objective aims to compare the procedure time between conventional real time ultrasound guidance and guidance with Needle-pilotTM device.
223414415|NCT00360061|BEHAVIORAL|Cognitive Behaviour Therapy|
223414416|NCT03424057|PROCEDURE|Asymmetric Primary Closure and Additional Skin Excision Technique|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
223560039|NCT07079436|DRUG|0.25% ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.25% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
223738961|NCT01997515|DRUG|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
224032201|NCT02053038|DEVICE|iFR|Treatment guided by instantaneous wave-free ratio
224032202|NCT02053038|DEVICE|FFR|Treatment guided by Fractional Flow Reserve
224032203|NCT06284148|DIAGNOSTIC_TEST|Screening for intimate partner violence|confidential screening using exam computer
224032204|NCT06284148|OTHER|Assessment and referral|confidential assessment and referral of high-risk patients using decision-support templates
224032205|NCT00520104|DRUG|intranasal ketamine|drug interaction
224032206|NCT05858268|GENETIC|Whole-genome sequencing|Whole-genome sequencing
224032207|NCT04484181|OTHER|Embryo culture in time lapse technology (TLT)|In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.
224032208|NCT04484181|OTHER|Embryo culture in conventional incubator|For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
224032209|NCT06700096|GENETIC|ANB-002|Adeno-associated viral vector carrying the FIX gene single infusion
223414417|NCT03424057|PROCEDURE|Standard Karydakis technique.|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
223414418|NCT00596817|DRUG|Placebo|capsules, daily, orally
223414419|NCT00596817|DRUG|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
223414420|NCT00869622|DRUG|Risedronate|35 mgs/week + calcium and vit d
223414421|NCT00869622|DRUG|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
223414422|NCT03063437|BIOLOGICAL|Encapsulated fecal microbiota preparation|30 capsules
224032210|NCT02347228|DRUG|OB318 capsule|Oral qd, at least 30 minutes before breakfast
224032211|NCT04424797|OTHER|Prone Positioning|Intervention is patient in prone positioning
224032212|NCT04424797|OTHER|Supine Positioning|Intervention is patient in supine positioning
224136319|NCT00751114|DRUG|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
223414423|NCT03063437|BIOLOGICAL|Encapsulated placebo|30 capsules
223738962|NCT01997515|DRUG|placebo|Group P (placebo) will receive the same amount of saline.
224032213|NCT03412370|OTHER|Cognitive Assessment|Complete cognitive assessments
224032214|NCT03412370|OTHER|Questionnaire Administration|Complete questionnaires
224032215|NCT02720536|DRUG|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
224136320|NCT00751114|DRUG|Sitagliptin|Oral administration. 100 mg film-coated tablets.
224136321|NCT00751114|DRUG|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
223414424|NCT04444011|DRUG|Anaprazole Sodium|Anaprazole Sodium isthePPI inhibitor
223414425|NCT04444011|DRUG|Amoxicillin|antibiotic
223414426|NCT04444011|DRUG|Clarithromycin|antibiotic
223414427|NCT04444011|DRUG|Bismuth|Bismuth is to protect the gastric mucosa
223414428|NCT04166942|DRUG|KD025|Single dose of 200 mg KD025 orally
223414429|NCT06922695|OTHER|Pill-in-pocket anticoagulation|Participants will stop their oral anticoagulation after a 30-day period free of AF episodes. After this, they will only take their anticoagulation in response to an episode of AF detected by their implantable cardiac monitor. The participants will receive an automated smartphone alert instructing them to commence their anticoagulation as soon as AF is detected.
223414430|NCT02375360|OTHER|Oral immunotherapy|
224032216|NCT06409780|DIAGNOSTIC_TEST|Comparative analysis of CUS, CAD and CXR in pulmonary TB|The strumental analysis of pulmonary TB signs with chest ultrasound, chest x-ray and CAD will be compared in two different settings: index cases and household contacts
224032217|NCT02837835|DRUG|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
224032218|NCT02837835|DRUG|ceftazidime|20 mg/kg over 30 min every 8 h
224032219|NCT04604678|DRUG|Metformin|Metformin at 1500 mg/day
224032220|NCT04604678|DRUG|Naltrexone|Naltrexone at 4.5 mg/day (LDN)
224032221|NCT03325998|DEVICE|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
224032222|NCT03130543|DIETARY_SUPPLEMENT|Rice cereal|Standard formula thickened with rice cereal
224032223|NCT03130543|DIETARY_SUPPLEMENT|Enfamil AR|Enfamil AR formula
224136322|NCT02476591|BEHAVIORAL|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
224136323|NCT05360420|DIAGNOSTIC_TEST|Immediate CEUS|Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
224136324|NCT05766865|PROCEDURE|Emergency neurosurgery|Surgical evacuation for intracerebral hemorrhage
224032224|NCT04750174|OTHER|Kinesiotaping|Kinesiotape (KT) has been used by Dr. Kenzo Kase for the first time as based on the opinion that more successful results can be obtained in a banding method similar to the structural characteristics and flexibility of human skin without limiting the joint movements for edema control, joint protection, and proprioception training. In recent years, KT have been applied with a wide variety of techniques including muscle techniques for the inhibition and stimulation of muscles, fascia correction technique which aims to reduce tension and adhesions by making vibration movement between the fascia layers and field correction technique aiming to reduce regional pressure in the presence of pain, inflammation or edema as well as lymphatic correction technique for regulating lymphatic circulation .
223414431|NCT06923163|BEHAVIORAL|Exercise intervention|"Exercise prescription for participant，~* 150Kcal for Weeks 1-4 (gradually increase to 150Kcal in the first two weeks as familiar stage),~* 250Kcal for Weeks 5-8,~* 350Kcal for Weeks 9-12."
223414432|NCT04018131|DRUG|Cimetidine|Antihistamine 2 antagonist
223414433|NCT04018131|DRUG|Placebos|Placebo drug
223414434|NCT00117273|DRUG|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
223414435|NCT00117273|DRUG|Seasonique (LNG/EE and EE)|1 tablet daily
223414436|NCT00117273|DRUG|Portia (LNG/EE)|1 tablet daily x 28 days
223414437|NCT00602836|BIOLOGICAL|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)
223414438|NCT00602836|DRUG|Cyclophosphamide|600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
223414439|NCT00602836|DRUG|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
223414440|NCT00602836|DRUG|Pentostatin|2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
224032225|NCT01048567|OTHER|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
224032226|NCT01048567|OTHER|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
224032227|NCT00234546|BIOLOGICAL|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
224032228|NCT00234546|DRUG|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
224032229|NCT06374355|DEVICE|Semibranch CMD branched aortic stentgraft|bEVAR with a custom made abdominal aortic multibranch, which incorporates the semibranch design
223414441|NCT03386591|DRUG|Naloxone|Comparing pharmacokinetics of naloxone
223414442|NCT03386591|DEVICE|Mucosal atomization device and syringe|Injection
223414443|NCT03386591|DEVICE|Narcan|Nasal Spray
223414444|NCT03386591|DEVICE|Intramuscular Auto Injector|Intramuscular injection
223560040|NCT07079436|DRUG|0.375% Ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.375% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
223560041|NCT07079436|DRUG|0.5% Ropivacaine|During breast quadrantectomy, intercostal nerve block is performed at the 2nd to 6th intercostal spaces along the posterior axillary line using an in-plane technique. 4ml of 0.5% ropivacaine (prepared from Naropin, 10ml:75mg) is injected into each intercostal space. Under ultrasound guidance, the needle tip is ensured to reach the space between the internal intercostal muscle (intercostal endomysium) and the innermost intercostal muscle below the rib margin. After aspiration shows no blood, the drug is injected, and anechoic fluid can be seen diffusing below the internal intercostal muscle, with the local parietal pleura gradually descending as the injected fluid volume increases.
223560042|NCT07079488|DIAGNOSTIC_TEST|Motor proficiency scales|AIMS, PDMS-2, HINE
223560043|NCT07080385|DRUG|Encaleret|Oral tablets, age-appropriate pediatric formulation (currently under development).
224032230|NCT05877625|PROCEDURE|Expectoration care|"1. Endotracheal aspiration: from discarded samples after expectoration care~2. BALF (bronchoalveolar lavage fluid): if patients with fiber bronchoscope examination, take the rest of the BALF after examination~3. Oropharyngeal swabs"
224136325|NCT05766865|PROCEDURE|Conservative treatment|Standard treatment for intracerebral hemorrhage
223414445|NCT00516672|DRUG|pazopanib|Pazopanib oral tablet
223414446|NCT00516672|DRUG|Lapatinib|Lapatinib oral tablet
223414447|NCT00086177|DRUG|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
223414448|NCT00086177|DRUG|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
223414449|NCT06939634|DEVICE|Hands-free exoskeleton|Having undergone at least on session with Atalante exoskeleton. Clinical, safety and session data are collected retrospectively.
223414450|NCT06939101|BEHAVIORAL|self-efficacy training|The principal investigator will supervise students and build this program to increase occupational, physical, and speech therapy student participation. There are two one-hour briefing meetings for onboarding to promote self-efficacy preparation and six 1-2 hours of debriefing after each clinical day.
223414451|NCT06939881|OTHER|"11 for Health training group"|"The 11 for Health intervention consisted of two 45-minute sessions per week for 11 weeks, implemented during school hours. Each week included one session focused on football-related physical activities (e.g., passing, dribbling, shooting) and another on health education topics (e.g., hygiene, nutrition, mental well-being), both delivered in an engaging and inclusive format. The program emphasized social interaction, autonomy-supportive teaching, and real-life applicability through take-home tasks."
223414452|NCT06939595|DRUG|CT-P51|CT-P51 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks
223414453|NCT06939595|DRUG|EU-approved Keytruda|Keytruda 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks
223414454|NCT06941350|BIOLOGICAL|NCR102 injection|Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.
224032231|NCT04471623|BEHAVIORAL|Use of DeTAP App and Home Devices|DeTAP App (data collection, televisit function, information and reminders), Bluetooth-connected 6-lead home (electrocardiogram) EKG device, Bluetooth-connected blood pressure (BP) cuff
224032232|NCT00091117|DRUG|bortezomib|Given IV
223560044|NCT07079956|DEVICE|TUBE Flow Diverter|TUBE Device
223560045|NCT07080424|PROCEDURE|Fistulectomy with Marsupialization|Patients with fistula in ano treated with Fistulectomy with Marsupialization and were compared for wound healing with other group
223560046|NCT07080424|PROCEDURE|Fistulectomy|Patients with fistula in ano treated with Fistulectomy and were compared for wound healing with other group
223560047|NCT07081542|DEVICE|IotaSoft Robotic Insertion System|The IotaSoft robotic insertion device is an FDA-approved tool designed to provide precise and controlled insertion of the cochlear implant electrode array to minimize trauma during implantation.
223560048|NCT07081542|PROCEDURE|Manual Cochlear Implant Insertion|Standard surgical technique for manually inserting the cochlear implant electrode array. This method reflects the current standard of care without the assistance of robotic tools.
223560049|NCT07080970|OTHER|observation of incidence of early vascular events|observation of difference incidence of early vascular events in the two cohorts
223560050|NCT07079553|DEVICE|Transcutaneous Electrical Diaphragmatic Stimulation (TEDS)|TEDS was applied using surface electrodes placed over the diaphragm region. The stimulation protocol was set at 50 Hz frequency, 300 μs pulse width, with 6 seconds of stimulation followed by 5 seconds of rest, daily for 12 weeks. It was combined with ACBT sessions.
223560051|NCT07079553|BEHAVIORAL|Active Cycle of Breathing Techniques (ACBT)|ACBT sessions included breathing control, thoracic expansion exercises, and forced expiration techniques (huffing). Sessions were performed daily for 12 weeks to aid in secretion clearance and improve lung function.
223560052|NCT07080242|DRUG|BL-M14D1|BL-M14D1 will be administered on D1 every 3 weeks.
224032233|NCT00091117|OTHER|pharmacological study|Correlative studies
224136326|NCT05350566|DIETARY_SUPPLEMENT|Olive leaf extract|A capsule containing 250 mg of an olive leaf extract preparation will be swallowed with a glass of water before exercise.
224136327|NCT05350566|DIETARY_SUPPLEMENT|Placebo|A capsule containing 336 mg of cellulose microcrystalline will be swallowed with a glass of water before exercise.
224136328|NCT05217992|OTHER|Genetic assessment (hemophilia testing)|Determination of carrier ship of hemophilia with molecular tests
223560053|NCT07081659|DRUG|sildosin 4mg|ondemand sildosin 4mg
223560054|NCT07081659|DRUG|dapoxetine 60mg|ondemand dapoxetine 60mg
223560055|NCT07081399|COMBINATION_PRODUCT|ETT cuff pressure monitoring, ETT suctioning, cough augmentation technique, swallowing exercises,: Nebulized budesonide 1mg and IV methylprednisolone 40 mg we|cough augmentation, larson maneuver, swallowing rehabilitation
223560056|NCT07080099|OTHER|BIMANUAL INTENSIVE THERAPY WITH PASSIVE SENSORY TRAINING|"Bimanual intensive therapy Bimanual coordination training ,Functional training of the hands ,Trask oriented training, Bilateral arm training,~Passive sensory training:~Electrical stimulation."
223560057|NCT07080099|OTHER|BIMANUAL INTENSIVE THERAPY WITH ACTIVE SENSORY TRAINING|"Bimanual intensive therapy:~* Bimanual coordination training ,Functional training of the hands~* Trask oriented training, bilateral arm reaching~Active sensory training:~sensory re education techniques ,touching different objects, massage, identifying different temperatures, and sensory locating."
223560058|NCT07079475|DRUG|DZD6008|DZD6008 will be administered orally at 40/60 mg QD or selected dose.
223560059|NCT07079475|DRUG|Sunvozertinib|Sunvozertinib will be administered orally at 100 mg QD or selected dose.
223560060|NCT07079475|DRUG|Osimertinib|Osimertinib will be administered orally at 80 mg QD
223560061|NCT07081906|DRUG|Oral Oxybutynin|The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.
223738963|NCT04521465|DEVICE|NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)|Eye drops
223738964|NCT05879406|DIETARY_SUPPLEMENT|VitaMedica® Clear Skin Formula capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Vitamin A (from Betatene® Carotenoid Blend) (7,500 IU/2,250 mcg RAE) Vitamin A (from Retinyl Palmitate) (5,000 IU/1,500 mcg RAE) Vitamin C (as Ascorbic Acid) (60 mg) Vitamin E (from d-alpha-Tocopheryl Acid Succinate) (30 IU/20 mg) Zinc (from Zinc Bisglycinate Chelate) (24 mg) Selenium (from Selenium Glycinate) (48 mcg) Chromium (from Chromium Nicotinate Glycinate Chelate) (150 mcg) MSM (Methylsulfonylmethane) (200 mg) Bromelain (200 mg) Burdock (Arctium lappa) root (50 mg) Oregon Grape (Mahonia aquifolium) root (25 mg) Dandelion (Taraxacum officinale) root (50 mg) Yellow Dock Extract (Rumex crispus) root (50 mg) Hypromellose Microcrystalline cellulose Magnesium Stearate Silicon Dioxide"
224032234|NCT05206019|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
224032235|NCT00280046|DRUG|biphasic insulin aspart|
224032236|NCT00100854|DRUG|erlotinib hydrochloride|Given orally
224032237|NCT00100854|DRUG|fulvestrant|Given intramuscularly
224032238|NCT01121120|DRUG|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
224032239|NCT01121120|DRUG|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
224032240|NCT02271516|RADIATION|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
224032241|NCT04878731|BIOLOGICAL|PF-06741086|single dose SC injection of 300 mg PF-06741086
224032242|NCT02234245|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
224032243|NCT02411682|OTHER|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
224136329|NCT00465491|DRUG|picoplatin|IV picoplatin 150mg/m2 q3wk
224136330|NCT00465491|OTHER|best supportive care|best supportive care
223414455|NCT06539403|BEHAVIORAL|Memory tasks|"Naturalistic Episodic Memory encoding: Participants will play short sessions of 3 board games with the researcher. The board games include Ludo, Snakes \& Ladders and Solitaire. Participants will play each boardgame for around 5 min. They will wear a head camera while playing the games.~Later participants will be tested on their memory of the naturalistic episodic memory task, a semantic memory task (memory of facts) and a perceptual task. Each task will consist of 2-3 sub-tasks of around 30 trials. These tasks will all take place on the computer and will take 30-40 minutes in total. In each trial participants will choose between two options. For example: Which of these two images is taken from your head camera? What colour piece did you use in 'snakes and ladders'?. After they choose their answer, they will report how confident they are in their choice. At the end of each task, they will be asked to report how well they think they performed on the task overall."
223414456|NCT02716168|OTHER|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
223414457|NCT01069198|DRUG|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged \<5 and \>=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
223414458|NCT01069198|OTHER|Placebo|Placebo
223414459|NCT03299660|DRUG|Avelumab|Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
223414460|NCT03299660|DRUG|5 Fluorouracil|5FU continuous infusion 225mg/m2/day during radiotherapy
223560062|NCT07081906|DRUG|transdermal oxybutinin|The oral form of oxybutinin was preferred for patients who had no difficulty swallowing and whose families preferred a conventional administration route. Medication was given under parental supervision to ensure adherence. Patients were monitored monthly for potential anticholinergic side effects. The patch form of oxybutinin was chosen for patients who experienced difficulties with oral intake or had previous intolerance to oral anticholinergics. Application sites were rotated to reduce the risk of local skin reactions. Families received instructions on proper patch application technique.
223560063|NCT07080645|OTHER|Pain Relieving|aim to relieve tooth pain with HMI Biosilicate
223560064|NCT07080645|OTHER|topical application|the operator will apply a solution to all the free surfaces of the selected teeth using a microapplicator. The solution will either be 10% Biosilicate® solution, fluoride varnish (Duraphat®), or distilled water . All products will be removed from their original containers and placed in identical 10ml plastic bottles, white and standardized. The different products will be applied equally for 15 seconds according to the application protocol.
223560065|NCT07081477|DRUG|Intravenous Anesthetic Induction with Ciprofol for Painless Colonoscopy in Elderly Patients|Cirpropofol is a 2,6-disubstituted phenol derivative that introduces a cyclopropyl group based on the chemical structure of propofol, increasing its affinity with GABA receptors and stereoeffect, thus its effect is 4-5 times that of propofol. Studies have found that the incidence of hypotension, injection pain, and respiratory depression during cirpropofol anesthesia is lower than that of propofol.
223560066|NCT07081477|DRUG|Propofol Intravenous Anesthesia Induction for Painless Colonoscopy in Elderly Patients|Propofol has favorable pharmacokinetic properties with minimal residue. Currently, it is widely used for endoscopic procedure sedation, but there are still many limitations, such as a narrow therapeutic window, injection pain, hypotension, and respiratory depression.
223560067|NCT07079605|OTHER|Standard treatment for sepsis of any focus|This group of patients will be treated for the sepsis of any focus as per standard.
223560068|NCT07079605|OTHER|Treatment for the sepsis with standard management of cardiac failure|This group of patients will be treated for the sepsis and management of cardiac failure with additional supportive care cocktails based on the specific indication.
223560069|NCT07081451|OTHER|Guided ımagery supported psychoeducation|Guided Imagery Technique is an effective, economical and therapeutic technique that can be easily used in nursing practices. Guided Imagery Technique is a set of stories that individuals create by visualising the symbols given by the practitioner after relaxation exercises. Within the scope of this technique, which is a window to the inner world of the person, the creation of his/her own unique story through symbols is encouraged
223560070|NCT07079293|OTHER|Preparation of Extended PRF|Whole blood (10 mL) will be centrifuged at 700 g for 8 minutes. The upper layer (yellow layer) shows the liquid plasma layer. The most upper layer of platelet- poor plasma (PPP) will be collected in a syringe. then PPP will be heated in a heat block device at 75°C for 10 minutes and thereafter cooled to room temperature for approximately 2 minutes. An injectable albumin gel will then be prepared. Then the liquid platelet-rich layer (liquid-PRF) including the buffy coat layer with accumulated platelets and leukocytes, will be collected in a separate syringe. The albumin gel and native liquid PRF will then be thoroughly mixed by utilizing a female-female luer lock connector. Now injectable e-PRF in final form is ready to be used .
224032244|NCT02411682|OTHER|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
224032245|NCT02208154|DRUG|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
223414461|NCT03299660|DRUG|Capecitabine Pill|Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
223414462|NCT03299660|RADIATION|Radiotherapy|50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
223414463|NCT03299660|PROCEDURE|Surgical Resection|Surgical resection of tumour mass post radiotherapy and chemotherapy
223414464|NCT01583062|DRUG|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
223414465|NCT01583062|DRUG|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
223414466|NCT06030297|PROCEDURE|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fib"
224032246|NCT02208154|DRUG|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10\^5 units. SOD will be applied to the mouth 4 times daily until extubation.
224032247|NCT02208154|DRUG|Selective Digestive Decontamination (SDD)|"SDD consists of both:~* SOD (described elsewhere)~* AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10\^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
223738965|NCT05879406|OTHER|Placebo Capsules|"After an initial screening period to determine eligibility, subjects will be randomly assigned to one of the following treatment arms: VitaMedica® Clear Skin Formula vs. Placebo for the duration of the twelve (12) week trial~Ingredients:~Magnesium Stearate (VEG) (NON-GMO) Silica (As Silicon Dioxide) Micro Cellulose (MCG) (NON-GMO)"
224032248|NCT00557388|DIETARY_SUPPLEMENT|Protein/Amino Acids|Casein Whey Leucine
223738966|NCT03583138|DRUG|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
224032249|NCT00557388|OTHER|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
224032250|NCT03538379|BEHAVIORAL|Bleeding Control Basic (B-Con) Course|The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
223414467|NCT06030297|DRUG|ZTlido 1.8 % Topical System|ZTLI(diethylamino)-N-(2,6-dimethylphenyl), has an octanol:water partition ratio of 43 at pH 7.4. Each ZTLIDO contains 36 mg of lidocaine (18 mg per gram adhesive) in a non-aqueous base and also contains the following inactive ingredients: butylated hydroxytoluene, dipropylene glycol, isostearic acid, mineral oil, polyisobutylene, silicone dioxide, styrene/isoprene/styrene block copolymer, and terpene resin. DO (lidocaine topical system) 1.8% is a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of ZTLIDO is 10 cm × 14 cm × 0.08 cm. Lidocaine, an amide local anesthetic, is chemically designated as acetamide, 2-
223414468|NCT06030297|DIAGNOSTIC_TEST|PeriCam PSI NR|It is a method that visualizes tissue blood perfusion in real time. LASCA provides new means to study the microcirculation in ways that were not possible in the past. PeriCam PSI System combines dynamic response and high spatial resolution in one instrument, providing both real-time graphs and video recordings of the tissue being studied. To further enhance its usability, dedicated application software, PIMSoft, has been developed.
223414469|NCT06030297|DIAGNOSTIC_TEST|Medoc Quantitative Sensory Testing|"Quantitative sensory testing (QST) is a method through which sensory nerve function is quantitatively measured, based on responses of the subject. The peripheral sensory nervous system responds to specific stimuli of specific modality and intensity in a specific manner, which is well-known through many decades of research into human sensation. Thermal QST provides information about the function of small diameter unmyelinated (C fibers) and thinly myelinated (A-delta fibers) nerve fibers for which no nerve conduction test, or other objective tests exist.~Small fiber nerve damage can manifest itself in thermal hypoesthesia (raised perception thresholds) or hyperalgesia (lowered pain thresholds)."
223414470|NCT06030297|OTHER|Inactive Topical System|Inactive, non-medicated topical system comprised of an adhesive material containing, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. The release liner is removed prior to application to the skin. The size of the system is 10 cm × 14 cm × 0.08 cm.
223414471|NCT06940453|DEVICE|CONDUIT|Arm Description: Group/Cohort Description: This cohort is composed of patients who will be prospectively enrolled (35 total). These patients will undergo spinal stabilisation for lumbar degenerative disease using the CONDUIT ALIF cage system with supplemental posterior fixation. This device is FDA approved thus this is post market observational intervention.
223414472|NCT03653962|BEHAVIORAL|video assisted group|
223414473|NCT03653962|BEHAVIORAL|non-video group|
223414474|NCT02227498|DEVICE|Effect of Argus II on Functional Vision|To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
223738967|NCT00437593|PROCEDURE|ppVE, MP, ICG|surgery with ILM staining
224032251|NCT00719563|DRUG|American ginseng|Given orally
224032252|NCT00719563|OTHER|placebo|Given orally
224032253|NCT05210296|BEHAVIORAL|Exercises|Therapeutic exercise will be applied to the elderly
224032254|NCT00420017|DRUG|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
224136331|NCT05319080|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp on the left side of the head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
223738968|NCT00437593|PROCEDURE|ppVE, MP, MB|Surgery with ERM staining
223738969|NCT00847457|BEHAVIORAL|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
223738970|NCT00847457|BEHAVIORAL|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
223738971|NCT01523886|DRUG|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
223738972|NCT01523886|DRUG|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
224136332|NCT00239486|DRUG|Pramipexole|
224136333|NCT03518814|OTHER|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
223414475|NCT04736498|OTHER|Inferior venacava Ultrasonography (IVC USG) guided fluid management|The IVC will be visualized using a paramedian long-axis view via a subcostal approach. A two-dimensional image of the IVC as it enters the right atrium will be first obtained. Variations in IVC diameter with respiration will be assessed using M-mode imaging performed 2 to 3 cm distal to the junction of right atrium and IVC. Maximum and minimum diameter will be measured from inner wall to inner wall and collapsibility index(CI) will be calculated using formula: CI = \[(dIVCmax - dIVCmin)/dIVCmax\] x 100% CI of ˃36% will be accepted as predicted fluid responder and ≤36% will be regarded as predicted fluid non responders. Predicted fluid responders will receive a bolus of 500 ml of Ringer's lactate over a time period of 15 min, after which the IVC diameter variation will be reassessed. Additional 250ml of Ringer's lactate bolus will be applied until a non fluid responder pattern is observed during IVC USG. Thereafter,spinal anaesthesia will be performed.
223414476|NCT00288405|DEVICE|Cordis Self Expanding Stent|
223414477|NCT05915247|DRUG|HER-096|Administered as a single dose via s.c. injection
223414478|NCT05915247|DRUG|Placebo|Administered as a single dose via s.c. injection
223414479|NCT00664378|DRUG|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
223414480|NCT01265745|DRUG|Normal Saline for Injection|Equivalent amounts to subjects weight, once over 120 minutes
223560071|NCT07079293|PROCEDURE|Harvesting of Free Gingival Graft and preparation of CTG|The region distal from the canines, commencing at least 2 mm from the gingival margin with a width of 5-8 mm and a desirable length to cover the entire recipient site is an ideal site for harvesting a FGG from the hard palate for root coverage. Harvesting of FGG is performed as follows: The graft is prepared by outlining with two parallel longitudinal incisions that are interconnected with vertical incisions. Graft deliberation is initiated along the paramarginal incision in a split-thickness fashion with a goal of removing an FGG of 1.5-2-mm thickness without touching the periosteum. The harvested free gingival graft will be de-epithelialized to obtain an DFGG. The donor site wound will be covered by gel foam which will be sutured in place and then healing will occur by secondary intention .
224032255|NCT00420017|OTHER|Control|No amiodarone
224032256|NCT02950324|BEHAVIORAL|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
224298361|NCT03869203|OTHER|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug \[300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)\] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
224298362|NCT01403064|BIOLOGICAL|ALD518|IV
224298363|NCT01403064|DRUG|0.9% saline|IV Infusion
223414481|NCT01265745|BIOLOGICAL|MDX1303|a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
223414482|NCT02658474|BEHAVIORAL|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
223414483|NCT03256929|BEHAVIORAL|Personalized Diet-driven microbiota|Based on the results of the individual microbiota profile, the investigators will formulate a specific diet aiming to enrich the distinct microbiota with organisms correlated to better mental health. The dietitian will visit each participant twice a month.
223414484|NCT03256929|BEHAVIORAL|General information on nutrition and health|General information on nutrition and health. The dietitian will visit each participant twice a month.
223414485|NCT00679029|DRUG|doxorubicin hydrochloride|Given IV
223414486|NCT00679029|DRUG|cyclophosphamide|Given IV
224032257|NCT02950324|BEHAVIORAL|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
224032258|NCT00440804|DRUG|ibuprofen l-lysine iv solution (NeoProfen (R) )|
224298364|NCT02945670|BEHAVIORAL|Focus Group|We had recruited 64 women and completed 7 focus group sessions
223414487|NCT00679029|BIOLOGICAL|bevacizumab|Given IV
223414488|NCT00679029|DRUG|paclitaxel|Given IV
223414489|NCT00679029|DRUG|gemcitabine hydrochloride|Given IV
224032259|NCT03235622|DIAGNOSTIC_TEST|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
224032260|NCT02706301|BEHAVIORAL|Telephone-Based Coping Skills Training (CST)|
224032261|NCT01631604|DEVICE|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
224032262|NCT01631604|DRUG|Muscle/nerve injection|Injection to muscle or nerve
223414490|NCT00679029|OTHER|laboratory biomarker analysis|Correlative studies
223414491|NCT00679029|BIOLOGICAL|pegfilgrastim|Given subcutaneously
223414492|NCT05208528|DIETARY_SUPPLEMENT|ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of Bifidobacterium longum ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
223414493|NCT05208528|DIETARY_SUPPLEMENT|HT-ES1 group|Participants will intake 2 capsules of 300 mg/capsule with 50 mg of HT-ES1 (1E09 CFU of probiotic/day, by taking 2 capsules) and 250 mg of maltodextrin.
223414494|NCT05208528|DIETARY_SUPPLEMENT|Control group|Participants will intake 2 capsules of 300 mg/capsule with 300 mg of maltodextrin.
223414495|NCT03124316|BEHAVIORAL|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
223414496|NCT03124316|BEHAVIORAL|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
223414497|NCT03124316|BEHAVIORAL|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
223414498|NCT00400660|DRUG|GSK615915A|GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
223414499|NCT00400660|DRUG|Placebo|Subjects will also receive placebo inhaler.
223414500|NCT00479050|PROCEDURE|chemoembolization ,Radiofrequency ablation|
223414501|NCT01108341|DRUG|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m\^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
223414502|NCT01108341|DRUG|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
223414503|NCT00290134|DRUG|Fispemifene once daily for 4 weeks|
223560072|NCT07079293|PROCEDURE|VISTA technique|Following Zadeh's (2011) protocol, under local anesthesia, a vestibular access incision is made depending on the treatment site (midline frenum for maxillary anterior, frenal area between canine and lateral incisor for maxillary posterior, and similar for mandibular regions). The incision passes through the periosteum to create a subperiosteal tunnel exposing the facial bone and root dehiscence. In the test group, the extended platelet-rich fibrin (e-PRF) membrane is inserted into the tunnel and secured to the flap with horizontal sutures; in the control group, a de-epithelialized free gingival graft (DFGG) is used similarly. Each tooth's facial enamel is briefly acid-etched, washed, and dried to attach vicryl sutures fixed with flowable composite resin to prevent apical relapse during healing. Finally, the access incision is closed and sutured with vicryl sutures
224032263|NCT01631604|PROCEDURE|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
224032264|NCT01631604|OTHER|Physical therapy treatment|
223414504|NCT03780803|OTHER|home cardiac rehabilitation and respiratory rehabilitation|
223414505|NCT06290843|PROCEDURE|Schroth method|Exercises from Schoth method
223414506|NCT06280144|BIOLOGICAL|Influenza Vaccine, Live, Nasal, Freeze-dried|The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50
223414507|NCT06280144|OTHER|Sterile water for inhalation|Sterile water for inhalation
223414508|NCT01648725|PROCEDURE|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
224032265|NCT05381831|DRUG|NatestoTM|Administering daily intranasal testosterone, Natesto nasal gel is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone
224032266|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
224032267|NCT00376181|DRUG|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
224032268|NCT00376181|DRUG|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
224032269|NCT05490979|BEHAVIORAL|Contemplative dyad meditation|Participants take part in a 3-hour group meditation training led by a professional meditation teacher. They receive detailed instructions and also practice contemplative dyad meditation for at least 30 minutes with another participant. During the 2 weeks following the training, participants meet in supervised group settings to practice the meditation method with alternating partners for up to 6 times.
223414509|NCT01648725|PROCEDURE|usual care|Standard care before induction of anesthesia
223414510|NCT06621758|OTHER|questionnaire|Questionnaire regarding biomarker counseling and diagnostic disclosure
223414511|NCT04402138|DRUG|Acalabrutinib|Acalabrutinib 129 mg will be self-administered orally twice daily (BID) starting from 100 day (+/- 7 days) Post-BMT on a 28-day schedule, with or without food, until the patient has reached approximately 2 years post-BMT.
223414512|NCT06613854|DRUG|Oral semaglutide|Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
223414513|NCT06613854|DRUG|Empagliflozin 10 mg|Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
223414514|NCT05215275|BEHAVIORAL|exercise|"the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds."
223414515|NCT03960008|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
223414516|NCT03960008|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation
223414517|NCT03960008|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
223414518|NCT02646475|DRUG|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
223414519|NCT02646475|DRUG|Saline|Normal saline will be used as a placebo comparator.
223414520|NCT06330129|DEVICE|CTT Pegasus|The intervention aims to assess the construct validity of trunk flexor, extensor, and rotator muscle strength using the CTT PEGASUS isometric dynamometer (Leipzig, Germany). This involves correlating muscle strength measured isometrically with its physiological determinants: MRI-based anatomical cross-sectional area (CSA) in the lumbar region and muscle activation measured via surface electromyography (EMG) of spine and trunk muscles. Additionally, the intervention will assess the test-retest reliability of isometric strength of trunk flexors, extensors, and rotators.
223414521|NCT02464423|BEHAVIORAL|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
223414522|NCT06544135|DEVICE|FLIR One Pro LT|Thermal imaging camera used to measure temperatures of the lower limb.
223414523|NCT05034211|PROCEDURE|Programmed intermittent bolus epidural|one arm will receive programmed intermittent boluses of local anesthetic via the epidural catheter on fixed time intervals. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
223414524|NCT05034211|PROCEDURE|Provider administered analgesia on patient request|one arm will receive bolus of local anesthetic via the catheter upon patient request. Standard 27G Tuohy needle epidural set with epidural catheter insertion on L2-L3 site, with the patient either sitting or in the lateral decubitus position will be used. Local injection with 6 ml lidocaine 2% will be performed before the insertion of the epidural needle
223414525|NCT04917822|BEHAVIORAL|Emotion regulation|Emotion regulation arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics include raising awareness of emotions (e.g., learning emotions theories), developing skills to manage emotions (e.g., attention deployment, cognitive changes, response modification), and facilitating parent-child relationship (e.g., gratitude). For children, the main topics are similar to that in parents' intervention. In this arm, we give more specific examples and simple explanations to the children.
224032270|NCT05490979|BEHAVIORAL|Fast friends|During 2 weeks, participants meet in supervised group settings to practice the 'fast friends' exercise with alternating partners for up to 6 times.
224032271|NCT00792805|DRUG|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
224032272|NCT00792805|DRUG|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
224032273|NCT00792805|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
224136334|NCT01502982|DRUG|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
224136335|NCT03569865|DEVICE|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
224136336|NCT00292448|DRUG|Ba 679 BR Respimat|
223414526|NCT04917822|BEHAVIORAL|Information provision|Information provision arm will provide the parents and children with four 2-hour weekly sessions. For the parents, the main topics in these four sessions include learning the general information about Hong Kong such as education and medical care, housing condition, employment and training. For children, the main topics include learning the general information about Hong Kong, such as education, community facility, and learning method.
223414527|NCT04657029|BEHAVIORAL|Treadmill|30 minutes of moderate-high intensity treadmill training.
224032274|NCT03224325|DRUG|TAK-831 Tablet T2|Tak-831 tablets.
224032275|NCT03224325|DRUG|Placebo|TAK-831 placebo-matching suspension.
224032276|NCT03224325|DRUG|TAK-831 Suspension|TAK-831 Suspension.
224032277|NCT02649153|DRUG|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
224032278|NCT02649153|DRUG|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
224032279|NCT01361295|PROCEDURE|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
224032280|NCT01361295|PROCEDURE|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
224298365|NCT01718470|PROCEDURE|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
223560073|NCT00107900|DRUG|DU-176b|
223560074|NCT02873455|OTHER|Short video clip including the circumstance of operation theater, and surgeon's interview|
223560075|NCT04786821|BEHAVIORAL|Standard Exercise Training|Participants will receive interventions by an exercise specialist for up to 30 minutes based on the participant's tolerance. The exercises used in control group will depend on the individual and their abilities as evaluated in the baseline assessment session. Possible exercises include arm crank, recumbent cycle, and chair exercises. These sessions will be delivered by a member of the research team.
224032281|NCT03259594|PROCEDURE|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
224032282|NCT03259594|DRUG|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
224032283|NCT01903018|DRUG|P276-00|
224032284|NCT01903018|RADIATION|Radiation Therapy|
224032285|NCT01903018|DRUG|Cisplatin|
224032286|NCT03290196|DRUG|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
224136337|NCT00292448|DRUG|Tiotropium (Spiriva) inhalation capsule 18 ug|
224136338|NCT01571648|DRUG|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
224136339|NCT04212286|DIAGNOSTIC_TEST|Diagnostic CEUS and EOB-MRI|Undergo Sonovue-CEUS and EOB-MRI
224136340|NCT01755468|DRUG|Intermittent insulin therapy|
224136341|NCT01755468|DRUG|Continuous metformin|
224136342|NCT01423773|DEVICE|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
224136343|NCT01423773|DEVICE|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
224136344|NCT01423773|DEVICE|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
224136345|NCT02358369|DRUG|Bimatoprost|Bimatoprost sustained release Ocular Insert
223414528|NCT03211884|BEHAVIORAL|Problem-Solving Thearpy|"The problem-solving therapy (PST)-based intervention consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet \& greet session, participants received written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7-steps to solve at least one problem together before ending the training. Participants keep a record of their problem-solving efforts between sessions and questions they had related to the application of PST. These records were used as a basis for discussion during the PST training sessions."
223414529|NCT00409136|BEHAVIORAL|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
223414530|NCT01934049|PROCEDURE|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
223414531|NCT01934049|DRUG|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
223414532|NCT04324970|DEVICE|Tookie Vest|Tookie Vest
223414533|NCT02076724|DEVICE|Biological mesh|
223414534|NCT02076724|DEVICE|Synthetic mesh|
223414535|NCT00596687|DRUG|Insulin glargine|Insulin glargine once daily SQ
223414536|NCT00596687|DRUG|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
223414537|NCT00596687|DRUG|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
223414538|NCT05142631|DRUG|Fruquintinib|To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
223414539|NCT03644823|DRUG|Atezolizumab|PDL1- inhibitor
224032287|NCT02120625|DEVICE|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
224032288|NCT00230438|PROCEDURE|External Beam Radiotherapy|
224032289|NCT01889056|DRUG|Erythropoietin (Epoetin beta)|
224032290|NCT01889056|DRUG|Placebo|0.9% sodium chloride solution
224032291|NCT00849719|DRUG|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
224032292|NCT00849719|DRUG|PCA MO only|When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
223414540|NCT03644823|RADIATION|Radiotherapy|6 Gy x 3
223414541|NCT06969092|OTHER|Oral Frailty|The exposure factor is the presence of oral frailty in patients before surgery, and oral frailty is evaluated using a scale.
224032293|NCT04434950|BEHAVIORAL|Promoting and implementing repeated HIV self-testing and online real-time counseling|At baseline, Month 6 and Month 12, participants will view an online video clip promoting the needs for HIV testing in general and HIV self-testing with online real-time counseling. A free HIV self-testing kit will be sent to participants. An HIVST administrator will provide online real-time pre-test and post-test counseling.
224032294|NCT00134316|BEHAVIORAL|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
223414542|NCT05462938|DRUG|Continuous infusion of propofol|Sedation under continuous infusion of propofol. Small doses of fentanyl will be administered if needed.
223414543|NCT05462938|DRUG|Continuous infusion of dexmedetomidine|Sedation under continuous infusion of dexmedetomidine. Small doses of fentanyl will be administered if needed.
223414544|NCT05162924|OTHER|Spinal Manipulation|Manual therapy technique applied by a chiropractor in the form of a high-velocity low-amplitude force to the lumbopelvic spine
223414545|NCT05162924|OTHER|Placebo|Placebo spinal manipulation consisting in the application by a chiropractor of a lower-velocity lower-amplitude force to gluteal muscles in a non-intentional direction
223414546|NCT06968364|DEVICE|Cervisense Intravaginal Probe V0.1 cervical stiffness evaluation.|The Cervisense Intravaginal Probe V0.1 measures cervical stiffness. It is an in-vivo predictive technology that, by using torsional waves, quantifies the mechanical properties (specifically the shear modulus, or resistance of the cervix to shear deformation (kPa), of cervical tissue with extremely high precision. Torsional wave is a type of mechanical wave characterized by a rotational motion and low energy levels (it uses 1000 times less energy than other mechanical waves such as ultrasound). These waves propagate through the tissue, and their propagation speed, which is related to the stiffness (waves propagate faster in stiffer tissues), is measured using piezoelectric sensors.
223414547|NCT06968364|DEVICE|Transvaginal ultrasound|Cervicometry measured with transvaginal ultrasound
223414548|NCT06967402|OTHER|Experimental (chlorhexidine)|Test group: administration of experimental antiseptic (CHX 0.12%+CPC 0.05%) for 3 weeks
223414549|NCT06967402|OTHER|Control (chlorhexidine with cetylpyridinium chloride)|Active comparator: administration of control antiseptic (CHX 0.2%) for 3 weeks
223414550|NCT06967090|DEVICE|Implant surgery using surgical guide|Dental implant surgical guides are customized device used to position dental implants to ensure that the implant is placed in the most ideal location, angulation and depth into the bone.
223738973|NCT05289011|OTHER|Interviews and questionnaires|"* Evaluation of inflammatory rheumatism~* Dietary survey~* International Physical Activity Questionnaire IPAQ~* BASDAI self-questionnaire~* Assessment of quality of life by ASQol questionnaire~* Assessment of fatigue by FACIT questionnaire~* Assessment of digestive symptoms~* Collection of demographic and general data~* Collection of treatment"
223738974|NCT04733365|OTHER|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
224032295|NCT01535183|DRUG|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
224032296|NCT03531281|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
224032297|NCT03531281|DRUG|Cyclophosphamide|Given IV
224032298|NCT03531281|DRUG|Etoposide|Given IV
224136346|NCT02358369|DRUG|Timolol 0.5%|BID drops OU, 0.5% ophthalmic solution
224136347|NCT02358369|DEVICE|Placebo Ocular Insert|Placebo ocular insert OU.
224136348|NCT02358369|DRUG|Placebo Eye Drops|Placebo eye drops BID OU.
224136349|NCT00747396|OTHER|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
224136350|NCT04872335|OTHER|Gong's Mobilization|Group A received Gong's mobilization and common treatnent (TENs,Hot pack and cervical stretches). Gong's mobilization which is concurrent application of Apophyseal joint gliding and end range passive physiological movements while the subject's cervical postures are passively Neutral in order to induce Normal Cervical Extension. The Subjects in Group A were treated three times in a week for 4 weeks.
224136351|NCT04872335|OTHER|Gradually Graded Exercise Therapy|"The Subjects in Group B were received Exercise Therapy and common treatment (TENs, Hot pack and cervical stretches) three times in a week continue for 4 weeks . Each exercise session will take 30 min. It will be consisted of 5 min warm-up exercises, 20 min stabilization exercises, 5 min cool-down, and stretching exercises including neck and shoulder girdle muscles.~The aim of Exercise program was to create a neutral spine and activate deep muscles of the cervical spine. The patients were educated to maintain neutral spine during the exercises and throughout the day as much as possible.~Scapulothoracic stabilization exercises were included\_ specific exercises for the muscles affecting scapular orientation related to neck pain. The subjects were educated to maintain the positions and contractions during the exercises including scapular retraction, eccentric scapular retraction, and combined scapular retraction with shoulder lateral rotation, forward punch, and dynamic hug."
224136352|NCT02607358|OTHER|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
224136353|NCT02357641|OTHER|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
224136354|NCT03259490|DRUG|Empagliflozin/linagliptin/metformin HCl|Once daily
224136355|NCT03259490|DRUG|Empagliflozin|Once daily
223414551|NCT06969170|DRUG|Psilocybin (drug)|Psilocybin 3mg Po (oral solution) administered daily for 28 days (Open-Label Run-in Phase) followed by Psilocybin 3mg Po (oral solution) OR Placebo for 28 days (Double-Blind Treatment Phase) in patients with Generalized Anxiety Disorder(GAD)
223414552|NCT06969170|OTHER|Placebo|Sucralose 0.2% oral solution
223414553|NCT06966752|OTHER|NIPPV|"NIPPV~* PEEP 6-8 cmH2O~* PIP: 14-16 cmH2O~* Tinsp: 0.3-0.5sec~  * \<28 weeks GA: 0.3 - 0.4 sec~ * \>28weeks GA: 0.4 - 0.5 sec~* Rate: 20-35 breaths per minute."
223414554|NCT06966752|OTHER|CPAP|CPAP pressure of 6-8 mmH2O
224136356|NCT03259490|DRUG|Linagliptin|Once daily
223414555|NCT06966687|DRUG|Ulinastatin and Thymosin α1|Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery
223414556|NCT06966687|DRUG|Ulinastatin only|Ulinastatin (100000U TID for 5 days) immediately after surgery
223414557|NCT06968585|DRUG|A166|intravenous(IV) infusion (Q3W)
223414558|NCT06968585|DRUG|T-DM1|intravenous(IV) infusion (Q3W)
223414559|NCT06968598|OTHER|blood sample|blood sample
223414560|NCT05406479|DRUG|BE-PEP (Bedaquiline)|Single dose of Bedaquiline
223414561|NCT05406479|DRUG|SDR-PEP|Single dose of Rifampicin
223414562|NCT05406479|DRUG|BE-PEP (Rifampicine)|Single dose of Rifampicin
223414563|NCT06968377|DEVICE|A novel airborne pathogen containment device.|The dome is placed over the patient's head during the full duration of a surgery (intubation and extubation included) as a method of preventing infection transmission through airborne aerosols throughout a hospital.
223414564|NCT06967857|DRUG|DEX IR tablets|tablet twice daily
223738975|NCT02221375|DRUG|BHT low|
223738976|NCT02221375|DRUG|BHT medium|
223738977|NCT02221375|DRUG|BHT high|
224032299|NCT03531281|DRUG|Goat Milk|Given human lysozyme goat milk PO
224032300|NCT03531281|OTHER|Laboratory Biomarker Analysis|Correlative studies
224032301|NCT03531281|BIOLOGICAL|Palifermin|Given IV
224032302|NCT03531281|DRUG|Sirolimus|Given PO
224136357|NCT03259490|DRUG|Metformin HCl|Once daily
224136358|NCT00274872|DRUG|fluorouracil|
224136359|NCT00274872|DRUG|leucovorin calcium|
224136360|NCT00274872|DRUG|oxaliplatin|
224136361|NCT01184716|OTHER|Vitamin D fortification|Bread and milk fortified with vitamin D3
224136362|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (low dose)|The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
224032303|NCT03531281|DRUG|Tacrolimus|Given IV and PO
224032304|NCT03531281|RADIATION|Total-Body Irradiation|Undergo FTBI
224032305|NCT04062773|BEHAVIORAL|TRF|time restricted feeding group
224032306|NCT04062773|BEHAVIORAL|Normal timing of food intake|no time restricted feeding
223414565|NCT06967857|DRUG|DEX XL|capsule once daily
223560076|NCT04786821|DEVICE|Phoenix Exoskeleton suit|Participants will aim to walk wearing the Exoskeleton for up to 30 minutes. Based on the participant's tolerance, the duration of walking can be shorter and can be split into shorter intervals to achieve more activity. Over the sessions, based on the participants' tolerance, gradually the duration of walking can be increased with shorter breaks. This will be delivered by a research physiotherapist.
224032307|NCT02571127|DRUG|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
224032308|NCT05976919|DIAGNOSTIC_TEST|Pulmonary function testing|Physiological assessment of pulmonary physiology (large and small airways), exercise capacity, physical activity and body composition.
224136363|NCT06350058|BIOLOGICAL|Inactivated rotavirus vaccine (high dose)|The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
224136364|NCT06350058|BIOLOGICAL|Placebo|Aluminum hydroxide adjuvant.
224136365|NCT00885417|DRUG|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
224136366|NCT00881855|DRUG|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
224136367|NCT00881855|DRUG|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
224136368|NCT00796601|DRUG|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
224136369|NCT00796601|DRUG|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
224298366|NCT01718470|PROCEDURE|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
224298367|NCT00393471|DRUG|Etanercept|
223414566|NCT06967857|DRUG|Placebo|Placebo to either capsule or tablet
223414567|NCT05801783|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
223414568|NCT06969235|BEHAVIORAL|intensive health behavior and lifestyle treatment|the IHLBT will consist of 18 group meetings over 6 months that teens and parents attend. Topics covered during the meetings will include discussions regarding nutrition and physical activity recommendations, family communication, and use of strategies like monitoring, planning, goal setting, and problem solving.
223414569|NCT06966843|DRUG|Dantrolene|Dantrolene sodium capsule 25 mg orally once daily for 4 weeks. Dose may be titrated to 50 mg daily after 1 week if tolerated. Used to assess impact on muscle pain and biomarkers of muscle injury in patients with statin-induced myopathy.
223414570|NCT06966843|DRUG|Placebo|Oral placebo capsule matching dantrolene in size and appearance, administered once daily for 4 weeks.
223414571|NCT06967649|DEVICE|TITANIUM IMPLANT|The surgical technique, type of implant installed, and selected prosthetic components will follow the manufacturer's recommendations (SIN Implant System, São Paulo, Brazil), always considering treatment options for optimal patient rehabilitation.
223738978|NCT02221375|DRUG|BI 54903 XX low|
223738979|NCT02221375|DRUG|BI 54903 XX medium 1|
224032309|NCT03686202|BIOLOGICAL|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
224032310|NCT05650099|DEVICE|One or two dental implants (Biomet3I dental implant system) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of missing posterior teeth and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
224136370|NCT01838967|DRUG|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
223560077|NCT03533959|DRUG|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
223560078|NCT05595070|PROCEDURE|Haematopoietic stem cell transplantation|Haematopoietic stem cell transplantation (HSCT) is widely used in the treatment of malignant and non-malignant conditions to reconstitute the immune system secondary to cytotoxic conditioning regimens. These regimens, consisting of chemotherapy with or without total body irradiation, cause severe immunosuppression prior to, during and after HSCT. Immune reconstitution takes place by infusion of stem cells either harvested from the patient (autologous HSCT) or from a donor (allogeneic HSCT).
223560079|NCT04219449|DIAGNOSTIC_TEST|PT|measuring PT drawn on citrated blood sample
223560080|NCT04219449|DIAGNOSTIC_TEST|Protein C|measuring protein C drawn on citrated blood sample
223560081|NCT04219449|DIAGNOSTIC_TEST|Platelet aggregation by ADP and arachidonic acid|measuring platelet aggregation drawn on citrated blood sample
223560082|NCT00006459|DRUG|gemcitabine hydrochloride|
223560083|NCT00006459|DRUG|paclitaxel|
224136371|NCT01838967|DRUG|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
224136372|NCT01838967|DRUG|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
224136373|NCT01838967|DRUG|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
224136374|NCT01838967|DRUG|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
224136375|NCT01838967|DRUG|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
224136376|NCT01288508|DIETARY_SUPPLEMENT|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
224136377|NCT01288508|DIETARY_SUPPLEMENT|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
224032311|NCT05792436|DEVICE|1-min interval oscillometric method|"Before induction of anesthesia, 20-gauge catheter is inserted to radial artery after local anesthesia with lidocaine, and continuous blood pressure monitoring is started. Anesthesia is induced using propofol, opioids (fentanyl or remifentanil), and neuromuscular relaxants (rocuronium, cisatracurium, or vecuronium). For maintenance of anesthesia, propofol infusion or inhalation anesthetics (sevoflurane or desflurane) are used.~From the start of anesthesia induction to 15 minutes after, arterial blood pressure is monitored at 1-min interval using oscillometric method. The display of continuous arterial pressure on the anesthesia monitor is turned off during the 15-min study period."
223414572|NCT06966947|BEHAVIORAL|Risk Early Warning Management|"This intervention involves a perioperative risk early warning management strategy for hip fracture patients. A dedicated team of nurses is responsible for monitoring vital signs (heart rate, blood pressure, respiratory rate, temperature, and consciousness level) to identify and respond to early signs of clinical deterioration.~The intervention follows a structured scoring system that classifies patients into different risk levels based on their vital signs:~Risk Score 0-4: Standard perioperative care and monitoring~Risk Score 5-7 (or single-item score ≥3): Intensive monitoring with vital sign checks every 4 hours and immediate physician notification if condition changes~Risk Score ≥7: Continuous monitoring, with immediate physician availability and ready access to emergency equipment The intervention aims to improve patient outcomes by ensuring early identification of deterioration and more rapid response to clinical changes. A red warning sign will also be placed at the patient's b"
223414573|NCT06966947|BEHAVIORAL|Standard Perioperative Care|"This is the standard care protocol for patients undergoing hip fracture surgery at the study hospital. It includes health education before surgery, regular vital sign monitoring, routine anticoagulation, and infection control management.~Patients will receive standard perioperative management, including preoperative counseling, assistance with rehabilitation exercises, and monitoring of clinical symptoms and vital signs throughout the surgical and recovery process.~There is no specific risk early warning scoring system in this group, and intervention is based on routine clinical monitoring."
223560084|NCT06789328|DRUG|perineural Dexamethasone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg perineural Dexamethasone
223560085|NCT06789328|DRUG|intravenous Dexamethsone 4mg|PENG block with 20ml 0.2% ropivacaine + 4mg intravenous Dexamethasone
224032312|NCT05792436|DEVICE|arterial catheterization method|During the same time window for 1-min interval oscillometric method, arterial blood pressure is monitored using continuous blood pressure monitoring.
224032313|NCT04533451|DRUG|Pembrolizumab|Given IV
224032314|NCT04533451|DRUG|Pemetrexed|Given IV
224032315|NCT04533451|DRUG|Carboplatin|Given IV
224136378|NCT04474119|DRUG|KN046|In combine therapy stage, KN046 is 5 milligram per kilogram, every 3 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
223560086|NCT02142400|DRUG|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
223560087|NCT02142400|DRUG|placebo|matching placebo capsules to DS-1093 capsules
223560088|NCT06093308|DRUG|Deuremidevir Hydrobromide Tablets|Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
223560089|NCT00531440|DRUG|Everolimus (RAD001)|
223560090|NCT00540241|DRUG|Pemetrexed|in-label use
224032316|NCT04533451|OTHER|Comprehensive Geriatric Assessment|Ancillary studies
223560091|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
223560092|NCT03388216|BIOLOGICAL|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
223560093|NCT03388216|BIOLOGICAL|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
223560094|NCT03388216|OTHER|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
223738980|NCT02221375|DRUG|BI 54903 XX medium 2|
223738981|NCT02221375|DRUG|BI 54903 XX high|
223738982|NCT02221375|DRUG|Ciclesonide|
223738983|NCT01976234|OTHER|Fresh RBC|Patients will receive fresh blood only
224032317|NCT04533451|OTHER|Questionnaire Administration|Ancillary studies
224032318|NCT04533451|OTHER|Quality-of-Life Assessment|Ancillary studies
224032319|NCT02537626|DEVICE|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
224032320|NCT02537626|DEVICE|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
224032321|NCT04576143|DRUG|Epirubicin|i.v. 90 mg/m2
224032322|NCT04576143|DRUG|Cyclophosphamid|i.v. 600 mg/m2
224032323|NCT04576143|DRUG|Docetaxel|i.v. 100 mg/m2
224032324|NCT04576143|DRUG|Paclitaxel|i.v. 175 mg/m2
223738984|NCT01976234|OTHER|Old RBC|
224032325|NCT05134870|BEHAVIORAL|Mimic- game and groove- Telerehabilitation|Participants will mimic the exergaming-based animation videos shown to them by the health coach. They will also wear a wearable device that will measure the heart rate and physical activity during the training. The intervention will have 12 sessions for 4 weeks, each session for 1.5 hours, including warm-ups and cool-down. Warm-up and cool down are for 20 minutes. Additionally, Participants are provided with a set of balance exercises which includes non-interactive balance games (stepping forward, backward, sideways), Tai-Chi, Weight shifting (to right leg, left leg and practice distributing equal weights on both the legs), Aerobic (stepping in place), dance, strength, and stretching
224032326|NCT00420251|DRUG|Genotropin|
224136379|NCT04474119|DRUG|KN046 placebo|"In combine therapy stage, KN046 placebo is 5 milligram per kilogram, every 3 weeks.~In maintain stage, KN046 placebo is 5 milligram per kilogram, every 2 weeks."
224136380|NCT03054467|DRUG|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
223414574|NCT06564675|DIAGNOSTIC_TEST|C-Trend Index|C-trend-Index is collected blinded from the patients using Brainstatus device. The device shows and collects also cEEG. These are analyzed retrospectively after all study patients have their 6-month follow-up data collected. The intervention does not affect clinical management or decision-making.
223414575|NCT02915770|PROCEDURE|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
223414576|NCT02915770|PROCEDURE|hepatectomy|
223414577|NCT02915770|DEVICE|T-tube|T-tube Drainage
223414578|NCT05220449|OTHER|Cross-frequency dual-site tACS|Dual site transcranial alternating current stimulation over the primary visual cortex (V1) and the mediotemporal cortex (MT/V5) using two different stimulation frequencies (Alpha and Gamma)
223414579|NCT04520542|OTHER|Acupressure Application|Acupressure was administered in a semi-sitting or supine position where the woman felt comfortable and the researcher could perform the practice comfortably to the acupressure points. The application was performed on the determined acupressure points by considering the direction of the meridian in a certain order. It was performed with the administration order of Spleen 6th point (SP 6) and Large Intestine 4th point (Li 4). In total, the administration was performed with 4 acupressure points including 2 points in the upper/lower extremity along with the parallel points in each intervention.
223414580|NCT03021083|DEVICE|IONSYS Patch|Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
223414581|NCT04652531|OTHER|Autologous extracellular vesicles from serum|Peri-wound injection of the vesicles will be performed in a sterile environment. Sterile gauze and an elastic-compression bandage will be applied.
223414582|NCT01284348|DRUG|Sotatercept 15 mg|Sotatercept 15 mg SC injection once every 42 days, up to four doses
223560095|NCT02374060|DRUG|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
223560096|NCT02374060|DRUG|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
223560097|NCT02374060|DRUG|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
223560098|NCT01034982|DRUG|AZD9668|20 mg
223560099|NCT01034982|DRUG|AZD9668|60 mg
223560100|NCT03671421|PROCEDURE|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
223560101|NCT07080411|RADIATION|short course radiotherapy using MR-linac|Patients in the MRgART group will receive standard total neoadjuvant therapy (TNT) and surgical treatment, including short-course radiotherapy and chemotherapy, with the addition of immunotherapy at the investigator's discretion based on individual patient characteristics.
224298368|NCT04813315|OTHER|Kendall exercise|consist of stretch of pectoralis major and neck extensor strengthening of deep neck flexors and scapular retractor
223560102|NCT01321255|DRUG|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
223560103|NCT01321255|DRUG|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
223560104|NCT07079878|OTHER|Group with Bed Head Height 30°|30 minutes before feeding, the bed head height of the preterm newborn is adjusted to 30° and vital signs are monitored. After 30 minutes, the newborn is fed and vital signs are monitored during feeding. The vital signs are monitored again 30 minutes after feeding. While evaluating nutritional tolerance, abdominal distension, abdominal circumference measurement and vomiting are monitored. Growth parameters of the newborn are recorded on the growth monitoring form for 7 days.
223414583|NCT01284348|DRUG|Sotatercept 30 mg|Sotatercept 30 mg SC injection once every 42 days, up to four doses
223414584|NCT03789760|DRUG|SaiLuoTong capsule|500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
223414585|NCT03789760|DRUG|placebo|500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
223414586|NCT03938844|PROCEDURE|BURCH Colposuspension|stress urinary incontinence surgery ( burch or tot)
223414587|NCT03938844|PROCEDURE|TOT|
223414588|NCT02166060|DRUG|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
223414589|NCT03510845|PROCEDURE|Arthroscopic ACL Primary Repair|"All patients (in both groups) will undergo diagnostic knee arthroscopy at the start of the procedure; those in the experimental arm repairable ACL tear, whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle."
223414590|NCT03510845|PROCEDURE|Arthroscopic ACL Reconstruction|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
223414591|NCT04511520|OTHER|Physical training program|
223414592|NCT04511520|DRUG|Trimetazidine|
223738985|NCT05266092|OTHER|Observational study|Observational study
223738986|NCT01481142|DEVICE|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
223738987|NCT03616899|DRUG|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
224298369|NCT04813315|OTHER|Gong's mobilization|it is combination of glide along the facet joint and concurrent movement of cervical spine
224298370|NCT02621034|PROCEDURE|Control|K-file hand instrumentation
224298371|NCT02621034|PROCEDURE|Reciproc|reciprocating rotary instrument
224298372|NCT02621034|PROCEDURE|One shape|full rotation protocol
224298373|NCT00929331|BIOLOGICAL|Fluviral®|Intramuscular injection, one dose
224298374|NCT01969448|PROCEDURE|Inframammary Fold Incision or Lateral Radial Incision|
224298375|NCT01969448|PROCEDURE|Lateral Radial Incision|
223414593|NCT05368220|OTHER|Whole genome sequencing|Each participant will have WGS performed in order to report on clinically actionable genetic variation in diabetes.
223560105|NCT07079878|OTHER|Group with Bed Head Height 45°|The bed head height of the preterm newborn is adjusted to 45° 30 minutes before feeding and vital signs are monitored. After 30 minutes, the newborn is fed and vital signs are monitored during feeding. The vital signs are monitored again 30 minutes after feeding. While evaluating nutritional tolerance, abdominal distension, abdominal circumference measurement and vomiting are monitored. Growth parameters of the newborn are recorded on the growth monitoring form for 7 days.
224032327|NCT05555056|DEVICE|MxN-9 HD-tES Stimulator (Soterix Inc.)|Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
223414594|NCT01699269|OTHER|peritumoral glial cell infiltration|
223414595|NCT04481269|DEVICE|Surface-modified composite coated orthopedic implants|The surface-modified composite coated orthopedic implants have the capacity of high binding strength, high tissue-inducing activity and intelligent bacteria-resistance. The implant devices are expected to be used in the prevention and treatment of plant-related infections in orthopedic surgeries.
223414596|NCT04481269|DEVICE|conventional orthopedic implants|conventional orthopedic implants
223414597|NCT01609855|DRUG|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
223414598|NCT01609855|DRUG|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
223414599|NCT00502112|DRUG|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
223560106|NCT07076992|PROCEDURE|Circumcision by Plastibell|Patients will undergo circumcision by Plastibell (PB).
223738988|NCT03616899|DRUG|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
223738989|NCT01038024|DIETARY_SUPPLEMENT|1 tablet composed of antioxidants and minerals|1 tablet daily
224032328|NCT05555056|DEVICE|Sham Stimulation|The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
224032329|NCT06357351|PROCEDURE|vestibular incision sub periosteal tunnel access ( VISTA) technique.|In comparison between the two groups, the first group uses collagen membrane and the other group uses advanced PRF using the same surgical technique (VISTA)
224032330|NCT04381091|DRUG|Idebenone 150 MG Oral Tablet|idebenone 900 mg/day
224136381|NCT03054467|DRUG|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
223414600|NCT00502112|DRUG|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
223414601|NCT00510536|DRUG|Acetaminophen|dose to be determined by investigator
223414602|NCT00510536|DRUG|NSAID|dose to be determined by investigator
223560107|NCT07076992|PROCEDURE|Circumcision by Gomco|Patients will undergo circumcision by the Gomco (GM).
223560108|NCT07080853|OTHER|Exercise with Overdressing|Run for 30 minutes followed by walk for 60 minutes in a temperate (gym-like environment) wearing overdressing ensemble.
223560109|NCT07080853|OTHER|Control Exercise|Run for 30 minutes followed by walk for 60 minutes in a temperate (gym-like environment) wearing control clothing ensemble.
223738990|NCT05339503|OTHER|enamel microabrasion|It is a non-restorative, conservative treatment that works both chemically and mechanically to remove up to 0.2 mm of affected enamel per application. Pumice either mixed with 18% hydrochloric acid or 5.25% sodium hypochlorite was used to remove fluorosis stains.
223738991|NCT02863133|DEVICE|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
223738992|NCT03448185|BEHAVIORAL|High intensity exercise|Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
224032331|NCT02243098|DRUG|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
224032332|NCT02243098|DRUG|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
224032333|NCT02243098|DRUG|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
224032334|NCT01927328|DRUG|Iron isomaltoside 1000|
224032335|NCT04984954|DRUG|MUSK pill|This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. Patients were treated with the trial drug or placebo in a 1:1 ratio. The experimental group was treated with MUSK pill (4 pills / day, 3 times / day) on the basis of conventional treatment until the end of follow-up
224298376|NCT01969448|PROCEDURE|Inframammary Fold Incision|
224298377|NCT01969448|DEVICE|Laser-assisted fluorescence angiography|
224298378|NCT01969448|DRUG|Indocyanine Green|
223414603|NCT02913443|DRUG|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
223414604|NCT00060242|DRUG|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
223414605|NCT02631122|PROCEDURE|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
223414606|NCT05026112|DIAGNOSTIC_TEST|ECG-Imaging|ECG imaging acquisition
223414607|NCT05026112|DIAGNOSTIC_TEST|Cardiac MRI scan|Cardiac MRI scan
223414608|NCT05510193|DEVICE|Aktio prosthesis|Transradial myoelectric prosthesis
223414609|NCT03028909|DRUG|Oseltamivir|Standard of care for influenza caused by Type A strains
223414610|NCT03028909|DRUG|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
223560110|NCT07080112|BEHAVIORAL|Peer education|The study was designed as a randomized controlled trial. The population consisted of third-year nursing students (84 students) enrolled in the spring semester of the 2024-2025 academic year. The entire population was included in the study. For randomization, the class list of 84 students was used based on their order, and randomization was performed via the website https://www.random.org/ to form the experimental and control groups.
223560111|NCT07081854|OTHER|Land-Based Plyometric Training|"Participants will perform traditional plyometric exercises on land aimed at improving lower-body power and neuromuscular performance.~Exercises:~1. Box Jumps: Jumping onto a box of progressively higher levels to build explosive strength.~2. Depth Jumps: Stepping off a box and immediately jumping vertically upon landing.~3. Jump Squats: Explosive vertical jumps starting from a squat position.~4. Lateral Bounding: Jumping side-to-side to enhance lateral agility.~5. Broad Jumps: Maximal horizontal jumps for distance.~6. Tuck Jumps: Jumping while bringing knees to the chest in mid-air."
223560112|NCT07081854|OTHER|Aquatic Plyometric Training|"Participants will perform plyometric exercises in a shallow pool, with the water depth fixed at the xiphoid process level (chest height). Greater peak mechanical power was observed for jumps performed in the water and was influenced by immersion depth.~Exercises:~1. Box Jumps: Jumping onto a box of progressively higher levels to build explosive strength.~2. Depth Jumps: Stepping off a box and immediately jumping vertically upon landing.~3. Jump Squats: Explosive vertical jumps starting from a squat position.~4. Lateral Bounding: Jumping side-to-side to enhance lateral agility.~5. Broad Jumps: Maximal horizontal jumps for distance.~6. Tuck Jumps: Jumping while bringing knees to the chest in mid-air.~Key Points:~* Encouraged to perform movements explosively while applying maximal effort.~* Proper execution is emphasized to maintain biomechanical integrity even in the water environment.~* Water temperature: 25-28 °"
223738993|NCT03448185|DIETARY_SUPPLEMENT|Omega-3 fish oil|Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
224032336|NCT03412305|DRUG|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
224032337|NCT03412305|OTHER|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
223414611|NCT03028909|DRUG|Placebo|Salt-water solution containing no active ingredients.
223414612|NCT01480466|OTHER|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
223414613|NCT00983060|DRUG|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
223414614|NCT00983060|DRUG|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
223414615|NCT01168466|BEHAVIORAL|QEEG-based Neurofeedback Training|EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
223414616|NCT04210063|OTHER|Inspiratory Muscle Training (IMT)|IMT is a breathing training technique customized to participant's breathing capacity. Using a handheld electronic manometer (Pro2Fit from Smithfield), a study personnel will initiate training at 40-60% maximal inspiratory pressure. Adjustments will be customized to where the participant reports a difficulty of training between 4-6 out of 10. Training sessions will be performed about 30 minutes a day for 28 consecutive days.
223414617|NCT02361463|DEVICE|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
223414618|NCT02361463|DEVICE|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
223414619|NCT03272295|OTHER|Reference cigarette|The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
223414620|NCT03272295|OTHER|Cigarette with carob bean extract|Based on reference cigarette with added ingredient
223414621|NCT03272295|OTHER|Cigarette with cocoa powder|Based on reference cigarette with added ingredient
223414622|NCT03272295|OTHER|Cigarette with fenugreek extract|Based on reference cigarette with added ingredient
223414623|NCT03272295|OTHER|Cigarette with fig juice|Based on reference cigarette with added ingredient
224032338|NCT04672174|DIAGNOSTIC_TEST|Questionnaire: DemTect|Questionnaire is handed out to subjects
224032339|NCT05519397|DIAGNOSTIC_TEST|Immune checkpoint measurement|Measurement of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9
224032340|NCT03840239|DRUG|Capecitabine, Oxaliplatin|Drug: Capecitabine, Oxaliplatin
224032341|NCT03840239|RADIATION|External beam radiotherapy|External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
224032342|NCT03840239|PROCEDURE|Surgery|'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
223414624|NCT03272295|OTHER|Cigarette with glycerol|Based on reference cigarette with added ingredient
223738994|NCT03448185|BEHAVIORAL|Yoga|Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
224032343|NCT03840239|OTHER|Watch and wait strategy|Watch and wait strategy recommendation and discussion for cCR patients
224032344|NCT03484520|DRUG|Venetoclax|tablet, oral
224032345|NCT03484520|DRUG|Dinaciclib|intravenous
223414625|NCT03272295|OTHER|Cigarette with guaiacol|Based on reference cigarette with added ingredient
223414626|NCT03272295|OTHER|Cigarette with liquorice extract powder|Based on reference cigarette with added ingredient
223414627|NCT03272295|OTHER|Cigarette plus I-menthol|Based on reference cigarette with added ingredient
223414628|NCT03272295|OTHER|Cigarette with propylene glycol|Based on reference cigarette with added ingredient
223414629|NCT03272295|OTHER|Cigarette with sorbitol|Based on reference cigarette with added ingredient
223414630|NCT03272295|OTHER|Cigarette with multiple ingredients|Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
223414631|NCT01517763|DEVICE|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
223414632|NCT01517763|DEVICE|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
224032346|NCT02796001|BIOLOGICAL|human rhinovirus|human rhinovirus
223414633|NCT01517763|DEVICE|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
223414634|NCT00444756|PROCEDURE|J-tip jet injection of 1% buffered lidocaine|
223414635|NCT00452582|DRUG|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
223414636|NCT00452582|OTHER|Usual care|Physical therapy, occupational therapy, speech therapy
223414637|NCT00232362|DRUG|Pioglitazone (Actos)|
223414638|NCT00232362|DRUG|Anti-diabetic agent other than pioglitazone or rosiglitazone|
223560113|NCT07081854|OTHER|General conditioning exercises|"Participants will follow a general conditioning routine that does not include plyometric exercises.~Exercises:~1. Bodyweight squats.~2. Lunges.~3. Core stability exercises (e.g., planks, bridges).~4. General cardio activities such as light jogging or cycling."
224136382|NCT03911336|DRUG|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
224136383|NCT03911336|DRUG|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
224136384|NCT03911336|DRUG|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
223560114|NCT01700959|DRUG|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
223560115|NCT01700959|DRUG|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
223560116|NCT00830375|DRUG|Memantine|10-30mg, by mouth, daily
223560117|NCT04169984|OTHER|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
223738995|NCT03448185|DIETARY_SUPPLEMENT|olive oil capsules|Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
223738996|NCT00177892|PROCEDURE|sleep disruption|experimentally-induced Sleep Fragmentation
223738997|NCT00177892|PROCEDURE|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
223738998|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 400|dose 400 UNT/day for 12 months
224032347|NCT02796001|OTHER|no intervention|4 volunteers were not re-challenged and did not participate in the second challenge
224136385|NCT06359743|PROCEDURE|Quadratus Lamborum versus superior hypogatric|Ultrasound Guided Quadratus Lumborum Block versus Laparoscopic Superior Hypogastric Plexus Block for Postoperative Analgesia after Laparoscopic Hysterectomy
224136386|NCT01892319|DRUG|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
223560118|NCT04169984|OTHER|Placebo|Exercises that do not alter the function or morphology of the upper airway.
224298379|NCT04250948|DRUG|JS001|JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.
224298380|NCT04250948|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
223414639|NCT00005580|DRUG|bryostatin 1|
223414640|NCT00005580|DRUG|fludarabine phosphate|
223414641|NCT00627965|DRUG|Sildenafil citrate|50mg tds
223414642|NCT00627965|DRUG|Placebo|Placebo tds
223414643|NCT04956601|RADIATION|vaginal brachytherapy/pelvic external beam radiotherapy|high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
223414644|NCT05461001|OTHER|Warm Up Exercises|The daily warm up exercises for male football players include full body stretch, high knees, lunges, squat and burpees.
223560119|NCT04165382|OTHER|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
223738999|NCT03691896|DIETARY_SUPPLEMENT|Cholecalciferol 800|dose 800 UNT/day for 12 months
223739000|NCT03691896|DRUG|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
223739001|NCT01799616|DRUG|Pamidronate|
223739002|NCT01799616|OTHER|Placebo|
224032348|NCT01995877|PROCEDURE|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
224032349|NCT03623685|DIAGNOSTIC_TEST|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
224032350|NCT00350662|DRUG|Deferiprone (L1)|75 mg/kg body weight daily
224298381|NCT04250948|DRUG|S1|S-1: 40\~60mg Bid，d1\~14, q3w
224298382|NCT04250948|DRUG|Capecitabine|Capecitabine: 1000mg/m2 Bid，d1-14, q3w
224298383|NCT05561530|DRUG|ALG-125755|single or multiple doses of ALG-125755
224298384|NCT05561530|DRUG|Placebo|single or multiple doses of placebo
224298385|NCT02000401|DRUG|Ketorolac Tromethamine|
223414645|NCT05461001|OTHER|Endurance Based Exercises|Sport-specific endurance-running (duration \[in minutes\], total distance \[in meters\], mean speed \[in meters per minute\], high-speed running \>15 km·h-1, and relative high-speed running \[\>75% and \>85% of maximal velocity\]) will be given to the experimental group. Athletes will run in excess of 15 km of total distance (TD) and 4 km of high-speed (\>15 km·h-1) distance per session 3 to 4 running-based endurance sessions per week for 6 weeks.
224032351|NCT00350662|DRUG|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
223560120|NCT04165382|OTHER|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
223739003|NCT04640519|OTHER|Usual care|Usual care patients will be seen by a primary care nurse practitioner and a stroke neurologist.
224032352|NCT01569360|DEVICE|Corset|the patients are assigned the use of a custome made corset during daytime
224032353|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 2.5 mg, twice daily, oral
224032354|NCT01776424|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Tablet, 5 mg, twice daily, oral
224032355|NCT01776424|DRUG|Aspirin|Tablet, 100 mg, once daily, oral
224032356|NCT01776424|DRUG|Aspirin placebo|Aspirin matching placebo, once daily, oral
224032357|NCT01776424|DRUG|Rivaroxaban placebo|Rivaroxaban matching placebo, twice daily, oral
224032358|NCT01776424|DRUG|Pantoprazole|Tablet, 40 mg, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole
224032359|NCT01776424|DRUG|Pantoprazole placebo|Pantoprazole matching placebo, once daily, oral, for participants who were not on a PPI and who were randomized to pantoprazole placebo
224032360|NCT04575753|OTHER|Study group|"Blood samples will be taken from ICU patients on the day of ICU admission, day 2 and day 5 after ICU admission.~Similarly, patients will be subjected to cognitive testing (CAM-ICU) to determine the presence of delirium"
224032361|NCT05601791|PROCEDURE|Epidural Steroid Injection|Epidural Steroid Injection transforaminal approach Drug: midazolam, fentanyl, lidocaine, levobupivacaine, methilprednisoloneacetat
224032362|NCT05601791|PROCEDURE|Percutaneous Laser Disc Decompression|Percutaneous Laser Disc Decompression Drug: midazolam, fentanyl, lidocaine
224032363|NCT04112446|DRUG|Saroglitazar magnesium|On Day 1, subjects will receive a single oral dose of \[14C\]-saroglitazar magnesium
224032364|NCT00404456|DRUG|Melatonin|Melatonin 3 mg once-daily
224032365|NCT03423823|DRUG|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Anti-VEGF injection
224032366|NCT03423823|DRUG|Ranibizumab|Anti-VEGF standard of care injection
224032367|NCT04100850|OTHER|Aquatic Exercises|twice a week, lasting 50 minutes, for two months.
224032368|NCT04100850|OTHER|Watsu|twice a week, lasting 50 minutes, for two months.
224032369|NCT02262923|DRUG|metoclopramide|
224032370|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
224032371|NCT00146757|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
224032372|NCT03886792|BEHAVIORAL|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
224032373|NCT03886792|BEHAVIORAL|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
224032374|NCT00438503|PROCEDURE|Procedure|
224032375|NCT04442360|BEHAVIORAL|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health|Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health
223414646|NCT03296410|BIOLOGICAL|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
223414647|NCT03296410|BIOLOGICAL|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
223414648|NCT03296410|BIOLOGICAL|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
223414649|NCT03296410|BIOLOGICAL|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
223414650|NCT03296410|BIOLOGICAL|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
223414651|NCT02944695|OTHER|audit|Practice adherence to guidelines
223414652|NCT00321295|DEVICE|Atrial synchronous bi-ventricular pacing|
223414653|NCT01199835|OTHER|High Calcium intake from dairy products|High dietary intake of calcium from dairy products (\~1200 mg/d)
223414654|NCT00410735|DRUG|Placebo|0 mg BID for 12 weeks
223414655|NCT00410735|DRUG|Pranlukast hydrate|225 mg BID for 12 weeks
223414656|NCT00034242|DRUG|high-dose intravenous immunoglobulin (IVIG)|
223414657|NCT03951883|OTHER|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
223414658|NCT03951883|OTHER|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
223414659|NCT03290261|OTHER|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
223414660|NCT03910205|DIAGNOSTIC_TEST|ELISA|Enzim linked immunoabsorbant assay
224032376|NCT03948217|OTHER|Circadian Lighting regimen|Circadian lighting regimen with one major fluctuation, high light intensity and color
224032377|NCT05411367|DRUG|SI-614|1 drop in each eye
223414661|NCT05393856|DRUG|CG-549|"PART A (open-label)~Period 1: single oral dose. Period 2: After PK evaluation of period 1. Period 3: After PK evaluation of period 2.~PART B (randomized)~* Period 1: a single oral dose of ZZ mg CG-549 on Day 1 in fed or fasted state.~* Period 2: a single oral dose of ZZ mg CG-549 on Day 1 in fasted or fed state."
223414662|NCT02763137|DRUG|Standard LD/CD|LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
224032378|NCT05411367|DRUG|Vehicle|1 drop in each eye
224032379|NCT04987567|DIETARY_SUPPLEMENT|ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)|Pearls of DHA (BrudyNen)
224032380|NCT04987567|DIETARY_SUPPLEMENT|PLACEBO (OLIVE OIL)|Pearls manufactured to mimic DHA (BrudyNen).
224032381|NCT01088191|BIOLOGICAL|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
224032382|NCT01088191|DRUG|Hyaluronan|Hyaluronan alone
224032383|NCT03152357|DEVICE|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
224032384|NCT03733067|DRUG|abatacept|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
224032385|NCT03733067|OTHER|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
223414663|NCT02763137|DRUG|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
223414664|NCT05206253|DIETARY_SUPPLEMENT|Whole egg powder|Nutritional supplementation during a 12 week resistance training program
223414665|NCT05206253|DIETARY_SUPPLEMENT|Whey protein powder|Nutritional supplementation during a 12 week resistance training program
223414666|NCT05206253|DIETARY_SUPPLEMENT|Maltodextrin placebo|Nutritional supplementation during a 12 week resistance training program
223414667|NCT03117660|DRUG|Vitamin A|vitamin A daily X3-4 weeks
223414668|NCT00879476|DRUG|Ramipril 10mg capsules|
223414669|NCT01919866|OTHER|Transplantation of CD3/CD19 depleted stem cells|
223414670|NCT02868489|DIETARY_SUPPLEMENT|LactoWise®|blend of bacillus coagulans and galactomannans
223414671|NCT02868489|OTHER|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
223414672|NCT02694926|OTHER|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
223414673|NCT03645395|DRUG|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
224032386|NCT04773613|OTHER|Experimental SLP|SLP was given to the infant during bottle-feeding.
224032387|NCT04773613|OTHER|Experimental SEP|SEP was given to the infant during bottle-feeding.
224032388|NCT00550368|BIOLOGICAL|Biological intervention: Enteropathogenic E. coli|5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.
223414674|NCT00324025|DRUG|Mycograb|
223414675|NCT00324025|DRUG|placebo|
224032389|NCT04193267|DEVICE|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
224032390|NCT03462472|BEHAVIORAL|Lower leg heating|Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
224136387|NCT01892319|DRUG|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
224136388|NCT04070170|DEVICE|Low-level Laser Therapy|Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
223414676|NCT01057810|DRUG|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
223414677|NCT01057810|DRUG|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
223414678|NCT01861899|DEVICE|SI-LOK|Sacro-iliac joint fusion
223414679|NCT05973305|DRUG|Dorzol 20 mg/ml|dosing schedule t.i.d.
223414680|NCT05973305|DRUG|Trusopt 20 mg/ml|dosing schedule t.i.d.
223414681|NCT06448507|DEVICE|INJEX [Needle less anesthesia]|already described
223414682|NCT06448507|DEVICE|Syringe Needle [ Traditional technique]|described
224032391|NCT03462472|BEHAVIORAL|Lower leg transcutaneous electrical nerve stimulation (TENS)|Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
224136389|NCT04070170|PROCEDURE|Orthodontic force|Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
224136390|NCT03594487|DRUG|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
223414683|NCT02088905|BEHAVIORAL|Parent Child Interaction Therapy|Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
224032392|NCT04156217|BIOLOGICAL|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
224136391|NCT03594487|PROCEDURE|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
223414684|NCT04560985|OTHER|Hydrophilic fissure sealant|Hydrophilic fissure sealant on first molars
223560121|NCT02701959|DIETARY_SUPPLEMENT|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).
224032393|NCT05392530|DRUG|Macitentan|Macitentan film coated tablets will be administered orally as per assigned treatment sequence.
224136392|NCT03594487|OTHER|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
224136393|NCT05982223|PROCEDURE|Acupuncture|The frequency of acupuncture will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
224136394|NCT05982223|PROCEDURE|Mind-body therapy|The frequency of mind-body therapy (hypnosis, guided imagery) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
223414685|NCT04560985|OTHER|Hydrophobic fissure sealant|Hydrophobic fissure sealant on first molars
224136395|NCT05982223|PROCEDURE|Touch therapy|The frequency of touch therapy (shiatsu, reflexology) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
224298386|NCT06304025|BIOLOGICAL|Wharton's jelly mesenchymal stem cells (WJ-MSCs)|Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days
224298387|NCT04941339|DRUG|MRG002|Administrated intravenously
223414686|NCT00827905|DEVICE|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
223414687|NCT03395145|DEVICE|Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
223414688|NCT02040051|BEHAVIORAL|Sound isolation / Music therapy|"Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)"
223414689|NCT05177276|DRUG|Selinexor|
223414690|NCT05177276|DRUG|Irinotecan|
223414691|NCT00003140|DRUG|letrozole|Given orally
223414692|NCT00003140|OTHER|placebo|Given orally
223414693|NCT01585740|DRUG|0.9% Normal Saline|Crystalloid fluid
223414694|NCT01585740|DRUG|Ringer's Lactate|Crystalloid fluid
223560122|NCT02701959|DIETARY_SUPPLEMENT|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
223560123|NCT03146559|DEVICE|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
223560124|NCT03146559|DEVICE|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
223560125|NCT07080138|DRUG|All kinds of INSTI medications|All kinds of INSTI medications, such as Bictegravir/Emtricitabine/Tenofovir alafenamide Fumarate, Dolutegravir/Emtricitabine/Tenofovir alafenamide Fumarate for PLWH
224032394|NCT03985215|OTHER|Questionnaires|Pediatric Quality of Life Inventory questionnaire. Self-designed questionnaire.
223414695|NCT04784429|DEVICE|Kenevo or C-Leg 4|Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.
223414696|NCT04784429|DEVICE|Non microprocessor controlled knee (NMPK)|NMPK consistent with current standards of care
223414697|NCT02663063|DEVICE|SSP treatment|SSP treatment 5 times a week
223560126|NCT07080138|DRUG|All kinds of conventional medications|All kinds of conventional medications, such as Abacavir, Efavirenz for PLWH
223560127|NCT05051293|OTHER|serum concentration of estrogen (E1 and E2) and testosterone ratio measurement|To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
223560128|NCT02242214|DRUG|Misoprostol|
224032395|NCT01246934|OTHER|ASR METHOD|
224032396|NCT04213027|PROCEDURE|native tissue repair procedures with conventional surgical instruments|Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
224032397|NCT04653168|DRUG|LY3041658|Administered SC
224032398|NCT00186069|DRUG|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
224032399|NCT00186069|OTHER|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
224032400|NCT01430806|DRUG|Dronedarone arm|PO Dronedarone 400 mg BID
223414698|NCT03330704|DRUG|3% Sodium Chloride|3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
223414699|NCT03330704|DRUG|23.4% Sodium Chloride|23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
223560129|NCT01696019|OTHER|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
223739004|NCT04640519|OTHER|TASC intervention|TASC patients will receive a BP monitoring kit and electronic tablet with patient tailored BP infographics. They will be scheduled with 5 telehealth visits over 3 months, including primary care nurse practitioner, pharmacy and stroke neurologist.
223739005|NCT00982475|PROCEDURE|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
224032401|NCT01430806|DRUG|Dronedarone|Dronedarone PO 400 MG BID
224136396|NCT05982223|PROCEDURE|Movement therapy|The frequency of movement therapy (Tai-Chi, Qi-Qong) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
224032402|NCT02913729|RADIATION|partial breast irradiation|irradiation
224032403|NCT05615753|BEHAVIORAL|Acupuncture|All participants will receive a semi-standardized acupuncture protocol with additional points for patient's particular pain location,
224136397|NCT05982223|DIETARY_SUPPLEMENT|Herbal supplements|The choice of herbal supplement will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
224136398|NCT05982223|BEHAVIORAL|Emotional treatment|The frequency of emotional treatments (counseling, spiritual guidance) will be defined by the integrative team in coordination with the patient, based on evidence-based data, patient's symptoms, and preferences. The duration of the intervention will be 6 months from recruitment.
224136399|NCT00119730|DRUG|Fludarabine|Given on days 1-3 of each 28-day cycle
224136400|NCT00119730|DRUG|Mitoxantrone|Given on day 1 of each 28-day cycle
224136401|NCT00119730|DRUG|Rituximab|Given on day 1 of each 28-day cycle
224136402|NCT00119730|DRUG|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
223414700|NCT03330704|DRUG|8.4% Sodium Bicarbonate|8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
223414701|NCT02459912|PROCEDURE|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
223414702|NCT02459912|DEVICE|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
223739006|NCT00862446|DRUG|Omegaven|1 gram/kg/day daily until on feeds
224032404|NCT00403728|DRUG|ciclosporine A|
224032405|NCT00595023|DEVICE|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
224032406|NCT05445583|BEHAVIORAL|Motivational Enhancement System (MES)|MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
224032407|NCT05445583|BEHAVIORAL|Supportive Accountability (SA)|Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
224136403|NCT02523820|DRUG|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
224136404|NCT02523820|DRUG|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
224136405|NCT05027516|DRUG|Rocephin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
224136406|NCT05027516|DRUG|Azithromycin|Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
224032408|NCT05445583|BEHAVIORAL|Text Messaging (SMS)|SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
223414703|NCT03292328|OTHER|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
223560130|NCT01696019|OTHER|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
223560131|NCT01696019|OTHER|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
223560132|NCT01696019|OTHER|Contact and testing only|
223560133|NCT00002412|DRUG|Emivirine|
223560134|NCT00002412|DRUG|Hydroxyurea|
223560135|NCT00002412|DRUG|Stavudine|
223560136|NCT00002412|DRUG|Didanosine|
223414704|NCT03292328|OTHER|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
223414705|NCT06065917|DIAGNOSTIC_TEST|Measurement of the total small bowel length using CT scan and MRI with 3D reconstruction and AI tool|The intervention consists in performing CT and MR imaging with small bowel length measurement before bariatric/metabolic surgery in obese patients. Then, during surgery the patients will undergo laparoscopic stretched small bowel measurement as the reference gold standard method to measure the small bowel length. The imaging of the training cohort will be used to trained an AI to set up an automatic method of small bowel length measurement via the analysis of CT and MRI imaging.
223560137|NCT07081282|BEHAVIORAL|Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)|Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB)
224032409|NCT05445583|BEHAVIORAL|Physical Activity Tracking (PAT)|All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
224032410|NCT02578862|DRUG|Propofol|
224032411|NCT02578862|DRUG|Sevoflurane|
224032412|NCT05722054|OTHER|Diagnostic tests|"Blood smears; rapid diagnostic tests; complete blood counts with differential; leucoconcentration; urine examination; nasal/throat swabs, stool examination."
223560138|NCT07081282|BEHAVIORAL|Centre-Based Exercise Health Session|Participants will receive one time centre-based exercise health programme each week.
223560139|NCT07081620|OTHER|Physical examination of chest skin|soft touch and thermal (cold and warm) examination
223560140|NCT07079787|DEVICE|TeleRehab DSS Pilot Test|Participants will perform an individualised multisensory balance rehabilitation program via augmented reality, while wearing motion sensors. The program will consist of multisensory balance exercises, cognitive games, and exergames. All participants will perform 2 sessions per week, carried in at each clinical site, over the course of 3-week.s
223560141|NCT07080398|DIAGNOSTIC_TEST|serum bilirubin level measurement|Total serum bilirubin levels and concurrent transcutaneous bilirubin measurements will be done and the results will be evaluated comperatively.
223560142|NCT07079566|BEHAVIORAL|Primal Reflex Release Technique (PRRT)he Primal Reflex Release Technique (PRRT) is a hands-on, non-invasive therapeutic approach designed to deactivate overactive protective reflexes believed to contr|The Primal Reflex Release Technique (PRRT) is a non-invasive, manual therapy that targets specific neurogenic reflex points to reduce muscle tension, pain, and dysfunction. It works by modulating the autonomic nervous system to interrupt hyperactive primal reflexes such as withdrawal and startle reflexes, which are often involved in chronic musculoskeletal pain conditions like plantar fasciitis. In this study, PRRT was applied to participants in the experimental group over a 3-week period, consisting of multiple sessions per week. Each session included a series of gentle manual techniques such as the sternocleidomastoid (SCM) release, startle reflex inhibition, and positional reflex modulation. These techniques aim to reset the body's reflex-driven pain responses and promote functional mobility. PRRT was performed by trained physiotherapists following a standardized protocol to ensure consistency throughout the study.
224032413|NCT05722054|OTHER|Equilibrate diet|Nutritionally-balanced Alimentation
224032414|NCT04704011|OTHER|2-1-1 United Way Healthy Missouri Hotline|This federally funded, free service connects callers with appropriate community services to help address their unmet basic needs.
224136407|NCT04191577|DRUG|CVN424 Low Dose|CVN424
223414706|NCT04281758|OTHER|Beverage|16 oz (473.2 ml)
223414707|NCT06534619|PROCEDURE|Electrotherapy|Therapeutic ultrasound: pulse mode - 1:4, frequency 3 MHz, intensity- 0.8 watt/cm2 for about 3-4 minutes.
223414708|NCT06534619|PROCEDURE|Rocabado exercises|6 Rocabado exercises 6 Reps each.
224136408|NCT04191577|DRUG|CVN424 High Dose|CVN424
224136409|NCT04191577|DRUG|Placebo|Placebo
224136410|NCT03655717|DRUG|Dronabinol|Dronabinol at physician determined doses of 10-80mg designed to produce intoxication.
223414709|NCT06534619|PROCEDURE|Maitland oscillatory mobilizations|"Mobilizations will be performed in Grade 1 initially and then progressed to Grade 2 and 3.~Techniques used are anterior, lateral and inferior glides"
223414710|NCT01985841|DRUG|Bevacizumb|Avastin
223414711|NCT01985841|DRUG|5-Fluorouracil|5-FU
224032415|NCT04704011|OTHER|National Comprehensive Cancer Network (NCCN) Distress Thermometer|Study participants will be asked to rate the amount of distress that they have experienced in the past week (scale of 0 to 10, 10=extreme distress) and indicate areas of concern including practical basic needs and family, emotional, spiritual, and physical problems. They will also be asked to rate the amount of distress (scale 0-10) that they attribute to their abnormal cervical cancer screen.
224032416|NCT04704011|OTHER|Basic needs survey|11-item survey with questions regarding safety, housing, food, and financial needs
224032417|NCT04704011|OTHER|2-1-1 survey|This brief, 5-minute survey will be performed either in person or by phone after the participants arrive to their colposcopy appointment or after 6 weeks of their scheduled visit if they are nonadherent. The research team will ask patients regarding any changes in the status of their unmet basic needs (resolved, improved, worsened, or stayed the same) and how useful they found the 2-1-1 resource.
224298388|NCT03970486|PROCEDURE|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
223414712|NCT01985841|DRUG|Epirubicin|Farmorubicin
223414713|NCT01985841|DRUG|Cyclophosphamide|Endoxan
223414714|NCT01985841|DRUG|Docetaxel|Taxotere
223414715|NCT04557241|BEHAVIORAL|Brief informational infographic|The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).
223414716|NCT04557241|BEHAVIORAL|Placebo control (non-behavioral infographic)|"The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style."
223414717|NCT04008719|OTHER|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
223414718|NCT04008719|OTHER|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
223414719|NCT04008719|OTHER|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
223414720|NCT06221241|DRUG|JMKX000623|tablets for oral administration.
223414721|NCT06221241|DRUG|Pregabalin|capsules for oral administration.
223414722|NCT06221241|DRUG|Placebo|matched to JMKX000623 and Pregabalin
223414723|NCT04421287|DRUG|Zhenyuan capsule|0.25g/ tablets, 2 tablets / TID, for 12 weeks
223739007|NCT03022760|BEHAVIORAL|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
224032418|NCT04704011|OTHER|Usual Care Reminder Call|-Automated phone call two weeks before their colposcopy appointment
224032419|NCT02303691|BEHAVIORAL|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
224032420|NCT02303691|BEHAVIORAL|Neutral Training|A control version of computerized attention training.
224032421|NCT01813708|BEHAVIORAL|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
224299165|NCT02923674|BEHAVIORAL|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
223414724|NCT02216942|DRUG|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
223414725|NCT02216942|DRUG|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
223414726|NCT01006876|DRUG|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
223414727|NCT01006876|DRUG|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
223414728|NCT01006876|DRUG|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
223414729|NCT00018876|PROCEDURE|Lumbar nerve root decompression|
223414730|NCT00018876|PROCEDURE|Preoperative low-dose external beam radiation|
223414731|NCT02022280|DRUG|Lansoprazole|
223414732|NCT02022280|DRUG|Placebo|Vitamin pill
223414733|NCT05371015|PROCEDURE|quadratus lumborum nerve block (ropivacaine )|Echo guided quadratus lumborum nerve block with ropivacaine
223414734|NCT05371015|PROCEDURE|quadratus lumborum nerve block (normal saline)|Echo guided quadratus lumborum nerve block with normal saline
223414735|NCT02276989|DRUG|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only."
223739008|NCT00668486|DRUG|Lactic acid (Dermacid)|
223414736|NCT02276989|DRUG|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
223414737|NCT02276989|DRUG|Riboflavin|"All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
223414738|NCT01091662|DRUG|Eslicarbazepine acetate 1600 mg|1600 mg once per day
223560143|NCT07079566|BEHAVIORAL|Conventional Physiotherapy Treatment This reflects the standard care or routine treatment used as a comparison in your randomized controlled trial on plantar fasciitis. Let me know if your control gr|"The control group in this randomized controlled trial received standard conventional physiotherapy treatment for plantar fasciitis. This treatment protocol consisted of traditional evidence-based physiotherapy interventions commonly used in clinical practice. Participants received supervised sessions including static and dynamic stretching exercises targeting the plantar fascia, Achilles tendon, and calf muscles. In addition, the intervention included modalities such as cryotherapy (application of ice packs), ultrasound therapy for soft tissue healing, and patient education on activity modification, proper footwear, and home exercise programs.~The conventional treatment was administered for 3 sessions per week over a period of 3 weeks. Each session lasted approximately 30 to 40 minutes. The objective of this intervention was to reduce inflammation, relieve pain, and improve foot function through mechanical and thermal means, without involving neuromuscular reflex reprogramming. This a"
223560144|NCT07079384|OTHER|The patient will be instructed about wearing the prosthesis. First, seat the prosthesis in a posterior undercut, then rotate the prosthesis slightly superiorly in the defect area and engage the anteri|"* The obturator will then be printed using Denture Base Resin and teeth.~* The printed obturator will be tried in, two magnets, one anteriorly and another posteriorly will be picked up then inserted into the patient mouth.~* The patient will be again instructed regarding the care of the prosthesis and hygiene maintenance as formerly. The patient will also be instructed to wear the obturator plate first, and once this is comfortably seated, the denture part will be inserted. During removal, the patient will be instructed to first remove the denture part gently to disengage the magnetic attraction after the obturator part as formerly instructed. The patient will be recalle"
223560145|NCT07081581|DRUG|Bupivacain|In Group B( control group), bupivacaine was given as additional medication in the serratus block application.
223560146|NCT07081581|DRUG|Bupivacaine and Magnesium sulfate|In Group M, bupivacaine and magnesium were given as additional medication in the serratus block application.
223560147|NCT07081581|DRUG|Bupivacaine and Dexmedetomidine ile Blokaj|In Group D, bupivacaine and dexmedetomidine were given as additional medication in the serratus block application.
223560148|NCT07081295|OTHER|Injection of hypertonic saline|Injection 10 mL of 10% NaCl through central venous catheter
223560149|NCT07081412|DEVICE|Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a test device at 12 week and 12 month|"T-PTNS treatment will be performed at home with an external generator and two surface electrodes SmartUric medical device. Each T-PTNS session will consist of test and treatment sections. The treatment will be planned and carried out by researchers.~The treatment dose is 1 day/week, 30 minutes/session, totaling 12 sessions. Treatment Pulse Frequency: 20 Hz, Treatment Pulse Width: 200us (microsecond)."
224032422|NCT01813708|BEHAVIORAL|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
224032423|NCT04707651|DIETARY_SUPPLEMENT|Formula diet|Formula diet for 12 weeks
224032424|NCT02569203|DIETARY_SUPPLEMENT|standard enteral nutrition|standard enteral nutrition
224032425|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
223560150|NCT07081412|DEVICE|Efficacy of remotely monitored transcutaneous posterior tibial nerve neuromodulation via a placebo device at 12 week|These are devices that have the same physical appearance, interface and feedback features, but are prepared in a way that they will not provide electrical stimulation during the treatment session. They are delivered to the Contract Research Organization (CRO) by the project manager and are randomized through the CRO and given to the researchers with a code. The duration and frequency of treatment will be the same as the treatment group.
224032426|NCT02569203|DIETARY_SUPPLEMENT|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
223414739|NCT01091662|DRUG|Eslicarbazepine acetate 1200 mg|1200 once per day
224032427|NCT02784197|DEVICE|Phase Signal Recorder|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
224032428|NCT04200157|OTHER|Online survey|Subjects will complete a single survey that takes 5-10 minutes to complete
224032429|NCT00885651|DRUG|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
223414740|NCT04190940|BEHAVIORAL|Behavioral Assessment|"Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment."
223414741|NCT01532960|BIOLOGICAL|poly-ICLC|poly-ICLC
223414742|NCT01532960|BIOLOGICAL|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA \& CTA derived breast cancer proteins.
223414743|NCT01532960|BIOLOGICAL|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
223414744|NCT00758173|GENETIC|polymorphism analysis|
223414745|NCT00758173|OTHER|laboratory biomarker analysis|
224032430|NCT00885651|DRUG|Placebo|
224032431|NCT03931720|BIOLOGICAL|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
224032432|NCT03644407|OTHER|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
224032433|NCT00562211|DRUG|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
224032434|NCT00562211|DRUG|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
224032435|NCT00759291|DRUG|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
224032436|NCT00759291|DRUG|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
224032437|NCT05380492|BIOLOGICAL|VOY-101|Intravitreal injection of VOY-101
223414746|NCT00758173|OTHER|questionnaire administration|
223414747|NCT01329874|PROCEDURE|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
223414748|NCT01222520|DRUG|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
223414749|NCT01222520|DRUG|Telmisartan|80 mg once a daily
223414750|NCT04109391|BIOLOGICAL|TX05 (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
223560151|NCT07080814|DEVICE|Tecnobody ProKin Balance Training|Balance training using Tecnobody ProKin dynamometric platform, administered 5 sessions per week for 3 weeks in addition to standard rehabilitation.
223560152|NCT07080814|BEHAVIORAL|Standard rehabilitation|The standard rehabilitation protocol includes cold pack application to the knee region, transcutaneous electrical nerve stimulation (TENS), quadriceps muscle stimulation, knee stretching, active-assisted and active range of motion (ROM) exercises, strengthening exercises for the knee extensors and hip abductors/extensors, gait training, and balance exercises. Each patient will undergo a total of 15 physical therapy sessions.
223560153|NCT07080710|PROCEDURE|Immediate implant placement|Immediate implant placement with socket grafting and soft tissue augmentation. In cases with a buccal dehiscence \>3mm only this technique is applied. In cases with a buccal dehiscence between 4-6mm a collagen membrane is applied prior to socket grafting. In cases with a buccal dehiscence \> 6 mm, a collagen membrane is also applied and a mixture of C-DBBM and autogenous bone chips (1:1 ratio) is used as grafting material.
224032438|NCT06140043|OTHER|Patient consultation|Providing information about the current clinical problem of orthognatic surgery patients and the proposed treatment for it.
224032439|NCT04101708|DRUG|Lansoprazole, Amoxicillin|high dose dual regimen
224032440|NCT04101708|DRUG|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
224032441|NCT01918553|OTHER|clinical parameters|
224032442|NCT01918553|OTHER|visual acuity exams|
224032443|NCT01918553|OTHER|retinophotography|
223414751|NCT04109391|BIOLOGICAL|Herceptin (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
223560154|NCT03831295|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IT or IV
223414752|NCT05976269|DEVICE|Dry needling|Dry needling will be performed by licensed physical therapists who are formally trained in dry needling and meet all of the requirements of the state of Ohio and agree to participate as key personnel in this study. These therapists will receive specialized training in the study protocol including appropriate documentation, standardized dry needling technique/procedures, and study communication. Dry needling will be performed in a clean field using sterile acupuncture needles of appropriate length to pierce muscle bellies based on patient size and muscle mass.
223414753|NCT01661101|DRUG|Dabigatran|Dabigatran 110 mg taken twice daily
223560155|NCT03831295|DRUG|TLR9 Agonist SD-101|Given IT
224032444|NCT01918553|OTHER|SD-OCT|
224032445|NCT01918553|OTHER|Intra ocular Pressure (IOP)|
224032446|NCT01918553|OTHER|retinal imaging (OPTOMAP)|
224032447|NCT01918553|OTHER|axial length (IOL master)|
224032448|NCT01091753|DRUG|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
224032449|NCT02920333|PROCEDURE|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
224032450|NCT02920333|DEVICE|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
224032451|NCT02920333|DEVICE|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
224032452|NCT02920333|DEVICE|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
224032453|NCT03313921|DIAGNOSTIC_TEST|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
224136411|NCT03655717|DRUG|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
224136412|NCT03655717|DRUG|Placebo dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
224136413|NCT03655717|DRUG|Placebo ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
223414754|NCT01661101|DRUG|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
223414755|NCT01661101|DRUG|Omeprazole|Omeprazole 20 mg capsule taken once daily
224032454|NCT01871311|DRUG|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
224032455|NCT00482508|DRUG|Omalizumab|
223414756|NCT01661101|DRUG|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
223414757|NCT02975986|OTHER|123I-BMIPP|Uptake of radioactive isotope by the kidney
223414758|NCT02975986|OTHER|99mTc-MAG3|Uptake of radioactive isotope by the kidney
223414759|NCT02156908|DRUG|D-serine|D-serine 60 mg/kg
223414760|NCT03146455|OTHER|no intervention|no intervention
223414761|NCT06192381|OTHER|Web-Based Learning Module (WBL)|To ensure a uniform starting point, the participants were recruited via faculty website and students' academic counseling services. At the baseline, after the initial assessment, the participants were randomized at a 1:1 allocation ratio into the following groups: 1) traditional health education group (control group) (n = 68) who received health education with traditional face-to-face method; 2) web-based health education group (intervention group) (n = 68) who received health education with Web-Based Learning Module (WBL).
223414762|NCT00001741|DRUG|Losartan|
223414763|NCT05130541|BEHAVIORAL|Proning|Rotating on long axis 90 degrees every 30 minutes
223414764|NCT05130541|OTHER|Supportive Care|Usual Care
223414765|NCT04415034|OTHER|VAS and 5-D itch pruritus assessment|All subjects were evaluated for presence of pruritus using VAS and 5-D itch scale
223414766|NCT04685824|DEVICE|Biofeedback Training|Audiovisual stimulation
223414767|NCT04685824|DEVICE|Immersive Virtual-Reality|Audiovisual stimulation
223414768|NCT01089608|DRUG|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
223414769|NCT01089608|DRUG|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
223414770|NCT06185179|DRUG|Metformin|Metformin will be distributed in 500mg pills.
223414771|NCT06185179|OTHER|Placebo|Placebo will be distributed in pill form
223414772|NCT00599287|DRUG|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
223414773|NCT00599287|DRUG|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
223414774|NCT00599287|DRUG|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
223414775|NCT06194370|OTHER|Training by BOPPPS Teaching Model|Training by BOPPPS Teaching Model
223414776|NCT06194370|OTHER|Training Regularly|Training Regularly
224032456|NCT05708326|BEHAVIORAL|5:2 Method (intermittent fasting regimen)|"Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference."
224032457|NCT05708326|BEHAVIORAL|16/8 Method (intermittent fast regimen)|Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
224032458|NCT02580955|DEVICE|LEGFLOW DCB|
224032459|NCT02893930|DRUG|Sapanisertib|Given PO
224032460|NCT04988256|DRUG|Cyclosporine|"Patients randomized to cyclosporine will be treated as mentioned under Arm/Group Description"
224032461|NCT04988256|DRUG|Methylprednisolone and Prednisone|All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.
224032462|NCT02305537|BEHAVIORAL|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
223414777|NCT03320382|DEVICE|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
223414778|NCT00279682|BEHAVIORAL|treatment guidelines and depression care management|
223414779|NCT04109274|BEHAVIORAL|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
223414780|NCT04109274|BEHAVIORAL|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
224032463|NCT01137526|DRUG|ABT-384|Subjects will take study drug once daily for 12 weeks
224032464|NCT01137526|DRUG|donepezil|Subjects will take study drug once daily for 12 weeks.
224032465|NCT01137526|DRUG|placebo|Subjects will take study drug once daily for 12 weeks
224032466|NCT02349360|BIOLOGICAL|L. johnsonii N6.2|L. johnsonii N6.2 10\^10 CFU in capsule form administered for 8 weeks
224032467|NCT02349360|BIOLOGICAL|Placebo|Encapsulated starch placebo administered for 8 weeks
224032468|NCT00512304|PROCEDURE|association chemotherapy and radiochemotherapy|
223414781|NCT04109274|BEHAVIORAL|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
223414782|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
223414783|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
223414784|NCT01492374|DRUG|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
223414785|NCT01492374|DRUG|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
223414786|NCT03364374|BEHAVIORAL|Postural counseling|A therapist will provide verbal/physical cues to improve the participants posture
223414787|NCT05616351|OTHER|Data collection in patients with diabetic foot syndrome and infections in the area of the foot|Data collection: on (surgical and antibiotic) treatment and implementation of the recommendations published 2019 with regard to the duration of antibiotic therapy.
223414788|NCT06023446|DIAGNOSTIC_TEST|Optical Coherence Tomography|The retina is imaged using infrared light. Images collected in light are compared to those collected in darkness to extract information about function.
223414789|NCT06248372|OTHER|Exercise|Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
223414790|NCT06176404|DRUG|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with SGB, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for SGB. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223414791|NCT06176404|BEHAVIORAL|Rehabilitation therapy|"The study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided."
223414792|NCT05702801|DEVICE|Stochastic Vibratory Stimulation (SVS)|Investigators implement stochastic vibratory stimulation (SVS) to alter proprioceptive performance by increasing excitement of type Ia afferents in muscle spindles. Based on previous preliminary data, vibration frequencies around 40Hz may provide adequate noise for enhancing aging-related proprioceptive deficits. To make a subsensory noise investigators set it to 90% of the sensory threshold amplitude, which has been effectively used previously for influencing mechanoreceptor sensation in older adults. Stimulation will be imposed bilaterally on: 1) distal ankle (tibialis anterior, peroneus longus, soleus, gastrocnemius); and 2) proximal hip (quadriceps, gluteus medius, and paraspinals). Investigators use Gaussian noise to reduce the anticipative and preemptive adjustments of muscle spindles to the vibration. For SVS investigators use a magnetic actuator system and a Universal Controller (C-2HDLF Tactor/TDK), to provide programmable frequency ranges.
223414793|NCT03869840|DEVICE|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
223560156|NCT06895915|PROCEDURE|dynamic navigation surgery|immediate implant placement assisted by dynamic navigation
224032469|NCT02404207|OTHER|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
224032470|NCT02404207|OTHER|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
223414794|NCT03219840|DRUG|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
223414795|NCT03219840|DRUG|Xylitol only chewing gum|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
223414796|NCT00445172|DRUG|E0302 (mecobalamin)|Intramuscular injection, mecobalamin twice a week.
223414797|NCT03867812|OTHER|SOBAR|SOBAR is a high protein nutrition bar optimized to delay gastric emptying
223414798|NCT03867812|OTHER|Control food|Chexmix (General Mills Inc.), Honey Nut Flavor
223414799|NCT03867812|OTHER|Full meal|Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
223414800|NCT02710812|PROCEDURE|Local Excision or Wait-and-See|"Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~1. A gross margin of at least 0.5 cm;~2. full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~3. determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist."
223414801|NCT01160081|OTHER|Serum sample|Serum samples collected
223414802|NCT04920396|DEVICE|E>Eye IRPL|Regulated intense pulsed light therapy
223560157|NCT06895915|PROCEDURE|robotic surgery|immediate implant placement assisted by robotic surgery
223560158|NCT07079579|DRUG|Enarodustat 2mg|initial phase：2mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
223560159|NCT07079579|DRUG|Enarodustat 3mg|initial phase：3mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
223560160|NCT07079579|DRUG|Enarodustat 4mg|initial phase：4mg QD for 4 weeks subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
223414803|NCT04920396|DEVICE|Warm compress|Fabric mask with anti-bacterial coating filled with BodyBeads® heated in a microwave for 30 seconds before application over the eyes for 5 minutes
224032471|NCT02404207|OTHER|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
224032472|NCT02404207|OTHER|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
223414804|NCT06437795|DIAGNOSTIC_TEST|Dry Needling Group|Participants in this group will receive dry needling therapy. This involves inserting thin needles into trigger points in the piriformis muscle to relieve pain and muscle tension. The therapy will be administered twice a week for 4 weeks, with each session lasting approximately 30 minutes.
224032473|NCT02020629|DRUG|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
224032474|NCT04875741|OTHER|Neural mobilization|Mobilization of the structures within and around the nervous system is broadly known as Neural Mobilization.
223414805|NCT06437795|OTHER|Cupping Therapy Group|Participants in this group will receive cupping therapy. This involves placing cups on the skin to create suction, which is believed to improve blood flow and reduce muscle tension. The therapy will be administered twice a week for 4 weeks, with each session lasting approximately 30 minutes.
223414806|NCT00384839|DRUG|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
224136414|NCT01185249|PROCEDURE|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
224136415|NCT05896618|DEVICE|TPA|1\. Group I (TPA group).In which patients will receive Transpalatal arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
224136416|NCT05896618|DEVICE|Nance appliance|2\. Group II (Nance group).In which patients will receive Nance holding arch appliance as a space maintainer. Before treatment, dental cast will be made.Lateral cephalometric radiograph and extra-oral and intra-oral photographs will be taken for each patient. After 6 month follow up period, new cast will be made. New lateral cephalometric radiographs and new extra-oral and intra-oral photographs will be taken for each patient.
224032475|NCT04875741|OTHER|Muscle energy technique|Manual therapy technique initially developed and used by the osteopaths is known as Muscle energy techniques(MET).This technique is effective for the pain reduction, lengthening of the shortened muscle and fascia, improvement in blood circulation and promoting lymph drainage.
224032476|NCT01176773|DEVICE|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
224032477|NCT02626754|DRUG|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
224032478|NCT04250987|DEVICE|SpeediCath(R)|IC SpeediCath ® connected to pressure sensor
224136417|NCT03488121|BEHAVIORAL|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
224136418|NCT03488121|BEHAVIORAL|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
224136419|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
224136420|NCT00634959|DRUG|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
224136421|NCT00634959|DRUG|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
223414807|NCT06015074|DRUG|Propofol|patients in Propofol group receive sufentanil(0.1ug/kg)+ propofol (1.5-2mg/kg) for anesthesia induction, and continuous infusion of propofol 5mg/kg/h for anesthesia maintain.
223414808|NCT06015074|DRUG|Ciprofol|patients in Ciprofol group receive sufentanil(0.1ug/kg)+ ciprofol(0.4-0.5mg/kg) for anesthesia induction, and continuous infusion of ciprofol 0.8mg/kg/h for anesthesia maintain.
223414809|NCT01262157|DEVICE|Extracorporeal Shockwave Therapy Generator (Vascuspec)|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
223414810|NCT01262157|DEVICE|Low intensity shock wave therapy|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
223414811|NCT06264102|OTHER|Physical exercise program|"Training sessions took place twice a week for 45 minutes each over a period of 12 weeks. Each training included rhythmic exercises using the Jaques-Dalcroze Eurhythmics (JDE) method with piano accompaniment and electronically played music. Training sessions were conducted by a JDE specialist.~Exercises with the use of this method consist mainly in the repetition of preset musical sequences using body movements. In addition to the physical layer, the cognitive layer was equally important: while performing a given movement exercise, participants often had to focus in order to react appropriately to additional tasks, such as changes in sound pitch and rhythm of the piece."
223414812|NCT04728048|PROCEDURE|Dural puncture epidural|already described
223414813|NCT04728048|PROCEDURE|Standard epidural|already described
223414814|NCT03054155|DEVICE|Alexandrite Laser|Alexandrite 755nm hair removal laser
224032479|NCT00004253|DRUG|carboplatin|
224032480|NCT00004253|DRUG|paclitaxel|
224032481|NCT00004253|RADIATION|radiation therapy|
224032482|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 soft gelatine capsules|
224136422|NCT00634959|DRUG|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
224032483|NCT02183285|DIETARY_SUPPLEMENT|Pharmaton PHL 00747 film-coated tablets|
224032484|NCT02183285|DIETARY_SUPPLEMENT|Placebo film-coated tablets (fct)|
224136423|NCT00634959|OTHER|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
224136424|NCT05518175|DEVICE|Traditional laparoscopy|Utilizes three or four 5 mm ports for access and retrieval.
224136425|NCT05518175|DEVICE|Single site laparoscopy|One port is placed via a 2 to 3 cm umbilical/fascia incision to accommodate the Gelpoint device, where several laparoscopic instruments are used. With this technique, there is a single incision, hidden in the umbilicus a
224032485|NCT02183285|DIETARY_SUPPLEMENT|Placebo soft gelatine capsules|
224032486|NCT00118820|DRUG|IV Preoperative antibiotic or placebo|
224032487|NCT02919657|DIETARY_SUPPLEMENT|Genepro Protein|weekly blood draws to measure blood protein levels
224032488|NCT02919657|DIETARY_SUPPLEMENT|Whey Protein|weekly blood draws to measure blood protein levels
224136426|NCT05518175|DEVICE|V-Notes surgery|One port placed trans-vaginally via a 2-3 cm vaginal incision with no abdominal scars
223414815|NCT06387212|DRUG|35 kDa hyaluronan fragment HA35 injection|First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
223414816|NCT04767555|PROCEDURE|ILM (inner limiting membrane) peeling|The standard technique for the removal of the inner limiting membrane is a dye-assisted ILM peeling established since 20 years as the standard of care to treat vision loss due to epiretinal membranes or macular holes in eyes with an otherwise stable retina, but not during retinal detachment surgery. Other dyes may show a stronger staining effect but since there is evidence of a potential toxicity of ICG the investigators use the well-tolerated and for this purpose approved trypan blue dye Membrane Blue ® (Dorc). This intervention will be performed in addition to standard vitreoretinal re-attachment surgery.
223414817|NCT06575114|OTHER|Self-determination theory-based health education measures|In the control group, a conventional intervention will be used, and health education brochures on the COVID-19 vaccine will be distributed for the study participants to read on their own time. The intervention group will receive self-determination theory-based interventions, with targete interventions proposed based on the self-determination theory-including health-related talks and sharing sessions. To ensure that older individuals with varying levels of literacy understood the intervention, the process will be conducted in the local native dialect.
223414818|NCT06524934|DEVICE|Use of virtual reality during the hysteroscopic procedure|In VR group patients underwent hysteroscopy with standard care but the addition of VRT provided by a VR headset and headphones with the use of a Hypno VR software.
223560161|NCT00911196|OTHER|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
224032489|NCT02854293|OTHER|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
224032490|NCT01614743|DRUG|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
224032491|NCT01614743|DRUG|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
224032492|NCT00604812|DRUG|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
224032493|NCT00604812|DRUG|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
224032494|NCT00604812|DRUG|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
224032495|NCT00604812|DRUG|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
224032496|NCT02729389|BEHAVIORAL|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
224032497|NCT02729389|BEHAVIORAL|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
224032498|NCT06134206|DIAGNOSTIC_TEST|Trans-burr hole ultrasound|All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
224032499|NCT00652860|BIOLOGICAL|aerosol sargramostim|
223414819|NCT03854825|PROCEDURE|Cardiac surgery|
223414820|NCT05423535|DEVICE|test group: collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland)|Following tooth extraction and wound debridement, the alveolar socket was filled with collagen-enriched deproteinized bovine bone mineral (C-DBBM, Bio-Oss Collagen® 100 mg or 250 mg, Geistlich Pharma AG, Wolhusen, Switzerland) up to the level of the oral bone crest. Subsequently, a collagen matrix (Mucograft Seal®, Geistlich Pharma AG, Wolhusen, Switzerland) or gelatin spons (Spongostan Dental® 1x1x1 cm, Ethicon, Johnson \& Johnson, New Brunswick, VS) was sutured on top with 4 to 6 single sutures (Seralon 6/0, Serag Weissner, Naila, Germany) to protect the underlying C-DBBM.
223414821|NCT03507322|OTHER|Ultrasound texturization|Along several visits to the clinic, the patients will be subjected to 2D/3D ultrasound scanning.
223414822|NCT06383897|DRUG|HS-10398|SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction
224032500|NCT00652860|BIOLOGICAL|sargramostim|
224032501|NCT00652860|DRUG|cisplatin|
224032502|NCT00652860|DRUG|doxorubicin hydrochloride|
224032503|NCT00652860|DRUG|ifosfamide|
224032504|NCT00652860|DRUG|mitomycin C|
224032505|NCT00652860|OTHER|flow cytometry|
224032506|NCT00652860|OTHER|immunological diagnostic method|
224032507|NCT00652860|OTHER|laboratory biomarker analysis|
224032508|NCT00652860|PROCEDURE|adjuvant therapy|
224032509|NCT00652860|PROCEDURE|multimodality therapy|
224032510|NCT00652860|PROCEDURE|neoadjuvant therapy|
224032511|NCT00652860|PROCEDURE|therapeutic conventional surgery|
224032512|NCT00652860|RADIATION|intraoperative radiation therapy|
224032513|NCT00652860|RADIATION|selective external radiation therapy|
224136427|NCT02470052|DEVICE|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
224032514|NCT01603329|OTHER|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
224136428|NCT03521193|DEVICE|patent foramen ovale closure|Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
224136429|NCT04452227|OTHER|questionnaire|Filling the menstrual distress questionnaire, short-form McGill pain questionnaire, present pain index, visual analog scale
223414823|NCT06383897|DRUG|HS-10398 Placebo|SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
223414824|NCT00280397|DRUG|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
223414825|NCT04821609|BEHAVIORAL|Resistance Training|The resistance training will be for arms and legs, self-loading type, and external weights.
223414826|NCT04517201|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
223414827|NCT04517201|DRUG|Physician based insulin regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
223414828|NCT04727060|DEVICE|patient with knee arthroplasty|
223414829|NCT03033862|DEVICE|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
223414830|NCT03033862|DEVICE|Drug Eluting Stent|Drug Eluting Stent
223414831|NCT00665262|DRUG|tramacet|2 tablets every 6 hours for 5 days
223414832|NCT05012722|DIAGNOSTIC_TEST|Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement|All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.
223414833|NCT06348030|DEVICE|Medtronic Signia Stapler|The Signia Stapler is a powered stapler that can be used for tissue dissection and vessel sealing during surgery.
223414834|NCT06348030|DEVICE|Vessel Sealer Extend Energy Device and SureForm Stapler|The Vessel Sealer Extend Energy Device is integrated with the da Vinci system and uses bipolar energy technology to facilitate tissue dissection and vessel sealing.
223414835|NCT02283996|OTHER|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients\_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
223414836|NCT02283996|DRUG|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
223560162|NCT07079722|BEHAVIORAL|Exercise|This project is a randomized controlled trial (RCT) with three distinct groups: a control group (CG), an online intervention group (OIG), and an in-person intervention group (IIG). The OIG will receive online educational sessions and structured home-based exercises, while the IIG will participate in in-person educational sessions and supervised physical exercise. The control group will not participate in educational sessions or structured physical exercise.
223560163|NCT03088930|DRUG|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
223414837|NCT01892410|OTHER|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
223560164|NCT06907888|DEVICE|Rhythm Express Wearable System|The Rhythm Express Wearable System consists of the FDA-cleared RX-1 mini Cardiac Monitor, an FDA-cleared pulse oximeter, and a cellular gateway to relay data from the pulse oximeter to the cloud-based RS-1 Server. The RS-1 Sleep Algorithm is a cloud-based software as a medical device (SWMD) that receives inputs from the two FDA-cleared wearable devices. The Algorithm, together with the two wearable devices, comprises the Rhythm Express Wearable System.
223560165|NCT06906549|DRUG|Rituximab 200mg/6months|perfusion of Rituximab 200mg
223560166|NCT06906549|DRUG|Rituximab 1g/6months|perfusion of Rituximab 1g
224136430|NCT01471704|DRUG|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
224136431|NCT01471704|DRUG|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
224136432|NCT01471704|DRUG|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
223414838|NCT06244550|DRUG|Ganwei|Capsules
223414839|NCT06244550|DRUG|Metformin|Tablets
223414840|NCT06244550|DRUG|Placebo|Matching capsules
223414841|NCT02337439|BEHAVIORAL|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
223414842|NCT02337439|BEHAVIORAL|Active Control Training|Commercially available educational software
223414843|NCT02696538|OTHER|Functional Gait Assessment|Balance assessment
223414844|NCT02696538|OTHER|mini-Balance Evaluation Systems Test|Balance assessment
224032515|NCT04384848|OTHER|EMPATHY Pilot|The goal of this pilot is to develop and pilot a tailored monitoring intervention targeting symptomatic, Patient-reported adverse events (AEs) in chronic myeloid leukemia (CML) Patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy. The tailored monitoring intervention will draw primarily from the PRO-CTCAE Item Library, with additional items drawn from the FACIT and EORTC Item libraries as necessary. After identifying the full set of AEs to be monitored, we will load the Patient assessment and report program into tablets for electronic administration in the busy clinic setting. We will then pilot a six-month intervention aimed to monitor and manage emerging AEs, coupled with assessment of intervention feasibility, Patient acceptability and satisfaction, provider acceptability and clinical management utility, adherence to TKI therapy, and HRQoL. We expect that adherence to therapy, clinical response, and HRQoL will be enhanced by such an intervention.
224032516|NCT00604864|DRUG|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
224032517|NCT00604864|DRUG|placebo|Placebo
224032518|NCT03392025|OTHER|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
224032519|NCT03392025|OTHER|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
224032520|NCT03392025|DIETARY_SUPPLEMENT|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
223414845|NCT02696538|OTHER|Berg Balance Scale|Balance assessment
223414846|NCT05938764|BEHAVIORAL|MICRA|see earlier description
223414847|NCT05938764|BEHAVIORAL|TAU|see earlier description
223560167|NCT04183465|OTHER|Health Education|Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients
224032521|NCT01640275|DRUG|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
224032522|NCT01640275|DRUG|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
224032523|NCT02318823|OTHER|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
224136433|NCT04363437|DRUG|Colchicine|People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.
224136434|NCT04363437|DRUG|Usual Care|COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
224136435|NCT00422409|PROCEDURE|Endoscopic stenting|
223414848|NCT03757728|PROCEDURE|Haemorrhoidectomy operations|for treatment of symptomatic 2 to 3 degree haemorrhoids
223414849|NCT06389760|DRUG|Nimotuzumab|When combined with the mFOLFIRINOX regimen, nimotuzumab (nimo) will be administered at a dose of 400mg on Day 1 and 15 of a 28-day cycle (6 cycles). When combined with the GX regimen, nimotuzumab will be given at 400mg on Day 1 and 8 of a 21-day cycle (8 cycles).
223414850|NCT06389760|DRUG|mFOLFIRINOX|Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).
223414851|NCT06389760|DRUG|GX|Patients will receive GX regimen as follows: Gemcitabine 1000 mg/m2 on Day 1 and 8 of a 21-day cycle; capecitabine 2000 mg/m2 on d1-14 a 21-day cycle(8 cycles).
223414852|NCT05485168|OTHER|Sequential Variety|3 different foods served in 3 successive courses
223414853|NCT05485168|OTHER|Single-Food|1 food served in 3 successive courses
223414854|NCT05485168|OTHER|Small Portion|Small meal portion size
223414855|NCT05485168|OTHER|Large Portion|Large meal portion size
223414856|NCT03562208|BIOLOGICAL|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
223414857|NCT02112630|DRUG|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
223414858|NCT02112630|DRUG|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
223414859|NCT02112630|DRUG|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
223414860|NCT02112630|DRUG|Boceprevir|800 mg PO three times daily starting at week 4
224032524|NCT02318823|OTHER|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
224032525|NCT01658098|BEHAVIORAL|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
223414861|NCT04150744|COMBINATION_PRODUCT|radiofrequency ablation|take advantage of RFA to destroy hepatocellular carcinoma by high temperature
223414862|NCT04144543|OTHER|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
224032526|NCT05127369|DRUG|Dental pulp mesenchymal cell injection|Dental pulp mesenchymal cell injection was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
224136436|NCT03329651|DRUG|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
224136437|NCT03329651|DRUG|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
224136438|NCT00406783|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
224136439|NCT00406783|DRUG|Placebo|Placebo tablet, once daily for 15 days
224136440|NCT03030911|DRUG|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
223414863|NCT04144543|OTHER|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
223414864|NCT04144543|OTHER|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
223414865|NCT02587390|DRUG|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
223414866|NCT02587390|DRUG|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
223414867|NCT03137472|DEVICE|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
223414868|NCT06413901|PROCEDURE|TIP|TIP hypospadias repair
223414869|NCT02257489|DRUG|ACE-083|recombinant fusion protein
224032527|NCT05127369|DRUG|Dental pulp mesenchymal cell vehicle|Dental pulp mesenchymal cell vehicle was administered intravenously on D1, D15 (2 weeks), D29 (4 weeks) and d43 (6 weeks); Fluoxetine hydrochloride capsule / simulant was administered orally daily.
224032528|NCT05127369|DRUG|fluoxetine hydrochloride capsule|fluoxetine hydrochloride capsule
224032529|NCT03124095|BEHAVIORAL|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
224032530|NCT02655302|OTHER|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
224032531|NCT02655302|OTHER|Lung function measure|Measure lung function and follow it during 4 years
224032532|NCT04644458|OTHER|Measuring the ulna length using meauring tape|the left ulna will be measured with a measure tape from the olecranon to mid point of styloid process.
223414870|NCT03239860|DRUG|GNbAC1 Monoclonal Antibody|Monthly IV
223414871|NCT04606394|DRUG|Trelegy Ellipta 100/62.5/25Mcg Inh 30D|Administration of Trelegy in all patients
223414872|NCT04606394|DRUG|Ventolin 90Mcg/Actuation Inhalation Aerosol|2 hours after the administration of Trelegy, administer Ventolin in all patients
223414873|NCT03095560|DEVICE|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
223414874|NCT06683326|DEVICE|ROKOKO smart-glove|ESD expert hands and fingers motion broadcasted by the ROKOKO smart-glove to trainees
223414875|NCT05040204|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
223414876|NCT05040204|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo (glucose powder)
224032533|NCT01118611|DRUG|Aurora B/C kinase inhibitor GSK1070916A|
224032534|NCT01118611|OTHER|laboratory biomarker analysis|
224032535|NCT01118611|OTHER|pharmacological study|
224032536|NCT01118611|PROCEDURE|diffusion-weighted magnetic resonance imaging + PET CT|
224032537|NCT01118611|RADIATION|fludeoxyglucose F 18 dynomic contrast|
223414877|NCT03397368|DIAGNOSTIC_TEST|Transperineal Ultrasound -|Every women with stress incontinence witll be subjected to urodynamics to confirm genuine stress incontinence then will be subjected Transperineal US
223414878|NCT06968247|PROCEDURE|PROMise Model of Care|Patients will go for blood tests and be sent PROMs questionnaire prior to planned clinic appointments. The results of the blood tests and questionnaire will be reviewed by a physician. The physician will postpone patient's appointment if the patient is assessed as stable. Any physician-endorsed medication will be sent via a medication delivery service.
224032538|NCT03916848|PROCEDURE|Combined Micro-Macro SEEG Electrodes|The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
224032539|NCT00730834|DEVICE|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
223414879|NCT01231724|DEVICE|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
223414880|NCT01231724|DEVICE|Placebo Nasal Spray|2 sprays in each nostril
223414881|NCT02827825|OTHER|No intervention|No intervention. It's a study on retrospective Data
224032540|NCT02582723|OTHER|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
224136441|NCT03030911|DRUG|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
224136442|NCT03030911|DRUG|Fentanyl|The drug will be administered in both groups
224136443|NCT03030911|DEVICE|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
224136444|NCT03360539|BEHAVIORAL|Nurse-Family Partnership|
224032541|NCT02582723|OTHER|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
224032542|NCT02582723|OTHER|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
224136445|NCT06553430|BEHAVIORAL|aerobics exercises|Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
223414882|NCT05040425|DRUG|Zi-Yin-Liang-Ge-San|Zi-Yin-Liang-Ge-San is composed of five herb ingredients, namely Rx. Scutellariae (Huang Qin), Rx. Glycyrrhizae (Gan Cao), Hb. Dendrobii (Shi Hu), Rx. Ophiopogonis (Mai Men Dong), and Hb. Menthae Haplocalycis (Bo He). It is orally administrated trice daily from the first day to the end of RT in the treatment group, aiming to prevent and manage the OM. ZYLGS is manufactured as a concentrated herbal extract, constituted 4 g per packet, and origin from pharmaceutical companies in Taiwan with good manufacturing practice (GMP).
223414883|NCT05171036|OTHER|Adapted Physical Activity|"* Group 1 Maintenance of autonomy: Patients in group 1 have no cardiovascular disorders, possibly some cognitive deficits but do not reside in a protected unit.~* Group 2 Prevention of the risk of falls: Patients in group 2 have no cardiovascular problems, possibly some cognitive problems, but can finally follow the indications of the cognitive assessment in the form developped for the study.~* Group 3 Prevention of the risk of falls and monitoring of cardiovascular disorders in the absence of cognitive impairment: Patients in group 3 have had a recent, and currently stabilised, cardiovascular event that may justify exercise reconditioning.~* Group 4 Prevention of the risk of falls and disorientation in a context of cognitive deficit: Patients in group 4 have moderate to severe cognitive disorders, or have Alzheimer's disease or a related disease at a stage of the disease requiring special attention."
223414884|NCT00002943|DRUG|carboplatin|
223414885|NCT00002943|DRUG|cyclophosphamide|
224298389|NCT01787539|DRUG|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
223414886|NCT00002943|DRUG|etoposide|
223414887|NCT00002943|PROCEDURE|autologous bone marrow transplantation|
223414888|NCT06966219|OTHER|Intracytoplasmic sperm injection|• All patients will commence controlled ovarian hyperstimulation (COH) on day 2 or 3 of their menstrual cycle. The initial treatment will be a daily administration of either highly purified human menopausal gonadotropin (hMG) or recombinant FSH (rFSH, Gonal-F 150 IU, Merck Serono, S.P.A, Italy) administered subcutaneously and intramuscularly for a duration of 10-12 days. The treatment will be continued until the final oocyte maturation. The starting dosage will be tailored based on the patient's age, antral follicle count (AFC), body mass index (BMI), serum FSH and AMH levels on days 2-3, as well as the patient's previous response to COH.
223414889|NCT04485325|DRUG|Tofacitinib|5 mg twice daily, p.o.
223414890|NCT04485325|BIOLOGICAL|Etanercept|50 mg once per week, s.c.
223414891|NCT05272293|BIOLOGICAL|NK cell infusions|Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
223414892|NCT06968143|DEVICE|Smart Knee Implant|"An important advancement in objective recovery data occurred when the first ever 'smart' knee implant for remote therapeutic monitoring (RTM) after total knee arthroplasty (TKA) was released in 2021. The implant includes both a prosthesis for TKA and a stem, the latter of which records the following metrics: step count, distance traveled, tibial range-of-motion (ROM), functional ROM, average walking speed, stride length, and cadence. The implant sends the recordings to a mobile platform. Additionally, it collects and analyzes patient across the entire population of users and creates percentiles for each metric based on patient age, gender and time since surgery. These recovery curves provide more objective data for practitioners and patients to evaluate recovery progress and make adjustments to their care plans accordingly."
223414893|NCT06967233|OTHER|Multimodal treatment|Surgical resection, locoregional liver-directed treatments and continuous systemic treatment in patients with liver metastatic pancreatic cancer
223414894|NCT05263271|DRUG|Gentulizumab|Gentulizumab will be administered by intravenous infusion once a week, with every 28 days as a dosing cycle .
224032543|NCT00079742|DRUG|Nutropin AQ [somatropin (DNA origin) injection]|
224032544|NCT00472329|PROCEDURE|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
224032545|NCT00472329|DRUG|fludarabine|
224298390|NCT01939925|OTHER|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
224032546|NCT00472329|PROCEDURE|TBI|
224032547|NCT05422287|OTHER|Virtual Reality Glasses|Group 1
224032548|NCT05422287|OTHER|Thermomechanical Stimulation Device|Group 2
224032549|NCT02727166|DIETARY_SUPPLEMENT|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
224032550|NCT02727166|DIETARY_SUPPLEMENT|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
224032551|NCT03661164|PROCEDURE|corneal cross linking|Iontophoretic corneal cross linking
224032552|NCT03478163|DRUG|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
224032553|NCT03478163|DRUG|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
224032554|NCT02018835|DEVICE|MRI|
224032555|NCT02018835|DEVICE|cardiac echography transthoracic|
224136446|NCT00012012|DRUG|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
224136447|NCT00012012|DRUG|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
224136448|NCT00012012|RADIATION|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
223414895|NCT01797861|PROCEDURE|Half-dose photodynamic therapy (PDT)|"At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds."
223560168|NCT04183465|OTHER|Multi-domain lifestyle intervention|The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members.
223560169|NCT06827886|BIOLOGICAL|GCAR1|GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor (CAR) that enables the specific targeting towards tumor cells expressing the cell surface protein glycoprotein non-metastatic B (GPNMB).
223560170|NCT06305793|DRUG|IVIG (intravenous immunoglobulin)|Participants will receive IVIG for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months).
223560171|NCT06305793|DRUG|IVIG Placebo|"Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo.~Participants will receive placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months)."
223560172|NCT06305793|BEHAVIORAL|Coordinated Care|Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
223560173|NCT06305793|BEHAVIORAL|Usual Care|Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with IVIG administration.
223560174|NCT04488159|DRUG|Capecitabine|Tablet
223560175|NCT04488159|DRUG|Oxaliplatin|Infusion
223560176|NCT04488159|DRUG|Fluorouracil|Infusion
223560177|NCT04488159|DRUG|Leucovorin|Infusion
223560178|NCT04488159|DEVICE|Immunoscore® assay|Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin
223560179|NCT04488159|OTHER|Physical exercise|Increasing stair walking exercise twice a week over 12 weeks total.
223560180|NCT04884490|DRUG|Co-trimoxazole|Tab. Co-trimoxazole 960 mg (trimethoprim 160mg + sulphamethoxazole 800mg) thrice (8 hourly) daily for 7 days orally.
223560181|NCT04884490|DRUG|Placebo|Placebo thrice (8 hourly) daily for 7 days orally.
223560182|NCT04058808|OTHER|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
223560183|NCT04058808|OTHER|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
223560184|NCT04058808|OTHER|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
223560185|NCT04058808|OTHER|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
223560186|NCT04058808|OTHER|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
224032556|NCT04581616|PROCEDURE|Intrathoracic Intercostal Nerve Block|Injection of local anesthetic into the subcostal groove, to achieve analgesia for chest region.
224032557|NCT04581616|PROCEDURE|Erector Spinae Plane Block|Injection of local anesthetic in the plane deep to the erector spinae muscles and superficial to the transverse processes, to achieve analgesia for chest region.
224032558|NCT00056355|DRUG|UVADEX and UVAR XTS Photopheresis System|
224032559|NCT00261001|BIOLOGICAL|Transcutaneous mode of administration|
224032560|NCT00261001|BIOLOGICAL|Intramuscular mode of administration|
224032561|NCT02422251|DEVICE|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
224032562|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
224032563|NCT02422251|DEVICE|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
224136449|NCT00012012|RADIATION|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
223414896|NCT01797861|PROCEDURE|Micropulse laser (ML) treatment|"The following ML treatment settings will be used: a power of 1800 mW\*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~\* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area."
223414897|NCT00224328|DEVICE|ODISsey Tissue Oximeter|
223414898|NCT05007028|DRUG|EMONO|Exposure to 1 hour of EMONO via facial mask
223414899|NCT05007028|DRUG|Medical Air|Exposure to 1 hour of Medical Air via facial mask
223414900|NCT06349993|BEHAVIORAL|Digital Intervention|game-based digital intervention app
223414901|NCT06349993|BEHAVIORAL|Health Education|traditional health education app
223414902|NCT04545151|DRUG|Verapamil SR 120 mg|"For use as a test product in this blinded study, the IMP will be modified by re-packaging. The film-coated tablets will be squeezed from their blisters and filled into HDPE Twist-Off bottles. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
223414903|NCT04545151|DRUG|Placebo|"The matching placebo will be filled into HDPE Twist-Off bottles, in the same way as the verum. Each bottle will be labeled as required per country requirement. Labels will be blinded.~Drug administration:~* from Day 0 to Week 4: 120 mg once daily~* from Week 4 to Week 8: 240 mg once daily~* from Week 8 to Month 12: 360 mg once daily"
223414904|NCT00066794|BIOLOGICAL|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
223414905|NCT00066794|BIOLOGICAL|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
223414906|NCT00066794|DRUG|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
223414907|NCT00066794|DRUG|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
223414908|NCT00066794|DRUG|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
223414909|NCT05348291|DEVICE|ventilation tubes|Transtympanic pressure equalising devices.
223414910|NCT04203602|PROCEDURE|telepresence discharge|Patients will be seen during ward rounds by the multidisciplinary team physically present, but with the surgeon remotely present via a telepresence robot.
223414911|NCT04203602|OTHER|Conventional discharge|Patients will be seen during ward rounds by the whole multidisciplinary team physically present, including the surgeon.
223414912|NCT05984940|DEVICE|Ortho MTA cement|Ortho MTA has a fine granularity for only 2 microns. It penetrates into dental tubules and fuses itself to the surface where it is applied. In addition, it prevents micro-leakage by forming an interfacing layer of hydroxyapatite (Hap) between the OrthoMTA and the canal wall.
223560187|NCT04058808|OTHER|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
224032564|NCT05615532|DRUG|LY3209590 (SC)|Administered SC.
224032565|NCT05615532|DRUG|LY3209590 (IV)|Administered IV.
224032566|NCT01762722|DEVICE|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
224032567|NCT05572333|DRUG|EP395|Capsule for oral use
223414913|NCT05984940|DEVICE|GP and AH Plus sealer|AH Plus Sealer is a calcium silicate-based root canal sealer. Tricalcium Silicate interacts with body fluids to release calcium and hydroxide ions that promote hydroxyapatite (HA) formation.
223414914|NCT05633940|BEHAVIORAL|Implementation of the service delivery model primary care behavioral health|The research project will study a real-world implementation of PCBH in routine primary care. The implementation is facilitated by a regional implementation group of psychologists with special training in PCBH. The active implementation period for each intervention center is 12 months, where continuous support, materials and training are offered by the implementation group.
223414915|NCT00955955|OTHER|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
223414916|NCT00955955|OTHER|Placebo|Inactive substance
223414917|NCT03265951|DRUG|Ramelteon|8 mg once daily administered within 30 minutes of bedtime
223414918|NCT03265951|OTHER|Usual Care|education brochure about sleep hygiene
223560188|NCT03970174|OTHER|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
223414919|NCT01385969|DEVICE|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
223414920|NCT01385969|DEVICE|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
223560189|NCT00161577|DRUG|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
224032568|NCT05572333|DRUG|Placebo|Capsule for oral use
224032569|NCT00126022|DRUG|Tedisamil sesquifumarate|
224032570|NCT00577161|DRUG|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
224032571|NCT00577161|DRUG|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
224032572|NCT02624323|PROCEDURE|Real-time ultrasound-guided central vein catheterization.|
224298391|NCT01939925|OTHER|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
223414921|NCT01385969|DEVICE|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
223414922|NCT01452893|PROCEDURE|Spiroergometry|"At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP)."
223414923|NCT04046770|DEVICE|Drug administration and Flushing procedure using Double-Chamber Syringe|The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
223414924|NCT04046770|DEVICE|Drug administration and Flushing procedure using Classic Syringe|To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
223414925|NCT03973411|DRUG|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
223414926|NCT03973411|DRUG|Placebo|Pacients will receibe standard spinal anesthesia
223560190|NCT00161577|OTHER|Placebo|Placebo Comparator
223560191|NCT00994734|DRUG|Mifepristone|home administration of mifepristone
223560192|NCT06489704|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
223414927|NCT06501378|DRUG|PD-1/PD-L1 inhibitor plus chemotherapy|Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.
223560193|NCT05409859|OTHER|Manual therapies|Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
223560194|NCT02658747|OTHER|No intervention|No intervention administered in this study
223414928|NCT06501378|RADIATION|SRT/WBRT|Active brain metastases (BM) patients will receive stereotactic radiotherapy (SRT) and whole brain radiation therapy (WBRT) according to their BM condition.
224136450|NCT03069846|DEVICE|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
223414929|NCT03216005|DEVICE|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
223560195|NCT05386719|OTHER|Prescreening|Eligible patients (history of early stage breast cancer and at least 3 months from completion of local and systemic therapy at Johns Hopkins, reads and speaks English) complete survey for demographics, smoking status \& questions about cardiovascular disease.
223560196|NCT05386719|OTHER|Screening and Enrollment|Consent
223560197|NCT05386719|BEHAVIORAL|Baseline|Behavioral Battery and Patient Reported Outcome Quality of Life questionnaires (EORTC QLQ-C30 and QLQ-BR23) Labs (Hba1c + lipid panel if not done within 12 months or if abnormal within 1 year) Abstract vitals from chart review
223560198|NCT05386719|BEHAVIORAL|Interpret BMI|Refer to Healthful Eating, Activity and Weight Program (HEAWP) if BMI ≥25 and not already on lifestyle intervention
223560199|NCT05386719|OTHER|Interpret HbA1c|"HbA1c results categorized as follows:~HbA1c \<5.7%; HbA1c 5.7-6.4%; HbA1c 6.5%+; or Known diabetic on medication"
224032573|NCT01644344|OTHER|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
224032574|NCT01644344|OTHER|Xray|
224136451|NCT04785391|DIAGNOSTIC_TEST|Urine collection for NEPHROCLEAR CCL14 Test|Urine will be collected and banked for future analysis with the NEPHROCLEAR CCL14 Test
223414930|NCT03703583|OTHER|There is no intervention in this observational study.|There is no intervention in this observational study.
224136452|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
223414931|NCT03423173|BIOLOGICAL|TAK-003|TDV subcutaneous injection
223414932|NCT03423173|BIOLOGICAL|Placebo|TDV Placebo-matching normal saline (0.9% NaCl) subcutaneous injection
223414933|NCT03229863|OTHER|Sweet Potatos|Plum Organics, Just Sweet Potato
223414934|NCT03229863|OTHER|Pears|Earth's Best, First Pears
223560200|NCT05386719|OTHER|Interpret lipid panel and assess other risk factors|"Based on above categories:~HbA1c \<5.7%: Any of these cardiovascular disease risk factors: current/former tobacco use, total cholesterol \>200, family history of Coronary Artery Disease/Heart Attack in first degree family \<55 year old male or \<65 year old female, systolic blood pressure \>130 HbA1c 5.7-6.4%: Refer to Primary Care Provider and consider Healthful Eating, Activity and Weight Program (HEAWP) HbA1c 6.5%+: Refer to Endocrinology if HbA1c ≥8% Known diabetic on medication: Refer to Endocrinology if HbA1c ≥7%"
223560201|NCT05386719|BEHAVIORAL|Assess 10 year risk of cardiovascular event|If risk factors are present - refer to Cardiovascular Disease Prevention Program
223560202|NCT05386719|BEHAVIORAL|Recommendations|Provide individual patient handout based on all above interventions
223560203|NCT05386719|BEHAVIORAL|Follow-Up|6 and 12 month labs (if prior abnormal) and Patient Reported Outcome questionnaires
223560204|NCT05873192|DRUG|ADT|Given by PO
223560205|NCT05873192|DRUG|Enzalutamide|Given by PO
223560206|NCT05873192|DRUG|Talazoparib|Given by PO
223560207|NCT05873192|DRUG|Degarelix|Given PO or given INJ
224032575|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream low-dose|travoprost ophthalmic topical cream low-dose once daily in the evening to both eyes
223414935|NCT03000426|PROCEDURE|Free gingival graft|Free gingival graft removal from palate for socket preservation
223414936|NCT03000426|DEVICE|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
223414937|NCT00887848|OTHER|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
223414938|NCT05934604|OTHER|Functional magnetic resonance imaging (fMRI)|Healthy subjects will complete two fMRI sessions after initial assessment and training in the Rest Focus Task (RFT). The first session will be the localizer session to identify the networks involved in switching in the RFT. The second fMRI session, real time functional magnetic resonance imaging neurofeedback (rtfMRI-NF) session, will use localizer information from the first fMRI session to develop a mask for the rtfMRI-NF, and deliver a neurofeedback (NF) stimulus while simultaneously measuring Blood Oxygenation Level Dependent (BOLD) activity for the STOP\>RECALL contrast.
223414939|NCT00894608|DRUG|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
224032576|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream mid-dose|travoprost ophthalmic topical cream mid-dose once daily in the evening to both eyes
224032577|NCT06152861|DRUG|Travoprost Ophthalmic Topical Cream high-dose|travoprost ophthalmic topical cream high-dose once daily in the evening to both eyes
224032578|NCT06152861|DRUG|Timolol maleate ophthalmic solution, 0.5%|timolol maleate ophthalmic solution, 0.5% twice daily (morning \& evening) to both eyes
224032579|NCT06152861|DRUG|Travoprost Ophthalmic Solution, 0.004%|travoprost ophthalmic solution, 0.004% once daily in the evening to both eyes
224032580|NCT00260117|BEHAVIORAL|Exercise|Referal to a website
224032581|NCT00735735|OTHER|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
224032582|NCT01794923|DRUG|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
224032583|NCT01794923|DRUG|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
224136453|NCT01373866|DEVICE|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
224032584|NCT01794923|DRUG|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
224032585|NCT01794923|DRUG|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
224032586|NCT00759330|DRUG|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
224136454|NCT01391819|OTHER|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
224136455|NCT01391819|PROCEDURE|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
223414940|NCT00894608|DRUG|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
223414941|NCT01408381|OTHER|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
223414942|NCT02064712|OTHER|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
223414943|NCT02064712|OTHER|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
223414944|NCT05364281|OTHER|Intracuff pressure measurement|The intracuff pressures were measured and noted after each position (neck extension and placement of mouth gag), at every 5th minute while the operation and before the extubating.
223560208|NCT05873192|DRUG|Luprolide|Given PO or given INJ
223560209|NCT05014139|DRUG|Enfortumab vedotin|Given into the bladder (intravesically)
223560210|NCT06338280|OTHER|Sonara|Sonara virtual dosing window and engagement platform
223560211|NCT01837446|DRUG|2% morphine solution|
223414945|NCT03852264|BEHAVIORAL|Pet dog|Children will interact freely with their pet dog for 25 minutes.
223414946|NCT03852264|BEHAVIORAL|Unfamiliar dog|Children will interact freely with an unfamiliar dog for 25 minutes
223414947|NCT03852264|BEHAVIORAL|Nonsocial control|Children will play with age-appropriate toys/games for 25 minutes.
223414948|NCT03524235|RADIATION|Total Body Irradiation|Pre-Transplantation Total Body Irradiation
223414949|NCT03524235|PROCEDURE|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation
223414950|NCT03524235|BIOLOGICAL|CD56-Enriched Donor Lymphocyte Infusion|CD56-Enriched Donor Lymphocyte Infusion
223414951|NCT03524235|DRUG|Bendamustine|Pre-Transplantation Bendamustine
223560212|NCT01837446|DRUG|Magnesium aluminum hydroxide|
223560213|NCT01837446|DRUG|2% viscous lidocaine|
223560214|NCT01837446|DRUG|Diphenhydramine|
223560215|NCT00875485|PROCEDURE|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
224032587|NCT00759330|DRUG|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
224032588|NCT00759330|DRUG|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
224032589|NCT00759330|DRUG|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
224032590|NCT00090090|DRUG|Elsamitrucin|
223414952|NCT03524235|DRUG|Fludarabine|Pre-Transplantation Fludarabine
223414953|NCT03524235|DRUG|Rituximab|Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
223414954|NCT05478135|DEVICE|NAVIFY Oncology Hub|NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
223414955|NCT00693238|RADIATION|Low Risk Proton Radiation|
223414956|NCT00693238|RADIATION|Intermediate Risk Proton Radiation|
223414957|NCT00244114|DRUG|blood draw|Single blood sample collected to perform histamine release assay.
223414958|NCT00244114|PROCEDURE|Blood draw|Single blood sample collected to perform histamine release assay.
223414959|NCT01539330|DRUG|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
223414960|NCT01539330|OTHER|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
224032591|NCT04617756|DRUG|Patients receiving neoadjuvant therapy before radical nephrectomy|Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
224032592|NCT06431009|OTHER|Treatment-as-usual|Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.
224032593|NCT03318809|DRUG|AMG 986|tablets for oral administration
224032594|NCT01525719|DRUG|Everolimus|10 mg everolimus
224032595|NCT04181151|OTHER|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
224032596|NCT03525990|OTHER|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
224032597|NCT00707512|DRUG|natalizumab|Administered as specified in the TOUCH Prescribing Program
224032598|NCT05828043|BEHAVIORAL|Multi-domain intervention|Each session comprises of 45 minutes physical fitness activities targeting on muscle strength, balance, and flexibility; 1-hour cognitive training primarily on reasoning and memory exercises; and 15-minute for nutritional advices based on national diet guidelines for older adults
224136456|NCT00050791|DRUG|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
223414961|NCT01094158|DRUG|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
223414962|NCT01094158|DRUG|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
223414963|NCT01094158|DRUG|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
223414964|NCT03999164|DRUG|[18F]DPA-714 Positron Emission Tomography Scan|All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
223414965|NCT03789149|RADIATION|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
223560216|NCT00875485|BIOLOGICAL|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
224032599|NCT00141323|DRUG|lasofoxifene|0.5 mg once per day, orally
224032600|NCT00141323|OTHER|placebo|placebo
224032601|NCT00141323|DRUG|lasofoxifene|0.25 mg once per day, orally
224136457|NCT00050791|BEHAVIORAL|Very Low Calorie Diet|placebo injections
224136458|NCT00691262|DRUG|tacrolimus ointment|transdermal
224136459|NCT01522040|DRUG|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
224136460|NCT01522040|DRUG|Placebo|Simple saline drip, without active drug
224136461|NCT04475822|BEHAVIORAL|Intermittent fasting|Intermittent fasting group:During the three-month intervention period, participants were allowed to eat for eight consecutive hours and fast for 16 hours a day.The eating time can be freely chosen in the following two periods: 8:00 -- 16:00;12:00 -- 20:00.No specific restriction shall be made on the type and quantity of food.
223414966|NCT01631149|DRUG|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
223414967|NCT01631149|DRUG|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
223414968|NCT02181582|DRUG|Emapunil|Single peroral administration
223414969|NCT02181582|DEVICE|PET|Positron emission tomography, which creates images by detecting radioactivity.
223414970|NCT06314646|PROCEDURE|Transanal Transection and Single-Stapled anastomosis (TTSS)|Low anterior rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)
223414971|NCT06314646|PROCEDURE|Double-stapled Total Mesorectal Excision (TME)|Low anterior rectal resection with double-stapled Total Mesorectal Excision (TME)
223414972|NCT02557932|DRUG|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
224032602|NCT02614573|DEVICE|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is \<2 or \>3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (\> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is \> 4, then verification by venous measure and refer to general practitioner."
223560217|NCT00798629|BIOLOGICAL|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
223560218|NCT01271010|DRUG|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m\^2 IV or 250 mg/m\^2 orally on Days 1-3 of each cycle.
223560219|NCT01271010|DRUG|Fludarabine|Participants received fludarabine 25 mg/m\^2 IV or 40 mg/m\^2 orally on Days 1-3 of each cycle.
223560220|NCT01271010|DRUG|Rituximab|Participants received 375 mg/m\^2 IV on Day 1 of Cycle 1, then 500 mg/m\^2 IV on Day 1 of each subsequent cycle.
223560221|NCT01611116|DRUG|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
223414973|NCT02557932|DRUG|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
224032603|NCT01074619|DRUG|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
223560222|NCT01611116|DRUG|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
223560223|NCT02637414|BEHAVIORAL|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
224032604|NCT01074619|DRUG|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
224032605|NCT00786396|BEHAVIORAL|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
224032606|NCT04664673|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|motor learning-based, intensive therapy originally developed for hemiplegic children.
224032607|NCT04664673|BEHAVIORAL|Regular care|customary or usual treatment given to any adult stroke survivor
224032608|NCT04239521|OTHER|Exposure of interest (studies 2 & 3).|Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
223560224|NCT00025298|DRUG|amifostine trihydrate|
224032609|NCT01337804|DRUG|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
224032610|NCT01337804|DRUG|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
224032611|NCT05945966|OTHER|Unilateral training group (UTG)|stroke patients will be undergone task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) for the hemi-paretic side
224032612|NCT05945966|OTHER|Bilateral training group (BTG).|stroke patients will be undergone strength training using frequency, intensity, type, time (FITT) principle to non-hemi-paretic side and task-oriented approach using motor relearning program (MRP) and proprioceptive neuromuscular facilitation (PNF) to hemi-paretic side
223414974|NCT04303520|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
223560225|NCT00025298|DRUG|carboplatin|
223560226|NCT00025298|DRUG|cisplatin|
223560227|NCT00025298|DRUG|paclitaxel|
223560228|NCT00025298|RADIATION|radiation therapy|
223560229|NCT02285582|OTHER|Registry study|No intervention.
224032613|NCT03107650|PROCEDURE|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
224032614|NCT03351881|OTHER|Description of Organ Donation Policy|Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
223414975|NCT04303520|DRUG|Fludarabine|30mg/m2/d
223414976|NCT04303520|DRUG|Cyclophosphamide|500mg/m2/d
223414977|NCT05195255|DIETARY_SUPPLEMENT|Prebiotic|Guar gum (8 g/d) will be administered for 18 days
223414978|NCT04879121|DRUG|Larotrectinib Sulfate|Given PO
223560230|NCT01631747|BEHAVIORAL|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer
223560231|NCT01631747|BEHAVIORAL|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
223560232|NCT01456195|DRUG|Placebo|Fasiglifam placebo-matching tablets
223560233|NCT01456195|DRUG|Fasiglifam|Fasiglifam tablets
224032615|NCT01290601|DRUG|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
223414979|NCT00878202|DEVICE|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
223414980|NCT05265442|DRUG|Methadone|titration of Zoryon (methadone): increase of posology untill pain relieved is reached
223414981|NCT06083961|DRUG|Alirocumab|Initial alirocumab, single dose of 300mg, subcutaneous injection
223414982|NCT05708157|DRUG|concomitant intranasal antihistamine and corticosteroid|concomitant intranasal administration with antihistamine and corticosteroid
223414983|NCT02217410|BIOLOGICAL|CFZ533|
223414984|NCT02217410|DRUG|Tacrolimus (Tac)|
223414985|NCT02217410|DRUG|Mycophenolate mofetil (MMF)|
223414986|NCT02217410|DRUG|Corticosteroids (CS)|
223414987|NCT02217410|BIOLOGICAL|anti-IL2 Induction|
223414988|NCT06665061|DEVICE|PCV|Patients were randomly assigned to receive PCV mechanical ventilation, with consistent ventilation parameters.
223414989|NCT06665061|DEVICE|VCV|Patients were randomly assigned to receive VCV mode mechanical ventilation, with consistent ventilation parameters.
223414990|NCT06665061|DEVICE|PRVC|Patients were randomly assigned to receive PRVC mode mechanical ventilation, with consistent ventilation parameters.
224032616|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
224032617|NCT01290601|DRUG|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
224032618|NCT01290601|DRUG|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
224032619|NCT00635726|DRUG|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
224032620|NCT00635726|DRUG|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
224032621|NCT00635726|DRUG|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
224032622|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
224032623|NCT00635726|DRUG|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
224032624|NCT00635726|DRUG|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
224032625|NCT02207270|BEHAVIORAL|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
224032626|NCT02207270|BEHAVIORAL|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
224032627|NCT00704002|PROCEDURE|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
224032628|NCT00704002|PROCEDURE|conservative treatment|conservative treatment with 2-finger splint for one week
224032629|NCT04071795|BEHAVIORAL|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
224032630|NCT04071795|BEHAVIORAL|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
223414991|NCT03055897|DEVICE|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
223414992|NCT03758222|DEVICE|XFLO Expander System|Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)
223414993|NCT06684210|PROCEDURE|Intercostal plane block of the external oblique muscle|Under ultrasound guidance, a single dose of 0.25% ropivacaine 20ml was given for bilateral intercostal muscle plane block of external oblique muscles
223414994|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.25 µg/kg
223414995|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.5 µg/kg
223414996|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 0.75 µg/kg
223414997|NCT06685081|DRUG|Dexmedetomidine|Dexmedetomidine was injected in dose of 1 µg/kg
223414998|NCT06685081|DRUG|lidocaine and triamcinolone|2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection
223414999|NCT05229523|OTHER|repeated assessments|validity and reliability of the Modified Four Square Step Test (mFSST) in children with cerebral palsy with the tests of Pediatric Berg Balance Scale (PBSS), Timed Up and Go Test (TUG), Pediatric Functional Reaching Test (PFUT)
223415000|NCT00661609|DRUG|AZD4877|Intravenous (IV)25mg/weekly
223415001|NCT03025815|OTHER|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
224032631|NCT01066468|DRUG|Gleevec/Glivec|
224032632|NCT05532254|DRUG|Aripiprazole 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
224032633|NCT05532254|DRUG|Abilify® 10 mg tablet|an immediate-release tablet containing 10 mg Aripiprazole
224032634|NCT04140279|DRUG|Latanoprostene Bunod|Ophthalmic solution
224032635|NCT04140279|DRUG|Placebo|Ophthalmic solution, no active ingredient.
224032636|NCT05332184|PROCEDURE|aortic valve surgery|
224032637|NCT03057808|BEHAVIORAL|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
223415002|NCT03025815|OTHER|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
223415003|NCT03477201|PROCEDURE|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
223415004|NCT03477201|PROCEDURE|Standard laparoscopic inguinal hernia repair|Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
223415005|NCT04859790|BEHAVIORAL|Social Concerns Appraisal Retraining|"SCAR consists of an hour-long intervention session, followed by a 2-week-long EMI. During the hour-long intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety), discuss popular misconceptions they may have about publicly observable anxiety symptoms (e.g., people can tell I'm anxious by looking at me), and complete exposure exercises (e.g., practicing facing feared physical sensations such as sweating). During the EMI, participants will report on their social anxiety symptoms four times per day. When participants endorse elevated social anxiety during this time, they will receive a targeted message reminding them of the topics covered in the intervention session."
223415006|NCT04308499|BEHAVIORAL|Digital cognitive-behavioral therapy for insomnia (dCBTI)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) structured into 6 weekly sessions accessed using either a computer or a smartphone
223415007|NCT04308499|BEHAVIORAL|Sleep hygiene education (SHE)|Recognized and commonly prescribed set of sleep hygiene instructions comprised of comprise a website and a downloadable booklet
223415008|NCT03747757|BEHAVIORAL|Cognitive Behavior Therapy|Undergo CBT
223415009|NCT03747757|OTHER|Quality-of-Life Assessment|Ancillary studies
223415010|NCT03747757|OTHER|Questionnaire Administration|Ancillary studies
223415011|NCT06682923|DEVICE|MolecuLight DX Imaging Device|The MolecuLight DX Imaging Device is a fluorescence imaging device intended to acquire images from wounds. This will not alter the participant's standard of care treatment.
223415012|NCT01455272|PROCEDURE|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
223415013|NCT00585845|BIOLOGICAL|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10\^8 cfu to 1x10\^10 cfu.
223415014|NCT00938847|DEVICE|PCI|Stent implantation after acute myocardial infarction
223415015|NCT03468166|OTHER|Chronic stroke|The data for motor function and gait pattern analysis was obtained.
223415016|NCT00637000|DRUG|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
223415017|NCT00637000|DRUG|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
223560234|NCT06517251|OTHER|Arm-hand BOOST|"Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.~The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation."
223560235|NCT06517251|OTHER|Lower limb BOOST|L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.
224032638|NCT03057808|BEHAVIORAL|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
224136462|NCT04475822|BEHAVIORAL|Low carb diet|Low carb diet:The daily carbohydrate intake of participants in this group was limited to 130g/ D, and the recommended diet was formulated according to the standard and combined with the local eating habits in Xi 'an, and dietary habit education was conducted. Participants could eat according to the recommended diet.
223415018|NCT00637000|DRUG|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
223415019|NCT04515706|DRUG|Iguratimod|Iguratimod is an anti-rheumatic drug that approved for treating rheumatoid arthritis in East Asia. Recent data reveal its independent anti-fibrosis effect.
223415020|NCT04515706|DRUG|Placebo|Placebo of Iguratimod
223415021|NCT03457116|DRUG|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
223415022|NCT03457116|DRUG|NSAID|Ibuprofen 400mg for post-operative pain
223415023|NCT04764370|DEVICE|WeFlow-Ach Moduler Embedded Branch Stent Graft System|The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
223415024|NCT01281670|OTHER|vibration|8 week vibration
223415025|NCT06341907|BIOLOGICAL|Neoantigen polypeptide vaccine|Completion of polypeptide neoantigen polypeptide vaccine (day 1, 4, 8, 15, 22, 54, and 84)
223415026|NCT00467727|OTHER|Phase Contrast Mammography|Standard and magnification views
223415027|NCT02751450|DEVICE|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
223415028|NCT02751450|OTHER|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
223415029|NCT06622616|DIETARY_SUPPLEMENT|EVALUATE THE EFFECT OF ACHETA DOMESTICUS POWDER CONSUMPTION ON GLUCOSE HOMEOSTASIS AND INTESTINAL DYSBIOSIS|"The study will have two arms, the functional group with A. domesticus powder (n=60) and a placebo group that will take a vegetable protein powder with a similar macronutrient composition (n=60). This population will be classified according to sex and BMI, and their nutritional-metabolic status (insulin resistance or not).~The study will include analysis of phenotypic data collection (medical history, lifestyle, diet, etc.); biochemical data: glucose, lipid, iron profile, blood count, and analysis of inflammation markers; genotyping, epigenetic analysis (methylation and mi-RNAs), targeted metabolomics (glycome and tryptophan) and metagenomic analysis of stool (16s rRNA sequencing for taxonomic identification study). Using continuous monitoring devices (glucose monitoring using a sensor and physical activity using an activity bracelet), lifestyle parameters (physical activity, circadian rhythms, sleep, stress, etc.) and blood glucose will be evaluated."
223415030|NCT05230368|DRUG|Decitabine cycle 1|Decitabine administration (5mg/m²) at days 1, 2, 3
223415031|NCT05230368|DRUG|Romidepsin cycle 1|Romidepsin administration (5mg/m²) at days 4, 11, 18
223415032|NCT05230368|DRUG|Decitabine cycle 2|Decitabine administration (5mg/m²) at days 35, 36, 37
223415033|NCT05230368|DRUG|Romidepsin cycle 2|Romidepsin administration (5mg/m²) at days 38, 45, 52
223415034|NCT05230368|DRUG|Decitabine cycle 3|Decitabine administration (5mg/m²) at days 70, 71, 72
223415035|NCT05230368|DRUG|Romidepsin cycle 3|Romidepsin administration (5mg/m²) at days 73, 80, 87
223415036|NCT05230368|DRUG|Decitabine cycle 4|Decitabine administration (5mg/m²) at days 105, 106, 107
224032639|NCT01704963|DRUG|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
223415037|NCT05230368|DRUG|Romidepsin cycle 4|Romidepsin administration (5mg/m²) at days 108, 115, 122
223415038|NCT06619496|BEHAVIORAL|Human-led fall prevention program|Human-led evidence-based fall prevention programs include Matter of Balance, Tai Chi Moving for Better Balance, Walk with Ease, or Arthritis Exercise
223415039|NCT06619496|BEHAVIORAL|Avatar-led fall prevention program|The avatar-led fall prevention program consists of the Otago Exercise Program
223415040|NCT01243216|DEVICE|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
223415041|NCT04287855|DRUG|Isatuximab|Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle
223415042|NCT04287855|DRUG|Carfilzomib|Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
223415043|NCT04287855|DRUG|Pomalidomide|Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.
223415044|NCT04287855|DRUG|Dexamethasone|Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
223415045|NCT06684938|DRUG|sacroiliac injection|sacroiliac injection with local anaesthetic and corticosteroids
223560236|NCT06397651|BEHAVIORAL|Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application|"Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment.~* Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits.~* Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements."
223415046|NCT00719238|BEHAVIORAL|Nutrition plus education|Nutritional instruction in small groups plus education
223415047|NCT00719238|BEHAVIORAL|Education only|Educational video and pamphlets
223415048|NCT06685419|OTHER|Propolis containing gum|Patients with moderate gingivitis will be asked to use gum containing propolis 5 times a day for a total of 3 weeks.
224032640|NCT00772213|PROCEDURE|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
224032641|NCT00947713|DRUG|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
224032642|NCT00947713|DRUG|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
223415049|NCT01290679|DRUG|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
223415050|NCT01290679|DRUG|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
223415051|NCT01290679|DRUG|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
223415052|NCT01290679|DRUG|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
223415053|NCT00562302|DEVICE|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
223415054|NCT04313179|OTHER|Music therapy|Mozart lullaby music
223415055|NCT04313179|OTHER|Sucrose|0.5 ml of 24% Sucrose
223415056|NCT01666743|DRUG|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
223415057|NCT01855243|DRUG|regular insulin|
224032643|NCT03730974|DEVICE|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
223415058|NCT01855243|DRUG|70/30 insulin|
223415059|NCT01855243|DRUG|Glargine|
223415060|NCT01855243|DRUG|glulisine|
223415061|NCT02126423|OTHER|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
223415062|NCT01219764|DRUG|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|"Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days."
223415063|NCT06666140|OTHER|Ultrasonic elastography|"The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive."
223415064|NCT00730795|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
223415065|NCT04582058|BEHAVIORAL|Mobile Health of lifestyle|Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
223415066|NCT06667206|BIOLOGICAL|Licenced Measles-Rubella vaccine|Licenced Measles-Rubella vaccine provided by the Ugandan EPI programme
223415067|NCT04411277|DEVICE|Application of the FreeStyle Libre Flash Glucose CGM.|Assessment of glycemic control and hypoglycemia, adherence to therapy and CGM use.
223415068|NCT04411277|DIAGNOSTIC_TEST|InBody 270 multifrequency bioimpedance|analysis of body composition to calculate appendicular skeletal muscle.
223415069|NCT05842447|DIETARY_SUPPLEMENT|367 mg Pomanox group|Treatment with 367 mg Pomanox®P30 during 12 weeks
223415070|NCT05842447|DIETARY_SUPPLEMENT|700 mg Pomanox group|Treatment with 700 mg Pomanox®P30 during 12 weeks
223415071|NCT05842447|DIETARY_SUPPLEMENT|Control group|Treatment with maltodextrin during 12 weeks
224032644|NCT03000361|PROCEDURE|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
223415072|NCT01871493|DRUG|LY2605541|Administered subcutaneous (SQ)
223415073|NCT01871493|DRUG|Insulin Lispro|Administered SQ
223415074|NCT00811330|DRUG|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
223415075|NCT00692848|OTHER|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
223560237|NCT06397651|BEHAVIORAL|Digital application with expert guidelines on lifestyle modification|24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.
223560239|NCT03866538|DRUG|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
223560240|NCT06789042|DRUG|0.9%NaCl|20ml 0.2% Ropivacaine + 2.0ml 0.9% NaCl
223560241|NCT06789042|DRUG|Dexamethasone 4mg|20ml 0.2% Ropivacaine + 4mg Dexamethasone
223560242|NCT05591768|PROCEDURE|Monopolar radiofrequency|In monopolar group : . Inferomedial, superomedial, and superolateral GN branches of the patients were identified with ultrasonography, and a 22 Gauge, 10 cm radiofrequency (RF) cannula with a 10 mm active tip was advanced to the targeted nerves under fluoroscopy guidance. The location of the RF cannula was visualized by anteriorposterior and lateral images. Sensory stimulation was applied at 50 Hz to determine the nerve position. Since the sensory stimulation threshold must be \< 0.6 V, nerve position was tested with the absence of fasciculation in the relevant area of the lower extremity upon 2.0 V stimulation at 2 Hz.
224032645|NCT04891328|OTHER|Intensive therapy program|The intensive therapy program consists of physical therapy, occupational therapy, and speech therapy 3-6 hours x 4-5 days/week for 4 weeks. The individual therapies received will vary with the child/caregiver goals and be based on neuroplasticity and motor learning principles.
224032646|NCT04864483|OTHER|Meal timing in relation to time of starting the fast|as described
224032647|NCT00615238|BEHAVIORAL|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
223415076|NCT00543972|DRUG|AVE9633|Intravenous Infusion
223415077|NCT02136212|BEHAVIORAL|Approach-positive AAT|
223415078|NCT02136212|BEHAVIORAL|Control AAT|
223415079|NCT02791321|OTHER|ADS severity|Evaluation of the ADS severity with the CARS scale
223415080|NCT02791321|OTHER|Adaptative and intellectual functioning|Evaluation with IQ and Vineland II scale
223415081|NCT02791321|OTHER|Psychiatric and somatic comorbidities|Evaluation with the Reiss, DSQIID and CIRS Scales
224032648|NCT00615238|BEHAVIORAL|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
224032649|NCT00615238|BEHAVIORAL|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
224032650|NCT05526729|OTHER|Beovu|Prospective observational study. There was no treatment allocation. Patients prescribed with Beovu for the first time for diabetic macular edema were eligible to enroll into this study.
224032651|NCT02073734|DRUG|Dexamethasone|Dexamethasone 8mg/IV
224032652|NCT02073734|DRUG|Placebo|Placebo given IV
224032653|NCT02761551|BEHAVIORAL|Reminder notifications via autodialer|
224136463|NCT04475822|BEHAVIORAL|Low carbon diet and intermittent fasting group|Low carbon diet and intermittent fasting group:Participants fasted for 16 hours a day and ate for eight consecutive hours on the same diet as the low-carb group.
223560243|NCT05591768|PROCEDURE|Bipolar radiofrequency|a similar technique will be used to insert the canula, except that, instead of one cannula two cannulae (approximately 10 mm apart) apart) will be inserted and no manipulation of cannulae was done to stimulate the target nerve as done in MRFA Target areas were similar to monopolar technique Each nerve will be ablated for 90 s in both the groups. All procedures were done by one pain physician who had more then 10 years' experience of radiofrequency procedures.
224032654|NCT05216900|RADIATION|Neoadjuvant radiotherapy|"The study examines the delivery NART.~In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied.~A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap."
224032655|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
224032656|NCT00752622|BIOLOGICAL|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
224032657|NCT00752622|BIOLOGICAL|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
224136464|NCT04291872|OTHER|Glass -Ionomer Cement with /without Led Light Cure|Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
223415082|NCT03315286|DEVICE|SHADE Ultraviolet Sensor|Patients will wear device for 6 months in addition to their own method of photo-protection.
223415083|NCT03315286|BEHAVIORAL|Standard of care counseling|Patients will use their own method of photo-protection
223415084|NCT05037357|DIAGNOSTIC_TEST|Plasma EBV DNA qPCR test|Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
223415085|NCT03003039|BIOLOGICAL|GB241|Single intravenous infusion (IV) 375 mg/m2
223415086|NCT03003039|BIOLOGICAL|Rituximab|Single intravenous infusion (IV) 375 mg/m2
223415087|NCT02604498|DRUG|Nemonoxacin|Single dose 500mg oral
223415088|NCT06968299|DIETARY_SUPPLEMENT|ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules|Product ingredients: microcrystalline cellulose, corn starch, SWP-CGPA01 Pediococcus acidilactici powder (1.0 x 10\^10 CFU); Capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gelatin.
223415089|NCT04423770|OTHER|No intervention|No intervention; this is a purely observational study
223415090|NCT03339193|DEVICE|Left atrial appendage closure|Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.
223415091|NCT06327503|OTHER|saliva samples collecting|non-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container
223415092|NCT06620120|DEVICE|Insoles|"At the D0 visit, if the patient is assigned to the arm with insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
223415093|NCT06620120|OTHER|Without insoles|"At the D0 visit, if the patient is assigned to the arm without insoles.~The patient completes the quality of life and symptom evaluation questionnaires, the plesthysmographic evaluation test, the analysis of walking without insoles and the oedema measurement.~Then, at D30, the patient repeated the same tests, with the exception of the gait and plesthysmographic evaluation tests.~The patient then switched to the other arm."
223415094|NCT00049465|PROCEDURE|fatigue assessment and management|
223415095|NCT00049465|PROCEDURE|management of therapy complications|
223415096|NCT00049465|PROCEDURE|psychosocial assessment and care|
224032658|NCT05048537|RADIATION|18F-FACBC PET/CT|10mCi 18F-FACBC IV injection, then whole body PET/CT after 4 mins
224032659|NCT04117009|DRUG|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
224032660|NCT04117009|DIAGNOSTIC_TEST|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
223415097|NCT03075891|DRUG|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
223415098|NCT03075891|DRUG|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
223415099|NCT03075891|OTHER|Oral placebo capsules|1 Capsule once-daily for 12 weeks
223415100|NCT06967766|BEHAVIORAL|health education based on the Metaphor-Embedded Integrated Behavioral Model|In each intervention scenario, health education information is set to target key behaviors in the scenario. In the main scenarios for obtaining antibiotics, such as township health centers, village clinics, and community pharmacies, scenario-driven interventions are carried out for two key behaviors: patients actively asking for antibiotics (led by doctors in township health centers) and customers buying antibiotics without prescriptions (led by community pharmacy staff).
224136465|NCT03172858|DEVICE|Intracervical balloon catheter|cervical ripening balloon
224136466|NCT03172858|DRUG|Oxytocin|medication used to induce contractions
224136467|NCT01745601|DRUG|escitalopram 10 mg|Reference product
223415101|NCT05326243|BIOLOGICAL|CD19-targeted chimeric antigen receptor T-cell|"Drug: Fludarabine~patients will receive a lymphodepletion chemotherapy with Fludarabine 25 mg/m2/day IV for 3 days on Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Drug: Cyclophosphamide~patients will receive a lymphodepletion chemotherapy with cyclophosphamide 300 mg/m2/day IV for 3 dys Day-5 to Day-3(a safe window for a small subset of patients will be D -7 to D -3).~Biological: CD19 CAR-T~CD19 CAR-T cells will be administered using as a single dose at 0.1-9\*10\^6 cells/kg on Day 0 after completion of the lymphodepletion chemotherapy. The body weight calculated for PL001 dose is the actual body weight on the day of leukapheresis."
223415102|NCT04957615|BIOLOGICAL|Nivolumab|Given IV
223415103|NCT01131169|DRUG|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
223415104|NCT01131169|DRUG|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
223415105|NCT00828568|DRUG|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
224032661|NCT03240757|DIETARY_SUPPLEMENT|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests \[one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)\]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
224032662|NCT03240757|OTHER|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
223415106|NCT00828568|DRUG|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
223415107|NCT00828568|DRUG|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
223415108|NCT00597610|OTHER|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
223415109|NCT01553422|OTHER|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
223415110|NCT01553422|OTHER|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
223415111|NCT02957253|OTHER|risk factors|monitoring risk factors due to deterioration of the liver disease
223415112|NCT02957253|OTHER|self-care|information and motivation to adherence to self-care instructions and medical treatment
223415113|NCT02957253|OTHER|nutrition|nutritional assessment and activities to prevent malnutrition
223415114|NCT02957253|OTHER|lifestyle|motivation of lifestyle changes essential for disease progress and
223415115|NCT02957253|OTHER|psychosocial needs|psychosocial care.
223415116|NCT02957253|OTHER|Nurse-led clinic|compensated disease once yearly, decompensated disease twice a month to every third month
223415117|NCT00841113|DRUG|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
223415118|NCT00841113|DRUG|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
223415119|NCT05495100|DRUG|Mitoxantrone liposome、Chidamide、Azacitidine|Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1\~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
223415120|NCT03177005|BIOLOGICAL|CSL830|
223415121|NCT03208998|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
223415122|NCT03411499|PROCEDURE|Early surgery|Surgery within 72 hours from endocarditis diagnosis
223415123|NCT03411499|PROCEDURE|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
223415124|NCT01270984|DRUG|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I \& II D1(crossover)
223415125|NCT01270984|DRUG|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I \& II D1(crossover)
224032663|NCT00894686|BIOLOGICAL|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
224032664|NCT01523639|DRUG|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
224032665|NCT00505817|DRUG|Cetrorelix and Leuprolide|
224136468|NCT01745601|DRUG|escitalopram 10 mg|Test product
224136469|NCT00278772|DRUG|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
224136470|NCT00278772|OTHER|Placebo|oral dose, placebo
224136471|NCT01547910|DIETARY_SUPPLEMENT|Fish Oil|Fish oil given in supplementary dose
224136472|NCT04433624|OTHER|Group (B)|Group (B) (n=15): will receive The bilateral ESP blocks were performed by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the erector spinae muscle and the transverse processes of the lumbar vertebrae
224032666|NCT05082129|DEVICE|TransiCap|The TransiCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan.
224032667|NCT00287339|DRUG|Esomeprazole|40mg capsule BID for 12 weeks
224136473|NCT01656317|OTHER|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
224136474|NCT03912025|OTHER|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
223415126|NCT03780881|BEHAVIORAL|Expectation confirmation|Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
224136475|NCT04682834|DRUG|Sulopenem Etzadroxil/Probenecid|Individual Patients
224136476|NCT00206895|PROCEDURE|Photodynamic therapy|
224136477|NCT02633995|PROCEDURE|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
224136478|NCT00920595|DRUG|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
224136479|NCT06692387|BEHAVIORAL|Step count increase with the use of a motivational application|The motivational app will encourage people to increase their physical activity for a short period of time (one month). Different treatment arms will receive different physical activity goals. People will get feedback and be motivated based on their own baseline level and actual activity level.
224136480|NCT05790811|OTHER|Physician-oriented Video|previously validated Hand and Wrist Examination Video by NEJM designed for usage by a physician in diagnosing common hand and wrist diagnoses
224136481|NCT05790811|OTHER|Patient-oriented video|"The previously validated Hand and Wrist Examination Video by NEJM was modified via the TogoTiki application and approved by a patient advisory council."
223415127|NCT03780881|BEHAVIORAL|Expectation disconfirmation|Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
223415128|NCT01965340|OTHER|Systematic Therapeutic Drug Monitoring for the intervention group|
223415129|NCT05603611|DEVICE|Pulmonary vein isolation|Local electrical isolation of PV ostia to prevent recurrence of AF due to ectopic PV-triggers
223415130|NCT04768413|OTHER|Teleconsultation either by phone or by computer consultation. Quantitative and qualitative approaches to analysis|A group of patients who have voluntarily adhered to the clinic's tele-assisted consultation and who receive remote, multidisciplinary team care without requiring physical displacement.
223415131|NCT04768413|OTHER|Care modalities. Quantitative and qualitative approaches to analysis|Group of patients who wish to continue with the usual face-to-face consultation, since for these patient's isolation measures allow trips to the care centers and who receive care from a multidisciplinary team on a regular basis.
223415132|NCT06063642|DEVICE|Neurofeedback training|Neurofeedback training is a type of non-invasive brain modulation technique that enables individuals to self-regulate brain activity patterns by providing them feedback on specific activity measures. Effective self-regulation is often linked to changes in cognition, behavior, and clinical symptoms.
223415133|NCT06063642|DEVICE|Sham feedback training|A controlled form of neurofeedback training that provides feedback irrelevant to the targeted mental process.
223415134|NCT03474731|BEHAVIORAL|Diabetes Self-Management Program (DSMP)|"The the Diabetes Self Management Program (DSMP) in a group setting: participants will attend a six week, evidence-based diabetes home self-management program. The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization."
224032668|NCT00287339|DRUG|Placebo|placebo capsule BID for 12 weeks
224032669|NCT00564018|DRUG|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
224032670|NCT00564018|DRUG|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
224032671|NCT00564018|DRUG|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
224032672|NCT01869075|OTHER|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
224032673|NCT00312533|DRUG|Hylan F- 20|
224032674|NCT00622882|OTHER|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
224032675|NCT03608540|DEVICE|Endomina|Suturing system with sutures apposition then bulging then cutting
224032676|NCT00388622|BEHAVIORAL|Pharmacist intervention|
224032677|NCT02918604|DEVICE|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
224032678|NCT02960347|DEVICE|High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor|Non-invasive focal neuromodulation
223415135|NCT03474731|BEHAVIORAL|Tailored Patient Navigation (PN) only|"Tailored Patient Navigation (PN) only: trained Community Health Workers (CHW) will meet one-on-one with participants to assess the barriers experienced in adhering to medical appointments and will implement a navigation program accordingly.~The goal of this arm of the project is to try to get participants to attend recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs."
223415136|NCT03474731|BEHAVIORAL|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : patient navigation followed by 6 weeks of DSMP classes after the 3 month post-test interview.
223415137|NCT03474731|BEHAVIORAL|Diabetes Self-Management Program (DSMP) Delayed|"Groups randomized to DSMP Delayed will receive 6 weeks of DSMP classes after the 3 month post-test interview.~Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization."
223415138|NCT00777270|PROCEDURE|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
223415139|NCT00777270|PROCEDURE|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
223415140|NCT05107193|DRUG|afatinib|afatinib
223415141|NCT03512613|DEVICE|c-FLOW 3310-P|"c-FLOW 3310-P is a continuous, non-invasive monitor of cerebral deep tissue blood flow used to measure relative changes in blood flow.~The device monitors regional micro circulatory blood flow in tissues, by using sensors placed near the area of interest."
223415142|NCT02432612|DRUG|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
224032679|NCT04580329|PROCEDURE|neuromuscular electrical stimulation (NMES) in addition to routine hospital care|"Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(\>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain."
224032680|NCT04580329|PROCEDURE|routine hospital care without NMES|routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
224032681|NCT04514666|OTHER|Breath analysis|The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified
224032682|NCT03731507|DEVICE|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
224032683|NCT06183749|OTHER|hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit|diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment
224032684|NCT01401907|OTHER|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
224032685|NCT05065372|DRUG|Metformin Hcl 1000Mg Tab|Agent used to modify insulin sensitivity
223415143|NCT05679102|DRUG|Amlodipine 5 MG Oral Tablet|one group will be given only Amlodipine 5MG once daily
223415144|NCT05679102|DRUG|Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet|one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily
223415145|NCT03710382|OTHER|Walking epidural|Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
223560244|NCT05720858|OTHER|Aerobic exercise|Reciprocal straight leg lift, Reciprocal hip knee flexion-extension, Lateral spinal rotation (Spinal rotation), Bridge Exercise, Elbow winging, Hip abduction, trunk extension, Shoulder elevation, Shoulder circulation, Shoulder flexion and extension, Shoulder abduction adduction, Reciprocal lateral trunk flexion and extension, Puching exercise, Mini Squat exercise, Reaching upward with hands reciprocally, Scapular adduction (Hands at waist), Push-ups on the wall, Knee Touch exercise, Arm Circles exercise, Reaching for feet in sitting position, Saw (The saw) exercise.
224032686|NCT05065372|DRUG|Aminohippurate Sodium 20 % Injection|Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
224032687|NCT05065372|DRUG|Iohexol 300 Mg/mL Injectable Solution|Diagnostic aid/agent used to measure glomerular filtration rate
224032688|NCT05065372|DRUG|Placebo|Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
224032689|NCT05286177|PROCEDURE|Volume-based EN|Bedside nurses will receive a total daily feed volume prescription to be administered to the participant over a 24-hour period. The bedside nurse will calculate the initial hourly rate by dividing the total daily feed goal by 24 hours at approximately 0700 hours. In this intervention group, they will be instructed to titrate the rate of feeds to accommodate for any feeding interruptions as follows: When feeds are held for \> 1 hour, the remaining daily feed volume will be divided by the remaining number of hours. A maximum infusion rate will be set at 2 times the patient's baseline 24-hour feed rate to ensure that a large bolus volume of feed is not administered over a too short period of time.
224032690|NCT05286177|PROCEDURE|Rate-based EN|Bedside nurses will receive an hourly feed rate prescription to administer the tube feedings over a 24-hour period. If feeds are held, they will be restarted at the same consistent hourly rate that was previously ordered. Nurses will not adjust feed rates to compensate for feed interruptions
224032691|NCT02607696|DRUG|Zolpidem Hemitartarate|
224032692|NCT04938024|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C is a commercially available over-the-counter food supplement.
224032693|NCT05617352|DIAGNOSTIC_TEST|Since the data were collected retrospectively, there were no interventions|Since the data were collected retrospectively, there were no interventions
224032694|NCT01496482|OTHER|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
224032695|NCT00446667|DRUG|mannitol|400mg BD for 2 days
224032696|NCT00767468|DRUG|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
224032697|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
224032698|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
223415146|NCT04637711|PROCEDURE|Focus clearing + whole breast exploration and washing + one-stage micro plastic surgery No Intervention: Extensive lesion excision|Only visible lesions and necrotic tissues, such as abscess cavity, sinus tract and fistula, were removed intraoperatively, while normal glands and fat were retained. Preoperative ultrasound was used to locate the lesion area and then the surgical incision was designed. Intraoperative ultrasound examination of latent small lesions, resection of lesions visible under ultrasound, and then a full breast exploration, one finger page incision interval.Radially cut from the base to the subcutaneous, lesions were found and treated locally. After removal of lesion, fully using the syringe, in turn, use of 3% hydrogen peroxide solution, 1% eniodine, saline water is widely jet pulse washing, and around the lesions base. After rinsing, soak in 1% active iodine for 10min, then rinse with normal saline until the liquid is clear. Breast tumor Surgery (Oncoplastic Breast Surgery, OBS) core technology (volume replacement and volume replacement).
223560245|NCT03420495|BEHAVIORAL|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
223560246|NCT03081819|DRUG|SH003|Herbal medicine for cancer treatment
223560247|NCT01851265|DRUG|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
223560248|NCT01851265|OTHER|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
224032699|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
224032700|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
224032701|NCT00106145|DRUG|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
224032702|NCT06327308|DIAGNOSTIC_TEST|MRI|The examination lasts between 45 minutes and one hour. The patient lies down in the MRI tube. He is fitted with headphones that muffle the noise produced by the machine and enable him to receive instructions from the technician. Four electrodes are applied to his chest to continuously record his heartbeat. Finally, his chest is covered with a plastic plate, which receives the MRI signals needed to form the image. Acquiring an MRI image takes between 2 and 20 seconds. To ensure that image quality is not impaired by respiratory movements, images are acquired in apnea. The technician will ask the patient to hold his or her breath repeatedly throughout the examination.
223415147|NCT00766636|DRUG|Gemcitabine|"Arm A:~1000 mg/M\^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M\^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day."
224032703|NCT06327308|BIOLOGICAL|Blood sampling|Additional blood will be drawn for dosing acylcarnitines, copeptin, interleukin-6 (IL-6), LPS-Binding Protein (LBP), Phospholipid TransferProtein (PLTP)/Cholesteryl Ester Tranfer Protein (CETP) activity, and for plasma banking. The volume of blood will be 20 ml in total (5 ml for each assay) at each visit. Patients participating in this study will have 3 visits. Total blood volume will therefore be 20 x 3, or 60 ml for the 3 visits.
223560249|NCT01851265|OTHER|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
224032704|NCT05810831|DIAGNOSTIC_TEST|Massage with post isometric relaxation exercises|Post isometric relaxation will be performed in supine position with neutrally positioned head.
224032705|NCT05810831|DIAGNOSTIC_TEST|Massage|conservative physiotherapy protocol including massage
224032706|NCT02350608|DEVICE|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
224032707|NCT03291587|OTHER|Personnel Training and Coaching Calls|"Training of Lung Cancer Screening Personnel on implementation of the US PHS Guidelines for Smoking Cessation and Performance Coaching during Implementation Phase of the Study~Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation."
224032708|NCT02197767|DRUG|rituximab|1000 mg infusion
224032709|NCT00796120|DRUG|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m\^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
224032710|NCT00796120|DRUG|Doxorubicin|Doxorubicin 60 or 75 mg/m\^2 will be given intravenously every 3 weeks until disease progression.
224032711|NCT00796120|DRUG|Ifosfamide|Ifosfamide 6 to 9 g/m\^2 will be given intravenously every 3 weeks until disease progression.
223560250|NCT01851265|OTHER|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
223560251|NCT04848220|DRUG|Temanogrel|Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)
223560252|NCT04848220|DRUG|Placebo|Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
223560253|NCT02923830|OTHER|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
223560254|NCT02923830|DRUG|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
223560255|NCT04748757|DRUG|recombinant human annexin A5|recombinant human annexin A5, manufactured as SY-005
223560256|NCT04748757|DRUG|Placebo|Normal saline 50 ml
223560257|NCT06350136|BEHAVIORAL|With Tele-Nursing|no With Tele-Nursing
223560258|NCT05755256|DIETARY_SUPPLEMENT|Probiotic|After randomization, participants will consume the probiotic for 12 weeks.
223560259|NCT05755256|DIETARY_SUPPLEMENT|Placebo|After randomization, participants will consume the placebo for 12 weeks.
223415148|NCT00766636|RADIATION|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
223415149|NCT00766636|DRUG|Erlotinib|100 mg daily by mouth on days 1-42.
223415150|NCT00766636|PROCEDURE|Surgery|Surgical removal of the pancreas and duodenum
223415151|NCT05686135|OTHER|90Second IBD|Patients will receive 90SecondIBD weekly at no charge via text message or email linked to a website.Each 90SecondIBD letter has an attractive photo, 250 words of targeted information on a specific topic and 3 specific action suggestions on the first page. The second page is a seven-item quiz on attitudes and behavior on the designated topic. The reader gets immediate feedback and advice. The third page is a personal story of someone with IBD about this topic. Finally, there is an evaluation of the specific 90SecondIBD issue and an opportunity to recommend topics.
223415152|NCT03271281|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
223415153|NCT03271281|DEVICE|PET/CT|Following injection of 68Ga-NODAGA-E\[c(RGDyK)\]2 the patients will be subjected to whole body PET/CT
223415154|NCT04657198|BIOLOGICAL|RSVPreF3 OA investigational vaccine (GSK3844766A)|RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).
223415155|NCT03359759|OTHER|Conected objects|"Every week, each patient report her symptoms and answer ten questions on the i-PAD. The connected watch reports the performance status (activtiy and time spent in bed or sitting), and the falls.~If nurses or doctors detect any problem, they ask the patient for a telemedicine to try to help her. During the same time, nurses or doctors send a message on a secure plateform to the local team (nurse, General Practitioner, and pharmacists) and they reserve a place for an hospitalization if necessary."
223415156|NCT05321043|OTHER|Vitamin B2 labeling|Using medical non-toxic fluorescent agents, VB2 solution, to mark the patient's hands before endoscopy examination.
223415157|NCT06250920|DEVICE|Virtual reality visual training|Children in intervention group were administered at home under the supervision of parents for 20 minutes per session every day with virtual reality visual training
223415158|NCT04797702|COMBINATION_PRODUCT|Glumetinib combined with Toripalimab|"Ib：All enrolled subjects received Glumetinib combined with Toripalimab on a 21-day cycle, starting with 200mg/ day continuous Glumetinib and 240mg/ 3 weeks Toripalimab.~II：The SMC will determine the dose group for the Phase II study based on the safety and initial efficacy data of the Phase Ib subjects. Approximately 62 evaluable subjects will be enrolled in the study to receive the recommended dose of Glumetinib once daily and continuous treatment with Toripalimab 240mg every 3 weeks."
223415159|NCT05357703|DEVICE|Standard treatment + Active B-Cure laser|The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/minute.
223415160|NCT06661954|DEVICE|Bed A - supine|Hercules dream air surface in supine position
223560260|NCT05825430|PROCEDURE|Direct pecs block|"Patients will receive direct PECS block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
223560261|NCT05825430|PROCEDURE|Ultrasound guided pecs block|"Patients will receive ultrasound guided pecs block after induction and before skin incision.~All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v."
223739009|NCT04287192|OTHER|Digital Bridge:Tool Intervention|Our Digital Bridge is an integration of the Care Connector and ePRO technologies that will support care transitions by: 1) inviting PCPs to access Care Connector while the patient is in hospital, allowing for asynchronous communication via the messaging feature for proactive discharge planning, 2) facilitating the inclusion of inter-professional recommendations in the discharge module (e.g. diet and mobility) typically missing from traditional physician generated discharge summaries, 3) electronic generation of PODS for use in patient-centred discharge teaching, 4) providing patients electronic access to PODS post discharge to facilitate use of information at home, 5) adoption of digital enabled goal-oriented process to engage patients and families in discharge process, and 6) providing ongoing self-management support for patients using ePRO for the vulnerable period 6 months post discharge.
224032712|NCT03453437|BEHAVIORAL|Mindful Self-Compassion|Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
224032713|NCT03739177|DIAGNOSTIC_TEST|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
224032714|NCT00182403|DRUG|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
224032715|NCT02027220|DRUG|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
224032716|NCT02027220|DRUG|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
223415161|NCT06661954|DEVICE|Bed B - supine|Oncare Skinguard surface
223415162|NCT06661954|DEVICE|Bed A - head of bed at 30 degrees|Hercules dream air surface with head of bed at 30 degrees
223415163|NCT06661954|DEVICE|Bed B - head of bed at 30 degrees|Oncare Skinguard surface with head of bed at 30 degrees
223415164|NCT02880475|DRUG|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
223415165|NCT01152346|DRUG|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
223415166|NCT01152346|DRUG|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
223415167|NCT02976558|BEHAVIORAL|Clown theatrical Performance|
223415168|NCT02976558|PROCEDURE|Acupuncture|Acupuncture according to Traditional Chinese Medicine
223415169|NCT02976558|BEHAVIORAL|Music Therapy TaKeTiNa|
223415170|NCT04164108|DIETARY_SUPPLEMENT|Intermittent Enteral Nutrition Protocol|Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
223739010|NCT05459103|OTHER|Bidirectional remote interaction intervention|Intervention group participants engaged in a 12-week bidirectional remote interaction. All interactions were conducted through the same group on Line. A one-hour interactive online group intervention was held every Monday to Friday from 14:30 to 15:30, for a total of 60 hours. The online interactive interventions were conducted in a structured course format, with a facilitator conducting live classes and alternating between static and dynamic classes.
223739011|NCT05459103|OTHER|Unidirectional remote interaction intervention|Control group participants engaged in a 12-week unidirectional remote interaction. All interactions were conducted through the same group on Line. Research assistants posted a YouTube video on the Line group at 14:30 every day, Monday through Friday, covering art, music, senior sports, long-term care resources, travel, and food preparation.
224032717|NCT02027220|DRUG|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
224032718|NCT02027220|DRUG|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
223739012|NCT05098665|COMBINATION_PRODUCT|Telemonitoring service|Patients in the active arm will receive a cellular network connected set of digital scales, and instructed to take their weight each morning at the same time. This device (BodyTrace) automatically uploads each daily weight reading to a central database. A clinical algorithm is applied to detect those at risk of acute and subacute decompensated heart failure. Patients are contacted within 24-48 hours of being flagged as at risk by a heart failure specialist. A clinical history is taken, and medication review undertaken, in line with a protocol. Diuretics are adjusted as per the protocolised changes, or for patients at ceiling of treatment, referral for local specialist review is made. A third protocol for follow-up is then followed to close the loop of intervention.
223739013|NCT03384979|DRUG|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
223739014|NCT01173718|DEVICE|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
223739015|NCT01525043|DRUG|Naproxen|Naproxen 500mg BID for the first 2 weeks
223739016|NCT01525043|DRUG|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
223415178|NCT05929768|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223415179|NCT05929768|DRUG|Carboplatin|Given IV
223415180|NCT05929768|DRUG|Cyclophosphamide|Given IV
223415181|NCT05929768|DRUG|Docetaxel|Given IV
223415182|NCT05929768|DRUG|Doxorubicin|Given IV
223415183|NCT05929768|DRUG|Paclitaxel|Given IV
223415184|NCT05929768|BIOLOGICAL|Pembrolizumab|Given IV
223415185|NCT05929768|OTHER|Quality-of-Life Assessment|Ancillary studies
223560262|NCT05825430|DRUG|general anaesthetic technique only|All patients will receive the same general anaesthetic technique: In the form of iv induction by propofol 2mg /kg ,fentanyl 2 mic/ kg and intubation will be facilitated by atracurium 0.5 mg/kg. Anaesthesia will be maintained by isoflurane 1.5 MAC and incremental doses of atracurium 0.15 mg/kg every 20 min. At the end of surgery neuromuscular blocker reversed by neostigmine 50 micg/kg + atropine 20 micg /kg i.v.
223560263|NCT02352272|OTHER|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
223560264|NCT00510718|DRUG|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
223560265|NCT04749758|BIOLOGICAL|SVF treatment|SVF treatment is developed by Cellab Laboratory (Celstem®). It is made following strict manufacturing guidelines and approved by Andorra's Government authorities. An abdominal fat liposuction is required to obtained Celstem®. The preparation of the product is carried out exclusively in a clean laboratory room under the conditions described by the AABB (American Association of Blood Banks) standards. The treatments application is carried out on the same day of the extraction, at some point between the next 6 hours from the end of the extraction. Firstly, ultrasound joint evaluation is performed. Under sterility measures, intraarticular infiltration of SVF treatment is performed at affected knee or knees. Previous synovial fluid aspiration is performed, if required. Once the procedure is completed, rehabilitation recommendations and clinical follow-up information is provided.
223739017|NCT01525043|DRUG|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
224032719|NCT00096811|DRUG|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
224032720|NCT02819206|OTHER|Blood sampling|Detection of bacteria will be performed on a blood sample
224032721|NCT03054402|DRUG|BAY1834845|Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
224298392|NCT00686530|PROCEDURE|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
223415186|NCT05929768|OTHER|Questionnaire Administration|Ancillary studies
223415187|NCT05929768|PROCEDURE|Surgical Procedure|Undergo surgery
223415188|NCT01075256|DEVICE|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
223415189|NCT01075256|DEVICE|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
223415190|NCT01075256|DEVICE|Placebo toothpaste|Placebo toothpaste
223739018|NCT01525043|DRUG|Naproxen|500mg bid
223739019|NCT01525043|DRUG|Synera|Topical appication of single patch to elbow for 12hrs/day
224032722|NCT03054402|DRUG|Placebo|Single dose of placebo
223415192|NCT00765336|DRUG|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
223415193|NCT00765336|DRUG|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
223560266|NCT04898790|BEHAVIORAL|CHAMPS-II adapted to adults 60+ years in HCT setting|CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
223560267|NCT00611442|DRUG|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
223560268|NCT00611442|DRUG|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
223560269|NCT05878327|OTHER|Thrombophilia screening|No intervention. Blood is drawn for analysis.
223560270|NCT04915170|DEVICE|Inspiratory muscle training|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O)
223560271|NCT06335537|DRUG|Potassium citrate|Urocit-K 30 mEQ orally taken in the morning and evening.
223560272|NCT06335537|DRUG|Sodium bicarbonate|Baking Soda dissolved in up to 250 mL of water ½ teaspoon (29.5 mEq) in the morning and ½ Teaspoon (29.5 mEq) in the evening.
223560273|NCT02582073|BIOLOGICAL|Placebo (0.5ml)|
223560274|NCT02582073|BIOLOGICAL|Placebo (1.0ml)|
224032723|NCT03536299|OTHER|Dual-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
223560275|NCT02582073|BIOLOGICAL|Grass MATA MPL (0.5ml) 5100SU|
223560276|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 10200SU|
223739020|NCT01525043|DRUG|Synera|Single patch applied to elbow for 4hrs/twice daily
224032724|NCT03536299|OTHER|Single-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
224032725|NCT02594605|DEVICE|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
224032726|NCT02594605|DEVICE|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
224032727|NCT02520284|BIOLOGICAL|Andecaliximab|Andecaliximab 150 mg administered via SC injection
224032728|NCT02520284|BIOLOGICAL|Placebo|Placebo matched to andecaliximab administered via SC injection
223415194|NCT04549090|DRUG|QL (quadratus lumborum) block administration|Fo the QL block group, they will be receiving bilateral QL block. A total of 40ml of 0.25% bupivacaine (Marcaine) and 10ml of liposomal bupivacaine (Exparel) will be administered
223415195|NCT05000554|PROCEDURE|Neoadjuvant Therapy|"Drug:~Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa\<1.25m2,40mg/time，twice a day；bsa1.25\~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14；~Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection"
223560277|NCT02582073|BIOLOGICAL|Grass MATA MPL (1.0ml) 18200SU|
223560278|NCT02582073|BIOLOGICAL|Grass MATA (0.5ml) 5100SU|
223560279|NCT01314170|DEVICE|Susanna Implant|device
223560280|NCT01511614|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS), a type of Non-invasive Brain Stimulation (NIBS), has the potential to modify neuronal circuits by application of a subthreshold conductive current through the scalp. Two potential targets for tDCS as a smoking cessation aid are the dorsolateral pre-frontal cortex (dlPFC), a node of the ECN, and the ventromedial prefrontal cortex (vmPFC), a node of the DMN. tDCS can potentially strengthen the control of the ECN through excitatory stimulation of the dlPFC, and weaken the influence of the DMN (Lerman et al 2014) by inhibitory stimulation of the vmPFC. The tDCS model we will use is the neuroConn DC-Stimulator MR (neuroCare Group GmbH, Munchen, Germany).
223560281|NCT01511614|DEVICE|sham|Sham Comparator
223560282|NCT01511614|DRUG|Nicotine patch|Dose-match Nicotine for non-deprived scan
223560283|NCT01511614|DRUG|Placebo patch|Nicotine deprived
223739021|NCT01279551|DRUG|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
223739022|NCT01279551|DRUG|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
224032729|NCT06375707|DRUG|physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS|"Docetaxel: 100mg/m2 IV every 21 days Paclitaxel: 175mg/m2 every 21 days, IV drip Vinorelbine: 25mg/ m2 on days 1 and 8 of each cycle, 1 cycle in 21 days, IV drip Capecitabine: 1000mg/m2, 2 times/d, 2 consecutive weeks of oral discontinuation for 1 week.~Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral"
224032730|NCT06375707|DRUG|Ribociclib combined with NSAI±OFS|Ribociclib: 600mg /d, 3 weeks continuous oral withdrawal for 1 week NSAI: Anastrozole 1mg, 1 time /d, oral or Letrozole: 2.5mg, 1 time /d, oral
224032731|NCT03418337|DRUG|dexilansoprazole (Dexilant 60 mg)|evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group
224032732|NCT03418337|DRUG|lansoprazole (Takepron OD 30 mg)|lansoprazole group
223415196|NCT05300009|COMBINATION_PRODUCT|topical methotrexate hydrogel 1% coupled with microneedling.|Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.
223415197|NCT05300009|OTHER|Liquid nitrogen|"The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area.~The sessions were performed every 2 week until complete clearance for a maximum of six sessions."
223415198|NCT04455087|OTHER|sensitization|sensitization of doctor to decrease the prescription of abuse exams
223415199|NCT01082705|DRUG|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
223415200|NCT01082705|DRUG|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
223415201|NCT02858583|PROCEDURE|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
223415202|NCT02858583|PROCEDURE|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
223415203|NCT03483233|OTHER|fMRI and EEG study|fMRI and EEG study
223415204|NCT05954195|OTHER|high intensity interval training|high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).
223415205|NCT00502970|DRUG|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
223415206|NCT00502970|DRUG|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
223415207|NCT04042688|DRUG|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
223415208|NCT04459000|BEHAVIORAL|STARS + maternal Attachment Biobehavioral Catchup home visiting model|Mothers receive up to 12 home visits from a licensed therapist focused on attachment and positive parenting in substance exposed babies. This includes 1 prenatal home visit and up to 11 postnatal visits.
223415209|NCT04459000|BEHAVIORAL|STARs Only|Participants receive prenatal care in the STAR clinic (a clinic specifically designed to support mothers with substance abuse who are at risk of losing their children to child welfare at birth).
223415210|NCT00666822|BEHAVIORAL|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
223415211|NCT00666822|OTHER|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
223415212|NCT00666822|OTHER|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
223739023|NCT01367158|BIOLOGICAL|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
223415213|NCT03706378|OTHER|Glucose Reference 1|Glucose contains 50g of available carbohydrates
223415214|NCT03706378|OTHER|Glucose Reference 2|Glucose contains 50g of available carbohydrates
223415215|NCT03706378|OTHER|Glucose Reference 3|Glucose contains 50g of available carbohydrates
223415216|NCT03706378|OTHER|Wheat Yellow Noodle|Wheat Yellow Noodle will contain 50g of available carbohydrate
223415217|NCT03706378|OTHER|Beta-glucan yellow Noodle|Beta-glucan yellow noodle will contain 50g of available carbohydrate
223415218|NCT03706378|OTHER|Rice Roll|Rice Roll will contain 50g of available carbohydrate
223415219|NCT03706378|OTHER|Rice Roll with resistant starch|Rice Roll fortified with resistant starch will contain 50g of available carbohydrate
223739024|NCT01367158|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
224032733|NCT03726710|BEHAVIORAL|Blood Pressure measurement and pharmacy|Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
224298393|NCT00686530|PROCEDURE|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
223739025|NCT01367158|BIOLOGICAL|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
223739026|NCT02850315|DEVICE|optimal coherence tomography|
224298394|NCT01776463|DRUG|Z-360|
224298395|NCT01776463|DRUG|placebo|
223415220|NCT03706378|OTHER|Sucrose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose
224032734|NCT04776785|DEVICE|Curodont™ Repair|"It is a product used in biomimetic remineralization of initial carious lesions. The product consists of smart P11-4 peptide molecules (CUROLOX® TECHNOLOGY) that within the lesion the molecules self-assemble to a 3D matrix. This bio-matrix enables the regeneration of the tooth tissue.~Test 1 lesions will be cleaned with a prophylaxis paste and isolated with cotton rolls. Then, the pellicle will be removed using 2% sodium hypochlorite (20 sec) and the inorganic deposits will be removed using 35% phosphoric acid (20 sec). The tooth surface will be rinsed with water and dried. Thereafter, Curodont™ Repair will be applied in compliance with the manufacturers' instructions and left for 5 minutes."
223415221|NCT03706378|OTHER|Isomaltulose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
223415222|NCT06318988|PROCEDURE|Radiofrequency ablation using Closure fast|Thermal ablation technique
223415223|NCT06318988|PROCEDURE|Aethoxysclerol|sclero-or foamsclerose
223415224|NCT06318988|DRUG|Daflon|Venoactive drugs
223415225|NCT06318988|DEVICE|Compression stocking|Compression
223415226|NCT01218087|DEVICE|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
223560284|NCT01511614|DRUG|Varenicline Pill|Treatment
223560285|NCT01511614|DRUG|Placebo pill|Active comparator to varenicline
224032735|NCT04776785|DEVICE|MI Varnish™|"MI Varnish™ is a 5% sodium fluoride (NaF) varnish that has a desensitizing action when applied to tooth surfaces. The product also contains RECALDENT™ (CPP-ACP): Casein Phosphopeptide-Amorphous Calcium Phosphate. The application leaves a film of varnish on tooth surfaces and also facilitates the tooth remineralization.~Test 2 lesions will be isolated with cotton rolls. Then, MI Varnish ™ will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
224136482|NCT06692478|BEHAVIORAL|Exercise regimen|"Age 4-6 years: Target lower extremity, core and upper extremity strengthening and activity tolerance. With supervision by the PT, the patient will walk in their room, and complete the following through play: squat, single leg stance, climb onto couch, half kneel to stand, quadruped and tall kneeling.~Age 7-21 years: First component will be strengthening exercises completed in bed or on a mat while sitting or standing. Multiple levels of exercises will be available, so that the program can be tailored to each patient and to their ability to perform activities. The exercises included will focus on core, hip musculature, and upper extremity strengthening; including exercises in quadruped and prone positioning, as well as supine, sitting and standing. Thera-Band will be used to increase resistance as needed. The second component will be endurance. Since the patients will be confined to their room this will include ambulation within the room, recumbent or pedal exerciser and step ups."
223415227|NCT01218087|DEVICE|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
223415228|NCT03979053|DEVICE|Multiparametric MRI Scan|Patients attending the clinic will have a MRI scan added to their standard of care.
223415229|NCT00203619|DEVICE|Wireless capsule endoscopy|wire less capsule endoscopy
223415230|NCT00203619|OTHER|standard care|standard diagnostic evaluation as decided by treating physician
223415231|NCT04402762|DRUG|Ovine Enoxaparin|The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
223415232|NCT04402762|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
223415233|NCT04499144|PROCEDURE|modified buccal flap and subepithelial connective palatal flap|The connective flap was harvested from the deeper area of the palatal mucosa. Pedicle flap dimensions were reported using the periodontal probe. The flap was then rotated to cover the oro antral communication (OAC) area. The rotation could be in mesial or distal direction, related to OAC position and for the convenience of the donor site. The connective palatal flap was sutured to the buccal periostium using mattress sutures.
223415234|NCT02948751|DEVICE|OncoCEE|The CSF sample will be to delivered to Biocept's laboratory for processing, and it will be evaluated for CTCs using OncoCEETM microchannel technology. This CSF sample will also be tested for cell-free circulating tumor DNA (ctDNA).
223415235|NCT02580409|BEHAVIORAL|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
223560286|NCT01511614|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing for smoking cessation preparation
223560287|NCT04975126|OTHER|CatInfo tool|Presentation about cataract surgery
223560288|NCT05867420|BIOLOGICAL|ASKG915|ASKG915 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle.
223560289|NCT01035437|DRUG|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
223560290|NCT02150057|DEVICE|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
223560291|NCT00489424|DRUG|Placebo|
223560292|NCT00489424|DRUG|Acetaminophen|
223560293|NCT00489424|DRUG|Fluvastatin|
223560294|NCT02616497|DRUG|Aspirin|COX-1 inhibitor
223560295|NCT02616497|DRUG|Triflusal|COX-1 inhibitor
223560296|NCT02545660|OTHER|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
223560297|NCT02545660|OTHER|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
223415236|NCT02619630|DRUG|nelarabine|"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil \>1 Giga/Liter~for a maximum of 5 blocks"
223415237|NCT04490291|OTHER|chronic pain team|enrollment in chronic pain team at study site
223415238|NCT04490291|OTHER|chiropractic team|enrollment in chiropractic team/intervention at study site
223415239|NCT06575829|DRUG|Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks|The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
223415240|NCT00511914|BIOLOGICAL|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
223415241|NCT03025529|DEVICE|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation or TMS is a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. This magnetic field can pass through the head safely and painlessly. TMS can be used to change activity in the brain.
223415242|NCT03025529|DEVICE|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation or sham TMS is like active TMS, a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. TMS can be used to change activity in the brain but in this intervention, the coil will be angled 90 degrees from the scalp, resting on one wing of the coil, and therefore will not be delivering active TMS.
223415243|NCT01001273|OTHER|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
224032736|NCT04776785|DEVICE|Profluorid® Varnish|"Profluorid® Varnish is a 5% sodium fluoride (NaF) varnish for surface application to enamel and dentin. The product will adhere to wet surfaces and is tolerant to moisture and saliva. Profluorid® Varnish is an ethanolic suspension of colophony with artificial flavors and sweetened with xylitol. It is also used in the remineralization of initial caries.~Control lesions will be isolated with cotton rolls. Then, Profluorid® Varnish will be applied as a thin layer in equal thickness with a disposable brush in accordance with the manufacturers' instructions. Thereafter, the tooth surface will be moistened with water or saliva to ensure that the material adheres to the applied area."
224136483|NCT06693232|PROCEDURE|Mobile micro-learning|Mobile micro-learning intervention contains a 10-minute video about cardiopulmonary resuscitation to continuously improve their self-confidence, motivation and reduce their stress
223415244|NCT04438837|DRUG|Hydroxychloroquine|Hydroxychloroquine post exposure prohylaxis
223415245|NCT04659954|OTHER|Application O'DIDE|The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.
224032737|NCT05097027|DEVICE|Blood flow restriction recovery|Soccer players included in experimental group I will carry out this program for 1 week setting the blood pressure to \~ 60% of limb occlusion pressure (LOP). After a month they will carry out the program without restriction of blood flow. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
224298396|NCT03479463|BIOLOGICAL|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
224298397|NCT02271139|DRUG|Alectinib|Alectinib 600 mg administered orally with food.
223415246|NCT03972189|DRUG|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
223415247|NCT03010800|DEVICE|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
223415248|NCT03010800|DEVICE|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
223415249|NCT05619354|OTHER|Survey study|Participants will be asked to complete and evaluate the Dutch version of the Headache Disability Index. Validity (face validity, content validity, convergent validity with the RAND-36 and HIT-6) will be determined. Second, internal consistency and test-retest reliability will be evaluated.
223415250|NCT04771598|OTHER|Breathing exercise with the phone application|"1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Respiratory exercises will be instructed to the individuals forming the intervention group and participants will be asked to do 3 times a day during one month and the exercises will be done by the researchers together with the individuals by establishing a connection with the phone application (zoom, watsapp) once a week from home."
223415251|NCT04771598|OTHER|Breathing exercise|"1. Respiratory Control:~2. Pursed Lip Breathing~3. Diaphragmatic Breathing Breathing exercises will be explained to the control group and visual material will be given. The participants will be asked to do 3 times a day during one month. In terms of physical activity, the patient will be encouraged to participate in the program by suggesting exercises such as walking and cycling at least three times a week for 20 minutes per week"
223415252|NCT00245089|BIOLOGICAL|dactinomycin|
223415253|NCT00245089|DRUG|cyclophosphamide|
223415254|NCT00245089|DRUG|vincristine sulfate|
223560298|NCT06179628|DRUG|Low bolus concentration and volume|Compare Low and Standard concentrations and volumes of bupivacaine boluses for continuous adductor block
223560299|NCT00394251|DRUG|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m\^2 intravenous, plus Cytoxan 600 mg/m\^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
224298398|NCT02955017|BEHAVIORAL|traditional follow_up|"* Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~* Two days of a complete medical check at 9 and 15 months"
224298399|NCT02955017|BEHAVIORAL|"distance follow-up new technologies"|"* Multidisciplinary support with long distance monitoring Mobile apps.~* Two days of a complete medical check at 9 and 15 months"
223415255|NCT03019601|BEHAVIORAL|Group Education|Structured group education on family planning facilitated by Peer Champions
223415256|NCT02556073|OTHER|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
223415257|NCT02556073|DRUG|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
223415258|NCT02705300|DRUG|Irinotecan 165 mg/m2 iv|Max. 4 months
223415259|NCT02705300|DRUG|Oxaliplatin 85 mg/m2 iv|Max. 4 months
223415260|NCT02705300|DRUG|Calcium folinate 200 mg/m2 iv|Max. 6 months
223415261|NCT02705300|DRUG|5-fluorouracil 3200 mg/m2|Max. 6 months
223415262|NCT02705300|DIETARY_SUPPLEMENT|Tocotrienol|Max. 2 years or at the discretion of the investigator
223415263|NCT02705300|DRUG|Placebo|Max. 2 years or at the discretion of the investigator
223415264|NCT01955278|DEVICE|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
223415265|NCT01955278|OTHER|Conventional definitive end colostomy|
223415266|NCT02921932|DIETARY_SUPPLEMENT|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
223415267|NCT02921932|OTHER|Cognitive Training, Memory Card Game|Preoperative memory card game
223415268|NCT02921932|DEVICE|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
223415269|NCT04552990|DRUG|Jet injection of ALA|The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).
223415270|NCT04552990|PROCEDURE|Surgical excision|In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).
223415271|NCT04552990|PROCEDURE|Illumination|For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).
223415272|NCT04552990|OTHER|Incubation|After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
223415273|NCT05276375|DRUG|Bronchipret|Bronchipret syrup (3x 5,4 ml daily) until day 14
223415274|NCT06926387|DRUG|YHP2407|Test drug: YHP2407, Comparator: YHR2502
223415275|NCT06926387|DRUG|YHR2502|Test drug: YHP2407, Comparator: YHR2502
223415276|NCT06014190|DRUG|HS-20089|All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
223415277|NCT02727946|OTHER|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
223415278|NCT01314872|DRUG|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
223415279|NCT01314872|DRUG|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
223415280|NCT01314872|DRUG|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
223415281|NCT01314872|DRUG|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
223415282|NCT01733667|DEVICE|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
223415283|NCT01733667|DEVICE|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
223415284|NCT03286556|DRUG|Autoantibody Reductive Therapy|TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
223415285|NCT03286556|DRUG|Treatment as Usual (TAU)|Antibiotics and steroids
223415286|NCT06252545|BEHAVIORAL|semistructured interviews|Black subjects with pancreatic cancer will provide insight on their experience discussing clinical trials and preferences for communicating clinical trial information
223415287|NCT06252545|BEHAVIORAL|feedback|Black subjects with pancreatic cancer will provide feedback on mHealth app prototype.
223415288|NCT06001307|BEHAVIORAL|Program STARS (Supporting Trans Affirmation, relationships, and Sex)|See description to the left.
223415289|NCT06001307|BEHAVIORAL|Relaxation and Stress Reduction|See description to the left.
223415290|NCT04211675|BIOLOGICAL|Natural Killer Cells|NK cells dose 1x 108 cells/ kg on day 8 of each cycle
223415291|NCT04211675|DRUG|Temozolomide|Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.
223560300|NCT00394251|DRUG|ABI-007|260 mg/m\^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
223415292|NCT04211675|DRUG|Irinotecan|Irinotecan 50mg/m2/dose IV daily on Days 1-5
223415293|NCT04211675|DRUG|Dinutuximab|Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5
223415294|NCT04211675|DRUG|Sargramostim|Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12
223415295|NCT03232931|BEHAVIORAL|Therapist skin-to-skin Care|"Skin-to-skin (STS) holding is part of the multisensory intervention where the therapist will wear a clean 100% cotton T-shirt with a clean hospital gown on top of the shirt and wrap the kangaroo positioner securely over the gown. A gauze square scented with parent's skin will be used to provide olfactory stimulation. Therapist STS sessions occur with simultaneous playing of mother's voice contingent on infant pacifier sucking."
223415296|NCT03232931|DEVICE|Contingent parent's voice exposure|The Pacifier Activated Lullaby® (PAL®) device, is a digital music delivery system that integrates a sensor, a pacifier routinely used in the NICU, and a receiver. It delivers a predetermined 10 seconds of recorded parent's voice singing lullabies upon detection of a suck that meets a preset pressure threshold. The original systems were modified for research use by decreasing the lower limit of activation thresholds for delivering the recording. Minimal effort is required to trigger the device. However, the settings ensure that regular attempts are needed to continue to receive continual presentation of the recording of mother's voice by requiring another suck after 10 seconds. The auditory stimulation with PAL will be provided when the infants are still awake (i.e., at the beginning of the session).
223415297|NCT03232931|BEHAVIORAL|Parental skin-to-skin care|The standard of care includes parental skin-to-skin care and exposure to parent's voice. During parental skin-to-skin care, infants are placed in a prone position with head positioned over the sternum, allowing transmission of breath and heart sounds to the developing ear. Deeper pressure is applied to offer support and feedback to the child's bottom. Session length is set to a minimum of 45 minutes per unit protocols.
223415298|NCT03232931|DEVICE|Recorded parent's voice|Per standard of care, preterm infants in the NICU currently receive noncontingent recorded parents' voice during two 20 minute sessions per day. Recordings are standardized and are played through a sterilizable device (DINO-egg).
223415299|NCT04594980|PROCEDURE|lumbar fusion|Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
223415300|NCT04294979|OTHER|Physical Therapy|The rehabilitation program will consist of both passive and active therapeutic exercises specifically aimed at restoring or maintaining muscular flexibility, range of motion, balance, coordination of movements, postural passages and transfers, and ambulation. . Furthermore, advanced robotic therapy such as Lokomat® exoskeleton (Hocoma AG, Volketswil, Switzerland), Biodex® Stability System (BSS, Biodex, Inc, Shirley, NY), G-EO System™ (Reha Technology AG, Olten, Svizzera) and Indego® Therapy (Parker USA), will be used to personalize rehabilitation treatment.
223560301|NCT00394251|DRUG|Taxol|175 mg/m\^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
223560302|NCT00394251|DRUG|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
223560303|NCT00394251|DRUG|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
223560304|NCT02304913|OTHER|Hypoglossal acupuncture|
223560305|NCT02304913|OTHER|Sham acupuncture|
223560306|NCT02304913|BEHAVIORAL|Dietary recommendations|
223560307|NCT05791565|DRUG|Salbutamol HFA-152a|Salbutamol HFA-152a will be administered.
223560308|NCT05791565|DRUG|Salbutamol HFA-134a|Salbutamol HFA-134a will be administered.
223560309|NCT05389423|DRUG|Vincristine|0.4 mg/m2/day administered by CIVI on days 1 to 4
223560310|NCT05389423|DRUG|Prednisone|60 mg/m2/day administered orally on days 1 to 5
223560311|NCT05389423|DRUG|Doxorubicin|10 mg/m2/day administered by CIVI on days 1 to 4
223560312|NCT05389423|DRUG|Etoposide|50 mg/m2/day administered by CIVI on days 1 to 4
223560313|NCT05389423|DRUG|Pomalidomide|An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.
224032738|NCT05097027|OTHER|Active recovery|Soccer players included in experimental group II will carry out this program for 1 week. After a month they will carry out the program with blood flow restriction. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
224032739|NCT01898923|DRUG|ON101 Cream|
223560314|NCT05389423|DRUG|Cyclophosphamide|750 mg/m2 administered IV on day 5
223560315|NCT05389423|DRUG|Rituximab|375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
223560316|NCT06581614|DIAGNOSTIC_TEST|masticatory function test|During the test, participants will be given a piece of chewing gum to assess their masticatory function when the second molar implant-supported fixed denture is in place.
223560317|NCT04612348|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound to measure gastric contents.
223560318|NCT05558592|DIETARY_SUPPLEMENT|Dietary supplementation with fresh oranges|"the subjects enrolled in this group, will have to consume 400gr of oranges Navelina net of waste / day / per person for a month. The oranges will be provided, to each participant, by the IRCCS Saverio de Bellis."
223560319|NCT05558592|DIETARY_SUPPLEMENT|Balanced Diet without oranges|the subjects enrolled in this group, will have to consume 400 gr of fruit (with the exception of citrus fruits) net of waste / day / per person for a month.
223560320|NCT06376669|RADIATION|Proton Stereotactic Body Radiation therapy (SBRT)|Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks
223560321|NCT06195046|DEVICE|Baroreflex Activation Therapy (BAT)|activation of BAROSTIM NEO system that affects autonomic modulation with BAT therapy.
223560322|NCT01558115|DRUG|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
223739027|NCT01764009|BIOLOGICAL|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
223739028|NCT04854811|DRUG|Roflumilast Oral Tablet|Once daily for 12 weeks
224032740|NCT01898923|OTHER|Aquacel® Hydrofiber® dressing|
224032741|NCT01477320|DRUG|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
224032742|NCT01477320|OTHER|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
224032743|NCT05961904|OTHER|Breastmilk|Study group with receive orally 2 ml breast milk before the heel prick.
224032744|NCT02926625|BEHAVIORAL|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~* Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~* Children who are getting worse should come back immediately or at any time for a re-assessment~* All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~* HEW should fill out a loose child assessment form~* If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
224032745|NCT02926625|BEHAVIORAL|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
224136484|NCT06693245|PROCEDURE|VAS scores of the puncture|All patients were evaluated by our team with CEAP grading and ultrasound measurements to record the diameter of the saphenous vein before surgery。We performed endovenous microwave ablation of the great saphenous vein along with foam sclerotherapy and point stripping treatment. We documented the operating room temperature, puncture site, VAS scores during puncture and catheter placement, the amount of injected tumescent fluid, radiofrequency generator used, and data at the conclusion of the surgery. A descriptive analysis of intraoperative pain scores was conducted to evaluate the level of pain experienced during the surgery. A nonparametric test was utilized to analyze the relationship between preoperative and intraoperative factors and the level of pain experienced during the surgery.
223415301|NCT05868005|OTHER|Clinical decision support system for screening of migrants using the ISMiHealth software tool.|"The implementation of the screening programme will be facilitated using a simple and user-friendly software tool (ISMiHealth).~When an individual attends the PCC for any reason, the tool will generate an alert for health professionals in the EPR system, with recommendations on the conditions that should be considered for screening, based on this patient's characteristics (country of birth, age and sex). Health professionals will decide what diseases/conditions should be screened for, supported by the recommendations of the digital software (intervention centres) or based on their knowledge on the epidemiological background of the diseases (control centres). In any case, health professionals will be responsible for requesting serology tests, chest radiographies and/or referrals to specialists."
223415302|NCT06957574|DRUG|Bubpivacaine|ESPB using local anesthetic 20 ml 0.25% bupivacaine on each side
223415303|NCT06957574|DRUG|Normal Saline (Placebo)|ESPB using normal saline 20 ml 0.25% bupivacaine on each side
223415304|NCT06225011|DRUG|Fluoxetine|Receive PO
223415305|NCT04556266|BIOLOGICAL|CAR T-Cell Infusion|Dose Level -1: 1 x 10\^4 cells/kg Dose Level 1: 1 x 10\^5 cells/kg Dose Level 2: 2 x 10\^5 cells/kg Dose Level 3: 4 x 10\^5 cells/kg
223415306|NCT06433921|DRUG|Salbutamol HFA-152a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
223415307|NCT06433921|DRUG|Salbutamol HFA-134a|A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.
223739029|NCT03613051|BEHAVIORAL|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
224032746|NCT04597528|OTHER|Elective Induction|"All patients admitted to the labour room would be approached to be enrolled in the study.~Those satisfying the inclusion and exclusion criteria would be prospectively enrolled to the study after procuring an informed consent. If a patient appears to meet the criteria for the study, she will be told about the study and asked for written informed consent to participate. Consent may be obtained anytime from 34 weeks 0 days to 38 weeks 6 days of gestation. Data would be procured on a pre set proforma, entered in real time and safely stored.~The data would later be abstracted to an excel sheet."
224032747|NCT01638494|DIETARY_SUPPLEMENT|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
224032748|NCT01251250|OTHER|laboratory biomarker analysis|Correlative studies
223415308|NCT06433921|DRUG|Placebo|A single placebo HFA-152a suspension or placebo HFA-134a suspension dose, given as at 20 second intervals.
223415309|NCT04925557|DRUG|Mayzent|PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
223415310|NCT04925557|DRUG|Ocrevus|PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
223415311|NCT06356025|DRUG|botulinum toxin type A|Botulinum toxin type A 75U dissolved in 3mL physiological serum injection in the upper esophageal sphincter
223415312|NCT06356025|DRUG|Sodium Chloride 0.9% Inj|Placebo: physiological serum 3mL injection in the upper esophageal sphincter
223415313|NCT05488470|DEVICE|LINQ/LINQ II|Algorithm developed and validated to continuously measure QT intervals for every beat using LINQ/LINQ II ECG. This study is aimed at determining if QT interval changes can be detected during antiarrhythmic drug loading by the designed QT detection algorithm from LINQ/LINQ II ECG.
223415314|NCT05221554|PROCEDURE|Computer-navigated THA surgery|Navigation software coupled with real-time modeling software will be used to plan optimal acetabular cup for patients undergoing THA.
223415315|NCT05221554|PROCEDURE|Standard of care THA surgery|Patients already underwent THA procedure with manual placement of acetabular cup with conventional instrumentation.
223415316|NCT05639088|BEHAVIORAL|Transition preparation program|"AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management.~Caregivers will attend a virtual or in-person session with a transition coach."
223415317|NCT05639088|OTHER|Educational materials|AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months
223415318|NCT03431090|DEVICE|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
223415319|NCT02966730|DRUG|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
223415320|NCT01941745|DRUG|Half normal saline|2 ml/kg
223415321|NCT01941745|DRUG|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
223415322|NCT01941745|DRUG|High dose rhCC10|5 mg/kg in 2 ml/kg
223415323|NCT05946798|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
223415324|NCT05946798|DRUG|Insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
223415325|NCT01653015|BIOLOGICAL|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
223415326|NCT01653015|BIOLOGICAL|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
223415327|NCT01527695|DRUG|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
223415328|NCT01527695|DRUG|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
223415329|NCT01527695|DRUG|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
223560323|NCT01558115|OTHER|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1: Receive active drug for year 1 and year 2 of the study~Group #2: Receive placebo for year 1 and active drug for year 2 of the study"
223560324|NCT01696994|OTHER|Laboratory Biomarker Analysis|Correlative studies
223560325|NCT01696994|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
223560326|NCT01696994|PROCEDURE|Ultrasound Imaging|Undergo TVU
223560327|NCT02733822|DRUG|Naloxone|
223415330|NCT01527695|DRUG|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
223560328|NCT03870451|DEVICE|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
223560329|NCT05438719|DEVICE|MOTUS Total Joint Replacement|The MOTUS Total Joint Replacement is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level from L1/L2 to L5/S1 for skeletally mature patients due to symptomatic lumbar degeneration with or without foraminal or recess spinal stenosis confirmed by radiographic imaging (CT, MRI, X-rays), with no more than a Grade 1 spondylolisthesis at the involved level.
223560330|NCT02850224|BEHAVIORAL|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
223415331|NCT04101682|DRUG|Bupivacaine|Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
223415332|NCT06600126|BEHAVIORAL|Coping Skills Training|The Coping Skills Training arm will consist of 12 weekly 30-minute sessions via videoconferencing or phone. A trained research staff member will deliver sessions that focus on building coping skills for patients with COPD, such as progressive relaxation training, pleasant activity scheduling, and building communication skills. Caregivers will also participate, learning how to support the patient in using these skills. Participants will complete assignments between sessions to reinforce their learning. Additionally, participants will receive a Coping Skills Training workbook.
223415333|NCT06600126|BEHAVIORAL|COPD Education|The COPD Education arm will consist of 12 weekly 10-minute sessions via videoconferencing or phone. A trained research staff member will provide scripted general support and encouragement without using specific psychoeducational techniques. Caregivers will also participate. Additionally, participants will receive a COPD Education workbook with material from The COPD Foundation, which is also available on the Foundation's website. This program augments usual care, providing an attention control for comparison.
223415334|NCT05770271|DEVICE|The novel electrolyzed water spray|Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild senile groin eczema, neurodermatitis and psoriasis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
223560331|NCT04588220|OTHER|Obstetric ultrasound and fetal-maternal assessment|melatonin, soluble urokinase-type plasminogen activator receptor, and orosomucoid 2 measurements
223560332|NCT01589146|DRUG|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
223739030|NCT05814458|DEVICE|tDCS|Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
224032749|NCT01251250|GENETIC|western blotting|Correlative studies
224032750|NCT01251250|GENETIC|gene expression analysis|Correlative studies
224032751|NCT01251250|OTHER|pharmacological study|Correlative studies
224032752|NCT01251250|OTHER|flow cytometry|Correlative studies
224032753|NCT01251250|GENETIC|fluorescence in situ hybridization|Correlative studies
224032754|NCT01251250|BIOLOGICAL|azadirachta indica|Given orally
223415335|NCT02986282|DEVICE|ABI measurement using both doppler and oscillometric method|
223415336|NCT06435143|DEVICE|Prelivia|Pad applied to skin provide electrical stimulation for 10 seconds every 10 minutes
223415337|NCT04938284|DEVICE|PAS|Paired associative stimulation is a combination of non-invasive transcranial magnetic stimulation (TMS) and non-invasive peripheral nerve stimulation (PNS)
223415338|NCT04938284|DEVICE|VNS|Non-invasive vagus nerve stimulation delivered through cymba concha \& cymba cavum of the ear.
223415339|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|Subconjunctival daily or bid
223415340|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical and systemic
223415341|NCT00734695|DIETARY_SUPPLEMENT|vitamin c|topical systemic
223415342|NCT06483711|OTHER|Lifestyle Kit|The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
223415343|NCT05162417|OTHER|Methylene Blue|1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
223560333|NCT04682223|BEHAVIORAL|Semantically-focused therapy tasks|1\) Semantic feature analysis (SFA; Boyle \& Coelho, 1995; Boyle, 2004). For each pictured stimulus the participant is prompted to name the picture. Then, s/he is encouraged to produce semantically related words that represent features similar to the target word. 2) Semantic barrier task. This approach includes features of the Promoting Aphasics' Communication Effectiveness (PACE; Davis \& Wilcox,1985). The goal of the task is for one participant (e.g., person with aphasia) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. 3) Verb network strengthening therapy (VNeST; Edmonds et al., 2009; 2014) targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the participant to generate verb-noun associates with the purpose of strengthening the connections between the verb and its thematic roles.
223739031|NCT05814458|DEVICE|Placebo|Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.
224032755|NCT01251250|GENETIC|reverse transcriptase-polymerase chain reaction|Correlative studies
224032756|NCT03444727|OTHER|Ice Pre-treatment|Topical application of ice prior to local anesthetic injection.
224136485|NCT06693791|DRUG|Romiplostim N01|Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.
224136486|NCT02300077|DRUG|methadone|Escalating dose of methadone up to .3mg/kg.
224136487|NCT02300077|DRUG|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
224136488|NCT05824637|DEVICE|Skin Prick Automated Test|skin prick test to detection sensitisation to aeroallergens
223415344|NCT05162417|OTHER|Toluidine Blue O|1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
224032757|NCT03444727|OTHER|Room Temperature Water Pre-treatment|Topical application of room-temperature water prior to local anesthetic injection.
224032758|NCT04130386|BEHAVIORAL|Motivational Interviewing|Participants receiving MI
223415345|NCT04973423|RADIATION|MRI|2 additional MRI will be done for the CALM + MRI group
223415346|NCT02926157|BEHAVIORAL|Life Style and Sleep Intervention|
223415347|NCT04849468|DRUG|Declofenac|evaluating the preemptive effect of intramuscular declofenac on postoperative analgesia in patients undergoing perianal surgeries under saddle block
223415348|NCT04849468|DRUG|saline|evaluating the preemptive effect of intramuscular saline on postoperative analgesia in patients undergoing perianal surgeries under saddle block as control
223415349|NCT04325568|BEHAVIORAL|PsyGist and Clinician Manual|This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis. Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
223415350|NCT04390503|BIOLOGICAL|Convalescent Plasma (anti-SARS-CoV-2 plasma)|Convalescent Plasma that contains antibody titers against SARS-CoV-2.
223415351|NCT04390503|BIOLOGICAL|Control (albumin 5%)|Albumin (Human) 5% is a sterile aqueous solution for intravenous use containing the albumin component human plasma.
223415352|NCT00833495|DRUG|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
223415353|NCT00833495|DRUG|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
224032759|NCT04130386|BEHAVIORAL|e-education|Participants receiving e-education
224032760|NCT00621387|DRUG|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
224032761|NCT00621387|DRUG|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
224032762|NCT01531647|DRUG|danoprevir|100 mg q12h Days 8-21
224032763|NCT01531647|DRUG|raltegravir|400 mg q12h Days 1-4 and 18-21
224032764|NCT01531647|DRUG|ritonavir|100 mg q12h Days 8-21
224032765|NCT02951741|OTHER|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
224136489|NCT05824637|DIAGNOSTIC_TEST|Skin Prick Manual Test|skin prick test to detection sensitisation to aeroallergens
224136490|NCT02304315|BIOLOGICAL|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
224136491|NCT02304315|BIOLOGICAL|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
223415354|NCT00833495|DRUG|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
223415355|NCT00833495|DRUG|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
223415356|NCT05472129|OTHER|self-administered questionnaires|The validation process of a linguistic translation must maintain conceptual and technical equivalence between the source and the target language.The questionnaire was submitted to women during a gynecological medical interview and they were asked to evaluate their perceived degree of difficulty in understanding each question item. After that, the final Italian version of the questionnaire was obtained
223415357|NCT04606004|OTHER|Stool application|Application of stool from the stoma bag 4 weeks prior, twice daily for 10 minutes at a time. However, with the stool application no barrier cream will be applied to the skin in order for the stool to achieve penetrance to the skin. Stool application will include removing any barrier creams gently, applying a thin layer of stool with a surface area shown in illustration to ensure consistent coverage, and placing a diaper on the subject. Depending on the type of the participant's ostomy, a medication cup, syringe, and/or tongue blade provided by the researchers, may be used to aid in the application of stool. After 10 minutes of application, the caregiver or inpatient healthcare provider will remove the entire thin layer of stool gently without excessive friction, just enough to remove the stool, a dabbing motion is preferred.
223415358|NCT04606004|OTHER|Standard of care skincare|"Standard of care for skin care pre-operatively: which is either no application of barrier cream, or an application of an over the counter (OTC) skin barrier such as Aquaphor, Desitin, or Vitamin A\&D if the patient is experiencing skin redness from urine incontinence.~Standard of care skin creams post op: 3M no-sting immediately post op, once begin stooling- stoma powder, 3M no-sting, Critic-aid thick barrier paste will be applied to the skin."
223415359|NCT00415818|BIOLOGICAL|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
223415360|NCT00415818|DRUG|1st line Chemotherapy|
223415361|NCT03187418|DEVICE|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
223415362|NCT03076034|DEVICE|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (\~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of \~375 µm."
223415363|NCT00477399|BEHAVIORAL|Long term follow up after intensive lifestyle intervention|
223415364|NCT01980459|DIETARY_SUPPLEMENT|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
223415365|NCT01068730|DRUG|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
223415366|NCT01068730|DRUG|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
223560334|NCT04682223|BEHAVIORAL|Phonologically-focused therapy tasks|1\) Phonological components analysis task (PCA; Leonard et al., 2008). The participant first attempts to name a given picture and then to identify the phonological features of the target words. 2) Phonological production task focuses on the identification of phonological features of targeted, imageable nouns and verbs. It requires the participant to sort picture stimuli based on the number of syllables and then to identify a hierarchy of phonological features. Once each targeted feature is identified for the pair of words, the participant is required to blend the syllables/sounds together. 3) Phonological judgment task relies on computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features (e.g. # of syllables, initial phonemes, final phonemes, rhyming).
224032766|NCT03583177|DIAGNOSTIC_TEST|No intervention|No intervention
224032767|NCT05387226|BIOLOGICAL|Oncolytic Virus Injection(RT-01)|RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
223560335|NCT04408391|OTHER|Brain MRI scan|Resting state, functional, structural and morphometric MRI; diffusion tensor imaging on a 3-Tesla MRI scanner
223560336|NCT04727450|BEHAVIORAL|Cognitive training|Involves participants engaging in selected games which require thinking skills to be played in a group of 2-4 people.
224032768|NCT04466826|OTHER|Headache Journal|Phase 1 of study to determine a baseline for headache frequency, headache intensity and medication usage patterns
224032769|NCT04466826|DRUG|Sphenopalatine Block|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
224032770|NCT04466826|DEVICE|Tx360|Phase 2 of study providing medication using 0.3ml of 0.5% Bupivacaine per nares delivered intranasal via the Tx360 device
224136492|NCT06419517|DEVICE|EMG-triggered ES|The ES treatment protocol consisted of daily endovaginal electrostimulation sessions for four weeks. We used a portable unit EVOSTIM ®, which allowed us to use different frequencies and length of impulse and a probe Perisphera ® The average current intensity was adjusted according to the sensation of discomfort in each patient.
224032771|NCT04792957|DIAGNOSTIC_TEST|immunohistochemical methods|The following immunohistochemical stains will be used to evaluate the expression of JAK/STAT pathway: JAK1, JAK2, JAK3, Tyrosine Kinase 2, STAT1, STAT2, STAT3, STAT3, STAT4, STAT5 and STAT6. Staining intensity will be recorded categorically (negative and positive). The positive staining will also be graded semi-quantitively as follows: mildly positive, moderately positive and strongly positive.
224032772|NCT00815672|BEHAVIORAL|Exercise|Progressive walking and resistance exercise treatment
223415367|NCT01068730|DRUG|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
223415368|NCT01068730|DRUG|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
223415369|NCT05251831|DRUG|Intradermal injection|Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
223415370|NCT00417924|BEHAVIORAL|Patient education|
223415371|NCT05771324|OTHER|Baby-Led Weaning (BLW)|BLW trainings given to mothers for 6-12 month old babies
223415372|NCT05771324|OTHER|Traditional Complementary Feeding (TCF)|TCF trainings given to mothers for 6-12 month old babies
223415373|NCT04687046|DEVICE|JUVÉDERM VOLUX®|JUVÉDERM VOLUX® injectable gel
223560337|NCT04727450|BEHAVIORAL|physical training|"Involves learning of preselected routines of line dancing taught by a line dance instructor."
224032773|NCT06000020|PROCEDURE|Laparoscopic appendectomy|Laparoscopic appendectomy as performed as standard world wide. Division of the appendix with laparoscopic stapler.
224032774|NCT03924908|BEHAVIORAL|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
224032775|NCT03924908|BEHAVIORAL|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
224032776|NCT02641223|DEVICE|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
224032777|NCT06382025|OTHER|showing cartoons -storybook|A goal-oriented 8-9 minutes animation cartoon that is informative and educational had been developed, and pediatric surgery patients had been asked to watch this animation during preoperative period
224032778|NCT06382025|OTHER|showing cartoons - standard|standard
224136493|NCT06419517|OTHER|Pelvic Floor Muscle Training|Standardization of the supervised PFMT To achieve standardization of supervised PFMT treatments, a written protocol for the physiotherapeutic examinations and PFMT program will be provided to the physiotherapists (or nurse or midwife) delivering the treatments (See Additional file).
224136494|NCT06712511|OTHER|Caffeine content|Participants will drink the same volume of water or coffee, caffeine content is 2mg/kg by body weight.
224136495|NCT00486538|DRUG|ABT-869|One oral dose daily.
223415374|NCT06502600|PROCEDURE|surgery time|This study is a retrospective observational study, with surgery time being one of the exposure factors under investigation.
223415375|NCT06502600|PROCEDURE|surgeon|This study is a retrospective observational study, with surgeon being one of the exposure factors under investigation.
223415376|NCT06502600|PROCEDURE|surgical procedure duration|This study is a retrospective observational study, with surgical procedure duration being one of the exposure factors under investigation.
223415377|NCT06502600|PROCEDURE|operating room|This study is a retrospective observational study, with surgical procedure duration being one of the exposure factors under investigation.
223415378|NCT06502600|PROCEDURE|type of surgery|This study is a retrospective observational study, with type of surgery being one of the exposure factors under investigation.
223560338|NCT04727450|BEHAVIORAL|Combination of cognitive and physical training (CCPT)-BIGMAP|BIGMAP is a program engaging participants in specially designed cognitive/memory games together with physical training (Fu \& Chow, 2019).
223560339|NCT01413243|DRUG|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
223560340|NCT02388165|BIOLOGICAL|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
223560341|NCT02388165|OTHER|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
224136496|NCT04250740|OTHER|Coffee with butter-1|250 mL brewed black coffee with hazelnut flavouring and 50 g water
224136497|NCT04250740|OTHER|Coffee with butter-II|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-I
223415379|NCT05965180|DEVICE|Fine Needle Photoacoustic Probe|Fine Needle Photoacoustic Probe guided by the standard biopsy system without tissue core extraction
223415380|NCT05802407|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
223415381|NCT06468878|BEHAVIORAL|Exposure Intervention Plus Music Induction|VR exposure for acrophobia with background music.
223415382|NCT06468878|BEHAVIORAL|Exposure Intervention With No Music Induction|VR exposure for acrophobia with no background music.
223415383|NCT06496685|OTHER|psychoeducational|A structured AAT program and usual treatment in Experimental group.
223415384|NCT01113385|DRUG|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
223415385|NCT03449329|PROCEDURE|SIP|The intervention group will receive a SIP block
223415386|NCT00713791|DRUG|ZD4054|Treatment period 1: 10mg oral solution
223415387|NCT00713791|DRUG|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
223415388|NCT00713791|DRUG|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
223415389|NCT00713791|DRUG|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
223415390|NCT06433778|OTHER|No Intervention|This is a non-interventional study.
223415391|NCT06683456|BEHAVIORAL|eMOTE|The intervention combines psychoeducation, mindfulness skills, emotion regulation skills, and distress tolerance skills, along with self-monitoring of meals, behaviours and feelings.
223415392|NCT03520153|PROCEDURE|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
223415393|NCT03520153|PROCEDURE|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
223415394|NCT03520153|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
223415395|NCT03722563|PROCEDURE|total laparoscopic hysterectomy with sacrocolpopexy|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
223415396|NCT03722563|PROCEDURE|total laparoscopic hysterectomy with lateral suspension|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
223415397|NCT03329703|BEHAVIORAL|Project UPLIFT|A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.
223415398|NCT02363413|OTHER|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
223415399|NCT02363413|OTHER|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
223415400|NCT04136379|DIAGNOSTIC_TEST|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
223415401|NCT03396315|DRUG|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
223415402|NCT03396315|DRUG|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
223415403|NCT02062164|PROCEDURE|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
223739032|NCT01749579|DRUG|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
224032779|NCT05242185|OTHER|Observational study|\- Baseline data of prognostic importance, including demographic, social information, lifestyle factors, medical history, underlying comorbidities, anthropometric measurements, clinical, laboratory, imaging and treatment records will be collected using a standard case report form. A detailed clinical examination including measurement of vital signs, blood pressure, pulse oximetry, anthropometric measurements, neurological, pulmonary, cardiovascular system examination, mental and fuctional status assessment. routine laboratory assays including complete blood count (CBC), serum alanine transaminase (ALT), serum creatinine, fasting capillary blood glucose using glucometer and urine routine examination, ECG, echocardiography, chest X-ray and pulmonary function test. Additional tests when required such as fasting blood sugar, glycated haemoglobin, MRI/CT scan of brain, Thyroid function tests such as FT4, FT3 and TSH and C peptide etc
224032780|NCT05213910|DIETARY_SUPPLEMENT|Lactichoc|dosage form: mix of 8 strains containing 1.2x10\^11 CFU frequency, and duration: 2 capsules/day during 10 days
224032781|NCT05213910|OTHER|Stool sampling|3 stool samples are taken during the study (D0, D10 and D30)
223415404|NCT02062164|OTHER|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
223415405|NCT00594100|DEVICE|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
223415406|NCT01270464|DRUG|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
223415407|NCT01270464|DRUG|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
223415408|NCT06660381|DRUG|Psilocybin|Participants will receive a moderately high dose (25mg) of psilocybin in week 5 of the 12-week counseling, and either another moderately high dose (25mg) or a high dose (35mg) in week 7.
223415409|NCT06665126|DIETARY_SUPPLEMENT|Prebiotic + Probiotic Supplement|This intervention includes a combination of prebiotics and probiotics designed to promote vaginal and digestive health. The supplement contains Biotin, Lactobacillus acidophilus (as LA-14®), Bifidobacterium lactis (HN019™), Lactobacillus rhamnosus (as HN001™), Lactobacillus crispatus (as CCFM1110™), Lactobacillus gasseri (as HLG13™), Lactobacillus reuteri (as HR7™), Bacillus subtilis (as DE111®), PreforPro®, White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
223415410|NCT06665126|DIETARY_SUPPLEMENT|Active Placebo Supplement|The active placebo supplement contains similar probiotic strains without the prebiotic component. Ingredients include Biotin, Lactobacillus acidophilus, Bifidobacterium lactis, Lactobacillus rhamnosus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus reuteri, Bacillus subtilis, Inulin (from Chicory Root), White Rice Flour, Magnesium Stearate (Vegetable Source), Silicon Dioxide (Bamboo Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
223415411|NCT06665126|DIETARY_SUPPLEMENT|Excipient Placebo Supplement|The excipient placebo supplement contains no active ingredients related to prebiotics or probiotics. It includes White Rice Flour, Magnesium Stearate (Vegetable Source), and Cellulose (Vegetable Capsule). Participants take two capsules daily with food for 30 days.
223415412|NCT04563975|DRUG|Toripalimab|Toripalimab，240mg，d1，Intravenous Infusion，q3w
223739033|NCT01749579|DRUG|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
223739034|NCT01749579|DRUG|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
223739035|NCT00161993|DRUG|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
223739036|NCT00161993|DRUG|Gammagard S/D (Solvent/Detergent)|
223415413|NCT04563975|DRUG|Docetaxel|Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
223415414|NCT04563975|DRUG|nab-paclitaxel|nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
224032782|NCT02787954|PROCEDURE|TACE|Procedure for giving chemotherapy directly to tumor cells.
223415415|NCT02524886|DEVICE|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
223415416|NCT02448537|DRUG|PM01183|
223415417|NCT02448537|DRUG|Doxorubicin|
223415418|NCT02448537|DRUG|Gemcitabine|
223415419|NCT03826264|PROCEDURE|TAVR|transcatheter aortic valve replacement (TAVR)
223415420|NCT00262132|DRUG|Mycophenolate|
223415421|NCT01046279|DRUG|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
223415422|NCT01265979|PROCEDURE|Whole body diffusion MRI|These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
223415423|NCT04106895|DRUG|Fibryga|Fibryga
223560342|NCT03067519|OTHER|Fast track surgery|early feeding and mobilization after surgery
223560343|NCT03067519|OTHER|Conventional management|Management per the primary surgeon
223739037|NCT05921019|DEVICE|laser acupuncture|This study will use the Handylaser Trion laser manufactured by RJ Laser, Germany.
224032783|NCT02787954|PROCEDURE|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
224032784|NCT02787954|PROCEDURE|MWA|Using heat to kill tumor cells.
224032785|NCT02787954|PROCEDURE|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
224032786|NCT00547365|BIOLOGICAL|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
224032787|NCT00504881|DRUG|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
224032788|NCT00504881|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
224032789|NCT04997759|DRUG|Neostigmine and Sugammadex|Compare both groups efficacy of reverse the neuromuscular blocking agent
224032790|NCT03557723|OTHER|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~1. Cultural mediation workshop~2. Supervised visit and tour of the museum~3. Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
223415424|NCT02372812|DRUG|dexamethasone|12 mg of dexamethasone
223415425|NCT02372812|DRUG|Placebo|
223415426|NCT03209622|PROCEDURE|Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge|when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
223415427|NCT03209622|DRUG|Nicotine patch|Arm A
223415428|NCT03209622|OTHER|the external consultation|without patch
223415429|NCT04262323|DEVICE|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the mobile phone application and the non-invasive reference method (upper arm cuff).
223415430|NCT03981900|DRUG|Tofacitinib|5 mg BID, oral administrtaion
223415431|NCT03981900|DRUG|Tofacitinib|tablet form 11mg once daily oral
223415432|NCT02669901|BEHAVIORAL|Naloxone Auto-Injector|Naloxone auto-injector is FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
223415433|NCT06666062|OTHER|implant placement and low level laser therapy|Laser biomodulation with low level laser therapy around delayed implant
223415434|NCT06666062|PROCEDURE|implant placement|Delayed implant placement restoring missed tooth
223415435|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.
223415436|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 2 mm.
223560344|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
223560345|NCT03049579|DIETARY_SUPPLEMENT|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
223560346|NCT00705250|DRUG|bendamustine hcl|Patients will receive bendamustine 120mg/m\^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is \> 1000/ul and the platelet count is \> 75,000/ul.
223560347|NCT00880269|DRUG|Panobinostat/LBH589|
223560348|NCT03637257|DEVICE|modified Guedel airway|Monitoring of breathing
223560349|NCT06174012|DRUG|Sodium Fluoride|Sodium fluoride was applied before radiotherapy, at 3 months, 6 months, and 12 months after radiotherapy.
223739038|NCT05921019|DEVICE|sham laser acupuncture|This study will use the sham Handylaser Trion laser manufactured by RJ Laser, Germany,and without any laser beam delivering
224136498|NCT04250740|OTHER|Coffee with butter-III|250 mL brewed black coffee with hazelnut flavouring and 50 g unsalted butter-II
224136499|NCT05669534|BEHAVIORAL|community-friendly health recovery program|Participants will receive 4 weekly 45 minute sessions HIV prevention sessions.
224136500|NCT05669534|DRUG|Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis|Participants will be prescribed Pre-exposure prophylaxis (PrEP) is a biomedical intervention.
224136501|NCT06888843|DRUG|Capecitabine|Capecitabine 2000mg/m2 from day 1 to 14
224136502|NCT06888843|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on day 1, cycle of 21 days
224136503|NCT06892119|DRUG|Celrixafor|Use a reduced-dose of generic plerixafor
223415437|NCT06667531|PROCEDURE|Implant|Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 1.5 mm.
223415438|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.
223415439|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 2 mm.
223415440|NCT06667531|PROCEDURE|Implant|Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 1.5 mm.
223415441|NCT02175394|DRUG|Microgynon®|
223415442|NCT02175394|DRUG|BI 1356|
223415443|NCT05419180|DRUG|Stiripentol|Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
223415444|NCT03611777|DRUG|Inhaled corticosteroid|Drug
223415445|NCT02741674|PROCEDURE|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
223415446|NCT02741674|PROCEDURE|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
223560350|NCT01610219|BEHAVIORAL|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
223560351|NCT01610219|OTHER|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
223560352|NCT01576146|DRUG|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
223560353|NCT00127452|DIETARY_SUPPLEMENT|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
223560354|NCT00351793|DEVICE|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
223560355|NCT02364427|DEVICE|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
223415447|NCT02741674|PROCEDURE|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
223415448|NCT00053157|BIOLOGICAL|sargramostim|
223415449|NCT04498689|DRUG|Camrelizumab|Patients firstly receive camrelizumab 200 mg per time (iv, no less than 20 minutes and no more than 60 minutes, rinse time included) on Day 1 and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
223415450|NCT04498689|DRUG|Nab paclitaxel|Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
223415451|NCT04498689|DRUG|Gemcitabine Injection|At last, patients receive gemcitabine 1000 mg/m2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
223415452|NCT03727048|DRUG|Ketorolac|the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
223415453|NCT03727048|OTHER|No ketorolac|standard of care post operative pain management protocol
223415454|NCT01369030|OTHER|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
223415455|NCT04863781|BEHAVIORAL|Mobile cognitive-behavioral stress management intervention|Each weekly module will consist of a cognitive component and a relaxation component. The cognitive component during the first 3 weeks will educate users about the Transactional Model of Stress, that discrimination is a type of stressor, and the impact of stress on health. Building on this information, users will then learn how to match coping responses to the changeability of stressors during weeks 4 and 5. The cognitive component will conclude by focusing on the four most common coping strategies used by African American women in response to stress. Modules 2 through 4 will teach progressive muscle relaxation through a series of tension and relaxation cycles. Modules 5 through 8 will train users in diaphragmatic breathing. Finally, users will be trained in three types of mindfulness mediations.
223415456|NCT04863781|BEHAVIORAL|Control|The introductory course defines stress, describes the different sources of stress, and the influence of personality on stress. The coping module includes training in cognitive coping skills, guided imagery, progressive relaxation, autogenic training, and the importance of physical activity to manage stress. All lessons include course assessments. During the intervention period, controls will receive weekly text messages encouraging completion of material.
223415457|NCT04988971|DRUG|a compound glutamine capsule|A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
223415458|NCT04988971|DRUG|a compound glutamine capsule simulated placebo|a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
223415459|NCT05030194|OTHER|Electronic Cigarette|Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.
223415460|NCT05030194|OTHER|Oral Nicotine Pouch|Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.
223560356|NCT02819258|OTHER|Endodontic treatment|
223560357|NCT04385472|RADIATION|3T MRI|The main method used will be 3 Tesla MRI, which is a high resolution imaging technique. The participants will be asked to undergo musculoskeletal MRI scanning (pelvis and lumbar spine).MRI is a non-invasive procedure which excludes the risk of radiation (in comparison to other imaging modalities: X-ray, CT
223739039|NCT00275951|DRUG|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
223739040|NCT02226003|DRUG|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
223415461|NCT04725812|DRUG|Eculizumab|Eculizumab Intravenous Solution
223415462|NCT06036043|DRUG|Botulinum toxin type A|"The treatment will be administered either as a) subcutaneous infiltration with BoNT, covering the painful area, identified as allodynia during sensory examination, or b) perineural injection corresponding to the peripheral nerve(s) innervating the area where the pain is localized.~1. 100 IU Xeomin is mixed with 4 ml NaCl. Injections are performed with a 1.5 cm spacing. Maximum of 40 injections (200 IU).~2. 100 IU of botulinum toxin is mixed with 10 ml NaCl. For administration around multiple nerves, 50-100 IU per nerve (maximum 300 IU).~The treatment will primarily be provided by the principal investigator, or an anesthesiologist specializing in nerve blocks.~The specific method will be determined on an individual basis.~If there is no effect after one to two treatments, the treatment will be considered ineffective and discontinued. A treatment interval of 3 months has been established in accordance with a previous larger study."
223415463|NCT00915486|PROCEDURE|Good Standard of Care (GSoC)|Procedural treatment twice per week
223415464|NCT00915486|BIOLOGICAL|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
223415465|NCT00915486|BIOLOGICAL|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
223415466|NCT03147131|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
223415467|NCT02977325|OTHER|water cure|
223415468|NCT04536038|BEHAVIORAL|Opt-out|A study coordinator will call the patient unless they opt-out. See arm description for more details.
223415469|NCT05359016|BEHAVIORAL|HPV testing of women for cervical cancer screening|Women enrolled in this study will receive HPV testing for cervical cancer screening. They will be offered self-sampling. And also they will be offered voluntary Family Planning services, as appropriate.
223415470|NCT06620445|BEHAVIORAL|Interventiion or CBT Group|This RCT aims to evaluate the effect of Cognitive Behavioral Therapy (CBT) compared to usual care (UC) in pediatric oncology patients. We hypothesize that those receiving CBT will report lower depression and anxiety and improved QoL six months post-enrollment.
223560358|NCT03593122|DEVICE|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
224032791|NCT05078216|OTHER|Physical exercise intervention|"12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity."
224032792|NCT03069612|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
223415471|NCT02775877|DRUG|Letrozole|
223415472|NCT02775877|DRUG|clomiphene|
223415473|NCT02775877|DRUG|HMG|
223415474|NCT06959706|DRUG|TGW101|TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) and a corresponding small molecule chemical trigger (TRG001) administered separately.
223415475|NCT00527644|DEVICE|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
223415476|NCT06731140|DRUG|Retinoic Acid|Retinoic acid 20mg tid, p.o.
223560359|NCT03322176|OTHER|Genetic testing|LYNCH genetic testing
223560360|NCT00374946|DEVICE|THA|
223560361|NCT06567210|BEHAVIORAL|CBCTi|The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.
223739041|NCT02226003|DRUG|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
223415477|NCT06731140|DRUG|anti-PD-1 antibody and chemotherapy|PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
223415478|NCT04012749|BEHAVIORAL|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
223415479|NCT04012749|BEHAVIORAL|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
223415480|NCT04012749|BEHAVIORAL|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
223739042|NCT02226003|DRUG|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
223415481|NCT04181606|DRUG|Esmolol infusion|The Esmolol loading dose will be 0.5 mg/kg fat free mass/min administered over the first 3 minutes, followed by a maintenance dose of 0.25 mg/kg fat free mass/min for the remainder of the protocol (maximum of 60 minutes).
223415482|NCT04181606|DRUG|Saline infusion|Saline will be rate/volume matched to the calculated esmolol dose.
223415483|NCT04181606|OTHER|Pre exercise baseline|Subject rests quietly while drug infusion begins (3 min loading dose followed by 10 min of maintenance dose) until heart rate and blood pressure stabilize.
223415484|NCT04181606|OTHER|Isometric handgrip exercise|The subject will grip at 40% of their maximum and maintain that grip for 90 seconds. Once at rest and once during heavy intensity cycling.
223415485|NCT04181606|OTHER|Semi-recumbent cycling|Subjects will pedal for 2-4 minutes at a very light intensity (20W), followed immediately by 5 minutes at a moderate intensity (at a workload intended to elicit 85% of the oxygen consumption observed at the lactate threshold), and 5 minutes of cycling at a heavy intensity (at a workload estimated to elicit oxygen consumption half way between those observed at the lactate threshold and respiratory compensation point). Subjects will then continue cycling at the heavy intensity for 90 seconds while performing isometric handgrip exercise.
223415486|NCT04271540|DRUG|Tildrakizumab|"Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months"
223415487|NCT05006443|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|a non-invasive assessment to determine severity of tricuspid regurgitation
223415488|NCT00742963|DRUG|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
223415489|NCT04697563|DEVICE|Laser|real laser beam administered
223415490|NCT04697563|DEVICE|Placebolaser|no laser beam admitted
223415491|NCT04696055|DRUG|Pembrolizumab|Pembrolizumab 400 mg to be administered as an intravenous (IV) infusion every 6 weeks (Q6W).
223415492|NCT04696055|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib to be given orally (p.o.) at a starting dose of 90 mg QD for 3 weeks of every 4 weeks (i.e., 3 weeks on, 1 week off). If the starting dose of 90 mg daily is well tolerated the dose should be escalated to 120 mg starting after the first 4-week cycle of regorafenib.
224032793|NCT01530165|BEHAVIORAL|Life style intervention|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat \<30 proportion of total energy, saturated fat \<10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
223415493|NCT06024109|DEVICE|Closure of the Vaginal Cuff after Total Hysterectomy|Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
224032794|NCT04233736|PROCEDURE|Bilateral lumbar erector spinae plane block|Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
224032795|NCT01121835|DRUG|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
224032796|NCT01121835|DRUG|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
223415494|NCT06295276|OTHER|teletherapy-guided exercise programme|"Exercise program guided by online sessions. Subjects perform this exercise program three times a week at home, so that they complete four sessions per week for six weeks. The duration of a session is approximately twenty minutes. There are six exercises with three sets and about fifteen repetitions. Subjects in the treatment group also receive an instructional video. The subjects keep a diary in which they record their adherence to the treatment protocol at home.~At the beginning of the intervention and after the sixth week, participants are assessed with ODI, NDI and SF36-Short and NRS-11 scales. At the end, we use the Global Rating Scale."
224032797|NCT01121835|DRUG|PREMIXED INSULIN|"Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~* 25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only"
224032798|NCT06089889|OTHER|ice application|"* Group 1 will undergo the first intervention, which involves the application of ice.~* Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~* The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~* pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential."
224136504|NCT06890624|DRUG|cmFOLFOXIRI plus PD-1 inhibitor|cmFOLFOXIRI: oxaliplatin 85 mg/m² , irinotecan 150 mg/m², folinic acid 400 mg/m², 5-FU 2400 mg/m² continuous 46h infusion, repeat once every 2 weeks. PD-1 inhibitor 200mg, repeat once every 2 weeks.
224136505|NCT06890624|DRUG|mFOLFOX6|mFOLFOX6: oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hours, repeat once every 2 weeks.
224136506|NCT06795399|DRUG|OPC-131461|OPC-131461 will be administered as oral tablets.
224136507|NCT06795399|DRUG|Placebo|OPC-131461 matched placebo will be administered as oral tablets.
224136508|NCT01966575|DRUG|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
223560362|NCT06567210|BEHAVIORAL|General sleep information|General sleep health information and access to daily sleep diaries during 8 weeks
223560363|NCT00125463|DRUG|Candesartan cilexetil|
223560364|NCT01748812|DRUG|Osteomalacia|
224136509|NCT01743963|BEHAVIORAL|Decision support|Clinical pharmacists mediated computerized decision support
224136510|NCT01743963|BEHAVIORAL|Usual Care|clinicians typical apporach for GID monitering
224136511|NCT00002057|DRUG|Nystatin|
224136512|NCT00088803|GENETIC|molecular genetic technique|
224136513|NCT00088803|GENETIC|polymerase chain reaction|
224136514|NCT00088803|GENETIC|polymorphism analysis|
224136515|NCT06899334|DRUG|LSD|A moderate to high oral dose of 150 µg LSD will be administered followed by 20 mg intravenous ketanserin after 3 h
224136516|NCT06899334|DRUG|Psilocybin|A moderate to high oral dose of 30 mg psilocybin will be administered followed by 20 mg intravenous ketanserin after 3 h
224032799|NCT06089889|OTHER|control group|"* Group 2 will be control group, which involves no ice application~* The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential."
223415495|NCT06295276|OTHER|Waiting list/control intervention/delayed teletherapy intervention|Subjects in the control group will be advised to maintain their daily routine but will be asked to refrain from other treatments to avoid co-interventions during the 6-week study period. However, the use of painkillers such as non-steroidal anti-inflammatory analgesics (NSAIDs) taken by study participants in all groups for more than 3 months is allowed and will be documented (taking a pragmatic approach). Any change in medication will be monitored and documented by the PT at each visit.
223415496|NCT03269994|DRUG|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
223415497|NCT03269994|DRUG|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
223415498|NCT04862117|DEVICE|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
223415499|NCT03969901|DRUG|IMI/REL|"Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 6 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 2 to \<6 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 months, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
223415500|NCT03969901|DRUG|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
223415501|NCT03969901|DRUG|Oral Switch|All oral switch medications will be investigator's choice from a list of acceptable approved agents for infection types cIAI, and cUTI and will be given per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines. Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
223560365|NCT00656149|PROCEDURE|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
223560366|NCT00656149|PROCEDURE|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
223560367|NCT00072930|BIOLOGICAL|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
223560368|NCT00072930|BIOLOGICAL|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
223560369|NCT01601106|DRUG|liposomal prednisolone|Two weekly dosages with 150 mg.
223560370|NCT01601106|DRUG|Placebo|
223560371|NCT02189044|OTHER|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
223560372|NCT05607511|OTHER|Probiotics baby immunity formula (SIM03)|Daily oral intake of a probiotics sachet
223560373|NCT00246181|PROCEDURE|radiation therapy|Patients will receive 3 fractions
223739043|NCT02226003|DRUG|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
224032800|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 0.5|0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
224032801|NCT02181712|BIOLOGICAL|Mesenchymal stem cell 1.0|1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
224032802|NCT02877758|OTHER|Tomorrowlabs cosmeceutical formulation|
224032803|NCT02877758|OTHER|Sham cosmeceutical formulation|
224032804|NCT01372865|DRUG|Mometasone furoate|
224032805|NCT01372865|DRUG|Mometasone furoate|
224032806|NCT00320125|DIETARY_SUPPLEMENT|Orange juice plus calcium|\> 1,200mg Ca (four glasses of orange juice plus calcium)per day
224032807|NCT00320125|DIETARY_SUPPLEMENT|Dairy products|\> 1,200mg Ca (by consuming milk, yogurt, and cheese)
224032808|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
224032809|NCT00351143|DRUG|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
224032810|NCT00502957|BEHAVIORAL|Biofeedback|
224136517|NCT06899334|DRUG|DMT|A moderate to high, dose-escalating, intravenous infusion up to 2 mg/min DMT will be administered followed by 20 mg intravenous ketanserin after 3 h
224136518|NCT06899334|DRUG|Placebo|An oral and an intravenous placebo will be administered followed by 20 mg intravenous ketanserin after 3 h
224136519|NCT05606536|DRUG|Crystalloid Solutions|Locally approved crystalloid solution will be given at the predefined infusion rate
223415502|NCT06959914|OTHER|Training group|Patients in the intervention group will receive AVF care training. The training will last for 8 weeks and is planned to be given once a week. In the first session, the patients in the intervention group will be introduced. Afterwards, general information will be provided about the purpose and applications of AVF training and the importance of participation in training will be emphasized. Afterwards, patients who agree to participate in the study will sign an informed consent form. In addition, the Patient Information Form, SF-12 Quality of Life Short Form, the Comfort Scale for Hemodialysis Patients and the Scale for Assessing Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients will be given and asked to answer. For those who cannot read or write, the researchers will read the survey forms. In the first session, the pre-test data of the patients will be collected and then the training books will be given.
223415503|NCT06090916|OTHER|Best Practice|Receive standard nutrition care
223415504|NCT06090916|OTHER|Dietary Intervention|Participate in weekly support sessions with diet prescription
224032811|NCT02652403|DEVICE|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
223415505|NCT06090916|OTHER|Medical Chart Review|Ancillary studies
223415506|NCT06090916|OTHER|Medical Device Usage and Evaluation|Record dietary and physical activity using MyFitnessPal smartphone app
223415507|NCT06090916|OTHER|Nutritional Assessment|Undergo malnutrition screening
223415508|NCT06090916|OTHER|Questionnaire Administration|Ancillary studies
223415509|NCT06966518|DRUG|Ketamine and Magnesium Sulfate|Patients will receive a bolus of 0.5 mg/kg of ketamine given over a period of ten minutes followed by a constant infusion of 0.25 mg/kg/hr and a bolus dose of 30 mg/kg of magnesium sulfate during a 10-minute period followed by a continuous infusion of 9 mg/kg/hr.
223415510|NCT06966518|DRUG|Saline 0.9%|Patients will receive saline 0.9% as a control group.
223415511|NCT04629911|DEVICE|THRIVE|Patients will receive HFNO therapy during laryngomicrosurgery. Patients will undergo a gastric ultrasound examination after HFNO therapy.
223415512|NCT06576453|BEHAVIORAL|Self-questionnaire WHOQOL-bref|Parents must complete the self-questionnaire WHOQOL-bref after the first and the last session of the Pepps program.
223415513|NCT06576453|BEHAVIORAL|Self-questionnaire Evaluation Inventory - Parent|Parents must complete the self-questionnaire Evaluation Inventory - Parent after the last session of the Pepps program.
223415514|NCT06576453|BEHAVIORAL|quiz of knowledge|Parents must complete the quiz of knowledge after the first and the last session of the Pepps program.
223415515|NCT06576453|BEHAVIORAL|semi-structured interviews (qualitative)|In the month following the last session of the program, the semi-structured interviews (qualitative) will be carried out with parents who have followed either all or part of the sessions of the band.
223415516|NCT02767024|DRUG|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
223415517|NCT02767024|DRUG|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
223415518|NCT02767024|DRUG|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
223415519|NCT04680000|BEHAVIORAL|Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)|BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
223415520|NCT04680000|OTHER|BCBT-CP Booster|The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
223560374|NCT02774200|DRUG|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
223560375|NCT04266301|DRUG|Sabatolimab|A dose of MBG453 800 mg will be administered intravenously (IV) every 4 weeks (Q4W).
223560376|NCT04266301|DRUG|Azacitidine|A dose of Azacitidine 75 mg/m2 will be administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.
223560377|NCT04266301|DRUG|Placebo|A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
224032812|NCT02652403|DEVICE|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
223560378|NCT05001152|DRUG|Ozanimod|Taste assessment
224032813|NCT03252171|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
224136520|NCT02763904|DIETARY_SUPPLEMENT|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
223560379|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 6 months in addition to standard of care
223560380|NCT05213104|DRUG|Flecainide|Flecainide 150 mg 3 months in addition to standard of care
223560381|NCT00316225|DRUG|pemetrexed|500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
223415521|NCT03688867|BEHAVIORAL|Prehabilitation regimen|"The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log."
223415522|NCT06231888|DEVICE|Aligner|Orthodontic alginer
223415523|NCT04411810|DEVICE|Nevisense 3.0|Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US. Nevisense 3.0 will be used as a one-time exposure of \<8 seconds per lesion. Disposable electrodes that contact the participant are 5mm x 5mm in size. Nevisense 3.0 measures electrical impedance of skin lesions and provides an output called the electrical impedence spectroscopy (EIS) score. Electrical impedance is a measure of a material's overall resistance to the flow of alternating electric currents of various frequencies. The principle is that electrical impedance is different in normal versus abnormal tissue.
223415524|NCT04411810|DEVICE|Dermlite Cam|Dermlite Cam is a digital camera that captures images of the skin under cross-polarized and non-polarized light and is 510(k) exempt. The DermLite Cam device appears as a single piece camera with a charging cable and USB computer cable. As part of the camera unit, an extensor arm exists to allow for the capture of standardized clinical images. The DermLite Cam will be used to acquire 3 images of \<5 seconds per lesion (one clinical, one polarized dermoscopic, and one non-polarized dermoscopic). NOTE - for the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
223415525|NCT04411810|PROCEDURE|Skin biopsy|A skin biopsy is a small procedure that removes a sample of skin from the surface of the body. The method utilized will be either a shave or punch technique. The maximum size of a punch biopsy will be 6mm and these wounds are generally closed with no more than 2-3 sutures. A skin biopsy takes \<15 minutes including preparation time, administration of intradermal anesthesia using lidocaine 1% with epinephrine 1:100,000, removal of the skin sample, achievement of hemostasis, dressing the wound, and providing instructions for home care. Samples will be placed formalin for routine processing.
223415526|NCT04411810|DEVICE|Barco Demetra|Barco Demetra is a non-invasive skin imaging system, which acquires multispectral and white light dermoscopic images and clinical photographs of the skin which can then be stored, retrieved, displayed, and reviewed by medical practitioners. The Barco Demetra received 510(k) Premarket approval (K192829). The system involves a hardware imaging device and a stand-alone software application. The hardware device is a portable, battery-powered medical device for acquiring and visualizing images of the skin and uploads all images to cloud storage. The software application is cloud software with an associated web application; it can be used to visualize images and related data and can generate consultation reports. For the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
224032814|NCT00680589|BIOLOGICAL|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
224032815|NCT03894254|OTHER|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
224032816|NCT02751567|OTHER|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
224032817|NCT02751567|OTHER|Untreated skin|One site is patched without treatment as control
224032818|NCT05720988|DRUG|Azacitidine|Given SC
224136521|NCT02763904|OTHER|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
224032819|NCT05720988|BIOLOGICAL|Tagraxofusp-erzs|Given IV
224032820|NCT04113083|OTHER|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
224032821|NCT04398953|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
224032822|NCT05958641|OTHER|Questionnaires|Participants will be asked to complete the questionnaire including general demographic information, the cognition, resistance and use of NPS as well as the behavioral expression of addiction susceptibility genes and adverse childhood experience.
224032823|NCT04211272|DRUG|Macitentan|Macitentan will be administrated as film-coated tablet in Part A and Part B.
224032824|NCT04211272|DRUG|Sildenafil|Sildenafil will be administrated as film-coated tablet in Part A.
224032825|NCT04211272|DRUG|Riociguat|Riociguat will be administrated as film-coated tablet in Part A.
224032826|NCT04211272|DRUG|Rosuvastatin|Rosuvastatin will be administrated as film-coated tablet in Part B.
224032827|NCT05748054|DRUG|Silver Diamine Fluoride|A colourless solution known with its alkaline nature; it simply consists of a union of silver, fluoride and ammonia. It can be applied on caries cavities using a micro-brush.
224032828|NCT03328403|DEVICE|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
224032829|NCT03328403|DEVICE|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
223415527|NCT02656004|OTHER|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
223415528|NCT02656004|OTHER|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
223415529|NCT04495972|DIETARY_SUPPLEMENT|Intestinimonas-capsules|Capsules containing microbiota (Intestinimonas)
223415530|NCT04495972|DIETARY_SUPPLEMENT|Placebo-capsules|Placebo capsules are identical to the active treatment
223415531|NCT05670665|OTHER|Threatened preterm labor|Presence of uterine contractions and cervical shortening between 24+0 and 36+6 weeks of gestation and/or rupture of the membranes between 24+0 and 36+6 weeks of gestation.
223415532|NCT06969131|PROCEDURE|Open Partial Nephrectomy|Patients underwent open partial nephrectomy.
223415533|NCT06969131|PROCEDURE|Laparoscopic Partial Nephrectomy|Patients underwent laparoscopic partial nephrectomy.
223415534|NCT06967376|PROCEDURE|Corneal Collagen Cross-Linking Solutions|Topical anaesthesia was achieved using 0.4% benoxinate hydrochloride drops. Epithelium was removed up to 9 mm diameter. Corneal thickness of the area to be treated was measured (without epithelium) aiming for a starting thickness of no less than 350μm. Corneas thicker than 500μm were dehydrated to reduce thickness by using 70% Glycerol drops applied topically at intervals of 2-3 seconds for a total of five minutes. A schematic representation of PACK-CXL protocol is provided in Figure 1. Iso-osmolar riboflavin drops were instilled topically on the cornea at regular intervals of 2 minutes for a total period of 30 minutes. Thickness was also re-measured every 5 min to ensure that it remained below 500µm during instillation of riboflavin. The cornea was illuminated using a UVX, UV-A 365 nm with an irradiance of 3 mW/cm2 for 30 minutes and a total dose of 5.4 J/cm2 during which riboflavin was instilled every 2 min and corneal pachymetry performed every 5 min. PACK-CXL was performed in a 9
223415535|NCT06967376|DRUG|Topical Antimicrobial/Antifungal Medications|Initial antimicrobial therapy for both groups consisted of fortified vancomycin eye drops 50 mg/ml, fortified ceftazidime eye drops 50 mg/ml hourly, and the antifungal agent itraconazole 100 mg orally twice per day. This regimen was subject to change according to microbiology culture sensitivities and/or results.
223415536|NCT01920958|OTHER|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
223415537|NCT06969365|OTHER|10-pound weighted lap-pad|10-pound weighted lap pad will be placed over the patient's chest and shoulders
223415538|NCT06969365|OTHER|blanket|A simple, unweighted blanket will be applied to patients during IUD insertion
223560382|NCT03660202|DEVICE|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
223560383|NCT04624386|OTHER|Thiol disulfide level|Venous blood is collected from all subjects and thiol disulfide levels will be determined from the serum samples obtained from the venous blood.
223560384|NCT06567028|DIAGNOSTIC_TEST|OSPM-Enhanced AI Model|Analyze tumor images using the model developed in our study
223415539|NCT06123169|DRUG|Antibioprophylaxis (Piperacillin-tazobactam)|antibiotic prophylaxis during surgery
223415540|NCT06123169|DRUG|5 days Antibiotherapy (Piperacillin-tazobactam)|5 days Antibiotherapy from surgery
223415541|NCT02866292|OTHER|Pelvic floor muscle and sexual function evaluation|"PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain."
223415542|NCT06966674|DRUG|Intracoronary tirofiban|Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).
223415543|NCT06966674|DRUG|Saline 0.9%|Patients will receive intracoronary saline 0.9% solution as a control group.
223415544|NCT06967844|PROCEDURE|Simultaneous motor-cognitive task training|"16 sessions (2 sessions per week) for 8 weeks, 40 min per session~1. walking while counting walk 5, 10 and 15 meters while counting backward by ones, threes and sevens~2. balancing on one foot while naming or solving puzzles stand on one foot for 10, 20 and 30 seconds while naming animals. solving simple and complex puzzles~3. ball toss and recall toss ball at 3, 5 and 7 meters distance while recalling three-word, five-word and seven-word lists"
223415545|NCT06967844|PROCEDURE|Sequential motor-cognitive task training|"16 sessions (2 sessions per week), for 8 weeks, 20+20 min per session with 20 min break in between~motor training~1. Standing on one foot standing on one foot for 10, 20 and 30 seconds~2. Heel to toe walk walking heel to toe for 5, 10 and 15 meters~3. Leg swings 10 swings, 15 swings and 20 swings per leg cognitive training~4. Memory games recall three-word, five-word and seven-word lists~5. Problem solving tasks simple, moderate and difficult arithmetic problems"
223560385|NCT04410562|DRUG|Hydroxychloroquine|Participants will receive a bottle containing 19 tablets of study medication. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days. (400 mg/day for three days, followed by 200 mg/day for 11 days).
223560386|NCT04410562|DRUG|Placebo|Participants will receive a bottle containing 19 tablets of placebo. They will be instructed to take two tablets for the first three days and one tablet for the following 11 days.
223560387|NCT00289068|PROCEDURE|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
223560388|NCT00289068|PROCEDURE|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
223560389|NCT00289068|PROCEDURE|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
223560390|NCT00345566|PROCEDURE|Nutrition composition|
223560391|NCT01811485|DRUG|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
223560392|NCT01811485|DRUG|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
223415546|NCT06576986|DIETARY_SUPPLEMENT|Symbiotic|The synbiotic used will be Simbioflora® (commercial preparation containing 5.5g of FOS added with four species of probiotic, Lactobacillus paracasei LPC-31; Lactobacillus rhamnosus HN001; Lactobacillus acidophilus NCFM; Bifidobacterium lactis HN019, at a concentration of 109 UFC per strain) supplied by Farmoquímica S.A. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
223415547|NCT06576986|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin, used as control, will be purchased from the company PRODIET® under the trade name Carboch®. Supplementation will be administered orally, twice a day, before lunch and dinner, for ten days before chemotherapy treatment. Patients will be guided by researchers on dilution (100 mL of filtered water) and the correct purchase of the modules. Consumption control will be carried out daily, via telephone contact.
223560393|NCT01811485|DRUG|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
223560394|NCT01545934|BEHAVIORAL|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
223415548|NCT06969144|PROCEDURE|cholecystectomy|The indications for elective cholecystectomy were symptomatic cholelithiasis, a GB polyp more than ten millimeters, a history of cholecystitis, biliary pancreatitis, or choledocholithiasis. Patients with cholecystitis and severe or moderately severe pancreatitis were operated on after six weeks of the event. Other patients received surgery at the earliest available date. All patients with choledocholithiasis underwent endoscopic retrograde cholangiopancreatography (ERCP) and stone clearance before cholecystectomy. Patients who underwent laparoscopic cholecystectomy were evaluated by surgical and anesthesia teams in outpatient clinics and co-morbid conditions were optimized. Preoperative antibiotic prophylaxis was given to all the patients before induction of anesthesia.
223560395|NCT04036474|OTHER|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
223560396|NCT04547335|DRUG|Voriconazole|This is an observational study and only the patients already on voriconazole treatment will be included in the study.
223560397|NCT03654404|BEHAVIORAL|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
223560398|NCT02767726|DEVICE|non-invasive multimodal imaging|
223560399|NCT02976636|BEHAVIORAL|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
223560400|NCT02976636|BEHAVIORAL|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
223560401|NCT02710981|DRUG|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
224298400|NCT01521416|OTHER|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
223560402|NCT02710981|DRUG|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
223560403|NCT05980273|BEHAVIORAL|Educational sessions|session for oral health education
223560404|NCT01576419|DRUG|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
223560405|NCT01576419|DRUG|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
224032830|NCT04599712|DRUG|Amivantamab|Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram \[mg\] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
224032831|NCT01791036|PROCEDURE|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
224032832|NCT01791036|PROCEDURE|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
224032833|NCT06799065|DRUG|ATX-295|ATX-295 Tablets will be taken orally
224298401|NCT01530763|DRUG|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing \> 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children \< 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
223415549|NCT03911063|BEHAVIORAL|CBT sessions|weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.
223415550|NCT03911063|BEHAVIORAL|Talking Sessions|20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
223415551|NCT06969248|BEHAVIORAL|Intervention Group|Fathers will be provided with a total of 8 weeks of training and videos. The training will cover the role of fatherhood and its historical development, the developmental stages and care needs of babies, ways for fathers to participate in baby care and the benefits of participation, father-infant bonding and influencing factors, and paternal depression. Videos on the subject will be shared with fathers.
223415552|NCT06967168|BEHAVIORAL|Virtual consultation|Virtual (telephone) consultation with a podiatrist, who will provide self-management advice to the participant including advice on footwear, massage, and stretching. Supplemented by written advice leaflets.
223415553|NCT06967168|BEHAVIORAL|Self-help video|Self-help video providing self-management advice to the participant including advice on footwear, massage, and stretching. Available online or as a DVD.
223415554|NCT06967168|DEVICE|Orthotics|"Provision of orthotics following an in-person musculoskeletal assessment by a podiatrist to check foot function, footwear, and position of feet, ankles, knees, and hip.~Podiatrists prescribe, produce, and fit orthotic devices to be worn inside footwear. The devices used in this feasibility study will be selected according to individual patient needs. All will have regulatory certification (CE mark) and will be used in accordance with the manufacturer's Instructions For Use."
223415555|NCT06967168|DEVICE|Shockwave therapy|"A 3-week course of Shockwave therapy following an in-person musculoskeletal assessment by a podiatrist to check foot function, footwear, and position of feet, ankles, knees, and hip.~Extracorporeal shockwave therapy (ESWT) is delivered by a podiatrist in an outpatient clinic. Most patients lie down during the procedure. The machine passes pulses of energy through the skin towards the injured area of the heel. This encourages the body to respond and aims to stimulate the healing process. Participants will need to attend the clinic approximately once a week for three weeks to complete the course of treatment."
223415556|NCT06968013|BEHAVIORAL|Well-Being Therapy|Participants will undergo Well-Being Therapy (WBT) sessions once daily for 50 minutes over a period of six weeks. The core elements of WBT include prompting participants to identify instances of well-being, contextualize these experiences using a structured diary, and recognize as well as restructure thoughts, beliefs, and behaviors that prematurely disrupt well-being. Additionally, the specific components of the six dimensions of the Psychological Well-Being (PWB) scale-autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance-are systematically integrated into different therapy sessions
223415557|NCT06968013|BEHAVIORAL|Sleep Hygiene Education|Participants will receive Sleep Hygiene Education (SHE) alone for 6 weeks. SHE involves education on maintaining consistent sleep schedules, creating a sleep-conducive environment, reducing stimulant use (e.g., caffeine, alcohol), and promoting healthy daily routines to improve sleep quality.
223415558|NCT01560234|DRUG|AZD8848|Single dose, oral inhalation (nebuliser solution)
223415559|NCT01560234|DRUG|Placebo|Single dose, oral inhalation (nebuliser solution)
223415560|NCT06969300|DEVICE|Gold micro needles|The treatment (with gold microneedles) was administered on the day of enrollment after the completion of the detection items. Follow-up visits were conducted at 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks. The follow-up contents included visia photography, camera photography, non-invasive skin examination, questionnaire assessment, etc. The study duration was 12 weeks.
223560406|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
224032834|NCT06523114|DEVICE|Transcatheter Arterial Embolization|After accessing the common femoral artery or radial artery, embolization is performed using embolic material after confirming abnormal blood vessel abnormalities, lesion hypervascularity, and lesion enhancement findings.
224032835|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
224032836|NCT05492500|DRUG|Main cohort (Cohort A): Ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
224032837|NCT05492500|DRUG|Main cohort (Cohort A): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
223415561|NCT06969300|DRUG|Gold micro-needles combined with salicylic acid|On the day of enrollment, the treatment was administered (gold microneedle + 30% salicylic acid on half of the face) after the completion of the detection items. A site follow-up was conducted one week later, and a follow-up was carried out two weeks later with the second acid brushing treatment. A follow-up was conducted four weeks later with the third acid brushing treatment. Follow-up was also conducted at the eighth and twelfth weeks. The follow-up contents included: Visia photography, camera photography, non-invasive skin examination, questionnaire assessment, etc. The study duration was 12 weeks.
223415562|NCT06968806|DRUG|Ketorolac|patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection preoperatively followed by 30mg twice daily for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.
223415563|NCT06968806|DRUG|0.9 % saline|0.9% saline
223415564|NCT06969222|PROCEDURE|Robotic TKA|Total knee replacement of arthritic knees either with robotic-assisted Skywalker device
223415565|NCT06969222|PROCEDURE|Conventional TKA|Total knee replacement of arthritic knees performed manually
223415566|NCT02815332|DRUG|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
223415567|NCT02815332|DRUG|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
224298402|NCT01530763|DRUG|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
223415568|NCT02815332|DRUG|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
223415569|NCT00005616|PROCEDURE|conventional surgery|
223415570|NCT00005616|PROCEDURE|neoadjuvant therapy|
223415571|NCT00005616|PROCEDURE|radionuclide imaging|
223415572|NCT00005616|RADIATION|iodine I 131 monoclonal antibody F19|
223415573|NCT04138537|OTHER|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
223415574|NCT04138537|OTHER|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
223415575|NCT01620190|OTHER|Laboratory Biomarker Analysis|Correlative studies
223415576|NCT01620190|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
223415577|NCT01514539|OTHER|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
223415578|NCT00478816|BIOLOGICAL|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
223415579|NCT00638716|DRUG|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
223415580|NCT00638716|DRUG|Placebo|Placebo
223415581|NCT00083759|DRUG|natalizumab|
223415582|NCT00083759|DRUG|placebo|
223415583|NCT00952159|BIOLOGICAL|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
223415584|NCT01476878|DEVICE|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
223415585|NCT06048328|BEHAVIORAL|Game Changers for Family Planning|Game Changers for Family Planning (GC-FP) intervention. The intervention will consist of 6 group sessions. The sessions will focus on stigma reduction, disclosure decision making, knowledge, and building skills for advocacy. The 2-hour, weekly sessions will be facilitated by 2 trained peers who are MC users, and conducted in Luganda using a structured manual, and group format to facilitate: sharing of experiences to build support, modeling and motivation; group problem solving and role playing to build skills and self-efficacy; and homework between sessions to practice skills and generate experiences to be processed in the group.
223415586|NCT05506566|DRUG|68Ga-FAP-CHX|The dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging
223415587|NCT05506566|DRUG|68Ga-FAP-CHX|68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) +/- 10% given intravenously at a single time prior to imaging； 68Ga-FAPI-04, the dose will be 1.8 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging； 18F-FDG, the dose will be 3.7 (MBq / kg) +/- 10% given intravenously at a single time prior to imaging；
223415588|NCT02702557|OTHER|Elastic Band Exercises|
223415589|NCT02390596|DRUG|Anakinra|The dose of Anakinra will be 2mg/kg (patients \<10kg and/or \<8 months: 4mg/kg). If the patient remains febrile (fever \>38°C), he will receive a double dose of anakinra 4mg/kg (patients \<10kg and/or \<8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients \<10kg and/or \<8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
224298403|NCT01530763|DRUG|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
223415590|NCT04623099|DRUG|Escitalopram|Escitalopram is FDA-approved for the treatment of major depressive disorder (MDD) in adolescents (12-17 years of age) and is commonly prescribed for adolescents with anxiety disorders.
223415591|NCT02915900|OTHER|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
224032838|NCT05492500|OTHER|Main cohort (Cohort A): Matched placebo|Matched placebo subcutaneous injection
224298404|NCT00345735|DRUG|Fentanyl|
224298405|NCT02201238|DRUG|Diclofenac sodium|Diclofenac sodium
224298406|NCT02201238|DRUG|Menthol|Menthol
223415592|NCT02915900|OTHER|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
223415593|NCT01859065|BEHAVIORAL|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
223415594|NCT01859065|BEHAVIORAL|Routine|Routine anticipatory guidance (control)
223415595|NCT00036972|BIOLOGICAL|cintredekin besudotox|
223415596|NCT00036972|PROCEDURE|adjuvant therapy|
223415597|NCT00036972|PROCEDURE|conventional surgery|
223415598|NCT00036972|PROCEDURE|neoadjuvant therapy|
223415599|NCT00746746|BIOLOGICAL|HyperAcute vaccine|1.8 mL weekly
223415600|NCT00746746|DRUG|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
223415601|NCT02857257|BIOLOGICAL|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
223415602|NCT03892395|DIETARY_SUPPLEMENT|B-vitamin supplementation on bone health|An intervention study to investigate the effect of B-vitamin supplementation for 2-years on bone health
223415603|NCT03892395|DIETARY_SUPPLEMENT|Control group; Vitamin D, a daily capsule containing 10 µg/day vitamin D|Vitamin D, a daily capsule containing 10 µg/day vitamin D
223415604|NCT04124835|OTHER|Swiss Ball|"Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation."
223415605|NCT04124835|OTHER|Control Grup|Habitual Care of the Service.
223415606|NCT02299232|DRUG|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
223560407|NCT02581046|PROCEDURE|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
223560408|NCT02581046|DRUG|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
224032839|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab low dose|ponsegromab low dose subcutaneous injection
224032840|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab medium dose|Ponsegromab medium dose subcutaneous injection
224032841|NCT05492500|DRUG|Open-label, PK Cohort (Cohort B): ponsegromab high dose|Ponsegromab high dose subcutaneous injection
224032842|NCT05492500|DRUG|Optional Cohort C: Ponsegromab low dose|Ponsegromab low dose subcutaneous injection
224136522|NCT06826976|OTHER|sensory electrical stimulation|peripheral sensory electrical stimulation on median, ulnar, and radial nerves of affected upper limb, simultaneously with Task Specific Training program which included four subtests of Action Research Arm Test scale.
224136523|NCT06826976|OTHER|task specific training program|received task specific training program only. Patients were tested pre and post treatment by Grip dynamometer, Pinch dynamometer, Digital goniometer and Action Research Arm Test Scale (ARAT).
223415607|NCT04141683|DIAGNOSTIC_TEST|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
223415608|NCT04141683|DIAGNOSTIC_TEST|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
223415609|NCT04141683|PROCEDURE|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
223415610|NCT04638283|BEHAVIORAL|Goal Attainment Scaling|Individual goals will be formulated and measured by Goal Attainment Scaling (GAS). GAS provides a method for quantifying the attainment of individualized goals, typically set in cognitive rehabilitation. Different levels of outcomes for each goal are operationalized in a five-point scale and given a numeric value. For each individual goal, minus two refers to the goal attainment much less than expected, minus one refers to a little less than expected, zero refers to expected outcome, plus one refers to a little bit better than expected and plus two refers to goal attainment much better than expected. The participants can establish as many goals as desired. Outcomes can be summed within different patient goals, as well as across patients to assess overall outcome of treatment outcomes.
223415611|NCT03596593|DIAGNOSTIC_TEST|SPANOM (identifying MSI status from ctDNA)|SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
223415612|NCT04724083|DIAGNOSTIC_TEST|biomarkers|new diagnostic biomarkers
223415613|NCT03567005|DEVICE|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
223415614|NCT03567005|DEVICE|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
223415615|NCT05508698|BEHAVIORAL|Precommitment Nudge|Ask participants to commit to a decision about getting a flu shot
223415616|NCT05508698|BEHAVIORAL|Salience|Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
223560409|NCT03215758|DRUG|QAW039|QAW039 once daily
223560410|NCT03215758|DRUG|Placebo|Placebo once daily
223560411|NCT02003638|DRUG|Niacin|Niacin titrated to 6000 mg daily
223560412|NCT02003638|DRUG|Placebo|Placebo provided in the same pill quantity as niacin arm
223560413|NCT04321473|PROCEDURE|PCI on left main|PCI on left main coronary stenosis
223560414|NCT01942668|DRUG|Estradiol|
223560415|NCT01942668|DRUG|Progesterone|
224032843|NCT05492500|OTHER|Optional Cohort C: Matched placebo|Matched placebo subcutaneous injection
224032844|NCT05492500|DRUG|Optional Cohort D: Ponsegromab high dose|Ponsegromab high dose subcutaneous injection
224032845|NCT05492500|OTHER|Optional Cohort D: Matched placebo|Matched placebo subcutaneous injection
224032846|NCT04750785|OTHER|No Intervention|Administered as specified in the treatment arm.
224032847|NCT05229731|PROCEDURE|Neurovisual evaluation|Standardized tests and scales classically used during a neurovisual evaluation,
224032848|NCT05229731|PROCEDURE|Cerebral MRI|"Sequences realized :~* 3D T1 TFE i1.0~* 3D FLAIR i1.0~* 2D T2 0.3 coro, centré sur les orbites~* 3D T2 i0.6~* SWIp 0.6~* 3D PD T2 NO, centré sur les orbites~* 3D ASL~* DTI 64dir"
224032849|NCT00810394|DRUG|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
224032850|NCT04742647|PROCEDURE|Double cerclage|Two cervical cerlages will be placed
224136524|NCT00479557|BIOLOGICAL|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
224136525|NCT00479557|BIOLOGICAL|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
224136526|NCT00479557|BIOLOGICAL|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
224298407|NCT02876783|OTHER|Observational - No intervention|
224298408|NCT01140490|PROCEDURE|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
224298409|NCT02603302|RADIATION|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
224298410|NCT02603302|PROCEDURE|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
224298411|NCT04688931|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
224298412|NCT04688931|PROCEDURE|TURBT|The current standard of care for treatment of LG-IR-NMIBC is TURBT under general anesthesia.
224298413|NCT04724044|DRUG|Tablets|Oral tablets of similar appearance to active study drug
224298414|NCT04724044|DRUG|Clarithromycin 500mg|Oral tablets of 500mg of clarithromycin
224032851|NCT04742647|PROCEDURE|Single cerclage|One cerclage will be placed
224032852|NCT00507364|DRUG|Local injection of activated macrophages to anal fissure|
224032853|NCT01927705|BIOLOGICAL|FURESTEM-AD Inj.|
224032854|NCT04903730|DRUG|AER-901 Solution for Nebulization|"Part A: participants will be enrolled into 1 of up to 5 sequential cohorts (A1 to A5). Inhaled AER-901 doses of 5, 10, 20, 40, and 80mg are planned.~Part B: participants will be enrolled into 1 of up to 3 cohorts (B1 to B3).~Cohorts B2 and B3 will commence following Part D of the study and following SRC review of safety, tolerability, and PK data. A decision to dose with either a propylene glycol formulation or a sterile water formulation will be made by the SRC at the time of the review of the Part D data.~Part D has a three-part design (Treatment Periods 1 \& 2 separated by a Washout period) and will compare placebo to a single-dose of AER-901 (5 mg/mL QD) followed by two doses of AER-901.~Each cohort will consist of 8 participants (6 receiving AER 901 and 2 receiving placebo)."
224032855|NCT04903730|DRUG|Placebo|0.45% sterile saline for injection delivered via the FOX MOBILE device.
224032856|NCT00269893|DRUG|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
224136527|NCT00479557|DRUG|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
224298415|NCT03290365|DRUG|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
224298416|NCT03290365|DRUG|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
224298417|NCT06124274|BEHAVIORAL|Protein tracer drink|Subjects will be fed a mixed-macronutrient beverage at rest (0.75g/kg lean body mass of carbohydrates; 0.125g/kg lean body mass of protein). Amino acid composition of the protein will be modelled off the composition of egg. Leucine content will be enriched to 5% with \[13 Carbon(13C)\]-leucine.
224299166|NCT02923674|BEHAVIORAL|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
224299167|NCT02923674|BEHAVIORAL|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level \<3).
223560416|NCT01942668|DRUG|Placebo|
224032857|NCT00269893|DRUG|Placebo|Matching Placebo soulution either bolus or infusion.
224032858|NCT01905137|DRUG|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
224136528|NCT04524286|OTHER|Interviews only.|Interviews will be conducted with childbearing women and midwives.
224136529|NCT00061126|DRUG|ABX-EGF|
224136530|NCT01745991|DEVICE|CoSeal spray|
224136531|NCT06532253|DRUG|NVDX3|NVDX3 is implanted during a single surgical intervention, that took place in the core trials (refer to NCT05961956 and NCT05987033)
224136532|NCT05507645|DRUG|Recombinant Human Prourokinase for Injection (rhPro-UK)|15mg of rhPro-UK intravenous bolus within 3 minutes, and the remaining 20mg intravenous drip within 30 minutes.
224136533|NCT05507645|DRUG|standard medical treatment|Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
224136534|NCT00088569|DRUG|0-15 Water|
224136535|NCT00313027|RADIATION|PET scan|
224136536|NCT00847938|DRUG|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
224136537|NCT00847938|DRUG|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
224136538|NCT00847938|DRUG|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is \> or = to 40 %
224136539|NCT00795353|DRUG|Amevive exposure|Commercial alefacept prescribed by Physician
224136540|NCT00216775|DRUG|interferon-alfa-2b and ribavirin|
224299168|NCT01261286|DRUG|verapamil|
223415617|NCT03533153|BIOLOGICAL|WJ-MSC cells implantation|Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4\~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
223415618|NCT03533153|DRUG|CTSTMD PBS without WJ-MSC|For Case-control study only.
224032859|NCT01905137|DRUG|placebo|
223415619|NCT03533153|DRUG|Conventional drug therapy|All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
223415620|NCT04017351|OTHER|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
223415621|NCT00820053|DRUG|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
223415622|NCT01511029|DRUG|Dexpramipexole|300 mg - Oral Tablets
223415623|NCT01511029|DRUG|Dexpramipexole|600 mg Oral Tablets
223415624|NCT01511029|DRUG|Dexpramipexole Placebo|Placebo - Oral Tablet
223415625|NCT01511029|DRUG|Moxifloxacin|400 mg - Oral Tablet
223415626|NCT04245631|DIAGNOSTIC_TEST|Recombinase aided amplification (RAA) assay|We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.
223415627|NCT01557374|DRUG|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
223415628|NCT01557374|DRUG|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~* If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~* If DAS 28 \> 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~* If DAS 28 \> 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
223415629|NCT04946435|COMBINATION_PRODUCT|Antibiotic Irrigation|The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation
223415630|NCT05198024|BEHAVIORAL|Nutrition knowledge|Nutrition knowledge either 'Usual care plus new education programme' or 'Usual care plus biggest loser'
223415631|NCT05931042|DRUG|Trastuzumab|Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)
223415632|NCT06353685|RADIATION|Continuous, hyperfractionated, accelerated radiotherapy(CHART)|high-risk CTV area (CTV1), 45Gy in total, fraction dose of 1.5Gy, twice a day, bioequivalent dose (BED) of 51.75Gy; Low-risk CTV area(CTV2), 39Gy in total , fraction dose of 1.3Gy, twice a day, BED of 44.07Gy; A total of 30 radiotherapy fraction were performed 10 times a week for 3 weeks.
223415633|NCT00281788|DRUG|capecitabine|
223415634|NCT00281788|DRUG|carboplatin|
223415635|NCT00281788|DRUG|paclitaxel|
223415636|NCT00281788|RADIATION|radiation therapy|
223560417|NCT03299205|BEHAVIORAL|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
223560418|NCT02182206|DRUG|BIBF 1120|
224032860|NCT05312151|DRUG|Psilocybin|Open label
224032861|NCT04042493|BEHAVIORAL|Connect for Health|The program includes (1) electronic health record (EHR)-based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence-based behavioral targets; and (4) social- and community-informed text messages for parents to support behavior change.
224032862|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin; Famitinib;|"Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib"
224032863|NCT04619433|DRUG|Camrelizumab;Pemetrexed and Carboplatin;Placebo|"Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo"
224032864|NCT03217266|DRUG|Navtemadlin|Given PO
224032865|NCT03217266|RADIATION|Radiation Therapy|Undergo radiation therapy
224032866|NCT03217266|PROCEDURE|Surgical Procedure|Undergo surgery
224032867|NCT00301522|DEVICE|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
224032868|NCT00301522|DEVICE|Express2|Coronary Stent System
224032869|NCT02591199|DRUG|URG101|
224032870|NCT02591199|DRUG|Placebo|
224032871|NCT02591199|DRUG|Lidocaine|
223415637|NCT05690607|OTHER|Doctors Laboratory TINIES small volume blood testing kit|Doctors Laboratory TINIES small volume blood testing kits comprise microcontainers manufactured by BD Diagnostics designed for sample collection from skin puncture, along with home testing pack with lancets, instructions and Royal Mail postal packs.
223415638|NCT05138770|DRUG|VC005 Tablets|VC005 Tablets 1、5、10、25、50、100mg single dose
224032872|NCT02591199|DRUG|Heparin|
224032873|NCT00413738|DEVICE|Antiseptic-coated central venous catheters|
224032874|NCT00265447|BEHAVIORAL|Strength training|3 months of strength training
223560419|NCT04224636|COMBINATION_PRODUCT|Atezolizumab Injection, Bevacizumab Injection|Atezolizumab and Bevacizumab will be administered prior to or in combination with TACE
223560420|NCT00808613|DEVICE|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
223560421|NCT00808613|DEVICE|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
223560422|NCT04240041|DIAGNOSTIC_TEST|Transcerebellar diamater|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, trans-cerebellar diameter is identified by obtaining an oblique view through posterior fossa that included visualization of midline thalamus, cerebellar hemispheres and cisterna magna.
224032875|NCT00265447|BEHAVIORAL|Aerobic conditioning|3 months of aerobic conditioning
224136541|NCT04231955|DIAGNOSTIC_TEST|numerical rating scale|patients were asked to marked their pain intensity level on numerical rating scale between 0 and 10 and the result was recorded as pain intensity level.
224136542|NCT04231955|OTHER|visual analogue scale|"Patients were asked to marked their pain intensity level on visual analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possible. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
223415639|NCT05138770|DRUG|VC005 Tablets Placebo|VC005 Tablets Placebo 1、5、10、25、50、100mg single dose
223560423|NCT04240041|DIAGNOSTIC_TEST|Placental thickness|Using SAMSUNG H60 convex probe 2-8 MHz Machine by the same sonographer, placental thickness will be measured at the level of the umbilical cord insertion excluding the myometrium and sub-placental veins
223560424|NCT04115748|DRUG|Filgotinib|Tablets administered orally once daily with or without food
223560425|NCT04115748|DRUG|Adalimumab|Injection administered subcutaneously once every 2 weeks
223560426|NCT04115748|DRUG|Placebo to match filgotinib|Tablets administered orally once daily with or without food
223560427|NCT04115748|DRUG|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
223560428|NCT00713349|DRUG|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
223560429|NCT00713349|OTHER|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
223560430|NCT03418311|DEVICE|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
223560431|NCT04245670|RADIATION|Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5|Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
223415640|NCT05138770|DRUG|VC005 Tablets food effects group|VC005 Tablets qd per period, for two periods
223415641|NCT05178160|OTHER|PEEP Standard Protocol|All the patients treated with CPAP receive a PEEP standard of 10 cmH2O with a fixed FiO2
223560432|NCT03478475|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|
223560433|NCT03478475|OTHER|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
223560434|NCT02363361|DRUG|Imatinib|Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
223560435|NCT02319161|DRUG|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
223560436|NCT00881998|PROCEDURE|Minimally Invasive Total Hip Arthroplasty|
223560437|NCT00881998|PROCEDURE|Conventional Total Hip Arthroplasty|
224032876|NCT00265447|BEHAVIORAL|Delayed exercise|delayed exercise control group
224032877|NCT01390181|DRUG|Cozaar|Angiotensin II Receptor Blocker
224032878|NCT05280951|OTHER|Focused-PPC Care|Individual clinical assessments and counseling for each group member will last about 15 minutes. Then, there will be 1 hour of group time dedicated to education and support. Each group session will be led by two trained and registered midwives who will provide both clinical care, education, and support as needed. In addition, each group session will be supported by a project assistant. Focused-PPC will be implemented in addition to newborn care.
224032879|NCT05280951|OTHER|Usual Care|Women in the control group will receive standard postnatal care (PNC) currently practiced in the health centers. This involves attending PNC visits at the health center within 14 days after birth, at 6 weeks, and monthly thereafter up to one year.
224032880|NCT06140472|BEHAVIORAL|Phoenix|Specific individualized nurse follow-up using the PHOENIX application.
224032881|NCT06140472|BEHAVIORAL|Journal de bord|Regular nursing follow-up, with the use of an electronic journal.
224032882|NCT05903339|DRUG|V3G CH848 Pr-NP1 60mcg|(60 mcg)
224032883|NCT05903339|DRUG|3M-052-AF 5mcg|(5 mcg)
224032884|NCT05903339|DRUG|Alum 500 mcg|(500 mcg)
224032885|NCT05903339|DRUG|V3G CH848 mRNA-Tr2 50mcg|(50 mcg)
224032886|NCT05903339|DRUG|ACU-026-001-1 2.0mg|(2.0 mg)
224136543|NCT04231955|OTHER|color analogue scale|"Patients were asked to marked their pain intensity level on color analogue scale, a straight line with one end indicating no pain and the other end indicating worst pain possibleand color change towards to worst pain possible end. Then the distance between no pain end and patients' mark was measured and recorded as pain intensity level."
224136544|NCT04231955|OTHER|faces rating scale|"Patients were asked marked their pain on a faces rating scale which consisted of six different faces representing different levels of pain intensity with the first face indicating no pain whilst last face indicating worst pain possible. The result was recorded as pain intensity level."
223415642|NCT02518282|OTHER|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
223415643|NCT02518282|OTHER|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
223415644|NCT02518282|OTHER|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
223415645|NCT03749746|BEHAVIORAL|Home Blood Pressure Monitoring|Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.
223560438|NCT03764631|DRUG|Empagliflozin|Drug
223560439|NCT03764631|DRUG|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
224032887|NCT05903339|DRUG|V3G CH848 Pr-NP1 100mcg|(100 mcg)
224032888|NCT02805725|DRUG|Phase 1: Trabectedin|"Phase I trial based on a dose escalating study design (3+3 traditional design) assessing four dose levels of Trabectedin in combination with metronomic cyclophosphamide (CP).~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)"
224032889|NCT02805725|DRUG|Phase 2: Trabectedin|"Patients will be included in a single-arm phase II trial. Administrated dose will be the RP2D defined in the dose escalation part of the trial. The design will follow a two-stage Simon's optimal design.~All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial."
224032890|NCT02805725|DRUG|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
224032891|NCT02805725|DRUG|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
224032892|NCT01728220|COMBINATION_PRODUCT|Inhaled NO delivered via INOpulse DS-C Device|Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
223560440|NCT02969291|BEHAVIORAL|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
223560441|NCT01200407|DRUG|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
224032893|NCT01728220|COMBINATION_PRODUCT|Placebo delivered via INOpulse DS-C Device|Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
224032894|NCT00112931|BIOLOGICAL|rituximab|
224032895|NCT00112931|OTHER|No treatment|
224032896|NCT01195545|DEVICE|Veritas® Collagen Matrix|biological mesh in hernia repair
224032897|NCT04968197|DEVICE|Vestibular Intervention via Portable Electrical Stimulator (VIPES) system|A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
224136545|NCT00003595|BIOLOGICAL|filgrastim|
223560442|NCT00006253|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
223560443|NCT00006253|BEHAVIORAL|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
224032898|NCT00234507|BIOLOGICAL|Botulinum toxin type A|
224136546|NCT00003595|BIOLOGICAL|rituximab|
224136547|NCT00003595|DRUG|CHOP regimen|
224136548|NCT00003595|DRUG|cyclophosphamide|
224136549|NCT00003595|DRUG|doxorubicin hydrochloride|
224136550|NCT00003595|DRUG|prednisone|
224032899|NCT06083922|DRUG|Cyclophosphamide|Days 1, 8 and 15, Cycles 1-8
224032900|NCT06083922|DRUG|Bortezomib|Days 1,8,15, Cycles 1-8, Days 1,15 Cycles 9+
224032901|NCT06083922|DRUG|Dexamethasone|Days 1,2,8, 9,15,16, 22, 23, Cycles 1-8
224032902|NCT06083922|DRUG|Daratumumab|Days 1,8,15,22, Cycles 1-2, Days 1,15 Cycles 3-6, Day 1 Cycles 7+
224032903|NCT04586595|OTHER|REVISiT intervention|REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
224032904|NCT01062945|DRUG|Placebo|Matching administration of a placebo pill.
224136551|NCT00003595|DRUG|vincristine sulfate|
224136552|NCT05724017|BEHAVIORAL|Street Games Intervention|The children to be included in the study will be grouped in groups of 10 according to their age groups. Groups of 10 people consist of six sessions in total, two days a week for three weeks. Applications will be made in the school garden. In the meetings, games that attract the attention of children will be discussed, suitable games will be played, origami, painting and story sharing will be made. In the study, the independent variable street games intervention will be applied.
224136553|NCT05128526|BEHAVIORAL|exercise|Short foot exercises without respiratory exercises
224136554|NCT05128526|BEHAVIORAL|respiratory|Short foot exercises with respiratory exercises
224136555|NCT05578768|OTHER|No intervention|Patients will receive standard of care.
224136556|NCT00067821|DRUG|2-Flourodeoxyglucose|
223415646|NCT03749746|BEHAVIORAL|Heart Health 4 New Moms|The intervention is comprised of four key components: (1) The online curriculum consists of 12 modules on healthy eating and physical activity adapted from the Diabetes Prevention Program and specifically targeting postpartum women. (2) Self-monitoring and tracking program, in which participants will be provided with a Bluetooth-enabled blood pressure cuff and digital scale and will be provided real-time feedback on their blood pressure and weight trends. (3) A registered dietitian will act as a lifestyle coach for participants with regular review of progress and provision of coaching notes, support and suggestions. (4) Finally participants will have access to a customized online toolbox, including dietary tracking sheets and recipes from the American Heart Association (AHA).
223560444|NCT03299881|DEVICE|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
224032905|NCT01062945|DRUG|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
224032906|NCT02425644|DRUG|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
224032907|NCT02425644|DRUG|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
224032908|NCT03668353|BIOLOGICAL|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
224136557|NCT00582699|BEHAVIORAL|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
224136558|NCT00587444|DRUG|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is \< 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is\>480 seconds
224136559|NCT00587444|DRUG|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is \<600 seconds anytime during CPB
224136560|NCT00587444|DRUG|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
224136561|NCT03182413|DRUG|Placebo|
224136562|NCT03182413|DRUG|Modafinil|
224136563|NCT03182413|DRUG|THN102|
224298418|NCT02926820|BEHAVIORAL|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
223415647|NCT03749746|OTHER|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
223415648|NCT04544657|OTHER|no intervention|No intervention for enrolled patients
223415649|NCT00006068|PROCEDURE|Pancreatic Islet Transplantation|
223415650|NCT03128138|DRUG|SPH3127|"Drug: SPH3127 Tablet~Drug: Placebo Tablet"
223415651|NCT04431258|DRUG|ABTL0812|ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
223415652|NCT04431258|DRUG|Folfirinox|"FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities."
223560445|NCT03299881|BEHAVIORAL|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
223560446|NCT01390831|DEVICE|THERMOCOOL® Catheter|Catheter-based renal denervation
223560447|NCT01242891|DEVICE|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
224032909|NCT02549560|DEVICE|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
224032910|NCT00225992|DRUG|Arsenic Trioxide|
224032911|NCT00657059|DRUG|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( \< 5 g NaCl/day), and then given a stable dose (150mg \~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
224032912|NCT00657059|DRUG|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
223415653|NCT04431258|DRUG|Placebo|Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
223415654|NCT05299554|DRUG|Chronocort|Hydrocortisone modified-release capsule 5 mg and 10 mg
223415655|NCT04420533|BEHAVIORAL|Behavior therapy alone|"1. reduction of fluid intake at specific times aimed at reducing urinary frequency when most inconvenient;~2. moderation of intake of caffeine or alcohol, which may have a diuretic and irritant effect, thereby increasing fluid output and enhancing frequency, urgency and nocturia;~3. use of relaxed and double-voiding techniques;~4. urethral milking to prevent post-micturition dribble;~5. distraction techniques such as penile squeeze, breathing exercises, perineal pressure, and mental tricks to take the mind off the bladder and toilet, to help control storage symptoms;~6. bladder retraining that encourages men to hold on when they have sensory urgency;~7. reviewing the medication and optimising the time of administration or substituting drugs for others that have fewer urinary effects (these recommendations apply especially to diuretics);~8. providing necessary assistance when there is impairment of dexterity, mobility or mental state;~9. treatment of constipation."
223415656|NCT04420533|DRUG|Mirabegron 50 MG Extended Release Oral Tablet|Betmiga prolonged-release tablets (mirabegron) 50mg QDAC PO
223415657|NCT05029375|BEHAVIORAL|PEERS® for Preschoolers|P4P is a 16-week manualized social skills treatment program, adapted from an existing empirically supported social skills intervention for young children with autism
224032913|NCT00657059|DRUG|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt \< 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
224032914|NCT02714725|DRUG|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
224032915|NCT02714725|DRUG|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
224032916|NCT02714725|DRUG|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
224032917|NCT05997927|DRUG|VC005 tablets|VC005 groups repeat administration for 12 weeks
223415658|NCT00887315|DRUG|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
223415659|NCT00887315|RADIATION|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
223415660|NCT03661242|BEHAVIORAL|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
223415661|NCT02339532|DRUG|FEC100|"3 cycles of FEC 100 administered IV q3w~* 5-Fluorouracil (5-FU) 500 mg/m²~* Epirubicin 100 mg/m²~* Cyclophosphamide 500 mg/m²"
223415662|NCT02339532|DRUG|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m² IV
223415663|NCT02339532|DRUG|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
223560448|NCT06323941|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
223560449|NCT06323941|BEHAVIORAL|Therapeutic exercises|Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
223560450|NCT01450696|DRUG|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
223560451|NCT01450696|DRUG|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m\^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
223560452|NCT01450696|DRUG|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
223560453|NCT01843673|PROCEDURE|computed tomography|Undergo FBCT
223560454|NCT01843673|PROCEDURE|cone-beam computed tomography|Undergo dual CBCT
223560455|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian kV OBI
224032918|NCT05997927|DRUG|VC005 Tablets Placebo|VC005 placebo groups repeat administration for 12 weeks
224032919|NCT06783751|PROCEDURE|Modified Vertical Sleeve Gastrectomy (mVSG)|The modified procedure preserves the gastric sling fibers and re-establishes the gastroesophageal flap valve (GEFV).
224032920|NCT06783751|PROCEDURE|Conventional Vertical Sleeve Gastrectomy (cVSG)|Vertical Sleeve Gastrectomy as standard procedure
224032921|NCT00124852|BEHAVIORAL|n-3 Fatty Acid Supplementation|
224298419|NCT06019520|DRUG|N-Acetylcysteine|Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.
224298420|NCT06019520|DRUG|Chemotherapy|Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
224032922|NCT01141738|BEHAVIORAL|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
224032923|NCT01141738|BEHAVIORAL|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
224032924|NCT01364363|PROCEDURE|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
224032925|NCT04510909|OTHER|COMMIT mHealth application|The investigators will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and adult depression patients.The tool will be used by community CHWs in Dolakha, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
224032926|NCT00439530|DRUG|oseltamivir|
224032927|NCT00439530|DRUG|probenecid|
224032928|NCT02772523|OTHER|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
224032929|NCT04206592|DEVICE|Oropharyngeal leak pressure during pneumoperitoneum.|Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
224032930|NCT01256658|DRUG|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
223415664|NCT02339532|DRUG|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
223415665|NCT02339532|DRUG|Carboplatin|CARBOPLATIN AUC 6 IV q3w
223415666|NCT00156611|PROCEDURE|Balloon Angioplasty|
223415667|NCT00156611|DRUG|ReoPro|
223415668|NCT04830111|DEVICE|heart rate variability biofeedback Application (Eureka iDestressor)|heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
223415669|NCT03612661|BEHAVIORAL|Group Intervention|Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
223415670|NCT03612661|BEHAVIORAL|Guided Self-Help|Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (\~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
223415671|NCT02582060|OTHER|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
223560456|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
224032931|NCT02797210|DEVICE|Continuous theta-burst stimulation|
224032932|NCT04643860|DIAGNOSTIC_TEST|Differential Leucocyte Count (CLDC) device and algorithm|Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.
224032933|NCT00909792|DEVICE|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
224032934|NCT00909792|DEVICE|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
224032935|NCT05188326|DRUG|Vidaza 100 milligram (mg) injection|1st cycle 50 mg/sqm s.c. or i.v. for 7 days (5 + weekend off + 2) every 28 days and increase dosing after 1st cycle, if well tolerated, to 75 mg/ m2 for further 5 cycles, followed by cycles every 56 days for 4 years and six months post-remission.
223560457|NCT01843673|PROCEDURE|radiography|Undergo 2-D x-ray with Varian MV OBI
224032936|NCT05188326|OTHER|Best Supportive Care|Best supportive care includes antibiotics, transfusions and fluids
224032937|NCT03305068|DRUG|Celecoxib|
224032938|NCT03513172|DRUG|topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)|The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
224032939|NCT02570893|RADIATION|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
224298421|NCT00121316|DRUG|Pimecrolimus|Pimecrolimus Cream 1 %
223415672|NCT06002451|BEHAVIORAL|WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG|A web-based preconceptional care and consultancy training platform has been developed. In line with the literature, a comprehensive preconceptional care and counseling training content was prepared for women between the ages of 18-49. Web-based training consists of a total of 9 modules.The videos created for uploading to the website were shot in a professional studio environment with professional equipment.Each video was shot and recorded by dividing the training content according to its subsections, with an average of at least 6 minutes and a maximum of 16 minutes. Each of the module videos is based on giving the main messages in line with the purpose and objectives of the presentation.women were allowed to watch all the videos within 2 weeks. A dialog box is opened on the website where women can communicate with their midwives 24/7. During and after the training, preconceptional care and counseling training was given in this area for a total of 10 weeks.
223560458|NCT01843673|PROCEDURE|electronic portal imaging|Undergo EPID imaging
223560459|NCT01843673|RADIATION|image-guided adaptive radiation therapy|Undergo IGART
223560460|NCT02321319|DRUG|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
223560461|NCT02406924|PROCEDURE|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
224032940|NCT02570893|RADIATION|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
224032941|NCT02570893|DRUG|Paclitaxel and carboplatin|
223415673|NCT00379080|PROCEDURE|conventional surgery|Undergo surgery
223560462|NCT02406924|RADIATION|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
223560463|NCT02406924|OTHER|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
224136564|NCT06402903|OTHER|Observation|"The clinical, post-surgical and anthropometric variables of the patients, as well as the time spent in the Intensive Care Unit and on the hospital ward (in days) were collected in the Clinical Histories.~The collection of data from the Clinical Histories will be carried out by the principal investigator, an employee of the Hospital Universitario Central de Asturias, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the patients whose data were collected.~The data from the Clinical Histories will be exported to an Excel file which will subsequently be anonymised. Access to the Excel file will require a password access that will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialties)."
224136565|NCT03305757|DRUG|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
223560464|NCT02406924|OTHER|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
223560465|NCT02182063|DRUG|BIBF 1120 low dose|
223560466|NCT02182063|DRUG|BIBF 1120 high dose|
223560467|NCT05062694|OTHER|Survey|It will be created a questionnaire to investigate, among Italian physiotherapists, their clinical approach to the patient with Central Sensitisation
223560468|NCT02249091|DRUG|Selinexor|Patients receive Selinexor as specified in arm/group description (8 doses of 40 mg/m\^2 or 6 doses of 60 mg per induction cycle).
223739044|NCT02226003|DRUG|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
223739045|NCT04057872|PROCEDURE|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
224032942|NCT01030679|DRUG|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
224032943|NCT01030679|DRUG|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
224032944|NCT01030679|DRUG|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
224032945|NCT01030679|DRUG|Placebo|orally, 1 tablet once daily for 8 weeks
224032946|NCT03473704|BEHAVIORAL|Treatment group (TG)|The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
224032947|NCT03473704|BEHAVIORAL|Control group (CG)|For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
224032948|NCT00567268|DRUG|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
224136566|NCT03305757|PROCEDURE|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
223739046|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_4000_20|application of radial extracorporeal shockwave therapy (rESWT) with 4000 pulses and 20 Hz
224032949|NCT02877472|DEVICE|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
224032950|NCT02877472|PROCEDURE|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
223415674|NCT00379080|DRUG|tandutinib|Given orally
223415675|NCT00379080|OTHER|pharmacological study|Correlative studies
223415676|NCT00379080|OTHER|Tissue samples|Correlative studies
223415677|NCT04219111|GENETIC|Clariom|Clariom S Assay
223415678|NCT00619892|DRUG|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
223415679|NCT00619892|DRUG|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
223560469|NCT02249091|DRUG|Idarubicin|Infusion, iv, 10 mg/m\^2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
223560470|NCT02249091|DRUG|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m\^2, iv,
223560471|NCT03392363|DEVICE|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
223560472|NCT05034497|DRUG|186RNL|"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."
223560473|NCT03976024|OTHER|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
223739047|NCT05308641|PROCEDURE|radial extracorporeal shockwave therapy_500_2|application of radial extracorporeal shockwave therapy (rESWT) with 500 pulses and 2 Hz
223739048|NCT05308641|PROCEDURE|standard multimodal pain therapy|standard multimodal pain therapy
223739049|NCT05751239|OTHER|Questionaire|All participants answered an online questionaire. Out of the 837 participants 641 were included
223415680|NCT02901067|DRUG|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
223415681|NCT02901067|DRUG|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
223415682|NCT01184820|BIOLOGICAL|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
223415683|NCT01184820|BIOLOGICAL|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
223415684|NCT04690231|DRUG|Apatinib Mesylate|apatinib orally daily and ifosfamide 1.8mg/m2/d d1-3, etoposide 100mg/m2/d d1-3
223415685|NCT04690231|DRUG|ifosfamide and etoposide|ifosfamide and etoposide
223415686|NCT00245973|DRUG|Bifeprunox|
223415687|NCT02355964|BEHAVIORAL|Exercise|Aerobe exercise 3 times a week in 8 weeks
224032951|NCT01418820|DEVICE|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
224032952|NCT01418820|DEVICE|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
223415688|NCT02355964|BEHAVIORAL|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
223415689|NCT00821964|DRUG|imiquimod|Given topically
224032953|NCT01868113|DRUG|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
224136567|NCT03305757|PROCEDURE|Conventional|Conventional closure after mastectomy
224298422|NCT00121316|DRUG|Placebo|Vehicle cream (placebo cream)
224298423|NCT04871763|OTHER|Retainers' Cleansing with Geldis®|Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
224298424|NCT04871763|OTHER|Retainers' Cleansing with tablets|Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
223415690|NCT00821964|DRUG|Abraxane|Given IV
223415691|NCT00821964|OTHER|laboratory biomarker analysis|Correlative studies
223415692|NCT00821964|GENETIC|RNA analysis|Correlative studies
223415693|NCT00821964|OTHER|immunoenzyme technique|Correlative studies
223415694|NCT05772221|OTHER|Screening|Screening assessments to measure social determinants of health in relation to cardiovascular disease.
223415695|NCT00313326|PROCEDURE|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
223415696|NCT01962766|BEHAVIORAL|Myofunctionnal therapy|
223415697|NCT01962766|BEHAVIORAL|instructions|
223415698|NCT00288366|DRUG|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
223415699|NCT00288366|DRUG|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
223415700|NCT02497820|DRUG|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
223415701|NCT02461069|DRUG|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
223415702|NCT00857896|DRUG|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
223415703|NCT00000825|DRUG|Aldesleukin|
223415704|NCT02846155|OTHER|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
223415705|NCT02846155|DRUG|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
223415706|NCT02846155|DRUG|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
223415707|NCT00387855|BEHAVIORAL|SOS program|screening and didactic programming to raise awareness of depression suicidality
223415708|NCT04111250|PROCEDURE|Maxillary sinus augmentation|Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
223560474|NCT03976024|OTHER|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
223560475|NCT05116319|DIAGNOSTIC_TEST|point-of-care HbA1c|The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
223415709|NCT03992924|PROCEDURE|function or imaging guided PCI|FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
223415710|NCT06575764|OTHER|The Heart Priority Programme|The programme is delivered by the Cardiac Rehabilitation (CR) team. It consist of two main parts: 1) an evidence-based identification form to identify patients at risk of dropout due to being in a vulnerable situation and 2) an add-on intervention to standard CR targeted these patients. The add-on intervention encompasses three core elements: 1) Assigning a contact person with specific responsibilities, 2) Systematically communicating patient information to colleagues in the CR team and 3) Systematic follow-up
223415711|NCT03505684|DIETARY_SUPPLEMENT|CTP|1,000 mg of CTP was orally administered per day for 12 weeks.
223415712|NCT03505684|DIETARY_SUPPLEMENT|placebo (starch)|placebo (starch)
223415713|NCT02907918|DRUG|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
223415714|NCT02907918|DRUG|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
223415715|NCT02907918|BIOLOGICAL|Trastuzumab|"* Or FDA approved biosimilar~* Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery."
223415716|NCT02907918|DRUG|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
223415717|NCT02907918|PROCEDURE|Breast surgery|Standard of care
223415718|NCT02907918|PROCEDURE|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
223415719|NCT02907918|PROCEDURE|Research bone marrow (OPTIONAL)|Baseline and surgery
223415720|NCT02907918|PROCEDURE|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
223415721|NCT02907918|GENETIC|Research blood for germline DNA|Baseline
224032954|NCT01868113|OTHER|Placebo|Placebo to be administered 12hourly
224032955|NCT00470210|DRUG|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
224032956|NCT00470210|DRUG|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
224032957|NCT00470210|DRUG|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
224032958|NCT00529724|BEHAVIORAL|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
224032959|NCT05898893|DEVICE|Microport NeuroTech Tubridge Plus flow-diverter Stent|Intracranial stent for wide-necked aneurysms
224032960|NCT03218462|BEHAVIORAL|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
224032961|NCT03393715|DRUG|Perindopril Oral Tablet|Perindopril oral tablet morning versus evening
224032962|NCT02693613|DRUG|ASP1517|Oral
224032963|NCT02693613|DRUG|Kremezin®|Oral
224032964|NCT05882669|OTHER|Questionnaire administration|All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
224032965|NCT01123954|BIOLOGICAL|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
224032966|NCT02405923|OTHER|HRF|The subject will take the formula for a period of 12 months.
224032967|NCT02405923|OTHER|eHF|The subject will take the formula for a period of 12 months.
223415722|NCT02907918|PROCEDURE|Blood for detection of circulating tumor cells|Baseline
223739050|NCT02467465|OTHER|Physical therapy modalities|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
224032968|NCT01320267|PROCEDURE|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
224032969|NCT05279703|DRUG|Epinephrine 0.03|epinephrine infusion rate of 0.03 mcg/kg/min
224032970|NCT05279703|DRUG|Epinephrin 0.02|epinephrine infusion rate of 0.02 mcg/kg/min
224032971|NCT05279703|DRUG|Epinephrin 0.01|epinephrine infusion rate of 0.01 mcg/kg/min
224032972|NCT00619190|DRUG|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
224032973|NCT02217943|PROCEDURE|Roux-en-Y gastric bypass|
224032974|NCT02217943|PROCEDURE|Sleeve gastrectomy|
224298425|NCT04871763|OTHER|Retainers' cleansing with water|Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
223415723|NCT04819516|PROCEDURE|high-intensity focused ultrasound therapy|Patients will receive high-intensity focused ultrasound therapy in local site.
223415724|NCT04819516|DRUG|Toripalimab|Toripalimab plus regorafenib
223415725|NCT02325388|DEVICE|ForeSite PT™ system|"XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts."
223415726|NCT01417091|DRUG|BPS804|
224298426|NCT00450619|RADIATION|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
224298427|NCT00450619|BIOLOGICAL|Sargramostim|100 mcg/injection x 4 days given subcutaneously
224298428|NCT00450619|BIOLOGICAL|Recombinant vaccinia-TRICOM vaccine|2 x 10\^8 PFU given subcutaneously on day 1.
224032975|NCT04544345|DEVICE|His bundle pacing, AV optimized|A Select Secure 3830 (Medtronic, MN, USA) pacing lead will be placed on the bundle of His. In case of unsuccessful His capture, left bundle branch area pacing is going to be targeted. Pacemaker will be programmed to a low base rate and a high tracking rate to allow for intrinsic sinus rhythm. AV delay will be optimized with echocardiography to the shortest AV delay without truncation of the A wave on transmitral pulse wave doppler.
224032976|NCT04544345|DEVICE|Backup VVI pacing|Pacemaker will be programmed to VVI (ventricular only) mode with low base rate as to allow for intrinsic sinus rhythm without AV optimization.
224032977|NCT04010513|BEHAVIORAL|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
224032978|NCT04010513|OTHER|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
224032979|NCT05555511|OTHER|Control Group|Patients will not receive N-Acetylcystiene and will receive standard care according to our institutional protocol
224032980|NCT00315003|DRUG|Telithromycin|
224136568|NCT04575831|BEHAVIORAL|Exercise, Nutrition, and Palliative Symptom Management|"1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake."
224136569|NCT02277340|PROCEDURE|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
224298429|NCT00450619|BIOLOGICAL|Recombinant fowlpox-TRICOM vaccine|1 x 10\^9 PFU given subcutaneously on days 15 and 29
223415727|NCT05021679|OTHER|AMP Implementation|Each study site will implement the Johns Hopkins AMP program at different times. The AMP program includes nursing staff training on the goals of AMP, how to complete mobility-focused outcome measures, set mobility goals, and to safely mobilize/ambulate patients. The AMP program also includes embedding these outcome measures and mobility goals into electronic medical records and producing weekly/monthly reports that show how often nursing staff score patient mobility and help patients meet daily activity goals.
223415728|NCT02973724|DRUG|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
223415729|NCT02973724|DRUG|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
223415730|NCT01587846|DIETARY_SUPPLEMENT|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
223560476|NCT06297317|DIAGNOSTIC_TEST|Ultrasound measurement of triceps surae muscle-tendon architecture|The resting plantar-flexors MTU architecture assessment was performed using a conventional B-mode and extended-field-of-view (EFOV) ultrasound imaging. Achille tendon cross-sectionnal area, Medial gastrocnemius thickness, pennation angle, fascicle length and muscle length were collected on the dominant lower limb.
223560477|NCT06094361|PROCEDURE|Iontophoresis Intervention|Iontophoresis was applied with a Chattanooga Physio (DJO Global, Herentals, Belgium) brand device. The galvanic current mode was selected for the intervention. Intervention area was cleaned to prevent irritation and active electrode pad (cathode-5 cm2) was immersed in 75 mg diclofenac sodium solution. The current intensity of the application for 10 minutes was 0.1-0.2 mA/cm2.
224032981|NCT00315003|DRUG|Azithromycin|
224032982|NCT04939623|DRUG|Probenecid|The Investigators aim to recruit 40 participants who will be followed for 12 weeks in duration. Participants will be randomized in a 2:2:1 ratio to one of probenecid 500 mg, 1000 mg, or placebo PO BID for 12 weeks. Justification for use of a non-active placebo comparator includes the fact that this trial is meant to identify tolerability and safety of probenecid in a population of patients living with chronic pain, this will be best measured by comparing to a non-active placebo.
224032983|NCT02589717|DRUG|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
224032984|NCT02376751|DRUG|sebelipase alfa|
224032985|NCT05397353|OTHER|Sleepio (TM)|Sleepio is a mobile Digital Cognitive Behavior Therapy for Insomnia (dCBT-I) app.
224298430|NCT05469217|OTHER|fMRI brain imaging|Structural MRI of gray and white matter, functional MRI during performance of the N-back task
223560478|NCT06094361|PROCEDURE|Phonophoresis|Phonophoresis was performed with a Chattanooga brand ultrasound device (Chattanooga, Intelect Legend Ultrasound, TN, USA). 75 mg gel containing 1% diclofenac sodium was applied to the shoulder area. The ultrasound was conducted continuously for 6 minutes with frequency of 1 MHz and an intensity of 1.5 watts/cm2.
223560479|NCT06094361|PROCEDURE|Conventional Therapy|All groups received a treatment program consisting of hot pack, Transcutaneous Electrical Nerve Stimulation and Shoulder girdle exercises for 30 minutes.
223560480|NCT06212115|DIAGNOSTIC_TEST|mNGS|metagenomics next generation sequencing
223560481|NCT05222893|DIAGNOSTIC_TEST|Respiratory monitoring|Measurement of the plateau pressure, positive end-expiratory pressure, driving pressure, end-expiratory lung volume, compliance of respiratory system on volume-controlled ventilation
223560482|NCT05222893|DIAGNOSTIC_TEST|Capnography|Measurement of end-tidal carbon dioxide tension, volume of CO2 eliminated per minute
223560483|NCT05222893|DIAGNOSTIC_TEST|Arterial blood gas|Measurement of the oxygen partial pressure and the carbon dioxide partial pressure
224032986|NCT00594529|PROCEDURE|Surgery|Liver resection for metastatic liver lesions
224032987|NCT03096366|DEVICE|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
223415731|NCT01587846|DIETARY_SUPPLEMENT|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
223415732|NCT01587846|DIETARY_SUPPLEMENT|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
223415733|NCT01587846|DIETARY_SUPPLEMENT|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
223415734|NCT00970840|DIETARY_SUPPLEMENT|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P\&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
223415735|NCT00497289|DRUG|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
223415736|NCT00497289|DRUG|Lipidem 20%|daily i.v. infusion for up to 5 days
223415737|NCT04067726|DRUG|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
223415738|NCT04067726|DRUG|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
223415739|NCT04067726|DRUG|Calcium|-Participants will be instructed to take calcium (at least 500 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
223415740|NCT04067726|DRUG|Vitamin D3|Participants will be instructed to take vitamin D3 (at least 400 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
223415741|NCT04067726|PROCEDURE|Core needle biopsy|Baseline and 12 months
223415742|NCT04067726|PROCEDURE|Blood draw|Baseline and 12 months
223415743|NCT02924168|DEVICE|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
223415744|NCT02924168|DEVICE|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
223415745|NCT06684158|DRUG|Mecapegfilgrastim|6 mg,HD d3,every 2weeks (Q2W)
223415746|NCT06684158|DRUG|Adebrelimab|Adebrelimab：1200 mg，iv d1，every2 weeks (Q2W)
223415747|NCT06684158|DRUG|Docetaxel|Docetaxel：50 mg/m2 iv gtt d1，every 2 weeks (Q2W)
223415748|NCT06684158|DRUG|Oxaliplatin|Oxaliplatin ：85 mg/m2 iv gtt d1，every2 weeks (Q2W)
223415749|NCT06684158|DRUG|5-Fluorouracil (5-FU)|5-FU ：2600 mg/m2 ，intravenous infusion， 24h ，d1，every 2 weeks (Q2W)
223415750|NCT06684158|DRUG|Leucovorin (LV)|LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)
223415751|NCT06967038|BIOLOGICAL|CAR-NK cell|Chimeric Antigen Receptor Natural Killer Cell
224032988|NCT03096366|OTHER|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
224032989|NCT04841551|DRUG|Kybella Flanks|10 subjects will be treated with Kybella in the flanks
224032990|NCT01012843|DRUG|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
224032991|NCT01012843|DRUG|Placebo|oral Placebo tablets two times a day for 10 days
224032992|NCT02525861|BIOLOGICAL|GLASSIA|Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
224032993|NCT00438321|DRUG|Zoladex|
223415752|NCT04418128|DRUG|Nafamostat Mesylate|The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
223415753|NCT01437254|DRUG|CPERT|Single 340 MBq CPERT scan in first 10 subjects
223415754|NCT01437254|DRUG|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
223415755|NCT00863356|DEVICE|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
223415756|NCT00860197|DIETARY_SUPPLEMENT|Fully torrefied coffee|Fully torrefied coffee
223415757|NCT00860197|DIETARY_SUPPLEMENT|Partially torrefied coffee|Partially torrefied coffee
223415758|NCT00557011|DRUG|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
223415759|NCT00557011|DRUG|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
223415760|NCT00557011|DRUG|Placebo|Placebo capsule taken once daily in the morning
223415761|NCT01553604|PROCEDURE|augmentation mammaplasty|Dressing is removed on the first postoperative day
223415762|NCT01553604|PROCEDURE|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
223415763|NCT02920008|DRUG|guadecitabine|In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m\^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
223415764|NCT02920008|DRUG|Treatment Choice (TC)|"* High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).~* Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.~* Best Supportive Care (BSC)."
223560484|NCT05222893|DEVICE|Esophageal pressure|Measurement the pressure in the lower third of esophagus during inspiration and expiration
224032994|NCT00438321|DRUG|Testosterone gel|
224032995|NCT00438321|DRUG|Anastrozole Pill|
224032996|NCT00438321|OTHER|Placebo|
224298431|NCT04327713|DIETARY_SUPPLEMENT|fish oil supplement|daily fish oil supplement vs. placebo
224032997|NCT06018272|BEHAVIORAL|Mentalization-Based Treatment (MBT)|Patients in MBT will receive a maximum of 58 sessions in total. Of those, 30 are weekly individual sessions. 28 sessions are weekly group sessions conducted by two therapists, and consisting of 8 introductory sessions of group psychoeducation followed by 20 group therapy sessions. The duration of MBT is 12 months. MBT is manualized and relies on validating the emotional experience of patients that aims to promote mentalizing. The proposed mechanism of change in MBT is to stabilize mentalizing in certain focus areas in order to create a psychic buffer between affect and behaviour to foster affect regulation, reduce impulsivity and promote functional supportive relationships.
224299169|NCT03097835|DRUG|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
224299170|NCT03097835|DRUG|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
223415765|NCT05323240|OTHER|PM exposure|To determine whether 3-day consecutive exposures to levels of fine particulate matter (PM2.5) that are close to the current 24-hr national standard will cause changes in inflammatory and cardiopulmonary endpoints.
223415766|NCT05323240|OTHER|Filtered air exposure|To determine whether 3-day consecutive exposures to filtered air will cause changes in inflammatory and cardiopulmonary endpoints.
223415767|NCT02737930|DRUG|Fluoxetine|
223415768|NCT02737930|DRUG|Placebo|
223415769|NCT02041117|DRUG|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
223415770|NCT04276116|BEHAVIORAL|Pulmonary age|Communication of pulmonary age
223415771|NCT04061512|DRUG|Dexamethasone, cyclophosphamide, rituximab|DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment
223415772|NCT04061512|DRUG|Rituximab, ibrutinib|RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
223415773|NCT00795470|DRUG|Antimicrobial|Appropriate antimicrobial based on urine culture results
223415774|NCT00795470|DEVICE|Catheter change|Change urine catheter
223415775|NCT05429281|OTHER|Pilates-based Core Strengthening Exercises|The PsCS group performed eight Pilates exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the supervision of a physical therapist who had more than 5 years of experience in Pilates.
223415776|NCT05429281|OTHER|Plyometric-based Muscle Loading Exercises|The PlyoML group performed 10 plyometric exercises over 45 minutes, three times per week for 12 successive weeks. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
223415777|NCT05429281|OTHER|Combined Pilates and Plyometrics|The combined training group performed the same exercises as the PsCS and PlyoML groups, although with half the number of sets/repetitions over 45 minutes, three times per week for 12 successive weeks. The PsCS and PlyoML were executed within the same session, with a 10-to-15-minute rest interval. The training was conducted under the close supervision of a licensed pediatric physical therapist. The safety and performance guidelines, defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association, were considered during training.
223415778|NCT03169881|DRUG|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
223415779|NCT03169881|DRUG|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
223415780|NCT00936143|DRUG|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
223415781|NCT01028014|DRUG|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
223415782|NCT01028014|DRUG|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
223415783|NCT01028014|DRUG|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
223415784|NCT01028014|DRUG|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
223415785|NCT01028014|DRUG|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
223560485|NCT00620178|DRUG|Candesartan Cilexetil|oral once daily dose
224032998|NCT06018272|BEHAVIORAL|Bona-Fide Treatment in Germany (BFT)|Patients in BFT will receive one to two weekly sessions of Bona-Fide-Treatment (Psychodynamic Therapy, PT, or Cognitive Behavioural Therapy, CBT) conducted by community experts delivered as short-term psychotherapy (\<24 sessions) or long-term psychotherapy (\>24 sessions). BFT can be delivered as individual, group or a combination of individual and group treatment as stated in the German psychotherapy regulations.
224032999|NCT02715154|DRUG|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
224033000|NCT02715154|DRUG|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
224033001|NCT00720655|OTHER|Dietary intervention|Fatty fish at least 4 meals per week.
223415786|NCT01028014|DRUG|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
223415787|NCT02516514|PROCEDURE|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
223560486|NCT00620178|DRUG|Losartan|once daily oral dose
223560487|NCT04120753|DRUG|OLOMAX 20/5/5mg|Tablets, Oral, QD
223560488|NCT04120753|DRUG|OLOMAX 20/5/10mg|Tablets, Oral, QD
223560489|NCT04120753|DRUG|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
223560490|NCT01858545|DEVICE|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
223560491|NCT01858545|DEVICE|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
223739051|NCT02467465|DEVICE|Invasive Physical therapy modalities|Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
223415788|NCT04246216|PROCEDURE|Percutaneous Electrical Nerve Stimulation|Experimental: Percutaneous Electrical Nerve Stimulation The experimental group will receive 3 sessions (once per week) of ultrasound-guided Percutaneous Electrical Nerve Stimulation targeted the median nerve. Once the median nerve is ultrasound identified, the needles will be left in situ at the identified points connected to an electrostimulator (ES-160 ITO co.) applying a biphasic continuous waveform, at low frequency (2 Hz)19 and with 250 microseconds pulse duration for 30mins.
223415789|NCT04246216|PROCEDURE|Endoscopic surgery of the carpal tunnel|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
224033002|NCT00720655|OTHER|Dietary intervention|Lean fish at least 4 meals per week.
224033003|NCT00720655|OTHER|Dietary intervention|Control diet with lean meat and chicken.
224033004|NCT02817230|DRUG|Statin|
223415790|NCT00436475|DRUG|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
223415791|NCT00436475|DRUG|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
223415792|NCT00436475|DRUG|Vitamin D3-Placebo|Vitamin D3-Placebo
224136570|NCT06017778|DEVICE|whole body vibration|patients will receive WBV training in addition to traditional training will be performed on a tri-planar (mostly vertical, Z axis) oscillating vibration platform (Power PlateR pro5™; Power Plate North America, Inc., Northbrook, IL,USA) for 20-30 minutes per session. WBV training will be supervised and performed in a clinic three days a week with at least one day between each session for four weeks (total of 12 sessions).
224136571|NCT06017778|OTHER|traditional exercise group|10 minutes warm-up (lower extremity stretching exercises), 20-30 minutes period of strength exercises with three sets of 10-15 repetitions (isometric quadriceps setting, knee extensions, double-legged wall squat), and 5 minutes cool-down (lower extremity stretching exercises). Lower extremity stretching exercises consisted of quadriceps, hamstring, gastrocnemius and iliotibial band stretching with 3 repetitions for 30 s each muscle.
224136572|NCT00647257|DRUG|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
223415793|NCT00436475|DRUG|Calcium-Placebo|Calcium-Placebo
223415794|NCT02698332|DEVICE|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
223415795|NCT02557802|BIOLOGICAL|Fluenz Tetra|Intranasal spray, 0.2 ml dose
224136573|NCT00647257|DRUG|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
224136574|NCT02066519|BEHAVIORAL|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
224136575|NCT02299713|DEVICE|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
224136576|NCT02151799|PROCEDURE|Abdominoplasty and liposuction|
224136577|NCT00251277|DRUG|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
224136578|NCT03073213|DRUG|Ixekizumab|Administered as subcutaneous (SC) injection
224136579|NCT00961662|DRUG|D-Tagatose|powder to be dissolved in water prior to dosage.
224136580|NCT01560897|DRUG|Oral C13|Ingestion of C13 and follow up of the ureogenesis
224136581|NCT05539105|PROCEDURE|Double tract reconstruction|Double tract reconstruction would be applied after radical proximal gastrectomy.
224136582|NCT05539105|PROCEDURE|Gastric conduit reconstruction|Gastric conduit reconstructionn would be applied after radical proximal gastrectomy.
224136583|NCT05539105|PROCEDURE|Other reconstructions|Other reconstructions except for double tract and gastric conduit reconstructions would be applied after radical proximal gastrectomy.
224299171|NCT03097835|OTHER|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
223415796|NCT02557802|BIOLOGICAL|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
223415797|NCT01103258|PROCEDURE|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
223415798|NCT01103258|PROCEDURE|FOAM|duplex guided foam sclerotherapy
223415799|NCT04614181|DIETARY_SUPPLEMENT|Nestle Resource drink|Beverage (Nestle RESOURCE). Each serving is 237ml containing 53.6g of carbohydrate and 9g of protein. Intervention group will consume two servings of the carbohydrate beverage (53.6g each, total of approximately 100g) on the day before surgery and one serving up to 6 hours prior to scheduled surgery time.
223415800|NCT04614181|OTHER|Usual care|Usual fracture care as determined by clinical team
223415801|NCT00839813|BEHAVIORAL|Yoga|10 weeks of a trauma-sensitive yoga class
224033005|NCT03205215|OTHER|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
224033006|NCT03205215|OTHER|Waitlist Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
224033007|NCT01516658|DEVICE|Hydrogel coil|at least one Hydrogel coil have to use for embolization
224033008|NCT01516658|DEVICE|Bare platinum coil|only bare platinum coil have to use for embolization
224033009|NCT04426955|DRUG|Camrelizumab|IV infusion
224033010|NCT04426955|DRUG|Paclitaxel|IV infusion
224033011|NCT04426955|DRUG|Cisplatin|IV infusion
224033012|NCT04426955|DRUG|Placebo|IV infusion
224033013|NCT04426955|RADIATION|Radiation|Concurrent Radiation
224033014|NCT01096888|BEHAVIORAL|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
224033015|NCT04081454|BEHAVIORAL|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
224033016|NCT04081454|BEHAVIORAL|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
224033017|NCT01621997|BEHAVIORAL|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
224033018|NCT02679950|GENETIC|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
224033019|NCT01794520|DRUG|Venetoclax|Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
224033020|NCT01794520|DRUG|Dexamethasone|Tablets were administered by mouth per the dexamethasone prescribing information.
224033021|NCT05304065|BEHAVIORAL|SAFETY-A within usual ED Care|SAFETY-A is a single session collaborative, strengths-based, developmentally nuanced, cognitive-behavioral intervention (CBT) to increase safety and mental health treatment initiation. The therapist works with the youth and family (or significant other, SO) separately and together to build hope and reasons for living, develop a personal safety plan, increase protective supports; and increase motivation for and linkage to treatment.
224033022|NCT05304065|BEHAVIORAL|Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts|COMB, includes SAFETY-A within usual ED care plus CLASP therapeutic and caring follow-up contacts designed to strengthen safety and treatment initiation and engagement. Core functions of CLASP include: building hope/reducing hopelessness; enhancing social/family support; strengthening problem-solving; and increasing treatment initiation and engagement.
224033023|NCT04155268|BEHAVIORAL|Flotation-REST|Floating in a specialized device (float pod or float cabin) used to attenuate sensory input.
224033024|NCT04155268|BEHAVIORAL|Dark Room|Participants will lay on an air mattress in a dark room with no cell phone and reduced sensory input.
224033025|NCT02212873|OTHER|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
224136584|NCT02286492|DRUG|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
224136585|NCT05271110|PROCEDURE|Liver resection (ablation)|Treatment of liver metastases from pancreatic cancer by surgery or ablation
224136586|NCT02732340|PROCEDURE|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
224136587|NCT01617655|DRUG|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
223415802|NCT05635435|OTHER|Detection of Immune and Inflammatory Indices in Peripheral Blood|We detected immune and inflammatory indices in peripheral blood at each patient's at first hospitalizatin from October 13th, 2006, to April 6th, 2022.
223415803|NCT00824902|PROCEDURE|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
223415804|NCT01665950|DRUG|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
223739052|NCT04577755|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223739053|NCT04577755|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223739054|NCT04577755|PROCEDURE|Computed Tomography|Undergo CT
224136588|NCT01617655|DRUG|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
224136589|NCT01617655|DRUG|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
224136590|NCT03483766|DEVICE|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
224298432|NCT05232084|DRUG|Bupivacaine + Fentanyl|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
224298433|NCT05222503|DEVICE|Knee Brace + OPUM Digital Knee|Knee Brace + OPUM Digital Knee
224298434|NCT05222503|DEVICE|Knee Brace|Knee Brace without OPUM Digital Knee
223415805|NCT01665950|DRUG|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
223415806|NCT01547143|DRUG|IST and/or alloHCT|"1\) Patients will be categorized by their initial serum ferritin level.~1. Mild ( ferritin\<3,000 μg/L): close observation~2. Moderate (ferritin: 3,000-10,000 μg/L):~   1. Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~  2. continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~3. Severe (ferritin\>10,000 μg/L):~   1. initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~  2. continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~      2\) AlloHCT for refractory or reactivated cases."
223415807|NCT00585832|BEHAVIORAL|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
223415808|NCT00585832|OTHER|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
224033026|NCT04214314|BEHAVIORAL|NeuronUp APT attentional program|NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
223415809|NCT01581242|DRUG|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
223415810|NCT01581242|DRUG|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
223415811|NCT01581242|DRUG|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
223415812|NCT06316232|DEVICE|STIM ON plus|increase of intensity of stimulation of 0.5 mA bilaterally
223415813|NCT06316232|DRUG|MED ON plus|administration of a 2x levodopa morning dose
223415814|NCT04826965|DEVICE|Wound Vac is applied|A wound vac or wound vac with cleanse choice dressing, track pad duo, and saline irrigation is applied.
223415815|NCT06140758|DRUG|Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
223415816|NCT06140758|DRUG|Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
223415817|NCT06140758|DRUG|Toms of Maine 0 ppm Fluoride Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
223415818|NCT06140758|DRUG|Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
223415819|NCT06140758|DRUG|1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
223415820|NCT06140758|DRUG|1100 ppm (0.454% Stannous fluoride) Dentifrice|Each subject will use this product during one of the six treatment periods in the crossover study design.
223415821|NCT06569706|PROCEDURE|Nipple-Sparing Mastectomy, with immediate breast reconstruction|It is an endoscopic approach for mastectomy using an axillary single port
223415822|NCT06041542|DIAGNOSTIC_TEST|10-second hand grip and release test|To grip and release hand in ten seconds
223415823|NCT02810717|DEVICE|theta-burst stimulation using a MagPro X1000|TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
223415824|NCT02810717|DEVICE|sham stimulation using a MagPro X1000|Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
223415825|NCT05448963|DEVICE|da Vinci SPⓇ Single-port System|Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
224033027|NCT02069925|BEHAVIORAL|Early Detection (ED)|This intervention consists of educational campaigns directed at patients \& families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
224033028|NCT02069925|BEHAVIORAL|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
224033029|NCT06383156|DEVICE|Double lumen endotracheal tube|correct position of LDLT during single lung ventilation
224033030|NCT02125305|DRUG|Metformin|
224298435|NCT05854888|PROCEDURE|Perineal Massage and Warm Compresses (PeMWaC)|Perineal Massage was performed in the II Hodge Plan, between maternal contractions and regardless of maternal position. Warm Compresses were applied by the midwife between Hodge plans III and IV, during pushing and regardless of maternal position.
224299172|NCT04989712|OTHER|Exposure|Participants randomised to one of the three exposures
223415826|NCT01864070|OTHER|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
223415827|NCT01864070|DRUG|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
223739055|NCT04577755|DRUG|Pomalidomide|Given PO
224033031|NCT06181201|PROCEDURE|Stool collection|"Stool collection is done with the Coll-off device (Zymo research, reference R1101-2-5) provided to the patient before and after the induction treatment and after the reference chemo-radiotherapy treatment (Cap50, Capecitabine). Collection must be carried out by the patient at home (collection using the Coll-off device and then transfer to a coproculture jar provided). The fresh sample is then picked up the same day by an approved transporter mandated by the promoter and will be stored at -20°C until the start of the analyses"
224033032|NCT06241742|DRUG|HT-6184|Single, oral dose of HT-6184
224033033|NCT06241742|DRUG|HT-6184 Placebo|Single, oral dose of placebo
224033034|NCT05728515|DRUG|68Ga-NY104|Patients will undergo PET/CT scans after receiving an intravenous injection of 68Ga-NY104
224033035|NCT05038462|DIETARY_SUPPLEMENT|Lactoferrin and DHA|The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
224033036|NCT05038462|OTHER|Placebo|Product with the same physical appearance and taste as the main intervention but without therapeutic effect
224033037|NCT01474798|DRUG|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing \> 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
224033038|NCT06450249|BEHAVIORAL|Humanitude® Care Methodology (HCM) training sessions|During a five-day training session healthcare professionals are trained to the HCM within their own care unit
223415828|NCT01864070|OTHER|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
223415829|NCT01127451|DRUG|Denileukin diftitox|Denileukin diftitox intravenous infusion over 30-60 minutes.
223415830|NCT03636724|BEHAVIORAL|E-intervention|The 10-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Week 9-10: self-monitoring. Self-efficacy will be a fixed intervention variable involved from week 2 to week 10. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
224033039|NCT06450249|BEHAVIORAL|Self-administered questionnaire|The self-administered questionnaire will be completed before and after participation in Humanitude® Care Methodology training sessions
224033040|NCT00495404|BEHAVIORAL|Physician Treatment Guidelines|
224136591|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
224136592|NCT01175213|BIOLOGICAL|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
224136593|NCT01175213|BIOLOGICAL|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
224136594|NCT03224585|DRUG|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
224136595|NCT03224585|DRUG|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
224299173|NCT03306524|DEVICE|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
224299174|NCT03306524|DEVICE|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
224136596|NCT00891163|DRUG|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
223415831|NCT00930774|DEVICE|FM system|Frequency modulation assistive device
223415832|NCT00930774|BEHAVIORAL|Auditory training|Participation in computerized auditory training program for eight weeks
223415833|NCT03200704|COMBINATION_PRODUCT|IC2000 and SPY-PHI|Investigational treatment to assess the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
223415834|NCT03200704|COMBINATION_PRODUCT|Tc-99m radioactive colloid and Gamma Probe|Comparator; standard of care for sentinel lymph node biopsy (SLNB) procedures in early stage breast cancer
224136597|NCT00891163|DRUG|Placebo Patch|placebo
224136598|NCT01921634|OTHER|Modified Pathologic Analysis|
224299175|NCT03306524|DEVICE|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
223415835|NCT00116155|BIOLOGICAL|CV787 (CG7870)|
223739056|NCT04577755|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
223739057|NCT01499563|DRUG|ITI-007|Capsules containing ITI-007 for 28 days
223739058|NCT01499563|DRUG|Placebo|Capsules containing inactive placebo for 28 days
223739059|NCT01499563|DRUG|Risperidone|Capsules containing risperidone for 28 days
223415836|NCT06685328|PROCEDURE|minimal posterior pole vitrectomy combined with a sodium hyaluronate gel-covered internal limiting membrane(ILM) flap with balanced saline filling and postoperative supine position|Vitrectomy of the posterior pole within the vascular arch was performed by a standard 25G ciliary flattening three-way tract procedure, followed by injection of a small amount of tretinoin suspension (TA) to mark the posterior vitreous cortex, which was excised. The inner limiting membrane (ILM) of the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the ILM around the hole was peeled off, leaving a semicircular piece of ILM attached to the hole, and then the single ILM flap was folded and covered with MH. 0.2 to 0.3 mL of hyaluronic acid gel (Bausch \& Lomb, Iviz) was injected over the inverted ILM flap using perfluorocarbon liquid for complete coverage. The perfluorocarbon liquid was aspirated. Postoperatively, the patient was advised to remain in a non-emergent supine position for 24 hours.
223415837|NCT06685328|PROCEDURE|Conventional vitrectomy combined with inner limiting membrane flap flip coverage with sterile air filling and postoperative prone position|A standard 25G ciliary flattening three-way tract procedure was taken to perform posterior and midperipheral vitrectomy, followed by injection of a small amount of tretinoin (TA) to label the posterior vitreous cortex and excision of the posterior vitreous cortex within the vascular arch. The ILM on the macular surface was stained with indocyanine green (ICG, 2.5 mg/ml), and the peripapillary ILM was peeled off with forceps, leaving a semicircular piece of ILM attached to the foramen ovale, and the individual ILM flaps were then turned over and covered with MH. Air-liquid exchange was then performed and subsequent surgery was routinely performed according to existing surgical concepts. Ultrasonic emulsification and IOL implantation were selectively performed depending on the extent of the cataract and the patient's surgical needs. Antibiotic ointment is applied at the end of the procedure. After surgery, patients were advised to remain in strict prone position for 3 days.
223415838|NCT00832871|DRUG|Mifepristone|Mifepristone 200 mg will be administered orally
223415839|NCT05214183|DRUG|Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma|Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
223415840|NCT04644926|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) procedure comprise three repetitions of brachial cuff inflation to 200 mmHg for five minutes following deflation to 0 mmHg for another five minutes. The procedure overall took 30 minutes.
223415841|NCT01335048|DRUG|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
223415842|NCT01335048|DRUG|Clopidogrel|Clopidogrel 150 mg daily
223415843|NCT03158480|BIOLOGICAL|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
223415844|NCT06670508|PROCEDURE|Transversus Abdominis Plane block|Group A, The patient was in the supine position then; the TAP block was given by a high frequency linear ultrasound transducer (Siemens acuson x300 3-5MHz ultrasound). After skin preparation and isolation, the transducer was placed 2 cm sub-xiphoid, then moved along the subcostal edge to identify the rectus abdominis muscle and the transversus abdominis then, a blunted tip, 20-gauge, short bevel needle (Pajunk Sonoplex, Geisingen, Germany) was introduced in-plane 2-3 cm lateral to the transducer, under direct ultrasound visualization. After confirming the correct placement of the needle and the negative aspiration probe, the rest of the anaesthetic substance was injected along the subcostal line in the transversus abdominis plane 20 ml 0.25% bupivacaine on each side after aspiration to avoid intravascular placement, and the dissection of the plane was observed. The block was performed bilaterally.
223415845|NCT06670508|PROCEDURE|Erector Spinae Plane block|Group B, the patient was placed in the prone position. Then, the Erector Spinae block was given by same ultrasound transducer . It was sagittaly placed against the target vertebral level (T7 transverse process) in the prone position and moved in approximately 3-cm lateral to the spinous process.. The Erector Spinae muscle and transverse process was identified, and a same blunted tip , 20-gauge, short bevel needle was advanced, using the in-plane approach, in cephalad-to-caudal direction, through the interfascial plane between the Erector Spinae and the underlying transverse process under strict aseptic precautions until the tip is deep to erector spinae muscle, as evidenced by visible hydro-dissection below the muscle plane. The block was performed bilaterally by injecting 40 mL of 0.25% bupivacaine (20 mL into each side) into the fascial plane between the deep surface of the Erector Spinae muscle and the transverse processes of the lumbar vertebrae laterally.
223415846|NCT06392113|BEHAVIORAL|ACTION FALLS|Falls prevention advice including booklet and videos
223415847|NCT00845208|BEHAVIORAL|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
223415848|NCT02125942|BEHAVIORAL|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
223415849|NCT02067884|PROCEDURE|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
223415850|NCT02067884|PROCEDURE|shear wave elastography|Undergo SWE
223415851|NCT02067884|DRUG|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
223415852|NCT02067884|DEVICE|Philips Shear Wave Elastography|Equipment used for SWE
223415853|NCT00767728|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
223415854|NCT00767728|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
223415855|NCT06293508|BEHAVIORAL|Standard Health Communication Intervention|Participants in this group will receive links and materials related to breast cancer screening from official sources (e.g. MOH, Non-governmental organizations (NGOs), etc.) that is already readily available and accessible by the Malaysian public. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
223415856|NCT06293508|BEHAVIORAL|Behavioural Change Health Communication Intervention|Participants receive health communication materials designed using persuasive behavioural change communication principles and behavior science to promote breast cancer screening. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
224136599|NCT00003476|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
224136600|NCT05381558|DRUG|Triamcinolone Injection|local injection in sinus tarsi
224033041|NCT05715970|DIAGNOSTIC_TEST|PoCT+questionnaire administration|"In Sicily, screening will be carried out in the general practitioner's clinics (GPs). GPs will have to submit the patients attending their clinics to the PoCT + software tools questionnaire. Subjects who are PoCT positive and/or who reach the minimum score in the questionnaire will be considered 'patients at risk of CD' and must be subjected, with prior consent, to in-depth diagnostics using standard serological methods. The subjects resulting positive in the serological investigations will then undergo the appropriate endoscopic and biopsy investigations to ascertain the presence of CD. In Malta the recruitment will exactly repeat the modalities already carried out in the ITAMA project, through the schools of Malta (Maltese takers), while the laboratory and endoscopic examinations of the subjects who tested positive for the PoCT and/or who will reach the minimum score in the software tools questionnaire will be centralized at the Mater Dei hospital."
224033042|NCT04862247|BEHAVIORAL|Imaginal Exposure Condition|Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.
224033043|NCT04862247|BEHAVIORAL|Writing and Thinking Condition|Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
224136601|NCT04137419|DIETARY_SUPPLEMENT|Probiotic lozenges|Probiotic strains
223415857|NCT06220175|DRUG|Strepsils Intensiv plus Xilocaine spray Arm|After Stepsils Intensiv ingestion, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
223415858|NCT06220175|DRUG|Xilocaine Spray Arm|After Xilocaine Spray pharyngeal topical anestesia, upper GI endoscopy will be performed with a standard diameter tube, with SpO2 non invasive monitoring.
223415859|NCT00839527|DRUG|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
223415860|NCT00839527|BIOLOGICAL|albiglutide|albiglutide weekly subcutaneous injection
223415861|NCT00839527|DRUG|metformin|metformin
223415862|NCT00839527|DRUG|glimepiride|glimepiride
223415863|NCT00839527|DRUG|pioglitazone|pioglitazone
224136602|NCT04137419|OTHER|Placebo|Similar to ProlacSan lozenges in taste in colour
224136603|NCT04656392|DIAGNOSTIC_TEST|Breath test (eNose) followed by uTNE.|All participants will receive the breath test with the eNose in the general practice, followed by the uTNE in the hospital.
224136604|NCT05278286|BEHAVIORAL|Crawling stimulation with the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.
224136605|NCT05278286|BEHAVIORAL|Tummy time without the crawliskate|Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
224136606|NCT03057951|DRUG|Empagliflozin|once daily
224136607|NCT03057951|DRUG|Placebo|once daily
224136608|NCT03904784|BEHAVIORAL|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
224136609|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
224136610|NCT00696436|DRUG|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
224136611|NCT00696436|DRUG|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
224136612|NCT00696436|DRUG|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
224136613|NCT00696436|DRUG|Placebo|Matching placebo, orally, once daily for up to six weeks.
224136614|NCT03405493|BEHAVIORAL|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
224136615|NCT03405493|BEHAVIORAL|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
224136616|NCT04859478|DIAGNOSTIC_TEST|Dual energy / spectral portal venous chest computed tomography|Each patient undergoes an additional dual energy / spectral chest CT in addition to standard care CTPA. The intervention is performed immediately after standard care CTPA.
223415864|NCT00839527|DRUG|placebo to match pioglitazone|pioglitazone matching placebo
223415865|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.1 greater or equal to 2 during the drug-off period at baseline
224033044|NCT04519112|PROCEDURE|Catheter Ablation|Catheter Ablation with RMN and MCN
224033045|NCT00281021|DRUG|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
224033046|NCT03382184|DEVICE|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
224033047|NCT03382184|DEVICE|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
224033048|NCT05531253|OTHER|Data collection using the Optical Gas Analyser|To allow the OGA to acquire certain physiological data during the study it will be necessary to slightly vary the tension of oxygen and carbon dioxide for short periods. The changes involved will be of a lesser magnitude than those often seen due to natural variation over time in critically ill patients. The FiO2 will be increased by around 20% from baseline for several minutes; this is a far more modest increase than is seen with the practice of pre-oxygenation - a transitory increase in fraction of inspired oxygen ( FiO2) to 100% - performed regularly in ICU patients to make certain routine interventions safer. The end-tidal CO2 level will also briefly (1-2 min) be altered by around 1 kPa by transient adjustment of the ventilator settings.
224136617|NCT01079533|BEHAVIORAL|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
224136618|NCT01079533|BEHAVIORAL|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
224136619|NCT03937258|DRUG|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
224136620|NCT03937258|DRUG|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
224136621|NCT00307424|DEVICE|AutoCPAP|
224136622|NCT00307424|DEVICE|FixCPAP|
224136623|NCT05398393|DRUG|oral Tenofovir Amibufenamide 25mg each day|patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
224136624|NCT05398393|DRUG|lipid lowering drugs (e.g. Atorvastatin and amlodipine.)|lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
224136625|NCT03034759|OTHER|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
224136626|NCT04350190|DRUG|Apatinib mesylate tablet|The dose of apatinib mesylate tablets is 250mg, oral, qd, continuous administration, 4 weeks (28 days) as an observation cycle.
224136627|NCT04350190|DRUG|PD-1|The dose of PD - 1 is 200 mg/ time, intravenous injection, q2w, 4 weeks (28 days) for an observation period.
224136628|NCT00000118|DEVICE|Sustained-Release Intraocular Drug Delivery System|
224136629|NCT02924688|DRUG|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
224136630|NCT02924688|DRUG|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
224136631|NCT02924688|DRUG|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
224136632|NCT02924688|DRUG|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
224136633|NCT02924688|DRUG|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
224136634|NCT02924688|DRUG|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
223415866|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.3 greater or equal to 2 during the drug-off period at baseline
223415867|NCT06685510|OTHER|the score of UPDRS item|The score of MDS-UPDRS item 3.10 greater or equal to 2 during the drug-off period at baseline
223739060|NCT03578081|DRUG|Palonosetron Hydrochloride|Given IV
224033049|NCT04796896|BIOLOGICAL|mRNA-1273|Sterile liquid for injection
224033050|NCT04796896|BIOLOGICAL|Placebo|0.9% sodium chloride (normal saline) injection
224033051|NCT04796896|BIOLOGICAL|mRNA-1273.214|Sterile liquid for injection
224136635|NCT02924688|DRUG|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
224136636|NCT02924688|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
224299176|NCT03306524|DEVICE|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
223415868|NCT06685510|OTHER|the score of UPDRS item|Any one of the MDS UPDRS 3.15-3.17 scores greater or equal to 2 during the drug-off period at baseline
224033052|NCT06313528|DRUG|LY3437943|Administered SC
224033053|NCT06313528|OTHER|Placebo|Administered SC
224033054|NCT04189757|DRUG|Acalabrutinib|Given PO
224033055|NCT06262607|DRUG|CLE-400|Topical CLE400 gel 0.28% administered once daily
224033056|NCT06262607|DRUG|Vehicle|Topical vehicle gel administered once daily
224033057|NCT04356183|OTHER|SWET: Supervised Weight loss and Exercise Training|Weight loss will occur via a dietitian-led intervention targeting weight loss over 16 weeks, with weekly weigh-ins and group support sessions. Exercise training will consist of three times per week of an interval-based aerobic program plus twice-weekly resistance training. Both weight loss and exercise training will be supervised to maximize safety and adherence.
224033058|NCT04356183|OTHER|CHAT: Counseling Health As Treatment|Control Arm over 16 weeks.
224033059|NCT06460844|GENETIC|RTx-015|Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
224033060|NCT06480370|DEVICE|ISIS IOM System|Application of TES at different stimulation circuits, with different stimulation parameters and recording montages.
224033061|NCT05080166|OTHER|Interview with Clinicians|One time, qualitative interview of clinicians for feedback on UPLYFT intervention
224033062|NCT05080166|OTHER|Field Test of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors for feedback
224033063|NCT05080166|BEHAVIORAL|Pilot of UPLYFT with Lymphoma Survivors|6 session of UPLYFT intervention with Lymphoma Survivors
224033064|NCT06378450|BEHAVIORAL|Mindfulness meditation guided practice|Participants will listen to recordings of mindfulness meditation practices from a newly developed 28-day program.
224033065|NCT03613116|DIETARY_SUPPLEMENT|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
224136637|NCT02924688|DEVICE|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
223415869|NCT06685510|OTHER|the score of UPDRS item|Sum of MDS UPDRS 4.1-4.2 scores greater than or equal to 3
223415870|NCT06666010|DRUG|PEX010-Assisted Therapy|The investigational medicinal product PEX010, containing 25 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
223415871|NCT06666010|DRUG|PEX010(01)|The investigational medicinal product PEX010(01), containing 1 mg psilocybin, is a capsule for oral administration that contains the drug substance PYEX.
224033066|NCT05679011|OTHER|4 and 6 meters walking test|A 10-meter and other 6-meter flats pathways were identified. Two-meter are provided for the acceleration zone and two-meter for deceleration for 6-meter walk test. One meter to acceleration and another to deceleration for 4-meter walk test. The participants are randomly to perform 3-time to comfortable speed and 3-time faster speed for 4-meter and 6-meter.
224033067|NCT05327933|PROCEDURE|Surgery plus endovascular MMA embolization|A micro catheter is inserted transfemorally into the branches of the middle meningeal artery (MMA) in a minimally invasive manner and the periphery is occluded using polyvinyl alcohol (PVA) particles to prevent future bleeding. If the desired catheter position cannot be achieved due to the anatomical conditions, a more proximal closure of the MMA using Onyx® or micro-electric coils is performed. Embolization of the MMA by PVA particles with sizes between 40-300 µm is preferred over embolization by coils and Onyx®, since the capillary network of the dura is entirely blocked when using particles. In order to identify the vessels to be closed, a digital subtraction angiography (DSA) is performed.
224033068|NCT05327933|PROCEDURE|Surgery alone|Evacuation of cSDH
224033069|NCT05442424|BEHAVIORAL|Produce Voucher|see arm/group description
224033070|NCT05442424|BEHAVIORAL|Wait-List Control|see arm/group description
224033071|NCT01177787|DEVICE|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
224033072|NCT01177787|DEVICE|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
224033073|NCT00002765|BIOLOGICAL|LMB-2 immunotoxin|
223415872|NCT05928429|DEVICE|Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA|Patients in the experimental arm will wear glycerine-containing Elasto-Gel™ gloves and socks (Elasto-Gel™ mitts for hands: TM7008, and slippers for feet: SL3000; Southwest Technologies, Inc., North Kansas City, MO, USA) over a disposable glove and sock liner secured by Velcro at the wrist and ankle on their hands and feet from 15 minutes before paclitaxel administration to 15 minutes after the infusion is complete (90 minutes in total).
224033074|NCT03265834|OTHER|< 10 days of antibiotics|Antibiotic duration
224033075|NCT03265834|OTHER|28 days of antibiotics|Antibiotic duration
224033076|NCT02170454|PROCEDURE|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
224033077|NCT02711488|BEHAVIORAL|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
224136638|NCT02924688|DEVICE|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
224136639|NCT02924688|DEVICE|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
223415873|NCT00067301|DRUG|Polyunsaturated Fatty Acids (PUFA)|
223415874|NCT00067301|DRUG|Citalopram|
223560492|NCT04218214|OTHER|LIFE-DM Group (Integrated Depression and Livelihood Group Intervention)|Livelihood Integration for Effective Depression Management (LIFE-DM) program aims to address the dual challenges of poverty and depression by integrating evidence-based treatment for depression management and microfinance services. The LIFE-DM group is a 12-session based on Behavior Activation and Problem Solving therapy for depression applied to both mood problems and livelihood stressors. Livelihood supports includes training on personal finance, referrals to vocational training, and access to microfinance loans. The group is provided at the local commune health stations, and facilitated by primary care health provider and a lay community provider from the Women's Union. The intervention generally lasts about 3-4 months.
224033078|NCT03314597|OTHER|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
224136640|NCT05034471|DEVICE|Mi-Chord™ Device Technologies|Mi-Chord™ System consists of LS-5™ ePTFE suture, the Mi-STITCH™ suturing device, the Mi-KNOT™ device and the Mi-KNOT™ titanium fastener. Mi-Chord™ system is designed to replace the chordae tendineae in order to enable mitral valve repair. These sub-devices (ePTFE suture, Mi-STITCH™, Mi-KNOT™ device, Mi-KNOT™ titanium fastener) can be considered as one system and refer to different aspects of the overall technology.
223560493|NCT00480558|BIOLOGICAL|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10\^7
223560494|NCT00397761|DRUG|capecitabine|
224136641|NCT03677895|DRUG|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
224136642|NCT00882102|DRUG|Decitabine|Decitabine 20 mg/m\^2 IV over 1-1/2 hours daily for 5 days.
223560495|NCT00397761|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223560496|NCT00397761|PROCEDURE|neoadjuvant therapy|
223560497|NCT00733161|OTHER|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
223560498|NCT00733161|OTHER|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
223560499|NCT06266468|BEHAVIORAL|Nutricity|Nutricity is a bilingual (English/Spanish) mobile website supplemented by an automated text-messaging system.
223560500|NCT00416065|DEVICE|PET/CT imaging|
223560501|NCT02672059|OTHER|Observation|No intervention
223560502|NCT02253563|BEHAVIORAL|Resistance Training|
223560503|NCT02253563|BEHAVIORAL|Balance Training|
223560504|NCT03840304|OTHER|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
223560505|NCT00964041|DRUG|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
223560506|NCT00964041|DRUG|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
224136643|NCT00882102|DRUG|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m\^2 IV on day 5.
223560507|NCT01257230|DRUG|tiotropium Respimat low dose|IMP
224136644|NCT00050999|DRUG|ONTAK|
224136645|NCT06160037|BEHAVIORAL|Transportation and Developmental Screening|Arm 1. Transportation and Screening The 514 families in this condition received: 1) free transportation for scheduled prenatal care; and 2) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life.
223415875|NCT05588973|OTHER|MEDISKIN cream|MEDISKIN cream with collagen
223560508|NCT01257230|DRUG|placebo Respimat|placebo representing comparator
223560509|NCT01257230|DRUG|tiotropium Respimat high dose|IMP
223415876|NCT05588973|OTHER|Panthenol cream|Panthenol cream
223415877|NCT04185012|BIOLOGICAL|Benralizumab|Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
223415878|NCT04185012|BIOLOGICAL|Placebo|Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period
223415879|NCT04431908|DEVICE|olfactory device|A quantitative non-biased olfactory device intended for the rapid identification of SARS-CoV-2 infected subjects (as identified by PCR).
223415880|NCT01704651|DRUG|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
223415881|NCT01704651|DRUG|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
223415882|NCT04322019|OTHER|Data record|Data record
223415883|NCT01676740|DRUG|Iron Supplement,|Pills to be swallowed
223415884|NCT01676740|DRUG|Placebo|Daily administration of active drug or placebo
223415885|NCT06967285|BEHAVIORAL|Prone ventilation|Cerebral Blood Flow Monitoring Before and After Prone Ventilation in Patients with ARDS.Cerebral blood flow,intracranial pressure,and systemic hemodynamic monitoring were performed at the following time points:before prone positioning(T0),1 hour after prone ventilation(T1),12 hours after prone ventilation(T2),1 hour after returning to the supine position(T3),and 7 days after returning to the supine position(T4).
223560510|NCT05193201|DRUG|recombinant human thrombopoietin injection|recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
223560511|NCT00378625|DRUG|Artesunate|
223560512|NCT02209545|DRUG|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
223560513|NCT02209545|DRUG|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
223739061|NCT03578081|DRUG|Ondansetron Hydrochloride|Given IV or PO
223739062|NCT03578081|DRUG|Dexamethasone|Given PO
224299177|NCT03306524|DEVICE|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
224299178|NCT03306524|DEVICE|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
224033079|NCT03314597|OTHER|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
223560514|NCT03401021|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
223560515|NCT01205061|DEVICE|Emervel Deep Lidocaine|20 mg/mL + 0.3% lidocaine
223560516|NCT01205061|DEVICE|Juvederm Ultra Plus|24mg/mL
223415886|NCT01789411|OTHER|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
223415887|NCT01789411|DEVICE|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
223415888|NCT01789411|DEVICE|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
223415889|NCT02076893|DRUG|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
223739063|NCT03578081|DRUG|Fosaprepitant Dimeglumine|Given IV
224033080|NCT02158520|BIOLOGICAL|Bevacizumab|Given IV
224033081|NCT02158520|BIOLOGICAL|Ipilimumab|Given IV
224033082|NCT02158520|OTHER|Laboratory Biomarker Analysis|Correlative studies
224136646|NCT06160037|BEHAVIORAL|Transportation, Screening, and Nurse-Visitation during Pregnancy and Infancy|"Arm 2. Transportation, Screening, and Nurse-Visitiation During Pregnancy and Infancy~The 228 families in this condition received: 1) free transportation for scheduled prenatal care; 2) intensive nurse home-visitation services during pregnancy and through the child's second birthday; and 3) developmental screening and referral services for the child at the 6th, 12th, and 24th months of the child's life."
223415890|NCT02076893|DRUG|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
223415891|NCT02076893|DRUG|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
223415892|NCT02076893|DRUG|Placebo|Simple syrup suspension
224136647|NCT03518099|BIOLOGICAL|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
223415893|NCT01084317|OTHER|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
223560517|NCT00491855|DRUG|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
223560518|NCT00491855|DRUG|Oxaliplatin|Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.
223560519|NCT00491855|DRUG|Paclitaxel|Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.
223739064|NCT03578081|DRUG|Olanzapine|Given PO
223739065|NCT03578081|OTHER|Placebo|Given IV
223739066|NCT05936996|DEVICE|MANTA Vascular Closure Device|The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
223415894|NCT00484562|DEVICE|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
223415895|NCT00484562|DEVICE|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
223415896|NCT00484562|DEVICE|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
223560520|NCT00369174|DRUG|rosiglitazone maleate|Given orally
223560521|NCT00369174|OTHER|laboratory biomarker analysis|Correlative studies
223560522|NCT04071262|DRUG|Abemaciclib|Administered orally
223739067|NCT05139563|OTHER|Placebo injection: Intralipid 20% fat emulsion|placebo intralipid 20% intramuscular (IM) injection
223739068|NCT05139563|OTHER|Placebo implant|placebo subdermal implant rod
223739069|NCT06806176|BEHAVIORAL|Cognitive analytic therapy guided self-help (CAT-GSH)|Six session CAT-GSH treatment
223739070|NCT06806176|BEHAVIORAL|Cognitive behavioural therapy guided self-help (CBT-GSH)|Six session CBT-GSH treatment
224033083|NCT02158520|DRUG|Nab-paclitaxel|Given IV
224033084|NCT02158520|OTHER|Pharmacological Study|Correlative studies
224033085|NCT00381368|DRUG|Ibandronic acid|
224136648|NCT00868959|DRUG|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
224299179|NCT03306524|DEVICE|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
223415897|NCT00484562|DEVICE|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
223415898|NCT03391869|BIOLOGICAL|Ipilimumab|Given IV
223415899|NCT03391869|PROCEDURE|Local Consolidation Therapy|Undergo radiation and/or surgery
223415900|NCT03391869|BIOLOGICAL|Nivolumab|Given IV
223415901|NCT03391869|OTHER|Quality-of-Life Assessment|Ancillary studies
223415902|NCT03391869|RADIATION|Radiation Therapy|Undergo radiation
223415903|NCT03391869|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223560523|NCT04071262|DRUG|Abiraterone Acetate|Administered orally
223560524|NCT04071262|DRUG|Prednisolone|Administered orally
223560525|NCT00765037|DEVICE|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
223560526|NCT01598883|DRUG|Heparin|150 U/kg
223560527|NCT01598883|DRUG|ATryn|1000 IU
223560528|NCT01320553|DRUG|SPARC1102 I|SPARC1102 I will be administered in both eyes
223415904|NCT06621615|BIOLOGICAL|CVL006 Injection|CVL006 injection, intravenous infusion, administered every 2 weeks. Every 28 days is a cycle. Until the subject cannot tolerate the disease progression or toxicity, or the researcher determines that the medication must be terminated or the sponsor terminates the study. SMC can adjust the dosing frequency based on safety, tolerability, and PK results data. If researchers consider that subjects enrolled in the lower dose group can benefit from the study intervention, they can allow them to continue treatment at a higher dose that has been proven safe based on the researcher's judgment.
224298436|NCT05854888|PROCEDURE|Control Group (Hands-on)|"The midwife placed the index, middle, and little fingers of the non-dominant hand together on the child's occiput, with the palm facing the anterior region of the perineum, when the child's head was crowning. In this way, the expulsion was controlled, maintaining the flexion of the head. Simultaneously, the dominant hand was flattened and placed on the posterior region of the perineum, with the index finger and thumb, forming a U, exerting pressure on the posterior region of the perineum during the crowning process. During the birth of the shoulders and the rest of the body, the dominant hand was kept in place, protecting the posterior region of the perineum."
223415905|NCT05403814|OTHER|observational screening procedure (no intervention)|observational screening procedure (no intervention)
223415906|NCT05882838|OTHER|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire|Myofascial Pain Syndrome Knowledge and Awareness Questionnaire is a questionnaire consisting of a total of 14 questions created by the researchers who are specialized in the field. The correct answer to each question is one point. A high score indicates a high level of knowledge and awareness, while a low score indicates a low level of awareness and knowledge.
223415907|NCT00224939|DRUG|Potassium Chloride|
223415908|NCT06967688|OTHER|Smartwatch-Supported Caregiver Intervention|This intervention involved informal caregivers of people with dementia using smartwatches to monitor and manage their own health parameters over an 8-week period. The primary goal was to enhance caregivers' self-efficacy and overall well-being by providing real-time health data through wearable technology. Caregivers were introduced to the smartwatch features, which included heart rate monitoring, inactivity alerts, sleep tracking, stress level monitoring, weight tracking, water intake reminders, and blood oxygen level measurements. Caregivers were instructed to track these parameters using the smartwatch and record their health behaviors in provided diaries.Weekly phone consultations lasting no more than 5 minutes were conducted throughout the 8-week intervention, where caregivers' use of the smartwatch and diaries was reviewed, and general discussions about their health and caregiving experiences took place. The intervention aimed to integrate health self-monitoring into the caregi
223415909|NCT03626402|BEHAVIORAL|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
223739071|NCT05784480|DIAGNOSTIC_TEST|Checklist for evaluation of reversible causes|Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
223415910|NCT01155908|DRUG|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
223415911|NCT00634803|BEHAVIORAL|CBT|Cognitive behavioral therapy
223415912|NCT00634803|DRUG|Buprenorphine|buprenorphine/naloxone
223415913|NCT00634803|OTHER|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
223415914|NCT00634803|OTHER|Physician Management|Brief physician counseling
223415915|NCT00778869|BIOLOGICAL|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
223415916|NCT03382236|OTHER|osteopathy|osteopathic techniques
223739072|NCT03242174|OTHER|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
223739073|NCT06419374|BIOLOGICAL|Pegozafermin|Subcutaneous injection
223739074|NCT06419374|DRUG|Placebo|Subcutaneous injection
223739075|NCT03293381|DEVICE|additional biopsies|additional biopsies
224298437|NCT00587015|DRUG|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
224298438|NCT04943978|OTHER||just observational blood and liver sampling
224298439|NCT00455611|DEVICE|CPAP (Continuous Positive Airway Pressure)|
224298440|NCT02018783|PROCEDURE|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
224298441|NCT02018783|PROCEDURE|Sensodyne|Digital application for 60 seconds.
223415917|NCT04696822|DRUG|Epinephrine Nasal Product, 1.6 mg|Single dose Nasal powder spray without allergen challenge
223415918|NCT04696822|DRUG|Epinephrine nasal product, 1.6 mg + allergen|Single dose Nasal powder spray with allergen challenge
223415919|NCT04696822|DRUG|Epinephrine Injection 0.3 mg|Intramuscular injection
223415920|NCT04696822|DRUG|Epinephrine Nasal Product, 3.2 mg|Twice dose Nasal powder spray without allergen challenge
223415921|NCT04696822|DRUG|Epinephrine Nasal Product, 3.2 mg + allergen|Twice dose Nasal powder spray with allergen challenge
223739076|NCT02795442|OTHER|Even protein|5 day intake of even protein 3 day rotating menu.
223739077|NCT02795442|OTHER|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
224298442|NCT02018783|PROCEDURE|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
224298443|NCT02018783|PROCEDURE|Cocorico|Digital application for 60 seconds
223415922|NCT01045811|BEHAVIORAL|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
223415923|NCT01045811|BEHAVIORAL|Stress management|Cognitive reconstructive strategies for stress management
223415924|NCT03825029|PROCEDURE|Pillow|A pillow to lessen the angle differences between hips so that the acetabular component can be placed in an optimal position.
223739078|NCT01572194|BIOLOGICAL|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
223739079|NCT01689584|GENETIC|salivary kit|The saliva samples will be made of selected related (DNA).
223739080|NCT06293053|DRUG|Dupilumab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous"
223415925|NCT06297330|BEHAVIORAL|Sleep|The sleep management intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to the sleep and fatigue levels will be recorded to assess the progress of each student.
223415926|NCT00328211|DIETARY_SUPPLEMENT|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
223415927|NCT00328211|DIETARY_SUPPLEMENT|Sphingomyelin|1000mg/day for 19 days
223415928|NCT00328211|OTHER|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
223415929|NCT00364923|DRUG|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
223415930|NCT05627505|DIAGNOSTIC_TEST|metagenomic next-generation sequencing|Collection of bronchoalveolar lavage fluid
223415931|NCT02209519|DRUG|Metronidazole (male partner)|500 mg PO BID for 7 days
223415932|NCT02209519|OTHER|Placeob (male partner)|matching placebo capsules PO BID for 7 days
223415933|NCT01985932|DEVICE|MRI|
223415934|NCT00276887|BEHAVIORAL|Cognitive Behavior Therapy|
223415935|NCT00276887|BEHAVIORAL|Psychiatric Consultation Letter|
223415936|NCT05622474|DRUG|Induction chemotherapy plus Concurrent chemotherapy|"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."
223415937|NCT05622474|DRUG|Concurrent chemotherapy|Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
223415938|NCT05622474|RADIATION|IMRT|Radical radiation: Intensity-modulated radiotherapy
223415939|NCT05468112|BEHAVIORAL|SKY Meditation and Mindfulness|The intervention is a 3-day in-person meditation and mindfulness workshop using the SKY meditation approach. It utilizes a unique set of standardized breathing techniques to rapidly reduce neuro-endocrine stress responses and the autonomic imbalance due to sympathetic overdrive, thus restoring autonomic homeostasis. These are interwoven with coping and stressor appraisal strategies, and simple stretching exercises. Classes will be 3 hours long on each of three consecutive days, and participants must be willing to attend all three sessions with an additional 7 consecutive days of online sessions immediately thereafter. In addition, participants will be asked to engage in daily 10 to 25 minute home resilience practice sessions performed five days per week. They will complete a follow-up session once per week in the subsequent 8 weeks.
223415940|NCT00893412|DRUG|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
223415941|NCT00893412|PROCEDURE|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
223415942|NCT00893412|DRUG|Placebo|
223415943|NCT04411394|OTHER|Questionnaire|Body Perception Questionnaire and Hospitalized Anxiety and Depression Scale
223415944|NCT05217134|PROCEDURE|DPEA|Dural puncture with 27 G Whitacre needle
223415945|NCT02912975|OTHER|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
223560529|NCT01320553|DRUG|SPARC1102 II|SPARC1102 II will be administered in both eyes
223560530|NCT01320553|DRUG|SPARC1102 III|SPARC1102 III will be administered in both eyes
223560531|NCT01320553|DRUG|Vehicle|Vehicle will be administered in both eyes
223560532|NCT05507021|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464, MegaMetalliQ|Pour Lactobacillus Plantarum DSM 33464 sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
223560533|NCT05507021|DIETARY_SUPPLEMENT|Placebo|Pour placebo sachet into moderate amount of water, slightly stir, fully dissolve, drink 0.5 hour before having meal, one at a time.
223560534|NCT03639636|OTHER|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
223560535|NCT02379026|DIETARY_SUPPLEMENT|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
223560536|NCT02379026|BEHAVIORAL|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
223560537|NCT02379026|DIETARY_SUPPLEMENT|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
223739081|NCT04414475|DRUG|Selinexor|Participants will receive Selinexor oral tablets.
223415946|NCT02912975|OTHER|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
223415947|NCT03902873|OTHER|Real-time audiovisual feedback|During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
223415948|NCT01217164|DIETARY_SUPPLEMENT|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
223415949|NCT01799512|DEVICE|experimental: real-time continuous glucose monitoring|
223415950|NCT01799512|DEVICE|Active comparator: blinded continuous glucose monitoring|
223415951|NCT04087720|BIOLOGICAL|Pegloticase|intravenous (IV) infusion
223739082|NCT04414475|DRUG|Dexamethasone|Participants will receive Dexamethasone oral tablets.
223739083|NCT04414475|DRUG|Bortezomib|Participants will receive Bortezomib SC injection.
223415952|NCT02743936|DEVICE|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
224298444|NCT03106831|DRUG|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
223415953|NCT02743936|DEVICE|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
223415954|NCT05862350|OTHER|aromatherapy inhalation with lavender essential oil|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep
223415955|NCT05862350|OTHER|aromatherapy inhalation with coconut essential oil.|patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
223415956|NCT03425084|DRUG|Morphine|The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
223415957|NCT01521390|DRUG|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
223415958|NCT01521390|DRUG|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
223415959|NCT01521390|DRUG|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
223415960|NCT01521390|DRUG|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
223415961|NCT01521390|DRUG|Placebo|Placebo, no active ingredient
223415962|NCT00850408|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
223415963|NCT04263441|BEHAVIORAL|NICE Intervention|Subjects enrolled in the intervention arm will be offered assistance in enrolling in healthcare coverage and provided assistance on where they can go for care immediately. Subjects will be followed for 1 year and information including lab tests and insurance coverage status will be collected. This information will be collected from medical record review.
223415964|NCT05896891|DIAGNOSTIC_TEST|esophagogastroduodenoscopy (EGD), buccal swab, blood withdrawal|During routine EGD, biopsy, blood and buccal saliva samples will be withdraw and stored at San Raffaele Hospital
223415965|NCT03706430|DEVICE|Pulse CO-Oximeter sensor|Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
223415966|NCT06682104|BEHAVIORAL|Individual intensive short term psychodynamic therapy|ISTDP aims to help patients explore and process unconscious emotions, particularly those linked to past trauma or unresolved conflicts, that may be contributing to their physical symptoms. Patients are guided to identify and express repressed feelings such as anger, grief, or fear. The therapist actively engages the patient in a focused and intensive manner, helping them to recognize emotional defenses, break through resistance, and experience these emotions directly in the therapeutic setting.
223415967|NCT03107884|DRUG|Metformin (Bed Rest)|A clinical oral dose of Metformin will be given to participant daily during bed rest
223415968|NCT03107884|DRUG|Placebo (Bed Rest)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
223560538|NCT02309983|OTHER|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
223560539|NCT02309983|OTHER|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
223560540|NCT01258465|BEHAVIORAL|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
223560541|NCT01258465|BEHAVIORAL|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
223560542|NCT01686425|PROCEDURE|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
223560543|NCT01693341|OTHER|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
223560544|NCT01293630|DRUG|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
223560545|NCT01293630|DRUG|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
223560546|NCT01293630|DRUG|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
223560547|NCT03894631|PROCEDURE|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
223560548|NCT03894631|PROCEDURE|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
223560549|NCT01997957|DRUG|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
224298445|NCT03106831|DRUG|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
224298446|NCT03752944|PROCEDURE|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
224298447|NCT04597294|COMBINATION_PRODUCT|FLOT + HIPEC + Surgery|HIPEC with irinotecan after 4 doses of preoperative FLOT chemotherapy
223739084|NCT05781269|OTHER|VLCKD|VLCKD diet treatment with medical food
223415969|NCT03107884|DRUG|Metformin (2 week run-in only)|A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
224033086|NCT04298463|DRUG|Xydalba|Drugs were administered i.v.
223739085|NCT05781269|OTHER|r-MedDiet|Mediterranean diet treatment
224033087|NCT04298463|DRUG|vancomycin, teicoplanin or daptomycin|Drugs were administered i.v.
224033088|NCT05350384|DRUG|Methylprednisolone|1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
224033089|NCT00402363|DRUG|omega-3-acid ethyl esters|
224136649|NCT04471064|DRUG|XY0206|Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
224136650|NCT04479917|DRUG|TPN171H|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
224136651|NCT04479917|DRUG|placebo|Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
224298448|NCT04597294|COMBINATION_PRODUCT|FLOT + Surgery|Perioperative FLOT chemotherapy (4 doses before and 4 doses after gastrectomy) and surgery
224298449|NCT05369286|DRUG|"MAX-40279-01 and Toripalimab"|"MAX-40279-01combined with Toripalimab"
224136652|NCT01962519|DIETARY_SUPPLEMENT|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
224298450|NCT03426566|OTHER|retrospective observational study with no intervention|no intervention
224298451|NCT04641065|OTHER|Music listening|An expert on the particular type of music will do the selection of the playlist of Traditional Turkish Military music, and this playlist will be listened to the patients by the researchers.
224298452|NCT00000408|PROCEDURE|Patient education evaluation|
224298453|NCT01679106|OTHER|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
224298454|NCT01679106|OTHER|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
223415970|NCT03107884|DRUG|Placebo (2 week run-in only)|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
223415971|NCT04694989|DRUG|CKD-386|QD, PO
223415972|NCT04694989|DRUG|D013, D326, D337|QD, PO
224033090|NCT00402363|DRUG|Placebo|
224033091|NCT00638612|BIOLOGICAL|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
224033092|NCT00638612|DRUG|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
224033093|NCT00597467|DEVICE|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
224033094|NCT00597467|DEVICE|Acuvue 2 Soft Contact Lens|Control device
224033095|NCT03245970|DRUG|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
224033096|NCT03245970|DRUG|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
224033097|NCT03245970|DRUG|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
224033098|NCT01612741|DRUG|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
224033099|NCT03458065|DEVICE|ICD|Implantable Cardioverter Defibrillator
224033100|NCT00475618|PROCEDURE|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
224033101|NCT00475618|PROCEDURE|professional cleaning|Daily use fluoride toothpaste 500 ppm.
224033102|NCT00475618|PROCEDURE|No fluoride toothpaste|Daily use no fluoride toothpaste.
224136653|NCT02095236|BEHAVIORAL|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
224298455|NCT05038579|PROCEDURE|Musiquence|The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
223415973|NCT00520533|BIOLOGICAL|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st \& 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (124I-cG250).~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No 124I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available."
223415974|NCT00520533|DRUG|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study."
223415975|NCT03435536|OTHER|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
223415976|NCT05694884|DRUG|Placebo|Placebo Comparator
223415977|NCT05694884|DRUG|ASLAN004|ASLAN004
223415978|NCT06667479|OTHER|Cold Water Immersion (CWI) - Cold Tub Immersion (CI)|Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.
223415979|NCT06667479|OTHER|Cold Water Immersion (CWI) - Cold Shower (CS)|Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete four full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary
223415980|NCT06667479|OTHER|Control Group (CO)|Participants will be encouraged to maintain their current diet and exercise across the duration of the 4 week intervention. Participants will still be subjected to the pre- and post-intervention data collection session.
224033103|NCT05604833|BEHAVIORAL|Progressive Muscle Relaxation Exercises|"In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects."
224033104|NCT05024630|PROCEDURE|Renal artery cryoablation|Renal denervation were achieved by cryoablation of renal artery with cryoballoon.
224033105|NCT05024630|PROCEDURE|Pulmonary vein cryoablation|Pulmonary vein isolation was achieved by cryoablation of pulmonary veins with cryoballoon.
224033106|NCT05024630|PROCEDURE|Renal arteriography|Renal artery was examined by renal arteriography
224033107|NCT02259998|DRUG|Persantin® new formulation|
224033108|NCT02259998|DRUG|Persantin® commercial formulation|
224033109|NCT00320333|PROCEDURE|pulmonary rehabilitation programme|
224033110|NCT00293722|DRUG|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223415981|NCT04448834|DRUG|Blinatumomab|liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
223415982|NCT01004640|GENETIC|DNA analysis|
224033111|NCT06348940|BEHAVIORAL|behavioral activation|Behavioral activation, an emerging psychological intervention approach, has potential in alleviating negative emotions among cancer patients. The intervention group underwent an eight-week behavioral activation program designed to promote engagement in meaningful activities that are physically and emotionally rewarding while reducing involvement in maladaptive emotional cycles.
224033112|NCT02300051|BEHAVIORAL|STPGP and RPGT|
224033113|NCT02300051|DRUG|TAU|
224033114|NCT00690625|DRUG|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
223415983|NCT01004640|GENETIC|Southern blotting|
223415984|NCT01004640|GENETIC|cytogenetic analysis|Correlative studies
223415985|NCT01004640|GENETIC|polymerase chain reaction|
224298456|NCT02773459|DRUG|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
223560550|NCT05280002|BIOLOGICAL|Adipose Tissue derived Total-Stromal-Cells (TOST)|Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
223560551|NCT03560752|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given via injection
223560552|NCT05611645|RADIATION|Hypofractionated Stereotactic Radiotherapy|Starting with low-dose bevacizumab, 25Gy in 5 fractions of 5 Gy each delivered on consecutive treatment days.
223560553|NCT05611645|DRUG|Bevacizumab|Staring within 2 weeks of randomization, IV 5mg/kg (experimental group) or 10mg/kg (comparison group) every two weeks until disease progression.
223560554|NCT02119195|PROCEDURE|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
223560555|NCT00057733|PROCEDURE|psychosocial assessment and care|
223560556|NCT00057733|PROCEDURE|quality-of-life assessment|
223560557|NCT02665351|DRUG|Peramivir|The two regimens of Peramivir were compared
223560558|NCT01581034|DRUG|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
223560559|NCT01581034|DRUG|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
223560560|NCT01880294|DRUG|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
223560561|NCT03900130|DIETARY_SUPPLEMENT|Preload|"In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low"
224033115|NCT00690625|DRUG|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
224033116|NCT03546933|DEVICE|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
223415986|NCT06623617|BEHAVIORAL|Three-dimensional breathing training|Engage in app-based three-dimensional breathing training and learn to use a biofeedback pressure device at home for proper and effective training. They will also be guided to log their daily training, manually inputting data such as duration and frequency. A virtual assistant will provide real-time feedback based on this data, including encouragement and adjustments to training intensity.
223415987|NCT06623617|BEHAVIORAL|control group：Health education|Provide participants with health education, which is conducted one-on-one by researchers during the recruitment of mothers. The content includes the etiology and risk factors of PPSUI (Pelvic Organ Prolapse during Straining), the benefits and precautions of pelvic floor muscle exercises and breathing techniques, as well as the implementation methods.
223415988|NCT00478777|DRUG|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
223415989|NCT00478777|DRUG|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
223415990|NCT05379283|DRUG|Lidocaine|effect of lidocaine on sweat production during exercise in the heat
223415991|NCT05379283|OTHER|control|one arm will be pretreated with topical lidocaine, the other arm will not
223415992|NCT01839214|DRUG|VB-201 160mg|
223415993|NCT01839214|DRUG|Placebo|
223415994|NCT01614717|DEVICE|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
223415995|NCT03334643|DIETARY_SUPPLEMENT|Fiber mix|Participants will test white bread or fiber mix over a span of 2 weeks. During each testing block, each food will be tested twice over two consecutive days. There are 4 testing blocks in total (one for white bread and three for fiber mix).
223415996|NCT04293419|DRUG|Durvalumab (MEDI4736)|6 cycles of mFOLFOX6 (oxaliplatin, leucovorin and fluorouracil) followed by long course chemoradiotherapy (50.4 Gy together with capecitabine) followed by surgery. Patients will receive durvalumab 1500 mg every 4 weeks during induction chemotherapy, chemoradiotherapy and waiting period until surgery.
223415997|NCT00183053|DEVICE|BedEx Patient Occupancy Monitoring System|
223415998|NCT06684886|OTHER|Ankle Brachial Index|"Normal ABI ranges from 1.0 - 1.4~* Pressure is normally higher in the ankle than the arm.~* Values above 1.4 suggest a noncompressible calcified vessel.~* In diabetic or elderly patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff pressures. The persistence of a signal at a high pressure in these individuals results in an artifactually elevated blood pressure value.~* An value below 0.9 is considered diagnostic of PAD.~* Values less than 0.5 suggests severe PAD.~* Individuals with such severe disease may not have sufficient blood flow to heal a fracture or surgical wound; they should be considered for revascularization if they have a non-healing ulcer."
223415999|NCT04345237|DIETARY_SUPPLEMENT|dietary supplement consumption|"Consumption of the product under study for 3 months, milk placebo or experimental product (leucine milk).~In addition, 5 of the arms perform physical activity training"
223739086|NCT06112782|DEVICE|Keravive by Hydrafacial Treatments|Scalp hydradermabrasion
224033117|NCT03394430|DRUG|Placebos|Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
224033118|NCT03394430|DRUG|Midazolam|Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
224033119|NCT03394430|DRUG|Dexmedetomidine|Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
224033120|NCT00309556|DRUG|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
224033121|NCT00309556|DRUG|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
223416000|NCT00876655|DRUG|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
223416001|NCT00876655|DRUG|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
223416002|NCT01070368|OTHER|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
223416003|NCT00806897|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
223739087|NCT00437099|DRUG|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
223739088|NCT00437099|DRUG|Placebo|Placebo
223739089|NCT06599697|BIOLOGICAL|Intravenously administered pooled human immunoglobulin (IVIG)|IVIG 2g/kg every 4 weeks for 12 weeks (3 doses)
223739090|NCT06819228|DRUG|Panitumumab IRDye 800|Study participation would last approximately 60 days from screening to follow-up visits. Participants dose of Panitumumab would be based on weight and Panitumumab IRDye800 is dosed the same for all participants.
223739091|NCT06661876|RADIATION|5 Gray Whole Heart external beam radiotherapy|EBRT will be delivered with photon energies restricted to 6 Megavoltage (MV) using intensity modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT). Patients will be treated with a single fraction treatment up to a dose of 5Gy prescribed to the 95% PTV-encompassing isodose line (PTVD95% ≥5Gy). The near-maximum dose is limited to 5.35Gy (PTV D2% ≤ 5.35Gy). The treatment can be performed both as an inpatient or outpatient procedure.
224033122|NCT00309556|DRUG|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
224033123|NCT00309556|DRUG|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
224033124|NCT04481477|OTHER|Nursing care to reduce anxiety, fear and loneliness|Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
224299180|NCT03306524|DEVICE|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
223739092|NCT04108026|DRUG|Durvalumab|1500 mg IV every 4 weeks
224033125|NCT05859438|OTHER|Communication aid support|Support to use voice input voice output communication aids
224033126|NCT01690611|PROCEDURE|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
224033127|NCT01690611|OTHER|Visual Feedback|Real time feedback regarding body motion while walking.
224136654|NCT02156869|OTHER|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
223416004|NCT06343415|OTHER|GAIT-assisted training|"GAIT duration starts when walking is started. The participant will walk as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Speed starts at 1 km/h and is adjusted accordingly.~The body weight support (BWS) is kept between 60-100% of total body weight. The BWS is adjusted so the knee flexion in the stance phase does not exceed 10 degrees. The guidance force is kept at 100% and symmetric in all sessions."
223416005|NCT06343415|OTHER|STEP-assisted training|"STEP duration starts when stepping and elevation are started. The participant will step as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Step cadence starts at 40 steps/minute and cadence is adjusted accordingly.~The leg loading starts a 5 kg and is, if possible, increased to a maximum of 40% of total body weight while adjusting knee extension to ≤10 degrees flexion in stance. The guidance force is kept at 100% and symmetric in all sessions."
223416006|NCT04339153|BEHAVIORAL|Parent Training for Disruptive Behaviours|Critically, PT also involves education about autism during the initial sessions, and thus benefits of PT are inferred to come from the specific training.
223416007|NCT05779683|DEVICE|Caretaker Device placement|placement of the device on the postoperative cardiac surgery patient that has a pulmonary artery catheter for comparison readings
223416008|NCT00308191|DRUG|Formoterol Fumarate|
223416009|NCT00308191|DRUG|Tiotropium Bromide|
223416010|NCT02168257|DEVICE|RAM Cannula|
223416011|NCT02168257|DEVICE|Binasal Prong CPAP|
223416012|NCT04576520|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
223416013|NCT04576520|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
223416014|NCT02406001|DEVICE|Tigran PTG|Open Flap Debridement
223416015|NCT02406001|PROCEDURE|Surgical intervention|Open Flap Debridement
223560562|NCT01891799|OTHER|Option B+|"* Using one low toxicity triple ARV regimen \[(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)\] for all women, rather than adapting regimens by CD4+~* Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~* Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
223560563|NCT03070171|DRUG|dabigatran etexilate|single dose
223416016|NCT05005195|RADIATION|Low dose abdominal computed tomography scan|A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
223560564|NCT02182661|DRUG|Ba253BINEB|
224033128|NCT03962452|GENETIC|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
224033129|NCT00572520|BEHAVIORAL|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
223560565|NCT03374683|BEHAVIORAL|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca.~Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
224033130|NCT00572520|BEHAVIORAL|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
224033131|NCT00572520|BEHAVIORAL|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
224033132|NCT04107350|DEVICE|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
224299181|NCT03306524|DEVICE|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
224033133|NCT02824263|OTHER|CPAP withdrawal|CPAP is discontinued for 3 nights.
224033134|NCT02679742|DIETARY_SUPPLEMENT|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
224033135|NCT02679742|DIETARY_SUPPLEMENT|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
224299182|NCT03306524|DEVICE|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
223416017|NCT06224816|DEVICE|Custom 3D mask (3DM) application in neonate|Premature infants with a birth weight less than 1500 g r first received 3D mask during 4 hour, then crossed over to traditional mask.
223416018|NCT06224816|DEVICE|Traditional mask (TM) application in neonate|Premature infants with a birth weight less than 1500 g r first received traditional mask during 4 hours, then crossed over to 3D mask.
223416019|NCT00144521|DRUG|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
223416020|NCT00144521|DRUG|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
223416021|NCT00144521|DRUG|MTX|8mg/week(p.o.) for 24 weeks
223416022|NCT00144521|DRUG|MTX placebo|0mg/week(p.o.) for 24 weeks
223416023|NCT04854512|DRUG|Metformin DR|Delay-Release Metformin
223739093|NCT06819007|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
223739094|NCT06819007|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15/mg/kg IV Q3W
223739095|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
223739096|NCT00813683|OTHER|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
223739097|NCT06517901|PROCEDURE|Software fusion prostate biopsy|Software fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using an image fusion platform such as UroNav or similar. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
224033136|NCT06150638|BEHAVIORAL|Biofeedback|Three sessions of biofeedback intervention will be performed during the first 3 weeks of the intervention period. Patients will be taught to control abdominal and thoracic muscular activity by providing instructions using an original video support. Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
224033137|NCT06150638|BEHAVIORAL|Placebo|Three sessions of placebo intervention will be performed during the first 3 weeks of the intervention period. Sham measurements of abdominal and thoracic motion will be performed, and a pill of placebo containing 0.21 g glucose will be administered; patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
224033138|NCT06470802|BEHAVIORAL|Familiar voice|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
224033139|NCT06470802|BEHAVIORAL|Nature sounds|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
224033140|NCT06470802|BEHAVIORAL|Control|"The recording is provided to the patient through a smartphone with a music player application, using noise-free Bluetooth earphones for 15 minutes per session, twice daily (morning and afternoon shift), for 7 consecutive days.~Each session is separated by at least a 2-hour interval"
224033141|NCT00667355|BIOLOGICAL|adalimumab|40 mg or 80 mg every other week, subcutaneous
224033142|NCT04212988|PROCEDURE|Increase the SCO2 value|The interwention process will be started once the SCO2 value below ideal levels (80% of the basic level or 50% of absolute value), by adjusting the position of extracorporeal circulation arteriovenous catheter, balancing arterial pressure, increasing oxygen supply , adjusting pump speed ,etc.
224033143|NCT04226807|OTHER|Early Postpartum Phone Call|Participants receive a phone call 2-3 weeks after birth asking about overall wellbeing, screening for complications and postpartum depression and referring to lactation or WIC as needed.
224033144|NCT01859078|DRUG|Baricitinib|Administered orally
224033145|NCT01859078|DRUG|Digoxin|Administered orally
224033146|NCT02141542|DRUG|Tremelimumab|
224033147|NCT02141542|DRUG|MEDI3617|
224033148|NCT01771068|BEHAVIORAL|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
224033149|NCT04047693|DRUG|dose dense MVAC with pegylated GCSF|Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
224033150|NCT00227188|DRUG|Pneumococcal 7-valent conjugate vaccine Prevnar|
224033151|NCT04595253|OTHER|acupressure|"The acupressure involves the  Vaccaria Semen within skin-colored adhesive tape that placed on the Neiguan and Shenmen acupoints as an intervention measure. Continue to massage the acupoints with fingertips for 10 minutes, 3 times per day (8 and 12 in the morning, and 4 in the afternoon) . The adhesive tape will be retained in situ for 2 days."
224033152|NCT03306836|DRUG|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
223416024|NCT04854512|DRUG|Metformin IR|Immediate Release Metformin
223416025|NCT04854512|DRUG|Metformin DR Placebo|Metformin DR Placebo
223416026|NCT04854512|DRUG|Metformin IR placebo|Metformin IR placebo
223416027|NCT06032195|DRUG|Custodiol-N|heart will preserved in and will be treated with Custodiol-N solution
223416028|NCT06032195|DRUG|Custodiol|heart will preserved in and will be treated with Custodiol solution
223416029|NCT06045676|DEVICE|ECG|ECG with special comment on QT interval. QT interval was measured as the distance from the beginning of the Q wave to the end of the T wave at least in eight leads from the standard ECG.
223416030|NCT00552396|DRUG|Anti-KIR (1-7F9)|human monoclonal antibody
224033153|NCT03306836|DRUG|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
224033154|NCT02336750|DRUG|Aprepitant|125mg D1, 80mg D2-3
224033155|NCT02336750|DRUG|Mirtazapine|15mg D2-4
223416031|NCT06577883|DIAGNOSTIC_TEST|Chest X-ray Tomosynthesis|An imaging device that uses X-rays projected from multiple angles to reconstruct a three-dimensional images of the chest
224033156|NCT01244776|DEVICE|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
224033157|NCT03260595|DRUG|Crisaborole ointment 2%|Crisaborole ointment 2%
223416032|NCT02378428|DRUG|MIBG|
223416033|NCT00713947|DRUG|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
223416034|NCT00713947|DRUG|Pantoprazole|6 months at 20 mg
223416035|NCT00713947|DRUG|Placebo Formula 515|26 weeks, one tablet per day
223416036|NCT04831255|DRUG|triamcinolone acetonide extended-release injectable suspension|ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.
223416037|NCT02553499|BIOLOGICAL|MK-1248|IV infusion
224136655|NCT01908517|BEHAVIORAL|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
224136656|NCT00848250|DRUG|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
223416038|NCT02553499|BIOLOGICAL|pembrolizumab|IV infusion
223416039|NCT05377307|GENETIC|Pell's lentiviral-based gene-edited immune cell therapy|No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
223416040|NCT03625648|DRUG|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
223416041|NCT03625648|DRUG|Placebo|placebo
223416042|NCT04073888|PROCEDURE|Semen collection|Semen collection for seminogram and spermocytogram
223416043|NCT06684132|OTHER|Inspiratory muscle training|The H-IMT will be performed in seven sets of three-minute cycles consisting of two minutes of training followed by one minute of rest in the training workload. Each session will consist of 14 minutes of loading and seven minutes of rest for a total of 21 minutes.
223416044|NCT06684132|OTHER|Exercise|Stretching exercises for pectoral muscles, neck muscles and back muscles, strengthening exercises for upper extremity and back muscles and posture exercises will be applied.
223416045|NCT05376449|BEHAVIORAL|HealthPartners NeuroWell Exercise Program|A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
223416046|NCT04538781|DEVICE|VASCADE MVP VVCS|The VASCADE MVP Venous Vascular Closure System (VVCS) is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 6 - 12F inner diameter (maximum 15F OD) procedural sheaths, with single or multiple access sites in one or both limbs.
223416047|NCT00842023|DRUG|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
223416048|NCT00842023|DRUG|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
223416049|NCT06575972|DIETARY_SUPPLEMENT|JoyRise Recovery Powder|JoyRise Recovery Powder is a dietary supplement that contains Dihydromyricetin (DHM) and other natural ingredients. It is designed to mitigate the aftereffects of alcohol consumption. Participants will mix one serving in 8-12 oz of water and consume it the morning after alcohol consumption.
223739098|NCT06517901|PROCEDURE|Cognitive fusion prostate biopsy|Cognitive fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using visual estimation and/or measurements of lesion. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
223739099|NCT05707195|OTHER|Questionnaire|"A questionnaire is offered to parents of patients who meet the eligibility criteria and who have given their non-objection.~This questionnaire aims to evaluate the quality of care perceived by the parents of children hospitalized in the pediatric intensive care unit"
224033158|NCT03260595|DRUG|Vehicle|Vehicle
224033159|NCT01440712|DRUG|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
224033160|NCT01440712|DRUG|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
224136657|NCT00848250|OTHER|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
224136658|NCT03277300|DIETARY_SUPPLEMENT|dietary supplement|good dietary supplement for critically ill patients
224136659|NCT01399749|OTHER|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
224136660|NCT00701155|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
223416050|NCT06575972|DIETARY_SUPPLEMENT|Placebo|A placebo solution that is visually and tastefully similar to JoyRise Recovery Powder but contains no active ingredients. It will be mixed in 8-12 oz of water and consumed the morning after alcohol consumption.
224033161|NCT04455438|RADIATION|SBRT dose escalation|Re-Stereotactic Body Radiation Therapy (SBRT) with increasing dose levels, from 30 Gy in 5 fractions to 50 Gy in 5 fractions.
224033162|NCT01677897|DRUG|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
224033163|NCT01680068|PROCEDURE|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
224033164|NCT04388241|BEHAVIORAL|The Balance Program|The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
224033165|NCT01270945|DRUG|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
224033166|NCT01270945|PROCEDURE|Standard of Care|
224033167|NCT00978692|DEVICE|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
224033168|NCT00978692|DEVICE|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
224033169|NCT04651907|OTHER|acupuncture|use disposable sterile steel needles to insert to the acupuncture point
224033170|NCT04651907|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
224033171|NCT03761511|DRUG|Nicotinamide|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
224033172|NCT03761511|DRUG|Placebo|Matching Placebo (capsules) once daily
224033173|NCT05386550|DRUG|Xevinapant|Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle.
224033174|NCT05386550|RADIATION|IMRT|Participants received 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days per week.
224033175|NCT05386550|DRUG|Placebo|Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle.
224033176|NCT06423248|DIETARY_SUPPLEMENT|Ginger|3g of dried powdered Ginger daily for 12 weeks
224033177|NCT06423248|DIETARY_SUPPLEMENT|black seed|3g of dried powdered Black Seed daily for 12 weeks
224136661|NCT05677191|DEVICE|Proximal Femoral Nail|open reduction
224136662|NCT05677191|COMBINATION_PRODUCT|Dual Mobility Arthroplasty|Hip Arthroplasty Surgery
224298457|NCT02887300|BEHAVIORAL|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
224298458|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
223416051|NCT06388954|DEVICE|True Transcutaneous auricular Vagus Nerve Stimulation (TaVNS)|"Vagus Nerve Stimulation (VNS) consists in the activation of the Vagus nerve using electrical current, Transcutaneous auricular VNS works through the placement of noninvasive electrodes on the neck or auricle for stimulation of the auricular branch of the vagus nerve.~Transcutaneous electrical nerve stimulation (TENS) electrodes will be used to stimulate the auricular branch of the Vagus nerve, The active electrode will be placed on the cymba concha of the left ear. This reduced the risk of taVNS side eﬀect on the heart. The reference electrode will be placed outside the left ear attached to the tragus. TENS parameters used were: 30 minutes treatment time, a pulse width of 300 microseconds, pulse frequency 20 hertz and a duty cycle of 25%. The stimulation intensity was set at super-threshold levels, such as 200% of patient perceptual threshold."
223416052|NCT06388954|DEVICE|Sham Trancutaneous auricular Vagus Nerve Stimulation|Sham transcutaneous vagal nerve stimulation will be performed by the same procedures of the study group but without electrical stimulation. The active electrodes will be attached to the left cymba conchae. The taVNS stimulator will be turned on and the stimulation intensity will be increased until the patient perceived the electrical stimulation and then the stimulator will be turned off.
223416053|NCT03136640|DRUG|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
223416054|NCT00957320|DRUG|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
223416055|NCT00957320|DRUG|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
223416056|NCT01736644|DEVICE|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
223416057|NCT01736644|DEVICE|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
224033178|NCT06423248|DIETARY_SUPPLEMENT|cinnamon|3g of dried powdered Cinnamon daily for 12 weeks.
224033179|NCT06423248|OTHER|Placebo|3g of powdered corn starch daily for 12 weeks.
224033180|NCT06555198|BEHAVIORAL|Foot(at)Work intervention|Foot(at)Work intervention is targeted for nurses working in clinical settings to promote their competence in lower extremity health self-care.
224033181|NCT04562987|BEHAVIORAL|Physical Activity|Mobile app intervention delivered during chemotherapy for breast cancer that combines goal setting, behavioral monitoring, and goal achievement badges with telecoaching to achieve physical activity prescriptions.
224136663|NCT06155760|DRUG|Prednisolone|10mg of prednisolone plus standard medical therapy for 60 days
224136664|NCT06155760|OTHER|Standard Medical therapy|IV Albumin, Diuretics, Multi vitamins as per clinicians decision
224136665|NCT06155760|DRUG|Placebo|Placebo
224136666|NCT02275767|DEVICE|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
224136667|NCT02275767|DEVICE|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
224136668|NCT02275767|DEVICE|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
224136669|NCT01010711|DIETARY_SUPPLEMENT|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
224136670|NCT00914043|GENETIC|gene expression analysis|
224136671|NCT00914043|GENETIC|microarray analysis|
224136672|NCT00914043|GENETIC|polymerase chain reaction|
224136673|NCT00914043|GENETIC|polymorphism analysis|
224136674|NCT00914043|GENETIC|reverse transcriptase-polymerase chain reaction|
224136675|NCT00914043|OTHER|biologic sample preservation procedure|
223416058|NCT04803344|BEHAVIORAL|Expressive Writing tecnique|Expressive Writing (EW), is a simple, potentially inexpensive, therapeutic intervention which involves writing daily for 15-20 min over 3-4 consecutive days. EW can be completed at home without the need for facilitation, a specialist therapist or a dedicated facility.
223416059|NCT04803344|BEHAVIORAL|Neutral Writing|Participants were asked to write on neutral objects or events.
223416060|NCT01710579|PROCEDURE|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
223416061|NCT01710579|PROCEDURE|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
223416062|NCT01710579|PROCEDURE|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
223416063|NCT03319732|DRUG|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
223416064|NCT01019759|PROCEDURE|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
223416065|NCT05056259|DEVICE|18F-FDG PET/CT|"The PET/CT procedure will be performed according to the institutional standard with 18F-FDG (0.8-1.2 mCi /kg) injection following 6 h fasting. Blood glucose was controlled to be \<150 mg/dl. PET/CT from the vertex to the middle femur will be obtained 60 min after FDG injection.~MDCT examination without IV contrast will be done for attenuation correction and anatomic localization followed by PET images from the skull vault to the mid-thigh region.~Images of CT and corresponding functional PET images are displayed in axial, coronal and sagittal planes.~PET/CT data will include tumor size and extension, LN invasion\& distant metastasis SUVmax will be calculated for all positive lesions, Metabolic parameters including SUVmax, SUVmean, TLG \& MTV will be calculated for primary tumor.~Data of PET will be compared with other diagnostic imaging and postoperative pathologic data."
223416066|NCT01006187|DRUG|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
224136676|NCT00914043|OTHER|enzyme-linked immunosorbent assay|
224136677|NCT00914043|OTHER|laboratory biomarker analysis|
224136678|NCT00914043|PROCEDURE|fatigue assessment and management|
224136679|NCT01682577|DRUG|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
224136680|NCT01682577|DRUG|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
224136681|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
223416067|NCT01006187|DRUG|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
223416068|NCT01006187|OTHER|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
223416069|NCT01006187|OTHER|Distraction|By means of self-selected reading material or video
223416070|NCT02802787|OTHER|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
223416071|NCT02092545|OTHER|Ketogenic diet|
223416072|NCT05445362|DEVICE|Diode laser disinfection|\- Disinfection with parameter of Power: 1.5 watt, Mode: pulse: SP: Ton=10ms; Toff10ms 50Hz (50% pulse mode), for 5 seconds in spiral movement in apical to coronal direction no stop with non-initiated endodontic tip 200 micron diameter and 15 mm length three times. Irrigation with NaOCl, irradiation with the laser, then irrigation with E.D.T.A and irradiation with the laser, for three times then final rinse with distilled water with paper point dryness in between irrigations.
224033182|NCT04562987|BEHAVIORAL|Attentional Control|Mobile app intervention delivered during chemotherapy for breast cancer that includes telecoaching on general and cancer-related health topics and basic physical activity monitoring.
224033183|NCT04822168|OTHER|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
224033184|NCT04822168|OTHER|Standard Care|Standard Care through office-based opioid treatment with B/N dosing, on-site counseling and regular urine toxicology screening
224033185|NCT00068588|BIOLOGICAL|GTI-2040|Given IV
224033186|NCT00068588|DRUG|capecitabine|Given orally
224033187|NCT05193500|BEHAVIORAL|Verbs|New verbs are introduced that are personally relevant to the child or neutral.
224033188|NCT05193500|BEHAVIORAL|Pronouns|Pronouns are used that directly refer to the child or are neutral.
224033189|NCT04600206|OTHER|Self-report questionnaires|"In this longitudinal cohort study, patients and caregivers will not receive an intervention. In addition to the outcomes named in the section Outcome Measures patients and caregivers will complete self-report questionnaires for~Existential distress (Demoralization Scale-II, Death and Dying Distress Scale, Depressive Experiences Questionnaire, Revised Loss Orientation and Life Engagement in Advanced Cancer Scale, Sense of Dignity Item, Patient Dignity Inventory, Marwit-Meuser Caregiver Grief Inventory, Caregiver Guilt Questionnaire)~Need for and utilization of psychosocial support~Resources (Sources of Meaning and Meaning in Life Questionnaire, Questionnaire on the Defiant Power of the Human Spirit) and~Control variables (Memorial Symptom Assessment Scale, PHQ-9 and GAD-7)"
223416073|NCT05445362|DEVICE|Diode Laser bio-stimulation.|"\- The diode laser bio-stimulation with Wiser Diode Laser, Irradiation of the periapical area from the labial mucosal surface, day after day day on-day off for one week, two sessions will be applied at the same day with two hours interval, first session immediately after filing (blood induction), with flat top hand piece , diameter 1cm at a distance between 0 and 105 cm, at 1 watt power for 50s with CW continues mode in order to obtain the 5 J/cm2 fluence."
223416074|NCT05445362|DRUG|Triple antibiotic paste disinfection|-The root canals will be copiously and slowly irrigated with 20 ml of 1.5% (17) sodium hypochlorite (NaOCl) solution for 5 minutes alternatively with 20 ml of 17% ethylene diamine tetra acetic acid (E.D.T.A) solution for 5 minutes with intermediated rinse of distilled water with paper point dryness in between irrigations. The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline . The doxycycline capsule content will be evacuated in a sterile mortar; a tablet of metronidazole and a tablet of ciprofloxacin will be crushed and ground into homogenous powder in the same mortar using a pestle. Saline drops will be added and mixed using the pestle until a creamy paste achieved . The canals Will be dried with paper points and medicated with triple antibiotic paste; the access cavity will be sealed with intermediate restorative material (I.R.M) .
223560566|NCT03374683|BEHAVIORAL|RR In-Person Workshop|Participants engage in a facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
223560567|NCT03374683|BEHAVIORAL|Position Statement on Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
223560568|NCT00703521|BIOLOGICAL|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
223560569|NCT03517514|OTHER|Physical Therapy service|routine physical therapy care
223560570|NCT02592720|DRUG|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
223560571|NCT02592720|DEVICE|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
223560572|NCT02592720|DEVICE|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
224033190|NCT06311981|RADIATION|carbon ion radiotherapy|The patient will receive carbon ion radiotherapy with 70Gy per 20 fractions. Patients with genetic mutations (including but not limited to EGFR, ALK, etc.) should receive targeted therapy as their systemic therapy. For patients who are not suitable for targeted therapy, we recommend single regimen chemotherapy in sequence with radiotherapy. The drugs include etoposide, platinum (carboplatin, cisplatin, nedaplatin or loplatin), vinorelbine, paclitaxel (including liposome paclitaxel and albumin paclitaxel), docetaxel, pemetrexel, gemcitabine, etc. If there is no contraindication to PD-1/PD-L1 immunotherapy, it can be combined with immunotherapy, such as Pembrolizumab. For patients who cannot tolerate chemotherapy, PD-1/PD-L1 immunotherapy is recommended. The progression-free survival rate, toxicity, local control rate, cause-specific survival rate and overall survival rate were observed with regular follow-up after treatment.
224033191|NCT06311981|OTHER|targeted therapy|targeted therapy
224033192|NCT06311981|OTHER|single regimen chemotherapy in sequence with radiotherapy|single regimen chemotherapy in sequence with radiotherapy
224033193|NCT03673865|DEVICE|office-based 3-dimensional printers (OB3DP)|In this treatment group subjects, using office-based 3-dimensional printers (OB3DP) a patient-specific pre-adjusted (pre-bend) orbital plates will be made using over-the-counter titanium plates that are manually adjusted according to the printed model. The plates are then send to sterilization for preparation.
224033194|NCT03673865|DEVICE|standard stock orbital plate|In this control group subjects will receive non-patient-specific orbital implants which is standard stock orbital plate that is adapted intraoperatively to the fractured orbit
224033195|NCT05535465|OTHER|Public health intervention|additional trained mobile health workers are hired to support and supervise the activities of community health workers
224033196|NCT04200131|DIAGNOSTIC_TEST|Biopsy of the cyst wall with the Moray™ forceps.|Tissue sample of the wall of the pancreatic cyst with micro Moray™ forceps during an ultrasound-guided puncture of a pancreatic cyst with a 19G needle.
223560573|NCT03094091|OTHER|News items with spin|Interpretation of news items with spin
223560574|NCT03094091|OTHER|News items without spin|Interpretation of news items without spin
224033197|NCT05213754|PROCEDURE|Endovascular Treatment|Re-open the occluded cerebral artery using endovascular treatment
224033198|NCT00452088|BIOLOGICAL|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
224033199|NCT00452088|BIOLOGICAL|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
224033200|NCT00452088|BIOLOGICAL|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
224033201|NCT04143750|DRUG|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes
224033202|NCT04581967|GENETIC|polymorphism analysis|"* DNA will be purified from whole blood samples by commercial DNA isolation kits.~* Genotyping and genetic polymorphism detection for some metabolic enzymes genes will be performed by real time PCR."
224033203|NCT04581967|DRUG|Doxorubicin-Cyclophosphamide regimen|Treatment with a combination of Doxorubicin and Cyclophosphamide, This regimen comprises 60 mg/m² Doxorubicin and 600 mg/m² Cyclophosphamide administered intravenously on day 1 of each 21-day cycle, and repeated for a total of four cycles.
224033204|NCT06159322|DRUG|Olanzapine|Antipsychotic medication
224033205|NCT06159322|DRUG|Clozapine|Antipsychotic medication
224136682|NCT02331615|DEVICE|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
224033206|NCT05781217|DRUG|triptorelin, goserelin, leuprorelin|ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
223416075|NCT05445362|PROCEDURE|"revascularization using the standard method Blood Clot"|"\- The root canal Will be over-instrumented using finger plugger size #25 to encourage bleeding up to cemento-enamel junction. The sterile finger plugger size # 25 will be used with sharp strokes into the periapical tissue beyond the apex until bleeding becomes evident at the cervical portion of the canal. Blood column will be left 10 minutes to clot covered by sterile cotton, a collagen orifice plug Collagen plugs will be used as matrix against mineral trioxide aggregate (M.T.A) condensation, M.T.A will be mixed according to the manufacturer's instructions and carried to the cavity with M.T.A carrier (Dovgan M.T.A Carrier) , and then compacted using wet cotton roll on pluggers (S- Kondenser) . Finally the cavity will be restored with a glass ionomer base and light cure composite resin ."
223416076|NCT00767455|DEVICE|HP828-101|21 day patches
223416077|NCT05334693|BIOLOGICAL|Expanded haploidentical NK cells|Two doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).
223416078|NCT02075931|OTHER|Physical activity feedback with group meetings|Physical activity feedback
223416079|NCT02075931|OTHER|Control|No intervention
223560575|NCT01260090|DEVICE|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
224033207|NCT02604433|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
224136683|NCT02331615|DEVICE|SHAM|no meaningful stimulation will be given
224136684|NCT00560222|DIETARY_SUPPLEMENT|bovine lactoferrin|1gm of lactoferrin will be given each day
224136685|NCT00560222|DIETARY_SUPPLEMENT|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
223416080|NCT00454376|OTHER|questionnaire administration|
223416081|NCT00454376|PROCEDURE|quality-of-life assessment|
223416082|NCT01102868|DEVICE|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
223416083|NCT01102868|DEVICE|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
223560576|NCT01260090|DEVICE|No stimulation|Vagus nerve stimulation
223560577|NCT06265792|BEHAVIORAL|routine rehabilitation treatment|All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
223560578|NCT06265792|PROCEDURE|Stellate ganglion block|The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224033208|NCT02604433|OTHER|Placebo|Placebo, Subcutaneous, every 21 days.
224033209|NCT04227548|DIAGNOSTIC_TEST|needle electromyography|Direct muscle stimulation was performed to deltoid and tibialis anterior muscles with a monopolar needle electrode. Recording was made with a concentric needle electrode.
224033210|NCT06108180|OTHER|Dry Needling|3 treatment to eliminate active trigger points that patients have
223416084|NCT03855527|DRUG|Silver Diamine Fluoride|SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
223416085|NCT03855527|DRUG|Chlorhexidine|Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
223416086|NCT03855527|PROCEDURE|Atraumatic Restorative Treatment without Disinfection|Atraumatic Restorative Technique will be performed without cavity disinfection
223416087|NCT02948660|DRUG|Zolpidem Tartrate Tablets|All participants were administered 10 mg of zolpidem tartrate tablets either via a feeding tube (for patients with prolonged disorders of consciousness) or orally.
223416088|NCT00433589|DRUG|anthracycline-based|
223416089|NCT00433589|DRUG|docetaxel and capecitabine|
223416090|NCT00433589|DRUG|tamoxifen|
223416091|NCT00433589|DRUG|Letrozole|
223416092|NCT05914662|DRUG|Zanubrutinib, Bendamustine and Rituximab|Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
223416093|NCT00031629|DRUG|Docetaxel|Given IV
223416094|NCT00031629|BIOLOGICAL|Filgrastim|Given SC
223416095|NCT00031629|DRUG|Gemcitabine Hydrochloride|Given IV
224033211|NCT03437278|DRUG|Ligelizumab|Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.
224033212|NCT03437278|DRUG|Placebo|Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
224136686|NCT00005812|DRUG|temozolomide|
224136687|NCT00571688|DRUG|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
224298459|NCT01630213|DIETARY_SUPPLEMENT|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
224033213|NCT02357381|DEVICE|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
223416096|NCT00031629|BIOLOGICAL|Pegfilgrastim|Given IV
223416097|NCT04559100|RADIATION|chest radiography|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
223416098|NCT04559100|RADIATION|thoracic computed tomography scan|6 and 12 months after hospital discharge, if the patient had a CT scan upon admission to the hospital. If the study is normal at 6 months it will not be repeated at 12 months.
223416099|NCT04559100|DIAGNOSTIC_TEST|spirometry|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
223416100|NCT04559100|DIAGNOSTIC_TEST|Diffusing capacity of carbon monoxide|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
223416101|NCT04559100|DIAGNOSTIC_TEST|6 minute walk test|6 and 12 months after hospital discharge. If the study is normal at 6 months it will not be repeated at 12 months.
223416102|NCT04559100|DIAGNOSTIC_TEST|saint george respiratory questionnaire|6 and 12 months after hospital discharge.
223416103|NCT05101889|DIETARY_SUPPLEMENT|Oral Impact®|3 ready-to-drink bottles/day
223416104|NCT04756973|BEHAVIORAL|Behavioral weight loss program|A 12 week small group weight loss program delivered via teleconference video technology
223416105|NCT06308692|DIAGNOSTIC_TEST|ARES PCR|"Real time PCR assays will be used for the identification of infecting microorganisms and the drug resistance they carry that allow their identification, such as KPC, VIM, IMP, NDM, Acinetobacter OXA, Oxa48, MCR.~The validation of the method will be carried out in 100 (based on availability in Tropica Biobank) clinical samples: blood n=50 (positive, as for the negatives reference will be made to those already provided in the GENRES study) and rectal swabs ( positive n=40 and negative n=10) provided by the DITM. Sensitivity and specificity will be analyzed. As a reference for positivity and negativity data, reference will be made to routine diagnostic data obtained through standard operating procedures at the DITM laboratories."
223416106|NCT03145454|DEVICE|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
224033214|NCT02202551|DRUG|ADS-5102|
224033215|NCT00233844|PROCEDURE|"Venipuncture with cough-trick"|
224136688|NCT00571688|DRUG|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
223416107|NCT03145454|DEVICE|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
223416108|NCT03145454|DEVICE|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
223416109|NCT03145454|DEVICE|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
223416110|NCT03145454|DEVICE|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
223416111|NCT03647579|DRUG|midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine|midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
223416112|NCT03647579|DRUG|Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine|Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
223416113|NCT06445751|BEHAVIORAL|"Step Up for STEM and Health Careers (Step Up) game"|"Step Up for STEM and Health Careers (Step Up) game is an interactive, digital resource to help high school students understand the importance of diversity in STEM and health careers, attain STEM/health career self-efficacy, and help them create an inclusive learning environment for others."
223560579|NCT01788839|BEHAVIORAL|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
224033216|NCT00548054|BIOLOGICAL|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
224033217|NCT00548054|BIOLOGICAL|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
224033218|NCT02779725|BEHAVIORAL|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
224033219|NCT02779725|BEHAVIORAL|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
224033220|NCT02779725|BEHAVIORAL|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
224033221|NCT02779725|BEHAVIORAL|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
224033222|NCT02779725|BEHAVIORAL|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
224136689|NCT04761029|OTHER|RIIS|unilateral Rhomboid intercostal and subserratus block
224136690|NCT04761029|DRUG|Tramadol|intravenous patient-controlled analgesia (tramadol)
224136691|NCT01921933|DEVICE|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
224136692|NCT05875220|OTHER|No intervention|No intervention
224136693|NCT06118580|DRUG|Alcohol (Ethanol)|95% Ethanol diluted in Grape-flavored drink
224136694|NCT06118580|DRUG|Placebo|Grape-flavored drink
223416114|NCT06445751|BEHAVIORAL|Educational PowerPoint Presentation on Diversity in STEM Careers|An educational PowerPoint on Diversity in STEM careers to increase adolescents' STEM/health career self-efficacy, and help them create an inclusive learning environment for others.
223416115|NCT01762202|DRUG|Cyclophosphamide|
223416116|NCT01762202|DRUG|Fludarabine|
223416117|NCT01762202|DRUG|Ofatumumab|
223560580|NCT01788839|OTHER|Blood draw|Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
223739100|NCT06855732|BEHAVIORAL|Usual Care|"Usual care refers to the standard of care that patients receive at their primary care clinic.~The standard of care for patients is to discuss chronic pain with their providers at their discretion, and for providers to offer buprenorphine for OUD and/or provide referrals to specialty addiction treatment programs in the local community.~Participants will continue to have access to usual care for chronic pain, which could include pain clinic visits, physical therapy, medication (e.g., gabapentin), and/or seeing a counselor, psychiatrist, or psychologist.~The study protocol will not interfere with usual clinical care."
224033223|NCT05827211|PROCEDURE|Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive systemic antibiotics
224033224|NCT05827211|PROCEDURE|Non-Antibiotic group|Partially or fully edentulous smoker patients will be treated by dental implants and will receive placebo
224033225|NCT03291704|DEVICE|Thermal therapy device|Thermal therapy of blocked Meibomian glands
224033226|NCT00288795|OTHER|Massage Therapy|Therapeutic Touch
224033227|NCT00288795|OTHER|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
224033228|NCT04307082|DRUG|[14C]-Ibrexafungerp|Radio-labeled Ibrexafungerp, single dose.
224033229|NCT01822977|DRUG|omeprazole|
224033230|NCT05823701|DRUG|Chidamide|20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
224033231|NCT05823701|DRUG|Azacitidine|100mg d1- d5 subcutaneous injection per cycle
224033232|NCT05823701|BIOLOGICAL|obinutuzumab|1000mg d4 intravenous infusion per cycle
224033233|NCT05823701|DRUG|Liposomal mitoxantrone|20mg/m2 d5 intravenous infusion per cycle
224033234|NCT02274636|DIETARY_SUPPLEMENT|Xylitol|A comparison between discs and gel
224033235|NCT02147353|DRUG|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
224033236|NCT02147353|DRUG|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
224033237|NCT01329016|DRUG|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
224298460|NCT04102852|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
224033238|NCT01329016|DRUG|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
224033239|NCT01329016|DRUG|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
224033240|NCT06140212|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA would be used to assess participants cognitive functioning.
224033241|NCT06140212|BEHAVIORAL|Chinese ICOPE screening tool (self-administration and interview versions)|The ICOPE screening tool would be used to assess participants health status, including cognitive decline, auditory and visual capabilities, mobility restrictions, nutritional status, and depressive symptoms.
224033242|NCT06140212|BEHAVIORAL|Frailty status assessment (Edmonton frail scale and Frailty criteria by Dr. Fried)|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status.
224033243|NCT05175612|DEVICE|Lung auscultation with LungPass device (electronic auscultation)|Lung auscultation with electronic stethoscope
224033244|NCT02949960|DRUG|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
223416118|NCT04138953|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process."
223416119|NCT04138953|OTHER|Sham TMS|Sham Transcranial Magnetic Stimulation (TMS)
224298461|NCT02044796|DRUG|Cladribine|Given IV
224298462|NCT02044796|DRUG|Cytarabine|Given IV
224298463|NCT02044796|BIOLOGICAL|Filgrastim|Given SC
224298464|NCT02044796|OTHER|Laboratory Biomarker Analysis|Correlative studies
224298465|NCT02044796|DRUG|Mitoxantrone Hydrochloride|Given IV
223416120|NCT02660957|BEHAVIORAL|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
223416121|NCT02660957|OTHER|placebo comparator|suggest a healthy life style as a placebo comparator
223416122|NCT06920940|OTHER|Ketogenic Therapy|During the keto therapy (16 weeks), the youth will participate in a strict ketogenic diet, with adjustments made as necessary from weekly dietitian coaching sessions.
223416123|NCT01554462|DIETARY_SUPPLEMENT|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
223416124|NCT01554462|DIETARY_SUPPLEMENT|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
223416125|NCT01554462|DIETARY_SUPPLEMENT|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
223416126|NCT01554462|DIETARY_SUPPLEMENT|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
223416127|NCT05025176|DEVICE|Non invasive arterial pressure monitoring|Non invasive arterial pressure monitoring
224033245|NCT02949960|DRUG|Vehicle Control|Topical Vehicle Gel applied twice daily
224033246|NCT02877160|DRUG|AL-794 suspension|
224033247|NCT02877160|DRUG|AL-794 tablet|
223416128|NCT05565833|BEHAVIORAL|SHUTi OASIS|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program
223416129|NCT05565833|OTHER|Patient Education|An educational website containing information on insomnia
223416130|NCT05646784|DRUG|Cerebiome|Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
223416131|NCT05646784|DRUG|Placebo|Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
223739101|NCT06855732|BEHAVIORAL|Pain Self-Management|"PSM is a manualized behavioral intervention tailored to patients in primary care with opioid misuse/OUD. The PSM intervention that consists of ten sessions/modules.~Participants will be offered a total of 10 PSM sessions, delivered weekly over a 12-week intervention period starting from the date of study enrollment.~A trained staff interventionist will lead the 60-minute sessions using a participant study manual that outlines the content for all 10 sessions.~The first two sessions, Introduction and Navigating Conversations About Opioids, are mandatory. Participants can choose the order of the remaining 8 sessions, prioritizing those they are most interested in. Additional session topics are: Stress Management and Your Pain, Relaxation Techniques to Help Your Pain, Thinking Differently About Your Pain, Sleeping Better to Help Your Pain, Physical Activity and Your Pain, Mood and Your Pain, and Communicating with Others."
223739102|NCT06615622|DIETARY_SUPPLEMENT|Placebo|Thiotacid 300 mg tab once/day
223560581|NCT01788839|DEVICE|Transvaginal ultrasounds|Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
224033248|NCT04934488|BEHAVIORAL|Online Peer-Delivered 1-Day CBT-Based Workshop|It is a day-long intervention delivered in 4 modules. Each participant is given a professionally designed manual to facilitate learning. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays.
224033249|NCT02785497|OTHER|Control group|will be turn on the equipment, positioning the patient but no put intensity
224033250|NCT02785497|OTHER|Treatment group|This group will receive electrostimulation
224033251|NCT02287376|DRUG|Diclofenac Potassium for Oral Solution|NSAID
224136695|NCT04323761|DRUG|Remdesivir|Intravenous infusion administered over a 30 to 120 minute period
224136696|NCT05433194|BIOLOGICAL|ABO1009-DP|Vaccine
224136697|NCT01893658|DRUG|Omalizumab|administration of a single dose together with the standard treatment
224136698|NCT01893658|DRUG|Prednisone|standard treatment
224136699|NCT00304317|DRUG|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
224136700|NCT00304317|OTHER|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
224033252|NCT05474066|DEVICE|ERP Testing|"* Attention \& Concentration:~* Continuous Visual Memory Test (CVMT):~* Flanker Task:~* Hayling Test:"
224136701|NCT03457103|DEVICE|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
224136702|NCT03457103|DEVICE|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
224136703|NCT01922284|BIOLOGICAL|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
223416134|NCT03524326|DRUG|Lenvatinib Pill|24 mg oral daily
223416135|NCT03524326|DRUG|Lenvatinib Pill|20 mg oral daily
223416136|NCT03524326|DRUG|Lenvatinib Pill|14 mg oral daily
223416137|NCT03524326|DRUG|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
223416138|NCT03524326|DRUG|Lenvatinib Pill|10 mg oral daily
223416139|NCT03524326|DRUG|Lenvatinib Pill|4 mg oral daily
223416140|NCT05707637|OTHER|Ablation|Unipolar and bipolar ablation
223416141|NCT04730011|BEHAVIORAL|Short and Intensive Treatment|Intensive Treatment Week with behavioural psychotherapy
223416142|NCT05917587|DRUG|Metformin Hydrochloride|12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
223416143|NCT05917587|OTHER|placebo|12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.
223416144|NCT06569602|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
223416145|NCT01763580|DRUG|Tacrolimus|Oral
223416146|NCT01763580|DRUG|Prednisolone|Oral
224136704|NCT01922284|BIOLOGICAL|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
224136705|NCT01922284|BIOLOGICAL|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
224136706|NCT01922284|BIOLOGICAL|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
224033253|NCT05406804|BEHAVIORAL|Olfactory stimulation|1\) For the premature infants who use non-invasive ventilation, place a single layer of gauze soaked in breast milk on the air outlet of the non-invasive ventilator. When inhaling oxygen with a high-flow nasal cannula, the same measure is performed, and the breast milk and sterile gauze soaked in breast milk are replaced every 4 hours. 2) For the premature infants who withdrawn from assisted ventilation, place the breast pad near the infants' nose, and replace the breast milk pad every 4 hours. Acquisition of breast milk pads: use the same brand of breast milk pads; put the breast milk pads used between 00:00 and 07:00 every day (use time \> 2 hours) into the same brand of milk storage bags, and use two left and right at the same time. 3) If the premature infants don't have any ventilation support, the breast milk stimulation method is the same as 2). This intervention will continue until premature infants discharge from hospital.
224033254|NCT05406804|BEHAVIORAL|Routine nursing care|Nursing is performed according to existing nursing practices. Nasal feeding is generally used.
224033255|NCT06563362|RADIATION|De-escalation of irradiated volume|De-escalation of elective clinical target volumes as recommended by a model-based approach
224033256|NCT04290442|PROCEDURE|adductor canal block|The block is performed in supine position under ultrasound guidance using 22 G Touhy needle advanced in plane and 15 cc of 0.5% Ropivacaine ( local anesthetic) with dexmedetomidine 20-30 mcg depending on the age of the patient is injected at midthigh level lateral to the femoral artery in adductor canal to provide sensory blockade to the anterior aspect of the knee.
223416147|NCT04308278|DRUG|2LEBV® / 2LXFS®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
223416148|NCT04308278|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
223416149|NCT05849415|DIAGNOSTIC_TEST|Periodontal Screening and Recording, periodontal evaluation.|Periodontal probing for the evaluation of bleeding on probing and Periodontal Screening and Recording
223416150|NCT05204862|DRUG|TU2218|orally administered
223416151|NCT05204862|DRUG|Anti-PD-1 antibody|Intravenously administered
223416152|NCT00068393|DRUG|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
223560582|NCT05721352|BEHAVIORAL|Virtual Reality Nature scene plus heart rate variability biofeedback phone application|phone app for slow- paced breath training with biofeedback in a virtual reality nature scene
223560583|NCT03737448|DRUG|Trimetazidine|Subjects with receive up to 60 mg daily
223560584|NCT02161094|BEHAVIORAL|Give incentives to physicians based on their patient's HbA1c improvement|
223560585|NCT02161094|BEHAVIORAL|Give incentives to patients based on their own HbA1c improvement|
223560586|NCT01471028|BIOLOGICAL|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
223560587|NCT01471028|OTHER|Standard of care (Control)|Control receives standard medical treatment.
224136707|NCT06175650|PROCEDURE|Cardiac surgery|Cardiac surgery of all types
224136708|NCT04641312|DRUG|LY3457263|Administered SC
224136709|NCT04641312|DRUG|Dulaglutide|Administered SC
224136710|NCT04641312|DRUG|Placebo|Administered SC
224136711|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
224136712|NCT04497298|BIOLOGICAL|Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2)
223416153|NCT00068393|DRUG|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
223560588|NCT04821375|DRUG|bazedoxifene plus conjugated estrogens|6 months of bazedoxifene (20 mg) and conjugated estrogens (0.45 mg) taken together daily.
223560589|NCT05157113|DRUG|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
223560590|NCT05157113|DRUG|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
223560591|NCT02415049|OTHER|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
223560592|NCT02415049|OTHER|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
223560593|NCT01812213|DRUG|[18F]NAV4694|
223560594|NCT05947461|DRUG|100mg diclofenac|All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
223560595|NCT05947461|DRUG|100mg indomethacin|All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
223560596|NCT00080080|DRUG|talabostat (PT-100) tablets|
223560597|NCT00080080|DRUG|Docetaxel|
223739103|NCT06994832|BEHAVIORAL|Visual Array|Single side-by-side visual array
223739104|NCT06994832|BEHAVIORAL|Narrative Visual Array|Evolving narrative with sequential visual arrays
224136713|NCT04497298|BIOLOGICAL|One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose|Live-attenuated recombinant measles vaccine virus vector expressing a modified surface glycoprotein of the novel Coronavirus (SARS-CoV-2) and placebo
224136714|NCT04497298|OTHER|Placebo|Physiological saline solution (0.9% NaCl)
224136715|NCT05779579|DRUG|HS-10517 Dose 1|HS-10517 Dose 1+Ritonavir
224136716|NCT05779579|DRUG|HS-10517 Dose 2|HS-10517 Dose 2+Ritonavir
224136717|NCT05779579|DRUG|HS-10517 Dose 3|HS-10517 Dose 3+Ritonavir
223416154|NCT00068393|DRUG|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
223416155|NCT00068393|DRUG|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
223416156|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - standard product|Single dose intervention with Standard product Coenzyme Q10 (ubiquinone) 2 capsules - 100 mg total coenzyme Q10
223416157|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - Investigational product IP1|Single dose intervention with Investigational product IP1; Q10 MICROENCAPSULATED 2 capsules - 100 mg total coenzyme Q10
223416158|NCT05272228|DIETARY_SUPPLEMENT|Dietary supplement - Investigational product IP2|Single dose intervention with Investigational product IP2; Final formulated product BQSM® 2 capsules - 100 mg total coenzyme Q10
223416159|NCT05509465|DEVICE|Ergonomic chinrest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting.
223416160|NCT05509465|DEVICE|Ergonomic chinrest used with a low Super Kun shoulder rest|The novel ergonomic chinrest (Kréddle®, Wyoming, US) is fully adjustable to accommodate each violinist's body type and performance style: regarding height, rotation and tilting. The low Super Kun shoulder rest has been adjusted to be in the lowest position for all legs attached to the violin before the violinists received it. All participants was told not to adjust the shoulder rest but adjust the chinrest.
223416161|NCT04699110|DRUG|Adrenaline|Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow
223416162|NCT04699110|DRUG|Adenosine|Control group will receive adenosine (100 to 400 mcg)
223416163|NCT02586610|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
223416164|NCT02586610|DRUG|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
223416165|NCT02586610|RADIATION|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
223416166|NCT00893997|BIOLOGICAL|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
223416167|NCT04543097|BEHAVIORAL|Vocational Support|"Participants randomised to receive vocational advice will all be offered:~Step 1, contact by phone to undertake an assessment with a trained Vocational Support Worker (VSW) to identify obstacles to Return to Work (RTW) and support RTW planning.~Step 2, face-to-face (in person or by videoconference) in-depth discussion of obstacles to RTW and further support for RTW planning.~Step 3, contact by the VSW (with participant consent) with the participants' workplace.~The frequency of contact will be individualised to the needs of participants and the offer of support continued until sustained RTW (defined as return to any work for at least 4 weeks) or until 6 months of absence, after which participants will be signposted to other services."
223416168|NCT06466681|OTHER|All included subjects|Administration of the subtest of divided attention of the Test of Attentional Performance (TAP), recording of the event related potentiels N200 and P300, measure of the variation of power in several frequency bands (theta, alpha and beta) and measure of the high-resolution EEG connectivity during an attentional task at several time-points : a first time during interictal period (no seizure for more than 24 hours) and 1, 3, 6 and 24 hours after a focal seizure.
223416169|NCT03318094|DRUG|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
223416170|NCT03318094|OTHER|Saline|Intrabrachial saline will be given this day
224033257|NCT04290442|PROCEDURE|SPANK|SPANK: The block is performed in supine position, using 22 G Touhy needle, under ultrasound guidance, needle is advanced in plane to posteromedial shaft of femur taking care to avoid popliteal artery, and 0.5% ropivacaine 15 cc, dexmedetomidine 20-30mcg and dexamethasone 4 mg is injected into inner thigh above the knee provide sensory block to posterior aspect of the knee.
224136718|NCT05779579|DRUG|HS-10517 Dose 4|HS-10517 Dose 4+Ritonavir
224136719|NCT05779579|DRUG|Placebo|Dose level A of placebo
223416171|NCT03318094|DRUG|Sodium Nitroprusside|Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine
224033258|NCT04290442|DRUG|Ropivacaine|ropivacaine 0.5% will be use in the block
224033259|NCT00447759|DRUG|Celecoxib|200-400mg daily in divided doses
224033260|NCT00447759|DRUG|Diclofenac|prescribed medication taken orally
224136720|NCT05469477|BEHAVIORAL|Persuasive education|The research team will use psychology and communications research to present information about seat belts and distracted driving in a way that builds intrinsic motivation to change. Because positively framed messages are more effective at promoting seat belt wearing, the team's messaging will employ this framing. Education will address common reasons that survey participants give for not consistently buckling up or for phone use while driving.
224136721|NCT05469477|BEHAVIORAL|WOOP (aka, mental contrasting with implementation intentions., Wish, Outcome, Obstacle, Plan)|Participants will receive an intervention on improving driving behavior with a specific goal in mind and how to reach that goal. Participants will do this by thinking through 4 parts: a wish, an outcome, an obstacle and a plan. This has been shown to build motivation, and help achieve the desired change.
224136722|NCT05469477|BEHAVIORAL|Customized Habit Tips|Participants will receive weekly text-message tips, informed by findings from survey responses, plus reminders to address stated obstacles.
224136723|NCT05469477|BEHAVIORAL|Raffle Financial Incentive|Each week, participants who adhere to seat belt use or abstain from phone use while driving get a chance at prize money. One winner will be randomly chosen for each target behavior and earn prize money; the rest will not receive compensation.
224136724|NCT05469477|BEHAVIORAL|Shared Pot Financial Incentive|This will be identical to the raffle incentive, except that each week participants who adhere to seat belt use or abstain from phone use while driving will be guaranteed an equal share of prize money.
224298466|NCT05102136|DRUG|REGN9933|Administered intravenously (IV) or subcutaneous (SC) per the protocol
224033261|NCT03321734|DRUG|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
224033262|NCT03321734|DRUG|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
224136725|NCT05469477|BEHAVIORAL|Weekly SMS Support text|Participants will receive a support SMS to troubleshoot, etc. if the Way to Drive app is not collecting trip data.
223416172|NCT05839067|BEHAVIORAL|Care-HF|Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
223416173|NCT05795244|DRUG|Nivolumab|\- Nivolumab 480 mg/every 4 weeks/IV infusion/6 cycles
223416174|NCT06566820|DRUG|Aroxybutynin and Atomoxetine|Fixed Dose Combination
223416175|NCT04286386|OTHER|Hyperpolarized Carbon C 13 Pyruvate|Given IV
223416176|NCT04286386|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
223416177|NCT04286386|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
223560598|NCT00610857|DRUG|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
223560599|NCT05618041|BIOLOGICAL|CAR-T Autologous T cell injection|Biological: CAR-T; Drug: Cyclophosphamide,Fludarabine；Procedure: Leukapheresis
224136726|NCT05469477|BEHAVIORAL|Weekly SMS Encouragement|Those who have a perfect streak going midway through each week will receive an additional encouraging message cheering them on.
224298467|NCT05102136|DRUG|Placebo|Placebo to match REGN9933 in same form; placebo administered IV or SC per the protocol
224298468|NCT00713999|DRUG|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
223416178|NCT06372834|DEVICE|piTBS being delivered using the Magstim Rapid2 stimulator|Magstim Rapid2 stimulator (Magstim Company, Ltd, Whitland, Wales, UK, SA340HR). See detail in arm/group descriptions regarding the intervention.
223416179|NCT06255522|PROCEDURE|Fully guided implant placement|Through guided surgery, previously planned and designed based on CBCT study and CAD/CAM scanning, implant placement of Conelog Progressive line implants (Biohorizons Camlog, Iberia) will be performed in maxilla or mandibula in a one stage surgery. Postoperative CBCT in ECO mode (35μSv) will be taken after the implant placement to assess the final position and comparing with the initial digital planning.
223416180|NCT03486444|DIAGNOSTIC_TEST|Phillips Lumify Diagnostic Ultrasound System|portable ultrasound device
223416181|NCT03486444|OTHER|Surveys|surveys assessing perception of ultrasound
224033263|NCT03295656|DRUG|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
224033264|NCT04916522|DRUG|Colchicine|0.5 mg once daily
224033265|NCT04916522|DRUG|Placebo|Once daily
224033266|NCT03780426|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
224033267|NCT03780426|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
224033268|NCT03082703|BEHAVIORAL|Text Messaging|Subjects contacted 3 times weekly via text messaging for the study period.
224033269|NCT04922489|PROCEDURE|Dental implant placement|Dental implant placemente on edentulous jaw.
224033270|NCT00642551|DIETARY_SUPPLEMENT|menaquinone-7|180 µg menaquinone-7 daily for three years
224033271|NCT00642551|DIETARY_SUPPLEMENT|placebo|1 placebo capsule daily for three years
224033272|NCT05997524|DRUG|Trastuzumab|Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w).
224136727|NCT04274660|BEHAVIORAL|DWELL (Diabetes and WELLbeing) Programme|12-week psychoeducational programme
224136728|NCT01284270|OTHER|Cardiac MRI|Cardiac MRI
224136729|NCT00637715|DRUG|Alfuzosin|
224298469|NCT00132171|DRUG|Sequential therapy|
224298470|NCT01016093|DRUG|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
224298471|NCT01016093|DRUG|Placebo|Placebo
224299183|NCT01620619|OTHER|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
223416182|NCT04876131|DRUG|Benzylpenicillin - single dose|"Participants will receive a single dose of IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours."
223416183|NCT04876131|DRUG|Benzylpenicillin - three days|"Participants will receive three days of this IV antibiotic (benzylpenicillin).~Benzylpenicillin dosing: 1 month - 18 years, IV or Intramuscular (IM) 30 mg/kg (maximum 1.2 g) every 6 hours. For severe infections, use up to 60 mg/kg (maximum 2.4 g) every 4-6 hours."
223416184|NCT04876131|DRUG|Gentamicin - single dose|"Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
223416185|NCT04876131|DRUG|Gentamicin - three days|"Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)"
223416186|NCT04876131|DRUG|Cefalexin - post single dose of IV antibiotics for the remaining two days|Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
223560600|NCT06477965|PROCEDURE|Artery Embolization|Embolic Solution are intended for use in occluding blood vessels for therapeutic or operative purposes. The embolic solution is used during an outpatient procedure, the physician will insert a small catheter onto the artery supplying the lining of the target joint or target localized pain. Tiny particles are then injected through the catheter into these arteries, reducing blood flow to the target area. This reduces the amount of inflammation associated with osteoarthritis, tendonitis, tenosynovitis or an injury, a process that can help decrease symptoms or eliminate the associated localized pain to this area. With understanding that it does not treat the underlying cartilage destruction or underlying condition causing pain but would like to determine the efficacy and validity of this treatment.
223560601|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, TID
223739105|NCT04392284|BEHAVIORAL|Diet Counseling|"Delivery of nutrition counseling intervention to improve diet quality. Suggested energy intake will be prescribed with the intent to maintain energy balance and current body weight. A total of 16 nutrition counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of nutrition counseling through the end of the study, meeting with the dietitian every other week. Starting at week 9, those identified as non-responding participants will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
223739106|NCT04392284|BEHAVIORAL|Exercise Counseling|"Delivery of exercise counseling intervention to increase engagement in physical activity. The exercise specialist will counsel participants to progressively increase their weekly physical activity. Weight loss is not a primary goal of these exercise counseling sessions. A total of 16 exercise counseling sessions lasting \~30 minutes will be scheduled with a frequency of 1 session per week for 1 month (5 sessions), 1 session every-other week for months 2-6 (11 sessions). Responding participants who have improved their insulin resistance as measured at the 8-week visit will continue receiving this level of exercise counseling through the end of the study, meeting with the exercise specialist every other week. Starting at week 9, those identified as non-responders will be re-randomized to 2nd stage interventions, of either receiving nutrition counseling for weight loss (meeting with the dietitian every other week) or the addition of a prescription for metformin."
224033273|NCT05997524|DRUG|Oxaliplatin|Oxaliplatin was administrated as a 130 mg/m2 infusion, q3w, for up to 6 cycles.
224033274|NCT05997524|DRUG|Capecitabine|Capecitabine 1000 mg/m2 was given orally twice daily on days 1-14 followed by a 7-day rest interval.
224136730|NCT06085261|BEHAVIORAL|home-based telerehabilitation group|Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
224136731|NCT06085261|BEHAVIORAL|center-based traditional rehabilitation group|"Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment.~The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group."
224136732|NCT02182141|DRUG|BIBF 1120 ES|
223416187|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - baseline|Baseline laboratory values will be obtained
223416188|NCT05538234|OTHER|Medical information 12 hours before organ harvesting|"* average hourly diuresis~* hypotension MAP\<65 Torr longer than 30 minutes (YES/NO)~* Furosemide administration (YES/NO)~* Mannitol administration (YES/NO)~* administration of anti-diuretic hormone (YES/NO)~* administration of vasopressors (YES/NO)~* polyuria \>3ml/kg/h (YES/NO)~* nephrotoxic agents during hospitalization (YES/NO)"
223560602|NCT01626118|DRUG|Indomethacin|capsules, 40 mg, BID
224033275|NCT00002863|DRUG|chemotherapy|
224033276|NCT00002863|PROCEDURE|conventional surgery|
224033277|NCT00002863|PROCEDURE|cryosurgery|
224033278|NCT06445283|OTHER|Determination of VTE risk levels|Determination of VTE risk levels of patients using IMPROVE risk assessment tool according to deep vein thrombosis and pulmonary embolism risk factors
224033279|NCT00696930|DRUG|90Y-SMT487|
224033280|NCT01938469|OTHER|Liquid Meal|
224033281|NCT01938469|OTHER|Solid Meal|
224033282|NCT04127149|DIAGNOSTIC_TEST|Ultrasound scan|The group uses an ultrasound device for the consultation.
224033283|NCT00292799|DRUG|Orlistat Vs Metformin|
223416189|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 12 hours after reperfusion|Laboratory values will be obtained 12 hours after reperfusion
223416190|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 48 hours after reperfusion|Laboratory values will be obtained 48 hours after reperfusion
223416191|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 7 days after reperfusion|Laboratory values will be obtained 7 days after reperfusion
223416192|NCT05538234|DIAGNOSTIC_TEST|Laboratory values - 90 days after reperfusion|Laboratory values will be obtained 90 days after reperfusion
223416193|NCT05538234|OTHER|Medical information during organ harvesting/transplantation|"Medical information during organ harvesting/transplantation~* hypotension MAP 65 Torr \> 5 minutes (YES/NO)~* vasopressor support (YES/NO, duration in minutes)"
223560603|NCT01626118|DRUG|Indomethacin|capsules, 20 mg, TID
223560604|NCT01626118|DRUG|Placebo|capsules
223560605|NCT06506032|DRUG|Intravenous Vancomycin administration|Vancomycin was administered to the patients at the discretion of the physician
224033284|NCT01207661|BIOLOGICAL|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
224033285|NCT03037619|BEHAVIORAL|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
224033286|NCT03037619|BEHAVIORAL|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
224033287|NCT05176184|DIAGNOSTIC_TEST|A deep learning model for predicting a difficult laryngoscopy based on a cervical spine lateral X-ray image|"The deep learning model uses the input of preprocessed C-spine lateral X-ray images and outputs the level of difficulty of a laryngoscopy. The easy laryngoscopy is defined as a combination of the Cormack-Lehane grades 1-2 and the difficult laryngoscopy is defined as a combination of grades 3-4.~In addition, before general anesthesia, airway evaluations related to the difficulty of laryngoscopy are performed and the results are compared with the actual level of difficulty."
223416194|NCT05538234|PROCEDURE|Organ harvesting|Organ harvesting for transplant
223416195|NCT05538234|PROCEDURE|Organ transplantation|Transplantation of the harvested organ
223416196|NCT03295240|DRUG|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
223416197|NCT03295240|DRUG|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
223416198|NCT03725592|OTHER|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
223416199|NCT03725592|BEHAVIORAL|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
223416200|NCT05127330|BEHAVIORAL|LifePlans|LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
223416201|NCT05127330|BEHAVIORAL|Treatment as Usual|Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
223416202|NCT04981470|DEVICE|baroloop System|vagal nerve stimulation
223739107|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
223739108|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
223416203|NCT03226821|DRUG|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
223416204|NCT05599646|BEHAVIORAL|traditional pedometer based walking intervention|Participants were recommended to monitor their step count using traditional pedometer and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
223416205|NCT05599646|BEHAVIORAL|gamified pedometer based walking intervention|Participants were recommended to monitor their step count using gamified pedometer, earn money, compete friends and to increase their steps by 10% compared with the prior week. the intervention will continue for 12 weeks
223416206|NCT05802472|OTHER|Polyphenolic beverage from extract of Vachellia farnesiana|During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
223560606|NCT06506032|OTHER|Standard postoperative therapy|The patients received standard postoperative therapy
223560607|NCT04355897|BIOLOGICAL|Convalescent COVID 19 Plasma|Subjects will be transfused intravenously with 500 mls of convalescent COVID 19 plasma
223560608|NCT02789423|PROCEDURE|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
223560609|NCT02843035|DRUG|venglustat (GZ402671)|"Pharmaceutical form: capsule or tablet~Route of administration: oral"
223560610|NCT02843035|DRUG|imiglucerase|"Pharmaceutical form: sterile lyophilized product~Route of administration: intravenous"
224033288|NCT02645513|BEHAVIORAL|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
224136733|NCT04518982|DRUG|Sintilimab and lenalidomide|Drug: Sintilimab 200mg ivgtt on day 1. Drug: lenalidomide 10mg orally once a day, day 1-14.
223560611|NCT06030466|OTHER|With virtual standardized patients|The virtual standardized patient is a software system that presents on a computer screen like a video conference, allowing medical students to interact with it for medical consultation. The virtual character modeling adopts 3D model, the expression of the character is delicate, and the voice feedback is clear. After the students' questions are asked by voice recognition and key words are extracted, appropriate responses are given.
223560612|NCT06030466|OTHER|With physical standardized patients|The physical standardized patient is a real person who has received professional training courses in the department of medical education of National Taiwan University Hospital, and can help medical students practice consultations.
223560613|NCT04826094|BIOLOGICAL|Env-C Plasmid DNA|2 mg per dose. Administered by intramuscular injection.
223560614|NCT04826094|BIOLOGICAL|HIV Env gp145 C.6980 protein|100 µg per dose. Administered by intramuscular injection.
223560615|NCT04826094|DRUG|Rehydragel®|Adjuvant. Aluminum hydroxide fluid gel. 500 µg per dose. Administered by intramuscular injection.
223560616|NCT04826094|BIOLOGICAL|ALF43|Adjuvant. Army Liposome Formulation-43% Cholesterol. 200 µg per dose. Administered by intramuscular injection.
223560617|NCT04826094|BIOLOGICAL|dmLT|Adjuvant. Recombinant double mutant Escherichia coli heat labile toxin. 50 µg per dose. Transcutaneous application (needle-free skin patch). 1 mL diluted dmLT added to gauze pad at site of injection.
223560618|NCT04826094|DRUG|Placebo (IM)|0.9% sodium chloride (sterile saline). Administered by intramuscular injection.
223739109|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
223739110|NCT02407028|DRUG|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
224033289|NCT02645513|BEHAVIORAL|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
224033290|NCT02645513|BEHAVIORAL|Control|No text message reminders
224136734|NCT04518982|DRUG|Sintilimab placebo and lenalidomide placebo|Drug: Sintilimab placebo ivgtt on day 1. Drug: lenalidomide placebo orally once a day, day 1-14.
224136735|NCT02525419|BEHAVIORAL|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
224136736|NCT02525419|BEHAVIORAL|HP-IF|High Protein, Intermittent Fast
223560619|NCT04826094|DRUG|Placebo (TCl)|Transcutaneous application (needle-free skin patch). 0.9% sodium chloride (sterile saline) added to gauze pad at site of injection.
223560620|NCT05604560|DRUG|Tislelizumab|Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
223560621|NCT05604560|DRUG|SX-682|Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
223560622|NCT04753970|DRUG|Cilostazol|Cilostazol 100mg BID
223560623|NCT06342024|OTHER|Pistachio group|Participants will be giving 1.5 ounces of pistachios to consume during the 6-month trial.
223560624|NCT04741789|DRUG|Capmatinib|Tablet for oral use, dose Up to 400mg, twice daily
224136737|NCT02525419|BEHAVIORAL|HH|Heart Healthy
224136738|NCT05859048|DIAGNOSTIC_TEST|NT-proBNP|blood sample to measure N-terminal prohormone of B-type natriuretic peptide at local laboratory
224136739|NCT05859048|DIAGNOSTIC_TEST|AI echocardiogram|Artificial intelligence driven transthoracic echocardiogram
224136740|NCT05859048|DIAGNOSTIC_TEST|electrocardiogram|tracing of electrical cardiac activity of the heart
223739111|NCT02407028|DRUG|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
223739112|NCT02407028|DRUG|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
223739113|NCT02407028|DRUG|Normobaric Hyperoxia (NBH)|100% fraction of inspired oxygen (FiO2) for 4.5 hours twice a day for five days or until patient following commands or brain dead
224033291|NCT02843971|DEVICE|Intraocular pressure measurement with the Sensimed triggerfish Device|
224033292|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single Dose 1x10\^10 DNase resistant particles (DRP) / mL joint volume
224033293|NCT00617032|GENETIC|tgAAC94 gene therapy vector|Single dose 1x10\^11 DNase resistant particles (DRP) / mL joint volume
224033294|NCT00617032|GENETIC|tgAAC94 placebo|Single dose
224033295|NCT01498289|DRUG|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
224033296|NCT01498289|DRUG|docetaxel|30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
224136741|NCT05859048|OTHER|Cardiovascular physical examination|basic physiological measurements to include height (cm), weight (kg) and hip circumference (cm) and blood pressure (mmHg)
223560625|NCT05902910|DEVICE|LUNA-EMG Robot|During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
223560626|NCT05529264|OTHER|Memory Tasks|Participants will be asked to view pictures and videos presented on a computer screen and will be asked to recall the details of presented pictures or videos sometime later.
223560627|NCT05529264|OTHER|Attention/arousal tasks|Participants will be asked to perform a continuous performance task, such as continuous addition of numbers. Additionally, participants may be presented with images and may be asked to rate the significance or arousal values for each image.
223739114|NCT02407028|OTHER|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
224136742|NCT06323694|BEHAVIORAL|quality of life|data collection through questionnaire and interview
224298472|NCT00714493|BIOLOGICAL|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
224298473|NCT02372071|DEVICE|BiliCare|Two measurements with the BiliCare device
224033297|NCT01498289|DRUG|fluorouracil|400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
224033298|NCT01498289|DRUG|irinotecan hydrochloride|65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
223416207|NCT03045744|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
223416208|NCT06272318|OTHER|Blood Pressure Cuff, EKG, PPG|A blood pressure cuff, an EKG, and a PPG will be utilized to collect subject vitals.
223416209|NCT05959031|DEVICE|kTMP|a new non-invasive brain stimulation tool
223416210|NCT05959031|DEVICE|Sham kTMP|a new non-invasive brain stimulation tool with sham setting selected
223416211|NCT00593684|DEVICE|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
223416212|NCT05571475|OTHER|Simulated competition|During a competition, athletes will typically compete for a reward, against opponents and in the presence of others. This will be replicated in the laboratory.
223416213|NCT01808599|DRUG|Chlorambucil|
223416214|NCT01808599|DRUG|Rituximab i.v.|
224033299|NCT01498289|DRUG|leucovorin calcium|400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
224033300|NCT01498289|DRUG|oxaliplatin|85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
224033301|NCT03715309|DRUG|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
223416215|NCT01808599|DRUG|Rituximab s.c.|
223416216|NCT03554733|BEHAVIORAL|ReInventing Yourself after SCI|6-week, manualized, cognitive-behaviorally based group educational intervention
223416217|NCT03055312|DRUG|TPC|"Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 \& days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 \& days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 \& days 8) every 3 weeks"
223416218|NCT03055312|DRUG|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
223416219|NCT00078767|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy|12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
224033302|NCT00802009|DRUG|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
223416220|NCT00078767|DRUG|Sertraline Pill|12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
223416221|NCT00078767|DRUG|Placebo Oral Tablet|12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
223416222|NCT00653133|DEVICE|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
223560628|NCT05529264|OTHER|Language tasks|Participants will be asked to view pictures of actions or things and will be asked to name them. Participants may also be asked to read words or passages.
223739115|NCT06858514|OTHER|Virtual reality|Students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses.
224033303|NCT00802009|DRUG|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
224033304|NCT04242160|OTHER|Modified Clamshell Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
224033305|NCT04242160|OTHER|Left Anterolateral Thoracotomy|Participants received standardized training on performing a MCT and LAT. Participants then performed the procedures on a fresh human cadaver model.
224033306|NCT02755623|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
223416223|NCT00653133|DEVICE|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
223416224|NCT02644993|RADIATION|Proton therapy|
223416225|NCT00527293|PROCEDURE|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
223416226|NCT00527293|RADIATION|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
223416227|NCT00527293|RADIATION|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
223416228|NCT05918887|DEVICE|NJOY ACE commercial e-cigarette|"The NJOY ACE is the commercial version of the Standardized Research E-Cigarette (SREC), which was developed by NIDA with NJOY for research purposes.~Nicotine pods:~* Sealed, pre-filled, non-refillable~* 1.9 mL e-liquid with 5% w/w nicotine~* Approx 300 (280-330) puffs/pod~Nicotine liquid characteristics:~* Volume of liquid per pod 1.9 mL~* Active (nicotine USP 5% wt/wt)~* Propylene Glycol USP \& Vegetable Glycerin USP - PG/VG Ratio 0.77~* Lactic Acid USP~Battery characteristics:~* USB Rechargeable~* Storage Capacity \~ 400 mAh~* Approx 200 (3s) puffs / charge~* 300 charge cycles to \> 80% initial capacity~* Time to full charge 75 - 85 min~* Voltage / Temperature settings not user adjustable"
223560629|NCT05529264|OTHER|Visuospatial tasks|Participants will be asked to copy 3 dimensional designs or make judgements of angle size.
223739116|NCT06858514|OTHER|Escape room|Students will perform crossword puzzles, word hunt and matching activities related to subcutaneous injection practice.
224033307|NCT02755623|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
224033308|NCT02873507|OTHER|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
224033309|NCT04162223|BIOLOGICAL|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
224033310|NCT04162223|BIOLOGICAL|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
223416229|NCT05498441|DEVICE|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
223416230|NCT05498441|DRUG|Antipsychotics, mood stabilizers, etc.|During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
223416231|NCT02119793|DEVICE|YVOIRE contour|YVOIRE contour injection into the anteromedial malar region
223416232|NCT05898932|OTHER|Medical Management|Participants will be managing condition with medication
223416233|NCT05898932|OTHER|Surgical Management|Participants will be managing condition with a surgery
223416234|NCT04414969|DRUG|Anti-PD-1 antibody+Peg-Asparaginase+Chidamide|Anti-PD-1 antibody 200mg ivdrip d1, PEG-ASP 2500U/m2 im d1, Chidamide, 30mg, po, on d1，d5，d8，d12，d15，d19. The regimen was repeated every 3 weeks for 4 cycles followed by involved-field radiotherapy after got CR and PR (patients with efficacy of SD and PD withdrew from the study). Intensity-modulated radiation treatment was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 54-56 Gy. During the radiotherapy, the anti-PD-1 antibody is administrated (200mg ivdrip, every 3 weeks) for 2 cycles. After the completion of radiotherapy, the subsequent 2 cycles of anti-PD-1 antibody + Peg-Asparaginase + Chidamide are administrated. After the end of all the above induction treatments , anti-PD-1 antibody (200mg ivdrip, every 3 weeks for up to 9 cycles) is given as maintenance therapy for 6 months (the total cycles of anti-PD-1 antibody is 17）.
224136743|NCT03685552|OTHER|Prog: Purify-2|"Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
223416235|NCT01259362|PROCEDURE|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
223416236|NCT01259362|PROCEDURE|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
223416237|NCT02919423|DEVICE|transcranial magnetic stimulation|
223416238|NCT02282631|BEHAVIORAL|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
223739117|NCT06308653|DRUG|Psilocybin 25 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Psilocybin.
224033311|NCT01146626|DRUG|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
224033312|NCT01146626|DRUG|Peg+ Ribavirine|Peg+ Ribavirine
224033313|NCT03208322|OTHER|Non-Interventional|Non-Interventional
224033314|NCT04709822|BEHAVIORAL|Visuospatial Interference|"Two remote intervention sessions with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) alongside accompanying information.~Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions)."
224136744|NCT00502320|DRUG|Ramelteon|one 8 mg tablet at bed for up to 4 months
224136745|NCT00502320|DRUG|Placebo|one tablet at bedtime for up to 4 months
224136746|NCT00348842|PROCEDURE|Newcastle Virus|
224136747|NCT02692170|BIOLOGICAL|CVI-HBV-001|Investigational Product
223416239|NCT05749978|BEHAVIORAL|Asana adjustment|Adjust the operating table to 15° head height and foot low in advance. The patient is then slowly turned over from the transport table to the operating table and completed in the prone position. After the patient's hemodynamic stability is smooth, adjust the operating table to the level.
223416240|NCT04662281|DRUG|Placebo|LX9211 matching-placebo, tablets will be administered orally.
223416241|NCT04662281|DRUG|LX9211|LX9211, 200 mg, tablets will be administered orally.
223416242|NCT01011530|DRUG|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
223416243|NCT05908032|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
223416244|NCT05908032|BIOLOGICAL|Placebo|Placebo
223416245|NCT00082446|BIOLOGICAL|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
224033315|NCT00248690|DEVICE|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
224033316|NCT04174456|DIAGNOSTIC_TEST|FDG PET|baseline and 6-month follow-up FDG PET
224033317|NCT06261164|DEVICE|Cytosorb® and Oxiris® adsorbents|The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
224033318|NCT05635916|DRUG|Liposomal bupivacaine|Adductor canal block with injection of 10cc 13.3% liposomal bupivacaine combined with 10cc 0.50% bupivacaine within one hour following surgery
224033319|NCT05635916|DRUG|Bupivacaine|Adductor canal block with injection of 20cc 0.5% bupivacaine within one hour following surgery
224033320|NCT03661944|DIAGNOSTIC_TEST|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
224033321|NCT03267940|DRUG|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arms.
224136748|NCT02692170|BIOLOGICAL|Conventional Hepatitis B vaccine (20 μg)|Investigational Product
224299184|NCT01620619|PROCEDURE|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
223416246|NCT00082446|BIOLOGICAL|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10\^8 will be administered intramuscularly to Group F on day 0 and day 28.
223560630|NCT05529264|OTHER|Auditory Tasks|Participants will be presented with short, approximately 8-minute clips of music from various genres ( i.e. classical, country, rock, etc.) with an attention task (modified sustained attention to response task) nested within each trial. Participants will receive approximately 8 music stimuli and 1 control stimulus (pink noise) twice over the course of two testing sessions ( 90 mins each). Additionally, participants will be asked to answer questions about their hearing, music preferences/training, and certain demographic information (age, handedness, and language proficiency).
223560631|NCT05529264|PROCEDURE|Brain Stimulation|A brain stimulator will be used to understand new functions of the brain. Participants will be presented with pictures on a computer screen and may be asked to tell researchers what is seen or remembered by participants. As pictures are viewed by the participants, the brain stimulator may be activated, which would not be something that would be felt by an individual participant.
223560632|NCT05529264|OTHER|Social Emotional Task|Participants will be asked to view presented pictures and videos of people engaged in social interaction. Additionally, participants will be presented with the standardized tasks that are designed to help the researchers with understanding the nature of emotions. Some of these images may be emotionally disturbing. If participants are not comfortable viewing such images, they will be asked to refrain from participation in this study.
223416247|NCT00082446|BIOLOGICAL|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10\^7, 5x10\^7, 1x10\^8, 1x10\^8, respectively, on days 0 and day 28.
223416248|NCT00082446|OTHER|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
223416249|NCT00082446|OTHER|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
223416250|NCT06217237|DIAGNOSTIC_TEST|AD FDT DBL GROUP|All participants will undergo an MRI session. The MRI protocol will include the clinical diagnostic protocol defined within the Network and research sequences as specified above (T1 3D, DTI, FLAIR 3D, QSM).
223416251|NCT02708537|BIOLOGICAL|PRGF in candidates for sperm donors|PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
223416252|NCT01421628|OTHER|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
223416253|NCT02469688|DRUG|ASP4070|intramuscular or intradermal
223416254|NCT02469688|DRUG|Placebo|intramuscular or intradermal
223416255|NCT02819752|DRUG|Pembrolizumab|Pembrolizumab
223416256|NCT02819752|RADIATION|Radiotherapy|Radiotherapy - Standard Treatment
223416257|NCT02819752|DRUG|Chemotherapy|Chemotherapy - Standard Treatment
223416258|NCT04950270|BIOLOGICAL|Blood copeptin monitoring|Blood copeptin monitoring during the first 6 days of ICU stay with PRES
223416259|NCT04950270|OTHER|phone interview|Structured phone interview at 3 months to collect vital status and modified Rankin Scale score
223560633|NCT05529264|OTHER|Recording of facial expressions|Some participants may be asked permission to record the video of their facial expressions during performance of a research task. Generally, this will include only research tasks investigating brain representation of social/emotional information. Automated analysis of facial expression may be used in certain experiments to provide information on experience of emotional states such as happiness and sadness related to the images being presented.
223560634|NCT05529264|OTHER|Judgement/Impulsivity Task|Certain study participants may be enrolled into research tasks designed to activate regions important for judgment and impulse control. These tasks will present participants with choices of varying monetary rewards and ask them to make judgements to measure one's tendency to prefer immediate over delayed rewards.
223560635|NCT04975659|BEHAVIORAL|Placebo and Nocebo effect|Positive suggestion and words is used on Placebo group Negative suggestion and words is used on Nocebo group
223416260|NCT02718989|DEVICE|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
223416261|NCT02718989|DEVICE|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
223416262|NCT02718989|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224033322|NCT03267940|DRUG|CIS|CIS will be administered as per the schedule specified in the respective arms.
224033323|NCT03267940|DRUG|GEM|GEM will be administered as per the schedule specified in the respective arms.
224033324|NCT03267940|DRUG|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arms.
224033325|NCT01340638|DEVICE|cookgas mask|This group will be assigned to use cookgas mask
224033326|NCT01340638|DEVICE|LMA mask|LMA mask
224033327|NCT00388154|DRUG|Gemcitabine|900 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
224033328|NCT00388154|DRUG|Cisplatin|30 mg/m\^2 by vein over 1 hour on Day 1 and Day 8.
224033329|NCT02925013|PROCEDURE|Blood sampling|Blood sampling for lipid profile
224033330|NCT02925013|OTHER|Dietary- Normal western diet|Normal western diet
224033331|NCT01948908|DRUG|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
223416263|NCT02967328|OTHER|RP% Measurement by FCM as a Diagnostic Test for ITP|
223416264|NCT01736397|DRUG|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
223416265|NCT01736397|DRUG|Placebo|
223416266|NCT01604928|DRUG|YM178|Oral
223416267|NCT01604928|DRUG|tolterodine|Oral
223416268|NCT01604928|DRUG|Placebo|Oral
223416269|NCT03469128|BEHAVIORAL|Cognitive processing therapy|Psychological treatment for patients suffering from PTSD and SUD symptoms.
224033332|NCT06153927|DIAGNOSTIC_TEST|CT-FFR|CT-FFR was calculated using HeartMedi+ 1.0 according to the manufacturer's instructions
223416270|NCT03469128|DRUG|Sertraline|Sertraline for the treatment of post-traumatic stress and SU disorders
223416271|NCT03469128|OTHER|Placebo Control|Placebo Control
224136749|NCT03685045|PROCEDURE|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
223416272|NCT06685497|DEVICE|Mobile application follow-up|Colorectal cancer patients enrolled in the 'Internet Plus' post-treatment management platform use the digital medical quality management system based on the 'COLORECTUM+' model for quality evaluation and continuous improvement. The platform integrates AI, using natural language processing and machine learning to analyze patient-reported symptoms, automatically assess severity, and generate alerts. Alerts are classified as yellow, orange, or red. Yellow indicates mild issues with self-care recommendations; consecutive yellow alerts prompt doctor contact within 24 hours. Orange indicates moderate severity, requiring doctor intervention within 24 hours. Red alerts signify serious symptoms or high-risk medication errors, prompting immediate notification of the doctor and emergency team. The system monitors symptom changes and updates alerts to support treatment optimization.
223416273|NCT05567211|OTHER|Free use of the virtual platform.|Access to the virtual platform + general healthy eating and physical activity recommendations. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
223416274|NCT05567211|OTHER|Personalized nutritional planning based on the Mediterranean diet + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning based on the Mediterranean diet + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
223416275|NCT05567211|OTHER|Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.|Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
223416276|NCT06084845|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223416277|NCT06084845|DRUG|Carboplatin|Given IV
223416278|NCT06084845|PROCEDURE|Chest Radiography|Undergo chest x-ray
223416279|NCT06084845|DRUG|Cisplatin|Given IV
223416280|NCT06084845|PROCEDURE|Computed Tomography|Undergo CT and/or PET-CT
223416281|NCT06084845|RADIATION|Image Guided Radiation Therapy|Undergo IGRT
223416282|NCT06084845|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223416283|NCT06084845|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224033333|NCT04844801|PROCEDURE|Risk control strategy|"* Magnesium sulfate 2g intravenous bolus over 20 mn (if creatinine clearance \>30 mL/min)~* Control of the modifiable NOSVA risk factors: hypovolemia, sepsis, metabolic disorders (e.g., hypokalemia, hyponatremia), acidosis, hypoxia, excess cardiac inotropism of vasopressors, central venous catheter malposition, hyperthermia."
223560636|NCT02325570|DEVICE|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
223560637|NCT02325570|PROCEDURE|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
223560638|NCT04405999|DRUG|Bromhexine Hydrochloride|Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
223560639|NCT05376059|BEHAVIORAL|How Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.
223739118|NCT06308653|DRUG|Inactive Placebo|The inactive placebo is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of Microcrystalline Cellulose (MCC). The MCC is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use.
223560640|NCT05376059|BEHAVIORAL|How and Why Nudge|We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.
223560641|NCT05376059|BEHAVIORAL|Incentive|Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
223560642|NCT04772352|DRUG|febuxostat treatment|According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
223560643|NCT04772352|BEHAVIORAL|lifestyle intervention|According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
223560644|NCT04757480|PROCEDURE|Thoracolumbar Interfascial Plane Block (TLIP)|(20ml) (plain bupivacaine 0.25% on each side toward the LG-MF interface.
223416284|NCT06084845|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223739119|NCT06308653|DRUG|Psilocybin 5 mg|The Psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active comparator is encapsulated within a hydroxypropyl methylcellulose (HPMC) capsule and contains 5 mg of Psilocybin.
223739120|NCT06308653|BEHAVIORAL|Psychosocial Support|Psychosocial Support, including psychoeducation, begins after the Double-blind Period and continues throughout the 1-year Follow-up Period in order to enhance participant safety and maximize retention for the entire trial duration.
224033334|NCT04844801|PROCEDURE|Rate control strategy:|"* Risk-control as described above~* Low dose amiodarone:~  * Intravenous bolus (day-1): 4 mg/kg over 1hr (maximum 300 mg i.e. 2 IVL vials over 1 hour )~ * Enteral dose maintenance (day-1 to day-7): 200mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)"
223416285|NCT06084845|DRUG|Xevinapant|Given PO
223416286|NCT02288845|DRUG|ITI-007|
223416287|NCT06133751|DRUG|black chokeberry (Aronia melanocarpa)|Black chokeberry capsules standardized for anthocyanin compounds
223416288|NCT06133751|DRUG|Placebo|Chokeberry fiber placebo capsules
223416289|NCT03603145|PROCEDURE|Immediate insertion|Immediate insertion of intrauterine contraception within 48 hours of medical abortion
223416290|NCT05284799|BIOLOGICAL|OVX836 480µg|One single administration intramuscularly at Day 1
223416291|NCT05284799|BIOLOGICAL|Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)|One single administration intramuscularly at Day 1
223560645|NCT04757480|PROCEDURE|Bilateral Erector Spinae plane Block (ESB)|Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
223560646|NCT00152828|DRUG|Celecoxib|
224136750|NCT01887782|DEVICE|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
224298474|NCT05005871|OTHER|Quadratus lumborum block after C-section surgery as postoperative pain management|To manage postoperative pain, the subjects will be allocated to either QLB or QLTB group to receive the respective intervention.
223416292|NCT05284799|BIOLOGICAL|Placebo|One single administration intramuscularly at Day 1
223416293|NCT00030394|DRUG|imatinib mesylate|Given orally
223416294|NCT00030394|OTHER|laboratory biomarker analysis|Correlative studies
223416295|NCT00030394|OTHER|pharmacological study|Correlative studies
223416296|NCT04115475|DEVICE|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components
224033335|NCT04844801|PROCEDURE|Rhythm control strategy:|"* Risk control as described above~* High dose amiodarone:~  * Intravenous bolus (day-1): 7 mg/kg over 1hr 1 hour (maximum 600 mg i.e. 4 IVL vials over 1 hour); followed by continuous intravenous maintenance: for a total of 1200 mg over the first 24 hrs (infusion pump)~ * Enteral dose maintenance Day-2 and day-3: 400 mg three times a day (720 mg continuous intravenous over 24 hrs if enteral route is unavailable).~Day-4 to day-7: 200 mg once a day (150 mg intravenous over 1hr if enteral route is unavailable)~\- Electrical cardioversion (only in patients intubated on mechanical ventilation) if:~* NOSVA persists after initial bolus of amiodarone AND norepinephrine base (or epinephrine base) doses \> 0.3 µg/kg/min;~* NOSVA persists more than 6 hrs after initial amiodarone bolus."
224033336|NCT00003232|DRUG|clodronate disodium|
224033337|NCT00003232|DRUG|mitoxantrone hydrochloride|
224033338|NCT00003232|DRUG|prednisone|
224033339|NCT00003232|PROCEDURE|quality-of-life assessment|
224033340|NCT03849001|BEHAVIORAL|Exercise Conditions|Light Exercise
224033341|NCT03849001|BEHAVIORAL|Exercise Conditions|Moderate Exercise
224033342|NCT03849001|BEHAVIORAL|Exercise Conditions|Vigorous Exercise
224033343|NCT03849001|BEHAVIORAL|Exercise Conditions|Seated Rest
224033344|NCT03845569|OTHER|Dietary protein intake reduction|Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
224033345|NCT03845569|OTHER|Three day Controlled Diet|Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
224033346|NCT00658099|DRUG|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
224033347|NCT00658099|DRUG|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
224033348|NCT04603950|PROCEDURE|CACB+IPACK|continue adductor canal block plus Infiltration between the Popliteal Artery and Capsule of the Knee
224033349|NCT04603950|PROCEDURE|CACB|continue adductor canal block
224033350|NCT04506268|BEHAVIORAL|Opt-out Recruitment Email|Behaviorally informed, opt-out framed recruitment email
224298475|NCT02619877|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
223416297|NCT01728818|DRUG|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
223416298|NCT01728818|DRUG|Afatinib|40mg flat dose, po, once daily
223416299|NCT01728818|DRUG|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
223416300|NCT05088603|DEVICE|Clear Mask|The clear mask has a 4.75 x 1.35 inch clear window that allows for clear visibility of the mouth.
223416301|NCT00122993|BEHAVIORAL|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
223416302|NCT00122993|BEHAVIORAL|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
223416303|NCT00122993|BEHAVIORAL|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
223416304|NCT05377502|DIAGNOSTIC_TEST|OGTT|OGTT
223416305|NCT03619239|DRUG|GX-I7|During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
223416306|NCT01847339|DRUG|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
223416307|NCT01847339|OTHER|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
223416308|NCT01024868|DRUG|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
223416309|NCT00730730|DEVICE|Complete SE Iliac Stent|Iliac stenting
223416310|NCT00730730|DEVICE|Complete SE Iliac Stent|Self-expanding stent
223416311|NCT00665860|DIETARY_SUPPLEMENT|Placebo|Three pills per day for two years
223416312|NCT00665860|DIETARY_SUPPLEMENT|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
223416313|NCT00665860|DIETARY_SUPPLEMENT|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
223416314|NCT01841762|DRUG|Macitentan|Macitentan tablet, dose of 10 mg, once daily
224033351|NCT04506268|BEHAVIORAL|Opt-in Recruitment Email|Standard, opt-in framed recruitment email
224033352|NCT03756246|BIOLOGICAL|Influenza Vaccine|The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
224033353|NCT00066989|DRUG|Staphylococcus aureus Immune Globulin (Human) 5%|
224033354|NCT03140774|BIOLOGICAL|Previously exposed to Ebola vaccine|Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
224033355|NCT02730741|DRUG|Lcr restituo® sachet|symptomatic treatment of diarrhoea
224033356|NCT02730741|DRUG|Placebo|
224033357|NCT03556241|DEVICE|Case management|Case management consists keeping patient's current pacemaker mode during surgery
224298476|NCT02619877|OTHER|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
224298477|NCT04976998|DIAGNOSTIC_TEST|imaging|imaging by ultrasonography and nerve conduction studies will be done for both grups
224298478|NCT00132093|DRUG|Eplerenone|
223416315|NCT01783028|BEHAVIORAL|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
223416316|NCT06683417|DEVICE|Vestibular Rehabilitation Aid|"The tablet-based VestAid system was developed to repair, restore and maintain vestibular-ocular function that is impaired in patients post-mTBI.~Each participant\&amp;#39;s treating physical therapist will develop their own personalized exercise prescription. The physical therapist will be asked to recommend that the patients complete a home exercise program at least 2-3 times per day for 6 weeks. The exercise prescription will be placed on the VestAid by the physical therapist for the patient to follow. The patient is not able to modify the exercise, only the physical therapist can modify the exercises. Exercises will be modified based on patient\&amp;#39;s response and symptom reports. The physical therapist and study coordinator will receive an alert on the VestAid online dashboard if the patient\&amp;#39;s symptoms are greater than or equal to 8/10."
223416317|NCT06683417|OTHER|Standard of care vestibular rehabilitation|Vestibular rehabilitation to include gaze stabilization exercises, optokinetic training, smooth pursuits and saccades
223416318|NCT03576690|BIOLOGICAL|REGN3470-3471-3479|
223416319|NCT03843749|DRUG|Pyrotinib|Pyrotinib in Combination With Trastuzumab
223416320|NCT06546956|BEHAVIORAL|Integrative Breathwork Intervention|GRMT has three core components: respiratory regulation (i.e., sustained conscious connected breathing pattern into the upper chest where there is no pause between inhale and exhale), mindfulness of somatic sensations while breathing (i.e., interoceptive awareness with acceptance), and relaxation of physical tension. These components are the primary focus in every breathwork session. The intervention is delivered 1-on-1 in-person with a trained facilitator. Participants lay supine throughout the 60 minute session. The facilitator observes the participant's breathing pattern and guides the participant to apply the three core components. Each session ends with spontaneous, relaxed breathing and an opportunity to briefly share what happened during the session.
223416321|NCT06665867|OTHER|Video consultation|Participants will have their follow-up consultation with the physician via video. The consultation takes place via the participant's/parent's own device.
223416322|NCT06665867|OTHER|Face-to-face consultation|The follow-up consultation with the physician will take place at the hospital.
223416323|NCT03260244|PROCEDURE|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.~Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
223416324|NCT06526143|BEHAVIORAL|M2VA Pain Care Pathway (M2VAPCP)|M2VAPCP is a manualized Motivational Interviewing-based intervention, designed to motivate Veterans to engage in multimodal nonpharmacological pain care and reduce substance misuse when present. The first session includes empathic exploration of the Veteran's MSD, pain experiences, and motivations for pain care; psychoeducation about the benefits of multimodal pain care and judicious use of non-opioid medications; information about available pain management services and treatments for conditions that might exacerbate chronic pain; screening for substance misuse, including prescription medications, and motivational enhancement to change behaviors related to positive screens; and for those interested, making plans to achieve these goals. Over 12 weeks, case managers will hold up to two additional sessions with participants to check on their goal achievement and continue motivational enhancement for multimodal pain treatment and reduced substance misuse.
223416325|NCT06526143|BEHAVIORAL|Implementation Facilitation|"Implementation facilitation teams consisting of internal and external facilitators will conduct activities for two purposes:~1. to build working relationships within the pain and addiction care pathways to achieve the shared goal of implementing high-quality M2VAPCP; and~2. to promote constructive, problem-solving oriented communication based on indicators of M2VAPCP implementation progress.~Activities will include Virtual Site Visits, all-side facilitation team meetings, local facilitation team meetings, M2VAPCP consultation groups, learning collaboratives, case identification reports and audit and feedback."
223416326|NCT05967832|OTHER|7T MRI|Patients and healthy volunteers will have a 7T MRI
223416327|NCT05445232|DRUG|LY3437943|Administered SC.
223416328|NCT05445232|DRUG|Midazolam|Administered orally.
223416329|NCT05445232|DRUG|Warfarin|Administered orally.
223416330|NCT05445232|DRUG|Caffeine|Administered orally.
223416331|NCT02954692|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
223416332|NCT02954692|DRUG|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223416333|NCT02954692|DRUG|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
223416334|NCT02954692|DRUG|meglitinides|"Pharmaceutical form: tablet~Route of administration: oral"
224033358|NCT04679688|OTHER|descriptive|Those who apply for IVF treatment and have an antral follicle number of 4-10 will be included in the treatment. The reason for including patients with this number of antral follicles in the study is to determine the follicle locations and to determine each growing follicle separately on the day of hCG and egg collection.
223416335|NCT02954692|DRUG|thiazolidinediones|"Pharmaceutical form: tablet~Route of administration: oral"
223416336|NCT02954692|DRUG|alpha-glucosidase inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
223416337|NCT02954692|DRUG|GLP1 Receptor Agonist|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
224033359|NCT00381303|DRUG|darunavir|600mg bid for 48 wks
224033360|NCT00381303|DRUG|ritonavir|100mg bid for 48 wks
223416338|NCT02954692|DRUG|Dipeptidyl peptidase-IV (DPP-IV) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
224033361|NCT06046963|DRUG|Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion|Sintilimab: 200 mg, intravenous infusion, d1, q3w; Nab-paclitaxel: 100 mg/m2 intraperitoneal infusion, d1, q3w; S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w; Oxaliplatin: 130 mg/m2, intravenous infusion, d1, q3w; The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects wil continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of informed Consent Form, or termination in the investigator's judgment.
223416339|NCT02954692|DRUG|Sodium-glucose transport-2 (SGLT-2) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
223416340|NCT03815799|PROCEDURE|Bilateral Erector Spinae Block|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
223416341|NCT03815799|OTHER|Control|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
223416342|NCT02828046|BIOLOGICAL|M281|
223416343|NCT02828046|OTHER|Placebo|
223416344|NCT03648437|DRUG|Paracetamol 10Mg/mL|Experimental drug
223416345|NCT03648437|DRUG|0.45% Sodium Chloride|Placebo comparator
223416346|NCT03648437|DRUG|Ibuprofen|Standard therapy
223416347|NCT03648437|DRUG|Indomethacin|Standard therapy
223416348|NCT01760915|OTHER|NC100182 Hyperpolarized 3He|Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
223416349|NCT03170531|DIAGNOSTIC_TEST|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
223416350|NCT03170531|DIAGNOSTIC_TEST|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
223416351|NCT04299061|DIAGNOSTIC_TEST|International Physical Activity Questionnaire|"This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting. Walking = 3.3 METs Moderate Intensity = 4.0 METs Vigorous Intensity = 8.0 METs Total MET-minutes/week = Walk (METs\*min\*days) + Mod (METs\*min\*days) + Vig (METs\*min\*days)~1\. Low: • No activity is reported OR • Some activity is reported but not enough to meet Categories 2 or 3. 2. Moderate: • 3 or more days of vigorous activity of at least 20 minutes per day OR • 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR • 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum of at least 600 MET-minutes/week. 3. High: • Vigorous-intensity activity on at least 3 days and accumulating at least 1500 MET-minutes/week"
223416352|NCT04299061|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index|"The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep. It differentiates poor from good sleep by measuring seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month.The client self rates each of these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. A global sum of 5or greater indicates a poor sleeper."
224033362|NCT06046963|OTHER|Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected|"Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected at diferent time points (if feasible, according to the samples taken in the standard practice):~at Baseline; After 1-2 cycles of treatment; at the time of the progression or recurrence, if applicable."
224033363|NCT00333385|DRUG|ceftazidime|
224033364|NCT00167960|DRUG|Piperacillin/tazobactam and other β-lactam/β-lactamase|
224033365|NCT03536260|DEVICE|Implant with NanoBone graft|Using of NanoBone graft to fill the gap in the socket after immediate implant placement
223416353|NCT04299061|OTHER|Physical Activity Awareness Questionnaire - prepared by the researchers|It consists of 13 questions to assess the physical activity level awareness of students. The questionnaire was prepared by the researchers therefore it does not have a validation.
224033366|NCT03536260|DEVICE|Implant with Xenograft|Using of Xenograft to fill the gap in the socket after immediate implant placement
224033367|NCT01800825|DRUG|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
224033368|NCT01800825|DRUG|Placebo|This will be an identical placebo comparator made of starch.
224033369|NCT01211522|DRUG|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
224033370|NCT01211522|DRUG|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
224033371|NCT01211522|DRUG|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
224033372|NCT02441062|DRUG|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
224033373|NCT05622851|DEVICE|Restylane Contour|Hyaluronic Acid dermal filler
224033374|NCT05622851|DEVICE|Juvederm Voluma|Hyaluronic Acid dermal filler
223416354|NCT04299061|DIAGNOSTIC_TEST|Perceived Stress Scale|The Perceived Stress Scale (PSS) is a classic stress assessment instrument that helps understand how different situations affect feelings and perceived stress. The questions in this scale ask about feelings and thoughts during the last month. It consists of 14 questions.
223416355|NCT02207803|BEHAVIORAL|Transition Assistance Program|
224033375|NCT03322748|OTHER|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
223416356|NCT05993897|DRUG|Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor|10 mg of Dapagliflozin orally once daily
223416357|NCT05993897|DRUG|Rhythm control and anticoagulation|"In acute stage: Cardioversion with D.C shock if haemodynamically unstable, after failure of pharmacological cardioversion or participant preference.~or pharmacological cardioversion with either IV cordarone in structurally abnormal heart (150mg over 10 minutes followed by1 mg/min infusion for 6 hours followed by 0.5 mg/min not exceeding 2.4 grams over 24 hours till restoration of sinus Rhythm. Then maintenance dose of 200 mg tab orally every 8 hours for 3 weeks then 200 mg tab orally once per day.~or Propafenone (Rytmonorm) 600 mg single oral dose in structurally normal heart then maintenance dose of 150mg tab orally every 8 hours.~\+ Rivaroxaban 20mg orally once daily if CHA2DS2 VASc score 1 or more for males and 2 or more for females."
223416358|NCT01828983|BEHAVIORAL|Telephone support groups|
223416359|NCT01828983|OTHER|Education webinars|
223416360|NCT01253551|DRUG|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
223560647|NCT02989818|OTHER|Endoscopic Submucosal Dissection|This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
223560648|NCT03668470|DRUG|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
224033376|NCT03322748|OTHER|Usual physical therapy|Usual physical therapy
224033377|NCT01777269|DRUG|Dutasteride plus tamsulosin|Take 1 capsule daily
224136751|NCT01887782|DEVICE|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
224033378|NCT01777269|DRUG|Placebo|Take one capsule daily
224033379|NCT04309344|DEVICE|WEREWOLF COBLATION System|The bipolar radiofrequency-based chondroplasty device is used in the COBLATION mode (yellow) with The WEREWOLF system and the wand FLOW 50 in Lo mode (low) which are approved by the FDA for chondroplasty and debridement of the articular cartilage; fibrillations were removed and the surface was smoothed. This low energy and low suction setting minimizes damage to healthy chondrocytes surrounding and is therefore the preferred setting for the removal of articular cartilage.
224033380|NCT04309344|PROCEDURE|control|mechanical debridement
224033381|NCT00282282|DRUG|tacrolimus|Given orally just prior to and following stem cell transplant
223416361|NCT01253551|DRUG|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
223416362|NCT00522106|BEHAVIORAL|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
224033382|NCT00282282|DRUG|sirolimus|Given orally just prior to and following stem cell transplant
224033383|NCT00282282|DRUG|fludarabine|Given once daily over 30 minutes for 4 days
223416363|NCT00522106|OTHER|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
223416364|NCT06048562|DIAGNOSTIC_TEST|echocardiography|evaluation idm for cardiomyopathy by echo
223416365|NCT04015089|DIETARY_SUPPLEMENT|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
223416366|NCT04015089|DIETARY_SUPPLEMENT|Standard formula (SF)|Infant formula with intact protein
223416367|NCT01575652|OTHER|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
223560649|NCT03668470|DRUG|Placebo|Placebo: one injection per week during 24 weeks
223560650|NCT05171400|PROCEDURE|Palatal Wound|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive 4.0 silk sutures.
223560651|NCT05171400|DEVICE|Palatal Wound treated with Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film and 4.0 silk sutures.
224033384|NCT00282282|DRUG|busulfex|Given intravenously over 3 hours for 4 days
224136752|NCT04011124|DRUG|Fluzoparib|single dose on Day 1 and Day 12
224136753|NCT04011124|DRUG|Rifampicin|QD on Day 5-14 for 10 days
224136754|NCT05911815|RADIATION|hysterosalpingography|hysterosalpingogram (HSG) is an X-ray visualization of the lumen of the uterus and fallopian tubes, which can detect abnormalities including blockage, polyps, and salinities
224136755|NCT04761172|PROCEDURE|Intraoperative near-infrared fluorescence imaging using indocyaninegreen|ICG administration before/during surgery and using near-infrared fluorescence imaging for intra-operative detection and identification of GISTs
224136756|NCT06419647|BEHAVIORAL|Intervention|Daily mood tracking tasks
224298479|NCT05824247|DEVICE|68Ga-FAPI-PET-CT|a new technology that using Fibroblast activation protein （FAP）inhibitor as the tracer of PET-CT
224298480|NCT00506129|DRUG|Fludarabine|25 mg/m\^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
224033385|NCT04825483|OTHER|Weight loss|"Participants will receive resources to support the weight loss program including a recipe book, activities book and how-to guide. The diet program comprises two phases: 1) intensive weight loss through a ketogenic Very Low Calorie Diet (VLCD), including meal replacements for two meals/day, and 2) transition from ketogenic VLCD onto a longer-term eating plan for weight maintenance. Meal replacements will be provided free of charge for up to 6 months. Participants will be encouraged to lose at least 10% body weight."
223416368|NCT01575652|OTHER|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
223416369|NCT05061277|DRUG|Recifercept|A lyophilized powder for solution for injection
223416370|NCT03473366|DEVICE|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
223416371|NCT03473366|DEVICE|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
223416372|NCT00870636|DRUG|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
223416373|NCT03932175|BEHAVIORAL|Intervention group|Behaviorial intervention on non-invasive ventilation use and adherence alongside lifestyle changes recommendations supported by an mHealth tool (MyPathway app)
223416374|NCT01071980|OTHER|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
223416375|NCT02155673|DRUG|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
223416376|NCT06663280|DEVICE|Digital health assistant ADELE|The digital health assistant ADELE Blood Pressure A0007 (ADELE for short) improves the daily lives of patients with high blood pressure and enhances patient care. Participants in the intervention group were provided with ADELE to use during the study period for voice-based recording, interpretation and classification of their vital signs and body conditions.
223416377|NCT03528369|DRUG|CGS-200-1|CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.
223416378|NCT03528369|DRUG|CGS-200-5|CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 5% for this study.
223416379|NCT03528369|DRUG|CGS-200 Vehicle|CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
223416380|NCT02162719|DRUG|Ipatasertib|Participants received ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
223416381|NCT02162719|DRUG|Paclitaxel|Participants received paclitaxel 80 milligrams per square meter (mg/m\^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
223416382|NCT02162719|DRUG|Placebo|Participants received oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
223416383|NCT00004875|DRUG|enoxaparin|
223416384|NCT00004875|DRUG|heparin|
223416385|NCT06667947|PROCEDURE|caudal block|For the caudal block, a caudal needle was used by the same anesthesiologist after the patients were placed in the left lateral decubitus position.
223739121|NCT06868329|OTHER|Superficial moist heat|Twenty minutes of automatic moist hot pack (Besmed© BE-267, Taiwan) of suitable size was used to apply superficial heat. The heat level was adjusted to the medium level. While the moist environment was assured by placing a moist sponge layer between the pack and its cotton outer coverage. The duration was calculated after 8 minutes of warming up (when the temperature reaches its maximum level). The patient-reported sensation should be moderate warmth. A thermal sensation test using two test tubes was performed before applying heat therapy to avoid any adverse effects
224136757|NCT05334680|DEVICE|ANNE Sensor|The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
223416386|NCT06664983|DRUG|TPC chemotherapy|The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
223416387|NCT06664983|DRUG|cadonilimab combined TPC chemotherapy|Cadonilimab was intravenously given at dose of 10 mg/kg on day 1. The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle
223416388|NCT01872598|DRUG|Masitinib|
223416389|NCT01872598|DRUG|Placebo|
223416390|NCT01872598|DRUG|Standard of care|stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.
223416391|NCT06666647|PROCEDURE|Treatment by ambulance or helicopter services with response times|Prehospital treatment by ambulance and/or helicopter services personnel of patients in acute conditions
223416392|NCT05431530|PROCEDURE|Cytoreductive surgery|Cytoreductive surgery including resection of tumors involving rectosigmoid colon.
223416393|NCT06666374|BEHAVIORAL|OHL program|This program used OHL as its core structure and incorporated elements of experiential learning and self-efficacy to enhance patient engagement and understanding. The program comprised seven steps designed to guide patients through key aspects of oral health care, enabling them to progressively build their skills and confidence. These steps included personalized education on oral health, hands-on practice of proper oral hygiene techniques, self-assessment exercises, and strategies for overcoming barriers to good oral health.
223416394|NCT06666374|BEHAVIORAL|Traditional program|Program primarily focused on providing information without the OHL components, self-efficacy strategies, or the interactive elements of the intervention program.
223416395|NCT02042326|DRUG|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
224033386|NCT04825483|OTHER|Exercise|"Participants will receive resources to facilitate the physiotherapy management plan, including information about the video-conference platform, osteoarthritis information, an exercise plan/log book and a booklet of possible exercises. The physiotherapist consultations include a structured, progressive exercise and physical activity plan. Participants will be given exercise resistance bands and a ankle weight for home exercises.~Physiotherapists will choose from a list of exercises, aiming to prescribe 5-6 at once. Intensity is determined using a modified Rating of Perceived Exertion (RPE) scale, where it should feel hard to very hard to perform a full set of each exercises. Participants are encouraged to complete exercises three times per week. Physiotherapists encourage the participant to increase their general and incidental levels of physical/aerobic activity based on their individual needs and goals, as well as their current level of activity."
223416396|NCT00757458|DRUG|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
223560652|NCT05171400|DEVICE|Palatal Wound treated with Insulin-loaded Silk Fibroin Film|With the goal to harvest the free gingival graft (FGG), an 8mm diameter scalpel will be used to ensure standardized wounds. Thereafter, a 2-mm thick FGG will be removed. The wound area will receive a silk fibroin film loaded with insulin and 4.0 silk sutures.
223560653|NCT00399217|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) system|
223560654|NCT00399217|DEVICE|ICD|
223560655|NCT03309033|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223560656|NCT03309033|OTHER|Questionnaire Administration|Complete questionnaire
223560657|NCT01830283|BIOLOGICAL|varicella vaccine|The providers would get varicella vaccine
223560658|NCT05851079|DIAGNOSTIC_TEST|TCT test|These tests were performed on cervical exfoliated cells.
223739122|NCT06868329|OTHER|Hamstring and back muscles stretching|Patients received manual passive stretch for the hamstring and lower back muscles. Three repetitions per session with every repetition sustained for 30 s. The patient assumed a long sitting position with both knees in full extension and feet together. The patient was then asked to bend forward from the hips to reach the furthest point towards the feet. The therapist applied over pressure by pressing hands on the patient's upper back and pushing forward.
223739123|NCT06868329|OTHER|posterior pelvic tilting exercises regular procedures|Patients will be asked to assume the supine position with both knees semi-flexed. A small billow will be placed under the low back, another billow will be placed under the flexed knees for comfort. The patient will be asked to tuck the abdominal muscles inward and press with the low back on the underlying billow and hold for six seconds, then relax. after a few seconds of rest, the patient should repeat this procedure for 3 sets X 10 repetitions per session during the first 2 weeks. the number of sets will be increased according to the adaptation of each patient and his/her fatigue threshold.
224033387|NCT05709015|OTHER|Neutral electrolyzed water|Use of mouthwash containing neutral electrolyzed water twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
224033388|NCT05709015|DRUG|Placebo|Use of mouthwash containing placebo twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
224033389|NCT05709015|DRUG|Chlorhexidine digluconate|Use of mouthwash containing chlorhexidine digluconate twice daily for 4 consecutive days instead of tooth brushing and usage of interdental cleaning devices.
224136758|NCT00195767|DRUG|divalproex sodium|
223416397|NCT00757458|OTHER|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
223416398|NCT00757458|OTHER|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
223416399|NCT00757458|OTHER|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
223416400|NCT05019196|DEVICE|GE 3.0T MRI|using GE 3.0T MRI to obtain anatomical and functional MR images and DTI images
223416401|NCT00697086|DRUG|Dronedarone (SR33589)|
223416402|NCT00697086|DRUG|Placebo|
223416403|NCT02796066|DRUG|Vehicle|Applied once a day
223560659|NCT05851079|DIAGNOSTIC_TEST|Vaginoscopy|To obtain the results of the patient's pathology report.
223560660|NCT05851079|DIAGNOSTIC_TEST|High throughput HPV typing and integration detection methods|This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).
223560661|NCT05851079|DIAGNOSTIC_TEST|Cobas HPV test|To obtain HPV typing results.
223560662|NCT03851328|OTHER|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
223560663|NCT00700882|DRUG|dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
223560664|NCT00683930|DRUG|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
223560665|NCT00683930|DRUG|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
223560666|NCT00683930|DRUG|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
223560667|NCT04933045|DEVICE|Arthrex InternalBrace|Placement of Arthrex InternalBrace for anatomic distal tibiofibular ligament augmentation to stabilize the ankle syndesmosis during surgery.
223560668|NCT02733770|PROCEDURE|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
223560669|NCT02733770|PROCEDURE|Laparoscopic mini gastric bypass|Doppler ultrasound.
223560670|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose L|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223560671|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose A|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223560672|NCT06134648|BIOLOGICAL|RSV/hMPV vaccine candidate Dose B|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223560673|NCT06134648|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223416404|NCT02796066|DRUG|TSN2898|Applied once a day
223416405|NCT02796066|DRUG|TSN2898|Applied once a day
223416406|NCT02796066|DRUG|TSN2898|Applied once a day
223416407|NCT05201963|PROCEDURE|Serratus Anterior Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).
223416408|NCT05201963|PROCEDURE|Erector Spinae Plane Block|Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
223416409|NCT02490787|DRUG|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
223416410|NCT02490787|DRUG|placebo|Administered subcutaneously (s.c., under the skin)
223416411|NCT04057547|DRUG|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
223416412|NCT06320236|DIAGNOSTIC_TEST|Adjust-Unlikely|"Pulmonary embolism will be excluded during emergency department assessment by the combination of:~1. 'Pulmonary embolism is the most likely diagnosis' as per the treating physician AND a D-dimer result \< 500 ug/L fibrinogen equivalent units;~2. 'Pulmonary embolism is not the most likely diagnosis' AND D-dimer \< age-adjusted threshold; or,~3. A negative computed tomography scan, planar ventilation perfusion scan or ventilation perfusion-SPECT.~Emergency departments will use their local laboratory D-dimer assay."
223560674|NCT04154293|DRUG|Isotretinoin|Topical Isotretinoin ointment
223416413|NCT01311375|DIETARY_SUPPLEMENT|w3 supplement in SCI|"supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group"
223416414|NCT01311375|OTHER|placebo|placebo+ capsule CA-D
223416415|NCT03201770|DRUG|pyronaridine artesunate|Antimalarial treatment
223416416|NCT04216199|DEVICE|Point of care Ultrasound|Point of care Ultrasound
223560675|NCT04154293|OTHER|Vehicle|Topical Vehicle Ointment
224033390|NCT01966471|DRUG|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
224033391|NCT01966471|DRUG|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
224033392|NCT01966471|DRUG|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
224033393|NCT01966471|DRUG|Paclitaxel|IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
224033394|NCT01966471|DRUG|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
224033395|NCT01966471|DRUG|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
224033396|NCT01966471|DRUG|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
224033397|NCT01966471|DRUG|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
223416417|NCT05473572|BEHAVIORAL|Fluency shaping exercises|Training for prolonged speech, easy onset, light contact and abdominal breathing moving from the level of single words till using short sentences describing pictures
223416418|NCT01728662|PROCEDURE|ELVR Procedure|Lung Volume Reduction Procedure
223560676|NCT04731298|DRUG|Emapalumab|"Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first."
224033398|NCT01966471|DRUG|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
224033399|NCT02463565|OTHER|no intervention|
224033400|NCT00095654|DRUG|Ramipril|
223416419|NCT00276991|DRUG|"Kallunk oxide (Immunotherapy) "|"The study was assigned only one Arm \>450 cu/mm\^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum."
223560677|NCT02387333|PROCEDURE|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
223416420|NCT03555565|DRUG|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
223416421|NCT00532194|DRUG|cediranib|Once-daily oral tablet starting dose 20mg
223416422|NCT00308594|DRUG|Dexamethasone|
223416423|NCT02838719|DRUG|Perineural Dexamethasone acetate|
223416424|NCT02838719|DRUG|Intravenous dexamethasone acetate|
223560678|NCT02387333|PROCEDURE|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
223560679|NCT01208961|DRUG|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
223416425|NCT01603745|DRUG|Zoely|1 pill every day
223560680|NCT01208961|DRUG|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
224033401|NCT00095654|DRUG|Rosiglitazone|
224033402|NCT03336996|BIOLOGICAL|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
223416426|NCT01603745|DRUG|Yasmin|1 pill every day
223416427|NCT05793879|BEHAVIORAL|Video 360|Patients will undergo 12 sessions, 3 per weeks, 4 weeks
223416428|NCT05793879|BEHAVIORAL|Standard videos|Patients will undergo 12 sessions, 3 per weeks, 4 weeks
223416429|NCT04471233|OTHER|Multimodal analgesia including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.
223416430|NCT04471233|OTHER|Multimodal analgesia not including pregabalin|Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.
223416431|NCT02096757|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
223416432|NCT02096757|OTHER|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
223416433|NCT06317194|DEVICE|kTMP|A new non-invasive brain stimulation tool
223560681|NCT00879151|BEHAVIORAL|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
223560682|NCT00879151|BEHAVIORAL|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
224033403|NCT03336996|PROCEDURE|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
224033404|NCT05000892|DRUG|Sintilimab , Carboplatin, Nab-paclitaxel|Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
224136759|NCT03737422|DIETARY_SUPPLEMENT|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
224136760|NCT03737422|OTHER|control|no supplementation
224136761|NCT00838006|DEVICE|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
223416434|NCT06317194|DEVICE|Sham kTMP|A new non-invasive brain stimulation tool with sham setting selected
223416435|NCT04537117|OTHER|Questionaire|Questionnaire addressing pediatric dentists behaviors and practices during the COVID-19 pandemic
223416436|NCT01672749|DEVICE|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
223416437|NCT01672749|DEVICE|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
223416438|NCT02593526|DRUG|Bumetanide|Diuretic
223416439|NCT02593526|OTHER|Cool Dialysate|Cool dialysate (35°C)
223416440|NCT00977704|DEVICE|Restylane and Perlane|
223416441|NCT06968481|DRUG|Oxytocin|Sublingual oxytocin 1000 IU, 3000 IU or 6000 IU
223416442|NCT06968481|DRUG|Oxytocin|Intramuscular oxytocin 10 IU
224298481|NCT00506129|DRUG|Melphalan|70 mg/m\^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
223416443|NCT06967883|DIAGNOSTIC_TEST|Ultrasonographic assessment of Cervical Multifidus and Longus Colli Muscle Thickness, Postural Balance and Limit of Stability using the balance platform,Cervical Flexion and Extension Strength|"Intervention Description~Participants in both groups will undergo ultrasonographic measurement of cervical multifidus and longus colli muscle thickness. Postural sway, Limits of Stability (LOS), and a 6-direction balance test (ABC-6) will be assessed using the HUR SmartBalance BTG4 platform under stable and unstable conditions with eyes open and closed. Functional balance will be evaluated with the Berg Balance Scale (BBS), Timed Up and Go (TUG) Test, and Single-Leg Stance Test. Isometric cervical flexion and extension strength will be measured bilaterally using a hand-held dynamometer. Ankylosing Spondylitis patients will additionally complete BASFI, BASMI, BASDAI, and ASQoL questionnaires."
223416444|NCT06968130|BEHAVIORAL|routine hemodialysis|Patients will receive routine hemodialysis without any additional intervention. The same scales will be administered at baseline and during two follow-ups one week apart.
223560683|NCT00879151|BEHAVIORAL|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
223560684|NCT02225847|OTHER|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
223560685|NCT02225847|PROCEDURE|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
223560686|NCT02225847|BEHAVIORAL|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
223739124|NCT06868329|OTHER|Postural correction with lumbar stabilization using TBed|These exercises consisted of pelvic rocking, and activation of the upper back and interscapular muscles. TBed from Techno body©, Italy was used to assist the patient to perform these exercises through VR video gaming interface. The patients in the experimental group will be asked to contract the targeted muscles and push down on the surface of the TBed. Patient's pressure will activate the sensors inserted inside the TBed, which will be reflected on the game as triggering of the gun that targets flying fruits. The game consists of three levels, easy, medium, and hard. The patient will be asked to play the game for the lower back where pushing the lower back against the bed (posterior pelvic tilting) triggered the gun and for the upper back where pushing the scapula against the bed was the triggering action.
223739125|NCT06870331|DIETARY_SUPPLEMENT|Probiotic|Participants will take one sachet BIOTICS-G (Burgerstein, Switzerland, 2.5 g) daily for eight weeks. The supplement contains 14 bacterial strains with a total viable cell count of 2.5 billion colony-forming units per sachet.
223739126|NCT06870331|DIETARY_SUPPLEMENT|Prebiotic|Participants will take 5 g of oat bran (Naturaplan Bio Haferkleie, Coop, Switzerland) daily for eight weeks.
223739127|NCT06045962|DEVICE|Ureteral stent|Used to open the ureter and help the kidney drain
224298482|NCT00506129|PROCEDURE|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
223560687|NCT04606706|OTHER|Mobile health nutrition education intervention|Nutrition education will be given through mobile phone
223560688|NCT03403361|DEVICE|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
223560689|NCT03403361|DEVICE|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
223560690|NCT04726150|OTHER|ILR implantation|If LGE is present on CMR, ILR implantation will be proposed
223560691|NCT03955224|DEVICE|Basic Oral Care + active LLLT|"* Compliance with the Basic Oral Care Associated with~* Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
223560692|NCT03955224|OTHER|Basic oral Care + inactive LLLT|"* Compliance with the Basic Oral Care Associated with~* Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
223560693|NCT03955224|OTHER|Basic Oral Care|Compliance with the Basic Oral Care only
223560694|NCT02185560|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
223560695|NCT06251466|DEVICE|iHealth Gluco-Smart application|iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
223739128|NCT06872060|DRUG|Glucagon|Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes.
223739129|NCT06872060|DRUG|Glucagon+Exendin9-39|Glucagon infusion at 5 ng·kg-¹·min-¹ from 0-30 minutes and 10 ng·kg-¹·min-¹ from 30-60 minutes, plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes
223739130|NCT06872060|DRUG|Sodium chloride|Placebo (0.9% NaCl).
224298483|NCT00506129|DRUG|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
224298484|NCT01968694|DRUG|IV Lidocaine|
224298485|NCT01968694|DRUG|IV diphenhydramine|
224298486|NCT03979781|DRUG|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
224298487|NCT03979781|DRUG|standard of care|antiplatelet selection using standard of care
224299185|NCT01194336|DRUG|Huperzine A|dosage form: tablet dose frequency: once only
224136762|NCT00838006|DEVICE|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
224136763|NCT00838006|DEVICE|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
223416445|NCT06968130|BEHAVIORAL|Breathing Exercise|Patients will perform deep breathing exercises guided by the researcher: 1 minute normal breathing, 3 minutes chest breathing, 3 minutes diaphragmatic breathing, 2 minutes pursed-lip breathing, and 1 minute normal breathing. Exercises will be conducted for 10 minutes before and after hemodialysis, repeated in two follow-up sessions one week apart, with post-session scale completion.
223416446|NCT06968130|DEVICE|Virtual Reality|After completing the initial scales, patients will watch a 20-minute nature simulation via virtual reality glasses before and after hemodialysis. This will be repeated in two follow-up sessions one week apart, followed by scale administration.
223416447|NCT01163851|BIOLOGICAL|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
223416448|NCT01163851|BIOLOGICAL|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
223416449|NCT06966869|DRUG|Transdermal fentanyl patch|The fentanyl patch will be applied as per standard ICU protocol for pain management. Blood levels will be monitored every 4 hours for 48 hours. Patients in this group require norepinephrine (\>5 drops/hour of 4 mg/50 mL) to maintain MAP ≥ 65 mmHg.
223416450|NCT06966869|DRUG|Transdermal fentanyl patch|The fentanyl patch will be applied as per standard ICU protocol for pain management. Blood levels will be monitored every 4 hours for 48 hours. Patients in this group maintain MAP ≥ 65 mmHg without norepinephrine infusion.
223416451|NCT06966895|DEVICE|a parent-child collaboration game app|This application is utilized throughout the entire behavioral process of a museum visit; it serves as an auxiliary tool to facilitate the parent-child groups\&#39; experience in the museum in a more targeted manner.
223416452|NCT06966895|OTHER|traditional text-based panels group|A traditional museum visitor\&#39;s manual, containing knowledge of similar content to that in the game.
223416453|NCT06968754|OTHER|Intervention Group|Pharmaceutical care will be provided by a clinical pharmacist in addition to conventional care. This includes assessment and resolution of drug therapy problems (DTPs) related to indication, effectiveness, safety, and compliance. Infection control interventions involve: patient education for early AV fistula use, topical antimicrobials at the catheter exit site (e.g., Mupirocin), antiseptic/antibiotic lock solutions to prevent bloodstream infections, and antimicrobial selection based on culture sensitivity. Patients will receive ongoing follow-up and support throughout the study period.
223416454|NCT03364465|OTHER|change of ventilatory settings|change of tidal volume during one-lung ventilation
223416455|NCT04000425|COMBINATION_PRODUCT|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
223416456|NCT03267082|OTHER|Laparoscopic management of perforated appendicitis|"1. Insertion of Ports~2. Exposure of the Appendix~3. peritoneal toilet and aspiration of pus after abdominal exposure~4. Isolation of Mesoappendicular Artery~5. Clipping and Dividing of the Artery~6. Application of 3 x Endoloops~7. Division of the Appendix~8. Retrieval of the Appendix in an Endobag"
223416457|NCT00140244|DRUG|r-metHuLeptin|
223416458|NCT00140244|DRUG|Placebo|
223560696|NCT06506474|DIAGNOSTIC_TEST|Provision of any of six different low-value health services for treatment of bronchiolitis|This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.
224136764|NCT02173392|DRUG|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
223560697|NCT05101629|DRUG|Pembrolizumab|Pembrolizumab 200 mg, IV, over 30 minutes every 3 weeks
224136765|NCT02277522|BIOLOGICAL|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
224136766|NCT00080886|BIOLOGICAL|rituximab|
223560698|NCT05101629|DRUG|Lenvatinib Capsules|Lenvatinib 8 mg for BW \< 60 kg / 12 mg for BW ≥ 60 kg oral, once daily for 3 weeks
224136767|NCT00080886|DRUG|carmustine|
224136768|NCT00080886|DRUG|cytarabine|
224136769|NCT00080886|DRUG|etoposide|
224136770|NCT00080886|DRUG|melphalan|
224136771|NCT00080886|PROCEDURE|autologous bone marrow transplantation|
224136772|NCT00080886|PROCEDURE|peripheral blood stem cell transplantation|
223416459|NCT01975142|DRUG|Trastuzumab - Emtansine|
223416460|NCT03192306|DRUG|Merlin|glycolic acid/ethanol solution
223416461|NCT03192306|DRUG|Ethanol|Ethanol solution
223416462|NCT06409598|OTHER|Non-immersive virtual reality home-based exercise.|This intervention aims include some exercises in the form of games to facilitate and improve the upper limb functions and static balance from sitting and standing positions among chronic stroke survivors.
223416463|NCT01469130|DRUG|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
224136773|NCT03654755|DRUG|ASN002|Daily dose of ASN002 for up to 110 weeks
224136774|NCT00796133|DRUG|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
224136775|NCT03058172|OTHER|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
224136776|NCT03058172|OTHER|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
224136777|NCT03111355|DIETARY_SUPPLEMENT|Brazil nut|one nut a day for 2 months, no intervention for 2 months
224033405|NCT05767671|OTHER|Non-Bronchoscopic Mini Bronchoalveolar Lavage|"A minimally invasive technique frequently used in the ICU to obtain alveolar fluid samples from mechanically ventilated patients. The technique uses a commercially available telescoping catheter with a curved distal tip that allows the operator to direct the catheter into the right or left lung. The catheter is passed through an air-tight adapter on the distal end of the endotracheal tube and gently advanced to the desired lung until resistance is encountered. The inner catheter is then advanced until resistance is again encountered, signifying that the distal catheter tip is wedged. 20ml of sterile saline is instilled into the catheter followed by 5 ml of air, and the fluid aspirated. Two additional 20ml aliquots of sterile saline are injected and aspirated in a similar fashion. Specimens are pooled and on average provide a combined volume of 10ml."
224033406|NCT06060093|DIETARY_SUPPLEMENT|Placebo|Water, 5% collagen(w/w), octoacetate (1 mM)
223416464|NCT05269446|PROCEDURE|percutaneous coronary intervention (PCI)|A family of minimally invasive procedures used to open clogged coronary arteries and restore blood flow. This is also a standard treatment for patients diagnosed with STEMI or SA
223416465|NCT05269446|DEVICE|total body PET/CT scan|all participants will receive a total-body PET/CT scan (uExplorer) after enrolment
223416466|NCT05269446|PROCEDURE|Coronary Angiography (CAG)|A procedure that uses X-ray imaging to visualize coronary arteries.
223416467|NCT05269446|DRUG|TSPO injection|Participants will receive one dose of the non-therapeutic administration of the radioactive TSPO tracer 18F-PBR06 before a whole-body scan by uExplorer
223416468|NCT02313168|OTHER|observation, inspection|
223416469|NCT04932655|DRUG|simufilam|Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
223416470|NCT05033717|OTHER|Tissue Flossing Technique|"Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total."
223416471|NCT05033717|OTHER|Static Stretching Technique|"Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total."
223416472|NCT04866758|OTHER|Survey|All data gathered will be quantitative in nature. In addition to participant completed surveys, additional demographic, and diagnosis/treatment related information will be collected from the patient's electronic medical record via Health Data Compass. Subsequent data collected as part of the patient's standard psychosocial and cancer related care (i.e., health outcomes, future utilization of UCCC psychosocial services) will also be gathered. This subsequent data collection will not include further participation, but continued access to the patient's medical record. Protected health information collected for this project will include dates (e.g., birth dates, date of diagnosis, date since last treatment, death dates) and participant zip codes. No other identifiable data will be collected. A separate survey emailed to the participant at the end of the study will collect information regarding the participant's completion status of the survey.
223416473|NCT04266834|OTHER|Experimental Arm|"First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case."
223560699|NCT03554356|DEVICE|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
224033407|NCT06060093|DIETARY_SUPPLEMENT|Ketone ester|A total of 75g ketone ester supplementation will be administered in 3 bouts of 25g in order to establish intermittent exogenous ketosis: twice immediately after training, and one 30 minutes before sleep. The ketone ester used is (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
224033408|NCT05629481|PROCEDURE|Fractional carbon dioxide laser treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) treatment sessions with 4-6 weeks intervals. The same laser device parameters (10 mJ, 10% density, spot diameter of 12×12 mm2) were used in participants. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The laser procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
224136778|NCT05511818|DIETARY_SUPPLEMENT|Rest Study Product Usage|Participants will use their Radicle Rest study product as directed for a period of 4 weeks.
224136779|NCT05301023|OTHER|Individualized antibiotic therapy|Individualized antibiotic therapy is based on the duration of illness after treatment initiation, as the antibiotic therapy can be stopped three days after the participant has become healthy. The participant is classified as healthy if he/she is afebrile (\<38.0 °C), has experienced significant clinical improvement, and have no flank pains or dysuria.
224299186|NCT01194336|DRUG|Donepezil|dosage form: tablet dosage frequency: once only
223560700|NCT03814382|DEVICE|Acupuncture needle|Acupuncture needle
223560701|NCT02152371|DRUG|Dulaglutide|Administered SQ
223560702|NCT02152371|DRUG|Placebo|Administered SQ
223560703|NCT02152371|DRUG|Insulin Glargine|Administered SQ
223560704|NCT02152371|DRUG|Metformin|Administered orally
223560705|NCT03400865|DRUG|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
223560706|NCT04380194|DIAGNOSTIC_TEST|nano-composite screening|Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
223739131|NCT07010471|DRUG|1.0mg/kg/day PRAX-562|Once daily orally or gastronomy/jejunostomy
223739132|NCT07010471|DRUG|1.5mg/kg/day PRAX-562|Once daily orally or gastronomy/jejunostomy
223739133|NCT07010471|DRUG|Placebo|Once daily orally or gastronomy/jejunostomy
223739134|NCT06864936|DRUG|Ublituximab|ublituximab
223739135|NCT06864936|OTHER|Other disease modifying therapies|Other disease modifying therapies for MS (not ublituximab)
223560707|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
223560708|NCT01214408|DRUG|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
223560709|NCT06387927|OTHER|home exercise program|Patients in group B were taught the core stability exercise in the first visit they received Arabic printed booklet for exercise description repetitions with diagrams in addition to Arabic illustration videos, they received a weekly telephone call to ensure their compliance to the exercise \& motivation.
223560710|NCT06387927|OTHER|the core stability exercise|supervised conventional core stability exercise
223560711|NCT04486430|DRUG|Neu2000KWL|1st infusion of 500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
223560712|NCT04486430|DRUG|Neu2000KWL|1st infusion of 750mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
223560713|NCT04486430|DRUG|Neu2000KWL|1st infusion of 1500mg in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
223739136|NCT06873334|DRUG|SKY-0515|"Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): Low, mid, high Route of Administration: Oral Dosage Frequency: Once daily Blinded Treatment Duration: 12 months~Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements."
223739137|NCT06873334|DRUG|SKY-0515 Placebo|"Route of Administration: Oral Dosage~Frequency: Once daily~Blinded Treatment Duration: 12 months~Use: Experimental~Sourcing: SKY-0515 placebo will be provided centrally by the Sponsor or subsidiary, or designee~Packaging and Labeling: Study drug will be provided in blinded bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements"
224136780|NCT05301023|OTHER|Standard antibiotic therapy|Standard antibiotic therapy is 10 days of antibiotic therapy regardless of the duration of illness after treatment initiation.
224136781|NCT04810585|DRUG|Aflibercept + FOLFIRI|"Day 1. Aflibercept + FOLFIRI~* aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~* Folinic acid: 400 mg/m2 IV infusion for over 2 hours~* Irinotecan: 150 mg/m2 IV infusion for over 1 hours~* 5-FU: 400 mg/m2 IV bolus injection for over 5 minute~* 5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity"
224136782|NCT04663984|BEHAVIORAL|publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation
224136783|NCT02000518|RADIATION|external beam radiotherapy|
224136784|NCT02854553|PROCEDURE|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
224136785|NCT02854553|PROCEDURE|rectus sheath block|ultrasound guided rectus sheath block
223560714|NCT04486430|DRUG|Placebos|1st infusion of the same volume of saline in patients within 6 hours following ischemic stroke onset followed by 9 consecutive infusions of the same volume of saline at intervals of 12 hours
223560715|NCT05352412|BEHAVIORAL|Shared Decision Making Aid - Patients|Patients will be randomized to the shared decision making aid intervention.
223560716|NCT05352412|BEHAVIORAL|Shared Decision Making Aid - Providers|Providers of patients randomized o the shared decision making aid intervention.
223560717|NCT06730867|BEHAVIORAL|EMDR Therapy Protocol|The intervention involves an eight-week program that details a specific EMDR protocol and questionnaire for people living with HIV. The EMDR sessions occur once a week for eight weeks under the supervision of the investigator.
223560718|NCT05704023|BEHAVIORAL|Reminder to exercise|Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
223560719|NCT06235632|BEHAVIORAL|Policy and Training Intervention|The intervention is a combination of a policy training and access to an in-depth training program to teach marijuana vendors the skills needed to refuse intoxicated customers
223560720|NCT06235632|BEHAVIORAL|Usual and Customary Policy and Training (UC-PT) (Control) Condition|The active control training that is already provided to marijuana vendors by the Oregon Liquor and Cannabis Commission
223560721|NCT06384313|DIETARY_SUPPLEMENT|butyrate/hexanoate-enriched triglycerides|The oils are consumed two times a day for 24 weeks (six months).
223560722|NCT04188067|DEVICE|ACTIVE rTMS|All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
223560723|NCT04188067|DEVICE|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
223560724|NCT00002552|BIOLOGICAL|filgrastim|
223560725|NCT00002552|BIOLOGICAL|sargramostim|
223560726|NCT00002552|DRUG|carmustine|
223560727|NCT00002552|DRUG|cyclophosphamide|
223560728|NCT00002552|DRUG|cytarabine|
223739138|NCT04371081|DEVICE|Amplatzer Piccolo Occluder|Interventional placement of vascular occluder
224136786|NCT03213977|DRUG|R-DA-EPOCH|R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
223560729|NCT00002552|DRUG|etoposide|
223560730|NCT00002552|DRUG|leucovorin calcium|
223560731|NCT00002552|DRUG|methotrexate|
223560732|NCT00002552|DRUG|perfosfamide|
223560733|NCT00002552|DRUG|therapeutic hydrocortisone|
223560734|NCT00002552|PROCEDURE|allogeneic bone marrow transplantation|
223560735|NCT00002552|PROCEDURE|autologous bone marrow transplantation|
223560736|NCT00002552|PROCEDURE|in vitro-treated bone marrow transplantation|
223560737|NCT00002552|PROCEDURE|peripheral blood stem cell transplantation|
223560738|NCT00002552|PROCEDURE|syngeneic bone marrow transplantation|
223560739|NCT00002552|RADIATION|radiation therapy|
224136787|NCT03213977|DRUG|R-CEOP90|R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
224136788|NCT01508494|DRUG|Galantamine|16 mg galantamine daily P/O
223416474|NCT01603849|RADIATION|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
223560740|NCT04442633|DRUG|Glutamine Cap/Tab|Glutamine Capsules: One capsule three times daily on an empty stomach for one month
223560741|NCT04442633|DRUG|Miconazole Oral gel|Miconazole oral gel: applied three to four times daily for three weeks
223560742|NCT04442633|DRUG|Kenacort in orabase|Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
223560743|NCT04382586|DRUG|Zanubrutinib|320 mg (4 x 80 mg) capsules administered orally once daily
223560744|NCT04382586|DRUG|Supportive Care|Supportive care treatment was selected and administered as deemed appropriate by the study investigator
223560745|NCT04382586|DRUG|Placebo|Placebo to match zanubrutinib
224136789|NCT01508494|DRUG|placebo|placebo
224136790|NCT01932281|DIETARY_SUPPLEMENT|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
223416475|NCT04404764|DRUG|Nusinersen Injectable Product|The patient´s treatment is provided by SUS. The following dosage scheme of nurinersen is the one approved by ANVISA (Brazilian National Health Surveillance Agency): Nusinersen, 12 mg (5 mL) on days 0 (zero), 14 and 28. A fourth dose will be on day 63 with a maintenance dose once every 4 (four) months. The study will NOT have direct influence on the care received by patients. Data on adherence, interventions, hospitalizations, mechanical ventilation, procedures and adverse events will be obtained from the patients´ medical records.
223560746|NCT02425956|DEVICE|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
223560747|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
223560748|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
224136791|NCT01932281|DIETARY_SUPPLEMENT|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
224136792|NCT02394808|DEVICE|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
224136793|NCT02394808|DEVICE|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
224136794|NCT00344955|DRUG|HMG-CoA reductase inhibition (atorvastatin)|
223416476|NCT01091506|OTHER|Placebo|Placebo once a day for 12 weeks
223416477|NCT01091506|OTHER|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
223560749|NCT04181008|DRUG|Amiloride|Amiloride Nasal Spray
223560750|NCT04616326|DRUG|Galcanezumab|Administered SQ
223560751|NCT04616326|DRUG|Placebo|Administered SQ
223560752|NCT03935867|BEHAVIORAL|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
223560753|NCT00983333|DEVICE|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
223560754|NCT00093899|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
223560755|NCT01258790|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
223560756|NCT01258790|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
223560757|NCT01943058|DRUG|megestrol acetate|Given PO
224136795|NCT05479266|OTHER|Muscle Energy Technique|METS-Post isometric relaxation will be applied for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
224136796|NCT05479266|OTHER|Myofascial release|Myofascial Release will be done for piriformis, iliopsoas and hamstrings muscle. There will be three repetitions for each muscle, once per day and thrice a week for three weeks
224298488|NCT00523224|PROCEDURE|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
224298489|NCT00523224|BIOLOGICAL|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
224298490|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
223416478|NCT05000671|DRUG|STC314 injection or Placebo(rate=58.3 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
223416479|NCT05000671|DRUG|STC314 injection or Placebo(rate=87.5 mg/hr)|To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
223416480|NCT06106412|DRUG|Ionomycin SIGMA|Oocytes will be activated with Ionomycin SIGMA
223416481|NCT06106412|DRUG|A23187|Oocytes will be activated with A23187
223416482|NCT04437290|DRUG|investigational radiotracer [18F]MK6240|Brain PET scan
223416483|NCT03660332|PROCEDURE|Infusion of a liquid meal intraduodenally|Infusion of IL-6/NaCL before a liquid meal intraduodenally
223416484|NCT01126814|DRUG|Imatinib (Gleevec)|
223416485|NCT02728505|DRUG|SinuSurf irrigation twice daily|
223416486|NCT02728505|DRUG|NeilMed Sinus rinse irrigation twice daily|
223416487|NCT01781845|PROCEDURE|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
223416488|NCT02780453|DEVICE|Negative pressure dressing|
223416489|NCT02780453|DEVICE|Standard wound dressing|
223416490|NCT01473433|PROCEDURE|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
223416491|NCT01473433|OTHER|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
223416492|NCT02132182|BIOLOGICAL|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
223416493|NCT05750329|PROCEDURE|assisted liver transplantation combined with two-stage hepatectomy|"Stage 1 Surgery: Left Hepatectomy, Left Lateral Graft Implantation, Portal Shunt to Graft Intermediate stage: continuous monitoring of liver function indexes and liver transplant donor volume after the first stage of surgery. Until the graft size reaches 0.8% of body weight (GBWR), or 35%-45% of the standard liver volume.~Stage 2 Surgery: Residual Right Hepatectomy"
223560758|NCT01943058|DEVICE|levonorgestrel-releasing intrauterine system|Given IUD
223560759|NCT01943058|OTHER|laboratory biomarker analysis|Correlative studies
223560760|NCT01943058|OTHER|questionnaire administration|Ancillary studies
223560761|NCT06094244|DRUG|Atorvastatin|Doses of atorvastatin of up to 20 mg/d.
223560762|NCT06094244|DRUG|Rosuvastatin|Doses of rosuvastatin of up to 10 mg/d.
223560763|NCT06094244|OTHER|No drugs|No drugs
223560764|NCT06137430|DRUG|Sodium-glucose cotransporter 2 inhibitor|Sodium glucose cotransporter 2 inhibitiors
223739139|NCT05908461|BEHAVIORAL|Early Childhood Friendship Project|Classroom-based intervention where teachers will implement 8 10-minute puppet shows, 7 5-minute active gross motor activities to reinforce the social skill of the week, and 7 5-minute passive rehearsal activities such as making their own puppet and practicing the steps of the week. Up to three 1 hour in vivo behavioral reinforcement periods will occur per week and during these free play sessions teachers and the main puppet will use developmentally appropriate praise to reinforce the use of the social skills of the week.
223416494|NCT02533050|DEVICE|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
223416495|NCT02159157|BEHAVIORAL|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
223416496|NCT05808426|DEVICE|Bonus Winner Mahjong|Bonus Winner Mahjong developed by Bonus Winner Online Entertainment Co., Ltd. The participants in experimental group played three times a week, each time requiring at least lasting 30 minutes, for half of a year.
223416497|NCT03838289|RADIATION|multimodal magnetic resonance imaging or computed tomography|multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
223416498|NCT05484089|DEVICE|CapFlex PIP implant|Patients receive the CapFlex PIP implant based on regular care. During surgery tantalum markers are placed in the bone surrounding the implant.
223560765|NCT02933424|DIETARY_SUPPLEMENT|Protein Powder|
223560766|NCT00750841|DRUG|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
223560767|NCT06078371|OTHER|Opioid-free pain treatment|Pain treatment includes any medications up to the medical team's discretion aside from opioids.
223560768|NCT06452394|DRUG|Doxycyclin|Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit
223560769|NCT06971614|BIOLOGICAL|T3011|T3011 will be administered at a dose of 1x10\^10 PFU intravesically.
223560770|NCT05927519|DEVICE|airtraq video laryngoscope|airtraq video laryngoscope will be used for intubations
223560771|NCT05278000|OTHER|Presence of scarcity mindset|"This observational study will examine whether~1. Individuals exhibiting a scarcity mindset have lower adherence to asthma controller medication~2. Individuals with higher rates of future discounting have lower adherence to controller medication~3. Individuals with unmet social needs are more likely to experience scarcity and have higher rates of future discounting, and whether these relationships mediate adherence to asthma controller medication"
223560772|NCT05360160|DRUG|SNDX-5613|Given by PO
223560773|NCT05360160|DRUG|Venetoclax|Given by PO
223560774|NCT05360160|DRUG|ASTX727|Given by PO
223739140|NCT07019662|DEVICE|Decannulation with a medical device|Wound Closure with a medical device
223739141|NCT07019662|PROCEDURE|Decannulation using surgical removal or manual compression|Wound closure using surgical removal or manual compression
223739142|NCT06533657|DRUG|Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)|Cancer patients meeting eligibility criteria will receive Trichomylin® and self-titrate to effective dose.
223739143|NCT06624969|OTHER|virtual reality|Virtual reality program to reduce pain in orthopedic fractures
223739144|NCT04112355|OTHER|Blood Collection|Blood draw
223416499|NCT02589626|DRUG|empagliflozin 10mg|
224033409|NCT05629481|PROCEDURE|Fractional carbon dioxide laser sham treatment|Participants underwent three vaginal fractional CO2 laser (AcuPulse, Lumenis, Yokneam Illit, Israel) sham treatment sessions with 4-6 weeks intervals. A special laser probe was inserted into the patient's vagina after cleaning and disinfection. The sham procedure was performed at the 0, 2, 4, 6, 8, and 10 o'clock positions by rotating the laser probe from the proximal vagina to the distal, and additional sham procedures were performed at the 11 and 1 o'clock positions 5 mm above the introitus vaginae.
224033410|NCT03541382|DEVICE|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
224033411|NCT00461487|BEHAVIORAL|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
224033412|NCT00461487|BEHAVIORAL|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
223416500|NCT02589626|DRUG|empagliflozin 25 mg|
223416501|NCT02589626|DRUG|Placebo|For blinding purposes
223416502|NCT06478966|BEHAVIORAL|Experimental|Stoma care training was delivered using the PechaKucha method for the intervention group.The presentation format involves 20 slides (usually containing images only) that are shown for 20 seconds each, for a total presentation length of 6 minutes and 40 seconds.
223416503|NCT02423330|DEVICE|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
223416504|NCT00567658|DRUG|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
223416505|NCT01690858|OTHER|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
223416506|NCT02189343|DRUG|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
223416507|NCT04283799|DIETARY_SUPPLEMENT|A new human milk fortifier|Contents of protein, protein/energy ratio, moderate hydrolysis of whey protein, medium-chain fatty acid are increased in the new HMF
223416508|NCT05297370|BEHAVIORAL|Mixed and match Intervention|Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
223416509|NCT05297370|OTHER|Control|Participants in the control group will receive a self-help quitting leaflet issued by the TACO
223416510|NCT01861652|DEVICE|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
223416511|NCT02564900|DRUG|DS-8201a (DP1)|DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
223416512|NCT02564900|DRUG|DS-8201a (DP2)|DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.
223416513|NCT02564900|DRUG|DS-8201a (DP)|DS-8201a (DP) is to be administered via intravenous (IV) dose.
223416514|NCT03612609|BIOLOGICAL|blood, urine and semen sample|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
223560775|NCT05549232|DEVICE|Hypoxic Red Blood Cells|Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced
223560776|NCT04724369|DRUG|18F-MFBG|Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
223560777|NCT04829682|BEHAVIORAL|ACT for Life|ACT for Life is a brief recovery oriented individual inpatient Acceptance and Commitment Therapy treatment protocol consisting of four modules typically administered in three to six inpatient sessions and one to four outpatient sessions in the 30 days following discharge from inpatient care. The immediate goals of ACT for Life are to increase the participant's psychological flexibility and readiness to cope effectively with future suicidal crises.
223560778|NCT04829682|BEHAVIORAL|Present Centered Therapy|PCT is an evidence-based treatment for PTSD but its principles can be applied to psychotherapy for a wide range of difficulties. The standard PCT manual was originally adapted for suicide prevention by Craig Bryan and his colleagues. Our study team made additional minor revisions to prepare the manual for use as an active control condition in the current efficacy trial. PCT includes two initial sessions focused on discussion of current symptoms, psychoeducation, and the rationale for PCT. Current life problems become the focus of the remaining sessions. PCT is expected to consist of three to six, 60-90-minute inpatient sessions and one to four outpatient sessions in the 30 days following discharge. Discontinuation will occur when the participant attends an individual outpatient mental health appointment or 30 days after discharge, whichever occurs first. PCT participants will receive caring communications from their therapist for 12-months following inpatient discharge.
224033413|NCT02343731|OTHER|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
224033414|NCT01030198|DEVICE|RevLite (Laser Treatment)|
224033415|NCT04050137|OTHER|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
224136797|NCT04220385|OTHER|Group A|Subjects will perform following exercises, Single Leg Extension, Arm and Leg Lift, Balance Bridge, Single-Leg Twist, Single Leg Reach, Sideways Leg Lift, Single Arm Stand, Torso Twists and Plank exercise with minimum one set and maximum two sets. 30 seconds will be rest time between each set. Subjects will be encouraged to increase the number of repetitions after every 2 weeks, except in Plank exercise in which holding position time will be initially 30 seconds in each set and will be encouraged to increase holding time after every 2 weeks.
224033416|NCT01748487|DRUG|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
224298491|NCT00251719|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
223416515|NCT05175911|OTHER|golden hour : an initial standardized stabilization|"This is a quality improvement project to evaluate the implementation of Golden hour, a standardized stabilization during the first hour of life in inborn preterm infants younger than 31 weeks of gestational age or weighting less than 1300 g in the NICU of the University of Liege.~There is no comparative arm."
223416516|NCT04782297|DEVICE|Long term hemodialysis catheter|There will be no interventions in this study. Strictly observational.
223416517|NCT00892151|DEVICE|GLUCOFACTS® Deluxe|Diabetes Data Management Software
223416518|NCT03217383|DEVICE|MATRx plus|The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
223416519|NCT04349345|DIAGNOSTIC_TEST|sperm count|total progressive sperm motile count
223416520|NCT05131373|DRUG|ORG101 - Experimental 1|C. acnes vaccine Injection, 25 mcg, 75 mcg, 225 mcg, 4 single i.m. injections given in monthly intervals
223416521|NCT05131373|DRUG|ORG101PL - Placebo 1|Injection, sterile aqueous solution of aluminium hydroxide, 4 single i.m. injections given in monthly intervals
223416522|NCT02699931|DEVICE|Electric3D|Oral-B 3D with orthodontic head
223416523|NCT02699931|DEVICE|Manual|Oral-B orthodontic
223416524|NCT04925882|PROCEDURE|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml."
223416525|NCT04925882|PROCEDURE|Erector spinae plane block|"After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%."
223416526|NCT02807727|DRUG|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
223416527|NCT02807727|DRUG|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
223416528|NCT02954029|DEVICE|ezClot (hemostasis pad)|ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
224033417|NCT01453530|DRUG|Sugammadex|A single dose of sugammadex 2 mg/kg iv
224033418|NCT01453530|DRUG|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
224033419|NCT01453530|OTHER|Placebo|Placebo
224033420|NCT02370043|DRUG|KQ-791|Capsules administered orally while fasting, in up to 3 periods
224033421|NCT02370043|DRUG|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
224033422|NCT02370043|DRUG|Placebo|Capsules, administered orally, in 1 period
224136798|NCT04220385|OTHER|Group B|Subjects will perform Side Bridge, Bird Dog and Beginner Curl-up exercise in the first three weeks and Side Bridge, Bird Dog and Intermediate Curl-up exercise in the last three weeks. Repetitions per set will be 5, 4, 3 in first two weeks, 7, 6, 5 in third and fourth weeks and 9, 8, 7 in last two weeks. 8-10 seconds will be holding time in each repetition. 30 seconds will be rest time between each set
224136799|NCT02882815|DEVICE|IrisFIT PFO Occluder|
224298492|NCT00251719|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
224298493|NCT05227300|DRUG|Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution|Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic
224033423|NCT04341766|OTHER|No special intervention|No special intervention : Ultrasound data will be collected
224136800|NCT01792245|DEVICE|Phototherapy|
224298494|NCT05227300|DRUG|2% lidocaine with 1:100,000 epinephrine|Septodont's standard formulation of 2% lidocaine with epinephrine
224298495|NCT01660399|DRUG|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
224298496|NCT01660399|DRUG|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
224033424|NCT03782025|DRUG|Phytomenadione|Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
224298497|NCT03324932|DRUG|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
223416529|NCT02954029|DEVICE|BloodSTOP ix pad|BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
223416530|NCT02954029|DEVICE|Rotary compression device|Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
223416531|NCT03090529|OTHER|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
223416532|NCT03409289|DEVICE|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
223416533|NCT01155440|DRUG|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
224033425|NCT03652025|PROCEDURE|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
224033426|NCT05198687|PROCEDURE|Long implant and partial overdentures|insertion of long implants anterior to the maxillary sinus to retain partial overdentures
224033427|NCT05198687|PROCEDURE|Sinus lift and long implant|performing sinus lift surgical procedure with simultaneous placement of long implants to support screw-retained prosthesis
224033428|NCT05198687|PROCEDURE|short implant without sinus lift|placement of short implants in the remaining bone above maxillary sinus to support screw-retained prosthesis without performing sinus lift
224033429|NCT05198687|DEVICE|Partial overdentures|Distal extension metallic partial dentures retained by attachments to the implants
224136801|NCT02835677|BEHAVIORAL|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
224136802|NCT04715256|BEHAVIORAL|Cognitive assessment of obsessive-compulsive and impulsive behaviours|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (attention, impulsivity) and a clinical assessment (impulsive behaviour, autistic traits,obsessive-compulsive behaviour).
224136803|NCT04715256|GENETIC|Genomic analysis|A genome-wide association study (GWAS) will be performed for all subjects to search for associations between KCNQ1 mutations, insulin regulation and psychological features.
224136804|NCT04715256|DIAGNOSTIC_TEST|Glucoregulation assessment|Fasted glycaemia and insulinaemia, glycated haemoglobin (HbA1c) and glycaemia following an oral glucose challenge test will be measured in all study subjects.
224136805|NCT03792165|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
224136806|NCT03792165|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
224136807|NCT05821348|DIAGNOSTIC_TEST|salivary markers|a description of the salivary biochemical profile of GER infants vs. GERD, so that we can develop non-invasive diagnostic strategies and detect personalized therapeutic treatments.
224136808|NCT05051865|DRUG|camrelizumab|camrelizumab combined with SHR1020 for advanced melanoma
224136809|NCT05051865|DRUG|SHR1020|camrelizumab combined with SHR1020 for advanced melanoma
224136810|NCT03445897|DRUG|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
224136811|NCT01219517|OTHER|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
224136812|NCT04415567|DRUG|Lenvatinib|The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
224136813|NCT05102396|DRUG|Topical oxybutynin spray|Participants will receive topical oxybutynin spray (10%).
224136814|NCT05102396|DRUG|Topical placebo spray|Participants will receive topical placebo spray.
224136815|NCT05102396|DRUG|Oral oxybutynin|Participants will receive oxybutynin (tablets).
224136816|NCT05535127|DIAGNOSTIC_TEST|"Palpation with  laryngeal handshake technique"|Information alredy included
224136817|NCT05535127|DIAGNOSTIC_TEST|Palpation strategy plus sequential ultrasound|Information alredy included
224136818|NCT05535127|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane with routine ultrasound|Information alredy included
224298498|NCT04539886|DEVICE|CellFX System|CellFX System consists of a console combined with a handpiece and coupled with a sterile single patient-use treatment tip (1.5 x 1.5mm, 2.5 x 2.5mm, and 5.0 x 5.0mm)
224298499|NCT04539886|DEVICE|Intralesional Electrodesiccation|Hyfrecator electrosurgical unit with a non-insulated needle-shaped electrode
223416534|NCT01155440|PROCEDURE|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
224033430|NCT05198687|DEVICE|Metal ceramic prosthesis on long implants|porcelain fused to metal fixed screw-retained prosthesis supported by long implants
224136819|NCT04619264|DRUG|Papacarie|First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.
224136820|NCT04619264|PROCEDURE|Atraumatic Restorative Treatment|The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
224136821|NCT05211011|DRUG|Fosfomycin|Infectofos 5 g
224298500|NCT04383236|OTHER|Probiotics|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
224033431|NCT05198687|DEVICE|Metal ceramic prosthesis on short implants|porcelain fused to metal fixed screw-retained prosthesis supported by short implants
224033432|NCT05665088|DRUG|BXCL501|Sublingual Film
224033433|NCT05665088|DRUG|Matching Placebo|Sublingual Placebo Film
224033434|NCT04137900|DRUG|TAB004|Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection
224033435|NCT04137900|DRUG|Toripalimab|a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
224033436|NCT03371030|PROCEDURE|Pronatus quadratus reparation|Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
223416535|NCT02799667|DEVICE|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
223416536|NCT02799667|DEVICE|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
223416537|NCT06178029|OTHER|Acupuncture|20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation and acupuncture treatment.
223416538|NCT06178029|OTHER|Conventional Rehabilitation|20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation
223416539|NCT02729766|OTHER|Induced hypotonic hyponatremia - SIAD model|
223560779|NCT06579404|DEVICE|CamAPS HX|"The automated closed loop system (CamAPS HX) will consist of:~YpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm"
223560780|NCT06579404|OTHER|Standard insulin therapy with glucose sensor|Participants usual insulin therapy with Freestyle Libre 3 glucose sensor
224033437|NCT05000502|BEHAVIORAL|Home-based exercise intervention|A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
224033438|NCT06250556|DIETARY_SUPPLEMENT|creatine|creatine supplementation (Creapure)
224033439|NCT04563338|DRUG|Atezolizumab|Atezolizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Atezolizumab binds to PD-L1 which is a protein involved preventing the body's immune system (defense system against infection and disease) from fighting cancer cells. Blocking PD-L1 is expected to help the immune cells to destroy the cancer cells.
223416540|NCT02729766|DRUG|Empagliflozin 25mg Tbl|
223416541|NCT02729766|DRUG|Placebo P-Tablet|
223560781|NCT06574087|DIAGNOSTIC_TEST|hrHPV test and cytology|Perfomance of hrHPV test and cytology
223560782|NCT06651268|DRUG|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T|while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
223560783|NCT06651151|DRUG|LTX-315 + pembrolizumab|LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
223560784|NCT06081179|DRUG|Psilocybin|Single dose of psilocybin (15mg), orally in form of capsules
224033440|NCT04563338|DRUG|Bevacizumab|Bevacizumab is a type of drug called a monoclonal antibody. Antibodies are proteins that are naturally found in the blood stream that fight infections. Monoclonal antibodies are a special kind of antibody that is created in a laboratory. These drugs bind (attaches) to specific proteins in the body that may be involved in cancers. Bevacizumab binds to vascular endothelial growth factor (VEGF) which is a protein involved with the growth of new blood vessels. Blocking VEGF will prevent blood vessels from forming and therefore stopping oxygen and nutrients to be supplied to cancer cells. Without oxygen and nutrients, the cancer cells will die.
223560785|NCT06081179|DRUG|3,4 Methylenedioxymethamphetamine|Single dose of MDMA (100mg), orally in form of capsules
223560786|NCT06081179|DRUG|Methylphenidate|Single dose of methylphenidate (60mg), orally in form of capsules
223560787|NCT05083884|OTHER|No Intervention|This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
223560788|NCT04763252|OTHER|Spectrum Therapeutics cannabis products|"For the purposes of this study, subjects enrolled will have been authorized Spectrum Therapeutics (ST) products that are commercially available in Canada. The full repertoire of Spectrum Therapeutics products are outlined on the website https://www.spectrumtherapeutics.com/canada/en/patients/products. It encompasses six colors (order from Red to Yellow follows the descending THC:CBD ratio), and five types of formulations: soft gels, spray, oil, flowers and vapes). Refer to webpage for the most up to date products available per country https://www.spectrumtherapeutics.com/canada/en/patients/products."
223560789|NCT03909906|DRUG|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
223560790|NCT03909906|DRUG|Placebo Oral Tablet|Placebo comparator
224033441|NCT06370468|OTHER|Epidemiological investigation|Epidemiological investigation
224033442|NCT00662779|DRUG|arformoterol|15 mcg arformoterol nebulizer
224033443|NCT00662779|DRUG|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
224033444|NCT00662779|DRUG|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
224033445|NCT02762812|BIOLOGICAL|BCD-055|
224033446|NCT02762812|BIOLOGICAL|Remicade®|
224033447|NCT01461239|PROCEDURE|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
224033448|NCT01461239|PROCEDURE|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
224033449|NCT01461239|PROCEDURE|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
224033450|NCT03186196|DIETARY_SUPPLEMENT|Diet containing Folate|
224033451|NCT04744441|PROCEDURE|CHOLECYSTECTOMY|Surgical treatment
224033452|NCT04744441|PROCEDURE|PERCUTANEOUS CHOLECYSTOSTOMY|Patients treated with a percutaneous cholecystostomy
224033453|NCT04744441|PROCEDURE|EXCLUSIVE ANTIBIOTICS|Patients that are treated only with i.v. antibiotics
224033454|NCT04270357|PROCEDURE|Cholecystectomy|Cholecystectomy is the surgical removal of the gallbladder. Cholecystectomy is a common treatment of symptomatic gallstones and other gallbladder conditions
224299187|NCT01194336|DRUG|Galantamine|dosage form: tablet dosage frequency: once only
224298501|NCT04383236|DRUG|Oracure oral gel|Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
224298502|NCT06398821|DIETARY_SUPPLEMENT|G3P-01|Nutritional supplement to promote healthy aging
224033455|NCT05438368|BIOLOGICAL|bi-4SCAR GD2/CD70 T cells|Infusion of bi-4SCAR GD2/CD70 T cells at 10\^6 cells/kg body weight via IV
224033456|NCT02776345|OTHER|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
224033457|NCT02776345|OTHER|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
224298503|NCT06398821|DIETARY_SUPPLEMENT|Placebo|Placebo
224298504|NCT03544996|COMBINATION_PRODUCT|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
224298505|NCT00666783|DRUG|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
224298506|NCT00666783|DRUG|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
224298507|NCT01340105|PROCEDURE|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
224298508|NCT01340105|PROCEDURE|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
224298509|NCT04068415|OTHER|Constipation risk assessment scale|questionnaires
224298510|NCT00688376|DRUG|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
224298511|NCT00688376|DRUG|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
224033458|NCT02776345|OTHER|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
224033459|NCT01004380|DRUG|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
224033460|NCT00688181|DEVICE|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
224298512|NCT02631967|PROCEDURE|Kono anastomosis|Kono anastomosis
224298513|NCT02631967|PROCEDURE|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
224298514|NCT00757757|DRUG|MCS110|Anti-M-CSF antibody
224298515|NCT02845765|DEVICE|Dynamic Vessel Analyzer (DVA)|
224298516|NCT02845765|DRUG|Phosphodiesterase type 5 Inhibitor (PDE5I)|
224298517|NCT01799122|DEVICE|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
224299188|NCT01194336|OTHER|Placebo|dosage form: tablet dosage frequency: once only
224299189|NCT03150849|DIAGNOSTIC_TEST|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
223416542|NCT04075682|OTHER|Inserts with efficacy messages|Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.
223416543|NCT04075682|OTHER|Pictorial warnings on packs|Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
223416544|NCT02317276|DRUG|Triamcinolone 0.1%|Topical ointment
223416545|NCT01448772|DRUG|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
223416546|NCT01448772|DRUG|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
223416547|NCT01665157|DIETARY_SUPPLEMENT|Enimaclin®|"Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy."
223416548|NCT01665157|OTHER|Self-controlled diet|Self-controlled low residue diet.
223416549|NCT01665157|DRUG|2L PEG-ELS|Normal volume of PEG-ELS
223416550|NCT01665157|DRUG|low volume 1.5L PEG-ELS|Low volume PEG-ELS
224033461|NCT05137860|DRUG|Bortezomib|Combination of Bortezomib with Standard Chemotherapy scheme for acute lymphoblastic patients in relapse.
224033462|NCT00321659|BEHAVIORAL|Aerobic|3x/week of walking and cycling
223416551|NCT06409338|DEVICE|Transcutaneous auricular vagus nerve stimulation (active）|Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
224033463|NCT00321659|BEHAVIORAL|Strength training|3x/week of resistance training activities
223560791|NCT04414592|OTHER|human umbilical cord mesenchymal stem cells|Twenty million human umbilical cord mesenchymal stem cells will be immediately injected into the degenerative discs of such patients who are diagnosed with lumbar disc herniation and operated with full endoscopy lumbar discectomy.
223560792|NCT02565758|DRUG|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
224033464|NCT00321659|BEHAVIORAL|Combination|3x/week of aerobic and strength training activities
224033465|NCT00321659|BEHAVIORAL|FSHC|Biweekly group education group meetings
224033466|NCT05317988|BEHAVIORAL|Intervention group|Participants receive a step-by-step demonstration video of detailed reconstitution procedures and text-based vaccine product information
224033467|NCT05317988|BEHAVIORAL|Control group|Participants receive a generic video of similar duration on basic facts of COVID-19 (unrelated to reconstitution procedures) and text-based product information
224033468|NCT06534190|RADIATION|89Zr-Df-crefmirlimab PET scan|"89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later. All patients will undergo a 89Zr-Df-crefmirlimab PET scan at baseline and after treatment with the PD-1 antibody. All patients participating in this imaging trial will undergo preferably 2 but at least one tumour biopsy. The biopsy procedure(s) will be performed after the 89Zr-Df-crefmirlimab PET scan at baseline and/or after the 89Zr-Df-crefmirlimab PET on-treatment.~After the first PET scan and tumour biopsy the patients will start treatment with PD-1 antibody nivolumab or cetrelimab."
224136822|NCT04820543|DRUG|injection of Botulinum type A|The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
224136823|NCT03348111|DEVICE|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
224136824|NCT05545579|OTHER|circuit trainng|Circuit training consisted of 6 exercises, divided in 2 blocks (1st block contains ½ squats, bench press and pushups and 2nd block contains burpees, squat thrust and lunges) of 3 minutes. The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
224136825|NCT05545579|OTHER|trunk stabilization techniques|The stabilization exercise group will repeat 6 exercises (Balance Ball with Pocket Knife, Reverse Crunch, Russian Return, Shuttle, Leg Lift, and Back extension) for 6 weeks. Lane agility drill, Sprint test, Vertical jump test, Star excursion test will used to evaluate outcomes
224136826|NCT04422106|DIAGNOSTIC_TEST|Predictors of intestinal anastomosis leakage, application of new predictors and new scores|Early detection of disruption and leakage of intestinal anastomotic sites whether small or large intestine by using biochemical markers as predictors and indicators of leakage with application of scoring scale to assess presence or absence of leakage.
224136827|NCT02473003|BEHAVIORAL|high intensity exercise|high intensity exercise 80-90%
224136828|NCT02473003|BEHAVIORAL|low/medium intensity exercise|low/medium intensity exercise 40-50%
224136829|NCT02473003|BEHAVIORAL|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
224136830|NCT02922192|DRUG|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
224136831|NCT02432248|DRUG|Dehydroepiandrosterone|75mg/day, PO for 90 days
223416552|NCT06409338|DEVICE|Transcutaneous auricular vagus nerve stimulation (sham）|In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
223416553|NCT00179439|PROCEDURE|nasal potential difference testing|
223416554|NCT00707525|PROCEDURE|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
223560793|NCT03016624|DEVICE|OCT guided PCI|oct guided
223560794|NCT03016624|DEVICE|Angiography guided PCI|angio guided
223739145|NCT06873438|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
224033469|NCT06534190|DRUG|Nivolumab|Immunotherapy treatment with Nivolumab
224033470|NCT06534190|DRUG|Cetrelimab|Immunotherapy treatment with cetrelimab
224033471|NCT06534190|OTHER|zirconium Zr 89 crefmirlimab berdoxam|89Zr-Df-crefmirlimab will be administered followed by a PET scan 24 hours later
224033472|NCT06348368|OTHER|Pentacam and autorefractometry|Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children
224136832|NCT02432248|OTHER|placebo(medical starch)|75mg/day, PO for 90 days
224136833|NCT03943953|BEHAVIORAL|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners."
224033473|NCT01050205|BEHAVIORAL|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
223416555|NCT01579422|BEHAVIORAL|social cognitive training|social cognitive training, 8-10 sessions
223416556|NCT02673125|GENETIC|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
223416557|NCT03820635|DIAGNOSTIC_TEST|Osteopontin (OPN)|the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
223416558|NCT05091541|DRUG|Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection|CT120 is an autologous CD19/22 targeted CAR-T cells injection. The dosage form is a cryopreserved injection solution. The T cells aphesis from subjects then been manufactured to express CAR to binding CD19 and CD22 on B-cell lymphoma.
223416559|NCT03768154|PROCEDURE|Supine + spontaneous effort|without muscle paralysis in supine position
223416560|NCT03768154|PROCEDURE|Supine + paralysis|administer muscle paralysis in supine position
224033474|NCT01050205|BEHAVIORAL|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
224033475|NCT03706950|DRUG|Elpida® + 2 NRTIs|Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
224033476|NCT05844787|DRUG|MT101-5|Tablet
223416561|NCT03768154|PROCEDURE|Prone + paralysis|change the patient position from supine to prone with muscle paralysis
223416562|NCT03768154|PROCEDURE|Prone + spontaneous breathing|cease the paralysis in supine position
224033477|NCT03450720|DRUG|GLPG2737 single dose|GLPG2737 oral suspension, single dose
224033478|NCT05805098|DRUG|Venetoclax|Starting on day 1, venetoclax will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 1, 200 mg on day 2 and 400 mg on day 3. The patient then continues to take the 400mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day.
224033479|NCT05805098|DRUG|Homoharringtonine|On day 1, homoharringtonine 1 mg/m2 IV will be given, and will continue for 5 days.
224033480|NCT05805098|DRUG|Cytarabine|On day 1, cytarabine 100 mg/m2 IV will be given, and will continue for 5 days.
224033481|NCT04834687|BEHAVIORAL|Exercise|Rope-skipping exercise for three times a week (90 minutes each time, and there is a 10 min break after 20 min Rope skipping). Exercise bracelet and smart bracelet would be used to record the energy consumption throughout the study.
224299190|NCT04476719|DRUG|ATAFENOVIR 200 MG KAPSUL|A 200 mg capsule 0ral administration with 240 ml water
223416563|NCT00282399|DRUG|Subcutaneous Decitabine|
223416564|NCT02425878|DRUG|Ulipristal Acetate|
223416565|NCT02425878|DRUG|Placebo|
223416566|NCT03193320|OTHER|Fluid therapy protocol|Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
223416567|NCT03046667|DIETARY_SUPPLEMENT|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
223416568|NCT03046667|DIETARY_SUPPLEMENT|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
223560795|NCT06678139|OTHER|physiotherapy|Bilateral gastrosoleus stretching, iliopsoas and hamstring stretching (if a shortness is detected), foot intrinsic and extrinsic muscle strengthening, lower extremity muscle strengthening and parkour walking training will be performed. Therapeutic exercises will be performed once a week for 12 weeks under the supervision of a physiotherapist. Parents will be asked to follow a 12-week home exercise program at home during the five days. The home exercise program will include the exercises performed in the pediatric physiotherapy and research laboratory. Parents will be instructed to perform each exercise twice a day at home. Children will be given a weekly exercise diary to increase adherence to the exercise program.
223739146|NCT06873438|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study will last 8 weeks and each subject will receive 3 follow-up visits (week 0, week 4, week 8).
223560797|NCT06073457|DEVICE|MagGJ System|Anastomoses achieved by magnetic compression.
223739147|NCT07029399|DRUG|NKT5097 CDK2/CDK4 dual degrader|NKT5097 will be distributed in tablet form and dosed daily or twice a day
223416569|NCT04448444|BEHAVIORAL|Motor Program Activating Therapy|Patients undergo ambulatory physiotherapy - Motor Program Activating Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the ambulatory section of the Department of Neurology, Kralovske Vinohrady University Hospital in Prague.
223416570|NCT04448444|BEHAVIORAL|Vojta reflex locomotion|Patients undergo ambulatory physiotherapy - Vojta Reflex Locomotion Therapy (2 months, twice a week, 1 hour of duration). Therapy was undertaken at the Department of Rehabilitation and Sport Medicine, Motol University Hospital.
223416571|NCT06270264|DEVICE|the Nociception level index monitoring|Nociception level index (NOL) monitoring (Medasense) is a non- invasive device differentiated from its alternatives by the use of five parameters: heart rate, heart rate variability, skin conductance level, photo-plethysmography waveform amplitude, number of skin conductance fluctuations, and their time derivatives.
224033482|NCT04834687|BEHAVIORAL|Diet|"Diet interventions include ten-hour time-restricted eating and a high-fiber diet.~1. Participants will be instructed to take food from 7:30 AM until 5:30 PM and completely abstain from caloric intake for the remainder of the day (14 hours fast:10 hours eat). Only noncaloric beverages were permitted outside of the eating widow.~2. According to the dietary recommendation proposed by Chinese Government and the existing dishes in the canteen , participants are instructed to eat following a high-diet recipe weekly from Monday to Friday which includes whole grain wheat rice, vegetables, fruits, and other foods rich in dietary fiber ."
223416572|NCT06161467|DEVICE|Ultrasound devices|Safe , no radiation
223739148|NCT06006923|DRUG|Regorafenib|A multi-kinase inhibitor that targets several receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), which may also have immunomodulatory affect in the tumor microenvironment.
224033483|NCT03475017|DIETARY_SUPPLEMENT|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
224033484|NCT03475017|DIETARY_SUPPLEMENT|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
224033485|NCT01119001|DEVICE|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
224033486|NCT02849301|DEVICE|Arabin cervical pessary|
224033487|NCT00954421|DEVICE|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
224033488|NCT03375528|DEVICE|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
224033489|NCT02913417|DEVICE|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert , reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
224033490|NCT02913417|DRUG|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
224033491|NCT02913417|DRUG|nivolumab|nivolumab 3mg/kg every 3 weeks x 4 then 480mg q 4 weeks
224033492|NCT03855423|DIETARY_SUPPLEMENT|Tocotrienol-rich Fraction (TRF)|TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
224033493|NCT00777946|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
224033494|NCT00777946|DRUG|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
224033495|NCT00777946|DRUG|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
224033496|NCT00777946|DRUG|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
224033497|NCT00777946|DRUG|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
224033498|NCT01576653|OTHER|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
224136834|NCT03832439|DIETARY_SUPPLEMENT|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
223416573|NCT03627026|OTHER|Blood samples will be collected at different time points:|"* Baseline~* Week 6 Day 1~* Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."
223416574|NCT01895374|PROCEDURE|laser treatments|
223416575|NCT01895374|OTHER|amniotic membrane application|
223416576|NCT01895374|DEVICE|hydrocolloid application|
223739149|NCT06006923|DRUG|Pembrolizumab|An anti-PD1 blockade / immune checkpoint inhibitor treatment approved for patients with high microsatellite instability (MSI-H) colorectal cancer (CRC) as first line therapy.
224033499|NCT01853982|DRUG|Ceftolozane/Tazobactam|
224033500|NCT01853982|DRUG|Piperacillin/Tazobactam|
224033501|NCT06245720|OTHER||
224033502|NCT03457454|OTHER|Primary Care Provider/Staff Participants Interview|-Approximately a 30 minute interview
224033503|NCT03457454|OTHER|Patient Participant Interview|-Approximately 45-60 minute interview
224033504|NCT03457454|OTHER|Patient Participant Anonymous Survey|-Survey completion will take approximately 15 minutes
224033505|NCT03457454|OTHER|Colonoscopy Provider/Staff Participants Interviews|-Approximately a 30 minute interview
224033506|NCT03714425|DEVICE|Quell|Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
224033507|NCT03019796|DRUG|MEDICATION AND EXERCISE TRAINING|"PARTICIPANTS WILL BE (IN A RANDOMIZED BLINDED FASHION) WITHDRAWN OF THEIR HYPERTENSIVE MEDICATION (I.E., PLACEBO) IN ONE OCCASION AND TESTED WITH THEIR MEDICATION IN ANOTHER, WITH A WEEK WASHOUT PERIOD.~THIS TESTING WILL BE REPEATED AFER 4 MONTHS OF EXERCISE TRAINING (48 SESSIONS OF 43 MIN EACH ONE)."
224033508|NCT05740436|OTHER|Geriatric rehabilitation program based on CGA|Geriatric rehabilitation program based on CGA will be performed under physicians tight control for 21 days and will include physical activity, psychological training, diet correction, adaptation measures, polypragmasia correction.
224033509|NCT05066724|DRUG|Centanafadine|400 mg total daily dose Centanafadine Sustained Release, oral tablets
224033510|NCT00436033|DRUG|milnacipran|
224033511|NCT00436033|DRUG|Placebo|
224136835|NCT03832439|DIETARY_SUPPLEMENT|microcrystalline cellulose|Placebo
223416577|NCT01289639|DRUG|fenofibrate|micronized fenofibrate 200 mg 1 po qd
223416578|NCT01289639|DRUG|pioglitazone|pioglitazone 30 mg po qd
223416579|NCT01289639|DRUG|placebo|placebo 1 capsule po qd
223416580|NCT05804422|DIETARY_SUPPLEMENT|Probiotic lysate (postbiotic and metabiotc)|Each capsule contains 100 mg of cell lysate and DNA fragments of the probiotic strain L. rhamnosus DV - NRRLB-68023 in powder
223560798|NCT06651853|DRUG|Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab|"Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent."
223560799|NCT06977113|OTHER|High Fibre Fermented Food Diet|Participants will be provided with and asked to consume specific foods high in various types of fibre to promote a variety of substrates for gut bacteria including inulin, galactooligosaccharides (GOS), and β-glucan. Participants will also be asked to consume 2 fermented items, yogurt and kefir. Study foods will be commercially available including a high-fibre bar made from chicory-derived inulin (1 bar of 35 g/d), oat-containing cakes (4 oatcakes of 35 g/d) or oat porridge (1 sachet of 38.5 g/d), shredded wheat cereal biscuits (2 biscuits of 45 g/d), hummus (½ pot of 100 g/d), and/or baked beans (½ can of 100 g/d) or lentil soup (1 can of 400 g/d), and low fat yogurt (1/3 pot of 150 g/d) and kefir (½ bottle of 250 ml/d). The total amount of fibre study foods will provide is approximately 25 g/day which will be consumed in addition to the habitual diet. The total amount of fibre will be expected to reach the 30 g/day recommendation and will range between 25 - 40 g/day.
223560800|NCT06977113|OTHER|Control Habitual Diet|Participants will follow their habitual diet and will not consume any of the study foods (i.e., high-fibre fermented foods). The population average fibre intake for women in Scotland is 16 g/day (The Scottish Health Survey 2021).
223560801|NCT06099223|DEVICE|Acupuncture needles|"The acupuncture intervention includes a combination of auricular and body acupuncture. The auricular points used are Shen men, Zero point, Tranquilizer point, and Master cerebral.~The body points used are the wrist PC6."
223560802|NCT02988947|OTHER|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
224033512|NCT03263286|DEVICE|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
224033513|NCT00486460|DRUG|Gemcitabine|
224033514|NCT00486460|DRUG|Curcumin|
224033515|NCT00486460|DRUG|Celebrex|
223560803|NCT01058681|DIETARY_SUPPLEMENT|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
224033516|NCT05001594|DEVICE|Active vibratory knee device|The active, wearable device is placed above and below the knee joint. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide vibratory feedback to the subject.
224033517|NCT02215382|DRUG|sugammadex|sugammadex 2 mg/kg
224136836|NCT01154179|OTHER|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
224136837|NCT00289185|BIOLOGICAL|RTS,S/AS02D|3-dose intramuscular injection in the thigh
224136838|NCT00289185|BIOLOGICAL|Engerix-B®|3-dose intramuscular injection in the thigh.
224033518|NCT02215382|DRUG|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
224136839|NCT00289185|BIOLOGICAL|TETRActHib™|3-dose intramuscular injection in the thigh.
224136840|NCT05861804|PROCEDURE|Rhomboid Intercostal Nerve Block|Before the induction of general anesthesia, under aseptic conditions, rhomboid intercostal nerve block will be performed with a single dose of 20 ml of %0,25 bupivacaine with ultrasound guidance, by the senior anaesthesiologist.
224136841|NCT01152736|DRUG|Nicotine|2 mg Single-dose
223416581|NCT05804422|DIETARY_SUPPLEMENT|Placebo|Placebo
223416582|NCT01559025|DRUG|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
223416583|NCT01405339|DEVICE|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
223416584|NCT01405339|DEVICE|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
223416585|NCT05899517|DRUG|oral lollipop with oxytocin (24IU)|For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.
224033519|NCT04789512|OTHER|Respiratory functions|Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players
224033520|NCT00181064|BEHAVIORAL|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
224033521|NCT00410085|DRUG|L-NMMA (N-mono.methyl-L-arginine)|
224033522|NCT00763867|DRUG|Placebo|
224033523|NCT00763867|DRUG|Sildenafil|
224033524|NCT01767805|PROCEDURE|Standard incubator|
224033525|NCT01767805|PROCEDURE|Mini incubator|
224033526|NCT01767805|PROCEDURE|5% oxygen|
224033527|NCT01767805|PROCEDURE|20% oxygen|
224033528|NCT02069353|DEVICE|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
224033529|NCT02069353|DEVICE|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
224033530|NCT00475033|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
224033531|NCT00475033|BIOLOGICAL|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
224299191|NCT04476719|DRUG|ARBIDOL 100 MG KAPSUL|Two 100 mg capsules will be administrated with 240 ml water orally.
223416586|NCT05899517|DRUG|oral lollipop with placebo|For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
223416587|NCT06099522|BEHAVIORAL|Internet-based cognitive behavioral therapy (iCBT)|The treatment is a newly developed iCBT 8 module program, with interventions targeting gambling-related loss of control, through 4 clinical processes: Gambling triggers, Gambling-related anticipation, the Gambling zone and Chasing behaviors. The treatment will be delivered with therapist support.
223416588|NCT04405635|OTHER|No intervention or exposure|No intervention or exposure
223416589|NCT02293135|DEVICE|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
223416590|NCT02293135|DEVICE|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
223416591|NCT00351702|DRUG|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
223416592|NCT01910584|PROCEDURE|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
223416593|NCT04478721|DRUG|Temocillin|The intervention of experimental arm will be Intravenous administration of temocillin.
223416594|NCT04478721|DRUG|Meropenem|The intervention of comparator arm will be intravenous administration of meropenem.
223416595|NCT00983203|OTHER|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
223416596|NCT00983203|OTHER|Soothe XP Lubricant Eye Drops|1 drop OU
223416597|NCT02069808|DRUG|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
223416598|NCT02069808|DRUG|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
223416599|NCT02069808|DRUG|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
223416600|NCT02069808|DRUG|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
223416601|NCT02069808|PROCEDURE|Transvaginal ultrasound guided needle aspiration of oocytes|
223416602|NCT05000008|OTHER|Exercises|Moderate aerobic and resistance exercise programe
223416603|NCT03461952|DRUG|Nivolumab|240mg
223416604|NCT03461952|DRUG|Ipilimumab|1mg/kg
223416605|NCT01931475|DRUG|Duloxetine|Administered orally
223416606|NCT01931475|DRUG|Placebo|Administered orally
223416607|NCT03055299|OTHER|COMEX intervention|Comprehensive Exercise
223416608|NCT04453280|DIAGNOSTIC_TEST|Quantitative analysis of anti-SARS-CoV-2-antibodies|Plasma sampling will be collected and archived for subsequent quantitative analysis of anti-SARS-CoV-2 antibodies - IgG, IgM and IgA.
223416609|NCT04453280|DIAGNOSTIC_TEST|SARS-CoV-2 diagnostic rapid test|The rapid test detects the presence of antibodies against SARS-CoV-2 by the immunochromatographic reaction.
223416610|NCT06684574|OTHER|Nordic walking program|The intervention is a defined program of Nordic walking and strengthening exercises for 10 weeks in a regimen of two days per week (two 75-minute sessions per week). In these sessions, they did Nordic walking three 5-minute breaks, where strength and proprioception exercises of the lower extremities were performed.
223416611|NCT06684574|OTHER|Educational advise|Patients in the control arm participated in a single session to advise them on the need for self-exercise.
223560804|NCT03981094|DRUG|BMS-986278|suspension
224033532|NCT05773989|DRUG|CYP2C19 genotype guided P2Y12 monotherapy|Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.
224033533|NCT05773989|DRUG|Clopidogrel|Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
223416612|NCT01910480|DRUG|NBI-98854 50 mg capsule once daily|
223416613|NCT01910480|DRUG|Ketoconazole 400 mg (200 mg twice daily)|
223416614|NCT04003831|DEVICE|Device: P200TxE|The P200TxE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
223416615|NCT03935776|BEHAVIORAL|Risk Factors Modification Programme|12- week supervised risk factor modification programme derived from the Euroaction study standards
223416616|NCT03935776|BEHAVIORAL|Standard Healthcare|Patients are advised to adjust lifestyle without the support of the structured supervised programme
223416617|NCT02547389|BEHAVIORAL|Community support group|
224033534|NCT00753051|DRUG|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
223416618|NCT02547389|OTHER|Printed material Supported|
223416619|NCT00115492|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
223416620|NCT00115492|DRUG|Salmeterol|
223416621|NCT01998802|DRUG|Active Comparator EBI-005|
223416622|NCT01998802|DRUG|Placebo Comparator|
223416623|NCT04810000|DEVICE|tourniquet|Tourniquet release before/after wound closure
223416624|NCT05788367|PROCEDURE|The pericapsular nerve group|patients received Ultrasound guided pericapsular nerve group block using 20 ml of bupivacaine 0.5%
223416625|NCT05788367|PROCEDURE|Interscalene brachial plexus block|patients will receive interscalene brachial plexus block using 15 ml of bupivacaine 0.5% before induction of general anesthesia
223416626|NCT02177916|OTHER|Education|
223560805|NCT03981094|DRUG|Pirfenidone|capsule
223739150|NCT06694727|DIETARY_SUPPLEMENT|Coenzyme Q10 100 Milligrams Oral Capsule|100 mg capsules given twice daily, per oral use.
224033535|NCT00753051|DRUG|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
224033536|NCT04891432|PROCEDURE|Lateral lumbar interbody fusion|oblique lumbar interbody fusion or direct lateral interbody fusion
223416627|NCT04240639|DEVICE|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
223416628|NCT05592665|OTHER|Survey Questionnaire|Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
223416629|NCT06223399|OTHER|Imaging-based programming|Preferred contact point(s) and settings for DBS programming will be determined based on the visualization of the electrodes in the patient-specific anatomy and the volume of tissue activated (VTA; i.e., the tissue enclosed within an iso-surface of the activation function). This will be determined with help of the software program Brainlab with the GUIDE XT module.
223416630|NCT06223399|OTHER|Threshold assessment-based programming|The preferred contact point(s) and settings for DBS programming will be determined according to current clinical practice. During the threshold assessment, the amount of electrical current needed to generate symptomatic improvement and the amount of electrical current needed to generate adverse-effects are determined for every contact point of both DBS leads by increasing current with 0.5 mA steps from 0 to approximately 5.0 mA. With each step, severity of Parkinson symptoms and presence of possible adverse-effects are assessed. For each side (i.e., left and right), the contact point with the most favorable trade-off between clinical improvement and adverse effects will be used for stimulation.
223416631|NCT03750149|DEVICE|EyeTracker|Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
223416632|NCT01901601|PROCEDURE|LALAK|"1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
223416633|NCT01901601|PROCEDURE|IEK|"1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
223416634|NCT01901601|DRUG|Retrobulbar Block or General Anesthesia|
224033537|NCT01377753|DEVICE|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
224033538|NCT04290169|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA will be injected in upper extremities according to recommended guidelines. Two methods will be used in the study: auditive electromyography (EMG) and ultrasound guided injection technique. The decision process of which muscles to inject will be based on information obtained through examination of hand function, the presence of increased muscle tone during the clinical examination as well as a positive response from auditive EMG
224033539|NCT04290169|DEVICE|Video game|"The study will include the Nintendo Switch or similar consoles that include games that require the players to move their bodies while holding motion controllers in order to progress. The games included in this project has been chosen by staff at our hospitals Virtual Gaming Lab. The participants are recommended to train 30 minutes each day, 4 days a week, during the training periods. It is expected that the amount of training will vary among the participants. Thus, each participant will be instructed to keep a training-diary and weekly report number of hours played/trained through an online reporting system created with online form, an electronic data collection system available through the University of Oslo"
224033540|NCT02739373|DRUG|BMS-986189|
224033541|NCT02739373|OTHER|Placebo|
224033542|NCT02858869|BIOLOGICAL|Pembrolizumab|Given IV
224033543|NCT02858869|RADIATION|Stereotactic Radiosurgery|Undergo SRS
224033544|NCT00508352|PROCEDURE|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
224033545|NCT02447757|DRUG|remifentanil|Remifentanil analgesia during delivery
224033546|NCT03516968|DRUG|Monthly bolus of cholecalciferol per os|Bolus therapy: first 50 000 IU and a second 50 IU after 6 weeks
224033547|NCT03516968|DRUG|Daily dose of cholecalciferol per os|Daily substitution, 1200 IU per day (4 drops), for 3 months
223416635|NCT01901601|DEVICE|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
223416636|NCT01901601|DRUG|Topical Anesthesia|
223416637|NCT01901601|DEVICE|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
223416638|NCT04292912|DRUG|GSK2798745|GSK2798745 will be administered.
224033548|NCT00985322|DRUG|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
224033549|NCT00985322|DRUG|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
224033550|NCT04770311|BEHAVIORAL|Microbiome friendly diet|Families in the intervention group will have a microbiome-friendly nutrition assessment and will also receive groceries one time per week for four weeks to help achieve a more microbiome-friendly diet.
224298518|NCT02774135|OTHER|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
224298519|NCT02059018|DRUG|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
223416639|NCT00905593|DRUG|Nilotinib|
223416640|NCT02464774|PROCEDURE|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
223416641|NCT02464774|PROCEDURE|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
224033551|NCT02617563|DEVICE|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
224033552|NCT05073068|BEHAVIORAL|Timing of exercise|An acute exercise bout of cycling performed in the morning at 9 AM or at 5 PM
224033553|NCT05073068|BEHAVIORAL|Control|No exercise
223416642|NCT02464774|DRUG|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
223416643|NCT02464774|RADIATION|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
224033554|NCT03583528|DIAGNOSTIC_TEST|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
223416644|NCT03211260|DEVICE|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
224033555|NCT03583528|DIAGNOSTIC_TEST|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
224033556|NCT06049407|BEHAVIORAL|Participation in a socio-emotional competence program through a technological platform (EMOWELL)|(1) Participants who meet the inclusion criteria will be contacted. (2) Participants will answer the questionnaire battery (T1) (3) Participants will participate in the intervention by remotely playing the EMOWELL desktop serious game and the EMOWELL app. (4) They will answer the T2 questionnaires.
223416645|NCT03072589|DRUG|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
223416646|NCT06175026|BEHAVIORAL|Health messages|Participants view messages about the health impacts of certain dietary substitutions.
223416647|NCT06175026|BEHAVIORAL|Environmental messages|Participants view messages about the environmental impacts of certain dietary substitutions.
223560806|NCT01652053|DEVICE|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
223560807|NCT05037695|DRUG|empagliflozin 25 MG|empagliflozin 25mg - daily
223416648|NCT06175026|BEHAVIORAL|Health and environmental messages|Participants view messages about the health and environmental impacts of certain dietary substitutions.
223416649|NCT06175026|BEHAVIORAL|Neutral messages|Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
223416650|NCT05325190|DRUG|Granisetron Transdermal Patch System|Granisetron transdermal patch 3.1mg was given 48 hours before the first day of chemotherapy, Dexamethasone 12mg was taken orally on the first day of chemotherapy and dexamethasone 8mg was taken orally on the second and third days of chemotherapy,3.1mg granisetron transdermal patch was replaced on the 5th day of chemotherapy. Granisetron transdermal patch was removed and discarded on the 12th day of chemotherapy.
223416651|NCT04081610|DRUG|lagricel ofteno multidose|"* Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic"
223416652|NCT04081610|DRUG|lagricel ofteno single dose|"* Dosage: 1 drop 4 times a day per 7 days, both eyes~* Route of administration: Ophthalmic"
223416653|NCT01786135|DRUG|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
223416654|NCT06968416|OTHER|Standard cleanser，standard moisturizer，standard sunscreen，Investigational serum|"Products Application and Usage Instruction~1. Mode of application: T-3W \~ T0~   Frequency:~   AM: Standard cleanser + standard moisturizer + standard sunscreen PM: Standard cleanser + standard moisturizer Caution: No any other skincare or facial make up products are used except provide products~2. Mode of application: T0 \~ T12W~Frequency:~AM: Standard cleanser + Investigational serum (face and eye) \[FLA #774715 21\] + standard moisturizer + standard sunscreen PM: Standard cleanser + Investigational serum (face and eye) \[FLA #774715 21\] + standard moisturizer~Caution: No any other skincare or facial make up products are used except provide products~Usage Instruction： Use serum \[FLA #774715 21\] 8-10 drops (0.3ml) on cleansed face and eye skin 2 times a day (AM \& PM)."
223739151|NCT06694727|DIETARY_SUPPLEMENT|Selenium 100 Micrograms Oral Tablets|100 μg tablets given twice daily, per oral use.
223560808|NCT04055272|BEHAVIORAL|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
223560809|NCT04338607|PROCEDURE|Subtalar (Talocalcaneal) arthrodesis|Subtalar (Talocalcaneal) arthrodesis with a novel sustained dynamic compression intramedullary nail
223560810|NCT04338607|DEVICE|DynaNail Mini|Utilization of a novel sustained dynamic compression pseudoelastic intramedullary nail
224033557|NCT04955743|DRUG|Pembrolizumab|200 mg intravenous (IV) is administered every 3 weeks
224033558|NCT04955743|DRUG|Lenvatinib|20 mg orally (PO) is administered daily
224033559|NCT03444324|BIOLOGICAL|BT524|BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.
224033560|NCT03444324|BIOLOGICAL|FFP/Cryo|FFP/Cryo was administered intravenously; dosage according to local standards. FFP, 15 mL per kg body weight (BW); Cryoprecipitate, fixed dose of 10 units.
224033561|NCT04328636|DRUG|Nebulized Magnesium Sulfate|Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
224033562|NCT04328636|DRUG|Intravenous Magnesium Sulfate|Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
224033563|NCT06150534|OTHER|No Intervention|This is a non-interventional study.
224033564|NCT05380778|DRUG|Deep anesthesia|"Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45"
224136842|NCT00505232|DRUG|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~1. Patients younger than 60 years who will receive 8 chemotherapy cycles~2. Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) \[0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets \< 100,000/µl\] will be administered 8 to 12 weeks after last chemotherapy."
224136843|NCT04157647|DEVICE|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
224136844|NCT04157647|DEVICE|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
224136845|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus carbohydrate|A high carbohydrate drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise.
224136846|NCT05417659|DIETARY_SUPPLEMENT|Exercise plus niacin|A dose of niacin to be consumed 30 minutes prior to exercise, at onset of exercise and 30 minutes into exercise.
224136847|NCT05417659|OTHER|Placebo|A placebo drink to be consumed 1 hour prior to exercise and every 15 minutes during exercise and placebo tablets to be consumed 30 minutes prior to exercise, at the onset of exercise and 30 minutes into exercise.
224136848|NCT01908959|BEHAVIORAL|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
224136849|NCT01260376|DRUG|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
224136850|NCT04580394|DRUG|AD109|Oral administration before bed
224136851|NCT04580394|DRUG|Atomoxetine|Oral administration before bed
224136852|NCT04580394|DRUG|R-oxybutynin|Oral administration before bed
224136853|NCT04580394|DRUG|Placebo|Oral administration before bed
224298520|NCT02059018|DRUG|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
224298521|NCT02059018|DRUG|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
224298522|NCT01376193|DRUG|Naratriptan|Collection of safety data
224298523|NCT03947671|DEVICE|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
224298524|NCT03947671|DRUG|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
224033565|NCT05380778|DRUG|Shallow anesthesia|"Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45"
223416657|NCT05704348|PROCEDURE|Sleeve gastrectomy with gastropexy|Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.
223416658|NCT05704348|PROCEDURE|Sleeve gastrectomy without gastropexy|Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.
223416659|NCT05169242|PROCEDURE|Endoclip|In the intervention arm, one or more endoclips will be used to completely close the mucosal defect after polypectomy. Prophylactic clipping will be applied to all post-polypectomy sites. The total number of endoclips used will be recorded.
223416660|NCT01312883|BEHAVIORAL|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
224033566|NCT01413854|DRUG|sugar pill|One tablet two times daily during four weeks
224033567|NCT01413854|DRUG|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
224033568|NCT06017986|OTHER|Ultra-processed food - Picture Set Meal|A meal containing ultra-processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
224033569|NCT06017986|OTHER|Ultra-processed food - Additives Meal|A meal containing ultra-processed foods that very on degree of additives.
224033570|NCT06017986|OTHER|Ultra-processed food - Ingredients Meal|a meal containing ultra-processed foods that very on degree of processing but not ingredients.
224033571|NCT06017986|OTHER|Minimally Processed Food - Picture Set Meal|a meal containing minimally processed foods derived from the picture set used in the Becker-Degroot-Marschak auction paradigm.
224298525|NCT02494609|DRUG|sotagliflozin|400 mg sotagliflozin
224298526|NCT02494609|DRUG|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
224298527|NCT02494609|DRUG|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
224033572|NCT06017986|OTHER|Minimally Processed Food - Additives Meal|A meal containing minimally processed foods that very on degree of additives.
224136854|NCT04580394|DIAGNOSTIC_TEST|Digit System Substitution Test|a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured.
224136855|NCT01717703|DIETARY_SUPPLEMENT|Water|
224136856|NCT01717703|DIETARY_SUPPLEMENT|Fruit drink|
224136857|NCT01717703|DIETARY_SUPPLEMENT|Cola|
224136858|NCT01717703|DIETARY_SUPPLEMENT|1% chocolate milk|
224136859|NCT05521217|DIAGNOSTIC_TEST|MyotonPRO|"Evaluation of biomechanics and viscoelastic properties of posture muscle in children with Spinal Muscular Atrophy.~The biomechanical and viscoelastic properties of the posture muscle in children with Spinal Muscular Atrophy. will be measured with the MyotonPRO device."
224298528|NCT04392583|DEVICE|ENTACT Septal Staple system|The ENTACT Septal Stapler delivers implantable septal staples which are intended to connect internal tissues to aid healing and for approximation of soft tissue during nasal septal surgery.
224298529|NCT03239912|DEVICE|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
224298530|NCT03239912|OTHER|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
224298531|NCT01672112|DRUG|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
224298532|NCT01672112|DRUG|Codeine|Oral Codeine 60mg 6hrly/prn
224298533|NCT03427502|DRUG|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
224298534|NCT03427502|DRUG|normal saline|normal saline
224298535|NCT03305406|OTHER|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
223416661|NCT05323448|DEVICE|Control Group|During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent).
224033573|NCT06017986|OTHER|Minimally Processed Food - Ingredients Meal|A meal containing minimally processed foods that very on degree of processing but not ingredients.
224033574|NCT06611124|PROCEDURE|k -wires fixation for metacarpals fractures|reduction and fixation of metacarpal fracture with k-wire
224136860|NCT03026335|BEHAVIORAL|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
224136861|NCT03026335|BEHAVIORAL|Control|Business as usual with students in non-itervened schools
224136862|NCT01368666|DEVICE|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
224136863|NCT00913133|DRUG|Desirudin|Desirudin SC 15mg q12h
224136864|NCT00642746|DRUG|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
224136865|NCT00642746|DRUG|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
224298536|NCT03305406|OTHER|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
224298537|NCT06095336|OTHER|telerehabilitation|The individuals included in the research will be divided into three groups. Group 1 (experiment): This is the exercise group followed by the telerehabilitation method. Group 2 (experiment): This is the group where traditional physical therapy methods will be applied. The 3rd group will be taken as the control group, there will be no intervention and they will be asked to continue their daily lives.
224298538|NCT02177656|BEHAVIORAL|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
224298539|NCT01725321|OTHER|Narrow band imaging|Colonoscopy with new narrow band imaging
224298540|NCT01527084|PROCEDURE|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
224033575|NCT06610851|DIAGNOSTIC_TEST|Blood sample|Blood sample and centrifugation
224136866|NCT00642746|DRUG|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
224136867|NCT00642746|DRUG|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
224136868|NCT00642746|DRUG|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
224136869|NCT05249985|DEVICE|NMES|Participants will undergo 12 weeks of neuromuscular electrical stimulation- (NMES) based resistance training on the quadriceps.
224136870|NCT05249985|DIETARY_SUPPLEMENT|Protein|Participants will consume a daily protein supplement
224298541|NCT03565393|COMBINATION_PRODUCT|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
224298542|NCT03041324|BIOLOGICAL|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
223416662|NCT05323448|DEVICE|ARISTA|"During the surgical procedure, hemostasis will be achieved using the standard of care (electrocautery, pressure, ligature or any hemostatic agent). Before surgical wound closure, the corresponding amount of ARISTA-AH will be applied to completely cover the bleeding site :~* 5g for 5 to 8 instrumented vertebra~* 10g fo 9 or more instrumented vertebra"
223416663|NCT01765348|BEHAVIORAL|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
223416664|NCT01765348|BEHAVIORAL|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
223416665|NCT04954001|DRUG|FCN-159|FCN-159 is administered orally in once daily schedule for 28 days a cycle.
224033576|NCT06610916|OTHER|Reinforced Communautary Support Program (PARC)|"Participants will complete the initial self-questionnaire collecting baseline socio-demographic, clinical characteristics, and all intermediate effectiveness outcome criteria \&amp;#34;before\&amp;#34;. Concurrently with their participation in the program, they will complete various intermediate effectiveness evaluation questionnaires (\&amp;#34;after\&amp;#34;) at 3 months (end of PARC) and 6 months (Post-PARC). Healthcare professionals running the PARC program will also complete questionnaires related to implementation indicators throughout the patients\&amp;#39; course (Adoption, Implementation, Maintenance).~Qualitative interviews will be conducted with patients and relevant healthcare professionals to explore barriers and drivers to the optimal deployment of the PARC program and to examine each of the Reach, Adoption, Implementation, Maintenance indicators through an organizational approach"
223416666|NCT01141946|PROCEDURE|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
223416667|NCT01141946|PROCEDURE|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
223416668|NCT04679350|DRUG|hzVSF-v13|Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)
223416669|NCT04679350|DRUG|Placebo (Normal saline solution)|Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7
223416670|NCT02453035|DEVICE|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
223560811|NCT02031991|BIOLOGICAL|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
223560812|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
223560813|NCT02031991|BIOLOGICAL|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
224136871|NCT01204333|DRUG|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
224136872|NCT01204333|DRUG|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
224136873|NCT00507598|OTHER|No intervention|Correlative study collecting serum and tissue samples
223416671|NCT02379702|OTHER|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
223416672|NCT00555464|DRUG|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
223416673|NCT00555464|DRUG|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
223416674|NCT06578286|DRUG|ARX788|ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle
223416675|NCT03024957|DRUG|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
223416676|NCT03024957|DRUG|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
223416677|NCT03024957|DRUG|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
223416678|NCT04115592|OTHER|Cocoa butter|Consumption of cocoa butter made with chocolate confectionery
223416679|NCT04115592|OTHER|Cocoa butter oleogel|Consumption of cocoa butter oleogel made with chocolate confectionery
223416680|NCT04115592|OTHER|Sal seed oil|Consumption of sal seed oil made with chocolate confectionery
223416681|NCT04115592|OTHER|Sal seed oleogel|Consumption of sal seed oleogel made with chocolate confectionery
223560814|NCT05877937|OTHER|Supportive care (Watching a comedy movie)|A 10.1 inch Android tablet (2 pieces) and disposable earplugs for each patient were used in the study. A comic film archive was created in line with the recommendation and consultancy of department of state conservatory and performing arts. In this regard, the officials of the Conservatory stated that they had no standardized comedy films specific to society and emphasized that the standardization of art limits art activities. Therefore, there should be no limitations for art. In the film archive cre-ated according to their suggestions, there were a total of five comedy movies, including three Turkish comedies, one foreign romantic comedy, and one foreign Turkish-dubbed family comedy. The original/licensed versions of the movies in this archive were ob-tained and uploaded to the tablet. The movies lasted 90-120 minutes (as long as the av-erage duration of IV treatment). The patients selected the movie that they would watch during the treatment.
223560815|NCT04475419|PROCEDURE|preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)|covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
223416682|NCT06685731|OTHER|Laughter Yoga|"Laughter Yoga Intervention:~Laughter Yoga is composed of four stages: deep breathing exercises, clapping and warm-up exercises, childlike play, and laughter exercises. These stages are designed to remove barriers to laughter, enhance emotional expression through childlike play, and prepare the lungs for laughter exercises.~Before the Laughter Yoga session begins, participants will be introduced to both the practice itself and to Laughter Yoga in general. The session will then proceed according to the following structure:~Deep Breathing Exercises: Participants inhale through the nose for 4-5 seconds, hold their breath for 2-3 seconds, and exhale through the mouth, with lips pursed, for one second longer than the inhalation, while smiling or laughing. This exercise is performed for 10-15 minutes.~Clapping and Warm-Up Exercises: Participants clap with palms and fingertips touching, keeping their hands parallel. This stimulates acupressure points in the hands. To increase group energy, a"
223416683|NCT01983033|BEHAVIORAL|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
223416684|NCT01983033|BEHAVIORAL|treatment as usual|12 weeks of no intervention other than treatment as usual
223416685|NCT03788031|OTHER|Acuity training|The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
223416686|NCT03788031|OTHER|Occlusion therapy|Participants will be required to patch the good eye for 20 days, 1 hour per day.
223416687|NCT03477253|PROCEDURE|Laparoscopic cholecystectomy|The use of laparoscopic cholecystectomy in management of acute calculous cholecysitits
223416688|NCT03462394|OTHER|Current Script|This is the version of the phone call script currently used at NYU Langone Health.
223416689|NCT03462394|OTHER|Alternate Script Iterations|Intervention includes various iterations of the phone call script (different wording or script structure).
223416690|NCT05911048|BIOLOGICAL|Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)|boost with Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C)
223416691|NCT05911048|BIOLOGICAL|Recombinant COVID-19 vaccine(Sf9 Cell) (WSK-V101)|boost with Recombinant COVID-19 vaccine (Sf9 Cell) (WSK-V101)
223416692|NCT06078774|BEHAVIORAL|Virtual Health Coach|"Dyads first session will be 60-minutes, totaling 1 hour. Dyads will participate in weekly 30-minute sessions for weeks 2-12, totaling 5.5 hours.~Dyads will participate bi-weekly 30-minute sessions for 12 weeks, totaling 3 hours.~Dyads will participate in weekly 30-minute exercise sessions for 24-weeks, totaling 12 hours.~Children will have 3, 30-minute visits with their primary care physician (PCP) every 3 months, totaling 1.5 hours.~Parents will have three, 60-minute individual sessions, totaling 3 hours. Total study duration is 24 weeks, with a total of 26 contact hours.~Sessions follow a behavior therapy approach, including guided goal-setting, self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks, maintenance and relapse prevention. Weight is assessed weekly by coaches, with MI-consistent, autonomy-supportive feedback provided. Parent sessions will focus on ways to support their child's weight management."
223416693|NCT02475265|DRUG|estradiol 0.045 mg/levonorgestrel 0.015mg|
223560816|NCT04475562|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
223560817|NCT02107625|BEHAVIORAL|Diet A i.e. Low FODMAP diet|
223560818|NCT02107625|BEHAVIORAL|Diet B, i.e. Traditional IBS diet|
223560819|NCT02370316|BEHAVIORAL|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
223560820|NCT02370316|BEHAVIORAL|Clinical Structured Treatment|structured case management and symptom-targeted medication
224033577|NCT07006571|DEVICE|Real tDCS|The electrodes of the device will be positioned according to the following scheme: one electrode (anode) will be applied on the skin overlying the motor cortices, one electrode (cathode) will be applied on the skin overlying the cervical cord, in the area corresponding to C6. Dosage: 4 mA for the anodal electrode and 4 mA for the cathodal electrode (intensity could be reduced if not tollerate by the patient). Duration of stimulation: 20 minutes per session. Frequency: 5 days per week (Monday - Friday) for 16 weeks.
223416694|NCT03407157|DIETARY_SUPPLEMENT|Probiotic supplementation|Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)
223416695|NCT03407157|OTHER|Placebo|Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
223416696|NCT06685666|OTHER|traditional warm-up method specific to handball|The traditional warm-up program specific to handball consists of 6 basic sections: static stretching, aerobic work, dynamic mobility exercises, passes and crosses, shooting on goal and shooting according to position, and lasts 17 minutes in total.
223560821|NCT05031117|PROCEDURE|Conventional Epidural Technique|Standard Lumbar Epidural Technique at L4-5 interspace using Tuhoy needle (18G) then epidural catheter (20G) inserted, then 15ml 0.5% Bupivacane and 50ug fentanyl given.
223560822|NCT05031117|PROCEDURE|25G Dural Puncture Epidural Technique|25G pencil point spinal needle will be inserted at L4-5 interspace through the tuhoy needle
223560823|NCT03435120|OTHER|No intervention|No intervention
223560824|NCT02604368|DRUG|SC411|Soft gelatin capsule
223560825|NCT02604368|DRUG|Placebo|Soft gelatin capsule
224033578|NCT07006571|DEVICE|Sham tDCS|The electrodes will be positioned in the same way as the active device, but the current flow will be limited to the ramp-up (start of stimulation) and ramp-down (end of stimulation) phase, mimicking the sensation of stimulation without providing actual treatment. Dosage: Simulation of stimulation without actual current. Duration of stimulation: 20 minutes per session. Frequency: 5 days per week (Monday - Friday) for 16 weeks.
224033579|NCT07012226|OTHER|Low-calorie diet|Low-calorie diet based on calculated calorie needs
223416697|NCT06685666|OTHER|elastic band exercises added to the traditional warm-up|The experimental group will be given elastic band exercises for 6 weeks after the static and dynamic exercises in the traditional warm-up and then continue with the warm-up with the ball. The exercise program was planned progressively. The exercises will be done in the first 3 weeks, 2 sets of 10 repetitions with a light resistance band. Then the exercises will be done in 3 sets of 10 repetitions with a medium resistance band. There are 8 band exercises in total.This exercise; Flexion and Extension Exercise in Diagonal Pattern, Internal and external rotation with the arm next to the body and the elbow in 90 degrees flexion, Internal and external rotation with the arm in 90 degrees abduction and the elbow in 90 degrees flexion, Scaption Exercise, Rowing, Biceps and Triceps (elbow flexion and extansion exercise), Wrist Flexors and Extensors (wrist flexion and extansion exercise).
223416698|NCT03702075|OTHER|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
224033580|NCT07020962|OTHER|laughter therapy|Laughter therapy/yoga, classified as complementary therapy in medicine, is a unique form of exercise consisting of a combination of laughter, yoga and breathing techniques that allows us to laugh without any sense of humour.
224033581|NCT07020962|OTHER|routine nursing care|routine nursing care
223416699|NCT01451970|OTHER|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
223416700|NCT02499653|BEHAVIORAL|Psychological Intervention|
223416701|NCT02499653|BEHAVIORAL|Videos|
223416702|NCT01211457|DRUG|sapacitabine and decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
223416703|NCT01211457|DRUG|sapacitabine and venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
223560826|NCT04930276|OTHER|Diet intervention|Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
223560827|NCT00257582|DRUG|Cetirizine Dry Syrup|
223560828|NCT03958864|DRUG|CC-90001|CC-90001
224033582|NCT07019701|DEVICE|High flow oxygen through nasal cannula and face mask and standard oxygen therapy through non-rebreather face mask, and measurement of oxygen and carbon dioxide fraction in the hypopharynx|High flow oxygen through nasal cannula and face mask, and standard oxygen therapy through non-rebreather face mask, and measurement of oxygen and carbon dioxide fraction in the hypopharynx of healthy volunteers in different physiological conditions
224033583|NCT07019272|DRUG|Neratinib (HKI-272)|"Sequential neratinib extended adjuvant therapy will be initiated within 6 months after completing standard trastuzumab-based adjuvant therapy, continuing for 1 year.~As a real-world non-interventional study, treating physicians will determine neratinib regimens per the prescribing information and current clinical practice.~Neratinib Dosing:~Standard regimen: 240 mg (6 tablets) once daily with food for 1 year；~Dose escalation (to mitigate diarrhea, per latest CSCO Breast Cancer Guidelines and FDA labeling):~Week 1: 120 mg/day (days 1-7) Week 2: 160 mg/day (days 8-14) Week 3 onward: 240 mg/day (days 15-365)"
224033584|NCT07021339|PROCEDURE|Anterior temporal lobectomy (ATL)|"Patients assigned to the experimental group will undergo an anterior temporal lobectomy (ATL) according to established protocols adapted from epilepsy surgery. ATL is a reproducible and anatomically well-defined procedure routinely performed in patients with pharmacoresistant temporal lobe epilepsy. On the non-dominant hemisphere, the neocortical resection typically extends 6.5 cm posteriorly from the temporal pole, while on the dominant side, the resection length is limited to 4.0 cm, both measured along the superior temporal gyrus and guided by the Sylvian fissure. Language dominance is determined based on handedness, as specified in the inclusion criteria. In most cases, the lateral neocortical segment can be removed en bloc.~The mesial component of ATL encompasses resection of the uncus, amygdala, and the anterior hippocampus, typically including both the head and body. Resection is carried out to the level of the tectal plate or, at minimum, to the lateral mesencephalic sulcus."
224136874|NCT04352595|DRUG|Hemay808|Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
224136875|NCT01811355|DRUG|Mexiletine|Sodium channel blocker
223416704|NCT03115138|OTHER|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
223416705|NCT03192670|DEVICE|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
223560829|NCT06341296|DRUG|Irinotecan Liposome|70 mg/m\^2 , d1, 14 days per cycle, 8 cycles.
223560830|NCT06341296|DRUG|5-FU|5-FU 400mg/m\^2, then 2400mg/m\^2, continuous intravenous infusion for 46-48h, d1-2, 14 days per cycle, 8 cycles.
223560831|NCT06341296|DRUG|LV|400mg/m\^2, d1, 14 days per cycle, 8 cycles.
223560832|NCT06341296|DRUG|Bevacizumab|5mg/kg, d1, 14 days per cycle, 8 cycles.
223560833|NCT00079391|DEVICE|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
223560834|NCT04734483|DIAGNOSTIC_TEST|spirometry|spirometry
224136876|NCT01811355|DRUG|Placebo|Placebo
224136877|NCT05728671|DRUG|IP2015|Test drug
224136878|NCT02175173|DRUG|Rufinamide|Administration of Inovelon 100mg or 200mg Tablets
224136879|NCT05380934|DRUG|TQH3821 tablets|TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
223560835|NCT04734483|RADIATION|MRI and CT|MRI and CT
224136880|NCT05380934|DRUG|TQH3821 tablets (Placebo)|TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
224136881|NCT05380934|DRUG|Methotrexate tablets|Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
223416706|NCT01194128|BEHAVIORAL|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
223416707|NCT01194128|BEHAVIORAL|Information only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information."
223416708|NCT06278363|OTHER|Sexual Nursing care|"The Sexual Nursing Care approach is a specialized intervention for stroke patients and partners, addressing sexual health needs. It includes personalized counseling sessions with trained nurses, assessing dysfunctions and medical history. Active partner involvement fosters intimacy and understanding. Both receive sexual education covering anatomy, physiology, and post-stroke changes. Recommendations for activities like Kegel exercises are provided. Structured outpatient sessions occur, lasting 45 minutes, facilitated by a nurse. Pre- and post-treatment assessments are conducted to identify contraindications. Emerging issues during treatment are promptly communicated for management. Sexual Nursing Care aims to holistically address post-stroke sexual health and relational needs, improving awareness and communication.~Coaching and Counselling can be provided also via telemedicine."
223416709|NCT06278363|OTHER|Standard Nursing Care|Group 2 patients receive standard nursing care without structured interventions for sexual dysfunctions. Management relies on clinical case and routine care procedures. No specific sexual sphere interventions are provided. Any emerging issues needing diagnostic investigation are reported to the specialist. Both groups are assessed quantitatively for counseling effects on sexual and relational aspects and qualitatively for psychorelational changes and mood impact on couple's quality of life.
223416710|NCT03279549|PROCEDURE|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
223416711|NCT03279549|PROCEDURE|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
223416712|NCT03279549|PROCEDURE|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
223416713|NCT03279549|PROCEDURE|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
223416714|NCT03808324|DIAGNOSTIC_TEST|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
223416715|NCT05775003|DIETARY_SUPPLEMENT|Exercise|8 week exercise training program - consisting of weight training and cardiovascular exercise
223416716|NCT04733937|OTHER|a2 Platinum® stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
223416717|NCT04733937|OTHER|Conventional, A1 and A2 β-casein containing stage 1 infant formula|Upon randomization (if not included in the breastfed group), each participant will be provided with up to 105 days' supply of the standardized formula and up to 28 days' supply of the allocated formula. Participants and study investigators will conduct the trial via a pre-determined randomization schedule.
223416718|NCT01686464|DRUG|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
223416719|NCT01686464|DEVICE|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2\~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2\~3.0 L / min for the same duration during all acupuncture sections.
223560836|NCT04734483|OTHER|Laryngoscopy|laryngoscopy
223560837|NCT04734483|OTHER|electromyography|electromyography
224136882|NCT04020146|OTHER|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
224136883|NCT03645772|OTHER|Exercise intervention|12-week progressive training intervention
224136884|NCT03337152|DRUG|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
224136885|NCT03337152|DRUG|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
224298543|NCT02321735|BEHAVIORAL|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
223416720|NCT04729829|BEHAVIORAL|Social and behaviour change communication|Each SBC treatment community will receive nutrition content and learning through savings groups. The group members will participate in skill-building activities that promote five key behaviours about fish nutrition and household decision making on fish consumption as part of facilitated discussions, interactive learning sessions, and a video-based facilitated dialogue. Increased fish consumption through SBC mass attendance events through marketing of fish vendors, interactive learning, and edu-tainment competitions promoting fish consumption. SBC will raise awareness of the benefits of eating fish as part of a balanced diet, with a particular focus on pregnant and lactating mothers, and children under 5 years of age.
223416721|NCT04729829|OTHER|Fish aggregating device|This is a moored line attached to buoys in coastal waters that attracts oceanic fish to it, to make it easier for small-scale fishers to catch them using their existing gear and boats. This FAD will work to increase the catch rate and hence, the availability of fish for sale in upland community markets.
223416722|NCT00220610|DEVICE|Transcranial magnetic stimulation|
223416723|NCT02449798|DEVICE|"AccuCath 2.25 BC Intravascular Catheter"|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
223416724|NCT00776438|BIOLOGICAL|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
223416725|NCT00776438|BIOLOGICAL|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
223416726|NCT00776438|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
223416727|NCT00776438|BIOLOGICAL|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
224033585|NCT07021339|PROCEDURE|Gross Total Resection (GTR)|Patients will be surgically treated with GTR in terms of removing 100% of the tumor tissue in gadolinium-enhanced MRI.
223416728|NCT05499754|OTHER|pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL|a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
223416729|NCT05263050|DRUG|Cabozantinib|Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
223416730|NCT05263050|DRUG|Nivolumab|Nivolumab injection is to be administered as an IV infusion at a dose of 480 mg on day 1 of each cycle
224033586|NCT07019714|BEHAVIORAL|Daoyin Technique|"On the basis of treatment guided by Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , the experimental group was given Daoyin Technique for treatment. For patients who are able to complete the respiratory guidance technique. For patients who are unable to complete the respiratory guidance technique but have stable vital signs (referring to the Expert Consensus on Respiratory Critical Care Rehabilitation Treatment Techniques in China), the supine guidance technique is selected. It is carried out 5 days a week, 2 times a day, and each training session lasts for 30 minutes."
223416731|NCT01376986|BEHAVIORAL|physical, psychological and social activation|
224033587|NCT07019714|BEHAVIORAL|Routine Comprehensive Training|"On the basis of treatment guided by IIdiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline,the experimental group was given Routine Comprehensive Training. According to the patient's condition, select aerobic training (such as walking) or upper - limb and lower - limb resistance training (such as lifting, chest - expanding, foot - pedaling movements, etc.) combined with respiratory training (such as pursed - lip breathing, abdominal breathing, etc.). The heart rate should reach the target heart rate range and last for more than 10 minutes. This training is carried out 5 days a week, 2 times a day."
223416732|NCT05956470|BEHAVIORAL|Meditation and breathing program : Sudarshan Kriya Yoga (SKY)|The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.
224033588|NCT07020455|DRUG|prolotherapy solution of 20% dextrose|Polotherapy, it involves injecting an irritant solution into weakened joints, ligaments, or tendons to stimulate collagen production and tissue repair at fibro-osseous junctions.
224033589|NCT07020455|DRUG|Arthrocentesis with ringer solution|Integrating arthrocentesis with prolotherapy may enhance therapeutic outcomes by addressing both the mechanical and inflammatory aspects of TMJ hypermobility. This dual-modality technique presents a promising minimally invasive option for clinicians managing patients with joint instability.
224033590|NCT07020819|DRUG|Tanruprubart|Solution for IV infusion.
224033591|NCT07019805|DRUG|Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam|This intervention refers to the standard induction of general anesthesia in geriatric patients undergoing elective non-cardiac surgery. Induction typically involves the administration of intravenous anesthetic agents such as propofol and fentanyl, based on institutional protocols and the anesthesiologist's discretion. This study does not modify or introduce any new treatment; it merely observes and records peri-induction parameters to identify factors associated with the occurrence of post-induction hypotension.
224033592|NCT07019805|DEVICE|Blood Pressure Continous Monitoring, syrnge pump for the anesthesia agent, and vasoconstrictor drug|This intervention involves the standard clinical use of non-invasive continuous blood pressure monitoring during the induction of general anesthesia in geriatric patients undergoing elective non-cardiac surgery. Intravenous anesthetic agents (e.g., propofol, fentanyl) and vasopressors (e.g., ephedrine, norepinephrine) are administered via syringe pumps based on the anesthesiologist's clinical judgment. The study does not introduce any experimental treatment but observes blood pressure changes in real time to identify risk factors for post-induction hypotension. The integration of continuous hemodynamic monitoring distinguishes this observational approach from routine anesthetic induction without such monitoring.
223739152|NCT06703489|DEVICE|Sphere-9 Catheter with the Affera Mapping and Ablation System|Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia due to prior myocardial infarction will be enrolled and undergo ablation with the Sphere-9 Catheter with the Affera Mapping and Ablation System.
223416733|NCT05956470|BEHAVIORAL|Stress management education|This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
223739153|NCT07123363|DRUG|bitopertin|bitopertin 60 mg will be taken once daily by mouth
223416734|NCT05362396|OTHER|Inspiratory Muscle Training with Powerbreath IMT device.|Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 5 sets of 10 repetitions, 5 days a week. The endurance of the device increases along the study, initiating with the 50% of their own maximum inspiratory pressure (MIP) during the first week, 2nd week: 55% MIP, 3rd week: 60% MIP, 4th week: 65% MIP, 5th week: 70% MIP, 6th week: 75% MIP, 7th week: 80% MIP and 8th week:80% MIP
223416735|NCT02398903|OTHER|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
223416736|NCT02398903|OTHER|DXA and impedancemetry|Body composition by DXA and impedancemetry
223416737|NCT05831644|DRUG|C21|C21 is an angiotensin II type 2 receptor agonist (ATRAG)
223416738|NCT02165189|DRUG|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
223739154|NCT06881888|DRUG|Octreotide (drug)|Participants will administer the DDM-octreotide nasal spray without priming in one nostril three times a day.
223739155|NCT06881888|DRUG|Placebo|Participants will administer the placebo nasal spray without priming in one nostril three times a day.
223739156|NCT03480438|DRUG|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
224298544|NCT05950230|DIAGNOSTIC_TEST|Assess Periodontal Health Status|"For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph."
223416739|NCT02165189|DRUG|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
223416740|NCT02165189|DRUG|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram (\[kg\]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
223739157|NCT05199285|BIOLOGICAL|Ipilimumab|Given IV
223739158|NCT05199285|BIOLOGICAL|Nivolumab|Given IV
223739159|NCT06721910|DRUG|Tocilizumab|Blockade of the interleukin-6 receptor
223739160|NCT06721910|OTHER|Placebo|Infusion of 100 ml normal saline
224033593|NCT07018947|DRUG|Atezolizumab and Bevacizumab|"Participants will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs first (neoadjuvant therapy).~The adjuvant therapy with Atezo + Bev will start between 4 and 12 weeks after the resection date, once the participant has fully recovered from the surgery. Participants will receive up to 12 months or 17 cycles of treatment, whichever occurs first, or until disease recurrence or unacceptable toxicity."
224033594|NCT07020195|PROCEDURE|Traditional SYNTAX scoring|Using traditional SYNTAX scoring to guide the selection of revascularization strategies
224033595|NCT07020195|PROCEDURE|QFR-Based Functional SYNTAX Score System|Using QFR-Based Functional SYNTAX Score System to guide the selection of revascularization strategies
223416741|NCT02165189|DRUG|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
223416742|NCT02165189|DRUG|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
223416743|NCT06285851|DIETARY_SUPPLEMENT|FeSC|Supplement
223416744|NCT05615363|DRUG|OPC 131461 10mg group|OPC-131461 5 mg tablet x 2，once-daily oral administration for 14 days
223416745|NCT05615363|DRUG|OPC 131461 5mg group|OPC-131461 5 mg tablet and placebo tablet，once-daily oral administration for 14 days
223416746|NCT05615363|DRUG|OPC 131461 2mg group|OPC-131461 1 mg tablet x 2，once-daily oral administration for 14 days
223416747|NCT05615363|DRUG|OPC 131461 1mg group|OPC-131461 1 mg tablet and placebo tablet，once-daily oral administration for 14 days
223416748|NCT05615363|DRUG|Placebo|Placebo tablet，once-daily oral administration for 14 days
224033596|NCT07021300|PROCEDURE|Early Laparoscopic Cholecystectomy|A standard four-port laparoscopic cholecystectomy performed within 72 hours of diagnosis of acute cholecystitis. Surgery is done under general anesthesia by an experienced surgeon. This group receives no prolonged preoperative conservative management. Timing aligns with Tokyo Guidelines 2013 recommendation for early intervention
223416749|NCT00000672|DRUG|Didanosine|
223739161|NCT06803147|OTHER|Discontinued endoscopic surveillance|Endoscopic surveillance is discontinued for eligible patients in line with the new guideline revision, and patients are then followed in this prospective cohort
223739162|NCT07046234|DEVICE|Lung ultrasound|Lung ultrasound software.
223739163|NCT07047651|COMBINATION_PRODUCT|Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram), 20 people|A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) with RECOVERYTRSGR (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions.
223739164|NCT07047651|COMBINATION_PRODUCT|Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants, 15 people|The combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants) and TAU (psychotherapy) for patients with treatment-resistant schizophrenia. 190 sessions. The control group of Group A
223416750|NCT01323387|DEVICE|Interbody Fusion|allograft spacer + anterior plate
223416751|NCT01726270|DRUG|tamsulosin|0.4 mg
223416752|NCT04288687|DRUG|Niraparib Pill|Niraparib 200 mg by mouth daily (2 x 100 mg pills)
223416753|NCT01609647|DRUG|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
223416754|NCT01609647|DRUG|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
223416755|NCT06664970|DRUG|Azacitidine or Ruxolitinib combined with Selinexor|"1. The initial dose of Selinexor combined with Azacitidine for the treatment of MDS patients is 40mg QW, adjusted according to blood tests, with the highest dose ≤ 60mg QW.~   Azacitidine: The initial dose is 75 mg/m ², administered subcutaneously or intravenously, with a cycle of 1-7 days and 28 days until ineffective or intolerant.~2. Selinexor combined with Ruxolitinib for the treatment of patients with MPN symptoms: Selinexor dose: 40mg QW; Adjust according to the blood count, with a maximum dose of ≤ 60mg QW.~Initial dose of Ruxolitinib: platelet count\>100 × 109/L before enrollment, initial dose is 15 mg BID; Platelets range from 50-100 × 109/L, with an initial dose of 10 mg BID. Until ineffective or intolerant."
223416756|NCT02502812|DRUG|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
223560838|NCT03139994|OTHER|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
223560839|NCT06170463|DRUG|Metformin Hydrochloride|Met Group Received metformin hydrochloride 500 mg tab 3 times Daily
223739165|NCT07047651|COMBINATION_PRODUCT|Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine|A combination of pharmacotherapy with RECOVERYTRSBDGR (antipsychotics, anxiolytics, antidepressants, mood stabilizers) for patients with treatment-resistant bipolar disorder. 140 sessions, 15 people
223739166|NCT07047651|COMBINATION_PRODUCT|Group D (Pharmacotherapy and TAU)Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, seropram, lithium, depakine)|A combination of pharmacotherapy (antipsychotics, anxiolytics, antidepressants, mood stabilizers) and TAU (psychotherapy). A control group to RECOVERYTRSBDGR. 140 sessions. 10 people
223739167|NCT06740110|DEVICE|Tooth extraction and GBR procedure|The intervention will include tooth extraction and GBR procedure. After clinical and radiographic assessment, local anaesthesia is applied. The dentist performs atraumatic extraction, cleans the socket, places investigational device (first arm) or standard of care (second arm) and applies gauze for hemostasis. The patient is given post-operative care instructions. After recovery the first and second stage of implantation will be performed.
223739168|NCT06785402|DRUG|Ceftriaxone treatment|9 infusions spaced out approximately every 5 days
223739169|NCT06785402|DRUG|Placebo|D5W (placebo)
223739170|NCT04366453|PROCEDURE|echocardiography|Four measurements in echocardiography performed in addition to standard care
223739171|NCT05436418|DRUG|Melphalan|"Matched HCT: 100 mg/m\^2 IV on day -2 over 30 minutes. Haplo HCT:~100 mg/m\^2 IV on day -6 over approximately 20-30 minutes."
224033597|NCT07021300|PROCEDURE|Interval Laparoscopic Cholecystectomy|A standard four-port laparoscopic cholecystectomy performed after 4 weeks of initial conservative management with antibiotics and analgesics. The procedure is conducted under general anesthesia by the same experienced surgeon, using the same technique as the early group. This approach represents delayed surgical management per traditional protocols.
224033598|NCT07016581|DIAGNOSTIC_TEST|Daily survey|All patients undergoing an spinal cord stimulation trial procedure (which will be conducted in accordance to standard clinical practices per site) will be given daily surveys to assess their analgesic and functional benefit.
224033599|NCT07020468|DRUG|NALIRIFOX|The patients with Locally Advanced Colorectal Cancer and Upper Rectal Cancer will undergo neoadjuvant treatment with irinotecan liposome combined with oxaliplatin + 5-FU/LV (NALIRIFOX), with each treatment cycle lasting 2 weeks, for a total of 3-6 cycles.
224033600|NCT04496986|DIAGNOSTIC_TEST|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
224033601|NCT04496986|DIAGNOSTIC_TEST|Simultaneous FEES and Videofluoroscopy instrumental swallowing exam|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
224033602|NCT04496986|OTHER|Voluntary Cough Peak Expiratory Flow (PEF) Testing|Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
224033603|NCT04496986|OTHER|Reflex Cough Screen|Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
224298545|NCT05950230|OTHER|Collecte GCF samples by paperstrip|GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).
224298546|NCT00942435|DRUG|YM150|oral
224298547|NCT00942435|PROCEDURE|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
223416757|NCT02502812|DRUG|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
223416758|NCT02502812|DRUG|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
223416759|NCT00996151|DRUG|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
223560840|NCT06170463|DRUG|MI/DCI combination in 40:1 ratio|MI-group received MI/DCI combination in 40:1 ratio twice daily
223560841|NCT06170463|DRUG|Combination of Metformin hydrochloride and MI/DCI|MM Group Received both Met and MI Groups Treatment
223416760|NCT00131950|OTHER|physiologic testing|
223416761|NCT00131950|OTHER|study of socioeconomic and demographic variables|
223416762|NCT00131950|PROCEDURE|breast imaging study|
223416763|NCT00131950|PROCEDURE|study of high risk factors|
223416764|NCT02165280|BEHAVIORAL|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
223560842|NCT06176430|DRUG|Ferrous Sulfate Oral Product|ferrous sulphate oral in the form of syrup
223560843|NCT05976646|DRUG|Placebo|Subjects who are randomized to placebo will receive identical capsules to the test product at the same time periods noted above, administered orally.
223739172|NCT05436418|DRUG|Sirolimus|Sirolimus: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg)\^d, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions and may be modified based on institutional practice.
223739173|NCT05436418|RADIATION|Total Body Irradiation (TBI)|Haplo HCT only: A dose of 200 cGy will be administered on day -1.
223739174|NCT05436418|DRUG|Cyclophosphamide|based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
223739175|NCT05436418|DRUG|Mycophenolate Mofeti|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
223739176|NCT05436418|DRUG|Fludarabine|Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2
223739177|NCT05436418|PROCEDURE|Allogeneic HSCT|Stem cell transplant
223739178|NCT05436418|DRUG|Mesna|equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.
223739179|NCT05436418|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.
223739180|NCT06745050|BEHAVIORAL|Text message mHealth Evidence-based intervention|MM! includes three messages per week in month one, then two messages per week for the six-month intervention period. Earlier messages include more informational and motivational content, while later messages include more behavioral skills.
223739181|NCT06786923|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulator|Intervention Timing of Transcutaneous Auricular Vagus Nerve Stimulator: The intervention will begin 30 minutes before anesthesia induction and continue until the end of the surgery, terminating after the removal of the endotracheal tube in the PACU. The stimulation parameters are set as follows: frequency 25 Hz, pulse width 200 μs, 30 seconds on / 30 seconds off, with the current intensity set to the maximum amplitude the patient can tolerate (just below the pain threshold).
223739182|NCT05695339|DRUG|Resiniferatoxin|An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
223416765|NCT06455293|DRUG|Psilocybin|"Single dose of psilocybin ranging from low (microdose) to high delivered orally with psychological support and monitoring"
223416766|NCT06575491|DEVICE|Ultrasound-guided supraclavicular approach|Patients submitted to Supraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
223416767|NCT06575491|DEVICE|Ultrasound-guided infraclavicular approach|Patients submitted to Infraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
223416768|NCT00582608|DRUG|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m\^2 dose \[intended specific activity of \~20 mCi/mg protein\]
223416769|NCT00582608|DRUG|8H9|administration of 50mg/1.73m\^2 of unlabeled 8H9.
223416770|NCT03714074|DEVICE|PEEK implant abutment|Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure
223416771|NCT03714074|DEVICE|Zirconia abutment|Imolants will be restored with zirconia abutments and a PEEK superstructure
223416772|NCT06736444|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.
223416773|NCT06736444|BEHAVIORAL|Brief Alcohol Screening and Intervention for College Students (BASICS)|Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
223560844|NCT05976646|DRUG|Auvelity|Orally-administered combination of 45 mg dextromethorphan with 105 mg Bupropion (trade name Auvelity). Auvelity will initially be administered orally once daily for three days. After 3 days on once daily AUVELITY, the participants will begin taking AUVELITY twice daily for 4 additional days as recommended in the FDA-approved prescribing information.
223416774|NCT06736444|BEHAVIORAL|Attention Control|Attention Control is comprised of 4 weekly 20-minute check-ins with a study therapists regarding the daily monitoring and mood/functioning. Referrals for additional services will be provided as needed.
224033604|NCT04496986|OTHER|Lingual Pressure Testing|Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
223416775|NCT03745976|PROCEDURE|questionnaire and Xray for all patients|questionnaire and Xray for all patients
223416776|NCT02756130|DRUG|Birinapant|Given IV
223416777|NCT02756130|DRUG|Carboplatin|Given IV
223416778|NCT02756130|OTHER|Laboratory Biomarker Analysis|Correlative studies
223416779|NCT02756130|OTHER|Pharmacological Study|Correlative studies
224033605|NCT04496986|DIAGNOSTIC_TEST|Speech Testing|"Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup."
224033606|NCT06693115|DEVICE|CGM with alerts|"CGM devices will be set to alert the care team when interstitial glucose levels hit 250 mg/dL and 150 mg/dL. Dexcom 7s automatically alert when glucose levels are 55 mg/dL or lower. Nurses will be instructed to check the glucose trends on the CGM device when alerted. They will be asked to check glucose levels with a FSBG according to the following instructions:~1. CGM alerts to interstitial glucose level of 250 mg/dL AND trend indicates rapidly decreasing glucose levels (indicated by double down arrow on Dexcom 7)~2. CGM alerts to interstitial glucose level of 150 mg/dL or less."
224136886|NCT06490419|DEVICE|Electrolipolysis|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute."
224298548|NCT05405972|BEHAVIORAL|The Connected Family Series - For Foster Families|A 4-week program involving videos and activities for both the parent and child in the home.
224299192|NCT03161964|DRUG|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
223416780|NCT06747364|OTHER|Alcohol (Ethanol)|Alcohol will be administered to participants by research staff. In Phase 1, participants will consume alcohol designed to produce a targeted blood alcohol concentration (BAC) of 0.06% using the modified Widmark equation.
223416781|NCT03691311|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Two injections on days 1 and 8 previous to surgery breast cancer excision
223416782|NCT06181084|DRUG|LY3410738|Administered orally.
223416783|NCT06181084|DRUG|Esomeprazole|Administered orally.
223416784|NCT01397877|DRUG|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
223416785|NCT00404001|DRUG|MD-0727|
223416786|NCT05142969|OTHER|2% Chlorhexidine bathing|Eight chlorhexidine-impregnated cloths are used in sequential order to wipe the body surfaces from neck to toe to avoid exposure of chlorhexidine to the mucous membranes of the eyes, ears and mouth.
223416787|NCT05389566|DIAGNOSTIC_TEST|Quantative Sensory Testing|Evaluation of small fiber neuropathy
223416788|NCT05389566|DIAGNOSTIC_TEST|NCStat-DPN-Check|Evaluation of large fiber neuropathy
223416789|NCT05389566|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|Evaluation of autonomic neuropathy
223416790|NCT05389566|DIAGNOSTIC_TEST|Computerized dynamic posturography|Evaluation of dynamic postural control
223416791|NCT05389566|DIAGNOSTIC_TEST|Video Head Impulse Test|Evaluation of vertigo and the vestibular organ
223416792|NCT05389566|DIAGNOSTIC_TEST|Accelerometer|Evaluation of gait pattern
223416793|NCT05389566|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
223416794|NCT05389566|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtimetry scan|Evaluation of body composition
223416795|NCT05389566|DIAGNOSTIC_TEST|Force Plate Platform|Evaluation of balance while standing still
223416796|NCT02313207|DIETARY_SUPPLEMENT|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
223416797|NCT02171234|DRUG|Placebo|
223416798|NCT02171234|DRUG|BIA 2-093|
223416799|NCT02036073|DRUG|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
223416800|NCT00048386|BIOLOGICAL|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
223416801|NCT02819973|OTHER|Educational Video1|
223416802|NCT02819973|OTHER|Educational Video 2|
223416803|NCT02819973|OTHER|Usual Care 3|
223416804|NCT05914597|OTHER|Setting up home delivery of Colon capsule endoscopy|Feasibility study of home delivery of CCE
223416805|NCT03767153|DEVICE|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
223416806|NCT03012997|OTHER|Fraction of inspired oxygen 40%|
223416807|NCT03012997|OTHER|Fraction of inspired oxygen 100%|
223416808|NCT04977427|DRUG|Dextenza 0.4Mg Ophthalmic Insert|Dexamethasone inserted into lower punctum at the end of cataract surgery in order to control inflammation in the eye for the following 30 days after surgery.
223416809|NCT04977427|DRUG|Prednisolone Acetate 1% Oph Susp|Standard Prednisolone taper following cataract surgery, QID for one week, followed by TID for one week, BID for one week, and QDaily for one week, then stop.
223416810|NCT04201574|DRUG|ALY688 0.1%|ALY688 0.1% Ophthalmic Solution
223416811|NCT04201574|DRUG|ALY688 0.4%|ALY688 0.4% Ophthalmic Solution
223416812|NCT04201574|DRUG|Vehicle|Vehicle Ophthalmic Solution
223416813|NCT01610882|DEVICE|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
223416814|NCT01610882|DEVICE|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
223560845|NCT01027494|DRUG|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
223416815|NCT01013272|DRUG|Entecavir|Entecavir 0.5mg orally daily
223416816|NCT01013272|DRUG|Lamivudine|Lamivudine 100mg orally, daily
223416817|NCT05596929|DIAGNOSTIC_TEST|Artificial intelligence|After the patients under triage classification to which randomly allocates in two groups. The group with AI intervention and the other without AI intervention.
223416818|NCT06192862|BEHAVIORAL|Assessment of screening intention and Transtheoretical Model stages for CRC screening|"Screening Intentions will be measured by asking the subject, How much do you agree or disagree: I am intending to have colon cancer screening within the next 6 months. Subjects who strongly disagrees or somewhat disagrees are considered not having screening intention. Subjects who somewhat agrees or strongly agrees are considered having screening intention. For subjects who has screening intention, they will be asked if they have plan to arrange a consultation with primary care physician to collect FIT kits in next 3 months."
223416819|NCT03813680|OTHER|Passive Vertebral Mobilization|Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
223416820|NCT03813680|OTHER|PNF exercise|The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
223416821|NCT03813680|OTHER|Routine Physiotherapy|Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
223416822|NCT04304430|DRUG|Dapagliflozin|Initiation of dapagliflozin according to clinical indication
223560846|NCT01773005|DRUG|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
223560847|NCT01773005|DRUG|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
223416823|NCT04304430|DRUG|DPP-4 inhibitor|Initiation of DPP-4i according to clinical indication
223416824|NCT05663073|DRUG|Irbesartan/Amlodipine FDC|Irbesartan/Amlodipine FDC
223416825|NCT05663073|DRUG|Irbesartan|Co-administration of Irbesartan and Amlodipine
223416826|NCT05663073|DRUG|Amlodipine|Co-administration of Irbesartan and Amlodipine
223416827|NCT01965366|BEHAVIORAL|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
223416828|NCT01965366|DRUG|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
223416829|NCT05424848|OTHER|Ultasonographic measurement|Ultrasonographic measurements of the patients will be evaluated by Dr. Merve Damla Korkmaz. Patients will be positioned in a semi-dark room with the knees fully flexed. Ultrasonographic measurements will be made to evaluate the femoral cartilage thickness of both knees, with images taken from the suprapatellar axillary position. Images of the intercondylar area, lateral and medial femoral condyles of the right and left knees will be taken and the measurements will be made from these areas, 3 measurements will be taken from each knee and the average of these measurements will be taken.
223416830|NCT04340037|PROCEDURE|percutaneous nephrolithotomy|percutaneous surgery using nephroscope
223416831|NCT00982332|DRUG|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
223416832|NCT00982332|DRUG|isotonic sodium chloride solution (placebo)|4 ml intramuscular
223560848|NCT00828802|DRUG|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
223560849|NCT00722722|DRUG|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
223560850|NCT02628600|DRUG|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
223560851|NCT02628600|DRUG|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
223560852|NCT06814886|BEHAVIORAL|wearable devices to initiate behavioral intervention|12 week wearable devices to initiate behavioral intervention including line APP recruited participants and give some behavior change advises, also give a APP-based motivational interviewing 15 minutes per week.
224298549|NCT06632522|DRUG|radiotherapy combined with Camrelizumab and Apatinib|Camrelizumab is administered intravenously (without preventive medication), with a fixed dose of 200mg, with an infusion of 30 min (not less than 20 min and not more than 60 min) every three weeks. Apatinib, 250 mg, taken orally within half an hour after meals, QD, continuously.
223416833|NCT00315133|PROCEDURE|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
223416834|NCT03271190|BEHAVIORAL|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
223416835|NCT03271190|BEHAVIORAL|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
223416836|NCT03204994|DRUG|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
223416837|NCT04861727|OTHER|MRPA procedure|The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure
223416838|NCT04861727|OTHER|Pharmaceutical intervention|The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
223416839|NCT04163120|OTHER|Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)|The KEMEPHY diet (24-29) is a Mediterranean low calories ketogenic protocol (about 1000/1100 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg) Table 1. Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (30). Liquid herbal extracts were used for their draining /toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis.
223416840|NCT03007082|DEVICE|Revive SE intracranial thrombectomy device|"1. Intra-arterial mechanical thrombectomy with Revive SE；~2. According to patient condition, the investigator could determine intravenous thrombolysis or not at his/her discretion"
223416841|NCT04832594|OTHER|AI selection for supplemental breast MRI|An AI tool will generate scores used to determine eligibility. Women randomized to MRI will be examined in an MRI scanner.
223416842|NCT04892329|OTHER|Artificial intelligence assistant system|The endoscopists in the experimental group will be assisted by EndoAngel, which can assist in identifying important anatomical structures adjacent to the pancreas in real time. The system is an non-invasive AI system .
223416843|NCT03258294|DRUG|Melatonin(Circadin®)|
223416844|NCT03258294|DRUG|Placebo Oral Tablet|
224298550|NCT00188110|PROCEDURE|Water-Enema Computed Tomography|
223416845|NCT06577480|OTHER|No intervention|No intervention
223560853|NCT06814886|BEHAVIORAL|12 week wearable devices monitor|12 week wearable devices monitor physical activity and sleep quality only
223560854|NCT06657092|PROCEDURE|Erector Spinae Plane Block|Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
223560855|NCT06657092|PROCEDURE|Standart therapy|Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
223560856|NCT01783197|DRUG|Paclitaxel|
223560857|NCT01783197|DRUG|Carboplatin|
224298551|NCT00428636|PROCEDURE|ileostomy|
224298552|NCT05549518|OTHER|Core stabilization + Traditional Physical Therapy|"In addition to the traditional physical therapy training, core stabilization exercises will be applied 3 days a week for 6 weeks, and 20 minutes in each session under the supervision of a physiotherapist. Core stabilization exercises; will gradually progress from easy exercises to difficult ones. Exercises will be performed in supine, hook position, sitting position, on stable and mobile surfaces. Exercises will progress from 1 set to 3 sets, from 7 to 10 reps, contractions from 3 seconds to 10 seconds. All exercises will be performed with breathing control.~The exercises will be progressed by gradually increasing them every week."
223560858|NCT01783197|DRUG|Selumetinib|
223560859|NCT01783197|DRUG|Pemetrexed|
223560860|NCT01783197|DRUG|Cisplatin|
223560861|NCT05500573|PROCEDURE|Sperm Sorting|Selection of gender specific spermatozoa using a multilayer density gradient solution
224299193|NCT03161964|DRUG|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
224299194|NCT00004800|BIOLOGICAL|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
224299195|NCT00004800|BIOLOGICAL|diphtheria-tetanus vaccine|
223416846|NCT02073929|DRUG|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
223416847|NCT02073929|DRUG|placebo|Placebo s.c. daily for 26 weeks
223416848|NCT04968080|DEVICE|Infrared Cameras Inc. (ICI) FMX 400 Infrared (IR) Camera System|Infrared thermal camera
223416849|NCT04968080|DEVICE|Welch Allyn SureTemp Plus 690|Oral thermometer
223416850|NCT04968080|DEVICE|Welch Allyn ThermoScan PRO 6000|Ear thermometer
223416851|NCT04968080|DEVICE|Infrared Cameras Inc. (ICI) HotSpot Infrared (IR) NonContact Infrared Thermometer|Forehead temperature gun
223416852|NCT04528940|DIAGNOSTIC_TEST|PD-1/PDL-1 staining|Every endometrial or ovarian carcinoma will be stained for PD-1/PDL-1. The stage and grade of the tumor will be determined and correlation between tumor grade and stage and PD-1/PDL-1 staining will be made.
223416853|NCT05027659|OTHER|virtual reality glasses|Virtual reality (VR) glasses have a detachable screen frame compatible with smartphones. A VR headset has earphones and sensors that track the user's head movements, giving them the impression that they are moving around in a virtual environment. The investigators used a smartphone and VR glasses to perform the intervention. They connected the phone to the VR headset via a 360 degree VR video app. Experimental participants wore the VR glasses and watched a 360 degree VR video of nature scenes with ambiance music during colonoscopy. They put on the VR glasses right before the procedure and took them off right afterward.
223416854|NCT02989038|OTHER|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
223416855|NCT02989038|OTHER|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
223416856|NCT02989038|OTHER|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
223416857|NCT04301869|DRUG|Antibiotics|Oral versus intravenous therapy
223416858|NCT06170476|DRUG|HSK21542-60μg|HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
223416859|NCT06170476|DRUG|HSK21542-120μg|HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
223416860|NCT06170476|DRUG|HSK21542-180μg|HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
223416861|NCT06170476|DRUG|Placebo|A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
223416862|NCT00430573|DRUG|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
223416863|NCT00430573|DRUG|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
223416864|NCT06576492|OTHER|RV4986A lotion|"* Application between Month -0.5 and Month 0 (before hair transplant): once a day on the entire scalp~* From 4 days after hair transplant and until Visit 4 (Month 0,5 post transplant): once a day on the recipient area~* Between Month 0.5 and Month 12: once a day on the entire scalp"
223739192|NCT05423717|DRUG|Daridorexant 10 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
223739193|NCT05423717|DRUG|Daridorexant 25 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
223739194|NCT05423717|DRUG|Daridorexant 50 mg|Daridorexant will be taken orally, once daily in the evening during the treatment period.
223739195|NCT05423717|DRUG|Placebo|Placebo will be taken orally, once daily in the evening during the treatment period.
224033607|NCT06700707|OTHER|Survey using a questionnaire.|"Permission was obtained from the original owner of the Athlete Disability Index Questionnaire (ADI) for the Turkish cultural adaptation, validity and reliability study.~120 athletes, determined by the number of questions times the rule of 10, will be asked to fill out the ADI, Oswestry Disability Index (ODI), and Roland-Morris Disability (RMDQ) questionnaires and 60 athletes will be asked to fill out the ADI questionnaire again 7 days later for test-retest reliability."
224033608|NCT06698328|DEVICE|Transauricular Vagus Nerve Stimulation|"Mild non-invasive electrical stimulation to the vagus nerve using electrodes or stickers that adhere to the ear and the surrounding area."
224033609|NCT06698328|DEVICE|Sham Stimulation|"Sham non-invasive electrical stimulation using electrodes or stickers that adhere to the ear and the surrounding area."
224033610|NCT05621109|BEHAVIORAL|Weight loss intervention|"Subjects will receive very low-calorie diet for 8-10 weeks to introduce a rapid weight loss of approximately 10%. Once target weight is achieved, participants will be reintroduced to foods to introduce weight stability.~The male will follow the maternal randomization, i.e. weight loss if BMI ≥25 until a BMI of 23 or a weight loss of approximately 10% is obtained.~During weight loss maintenance, subjects will receive dietary counseling to follow a diet high in protein (corresponding to 22-25E%), high fiber and wholegrain while fulfilling the requirements for essential fatty acids, micronutrients and trace elements in accordance with Nordic Nutrition Recommendations (NNR) 2012.~Throughout the study period participants will be encouraged to follow the official recommendations for physical activity as recommended by the Danish health authorities 2022."
224033611|NCT07020325|PROCEDURE|Bipolar Enucleation of the Prostate|Bipolar enucleation of the prostate involves the removal of prostate tissue using a bipolar electrode. This procedure is performed for patients with benign prostatic hyperplasia (BPH), with different electrode types used for comparison in this study
224033612|NCT07020325|DEVICE|Bipolar electrode From Wolf company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
224033613|NCT07020325|DEVICE|Bipolar electrode From Storz company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
224033614|NCT07020325|DEVICE|Bipolar electrode From Olympus company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
223416865|NCT06576492|OTHER|RD0057H shampoo|"* Application between Month -0.5 and Month 0 (before hair transplant): at usual frequency when required on the entire scalp~* From 2nd day after hair transplant and until the 7th day after hair transplant: application on the recipient area with a spray containing mixture of water and shampoo. For the rest of the head application with the same modalities than before hair transplant~* From the 8th day after hair transplant to the 15th day: application with a sponge on the recipient area~* From the 16th day after hair transplant and for the next 12th months: application with the same modalities than before hair transplant"
223416866|NCT03046589|DRUG|DP13|dose escalation
223416867|NCT03046589|DRUG|placebo|control to dose-escalation
223416868|NCT00613964|DRUG|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
223416869|NCT00613964|DRUG|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
223416870|NCT04463251|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
223416871|NCT04463251|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
223416872|NCT05020665|DRUG|Entospletinib|400 mg, Orally as tablets
223560862|NCT06662084|DIAGNOSTIC_TEST|phenotype|"Eligible patients will receive orally the cocktail probe drugs ( via a naso-gastric tube at D3 after tMCS implantation or after the beginning of the cardiogenic shock for the control group) and via an oral administration at 14 days after tMCS explantation (or cardiogenic shock termination for the control group defined as: no need to use inortropic or vasopressive agent and absence of organ insufficiency). The phenotyping probe drugs of the Geneva Cocktail will be given as: one capsule containing the remaining probe 'cocktail' drugs. According to clinical experience in our intensive care unit department, inflammation related to tMCS peaks at D3 after tMCS implantation.~Blood samples will be collected from the central venous line 2 hours after drug administration for CYP phenotyping and genotyping. Inflammatory markers blood levels (Il-6, TNF-α, Il-1β, IFN-γ) will be measured at tMCS implantation or shock initiation and at the same time than CYP phenotyping."
223560863|NCT06855654|BEHAVIORAL|Promoting Resilience in Women with Breast Cancer (PRISM)|PRISM is a brief, skills-based intervention targeting 4 core resilience resources (stress management, goal setting, cognitive reframing, and meaning-making) followed by an optional family session. This adapted version of the PRISM intervention will be delivered1:1 by trained coaches who speak English or Spanish via HIPAA-compliant video conference.A single coach conducts the program with a single patient. Each session is 30-60 minutes, for a total of 2- 4 hours. Sessions are delivered every 1-2 weeks per patient's preference. To facilitate on-demand skills-practice between sessions, all participants have access to the PRISM app, available for iOS/Android, and thus available to the \>90% of U.S. adults who own a smartphone. Participants will be assisted to download the PRISM app to their device at the time of registration; however, coaches can also provide assistance with app access during intervention sessions.
223560864|NCT06660940|DRUG|Keluoxin Capsules|Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day
223560865|NCT06660940|DRUG|Keluoxin Capsule Simulants|Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day
223739196|NCT05689320|OTHER|Behavioral: EMA-based intervention|This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
223739197|NCT04087798|BEHAVIORAL|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
223416873|NCT05020665|DRUG|Placebo|Orally as tablets
223416874|NCT05020665|DRUG|Cytarabine|Continuous infusion
223416875|NCT05020665|DRUG|Anthracycline|Either daunorubicin or idarubicin was administered via slow intravenous (IV) push
223416876|NCT01343680|DRUG|Heparin|5ml 10 units/ml IV heparin 3 times per week
223416877|NCT01343680|DRUG|Normal saline|10ml normal saline IV weekly
224033615|NCT07020325|DEVICE|Bipolar electrode From Lamidey company|This study involves bipolar transurethral resection of the prostate (TURP) using four different bipolar electrosurgical systems, each provided by a distinct manufacturer. The aim is to evaluate and compare the efficacy, safety, and clinical outcomes associated with each system.
223416878|NCT01732640|DRUG|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
223416879|NCT01732640|DRUG|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
223416880|NCT01732640|DRUG|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
223416881|NCT01732640|DRUG|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
223416882|NCT01732640|RADIATION|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
223416883|NCT02240940|DEVICE|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
223416884|NCT04182308|OTHER|dissection|Dissection of lisfranc ligament from 30 aldult Vietnamese cadavers's foot
223416885|NCT05342623|DRUG|Difelikefalin 1 mg Oral Tablet|Difelikefalin 1 mg medication taken orally 1 time/day
223416886|NCT05342623|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
223560866|NCT06660940|DRUG|Irbesartan|"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"
223560867|NCT06661967|DRUG|Lidocaine spray|Comparison of the success rate of endotracheal intubations between lidocaine spray and placebo
224033616|NCT06881511|OTHER|No intervention (Control Group)|Patients in this group will receive standard care and undergo regular follow-up and monitoring without any additional treatment.
223416887|NCT02275455|BEHAVIORAL|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
223416888|NCT03964675|DEVICE|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
223416889|NCT03070002|BIOLOGICAL|Denosumab|Given SC
223416890|NCT03070002|OTHER|Laboratory Biomarker Analysis|Correlative studies
223416891|NCT05577208|DEVICE|"Symplicity Spyral multi-electrode renal denervation catheter and Symplicity G3 generator (Renal Denervation System)"|Minimally invasive percutaneous interventional therapy aimed to modulate the sympathetic nervous system through endovascular ablation of both renal arteries
223416892|NCT05018923|DRUG|Rabeprazole|20mg bid
223416893|NCT05018923|DRUG|Bismuth potassium citrate|0.6g bid
223416894|NCT05018923|DRUG|Metronidazole|0.4g qid
223416895|NCT05018923|DRUG|Doxycycline|0.1g bid
223416896|NCT05018923|DRUG|Tetracycline|0.5g qid
223416897|NCT03682861|BEHAVIORAL|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
224033617|NCT06881511|DIETARY_SUPPLEMENT|Oral betaine hydrochloride (2 capsules, 3 times daily)|Oral betaine hydrochloride (with pepsin). Patients will take 2 capsules (648 mg per capsule) of betaine hydrochloride, 3 times daily with meals.
224033618|NCT06886581|BEHAVIORAL|Evidence-based leadership training|The structure of the course will follow the steps of the evidence-based approach: (1) each participant will identify their specific unit problem to be solved together with the team and unit leader will work with this problem during the course; (2) organisational data will be collated and analysed to understand the key problem of the unit; (3) scientific literature will be searched for, and critically appraised; (4) the views of stakeholders (patients, family members, etc.) will be considered along with implications; and (5) all sources of information will be collated together and the solution will be implemented into practice; the real situation will be evaluated. Each module includes specific learning material (power points, scientific articles), peer-group discussions, clinical exercises, and self-assessment and self-reflection. The unit leaders will work together their unit members. The course will be run in small group (about 15/agroup) and supported by tutors.
224033619|NCT06884384|BIOLOGICAL|Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml)|"At inclusion, the blood sample is used to perform thrombin generation tests (activated protein C resistance profile and ratio), classical and innovative aPL assays centrally to limit the fluctuation inherent in the tests used and enable comparison between patients, immunothrombosis markers: circulating neutrophil extracellular traps (NETs) assay, sTREM-1 assay~In the event of recurrence, blood sampling can be used to confirm compliance with treatment by measuring the anti Xa activity of the drug or INR"
224033620|NCT06884384|BEHAVIORAL|Completion of a questionnaire on compliance with anticoagulant treatment|The Girerd questionnaire (6 questions) will be proposed to patients in order to estimate the degree of compliance with AODs and VKAs at inclusion and at each follow-up visit for the duration of their participation in the study.
224033621|NCT06884384|BEHAVIORAL|Completion of a questionnaire on satisfaction with treatment anticoagulant|The ACTS questionnaire (15 questions) will be proposed to them in order to estimate their satisfaction with their anticoagulant treatment (AOD or AVK) at inclusion and at each follow-up visit for the duration of their participation in the study.
224033622|NCT06746337|BEHAVIORAL|IMAGINE|IMAGINE is a digital group cognitive behavioral therapy intervention
224033623|NCT06859697|PROCEDURE|Herbal medicine treatment|Herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients
223416898|NCT03682861|BEHAVIORAL|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
223416899|NCT06651827|DIAGNOSTIC_TEST|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment|Dentin sensitivity was measured using the Yeaple Probe and air stimulation tests before and after treatment. The effectiveness of the treatment was assessed at baseline, 30 minutes, 1 week, and 1 month post-treatment using the Visual Analog Scale (VAS) and Yeaple Probe scores.
223416900|NCT05728827|OTHER|Blood flow restriction training + Anti-gravity treadmill|Blood flow restriction training is administered via straps applied to the proximal limb with the possibility to adjust the applied occlusion pressure in order to prevent venous return leaving the arterial flow partially free. The consequent blood pooling causes a reduction in tissue saturation with oxidative stress and an increased growth factors secretion. The intervention will be applied while walking/running on the anti-gravity treadmill.
223416901|NCT05728827|OTHER|Anti-gravity treadmill|The intervention will be applied walking/running on the anti-gravity treadmill.
223416902|NCT02147158|DRUG|Ulipristal acetate (UPA)|Ulipristal acetate (UPA) tablet.
223416903|NCT02147158|DRUG|Placebo|Matching placebo tablet.
223416904|NCT02063945|DRUG|Methylphenidate|As stated in arm/group
223416905|NCT02063945|DRUG|Risperidone|As stated in arm/group
223416906|NCT03425396|DRUG|Omadacycline tablets|Oral Omadacycline
223416907|NCT03425396|DRUG|Nitrofurantoin capsules|Oral Nitrofurantoin
223416908|NCT02428309|BIOLOGICAL|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
223416909|NCT00301353|DRUG|Isoflavones-enriched foods|
223416910|NCT02112383|BEHAVIORAL|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
223560868|NCT06662240|DEVICE|The effect of vibration anesthesia on pain, ecchymosis and comfort level in subcutaneous heparin injection|The patient in the experimental group received one vibrating injection and one non-vibrating injection into the abdomen. The patient in the control group received 2 standard subcutaneous injections in the abdomen without vibration.
223560869|NCT06659302|BEHAVIORAL|I-inTERACT North Step 1|Initial questionnaires completed followed by initial meeting with therapist for baseline evaluation.
223560870|NCT06659302|BEHAVIORAL|I-inTERACT North step 2|Two online modules completed by family plus two online zoom coaching sessions with therapist.
223560871|NCT06659302|BEHAVIORAL|I-inTERACT North|Full program will consist of an additional 5 sessions with online modules and virtual coaching sessions with therapist.
223560872|NCT06659003|OTHER|Pilot Implementation of Network Canvas into HBH Partner Services|Our team deployed our network data capture software - Network Canvas - into Partner Services at HBH to examine feasibility and acceptability and to provide initial evidence of efficacy (examining impacts on data quality, number of partners notified, and timeliness). Further, our team worked closely with HBH on developing implementation strategies, a Network Canvas interview protocol, evaluation measures, and training materials for their staff. Finally, we provided the HBH team technical support, and regular coaching, supervision, and evaluation.
223560873|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Floragyn® probiotic tablets (Lapi, Indonesia)|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~One tablet Floragyn contains Lactobacillus rhamnosus and lactobacillus reuteri, bacteria that are normal flora (good bacteria) of the vagina."
223560874|NCT06659380|DIETARY_SUPPLEMENT|Metronidazole + Cal95|"Metronidazole, sold under the brand name Flagyl among others, is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis, and bacterial vaginosis. It is effective for dracunculiasis, giardiasis, trichomoniasis, and amebiasis.~Cal 95 is a supplement containing multivitamins and minerals including: Calcium, Zinc, Boron and Magnesium. This tablet is used to help meet calcium needs and maintain bone health in menopausal women."
223560875|NCT06659380|DIETARY_SUPPLEMENT|Floragyn® probiotic tablets (Lapi, Indonesia)|Given to the control group to ensure the ability of probiotics to maintain a healthy vaginal ecosystem and not the opposite.
223560876|NCT06659133|OTHER|Music intervention|"The women participating in the study were divided into control and experimental groups.~The control group included women who underwent pipelle endometrial biopsy with routine care, and the experimental group included women who underwent pipelle endometrial biopsy accompanied by music. Pipelle endometrial biopsy was performed by the same physician working in the Department of Obstetrics and Gynecology at the hospital. Patients in both groups were interviewed 10 minutes before the endometrial biopsy procedure and the Personal Information Form and State and Trait Anxiety Scale were applied. The application of the GKO was explained to the patients before the pipelle endometrial biopsy procedure. Before the pipelle endometrial biopsy, all patients were routinely given local anesthesia with 8 cc of 2% lidocaine solution and waited for 5 minutes after the application of local anesthesia.~During the pipelle endometrial biopsy, the experimental group was given a music recital from an mp3 play"
223560877|NCT06332768|DEVICE|Respiratory support|High-flow nasal oxygenation
223560878|NCT03838601|DRUG|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
223560879|NCT04150237|OTHER|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
223560880|NCT06850363|DEVICE|ExaStim Stimulation System|Transcutaneous Spinal Cord Stimulation
224033624|NCT06859697|PROCEDURE|Life Guidance|Educational materials will be distributed, and education on daily life management for weight loss will be conducted. The educational materials consist of information on the definition and causes of obesity, explanations on weight reduction and daily life management applicable to various situations such as exercise and diet, and the effects of these practices.
224033625|NCT06897137|OTHER|Surveys/Questionnaires|Participants will complete self-report questionnaires via Slice MR's secure, web-based platform. The questionnaires should take less than 30 minutes and will include the following options based on their relevance to each sample : 1) sociodemographic and clinical information) newly developed item pools for body image, fertility, and financial burden) legacy measures for body image, fertility, and financial burden) the PROMIS AYA Health Status Profile) the PROMIS Global) items about meditation practices (for descriptive purposes to inform future research).
224299196|NCT00107549|BIOLOGICAL|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
223560881|NCT06661005|DRUG|Nitrous oxide|The Nitrous oxide group will receive instructions to arrive at clinic 30 minutes before her procedure in order to sign consent forms. She will not be given instructions to remain NPO and will not be required to have someone bring her to and from the appointment. No IV will be placed. Anesthesia induction will be done by an anesthesiologist with a nitrous oxygen mixture at a 70:30 ratio
223560882|NCT06661005|DRUG|IV Sedation|Anesthesia induction will be done by an anesthesiologist with propofol per standard protocol. A pulse oximeter will be placed and oxygen will be administered through a nasal cannula and the patient will be instructed to breath.
223416911|NCT02112383|BEHAVIORAL|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
223416912|NCT01441765|DRUG|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
223416913|NCT01441765|BIOLOGICAL|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
223416914|NCT05931341|DIETARY_SUPPLEMENT|Rosemary extract|Softgel capsule including rosemary extract
223416915|NCT02893033|DEVICE|repetitive transcranial magnetic stimulation|rTMS
223560883|NCT06614101|OTHER|Exhaled air analysis|The patient takes two breaths into two different Module In a Box devices (one measurement per device) which will give two measurements of the volatile organic compounds in the exhaled air. No estimate of blood glucose by breath will be displayed: the Module In Boxes will be set to only display the indication valid measurement/invalid measurement.
223560884|NCT06995339|DRUG|Febuxostat Tablets|Febuxostat is a selective xanthine oxidase inhibitor (XOI) that targets uric acid generation. It has been used as a SUA lowering agent in patients not responding to allopurinol
223560885|NCT06995339|DRUG|Metformin|Metformin is an oral antihyperglycemic drug widely used in type 2 diabetes (T2DM) treatment. Most of its effects are exerted via an indirect induction of the phosphorylated activation of AMP-activated protein kinase (AMPK)
223560886|NCT06152172|DRUG|KYV-101|The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.
224033626|NCT06830031|BIOLOGICAL|C402-CD19-CAR|Enrolled subjects will undergo apheresis to acquire peripheral blood mononuclear cells. C402-CD19-CAR will be generated from the subject's autologous T cells modified from the apheresis product. After C402-CD19-CAR production and product release, subjects will be administered with a single dose of C402-CD19-CAR via subcutaneous injection.
224033627|NCT06196892|DIETARY_SUPPLEMENT|Probiotic BBr60|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
223416916|NCT02274012|DRUG|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
223416917|NCT02274012|DRUG|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
223416918|NCT04520997|DEVICE|Restylane Defyne|Up to 2 milliliters (ml) of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at baseline, up to 2 ml of Restylane Defyne per NLF and ML at week 3 and optional up to 2 ml of Restylane Defyne per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
223416919|NCT04520997|DEVICE|Restylane Defyne|Up to 2 ml of Restylane Defyne per NLF and ML at baseline, up to 2 ml of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at week 3 and optional touch-up of up to 2 ml per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
224033628|NCT06196892|DIETARY_SUPPLEMENT|Placebo|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking maltodextrin.
224033629|NCT06769438|OTHER|ERAS|ERAS
223416920|NCT02863445|DRUG|Levonorgestrel-based emergency contraception 1.5 mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
223416921|NCT02863445|DRUG|Levonorgestrel-based emergency contraception 3.0mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
223416922|NCT03439592|DIAGNOSTIC_TEST|collection of fecal material|in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
223416923|NCT02981082|DRUG|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
223416924|NCT02981082|DRUG|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
223560887|NCT06152172|DRUG|Cyclophosphamide|Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2
223560888|NCT06152172|DRUG|Fludarabine|Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)
223560889|NCT05041907|DRUG|Nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Nirmatrelvir 300mg BD for 5/7 Ritonavir 100mg BD for 5/7
223560890|NCT05041907|DRUG|Nitazoxanide|Nitazoxanide 1.5g BD 7/7
223560891|NCT05041907|DRUG|Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)|Molnupiravir 800mg BD for 5/7, Nirmatrelvir 300mg BD for 5/7, Ritonavir 100mg BD for 5/7
223560892|NCT05041907|DRUG|Hydroxychloroquine|Hydroxychloroquine 400mg D0 BD and 400MG OD for a further 6/7
223560893|NCT05041907|OTHER|No treatment|No treatment (except antipyretics- paracetamol)
223560894|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 300mg tixagevimab/ 300 mg cilgavimab given once on D0
223560895|NCT05041907|DRUG|Fluoxetine|Fluoxetine 40mg OD for 7/7
223560896|NCT05041907|DRUG|Molnupiravir|Molnupiravir 800mg BD for 5/7
223560897|NCT05041907|DRUG|Sotrovimab|Sotrovimab 500mg given once on D0
223560898|NCT05041907|DRUG|Ensitrelvir|Ensitrelvir 375mg OD D0 and 125mg OD for a further 4/7
223560899|NCT05041907|DRUG|Monoclonal antibodies|Monoclonal antibodies: 600mg casirivimab/ 600mg imdevimab given once on D0
224033630|NCT06769438|OTHER|ROFIM|teleexpertise solution connecting extra-hospital and intra-hospital practitioners
224033631|NCT06769438|OTHER|DEEPSEN|virtual reality headset to reduce anxiety
224033632|NCT06769438|OTHER|RDS|patch to continuously monitor patients' physiological parameters at home
224033633|NCT06769438|OTHER|Get ready|digital solution for managing patients at home
224033634|NCT06769438|OTHER|Lumiradx|taking CRP at home
224033635|NCT06769438|OTHER|Digital Surgery|recording of the different operating times
224033636|NCT06747182|OTHER|mobile phone-based intervention|Participants in intervention group will receive a 12-week mobile phone-based intervention with follow-up at week 26.
224033637|NCT06755554|DRUG|Endoscopic injection of Indocyanine green|ICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.
223416925|NCT03689374|DRUG|Semaglutide|Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
223416926|NCT03689374|DRUG|Insulin aspart|Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
223416927|NCT03689374|DRUG|Insulin glargine U100|Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
223416928|NCT01023945|DRUG|ASP1941|oral
223416929|NCT01023945|DRUG|Placebo|oral
223416930|NCT05367973|DEVICE|IVR Dose 1|Estradiol 80 ug/day + progesterone 4 mg/day
223416931|NCT05367973|DEVICE|IVR Dose 2|Estradiol 160 ug/day + progesterone 8 mg/day
223560900|NCT05041907|DRUG|Favipiravir|Favipiravir 1800mg BD D0 and 800mg BD for a further 6/7
223560901|NCT05041907|DRUG|Ivermectin|Ivermectin 600micrograms/kg/day for 7/7.
223739198|NCT04087798|BEHAVIORAL|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over an 11-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
223416932|NCT03098654|DIAGNOSTIC_TEST|Blood glucose and blood pressure testing|Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
223416933|NCT03098654|BEHAVIORAL|Diet and lifestyle counseling|All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
223416934|NCT03098654|DRUG|DM/HTN medications as needed|Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
223416935|NCT01961154|DRUG|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
223416936|NCT02805660|DRUG|Mocetinostat - 50 mg|Participants received mocetinostat three times weekly as an oral capsule.
223416937|NCT02805660|DRUG|Mocetinostat - 70 mg|Participants received mocetinostat three times weekly as an oral capsule.
223560902|NCT05041907|DRUG|Remdesivir|Remdesivir 200mg D0 and 100mg for a further 4/7.
223560903|NCT05041907|DRUG|Atilotrelvir/ritonavir|Atilotrelvir 150mg BD for 5/7 Ritonavir 100mg BD for 5/7
223560904|NCT05041907|DRUG|Metformin|Metformin 500mg TDS 5/7
223560905|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 300mg BD for 5/7 Ritonavir 50mg BD for 5/7
223739199|NCT07083583|DRUG|IV Iron (standard of care)|Participants will receive IV iron therapy as part of standard management for iron deficiency
223739200|NCT07122739|BEHAVIORAL|Active Real-time fMRI Neurofeedback|Active neurofeedback to target a functional connection associated with increased memory control ability
223739201|NCT07122739|BEHAVIORAL|Sham Real-time fMRI neurofeedback|Sham neurofeedback
223739202|NCT07084961|DRUG|TS-172|Oral administration of TS-172 20 mg immediately before meal
223739203|NCT07084961|DRUG|TS-172|Oral administration of TS-172 20 mg immediately after meal
223560906|NCT05041907|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir 150mg BD for 5/7 Ritonavir 50mg BD for 5/7
223560907|NCT05041907|DRUG|Nirmatrelvir|Nirmatrelvir 300mg BD for 5/7
223560908|NCT04580836|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223560909|NCT04580836|OTHER|Questionnaire Administration|Ancillary studies
223560910|NCT04580836|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223739204|NCT07078344|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|The oil-based supplements will include the Ultra Omega-3 product that delivers 683 mg EPA and 252 mg DHA (as ethyl esters) per capsule. A daily dose will provide 2.8 g of EPA+DHA (as ethyl esters). This product is part of the Nature Made line manufactured by Pharmavite (see Letter of Support). Three capsules will be self-administered orally by study participants, preferably at a single mealtime.
224033638|NCT05643963|OTHER|Dietary regimens|Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
224033639|NCT06786884|DEVICE|paraffin wax|This is the treatment group that will receive exercise and paraffin wax
224033640|NCT06786884|DEVICE|standard of care exercise therapy|This is the group that will only receive exercise therapy and no paraffin wax.
224033641|NCT06810947|DEVICE|ALLERSPRAY-G (device A)|Symptomatic treatment consists of 3 sprays of medical device A in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.
223416938|NCT02805660|DRUG|Mocetinostat - 90 mg|Participants received mocetinostat three times weekly as an oral capsule.
223416939|NCT02805660|DRUG|Mocetinostat - Recommended Phase 2 Dose (70 mg)|Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).
223416940|NCT02805660|DRUG|Durvalumab - 1500 mg|Participants received durvalumab as an intravenous infusion every 4 weeks.
223416941|NCT05892276|BEHAVIORAL|Trauma Memory Reactivation|Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
223416942|NCT05892276|DIETARY_SUPPLEMENT|Cannabidiol (CBD) Broad-Spectrum Oil|300mg CBD broad-spectrum oil.
223416943|NCT05892276|DIETARY_SUPPLEMENT|Placebo Oil|3ml oral dose of medium-chain triglycerides (MCT) coconut oil.
223416944|NCT02048098|DRUG|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
223416945|NCT02048098|DRUG|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
223416946|NCT02923453|DIETARY_SUPPLEMENT|CNT 2000 American ginseng extract|
223416947|NCT02923453|DIETARY_SUPPLEMENT|Placebo|
223416948|NCT03685253|DRUG|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
223416949|NCT03685253|DRUG|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
223416950|NCT00006160|BEHAVIORAL|home based worker|
223416951|NCT04769089|PROCEDURE|Treatment with Pulse Dye Laser|Pulse Dye laser treatment will be applied to one randomized area with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s.
223416952|NCT04769089|PROCEDURE|Treatment with CO2 Laser|CO2 laser treatment will be applied to one randomized area with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
223416953|NCT04769089|PROCEDURE|Treatment with combination of pulse dye laser and CO2 laser.|Pulse Dye laser and CO2 treatment will be applied to one randomized area. Pulse Dye will be applied with the 10mm hand piece, duration of 0.45ms, and fluence of 5.25J/s followed by the CO2 laser treatment with the deep Fx hand piece, 300Hz, 15mJ, 15% density.
223560911|NCT07033325|DIAGNOSTIC_TEST|Rapid diagnostic test (RDT) for Trypanosoma cruzi infection.|Rapid diagnostic tests (RDTs) for the detection of Trypanosoma cruzi infection are performed in university facilities, outside of a clinical care setting, using a point-of-care approach. The study population includes adult male and female participants from the university community. This intervention differs from most existing strategies that target exclusively women of reproductive age and/or newborns to control vertical transmission; instead, it focuses on broader population-based screening and linkage to care for chronic infections.
223739205|NCT07078344|OTHER|Placebo|Safflower oil (placebo) that delivers 70-80% oleic acid and 10-14% LA. The placebo is identical in appearance and shape to the active study agent. Three capsules will be self-administered orally by study participants, preferably at mealtimes.
224033642|NCT06810947|DEVICE|PCNS (device B)|Symptomatic treatment consists of 3 sprays of medical device B in each nostril while breathing in slightly. This process should be repeated 4 times a day for 14 days by patients participating in the study.
223416954|NCT04769089|OTHER|Control|One area will be randomized to receive no laser treatment.
223416955|NCT06822699|DEVICE|Leg elevation|leg will be raised 30 degrees after spinal anesthesia using standardized pillow
224033643|NCT06752421|PROCEDURE|Group B: Low tidal volume|In the LTV group, mechanical ventilation will be maintained with low tidal volume parameters after the aortic cross-clamp procedure. This intervention includes a tidal volume of 3-4 mL/kg, respiratory rate of 12-14 breaths/min, PEEP of 5-8 cmH₂O, and FiO₂ of 50%. Minute ventilation (MV) will not exceed 12 L, and the parameters are adjusted according to ideal body weight. This group is designed to evaluate the protective effects of low tidal volume ventilation during surgery.
224033644|NCT06900751|DRUG|NEU-627|Investigational medicinal product
224033645|NCT06900751|OTHER|Placebo|Placebo
224033646|NCT06903715|DRUG|Belzutifan|Oral administration
224033647|NCT06903715|DRUG|Phenytoin|Oral administration
223416956|NCT06372379|OTHER|no intervention|no intervention
223416957|NCT06373718|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
223416958|NCT03774524|DRUG|Misoprostol|400 μg of sublingual misoprostol
223416959|NCT03774524|DRUG|TA|1 gm of tranexamic acid in 100 ml saline iv
223560912|NCT07032987|OTHER|Not an intervention study|This is not an intervention study
223739206|NCT07079306|BEHAVIORAL|BeFree+Bot|Text messaging program called BeFree and access to BBot, ChatGPT chatbot
223739207|NCT07079306|BEHAVIORAL|BeFree|Text messaging program called BeFree
223739208|NCT06930664|BIOLOGICAL|Sotatercept|Subcutaneous Injection
223739209|NCT06930664|BIOLOGICAL|Sotatercept Autoinjector|Subcutaneous Auto Injection
223739210|NCT06905470|PROCEDURE|Eccentric (KREHA) training|20 eccentric resistance training sessions will be performed on a symmetric arm-crank ergometer in a supine position.
223416960|NCT03774524|DRUG|placebo to misoprostol|placebo tablets to misoprostol subligual
223416961|NCT03774524|DRUG|placebo to TA|110 ml saline iv
223560913|NCT07034625|OTHER|Low Level Laser Therapy|940 nm wavelength diode laser was applied to the wound area on the surgery day, 3rd, 5th and 7th days postoperatively. The power of the laser was set to 3W, power density 1.07 W/cm2, probe spot size 2.8 cm2, application mode continuous wave, application distance 1mm and application type stable.
223560914|NCT07034625|OTHER|Gengigel Spray|Patients were given a high molecular weight hyaluronic acid spray and instructions for use were explained. Accordingly, the patients applied the spray to the wound area twice a day for the first 7 days.
223560915|NCT07032805|PROCEDURE|personalized outpatient rehabilitation treatment after TKA|personalized outpatients rehabilitation treatment after TKA, including posturographic assessment, psychomotivational framing, and telemedicine-based rehabilitation interventions
223560916|NCT07032805|PROCEDURE|standard outpatient rehabilitation treatment after TKA|standard outpatient rehabilitation treatment after TKA
223560917|NCT07032740|DIAGNOSTIC_TEST|Bruce test|In the Bruce test, a breath pattern was obtained by means of an OEP (once with a respirator and once without a respirator).
223560918|NCT07079670|BIOLOGICAL|NVX-CoV2705|Intramuscular (deltoid) injection at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant.
223560919|NCT07080697|PROCEDURE|Splenectomy|Open Debridement combined with distal pancreatectomy and total splenectomy
223560920|NCT07080697|PROCEDURE|Control|Open Debridement alone
223560921|NCT03840044|OTHER|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during\*/post§ of heart rate (HR)§\* and blood pressure (BP)§\*, spirometry§\*, PNIF§, FeNO§, electrocardiogram (ECG)§\*, body \& exhaled air temperature§\*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
223560922|NCT02085044|DIETARY_SUPPLEMENT|Ready-to-Used Supplement Food administration|
223560923|NCT03915990|DIAGNOSTIC_TEST|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
223560924|NCT00086528|DRUG|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
223560925|NCT02644096|OTHER|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
223416962|NCT06620731|DRUG|FCN-437c capsule|Take 200 mg of FCN-437c capsules with approximately 240 mL of warm water in the morning on an empty stomach.
223416963|NCT05640726|DRUG|PD-1|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
223416964|NCT05640726|RADIATION|SCRT|Radiotherapy dose: 5×5 Gy
223560926|NCT04105192|DIETARY_SUPPLEMENT|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
223560927|NCT07080788|BEHAVIORAL|Smoking Cessation|Investigators will provide financial incentives for biochemically verified abstinence at 4 weeks following treatment. This incentive is consistent with recent research using macro-level financial incentives and incorporates both short-term and long-term incentives to shape behavior.
223560928|NCT07080047|OTHER|Mackenzie exercise for lateral shift|Participants in the McKenzie group will perform standing side glide exercises, where they stand perpendicular to a wall (painful side away), press their hips toward the wall, and hold for 2-3 seconds, repeated 30 times
224298553|NCT05549518|OTHER|Traditional Physical Therapy|"Traditional physical therapy training will be given for 40 minutes each session, 3 times a week for 6 weeks under the supervision of a physiotherapist. As a traditional physical therapy program, a rehabilitation program that increases mobility and daily living activities will be applied to patients.~* Joint range of motion exercises~* Stretching exercises~* Strengthening exercises~* Bobath-based neurophysiological approaches~* Task-oriented training~* 15 minutes of neuromuscular electrical stimulation (NMES) application"
224298554|NCT03466437|DEVICE|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
223416965|NCT05640726|DRUG|Bevacizumab|Participants will receive bevacizumab，5mg/kg，intravenously over 60 - 90 minutes, day 1 of every 2 weeks
223560929|NCT07080047|OTHER|Traditional physical therapy|Participants in the traditional therapy group will receive posteroanterior lumbar mobilizations (30 repetitions × 3), 10-minute hot pack application, myofascial release of paraspinal muscles, and core stability exercises (plank and bridging).
223560930|NCT01198210|DRUG|saline|local peritonsillar infiltration of 2 ml saline,
223739211|NCT06905470|PROCEDURE|Standard clinical routine strength (STAN) training|The regular strength training intervention consists of a total of 20 training sessions at the gym of the study center, performed following clinical routine procedures.
223416966|NCT05640726|DRUG|Oxaliplatin|Participants will receive Oxaliplatin，85mg/m2，day1
223416967|NCT05640726|DRUG|Calcium folinate|Participants will receive calcium folinate ，400mg/m2，day1
223416968|NCT05640726|DRUG|5-fluorouracil|Participants will receive 5-fluorouracil ，400mg/m2，day1
223416969|NCT05280457|DRUG|nivolumab-GX-188E-GX-I7|"* Nivolumab 3 mg/kg IV administered every 2 weeks~* GX-188E 2 mg IM at Weeks 1, 2, 4, 7, 10, 13, and 19~* GX-I7 1200 μg/kg or the recommended dose of the introductory safety cohort is administered at weeks 2, 10, and 18"
223416970|NCT06803121|OTHER|Traditional treatment|Traditional exercises for scoliosis include breathing exercises, posture training, spinal flexibility exercises, stretching exercises for the involved muscles (especially for the concave side of the curve), and general strengthening exercises for the main muscle groups of trunk, pelvis, and shoulder girdle muscles (especially for the convex side of the curve).
223416971|NCT06803121|OTHER|Core stability exercises|The CS training program includes local muscle stability training (transverses abdominis, multifidus, and diaphragm), global muscle stability training (oblique abdominal muscles, psoas major, quadratus lumborum, and pelvic floor muscles), global muscle mobility training (rectus abdominis, back extensors, and hamstring muscles), and strength training of the core muscles through the thoracolumbar fascia by maintaining the neutral spine position. Diaphragmatic breathing technique will be used during exercises.
223416972|NCT05062707|PROCEDURE|Blood sampling|Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
224033648|NCT06790823|DRUG|The probiotic supplement (Moodamin capsuls)|The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively.Excipients include xylitol, maltodextrin, plum flavor, and malic acid.
223416973|NCT06179017|OTHER|Experimental group:Intervention Group|Intervention Group:Interventionist choose the optimal endovascular treatment (EVT) strategy and device based on the patient's condition and local guidelines. The patient will receive the best medical treatment according to the local guidelines.
224136887|NCT06490419|DEVICE|ultrasound cavitation|"Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes."
224136888|NCT00777231|BIOLOGICAL|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
224298555|NCT03466437|DEVICE|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
223416974|NCT06179017|OTHER|Control group:best medical treatment|Best medical treatment:Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.
223560931|NCT01198210|DRUG|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
223560932|NCT01198210|DRUG|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
223560933|NCT01198210|DRUG|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
223560934|NCT02461290|RADIATION|Chemotherapy|
223560935|NCT02461290|DRUG|Rituximab|
223560936|NCT01518686|DEVICE|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
223560937|NCT03990623|RADIATION|Computed Tomography Perfusion Imaging|Undergo perfusion CT
224033649|NCT06790823|DRUG|Placebo|The probiotic supplement (Moodamin capsuls) provided from Amin pharmacytical company, Iran, was freeze-dried containing Lactobacillus helveticus and Bifidobacterium Longum bacteria at a dose of 2.682 × CFU and 0.318 × CFU each capsule, respectively. Excipients include xylitol, maltodextrin, plum flavor, and malic acid. A placebo product used for the control group was made up of excipients only.
224033650|NCT06515483|DEVICE|Brushing and Flossing of teeth|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects in the experimental group will brush and floss with the provided stretchable loop floss at least twice a day. To assess compliance, each subject will be asked to fill out a diary every time they brush/floss. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
224033651|NCT06515483|OTHER|Brushing Only|32 subjects will be instructed to clean their teeth daily using only the provided toothbrush with an assigned ADA-accepted fluoride dentifrice. Subjects assigned to the control group will brush their teeth at least twice a day only. On day 15 (+/- 2) day of product use, subjects will receive a phone call from the study coordinator or designee to assess brushing/flossing compliance. At day 30 (+/- 2), study hygiene and gum chewing restrictions as well as eating restriction will apply, and the efficacy assessments will be repeated, subjects will be dismissed, and the study will finish.
224298556|NCT03466437|DEVICE|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
224298557|NCT06072365|OTHER|nutritional intake questionnaire|patients completed a nutritional intake questionnaire before to start the treatment, 3mounths after and twelve months after
224299197|NCT00107549|BIOLOGICAL|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
223416975|NCT02118649|BEHAVIORAL|Game|
223560938|NCT03990623|PROCEDURE|Liver Biopsy|Undergo liver biopsy
223560939|NCT03076060|BEHAVIORAL|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
223416976|NCT06204315|RADIATION|Stereotactic Radiosurgery|Given by RTx
223416977|NCT02087826|OTHER|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
223416978|NCT02087826|DRUG|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
223416979|NCT06189859|PROCEDURE|endoscopic submucosal dissection using SPRAY COAG mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Spray coag mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
223560940|NCT03076060|BEHAVIORAL|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
223560941|NCT07074990|DRUG|conventional sepsis therapy alone|fluid resuscitation a minimum of 30 mL/kg of intravenous (IV) crystalloid fluid administered during the initial 3 hours of resuscitation, along with empiric antibiotic therapy aimed at the suspected pathogens and infection sites, ideally starting within the first hour.
223560942|NCT07074990|DRUG|colchicine 500 mcg oral twice daily plus conventional sepsis therapy.|colchicine 500 mcg oral twice daily plus conventional sepsis therapy for 5 days.
223560943|NCT07081373|DRUG|A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.|At surgical closure, a single dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered without concurrent analgesics. The total 20 mL volume is divided into six equal aliquots (≈3.3 mL each) and infiltrated circumferentially around the incision using a 25-gauge or larger-bore needle. Injections target tissue layers above and below the fascia and within the subcutaneous plane, with frequent aspiration during administration to mitigate intravascular injection risk. Seventy-two hours postoperatively, a repeat dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered. Prior to infiltration, topical lidocaine cream is applied to the per-incisional skin for ≥20 minutes. The full 20 mL volume is then injected uniformly around the incision via circumferential needle advancement into pericicatricial tissues.
223560944|NCT07081490|OTHER|Virtual Escape Room Game|Virtual escape rooms are digital versions of physical escape rooms that can be accessed remotely. Virtual escape rooms are adaptations of physical escape rooms that use online interactive environments where participants aim to solve puzzles within a set timeframe.
223560945|NCT07080164|OTHER|mini implant retained overdenture|mini implant retained overdenture
223739212|NCT03973268|DEVICE|Arm 1, 2, 3 device interventions|MagPro 100 TMS Therapy System
224033652|NCT05401214|DRUG|Niraparib plus Abiraterone Acetate (Nira/AA) combination|Nira 100 milligrams (mg)/AA 500 mg combination will be administered orally as immediate-release film coated tablets.
224033653|NCT05401214|DRUG|Prednisone/Prednisolone|Prednisone/Prednisolone 10 mg will be administered orally.
224033654|NCT06908473|DRUG|Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.|"Intervention Agent: The study employs Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine compound formulated based on TCM theory. It has the functions of Nourishing Yin, clearing heat and activating blood circulation, and can comprehensively regulate glucose and lipid metabolism as well as improve cardiovascular and cerebrovascular functions.~Intervention Population: The study focuses on patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS) who meet the TCM criteria for Qi-deficiency and Blood Stasis syndrome, reflecting personalized and precision intervention.~Intervention Design: A long-term study design with 26 weeks of intervention followed by 26 weeks of follow-up is adopted to comprehensively assess the short-term efficacy and long-term cardiovascular benefits of TJC.~Control Design: The study employs a double-blind, randomized, placebo-controlled method."
224033655|NCT06908473|DRUG|A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC|Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.
224033656|NCT06795659|DRUG|Esketamine (Intranasal Spray)|Esketamine doses will be administered via insufflation with a starting dose of 1 spray of 14 mg per nostril (28 mg/total). Based on tolerability, total dose will be increased to a target dose of 84 mg delivered as three bouts separated by 5 minutes per bout (total dose administered in 15 minutes).
224033657|NCT06795659|BEHAVIORAL|Massed Prolonged Exposure (PE)|Eligible participants will be enrolled to receive 10 sessions of PE delivered in massed (daily) format over 2 weeks (weekdays, not including weekends and holidays)
224033658|NCT06115382|BEHAVIORAL|Self Cueing Training|Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
224033659|NCT06115382|BEHAVIORAL|External Cueing Training|Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.
224298558|NCT01094418|OTHER|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
223739213|NCT03973268|OTHER|Arm 2 Interventions|Placebo
223739214|NCT03973268|DRUG|Arm 1, 2, 3 drug Interventions|Ketamine
223739215|NCT03973268|DRUG|Arm 1 and 2 Interventions|Perampanel
223739216|NCT06828848|DRUG|Meropenem plus vaborbactam|Meropenem plus vaborbactam fixed dose combination adjusted by body weight up to 2g/2g
223739217|NCT06029673|DRUG|Cabergoline 1 MG|Dopamine agonist
223739218|NCT06029673|DRUG|Placebo|Placebo
223416980|NCT06189859|PROCEDURE|endoscopic submucosal dissection using Precisect mode|After initial mucosal incision, submucosal dissection will be performed down to 2cm below the cardia using Precisect mode using ERBE VIO3 generator and a Hybrid knife (T-type) aided by ERBEJET for submucosal injection
223416981|NCT05287919|OTHER|Patients received the standard physical therapy (SPT) programme (passive mobilization) twice a day.|All participants have received standard physical therapy (SPT) sessions based on a passive range of motion mobilization protocol for the lower limbs. It consisted of a bilateral series of 10 repetitions of hip flexion, knee flexion and extension, and ankle flexion and extension. The procedure was performed twice a day: a morning (between 8am - 12pm) and an afternoon session (between 2pm - 6pm).
223560946|NCT07080346|DRUG|Upadacitinib 15 MG|All the BS patients discontinued other biologic agents and received oral upadacitinib treatment at a dose of 15mg per day with background glucocorticoids and immunosuppressants for 48 weeks. All the patients will be followed up prospectively for 48 weeks.
223560947|NCT07080073|OTHER|Maitland Mobilization Group|"Participants in this group will receive Maitland Grade III central posterior-anterior spinal mobilizations targeting the lumbar spine. The intervention will be administered by a licensed physiotherapist with the patient in a prone position, applying oscillatory mobilization for 3 sets of 40 seconds with 1-minute rest intervals.~Canal enlargement exercises (bilateral knee-to-chest, LION stretch, cat-camel exercise) The total treatment will be administered four sessions per week for three weeks (12 sessions total)."
223560948|NCT07080073|OTHER|Mulligan Mobilization Group|"Participants in this group will receive Mulligan spinal mobilizations with lower limb movement (SNAGs). The therapist will apply sustained passive glides to the lumbar spinous process while the patient actively elevates the leg in a pain-free range. Mobilizations will be performed in 3 sets of 7-10 repetitions.~Canal enlargement exercises (bilateral knee-to-chest, LION stretch, cat-camel exercise) The total treatment will be administered four sessions per week for three weeks (12 sessions total)."
223560949|NCT07079319|OTHER|MET + Biofeedback Strengthening + Kinesiotaping|Participants in this group will receive the same treatment protocol as Arm 1 (MET and biofeedback strengthening), with the addition of Kinesiotaping (KT) applied across the shoulder girdle. KT will be applied with 50-70% stretch from the anterior acromion to the opposite scapula, 3 times per week for 4 weeks. The tape will be worn for 14-16 hours per application. Standard physiotherapy (heat, ultrasound, neck isometrics, and stretching) will also be administered as part of the protocol.
223560950|NCT07079319|OTHER|MET + Biofeedback Strengthening|Participants in this group will receive Muscle Energy Technique (MET) for the upper trapezius, levator scapulae, pectoralis major, and pectoralis minor using post-isometric relaxation technique. Additionally, they will perform biofeedback-based cranio-cervical flexion exercises using a pressure biofeedback unit (PBU). The intervention will be administered 3 times per week for 4 weeks, with a total of 12 sessions. Standard physiotherapy (heat application, ultrasound, neck isometrics, and stretching exercises) will also be provided.
223560951|NCT07081737|OTHER|Interdisciplinary treatment (IDT) + Clinical Decision Support System (CDSS)|Interdisciplinary treatment (IDT) combined with Clinical Decision Support System (CDSS)
223560952|NCT07081737|OTHER|Interdisciplinary treatment (IDT)|Interdisciplinary treatment (IDT)
224033660|NCT06862609|OTHER|Quadro iliac plane block|Patients in Group Q will be placed in the lateral position. A low-frequency convex transducer and a 100-mm block needle will be used. Following sterilization, the transducer will be placed parasagittally at the distal attachment of the quadratus lumborum muscle to the iliac crest. The iliac crest and quadratus lumborum muscle will be visualized, with the erector spinae muscle above and the psoas major muscle below. Using an in-plane technique, the needle will be directed toward the iliac crest. After confirmation with 5 mL of isotonic sodium chloride, 40 mL of 0.25% bupivacaine will be injected incrementally with intermittent aspiration.
224033661|NCT06862609|OTHER|Control group|All patients will receive IV paracetamol (1 g, 3×1) and IV tenoxicam (20 mg, 2×1).
224033662|NCT06931522|OTHER|Mat Pilates|In Mat Pilates training, exercise balls and elastic bands will be used. The exercises will be done with 10 repetitions for the first 4 weeks, and with 20 repetitions for the last 4 weeks. The difficulty level of the exercises will be increased in the following weeks according to the patient's condition.
224033663|NCT06931522|OTHER|Reformer Pilates|In the Reformer Pilates group, the difficulty level of the exercises will be provided by different positions, and the springs' resistance will be increased.
224033664|NCT05945641|BEHAVIORAL|Low Load Resistance training|Performing single leg knee extension exercise with using equivalent to \~30%1-RM to failure,
224033665|NCT05945641|BEHAVIORAL|Sprint/High Intensity Interval Training|Performing repeated submaximal/maximal 30second-60 seconds (1-3 minute rest between) aerobic intervals on a Kicking ergometer (modified bike that allows cycling to be performed with one leg using a kicking motion).
224033666|NCT05808686|OTHER|Ischemic Conditioning|We will use a randomized block design to randomize individuals into either Ischemic Conditioning-Low or Ischemic Conditioning-High group using an online randomizer. A handheld sphygmomanometer and blood pressure cuff will be given to study participants. For the Ischemic Conditioning-High group participants, while sitting, the cuff will be placed around the non-dominant upper arm and inflated to 225 mmHg for 5 min, then released for a 5-min recovery period. A 5-min inflation period is most used. Five cycles of inflation/recovery will be performed. For the Ischemic Conditioning-Low group participants, the cuff will be inflated to 10 mmHg instead. All participants will perform the intervention daily for 2 weeks. Participants will complete daily log sheets documenting the time and pressure of each cuff inflation.
223560953|NCT07079410|DRUG|Sintilimab+Cetuximab|Neoadjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week/cycle) and Cetuximab (400 mg/m2 first time and followed 250 mg/m2, day 1, day 8, day 15) for 2 cycles. Adjuvant treatment: the participants will receive Sintilimab 200 mg (each 3-week cycle, a total of 17 cycle) for a total of one year.
224033667|NCT03878004|BIOLOGICAL|GamTBvac vaccine|introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.
224136889|NCT01548898|DEVICE|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
224136890|NCT04109872|DRUG|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
224136891|NCT04798391|DRUG|Dexamethasone|Steroids and analgesics
223416982|NCT05287919|OTHER|Patients received the low-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands). The low-frequency protocol consisted of 100 Hz and 400 ms width pulses, delivered in trains of 5 s ON (ramp-up time: 1 s, plateau: 3 s, ramp-down time: 1 s) and 10 s OFF. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
223416983|NCT05287919|OTHER|Patients received the medium-frequency neuromuscular electrical stimulation (NMES)|Electrical stimulation was performed twice a day after SPT. Two electrodes were attached to each thigh at the motor points of the quadriceps muscle. The point halfway between the anterior superior iliac spine and the base of the patella was used as reference and electrodes were placed 15 cm apart each other, 5 cm proximal and 10 cm distal from the reference point. After the first measurement, semi-permanent markers were used to indicate the position of electrodes. Electrical stimulation was performed using a 4-channels device (Sonopuls 492, series 4, Enraf-Nonius®, Rotterdam, Netherlands).The medium-frequency protocol had similar parameters, but a carrier frequency of 2500 Hz and burst frequency of 100 Hz. Sessions had 20 min of duration (total of 40 min/day) and the current amplitude (mA) was adjusted to the identification of visible and palpable contractions and was rectified every 3 min to sustain the initial level of contraction.
223416984|NCT03806855|DIAGNOSTIC_TEST|Bladder diary|3-day bladder diary
223416985|NCT01957436|DRUG|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
223560954|NCT07080281|DEVICE|Oculus Meta Quest 2 All In-One model virtual reality glasses|"During the caesarean section, Meta Quest 2 All In-One model virtual reality glasses from Oculus were used for 15 minutes. In this virtual environment, the licensed product video Breathe- Relax and Meditate was watched via the Meta Horizon application."
223560955|NCT07079514|DRUG|Placebo|normal saline in 100ml piggy bag
223416986|NCT01957436|RADIATION|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
223416987|NCT01957436|OTHER|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
223560956|NCT07079514|DRUG|Magnesium|Magnesium Sulphate will be given as doses of 20-50mg/kg in 2 -3 minutes. In order to standardize the dose in every patient we will be using 3g
223560957|NCT06437288|PROCEDURE|photodynamic therapy|Receive an intravenous infusion of hematoporphyrin injection
223560958|NCT02227069|DRUG|M518101|
223560959|NCT02227069|DRUG|M518101 Vehicle|
223739219|NCT05157620|OTHER|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
224033668|NCT03878004|BIOLOGICAL|placebo|introduction of placebo twice into a shoulder with an 8-week interval.
224033669|NCT05737199|DRUG|MK-3475 (pembrolizumab)|MK-3475 (pembrolizumab) 200mg IV every 3 weeks \[Q3W\] Treated for 2 years (35 cycles), or until PD, unacceptable toxicity, or study withdrawal.
224033670|NCT04726462|OTHER|Functional exercises|The exercise program is planned as a function-oriented exercise program aimed at improving balance skills, increasing lower extremity muscle strength and functions.
224033671|NCT04726462|OTHER|Posture exercises|The exercise program was planned by focusing on posture exercises in order to increase the postural smoothness of the participants.
224033672|NCT04344691|PROCEDURE|Rectus femoris stretching|Patient lying prone with the non-implicated leg outside the treatment table resting on the floor. Physical therapist flexes patients knee until tension is felt. In that position 5 seconds' isometric contraction is asked and physical therapist progresses in knee flexion range of motion until new tension is felt. After three contract-relax procedures physical therapist holds the range of motion for 30 seconds.
223416988|NCT01957436|DRUG|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
224033673|NCT00819260|DEVICE|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
223416989|NCT06462352|DEVICE|Navicam SB capsule|Exploration of the small bowel by Navicam SB endoscopic capsule.
223416990|NCT06462352|DEVICE|Pillcam SB3|Exploration of the small bowel by Pillcam SB3 endoscopic capsule.
223416991|NCT05225844|DRUG|Camrelizumab|Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
223416992|NCT05225844|DRUG|Apatinib Mesylate|Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle
223560960|NCT02227069|OTHER|sodium lauryl sulfate|
223560961|NCT02227069|OTHER|saline|
223560962|NCT00526656|DRUG|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
223560963|NCT05064020|DRUG|Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]|Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
223560964|NCT06896656|BEHAVIORAL|Marigold Mobile Peer Support Intervention|"The MPS App is a secure platform that allows text-based peer support for individuals in recovery from OUD. Participants assigned to this condition will be enrolled on a rolling basis into a peer support group on the app. All participants will receive onboarding assistance and will have access to the app for 6 months.~The app will include live moderation from a certified Peer Recovery Support Specialist and trained research assistants. Moderators will begin discussions with prompts and regulate the flow of conversation with standardized text language. Moderators will be able to respond in real-time to malicious messages or other flags that could impact participant safety. Built in natural language processing algorithms will also detect language requiring intervention and automatically alter the moderators and on-call clinicians."
223560965|NCT06896656|BEHAVIORAL|Resources|A list of online peer support and mental health resources, drawn from SAMSHA and equivalent websites, will be provided to all participants, as an enhanced adjunct to their standard recovery plans.
223416993|NCT05902273|DIAGNOSTIC_TEST|hemodynamic monitoring|Baxter Starling Monitor for measuring cardiac output and systemic vascular resistance (SVRI) which is using bioreactance technology. We need to place four electrodes on chest wall (upper left, upper right, down left, down right) and input monitor demographic parameters. Also enter mean arterial pressure (MAP) for calculating SVRI so we input MAP every minute.Patient bed set as 45 degree head elevated and legs 0 degree. Just after start measuring, monitor needs to synchronize itself for patient. After synchronisation we start fluid challenge with passive leg raising option. This test has two stages. First stage calculating baseline parameters which takes 3 minutes and second stage is measuring difference with fluid challenge which also takes 3 minutes. At the end of first stage monitor shows to perform passive leg raise and we perform trendelenburg maneuver till head comes to 0 degree. After second stage measurement has finished.
223416994|NCT05902273|DIAGNOSTIC_TEST|resistive index|We use ultrasonography at the same time with cardiac output monitor in both stages. First we determine the location of radial artery at wrist snuffbox at 1.5 centimeters depth with linear probe and confirm pulsatile flow with color mode. In Starling's baseline stage we measure and calculate resistive index with doppler P-mode in triplex setting 3 times. When received 3 same result successively we noted as SBRI-1. Second measurement is initiated at last 30 seconds of passive leg raising as described before and we noted our measurement as SBRI-2
223416995|NCT05902273|DIAGNOSTIC_TEST|Pleth variability index|During all stages Masimo Rad-87 rainbow probe is placed patients index or middle finger and we note PVI-1 and PVI-2 at the same time with SBRI-1 and SBRI-2
223416996|NCT00809471|DRUG|placebo|30 minutes orally prior to initiation of sexual activity
223416997|NCT00809471|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
223416998|NCT00809471|DRUG|avanafil|30 minutes orally prior to initiation of sexual activity
223416999|NCT02993328|DRUG|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
223417000|NCT02993328|DRUG|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
223417001|NCT00849511|DRUG|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
223417002|NCT00831311|BIOLOGICAL|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
223417003|NCT00831311|BIOLOGICAL|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
223417004|NCT05856383|DRUG|Inetetamab Combined With Pyrotinib and Vinorelbine|Inetetamab Combined With Pyrotinib and Vinorelbine
223560966|NCT06895330|OTHER|Virtual Reality Group|A brief orientation regarding the use of the virtual reality headset will be provided to the children. One minute prior to the vaccination procedure, the selected video-either a roller coaster or Formula 1 experience, based on the child's preference-will be initiated through the virtual reality headset. Throughout the procedure, the children will continue to watch the video using the virtual reality headset.
223560967|NCT06895330|OTHER|Helfer Skin Tap Group|"The Helfer Skin Tap technique is applied to reduce pain and muscle tension during intramuscular injection by stimulating large nerve fibers through rhythmic tapping. After determining the injection site and preparing the skin with alcohol, the area is tapped for approximately 5 seconds using the dominant hand. The syringe is then held in the dominant hand while a V shape is formed with the non-dominant hand to tap the skin firmly three times. On the count of three, the needle is inserted at a 90° angle. After aspiration, the medication is injected slowly while gentle tapping continues to maintain muscle relaxation. The procedure concludes with simultaneous needle withdrawal and a final V-shaped tap to minimize discomfort."
223560968|NCT07080879|DEVICE|Linear Anastomat|The product registration certificate numbers of linear anastomat is Su Wei registered 20202021581.
223560969|NCT07080879|DEVICE|Tubular Anastomat|The product registration certificate numbers of tubular anastomat is Su Wei registered 20182020305.
224033674|NCT00819260|DEVICE|Electrocautery|Electrocautery used to reduce breast on this side
223417005|NCT03620123|DRUG|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
224033675|NCT04011254|PROCEDURE|haemodialysis|Routine haemodialysis session
224033676|NCT00820976|DRUG|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
224033677|NCT04139265|DIAGNOSTIC_TEST|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
224033678|NCT01539304|DRUG|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
223417006|NCT03620123|DRUG|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
223417007|NCT05557643|DRUG|Psilocybin|Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the issues that arise in this participant population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.
224033679|NCT01539304|DRUG|Placebo|Placebo dry syrup, b.i.d
224033680|NCT02253368|OTHER|sleep|
224033681|NCT05678023|OTHER|Effect on contrast media depending on the time of its administratsion|CM is a common practice when it comes to the management of small bowel obstruction. However there is no consensus as when it should be administered
224033682|NCT03025399|DRUG|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
224033683|NCT03025399|DRUG|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
224033684|NCT05389319|BIOLOGICAL|Prime-2-CoV_Beta|1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
224033685|NCT05714007|DRUG|Ferric derisomaltose|Single intravenous dose ferric derisomaltose
224033686|NCT05714007|DRUG|Ferrous succinate|Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
224033687|NCT05543044|BEHAVIORAL|Peer mentor intervention|Peer mentor delivered intervention for transitions to adult-oriented treatment for eating disorders
223560970|NCT03689491|BEHAVIORAL|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
223560971|NCT03689491|BEHAVIORAL|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
223560972|NCT03689491|BEHAVIORAL|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
223560973|NCT05915416|BEHAVIORAL|Child Abuse and Neglect Prevention Program|The Child Abuse and Neglect Prevention Program was then revised in line with the opinions and suggestions of the experts. Power-point presentations and training booklet prepared for the final form of this program have been prepared in such a way that the content is exactly the same. Training booklet was distributed to the experiment group after the pre-test and to the control group after the re-test. This booklet is designed as a resource that participants can refer to whenever they need it. Trainings were provided online through the Google Meet application, in a total of four sessions with an average of 30 minutes per session. The contents of the trainings are child neglect, physical abuse, emotional abuse and sexual abuse, respectively. Four different power-point presentations, addressing these sub-dimensions, were prepared for training purposes.
223560974|NCT07080060|OTHER|Niel-Asher Technique|"Participants in this group will receive the Niel-Asher Technique, a manual therapy approach focusing on trigger point release and myofascial decompression of the shoulder girdle. Treatment will involve structured pressure techniques applied to specific muscular trigger points including the infraspinatus, supraspinatus, subscapularis, and levator scapulae. The intervention will be delivered in side-lying and sitting positions.~Conventional physiotherapy, includes a 10-minute hot pack, 15-minute TENS, Codman exercises, finger ladder exercises (2-3 sets, 3-5 repetitions), and capsular stretching (20-30 sec hold, 2-4 repetitions). Sessions will be conducted 3 times per week for 4 weeks."
223560975|NCT07080060|OTHER|Spencer Technique|"Participants in this group will receive the Spencer Technique, an osteopathic manual therapy consisting of eight mobilization steps: extension, flexion, circumduction with compression, circumduction with distraction, abduction, adduction with external rotation, internal rotation, and traction stretch. Each movement will be performed with patient participation using muscle energy techniques.~Conventional physiotherapy, includes a 10-minute hot pack, 15-minute TENS, Codman exercises, finger ladder exercises (2-3 sets, 3-5 repetitions), and capsular stretching (20-30 sec hold, 2-4 repetitions). Sessions will be conducted 3 times per week for 4 weeks."
223417008|NCT05557643|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) is a well-established evidence-based mindfulness training program initially developed by Jon Kabat-Zinn that has been shown to reduce symptoms of depression, anxiety, and burnout. The 8-week MBSR curriculum provides training in formal meditation practices including body scan techniques, mindfulness meditation, and yoga. Mindfulness can be understood as the non-judgmental acceptance and investigation of present experience, including body sensations, internal mental states, thoughts, emotions, impulses and memories, in order to reduce suffering or distress and to increase well-being.
223417009|NCT03403296|GENETIC|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
223417010|NCT03526536|DRUG|IV Novolin R human insulin|Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
224136892|NCT03214692|DIETARY_SUPPLEMENT|Gum Arabic|Oral intake of GA in powder from30 grams per day
223560976|NCT07080684|DRUG|Ticagrelor 60 mg|"Patients in this arm will receive dual antiplatelet therapy (DAPT) consisting of low-dose ticagrelor (60 mg twice daily) plus aspirin (75-100 mg once daily) for 1 month, followed by ticagrelor 60 mg monotherapy for 5 additional months (total 6 months of therapy).~This strategy aims to reduce ischemic events while minimizing bleeding risk by leveraging the potent antiplatelet effect of ticagrelor at a lower maintenance dose."
223560977|NCT07080684|DRUG|clopidogrel 75 mg|"Patients in the control group will receive standard DAPT consisting of clopidogrel 75 mg once daily plus aspirin 75-100 mg once daily for 6 months.~This represents the current standard of care in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents."
224136893|NCT00514202|DRUG|Placebo|matched placebo
223417011|NCT06259903|DRUG|MD-18|Subcutaneous Administration of MD-18 in Healthy Subjects.
224033688|NCT01246752|BIOLOGICAL|Human Stem Cell Transplantation|Human allogenic stem cells
224033689|NCT01246752|DRUG|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
224033690|NCT00167817|DRUG|Aripiprazole|
224033691|NCT03155854|PROCEDURE|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
224033692|NCT03155854|PROCEDURE|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
224033693|NCT01266733|BEHAVIORAL|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
223417012|NCT02729363|BEHAVIORAL|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention.
223417013|NCT02729363|BEHAVIORAL|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
223417014|NCT02364323|BEHAVIORAL|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
223417015|NCT02364323|OTHER|Normal usual care|General education on diabetes and diabetic complications
223417016|NCT05212662|DRUG|TTI-0102|"The study treatment is a precursor to cysteamine, TTI-0102 (cysteamine-pantetheine disulfide). Each molecule of TTI-0102, after reduction and metabolism in the digestive tract, allows the absorption of 2 molecules of cysteamine and one molecule of pantothenic acid (Vit B5). Each dose of TTI-0102 comes in a vial as a powder to dissolve in water and absorb orally. Each vial contains 5.5g of TTI-0102, corresponding to the equivalent of 2.4g of cysteamine base. This single dose is less than the maximum daily dose authorized with other formulations of cysteamine (Cystagon or Procysbi, 1.95 g/m2/day) for patients over 1.25 m2 or 40 kg (88 lbs).~This dose of 5.5 g is justified by the need to maintain a thiol/disulfide ratio in favor of cysteamine over 24 h. It has been tested in healthy volunteers and has no side effects due to the specific pharmacokinetics of cysteamine after administration of TTI-0102."
223417017|NCT05212662|DRUG|Placebo|Placebo comparator supplied in vials identical to the active intervention, TTI-0102
223417018|NCT04286581|DEVICE|I-Gel Laryngeal Mask Airway|The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
223417019|NCT04286581|DEVICE|Ambu Auragain Laryngeal Mask Airway|The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
223417020|NCT03793673|BEHAVIORAL|CoYoT1 Care|Selected providers will be trained in the CoYoT1 Care protocol for completing medical appointments (both telehealth/standard appointments). There are three key components: (1) Shared decision making: Providers and YA will mutually agree on priorities for each medical visit using a shared decision making tool completed by both the provider and patient. (2) Autonomy supportive care: Providers will be trained in communication strategies, such as motivational interviewing, designed to support YA autonomy and intrinsic motivation. YA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach YA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate.
223417021|NCT03793673|OTHER|Standard Care|"Providers selected for the Standard Care group will complete medical appointments in their usual manner, without specific training or guidelines regarding how to deliver care.~NOTE: Per COVID-19 hospital policies, current clinic appointments consist of telehealth appointments."
223417022|NCT05200013|BIOLOGICAL|BAT7104|Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage
223560978|NCT06749847|OTHER|Women receive invitation letter with HPV self-sampling kit|Direct mailing of HPV self-sampling kit. Women receive HPV self-sampling kit with instructions. SMS reminder at 3 months if no participation. Assistance provided for triage cytology if HPV positive.
223417023|NCT05103280|OTHER|Assistive tennis shoes|Assistive shoes include carbon-fiber and spring loaded shoes.
223560979|NCT06749847|OTHER|Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider|Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.
223560980|NCT07080983|PROCEDURE|Crosslinking|Corneal Cross-Linking (CXL) is a minimally invasive procedure used to strengthen the cornea by increasing the chemical bonds between collagen fibers. It is primarily used to treat keratoconus and corneal ectasia, conditions where the cornea becomes progressively thinner and weaker.
223560981|NCT01519687|DRUG|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
223739220|NCT05157620|OTHER|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
223739221|NCT06748092|DEVICE|iCare IC1000|Measurement of Intraocular Pressure (IOP) in sitting and supine position
224136894|NCT00514202|DRUG|Dextroamphetamine SR|60 mg/day
223417024|NCT06277882|BIOLOGICAL|HAVRIX|intramuscular injections
223417025|NCT01542723|DRUG|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
223417026|NCT02402257|BEHAVIORAL|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
223560982|NCT00420082|DRUG|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
223560983|NCT00420082|DRUG|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
223560984|NCT00420082|DRUG|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
223560985|NCT00420082|DRUG|Placebo|Encapsulated Placebo tablets Q.D.
223560986|NCT01269229|DRUG|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -\> 2400mg/m2 46hrs continuous
223560987|NCT01269229|RADIATION|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
223560988|NCT04742803|DEVICE|Straberi Epistamp Microneedling Treatment|"The patient's entire face will be treated with the Straberi Epistamp needling device.~The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm"
223739222|NCT06748092|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP) in sitting and supine position
223739223|NCT06748092|DEVICE|GAT|Measurement of Intraocular Pressure (IOP) in sitting position
223739224|NCT06748092|DEVICE|Perkins|Measurement of Intraocular Pressure (IOP) in supine position
224298559|NCT02502279|DEVICE|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
224298560|NCT02502279|DEVICE|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
223417027|NCT01554865|DIETARY_SUPPLEMENT|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
223417028|NCT01554865|BEHAVIORAL|Conventional diet counseling|
223417029|NCT01159366|PROCEDURE|percutaneous coronary intervention|early timing
223417030|NCT04836026|DEVICE|HF20™|HF20™ will be used for CRRT
223417031|NCT06666868|BEHAVIORAL|Sustained CARD|This group is using CARD for the 2nd year in a row in participating pharmacies as the vaccination delivery framework (It was used in the 2023-2024 fall/winter vaccination season and is now being sustained in the 2024-2025 fall/winter vaccination season).
224136895|NCT03357809|PROCEDURE|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
223417032|NCT06666868|BEHAVIORAL|First-time CARD|CARD is being used for the 1st time in participating pharmacies as the vaccination delivery framework (2024-2025 fall/winter vaccination season).
223417033|NCT03329170|BEHAVIORAL|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is \<12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
223417034|NCT00905281|OTHER|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
223417035|NCT00905281|OTHER|Standard care|No specific intervention
223417036|NCT00394836|DRUG|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
223417037|NCT00394836|DRUG|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
223560989|NCT02889289|OTHER|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
223560990|NCT04041544|DRUG|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
223560991|NCT04041544|DRUG|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
223739225|NCT06763796|OTHER|Postural Decryption Technique|"Assessment:~PDT begins with visual inspection and palpation to check postural alignment and identify joint or muscle imbalances. Evaluations proceed distal to proximal, examining the spine and shoulder complex in coronal, sagittal, and transverse planes to assess symmetry and neutral positioning.~Treatment Process:~PDT applies the 4R Technique:~1. Reposition - Correct joint alignment.~2. Restore - Release muscle tension and adhesions.~3. Reinforce - Strengthen stabilizing muscles.~4. Retrain - Improve movement patterns and posture.~Key Techniques:~1. Spinal and Shoulder Adjustments: Manual traction, mobilizations, and stretches.~2. Joint Mobilization: Multi-directional gliding within pain-free ranges.~3. Trigger Point Therapy: 5-10 seconds of pressure to relieve localized pain.~4. Proprioception Training: Balance challenges to improve stability and control."
223739226|NCT06763796|OTHER|Traditional Chinese Medicine (TCM) Massage Therapy|"Definition:~A manual therapy based on Traditional Chinese Medicine (TCM) principles, using techniques like kneading, pressing, rolling, and stretching to relieve pain, improve circulation, and enhance mobility.~Key Features:~1. Techniques: Soft tissue manipulation, joint mobilization, and acupressure.~2. Focus: Pain relief, joint function recovery, and muscle relaxation.~Treatment Plan:~4 weeks, 5 sessions per week, 40 minutes per session."
223739227|NCT06878118|DEVICE|Single-vision contact lens|Standard single vision contact lens
224136896|NCT04022174|BEHAVIORAL|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
224136897|NCT04022174|BEHAVIORAL|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
224136898|NCT04022174|BIOLOGICAL|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
224136899|NCT04022174|BEHAVIORAL|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
224136900|NCT06282497|RADIATION|Optimised neck CTV|neck CTV delineation extends from the lateral process of C1
224136901|NCT06282497|RADIATION|standard neck CTV|neck CTV delineation extends from skull base
224298561|NCT03587389|BIOLOGICAL|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
223417038|NCT03863171|DIAGNOSTIC_TEST|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
223417039|NCT03863171|DIAGNOSTIC_TEST|Fundus fluorescein angiography|Fundus fluorescein angiography test
223417040|NCT06210035|BEHAVIORAL|Belly-focus meditation|Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.
223417041|NCT06210035|BEHAVIORAL|Belly-focus meditation with slow breathing|Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
223417042|NCT06967363|PROCEDURE|Nerve Block|"The nerve block intervention in this study involves the targeted administration of anesthetic agents and corticosteroids to specific nerves or nerve roots to alleviate pain associated with low back pain. This procedure is performed under imaging guidance (e.g., fluoroscopy or ultrasound) to ensure precise delivery of the medication to the affected nerve. It aims to temporarily block the transmission of pain signals from the affected area to the brain, providing relief and allowing for a better assessment of the underlying pain mechanism. The nerve block is distinguished from other interventions in this study by its localized approach, focusing on pain modulation through direct neural targeting, rather than systemic pain management methods. The procedure may be used either as a standalone treatment or in conjunction with other therapies (e.g., physical therapy, medications) based on the patient's individual needs and response to treatment."
223417043|NCT06967363|PROCEDURE|endoscopic spinal disecetomy|"The Endoscopic Lumbar Discectomy is a minimally invasive surgical procedure designed to treat symptomatic lumbar disc herniations by removing the protruding or damaged disc material that is pressing on the nerve roots. This intervention is distinguished by the use of endoscopic technology, which allows for a smaller incision, real-time visualization of the affected area via an endoscope, and the removal of herniated disc tissue with minimal disruption to surrounding structures. Unlike traditional open discectomy, which requires larger incisions and muscle dissection, endoscopic discectomy involves the use of a small tubular retractor and specialized instruments, leading to reduced blood loss, shorter recovery times, and less postoperative pain.~This procedure is typically performed under local anesthesia, and the patient is often able to go home the same day. It is specifically designed for patients with lumbar disc herniations who have not responded to conservative way."
223417044|NCT06967363|DRUG|Medication|The treatment of lumbar pain typically involves a multimodal approach combining medications based on the specific type of pain and patient needs. NSAIDs, acetaminophen, and muscle relaxants are often first-line treatments for nociceptive pain, while opioids and anticonvulsants like pregabalin are used for more severe or neuropathic pain. The choice of medication is guided by the severity of the pain, its underlying causes, and the patient's response to treatment. Each class of medication has its strengths and limitations, and the decision to use them must take into account factors like patient safety, the risk of side effects, and long-term efficacy.
223417045|NCT06967363|BEHAVIORAL|Psychotherapy|"Cognitive Behavioral Therapy (CBT): This structured, goal-oriented therapy focuses on identifying and changing negative thought patterns, cognitive distortions, and maladaptive behaviors associated with chronic pain. CBT equips patients with coping strategies to reframe thoughts, reduce pain-related anxiety, and enhance emotional regulation, thereby improving overall function and quality of life. CBT can include techniques such as cognitive restructuring, relaxation training, and behavioral activation.~Acceptance and Commitment Therapy (ACT): ACT encourages individuals to accept pain and distressing emotions rather than avoiding them. It emphasizes mindfulness, acceptance, and values-based living, helping patients focus on behaviors that align with their values, despite ongoing pain."
223417046|NCT06968910|DEVICE|CANNEFF® SUP rectal suppositories|CANNEFF® SUP suppositories with cannabidiol (CBD = 100 mg) and hyaluronic acid (HA = 6.6 mg) as active ingredients
223417047|NCT06968923|BEHAVIORAL|in person treatment|The group undergoes a 5-week treatment, twice a week, for a total of 10 rehabilitation sessions. Each session lasts approximately 60 minutes. The treatment follows standard in-person clinical practice.
223417048|NCT06968923|BEHAVIORAL|Telerehabilitation|The group undergoes a 5-week treatment, with 2 hours per week, for a total of 10 hours at home. Each session lasts approximately 20 minutes. The treatment consists of a sequence of exercises performed using the Euleria Home® device, a medical software that enables the delivery of personalized exercise therapy programs designed by a healthcare professional.
223417049|NCT06967506|DEVICE|Blowing exercise group|Maximum effort exhalation exercises using the AirOFitPRO will be performed three times daily. Each session will be conducted for a minimum duration of five minutes, with 30-second intervals between each effort.
223417050|NCT02028767|DRUG|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
223560992|NCT04544930|BEHAVIORAL|therapist-guided|Therapist-guided Internet treatment comprises eight text modules on the Internet that include psychoeducation, tasks and exercises. Key elements are setting goals for treatment, identifying and challenging negative automatic thoughts through a number of exercises and behavioral experiments, as well as making a plan for relapse prevention. Therapist guidance is secondary to the self-help modules, and the therapist provides feedback to the patient online in the secured program once a week
223560993|NCT04732702|OTHER|no intervention|There will be no intervention.
223560994|NCT06062667|OTHER|accompany the birth|Fathers will accompany their husbands during the birth process
223560995|NCT01787396|DRUG|Gemigliptin 50mg|
223560996|NCT01787396|DRUG|Placebo(Metformin)|
223560997|NCT01787396|DRUG|Metformin|
223560998|NCT01787396|DRUG|Placebo(Gemigliptin)|
224136902|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
224298562|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
224298563|NCT01465620|BEHAVIORAL|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
223560999|NCT05446766|BEHAVIORAL|Self-guided Exposure-based Digital Intervention for Health Anxiety|"An 8-week self-guided internet based CBT intervention which consists of text, exercises, examples and automated support. The format, potentially more accessible compared to traditional ICBT, will be developed with the aim to enhance treatment comprehension and motivation in the participants. The program consists of eight modules (chapters) where the main therapeutic focus is exposure with response prevention.~Participant will be interviewed before the program starts, after 8 weeks and 3 months after the program ends. If in need for technical support, participant will be able to ask for assistance via the program and will then be contacted by a clinician via telephone within a couple of days."
223561000|NCT01244789|DRUG|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
223739228|NCT06878118|DEVICE|A.R.R.E.S.T.® contact lens|Contact lens with edge pattern
223417051|NCT02028767|DRUG|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
223417052|NCT02028767|DRUG|Metformin 500 mg|Metformin 500 mg tablet
223417053|NCT02028767|DRUG|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
223417054|NCT00447824|PROCEDURE|Introduction of better conditions during blood sampling|
223417055|NCT02641626|PROCEDURE|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
223417056|NCT02641626|PROCEDURE|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
223417057|NCT02467062|DEVICE|MRI|MRI measurement to evualuate for 4D blood flow pattern
223417058|NCT05778968|PROCEDURE|low etco2|Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
223417059|NCT05778968|PROCEDURE|normal etco2|Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
223417060|NCT05778968|PROCEDURE|high etco2|Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
223417061|NCT00347139|DRUG|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
223417062|NCT00347139|DRUG|Salmeterol 50mcg|Salmeterol 50mcg
223417063|NCT06475755|DRUG|Immunochemotherapy combined with antiangiogenic|neoadjuvant： Tislelizumab 200mg iv，d1，q3w， Anlotinib 10mg，po，qd1-14，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
223417064|NCT06475755|DRUG|Immunochemotherapy|neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
223417065|NCT01533324|DRUG|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
223417066|NCT02780713|DRUG|AZD9496 (Reference)|AZD9496 (Reference)
223561001|NCT01244789|OTHER|observation|active observation
223739229|NCT07091422|DEVICE|Etch-Free Adhesive|A self-adhesive orthodontic bonding material applied directly to enamel without prior phosphoric acid etching or primer application. Brackets are bonded following the manufacturer's instructions.
224136903|NCT01255826|PROCEDURE|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
223417067|NCT02780713|DRUG|AZD9496 Variant A|AZD9496 Variant A.
223417068|NCT02780713|DRUG|AZD9496 Variant B|AZD9496 Variant B
223417069|NCT02780713|DRUG|AZD9496 Variant C|AZD9496 Variant C
223561002|NCT06206720|DRUG|Deuremidevir Hydrobromide for Suspension|"15 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg BID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension once every 12 hours, total 10 times.~20 mg/kg TID group: 15 subjects will receive Deuremidevir Hydrobromide for Suspension 3 times every day, total 15 times."
223417070|NCT02780713|DRUG|AZD9496 Variant D|AZD9496 Variant D
223417071|NCT01983696|OTHER|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
223417072|NCT05126394|PROCEDURE|ultrasound guided serratus anterior plane block|the patients receive local anesthetic (20 ml of Bupivacaine 0.25 %), injected superficial to the serratus muscle under ultrasound guidance.
223739230|NCT07091422|DEVICE|Conventional Etch-and-Bond Adhesive|A standard orthodontic bonding protocol using 35-37% phosphoric acid etching, primer application, and a conventional light-cure adhesive. Brackets are bonded following the manufacturer's recommended procedure.
223739231|NCT05821972|DRUG|Nebulization of dexmedetomidine and ketamine|Pre-operative nebulization of dexmedetomidine and ketamine
223417073|NCT00842920|DRUG|Simvastatin 60 mg|60 mg once daily
223417074|NCT00842920|DRUG|Placebo|one tablet once daily
223417075|NCT00842920|DRUG|Simvastatin 20 mg|20 mg once daily
223417076|NCT01522001|BEHAVIORAL|Shared Care model|"* First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~* Dietary counseling with dietician~* Exercise (1 hour, 2 timer pr week for 12 weeks)~* Smoking cessation if smoker with educated smoking cessation instructor~* Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~* Examination by the patient´s general practitioner 8-12 weeks after discharge."
223739232|NCT05821972|DRUG|Nebulization of dexmedetomidine|Pre-operative nebulization of dexmedetomidine
223739233|NCT06909214|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
223739234|NCT06902818|DRUG|AD-115A, AD-1151|AD-115A , AD-1151 Oral Tablet
224136904|NCT01069523|DRUG|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
224136905|NCT01069523|DRUG|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
224136906|NCT01156610|BEHAVIORAL|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
224136907|NCT02820376|OTHER|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
223561003|NCT06206720|DRUG|Placebo|"15 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg BID group: 5 subjects will receive placebo once every 12 hours, total 10 times.~20 mg/kg TID group: 5 subjects will receive placebo 3 times every day, total 15 times."
223561004|NCT06242847|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|Participants ingest 75 g of glucose in 10 fl oz aqueous solution (fruit flavored) after an overnight fast. Blood is drawn at baseline (t = 0 min) and at 120 min after ingestion. This test is non-experimental.
223561005|NCT06242847|PROCEDURE|Skin punch biopsy|Punch biopsies are taken from lesional (psoriatic) and non-lesional skin after an overnight fast and at 120 min after ingestion of glucose during OGTT. This procedure is non-experimental.
223561006|NCT05229263|DIAGNOSTIC_TEST|Non- contrast Enhanced Multiparametric Renal Magnetic Resonance|MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
223561007|NCT06025734|DEVICE|Transcutaneous Tibial Nerve Stimulation (TTNS) treatment|Spina Bifida pediatric patients with neurogenic bladder will be in Transcutaneous Tibial Nerve Stimulation (TTNS) treatment. Patient will complete 6 weeks of 30 minute treatment sessions (these can be done at home after the first teaching session)
223561008|NCT05978102|DRUG|STI-7349|Administered by intravenous infusion (IV)
223561009|NCT05978102|DRUG|Pembrolizumab|Administered by intravenous infusion (IV)
223561010|NCT05978102|DRUG|Standard treatment（SoC）|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines.
223561011|NCT05978102|DRUG|approved PD-1/PD-L1 inhibitors (e.g., Tislelizumab, etc.)|Depending on the treatment stage of enrolled subjects, the investigator will determine the standard treatment regimen and dosage with reference to the CSCO or other current guidelines or the corresponding drug Labeling.
223561012|NCT05728281|OTHER|Recommended time after hysterectomy|Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
223739235|NCT05456321|DEVICE|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS)
224136908|NCT00131040|DRUG|Aprotinin|
224136909|NCT02864537|OTHER|Training|Patients were trained to measure INR and dose warfarin
224136910|NCT00863837|DRUG|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
223561013|NCT06283459|BIOLOGICAL|IMNN-101|IMNN-101 is a DNA vaccine encoding SARS-CoV-2 Omicron XBB.1.5 spike antigen. The drug product is a suspension of the DNA plasmid formulated with the facilitating agent, bis-(aza-18-crown-6)-poloxamer (Crown poloxamer, CP), and adjuvant AlPO4.
223561014|NCT03255577|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
223561015|NCT05879354|OTHER|Active Cycle of Breathing Techniques|Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
223561016|NCT03884192|DRUG|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
223561017|NCT03224403|DRUG|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
223561018|NCT03224403|DRUG|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
223561019|NCT03224403|DRUG|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
223561020|NCT03224403|DRUG|Placebo|2 placebo caplets
223561021|NCT04720716|DRUG|IBI310|IBI310 IV d1, Q6W
223561022|NCT04720716|DRUG|Sintilimab|sintilimab IV d1, Q3W
223561023|NCT04720716|DRUG|Sorafenib|Sorafenib 400mg po
223739236|NCT05456321|BEHAVIORAL|Cognitive Training|Computerized Cognitive Training
223739237|NCT05456321|DEVICE|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS)
223739238|NCT05095116|DRUG|APT-1011 3 mg HS|APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
223739239|NCT00597012|PROCEDURE|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
224136911|NCT00863837|DRUG|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
223417077|NCT03106363|DRUG|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
223417078|NCT03106363|DRUG|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (\<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
223417079|NCT03106363|DRUG|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
224136912|NCT03886142|PROCEDURE|radiofrequency|radiofrequency of the genicular nerves
224136913|NCT03886142|PROCEDURE|platelet rich plasma injection|intra articular injection of platelet rich plasma
224136914|NCT02860806|DRUG|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
223417080|NCT03106363|DRUG|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
223417081|NCT00162188|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
223417082|NCT01267461|OTHER|Tissue sample from tumor|Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
223561024|NCT03840772|DRUG|Eribulin|Treatment with eribulin
223739240|NCT00597012|OTHER|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
223739241|NCT00597012|OTHER|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
223739242|NCT07090785|DRUG|LY4088044|Administered IV
223739243|NCT07090785|DRUG|LY4088044|Administered SC
223739244|NCT07090785|DRUG|Placebo|Administered IV
224136915|NCT02860806|DRUG|Placebo|Intravenous infusion of matching placebo.
224136916|NCT01886131|OTHER|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
224136917|NCT01594138|OTHER|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
223739245|NCT07090785|DRUG|Placebo|Administered SC
223739246|NCT03913845|DRUG|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
224136918|NCT02941913|DRUG|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
223417083|NCT02566382|PROCEDURE|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
223417084|NCT02454465|OTHER|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
223417085|NCT04786340|DRUG|Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution|WST-057
223417086|NCT04786340|DRUG|Placebo: WST-057 4mL topical solution|Placebo
223417087|NCT06379646|OTHER|YTS109|Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study.
223417088|NCT06967025|PROCEDURE|Ischemic Postconditioning|Ischemic Postconditioning will consist of 4 cycles of 2-minute cycles of balloon inflation (occlusion) followed by 2 minutes of deflation (reperfusion), and will be initiated immediately upon successful recanalization (eTICI 2b-3) using low pressure balloon in situ of the location of thrombus.
223417089|NCT06967025|PROCEDURE|Endovascular Thrombectomy|Thrombectomy alone.
223417090|NCT00117104|DRUG|Aranesp®|
223417091|NCT02254967|DRUG|Fidaxomicin|oral tablets administered in an extended pulsed regimen
223417092|NCT02254967|DRUG|Vancomycin|oral capsule
223417093|NCT00730860|PROCEDURE|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
223417094|NCT00730860|PROCEDURE|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
223561025|NCT02463747|DRUG|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
223561026|NCT02463747|DRUG|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
223561027|NCT02463747|DRUG|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
223561028|NCT02463747|DRUG|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
223417095|NCT02225860|BEHAVIORAL|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
224136919|NCT04703348|DIAGNOSTIC_TEST|Motor imagery Questionnaire - Revised Second (MIQ-RS)|"Patients fulfill a questionnaire measuring individuals capacities to realize mental imagery. For more facilities and less risk of bias, the MIQ-RS was written on an online version with questions recorded in audio format. No official cut-off exists but studies seem to prove that people with :~* a score less than 48/98 are unable to do motor imagery~* a score between 49 and 73/98 have disturbed motor imagery capacities~* a score more than 74/98 have normal motor imagery capacities."
224136920|NCT01165151|BEHAVIORAL|behavioral weight loss program|weekly, group-based lifestyle weight loss program
223417096|NCT04726072|BEHAVIORAL|Kundalini Yoga|Participants met once a week for two hours for 12 weeks total. The Kundalini yoga intervention is a mixture of basic yoga, breathing exercises, and meditation. Participants were also asked to do at-home practice for half an hour daily.
223417097|NCT04726072|BEHAVIORAL|Psychoeducation|Participants met once a week for two hours for 10 weeks total. The psychoeducation group acted as our control group and consisted of teaching participants about healthy aging. Participants were asked to do at-home practice for half an hour daily.
223417098|NCT02857946|DRUG|Prevaglip (linagliptin)|1 tablet contains 5 mg linagliptin
223417099|NCT02857946|DRUG|Trajenta (linagliptin)|1 tablet contains 5 mg linagliptin
223417100|NCT02022384|OTHER|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
223417101|NCT01597414|DRUG|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
223417102|NCT01597414|DRUG|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
223739247|NCT03913845|DRUG|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
223739248|NCT06127043|DRUG|Rosnilimab|PD-1 agonist antibody
224033694|NCT01266733|BEHAVIORAL|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
224033695|NCT06062225|PROCEDURE|Kamikawa|Kamikawa reconstruction after proximal gastrectomy
224033696|NCT06062225|PROCEDURE|STJI|Single-Tract Jejunal Interposition(STJI) reconstruction after proximal gastrectomy
224033697|NCT06062225|PROCEDURE|SOFY|SOFY reconstruction after proximal gastrectomy
224033698|NCT01159379|DRUG|ertapenem|intravenous, 1 gram, once
224033699|NCT00003941|BIOLOGICAL|bleomycin sulfate|
224136921|NCT02754830|DRUG|LY3303560 - IV|Administered IV
224136922|NCT02754830|DRUG|Saline Solution - IV|Administered IV
224136923|NCT02754830|DRUG|LY3303560 - SC|Administered SC
224136924|NCT04365439|BIOLOGICAL|Blood plasma|Convalescent plasma after COVID-19
224136925|NCT05585892|OTHER|Elaboration and individual mailed feedback|see above
223417103|NCT03131414|OTHER|Diet|Dietary intake
223417104|NCT03131414|OTHER|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
223417105|NCT04850352|DIETARY_SUPPLEMENT|Heukcha Extracts|Experimental group: Heukcha Extracts
223417106|NCT04850352|DIETARY_SUPPLEMENT|Placebo|Placebo group
223417107|NCT05225870|GENETIC|immunohistochemical staining|sections from colorectal carcinoma will be immunohistochemically stained by anti-Cortactin antobody.
223417108|NCT06371495|DRUG|rosuvastatin|"Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset."
223739249|NCT06127043|DRUG|Placebo|Administered via SC
223739250|NCT07092527|DRUG|Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution|Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.
223739251|NCT07096310|DRUG|Meropenem I.V. 2g as a 3 hour infusion every 8 hours|Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day
223739252|NCT07096310|DRUG|Tazocin (pipercillin/tazobactam)|Non C group will receive non Carbapenems (Tazocin) 4.5 gm IV slow infusion over 20 minutes every 8 hours per day
224033700|NCT00003941|BIOLOGICAL|filgrastim|
224033701|NCT00003941|DRUG|cisplatin|
224033702|NCT00003941|DRUG|etoposide|
224033703|NCT00003941|DRUG|ifosfamide|
224033704|NCT00003941|PROCEDURE|bone marrow ablation with stem cell support|
224033705|NCT00003941|PROCEDURE|peripheral blood stem cell transplantation|
224136926|NCT04729582|BIOLOGICAL|Primary human muscle stem cells (Satori-01)|Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.
224033706|NCT01475552|DRUG|Abciximab|Patients, who showed PRU \>270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
223417109|NCT04426721|DRUG|Ozone|10 cc of oxygen-ozone
223417110|NCT04426721|DRUG|Hyaluronic Acid|Sinovial forte 32 mg\\2ml
223417111|NCT03981484|BIOLOGICAL|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
223417112|NCT03981484|BIOLOGICAL|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
223417113|NCT03807479|DRUG|Ponatinib|2 film-coated tablets à 15mg for oral administration on a daily basis
223417114|NCT05338502|DRUG|Selpercatinib|Administered orally.
223417115|NCT05338502|DRUG|Ranitidine|Administered orally.
223417116|NCT05338502|DRUG|Omeprazole|Administered orally.
223417117|NCT04279470|DRUG|CAR T-cell and Cellular Therapies|Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy
223417118|NCT05410275|DRUG|Rivaroxaban|Experimental group Each patient will receive successively over 3 distinct periods the 3 doses of rivaroxaban to be evaluated, i.e., 5 mg, 10 mg, and 15 mg as a single daily dose (once daily over 3 days for each dose).
223417119|NCT00647738|DRUG|Baclofen|Single-dose 20 mg immediate-release oral tablets
223561029|NCT03024333|OTHER||Investigators will use the blender to prepare different viscous foods and liquids. Then, a sound detection device will be attached on the participant's neck. The device will record three times of swallowing sounds at three placements (Apleft, Apright, B) separately with participants' head-trunk in neutral position and also record sounds in the neck such as breathing sound, throat clearing and cough sounds. Participants will use 5 ml spoon to intake different viscous foods or liquids. The conversation will also be recorded using a Sony recorder (ICD-SX713) in each data collection session. The voice recording will not be analyzed, which only provides the additional information about which foods or liquids subjects swallow or at which placement sensor records swallowing sounds.
223561030|NCT02109432|BEHAVIORAL|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
224033707|NCT01475552|DRUG|control|"Patients,who showed PRU \>270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
223417120|NCT00647738|DRUG|Baclofen|Single-dose 20 mg immediate-release oral tablet
223417121|NCT05043025|OTHER|Identification of the cricothyroid membrane|The cricothyroid membrane is identified using a laryngeal handshake technique in different patient positions.
223561031|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
223417122|NCT05105542|DRUG|11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor|The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.
223417123|NCT05105542|DEVICE|PET Scan|PET scanner with high sensitivity and resolution available for human brain imaging
223417124|NCT02218099|DRUG|ASP8232|Oral
223417125|NCT02218099|DRUG|Placebo|Oral
223561032|NCT02109432|BEHAVIORAL|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
223561033|NCT00002598|BIOLOGICAL|recombinant interferon alfa|
223417126|NCT06640257|DRUG|SHR-1314 injection|SHR-1314 injection
223417127|NCT06640257|DRUG|Placebo|Placebo
223417128|NCT04046510|DRUG|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
223417129|NCT04424706|DIAGNOSTIC_TEST|diagnosed as type 2 diabetes without atherosclerosis|patients diagnosed as type 2 diabetes without atherosclerosis
223417130|NCT04424706|DIAGNOSTIC_TEST|diagnosed as type 2 diabetes with atherosclerosis|patients diagnosed as type 2 diabetes with atherosclerosis
223417131|NCT04424706|DIAGNOSTIC_TEST|people without type 2 diabetes or atherosclerosis|normal people without type 2 diabetes or atherosclerosis
223417132|NCT02655991|BEHAVIORAL|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
223417133|NCT02655991|BEHAVIORAL|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
223417134|NCT05200182|DEVICE|Neurofeedback with functional near infra-red spectroscopy|"the neurofeedback protocol will last 15 minutes per session, and during each session, the volunteer will have to increase the brain activity of his/her dorsolateral prefrontal cortex using a visual gauge representing the activity level of his/her own dorsolateral prefrontal cortex. No specific instructions will be given to the volunteer so that he/she can develop his/her own internal strategy to increase this activity level."
223417135|NCT05200182|DEVICE|Sham Neurofeedback|the participants will receive the same instruction but will be shown a random signal
223417136|NCT05200182|OTHER|oral microbiota collection|an examination and oral swab for oral microbiota analysis will be performed by a dentist
223417137|NCT05200182|OTHER|Questionnaires|questionnaires for pre-intervention behavioral characterization
223561034|NCT00002598|BIOLOGICAL|sargramostim|
224033708|NCT00912652|BEHAVIORAL|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
224033709|NCT00912652|BEHAVIORAL|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
224033710|NCT02636933|OTHER|Lung Function Assessment|Lung Function Assessment
224136927|NCT04729582|OTHER|Placebo|Placebo is the injection solution without muscle stem cells.
224136928|NCT02497157|DRUG|Oxaliplatin (L-OHP)|
224136929|NCT02497157|DRUG|Irinotecan hydrochloride hydrate (CPT-11)|
224136930|NCT02497157|DRUG|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
223417138|NCT05200182|DEVICE|resting-state fMRI|characterize the brain function of volunteers by resting-state fMRI
223417139|NCT05200182|DEVICE|Electro gastrogram|Volunteers will also be equipped with an MRI-compatible electro-gastrogram device to correlate gastric signals with brain activity during rsMRI acquisition.
224033711|NCT01676909|BEHAVIORAL|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
224136931|NCT02497157|DRUG|Levofolinate calcium (l-LV)|
224136932|NCT02497157|DRUG|Bevacizumab (Bmab)|
224136933|NCT03184298|OTHER|Surveys|The purpose of the surveys is to collect quantitative data to determine the relative impact of the intervention program on participants' sexual behaviors and alcohol use.
223417140|NCT05200182|BEHAVIORAL|Emotional Stroop task|an emotional Stroop task adapted to food and body image representation
223417141|NCT03575793|DRUG|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
223417142|NCT03575793|DRUG|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-\[\[5-(1,1-dimethylethyl)-1H-imidazol-4-yl\[methylene\]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
223417143|NCT03575793|DRUG|Ipilimumab|Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
223417144|NCT00790244|DRUG|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
223417145|NCT00790244|DRUG|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
223417146|NCT00790244|DRUG|doxorubicin, ifosfamide|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
223417147|NCT00790244|DRUG|doxorubicin, ifosfamide|"\<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(\>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
223417148|NCT01250873|DRUG|LY2216684|po administration
223417149|NCT01250873|DRUG|Sertraline|po administration
223417150|NCT05581940|COMBINATION_PRODUCT|Group A Caudal Epidural Anesthesia with bupivacaine 0.25% and group B with opioid intervenors|(CEB) in group A using drugs bupivacaine 0.25% commonly used in children including neonates in group A In infraumbilical operations, it is used as a supplement to GA and to control postoperative pain It is a safe, easy, and effective type of central neuraxial block.\[ The patient will be intubated and the caudal block will be performed under GA after securing the airway. The patient's position will be turned onto the lateral decubitus then a landmark-based, blind technique will be used. In children, the success rate with the blind technique is above 96% but the occurrence of side effects is reported. Group B uses general anesthesia (GA) alone for intraoperative and perioperative pain control used the opioid intervious without caudal block .
224136934|NCT03184298|OTHER|Interviews|These Motivational Interviews aim to promote change in behavior through open-ended questions, affirmations, and reflections.
224136935|NCT03184298|OTHER|Group Discussions|The purpose of the group workshop is to create discussions surrounding perceived and collective social norms found among male soldiers that have been connected to sexual aggression. These discussions are used to promote bystander intervention among participants and help identify the prosocial attitudes that may be more common than previously perceived.
224136936|NCT02634931|DRUG|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
223417151|NCT04805801|DRUG|Emicizumab subcutaneous injection|Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.
223561035|NCT00002598|DRUG|cyclophosphamide|
224136937|NCT06195384|BIOLOGICAL|Neoantigen mRNA Vaccine|Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
224136938|NCT03628430|PROCEDURE|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
224136939|NCT03628430|PROCEDURE|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
224136940|NCT03628430|PROCEDURE|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
224136941|NCT03672877|BEHAVIORAL|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
223417152|NCT04342637|OTHER|Practice details|Physicians will report details of their endoscopy practice through answering the questions of the questionnaire
223417153|NCT03687333|DRUG|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
223417154|NCT05094674|DIAGNOSTIC_TEST|Breath Sample analysis|The participant's breath sample is taken by blowing preferably three times into a disposable tube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis. This will take place once during the study.
223417155|NCT03781362|DRUG|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
223417156|NCT03781362|DRUG|Capecitabine|Capecitabine will be administered 1000 mg/m2 orally twice a day for 2 weeks followed by a 7-day rest period
223417157|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
223561036|NCT00002598|DRUG|cytarabine|
223561037|NCT00002598|DRUG|etoposide|
223561038|NCT00002598|DRUG|methotrexate|
223561039|NCT00002598|DRUG|mitoxantrone hydrochloride|
223417158|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
223417159|NCT02510963|DRUG|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
223561040|NCT00002598|PROCEDURE|bone marrow ablation with stem cell support|
223561041|NCT00002598|RADIATION|radiation therapy|
223561042|NCT04374591|DRUG|Sodium Bicarbonate|Inhalation of Sodium Bicarbonate 8.4% via nebulizer
223561043|NCT06543498|DIAGNOSTIC_TEST|Lactulose/Mannitol Ratio Test|To test for gut permeability, Urine collected over 8hrs after ingestion of lactulose/mannitol drink.
223561044|NCT06543498|DIAGNOSTIC_TEST|Serum biomarkers of intestinal permeability|Phlebotomy and subsequent lab tests to analyse concentration of LPS, LPB, sCD14, Zonulin and Occludin.
223561045|NCT06543498|OTHER|Rome IV questionnaire|Diagnositic questionnaire for IBS-D
223561046|NCT06543498|OTHER|Irritable bowel severity scoring system|Questionnaire to determine severity of abdominal and bowel symptoms
223561047|NCT06543498|OTHER|Bowel Habit diary|Assess bowel habit at baseline and changes in bowel habit over the study
223417160|NCT00081757|DRUG|Thalidomide|
223561048|NCT06543498|OTHER|3 day dietary record|Used to verify compliance to exclusion criteria #5.
223561049|NCT06543498|DIETARY_SUPPLEMENT|NCT and NFT|N-transcaffeoyltyramine and N-transferuloyltyramine supplement taken once per day.
223561050|NCT06543498|OTHER|Placebo|Placebo supplement taken once per day.
223561051|NCT02908685|DRUG|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
223561052|NCT02908685|DRUG|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
223561053|NCT02511834|DEVICE|VEST External Support|
223561054|NCT02511834|PROCEDURE|Coronary Artery Bypass Surgery|
223561055|NCT01359241|PROCEDURE|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
223417161|NCT04036435|DRUG|BMS-986165|Specified dose on specified days
224033712|NCT01676909|BEHAVIORAL|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
223417162|NCT06261125|RADIATION|Stereotactic body radiotherapy|Patients in both cohorts will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 33-48 Gy in 6 fractions over 2 weeks.
223417163|NCT06261125|DRUG|Adebrelimab|All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.
223417164|NCT06261125|DRUG|Lenvatinib|All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.
223417165|NCT02278939|BEHAVIORAL|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
223417166|NCT01329042|DRUG|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
223561056|NCT01359241|DRUG|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
223561057|NCT04983485|OTHER|Observational|Respiratory muscle electromyographic activations of individuals will be evaluated during the test while breathing rapidly and deeply from the beginning of the constant threshold load endurance test and the increasing threshold load endurance test until the end of the test, and at rest. Respiratory muscle endurance will be evaluated with constant threshold load endurance test and increasing threshold load endurance test, respiratory functions with pulmonary function test, respiratory muscle strength with intraoral pressure measurement device, health condition disorder with Chronic Obstructive Pulmonary Disease Assessment Scale, dyspnea with Modified Medical Research Council Dyspnea Scale and Modified Borg Scale. Participants' names, anthropometric measurements, demographic data, contact information and medical history will be collected and recorded with the patient anamnesis form.
223561058|NCT02518087|DEVICE|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
223561059|NCT02518958|DRUG|RRx-001|
223561060|NCT02518958|DRUG|Nivolumab|
223561061|NCT01121627|OTHER|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
223561062|NCT04272866|OTHER|Clinpro sealant|Resin based sealant
223561063|NCT04272866|OTHER|Embrace wetbond sealant|Moisture tolerant hydrophilic resin based sealant
223561064|NCT04272866|OTHER|Triage sealant|Glass ionomer sealant
223561065|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
223561066|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
223561067|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
224136942|NCT03384225|DRUG|Cladribine|
224136943|NCT03384225|DRUG|Fludarabine|
224136944|NCT03384225|DRUG|Busulfan|
224136945|NCT03384225|DRUG|Cytarabine|
224136946|NCT05739812|DEVICE|telesurgery by domestic surgical robot|telesurgery of urological diseases by domestic surgical robot
224136947|NCT02344069|DRUG|Fibrinogen|Human fibrinogen concentrate as a injection
223417167|NCT04828213|DEVICE|Rapid Maxillary Expansion Treatment with Tooth-borne RME appliance (Hyrax)|The patients were treated with a expansion appliance containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
223417168|NCT04828213|DEVICE|Rapid Maxillary Expansion Treatment with Hybrid hyrax RME appliance|The patients were treated with a Hybrid hyrax RME appliance containing a Hyrax expansion screw positioned parallel to the second premolars and mini-screws. RME activation was performed twice a day for the first week and then once per day. When it was decided that the expansion was sufficient (until the palatal tubercles of the upper molars came into contact with the buccal tubercles of the lower molars), the screw was fixed with the 0.012-inch ligature wire (American Orthodontics) and the appliance was kept in the mouth without being activated for 3 months.
223417169|NCT02669836|PROCEDURE|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
223417170|NCT02669836|PROCEDURE|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
223417171|NCT01070212|OTHER|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
223417172|NCT01070212|OTHER|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
223561068|NCT01691014|OTHER|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
223561069|NCT02370537|DRUG|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
223739253|NCT06125691|BIOLOGICAL|ARCT-2138|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
223739254|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for younger adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
223739255|NCT06125691|BIOLOGICAL|Licensed Quadrivalent Vaccine for older adults|Each participant will receive one 0.5 mL intramuscular (IM) dose into the deltoid muscle.
224136948|NCT02344069|DRUG|Placebo|Saline 0.9% as a injection
224136949|NCT01035242|BEHAVIORAL|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
224136950|NCT01035242|BEHAVIORAL|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
224136951|NCT02692339|DRUG|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
224136952|NCT02692339|DRUG|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
224136953|NCT00150371|DRUG|atorvastatin|
223561070|NCT02370537|DRUG|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
223561071|NCT02612701|OTHER|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
223561072|NCT02612701|OTHER|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
223561073|NCT02612701|OTHER|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
223739256|NCT00436254|BIOLOGICAL|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
223739257|NCT00436254|BIOLOGICAL|sargramostim|Given intradermally
223561074|NCT02612701|OTHER|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
223561075|NCT03591614|BIOLOGICAL|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
223739258|NCT00436254|OTHER|flow cytometry|Correlative studies
223739259|NCT00436254|OTHER|immunologic technique|Correlative studies
223739260|NCT00436254|OTHER|immunoenzyme technique|Undergo ELIspot (correlative studies)
223739261|NCT00436254|GENETIC|protein expression analysis|Undergo ELISA (correlative studies)
223739262|NCT00436254|PROCEDURE|biopsy|Undergo punch biopsy (correlative studies)
223417173|NCT01070212|OTHER|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
223417174|NCT03428113|OTHER|Bladder Volume Measurement bladder scanner RN|Measure Urine Volume with Bladder Scanner by RN
223417175|NCT03428113|OTHER|Bladder Volume Measurement Ultrasound APRN|Measure Urine Volume with Point of Care Ultrasound by APRN
223417176|NCT03428113|OTHER|Bladder Volume Measurement bladder scanner APRN|Measure Urine Volume with Bladder Scanner by APRN
223417177|NCT03428113|OTHER|Bladder Volume Measurement Ultrasound MD|Measure Urine Volume with Point of Care Ultrasound by MD
223417178|NCT03428113|OTHER|Intermittent Straight Catheterization|Measure Urine Volume with Intermittent Straight Catheterization
223417179|NCT05169918|OTHER|Core stabilization|"The progressive core stabilization exercise approach created by Kumar et al. will be used.~* Stage 1; Isolation and facilitation of target muscles~* Stage 2; Trunk stabilization training with increased load under static conditions~* Stage 3; Development of trunk stabilization during slow controlled movement of the lumbar spine.~* Stage 4 and 5; Lumbar stabilization during high speed and dexterous movements. The exercises will last 20-30 minutes in each sessions and twice a week for 10 weeks. The level of stage will be increased when the patients reach the aim of the stage where he/she is at. The duration of the each stage will change depending on the days the patients' need to achieve the aim of the level. For each level, at least four exercise is described."
223417180|NCT05169918|OTHER|Sensorial Discrimination Training|Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
223417181|NCT06630364|DRUG|ketamine|Induction: Sevoflurane in N2O/O2, Propofol (1-1.5 mg/kg) Analgesia: Ketamine (0.5 mg/kg) Maintenance: Sevoflurane
223417182|NCT06630364|DRUG|fentanyl|Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
223417183|NCT01094470|DEVICE|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
223417184|NCT05007743|DEVICE|Transcutaneous vagus nerve stimulation|"Frequency of 30 Hz, biphasic, rectangular pulses with a pulse width of 250 µs and an intensity of 20 mA.~Device: Easy Tens+ device (body clock, London, UK)"
223417185|NCT02088671|DRUG|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
223417186|NCT02088671|DEVICE|Recording of EEG using NeuroSENSE|"The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest."
223417187|NCT02088671|OTHER|Data collection|"Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information."
223561076|NCT02933840|DEVICE|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
223561077|NCT00087776|DRUG|Taxoprexin|Administered by intravenous infusion over 2 hour infusion on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course
223417188|NCT02088671|OTHER|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
223417189|NCT00660933|DRUG|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
223561078|NCT00087776|DRUG|Dacarbazine|Administered by intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course
223561079|NCT06252961|DRUG|Levamisole 3 days|Levamisole for 3 days (2,5 mg/kg) then placebo for 2 days
223561080|NCT06252961|DRUG|Levamisole 5 days|Levamisole for 5 days (2,5 mg/kg)
223561081|NCT06252961|DRUG|Placebo|Placebo for 5 days
223561082|NCT05897242|BEHAVIORAL|Smartphone app|Use ACT on Vaping smartphone app
223561083|NCT05897242|OTHER|Text Message|Receive text messages
223561084|NCT05897242|OTHER|Survey Administration|Ancillary studies
223561085|NCT03804021|GENETIC|No Intervention|Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
223561086|NCT04439539|DRUG|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously.
223561087|NCT04439539|DRUG|PegIFN-alpha-2a|PegIFN-alpha-2a injection will be administered subcutaneously.
223561088|NCT04439539|DRUG|Tenofovir disoproxil|Tenofovir disoproxil film-coated tablet will be administered orally.
223561089|NCT04439539|DRUG|Tenofovir alafenamide|Tenofovir alafenamide film-coated tablet will be administered orally.
223561090|NCT04439539|DRUG|JNJ-56136379|JNJ-56136379 will be administered orally.
223561091|NCT05820152|DRUG|NFS-02 Injection|The starting dose is 1.5×108 vg, 0.05 mL eye/dose. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be escalated to 5.0×108 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in \< 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the 5.0×108 vg, 0.05 mL eye/dose, the dose can be escalated to 1.5×109 vg, 0.05 mL eye/dose after the approval by SRC. If drug-related dose-limiting toxicity (DLT) events are observed in ≥ 2 of the 6 evaluable subjects within 6 weeks after the dosing of NFS-02 at the starting dose, the dose can be de-escalated to 5.0×107 vg, 0.05 mL eye/dose after the approval by SRC.
223561092|NCT05467839|DEVICE|derma pen|Derma pen is automatic and rechargeable device (vibrating frequency:6500-10000 r/m, vibration speed level 5, model: Ultima A6, company: Dr. Pen and country: Korea). With every case the needle should be replaced. Needle length is adjustable from 0.25mm to 2mm according to the treated areas. The pen is convenient in treating narrow areas such as the nose, around the eye and the mouth. The vibration speed of the pen can be controlled in 5 levels
223561093|NCT06224998|BEHAVIORAL|Exercise|Exercise is the most appropriate treatment for low and moderate AIS cases due to its low cost and low risk of complications. Exercises prevent the development of many problems by controlling the severity of curvature and preventing the progression of curvature. It is thought that scoliosis exercises can delay or even prevent surgery and reduce the duration or degree of brace, especially in patients with low-to-moderate curvature during growth. One of these exercise approaches, the Schroth technique, is primarily based on isometric muscle contraction exercises that aim to rotate, lengthen and stabilize the spine. The core component of the Schroth method is autocorrection, defined as the patient's ability to reduce spinal deformity through active postural realignment of the spine in three dimensions.
223561094|NCT00680979|BEHAVIORAL|Interpersonal Psychotherapy|
224136954|NCT05080179|BEHAVIORAL|Self-Benefit/Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. and Over 650,000 Pennsylvanians have already downloaded the app!"
223417190|NCT00660933|DRUG|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
223417191|NCT03428672|PROCEDURE|total hip arthroplasty|Bone samples from Hip fracture were collected from the femoral head which has been replaced
223417192|NCT06668415|PROCEDURE|Hydro dilation|The hydro dilation injections comprises of Depomedrol 80mg and normal saline 0.9%. It is performed under fluoroscopic guidance by the orthopedic surgeon.
223417193|NCT06668415|PROCEDURE|Spencer muscle energy technique|Spencer muscle energy technique is a seven 7 step procedure which consists of shoulder extension with elbow flexed, shoulder flexion with elbow flexed, circumduction with compression, circumduction with traction, Abduction then adduction with external rotation and glenohumeral pump. Following the complete action, patients will be encouraged to use their muscles for 3 to 5 seconds against little resistance provided by the therapist
223417194|NCT06668415|PROCEDURE|Passive Stretching|The low intensity stretches will be given in supine for all the movements ie Flexion ,Abduction , Internal Rotation and External Rotation for 5 repititions with 30 sec hold.
223417195|NCT06100263|OTHER|Individualized exercise program|guided exercise program for 12 weeks
223417196|NCT06100263|OTHER|Control Arm|American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided
223417197|NCT01496963|OTHER|Physician standard-of-care according to ESC/ERS Guidelines|Physician standard-of-care
223561095|NCT00680979|BEHAVIORAL|Health Education|
223561096|NCT02920528|DRUG|Ketamine|sub-dissociative ketamine
223561097|NCT02920528|DRUG|Placebo|Normal Saline
223561098|NCT02483793|DRUG|Tamsulosin|
223561099|NCT02483793|DRUG|Oxybutynin|
223561100|NCT05793255|BEHAVIORAL|Social Phone Calls|Following the collection of baseline data, the study participant will be randomly assigned to a student volunteer to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6weeks. Each phone call is expected to last around 1 hour with flexibility to be shorter or longer. The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer. If the stroke survivor and student volunteer wish to speak more than the designated one call a week, that will be allowed if both parties agree. The same student volunteer will conduct all six sessions
223561101|NCT02481648|OTHER|Exercise|
223417198|NCT03996174|OTHER|Interview|Interview bases on the use of an interview guide, during one hour maximum
223417199|NCT02149446|DEVICE|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
223417200|NCT04296825|DIETARY_SUPPLEMENT|Camel milk containing Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
223417201|NCT04296825|DIETARY_SUPPLEMENT|Camel milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
223417202|NCT04296825|DIETARY_SUPPLEMENT|Bifidobacterium animalis A6|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
223417203|NCT04296825|DIETARY_SUPPLEMENT|Cow milk|Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
223417204|NCT01726725|DRUG|desflurane|
223417205|NCT06364501|DRUG|KH801|KH801 is an injection solution
223417206|NCT02818985|DRUG|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
223417207|NCT02818985|DRUG|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
223417208|NCT02818985|DRUG|Saline|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
223561102|NCT03245554|DRUG|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
223561103|NCT03883347|DRUG|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
223561104|NCT03883347|DRUG|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
223561105|NCT02547038|DRUG|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
223561106|NCT02547038|DRUG|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
223417209|NCT06641193|DEVICE|high frequency-repetitive transcranial magnetic stimulation|rTMS involves the repeated application of magnetic pulses to specific areas of the brain. These pulses are delivered using a coil placed on the scalp, which generates a magnetic field that induces electrical currents in the brain tissue.
223417210|NCT06641193|DEVICE|sham stimulation|The sham group receives 10 sessions of rTMS stimulation with a sham stimulation coil, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
223417211|NCT03727152|DRUG|generic single tablet TAF/FTC/DTG|HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
223417212|NCT06682390|BEHAVIORAL|Hypocaloric anti-inflammatory diet|The anti-inflammatory hypocaloric diet combines the exclusion of pro- inflammatory constituents and inclusion of anti-inflammatory nutrients. Excluded food items will be refined carbohydrates, soda and alcoholic beverages, ultra- processed foods, smoked foods, fatty foods, packaged foods, canned products, preservatives, emulsifiers, and sauces. Reduce or eliminate red/processed meats. Included food items will be a defined minimum diversity of fruits, vegetables, and nuts based on complementary phytonutrient contents, particularly those rich in phenolic compounds such as ellagitannins and sulforaphanes. Selected herbs (e.g., turmeric, ginger, garlic, black pepper, rosemary, cardamon, cinnamon), green tea, fermented foods, fats (e.g., avocado), and oils (e.g., olive oil) will be encouraged. The goal is to have 5 servings of vegetables, 2 fruits per day, and 5 vegetable color groups per week. Participants will also be asked to reduce their kcal by 500/day and walk for 1 gr 3x per week.
223417213|NCT05045079|PROCEDURE|Inferior Vena Caval (IVC) Occlusion maneuver|During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
223417214|NCT04198038|BEHAVIORAL|Songwriting with licensed music therapist|Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
223417215|NCT04128254|DRUG|Apixaban Oral Tablet|Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
223417216|NCT01663090|DRUG|Ferumoxytol|
223417217|NCT04443075|DEVICE|faecal sample collector|The frontline medical workers mainly exposed under the stress of fighting against 2019-nCoV
223417218|NCT03119675|DEVICE|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
223417219|NCT03119675|DEVICE|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
223417220|NCT06104761|OTHER|Release group|i will make release for these muscles ( upper trapizius , levator scapulae , strenomastoid ) in addition to sub occipital fascia , then I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
223417221|NCT06104761|OTHER|strength exercises and stretching for upper crossed syndrome|I will apply conventional physical therapy in form of stretching exercises (Trapezius (upper fibers) muscle , Levator scapulae muscle , Pectoralis major and Sternocleidomastoid muscles) and strengthening exercises for these muscles (Deep neck flexors, Trapezius (middle and lower fibers), Rhomboids and Serratus anterior muscles).
223561107|NCT01368692|PROCEDURE|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
223561108|NCT01368692|PROCEDURE|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
223561109|NCT02196883|PROCEDURE|Transforaminal Epidural Steroid Injection|
223417222|NCT03813836|DRUG|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
223417223|NCT06621095|DRUG|anlotinib + benmelstobart + nab-paclitaxel + gemcitabine|"1. Before 8 cycles, anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
223417224|NCT06621095|DRUG|nab-paclitaxel + gemcitabine|"1. Before 8 cycles, nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
223417225|NCT04094987|DEVICE|inter-fascial pressure|The pressure between the fascia and the pressure line added to the catheter tip will be measured.
223417226|NCT01335074|DRUG|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
223417227|NCT02745613|OTHER|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
223417228|NCT04544488|PROCEDURE|Recording of expulsive efforts by connection of a pressure sensor to the women's bladder probe|"Using a pressure probe connected to a Foley Catheter, intra bladder pressure wille be registered during the whole duration of expulsive phase.~The device will be inserted into women's bladder using usual guidelines for insertion of Foley catheter"
223561110|NCT01340625|DRUG|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
223561111|NCT01340625|DRUG|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
223561112|NCT04463342|COMBINATION_PRODUCT|Non Coated Glass Ionomer|KetacTM Universal AplicapTM Glass Ionomer Restorative saves time by eliminating the need for a coating-yet still delivers the compressive strength and surface hardness that are higher than several competitive glass ionomers which require one.
223561113|NCT04463342|COMBINATION_PRODUCT|Conventional Glass Ionomer with Coat|Conventional Glass Ionomer with Coat
223561114|NCT05400473|OTHER|Therapeutic exercise|This group will consist of 30 participants. A program consisting of specific therapeutic exercises for the cervical region will be applied.
223561115|NCT05400473|OTHER|Photobiomodulation|Photobiomodulation will be applied on the cervical region. To perform the photobiomodulation protocol, a low power infrared laser therapy unit will be used.
223561116|NCT00066703|DRUG|exemestane|
223561117|NCT00066703|DRUG|tamoxifen|
224033713|NCT06088212|OTHER|Disease management program|"The components of our DMP include:~1. Intensive post-discharge education~2. Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer.~3. Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period.~4. Exercise program delivered by an exercise physiologist~5. Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly."
224033714|NCT02215837|DRUG|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
223417229|NCT06642207|DIAGNOSTIC_TEST|CBC|to compare platelet count in Ankylosing Spondylitis patients in treatment with Anti-TNF- α and patients with IL17 Inhibitor
223417230|NCT06474988|OTHER|Skin tests|Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests
223417231|NCT01909193|BEHAVIORAL|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
223417232|NCT01909193|BEHAVIORAL|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
223417233|NCT03436693|DRUG|Canagliflozin|Canagliflozin 100mg orally once daily
223417234|NCT03436693|DRUG|Placebo|Placebo orally once daily
223417235|NCT02375893|OTHER|No intervention|Collecting blood and feces samples
223417236|NCT02375893|OTHER|Healthy subject|Collecting blood and feces samples
223417237|NCT06681961|OTHER|squatting with hip adduction (SQU-HA) group|The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.
223417238|NCT06683261|BIOLOGICAL|Omalizumab|biological prescribed as add-on treatment as part of the standard of care
223417239|NCT06683261|BIOLOGICAL|Dupilumab|biological prescribed as add-on treatment as part of the standard of care
223417240|NCT06683261|BIOLOGICAL|Mepolizumab 100 mg|biological prescribed as add-on treatment as part of the standard of care
224033715|NCT02215837|BIOLOGICAL|Ag-D-CIK|8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
223417241|NCT01793961|OTHER|electroretinogram|
223417242|NCT01793961|OTHER|contrast sensitivity tests|
223561118|NCT00066703|DRUG|triptorelin|
223561119|NCT06473831|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
223561120|NCT04460339|OTHER|Swimming participants in the 25-km|The 25-km race was the French national Open Championship event and participants were the swimmers registered for the race who volunteered to participate in this study
223561121|NCT04847258|OTHER|Standard rehabilitation|Patients follow standard municipal rehabilitation
223561122|NCT06346483|PROCEDURE|Dusting without Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
224033716|NCT04350554|OTHER|Pregnancy|To measure and characterize pregnancies and describe the clinical course during pregnancy
223417243|NCT01680861|DRUG|Tacrolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
223417244|NCT01680861|DRUG|Everolimus|Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
223417245|NCT01680861|DRUG|Enteric Coated Mycophenolate Sodium (EC-MPS)|EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
223417246|NCT01680861|DRUG|Corticosteroids|Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
223417247|NCT02111577|BIOLOGICAL|DCVAC/PCa|DCVAC/PCa concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). DCVAC/PCa was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of DCVAC/PCa was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
223417248|NCT02111577|BIOLOGICAL|Placebo|Placebo concurrently with docetaxel plus prednisone every 3 weeks (± 7 days). Placebo was administered at least 7 days before or and at least 7 days after the nearest chemotherapy (days 8-15 of chemotherapy cycles). After discontinuation of chemotherapy for any reason, each following dose of placebo was given every 4 weeks (-7/+14 days) for up to a total of 15 doses.
223417249|NCT05783297|BEHAVIORAL|Treatment Text (TXTXT)|This study will test a tailored, personalized SMS text message reminder intervention to improve adherence to ART among non-adherent youth and young adults with HIV. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the 6-month intervention period. Participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
223417250|NCT05783297|BEHAVIORAL|Standard of Care|Standard of care ART adherence support includes adherence counseling during visits scheduled at least twice annually and appointment reminders.
223417251|NCT04979780|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Retrospective cohort analysis using US Optum De-Identified EHR data.
223417252|NCT04979780|DRUG|Low molecular weight heparin (LMWH)|Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
223561123|NCT06346483|PROCEDURE|Dusting with Moses 2.0 Modulation|Dusting is when a laser is used to break a stone down into tiny fragments that are able to pass through the urine.
223561124|NCT06346483|OTHER|Moses 2.0 Modulation|Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology used for lithotripsy and BPH treatments
223739263|NCT04889352|OTHER|Access to colonoscopy web app|There is a very high utilization of colonoscopy at both shorter and longer time intervals than the recommended guidelines. Investigators have developed a clinical support tool in which the characteristics of the patients can be inputted and the guideline recommended time interval for surveillance colonoscopy is then provided. This tool uses the recommendations from the current North American national guidelines. The tool has been developed as a web-based application as well as a smart phone application.
223417253|NCT04979780|DRUG|Direct Oral Anticoagulants (DOAC)|Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
223417254|NCT03403829|DRUG|Gemcitabine|Gemcitabine maintenance chemotherapy
223417255|NCT03403829|RADIATION|standard chemoradiotherapy|standard chemoradiotherapy
223417256|NCT03745729|DRUG|allopurinol sustained-release capsules|allopurinol sustained-release capsules (0.25g), once a day, one pill at a time
223417257|NCT03745729|DRUG|placebo capsules|placebo sustained-release capsules, once a day, one pill at a time
223417258|NCT04798729|DEVICE|Digital Occlusal Recording with T-Scan|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the T-Scan (T-Scan III, version 9.1, Tekscan Inc., South Boston, USA).
223417259|NCT04798729|DEVICE|Digital Occlusal Recording with Cerec Omnicam|Occlusal contact recordings of all the teeth were obtained digitally under conditions of maximum bite force and centric occlusion only with the CEREC Omnicam™ (version 4.2, Sirona Dental Systems, New York, USA).
223417260|NCT05342389|DRUG|Camrelizumab|a PD-1 antibody
223417261|NCT05342389|DRUG|Apatinib Mesylate|an oral tyrosine kinase inhibitor
223417262|NCT06093165|RADIATION|Re-irradiation|20Gy on 10 fractions
223417263|NCT02880280|DRUG|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
223417264|NCT02880280|DRUG|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
223561125|NCT04314193|DRUG|Methotrexate|Oral methotrexate (15 mg weekly to be increased to 25 mg weekly) for 24 weeks.
224033717|NCT04350554|OTHER|Pregnancy|To evaluate attitudes towards pregnancy (ie. planned pregnancy) and social support among women who become pregnant during the year 2020
224033718|NCT01762670|DRUG|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
224033719|NCT01762670|DRUG|Metronidazole|500 mg twice daily for 7 days
223561126|NCT04314193|DRUG|Prednisone|Oral prednisone (start 40 mg daily, to be tapered to 10 mg daily) for 24 weeks.
223561127|NCT01696968|OTHER|Screening Questionnaire Administration|Undergo questionnaire assessments
223561128|NCT01696968|PROCEDURE|X-Ray Imaging|Undergo a chest x-ray
224033720|NCT02031289|DRUG|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
224136955|NCT05080179|BEHAVIORAL|Self-Benefit/No Social Norm|"As part of their email, they will read, It can help you determine where and when to get testing, and how to get care if you need it. They will not read any information about the number of Pennsylvanians who downloaded the app."
223417265|NCT05801289|DRUG|Quetiapine|Giving the drug to group Q
223417266|NCT04136704|PROCEDURE|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
224136956|NCT05080179|BEHAVIORAL|Other Benefit/Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. and Over 650,000 Pennsylvanians have already downloaded the app!"
223417267|NCT00062881|DRUG|Intrathecal Mafosfamide|
223417268|NCT01366235|DRUG|chloroquine phosphate 1000 mg|1000 mg, 1day
223417269|NCT06181734|DRUG|Ivosidenib|inhibitor of mutant IDH1
223417270|NCT03832517|DRUG|Single intravenous doses of RC-01|Intravenous single escalating doses of RC-01
223417271|NCT03832517|DRUG|Single intravenous doses of placebo|Intravenous single doses of placebo to match RC-01
223417272|NCT03832517|DRUG|Multiple intravenous doses of RC-01|Multiple ascending doses of RC-01 given intravenously two or three times daily for 10 days
223417273|NCT03832517|DRUG|Multiple intravenous doses of placebo|Multiple doses of placebo to match RC-01 given intravenously two or three times daily for 10 days
223417274|NCT00654875|DRUG|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
223417275|NCT00654875|DRUG|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
223417276|NCT04967885|BEHAVIORAL|Ecological Momentary Implementation Intentions Intervention (EMI-II)|To reduce smoking, this text messaging intervention will use a self-regulatory strategy, Implementation Intentions (II) to deliver appropriate alternative responses to cigarette smoking. Participants will create personalized II messages before starting the two-week intervention period. Then during the intervention period, after receiving Ecological Momentary Assessments (EMAs), participants will be micro-randomized to receive the EMI-II. During the EMA + EMI-II period, participants will complete five daily EMAs. After approximately 40% of these EMAs, participants will also receive the personalized EMI-II by text messaging.
223417277|NCT05838365|DEVICE|Zirconia implant|(Test group; within 7 days of implant placement) versus delayed (Control group; 8 weeks after implant placement)
223417278|NCT03694964|DRUG|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
223417279|NCT03694964|DRUG|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
223417280|NCT03921840|BEHAVIORAL|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps \& minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
223417281|NCT03921840|OTHER|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
223417282|NCT02042950|DRUG|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m\^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
223417283|NCT01756781|DRUG|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
223417284|NCT01756781|DRUG|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
223417285|NCT01756781|DRUG|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
223417286|NCT01756781|DRUG|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
223417287|NCT02935179|DIETARY_SUPPLEMENT|White sweet potato diet|The diet were supplied 516 kcal daily
223561129|NCT06116253|DEVICE|Magnetic Resonance Imaging (MRI) Scan|Participants will undergo a 1-hour research MRI scan.
223561130|NCT06116253|DRUG|Tc-99m Pentetate|Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
223561131|NCT05357339|OTHER|20% Albumin|100ml boluses 20% Albumin
223561132|NCT05357339|OTHER|Crystalloid|100ml bolus of crystalloid
223561133|NCT05290246|BEHAVIORAL|Time restricted eating|Limiting daily eating time to an 8 hour window
223561134|NCT05290246|BEHAVIORAL|Caloric reduction|Cut caloric intake by 15%
223561135|NCT06342310|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
223561136|NCT03165240|DRUG|BI 690517|Film-coated tablet
223561137|NCT03165240|DRUG|Eplerenone|Film-coated tablet
223561138|NCT03165240|DRUG|Placebo|Film-coated tablet
224136957|NCT05080179|BEHAVIORAL|Other Benefit/No Social Norm|"As part of their email, they will read, It can help you reduce your risk of unknowingly spreading the virus to your friends, family, and larger community. They will not read any information about the number of Pennsylvanians who downloaded the app."
224136958|NCT03945045|PROCEDURE|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
224136959|NCT03945045|PROCEDURE|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
224136960|NCT02848300|DRUG|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
224136961|NCT02848300|DRUG|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
224136962|NCT01662700|DRUG|Artesunate|
223417288|NCT06588751|OTHER|Scalp block|After the surgical procedure, patients in Group S were placed in a semi-sitting position. Following skin antisepsis with 5% povidone-iodine, a sterile drape was applied. A circumferential scalp block with 2 cc of 0.25% bupivacaine was done on each of the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater occipital, and lesser occipital nerves that supply the forehead and scalp with sensory information. The procedure was performed bilaterally. The supratrochlear and supraorbital nerves were blocked at the brow, close to the upper middle edge orbit, and over the supraorbital notch that could be felt. The zygomaticotemporal nerve was blocked between the posterior edge of the zygomatic arch. The auriculotemporal nerve was blocked at the level of the tragus. The greater and lesser occipital nerves were blocked at the medial and lateral thirds of the superior nuchal line.
223561139|NCT06447337|DIAGNOSTIC_TEST|Continous body temperature monitoring|The investigational product will be placed on the participants' body in axilar joint and connected to the mobile phone. The values of the current temperature will apear on the monitor and it will be recorded in the database with date and time for each record. In parallel, study staff will occasionally measure the temperature using standard hospital thermometer.
224033721|NCT03236051|PROCEDURE|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
223417289|NCT04339985|DRUG|ATx201|Topical
223417290|NCT04339985|DRUG|ATx201 OINTMENT vehicle|ATx201 OINTMENT vehicle
223561140|NCT05624931|BEHAVIORAL|Brief CBT-Based Intervention|"Aims 1 (n=30) and 2 (n=18) will inform the Aim 3 intervention. We anticipate that the intervention will be comprised of four treatment sessions. These sessions will likely target two pathways to PrEP adherence and persistence: (1) decreased withdrawal and avoidance and (2) behavioral skill building to increase self-care/health behaviors. To decrease withdrawal and avoidance, we will likely include CBT-based exercises that improve distress tolerance and coping. To help participants build new behavioral skills, we will likely incorporate behavioral activation and problem-solving. Behavioral activation is a CBT strategy that promotes scheduling activities that align with an individual's values, which will also break maladaptive patterns of withdrawal and avoidance. Problem-solving is an empirically-supported treatment for depression; training patients to problem-solve adaptively will help them approach PrEP use by navigating barriers."
223561141|NCT05624931|OTHER|Enhanced Treatment as Usual|This is the control intervention. Participants will receive antenatal care as usual, which is monthly visits to the MOU, information about using PrEP during pregnancy (information sheet or pamphlet), and a psychological services referral.
223561142|NCT04506164|OTHER|Multicomponent Implementation Strategy|The eScreening MCIS was developed over the past seven years and consists of: 1) eScreening software provision, 2) training, 3) RPIW, and 4) ongoing blended facilitation. The investigators developed our MCIS to address specific eScreening implementation barriers found in the investigators' prior research.
223561143|NCT04506164|OTHER|eScreening|eScreening is a clinical patient self report system that allows Veterans to complete clinical reminders and other self report screens using a secure connection from any internet connected device.
223739264|NCT07104370|PROCEDURE|Bone augmentation using an autologous bone block|"* Under local anesthesia, a crestal and mesial releasing incision is made, followed by preparation of a full-thickness mucoperiosteal flap.~* In the control group, an autologous bone block graft is harvested from the retromolar donor area using rotary instruments and piezoelectric surgery.~* The block is fixed to the recipient site with two screws.~* The flap is mobilized, and the wound is closed tension-free with mattress and simple interrupted sutures.~* Sutures are removed two weeks postoperatively.~* All patients receive therapeutic-dose antibiotics: amoxicillin and clavulanic acid 2x1 for one week. In the case of an amoxicillin allergy, clindamycin 4x1 for seven days is administered. Non-steroid anti-inflammatory treatment with diclofenac 3x1 is also provided.~* Patients do not wear temporary prostheses during the healing period."
224136963|NCT01662700|DRUG|Chloroquine|
224136964|NCT04059445|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
223561144|NCT05354466|DRUG|Sugammadex injection|sugammadex as reversal agent
223561145|NCT05354466|DRUG|Neostigmine|neostigmine as a reversal agent
224136965|NCT04059445|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
224136966|NCT00143221|DRUG|Viagra|
224136967|NCT00143221|DRUG|Placebo|
224136968|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
224136969|NCT00711269|DRUG|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
224136970|NCT00711269|DRUG|Placebo|
224136971|NCT00711269|DRUG|Risperidone|
223561146|NCT03566771|BEHAVIORAL|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
224136972|NCT01551758|DRUG|FF/VI|FF/VI
224136973|NCT01551758|OTHER|Existing Maintenance Therapy|"Existing Maintenance Therapy:~* Long acting bronchodilator therapy alone~* ICS alone or in combination with a long acting bronchodilator~* Triple maintenance therapy"
223417291|NCT01235026|DIETARY_SUPPLEMENT|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10\^10 CFU/g), twice a day, for 6 weeks."
223417292|NCT01235026|DIETARY_SUPPLEMENT|Placebo|6g of maltodextrin, twice a day for 6 weeks.
224033722|NCT03236051|PROCEDURE|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
224033723|NCT04213924|DRUG|Bupivacaine HCl 0.5 % in 10 ml and 2 % lidocaine in 10 ml|Erector spinae plane block, 30 min before the ESWL procedure.
224033724|NCT04213924|DRUG|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously|5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
224136974|NCT06064786|DIAGNOSTIC_TEST|GCF levels of fetuin A and hsCRP evaluation|ELIZA kits are used for GCF levels of fetuin A and hsCRP evaluation
224136975|NCT02027116|BIOLOGICAL|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
224136976|NCT02623634|BEHAVIORAL|Position, waveform|different positions and waveform
224033725|NCT01842685|PROCEDURE|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
223417293|NCT00886743|DRUG|oprelvekin|injection, 50 mg/kg, once daily
223417294|NCT00305708|BIOLOGICAL|anti-thymocyte globulin|
223417295|NCT00305708|DRUG|busulfan|
223417296|NCT00305708|DRUG|fludarabine phosphate|
223417297|NCT00305708|PROCEDURE|allogeneic bone marrow transplantation|
223417298|NCT00305708|PROCEDURE|peripheral blood stem cell transplantation|
223417299|NCT00305708|PROCEDURE|umbilical cord blood transplantation|
223417300|NCT00305708|RADIATION|radiation therapy|
223417301|NCT05594836|BEHAVIORAL|Infant Calming Training|Perception of Maternal Role, Maternal Attachment and Breastfeeding Self-Efficacy during Infant Calming Training
223561147|NCT03566771|BEHAVIORAL|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
224033726|NCT02521311|DRUG|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
224033727|NCT02521311|DRUG|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
224033728|NCT04058951|OTHER|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
224033729|NCT04058951|OTHER|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
224033730|NCT02849340|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
223561148|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
223561149|NCT01375127|DRUG|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
224033731|NCT02849340|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
224033732|NCT02841228|RADIATION|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
223561150|NCT05240157|DRUG|Corticosteroid Derivatives|observational
224033733|NCT04286698|OTHER|Complex decongestive physiotherapy|MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes \[25\]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.
223417302|NCT05684575|OTHER|Phone satisfaction questionnaire|Evaluation of the outcome of Covid-19 patients discharged home on oxygen therapy
223417303|NCT01940887|DRUG|E10030|
223417304|NCT01940887|DRUG|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
223417305|NCT01940887|DRUG|E10030 sham injection|Pressure on the eye with a syringe with no needle
223417306|NCT01906307|DRUG|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
223417307|NCT00749307|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA)|
223417308|NCT00749307|DIETARY_SUPPLEMENT|Placebo|
223417309|NCT06622928|DIAGNOSTIC_TEST|Echocardiogram|"Echocardiographic Assessments:~Pre-Hemodialysis Echocardiography:~Before each hemodialysis session, echocardiograms will be performed to evaluate cardiac function and gather baseline data on ventriculo-arterial coupling (VAC) parameters. This will include recording three apical echocardiographic views (4-chamber, 2-chamber, and 3-chamber) by a trained sonographer.~Post-Hemodialysis Echocardiography:~Following the completion of the hemodialysis session, echocardiographic assessments will be repeated to measure changes in VAC parameters and other relevant cardiac metrics."
223417310|NCT04807205|DEVICE|RF Non-Invasive Treatment|Self-controlled single-arm group using the Elite IQ device
223417311|NCT04523038|DIAGNOSTIC_TEST|S-Albumin|Preoperative serum albumin levels
223417312|NCT05982236|OTHER|Questionnaire|Questionnaire on WEPI software (secure data), with link sent by e-mail to patients included in the study, including PCOSQOL, HADS, FACT G7 et ASEX scores.
223417313|NCT04914884|DIAGNOSTIC_TEST|intraocular fluid detection|This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
223561151|NCT01983384|OTHER|Processed EEG-guided anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
223417314|NCT04427475|DRUG|pabolizumab|100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
223417315|NCT04427475|DRUG|nafulizumab|nafulizumab
223417316|NCT03169075|BEHAVIORAL|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
223417317|NCT03169075|BEHAVIORAL|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
223417318|NCT02429778|BEHAVIORAL|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
224033734|NCT04286698|OTHER|Home program|Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point \[3\]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
223417319|NCT02429778|BEHAVIORAL|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
223417320|NCT06666556|COMBINATION_PRODUCT|Bowel preparation before colonoscopy|In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
223561152|NCT01224340|BEHAVIORAL|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
223561153|NCT01224340|BEHAVIORAL|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
224033735|NCT00065325|DRUG|Fulvestrant|intramuscular injection
223561154|NCT01224340|OTHER|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
223561155|NCT01716039|DRUG|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
224033736|NCT00065325|DRUG|Exemestane|oral capsule
224033737|NCT01176968|DRUG|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
224033738|NCT01176968|DRUG|Placebo|Matching placebo tablets
224033739|NCT04376970|DRUG|FLUCON®|"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."
224033740|NCT04376970|DRUG|Cyclosporine A eye drops 0.5%|The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.
224033741|NCT02842840|BEHAVIORAL|Patient-based intervention|
224033742|NCT02842840|BEHAVIORAL|Family based intervention|
224033743|NCT02842840|OTHER|Routine counseling|
224033744|NCT02485535|OTHER|Laboratory Biomarker Analysis|Correlative studies
224033745|NCT02485535|DRUG|Selinexor|Given PO
224033746|NCT02701426|BEHAVIORAL|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
224033747|NCT00559442|OTHER|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
223417321|NCT06666556|COMBINATION_PRODUCT|Bowel preparation before colonoscopy|In this multicenter single-blind randomized clinical trial study we will provide each patient that meets our inclusion criteria a randomized folio to include them in one of both arms in our protocol, meaning one of the groups and the bowel preparation assigned to perform the colonoscopy, they will be explained the benefits and minimum risks of participating and they will also be asked to sign an informed consent form so we can continue with the colonoscopy and collect all the data we need for our protocol and the analysis of the variables.
223417322|NCT01663285|DRUG|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
223417323|NCT04570865|DRUG|Dapagliflozin|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
223417324|NCT04570865|DEVICE|CardioMEMS|The focus of this study is to investigate the use of Dapagliflozin in HFrEF (NYHA II-IV) patients with or without diabetes who have CardioMEMS® implanted to assess the impact on pulmonary artery pressure measurements after 12 weeks of therapy.
224033748|NCT02463825|DRUG|Pimozide 2 mg per day|
223417325|NCT05906563|DRUG|Melatonin gel|local application of Melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
223417326|NCT05906563|DRUG|Metformin and melatonin gel|local application of Metformin and melatonin gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack
223417327|NCT05906563|DRUG|placebo gel|Local application of empty nanoparticles gel into the periodontal pocket using a syringe with a blunt cannula until the pocket will be completely filled. It will be applied once weekly for four weeks. After insertion of the local drug delivery system, the region will be secured with a periodontal pack.
223561156|NCT01716039|DRUG|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
223561157|NCT01716039|DRUG|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
223561158|NCT03155087|DRUG|Metformin|
223561159|NCT01879462|DRUG|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
223561160|NCT01879462|DRUG|Placebo|Visually matching GSK2878175
223561161|NCT03398642|BEHAVIORAL|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
224033749|NCT02463825|DRUG|Pimozide 4 mg per day|
224033750|NCT02463825|DRUG|Placebo (Lactose tablet)|
224033751|NCT00833911|DRUG|Tramadol Once A Day|
224033752|NCT00718640|DRUG|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
224033753|NCT00718640|DRUG|Bortezomib|Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
224033754|NCT02709525|DRUG|hyaluronic acid|
224033755|NCT02709525|OTHER|Placebo|
224033756|NCT04100473|DRUG|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
224033757|NCT04100473|DRUG|Insulin Lispro (Humalog U-100)|Lispro
224033758|NCT01835197|DRUG|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
224033759|NCT01835197|DRUG|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
224033760|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
224033761|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
223561162|NCT02348879|DRUG|AMG 403|AMG 403 is for treatment of subjects with chronic pain
224033762|NCT01835197|DRUG|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
223561163|NCT02348879|DRUG|Placebo|contains no active drug
224033763|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
224033764|NCT01835197|DRUG|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
224033765|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
224033766|NCT01835197|DRUG|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
224033767|NCT01835197|DRUG|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
224033768|NCT02431650|DRUG|OZ439|
224033769|NCT02431650|DRUG|Primaquine|
224033770|NCT01888835|DRUG|Mirtazapine|
224033771|NCT01888835|DRUG|Placebo|
223417328|NCT05906563|PROCEDURE|scaling and root planning|full mouth supra- and subgingival scaling and root planning will be performed, and all periodontitis patients will be treated with ultrasonic tips and Gracey curettes for meticulous removal of subgingival and supragingival plaque and calculus.
223417329|NCT04927130|DIAGNOSTIC_TEST|ARNA Breast|A specific DNA fragments and globulins will be detected in blood plasma.
223417330|NCT06125938|PROCEDURE|tent pole technique|The screw tent-pole method is an effective technique to achieve initial reconstruction of alveolar bone deficiencies
223417331|NCT06125938|PROCEDURE|Autogenous bone block technique|Bone block graft has been the gold standard for restoring deficient regions.
223417332|NCT06667518|DEVICE|Neuromuscular Activity Assessment|"K-Pull dynamometer is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions.~K-Myo (non-invasive EMG sensor) is an assessment tool used to detect muscle activation and tracking patient's improvement."
223417333|NCT06668519|OTHER|Magnetoencephalography|Magnetoencephalography
224033772|NCT00764933|BEHAVIORAL|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
223417334|NCT00784303|DRUG|Lenvatinib (DTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
223417335|NCT00784303|DRUG|Lenvatinib (MTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
223417336|NCT04128306|BEHAVIORAL|Behavioral task|In the task, participants will see an object approaching toward them. During its movement, the object disappears, and the participants have to press a button to indicate when they estimate the object to contact with them. The motion parameters of the ball will be varied. The pre and post-surgery phases will test the participants in a long duration version of the task, approximately 30 minutes. The per surgery phase will be made of a 5 minutes version of the task, and the participants will receive a direct cortical stimulation for 4 seconds, at an intensity of 1 to 10 milliampere (mA), in the premotor ventral area, or posterior parietal cortex or somesthetic associative areas.
223561164|NCT02479685|PROCEDURE|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
223561165|NCT02058316|DEVICE|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
223561166|NCT01015495|DRUG|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
224033773|NCT00764933|OTHER|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
224033774|NCT05628116|DRUG|XC243 50 mg single|The volunteers will receive a single dose of the ID (1 tablet once, 50 mg)
224033775|NCT05628116|DRUG|XC243 100 mg single|The volunteers will receive a single dose of the ID (2 tablets once, 100 mg)
224033776|NCT05628116|DRUG|Placebo single|The volunteers will receive a single dose of the ID (1 or 2 tablets once)
224033777|NCT05628116|DRUG|XC243 200 mg single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets, 200 mg)
224033778|NCT05628116|DRUG|Placebo single-dose food effect|The volunteers will receive single dose of the ID during first on an empty stomach, and after the washing period after eating (4 tablets)
224033779|NCT05628116|DRUG|XC243 200 mg multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily, 200 mg each)
224033780|NCT05628116|DRUG|Placebo multiple|The volunteers will receive multiple doses of the ID during 14 days (4 tablets daily)
224033781|NCT01742598|DEVICE|Portico Transapical Aortic Valve System|
224033782|NCT04559828|OTHER|Experimental meal|Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
223561167|NCT01586598|BEHAVIORAL|sensory retraining protocol|"1. within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~2. one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~3. three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
223561168|NCT01179750|DEVICE|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
223561169|NCT00182715|BIOLOGICAL|cetuximab|
223561170|NCT00182715|DRUG|capecitabine|
223561171|NCT00182715|DRUG|fluorouracil|
223561172|NCT00182715|DRUG|leucovorin calcium|
223561173|NCT00182715|DRUG|oxaliplatin|
224033783|NCT02272855|BIOLOGICAL|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10\^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
224033784|NCT01596907|DRUG|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
224033785|NCT01596907|DRUG|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
224033786|NCT06146023|DEVICE|Robotic anastomosis (Symani surgical system and RoboticScope)|Robot-assisted microvascular anastomosis on 1.0-mm-diameter silicone vessels using the Symani surgical system and RoboticScope
224033787|NCT06146023|PROCEDURE|Conventional anastomosis|Conventional microvascular anastomosis on 1.0-mm-diameter silicone vessels using conventional microsurgical instruments and conventional surgical microscope
223417337|NCT04128306|PROCEDURE|Awake surgery|"The patient is first anesthetized for opening the scalp and skull, then awake. During this waking phase, the surgeon passes a few quick and simple tests to the patient, visual (for example, line bisection), language (for example, repeating a list of words) etc. While doing this task, the neurosurgeon disrupts the functioning of certain brain regions by direct electrical stimulation of the cortex in order to identify the regions whose dysfunction will have an impact on the current task.~During the operation, the areas involved in the construction of the peri-personal space will be stimulated by direct electrical stimulation, for a duration of 4 seconds at an intensity of 1 to 10 mA. These areas are:~* Ventral premotor cortex (with the exception of the primary motor cortex controlling the dominant hand, so as not to interfere with the motor response of the patient)~* Posterior parietal cortex~* Associative somesthetic areas"
223417338|NCT04128306|OTHER|Neurological assessment|The Mini Mental State Evaluation, which generally assesses the cognitive state of an individual through his 6 subtests testing both working memory, episodic and semantic praxies as well as spatio-temporal orientation capacity.
223417339|NCT04128306|OTHER|Neurological assessment|The Wechsler Adult Intelligence Scale was selected for two of its subtests: The Subtest Codes checking the processing of information, visuo-constructive abilities but also attention. The subtest Cubes evaluates the capacities of visuospatial and constructive organizations as well as the referencing of the space in relation to the subject.
223417340|NCT04128306|OTHER|Neurological assessment|The State-Trait Anxiety Inventory, consisting of two self-administered questionnaires: Questionnaire A, measuring the state of anxiety of the person on the present moment and B measuring anxiety as a character trait of the person
223417341|NCT04128306|OTHER|Neurological assessment|The Verbal Fluences test, in its oral version. Categorial and lexical fluences make it possible to quickly realize a possible lack of the word of the person as well as disturbances of working memory or the capacity of inhibition.
223417342|NCT04128306|OTHER|Neurological assessment|The board of the Corsi cubes that evaluates the non-verbal visual-spatial working memory of the participants with a reminder location that tests the visuo-spatial notebook and a reminder to who tests the central administrator of the working memory.
223417343|NCT04128306|OTHER|Neurological assessment|The neurocognitive naming test was chosen to verify correct access to both semantic memory and lexicon, as well as to test the early visual process of image processing necessary for our task.
223417344|NCT04128306|OTHER|Neurological assessment|Benton lines are commonly used to determine possible deficits in the localization of isolated objects or judgment of line direction.
223417345|NCT04128306|OTHER|Neurological assessment|The patient will finally pass a depression assessment test, answering Beck's questionnaire.
223417346|NCT00819559|RADIATION|PCRT|Preoperative chemoradiotherapy
223417347|NCT05256459|OTHER|Long term follow-up|No extra intervention.
223417348|NCT01468259|DRUG|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
223417349|NCT04053712|DRUG|Glucagon|GlucaGen(R), Novo Nordisk, DK
223417350|NCT04053712|DEVICE|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
223417351|NCT03749967|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
223417352|NCT03870308|DIAGNOSTIC_TEST|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
223417353|NCT05183308|DRUG|Clodronic Acid|Osteoporotic fracture treated with surgical and medical therapy
223561174|NCT01196468|OTHER|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
223561175|NCT01196468|OTHER|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
223561176|NCT06509997|DRUG|MRG003 combined with Dalpicicilip|MRG003, intravenous infusion, D1, once every 3 weeks; Dalpicicilip, taking orally, D1-21, once every 4 weeks, maintain use until progression or emergence of intolerable toxicity.
223561177|NCT01707433|OTHER|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
224033788|NCT05964803|DIAGNOSTIC_TEST|Questionnaires|MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).
224033789|NCT00483314|DRUG|N-acetylcysteine|2 g p.o. BID x 60 days
224033790|NCT04660071|OTHER|ultrasonographic Assessment,|Ultrasound assessment was performed on rectus femoris (RF), vastus intermedius (VI), vastus medialis (VM) and vastus lateralis (VL) muscles using with an ultrasound-imaging device (Philips Medical Systems EPIQ 5 Release 5.0.2, Amsterdam).
223417354|NCT05817747|OTHER|Dialogue support tool|The dialogue support tool will be used as a support for the participant and surgeon to decide on which treatment arm is optimal for the participant.
223417355|NCT04931823|DRUG|CPO-100|Docetaxel albumin-bound
223417356|NCT04028895|DIAGNOSTIC_TEST|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
223417357|NCT05847738|BEHAVIORAL|Pain assessment|Pain was assesd postoperatively in both groups at time intervals
223561178|NCT03055325|OTHER|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
223417358|NCT06251635|DRUG|Olanzapine 2.5Mg Oral Tablet|"Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg"
223561179|NCT04554966|DRUG|ABBV-382|Intravenous (IV) infusion
223417359|NCT06251635|DRUG|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule during one research visit of each menstrual cycle phase.
223417360|NCT06251635|DRUG|Insulin Lispro 100 UNT/ML|At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.
223417361|NCT06251635|DRUG|Saline|At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.
223417362|NCT04512534|DRUG|PD-1 antibody+ HDAC inhibitor|"Patients receive anti-PD-1 antibody Sintilimab+ HDAC inhibitor Chidamide three weeks for a cycle, detailed as follows:~* Anti-PD-1 antibody (Sintilimab): Fixed dose of 200 mg every 3 weeks, intravenous drip (without pretreatment), infusion time: 30 minutes (no less than 20 mins, no more than 60 mins), the maximum treatment period is 2 years (up to 35 doses), complete remission（CR）patients confirmed by imaging assessment can be considered off anti-PD-1 treatment after 12 treatment cycles.~* Chidamide: Chidamide is administered orally at a dose of 30mg (initial dose). It is recommended to be administered within 0.5h after a meal with a fixed time. Chidamide will be given until disease progression or intolerant toxicity. The maximum treatment is 2 years. If chidamide therapy requires to be continued over 2 years due to clinical benefit, the prescription/decision should be made after discussion with the principal investigator."
223417363|NCT04844034|DIETARY_SUPPLEMENT|High-EPA multinutrient supplement.|"Three capsules with the largest meal of the day providing:~* 1,125 mg EPA~* 441 mg DHA~* 330 mg Magnesium~* 7.5 mg a-tocopherol"
223417364|NCT04844034|OTHER|Placebo|"Three capsules with the largest meal of the day providing:~* 3,060 mg sunflower seed oil~* 60 mg lecithin~* 300 mg glyceryl monostearate~* 465 mg EPA/DHA (18%/12% respectively for blinding)"
223417365|NCT05628038|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w
223417366|NCT05628038|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
223417367|NCT05628038|DRUG|5FU|400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
223417368|NCT05628038|DRUG|folinic acid|400 mg/m2 q2w
223417369|NCT05628038|DRUG|Oxaliplatin|130 mg/m² q3w or 85 mg/m² q2w
223561180|NCT04554966|DRUG|ABBV-382|Subcutaneous (SC) injection
223561181|NCT04554966|DRUG|Placebo for ABBV-382|Intravenous (IV) infusion
224033791|NCT04660071|OTHER|Echo intensity Measurements|All images were analysed using the Image J software (Version 1.48v, National Institutes of Health, Bethesda, MD, USA) by two different analysers (five years and one-year of experience in US image analysis).
224033792|NCT05297617|DRUG|Anti-aromatase inhibitor|"Treatment will be either:~* Letrozole, given per os, 2.5 mg daily~* Anastrozole, given per os, 1 mg daily~* Exemestane, given per os, 25 mg daily"
224033793|NCT02885298|PROCEDURE|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
223561182|NCT04998994|DIETARY_SUPPLEMENT|wheat sprouts supplement|Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy
224033794|NCT01137955|DRUG|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
224033795|NCT01137955|DRUG|Placebo|Placebo orally three times a day for 10 days total
224033796|NCT01207596|DRUG|Hydromorphone|Oral hydromorphone extended release, once daily
224033797|NCT00819286|DEVICE|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
224033798|NCT00819286|DEVICE|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
224033799|NCT03366493|COMBINATION_PRODUCT|FRD|The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
223561183|NCT01033006|PROCEDURE|Active Comparator: Arm 1: catheter injection|
223561184|NCT01033006|PROCEDURE|Active Comparator: Arm 2: transarterial injection|
223561185|NCT01033006|PROCEDURE|Active Comparator: Arm 3: catheter and transarterial injection|
224033800|NCT03366493|OTHER|Cytology|Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
224033801|NCT03366493|OTHER|HPV testing|HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
224033802|NCT03366493|PROCEDURE|Colposcopy|During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
224033803|NCT03366493|PROCEDURE|ECC|If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
223417370|NCT05628038|DRUG|Irinotecan|180 mg/m² q2w and 200 mg/m² q3w
223417371|NCT05628038|DRUG|Raltitrexed|2 mg/m² q2w and 3 mg/m² q3w
223417372|NCT05628038|DRUG|Cetuximab|400 mg/m² q2w
223417373|NCT05628038|DRUG|Bevacizumab|5 mg/kg q2w or 7.5mg/kg q3w
223417374|NCT05628038|RADIATION|Radiation|"25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor."
223417375|NCT06539624|GENETIC|EXG110 injection|EXG110 is a recombinant adeno-associated virus (rAAV) that not only significantly increases plasma AGA activity, but is also highly expressed in target organs such as the heart and kidneys.EXG110 will be administered in a single dose by intravenous infusion.
223417376|NCT04450524|BEHAVIORAL|Hypnosis|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
223417377|NCT04450524|BEHAVIORAL|Food inhibition training|Training the associations between foods and motor inhibition using a GO-NO-GO computer task.
223417378|NCT04450524|BEHAVIORAL|Control|A simple GO-NO-GO task
223561186|NCT02797665|DRUG|corticosteroids|prednisone 0.6mg/kg/d
223417379|NCT06683963|DEVICE|Rebee|Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
223417380|NCT03055481|OTHER|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
223417381|NCT03055481|OTHER|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
223561187|NCT02797665|PROCEDURE|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
223561188|NCT04960059|OTHER|No intervention|This is an observational study
223561189|NCT01054131|BEHAVIORAL|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
223739265|NCT07104370|PROCEDURE|Bone augmentation using freeze-dried allograft block|"* Under local anesthesia, a crestal and mesial releasing incision is made, followed by preparation of a full-thickness mucoperiosteal flap.~* In the test group, a freeze-dried allograft bone block is prepared to the required size using rotary instruments.~* The block is fixed to the recipient site with two screws.~* The flap is mobilized, and the wound is closed tension-free with mattress and simple interrupted sutures.~* Sutures are removed two weeks postoperatively.~* All patients receive therapeutic-dose antibiotics: amoxicillin and clavulanic acid 2x1 for one week. In case of amoxicillin allergy, clindamycin 4x1 for seven days is administered. Non-steroid anti-inflammatory treatment with diclofenac 3x1 is also provided.~* Patients do not wear temporary prostheses during the healing period."
223739266|NCT07104370|DIAGNOSTIC_TEST|preoperative cone beam computed tomography (CBCT)|• Preoperatively, a CBCT scan is performed to assess inflammatory and other pathological changes and anatomical variations in the dentomaxillofacial region.
224033804|NCT03366493|PROCEDURE|Biospy|"According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review."
224033805|NCT03945006|OTHER|Incontinence Severity|The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
224033806|NCT03945006|OTHER|Balance|The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
224033807|NCT03945006|OTHER|Trunk impairment|Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
224033808|NCT03945006|OTHER|Fear of falling|Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
224033809|NCT06568068|BEHAVIORAL|training|"The intervention group that will receive training determined after randomization; In Stage 1 An introductory meeting will be held, ERGEP will be announced and educational materials will be distributed. Pretest applications will be done. In Stage 2 A week consisting of four weeks and eight sessions on the following topics determined within the scope of ERGEP Trainings planned to be held in two sessions will be given once.~1. Developmental periods (oral, anal, phallic, latent, genital)~2. Physical, psychological and social changes experienced in girls and boys during adolescence~3. Being an adolescent parent and healthy communication~4. Risky behaviors in life and sexual matters during adolescence In Stage 3 At the end of the training, measurement tools will be applied again. In Stage 4 Measuring tools will be repeated after 21 days"
224033810|NCT04427150|BEHAVIORAL|Auditory Training|A series of psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
224033811|NCT04427150|BEHAVIORAL|Non-auditory training|A series of non-psychoacoustic training exercises through Posit Science - BrainHQ (mobile app or web-browser version). Each training is approximately 2 minutes
224033812|NCT06428487|DRUG|Prolgolimab|Prolgolimab infusions 1 mg/kg
223417382|NCT03804424|DRUG|64Cu-LLP2A|-64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
223417383|NCT03804424|DEVICE|PET/MR|-All PET imaging will be performed as PET/MR or PET/CT
223561190|NCT04827342|OTHER|data collection in the Ada DDSS prototype|Entry of patients' data (medical history, symptoms and findings) in the Ada DDSS prototype. The tool then automatically creates a list of possible diagnostic suggestions based on the information, which are compared with the diagnoses of the attending physician.
223561191|NCT00426595|DRUG|Administration of omeprazole suspension|
223561192|NCT00426595|DRUG|omeprazole administered as a multi-unit-pellet system|
224033813|NCT06356961|BEHAVIORAL|(Feedback Informed Therapy) with Clinical Support Tools and ah hoc training|Therapists in the condition (OPM-F) will receive specific training on the procedures and techniques inherent in feedback informed therapy (FIT); during the intervention phase (lasting 15 sessions) the Clinical Support System in FIT will guide them in the clinical application of the procedures. In addition, they will receive monthly supervision (for three months) apt to provide on-going clinical support on FIT and ROM, with practical discussion of the most difficult clinical cases and possible solutions to be implemented in therapy.
223417384|NCT03804424|PROCEDURE|Blood samples for serum stability|-3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
223417385|NCT03804424|PROCEDURE|Blood samples for metabolite analysis|-Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
223417386|NCT03804424|PROCEDURE|Urine sample|-Cohort 1 only
223561193|NCT02818023|DRUG|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
223561194|NCT02818023|DRUG|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
223561195|NCT02818023|DRUG|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
223561196|NCT05137288|DRUG|Ondansetron , atropine and bupivacaine|"Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) ."
223561197|NCT03036683|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
223739267|NCT07104370|DIAGNOSTIC_TEST|post-operative cone beam computed tomography (CBCT)|Postoperatively, a CBCT scan is performed to assess bone quantity and quality before implantation.
223739268|NCT07104370|PROCEDURE|Dental implant placement|Following the 3-month-long healing period following bone augmentation, dental implants are placed non-submerged in the augmented bone under local anaesthesia.
224033814|NCT06356961|BEHAVIORAL|Feedback and ROM (basic)|Process and outcome monitoring (OPM) in which patients will complete process and outcome measures related to each psychotherapy session but therapists will receive basic feedback on these measures
224033815|NCT02863887|BEHAVIORAL|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
224136977|NCT04604236|BEHAVIORAL|Mapping Enhanced Counseling|Practitioner-led, collaborative discussion with the youth and their caregiver on co-creating guide maps for decision making around starting treatment and continuing substance use that can help users organize information and think through a series of steps, questions, and behavior choices. encountered when attempting to initiate substance use treatment services. MEC is a communication and decision-making approach that uses graphic visualization tools to train individuals to monitor and control their decision making, improve judgment and behavioral choices (self-regulation), and improve communication and mutual understanding.
223417387|NCT03804424|PROCEDURE|Tumor biopsy|-Cohort 2 only and only if there hasn't been a recent biopsy of disease
223561198|NCT03036683|DEVICE|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
223417388|NCT03804424|PROCEDURE|Electrocardiogram|-A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
223561199|NCT02350166|PROCEDURE|laparoscopic surgery|laparoscopic-assisted small-incision surgery
223739269|NCT07104370|DIAGNOSTIC_TEST|Bone core biopsy|At the time of dental implant placement, a rotary instrument is used to harvest a bone core biopsy sample from the augmented bone. The bone core biopsy samples are subjected to histomorphometric and microCT analysis.
223739270|NCT07104370|PROCEDURE|Fixed dental prosthesis (FDP) fabrication|After 3 months of dental implant placement, fixed dental prosthesis are delivered on the dental implants.
223739271|NCT07104370|DEVICE|Bone grafting|Freeze-dried bone allograft block
223739272|NCT06914323|PROCEDURE|Acupressure|improvements in pain, limb swelling, and comfort
224033816|NCT05990218|DEVICE|Artificial intellegence. CADe syste,|The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.
224033817|NCT05990218|DEVICE|control|The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
224033818|NCT05550740|DEVICE|RLRL|In addition to SVS with power for correcting distance refraction, RLRL will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.
223561200|NCT05920681|PROCEDURE|Transanal irrigation|The patient lies on the left or right side, depending on the main hand, the knees are bent. With the main hand, he carefully introduces the TAI tip lubricated with lubricant. The TAI bag is filled with warm water - d it can be boiled or just from the tap. The contents of the TAI bag are slowly administered through the anus. The duration of the TAI is about 15-20 minutes. Afterwards, the subject goes to defecate until the bowel is empty. This action should be repeated daily.
224033819|NCT05691790|BEHAVIORAL|MMA and patient activation intervention scheme|"Design of booklet for older people's preventive care: We propose that the booklet will include 8 main topics based on what experts and current academic literature believe are important for encouraging older people's preventive care utilization. To add the social norms-related cues for the later three topics of the booklet, one qualitative study on older adults who are active in preventive care is needed. Therefore, we will interview \~20 older adults aged 70 years or above who are active in taking preventive care. We will conduct one-to-one in-depth interview to explore how participants overcome difficulties during decision making for vaccination and their positive feelings after making achievements. We will also explore and identify older adults who have a positive future perspective.~Patient activation sections: . Four undergraduate medical students will be trained as the coaches to deliver the patient activation sections over six weeks. Each section will be around 20 min."
223417389|NCT03804424|DEVICE|PET/CT|-All PET imaging will be performed as PET/MR or PET/CT
223417390|NCT05448417|DEVICE|Non-invasive high-frequency oscillatory ventilation|Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
223417391|NCT05448417|DEVICE|Noninvasive Bilevel Positive Pressure Ventilation|Noninvasive Bilevel Positive Pressure Ventilation
223561201|NCT05920681|COMBINATION_PRODUCT|Best supportive care|Diet modification, Loperamidum if needed, diapers, etc.
223561202|NCT02503358|OTHER|Laboratory Biomarker Analysis|Correlative studies
224136978|NCT04604236|BEHAVIORAL|Active Linkage|Practitioner-led, collaborative discussion with the youth and their caregiver on how to overcome barriers encountered when attempting to initiate substance use treatment services. Discussion focuses around the top barriers identified through assessment and identification of 1 or more treatment agency/options that fit the family's needs. Practitioner takes a more active role in addressing barriers to treatment by helping the family find ways to access resources for payment, childcare, or other needs, and actively linking them to the treatment provider (e.g., scheduling the initial appointment with family present).
224136979|NCT01465711|PROCEDURE|All abdominal surgical procedures|Laparotomy, Laparoscopy
223417392|NCT04791319|DRUG|Placebo|Placebo will be administered subcutaneously.
223417393|NCT04791319|DRUG|Bermekimab|Bermekimab will be administered subcutaneously.
223417394|NCT04791319|DRUG|Dupilumab|Dupilumab will be administered subcutaneously.
224136980|NCT01465711|PROCEDURE|Intubation|Ventilatory support
224136981|NCT01465711|RADIATION|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
224136982|NCT04196361|DIAGNOSTIC_TEST|Ultrasound|Point of care ultrasound as part of routine physical examination
224136983|NCT06422351|BIOLOGICAL|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
224136984|NCT03930212|DRUG|Progesterone|received rectal progesterone suppositories 400 mg once daily
224136985|NCT03930212|DRUG|Placebos|received placebo suppositories rectally once daily.
223561203|NCT02503358|DRUG|Paclitaxel|Given IV
223561204|NCT02503358|OTHER|Pharmacological Study|Correlative studies
223561205|NCT02503358|DRUG|Selumetinib|Given PO
223561206|NCT05175222|RADIATION|Laser therapy|Patients receive laser therapy in 7 points in oral cavity every day from the first day of conditioning chemotherapy till the second day post HSCT. Each point is irradiated for 1 minute.
223561207|NCT02118181|DIETARY_SUPPLEMENT|HMB|
223561208|NCT04089241|OTHER|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
223561209|NCT03924063|DEVICE|Hemiverse|Implantation of the hemiverse shoulderprothesis
223561210|NCT05099055|DRUG|Dexmedetomidine 0.004 MG/ML [Precedex]|Injection of 3 mcg of dexmedetomidine and 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
223561211|NCT05099055|DRUG|Opioids|Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.
223561212|NCT04348565|OTHER|Diabetes Care Programme|20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
223561213|NCT01519791|BIOLOGICAL|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
223561214|NCT01519791|OTHER|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
223417395|NCT04796506|OTHER|Progressive Resistance Training (PRT)|PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by \>24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).
223417396|NCT04796506|OTHER|Delayed Exercise Training (DE)|PD subjects randomized to the exercise control group (1:1) will not exercise during the first 12 weeks of the study. During that time, they will be asked not to change their physical activity levels or dietary habits. All participants in the delayed-exercise group will begin PRT at completion of the 1st 12-week period.
223417397|NCT04796506|OTHER|Endurance Training (ET)|Non-responders to PRT will transition too ET during 2nd 12 weeks of the study. This intervention is supervised endurance training, 3 times per week for 12 weeks. Each session lasts approximately 75 min., comprised of warm-up, stimulus phase for 50-60 min., and cool-down. Sessions are split between cycle ergometer and treadmill exercise. Participant heart rate is monitored to maintain target exercise intensity of 60-80% (±5%) of heart rate reserve (HRR).
224033820|NCT05691790|BEHAVIORAL|Control Group|"Participants in the control group will receive a pamphlet about recommendation for influenza, pneumococcal, and COVID-19 vaccines (if appropriate) for older people using information from Hong Kong Department of Health. As a control for the patient activation interviews, the control group will also be informed that they will join our telephone-based elderly care project by the end of the baseline assessment but instead of receiving the patient activation interviews, this group will receive six control telephone care visits over six weeks. Each control telephone care visit will be around 5-10 min during which the student helper will give general guidelines about dietary health and exercise for older people. The control messages are mainly educational and designed using information derived from the websites of Hong Kong Department of Health."
224033821|NCT06084494|DIAGNOSTIC_TEST|analytical determination and interpretation of heat stress using calculation of the Predicted Heat Strain and Wet Bulb Globe Temperature|The temperature inside the climatic chamber was set at 40 C and 31 C at a relative humidity of 20 % and 70 % respectively to count for a WBGT level of 28 C. The subject does walk at 5 km/h and jog at 8 km/h under these conditions for up to 70 minutes. The test includes the measurement of the height and weight of the subjects, heart rate, oxygen consumption, body weight loss (sweat evaporation), skin temperature, and core body temperature under hot environmental conditions. Subjective responses will also be recorded. WBGT was recorded after every ten minutes by heat stress meter and Bruel Kjaer.
223417398|NCT00006471|DRUG|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
223417399|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level -1: 5 x 10\^5 CAR-20/19-T cells/kg"
223417400|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10\^6 CAR-20/19-T cells/kg (starting dose level)"
224033822|NCT06268990|PROCEDURE|Fecal microbiota transplantation|FMT is the transfer of fecal material containing gut microorganisms from a donor into the intestinal tract of a recipient
224033823|NCT03098589|DRUG|Revlimid|Revlimid
223417401|NCT04049383|BIOLOGICAL|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)"
223561215|NCT01519791|BIOLOGICAL|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
223561216|NCT03713398|BEHAVIORAL|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
224033824|NCT05843123|OTHER|Respiratory support a|Invasive mechanical ventilation mode
224033825|NCT05843123|OTHER|Respiratory support b|Invasive mechanical ventilation mode
224033826|NCT05645588|BEHAVIORAL|Pranayama assisted trauma-focused standard psychotherapy (TF-SPT)|To prepare patients for the TF-SPT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-SPT units.
224033827|NCT05645588|BEHAVIORAL|Trauma-focused standard psychotherapy (TF-SPT)|Patients wait for 10 TF-SPT units and then are offered to learn pranayama
224033828|NCT03844360|DRUG|Bortezomib|bortezomib was administered follow the doctor's advice.
224033829|NCT03844360|DRUG|Eltrombopag|eltrombopag was administered follow the doctor's advice.
224033830|NCT03844360|DRUG|Imatinib|imatinib was administered follow the doctor's advice.
224033831|NCT03844360|DRUG|dasatinib|dasatinib was administered follow the doctor's advice.
224033832|NCT03844360|DRUG|Pegaspargase|pegaspargase was administered follow the doctor's advice.
224033833|NCT03844360|DRUG|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
224033834|NCT03844360|DRUG|PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor|pegaspargase was administered follow the doctor's advice.
224033835|NCT00245934|DRUG|Enbrel|
224033836|NCT04251650|OTHER|subgingival plaque sample|for subgingival plaque sample, on three affected sites (PD\>3mm) and three healthy sites (PD≤3mm), after supra-gingival plaque removal, sterile endodontic paper points were inserted in selects pockets for 30s to collect the subgingival plaque. The material was transferred into eppendorf tube, one for affected samples and one for healthy samples.
224033837|NCT04251650|OTHER|CGF sample|each site was sampled with a PerioPaper Strip® (Oraflow), and the volumes collected were measured with a Periotron® (Oraflow). Then samples of affected sites were stowed in an eppendorf tube with 120µL of PBS Tween. The same procedure was performed for the healthy sites
224033838|NCT00895336|BIOLOGICAL|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
224033839|NCT03959371|DRUG|Ruxolitinib|"Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications."
224033840|NCT04003935|OTHER|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
224033841|NCT04003935|DIETARY_SUPPLEMENT|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
224033842|NCT00078754|DRUG|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
224033843|NCT00078754|DRUG|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
224136986|NCT05342129|OTHER|exercise bike|exercise is to use an exercise bike, start pedaling on the first day, time setting: 20 minutes, speed: 2, and adopt passive mode. If you can complete the exercise on the first day, the time will be adjusted to 30 minutes on the second day. If you cannot complete the exercise on the first day, the time will still start from 20 minutes on the second day. The maximum time is 30 minutes. If you can complete 30 minutes of passive exercise for 3 consecutive days, the fourth day will be adjusted to active exercise. The entire exercise training is seven days a week, once a day, once a 30-minute, at least 5 days. Those who were discharged to the general ward continued to complete this exercise training for up to 28 days.
224298564|NCT05875792|DEVICE|EvolvRehab - MoveWell|The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
224298565|NCT02393443|DRUG|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
224298566|NCT02393443|DRUG|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
224033844|NCT00078754|DRUG|Placebo|Placebo capsules by mouth, up to 8 capsules daily
224033845|NCT05033808|DRUG|Epirubicin|Epirubicin is given once over 15 Minutes via a central line
224033846|NCT05033808|DRUG|Placebo|NaCl is given once over 15 Minutes via a central line
224033847|NCT01520896|DRUG|NKTR-118|Oral 25 mg
224033848|NCT01520896|DRUG|Ketoconazole|Oral 400 mg
224033849|NCT02022319|DEVICE|Ultrasonographic Shear Wave Elastography|
224033850|NCT00934141|OTHER|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
224033851|NCT00934141|OTHER|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
224033852|NCT00934141|OTHER|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
224033853|NCT00934141|OTHER|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
224033854|NCT05185544|OTHER|Neoadjuvant pemetrexed and cisplatin chemotherapy|neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
224033855|NCT04579965|DRUG|medical treatment of isthmocele|comparison between different drugs
223417402|NCT04049383|BIOLOGICAL|CAR-20/19-T cells|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~The dose expansion dose level is still to be determined and this section will be updated."
223417403|NCT05015998|OTHER|Non-interventional|Epidemiology of anemia associated with chronic kidney disease, rather than to evaluate specific drugs
223417404|NCT02764957|DIETARY_SUPPLEMENT|green coffee extract|
223417405|NCT02764957|DIETARY_SUPPLEMENT|placebo|
224033856|NCT05620043|DEVICE|Sculptra|Biostimulator
224033857|NCT05620043|DEVICE|Radiesse Plus|Semi-permanent filler
224298567|NCT04111393|PROCEDURE|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
224298568|NCT01070771|DEVICE|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
224033858|NCT01349725|DRUG|ARRY-502|Oral; multiple dose, escalating
224033859|NCT01349725|DRUG|Placebo|Oral; matching placebo
224033860|NCT00639561|DIETARY_SUPPLEMENT|10 g of fibres per day|10 g of fibres per day
224033861|NCT00639561|DIETARY_SUPPLEMENT|40 g of fibres per day|40g of fibres per day
224298569|NCT00870597|PROCEDURE|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
223417406|NCT04062162|BEHAVIORAL|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
223417407|NCT04709692|DRUG|(+)-SJ000557733 (SJ733)|Anti-Malarial
223417408|NCT03253289|DRUG|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 28 (up to 35) days.
223417409|NCT00623740|DRUG|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
223417410|NCT00623740|DRUG|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
223417411|NCT00004465|DRUG|SYNSORB Pk|
223417412|NCT00004465|DRUG|Placebo|
223417413|NCT02982174|DEVICE|3D OCT-1 Maestro|Image acquisition of the posterior surface of the eye
223417414|NCT02982174|DEVICE|DRI OCT Triton|Image acquisition of the posterior surface of the eye
223417415|NCT03636204|BIOLOGICAL|AL001|Active dose of AL001
223417416|NCT03636204|OTHER|Placebo|Saline solution administered as a single infusion as palcebo.
223417417|NCT03880968|DRUG|tapering or discontinuation of etanercept|Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
223561217|NCT00774839|BEHAVIORAL|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
223417418|NCT00399646|DEVICE|Metricath Gemini System|
223417419|NCT05526846|BEHAVIORAL|Plant-based diet education|"Participants will receive weekly emails with information about plant-based diets and a goal/task for each week.~There will be a 'core curriculum' that will be sent to all participants, as well as additional information according to the participant's stage of change and food choice preferences.~All information will be available on a website that will be created for this study. The website will feature curated information about plant-based diets, that is tailored to patients who had recent colorectal operations and may have a colostomy or an ileostomy."
223417420|NCT06654830|PROCEDURE|RATT|Robotic-assisted thoracoscopic thymectomy (RATT) will be performed using Da Vinci Robotic Surgical Systems.
223417421|NCT06654830|PROCEDURE|VATT|Video-assisted thoracoscopic thymectomy (VATT) was performed using traditional thoracoscopic systems.
223417422|NCT00280358|DRUG|Fluticasone Propionate|
223417423|NCT00280358|DRUG|Formoterol Fumarate|
223417424|NCT06665958|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
223417425|NCT03386396|DIETARY_SUPPLEMENT|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
223417426|NCT03386396|DIETARY_SUPPLEMENT|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
223561218|NCT01941979|DRUG|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
223561219|NCT00925106|DRUG|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
223561220|NCT00925106|DRUG|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
223561221|NCT00925106|DRUG|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
223561222|NCT00925106|DRUG|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
223561223|NCT00529230|BEHAVIORAL|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
223561224|NCT00529230|OTHER|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
223417427|NCT03989206|DRUG|Nemolizumab|Nemolizumab
223417428|NCT03976687|DRUG|EYP001a|Oral tablets
223417429|NCT05495152|DRUG|Sintilimab|Patients in adjuvant arm receive 17 cycles of Sintilimab within 4 to 12 weeks after esophagectomy for ESCC. Sintilimab was administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks.
223417430|NCT02726906|BEHAVIORAL|Moderate-aerobic walking|
223417431|NCT02726906|RADIATION|Positron Emission Tomography (PET) scan|Radioligand that binds to proteins using a PET/CT scanner.
223417432|NCT02726906|BEHAVIORAL|Healthy living education|
223417433|NCT02726906|DEVICE|Physical activity monitor|Wrist device that will track daily physical activity
223417434|NCT05522205|OTHER|Regulated cannabis access in pharmacies|The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.
223561225|NCT04925076|DRUG|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
223561226|NCT04925076|OTHER|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
224033862|NCT05145062|DRUG|BIVV003|Solution for intravenous administration
224033863|NCT05145062|DRUG|ST-400|Solution for intravenous administration
224298570|NCT00870597|PROCEDURE|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
224298571|NCT05750862|PROCEDURE|Marking of the intended axis of IOL-Implantation manually with an ink and marking device on the surface of the eye|The marking of the intended implantation axis of the interocular lens will be marked in all patients with topography guided in the corneal stroma with laser and in addition manually with a caliper and ink on the corneal surface
223417435|NCT00355147|BEHAVIORAL|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
224033864|NCT05107050|DEVICE|Normal Saline and Amorphous gel|Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers
224033865|NCT05107050|DEVICE|BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel|"Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site.~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue."
224033866|NCT01585636|DRUG|SQ109|Single oral dose
224033867|NCT05917041|DEVICE|SAT-001(Software as Medical Device)|Using SAT-001 application for 48 weeks and wearing glasses or not
223417436|NCT00355147|BEHAVIORAL|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
223417437|NCT00355147|OTHER|Attention Control Group|Received Phone Calls from Staff to Control for Attention
223417438|NCT06594133|DRUG|Antibiotic Treatment|"For lung transplant recipients with Nocardia infection, the treatment regimen could include:~Sulfamethoxazole/Trimethoprim (Bactrim): 800 mg/160 mg orally or intravenously twice daily for at least 6 months.~Imipenem: 500 mg intravenously every 6 hours for severe cases. Monitoring: Regular monitoring of blood levels of the drug to avoid toxicity and adjust doses accordingly."
223417439|NCT01118260|PROCEDURE|total intravenous anaesthesia|propofol and remifentanil
223417440|NCT01118260|PROCEDURE|spinal anaesthesia|bupivacaine and fentanyl
223417441|NCT02348346|OTHER|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
223417442|NCT05038722|OTHER|Platelet transfusion|Transfusion of platelet concentrates according to routine practice.
223417443|NCT02717416|DEVICE|Endo-Clot|After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
223417444|NCT02717416|DEVICE|hemoclip or electrical coagulation|After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
223417445|NCT02015416|BIOLOGICAL|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
223417446|NCT06966661|BEHAVIORAL|Peer Support Intervention|In addition to all components of Standard Health Education, participants join biweekly, small-group meetings (6-8 peers) facilitated by trained upper-year student mentors who guide goal-setting, experience sharing, and mutual accountability. A moderated online chat forum provides daily encouragement, peer-to-peer Q\&A, and group reminders, distinguishing this arm by its structured social support network.
223417447|NCT06966661|BEHAVIORAL|Peer Support and eHealth Intervention|This arm integrates the full Peer Support Intervention with a custom mobile/web application that delivers weekly, interactive modules on nutrition, exercise, and mental health; offers in-app self-monitoring tools for weight, dietary intake, and mood; and hosts monthly live Q\&A webinars with clinical nutritionists and mental health professionals. The combination of real-time peer interaction and scalable digital content differentiates it as a multifaceted, blended-delivery intervention.
223417448|NCT06968065|PROCEDURE|Ultrasound-guided serratus anterior plane block and serratus-intercostal interfascial plane block with bupivacaine|Participants will receive an ultrasound-guided serratus anterior plane (SAP) block using 30 mL of 0.25% bupivacaine combined with a serratus-intercostal interfascial plane (SIP) block using 10 mL of 0.25% bupivacaine. Both blocks will be administered after surgery but before emergence from anesthesia. This combination targets multiple interfascial planes to enhance postoperative analgesia in patients undergoing minimally invasive cardiac surgery (MICS).
224033868|NCT02292966|DRUG|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
224033869|NCT02030405|DRUG|Ixazomib|Given orally (PO)
224033870|NCT00986440|DRUG|CS-7017|CS-7017
224033871|NCT00986440|DRUG|Placebo|Placebo
224033872|NCT02896504|DRUG|Exposure: Adjuvant chemotherapy treatment|
224033873|NCT02896504|DRUG|Exposure: Adjuvant hormonal therapy treatment|
224033874|NCT02070796|DRUG|Rotigotine PR2.2.1|"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
224033875|NCT02070796|DRUG|Rotigotine PR2.1.1|"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm\^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
224033876|NCT05830409|BEHAVIORAL|Multisensorial Stimulation|Strategies such as touching, calling, making sense of smell, entering the eye area, and activating the sense of taste will be applied to activate the five senses of the newborn.
224033877|NCT04115085|PROCEDURE|Hand therapy (18 treatments)|18 treatments (ea. 20 Min) within 9 weeks
224033878|NCT04115085|PROCEDURE|Therapeutic ultrasound (18 treatments)|18 treatments (ea. 10 Min) within 9 weeks
224033879|NCT04115085|PROCEDURE|Combined hand therapy and therapeutic ultrasound (18 treatments)|18 treatments (ea. 30 Min) within 9 weeks
224033880|NCT04115085|PROCEDURE|Sham ultrasound group (18 treatments)|Sham ultrasound group receive 18 treatments (ea. 10 Min) within 9 weeks
223417449|NCT06968065|PROCEDURE|Local wound infiltration with bupivacaine|Participants will receive local wound infiltration with 40 mL of 0.25% bupivacaine applied to the surgical and drain sites following surgery. This approach represents a standard method for managing postoperative pain in MICS patients and serves as the active comparator.
223417450|NCT03798301|BIOLOGICAL|CMV-specific T-cells|Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
223417451|NCT00964990|DRUG|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
223417452|NCT00964990|DRUG|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
223417453|NCT06967116|PROCEDURE|Procedure Steps|The data of the study were collected with the 'Patient Identification Form' and 'Meatal Pressure Injury Daily Monitoring Form'.
223417454|NCT00225225|DRUG|Rosiglitazone|
223417455|NCT00225225|BEHAVIORAL|dietary recommendation for weight maintenance|
223561227|NCT03041675|DEVICE|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
223561228|NCT03041675|DEVICE|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
224033881|NCT03032471|OTHER|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
224033882|NCT04694404|DRUG|S-1,Oxaliplatin|Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area \< 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area \>1.5 m2; D1-10, q2w)
223417456|NCT05889364|DIAGNOSTIC_TEST|"AI-based x-ray analysis and triage (normal/tuberculosis suspected)"|All included x-rays will be analysed by the AI-based system. Then results will be compared with opinions of 2 experienced radiologists (they make peer-review of all included images independently of each other).
223561229|NCT01192503|DRUG|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
223561230|NCT01192503|DRUG|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
224033883|NCT03498482|BEHAVIORAL|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
224298572|NCT05713968|OTHER|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM|patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
223417457|NCT03156608|DEVICE|Novii ECG/EKG System|External fetal heart rate monitoring
223417458|NCT03156608|DEVICE|External fetal heart rate monitoring|External fetal heart rate monitoring
223561231|NCT00731653|DRUG|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
223561232|NCT04727632|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT
224298573|NCT05713968|OTHER|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2|patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
223561233|NCT01996488|DRUG|Olanzapine Orally Disintegrating Tablets 5mg|
223561234|NCT01720004|OTHER|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
223561235|NCT04723472|DRUG|Cefuroxime containing bismuth quadruple treatment|"Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days."
223561236|NCT04723472|DRUG|Classic bismuth quadruple treatment|"Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days."
223561237|NCT04233398|DEVICE|Device: Echopulse (HIFU ablation)|High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
223561238|NCT03403530|DRUG|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
224033884|NCT04779372|BEHAVIORAL|smartphone-based dCBT-I from a Wechat applet|Participants will receive 6-week smartphone-based dCBT-I from a Wechat applet.
224033885|NCT04779372|BEHAVIORAL|sleep education|Participants will receive sleep education like the advices getting from common sleep clinic.
224033886|NCT04748900|DIAGNOSTIC_TEST|spirometer|different values are measured on the spirometer after training in respiratory physiotherapy.
224033887|NCT00803270|DRUG|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
224298574|NCT05890495|DRUG|Lidocaine topical|4% aqueous solution
224298575|NCT05890495|DEVICE|Tampon|Tampon with plastic applicator provided
223417459|NCT06666959|DRUG|Anesthesia Agent|intravenous anesthetic and inhalation anesthetic
223417460|NCT02990585|OTHER|Back school|
223417461|NCT02798289|DEVICE|Oculeve Intranasal Neurostimulator|Neurostimulation device
223417462|NCT02912260|DRUG|MGL-3196|
223417463|NCT02912260|DRUG|Placebo|
223417464|NCT02303223|DRUG|Propofol|
223417465|NCT02688062|BIOLOGICAL|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
223417466|NCT02688062|PROCEDURE|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
223417467|NCT01298726|OTHER|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
223417468|NCT01298726|OTHER|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
223561239|NCT04015427|DEVICE|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
223561240|NCT03533816|DRUG|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
223561241|NCT03533816|DRUG|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
223561242|NCT03462927|DRUG|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
223561243|NCT03462927|DRUG|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
223561244|NCT00077714|DRUG|Paliperidone ER|
223561245|NCT01289275|DRUG|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
223561246|NCT01289275|BEHAVIORAL|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
223561247|NCT01289275|BEHAVIORAL|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
223561248|NCT05761639|OTHER|conventional rehabilitation|The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
223561249|NCT05761639|BEHAVIORAL|Education|1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
223561250|NCT05761639|OTHER|telerehabilitation|"The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform"
223561251|NCT05761639|BEHAVIORAL|follow-up|Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
223561252|NCT04624919|OTHER|Hot/Dry|Work is completed in a hot/dry environment.
224033888|NCT00803270|PROCEDURE|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
224033889|NCT05584267|RADIATION|radiotherapy|Different cohorts received different doses of radiotherapy
223561253|NCT04624919|OTHER|Warm/Humid|Work is completed in a warm/humid environment
224033890|NCT05584267|DRUG|Chemotherapy + immunotherapy|Chemotherapy + immunotherapy
223561254|NCT06537128|BEHAVIORAL|LUNA-Adolescent|Learning to Understand and Navigate Anxiety-Adolescent (LUNA-Adolescent) includes parent-led, internet-based cognitive behavioral therapy (CBT) for anxiety among autistic youth.
223561255|NCT06537128|BEHAVIORAL|Treatment as Usual|Treatment as Usual includes 12 weekly sessions of transdiagnostic cognitive behavioral therapy (CBT) for anxiety in autistic youth.
223561256|NCT05289817|DEVICE|Transcutaneous Vagus Nerve Stimulation (t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
224033891|NCT02583139|BEHAVIORAL|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other."
224033892|NCT02737917|OTHER|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
224033893|NCT02737917|OTHER|Standard of care|Rapid sequence intubation
224136987|NCT02657668|BEHAVIORAL|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
223417469|NCT04497870|DRUG|Peppermint oil|Administration of peppermint oil at one of two daily doses.
223417470|NCT02401048|DRUG|Ibrutinib|
223417471|NCT02401048|DRUG|MEDI4736|
224033894|NCT04048954|DEVICE|Applitabac|Smartphone application in screening on tabagism complications
224033895|NCT00569595|BEHAVIORAL|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
224136988|NCT04593940|DRUG|Infliximab|study drug or matching placebo
224136989|NCT04593940|DRUG|Abatacept|study drug or matching placebo
223417472|NCT06060951|DIAGNOSTIC_TEST|Estimated intraperitoneal pressure|"The following anthropometric measurements are required:~1. Height: measured standing with shoes off~2. Weight: dry weight should be used~3. The distance from the decubitus plane to the mid-axillary line was measured~4. Waist circumference: measured with a tape measure wrapped above the iliac crests around the level of the umbilicus.~The estimated IPP will be assessed using different equations."
223417473|NCT03240068|DRUG|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
224033896|NCT00569595|BEHAVIORAL|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
223417474|NCT03240068|DRUG|Saline|Normal saline will be used as the placebo comparator.
223417475|NCT05094869|BEHAVIORAL|Use of mobile health application|The APP would regularly send messages including the medication reminder, health education knowledge, etc.
223417476|NCT05094869|BEHAVIORAL|Online interaction|The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.
223417477|NCT05094869|BEHAVIORAL|Self follow-up reminders|The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)
223417478|NCT05094869|BEHAVIORAL|Intelligent follow-up reminders|The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
223417479|NCT02304731|OTHER|Physical Exercise|Incremental running
223417480|NCT04634591|PROCEDURE|Bariatric surgery|Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
223417481|NCT03644394|DEVICE|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
223417482|NCT03138837|DIAGNOSTIC_TEST|Magnetic resonance imaging|Diffusion Weighted Magnetic resonance imaging
223417483|NCT05051280|PROCEDURE|cone-beam computed tomography fusion image|Left Atrial Appendage Occlusion Under Cone-beam Computed Tomography Fusion Image Guidance
223417484|NCT00827216|DRUG|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
223417485|NCT00827216|DRUG|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
223417486|NCT05423496|DIAGNOSTIC_TEST|KidneyCare|Using KidneyCare platform as a tool to successfully augment immunosuppressant agents through regular surveillance allowing minimization of doses and number of agents.
223417487|NCT05423496|DRUG|steroid|optimization of steroids
223417488|NCT05423496|DRUG|MMF|optimization of MMF
223417489|NCT03408301|PROCEDURE|Tourniquet deflation|Tourniquet deflation
223417490|NCT00650013|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fed
223417491|NCT00650013|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fed
223417492|NCT05707026|OTHER|cross fiber fascial manipulation|The group A received three sessions of fascial manipulation in two weeks. FM applied for 5 to 8 minutes at each point.
224136990|NCT04593940|DRUG|Remdesivir|Standard of Care
223417493|NCT05707026|OTHER|stretching techniques(sleeper stretch and cross body adduction stretch)|Group B received three sessions of sleeper and cross body adduction stretches. Group B received three sessions of sleeper stretch in a side lying position in 90o abduction, elbow at 90o flexion and then performing shoulder IR and cross-body adduction stretch was done in sitting position. Three sets of the each stretch position were held for 30 seconds with a 1 minute break between sets.
223739273|NCT06914739|BEHAVIORAL|The Health Empowerment Theory (HET) program|The intervention group received the HET-based intervention program for 12 weeks. From the first week to the fourth week, community nurses interacted with the participants face-to-face to analyze and establish their problems and needs in health management (usual community health services utilization, such as medicine purchases and vaccinations) and helped clarify the importance of health management and their strengths (such as existing health knowledge). From the fifth to twelfth weeks, participants attended health knowledge lectures led by community nurses, covering topics such as: a) healthy lifestyle, primarily diet, exercise, and disease prevention and management for older adults; and b) community health services, which included recent or long-term community health services (such as health examinations for older adults and family doctor contracts). WeChat groups and offline gatherings at community health centers (with groups of eight to ten peers) were organized to interact and comm
223739274|NCT06914739|BEHAVIORAL|routine community care|The control group received routine community care, including notifications of community- related activities and lectures through WeChat group chats or telephone calls, and had questions answered by researchers and community nurses.
224136991|NCT04593940|DRUG|cenicriviroc (closed to enrollment as of 3-Sep-2021)|study drug or matching placebo
224136992|NCT02077634|DRUG|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
224136993|NCT02077634|DRUG|abiraterone acetate + prednisone|ormon therapy will be stopped
224136994|NCT02645058|PROCEDURE|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
224136995|NCT02645058|PROCEDURE|ESWL|Treatment by extracorporeal shock waves lithotripsy
224136996|NCT02645058|DEVICE|Rigid and flexible ureteroscope|
224136997|NCT02645058|DEVICE|Lithotripter|
224136998|NCT02645058|DEVICE|Holmium laser|
223561257|NCT05289817|DEVICE|Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes"
224033897|NCT06341153|BEHAVIORAL|Breast Milk Odor Stimulation|In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.
224033898|NCT06341153|BEHAVIORAL|Stimulation of Breast Milk Smell and Taste|In this group in which the breast milk sniffing method was applied; two drops of breast milk were dripped onto a sponge in accordance with the literature and this sponge was placed as close to the nose as possible without touching the nose and the baby was allowed to smell the smell of breast milk for about 1 minute. Then the baby was given to the mother. The mother was asked to express milk manually and to apply/drip approximately 0.2 ml (approximately two drops) of the expressed colostrum starting from the tip of the baby's tongue, along the tongue surface, on both cheeks of the baby, as applied in studies using oral colostrum as a reference. The mother was also asked to express a drop of milk from her breast and manually apply it to the areola. Breastfeeding was then initiated as in routine practice.
224033899|NCT00302627|DRUG|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
224033900|NCT00302627|DRUG|vitamin D|baseline, 6,12 months
223417494|NCT02454816|DEVICE|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
223417495|NCT02454816|DEVICE|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
223417496|NCT02986542|PROCEDURE|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
223417497|NCT02148757|PROCEDURE|Doppler Ultrasound|
223417498|NCT05507385|BEHAVIORAL|IMAGINE-POSITIVE|The intervention will combine aspects of Memory Specificity Training (MeST), which includes information about the links between memories and emotions, with Positive Prospective Mental Imagery (PPMI), to increase vividness and savouring of positive future images, in order to harness positive affect. IMAGINE-PA will follow a treatment manual and delivery will be accompanied by a therapy workbook.
223417499|NCT05507385|BEHAVIORAL|Control|Non-directive supportive therapy (NDST) consists of individual sessions, with an empathetic, emotionally supportive practitioner and provides non-directive problem solving and monitoring. Using NDST will control for factors that may contribute to change, which are not active components e.g. speaking to an empathetic therapist. NDST will follow treatment guidelines.
224033901|NCT00302627|DRUG|Calcium Carbonate|baseline, 6,12 months
223417500|NCT00646815|DRUG|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
223417501|NCT04221256|DRUG|Administration of SSRI escitalopram|Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation
223561258|NCT05289817|DEVICE|Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)|"Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes"
223417502|NCT04221256|BEHAVIORAL|Paired Associative stimulation|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
223417503|NCT04221256|DRUG|Administration of Placebo|Participants will be administered a placebo prior to paired associative stimulation
223561259|NCT04496206|OTHER|No intervention|No intervention, it is retrospective study.
223739275|NCT07191106|PROCEDURE|adapted physical activity|Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application
224033902|NCT00210730|DRUG|epoetin alfa|
224033903|NCT03695666|OTHER|Clerical policy|Clerical policy introduction
224033904|NCT06415006|PROCEDURE|Measurement of hemodynamic parameters.|The measurement and recording of Heart Rate (HR), Systolic Arterial Blood Pressure (ABPsys), Diastolic Arterial Blood Pressure (ABPdias), Mean Arterial Blood Pressure (ABPmean), and age parameters.
224033905|NCT03349892|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
224033906|NCT00327054|DRUG|Nigella sativa seed|
223417504|NCT05356949|BEHAVIORAL|Intervention|The participants receive a psychological intervention including six weekly sessions. The intervention is based on methods of cognitive-behavioral therapy and delivered by a psychiatric nurse working in the participant's school.
223417505|NCT06491875|BEHAVIORAL|Digital Storytelling (DST)|The DST activity emphasized the use of multimedia to bring the stories to life. At the beginning of the workshop, interactive circles were formed for informative interactions. Children with autism and typically developing children were asked to prepare a short video reflecting a personal experience from their own lives. The children's habits and interests were identified and they were made to work on preparing materials such as pictures, photographs, handicrafts, dough toys, etc. to be uploaded to the computer program. It was explained that they could also choose from ready-made photos in the video editing/editing program for their stories, and that they could make short audio recordings if they wished. Digital stories are usually prepared as videos that combine audio, video, and video clips to tell a story. The DST study was conducted for 16 hours over two months. During the DST, the mothers who wanted to participate and watch also participated in the study.
223417506|NCT06491875|BEHAVIORAL|Sensory Integration Therapy (SIT)|Sensory integration training for children with ASD was conducted 2 days per week for 2 months. Taking into account the results of the Dunn Sensory Profile Scale, sensory approach strategies were determined for children with ASD, taking into account low and high neurological thresholds and hyper- and hyposensitive responses in the auditory, visual, tactile, vestibular and kinesthetic sensory systems. Sensory-motor activities with deep pressure and proprioceptive stimuli were used for children sensitive to tactile stimuli, and activities with linear and slow vestibular stimuli and resistive movement were used for children with kinesthetic sensitivity. In the intervention, swings, ball pools, ramps, rotation, and fast motion inputs were used in swing for children with hypersensitivity to motion, and sensory materials with different textures, play dough, and some other sensory materials were used for children with hypersensitivity to tactile sensory system.
223417507|NCT05404477|DEVICE|TransAeris System|The TransAeris System includes four TransLoc® intramuscular diaphragm electrodes, the TransAeris external stimulator, and the FrictionLoc® connectors which provide the interface between the TransLoc electrodes and the TransAeris stimulator.
223417508|NCT02246543|DIETARY_SUPPLEMENT|Control|Water, Toast \& Egg (Yolk only) + 0.1g 13C Octanoic Acid
223417509|NCT02246543|DIETARY_SUPPLEMENT|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
223417510|NCT02246543|DIETARY_SUPPLEMENT|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
223417511|NCT02246543|DIETARY_SUPPLEMENT|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
223417512|NCT02246543|DIETARY_SUPPLEMENT|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
223417513|NCT02308072|DRUG|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
223417514|NCT02308072|DRUG|Cisplatin|35 mg/m\^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m\^2)
223417515|NCT02308072|RADIATION|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
223417516|NCT00449358|PROCEDURE|apply methyl-ALA cream|
223417517|NCT05902299|DRUG|Antibiotic|Evaluate the choice of antibiotic therapy prescribed for P. aeruginosa ou S. aureus infection
223417518|NCT01479569|PROCEDURE|Pericardiocentesis|
223417519|NCT02164331|BEHAVIORAL|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
223417520|NCT02659280|OTHER|Adjunct Therapy|"Store and Forward Tele-heath"
224136999|NCT02645058|DEVICE|Basket for fragment removal|
224137000|NCT02645058|PROCEDURE|General or spinal anesthesia|
223417521|NCT02659280|OTHER|Standard of Care|Standard of Care Outpatient Physical Therapy
223417522|NCT02524743|DRUG|acetaminophen|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
223417523|NCT02524743|DRUG|Lidocaine|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
223417524|NCT02524743|OTHER|Placebo|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated 5 ml iv normal saline before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
224033907|NCT06178406|BEHAVIORAL|dysmenorrhea|Dysmenorrhea, defined as painful menstrual cramps of uterine origin, is the most common gynecological condition among women of reproductive age.
224033908|NCT00596778|OTHER|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
224033909|NCT05274984|DRUG|Placebo|the control group will be given the same volume of saline.
224033910|NCT05274984|DRUG|Lidocaine|the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
224033911|NCT00234806|OTHER|Health-e-Access|telemedicine intervention
224137001|NCT02645058|DRUG|Intravenous pain medication|If required by the patient
223417525|NCT02239133|DEVICE|ProVATE vaginal pessary|
223417526|NCT01707108|DEVICE|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
223417527|NCT02397122|BIOLOGICAL|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
224033912|NCT00593957|DRUG|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
224033913|NCT00593957|DRUG|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
224033914|NCT05657483|DIAGNOSTIC_TEST|Venous blood sample|Blood chemistry tests: neutrophil; lymphocyte; monocyte; platelet counts.
224033915|NCT05657483|OTHER|Surgical staging of endometrial cancer|Endometrial, adnexal, and lymphoid tissue samples.
224033916|NCT01604707|OTHER|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
224033917|NCT03481023|DEVICE|EnsoETM|Use of esophageal thermal regulation device during radiofrequency ablation.
224033918|NCT03481023|PROCEDURE|Conventional Care|Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
224137002|NCT02645058|DEVICE|X-ray|To focus the stone
224137003|NCT02645058|DEVICE|Ultrasound|To focus the stone
224298576|NCT02816099|BIOLOGICAL|Prise de sang|
223417528|NCT02397122|PROCEDURE|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
223417529|NCT02397122|PROCEDURE|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
223417530|NCT00020644|DRUG|gemcitabine hydrochloride|
223417531|NCT05193916|DRUG|chiglitazar sodium tablets|the drugs will be given orally once a day
223417532|NCT05193916|DRUG|Placebo|no active drug contained
223417533|NCT06330246|DIETARY_SUPPLEMENT|Low oxalate fixed diets pre-colonization|4 days of fixed eucaloric diet with low oxalate (\< 60 mg/day), normal calcium (600-1000 mg/day)
223417534|NCT06330246|DIETARY_SUPPLEMENT|Moderately high oxalate fixed diets pre-colonization|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium (600-1000 mg/day)
223417535|NCT06330246|DIETARY_SUPPLEMENT|Colonization with Oxalobacter formigenes|Ingestion of live Oxalobacter formigenes
223417536|NCT06330246|DIETARY_SUPPLEMENT|Low oxalate fixed diets post-colonization|4 days of fixed eucaloric diet with low oxalate (\< 60 mg/day), normal calcium (600-1000 mg/day)
223561260|NCT06308341|OTHER|Virtual Reality technique + Motor Imagery technique + Routine Physical Therapy|Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min
223561261|NCT06308341|OTHER|Virtual Reality + Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with cycling and walking for 10-15 minutes.~VR techniques for 10-15 minutes The first eight weeks focus on simple activities to enhance balance and motor function, such as tennis, boxing, bowling, kicking, soccer, table tilt, penguin slide, tilt city, single-leg extension, and torso twist. Exercise difficulty is adjusted based on performance, gradually progressing from easier to more challenging activities."
223561262|NCT06308341|OTHER|Motor Imagery +Routine Physical Therapy|"Routine physical therapy protocol will be given for 30 minutes along with Cycling and walking for 10-15 minutes MI techniques for 10-15 minutes The motor imagery program me will be performed in three steps; STEP I: The patients will watch the videos recorded by the examiner. STEP II: The patients will be asked to close their eyes, focus, and imagine how they are doing the task they had previously observed ten times.~Step III: The patient will be asked to attempt the activity with his affected limbs according to the verbal command of the examiner Routine physical therapy for 30 minutes is explained as: warm up for 10 mins, stretching of lower limb and upper limb for 10 min, task specific training, gait training and balance training exercises for 15min, strengthening exercises for 10 min."
223561263|NCT02412891|DEVICE|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
223561264|NCT02412891|DEVICE|Sham UroShield device|
224137004|NCT00180596|DEVICE|Contak heart failure devices|
224137005|NCT03739463|DIETARY_SUPPLEMENT|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
224137006|NCT03739463|DIETARY_SUPPLEMENT|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
224137007|NCT03989219|PROCEDURE|plasma cfDNA methylation|plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
223417537|NCT06330246|DIETARY_SUPPLEMENT|Moderately high oxalate fixed diets post-colonization|4 days of fixed eucaloric diet with moderately high oxalate (250-300 mg/day), normal calcium (600-1000 mg/day)
223417538|NCT03453034|DRUG|TQ-B3233|QD or BID in different stage of this research
223417539|NCT02749994|DRUG|Rosuvastatin|
223417540|NCT02749994|DRUG|Ezetimibe|
223417541|NCT00520611|BEHAVIORAL|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
223417542|NCT00520611|BEHAVIORAL|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
223417543|NCT00542906|OTHER|localization|localization of the several types of somatosensory stimuli
223417544|NCT04164043|BEHAVIORAL|Wellness Recovery Program|12-week community-based recreation therapy
223417545|NCT06056687|DRUG|Alpha Lipoic Acid 600 MG Oral Tablet|Alpha Lipoic Acid 600 MG Oral Tablet once daily
223417546|NCT06056687|OTHER|Placebo Tablet|Placebo Tablet once daily
223417547|NCT06296550|OTHER|Dulce Digital Text Messaging Intervention|"Text-based education support program:~* Participants will receive text messages about diabetes and how to take care of diabetes and health. Participants will receive 2-3 messages every day for first 3 months, and then will slowly decrease over the last 3-months.~* Participants will also receive text messages that will ask them to test their blood sugar and text back blood sugar reading."
223561265|NCT04378998|OTHER|Acupuncture|The intervention group received usual care plus acupuncture for three days. The acupuncture spots: Pericardium-6, Stomach-36, Liver-3 and Yin Tang were used. The control group received usual care.
223561266|NCT05566691|OTHER|Positive thinking|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
224033919|NCT03832296|BEHAVIORAL|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
224033920|NCT03832296|BEHAVIORAL|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
224033921|NCT00494481|DRUG|Vandetanib (ZD6474)|once daily oral dose
224033922|NCT00494481|DRUG|Docetaxel|intravenous infusion
224033923|NCT02973048|DRUG|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
224033924|NCT02973048|DRUG|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
224033925|NCT00332189|DRUG|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
224033926|NCT05959694|DRUG|TQB3909 tablet|TQB3909 is an inhibitor targeting at B-cell lymphoma (BCL)-2 protein.
224033927|NCT04100642|DRUG|Hemay808|topical apply
224033928|NCT04100642|DRUG|Placebo|topical apply
224033929|NCT03545659|OTHER|Mode of relapse/SMN detection|Mode of relapse/SMN detection: whether the relapse/SMN was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.
223417548|NCT06296550|OTHER|CGM Device|Participants will be provided continuous glucose monitors (Dexcom G7) to actively monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months). In addition, participants will attend an information session (group or individual; in-person or virtual) that will provide instructions on using continuous glucose monitors.
223417549|NCT00598312|DRUG|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
223417550|NCT04736277|OTHER|Preoperative HbA1c|Documentation of the preopetative HbA1c in patients undergoing noncardiac surgery under general anesthesia
223417551|NCT00680602|BEHAVIORAL|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
223417552|NCT00680602|DRUG|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
223561267|NCT05566691|OTHER|Positive thinking + Mood induction|Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
223561268|NCT05566691|OTHER|Thought reevaluation|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts.
223561269|NCT05566691|OTHER|Thought reevaluation + Mood induction|Participants will be provided with information about how to cope with negative thoughts using thought reevaluation and asked to complete a worksheet walking them through the steps of reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.
223561270|NCT01490008|DRUG|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
223561271|NCT01490008|OTHER|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
224033930|NCT00368160|DRUG|Eszopiclone|eszopiclone 3 mg
224033931|NCT00368160|DRUG|Placebo|Placebo tablet
224033932|NCT03467503|DIETARY_SUPPLEMENT|Blueberry + soluble fiber|Dietary frozen blueberries and soluble fiber for 20 weeks
224033933|NCT03787225|DRUG|NNC0174-0833|Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
224033934|NCT03787225|DRUG|Placebo (NNC0174-0833)|Participants will receive NNC0174-0833 matched placebo subcutaneously.
224033935|NCT06076603|DRUG|nebulized polymyxin B|The experimental group received intravenous combined nebulization of polymyxin B
224033936|NCT04233593|BIOLOGICAL|Lipopolysaccharide|Endotoxin E Coli
224033937|NCT00504010|DRUG|Arnica Montana|Applied to lower extremity once a day for 3 days
224033938|NCT00504010|DRUG|placebo cream|placebo cream applied to leg daily for 3 days
224033939|NCT05419063|BEHAVIORAL|weight loss strategies|Participants will receive recommendations on how to decrease caloric intake, monitor their weight and track the related behaviors and progress.
223417553|NCT04242290|DIAGNOSTIC_TEST|Lateral radiography|The lordosis angles were measured on the lateral cervical graphs of all patients.
223417554|NCT06424171|DIAGNOSTIC_TEST|Cardiac and brain magnetic resonance imaging.|Cardiac magnetic resonance imaging with analysis using 4D flow. Brain magnetic resonance imaging to detect strokes, including microvascular strokes.
223417555|NCT00970541|DIETARY_SUPPLEMENT|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
223417556|NCT00970541|DIETARY_SUPPLEMENT|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
223417557|NCT05320705|DRUG|Intra Operative Dexmedetomidine|Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
223417558|NCT01651520|DRUG|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
223417559|NCT06049186|BEHAVIORAL|CRD|During the initial 8 weeks of the trial, polycystic ovary syndrome (PCOS) patients are instructed to follow a diet of 1200 to 1500 kcal per day supervised by dietitians. The CRD includes a combination of 40 to 55% of calories from carbohydrates, 15 to 20% from protein, and 20 to 30% from fat; this regimen represented approximately 75% of the participants' daily caloric intake at baseline. All the participants receive dietary counseling daily during the trial.
223417560|NCT06049186|DRUG|Metformin|After randomization, patients entering the metformin group will be given 1500 mg daily (bid/tid) metformin and regular diets as control. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.
223417561|NCT00926848|BEHAVIORAL|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
223417562|NCT00650325|DRUG|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
223417563|NCT00650325|DRUG|Zoloft® Tablets 100 mg|100mg, single dose fasting
223417564|NCT02650258|BEHAVIORAL|treadmill walking|all participants walking at increasing speeds on a treadmill
223417565|NCT03606304|BEHAVIORAL|Problem-solving therapy|See previous
223417566|NCT00625417|PROCEDURE|breast biopsy|
223417567|NCT00625417|PROCEDURE|histopathologic examination|
223417568|NCT00625417|PROCEDURE|light-scattering spectroscopy|
223417569|NCT00625417|PROCEDURE|therapeutic conventional surgery|
223417570|NCT04751955|DRUG|Olinvacimab added to Capecitabine|Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
223417571|NCT01139957|PROCEDURE|Evaluation of Cancer Risk Factors|Ancillary studies
223417572|NCT01139957|OTHER|Quality-of-Life Assessment|Ancillary studies
223417573|NCT01139957|OTHER|Questionnaire Administration|Ancillary studies
223417574|NCT01139957|PROCEDURE|Study of High Risk Factors|Ancillary studies
223417575|NCT03595514|OTHER|Single injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
223739276|NCT07186192|OTHER|Intervention Arm (Digital health intervention)|Patients and family caregivers that are randomized into the intervetnion arm (Digital health intervention) will receive a 90 day nurse-drive, digital health intervention.
224033940|NCT05419063|BEHAVIORAL|text-based and email feedback|Participants will receive weekly text-based feedback based on dietary strategy tracking and weight tracking. Participants will receive tailored email support and synchronous problem solving sessions as needed.
224033941|NCT02340091|DEVICE|HA IDF plus|
223417576|NCT03595514|OTHER|Double injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
223417577|NCT03595514|DRUG|lidocaine, bupivacaine, epinephrine, dexamethasone|lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
223417578|NCT05346081|DEVICE|Electrical impedance tomography|Electrical impedance tomography (EIT) is a potential alternative non-invasive diagnostic screening measure to spirometry.
223417579|NCT02329379|DRUG|Levothyroxine|
223417580|NCT01014364|DRUG|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
223417581|NCT01014364|DRUG|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
223417582|NCT04644705|DRUG|Niclosamide|Niclosamide will be applied in various dosage steps, galenic preparations and in combination with camostat
223417583|NCT04644705|DRUG|Placebo|placebo to the interventional drug
223417584|NCT01040637|DRUG|TD-1211|Dose level 1
223417585|NCT01040637|DRUG|TD-1211|Dose level 2
223417586|NCT01040637|DRUG|TD-1211|Dose level 3
223417587|NCT01040637|DRUG|TD-1211|Dose Level 4
223417588|NCT01040637|DRUG|TD-1211|Ascending doses
223417589|NCT01040637|DRUG|TD-1211|Ascending doses
223417590|NCT01040637|DRUG|TD-1211|Ascending doses
223417591|NCT01040637|DRUG|TD-1211|Ascending doses
224033942|NCT02340091|DEVICE|HA IDF|
224033943|NCT02727465|OTHER|Meningitis cases|None - blood draw only
224033944|NCT01454518|PROCEDURE|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
224033945|NCT01454518|PROCEDURE|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
224033946|NCT03093987|OTHER|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
223417592|NCT01040637|DRUG|TD-1211|Ascending doses
223417593|NCT01040637|DRUG|Placebo|Ascending doses
224033947|NCT03048643|BEHAVIORAL|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
224033948|NCT03364712|OTHER|routine medical care, venipuncture|
224033949|NCT02311946|DRUG|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
224033950|NCT02311946|DRUG|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
224033951|NCT02279862|DRUG|Ipilimumab|
224033952|NCT01244451|DRUG|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
224033953|NCT01244451|DRUG|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
224033954|NCT00499629|DRUG|FXR 450|capsule, single oral doses from 10 mg to 450 mg
224033955|NCT00499629|DRUG|placebo|capsule similar to active drug
224033956|NCT04673565|BEHAVIORAL|Motivational interviewing|Each participant in the treatment group will attend a 1-hour MI group session with 9 other participants hosted by a practicing MI therapies via Zoom at one month after the initial visit. This session will utilize MI to elicit motivation in each participant. Participants will also receive standard care delivered at in-person audiology clinic visits.
224033957|NCT02901366|DRUG|14C-FYU-981|14C-FYU-981, (Oral single dosing)
224033958|NCT02928107|OTHER|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
223417594|NCT05107609|BEHAVIORAL|Acute Self-Compassion Intervention|Participants will be guided through a 30-minute behavioural self-compassion intervention that seeks to mitigate their psychobiological responses to the subsequent weight stigma induction. The intervention is intended to induce a flexible self-compassionate mindset that will facilitate more adaptive psychological responding to stress and activate affiliative/self-soothing physiological systems that can dampen psychobiological stress reactivity. This acute self-compassion intervention will employ a multimodal, experiential approach that is regularly utilized in self-compassion training, drawing from approaches developed in Compassion-Focused Therapy and Mindful Self-Compassion.
223417595|NCT02698527|DRUG|Non-Buffered Lidocaine|Active comparator
223417596|NCT02698527|DRUG|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
223417597|NCT01686126|DRUG|Levonorgestrel|Intrauterine device
223417598|NCT01686126|DRUG|Metformin|oral medication
223417599|NCT03194880|DEVICE|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~1. User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~2. The laboratory component: For each test we will evaluate:~   * The percentage of assays completed~  * The percentage of assays incomplete (i.e. invalid result on two attempts)~  * Reasons for incomplete assays, e.g.~     * The sample could not be delivered to the strip or cartridge correctly~    * Invalid control~    * Results could not be interpreted~    * Others"
223417600|NCT05335980|DEVICE|Nu-V3|The Nu-V3 device provides a continuous flow of intermittent, low frequency electrical pulses to the ear's specific cranial nerve endings. This treatment is delivered 24 hours a day for the first 12 weeks, then is delivered two weeks on, one week off for the following 12 weeks.
223417601|NCT02642120|DEVICE|"Dental device Laboraide"|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
223417602|NCT00072280|BIOLOGICAL|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose \< 1yr 0.025 mg/kg \> or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
223417603|NCT00072280|DRUG|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
223417604|NCT00072280|DRUG|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
223417605|NCT00072280|DRUG|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
224033959|NCT02928107|OTHER|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
223417606|NCT00072280|DRUG|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
224033960|NCT04144634|OTHER|Strengthening exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
224033961|NCT04144634|OTHER|Stretching exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
224033962|NCT01394653|DRUG|YM060|oral, with water
224033963|NCT06328907|BEHAVIORAL|comprehensive rehabilitation therapy|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224137008|NCT05339724|OTHER|platelet count and mean platelet volume are obtained from whole blood count|The records of cystic fibrosis patients will be retrospectively evaluated for acute pulmonary exacerbation, chronic airway colonization for bacteria, clinical stable status. PC and MPV will be obtained and matched in 6 groups (described above). Then, PC and MPV will be compared among the groups.
223417607|NCT00072280|PROCEDURE|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
223417608|NCT00072280|BIOLOGICAL|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
223417609|NCT00072280|BIOLOGICAL|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
223417610|NCT00020865|DRUG|cefepime hydrochloride|
223417611|NCT00020865|DRUG|levofloxacin|
223417612|NCT03763929|DRUG|Trans-Sodium Crocetinate|In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.
223417613|NCT03763929|OTHER|Placebo|The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
223417614|NCT02767466|PROCEDURE|Physical therapy and robotic assisted gait training|
224033964|NCT06328907|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224033965|NCT06328907|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224298577|NCT03525652|BIOLOGICAL|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
223417615|NCT01725022|OTHER|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
223417616|NCT03811548|DRUG|Janagliflozin 25mg|Tablets, Oral, 25 mg, Tablets, Oral, 50 mg
223417617|NCT03811548|DRUG|Janagliflozin 50mg|Tablets, Oral, 25 mg, Once daily, 52 weeks
223417618|NCT03811548|DRUG|Placebo/Janagliflozin|Tablets, Oral, 25 mg, Once daily, 52 weeks
223417619|NCT03384030|OTHER|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
224298578|NCT03525652|BIOLOGICAL|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
224298579|NCT04536532|DRUG|HEC121120 tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
223417620|NCT01172925|DRUG|Tiotropium|Inhaler
223417621|NCT01172925|DRUG|Placebo|Inhaler
223417622|NCT06577701|DRUG|traditional Chinese medicine (TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
223417623|NCT06577701|DRUG|non traditional Chinese medicine (non-TCM)|Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
223417624|NCT03297645|BEHAVIORAL|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
223417625|NCT03297645|BEHAVIORAL|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
223417626|NCT03297645|BEHAVIORAL|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
223417627|NCT03297645|BEHAVIORAL|Informational mail|Family will be mailed publicly available asthma information every 3 months.
224033966|NCT02880202|OTHER|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
223417628|NCT00022698|DRUG|Capecitabine|
223417629|NCT00022698|DRUG|Irinotecan|
223417630|NCT04397497|DRUG|Mavrilimumab|human monoclonal antibody targeting GM-CSF receptor-alpha
223417631|NCT04397497|DRUG|Placebo|matching volume of diluent
223417632|NCT06576245|DEVICE|Quantum Molecular Resonance (QMR) Therapy|Quantum Molecular Resonance (QMR) therapy will be administered using the RexonEye® device (Resono Ophthalmic, Trieste, Italy). The device delivers low-intensity, high-frequency electrical waves ranging from 4-64 MHz through specialized contact electrodes. Participants will receive 4 QMR treatment sessions over 6 weeks. Each session lasts for 20 minutes, with a 30-second alternation between the eyes. The goal of QMR therapy is to stimulate cellular regeneration and improve tear production by targeting the lacrimal gland.
223417633|NCT06576245|DEVICE|Intense Pulsed Light (IPL) Therapy|Intense Pulsed Light (IPL) therapy will be performed using the OptiLIGHT® device (Lumenis Be Ltd., Yokneam, Israel). IPL treatment involves the application of high-intensity, non-coherent, polychromatic light within the 500 to 1200 nm wavelength spectrum. Participants will receive 3 IPL sessions over 6 weeks, with sessions targeting the periocular area and upper eyelids to improve meibomian gland function. Each session includes the application of 50 light pulses to the periocular area and upper eyelids using specified parameters (e.g., fluence 14 J/cm² for the periocular area, fluence 11 J/cm² for the upper eyelids).
223417634|NCT06576245|DRUG|Tear Substitute Treatment (Supportive Therapy)|"All participants will also receive supportive therapy with tear substitutes throughout the study period. This includes:~Idroflog® (0.2% Hyaluronic Acid with 0.001% Hydrocortisone): Applied 3 times per day.~VisuXL gel® (Cross-linked Carboxymethyl Cellulose with Coenzyme Q10): Applied once a day.~Artelac® Nighttime Gel (0.24% Sodium Hyaluronate with Carbomer): Applied before sleeping. These tear substitutes are intended to provide symptomatic relief and support tear film stability during the treatment period."
223417635|NCT02504827|DRUG|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
223417636|NCT05248373|BIOLOGICAL|Gam-COVID-Vac|two-component combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus
223417637|NCT05248373|OTHER|Placebo|solution with same composition as for vaccine formulation except rAds
223417638|NCT05053620|DEVICE|Calculation of the arcuate intrasomal incisions|All patients participating in the study will undergo femtosecond laser treatment for the correction of astigmatism through arcuate intrastromal incisions with the Catalys laser (Johnson \& Johnson, USA, CE marked). The calculation of intrastromal arcuate incisions will be carried out using the following nomogram indicated on the laser: 9.0 mm optical zone and symmetrical incisions of 50 degrees for 0.50D, 55 degrees for 0.75D, 60 degrees for 1.00D and 65 degrees for 1.25D of corneal astigmatism. After the incisions, conventional cataract surgery will be performed using the Centurion phacoemulsifier equipment (Alcon, USA, with CE marking) in the ZCB00 monofocal intraocular lens (IOL) implant (Johnson \& Johnson, USA, with CE marking). All patients will be treated according to standard clinical practice.
223417639|NCT01055691|DRUG|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
223417640|NCT01055691|DRUG|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
223417641|NCT01055691|DRUG|Metformin|metformin IR tablet 850 mg Oral Single dose
223417642|NCT01055691|DRUG|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
224033967|NCT04523766|BEHAVIORAL|Mindfulness of Breath|The Mindful Breathing intervention will be adapted from a validated, brief mindfulness training model. Participants will be instructed to focus on the sensations of the breath (i.e., at the tip of the nose and in the nostrils, abdomen and back) and, if a pain arises in the body, acknowledge it without judgement and return attention to the breath.
224033968|NCT04523766|BEHAVIORAL|Mindful Interoceptive Mapping|The MIM intervention will be adapted from the core MORE meditation practice. Participants will be instructed to (1) zoom in to deconstruct pain into its constituent affectively-valenced physical sensations and precisely map each sensation's spatial location, (2) zoom out to broaden the field of attention to include previously neglected sensory elements (i.e., spaces within the body that are absent of sensation and pleasant sensations), and (3) savor any pleasant sensations or experiences occurring during the mindfulness practice.
223417643|NCT01055691|DRUG|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
223417644|NCT01055691|DRUG|Metformin|metformin IR tablet 1000 mg Oral Single dose
223417645|NCT00322231|BIOLOGICAL|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
223417646|NCT00322231|BIOLOGICAL|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
223417647|NCT02965729|BEHAVIORAL|Family-based weight management|"The Our Lifestyles, Our Lives family-based weight management intervention consisted of 10 weekly 90-minute group sessions focused on physical activity, nutrition, and behavioral modification. Parents and siblings were encouraged to join the participant in these sessions. Sessions were interactive and included cooking demonstrations, light to moderate intensity physical activity that engaged all family members, and behavioral counseling sessions in both mixed (parent and child) and parent-only format."
223417648|NCT02965729|BEHAVIORAL|Pedometer|In addition to participating in the family-based weight management intervention, participants were given a pedometer (Omron HJ-324U, Omron Healthcare, Lake Forest, IL) and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10.
223417649|NCT02965729|BEHAVIORAL|Individualized step goals|In addition to participating in the family-based weight management intervention, participants were given a step goal to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
223739277|NCT07186192|OTHER|Standard of Care Arm (Enhanced usual care)|Patients and family caregivers that are randomized into the Standard of Care Arm ( Enhanced usual care) will receive standard CAR-T print materials only.
223417650|NCT01267565|OTHER|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
223417651|NCT00568230|DEVICE|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
223417652|NCT02425124|BEHAVIORAL|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
223417653|NCT00725361|DRUG|Ambrisentan|
223417654|NCT01726907|DEVICE|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
223417655|NCT01726907|DEVICE|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson \& Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
223417656|NCT02569151|DEVICE|HBP & CBP measurement using systo 130 mmHg|
223417657|NCT00998647|DEVICE|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
223417658|NCT00819845|DRUG|carvedilol|carvedilol vs ramipril
223417659|NCT00819845|DRUG|ramipril|carvedilol vs ramipril
223417660|NCT01832792|OTHER|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
223417661|NCT01832792|OTHER|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
223417662|NCT01832792|OTHER|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
223417663|NCT01037179|DRUG|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
223417664|NCT04574908|DEVICE|ViSi device|Mobile patient monitoring system for vital signs.
223417665|NCT02752061|OTHER|Potlako intervention|"Multicomponent intervention including:~* provider training on early detection and diagnostic approaches to cancer~* patient education on importance of obtaining timely cancer diagnosis~* provision of a patient navigator to facilitate diagnosis and entry into care~* provision of transportation support to vulnerable patients"
223561272|NCT02991794|DEVICE|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
223561273|NCT05295901|DEVICE|mKOAH application|mobile app installed group
223417666|NCT00877487|DRUG|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
223561274|NCT02958891|OTHER|Data collection|Collection epidemiological dental measures
223417667|NCT00877487|DRUG|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
223417668|NCT04846283|PROCEDURE|Elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure|We considered all the procedures that required an intestinal anastomosis in colo-rectal surgery
223417669|NCT05362877|DEVICE|Earplug|Using earplugs to reduce the symptoms of temporomandibular disorder
223417670|NCT05362877|DEVICE|occlusal splint|Using occlusal splints to reduce the symptoms of temporomandibular disorder
223417671|NCT05362877|OTHER|exercise|Applying exercise to reduce the symptoms of temporomandibular disorder
223417672|NCT01289860|DIETARY_SUPPLEMENT|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
223417673|NCT01289860|DIETARY_SUPPLEMENT|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
224033969|NCT01849484|RADIATION|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
224033970|NCT01849484|RADIATION|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
224033971|NCT04386187|OTHER|GSH Foods|The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
223561275|NCT05659407|DRUG|Belimumab in SLE patients / Rituximab in RA patients|Belimumab and Rituximab are the the investigated treatments, respectively in the SLE and RA group. They are administrated according to the approved indications and in compliance with the current recommendations and the good clinical practice, independently to the aim of the present observational study.
223561276|NCT01289353|DRUG|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
223561277|NCT01289353|RADIATION|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
223561278|NCT01549886|DRUG|Y-90-Zevalin|Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
223417674|NCT00016432|DRUG|exemestane|25 mg for 5 years
223417675|NCT00016432|DRUG|Placebo|Placebo
223417676|NCT04384042|OTHER|Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances|This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
223417677|NCT05072249|DRUG|Naloxone|Take Home Naloxone for reversing opioid overdose
223417678|NCT00151242|DRUG|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
223417679|NCT00151242|DRUG|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
223417680|NCT00151242|DRUG|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
223417681|NCT00151242|DRUG|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
223417682|NCT00151242|DRUG|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
223417683|NCT05664152|BIOLOGICAL|MG1111|BARYCELA inj.
223417684|NCT05972486|DEVICE|Muse-S™ headband system|Clinical grade, headband-style wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (a smartphone or tablet). The device is a soft, stretchy band that fits around the forehead to the back of the head.
223417685|NCT04266327|RADIATION|3D-printing Template-assisted CT-guided I-125 Seed Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seed implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume;Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc.Regular follow-up was conducted after treatment.
223561279|NCT01549886|DRUG|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m\^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily"
224033972|NCT04386187|OTHER|Nutrition education about glutathione sources in the diet|Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
224033973|NCT04386187|OTHER|Standard of care nutrition education for type 2 diabetes|The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
224033974|NCT04021251|DEVICE|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
224033975|NCT03099200|OTHER|No Intervention|
224033976|NCT01936142|DEVICE|Use of RenalGuard|
224033977|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
223417686|NCT02754427|BEHAVIORAL|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
224033978|NCT01220232|DRUG|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
224033979|NCT01220232|DRUG|Lersivirine|Lersivirine 750 mg QD for 10 days
224033980|NCT03707925|PROCEDURE|Cone-Beam Computed Tomography|Undergo CBCT
224033981|NCT03707925|PROCEDURE|Conventional Surgery|Undergo standard resection
224033982|NCT03707925|PROCEDURE|Laser Ablation|Undergo bronchoscopic laser ablation
223417687|NCT02754427|BEHAVIORAL|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
223417688|NCT00889876|DRUG|Metformin group|2000 mg/day for one year
223417689|NCT00889876|BEHAVIORAL|Exercise|3 times/week with a personal coach for one year. Endurance training.
223561280|NCT01549886|DRUG|Rituximab|Day 1 and Day 8: Rituximab 250 mg/m\^2 intravenous infusion
223561281|NCT04613557|BIOLOGICAL|CYAD-211|Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell
223561282|NCT04613557|DRUG|Endoxan|Preconditioning chemotherapy
223561283|NCT04613557|DRUG|Fludara|Preconditioning chemotherapy
223561284|NCT03199326|OTHER|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
223561285|NCT04049253|DRUG|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
224033983|NCT04888325|OTHER|Oral glucose|Oral glucose consumption (1.25 grams/kg in 200 ml water at time 0 and the same amount again at 3 hours). During the 6-hour observation period infusion of normal saline (NaCL 0,9%) at a rate of 0.83 plus Heparin, 800 IU/h with a priming dose of 1000 IU.
224033984|NCT04888325|OTHER|Intravenous glucose|10% intravenous glucose infusion at a rate of 3.6 ml/kg/h plus Heparin 800 IU/h with a priming dose of 1000 IU will be administrated for 6 hours. Consumption of 300 ml of water at 0 and 3 hours
224033985|NCT05089136|DEVICE|transcatheter paravalvular leak closure|Transcatheter paravalvular leak closure (PVLc) was first described in 1992 and has since then emerged as an attractive alternative to repeat surgery. Many implantable devices that can be used for transcatheter PVLc have been marketed, although few are specifically designed for this purpose. It consist in implanting an occluder in the paravalvular leak to stop or reduce the regurgitant flow.
224033986|NCT00797498|OTHER|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
224033987|NCT02457312|DRUG|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
223417690|NCT03512444|DEVICE|Negative Pressure System|Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
223417691|NCT06085469|BEHAVIORAL|Temporal Adaptation Approach|the temporal adaptation: It includes giving importance to the use of time, choosing meaningful activities, adjusting the time used during these activities and improving it. Such adaptation serves to improve an individual's quality of life, health, and occupational participation.
223417692|NCT03973879|BIOLOGICAL|PVSRIPO|Oncolytic polio/rhinovirus recombinant
223417693|NCT03973879|DRUG|Atezolizumab|Antibody
223417694|NCT04781608|BEHAVIORAL|English: In It Together (IIT)|Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
223417695|NCT05908721|BIOLOGICAL|CM310|IL-4Rα monoclonal antibody
223417696|NCT00199238|DRUG|Rupatadine Fumarate|
223417697|NCT00712543|DRUG|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
223417698|NCT00712543|DRUG|liquid lactulose|Liquid to be taken as prescribed.
223417699|NCT00235885|DRUG|adalimumab|
223417700|NCT05953688|DRUG|ESK-001|Oral tablet
223417701|NCT05198037|DEVICE|Bihemispheric tDCS|The anode and cathode are placed over the ipsilesional and contralesional primary motor cortex (C3 or C4 based on 10-20 system), respectively. The size of the electrode is 5x5 cm.
223417702|NCT06238687|BIOLOGICAL|STRO-002|STRO-002 is an Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the anti-tumor activity of cytotoxic drugs.
223417703|NCT04043533|BEHAVIORAL|Exercises|The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
223417704|NCT02083432|BEHAVIORAL|5 session of CBT performed by specially trained dentists|"A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV)."
223417705|NCT00389532|BIOLOGICAL|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
224033988|NCT02457312|DRUG|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
224033989|NCT05204693|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
224033990|NCT05204693|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
224033991|NCT02957721|OTHER|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
224033992|NCT04345835|PROCEDURE|Percutanous nephrolithotomy (PCNL)|different procedure positioning
224033993|NCT03782142|DRUG|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
224033994|NCT03782142|DRUG|Rilpivirine|NNRTI
223417706|NCT00389532|BIOLOGICAL|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
223417707|NCT06363370|DRUG|Human interferon α1b Inhalation Solution|Participants will receive Human interferon α1b Inhalation Solution
223417708|NCT06363370|DRUG|Inhalation Solution Placebo|Participants will receive Inhalation Solution Placebo
223417709|NCT03439761|DRUG|PT-112 Injection|PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
223417710|NCT06128928|BEHAVIORAL|REDES|Training on motivational interviewing (MI) led by community health workers on how to use MI to address vaccine hesitancy using a guiding approach, open-ended questions, affirmations, reflections, and summaries.
223417711|NCT06128928|BEHAVIORAL|Control|Brief CHW-led training about the safety and efficacy of the COVID-19 vaccine. Participants will have the opportunity to ask clarifying questions from the CHWs during the training.
223561286|NCT05049707|DRUG|IV magnesium sulfate|15 grams magnesium in 500 cc normal saline delivered at a rate of 15 mg/kg/hr
223561287|NCT05049707|OTHER|Placebo|500 cc normal saline delivered in equivalent rates as the treatment group
224033995|NCT03782142|DRUG|Prezcobix|PI
224033996|NCT03782142|DRUG|Dolutegravir|II
224033997|NCT06227663|BEHAVIORAL|KOALOU(®) digital application|Digital app that prepares children for the ambulatory surgery care pathway by assessing their anxiety and educating them about anesthesia and surgery
224033998|NCT03431857|DEVICE|TESS V2|Patients requiring the TESS V2 prosthesis.
224033999|NCT03099005|DRUG|Cannabis|vaporization of cannabis
223417712|NCT02729051|DRUG|FF/UMEC/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
223561288|NCT01628679|BEHAVIORAL|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
223561289|NCT06004895|DEVICE|Actual IPL|Five light pulses along lower lid region of one eye of the participant ranging from 59 to 69 Joules (J) over an area of 2.5cm by 4.5cm for each pulse
223561290|NCT06004895|DEVICE|Sham IPL|Simulated five light pulses along lower lid region of the other eye of the same participant
223561291|NCT06004895|DEVICE|LLLT|Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed
223561292|NCT03946774|DIETARY_SUPPLEMENT|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
223739278|NCT07195045|DIAGNOSTIC_TEST|Thai PainPREDICT Questionnaire and Mobile Application|The Thai PainPREDICT Questionnaire is a culturally adapted and validated version of an internationally recognized neuropathic pain assessment tool. In this study, it is administered via both paper form and a secure mobile application designed for Thai patients with diabetes. The app automates scoring, provides real-time feedback, and securely stores data in REDCap in compliance with Thai Personal Data Protection Act (PDPA). The intervention is used to screen for painful diabetic neuropathy and compare results against clinical diagnosis and neurophysiological testing, including DN4, nerve conduction studies, and quantitative sensory testing.
223739279|NCT07192237|DRUG|Blinatumomab|Given by IV
224034000|NCT05809817|PROCEDURE|Periodontal treatment|Scaling and root planing
224034001|NCT04195958|DRUG|Omalizumab|Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.
224034002|NCT01088100|GENETIC|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
224034003|NCT05121363|DRUG|TQB2858 injection|TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein
224137009|NCT03670641|DRUG|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
223417713|NCT02729051|DRUG|FF/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
223417714|NCT02729051|DRUG|UMEC|This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
224034004|NCT05121363|DRUG|Anlotinib Hydrochloride capsules|Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
224034005|NCT00818181|DRUG|Biological: AL0206st|
224034006|NCT01208090|DRUG|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
224034007|NCT01208090|DRUG|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
224034008|NCT00651157|BIOLOGICAL|wild-type reovirus|Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
224137010|NCT03670641|DRUG|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
223417715|NCT02729051|DRUG|Placebo|This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
223417716|NCT02729051|DRUG|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
223417717|NCT01134445|DEVICE|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
223417718|NCT04790461|OTHER|Pre-post test|Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
223417719|NCT04790461|BEHAVIORAL|face-to-face training + PMR exercise|4 weeks Roy adaptation-based face-to-face training + PMR exercises to be taught, 4 weeks exercise counseling
223417720|NCT04790461|BEHAVIORAL|mobile health education + PMR exercise|To provide awareness and exercise with 8 weeks Roy adaptation model-based training and mobile application access with PMR exercise content
223417721|NCT04790461|BEHAVIORAL|face-to-face and mobile health education + PMR exercise|4 weeks face-to-face training based on Roy adaptation model + teaching PMR exercises and 4 weeks based training on Roy adaptation model and mobile application access with PMR exercise content
223417722|NCT03686228|PROCEDURE|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
223417723|NCT03686228|DRUG|No-PB-MNC therapy|Patients will receive ASA 81 mg once daily and wound care and pain killer drug
223417724|NCT02702388|DRUG|Lenvatinib|Lenvatinib capsule.
223417725|NCT02702388|DRUG|Lenvatinib matching placebo|Lenvatinib matching placebo capsule.
223417726|NCT04496193|PROCEDURE|Quadratus Lumborum block|Quadratus Lumborum block is a type of plane block where local anesthetic is injected adjacent to the quadratus lumborum muscle with the goal of anesthetizing the thoracolumbar nerves.
223417727|NCT01496378|BEHAVIORAL|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
223417728|NCT06558383|OTHER|augmented posterior oblique sling activation|activation of posterior oblique sling for 18 sessions, three sessions per week for six weeks
223417729|NCT06558383|OTHER|selected physical therapy program|selected physical therapy program for 18 sessions, three sessions per week for six weeks in form hot packs, soft tissue techniques, mobilization and manipulation of lumbar spine, and neurodynamics and stabilization exercises
223417730|NCT00530127|DRUG|placebo|Same dose and frequency as treatment
223417731|NCT00530127|DRUG|deferiprone|100 mg/mL
223417732|NCT00530127|DRUG|deferiprone|100 mg/mL
223417733|NCT00530127|DRUG|placebo|Same dosage and frequency as study drug
223417734|NCT00530127|DRUG|deferiprone|100 mg/mL
223417735|NCT02128373|PROCEDURE|Usual care|Health care provided by physician, physician's nurse, and social worker
223561293|NCT06468605|BIOLOGICAL|JCXH-211|JCXH-211 is a lipid nanoparticle (LNP) encapsulated srRNA, encoding the human IL-12 protein.
223561294|NCT04522882|DEVICE|Actimetry|Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
223417736|NCT02128373|OTHER|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
223417737|NCT02128373|OTHER|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
223417738|NCT02128373|OTHER|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
223417739|NCT02128373|OTHER|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
223417740|NCT02128373|OTHER|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
223417741|NCT04674280|PROCEDURE|aHSCT|Autologous haematopoietic stem cell transplantation
223417742|NCT05127876|DRUG|Ondansetron 4 MG|Ondansetron 4mg was given over 1 min, 5 min before spinal anesthesia
223417743|NCT05127876|DRUG|Ondansetron 8mg|Ondansetron 8mg was given over 1 min, 5 min before spinal anesthesia
223417744|NCT05127876|DRUG|EPHEDrine 10 Mg/mL-NaCl 0.9% Intravenous Solution|Ephedrine 10mg was given over 1 min, 5 min before spinal anesthesia
223417745|NCT05127876|OTHER|10 mL normal saline|10 mL normal salinwe 0.9% was given over 1 min, 5 min before spinal anesthesia
223417746|NCT03231202|PROCEDURE|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist."
223417747|NCT03687684|DRUG|TAK-831|TAK-831 Tablets.
223417748|NCT03687684|DRUG|Placebo|TAK-831 Matching Placebo Tablets.
223417749|NCT00802984|DEVICE|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
223417750|NCT05386017|OTHER|Anthropometric measurements and sociodemographic and health data collection|"Anthropometric measurements : weight, height, abdominal circumference, abdominal circumference, percentage of fat mass, percentage of lean body mass, and estimated visceral fat level, visceral fat.~Sociodemographic and health data collection : Collect over a 7-year period changes in physical activity practices, eating habits and behaviours and the motivations for these changes or the initiatives to change the weight, Perceived stress and control, Life courses, events and impact perception Status, level of education, social background, place of residence, relationship with family Diet, tobacco and alcohol consumptions Physical activity behaviour and barriers, sedentary behaviour, quality of life perceived, exploring possible behavioural eating disorders, anxiety, depression"
223739280|NCT07193927|DIETARY_SUPPLEMENT|Lactiplantibacillus plantarum Probiotic Mixture|A daily oral probiotic capsule containing three specific strains of Lactiplantibacillus plantarum (KABP011, KABP012, KABP013) 1,2 billion CFU with vitamin B1, designed to modulate gut microbiota and improve liver health in MASLD patients. It is compared to a placebo in a 6-month, double-blind, mechanistic trial.
223561295|NCT04522882|OTHER|Questionnaires|Patients will complete food and medication intake questionnaires for 7 days.
223739281|NCT07193927|DIETARY_SUPPLEMENT|Placebo comparator containing maltodextrin|Placebo comparator containing maltodextrin
223739282|NCT07197749|DRUG|Vitamin C (Ascorbic Acid)|"All patients enrolled on this trial will receive steroids at a minimum dose of prednisone 2 mg/kg/day PO (or methylprednisolone 1.6 mg/kg/day IV) divided into 1-2 daily doses as therapy for acute GVHD. For patients that weigh over 100 kg, maximal starting dose of prednisone will be 200 mg (or methylprednisolone-equivalent).~Patients will be treated with intravenous (IV) or oral (PO) vitamin C depending on the severity of symptoms, ability to tolerate PO intake, and location of treatment (inpatient versus outpatient setting): IV dosing:~50 mg/kg/day divided TID (max 4 grams total/day) PO dosing: 500 mg BID or 1000 mg daily (depending on the prescribed formulation)~Vitamin C will be administered through day 56 from start of vitamin C treatment. Patients initially receiving IV administration may be transitioned to PO formulation once tolerating PO intake; per treating physician discretion."
223739283|NCT07199647|OTHER|Questionnaire Administration|Participants completed a sociodemographic questionnaire, the Hospital Anxiety and Depression Scale, the Pain Beliefs Questionnaire, the Complementary, Alternative, and Conventional Medicine Attitude Scale, the Complementary and Alternative Medicine Health Belief Scale, and the Three-Factor Spiritual Well-Being Scale.
223561296|NCT04522882|OTHER|Glucose level and insulin administration|Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
223561297|NCT05875207|BEHAVIORAL|Mindfulness based practice|Physical therapists who are randomized to this arm will receive mindfulness training. This training will teach physical therapists to use the following with their patients: 1) use mindfulness to strengthen self-regulation of habitual and compulsive opioid use, and to mitigate pain by reinterpreting these experiences as innocuous sensory information, 2) use reappraisal to reframe stressors and maladaptive thoughts to decrease negative emotions and engender meaning in life, 3) use savoring of pleasant events and pleasurable sensations to enhance positive emotions and reward and, 4) to integrate mindfulness, reappraisal and savoring with evidence-based physical therapy.
223561298|NCT05875207|BEHAVIORAL|Control/Standard Physical Therapy|Physical therapists randomized to this arm will receive no additional training and will provide standard care to patients with chronic musculoskeletal pain and long-term opioid treatment. Patients with chronic musculoskeletal pain and long-term opioid treatment who seek care from a physical therapist in this arm will be approached to participate in the study. If eligible and willing to participate in the study they will be asked questions about their pain and opioid use before and after treatment. We plan on enrolling 2 patients for each physical therapist.
223561299|NCT00100568|DRUG|Efavirenz|600 mg tablet taken orally daily
224137011|NCT03670641|DEVICE|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
224034009|NCT00666809|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
224034010|NCT00666809|DRUG|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
224034011|NCT05440266|DIAGNOSTIC_TEST|Study Intervention: 25 ms half-sine wave stimulation|Part I: Threshold detection and Flare response: 6 pulses of 25 ms half-sine are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 25 ms half-sine is administered continuously.
224034012|NCT05440266|DIAGNOSTIC_TEST|Control Intervention: 500 µs rectangular shaped stimulation|Part I: Threshold detection and Flare response: 6 pulses of 500 µs rectangular shaped stimulation are given at 2 Hz each, increasing current intensity (mA) until detection threshold, pain threshold and pain level (3 out of 10 NRS) are reached. Determined intensity values reapplied during 214 impulses. Line scan to visualize changes in local skin blood flow done. Part II: Hyperalgesia, Allodynia, Pain and flare response of 65 minutes. Baseline assessment of local skin perfusion and spatial extent of allodynia by using cotton swab and pinprick hyperalgesia. Current intensity is reapplied, adjusted until pain level of 6 reached. After 5 minutes axon reflex flare, allodynia and secondary hyperalgesia are measured and repeated proximal every 10 minutes with last measurement after 65 minutes. In first 15 minutes current intensity is adapted to maintain NRS level of 6. During this 65 minutes' period, 500 µs rectangular shaped stimulation is administered continuously.
224034013|NCT03501186|OTHER|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
224137012|NCT03010995|DRUG|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
224137013|NCT03246217|BEHAVIORAL|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
224137014|NCT03246217|BEHAVIORAL|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
223561300|NCT00100568|DRUG|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
223739284|NCT07199088|OTHER|Acetazolamide|A carbonic anhydrase inhibitor, 500 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients.
223739285|NCT07199088|OTHER|Metolazone|A thiazide-like diuretic, 5 mg orally once a day as an adjunct to loop diuretics for enhancing diuresis and improving decongestion in ADHF patients.
224137015|NCT03246217|BEHAVIORAL|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
224137016|NCT04331873|DIAGNOSTIC_TEST|Ultrasound|An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
224137017|NCT00347555|BIOLOGICAL|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
224137018|NCT00347555|DRUG|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
223417754|NCT00823147|BEHAVIORAL|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
223417755|NCT05620498|DRUG|tislelizumab+lenvatinib+GMOX|tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2
223417756|NCT05620498|DRUG|tislelizumab+GEMOX|tislelizumab+GEMOX
223417757|NCT02118727|DRUG|Memantine|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
223417758|NCT02118727|DRUG|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
223417759|NCT00577980|DRUG|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
224034014|NCT01721603|DRUG|Dabrafenib|150 mg capsule by mouth twice daily
223417760|NCT01497912|DRUG|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
223739286|NCT07199387|OTHER|App Users (Structured Implementation)|The structured implementation (intervention) group will follow a structured protocol designed to promote weekly app engagement. This includes regular updates to customized content, reminders to use the app, and feedback on use. Weekly content updates and push notifications will be provided through the app, and the research team will communicate monthly with organizational champions with feedback reports on app utilization to reinforce engagement.
224034015|NCT01721603|PROCEDURE|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
224034016|NCT01721603|DRUG|Trametinib|2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
224034017|NCT00290108|DRUG|Propofol|
224137019|NCT00347555|BIOLOGICAL|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
224034018|NCT05033418|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|4-session CBT-I group in addition to IPRP
224034019|NCT05033418|BEHAVIORAL|Interdisciplinary Pain Rehabilitation Program (IPRP)|10-week IPRP usual care
224034020|NCT04191044|OTHER|A complete cardiovascular and liver characterization will be carried out|A complete cardiovascular and liver characterization will be carried out, including some supplementary tests with minimal risks (e.g. hemodynamic study). If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
224137020|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water"
223417761|NCT01497912|DRUG|Placebo|Placebo tablet once daily for 8 weeks
223417762|NCT05010252|BEHAVIORAL|Cycled light Experimental|The preliminary plan of this study is to carry out empirical evidence and expert advice to confirm precise lighting and develop care intervention strategies for preterm infants based on evidence. It is planned to be in the Neonatal Intermediate Care Nursery, National Taiwan University Children's Hospital, and the subjects are premature babies born 32 weeks old. Divided into two groups of light intervention group and control group, longitudinal tracking intervention effect and six-weeks and three-months delay effect.
223417763|NCT02737943|DRUG|Moist Exposed Burn Ointment (MEBO)|is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
223417764|NCT02737943|DRUG|Zagazig|Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
223417765|NCT05515211|DIAGNOSTIC_TEST|Foot length|Foot length will be measured from the midpoint of the heel to the longest toe.
223739287|NCT07199387|OTHER|App Users (Standard Implementation)|The standard implementation (control) group will receive baseline support, allowing firefighters to use the app as they choose. The research team will provide an initial orientation for organizations and peer supporters, but the organizational champion will be responsible for communication and follow-up. The research team will respond to questions and prompt data collection.
223739288|NCT07199556|DIETARY_SUPPLEMENT|Food supplement|Tenflex® is an authorized food supplement.
224034021|NCT04657757|OTHER|Intraoral apparatus|Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
224034022|NCT02472080|DRUG|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
224034023|NCT00593801|DRUG|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
224034024|NCT00593801|DRUG|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
224137021|NCT04671316|DRUG|DA-5209 60mg Tab|"single oral administration of 1 tablet of DA-5209 60mg Tab without water"
223417766|NCT00449137|DRUG|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
223417767|NCT00449137|DRUG|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
223417768|NCT00449137|DRUG|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
223417769|NCT00449137|OTHER|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
223417770|NCT00449137|GENETIC|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
223417771|NCT00449137|PROCEDURE|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
223417772|NCT03533361|DRUG|Lenvatinib|Oral capsules: 4 milligrams (mg) and 10 mg
223417773|NCT00164528|BEHAVIORAL|Positive Behavior Support|
224034025|NCT04508634|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
224034026|NCT04508634|DRUG|Metformin Pill|Metformin 1000mg bid
224034027|NCT01104142|DEVICE|CGM|Continuous Glucose Monitoring System
224034028|NCT04441112|DRUG|Ketorolac Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
224034029|NCT04441112|DRUG|Triamcinolone Intraarticular Injection|Injections will be given under ultrasound guidance with one of two possible medications.
224034030|NCT02884765|PROCEDURE|Non-surgical|Non-surgical treatment in both condylar fractures
224034031|NCT02884765|PROCEDURE|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
224034032|NCT02884765|PROCEDURE|Surgical|Surgical treatment in both condylar fractures
224034033|NCT02779738|DRUG|Merestinib|Administered orally
224034034|NCT00723879|BIOLOGICAL|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
224137022|NCT04671316|DRUG|Lixiana 60mg Tab|"single oral administration of 1 tablet of Lixiana 60mg Tab with 150mL water"
223417774|NCT01045577|DRUG|Masitinib|6 mg/kg/day
224034035|NCT00723879|DRUG|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
224034036|NCT00723879|BEHAVIORAL|Patient assistance program|"Patient assistance programs will be classified as follows:~1. medications, including psychiatric medications (antidepressants);~2. other interventions, including nurse telephone calls and nurse support in the office: and~3. educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
223417775|NCT01045577|DRUG|Masitinib|3 mg/kg/day
223417776|NCT01045577|DRUG|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
223417777|NCT05903105|OTHER|Questionnaires|Patients fill in a questionnaire
223417778|NCT06302153|PROCEDURE|Progressive Loading Exercises|At start of study, a formal educational session, lasting about 30 minutes will be given by the physiotherapist dealing with the treatment/interventions. Whole treatment plan will be given for six weeks. Pre and post intervention measurements will be taken.
223417779|NCT02519998|OTHER|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
223417780|NCT04088695|OTHER|Video through a web page|Participants will see a video about blood donation.
223417781|NCT04088695|OTHER|Informative text|Participants will see a brief text about blood donation.
223417782|NCT04740827|DRUG|Atogepant 60 mg|Atogepant tablets.
223417783|NCT04740827|DRUG|Placebo|Atogepant matching placebo tablets.
223417784|NCT00831298|OTHER|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
223417785|NCT06664996|RADIATION|stereotactic body radiation therapy (SBRT)|SBRT will be administered on days 1, 3, and 5 at a dose of 8 Gy per fraction, totaling 3 fractions.
223417786|NCT06664996|DRUG|Sintilimab (approved)|patients will receive a first dose of sintilimab at 200 mg on day 1, followed by a second dose of 200 mg on day 22 (week 4, ±3 days).
223417787|NCT03691051|DRUG|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
224034037|NCT01168739|DIETARY_SUPPLEMENT|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
224034038|NCT01168739|DIETARY_SUPPLEMENT|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
224034039|NCT02422485|DRUG|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
224034040|NCT01163721|DRUG|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
224034041|NCT01163721|DRUG|Placebo|Placebo to match ranolazine administered orally twice daily
224137023|NCT03759457|DEVICE|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
224137024|NCT01319643|DRUG|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
223561301|NCT05592327|PROCEDURE|Citric acid abutment|The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
223739289|NCT07199608|PROCEDURE|subcision|patients will undergo subcision procedure alone using 18 gauge blunt cannula to release fibrous bands under atrophic acne scars.this group will serve as control comparator
223417788|NCT02380833|BEHAVIORAL|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
223417789|NCT02380833|BEHAVIORAL|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
223417790|NCT02380833|BEHAVIORAL|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
223417791|NCT02380833|BEHAVIORAL|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
223417792|NCT00065754|DRUG|placebo|
223417793|NCT06577064|PROCEDURE|Sacral erector spinae plane block|30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side
223417794|NCT00003571|GENETIC|mutation analysis|
223417795|NCT00003571|GENETIC|tumor replication error analysis|
223417796|NCT06024798|DIAGNOSTIC_TEST|Photon-Counting-Computed-Tomography|Initial and follow up (after 4 weeks) PCCT acquisition of the affected area of the lower extremity. Image acquisition will be performed on the PCCT
223417797|NCT04710784|BEHAVIORAL|Sexual health information|We will provide participants with sexual health information, that is basic, accurate, and directly contributes to health-promoting decisions and behavior, once a week at the beginning of the study.
223417798|NCT04710784|BEHAVIORAL|I-TEST branded HIVST package|The I-TEST branded HIVST package will include HIV self-testing (HIVST) kits, referral coupons, condoms, female or male hygiene products, and instructions on how to use the I-TEST photo verification App or USSD (Unstructured Supplementary Service Data) system to verify the HIVST results. Study participants will be referred to a youth-friendly health clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment and PrEP referral.
223417799|NCT04710784|OTHER|Follow-up testing and clinic assessments|Information to encourage routine retesting for HIV every 6 months and linkage to the youth-friendly clinic for confirmatory HIV testing, STI testing (syphilis, gonorrhea, chlamydia, and hepatitis B), STI treatment, and PrEP referral. Additionally, follow-up surveys will be administered to assess HIV testing, sexual behavior history, youth participation experience, and other related outcomes will be collected from enrolled participants.
223417800|NCT04610567|DRUG|Methotrexate-LDE phase 1|"3 patients will receive MTX-LDE at the dose of 15mg IV each 7 days during hospitalization, up to 3 times . After that, 9 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times .~All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE"
223739290|NCT07199608|PROCEDURE|subcision+fractional co2 laser|patients will undergo subcision procedure followed by fractional co2 laser applied to right side of face, the left side will receive subcision alone
223739291|NCT07199608|BIOLOGICAL|subcision+PRP|patients will undergo subcision procedure followed by intradermal injection of autologous PRP prepared from patients blood on right side.left side will receive subcision alone
223739292|NCT06525506|BIOLOGICAL|IBI311 (20 mg)|Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.
223739293|NCT06525506|BIOLOGICAL|IBI311 (3-20 mg)|Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.
224034042|NCT03975023|DEVICE|NeuroCatch Platform (NCP)|The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
224034043|NCT01369901|BEHAVIORAL|A functional exercise program|
224034044|NCT01369901|BEHAVIORAL|A stretching exercise program|
224034045|NCT00413296|DRUG|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
223417801|NCT04610567|DRUG|Methotrexate-LDE phase 2|44 patients will receive MTX-LDE at the dose of 30mg IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of MTX-LDE
224034046|NCT00413296|DRUG|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
223417802|NCT04610567|DRUG|Placebo-LDE phase 2|44 patients will receive Placebo-LDE IV each 7 days during hospitalization, up to 3 times dose of 30mg IV each 7 days during hospitalization, up to 3 times . All patients will receive Leucovorin (calcium foliate) 25mg IV, 24hr after administration of Placebo-LDE
223417803|NCT05331755|DRUG|Dupilumab|start medication in cohort
223417804|NCT02060058|DRUG|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
223739294|NCT06525506|BIOLOGICAL|IBI311 (10 mg)|Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.
224034047|NCT00413296|DRUG|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
223561302|NCT02594930|PROCEDURE|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
223561303|NCT06115473|DRUG|epinephrine|patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.
223561304|NCT06115473|DRUG|isotonic fluid|patients will receive IV bolus isotonic fluid 500 ml
223739295|NCT06525506|BIOLOGICAL|IBI311 (3-10mg/kg)|Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
223739296|NCT02481245|DRUG|Bezafibrate|30 patients with Bipolar I or Bipolar II disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
224034048|NCT04300582|PROCEDURE|Cardiac catheterization standard strategy|Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients
224034049|NCT04300582|PROCEDURE|Cardiac catheterization fast strategy|Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients
224034050|NCT05871866|PROCEDURE|"minimally invasive internal fixation device infix"|An INFIX involves the insertion of spinal pedicle screws in the anterior pelvis (supra-acetabular entry) and the placement of a connecting rod in the subcutaneous tissue of the patient
223739297|NCT07205471|PROCEDURE|Laparoscopic Partial Splenectomy|The laparoscopic partial splenectomy technique involved preserving the short gastric vessels and the splenic suspensory ligament, with resection conducted along the demarcation line.
223739298|NCT07205029|COMBINATION_PRODUCT|Experimental: Nutritional and Virtual reality intervention|Over a 6-month period, the experimental group received nutritional recommendations based on the Mediterranean Diet from the nutritionist. In each session, the participant went through the 4D body modelling machine, which captures the morphological changes of each participant over time. The experimental group observed the changes in their bodies through immersive virtual reality goggles. After visualising their bodies, all participants in the experimental group completed a questionnaire designed to assess their perception of body image. Personal and sociodemographic data, clinical information, general health status, anthropometric, nutritional, and lifestyle data, as well as psychological and neuropsychological variables, were collected at two time points: at the beginning (pre-test measures) and at the end of the intervention (post-test measures).
224034051|NCT00225576|OTHER|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
224034052|NCT01786239|DRUG|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
224034053|NCT01786239|DRUG|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
224137025|NCT03018626|DRUG|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
223561305|NCT04424823|PROCEDURE|LED photobiomodulation|Patients were submitted to photobiomodulation therapy with wavelengths of both 630-nm and 850-nm for RED and near-infrared LEDs, with power density set to 8.5 mW/cm2 and 12.5 mW/cm2, respectively. The LED device (name of device, Applied BioPhotonics) was designed in Silicon Valley, United States, and was approved by the United States Food and Drug Administration for the treatment of minor muscle and joint pain. LED therapy was applied by placing the device on the skin at a 90° angle. Both groups underwent six times therapy sessions (i.e., three times a week for 2 weeks), and during the therapy, only the researcher in charge of programming the LED device was aware of the treatment employed; the programmer did not participate in the execution of the treatments, evaluations, or data analysis.
223561306|NCT01935323|OTHER|High Intensity Interval Training|
224034054|NCT01786239|DRUG|Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
224034055|NCT01472380|DRUG|efavirenz|600 mg
224034056|NCT01472380|DRUG|fenofibric acid 105 mg|fenofibric acid 105 mg
224034057|NCT02511678|DEVICE|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
224034058|NCT06312280|BEHAVIORAL|Mediterranean diet|The composition of the diet will be distributed as follows: 55-60% of carbohydrates (45-50% complex carbohydrates and no more than 10% of simple sugars), 25-30% of lipids and 15% of proteins. It will be studied in accordance with the LARN (Italian Society of Human Nutrition, 2014) guidelines.
224034059|NCT01295281|DEVICE|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
224034060|NCT01295281|DEVICE|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
224034061|NCT00292461|DRUG|Zonisamide|Tablet once or twice daily orally for 16 weeks
224034062|NCT00292461|DRUG|Lamotrigine|Tablet once daily orally for 16 weeks
224034063|NCT02496910|DRUG|YH22162|
224034064|NCT02496910|DRUG|Telmisartan/Amlodipine 80/5 mg (FDC)|
223561307|NCT01935323|OTHER|Moderate Intensity Training|
224034065|NCT02496910|DRUG|Chlorthalidone 25mg|
224034066|NCT06071910|DEVICE|ER-REBOA catheter|To achieve rapid aortic occlusion
224034067|NCT00420602|DIETARY_SUPPLEMENT|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
224034068|NCT04110119|DRUG|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
224034069|NCT04110119|OTHER|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
224034070|NCT00680823|DRUG|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
224034071|NCT00680823|DRUG|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
224034072|NCT05576467|BEHAVIORAL|MBCT-Telephone|Classes follow MBCT protocol delivered via telephone by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
224034073|NCT05576467|BEHAVIORAL|MBCT-Video|Classes follow MBCT protocol delivered via video by a master's level or higher mental health provider under the supervision of a licensed clinical psychologist, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.
224034074|NCT05576467|BEHAVIORAL|Enhanced Usual Care (EUC)|Weekly online modules follow migraine and behavior principles delivered via web portal developed by a team of licensed clinical psychologists, neurologists, and mental health providers.
224034075|NCT02414724|DRUG|Gemcitabine Hydrochloride|Given IV
223417805|NCT02737254|DRUG|Oxytocin|40 IU/ML nasal spray. One administration: children \<40kg administer 12IU, children \>40kg administer 24IU.
223417806|NCT02737254|DRUG|Placebo|NaCl 0,9 % nasal spray.
223417807|NCT02737254|OTHER|Secure CBM training|Children are trained to interpret ambiguous maternal behavior in a secure way.
223417808|NCT02737254|OTHER|Neutral CBM training|Children receive a training unrelated to the interpretation of maternal behavior.
223417809|NCT02772770|OTHER|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
223417810|NCT02772770|PROCEDURE|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
223417811|NCT02772770|PROCEDURE|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
223417812|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
223417813|NCT02772770|PROCEDURE|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
223417814|NCT06160492|DRUG|5-aminolevulinic acid|Patients were randomly assigned to 5-aminolevulinic acid (20 mg/kg bodyweight）Those randomly allocated to 5-aminolevulinic acid were scheduled to receive freshly prepared solutions of 5-aminolevulinic acid orally 3 h (range 2-4) before induction of anaesthesia. Solutions were prepared by dissolving the contents of a vial (1·5 g) in 50 mL of drinking water.
223417815|NCT05731947|DRUG|Revumenib|Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
224034076|NCT02414724|OTHER|Laboratory Biomarker Analysis|Correlative studies
224034077|NCT02414724|OTHER|Pharmacological Study|Correlative studies
224034078|NCT02414724|DRUG|Ribociclib|Given PO
223417816|NCT05731947|DRUG|Chemotherapy|Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
223561308|NCT05306834|PROCEDURE|Retinal Imaging|Auto-Refractometry / Adaptative Optics (OA) / Swept Source Optical Coherence Tomography (SS-OCT-A) / Globe Axial length measurements / Color Retinophotography of the retina.
223561309|NCT05306834|GENETIC|Blood sample|Analyses of molecular biomarkers including
223561310|NCT05306834|PROCEDURE|Evaluation of cardiovascular risks|Measurement of blood pressure and arterial stiffness
223561311|NCT05306834|PROCEDURE|Brain imaging (MRI)|3DT1 / 3DFLAIR / T2GRE / DTI 15 directions (and B0MAP)
223561312|NCT05306834|OTHER|Cognitive Tests|Mini Mental State Examination (MMSE) / Montreal Cognitive Assessment (MoCA) / 16 items Free and Cued Recall (RL/RI 16 items) / Trail Making Test A et B (TMT A et B) / Frontal Assessment Battery (FAB) / Phonemic (letter P) and semantic (animals) verbal fluency tests / Digit Symbol Substitution Test (DSST)
223561313|NCT05306834|OTHER|Geriatric Depression Scale (GDS)|15 items
223561314|NCT05306834|OTHER|Instrumental Activities of Daily Living (IADL)|Instrumental Activities of Daily Living (IADL)
223561315|NCT05306834|DIAGNOSTIC_TEST|Unipodal standing test|Unipodal standing test
224034079|NCT05484050|OTHER|Immunohistochemistry analysis|Estimation of VEGF through Immunohistochemistry
224034080|NCT04398641|OTHER|Evaluation of pre- and postoperative gastrointestinal functional outcomes|Gastrointestinal functional outcomes will be evaluated using the LARS and the GIQLI by Eypasch questionnaires.
224034081|NCT00892619|PROCEDURE|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
224034082|NCT00892619|PROCEDURE|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
224034083|NCT04894162|OTHER|Questionnaire|Consecutive, eligible inpatients in a participating specialist palliative care unit will be invited to participate in the research: those who wish to participate will complete a research questionnaire about research preferences.
224034084|NCT06502106|BEHAVIORAL|Condensed Internet delivered prolonged exposure (CIPE)|Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
224034085|NCT05497648|BEHAVIORAL|Choose to Move|"CTM (phase 3) is a 6-month, flexible, evidence- and choice-based program for low active older adults.~CTM includes~* One-on-One Consultation Participants meet 1-on-1 with their activity coach at the start of the program to set goals and develop an action plan tailored to their abilities, interests and resources. Older adults can choose to participate in individual or group-based activities.~* Group Meetings Over the first three months, participants will attend five, 1-hour group-based meetings (up to 12 participants total) led by their activity coach. Meetings cover a discussion topic and provide time and space for social connection between participants.~* Check-ins Over the six month program, activity coaches will provide six brief telephone check-ins (approximately 15 minutes each and once/month) to discuss their Action Plan and ask questions."
224034086|NCT03536390|DRUG|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
224034087|NCT03536390|DRUG|Placebo|Placebo
224034088|NCT04850157|DRUG|Tislelizumab|200mg, Q3W
224034089|NCT04850157|RADIATION|IMRT|4 Gy\* 5 Fx,5Fx/Week
224034090|NCT05625412|DRUG|BMS-986360|Specified dose on specified days
223417817|NCT03459885|DEVICE|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
223417818|NCT05261477|BEHAVIORAL|Bilingual Brain Injury Education and outpatient Navigation for Hispanic families|1st BIEN was informed by Hispanic parents and clinical providers working with them. It considers their specific needs including lack of familiarity with shared decision models and of knowledge about patient rights and eligibility for community and school services. Based on principles of Social Cognitive Theory, 1st BIEN provides TBI education, teaches problem-solving skills to promote self-efficacy and advocacy; and provides outpatient navigation that allows for observational and experiential learning while supporting access to services in a timely manner. Central to the development of our intervention is the recognition of heterogeneity in individuals' level of readiness to adopt a health behavior according to their level of self-efficacy, expectations, and environment. The 1stBIEN intervention flexibly reduces barriers to access care, and simultaneously improves parental knowledge, health literacy, and self-efficacy to optimize outcomes.
224034091|NCT05625412|DRUG|Docetaxel|Specified dose on specified days
224034092|NCT05625412|DRUG|Nivolumab|Specified dose on specified days
224034093|NCT05625412|DRUG|Capecitabine|Specified dose on specified days
224034094|NCT04687761|DRUG|Azacitidine|AZA 75 mg/m2/daily SC days 1 to 7 or on a 5-on/2-off \[weekend\]/2-on schedule in 28-day cycle
224034095|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 400 mg/daily oral days 1 to 28
224034096|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days, 8 to 28
224034097|NCT04687761|DRUG|Cytarabine|Low-dose subcutaneous cytarabine (LDAC) 20 mg/m2/daily SC, days 1 to 10
224034098|NCT04687761|DRUG|Venetoclax|Venetoclax (ramp-up) 600 mg/daily oral, days 1 to 28
224034099|NCT04687761|DRUG|Quizartinib|Quizartinib 40 mg/daily oral, days 8 to 28
224034100|NCT05773950|DRUG|fosaprepitant|"The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."
224137026|NCT03018626|DRUG|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
223417819|NCT06437028|OTHER|Dual-layer perinatal tissue allograft|The dual-layer perinatal tissue allograft is an amnion - amnion allograft
223417820|NCT06437028|OTHER|Three-layer fenestrated perinatal tissue allograft|The three-layer fenestrated perinatal tissue allograft is an amnion - chorion - amnion allograft
223561316|NCT05306834|OTHER|Walking speed measurement|over 5 meters
223561317|NCT04624867|DRUG|HP-1050 Patch|Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
223561318|NCT06245109|DRUG|Duloxetine|60 mg, oral
223561319|NCT06245109|DRUG|Celecoxib|200 mg, oral
223561320|NCT06245109|DRUG|Placebo|Matching placebo, oral
223561321|NCT00630006|GENETIC|TNF-alpha and IL-10|
223561322|NCT01709617|DIETARY_SUPPLEMENT|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
223561323|NCT03783000|DRUG|BI 425809|Treatment T
223561324|NCT03783000|DRUG|BI 425809 mixed with [C-14]-BI 425809|Treatment R
223561325|NCT00967694|DRUG|Nitrous oxide|Nitrous oxide sedation by inhalation
223561326|NCT04963244|OTHER||
224034101|NCT05773950|DRUG|normal saline|"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes."
223561327|NCT06153849|DIAGNOSTIC_TEST|urine sample collection|Urine samples from patients receiving BCG instillation was collected for LC-WGS to evaluate CIN and urinary microbiome.
223561328|NCT02690688|DEVICE|determination of dynamic preload variables|
224034102|NCT06262854|DEVICE|Calcium-sulphate granules with tobramicina+vancomicina|Local calcium-sulphate antibiotics deliver for the treatment of diabetic foot osteomyelitis
224034103|NCT02721823|BEHAVIORAL|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
224137027|NCT03018626|DRUG|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
224137028|NCT03018626|DRUG|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
223561329|NCT00699387|DRUG|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
223417821|NCT06437028|OTHER|Standard of care|Standard of care (SOC) will include cleansing of the index wound with sterile normal saline solution, followed by sharp debridement to remove necrotic tissue, application of appropriate dressings and wound off-loading.
223417822|NCT06156254|BEHAVIORAL|Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)|Patients randomized to the CHW intervention will receive up to 3 psychoeducational sessions in English or Spanish targeting the specific reason(s) why a patient is not up to date with their COVID-19 vaccine. CHWs will use motivational interviewing techniques to promote vaccination behaviors.
223417823|NCT06046534|OTHER|None (Observational study)|Not applicable since this is observational study.
223417824|NCT06240585|OTHER|presence of gastroparesis as an early sign for sepsis (bacteremia)- measurement of gastric residual volume|presence of gastroparesis as an early sign for sepsis (bacteremia)-measurement of gastric residual volume
223417825|NCT01328145|DRUG|Acetylsalicylic acid|500 mg /day
223417826|NCT03866083|DRUG|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
223417827|NCT03866083|DRUG|Standard Medical Treatment|Standard Medical Treatment
223417828|NCT01190410|DRUG|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to \< 40 kg
223417829|NCT01190410|DRUG|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to \< 40 kg
223417830|NCT06667388|DIAGNOSTIC_TEST|Group A|each participant of this groups will receive 4 weeks of FWT and 4 weeks of BWT (the training order of A group will FWT and BWT), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
223417831|NCT06667388|COMBINATION_PRODUCT|Grojup B|each participant of B group will receive 4 weeks of BWT and 4 weeks of FWT (the training order of group B will be BWT and FWT, opposite to group A), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
223417832|NCT01582633|BIOLOGICAL|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~* influenza A/California/7/2009 (H1N1)~* influenza A/Perth/16/2009 (H3N2)~* influenza B/Brisbane/60/2008 Single dose."
223417833|NCT06049966|DRUG|Atezolizumab|TECENTRIQ C/S.SOL.IN 1200MG/VIAL (20ML) 1 VIAL x 20ML
223417834|NCT06049966|DRUG|Carboplatin|SOL.INF 450MG/45ML VIAL ΒΤx1VIALx45ML
223417835|NCT06049966|DRUG|Etoposide|ETOPOSIDE/PHARMACHEMIE SOL.INF 100MG/5ML VIAL BT x 10 VIALS x 5 ML
223739299|NCT07205029|COMBINATION_PRODUCT|Control: Nutritional intervention|Over a 6-month period, the control group received nutritional recommendations based on the Mediterranean Diet from the nutritionist. In each session, the participant went through the 4D modelling machine, which captures the morphological changes of each individual over time. The control group did not visualise these morphological changes through the virtual reality goggles. Personal and sociodemographic data, clinical information, general health status, anthropometric, nutritional, and lifestyle data, as well as psychological and neuropsychological variables, were collected at two time points: at the beginning (pre-test measures) and at the end of the intervention (post-test measures).
223739300|NCT07206758|DRUG|SHR-2173 Injection|SHR-2173 injection treatment
224137029|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
224137030|NCT03018626|DRUG|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
223417836|NCT04827966|OTHER|Clinpro® 5% sodium fluoride plus tri calcium phosphate varnish|Clinpro® is 5% sodium fluoride varnish and is indicated to be used for hypersensitive as well as for demineralized teeth. It flows smoothly on moist teeth and binds firmly to their surfaces. 1ml of Clinpro® contain 50 mg of sodium fluoride
223417837|NCT04827966|OTHER|Tooth Mousse® - Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP)s|Tooth Mousse® contains Casein phosphopeptide-Amorphous calcium phosphate (CPP - ACP) is product from the milk casein. This delivers the necessary Calcium and Phosphate ions to the tooth, which will reduce the risk of caries and white spot by enhancing tooth remineralization.
223417838|NCT04827966|OTHER|MI Paste® -Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF)|MI Paste® which is Casein phosphopeptide-Amorphous calcium phosphate fluoride (CPP-ACPF) additional contains fluoride in addition to CPP-ACP. The level of fluoride is 900ppm which approximates that in adult strength toothpastes.
223417839|NCT04827966|OTHER|Zap® 1.23% APF gel - Acidulated phosphate fluoride|1.23% APF (Acidulated phosphate fluoride) gel is routinely used professional based fluoride for patients with high caries risk.
223417840|NCT04827966|OTHER|Listerine fluoride mouthrinse|Listerine® Sodium fluoride (0.2%) mouth rinses are effective in reducing caries and inhibit carbohydrate utilization of oral microorganisms by blocking enzymes involved in the bacterial glycolytic pathway studies have shown sodium fluoride mouth rinse to be effective in reducing S. mutans counts
223561330|NCT00641238|DEVICE|Radiofrequency ablation|Radiofrequency ablation
223561331|NCT05570110|DRUG|Enoxolone|one capsule of active or placebo in the evening
223561332|NCT06185907|OTHER|Surgery|We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
223561333|NCT00693537|BEHAVIORAL|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
223561334|NCT06532526|OTHER|Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)|A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
224137031|NCT03018626|DRUG|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
224137032|NCT03018626|DRUG|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
223561335|NCT06532526|OTHER|Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)|Fluoride gel that applied on the teeth to reduce tooth sensitivity
224137033|NCT03018626|DRUG|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
224137034|NCT03018626|DRUG|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
223417841|NCT04831697|BEHAVIORAL|Multi-Caregiving Intervention|The multi-caregiving intervention consists of individual-based, social support, and health educator facilitation and includes: a. Storytelling/sharing of experiences (5 minutes); social support and problem solving (15 minutes); Coping strategies (15 minutes); and Structured Diabetes Education and Skills Training (15 minutes). The last 5 minutes will be used to debrief and review goals.
223417842|NCT04831697|BEHAVIORAL|Diabetes Enhanced Usual Care Intervention|This is composed of individual-based, health educator-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
223417843|NCT00995046|DRUG|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
223417844|NCT00995046|DRUG|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
223417845|NCT00887523|BEHAVIORAL|radiation in prone position|radiation in prone position
223417846|NCT00887523|BEHAVIORAL|radiation in supine position|radiation in supine position
223417847|NCT03671109|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision
223417848|NCT03671109|DRUG|Placebo Oral Tablet|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
223417849|NCT04606823|PROCEDURE|Minimally invasive surgery|The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.
223417850|NCT04606823|OTHER|Glasgow Benefit Inventory (GBI)|A quality of life-questionnaire is to be completed by the subjects at one occasion.
223417851|NCT04606823|OTHER|Additional follow-up visits after surgery|There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
223417852|NCT06622993|OTHER|Psychotherapy|The experimental group will receive the SKILLS program, i.e. 10 group psychotherapy sessions.
223561336|NCT06532526|OTHER|Placebo gel without any active ingredients.|Water-based glycerin gel is used as the Placebo gel without active ingredients
224034104|NCT02721823|BEHAVIORAL|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
224034105|NCT00979251|DRUG|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
224137035|NCT02960048|DEVICE|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
223417853|NCT03652636|DRUG|Sulfur Hexafluoride Microspheres|2.5 mL intravenous injection given at the time of ultrasound, with second 2.5 mL intravenous injection given during ultrasound as needed to improve visualization
223417854|NCT04699201|PROCEDURE|Hincisional hernia prevention by onlay prosthesis trocar closure|Hincisional hernia prevention by onlay prosthesis trocar closure
223417855|NCT04699201|PROCEDURE|laparoscopic cholecystectomy|Laparoscopic cholecystectomy with or without common bile duct exploration
223417856|NCT04699201|DIAGNOSTIC_TEST|Abdominal ultrasound|Ultrasound focused in abdominal wall defects on the trocar incisions, 12 months after the surgery
223417857|NCT05604222|DRUG|Mirabegron 50 MG|Medication to treat overactive bladder
223417858|NCT05604222|BEHAVIORAL|Brief Behavioral Treatment for Insomnia|A behavioral intervention for insomnia
223561337|NCT03770325|DRUG|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
223561338|NCT03770325|DRUG|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
223561339|NCT02814240|OTHER|NMR|
223561340|NCT02814240|BIOLOGICAL|Blood samples|
223561341|NCT02814240|OTHER|fibroscan|
223561342|NCT06084182|OTHER|Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment|6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
223561343|NCT04452058|OTHER|Radiomic Algorithm|Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
224034106|NCT00979251|DRUG|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
223417859|NCT05271318|BIOLOGICAL|TILT-123|Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123
223417860|NCT05271318|BIOLOGICAL|pembrolizumab|pembrolizumab, a monoclonal antibody binding PD-1
224034107|NCT02880826|BEHAVIORAL|Measure the culture of safety in the reanimation units|
224034108|NCT00902954|DRUG|anastrozole|anastrozole 1 mg qd
224034109|NCT00902954|DRUG|letrozole|letrozole 2.5 mg qd
224034110|NCT00902954|DRUG|exemestane|exemestane 25 mg qd
224034111|NCT04009317|DRUG|TQ-B3139|a multi-target protein kinase inhibitor.
224034112|NCT04009317|DRUG|Crizotinib|a multi-target protein kinase inhibitor.
223417861|NCT05271318|DRUG|pegylated liposomal doxorubicin|Pegylated Liposomal Doxorubicin is a chemotherapy and a pegylated liposomal form of the anthracycline topoisomerase inhibitor, doxorubicin.
223417862|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (2 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
223417863|NCT04373512|DRUG|Culturelle 10 Billion CFU Capsule (4 doses)|"For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules"
223417864|NCT01483274|BIOLOGICAL|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
223417865|NCT05877690|DRUG|Bupivacaine 0.5% Injectable Solution|Patient will be received the drug intrathecal
223417866|NCT05877690|DRUG|Prilocaine Hydrochloride 2% Injection|Patient will be received the drug intrathecal
223417867|NCT05822141|DIETARY_SUPPLEMENT|Fish Oil|For 12 weeks subjects will ingest 6 capsules per day of fish oil (7.8 g/day total omega--3 fatty acids: 3.75 g/day EPA and 1.5 g/day DHA)
223417868|NCT05822141|DIETARY_SUPPLEMENT|Placebo|For 12 weeks subjects will ingest 6 capsules per day of olive oil (each capsule contains 990 mg of olive oil)
223417869|NCT05011266|DRUG|Buprenorphine/naloxone|5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
223417870|NCT05011266|DRUG|Placebo|placebo sub-lingual tablet daily
223417871|NCT06554522|DRUG|Surfactant|Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)
223417872|NCT01729338|DRUG|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles \[10,12,14, etc.\]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
223417873|NCT01729338|DRUG|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
223417874|NCT01729338|DRUG|Revlimid|"Lenalidomide (odd cycles \[9,11,13, etc.\]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
223417875|NCT04188015|BIOLOGICAL|2.5mg ANX007|A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
223561344|NCT00582543|OTHER|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
223561345|NCT01835977|DEVICE|Irreversible Electroporation (Nanoknife)|
223561346|NCT03825146|BIOLOGICAL|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10\^8 (0.5 to 5.0 x 10\^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
223561347|NCT02429219|DRUG|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
223561348|NCT02429219|PROCEDURE|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
223561349|NCT02429219|PROCEDURE|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
223739301|NCT07206862|DEVICE|DEBRICHEM®|Single topical application of DEBRICHEM® (desiccant gel for chemical debridement) at inclusion, then standard wound dressings and care.
224298580|NCT04536532|DRUG|HEC121120 placebo tablets|"single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study."
224298581|NCT04536532|DRUG|entecavir tablets|Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
223561350|NCT05406219|DRUG|BAY2395840|Immediate release (IR) tablet, oral administration
223417876|NCT04188015|BIOLOGICAL|5.0mg ANX007|A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.
223417877|NCT04188015|OTHER|Sham Procedure|The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.
223417878|NCT04645901|DRUG|Drug: SYHA1805 tablets|Oral tablets of SYHA1805 with several doses
223417879|NCT04645901|DRUG|Placebo|Oral tablets of placebo with matching several doses
223561351|NCT05289141|DEVICE|Use of high flow nasal oxygen therapy|Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).
223561352|NCT05289141|DEVICE|Use of other non-invasive ventilation or high concentration oxygen masks|Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
223561353|NCT00003191|DRUG|fenretinide|
223561354|NCT03877315|DEVICE|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
223561355|NCT03877315|DEVICE|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
223561356|NCT02546258|DEVICE|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
223561357|NCT02957747|BEHAVIORAL|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
223561358|NCT05156840|BEHAVIORAL|Telehealth follow-up|A telehealth follow-up visit will be conducted via the Epic electronic medical record with a pediatric hospitalist following hospital discharge.
223739302|NCT07206277|OTHER|Immunosuppression reduction|In patients with LSM \< 8.4 kPa we will gradually reduce IS by 30% (e.g. if on tacrolimus 6 mg daily, dose will be reduced to 4 mg daily) over three months. In patients with immunosuppression reduction we will perform TE at 4, 7 and 12 months after IS reduction to ensure there is no change in LSM. We will get liver biochemistry every 2 weeks x 4 months to ensure labs remain within normal range. Following this, patients will resume monthly labs.
224034113|NCT03430219|DEVICE|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
224034114|NCT01674335|BEHAVIORAL|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
224034115|NCT01674335|BEHAVIORAL|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
224298582|NCT04536532|DRUG|entecavir placebo tablets|Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
223417880|NCT00032136|DRUG|exemestane|
223417881|NCT00032136|DRUG|tamoxifen citrate|
223417882|NCT00032136|PROCEDURE|adjuvant therapy|
223561359|NCT06111040|OTHER|Measurement|The only interventions are at the measurement level and consist of two behavioral protocols designed to assess children's eating behavior, where food stimuli are provided and children's behavioral responses are recorded.
223561360|NCT04660851|BEHAVIORAL|Coached|10-weeks of diet coaching weekly by telephone to improve dietary protein intake
223561361|NCT04092894|DRUG|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
223417883|NCT01092819|OTHER|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
223417884|NCT00251303|DRUG|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
223417885|NCT00251303|DRUG|Placebo|Capsules matched active drug in appearance.
223561362|NCT04092894|DRUG|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
223561363|NCT06013358|GENETIC|AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.
223561364|NCT01578642|DEVICE|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
223417886|NCT04532619|BEHAVIORAL|Fathering Through Change|Fathering Through Change is an adaptation of Parent Management Training Oregon. This pilot provides a limited version of Fathering Through Change via text messaged and emailed weekly video content and includes individual coaching calls.
224034116|NCT05912803|DEVICE|Simulated Equestrian Therapy|"The treatment group will receive Simulated Equestrian Therapy for 12 weeks thrice per week using 2 horse simulators (wooden and mechanical) in two phases.~Phase I The child will be instructed to ride the mechanical simulator in a pre-defined area measuring 10 yards and complete a total of 4 rounds of this area. Rest periods in between and after will be provided to the child when required. Major muscles of the body will be targeted here to strengthen the core.~Phase II The child will be instructed to ride the wooden simulator and a combination of goal directed activates will be performed."
224034117|NCT05912803|OTHER|Neuro-Motor Therapy|This group will perform overall stability and body balancing exercises to strengthen the core and develop the coordination and balance required for task performance. Each activity will be performed in a set of 2-3, considering the activity level of the child, with 8-12 repetitions attaining the available ROM and flexibility of the child. The participants will undergo warm-up before the exercise and cool-down afterwards.
224034118|NCT05328583|DRUG|HRS5685；Placebo|"Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H"
224034119|NCT00347165|DRUG|bevacizumab intravitreal injection|
224034120|NCT03571529|DEVICE|EMG-driven exoskeleton hand robot|"Primary Outcome Measurement:~1\. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record."
224034121|NCT03571529|OTHER|Conventional physiotherapy|"Primary Outcome Measurement:~1\. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~1. Action Research Arm Test~2. Motor Activity Log~3. Data from force and EMG measurement records of HOH robot~4. Grip strength (with hand dynamometer)~5. Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~6. Manuel muscle testing for wrist and finger muscles.~7. Modify Asworth sclale"
224034122|NCT05409287|PROCEDURE|Immediate Implant Loading|A single implant crown will be mounted on the implant immediately after implant placement
223417887|NCT00177840|PROCEDURE|acupuncture|
223417888|NCT02511067|DRUG|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
223417889|NCT02511067|DRUG|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
223417890|NCT01993901|OTHER|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
223417891|NCT00593710|DRUG|Losartan|Losartan (25mg OD)
223417892|NCT00593710|DRUG|Atenolol|Atenolol (25-50mg OD)
223417893|NCT02460250|PROCEDURE|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
223417894|NCT01976650|DRUG|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
223417895|NCT00453531|PROCEDURE|Limb Ischemia|
223417896|NCT00453531|DRUG|Acetylcholine|
223417897|NCT06222060|OTHER|Questionnaire about Shaken Baby Syndrome|Knowledge assessment questionnaire completed in the maternity ward by both parents
223417898|NCT03976167|DEVICE|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
223417899|NCT03976167|DEVICE|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
223561365|NCT04352764|DIAGNOSTIC_TEST|CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test|The tests are being distributed under section IV.D of the current United States Food and Drug Administration (FDA) policies for diagnostic tests for coronavirus disease 2019. The test is available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19
223561366|NCT03692377|DEVICE|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
223417900|NCT02260869|PROCEDURE|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
224034123|NCT05409287|PROCEDURE|Early Implant Loading|A single implant crown will be mounted on the implant 4 weeks after implant placement.
224137036|NCT02960048|DEVICE|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
224137037|NCT02007330|DRUG|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
223417901|NCT02260869|DEVICE|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
224034124|NCT04354090|DRUG|JY09|Subcutaneous injection
223417902|NCT02572596|DRUG|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
223417903|NCT02572596|DRUG|CTX|CTX 2.5/m2 for 2 days.
223561367|NCT02842515|OTHER|teeth avulsion|
223561368|NCT00632827|DRUG|Gemcitabine|Chemotherapy medication used to treat a number of types of cancer
223561369|NCT00632827|DRUG|Navelbine|Navelbine is an chemotherapy medication used to treat a number of types of cancer
223561370|NCT00632827|DRUG|Doxorubicin Hydrochloride Liposome Injection|Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
223561371|NCT00632827|DRUG|Granulocyte-colony stimulating factor (G-CSF)|G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
223739303|NCT07207252|DIETARY_SUPPLEMENT|Tea Theanine Casein Hydrolysate Pressed Candy|Take 4 candies once a day. It is recommended to consume it one hour before bedtime.
223739304|NCT07207252|DIETARY_SUPPLEMENT|Pressed Candy|Take 4 candies once a day.
224034125|NCT05125679|DRUG|Guselkumab|Guselkumab will be administered by subcutaneous injection.
224034126|NCT05629962|DRUG|Bemnifosbuvir (BEM)|BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
224137038|NCT02007330|DRUG|Normal saline infusion|In group C, the patients receive same volume of normal saline
224137039|NCT04229589|OTHER|Clinic follow-up|Patients are regularly evaluated to asses the occurrence of syncopal relapses
224137040|NCT01449591|DRUG|BFH772 1% ointment|
224137041|NCT01449591|DRUG|Vehicle ointment|
223739305|NCT07206342|PROCEDURE|embolization therapy|Patients will undergo embolization alone, which involves temporarily blocking the uterine artery or arteries supplying a hypervascular abnormality using resorbable gelatin fragments.
224034127|NCT05629962|DRUG|Placebo|Placebo tablets administered orally every 12 hours (twice a day) for a total of 5 days
224137042|NCT01449591|DRUG|Noritate® 1% cream|
223561372|NCT00632827|DRUG|Pegfilgrastim|Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
224034128|NCT01320982|DRUG|minocycline|minocycline 100 mg/bid
224034129|NCT01320982|DRUG|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
224137043|NCT02634918|OTHER|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
224137044|NCT03571334|DRUG|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
223417904|NCT02572596|DRUG|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10\^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
223417905|NCT00006617|DRUG|Abacavir sulfate|
223417906|NCT00006617|DRUG|Amprenavir|
223417907|NCT00006617|DRUG|Lamivudine|
223561373|NCT00632827|DRUG|Cyclophosphamide|Cancer medication that interferes with the growth and spread of cancer cells in the body
223561374|NCT00632827|DRUG|Vincristine|Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
223561375|NCT00632827|DRUG|Leucovorin|Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
223561376|NCT00632827|DRUG|Methotrexate|Methotrexate is a chemotherapy medication used to treat cancer
223417908|NCT00006617|DRUG|Zidovudine|
223417909|NCT06623747|BEHAVIORAL|Diet|15 kcal per kg fat-free mass
223417910|NCT06623747|BEHAVIORAL|Diet|45 kcal per kg fat-free mass
223417911|NCT03490838|DRUG|177Lu-PSMA-R2|radio-ligand therapy
224034130|NCT01320982|DRUG|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
224034131|NCT01320982|DRUG|placebo|placebo bid
224034132|NCT05241782|OTHER|auricular acupressure|"Auricular therapy, as defined by Oleson, refers to a healthcare modality by stimulating the external surface of the ear to alleviate pathological conditions in other parts of the bodyExperimental group will receive acupressure treatment by the second week, trice daily, 3\~5minutes each session for a course of four weeks"
224034133|NCT01955447|DIETARY_SUPPLEMENT|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
224034134|NCT01955447|DIETARY_SUPPLEMENT|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
224034135|NCT01955447|DIETARY_SUPPLEMENT|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
224034136|NCT01955447|DIETARY_SUPPLEMENT|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
223561377|NCT00632827|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
223561378|NCT00632827|DRUG|Cytarabine|Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
223561379|NCT00632827|DRUG|Etoposide|Etoposide is a is a chemotherapy medication used to treat cancer
223561380|NCT00632827|DRUG|Carmustine|Carmustine is a chemotherapy medication used to treat cancer
224034137|NCT03156751|DIAGNOSTIC_TEST|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
224034138|NCT06087679|BEHAVIORAL|PPS guided selfcare based intervention program|Guided selfcare programme (Please refer to project description)
224137045|NCT03571334|DRUG|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
224137046|NCT01096849|DRUG|levofloxacin|
224137047|NCT01096849|DRUG|plazomicin|
223561381|NCT00632827|DRUG|Denileukin diftitox|Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
223561382|NCT03554057|DIAGNOSTIC_TEST|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
223561383|NCT04956276|DRUG|ALXN1830|Administered as an SC infusion.
224137048|NCT01096849|DRUG|placebo|
224137049|NCT03412318|DEVICE|Twisted file|Use of twisted file during cleaning and shaping of root canals
224137050|NCT03412318|DEVICE|Mpro|Use of Mpro during cleaning and shaping of root canals
224137051|NCT03744884|BEHAVIORAL|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
224137052|NCT04460690|DEVICE|Rapid Onsite COVID-19 Detection|saliva assay test for high concentrations of SARS-CoV-2
224137053|NCT01542359|OTHER|Yogic practice|breathing, meditation, physical postures
223561384|NCT04956276|DRUG|Placebo|Administered as an SC infusion.
223561385|NCT06362330|OTHER|magnetic resonance imaging|Patients of bladder cancer underwent multiparameter magnetic resonance imaging before surgery
223561386|NCT01097317|DRUG|carboplatin|
223561387|NCT01097317|DRUG|vinorelbine tartrate|
223561388|NCT01097317|OTHER|neuromuscular electrical stimulation|
223561389|NCT01097317|OTHER|physiologic testing|
223561390|NCT01097317|PROCEDURE|fatigue assessment and management|
223561391|NCT01097317|PROCEDURE|quality-of-life assessment|
223561392|NCT04630860|DRUG|LY03003|Rotigotine,extended-release microspheres
223739306|NCT07206342|PROCEDURE|embolization followed by aspiration|"Patients will undergo embolization prior to endometrial aspiration. Embolization will be performed in the same manner as in group Embolization alone but will be followed within 48 hours by a second procedure to remove the intrauterine residue that will have been devascularized (= deprived of blood) by the embolization."
223739307|NCT07206706|DRUG|Tadalafil 5Mg Tab|PDE5 inhibitor
224034139|NCT04274283|OTHER|Matched Tumour and Blood Sample - Research Pathway|"For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.~Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites"
224034140|NCT04274283|OTHER|Matched Tumour and Blood Sample - NHS GMS pathway|Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
223417912|NCT05906550|DIAGNOSTIC_TEST|Vascular access monitoring|Patients are referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present. These include physical signs, problems during dialysis, or an unexplained, sustained fall in dialysis adequacy. Patients will be referred for correction of the underlying stenosis when clinical signs of flow dysfunction are present.
223739308|NCT07206706|DRUG|Darifenacin 7.5 MG|anti muscarinic
223739309|NCT07206329|DRUG|Polyethylene Glycol plus Ascorbic Acid (PEG-Asc)|Participants receive a split-dose bowel preparation with 1 L polyethylene glycol plus ascorbic acid (PEG-Asc). The first dose is administered at 20:00 the evening before the procedure (500 mL PEG-Asc solution consumed over 1 hour, followed by 500 mL clear liquids). The second identical dose is taken at 06:00 on the day of the capsule procedure.
224034141|NCT05953064|OTHER|DHA-NAT|Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid
223739310|NCT07206329|DRUG|Sodium Picosulfate with Magnesium Citrate (SPMC)|Participants receive sodium picosulfate with magnesium citrate (SPMC) in a split-dose regimen. The first sachet is dissolved in 150 mL water and followed by 1.5-2 L of clear fluids the evening before the procedure, and the second sachet is taken with the same fluid regimen on the morning of the procedure.
223739311|NCT07206043|BIOLOGICAL|RPH-104 80 mg|solution for intravenous injection, 40 mg/mL
224034142|NCT05953064|OTHER|Placebo|Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
224034143|NCT04887324|OTHER|no intervention|no intervention
224034144|NCT04385108|BIOLOGICAL|Blood collection on admission and longitudinally|33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
224034145|NCT04385108|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|33 mL of blood collected on their first consultation and 10 to 14 days later
224034146|NCT05538598|PROCEDURE|Intramuscular Dry Needling|The insertion of thin monofilament needles (without injectate) into a tight band of muscle. The needles will be inserted into the muscle for \~10 seconds.
224034147|NCT04731857|GENETIC|Retrospective data analysis|The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
224034148|NCT05457582|DRUG|Placebo plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
224034149|NCT05457582|DRUG|PCSK 9 Inhibitor plus high-intensity statin|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen, Q2W, and oral administration of rosuvastatin (20 mg, once daily).
223739312|NCT07206043|BIOLOGICAL|RPH-104 160 mg|solution for intravenous injection, 40 mg/mL
223739313|NCT07206043|BIOLOGICAL|RPH-104 320 mg|solution for intravenous injection, 40 mg/mL
224137054|NCT01542359|OTHER|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
224137055|NCT05115500|DRUG|ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2|RC48-ADC combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2
224137056|NCT03154632|DEVICE|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
223417913|NCT05906550|DIAGNOSTIC_TEST|Vascular access blood flow measurement|Monthly surveillance of vascular access blood flow volume by ultrasound dilution measurements during hemodialysis sessions. Patients will be referred for correction of the underlying stenosis at an access flow volume \<500mL/min.
223739314|NCT07206043|BIOLOGICAL|RPH-104 320 mg|solution for subcutaneous injection, 80 mg/mL
223739315|NCT07206043|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous injection, 40 mg/mL
223739316|NCT07206043|BIOLOGICAL|RPH-104 80 mg|solution for subcutaneous injection, 80 mg/mL
223739317|NCT07206043|DRUG|Placebo|0.9% Sodium Chloride solution for Injection
223739318|NCT07207161|BEHAVIORAL|Infant Massage|A standardized infant massage protocol applied by a physiotherapist, including gentle tactile stimulation to promote growth, relaxation, and neuromuscular development in premature infants.
224034150|NCT06472908|DRUG|Colchicine 0.5 mg|Colchicine 0.5 mg, one pill a day, oral intake
223417914|NCT05097534|OTHER|iDSMES|Intensive Diabetes Self-Management Education and Support combined with Addressing Social Determinants of Health
223417915|NCT05097534|OTHER|Standard of Care|Standard of Care for patients with type 2 diabetes
223417916|NCT05242458|DRUG|Ustekinumab|No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.
223417917|NCT00504725|DRUG|Ketamine|Interventional
223417918|NCT00504725|DRUG|0.9% saline|placebo
223417919|NCT05311839|OTHER|Exercise|Hot packs, active range of motion exercises, pendular exercises, wall climb exercises, mobilization exercises, and shoulder capsular stretching
223739319|NCT07207161|BEHAVIORAL|Physiotherapy (Moyer-Mileur Protocol)|A single-session physiotherapy intervention consisting of gentle range of motion and flexion-extension exercises following the Moyer-Mileur protocol to stimulate musculoskeletal and neuromotor development in premature infants.
223417920|NCT05311839|OTHER|Thera band|graded Thera band exercises for shoulder flexion, abduction, internal, and external rotation
223417921|NCT05789888|GENETIC|MT-ATP6 mtDNA gene variability in obesity and normal body weight patients.|As part of the research, the MT-ATP6 gene was tested in order to influence the modulation of the amount of fat contained.
223417922|NCT05789888|GENETIC|SCD gene variability in obesity and normal body weight patients.|As part of the research, the SCD gene was tested in order to influence the modulation of the amount of fat contained.
224034151|NCT06472908|DRUG|Colchicine 0.375 mg|Colchicine 0.375 mg, one pill a day, oral intake
223417923|NCT05789888|OTHER|Finding TOFI and FOTI phenotypes in participants with obesity and normal weight.|As part of the research, we measured the amount of VAT and SAT and calculate VAT/SAT ratio as a marker to determine the phenotype of fat tissue.
223417924|NCT03060174|OTHER|monitoring and non-medical prophylaxis of delirium|
223417925|NCT01435018|DRUG|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade \>= 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade \>= 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
223417926|NCT01435018|DRUG|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m\^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
223417927|NCT01435018|DRUG|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m\^2 body surface area (BSA) every 3 weeks.
223417928|NCT01435018|DRUG|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~1. EFV/FTC/TDF (Atripla) 200 mg/300 mg/600 mg orally once daily at bedtime or~2. FTC/TDF 200 mg/300 mg (Truvada) orally once daily at bedtime plus EFV (Stocrin) 600 mg orally once daily at bedtime or~3. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~4. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus PI/r at standard dosing or~5. FTC/TDF 200 mg/300 mg (Truvada) orally once daily plus integrase inhibitor at standard dosing"
223417929|NCT02064504|DRUG|GSK961081|Dry white to off white powder
223417930|NCT02064504|DRUG|Fluticasone furoate|Dry white powder
223417931|NCT04019613|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
223417932|NCT06502795|OTHER|Protected Range Quadriceps Strengthening group|"Warm-up: Start with 5 minutes of stationary biking. Then, proceed with two sets of 30-second dynamic stretches targeting the quadriceps, hamstrings, calf muscles, and adductors, followed by static stretching for the abductors.~Strengthening: Complete 3 sets of 8-12 repetitions for each exercise, aiming for a perceived effort level on the Borg scale between 60% and 80%. Increase the load by 2%-10% when the patient can perform 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~For the Leg Extension Machine, maintain a range of motion between 90 to 45 degrees. During Squats and Bulgarian Squats, aim for a range of motion between 0 to 45 degrees."
223417933|NCT06502795|OTHER|Patient-Guided Range Quadriceps Strengthening group|"Warm-up: 5 minutes of stationary biking. Next, perform two sets of 30-second stretches for the quadriceps, hamstrings, calf muscles, adductors and abductors hip.~Strengthening: Patients will complete 3 sets of 8 to 12 repetitions for each exercise, aiming for a perceived effort level of 60% to 80% on the Borg scale. Load will be increased by 2% to 10% when patients can complete 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~Quadriceps strengthening will be performed at the patient's maximum range guided by symptoms, with pain intensity capped at 5 points on the NPRS. The patient-guided range will be adjusted based on pain intensity, comfort, and patient response, using a shared decision-making approach. The goal is to maintain exercises at the maximum possible range of motion.~For the Leg Extension Machine, Squats, and Bulgarian Squats, the range of motion will be guided by the patient's pain tolerance."
224034152|NCT06472908|DRUG|Placebo|Placebo, one pill a day, oral intake
224137057|NCT03154632|DEVICE|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
224137058|NCT01457859|DRUG|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
224137059|NCT01457859|OTHER|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
224137060|NCT05145075|OTHER|Survey|Patients are asked to fill in a survey concerning teleconsultations
224137061|NCT00174707|DRUG|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
223417934|NCT02926586|DRUG|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
223417935|NCT02926586|DRUG|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
223417936|NCT06684366|DRUG|Statins (atorvastatin or simvastatin)|A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone
223417937|NCT00272207|DRUG|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
223417938|NCT00137007|DRUG|Azithromycin|
223417939|NCT00137007|DRUG|Ampicillin/sulbactam|
223417940|NCT02534077|DIETARY_SUPPLEMENT|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
223417941|NCT02534077|DRUG|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
223417942|NCT02534077|DRUG|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
223417943|NCT06090903|PROCEDURE|Biospecimen Collection|patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.
223561393|NCT05155761|DEVICE|FeetMe® Monitor|"Each patient will be asked to go to 3 visits at the Cochin hospital, and to wear the soles after each of these visits during 3 days, at home, to record the data, so that it reflects walking patterns of the patient in his/her daily life and activities.~At each visit, clinical tests to assess fall risk will be performed (Timed Up and Go test, one foot stance, Short Physical Performance Battery and 6 minutes walking test ).~The patients will be supplied with a pair of FeetMe® Monitor insoles, return home and walking parameters will be recorded for 3 to 10 consecutive days."
223561394|NCT01522521|DRUG|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
224034153|NCT05640648|BEHAVIORAL|User-Centered Implementation Strategy|"1. 4 participant-facing components: 1a) TB education pamphlet helps index TB persons disclose the need for household screening to contacts. 1b) Contact identification algorithm helps CHWs and index TB persons accurately enumerate contacts. 1c) Sputum collection video instructs contacts to expectorate good-quality sputum. 1d) Community Health Riders transport CHWs, index persons with TB, and contacts by motorcycle taxi, and collect and transport sputum.~2. 3 community health-worker-facing components: a) Weekly CHW meetings create communities of practice (CoP), professionals organized for peer support and systematic learning. Meetings involve problem solving, review of audit and feedback reports, and didactics on TB care, among other activities. 2b) Audit and feedback reports on contact investigation performance indicators weekly (individual CHW) and monthly (health facility). 2c) A group-chat application facilitates peer support among CHWs."
224034154|NCT05640648|BEHAVIORAL|Standard Implementation Strategy|Once an eligible TB patient agrees to participate, CHWs will visit the patient to assess the eligibility of close contacts to participate. For eligible contacts who agree to participate, the CHW will perform TB symptom screening and arrange subsequent microbiologic, clinical, and/or radiographic evaluation. Those screening TB symptom-positive will be asked to expectorate a sputum sample, unless under age 5. If under age 5 or unable to produce sputum, contacts will be referred to the health centre for evaluation. A CHW will transport sputum samples to the health-centre laboratory for microbiologic evaluation and later report the test results back to the contact. During the standard implementation strategy period, CHWs at all sites will receive the standard TB program training on TB contact investigation and supportive supervision from the on-site National TB Program focal person.
224137062|NCT00174707|DRUG|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
223561395|NCT01522521|DRUG|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
223561396|NCT00797745|BIOLOGICAL|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
223417944|NCT06090903|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
224137063|NCT00174707|DRUG|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
224137064|NCT04445493|DEVICE|MindRhythm Harmony|Passive recording of the head pulse
223417945|NCT06090903|OTHER|Medical Chart Review|Review Medical Chart
223417946|NCT02177903|DEVICE|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
223417947|NCT00769067|DRUG|Erlotinib|Continuous oral dosing at 150 mg daily.
223417948|NCT00769067|DRUG|PF-00299804|Continuous oral dosing at 45mg daily
223417949|NCT06292598|OTHER|Blood sample|Sample taken to test plasma permeability markers
223417950|NCT06292598|OTHER|Stool sample|Sample taken to test microbial diversity and composition
223417951|NCT06292598|OTHER|CSF sample|Sample taken to test orexin level
223417952|NCT02114944|DEVICE|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
223417953|NCT02114944|DEVICE|CPAP|Patient treated, as per attending physician's decision, with CPAP
223417954|NCT02114944|DEVICE|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
223417955|NCT02114944|DEVICE|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
223561397|NCT00797745|DRUG|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
223561398|NCT00797745|DRUG|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
223561399|NCT00797745|DRUG|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
223739320|NCT07207122|DEVICE|Transcranial focused ultrasound modulation administered to a region involved in disease pathology.|Using Sanmai's device to administer tFUS to regions of interest.
224034155|NCT06779591|OTHER|CareAide® Medication Adherence Mobile Application|CareAide® app is one of the mobile apps in assisting and improving patients' adherence to medications. It is an unique health-tech and insure-tech company with expertise in behavioural science, chronic condition management and technology. The app aims to help patients with chronic conditions live a better everyday life and empower their families and the ecosystem around the patients to drive better outcomes. They have the clinically validated approach to improving adherence. Using behavioural science and smart tech, they improve the day-to-day life of patients, and importantly, empower both patients and health care providers with the digital tools and near real-time insights to proactively manage risks, intervene early to avoid patient emergencies and to help to provide a better customer satisfaction.
223417956|NCT06584422|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
223417957|NCT06584422|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
223417958|NCT03073577|DRUG|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
223417959|NCT04810494|DRUG|2% Lidocaine HCl topical solution|0.5mL of 2% Lidocaine will be administered intranasally in each nostril with a mucosal atomization device.
223417960|NCT04810494|DRUG|0.9% Sodium chloride|0.5mL of 0.9% Sodium chloride (normal saline) will be administered intranasally in each nostril with a mucosal atomization device.
223417961|NCT04069832|BEHAVIORAL|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
223417962|NCT05319873|DRUG|Carboplatin|Given IV
223561400|NCT04801238|PROCEDURE|LCBDE + LC|"Experimental group: Laparoscopic common bile duct exploration (LCBDE) + laparoscopic cholecystectomy (LC) is performed under full anaesthesia. Once the dissection has exposed the cystic a clip or ligature is placed peripherally on the cystic duct. Through an incision in the duct central to the clip or ligature a cholangiogram catheter is introduced into the cystic duct and the cholangiogram is completed.~After identification of the bile duct stones and anatomy, a cholangioscope is introduced through the duct incision into common bile duct. The stones are identified visually and removed by Dormia basket. If the stones are very large, they may be partitioned mechanically or by electrohydraulic lithotripsy. In the presence of CBDS wedged in the papilla these stones will be removed and a secondary cholangiogram will be performed. Subsequently, the cholangioscope is taken out. Then the cystic duct is divided and the gallbladder is dissected out from the liver by hook cautery and removed."
223739321|NCT07206225|DRUG|PF-08052667|PF-08052667 will be administered intravesical (IVe) instillation following a PF-02921367 (DDM) bladder pre-wash
224034156|NCT04484259|DRUG|Ticagrelor monotherapy|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
224034157|NCT04484259|DRUG|Ticagrelor plus aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
224137065|NCT05717452|DIETARY_SUPPLEMENT|Blueberry drink|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder mixed with 250 ml water.
224137066|NCT05717452|DIETARY_SUPPLEMENT|Placebo drink|22 g placebo powder matched for macronutrients, color, and flavor mixed with 250 ml water.
224137067|NCT02024893|OTHER|Observational study|"Observation and type of data collected are listged in detail under 'description"
223417963|NCT05319873|DRUG|Docetaxel|Given IV
223417964|NCT05319873|DRUG|Fulvestrant|Given SC
223417965|NCT05319873|BIOLOGICAL|Pertuzumab|Given IV
223417966|NCT05319873|OTHER|Quality-of-Life Assessment|Ancillary Studies
223417967|NCT05319873|DRUG|Ribociclib|Given PO
223417968|NCT05319873|BIOLOGICAL|Trastuzumab|Given IV
223417969|NCT05319873|DRUG|Tucatinib|Given PO
223739322|NCT07206225|DRUG|Sasanlimab|Sasanlimab will be administered as subcutaneous (SC) injection
223739323|NCT07206225|DRUG|BCG|BCG will be administered intravesical (IVe) instillation
224137068|NCT00002207|DRUG|Stavudine|
224137069|NCT00002207|DRUG|Didanosine|
224137070|NCT00392262|DRUG|valsartan + amlodipine|
224137071|NCT00118482|DRUG|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
224137072|NCT06151366|OTHER|non interventional|non interventional
223417970|NCT03806933|DRUG|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).
223417971|NCT01527656|DRUG|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
223417972|NCT06124950|BEHAVIORAL|Gender-transformative intervention|"A multidisciplinary team of experts, including 8-10 experts in reproductive medicine, nursing, social work, psychiatry, family law, and evidence-based medicine, will be established to support the development of the intervention.~Five 60-minutes intervention sessions will be delivered by trained nurses and social workers throughout participants' fertility treatment cycle. Intervention will be carried out at the 5 critical windows of opportunity for infertility treatment: (1) before entering the cycle; (2) during follicular monitoring; (3) before oocyte retrieval; and (4) 2 weeks after the embryo transfer; and (5) 28-30 days after the embryo transfer.~The intervention components will equip couples with educational information on health and relationship and skills obtained from interactive activities designed with an explicit focus on challenging gender stereotypes, all of which could incite reflection on sociocultural norms and gender-related power inequality."
223417973|NCT02490046|DIETARY_SUPPLEMENT|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
223417974|NCT04108468|DRUG|Golimumab|Simponi
223417975|NCT04108468|DRUG|Methotrexate|Methotrexate
223417976|NCT03316014|OTHER|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
223561401|NCT04801238|PROCEDURE|ERC + LC|Control intervention: (First step) Endoscopic retrograde cholangiography (ERC) is routinely performed in sedation but or in full anaesthesia. ERC is performed with the patient in the supine position. The endoscope is passed down to the second part of the duodenum where the papilla is identified. Cannulation of the papilla and the common bile duct is performed with a papillotome and a guidewire. A cholangiography will confirm the presence, location and size of the CBDS and aims in further choice of extraction method. Stones can be extracted by papillotomy and by either balloon or by a basket. Additional balloon dilation of the papilla, or lithotripsy may be required. If stone extraction is incomplete or if the conditions are unclear a temporary common bile duct stent is placed which has to be removed with additional ERC after 1-2 months (Second step) laparoscopic cholecystectomy is performed after 2-14 days
223561402|NCT02652208|BEHAVIORAL|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
223561403|NCT02652208|BEHAVIORAL|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
223561404|NCT04969601|BIOLOGICAL|vaccine COMIRNATY® (BNT162b2)|two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
223561405|NCT06439433|DRUG|Aminolaevulinic acid (500-mg bottle)|once a week for 6 weeks
223561406|NCT06439433|DRUG|Aminolaevulinic acid (750-mg bottle)|once a week for 6 weeks
223561407|NCT06439433|DRUG|Placebo|once a week for 6 weeks
223561408|NCT04186988|DRUG|Fluorine F 18 Ara-G|Given IV
223561409|NCT05354895|DEVICE|Transcranial infrared laser stimulation|non-invasive, non-pharmacologic photobiomodulation device
223561410|NCT02601235|DRUG|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
224034158|NCT04484259|DRUG|Clopidogrel with aspirin|Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
223417977|NCT05197608|OTHER|System Navigator|Participants will be connected to a System Navigator, who is a trained staff embedded within their primary health clinic to support and help navigate biological, psychological and social needs in proactively identified vulnerable patients.
223417978|NCT05197608|OTHER|Tailored list of resources|Control group will be provided a tailored list of resources
224034159|NCT05828927|BEHAVIORAL|Eco-mapping tool|The web application allows caregivers to visually identify and organize their existing social network (family, friends, community of worship, and others) to assist with their support needs, tailored to their context. For each of the six support social support domains (in-home, informational, communication, financial, emotional and spiritual, transportation (e.g., emotional, informational, practical), the enCompass web application prompts the individual to identify members of their network. After completing each domain, caregivers are presented with a visual social support
224034160|NCT05828927|BEHAVIORAL|Caregiver-coach study visits|Caregivers engage in up to 8 manualized, telephone/videoconference visits with a trained caregiver coach. The caregiver coach uses the study manual and interview guide to provide support for caregiver support-seeking and problem-solving.
223417979|NCT03625466|DRUG|LUM/IVA|FDC tablets or granules for oral administration.
224034161|NCT02989636|OTHER|Laboratory Biomarker Analysis|Correlative studies
223561411|NCT02601235|DRUG|Afrin|2 pumps in each nostril every 12 hours.
223561412|NCT03294174|DRUG|Ropivacaine injection|Ropivacaine administered to provide nerve block
223561413|NCT03991403|DRUG|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
223561414|NCT03991403|DRUG|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
223561415|NCT03991403|DRUG|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
223561416|NCT03991403|DRUG|Carboplatin|Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min
224034162|NCT02989636|BIOLOGICAL|Nivolumab|Given IV
223417980|NCT03625466|DRUG|LUM/IVA|FDC granules for oral administration.
223561417|NCT03991403|DRUG|Paclitaxel|Paclitaxel(175 mg/m2 IV); Over 3 hours
223739324|NCT07206225|DRUG|PF-02921367|PF-02921367 (DDM) is a 10-min pre- wash and will be administered intravesical (IVe) instillation
224034163|NCT02989636|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223417981|NCT03625466|DRUG|Placebo|Placebo matched to LUM/IVA for oral administration.
223417982|NCT02841670|DEVICE|InFo - Instant Focus (c) lens implantation|
223417983|NCT04082572|BIOLOGICAL|Pembrolizumab|Given IV
223417984|NCT03427099|BEHAVIORAL|Rehabilitation with a biopsychosocial focus|Rehabilitation with a biopsychosocial focus
223417985|NCT03427099|BEHAVIORAL|Control group|usual care
223417986|NCT01058993|DRUG|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
223417987|NCT01713114|OTHER|Acute measures of satiety and food intake at next meal|
223417988|NCT05231772|DRUG|Saccharomyces Boulardii Probiotic Supplement|Probiotic yeast
223417989|NCT05231772|DRUG|Placebo|Placebo
223417990|NCT02180139|DEVICE|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
223417991|NCT01172223|DRUG|Myocet (Non-pegylated liposomal doxorubicin (NPLD))|60 mg/m\^2 i.v. day 1 q3 weeks
223417992|NCT01172223|DRUG|Paclitaxel|175 mg/m\^2 i.v. day 1 q3 weeks
223417993|NCT01172223|DRUG|Lapatinib (GW572016, Tykerb)|750-1500 mg/d orally daily until the day of the definitive surgery
223561418|NCT03991403|DRUG|Carboplatin or cisplatin|Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
223561419|NCT03490422|PROCEDURE|Pulpotomy|Pulpotomy in mature carious permanent teeth
223561420|NCT03392831|OTHER|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
223561421|NCT03392831|OTHER|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
223561422|NCT06187766|DIAGNOSTIC_TEST|Social Media Addiction|Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
223561423|NCT05740163|DIETARY_SUPPLEMENT|Egg product including egg white and yolk allergens|Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
223561424|NCT05957393|OTHER|Quantity of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
224034164|NCT04124341|DEVICE|Prefrontal Cortical Stimulation (PCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
224034165|NCT06461429|DRUG|Erythromycin|Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
224137073|NCT00242580|DRUG|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
223417994|NCT04845919|DRUG|5-Aminolevulinic Acid|"SDT treatment with 5-ALA using the ExAblate Model 4000 Type-2 Neuro-System."
223417995|NCT06056960|OTHER|Tailored Physical Activity|"The intervention will comprise 16 sessions (2 sessions/week). 30 minutes of walking training wearing a heart rate (HR) monitor to keep exercise intensity below 70% of maximal HR.~Right after, 30 minutes of balance exercises will be performed. An experienced physical therapist will tailor exercises. Subjects will be taught how to perform the exercises by themselves. A booklet will be provided to provide guidelines. A physical therapist will call subjects, every training day to check for any problem."
223417996|NCT04713254|DRUG|Lu AG06466|10, 20, 30 mg/day oral capsules on Day 5-18
223417997|NCT04713254|OTHER|Midazolam|4 mg syrup, oral single dose on Day 1 and Day 15
223417998|NCT04713254|OTHER|Metoprolol|100 mg tablets, oral single dose on Day 1 and Day 15
223417999|NCT04713254|OTHER|Bupropion|100 mg tablets, oral single dose on Day 3 and Day 17
223418000|NCT06565026|GENETIC|CS-206|Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
223418001|NCT01868438|DRUG|Pyronaridine-artesunate granules|
223418002|NCT01868438|DRUG|Pyronaridine-artesunate tablets|
223418003|NCT04996602|DRUG|2.0 GBq of 177Lu-EB-PSMA|Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.
223418004|NCT05667116|DRUG|EVUSHELD|EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)
223418005|NCT02497040|DRUG|Levobupivacaine|local injection
223418006|NCT02497040|DRUG|Bupivacaine|local injection
223418007|NCT02497040|DRUG|placebo|local injection
223418008|NCT05076032|DRUG|OXO-001|OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
223418009|NCT05076032|DRUG|Placebo|Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
223561425|NCT05957393|OTHER|Quality of vaccination recommendations|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
223561426|NCT05957393|OTHER|Control|The survey contains a messaging intervention using a 2x2 randomized factorial design, where the investigators attempt to increase the quantity and/or quality of physician and APP vaccination recommendations (Quantity (present vs. absent) x Quality (present vs. absent)).
223561427|NCT02255448|DEVICE|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
223418010|NCT03551769|DRUG|tricaprilin|Tricaprilin formulated as AC-SD-01
224034166|NCT06461429|DRUG|Amoxicillin and Erythromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
223418011|NCT03551769|OTHER|standard meal|standard meal
223418012|NCT03551769|OTHER|high-fat meal|high-fat meal
223418013|NCT03551769|OTHER|overnight fast|fasting for at least 9 hours
223418014|NCT00801203|DRUG|IRCT|Up to two administrations of the IRCT during a single cough testing session
223418015|NCT00956592|DEVICE|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
223418016|NCT00956592|DEVICE|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
223418017|NCT01089764|BEHAVIORAL|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
223561428|NCT02354131|DRUG|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
223561429|NCT02354131|DRUG|Bevacizumab|
223561430|NCT03425006|DRUG|Itacitinib|a JAK 1 selective small molecule inhibitor
223561431|NCT03425006|BIOLOGICAL|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
223561432|NCT02007057|PROCEDURE|Suprascapular nerve block|
223561433|NCT02007057|PROCEDURE|Interscalene nerve block|
223561434|NCT00614445|DRUG|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
223561435|NCT00614445|DRUG|Placebo|2 to 4 tablets daily titrated according to the protocol
223561436|NCT01467037|OTHER|No intervention done|Not applicable because no intervention was done.
223561437|NCT01922947|BEHAVIORAL|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
223561438|NCT01922947|BEHAVIORAL|Active Control Condition|20-minute health counseling
223561439|NCT05247970|DRUG|S-309309|Capsule administered orally
223561440|NCT05247970|DRUG|Midazolam|Syrup administered orally
223561441|NCT05247970|DRUG|Placebo|Matching capsule to S-309309 administered orally
223561442|NCT06602674|OTHER|Observe the medical images|Observe the medical images via work station or local image analysing software
223561443|NCT06602674|OTHER|Feature extraction|Extracting image feature via radiomics or deep learning methods
223561444|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
224034167|NCT06461429|DRUG|Azithromycin|Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
223418018|NCT02735525|DEVICE|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
223418019|NCT01083888|DRUG|roxadustat|oral
223418020|NCT06622356|OTHER|MRI with Eovist|The study was retrospective and did not design an intervention
223418021|NCT00076752|DRUG|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m\^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
223418022|NCT00076752|DRUG|cyclophosphamide|Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
223561445|NCT01884506|DIETARY_SUPPLEMENT|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
223561446|NCT02182024|DRUG|Dabigatran etexilate high dose|
223561447|NCT02182024|DRUG|Dabigatran etexilate low dose|
223561448|NCT05487651|GENETIC|KUR-502|KUR-502 (CD19.CAR-aNKT cells) consists of transduced allogeneic natural killer T cells (aNKT) genetically modified with additional features to enhance their anti-tumor activity against CD19+ B-cell malignancies. Following intravenous (IV) infusion, the product is expected to kill CD19+ tumor cells by direct interaction with the chimeric antigen receptor (CAR), and activation of the NKT cells to kill tumor through their innate cell killing.
223561449|NCT03252249|OTHER|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
223561450|NCT03252249|OTHER|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
223561451|NCT00888329|DRUG|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
223561452|NCT00888329|DRUG|Placebo|Placebo
223561453|NCT01203436|PROCEDURE|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
223561454|NCT01203436|PROCEDURE|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
224034168|NCT06461429|DRUG|Caffeine citrate 20 mg/kg load and 10 mg/kg daily maintenance.|Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
224137074|NCT00242580|DRUG|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
224034169|NCT06461429|DRUG|Caffeine citrate 30 mg/kg load and 15 mg/kg daily maintenance.|Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
223418023|NCT00076752|BIOLOGICAL|Rituxan (rituximab)|Priming regimen: 375 mg/m\^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m\^2 intravenous infusion, day -7.
223418024|NCT00076752|BIOLOGICAL|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC \>500 microliters.
223418025|NCT00076752|DRUG|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
223418026|NCT00076752|OTHER|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
224034170|NCT06461429|DRUG|Caffeine citrate 40 mg/kg load and 20 mg/kg daily maintenance|Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
224034171|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 1)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
224034172|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 2)|"* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™(D168)"
224034173|NCT06320535|BIOLOGICAL|R21/Matrix M™ (Group 3)|"* 10 mcg R21 in 50 mcg Matrix-M™ (D0)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)"
224034174|NCT06320535|PROCEDURE|Fine needle aspiration (FNA)|Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
224034175|NCT05004259|DRUG|Daratumumab / Hyaluronidase Injection|Subcutaneous injection of daratumumab and hyaluronidase
224034176|NCT05639972|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
224034177|NCT05639972|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
224034178|NCT05163288|DRUG|N-Acetyl-L-Leucine|N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet)
224034179|NCT05163288|OTHER|Placebo|Matching Placebo Sachet
224034180|NCT04908189|DRUG|Deucravacitinib|Specified dose on specified days
224137075|NCT00242580|DRUG|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
224137076|NCT03870126|OTHER|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
223418027|NCT00076752|OTHER|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
223418028|NCT00076752|PROCEDURE|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
223418029|NCT00076752|DRUG|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
223418030|NCT00076752|DRUG|Mesna|Priming regimen: 600 mg/m\^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m\^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
223418031|NCT03138252|DRUG|Oxytocin|
223418032|NCT06221592|DEVICE|defocus spectacle lenses|To evaluate the differences in controlling the progression of myopia in adolescents and the safety and comfort of wearing different types of defocus incorporated multiple segments spectacle lenses, to explore the feasibility of effective defocus micro lens design, and apply personalized defocus frame lenses for myopia prevention and control.
223418033|NCT04804748|OTHER|No intervention|no intervention
223418034|NCT00563810|DRUG|MYO-029|
224137077|NCT05745324|PROCEDURE|Scaling and root planing|SRP is cleaning the sub gingival and supra gingival plaque and calculus from the teeth
224137078|NCT01241669|DRUG|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
224137079|NCT01241669|DRUG|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
224137080|NCT04892758|DRUG|Formoterol fumarate 10 mcg|Formoterol fumarate 10 mcg dispensing claim is used as the reference group.
224137081|NCT04892758|DRUG|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID dispensing claim is used as the exposure group.
224137082|NCT00217867|BEHAVIORAL|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
223418035|NCT00100113|DRUG|GBR 12909|
223418036|NCT03076788|OTHER|electrocardiogram and echocardiography|"We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.~* Standard 12 lead ECG~* Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow."
223418037|NCT05499260|DRUG|CB03-154|CB03-154 tablet once daily.
223418038|NCT05499260|DRUG|Placebo|Placebo tablet once daily.
223418039|NCT04875988|PROCEDURE|Butterfly iQ+ Ultrasound|ultrasound will be used in the intervention group for IV access
223418040|NCT04875988|PROCEDURE|Traditional|ultrasound will not be used in the traditional IV placement group
223418041|NCT05906173|OTHER|Augmented Reality (AR)|AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
223418042|NCT06968455|OTHER|parabens|endocrine disruptors
223418043|NCT03137940|DEVICE|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
223418044|NCT03137940|DEVICE|sham tDCS|one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
223418045|NCT04594369|DRUG|Brensocatib 10 mg|Oral tablet.
223418046|NCT04594369|DRUG|Brensocatib 25 mg|Oral tablet.
223418047|NCT04594369|DRUG|Placebo|Brensocatib-matching oral tablet.
223418048|NCT06287632|DEVICE|Recruitment/ITP-CPAP (Intervention A)|Participant will receive a recruitment maneuver followed by CPAP set to the level of end-expiratory esophageal pressure (measured during atmospheric pressure breathing). The intervention will last for 20 minutes.
223418049|NCT06287632|DEVICE|Standard CPAP (Intervention B)|Participant will receive their home CPAP (if on CPAP at home) or CPAP at 8-10 cmH20 (if not on CPAP at home or no known diagnosis of OSA). The intervention will last for 20 minutes.
223418050|NCT06287632|DEVICE|Atmospheric Pressure|Participant will breathe at atmosphere pressure (no CPAP) with supplemental oxygen as needed per clinical guidance.
223418051|NCT02632409|BIOLOGICAL|Nivolumab|
223418052|NCT02632409|OTHER|Placebo|
223418053|NCT06094283|DRUG|YCT-529|Single oral dose (planned doses of 10, 30, 90 and 200 mg; dose levels will not exceed 250 mg
223418054|NCT06094283|DRUG|YCT-529 Placebo|YCT-529 Placebo
223418055|NCT00604097|BEHAVIORAL|Attachment-Based Family Therapy|12-16 week family-based therapy
223418056|NCT00604097|BEHAVIORAL|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
223418057|NCT05278546|DRUG|ILB2109|ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
223561455|NCT05754151|BEHAVIORAL|MAYA Mobile Application|The mobile cognitive behavioral therapy (CBT) application, MAYA, teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, exposure and psychoeducation (i.e. information about anxiety and depression). The application includes an interactive dashboard to provide the user with statistics for tracking progress toward their goals. Although the MAYA application is new, its content and structure are similar to how CBT- a well-established and widely used psychosocial intervention - is commonly delivered in the more traditional setting of a psychotherapist's office.
223561456|NCT05980871|DRUG|Doxycycline|doxycycline (100 mg orally twice daily for 7 days)
223561457|NCT05980871|DRUG|Ceftriaxone|Ceftriaxone (1g intramuscularly once)
224034181|NCT04908189|OTHER|Placebo|Specified dose on specified days
224034182|NCT04908189|DRUG|Apremilast|Specified dose on specified days
224034183|NCT06005064|DIETARY_SUPPLEMENT|Krill oil|Superba krill oil
223418058|NCT02102620|DRUG|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
223418059|NCT02102620|DRUG|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
223561458|NCT05980871|DRUG|benzathine penicillin G|benzathine penicillin G (2.4 MU intramuscularly once)
223561459|NCT06440980|DRUG|Orforglipron|Administered orally
223561460|NCT05085340|DRUG|Intermittent preventive treatment of malaria in infants (IPTi) with sulfadoxine-pyrimethamine (SP)|IPTi will be administered as full therapeutic courses of SP alongside routine EPI immunisations at defined intervals corresponding to vaccination schedules - usually at 10 weeks, 14 weeks, and 9 months of age - to infants living in project districts. Additional doses of IPTi will be administered at 6, 12, and 15 or 18 months of age, coinciding with vitamin A administration and measles booster immunisation. The number of doses of IPTi a child will receive will depend of the EPI schedule in the country, with a maximum of six doses in the first two years of life.
223561461|NCT04314531|DRUG|TILD|one 1 mL injection of study medication
223561462|NCT04314531|DRUG|matching placebo injections|one 1 mL injection of placebo
224034184|NCT06005064|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
224034185|NCT05838300|DEVICE|Warm humidified CO2|Participants will receive warm (37°C) and humidified (95%) CO2.The humidification and warming device to be used is AlwaysPneumo® AP 50/30 InsuflowPort® (Lexion Medical, FDA approved) which is a specialized port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source
223418060|NCT01337492|DRUG|Nexavar|400 mg of Sorafenib
223418061|NCT06294366|DEVICE|Bipolar Bowa device|Bipolar Bowa device used in prostatic resection and enucleation
223418062|NCT06284057|PROCEDURE|Bifurcation PCI with two stent technique Culotte Technique or Double Kiss (DK) Culotte|Patient with CAD and coexisting bifurcation lesion requiring two-stent approach treated with Culotte Technique or Double Kiss (DK) Culotte due to operator distraction.
223418063|NCT00049166|DRUG|erlotinib hydrochloride|Given orally
223418064|NCT00049166|DRUG|cisplatin|Given IV
223418065|NCT00049166|RADIATION|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
223418066|NCT00049166|OTHER|laboratory biomarker analysis|Correlative studies
223418067|NCT01397396|PROCEDURE|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of \>50% Pi,max
223418068|NCT01867710|DRUG|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
223418069|NCT01867710|DRUG|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
223561463|NCT04450771|BEHAVIORAL|Family-based Treatment for ARFID|This treatment includes 14 1-hour sessions that will be conducted approximately weekly over a 4 month period. It is a manualized treatment based on the model of FBT that employs the same interventions as standard FBT for AN and BN: externalization, agnosticism, parental empowerment, a behavioral focus on changing eating behavior.
224034186|NCT05838300|DEVICE|Dry CO2|Participants will receive standard cold (19-21 °C) and non-humidified (0%) CO2 insufflation with Airseal Insufflator
223418070|NCT01867710|DRUG|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
224034187|NCT06107153|DRUG|Insulin Glargine 100 UNT/ML Pen Injector [Lantus]|Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
223418071|NCT01867710|DRUG|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
223418072|NCT01867710|DRUG|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
223418073|NCT00644410|BIOLOGICAL|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
223561464|NCT04450771|BEHAVIORAL|Manualized Non-Specific Usual Care for ARFID|This treatment is a manualized non-specific psycho-educational and motivational enhancement approach that is based on a supportive non-directive psychotherapy model. It consists of sessions with the child alone and 5 parent-only meetings, all of which are 1-hour over a 4 month period.
223418074|NCT00644410|BIOLOGICAL|Saline|12 injection with 0.2 ml saline
223418075|NCT06676475|DRUG|MgSO4|2ml MgSo4 (Magnesium sulfate sterile ampoule 10 ml, 100 mg/ml = 0.41 mMol/ml. Egyptian Int. Pharmaceutical Industries Co., Egypt).
223418076|NCT06676475|DRUG|BOTOX-A|2ml of BTX
223418077|NCT06676475|DRUG|Saline (NaCl 0,9 %) (placebo)|2 ml of saline
223418078|NCT02216656|DRUG|Placebo|Oral administration
223418079|NCT02216656|DRUG|KHK7580 low dose|Oral administration
223418080|NCT02216656|DRUG|KHK7580 middle dose|Oral administration
223418081|NCT02216656|DRUG|KHK7580 high dose|Oral administration
223418082|NCT02216656|DRUG|KRN1493|Oral administration
223561465|NCT06580249|DEVICE|Repetitive transcranial magnetic stimulation|The true stimulus group acted directly, whereas the pseudo stimulus group reversed the head to produce no effect. Both groups were treated with sertraline medication。
223561466|NCT05467410|BEHAVIORAL|COG-AM|Participants who are randomized to the COG-AM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during morning hours (between 09:00-12:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
223561467|NCT05467410|BEHAVIORAL|COG-PM|Participants who are randomized to the COG-PM intervention group will be asked to complete 30-minute computerized cognitive training (Lumosity cognitive training program) sessions during late afternoon/early evening hours (between 15:00-18:00), for a total of 7 days or until hospital discharge, whichever comes first. Participants will complete cognitive training sessions in each of the following subdomains: memory, attention, problem solving, cognitive flexibility, and processing speed.
223561468|NCT05120570|DRUG|VIC- 1911|25 mg, 50 mg, or 75 mg administered twice a day from day 5 post HCT to day 45, and the dose escalation will stop once we identify the lowest biologically active and safe dose of VIC.
224034188|NCT06107153|DRUG|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg|Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
224034189|NCT06107153|DRUG|Pioglitazone 30mg|Pioglitazone 30mg
224034190|NCT05666050|BEHAVIORAL|Mobile health intervention|Pregnant women with 26-28 weeks of gestation(based on world health organization eligibility criteria) will be recruited and baseline data will be collected at selected clusters. Women who will provide informed consent will be asked to complete a post-consent eligibility assessment including access to a mobile phone, and willingness to receive health messages on their mobile phone. Women who meet these eligibility criteria will be enrolled in the study and administered the baseline interview. Intervention will be started among randomly selected clustered pregnant women at 30 weeks of gestation and will be continued up to 6 weeks of post partum period for 4 months.
223418083|NCT06610578|DIAGNOSTIC_TEST|fundus imaging|Fundus photography, OCT or OCTA
223418084|NCT03521115|BEHAVIORAL|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
223418085|NCT06043960|OTHER|Humac Norm İsokinetic Machine|Tecno Body Prokin Isokinetic Balance System CSMI (CYBEX) Humac Norm Isokinetic Testing and Exercise System Romberg Test Mini Mental Test (MMSE) Fugl-Meyer Assessment of the lower limb
223418086|NCT03903094|OTHER|Non-Interventional|Overview of anticholinergic burden, rather than to evaluate specific drugs
223418087|NCT04792801|RADIATION|PET TDM FDG-Choline|Performing an FDG TDM PET and a Choline TDM PET at two different times
223418088|NCT00714012|OTHER|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
223418089|NCT01470625|OTHER|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
223418090|NCT01461317|DRUG|Etrolizumab|Participants will receive etrolizumab at a dose of 100 mg.
223418091|NCT01202942|OTHER|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
223418092|NCT04501640|DRUG|mirabegron|Oral adminstration
223418093|NCT05961072|DEVICE|Vibrotactile sensory feedback device|"The company Saphenus Medical Technology GmbH will provide all of the devices for this study. The non-invasive vibrotactile sensory feedback device consists of 4 vibration -motors, which are placed in a cuff or pant on the patient's residual limb (RL). Furthermore, the system consists of a foot sole with integrated sensors and transmitters. The patient will put the sole of their foot into the shoe of the amputated side.~There are 4 sensors matching the vibration motors - 3 under the forefoot and 1 on the heel - in the foot sole. Depending on whether the patient loads their forefoot or their heel while walking, the assigned vibration motor vibrates on the skin of their RL. The patient will learn which vibration motor is assigned to their forefoot and which to their heel. This gives the patient sensory feedback without having to check with their eyes which part of the prosthetic foot is currently touching the ground."
223418094|NCT05670795|DRUG|Recombinant Follicle Stimulating Hormone|clinical pregnancy rates
223418095|NCT05670795|DRUG|Recombinant Follicle Stimulating Hormone and Clomiphene Citrate|clinical pregnancy rates
223418096|NCT04765150|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
223561469|NCT05817058|DRUG|AFM28|AFM28 dose escalation
223561470|NCT05170724|DRUG|Remibrutinib|Remibrutinib should be taken in accordance with the recommendations in the treatment plan.
223561471|NCT03910751|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
223561472|NCT03931382|BEHAVIORAL|Virtual Reality Simulator|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
223561473|NCT03931382|BEHAVIORAL|Mock MRI Simulator|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
223561474|NCT03931382|BEHAVIORAL|Standard Preparation Manual|The standard MRI preparation manual provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
224034191|NCT04683731|BEHAVIORAL|Decision aid without personalized message|The decision aid without personalized message consists of a PowerPoint presentation converted to mp4 (video) with text, photos, and an audio track, that is advanced by the viewer and can be viewed online. It begins with a 60 sec video on CRC screening produced by the Centers for Disease Control and Prevention (CDC), followed by slides summarizing the advantages and disadvantages of colonoscopy and stool testing with the fecal immunochemical test (FIT) and DNA+FIT (Cologuard). The presentation is approximately 10 minutes long.
224034192|NCT04683731|BEHAVIORAL|Decision aid with personalized message|The decision aid with personalized message will first present the decision aid without personalized message followed by additional PowerPoint slides converted to mp4 (video) with text, photos, and an audio track briefly explaining the risk tool, the participant's score on the 5 risk factors, total score, ACN risk, and implications for screening and test choice. The presentation is approximately 14 minutes long.
224034193|NCT04683731|BEHAVIORAL|Provider notification without personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
224034194|NCT04683731|BEHAVIORAL|Provider notification with personalized message|Providers will receive a message informing them that their enrolled patient is due for CRC screening. The notification will also include the patient's ACN risk (very low, low, moderate, high-average) and implications for screening decisions and test choice. Links to a web landing page containing a more detailed explanation of the risk tool and additional references will be included. The notification will be sent to them through the electronic health record (EHR) within 24 hours of their visit with the enrolled patient.
224034195|NCT04738825|BEHAVIORAL|Contingency Management with stepped care to PrEP adherence and support services (CoMPASS)|"Participants will receive contingency management sessions (n=9). Participants who do not demonstrate PrEP adherence by week 12 will be stepped up to receive PrEP adherence and support services (n=5)."
224034196|NCT04494360|OTHER|No intervention|No investigational medicinal product will be administered as a part of this study.
223418097|NCT04765150|OTHER|Electronic Health Record Review|Medical charts are reviewed
223561475|NCT04303013|BEHAVIORAL|Meditation|Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
223561476|NCT04303013|OTHER|Standard of Care|Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
223561477|NCT05457907|DEVICE|Ultrasound device|Low energy ultrasound therapy will be administered to the spleen
224034197|NCT05236231|DRUG|Macitentan 10 mg|Macitentan 10mg tablet will be administered orally as per assigned treatment sequence.
224034198|NCT05236231|DRUG|Tadalafil 20 mg|Tadalafil 20mg tablet will be administered orally as per assigned treatment sequence.
223561478|NCT05623475|BEHAVIORAL|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
223561479|NCT05623475|BEHAVIORAL|Lecture|Face-to-face Education using Delirium Care Flip Chart
223561480|NCT05623475|BEHAVIORAL|E-learning|Delirium care video
223561481|NCT00542490|RADIATION|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
224034199|NCT05236231|DRUG|Macitentan 10 mg/Tadalafil 20mg FDC|FDC of Macitentan 10 mg/Tadalafil 20 mg will be administered orally as single dose tablets.
223561482|NCT05271253|DRUG|Dexmedetomidine|0.5 mic /kg dexmedetomedine is injected after induction of anaesthesia.
223561483|NCT05271253|DRUG|bupivacaine|0.25% bupivacaine is injected in the caudal epidural space
223561484|NCT05271253|DRUG|normal Saline|injection of normal Saline
223418098|NCT06667050|DRUG|Chemotherapy plus sintilimab and bevacizumab|"Laparoscopic exploration should be performed to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum.~3 cycles of neoadjuvant therapy will be administered: capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w. Radical D2 gastric cancer resection will be performed within 6-8 weeks after the last administration of chemotherapy plus sintilimab and bevacizumab biosimilar (IBI305).~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with CAPOX regimen for up to 3 cycles."
223418099|NCT03116555|DRUG|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
223418100|NCT03116555|DRUG|Irinotecan|Irinotecan was used as second line treatment with AGC
223418101|NCT01623635|DRUG|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
223418102|NCT01623635|DRUG|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~* each subdiaphragmatic area 3.5 ml + 3.5ml~* surgical dissection site 3 ml~* diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
223418103|NCT02960035|DRUG|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
223418104|NCT02960035|DRUG|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
223418105|NCT02960035|DRUG|placebo|
223418106|NCT04661241|OTHER|Automatic DRT/VIM target-recognition method using MR-SISET and ML approaches|The proposed sequence (\<15 minutes) will be added as a supplementary sequence only for the preoperative imaging for subjects who agree to participate: a 3D multi-echo GRE sequence will be performed during a preoperative MR imaging, using the following parameters: field of view = 220x170x75 mm3, matrix = 176x136x60, 1.25-mm isotropic resolution, flip angle = 22 degrees, TR = 92 ms, 20 TEs = 1.90 - 45.98 ms with echo spacing of 2.32 ms, bandwidth = 840 Hz/pixel.
223418107|NCT04661241|OTHER|Routine clinical MRI protocol|MRI will be performed using 3T scanner (Skyra, Siemens, Erlangen, Germany). All patients will undergo preoperative MRI of the brain including routine clinical MRI protocol (T1-/T2-weighted and diffusion imaging) under general anesthesia to reduce movement artifacts.
223418108|NCT04259658|COMBINATION_PRODUCT|Calcium electroporation|Patients with cutaneous metastases will be treated with calcium electroporation.
223418109|NCT06350435|DEVICE|Prefabricated foot orthoses (PFO) with metatarsal pads|A pair of prefabricated foot orthoses, each with a metatarsal pad to be affixed underneath
223418110|NCT06350435|DEVICE|Prefabricated foot orthoses (PFO) without metatarsal pads|A pair of prefabricated foot orthoses only
223418111|NCT02229279|DEVICE|Teleconsulting|
223561485|NCT05213637|BIOLOGICAL|Expanded Activated Lymphocytes (EAL)|12\~20 doses of EAL (1×10\^9\~2×10\^10 cells per dose) will be infused into patients.
223418112|NCT01981954|DRUG|Solifenacin succinate|Oral suspension
223418113|NCT06682377|PROCEDURE|Radiofrequency ablation alone|No touch RFA with dual switching monopolar + bipolar mode
223418114|NCT00527033|DRUG|YM178|Oral
224034200|NCT05101707|DEVICE|transcutaneous auricular vagus nerve stimulation|Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
224034201|NCT05101707|OTHER|Constraint induced movement therapy|Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
223418115|NCT00527033|DRUG|Placebo|Oral
223418116|NCT01404754|DRUG|Lactose (inactive placebo)|Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
223561486|NCT05213637|PROCEDURE|transarterial chemoembolization (TACE)|After angiography, fluorouracil will be injected into the proper hepatic artery or the segment of liver where the original lesion is located, and then microcatheter will be introduced into the segment of liver artery where the incision margin is located, and iodized oil injection and epirubicin will be mixed and embolized.
224034202|NCT06559527|DRUG|NNC0487-0111|Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
224034203|NCT06111807|DIAGNOSTIC_TEST|ctDNA|ctDNA will be tested retrospectively, no treatment decisions will be made prospectively
224034204|NCT01630044|DEVICE|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
224034205|NCT05596799|BEHAVIORAL|Facing Eating Disorder Fears Condition|The first session consists of diagnosis and general psychoeducation on anorexia nervosa and treatment for anorexia nervosa. After psychoeducation and baseline questionnaires are complete, sessions 2-12 include exposure-based virtual treatment for common eating disorder fears (food, weight gain, body sensations, and social situations).
224034206|NCT05834816|BEHAVIORAL|Negative Affect Task|fMRI stress task
223418117|NCT01404754|DRUG|midomafetamine HCl|120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
223418118|NCT00971607|DRUG|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
223418119|NCT00971607|DRUG|Oxygen (placebo)|Control will receive oxygen only.
223418120|NCT03655470|BEHAVIORAL|Safety Planning|Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
223418121|NCT03655470|BEHAVIORAL|Standard care|Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
223418122|NCT06304285|OTHER|Acupuncture treatment|Acupuncture was performed according to the corresponding acupoint of the patient
223418123|NCT06304285|OTHER|Sham acupuncture treatment|The needle only touches the patient's skin and does not penetrate the skin
223418124|NCT06624007|OTHER|pediatric Nursing Excellence (PNE) model|The intervention group will apply pediatric Nursing Excellence (PNE) model included 28 Likert-type questions to assess nurses' general excellence level regarding the care of children undergoing orthopedic surgeries grouped under five main categories including engagement, values, principles, care delivery and continuous improvement.
223418125|NCT02272907|OTHER|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
223418126|NCT06682715|DIETARY_SUPPLEMENT|whey protein|10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
223418127|NCT06682715|DIETARY_SUPPLEMENT|maltodextrin|10 out of 20 participants will be randomly added in this group after initial consent in which they will be fully informed about all benefits, risks, and discomforts of this investigation. Screening process will include (1) subjects of age 18-30 years of age; (2) subjects should be free of any recent history of illnesses, musculoskeletal problems, and metabolic diseases; (3) are not using any supplements and medications; and (5) participated in ≥5 training sessions/week.
223418128|NCT06682715|BEHAVIORAL|nutrition education|Nutrition for sports knowledge questionnaire will be used to assess the pre-nutrition education and post-nutrition education knowledge of athletes. Nutrition education will be given using evidence based nutrition education hand-outs and one-on-one counselling for each athlete in which they will be guided about sources of high biological value protein sources to meet daily protein requirement. Dietary intake will be monitored using 3 day food record method during 2-6 weeks of supplementation. Food logs will be filled out by participants during each weeks to monitor their protein intake. Three food logs (2 weekdays \[Mon-Thurs/Tue-Fri\] and 1 weekend day \[Sat/Sun\]) will be submitted by each subject every week.
223418129|NCT03865615|DRUG|Oxytocin|intranasal oxytocin 40IU/mL
223418130|NCT03865615|DRUG|Placebo|Placebo
223418131|NCT01403688|PROCEDURE|RPFNA|"1. Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~2. Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~3. Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
223418132|NCT06200311|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation using pulsed field ablation (PFA), cryoballoon or radiofrequency ablation (RFA)
223418133|NCT06200311|DRUG|Pharmacological rhythm management|1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
223418134|NCT06685471|DIAGNOSTIC_TEST|Screeing test|Simulation-Based Training Program Effect on Pediatric Nurses' Knowledge and Performance Regarding Heel-Prick during Newborn Blood Screening Test
224034207|NCT05867537|DIETARY_SUPPLEMENT|Gluten-free diet|Implementation a 78-week dietary intervention to patients with ulcerative colitis, crohn´s disease and UC patients with associated PSC (PSC-IBD).
224034208|NCT04181684|DEVICE|Procedure: LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
224034209|NCT04181684|RADIATION|Hypo-Fractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
224034210|NCT06443203|OTHER|Trimodal prehabilitation|Trimodal prehabilitation program (4-week physical exercise before surgery, nutritional optimization, and psychological support) in patients undergoing ERAS colorectal resection for cancer
224034211|NCT04577547|OTHER|DGA diet WL & exercise|Intake of DGA weight loss 8 day rotating menu \& PAGA-recommended exercise
224034212|NCT04577547|OTHER|DGA diet WL & no exercise|Intake of DGA weight loss 8 day rotating menu \& no exercise
224034213|NCT04577547|OTHER|DGA diet WM & exercise|Intake of DGA weight maintenance 8 day rotating menu \& PAGA-recommended exercise
224034214|NCT04577547|OTHER|DGA diet WM & no exercise|Intake of DGA weight maintenance 8 day rotating menu \& no exercise
224034215|NCT04577547|OTHER|Western diet WL & exercise|Intake of Western-type weight loss 8 day rotating menu \& PAGA-recommended exercise
224034216|NCT04577547|OTHER|Western diet WL & no exercise|Intake of Western-type weight loss 8 day rotating menu \& no exercise
224034217|NCT04577547|OTHER|Western diet WM & exercise|Intake of Western-type weight maintenance 8 day rotating menu \& PAGA-recommended exercise
224034218|NCT04577547|OTHER|Western diet WM & no exercise|Intake of Western-type weight maintenance 8 day rotating menu \& no exercise
224034219|NCT03685175|DRUG|Formal study using hyperpolarized 13C-pyruvate injection|Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)
224034220|NCT03685175|DRUG|Feasible study using hyperpolarized 13C-pyruvate injection|Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy
223418135|NCT04723628|BEHAVIORAL|Intervention group (telephone counseling)|Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
223418136|NCT00887783|DRUG|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
223418137|NCT00887783|RADIATION|66 Gy/33F|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
223561487|NCT03589989|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
223561488|NCT03589989|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
223561489|NCT04379687|OTHER|Virtual reality|Use of virtual reality glasses for balance work
223561490|NCT04379687|OTHER|Control group|Balance treatment with according to Bayouk physiotherapy
223561491|NCT03316118|DRUG|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
223561492|NCT03316118|DRUG|saline|Group 2 will receive genicular nerve block using normal saline
223561493|NCT02621541|DEVICE|PET/CT|
223561494|NCT00100074|DRUG|Lobeline|
223561495|NCT01618435|BIOLOGICAL|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
223561496|NCT00472654|BEHAVIORAL|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
223561497|NCT00472654|DIETARY_SUPPLEMENT|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
223561498|NCT00472654|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 weeks
223739325|NCT07206446|DEVICE|RiSolve|"RiSolve is a Class I device in accordance with Rule 11 of Annex VIII of EU Medical Device Regulation (MDR) 2017/745. The RiSolve App is a smartphone application that users can download following a diagnosis of OAB by a healthcare provider, and following prescription of the RiSolve App. RiSolve consists of an 8-week program including activities to set baselines and assess progress, treatment modules, and modules to enhance engagement.~As part of setting baselines and assessing progress, participants complete a series of clinically validated questionnaires. This data is presented to users to promote self-monitoring of behaviours and a deeper understanding of their symptoms. A patient report is auto-generated at the end of treatment. This is sent to the patient and contains their in-app self-generated data, their questionnaire results and their bladder diary data (see Appendix 1: RiSolve Patient Report). This information is also provided to the prescribing healthcare provider as an object"
224034221|NCT05484206|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection.
224034222|NCT05484206|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection.
223418138|NCT00887783|RADIATION|60 Gy/30F|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
223418139|NCT05420298|OTHER|cervical mobilization|All participants will receive only single session of cervical mobilization
223418140|NCT05420298|OTHER|cervical manipulation|All participants will receive only single session of cervical manipulation
223561499|NCT04715854|DEVICE|Mask|addition of the mask above the nasal cannulas
223561500|NCT06237127|DIETARY_SUPPLEMENT|Goji berry|Participants will be instructed to consume 14 grams of goji berries 5 days a week for 6 months
223561501|NCT06237127|DIETARY_SUPPLEMENT|Fiber|Participants will be instructed to consume the fiber supplements 5 days a week for 6 months
223561502|NCT00908323|BIOLOGICAL|JS7 DNA vaccine|
223561503|NCT00908323|BIOLOGICAL|MVA/HIV62 vaccine|
223561504|NCT05017389|DIAGNOSTIC_TEST|Griffiths development scales|Griffiths development scales Chinese Edition (gds-c) was used to evaluate the development levels of children up to 6 years and WISC for children more than 6 years.
223561505|NCT01152593|DRUG|Mupirocin|Intranasal cream given to patient after confirmation of colonization
223561506|NCT02274480|DEVICE|cardiac MRI with DWI|
223561507|NCT04641728|DRUG|Pembrolizumab|pembrolizumab 200 mg every three weeks (Q3W)
223561508|NCT04641728|DRUG|Olaparib|olaparib 300 mg twice daily (BID)
223561509|NCT06493786|OTHER|Collection of body odor samples|"Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion."
223561510|NCT01731340|DIETARY_SUPPLEMENT|Calcium Citrate|750mg
223561511|NCT01731340|OTHER|Low Dietary Calcium|450 mg
223561512|NCT01731340|OTHER|High Dietary Calcium|1200 mg
224034223|NCT06506058|DEVICE|EVS and EEG|"The participant can choose to participate in one or more of the following experiments. (Any two of these visits will be separated by at least one week.) Experiment 1: EVS during gait initiation (forward stepping, 2 visits) Experiment 2: EVS during turning (1 visit) Experiment 3: EEG during gait initiation (forward stepping, 1 visit) Experiment 4: EEG during RAMS (1 visit)~vestibular activity will be assessed using the noninvasive neuromodulation technique of electrical vestibular stimulation (EVS, Experiments 1 and 2) and cortical activity will be assessed by recording via electroencephalography (EEG, Experiments 3 and 4, no stimulation included)."
223418141|NCT04335409|DIAGNOSTIC_TEST|Questionnaire|The patients are asked to complete a questionnaire (paper version) once a week during the period of radiotherapy and up to 24 weeks following radiotherapy. In this questionnaire, the patients are asked to state and rate their symptoms potentially associated with pneumonitis. Scoring points are assigned to the severity of the symptoms (symptom scores), and the resulting sum score (patient score) will be used for identification of radiation pneumonitis.
223561513|NCT00203866|DRUG|G250 peptide|
223561514|NCT00203866|DRUG|IL-2|
223561515|NCT01049204|DRUG|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
223561516|NCT01049204|DRUG|placebo|Placebo twice daily for 24 weeks
224034224|NCT05492396|DEVICE|Standard gluteus medius repair with Tapestry Biointegrative implant|Patients will undergo standard gluteus medius repair utilizing augmentation.
224034225|NCT06385652|DRUG|68Ga-NB381|"Lei Kang from Peking University First Hospital and Bing Jia's team from the School of Basic Medical Sciences at Peking University have developed a targeted CD38 nanobody sequence using genetic engineering technology. They have optimized its structure, functionalized it with labeling, and conducted imaging and other evaluations, ultimately producing the CD38-targeted nuclear medicine small molecule diagnostic and therapeutic agent-68Ga-labeled nanobody NB381. The post-labeling quality control of the drug meets clinical trial requirements with a radiochemical purity (PCR) greater than 98% and in vitro stability not less than 90%.~Preliminary PET imaging results of 68Ga-NB381 indicate that the nanobody is primarily concentrated in the kidneys, bladder, and MM.1S and Ramos or H929 tumors (CD38+). Additionally, the cold antibody NB381 significantly inhibits the uptake of 68Ga-NB381 in tumors, confirming the high specificity of this nanobody's binding to the CD38 protein."
224034226|NCT06538597|BEHAVIORAL|Self-compassion intervention (Self-Compassion for Healthcare Communities course)|An online 6-week mindful self-compassion course with weekly sessions.
224034227|NCT05428254|OTHER|Capacitive and Resistive Radiofrequency therapy|"TECAR or CRRT is electromagnetic waves produced by high frequency electrical current that are able to penetrate very deep and produce a long-lasting heat which stimulates the superficial and dep tissues and produce a potent long-lasting pain-relieving effect. Mild intensity of heat produced by the long wave diathermy may be used to promote proliferation (Hernández-Bule et al., 2014) and improve the vascularization of skin and muscles.~The integration of two operational modes, Capacitive (CAP) and Resistive (RES), makes it possible to combine sub-thermal (electric) and thermal effects. Indiba radiofrequency has output frequency: 448kHz ± 1 kHz with Maximum output power in RES mode: 100 W and in CAP mode: 350 VA. The capacitive used an isolated metal coated electrode acts as a dielectric surface which concentrate the electrical charges near the capacitive electrode While the resistive electrode causing the diffusion of electrical charges which accumulate near bone and soft tissues."
224034228|NCT05428254|OTHER|Exercise therapy|Stretching of the neck extensor, upper fibers of trapezius, levator scapulae and scalenus muscles. stretching is applied for at least 15 seconds and repeated ten times in each session.
224034229|NCT02857998|DRUG|HMPL-523|Oral administration, once daily
224034230|NCT00416377|BIOLOGICAL|bleomycin sulfate|
224034231|NCT00416377|DRUG|chlorambucil|
224034232|NCT00416377|DRUG|dacarbazine|
224034233|NCT00416377|DRUG|doxorubicin hydrochloride|
224034234|NCT00416377|DRUG|prednisolone|
224034235|NCT00416377|DRUG|procarbazine hydrochloride|
224034236|NCT00416377|DRUG|vinblastine sulfate|
224034237|NCT00416377|DRUG|vincristine sulfate|
224034238|NCT00416377|RADIATION|radiation therapy|
224137083|NCT01743339|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
224137084|NCT01743339|BEHAVIORAL|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
224137085|NCT05232422|BEHAVIORAL|Hatha yoga course|Participants will join a free hatha yoga course, conducted by a professional yoga teacher, over a time period of eight weeks with a frequency of at least three up to five times a week. The quality of the implementation of the intervention will be checked through post-monitoring by short questionnaires to be filled out by participants.
224137086|NCT03104335|DRUG|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) \> 1.5 and 500mg daily for BSA \<1.5. Half an hour after meal and everyday at the same time is usually advised.
224137087|NCT04136613|DEVICE|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
223418142|NCT04335409|OTHER|Mobile Application|In 10 patients, the paper version of the symptom-based scoring system (questionnaire) will be supplemented by a mobile application (app) asking the same questions regarding symptoms potentially associated with pneumonitis.
223561517|NCT04556955|DEVICE|Graston technique|Experimental group included Graston technique :The protocol consist of Longitudinal stroking parallel to muscle fiber for 1min , spin over trigger points for 1 min using knob of instrument and fanning for 2 min.
223561518|NCT04556955|OTHER|post isometric relaxation|Post Isometric Relaxation, 5 rep , 20% isometric contraction 10 sec , 20 sec of stretch hold beyond resistance barrier
223561519|NCT00711230|BIOLOGICAL|DermaVir|
223561520|NCT00711230|BIOLOGICAL|Placebo|glucose/dextrose
223561521|NCT00778375|DRUG|Clofarabine|20 mg/m\^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
223561522|NCT00778375|DRUG|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
223418143|NCT05517109|OTHER|Hemodynamic goal including lower goal of systolic blood pressure|Different hemodynamic goals in different study arms
223418144|NCT04349462|DIAGNOSTIC_TEST|VideoFlurosocopy Swallow Study|VFSS is a radiological examination that can identify the presence, nature and severity of any abnormalities in oropharyngeal, laryngeal and upper esophageal swallow physiology. The VFSS will be administered via a standardized protocol by a registered speech-language pathologist (SLP). During the VFSS, the patient is seated upright and swallows a variety of consistencies (eg. liquids, semisolids and solids) and volumes of barium-coated foods. A dynamic fluoroscopic image will be digitally captured and recorded.
223561523|NCT00778375|DRUG|Decitabine|20 mg/m\^2 as a 1- to 2-hour infusion daily for 5 days.
223561524|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat|A preparation of autologous microfat (5mL) will be injected intra-articularly.
223561525|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
224034239|NCT06241508|DEVICE|Transcranial magnetic stimulation|A standard 600-pulse TBS \[16\] will be administrated using a MagPro X100 stimulator (MagVenture, Denmark) and a 65-mm figure-of-eight coil. The measurement of the motor hotspot and individual RMT will be in accordance with our established methodology \[3, 9\]. For patients with stroke, the intensity of real stimulation will be 55% or 70% RMT of the unaffected M1 \[17\], depending on their assigned condition. Sham stimulation will be delivered using the same coil with 20% RMT of the unaffected M1 \[4, 6\]. The priming and conditioning sessions will be delivered to the ipsilesional M1 sequentially. In line with previous works, the interval between them will be 10 minutes \[2, 3\]. For healthy adults, the stimulation will be applied exclusively to the non-dominant (right) M1.
224137088|NCT05201183|COMBINATION_PRODUCT|Fludarabine + Total Marrow Irradiation|"Patients will receive total marrow irradiation TMI on Day -11 to Day -7 in two fractions per day. The TMI dose will be escalated in successive cohorts compromised of 3-6 patients as follows:~Cohort 1 1.4 (Gy/fraction) Cohort 2: 1.6 (Gy/fraction) Cohort 3 1.8 (Gy/fraction) Cohort 4 2.0 (Gy/fraction) Cohort 5 2.2 (Gy/fraction)~Patients will receive Fludarabine (30 mg/m2/day) on Day -6 to Day -2 followed by allo-HSCT on Day 0."
224137089|NCT04791683|OTHER|sexaul counseling|Sexual counseling includes interviews about sexual problems in couples who are in the process of infertility treatment and suggestions for solving these problems.
224137090|NCT00029991|DRUG|Gingko Biloba (Herb)|
224137091|NCT01232894|DRUG|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
224137092|NCT01232894|DRUG|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
224137093|NCT04720586|PROCEDURE|lower eyelid blepharoplasty , retractor plication and wedge resection|combined lower eyelid blepharoplasty , retractor plication and wedge resection
224137094|NCT04720586|PROCEDURE|lower eyelid blepharoplasty and retractor plication|combined lower eyelid blepharoplasty and retractor plication procedures
224137095|NCT00753935|DRUG|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
224137096|NCT00753935|DRUG|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
223418145|NCT04349462|DIAGNOSTIC_TEST|Water Sip Test|The steps of the water sip test include; 1. The patient will be given 5 ml of water, and if tolerated 20 ml followed by 50 ml of water (thin fluid) and the patient is assessed for cough/chocking during or after swallowing, wet or weak cough after swallowing. 2. The patient is asked to produce sustained vowel /a/ before and after swallowing of water and voice change after swallowing will be observed and recorded.
223418146|NCT05194891|DIAGNOSTIC_TEST|Specular Microscopy|Phacoemulsification
223418147|NCT04793529|DRUG|Cholecalciferol|Cholecalciferol injection
223418148|NCT03063086|DRUG|QVM149 150/50/80 μg o.d.|A
223418149|NCT03063086|DRUG|QVM149 150/50/160 μg o.d.|B
223418150|NCT03063086|DRUG|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
223418151|NCT02070016|DEVICE|Transcranial Magnetic Stimulation|
223418152|NCT00489086|DRUG|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
223418153|NCT02222350|DRUG|10mg DS-8500a tablet|
223561526|NCT06084637|BIOLOGICAL|Intra-articular injection of autologous microfat and platelet-rich plasma|A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
223561527|NCT01516580|DRUG|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
224034240|NCT05833074|BEHAVIORAL|Couples HIV testing and counseling|Couples HIV testing follows a CDC published protocol for delivery of HIV testing to relationship partners. HIV test results are obtained from Oraquick (FDA approved for at home HIV testing)
224137097|NCT04546386|PROCEDURE|Endoscopic endonasal pituitary surgery|Surgical treatment consisted of an endoscopic endonasal approach using a rigid 0-degree endoscope, 18 cm in length and 4 mm in diameter
224137098|NCT03970395|OTHER|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
223418154|NCT02222350|DRUG|75mg DS-8500a tablet|
223418155|NCT02222350|DRUG|placebo|
223418156|NCT05426486|DRUG|ARX788|HER2 antibody-drug conjugate
223418157|NCT05426486|DRUG|Pyrotinib maleate|EGFR/HER2 dual inhibitor
223418158|NCT05426486|DRUG|Trastuzumab|anti-Her2 monoclonal antibody
223418159|NCT05426486|DRUG|Pertuzumab|anti-HER2 monoclonal antibody
223418160|NCT05426486|DRUG|Docetaxel|Cytotoxic chemotherapy
223418161|NCT05426486|DRUG|Carboplatin|Cytotoxic chemotherapy
223418162|NCT05283343|DEVICE|SP-1P|A subject undergoes corneal thickness measurement with pachymeter.
223418163|NCT04590586|DRUG|Standard of care|Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
223418164|NCT04590586|DRUG|Apremilast|Apremilast administered orally as a tablet.
223418165|NCT04590586|DRUG|Apremilast placebo|Matching apremilast placebo administered orally as a tablet.
223418166|NCT04590586|DRUG|Lanadelumab|Lanadelumab administered as an intravenous (IV) infusion.
223418167|NCT04590586|DRUG|Lanadelumab placebo|Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
223418168|NCT04590586|DRUG|Zilucoplan|Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
223561528|NCT01516580|DRUG|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
223561529|NCT02110654|DRUG|Montelukast|
223561530|NCT02110654|DRUG|mometasone furoate nasal spray|
223561531|NCT02030925|DRUG|IW-3718|
223561532|NCT02030925|DRUG|Matching Placebo|
223561533|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
223561534|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
223561535|NCT01399151|DIETARY_SUPPLEMENT|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
223561536|NCT05210699|OTHER|Product A|Usual Brand (UB) filtered, menthol combustible cigarette
223561537|NCT05210699|OTHER|Product B|Flavor variant P1211216 of a 1.5% nicotine ENDS product
223561538|NCT05210699|OTHER|Product C|Flavor variant P1211217 of a 2.4% nicotine ENDS product
223561539|NCT05210699|OTHER|Product D|Flavor variant P1211222 of a 5.0% nicotine ENDS product
224034241|NCT05833074|BEHAVIORAL|Individual HIV testing and counseling|Individual HIV testing and counseling uses a counseling protocol based on the standard of care for routine HIV pre- and post-test counseling. HIV test results are obtained from Oraquick (FDA approved for at home testing)
224034242|NCT04569695|DRUG|JNJ-70033093|JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
223418169|NCT04590586|DRUG|Zilucoplan placebo|Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
223418170|NCT05187286|DRUG|Apixaban|Administered as directed by treating physician
223418171|NCT05121714|DRUG|Caffeine|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
223418172|NCT05121714|DRUG|ABX464|This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).
223418173|NCT05121714|DRUG|Fluvoxamine|his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).
223418174|NCT01893281|DRUG|Topical Testosterone Solution|Administered topically to axillae.
223561540|NCT05210699|OTHER|Product E|Flavor variant P1213616 of a 1.5% nicotine ENDS product
223561541|NCT05210699|OTHER|Product N|Nicorette® White Ice Mint 4 mg nicotine gum
224034243|NCT06571149|DRUG|Tenecteplase or Alteplase|Patients randomized to intravenous thrombolysis (IVT) treatment will receive intravenous Tenecteplase or Alteplase.
224034244|NCT03733639|DRUG|Tisseel|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
224034245|NCT03733639|DEVICE|No Tisseel|No reinforcement of esophagojejunal anastomoses after total gastrectomy
224034246|NCT00898183|GENETIC|gene expression analysis|
223418175|NCT03470155|PROCEDURE|mitral valve repair|operative reconstruction
223418176|NCT05879523|DRUG|HRS-1893|subcutaneous, single dose, multiple doses
223418177|NCT05879523|DRUG|Placebo|subcutaneous, single dose, multiple doses
223561542|NCT00939029|DRUG|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
223561543|NCT00939029|DRUG|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
223561544|NCT01421303|DRUG|Enbrel|Enbrel
223561545|NCT00142168|DRUG|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
223561546|NCT00142168|DRUG|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
223561547|NCT01496326|DRUG|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
223561548|NCT01496326|DRUG|placebo|2 grams of placebo cream for 14 days
223561549|NCT03772028|DRUG|cisplatin|HIPEC with cisplatin after cytoreductive surgery
223561550|NCT02250079|DEVICE|polyethylene plastic bag|Inborn neonates with both a gestational age \>29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
223739326|NCT07205835|BEHAVIORAL|ChatGPT Exercise Group|Participants in the ChatGPT group will follow an exercise program generated by ChatGPT and supervised by a physiotherapist. The program will be delivered twice weekly for 6 weeks, with each 50-minute session including exercises designed to improve posture, flexibility, and musculoskeletal function.
224034247|NCT00898183|GENETIC|polymorphism analysis|
224034248|NCT01411839|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
224034249|NCT02932007|DRUG|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
224034250|NCT03160651|DRUG|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
224034251|NCT05848271|OTHER|Patient Registry|Participants who have been diagnosed with HPDL mutations will be enrolled to patient registry.
223418178|NCT05130710|PROCEDURE|staging laparoscopy|All patients of both groups underwent staging laparoscopy by the same two attending onco-surgeon, using the same technique and the same laparoscopic device. Under general anesthesia and in supine position SL was performed. A 10 mm optic laparoscopic port was inserted via the midline incision below the umbilicus using Hasson technique. All four quadrants of the abdomen as well as pelvis were inspected during laparoscopy and biopsy was taken from any suspicious lesion through insertion of 5mm port. All specimens underwent cytological evaluation by two independent pathologists. The presence of any malignant cells, regardless of the number, confirmed the positive cytology. In the event of discordant reports between two pathologists, specimens were sent for the third review by a pathologist who was blinded to the previous results. Laparoscopic evaluation was considered positive as if adjacent organ involvement, omental involvement or peritoneal seeding were seen.
223418179|NCT03512717|DEVICE|Potenfill|Maximum: 22ml
223418180|NCT03512717|DEVICE|Powerfill|Maximum: 22ml
223418181|NCT02218736|DRUG|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
223418182|NCT02218736|DRUG|placebo|oral dosing of 10 mg placebo daily for 8 weeks
223418183|NCT03374696|BEHAVIORAL|SAFETY|
223418184|NCT03374696|BEHAVIORAL|Standard education|
223418185|NCT03778918|OTHER|inflammatory bowel disease|blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
223418186|NCT03778918|OTHER|IBS or Normal Control|blood based biomarker compared normal control with IBD
223418187|NCT03341442|PROCEDURE|No hip precautions|No hip precautions practiced after THA surgery
223418188|NCT00761670|DRUG|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
223418189|NCT01914471|BEHAVIORAL|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
223739327|NCT07205835|BEHAVIORAL|Clinical Pilates Group|Participants in this arm will perform supervised clinical Pilates exercises twice weekly for 6 weeks. Each session will last 50 minutes and include core stabilization, postural correction, and flexibility exercises.
224034252|NCT05848271|OTHER|Dry blood spots sampling|Dry blood splots require 500nl of blood.
224034253|NCT04634656|DRUG|Lidocaine|Patients will receive lidocaine in a loading dose of 1 mg/ kg diluted in 10 ml of normal saline that will be infused over 5 minutes after induction of anesthesia then followed by a continuous infusion at 1.5 mg/ kg/ h diluted in normal saline to a volume of 50 ml until the end of surgery
224034254|NCT04634656|DRUG|Normal saline|Patients will receive normal saline after induction of anesthesia with the same volume and rate changes as lidocaine group until the end of surgery
224034255|NCT06528067|BEHAVIORAL|Meditation|10 minute per day, 8 week digital meditation
224034256|NCT06528067|BEHAVIORAL|Mindful Motivation|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
224034257|NCT00458341|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, or apple juice. Participants are to receive a total of 42 doses of ataluren during each cycle, for a total of 84 doses of ataluren in both cycles.
224137099|NCT03970395|OTHER|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
224137100|NCT03970395|OTHER|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
224137101|NCT00125190|DRUG|rhIGF-1 (mecasermin) for a period of 86 weeks|Once a day rhIGF-1 injections
224137102|NCT04257955|BEHAVIORAL|Interview and evaluation of Engagement|(i) the completion of the scheduled outpatients visit (ii) filling of the PHE-Scale® questionnaire by the patient to investigate the level of engagement and (iii) the completion of a semi-structured interview to assess the rate of understanding of the information received from the doctor.
224137103|NCT02817152|PROCEDURE|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
224137104|NCT02817152|DEVICE|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
223418190|NCT05017311|DRUG|Escitalopram|All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).
223418191|NCT05017311|DRUG|Brexpiprazole|Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.
223418192|NCT02370628|PROCEDURE|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~* Step 1: facet block~* Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
223418193|NCT02370628|PROCEDURE|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
224034258|NCT00376454|DRUG|GW493838|
224034259|NCT01787409|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
224034260|NCT01787409|OTHER|Laboratory Biomarker Analysis|Correlative studies
224034261|NCT06389838|DEVICE|Kranus Mictera|An app-based digital therapy program aimed at multimodal self-treatment for incontinence. The app is certified class I medical device (MDR).
224137105|NCT02266186|BEHAVIORAL|Traditional Cognitive behavioural therapy|Therapist supported live therapy
223418194|NCT06260111|DEVICE|Photobiomodulation|"Photobiomodulation will be used in sessions of approximately 5 to 10 minutes each. An InGaIP diode laser will be used with the following parameters: wavelength of 660 nm, output power of 40 mW, and an energy density of 4 J/cm2 measured at the end of the fiber optic with 0.04 cm2 of section area. The laser will be applied at 10 points in each oral region, with an exposure time of 4 s per point, using 0.16 J of energy per point.~The protocol was based on previous studies."
223418195|NCT06260111|OTHER|Usual care|Usual care for oral mucositis includes education, cryotherapy, and mouth hygiene.
223418196|NCT04767997|DIETARY_SUPPLEMENT|Probiotic formulation|Participants will be asked to take one capsule daily, containing 3 billion CFU of the probiotics.
223418197|NCT04767997|DIETARY_SUPPLEMENT|Placebo|Participants will be asked to take a placebo capsule daily.
223418198|NCT04026828|GENETIC|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
223418199|NCT05407870|DRUG|Etomidate Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
223418200|NCT05407870|DRUG|Propofol Injection|"Proofol and etomidate are drugs used for sedation and have the same white color.~Gastric endoscopic submucosal dissection is performed using propofol in the control group and etomidate in the experimental group.~Efficacy and safety of sedatives were confirmed using propofol and etomidate."
223418201|NCT00829140|DRUG|Placebo|
223561551|NCT02250079|DEVICE|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
223561552|NCT03220464|RADIATION|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
224034262|NCT03952754|BEHAVIORAL|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
223418202|NCT00829140|DRUG|Lorcaserin 10mg BID|
223418203|NCT04114201|PROCEDURE|PSI|Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
223418204|NCT04114201|PROCEDURE|Conventional|Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
223418205|NCT03138031|PROCEDURE|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
223418206|NCT03879525|OTHER|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
223418207|NCT03879525|OTHER|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standard delivery method.
223418208|NCT05481125|DEVICE|Clareon IOL|Alcon Clareon Aspheric Hydrophobic Acrylic IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
223418209|NCT05481125|DEVICE|Clareon Toric IOL|Clareon Toric Aspheric Hydrophobic Acrylic Toric IOL for the visual correction of aphakia with pre-existing corneal astigmatism in adult patients in whom a cataractous lens has been removed. The lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye, replacing the natural crystalline lens. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
224034263|NCT03952754|BEHAVIORAL|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
224034264|NCT01197885|DRUG|IMAB362|Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
224034265|NCT05461794|DRUG|Sitravatinib|100 mg orally once daily
224034266|NCT05461794|DRUG|Tislelizumab|200 mg intravenously once every 3 weeks
224034267|NCT05461794|DRUG|Docetaxel|75 milligrams per square meter of body surface area (mg/m2) intravenously on Day 1 of every 21-day cycle
224034268|NCT05461794|DRUG|Irinotecan|125 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle
224034269|NCT02769559|PROCEDURE|Reduction mammaplasty|Surgical removal of excess breast tissue
224034270|NCT06235944|PROCEDURE|Caudal block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume 1ml/ kg max 20 ml via Ultrasound Guided caudal Block.
224034271|NCT06235944|PROCEDURE|Sacral erector spinae block|Patients were received (plain bupivacaine 0.25% 1 mg/kg + 2 % lidocaine 3 mg /kg) in total volume of 1 ml/ kg maximum 20ml divided in both sides via ultrasound guided sacral erector spinae plain block (ESPB).
224034272|NCT05525013|DRUG|Simvastatin Powder|Simvastatin gel placed as an intracanal medication
224034273|NCT05525013|DRUG|Calcium Hydroxide|Calcium hydroxide intracanal medication
224034274|NCT00381277|DRUG|Gatorade|
224034275|NCT00381277|DRUG|Performance|
224034276|NCT03736473|DRUG|MEDI9447 (oleclumab)|MEDI9447 administered intravenously
223418210|NCT05481125|DEVICE|Eyhance IOL|TECNIS Eyhance IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
223418211|NCT05481125|DEVICE|Eyhance Toric IOL|TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag. IOLs are implantable medical devices and are intended for long-term use over the lifetime of the pseudophakic subject.
223418212|NCT05481125|PROCEDURE|Phacoemulsification surgery|Cataract removal by routine small incision phacoemulsification surgery
223418213|NCT02244463|DRUG|MLN0128|
223418214|NCT05017896|DIAGNOSTIC_TEST|Normal CT Renal Perfusion imaging indexes|A CT imaging which indicates the status of renal perfusion is normal.
223418215|NCT05017896|DIAGNOSTIC_TEST|Low CT Renal Perfusion imaging indexes|A CT imaging which indicates the status of renal perfusion is low.
223418216|NCT01769508|DRUG|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
223418217|NCT01769508|DRUG|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
223418218|NCT01769508|DRUG|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
223418219|NCT01769508|RADIATION|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
223418220|NCT06439381|DRUG|300mg/600mg of TQH2722 injection|TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
223418221|NCT06685458|OTHER|Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling|This study involves preoperative evaluation of clinical and imaging features for constructing a predictive model to differentiate benign and malignant solid pulmonary nodules. Surgical resection is performed to obtain pathological confirmation as the reference standard.
223418222|NCT02940418|BIOLOGICAL|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
223418223|NCT02667964|OTHER|spiroergometry|Spiroergometry on a bicycle ergometer
223418224|NCT00910208|DEVICE|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
223561553|NCT03220464|RADIATION|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
223561554|NCT03220464|DIAGNOSTIC_TEST|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
223561555|NCT01058915|DRUG|Rosuvastatin 5mg|Rosuvastatin 5mg/day
223561556|NCT01058915|DRUG|Rosuvastatin 40mg|Rosuvastatin 40mg/day
223418225|NCT00910208|DRUG|morphine|Intravenous morphine
224034277|NCT05373160|OTHER|Assessment study|Assessment of functional tests with and without dual tasks
223418226|NCT05875779|BEHAVIORAL|Peer-led vaccine education intervention|"The intervention will be delivered face-to-face by a trained peer-educator and will consist of one session of 10-20 minutes.~Peer vaccine educators will receive written vaccine materials for distribution. These materials will present content that accurately represents the risks and benefits of vaccination.~Responsibilities of the vaccine educators will be to: provide motivational interviewing with patients, provide vaccine counseling, address questions and concerns regarding available vaccines, brief clinical provider on hesitant patients and areas of their vaccine-related concerns, and provide follow-up with participants at day 30, day 60 and day 90 for additional engagement."
223418227|NCT01624779|DRUG|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1\&2
223561557|NCT06003777|DRUG|PF-06954522|PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
223561558|NCT06003777|DRUG|Placebo|Placebo will be administered as oral suspensions as escalating single doses to be determined.
223561559|NCT05760131|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
224034278|NCT03751059|DRUG|Bromfenac 0.07% Oph Susp|Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
224034279|NCT03751059|DRUG|Dexamethasone|Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
224034280|NCT05764941|DRUG|Inetetamab|8mg/kg for the first dose, 6mg/kg for the following doses, every 3 weeks for one cycle.
224034281|NCT05764941|DRUG|Pyrotinib|400mg, oral, every day.
224034282|NCT05764941|DRUG|Vinorelbine|25 mg/m2, D1, D8, every 3 weeks for one cycle.
224034283|NCT06068595|OTHER|musculoskeletal ultrasound|After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.
224034284|NCT03272126|DRUG|Vitamin D|vitamin D given as bolus versus daily dosing
224034285|NCT03272126|DRUG|Placebo|identical looking as vitamin D
224034286|NCT00109382|DRUG|Aspirin|
224034287|NCT00109382|DRUG|Clopidogrel|
224034288|NCT00109382|DRUG|Simvastatin|
224034289|NCT03668184|OTHER|preeclampsia|occurrence of pre-eclampsia
224137106|NCT02266186|BEHAVIORAL|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
224137107|NCT01015482|DRUG|Remifentanil|Remifentanil Infusion
224137108|NCT01015482|DRUG|Midazolam|Midazolam Infusion
224137109|NCT00578799|DIETARY_SUPPLEMENT|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
224137110|NCT00578799|DIETARY_SUPPLEMENT|placebo|placebo capsules (potato starch
223418228|NCT03783585|BEHAVIORAL|Cognitive behavioral therapy for insomnia|The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
223418229|NCT03783585|BEHAVIORAL|Cognitive behavioral therapy for insomnia + biweekly support|Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
223418230|NCT03770962|BEHAVIORAL|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her."
223418231|NCT05799612|DRUG|Paclitaxel|Given by IV (vein)
223418232|NCT05799612|BIOLOGICAL|mRNA plus Lysate-loaded Dendritic Cell Vaccine|Given by IV (vein)
223418233|NCT05799612|DRUG|PEGYLATED-INTERFERON ALPHA-2A|Given by IV (vein)
223561560|NCT01151059|BIOLOGICAL|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
223418234|NCT05799612|DRUG|Filgrastim|Given by IV (vein)
223418235|NCT01298869|BIOLOGICAL|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
223418236|NCT05571124|BEHAVIORAL|Therapeutic Exercise Intervention|Participants will perform stretching and mobility exercises in short bouts of time.
223561561|NCT04189965|OTHER|Validation of virtual environment and auditive stimulation with virtual reality glasses (Pilot phase)|The goal of this phase is the development of the experimental protocol in virtual reality. Virtual environment will be checked and auditive stimulation will be graduated.
224034290|NCT04848532|BEHAVIORAL|Weight loss treatment|The intervention will consist of group-based, weekly or biweekly weight loss coaching (75 minutes per session), which will occur via Zoom videoconferencing software. This intervention is designed to facilitate a 5-10% weight loss and engagement in up to 250 min/week of moderate-to-vigorous physical activity, which is the standard recommendation in lifestyle modification programs for adolescents. Participants will also be asked to download and utilize the smartphone app, Fitbit, to track eating behavior. Weight loss coaches will be experts in lifestyle modification who have graduate degrees in psychology or a related field. Participants will be given guidance on how to reduce your calorie intake (using a balanced deficit diet) and gradually increase your physical activity. Participants will learn to set goals for diet, weight, and physical activity.
224034291|NCT01516242|OTHER|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
223418237|NCT06365710|OTHER|Telerehabilitation|Telerehabilitation program
223418238|NCT06365710|OTHER|Traditional physiotherapy|Guided rehabilitation program with physiotherapist appointments
223418239|NCT06068881|DRUG|Tazverik (Tazemetostat)|Oral Tablet
223418240|NCT00595738|OTHER|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
223418241|NCT04490603|BEHAVIORAL|Virtual reality experience|Patients are to experice virtual reality with virtual reality experience equipment (headsets, headphones, smartphones) and virtual reality experience programs. The equipments and programs are commercialized products on the market rather than medical products.
223418242|NCT01598090|BIOLOGICAL|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
223418243|NCT01598090|BIOLOGICAL|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
224034292|NCT03221192|OTHER|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, \>3-7 (or \>30-70) as moderate disease and \>7-10 (or \>70-100) as severe disease.
223418244|NCT01598090|DRUG|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
223418245|NCT01598090|DRUG|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
223418246|NCT03615144|DRUG|Melphalan|Melphalan 70 mg/m2/day x 2
223418247|NCT03615144|DRUG|Thiotepa|Thiotepa 7.5 mg/kg/day x 2
223418248|NCT03615144|DRUG|Clofarabine|Clofarabine 20-30 mg/m2/day x 5
223418249|NCT03615144|DRUG|Fludarabine|Fludarabine 30 mg/m2/day x 5
224034293|NCT03221192|OTHER|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
224034294|NCT03221192|OTHER|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
224034295|NCT03543501|DEVICE|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
223418250|NCT03615144|DRUG|Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)|antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
223418251|NCT03615144|PROCEDURE|CliniMACS reagents|Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
223418252|NCT00000260|DRUG|Nitrous oxide|
223418253|NCT06665750|BEHAVIORAL|Exercise|A progressive upper extremity neuromuscular exercise program was performed face to face with the researcher physiotherapist for the study group. The exercise program was applied for approximately 20 minutes, 2 days a week for 6 weeks, on the same days of the week, before the participants' tennis training. The exercise content and number of repetitions in the training program changed every 2 weeks with increasing difficulty.
223418254|NCT06668337|DRUG|Normal Saline (Placebo)|Participants in the control group receive a continuous intravenous infusion of normal saline, which serves as an inert placebo with no pharmacological effect. This intervention mimics the administration of the active treatments, allowing for direct comparison with the ephedrine groups to assess the effectiveness of the drug in preventing maternal hypotension during spinal anesthesia.
223561562|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Principal Experimental phase)|This phase is the principal step of the study: during moving in virtual environment, electrical stimulation on one hand and auditive stimulation will be applied. EEG, ECG and skin conductance will be measured during conditioning phase and extinction phase (day 1, 30 minutes each phase). Behavioral measures will be done throughout the 3 sessions (day 1, day 2 and day 30)
223561563|NCT04189965|OTHER|Electrical cutaneous stimulation and auditive stimulation (Secondary Experimental phase)|This phase is the same of the Principal Experimental phase except for the EEG that will not be performed.
224034296|NCT03543501|DEVICE|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
223561564|NCT03951493|COMBINATION_PRODUCT|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
223561565|NCT03951493|RADIATION|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~* 20 Gy in 1 fraction;~* 27 Gy in 3 fractions of 9 Gy~* 30 Gy in 5 fractions of 6 Gy."
223561566|NCT02943330|OTHER|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
223561567|NCT05467332|DEVICE|HIGH FLOW NASAL OXYGEN|"BEFORE EXTUBATION, AN AIRWAY EXCHANGE CATHETER (AEC) WILL BE PUT INTO THE PATIENTS' TRACHEA AND IT WILL REMAIN IN SITE AFTER EXTUBATION. THROUGH AN AEC CONNECTED TO A PRESSURE MONITOR, IT WILL BE RECORDED TRACHEAL PRESSURE DURING SPONTANEOUSLY BREATHING PATIENT AT DIFFERENT FLOW RATES OF HFNC THAT WILL BE APPLIED JUST AFTER EXTUBATION.~MEANWHILE, VITAL PARAMETERS RECORDED WITH A MULTIPARAMETRIC MONITOR WILL BE RECORDED.~FINALLY, MONITORING OF ELECTRICAL ACTIVITY OF DIAPHRAGM WILL BE RECORDED THROUGH A DEDICATED NASOGASTRIC TUBE TO EVALUATE IT AT DIFFERENT FLOW RATES."
224034297|NCT02440230|DRUG|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
224034298|NCT02440230|DRUG|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
224034299|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
224034300|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
224034301|NCT01108107|DRUG|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
224034302|NCT01108107|DRUG|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
224034303|NCT01108107|BIOLOGICAL|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
224034304|NCT01211743|OTHER|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
224034305|NCT01211743|OTHER|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
224034306|NCT02948023|BIOLOGICAL|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
224034307|NCT05991687|OTHER|In-home drug disposal pouch|Will receive a drug disposal pouch to inactivate leftover prescription opioids for disposal after surgery.
224034308|NCT05991687|OTHER|Mail-in prepaid envelope|Will receive a prepaid envelope to mail leftover prescription opioids for disposal after surgery
224137111|NCT04793386|DIAGNOSTIC_TEST|carotid ultrasound|Every time checking pulse, evaluate the carotid artery compressibility and pulsatility by ultrasound
224034309|NCT05044273|DEVICE|Synergy XD stent or Synergy Megatron™ Stent|Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent
224034310|NCT01491893|BIOLOGICAL|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
224034311|NCT04470167|BIOLOGICAL|TPX-115|Ultrasound-guided intratendinous injection of allogeneic fibroblasts(TPX-115)
223418255|NCT06668337|DRUG|Ephedrine|The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
223418256|NCT06668337|DRUG|Ephedrine|The interventions in this study include a control group receiving normal saline, which serves as an inert placebo to assess the effectiveness of the active treatments. Participants in Group B receive an ephedrine infusion at 1.25 mg/min, while those in Group C receive a higher dosage of 1.5 mg/min. This design allows for direct comparison of the two dosages of ephedrine against the control, enabling evaluation of their effectiveness in preventing maternal hypotension following spinal anesthesia during cesarean sections.
223418257|NCT02358109|BEHAVIORAL|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
223418258|NCT04548115|BEHAVIORAL|ARTISAN Condition|Youth and senior participants will be randomly paired and engage in the 5-weekly, 3-hour ARTISAN intervention as dyads (totaling 15 hours of intervention). In the first four weeks of the ARTISAN, dyads will engage in themed museum tours facilitated by a docent (45min), guided storytelling (45 min) and professionally-led art-making (45 min). The remaining time (45 min) is allocated for session breaks, session introduction/closing, and buffer time for movement around the gallery. The final week involves an exhibition where participants share their artworks with the public and reflect on their experiences and artworks. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
223418259|NCT04548115|BEHAVIORAL|Intergenerational Participatory Arts Condition|Youths and senior participants in this condition will be randomly paired and engage in a 5-weekly 45-minute group-based art activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). A professional artist or art therapist will facilitate art-making sessions with the participants in a community space, utilizing the same mediums that were used in ARTISAN. The weekly session themes are as follows: Week 1: Discovering our National Heritage (Art medium: Clay); Week 2: Strengthening Social Bonds (Art medium: Acrylic Paints); Week 3: Overcoming Adversities and Resilience (Art medium: Beads); Week 4: Building Dreams and Aspirations (Art medium: Recycled Materials); Week 5: Sharing our Stories and Legacies (Community Showcase)
224034312|NCT04470167|OTHER|Placebo|Ultrasound-guided intratendinous placebo injection
224034313|NCT05923957|OTHER|TENS and Exercise|High frequency electrical stimulation was done for thirty minutes per day for five days a week for four consecutive weeks. The stimulator provides a biphasic current of 100 Hz frequency. The pulse duration was 200 msec with an (on-off). Stimulus mode (20sec stimulation, 20 sec pause). The maximal stimulation amplitude was 40 - 60 mA
224034314|NCT01658826|DRUG|AIC316|100 mg oral administration
224034315|NCT01658826|DRUG|Valacyclovir|500 mg oral administration
224034316|NCT00000730|DRUG|Trimetrexate glucuronate|
224034317|NCT00000730|DRUG|Methylprednisolone|
224034318|NCT00000730|DRUG|Pentamidine isethionate|
224034319|NCT00000730|DRUG|Sulfamethoxazole-Trimethoprim|
224034320|NCT00000730|DRUG|Leucovorin calcium|
224034321|NCT04724226|DRUG|Camrelizumab; Apatinib|"Cryoablation~Drug: Camrelizumab and Apatinib Camrelizumab (200mg), iv, Q3W; Apatinib (250mg), po, QD"
224034322|NCT05466539|DRUG|AbobotulinumtoxinA|Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
224137112|NCT05242549|BEHAVIORAL|Fitness and Nutrition Program for Seniors|"Fitness and Nutrition Program for Seniors uses the Trans-Theoretical Model (TTM) as the framework, which includes physical activity training, nutrition education- nursing Information, home-based training, and telecare group care (including APP assistance).~Physical activity training comprised muscle training, joint strengthening, and upper and lower limb resistance exercises for older adults who were frail. After administering nutrition education- nursing Information, participants were encouraged to set their own goals to improve their diet. Home-based training and telecare group care depends on the stages of TTM behavior change of the elderly."
224137113|NCT04868591|OTHER|Single session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.
223418260|NCT04548115|BEHAVIORAL|Intergenerational Art-space Condition|Youths and senior participants in this condition will engage in a 5-weekly 45-minute group-based curated museum tour that follow the ARTISAN themes with 15 minutes of preparation/break time, and conducted by a trained docent at the National Museum Singapore (totaling 5 hours of intervention).The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
223418261|NCT04548115|BEHAVIORAL|Intergenerational Storytelling Condition|Youths and senior participants in this condition will be paired to engage in a 5-weekly 45 minute group-based storytelling activity conducted in a community space with 15 minutes of preparation/break time (totaling 5 hours of intervention). Storytelling sessions will be conducted by a trained facilitator, and conversation starters from ARTISAN intervention will be used. The weekly session themes are as follows: Week 1: Discovering our National Heritage; Week 2: Strengthening Social Bonds; Week 3: Overcoming Adversities and Resilience; Week 4: Building Dreams and Aspirations; Week 5: Sharing our Stories and Legacies.
223418262|NCT04548115|BEHAVIORAL|Control Condition|Participants in this condition will engage in a 5-weekly 45 minute group-based physical activity session conducted in the community with 15 minutes of preparation/break time (totaling 5 hours of intervention). Physical activity was selected over basic psychosocial care to test the effects of inter-generational contact independent of arts and heritage-based engagements.
223418263|NCT05326828|DEVICE|CONFIRM Rx implantable cardiac rhythm monitor (Abbott)|Implantation of CONFIRM Rx ICM
223418264|NCT05326828|DIAGNOSTIC_TEST|Systematic etiologic work-up for underlying causes of MINOCA|Intracoronary optical coherence tomography, cardiac magnetic resonance imaging, transesophageal echocardiography, vasospasm testing, thrombophilia screening, Holter ECG (only non-ICM group)
223418265|NCT02587598|DRUG|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
223418266|NCT02587598|DRUG|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m\^2. Cytarabine will be administered as an intravenous (IV) infusion.
223418267|NCT02587598|DRUG|Azacitidine|Azacitidine dose will be 75 mg/m\^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
223418268|NCT02587598|DRUG|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
223418269|NCT05437861|BEHAVIORAL|Brief Intervention|A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
223561568|NCT01671293|BEHAVIORAL|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer \& waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
223561569|NCT01671293|OTHER|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
223561570|NCT06400576|OTHER|Headphone and Smartphone Intervention|Asessment of participants' static balance and pressure distrubiton, posturographic balance and dynamic balance whilst using headphones and messaging.
224034323|NCT05466539|DRUG|Placebo|Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
224034324|NCT00713115|PROCEDURE|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
224034325|NCT03645954|PROCEDURE|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
224137114|NCT04868591|OTHER|Multiple session of education and exercise provided by an advanced practice physiotherapist.|In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
224137115|NCT04102878|DRUG|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
223418270|NCT04455477|DRUG|Nesiritide|The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.
223418271|NCT03244631|PROCEDURE|Lumbar Plexus BLock|Peripheral nerve block
223418272|NCT03244631|PROCEDURE|Pericapsular injection|Injection around the area undergoing surgery
223418273|NCT04912440|DEVICE|MSE-ERCP|No interventional study, MSE-ERCP performed within routine treatment, (approved indication of device)
224034326|NCT03645954|PROCEDURE|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle \& Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
224034327|NCT00591045|DRUG|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
224034328|NCT05786833|DRUG|Dexmedetomedine|Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.
223418274|NCT04144582|DRUG|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
223418275|NCT00974467|BEHAVIORAL|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
223418276|NCT00974467|OTHER|Control|Usual hospital care provided.
223418277|NCT04782453|BEHAVIORAL|ToQuit, a technology delivered tobacco cessation intervention|"The intervention messages will consist of specific content areas derived from the formative research of the study. Some of the components of the intervention include~* Psychoeducation about consequences of tobacco use and benefits of quitting;~* goal setting;~* managing goals and self-monitoring of behavior;~* avoidance strategies;~* self-awareness and reflection messages;~* social and pharmacological support, and help-seeking;~* identifying and managing cravings;~* relapse prevention strategies."
223418278|NCT04782453|BEHAVIORAL|Tobacco quitting helplines|Participants from the control group will be sent the details of other functional tobacco helplines in India.
223418279|NCT03998644|OTHER||
223418280|NCT04286789|DRUG|Low dose ORTD-1|Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
223418281|NCT04286789|DRUG|Low dose vehicle control|Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.
223418282|NCT04286789|DRUG|High dose ORTD-1|Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
223418283|NCT04286789|DRUG|High dose vehicle control|Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
223418284|NCT03492814|PROCEDURE|partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
223418285|NCT03492814|PROCEDURE|total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
223418286|NCT04287725|DEVICE|exercise + photobiomodulation therapy|Treatment sessions will be provided twice a week for 6 weeks (totaling 12 sessions) with participants receiving either placebo or active PBMT + exercise protocol.
223418287|NCT03551717|OTHER|Optical Coherence Tomography angiography|At the inclusion visit for all patients and at M3 only for 50 patients.
223418288|NCT03551717|OTHER|Fundus|At the inclusion visit for all patients and at M3 only for 50 patients.
223418289|NCT03551717|OTHER|cardiac ultrasound scan|Only for 50 patients, 3 months after the initial cardiovascular event
223418290|NCT01144039|DRUG|LG-group|
223418291|NCT01144039|DRUG|HG-group|
223418292|NCT01144039|DRUG|Placebo-group|
223418293|NCT06620536|DEVICE|Electrical stimulation|Electrical stimulation of peripheral nerves for the recovery of hand function in tetraplegic patients of fundamental importance in improving quality of life.
223418294|NCT02980419|BEHAVIORAL|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
223561571|NCT04827147|DEVICE|Multi-Periscopic Prism (MPP) glasses|Spectacles with multi-periscopic prisms mounted as oblique peripheral prism segments
224034329|NCT05786833|DRUG|Ketofol|Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment. McFarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from half to 1 and 10 mg/kg/h from 1 to 2 hours.
224034330|NCT05786833|DRUG|isotonic saline 0.9%|Patients will receive intravenous infusion of equivalent volume of isotonic saline 0.9%.
224034331|NCT00000193|DRUG|Gamma hydroxybutyric|
224034332|NCT00675805|DEVICE|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
224034333|NCT00675805|DEVICE|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
224034334|NCT01422850|BIOLOGICAL|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
223418295|NCT06084819|DRUG|Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor|"1. Azacytidine (75mg/m2/day, days 1 to 7).~2. Cytarabine (75-100mg/m2 q12h, days 1 to 5).~3. Aclacinomycin(20mg/day, days 1,3,5).~4. Chidamide(30mg/day , days 1,4,8,11).~5. Venetoclax (100mg on day 1,200mg on day 2,400mg on days 3-14).~6. Granulocyte colony stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"
223561572|NCT04827147|DEVICE|Fresnel Peripheral Prism (FPP) glasses|Spectacles with conventional permanent Fresnel prisms mounted as oblique peripheral prism segments
223561573|NCT04154605|DEVICE|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
224034335|NCT02947477|BEHAVIORAL|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
224034336|NCT01909687|DEVICE|Blood glucose monitoring systems|
224034337|NCT03744325|DIETARY_SUPPLEMENT|Hen's egg OIT|Increasing doses of egg white protein administered orally
223418296|NCT06084819|DRUG|Best-Available Therapy(BAT) Regimen|"1. FLAG regimen:Fludarabine(30mg/m2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~2. CLAG regimen:Cladribine(5mg/2,days 1-5)+Cytarabine (1-2g/m2 applied 4h after fludarabine, days 1 to 5)+Granulocyte colony-stimulating factor(300ug/day,days 0 to 5)~3. MAE regimen:Mitox(10mg/m2,days 1 to 5)+VP-16(100mg/m2,days 1 to 5)+Cytarabine (100-150mg/m2,days 1 to 7)~4. DCAG regimen:Decitabine(20mg/m2,days 1 to 5)+Aclacinomycin(20mg/day on days 1,3,5)+Cytarabine (100mg q12h,days 1 to 5)+Granulocyte colony-stimulating factor(300 ug/day,day 0 until agranulocytosi recovery)~5. HAA regimen:HHT(2mg/m2,days 1 to 7)+Aclacinomycin(20mg/day,days 1 to 7) and Cytarabine (100-200 mg/m2, days 1 to 5);~6. HAD regimen:HHT(2mg/m2,days 1 to 7)+Daunorubicin(45mg/m2/day,days 1 to 3)+Cytarabine (100-200 mg/m2,days 1 to 5)."
223418297|NCT04721119|PROCEDURE|Local Infiltration Anesthetic|For the local infiltration anesthetic, patients will receive 20 cc of 0.5% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision.
223418298|NCT04721119|PROCEDURE|Local Infiltration Anesthetic + Adductor Canal Block|For the local infiltration anesthetic, patients will receive 20 cc of 0.25% ropivacaine, by intra-articular injection performed by the surgeon. The injection is done at the end of the surgical procedure, after suturing the incision. For the adductor canal block, patients will receive 20 cc of 0.25% ropivicaine, through injection performed by the anesthesiologist. The injection is done under the sartorius muscle, in mid-thigh, using ultrasound guidance.
223418299|NCT04725318|OTHER|One-lung ventilation|One-lung ventilation as part of routine clinical care for patients undergoing thoracic surgery under general anesthesia
223561574|NCT04154605|DEVICE|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
223561575|NCT02374788|BEHAVIORAL|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
223561576|NCT02374788|BEHAVIORAL|Group meetings|Participants receive 12 group meetings over two years' time.
223561577|NCT02374788|BEHAVIORAL|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
223561578|NCT00113633|BEHAVIORAL|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
223561579|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
223561580|NCT03776669|PROCEDURE|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
223561581|NCT03935672|PROCEDURE|PET-CT scans|"Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV\_P. bGTV\_P will then be used as an adjunct to help us delineate the GTV\_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV\_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
223561582|NCT03935672|PROCEDURE|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV\_P and bGTV\_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
223561583|NCT03935672|PROCEDURE|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
223561584|NCT03935672|PROCEDURE|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
223561585|NCT00675441|DRUG|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
223561586|NCT00392587|DRUG|GW856553|
223561587|NCT04377321|DRUG|Colchicine Tablets|colchicine tabletes for 6 months
223561588|NCT04432649|BIOLOGICAL|4SCAR-276|The 4SCAR-276 T cells can recognize and kill tumor cells through the recognition of CD276 .This study will evaluate the side effects and effective doses of 4SCAR-276 T cells in treating refractory and recurrent solid tumors
223561589|NCT03730233|PROCEDURE|Hiatal hernia repair by tension-free mesh closure|
223561590|NCT03730233|PROCEDURE|Hiatal hernia repair by simple suturing|
224137116|NCT04102878|PROCEDURE|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
223561591|NCT00256360|DRUG|dose dense with neulasta|
223561592|NCT00599534|DRUG|Montelukast|4 mg oral tablets
223561593|NCT00599534|DRUG|Placebo|5mg tablets
223561594|NCT00154700|DRUG|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
223561595|NCT05049564|PROCEDURE|keyhole microneurosurgery|microsurgical clipping via keyhole approach
223561596|NCT05049564|PROCEDURE|conventional microneurosurgery|microsurgical clipping via conventional craniotomy
223561597|NCT05049564|PROCEDURE|endovascular coiling|endovascular coiling via femoral approach
223561598|NCT01232504|DRUG|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
224137117|NCT04102878|PROCEDURE|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
223418300|NCT06967103|DRUG|QL1706|bispecific antibody targeting PD-1 and CLTA-4
223418301|NCT06967103|DRUG|Nab-PE|Nab-paclitaxel+Epirubicin
223418302|NCT01146379|OTHER|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
223418303|NCT06969118|PROCEDURE|Minimalism Transcatheter LAAC Group|Patients will undergo transcatheter LAAC under local anesthesia, guided by DSA and TTE, using the WATCHMAN FLX system. The release criteria (PASS: Position, Anchor, Size, Seal) will be confirmed through DSA and TTE.
223418304|NCT06969118|PROCEDURE|Standard Transcatheter LAAC Group|Patients will undergo LAAC under general anesthesia, guided by TEE, using the WATCHMAN FLX system, following the steps outlined in the product manual.
223418305|NCT00222365|DRUG|Arnica montana, 5 CH|
223418306|NCT00222365|DRUG|Bryonia alba, 5 CH|
223418307|NCT00222365|DRUG|Hypericum perforatum, 5 CH|
223418308|NCT00222365|DRUG|Ruta graveolens, 3 DH|
223418309|NCT06560229|OTHER|Grocery gift card|Monthly $100 grocery gift cards for 12 months
223418310|NCT04079192|DEVICE|Biolimus A9 Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
223418311|NCT04079192|DEVICE|SeQuent Please Paclitaxel Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
223418312|NCT03637140|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
223418313|NCT03637140|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
223418314|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A|Vitamin A supplements
223418315|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
223418316|NCT02878265|DIETARY_SUPPLEMENT|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
223418317|NCT02394340|DRUG|Omeprazole 40 mg|Oral capsule to be taken as per the instructions regarding proper dosing technique.
223418318|NCT02394340|DRUG|Luliconazole Cream 1%|Topical cream to be applied as per the instructions regarding proper study drug application technique.
223418319|NCT06665230|DRUG|MK-6552|Oral administration
224034338|NCT04484831|BEHAVIORAL|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
224137118|NCT04102878|OTHER|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
224137119|NCT04102878|OTHER|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
223418320|NCT06665230|DRUG|Modafinil|Oral administration
223418321|NCT04169048|BEHAVIORAL|Group training for mothers with Borderline Personality Disorder|The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
224137120|NCT04102878|PROCEDURE|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
224137121|NCT00059722|DRUG|ZD6474|
223418322|NCT02828124|BIOLOGICAL|BMS-986183|specified dose on specified days
223418323|NCT02828124|BIOLOGICAL|Nivolumab|specified dose on specified days
223418324|NCT05942014|BEHAVIORAL|dental anxiety|Evaluate dental anxiety in children and its relation with screen time exposure
223418325|NCT00620360|DIETARY_SUPPLEMENT|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
223418326|NCT00620360|DIETARY_SUPPLEMENT|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
223418327|NCT06968832|BEHAVIORAL|Massed Prolonged Exposure Therapy (M-PE)|Massed Prolonged Exposure (M-PE) is a trauma-focused, evidence-based behavioral intervention for posttraumatic stress disorder (PTSD). It is delivered over a compressed timeline (e.g., 10 sessions over 2-4 weeks) as opposed to weekly sessions over 3-4 months. This format has been shown to accelerate PTSD symptom reduction and reduce treatment dropout. In this study, M-PE will be delivered concurrently with an Intensive Outpatient Program (IOP) for substance use disorder (SUD) at Gateway Community Services. Sessions will be led by trained clinicians using a standardized PE protocol, with treatment including imaginal exposure, in vivo exposure, and processing.
224034339|NCT04484831|OTHER|Enhanced Care|This includes 15 handouts on elements of a healthy lifestyle and a midpoint one-on-one nutrition consultation with a registered dietitian.
224034340|NCT04525482|OTHER|Early goal-directed sedation programs|A. Provide sedation at the beginning of the titration of dextrometomidine; b. Optimize sedation when dextrometomidine is used alone and at a maximum dose not sufficient to provide comfort and safety to the patient and to achieve a level of sedation at any time specified by the treating physician. C. Provides immediate recovery and sedation, and can control sudden agitation at any time
224137122|NCT00059722|DRUG|Placebo|
224137123|NCT00059722|DRUG|ZD1839|
224137124|NCT05449613|DRUG|acupoint application|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
224137125|NCT05449613|OTHER|placebo|During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
224137126|NCT00929734|DRUG|Rosuvastatin|10mg tablets, once daily in three months
223418328|NCT06968832|BEHAVIORAL|Standard outpatient SUD care|"Patients randomized to usual care will receive standard intensive outpatient SUD treatment.~* Resilience group (weekly)~* Peer support~* Individual therapy from a variety of modalities"
223561599|NCT01232504|DRUG|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
223561600|NCT01232504|DRUG|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
223561601|NCT00135538|DEVICE|Noninvasive positive pressure ventilation|
224034341|NCT03188354|DIAGNOSTIC_TEST|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
224034342|NCT03188354|DIAGNOSTIC_TEST|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
224034343|NCT03188354|DIAGNOSTIC_TEST|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
224034344|NCT03584113|OTHER|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
224034345|NCT03584113|OTHER|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase \[5mg\] and alteplase \[10mg\] Q12hours).
224034346|NCT02370082|DEVICE|Localization of breast lesion|localization of breast lesion for removal
224034347|NCT04423354|PROCEDURE|Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Type Ⅱ Adenocarcinoma of Esophagogastric Junction|Patients diagnosed with Siewert Ⅱ adenocarcinoma of esophagogastric junction and met the inclusion criteria will be assigned to the research group and carry out transthoracic single-hole assisted laparoscopic radical gastrectomy by the fixed surgical group.The same model surgical instruments will be provided by the same instrument company.
224034348|NCT02916680|PROCEDURE|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
224137127|NCT00929734|DRUG|Placebo|1 tablet, once daily in three months
224034349|NCT04778774|PROCEDURE|Nerve block|Two different nerve block types, Adductor canal block group and Femoral nerve block group
224034350|NCT03330353|DIAGNOSTIC_TEST|Pupillometry|Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
223418329|NCT06968273|BEHAVIORAL|Combined respiratory physiotherapy and cardiovascular-strength training program|20-session supervised hospital-based program including respiratory physiotherapy, aerobic training (guided by Borg scale and HR monitoring), and strength training using progressive loads (based on 1RM). Duration: 4 weeks (5 sessions/week).
223418330|NCT05280366|DEVICE|Streamline Surgical System|Completion of the Streamline Surgical System procedure
223418331|NCT05280366|DEVICE|iStent Inject W|Implantation of competitor device
223418332|NCT06618391|DRUG|Envafolimab|Envolimab :150 mg/time, intratumoral injection, at least 5 sites; Recombinant human endostatin： Q3W for 4-6 cycles，Maintenance therapy 210 mg ,CIV 72 hours ,administered as continuous intravenous pump, administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
223561602|NCT05948527|DEVICE|high flow nasal canula|administration of high flow nasal canula at initial flow 35 liters per minute and Fio2 (fraction of inspired oxygen of 50%) with titration to reach oxygen saturation of 88-92%.
223561603|NCT01803100|OTHER|No intervention|There is no intervention in this trial
224034351|NCT02244996|DIETARY_SUPPLEMENT|Lycium Barbarum|Traditional Chinese Herbs
224034352|NCT02244996|DIETARY_SUPPLEMENT|Placebo|Placebo
224034353|NCT04556058|DRUG|Perindopril tert-Butylamine tablets （ Produced by Haisco）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
224034354|NCT04556058|DRUG|Perindopril tert-Butylamine tablets（ACERTIL®）|The trial is divided into two cycles, between of two cycle with a 14-day wash-out period. In the first cycle, the subjects in experimental group took the test preparation perindopril tert-butylamine tablets on an empty stomach, and the subjects in control group took the reference preparation ACERTIL® on an empty stomach. The subjects of the two groups exchanged on the 15th day after the first administration take medicine. A single oral administration was used for both cycles, and the dose was 4 mg.
224034355|NCT06001541|BEHAVIORAL|Web-SUCCEED|web-SUCCEED (Web-based Self-management Using Collaborative Coping EnhancEment in Diseases), a theoretically-derived, dyadic, self-management program.20,21 Web-SUCCEED is designed to improve self-management by improving dyadic stress coping and strengthening collaboration and communication.21 Web-SUCCEED comprises: 1) a three-module, self-paced behavioral intervention that Veterans and caregivers complete individually (one audio/video module per week) on the web-SUCCEED website; 2) brief, staff-led telephone calls in which dyads participate simultaneously after each module; and 3) peer support via a study-specific discussion board. Dyads learn and practice cognitive behavioral skills to reduce individual and relationship stress; improve positive emotions; improve communication and collaboration; increase pleasant activities; and maintain behavior change.
224034356|NCT01349335|DRUG|Tolvaptan|tablet, 15 mg, Qd, for 7 days
224034357|NCT01349335|DRUG|Tolvaptan|tablet, 30 mg, Qd, 7 days
224034358|NCT01349335|DRUG|placebo|tablet, 30 mg, Qd, 7days.
223561604|NCT05962684|OTHER|ERAS|Implementation of ERAS protocol in elective craniotomy patients
223561605|NCT01634880|DRUG|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
223561606|NCT00344318|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
223561607|NCT00344318|BIOLOGICAL|Prevenar|3 Intramuscular injections
224034359|NCT02736604|DRUG|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
224034360|NCT02736604|DRUG|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
224137128|NCT02200367|BEHAVIORAL|e-mental health collaborative programme|
224137129|NCT02200367|OTHER|Usual Care|
223418333|NCT06618391|DRUG|Recombinant human endostatin|Recombinant human endostatin: 15mg/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
223418334|NCT06618391|DRUG|recombinant human adenovirus type 5|Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
223418335|NCT03631914|PROCEDURE|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
223418336|NCT01092039|DIETARY_SUPPLEMENT|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
223418337|NCT01092039|DIETARY_SUPPLEMENT|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
223418338|NCT03909750|PROCEDURE|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
223418339|NCT03909750|PROCEDURE|AD-cSVF|Isolation of AD-cSVF
223418340|NCT03909750|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
223418341|NCT03093649|OTHER|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
223418342|NCT03093649|OTHER|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
223418343|NCT03589638|DEVICE|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
223561608|NCT00344318|BIOLOGICAL|Tritanrix-HepB|3 Intramuscular injections
223561609|NCT00344318|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix before injection
223561610|NCT00344318|BIOLOGICAL|Polio Sabin.|3 oral doses.
224034361|NCT02736604|DEVICE|laryngeal mask airway (LMA Supreme Size 3/4|
224137130|NCT02921919|DRUG|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
224137131|NCT04073940|BEHAVIORAL|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
223418344|NCT03589638|DEVICE|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
223418345|NCT03589638|DEVICE|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
223418346|NCT00256854|DRUG|Ropinirole IR 1 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
223561611|NCT00344318|BIOLOGICAL|Poliorix.|3 intramuscular injections
223561612|NCT00386217|BEHAVIORAL|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
224034362|NCT02736604|DRUG|sevoflurane|
224034363|NCT01335009|BIOLOGICAL|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
224034364|NCT04492605|DIETARY_SUPPLEMENT|Placebo|consume 1 capsule per day for 2 months
224034365|NCT04492605|DIETARY_SUPPLEMENT|TCI378 Probiotics|consume 1 capsule per day for 2 months
224034366|NCT04492605|DIETARY_SUPPLEMENT|TCI507 Probiotics|consume 1 capsule per day for 2 months
224137132|NCT03331094|PROCEDURE|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
224137133|NCT03331094|PROCEDURE|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
224137134|NCT00980980|DRUG|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
223418347|NCT00256854|DRUG|Ropinirole IR 2 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
224034367|NCT06281964|DRUG|PLB1004|Participants received oral PLB1004 240mg on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 240mg and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
223418348|NCT00256854|DRUG|Ropinirole IR 1 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
223418349|NCT00256854|DRUG|Ropinirole IR 2 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
223418350|NCT00256854|DRUG|Ropinirole CR 2 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
223418351|NCT00256854|DRUG|Ropinirole CR 3 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
223418352|NCT00256854|DRUG|Ropinirole CR 2 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
223418353|NCT00256854|DRUG|Ropinirole CR 3 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
223418354|NCT02353442|OTHER|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
223418355|NCT02353442|OTHER|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
223418356|NCT02353442|OTHER|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
223418357|NCT02353442|OTHER|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
223418358|NCT02353442|OTHER|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
223418359|NCT02353442|OTHER|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
223418360|NCT03514485|BEHAVIORAL|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
223418361|NCT03514485|BEHAVIORAL|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
223418362|NCT03514485|BEHAVIORAL|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~1. Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~2. Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~3. Asthma education for school staff/personnel at the start of each school year.~4. School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
223418363|NCT03895606|OTHER|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
223418364|NCT01041846|DRUG|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
224034368|NCT06281964|DRUG|Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab|Participants received IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 5 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive oral PLB1004 and 500 mg/m\^2 of pemetrexed on Day 1 q3w and Sintilimab 200mg intravenously administered on day 1 q3w per investigator's decision. until disease progression in the maintenance period.
224034369|NCT04821869|DRUG|ProAir Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
224034370|NCT04821869|DEVICE|Digihaler|Monitor parameters transmitted from the Proair Digihaler to the Digihaler Dashboard, including peak inspiratory Flow, inspiratory volume and frequency of rescue use
224034371|NCT03543267|OTHER|MRI exam|MRI before and after resection surgery
224034372|NCT00006203|DRUG|Naltrexone 50 Mg|Daily 50 mg for 3 weeks
223418365|NCT01614782|DRUG|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
223418366|NCT01614782|OTHER|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
223418367|NCT05667831|OTHER|Alginate silver silver ion dressing|Alginate silver silver ion dressing is a soft, comfortable wound dressing with a high mannuronic acid content. Gels on contact with wound exudate or blood, creating a moist wound environment for optimal wound healing. Silver ions protect the dressing from a range of microorganisms.
223418368|NCT00791661|DRUG|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
223418369|NCT00791661|DRUG|Placebo|Matching placebo to MK-1006 in a single oral dose
223418370|NCT02354755|DEVICE|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
223418371|NCT05332990|DIAGNOSTIC_TEST|HFO analysis|We use an automated data-independent prospective definition of clinically relevant HFO that has been validated in data from two independent epilepsy centers.
223418372|NCT03775863|PROCEDURE|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma
224034373|NCT00006203|DRUG|Placebo|Daily doses of placebo for 3 weeks
223418373|NCT00831714|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
224034374|NCT06307977|BEHAVIORAL|Couples Health Project|A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
224034375|NCT05007730|DIETARY_SUPPLEMENT|Transitional-state food therapeutic nutrition supplement|"Participants will consume at least one snack-sized package of the transitional-state food supplements per day across the intervention trial."
224034376|NCT01377051|DRUG|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
223418374|NCT00831714|DRUG|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
223418375|NCT03369834|DEVICE|Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
223418376|NCT03369834|DEVICE|Infrared Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
223561613|NCT01923363|DRUG|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
223561614|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
223561615|NCT00913887|DRUG|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
223561616|NCT00913887|DRUG|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
223561617|NCT06382103|DIAGNOSTIC_TEST|ctDNA monitoring|The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
224034377|NCT01377051|DRUG|Placebo|Dry powered, same to study drug, only one inhalation
224034378|NCT03298685|OTHER|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
224034379|NCT02729623|DRUG|Kite Systems cannaHALER cannabis Inhaler.|
224034380|NCT03686319|OTHER|Reflexology|Reflexology: foot massage
224034381|NCT00308269|DRUG|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
224034382|NCT00308269|DRUG|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
224034383|NCT06814743|BEHAVIORAL|Pelvic floor exercises program guided with an intravaginal biofeedback device|Use of the mobile application to perform a exercise program for pelvic floor musculature, while using an intracavitary biofeedback device that will inform about vaginal pressure. Behavioral: mobile application with access to information about pelvic floor and direct communication with healthcare team.
224034384|NCT06814743|BEHAVIORAL|Pelvic floor exercises program|"Use of the mobile application to perform a exercise program for pelvic floor musculature.~Behavioral: Information about pelvic floor and communication with health professionals Use of the mobile application with access to information about pelvic floor and direct communication with healthcare team."
224034385|NCT06814743|BEHAVIORAL|Information about pelvic floor and communication with health professionals|Use of the mobile application with access to information about pelvic floor and direct communication with healthcare team.
223418377|NCT03369834|DEVICE|Infrared and Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
224034386|NCT06014710|OTHER|Swallowing evaluation|"For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)"
223418378|NCT03369834|DEVICE|Sham|LED device off.
224034387|NCT06979752|PROCEDURE|Tran canula|After phacoemulsification, implantation of the intraocular implant and aspiration of the viscoelastic, we connect the TranCanula® to the irrigation system. Then we treat the trabecular mesh.
224034388|NCT06979752|PROCEDURE|augmented irrigation|After phacoemulsification, We use the classical aspiration cannula to irrigate the trabecular mesh.
224034389|NCT00658684|DRUG|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
224034390|NCT00824447|DRUG|Oralgen|allergen solution sublingually
224034391|NCT00824447|OTHER|placebo|placebo control
224034392|NCT06265870|DRUG|Albendazole|Participants receive empiric anthelminthic treatment which is albendazole 400 mg twice a day for seven consecutive days
224034393|NCT06265870|DRUG|Ivermectin or albendazole|Participants will receive specific anthelminthic treatment tailored to the results of the stool tests
224034394|NCT04291261|DRUG|Uvadex|Extracorporeal photopheresis (ECP) with Uvadex is scheduled 3x/week in weeks 1+2, 2x/week thereafter till day 28 and 1x/week till day 56
224034395|NCT06588582|OTHER|Water Temperature Variation - WW|Participants are assigned to warm water temperature.
224034396|NCT06588582|OTHER|Water Temperature Variation - CW|Participants are assigned to cold water temperature and are video recorded.
224034397|NCT06599671|PROCEDURE|Transvaginal niche resection|In short: the bladder was carefully dissected away from the uterus towards the abdominal cavity to open the vesicovaginal space and reach the peritoneum. The fingers on the anterior wall isthmus could touch the obvious scar-like defect. The weak scar tissue then thoroughly was removed.
223418379|NCT06617819|DEVICE|CR prosthesis|For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
223418380|NCT06617819|DEVICE|PS prosthesis|For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
223418381|NCT05568121|DRUG|L04RD1|1 tablet of L04RD1
223418382|NCT05568121|DRUG|L04TD1|1 tablet of L04TD1
223418383|NCT05568121|DRUG|L04TD1|1 tablet of L04TD1
223418384|NCT05568121|DRUG|L04RD1|1 tablet of L04RD1
223418385|NCT05453279|COMBINATION_PRODUCT|Delcetravir dry powder inhaler|Placebo dry powder inhaler
223418386|NCT06388707|DEVICE|NaviFUS System|FUS treatment will be conducted with following exposure parameters: intracranial spatial-peak temporal-average intensity (ISPTA) ceiling level: 2.8 W/cm2, burst length: 3 ms, duration: max. three consecutive 10-minute FUS exposures with two 5-minute intermission intervals.
223418387|NCT06969378|DEVICE|Pulsed field ablation using a pentaspline ablation catheter|After conclusion of AT ablation, transseptal or transbaffle puncture will be performed under fluoroscopic and intracardiac echocardiography guidance to access the left atrium (LA) or pulmonary venous atrium (PVA) if not already done so. PFA will be performed using a pentaspline catheter (Farawave, Boston Scientific) and a steerable sheath to achieve PVI of all veins draining to the LA/PVA with entrance and exit block confirmed at each vein. In patients where PFA is unable to achieve PVI, touch-up RFA will be performed. Programmed atrial stimulation will be performed to investigate for inducible atrial tachycardias. An implantable loop recorder will be placed at the conclusion of the procedure.
224034398|NCT06286007|DIAGNOSTIC_TEST|PCR|Depending on the symptoms presented and date of symptom onset, for pertussis, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 3 weeks For RSV, patients will undergo a nasopharyngeal swab specimen for PCR if onset of the symptoms was within the past 72 hours.
223561618|NCT06382103|DIAGNOSTIC_TEST|Plasma proteomic analysis|plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
224034399|NCT00091585|DRUG|SNS-595|
224034400|NCT06609915|DEVICE|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany)|supraglottic superimposed high frequency jet ventilation ventilation using the Monsoon 4 (Thora Tech GmbH, Giessen, Germany). Initially FiO2 at 1.0, reduced to 0.3 during laser interventions. Frequency and pressure set according to the local standards
224034401|NCT06609915|DEVICE|High-flow nasal supplemental oxygen via nasal cannula with the Optiflow (Fisher & Paykel, Auckland, New Zealand)|up to 70 L/min FiO2 1.0 high flow oxygen via nasal cannula with the Optiflow (Fisher \& Paykel, Auckland, New Zealand) initially. Reduced FiO2 to 0.3 during laser intervention.
224034402|NCT06610786|PROCEDURE|foldable capsular scleral buckling|Using foldable capsular vitreous body as a novel scleral buckle material to treat the primary rhegmatogenous retinal detachment (RRD) of medium complexity
224034403|NCT06610786|PROCEDURE|vitrectomy|Using vitrectomy to treat primary rhegmatogenous retinal detachment (RRD) of medium complexity.
224137135|NCT03206242|OTHER|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
223418388|NCT06968780|PROCEDURE|Buccal Fat Pad|BFP has a long successful history in oral surgery for its use in closure of Oroantral communication and taking advantage of the fact that it contains progenitor stem cells showing similar phenotype with (ASC) adipose-derived stem cells characteristics, which can similarly differentiate into the chondrogenic, adipogenic, or osteogenic lineage. Making them an invaluable reservoir for tissue engineering.
223418389|NCT06968780|PROCEDURE|Palatal Rotation Scarf Graft|This technique uses tissue from the palatal area, which has a rich blood supply placed around the neck of the zygomatic implant aiming to protect the mucosal tissues buccal to the exteriorized implants from capillary compression and subsequent soft tissue recession. The palatal rotation scarf graft has been proven to provide a robust, resilient soft tissue flap with good potential for long-term stability and esthetic outcomes around implants.
223418390|NCT06967831|PROCEDURE|skin biopsy|Taking a punch skin biopsy of 3 mm diameter under local anesthesia and culturing skin fibroblasts from them.
223418391|NCT06967831|OTHER|generation of iPSCs|Using cultured skin fibroblasts of the patients, iPSCs will be generated according to standard procedures.
223418392|NCT06967831|DIAGNOSTIC_TEST|blood drawing|Drawing blood from a peripheral vein for DNA and RNA isolation. The degree of heteroplasmy (mutation load) for the mtDNA mutation will be determined in the blood DNA.
223418393|NCT06967831|DRUG|off-label compassionate drug use|In case the investigators identify a positive hit during drug repurposing with FDA and EMA approved substances, they will offer it as off-label compassionate use to patients for whom no standard treatment is available.
223418394|NCT03033927|DIAGNOSTIC_TEST|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
223418395|NCT05336188|DEVICE|Smartphone|Adjunctive Smartphone app for improving MAT outcomes
223561619|NCT03580278|BIOLOGICAL|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
223561620|NCT01877486|PROCEDURE|Ablation|Pulmonary vein isolation following dofetilide
223561621|NCT00869791|DRUG|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
223561622|NCT00869791|DRUG|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
223561623|NCT03714217|BEHAVIORAL|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
224034404|NCT06609707|BEHAVIORAL|Tuning in to Kids|Tuning in to Kids is an evidence-based, emotion-focused, group parenting program designed to teach caregivers skills in recognizing, understanding, and managing their own and their children's emotions. The program includes six 90-minute, weekly, online group sessions and two optional 'booster' sessions to consolidate skills. Parents are taught five steps of emotion coaching and participate in exercises sequentially targeting each step. Intervention components include psychoeducation, emotion coaching demonstrations, role plays, group discussion, written resources, and home practice exercises. The program teaches parents skills in emotion coaching as a way of responding to their child's emotions. These skills help children to understand and regulate their emotions. As per the Tuning in to Kids manual, two trained, licensed health professionals will co-facilitate each group.
223561624|NCT04626687|DEVICE|test DCB|use paclitaxel coated coronary balloon catheters to treat SVD
223561625|NCT04626687|DEVICE|RESTORE DCB|use paclitaxel coated coronary balloon catheters(RESTORE DCB) with NMPA approval indication for treating SVD
223561626|NCT00559429|DRUG|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
223561627|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
223561628|NCT00559429|DRUG|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
223561629|NCT00559429|DRUG|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
224034405|NCT06610409|DIAGNOSTIC_TEST|blood sampling|Blood sample for CXCL5 Level
223418396|NCT06679049|PROCEDURE|micromotion intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal tibial interlocking screw
223418397|NCT06679049|PROCEDURE|standard intramedullary nail cohort|use of at least 2 distal interlocking screws and the use of a minimum of 1 proximal interlocking screw
223418398|NCT04398238|COMBINATION_PRODUCT|evaluation by transfusion medicine specialist|screening for anemia causes and treatment: iron/folate/vitamin B12 supplementation, Erythropoietin administration if indicated
223418399|NCT01721096|DEVICE|XIENCE PRIME - Long Length (LL)|Long Length
223418400|NCT01721096|DEVICE|XIENCE PRIME - Core Size|Core Size
223418401|NCT06051266|DEVICE|Dynamic navigation|Dynamic navigation eliminates the need for a laboratory fabrication process and allows for direct visualisation of the operative area during implant placement. Moreover, it can avoid interfering with water cooling. Navigation-assisted surgery makes it possible to modify the implant system, length, diameter or position in real time, both in the perioperative period and during surgery.
223561630|NCT03572959|DRUG|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
223561631|NCT03572959|DEVICE|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
223561632|NCT02661737|DEVICE|YVOIRE volume s|
223561633|NCT03548025|DEVICE|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
223561634|NCT05686746|DRUG|Baricitinib 4 MG|4 mg oral daily
223561635|NCT05686746|DRUG|Baricitinib 2 MG|2 mg oral daily
223561636|NCT05686746|DRUG|MMF|1000 mg oral daily
223561637|NCT05894980|DEVICE|active tDCS stimulating left DLPFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
224034406|NCT06825338|OTHER|CATCH My Breath|CATCH My Breath (CMB) is a school-based vaping prevention curriculum based on best practices from earlier prevention studies that works by fostering social competence and social influence resistance skills. The curriculum design and content targets two key constructs of Social Cognitive Theory: self-efficacy and behavioural capacity (i.e., knowledge and skills). The curriculum provides students with knowledge of why and how to resist vaping. It is delivered through two 60-minute lessons by a trained Public Health Unit presenter. The curriculum lessons provide information about: 1) the physical, mental, and addiction risks associated with vaping, 2) social norms of vaping (e.g., most youth don't vape), 3) media literacy (e.g., how to recognize and decipher marketing of vapes), 4) strategies to resist and avoid vaping, 5)school and provincial policies about vaping. To solidify the content, in-class activities allow students to discuss what they are learning and practice refusal skills.
224137136|NCT03172520|DEVICE|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
224137137|NCT03172520|DEVICE|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
224137138|NCT06336551|BEHAVIORAL|Acceptance and Commitment Therapy for insomnia (ACT-I)|During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
223418402|NCT06051266|DEVICE|Static template|In most clinical situations, a static template can be used to assist in guiding the placement of implants precisely. The static guide has some limitations in that it requires additional fabrication time, has insufficient cooling in the surgical field and is not suitable for simultaneous grafting procedures.
224137139|NCT03790462|OTHER|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes \& data collected."
223561638|NCT05894980|DEVICE|active tDCS stimulating right OFC|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
224137140|NCT03612180|DRUG|Metoprolol Succinate|Pharmacokinetics
224137141|NCT00121992|DRUG|Docetaxel|
224137142|NCT00121992|DRUG|5-fluorouracil|
224034407|NCT05344235|OTHER|SBRT|stereotactic radiotherapy of the primary prostate
224034408|NCT02918578|OTHER|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
224137143|NCT00121992|DRUG|Doxorubicin|
224137144|NCT00121992|DRUG|Cyclophosphamide|
224137145|NCT04079894|OTHER|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
224137146|NCT04079894|DEVICE|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
224137147|NCT02085876|OTHER|2 additional MRI sequences|
224137148|NCT02085876|OTHER|An additional blood sample|
224137149|NCT06162260|PROCEDURE|ICU readmission|Children who underwent liver transplantation at Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 1, 2018 to December 31, 2021 and were transferred out of ICU for the first time during the same hospitalization cycle.
223418403|NCT01864551|DRUG|Lamotrigine|
223418404|NCT01864551|DRUG|Olanzapine|
223418405|NCT01528982|BEHAVIORAL|Mindfulness|Subjects receive mindfulness training
223561639|NCT05894980|DEVICE|sham tDCS|20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
224034409|NCT02918578|OTHER|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
224137150|NCT00024076|PROCEDURE|radiofrequency ablation|
224137151|NCT06011746|DRUG|Ketamine + Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with 1ml ketamine (50mg)
224137152|NCT06011746|DRUG|Levobupivacaine|Skin infiltration will be done using 3 ml lidocaine 2% and a 22-gauage block needle will be advanced using the in-plane approach craniocaudally. Once the costotransverse ligament is reached, negative aspiration of blood and air will be confirmed. Under ultrasound visualization, 19 mL of 0.5% levobupivacaine with (50mg) or normal saline
224137153|NCT04353921|OTHER|No intervention will be administered as part of this study.|No intervention will be administered as part of this study.
224137154|NCT03282357|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
224137155|NCT03282357|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection
223418406|NCT01528982|BEHAVIORAL|Cognition|Subject receive cognitive training
223561640|NCT01824810|PROCEDURE|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
223561641|NCT01824810|PROCEDURE|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
223418407|NCT06023381|OTHER|Sliding sign|"All women had Transabdominal Ultra-sonography using SAMSUNG WS80 elite ultrasound machine during the preoperative examination, using the real-time Transabdominal pelvic features (the relative motion between the maternal abdominal and uterine wall).~The patient was asked to breathe deeply, accentuating her respiratory movements and the sonographer recorded a video clip in a mid-sagittal plane lateral to umbilicus focus on the infra-umbilical space, to determine whether the structure glided freely in relation to adjacent structures. To be considered as sliding, the structures had to glide easily, one against the other (positive sliding sign); no motion of the structure in question signaled a negative sliding sign."
223418408|NCT05268783|PROCEDURE|EORTC QLQ-C30|Quality of life questionnaire that has to be completed every 6 months
223561642|NCT01824810|PROCEDURE|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
223561643|NCT01824810|PROCEDURE|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
223561644|NCT06009237|DRUG|ABBV-903|Tablet; oral
224034410|NCT02918578|OTHER|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
224034411|NCT01131871|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
224034412|NCT01131871|BEHAVIORAL|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
224034413|NCT06993116|DRUG|SHR-4712 Injection|SHR-4712 injection.
224034414|NCT06607016|DRUG|KJ103 for Injection|Subjects will administered KJ103 intravenously on D1 and adjunctively on D8
224034415|NCT06607016|DRUG|Cyclophosphamide|Hence treatment prevents formation of new anti-GBM antibodies.
224034416|NCT06607016|DRUG|Glucocorticoids|Glucocorticoids inhibit the inflammation process.
224034417|NCT06607016|PROCEDURE|Plasma exchange (PE)|PLEX removes the patient\&#39;s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.
224034418|NCT06991192|BEHAVIORAL|Rehabilitation with Exercise and Psychological Support (REPS)|Rehabilitation with Exercise and Psychological Support (REPS) is a rehabilitation approach that integrates exercise with psychological support provided by physical therapist and patient training videos.
224034419|NCT05647239|DEVICE|Shotblocker|Shotblocker is a small plastic tool that can be used in all age groups in reducing pain due to injection, is non-medicinal, non-invasive, easy to use, and inexpensive and does not require material preparation
224034420|NCT03944135|OTHER|Web platform: Neuronup|Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
224034421|NCT00724308|OTHER|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
224034422|NCT00724308|OTHER|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
224034423|NCT05217888|DEVICE|Sentinel|cerebral protection devices during transfemoral transcatheter aortic valve replacement
224137156|NCT04635072|DRUG|Stabilised Whole Rice Bran|Patients with mild Atopic Dermatitis (AD) will be given SWRB in powder form, to be used as a cleanser after adding water to it according to set proportions given as instructions, once a day. Patients with moderate disease will use SWRB as a cleanser. In addition, they will also use SWRB as an emollient.
224137157|NCT05671601|DIAGNOSTIC_TEST|Automatic picture recognition|A machine that processes photographs automatically taken
224137158|NCT05671601|DIAGNOSTIC_TEST|Manual Assessment Group|Manual recognition of pictures
224137159|NCT05894473|OTHER|Motor-Motor Dual Task Physical Exercises|Only physical exercise and motor dual tasks will be given
224137160|NCT00642655|DRUG|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
223418409|NCT05268783|PROCEDURE|EORTC QLQ-GI.NET21|Quality of life questionnaire that has to be completed every 6 months
223418410|NCT05268783|PROCEDURE|Satisfaction survey|Questionnaire regarding satisfaction of care that has to be completed on Day 1.
223561645|NCT06009237|DRUG|Placebo for ABBV-903|Tablet; oral
223561646|NCT02974959|DEVICE|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
223561647|NCT02974959|DEVICE|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
223561648|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
223561649|NCT02016248|RADIATION|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
223561650|NCT02952508|DRUG|Iopofosine I 131 single dose|Radiopharmaceutical
223561651|NCT02952508|DRUG|Iopofosine I 131 multiple dose|Radiopharmaceutical
223561652|NCT02952508|DRUG|Iopofosine I 131 fractionated dose|Radiopharmaceutical
223561653|NCT02904629|BEHAVIORAL|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
223561654|NCT02904629|OTHER|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
223561655|NCT00656058|DRUG|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
223561656|NCT05484505|DRUG|Nicotine patch, Nicotine gums|"Nicotine patch 21mg, 12 weeks post quit date and nicotine chewing gums 4mg for 12 weeks post quit date~* 14 mg: Next 4 weeks~* 7 mg: Last 4 weeks"
224034424|NCT06092372|BEHAVIORAL|Diet intervention program|"Participants will get 5 meals/day based on their calorie needs minus 500 kcal/day less than their daily calorie expenditure. All meals will be tracked via a mobile application, including any meals outside the recommended food plan. The calories will be calculated based on the information provided.~To calculate the calories burned from any activities, all participants in the diet intervention arm will get an activity tracking device. The first calorie level is calculated based on the information in the registration form: age, height, weight, gender, and personal view of the daily activity. After that, and once the activity tracker is synced to the program, the calorie level is calculated based on the 7-day average calories burned.~The external diet intervention provider will be blinded to whether the study participants belong to the top or bottom 5% of the polygenic score for BMI."
223561657|NCT05484505|BEHAVIORAL|Brief Advice (5 A's & 5 R's)|Brief Advice (5 A's \& 5 R's) at Day 0, 1 month, 3,6,9 \& 12 months
223561658|NCT05484505|DRUG|Nicotine Patch: Preloading for 4 weeks|Nicotine Patch: Preloading for 4 weeks - 21 mg: 4 weeks before quit date
223561659|NCT04569864|PROCEDURE|Hypothermic circulatory arrest with unilateral selective anterograde cerebral perfusion|Hypothermic circulatory arrest provides protection to cerebral and visceral organs.
223561660|NCT00061815|BIOLOGICAL|cetuximab|400 mg/m2 IV
223561661|NCT00061815|DRUG|oxaliplatin|85 mg/m2 IV
223561662|NCT00061815|DRUG|leucovorin|200 mg/m2 IV
223561663|NCT00061815|DRUG|5-fluorouracil|400 mg/m2 IV
223561664|NCT00061815|DRUG|5-fluorouracil|600 mg/m2 IV
223561665|NCT00061815|BIOLOGICAL|cetuximab|250 mg/m2 IV
223561666|NCT01794663|DRUG|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
223561667|NCT01794663|DRUG|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
223561668|NCT06359028|DRUG|Stannous fluoride toothpaste|Toothpaste containing 0.454 % weight/weight (w/w) SnF2
223561669|NCT06359028|DRUG|Crest cavity protection toothpaste|Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
223561670|NCT06241924|PROCEDURE|High Resolution Electroencephalogram (EEG-HR)|Local field potentials (LFP) recording using EEG-HR
224137161|NCT02410850|DEVICE|Oral Appliance|Mandibular Advancement Splints
224137162|NCT06365814|OTHER|enhanced recovery after surgery|ERAS is a comprehensive perioperative interventions, including preoperative patient education, prehabilitation, nutritional support, minimally invasive surgery and other methods, can reduce surgical stress and promote patient recovery
224137163|NCT06365814|OTHER|conventional perioperative management|conventional perioperative management
223561671|NCT06241924|PROCEDURE|Stereo-electro-encephalography (SEEG)|Local field potentials (LFP) recording using sEEG
223561672|NCT06007339|DEVICE|PerQseal ELITE|"The term PerQseal Elite used singularly refers to the closure system comprising the closure device and Introducer. These individually are referred to as: PerQseal Elite VCD or PerQseal Elite closure device and/or PerQseal Elite Introducer."
223561673|NCT03515551|DRUG|IMCnyeso|Weekly IV infusions of IMCnyeso
223561674|NCT04677595|DRUG|Capmatinib|400 mg of capmatinib tablets, administered orally twice daily
223561675|NCT04021108|DRUG|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
223561676|NCT05364684|DRUG|LUM-201|LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.
223561677|NCT02209558|BEHAVIORAL|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
223561678|NCT00920387|DRUG|200 mcg LSD|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
223561679|NCT00920387|DRUG|20 mcg LSD|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
223561680|NCT00920387|BEHAVIORAL|Therapy|Therapy provided by male and female co-therapists
223418411|NCT04684537|PROCEDURE|Extracorporeal shockwave therapy (ESWT)|The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.
223418412|NCT04684537|PROCEDURE|Ultrasound-guided piriformis steroid injection|all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.
223418413|NCT01355575|DRUG|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
223418414|NCT01213732|OTHER|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
223561681|NCT03641768|DEVICE|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
223561682|NCT03641768|DEVICE|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
223561683|NCT03641768|DEVICE|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
223561684|NCT03641768|DEVICE|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
223561685|NCT05307640|BEHAVIORAL|CG-Well|CG-Well is a web \& phone based psychosocial intervention that teaches caregivers how to obtain information, education \& support
223561686|NCT05307640|BEHAVIORAL|Information Support & Referral (ISR)|Attention control group that receives phone calls and modules from the Brain Injury Association of America.
223561687|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in cases group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in cases group. Clinical data will be compiled.
223561688|NCT06232668|PROCEDURE|Chorionic biopsy and peripheral blood collection in control group|Chorionic villi will be collected from women who have a recommendation for aneuploidy testing, and the remaining fragment will be used for this study and peripheral blood collection in control group. Clinical data will be compiled.
224034425|NCT06863259|DRUG|Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone|"Subjects will receive a course of inotuzumab ozogamicin administered by central venous catheter over 60 minutes on days 1, 8, and 15.~Venetoclax (by mouth or NG) and dexamethasone (by mouth, NG, or IV) are given daily per assigned dose level. Venetoclax and dexamethasone are started 2 days prior to inotuzumab to limit risk of tumor lysis syndrome with a two-day venetoclax ramp up in cycle 1. On days 1 and 8, venetoclax administration should be scheduled for 4 hours after the beginning of inotuzumab ozogamicin administration. If the patient is not able to ingest venetoclax at the scheduled time, it may still be given later in the day, but efforts should be made to administer the venetoclax within 2 hours of the scheduled time whenever possible."
224034426|NCT06862323|BEHAVIORAL|Time-Restricted Eating|TRE will be defined as a 16 hour fast with an 8 hour feeding window, with the option of a longer feeding window one day per week. All participants will adhere to the fasting intervention for either 90 days (3 months) or 180 days (6 months) based on their preference. Participants will be provided guidance (see appendix 7, Fasting Guidelines) on how to achieve an 8 hour feeding window by day 9 of the study and are recommended to adhere to the 16 hour fast/8 hour feeding window daily for the remainder of the study.
224034427|NCT06993623|DIAGNOSTIC_TEST|heparin binding protien|compare between Heparin binding protien and platelet count and mean platelet volume kinetics in diagnosis and prognosis of VAP
223561689|NCT02265536|DRUG|LY3022855|Administered IV
223561690|NCT06481878|DIAGNOSTIC_TEST|faecal analysis|Collection of medical data and stool sampling
223561691|NCT05975619|DEVICE|HyperSight imaging|Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.
223561692|NCT05913713|BEHAVIORAL|12-week Intervention Period|Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
223418415|NCT05087316|DEVICE|biomimetic oral appliance therapy (BOAT)|BOAT appliance is designed to correct maxillo-mandibular underdevelopment in both children and adults (Singh and Lipka, 2009). However, adults will only use for this study. Typically, a BOAT appliance consists of 6 patented, anterior 3-D Axial Springs™, a midline actuator (such as omega loops or screws), posterior occlusal rests, and a round labial bow (Figure 1). Patients will be trained on activation of the screw
223561693|NCT05913713|BEHAVIORAL|12-week Observation Period|After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
223561694|NCT02905539|DRUG|Iron Isomaltoside 1000|
223561695|NCT02905539|DRUG|Ferric Carboxymaltose|
223561696|NCT05031299|BEHAVIORAL|Standard care|Participants will receive only the standard care as provided by the local and national healthcare system as well as one face-to-face counselling session for lifestyle modification to improve their risk factors.
223561697|NCT05031299|BEHAVIORAL|Health-promotion application for self-management|Participants will be provided with a health-promotion application for self-management for 3 months, additionally to the standard care.
223418416|NCT05087316|DEVICE|Standard hospital treatment|Use of CPAP and similar methods
223418417|NCT02420080|DRUG|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
223418418|NCT02208713|BIOLOGICAL|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
223418419|NCT06578013|OTHER|acupressure ice massage|"* It will be used for participants in group (A), 2 cm diameter circular ice pieces will be placed inside plastic bags and covered with a thin gauze to prevent moisture transmission and direct ice contact with the skin to apply ice massage.~* Ice massage will carried out rotationally each 1 minute (30 seconds clockwise and 30 seconds counterclockwise) on L14 point for 10 minutes and on SP6 point for another 10 minutes."
223418420|NCT06578013|OTHER|pelvic rocking exercises|"* Pelvic rocking exercise will be used for all participants in both groups (A \& B).~* Each participant will be encouraged to lie down on her back on matrix with a pillow under head then bend her knees and keep her foot flat on the floor and place one hand under curve of her back and the other hand on the top of. her abdomen then tighten buttocks and abdominal muscles simultaneously. After that each participant will be encouraged to inhale and hold (1-2-3-4) then exhale and hold 4-3-2-1 then relax muscles and feel her back flat on the underneath hand. Finally, each participant will be encouraged to repeat the last two steps about 10 times each session.~* The exercise will be repeated for 15times/ session, 3 times /week, for 3 successive menstrual cycles."
223418421|NCT04037475|DEVICE|photodynamic therapy herpes labialis|Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
223418422|NCT03053791|PROCEDURE|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
223418423|NCT03053791|DEVICE|Implantation of a Deep brain stimulation system|Implantation of a Medtronic Percept PC Impulse Generator for chronic Stimulation of the selected target.
223561698|NCT05031299|DEVICE|Wearables and devices|Participants will be provided with wearables and devices, including a weighing scale (assessing also body composition) device and a smartwatch/wristband to assess physical activity but also sleep pattern, for 3 months, additionally to the standard care and the Health-promotion application.
223561699|NCT05961111|DRUG|Recombinant oncolytic herpes simplex virus type 1 (R130)|R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
223561700|NCT00883818|DRUG|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
223561701|NCT04207593|DRUG|Oxygen|Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.
223561702|NCT05822570|DIAGNOSTIC_TEST|Assessment of Oxygen Dissociation Curve (ODC)|ODC will be assessed at 5 timepoints: T0 after installation of arterial catheter, T1 before clamping of the liver, T2 5-10 min before reperfusion of the liver graft, T3 45 min after reperfusion, T4 1 h after T3 or at end of surgery
223561703|NCT01866111|DRUG|YKP3089|
223561704|NCT01866111|DRUG|Placebo|
223561705|NCT02789436|DRUG|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
224034428|NCT06588257|BIOLOGICAL|Non-infectious adjuvanted recombinant nonavalent HPV vaccine|Non-infectious adjuvanted recombinant nonavalent HPV vaccine. Three doses (0, 2, 6 months). (Trade name GARDASIL 9 -MSD).
224034429|NCT05437185|DEVICE|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a non-invasive neuromodulatory method utilizing weak electrical currents to elicit short and long-term central nervous system changes.
224034430|NCT05437185|DEVICE|Sham Transcranial Direct Current Stimulation|The sham was administered using the same tDCS devices as in the active group with a preprogrammed sham protocol of 20 minutes to be virtually indistinguishable from the active stimulation.
223561706|NCT02789436|OTHER|Placebo lozenges|Twice daily, for 28 days
223561707|NCT06078592|DRUG|BRIDIN-plus Eye drops|BRIDIN-plus Eye drops
223561708|NCT06078592|DRUG|Combigan Eye drops|Combigan Eye drops
223561709|NCT05596734|BIOLOGICAL|bivalent BNT162b2 (original/Omi BA.4/BA.5)|Intramuscular injection
223561710|NCT05596734|BIOLOGICAL|qIRV (22/23)|Intramuscular injection
224034431|NCT04530331|BEHAVIORAL|Nutrition education|Dietitians visited the worksites of the intervention group once a week to deliver a nutrition education session and provide dietary advice for each participant.
224034432|NCT07006090|DEVICE|Histolog Scanner|Histolog Scanner intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture.
224034433|NCT06496646|BEHAVIORAL|Reminders|We will send daily text messages to participants for 12 weeks reminding them to take their antidepressant medication. These reminders will be tailored, personalized and patient-centric, grounded in behavioral economics principles.
223561711|NCT05596734|BIOLOGICAL|QIV|Intramuscular injection
223561712|NCT05596734|BIOLOGICAL|bIRV|Intramuscular injection
223561713|NCT05596734|BIOLOGICAL|tIRV|Intramuscular injection
223561714|NCT04113018|DRUG|Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab|Experimental
224034434|NCT06496646|BEHAVIORAL|Incentives|In addition to daily text messages, participants will receive financial incentives for 6 weeks based on contingency management principles. Participants assigned to the Reminders and Incentives arm of the study will receive a $2/day incentive, increasing by $1/day conditioned on each week that they consistently take their antidepressant over the first 6 weeks, for a maximum total payment of $189 ($2, $3, $4, $5, $6, $7 in weeks 1 through 6, respectively).
223418424|NCT05577013|OTHER|kinesiotaping|It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint
223418425|NCT05577013|OTHER|motor relearning program|Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
223418426|NCT03113942|DRUG|Pomalidomide 2 MG Oral Capsule [Pomalyst]|Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
223418427|NCT03179020|OTHER|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
223418428|NCT03179020|OTHER|Usual care|Management of the potential donor according usual care.
223418429|NCT02294396|DRUG|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
223418430|NCT02294396|DRUG|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
223418431|NCT02294396|DRUG|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
223561715|NCT03441035|OTHER|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
223561716|NCT05005013|OTHER|Transcranial Direct Current Stimulation (tDCS)|tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through sponge electrodes placed on the scalp.
223561717|NCT05005013|OTHER|Sham - Transcranial Direct Current Stimulation (tDCS)|The tDCS device is programmed to mimic active tDCS.
223561718|NCT05005013|OTHER|Mindfulness|Participants will follow an audio track for guided mindfulness during the stimulation.
223561719|NCT06977594|OTHER|Proactive immune tolerance induction|Proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles
223561720|NCT06977594|OTHER|Standard Treatment|Standard treatment throughout all chemotherapy cycles
223561721|NCT06977594|DRUG|Paclitaxel and carboplatin|A chemotherapy regimen for gynecologic cancers.
223561722|NCT06977594|DRUG|Standard premedication (20 mg)|Premedication includes 20 mg of dexamethasone.
224034435|NCT07010146|DRUG|transdermal 17β-E2 with cyclic progestin|100-mcg transdermal 17β-E2 patch (to be applied twice weekly) (continuous use), with 200 mg micronized progesterone given for 12 days of every month
223561723|NCT06977594|DRUG|Reduced premedication (10 mg)|Premedication includes 20 mg of dexamethasone.
224034436|NCT07010146|DRUG|oral 17β-E2 with cyclic progestin|2 mg of oral 17β-E2 pills daily, with 200 mg micronized progesterone given for 12 days of every month
224137164|NCT02871115|OTHER|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
223561724|NCT06977594|DRUG|Reduced premedication (5 mg)|Premedication includes 5 mg of dexamethasone.
223561725|NCT02526810|DRUG|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
223561726|NCT02526810|DRUG|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
224034437|NCT07010146|DRUG|transdermal EE+LNG|transdermal EE (30 mcg) + LNG (120 mcg) contraceptive patch (TWIRLA). Patch will be applied once a week for 3 consecutive weeks, with the 4th week off the patch (to be repeated after 4 weeks).
224137165|NCT02871115|OTHER|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
223561727|NCT01447498|OTHER|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; \>=80: 3 \_\_\_ Dyspepsia: 1 \_\_\_ Uncomplicated ulcer: 2 \_\_\_ Complicated ulcer 3 \_\_\_ NSAID 2 \_\_\_ Steroids 2 \_\_\_ SSRI 2 \_\_\_ Anticoagulant Tx 2 \_\_\_"
223561728|NCT02143453|OTHER|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
224034438|NCT03237182|DRUG|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
223418432|NCT02294396|DRUG|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
223561729|NCT02143453|OTHER|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
223561730|NCT02274935|OTHER|Exercise|Balance and gait exercise twice a week for an hour
223561731|NCT04787549|DEVICE|Virtual reality exergames|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for exergames using fully immersive virtual reality under the assistance of an occupational therapist.
223561732|NCT05420311|OTHER|MedDiet Arm|A balanced hypocaloric diet in macronutrients (MedDiet)
223561733|NCT05420311|OTHER|KetoDiet Arm|A very low carbohydrate diet (KetoDiet).
223561734|NCT05420311|OTHER|IF Arm|An intermittent fasting (IF) approach
223561735|NCT01802580|BEHAVIORAL|Internet Survey|
223561736|NCT01802580|DRUG|fluocinonide 0.05% ointment|
223561737|NCT01931488|OTHER|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
223561738|NCT01931488|DEVICE|SPECT imaging|
223561739|NCT05252013|OTHER|Experimental: Bean Hull Bread|The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
223739328|NCT07206264|DRUG|Bendamustine + anti-CD20 monoclonal antibody/orelabrutinib + anti-CD20 monoclonal antibody|"Induction phase (cycle 1-6):~Bendamustine (90 mg/m², day 1-2) +anti-CD20 monoclonal antibody (375 mg/m², day 0) from cycles 1-4. Patients who achieve CR and MRD negative continue to receive bendamustine (90 mg/m², day 1-2) + anti-CD20 monoclonal antibody (375 mg/m², day 0) from cycles 5-6; MRD positive patients receive orelabrutinib (150 mg) + anti-CD20 monoclonal antibody (375 mg/m², day 0).~Maintenance phase (cycle 7-24):~Patients who achieve CR and are MRD negative at cycle 4 receive bendamustine (90 mg/m², day 1-2) + anti-CD20 monoclonal antibody (375 mg/m², day 0); MRD-positive patients receive orelabrutinib (150 mg) + anti-CD20 monoclonal antibody (375 mg/m², day 0)."
224034439|NCT03237182|DRUG|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
224034440|NCT07016633|DRUG|IMM-H014|Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.
224034441|NCT07016633|DRUG|Placebo|Each group will consist of 10 participants who will be randomly assigned to receive IMM-H014 and placebo in a ratio of 4:1, once a day for a total of 12 weeks.
224137166|NCT04922515|OTHER|Oral and rectal swabs for microbiome sequencing|Oral swabs and rectal swabs are collected non-invasively.
224137167|NCT04096352|BEHAVIORAL|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
224137168|NCT04096352|BEHAVIORAL|Indirect Method|Information on voice function and voice hygiene.
223418433|NCT02294396|DRUG|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
223418434|NCT03243669|DIAGNOSTIC_TEST|High-definition|High-definition colonoscopy
223418435|NCT03243669|DIAGNOSTIC_TEST|Virtual chromoendoscopy|Virtual chromoendoscopy
223418436|NCT03243669|DIAGNOSTIC_TEST|Standard|Standard colonoscopy
223418437|NCT04559438|OTHER|Rotary Neoniti GPS file|Glide path creation will be achieved using Neoniti GPS file (15/.03). The file will be introduced passively inside the canal, in continuous rotation at a constant speed between 300 and 500 rpm and torque of 1.5 N.
223418438|NCT04559438|OTHER|Manual stainless steel K-files|Glide path preparation will be done by hand instrumentation using K-files #10 and 15.
223561740|NCT05252013|OTHER|Experimental: Plain Bread|The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
223561741|NCT03686306|DRUG|Sildenafil|"Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks. + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
223561742|NCT03686306|DRUG|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 24 weeks.~Treatment will be proposed in addition to optimal treatment (Antiplatelet / Direct Oral Anticoagulant + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
223561743|NCT01555034|BEHAVIORAL|movement therapy|exercise, nutrition, movement therapy
223561744|NCT01555034|OTHER|exercise plus nutrition|exercise, nutrition
223561745|NCT02264379|RADIATION|normal fractionated irradiation|25\*2 Gy (once a day, 5 days a week)
223561746|NCT02264379|RADIATION|hypo fractionated irradiation|3\*10 Gy (once a day, 2-3 days a week)
223561747|NCT02832557|OTHER|Salivary collection|Collection of saliva via swab for miRNA processing
224034442|NCT07016009|BEHAVIORAL|Thrive Program|Thrive is a person-centered planning intervention that is based on self-determination theory and integrates elements of social network interventions. The proposed Thrive intervention has four phases: 1) Strengths \& Network Assessment, 2) Network Engagement, 3) Goal Setting \& Planning, and 4) Plan Implementation \& Monitoring. It involves about 10-13 sessions and is delivered by a trained facilitator over Zoom.
223418439|NCT06685406|DIAGNOSTIC_TEST|Thorathic fluid content measurement by cardiometry|Thorathic fluid content measurement by using cardiometry
223418440|NCT02154503|DEVICE|topical 5% Minoxidil (Microneedling)|
223418441|NCT02120833|DEVICE|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
223418442|NCT02120833|DRUG|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
223418443|NCT01386398|DRUG|bortezomib|
223418444|NCT01386398|DRUG|vorinostat|
223418445|NCT01386398|OTHER|laboratory biomarker analysis|
223418446|NCT02438826|DRUG|Galcanezumab 300 mg|Administered SC
223418447|NCT02438826|DRUG|Placebo|Administered SC
223418448|NCT02830113|PROCEDURE|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
223418449|NCT04523103|BEHAVIORAL|Artificial Assisted Activation|Artificial assisted activation represents an effective technique to rescue the fertilization failure.
224034443|NCT07010120|DRUG|Tislelizumab|200mg IV Q3W
224034444|NCT07010120|DRUG|Afatinib|30mg PO QD
224034445|NCT07010120|BIOLOGICAL|Lysogenic HSV virus.|Lysosomal HSV virus injection (divided into a dose-escalation phase and a dose-expansion phase; in the dose-escalation phase, Group 1 took 106 pfu/mL and Group 2 took 108 pfu/mL, and in the dose-expansion phase the dose of lysosomal HSV virus with the highest MPR of the escalation phase was taken.) .. The dose of intralymph node injection of lysosomal HSV virus in patients was determined according to the size of metastatic lymph nodes, (diameter less than or equal to 1.5 cm, maximum 1 mL; diameter 1.5-2.5 cm, maximum 2 mL; diameter greater than 2.5 cm, maximum 4 mL). Two injections were given per patient, with each dose separated by 2 weeks.
224137169|NCT06473285|DRUG|Drug: Esketamine (Continuous infusion)|Continuous intravenous infusion of ketamine at a dose of 0.3mg/(kg · h). Collect resting state EEG and auditory event-related potential (ERP) before administration (baseline), 60 minutes after administration, 30 and 60 minutes after discontinuation.
223418450|NCT06666686|DEVICE|Active noise control headphone|This is the group where active noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
223418451|NCT06666686|DEVICE|Passive noise control headphone|This is the group where passive noise control headphones are applied. Headphones will be applied to patients from the beginning to the end of anesthesia induction.
223418452|NCT02622412|OTHER|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
224137170|NCT01586156|DRUG|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
224137171|NCT01586156|DRUG|placebo|Placebo will be taken twice daily for 6 months
224137172|NCT01912937|DEVICE|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
224137173|NCT02508688|PROCEDURE|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (\> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
223418453|NCT02622412|OTHER|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
223418454|NCT03939780|DIAGNOSTIC_TEST|[F18]RO-948|Single radiotracer IV injection with subsequent emission scan
223418455|NCT03939780|DIAGNOSTIC_TEST|[F18]MK-6240|Single radiotracer IV injection with subsequent emission scan
223418456|NCT03939780|DIAGNOSTIC_TEST|[F18]AV1451|Single radiotracer IV injection with subsequent emission scan
223418457|NCT02836379|OTHER|No intervention|No intervention
223418458|NCT04563910|OTHER|young mania rating scale|questionnaires to the patients and their family after their written consent
223418459|NCT00305084|DRUG|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
223418460|NCT00305084|DRUG|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
223418461|NCT04105218|BEHAVIORAL|Exercise|Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
223418462|NCT00714857|DRUG|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
223418463|NCT01435460|DRUG|Loteprednol etabonate 0.2%|1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
223418464|NCT01435460|DRUG|Olopatadine 0.1%|1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
223418465|NCT01706939|RADIATION|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy
223418466|NCT01706939|RADIATION|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy
223418467|NCT01706939|DRUG|Carboplatin|Day 1, every 7 days ( + 2 days)
223418468|NCT00853645|DEVICE|Subcutaneous Implantable Defibrillator (S-ICD) System|
223418469|NCT01046903|DRUG|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
223418470|NCT02404636|OTHER|Interview|Brief structured interview
223418471|NCT03300349|OTHER|Fulfillment of a preventive programme|Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
223418472|NCT03300349|OTHER|No fulfillment of a preventive programme|No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
223418473|NCT05910138|DIAGNOSTIC_TEST|Serum Interlukin-15|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
223418474|NCT05910138|DIAGNOSTIC_TEST|Serum Interlukin-21|Evaluate its serum level and detect its relation to the activity and severity of Alopecia Areata.
223418475|NCT04047836|OTHER|Low Nicotine E-Liquid|Participants will vape e-liquid with nicotine concentration of 3 mg/ml.
223418476|NCT04047836|OTHER|Medium or High Nicotine E-Liquid|Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
223418477|NCT02131285|OTHER|Sensory training|
223418478|NCT00098137|DRUG|Olmesartan|
223561748|NCT02832557|OTHER|Vineland Adaptive Behavior Scale-III Assessment|
223561749|NCT02832557|OTHER|Medical history questionaire|
223561750|NCT02832557|OTHER|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
223418479|NCT02868190|DEVICE|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
223561751|NCT02832557|OTHER|Mullen Scales of Early Learning|
223561752|NCT00551343|DRUG|Exenatide|10ug Exenatide single s.c. injection
224137174|NCT00547378|DEVICE|InterStim|
223418480|NCT03621306|DEVICE|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
223418481|NCT02674958|DRUG|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
223418482|NCT01130259|DRUG|iniparib|5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
223418483|NCT01328977|BEHAVIORAL|education|teaching
223418484|NCT05893251|OTHER|Manual therapy|"Within the manual therapy protocol carried out in the experimental group, we performed a series of passive maneuvers. The patient remains in supine position on a treatment table throughout the treatment, while the therapist sits at the head of the patient on a stool. The sequence of application is as follows:~Suboccipital inhibition technique Cervical spinal mobilization Posterior fascia stretching"
223418485|NCT05893251|OTHER|Postural exercises|The treatment plan includes active postural exercises for the cervical spine.
223418486|NCT06212700|BEHAVIORAL|Preoperative Exercise|Aerobic (HIIT) Endurance Respiratory Muscle Strength Education
223418487|NCT06212700|BEHAVIORAL|Postoperative Exercise|Aerobic Muscle Strength Walking Program Education
223418488|NCT06212700|DIETARY_SUPPLEMENT|Preoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
223418489|NCT06212700|DIETARY_SUPPLEMENT|Postoperative Nutrition|Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
223418490|NCT06212700|BEHAVIORAL|Preoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
223418491|NCT06212700|BEHAVIORAL|Postoperative Psychology|CBT skills Skills training Emotional validation Behavioural activation Psycho-education
223418492|NCT06212700|OTHER|Preoperative Nursing|Comorbidities Managing pain Wound care Complications Surgical education ERAS
223418493|NCT06212700|OTHER|Postoperative Nursing|Managing pain Cardiovascular stability Wound care Bowel function/Stoma Complications Education
223418494|NCT06212700|OTHER|Preoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
223418495|NCT06212700|OTHER|Postoperative Peer Support Group|"Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education"
223418496|NCT06212700|OTHER|Usual Care|Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
223418497|NCT03163498|OTHER|No intervantion. It´s a Cross-Sectional Study|No intervential
223418498|NCT01981941|DRUG|Gabapentin enacarbil|Oral
223418499|NCT04839523|DEVICE|Exufiber|A sterile nonwoven wound dressing made from highly absorbent PVA fibers.
223561753|NCT02504398|OTHER|Fast injection speed by immunizer|
223561754|NCT02504398|OTHER|Slow injection speed by immunizer|
223561755|NCT05475743|OTHER|Pain Informed Movement program|The patients included in the experimental group attended an 8-week Pain Informed Movement program in addition to standard medical care. The program was led by a physical therapist with experience in treating patients with chronic pain. This program consisted of 2 face-to-face sessions per week, and they were asked to complete two sessions at home weekly. The first face-to-face session was a group session with 3-6 participants, and the second face-to-face session was individual. Both sessions lasted approximately 1 h. In the group sessions, pain neuroscience education was conducted. In the individual sessions, an individualized functional exercise program was performed by each patient, as well as relaxation techniques. Patients were asked to perform the functional exercises and relaxation techniques at home. Participants were asked to record their compliance with the program and their progress.
223739329|NCT07205900|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
223739330|NCT07205900|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
224034446|NCT07021001|BEHAVIORAL|UP-A, a cognitive-behavioral structured group intervention, was adapted as a universal preventive intervention to be delivered in school settings (UP-A Kind).|The UP-A Kind is a school-based universal prevention intervention that aims to promote adaptive emotion regulations strategies, enhance mental well-being and prevent emotional disorders with the following contents: motivating to take care of mental well-being, psychoeducation about emotions, awareness of physical sensations, cognitive lexibility, behavioral experiences, recognizing warning signs, and promoting a compassionate attitude towards the self and others.
223418500|NCT04839523|DEVICE|Exufiber Ag+|A sterile nonwoven wound dressing made from highly absorbent PVA fibers, and coated with silver sulphate.
224034447|NCT07020156|DRUG|OX118 or placebo|OX118 is a human monoclonal antibody targeting OX40 ligand (OX40L).
224034448|NCT07020845|OTHER|Observation only|This is an observational study with no intervention applied to participants. Data were collected through questionnaires and clinical assessments only
223418501|NCT06299878|DIAGNOSTIC_TEST|Gut microbiota analysis|Patients with resectable stage IIIB-D melanoma will have a lymph node core biopsy to confirm metastatic lesions, following standard procedures. Additionally, a portion of the tumor tissue will be preserved for biomarker analysis. Participants will then be instructed to submit fecal samples and complete a dietary questionnaire before receiving three doses of PD1 monotherapy, in accordance with the center\&#39;s routine practice, typically spanning 6-10 weeks. Between weeks 10 and 12, a radiological assessment of the response will be conducted. Following this, participants will undergo regional lymphadenectomy, and the pathological response will be evaluated. After surgery, patients will be placed on adjuvant therapy for 12 months as per routine practice of the center . Subsequently, they will be monitored for five years, adhering to the institution\&#39;s standard follow-up protocol.
223418502|NCT06667778|DEVICE|Osseodesification densah burs|"Drill no. VT1525 (2mm) of densah burs will be used first in counter clockwise (in the osteotomy site).~Then drill no. VT2535 (3mm) of densah burs will be used in counter clockwise to put 3.5mm implant diameter."
223418503|NCT06667778|DEVICE|Microdent|"No. 1 Microdent expander will be placed and screwed slowely (to avoid heat generation) into the osteotomy site till reaching the full desired length.~N0. 2 microdent expander will be placed and screwed into the osteotomy site as the same step.~Then no. 3 Microdent expander will be inserted for placing 3.5mm implant diameter"
223418504|NCT00800774|PROCEDURE|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (\>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
223418505|NCT05051553|DRUG|Fedratinib|Specified dose on specified days
223561756|NCT05475743|OTHER|Standard medical care and leaflet education|In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
224034449|NCT07020975|DEVICE|VR Glasses|VR Glasses is used to help people be in a virtual reality other than their real life. What we use this for; to get away infertile women from her stressfull environment to another virtual reality before their embryo transfer.
224034450|NCT07019649|BEHAVIORAL|AYUDA Program|Participants randomized to the intervention arm will be enrolled in the AYUDA program, where they will receive text messages twice a week over 12 weeks containing diabetes education and self-management resources, including links to resources available to all KPNC members.
223418506|NCT05454761|BEHAVIORAL|Group-based Lifestyle Medicine Program|Participants will receive four core modules that focus on lifestyle modifications. Core Module 1 will be Diets and Nutrition. This module aims to provide simple and evidence-based information regarding nutrition for improving and maintaining mental health. Core Module 2 will be Physical Activity. Participants will practice various types of gentle and adaptable exercises during the session and learn simple ways to incorporate exercise into their daily lives. Core Module 3 will be Sleep Management. This module will include basic facts about sleep, with a focus on psychoeducation on insomnia and how the relationship between circadian and social rhythms relate to sleep and mental health. Core Module 4 will be Stress Management. This module will include psychoeducation about stress, worry management, the cultivation of positive psychology, and relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation.
224034451|NCT07019090|DRUG|HSK44459|HSK44459
223561757|NCT02066831|BEHAVIORAL|Telemedical coaching|
223561758|NCT02066831|OTHER|Telemedicine|
223561759|NCT02791516|DRUG|Romosozumab|Administered by subcutaneous injection once a month (QM)
223561760|NCT02791516|DRUG|Placebo|Administered by subcutaneous injections once a month
223561761|NCT02200003|BEHAVIORAL|attention bias modification for anxiety|
223739331|NCT07206095|GENETIC|Analysis of genetic modifiers|Genetic modifiers for rare anemia disorders will be analyzed through massive sequencing.
224034452|NCT07019870|DIAGNOSTIC_TEST|EBV biomarker testing|"15 ml of blood will be collected for EBV EA IgA serology and plasma EBV DNA testing by a trained nursing/phlebotomy staff. If the initial plasma EBV DNA test is positive, a second blood draw will be performed for repeat plasma EBV DNA testing.~Additionally, 2-3 ml of saliva will be collected for EBV strain identification, however, this information is not used for risk stratification in this study.~Demographic characteristics, clinical history and symptoms will be collected through a questionnaire."
224034453|NCT07020442|OTHER|integrated neuromuscular training|a 12-week integrated neuromuscular training (NMT) program. All participants completed two NMT sessions weekly.
224034454|NCT07019142|DIETARY_SUPPLEMENT|HFD|Luminal challenge with standardized volume, amount, calories of fat
224034455|NCT07019311|OTHER|Thera-Band exercises|Participants in the first experimental group performed a Thera-Band exercise program 3 sessions weekly, for 8 weeks with progressive resistance, divided into four 2-week phases. Each 60-minute session included a 10-min warm-up (walking, jogging, and calisthenics), 45-min Thera-Band exercises, and 5-min cool-down. Phase 1 focused on major muscle groups (e.g., shoulder press, biceps curl). Phase 2 included trunk and leg-focused moves (e.g., reverse flies, lunge). Phase 3 added advanced resistance (e.g., chest press, deadlift). Phase 4 targeted core and lower body (e.g., diagonal chop, squat). Exercises changed every phase to progressively strengthen different muscle groups.
224137175|NCT00547378|DRUG|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
223418507|NCT03847753|OTHER|Organic Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
224034456|NCT07019311|OTHER|Swiss ball exercises|Participants in the second experimental group performed Swiss ball exercises 3 sessions weekly, for 8 weeks. Exercises included warm-up (15-5 mins), core Swiss ball training (progressing from 1 to 4 sets), and cool-down. Each session focused on abdominal, back, leg, trunk, and balance training using varied exercises performed for 30 seconds with rest. Exercise intensity ranged from 80-95% of max effort, increasing weekly. The Swiss ball size was selected based on patient height to ensure proper posture. Sessions gradually increased in duration and difficulty, ending with breathing and stretching for recovery.
224034457|NCT07019311|OTHER|Traditional physical therapy program|Participants in both experimental groups performed a traditional physical therapy program in the form of complex decongestive physical therapy(CDPT), including (manual lymphatic drainage, compression, exercise and skin care) and balance training, 3 sessions weekly, for 8 weeks.
223418508|NCT03847753|OTHER|Substance Use Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418509|NCT03847753|OTHER|Schizophrenia Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418510|NCT03847753|OTHER|Mood disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418511|NCT03847753|OTHER|Neurotic disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418512|NCT03847753|OTHER|Eating Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418513|NCT03847753|OTHER|Personality Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418514|NCT03847753|OTHER|Intellectual Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418515|NCT03847753|OTHER|Developmental Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418516|NCT03847753|OTHER|Behavioral Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
223418517|NCT02674308|DRUG|Vedolizumab|
223418518|NCT02674308|OTHER|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
223418519|NCT02275260|DEVICE|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
223418520|NCT02275260|DEVICE|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
223418521|NCT02275260|OTHER|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
223418522|NCT04678232|BEHAVIORAL|Positive Processes and Transition to Health (PATH)|See arm/group description for details regarding this intervention
223418523|NCT00004494|DRUG|vasoactive intestinal peptide|
223418524|NCT06659094|OTHER|stepped-care Internet-based cognitive behavioral therapy(SC-ICBT)|"Using a WeChat mini-program, we offer personalized OCD SC-ICBT remote services. Training is customized based on individual assessments, focusing on psychological education and homework to simulate CBT therapy. If a patient's YBOCS score drop from baseline isn't 25% after four therapist sessions (one week of theory, two sessions/week), they get three more weeks of online guidance.~The program includes four structured lessons over six weeks:~Lesson 1: Psychological Health Education on OCD and related disorders. Lesson 2: ERP theory, exposure item lists, and related info. Lesson 3: Daily ERP practice for about an hour, followed by two weeks of therapist guidance.~Lesson 4: Retrospection and relapse prevention."
223418525|NCT06659094|OTHER|Cognitive Behavioral Group Therapy (CBGT)|The CBGT group will receive cognitive-behavioral group therapy for 6 weeks, twice a week, each session lasting 2 hours, at the Shanghai Mental Health Center. The CBGT program follows a structured process for treating OCD. During the prep phase, therapists assess patients for 50 minutes, collect data, and set CBGT groundwork. In Session 1, families join to understand CBGT, with goals reinforced and OCD education provided. Session 2 reviews homework and develops ERP strategies. Session 3 initiates ERP practice. Sessions 4-11 continue homework review and group ERP practice. The final session involves families in a review, discussing challenges, celebrating achievements, and focusing on relapse prevention.
223418526|NCT06659094|DRUG|conventional medical treatment (TAU)|Drug therapy, managed by a deputy chief psychiatrist unaware of patient groupings, utilizes China Food and Drug Administration (CFDA)-approved SSRIs for OCD. These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine. The maximum dosage adheres to the instructions. Benzodiazepines may assist with sleep, but usage is capped at two weeks; no other psychotropics are co-administered. Common side effects comprise dry mouth, constipation, nausea, indigestion, dizziness, fatigue, and sweating. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
223418527|NCT03925233|DRUG|Trastuzumab|Trastuzumab Injection
223418528|NCT03925233|DRUG|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride Injection
223418529|NCT03925233|DRUG|Epirubicin hydrochloride|Epirubicin hydrochloride injection
223418530|NCT03925233|DRUG|Fluorouracil|Fluorouracil injection
223418531|NCT03925233|DRUG|Paclitaxel|Paclitaxel injection
223418532|NCT03925233|DRUG|Gemcitabine|Gemcitabine injection
223418533|NCT03925233|DRUG|Cisplatin|Cisplatin injection
224034458|NCT07021287|OTHER|mixed ice and water, continuous ice application|the ice pack was placed on the knee joint immediately after returning to the ward for 24 hours, and the ice pack was replaced every 3 to 4 hours, if it melted, replaced immediately.
223561762|NCT02620878|DEVICE|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
223561763|NCT02620878|OTHER|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
224137176|NCT06063252|BEHAVIORAL|NISMA|"The intervention NISMA is a nine-month intervention and consisted of four individual sessions and two group sessions. The theoretical frame is Social Cognitive Theory, along with Acceptance and Commitment Therapy (ACT), to support the enhancement of self-efficacy. It involves four individual face-to-face sessions with a nurse and two group sessions (5-7 patients) with a nurse, an occupational therapist (OT), and a physiotherapist (PT), with the nurse being the facilitator. Every session has a specific topic and, in every session, a person-centered approach was used to address current problems and secure relevance.~Participants in the control group receive usual care, and the intervention group receives both usual care supplemented with the intervention."
223418534|NCT03925233|DRUG|Recombinant Human Endostatin|Recombinant Human Endostatin Injection
223418535|NCT03925233|DRUG|Pirarubicin hydrochloride|Pirarubicin hydrochloride injection
223418536|NCT03925233|DRUG|Pyrrolidine|Pyrrolidine tablets
223418537|NCT03925233|DRUG|Ixabepilone|Ixapilone Injection
223418538|NCT03925233|DRUG|Tamoxifen citrate|Tamoxifen citrate tablets
223418539|NCT03925233|DRUG|Vinorelbine tartrate|Vinorelbine tartrate injection
223418540|NCT03925233|DRUG|Carboplatin|Carboplatin injection
223418541|NCT03925233|DRUG|Methotrexate|Methotrexate injection
223418542|NCT03925233|DRUG|Eribulin mesylate|Eribulin mesylate injection
223418543|NCT03925233|DRUG|Toremifene citrate|Toremifene citrate tablets
223418544|NCT03925233|DRUG|Anastrozole|Anastrozole tablets
223418545|NCT03925233|DRUG|Letrozole|Letrozole tablets
223418546|NCT03925233|DRUG|Exemestane|Exemestane tablets
223418547|NCT03925233|DRUG|Fulvestrant|Fulvestrant injection
223418548|NCT03925233|DRUG|Olaparib|Olapani pill
223418549|NCT03925233|DRUG|Bevacizumab|Bevacizumab injection
223418550|NCT03925233|DRUG|Apatinib mesylate|Apatinib mesylate tablets
223418551|NCT03925233|DRUG|Pattozumab|Pattozumab injection
223418552|NCT03925233|DRUG|Capecitabine|Capecitabine tablets
223418553|NCT03925233|DRUG|Ear particles|Ear particles
223418554|NCT03925233|DRUG|Aidi Injection|Aidi Injection
223418555|NCT03925233|DRUG|Cyclophosphamide|Cyclophosphamide injection
223418556|NCT03831360|BEHAVIORAL|Yoga|Hatha yoga for depressed adolescents
223418557|NCT03831360|BEHAVIORAL|Group CBT|Group cognitive behavioral therapy for depressed adolescents
223418558|NCT05529875|DRUG|Propofol|intravenous propofol using target-controlled infusion (TCI) devices.
223418559|NCT05529875|DRUG|sevoflurane|inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
223418560|NCT06684340|PROCEDURE|Exposure to major abdominal surgery|This study is a retrospective cohort study. The 'exposure' situation is based on historical records and observation, and no active intervention has been conducted on the study subjects to change their exposure status.
223418561|NCT06683287|DEVICE|red light and distant image screen|red light plus distant image screen, children use these two devices at the same time
223418562|NCT06683287|DEVICE|red light|children use red light for 3 minutes each time, twice a day
223418563|NCT06683287|DEVICE|distant image screen|Children in this group were asked to use this device for ≥1 hour/day
223418564|NCT03388645|BIOLOGICAL|10^6.3 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10\^6.3 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
223418565|NCT03388645|BIOLOGICAL|10^7 PFU of RSV A2|Each adult volunteer will receive a single intranasal inoculation of 10\^7 PFU of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
223418566|NCT05504798|OTHER|Selected physical therapy program|Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.
223418567|NCT05504798|PROCEDURE|Interrupted serial casting|Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.
223418568|NCT05504798|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
223418569|NCT06622798|OTHER|Non-interventional|Non-interventional
223418570|NCT04366297|DEVICE|Intravenous access|obtaining intravascular access using a standard intravenous cannula
223418571|NCT04366297|DEVICE|Intraosseous access|obtaining intravascular access using a ready intravenous NIO needle set
223418572|NCT00001353|DRUG|Genetically Marked Syngeneic T Lymphocytes|
223418573|NCT06015295|DIAGNOSTIC_TEST|18F-Fluciclovine (Axumin)|Given by Injection
223418574|NCT06015295|DIAGNOSTIC_TEST|Pet Scan|Scans
223418575|NCT02396277|PROCEDURE|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
223561764|NCT02664311|DEVICE|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
223561765|NCT02664311|DEVICE|Conventional ventilation|Conventional ventilator - control arm
223561766|NCT03216343|DRUG|Chiauranib|CS2164
223561767|NCT04239066|PROCEDURE|Tourniquet|tubularized incided plate (TIP) urethroplasty plus tourniquet
223561768|NCT04239066|PROCEDURE|Non-tourniquet|tubularized incided plate (TIP) urethroplasty plus non-tourniquet
223561769|NCT01016119|DRUG|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
223561770|NCT01016119|DRUG|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
223418576|NCT06968000|DEVICE|EOX Anion-Enriched Hospital Room|Participants are assigned to hospital rooms equipped with an operational EOX device, which actively regenerates air and releases bioavailable anions through cold atmospheric plasma. Exposure lasts for 96 hours postoperatively. The intervention aims to enhance postoperative recovery by modulating oxidative stress, improving mitochondrial function, and promoting sleep quality.
223418577|NCT06567405|PROCEDURE|mechanical periodontal treatment|Patients will undergo subgingival scaling employing a Piezoelectric ultrasonic scaler to eliminate local factors.
223418578|NCT06567405|DEVICE|Derma pen with topical ascorbic Acid|local anesthesia of 2% lignocaine will be administered by infiltration technique in the anterior maxillary region. Microneedling of the mucosa will be performed using dermapen needles, employing an intermittent back-and-forth motion in the anterior maxillary and mandibular region for 30-40 seconds, reaching a depth of 1.5 mm. This will involve the creation of microholes in the gingival tissue using derma pen to enhance the concentration and penetration of the ascorbic Acid through the gingival tissues.
223418579|NCT05988983|OTHER|Availability of OTC contraceptive pill|Over the counter contraceptive pill
223418580|NCT04167033|DRUG|Hormone replacement therapy:effect on ventricular repolarization|Hormone replacement therapy and QTc measurement
223561771|NCT06395675|DIAGNOSTIC_TEST|ID NOW™|"The ID NOW™ CT/NG is an in vitro qualitative molecular assay for the rapid differential.~detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in urine, and self-collected vaginal swabs (SVS) in symptomatic and asymptomatic individuals."
223561772|NCT00562263|BEHAVIORAL|Lifestyle modification|Dietary modification and regular physical activity
223561773|NCT05805696|BEHAVIORAL|Impostor tasks|Tasks to do every week
223561774|NCT04164095|PROCEDURE|lappg|Preservation of pylorus and vagus nerve by laparoscopy
223561775|NCT02896491|RADIATION|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
223561776|NCT00121758|BIOLOGICAL|LIPO-5|
223561777|NCT06306729|DIAGNOSTIC_TEST|Computed Tomography, Magnetic Resonance Imaging|Computed Tomography, Magnetic Resonance Imaging
223561778|NCT02533986|DIETARY_SUPPLEMENT|Berry peel drink|
224034459|NCT07021287|OTHER|mixed ice and water, intermittent ice compress|within 72 hours after operation, the patients were given ice compress for 20 minutes each time, with an interval of 2 hours, 3 times a day
224034460|NCT07021287|OTHER|full ice, continuous ice compress|After returning to the ward, an ice pack should be placed on the knee for 24 hours. The ice pack should be replaced every 3-4 hours and replaced immediately if melted
224137177|NCT05041452|DIAGNOSTIC_TEST|Cardiac magnetic resonance scan|Multiparametric cardiac magnetic resonance, including functional and structural parameters
223561779|NCT02533986|DIETARY_SUPPLEMENT|Control drink|
223561780|NCT03759886|DRUG|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
223561781|NCT03475706|DRUG|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
223561782|NCT03475706|DRUG|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
223561783|NCT03475706|DRUG|Matching Placebo|twice daily for 12 weeks.
223561784|NCT05137197|DEVICE|Predictix Genetics Antidepressant|Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
223561785|NCT02674919|OTHER|Nordic Hamstring|
223561786|NCT02674919|OTHER|Control|
223561787|NCT04470804|DRUG|Sirolimus|Sirolimus treats in experimental group
223561788|NCT04470804|DRUG|Cyclosporine A|Cyclosporine A uses for active comparator group.
223561789|NCT04935190|DIAGNOSTIC_TEST|Vitalpercept|Comparison of resting heart and respiratory rate measurements acquired by contactless radar sensors, electrocardiography, and capnography
223561790|NCT05707442|PROCEDURE|Stent Implantation|Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to \> 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
223561791|NCT05707442|DRUG|Acetazolamide-based medical therapy|The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
223561792|NCT05707442|BEHAVIORAL|Weight loss|The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
223561793|NCT03236909|DEVICE|MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System|Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
224034461|NCT07021287|OTHER|full ice, intermittent ice compress|Within 72h after surgery, the patient applied ice for 20min each time, with an interval of 2h,3 times a day.
224137178|NCT00414960|DRUG|Enzastaurin|500 mg po QD for 6 months
224137179|NCT00414960|DRUG|Placebo|po QD for 6 months
224137180|NCT02266082|OTHER|No intervention|There is no intervention in this study.
223418581|NCT04167033|DIAGNOSTIC_TEST|ECG|QTc measurement
224137181|NCT04105244|BEHAVIORAL|Resourcefulness Training©|The intervention includes self-help and help-seeking skills.
224034462|NCT07020715|BIOLOGICAL|Tolerogenic dendritic cells (tolDC)|In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.
223418582|NCT03000998|BEHAVIORAL|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
223418583|NCT03000998|BEHAVIORAL|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
223418584|NCT00482677|DRUG|temozolomide|Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
223418585|NCT00482677|GENETIC|DNA methylation analysis|A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
223418586|NCT00482677|PROCEDURE|quality-of-life assessment|prior to randomization until end of study
223418587|NCT00482677|RADIATION|Radiation|Short course radiotherapy
223418588|NCT04215211|DIAGNOSTIC_TEST|Survival prediction for glioma patients|Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI
223418589|NCT03554395|BIOLOGICAL|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
223739332|NCT07206095|DIAGNOSTIC_TEST|Disease phenotyping|Peripheral blood samples will be used for conventional phenotyping characterization including among others: RBCs morphology, fragility osmotic test, hemoglobin fraction and quantification, hemoglobin stability test, EMA binding test, RBC enzymes quantification assay, RBC rheological properties through Lorrca Maxsis Osmoscan/Oxygescan (Lorrca®)
223739333|NCT07205484|BEHAVIORAL|Parent-Mediated Intervention (PMI)|The PMI consisted of weekly, 1-hour intervention sessions via Zoom for 6 months. In total, the intervention consisted of 26 intervention sessions.
224034463|NCT07018999|DEVICE|Immersive virtual reality operating theatre tour|In a joint project involving the Department of Computing of Hong Kong Polytechnic University, the Department of Computer science Center for Innovative Applications of Internet and Multimedia Technologies of the City University of Hong Kong and the Hong Kong Children's Hospital (HKCH), an immersive VR operating theatre tour will be designed as part of preoperative education for participants. A simulation of the perioperative journey in HKCH operating theatre will be created to help participants form realistic expectations of their perioperative journey, and virtual exposure of different medical equipment helps participants cope with their worries for the anticipated procedures. Parents/legal guardians will be able to monitor the VR experience on tablets via the monitoring software, which displays what the participants see in VR.
224034464|NCT07020247|DRUG|Anti-PD-1 antibody drug named Serplulimab|Serplulimab
223418590|NCT03554395|PROCEDURE|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
223418591|NCT02992977|BIOLOGICAL|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
223418592|NCT04192071|OTHER|virtual technology - high interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer and dietary intake. Interactive nutrition risk feedback will be customized based on user input.
223418593|NCT04192071|OTHER|virtual technology - low interactive|Participants engage with web-based cancer prevention content and answer a short series of questions designed to assess their baseline risk for colon cancer. Minimally interactive risk feedback will be delivered.
223418594|NCT04192071|OTHER|non-colorectal cancer related module|Participants engage with web-based content not related to colorectal cancer or nutrition.
223418595|NCT06291038|DIETARY_SUPPLEMENT|• Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks|treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
223739334|NCT07207200|DEVICE|Morning Light Therapy|One hour of morning light therapy each day for four weeks
224034465|NCT07020247|RADIATION|Radiotherapy|Radiotherapy is delivered using intensity-modulated radiotherapy (IMRT/VMAT) at a dose of 50-50.4Gy/ 25-28f(1.8-2.0Gy/d, 5f/w). For patients in the experimental group who achieve partial remission (PR) or better during the induction phase, an additional local boost dose of 6Gy/3f(2.0Gy/d, 5f/w) is administered to the PGTV.(No PGTV dose was given in the control group). For the treatment of lymph node metastasis in the lateral pelvic wall outside the mesorectal area: no additional dose is required when surgery is feasible, a sequential boost dose of 15Gy/3f is added when the lymph nodes are not surgically resectable.
224034466|NCT07020247|DRUG|Chemotherapy|Capox
223418596|NCT06291038|DIETARY_SUPPLEMENT|• Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.|treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
223418597|NCT06612762|DIETARY_SUPPLEMENT|The daily ingestion of capsules containing naringenin|Following surgical intervention, patients will be administered two capsules (equivalent to 500 mg) daily for a period of 14 days. Subsequently, patients will ingest the maintenance dose of 250 mg per day until the 90th day post-surgery.
223418598|NCT06612762|DIETARY_SUPPLEMENT|Placebo|The daily ingestion of capsules containing placebo
223418599|NCT04097262|OTHER|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
223418600|NCT04097262|OTHER|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
224034467|NCT04420884|DRUG|Dazostinag|Dazostinag intravenous infusion.
224034468|NCT04420884|DRUG|Pembrolizumab|Pembrolizumab intravenous infusion.
223561794|NCT00663884|DRUG|Mitiglinide|mitiglinide 10mg three times a day before a meal
223561795|NCT00663884|DRUG|Voglibose|voglibose 0.2mg three times a day before a meal
223561796|NCT06061705|PROCEDURE|Tumor Biopsy|"Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180. This will only be carried out if the tumour tissue is externalized and therefore accessible, and if the biopsy can be performed under local anaesthetic without any constraints for the patient (pain, risk of bleeding).~It consists of a superficial sampling of the externalized tumour lesion under local anaesthetic (xylocaine spray 5%, or xylocaine injectable 1%).~Biopsy of cervico-facial lesions under local anaesthetic is a commonly performed procedure. The main risk of this procedure is bleeding, which is very rare.~The biopsy will not be performed if the surgeon considers that the risk of bleeding is too great. Given the externalized nature of the lesion, biopsy does not entail any risk of tumour dissemination (possible for deep biopsies).~* Four 10-mL blood samples from two heparinized tubes~* Four 5-mL unstimulated saliva samples: non-invasive examination."
223561797|NCT06797856|DIAGNOSTIC_TEST|Refractive Error|"* Refractive error centrally (on-axis) and peripherally in both nasal and temporal visual fields~* Ocular wavefront measured centrally (on-axis) and peripherally in both nasal and temporal visual fields"
223561798|NCT06658106|BEHAVIORAL|Thera-Band Elastic Band-Assisted Progressive Resistance Training|Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
223739335|NCT07206537|DRUG|Vitamin K 2|Oral vitamin K2 supplementation
224034469|NCT04420884|DRUG|Platinum|Carboplatin or Cisplatin intravenous infusion
224034470|NCT04420884|DRUG|5-fluorouracil|5-fluorouracil intravenous infusion
224034471|NCT05452811|PROCEDURE|Burch colposuspension|Anti-incontinence surgery for stress urinary incontinence
224034472|NCT02445196|BEHAVIORAL|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
224034473|NCT02445196|DEVICE|Smartphone|All participants must have a smartphone, either apple or android.
224034474|NCT01782365|DEVICE|SHAM stimulation|no stimulation
223418601|NCT05313568|OTHER|static stretching|The stretch will be done by placing both feet on a raised platform, lowering the heel off the platform without touching the ground, and held in this position to perform a static stretch. They will perform 5 repetitions, 15 seconds of rest and 1 minute of stretching.
224034475|NCT01782365|DEVICE|0,75 Hz stimulation|
223418602|NCT05313568|OTHER|self massage|In addition to the self-stretching application, plantar self-massage will be applied. Plantar self massage will be shown to the participants by the physiotherapist with a 7 cm spiky massage ball. Then, participants will be asked to self-massage the plantar sole of the foot for 5 minutes with a 7 cm spiky massage ball.
223418603|NCT05313568|OTHER|Manual Stimulation|"In addition to the self-stretching application, manual stimulation will be applied.~Manual protocol:~A) Pressure will be applied in each interdigital space and on the longitudinal arch with shear in the longitudinal direction (5 repetitions of 10 seconds each).~B) Pressure with transverse shear on the metatarsal heads (5 repetitions of 5 seconds each) C) Static pressure will be applied to the first and fifth metatarsal head, center of the midfoot, and heel (5 repetitions per 10-second period each)."
223418604|NCT00392938|DRUG|antiandrogen therapy|
223418605|NCT00392938|DRUG|docetaxel|
223418606|NCT00392938|DIAGNOSTIC_TEST|C-11 acetate PET scan|
223418607|NCT00392938|DIAGNOSTIC_TEST|F-18 FDG PET scan|
223418608|NCT00392938|DIAGNOSTIC_TEST|Tc-99m bone scan|
224034476|NCT01910909|RADIATION|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
223418609|NCT00392938|DIAGNOSTIC_TEST|CT scan of the chest, abdomen and pelvis|
223418610|NCT06206577|PROCEDURE|Horizontal ridge augmentation by symphyseal bone block placed and fixed buccally as onlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed buccally in deficient area with fixation screws
223418611|NCT06206577|PROCEDURE|Horizontal ridge augmentation by symphyseal bone block interpositioned in space created between buccal and lingual cortex as inlay graft|autogenous bone block harvested from chin area using piezosurgery and fixed in bone split created at deficient area with fixation screws
223418612|NCT06669949|OTHER|no intervention|No interventions are involved in this observational study.
223418613|NCT05021874|OTHER|Four different physiotherapy treatment|Four different physiotherapy treatment will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 10th day of therapy, it will be measured ROM.
223418614|NCT01399463|DEVICE|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
223418615|NCT01399463|DEVICE|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
223418616|NCT06147596|OTHER|Head impact exposure|The cohort is exposed to naturalistic head impacts (heading) during voluntary participation in a soccer match. All participants are regular soccer players and are therefore not exposed to excessive head impacts compared to their regular exposure.
224034477|NCT01837069|DRUG|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
224034478|NCT01837069|DRUG|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
224034479|NCT01837069|DRUG|Atorvastatin|80mg PO QD at preadmission testing
224034480|NCT01837069|BEHAVIORAL|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
224034481|NCT03930147|PROCEDURE|ASV ventilation|Ventilation on ASV mode
224137182|NCT02112994|DRUG|Sebelipase Alfa|IV infusion of sebelipase alfa
223418617|NCT04737252|BEHAVIORAL|Sage (formerly known as COMPASS)|Sage is a remote 12 session intervention for couples wherein one individual has Borderline Personality Disorder (BPD) and engages in self-injury thoughts and behaviours. The intervention consists of elements of Cognitive Behavioural Conjoint Therapy (CBCT) and has been adapted for this population. Couples will meet remotely with a clinician (registered psychologists and/or graduate level clinicians) for 8-12 sessions via Zoom Healthcare. The primary outcomes are self-injury thoughts and behaviours (as measured by the Suicide Attempt and Self-Injury Interview-modified, and the Beck Scale for Suicidal Ideation and ecological momentary assessment) and borderline personality disorder symptoms (as measured by the Borderline Symptom List-23).
223418618|NCT05658263|DIETARY_SUPPLEMENT|Standard Diet|Participants receiving only standard of care (SOC) nutrition advice, which is SOC Dietary Instructions, as provided by routine surgical consults and one protein shake per day for 4 weeks prior to surgery (SOC).
223418619|NCT05658263|DIETARY_SUPPLEMENT|BIG MACS Diet|Participants will be instructed to consume the study diet, referred to as the 'BIG MACS Diet' and one protein shake per day for 4 weeks prior to surgery (SOC). Following surgery, participants will continue to follow the BIG MACS Diet for an additional four weeks, with solid food reintroduction after surgery as early as tolerated.
223418620|NCT05886140|DRUG|Carrilizumab with albumin-binding paclitaxel|All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.
223418621|NCT06139198|BEHAVIORAL|Self-MAnagement intervention for Reducing The epilepsy burden among Ugandans|SMART-U sessions are operationalized in written curricula, including an intervention manual, participant manual, slides, and handouts typically delivered over a period of 10-12 weeks.
223418622|NCT06727565|DRUG|Domvanalimab|Administered intravenously
223418623|NCT06727565|DRUG|Zimberelimab|Administered intravenously
223418624|NCT06727565|DRUG|Paclitaxel|Administered intravenously
223418625|NCT06727565|DRUG|Carboplatin|Administered intravenously
223418626|NCT06735911|OTHER|Spa therapy|Thermal treatments among the following: Filiform shower, simple bath, aerated bath, general shower, compresses, nebulization inhalation, multiple local mud applications, and drinking cure.
223418627|NCT02894944|BIOLOGICAL|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
223561799|NCT06658106|BEHAVIORAL|Conventional Diabetes Management|Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
223561800|NCT06051019|OTHER|Aerobic training|Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).
223561801|NCT06051019|OTHER|Balance training|Balance training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Treatments will be performed with a physical therapist and will consist of the following exercises: 1) standing with feet together, 2) standing with closed eyes, 3) standing on unstable surfaces, 4) standing while performing upper limbs movements; 5) standing while performing head rotations; 6) walking on a treadmill at alternating speeds; 7) leg press and chest press exercises for training trunk balance during ballistic movements of the upper and lower limbs. These constituents of balance training can be combined in the same task according to the participant's ability.
223739336|NCT07206693|DIAGNOSTIC_TEST|Prostate specific antigen (PSA)|Prostate specific antigen (PSA) for prostate cancer screening
224034482|NCT01733342|DEVICE|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
224034483|NCT01733342|PROCEDURE|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
223418628|NCT05872269|DRUG|Saroglitazar|4 Mg Oral Tablet
223418629|NCT04152837|DRUG|Lixivaptan|Oral vasopressin V2 receptor antagonist
223418630|NCT01416493|DRUG|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
224034484|NCT01733342|DEVICE|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
224034485|NCT03873766|DRUG|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
224034486|NCT03873766|PROCEDURE|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
224137183|NCT01525927|DRUG|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
224137184|NCT01525927|RADIATION|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
224137185|NCT01525927|RADIATION|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
224137186|NCT02768194|DEVICE|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
224137187|NCT02768194|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
224137188|NCT02768194|OTHER|Mineral water|Commercially available mineral water
224137189|NCT03684291|PROCEDURE|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
224137190|NCT05787912|DEVICE|Photobiomodulation|The surgical sites were irradiated with a diode laser (980 nm, 0.2W) only.
224137191|NCT05787912|OTHER|Hyaluronic acid after photobiomodulation|The surgical sites after gingivectomy were irradiated with a diode laser (980 nm, 0.2W) then covered by 2% Hyaluronic acid gel loaded in a special appliance for each patient.
224034487|NCT03873766|PROCEDURE|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
224034488|NCT03873766|PROCEDURE|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (\>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
224137192|NCT01321502|DRUG|famciclovir|500 mg tablet
223418631|NCT02214329|DEVICE|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
223418632|NCT02214329|OTHER|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
223418633|NCT00684320|BEHAVIORAL|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
223561802|NCT06669507|BEHAVIORAL|Chronotherapy|"1. The effect of light exposure follows a phase-response curve where circadian phase advancement is strongest in the biological morning, whereas light in the biological evening/night may lead to a phase delay. Light therapy is provided by 30 min light exposure using 10 000 lux light boxes.~2. Melatonin 3 milligram is prescribed in tablet forms (not depot), usually 12 hours before the planned rise time.~3. Additionally, blue-light-blocking glasses are used to block light exposure at night, which has been found to advance circadian rhythms. Patients are advised to wear their blue-blocking glasses 12 hours before rise time.~Which chronotherapeutic interventions that are used, is considered individually by the clinicians in the Sleep Clinic, but often all three treatment components are used at the same time. Duration of chronotherapy given in the Sleep Clinic vary from 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment."
223561803|NCT06669507|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|All participants will receive treatment as usual. CBT-I has several components and consists of the following interventions including psychoeducation about sleep: sleep hygiene, sleep restriction therapy, stimulus control, and challenging beliefs and perceptions of sleep. Special emphasis is placed on providing a rationale for behavior change as a primary means of improving sleep as well as addressing dysfunctional beliefs the patients may hold about sleep. During treatment, tapering sleep medication is not necessary. However, if the patients are motivated to do so, this is discussed and a plan for tapering is provided. Treatment duration is typically between 4 to 8 consultations over 1 to 4 months depending on the patients' needs and progress during treatment.
223561804|NCT06669442|BEHAVIORAL|Guided Imagery|Guided imagery is a mindfulness based therapeutic technique that involves utilizing positive imagery allowing one to cultivate awareness of their mental state and shift their attention from ruminative thought patterns to the present moment. Evidence-based research shows that benefits of Guided imagery include relaxation, stress reduction, anxiety reduction, immune system enhancement, and overall well-being.
223561805|NCT06604858|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered every three weeks intravenously on day 1 of each cycle.
223561806|NCT06604858|DRUG|Carboplatin|Carboplatin: area under the curve (AUC) 1.5, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
223739337|NCT07205185|DRUG|QL1706 + Eribulin + Anlotinib + Radiotherapy|"QL1706: 5 mg/kg, intravenous injection (IV) on Day 1, every 3 weeks (Q3W). Eribulin : 1.1 mg/m², intravenous infusion (IV) on Days 1 and 8, Q3W. Anlotinib : Oral administration before breakfast, 12 mg once daily (QD) on Days 1-14, followed by a 1-week drug holiday, Q3W.~Radiotherapy : Hypofractionated radiotherapy, 15-60 Gy delivered in 5-8 fractions.~Eribulin is administered for 6 cycles. Epalizumab and anlotinib are continued until disease progression, intolerable toxicity, initiation of new anti-tumor treatment, loss to follow-up, death, or withdrawal from the study (whichever occurs first)."
223418634|NCT00684320|BEHAVIORAL|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
223418635|NCT00226460|DRUG|Fetal porcine cells, Neurocell-PD|
223418636|NCT02607774|DRUG|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
223739338|NCT07206849|DRUG|Tovorafenib|Tovorafenib will be given orally once weekly (QW) throughout each cycle.
224137193|NCT05611359|PROCEDURE|Thermal Ablation|Thermal hepatic ablation Combined with Chemotherapy
224137194|NCT05611359|DRUG|Chemotherapy|Chemotherapy
224137195|NCT01782456|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
224137196|NCT05637723|OTHER|schroth exercise|The schroth exercise program will be given 3 days a week for 6 weeks.
223418637|NCT02607774|DRUG|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
223418638|NCT03813082|BEHAVIORAL|Prolonged wakefulness|40 hours of prolonged wakefulness
223418639|NCT03674320|DRUG|Testosterone Enanthate|Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
223418640|NCT03674320|DRUG|Placebo|Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
224034489|NCT03873766|RADIATION|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
223418641|NCT00101166|BIOLOGICAL|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
223418642|NCT03260829|DRUG|vitamin C|25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
223418643|NCT04671498|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223418644|NCT04671498|PROCEDURE|Droplet-BC Test|Undergo Droplet-BC Test
223418645|NCT04671498|OTHER|Electronic Health Record Review|Medical records are reviewed
223418646|NCT00686829|DRUG|Vicriviroc maleate|VCV 30 mg tablet once daily by mouth.
223418647|NCT04161404|DRUG|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
223418648|NCT04161404|DRUG|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
223418649|NCT04161404|DRUG|Metformin (Glucophage) 1000mg|Metformin is an oral glucose-lowering drug of the biguanides class. Drug: Period 1 Subjects
223418650|NCT03314532|PROCEDURE|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
223418651|NCT03955913|OTHER|Archival Tumor Tissue Sample|Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
223418652|NCT04679311|BIOLOGICAL|High ACE Activity Fresh Frozen Plasma|Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L
223418653|NCT04679311|OTHER|Normal Saline|Subjects will be treated with normal saline 500 cc
223418654|NCT00322270|DRUG|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
223418655|NCT05807698|BEHAVIORAL|laughter therapy|Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
223418656|NCT02985645|PROCEDURE|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
223418657|NCT02985645|DEVICE|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
223418658|NCT01217476|DRUG|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
223418659|NCT02953847|DRUG|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
223418660|NCT02953847|DRUG|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
223739339|NCT07207174|BEHAVIORAL|Brief Mindfulness Oriented Recovery Enhancement|B-MORE is a 2-hour adaptation of the traditional MORE program.
224034490|NCT03873766|OTHER|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
224137197|NCT05637723|OTHER|traditional scoliosis exercises|The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
224137198|NCT01989234|DRUG|YKP10811|
223561807|NCT06604858|DRUG|Paclitaxel|Paclitaxel: 80 mg/m2, intravenously on day 1, day 8 and day 15 of each 21-days cycle.
223561808|NCT06613711|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
223739340|NCT07207174|BEHAVIORAL|Brief Cognitive-Behavioral Therapy|B-CBT is a 2-hour adaptation of a traditional 8-week CBT for Chronic Pain manual.
224137199|NCT01989234|DRUG|Placebo|
223561809|NCT00211757|DRUG|Divalproex sodium|Study drug.
223561810|NCT00211757|DRUG|Placebo|Placebo comparator.
223561811|NCT06625385|DEVICE|3M™ V.A.C.® Peel and Place Dressing|Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
223739341|NCT07205757|DRUG|Lidocaine Hydrochloride|6.5 ml of 2% lidocaine (Lidocaine HCL -Sunny Pharmaceutical)
223418661|NCT02953847|DRUG|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
223418662|NCT03764397|BEHAVIORAL|Prehabilitation for behavioural change|The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
223561812|NCT06657794|DEVICE|Implantation of Physician-Modified Terumo Aortic TREO abdominal stent graft system|A Physician Modified Endograft is a commercially available, off-the-shelf endograft that has been altered at the time of the procedure by creating fenestrations in the seal zone of the graft to preserve blood flow into vital branch vessels. These fenestrations are marked with medical grade gold markers to facilitate fluoroscopic visualization during the procedure. In order to prevent branch vessel occlusion, these branch vessels are typically stented with covered balloon expandable stents using standardized techniques.
223561813|NCT07024953|OTHER|Chronic Kidney Disease Structured Agenda-Setting Tool|Chronic Kidney Disease (CKD) Topics is a novel clinical visit agenda-setting intervention developed through participatory research methods for people with CKD living in rural areas. CKD Topics includes structured discussion topic areas.
223561814|NCT07023471|DEVICE|Group A (Trainee --> expert)|The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy (white-light mode) without AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy (white-light mode) without AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.
223561815|NCT07023471|DEVICE|Group B (Trainee +AI --> expert)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy with AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy (white-light mode) without AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
223739342|NCT07205757|DRUG|Custodiol Solution|cardioplegia solution will be administered as a single dose of 20 mL/kg over 6-8 minutes at a temperature of 5-8 °C. An additional half dose of the same solution will be prepared and infused if the procedure exceeds 180 minutes after the initial dose is completed.
223739343|NCT07204951|DEVICE|Gurunanda - Water Flosser|"Mode of Usage: Follow the below listed steps for product usage post brushing of teeth.~1. Fill - Add water to the tank of the Flosser~2. Insert - Add the tip to the flosser~3. Select - Choose the level of pressure~4. Floss - Guide the stream between your teeth and along the gumline~5. Clean - After use, insert the tip in the water tank and sanitize Frequency: Use twice a day after brushing. Route of administration: Topical - Oral Storage Condition: Store in a cool, dry place, away from direct sunlight, and do not submerge in water."
223739344|NCT07204951|OTHER|No water Flossing|No water Flossing
223739345|NCT07206953|BEHAVIORAL|Peer Functional Relationship Enhancement Program|The Peer Functional Relationship Enhancement Program is a 9-week psychoeducational intervention for early adolescents. It consists of weekly group sessions that include cooperative activities, role-play, and creative exercises designed to strengthen peer relationships, improve attitudes toward bullying, enhance self-efficacy, and develop critical thinking skills. This program is structured and standardized to ensure consistent delivery across participants and is distinct from other behavioral or social skills programs targeting similar age groups.
223739346|NCT07207070|DRUG|JS105|Patients will receive oral JS105 on Days 1-28 of each 4-week cycle.
223739347|NCT07207070|DRUG|Dalpiciclib|Patients will receive oral Dalpiciclib for 3 weeks, followed by 1 week off in each 4-week cycle；
224034491|NCT03873766|RADIATION|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
224034492|NCT03873766|BEHAVIORAL|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
224034493|NCT05573087|OTHER|Aquatic Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
224034494|NCT05573087|OTHER|Land Based Exercise|10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
223418663|NCT01577953|DRUG|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
223418664|NCT01577953|DRUG|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
223418665|NCT06152874|OTHER|consumption of glucose solution 1|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
223418666|NCT06152874|OTHER|consumption of glucose solution 2|glucose solution prepared dissolving 55 g of monohydrate glucose powder in 250 mL of water
223418667|NCT06152874|OTHER|consumption of Bread A and oral processing|bread made with 95% durum wheat fine semolina (\< 400 micrometer) + 5% of gluten + 1.2% of yeast + 1% of salt + 59%of water) (portion corresponding to 50 g available carbohydrates) + 250 mL water
223418668|NCT06152874|OTHER|consumption of Bread B and oral processing|bread made with 80% durum wheat fine semolina (\< 400micrometer) + 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
223418669|NCT06152874|OTHER|consumption of Bread C and oral processing|bread made with 80% durum wheat coarse semolina (\> 500micrometer)+ 20% of gluten+ 1.2% of yeast + 1% of salt + 59%of water (portion corresponding to 50g available carbohydrates) +250 mL water
223561816|NCT07023471|DEVICE|Group C (Trainee --> expert + AI)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy (white-light mode) without AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy with AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
223739348|NCT07207070|DRUG|Fulvestrant 50 Mg/mL Intramuscular Solution|Patients will receive intramuscular Fulvestrant on day 1 and day 15 of the first cycle and then on day 1 of each subsequent 4-week cycle.
223739349|NCT07206602|DEVICE|AI-assisted Left Bundle Branch Area Pacing|Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure using AI assisted technology
223739350|NCT07206602|PROCEDURE|Left Bundle Branch Area Pacing|Patients will undergo a Left Bundle Branch Area Pacing (LBBAP) procedure
223739351|NCT07205926|BIOLOGICAL|IVT Shigella-04|Preventative vaccine for Shigella protection against 4 unique serotypes
223418670|NCT03033602|BEHAVIORAL|written exposure therapy|five sessions of writing about traumatic experience.
223418671|NCT03033602|BEHAVIORAL|CPT, cognitive only|12 sessions of cognitive therapy related to traumatic experience.
223418672|NCT00680485|DRUG|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
223418673|NCT03738813|DEVICE|Gloreha Aria|Device offers specific programs that help patients to move arm, wrist and fingers
223418674|NCT03738813|OTHER|Usual care|Conventional occupational therapy
223739352|NCT07205926|BIOLOGICAL|Placebo (0.9% saline)|Subjects dosed with 0.9% saline
223739353|NCT07206940|DEVICE|Drainage with Headset Hypno VR|Pleural effusion and pneumothorax will be drained with the patient wearing the virtual reality headset.
223739354|NCT07205094|OTHER|Telerehabilitation exercise program|8-week telerehabilitation program including range of motion, stretching, strengthening, and stabilization exercise
223418675|NCT03131973|DRUG|BMS-986195|Specified dose on specified days
223418676|NCT03131973|DRUG|Methotrexate|Specified dose on specified days
223739355|NCT07205094|OTHER|Conventional physiotherapy program|8-week conventional face-to-face physiotherapy program including range of motion, stretching, strengthening, and stabilization exercises
223739356|NCT07205237|DIETARY_SUPPLEMENT|Diet without Red and Processed Meat|Participants replaced red and processed meat in their daily diet with fish, eggs, or white meat, while keeping the food proportions of their meals unchanged.
223739357|NCT07206147|OTHER|FaStEx - Structured strength training|Strength training in group session, 2 times a week for 8 weeks. 150 minutes of physical activity per week that is carried out independently.
223739358|NCT07206147|OTHER|Control group|150 minutes of physical activity per week that is carried out independently.
223739359|NCT07205081|DRUG|ATTO-3712|ATTO-3712
223739360|NCT07205081|DRUG|Placebo|Placebo preparation to match ATTO-3712 dose
223418677|NCT03131973|DRUG|Leucovorin|Specified dose on specified days
223418678|NCT03131973|DRUG|Caffeine|Specified dose on specified days
223418679|NCT03131973|DRUG|Montelukast|Specified dose on specified days
223418680|NCT03131973|DRUG|Flurbiprofen|Specified dose on specified days
223418681|NCT03131973|DRUG|Omeprazole|Specified dose on specified days
223418682|NCT03131973|DRUG|Midazolam|Specified dose on specified days
223418683|NCT03131973|DRUG|Digoxin|Specified dose on specified days
223418684|NCT03131973|DRUG|Pravastatin|Specified dose on specified days
223418685|NCT04445714|DRUG|dapagliflozin and saxagliptin|Combination of dapagliflozin and saxagliptin tablet once daily fixed dose combination of Dapa/Saxa 10 mg/5 mg administered orally
223418686|NCT00536159|OTHER|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
224034495|NCT02558933|DIETARY_SUPPLEMENT|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
224034496|NCT03513510|BEHAVIORAL|iChoose|
224034497|NCT00647322|OTHER|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
224034498|NCT00647322|PROCEDURE|No drug change|No change in anti-epileptic treatment
224034499|NCT02477579|DEVICE|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
224034500|NCT00146328|DRUG|Tipranavir|
224034501|NCT05781919|OTHER|Immersive virtual reality imaging|Segmentation and post-processing of DICOM 2D imaging will generate a 3D file able to be used in immersive virtual reality googles, for further analysis of the tumor and anatomic structures that could facilitate surgical planning.
224034502|NCT05781919|OTHER|Gold standard imaging|Use of traditional gold standard 2D imaging (TC and/or MRI) for surgical planning
223418687|NCT00536159|OTHER|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
223418688|NCT05891223|OTHER|Session 1: How We Evolved - Threat, Impulse, and Soothing Systems|"The practice of Breath break with kindness will be applied for 5 minutes. Afterwards, 15 minutes of information on threats, impulses and soothing systems, A safe place application for 11 minutes, Courtesy meditation for 10 minutes. After each application, 10 minutes of feedback will be received from the participants."
223418689|NCT05891223|OTHER|Session 2: Threat and Self-Compassion|"The practice of breathing with kindness will be done for 7 minutes. The practice of Building a compassionate relationship with resilience will be held for 12 minutes, and the practice of Kindness meditation: a benevolent will take place for 11 minutes. A hand over your heart application will be made for 3 minutes and A compassionate comrade application will be done for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223561817|NCT07023471|DEVICE|Group D (Trainee + AI --> expert + AI)|"The expert endoscopist insert to cecum in both passes. First pass: Trainee withdraw colonoscopy with AI. The polyps detected can be removed as suitable. The pathology for polyp will be sent. Second pass: Expert withdraw colonoscopy with AI. The polyps detected (which is missed from the first pass) can be removed as suitable. The pathology for polyp will be sent.~Artificial intelligent (AI) assisted colonoscopy; ENdoscopy as AI-powered Device (ENAD) ENAD system (ENdoscopy as AI-powered Device, AINEX Corporation, Seoul, South Korea) is the system using CADe system (Computer-aided detection) which developed from 66,397 images and 8,756 polyps via deep learning-based object detection algorithm (YOLOv4) . It was validated by 15,753 images of polyp from 80 colonoscopy videos and 90,144 images of non-polyps from 50 colonoscopy videos. This system decreases false positive rate from 3.2% to 0.6% and increases sensitivity from 86.4% to 87.1%."
224034503|NCT00300781|DRUG|neratinib|
224034504|NCT05813717|DRUG|BMS-986325|Specified dose on specified days
224034505|NCT05813717|DRUG|Placebo|Specified dose on specified days
224034506|NCT02715167|DRUG|Budesonide novolizer|
224034507|NCT02715167|DRUG|Placebo|
224034508|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of tributyrin (intervention)|Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days
224034509|NCT06147635|DIETARY_SUPPLEMENT|Micro-encapsulated granules of sunflower oil (placebo)|Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
224034510|NCT05202717|DEVICE|PHENIX U4+|The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.
224034511|NCT05202717|DEVICE|Traditional pelvic floor treatment instrument|Traditional pelvic floor treatment instrument commonly used in clinical practice
224034512|NCT02410941|BEHAVIORAL|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
224034513|NCT02702622|OTHER|Provitamin A-biofortified transgenic bananas|
224034514|NCT05039398|BEHAVIORAL|Treatment as usual|The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
224034515|NCT05039398|BEHAVIORAL|Dialogue and guidance over telephone|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone."
224034516|NCT05039398|BEHAVIORAL|Dialogue and guidance at physical meeting|"In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting."
224034517|NCT00732628|DEVICE|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
224034518|NCT04100395|DEVICE|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
223418690|NCT05891223|OTHER|Session 3: Unraveling the Knots of Desire and Patterns|"The practice of breathing with kindness will be done for 7 minutes. Building a compassionate relationship with desire 12 minutes, Guided meditation to discover the inner pattern 10 minutes and Courtesy meditation: a good friend 11 minutes. Except for the breath break with kindness application, 3 minutes of feedback will be received from the participants after each application."
223418691|NCT05891223|OTHER|Session 4: Internalizing compassion|"The pretend-to-be practice for the participants to observe themselves will be made for 10 minutes. The practice of internalizing compassion will be done for 7 minutes, kindness meditation: a neutral person practice for 10 minutes, and kindness towards your body for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223418692|NCT05891223|OTHER|Session 5: Me and others - Expanding the circle|"The a compassionate letter practice with the participants will continue for 15 minutes. Courtesy meditation: the 'difficult' person 8 minutes, compassion and breathing: yourself 10 minutes and compassionate breathing: others 7 minutes. A compassionate break application is performed for 7 minutes."
223418693|NCT05891223|OTHER|Session 6: Growing happiness|"The practice of Revisiting the good is carried out for 10 minutes with the participants. Forgive yourself, wish for forgiveness, forgive others, gratitude practices will be held for 5 minutes each and will take 20 minutes in total. Courtesy meditation: groups and all beings will be practiced for 10 minutes. After each application, 3 minutes of feedback will be received from the participants."
223418694|NCT05891223|OTHER|Session 7: Weaving Wisdom and Compassion into Daily Life|"Participants will be given 10 minutes to choose a day in their life and allow a few minutes to pause mindfully. The practice of a breather for wise and compassionate action is 10 minutes, the practice of calmness meditation is 8 minutes, and the practice of sharing the joy meditation is 8 minutes. After each application, 3 minutes of feedback will be received from the participants."
223418695|NCT05891223|OTHER|Session 8: Living with the Heart|"The participants are told about the applications they can apply for, where they need help to develop compassion towards self-healing skills, and the entire training will be evaluated for 20 minutes. The river of life application is carried out for 20 minutes. 10 minutes of feedback will be received after the application."
223561818|NCT07027059|BEHAVIORAL|median nerve mobilization|An exercise to increase median nerve mobility by flexing and extending fingers, wrist, elbow, shoulder, and neck
223561819|NCT07027059|BEHAVIORAL|routine exercises for lateral epicondylisits|eccentric strengthening exercises
224034519|NCT01351012|OTHER|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
224034520|NCT01351012|OTHER|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
223418696|NCT04588870|DEVICE|Pre operative computer based cochlear implant surgical simulation|Prior to surgery, the surgeon will perform virtual cochlear implant surgery on patient specific imaging data within a computer simulation program. The surgeon will be able to iterate the procedure on the simulator until achieving the best electrode array location is achieved with respect to scalar location and modiolar distance. A written and graphical surgical plan will then be developed that the surgeon can use in the actual surgery.
223418697|NCT01672710|DRUG|plain crystalline niacin, exercise, sauna|A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
223561820|NCT04691622|BIOLOGICAL|Norovirus -specific T-cell (NST) therapy|"Arm A: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion.~Arm B: Investigators will test three doses: 1 x 107 /m2, 2 x 107 /m2, and 4 x 107 /m2. After infusion, participants will have a 45-day safety monitoring period for immediate toxicities following infusion."
223561821|NCT05534594|DRUG|18F-PSMA-1007|As explained under 'Arms'.
224034521|NCT01351012|OTHER|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
224034522|NCT01351012|OTHER|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
224034523|NCT01351012|OTHER|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
223418698|NCT05122247|OTHER|Machine learning algorithm|machine learning directed identification of chemotherapy patients at high-risk for emergency department acute care and/or hospitalization
223418699|NCT04404517|DRUG|Adalimumab|Monoclonal antibody used in IBD treatment
223561822|NCT07032792|DRUG|FEIBA|Subjects randomized to FEIBA will receive up to 2 vials of 500U of FEIBA through a preexisting central line at a rate that does not exceed 2 units per kg of body weight per minute for the study intervention.
223561823|NCT07032792|DRUG|FFP|Subjects randomized to FFP will receive up to 2 units of FFP intravenously through a preexisting central line.
223561824|NCT07034599|DEVICE|Negative pressure ventilation|All participants are ventilated with negative pressure ventilation first
223561825|NCT07034599|DEVICE|positive pressure ventilation|All participants are ventilated using positive pressure ventilation after negative pressure ventilation
223561826|NCT07033377|OTHER|Self-administered paper-based questionnaires|Participants will complete the Persian version of the CBQ-NSCLBP and other self-report measures as part of a psychometric validation study. No clinical or therapeutic intervention is involved.
223561827|NCT07034521|DEVICE|HIWIN MRG-P110|HIWIN MRG-P110 is a robotics for lower limbs rehabilitation
224034524|NCT02072434|DRUG|Edoxaban|Edoxaban 30 mg tablets for oral administration
224034525|NCT02072434|DRUG|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
224034526|NCT02072434|DRUG|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
224034527|NCT02964637|OTHER|Observational Study|
224034528|NCT00120913|DRUG|Birth control pills|
224034529|NCT00253487|DRUG|O6-benzylguanine|
223418700|NCT05786469|DRUG|Veltassa Oral Powder Product|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
223418701|NCT05786469|OTHER|Placebo|"The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient"
223418702|NCT04959240|DRUG|Velmanase Alfa|
223418703|NCT04999163|DEVICE|Aortix System|Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
223418704|NCT05457036|DEVICE|Spry Belt|The Spry Belt is a device worn around the hips which delivers gentle energy to the lower back. The level of energy is controlled by an internal microprocessor (computer) so that it is safe and comfortable. The energy is at a level that may or may not be perceptible to the user. The device is powered by an internal lithium-ion battery which must be recharged periodically. The device is designed to be used with its companion Spry app (via Bluetooth Low Energy (BLE)) so that anonymous usage statistics may be monitored. The expected shelf life of the device is longer than 2 years and the expected use life is at least 12-18 months.
223418705|NCT05457036|DEVICE|Sham Spry Belt|The Sham Spry Belt is a device worn around the hips which does not deliver gentle energy to the lower back. The device instead provides a clicking noise similar to a motor. The device is powered by an internal lithium-ion battery which must be recharged periodically. The device is designed to be used with its companion Spry app (via BLE) so that anonymous usage statistics may be monitored. The expected shelf life of the device is longer than 2 years and the expected use life is at least 12-18 months.
223418706|NCT06683651|DRUG|STN1013800 ophthalmic solution|Investigational Product: 0.1% STN1013800 ophthalmic solution
223418707|NCT06683651|DRUG|STN1013800 ophthalmic solution Liquid Base, without STN1013800|Placebo control: STN1013800 ophthalmic solution Liquid Base, without STN1013800
223418708|NCT06428721|DEVICE|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
223418709|NCT06959329|OTHER|Active and passive physical therapy without intensified sensory stimulation|"Intervention: Passive and active therapy without high sensory stimulation Duration: 4 weeks Frequency: 3 sessions per week Session duration: 60 minutes~Intervention structure:~Passive therapy (30 minutes):~• Stroking and rubbing techniques from classic massage applied in the area of arm forearm and hand with low force and frequency upper limb massage - 15 minutes per limb~Active therapy (30 minutes): upper limb muscle strengthening exercises (without globalized vibration); difficulty level individually adjusted to meet participants' current potential, so that in the last sets/reps little manual assistance from the therapist is needed:~* Supine pull-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing pull-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing push-ups - 3 sets of 8 reps, \~45 seconds rest between sets~* Standing elbow extensions - 3 sets of 8 reps, \~45 seconds rest between sets"
223418710|NCT06959329|OTHER|Active and passive physical therapy with intensified sensory stimulation|"Intervention: Passive and active therapy incorporating high sensory stimulation Duration: 4 weeks Frequency: 3 sessions per week Session duration: 60 minutes~Intervention structure:~Passive therapy (30 minutes): stimulation of joint receptors, muscle spindles, and tactile pathways:~* High-frequency soft tissue mobilisations~* Localised high-amplitude vibration (30-50 Hz; Galileo Mano 30, Novotec Medical GmbH)~* Deep pressure techniques - Wilbarger brushing protocol followed by joint compressions Active therapy (30 minutes): upper limb and shoulder girdle muscle strengthening exercises with globalized vibration using Redcord Stimula (30-50 Hz; Redcord AS, Norway); difficulty level individually adjusted to meet participants' current potential. Excercises the same as in the control group."
223561828|NCT07034443|DEVICE|High Intensity Focused Electromagnetic Stimulation|Patients will sit on the device, the high intensity for 28 minutes, twice a week for three weeks
223561829|NCT06729502|OTHER|Questionnaire - Pictorial Fit-Frail Scale|All patients over 60 years old, or their caregivers, will be asked to fill the PFFS questionnaire
223561830|NCT00050830|DRUG|CI 1033|
224034530|NCT00253487|DRUG|busulfan|
224034531|NCT00253487|DRUG|temozolomide|
224034532|NCT00253487|PROCEDURE|adjuvant therapy|
224034533|NCT00253487|PROCEDURE|autologous bone marrow transplantation|
224034534|NCT00253487|PROCEDURE|conventional surgery|
224034535|NCT00253487|PROCEDURE|peripheral blood stem cell transplantation|
224034536|NCT00253487|RADIATION|radiation therapy|
224034537|NCT03711890|PROCEDURE|Optical Coherence Tomography|Undergo OCT
224034538|NCT03711890|PROCEDURE|Therapeutic Conventional Surgery|Undergo resection will be undertaken
224034539|NCT03711890|DIAGNOSTIC_TEST|Laboratory Evaluation|Labs will be obtained to test for cancer cell derived exosomes
223418711|NCT06958120|PROCEDURE|superficial parasternal intercostal Plane block|A high-frequency linear transducer was used to guide the insertion of a needle 2 cm lateral to the sternum. After identifying key anatomical structures, the needle was advanced in-plane into the pectointercostal fascial plane between the pectoralis major and internal intercostal muscle. Correct placement was confirmed with a saline injection, and then a local anesthetic (0.4 ml/kg of a 1:1 mix of bupivacaine 0.25% and lidocaine 1%) was injected bilaterally at the second and fourth ribs.
223418712|NCT06958120|PROCEDURE|Erecto spinea plane block|Using ultrasound, a needle is inserted near the T5 vertebra into the plane beneath the erector spinae muscle. After confirming correct positioning with saline, a local anesthetic mixture is injected in the fascial plane.
223418713|NCT03016130|OTHER|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
223418714|NCT04437225|DIETARY_SUPPLEMENT|Low oxalate controlled Diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
223418715|NCT04437225|OTHER|Primed, continuous intravenous infusion of 13C2-Glycolate|Participants will receive a continuous intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, over the course of several hours until steady-state is achieved, using an IV catheter.
223418716|NCT04437225|OTHER|Bolus intravenous infusion of 13C2-Glycolate|Participants will receive a bolus intravenous administration of carbon-13 glycolate, a naturally occurring form of glycolate, using an IV catheter.
223418717|NCT04437225|OTHER|Oral bolus administration of 13C2-Glycolate|Participants will orally ingest a single dose of carbon-13 glycolate, a naturally occurring form of glycolate.
223561831|NCT07075510|DRUG|Daratumumab Injection|Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen
223561832|NCT07074015|DEVICE|Use of IntelliWell to identify and localize sperm for ICSI|The experimental arm will have surgically extracted testicular sperm processed with IntelliWell. If identified and confirmed by embryology, cryopreservation of sperm will occur. On day of ICSI, thaw of testicular sperm will occur and be processed by IntelliWell for identification and localization for use in ICSI.
223418718|NCT06005285|BEHAVIORAL|Early Start Denver Model (ESDM)|The Early Start Denver Model focuses on teaching inside children's play and care activities, carried out within a joint activity structure. Adults follow children's leads into activities, embed teaching objectives inside the play, use the play as the reward, and build targeted skills following developmental science and ABA principles.
223418719|NCT06005285|BEHAVIORAL|Early Intensive Behavioral Intervention (EIBI)|Treatment as usual provided by community-based autism agencies
223418720|NCT04342767|DEVICE|EZ Debride®|EZ Debride ® is intended for the mechanical debridement of topical wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post Mohs' surgery, post-laser surgery, podiatric, wound dehiscence) trauma wounds (abrasions, lacerations, second-degree burns and skin tears), draining wounds and tunnelled /undermined wounds.
223418721|NCT01399047|DRUG|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
223418722|NCT01399047|DRUG|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
223418723|NCT06431555|DEVICE|MRI|Non-contrast, free-breathing MRI scan
223418724|NCT00836888|BIOLOGICAL|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
223418725|NCT00001810|DRUG|Voriconazole|
223418726|NCT02046005|BEHAVIORAL|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
223561833|NCT06902701|PROCEDURE|Endoscopic Submucosal Dissection (ESD)|Endoscopic excision of the rectal lesion by submucosal injection and circumferential mucosal incision using an electrosurgical knife with en-bloc resection intent
223739361|NCT07207278|DRUG|Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line|Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line therapy. Clinical response will be assessed via RECIST v1.1 criteria using serial CT imaging (baseline, 8 weeks, and every 12 weeks thereafter). Correlative analyses will evaluate TKI efficacy in relation to TIME subtype, ALK fusion variant, and multi-omic signatures.
224034540|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CBF|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CBF : The CBF will be performed using a standard biopsy forceps (Gluton Life ® Life Partners). Multiple biopsies bites were taken until complete resection (as many as needed).
224034541|NCT04727918|PROCEDURE|Polypectomy of diminutive colorectal polyps will be performed by CSP|All polypectomy procedures will be standardized amongst the study centers. Endoscopists with a minimal experience of at least 50 CBF and CSP performed the polypectomies CSP : The CSB procedure will be performed using a 9 mm cold snare (Exacto ® Life Partners). One to two mm of normal surrounding mucosa will be ensnared around the base of the polyp, followed by mechanical excision without electrocautery
224137200|NCT01611129|BEHAVIORAL|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI \& CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
223418727|NCT02046005|BEHAVIORAL|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
223418728|NCT02046005|BEHAVIORAL|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
223418729|NCT05895890|GENETIC|Sequential sampling (stool, saliva, serum) .|Sequential sampling (stool, saliva, serum) prior to the occurrence of AAH episodes in heavy drinking patients to identify protective or deleterious profiles.
223418730|NCT00355225|PROCEDURE|ITN distribution channel|
223418731|NCT04803422|DRUG|Antibiotic|The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
223418732|NCT03864731|DEVICE|Bone conduction device (ADHEAR)|adhesive bone conduction device
223418733|NCT06520982|DRUG|Norepinephrine|Infused intra-arterially in a dose-response fashion
223418734|NCT06520982|DRUG|Isoproterenol|Infused intra-arterially in a dose-response fashion
223418735|NCT06520982|DRUG|Acetylcholine|Infused intra-arterially in a dose-response fashion
223418736|NCT06520982|DRUG|Nitroprusside|Infused intra-arterially in a dose-response fashion
224034542|NCT06046911|OTHER|Tai Chi|In this study, Tai Chi has a total of 24 movements, which are connected step by step according to the principles of sports training.
224034543|NCT06046911|OTHER|Daily activity group|The daily activity group does not receive special intervention, and the subjects must maintain their daily habits and complete the 12-week test.
224034544|NCT01726452|DRUG|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
224034545|NCT01726452|DRUG|Cisplatin / Oxaliplatin|Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
223418737|NCT06520982|DRUG|Estrogen|Infused intra-arterially
223418738|NCT02041143|DIETARY_SUPPLEMENT|Milk protein|Study product will provide 25 g of protein to subjects.
223418739|NCT02041143|DIETARY_SUPPLEMENT|Placebo|Product with no protein
223418740|NCT06206551|OTHER|Spiritual Needs Questionnaire|This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
223418741|NCT03933579|DIAGNOSTIC_TEST|Deep phenotyping|Each participating hospitals will be collecting whole blood from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multi-omics analysis.
223418742|NCT05136339|BEHAVIORAL|Community-based mentoring and education sessions|Community-based mentoring and education sessions, group activities, and application of a community toolkit for healthy weight loss delivered by trained Health Promoters from Hispanic and Somali communities to their social networks.
223418743|NCT05550909|DRUG|Artesunate-amodiaquine combination|Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines
223418744|NCT05550909|DRUG|Primaquine Phosphate|The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
223418745|NCT05550909|DRUG|Artemether-lumefantrine|Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines
223418746|NCT05550909|DRUG|Amodiaquine|Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.
223418747|NCT04842617|DRUG|SHR6390|SHR6390 combined with endocrine therapy
223418748|NCT04842617|DRUG|placebo|placebo combined with endocrine therapy
224034546|NCT01726452|DRUG|5 Flourouracil/ Capecitabine|5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
224034547|NCT01726452|RADIATION|(41.4 Gy/23 fractions)|Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
224034548|NCT01726452|DRUG|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
224034549|NCT01726452|DRUG|Carboplatin|Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
224034550|NCT01726452|DRUG|Docetaxel|Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
223739362|NCT07207213|BEHAVIORAL|PEERS|The Program for the Education and Enrichment of Relational Skills (PEERS®) is world-renowned for providing evidence-based social skills treatment to adolescents with autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and other socio-emotional problems.
224034551|NCT01726452|DRUG|Oxaliplatin|85 mg/m², day 1 of each cycle (i.e. every 14 days)
224034552|NCT01726452|DRUG|Leucovorin|200 mg/m², day 1 of each cycle (i.e. every 14 days).
224034553|NCT01726452|DRUG|5-Fluorouracil|2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
224034554|NCT03904745|DRUG|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
224034555|NCT00962156|DRUG|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
223418749|NCT04611867|OTHER|Supportive application with integrated weekly PRO|Patients will fill in a web-based application PRO-CTCAE with integrated preparation questionnaire every week. If their weekly reported symptoms exceed a predefined threshold of severity, this results in a notification on the staff application interface and a nurse will contact a patient for verification of symptoms. Nurse will review patient recent treatment and PRO reports and advise patient according to the local practice for symptom management and reinforce reporting. Nurse will consult with or refers to (if possible) treating physician if patient will require medical intervention and/or physician assistance.
223418750|NCT04081090|BEHAVIORAL|Brain HQ Cognitive Modules|Online personalized cognitive therapy modules to address and improve neuroplasticity.
223418751|NCT06482723|DEVICE|mGlobal L+AS|The investigated dermal filler mGlobal L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
223418752|NCT06074809|DRUG|Modified Guizhi Fuling granules|Modified Guizhi Fuling granules will be orally administered to patients in the TCM treatment group twice a day throughout the treatment period, which lasts for 8 weeks.
223418753|NCT06074809|OTHER|Placebo|Placebo will be orally administered to patients in the placebo group twice a day throughout the treatment period, which lasts for 8 weeks.
223418754|NCT06085144|DRUG|Galcanezumab|Receiving either 120mg or 300mg injections.
223418755|NCT06350695|DEVICE|low grade compression stockings (10-15 mmHg)|Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
223418756|NCT06350695|DEVICE|high grade compression stockings (20-30 mmHg)|Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
223418757|NCT04234295|PROCEDURE|Fat Tissue Biopsy|If subjects are scheduled for a surgical procedure a fat sample will be collected during the beginning of the surgery. If subjects are not scheduled for a surgical procedure, a small sample of subcutaneous (superficial) fat tissue from subjects abdomen area will be collected.
223418758|NCT01167738|DRUG|capecitabine|1250 mg/mq days 1-28 every 4 weeks
223418759|NCT01167738|DRUG|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
223418760|NCT01167738|DRUG|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
223418761|NCT01167738|DRUG|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
223418762|NCT01167738|DRUG|metformin|2 g days 1-28 every 4 weeks
223418763|NCT02568020|DRUG|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
223418764|NCT03105635|OTHER|Mixed method feasibility study|"Participating practices will receive the following:~1. Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~2. Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~3. Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~4. Navigator: The services of a Navigator"
223418765|NCT05197647|OTHER|Patients with symptomatic COVID-19 disease not requiring hospitalization.|Patients with symptomatic COVID-19 disease not requiring hospitalization.
223739363|NCT07207213|BEHAVIORAL|Control|This group will also consist of children diagnosed with high-functioning ASD. However, these children will not receive PEERS therapy. Instead, they will continue their usual treatments in their local settings without participating in the PEERS therapy sessions. This group\&#39;s outcomes will be compared with the experimental group to assess the effectiveness of PEERS therapy.
223739364|NCT07206394|OTHER|ScarWork therapy|ScarWork is a manual therapy technique involving gentle, hands-on massage of scar tissue. It is designed to improve the mobility and integration of scar tissue, reduce discomfort, and support tissue healing. The approach is tailored to each individual, based on the characteristics of their scar and sensitivity of the surrounding tissue. It is commonly used with people recovering from surgery or radiotherapy to help address symptoms such as pain, tightness, numbness, or altered sensation. In this study, participants in the intervention group will receive up to five ScarWork sessions delivered by a trained therapist, in addition to standard care.
224034556|NCT00962156|DRUG|Ringers acetate|Infusion for volume expansion in the ICU
223418766|NCT03258840|DIETARY_SUPPLEMENT|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
223418767|NCT03258840|DIETARY_SUPPLEMENT|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
224034557|NCT03803501|OTHER|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
224034558|NCT01727583|DIETARY_SUPPLEMENT|meal intake|Intake of meals characterized by lipid composition
224034559|NCT01727583|DIETARY_SUPPLEMENT|Placebo|
224034560|NCT05833048|PROCEDURE|Rectus sheath block|Participants will receive an ultrasound guided rectus sheath block with local anesthetic
223418768|NCT01283334|DRUG|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
223418769|NCT01283334|DRUG|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
223418770|NCT01283334|DRUG|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
224034561|NCT05644795|DIETARY_SUPPLEMENT|Wheat/milk free diet (W/MFD) group|Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
224034562|NCT05644795|DIETARY_SUPPLEMENT|Rice/turkey free diet (R/TFD) group|Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.
224298583|NCT05325307|OTHER|Acupressure|The experimental group will start with HT7 points and continue LI4 and EX-NH3 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
223418771|NCT03467217|DRUG|Losartan potassium|Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
223418772|NCT03467217|DRUG|Placebo losartan capsule|Matching placebo losartan oral capsule
223418773|NCT04265638|BEHAVIORAL|Exercise|One on one exercise with a cancer exercise specialist 1 hour 3 times a week for 12 weeks.
223418774|NCT04530266|DIAGNOSTIC_TEST|Six minute walk test|Assessment of walking related performance fatigability using six minute walk test
223418775|NCT04833725|DEVICE|wearable devices|All patients use wearable devices and IoT technology for information collection and data management. Specifically, we build standards from the analysis of sleep monitoring information, and we form an OSA screening model by applying machine learning algorithms.
223418776|NCT01770366|DEVICE|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
223418777|NCT01770366|DEVICE|Usual Care|
223418778|NCT00006024|DRUG|lomustine|
223418779|NCT00006024|DRUG|temozolomide|
224034563|NCT00249353|DRUG|methylphenidate hydrochloride|
224034564|NCT04844528|DRUG|Nicotinamide|Oral nicotinamide 500 mg twice daily (BID).
224034565|NCT04844528|DRUG|Placebo|Oral placebo twice daily for the first year.
224034566|NCT06034522|DEVICE|Adipearl|Injection of the investigational device in the face.
224034567|NCT02634346|DRUG|ALK3831|Daily dosing
224034568|NCT02634346|DRUG|Olanzapine|Daily dosing
224034569|NCT02634346|DRUG|Placebo|Daily dosing
224034570|NCT05933408|DIAGNOSTIC_TEST|TREM-1|The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
224034571|NCT00465244|DRUG|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
224034572|NCT00465244|DRUG|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
224034573|NCT01570036|DRUG|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
224034574|NCT01570036|DRUG|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
223418780|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
223418781|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
223418782|NCT00550134|BEHAVIORAL|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
223418783|NCT03281187|DRUG|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
223418784|NCT03281187|DRUG|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
223418785|NCT03281187|OTHER|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
223418786|NCT03281187|OTHER|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
224034575|NCT01570036|DRUG|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
223418787|NCT02796859|DRUG|Siltuximab|Investigational agent
223418788|NCT02796859|DRUG|normal saline|Placebo
223418789|NCT00481052|DRUG|Nilotinib|
223418790|NCT04635826|DRUG|Adderall 10Mg Tablet|Participants will be administered Adderall
223739365|NCT07205783|PROCEDURE|open radical prostatectomy|open surgery to remove prostate gland and the tumor
224034576|NCT00969878|DRUG|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
224034577|NCT00969878|OTHER|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
223418791|NCT04635826|DRUG|Placebo|Participants will be administered placebo
224034578|NCT00802425|DRUG|AM-111|single intratympanic injection
223418792|NCT00964938|DEVICE|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
223418793|NCT00367731|DRUG|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
223418794|NCT04027725|BEHAVIORAL|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
224034579|NCT00802425|DRUG|placebo|single intratympanic injection
223418795|NCT06513143|OTHER|CT images into virtual 3D model demonstration|The investigators have finished is personalized 3D model translation from CT images into virtual 3D model demonstrated in VR glasses using Synapse.
223418796|NCT02787824|DRUG|Iron Sucrose Supplement|
223418797|NCT04480671|PROCEDURE|Level III support procedure|A level III support procedure is aimed at repairing the distal support of the vagina with either a posterior colporrhaphy and/or a perineorrhaphy.
223418798|NCT04480671|PROCEDURE|Minimally Invasive Sacrocolpopexy|All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.
223418799|NCT04480671|OTHER|Transperineal ultrasound of the Pelvic Floor|Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
223418800|NCT06683872|PROCEDURE|surgical myectomy|Our procedure was performed via a right infra-axillary incision (4-5 cm), enter the thoracic cavity through the third intercostal space lateral to the pectoralis major muscle. Generally, neither rib resection nor division of the pectoralis major muscle were required. The intervention utilized femoral-femoral cardiopulmonary bypass (CPB). The aorta was clamped using a Glauber clamp (CardioVision MICAortic Clamp, Cardiomedical GmbH). Myocardial protection was achieved with antegrade Del Nido cardioplegia. After inducing of cardiac asystole, a transverse incision was made in the aorta and the aorta incision was suspended to enhance visualization. A mesh retractor (FEHLING INSTRUMENTS, Karlstein, Germany) was placed in the aortic sinus to protect the aortic leaflets. The extent of the septal myectomy, determined based on preoperative TEE, started 5 mm below the midpoint of the right coronary cusp. It extended counterclockwise towards the anterior commissure of the mitral valve a
223418801|NCT02989246|OTHER|Ventilator protocol|Open loop ventilator management by a computer based protocol
223418802|NCT02989246|DEVICE|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
223418803|NCT04113655|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
223418804|NCT04113655|BIOLOGICAL|Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
223418805|NCT04113655|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202"
224137201|NCT06447324|DEVICE|Fender Mate matrix system|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
224137202|NCT06447324|DEVICE|T-band matrix|Matrix Systems used for Restoration of Class II Cavities in Primary Molars
224137203|NCT05391568|OTHER|Real Dry Needling|"Needle will be placed at trapezius muscle. Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
223561834|NCT06902701|PROCEDURE|Transanal Endoscopic Surgery (TES)|Transanal endoscopic surgery procedures include Transanal Minimally Invasive Surgery (TAMIS) and Transanal Endoscopic Operation (TEO). TAMIS will be performed using a single-port transanal access platform with standard laparoscopic instruments, including a high-definition camera, an insufflation system, and endoscopic graspers. The lesion will be circumferentially excised using electrocautery or an energy device, ensuring full-thickness resection when necessary. The defect will be managed based on its size, with primary closure using absorbable sutures or left to heal by secondary intention. TEO will be conducted using a rigid transanal endoscopic platform with a stereoscopic optical system to enhance visualization. The lesion will be marked, and a full-thickness or submucosal excision will be performed using endoscopic instruments and electrosurgical devices. Post-resection, the rectal wall defect will be assessed, and primary closure will be performed when indicated to minimize post
223418806|NCT02610543|DRUG|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
223418807|NCT02610543|DRUG|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
224034580|NCT03811353|DIAGNOSTIC_TEST|T-MOE|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
224034581|NCT04316208|PROCEDURE|PEEP variations|Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
223418808|NCT03429933|DRUG|BMS-986278|Specified dose on specified days
224034582|NCT04372407|DRUG|Surufatinib|Surufatinib: 200 mg as single dose on Days 1 and 9
224034583|NCT04372407|DRUG|Itraconazole|Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
223418809|NCT03429933|OTHER|Placebo|Specified dose on specified days
223418810|NCT00287196|RADIATION|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
223418811|NCT01477996|PROCEDURE|27-gauge|27-gauge needle for IVT
223418812|NCT01477996|PROCEDURE|30-gauge|30-gauge needle for IVT
223418813|NCT01713010|OTHER|Predictive indexes of weaning from mechanical ventilation|
223418814|NCT00613691|DRUG|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
223418815|NCT02990936|OTHER|Tumor delineation|Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
223418816|NCT02649244|BEHAVIORAL|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
223418817|NCT03233529|DRUG|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
223418818|NCT03233529|DRUG|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
223561835|NCT00322452|DRUG|Gefitinib|oral tablet
223561836|NCT00322452|DRUG|Carboplatin|IV
223561837|NCT00322452|DRUG|Paclitaxel|IV
224034584|NCT04242511|DIAGNOSTIC_TEST|Measurement of tuberculosis medications level|Measurement of tuberculosis medication levels at 2 hours post-dose
224034585|NCT03149471|DIAGNOSTIC_TEST|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
224034586|NCT01409863|PROCEDURE|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
224034587|NCT00568321|DRUG|RN624|50 mcg/kg
224034588|NCT00568321|DRUG|RN624|200 mcg/kg
224034589|NCT00568321|DRUG|Placebo|placebo
224034590|NCT03318705|DEVICE|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
224034591|NCT00506428|BEHAVIORAL|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
224034592|NCT01649570|DRUG|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
224034593|NCT02610153|DRUG|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
224034594|NCT00016029|OTHER|screening questionnaire administration|
224034595|NCT00016029|PROCEDURE|barium enema injection|
224034596|NCT00016029|PROCEDURE|computed tomography|
224034597|NCT00016029|PROCEDURE|computed tomography colonography|
224034598|NCT00016029|PROCEDURE|diagnostic colonoscopy|
224034599|NCT00016029|PROCEDURE|screening colonoscopy|
224034600|NCT05178550|DRUG|Heparin|intravenous \[iv\] injection
224034601|NCT00285883|DRUG|Invirase|
224034602|NCT00285883|DRUG|Norvir|
224137204|NCT05391568|OTHER|Sham Dry Needling|"Sham needle will be placed at trapezius muscle. Simulated Fast-in, Fast-out technique will be used at the active trigger point of upper trapezius muscle."
224137205|NCT00022035|BIOLOGICAL|trivalent influenza vaccine|
223418819|NCT04166344|BEHAVIORAL|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online \& offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
224034603|NCT02271074|OTHER|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
223418820|NCT05194761|DRUG|Normal saline|Using normal saline nebulization in neonates postextubation
223418821|NCT01177293|DRUG|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
223418822|NCT01177293|DRUG|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
223418823|NCT03858361|DEVICE|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
223418824|NCT06525805|OTHER|Long Abstract|"The intervention and control group will be provided with a structured abstract of the review by Soderberg et al., entitled Percutaneous nephrolithotomy vs. retrograde intrarenal surgery for renal stones. This review was published once in the Cochrane Database of Systematic Reviews and once in the journal BJU International. The length of the abstract differs significantly depending on the journal.~The participants assigned to this study arm will be presented with the longer version published in the Cochrane Database, comprising 771 words (PMID: 37955353)."
223418825|NCT06525805|OTHER|Short Abstract|The participants assigned to this study arm will be presented with the shorter version published in BJU International, comprising 277 words (PMID: 37942649).
223418826|NCT01003483|DRUG|orlistat|Tablet,120mg,three times a day,three months
223418827|NCT00052130|BIOLOGICAL|CancerVax vaccine (CANVAXIN)|
223418828|NCT00574470|DRUG|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
223418829|NCT00633815|OTHER|Supine positioning|Subjects underwent exercise testing on a stationary bicycle in the supine position
223561838|NCT03353363|DRUG|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
224034604|NCT02271074|BEHAVIORAL|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
224034605|NCT02271074|OTHER|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
223418830|NCT00633815|OTHER|Upright positioning|Subjects underwent exercise testing on a stationary bicycle in the upright position
223561839|NCT03353363|DRUG|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
224034606|NCT06960317|DRUG|Buffered Lidocaine|To determine if a 20 cc buffered (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) lidocaine paracervical block decreases pain with IUD placement
224034607|NCT06960317|OTHER|Sham Comparator|None - capped needle will not be injected nor will it contain any medication.
223418831|NCT03614468|OTHER|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
223418832|NCT03614468|OTHER|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
223418833|NCT00287872|DRUG|bortezomib|
223418834|NCT00287872|DRUG|thalidomide|
223418835|NCT05418582|DRUG|DZD9008 and intraconazole|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with itraconazole after the wash-out period.
223418836|NCT05418582|DRUG|DZD9008 and carbamazepine|All subjects will receive DZD9008 single dose on Day 1, and the second dose of DZD9008 along with carbamazepine after the wash-out period.
224034608|NCT06960317|DRUG|Unbuffered lidocaine|To determine if a 20 cc unbuffered (1% lidocaine) lidocaine paracervical block decreases pain with IUD placement
223418837|NCT01355016|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
223418838|NCT01883050|DEVICE|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
223418839|NCT03917316|OTHER|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
223418840|NCT02171338|OTHER|PCT-level|PCT-level is available to the treating doctor.
223418841|NCT02171338|BEHAVIORAL|Antibiotic treatment based on PCT-level|"PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above."
223418842|NCT00751049|DRUG|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
223418843|NCT00751049|DRUG|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
224034609|NCT06960317|DRUG|Xylocaine jelly 2%|To determine if a Xylocaine jelly (2% infused lidocaine) decreases pain with paracervical block
224137206|NCT06148896|BEHAVIORAL|GrExPACT|Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy
224137207|NCT06148896|BEHAVIORAL|GrEx|Group physiotherapy exercise
223418844|NCT00160706|BIOLOGICAL|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."
223418845|NCT03214380|DRUG|LY900014|Administered SC
223418846|NCT03214380|DRUG|Insulin Lispro|Administered SC
223418847|NCT03214380|DRUG|Insulin Glargine|Administered SC
223418848|NCT03214380|DRUG|Insulin Degludec|Administered SC
223418849|NCT03214380|DRUG|Metformin|Administered orally.
223418850|NCT03214380|DRUG|SGLT2 inhibitor|Administered orally.
223418851|NCT00981669|BIOLOGICAL|rotavirus vaccine|3 doses with 6 weeks interval
223418852|NCT00981669|BIOLOGICAL|placebo|3 doses with 6 weeks interval
223418853|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
223561840|NCT03353363|DRUG|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
224034610|NCT06960317|DRUG|Surgilube|To determine if a placebo gel is inferior to lidocaine gel for pain with paracervical block
223561841|NCT07079371|PROCEDURE|Micellar Water Application (No Rinse)|Participants apply micellar water to the forehead once daily and leave it on the skin without rinsing for 21 days.
224034611|NCT02573220|BIOLOGICAL|Cetuximab|Given IV
224034612|NCT02573220|DRUG|Fluorouracil|Given IV
224034613|NCT02573220|DRUG|Irinotecan Hydrochloride|Given IV
224034614|NCT02573220|DRUG|Leucovorin Calcium|Given IV
224034615|NCT05059834|BEHAVIORAL|online mindfulness resources|a free mindfulness resource online for patients with general anxiety disorder
224034616|NCT05059834|BEHAVIORAL|usual care|patient will continue to receive drug and advice from doctors and nurses for their anxiety disorder
224034617|NCT01803568|OTHER|Exercise|12 weeks of exercise; 4 times pr week
224034618|NCT02175004|DRUG|Inotersen|Inotersen SC
224034619|NCT03265041|DIAGNOSTIC_TEST|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
224034620|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
224034621|NCT03167957|DRUG|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
224034622|NCT00122694|DRUG|carbon monoxide|
224034623|NCT02960854|BIOLOGICAL|Nivolumab|Specified dose on specified days
224034624|NCT00221195|DRUG|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
224034625|NCT05937139|OTHER|Breastfeeding education|Breastfeeding education will be given to fathers.
224034626|NCT03138720|DRUG|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
224034627|NCT00701870|DRUG|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
224034628|NCT04291352|DIETARY_SUPPLEMENT|Taurine|675mg taurine four times daily
224034629|NCT04291352|OTHER|Placebo|placebo four times daily
224034630|NCT03686280|OTHER|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index , LBA, SSA and SSV, measurement of spasticity and sensitivity(D0, D30 and D90)
224034631|NCT03686280|OTHER|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
224034632|NCT03686280|OTHER|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
224034633|NCT03686280|OTHER|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above. (D0, D30 and D90)
223418854|NCT00800657|PROCEDURE|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
223418855|NCT03438604|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
223418856|NCT01491204|DRUG|Paclitaxel+HM30181|oral, 3times for 4weeks
223418857|NCT01694069|DRUG|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
223418858|NCT01623401|DRUG|TR-701 FA|TR-701 FA 200 mg once daily
223418859|NCT01702480|DRUG|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
223418860|NCT01702480|DRUG|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
223418861|NCT00648622|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
223418862|NCT00648622|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
223418863|NCT02053142|DRUG|Acyclovir|Single dose of acyclovir 200mg was given for pk study
223418864|NCT02053142|DRUG|Placebo|
223418865|NCT02230696|DRUG|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
223418866|NCT02230696|DRUG|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
223418867|NCT02230696|DRUG|Placebo nasal spray|Placebo nasal spray
223418868|NCT02837939|DRUG|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~* 3 x TF in first week: day 1,3,5~* 2 x TF in week 2: day 8 , 11~* 1 xTF in week 3 and 4 : day 15, 22~* 1 x TF once a month up to 6 month"
223418869|NCT02837939|DRUG|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~* 3 doses in first week: day 1,3,5~* 2 doses in week 2: day 8 , 11~* 1 dose in week 3 and 4 : day 15, 22~* 1 dose once a month up to 6 month"
223418870|NCT03005275|OTHER|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
223418871|NCT03005275|OTHER|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
224034634|NCT03686280|OTHER|An assessment of patient acceptance of robotic rehabilitation|An assessment of patient acceptance of robotic rehabilitation (for patients in the robot group): self-questionnaire to be filled in by the patient (before carrying out the gait tests in order to avoid influence the results) (D30 ans D90)
224034635|NCT03686280|OTHER|cognitive assessment|An evaluation of cognitive functions (between D0 and D30): research dysexual cognitive-behavioural syndrome, hemineglect visio-spatial, memory disorders. Done by a doctor evaluator.
224034636|NCT03686280|OTHER|An evaluation of how to use the robot|An evaluation of the robot's modalities of use (for patients in the robot group): time of use, distance travelled, walking speed, exercise duration, percentage of regulated suspension, number of breaks, average length of breaks, total length of breaks. (D30)
224034637|NCT04056936|PROCEDURE|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
224034638|NCT05363696|PROCEDURE|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting surgery procedure
224034639|NCT05363696|PROCEDURE|Heart valve surgery|Heart valve surgery procedure
224034640|NCT04367987|DIAGNOSTIC_TEST|Heart Rate Variability|Heart rate and RR interval Post-anonymized analysis of heart rate variability using the KUBIOS software
224034641|NCT03188926|PROCEDURE|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
223418872|NCT02339324|DRUG|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
223418873|NCT03425409|DEVICE|Integra Pulse Portable- Continuous flow|4 liters per minute oxygen flow
223418874|NCT03425409|DEVICE|Integra Pulse Portable- Pneumatic pulsed flow|Oxygen flow determined by test device
223418875|NCT02590575|DEVICE|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"1. With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~2. Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
223561842|NCT07079371|PROCEDURE|Micellar Water Application (With Rinse)|Participants apply micellar water to the forehead once daily and rinse it off after application for 21 days.
223561843|NCT04091581|DRUG|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
224034642|NCT01080378|PROCEDURE|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
223418876|NCT02807571|PROCEDURE|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
223418877|NCT02297178|PROCEDURE|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
223561844|NCT03296748|PROCEDURE|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
223561845|NCT03296748|PROCEDURE|anterior colporraphy|
224034643|NCT00823901|DRUG|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
224034644|NCT00823901|DRUG|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
224034645|NCT04828694|DRUG|BICX104|Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.
223418878|NCT02297178|PROCEDURE|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
224034646|NCT04828694|DRUG|Vivitrol|Intramuscular injection containing 380 mg of naltrexone.
224034647|NCT01308957|DIETARY_SUPPLEMENT|Omega-3 fatty acids|4 grams per day for 24 weeks
224034648|NCT01308957|DIETARY_SUPPLEMENT|corn oil|4 grams per day for 24 weeks
223418879|NCT05441111|BEHAVIORAL|Common Elements Toolbox|"COMET consists of the following modules: cognitive restructuring (labeled flexible thinking), behavioral activation (labeled positive activities), gratitude, and self-compassion. Participants complete these COMET modules by themselves. The format is reading psychoeducational along with completing specific activities"
223418880|NCT05441111|BEHAVIORAL|Doing What Matters in Times of Stress: An Illustrated Guide|"From the WHO's website: Doing What Matters in Times of Stress: An Illustrated Guide is a stress management guide for coping with adversity. The guide aims to equip people with practical skills to help cope with stress. A few minutes each day are enough to practice the self-help techniques. The guide can be used alone or with the accompanying audio exercises.~Informed by evidence and extensive field testing, the guide is for anyone who experiences stress, wherever they live and whatever their circumstances."
223418881|NCT05441111|BEHAVIORAL|Guided self-help|"Participants in the guided self-help condition are assigned an eCoach who provides emotional support as well as who promote adherence to the intervention"
223418882|NCT03305861|PROCEDURE|ThuLEP|Thulium laser enucleation of prostate
223418883|NCT03305861|PROCEDURE|Green LEP|Greenlight laser enucleation of prostate
223418884|NCT01905553|DRUG|SSP-004184SS|Disodium salt
223418885|NCT02240927|DRUG|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
223418886|NCT02240927|DRUG|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
223561846|NCT04473274|DRUG|Pioglitazone|Receive pioglitazone 15mg - 30mg daily
223561847|NCT05921695|DRUG|Normal Saline infusion and Ringer lactate infusion|The heat stroke patients will be infused with different chlorine concentrations fluid during the emergency department.
223561848|NCT03284333|DEVICE|other|no arm
223561849|NCT06385093|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
223561850|NCT06385093|DRUG|Alfacalcidol tablets|Oral Alfacalcidol 0.5μg daily
223561851|NCT06385093|DRUG|Calcium carbonate tablets|1.5g Calcium carbonate daily
224034649|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- real tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, 2 mA stimulation with 1x1 tDCS mini-CT device by Soterix Medical
224034650|NCT06416553|DEVICE|Home-based transcranial direct current stimulation- sham tDCS|Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, sham stimulation with tDCS mini-CT device by Soterix Medical
224034651|NCT06416553|BEHAVIORAL|Lee-Silverman voice treatment|Remote Lee Silverman Voice Treatment (LSVT) delivered via telepractice by speech therapist. LSVT is a high-effort speech therapy that is primarily focused on improving speech loudness during 16 individual one-hour sessions in one month.
224034652|NCT01369511|DRUG|LY2495655|Administered subcutaneously
224034653|NCT01369511|DRUG|Placebo|Administered subcutaneously
224034654|NCT01247571|DRUG|Pazopanib Hydrochloride|Given PO
224034655|NCT00226850|BEHAVIORAL|hypnosis|
224034656|NCT04208776|DRUG|Propranolol|maximum tolerated dose of propranolol with initial dosage of 20mg once a day and uptitrating every 2nd day by 20 mg.
224034657|NCT04208776|DRUG|Midodrine|It will be started at 2.5mg TDS and will be uptitrated every 2nd day to a max of 10mg TDS to attain a MAP of atleast 70mm Hg and then uptitate the beta blocker simulataneously to attain the target heart rate
224034658|NCT06397807|DRUG|Dinalbuphine sebacate|Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.
224034659|NCT06397807|DRUG|Analgesic injectables|Opioids, NSAIDs or acetamol will be administrated as need.
224034660|NCT06397807|DRUG|Enteral analgesics|Opioids, NSAIDs or acetaminophen will be prescribed if necessary.
224034661|NCT02718807|OTHER|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
224034662|NCT04782843|OTHER|HEP score assessement|Assessement of the HEP score between 2 physician.
224034663|NCT05057923|BIOLOGICAL|Bacillus subtilis|Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.
224034664|NCT04873219|DEVICE|manufacturing a complete dental prosthesis|dental treatment to replace missing teeth
224034665|NCT02809573|DRUG|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
224034666|NCT02809573|DRUG|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration
224034667|NCT02809573|DRUG|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.
224034668|NCT02809573|DRUG|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.
223418887|NCT02240927|DRUG|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
223418888|NCT02240927|DRUG|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
223418889|NCT05118776|DRUG|ASC40 tablets|ASC40 tablets administered orally once daily
223418890|NCT05118776|DRUG|Placebo tablets|Placebo administered orally once daily.
223418891|NCT05118776|DRUG|Bevacizumab|Bevacizumab once every 2 weeks, intravenous drip.
223418892|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
223418893|NCT06328400|DRUG|Deuremidevir Hydrobromide for Suspension Placebo|Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
223418894|NCT01233960|DRUG|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
223418895|NCT05632198|OTHER|Survey|Valid and reliable questionnaires covering perceived uncertainty, self-care behaviors and quality of life will be administered.
223418896|NCT00270153|DRUG|enalapril|5mg enalapril daily for 6 months
223418897|NCT00270153|DRUG|Placebo|5mg enalapril-matching placebo daily for 6 months
223418898|NCT05241405|DIETARY_SUPPLEMENT|QISENG|2 capsules/day for 8 weeks.
223561852|NCT04670458|OTHER|no intervention|no intervention
223561853|NCT04217135|DRUG|evidence-based medications vs. high-dose hydralazine + evidence-based medications|randomized in 1 to 1 fashion After discharge, high-dose hydralazine is maintained except any adverse effect and up-titration of other evidence-based medications to maximal tolerable dose will be done. The dose of medications is adjusted by clinical signs, especially peripheral perfusion, not only simply by blood pressure. If participant had low blood pressure (for example, systolic blood pressure less than 90 mmHg) but no sign of postural hypotension, or low cardiac output (cold limbs, decreased urine output, dizzy), the investigators will keep up-titration of medications.
223561854|NCT05751590|DEVICE|comined use of gliddescope and fiberoptic broncscopy|endotrachotreal intubation will be done by combined use of Glidescope and Fiberoptic broncscopy
224034669|NCT02809573|DRUG|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
224034670|NCT02189356|BEHAVIORAL|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
223418899|NCT05241405|DIETARY_SUPPLEMENT|PLACEBO|2 capsules/day for 8 weeks.
223418900|NCT03879980|DRUG|Bilateral QL block|Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.
223418901|NCT03879980|DRUG|Non-QL block|Only received fentanyl IV during surgery.
223418902|NCT02951221|DRUG|BIIB074 Treatment A|Lower dose RCF fasted
223418903|NCT02951221|DRUG|BIIB074 Treatment B|Lower dose DCF fasted
223418904|NCT02951221|DRUG|BIIB074 Treatment C|Higher dose DCF fasted
223561855|NCT05751590|DEVICE|fiberoptic bronscopy|endotrachotreal intubation will be done by Fiberoptic broncscopy
223561856|NCT03062553|BEHAVIORAL|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
224034671|NCT02189356|BEHAVIORAL|standard care|standard pregnancy follow up
224034672|NCT02852161|DEVICE|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
224034673|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster (simplified version)|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
223418905|NCT02951221|DRUG|BIIB074 Treatment D|Higher dose DCF fed
224034674|NCT04708756|BEHAVIORAL|Collabree Mobile Phone Application Medication Adherence Booster|Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone. Patients will receive standard care.
224034675|NCT05181865|DRUG|1 mg/kg IV FL-301|N = 1
224034676|NCT05181865|DRUG|3 mg/kg IV FL-301|N = 3-6
224034677|NCT05181865|DRUG|10 mg/kg IV FL-301|N = 3-6
223418906|NCT04181047|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|Psychotherapy.
223418907|NCT04181047|OTHER|Usual care|Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
224034678|NCT05181865|DRUG|20 mg/kg IV FL-301|N = 3-6
224034679|NCT05181865|DRUG|30 mg/kg IV FL-301|N = 3-6
224034680|NCT05181865|DRUG|RP2D, IV FL-301|Pancreatic Cancer N = 30
224034681|NCT05181865|DRUG|RP2D, IV FL-301|Gastric Cancer (Including GEJ) N = 30
224034682|NCT05181865|DRUG|RP2D, IV FL-301|Other Solid Tumors N = 30
224034683|NCT00328900|DRUG|Administration of 0,7 mg of atropine|
224034684|NCT00328900|DEVICE|Measurement of skin conductance with Pain detector|
223418908|NCT03459898|DEVICE|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
223418909|NCT02644629|DRUG|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
223418910|NCT02644629|DRUG|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
223418911|NCT02644629|DRUG|Ketamine (2st phase)|Patients failing to achieve response (\<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
223561857|NCT03062553|BEHAVIORAL|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
223561858|NCT03062553|DEVICE|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
223561859|NCT00305032|PROCEDURE|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
223561860|NCT00822705|DRUG|Placebo tablet|Control arm
223561861|NCT01809145|OTHER|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
223561862|NCT02279771|PROCEDURE|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
223561863|NCT02279771|PROCEDURE|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
223561864|NCT02279771|DEVICE|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
223561865|NCT02968160|DRUG|Telmisartan 40mg + Rosuvastatin 20mg|
223561866|NCT02968160|DRUG|Telmisartan 80mg + Rosuvastatin 20mg|
223418912|NCT02538289|BEHAVIORAL|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
223418913|NCT01450826|DRUG|aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
223561867|NCT02968160|DRUG|Telmisartan 40mg, 80 mg|
223561868|NCT02968160|DRUG|Rosuvastatin 20mg|
223561869|NCT02987907|DRUG|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
223561870|NCT02987907|DRUG|Normal Saline|use normal saline 2ml I.A. during TACE
223561871|NCT06195969|BEHAVIORAL|automated instant message-guided hypertension management intervention group|Participants in intervention group will receive the EMI for 4 weeks. Based on the steps of mobile message development recommended by Abroms, et al., we will develop a message content library and protocol for EMI delivery
224137208|NCT03106506|PROCEDURE|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
223418914|NCT01450826|DRUG|ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
223418915|NCT02586519|DEVICE|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
223418916|NCT02223650|DEVICE|Overminus treatment|2.50D overminus spectacles
223418917|NCT02223650|DEVICE|Non-overminus treatment|spectacles without overminus or no spectacles
223418918|NCT04453072|OTHER|Interview|Participate in interviews
224137209|NCT00264849|DRUG|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
224137210|NCT00264849|OTHER|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
224137211|NCT05255913|DRUG|Nanosilver|preventive material for arresting caries
224137212|NCT05255913|DRUG|Silver diamine fluoride|preventive material for arresting caries
224137213|NCT05059418|DRUG|Clonazepam 0.5 MG|Topical treatment of oral mucosa with lozenge pill
223418919|NCT04453072|OTHER|Media Intervention|Receive iPhone with W8Loss2Go app
223418920|NCT04453072|OTHER|Questionnaire Administration|Complete questionnaires
223418921|NCT04453072|OTHER|Scale Device|Receive body scale and food scale
223418922|NCT04453072|BEHAVIORAL|Telephone-Based Intervention|Receive telephone calls
223418923|NCT04453072|OTHER|Text Message|Receive text message
224137214|NCT05059418|DRUG|Capsaicin Topical|Topical treatment of oral mucosa with capsaicin rinse
224137215|NCT05059418|OTHER|Placebo|Mouth rinse with no capsaicin
224137216|NCT01757613|DRUG|AK 3012|cutaneous use twice a day
224137217|NCT01788306|DRUG|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
224137218|NCT03614442|OTHER|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
223561872|NCT03511508|BEHAVIORAL|ChroPreg + standard care|"* Ongoing update of individual maternity care plan.~* Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~* Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~* Possibility for psychologist consultation.~* Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~* Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
223561873|NCT03372551|DEVICE|somofilcon A 1 day test lens|Contact lens
223418924|NCT04885179|OTHER|no intervention|No interventions are involved in this observational study.
223561874|NCT03372551|DEVICE|somofilcon A 1 day control lens|Contact lens
223561875|NCT06178289|DEVICE|3M Cavilon Advanced Skin Protectant|3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
223561876|NCT06178289|DEVICE|Standard hospital wound treatment protocol|Comparator: Standard hospital wound treatment protocol
223418925|NCT00655707|BIOLOGICAL|Autologous Expanded CD34+ Haemopoietic cells|"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"
223418926|NCT06494332|OTHER|Exercise and stretching programe|It consists in: a serie of mobility exercises, which were used as warp-up; the mobility of the elbow, forearm, wrist and fingers of both upper limbs was worked on; and, exercises were performed to strengthen the muscles of both forearms.
223418927|NCT02410421|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
223561877|NCT05512065|DEVICE|Ultrasound|Ultrasound scan of the right and left uterine arteries and umbilical artery.
223561878|NCT05760313|DRUG|Linaclotide|Capsule; oral
223561879|NCT05760313|DRUG|Placebo|Capsule; oral
223561880|NCT05103579|DEVICE|MindMics|Patients rhythms was recorded using MindMics device
223561881|NCT03257111|OTHER|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
223561882|NCT03509363|BEHAVIORAL|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
223561883|NCT05013918|OTHER|Observational study|No intervention
224137219|NCT05618899|OTHER|HIGH INTENSITY INTERVAL TRAINING|Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
224137220|NCT05618899|OTHER|MODERATE INTENSITY EXERCISE|moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
224137221|NCT04679259|DIAGNOSTIC_TEST|Blood sampling for assessment of the level of D-Amino Acid Oxidase, D-serine and Serine in blood|Blood sampling is done before surgery and at 1, 2, and 7 day after surgery. The level of D-Amino Acid Oxidase, D-serine and Serine in blood are assessed.
224137222|NCT04679259|DIAGNOSTIC_TEST|Neurocognitive test|Neurocognitive test is performed before surgery and at 7 day after surgery
224137223|NCT04679259|DIAGNOSTIC_TEST|Assessment of delirium|Postoperative delirium is assessed daily during 7 days after surgery.
224137224|NCT03019770|BEHAVIORAL|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
224137225|NCT06043206|PROCEDURE|Bariatric Surgery|Bariatric Surgery
224137226|NCT00099359|DRUG|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) \> 2000 grams 8 mg PO BID if BW \< 2000 grams
224137227|NCT00099359|DRUG|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW \> 2000 grams, 8 mg PO per dose if BW \< 2000 grams"
223418928|NCT02603068|DRUG|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
223418929|NCT01323153|DRUG|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
223418930|NCT01323153|DRUG|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
223561884|NCT06402279|DEVICE|Efferon CT therapy|Efferon CT is a cylindrical body made of polycarbonate, filled with spherical granules of polymer hemocompatible macroporous styrene-divinylbenzene copolymer of super cross- linked type and isotonic sodium chloride solution. The device is manufactured according to TU 32.50.50-001-12264678-2018, has passed the necessary tests and is registered in Russia as a medical product RZN 2019/8886. Hemoperfusion procedures were performed using the Efferon CT device no later than 6 hours after the start of invasive ventilation. Hemosorption was performed twice within 12 hours, with an interval of 24 hours between hemoperfusion.
223561885|NCT03727646|DIETARY_SUPPLEMENT|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
223561886|NCT05255549|PROCEDURE|ESWT + Stretching|"3 weeks intervention:~* 3 sessions of ESWT, once a week~* 6 sessions of passive stretching, twice a week"
223561887|NCT05255549|PROCEDURE|ESWT and SHAM + Stretching|"3 weeks intervention:~* 1 sessions of ESWT + 2 sessions of Sham, once a week~* 6 sessions of passive stretching, twice a week"
223561888|NCT00195052|DIAGNOSTIC_TEST|Intrinsic signal imaging of human cortex|Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
223561889|NCT05280158|DRUG|mRNA-1273 (Moderna COVID-19 vaccine)|Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
223561890|NCT04610645|DEVICE|OCT|3x3 OCT volume scans on treated and opposite side of the irreadiated area on head and neck
223561891|NCT04610645|DEVICE|Dermatoscope|2x2 pictures taken with a dermatoscope
223561892|NCT04610645|GENETIC|3-Colour FISH|Blood sample is examined for breaks per metaphase to determine radiation sensibility of the individual
223418931|NCT06968767|OTHER|bioflx crown|"(Group A: Preformed Biofix Crown - Assigned Intervention)~Crown Selection \& Tooth Preparation:~Measure the mesiodistal width using calipers to select an appropriately sized crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection. Choose the crown that closely matches the measured mesiodistal width. Select the smallest crown that preserves proximal contacts using a trial-and-error approach. If crimping is necessary, use Howe's pliers.~Perform 1-1.5 mm occlusal reduction using a tapered diamond bur.~Reduce proximal areas by approximately 0.5 mm to clear the contact area.~Crown Placement \& Cementation:~Ensure a snug fit of the selected crown. Apply a thin layer of glass ionomer cement inside the crown. Seat the crown firmly using finger pressure. Have the child bite down gently to ensure proper seating.~Final Adjustments \& Cleanup:~Remove excess cement with floss or an explorer. Verify the crown's fit, occlusion, and stability."
223418932|NCT06968767|OTHER|zirconia crown|"Group B: Preformed Zirconia Crown - Assigned Intervention)~Crown Selection:~Measure the mesiodistal width using calipers to select the appropriate crown. If a mesial or distal wall is missing, use the contralateral tooth for size selection. Choose the one that closely matches the mesiodistal width. Select the smallest crown that preserves proximal contacts.~Tooth Preparation:~Reduce the occlusal surface by 1.5-2 mm using a tapered diamond bur.~Reduce interproximal areas by 1-1.5 mm, ensuring a feather-edge finish.~Perform a 1-2 mm subgingival preparation in passively placed fissure bur.~Crown Placement \& Passive Fit Check:~Place the selected crown on the prepared tooth.~Cementation of the Crown:~Apply a thin layer of glass ionomer cement inside the crown. Seat the crown with passive finger pressure. Have the child bite down gently to ensure seating."
223418933|NCT06968169|BEHAVIORAL|Supportive learning|All interventions are manipulations to the stimuli that the child hears with the goal of discovering which manipulations support verbal learning.
223418934|NCT06968169|BEHAVIORAL|Cascades|The intervention is a manipulation of word instruction with the goal of discovering whether weaker word learning results in cascading effects on semantic category memory and sentence comprehension.
223418935|NCT06968819|OTHER|Non-immersive virtual reality|Non-immersive virtual reality-based robot-assisted intervention includes balance and coordination training, muscle strengthening exercises as well as cognitive stimulation activities on an interactive treadmill, stabilometric platform and robot-assisted upper limb rehabilitation device. In addition, the experimental group takes part in group sessions featuring active and isometric exercises or motor coordination training.
223561893|NCT06472128|BEHAVIORAL|DREAMLAND|Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
223561894|NCT06472128|BEHAVIORAL|VITAL WELLNESS|Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
223561895|NCT04047875|DRUG|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
223561896|NCT04047875|DRUG|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
223561897|NCT01688245|BEHAVIORAL|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
224034685|NCT01297413|BIOLOGICAL|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
224298584|NCT05325307|OTHER|Placebo acupressure|In the placebo acupressure group , the points 1.5 cm away from the HT7, LI4, and EX-NH3 points will be applied for an average of 15 minutes. Less pressure will be applied.
223561898|NCT01688245|BEHAVIORAL|SMS Assessments|Weekly post-weekend drinking outcome assessments
223561899|NCT05980130|BEHAVIORAL|Rumination-Focused Cognitive Behavior Therapy|The RFCBT exclusively addresses one possible mechanism underlying depression, rumination. In general, a participant and their therapist will identify when the participant ruminates in an unhelpful manner, what triggers the rumination, what function the rumination fulfills for the participant, and how the participant already does to stop ruminating. Building on this knowledge both together will change the environment to reduce the likelihood of the participant to ruminate, use consciously strategies to stop rumination when it occurs, and replace rumination by more helpful strategies. In the proposed single subject study, the participant and the therapist will meet in person or using a UofL approved video platform up to 18 times for 50-minutes.
224034686|NCT01180998|DEVICE|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
224034687|NCT01180998|DEVICE|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
224034688|NCT01376349|DRUG|prasterone|Applied vaginally
224034689|NCT01376349|OTHER|placebo|Applied vaginally
224034690|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist plus Montelukast|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease
224034691|NCT04322422|DRUG|Inhaled corticosteriod/long-acting beta-agonist only|Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
224034692|NCT01363167|DIETARY_SUPPLEMENT|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
224034693|NCT06206369|OTHER|No intervention, retrospective study|No intervention, retrospective study
224034694|NCT05784987|DRUG|Rituximab|375 mg/m2, d0, Cycle 1\~4
224034695|NCT05784987|DRUG|Mitoxantrone hydrochloride liposome|20 mg/m2, d1, Cycle 1\~4
224034696|NCT05784987|DRUG|Isophosphamide|1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1\~4
224034697|NCT05784987|DRUG|Etoposide|65 mg/m2, d1-3, Cycle 1\~4
224034698|NCT05784987|DRUG|X: Orelabrutinib|MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2\~4
224034699|NCT05784987|DRUG|X: Chidamide|EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2\~4
224034700|NCT05784987|DRUG|X: Penpulimab|TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2\~4
224298585|NCT03994497|OTHER|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
224034701|NCT05784987|DRUG|X: Lenalidomide|Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2\~4
224034702|NCT00162032|DRUG|Sestamibi|Sestamibi
224034703|NCT00010062|DRUG|fluorouracil|
224034704|NCT00010062|RADIATION|radiation therapy|
224034705|NCT04780750|DRUG|Docetaxel|Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
224034706|NCT02442713|DRUG|fluvoxamine|fluvoxamine: 50-300mg/day
224034707|NCT01290705|BEHAVIORAL|High exercise therapy|
224034708|NCT01290705|BEHAVIORAL|Low exercise therapy|
224034709|NCT00216203|DRUG|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
224034710|NCT00216203|DRUG|Cetuximab|"Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"
224034711|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
224034712|NCT02661698|DIETARY_SUPPLEMENT|Placebo|3 x 1 g capsules Placebo: olive oil
223418936|NCT06968819|OTHER|Standard physical therapy|Participants receive standard physical therapy, which includes individual sessions focused on muscle strengthening, balance training, stretching, suspension therapy, and treadmill exercises. In addition, they take part in group sessions featuring active, isometric exercises or motor coordination training.
223418937|NCT06966739|OTHER|MSOT of musculature|All measurements using multispectral optoacustic tomography (MSOT) are performed on the paraspinal muscles as well as the trapezius, rectus abdominus and the proximal and distal limb muscles in a right vs. left comparison (leg proximal: quadriceps and ischiocrural muscle, leg distal triceps surae muscle, tibialis anterior muscle; arm proximal: M. biceps, distal: forearm flexors).
224034713|NCT02661698|DIETARY_SUPPLEMENT|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
224034714|NCT00119145|DRUG|artesunate-amodiaquine|
224034715|NCT00119145|DRUG|coartem|
224034716|NCT00119145|DRUG|artesunate-lapdap|
224034717|NCT04098068|DRUG|MK-3475|MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
223418938|NCT04080024|DRUG|SN132D|Novel manganese-based macromolecular MRI contrast agent
223418939|NCT05668585|DRUG|CFT1946|Specified oral dose on specified day
223418940|NCT05668585|DRUG|Trametinib|Specified oral dose on specified day
223418941|NCT05668585|DRUG|Cetuximab|Specified intravenous dose on specified day
223418942|NCT03322761|COMBINATION_PRODUCT|Systematic exercise training|Combination of standard medical treatment and systematic early exercise training in persons with MS.
223418943|NCT03322761|BEHAVIORAL|Educational program|Informations regarding health benefits of physical activity and exercise.
223418944|NCT05147402|DRUG|midomafetamine|100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).
223418945|NCT06965153|DRUG|Dual NRT|Dual nicotine replacement therapy
223418946|NCT06965153|BEHAVIORAL|PeerTTS|Peer recovery coach delivered tobacco cessation coaching
223418947|NCT05629221|OTHER|TreC Diabete App|Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).
223561900|NCT03150966|DRUG|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
223561901|NCT03150966|DRUG|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
224034718|NCT05489887|DRUG|Naxitamab|Naxitamab is a humanized (IgG1) anti-GD2 (hu3F8) monoclonal antibody for the treatment of neuroblastoma, osteosarcoma and other GD2-positive cancers. Naxitamab was granted accelerated approval by the FDA in 2020 as treatment (in combination with granulocyte-macrophage colony-stimulating factor - GM-CSF) for pediatric patients at least one year of age and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy
224034719|NCT03871829|DRUG|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m\^2 will be administered intravenously (IV).
224034720|NCT03871829|DRUG|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m\^2 will be administered IV.
224034721|NCT03871829|DRUG|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
224034722|NCT03871829|DRUG|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
224034723|NCT03871829|DRUG|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
224034724|NCT01106014|DRUG|Selexipag|Selexipag 200 µg tablets
224034725|NCT01106014|DRUG|Placebo|Placebo tablets matching selexipag
224034726|NCT06110611|DEVICE|Astra Tech Osseospeed EV® dental implant|Prospective study of a group of 50 patients which were treated 5 years ago with a dental implant and a screw-retained implant-supported zirconia restoration because of a missing tooth in the posterior region.
224034727|NCT06774066|OTHER|High volume image guided injection|High volume image guided injection consists of 9.5ml of bupivacaine, 0.5ml 20mg Depo-medrol, and 40ml of injectable saline. This procedure will be commenced with a thorough disinfection of the injection site. The mid-portion of the Achilles tendon will then be imaged in the short axis to obtain a cross-sectional view of the tendon, alongside the anterior region, including Kager's fat pad, particularly in areas of maximal pain and increased neovascularity. Once the needle is correctly positioned, the high-volume fluid will be infiltrated under pressure, with ultrasound guidance confirming the reduction or complete disappearance of neovascularisation.
224137228|NCT00099359|DRUG|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW \> 2000 grams 4 mg po bid if BW \< 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW \> 3000 grams 150 mg po bid if BW \> 2,000 - 3000 grams 100 mg PO BID if BW \< 2000 grams"
224137229|NCT00099359|DRUG|Nelfinavir (NFV)|200 mg BID if birth weight (BW) \> 3000 grams for 2 weeks;150 mg BID if BW \> 2000-3000 grams for 2 weeks; 100 mg BID BW \</= 2000 grams for 2 weeks
223418948|NCT04905472|DEVICE|Vestibular prosthesis/implant|The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
224034728|NCT06774066|OTHER|Progressive rehabilitation exercise programme|A comprehensive explanation of the progressive exercise program will be provided to patients, along with a detailed booklet that includes four tiers of exercises, ranging from the easiest to the most challenging. Exercises include several eccentrics, isometrics and heavy slow resistance exercises. These exercises are to be performed once a day and the intensity and number of repetitions will be based on the patients' status. The progressive exercise program is designed to avoid exacerbating the patient's symptoms; however, some pain is permitted during the sessions following the pain monitoring model proposed by Thomee (1997)
224034729|NCT05873569|BEHAVIORAL|Mothers and Babies Virtual Group Intervention|The Mothers and Babies Virtual Group (MBVG) intervention is a 10-session intervention built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and are led by a trained MBVG facilitator.
223418949|NCT04905472|DEVICE|Vestibular Implant Stimulation|VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
224034730|NCT04092101|OTHER|Cigarettes with varying nicotine content|1\) Altering the nicotine content of the tobacco research cigarette
224034731|NCT04092101|OTHER|E-Cigarettes|1\) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
223418950|NCT02173522|DEVICE|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
224137230|NCT05138406|OTHER|Graded Motor Imagery|The graded motor imaging program will be set to 2 weeks each component. Participants will receive lateralization for the first 2 weeks, motor imagery for 2 weeks, and mirror therapy for 2 weeks. At the same time, standard rehabilitation will be applied for 6 weeks. Treatments will begin 24-48 hours after surgery. Treatments will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
223418951|NCT00522639|OTHER|18F-deoxyglucose (FDG)|contrast medium
223418952|NCT06665503|DIETARY_SUPPLEMENT|Zinc Supplement, probiotic|received oral zinc supplementation; 2.5 ml every 12 hours for children aged \<1 year and 5 ml every 12 hours for older children; the probiotics group received oral probiotics; 1 probiotic sachet
223418953|NCT04019340|OTHER|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
223418954|NCT04678154|DRUG|Standard of care|Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
223418955|NCT04678154|DRUG|Vancomycin and Tobramycin|The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
223418956|NCT06665451|OTHER|Non coated dental implants|Patients with fresh extraction sockets in the anterior maxilla will be treated by non coated immediate implant .
223418957|NCT06665451|OTHER|Erythropoietin gel coated implants|Patients with fresh extraction sockets in the anterior maxilla will be treated by immediate implant coated by erythropoietin gel.
223418958|NCT05334342|DIETARY_SUPPLEMENT|Low-GI Diet|Participants will be given a low glycemic index diet
223418959|NCT05334342|DIETARY_SUPPLEMENT|High-GI Diet|Participants will be given a high glycemic index diet
223418960|NCT00882778|DRUG|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
224034732|NCT02283554|PROCEDURE|open flap debridement (OFD)|
223418961|NCT01014988|DRUG|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
224034733|NCT02283554|OTHER|Platelet rich fibrin (PRF)|
224137231|NCT05138406|OTHER|Standard Rehabilitation|Standard rehabilitation consisting of cold therapy, stretching and strengthening exercises will be applied. Treatment will be applied under the control of a physiotherapist 3 days a week and as home exercise 3 days a week.
223418962|NCT00986128|DRUG|topiramate|100 mg tablet twice daily for 3 weeks
223418963|NCT00986128|DRUG|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
224034734|NCT02283554|DRUG|Metformin|
224034735|NCT02149082|DEVICE|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
224137232|NCT01123577|OTHER|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
223418964|NCT03604393|BEHAVIORAL|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
223418965|NCT06682611|DRUG|SYHA1813|In accordance with the protocol
224034736|NCT04977726|BEHAVIORAL|STRIVE curriculum|STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session.
223561902|NCT01534585|DRUG|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
223418966|NCT06682611|DRUG|SG001|In accordance with the protocol
224137233|NCT04627298|BEHAVIORAL|educational video game for preteens to support HPV vaccination|An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
224137234|NCT05197673|BEHAVIORAL|Theory of planned behaviours (TPB) based intervention|Intervention group will receive TPB-based education program to improve workers' attitude toward SARS-CoV-2 and raise their intention to vaccination and virus testing. The intervention will be implemented at the baseline with measurements repeated at the 3rd month, 6th month and 9th month. The standardized mode of intervention includes face-to-face/online seminar (depends on the COVID-19 situation), message via mobile phone, promotion pamphlet, etc.
223561903|NCT01534585|RADIATION|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
223561904|NCT01534585|DRUG|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
223561905|NCT01534585|OTHER|Quality of life|The EORTC QLQ-C30 and H\&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
223561906|NCT01534585|GENETIC|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
224034737|NCT01720173|BIOLOGICAL|Dalantercept|Given SC
224034738|NCT01720173|OTHER|Laboratory Biomarker Analysis|Correlative studies
224034739|NCT00784693|BIOLOGICAL|Tanezumab|15 mg IV single dose
224034740|NCT00784693|DRUG|Placebo|Placebo IV single dose
224137235|NCT01463865|DRUG|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
224137236|NCT01463865|DRUG|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
223418967|NCT06682611|DRUG|HB1801|In accordance with the protocol
223418968|NCT06682611|DRUG|Carboplatin|In accordance with the protocol
223418969|NCT06682611|DRUG|Cisplatin|In accordance with the protocol
223418970|NCT06682611|DRUG|Paclitaxel|In accordance with the protocol
223561907|NCT00274235|DRUG|sulfadoxine-pyrimethamine / mefloquine|
223561908|NCT03019328|OTHER|Peanut in diet|
223418971|NCT06682611|DRUG|Etoposide|In accordance with the protocol
223418972|NCT06682611|DRUG|Everolimus|In accordance with the protocol
223561909|NCT01537159|DEVICE|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
223561910|NCT00327015|DRUG|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
224034741|NCT05458479|DRUG|Fluoxetine|All participants in the study will receive open-label treatment with orally administered fluoxetine for the full duration of the 16-week trial. Fluoxetine is a selective serotonin reuptake inhibitor. It is approved for the management of major depressive disorder in adults.
224034742|NCT02650882|PROCEDURE|Device POWERbreathe|
224034743|NCT05848505|DRUG|Dexmedetomidine|Intranasal administration Dosage 2 mcg/kg
224137237|NCT02713191|DRUG|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
224137238|NCT02713191|DRUG|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
224137239|NCT02713191|OTHER|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
224137240|NCT02713191|DRUG|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
224137241|NCT02713191|DRUG|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
223418973|NCT06682611|DRUG|Regorafenib|In accordance with the protocol
223418974|NCT05631093|DRUG|ART|Standard of care ART, per approved product list, taken orally
223418975|NCT05631093|DRUG|DOR/ISL|Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
223418976|NCT02880878|PROCEDURE|Early Surgical Hematoma Evacuation|Early Minimally Invasive Parafascicular Surgery (MIPS)
223561911|NCT00327015|DRUG|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
223561912|NCT00327015|DRUG|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
223561913|NCT00327015|DRUG|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
223561914|NCT00327015|DRUG|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
223418977|NCT03850730|DRUG|Pazopanib|Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
223418978|NCT01683266|DRUG|HOE901-U300 (Insulin glargine new formulation)|
223561915|NCT05955820|DEVICE|Suspension system|Participants will be tested by four exercises designed for impingement syndrome using the suspension system
223561916|NCT05955820|DEVICE|Dumbbells|Participants will be tested by four exercises designed for impingement syndrome using Dumbbells
223561917|NCT05611567|PROCEDURE|POSE2.0 procedure|The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
224034744|NCT02456077|BEHAVIORAL|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
224034745|NCT00655694|PROCEDURE|sputum, blood, urine, exhaled breath, lung function|
224034746|NCT05276115|OTHER|Interview|Interview discussion with individuals with ptsd.
223418979|NCT01683266|DRUG|Lantus (Insulin glargine)|
224034747|NCT02851082|OTHER|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
224137242|NCT01485926|DRUG|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
224137243|NCT01485926|DRUG|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
224137244|NCT05392894|PROCEDURE|Haploidentical stem cell transplantation|Stem cell transplant from bone marrow or peripheral blood from haploidentical donor using standard nationally approved transplant procedure.
223418980|NCT03766165|BEHAVIORAL|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
223561918|NCT05611567|BEHAVIORAL|Life style and behavioral intervention|The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
224034748|NCT00121277|DRUG|capecitabine|
223418981|NCT03766165|BEHAVIORAL|Control|Participants will receive job announcements only.
224034749|NCT00121277|DRUG|vorinostat|
224137245|NCT05392894|OTHER|Standard medical care|Standard medical care may include any currently available therapies for SCD patients. These may or may not include regular elective transfusion therapy or medications such as hydroxycarbamide.
223418982|NCT00096616|DRUG|Combivent® CFC MDI|
223418983|NCT00096616|DRUG|Albuterol HFA MDI|
223418984|NCT06220981|OTHER|Endovascular treatment|
223418985|NCT06532812|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Tumor Infiltrating Lymphocytes (TIL) IV
223418986|NCT06532812|DRUG|Cyclophosphamid|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
223418987|NCT06532812|DRUG|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
223561919|NCT03114579|DEVICE|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
223561920|NCT03114579|DEVICE|NEXFIN HD|
223561921|NCT04433689|DEVICE|Non-Contact measurement of corneal properties|Corneal Properties will be measurement with the non-contact Corvis ST Air-Puff Tonometer by Oculus Inc.
223561922|NCT03055728|DIAGNOSTIC_TEST|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
224034750|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
223418988|NCT06532812|DRUG|Interleukin-2|After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
223418989|NCT06532812|DRUG|Pembrolizumab|Intravenous (IV) infusion
223418990|NCT00011258|DRUG|Paraoxonase|
223418991|NCT00000818|DRUG|Zidovudine|
223418992|NCT04001218|DRUG|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
223418993|NCT04001218|DRUG|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
223418994|NCT00626821|DEVICE|SenSura|Real life assessment of SenSura
224034751|NCT02860663|DIETARY_SUPPLEMENT|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
224034752|NCT02860663|DIETARY_SUPPLEMENT|25OHD|10 ug/d of vitamin D3 for 6 weeks
224034753|NCT03159923|OTHER|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
223418998|NCT00756236|DRUG|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
223418999|NCT00756236|DRUG|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
223419000|NCT00756236|DRUG|P-Group|0.9%NaCl dispensed in 60ml \& 5ml syringes
223419001|NCT01800643|OTHER|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
223419002|NCT06261983|PROCEDURE|Sentinel node biopsy guided by magnetic probe|Sentinel nodes exeresis guided by magnetic probe after injection submucosally and peritumorally of super-para-magnetic contrast. Standard neck dissection (levels I-II) were carry out after sentinel node biopsy
223419003|NCT00210197|PROCEDURE|Blood collection (pre and postoperative): plasma coagulation parameters|
223419004|NCT02644863|DRUG|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
223419005|NCT02644863|BIOLOGICAL|DC-CIK|Antigen-sensitized DC-CIK 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
223419006|NCT02644863|DRUG|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
223561923|NCT03055728|DIAGNOSTIC_TEST|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
223561924|NCT01618045|DIETARY_SUPPLEMENT|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
224034754|NCT01067157|BEHAVIORAL|LOGIC|"Experimental group:~Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)"
223419007|NCT03609931|PROCEDURE|Mitral Valve Model|Creation of a mitral valve patient specific model to see if it mimics the patients valve
223561925|NCT02330666|BEHAVIORAL|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
223561926|NCT03269916|OTHER|Anti Mueller hormone|used to assess ovarian reserve parameters
223561927|NCT03269916|OTHER|Estrogen|used to assess ovarian reserve parameters
224034755|NCT03299257|DRUG|donepezil treatment|30-day donepezil treatment
223419008|NCT05269173|DRUG|Flos gossypii flavonoids tablet|The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
223419009|NCT04040231|BIOLOGICAL|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
223419010|NCT04040231|DRUG|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
223561928|NCT03269916|OTHER|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
223561929|NCT03269916|OTHER|Antral alveolar cell count|used to assess ovarian reserve parameters
223561930|NCT00097227|BIOLOGICAL|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
223561931|NCT00097227|DRUG|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
223561932|NCT00097227|DRUG|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
223561933|NCT00284284|DEVICE|Use of a rehabilitation brace|
223561934|NCT00697866|BIOLOGICAL|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
223561935|NCT00697866|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
224034756|NCT04201756|DRUG|Afatinib|"①Neoadjuvant treatment stage: the enrolled patients take afatinib at a dosage of 40mg per day, 8-16 weeks in total; and receive CT scan re-examination in the 4th/8th/12th post-therapy week.~②Surgical treatment stage: the patients who respond to alfatinib treatment (CR+PR) and the patients who do not respond to alfatinib therapy but could still undergo surgery (SD and PD) will receive radical lung lobectomy+systematic lymph node dissection.~③Adjuvant treatment stage: The CR, PR and SD patients who have been treated surgically will take alfatinib at a dosage of 40mg per day for at least 1 year. The SD and PD patients who could not receive operation and the PD patients who have received operation will be transferred into medical oncology or/and radiation oncology and receive comprehensive therapy (chemotherapy or/and radiotherapy, the regimen is designed by oncologist and radiologist)"
224034757|NCT03227796|DRUG|LEVI-04|LEVI-04 intravenous infusion
224034758|NCT03227796|DRUG|Placebo|Placebo intravenous infusion
223561936|NCT04812769|DEVICE|eCARE-ID|The intervention, eCARE-ID, consists of: 1) telehealth video clinical consultation services for nursing homes residents; 2) electronic consultation services for healthcare personnel; 3) telehealth video antibiotic stewardship services for healthcare personnel
223561937|NCT04812769|OTHER|Standard of Care|Standard of care will be delivered to the control home.
223561938|NCT03528239|OTHER|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
223561939|NCT03761888|DIAGNOSTIC_TEST|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
223561940|NCT00388388|DRUG|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
224034759|NCT01642173|DEVICE|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
224034760|NCT01964807|OTHER|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
224034761|NCT01964807|OTHER|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
224034762|NCT01964807|OTHER|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
224034763|NCT01964807|OTHER|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
224034764|NCT01964807|OTHER|Moist snuff|Use moist snuff for 30 minutes
224034765|NCT01964807|OTHER|Sham Smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
224034766|NCT01964807|OTHER|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
224034767|NCT01964807|OTHER|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
224034768|NCT01964807|OTHER|Sham Moist Snuff|Chew gum for 30 minutes
224034769|NCT00908232|DRUG|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
224034770|NCT00908232|DRUG|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
223561941|NCT00837265|BIOLOGICAL|Balugrastim|Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
223561942|NCT00837265|DRUG|Pegfilgrastim|Pegfilgrastim will be administered per dose and schedule specified in the arm description.
223561943|NCT00837265|DRUG|Chemotherapy Regimen|The chemotherapy regimen consisting of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 will be administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
223561944|NCT03183258|OTHER|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
224034771|NCT00908232|DRUG|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
224034772|NCT00908232|DRUG|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
224034773|NCT03678987|DIAGNOSTIC_TEST|P-MPA concentration|We will calculate AUC\_0-12 of MPA based on 4 measurements of P-MPA
223561945|NCT03289910|DRUG|Carboplatin|Given IV
224034774|NCT03678987|DRUG|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
224034775|NCT02025569|OTHER|Strain Counterstrain|
224034776|NCT02025569|OTHER|Sham strain counterstrain|
224034777|NCT03296462|OTHER|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
224034778|NCT03296462|OTHER|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
224034779|NCT02260882|BIOLOGICAL|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
223561946|NCT03289910|DRUG|Topotecan|Given IV
223561947|NCT03289910|DRUG|Topotecan Hydrochloride|Given IV
223561948|NCT03289910|DRUG|Veliparib|Given PO
223561949|NCT02584231|DRUG|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: \>6 months and \< 2years: 60µg; ≥2 years and \<4 years: 120µg PO and ≥4 years and \<8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
223561950|NCT05665660|BEHAVIORAL|CARE|CARE is a culturally tailored mammography education module.
223561951|NCT05665660|BEHAVIORAL|CARE + COACH|CARE + COACH is a culturally tailored mammography education module + access to an Apache paraprofessional women's health coach who functions as a patient navigator
224034780|NCT00516451|DRUG|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
224034781|NCT04034550|OTHER|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
224034782|NCT00872196|DRUG|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
224034783|NCT02119325|DIETARY_SUPPLEMENT|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
224034784|NCT02119325|DIETARY_SUPPLEMENT|0% fibre|Placebo is an energy matched powdered beverage
224034785|NCT01875822|DIETARY_SUPPLEMENT|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
224034786|NCT01513525|DRUG|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
224034787|NCT01386658|DRUG|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
224034788|NCT05398510|DRUG|SHR-2010 injection|Treatment for intravenously: 6 subjects for SR-2010 injection. Treatment for subcutaneously: 8 subjects for SR-2010 injection.
224034789|NCT05398510|DRUG|SHR-2010 injection placebo|Treatment for intravenously: 2 subjects for placebo. Treatment for subcutaneously: 2 subjects for placebo.
223561952|NCT03337802|BEHAVIORAL|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
223739366|NCT07205354|OTHER|ADAPTATION|"For each patient (set of at least 35 patients), the assessor will ask the patient:~* Have you ever eaten this food? YES or NO~* Does the photo match the description? YES or NO~* 20 photos of foods per category are provided (10 + 10)~* If the foods tested are recognised (YES answer to both questions) by more than 80% of the study population, they will be retained.~* The 16 foods (8+8) with the highest recognition rates will be retained.~* If fewer than 16 foods (8+8) per category are recognised, the list will be modified by retaining the recognised foods and adding new foods to obtain the 'modified list'.~  2- If the criteria are not validated, a modified list is resubmitted to a new sample of 35 patients until the objectives are validated and a suitable questionnaire is obtained.~Obtaining an ADAPTED DYSPHAGING PREFERENCES QUESTIONNAIRE is a prerequisite for moving on to the test-retest reliability phase"
223419011|NCT04040231|BIOLOGICAL|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
223419012|NCT00200174|DRUG|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
223419013|NCT00200174|DRUG|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
223419014|NCT03118362|DRUG|Plasmalyte|"Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
223419015|NCT03118362|DRUG|Ringer lactate|"Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
223419016|NCT06160895|DRUG|TQ-A3334 tablets|TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
223419017|NCT06160895|DRUG|TQ-A3334 placebo tablets|TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
223561953|NCT00320554|BEHAVIORAL|Durometer analysis|
224034790|NCT05309434|BEHAVIORAL|Coach|The coach coordinates the initiation of CPR, communicates feedback device data to assist those performing compressions, communicates average targets for compressions and ventilations and coordinates operations to achieve those values, and communicates with the team to reduce pauses in compressions.
224034791|NCT02267356|DRUG|VT-1161|
224034792|NCT02267356|DRUG|Placebo|
224034793|NCT00309868|DRUG|neseritide|
224137246|NCT04724382|BEHAVIORAL|Culturally tailored healthy eating advice|Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
223419018|NCT05712213|PROCEDURE|Intraperitoneal onlay mesh reinforcement with defect closure before placement of mesh (pIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. The laparoscopic closure of the hernia defect was performed with non-reabsorbable detached stitches of prolene 1/0 suture at a distance of 1.5 cm from stich to stich using a Reverdin' needle. The final fixation of the mesh took place with a non-resorbable tacks.
224034794|NCT04052529|OTHER|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
224034795|NCT01688583|DRUG|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
224034796|NCT03575390|DIETARY_SUPPLEMENT|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
224034797|NCT03575390|DIETARY_SUPPLEMENT|Pomegranate|Pomegranate extract 500mg
224034798|NCT01522157|DIETARY_SUPPLEMENT|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
224034799|NCT01522157|DIETARY_SUPPLEMENT|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
224034800|NCT01522157|DIETARY_SUPPLEMENT|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
224034801|NCT06267573|DEVICE|Fenestrated and branched endovascular devices for TAAA|Devices for TAAA
224034802|NCT05659355|OTHER|Constraint Induced Movement Therapy (CIMT)|I will apply CIMT on effected hand to observe the hand dexterity and grip strength
224034803|NCT05659355|OTHER|Mirror Therapy (MT)|I will apply Mirror Therapy on effected hand to obeserve the hand dexterity and grip strength
224137247|NCT04724382|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations
223419019|NCT05712213|PROCEDURE|Standard intraperitoneal onlay mesh repair (sIPOM)|The pneumoperitoneum (12-15 mmHg) was built up with Veres in the Palmer'point. The primary optical trocar was set in the left upper abdomen, two other trocars were set in the left middle and lower abdomen. If necessary, adhesiolysis was firstly performed. The hernia gap was deperitonealized in order to prevent a seroma formation and, if possible, all hernia sac was removed to facilitate the healing of the hernia defect after the laparoscopic suture. This also included the transection of the ligamentum teres hepatis. We reduced the intraabdominal pressure to approx. 5 mmHg and measured the hernia gap through an intraperitoneal graduated mark. The choice of mesh size was done with an overlap of more than 5 cm. In sIPOM, the defect was not closed. The final fixation of the mesh took place with a non-resorbable tacks.
223419020|NCT01062113|DRUG|Celecoxib|"Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS"
223419021|NCT01062113|DRUG|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
223419022|NCT01062113|DRUG|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
223419023|NCT06663202|PROCEDURE|Fiber retention osseous resective surgery|"At the buccal and lingual sides, paramarginal or intrasulcular incisions will be made based on probing pocket depth values and the width of keratinised tissues.~Thinned palatal flap technique will be performed on the palatal side. Bone remodelling will be carefully made using manual or rotary instruments in order to reshape positive attached fibres/bony architecture utilising the FibReORS technique, great attention will be made to distinguish between inflammatory granulation tissue and connective tissue fibres attached to root cementum by means of periodontal probe. Flaps will be positioned at the level of the alveolar crest without tension."
223419024|NCT06663202|PROCEDURE|Papilla preservation flap|Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used. Suturing will be performed with external vertical mattress sutures to achieve primary intention closure.
223419025|NCT06663202|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
223419026|NCT05832502|DRUG|GBS6|The investigational products are GBS6 and placebo (saline control). The GBS6 dose will be GBS6 20mcg without AlPO4 (equivalent to 240 mcg/mL) 0.5mL dose or 20 mcg CPS/serotype).
223419027|NCT05832502|DRUG|Placebo|Placebo (saline control) administered intramuscularly by injecting 0.5 mL into the deltoid muscle
223419028|NCT03098238|BIOLOGICAL|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
223419029|NCT02671084|DRUG|sevoflurane|compare effect of sevoflurane when administered before PCI
223419030|NCT06598202|DRUG|exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop|Exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop (administered once daily, twice a week, for a total of two weeks, based on the recommended dose during the dose-escalation phase).
223419031|NCT06598202|DRUG|a placebo of exosomes derived from human umbilical cord blood mesenchymal stem cells for nasal drop|Exosomes placebo
223419032|NCT02675621|OTHER|Phenolic Beverage|
223419033|NCT02727790|DEVICE|Stimulator|
223419034|NCT03173690|OTHER|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
223419035|NCT03173690|OTHER|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
223419036|NCT04270409|DRUG|Isatuximab SAR650984|Pharmaceutical for: Solution for infusion Route of administration: Intravenous
223419037|NCT04270409|DRUG|Lenalidomide|Pharmaceutical form: Capsules Route of administration: Oral
223419038|NCT04270409|DRUG|Dexamethasone|Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
224034804|NCT04845360|DEVICE|pressure transducer (PSL-200GL, Kyowa Electronic Instrument Co. Ltd., Japan)|The device was fixed on the patient's skin with Scotch™ tape, along with an adjustable belt with a small button to give suitable pressure on the transducer.
224034805|NCT00954174|DRUG|Carboplatin|Given IV
224034806|NCT00954174|DRUG|Ifosfamide|Given IV
224034807|NCT00954174|DRUG|Paclitaxel|Given IV
224034808|NCT00954174|OTHER|Quality-of-Life Assessment|Ancillary studies
224034809|NCT00672061|DRUG|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
224034810|NCT01956656|DRUG|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
224034811|NCT00592761|BEHAVIORAL|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
223419039|NCT04270409|DRUG|Montelukast or equivalent|Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;
223419040|NCT04270409|DRUG|Acetaminophen|AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
223419041|NCT04270409|DRUG|Diphenhydramine or equivalent|AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous
223419042|NCT04270409|DRUG|Methylprednisolone or equivalent|AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
223419043|NCT00226785|DRUG|Dexmedetomidine|
223419044|NCT06666985|DRUG|ITM + Usual Care|The participants allocated to this group will receive ITM (Intrathecal Morphine) in addition to usual care with opioid-based PCA(Patient-Controlled Analgesia). ITM consists of an intrathecal injection of 300 micrograms (0.3mg) of preservative-free morphine.Usual care involves postoperative analgesia with opioid-based PCA without postoperative continuous infusion of opioids. No other drugs other than opioids are allowed in the PCA.
223419045|NCT06666985|DRUG|Sham ITM + Usual Care|The sham ITM mimics the ITM procedure, but the dura is not breached.
223419046|NCT00595985|DRUG|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
223419047|NCT05193344|DEVICE|A digital care solution for patients with Heart Failure|A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
223419048|NCT05193344|OTHER|Standard of Care for patients with Heart Failure|The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
223419049|NCT01471340|DRUG|Mometasone Furoate/Formoterol MDI 100/5 mcg|two inhalations BID
223561954|NCT05962619|PROCEDURE|arthrocentesis alone|The procedure is done under general anesthesia. The patient is seated inclined at a 45 degree angle with the head turned to contralateral side. The points of needle insertion on the skin, are as follow: a line is drawn from the middle of the tragus to the outer canthus of the eye. The posterior entrance point is located along the canthotragal line, 10 mm from the middle of the tragus line and 2 mm below, the anterior entrance point is placed 10 mm further forward along the line and 10 mm below it . A needle connected to a 10 ml syringe with the Ringer's lactate solution is then inserted into the superior compartment (posterior point), and solution is injected . Another needle is then inserted into the area of articular eminence to enable the free flow of solution through the superior compartment. During the lavage, the mandible is moved through opening, excursive, and protrusive movements to facilitate lysis of adhesions
223561955|NCT05962619|PROCEDURE|arthrocentesis with hyaluronic acid injection|in this group Once arthrocentesis is completed, an ampule of sodium HA (Hyalgan 1 ml) is connected to the needle in situ And 0.5 ml injected into the superior joint space. Pressure dressing is placed in site of injection. so We use arthrocentesis hyaluronic acid injection in management of temporomandibular joint dysfunction in the form of anterior disc displacement with reduction
223561956|NCT02855866|PROCEDURE|thyroidectomy|
223561957|NCT02855866|OTHER|cryotherapy|
223561958|NCT02855866|DRUG|cortisone aerosol|
223561959|NCT02855866|DRUG|Dexamethasone acetate|
223419050|NCT01471340|DRUG|Mometasone Furoate/Formoterol MDI 200/5 mcg|two inhalations BID
223419051|NCT01471340|DRUG|Mometasone Furoate MDI 100 mcg|two inhalations BID
223561960|NCT02855866|DRUG|paracetamol|
223419052|NCT01471340|DRUG|Mometasone Furoate MDI 200 mcg|two inhalations BID
223419053|NCT01471340|DRUG|Albuterol 90 mcg /salbutamol 100 mcg HFA MDI|use as needed for asthma symptoms
223419054|NCT01471340|DRUG|Prednisone/prednisolone|Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
223561961|NCT01080924|DEVICE|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
223561962|NCT05852652|DEVICE|cryolipolysis and aerobic exercise|"the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park"
223561963|NCT05118464|OTHER|Dual-task training|Dual-task training includes simultaneous execution of motor and cognitive tasks. The motor tasks in this study will be walking, going up and downstairs, turning, throwing, and holding a ball. Cognitive tasks will be an n-back test, verbal fluency, remembering sequences of numbers, and performing simple summing.
223561964|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention|The BAI contained components of effective interventions developed for young adult drinkers both in health care and educational settings and was specifically tailored to the unique needs and risk factors of Airmen. The 1-hour group intervention was administered using the principles of motivational interviewing (MI) in an interactive Socratic style to generate feedback and discussion. Open-ended questions, reflections, as well as the decisional balance scale were used to increase Airmen's motivation to remain alcohol free.
223419055|NCT03999827|OTHER|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
223419056|NCT03662191|DRUG|Tafamidis|bioavailability study
223419057|NCT01319474|OTHER|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
223419058|NCT00059891|PROCEDURE|conventional surgery|
223419059|NCT00059891|PROCEDURE|management of therapy complications|
224034812|NCT02783131|DEVICE|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
223419060|NCT06093048|PROCEDURE|Endoscopic retrograde cholangiopancreatography|saftey and outcome in patients older than 65 years old
223419061|NCT02261948|DRUG|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
223419062|NCT02261948|DRUG|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
223419063|NCT03377504|BEHAVIORAL|mirror therapy|Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
223419064|NCT03377504|BEHAVIORAL|Routine physical therapy and exercise program|Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
223419065|NCT03481101|DEVICE|PET/CT|3 extra scans with FDG-PET/CT and 4 blood samples
223419066|NCT00526669|DRUG|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
223419067|NCT00544323|DEVICE|oral implant|
223419068|NCT05975034|DIETARY_SUPPLEMENT|Probiotic|Probiotic taken daily for 12 weeks.
223419069|NCT05975034|DIETARY_SUPPLEMENT|Placebo|Placebo taken daily for 12 weeks.
223419070|NCT05162625|DRUG|Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution|Topical moxifloxacin 0,5% 01 drop every 3 hours
223419071|NCT05162625|DRUG|Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]|Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
223419072|NCT00641290|DEVICE|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
223419073|NCT05083936|DRUG|[18F]FET|Imaging evaluation using LAT1/4F2hc substrate overexpressed in brain tumor
223419074|NCT00151190|BEHAVIORAL|Education for diabetes self-management|
223419075|NCT04647799|DEVICE|smartphone|Samsung A 71
223419076|NCT03499899|DRUG|LAG525|LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
223419077|NCT03499899|DRUG|PDR001|Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
223739367|NCT07205354|OTHER|test-retest reliability|"For each patient (new set of 35 patients)~* the DYSPHAGING preferences questionnaire (including previously adapted pictures) will be assessed and preference indexes will be determined.~* Within 3-7 days, each patient will be asked for the forced choice in the second step of phase 2. A new preference index will be determined using the first recognition and the second forced choices answers.~* Test-retest reliability will be assessed by determination of an intra-class correlation coefficient between the two indexes obtained for each patient tested. (Good test-retest reliability will be considered with an intra-class correlation coefficient upper than 0,75 in each category and will be expected in at least 4 of the 6 tested categories to perform the cross-sectional study (phase 3)"
224034813|NCT03930368|OTHER|low GI diet with regular supplementation of raw corn starch|Patients will be guided with a low GI diet with 60%\~70% of energy from carbohydrates. RCS constituted 30%\~50% of daily carbohydrate, and was supplemented as snacks every 4\~6 hours (25g per time) especially at night.
224034814|NCT00435474|PROCEDURE|Wound treatment|wound treatment (silver product, alginate and foam dressing)
224034815|NCT00435474|PROCEDURE|wound treatment|wound treatment (honey product, alginate and foam dressing)
223419078|NCT03499899|DRUG|Carboplatin|Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
223419079|NCT00905892|DIETARY_SUPPLEMENT|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
223419080|NCT02033967|PROCEDURE|vasodilator induced hypovolemia|
223419081|NCT01382472|DRUG|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
223419082|NCT01382472|DRUG|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
223419083|NCT00247650|DRUG|Zoledronic Acid; Letrozole|
223419084|NCT04723498|DIAGNOSTIC_TEST|screening questionnaire|Fill in screening questionnaire
223419085|NCT03408509|BEHAVIORAL|Computerized cognitive training|Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
223419086|NCT00166309|DRUG|FEIBA and NovoSeven|
223419087|NCT03406585|DRUG|ProTrans: Allogeneic transplantation with WJMSCs|The drug is a cell suspension with allogeneic mesenchymal stromal cells derived from umbilical cord tissue.
223419088|NCT03406585|DRUG|Placebos|Placebo treatment
223419089|NCT06664385|OTHER|concurrent physical exercise|It consists of a periodization which consists of three moments adapted to the patient's needs distributed in 6 weeks and increasing the intensity gradually.
223419090|NCT06166407|OTHER|no intervention|no intervention
224137248|NCT01546389|BIOLOGICAL|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
224034816|NCT00435474|OTHER|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
224034817|NCT00435474|OTHER|relaxation therapy|relaxation therapy
224034818|NCT04624451|DRUG|Dalbavancin|Dalbavancin 1500 mg intravenously x 1 dose
224034819|NCT02900469|BIOLOGICAL|denosumab|denosumab: 120 mg subcutaneous injection
224034820|NCT02900469|PROCEDURE|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
224034821|NCT05373953|DRUG|CHF6001|CHF6001 will be administered using the NEXThaler® DPI device
224034822|NCT02157350|PROCEDURE|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
224034823|NCT05706012|OTHER|Survey|Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients
224034824|NCT03909204|PROCEDURE|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
224034825|NCT01919320|DEVICE|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
224034826|NCT01919320|DEVICE|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
224034827|NCT04209621|DRUG|Duvelisib|twice daily as tolerated until disease progression
224137249|NCT01546389|DRUG|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
224137250|NCT05902546|OTHER|High intensity interval training|Patients will receive interval training exercise of high intensity. This includes several rounds that alternate between several minutes of high intensity movements to significantly increase the heart rate to at least 80% of one's maximum heart rate, followed by short periods of rest
224137251|NCT05902546|OTHER|moderate intensity aerobic exercise|Patients will receive moderate intensity continuous aerobic exercise (walking) for 40 minutes (preceded by 10 minutes warming up and followed by 5 minutes cooling down)
224137252|NCT02756650|DRUG|Canakinumab|150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
224137253|NCT01097473|PROCEDURE|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
223419091|NCT00055653|BIOLOGICAL|anti-thymocyte globulin|
223419092|NCT00055653|BIOLOGICAL|filgrastim|
223419093|NCT00055653|DRUG|busulfan|
223419094|NCT00055653|DRUG|cyclophosphamide|
223419095|NCT00055653|DRUG|cyclosporine|
223419096|NCT00055653|DRUG|fludarabine phosphate|
223419097|NCT00055653|DRUG|melphalan|
223419098|NCT00055653|DRUG|methylprednisolone|
223419099|NCT00055653|PROCEDURE|umbilical cord blood transplantation|
223419100|NCT00055653|RADIATION|radiation therapy|
224034828|NCT04209621|DRUG|Ibrutinib|daily for the first six 28-day cycles
224034829|NCT05851274|PROCEDURE|transradial access|In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm
224034830|NCT05851274|PROCEDURE|Transfemoral access|In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
224034831|NCT06494917|OTHER|pelvic floor exercises|First arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied.
224034832|NCT06494917|OTHER|Pelvic floor exercises and manual therapy techniques|Second arm; Pelvic Floor Exercises (PFE) consisting of diaphragm breathing training, bridge exercise to strengthen the pelvic floor, 3-dimensional diaphragm exercise, 'I Love you massage' for intestinal motility, happy baby pose, child position exercise, full squat, adductor and iliopsoas stretching, mermaid position exercise, 'Shhh' sound exercise, 'Üüüü' sound exercise will be applied. In addition to diaphragmatic breathing training and pelvic floor exercises, manual therapy methods such as momentum minus mobilisation, sphincter opening, colon massage, global fascia manipulation, trigger point and myofascial release will be applied.
224034833|NCT02249767|DRUG|Tretinoin|Treatment of acne once daily in evening
224034834|NCT01372410|DRUG|GSK573719|125 mcg once daily
224034835|NCT01372410|DRUG|GSK573719|62.5 mcg once daily
224034836|NCT01372410|DRUG|GSK573719|31.25 mcg once daily
224034837|NCT01372410|DRUG|GSK573719|15.6 mcg once daily
224137254|NCT04569331|PROCEDURE|Stimulation of efferent loop|"Stimulation of efferent loop: 3 weeks before the ileostomy closure surgery, efferent loop will be stimulated with 250 ml of water and thickened.~This procedure consists of introducing through the light efferent loop ileostomy 250 ml of water with thickener every 48-hours during the first two weeks and once daily the thrid week with a Foley catheter. Patient will be provided with all the material and the procedure sheet for all the stimulation of the efferent loop sessions. This technique will be performed at patient's home until the day before the ostomy patient closure surgery."
223419101|NCT03269721|BEHAVIORAL|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
224034838|NCT01372410|DRUG|GSK573719|31.25 mcg twice daily
224034839|NCT01372410|DRUG|GSK573719|15.6 mcg twice daily
223419102|NCT03269721|PROCEDURE|Spirometry|Pre and post bronchodilator spirometry will be administered according to the American Thoracic Society (ATS) guidelines.
223419103|NCT03269721|PROCEDURE|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
223419104|NCT03269721|PROCEDURE|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
223419105|NCT03269721|DIAGNOSTIC_TEST|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
224034840|NCT01372410|DRUG|Tiotropium|18 mcg once daily
224034841|NCT01372410|DRUG|Placebo|once or twice daily
224034842|NCT00187772|BEHAVIORAL|Child-Parent Psychotherapy (CPP)|
223419106|NCT03269721|PROCEDURE|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
223561965|NCT01398319|BEHAVIORAL|Group Brief Alcohol Intervention Booster|The 1-hour booster intervention was delivered using MI to extend the effective elements found in the original BAI intervention with elements from behavioral economic theory. A behavioral economic approach to alcohol use suggests that decisions to drink are more likely when 1) there is a lack of access to or engagement in alternative alcohol-free reinforcing activities, and 2) there is a greater relative focus on immediate, relative to delayed, rewards (i.e., steep delayed reward discounting). The intent of the intervention is to bring important long-term goals into the present so that the immediate awareness of this goal might diminish the relative benefit of drinking. Another goal was to have the Airmen identify enjoyable and goal-consistent alcohol-free activities they could engage in during their free time. The booster also included a reminder of the U.S. Air Forces rules and policies on alcohol use and harm reduction drinking strategies.
224137255|NCT04569331|PROCEDURE|Rehabilitation pelvic floor|3 months after the closure of the ileostomy, you will be referred to the pelvic floor rehabilitation unit,where will start 15 individual sessions, 2 days a week (8 weeks of sessions), with reeducation of defecatory habits and hygienic-dietary measures, defecation record where assess stool consistency using the Bristol Scale and number of bowel movements that take place in 24 hours, muscle toning exercises (Exercises Kegel), Biofeedback (BF), rectal balloon work to improve sensitivity and accommodation, reeducation of the expulsive maneuver, and perineal block in situations hyperpressive.
224137256|NCT01424826|DRUG|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
223419107|NCT03269721|BIOLOGICAL|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
223419108|NCT03269721|BEHAVIORAL|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
223419109|NCT03269721|PROCEDURE|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
223419110|NCT03154463|PROCEDURE|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
224034843|NCT05232123|DRUG|Placebo|Placebo oral product formulated in MCT (medium chain triglyceride) oil
223419111|NCT03154463|PROCEDURE|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
223419112|NCT05887258|DRUG|Opioid free anesthesia|It administers a combination of drugs to replace the opioid derivatives. Among them, we will use lidocaine, ketamine, dexmetomidine, and magnesium sulfate in continuous infusion adjusted to the patient's weight during surgery.
223419113|NCT05887258|DRUG|Opioid based Anesthesia|administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.
224034844|NCT05232123|DRUG|Cannabidiol|Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
224034845|NCT02091895|PROCEDURE|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
224034846|NCT02936063|PROCEDURE|Surgical staples|Closure of surgical wound at skin level with surgical staples
224034847|NCT02936063|PROCEDURE|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
224034848|NCT04585646|DEVICE|Orion daily disposable contact lens|Subjects will be randomized to wear Orion lens for 2 weeks.
224137257|NCT01424826|DRUG|Rifampicin|\< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days \> 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
224137258|NCT01424826|DRUG|Raltegravir|800 mg bd for 4 days
224137259|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with less ≤ 3mm from each other.|Implant Placement of 2 contiguous dental implants with less ≤ 3mm from each other.
224137260|NCT06364982|DIAGNOSTIC_TEST|Two contiguous dental implants placed with > 3mm from each other.|Implant Placement of 2 contiguous dental implants with \> 3mm from each other.
223419114|NCT03341143|DRUG|Fecal Microbiota Transplant with Pembrolizumab|"FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
223419115|NCT01983943|DIETARY_SUPPLEMENT|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
223419116|NCT01983943|DIETARY_SUPPLEMENT|Placebo|A 40mg placebo will be taken once per day for 6 months.
223419117|NCT01983943|BEHAVIORAL|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
223419118|NCT01983943|DEVICE|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
223561966|NCT01398319|BEHAVIORAL|Bystander Intervention|"The 1-hour Bystander intervention was a non-alcohol related briefing that served as the control condition. The intervention focused on increasing Airmen's awareness of the qualities of being a good wingman (e.g., watching for their peers) and how those are tied to the Air Force Core Values. It aimed to increase participants' perceived responsibility to act in certain situations. The intervention draws on the philosophy that members in a community have a role in shifting social norms to prevent violence (Coker et al., 2011). While the intervention did not directly discuss alcohol use, the focus on military values and taking responsibility for one's self and others could contribute to healthier drinking-related choices."
224034849|NCT04585646|DEVICE|Gemini daily disposable contact lens|Subjects will be randomized to wear Gemini lens for 2 weeks.
223419119|NCT06398496|BEHAVIORAL|Aerobic Exercise|Aerobic exercise intervention will involve multiple exercise sessions completed (unsupervised) by participants. Exercise programs will be given to participants, matched to their current level of fitness as determined via a maximal cardiorespiratory fitness test, and will be adjusted via progressive overload every 1-2 weeks by an exercise and sports science professional.
224034850|NCT02736136|BEHAVIORAL|joint observation and video feedback|
224034851|NCT04580797|DRUG|PF-06700841 IR|Immediate release formulation
223419120|NCT06233916|DRUG|[14C] D-1553|\[14C\] D-1553 (approximately 400 mg/80 μCi)
223419121|NCT01951612|BEHAVIORAL|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
223419122|NCT01951612|BEHAVIORAL|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
223419123|NCT04257123|DEVICE|Gelesis100|Participants will administer Gelesis100 before lunch and dinner meals.
223419124|NCT04257123|OTHER|Placebo|Participants will administer a placebo before lunch and dinner meals.
223419125|NCT00685724|BEHAVIORAL|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
223561967|NCT00538967|DRUG|doxycycline|2 weeks once daily
224034852|NCT04580797|DRUG|PF-06700841 MR1|Modified release formulation 1
224034853|NCT04580797|DRUG|PF-06700841 MR2|Modified release formulation 2
224034854|NCT04580797|DRUG|PF-06700841 MR3|Modified release formulation 3
224034855|NCT04580797|OTHER|Placebo|Matching placebo
224034856|NCT05932004|OTHER|Reformer pilates exercise|The reformer Pilates group will receivea 6-week exercise program (45 minutes/twice per week) , while the participants in the control group will be selected from those on the exercise list who will start exercise after the study finishes, but are on a waiting exercise program list
223419126|NCT00685724|BEHAVIORAL|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
223419127|NCT05779033|BEHAVIORAL|scapular stabilization exercises|scapular stabilization exercises 3 times per week for 4 weeks.
223419128|NCT05779033|DEVICE|ultrasound|Ultrasound 3 times per week for 4 weeks.continuous US operated at a frequency of 1 MHz and at an intensity of 1.5 W/cm2 for 5 minutes
224034857|NCT02223403|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
224034858|NCT02223403|DIETARY_SUPPLEMENT|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
224034859|NCT04032769|OTHER|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~\- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
224034860|NCT06050954|DRUG|Pembrolizumab (200mg)|200mg Pembrolizumab every six weeks via IV infusion.
224034861|NCT06050954|DRUG|Pembrolizumab (400mg)|400mg Pembrolizumab every six weeks via IV infusion.
224137261|NCT03733873|DRUG|Desmopressin|take desmopressin for 3 months
224137262|NCT03733873|DRUG|Suoquan|take Suoquan mixture for 3 months
224137263|NCT01822691|DRUG|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
223419129|NCT05779033|OTHER|Kinesio Tape|"Kinesiotape 3 times per week for 4 weeks. We will apply taping to two muscles (deltoideus and supraspinatus). A Y' tape was placed over the deltoid muscle using the muscle stimulation (KT strip arms were located by stretching slightly by 15%-25%) and mechanical correction techniques (KT strip arms were located with maximal stretching). Another Y tape was placed over the supraspinatus muscle using the muscle inhibition technique (the starting point of the tape was attached to the sub acromial-greater tubercle with submaximal (75%) stretching and without stretching on strip arms)."
224137264|NCT01804322|OTHER|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~* The cause and nature of the adverse event and/or drug interaction~* The tolerability profile of each drug present in the schedule~* The clinical manifestations associated with the current drug interactions~* Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~* The reasons for and the potential benefits of the suggested treatment change~* An encouragement to withdraw any potentially interfering or contraindicated drug"
224298586|NCT02293291|DIETARY_SUPPLEMENT|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
223419130|NCT06432075|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
223419131|NCT03655093|OTHER|Validation of AMSQ questionnaire|"Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management."
223419132|NCT05529615|PROCEDURE|detection of ctDNA|the ctDNA will be detected during the treatment and served as the andomization basis
223419133|NCT04024111|BEHAVIORAL|KONTAKT(c)|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes facilitated by two health professionals with experience of running groups for autistic children
223561968|NCT02599207|BIOLOGICAL|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
223561969|NCT04319341|OTHER|To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS|ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
224034862|NCT06050954|DIAGNOSTIC_TEST|Monitoring|active surveillance and monitoring via continued serial ctDNA testing and radiographic assessments at regular intervals.
224034863|NCT00338364|BEHAVIORAL|PAT|Coping and Distraction Intervention
224034864|NCT05878301|OTHER|vegetable and protein first followed by carbohydrates (VPF) meal sequence|vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
224034865|NCT02465463|PROCEDURE|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
224034866|NCT02465463|DEVICE|flexible sigmoidoscopy|
224034867|NCT04720404|BEHAVIORAL|Mindfulness-Based Stress Reduction|Participants in the intervention group will follow a 4-week adapted MBSR training. The training consists of biweekly sessions of 1,5 hours. The training is structured based on the Mindfulness-Based Stress Reduction training as originally designed by John Kabat Zinn. The program includes both formal and informal meditation exercises.
224034868|NCT04720404|OTHER|Self-help mindfulness/compassion exercises|Participants in the self-help group will receive a 4-week program with daily suggestions for mindfulness/compassion exercises of 30 minutes on a YouTube-channel. Participants can schedule the exercises themselves.
224034869|NCT04720404|OTHER|Support as usual|Support as usual (SAU) consists of facilities or interventions already available healthcare organisations provided to their healthcare workers (e.g. buddy-, team- and peer support system, shopping/dinner service etc.).
224034870|NCT01368809|DRUG|Saline|2 ml at induction 1-2 ml boluses as needed
224034871|NCT01368809|DRUG|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
224034872|NCT02719431|DRUG|Warfarin|
224034873|NCT02719431|DRUG|K-877|
224034874|NCT02191020|DRUG|Total glucosides of paeony & Acitretin Capsules|
224034875|NCT02191020|DRUG|Acitretin Capsules|
224137265|NCT01804322|OTHER|usual care|usual care according to the participating Epilepsy Centers
224137266|NCT03408548|PROCEDURE|Scaling root planning|Periodontal treatment
224137267|NCT03408548|DIETARY_SUPPLEMENT|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
224137268|NCT03408548|OTHER|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
224137269|NCT01897922|OTHER|An investigational infant formula containing a probiotic source|
224298587|NCT00143429|DRUG|Xalatan|
223419134|NCT04024111|OTHER|Art group|Art program, a manualized Art group delivered in a social format, has been designed for children on the Autism Spectrum delivered by health professionals with experience of running social groups for Autistic children. The Art program's participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes.
223419135|NCT01082211|RADIATION|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
223419136|NCT06684145|OTHER|Kinesiotape application|Kinesiotape application will be performed by a certified researcher using 5cm x 5cm kinesiotape material. The standing patient, prepared in terms of clothing and skin, will be asked to lean forward. While adhering the tape to the right paravertebral region, the lower end of the tape will be adhered 7 cm below the sacroiliac joint at the level of the paravertebral muscles. The patient, still leaning forward, will be then asked to make a slight rotation to the left; in this position, the tape will be adhered upwards on the paravertebral muscles without any tension. For the left paravertebral region, the procedure will be reversed as compared to the right, ensuring that the tape was not stretched at all.
223419137|NCT06684145|OTHER|Exercise|Patients will be given a 30-day home exercise program. This consists of passive lumbar flexion (single and double leg stretching), hamstring stretching, pelvic tilt, half sit-up, bridge, straight leg raises, and hip and back extensor strengthening exercises.
223419138|NCT06665412|DRUG|Radotinib Hydrochloride|200mg BID, every day up to 12months
223419139|NCT06682195|DRUG|Neoadjuvant chemotherapy combined with Toripalimab|"1, Neoadjuvant Chemotherapy Phase Combined with Toripalimab~1. First Phase of Neoadjuvant Chemotherapy: Epirubicin + Cyclophosphamide + Toripalimab. Administered intravenously: 100 mg/m² Epirubicin + 600 mg/m² Cyclophosphamide + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2. Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab. Administered intravenously: 260 mg/m² Albumin-bound Paclitaxel + 240 mg Toripalimab, every 3 weeks for a total of 6 weeks.~2, Receive Breast Cancer Radical Surgery After 4 Cycles of Neoadjuvant Chemotherapy 3, Postoperative Adjuvant Therapy~1. If pathology indicates pCR: Continue immunotherapy, administering 240 mg Toripalimab intravenously every 3 weeks for a total of 1 year.~2. If pathology indicates non-PCR: Continue postoperative adjuvant chemotherapy combined with Toripalimab.~4, Perform Gene Testing on Biopsy Tissue Before Treatment, and Collect Blood Samples for ctDNA Testing Before and After Treatment."
223419140|NCT03834766|DRUG|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
223419141|NCT03834766|DRUG|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
224034876|NCT02804243|DEVICE|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
224137270|NCT01897922|OTHER|Control: Marketed routine infant formula|
224137271|NCT04872816|DEVICE|Continuous airway positive pressure|The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
224137272|NCT03734081|DEVICE|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
224137273|NCT03734081|DEVICE|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
224137274|NCT04123717|DRUG|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
224137275|NCT01553916|DRUG|Lithium Carbonate|
224137276|NCT01553916|RADIATION|Prophylactic cranial irradiation|
223419142|NCT05713396|DRUG|Quinapril|Per os
223419143|NCT05713396|DRUG|Losartan|Per os
224034877|NCT01606020|OTHER|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
224034878|NCT01606020|OTHER|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
224034879|NCT03864445|DRUG|KHK7791|oral administration
224034880|NCT03864445|DRUG|Placebp|oral administration
224137277|NCT02569619|BEHAVIORAL|Activity Intervention|
224137278|NCT02569619|BEHAVIORAL|Healthy Diet Intervention|
224137279|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
223419144|NCT05713396|DRUG|Quinapril + Losartan|Per os
223419145|NCT03753919|DRUG|Durvalumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
223419146|NCT03753919|DRUG|Tremelimumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
223419147|NCT06682819|DIAGNOSTIC_TEST|Optical coherent tomography|We compare the metabolomics profile of healthy patients based on the OCT appearance of the optic disc and RNFL
223419148|NCT04623034|DRUG|Ademetionine|
223419149|NCT00059696|PROCEDURE|Constraint-Induced Movement Therapy|
223419150|NCT02374710|PROCEDURE|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
223419151|NCT02374710|PROCEDURE|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
223419152|NCT05996341|DEVICE|blood flow restriction|12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
223419153|NCT05851313|COMBINATION_PRODUCT|Vitamin-D|The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
223419154|NCT00002641|BIOLOGICAL|filgrastim|
224034881|NCT04559204|BIOLOGICAL|IIV4 and PPV23|imultaneously immunization of 23-valent pneumococcal polysaccharide vaccine (PPV23) and quadrivalent inactivated influenza vaccine (IIV4)
224034882|NCT04559204|BIOLOGICAL|IIV4|administrated with IIV4 only
224034883|NCT04559204|BIOLOGICAL|PPV23|administrated with PPV23 only
224034884|NCT05303870|OTHER|Improving access to psychological therapies (IAPT)|"IAPT services provide evidence-based treatments for people with depression and anxiety disorders, and comorbid long-term physical health conditions or medically unexplained symptoms. IAPT services are characterised by three key principles:~1. Evidence-Based psychological therapies at the appropriate dose: NICE recommended therapies matched to the mental health problem, at the intensity and duration designed to optimise outcomes.~2. Appropriately trained and supervised workforce.~3. Routine outcome monitoring."
223419155|NCT00002641|DRUG|doxorubicin hydrochloride|
223419156|NCT00002641|DRUG|ifosfamide|
223419157|NCT00002641|DRUG|isolated perfusion|
223419158|NCT00002641|PROCEDURE|adjuvant therapy|
223419159|NCT00002641|PROCEDURE|conventional surgery|
223419160|NCT00002641|RADIATION|radiation therapy|
223419161|NCT05127213|PROCEDURE|Intragastric balloon system|Intragastric balloon system (PA450) developed and produced by Changzhou Zhishan Medical Technology Co., Ltd. It is a swallowable capsule intragastric balloon.The degradable material on the intragastric balloon can be degraded naturally, and the balloon is naturally discharged from the body through the gastrointestinal tract
224034885|NCT01115842|DRUG|Vitamin D|Vitamin D 4000IU per day for 5 days
224034886|NCT02228655|DRUG|FMX-8|
224034887|NCT04395703|OTHER|Interviews and focus groups|Unstructured and semi-structured interviews with open ended questions.
224034888|NCT04496063|DRUG|Ustekinumab|Intravenous induction (6mg/kg) followed by Ustekinumab subcutaneous 90mg every 8 weeks
224034889|NCT04496063|DRUG|Placebo|Placebo intravenous followed by Placebo subcutaneous every 8 weeks
224034890|NCT02807792|DEVICE|Perianal access device|Perianal access device
224034891|NCT02905994|DRUG|Volasertib|Polo-Like Kinase Inhibitor
224034892|NCT02905994|DRUG|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
224034893|NCT02905994|DRUG|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
224034894|NCT02905994|PROCEDURE|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
224034895|NCT01487031|OTHER|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
224034896|NCT01487031|OTHER|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
224034897|NCT01414777|DRUG|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
224034898|NCT01414777|DRUG|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
224034899|NCT03622853|DRUG|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
223419162|NCT05127213|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy is the use of laparoscopy to cut out the greater curvature of the stomach, mainly for weight loss.
223419163|NCT02866149|BIOLOGICAL|Blood sampling|Up to 5 blood samplings can be performed at different time points
223419164|NCT02866149|PROCEDURE|Tumor sampling|One tumor sampling can be performed, if applicable
223419165|NCT02866149|OTHER|Stool sampling|Up to 5 blood samplings can be performed at different time points
223419166|NCT03933618|DRUG|Anastrozole 1mg|
223419167|NCT03933618|DRUG|Clomiphene Citrate 25mg|
223419168|NCT03933618|DRUG|Placebo - Cap|
223419169|NCT01080118|DEVICE|Airtraq|Subjects were taught with the Airtraq video laryngoscope
223419170|NCT01080118|OTHER|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
223419171|NCT00510913|DRUG|tacrolimus|
223419172|NCT06667258|DEVICE|Ear ECG/PPG sensors|Medical graded electrodes placed in the mastoid, in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes, off-the-shelf pulse oximeter placed behind the ear
224034900|NCT01067326|DRUG|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
224034901|NCT01067326|DRUG|Placebo|1 pill per day by mouth for 4 months
224034902|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
224137280|NCT06241755|DRUG|BCG for Therapeutic Use|"Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h."
223419173|NCT05283902|BIOLOGICAL|ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine|In a Technical Note, the State of Espírito Santo decided to recommend the application of the fourth dose with vaccines using messenger RNA (mRNA) technology or viral vector vaccine, for all people aged 60 years or older, with an interval of 90 days from of the third dose, considering that, while there is no availability of vaccines adapted to the new variants, boosters with available vaccines are still the most appropriate ways to prevent hospitalization and deaths.
223419174|NCT06683690|PROCEDURE|Measurement of TGF- β1 in leprosy patients|Study TGF- β1gene polymorphism in leprosy patients, and Correlate their results with different types of leprosy before and after treatment.
223419175|NCT01744379|DRUG|Lesinurad|
223419176|NCT01744379|DRUG|Placebo|
223419177|NCT04016779|DRUG|Placebo|Placebo will be administered once daily
223419178|NCT04016779|DRUG|SPN-812|SPN-812 will be administered once daily and compared to Placebo
223419179|NCT02295020|DRUG|Standard treatment only|Standard treatment such as NSAIDs and injections
223561970|NCT01152255|DRUG|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose \<= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose \<= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
223561971|NCT01152255|DRUG|Comparator: Placebo|Placebo tablets taken orally for seven day
224034903|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
224034904|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
224137281|NCT00583323|DRUG|Lomotil|Orally 10ml of Lomotil
223419180|NCT02295020|DEVICE|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
223419181|NCT01511874|DRUG|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
223561972|NCT02745782|OTHER|Observational Study|Observational Study
223561973|NCT03859440|DEVICE|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
223561974|NCT03859440|DEVICE|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
224034905|NCT00696761|DRUG|Alfuzosin|10mg, once daily, 12months
224034906|NCT06294522|PROCEDURE|reconstruction of alveolar cleft|after elevation of mucoperiosteal flap related to cleft side. suturing of nasal floor and palatal tissue. harvesting of autogenous graft and reconstruction of nasal floor and labial plate of cleft then suturing of flap labially without tension
224034907|NCT02623881|DEVICE|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
224034908|NCT02623881|DRUG|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
224034909|NCT00000274|DRUG|Flupenthixol|
224034910|NCT01230788|DRUG|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
224034911|NCT06372028|DEVICE|transcutaneous vagus nerve stimulation (tVNS)|tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
224137282|NCT00583323|OTHER|Normal saline|10 ml orally
223419182|NCT01604980|DIETARY_SUPPLEMENT|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
223419183|NCT00312260|DRUG|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
223419184|NCT00312260|DRUG|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (\~2000h) for the first 3 days, one pill at night and one pill in the morning (\~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (\~1400h) for the reminder of the trial.
223419185|NCT02740868|DRUG|Xenon-129 and Perfluoropropane (19F)|Xenon gas and perfluoropropane to be inhaled by research participants
223419186|NCT02740868|DEVICE|Magnetic Resonance Imaging|Lung imaging will be performed for participants using MRI for all 3 arms
223419187|NCT02740868|DEVICE|Lung Clearance Index|Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
223561975|NCT00733837|OTHER|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
224137283|NCT01015664|DRUG|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
223419188|NCT03572816|DEVICE|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
223419189|NCT03046316|OTHER|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
223419190|NCT02658955|PROCEDURE|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
223419191|NCT02721810|BEHAVIORAL|Consideration of 3-month functional prognosis|
223419192|NCT03776110|DRUG|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
223419193|NCT03776110|DRUG|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
223419194|NCT05971238|OTHER|Indoor vs. outdoor scenes|Light conditions in indoor (artificial light) and outdoor (daylight) settings
223561976|NCT04686851|OTHER|Comprehensive Geriatric Assessment and follow-up|"All patients will receive standardized oncological treatment according to national guidelines. For patients randomized to the intervention arm, a full Comprehensive Geriatric Assessment (CGA) and corresponding interventions on identified health issues will be performed alongside oncologic treatment. The domains are assessed using validated tests based on a Danish version of the Geriatric Core Dataset (G-CODE). The domains are cognition, mood, comorbidity, functional status, physical status, polypharmacy, nutrition, fall risc and social support. The CGA will be performed by the PhD-student (geriatric resident) or a geriatrician together with geriatric nurses at the Department of Geriatric Medicine, OUH. Nutritional status and interventions are assessed by a dietician. A physical therapist will evaluate the physical performance as part of the CGA.~Follow-up on initial treatment plan is scheduled to one month after baseline CGA."
223561977|NCT00473668|BIOLOGICAL|Zilbrix-Hib|Intramuscular injection, 1 dose
223561978|NCT00473668|BIOLOGICAL|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
224034912|NCT05997251|OTHER|Keeping a 1-day food consumption record by the patient|Checking and receiving the 1-day food consumption record recorded by the patient by the researcher
224034913|NCT05997251|OTHER|Measurement of adiponectin level|Adiponectin level will be measured for each group
224034914|NCT00443638|BEHAVIORAL|nurse home visitation|Nurse home visitation
224137284|NCT01015664|DRUG|cisplatin|75 mg/m2 IV over 60 minutes on day 1
224137285|NCT01015664|DRUG|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
223419195|NCT05279235|DRUG|JT001|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
223419196|NCT05279235|DRUG|JT001 placebo|Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days
223561979|NCT01952548|DRUG|K-312|
223561980|NCT01952548|DRUG|Placebo|
223561981|NCT02965183|OTHER|Temperature measurements|
223561982|NCT02226562|DRUG|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
223561983|NCT02226562|DRUG|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
223561984|NCT03902457|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
224137286|NCT04626843|OTHER|Intermittent fast|16/8 fasting method: fast for 16 hours of the day with an 8 hours feeding window for a duration of 3 months.
223419197|NCT05279235|DRUG|Favipiravir|Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
223561985|NCT06283940|OTHER|Physiotherapist-led exercise based cardiac rehabilitation (PT-X)|Individually prescribed centralcirculatory aerobic exercise and muscular endurance training twice a week for 60 minutes each session over 12 weeks in a hospital-based setting, and two sessions of home-based exercise recorded in an exercise diary.
223561986|NCT03257202|DRUG|Clindamycin 1% Gel|topical clindamycin
223561987|NCT03257202|DRUG|Benzoyl peroxide 5% gel|topical benzoyl peroxide
223561988|NCT03257202|DRUG|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
224034915|NCT03786939|PROCEDURE|On-pump CABG.|On-pump coronary artery bypass grafting.
224034916|NCT03786939|PROCEDURE|Off-pump CABG.|Off-pump coronary artery bypass grafting.
224034917|NCT03786939|PROCEDURE|Pump-assisted CABG.|Pump-assisted CABG.
224298588|NCT02140307|BEHAVIORAL|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
223419198|NCT05279235|DRUG|Favipiravir placebo|Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
223419199|NCT06215989|DRUG|Colchicine Pill|Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines
223419200|NCT06215989|DRUG|Placebo|Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
223419201|NCT03394898|OTHER|body mass index, eating behaviour|The patients' weights and heights will be measured and the body mass index will be calculated from the measured values.Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
224034918|NCT03739541|DRUG|[14C]-Benznidazole|A single dose level of 100 mg; 200 μCi (7.4 MBq)
224034919|NCT06472583|DRUG|Keytruda|Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
224034920|NCT06472583|RADIATION|Preoperative radiation therapy|Boost of preoperative robotic stereotactic radiotherapy
224034921|NCT06472583|DRUG|Placebo|0,9% NaCl in the volume 100 ml
224034922|NCT01629784|BEHAVIORAL|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
224034923|NCT03854396|DRUG|Prasterone|Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
224034924|NCT03854396|DRUG|Placebo|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
223561989|NCT04147897|DEVICE|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
224137287|NCT00230100|BEHAVIORAL|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
224137288|NCT00230100|BEHAVIORAL|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
223561990|NCT00562497|DRUG|Prochymal®|Prochymal® intravenous infusion.
224034925|NCT03885830|DRUG|Bosutinib|Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
224034926|NCT03885830|DRUG|Dasatinib|Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
224034927|NCT03885830|DRUG|Imatinib|Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
224034928|NCT03885830|DRUG|Nilotinib|Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
224034929|NCT06509178|OTHER|Peyton group|The same procedures were applied to the students in the experimental group as the students in the control group, except for laboratory applications. Students were asked to watch the video contents after the theoretical course, and in the laboratory practice, sterile urinary catheter application was taught to the students according to Peyton's 4-step approach. Before the skill demonstration, students were given information about the research. Students were given 15-20 minutes to fill out the voluntary consent form and the urinary catheterization success pre-test. Students were taught the sterile urinary catheter procedure in accordance with Peyton's 4-step approach.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
224137289|NCT05403749|BIOLOGICAL|dose 1 IBI302|After 4 loading monthly intravitreal injections of dose 1 IBI302，the following IBI302 IVT is given as descript in protocol.
224137290|NCT05403749|DRUG|Aflibercept|Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
224298589|NCT00144911|DRUG|Salmeterol|
224034930|NCT06509178|OTHER|Halsed group|After the control group students attended the course in accordance with the routine procedures, the students were asked to watch videos of the online urinary catheter application course and the students were taught how to apply sterile urinary catheter using the Halsted method (see one and do it), which is traditionally used in laboratory practice. Students were informed about the research and voluntary consent forms were obtained. Students were given 15-20 minutes to complete the urinary catheterization success pre-test. During the demonstration, the students' questions were answered, the researcher went over the points that the student did not understand, corrected any incorrect behavior, and gave feedback. Afterwards, each student was asked to demonstrate the skill steps individually.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
224034931|NCT00959972|DRUG|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
224034932|NCT00959972|DRUG|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
224034933|NCT06502899|OTHER|Cardiac MRI|Patients with a diagnosis of MINOCA and completed CMR were included in this study
224298590|NCT00144911|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
224298591|NCT00975403|DEVICE|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
224298592|NCT00975403|DEVICE|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
224298593|NCT06085118|OTHER|Pepticate® Syneo®|Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
223561991|NCT00562497|OTHER|Placebo|Placebo-matching Prochymal® intravenous infusion.
223561992|NCT00562497|OTHER|Corticosteroid|Administration will be intravenously as prescribed by the caregiver.
223561993|NCT04187508|DRUG|AZD8154 nebulizer suspension, 20 mg/mL|Subjects will receive AZD8154 from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing and delivered dose will be 3mg.
223561994|NCT04187508|DRUG|Placebo|Subjects will receive AZD8154 matching placebo (placebo nebulizer suspension, glucose solution for infusion 50 mg/mL) QD from Day 1 to Day 10 (10 consecutive days) by using nebulizer and dosimeter system as inhaled dosing.
223561995|NCT04424628|RADIATION|Low dose radiotherapy A|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
223561996|NCT04424628|RADIATION|Low dose radiotherapy B|Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
223561997|NCT05196230|DEVICE|Control Condition (Social Story)|The control condition is a social story, which is treatment as usual for preparing clients for their initial visit at Holland Bloorview's dental clinic. The control condition will be delivered through the study tablet. The investigators will ask parents to read it to their child once a day for the week leading up to their appointment. If the child is reading on their own, the investigators will request that parents be in the room with participants while they are. The social story takes approximately five minutes to read.
223561998|NCT05196230|DEVICE|Experimental Condition (360° Video)|The 360° video is from the point of view of a seated dental client and the participant will be able to explore the scene around them (navigating through the tablet's touch screen). The simulation will include scenes/features that may be anxiety-provoking for some participants. These will include loud noises commonly encountered in the dentist's office (e.g. tooth brushing, dental drills), as well as social stimuli (e.g. the dental clinician), and new environments (e.g., the dental visit room). The investigators will ensure that participants understand that they can stop at any time (e.g., if they are feeling anxious or overwhelmed), and the investigators will ask parents to explore the 360° video with their child for the week leading up to their appointment.
223561999|NCT06484257|BEHAVIORAL|Myopia|Participants in this arm would receive progressive addition lenses specifically designed to correct myopia. These lenses would typically have a prescription for correcting nearsightedness (myopia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
223562000|NCT06484257|OTHER|Hypermetropia|Participants in this arm would receive progressive addition lenses specifically designed to correct hypermetropia. These lenses would typically have a prescription for correcting farsightedness (hypermetropia) in addition to any other vision corrections needed, such as astigmatism correction and presbyopia. The participants would wear these lenses while using computers according to the study protocol.
223562001|NCT01474772|DRUG|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
223562002|NCT01474772|OTHER|placebo|matching placebo capsules given in 3 divided doses
223562003|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 12
223562004|NCT01637636|DRUG|tasimelteon|20mg, oral capsule, once, Days 1 and 6
223562005|NCT01637636|DRUG|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
223562006|NCT01637636|DRUG|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
224034934|NCT06057545|DRUG|Envarsus®|Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
223562007|NCT00649766|BEHAVIORAL|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
223562008|NCT00649766|BEHAVIORAL|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
224034935|NCT06057545|DRUG|Prograf|Treatment sequence: 4 weeks intermediate-release tacrolimus (Prograf®) twice daily
224034936|NCT01938807|BEHAVIORAL|CareCoach mobile application to assist in diabetes management|
224034937|NCT03270332|DRUG|Albuterol|inhalation of 270μg albuterol through a spacer
224034938|NCT03270332|DRUG|Placebo|inhalation of placebo through a spacer
224034939|NCT05374720|PROCEDURE|salpingectomy|Removal of one of the fallopian tubes.
224137291|NCT05403749|BIOLOGICAL|dose 2 IBI302|After 4 loading monthly intravitreal injections of dose 2 IBI302，the following IBI302 IVT is given as descript in protocol
224137292|NCT04593693|DEVICE|Invia Motion Endure NPWT system|lightweight portable single patient use pump, that provides continous or intermittent operation and multiple negative pressure selection options
224034940|NCT05374720|PROCEDURE|hysterectomy|remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.
224034941|NCT04641507|DRUG|Tadalafil versus tamsulosin as MET|166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
224137293|NCT03455309|BIOLOGICAL|NDV-3A|Single dose administered by intramuscular injection
224034942|NCT02248220|DRUG|Pramipexole|
224034943|NCT01367964|DRUG|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
224137294|NCT03455309|BIOLOGICAL|Placebo|Single dose administered by intramuscular injection
224137295|NCT03615911|BIOLOGICAL|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
224137296|NCT05764278|OTHER|exercise|exercise group: first bed exercise after 0\~24hr onset ; sit at bed after 24\~48hr onset control group: first bed exercise after 24\~48hr onset ; sit at bed after 48\~72hr onset
224137297|NCT04123756|BEHAVIORAL|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
224137298|NCT00053261|PROCEDURE|management of therapy complications|
224137299|NCT01287533|DRUG|Ibandronate|monthly dosage of ibandronate 150mg
224137300|NCT01287533|DRUG|Placebo|monthly dosage of placebo
224137301|NCT01390961|DRUG|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
224137302|NCT05941351|PROCEDURE|flap fixation|flap fixation using running or interrupted sutures
224137303|NCT01783717|DRUG|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
224137304|NCT04465396|DRUG|Teduglutide|Participants received 3 mg or 4 mg of Teduglutide SC syringe injection followed by pen injector or vice versa depending upon the treatment sequence AB or BA on Day 1 of Treatment Periods 1 and 2.
224137305|NCT04465396|DEVICE|Syringe Injection|Teduglutide was administered using syringe.
224137306|NCT04465396|DEVICE|Pen injector|Teduglutide was administered using pen injector.
224137307|NCT02648724|DRUG|Sym015|Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
224137308|NCT02821455|PROCEDURE|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
224137309|NCT00547638|DEVICE|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
224137310|NCT00547638|DEVICE|cyanoacrylate|Topical Skin Adhesive
223562009|NCT01112774|DEVICE|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
223562010|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
223562011|NCT06100848|DIAGNOSTIC_TEST|Microbiological analysis after Caries treatment and fumigation|Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
223562012|NCT06511596|OTHER|BR-AC|BR-AC is an amnion layer, intermediate layer, and chorion layer placental membrane processed together with no separation of the layers. BR-AC is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.
223562013|NCT06511596|OTHER|Standard Care|"Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device."
223562014|NCT00223808|OTHER|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
223562015|NCT00223808|OTHER|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
223562016|NCT00223808|OTHER|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
223562017|NCT00000467|BEHAVIORAL|diet|
224034944|NCT05761730|DRUG|Dexamethasone Oral|For a patient suffering from an irreversible pulpitis on a lower mandibular molar , 4mg of dexamethasone are administered at baseline , after inferior alveolar nerve block injection and 4mg are administered 8 hours after the first dose at office
223562018|NCT00000467|BEHAVIORAL|exercise|
223562019|NCT00000467|BEHAVIORAL|smoking cessation|
223562020|NCT01588340|PROCEDURE|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
223562021|NCT01588340|PROCEDURE|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
224034945|NCT05483400|DRUG|Tiragolumab and atezolizumab|three weekly tiragolumab 1200 mg intravenous plus tiragolumab 600 mg intravenous.
224034946|NCT01348386|DRUG|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
223562022|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
223562023|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
223562024|NCT01131429|DRUG|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
223562025|NCT01131429|DRUG|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
223562026|NCT01131429|DRUG|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
223562027|NCT01131429|DRUG|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
224034947|NCT01348386|DRUG|Placebo|
224137311|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc Q3W combination with gemcitabine and cisplatin.
224137312|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|JS001sc long period combination with gemcitabine and cisplatin.
224137313|NCT05751486|BIOLOGICAL|Toripalimab /JS001|JS001 IV (if applicable) .
224298594|NCT05829213|PROCEDURE|"arch-bridge-type esophagogastric reconstruction after proximal gastrectomy"|"1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. Creating the seromuscular flap (arch-bridge)~4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis."
224298595|NCT02623348|BEHAVIORAL|pedometer|pedometer-based physical activity recommendations
223562028|NCT05699252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT intervention will be used to help participants learn about the role of cognitions (particularly pain catastrophizing), pain beliefs (including perceived control), and maladaptive or unhelpful coping behaviors in chronic pain. This technique will help participants: (1) identify and change or restructure unhelpful or negative thinking about pain; (2) utilize positive coping strategies including positive coping self-statements; relaxation techniques; behavioral activation (including setting goals for activation), activity pacing and scheduling; and (3) cope with pain flare-ups.
224137314|NCT05751486|BIOLOGICAL|Toripalimab injection(subcutaneous)/JS001sc|Additional cohort (if applicable)
224137315|NCT04198324|PROCEDURE|Closure of the uterus with endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed with suturing the endometrium.
224137316|NCT04198324|PROCEDURE|Closure of the uterus without endometrium at the time of cesarean|Closure of the uterus at the time of primary cesarean will be performed without suturing the endometrium.
224137317|NCT00042484|PROCEDURE|Community-level intervention & policy change|
224298596|NCT05870137|DEVICE|HoloLens2TM|Participants assigned to Mixed Reality-supported care used the HoloLens2 device, which provided support using technology that was permitted by the device. This support included remote assistance and holographic versions of patient-specific investigation results, such as radiological findings, biochemistry, and guidelines for completing the procedure (insertion of chest drain).
224298597|NCT05870137|OTHER|Standard care|The standard care for the intervention involved participants performing the invasive technical procedure to treat a tension pneumothorax using their standard clinical skills and knowledge, without the aid of the HoloLens2 device. The participants in the standard care group did not receive any additional support or guidance beyond what is typically available in a clinical setting. The goal of the study was to compare the effectiveness of the standard care approach with the use of Mixed Reality-supported care using the HoloLens2 device.
224298598|NCT00857259|DRUG|Everolimus|5 mg oral tablet
224298599|NCT00857259|DRUG|Ranibizumab|0.5 mg administered by intravitreal injection
223419202|NCT06662461|PROCEDURE|ultrasound guided Greater occipital nerve block|"Patients will be positioned in a prone position with their neck slightly flexed.~The trapezius , semispinalis, obliqus capitis muscles will be revealed on short-axis view.~A 25- or 21 gauge is used, with puncture point 1-1.5 cm away from the ultrasound probe.~Under the guidance of the ultrasound, GOB will performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine."
224034948|NCT02918760|DRUG|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
223419203|NCT06662461|PROCEDURE|Ultrasound guided Stellate ganglion block|"Patients are positioned in a lateral position with their necks slightly hyperextended. Assisted by ultrasound imaging equipment the C7 level is confirmed. The thyroid gland, carotid artery, compressible internal jugular vein, vertebral artery, brachial plexus and the oval-shaped structure of the longus collis muscle are revealed on this short-axis view.~A 25- or 21 gauge is used and the puncture point is 1-1.5 cm away from the ultrasound probe The tip of the needle reach the surface of the longus collis muscle and the 5 o'clock position of the carotid artery. Under the guidance of the ultrasound, SGB is performed by injection using 40 mg triamcinolone and 1ml of 2% lidocaine."
223419204|NCT05160246|OTHER|kinesiology tape|The tape will be fixed without any tension 10 cm below the origin of the rectus femoris muscle. Then 35-50% tension will be applied to the band and descended to the patella. After this point, the Y-shaped band will be terminated to wrap the patella medially and laterally without any tension.
223419205|NCT05160246|OTHER|Placebo tape|The tape will attach to the rectus femoris without any tension.
223419206|NCT01946958|BEHAVIORAL|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
223419207|NCT01946958|OTHER|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
223419208|NCT04310605|BEHAVIORAL|CBT 1|CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
223419209|NCT04310605|BEHAVIORAL|CBT 2|Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
223419210|NCT00001016|DRUG|Trimetrexate glucuronate|
223419211|NCT00001016|DRUG|Leucovorin calcium|
223419212|NCT01183208|DRUG|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
223419213|NCT01183208|DRUG|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
223419214|NCT01183208|DRUG|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
223419215|NCT01183208|DRUG|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
224034949|NCT02918760|OTHER|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
224034950|NCT03836755|DIAGNOSTIC_TEST|Metacos|Evaluation of stability of implant by RSA technique
224137318|NCT03076190|BEHAVIORAL|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
223419216|NCT01183208|DRUG|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
223562029|NCT05699252|BEHAVIORAL|Hypnotic Cognitive Therapy (HYP-CT)|The HYP-CT intervention will be used to help participants learn about the role of hypnosis to reduce pain, increase comfort and well-being, and to instill and reinforce healthy, adaptive cognitions. This technique will help participants to use their ability to enter a state of focused attention to then increase their acceptance of new adaptive ideas about pain provided both by (1) clinicians during sessions and on audio recordings, as well as (2) the participants themselves during self-hypnosis practice.
223562030|NCT05699252|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will be used to help participants learn about the role of MBCT in training the mind to respond more adaptively to pain. This technique will help participants: (1) apply the skills they learn not only to pain but also to the problems pain causes for them, including sleep disturbance, depressed mood, stress, and other problems; (2) build on their strengths and their innate ability to focus their attention at will, and to use this ability to mindfully perceive experience in a non-judgmental, non-reactive way; and (3) notice their moment-to-moment experience and to shift their relationship to this experience. With enhanced mindful awareness comes the opportunity to then mindfully choose how to respond to the pain in a way that reduces stress and is most helpful or adaptive.
223562031|NCT05365061|OTHER|periosteal electrical dry needling with no maintenance treatments|periosteal electrical dry needling
223562032|NCT05365061|OTHER|periosteal electrical dry needling with maintenance treatments every other month|periosteal electrical dry needling with maintenance treatments every other month
223562033|NCT05365061|OTHER|periosteal electrical dry needling with monthly maintenance treatments|periosteal electrical dry needling with monthly maintenance treatments
223562034|NCT03153644|BEHAVIORAL|Interview|1 hour semi-structured
223562035|NCT03153644|BEHAVIORAL|Observation|Field Observation
223562036|NCT00724269|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
223562037|NCT00724269|DEVICE|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
223562038|NCT05281328|DRUG|CAM2029|SC injection using a pre-filled pen
223419217|NCT06966973|OTHER|Polysomnograpy|All successive patients who underwent polysomnography
223419218|NCT02079467|PROCEDURE|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
223419219|NCT02079467|PROCEDURE|Standard rehabilitation|Standard care range of motion restrictions will remain in place
223419220|NCT01590121|OTHER|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
223419221|NCT01590121|OTHER|Questionnaire|Flight by aeroplane (previous)
223419222|NCT00759460|DRUG|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
223419223|NCT00759460|DRUG|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
223419224|NCT01925066|DRUG|Vancomycin|
224034951|NCT02294123|OTHER|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
224034952|NCT06331780|DEVICE|Visual acuity|VA will be measured with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
224034953|NCT06331780|DEVICE|Objective refraction|Objective refraction will be measured using an auto-kerato-refractometer/aberrometer
223419225|NCT01488422|BEHAVIORAL|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
223562039|NCT05281328|DRUG|Placebo|SC injection using a pre-filled pen
223562040|NCT01991080|BEHAVIORAL|biofeedback|Patients will go through biofeedback sessions
224034954|NCT06331780|DEVICE|Objective monocular accommodation amplitude measurement|Objective monocular accommodation amplitude measurements are obtained dynamically by measuring the subject's dioptric change while the participant focuses on a virtual object that moves from distance
224034955|NCT06331780|DEVICE|"Subjective monocular accommodation amplitude measurement with the Push-Up method"|"The subjective monocular accommodation amplitude measurements are carried out by the push-up method and proceeds as follows:~* The ECP presents a near vision test card corresponding to a 0.8 (8/10) acuity line, or the smallest readable line if acuity is poor, or the smallest readable text.~* Instructions to the subject: Look at the smallest line of letters and try to see them clearly for as long as possible when I bring them closer; tell me when they start to blur and stay blurred.~* The ECP slowly brings the test card closer~* The ECP note the distance of the test card from the glasses as soon as the vision is blurred. Continue to move the test closer to check that vision remains blurred.~The amount of accommodation in this eye is equal to the proximity (= 1/distance) of the test when the blur is just perceived."
224034956|NCT06331780|DEVICE|"Subjective monocular accommodation facility measurement with the Rock method:"|"The subjective monocular accommodation facility measurements are carried out by the Rock method and proceeds as follows:~* The ECP presents at 40cm a near vision test card corresponding to 80% of the VA.~* The ECP gives to the participant a flipper +/- 2 Dioptre~* Instructions to the subject: Look at the test and add the -2.00 D (Sphere) flipper, as soon as it's clear, return the flipper to present a +2.00 D (Sphere), as soon as it's clear, return the flipper etc… You have to do the maximum number of rotations in one minute."
224034957|NCT06331780|OTHER|CISS Questionnaire|This questionnaire relating to the use of the near vision will be submitted
224137319|NCT02461836|DRUG|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
223419226|NCT02069912|BEHAVIORAL|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
223419227|NCT06499610|DRUG|Irinotecan Hydrochloride Liposome Injection|At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.
224137320|NCT02461836|RADIATION|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
223419228|NCT06966999|PROCEDURE|Botulinum Toxin Type A Injection [Botox]|for patients \>12 years presenting with large-angle esotropia (\>50 PD), primary surgical intervention was recommended as the preferred approach to minimize failure and recurrence risk. Conversely, for patients ≤12 years, BTXA injection was maintained as the first-line treatment regardless of the deviation angle.
223419229|NCT06438523|PROCEDURE|PULPOTOMY OF MATURE PERMENANT TEETH|Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp
223419230|NCT01376921|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
223562041|NCT01991080|DRUG|Wheatgerm juice|Patient will drink wheatgerm juice
223562042|NCT03195660|DEVICE|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
223562043|NCT00961246|BEHAVIORAL|general health information|participants received general health information
223562044|NCT00961246|BEHAVIORAL|individually-tailored intervention|participants received individually-tailored intervention
223562045|NCT03713294|DRUG|Dexamethasone|Given IV and PO
223562046|NCT03713294|BIOLOGICAL|Elotuzumab|Given IV
223562047|NCT03713294|DRUG|Pomalidomide|Given PO
223562048|NCT05260073|DRUG|Tirbanibulin|Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
223562049|NCT03458910|BEHAVIORAL|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
223562050|NCT04800575|DEVICE|semi-permeable film|Experiment group use semi-permeable film as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or or whenever the dressing is soiled, bloody, or fell off.
223562051|NCT04800575|DEVICE|sterile gauze and tape|Control group use sterile gauze and tape as dressing in exit-site of CVC and dressings will be changed per hemodialysis session, or whenever the dressing is soiled, bloody, or fell off.
223562052|NCT06381063|DRUG|pain management|o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin
223562053|NCT06381063|DRUG|ketoprofen|Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration
223419231|NCT01307137|BEHAVIORAL|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~* Weight management success is defined as a loss of at least 5% of the weight since enrollment~* Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
223419232|NCT01307137|BEHAVIORAL|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
223419233|NCT06586788|DIAGNOSTIC_TEST|Eyelink Portable Duo|Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on a caregiver's lap and will face a computer monitor. After a sticker is applied to the child's forehead and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.
223419234|NCT06586788|DIAGNOSTIC_TEST|Integrated PCP Diagnosis and Eye-tracking Biomarker|A Classification and Regression Tree (CART) Analysis, based on recursive partitioning, was used to determine which combination of variables (EE Hub PCP diagnosis, diagnostic certainty, composite biomarker, and biomarker frequency \[sum of all individual biomarkers (0-6) that exceeded the 95% specificity threshold for each child\]) best predicted reference standard autism diagnosis.
223419235|NCT03613909|DEVICE|CP950 OTE Sound processor|CP950 is Off The Ear (OTE) Cochlear Implant Sound Processor
223419236|NCT00993343|DRUG|Sirolimus/tacrolimus|Standard GVHD prophylaxis
223419237|NCT00993343|DRUG|cyclosporine/methotrexate|Standard GVHD prophylaxis
223419238|NCT03200730|BEHAVIORAL|Family Dignity Intervention group|A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
223419239|NCT05885035|DRUG|Calcium Hydroxyapatite|Each syringe of CaHA contains 1.5 cc of product, and it will be diluted 1:1 with 1.0 cc of normal saline solution and 0.5 cc of 1% Lidocaine with a ratio of 1:100,000 epinephrine in the target sites.
223419240|NCT03944759|PROCEDURE|serratus anterior plan block|serratus anterior plan block
223419241|NCT05501015|OTHER|Ice chips|Consuming small amounts of ice chips with supervision
223419242|NCT00783315|BEHAVIORAL|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
223562054|NCT06381063|DRUG|PLacebo|Placebo twice a day, during 48 h after surgery, intravenous administration
223562055|NCT05023980|DRUG|Pirtobrutinib|Oral
223562056|NCT05023980|DRUG|Bendamustine|IV
223562057|NCT05023980|DRUG|Rituximab|IV
223562058|NCT04484649|BEHAVIORAL|Sleeping Healthy/Living Healthy|Sleeping Healthy/Living Healthy will be a school based health center (SBHC)-based intervention integrating mind-body integrative health (MBIH) and sleep hygiene strategies to improve sleep quality in urban adolescents. The Sleeping Healthy/Living Healthy intervention content and format will be determined in a Development Phase 1. The investigator anticipates the intervention will consist of two group and two one-on-one sessions. The intervention will be grounded in social-cognitive theory and use motivational interviewing to support MBIH and sleep hygiene strategies. Sessions will be delivered once per week by SBHC providers and health educators.
223739368|NCT07205354|OTHER|Cross-sectional study|"For each patient (new set of 174 patients)~* the DYSPHAGING preferences questionnaire (including previously adapted pictures) will be assessed and preference indexes will be determined.~* In addition, for each patient, collection of geriatric covariates obtained in routine care will be performed for analyses ( demographic characteristics (age, sex, functionality according to the activity of daily living (ADL)8 and instrumental ADL6 scores), local and factors affecting taste, mastication or dietary patterns (dental condition/dental apparatus, alcoholism, smoking, food allergies, comorbidities, treatments), nutritional status (ideal and current weight/height/BMI, albumin, pre-albumin, Vitamins B12, B9, D), comedications (as described as according to the galenic form and drug class prescribed) and swallowing disorders (EAT-10 score with cut-off of 3)"
224034958|NCT06331780|OTHER|Difficulty assessment questionnaire|After each near vision measurement, the participant should rate, on a Visual Analogic Score (0-10), the difficulty encountered, from 0: extremely easy to 10: extremely difficult. The participant may also specify the reasons for the difficulty(ies) encountered during the measurement.
224034959|NCT06331780|OTHER|Subjective evaluation questionnaire|A subjective evaluation questionnaire will be submitted to the participants at the end of the visit.
223419243|NCT00783315|BEHAVIORAL|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
223419244|NCT00783315|BEHAVIORAL|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
224034960|NCT04061551|OTHER|EC clinic support - whole of practice interventions delivery through nurse-led model|"The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~* Patient support to reduce the impact of hepatitis C and other blood borne viruses~* Provider support to reduce the impact of hepatitis C and other blood borne viruses~* Practice support to reduce the impact of hepatitis C and other blood borne viruses"
224034961|NCT06277336|DRUG|Placebo|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)"
224137321|NCT01378936|BEHAVIORAL|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
223419245|NCT01053962|DRUG|SP-304 0.3 mg|SP-304 0.3 mg
223419246|NCT01053962|DRUG|SP-304 1.0 mg|SP-304 1.0 mg
223419247|NCT01053962|DRUG|SP-304 3.0 mg|SP-304 3.0 mg
223419248|NCT01053962|DRUG|SP-304 9.0 mg|SP-304 9.0 mg
223419249|NCT01053962|DRUG|Placebo|Placebo
223419250|NCT00679289|DRUG|HDI|20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
223562059|NCT04484649|BEHAVIORAL|Attention Control|"The Attention Control Intervention condition will meet the requirements for a comparison treatment for testing behavioral interventions - equivalent in contact time, credible and interesting, and exert limited treatment effects.~In the same number of sessions and format as the Sleeping Healthy/Living Healthy intervention (anticipated to be two group and two one-on-one sessions delivered once per week by SBHC providers and health educators), the study will teach participants about sleep and other health topics relevant to adolescents (e.g., nutrition, injury prevention) devoid of the MBIH elements in our integrated intervention."
223562060|NCT03548311|DRUG|methylcobalamin|Patients receive methylcobalamin 50mg intramuscular injection twice a week.
223562061|NCT03548311|DRUG|saline solution|Patients receive saline solution intramuscular injection twice a week.
223562062|NCT06252870|DRUG|Methotrexate|15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
224137322|NCT01378936|BEHAVIORAL|Motivational Interview only|45 minute Motivational Interview session
224137323|NCT01665521|OTHER|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
223419251|NCT00679289|DRUG|KW2871|5 mg/m\^2 IV every 2 weeks until disease progression
223419252|NCT00679289|DRUG|KW2871|10 mg/m\^2 IV every 2 weeks until disease progression
223419253|NCT00679289|DRUG|KW2871|20 mg/m\^2 IV every 2 weeks until disease progression
223419254|NCT06647992|BEHAVIORAL|Nurse Navigation Program|"It is planned to provide Cervical Cancer Education and Counseling to women in the experimental group about cervical cancer. Training and counseling is planned to be implemented face to face. An information booklet will be given to the experimental group. After 30 and 60 days after the training and counseling given to the experimental and control groups, it was planned to provide online (WhatApp) training and counseling to the patients in the experimental group:~Participants will be given a contact number that they can reach during the day when they want to receive counseling about HPV-DNA or Pap smear. Interviews will be scheduled between 08.00-20.00.~Individuals who are not screened will receive a reminder message by phone on the 45th and 75th day. Transtheoretical Model In the study, interventions will be planned for the experimental group according to the stages of the transtheoretical model.~The researcher will conduct motivational interviews with the individuals."
223419255|NCT00493662|DRUG|Polyethylene Glycol 400 0.4%|
223419256|NCT00493662|DRUG|Propylene Glycol 0.3%|
223419257|NCT00493662|DRUG|0.15% sodium Hyaluronate|
223419258|NCT00493662|DRUG|sodium chloride|
223419259|NCT00493662|DRUG|sodium phosphate monobasic|
223419260|NCT03928262|BIOLOGICAL|Benralizumab|Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
223562063|NCT06252870|DRUG|Post-Transplant Cyclophosphamide|50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
223562064|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
223562065|NCT06252870|DRUG|Cycophosphamide|Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
223562066|NCT06252870|DRUG|Anti-Thymoglobulin|Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)
223562067|NCT06252870|RADIATION|total body irradiation|2 grays on Day-1 before graft (=Day0)
224034962|NCT06277336|DRUG|Apelin Low Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 1 nmol/min (60ml per h)"
224137324|NCT01642836|BEHAVIORAL|MMM|"1. a theory-based community team sports program designed specifically for overweight and obese children,~2. a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~3. a primary care provider behavioral counseling intervention linked to the community and home interventions."
223419261|NCT05210465|OTHER|speckle tracking mode of the stress ECHO test with dobutamine|speckle tracking mode of the stress ECHO test with dobutamine
223419262|NCT02772874|OTHER|No intervention|No intervention
223419263|NCT01785225|DEVICE|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
223419264|NCT01839617|DIETARY_SUPPLEMENT|Early parenteral nutrition|
223419265|NCT01839617|DIETARY_SUPPLEMENT|Late parenteral nutrition|
223419266|NCT03360409|PROCEDURE|ACD|Undertake anterior cervical discectomy without fusion
223419267|NCT03360409|PROCEDURE|ACDF|anterior cervical discectomy with fusion
223562068|NCT06252870|OTHER|hematopoietic stem cells|High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)
223562069|NCT06252870|OTHER|Graft nuclear cells|Graft nuclear cells CD3+ cells if needed after transplantation
223562070|NCT06252870|OTHER|Donor Lymphocytes Injection|DLI with CD3+ if relapse after transplantation or in prevention of relapse
223562071|NCT06252870|DRUG|Clofarabine|Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)
223562072|NCT06252870|DRUG|Thiotepa|Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)
223739369|NCT07205939|DEVICE|Mobile Application usage|"Articipants complete a brief symptom questionnaire and upload a standardized photo of the cesarean incision on postpartum days 3, 7, and 15 (±1 day) via the study mobile platform. Patients will be reminded remotely on these mandatory days. They will be informed that if they have concerns about the wound outside of these mandatory days, they can use the app and share their survey and image data.~The surveys and images uploaded to the app will be evaluated by the researcher and reviewed by a clinician. Retakes will be requested for photos that are not of sufficient quality for evaluation. Clinical recommendations after review will be based on the patient's reported symptoms, and the wound images will provide additional information on this topic. One month after the cesarean section, all participants will be contacted by the researcher. They will be asked about the current status of their wounds and a patient satisfaction survey will be administered."
223419268|NCT03360409|PROCEDURE|ACDA|anterior cervical discectomy with arthroplasty
223419269|NCT03580109|OTHER|Immediate spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
223419270|NCT03580109|OTHER|Late spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
223419271|NCT04871061|PROCEDURE|PENG Block|Pericapsular Nerve Group Block
223419272|NCT04871061|DRUG|Conventional opioid analgesia (Fentanyl)|standardised intravenous opioid
223419273|NCT01690728|BEHAVIORAL|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
223562073|NCT06252870|DRUG|Busulfan|Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)
223562074|NCT06252870|DRUG|Fludarabine|Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)
223562075|NCT06434363|DRUG|Tafasitamab|Given by vein (IV)
223562076|NCT06434363|DRUG|Fludarabine phosphate|Given by vein (IV)
223562077|NCT06434363|DRUG|Cyclophosphamide|Given by vein (IV)
223562078|NCT06434363|DRUG|Tafasitamab and NK cells|Given by vein (IV)
223419274|NCT06407661|OTHER|"Disaster Nursing course/education"|"In this study, the Disaster Nursing course, which was integrated into the nursing curriculum, was an elective course, and it was carried out as a theoretical course for two hours a week. The topics in the content of this course regarding prevention, preparedness, response and recovery stages were designed in line with Jennings Disaster Nursing Management Model. The purpose of its development was to educate students on disaster management and disaster nursing. The course content included identification of risks and resources for disasters at the primary protection level, nurse's caregiver (triage and holistic care) and case manager role at the secondary protection level, reassessment of individuals' care needs at the tertiary level, and review of education and the current disaster plan at the protection level."
223419275|NCT02648893|OTHER|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
223419276|NCT02648893|OTHER|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
223419277|NCT03699462|DRUG|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
223562079|NCT04265651|DRUG|Infigratinib 0.016 mg/kg|"Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
223562080|NCT04265651|DRUG|Infigratinib 0.032 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
223562081|NCT04265651|DRUG|Infigratinib 0.064 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
223562082|NCT04265651|DRUG|Infigratinib 0.128 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
223562083|NCT04265651|DRUG|Infigratinib 0.25 mg/kg|"Subsequent cohort dose escalation based on protocol-specific criteria.~Infigratinib tablets to be administered by mouth."
223419278|NCT03699462|DRUG|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
223419279|NCT03931473|OTHER|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
223419280|NCT00937040|DRUG|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
223419281|NCT00937040|DRUG|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
223419282|NCT00937040|DRUG|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
223419283|NCT00937040|DRUG|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
223419284|NCT03431025|DEVICE|Wearable sensors and biofeedback|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
223562084|NCT04643873|OTHER|physical activity counseiling +pilates exercise group|It is planned to do the pilates exercises for 50 minutes a day, 2 days a week during 12 weeks with physiotherapist. Pilates group patient will make pilates exercise once a week alone During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided
223419285|NCT00638443|DRUG|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
223419286|NCT00638443|DRUG|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
223419287|NCT03898479|DRUG|CTP-543|Twice daily dosing
223562085|NCT04643873|BEHAVIORAL|physical activity counseiling group|During physical activity counseling, considering the current physical and metabolic status of the person, the person-based 5A model of ACSM will be adapted to individuals with diabetes and physical activity consultancy will be provided. Patients make aerobic and strengthening exercises by theirself based on phyiotherapist's suggestions
223562086|NCT03356834|DRUG|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
223562087|NCT03356834|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
223562088|NCT04054479|DRUG|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
223562089|NCT04054479|DRUG|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
223562090|NCT03586895|BEHAVIORAL|e-Connect|e-Connect
223739370|NCT07205549|RADIATION|MSK Ultrasound with Doppler on joints, muscles & tendons|Musculoskeletal Ultrasound (MSK-US) is a non-invasive, real-time, and sensitive imaging modality that can detect synovial hypertrophy, joint effusion, enthesitis, tenosynovitis, bursitis, and power Doppler (PD) signal indicative of active inflammation. Unlike standard clinical assessment, which may miss subclinical inflammation.
223739371|NCT07205250|DRUG|enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet)|Patients will be randomly divided into two groups: the aspirin group and the placebo group. Patients in the aspirin group will begin oral administration of enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet) on the first postoperative day. Patients in the placebo group will receive a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets. The oral medication course will last for six months.
223419288|NCT02410798|DEVICE|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
223419289|NCT05526807|DRUG|Ursodeoxycholic acid|Oral
223419290|NCT03740555|DRUG|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
223419291|NCT03740555|DRUG|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose, matching placebo
223419292|NCT03740555|DRUG|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg
223419293|NCT03740555|DRUG|Placebo multiple ascending doses|Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
223562091|NCT00346658|DRUG|magnesium|
223562092|NCT04909606|OTHER|nurse-led prevention program|"Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures"
224034963|NCT06277336|DRUG|Apelin High Dose|"Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours at an infusion rate of 10 nmol/min (60ml per h)"
224034964|NCT06277336|DRUG|Selected Apelin Dose|"Study infusions (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)~* 180-ml infusion of \[Pyr1\]apelin-13 in NaCl 0.45% over 3 hours based on the best performing apelin dose (from Low Dose or High Dose) in healthy volunteers corresponding to one of the following options:~  1. at an infusion rate of 1 nmol/min (60ml per h) OR~ 2. at an infusion rate of 10 nmol/min (60ml per h)~In case both apelin dosis performed equally well in the healthy volunteers population the lower dose will be selected."
224034965|NCT05645237|RADIATION|radiotherapy|Radiotherapy is delivered with linear accelerators or cyberknife (external beam radiotherapy), or local irradiation with high dose rate brachytherapy (brachytherapy)
224034966|NCT00101881|DEVICE|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
224034967|NCT03271203|OTHER|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
224034968|NCT03271203|OTHER|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
224034969|NCT04805775|DRUG|Desflurane Inhalation|Subjects were randomized in a 1:1 ratio to undergo breast surgery under maintenance of anesthesia with the classical intravenous anesthetic drug propofol (reference group) or the inhaled anesthetic drug desflurane (test group).
224034970|NCT05914441|OTHER|Standard clinical practice|The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
224034971|NCT01879215|PROCEDURE|Intramedullary nailing of the tibia|Standard care surgery
224034972|NCT01018121|BEHAVIORAL|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
223739372|NCT07205250|OTHER|a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets|Patients will be randomly divided into two groups: the aspirin group and the placebo group. Patients in the aspirin group will begin oral administration of enteric-coated aspirin tablets (100 mg once daily, Bayer Healthcare, specification: 100 mg/tablet) on the first postoperative day. Patients in the placebo group will receive a placebo with identical or similar appearance, taste, smell, and packaging to the aspirin tablets. The oral medication course will last for six months.
224034973|NCT01018121|OTHER|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
224034974|NCT03120767|BEHAVIORAL|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
224034975|NCT03120767|BEHAVIORAL|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
224034976|NCT02647229|OTHER|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
224034977|NCT02647229|OTHER|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
224034978|NCT04134676|DRUG|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
224034979|NCT04278001|DEVICE|Dual 24-hour ABPM|Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
224034980|NCT05918939|BIOLOGICAL|Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg|"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."
223739373|NCT07205445|DEVICE|Tensi+|Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
224034981|NCT05918939|BIOLOGICAL|CoronaVac Biofarma COVID-1 9 Vaccine 3 µg|Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
224137325|NCT01642836|BEHAVIORAL|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~1. notification of primary care providers about metabolic measures and blood pressure~2. state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
223419294|NCT05122910|BEHAVIORAL|Stress Management and Resilience Training - Moral Resilience (SMART-MR) program|All participants will attend an initial 2.5 hour workshop and a 1-hour follow-up workshop. The workshop will include general resilience strategies with a focus on the moral/ethical dimensions of clinical practice to offer participants specific skills to address ethical challenges. In addition to the workshops, there will be follow-up supplemental resources.
223739374|NCT07205055|OTHER|video training|No study in the literature has examined the effectiveness of video-based diaper dermatitis education.
224034982|NCT03882242|BEHAVIORAL|Facilitation of a school-based program|Participants deliver the prevention program (described in previous research) to school-children.
224034983|NCT02912325|DIETARY_SUPPLEMENT|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
224034984|NCT00052754|DRUG|gefitinib|
223419295|NCT03078179|DIETARY_SUPPLEMENT|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
223419296|NCT03078179|DIETARY_SUPPLEMENT|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
223562093|NCT04909606|OTHER|Current care|Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
223562094|NCT06002477|DRUG|Mecamylamine Challenge|Mecamylamine 20 mg oral pill administered once
223562095|NCT06002477|OTHER|Placebo Comparator Challenge|Matching placebo oral pill administered once
223562096|NCT05547503|DRUG|AFA-281|Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
223739375|NCT07206810|DRUG|Bortezomib, Lenalidomide, and Dexamethasone|In this study, transplant-eligible patients underwent autologous hematopoietic stem cell transplantation (auto-HSCT) after four cycles of VRD induction therapy, followed by two cycles of VRD consolidation therapy. Chemotherapy was administered in 28-day cycles as follows: subcutaneous bortezomib 1.3 mg/m² on days 1, 4, 8, and 11; oral lenalidomide 25 mg/day (or a dose-adjusted 10 mg based on renal function) from days 1 to 14; and intravenous dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12. Standard-risk patients received oral lenalidomide as maintenance therapy until disease progression. High-risk patients, defined as those with t(4;14), t(14;16), or del(17p), received bortezomib plus lenalidomide (V+R) as maintenance therapy until disease progression. Enrolled patients had complete clinical information at the time of initial diagnosis and received at least two cycles of VRD therapy.
223739376|NCT06419985|DRUG|80mg/day Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 40mg BID
223419297|NCT01125670|DRUG|YM150|oral
224034985|NCT00405470|DEVICE|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
224137326|NCT04224285|OTHER|Dayzz app|Personalized sleep training app that evaluates sleep issues and offers a complete, holistic sleep improvement solution
223419298|NCT05550987|OTHER|Rehabilitation program with the use of mechanical vibration using the Vibramoov device and conventional physiotherapy|The Vibramoov device (Techno Concept, France) will be used in the rehabilitation program. Before starting the training session, each subject will undergo a diagnosis in order to qualify for the use of Functional Proprioceptive Vibration. Before starting the therapy, pads are placed on the patient's body to fix the vibrating modules in the places to be treated (lower limbs, left upper limb or right upper limb). Then the vibrating modules are attached to the supports. The therapy carried out with the use of the Vibramoov device consists in the targeted and individualized stimulation of the nervous system, as in the course of natural movements of the upper or lower limbs with the use of visual biofeedback. Therapy with the use of the Vibramoov device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
223419299|NCT05550987|OTHER|Rehabilitation program with gait training using the Ekso GT exoskeleton and conventional physiotherapy|The Ekso GT ™ exoskeleton (Ekso Bionics, Inc. Richmond, CA, USA) used in the rehabilitation program has been approved by the Food and Drug Administration (FDA). Before starting the training session, each subject will undergo a thorough diagnosis to individually adjust the bionic skeleton. After entering the patient's data into the device's software, the physiotherapist selects the optimal training parameters. As the patient progresses during the training unit, the therapist will update the exoskeleton settings on an ongoing basis, so that the training is best suited to the current capabilities of the subject. Therapy with the use of the exoskeleton device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
223419300|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of a RoboGait stationary robot and conventional physiotherapy.|The RoboGait stationary robot (Bama technologist, Turkey) will be used in the rehabilitation program. Before starting the training session, each subject will undergo detailed diagnostics in order to individually adjust the orthoses. The next step will be to put on a vest and inguinal straps on a wheelchair or standing, and then lift it up with the device, then attach it to the Robogait orthoses. After entering the patient's data into the software of the device, the physiotherapist selects the optimal training parameters. During the session, biofeedback is also displayed informing the patient and the therapist about the patient's activity level in the transfer phase and the support during walking for both lower limbs. Therapy with the use of the RoboGait device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
223562097|NCT01764269|OTHER|text message surveillance for fever|
223562098|NCT00020098|PROCEDURE|evaluation of cancer risk factors|
223562099|NCT01157572|DRUG|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
223562100|NCT01157572|DRUG|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
223562101|NCT02731820|DIETARY_SUPPLEMENT|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
223562102|NCT02731820|DIETARY_SUPPLEMENT|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
223562103|NCT02731820|DIETARY_SUPPLEMENT|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
223562104|NCT02731820|DIETARY_SUPPLEMENT|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
223419301|NCT05550987|OTHER|Rehabilitation program with the use of gait training with the use of the ZEBRIS treadmill and conventional physiotherapy|The Zebris FDM-T treadmill will be used in the rehabilitation program for gait analysis. Before each session, patients will be equipped with a harness for safety reasons. The need for a handrail will be assessed prior to each session and patients will be encouraged to support their hands as little as possible. Before starting the training session, each subject will undergo a thorough diagnosis in order to individually adjust the training parameters. Therapy with the use of the Zebris FDM-T treadmill will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
223419302|NCT05550987|OTHER|Rehabilitation program with the use of upper limb function training with the use of the PABLO device and conventional physiotherapy|The Pablo (Tyromotion) device will be used in the rehabilitation program. Before the start of the training session, each subject will undergo detailed diagnostics assessing the range of mobility in the shoulder, radiocarpal (frontal and sagittal plane), elbow (sagittal plane), and explosive strength of the cylindrical, pinch and lateral and three-point grip. The Force Control Index will also be designated. The next stage will be training on the Pablo device using visual and auditory biofeedback. The physiotherapist selects the optimal training parameters (type of pad, type of game, level of the game). Each training session will be stored in the software and recorded in the patient's medical records. Therapy with the use of the Pablo device will be carried out 4 times a week for 50 minutes a day. Additionally, individual physiotherapy (50 minutes) and upright standing (50 minutes) will be conducted 5 times a week.
224034986|NCT06317896|DIAGNOSTIC_TEST|circulating tumor cells|blood sample and tissue specimen for circulating tumor cell and DNA will be done to patient with hepatocellular carcinoma
224034987|NCT02949258|DRUG|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
224034988|NCT02949258|DRUG|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
224034989|NCT02949258|DRUG|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
224137327|NCT00306774|DIETARY_SUPPLEMENT|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
224137328|NCT00306774|DIETARY_SUPPLEMENT|Placebo|Placebo capsule per day for 2 years
223419303|NCT05550987|OTHER|Control Group|In control Group the rehabilitation program will be carried out for a period of 4 weeks. In each of the studied groups, the rehabilitation program will include conventional physiotherapy sessions performed 5 times a week, consisting of 50 minutes a day of individual physiotherapy and 50 minutes a day of standing upright.
223419304|NCT02573558|DRUG|Dexmedetomidine|
223419305|NCT02573558|DRUG|Propofol|
223562105|NCT04706312|OTHER|stem cells|hAMSCs injection via venous in the dorsum of hand
223562106|NCT04075747|DRUG|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
223562107|NCT04075747|DRUG|Venetoclax|Will be administered over specified duration during induction and consolidation courses
223562108|NCT04075747|DRUG|Midostaurin|Will be administered over specified duration during induction and consolidation courses
223562109|NCT04075747|DRUG|Enasidenib|Will be administered over specified duration during induction and consolidation courses
223562110|NCT05742646|BEHAVIORAL|MATADORS|Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
223562111|NCT05742646|BEHAVIORAL|MATADORS Control|Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.
223562112|NCT05275387|OTHER|observational study, no intervention|observational study, no intervention
223562113|NCT00152477|DRUG|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
223562114|NCT00152477|DRUG|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
223562115|NCT00152477|DRUG|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
223562116|NCT00152477|DRUG|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
223562117|NCT06467955|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
224034990|NCT02949258|DRUG|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
224034991|NCT05313126|OTHER|sterile insect technique (TIS)|Sterile male Aedes albopictus mosquitos are released in the area/neighborhood
223562118|NCT01835288|DRUG|arsenic trioxide|Given IV
223562119|NCT01835288|OTHER|laboratory biomarker analysis|Correlative studies
223739377|NCT06419985|DRUG|160mg/day Ketamine HCl Prolonged Release|Administration of Ketamine HCl Prolonged Release - 80mg BID
223739378|NCT00587561|BEHAVIORAL|Social Cognition Interaction Training|manualized group therapy
223739379|NCT00587561|BEHAVIORAL|WLC|wait-list control for 6 months, followed by the experimental group therapy
223739380|NCT06207591|DEVICE|ECoG (electrocorticography) sensing|Implant electrodes and pedestal connector and use, through amplifier and decoding, for control of BCI
224034992|NCT02600338|OTHER|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
224034993|NCT03875677|DEVICE|HD-tDCS group|5 sintered Ag/AgCl ring electrodes will be used at a radius of \~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
224034994|NCT03875677|DEVICE|Conventional tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
224034995|NCT03875677|DEVICE|Sham HD-tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
224137329|NCT00434122|DRUG|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
223419306|NCT06967493|BEHAVIORAL|Amazonian Dance|"Dance intervention consists of 24 Amazonian Dance, 2 times/week, lasting 1 hour, over a period of 12 weeks. Classes will be taught by qualified dance professionals with experience teaching PwPD and will take place in a specific practice room (air-conditioned, spacious, and leveled), with adequate facilities, floors, chairs, bars, mirrors, and sound system.~Classes will be divided into 4 parts. The part 1 (10-15 min.) consists of welcoming students, warm-up exercises, and body awareness activities. In the Part 2 (10-15 min.) Weight transfer activities, static and dynamic balance, motor coordination, strengthening of lower and upper limbs will be carried out. The part 3 (25-30 min.) will be based on the Amazonian Lundum and Carimbó dances. In the part 4 (5-10 min.), the final part of the class, the calm down activity will be carried out, with breathing, stretching and relaxation activities."
223419307|NCT06967493|BEHAVIORAL|Nordic Walking|The Nordic walking protocol consists of 3 moments: warm-up (10min), main part (40min) and final part (10min). At the beginning of the activity, a joint warm-up is performed and free walking, without poles, at a comfortable speed. Then, in the main part of the class, the participants performed an individual and daily training that is inserted in their general training cycle, elaborated from the specific and individual functional capacity, measured from the application of the 6-minute walk test. In the final part, return to calm and stretching.
223419308|NCT06390514|OTHER|vibrating floor|activities with vibrating floor
223419309|NCT06390514|OTHER|No vibrating floor|activities without vibrating floor
223419310|NCT05074121|DRUG|N-acetylcysteine|N-acetylcysteine
223419311|NCT05074121|OTHER|Placebo|Placebo
223419312|NCT00056238|DRUG|NC-758 (Anti amyloidotic [Aß] agent)|
223419313|NCT00002172|BIOLOGICAL|HIV-1 Immunogen|
223419314|NCT03125538|OTHER|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
223419315|NCT03125538|OTHER|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
223419316|NCT03050853|BEHAVIORAL|E-cigarette|The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
223419317|NCT05748847|PROCEDURE|Intrastromal corneal ring segment implantation (Pocket)|"Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted pocket creation.~The device creates an intrastromal corneal pocket of 8-mm diameter and a depth of nearly 80% of the corneal thickness at the thinnest location with a superior tunnel incision at 90° of 5-mm width."
223419318|NCT05748847|PROCEDURE|Intrastromal corneal ring segment implantation (Tunnel)|"Patients in this group are planned to undergo ICRS implantation through a femtosecond laser-assisted tunnel creation.~The device creates an intrastromal tunnel with a depth of nearly 80% of the corneal thickness at the site of implantation. The tunnel inner and outer diameters are at 5 and 6 mm from the corneal center, respectively with the incision located at the steepest keratometry axis."
223739381|NCT06450470|DEVICE|Therapeutic lens alone|Therapeutic lens will be apposed on the patient's eye after crosslinking. Therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
223739382|NCT06450470|COMBINATION_PRODUCT|Therapeutic lens + amniotic membrane (Visio-AMTRIX)|Amniotic membrane (Visio-AMTRIX) will be apposed under therapeutic lens on the patient's eye after crosslinking. Amniotic membrane and therapeutic lens will be maintained without interruption until the first postoperative visit (Day 2) when it will be removed by the investigator.
223739383|NCT05260307|OTHER|hearing aid condition|The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
223739384|NCT06217094|DRUG|NP-101 (3 g)|Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
223739385|NCT06217094|DRUG|NP-101 (4.8 g)|Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
223739386|NCT06217094|DRUG|NP-101 (6 g)|Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
223739387|NCT04983823|OTHER|Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)|A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
223739388|NCT04983823|OTHER|Usual care|This will be provided by participants' usual healthcare professional(s).
224034996|NCT00541723|DRUG|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
223419319|NCT04764981|OTHER|Essence oils|Consists in olfactory training using essence oils
223419320|NCT01088672|PROCEDURE|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
223419321|NCT03831464|DRUG|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
223419322|NCT03831464|DRUG|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
224034997|NCT00541723|DRUG|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
224034998|NCT02148614|DRUG|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
224034999|NCT02148614|DRUG|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
223419323|NCT02614742|DRUG|SFX-01|An intervention releasing sulforaphane.
223419324|NCT02614742|DRUG|Placebo|Placebo otherwise identical to Active product
223419325|NCT05026437|OTHER|Cardiac surgery score and APACHE II scoring|Cardiac surgery score and APACHE II will calculated on the first postoperative day.
223419326|NCT03282721|PROCEDURE|precise location of commissure|
223562120|NCT02570152|PROCEDURE|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever \[body temperature ≥ 38°C/≥ 100.4°F\] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
223562121|NCT01832129|DRUG|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
223562122|NCT01832129|DRUG|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
223562123|NCT05016661|DRUG|ABP-450|ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
223562124|NCT05203757|PROCEDURE|ArthroCT scan|Conventional CT arthrogram as routine care
223562125|NCT05203757|PROCEDURE|CBCT|Cone Beam CT scan.
223562126|NCT00885586|DEVICE|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
223562127|NCT00885586|DRUG|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
223562128|NCT00885586|PROCEDURE|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
223562129|NCT01707654|DEVICE|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
223562130|NCT04155918|DRUG|Group 1: AR882 Alone and in Combination with Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
223562131|NCT04155918|DRUG|Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
223562132|NCT00923975|DEVICE|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
223562133|NCT05587296|DRUG|Elinzanetant (BAY3427080)|120 mg elinzanetant orally once daily
223419327|NCT03036865|DRUG|BOS161721|Single dose administered IV or SC
223419328|NCT03036865|DRUG|Placebo|Single dose administered IV or SC
223419329|NCT00526357|DRUG|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
223562134|NCT05587296|DRUG|Placebo|Matching placebo orally once daily
223739389|NCT06247345|DRUG|ADEL-Y01 - healty participants|In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
223419330|NCT05898984|DRUG|Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI|"CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[200 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg.~Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg.~Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve)."
223562135|NCT01328535|DRUG|temozolomide|Given PO
223562136|NCT01328535|OTHER|flow cytometry|Correlative studies
223562137|NCT01328535|OTHER|staining method|Correlative studies
224137330|NCT00434122|DRUG|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
223419331|NCT05898984|DRUG|Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI|with HFA 134a propellant (fixed combination of BDP \[100 μg\], FF \[6 μg\] and GB \[12.5 μg\] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
223562138|NCT01328535|PROCEDURE|biopsy|Optional correlative studies
223562139|NCT01328535|OTHER|laboratory biomarker analysis|Correlative studies
223562140|NCT02974127|RADIATION|Radiotherapy|Multisession radiosurgery
223562141|NCT05859412|OTHER|Neurodynamic exercises|The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
223562142|NCT05859412|DRUG|Steroid injection (Depomedrone 40mg)|Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
223562143|NCT05859412|OTHER|Advice|Group receiving advice but no additional treatment
223562144|NCT01005316|DRUG|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
223419332|NCT05898984|DRUG|Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)|pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
223419333|NCT06685315|OTHER|Participants fill out the questionnaire|Participants fill out the questionnaire
223562145|NCT01005316|DRUG|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
223562146|NCT01005316|DRUG|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
223562147|NCT01005316|PROCEDURE|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
223562148|NCT01005316|PROCEDURE|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
223562149|NCT01005316|DRUG|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
223562150|NCT01005316|DRUG|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
223739390|NCT06247345|DRUG|Placebo - Healthy Participants|In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
224035000|NCT01222260|DRUG|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
224035001|NCT01222260|DRUG|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
224035002|NCT02020382|DEVICE|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
224137331|NCT01343134|DEVICE|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
224137332|NCT00975195|DRUG|tiotropium inhalation|
224137333|NCT00975195|DRUG|salmeterol xinafoate|
224137334|NCT00975195|DRUG|fluticasone propionate|
224137335|NCT00975195|DRUG|placebo matched for fluticasone propionate|
223419334|NCT03502070|DRUG|Placebo|One dose (4 capsules) of placebo
223562151|NCT02687971|DRUG|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
223562152|NCT01490736|DRUG|Lemuteporfin|lemuteporfin topical solution, 1%
223562153|NCT06052254|DRUG|12 cm2 - 2 Active DMTS Patches|2 Active DMTS patches applied to the upper back followed 7 days later by another application of 2 Active DMTS patches. Each application will be worn for 4 days (96 hours)
223562154|NCT06052254|DRUG|6 cm2 - 1 Active and 1 Placebo DMTS Patches|1 Active and 1 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 1 Active and 1 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
223562155|NCT06052254|DRUG|Placebo - 2 Placebo DMTS Patches|2 Placebo DMTS patches applied to the upper back followed 7 days later by another application of 2 Placebo DMTS patches. Each application will be worn for 4 days (96 hours)
223562156|NCT00960011|DEVICE|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
224035003|NCT03211650|DRUG|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
224035004|NCT03211650|DRUG|hyaluronic acid|Intra-articular injections of hyaluronic acid
224035005|NCT03211650|DRUG|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
223419335|NCT03502070|DEVICE|Tobi Podhaler|The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
224035006|NCT04870853|OTHER|Electronic Health Record Review|Medical records reviewed
223419336|NCT03468413|DRUG|CP1050 or Placebo|Randomised, double-blinded, placebo-controlled
223419337|NCT05712629|OTHER|Bread and vla dadiah|Consumption bread and vla dadiah to pregnant women 1 Pieces a day during 12 weeks.
223419338|NCT05712629|OTHER|Bread and vla without dadiah|Consumption bread and vla without dadiah to pregnant women 1 Pieces a day during 12 weeks.
223419339|NCT03466203|BIOLOGICAL|LLF580|LLF580 300mg
223419340|NCT03466203|DRUG|Placebo|Placebo to LLF580
223419341|NCT03417089|PROCEDURE|Falciform ligament suspension|routine of falciform ligament suspension during Mini gastric bypass
223419342|NCT03417089|PROCEDURE|no suspension|working without of falciform ligament suspension during Mini gastric bypass
223419343|NCT04525014|DRUG|RRx-001|RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).
223419344|NCT04525014|DRUG|Temozolomide|100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children \<0.5 m2) daily for 5 days beginning on day 1 of each cycle
223419345|NCT04525014|DRUG|Irinotecan|90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
223419346|NCT03361969|DRUG|Estetrol|estetrol formulated in tablets
223419347|NCT03361969|DRUG|Placebo Oral Tablet|placebo tablets
224137336|NCT05680194|PROCEDURE|operation|operation methods: breast-conserving surgery, mastectomy, axillary lymph node dissection, sentinal lymphnodes biopsy; chemotherapy regimens: AC, TC, AC-T/P, TCrb, TAC, capecitabine; ovarian protection:GnRHa; endocrine therapy: Aromatase inhibitor, TAM, Fulvestrant, CDK4/6 inhibitors; target therapy: trastuzumab，patuzumab, Pyrotinib.
224137337|NCT05680194|DRUG|Bisphosphonate|Bisphosphonate
223419348|NCT02805179|RADIATION|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
223419349|NCT02805179|DRUG|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m\^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m\^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
223419350|NCT02748135|DRUG|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
223419351|NCT02748135|DRUG|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
223419352|NCT02748135|DRUG|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
223419353|NCT02748135|DRUG|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
223419354|NCT01921790|BIOLOGICAL|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
223419355|NCT01921790|DRUG|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
223562157|NCT00960011|DEVICE|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
223562158|NCT02431910|OTHER|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
223739391|NCT06247345|DRUG|ADEL-Y01 - MCI/AD|"In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy."
223419356|NCT01921790|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
223419357|NCT01921790|DRUG|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
223419358|NCT01921790|DRUG|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
223419359|NCT02380261|OTHER|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
223419360|NCT06071143|BIOLOGICAL|KDSTEM Inj.|"1. Low dose: The following study drugs are pre-mixed with 90mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 1.0x10\^8 cells/10mL/2 syringes)~2. High dose: The following study drugs are pre-mixed with 70mL of 0.9% normal saline and injected intravenously three times over the duration of the study. (Treatment group: KDSTEM Inj. 3.0x10\^8 cells/30mL/6 syringes)"
223562159|NCT02431910|OTHER|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
223562160|NCT03201926|DIETARY_SUPPLEMENT|mealworms|10g , 3 times a day , po, 2 months
223562161|NCT03201926|DIETARY_SUPPLEMENT|grain powder|grain powder, 10g ,3times one day,2months
223562162|NCT05021302|PROCEDURE|NOVAMAG NT-60|The Electromagnetic stimulation consists of 15 sessions with 20 minutes duration and three times a week. The total length of therapy is five weeks.
223562163|NCT05021302|BEHAVIORAL|Kegel Exercises|Self-supporting pelvic floor muscle strengthening exercises performed at home by contracting and relaxing quickly (2 seconds of contraction and 4 seconds of rest), followed by a slow contraction (contraction for 5 seconds, and rest for 10 seconds with five times each) five sets per day. The average length of exercise for each session is 2 minutes, with total exercise per day is 50 times. Thus, the total length of exercise is 10 minutes. It was done every day for eight weeks.
223562164|NCT04605497|DIAGNOSTIC_TEST|Continuous glucose monitoring (CGM)|Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period
224035007|NCT03745482|OTHER|Lumbar Mobilisations|The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
224035008|NCT05062083|DRUG|11C-MC1|Up to 20 mCi injected IV followed by PET scanning
223419361|NCT00595517|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
223419362|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 1|Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
223419363|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 2|Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
223419364|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 3|Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
223419365|NCT05299164|DRUG|Liposomal Mitoxantrone Hydrochloride dose level 4|Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
223419366|NCT00426296|DRUG|atazanavir (Reyataz)|
223419367|NCT00426296|DRUG|ritonavir (Norvir)|
223419368|NCT00005891|DRUG|cyclophosphamide|
223419369|NCT00005891|PROCEDURE|Allogeneic Bone Marrow Transplantation|
223562165|NCT04605497|DIAGNOSTIC_TEST|Self-Capillary Blood Glucose Monitoring (SCBG)|Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
223419370|NCT06419842|OTHER|hypnosis|the patient benefits from a dedicated nurse consultation. During this consultation, the nurse will explain the highlights of the hospitalization, the procedure and anticipate the hypnosis technique to be used. The technique chosen during the consultation will be applied during the test. The nurse is positioned at the head of the patient and with physical contact.
223419371|NCT06419842|OTHER|comfort|the patient benefits from a nurse consultation. Non-medicinal techniques are not offered. During the infusion test, the nurse will be positioned at the patient's head allowing proximity but without oral or physical intervention.
223419372|NCT06530251|DRUG|AK112|Following a predefined dose and date.
223419373|NCT06530251|DRUG|Cadonilimab|Following a predefined dose and date.
223419374|NCT06530251|DRUG|AK127|Following a predefined dose and date.
224035009|NCT05062083|DRUG|11C-PS13|Up to 20 mCi injected IV followed by PET Scanning
224035010|NCT05062083|DRUG|Ketoprofen|Ketoprofen 75 mg orally once
224035011|NCT05062083|DRUG|Celecoxib|celecoxib 600 mg orally once
223419375|NCT06530251|DRUG|AK130|Following a predefined dose and date.
223419376|NCT06530251|DRUG|Sintilimab Injection|Following the local label direction.
223419377|NCT06530251|DRUG|Bevacizumab biosimilar|Following the local label direction.
223419378|NCT06499454|DIAGNOSTIC_TEST|Ruby ROSE evaluation|Creation and digitization of ROSE slides produced using Ruby's instrument from bronchoscopic biopsy samples
223419379|NCT04468308|OTHER|Questionnaire|Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.
223419380|NCT01962077|PROCEDURE|MedCem MTA pulpotomies in primary teeth.|
223419381|NCT03570411|DIAGNOSTIC_TEST|T-SPOT®.CMV Test|The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
223419382|NCT06487000|DRUG|EC-18|oral administration, QD
223419383|NCT06487000|DRUG|Placebo EC-18|oral administration, QD
223419384|NCT03770039|DRUG|Oral PF-06700841 containing 14C microtracer|Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
224035012|NCT04094792|DEVICE|Happify Breather App|Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
224035013|NCT05691556|PROCEDURE|HABIT ILE rehabilitation course|"The HABIT-ILE course, created by the Belgian team of Prof. Yannick Bleyenheuft, is a rehabilitation of the upper and lower limbs, following the concepts of structured motor learning and intensive therapy. The internships last 2 weeks and are performed on a multi-year basis since 2018 at the SSR pediatric, Fondation Ildys, Site de Ty Yann in Brest.~In this group, upper limb assessments are performed the week before and the week after the HABIT ILE training course"
223419385|NCT03770039|DRUG|Oral unlabeled PF-06700841|60 mg unlabeled PF-06700841 oral dose in 2nd period
223419386|NCT03770039|DRUG|IV 14C-labeled PF-06700841|30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
223419387|NCT04102748|PROCEDURE|I-incision, M-flap and conventional implant exposure techniques|Implant uncovering in the second stage using 3 different exposure techniques
223419388|NCT00297180|DRUG|GW869682|
223562166|NCT04775862|DRUG|investigator choice re-challenge with anti EGFR Rx|Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
223562167|NCT05771441|OTHER|neck stabilization exercise (nse)|neck stabilization exercise (nse)- exercise
224035014|NCT05691556|PROCEDURE|botulinum toxin injections|"Toxin injections are used for their effect on the local reduction of spasticity after intramuscular injection. This treatment is usually offered to these children every 6 months or so for functional improvement.~These botulinum toxin injections are organized on a weekly basis in a pediatric day hospital (CHU Morvan in Brest).~In this group, upper limb assessments were performed 0-2 weeks before and then 4 to 6 weeks after the botulinum toxin injections (see table below), at the peak of the toxin's efficacy."
223419389|NCT06681948|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic diet
223562168|NCT05771441|OTHER|NSE + HOT PACK THERAPY|NSE + HOT PACK THERAPY- exercise plus heat therapy
223562169|NCT05771441|OTHER|NSE + infrared therapy|NSE + infrared therapy- exercise plus heat therapy
223562170|NCT05771441|OTHER|NSE + ultrasound therapy|NSE + ultrasound therapy exercise plus heat therapy
223562171|NCT04417218|DIETARY_SUPPLEMENT|Lysine|Lysine is an essential amino acid which is acquired from dietary sources.
223419390|NCT06681948|DIETARY_SUPPLEMENT|placebo|placebo
223419391|NCT02258373|DEVICE|CGM+BGM|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
223419392|NCT02258373|DEVICE|CGM Only|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
223419393|NCT01694290|OTHER|Chemical Cold Pack|
223419394|NCT01167881|DRUG|BI 10773|Medium dose once daily
223419395|NCT01167881|DRUG|Glimepiride|1-4 mg once daily
223419396|NCT01167881|DRUG|Placebo|Placebo matching BI 10773
223419397|NCT01167881|DRUG|Placebo|Placebo matching Glimepiride
223419398|NCT05481385|BEHAVIORAL|Reference preparation-Reference preparation-Test Preparation|Under fed conditions, subjects randomly divided into RRT group were given one tablet of reference preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of test preparation after cleaning period.
224035015|NCT05319275|DRUG|Acetyllevocarnitine Hydrochloride Tablets|500 mg (2×250 mg/tablet) after meal, 3 times per day
224035016|NCT05319275|DRUG|Placebo|500 mg (2×250 mg/tablet) after meal, 3 times per day
224035017|NCT06428591|DEVICE|t:slim X2 insulin pump with Tandem Freedom Algorithm|Participants will use the Tandem Freedom system for 3 day/nights in a supervised hotel setting, performing meal and exercise challenges.
224035018|NCT03975452|RADIATION|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
224035019|NCT01510496|PROCEDURE|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
223419399|NCT05481385|BEHAVIORAL|Reference preparation-Test Preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of reference preparation first, and then one tablet of test preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
223419400|NCT05481385|BEHAVIORAL|Test Preparation-Reference preparation-Reference preparation|Under fed conditions, subjects randomly divided into RTR group were given one tablet of test preparation first, and then one tablet of reference preparation after cleaning period, and then one tablet of reference preparation after cleaning period.
223419401|NCT06618690|OTHER|Exercise program|"A supervised training plan will be carried out for 12 weeks with a frequency of 3 sessions per week with a duration of 60 minutes, an ideal estimate according to the meta-analysis of Montaño-Rojas et al. The first two weeks the group exercises will be performed to familiarize the participants with the exercises and then each participant will perform them at home with a review every two weeks to assess the increase of the load.~The exercises and loads included in this treatment plan have been designed and modified based on previous clinical trials. The training plan will work upper limbs, lower limbs and trunk. All sessions begin with a general warm-up, which will be previously instructed to the participants, in which the heart rate will be increased (see Multimedia Appendix 1). After a two-minute break, the specific block of each session will begin (see Table 1 and Multimedia Appendix 1). All exercises will be performed with dumbbells, elastic bands and a ball."
223419402|NCT04002245|PROCEDURE|antiseptic application|The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
223419403|NCT04982354|DRUG|CPX-351|For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.
223419404|NCT04982354|DRUG|Midostaurin|The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.
223419405|NCT04982354|DRUG|Busulfan|0.8 mg/kg/dose every six hours x 12 doses administered intravenously
223419406|NCT04982354|DRUG|Melphalan|70 mg/m2/day x 2 doses administered intravenously
223419407|NCT04982354|DRUG|Fludarabine|25 mg/m2/day x 5 doses administered intravenously
223562172|NCT04417218|DIETARY_SUPPLEMENT|Controlled Diet|Individuals will be instructed to consume specific foods, to adhere to a controlled lysine diet.
223562173|NCT00625196|DRUG|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
224035020|NCT01510496|PROCEDURE|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
224035021|NCT01510496|PROCEDURE|Thoracotomy .|Thoracotomy (non laparoscopic).
224035022|NCT05937087|OTHER|Community engaged research|The university is working with Navajo communities to conduct an intervention study integrating community based participatory research using an Indigenous research paradigm. The innovative proposed project uses two approaches to build a research partnership to create capacity in the community for community-engaged multilevel behavioral and mental health research. Members from the three Navajo communities have never previously been involved in health research focused on wellbeing. Integrating CBPR with DCSR methodology becomes a powerful innovative intervention as the: 1) the community is driving the research to identify culture-based solutions for health related disparities; 2) the community is provided opportunities through research to center their perspectives and understandings about behavioral and mental health interventions; and 3) the community draws upon their collective community Indigenous knowledge.
224035023|NCT03559478|PROCEDURE|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
224035024|NCT03559478|PROCEDURE|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
223562174|NCT00625196|DRUG|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
223562175|NCT00625196|DRUG|Vilanterol|Vilanterol will be available as dry powder inhaler.
223562176|NCT00625196|DRUG|Placebo|Placebo will be supplied as dry powder inhaler.
224035025|NCT03968120|OTHER|Change of ventilatory settings|Change of Positive End-Exspiratory Pressure during one-lung ventilation
224035026|NCT01375361|DRUG|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
223562177|NCT06232603|OTHER|Education of medication management|Video and handout materials will be provided
223562178|NCT00199472|PROCEDURE|Dynamic Contrast Enhanced CT & Diuretic Renogram|
223562179|NCT06019663|BEHAVIORAL|The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP|"YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change."
224035027|NCT01375361|DRUG|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
224137338|NCT06051981|DRUG|5% sodium fluoride|a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
223419408|NCT04982354|BIOLOGICAL|CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor|Allogeneic stem cell transplant infused intravenously
223419409|NCT06969352|DRUG|Vorasidenib|"Treatment group: recommended dosage in adults and paediatric patients 12 years of age and older:~* For patients weighing at least 40 kg: 40 mg, orally, once daily.~* For patients weighing less than 40 kg: 20 mg, orally, once daily."
223419410|NCT01894100|DEVICE|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
223419411|NCT06513013|PROCEDURE|transversus abdominis plane (TAP) block in cesarean section|.an intravenous (IV) access will be secured . Standard ASA monitoring will be instituted which include(SpO2), ECG and (NIBP) . At the end of surgery , a bilateral USG-guided TAP block will be carried out under strict aseptic precautions, and 20 mL of study solution was injected into each side. After draping the abdominal region between the 12th rib and anterior superior iliac crest with the umbilicus in the center, the external oblique muscle, internal oblique muscle, transversus abdominis muscle , and their fascia will be located beneath the skin and subcutaneous tissue using a linear high-frequency probe 6-13 Megahertz of the SonoSite Micromax machine. A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered.
223419412|NCT06513013|DRUG|Magnesium sulfate|25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 250 mg of MgSO4) to keep the total volume the same in both group
223419413|NCT06513013|DRUG|Neostigmine|"25ml volume on each side (20ml of 0.25% bupivacaine plus 5ml of normal saline containing 500 mcg neostigmine.~A 22-gauge spinal needle will be advanced using the in-plane technique at the anterior axillary line, and the precise position of the needle tip between the internal oblique and transverse abdominis muscle will be visualized. To expand the plane, 2 mL of normal saline will be administered. Following the affirmation of a hypoechoic region on the USG image, the study solutions will be injected as per group allocation. Postoperatively,both groups of patients received an injection of paracetamol 1gm intravenously every 8th hourly as a part of multimodal analgesia and the patients will be evaluated for pain, nausea or vomiting in the post anaesthesia care unit at time 0 (time of completion of TAP block), 2, 4, 6,12 and 24 h by an investigator blinded to the group assignment. Whenever the NRS \>4, Nalbuphine 0.1 mg/kg IV will be administered as a rescue analgesic."
223419414|NCT02838914|PROCEDURE|radiofrequency ablation (RFCA)|Patients undergo radiofrequency ablation (RFCA)
223419415|NCT00000743|DRUG|Alvircept sudotox|
223419416|NCT00000743|DRUG|Zidovudine|
223419417|NCT03857386|PROCEDURE|PECS group|Pecs block performed using ultrasound guidance
223419418|NCT03857386|PROCEDURE|Control group|Local infiltration anesthesia performed during the operation
223562180|NCT03771131|BEHAVIORAL|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
223562181|NCT00685269|DRUG|Eszopiclone|Eszopiclone 3 mg QD
223562182|NCT00685269|DRUG|Placebo|Placebo tablet
223562183|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
223562184|NCT01074463|DRUG|Pramipexole Dihydrochloride|0.25 mg Tablet
223562185|NCT00737854|PROCEDURE|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
223562186|NCT02375737|BEHAVIORAL|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
223562187|NCT01734395|DRUG|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
223562188|NCT02425228|DEVICE|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
223562189|NCT05849935|DIAGNOSTIC_TEST|abioSCOPE|The abioSCOPE device with the PSP assay is intended to be indicated for ICU admitted patients at risk of developing sepsis. Results of abioSCOPE PSP assay may aid to identify sepsis in critically ill patients, together with all other clinical assessment and laboratory findings.
223562190|NCT05349409|DRUG|SHR-A1811|SHR-A1811 for Injection: Given IV.
223562191|NCT05349409|DRUG|Fluzoparib Capsule|Fluzoparib Capsule: Given PO.
223562192|NCT02839447|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
223562193|NCT04379245|OTHER|Data research, database analysis|"Extraction of virological data at the virology laboratory (date, SARS-COV2 PCR result, identification number, sex, date of birth) (Excel file)~* Extraction of demographic and viro-immunological data from patients infected with HIV and on PrEP followed at the Hospices Civils de Lyon, France, over the period concerned (Access extraction)~* Data crossing (Excel / Access) and statistical analysis~* Calculation of the positivity rate per calendar period (= number of diagnosed cases / number of patients tested) and the attack rate per calendar period (number of diagnosed cases / number of people exposed (= active file of patients followed reduced by the number already known to be positive))."
223419419|NCT06621745|BEHAVIORAL|Gratitude Intervention App|The GIA app, an iOS application designed for this study, is based on effective gratitude interventions and tailored for youth. Access required a unique login. It features five exercises: a journal, photo book, imagine exercise, speech exercise, and meditation. The journal encourages daily entries. The photo book involves uploading photos of things users are grateful for, promoting mindfulness. The imagine exercise reflects on gratitude, while the speech exercise records users' gratitude. The meditation exercise enhances well-being. During the three-week study, daily notifications prompted exercise completion. The app, green and white with a flower-heart icon, offers email support for technical issues.
223419420|NCT05283980|DRUG|0.25% Bupivacaine|The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
223419421|NCT05700175|DIAGNOSTIC_TEST|Transcriptomic, epigenetic and proteomic analysis|"Next-generation sequencing will be used to identify differences in expression of circulating transcripts (protein-coding and not) in patients affected by Marfan Syndrome (MFS), subdivided based on the presence or absence of thoracic aortic aneurysms (TAA) and indication of TAA-surgery (TAA\_MFS\_signature).~The obtained TAA\_MFS\_signature will be correlated to fundamental biological parameters by analysing:~Blood-levels of cytokines and chemokines relevant for inflammation. Transcriptomic and epigenetic (Cytosine methylation) changes in aortic aneurysms tissue by Next-generation sequencing.~Progression of biomarkers in surgical-patients before and at 6 and 12 months after surgery."
223419422|NCT04218656|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|2.5 mg rivaroxaban twice a day in addition to Aspirin 100mg once a day (standard care).
223419423|NCT06044636|OTHER|Digi-physical breastfeeding support|"* Breastfeeding support after birth is provided via chat~* Extended home visits by a pediatric nurse after discharge from the maternity ward~* Extra support from a lactation counselor when needed after discharge until one year after childbirth"
223419424|NCT01455532|DRUG|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
223419425|NCT01455532|DRUG|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
223562194|NCT02464995|DEVICE|Bronchial thermoplasty with the Alair System|
223739392|NCT06247345|DRUG|Placebo - MCI/AD|"In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions."
223739393|NCT04537026|DRUG|Amniotic Fluid Allograft|Amniotic Fluid Allograft will be mixed with sterile water and injected using transforaminal approach
223739394|NCT04537026|DRUG|Dexamethasone sodium phosphate|Dexamethasone phosphate mixed with sterile water will be injected by transforaminal approach
223419426|NCT01455532|DRUG|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
223562195|NCT01032291|DRUG|cetuximab|Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
223562196|NCT01032291|DRUG|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
223562197|NCT04609358|OTHER|intervention group|When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
223562198|NCT03699059|OTHER|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
223562199|NCT06372171|DIETARY_SUPPLEMENT|Satge 1|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 1-10 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 11-20
223562200|NCT06372171|DIETARY_SUPPLEMENT|Stage 2|General vitamin C powder group (Contains 1500 mg Vitamin C) Number 11-20 liposomal encapsulation C powder group (Contains 1500 mg of vitamin C and lecithin and is coated) Number 1-10
223562201|NCT03600636|PROCEDURE|Diffusion tensor imaging MRI|"1. axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~2. Fluid-attenuated inversion recovery~3. three-dimensional axial image weighted in T1~4. axial echo-planar image sequence~5. three-dimensional pulse sequence axial flight time"
223739395|NCT05417516|RADIATION|Whole Breast Irradiation (WBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
223739396|NCT05417516|RADIATION|Partial Breast Irradiation (PBI)|The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
223739397|NCT06611423|BIOLOGICAL|AZD3427|AZD3427 SC injection to be prepared using AZD3427 diluent
223739398|NCT06611423|OTHER|AZD3427 Placebo|AZD3427 Placebo
223739399|NCT06611423|DRUG|Dopamine|Dopamine Hydrochloride 50mg/5mL
223739400|NCT06611423|OTHER|Radiolabelled ligand|Injection of radioligand for PET examinations
223739401|NCT06611423|OTHER|Saline|Saline solution
223739402|NCT05367440|DRUG|AZD5305|Patients will receive an oral dose of AZD5305 once daily
223739403|NCT05367440|DRUG|Enzalutamide|Patients will receive an oral dose of Enzalutamide once daily
224137339|NCT06051981|DRUG|Intensive 5% sodium fluoride|Intensive FV will be applied three times a week for a week (every two days).
224035028|NCT03397849|BEHAVIORAL|Intervention using mobile technology|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
224035029|NCT03717831|OTHER|Observational study of standard of care|Observational cohort study
223419427|NCT01455532|DRUG|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
224137340|NCT06051981|DRUG|Casein Phosphopeptide-Amorphous Calcium Phosphate|for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
223419428|NCT01455532|DRUG|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
223419429|NCT04674917|OTHER|Decompression + Hot pack, TENS, Mobilization, Exercise Therapy|"Group A which includes the acute group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 ) Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
223419430|NCT04674917|OTHER|Decompression + Hot pack , TENS , Mobilization , Exercise Therapy|"Group B which includes the chronic group to study the effects of decompression we will apply the three main basic treatments along with decompression which is our main goal..~The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine All these treatments must given in combination with the decompression."
223419431|NCT04674917|OTHER|Hot pack , TENS, Mobilization, Exercise therapy|"Group C which is our control group to compare it with the groups A and B to study the effects of decompression on lumbar radiculopathy The basic treatments are~1. Hot Pack~2. TENSE~3. Mobilization ( on lumbar L1 toL5 )~Our first modality which is hot pack will be given to the patients for a duration of 15 minutes The next modality TENSE will be given for 10 minutes~The third treatment which is mobilization will be given 1 time on each joint of lumbar spine It is kept in mind that in this group we will not apply the decompression along with the above treatments."
223419432|NCT04013672|DRUG|Pembrolizumab|200 mg IV every 3 weeks
223419433|NCT04013672|DRUG|SurVaxM|500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
223419434|NCT04013672|DRUG|Sargramostim|100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
223419435|NCT04013672|DRUG|Montanide ISA 51|1 ml per dose dosed every two weeks for 4 doses and then every 3 months
223562202|NCT05027126|DRUG|Dexketoprofen 25 MG|Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
223562203|NCT05027126|DRUG|Fixed dose Dexketoprofen-Vitamin B Complex|Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
223739404|NCT05367440|DRUG|Abiraterone Acetate|Patients will receive an oral dose of Abiraterone Acetate once daily
224137341|NCT06051981|DRUG|Resin infiltration|resin infiltration will be applied as specified by the manufacturer.
223419436|NCT06744582|OTHER|VO2 max|The aim of this study is to generate data on the estimation of natural variation in VO2 max changes before and after surgery using seismocardiography.
223419437|NCT06383910|BEHAVIORAL|Square Stepping Exercise|The exercise is performed on a thin exercise mat divided into 40 small squares. Participants are shown specific step patterns on this mat and are instructed to repeat the same step pattern until the end of the exercise mat. Once a pattern is completed on the exercise mat, its mirror-image pattern is also performed. The basic pattern is repeated 3-5 times, followed by the same number of repetitions for the mirror-image pattern. However, if participants struggle with the pattern, it is repeated until they learn it. Individuals execute the demonstrated pattern on the exercise mat and return to the beginning of the mat after completing it.
223562204|NCT05834933|BEHAVIORAL|Individualized breast cancer risk assessment|Individualized breast cancer risk assessment: The Nigerian Breast Cancer Study (NBCS) absolute risk prediction model was used to predict the 5-year and lifetime breast cancer risks of the participants. The model utilized individual breast cancer risk factors.
223562205|NCT05834933|BEHAVIORAL|Individualized breast cancer risk counselling|Individualized breast cancer risk counselling: The Principal Investigator (PI) and other trained risk counsellors discussed the results of the NBCS risk prediction model with participants and counselled them about the risk of developing breast cancer. The
223562206|NCT00320905|BEHAVIORAL|Observational|No intervention
223562207|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
223562208|NCT00313313|DRUG|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
223739405|NCT05367440|DRUG|Darolutamide|Patients will receive an oral dose of Darolutamide twice daily
223562209|NCT00313313|DRUG|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
223562210|NCT00313313|DRUG|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
223562211|NCT00313313|DRUG|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
223562212|NCT00313313|DRUG|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
223562213|NCT03923621|PROCEDURE|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
223739406|NCT05367440|DRUG|Apalutamide|Patients will receive an oral dose of Apalutamide once daily
223562214|NCT03923621|PROCEDURE|Excision|Surgery to remove all affected tissue, followed by wound closure.
223739407|NCT06262113|OTHER|Letters about NF1 Care (Content Type 1)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
224137342|NCT01450956|DRUG|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
223419438|NCT01976429|OTHER|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
223419439|NCT01976429|OTHER|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
223419440|NCT01976429|OTHER|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
223562215|NCT00904930|DEVICE|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
223562216|NCT00904930|DEVICE|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
223739408|NCT06262113|OTHER|Letters about NF1 Care (Content Type 2)|Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
223739409|NCT06814795|OTHER|Medically tailored meals|"The intervention will be 12-weeks in duration, with doses (meal deliveries) of up to 10 healthy, frozen meals per week for household use as needed, plus selected condiments for personalization"
223739410|NCT00410761|DRUG|ZD6474 (Vandetanib)|once daily oral tablet
223739411|NCT03694171|OTHER|Any cancer treatment|
223739412|NCT06785675|OTHER|Secukinumab|This is an observational study. There is no treatment allocation.
223739413|NCT05296265|BEHAVIORAL|VR treatment for phantom limb pain|8 twice-weekly interventions of 1 hour; baseline, pre-intervention; immediately after the end of the in intervention; 1 week after the end of the intervention; 8 weeks after the end of the intervention
223739414|NCT06703073|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
224035030|NCT02411578|DRUG|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)"
223739415|NCT06703073|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
223739416|NCT06703073|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
224035031|NCT02411578|OTHER|Glucose Tablets|"1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is \>=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
224035032|NCT05706753|DRUG|Milvexian|Milvexian will be administered orally.
224035033|NCT05706753|DRUG|Midazolam|Midazolam will be administered orally.
224035034|NCT05706753|DRUG|Ethinylestradiol|Ethinylestradiol will be administered orally.
224035035|NCT05706753|DRUG|Drospirenone|Drospirenone will be administered orally.
223419441|NCT00385047|BIOLOGICAL|Group A FMP2.1/AS01B|
223419442|NCT00385047|BIOLOGICAL|Group B FMP2.1/AS02A|
223419443|NCT03773029|DIETARY_SUPPLEMENT|soy isoflavone|100 mg soy isoflavone (as 2 capsules)
223419444|NCT03773029|OTHER|placebo|2 capsules of placebo
223419445|NCT03616574|DRUG|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
223419446|NCT03616574|DRUG|LONSURF|LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
223739417|NCT06703073|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
223739418|NCT06703073|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
223739419|NCT06703073|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
223739420|NCT06829329|DRUG|AHB-137|AHB-137 will be administered .
223739421|NCT06829329|DRUG|NAs|NAs will be administered.
224035036|NCT02842892|OTHER|Tissue stiffness|
224035037|NCT06001086|DRUG|Disitamb Vedotin ,pyrotinib|Disitamb Vedotin combined with pyrotinib
223419447|NCT01827267|DRUG|neratinib|
223739422|NCT06829329|DRUG|Placebo|Placebo will be administered .
223739423|NCT02926924|DEVICE|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
223739424|NCT02926924|OTHER|Standard Dressing|standard dressing with drain tube and bandage
223419448|NCT01827267|DRUG|temsirolimus|
223419449|NCT00669565|DRUG|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
223419450|NCT03321851|DEVICE|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
223419451|NCT01991509|BIOLOGICAL|LBR-101 IV|LBR-101 Administered Intravenously
223419452|NCT01991509|BIOLOGICAL|LBR-101 SC|LBR-101 Administered Subcutaneously
223419453|NCT04222998|OTHER|Home-based growth charts|The growth chart contains simple information of nutritious food, health, and sanitation information at the top and height chart is located at the bottom where caregivers can measure their child's linear growth. Growth charts will be installed in intervention group homes just after the baseline survey.
223419454|NCT04222998|OTHER|Home visits for baseline surveys|Households will be visited for baseline surveys.
223419455|NCT04222998|OTHER|Home visits for end line surveys|Households will be revisited after 1 year of grace-period for baseline end line surveys.
223419456|NCT04222998|OTHER|Measurement of child's height-for-age and weight-for-age|The child's height-for-age and weight-for-age will be measured for participating dyads at the time of the baseline and end line surveys.
223419457|NCT01432301|DRUG|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
223419458|NCT01408316|DRUG|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
223419459|NCT00406263|PROCEDURE|Scheimpflug crystalline lens photographs|scheimpflug photographs
223419460|NCT02882217|DRUG|XC8 (histamine glutarimide)|
223419461|NCT02882217|DRUG|Placebo|
223419462|NCT05533008|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg as a bolus injection
223419463|NCT05533008|OTHER|Placebo|IV Placebo as a bolus injection
223419464|NCT02119455|DEVICE|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
223419465|NCT03860402|OTHER|Temperature|temperature of drug
223419466|NCT02439814|DRUG|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
223419467|NCT02439814|OTHER|Placebo|Inactive comparator
223419468|NCT02792543|DEVICE|Entéromate™|Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
223419469|NCT02792543|DRUG|parenteral nutrition|Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
223419470|NCT03418233|DRUG|CardioCell|"Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
223419471|NCT03418233|DRUG|Placebos|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
223419472|NCT06572306|DEVICE|FreeStyle Libre 2 Continuous Glucose Monitor|Subjects included in the intervention group (continuous glucose monitoring) will be recruited from the USF Health Department of Family Medicine. Each subject will be enrolled for 12 weeks.
223419473|NCT01745536|PROCEDURE|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
223419474|NCT01745536|PROCEDURE|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
223419475|NCT00134706|DRUG|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
223419476|NCT00134706|DRUG|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
223419477|NCT02400554|BEHAVIORAL|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, \& women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership \& personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion \& synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal \& leadership goals \& experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD \& obesity prevention. Includes: digital storytelling training to create a story related to ATOD \& obesity prevention \& an individual MI booster session to revise their personal \& community leadership goals.~Month 12: Share digital stories \& community event experiences \& undergo a ceremony to transition to health leaders within their communities."
223419478|NCT04813575|OTHER|Cryo lung biopsies|Bronchoscopic lung biopsy utilizing the cryo technique
223419479|NCT06111859|DIAGNOSTIC_TEST|Ultrasound based Elastography and fat quantification|Correlation of ultrasound-based elastography and fat quantification on liver biopsy
223419480|NCT04152070|OTHER|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
223419481|NCT02693028|DRUG|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
223562217|NCT02419222|BEHAVIORAL|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
223562218|NCT02934880|OTHER|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
224035038|NCT00867282|DRUG|Treatment A|PF-00241939 750ug using inhaler A
223419482|NCT02693028|DRUG|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
223419483|NCT02693028|DRUG|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
223419484|NCT02693028|DRUG|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
223419485|NCT02693028|DRUG|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
223419486|NCT05154019|BEHAVIORAL|Managing Minds at Work Online Training|"The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them."
223419487|NCT03636971|DRUG|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
223419488|NCT03636971|DRUG|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
223419489|NCT03636971|DRUG|Placebos|single shot injection of saline, same volume
223419490|NCT03324347|PROCEDURE|Therapydog|Presence of a therapydog during a clinical examination in a dental clinic
223562219|NCT02934880|OTHER|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
223562220|NCT00758264|BIOLOGICAL|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
223419491|NCT06416891|DRUG|bupivacaine 0.25%|SCPB using 10 ml of bupivacaine 0.25%
223419492|NCT06416891|DRUG|dexamethasone 2 mg in bupivacaine 0.25%|SCPB using dexamethasone 2 mg in 10 ml of bupivacaine 0.25%
223419493|NCT04159454|DEVICE|PITA|Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate \~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
223419494|NCT01268930|PROCEDURE|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
223419495|NCT01268930|PROCEDURE|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
223419496|NCT03759015|BEHAVIORAL|Health education|All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
223739425|NCT06701669|DRUG|Cohort B: paridiprubart|Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1
223419497|NCT06479967|OTHER|The VR glasses group|"The Virtual Reality glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine The VR glasses group watched a cartoon video of \&#34;Rafadan Tayfa Gizli Hazine After the SPT, the VR glasses group took a 1-minute break from watching videos and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the VR glasses group continued watching cartoon"
223419498|NCT06479967|OTHER|the music group|The music group listened to classical piano \&#34;The Best of Chopin.\&#34; After the music group took a 1-minute break from listening to music, and the child\&#39;s pain was assessed with WBFPS. During the 15-minute SPT assessment, the music group continued to listen to the music. During the SPT evaluation, the music group took a 1-minute break from listening to music at 5, 10, and 15 minutes, and the child evaluated the level of itching from 1 to 10.
223419499|NCT03424772|DIAGNOSTIC_TEST|Whole genome sequencing|WGS will be performed for the trio
223419500|NCT02660281|RADIATION|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
223419501|NCT02660281|DRUG|Fludarabine|Fludarabine
223419502|NCT02660281|DRUG|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
223419503|NCT02660281|DRUG|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
223562221|NCT00758264|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
223562222|NCT01274923|DEVICE|"MEDISPEC treatment probe"|shock wave treatment
223739426|NCT06701669|DRUG|Cohort B: placebo|Administered as a single IV dose of placebo on Day 1
223739427|NCT05606809|DIAGNOSTIC_TEST|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
223739428|NCT05695248|DRUG|STAR-0215|STAR-0215 will be administered as a subcutaneous bolus injection.
224035039|NCT00867282|DRUG|Treatment B|PF-00241939 750ug using inhaler B
224035040|NCT00909454|DIETARY_SUPPLEMENT|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
224035041|NCT00909454|DIETARY_SUPPLEMENT|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
224035042|NCT02519309|OTHER|Virta Program|
224035043|NCT00208897|DRUG|Fluoxetine|
224035044|NCT04097522|OTHER|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
224035045|NCT00324701|BEHAVIORAL|Telepsychology|therapy done at patients house
224035046|NCT00324701|BEHAVIORAL|Face-to-face therapy|therapy delivered at the VAMC
224035047|NCT06188585|DEVICE|UI-EWD|Hemostatic powder administered at index endoscopy
224035048|NCT06188585|DEVICE|Conventional therapy|Conventional endoscopic therapy (bipolar electrocoagulation or clips or argon plasma coagulation, with or without epinephrine injection) administered at index endoscopy
223419504|NCT02660281|DRUG|Busulfan|Busulfan
223419505|NCT02660281|DRUG|Melphalan|Melphalan
223419506|NCT02660281|PROCEDURE|Stem Cell Infusion|Stem cell infusion
223419507|NCT02660281|DRUG|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
223419508|NCT02660281|DRUG|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
223419509|NCT02660281|DRUG|Thiotepa|Thiotepa
223419510|NCT00813813|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
223419511|NCT00986921|DRUG|mifepristone 200 mg|mifepristone would be given the day before the procedure
223419512|NCT00986921|DEVICE|osmotic dilator insertion|osmotic dilators (3-6) would be inserted as usual the day before the procedure
223419513|NCT03953495|BEHAVIORAL|Better Together|The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
223419514|NCT03371017|DRUG|Atezolizumab|"Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
223419515|NCT03371017|DRUG|Placebo|"Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
223419516|NCT03371017|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
223419517|NCT03371017|DRUG|Capecitabine|Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
223419518|NCT03371017|DRUG|Carboplatin|Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
223419519|NCT03582982|BEHAVIORAL|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
223419520|NCT01612689|DEVICE|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
223419521|NCT02527252|OTHER|Craniosacral therapy|
223419522|NCT02527252|OTHER|Classic Massage|
223419523|NCT01436877|DEVICE|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
223419524|NCT02480374|BIOLOGICAL|IMNN-001|
223419525|NCT05747573|DRUG|GB1211|Hard tablet or capsules for oral use
223739429|NCT05544513|DRUG|Ferrous sulfate 3 days week|Participants will receive one ferrous sulfate capsule (120 mg of elemental iron) on Mondays, Wednesdays and Fridays
223739430|NCT05544513|DRUG|Ferrous sulfate daily|Participants will receive one ferrous sulfate (120 mg of elemental iron) capsule daily (except on Sundays)
223419526|NCT01684943|OTHER|Multiplex pharmacokinetic profiling|
223419527|NCT01684943|OTHER|Continuous insulin monitoring|
223419528|NCT02320773|DRUG|Betmiga®|Oral
223419529|NCT00379444|BEHAVIORAL|Standard intervention (counseling + self-help written materials)|counseling
223419530|NCT00379444|BEHAVIORAL|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
223419531|NCT02511392|PROCEDURE|rTMS-1Hz|
223419532|NCT02511392|PROCEDURE|rTMS-10 Hz|
223419533|NCT02511392|PROCEDURE|Sham rTMS|
223419534|NCT03918902|BEHAVIORAL|Qestinnaires|Questionnaires
223419535|NCT04223635|DRUG|Pexidartinib|Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.
223419536|NCT04443062|DRUG|177Lu-PSMA-617|PSMA radioligand therapy
223419537|NCT00268177|DRUG|Salmeterol/fluticasone propionate 50/500mcg Diskus|
223419538|NCT00806663|DRUG|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
223419539|NCT06068673|DRUG|Clindamycin 600 mg|Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.
223419540|NCT06068673|DRUG|standard regimen|standard regimen
223419541|NCT00725790|DRUG|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
223739431|NCT05544513|DRUG|Ferrous sulfate higher concentration|Participants will receive one ferrous sulfate capsule (240mg of elemental iron) on Mondays, Wednesdays and fridays
223739432|NCT05123053|DRUG|Amifampridine|10mg tablet
223739433|NCT05907057|DRUG|Ivosidenib 500mg Oral Tablet|Provided as tablets, taken orally as two 250mg tablets once daily.
223419542|NCT00725790|DRUG|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
223419543|NCT04181515|DRUG|Placebo oral tablet|placebo stressor
223419544|NCT04181515|DRUG|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
223419545|NCT04181515|DEVICE|sham rTMS|sham rTMS (inactive coil)
223419546|NCT04181515|DEVICE|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
223419547|NCT05164640|OTHER|not required|This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
223419548|NCT00972816|BIOLOGICAL|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
223739434|NCT05907057|DRUG|Azacitidine|Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.
223739435|NCT04624373|OTHER|Molecular analysis of surnatant|"The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing)."
224035049|NCT05300269|DRUG|SHR-1701；Capecitabine；Oxaliplatin|"Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy.~Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w"
224035050|NCT04742634|DRUG|DEC-C|"* DEC-C will be provided by Taiho Pharmaceuticals.~* Cycle 1 Day 1 may take place between Day 42 \& Day 100 post-transplant."
224035051|NCT04742634|DEVICE|MyeloSeq-HD|-Laboratory test developed at Washington University School of Medicine
224035052|NCT05415384|DEVICE|Cryoablation of Intercostal Nerves|Using Atricure device, cryoice, intercostal nerves 3-8 will be ablated in the experimental arm. This is in addition to mechanical fixation of rib fractures and multimodal systemic therapy.
224035053|NCT05415384|PROCEDURE|Standard surgical treatment of patients with multiple rib fractures|Standard surgical treatment of patients with multiple rib fractures
223419549|NCT05839652|DRUG|Midodrine Hydrochloride|Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
223419550|NCT03916367|RADIATION|CT-guided Radioactive I-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
223419551|NCT02615015|OTHER|Blood draw|
223419552|NCT02533557|DEVICE|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
223419553|NCT02533557|DRUG|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
223419554|NCT00801281|DRUG|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
223419555|NCT00801281|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
223419556|NCT00801281|DRUG|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
223419557|NCT00801281|DRUG|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
223419558|NCT00801281|DRUG|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
224035054|NCT02075411|DRUG|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
224035055|NCT02075411|DRUG|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
224035056|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
224035057|NCT02075411|DEVICE|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
224035058|NCT05638750|OTHER|Rehabilitation Intervention|12-week treatment intervention \& home exercised, then 12-week non-intervention period, follow-up visit at end of non-intervention period.
224137343|NCT01450956|OTHER|Control|Patients will receive only oxygen and air through oxygenator
223419559|NCT00801281|DRUG|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
223419560|NCT02358525|BEHAVIORAL|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
223419561|NCT02958358|OTHER|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
224035059|NCT02000427|DRUG|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
223419562|NCT00878566|OTHER|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
223419563|NCT00878566|OTHER|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
223419564|NCT03147079|BEHAVIORAL|Lifestyle intervention|
223419565|NCT05713669|BEHAVIORAL|Encounter visit with Patients|Participants in this encounter group will be asked to complete a pre and post-intervention survey, participate in a meeting with a former ICU patient at a post-ICU clinic, and undergo an in-person interview within fourteen days following the encounter.
223419566|NCT05713669|BEHAVIORAL|Non-encounter surveys|Surveys will be completed pre and post patient follow-up.
223419567|NCT03490461|DRUG|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
223419568|NCT05233748|DEVICE|Stochastic Resonance (SR)|The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
223419569|NCT06010693|DRUG|Daridorexant|Participants will receive one Daridorexant 50mg tablet, orally, once daily for about 28 consecutive night on each night approximately 30mintues before participants intends to try to sleep.
223419570|NCT06010693|DRUG|Placebo|Participants will receive one placebo matched to daridorexant 50 mg tablet , orally, once daily for about 28 consecutive nights on each night approximately 30mintues before participants intends to try to sleep.
223419571|NCT01105078|PROCEDURE|Flow rate|Different flow rate during cardiopulmonary bypass
223419572|NCT00811811|BEHAVIORAL|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
223419573|NCT00811811|BEHAVIORAL|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
223419574|NCT06685653|BIOLOGICAL|Adebrelimab+RGL-270|"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"
223419575|NCT06685653|BIOLOGICAL|Adebrelimab+RGL-270/single RGL-270|"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"
223419576|NCT06086145|OTHER|No intervention|No intervention
223419577|NCT04126902|OTHER|interleukin-6, presepsin and pentraxin-3|measurements and compare
223419578|NCT06684509|DRUG|Atrovastain|atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
223419579|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 1 ml/kg
223562223|NCT01177553|PROCEDURE|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
224035060|NCT05269836|DEVICE|Surgify Safety Burr|Use of Surgify Safety Burr in hard tissue cutting, head and spine area
224035061|NCT05488236|OTHER|Nuclear magnetic resonance analysis of embryo culture medium|Analysis of culture medium from euploid and aneuploid embryos by magnetic nuclear resonance.
224137344|NCT00305747|DRUG|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
223419580|NCT05117281|DRUG|Levobupivacaine|Plain, isobaric levobupivacaine (0.25%) 0.25 mg/kg
223419581|NCT04183153|DEVICE|Repetitive Transcranial Magnetic Stimulation|Participants will receive repetitive transcranial magnetic stimulation (rTMS) to determine if stimulating areas with activating functional connectivity will activate the hypothalamus and in turn, have a measurable effect on hormone levels.
223419582|NCT06667349|DRUG|Ticagrelor|Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
223419583|NCT06395506|DIETARY_SUPPLEMENT|Creatine|Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
223419584|NCT05902091|BEHAVIORAL|Neurophysiology-based intervention|
223419585|NCT01038401|PROCEDURE|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
223419586|NCT01038401|BIOLOGICAL|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
223419587|NCT03719248|DEVICE|thoracic epidural|high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
224035062|NCT01109836|BEHAVIORAL|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
224137345|NCT01179347|DRUG|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
224137346|NCT01179347|DRUG|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
224137347|NCT02692456|DEVICE|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
223419588|NCT03088163|DEVICE|Diffusion weighted magnetic resonance imaging|The enrolled colorectal liver metastases patients will receive DWI-MRI screening to evaluate the liver metastases before the chemotherapy, after the first cycle of chemotherapy and in the regular efficacy evaluation time, respectively.
223419589|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with the bypassed length of the small intestine set at 150 centimeters from the duodenojejunal junction. This shorter limb length is designed to achieve weight loss while potentially reducing the risk of nutritional deficiencies. The procedure is performed laparoscopically, with the stomach divided to create a gastric tube attached to a loop of the small intestine. Postoperative outcomes will include assessments of weight loss, total weight loss percentage, excess weight loss percentage, and nutritional markers such as albumin, calcium, and iron.
223419590|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction)|This intervention involves performing a One Anastomosis Gastric Bypass surgery with a bypassed length of 170 centimeters from the duodenojejunal junction, offering an intermediate limb length. This distance is intended to balance weight loss effectiveness with moderate risks of nutritional deficiencies. The laparoscopic procedure involves creating a gastric tube attached to a segment of the small intestine, bypassing the proximal portion. Outcomes monitored postoperatively include weight loss, percentage of total and excess weight loss, and nutritional parameters such as albumin, calcium, and iron levels.
223419591|NCT06664099|PROCEDURE|One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)|This intervention consists of performing a One Anastomosis Gastric Bypass with the bypass length set at 200 centimeters from the duodenojejunal junction. This longer bypass length is designed to maximize weight loss outcomes but may carry a higher risk of nutritional deficiencies. The procedure is done laparoscopically, where the stomach is divided, creating a tube that is joined to the small intestine at the specified length. Postoperative assessments will focus on weight loss effectiveness, total and excess weight loss percentages, and the risk of nutritional deficiencies by measuring markers such as albumin, calcium, and iron.
223419592|NCT04194762|OTHER|Non pharmacological therapy|treadmill training and cycling training in equal intensity exercise.
223419593|NCT03473639|DRUG|Entinostat|In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
224035063|NCT03859726|DIAGNOSTIC_TEST|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
223419594|NCT03473639|DRUG|Capecitabine|In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
223419595|NCT05482373|DIETARY_SUPPLEMENT|Oleuropein from olive tree|The capsules intake will last for a total of 4 months.
223562224|NCT01177553|DEVICE|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
224035064|NCT03859726|DIAGNOSTIC_TEST|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
224035065|NCT02304848|OTHER|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
224035066|NCT01288872|DRUG|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
223419596|NCT05482373|DIETARY_SUPPLEMENT|Placebo|The capsules intake will last for a total of 4 months.
224035067|NCT01162213|DIETARY_SUPPLEMENT|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
223562225|NCT01969396|DEVICE|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
223562226|NCT01969396|DEVICE|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
223562227|NCT01076868|DRUG|Primaquine|Primaquine x 14 days
224035068|NCT02208297|DRUG|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
224035069|NCT02208297|DRUG|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
223419597|NCT06068829|DRUG|Inebilizumab|Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
223419598|NCT06068829|DRUG|Rituximab(RTX)|RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
223562228|NCT03319563|DRUG|Local anesthetic-epinephrine|"* Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~* Lidocaine 5 mg/Kg.~* Epinephrine 5 mcg/ml of the total volume.~* Add normal saline to a total volume of 100 ml/10 cm of the wound length."
223562229|NCT03319563|DRUG|Saline|normal saline 100 ml/10 cm of the wound length
224035070|NCT04160351|DEVICE|Theranova 400|medium cut-off dialyser
224035071|NCT04160351|DEVICE|Elisio-19H|high flux dialyser
224035072|NCT05227872|DEVICE|ultrasound|POCUS
224035073|NCT03565276|DRUG|Tranexamic Acid|A single dose of intravenous TxA in 100ml of 0.9% sodium chloride at 50mg/min, via a dose-escalation design
224137348|NCT02692456|DEVICE|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
224298600|NCT02701413|DEVICE|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
224298601|NCT02701413|DEVICE|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
223419599|NCT01767506|OTHER|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
224298602|NCT00887328|DRUG|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
223419600|NCT01767506|OTHER|Usual care|Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
224035074|NCT00792454|BEHAVIORAL|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
224137349|NCT01540968|BEHAVIORAL|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
224298603|NCT00887328|DRUG|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
224298604|NCT04654897|DRUG|[14C]-NT-814|120 mg radioactive labeled elinzanetant (\[14C\]-NT-814) oral suspension containing NMT (not more than) 5.6 MBq (megabecquerel) \[14C\].
223419601|NCT03854370|OTHER|Baby shampoo|baby shampoo will be used to prepare the surgical site prior to incision
223419602|NCT03854370|OTHER|Betadine|Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision
223419603|NCT03854370|OTHER|Peridex|Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision
224035075|NCT02708095|DRUG|Baricitinib|Administered orally
223419604|NCT03854370|OTHER|TechniCare|TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
223419605|NCT06545773|PROCEDURE|Root Canal Treatment with ProTaper Next Nickel-Titanium File (PTN)|ProTaper Next (Dentsply Sirona) is a rotational system made of a nickel-titanium alloy called M-Wire. It has a rectangular cross-sectional design; thus, only two sides touch the root canal. Five files are available: X1 17/. 04, X2 25/.06, X3 30/. 07, X4 40/.06, and X5 50/.06. This file aggressively removes the coronal dentine of root canals due to its large taper. PTN nickel-titanium systemis used in root canal treatments to debride and shape the root canals.
223419606|NCT06545773|PROCEDURE|Root Canal Treatment withTruNatomy Nickel-Titanium File (TN)|TruNatomy (Dentsply Sirona) is a heat-treated nickel-titanium system that consists of an orifice modifier, glide path, and shaping files. The TruNatomy Small, Prime, and Medium files have sizes of 20/.04, 26/.04, and 35/.04, respectively. It has a rectangular cross-section and a regressive taper. Its slim design allows for a conservative preparation of root canals and the preservation of the coronal dentine. TN nickel-titanium system is used in root canal treatments to debride and shape the root canals.
223419607|NCT04071548|OTHER|HIIT Exercise|"HIIT exercise bike protocol~* 3 minute warm up~* Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~* 10x60 second Recovery period~* 5 minute cool-down"
223419608|NCT00452673|DRUG|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
223419609|NCT00452673|DRUG|Capecitabine|Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
224035076|NCT02708095|DRUG|Placebo|Administered orally
224035077|NCT04388501|DRUG|Milvexian|Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.
224035078|NCT04388501|DRUG|Atorvastatin|Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.
224137350|NCT06171672|OTHER|Semi-structured interview|Pediatric intensive care nurses in Hong Kong will be invited to join an individual in-depth semi structured interview.
224298605|NCT03804398|DEVICE|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
224298606|NCT03804398|DEVICE|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
224298607|NCT00472797|DRUG|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
224298608|NCT00472797|DRUG|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
224298609|NCT03876977|PROCEDURE|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
223419610|NCT03152331|BEHAVIORAL|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
223419611|NCT02656290|DEVICE|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
223419612|NCT04259203|BEHAVIORAL|Erickson hypnosis|Erickson hypnosis sessions performed by an experienced hypnotherapist, according to a pre-established protocol : 5 sessions (1 per week). Between each session : exercise of auto-hypnosis by the patient himself, at home
223419613|NCT05504486|DRUG|Brexpiprazole|Oral tablet; take once daily; target daily dose of 2 mg
223419614|NCT04638881|DRUG|Magnesium sulfate|Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.
223419615|NCT04638881|DRUG|Normal Saline|Placebo. Bolus and infusion administered similarly under general anesthesia.
223419616|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
223419617|NCT05195918|COMBINATION_PRODUCT|EGCG 300 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 300 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
223419618|NCT05195918|COMBINATION_PRODUCT|Placebo 2 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
223419619|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Nintedanib|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib"
223419620|NCT05195918|COMBINATION_PRODUCT|EGCG 600 mg + Pirfenidone|"Dietary Supplement: EGCG Capsules with Teavigo EGCG (at least 94% purity). 600 mg EGCG (2 capsules) taken orally daily for 12 weeks.~Drug: Pirfenidone"
223419621|NCT05195918|COMBINATION_PRODUCT|Placebo 4 capsules + Nintedanib or Pirfenidone|"Dietary Supplement: Placebo Placebo (4 capsules) taken orally daily for 12 weeks.~Drug: Nintedanib~Drug: Pirfenidone"
224035079|NCT02749448|OTHER|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
224137351|NCT06332027|DIAGNOSTIC_TEST|Hystro-Salpingo-Foam-Sonography (HYFOSY)|antibiotic prophylaxis oral azithromycin 500 mg per day 3 days the patient lie in dorsal lithotomy cervix visualized by Cusco speculum, cleaned with betadine 7% 6-Fr pediatric Foley's balloon catheter will be introduced into the cervical canal inflated with 2 ml of saline to prevent backflow of contrast through the cervix TV-US probe will be introduced,The foam will be created by mixing 3-4ml of 2% rialocaine gel (lidocaine hydrochloride 2%, Riadh Pharma,Saudi Arabia) with 16-17 ml of saline shaking the mixture between two syringes until a whitish suspension 20ml of lidocaine foam infused into uterine cavity observing the flow in each fallopian tube using greyscale and power Doppler (PD) 2D ultrasound Foam flow over the whole length of the tube fimbrial outflow, or peritoneal spillage of contrast provided evidence of tubal patency Patients observed for15-30 min for any complication or increase in pain Comparison between results and that of laparoscopy in operative list
223419622|NCT05554536|PROCEDURE|PEEP titration trial|PEEP trial, starting from clinical PEEP 16 cmH2O and ending at PEEP 6 cmH2O. The PEEP trial will be stopped for haemodynamic instability (defined as arterial pressure \< 80 mmHg and /or heart rate \> 150 bpm) or desaturation (defined as SpO2 \< 92%).
223419623|NCT01608087|DRUG|BI 695502|BI 695502 single i.v. infusion
223419624|NCT01608087|DRUG|bevacizumab|bevacizumab single i.v. infusion
223419625|NCT01608087|DRUG|bevacizumab|bevacizumab single i.v. infusion
223562230|NCT01152047|DRUG|oxytocin|40mU/min as infusion of oxytocin
223562231|NCT02126553|OTHER|Laboratory Biomarker Analysis|Correlative studies
223562232|NCT02126553|DRUG|Lenalidomide|Given PO
223419628|NCT02760212|DEVICE|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
223419629|NCT02760212|OTHER|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
223419630|NCT04984863|DEVICE|Magnetically controlled capsule endoscopy|Magnetically controlled capsule endoscopy (MCE) is a non-invasive detection method independently developed in China that covers the whole digestive tract (except colon) mucosa.
223419631|NCT01671072|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
223419632|NCT01671072|DRUG|Normal Saline|Sodium chloride 0.9%, 3.5ml
224035080|NCT05067998|DIETARY_SUPPLEMENT|IV Vitamin Infused Therapy Treatment|Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
224035081|NCT05067998|DRUG|Herbal medicine|Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
223419633|NCT04958681|OTHER|exercise|The participants were subsequently asked whether the pandemic had altered their physical activity status and rate the severity of reduction in mobility level compared to the period before the Covid-19 with the following options: none, 0; mild, 1; moderate, 2; severe, 3. Then, the participants were also asked whether they perform a physical exercise in a home setting. We recorded regular outdoor physical activity and home-based exercises (only after the pandemic) as a dichotomous variable (yes or no). The number of physical activity days per week was also obtained.
223562233|NCT01218750|PROCEDURE|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
223562234|NCT04082390|DIETARY_SUPPLEMENT|RELEASE|Dietary supplement
223419634|NCT00348595|DRUG|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
223562235|NCT04082390|DIETARY_SUPPLEMENT|Placebo|Placebo
223562236|NCT01194089|DRUG|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
224035082|NCT04457895|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)"
224035083|NCT04457895|OTHER|no intervention|no yoga session at home and no yoga -therapeutic educatuion session
224035084|NCT06445608|DEVICE|Percutaneous Mechanical Circulatory Support|Patients are randomized to receive one of two types of percutaneous mechanical circulatory support devices during a high-risk PCI procedure.
224035085|NCT05207917|PROCEDURE|Gastric bypass|In Roux-en-Y gastric bypass (RYGB), the left crus will be dissected free, any hiatal hernia left in place. The minor curvature is opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch will be created by firing one horizontal and two vertical staple loads. The ligament of Treitz is then identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one linear stapler (full length of the stapler), creating an antecolic, antegastric alimentary limb. The opening will be closed using a single row, running absorbable suture. An entero-enteroanastomosis will be made 120 cm distal of the gastro-enteroanastomosis. The introductory opening is closed with a single row, running absorbable suture. The small intestine will be divided with one load between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a biliopancreatic limb of 60 cm.
224035086|NCT05207917|PROCEDURE|Sleeve gastrectomy|In sleeve gastrectomy (SG) a large part (80%) of the ventricle is removed. The greater curvature will be dissected free starting 4-5 cm from the pylorus up to the angle of Hiss. The left crus is then visualized and inspected for hiatal hernia. Small sliding hernias and wide hiatus are left in situ. The ventricle will then be lifted and any adhesions in the lesser sac divided. A 35 Fr bougie is placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads are always green or purple, while blue or tan loads are used for the rest of the ventricle. The last stapler is placed 5 mm laterally to the angle of Hiss. The staple line will then be inspected and secured with clips for additional haemostasis, no oversewing or buttressing material is routinely used.
224035087|NCT05207917|PROCEDURE|Single anastomosis sleeve ileal (SASI) bypass|The SASI bypass will performed with a similar entry of the abdominal cavity. A 6-port set up and a liver retractor is utilized. The small bowel is measured 300cm from the ileocecal valve, in sequences of 10cm, with the small bowel stretched and markers placed on the graspers, and connected to the antrum of the stomach with a 45mm stapler. The anastomosis is positioned slightly ventral on the antrum. The antrum is opened ventrally 5 cm proximal to the pylorus, just below the horizontal axis of canalis pylori. A 12 mm port positioned left to the midline is used for introduction of the stapler, which is directed distally from the patient's left to right side. 2.5 cm of the 45 mm stapler device is used for firing the anastomosis, which is completed with a 2-0 PDS running suture. The fascia defect is closed for the port where the specimen is extracted. The mesenteric defect is not closed.
224035088|NCT02366819|DRUG|Oxaliplatin|Given IV
224035089|NCT02366819|DRUG|Leucovorin Calcium|Given IV
223562237|NCT01194089|DRUG|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
224035090|NCT02366819|DRUG|Irinotecan Hydrochloride|Given IV
224035091|NCT02366819|DRUG|Fluorouracil|Given IV
224035092|NCT02366819|PROCEDURE|Conventional Surgery|Undergo surgery
224137352|NCT01570933|DEVICE|NivNava|Non-invasive Nava ventilation mode on nasal cannula
224137353|NCT01570933|DEVICE|Cpap|nasal Cpap on nasal cannula
223562238|NCT00072943|DRUG|anti-Interferon-gamma monoclonal antibody|
223562239|NCT05781334|OTHER|Virtual Consult Intervention|The intervention will consist of a quality improvement (QI)-based virtual consult designed by a multi-disciplinary team that will aim to address provider-level, patient-level, and system-level barriers to cardio-renal-metabolic disease medications
223562240|NCT06428942|OTHER|low-potassium vegetables|low-potassium vegetables 3 to 5 serving according to their daily suggested requirement
224137354|NCT01031485|DIETARY_SUPPLEMENT|Milk peptides and plant sterols|
224137355|NCT01031485|OTHER|Placebo|
224137356|NCT02142257|PROCEDURE|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
224137357|NCT02142257|DEVICE|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
224137358|NCT03036111|DRUG|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
224137359|NCT03036111|PROCEDURE|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
223419635|NCT05213013|OTHER|inhaler treatment with the toy-type nebulizer and training on on the use of a nebulizer/mask|"The children (experimental group), will receive training and inhaler treatment with the toy-type nebulizer. The training topics is as follows:~* For effective nebulization, it should be ensured that the parts of the mask are assembled completely and correctly.~* The child should be in an upright sitting position during nebulization.~* During the procedure, normal breathing should be given into the mask.~* As the medicine is finished, a sizzling sound is heard from the device.~* After the nebula is over, the face should be washed and the mouth should be rinsed to remove the drug residues accumulated on the face and mouth."
223419636|NCT05475587|OTHER|Routine care|Both two groups received the same routine care.
223419637|NCT05427760|DRUG|Oxygen|After changing the diaper, free flow oxygen will be provided to the diaper area for 1 hour with an oxygen cannula placed inside the diaper (oxygen flow is %21 Fio2, 5 L/min)
223419638|NCT04457375|DIAGNOSTIC_TEST|TDC|measurements
223419639|NCT00665587|PROCEDURE|Cox-MAZE III|Maze procedure according to standards of the department
223419640|NCT00459004|DRUG|rimonabant (SR141716)|
223419641|NCT00245076|BEHAVIORAL|smoking cessation intervention|
223419642|NCT00245076|OTHER|internet-based intervention|
223419643|NCT04898283|BIOLOGICAL|10,000 MG01 +10,000 T521|Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
223419644|NCT04898283|BIOLOGICAL|30,000 MG01 +10,000 T521|Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
223419645|NCT04898283|OTHER|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients
223562241|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
223562242|NCT00695955|DRUG|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
223419646|NCT04587791|DRUG|400mg Cannabidiol|Participants will receive 400mg
223419647|NCT04587791|DRUG|800mg Cannabidiol|Participants will receive 800mg
223419648|NCT04587791|DRUG|1200mg Cannabidiol|Participants will receive 1200mg
223419649|NCT04587791|DRUG|Saline|Participants will receive saline
223419650|NCT06968572|DRUG|HSK41959|Oral administration, QD
223562243|NCT06635785|DRUG|AI-081|AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.
223562244|NCT01384552|OTHER|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
223562245|NCT01384552|OTHER|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
223419651|NCT06968546|DRUG|Intranasal Sufentanil|After randomization, the children will receive intranasal Sufentanil .
223419652|NCT06968546|DRUG|Intranasal Ketamine (IN)|After randomization, chidren will receive intranasal Ketamine
223419653|NCT06966635|DRUG|Sodium Bicarbonate Oral Capsule|On the basis of the standard uric acid-lowering treatment plan, sodium bicarbonate should be taken three times a day, 1.0g each time
223562246|NCT03026114|OTHER|No intervention is planned in our study.|No intervention is planned in our study.
223562247|NCT04446624|OTHER|Music therapy intervention|Group psychotherapy with music intervention
223419654|NCT06966635|DRUG|Potassium Citrate Tablets|On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time
223419655|NCT06966635|DRUG|uric-acid-lowering drug|The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable. The treatment plan for lowering uric acid remained unchanged for 4 weeks after enrollment in the clinical study until the endpoint.
223562248|NCT02660450|OTHER|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
223562249|NCT02660450|OTHER|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
224137360|NCT01481909|DRUG|Rupatadin|20 mg, 28 days over 60 days
224137361|NCT04415619|PROCEDURE|Xenograft bone substitute (Osteo-biol)|Xenograft bone substitute will be placed over the implant to cover the bone defect after extraction.
224137362|NCT00425126|DRUG|Epoetin Alfa|
224137363|NCT02800772|DIETARY_SUPPLEMENT|acetic acid|
224137364|NCT02800772|DIETARY_SUPPLEMENT|saline|
224137365|NCT02517593|GENETIC|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (\<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (\>40%).
223419656|NCT01351792|DRUG|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
223419657|NCT01351792|DRUG|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
223419658|NCT01916681|DEVICE|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
223419659|NCT01916681|DRUG|Misoprostol Alone|Misoprostol will be used alone to induce the patient
223419660|NCT01916681|DEVICE|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
223419661|NCT01916681|DEVICE|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
223562250|NCT02660450|OTHER|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
224035093|NCT06105723|BEHAVIORAL|Pathway to Healthy Aging care|The ICOPE-based personalized care planning comprises two home visits. In 1st visit, a comprehensive assessment proposed by the WHO-ICOPE model is conducted to identify eight possible health problems including malnutrition, reduced physical fitness, fall risk, cognitive decline, insomnia, pain, psychological distress and social loneliness. After health problem identification, each participant receives a personalized care prescription. 2nd visit adopts a goal-oriented empowerment 3-step cycle to personalize the care planning: 1) communicating assessment results to increase healthy self-awareness; 2) supporting setting person-directed goals to address health problems; 3) identifying health actions and personalizing goal setting to participants' contexts. The 12-week healthy aging empowerment comprises three core activities for healthy aging promotion, including interactive health education, health message broadcasts, and three case conferences for goal monitoring and health counseling.
224298610|NCT04072016|DEVICE|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
224298611|NCT00988689|OTHER|Dietary Intervention|soup with or without starch
224298612|NCT00148330|DRUG|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.
223419662|NCT05707468|DRUG|ADT combined with abiraterone|The patients will receive long-term ADT combined with abiraterone.
223419663|NCT05707468|RADIATION|neoadjuvant hormone and RT|The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
223419664|NCT02821338|DRUG|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
223419665|NCT02476812|BEHAVIORAL|Positive Piggy Bank|Already noted.
223419666|NCT02014493|PROCEDURE|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
223419667|NCT02014493|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
223419668|NCT01942486|DEVICE|Investigational Coating|
223419669|NCT03728426|DRUG|Letermovir|"Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day."
223419670|NCT06608563|PROCEDURE|Fissure sealant without adhesive system (NO BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~5. Lightcuring: The material will be lightcured for 20 seconds."
223419671|NCT06608563|PROCEDURE|Fissure sealant with adhesive system (BOND)|"1. Cotton roll isolation~2. Etching of the enamel surface: 17% phosphoric 15 seconds over the surface to be sealed (Phosphoric etchant gel - Vococid, VOCO)~3. Washing/drying: a 3-1 syringe will be used to rinse all etch material from the toothsurface.~4. Adhesive system application: the adhesive system (Futurabond, VOCO) single dose capsule will be applied over the surface to be sealed for 5 seconds using a microbrush. The adhesive system will be air thin dried and lightcured for 10s before sealant placement.~5. Sealant application: a light-curing nano-hybrid fissure sealant material (Grandio Seal; VOCO) will be applied using the applicator tip.~6. Lightcuring: The material will be lightcured for 20 seconds."
223419672|NCT06685341|DRUG|YZJ-1139|YZJ-1139
223419673|NCT06685341|DRUG|Placebo|Oral tablet
223419674|NCT06685341|DRUG|Zolpidem|Oral tablet
223419675|NCT04616638|BEHAVIORAL|Resistance Training for Empowerment (RT-POWER)|The EG intervention was designed using the Social Cognitive Theory and its four sources of self-efficacy to promote a participant's (a) involvement in exercise planning, (b) muscular strength, and (c) independent functional performance. It consisted of three phases, which were adapted from the Self-Determined Learning Model of Instruction (Wehmeyer et al., 2000). This model draws from theory and research on self-management and self-control (Bandura, 1986; Martin et al., 1988). Participants were taught by their coaches how to (a) set a goal to meet fitness needs (Phase 1), (b) make a plan to meet goals (Phase 2), and (c) adjust actions to complete the plan (Phase 3).
223562251|NCT01961284|DEVICE|Zygomatic implant placement|
223562252|NCT01961284|DEVICE|conventional implants and augmentation of maxilla|
224298613|NCT01621191|DRUG|Duloxetine|Administered Orally
224298614|NCT01389583|DRUG|AUY922|70 mg/m2 60-min i.v. infusion weekly
223562253|NCT03626272|OTHER|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
224298615|NCT01884428|DRUG|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
223419676|NCT04616638|BEHAVIORAL|A traditional RT intervention|The control intervention also consisted of a three-phase instructional process. Consistent with traditional RT interventions (ACSM, 2009), the coaches rather than the participants, were the primary agents for goal-setting, exercise planning, goal attainment monitoring, and readjusting of the exercise plan. Neither the visual activity schedules nor the system of least-to-most prompts was used in this intervention.
223419677|NCT02176863|BIOLOGICAL|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
223419678|NCT02176863|DRUG|Placebo|Normal saline solution
223419679|NCT00860535|OTHER|Comparator: Biomarker evaluation|"Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a \~3.5 month period.~Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day \[qd\]), dasatinib (recommended dose 70 mg twice a day \[bid\]), or nilotinib (recommended dose 400 mg bid).~Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I."
223419680|NCT02989376|PROCEDURE|After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.|When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
223419681|NCT00005807|DRUG|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
223419682|NCT03024762|PROCEDURE|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
223419683|NCT00231114|DEVICE|Alair System|Treatment of airways with the Alair System
223419684|NCT00231114|DEVICE|Alair System|Sham treatment of airways with the Alair System
223419685|NCT06335693|OTHER|Radiotherapy|The patients after radical prostatectomy with high-risk pathological factors will receive adjuvant hypofractionated radiation therapy in 15 fractions.
223419686|NCT01949844|DRUG|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
223419687|NCT01949844|DRUG|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
223419688|NCT01949844|DEVICE|Myocardial perfusion MRI|
223419689|NCT03748810|DRUG|Empagliflozin|Empagliflozin 25 mg once daily add on the background OADs for 3 years
223419690|NCT03748810|DRUG|Dapagliflozin|Dapagliflozin 25 mg once daily add on the background OADs for 3 years
223419691|NCT03909061|BEHAVIORAL|Wheelchair Maintenance Training|Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
223419692|NCT02048826|DEVICE|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
223419693|NCT02048826|DEVICE|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
223419694|NCT04490044|OTHER|Under & Over rehabilitation tool|Under \& Over is a tool consisting of a 40cm x 40cm white plastic board, two coloured laces and a series of patterns to complete. It enables people to create patterns by threading each lace under, and over the board. It has been designed and developed with people whose upper limb function is affected by their MS. Administration time can be dependent on the person completing it.
223419695|NCT06683027|BEHAVIORAL|Nonattachment for Post Traumatic Stress|"This study seeks to cultivate nonattachment specifically for the alleviation of symptoms of post-traumatic stress. This is an 8-week online intervention where, following a Qualrics-hosted pre-screen, users are directed to www.npts.online to use as they wish. Users are then solicited to re-take quantitative assessments, and a subset of 10 (target number) will be recruited for a qualitative interview regarding their experience of the intervention.~A final prompt for assessment re-takes will follow at 3 months post-intervention to determine longitudinal efficacy."
224137366|NCT00866268|DEVICE|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
223419696|NCT05340933|OTHER|Voice registration|Voice registration
223419697|NCT04436562|DRUG|[14C]-Poziotinib|Single oral administration of 8 mg (as the hydrocholoride salt) of \[14C\]-poziotinib
224298616|NCT01884428|DRUG|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
224298617|NCT01884428|DRUG|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
224298618|NCT01884428|DRUG|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
224298619|NCT01884428|DRUG|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
223419698|NCT03721692|DEVICE|RIC|The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
223419699|NCT00419848|DRUG|Doxycycline|Cap 100mg- 100mg/daily
223419700|NCT00419848|DRUG|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
223419701|NCT03592667|DRUG|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
223419702|NCT03592667|DRUG|Placebo - Cap|One per day before breakfast during 12 weeks.
223419703|NCT04470544|DRUG|Camostat Mesilate|Given PO
223419704|NCT04470544|OTHER|Standard of Care|At Investigator discretion
223419705|NCT04379531|DIAGNOSTIC_TEST|Low-dose Chest CT|Patients referred by the primary care physician with suspected pneumonia.
223419706|NCT00823069|DEVICE|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
224298620|NCT04145583|DRUG|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
224298621|NCT04145583|DRUG|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
223419707|NCT05296668|DEVICE|Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)|(group C) to receive a cuffed ETT for airway management.
223419708|NCT05296668|DEVICE|Uncuffed ETT group|(group U) to receive an uncuffed ETT for airway management.
224298622|NCT04928274|OTHER|ball attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
223419709|NCT00712881|DRUG|Liposomal doxorubicin hydrochloride|Liposomal doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
223419710|NCT00712881|DRUG|Cyclophosphamide|Cyclophosphamide will be administered per dose and schedule specified in the arm description.
223419711|NCT00712881|DRUG|Trastuzumab|Trastuzumab will be administered per dose and schedule specified in the arm description.
223419712|NCT00712881|DRUG|Free doxorubicin hydrochloride|Free doxorubicin hydrochloride will be administered per dose and schedule specified in the arm description.
223419713|NCT00712881|DRUG|Docetaxel|Docetaxel will be administered per dose and schedule specified in the arm description.
223419714|NCT05991336|GENETIC|Gene therapy|Autologous edited hematopoietic stem cell transplantation
223419715|NCT00113854|DRUG|Mannitol|
223419716|NCT02931084|OTHER|Rehabilitation|In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
223419717|NCT02931084|PROCEDURE|ACL reconstruction|Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
223419718|NCT06682351|DRUG|Metformin|16 weeks of using metformin: Dosing will initiate at 500mg TID and increased to 1000mg BID after one week.
223419719|NCT06682351|DRUG|GLP-1A|16 weeks using GLP1a: Dosing will be titrated per clinical guidelines and as per FDA approved clinical protocols.
223419720|NCT06682351|DIETARY_SUPPLEMENT|MED|16 weeks of following a Mediterranean diet: a mostly plant-based diet that includes vegetables, whole grains, whole fruits, legumes, nuts and seeds, with fish being the primary animal protein, and olive oil the primary fat.
223419721|NCT06618820|DRUG|Tranexamic acid|One dose consists of three 650 milligram (mg) capsules, to be taken orally.
223419722|NCT06618820|DRUG|Placebo|One dose consists of three microcrystalline cellulose capsules.
223419723|NCT00002251|DRUG|Ganciclovir|
223419724|NCT02609620|DEVICE|Peristaltic Feeding Tube|
223419725|NCT02609620|DEVICE|ConvaTec Levin Duodenal Tube|
223419726|NCT05845762|DRUG|Obinutuzumab Injection|1000mg intravenous injection
224035094|NCT06458205|COMBINATION_PRODUCT|Multi-component intervention for smokers|"1. Community-based spirometry pulmonary function tests and result interpretations and health education;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for smokers whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to smokers with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients or asthma patients;~7. To actively include smokers whose blood pressure's higher than 140/90 mmHg or/and whose random blood glucose higher than11.1mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \<18.5;~9. Pay-for-population mechanism for medical practitioners."
224035095|NCT05928403|OTHER|total knee prosthesis|Comparison of three cohorts on the return to sport of patients after total knee prosthesis according to the type of prosthesis
224035096|NCT04108897|DRUG|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
224035097|NCT04108897|DRUG|Ivermectin Topical|1% topical ivermectin.
224035098|NCT05825261|OTHER|voice sampling|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
223419727|NCT00966004|DRUG|YM178|oral
223419728|NCT00966004|DRUG|Placebo|oral
223419729|NCT00966004|DRUG|tolterodine|oral
223419730|NCT02610335|OTHER|Control group (C)|"* kyphosis reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home."
223419731|NCT02610335|OTHER|Test group|"* spinal mobility reeducation on Huber platform during 2 weeks,~* patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~* flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~* exercises on cycle ergometer or walking on treadmill : to continue at home."
223419732|NCT00060203|DRUG|brostallicin|"Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
223419733|NCT01194999|DEVICE|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
223419734|NCT01609699|DEVICE|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
223419735|NCT01609699|DEVICE|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
223419736|NCT04176315|OTHER|Conventional Home-based Rehabilitation Plan|Usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients. Participants receive inpatient care and rehabilitation for 2 weeks. At discharge, they receive a 5-exercise home-based rehabilitation plan. For the sake of homogeneity of all participants, they receive from 2 to 4 of training prior to discharge. At home, participants shall perform the exercises in the rehabilitation plan daily.
223419737|NCT04176315|DEVICE|ReHub Home-based Rehabilitation Plan|"Combination of the usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients with ReHub, a telerehabilitation platform that serves as a guide to perform the TKA rehabilitation exercises.~Participants receive inpatient care and rehabilitation at San Camillo for 2 weeks. At discharge, a 5-exercise home-based rehabilitation plan is carried out by a site physiotherapist by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor. Participants receive from 2 to 4 sessions of ReHub prior to discharge.~At home, participants shall perform the exercises in the rehabilitation plan with ReHub daily. The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. Participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
223562254|NCT02613494|DRUG|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
223562255|NCT02613494|DRUG|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
223562256|NCT02613494|OTHER|Placebo|Placebo twice daily, increasing to placebo three times daily
223562257|NCT01804933|DRUG|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively
223562258|NCT02793349|DEVICE|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
223562259|NCT03466281|BEHAVIORAL|Structured patient group education|Patient education in a group setting
223562260|NCT03466281|BEHAVIORAL|Education via Internet|Patient education via the internet
223562261|NCT03621176|OTHER|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
223419738|NCT05262907|DEVICE|Transthoracic Echocardiogram or Cardiac MRI|Non-invasive imaging of the heart to evaluate structure and function.
223562262|NCT03773536|DRUG|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
223562263|NCT04588857|DRUG|Dexamethasone|The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.
223562264|NCT04588857|DRUG|Saline|The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.
223562265|NCT01263431|PROCEDURE|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
223562266|NCT01263431|PROCEDURE|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
224035099|NCT05825261|OTHER|capnometry|Patients with COPD will perform several voice-related tasks and capnometry at rest. Thereafter a 5-STS will follow and the voice-related task/capnometry will be repeated
224035100|NCT03187977|BEHAVIORAL|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
224035101|NCT05055414|DRUG|UI030|Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days
224035102|NCT03454308|BEHAVIORAL|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
223562267|NCT04105348|DIAGNOSTIC_TEST|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
223562268|NCT01106651|DRUG|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
223562269|NCT01106651|DRUG|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
223562270|NCT01106651|DRUG|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
223419739|NCT05262907|DEVICE|Ventripoint Echocardiogram|Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
224298623|NCT04928274|OTHER|locator attachment to retain mandibular over denture|each patient in group receive 3 locator attachment for over denture retention
224298624|NCT04928274|OTHER|telescopic attachment to retain mandibular over denture|each patient in group receive 3 telescopic attachment for over denture retention
223419740|NCT01985607|DIETARY_SUPPLEMENT|new extensively hydrolysed formula|
223419741|NCT01985607|DIETARY_SUPPLEMENT|Extensively hydrolysed formula|
223562271|NCT01106651|DRUG|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
223562272|NCT00602004|DRUG|losartan|losartan 50 mg a day
223562273|NCT06187194|DEVICE|IRE System|Irreversible Electroporation (IRE) System for Tonsil Reduction for The Treatment of Chronic Symptomatic Tonsillar Hypertrophy
223562274|NCT00190021|DRUG|donepezil|
223562275|NCT00144989|DRUG|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
223739436|NCT05449054|PROCEDURE|Anterior colporrhaphy|All patients will be operated by the vaginal route. They are prepared under strict aseptic conditions in the dorsal lithotomy position. The bladder is emptied preoperatively with a thin disposable catheter and antibiotic prophylaxis (cefazolin) is administered before incision. A vasoconstricting solution (combination of vasopression and NaCl) is administered and a vertical anterior vaginal incision is made from the apex to two centimeters short of the external urethral meatus using an electric cautery or a scalpel. The vaginal epithelium is grasped on both sides and the fibromuscular layer of the anterior vaginal wall is sharply dissected laterally to the inferior pubic ramus. The bladder is completely dissected from the apex and up to 4 to 6 cm from the pubic ramus. The anterior colporrhaphy is defined as a native tissue repair and rows of absorbable sutures (2/0 vicryl) are used.
223739437|NCT00000533|BEHAVIORAL|social support|
224035103|NCT03454308|BEHAVIORAL|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
224298625|NCT04780841|DRUG|RDX013|RDX013 is an experimental drug that is a potassium secretagogue
224298626|NCT04780841|DRUG|Placebo|Placebo treatment that looks identical to experimental treatment
224298627|NCT01077466|DRUG|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
223419742|NCT04370756|DIETARY_SUPPLEMENT|Beetroot Juice|Participants randomly assigned to the EX + BR group will consume 140 mL beetroot juice containing approximately 12 mmol of nitrate 3 hours prior to the supervised exercise training component.
223419743|NCT04370756|OTHER|Exercise Training|Participants will perform 8 weeks of supervised exercise training at a frequency of 3x per week.
223562276|NCT00144989|DRUG|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
223562277|NCT06319469|DRUG|silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
223562278|NCT06319469|DRUG|silodosin 8 mg capsule|The participants were assigned to groups A and B. Group B received the 8 mg silodosin capsule. In contrast, Group A was administered the silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet. Over a week, each group administered their designated drug once per day
223562279|NCT03620578|DRUG|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
223562280|NCT00612417|DRUG|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
223562281|NCT03819556|OTHER|Milk protein in fresh milk|Milk protein in increasing doses.
224298628|NCT04514965|OTHER|Blood sampling|Blood sampling
224298629|NCT04514965|DEVICE|Fibroscan|Measurement of liver stiffness
224298630|NCT04514965|OTHER|Question|Question about pruritus
223419744|NCT02135185|OTHER|custom work endurance|Experimental: Rehabilitation effort
223419745|NCT02135185|BEHAVIORAL|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
223419746|NCT06200415|DRUG|Glucosamine Sulfate|Glucosamine sulphate (GLcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of the chitosan with significant anti-inflammatory action.
224298631|NCT00706381|DRUG|Sincalide|
224298632|NCT00706381|DRUG|Ursodiol|
224298633|NCT00706381|PROCEDURE|Fat Meal|600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate
224298634|NCT00706381|PROCEDURE|Carb meal|600 calorie meal containing 100% carbohydrate
224298635|NCT00706381|DRUG|Placebo|IV and/or oral placebo
224298636|NCT00973401|OTHER|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
224298637|NCT02546336|DEVICE|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
224298638|NCT00276952|DRUG|Gonyautoxin|
224298639|NCT00954330|PROCEDURE|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
223562282|NCT05750056|DRUG|lidocaine|Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
223562283|NCT05750056|DRUG|0.9% saline|Patients received a perioperative saline infusion at the same rate and volume as the lidocaine infusion.
223562284|NCT05750056|DRUG|Propofol|An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
223562285|NCT05750056|DRUG|Sufentanil|Sufentail 0.1 ug/kg was administered for sedation induction.
223562286|NCT06045793|DRUG|TNX-1300 (Injection)|Patients will receive a single IV injection of TNX-1300.
223562287|NCT06045793|DRUG|Placebo (Injection)|Patients will receive a single IV injection of placebo with usual care (UC).
223562288|NCT04590404|BEHAVIORAL|Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.|Automated calls to assess smoking status, medication use, and additional support for quit attempt.
223562289|NCT04590404|DRUG|Nicotine Replacement Therapy|FDA-approved forms of nicotine replacement therapy for smoking cessation.
223562290|NCT04590404|DRUG|Varenicline|FDA-approved smoking cessation medication.
223562291|NCT04590404|OTHER|Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)|Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.
223562292|NCT03511014|DEVICE|Microcurrent|Micrucurrent will be apply
223562293|NCT02445014|DEVICE|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
224035104|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Commitment nudge|EHR clinical decision support alerts-clinician commitment to discuss high risk polypharmacy
223562294|NCT03972462|DRUG|NPC-12G Gel 0.2%|Period 1
223562295|NCT03972462|DRUG|Rapamune® 2 mg tablet|Period 2
223562296|NCT00718575|PROCEDURE|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
223562297|NCT05288790|DIETARY_SUPPLEMENT|Probiotic|Dietary supplement
223562298|NCT05288790|DIETARY_SUPPLEMENT|Placebo|Placebo sachet
223562299|NCT04972396|DRUG|Pemvidutide|Injected subcutaneously (SC)
223562300|NCT04972396|DRUG|Metformin|Taken by mouth (PO)
223562301|NCT04972396|DRUG|Atorvastatin|Taken by mouth (PO)
223562302|NCT04972396|DRUG|Warfarin|Taken by mouth (PO)
223562303|NCT04972396|DRUG|Digoxin|Taken by mouth (PO)
223562304|NCT04972396|DRUG|Ethinylestradiol and Levonorgestrel|Taken by mouth (PO)
223562305|NCT02110355|DRUG|AMG 232|Given as an oral tablet in escalating doses
223562306|NCT02110355|DRUG|Trametinib|Trametinib is an anti-cancer agent
223562307|NCT02110355|DRUG|Dabrafenib|Dabrafenib is an anti-cancer agent
223562308|NCT00251368|DRUG|9-Aminocamptothecin (9-AC)|
223562309|NCT00419211|BEHAVIORAL|Exercise|Tailored exercise program
223562310|NCT01581021|DEVICE|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
223562311|NCT01581021|DEVICE|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
223562312|NCT03085134|OTHER|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
223562313|NCT03085134|OTHER|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
223562314|NCT02471534|PROCEDURE|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
223562315|NCT03116035|OTHER|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
223562316|NCT03116035|OTHER|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
223562317|NCT05848466|DRUG|BAT8010 for Injection|Intravenous
223562318|NCT01006655|DRUG|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
223562319|NCT01006655|DRUG|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
223562320|NCT01198704|OTHER|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
223562321|NCT01266109|BEHAVIORAL|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
224035105|NCT05656560|OTHER|Clinician education|Brief, online education module for primary care clinicians
224035106|NCT05656560|BEHAVIORAL|Clinical decision support (CDS)-Justification nudge|EHR clinical decision support alerts-clinician rational for high risk polypharmacy
224035107|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, CSD|Measurement of the stone burden by cumulative stone diameter, the sum of linear longest diameters of all the stones to be treated within one patient as measured on the CT or by additional rendering software
224035108|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, SA|Measurement of the stone burden by surface area, the sum of surface areas of all the stones to be treated within one patient as measured on the CT or by additional rendering software
223562322|NCT01266109|OTHER|Usual Services (US)|Typical community-based substance abuse treatment services
223562323|NCT00054327|DRUG|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
224035109|NCT04746378|DIAGNOSTIC_TEST|Computed Tomography, 3D|Measurement of the stone burden by volume of all the stones to be treated within one patient, as measured on the CT or by additional rendering software
224137367|NCT00866268|DEVICE|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
224035110|NCT04321200|DIAGNOSTIC_TEST|PANDA Gym|Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.
224137368|NCT02586077|DRUG|Exparel|
224298640|NCT00954330|DEVICE|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
224298641|NCT00054912|BIOLOGICAL|EP2101|
224298642|NCT02017548|BEHAVIORAL|Life-extension default advance directive|
224298643|NCT02017548|BEHAVIORAL|Comfort default advance directive|
224298644|NCT03664895|DRUG|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
224298645|NCT02477163|OTHER|Ayurveda treatment|"1. Gokshuradi Guggulu (compound Ayurvedic preparation: Gokshura + Guggulu + Triphala + Trikatu + Musta) - 1 g, 3 times in a day after food with warm water.~2. Varunadi kvath (ingredients: Varuna tvak + Bilva moola + Apamarga + Chitrak moola + Arani + Shigru + Bruhati + Kirattikta + Karanja + Shatavari) - 40 ml 2 times in a day after food.~3. Rasayan Churna (powder of Gokshura + Amalaki + Guduchi in equal quantities ) - 3 g, 3 times a day with water.~4. Bhumyamalaki (Tamalaki Rasayan) tablet - 1 g, 2 times in a day after food with water.~5. Uricare (of Punarvasu Pharmacy, Petlad road, Nadiad) tablet - 1 g, 3 times in a day after food with warm water.~6. Niruha Basti (procto-colonic administration of ayurvedic medicine) with Punarnavadi kvath (decoction) - in the morning, before one hour of the lunch."
224298646|NCT06074484|DRUG|RC48-ADC|4 preoperative cycles of RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 6 cycles of postoperative RC48-ADC（2.0 mg/kg，intravenous (IV) infusion，Q3W）
224298647|NCT06074484|DRUG|AK104|4 preoperative cycles of AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）, followed by surgery, followed by up to 14 cycles of postoperative AK104（10 mg/kg，intravenous (IV) infusion，Q3W）
224298648|NCT00587600|PROCEDURE|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
224298649|NCT00587600|PROCEDURE|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
224298650|NCT01930955|DRUG|Amoxicillin|β-lactam antibiotics
224298651|NCT05243953|DRUG|Levcromakalim|Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
224298652|NCT05243953|DRUG|Placebo|Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
224298653|NCT05530148|BEHAVIORAL|Martial Arts Training Group|Participants in the experimental intervention group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, they will be instructed in the three exercises practiced in the experimental group, known as hubud, chi sau and padwork. Hubud is a turn-based, partnered, coordination drill involving moves derived from numerous martial arts, most often seen in the Filipino martial art of Kali. Chi Sau is a simultaneous contact drill from Chinese Kung Fu, specifically the Wing Chun school. Padwork is an amalgam of punching and kicking combinations used against focus pads or padded sticks to improve coordination, most commonly seen in kickboxing and Muay Thai. Participants will aim to reach a level of comfort and competency in the basic, non-competitive aspects of these exercises by the end of their participation in this intervention.
223562324|NCT00054327|DRUG|cyclophosphamide|Given IV
223562325|NCT00054327|DRUG|cytarabine|Given IV
223562326|NCT00054327|RADIATION|radiation therapy|Patients undergo total body irradiation
223562327|NCT00054327|DRUG|Etoposide|infusion
223562328|NCT00054327|PROCEDURE|Stem Cell Transfusion|
223562329|NCT04044053|DRUG|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
223562330|NCT04044053|DRUG|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
223562331|NCT04044053|DRUG|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
223562332|NCT04044053|DRUG|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
224298654|NCT05530148|BEHAVIORAL|Flexing, Toning and Balance|Participants in the active comparator group will attend as many of the 24 in-person training sessions as possible, and complete remote solo training at their leisure, for the duration of the intervention period. During the in-person sessions, participants will start with a 5-minute warmup of basic joint mobilization exercises and dynamic stretching techniques. After this, participants will engage in a mild intensity circuit of exercises using resistance bands, bodyweight exercises and stability/balance exercises for approximately 50 minutes. The last 5 minutes of the session will be left for cooldown exercises and light stretching. Heartrate will be monitored regularly in order to prevent these exercises exceeding the relative intensity of the Martial Arts intervention group. Participants will be allowed to talk and interact with research assistants in order to keep socialization effects consistent across groups.
223739438|NCT04742101|DRUG|S65487 and azacitidine|Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
223739439|NCT02150655|BIOLOGICAL|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
223739440|NCT02150655|BIOLOGICAL|Placebo|
224137369|NCT04342520|OTHER|Dyads Patient / caregiver|adult patient / caregiver couples, patient are 55 years of age or older and have Alzheimer's disease or a related disease
224137370|NCT01376726|BIOLOGICAL|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
224137371|NCT01376726|BIOLOGICAL|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
224137372|NCT01965418|DRUG|Fufang Biejia Ruangan Tablet|
224137373|NCT01965418|DRUG|Placebo|
224298655|NCT00914914|DRUG|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
224298656|NCT00160641|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
224298657|NCT03435718|DRUG|Oxfendazole|oral suspension
224298658|NCT03435718|DRUG|Albendazole|tablet
224298659|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with Listerine|
224298660|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with CHX|
224298661|NCT03468595|DEVICE|ultrasonic (Piezon Master 700) performed with serum|
224298662|NCT00254228|DEVICE|Electrotactile sensory substitution|
224298663|NCT04271553|OTHER|Video|In addition to standard workflow, participants will also receive the PFO bundle which consists of: 1) A cartoon video of about 6 minutes duration illustrating the events occurring during admission, anaesthesia and surgery and 2) Sets of activity sheets which have been tailored for different age groups. Families would be encouraged to complete activity sheets together.
224298664|NCT03418090|DRUG|129Xe MRI|Evaluation of pulmonary function
224298665|NCT03418090|DRUG|133XE scintigraphy|Evaluation of pulmonary function
224298666|NCT03529461|DEVICE|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
224298667|NCT03529461|DEVICE|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
224298668|NCT03529461|OTHER|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
224298669|NCT02281331|DIETARY_SUPPLEMENT|Supplement|supplement/placebo plus exercise training
224298670|NCT02003911|DRUG|Azithromycin|Azithromycin suspension (200mg/5mL)
224298671|NCT02003911|DRUG|Placebo|
224298672|NCT05507593|BIOLOGICAL|DLL3-CAR-NK cells|Patients of Group A will be received 1x10\^7 DLL3-CAR-NK cells infusion treatment，of group B will be received 1x10\^8 DLL3-CAR-NK cells infusion treatment，and of group C will be received 1x10\^9 DLL3-CAR-NK cells infusion treatment.
223419747|NCT06200415|DRUG|Ginger Oil|Ginger (Zingiber officinale Roscoe) has been found to have biological activities such as antioxidant, anti-inflammatory, antimicrobial, and anticancer activities.
223419748|NCT03937921|DRUG|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
223419749|NCT01011465|DRUG|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
223419750|NCT01011465|DRUG|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
223419751|NCT01011465|BEHAVIORAL|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
223419752|NCT01011465|BEHAVIORAL|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
224035111|NCT04321200|OTHER|Mobile App|"The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app."
224035112|NCT06682988|DRUG|Mirvetuximab Soravtansine|intravenous (IV) infusion
223419753|NCT03927521|PROCEDURE|Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance|Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
223419754|NCT00800592|DRUG|sildenafil|10 mg sildenafil bolus
223419755|NCT04437875|BIOLOGICAL|Gam-COVID-Vac Lyo|adenoviral-based vaccine against SARS-CoV-2
223419756|NCT00068367|DRUG|erlotinib hydrochloride|150 mg per day, daily until disease progression
223419757|NCT06682026|OTHER|listening to music or chatting|"Written consent will be obtained from the patients just before they enter the procedure, and Personal Information Forms and the State Anxiety Inventory (STAI) will be applied to all participants.~Women in the experimental group will be asked to listen to a lively music of their own choosing during the mammography, or for those who do not want music, their attention will be drawn in a different direction by chatting.~At the end of the procedure, the Visual Acuity Scale (VAS) pain scale and the State Anxiety Inventory (STAI) will be applied to both groups."
223419758|NCT04024540|DIETARY_SUPPLEMENT|isocaloric dietary restriction|Very low caloric diet
223419759|NCT04024540|PROCEDURE|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
223419760|NCT04610112|DEVICE|cochlear implantation|patients receive a cochlear implantation within clinical routine
223419761|NCT03010150|PROCEDURE|Biospecimen Collection|Provide blood samples
223419762|NCT03010150|OTHER|Questionnaire Administration|Ancillary studies
224137374|NCT05388019|OTHER|Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)|Subject will receive care from a multidisciplinary team (physical therapy, occupational therapy, palliative care, social work) in addition to their standard of care VAD clinic visits. Subject will also perform a CPET, six-minute-walk-test, MoCA, and be administered quality of life questionnaires.
224137375|NCT05388019|BEHAVIORAL|Caregiver Self-Assessment|Primary caregivers of both interventional VAD patient cohorts will be administered a Caregiver Self-Assessment to assess burnout.
224137376|NCT01245764|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
223419763|NCT04698538|BEHAVIORAL|JASPER|JASPER is a naturalistic, developmental, behavioral intervention (NDBI) that focuses on developing social communication and language skills in the context of a play based intervention.
223419764|NCT06668701|DEVICE|"ich bin alles"|"The web-based information platform ich bin alles (www-ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy of the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. It is aimed at children and adolescents with depression, healthy children and adolescents and parents. The project focuses on education, prevention, support and destigmatisation through the transfer of evidence-based knowledge."
223419765|NCT03597750|DEVICE|Repose®|"* Repose® Mattress~* Repose® Cushion~* Repose® Wedge or Foot Protectors"
223419766|NCT02584595|DEVICE|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
223419767|NCT04115917|DEVICE|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
223739441|NCT04945460|DRUG|Sotatercept 0.3 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
224137377|NCT01245764|BIOLOGICAL|Placebo|
224137378|NCT04493957|BEHAVIORAL|ACCOMPAGNE Education Program|"The following workshops will be organised :~* Presentation workshop~* Cognitive skills workshop~* Perception and Environment workshop~* Responsibilities workshop~* Representation workshop -~* Caregivers workshop,~* Solutions workshop"
223419768|NCT04115917|DEVICE|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
223419769|NCT00723008|DEVICE|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
223739442|NCT04945460|DRUG|Placebo|Administered by subcutaneous injection
224137379|NCT04493957|BEHAVIORAL|Usuals recommandations|Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
224137380|NCT02500368|DEVICE|silicone hydrogel lens (test)|contact lens
223419770|NCT02484781|OTHER|Gait analysis on a trendmill|"Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining"
223419771|NCT04409808|DEVICE|IRIS|prototype IRIS vitrectomy device.
223419772|NCT00325481|DRUG|FluMist|
223419773|NCT02879617|DRUG|durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
223419774|NCT01514058|PROCEDURE|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
223562333|NCT02021383|BEHAVIORAL|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
223562334|NCT02021383|BEHAVIORAL|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
224035113|NCT02083705|PROCEDURE|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
224035114|NCT02083705|PROCEDURE|3:1 CPR|CPR using 3:1 ratio (control group)
224035115|NCT05714995|OTHER|hypnosis|"The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
224035116|NCT05714995|OTHER|Hypnosis with aromatherapy|"for patients in the hypnosis with aromatherapy group, before starting the hypnosis session, they will first choose an essential oil among the 5 proposed.~They will pour a drop on their wrist then they will rub it and inhale deeply.~The hypnosis session involves the following steps:~1. Preparation for the activation of the hypnotic trance~2. Activation of the hypnotic trance~3. Deepening the hypnotic trance~4. Maintaining hypnotic trance~5. Coming out of the hypnotic trance"
224137381|NCT02500368|DEVICE|enfilcon A lens (control)|contact lens
224137382|NCT04568018|DRUG|Surfactant|Inhalation of surfactant emulsion at 150 mg
224137383|NCT03956329|OTHER|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
224137384|NCT03956329|OTHER|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
224137385|NCT00745381|OTHER|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
224137386|NCT00351169|DRUG|Quetiapine SR|
224137387|NCT00351169|DRUG|Escitalopram|
224137388|NCT00781963|BEHAVIORAL|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
224137389|NCT00781963|BEHAVIORAL|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
224137390|NCT03098524|PROCEDURE|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
224137391|NCT03098524|PROCEDURE|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
224137392|NCT03098524|PROCEDURE|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
224298673|NCT01782482|DEVICE|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
224035117|NCT06161402|BEHAVIORAL|Elastic band-based progressive resistance training (EB-PRT)|EB-PRT will be implemented during week 1-14. The EB-PRT comprises a 4-week training phase, 6-week consolidation phase and a 4-week maintenance phase.
224035118|NCT05274152|DEVICE|Immersive Virtual Reality Lower Limb and Knee Rehabilitation|Patients wore a VR headset while undergoing their rehabilitation session
224035119|NCT02874339|DEVICE|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
224035120|NCT02874339|DEVICE|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
224035121|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg with phytase supplement 176mg (800FTU)|zinc gluconate 50 mg1 per day with phytase supplement 176mg (800FTU) (Goodphyte company) 2 tablets per day
224035122|NCT06577285|DIETARY_SUPPLEMENT|zinc gluconate 50 mg|zinc gluconate 50 mg 1 per day, 4 days before botulinum toxin injections.
224035123|NCT06353438|OTHER|Exercise Program|Concentric strengthening of multiple muscle groups 2x/week for 6 weeks.
224035124|NCT00890487|OTHER|hyaluronic acid pill|pill, 220 mg, once a day, three months
224035125|NCT05603091|PROCEDURE|cryoablation of pulmonary veins|Procedures are guided by pressure waveforms analysis, which are obtained by connecting the internal lumen of the catheter through the lateral port of the hemostatic valve attached to the catheter, to a pressure transducer connected in turn to a heparinized saline serum bag and to the cryoablation console.
224035126|NCT05455138|PROCEDURE|Arterial bypass grafting|Arterial bypass grafting in patients with critical limb ischemia due to peripheral artery disease
224035127|NCT06248346|DRUG|Dexmedetomidine|whether intraoperative dexmedetomidine was administered adjunct to propofol for patients undergoing surgeries under general anaesthesia
224035128|NCT04543487|OTHER|Therapeutic touch|Therapeutic touch was applied twice to the women in the intervention group in addition to routine practices. The first application was performed in the active phase of the first stage of labour, and the second was done in the second stage of labour.
224035129|NCT06419829|OTHER|psychoprophylactic program aimed at normalizing body weight through medical training|"Based on the assessment of body weight and composition, a 12-week physiophylactic program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that reduce fat mass, increase the flexibility and productivity of muscle mass. The classes will be conducted as part of medical training with a training load increasing to at least 85% of HR Max.~The project will include theoretical classes for parents, children and seniors on eating habits, a proper age-appropriate diet, diet changes depending on the subject's health condition and physical activity, and the impact of diet on the process of puberty, adulthood and aging."
224035130|NCT06419829|OTHER|psychoprophylactic program aimed at improving body posture|"Based on the body posture assessment, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the subjects. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises that strengthen the muscle corset, reducing asymmetrical positioning, habitual and during the implementation of professional tasks. The classes will be conducted using medical training and resistance exercises.~The project will include theoretical classes for parents on sitting habits, the importance of physical activity in a child's development, the selection of footwear..."
224035131|NCT06419829|OTHER|psychoprophylactic program aimed at improving physical fitness|Based on the assessment of physical fitness, a 12-week physiotherapy program will be carried out, adapted to the age and gender of the participants. The program will be carried out twice a week for 30 to 60 minutes (depending on the group). The basis of the program will be the implementation of exercises aimed at improving physical fitness, with particular emphasis on impaired motor skills. The classes will be conducted using functional training, resistance and stretching exercises, strengthening all muscle groups. In the case of children, special attention will be paid to the strength of the upper limbs, in the case of seniors, balance and coordination exercises will be introduced to improve time and space orientation. In all groups, the main goal is to improve functional fitness The project will include theoretical classes for parents, children and seniors on the importance of physical activity in the quality of life, in the process of maturation and aging.
224035132|NCT06419829|DIAGNOSTIC_TEST|Body composition assessment|"Body composition assessment will be carried out using the BIA method on an eight-electrode body composition analyzer from TAnita. They will be marked:~total mass, Total fat mass (FM) and segmental fat mass for five body segments: right leg (RL FM), Left leg (LL FM), right arm (RA FM), Left Arm (LA FM) trunk (TR FM).~total fat-free mass (FFM) and segmental for five body segments: right leg (RL FFM), Left leg (LL FFM), right arm (RA FFM), Left Arm (LA FMM) trunk (TR FMM).~Predicted total and segmental muscle mass (PMM) for five body segments: right leg (RL PMM), Left leg (LL PMM), right arm (RA PMM), Left Arm (LA PMM) trunk (TR PMM).~Total water content (TBW) including intracellular water (ICW) and extracellular water (ECW)"
224137393|NCT05855395|DRUG|Glucocorticoid|standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)
224137394|NCT02064205|DIETARY_SUPPLEMENT|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
223419775|NCT01514058|PROCEDURE|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
224137395|NCT02064205|DIETARY_SUPPLEMENT|glucose syrup|Glucose syrup is used a control product for the polydextrose
224137396|NCT00680953|DRUG|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
224137397|NCT00680953|DRUG|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
224137398|NCT00680953|DRUG|Alendronate sodium hydrate|Oral tablet once a week for 24 months
224137399|NCT01967472|DRUG|amodiaquine-artesunate (AQAS) fixed-dose|
224137400|NCT01967472|DRUG|Artemether-lumefantrine combination (AL) dispersable|
224298674|NCT01782482|DEVICE|Phemfilcon A contact lens with color|Hydrogel contact lens with color
224298675|NCT00511992|DRUG|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
224298676|NCT00511992|DRUG|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
224298677|NCT00511992|DRUG|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
224298678|NCT05051501|DIETARY_SUPPLEMENT|Probiotics C2P|Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.
224298679|NCT03895723|PROCEDURE|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
224298680|NCT03895723|PROCEDURE|open surgery|using open surgery procedure for liver resection
224298681|NCT06085716|BEHAVIORAL|Psychoeducational Intervention|Participants in the PI group will complete the educational sessions only.
224298682|NCT06085716|DRUG|Open Label Placebo|This group will only take placebo capsules every day.
224298683|NCT06085716|BEHAVIORAL|Psychoeducational Intervention+Placebo|This group will take the placebo capsules every day, as well as completing the educational sessions.
224298684|NCT03361852|DRUG|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
224298685|NCT03361852|BIOLOGICAL|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
224298686|NCT03361852|DRUG|Pembrolizumab|Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
223419776|NCT05534386|BEHAVIORAL|Cancer survivorship care intervention|A one-off face-to-face assessment and personal advice by members of a multidisciplinary team
223419777|NCT05534386|BEHAVIORAL|Step-up targeted personalized intervention|To provide a more personalized intervention to the participants, but focusing more on symptom management and weight control.
223562335|NCT05684445|OTHER|Distant reiki group|According to Classical Usui Reiki, Reiki II. Remote Reiki will be practiced every day for 10 days by researchers who have completed the Phase 1 training. The time of remote reiki application will be planned by talking with the patient.
223562336|NCT00386750|DRUG|Artemether-lumefantrine|
223562337|NCT03160248|DRUG|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
223562338|NCT03160248|DRUG|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
224035133|NCT06419829|DIAGNOSTIC_TEST|assessment of body posture using the Kasperczyk method|The Kasperczyk method was used to assess body posture, including physiotherapeutic assessment in both standing and sitting positions. The symmetry of the head, shoulders, spine curvatures, knee joints and foot positioning were assessed. The symmetry of the head position was examined in all three planes and in all movements, i.e. flexion - extension, right turn - left turn, rotation and combined movements. The lateral curvatures of the spine (scoliosis) and their physiological curvatures, their deepening or shallowing in all sections of the spine, as well as the mobility of the spine in all physiological planes of movement were assessed. The position of the shoulder and hip girdle was assessed, as well as the position of the upper limbs at the level of the knees and feet. The mobility of the lower and upper limbs was examined.
224035134|NCT06419829|DIAGNOSTIC_TEST|Assessment of physical fitness|It depends on the age of the person being examined. In the case of children, the EUROFIT physical fitness test is carried out with modifications for age and gender. For the senior group, the Rikli and Jones test is used
223419778|NCT05534386|BEHAVIORAL|First stage control intervention|A set of skill-based pamphlets will be given.
223419779|NCT05534386|BEHAVIORAL|Second stage control intervention|Those in the survivorship clinic arm will be asked to follow the advice given by the multidisciplinary team in the initial visit and for those in the control arm will be asked to follow the advices printed in the skill-based self-management pamphlet
223562339|NCT00140049|DRUG|Xalacom|
223562340|NCT00140049|DRUG|Cosopt|
223419780|NCT01928602|BEHAVIORAL|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, \& adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
223419781|NCT01928602|BEHAVIORAL|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
223419782|NCT06123221|PROCEDURE|Osseodensification with Versah system|Access to the bone crest will be performed through a slightly palatinized crestal incision, and a full-thickness mucoperiosteal flap will be elevated. Implant site preparation will be performed according to the bone densification drilling sequence established by the Densah® technique protocol
223419783|NCT06123221|PROCEDURE|Lateral window|A full-thickness mucoperiosteal flap will be elevated. The lateral window will be made with a spherical diamond drill (number 8) at 20,000 rpm. The mesiodistal and apicocoronal dimensions of the lateral access window to the sinus will be measured in all the participants using a caliper. Sinus membrane elevation will be performed with manual instruments.
223419784|NCT02089308|DRUG|Test treatment : V0116 transdermal patch|
223419785|NCT02089308|DRUG|Reference treatment : Nicotine transdermal patch|
223419786|NCT00186979|DRUG|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
223419787|NCT04290208|DRUG|Acetaminophen|IV Acetaminophen
223419788|NCT04290208|DRUG|Acetaminophen|Acetaminophen liquid syrup
223419789|NCT04290208|DRUG|Placebos|Flavored, non-medicated (placebo) liquid syrup
223419790|NCT04290208|DRUG|Placebos|IV salt solution (non-medicated)
223562341|NCT01268592|PROCEDURE|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
223562342|NCT04166578|DRUG|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
223562343|NCT04166578|PROCEDURE|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
223562344|NCT04166578|PROCEDURE|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
223562345|NCT04166578|BEHAVIORAL|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
223419791|NCT01703247|PROCEDURE|Pulmonary vein isolation|
223419792|NCT01703247|PROCEDURE|Ganglionated plexi ablation|
223562346|NCT04166578|BEHAVIORAL|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
223562347|NCT04166578|DIAGNOSTIC_TEST|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
223562348|NCT04166578|DIAGNOSTIC_TEST|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
223562349|NCT02607475|DEVICE|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
223562350|NCT02607475|DEVICE|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
223562351|NCT02591537|DEVICE|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
223562352|NCT06531213|OTHER|experimental|"Experimental Group: Baseline rehabilitation, Visual Perception Interventions. Home base activities, Baseline Rehabilitation (Strengthing exercise, achieving missing milestones).~Visual Perception Interventions~• Puzzle:Give step-by-step • printable activities • Sudoku. SET, Search Word, Spot it, what is missing, Tic Tac Toe, I Spy"
223562353|NCT06531213|OTHER|controlled|Controlled: Baseline rehabilitation. Home-based activities, Baseline Rehabilitation (strengthening exercise, achieving missing milestones).3. Activities Play Dough ( Manipulation) Draw on sketch Cup stacking.
223562354|NCT00911976|DEVICE|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
223562355|NCT02540187|OTHER|blood specimen|
223562356|NCT02765815|DRUG|Liposomal bupivacaine, 266mg|
223562357|NCT02765815|DRUG|Bupivacaine 0.5 % with Epinephrine|
223562358|NCT02765815|DRUG|Ketorolac 30mg|
223739443|NCT04945460|DRUG|Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg|Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
223739444|NCT02742012|OTHER|the study is observational|the study is observational
223739445|NCT04842266|DEVICE|IlluminOss pelvic implant for oncologic indication|Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis
223739446|NCT04842266|DEVICE|IlluminOss pelvic implant for geriatric trauma indication|Pelvic fragility fracture in a geriatric patients (age 65 or older)
223739447|NCT05300490|DRUG|Prednisolone|In this routine care study, all patients will receive a joint injection of prednisolone at a dose left to the discretion of the physician. The urinary excretion kinetics of this product and its metabolites will then be followed at different times. An association with metabolic genetic profile will be done.
223419793|NCT01703247|PROCEDURE|Linear Lesion Ablation|
223419794|NCT00826254|DRUG|Vitamin K|180 micrograms vitamin K daily
223739448|NCT01811927|DEVICE|PRO-Kinetic Energy Stent|Bare-metal stent
223739449|NCT02504567|DEVICE|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
223739450|NCT02504567|DEVICE|RF ablation|Pulmonary vein isolation using the RF ablation catheter
224035135|NCT06419829|DIAGNOSTIC_TEST|Balance assessment|"Balance assessment using the Zebris platform Static measurement - with eyes open and closed, assessing the load on the limbs during standing expressed in %, Balance analysis measurement - with eyes open and closed, test in a standing position, barefoot. The measurement duration is 30 seconds and the break between measurements is 30-60 seconds.~Deflections of the center of gravity in the frontal and sagittal planes Length of the center of gravity swing path CoP - SPL \[cm\]. Inside the calculated ellipse lies 95% of the CoP location measurement data: amplitude, amplitude height, ellipse area (orientation of the direction of the ellipse's longitudinal axis relative to the platform's longitudinal axis, indicating clockwise rotation)."
223419795|NCT00826254|DRUG|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
223419796|NCT03268200|OTHER|segmental reexamination|segmental reexamination during colonoscopy
223419797|NCT04102254|PROCEDURE|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
223739451|NCT05023226|PROCEDURE|RM|RM refers to that under FiO2=100% oxygen concentration and fixed inspiratory pressure (15cmH2O), the PEEP starts from 10 cmH2O and increases at a pressure of 5 cmH2O every minute until the Peak inspiratory Pressure(PIP) reaches 55cmH2O, and the level was fixed to 40 seconds in each increment. Then, the ventilator was transferred to PEEP-titration phase, the PEEP was adjusted to 25 cm H2O, and it was reduced by increments of 5 cm H2O each time. The each increment was fixed to 5 minutes till the end-maneuver PEEP.
223739452|NCT05023226|PROCEDURE|LPVS|LPVS was used by the pressure-controlled mode and the PEEP was titrated by the level of FiO2 to keep the saturation of oxygen (SaO2) more than 90%. The level of pressure control was adjusted to maintain low tidal volume (6-8 mL/kg predicted body weight \[PBW\]) strategy. The respiratory rate and tidal volume were setting to avoid unstable hemodynamic data and adjusted by blood gas data and lung mechanics.
223739453|NCT04996849|OTHER|Data Capture|Data collected
223739454|NCT04996849|OTHER|Questionnaire Administration|Ancillary studies
223739455|NCT03474887|OTHER|Physical Consultation|Regular physician consultation at the primary care clinic.
223419798|NCT06648200|DRUG|JS004|Specified dose on specified days.
223419799|NCT06648200|DRUG|Toripalimab|Specified dose on specified days.
223419800|NCT06648200|DRUG|Etoposide|Specified dose on specified days.
223419801|NCT06648200|DRUG|Platinum|Specified dose on specified days.
223419802|NCT02844842|BIOLOGICAL|Allergovac Poliplus|
223419803|NCT01404156|DRUG|(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1\) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2\) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)"
223562359|NCT02765815|DRUG|Morphine 10mg|
223562360|NCT02765815|DRUG|Bupivacaine 0.25% with Epinephrine|
223562361|NCT01454505|DRUG|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
223562362|NCT01454505|OTHER|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
223419804|NCT01404156|OTHER|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~* paclitaxel: 50 mg / m2 IV over 1 hour~* carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1\. Dose specifications:~1. Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~2. Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
223419805|NCT06668688|DEVICE|"ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de)"|"The web-based information platform for educational professionals ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. The website is intended to provide low-threshold information about depression and mental health in the school context."
223419806|NCT06289478|DRUG|Topical tranexamic acid administration|Tranexamic acid will be topically administered in intervention groups
223419807|NCT02666378|OTHER|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
223419808|NCT02666378|OTHER|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
223562363|NCT03402204|DRUG|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
224298687|NCT02974036|OTHER|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
223419809|NCT05835011|DRUG|Decitabine/Cedazuridine|Oral FDC tablets administration
223419810|NCT05835011|DRUG|Magrolimab|IV administration
223419811|NCT03208478|PROCEDURE|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
223419812|NCT03208478|PROCEDURE|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
223419813|NCT03208478|DEVICE|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
223419814|NCT04675918|PROCEDURE|Cardiac arrest|Definition of characteristics of cardiac arrest and resuscitation as well as post-resuscitational care and follow up.
223419815|NCT02737085|BIOLOGICAL|Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells|Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
223419816|NCT01859117|BIOLOGICAL|3 x 10^6 cells|3 x 10\^6 cells administered on Study Days 1 and 8
223419817|NCT01859117|BIOLOGICAL|10 x 10^6 cells|10 x 10\^6 cells administered on Study Days 1 and 8
223419818|NCT01859117|BIOLOGICAL|30 x 10^6 cells|30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
223419819|NCT01859117|BIOLOGICAL|100 x 10^6 cells|100 x 10\^6 cells administered on Study Days 1 and 8
223419820|NCT02698657|DRUG|ASP5094|Intravenous (IV)
223419821|NCT02698657|DRUG|Placebo|Intravenous (IV)
223419822|NCT04080843|DRUG|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
223419823|NCT04080843|DRUG|Capecitabine|Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
223419824|NCT04080843|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m2,D1
223419825|NCT00823043|DRUG|timolol hemihydrate|timolol hemihydrate 0.5% solution
223419826|NCT00823043|DRUG|timolol maleate|timolol maleate in sorbate
223562364|NCT03402204|DRUG|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
223419827|NCT04091412|DRUG|Butylphthalide Soft Capsules|The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
223419828|NCT01782625|OTHER|NO exercise at depth|Subjects will NOT exercise while at depth
223419829|NCT01782625|OTHER|exercise at depth|Subjects will exercise while at depth
223562365|NCT00119769|DRUG|Placebo|Placebo, 0.7 mg/day injected subcutaneously
223562366|NCT00119769|DRUG|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
223562367|NCT00290771|DRUG|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
223562368|NCT00290771|DRUG|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
223562369|NCT00005901|DRUG|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
223562370|NCT02677207|DRUG|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
223562371|NCT02677207|DRUG|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
223562372|NCT00244933|DIETARY_SUPPLEMENT|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
223562373|NCT00244933|DRUG|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
223562374|NCT00244933|PROCEDURE|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
223562375|NCT05223569|DEVICE|Home OCT monitoring model|A home monitoring set, which includes a self-administrated OCT, and a self-administrated smartphone-based visual acuity tester
223419830|NCT04259424|DEVICE|Aerobic Exercise + Duck Duck Punch|"Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. On each session the target intensity of aerobic exercise will be 70% heart rate reserve.~Following a 10-minute rest break subjects will perform 200 repetitions on an upper extremity rehabilitation game called Duck Duck Punch (DDP). Duck Duck Punch is an interactive game with an old school carnival theme. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. A therapist will oversee the subject's safety and progress during DDP. DDP will be dosed based on the number of repetitions performed. A repetition is recorded when the player moves his/her arm so that the avatar leaves a start position. The goal dose for subjects will be 200 repetitions per DDP session."
223419831|NCT02300038|DRUG|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
223419832|NCT02300038|DIETARY_SUPPLEMENT|NaCl|perineuromally administration of NaCL
223419833|NCT01176149|BEHAVIORAL|SMBG plus intensive education|
223419834|NCT05094635|DIAGNOSTIC_TEST|SARS-CoV-2 IgG II Quant|3ml of blood samples are collected, contained in heparin-free tubes, and centrifuged. Blood serum samples are collected and stored at the -80 Celcius degree. SARS-CoV-2 IgG antibodies in human serum and plasma are detected using chemiluminescent microparticle immunoassay (CMIA) technology on the ARCHITECT I 1000r System. Quality Control procedures will take place once daily, with three levels: one negative control and two positive controls. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated. The SARS-CoV-2 IgG antibodies present in the sample bind to the antigen-coated microparticles. The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the titres of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Interpretation of Results: \< 50.0 AU/mL, Negative, ≥ 50.0 AU/mL, Positive
223562376|NCT05223569|DEVICE|Hospital-based monitoring with a staff-administrated OCT|Participants come back to the clinic to receive traditional OCT and VA examinations operated by the study coordinators
223562377|NCT00488449|DRUG|GSK256073A tablets|
223562378|NCT00939289|DEVICE|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
223562379|NCT04129268|OTHER|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
224035136|NCT06477822|PROCEDURE|Sequence of manual therapy techniques|Receive a sequence of manual therapy techniques composed by: suboccipital decompression technique, suboccipital release technique, fourth ventricle compression technique, vagus nerve neurodynamic technique
224035137|NCT06477822|PROCEDURE|Simulated manual therapy techniques|Receive a sequence of simulated manual therapy techniques composed by four maneuvers without effect on autonomic nervous system
223562380|NCT04818502|DEVICE|Tendyne™ Mitral Valve System|Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
223562381|NCT03316716|PROCEDURE|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
223562382|NCT05451706|BEHAVIORAL|Mental help-seeking self-persuasion|Employing a longitudinal design, this study used a self-persuasion framework in a 4-arm intervention to increase college students' help-seeking intentions during the COVID-19 pandemic.
223562383|NCT00171457|DRUG|Tegaserod|
224035138|NCT02950064|DRUG|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
224035139|NCT01262703|DEVICE|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
224035140|NCT00958620|PROCEDURE|Shock Wave Therapy|Extracorporal shock-wave therapy
224035141|NCT04568720|DIAGNOSTIC_TEST|blood sample|Isolated the blood sample and detected the CTC
224035142|NCT02330783|DRUG|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
224035143|NCT02330783|DRUG|Sorafenib|400mg twice daily by oral of each 4-week cycle
224035144|NCT00076362|DRUG|Sandostatin LAR|
224035145|NCT00276588|DRUG|carboplatin|
224035146|NCT00276588|DRUG|gemcitabine hydrochloride|
224035147|NCT00276588|DRUG|paclitaxel|
224137401|NCT03095716|OTHER|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
223562384|NCT05993312|OTHER|quality of life|To describe the relationship between distant sequelae of trauma assessed by the GOSE scale and quality of life
223562385|NCT00348699|DRUG|AFP464|Given IV
223562386|NCT00348699|OTHER|pharmacological study|Correlative studies
223562387|NCT00348699|OTHER|laboratory biomarker analysis|Correlative studies
223562388|NCT00183781|BEHAVIORAL|FITT: Family Intervention - Telephone Tracking|
223562389|NCT05550870|DIETARY_SUPPLEMENT|Raw fenugreek seed powder|It will be given to group 1
224137402|NCT02062463|DRUG|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)
224137403|NCT02062463|DRUG|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)
224137404|NCT01889628|DIETARY_SUPPLEMENT|Liquid-based Nutritional Formulae and liquid glucose|
224298688|NCT00038649|DRUG|Gleevec|400 mg orally twice daily
223562390|NCT05550870|DIETARY_SUPPLEMENT|Roasted fenugreek seed powder|It will be given to group 2
223562391|NCT01404403|DEVICE|Rapid System|
223562392|NCT05548712|DEVICE|Pulse Electromagnetic Field|Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
223419835|NCT01913535|DRUG|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
223419836|NCT01913535|DRUG|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
223419837|NCT04180137|PROCEDURE|Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins|"Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density - 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm."
223419838|NCT04180137|DRUG|Pharmacotherapy|After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
223419839|NCT02274870|DRUG|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
223419840|NCT02274870|DRUG|Bupivacaine HCl|Administered via CFNB
224137405|NCT00921882|PROCEDURE|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
223419841|NCT04121156|DEVICE|HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
223419842|NCT04121156|DEVICE|sham (placebo) HD-tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
223419843|NCT01310088|BEHAVIORAL|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
223419844|NCT01864109|DRUG|Cyclophosphamide|
223419845|NCT01864109|DEVICE|Doxorubicin|
223419846|NCT01864109|DRUG|Vincristine|
223419847|NCT01864109|DRUG|Ifosfamide|
223562393|NCT05548712|DEVICE|Sham Pulse Electromagnetic Field|Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
223562394|NCT03641716|BEHAVIORAL|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
223562395|NCT01292356|DRUG|cetuximab|
223562396|NCT02365610|DRUG|GWP42006|
223562397|NCT02365610|DRUG|Placebo Control|
223562398|NCT00311740|DRUG|Valsartan|
223562399|NCT00311740|DRUG|Hydrochlorothiazide|
223562400|NCT05998070|OTHER|Training group|Hip strengthening exercises will be performed 3 times a week for 6 weeks in the training group. 3 exercises consisting of 2 sets and 10 repetitions will be performed every week. A rest interval will be given between sets.
223562401|NCT06105775|DIETARY_SUPPLEMENT|Inorganic Nitrate Capsule|Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing 400 mg of inorganic nitrate. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
223739456|NCT03474887|OTHER|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
224137406|NCT01974986|OTHER|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
224137407|NCT01974986|OTHER|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
223419848|NCT01864109|DRUG|Etoposide|
223419849|NCT01864109|PROCEDURE|Surgery|
223419850|NCT01864109|RADIATION|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
223419851|NCT01864109|DRUG|Temozolomide|
223419852|NCT01864109|DRUG|Irinotecan|
223419853|NCT01864109|DRUG|Mesna|Mesna 2,100 mg/m2 (or 70 mg/kg if \< 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
223419854|NCT01864109|DRUG|Dexrazoxane|Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
223419855|NCT01864109|DRUG|G-CSF|G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
223419856|NCT05449587|OTHER|MRI and PRO|MRI as a standard of care for the analysis of silent rupture. BREAST-Q Postoperative Augmentation module scales to record patients for satisfaction: Satisfaction with breasts; Satisfaction with outcome; Psychosocial well-being; Physical well-being
224137408|NCT01974986|OTHER|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
224137409|NCT00707655|DRUG|Zalutumumab|Eight weekly infusions
224137410|NCT02925663|BEHAVIORAL|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
223419857|NCT03119753|DEVICE|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
223419858|NCT03119753|DEVICE|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
223419859|NCT02976753|DRUG|efmoroctocog alfa|extended half-life factor VIII product
223419860|NCT02976753|DRUG|Factor VIII|conventional factor VIII product
223419861|NCT06666595|PROCEDURE|Titanium dental implant (Conical SPI, Vitronix, Italy), Medical device that interfaces with the jawbone to support a dental prosthesis.|Placement of titanium dental implant to retain and support Kennedy class 1 removable partial denture (RPD).The implant fuses with the bone through a process called osseointegration.
223419862|NCT02410434|OTHER|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
223419863|NCT04290910|BEHAVIORAL|Weight Loss Program|There are three components of the intervention, this includes: psychology, nutrition, and physical activity. For the psychological portion, a therapist will assess the participant at baseline to determine if there are barriers associated with making lifestyle changes. For nutrition, the dietitian will assess the participant and create a meal plan based on their nutritional needs and guide the participant to reaching their nutritional goals. The psychological and nutrition portion may be interchangeable depending on the participants needs. For physical activity, the personal trainer will assess the participant and create an exercise plan that consists of resistance training and weight bearing exercises suitable for the participant while also guiding the participant to reach their exercise goals.
223419864|NCT03383835|DIETARY_SUPPLEMENT|Omega-3 Supplementation|"DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months"
223419865|NCT04270071|DRUG|Yangxin Shengmai|Yangxin Shengmai Granules
223419866|NCT04270071|DRUG|Yangxin Shengmai placebo|Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.
223419867|NCT04270071|DRUG|nitroglycerin tablets|Be used when angina attack
223419868|NCT00217893|BEHAVIORAL|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
223419869|NCT00217893|BEHAVIORAL|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
223419870|NCT00217893|BEHAVIORAL|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
223419871|NCT00217893|BEHAVIORAL|Usual education program|Participants will receive the usual education about ETS.
223419872|NCT03032328|DIETARY_SUPPLEMENT|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
223419873|NCT01316211|DEVICE|Implantation of coflex™ after surgical decompression|The device will be implanted after surgical decompression in patients with spinal stenosis.
223419874|NCT01316211|PROCEDURE|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
223419875|NCT01513265|OTHER|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
223739457|NCT02893072|BEHAVIORAL|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
223739458|NCT05174910|DEVICE|Obsidian ASG|Application of an autologous platelet-rich fibrin matrix
223419876|NCT05032495|OTHER|Surveys|Surveys to evaluate prior experience, opinions and intervention acceptability.
223419877|NCT05032495|OTHER|Focus group|To answer any questions and discuss topics covered in the standard presentation.
223419878|NCT03702010|DEVICE|spinal cord stimulation conventional|If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
223419879|NCT03702010|DEVICE|spinal cord stimulation experimental|If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
223419880|NCT03999736|DEVICE|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
223739459|NCT01892930|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223419881|NCT03878836|OTHER|Routine assessments|Routine assessments, no specific intervention
223419882|NCT01185184|DRUG|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
223419883|NCT03444948|DEVICE|EUS-RFA using Habib Tm as a probe|3 EUS-RFA interventions at 1-month interval
223419884|NCT03444948|PROCEDURE|EUS|Standard intervention
223419885|NCT03990194|DRUG|Leuprolide Acetate|Administration of Leptoprol implant every 3 months
223419886|NCT03922217|BEHAVIORAL|Mindful My Way|Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
223419887|NCT01594190|BEHAVIORAL|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
223419888|NCT01594190|BEHAVIORAL|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
223419889|NCT05080114|PROCEDURE|Modified Bakay technique (MT)|The conventional standard technique for laparoscopic hysterectomy was followed until the colpotomy. The remaining steps were as follows: A 0-Monocryl™ violet (poliglecaprone-25) or a 0-PDS-II (polydioxanone) suture with a 36-mm needle (Ethicon Inc., NJ, USA) was placed first on the right USL, proximal to the ischial spine and 1-3 cm away from its uterine insertion, then helically proceeded by 1 to 3 bite(s) (depending on the length of the ligament) for suspension/plication. The suture continued circumferentially in counter clockwise direction on the line between the cervicovaginal junction and the bladder in a full-thickness purse string fashion, at least 1 cm away to the bladder. This suture symmetrically ended in the left USL, with forming nearly an Ohm sign (Ω). Colpotomy was performed circumferentially using laparoscopic cold scissors and/or knife, maintaining a safe distance from the suture line. Following removal of the uterus, both ends of the prior suture line were knotted.
223419890|NCT05080114|PROCEDURE|Standard technique (ST)|"The conventional standard total laparoscopic hysterectomy technique was used in this control group.~All operations were performed under general anaesthesia with nasogastric intubation and a bladder catheter in place. Cefazolin 2 g was administered to all patients for prophylaxis 30 min prior to surgery. Operations were performed with a 10-mm laparoscope (Karl Storz, Germany) through the trocar placed usually in the umbilicus. Two lateral 5-mm trocars and one midline 10-mm trocar were used. The placement of trocars varied according to the uterine size. Haemostasis was usually performed using bipolar forceps (Karl Storz Robi, Germany), whereas dissection was performed using the LigaSure™ (Covidien, Medtronic, USA). Maryland jaw laparoscopic sealer/divider, bipolar forceps and scissors. Colpotomy was performed with electrocautery devices and sutured intracorporeally."
223419891|NCT01137110|OTHER|Brief LEV|Levetiracetam 1000mg BID x 3 days for prophylaxis
223419892|NCT01137110|OTHER|Extended LEV|Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
223419893|NCT02058784|DRUG|pracinostat|
223419894|NCT02960165|BEHAVIORAL|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
223419895|NCT02960165|BEHAVIORAL|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
223419896|NCT03229928|DEVICE|MOCHA|"* MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants)."
223419897|NCT04779528|PROCEDURE|Fiberoptic intubation in supine position.|"Patients will be placed in supine position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
223419898|NCT04779528|PROCEDURE|Fiberoptic intubation in lateral position.|"Patients will be placed in lateral position after the establishment of full vital signs monitoring and the insertion of an intravenous line.~Under sedation via intravenous infusion of remifentanil plus topical anesthesia with 10 ml of Lidocaine 1% via a 3.7mm bronchoscope. After applying a standard monitoring and preparation of the nose by decongestant and local anesthesia. A loaded flexible scope (by an endotracheal tube ETT) will be introduced through the nostril to reach the carina, then the ETT will be pushed over the scope 3cm above the carina."
223419899|NCT02880774|OTHER|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
223419900|NCT02880774|OTHER|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
223419901|NCT06662474|OTHER|1. cognitive stimulation|sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks
223419902|NCT06662474|OTHER|2. psychoeducation and cognitive stimulation|sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks and also hold open group meetings for psychoeducation (1 meeting every 2 weeks, 6 meetings in total)
223419903|NCT06662474|OTHER|3. no intervention|maintaines their lifestyle up until their inclusion in the study without following additional measures
223419904|NCT00543517|DRUG|MK0767|
223739460|NCT01892930|PROCEDURE|therapeutic conventional surgery|Undergo partial or radical nephrectomy
223739461|NCT01892930|OTHER|laboratory biomarker analysis|Correlative studies
223739462|NCT03411473|BIOLOGICAL|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
224137411|NCT03016026|PROCEDURE|ERAS|Undergo an ERAS program
223419905|NCT03452384|OTHER|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
223419906|NCT04980820|OTHER|No mask|The participant is asked to wear no mask for 10 minutes.
223419907|NCT04980820|DEVICE|Filtering face mask 2 (FFP2)|The participant is asked to wear a FFP2 mask for 1 hour during work.
223419908|NCT04980820|DEVICE|Filtering face mask 3 (FFP3)|The participant is asked to wear a FFP3 mask for 1 hour during work.
223419909|NCT03557931|DRUG|ASP4345|oral administration
223419910|NCT03557931|DRUG|placebo|oral administration
223419911|NCT03557931|DRUG|risperidone|oral or depot administration
223419912|NCT03557931|DRUG|quetiapine|oral administration
223419913|NCT03557931|DRUG|olanzapine|Oral or depot administration
223419914|NCT03557931|DRUG|ziprasidone|Oral or depot administration
223419915|NCT03557931|DRUG|aripiprazole|Oral or depot administration
223419916|NCT03557931|DRUG|brexpiprazole|Oral administration
223419917|NCT03557931|DRUG|paliperidone|Oral or depot administration
223419918|NCT03557931|DRUG|lurasidone|Oral administration
223419919|NCT04259931|DIAGNOSTIC_TEST|microbiome analysis|gut microbiome composition of C. difficile infected patients with relapsing (basal, at the end of first treatment, at the begin of the relapses and at four and twelve weeks after definitive treatment) and non-relapsing ( basal and four and twelve week after treatment) , will be analyzed.
223419920|NCT00239746|DRUG|Ibuprofen|200mg taken orally daily for 6-12 weeks
223419921|NCT00239746|DRUG|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
223419922|NCT05888389|PROCEDURE|Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia|Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring. At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.
223419923|NCT05888389|PROCEDURE|General Anesthesia|Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .
223419924|NCT02829723|DRUG|BLZ945|"BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days."
223419925|NCT02829723|DRUG|PDR001|PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
223419926|NCT01010295|DRUG|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
223419927|NCT06967428|COMBINATION_PRODUCT|Combined metabolic modulator|This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to support energy metabolism.
223419928|NCT06967428|DIETARY_SUPPLEMENT|Rice Protein Powder with Vitamin C|Rice Protein Powder (39g) with Vitamin C (1g) daily
223419929|NCT02989649|DRUG|Alogliptin|Alogliptin tablets
223419930|NCT02989649|DRUG|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
223419931|NCT02989649|DRUG|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
223419932|NCT04457102|DEVICE|MANIV|mechanical ventilator (Bellavista 1000, IMTmedical) will be used on Varian® Halcyon LINAC and Infinity Elekta® linac
223419933|NCT04457102|OTHER|Spontaneous DIBH|performed on Varian® Halcyon LINAC and Infinity Elekta® linac
223419934|NCT03957603|DIETARY_SUPPLEMENT|Enteral Nutrition Suspension (TFP-DM)|Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)
223419935|NCT03957603|BEHAVIORAL|Medical Nutrition Therpay|Individualized dietary and lifestyle intervention
223419936|NCT01677884|DRUG|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
223419937|NCT01677884|DRUG|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
223562402|NCT06105775|DIETARY_SUPPLEMENT|Placebo Capsule|From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing sodium chloride with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard preeclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
223739463|NCT04095507|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
223419938|NCT01677884|DRUG|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
223419939|NCT00006251|RADIATION|total-body irradiation|Undergo TBI
223419940|NCT00006251|DRUG|fludarabine phosphate|Given IV
223419941|NCT00006251|DRUG|cyclosporine|Given PO
223562403|NCT00004112|BIOLOGICAL|rituximab|
223562404|NCT00004112|DRUG|CHOP regimen|Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
223739464|NCT04433468|DEVICE|RIPC|The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
223419942|NCT00006251|DRUG|mycophenolate mofetil|Given PO
223419943|NCT00006251|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
223419944|NCT00006251|BIOLOGICAL|donor lymphocytes|Undergo DLI
223419945|NCT00006251|PROCEDURE|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
223419946|NCT00006251|OTHER|laboratory biomarker analysis|Correlative studies
223562405|NCT00004112|DRUG|cyclophosphamide|
223562406|NCT00004112|DRUG|doxorubicin hydrochloride|
223562407|NCT00004112|DRUG|prednisone|
223562408|NCT00004112|DRUG|vincristine sulfate|
223419947|NCT03840759|OTHER|inpatient geriatric consultation team|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
223562409|NCT02487654|PROCEDURE|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
223562410|NCT02487654|PROCEDURE|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
223562411|NCT06458764|OTHER|Questionnaire|none, it's a incidence-prevalence study
223562412|NCT04038632|OTHER|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
223562413|NCT05262530|BIOLOGICAL|BNT142|Intravenous bolus/infusion
223562414|NCT03803358|OTHER|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
223562415|NCT03803358|OTHER|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
223739465|NCT02894710|DRUG|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
224035148|NCT06387368|DRUG|Huaier Granule|Huaier Granules: Oral administration, 10g once, 3 times a day. Capecitabine: oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
223419948|NCT03257852|DRUG|ASP5094|intravenously administration
223419949|NCT03257852|DRUG|Placebo|intravenously administration
223562416|NCT02247011|OTHER|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
223562417|NCT02247011|RADIATION|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
223562418|NCT02247011|RADIATION|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
223419950|NCT03257852|OTHER|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
223419951|NCT01873456|OTHER|multifactorial nutritional intervention|
223562419|NCT02247011|OTHER|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
223562420|NCT05598944|BEHAVIORAL|The MBSR program|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA. It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction), together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of MBSR; The Perception of Reality; Power in Being Present; Understanding Stress: The Mind-Body Relation; Responding to Stress; Communication and Personal Relations; Daily Life Management; My Personal Plan: What lies ahead."
223739466|NCT02894710|DRUG|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
223739467|NCT03492255|DRUG|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
223739468|NCT03492255|DRUG|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone \[750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
223739469|NCT03492255|DRUG|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
223739470|NCT03492255|DRUG|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
224035149|NCT06387368|DRUG|Capecitabine|Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d), day 1-14, once every 3 weeks.
224035150|NCT05558982|DRUG|BXCL701|BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days
224035151|NCT05558982|DRUG|Pembrolizumab|Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.
224035152|NCT03891524|DRUG|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
223419952|NCT05503602|OTHER|Classical Physiotherapy|Only classical physiotherapy application, 5 sessions per week for 4 weeks.
223419953|NCT05503602|OTHER|IASTM Technique Application|Instrument-assisted soft tissue mobilization application 2 sessions per week together with 3 sessions of classical physiotherapy per week for 4 weeks. IASTM application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
223419954|NCT05503602|OTHER|Foam Roller Technique Application|2 sessions of foam roller technique per week along with 3 sessions of classical physiotherapy per week for 4 weeks. Foam roller application; A total of 4 minutes will be applied to the sternocleidomastoideus, levator scapula, scalene muscles and upper part of the trapezius for a total of 4 minutes (2 minutes to the right, 2 minutes to the left region).
223419955|NCT02004886|DRUG|MK-0893|10 mg and 100 mg tablets
223419956|NCT02004886|DRUG|Metformin|500 mg metformin tablets
223419957|NCT02004886|DRUG|Placebo|Placebo tablets matching MK-0893
223419958|NCT02004886|DRUG|Placebo|Placebo tablets matching metformin
223562421|NCT05598944|BEHAVIORAL|Más Presente, the UGRComp program|"Más Presente, the UGRComp program is based upon the European LifeComp framework (Sala, Punie, Garkov and Cabrera Giraldez 2020) and covers intra and interpersonal, emotional, cognitive and metacognitive aspects. Created at the University of Granada by an interdisciplinary group of experts, it focuses on three core elements (self-regulation, empathy and growth mindset) as they are the pre-requisites for developing all other elements across framework areas. It consists of 8 weekly classes, 2 hours each, together with a day of intensive practice.~The program is structured along the following topics: The Underpinnings of Más Presente; Awareness and Concentration: our Body; Managing our Emotional Laberynth; Walking with Directionality, Sense and Conscience; Empathy, Presence and Connection; Empathic Listening and Honest Expression: Non-violent communication; Growth Mindset, Creativity and Divergent Thinking; And Now what? The First Day of the Rest of My Life."
223562422|NCT05598944|OTHER|Neuro-muscular stimulation|Subjects will receive weekly sessions with a combination of educational sessions and specific physical exercises to enhance physical wellbeing and prevent neuro-degeneration . After spotting the therapeutic targets for each subject, a 4-phase program will be designed for each subject aimed at improving lifestyle habits and general wellbeing.
223562423|NCT04958993|DRUG|Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy|radiotherapy (five days a week to accept chest radiotherapy, once per day, every time 1.8-2.0 Gy, total dose 54-66 Gy) AND chemotherapy (Squamous cell carcinoma selective platinum + docetaxel and Adenocarcinoma selective platinum + Pemetrexed) AND Anlotinib Hydrochloride capsule (12mg QD PO d1-14, 21 days per cycle)
223562424|NCT04683276|PROCEDURE|pars plana vitrectomy with ILM inverted flap|Complete vitrectomy was done with the aid of triamcinolone acetonide followed by fluid-air exchange. Staining of the ILM was carried with 0.05% solution of Brilliant Blue dye (BBG), (Ocublue plus, Aurolab, India) for 30 seconds, ILM peeling was proceeded leaving a circle of ILM measuring approximately 1-2 DD in SF groups and \>2 to 4DD in LF group, centered around the MH. The ILM outside the parafoveal area was peeled to the arcade. The ILM around the hole was then detached from the retina up to the edge of the hole. The ILM flap around the edge of the hole was inverted over the MH using a scraper.
223562425|NCT06205381|DRUG|AV078|Oral solution containing active ingredient, AV078
223562426|NCT06205381|DRUG|Placebo|Oral solution with no active ingredients
223562427|NCT06205381|DRUG|Itraconazole|Once daily oral dose of 200 mg itraconazole administered for 9 days
223562428|NCT06205381|DRUG|Midazolam|2.5 mg midazolam administered orally on day 1 and day 18
223562429|NCT06205381|DRUG|Fexofenadine|120 mg fexofenadine administered orally on day 1 and day 18
223562430|NCT00876850|DRUG|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
223562431|NCT00876850|DRUG|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
223562432|NCT00616018|DRUG|acetaminophen|4 g/day for 10 consecutive days
223562433|NCT03331601|DRUG|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
223562434|NCT06290466|DRUG|Low dose group|300 mg,single dose.
223562435|NCT06290466|DRUG|High dose group|400 mg, single dose.
223562436|NCT02483156|DRUG|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
223562437|NCT02483156|DRUG|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
223562438|NCT02483156|DRUG|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
223562439|NCT00499291|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223562440|NCT00499291|PROCEDURE|gene expression analysis|
223562441|NCT00499291|PROCEDURE|laboratory biomarker analysis|
223562442|NCT00499291|PROCEDURE|pharmacological study|
223562443|NCT00499291|PROCEDURE|polymerase chain reaction|
223562444|NCT03718884|DRUG|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
223562445|NCT03718884|DRUG|Mirikizumab|Administered SC
223419959|NCT04052386|BEHAVIORAL|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. The personalized feedback intervention included tailored feedback on drinking quantity and frequency of alcohol, BAC, alcohol-related consequences, normative perceptions of peer drinking, alcohol outcome expectancies, family history of risk, and financial costs of alcohol. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
223562446|NCT00349921|DRUG|clonidine|Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
223562447|NCT00349921|DRUG|adenosine|Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
223562448|NCT00349921|DRUG|placebo|inactive substance
223562449|NCT00349921|DRUG|placebo|inactive substance
223419960|NCT03474016|DIAGNOSTIC_TEST|Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction|Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
223419961|NCT01813214|DRUG|Vemurafenib|
223419962|NCT01813214|DRUG|Cobimetinib|
223419963|NCT00733239|DRUG|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
223419964|NCT04150484|OTHER|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
223419965|NCT06437821|DIAGNOSTIC_TEST|Petrissage|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
223419966|NCT06437821|OTHER|Graston Technique|The calf muscles will receive a firm, deep-circulation massage with fingertip pressure
223419967|NCT03265821|PROCEDURE|Healing after treatment|
223419968|NCT01876784|DRUG|Vandetanib (SAR390530)|"Pharmaceutical form: tablet~Route of administration: oral"
223562450|NCT05519436|OTHER|Assessment|"Bioelectrical impedance analysis method was used to evaluate the body composition of the cases. Muscle, fat, water ratio was made with Inbody Bioelectrical Impedance Device. Static and dynamic plantar pressure analyzes were evaluated with Sensor Medica pedobarographic measuring device, and postural sway was evaluated with bilateral comparison tests, one of the dynamic balance tests of Biodex Balance System."
223562451|NCT02072135|DRUG|Exparel|
223562452|NCT05359003|BEHAVIORAL|12-week physical activity program|Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
223562453|NCT03383913|BEHAVIORAL|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
223562454|NCT04700540|DEVICE|Smartwatch Reminder (SR) system|The Smartwatch Reminder (SR) system will automatically transmit pictures and relevant information, such as name or relationship, to a smartwatch worn by the PWMC when family or friends visit.
223562455|NCT06718036|OTHER|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice|Validation and evaluation of the use of the ICF Rehabilitation Set in clinical practice
223562456|NCT05085093|BIOLOGICAL|HPV vaccine|Patients choose to be vaccinated or not to be vaccinated with HPV vaccine according to their own wishes
223562457|NCT05337124|DRUG|LUPKYNIS|LUPKYNIS treatment per the approved US Prescribing Information
224298689|NCT03785535|DEVICE|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
223562458|NCT06853301|OTHER|Blood culture sampling|Patients with blood culture sampling as standard of care. Two to four additional blood culture bottles sampled that will be spiked with known bacterial species to determine their electrochemical profiles
223562459|NCT02543073|BIOLOGICAL|MSCs|MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.
224035153|NCT03891524|DRUG|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
224035154|NCT03891524|DRUG|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
223419969|NCT01876784|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223419970|NCT03425578|DIETARY_SUPPLEMENT|MSG|150 mg/kg body mass monosodium glutamate (MSG).
223419971|NCT03425578|DIETARY_SUPPLEMENT|CHO|75g CHO (i.e. dextrose)
223419972|NCT03425578|DIETARY_SUPPLEMENT|Placebo A|A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
223562460|NCT02543073|DRUG|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
223562461|NCT02543073|DRUG|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
223419973|NCT03425578|DIETARY_SUPPLEMENT|Placebo B|A non-caloric placebo composed of flavoured water.
223562462|NCT02342847|OTHER|N/A (non-interventional study)|
223562463|NCT05131334|DEVICE|auriStim, for auricular vagal stimulation|For auricular vagal stimulation we used auriStim (AU0115, Multisana GmbH, Vienna, Austria). Using a green light-emitting diode (LEDs) flashlight, blood vessels in the cymba conchae of the left ear side were detected. Minimal invasive needles (penetrating 1-2mm) were placed close to the vessel-bifurcation to provide efficient stimulation of the auricular branch of the vagus nerve. The built-in microchip controls monophasic volt pulses of 1 ms, with alternating polarity, a frequency of 1 Hz and an amplitude of 4V. Stimulation lasted for 72h in total with alternating on/off periods of three hours. Thereafter, the device was removed, and patients continued their therapy consisting of anti-withdrawal medication.
223562464|NCT05109429|BEHAVIORAL|Neutral Cue-induced Craving|For the neutral cue condition, the participant will be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of water bottles via E-Prime software (Psychology Software Tools Inc., PA), presented for five seconds each in randomized order. The images will include pictures of a water bottle alone, water being poured from a bottle to a glass, and an individual drinking from a bottle of water. Next, participants will watch as research staff open a bottle of water, pour it into a glass, and place it on a table in front of the participant. Participants will also be asked to look at a water bottle, hold it, sniff it, and take a drink of water.
224298690|NCT03831763|DEVICE|ColdZyme|"ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (\<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap."
223419974|NCT03605862|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
223419975|NCT03605862|DRUG|Placebo|Placebo administered orally twice daily for five days
223562465|NCT05109429|BEHAVIORAL|Visual Opioid Cue-induced Craving|For the visual opioid cue-induced craving condition, the participant will again be seated in front of a 16-inch monitor and instructed to sit upright to view 20 pictures of opioid-related imagery, presented for five seconds each in a randomized order. The opioid-related imagery will be customized for heroin or prescription opioids based upon the participant's primary opioid of choice. The images will include pills and white powder, stages of drug taking preparation (e.g., holding spoon over flame, pills being crushed).
223419976|NCT00818467|OTHER|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
223419977|NCT00818467|OTHER|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
223739471|NCT04454372|OTHER|demographic and clinical data obtained from hospital's electronic medical record.|This retrospective observational study. . Demographic and severity data will include age, sex, SAPS 3 and SOFA scores at admission, nutritional risk determined by NRS-2002 and commodities. Clinical and laboratory data on arrival at the ICU including PaO2 / FIO2, blood count and PCR D-dimer, ferritin, fibrinogen, DHL. Drug interventions including use of hydroxychloroquine, corticosteroids, heparin, tocilizumab. Characteristics of invasive and non-invasive respiratory support, use of prone position and ECMO and vasoactive drugs. The main complications, acute kidney injury requiring renal replacement therapy, secondary infectious complications will be documented as well as the outcomes.
223419978|NCT03891862|DRUG|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
223419979|NCT03891862|DRUG|Placebo oral capsule|non-active dosage form
223419980|NCT05239494|DEVICE|DT1 Sphere Contact Lenses|Devices: Dailies Total 1 Sphere Contact Lenses
223419981|NCT03322774|BEHAVIORAL|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
223419982|NCT03322774|BEHAVIORAL|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
223739472|NCT01829750|GENETIC|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
223739473|NCT05325879|OTHER|VAGUS-NDT|Neurodynamic test for vagus nerve
223739474|NCT04296903|DEVICE|MID-C System|Minimal invasive deformity correction system for the treatment of AIS
223739475|NCT00211445|PROCEDURE|Photodynamic Therapy with Verteporfin|
223739476|NCT00211445|DRUG|verteporfin|
223739477|NCT01477060|DRUG|Lapatinib|1250 mg/ die, os
223739478|NCT01477060|DRUG|Metformin|1500 mg/die, os
223419983|NCT03322774|BEHAVIORAL|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
223419984|NCT03250767|DEVICE|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
223419985|NCT01194531|DEVICE|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
223419986|NCT01531530|BIOLOGICAL|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
223739479|NCT00555750|DRUG|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
223739480|NCT00555750|DRUG|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
223739481|NCT00485407|DRUG|Atomoxetine Hydrochloride|
223739482|NCT04407000|DRUG|Test: Favipiravir 200 mg (LOQULAR)|Test Drug
223739483|NCT04407000|DRUG|Reference: Favipiravir 200 mg (Avigan)|Reference Drug
223739484|NCT06178328|BEHAVIORAL|Things You Do Course|Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
223739485|NCT05111886|BEHAVIORAL|Communication Skills Training|The training will focus on communication skills based on key constructs in the Health Belief Model and motivation/resistance research (described in section A3), the training will focus on: (1) conveying the benefits of parenting programs, (2) knowledge of and responses to common perceived barriers to attending parenting programs, and (3) skills and strategies to effectively motivate and refer parents in ways that are least likely to elicit resistance. The in-person training will last 60-90 minutes. It will include a theoretical background and experiential learning; each step of the referral process will be demonstrated and role-played. The investigators will work to ensure that personnel receive continuing education credits for the training.
223739486|NCT05111886|BEHAVIORAL|eHealth GenPMTO|The GenPMTO is delivered over the phone (not online). This version is up to 6 sessions in length. This brief eHealth version of GenPMTO will be delivered through community therapists. The program will be delivered one-on-one (i.e., between a therapist and a parent or couple).
223739487|NCT05111886|BEHAVIORAL|Written Referral Process|"A written summary and process map of the referral process, modeled on the Institute for Healthcare Improvement (IHI) 9-step process for closing the loop on referrals."
224035155|NCT03891524|DRUG|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
224035156|NCT03891524|DRUG|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
223419987|NCT01531530|OTHER|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
223419988|NCT02370589|BIOLOGICAL|Base Dose EBOV GP Vaccine|
223562466|NCT05109429|BEHAVIORAL|Visual and Tactile Opioid Cue-induced Craving|For the visual and tactile opioid cue condition, procedures will differ depending on the participants' most preferred route of administration. . Intranasal users will be instructed to watch as research staff opens a wallet, removes a $1 bill, removes a packet of powder mimicking heroin/crushed pills, open the packet, and roll the dollar bill. The participant will then be given the packet and the dollar bill to hold for approximately 30 seconds. Intravenous users will be instructed to watch the research nurse open the packet of fake heroin, pour its contents into a spoon, added a few drops of water to the spoon, hold an open flame from a lighter under the spoon, add cotton to the spoon, and draw the fluid into a syringe.
223562467|NCT02289911|OTHER|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
223562468|NCT02255058|OTHER|No intervention|The study is a Prospective observational cohort study
224035157|NCT03891524|DRUG|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
223562469|NCT03316287|DEVICE|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
223562470|NCT03316287|DEVICE|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
223562471|NCT03316287|DEVICE|Sensor|Wearable biosensor for the collection of physiological data
223562472|NCT00044837|DRUG|Medroxyprogesterone acetate|
223562473|NCT00044837|DRUG|Estradiol|
223739488|NCT05111886|BEHAVIORAL|One Session Education about Resources|"One online or phone conversation with the therapist in which the therapist guides the parent to the following resources: (a) a book, Raising Cooperative Kids, by GenPMTO co-developer Marion Forgatch; (b) a website, behaviorchecker.org, which includes behavioral prescriptions for common behavior issues; and (c) information about Early Childhood and Family Education classes, which are provided for free in Minnesota through public schools."
224035158|NCT05309265|OTHER|Multidisciplinary vocational rehabilitation intervention|"* Information aims to provide tailored information concerning the work law protection (this support is already provided for all patients, regardless the type of disease, and also for citizens);~* Occupational therapy aims to facilitate the reintegration in the previous workplace through the development of a rehabilitation intervention to overcome work difficulties in agreement with employee, employer and occupational physician,~* Social support aims to find new job opportunities (for those who have lost the employment due to the disease) through the giving of support in job search, curriculum preparation, skill analysis, professional retraining and education."
224035159|NCT03178539|DRUG|diclofenac|non steroidal anti-inflammatory drug
224137412|NCT01733901|PROCEDURE|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
224137413|NCT01733901|PROCEDURE|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
224137414|NCT00983840|OTHER|Family Eats|8-session web-based program on healthy eating for African American families
224137415|NCT05136378|DRUG|Low Dose Selenious Yeast Tablets|Low dose of Selenious Yeast Tablets
224137416|NCT05136378|DRUG|High Dose Selenious Yeast Tablets|High Dose Selenious Yeast Tablets
224137417|NCT00055536|DRUG|natalizumab|
224137418|NCT00649441|DRUG|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
223419989|NCT02370589|BIOLOGICAL|2x Base Dose EBOV GP Vaccine|
223562474|NCT05818956|DRUG|TAK-227|TAK-227 capsules.
223562475|NCT05238207|DRUG|BBI-001|Part A: 1 dose BBI-001 administered in a crossover fashion Part B: 2 doses BBI-001 administered in a crossover fashion
223562476|NCT05238207|DIETARY_SUPPLEMENT|Original Fibre Metamucil|Part A: 1 dose placebo administered in a crossover fashion Part B: 2 doses placebo administered in a crossover fashion
223419990|NCT02370589|BIOLOGICAL|4x Base Dose EBOV GP Vaccine|
223419991|NCT02370589|BIOLOGICAL|8x Base Dose EBOV GP Vaccine|
223419992|NCT02370589|BIOLOGICAL|Placebo|
223419993|NCT02370589|BIOLOGICAL|Matrix-M Adjuvant|
223419994|NCT05763394|OTHER|Polarized workout program|Polarized workout lasting approximately 40 minutes (two sessions/day, 5 days a week), characterized by a 5-minute warm-up performed at 50% of the peak V'O2, followed by 3 sets of 2 minutes at 95% of peak V'O2, interspersed with 1 minute of recovery at 40% of peak V'O2, followed by 30 minutes of moderate activity at 60% of V'O2 peak. Total of 24 sessions in 12 days.
223419995|NCT05763394|OTHER|High intensity workout program|High intensity workout (HIIT) (two sessions/day, 5 days a week), characterized by a 10-minute warm-up performed at 50% of peak V'O2 , followed by 6 series of 40 s of high-intensity walking corresponding to 95% of peak V'O2, interspersed with 5 minutes of walking at 40% of peak V'O2, ending with 5' of cool-down at 50% of the peak V'O2. Total of 24 sessions in 12 days.
223562477|NCT00189800|DRUG|Solifenacin succinate|
223562478|NCT00777985|DRUG|bosentan|62.5 mg b.i.d for 4 weeks
223739489|NCT05111886|DIAGNOSTIC_TEST|Survey of Experience|Satisfaction with referral process
223739490|NCT01799499|DEVICE|TC-3 hydrogel|
223739491|NCT01799499|DEVICE|TC-3 hydrogel|
223739492|NCT01799499|DEVICE|TC-3 hydrogel|
223562479|NCT00777985|DEVICE|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
223562480|NCT01738607|DIETARY_SUPPLEMENT|Psyllium|
223562481|NCT01738607|DIETARY_SUPPLEMENT|Gum Arabic|Gum acacia dietary fiber
223562482|NCT01738607|DIETARY_SUPPLEMENT|carboxymethylcellulose|dietary fiber
223739493|NCT01927406|DRUG|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
223739494|NCT01927406|DRUG|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
223739495|NCT00988507|DRUG|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
223739496|NCT00988507|DRUG|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
223739497|NCT00988507|DRUG|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
223739498|NCT02093598|DRUG|Temsirolimus|
223739499|NCT06329401|DRUG|AP01|Oral inhalation solution
223739500|NCT06329401|OTHER|Placebo|Placebo oral inhalation solution
223739501|NCT03099044|OTHER|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
223739502|NCT03099044|OTHER|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
223739503|NCT03099044|OTHER|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
224298691|NCT02701166|DRUG|Bezafibrate|bezafibrate 400mg per day
224298692|NCT02701166|DRUG|Placebo|placebo 400mg per day
223739504|NCT00002304|DRUG|Ketoconazole|
224298693|NCT03519984|DRUG|Cytarabine|Given IV
224298694|NCT03519984|OTHER|Laboratory Biomarker Analysis|Correlative studies
224298695|NCT03519984|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
224298696|NCT03519984|DRUG|Vincristine Liposomal|Given IV
224298697|NCT05410054|OTHER|no intervention|observational research
224298698|NCT00995085|DRUG|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
223562483|NCT01738607|DIETARY_SUPPLEMENT|Placebo|
223562484|NCT06232746|DEVICE|Magnet System, DI Biofragmentable|Anastomoses achieved by magnetic compression.
223562485|NCT05617508|OTHER|Placebo|Placebo capsules administered twice daily for a total of 12 weeks.
223562486|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside supplementation 1000mg daily in total|Nicotinamide Riboside supplementation 1000mg daily in total
223562487|NCT05617508|DIETARY_SUPPLEMENT|Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)|Nicotinamide Riboside supplementation up to 3000mg daily in total
223562488|NCT02835313|BEHAVIORAL|FAST alone|Subjects participate in fast walking training 3x/week for 12 weeks.
223562489|NCT02835313|BEHAVIORAL|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
223562490|NCT02835313|BEHAVIORAL|SAM alone|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
223562491|NCT04084366|DRUG|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
223562492|NCT04084366|DRUG|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
223739505|NCT00002304|DRUG|Fluconazole|
223739506|NCT04267003|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
223739507|NCT04568590|BEHAVIORAL|educational intervention|If the guardian screens positive for vaccine hesitancy (i.e., vaccine hesitancy score average \> 3), they will be given the informational handout along with a brief script.
223739508|NCT03631901|DRUG|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
223739509|NCT03631901|DRUG|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
223739510|NCT02540460|DRUG|LCB01-0371 800mg|LCB01-0371 800mg
223739511|NCT02540460|DRUG|LCB01-0371 800mg BID|LCB01-0371 800mg BID
223739512|NCT02540460|DRUG|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
223739513|NCT02540460|DRUG|Placebo|Placebo
223739514|NCT06488482|DRUG|nivolumab or pembrolizumab|See above
223739515|NCT02599155|DRUG|Crystalloid|normal saline administration for volume expansion in hypovolemic status
224298699|NCT05946954|PROCEDURE|Immediate Dentoalveolar Restoration|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
224298700|NCT05946954|PROCEDURE|Ice cream cone technique|"Topical anesthesia will be administered using an infiltration technique. • Atraumatic extraction will be done with the aid of periotome and Luxators. • The extraction socket will be debrided to remove any residual debris or granulation tissue. •. Socket walls will be checked using a periodontal probe to ensure integrity of all sockets walls except the labial bone plate which must show a dehiscence.~• Implant placement will be done according to manufactures' instructions; drills will be used sequentially in a more palatal direction leaving a buccal jumping gap of at least 2mm. All implants will engage at least 3 mm apical to the apical end of the socket with adequate primary stability"
224298701|NCT04088266|COMBINATION_PRODUCT|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
223562493|NCT05582707|DRUG|Pioglitazone 15mg|Study participants will be administered pioglitazone (15 mg tablet) either p.o. or enteral (via nasogastric tube). The first dose may be administered prior to surgery or within 3 hours of the end of surgery but must be administered within 24 hours of the index event or time last known normal (TLKN). Pioglitazone (15 mg tablet) administration will continue 3 times daily for 3 weeks, including after hospital discharge, if applicable.
223562494|NCT03869385|DRUG|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
223562495|NCT02602275|DRUG|Neurexan|0.6 mg / tablet
223562496|NCT02602275|DRUG|Placebo|Neurexan-matched Placebo tablet
223562497|NCT03574766|BEHAVIORAL|Meditation|Daily meditation
223562498|NCT03742310|DRUG|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
223562499|NCT00394043|PROCEDURE|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
223562500|NCT00394043|PROCEDURE|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
223562501|NCT03267979|OTHER|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
223562502|NCT03267979|OTHER|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
223419996|NCT03373994|DIAGNOSTIC_TEST|18F-FDG PET/CT initial-time imaging|18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
223419997|NCT03373994|DIAGNOSTIC_TEST|18F-FDG PET/CT balanced-time imaging|18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
223419998|NCT04303026|DRUG|Zoledronic Acid|5mg IV infusion
223419999|NCT04303026|DRUG|Saline 0.9%|Placebo Group. Saline 0.9% 100 ml infusion
223420000|NCT03247465|OTHER|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
223739516|NCT02599155|DRUG|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
223739517|NCT00533533|DRUG|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
223739518|NCT06786819|OTHER|ERACS with Digital Platform|The assistance provided to patients in the intervention group will be sequential and prospective. The project will utilize an app based on protocols that prepare patients for rapid recovery (ERAS), starting before surgery and extending up to 30 days post-discharge. This includes pre-operative evaluations (dental, psychological, nutritional, and others), scheduling and confirming hospital admission, and following specific protocols during surgery and intensive care. The app aims to enhance communication and teamwork, improving patient-centered care. It will feature modules for patient and family education, team communication, and activity management through a dashboard. Additionally, it will facilitate interaction with patients through messages and surveys, monitor multidisciplinary team communication, and collect patient-reported outcomes 30 days after the surgical procedure.
223739519|NCT04930679|DRUG|Andiabet|Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
223739520|NCT06065761|OTHER|Comprehensive ED heart failure management tool|The investigators plan a regional implementation of an electronic health record-based heart failure decision support tool across 21 EDs of Kaiser Permanente Northern California (KPNC).
223739521|NCT03250546|PROCEDURE|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
224035160|NCT03178539|DRUG|ketorolac|non steroidal anti-inflammatory drug
224035161|NCT02867319|BIOLOGICAL|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
223420001|NCT03269617|DIETARY_SUPPLEMENT|Bacteriophage mixture|Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.
223420002|NCT03269617|OTHER|Placebo Control|Placebo control capsule consisting of rice maltodextrin
223562503|NCT02048137|DEVICE|Transcranial direct current stimulation|
223562504|NCT06149520|DRUG|BAY3018250|Dose 1 or dose 2 of BAY3018250
223562505|NCT06149520|DRUG|Placebo to BAY3018250|Matching placebo to BAY3018250
223562506|NCT06069856|DIETARY_SUPPLEMENT|Iron Folic Acid Tablets with 60 mg of iron|IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization
223562507|NCT06069856|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements with 60 mg of elemental iron|MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
223562508|NCT03057002|DIAGNOSTIC_TEST|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
224035162|NCT01362777|BEHAVIORAL|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~* 15' start warming up muscles~* 30' muscle strengthening exercise for arms and abdominal muscles~* 45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~* 15' stretching~* 15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
223420003|NCT02012842|OTHER|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
223420004|NCT05785585|DIETARY_SUPPLEMENT|Methylcobalamin|Treatment with Methylcobalamin during 12 weeks
223420005|NCT05785585|DIETARY_SUPPLEMENT|Cyanocobalamin group|Treatment with Cyanocobalamin during 12 weeks
223420006|NCT05785585|DIETARY_SUPPLEMENT|Control group|Treatment with microcrystalline cellulose during 12 weeks
223420007|NCT01329809|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
224035163|NCT01362777|BEHAVIORAL|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~* Physiological mechanisms of apneas/hypopneas~* Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~* Beneficials effects of CPAP and/or advanced mandibular orthosis~* Description of sleep stages and physiological roles of sleep~* Known effects of exercise on sleep and metabolism~* Importance of good nutritional status and sleep hygiene on quality of life~* How to apply theses lessons of rehabilitation in daily life"
224035164|NCT02180022|DRUG|Placebo|After randomization, placebo was treated for 12 weeks
224035165|NCT02180022|DRUG|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
224035166|NCT02941562|RADIATION|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
224035167|NCT02941562|DRUG|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
224137419|NCT00649441|DRUG|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
224137420|NCT00611221|PROCEDURE|Massage|Massage therapy by an RMT during labour
224137421|NCT00611221|PROCEDURE|Massage|Massage by anyone else, eg. husband, nurse, doula
224137422|NCT03179579|PROCEDURE|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
224137423|NCT03179579|PROCEDURE|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
224137424|NCT04994652|DEVICE|Videolaryngoscopy|Indirect laryngoscopy using the C-MAC videolaryngoscope
223420008|NCT02966678|PROCEDURE|Color Vision Test|Farnsworth Panel D15/Hue test plus Ishihara charts
223420009|NCT01747889|DEVICE|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
223420010|NCT03212092|DIETARY_SUPPLEMENT|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
223420011|NCT03212092|DIETARY_SUPPLEMENT|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
223420012|NCT02657057|DEVICE|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
223739522|NCT03250546|PROCEDURE|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
224035168|NCT02941562|RADIATION|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
224035169|NCT02941562|DRUG|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
224035170|NCT02941562|PROCEDURE|Radical rectal cancer resection|Radical rectal cancer resection
224035171|NCT02941562|DRUG|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
224035172|NCT06062446|PROCEDURE|Modified Lumbar Puncture|The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
224035173|NCT03012607|DRUG|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
224137425|NCT04994652|DEVICE|Direct laryngoscopy|Direct laryngoscopy with a standard laryngoscope
224137426|NCT00518232|DRUG|OROS-methylphenidate|
224137427|NCT04124692|DEVICE|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
224137428|NCT03427541|PROCEDURE|Surgeries|Surgeries
224137429|NCT03703687|BEHAVIORAL|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
224137430|NCT00205699|DRUG|risperidone|randomized to begin 12 week trial of risperidone
224137431|NCT00205699|DRUG|olanzapine|randomized to begin 12 week trial of olanzapine
224137432|NCT00205699|DRUG|aripiprazole|randomized to 12 week trial of aripiprazole
224298702|NCT02969993|OTHER|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
223420013|NCT02657057|DEVICE|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
223420014|NCT05104216|BIOLOGICAL|Inactivated COVID-19 vaccine|receive a third dose of inactivated COVID-19 vaccine
223420015|NCT01858779|BEHAVIORAL|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
223420016|NCT01858779|DEVICE|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
223420017|NCT03852368|OTHER|Exercise|The effects of exercise with different intensity on the executive functions of adolescents
223420018|NCT06591884|DRUG|Tacrolimus modified-release|0.08% tacrolimus nanoencapsulated aqueous solution spray
223420019|NCT06591884|DRUG|tacrolimus ointment 0.1%|0.1% free tacrolimus commercial ointment
223420020|NCT06519643|BEHAVIORAL|career planning application|"Arm 1 \[Experimental group\]: The experimental group will be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. They will receive the full career planning mobile application intervention along with two online career mentoring sessions.~Arm 2 \[Control group\]: The control group will also be assigned to participate in a career planning application named Building Your Successful Nursing Career App for six months. However, the control group will only receive a sham treatment. They will only access a few interfaces of the app."
223420021|NCT00004638|PROCEDURE|pathogenesis study|
223420022|NCT00171938|DRUG|imatinib mesylate|
223420023|NCT06390774|DRUG|SSGJ-705|anti-PD-1 and anti-HER2 bispecific antibody
223420024|NCT05337540|DEVICE|EVI-01|Single intra-articular injection of high molecular weight hyaluronic acid
223420025|NCT05337540|DEVICE|Active comparator Synvisc-One|Single intra-articular injection of active comparator Synvisc-One
223420026|NCT05512806|DRUG|AZD5462|Participants will receive AZD5462 orally.
223420027|NCT04603482|BEHAVIORAL|Resourcefulness training|Resourcefulness training is a cognitive behavioral intervention that consists of teaching and reinforcing personal (self-help) and social (help-seeking) strategies to overcome adversity.
223420028|NCT04603482|BEHAVIORAL|Biofeedback|Biofeedback training combines teaching slow, deep, paced breathing with real-time tracking to increase an individual's heart rate variability and ultimately improve self-regulation.
223420029|NCT04603482|BEHAVIORAL|Attention Control|Participants randomly assigned to this intervention will receive suggested Diversional Activities, presented in an audiovisual format.
223420030|NCT05232604|OTHER|Aerobic exercise|30-45 minutes of aerobic exercise in a cycle ergometer will be applied in three different intensities (low, moderate and high) along 12 weeks of treatment.
223420031|NCT05232604|OTHER|Neck motor control exercise|An specific neck motor control exercise targeted to the neck flexor and extensor muscles supervised by a physical therapist will be applied during 12 weeks of treatment.
223420032|NCT03500913|DRUG|Growth Hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
223420033|NCT06648174|DEVICE|Continuous glucose monitor|"Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear."
223420034|NCT06648174|BEHAVIORAL|Perinatal nursing care for gestational diabetes|Individual nursing care and consultation for women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum.
223420035|NCT06648174|OTHER|Blood glucose meters (BGM)|Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery, another glucose monitor reports will be given to the participants.
223420036|NCT06966856|DRUG|Cyanocobalamin 1000 Mcg Oral Tablet|Oral cyanocobalamin supplement administered as a 1000 mcg tablet taken once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.
223420037|NCT06966856|DRUG|Cyanocobalamin 1000 Mcg Sublingual Tablet|Sublingual cyanocobalamin supplement administered as a 1000 mcg tablet placed under the tongue once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.
223562509|NCT05772455|DRUG|XZB-0004|Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
223420038|NCT06966856|OTHER|Proton Pump Inhibitor therapy only|This group will continue their standard PPI therapy without receiving any vitamin B12 supplementation, serving as a control group for the comparison of B12 correction efficacy.
223420039|NCT06452836|OTHER|Green color exposure|Patients will wear green colored glasses before and during the surgery.
223420040|NCT06452836|OTHER|Red color exposure|Patients will wear red colored glasses before and during the surgery.
223420041|NCT06452836|OTHER|Blue color exposure|Patients will wear blue colored glasses before and during the surgery.
223420042|NCT06452836|OTHER|control|Patients will wear translucent glasses before and during the surgery.
223420043|NCT03617263|DRUG|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
223420044|NCT03617263|DRUG|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
223420045|NCT05955326|DRUG|Sovateltide|Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.
223420046|NCT05955326|OTHER|Normal Saline|Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.
223420047|NCT03665545|DRUG|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
223420048|NCT03665545|DRUG|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
223420049|NCT00179673|DRUG|Lenalidomide|
223420050|NCT03411174|RADIATION|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
223420051|NCT03686943|OTHER|Family pharmacy|Observation of the family pharmacy in elderly group
223420052|NCT03445741|OTHER|Supervised treadmill group (%70 VO2 max) (group 1)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.
223420053|NCT03445741|OTHER|Supervised treadmill group (%50 VO2 max) (group 2)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
223420054|NCT03445741|DEVICE|ECE PEDO pedometer group (%50 VO2 max) (group 3)|Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
223420055|NCT02426905|DRUG|trientine dihydrochloride|A retrospective review of patients' medical records
223420056|NCT06967571|PROCEDURE|Jejunal Pouch reconstruction.|The JP will be fashioned with a standard length of 12 cm using two 60 mm staple lines, the esophago-pouch anastomosis will be performed with a circular mechanical 25 mm stapling device, and finally the staple entrance on the pouch will be closed with two layers of running sutures in Vicryl 3/0
223420057|NCT06968871|PROCEDURE|Modified Pap test|For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.
223420058|NCT01547442|DEVICE|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
223562510|NCT02333396|OTHER|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
223562511|NCT02333396|OTHER|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
224035174|NCT04098757|DIETARY_SUPPLEMENT|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
224035175|NCT06347887|DIAGNOSTIC_TEST|ColonAiQ test and Colonoscopy|Diagnostic Test
224035176|NCT05764993|BIOLOGICAL|CUVITRU - Ig subcutaneous human 20%|Subcutaneous Immunoglobin Replacement Therapy, SCigR
224035177|NCT05764993|OTHER|Standard Medical Therapy|Standard Medical Therapy
224035178|NCT03456284|DEVICE|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
224035179|NCT06307899|OTHER|Unilateral Corner Stretch|Individuals will be positioned in a standing position with the elbow in 90° flexion and the shoulder in 90° abduction, placing the palm on a flat surface. For stretching, individuals will be asked to increase shoulder horizontal abduction by rotating the trunk anteriorly and contralaterally. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
223420059|NCT03943069|PROCEDURE|Thoracoscopic bullectomy alone|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.
223420060|NCT03943069|PROCEDURE|Thoracoscopic bullectomy with pleurodesis|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.in addition to mechanical pleurodesis.
223420061|NCT01691495|DRUG|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
223420062|NCT03220295|DRUG|Single Dose of VU319|Single dose of VU319
223420063|NCT03220295|DRUG|Single Dose Placebo|Single dose of placebo
223420064|NCT03220295|OTHER|Fed State|drug is given 30 minutes after a high fat breakfast
223420065|NCT03220295|OTHER|Fasted State|drug is given after an overnight fast
223420066|NCT03220295|DRUG|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
223420067|NCT03220295|DRUG|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
223420068|NCT03835624|DIAGNOSTIC_TEST|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its relative mRNA expression in peripheral blood mononuclear cells by PCR
223420069|NCT02685358|BEHAVIORAL|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
223420070|NCT02685358|BEHAVIORAL|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
223420071|NCT00065936|DRUG|Naltrexone hydrochloride|
223420072|NCT00065936|PROCEDURE|Transcutaneous sensory nerve stimulation|
224035180|NCT06307899|OTHER|Manual Stretching|Individuals will be positioned supine with the shoulder in 90º abduction and external rotation and the elbow in 90º flexion. Stretching will be applied by the physiotherapist from just distal to the elbow in the direction of horizontal abduction of the shoulder. The position will be maintained for 30 seconds and will be repeated 4 times with a 30-second rest between repetitions.
223420074|NCT01366703|DEVICE|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
223420075|NCT05245149|DIAGNOSTIC_TEST|Cardiac CTA on a photon-counting detector CT (PCD-CT)|Cardiac CTA will be performed on a dual-source photon-counting CT
223420076|NCT05245149|DIAGNOSTIC_TEST|Cardiac CTA on a regular CT with Energy-Integrating Detector (EID-CT)|Cardiac CTA was performed on a dual-source CT with regular energy-integrating detector (EID-CT)
223420077|NCT05932589|OTHER|EEG and Auditory and Visual Evoked Potentials (AEP and VEP)|Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.
223420078|NCT05932589|OTHER|Clinical assessment|Established clinical measures for RTT will be collected for RTT participants
223420079|NCT05346315|OTHER|RDN Medical Nutrition Therapy|The RDNs will provide bi-monthly nutrition care, counseling, and dietary recommendations for a 6-month intervention, delivered either in-person or via telehealth, to the grocery store patrons during the study intervention. The RDN will provided care to the participant based upon the participant's unique dietary and nutritional needs. The RDN will provide nutrition recommendations and create meal plans via NutriStyle for the participants to follow. The meal plans will be uploaded into the grocery store's E-commerce shopping platform, which the participant can utilize to purchase foods that are needed to follow the RDNs nutrition recommendations for an individual person.
223420080|NCT04937933|DRUG|Coolant spray (Cryos ®Spray, Phyto Performance, Italy)|The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
223562512|NCT00129584|PROCEDURE|Emphasys Endobronchial Valve and procedure|
224035181|NCT06307899|OTHER|PNF Stretching|Individuals will be in a sitting position with their hands clasped behind the head. The PM muscle will be stretched in the direction of horizontal abduction by placing the physiotherapist's hands anterior to the elbows. Passive stretching will be continued for 10 seconds, followed by 6 seconds of maximum voluntary isometric contraction of the PM muscle. The procedure will be repeated four times with 30 seconds of rest.
224035182|NCT01210118|BEHAVIORAL|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
223420081|NCT04937933|DRUG|Saline solution|saline solution
223420082|NCT03189667|DEVICE|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~* All lesions to be predilated with high pressure balloons until waist is obliterated.~* At least two minutes dilatation.~* Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~* Multiple lesions:~  * To be treated with single balloon if possible.~ * To be treated with multiple inflation if cannot be covered with single balloon."
223420083|NCT03189667|DEVICE|Plain balloon angioplasty|"Plain balloon angioplasty~* Vessel treatment with additional Plain balloon angioplasty:~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to predilation balloon."
223562513|NCT05481502|PROCEDURE|Tumor biopsy|3 biopsies will be collected: at baseline, at day+15 and optionally at relapse
223562514|NCT05481502|PROCEDURE|Blood sample|7 blood samples (25ml) will be taken: at day-7 before treatment start, at day0, at day+3, day+7, day+15, month+3 and at relapse
223562515|NCT05481502|PROCEDURE|Bone marrow sample|If a bone marrow biopsy or aspiration is performed as part of routine care, 1 mL of bone marrow aspiration or one more biopsy will be sampled
223562516|NCT05493254|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
223562517|NCT05493254|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
223420084|NCT03189667|DEVICE|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~* Inflation to nominal pressure for at least 1 minute.~* Balloon size: similar to the predilation balloon.~* New drug coated balloon will be required for each lesion."
223420085|NCT01297439|PROCEDURE|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
223420086|NCT01297439|PROCEDURE|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
223420087|NCT02602132|PROCEDURE|Clamping|To clamp before the removal of short-term indwelling urethral catheters
223420088|NCT00417716|DRUG|Intravitreal Bevacizumab|
223420089|NCT01415713|DRUG|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
223420090|NCT00977314|DEVICE|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
223420091|NCT00977314|DEVICE|SoundBite|
223420092|NCT00977314|DEVICE|SoundBite Hearing System|
223420093|NCT02107859|DRUG|Ataluren|Ataluren will be administered per dose and schedule specified in the arm.
223420094|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|phase 3 tablets
223420095|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|registration tablets
223420096|NCT06347861|DRUG|single dose of vepdegestrant as tablet formulation (Treatment C)|registration tablets
223420097|NCT03884517|DRUG|BAT8003|Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
223420098|NCT00162045|DRUG|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
223420099|NCT03297918|BEHAVIORAL|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
223420100|NCT00555919|DRUG|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
223420101|NCT00555919|DRUG|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
223420102|NCT03557216|DIAGNOSTIC_TEST|Colonoscopy|Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
223420103|NCT03557216|DIAGNOSTIC_TEST|Fecal immunochemical and occult blood test|A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
223420104|NCT03557216|DIAGNOSTIC_TEST|Fecal calprotectin test|Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
223420105|NCT02344251|DEVICE|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
223420106|NCT02344251|DEVICE|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
223420107|NCT03264924|BEHAVIORAL|IPAIR|Motivational interview training
223420108|NCT04588051|DRUG|Cabozantinib|60mg daily
223562518|NCT04113733|OTHER|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
224035183|NCT01210118|BEHAVIORAL|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
224035184|NCT04225221|DRUG|Estradiol|During estradiol administration, 2mg of estradiol is given twice daily via oral capsule.
223420109|NCT02901119|DIETARY_SUPPLEMENT|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
223420110|NCT04563533|BIOLOGICAL|Low-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 12.5μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 1 μg, sodium dihydrogen phosphate: 47 μg, disodium hydrogen phosphate: 87 μg."
223420111|NCT04563533|BIOLOGICAL|High-dose vaccine|"Active ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoV GII.4-VP1 protein and recombinant ReNoV GII.17-VP1 protein each 25μg.~Other ingredients: aluminum hydroxide adjuvant 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg."
223420112|NCT04563533|BIOLOGICAL|Placebo (containing aluminum)|Active ingredients: none Other ingredients: aluminum hydroxide adjuvant: 0.25 mg, L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
223739523|NCT00202644|DRUG|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
223739524|NCT00202644|DRUG|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
223420113|NCT04563533|BIOLOGICAL|Placebo (without aluminum)|Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
223420114|NCT02482714|BEHAVIORAL|Physical activity.|Have subject do moderate physical activity.
223420115|NCT05236738|DRUG|Atazanavir|Specified dose on specified days
223420116|NCT05236738|DRUG|Cobicistat|Specified dose on specified days
223420117|NCT05236738|DRUG|Atazanavir/Cobicistat Mini-tablet|Specified dose on specified days
223420118|NCT06044350|DRUG|BAT4406F Injection|Intravenous infusion; Dosage:500mg/time
223420119|NCT06044350|DRUG|BAT4406F Placebos|Intravenous infusion; Dosage:500mg/time
223420120|NCT06419543|DRUG|Remimazolam|Observe the incidence of paradoxical reactions after the first induction.
223420121|NCT05938660|OTHER|acupressure at Sanyinjiao point|When pressing Sanyinjiao point, the subject should be in a comfortable sitting position. Press the acupoints with the thumb until the subject feels soreness, then press and knead in a circle according to the strength acceptable to the subject. Press and knead once a second, and rest for 1 second every 5 seconds are one cycle, the speed is 10 cycles/minute, and it lasts for five minutes.
223420122|NCT01094301|DEVICE|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
223420123|NCT00135512|DRUG|bupropion hydrochloride|Study drug
223420124|NCT06459414|OTHER|: Oropharyngeal Administration Of Colostrum|Preterm less than 34 weeks gestation will receive Oropharyngeal Colostrum for 3 days ( the first group) and for 10 days( the second group)
223420125|NCT02357160|BEHAVIORAL|Artwork|Prints by local artists that are hung on the walls of patient rooms.
223420126|NCT05754762|DRUG|Remifentanil|Advanced intravenous injection of remifentanil before the etomidate injection
223420127|NCT06254001|DRUG|Bupropion|Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy
223420128|NCT06254001|DRUG|Nicotine replacement therapy (Nicotine patches)|Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy
223420129|NCT06610981|DEVICE|Laser acupuncture|Laser acupuncture will be used in this study with energy of 4 J per point for 80 s, with a total dosage of 24 J in each session, 2 times /week for 4 weeks
223420130|NCT06610981|OTHER|traditional physical therapy|exercise program consisted of stretching for hamstring, gastrocnemius and iliotibial band, and strengthening exercises, which include isometric quadriceps exercises, straight leg raising, lateral straight leg raise, isometric hip adduction and squat to 30° knee flexion, 2 times /week for 4 weeks
223739525|NCT00602576|DRUG|sorafenib tosylate|Given orally
223420131|NCT06610981|DEVICE|Sham laser acupuncture|Participants will receive laser acupuncture while the device is turned off.
223420132|NCT02526420|DRUG|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
223420133|NCT02235077|DRUG|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
223420134|NCT02235077|DRUG|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
223420135|NCT06651112|DRUG|Antipsychotic drugs|Any Antipsychotic drugs prescripbe as standrd of care for this specific populaton
223562519|NCT06407869|OTHER|Functional Progressive Strength Training|The Functional Progressive Resistance Exercise (FPRE) protocol is designed to improve functional strength through structured workouts. It begins with a 3-minute warmup involving stretching and range of motion exercises, followed by progressively intense sit-to-stand exercises over six weeks. Participants also perform half-kneeling, standing up, and side-step-up exercises, with 20 minutes of total activity and rest intervals. The session ends with a 2-minute cooldown. Weights are gradually increased up to 15 times the initial load, with a minimum of one-minute rest between sets. The regimen is tailored through trial and error to find the maximum load participants can effectively manage.
223562520|NCT06407869|OTHER|Control|conventional physical therapy techniques will be applied
223739526|NCT00602576|DRUG|temozolomide|Given orally
223739527|NCT04611750|DRUG|AD036|AD036 will be given for 14 days
224035185|NCT04225221|DRUG|Micronized progesterone|During progesterone administration, 200mg of progesterone is given twice daily via oral capsule.
224035186|NCT04225221|DRUG|Leuprolide Acetate|Initial 3.75 mg intramuscular injection administered approximately Day 6 of menstrual cycle and then monthly thereafter for a total of 3 months.
224035187|NCT04225221|DRUG|Placebo Oral Capsule|Placebo is administered during the addback phase when participants are not taking active medication. Placebo is given so that medication administration occurs throughout the entire 8-week addback period in order to blind participants to when and for how long they are on the active medication.
224035188|NCT02958267|BIOLOGICAL|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
224035189|NCT02958267|BIOLOGICAL|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
224035190|NCT02958267|DEVICE|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution \[10 mg/mL\], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
224035191|NCT00162357|DRUG|Technetium Tc99m Sestamibi|
224035192|NCT03635593|DRUG|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
223420136|NCT04984369|DRUG|HLX208|HLX208 450mg bid po OR 600mg bid po OR 900mg bid po
223420137|NCT04984369|DRUG|Cetuximab Injection [Erbitux]|Cetuximab 500 mg/m2 IV Q2W
223420138|NCT04590911|BEHAVIORAL|Cognitive Enrichment Program (CEP)|Multimodal cognitive rehabilitation program for individuals having sustained a traumatic brain injury during older adulthood
223420139|NCT03852628|DRUG|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
223420140|NCT03852628|DRUG|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
223420141|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies, until ANC recovery at 100mg/kg (max 4g) 6 hourly.
223420142|NCT04948463|DRUG|Cefepime Injection|Given if patient has non life-threatening hypersensitivity (preferred option), until ANC recovery at 50mg/kg (max 2g) 8 hourly.
224035193|NCT03635593|DRUG|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
224035194|NCT03635593|OTHER|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
224035195|NCT04265833|OTHER|Biodentine|Biodentine has been shown to cause increased calcium ion release and this increase has been associated with the presence of pure tricalcium silicate and calcium chloride and the increased Ca(OH)2 formation
224035196|NCT04265833|OTHER|TheraCal LC|TheraCal LC (Bisco Inc, IL, USA) is a light-cured, resin-modified, calcium silicate-based material designed as a direct/indirect pulp-capping material. This agent has been shown to increase the pH on the pulpal surface thereby stimulating regenerative processes in the pulp, and ultimately contributing to the formation of dentin bridge
224035197|NCT04265833|OTHER|Calcium hydroxide|Calcium hydroxide (Ca\[OH\]2) is a successful pulp-capping agent activating the repair mechanism by stimulating the dentin-pulp complex. Ca(OH)2, with its bactericidal effects, protects the complex from bacterial effects and also has a stimulating effect on dentin remineralization
224035198|NCT03857074|DEVICE|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
224035199|NCT01795027|DRUG|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
224035200|NCT01795027|DRUG|S-1 single|16 courses S-1 single after d D2 resection
224035201|NCT01928498|DEVICE|Paclitaxel Eluting Balloon Angioplasty|
224035202|NCT01928498|DEVICE|Percutaneous Transluminal Angioplasty (PTA)|
223420143|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option), given until ANC recovery at 50mg/kg (max 2g) 8 hourly
223420144|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin, given until ANC recovery at 15mg/kg (max 500mg) 6 hourly
223562521|NCT03802630|DRUG|Brolucizumab 6 mg|Solution for injection (intravitreal use)
223562522|NCT03802630|DRUG|Aflibercept 2 mg|Solution for injection (Intravitreal use)
224035203|NCT01003678|DRUG|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
224035204|NCT02684357|DRUG|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
224035205|NCT02684357|DRUG|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
224035206|NCT02684357|DRUG|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
223420145|NCT04948463|DRUG|Amikacin Injection|Given until ANC recovery at 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s.
223420146|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin, given until ANC recovery at 10 mg/kg (max 400 mg) 12 hourly
223420147|NCT04948463|DRUG|Piperacillin and Tazobactam for Injection|Given if patient has no known allergies at 100mg/kg (max 4g) 6 hourly, stopping 48 hours post-fever resolution.
223420148|NCT04948463|DRUG|Cefepime Injection|If non life-threatening hypersensitivity (preferred option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
223420149|NCT04948463|DRUG|Ceftazidime Injection|If non life-threatening hypersensitivity (second option) at 50mg/kg (max 2g) 8 hourly, stopping 48 hours post-fever resolution
223562523|NCT03802630|OTHER|Sham injection|"Empty sterile syringe without a needle administered as a sham injection for masking purposes.~From Week 24 to Week 72 inclusive, a sham treatment was performed to maintain subject masking in case treatment with brolucizumab or aflibercept was not deemed necessary by the investigator."
223562524|NCT01108731|DRUG|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
223562525|NCT01108731|DRUG|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
223562526|NCT00157196|BIOLOGICAL|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
223420150|NCT04948463|DRUG|Vancomycin Injection|If life-threatening hypersensitivity given with ciprofloxacin at 15mg/kg (max 500mg) 6 hourly, stopping 48 hours post-fever resolution
223420151|NCT04948463|DRUG|Amikacin Injection|At 18-22.5mg/kg (max 1.5g) daily in combination with other antibiotic/s, stopping 48 hours post-fever resolution
223420152|NCT04948463|DRUG|Ciprofloxacin|If life-threatening hypersensitivity given with vancomycin at 10 mg/kg (max 400 mg) 12 hourly, stopping 48 hours post-fever resolution
223420153|NCT01232686|OTHER|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
223420154|NCT02855372|PROCEDURE|Lung transplantation|
223420155|NCT06030232|DEVICE|Therasphere|Transarterial radioembolization
223420156|NCT06628037|BIOLOGICAL|SN514-066b|Enzyme debrider
223420157|NCT02526979|DRUG|mirabegron|oral
223420158|NCT00544401|OTHER|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
223420159|NCT06686680|DEVICE|extracorporeal shockwave therapy (ESWT)|Participants will receive ESWT administered by research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-top focus.Radial pressure waves will be applied using the Extracorporeal Pressure Activation Treatment (EPAT) device. For the anterior knee, patella tendon, vastus lateralis, and vastus medialis, treatment will aim for 1500 strikes at induction dose of 1.5 bars and titrating up by 0.5 bars to 3 bars and this will be performed to participant tolerance to pain, as pain is experienced due to clinical focusing technique which is standard of care in delivering effective treatment. For the calf muscles, the patient will be positioned prone and a similar protocol of starting at 1.5 and titrating up as tolerated to 3 bars. Focused shockwave therapy will be applied for 1000 shocks to four anatomical locations for a total of 4000 shocks. Each site will receive 1000 shocks: medial and lateral tibial plateau and medial and lateral femoral condyle.
223420160|NCT06686680|DEVICE|Sham Comparator|All participants will review the exercise program prior to randomization and receiving sham ESWT treatment. The standard operating procedures for ESWT will be followed and will include review of procedure protocol and post-procedure care. Participants will come into the office for three treatment visits separated by seven days +/- 7 day. Sham ESWT will administered by trained research personnel, using the OrthoPlus Ultra 100/radial D-Actor and Duolith SD1 T-Top focused shockwave devices. The device will be placed on the same landmarks as that of the ESWT treatment group; however, no shockwaves will be administered; rather, an audio recording that mimics the sound of shockwave will be played. A curtain will obscure participants from viewing their knee and the device to blind them from treatment they are receiving.
223420161|NCT05486533|OTHER|Acupressure|The experimental group will start with LI4 points and continue P6 and LI11 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
223420162|NCT01073813|DRUG|Minocycline|100mg twice daily
223420163|NCT05476250|DEVICE|INVSENSOR00057|Noninvasive wearable health monitoring device
223420164|NCT00004642|DRUG|SDZ MSL-109|
223562527|NCT00157196|DRUG|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
223739528|NCT04611750|DRUG|Placebo|Placebo will be given for 14 days
224035207|NCT02684357|DRUG|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
224035208|NCT02911493|BEHAVIORAL|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
224035209|NCT02911493|BEHAVIORAL|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
224035210|NCT01079130|DRUG|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
224035211|NCT01079130|DRUG|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
224137433|NCT05871593|GENETIC|Molecular genetic diagnostic|With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
223420165|NCT01209585|OTHER|Blood samples|Subjects will have visits on Days 1, 30 and 120.
223420166|NCT01209585|OTHER|Synovial fluid aspiration|Subjects will have visits on Days 1, 30, and 120.
223562528|NCT00157196|OTHER|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
223562529|NCT04210245|BIOLOGICAL|aldafermin|aldafermin
223562530|NCT04210245|OTHER|Placebo|Placebo for aldafermin
223739529|NCT03642392|OTHER|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
223739530|NCT01629368|DRUG|Carbamazepine|Multiple doses of carbamazepine
224035212|NCT01079130|DRUG|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
224035213|NCT01079130|DRUG|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
224035214|NCT01988623|BEHAVIORAL|Pivotal Response Treatment (PRT)|
224035215|NCT00002301|DRUG|Foscarnet sodium|
223420167|NCT01209585|OTHER|Synovial tissue sample|Subjects will have visits on Days 1, 30, and 120.
223420168|NCT02078440|DRUG|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
223420169|NCT01157104|DRUG|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
223420170|NCT01157104|DRUG|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
223420171|NCT01157104|DRUG|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
224137434|NCT02644837|DEVICE|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
224137435|NCT02644837|DEVICE|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
224137436|NCT02644837|DEVICE|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
224137437|NCT02644837|DEVICE|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
224137438|NCT02644837|DEVICE|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
224137439|NCT02644837|DEVICE|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
224137440|NCT02644837|DEVICE|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
224137441|NCT02644837|DEVICE|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
224137442|NCT02521909|DEVICE|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
224137443|NCT02521909|DEVICE|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
224137444|NCT02521909|DEVICE|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
224137445|NCT02970227|OTHER|Observation|None, observation only
224137446|NCT03945734|BEHAVIORAL|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
224137447|NCT05340322|DEVICE|Colposcopy using pocket colpscope and thermocoagulator|If HPV+, visualization with pocket colposcope and treatment with thermocoagulator
224137448|NCT02574858|DRUG|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
224137449|NCT05924516|BEHAVIORAL|Adhera® Fatigue Digital Program|The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
224137450|NCT01726712|OTHER|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
224137451|NCT00635557|DRUG|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
224137452|NCT02357953|OTHER|Measurement of cardiac index|
224137453|NCT04917497|DRUG|Levosimendan|Levosimendan was administered according to a standardized treatment protocol. A total dose of 12.5mg or 25mg (corresponding to one or two ampoules) was given at an infusion rate of 0.05 μg/kg/min to 0.2μg/kg/min with or without a loading dose (6 μg/kg or 3 μg/kg over 10 minutes). The decision about total dose, infusion rate and loading dose was at the discretion of the treating physician.
224137454|NCT05619679|OTHER|Kidney Transplantation|Kidney transplantation
224137455|NCT01541267|DRUG|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
224137456|NCT02294149|DRUG|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
224137457|NCT02294149|DRUG|placebo|
224137458|NCT03391687|DIAGNOSTIC_TEST|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
224137459|NCT05923476|DRUG|Lithium|Placebo + ECT
224137460|NCT03656120|DRUG|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
224137461|NCT03656120|DRUG|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
224137462|NCT03656120|DRUG|placebo control group|Participants only take placebos for 12 weeks during the research.
223420172|NCT01157104|DRUG|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
223420173|NCT00586820|DRUG|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
223420174|NCT00586820|DRUG|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
223420175|NCT03198312|DEVICE|CathiportTM|fully implanted
223420176|NCT03198312|DEVICE|Implant Port|fully implanted
223739531|NCT01629368|DRUG|RO4917523|Single dose of RO4917523
223739532|NCT04877938|BEHAVIORAL|Echolgical physical activity Intervention|'Ecological-Exercise-Intervention'(EEI), would be to limit sitting time to no more than 2 hours/day, and to stand up and move after 30 minutes of continuous sitting. In accordance with several epidemiologic evidences light-intensity activities would be encouraged to substitute sedentary time (e.g., standing up while talking on the telephone, ironing while watching TV).
223562535|NCT02457689|BIOLOGICAL|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
223562536|NCT02457689|OTHER|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
223562537|NCT04931797|BEHAVIORAL|video decision aid|advance care planning video decision aid
223562538|NCT04931797|BEHAVIORAL|control arm ACP information sheet|control arm ACP information sheet
223562539|NCT05974384|DEVICE|No Music|No listening to music while intervention is carried out
224035216|NCT02710903|PROCEDURE|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
224035217|NCT01839487|DRUG|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
223420177|NCT03887442|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
223420178|NCT03887442|DRUG|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
223420179|NCT01283451|BEHAVIORAL|Muscle contraction|Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
223562540|NCT05974384|DEVICE|Music|Listening to music while intervention is carried out
223562541|NCT04381624|OTHER|Exercise program|exercise program in 12 sessions, of approximately one hour, distributed in 3 sessions per week during a month
223739533|NCT03662984|DRUG|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
223420180|NCT03620305|OTHER|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
223562542|NCT02488135|DEVICE|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
223739534|NCT03662984|DRUG|Placebo Oral Tablet|To compare ciprofibrate
224035218|NCT01839487|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
224035219|NCT01839487|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
224035220|NCT01839487|DRUG|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
224035221|NCT01839487|DRUG|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
224035222|NCT02694939|BEHAVIORAL|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
224035223|NCT02694939|BEHAVIORAL|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
224035224|NCT00190567|DRUG|duloxetine|
224137463|NCT06390917|DEVICE|PVA recognition function|Ventilator with the function of identify and judge PVAs
223562543|NCT02488135|PROCEDURE|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
223739535|NCT00302042|BEHAVIORAL|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
223739536|NCT00302042|BEHAVIORAL|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
223420181|NCT01868022|DRUG|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
223420182|NCT01868022|DRUG|paclitaxel|paclitaxel will be from commercial stock.
223420183|NCT01868022|DRUG|carboplatin|carboplatin will be from commercial stock.
223420184|NCT01868022|DRUG|docetaxel|docetaxel will be from commercial stock.
223420185|NCT01868022|DRUG|pemetrexed|pemetrexed will be from commercial stock
223420186|NCT01868022|DRUG|cisplatin|cisplatin will be from commercial stock
224035225|NCT00190567|DRUG|Placebo|
223739537|NCT00829543|PROCEDURE|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
223739538|NCT03561623|OTHER|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
223739539|NCT03561623|OTHER|quantitative muscle force assessment|quantitative assessment of muscle force
223739540|NCT06482476|DIAGNOSTIC_TEST|Measurement of Lp(a) levels|Collection of a venous blood sample for the measurement of Lp(a) levels using standardized laboratory methods
223739541|NCT03666923|DRUG|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
223739542|NCT03666923|DRUG|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
223739543|NCT03666923|DRUG|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
224035226|NCT04596696|BIOLOGICAL|Rotavac|Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
224035227|NCT06976086|DEVICE|Active transcutaneous bone conduction system|The Sentio system consists of the Sentio 1 Mini sound processor (SP) and Sentio Ti implant with fixation band and screws.
224035228|NCT05517304|DEVICE|tcVNS|active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)
224035229|NCT05517304|DEVICE|sham|sham stimulation
224035230|NCT06108804|OTHER|mulligan pain release phenomenon with tapping|Participants in Group A will receive mulligan pain release phenomenon with tapping.First, demographic information will be gathered, pain severity will be measured using NPRS, knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.Two sessions of treatment per week with a total of eight session will be given in four weeks
224035231|NCT06108804|OTHER|mulligan pain release phenomenon|Two sessions of treatment per week with a total of eight session will be given in four weeks.Group B will receive mulligan pain release phenomenon only. First, demographic information will be gathered, pain severity will be measured using NPRS. knee joint range of motion (flexion/extension) will be measured using a goniometer, and functional limitation will be evaluated using a Kujala score.
224035232|NCT03171831|DRUG|Busulfan|Busulfan（4 mg/kg/day,4 days）
224035233|NCT03171831|DRUG|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
224035234|NCT03171831|DRUG|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
224035235|NCT03171831|DRUG|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
224035236|NCT03171831|DRUG|Tacrolimus|Tacrolimus（0.03mg/kg/day）
224298703|NCT05213143|DRUG|Lurasidone|Lurasidone was oral administrated with a meal or within 30 min after eating in the evening. The maintenance dose of olanzapine from Day 0 to Day 6, than tapered until discontinuation from Day 7 to Day 27. Lurasidone initiated with 40mg/d on Day 0, maintained until Day 13, with a flexible dose (40-80mg/d, qd) from Day 28 to Day 111.
224298704|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose level 1 or 2|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
223739544|NCT01763424|DRUG|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
223739545|NCT01763424|DRUG|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
224035237|NCT03171831|DRUG|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
224035238|NCT03171831|DRUG|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
224035239|NCT03171831|DRUG|Basiliximab|Basiliximab（10mg on day 0 and +4）
224035240|NCT00510679|BEHAVIORAL|Health worker supports (supervision, job aids, incentives)|
224035241|NCT01216384|DRUG|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
224035242|NCT01216384|DRUG|placebo|Subjects will receive according to the dose group matching number of placebo tablets
224298705|NCT03736928|OTHER|placebo|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
224298706|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 3|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
224298707|NCT03736928|BIOLOGICAL|AbobotulinumtoxinA dose 4|Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
224298708|NCT03662906|OTHER|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
223739546|NCT04148950|OTHER|Kinesio Tape|
223739547|NCT04148950|OTHER|Compression Stockings|
223739548|NCT04148950|OTHER|Exercise Program|
224035243|NCT06434948|DRUG|Omega-3 Ethyl Esters 4 g|4 grams = 4 capsules, once daily
224035244|NCT06434948|DRUG|Omega-3 Ethyl Esters 2 g|2 grams = 2 capsules, once daily
223420187|NCT01628198|DEVICE|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
223420188|NCT06218537|DIAGNOSTIC_TEST|Test group|Contains protease from KREON capsules, activated by adding sodium bicarbonate.
223420189|NCT06218537|DIAGNOSTIC_TEST|Control group|Contains only sodium bicarbonate.
223420190|NCT04901247|BEHAVIORAL|media refreshment|20µL of culture medium is aspirated using Eppendorf PCR tips, and freshly, overnight equilibrated 20µL global total LP will be added to the same well
224035245|NCT03456531|DEVICE|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
224035246|NCT03456531|DRUG|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
224035247|NCT03471871|DRUG|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
224035248|NCT03471871|DRUG|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
224035249|NCT03471871|DRUG|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
224035250|NCT03471871|DRUG|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
223420191|NCT04901247|BEHAVIORAL|embryo grading|embryo grading should be done prior to media refreshment
223420192|NCT04896398|DEVICE|ESWT|In the study group, a total of 5 sessions of focused ESWT (1000 shock, 1.6 bar, 5 Hz) will be applied to the affected wrist within 2 weeks.
223420193|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
223420194|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
223420195|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
223420196|NCT02367027|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
223420197|NCT05580627|OTHER|Livestream Modality (treatment)|For this evaluation, the livestream modality is considered the treatment group.
223420198|NCT05580627|OTHER|Live Modality (control)|For this evaluation, the live modality is considered the control group.
223420199|NCT00537576|BIOLOGICAL|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10\^8 CFU), administered vaginally once a day for 5 consecutive days
223420200|NCT00537576|BIOLOGICAL|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
223420201|NCT00537576|BIOLOGICAL|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days
223420202|NCT00537576|OTHER|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
223420203|NCT00537576|OTHER|Medium dose Placebo|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
223420204|NCT00537576|OTHER|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
223420205|NCT03222089|DRUG|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
223420206|NCT03222089|DRUG|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
223420207|NCT03222089|DRUG|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
223420208|NCT03222089|DRUG|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
224035251|NCT03471871|DRUG|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
224035252|NCT01946841|DIETARY_SUPPLEMENT|RealDiet®Renal|
223420209|NCT03222089|DRUG|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
223420210|NCT03222089|DRUG|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
223420211|NCT06129435|BEHAVIORAL|Visuospatial Task (VST)|Participants randomized to the VST condition will play a visuospatial game (i.e., Tetris). Participants will be given two minutes to practice Tetris and then will be instructed to play for 15 minutes without stopping.
223420212|NCT06129435|BEHAVIORAL|Word Association Task (WAT)|Participants randomized to the WAT condition will play a word association game. Research staff members will read from a list of 300 words, not associated with trauma, to the participant. The participant will verbally respond to each word out loud with the first word that comes to their mind. This word association task will continue for 15 minutes or until all 300 words are read, whichever occurs first.
223420213|NCT01741766|OTHER|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
223420214|NCT05401500|BIOLOGICAL|blood sample|blood sampling
223739549|NCT06069973|OTHER|No intervention, observational study|No intervention
224035253|NCT06245642|DRUG|Compound Ciwujia Granules, Guipi Granules|Experimental group: Basic treatment + Compound Ciwujia Granules + Guipi Granules simulator orally for 6 weeks; Positive drug control group: basic treatment + Guipi Granules + Compound Ciwujia Granules simulant orally for 6 weeks.
224035254|NCT04273698|BEHAVIORAL|Parent-infant psychotherapy|Brief psychoanalytic parent-infant psychotherapy
224035255|NCT06588699|DRUG|Digoxin|Taken orally once daily
224035256|NCT06588699|DRUG|Placebo|Matched Placebo taken orally once daily
224035257|NCT06666322|DRUG|Standard of care|"2022 WHO First Line Induction Therapy:~1. Liposomal Amphotericin B 10mg/kg IV given once~2. Flucytosine 100mg/kg/day for 14 days in divided doses~3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum"
223739550|NCT04283162|DRUG|Calcium Dobesilate|use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
224035258|NCT06666322|DRUG|Oteseconazole - antifungal therapy 1|"Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)~* Loading doses of oral Oteseconazole 600 mg twice daily for 10 days, then 600 mg oteseconazole weekly on weeks 3, 4, 5, and 6.~* Liposomal Amphotericin B 10 mg/kg IV once.~* No fluconazole or 5FC to be given."
224298709|NCT03662906|OTHER|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
224298710|NCT04080609|DRUG|Dorzagliatin|GKA currently under clinical development
223739551|NCT04283162|OTHER|conventional treatment|maintain lifestyle habits and the usual treatment
223739552|NCT04695860|DRUG|Burosumab|Q4w, 1mg/kg Body weight, s.c.
223739553|NCT00817895|DRUG|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
223739554|NCT00817895|DRUG|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
224298711|NCT02662088|PROCEDURE|laparoscopic-lavage|
224298712|NCT06417333|DEVICE|xiaomi mi band 7 smart wristband|Patients with mild dementia have been distributed xiaomi mi band 7 smart wristbands for health data collection
224298713|NCT01084382|DIETARY_SUPPLEMENT|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
224298714|NCT03261882|OTHER|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
224298715|NCT01700426|DRUG|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
224298716|NCT01700426|OTHER|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
224298717|NCT04572282|DEVICE|Mentora app|Remote monitoring mobile app
224298718|NCT04178265|OTHER|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
224298719|NCT01345994|PROCEDURE|electro-acupuncture|acupuncture stimulation with electricity
224298720|NCT03663439|PROCEDURE|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
224298721|NCT02145312|DRUG|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
224298722|NCT01090999|OTHER|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
224298723|NCT02239198|OTHER|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
224298724|NCT05748327|DEVICE|Alcasite restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing
224298725|NCT05748327|DEVICE|Bulk fill glass hybrid restorative material|Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
224298726|NCT02714231|DRUG|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
224298727|NCT02714231|DRUG|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
224298728|NCT01640873|DRUG|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
224298729|NCT01640873|DRUG|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
224298730|NCT02614313|PROCEDURE|Open breath test with fructose|Open randomised fructose 35g during breath test
224298731|NCT02614313|PROCEDURE|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
224298732|NCT02614313|PROCEDURE|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
224298733|NCT02614313|PROCEDURE|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
224298734|NCT01135628|OTHER|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
224298735|NCT01135628|DIETARY_SUPPLEMENT|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
223739555|NCT00817895|PROCEDURE|TACE|All patients will accept TACE one month after tumor was resected.
224298736|NCT01135628|DRUG|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
224298737|NCT06167954|DEVICE|EXPLORER|8 sessions of use of the device in the home and the community of the participants
224298738|NCT01321008|RADIATION|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
224298739|NCT01321008|DRUG|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
224298740|NCT01321008|DRUG|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
224298741|NCT01321008|DRUG|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
224298742|NCT01321008|DRUG|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
224298743|NCT02283450|DRUG|Qiliqiangxin Capsule|
224298744|NCT03356886|PROCEDURE|Spinal Manipulative Technique|1\) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
224298745|NCT03356886|BEHAVIORAL|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
224298746|NCT01727986|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
224298747|NCT05990842|DRUG|Antibiotic|the individual will receive 1 dose of antibiotic during anesthetic induction
224298748|NCT05990842|OTHER|placebo|the individual will receive 10 ml of saline during anesthetic induction
224298749|NCT02749292|DRUG|Rituximab|re-dosing dependent on interventional arm parameter.
224298750|NCT00251641|DRUG|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
224298751|NCT00251641|DRUG|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a \<25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
224298752|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
224298753|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
224298754|NCT01387763|DRUG|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
224298755|NCT01387763|DRUG|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
224298756|NCT01387763|DRUG|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
224298757|NCT02093221|BIOLOGICAL|180 mg/kg Alpha1-PI|
224298758|NCT02093221|BIOLOGICAL|90 mg/kg Alpha1-PI|
224298759|NCT02093221|BIOLOGICAL|Placebo|
224298760|NCT02147249|DRUG|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
224298761|NCT03516136|DEVICE|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
224298762|NCT01519102|DEVICE|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
224298763|NCT02658513|OTHER|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
224298764|NCT02658513|OTHER|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
224298765|NCT00517959|RADIATION|Stereotactic Conformal radiotherapy|SCRT
224298766|NCT00517959|RADIATION|Conventional radiotherapy|
224298767|NCT04792359|DEVICE|Equinometer|Measurement of dorsiflexion of the ankle will be reproduced three times on each ankle in two positions, with a force applied
224298768|NCT00043537|BEHAVIORAL|Social Effectiveness Therapy for Children (SET-C)|
224298769|NCT00043537|DRUG|Fluoxetine|
224298770|NCT00043537|DRUG|Pill Placebo|
224298771|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
224298772|NCT00062751|DRUG|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
224298773|NCT00062751|DRUG|Letrozole|Letrozole 2.5 mg daily
224298774|NCT05672693|OTHER|Several Calculation Formulas of Intraocular Lens|Comparison of the accuracy of several intraocular lens calculation formulas
224298775|NCT04078438|DEVICE|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
224298776|NCT04078438|DRUG|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
223420215|NCT06533956|OTHER|10-week gait training program combined with simultaneous blood flow restriction (BFR).|The children will receive a 10-week intervention (1 week of habituation without BFR + 9 weeks with BFR) comprising 3 30-minute treadmill sessions per week. At each session, the first 5 minutes will enable a gradual increase in speed, and then the maximum tolerated walking speed will be sought. Maximum speed corresponds to the walking speed maintained by the child for an effort of between 5 and 7 on Borg's 10-point VAS. The rehabilitator will encourage the child to maintain this speed and provide feedback on performance. The BFR setting will maintain an occlusion, at the root level of both lower limbs, of 60% of the total occlusal pressure.
223420216|NCT06401473|BEHAVIORAL|Ipsilateral Scratch Task|Patients scratch the skin within the relevant cervical dermatome, ipsilateral to the injection site
224035259|NCT06666322|DRUG|Sfu-AM2-19 Injection - antifungal therapy 2|Ambisome 10 mg/kg IV administered once Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 1.5 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
223420217|NCT06401473|BEHAVIORAL|Motor Distraction Task|Patients scratch the skin of the shoulder/neck contralateral to the injection site
223420218|NCT04450277|PROCEDURE|Emergency surgery|Emergency surgery vs conservative management
224137464|NCT04411212|DRUG|Granulocyte colony-stimulating factor and platelet-rich plasma group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Autologous platelet-rich plasma is prepared from the blood using the two step centrifuge process. Under ultrasound guidance and complete aseptic procedures, 1 ml of the PRP is infused inside the uterus while performing the mock embryo transfer. Moreover, G-CSF (Filgrastim®, 300μg/0.5ml) is injected subcutaneously. G-CSF is injected weekly until the 12th gestation week or negative pregnancy test.
223420219|NCT02429661|BEHAVIORAL|Peer support groups|
223420220|NCT06363773|RADIATION|Stereotactic Radiotherapy|"Patients will perform stereotactic radiotherapy with 3 sessions (8 Gy) during 20 minutes each and with 72 hours in-between.~Patients enrolled in the study would not have received this stereotactic radiotherapy outside the study, that is why this procedure is additional (compared to Standard of care) and considered as burdensome (as this is radiation). Before performing the stereotactic radiotherapy, patients will do a radiotherapy CT scanner (no injected) in order to prepare precisely the radiotherapy (treatment plan)."
223420221|NCT06406907|OTHER|High Frequency Blood Flow Restriction Training Group|"Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
223420222|NCT06406907|OTHER|Low Frequency Blood Flow Restriction Training Group|"Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
223420223|NCT06406907|OTHER|High Frequency Blood Flow Restriction Training Instability Group|"Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
223420224|NCT06406907|OTHER|Low Frequency Blood Flow Restriction Training Instability Group|"Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
223420225|NCT06406907|OTHER|Control Group|"The subjects of this group will perform squat exercise 6 days a week but without BFR. Pneumatic cuff will be wrapped around the thigh of the subjects but it would not be inflated.~Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise."
223420226|NCT00541411|DRUG|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
223420227|NCT04326946|DEVICE|Alfapump|alfapump implementation
223739556|NCT01893554|BIOLOGICAL|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10\^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10\^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
223739557|NCT01893554|BIOLOGICAL|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
223739558|NCT06129721|PROCEDURE|Emergent Stenting|Emergent Stenting In Acute Vertebrobasilar Occlusions
224035260|NCT06666322|DRUG|Antifungal therapy 3|To be determined
224035261|NCT06666322|DRUG|Antifungal therapy 4|To be determined
224035262|NCT01455493|DRUG|GDC-0980|Oral daily dose
224035263|NCT06657820|PROCEDURE|Hypoxia in healthy individuals|"The subject will undergo a graduated desaturation procedure. Arterial saturation targets are as follows:~1. 100%~2. 99%~3. 96%~4. 93%~5. 90%~6. 87%~7. 84%~8. 81%~9. 78%~10. 75%~11. 72%~12. 69%~13. 99%"
224035264|NCT06657820|DEVICE|Cerebral Oximetry|Each subject will be continuously monitored with the cerebral oximetry device throughout the desaturation procedure.
224137465|NCT04411212|OTHER|Control group|Antagonist protocol is used . Oocyte retrieval under transvaginal ultrasound guidance is performed 34 to 36 hours after HCG administration. Mock embryo transfer is performed without injecting anything inside the uterus.
224137466|NCT01866878|DEVICE|equipment rehabilitation stereognosis|
224137467|NCT01866878|DEVICE|TENS|
224137468|NCT03812523|DRUG|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
223420228|NCT00535717|PROCEDURE|uttarbasti (per urethral administration of medicated oil )|
223420229|NCT02573415|PROCEDURE|Uterus Transplant|transplant of a deceased donor uterus.
223420230|NCT06240273|DIETARY_SUPPLEMENT|Corn silk powder|Corn silk (CS) is abundant in phenolic compounds, especially flavonoids. It also contains proteins, vitamins, carbohydrates, calcium, potassium, magnesium, sodium salts, volatile oils, sterols like sitosterol and stigmasterol, alkaloids, and saponins. Numerous studies have explored the pharmacological activities associated with CS.
223420231|NCT01421160|DRUG|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
223420232|NCT06675526|BEHAVIORAL|Detour|"Detour is a mobile game designed to assist youth with smoking cessation. First, Detour targets stimuli devaluation using a gamified go/no-go training. Second, the researchers aimed to reduce delay discounting in two ways; 1) players can replace neutral images in the go/no-go training with positive images from their own lives related to their future self; 2) players can set and monitor personal goals via the game, to promote future-self priming. Third, participants join a social shell comprising Instagram and TikTok content to provide psychoeducation about quitting smoking and to interact with fellow players who quit simultaneously. Finally, the timing and content of in-game messaging is personalized to each participant based on information provided in an ecological momentary assessment component and a stop plan filled out during the week before the quit attempt."
223420233|NCT06675526|BEHAVIORAL|Self-help brochure|The brochure provides guidelines to independently design a stop-plan including questions about seeking support from others, strategies to fight cravings, and setting rewards for milestones after quitting. Participants will be encouraged to complete this stop-plan in week 0 of the intervention, so the week before quit day. Additionally, the brochure includes psychoeducational information that is valuable when planning to quit smoking.
223420234|NCT00001344|DRUG|dextromethorphan|
223420235|NCT03129945|DRUG|Nifedipine|Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
223420236|NCT03129945|DRUG|Indomethacin|Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
223420237|NCT06389045|OTHER|Procedural Sedation|Profopol Sedation in Endoscopic Ultrasonography
223420238|NCT04673474|DRUG|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
223420239|NCT04673474|DRUG|Hemay022|Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
223420240|NCT05397392|OTHER|guideline recommended routine treatment|
223420241|NCT03183089|DRUG|Rohto Dry-Aid®|
223420242|NCT03183089|DRUG|Systane® Ultra|
223420243|NCT03082157|BEHAVIORAL|Mighty Men Intervention|African American men assigned to this condition will receive: tailored goals/ messages, self-monitoring, small group meetings and educational and community-based information and resources.
223420244|NCT02953444|OTHER|Thirty-Second Mindfulness Practice|
224035265|NCT06657820|DIAGNOSTIC_TEST|Blood Gas Sampling|At each arterial saturation plateau venous and arterial blood gas measurements will be taken from the jugular bulb, and the radial artery respectively.
224035266|NCT04326127|DEVICE|Intervention is the validation of a sleep monitoring device (i.e. Somfit) against the gold-standard polysomnograph with electroencephalograph (i.e. the Greal system)|Data were recorded overnight by both devices simultaneously
224035267|NCT07013669|BEHAVIORAL|Receptive Music Therapy - Solfeggio Frequencies|Music featuring Solfeggio frequencies (174 Hz, 285 Hz, 396 Hz, 528 Hz) is played through standardized speakers in a sound-isolated room during IDT. Duration includes five minutes before and throughout the procedure
224035268|NCT07013669|BEHAVIORAL|Receptive Music Therapy - Traditional Turkish Music|Selected Turkish Classical Music pieces (makams: Rast, Hicaz, Uşşak, Neva, Saba) are played via speakers in a sound-isolated room during IDT. Music begins five minutes prior and continues during the procedure.
223420245|NCT02953444|OTHER|Three-Minute Mindfulness Practice|
223420246|NCT05736640|DRUG|Denosumab|
223420247|NCT05736640|DRUG|Placebo|
223420248|NCT06398067|BEHAVIORAL|Vietnamese Self-Help Plus (vSH+)|vSH+ is a stress management program delivered through four 75-minute sessions. It includes the five core SH+ skills. Healthcare workers (nurses and social workers) function as lead facilitators (called 'HW Facilitators') and cancer survivors as co-facilitators (called 'Peer Facilitators').
223420249|NCT06398067|OTHER|'Doing What Matters in Times of Stress' (DWM) Guide|An illustrated guide developed by WHO to equip people with practical skills to help cope with stress which has been translated to Vietnamese and reviewed and revised by the investigators.
223420250|NCT05566704|DEVICE|Modulus ALIF System|The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.
223420251|NCT05353855|OTHER|No intervention|No intervention
223420252|NCT06234748|RADIATION|Radiation|"Patients will undergo 2 phases of RT replanning:~1. Based on 2-week DCE-MRI low BV tumor subvolume, patients will have a PTVboost1 that will start to receive 2.5Gy/day with fraction 16. PTVboost1=(persistent lowBVsubvolume\_2 wks+ MTV3\_2 weeks)+ 3mm margin.~2. Based on 4-week FDG-PET MTV3, patients with have a PTVboost2 cone down that will receive 2.5Gy/day starting with fraction 23. PTVboost2=(LBV\_2 wks + MTV3\_4wks)+ 3mm margin~3. Thus, the tumor subvolumes that are included in the boost from fx16-35 will receive 86 Gy EQD2 (80Gy physical dose) and the FDG-avid subvolumes which start boost at 2 weeks but are not persistently avid at 4 wks will receive 76Gy EQD2 (74Gy physical dose)."
223420253|NCT06234748|DRUG|Platinum based chemotherapy|Standard of care therapy, weekly, with either Cisplatin or Carboplatin
223420254|NCT01528826|DRUG|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
223420255|NCT02017795|OTHER|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
223420256|NCT02017795|OTHER|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
223420257|NCT00419484|DRUG|pioglitazone|
223420258|NCT01167114|DRUG|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
224035269|NCT07020104|DRUG|Hydrochlorothiazide|"Each patient will receive 1 tablet of hydrochlorothiazide 12.5mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dosage is doubled to 2 tablets of hydrochlorothiazide 12.5mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
223420259|NCT01220388|DIETARY_SUPPLEMENT|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
223420260|NCT01220388|DIETARY_SUPPLEMENT|placebo|placebo, 3 times a day, orally, during meals
223420261|NCT01720654|BEHAVIORAL|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
223420262|NCT00250627|DRUG|Saredutant succinate (SR48968C)|
223420263|NCT00003427|DRUG|irinotecan hydrochloride|
223420264|NCT00003427|DRUG|oxaliplatin|
224035270|NCT07020104|DRUG|Spironolactone|"Each patient will receive 1 tablet of spironolacton 12.5mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dose is doubled to 2 tablets of spironolacton 12.5mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
223420265|NCT00833482|DRUG|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
223420266|NCT00833482|DRUG|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
223420267|NCT00833482|DRUG|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
223420268|NCT01710189|DRUG|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
223420269|NCT01128998|DRUG|Sorafenib|"1. Name: Sorafenib~2. Dosage form: 200 mg / Tablet~3. Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1"
223420270|NCT01128998|DRUG|S-1|"1. Name:S-1~2. Dosage form: 20 mg or 25 mg / Capsule~3. Dosing schedule: 20-40 mg/m2 bid,po, 14 days on \& 7 days off"
223420271|NCT05866744|OTHER|Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
223420272|NCT05866744|OTHER|Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet|18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks
223420273|NCT05866744|OTHER|Hypocaloric Mediterranean Diet Without Time Restriction In Feeding|18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks
223420274|NCT04412343|BEHAVIORAL|Virtual Group Intervention|Participants will receive weekly exercise courses delivered virtually to a group of older adults. This intervention will last for 12 weeks. Participants in addition to participating in exercise will have designated time after each exercise class to socially connect. Participants in this condition will also receive a t-shirt.
223739559|NCT03011255|BIOLOGICAL|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
223739560|NCT05028179|DIAGNOSTIC_TEST|EchoGo|EchoGo Pro is an software Medical Device which is able to assess Stress Echocardiograms and provide a binary classification of risk of CAD
224035271|NCT07020104|DRUG|Lercanidipine|"Each patients will receive 1 tablet of lercanidipine 10mg once a day for the first 3 weeks of the drug cycle. If clinical and biochemical parameters allow, the dose is doubled to 2 tablets of lercanidipine 10mg once daily for the following 3 weeks.~If the laboratory results and clinical parameters do not allow dose intensification, the initial dosage will be continued during the second half of the drug cycle."
224137469|NCT03812523|DRUG|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
224137470|NCT00613418|DEVICE|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
224137471|NCT02404883|OTHER|Online Decision-Aid Tool|
223420275|NCT04412343|BEHAVIORAL|Personal Exercise Intervention|Participants will receive weekly exercise courses delivered virtually. These classes will be pre-recorded so the individual can complete sessions at any time that is convenient for them.
223562544|NCT04746118|BEHAVIORAL|DIET CHANGE|Nutritional supervision will be carried out individually based on the Food Guide for the Brazilian Population, ensuring an accessible, hygienic and contextualized diet according to the subject's culture and physiology. The protocol includes an initial assessment to define the meal plan and individual reassessments every four weeks. In the first evaluation participants will receive an eating plan with a 20% reduction in the total calories consumed or even the equivalent of their daily energy needs with a distribution of macronutrients comprised of 65% carbohydrate, 15% protein and 20% fat. The intention is to promote a reduction in weekly consumption by about 2000 kilocalories (Kcal). The prescription and diet control plan will include and be conducted by a team coordinated by a clinical nutritionist.
223562545|NCT04746118|BEHAVIORAL|PHYSICAL ACTIVITY|The physical activity program will consist of daily walking sessions performed outdoors and on a flat surface suitable for hiking. Each session will last 70 minutes and will be performed between 55% -60% of the maximum oxygen consumption (VO2), six times a week, for 24 weeks, with alternate on-site supervision on odd days and remote monitoring on even days. On-site supervision will be carried out by a team coordinated by a Physical Education teacher and implemented at two times in the morning and another two in the afternoon with meeting points previously defined. At the end of each supervised walking session, 20 minutes of exercise will be performed using the equipment available at the Senior Citizens Academy set up in public squares in the region so that the total expenditure of calories spent weekly with physical activities reach about 2000 kilocalories.
223562546|NCT04746118|OTHER|INTEGRATIVE PRACTICES|The health integrative practices will includes Mind-Fullness, auriculotherapy and laying on of hands. A suitably qualified professional, using it use a practical manual so that the practice became uniform among the subjects, will apply the practice of Mind-Fullness in weekly 1-hour sessions to individuals. The practice of auriculotherapy will be applied to individuals by a professional qualified to perform the technique, which consists in the selection of auricular points according to the health problems presented and the therapeutic objectives that are to be achieved, followed by the insertion of the mustard seed at specific points in the ear over a six-month period. The laying on of hands will be carried out by properly trained individuals.
223420276|NCT06665087|DRUG|Ultrafractionated RT and CGA Guided systemic treatment.|in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed, with/without targeted therapy, and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, with/without targeted therapy, and BSC.
223420277|NCT06665087|RADIATION|Ultrafractionated Radiotherapy|1Fx every 3 or 4weeks
223420278|NCT06665087|DRUG|PD-1 antibody|Sintilimab
223420279|NCT06665087|DRUG|Chemotherapy (Fluorouracil)|5-Fluorouracil or capecitabine
223420280|NCT06665087|DRUG|Chemotherapy (Raltitrexed)|Raltitrexed
223420281|NCT06665087|DRUG|Chemotherapy (Oxaliplatin)|Oxaliplatin
223562547|NCT00221000|DRUG|Methoxsalen|
223562548|NCT00221000|PROCEDURE|Extracorporeal Photopheresis|
223739561|NCT04001881|OTHER|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
223562549|NCT00298623|DRUG|XP13512 (GSK1838262)|
223739562|NCT04001881|DRUG|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
223739563|NCT04022720|PROCEDURE|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
223739564|NCT04345575|DEVICE|PainCare VR|Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
224137472|NCT05941169|PROCEDURE|Cytoreductive Nephrectomy|The experimental intervention consists of cytoreductive nephrectomy (CN) or any ablative local therapy within 6 months and 1 year after start of systemic treatment. All types of ablative local therapy are allowed as a substitute for CN
224137473|NCT02558556|DEVICE|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
223562550|NCT00298623|OTHER|placebo|
223739565|NCT04345575|OTHER|Audio content|The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
223739566|NCT00115856|PROCEDURE|Intravascular MRI|Arterial imaging of atherosclerosis
223739567|NCT06164470|BEHAVIORAL|Support Group|monthly virtual patient support with multidisciplinary education for 12 sessions
223739568|NCT01962129|BIOLOGICAL|Sampling of blood|
223739569|NCT03454074|BEHAVIORAL|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
224137474|NCT02558556|OTHER|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
223739570|NCT03454074|BEHAVIORAL|Education|Education about healthy brain aging behaviors provided.
223739571|NCT05665790|RADIATION|radiotherapy|radiotherapy
223739572|NCT05665790|PROCEDURE|palliative surgery|palliative surgery
223739573|NCT00539578|DRUG|MK0777|Duration of Treatment: 4 weeks
223739574|NCT00539578|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
223420282|NCT06665087|DRUG|Chemotherapy (CPT-11)|Irinotecan
223420283|NCT06665087|DRUG|Targeted Therapy (anti-VEGF)|anti-VEGF antibody
223420284|NCT06665087|DRUG|Targeted Therapy (anti-EGFR)|anti-EGFR antibody
223420285|NCT05711056|BEHAVIORAL|Sociobehavioral Intervention|"Utilizes two primary evidence-based strategies:~* Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~* Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation."
223420286|NCT05956132|OTHER|retrospective study|data collection from clinical history and medical records
223420287|NCT04153149|DRUG|Vutrisiran|Vutrisiran will be administered by SC injection.
223420288|NCT04153149|DRUG|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection.
223420289|NCT02778074|BEHAVIORAL|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
223562551|NCT02353702|PROCEDURE|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
223739575|NCT01061242|BEHAVIORAL|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
224137475|NCT04494464|OTHER|No intervention|
223739576|NCT00745992|OTHER|Blood drawn (lab data)|"1. Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~2. Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
223739577|NCT01559896|DIETARY_SUPPLEMENT|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
223739578|NCT04976842|DEVICE|OFA|Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
224035272|NCT07020104|DIETARY_SUPPLEMENT|High sodium dietary intake (>200mmol/l)|The patients will receive a 2-week high sodium diet. The patients will receive dietary advice to achieve this goal of \>200mmol/l sodium (\>12g salt) intake per day.
224035273|NCT07020104|DIETARY_SUPPLEMENT|Low sodium dietary intake (<50mmol/l)|The patients will receive a 2-week low sodium diet. The patients will receive dietary advice to achieve this goal of \<50mmol/l sodium (\<3g salt) intake per day.
224035274|NCT07020104|DIETARY_SUPPLEMENT|High water intake|During the increased water intake period, the patients will be instructed to drink 1 L more than their mean 24-hour urine volume at screening and baseline.
224035275|NCT07020104|DIETARY_SUPPLEMENT|Habitual water intake|During this part of the intervention, the patients will be instructed to maintain their habitual water intake.
224035276|NCT07020338|OTHER|Yoga Exercise Program|Participants in the intervention group received a structured yoga-based exercise program consisting of 50-minute sessions, conducted twice per week over a period of approximately 10-12 weeks (three menstrual cycles). The program was based on Hatha Yoga principles
224137476|NCT02205827|OTHER|Single-arm|collection of blood for assessment of whole blood clotting time
224137477|NCT01933165|DEVICE|LipiView|
224137478|NCT00367198|DIETARY_SUPPLEMENT|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
224035277|NCT07019610|DEVICE|ClearGuard HD|The ClearGuard HD end cap is a male luer lock end cap that incorporates an antimicrobial treatment (Chlorhexidine) on its surface designed to reduce microbial colonisation within a haemodialysis catheter hub.
224035278|NCT07019610|DEVICE|B Braun Combi-stopper|Standard practice caps used within the Metro North Kidney Health Service
223420290|NCT02778074|BEHAVIORAL|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
223420291|NCT05607680|DRUG|Placebo|Placebo administered subcutaneously (SC) once a week.
223420292|NCT05607680|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
223562552|NCT02353702|DRUG|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
223562553|NCT02353702|DEVICE|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
223562554|NCT02353702|DRUG|Infusion of placebo during 48 hours|
223562555|NCT02353702|DRUG|NaCl|
223562556|NCT00189579|DRUG|Herceptin|
224035279|NCT07020754|DIETARY_SUPPLEMENT|L-arginine Oral Suspension|"Type: Dietary supplement~Dosage: 5 g L-arginine + 5 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
224035280|NCT07020754|DIETARY_SUPPLEMENT|L-glutamine Oral Suspension|"Type: Dietary supplement~Dosage: 5 g L-glutamine + 5 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
224137479|NCT02909569|DRUG|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
224137480|NCT01122030|DRUG|Naldemedine|Tablets or solution for oral administration
224137481|NCT01122030|DRUG|Placebo|Tablets or solution for oral administration
224137482|NCT03332901|OTHER|this is an observational study, no intervention required|this is an observational study, no intervention required
224137483|NCT04605939|DEVICE|PET/MR|Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
224137484|NCT04605939|DEVICE|PET/CT|Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
223420293|NCT02876991|PROCEDURE|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
223420294|NCT02779764|DRUG|roxadustat|Oral
223420295|NCT01392027|PROCEDURE|Blood Draw|Blood draw for research specimens only
223420296|NCT04229329|COMBINATION_PRODUCT|Intensive Finger Individuation Therapy|Interactive robot-mediated treatment aimed at increased individuation done repeatedly for at least1 hour per day for 2 weeks (5 training days a week).
223420297|NCT04229329|COMBINATION_PRODUCT|Intensive non-directed finger movement therapy|Interactive robot-mediated treatment not aimed specifically at increased individuation done repeatedly for at least 1 hour per day for 2 weeks (5 training days per week)
223420298|NCT06684808|OTHER|Fitness|The Fitness group engaged in active breaks aimed at improving cardiovascular efficiency. These breaks were designed to provide moderate to vigorous physical activity, incorporating both strength and aerobic exercises such as squats, jumping jacks, lunges, and running in place. Children were instructed to imitate the teacher's movements.
223420299|NCT06684808|OTHER|Creative|The Creative group participated in active breaks that combined cognitive-creative and physical demands, incorporating activities like improvisations, dramatizations of events or short stories, simulation, and imitation games. These activities aimed to stimulate the creative process and enhance emotional expression within environmental constraints. Constraints, set by the teacher-such as specific rules, partner positioning, or speed of execution-limited movement options, encouraging students to explore new solutions to complete each task.
224137485|NCT02705768|DRUG|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
223420300|NCT06684808|OTHER|Combined|The Combined group took active breaks by combining the Fitness protocol in the first break and the Creative protocol in the second.
223420301|NCT06684808|OTHER|Control|Regular physical activity at school during the weeks.
223420302|NCT04454684|DRUG|Midomafetamine|Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.
223420303|NCT04454684|BEHAVIORAL|Non-directive therapy|Non-directive therapy will be conducted during Experimental Sessions.
223420304|NCT04454684|BEHAVIORAL|Therapy|Therapy will be conducted during Preparatory Sessions and Integrative Sessions.
223420305|NCT06209970|DRUG|HA35|All the freshly made HA35 or B-HA samples were diluted to a final concentration of 5 mg/ml. The filter membrane with 220nm pore size was used to filter freshly made HA35 or B-HA injection in order to test its human tissue permeability as \<220nm nino-particle.
223420306|NCT04173975|DEVICE|With knee exoskeleton|BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
223420307|NCT06684197|DRUG|Dexmedetomidine|Intravenous dexmedetomidine will be given as a bolus (0.5 μg.kg-1) over 10 minutes. A perfusion of 0.5 mcg.kg-1.h-1 of dexmedetomidine will be programmed and maintained up until the pneumoperitoneum is deflated or up until a total dose of 2.5μg.kg-1 has been administered.
223420308|NCT06684197|DRUG|Placebo|Saline will be used instead of dexmedetomidine
223420309|NCT06079177|DEVICE|Ultrasound|LUS using B-lines Caval-Aorta index using ultrasound
223420310|NCT04538547|RADIATION|Accelerated Radiotherapy|Accelerated Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 6 days per week from Monday to Saturday
223420311|NCT04538547|RADIATION|Non Accelerated Radiotherapy|Chemoradiotherapy followed by 3 cycles of Adjuvant chemotherapy. Patients will be treated with radiotherapy for 5 days per week from Monday to Friday
223420312|NCT00481598|PROCEDURE|magnet resonance spectroscopy|magnet resonance spectroscopy
223420313|NCT00621868|DRUG|ipragliflozin|Oral
223420314|NCT00621868|DRUG|Placebo|Oral
223420315|NCT05861492|OTHER|Fatigue Differential Diagnosis Aid|The Fatigue Differential Diagnosis Aid is a systematic questionnaire covering the symptoms and signs of fatigue and the collateral clinical data trying to facilitate the diagnostic process in the care of patient with symptoms of fatigue.
223420316|NCT03892382|DEVICE|rTMS|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
223420317|NCT02231138|DRUG|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
223420318|NCT05402969|PROCEDURE|Transimedance Matrix measurements|TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes
223420319|NCT05402969|PROCEDURE|Depth sounding and spectroscopy|Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.
223420320|NCT05402969|PROCEDURE|Cone Beam Computer Tomography|CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.
223420321|NCT01062542|PROCEDURE|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
223420322|NCT00487006|OTHER|Serum Lab testing|Serum Lab testing
223420323|NCT03764878|DIAGNOSTIC_TEST|functional MRI|Participants will undergo a functional MRI using multiple imaging modalities.
223420324|NCT05742009|DEVICE|iCare ST500|Measurement of Intraocular Pressure (IOP)
223420325|NCT05742009|DEVICE|GAT|Measurement of Intraocular Pressure (IOP)
223420326|NCT05742009|DEVICE|iCare IC200|Measurement of Intraocular Pressure (IOP)
224035281|NCT07020754|DIETARY_SUPPLEMENT|Maltodextrin Oral Suspension (Control)|"Type: Placebo comparator~Dosage: 10 g maltodextrin~Route: Oral (swish-and-swallow)~Frequency: Three times daily, 30 minutes before meals~Duration: From the 2nd to the 7th week of radiotherapy"
223420327|NCT02587507|OTHER|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
223420328|NCT02587507|OTHER|Water|Individuals will consume the HFHC meal with 500mL of water.
223420329|NCT02587507|OTHER|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
224035282|NCT07019675|DRUG|SKB518 for injection|SKB518 for injection is administered every 3 weeks(Q3W) until radiographic disease progression, intolerable toxicity, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
224035283|NCT07020260|OTHER|CAR T-cell and Cellular Therapies|A single IV infusion of huCAR 19 T-cells on day 0. In phase I 3 dose levels are tested to determine the RP2D.
223420330|NCT03489707|BEHAVIORAL|Home-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
223420331|NCT03489707|BEHAVIORAL|Clinic-based human papillomavirus (HPV) DNA screening|Persons randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
223420332|NCT01817582|DRUG|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
223420333|NCT01817582|DRUG|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
223420334|NCT01817582|DRUG|Soothe® Lubricant Eye Drops|
223420335|NCT06094660|PROCEDURE|Diagnostic genicular nerve block|Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.
223420336|NCT06094660|PROCEDURE|Genicular nerve block with Radiofrequency Ablation (RFA)|"Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds."
223420337|NCT06094660|PROCEDURE|Genicular nerve block with Phenol 6%|"Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary."
223420338|NCT06576440|DRUG|Ghrelin|Participants in this arm will receive a subcutaneous injection of acyl-ghrelin as the active condition.
223420339|NCT06576440|DRUG|Saline|Participants in this arm will receive a subcutaneous injection of saline as placebo control condition.
223420340|NCT01092091|BIOLOGICAL|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
223420341|NCT02358096|DRUG|ASP8232|oral capsule
223420342|NCT02358096|DRUG|Placebo|oral capsule
223420343|NCT03799692|DRUG|Chemotherapy|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15."
223420344|NCT06057662|OTHER|personalized comprehensive diabetes support|personalized comprehensive diabetes support
223420345|NCT05432154|DEVICE|Film forming silicone gel (7-0940)|"Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances."
223739579|NCT04976842|DRUG|OBA|Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
223739580|NCT02052232|OTHER|Experimental protein powder sachet|mixed with 8 oz. water
223420346|NCT04233047|DRUG|Fostemsavir|Fostemsavir 600 mg extended release tablets, administered 600 mg twice daily, will be supplied for compassionate use for the identified individual patient.
223420347|NCT01489215|BEHAVIORAL|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
223420348|NCT01489215|BEHAVIORAL|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
223420349|NCT04744233|OTHER|Orange juice|Subjects were enrolled to consume 500 mL of orange juice/day during three consecutive 14 days periods separated by 1 - 1.5 month washouts. The orange juices assayed were: freshly squeezed (FS), commercially available low pasteurized juice (LP) and juices treated by high-pressure processing (HPP) and by pulsed electric fields (PEF). All participants consumed the LP and the HPP orange juices. Six subjects consumed PEF-orange juice and other six consumed the FS-orange juice.
223739581|NCT02052232|OTHER|Control protein powder sachet|mixed with 8 oz. water
224035284|NCT07018817|BEHAVIORAL|motor execution motor imagery|Participants will perform motor execution tasks and motor imagery tasks following standardized instructions under controlled conditions.
223420350|NCT04630691|PROCEDURE|Implantation|Patients received narrow diameter implants in posterior mandible or maxilla
223420351|NCT06769256|DRUG|rhTNK-tPA, 4-8 mg|Intracoronary influsion of rhTNK-tPA (4 mg). After 10 minutes of administration, 4 mg may be given again if the thrombus burden is not significantly reduced.
223420352|NCT06769256|DRUG|Tirofiban|Intracoronary influsion of Tirofiban (10 µg/kg) , and then administered intravenously at 0.075-0.15 µg/kg.min for 36 h or longer
223420353|NCT04690192|BIOLOGICAL|CNCT19|2×10\^6/kg, infused in a single-dose on day +2, +3 or +4 following stem-cell infusion
223420354|NCT04690192|DRUG|Gemcitabine Injection|600mg/m2/h, infused for 3 hours with loading bolus of 75mg/m2, day -7, -3,
223420355|NCT04690192|DRUG|busulfan|105mg/m2, day -7 until -5,
223420356|NCT04690192|DRUG|Melphalan Injection|60mg/m2, day -3, -2
223420357|NCT04237103|DRUG|Methotrexate|oral capsules taken once a week
223420358|NCT04237103|DRUG|Placebos|Administered identically to the experimental group
223420359|NCT00170625|DRUG|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
223420360|NCT05305885|DRUG|Pemetrexed|Intrathecal administration, intraventricular administration or via lumbar puncture, pemetrexed plus dexamethasone, first induction intra-cerebrospinal fluid chemotherapy twice per week for 2 weeks, then once per week for 4 times, 6 weeks in total.
223420361|NCT05305885|RADIATION|Radiotherapy|Concurrent radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40 Gy.
223420362|NCT04514445|OTHER|Observational|
223420363|NCT01659593|OTHER|procog|3 to 5 people group program
223420364|NCT01659593|OTHER|Placebo|
223420365|NCT00685204|DRUG|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
224137486|NCT02705768|DRUG|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
224137487|NCT00722709|DRUG|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
223420366|NCT01600456|BEHAVIORAL|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
223420367|NCT01600456|OTHER|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
223562557|NCT01252186|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
223739582|NCT00112658|DRUG|fluorouracil|
223739583|NCT00112658|DRUG|gemcitabine hydrochloride|
223420368|NCT05550454|DEVICE|Automatic Mechanical Ventilation|"Ventilation settings:~Mode: (S)Continuous Mandatory Ventilation Rate: 10 b/min. Tidal Volume: 500 ml (male), 450 ml (female) I:E=1:1 Positive end expiratory pressure (PEEP): 5 cmH2O Flow trigger: off Oxygen: 100% Alarms: Pressure 70 cmH20, Tidal volume 100 \~ 1,000 ml"
223420369|NCT05550454|DEVICE|Manual Ventilation|Ambu-bagging (It is recommended in the guidelines as a ventilation method.) Methods: 10 times per minutes by medical personnel
223739584|NCT00112658|DRUG|irinotecan hydrochloride|
223739585|NCT00112658|DRUG|leucovorin calcium|
223420370|NCT03491046|DEVICE|PET scan|low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence
223420371|NCT03491046|DEVICE|MRI scan|standard of care MRI
223562558|NCT01252186|DRUG|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
223562559|NCT01252186|DRUG|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
223562560|NCT00116675|DRUG|Resiquimod|
223562561|NCT04017572|PROCEDURE|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
223562562|NCT01621256|DRUG|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
223562563|NCT01621256|DRUG|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
223562564|NCT02524275|DRUG|Capecitabine|Given PO
223562565|NCT02524275|DRUG|Docetaxel|Given IV
223562566|NCT02524275|OTHER|Quality-of-Life Assessment|Ancillary studies
223562567|NCT02524275|OTHER|Questionnaire Administration|Ancillary studies
223562568|NCT03007329|DRUG|Exenatide|Exenatide will be combined with Dapagliflozin
223562569|NCT03007329|DRUG|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
223562570|NCT03007329|DRUG|Dapagliflozin|Dapagliflozin, in both arms
223562571|NCT02407340|DRUG|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
223562572|NCT02407340|DRUG|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
223739586|NCT00112658|DRUG|oxaliplatin|
223739587|NCT04052269|DRUG|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
223739588|NCT01734330|BEHAVIORAL|Cognitive behavioral therapy in group|
223739589|NCT01734330|DRUG|Nicotine replacement|
223739590|NCT01950533|PROCEDURE|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
223739591|NCT05777915|OTHER|Usability testing|Usability testing
223420372|NCT02122887|BEHAVIORAL|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
223420373|NCT05175664|OTHER|Long-term study|No intervention. Investigations: cognitive tests, blood samples, pupillometry, actigraphy, and FDG-PET/MR brain scan.
223420374|NCT05175664|OTHER|Short-term study|No intervention. Investigations: blood samples and pupillometry.
223739592|NCT01571206|BIOLOGICAL|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
223739593|NCT03724812|DEVICE|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
224035285|NCT07020078|RADIATION|Salivary redox biomarkers|Salivary redox biomarkers
224035286|NCT07020832|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
224035287|NCT07020832|OTHER|Placebo|Sterile solution of equal volume to active arm
224035288|NCT07019207|BEHAVIORAL|VR-Based Dual-Task Training with Motor Imagery|Participants will perform the game consisting of 3 different stages during one session. The motor task will include crossing the street between cars and walking on the sidewalk without hitting people. The difference between the stages will be the cognitive task, which becomes more difficult with each stage. The cognitive task in the first stage of the game will involve the colors that the patient will see and the simultaneous sound of the colors. The cognitive task in the second stage of the game will involve writing the names of some colors with black paint and reading them simultaneously. In the third stage of the game, the patient will see color names written with some colors. Every 5 seconds a new match will appear and the number of errors made during the matches will be recorded. In addition, upper extremity strengthening with PNF methods such as hold relaxation, rhythmic stabilization and repetitive stretches will be studied.
224035289|NCT07019207|BEHAVIORAL|VR-Based Dual-Task Training without Motor Imagery|The difference of this group from the first group is that they will see that they provide mobility with a wheelchair instead of walking, which is a motor task. In this case, there will be no motor imagery of walking. Simultaneously with the game, an environment where the wheelchair can move safely will be created in order to prevent symptoms such as dizziness and nausea in the patients and the wheelchair will be moved in this environment by the researcher. The difference between the stages will be the cognitive task that becomes more difficult at each stage and it will take a total of 20 minutes to complete all stages of the game. In addition, upper extremity strengthening will be practiced with PNF methods of hold and relax, rhythmic stabilization and repetitive stretches.
224137488|NCT00722709|DRUG|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
224137489|NCT03755284|OTHER|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
224137490|NCT06120959|OTHER|Stabilization exercise|The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
224137491|NCT06120959|OTHER|Pelvic floor exercise|The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
224137492|NCT03055403|DRUG|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
224137493|NCT03055403|DRUG|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
224137494|NCT05157451|OTHER|Quality of Life|Ancillary studies
224137495|NCT05157451|OTHER|Questionnaire Administration|Ancillary studies
224137496|NCT05157451|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224137497|NCT05157451|PROCEDURE|Yttrium-90 Microsphere Radioembolization|Given via injection
223420375|NCT05175664|OTHER|Cross-sectional study|No intervention. Investigations: cognitive tests, pupillometry and actigraphy.
223420376|NCT04321174|DRUG|Lopinavir/ritonavir|The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.
223420377|NCT04435990|BIOLOGICAL|10,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 10,000 UT / mL
223739594|NCT00138944|DRUG|placebo|od
223739595|NCT00138944|DRUG|eplerenone|50mg od
223739596|NCT04248608|PROCEDURE|serratus plane block|ultrasound guided block
223739597|NCT04248608|PROCEDURE|erector spinae block|ultrasound guided block
223739598|NCT04248608|DRUG|Morphine Sulfate|intravenous morphine sulfate 0.1 mg/kg
223420378|NCT04435990|BIOLOGICAL|30,000 MM09|Purified allergenic extract, and adsorbed in aluminum hydroxide and polymerized with glutaraldehyde, mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae). The concentration is 30,000 UT / mL
223420379|NCT04435990|BIOLOGICAL|Placebo subcutaneous|The same solution and presentation as the active treatment, but without active ingredients.
223420380|NCT01809301|DRUG|Niaspan|
223420381|NCT01809301|DRUG|TRIA-662|
223420382|NCT06946914|DRUG|Misoprostol|administration of 100mg of misoprostol to evaluate the efficacy of Misoprostol before elective cesarean section in pregnant women with gestational age less than 38 weeks for preventing the occurrence of neonatal respiratory morbidity.
223420383|NCT00880854|DRUG|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
223420384|NCT04383938|DRUG|APR-246 (eprenetapopt) + Pembrolizumab|APR-246 D1-4 + Pembrolizumab D3
223420385|NCT03070769|PROCEDURE|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
223420386|NCT02589236|DRUG|Cavosonstat|GSNOR inhibitor
223420387|NCT02589236|DRUG|Placebo|Control sample with only capsule excipients and fillers
223420388|NCT03760367|OTHER|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
223420389|NCT03760367|OTHER|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
223420390|NCT05299944|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in opioid consumption, opioid craving, pain, peripheral markers of inflammation, and anxiety, as well as changes in sleep, AEA, and cognition.
223420391|NCT05299944|DRUG|Placebo|Placebo arm
223420392|NCT00811317|DEVICE|Closed-loop|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
223420393|NCT01803503|DRUG|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
223420394|NCT01803503|DRUG|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
223420395|NCT06035081|DRUG|Prednisolone|see arm description
223420396|NCT06035081|OTHER|Placebo|Placebo similar to prednisolone
223420397|NCT03928756|BEHAVIORAL|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
223420398|NCT03928756|BEHAVIORAL|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
223420399|NCT03928756|BEHAVIORAL|No Push Notifications|Participants will not receive a push notification.
223420400|NCT04809857|OTHER|Exercise|
223420401|NCT03806699|BIOLOGICAL|Placebo|Sterile normal saline
223420402|NCT03806699|BIOLOGICAL|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
223420403|NCT00115245|DRUG|Telbivudine (LdT)|
223420404|NCT00115245|DRUG|Adefovir Dipivoxil|
223420405|NCT05830981|OTHER|Educational intervention|3 months of educational intervention (Lectures, information bulletin, handbook and hardcopy presentation slides) among professionals and patients.
223420406|NCT00378508|DRUG|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
223420407|NCT00378508|DRUG|Placebo Arm|
223420408|NCT00006485|DRUG|alvocidib|
223420409|NCT00006485|DRUG|irinotecan hydrochloride|
223420410|NCT04827628|DIETARY_SUPPLEMENT|Oryza Sativa Extract|The product is a suspension of 5.6 gram/100 mL given once daily, contains 71.9%, purple in color, range pH 3-5. Stored in the darker bottle. The frequency of administration is once-daily after the meal.
223420411|NCT04827628|DIETARY_SUPPLEMENT|Control|citric acid 0.1g/oz and 1% sorbitol mixture, given once daily after meal
223420412|NCT04289207|DRUG|Romiplostim and danazol|Treatment with romiplostim and danazol
223420413|NCT05697237|DRUG|Carrelizumab|Carrelizumab 200mg/3 weeks
223420414|NCT05697237|DRUG|Solfantinib|Solfantinib 300mg/d
223420415|NCT04960683|DEVICE|Lokomat training|"Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~* 5 sessions of 45 minutes a week, each session includes:~* 5 minutes of stretching exercise~* 20 minutes of strengthening exercise~* 10 minutes of balance exercise~* 10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~* 5 sessions of 45 minutes of conventional therapy (same as above) per week~* 5 sessions of 45 minutes on Lokomat per week"
223562573|NCT04018820|OTHER|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
223420416|NCT00950040|BEHAVIORAL|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
223420417|NCT00950040|BEHAVIORAL|General health education|The intervention will consist of information about several general health behaviors.
224035290|NCT07019207|BEHAVIORAL|Proprioceptive Neuromuscular Facilitation|The patients in the group will be applied only the resistance band strengthening methods including the upper extremity proprioceptive neuromuscular facilitation (PNF) patterns and methods applied as standard in rehabilitation. Strengthening will be worked on in all upper extremity PNF patterns using the resistance band with the PNF methods of hold-relax, rhythmic stabilization and repetitive stretching.
224035291|NCT07021131|PROCEDURE|new type of peripheral block Serratus Posterior Plane Block|Intervention will be Serratus Posterior Plane Block.
224035292|NCT07017751|OTHER|Heart failure medication|intervention group will receive 45 minutes online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. Two weeks, one month, and two months after the initial education, participants will be contacted to obtain feedback on their post-education dietary behaviours, medication compliance, and symptoms.
224035293|NCT07019480|PROCEDURE|implant insertion|"Following local anesthesia (articaine 4% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills and the implant will be inserted. Implant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden).~The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol)."
224035294|NCT07020624|OTHER|SAPB|Ultrasound guided serratus anterior plane block will be performed.
224035295|NCT07020624|OTHER|SPSIPB|Ultrasound guided serratus posterior superior intercostal plane block will be performed.
224035296|NCT07018921|DIETARY_SUPPLEMENT|rebaudioside A|rebaudioside A encapsulated in a vegetarian capsule
223420418|NCT00559624|DRUG|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
223420419|NCT05454969|BEHAVIORAL|One-4-ALL Initiative|We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
223420420|NCT05454969|BEHAVIORAL|Control|Patients will receive standard of care.
223420421|NCT02393924|OTHER|No intervention|
223562574|NCT06658769|OTHER|Theta Burst Stimulation|Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
223562575|NCT06658769|OTHER|Theta Burst Stimulation Sham|Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
223420422|NCT02478034|OTHER|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
223562576|NCT02408718|BEHAVIORAL|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
224035297|NCT07018921|DIETARY_SUPPLEMENT|Placebo|carboxymethylcellulose encapsulated in a vegetarian capsule
224035298|NCT07020403|BEHAVIORAL|Mindfulness-Based Emotional Eating Reduction Program (MB-EER)|The MB-EER program was delivered to participants in the intervention arm over 7 weeks. Each session lasted 2 hours and was conducted weekly via Zoom. Participants attended in small groups, and sessions were led by trained facilitators. The intervention focused on guided mindfulness practices, mindful eating exercises, and group discussions.
224137498|NCT02225873|OTHER|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
224137499|NCT02225873|OTHER|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
223420423|NCT01556568|DRUG|MEK162|
223420424|NCT01665820|DEVICE|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
223420425|NCT04967547|OTHER|Self-care PD ability assessment form|Subjects will be evaluated using the self-care PD feasibility assessment tool within 7 days after randomization. The evaluation results will be provided to the patient on the same day
223420426|NCT04967547|OTHER|Education|Education on renal replacement therapy and dialysis
223420427|NCT06648057|DRUG|lenvatinib plus pembrolizumab|"* The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens)."
223562577|NCT00256035|PROCEDURE|Measuring IL-4 levels|
223562578|NCT04283994|BEHAVIORAL|Survey-based Patient/Clinician Jumpstart|"The Jumpstart Guide is a communication-priming intervention for clinicians, patients and their families that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The Jumpstart takes two forms. One is EHR-based and provides information to the clinician about prior advance care planning documentation derived from the EHR. The other is bi-directional and patient-specific (Survey-based Patient/Clinician Jumpstart Guide). It provides the same information as the EHR-based Clinician Jumpstart Guide but also includes information about patients' self-reported preferences for communication and care as well as primary barriers and facilitators to this communication. The Jumpstart Guides include tips to improve this communication for clinicians, patients and families."
224035299|NCT04740528|DIAGNOSTIC_TEST|fto gene testing|Blood samples were collected after a 12-h fasting by Prodia Laboratory for DNA isolation and biochemical analysis
224035300|NCT06096389|OTHER|100 Drop Jumps|100 drop jumps from 60 cm height. Divided into 5 sets of 20 reps
223420428|NCT03940274|BEHAVIORAL|walking training|Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
223420429|NCT01607229|OTHER|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
223420430|NCT04760041|DRUG|Midazolam nebulized|midazolam nebulized
223420431|NCT04760041|DRUG|Midazolam oral solution|midazolam given oral
223420432|NCT01585324|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
223420433|NCT01585324|DRUG|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
223420434|NCT01037517|DRUG|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
223420435|NCT01037517|OTHER|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
223420436|NCT05156372|OTHER|High Intensity Interval Training|Participants will perform high-intensity aerobic and resistance exercise
223420437|NCT06619314|DRUG|MK-1084|Oral Tablet
224137500|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
223420438|NCT06619314|DRUG|PPI|Oral Capsule
223739599|NCT06115811|BEHAVIORAL|Radiation Treatment Plan Evaluation Learning Tool|Web-based program comprised of a systematic, oncology treatment plan review system and learning modules. The case bank of radiation treatments plans is accessible via econtour.org.
224035301|NCT06096389|DIETARY_SUPPLEMENT|Whey supplementation|Consume whey protein isolate based on subjects' daily protein intake
224035302|NCT06096389|DIETARY_SUPPLEMENT|Carbohydrate supplementation|Consume carbohydrate (isocaloric to whey)
224035303|NCT06096389|DIETARY_SUPPLEMENT|House cricket supplementation|Consume defatted house cricket powder based on subjects' daily protein intake
224137501|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
224137502|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
224137503|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
224137504|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
223420439|NCT05830136|DRUG|sodium bicarbonate Ringer's solution|Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
223420440|NCT02461706|DRUG|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
223420441|NCT02461706|OTHER|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
223420442|NCT03659175|OTHER|SIBO|SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
223420443|NCT03430479|DRUG|Cohort A|Radiation + Nivolumab + hormone therapy
223420444|NCT03448575|OTHER|Control - Provider Medication Alert Only|Simple text medication alert referencing Choosing Wisely guidelines.
224137505|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
224137506|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
224137507|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
223420445|NCT03448575|OTHER|Intervention - Alert + CAP Review AND Enhanced BH Access|Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
223420446|NCT03303573|DRUG|recombinant human erythropoietin|Subcutaneous rhEPO injection
223420447|NCT06666166|DRUG|SHR-A1811 & Apartinib|SHR-A1811 injection will be administered by intravenous infusion. And apatinib will be administered orally.
223420448|NCT04796623|DRUG|TQB3616 capsules|TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.
223420449|NCT04796623|DRUG|Fulvestrant injection|Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.
223420450|NCT04677751|DEVICE|Acupuncture intervention|Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
223420451|NCT03917472|DRUG|Brolucizumab|Intravitreal injection
224035304|NCT06686693|DRUG|Injectafer|Injectafer - 15 mg/kg up to 1000 mg
224035305|NCT06686693|OTHER|Placebo|Placebo
224035306|NCT03187210|DRUG|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
224035307|NCT03187210|DRUG|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
224137508|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
224137509|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
224137510|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
224137511|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
224137512|NCT05905341|DRUG|PF-07224826|Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
224137513|NCT05905341|COMBINATION_PRODUCT|Fulvestrant|Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
223420452|NCT03917472|DRUG|Aflibercept|Intravitreal injection
223420453|NCT03788434|DRUG|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under Good Manufacturing Practices (GMP) conditions.
223420454|NCT03788434|DRUG|Placebo|Placebo capsules contained microcrystalline cellulose and were visually identical to VE303 capsules. Placebo capsules did not contain any VE303 Drug Product.
223420455|NCT01261572|DRUG|degarelix|periodic injection
223420456|NCT01953601|DRUG|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
223420457|NCT01953601|DRUG|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
223420458|NCT01953601|OTHER|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
223420459|NCT06667492|DEVICE|Traction Dynamometry|K-Pull dynamometer (Model MP.09.02.FN, Kinvent, Montpellier, France) is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions. This instrument will be used to evaluate isometric activity (maximum and average torque values) of the hip and knee flexors and extensors at specific joint angles.
223420460|NCT06430372|DRUG|Bev-ICG|Probe targeting VEGF-A that is topically administrated during the endoscopy
223420461|NCT06430372|DEVICE|NIR-II fluorescence endoscopy platform|An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
223420462|NCT06191328|DRUG|Chiglitazar sodium|In patients with type 2 diabetes mellitus (T2DM), on the basis of one or two oral hypoglycemic agents combination with Chiglitazar sodium.
223420463|NCT05800197|DRUG|Tamoxifen 20mg|Selective estrogen receptor modulator
223420464|NCT05800197|DRUG|Anastrozole 1mg|Aromatase Inhibitor
223420465|NCT05800197|DRUG|Letrozole 2.5mg|Aromatase Inhibitor
223420466|NCT05800197|DRUG|Goserelin|Gonadotropin Releasing Hormone (GnRH) agonist
223420467|NCT05800197|DRUG|Triptorelin|Gonadotropin Releasing Hormone (GnRH) agonist
223420468|NCT05225298|BEHAVIORAL|Offering SARS-CoV-2 test|A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
223420469|NCT06263998|DRUG|NCP112|NCP112 topical ophthalmic solution
223420470|NCT06263998|DRUG|NCP112 Placebo|Placebo comparator
223420471|NCT05234879|OTHER|Frame Running|Frame Running (FR) provides an opportunity for people with walking and balance problems to walk or run safely without the risk of falling. The frame consists of three wheels and has a saddle and handlebars like a trike without pedals.
223420472|NCT02753387|DRUG|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
223420473|NCT02753387|DEVICE|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
223420474|NCT05167370|DRUG|Amifostine|Amifostine (Ethyol) 1125 mg/m2 will be given intravenously daily over 5 minutes starting 30 minutes prior to chemotherapy (melphalan or thiotepa) on days -5, -4, -3, -2, and on day -1 twenty four hours after prior dose of amifostine.
223420475|NCT00570544|DRUG|tiotropium|18ug capsule daily for 30 days
224137514|NCT03182400|BEHAVIORAL|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
224137515|NCT03182400|BEHAVIORAL|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
224137516|NCT05091294|OTHER|Local anesthetic injection rate in spinal anesthesia|Administering intrathecal local anesthetics for all patients according to height and weight.
223420476|NCT02180984|DEVICE|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
223420477|NCT04887090|DEVICE|Acupuncture and Drug Compound Technology|Before operation: The points of the meridian: Hegu, Neiguan, Chize, Zusanli, both sides are taken. TEAS (transcutaneous electrical acupoints stimulation) was performed every day for three days before the operation, using the Han's acupoint nerve stimulator to adjust the density and density waveforms at a frequency of 2/100 Hz (Hz). Current intensity is 10mA, and all acupuncture points are continuously stimulated for 30 minutes. During the operation: take the acupoints Hegu, Neiguan, Houxi, and Zhigou on both sides and give TEAS 30 minutes before induction of anesthesia. The stimulation intensity and frequency are the same as those before the operation until the end of the operation. Postoperative: Take the acupoints Chize, Waiguan, Taichong, and Yanglingquan, and take both sides. TEAS will be performed every 12 hours from the first day after surgery. Each treatment is 30 minutes until 48 hours after surgery. The intensity and frequency are the same as before surgery.
223420478|NCT04887090|OTHER|Routine perioperative management|Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.
223420479|NCT01740271|DRUG|Epirubicin|
223420480|NCT02428049|RADIATION|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
223420481|NCT00489775|DRUG|Duloxetine|
223420482|NCT00489775|DRUG|Paroxetine|
223420483|NCT01828541|BEHAVIORAL|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
224137517|NCT03269890|PROCEDURE|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
223420484|NCT01828541|OTHER|Standard of Care|
223420485|NCT04826887|OTHER|SOLTIVE Thulium Laser|Use of SOLTIVE Thulium laser for HoLEP
223420486|NCT04826887|OTHER|Standard of Care (Holmium Laser)|Use of Holmium laser for HoLEP
223420487|NCT03831412|BEHAVIORAL|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
223420488|NCT03831412|BEHAVIORAL|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
223420489|NCT06622772|DEVICE|Valsalva assist device|A valsalva assist device designed to provide the recommended resistance to exhalation at a pressure of 40 mmHg.
223420490|NCT06622772|OTHER|standard Valsalva manoeuvre|The Valsalva manoeuvre is carried out without any device.
223420491|NCT05796284|BEHAVIORAL|Breast pressure relief intervention at the end of pregnancy|When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .
223420492|NCT05796284|OTHER|Routine care|Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
223420493|NCT04450784|OTHER|collection of the clinical and biological characteristics of secondary AMLs in children|to record scientific and medical information on cases of secondary Acute Myeloid Leukemias that have occurred in France since 2013
223420494|NCT01192529|DIETARY_SUPPLEMENT|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
223420495|NCT01192529|DIETARY_SUPPLEMENT|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
223420496|NCT06618716|BIOLOGICAL|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|Intravenous administration of endotoxin (0.8 ng/kg body weight)
223420497|NCT06618716|OTHER|Placcebo|Placebo injection of 0.9% NaCl
223420498|NCT03761758|DEVICE|Spectacle lenses|Spectacle lenses with clear central apertures
223420499|NCT01306318|DRUG|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
223420500|NCT01306318|DRUG|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
223420501|NCT06648018|BEHAVIORAL|Nutritional information|Written nutritional information about food with high content of iron.
223420502|NCT06648018|DIETARY_SUPPLEMENT|Iron-succinate|100 mg of Iron-succinate per day.
223420503|NCT05785013|DIETARY_SUPPLEMENT|Zinc|Zinc Supplementation
223420504|NCT03309657|DRUG|Ceftolozane/tazobactam|This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
223420505|NCT02883075|OTHER|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
223420506|NCT02883075|OTHER|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
223420507|NCT02883075|OTHER|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
223420508|NCT05700916|DRUG|Milk Polar Lipid-Rich Dairy Powder|Effects of the addition of 6.5 g of milk polar lipids to dairy powder.
223420509|NCT05700916|DIETARY_SUPPLEMENT|Dairy Powder|Effects of dairy control powder
223420510|NCT06967909|BEHAVIORAL|Tai Chi training|Participants will receive 24 weeks of Tai Chi training. For the first 12 weeks, they will receive 3 instructor-led Tai Chi training sessions per week, and practice 2 Tai Chi sessions by themselves. In the next 12 weeks, they will receive 1 instructor-led Tai Chi session and self-practice 2 Tai Chi sessions per week. A modified 33-short form Yang-style Tai Chi Chuan will be adopted. The Tai Chi sessions will be operated by qualified instructors. Each 1-hour training session consists of 10 minutes brief warm-up stretching session followed by 45 minutes standard Tai Chi routine activities, and 5 minutes of cool-down stretching. The Tai Chi instructors are required to attend a training session that ensure all of them to deliver the same intervention protocol throughout the study. The research assistant will monitor the fidelity of intervention by visiting the Tai Chi sessions frequently. The training session will be delivered in group. The group size is 25-30 persons.
223420511|NCT06967909|PROCEDURE|Acupuncture|Participants in the acupuncture group will receive 30 acupuncture treatment sessions, each last for 1 hour. Acupuncture will be performed every 2 days within one week, followed by a 3-day break, i.e., twice a week for the first 12 weeks; then it will be performed once every two weeks for the next 12 weeks. In total 30 sessions during 24 weeks treatment period. All acupuncture sessions will be administered by registered Traditional Chinese Medicine practitioners in Hong Kong with at least three years of clinical experience.
223420512|NCT03991299|DRUG|Botox 200 UNT Injection|Botox will be injected into duodenums of subjects by endoscopy.
223420513|NCT00155272|DRUG|Thalidomide|
223420514|NCT05021016|BIOLOGICAL|EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)|"The EpiVacCorona vaccine is intended to prevent COVID-19. The vaccine relies on chemically synthesized peptide antigens of SARS-CoV-2 proteins conjugated to a carrier protein and adsorbed on an aluminum-containing adjuvant (aluminum hydroxide).~The vaccine induces the specific immunity against the SARS-CoV-2 coronavirus following two intramuscular injections spaced 21 to 28 days apart.~The EpiVacCorona vaccine contributes to the development of protective immunity against SARS-CoV-2 coronavirus following two intramuscular administrations given 21 to 28 days apart."
223420515|NCT04122703|DEVICE|percutaneous tibial nerve stimulation (PTNS)|The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
223420516|NCT04122703|DEVICE|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
223420517|NCT00163761|DRUG|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
223420518|NCT00163761|DRUG|gemcitabine, vinorelbine, filgastrim|Drug
223420519|NCT06968260|OTHER|Education Type|Machine Guidance group will receive education from a software, while the Instructor Guidance Group will receive education from a human instructor.
223420520|NCT00495209|OTHER|Qigong|EQT daily for 5 consecutive days prior to surgery.
223420521|NCT05537779|DEVICE|CT examination|Administration of contrast medium using the power injector
223420522|NCT06522087|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
223420523|NCT00792974|BEHAVIORAL|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
223420524|NCT04189939|OTHER|clinical assessments|"Behavioral tasks will be executed via a computer interface. Below, we provide an estimated timeline for each visit and subsequently provide detail for the relevant stages.~Each participant's visit will last approximately 4-5 hours. Each visit will consist of the following tasks (in this order):"
223420525|NCT01881334|BIOLOGICAL|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
223420526|NCT00484835|PROCEDURE|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
223420527|NCT02064270|DEVICE|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
223420528|NCT02064270|DEVICE|Standard postsurgical dressings|Use of Standard postsurgical dressings
223420529|NCT04792593|BIOLOGICAL|Senl-h19 CAR-T|Biological: Senl-h19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
224035308|NCT07019363|DRUG|Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)|Standard endocrine therapy
224035309|NCT07019363|DRUG|Standard endocrine therapy combined with CDK4/6 Inhibitor|CDK4/6 inhibitor therapy for 2 years in combination with standard endocrine therapy
224035310|NCT07019103|DRUG|Gabapentin (Neurontin® (Registered Trademark))|Additionally, during this phase, patients will be educated on how to report their perceived pain, rated from 0 to 10 on the visual analog scale (VAS). Subsequently, another dedicated pain-management specialist will engage with each patient to formulate and document an individualized pain management plan, taking into consideration the patient's medical history, previous pain experiences, and preferences for pain management strategies. As part of preemptive analgesia, patients receive 300 mg of gabapentin orally 2 hours prior to surgery, unless contraindicated.
224035311|NCT07020286|PROCEDURE|Structural heart interventions|The study allows us to understand the trend of transcatheter interventions in structural heart disease, clinical outcomes and allows the comparison of the outcomes of structural heart interventions to medical therapy and surgery at PWH, and to HA hospitals.
223420530|NCT04429555|DRUG|Ibudilast|50 mg (5 x 10 mg capsules) twice daily for 7 days
223420531|NCT04429555|DRUG|Placebo|0 mg (5 matching capsules) twice daily for 7 days
223562579|NCT04283994|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page EHR-based Clinician Jumpstart Guide provides information to the clinician about prior advance care planning documentation derived from the EHR. The EHR-based Clinician Jumpstart Guide includes tips to improve goals-of-care communication.
224035312|NCT07020169|PROCEDURE|an AI-based real-time image-guided kidney model system|Use the AI-model to locate kidney and tumour, assisting surgeon with the operation
223562580|NCT06342492|OTHER|Coronary Sinus Lead Revision|Coronary Sinus Lead Revision
224035313|NCT07019519|OTHER|Saline/Placebo|NaCl(9mg/ml)
224035314|NCT07019519|OTHER|GIPR antagonist|GIP(3-30)NH2
224035315|NCT07019519|OTHER|GLP-1R antagonist|GLP-1(9-39)NH2
224035316|NCT07019519|OTHER|CCK agonist|CCK-8
224035317|NCT06452186|DEVICE|direct EMG controlled prosthetic ankle|Patients are trained to use the powered prosthetic ankles
223562581|NCT03763656|DRUG|Oral Hydroxyurea (100 mg/mL) Solution|Participants received Oral Hydroxyurea 15 mg/kg once daily. Escalated by 5 mg/kg/day every 8-12 weeks until maximum tolerated dose achieved, up to a maximum 35 mg/kg/day.
224035318|NCT06452186|BEHAVIORAL|PT guided prosthetic training|Amputees are trained to use prosthetic ankles
224035319|NCT07019298|PROCEDURE|AH Plus (Dentsply Sirona, Charlotte, NC, USA)|Root canal obturation using AH Plus (Dentsply Sirona, Charlotte, NC, USA), a resin-based sealer with low solubility and shrinkage. Used in combination with gutta-percha for root canal filling.
224035320|NCT07019298|PROCEDURE|NeoSealer Flo|Root canal obturation using NeoSealer Flo (Avalon Biomed, Houston, TX, USA), a premixed bioceramic sealer based on calcium silicate. Used in combination with gutta-percha to enhance apical healing and biocompatibility.
223420532|NCT04541108|BIOLOGICAL|Rilvegostomig|Intratumoral microdose injection by the CIVO device.
223420533|NCT04541108|BIOLOGICAL|Volrustomig|Intratumoral microdose injection by the CIVO device.
223420534|NCT04541108|BIOLOGICAL|Sabestomig|Intratumoral microdose injection by the CIVO device.
223420535|NCT04541108|BIOLOGICAL|Pembrolizumab|Intratumoral microdose injection by the CIVO device.
223420536|NCT04711928|BEHAVIORAL|Physical activity and sedentary behaviour|Athletes with a high physical activity and a low or high sedentary time
223420537|NCT04483817|DEVICE|Transcutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
223420538|NCT04483817|DEVICE|Percutaneous tibial nerve stimulation|Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
223420539|NCT02027597|OTHER|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
223420540|NCT02027597|OTHER|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
223420541|NCT02027597|OTHER|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
223420542|NCT00230854|DRUG|EMZ702|
223420543|NCT04719052|OTHER|Diet and behavioural intervention|Intervention will receive a specific diet designed following the characteristics of Mediterranean Diet
223420544|NCT04719052|OTHER|Diet and behavioural intervention|Control group will receive a specific diet designed following the characteristics of Low fat Diet.
223420545|NCT05839197|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
223420546|NCT05839197|DRUG|Camrelizumab plus Apatinib|"Apatinib(250 mg; p.o.; qd.); camrelizumab (200 mg; iv drip; q3w) If the liver function was grade Child-Pugh A, Camrelizumab was given intravenously once every 3 weeks (D1) on the same day, 200mg/, once every 3 weeks (D1).~Apatinib capsule was given orally to 250mg within half an hour after breakfast on the second day (D2) after the first HAIC. The drug was given continuously once a day and stopped on the same day of each HAIC."
223420547|NCT03834974|BEHAVIORAL|Sun Safety Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about sun safety and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should include a sun safety message (e.g., promoting sunscreen use and protective clothing/hats or discouraging risk behaviors like tanning and burning). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
224035321|NCT07019298|PROCEDURE|Continuous Wave Condensation|A warm vertical compaction technique using heat-softened gutta-percha to obturate the canal in three dimensions. Considered the gold standard for achieving dense and homogenous root canal fillings.
223420548|NCT03834974|BEHAVIORAL|Digital Health Social Media Challenge|Participants will attend a webinar to learn how to create effective social media posts about using technology to get healthy and be oriented to the social media accounts on which the messages will be posted. They will be informed that posts should mention some way that technology (e.g., mobile apps, wearables) can be used to promote a healthy habit (e.g., diet, exercise). They will be encouraged to be creative so that the message gets likes and shares. Participants will be encouraged to follow the feeds to see the engagement on their posts, to share the posts in their feed, and to see other participants' posts. Participants will receive a $10 Amazon gift card per post for a maximum of 6 posts ($60). The participant who created the post that receives the most likes, comments, and shares each week will win a $50 Amazon gift card.
223562582|NCT06362876|BEHAVIORAL|Breastfeeding Counseling Based on Motivational Interviewing|Breastfeeding Counseling Based on Motivational Interviewing Program The breastfeeding counseling based on motivational interviewing program consists of 6 sessions and 4 hours. It includes information about breastfeeding, motivational preparation for the breastfeeding experience.
223562583|NCT06362876|BEHAVIORAL|Standard Breastfeeding Consultancy|Standart Breastfeeding Consultancy The standard breastfeeding consultancy program consists of 6session and 4 hours. It contains only information and applications about breastfeeding
223562584|NCT06996145|OTHER|dynamic 4D scanner|dynamic 4D scanner
223562585|NCT07004244|BIOLOGICAL|KRAS-mutated mRNA vaccine|"Cohort 1:From the initial dose, the dose was increased using a dose escalation scheme. Each subject only received one corresponding dose.~Cohort 2:KRAS-mutated mRNA vaccine+ Toripalimab + pemetrexed + carboplatin as neo-adjuvant treatment followed by surgery"
223562586|NCT07004244|BIOLOGICAL|TORIPALIMAB|intravenous injection
223562587|NCT07004244|DRUG|Pemetrexed+carboplatin|intravenous injection
223562588|NCT07003217|BEHAVIORAL|Virtual Reality-based practical education|VR-based practical education is an interactive learning method that utilizes virtual reality, where participants engage in a 3D environment for learning.
224035322|NCT07019298|PROCEDURE|Single Cone Technique|A cold hydraulic condensation technique using a single gutta-percha cone matched to the last rotary file, combined with a high-flow sealer. Designed for simplified obturation with minimal operator variability.
223420549|NCT01055275|DEVICE|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
223562589|NCT07003217|BEHAVIORAL|Video Watching-based practical education|Video Watching-based practical education is a passive learning method, where information is delivered solely through video viewing.
223562590|NCT05034627|PROCEDURE|Biopsy|Undergo biopsy
223562591|NCT05034627|DRUG|Calaspargase Pegol-mknl|Given IV
223562592|NCT05034627|DRUG|Cobimetinib|Given PO
223562593|NCT07013916|DIETARY_SUPPLEMENT|fructose|Fructose powder
223562594|NCT07013916|DIETARY_SUPPLEMENT|glucose|Glucose powder
223420550|NCT03927261|DRUG|PRGN-3006 T Cells|Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.
223420551|NCT02482948|DEVICE|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
223420552|NCT02482948|DRUG|Collagenase|Study agent to be applied daily to the wound.
223420553|NCT01337466|RADIATION|[124I]FIAU|This is a single dose study of 2 mCi \[124I\]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
223420554|NCT03730467|BEHAVIORAL|Phone call to the patient|Phone call to the patient
223420555|NCT00941863|DRUG|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
223420556|NCT00941863|DRUG|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
223420557|NCT00941863|DRUG|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
223420558|NCT00941863|DRUG|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
223420559|NCT00941863|DRUG|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
223420560|NCT05329363|DIAGNOSTIC_TEST|PEPITS Programme|"The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery."
223420561|NCT05329363|OTHER|Usual care|Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
223420562|NCT01402843|DRUG|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
223420563|NCT02655510|DRUG|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
223420564|NCT04533412|BEHAVIORAL|Self-management barrier support|For the intervention, community health workers will assess barriers to good self-management behaviors that lie within 4 domains: 1) social context, 2) physical health and functioning, 3) cognitive factors, and 4) psychological factors. They will work with participants for 6 months to help them work through their barriers to self-management of COPD. Participants can also participate in home-based pulmonary rehabilitation and can receive emergency pack/action pack medication for COPD exacerbations.
223562595|NCT07014085|PROCEDURE|"Histomorphometric Evaluation of Bone Augmentation Using Xenografts Versus Autologous Bone Grafts in Dental Implant Patients: A Comparative Clinical Study"|Split mouth comparative clinical prospective study xenograft vs autologous graft
223420565|NCT04533412|BEHAVIORAL|Basic COPD Education|"The attention control will consist of 4 visits by a COPD educator to the home to review the COPD education booklet. During the first visit, this COPD educator will review the COPD 1-2-3 booklet in its entirety with the patient. During visits 2 and 3, the COPD educator will make a visit to check in with the patient, ask how they are doing with their respiratory symptoms, and review any sections of the COPD 1-2-3 booklet the patient chooses. The COPD educator will recommend visits every 2 months but the patient and COPD educator may choose to modify the interval as needed. If the patient appears to be experiencing worsening respiratory symptoms during any visit, the COPD educator will notify the patient's physician."
223420566|NCT05182814|DIETARY_SUPPLEMENT|Placebo drink|Blank
223420567|NCT05182814|DIETARY_SUPPLEMENT|Collagen Juice Drink|Testing product
223420568|NCT02582450|OTHER|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
223562596|NCT06682728|DRUG|Sacituzumab Govitecan (SG)|Given IV
223562597|NCT06682728|DRUG|Nivolumab|Given IV
223562598|NCT06692348|DRUG|Orforglipron|Administered orally
223562599|NCT06875635|OTHER|Pre and Post op pelvic floor muscle training|pre op exercises: Breathing exercise ,Kegel exercise ,Abdominals exercise include pelvic tilt ,knee rolling with abdominal contraction post op exercise :breathing exercise, circulatory exercise i.e ankle pump and heel slides, and bed mobility along with pre op exercise
223562600|NCT06875635|OTHER|Only post op pelvic floor muscle training|post op exercise :breathing exercise, circulatory exercise i.e ankle pump and heel slides, and bed mobility along with pre op protocol
223420569|NCT03300635|OTHER|Mental distress and relaxation test|
223562601|NCT06875635|OTHER|Routine medical care|Circulatory exercise Breathing exercise Administrating analgesic Nursing care
223562602|NCT07023328|BEHAVIORAL|A structured ball exercise program|Pre-frail older adults will undergo a structured ball exercise program
223420570|NCT03300635|OTHER|Glucose tolerance test|
223420571|NCT03300635|OTHER|Exercise test|
223420572|NCT01808079|OTHER|Laboratory Biomarker Analysis|Correlative studies
223420573|NCT04030390|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
223420574|NCT04030390|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
223562603|NCT07025746|DEVICE|Dynamic foam rolling|The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
223739600|NCT00746993|OTHER|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
223562604|NCT07028372|OTHER|Short Form Health Survey (SF-36)|Heath-related quality-of-life is assessed using the SF-36 questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.
223562605|NCT07028372|OTHER|Modified Rankin Score (mRS)|The degree of disability/dependence is evaluated using the mRS scale at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
224035323|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
224035324|NCT01445067|DRUG|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
223420575|NCT05113979|DEVICE|AccuraSee IOPCL with +3.0D add|The IOPCL (intraocular pseudophakic contact lens) consists of a 4.5mm diameter optic. All subjects will receive a +3.0 power regardless of diopter power based on IOL Master. This IOPCL will be coupled to a Bausch and Lomb Model LI61SE or LI61AO intraocular lens to correct residual refractive errors after cataract surgery.
223420576|NCT05109884|DIAGNOSTIC_TEST|PSMA PET Scan|\[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan
223420577|NCT05109884|DIAGNOSTIC_TEST|FDHT PET Scan|\[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
223420578|NCT03386643|DRUG|Bifidobacterium animalis subsp. lactis HN019|The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
223420579|NCT03386643|DRUG|Clobetasol propionate 0.05%|The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
223420580|NCT02355821|DRUG|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
223420581|NCT02355821|DRUG|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
223420582|NCT05616507|DIETARY_SUPPLEMENT|fucoidan|It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
223420583|NCT03380078|BEHAVIORAL|Teams Leadership Institute (TLI)|TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
223420584|NCT03380078|BEHAVIORAL|Motivational Enhancement (TIPS for Training)|The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
223420585|NCT03380078|BEHAVIORAL|Classroom Pivotal Response Teaching (CPRT)|CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curriculum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
223420586|NCT03380078|BEHAVIORAL|An Individualized Mental Health Intervention for ASD (AIM HI)|A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
223420587|NCT03380078|BEHAVIORAL|Team-Enhanced Teams Leadership Institute (TLI)|TLI-2 enhances TLI training by (a) including additional team members important to EBI implementation (e.g., supervisors, support staff) and (b) including the team in the development of an implementation plan using a team charter process. TLI-2 includes 5 components : 1. Assessment: The Implementation Climate Scale (ICS) will be completed by team members, providers, and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training for the implementation team in implementation climate and development of an implementation plan. 3. Coaching: Bi-monthly, brief (15-30 min) coaching calls keep the team on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up: At month 4, team members attend a 2-hour booster session . 5. Graduation: TLI-2 programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
223420588|NCT01372488|PROCEDURE|Suture self removal|Suture self removal
224137518|NCT03269890|PROCEDURE|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
224137519|NCT04116476|DRUG|MT-7117|Single Dose of MT-7117
224137520|NCT00257491|DRUG|Telmisartan|
224137521|NCT00257491|DRUG|Telmisartan/HCTZ|
224137522|NCT02769351|DEVICE|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
224137523|NCT01835613|OTHER|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
224298777|NCT04078438|OTHER|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
224298778|NCT03589521|BEHAVIORAL|ABCT_Military|15 Weekly Couple Therapy Sessions
223420589|NCT01372488|PROCEDURE|Suture removal by family doctor or clinic|As above
223420590|NCT03631615|DRUG|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~1. induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~2. within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~3. consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
223420591|NCT04884360|DRUG|Olaparib|Olaparib tablets 300 mg oral twice daily
223420592|NCT04884360|OTHER|Matching placebo|Matching placebo tablets taken orally at a dose of 300 mg twice daily
223420593|NCT04561557|BIOLOGICAL|CT103A cells|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT103A cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT103A cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CAR+ T cells/kg will be infused on day 0.
224035325|NCT04600791|DEVICE|BATwire Implant Kit|The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.
224035326|NCT03516461|PROCEDURE|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy or colonic TET tube
223420594|NCT04561557|DRUG|Cyclophosphamide and fludarabine|"Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
223420595|NCT03871946|DIAGNOSTIC_TEST|oral glucose tolerance test (OGTT)|Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.
223420596|NCT06685367|DEVICE|Acura AKI|When the AI algorithm (Acura AKI) identifies a high-risk AKI patient, nephrologists and ICU pharmacists will receive an alert message. Upon receiving the alert, they will review the patient's electronic health record and make treatment suggestions based on AKI bundle care protocols. They will also coordinate with the patient's primary care team to ensure that the recommendations are implemented
223420597|NCT00879346|DRUG|AZD8931|160mg oral single dose (4 x 40mg tablets)
223420598|NCT00968981|DRUG|GDC-0449|Daily oral repeating dose
223420599|NCT00968981|DRUG|GDC-0449|Three times weekly oral repeating dose
223420600|NCT00968981|DRUG|GDC-0449|Once weekly oral repeating dose
224035327|NCT06713811|OTHER|Telemonitoring|Cureety is a digital telemonitoring platform specially designed to monitor cancer patients through self-reporting of adverse events. It supports patients and medical teams to complement existing care practices.
224035328|NCT05414032|BIOLOGICAL|AZD2936|AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.
224035329|NCT04730882|DIETARY_SUPPLEMENT|Mixed Meal|the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
224298779|NCT04920903|DRUG|COR588|Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
223420601|NCT03014895|DRUG|Placebo|Intravenous infusion
223420602|NCT03014895|DRUG|E3112|Intravenous infusion
223420603|NCT05875025|OTHER|Placebo formulated with HFA-152a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
224035330|NCT03024853|BEHAVIORAL|BPS PAST|
224298780|NCT04920903|DRUG|Placebo|Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.
223420604|NCT05875025|OTHER|Placebo formulated with HFA-134a propellant via pMDI|5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8
223420605|NCT00697125|BIOLOGICAL|Engerix™-B|Intramuscular injection, 3 doses
223420606|NCT00697125|BIOLOGICAL|HBV-MPL vaccine (208129)|
223420607|NCT00697125|BIOLOGICAL|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
223420608|NCT02149758|DRUG|Etoricoxib|
223420609|NCT06665334|DRUG|Huaier granule|Oral administration, 10g per dose (1 bag), 3 times a day, recommended for at least 6 months.
223562606|NCT07028372|OTHER|Activity of Daily Living (ADL) questionnaire|Level of independence is evaluated using the ADL questionnaire, which is administered at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, in the form of a telephone interview.
223562607|NCT07028372|OTHER|New York Heart Association (NYHA) Classification|The extent of heart failure is assessed using the NYHA functional classification at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
223562608|NCT07028372|OTHER|St George's Respiratory Questionnaire (SGRQ)|Respiratory status is assessed using the SGRQ questionnaire at the inclusion visite, then at month 6, year 1, year 2, year 3, year 4 and year 5, via telephone interview.
223739601|NCT03394092|DIAGNOSTIC_TEST|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
223739602|NCT04931498|OTHER|Questionnaire|Medical history, demographics and lifestyle factors will be assessed by the participant.
223420610|NCT05147922|BEHAVIORAL|Booster Training with the Neonatal Resuscitation Quality Improvement Cart|The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
223420611|NCT00643825|DRUG|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
223420612|NCT00643825|DRUG|Temozolomide|Observation till Progression then rechallenging with TMZ
223420613|NCT06665490|OTHER|CLn Body Wash|All enrolled patients will self-administer at home the commercially available study product (CLn Body Wash) containing 0.006% NaOCl body wash in a sealed, child-safe pump dispenser to use daily for 8 weeks by wetting the body thoroughly with showering, lathering the study product on the body with special attention to affected areas, leaving on the skin for 2 minutes, and rinsing off with warm water.
223420614|NCT06683443|BEHAVIORAL|Robotic Joy for All™ pet|Patients will be provided with the robotic pet within 48 hours of admission and have access to the pets throughout their hospitalization to provide comfort and engagement.
223420615|NCT06074796|BEHAVIORAL|No intervention.|"No intervention. This is a retrospective study. Data will have been collected in routine consultations as part of the transition process for transgender patients.~Description of the collected informations : gender of destination, BMI, siblings, children, moral, previous hormone therapy, when the project was born, change of marital status desired or carried out, ALD status, psychiatric assessment, desire for future care for the transition course. Desire to preserve erectile function, parenthood desire, couple projections, type of couple, cryopreservation desired, done or not, desire of pregnancy, ultrasound count of antral follicles, initial hormone assays and tests : BMD, pelvic ultrasound? Data relating to stimulation and ovarian puncture and sperm collection."
223420616|NCT04988906|DEVICE|Zoll Accuvent Ventilation Monitor|Provides real-time ventilation quality monitoring (rate and volume)
223420617|NCT00119691|DRUG|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
224035331|NCT03024853|BEHAVIORAL|BPS PRESENT|
224035332|NCT03024853|BEHAVIORAL|BPS FUTURE|
224035333|NCT03024853|BEHAVIORAL|CONTROL|
223420618|NCT03821714|DRUG|Glucocorticoid combination therapy|Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C, and vitamin B1.
224035334|NCT06526832|BIOLOGICAL|BST02|BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.
224035335|NCT02112487|DRUG|Macitentan|10 mg once daily
224035336|NCT06466577|DIAGNOSTIC_TEST|CT 5400 RT System|Computed Tomography X-RAY System is intended to produce images of the head and body by computer reconstruction of x-ray transmission data taken at different angles and planes.
224035337|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block using 2% lidocaine|Sphenopalatine ganlion block with 2ml of 2% lidocaine and 0.5ml of diluted adrenaline after general anesthesia in patients undergoing enoscopic hypophysectomy.
224035338|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganlion block with will receive 2ml of 4% prilocaine and 0.5ml saline after general anesthesia in patients undergoing enoscopic hypophysectomy.
224035339|NCT07188987|PROCEDURE|Sphenopalatine Ganglion Block|Sphenopalatine ganlion block with will receive 2ml of 4% prilocaine in addition to 0.5ml of diluted adrenaline. after general anesthesia in patients undergoing enoscopic hypophysectomy.
224035340|NCT07187856|DRUG|PG-102|PG-102 is administered subcutaneously once weekly with a titration regimen.
224035341|NCT07187856|DRUG|Placebo|Placebo is administered subcutaneously once weekly.
224035342|NCT07187856|DRUG|Semaglutide|Open-label semaglutide is administered subcutaneously once weekly with titration regimen.
223420619|NCT03821714|DRUG|Glucocorticoid|The glucocorticoid group was defined as the use of hydrocortisone alone.
223420620|NCT03669055|OTHER|Magnetic Resonance Imaging|Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
223739603|NCT04931498|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
223739604|NCT04931498|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
224035343|NCT07187687|PROCEDURE|Early Minimally Invasive Surgery with Thrombolysis (eMIST)|Subjects will undergo minimally invasive catheter evacuation in the early stage of intracranial hemorrhage. Up to 10 doses of 50000U of urokinase will be administered through the catheter that was placed directly into the intracerebral hemorrhage.
224035344|NCT06120881|DRUG|Metformin|Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
224035345|NCT02316314|PROCEDURE|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
224035346|NCT02316314|PROCEDURE|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
224035347|NCT02316314|PROCEDURE|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
224035348|NCT02316314|PROCEDURE|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
224035349|NCT05668338|DEVICE|Implantable or non-implantable MED-EL hearing solution|Receipt of an implantable or non-implantable MED-EL hearing solution
224035350|NCT06243458|DRUG|RVU120 (SEL120)|RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
224035351|NCT05333458|BIOLOGICAL|Atezolizumab|Given IV
224035352|NCT05333458|PROCEDURE|Biopsy Procedure|Undergo biopsy
223420621|NCT05286255|BIOLOGICAL|Allogeneic Mesenchymal Stromal Cells|Intravenous MSCs 1.2-1.5 x 10\^6 cells/kg on Days 1 and 3 after study enrollment
223420622|NCT05131464|DRUG|CM310|CM310, 300 mg/2 mL, SC, every 2 weeks
223420623|NCT03453879|OTHER|no intervention|No intervention - only observation of teams delivering acute obstetric care
223420624|NCT01489254|DRUG|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
223420625|NCT01489254|DRUG|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
223420626|NCT01489254|DRUG|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
223420627|NCT04073433|DRUG|Midomafetamine HCl|120 mg midomafetamine HCl
223420628|NCT04073433|BEHAVIORAL|Therapy|Non-directive therapy conducted during MDMA-assisted therapy session
223420629|NCT00078975|DRUG|gemcitabine hydrochloride|
224035353|NCT05333458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224035354|NCT05333458|PROCEDURE|Computed Tomography|Undergo CT
223420630|NCT00078975|DRUG|triapine|
223420631|NCT05950737|PROCEDURE|Sentinel node biopsy|All patients have undergone completion neck dissection following SNB in the process of standardization.
223420632|NCT03149133|OTHER|Heavy hypertrophy training|Training with 75-80 % of 1-RM
223420633|NCT03149133|OTHER|Light hypertrophy training|Training with 35-50 % of 1-RM
224035355|NCT05333458|PROCEDURE|Echocardiography Test|Undergo ECHO
224035356|NCT05333458|DRUG|Selinexor|Given PO
224035357|NCT05847426|OTHER|Provision of standard audiological + fNIRS test results|Infants with hearing loss will be tested using functional near-infrared spectroscopy (fNIRS) and a patented analysis algorithm to measure sound detection and discrimination. Their standard audiological test results will also be collected from their audiology service provider/s. Both sets of test results will be given to the participating audiologists in the experimental arm.
224035358|NCT05847426|OTHER|Provision of standard audiological test results only|The provision of test results to the audiologist will be the same as in the experimental arm, but without the fNIRS test results included.
224035359|NCT06101329|DRUG|Lenacapavir Tablet|Tablets administered orally without regard of food
224035360|NCT06101329|DRUG|Lenacapavir Injection|Injection administered subcutaneously
224035361|NCT06101329|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)|200/300mg fixed dose combination (FDC) tablets administered orally
224035362|NCT05594563|DRUG|DFMO|DFMO orally twice a day
224035363|NCT05594563|DRUG|Placebo|Placebo orally twice a day
223420634|NCT06684756|PROCEDURE|Retrograde intrarenal surgery|Flexible optic devices and lasers fragment kidney stones during this operation. In this surgery, an ureteral access sheath is recommended to be used.
223739605|NCT04931498|PROCEDURE|Venepuncture (GMPR)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key erythroid markers~* Proteomic analysis of isolated erythrocytes using mass spectrometry"
224035364|NCT03971422|DRUG|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
224035365|NCT03971422|OTHER|Placebo|Subjects will receive placebo at pre-specified time points.
224035366|NCT04596384|OTHER|Best Practice|Participate in a surgeon-only perioperative care program
223420635|NCT06229288|DRUG|Amoxicillin|"Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily).~Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)"
223420636|NCT06229288|DRUG|Amoxicillin/clavulanate|"Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections.~Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)"
223420637|NCT03199807|BIOLOGICAL|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5\~1 x 10\^10, will be i.v.Q3 weeks for total 4-6 doses.
223420638|NCT03199807|RADIATION|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F \* 10F
223420639|NCT04199078|DEVICE|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a singledose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
223420640|NCT02968693|DEVICE|antibiotic-loaded calcium sulfate|To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
224035367|NCT04596384|PROCEDURE|Functional Assessment|Complete a functional assessment
224035368|NCT04596384|OTHER|Medical Device Usage and Evaluation|Wear an actigraph
224035369|NCT04596384|PROCEDURE|Nutritional Assessment|Complete a nutritional assessment
224035370|NCT04596384|OTHER|Quality-of-Life Assessment|Ancillary studies
224035371|NCT04596384|OTHER|Questionnaire Administration|Ancillary studies
224035372|NCT04596384|OTHER|TapCloud|Use TapCloud app
224035373|NCT05934786|BEHAVIORAL|Cognitive rehabilitation|Six individual one-hour therapy sessions with certified psychologists followed by two group sessions (a total of two months per patient). The intervention will consist of all parts of the Strategies-Outsourcing-Social support toolbox (Baxendale, 2020) and include psychoeducation, lifestyle issues, coping strategies and homework.
224035374|NCT06188481|OTHER|whole-body electromyostimulation training|The duration of the intervention is 16 weeks, the training frequency is 1.5 times a week and the exercise program consists of 20 minutes.
223420641|NCT02968693|DEVICE|antibiotic-loaded polymethyl methacrylate|One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
223420642|NCT02968693|DRUG|Vancomycin|Vancomycin powder was added into the combination therapy group and PMMA groups
223420643|NCT01975571|DEVICE|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
223420644|NCT01975571|DEVICE|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
223420645|NCT04486053|OTHER|Screening|The patients who agreed to participate to the study were assessed with a survey which included age, gender, height, weight and hand dominancy questions. Sensory, motor and functional assessments of the bilateral hand were performed.
223562609|NCT07033260|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive ultrasonographic measurement of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
223562610|NCT07033715|OTHER|Exercise|"The exercise sessions will have a frequency of 3 times a week and a duration of 60 minutes per session. Exercise intensity will be gradually increased throughout the program and will be monitored every session using Borg's Rated Perceived Exertion scale, aiming at levels of 12-13 (fairly light to somewhat hard). The program will be mainly composed of cardiorespiratory exercises and resistance exercises. It will also comprise flexibility exercises to improve joint range of motion and neuromotor exercises involving motor skills (balance, agility, coordination, gait...), proprioceptive training and multifaceted activities (tai ji, yoga...)."
223420646|NCT00952796|DRUG|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
223562611|NCT07034807|DRUG|the traditional Chinese medicine prescription ' Shenzhuo Decoction '|The traditional Chinese medicine prescription ' Shenzhuo Decoction ' is composed of Astragalus membranaceus, Salvia miltiorrhiza, Leech, Raw Rhubarb, Epimedium, Motherwort. It is a traditional Chinese medicine prescription for the treatment of diabetic kidney disease, which was founded by Tong Xiaolin, an academician of the Chinese Academy of Sciences.
223562612|NCT07034807|COMBINATION_PRODUCT|basic treatment|Basic treatment includes six aspects : nutrition, lifestyle, hypoglycemic, hypotensive, lipid-lowering, and control of other risk factors, which are implemented in accordance with clinical standard treatment specifications.
223562613|NCT07033611|DIETARY_SUPPLEMENT|Creatine|Five grams of creatine were administered to each patient daily for eight weeks.
223562614|NCT07033039|DEVICE|Photobiomodulation|The photobiomodulation device used in this study will be the ECCO Reability (Ecco Fibras, Campinas, SP, Brazil), which is approved for clinical use by the Brazilian Health Regulatory Agency (ANVISA) under registration number 80323310001. The equipment is also certified by INMETRO, ensuring adherence to nationally established safety and performance standards.
223562615|NCT07033039|OTHER|Simulation of Photobiomodulation|In the sham group, the photobiomodulation procedure will be simulated with the device turned off. To preserve blinding, the equipment will be positioned as in the active treatment and its operational sound will be reproduced during the simulation, ensuring that the intervention remains indistinguishable from the actual PBM application.
223562616|NCT07033039|PROCEDURE|Standard treatment protocol|Participants in the control group will receive the standard medical protocol. No medication will be given preoperatively. Intraoperatively, dexamethasone 4 mg and tranexamic acid 1 g will be administered IV. Postoperative hospital care will include hydrocortisone 200 mg IV, tranexamic acid 250 mg IV, dipyrone 1 g IV, and cefazolin 1 g IV every 8 hours, plus ketorolac 10 mg sublingual as needed. At home, patients will take cefuroxime axetil 500 mg orally every 12 hours for 10 days, prednisolone 40 mg orally in the morning for 3 days, and dipyrone 1 g orally as needed. They will also apply a fibrinolysin and chloramphenicol ointment twice daily for 30 days and perform nasal irrigation with 0.9% sodium chloride six times daily for 60 days.
223562617|NCT07034781|DRUG|Comparator 1|Dapagliflozin 10mg + Linagliptin 5mg
223562618|NCT07034781|DRUG|Comparator 2|Metformin 1000mg
223562619|NCT07034781|DRUG|Test Drug|Fixed-dose combination tablet (AJU-A53)
223562620|NCT07033819|DRUG|Neoadjuvant therapy with fluazoparib in combination with apatinib|"Neoadjuvant Treatment Period Furazopanib: 150 mg, twice daily, orally, either before or after meals. It is recommended to take it within 0.5 hours after breakfast and dinner. Continuous administration for 3 weeks constitutes one cycle, for a total of three cycles.~Apatinib: 250 mg, once daily, orally, recommended to be taken within 0.5 hours after breakfast. Continuous administration for 3 weeks constitutes one cycle, for a total of three cycles."
223562621|NCT07033819|PROCEDURE|Preoperative Period|Discontinue Furazopanib 7 days before surgery. Discontinue Apatinib 14 days before surgery. The specific timing will be assessed by the investigator based on postoperative wound healing.
223562622|NCT07033819|DRUG|Chemotherapy|Postoperative Adjuvant Chemotherapy Period (≥4 cycles) Paclitaxel: 150-175 mg/m², intravenous infusion, every 3 weeks (Q3W). Carboplatin: AUC 4-5, intravenous infusion, every 3 weeks (Q3W).
224035375|NCT06188481|OTHER|activity tracker|Participants wear the activity tracker on their wrist for the entire 16-week study period.
223420647|NCT00952796|DRUG|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
223420648|NCT03722758|DEVICE|Spectrum TPH3|tooth restoration with two different restorative materials
223420649|NCT03722758|DEVICE|Riva LC|tooth restoration with two different restorative materials
223420650|NCT06622902|OTHER|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours|change flow from 6 to 2 LPM. Follow TcCO2 for 3 hours
223420651|NCT06622902|OTHER|change flow from 2 to 6 LPM. Follow TcCO2 for 3h|change flow from 2 to 6 LPM. Follow TcCO2 for 3h
223420652|NCT04079413|DRUG|GP40071|GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
223420653|NCT04079413|DRUG|NovoRapid® Penfill®|NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
223420654|NCT03805984|DRUG|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
223420655|NCT03805984|DRUG|Placebo|Placebo will be administered ID on Day 0 and Week 4.
223420656|NCT03805984|DEVICE|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
223420657|NCT02196688|DRUG|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
223420658|NCT02196688|DRUG|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
223420659|NCT03024203|BEHAVIORAL|Cognitive Remediation - Executive Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
223420660|NCT03024203|BEHAVIORAL|Cognitive Remediation - Perceptual Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
223420661|NCT02877810|OTHER|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
223420662|NCT02877810|OTHER|Telephone|Consultations will be given over telephone.
223420663|NCT00737295|PROCEDURE|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
223420664|NCT06051838|PROCEDURE|surgery|if the patients is TD positive, we recommond careful surgery and pathological examination.
223420665|NCT06411535|BEHAVIORAL|Full-mouth ultrasonic debridement plus Nutritional counseling|After diagnosis of gingivitis, patients will receive a nutritional counseling focused on ultra-processed foods entails educating individuals about the nutritional content and potential health implications of highly processed food products. They will undergo a session of full-mouth ultrasonic debridement and reinforcment of dietary counseling. Between consecutive time points, patients will receive motivational emails.
223420666|NCT06411535|OTHER|Full-mouth ultrasonic debridement|After diagnosis of gingivitis, patients will receive a session of full mouth ultrasonic debridement
223562623|NCT07033819|DRUG|Maintenance treatment|"Maintenance Treatment Period Furazopanib: 150 mg, twice daily, orally. Continuous administration for 3 weeks constitutes one cycle.~Apatinib: 250 mg, once daily, orally. Continuous administration for 3 weeks constitutes one cycle.~Treatment will continue until disease progression, intolerable toxicity, or other reasons as specified in the protocol."
224035376|NCT06188481|OTHER|evidence-based lifestyle education program|Participants receive an evidence-based lifestyle education programme (6 x 20 minutes for the period of 3 month).
223420667|NCT04158895|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
223420668|NCT05177536|DRUG|Iberdomide|Iberdomide is a novel potent cereblon E3 ligase modulator
223420669|NCT01858116|DRUG|[68Ga]ABY-025|Intravenous injection followed by PET imaging
223420670|NCT06246123|OTHER|Non-interventional|No intervention will be administered.
223420671|NCT01524939|DRUG|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
223420672|NCT00589134|DIETARY_SUPPLEMENT|Gatorade Endurance Formula|carbohydrate electrolyte beverage
223420673|NCT00589134|OTHER|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
223420674|NCT06069349|OTHER|Early Rehabilitation|Early Rehabilitation for patients after cardiac surgery
223420675|NCT06069349|OTHER|usual treatment|Patients are not allowed to exercise Early Rehabilitation
224298781|NCT00109759|BIOLOGICAL|RagweedMATAMPL|
224298782|NCT00109759|DRUG|Placebo|
223420676|NCT00611949|OTHER|Geranium oil|2 applications of topical oil per week for 2 weeks
223420677|NCT06038344|BEHAVIORAL|Gluten-free food guide teaching|Teaching the gluten-free food guide will be done over Zoom within 1-2 weeks of the dietitian's standard of care teaching (group Zoom session). This teaching will take 30-45 minutes and will be conducted by a trained researcher. The investigators will use the gluten-free food guide as teaching materials with a focus on the GF plate model, the rationale for the GF plate model, nutritional consideration of gluten-free diet and content related to the additional 24 teaching materials (e.g. folate, fibre, eating out, school lunches etc.) contained within the guide. Individualized dietary suggestions based on participants' food records will also be provided.
223420678|NCT06967870|OTHER|Osteopathic intervention|"Researcher will use osteopathic techniques on cranial area includes light touch.~Home based exercises will be show on cases and demand to do exercise regularly"
224298783|NCT00851643|BIOLOGICAL|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
224298784|NCT00851643|BIOLOGICAL|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
223420679|NCT06967870|OTHER|Home based exercise education|Home based exercises will be show on cases and demand to do exercise regularly.
223420680|NCT00737204|DRUG|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
223420681|NCT00737204|DRUG|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
223420682|NCT06457412|OTHER|Intervention group for the treatment of childhood obesity|Intervention for children aged 6 to 12 years with childhood obesity (with a BMI greater than the 99th percentile), fostering motivation and encouraging changes toward healthy lifestyle habits to achieve greater adherence and to improve health. The program comprises 9 educational sessions designed by specialized professionals (code of Spanish register: 2007144741729) to be conducted in a health center. The sessions will be held every 15 days, with a duration of 90 minutes for a group of 10 children and another group of 10 family members and/or caregivers. Professionals from different disciplines (paediatricians, psychologists, nurses and nutritionists), will meet with groups of pediatric patients and in another group with their family members or primary caregivers.
223562624|NCT07034222|DRUG|Administer Leqemi 10 mg/kg, every two weeks.|Receive 10 mg/kg of Leqembi once every two weeks. Dissolve Leqembi in normal saline and administer it intravenously over 60 minutes. The infusion system must use a 0.2-μM terminal line filter for administration.
223562625|NCT07033741|BEHAVIORAL|EMDR|The EMDR process follows an eight-phase protocol that includes (1) history taking: gathering patient's background information and planning treatment, (2) preparation: preparing the patient for processing target, (3) assessment: accessing target of the traumatic memories, (4) desensitization: processing target memories using dual task , (5) installation: strengthening the alternative positive cognition, (6) body scan: noting any physical sensations related to the target memory, (7) closure: ensuring patient's stability at the end of the session, and (8) revaluation: assessing effectiveness of the session and future planning.
223562626|NCT06829849|DIAGNOSTIC_TEST|Landing error assessment during a SHD task using the SHD-LESS scale|Participants will perform a 2D-camera-recorded SHD task, with the SHD-LESS scored by two sports medicine physicians. Additional tests include isokinetic muscle testing, as well as functional and psychological status assessments, following standard clinical practice.
223562627|NCT07033273|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive measurement of Inferior Vena Cava Collapsibility Index (IVCCI) using ultrasound and routine blood pressure monitoring before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
223562628|NCT07033637|OTHER|Dietary Supplement|A daily oral capsule containing 1 x 10⁹ CFU of Lactiplantibacillus plantarum CECT 7481 (32.5 mg), microcrystalline cellulose (304.1 mg), and magnesium stearate (3.4 mg). Administered once daily before the main meal for 6 weeks. Used to evaluate its effects on gut microbiota and physical health in older adults.
223562629|NCT07033637|OTHER|Placebo|A daily oral capsule identical in appearance to the probiotic capsule, containing maltodextrin instead of Lactiplantibacillus plantarum. Administered once daily before the main meal for 6 weeks. Used to control for placebo effects in the assessment of probiotic efficacy.
223739606|NCT04931498|PROCEDURE|Venepuncture (SWAP70)|"A blood sample of approximately 50 ml of venous blood will be taken. From the obtained blood sample, measurements will include a full blood count and the following phenotyping tests:~* Flow cytometry to quantify cell surface expression of key markers~* Fluorescence-Activated Cell Sorting (FACS) to assess B-cell receptor signalling and to isolate cell type-specific RNA for transcriptome analysis~* Immunoglobulin isotype titre analysis in plasma~* Isolation of monocytes for subsequent use in phagocytosis assays"
224035377|NCT05684068|PROCEDURE|Gum Graft Placed on Denuded Bone|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will remove all of the subject's tissue, so that the bone is fully exposed before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
224035378|NCT05684068|PROCEDURE|Gum Graft Placed on Split Thickness Periosteal Bed Preparation|The provider will administer local anesthesia into the subject's gum in order to numb both the subject's donor and recipient areas for gum grafts. Next, the provider will use a surgical blade to dissect the gum graft from the subject's donor site. At the subject's recipient gum recession defect site, the provider will dissect some of the tissue at the subject's recipient site but still keep a small layer of tissue at the subject's recipient site before placing a gum graft from the donor site. Afterward, the provider will place sutures in the subject's recipient site in order to promote healing/re-growth.
223420683|NCT04975750|BEHAVIORAL|Problem solving intervention|The intervention focuses on the individual employee and his/her work situation and work-private life balance. The following steps are implemented: inventory and prioritization of problems; brainstorming options and solutions; formulation of an action plan; evaluation, and follow-up. The intervention is carried out in about 3 planned meetings (30 - 45 min) between the manager and the employee. However, given the lack of research regarding the intervention delivered to this specific population and which dose that should be considered as beneficial as well as the complexities of the identified problems, the number of meetings is not specified
223420684|NCT04975750|BEHAVIORAL|Care as usual|The managers and the employee have meetings regarding the employee and his/her work situation and work-private life balance. However, the managers are not educated in and do not use the problem solving intervention. They are instead instructed to use their usual procedures.
223420685|NCT02470065|DRUG|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
223420686|NCT02470065|PROCEDURE|Immediate surgery|anatomical resection and systematic lymph node dissection
223420687|NCT03476408|OTHER|Correlation / Observational|correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
223420688|NCT06666881|OTHER|HIIT only|After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times a week and total 24-36 times.
224035379|NCT04751656|BEHAVIORAL|Steady Intervention|"Participants will be asked to weigh themselves daily via a smart scale that transmits weight data directly to the study team via the cellular network for 12 months. Every-other week, participants will be sent text messages providing brief feedback encouraging continued self-weighing. Moreover, if a small weight gain is observed, participants will be sent text messages aiming to engage them in commercial or community-based evidence-based weight management resources."
223562630|NCT07033637|BEHAVIORAL|Structured Physical Activity Program|A 12-week supervised physical activity program conducted at municipal sports centers. Participants engage in moderate-intensity exercise at least 2 times per week. Designed to assess the impact of physical activity on gut microbiota, physical condition, and quality of life in older adults.
224035380|NCT04244487|PROCEDURE|laparoscopic splenectomy and azygoportal disconnection with intraoperative endoscopic variceal ligation|"The modified procedure was implemented in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, divide the left lateral surface of the distal esophagus; (3) divide the posterior surface of the distal esophagus; (4) divide the anterior surface of the distal esophagus; (5) divide the lesser omental sac via the bottom right crural diaphragm; (6) transect en bloc the left gastric artery and vein and posterior gastric veins using a linear laparoscopic vascular stapler; (7) find the right crural diaphragm by dividing a small portion of the hepatogastric ligament at the left lateral esophagogastric junction; and (8) via the surface of the right crural diaphragm, divide the right lateral surface of the distal esophagus.~After the procedure of laparoscopic azygoportal disconnection, intraoperative endoscopic variceal ligation was made if the diameter of the esophageal varices was \>5 mm."
224035381|NCT04960423|PROCEDURE|Long Segment Fixation and Fusion|Long Segment Fixation and Fusion
224035382|NCT03566810|DRUG|Test GXR|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
223420689|NCT06666881|OTHER|HIIT & Record of physical activities at home.|After CCRT treatment 4-5 week, arrange participants do the HIIT exercise for two to three times in a week and total 24-36 times. And do the recording of physical activities at home.
223420690|NCT05192590|OTHER|Educational Materials and Chronic Disease Management Test (CDMT)|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the CDMT technology. These materials are comprised of a PowerPoint presentation.~Intervention 1 participants only will receive the CDMT test results whether they select it or not, and Intervention 2 participants will receive the CDMT test results only if they select it during the second round of case simulations."
224035383|NCT03566810|DRUG|Reference GXR|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
224035384|NCT04694508|DEVICE|Headphones (Disok, Alicante, España)|A pair of non-reusable headphones (Disok, Alicante, Spain)
223420691|NCT06969326|DRUG|Use of topical estradiol|The investigators will conduct a double blinded randomized control pilot trial. Participants will be randomized in 1:1 fashion to either receive no treatment or receive 2g of estradiol cream, placed after clearing the vaginal vault of any blood and discharge, at the conclusion of the surgery.
223420692|NCT06969326|OTHER|No intervention|This arm will not receive estradiol or other cream
223420693|NCT04662866|DRUG|Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg|Comparison of 4 different antihyperglycemic drugs
223420694|NCT06487221|DRUG|Avutometinib|3.2mg orally
223420695|NCT06487221|DRUG|Defactinib|200 mg orally
223420696|NCT00003779|BIOLOGICAL|Connaught|Compare two strains of BCG
223420697|NCT00003779|BIOLOGICAL|Tice|Compare two strains of BCG
223420698|NCT06052423|DRUG|HS-20093|HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
223420699|NCT02251145|DRUG|Tipranavir low dose|
224035385|NCT00164125|DRUG|polyethyleneglycol3350|
224035386|NCT04631627|DRUG|Aspirin|With the result of risk assessment for high risk and the risk of pregnant women, with each research center stratified random aspirin drug intervention, for each center screening high-risk and accord with the standard drug intervention study phase into eliminate pregnant women by using stochastic indicator 1:1 randomly into low-dose aspirin to prevent group and observation group, for each center in screening for risk and comply with the drug intervention study phase into the exclusion standard 1:1 by random indicator method pregnant women randomly into low-dose aspirin to prevent group and observation group.
224035387|NCT01475604|DEVICE|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
224035388|NCT01475604|DEVICE|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
224035389|NCT01062048|DRUG|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
224035390|NCT01062048|DRUG|Sulfonylurea|Sulfonylurea administered in general use according to the local label
224035391|NCT01062048|BIOLOGICAL|Insulin|Insulin administered in general use according to the local label
223420700|NCT02251145|DRUG|Tipranavir high dose|
223420701|NCT02251145|DRUG|Ritonavir low dose|
223420702|NCT02251145|DRUG|Ritonavir high dose|
223739607|NCT06168409|DRUG|Baxdrostat|"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~• 2 mg per tablet."
223739608|NCT06168409|DRUG|Placebo|Placebo tablet matching baxdrostat, administered orally, once daily (QD).
223739609|NCT04095676|PROCEDURE|VATS group|VATS procedure with drainage, including rinse with NaCl
223739610|NCT04095676|PROCEDURE|Drain and intrapleural therapy group|Drainage with pigtail and Intrapleural therapy
223420703|NCT02251145|DRUG|Tenofovir disoproxil fumarate|
223420704|NCT01542437|DRUG|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."
223420705|NCT00281632|DRUG|GW786034|800 mg GW786034 administered orally on a daily basis.
223420706|NCT05827042|DRUG|Intravenous thrombolysis|Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.
223420707|NCT05827042|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy
223420708|NCT04510506|DEVICE|Artificial Pancreas (AP)|The AP system used in this trial is the Tandem t:slim insulin pump with Control-IQ Technology. This system is FDA approved for use starting at age 14 years.
223420709|NCT05728606|PROCEDURE|Robot-assisted D2 distal gastrectomy|Robot-assisted D2 distal gastrectomy after 3-Cycle SOX neoadjuvant chemotherapy
223420710|NCT06307756|OTHER|Music group|"Mothers will be informed about the application before the procedure. Mothers who agree to participate in the study will be asked to listen to music that relaxes them for 20 minutes a day for 4 days. The mothers' state anxiety levels and milk quantities will be evaluated before starting the application and every day during the application. Mothers' anxiety levels will be evaluated with the State Anxiety Inventory. Mothers' anxiety levels and milk quantities will be evaluated every day at 11.45 when they come to the NICU to express milk."
223420711|NCT04861285|DEVICE|RACESTYPTINE Solution with cord|The dentist inserts a non-medicated gingival retraction cord into the sulcus and then impregnates the cord in situ with a few drops of RACESTYPTINE Solution. The impregnated cord is left in place a few minutes and then removed. The gingival sulcus is washed and gently air-dried before taking impression.
223420712|NCT04861285|DEVICE|RACEGEL with cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth, and then inserts a non-medicated gingival retraction cord into the sulcus. The impregnated cord is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
223420713|NCT04861285|DEVICE|RACEGEL without cord|The dentist applies a sufficient amount of RACEGEL directly into the sulcus, following the contour of the prepared tooth. The gel is left in place a few minutes and then removed. The sulcus is washed and gently air-dried before taking impression.
224035392|NCT00955487|DRUG|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
224035393|NCT00955487|DRUG|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
224035394|NCT01686854|BEHAVIORAL|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
223420714|NCT03996356|OTHER|No study intervention - observational study|This is an observational study where the comparative groups will be determined by the genetic variants (SNPs) of subjects and not an intervention, per se.
223420715|NCT03990571|DRUG|Avelumab|Given IV
223420716|NCT03990571|DRUG|Axitinib|Given PO
223420717|NCT03432793|DRUG|TD-9855|oral tablet, QD
223420718|NCT03432793|DRUG|Fluvoxamine|oral tablet, QD
223420719|NCT03432793|DRUG|Itraconazole|oral tablet solution, QD
223420720|NCT03432793|DRUG|Caffeine|oral solution, single dose
223420721|NCT03562611|DRUG|Nalbuphine|Nalbuphine administration during surgery
223420722|NCT03562611|DRUG|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
223420723|NCT03562611|DRUG|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
223420724|NCT05657197|BEHAVIORAL|Exercise intervention|A 12-week exercise program consisting of three times per week 1-hour sessions, including 30-minutes aerobic- and 30-minutes progressive resistance training. The intensity of training will be adjusted to each individual, based on a cardiopulmonary exercise test. Training sessions will be performed in groups of 10 participants under supervision of a sports physical therapist.
223420725|NCT05657197|OTHER|Usual care|Usual care, including general advice concerning chronic fatigue.
223420726|NCT01945970|OTHER|Black tea extract|Black tea extract
223420727|NCT01945970|OTHER|Positive control|Positive control
223420728|NCT01945970|OTHER|Placebo|Placebo
223420729|NCT03830684|DRUG|Baicalein Tablets 400mg|4 Baicalein Tablets and 2 placebo per time, three times a day
223420730|NCT03830684|DRUG|Baicalein Tablets 600mg|6 Baicalein Tablets per time, three times a day
223420731|NCT03830684|DRUG|blank control 0mg|6 placebo per time, three times a day
223420732|NCT02587585|BEHAVIORAL|Feedback against tailored target|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
223420733|NCT02587585|BEHAVIORAL|No feedback|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
223420734|NCT04850261|DRUG|hCG Injection|Ovulation will be induced by subcutaneous hCG injection
223420735|NCT04850261|DRUG|Nafarelin nasal spray|Ovulation will be induced by nasal application of Nafarelin
223739611|NCT06361537|DRUG|OCTA-C1-INH|OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
223420736|NCT00782184|DRUG|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
223420737|NCT00782184|DRUG|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
223420738|NCT00782184|DRUG|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
223420739|NCT00447031|DRUG|intravitreal bevacizumab and triamcinolone acetonide|
223420740|NCT02406079|PROCEDURE|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
223420741|NCT01173731|DRUG|AFQ056|
223739612|NCT06361537|OTHER|Placebo|0.1 mL/kg BW 0.9% sodium chloride injection
223739613|NCT06370780|OTHER|EPI LOVE|Observational cohort only
224035395|NCT01686854|OTHER|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
224298785|NCT00851643|BIOLOGICAL|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
224298786|NCT00851643|BIOLOGICAL|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
223420742|NCT04216693|DRUG|Digoxin tablet|The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.
223420743|NCT04216693|OTHER|Placebo|The control group will receive the digoxin-like placebo treatment.
223420744|NCT03614078|DRUG|PRCL-02|Oral tablets
223420745|NCT03614078|DRUG|Placebo|Oral tablets
223420746|NCT02894125|OTHER|SPA Therapy|
223420747|NCT00260312|BIOLOGICAL|Inactivated Polio Vaccine given at an accelerated schedule|
223420748|NCT01369108|DEVICE|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
223420749|NCT01369108|DEVICE|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
223420750|NCT00399412|DEVICE|subcutaneous ICD|
223420751|NCT05150808|OTHER|IRS insecticide: Vectron T500|public health insecticide
223420752|NCT04335981|DEVICE|FT-CC and Swallow Exercises|Once daily treatment with FT Plus with investigational connectivity software and standard of care swallow exercises.
223420753|NCT04335981|OTHER|Swallow Exercises|Standard of care swallow exercises.
224035396|NCT03786250|PROCEDURE|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
224035397|NCT04158635|DRUG|Bosentan|Given PO
224298787|NCT00851643|BIOLOGICAL|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
224298788|NCT01681966|DRUG|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
224298789|NCT06088849|PROCEDURE|Venipuncture|The lactating mother will be asked to collect milk samples and donate 2 blood samples, which is not a part of their normal follow-up/treatment. We will also aks the parents if we can collect a blood sample fo the infant (0-6 months).
223420754|NCT06648538|DEVICE|Phonix Care|Phonix Care consists of a 5-month digital therapeutic program that encourages the user to engage in non-digital activities through pre-defined screen rules and off-screen challenges validated by smartphone sensors.
223420755|NCT04090138|DIETARY_SUPPLEMENT|Setria performance blend|Oral capsules
223420756|NCT04090138|DIETARY_SUPPLEMENT|Placebo|Oral capsules
223420757|NCT00295035|DRUG|CELECOXIB|
223420758|NCT00295035|DRUG|CURCUMIN|
223420759|NCT04282317|OTHER|MRI scan|MRI scan
223562631|NCT06722989|BEHAVIORAL|mobile-guided exercise|"Exercises for pregnant women in the SG will fall into moderate physical activity. They will be previously assessed by a perinatologist with a license to guide exercise during pregnancy. Each exercise will last 30 minutes, including initial warm-up exercises and final stretching exercises.~The recommended moderate activity for pregnant women is at least 150 minutes per week, achieved on at least three days. For pregnant women aged 29 years or less, this means within the limits of a heart rate of 125 to 146 beats/min. For pregnant women aged 30 years or more, it is within the limits of a heart rate of between 121 and 141 beats per minute. According to the Borg scale of perceived exertion from six to 20, moderate exercise is rated between 13 and 14, corresponding to the specified heart rate thresholds. The pregnant woman will rate her exercise on the Borg perceived exertion scale from six to 20. The recommended number of steps per day will be at least 6,000."
223562632|NCT06722989|BEHAVIORAL|Unguided physical activity|In this group, pregnant women will be physically active at their discretion.
223420760|NCT05929196|DIAGNOSTIC_TEST|In vitro full blood diagnostic test.|Participant will donate approximately 5 ml blood sample. Later in a laboratory the sample will be processed in the microwave metamaterial sensor for non invasive blood glucose monitoring and standard biochemical analyzer. Specific dielectric properties and scattering parameters will be measured for blood glucose level determination.
223420761|NCT00370318|BIOLOGICAL|10 valent pneumococcal conjugate vaccine|
223420762|NCT00370318|BIOLOGICAL|Infanrix Hexa|
223420763|NCT00370318|BIOLOGICAL|Rotarix|
223420764|NCT00370318|DRUG|Paracetamol|
223420765|NCT04748458|DEVICE|Conical tapered stem|Implantation of conical tapered stem
223420766|NCT02698202|DEVICE|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
223420767|NCT04894149|OTHER|Physiotherapy|Supervised physiotherapy one hour twice weekly and 20 minutes three times weekly during 14- 17 weeks before surgery during neoadjuvant chemotherapy or chemoradiotherapy and during eight weeks after surgery (sometimes during adjuvant chemotherapy)
223420768|NCT06624306|PROCEDURE|Prone PNL|Prone PNL
223420769|NCT06624306|PROCEDURE|Prone-flexed PNL|Prone-flexed PNL
223420770|NCT04143594|DRUG|Oral Lenacapavir|Tablets administered without regard to food
223420771|NCT04143594|DRUG|F/TAF|Tablets administered without regard to food
223420772|NCT04143594|DRUG|Subcutaneous Lenacapavir|Administered in the abdomen via subcutaneous injections
223420773|NCT04143594|DRUG|TAF|Tablets administered without regard to food
223420774|NCT04143594|DRUG|BIC|Tablets administered without regard to food
223420775|NCT04143594|DRUG|B/F/TAF|Tablets administered without regard to food
223562633|NCT07034898|DRUG|Dexmedetomidine|Participants in this arm will receive dexmedetomidine at a dose of 0.5 mcg/kg, diluted with normal saline to a total volume of 50 mL. The solution will be administered intravenously via a syringe pump at an infusion rate of 300 mL/hour, completing over 10 minutes immediately prior to extubation.
224035398|NCT04158635|DRUG|Gemcitabine|Given IV
224035399|NCT04158635|DRUG|Nab-paclitaxel|Given IV
224035400|NCT04158635|OTHER|Quality-of-Life Assessment|Ancillary studies
224035401|NCT04158635|OTHER|Questionnaire Administration|Ancillary studies
224035402|NCT05223114|OTHER|Not applicable (N/A)|Not applicable to this study
224035403|NCT00509665|DRUG|doxorubicin hydrochloride|given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
224035404|NCT00509665|DRUG|gemcitabine hydrochloride|given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
224298790|NCT01019707|DRUG|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
223420776|NCT00940966|DIETARY_SUPPLEMENT|standard ADA diet|standard ADA diet
223420777|NCT00940966|DIETARY_SUPPLEMENT|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
223420778|NCT00940966|DIETARY_SUPPLEMENT|low glycemic diet|restricted ketogenic diet
223420779|NCT04711174|BEHAVIORAL|LMA removal|the timing when conducting LMA removal
224035405|NCT01969591|PROCEDURE|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
223420780|NCT01608243|BIOLOGICAL|SLIT tablets of house dust mite allergen extracts|10 dosing days
223420781|NCT01608243|BIOLOGICAL|Matching placebo|10 dosing days
223420782|NCT00746824|DRUG|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
223420783|NCT03228524|DRUG|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
223420784|NCT03228524|BEHAVIORAL|Therapeutic exercise|Standard physiotherapy
223420785|NCT03228524|DRUG|Placebo Oral Tablet|Placebo
223420786|NCT04178707|DEVICE|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
223420787|NCT01773161|PROCEDURE|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
223420788|NCT00306358|DRUG|Vitamin B12 (Cyanocobalamin)|
223420789|NCT00285116|PROCEDURE|Clinical examination and radiological evaluation|
223420790|NCT00000238|DRUG|Buprenorphine|
223420791|NCT01050010|OTHER|MRI|dedicated extremity MRI
223420792|NCT02078895|DRUG|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
223420793|NCT02140216|BIOLOGICAL|No blood transfusion|No blood transfusion
223420794|NCT02140216|BIOLOGICAL|Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
223420795|NCT02140216|BIOLOGICAL|Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
223420796|NCT04010903|DIAGNOSTIC_TEST|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
223420797|NCT06201975|OTHER|Thyme honey|Thyme honey will be delivered to the sites until overflows using a syringe with plastic catheter of cannula 20 g (B Braun) attached to it. Patients will be reviewed at 6 weeks to re-evaluate the clinical periodontal parameters
223739614|NCT00576134|DEVICE|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
223739615|NCT05594017|DRUG|Scopolamine (0.4mg)|Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.
223739616|NCT05594017|DRUG|Placebo|Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.
224035406|NCT01969591|OTHER|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
224035407|NCT00584168|DRUG|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
223420798|NCT04867993|DRUG|Amikacin|15 mg/kg/36h
223420799|NCT03706885|DRUG|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
223420800|NCT02199353|OTHER|Stimulation of Activities Daily Living|"Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
223420801|NCT02199353|OTHER|Conventional ADLOccupational Therapy|"Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
223420802|NCT06041308|OTHER|valve|bioprothetic valve versus mechanical valve
223420803|NCT04866628|DIETARY_SUPPLEMENT|Helichrysum italicum infusion|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum italicum infusion.
223420804|NCT04866628|DIETARY_SUPPLEMENT|Helichrysum arenarium|Comparison of metabolic syndrome components before and after four weeks of daily consumption of Helichrysum arenarium infusion.
224035408|NCT00584168|DRUG|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
224035409|NCT01955122|DEVICE|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
224035410|NCT00826111|DRUG|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
223420805|NCT06617221|BIOLOGICAL|Composite graft plug|after tooth extraction the socket was grafted with a composite graft plug
223420806|NCT06617221|BIOLOGICAL|Allograft|after tooth extraction the socket was grafted with allograft
223420807|NCT06614998|DRUG|Patients diagnosed with HLH-94 should be treated as soon as possible|For some highly suspicious patients, after diagnosis, according to the patient's etiology, the treatment plan should be determined as soon as possible, such as lymphoma-related patients treated with hormones combined with etoposide, which can greatly improve the prognosis of patients
223562634|NCT07034898|DRUG|Labetalol|Participants in this arm will receive labetalol at a dose of 0.5 mg/kg, diluted with normal saline to a total volume of 50 mL. The solution will be administered intravenously via a syringe pump at an infusion rate of 300 mL/hour, completing over 10 minutes immediately prior to extubation.
223562635|NCT07034417|OTHER|Exercise|Cognitive Exercise Therapy Approach
224035411|NCT00826111|DRUG|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
224035412|NCT01672788|DRUG|Empagliflozin|empagliflozin tablets and metformin tablet
224035413|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
224035414|NCT01672788|DRUG|Metformin|empagliflozin tablets and metformin tablet
224035415|NCT01672788|DRUG|Metformin|empagliflozin tablet and metformin tablet
224035416|NCT01672788|DRUG|Empagliflozin + Metformin|fixed dose combination tablet (low)
224035417|NCT01672788|DRUG|Empagliflozin|empagliflozin tablet and metformin tablet
224035418|NCT04229953|DEVICE|US scan with 3D/4D VRU software|"Every patient will be evaluated by grayscale 2D-ultrasound and color Doppler. Then, a Samsung WS 80A Elite US scanner with 3D/4D VRU software will be used to assess the placental invasion by applying the two modes (crystal vue and realistic vue). The image analysis will be performed after obtaining the volume dataset. Data will be compared with the intraoperative findings and histopathological confirmation if hysterectomy will be done."
224298791|NCT01019707|DRUG|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
224298792|NCT01078337|PROCEDURE|bone marrow aspiration|
224298793|NCT01078337|PROCEDURE|peripheral blood sampling|
223420808|NCT03415789|DIAGNOSTIC_TEST|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
223420809|NCT03415789|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
223420810|NCT03415789|DIAGNOSTIC_TEST|Brain Magnetic Resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
223420811|NCT03415789|DIAGNOSTIC_TEST|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
223420812|NCT04804267|DRUG|Linaclotide|Manufactured by Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug: Linaclotide 145μg orally once daily
223420813|NCT04804267|DRUG|LINZESS®|Manufactured by Almac Pharma Services Limited Drug: Linaclotide 145μg orally once daily
223420814|NCT04804267|DRUG|Placebo|Drug: Placebo orally once daily
223420815|NCT04007068|DIAGNOSTIC_TEST|FDG PET/CT|FDG PET/CT baseline, month 1, month 4, month 10, than every 6 months
223420816|NCT05051267|OTHER|Non-Pharmacological Methods|All of the applications that increase the effectiveness of drugs when used together with analgesics and provide the elimination of pain by releasing our body's natural morphine and endorphins without the use of analgesics are called non-pharmacological treatment.
223562636|NCT07034417|OTHER|Home exercise|Home exercise
223739617|NCT04607772|DRUG|Selinexor|Dose: 40 mg (2 tablets of 20 mg), 60 mg (3 tablets of 20 mg), 80 mg (4 tablets of 20 mg)
223739618|NCT04607772|DRUG|Rituximab|Dose: 375 mg/m\^2
223739619|NCT04607772|DRUG|Bendamustine|Dose: 90 mg/m\^2
224035419|NCT04219813|OTHER|Urinary test|Detection of the presence of gluten immunogenic peptides (GIP) in the urine of NCGS/NCWS patients, evaluated two times per week, for 5 weeks, and in the event of symptoms/signs that the patients attribute to the accidental intake of gluten, within the same 5 weeks.
224035420|NCT04699734|DIAGNOSTIC_TEST|Xylocaine 1%|Nerve block
224035421|NCT04699734|DIAGNOSTIC_TEST|NaCl 9mg/ml|Nerve block
224035422|NCT05765006|BIOLOGICAL|Relma-cel|CD19-targeted Chimeric AntigenReceptor (CAR) T Cells; Relma-cel be administrated at four dose level:25×106 CAR+ T cells、50×106 CAR+ T cells、100×106 CAR+ T cells/150×106 CAR+ T cells
224035423|NCT00261612|DRUG|bortezomib|
224035424|NCT00261612|DRUG|rituximab|
224035425|NCT00261612|DRUG|dexamethasone|
224035426|NCT00261612|PROCEDURE|treatment protocol|
224035427|NCT01099163|DIETARY_SUPPLEMENT|Tonalin SG1000T FFA|
224035428|NCT03874325|DRUG|Durvalumab|1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.
224035429|NCT03874325|DRUG|Anastrozole 1mg|Participants will self administer 1 mg anastrozole by mouth daily for 6 months.
224035430|NCT03874325|DRUG|Letrozole 2.5mg|Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.
224298794|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3|600 IU Vitamin D3 capsule daily
224298795|NCT00571285|DIETARY_SUPPLEMENT|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
223420817|NCT02289508|DEVICE|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
223420818|NCT02289508|DEVICE|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
223420819|NCT01909323|OTHER|maltitol 85% / FOS15%|
223420820|NCT01909323|OTHER|maltitol alone|
223420821|NCT01909323|OTHER|maltitol 68% / FOS 32%|
223420822|NCT01909323|OTHER|maltitol 50% / FOS 50%|
223562637|NCT06888258|PROCEDURE|Ultrasound guided Erector Spinae Plane block|"Group E: The block will be performed preoperatively with full aseptic precautions. The ultrasound probe will be placed on the back in a vertical orientation on the lateral side of the posterior median line to identify the transverse process of the 5th thoracic vertebra and erector spine muscle.~A skin wheal using 3ml of 1% lidocaine will be made 2 to 3 cm superior to the superior aspect of the transducer. The puncture will be performed using the intra-plane needling technique after local anaesthesia infiltration. A 20-gauge Tuohy needle connected to a syringe containing the anesthetic mixture or saline will be advanced. When the puncture needle touch the transverse process, with no blood, gas, or cerebrospinal fluid observed on aspiration, 20 mL of 0.25% bupivacaine will be administered between the erector spine muscle and transverse process.~Local anesthetic diffusion between the transverse process and erector spinae muscle is an indication of a successful puncture."
223739620|NCT04607772|DRUG|Polatuzumab Vedotin|Dose: 1.8 mg/kg
223739621|NCT04607772|DRUG|Ibrutinib|Dose: 420, 560 mg
224035431|NCT03874325|DRUG|Exemestane 25 MG|Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
224035432|NCT05149183|OTHER|cervical stability training|cervical stability training will be contain three phases, each phase has six positions ( supine, forearms, sidelying, four point kneeling, sitting and standing position)
224035433|NCT05149183|OTHER|traditional treatment|TENS, hot packs, stretching exercise of superficial neck muscles, and postural advice.
224035434|NCT06617494|OTHER|Pain modulation testing|During the visit, noxious heat stimuli will be applied bilaterally to the face and distant body sites as part of conditioned pain modulation (CPM) testing. The test stimuli will be individually tailored to be moderately painful, while the conditioning stimulus will vary in intensity: moderately painful, non-painful, and sham heat. Participants will also record daily TMD pain intensity ratings for seven days before and after the visit.
223739622|NCT04607772|DRUG|Lenalidomide|Dose: 20, 25 mg
223739623|NCT04607772|DRUG|Tafasitamab|Dose: 12 mg/kg
224035435|NCT01805596|DRUG|clopidogrel|
223739624|NCT04607772|DRUG|Venetoclax|Dose: 200, 400, 600, 800 mg
223739625|NCT04607772|DRUG|Gemcitabine|Dose: 1000 mg/m\^2
223739626|NCT04607772|DRUG|Oxaliplatin|Dose: 100 mg/m\^2
223739627|NCT05837897|DRUG|Vedolizumab IV|Vedolizumab IV infusion
224035436|NCT01805596|DRUG|Ticagrelor|
224035437|NCT05048953|DIAGNOSTIC_TEST|Muscle ultrasound measurements (the index test)|"The following parameters will be measured by muscle ultrasound~1. Muscle thickness~2. Muscle echogenicity~3. Muscle fasciculations"
224035438|NCT03511053|PROCEDURE|Epidural Steroid Injection with Lavage|All participants will receive a saline lavage prior to the epidural steroid injection.
224035439|NCT03985475|OTHER|skin sample|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
224035440|NCT02877563|OTHER|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
224298796|NCT00571285|DIETARY_SUPPLEMENT|Placebo|Placebo capsule given once a week
223420823|NCT01909323|OTHER|FOS alone|
223420824|NCT01909323|OTHER|Placebo|
223420825|NCT06643364|OTHER|Vision Training Program|Vision Training Programme: A training programme including exercises such as saccadic movements of the eye, spiral movements, converging-diverging exercises, peripheral walking was applied.
223420826|NCT06643364|OTHER|Routine Training Program|All athletes continued their routine training programmes planned by the national team coaches for karate sport during the training period.
223420827|NCT05956418|DRUG|Centhaquine|Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
223420828|NCT04125914|BEHAVIORAL|Behavioral Dietary Intervention|Record food intake
223420829|NCT04125914|OTHER|E-mail|Receive e-mails
223420830|NCT04125914|BEHAVIORAL|Exercise Intervention|Undergo exercise
223420831|NCT04125914|OTHER|Health Promotion and Education|Receive text messages
223420832|NCT04125914|OTHER|Internet-Based Intervention|Join Facebook page
223420833|NCT04125914|OTHER|Questionnaire Administration|Ancillary studies
223420834|NCT04125914|BEHAVIORAL|Telephone-Based Intervention|Receive telephone coaching
223420835|NCT01054196|DRUG|lenalidomide|daily dose dependent on dose-escalation schedule
223420836|NCT01054196|DRUG|melphalan|100 mg/m2 given Days -2 and -1
223739628|NCT05837897|DRUG|Placebo|Vedolizumab placebo-matching IV infusion
223739629|NCT05880927|DRUG|Pyrotinib|Patients receive pyrotinib 400mg/day for half or one year
223562638|NCT06888258|PROCEDURE|Ultrasound guided Mid-point to Pleura block|"Group M: The block will be performed preoperatively with full aseptic precautions. The ultrasound probe will be placed on the back in a vertical orientation on the lateral side of the posterior median line to identify the transverse processes of the 4th and 5th thoracic vertebrae and pleura.~A skin wheal using 3ml of 1% lidocaine will be made 2 to 3 cm superior to the superior aspect of the transducer. Using the in plane needling technique in the space between the transverse processes of the 4th and 5th thoracic vertebrae, the puncture needle needle tip will be placed at the mid-point between the transverse process and pleura, with no blood, gas, or cerebrospinal fluid observed on aspiration, 20 mL of 0.25% bupivacaine will be administered. The local anesthetic spread will be noted in the area midway between the transverse process and pleura is an indication of a successful puncture."
223739630|NCT06641310|PROCEDURE|Endurance Exercise Therapy|"* Exercise: Endurance exercise therapy comprising treadmill walking administered by exercise physiologists via a study-kit which includes a smart-watch (activity tracker), heart rate monitor, blood pressure cuff, body composition scale, and etablet)~* Exercise escalation trial testing 3 exercise levels (150, 225, and 300 minutes per week), with one de-escalation exercise of 90 minutes per week, if required.~* The phase 1b trial will evaluate the highest feasible exercise level and one exercise below identified in the phase 1a study."
223739631|NCT06179472|DEVICE|BALT GOLDBAL2 Balloon|Placement and retrieval of the GOLDBALLOON Detachable Balloon for severe CDH
223739632|NCT05747625|BIOLOGICAL|Panitumumab|Given IV
223739633|NCT05747625|DRUG|Zirconium Zr 89 Panitumumab|Given IV
223739634|NCT05747625|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223739635|NCT05747625|PROCEDURE|Computed Tomography|Undergo PET/CT
223739636|NCT05747625|OTHER|Electronic Health Record Review|Ancillary studies
224035441|NCT01128361|BEHAVIORAL|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
223420837|NCT03888404|OTHER|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
223420838|NCT03888404|OTHER|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
223420839|NCT03888404|OTHER|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
223420840|NCT03888404|OTHER|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
223420841|NCT04276857|DEVICE|Irreversible electroporation (NanoKnife® )|IRE is a unique treatment modality as it ablates tumor cells without using heat or radiation and hence does not cause injury to nearby blood vessels, ducts, and bowel. This makes it particularly appealing for the treatment of locally advanced unresectable pancreatic cancers. This local treatment for cancer involves delivering brief pulses of high voltage electrical current across the tumor (either percutaneously or open surgery), which results in the formation of tiny holes (nanopores) in the cell membranes.
223420842|NCT00492648|PROCEDURE|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
223420843|NCT05986838|DEVICE|aser puncture|laser puncture (3 sessions per week)
224035442|NCT01128361|BEHAVIORAL|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
223420844|NCT05986838|DEVICE|ultraviolet radiatio|ultraviolet radiation (3 sessions per week)
223739637|NCT03280862|DEVICE|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
223739638|NCT05645536|DRUG|TOL2506|Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months
223739639|NCT05645536|DRUG|Tamoxifen|20 mg once daily or 10 mg 2 times daily - either tablet of solution
223739640|NCT05645536|DRUG|Letrozole tablets|One 2.5 mg tablet taken orally once daily
223739641|NCT05645536|DRUG|Anastrozole Tablets|One 1 mg tablet taken orally once daily
223739642|NCT05645536|DRUG|Exemestane Tablets|One 25 mg tablet taken orally once daily
223739643|NCT04760366|OTHER|fascial- muscular lengthening therapy|"Patients in this group will receive interventional therapy~To perform this technique:~1. Have the patient in side lying position~2. Hip is maximally flexed to shorten the iliopsoas muscle.~3. Therapist fingers should be on to the targeted area.~4. Apply gentle pressure in upward direction.~5. While maintain the pressure, stretch the muscle by moving the hip in extension through full ROM.~6. Therapist will maintain the pressure in opposing direction. This is considered as one pass. This technique is performed bilaterally. Patients in this group will also receive the conventional therapy which will include:~   * Hot pack for 15 minutes.~  * Myofascial release of iliopsoas.~  * TENS for 15 minutes."
223739644|NCT04760366|OTHER|Stretching's of iliopsoas muscle|"Patients in this group will receive the interventional therapy which will include:~Stretching's of iliopsoas muscle which can be done in two positions:~1. modified lunge position.~2. The prone stretch.~Patients in this group will also receive the conventional therapy which will include:~* Hot pack for 15 minutes.~* Myofascial release of iliopsoas~* TENS for 15 minutes."
223420845|NCT05986838|DRUG|Metformin|for 3 months
223420846|NCT00282113|DIETARY_SUPPLEMENT|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
223420847|NCT00282113|DIETARY_SUPPLEMENT|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
223420848|NCT00282113|OTHER|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
224298797|NCT00552383|PROCEDURE|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff \[this includes 3 of the investigators\], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
223420849|NCT03775902|DRUG|Placebo|placebo tablet
223420850|NCT03775902|DRUG|Nicorandil|20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
223420851|NCT04348864|DIAGNOSTIC_TEST|COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support|An immunodiagnostic rapid (5-20 minute) test detects circulating antibodies in the blood, serum or plasma of individuals who have been infected with the novel coronavirus SARS-COV-2 as detected by rapid antigen test or LAMP/PCR-based molecular test taken from nasopharyngeal swab samples in the recent past.
223420852|NCT04348864|OTHER|Telemedicine|Imaging of the test using the software application COVIDscanDX and upload to server by the subject and phone, video or messaging consult with a clinician for interpretation and instructions establishes the telemedicine (i.e. virtual point-of-care).
224035443|NCT00626704|DRUG|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
224035444|NCT00626704|OTHER|Placebo|Inactive dummy AMG 655 (to maintain blind)
224035445|NCT00626704|DRUG|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
224035446|NCT00910351|DRUG|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
224035447|NCT06678555|DRUG|Lorlatinib|Lorlatinib is an ALK/ROS1 tyrosin kinase inhibitor.
224035448|NCT03157505|DRUG|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
223420853|NCT01204684|BIOLOGICAL|autologous tumor lysate-pulsed DC vaccination|
223420854|NCT01204684|BIOLOGICAL|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
223420855|NCT01204684|BIOLOGICAL|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
223420856|NCT02949843|DRUG|Chemotherapy|Receive other treatment
223420857|NCT02949843|BIOLOGICAL|Immunotherapy|Receive other treatment
223420858|NCT02949843|OTHER|Laboratory Biomarker Analysis|Correlative studies
223739645|NCT04760366|OTHER|the conventional therapy|the conventional therapy
224035449|NCT03157505|OTHER|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
224035450|NCT01929980|DRUG|Bortezomib|
224035451|NCT03030170|DEVICE|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
224035452|NCT03030170|DEVICE|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
224035453|NCT03368911|DEVICE|Oral/Nasal Endotracheal Tube, Reinforced (Covidien)|Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
224035454|NCT03368911|DEVICE|TaperGuard oral tracheal tube (Covidien)|Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
224035455|NCT01721005|OTHER|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
224035456|NCT00649090|DRUG|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
224035457|NCT00985166|BIOLOGICAL|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
224298798|NCT01244061|DRUG|Varenicline|Varenicline 1mg twice daily
224298799|NCT01244061|DRUG|Placebo|Matched placebo twice daily
223420859|NCT02949843|BIOLOGICAL|Nivolumab|Given IV
223420860|NCT02949843|BIOLOGICAL|Pembrolizumab|Given IV
223420861|NCT02949843|DRUG|Targeted Molecular Therapy|Receive drug targeting secondary mutation
223420862|NCT02949843|DRUG|Tyrosine Kinase Inhibitor|Given PO
223420863|NCT03994133|OTHER|Measurement of the hydration state by bio-impedance spectroscopy|"* The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~* The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~* The measurement will be done in pre-dialytic"
223420864|NCT06363110|DRUG|Vericiguat (Verquvo, BAY1021189)|Follow clinical practice/administration
223420865|NCT01490879|DRUG|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
224035458|NCT00985166|BIOLOGICAL|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
224035459|NCT00985166|BIOLOGICAL|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
224035460|NCT00985166|BIOLOGICAL|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
224035461|NCT06785818|OTHER|Tisagenlecleucel|This is an observational study. There is no treatment allocation. The decision to initiate tisagenlecleucel will be based solely on clinical judgement.
224035462|NCT04973878|PROCEDURE|EGD first|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
224035463|NCT04973878|PROCEDURE|Colonoscopy first|In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
224035464|NCT02765607|PROCEDURE|Heart surgery|
224035465|NCT02855424|OTHER|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
224035466|NCT02855424|OTHER|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
224035467|NCT05241275|DRUG|Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
224035468|NCT02523053|PROCEDURE|Hepatectomy|Surgical removal of all lesions
224035469|NCT02523053|DRUG|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
224137524|NCT04786132|OTHER|Cognitive-motor training|"A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise."
224137525|NCT04786132|OTHER|Motor training|A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.
224137526|NCT01199055|DRUG|CS-7017|Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks)
224137527|NCT01199055|DRUG|Carboplatin|Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
224298800|NCT00974961|DRUG|bupivacaine, levobupivacaine|intrathecal injection 15\~20mg(for Levobupivacaine) or 10\~15mg(for Bupivacaine) once
224298801|NCT01641133|BIOLOGICAL|Synflorix (3-Dose)|3 doses administered intramuscularly
224298802|NCT01641133|BIOLOGICAL|Synflorix (2-Dose)|2 doses administered intramuscularly
224298803|NCT01641133|BIOLOGICAL|Synflorix (Single Dose)|1 dose administered intramuscularly
224298804|NCT01641133|BIOLOGICAL|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
224298805|NCT01641133|BIOLOGICAL|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
223420866|NCT01490879|DRUG|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
223420867|NCT01490879|DRUG|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
223420868|NCT01490879|DRUG|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
223420869|NCT04722510|DEVICE|repeated transcranial magnetic stimulation|Transcranial magnetic stimulation is a non-invasive brain modulation technique that has proven to be a useful study and treatment tool in neuropsychiatric disorders. This technique allows to increase (with high frequency protocol, \> 1 Hz) or decrease (with low frecuency protocols, 1 hz or less) neuronal excitability in a focused cortical area.
223420870|NCT00421018|DRUG|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
223420871|NCT05069402|DIETARY_SUPPLEMENT|Immunonutrition|diet with immunonutrients
223420872|NCT05069402|DIETARY_SUPPLEMENT|High-protein|Oral nutrition with high-protein content
223420873|NCT05069402|DIETARY_SUPPLEMENT|Standard ONS|Oral nutrition with standard ingredients
223420874|NCT05794984|OTHER|Focus group discussions and survey questionnaire|Questions regarding internet and social media usage, as well as telemedicine concept and knowledge. Assessment of the feasibility, acceptability and accessibility of social media and telemedicine as methods to obtain healthcare. Perceptions for high-quality healthcare access, confidentiality, privacy, and security, will also be explored.
223420875|NCT00764036|DRUG|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
223420876|NCT01363245|BEHAVIORAL|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
223420877|NCT01363245|BEHAVIORAL|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
223420878|NCT03328871|DEVICE|Fractional CO2 Laser|Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
223420879|NCT03328871|PROCEDURE|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
223420880|NCT03328871|PROCEDURE|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
224298806|NCT00940797|DRUG|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
223420881|NCT04293029|DRUG|SHR0302|SHR0302
223420882|NCT05890989|DIAGNOSTIC_TEST|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT|EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
223420883|NCT01927003|PROCEDURE|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
223420884|NCT06597448|BEHAVIORAL|Cognitive Behavioral Therapy for Postpartum Depression (PPD)|Cognitive Behavioral Therapy (CBT) is a type of psychotherapy (talk therapy). The intervention consists of 9- 2hr sessions, the first half involves teaching and practice of CBT skills (cognitive restructuring, thinking errors, problem solving etc) followed by one hour of unstructured discussion around topics relevant to participants with Postpartum Depression (PPD) (sleep, supports, transitions, etc). Each group will be delivered by one randomly selected PHN and one randomly selected peer using our intervention manual.
223562639|NCT06727903|OTHER|laboratory biomarker analysis|Results of laboratory biomarker analysis will be analyzed as predictors for mortality
224298807|NCT00940797|DRUG|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
223420885|NCT04028869|DRUG|Glycyrrhizic acid preparation|To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
223420886|NCT02594904|DRUG|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
223562640|NCT06886828|DEVICE|Virtual reality goggles during HFNC|HFNC oxygen therapy will be started with video demonstration accompanied by virtual reality glasses. Physiological parameters and anxiety level will be recorded 10 minutes after HFNC oxygen treatment. Video recording will be terminated. Since the parameters in the scales should be evaluated by 2 nurses independent of the study during the study, only the behaviours of the child during the procedure should be video recorded by a mobile phone. For the participants and parents who want to participate in the study but do not approve the video recording, the parameters will be evaluated instantly by a researcher independent from the study. The study will continue until the 30-person intervention group is completed.
223562641|NCT06886828|DEVICE|HFNC oxygen therapy with routine service application|HFNC oxygen therapy will be started with routine ward practice. Physiological parameters and anxiety level will be recorded 10 minutes after HFNC oxygen treatment. Video recording will be terminated. Since the parameters in the scales should be evaluated by 2 nurses independent of the study during the research, only the behaviours of the child during the procedure should be video-recorded by means of a mobile phone. For participants and parents who want to participate in the study but do not approve the video recording, the parameters will be evaluated instantly by a researcher independent from the study
223562642|NCT06725927|BIOLOGICAL|Influenza vaccination|Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
223420887|NCT05927740|DIAGNOSTIC_TEST|Optic coherence tomography|Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
223562643|NCT06885385|BIOLOGICAL|JS207|JS207 will be administered every 3 weeks for a treatment cycle of 21 days
223562644|NCT06885385|BIOLOGICAL|JS015|JS015 will be administered every 3 weeks for a treatment cycle of 21 days
223562645|NCT06885385|DRUG|Capecitabine|Capecitabine of 1000mg/m2 will be administered orally twice daily from day 1 to 14 every 21 day cycle
223562646|NCT06885385|DRUG|Oxaliplatin|Oxaliplatin of 130mg/m2 will be administered intravenously (IV) on day 1 every 21 day cycle
223562647|NCT06738082|BIOLOGICAL|Influenza vaccine|Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.
223562648|NCT06885320|BEHAVIORAL|IMPROVE|IMPROVE is an individual manualized intervention. Session1 includes: • psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations • guided discussion of maladaptive thoughts about bodily sensations related to anxiety • how to challenge bodily sensations cognitively • generating three takeaways about the benign nature of anxiety Session 2 includes: • review of homework • psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty. • when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty. Session 3 includes: • review interoceptive exposure (IE) and behavioral exercises (BE) for progress • revisit beliefs related to cognitive biases • discuss areas where skills can be used moving forward
224035470|NCT02915471|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
224035471|NCT04007510|COMBINATION_PRODUCT|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
224035472|NCT04007510|DIAGNOSTIC_TEST|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
224137528|NCT01199055|DRUG|Paclitaxel|Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks)
224137529|NCT06065358|PROCEDURE|Tumor biopsy|Patients with advanced suspected HGSOC will be considered eligible (FIGO stage from III C or greater). At the time of surgery, patients' disease extension will be assessed with the Fagotti score (PIV) and the Vizzielli score (VS). Only patients who are not considered operable in the first place, will be enrolled. Samples will be taken during surgery that will take place in the operating rooms of oncological gynaecology.
224137530|NCT02010437|DRUG|Sodium Tetradecyl Sulphate (STS)|
223420888|NCT04974281|COMBINATION_PRODUCT|PD-1 and Lenvatinib Plus TACE|PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
223420889|NCT05277636|DRUG|3,4-methylenedioxymethamphetamine|A dose of 125 mg racemic MDMA will be administered.
223420890|NCT05277636|DRUG|S-3,4-methylenedioxymethamphetamine|A dose of 125 mg enantiomeric S-MDMA will be administered.
224298808|NCT01706848|OTHER|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
223420891|NCT05277636|DRUG|R-3,4-methylenedioxymethamphetamine (125 mg)|A dose of 125 mg enantiomeric R-MDMA will be administered.
223420892|NCT05277636|DRUG|R-3,4-methylenedioxymethamphetamine (250 mg)|A dose of 250 mg enantiomeric R-MDMA will be administered.
223420893|NCT05277636|OTHER|Placebo|Placebo (Mannitol)
223739646|NCT05056948|OTHER|artificial intelligence (AI) computer assisted design (CAD)|Maxillary right first molar will be removed in the computer and will be designed by artificial intelligence system
224137531|NCT04380974|PROCEDURE|OCTA plus OCT guided 3+PRN regimen|"For the OCTA plus OCT guided 3+PRN regimen, we recorded patients' data after retreatment by 3 monthly intravitreal injections of anti-VEGF drug. Subsequent reinjections were given as needed according to the changes in patients' visual acuity, activity of PCV lesions shown by OCTA and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, OCTA and OCT.~In case of BVN increased or polypoidal lesion progressed on OCTA scans, persistent subfoveal or perifoveal fluid, macular intraretinal edema on OCT scans, or visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
224137532|NCT04380974|PROCEDURE|OCT guided 3+PRN regimen|"For the OCT guided 3+PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Anti-VEGF drugs. Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four weeks after the third and last injection, all patients in this group underwent an examination, including ETDRS visual acuity, fundus photography, and OCT.~In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of \>5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later."
224137533|NCT04380974|DRUG|Anti-VEGF drug|Conbercept or other anti-VEGF drugs
224137534|NCT03268694|BEHAVIORAL|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
224298809|NCT01706848|OTHER|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
223420894|NCT04715542|DRUG|Stibium metallicum praeparatum 6x|Stibium metallicum praeparatum 6x will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
223420895|NCT04715542|DRUG|Placebo|Placebo will be administered with subcutaneous injections 3 times a week at 1 ampoule at 1 mL during the chemotherapy and shall be continued during 6 weeks after the end of chemotherapy . The first injection will be administered on the day of the first dose of chemotherapy, before the injection of the first dose of chemotherapy.
223420896|NCT06668532|DEVICE|Digital toolkit|Access to the Flourish app and instruction to use at least twice a week for 6 weeks.
223420897|NCT06668532|OTHER|National mental health resources|Access to national mental health resources from Mental Health America, which can be found here: https://mhanational.org/ten-tools. Participants will receive one resource each week for 6 weeks and each time, will be asked to reflect on how the information can be applied to their own lives.
223420898|NCT05655910|DIETARY_SUPPLEMENT|Ensure Surgery Immunonutrition shake|Nutrition shake to support immune health and recovery from surgery.
223420899|NCT03912649|DEVICE|RemovAid|The RemovAid device is used for removal
223420900|NCT03808597|OTHER|Digital health promotion intervention|Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
223420901|NCT05450003|DEVICE|Irrigation activation using xp endo finisher file , new sonic eddy tip and conventional needle syringe irrigation|irrigation activation using 3 different irrigation activation systems including xp endo finisher file , new sonic eddy system and conventional needle syringe irrigation
223420902|NCT00474201|DRUG|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
223420903|NCT00474201|DRUG|Gemfibrozil|Control arm (no intervention used in this arm)
223420904|NCT05370586|OTHER|Pericapsular nerve Group Block|Patients of study group will receive PENG block with 20 mL of 0,375% levobupivacaine with 4 mg of dexamethasone
223562649|NCT06885320|BEHAVIORAL|HET|"Clinicians will administer HET using a PowerPoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. HET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs."
223739647|NCT04621188|DRUG|Lorlatinib|100 mg once daily
223739648|NCT01128257|DRUG|alendronate|As prescribed by physician
223739649|NCT01128257|DRUG|ibandronate [Bonviva/Boniva]|As prescribed by physician
223739650|NCT02268864|DRUG|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
223420905|NCT05370586|OTHER|Infrainguinal Fascia Iliaca Block|Patients of control group will receive an infrainguinal fascia iliaca block with 30 mL of 0,25 % levobupivacaine with 4 mg of dexamethasone
223420906|NCT05265923|DRUG|CM310|IL-4Rα monoclonal antibody
223420907|NCT05265923|OTHER|Placebo|Placebo
223739651|NCT02268864|DRUG|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
223420908|NCT03788408|BEHAVIORAL|Intensive Psychotherapy and case management for refugee trauma|CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
223739652|NCT03233282|OTHER|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
223739653|NCT03233282|OTHER|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
224035473|NCT04025723|OTHER|Downhill running|60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
224035474|NCT04239716|OTHER|regional anesthesia|combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
224035475|NCT05933330|OTHER|Brain MRI|All included patients receive an MRI of the brain
224035476|NCT02732054|BIOLOGICAL|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
224035477|NCT01580280|OTHER|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
224035478|NCT01580280|OTHER|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
224137535|NCT03268694|BEHAVIORAL|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
224137536|NCT03268694|BEHAVIORAL|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
224137537|NCT04675606|BEHAVIORAL|Regular diet|Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
224137538|NCT04675606|BEHAVIORAL|Low fiber diet|Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
224137539|NCT02307071|DEVICE|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
224298810|NCT04681651|DRUG|Normobaric Hyperoxia|Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
223420909|NCT01500187|DEVICE|Vanish Varnish|5% sodium fluoride varnish with tricalcium phosphate
223420910|NCT01500187|DEVICE|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
223420911|NCT04804670|DEVICE|Power device A|Oral hygiene regimen completed daily
223420912|NCT04804670|DEVICE|Power device B|Oral hygiene regimen completed daily
223420913|NCT04804670|DEVICE|Routine Oral Hygiene|Oral hygiene regimen completed daily
223420914|NCT03503643|DEVICE|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
223420915|NCT02180295|BIOLOGICAL|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
223420916|NCT02180295|BIOLOGICAL|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
223420917|NCT02180295|BIOLOGICAL|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
223420918|NCT06239571|BEHAVIORAL|Resilient Families (R-FAM)|Dyadic, resiliency intervention that aims to reduce depression, anxiety, and posttraumatic stress among parents of babies in the NICU
223420919|NCT02521051|DRUG|Alectinib|
223420920|NCT02521051|DRUG|Bevacizumab|
223420921|NCT02784613|DRUG|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
224035479|NCT02532153|DRUG|Ketamine Hydrochloride|Single open-label infusions
224035480|NCT04703478|OTHER|Breathing exercise|Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
224035481|NCT03509233|OTHER|Q-SRP|Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
224035482|NCT03509233|OTHER|FMS|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
224035483|NCT03509233|OTHER|FMD|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
224035484|NCT03509233|OTHER|FMDP|FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
224137540|NCT06443476|PROCEDURE|Tenting abutment technique|To evaluate a novel method using a designed tenting abutment to reduce number of surgeries and the edentulous healing period is shortened. In addition, to prevent vertical and horizontal collapse of the bone graft and minimizes resorption of the bone graft during the healing the atrophic posterior mandible.
223420922|NCT06414395|DRUG|Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection|The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
223420923|NCT06414395|OTHER|C group: Patients received saline infusion over 10 minutes|the group will receive normal saline infusion over 10 minutes.
223420924|NCT05808868|OTHER|Screening|"The detailed management is not different from that usually practiced in our department.~Each patient benefits from an ENT consultation where an interrogation is carried out concerning the sleep disorders, the answer to the usual questionnaires screening for sleep disorders, a detailed ENT clinical examination including a nasofibroscopy. Each patient then benefits from a sleep recording by ventilatory polygraph."
223420925|NCT05819086|BEHAVIORAL|Rate Emotional Response|Participants will view their assigned video package, and will be asked to rate their emotional response to the message
223420926|NCT05819086|BEHAVIORAL|Rate Impact of Message|Participants will view their assigned video package, and will be asked to rate the impact of the presented messages on motivation to quit smoking.
223420927|NCT03670446|OTHER|Pharmacists' intervention|"1. Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~2. Establish a medical record and remind their follow-up by message, phone every 2 weeks.~3. Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months."
223562650|NCT06891495|OTHER|Expert Evaluation of Adapted Questionnaire|This intervention involves inviting a group of subject matter experts-including dental specialists, public health professionals, and communication experts-to evaluate the adapted questionnaire. The questionnaire, derived from the Questionnaire for Assessing Educational Podcasts (QAEP) and tailored for assessing an AI-generated health podcast, covers four dimensions: Access and Use, Design and Structure, Content Adequacy, and Value as an Aid to Learning. Experts will complete a structured online survey (via Google Form) to rate each item's clarity, relevance, and necessity. Their feedback is integral to refining and validating the instrument prior to its use with the general public.
223562651|NCT06891495|OTHER|AI-Generated Health Podcast Evaluation|Participants in this group will first listen to a 4-minute AI-generated health podcast on gum health and prevention. The podcast was produced using Google NotebookLM and is based on publicly available information from the American Academy of Periodontology, with appropriate source credit. After listening, participants will complete a validated questionnaire (administered via Google Form) that assesses the podcast's accessibility, design, content adequacy, and educational value. This intervention is designed to measure public perception, engagement, and overall feasibility of using AI-generated podcasts as an educational tool for health communication.
223562652|NCT06890754|DIAGNOSTIC_TEST|Diagnostic hysteroscopy|Diagnostic hysteroscopy. An IHC study of the expression of the plasma cell marker CD138 was systematically performed for all samples studied
223562653|NCT06632405|DRUG|Camrelizumab|Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
223562654|NCT06632405|DRUG|Nab paclitaxel|Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
223562655|NCT06632405|DRUG|Levocetirizine Hydrochloride|5mg daily, start 3 days before the 1st administration
223739654|NCT03233282|OTHER|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
224035485|NCT01028222|DRUG|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
224035486|NCT01028222|DRUG|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
224035487|NCT02235974|BEHAVIORAL|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
223739655|NCT03233282|OTHER|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
223739656|NCT03233282|OTHER|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
223420928|NCT06685393|PROCEDURE|Platelet rich plasma (PRP)|At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (PRP) at test side only at baseline,3ed, 6th week.
223420929|NCT06685393|PROCEDURE|INJECTABLE PLATELET RICH FIBRIN(I-PRF)|At the 1st visit, each quadrant is scaled and root planned using an ultrasonic scaler and manual instruments until tactile sensation detects smooth crown and root surfaces these procedures were repeated on both sides starting from 1st visit of treatment,2nd,4th, and 6th-week intervals local anesthetic was utilized in some instances where it was the necessary and subgingival application of (I-PRF) at test side only at baseline,3ed, 6th week.
224035488|NCT02235974|BEHAVIORAL|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
224035489|NCT02235974|BEHAVIORAL|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
224035490|NCT02235974|BEHAVIORAL|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
224137541|NCT06443476|PROCEDURE|Tent pole technique|using the Tent pole technique to gain bone vertical and horizontal loss
224137542|NCT00398385|DRUG|cisplatin|
224035491|NCT06296134|BEHAVIORAL|perineal massage|"women affected by LAM co-activation allocated to the intervention perineal massage are asked to perform the perineal massage once daily from 34 gestational weeks until delivery. Women are trained to correctly perform the perineal massage at 30 gestaitonal weeks."
224035492|NCT00679588|DRUG|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
224035493|NCT00679588|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
224035494|NCT00679588|DRUG|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
224035495|NCT04393051|DRUG|Baricitinib Oral Tablet|Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
224035496|NCT04745767|DRUG|TAK-994|T2 formulation.
224137543|NCT00398385|DRUG|gemcitabine hydrochloride|
224137544|NCT00398385|PROCEDURE|adjuvant therapy|
223420930|NCT02851589|BIOLOGICAL|PCAR-019 (anti-CD19 CAR-T cells)|
223420931|NCT05561322|OTHER|Consultation involving pain evaluation, questionnaires and the Lasègue Manoeuver|Raising the lower limb with the knee in extension reproduces sciatica pain if there is an impression of discal pain with its origin at the roots of the sciatica nerve L5 and S1. This test is evaluated by the degree of elevation of the lower limb relative to the examination table. During the Lasègue manoeuvre the sciatica pain is improved during dorsal flexion of the foot.The doctor notes whether the Lasègue manoeuvre done on the healthy side exacerbates the pain on the opposite side. It is said that contralateral Lasègue sign is positive.
223420932|NCT05561322|OTHER|Magnetic Resonance Imaging of the lumbar spine|Sagittal proton density-weighted Dixon sequence on the lumbar spine and axial T2-weighted spin echo sequence on the lumbar discs.
223420933|NCT05667363|COMBINATION_PRODUCT|Digital Intervention|Digital therapeutics are consist of a smartphone app and an intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
223420934|NCT00355563|DEVICE|PAS-Port Automated Proximal Anastomosis System|
223420935|NCT01082263|DRUG|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
223420936|NCT06446115|DEVICE|Virtual Reality|Virtual Reality Headset applied to the participants during chemotherapy session. Participants select their preferred virtual reality experience (i.e., nature videos, meditations, interactive applications, etc). Virtual reality (VR) by definition, is a simulated experience consisting of an experiential environment created by hardware and software technology capable of provoking sensations of real experiences. It can be further divided into 1) immersive; 2) semi-immersive; and 3) non-immersive. Immersive VR employs head-mounted display (HMD) system technology to separate users from their surroundings and engage in real-time with a three-dimensional environment generated by a computer.
223420937|NCT06446115|OTHER|Preferred activity|Participants will engage in a preferred activity such as reading, watching television, coloring, etc. during chemotherapy.
223420938|NCT06446115|OTHER|Questionnaires|Participants will be administered multiple pre and post intervention questionnaires including NCCN Distress thermometer, GAD-7 and CCVA.
223739657|NCT03233282|OTHER|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
224035497|NCT04745767|DRUG|TAK-994|T1 formulation.
224035498|NCT04745767|DRUG|TAK-994|T3 formulation.
224035499|NCT04745767|DRUG|TAK-994|T4 formulation.
224035500|NCT04745767|DRUG|TAK-994|T5 formulation.
224137545|NCT00398385|PROCEDURE|conventional surgery|
224137546|NCT00398385|PROCEDURE|neoadjuvant therapy|
224137547|NCT04233359|PROCEDURE|Local anesthetic thoracoscopy|Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
224035501|NCT05330637|OTHER|Climate and environment in Sanya|Sanya have unique island climate and environment campared with the north of China, with a feature of warm, moist and long-sunshine.
224035502|NCT04903808|DRUG|Allium Sativum Oil|Garlic oil Captain Company (CAP-PHARM)
224035503|NCT04903808|DRUG|Mineral Tri-Oxide Aggregate|ProRoot MTA, Dentsply
224035504|NCT03903874|BEHAVIORAL|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
224035505|NCT06383026|DIAGNOSTIC_TEST|Breast Cancer Screening|Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
224035506|NCT06383026|OTHER|Survey/Interview|A mixed-methods approach including electronic surveys and one on one interviews.
224035507|NCT06383026|OTHER|Focus Group|A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for individuals on hormone therapy.
224137548|NCT04233359|PROCEDURE|US-guided pleural biopsy|In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
224137549|NCT06515769|DIAGNOSTIC_TEST|TERMOGRAPHY|Obtaining an image of the foot using a thermographic camera
224137550|NCT05055167|DRUG|Envafolimab|single agent, 300mg Q3W IH until disease progressed
224137551|NCT05256056|DRUG|Bupivacain|efficacy of bupivacaine in different volumes
224137552|NCT03284008|OTHER|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
224137553|NCT03284008|OTHER|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
224137554|NCT00077610|DRUG|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
224137555|NCT00077610|DRUG|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
223420939|NCT05410405|PROCEDURE|implant site preparation|piezoelectric bone surgery osseodensification drills
223562656|NCT06896786|OTHER|dialysis assisted with the sodium management tool|"Sodium management tool is a modul of the fresenius 6008 dialysis machine. This model approximates changes in plasma electrolyte concentrations during dialysis and allows the estimation of sodium concentration based on dialysate conductivity. Na control biosensor continuously (every minute) monitors the dialysate side sodium balance based on measurements of fresh and spent dialysate conductivities and the application of a kinetic model to account for the typical influence of other ions on dialysate conductivity. In activated Na control, as zero diffusive mode, dialysate sodium is then adjusted continuously to minimize diffusive Na transfer. SMT is part of the 6008 Machine and its certification is included in the Fresenius 6008 Machine certification. Untill now there is no data if this modul benefits. in this study the investigator compares standard of care dialysis (Arm 1) with dialysis assisted with the SMT (Arm ) on clinical outcome"
223562657|NCT06890221|DIETARY_SUPPLEMENT|B-Crobes intake complete nutrition|Contains whey and plant based proteins, enriched with prebiotics and probiotics, Ca-Hmb, minerals and multivitamins.
223562658|NCT06890221|DIETARY_SUPPLEMENT|Placebo|Contains full cream dairy milk
223562659|NCT06606288|DEVICE|Conduction system pacing|Implant with a Medtronic dual-chamber transvenous pacemaker on or after the study data with lead type and placement data indicating conduction system pacing
223562660|NCT06606288|DEVICE|Bi-ventricular pacing|Implant with a Medtronic bi-ventricular pacemaker (CRT-P) on or after the study date
223562661|NCT01402557|BEHAVIORAL|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
223562662|NCT01402557|BEHAVIORAL|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
223562663|NCT01402557|BEHAVIORAL|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
223562664|NCT01098253|BEHAVIORAL|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
223562665|NCT01540526|DRUG|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
223562666|NCT05271734|DEVICE|Lid retractor placement|Insertion of a lid retractor to find out if the corneal limbus is exposed in 360 degress
223562667|NCT02048644|DRUG|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
223739658|NCT03233282|OTHER|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
223562668|NCT02048644|DRUG|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
223562669|NCT06644482|OTHER|Exercise group in a hospital setting|Participants will exercise in a group once a week for 16 weeks in a hospital setting.
223562670|NCT00501722|DRUG|satavaptan (SR121463B)|
223562671|NCT01794208|DRUG|Follitropin Epsilon|
223562672|NCT01794208|DRUG|Follitropin Alfa|
223562673|NCT07080931|DRUG|5% minoxidil foam|Participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
223739659|NCT03233282|OTHER|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
224035508|NCT02685670|BIOLOGICAL|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
224035509|NCT02685670|DRUG|Fludarabine|
224035510|NCT02685670|DRUG|Cyclophosphamide|
224035511|NCT04697264|DIAGNOSTIC_TEST|Blood and tissue sample collection from patients|Blood and tissue sample (endometrial and adipose tissue) collection from endometrial cancer patients. Blood from all control patients, endometrial sample from benign patients having surgery for benign gynaecological conditions.
224035512|NCT03840850|OTHER|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
224035513|NCT04162925|BEHAVIORAL|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
224035514|NCT04556643|OTHER|Breathing exercises|The main components of breathing exercises during training will be as follows (A) First, fill your stomach and then your lungs with air while breathing in; (B) Feel the expansion in the stomach; (C) Make sure the muscles from your stomach to your knee are relaxed, as if you are urinating while breathing out; (D) When there is pain, perform deep abdominal breathing exercises, and take a deep breath in and hold as much as you can; (E) Try to push the baby downward; (F) You can do it by holding your breath or breathing out quite slowly from your mouth; (G) The most important point in this stage is that you should not fill up the stomach with air, and you should push downward to deliver the baby; (H) You should continue the pushing until the pain is relieved
223420940|NCT01551264|DEVICE|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
223420941|NCT02570412|DRUG|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
223420942|NCT05063357|DRUG|131I-Omburtamab|Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
224137556|NCT00077610|DRUG|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
223420943|NCT05063357|DEVICE|Convention Enhanced Delivery|The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
223420944|NCT05421702|PROCEDURE|laparoscopic conventional colectomy|Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.
223420945|NCT05421702|PROCEDURE|laparoscopic complete mesocolic excision|Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
223420946|NCT03086928|OTHER|lava ultimate|resin nano ceramic material
223562674|NCT07080931|DRUG|Placebo for 5% Minoxidil Foam|Participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
223562675|NCT05969639|BEHAVIORAL|HEYA|The HEYA program is a 12-week app-delivered psychoeducational program that comprises of nutrition education, skills training on self-regulation, and weekly feedback.
224035515|NCT01257789|PROCEDURE|laparoscopic gastric bypass|laparoscopic gastric bypass
224035516|NCT04722523|DRUG|Cisplatin|Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8
224035517|NCT04722523|DRUG|Carboplatin|Carboplatin AUC 5 on weeks 2, 5, and 8
224035518|NCT04722523|DRUG|Docetaxel|Docetaxel 75mg/m2 on weeks 2, 5, and 8
224035519|NCT04722523|DRUG|Cetuximab|Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10
224035520|NCT04722523|DRUG|Cemiplimab|Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37
224035521|NCT04722523|PROCEDURE|Surgical Resection of Primary +/- Neck Dissection|Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).
224035522|NCT04722523|RADIATION|Post-operative radiation therapy|Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of \>0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines \[2\]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.
224035523|NCT04722523|DRUG|Paclitaxel|If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.
224035524|NCT00841893|DIETARY_SUPPLEMENT|Mustard (dijon)|The specific spice added to a brunch meal
224035525|NCT00841893|DIETARY_SUPPLEMENT|Placebo|Placebo added to a brunch meal
224035526|NCT03236246|DRUG|KRX-0502|Oral ferric citrate with meals
224035527|NCT05898386|BEHAVIORAL|Behaviour and Lifestyle Changes in Urinary Incontinence|"The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made."
224035528|NCT02882919|BEHAVIORAL|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
224137557|NCT05673473|RADIATION|scoliosis radiographs|Low dose fluoroscopic imaging technique for scoliosis x-rays
224137558|NCT01634321|DRUG|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
224137559|NCT03953261|DRUG|Curcumin supplement|Intervention is 2 grams of curcumin supplement per day
224137560|NCT04068311|OTHER|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
224137561|NCT03921255|OTHER|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark \& Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark \& Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey \& Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
223420947|NCT03086928|OTHER|E.max cad|Lithium disilicate glass ceramic
223420948|NCT05016141|BEHAVIORAL|digital fall prevention program|The participants will receive a digital fall prevention program consisting of fall risk reduction education (modified Matter of Balance), Otago Exercise Program, Personalized S.M.A.R.T Goals, and will use the app to keep track of their health and health events, including falls.
223420949|NCT01826578|PROCEDURE|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
223420950|NCT02983188|DRUG|Berberine|Berberine tablets, 0.3g every time, two times daily
223420951|NCT02983188|DRUG|Placebos|Placebo tablets, 0.3g every time, two times daily
223562676|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
223420952|NCT02983188|DRUG|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
223420953|NCT01665625|PROCEDURE|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
223420954|NCT03568370|OTHER|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
223420955|NCT01303406|DRUG|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
223420956|NCT01303406|DRUG|Placebo|
223420957|NCT00039351|DRUG|cyclophosphamide|
223420958|NCT00039351|DRUG|prednisone|
223420959|NCT00039351|DRUG|vincristine sulfate|
223420960|NCT00039351|RADIATION|radiation therapy|
223562677|NCT01304992|DIETARY_SUPPLEMENT|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
223562678|NCT07081607|DRUG|golidocitinib with azacytidine and chidamide|"In Phase I, a 3+3 dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).~In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma"
223562679|NCT02497144|OTHER|NMES Group|Neuromuscular electrical stimulation
224035529|NCT03533621|DIETARY_SUPPLEMENT|Probiotic - VSL#3|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
224035530|NCT03533621|DIETARY_SUPPLEMENT|Placebo pill - soy protein powder|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
224137562|NCT04004078|DEVICE|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
224137563|NCT05312931|OTHER|OSCE|Students undergo OSCE (objective structured clinical exams). It means students will perform CPR for 2 min and their success rate will be monitored.
224137564|NCT00361127|DRUG|isotonic saline infusion|
223420961|NCT05236777|DRUG|Natalizumab|Administered as specified in the treatment arm.
223420962|NCT00153543|BIOLOGICAL|PCV7 + PPV23, 2 months|
223420963|NCT00153543|BIOLOGICAL|PCV7 + PPV23, 6 months|
223420964|NCT03953053|DEVICE|Femtosecond Laser Assissted Cataract Surgery|During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body
223562680|NCT02497144|OTHER|Control Group|Breathing exercises
223562681|NCT00494650|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
223739660|NCT03233282|OTHER|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
223739661|NCT03233282|OTHER|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
224035531|NCT00122928|BEHAVIORAL|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
224035532|NCT00122928|BEHAVIORAL|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
224035533|NCT00122928|BEHAVIORAL|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
224035534|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Bolus)|IM in the deltoid
224035535|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
224035536|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Bolus)|SC in the upper arm
224137565|NCT00994656|DEVICE|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
224137566|NCT02245451|DRUG|Tipranavir|
223420965|NCT02001844|DEVICE|Trial Foot Orthoses (FOs)|"Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
223420966|NCT02001844|DEVICE|placebo foot orthoses (FOs)|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
223420967|NCT01548911|DRUG|gemtuzumab ozogamicin|Given IV
223420968|NCT01548911|OTHER|laboratory biomarker analysis|Correlative studies
223420969|NCT01658124|DRUG|Tranexamic Acid|
223420970|NCT01658124|DRUG|Placebo|
223420971|NCT01752881|BIOLOGICAL|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
223420972|NCT01752881|BIOLOGICAL|AdimFlu-S|
223420973|NCT05804019|BEHAVIORAL|Nutritional and physical interventions|The intervention is developed with a focus on nutritional needs and physical activities. The Plan-Do-Study-Act (PDSA) model is used to redefine issues and relevant actions together with residents, relatives, care staff, and nursing home management. The intervention will be developed based on new knowledge from sub-study 1, previous studies, practical experiences, the participant's experiences and wishes as well as the staff's experiences and wishes. Together they will form an implementation catalog, from here, the intervention nursing homes can select a relevant number of components, which will be tested and implemented in practice. The implementation duration is 6 months and the PDSA model is repeated at two-month intervals to strengthen and qualify the intervention. The PDSA model is known to the city's staff in advance and is additionally used in connection to continuing education. The Usual Care Group will continue the usual care.
224137567|NCT02245451|DRUG|Ritonavir|
223420974|NCT01343277|DRUG|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
223420975|NCT01343277|DRUG|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
223420976|NCT04190511|DIETARY_SUPPLEMENT|Prebiotic-containing dairy|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition. On this basis, intervention was carried out using prebiotic-containing dairy products (200g/day).
223420977|NCT04190511|DIETARY_SUPPLEMENT|Dietary intervention|The trained dietitian gives guidance on diet, exercise, and weight gain during pregnancy based on the Maternal Dietary Guidelines and Dietary Pagoda recommendations developed by the Chinese Institute of Maternal and Child Nutrition.
223420978|NCT02078453|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
223420979|NCT04435977|DRUG|Cabozantinib 60 MG|"• The assigned dose for study treatment is 60 mg qd. Two dose reductions will be permitted (Table 2):~* 60 mg qd to 40 mg qd (level 1)~* 40 mg qd to 20 mg qd (level 2)"
223420980|NCT06060990|OTHER|trace elements|trace elements as biomarkers for response to systemic therapy in metastatic BTCs
223420981|NCT01926613|BEHAVIORAL|Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
223420982|NCT01926613|BEHAVIORAL|Supported Employment|Supported Employment is an evidence based vocational rehabilitation program
223562682|NCT00494650|BEHAVIORAL|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
224035537|NCT06033209|BIOLOGICAL|N332-GT5 gp140 (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
223420983|NCT05545514|DRUG|One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,|To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
223420984|NCT01101945|DRUG|dutogliptin|400 mg QD
223562683|NCT03459001|OTHER|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
223562684|NCT02229305|BEHAVIORAL|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
223562685|NCT02229305|BEHAVIORAL|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
223562686|NCT04743336|OTHER|Measuring pocket depth|Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
224035538|NCT06033209|BIOLOGICAL|SMNP (IM, Bolus)|IM in the deltoid
224035539|NCT06033209|BIOLOGICAL|SMNP (IM, Fractioned)|IM in the deltoid, Fractionated escalating dose for prime
224035540|NCT06033209|BIOLOGICAL|SMNP (SC, Bolus)|SC in the upper arm
224035541|NCT06033209|BIOLOGICAL|SMNP (SC, Fractioned)|SC in the upper arm, Fractionated escalating dose for prime
224035542|NCT06321289|BIOLOGICAL|Allogeneic CD19-STAR T cell|Phase 1 dose escalation (3+3): dose 1 (2×10\^6 cells/kg), dose 2 (6×10\^6 cells/kg), dose 3 (1.8×10\^7 cells/kg); Phase 2: dose of RP2D. No more than 5 × 10\^4 per kilogram of allogenic residual TCR-positive T cells harbouring in grafts can only be released for recipient infusion.
223562687|NCT00992199|DRUG|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
223562688|NCT01795495|DRUG|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
223562689|NCT01795495|DRUG|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
223562690|NCT01795495|DRUG|Remifentanil|
223562691|NCT00729495|DRUG|celecoxib|dose form
223562692|NCT04577300|DRUG|NT-501|Implant of Neurotech NT-501 device(s)
223562693|NCT04577300|OTHER|Sham comparator|Sham implantation
223562694|NCT06396169|OTHER|Yoga Exercise|Yoga Exercises
223562695|NCT06396169|OTHER|Calisthenic Exercise|Calisthenic Exercises
223739662|NCT03233282|OTHER|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
224298811|NCT04681651|DRUG|Sham Normobaric Hyperoxia|For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%；
224298812|NCT04681651|PROCEDURE|Endovascular Thrombectomy|EVT is the international guidelines for the treatment of acute ischemic stroke with lage vessel occlusion.
224298813|NCT00000824|DRUG|Lymphocytes, Activated|
224298814|NCT04333381|OTHER|Educational and organizational intervention|"Patients included after a systematic educational and organizational intervention for early diagnosis and care in myocardial infarction, aimed at emergency nurses of a tertiary Hospital capable in primary PCI.~1. The educational intervention will consist:~   Systematized educational intervention on acute myocardial infarction for emergency triage nurses will consist of theoretical and practical training through case presentations and clinical simulation.~2. The organizational intervention will consist:~   * Development and dissemination of an early diagnostic tool for acute myocardial infarction: STEMI infographics. It will be provided to all emergency nurses and emergency triage boxes~  * Update the STEMI hospital protocol and adapt it to the current clinical guidelines of the European Society of Cardiology (ESC)~  * Review organizational strategies and definition of new improvement measures~  * Audit the delays in STEMI~  * Periodic multi-disciplinary update sessions"
224298815|NCT04333381|OTHER|Common Practice|Common practice is based on care by emergency nurses who did not receive any systematized education of acute myocardial infarction led by interventional cardiology nurses. On the other hand, emergency management is based on Plan-Do-Study-Act methodology and in the historical sample some organizational improvement strategies did not exist or were beginning to be implemented
224298816|NCT02040311|DRUG|Topiramate 96 mg daily|
224298817|NCT02040311|DRUG|Topiramate 192 mg daily|
224298818|NCT02040311|DRUG|Placebo|
224298819|NCT00766155|DRUG|capecitabine|Given orally
224298820|NCT00766155|DRUG|oxaliplatin|Given IV
224298821|NCT05960474|OTHER|Outcomes for Patients with CMD|Our objective is to perform a retrospective/prospective descriptive study on the short term to longterm (up to 5 years of follow-up) outcomes of patients with coronary microvascular disease diagnosis invasively
224298822|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
224298823|NCT01289951|DRUG|Raltegravir 400 mg/12hours|
224298824|NCT06451393|DRUG|Neoadjuvant chemotherapy with radical tumor resection surgery|All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).
224298825|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
224298826|NCT01929031|DRUG|ibuprofen|tablet.
224298827|NCT01929031|DRUG|ibuprofen|tablet
224298828|NCT01929031|DRUG|caffeine|tablet
224298829|NCT01929031|DRUG|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
224298830|NCT01929031|DRUG|placebo|tablet
224298831|NCT01929031|DRUG|placebo|tablet
224298832|NCT01929031|DRUG|caffeine|tablet
224298833|NCT01929031|DRUG|ibuprofen|tablet
224298834|NCT01929031|DRUG|ibuprofen + caffeine|FDC tablet
224298835|NCT02150759|DRUG|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
223562696|NCT01331837|DRUG|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
223562697|NCT01331837|DRUG|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
223562698|NCT03345160|DRUG|Peanut Flour|open label oral immunotherapy
223562699|NCT04994912|DRUG|EI-001|EI-001 IV infusion
223562700|NCT04994912|OTHER|Placebo|Placebo IV infusion
223562701|NCT00969592|DRUG|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
223739663|NCT03849885|DRUG|Benzoyl peroxide gel|Skin prep with Chlorohexidine wipes and BPO.
224035543|NCT06321289|DRUG|Fludarabine|Intravenous fludarabine 30-50 mg/m\^2/day on days -5, -4, and -3.
224298836|NCT02150759|DRUG|Fentanyl|add dexmedetomidine during position change
224298837|NCT02150759|DRUG|Ketamine|add dexmedetomidine during position change
224298838|NCT05816200|DEVICE|Low-Level Light Therapy|Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.
224298839|NCT05816200|DEVICE|Transcutaneous Electric Nerve Stimulation|Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
223562702|NCT00969592|DRUG|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
223562703|NCT06896149|DIAGNOSTIC_TEST|Obstetric ultrasound|Ultrasound focus on fetal renal pelvis, amniotic fluid assessment, and fetal weight estimation.
224035544|NCT06321289|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500-1000 mg/m\^2/day on days -5, -4, and -3.
224035545|NCT06120582|GENETIC|ANB-002, dose 1|Adeno-associated viral vector carrying the FIX gene single infusion at dose 1.
224298840|NCT04352270|OTHER|AD printed educational materials|Printed educational materials in Spanish and English about coping with Atopic Dermatitis, specifically geared towards children and parents will be given to participants.
224298841|NCT04352270|OTHER|AD educational videos|Short, educational videos in English and Spanish about coping with Atopic Dermatitis, specifically geared towards children and parents will be developed. There will be Spanish and English versions of the videos, minimal text, comprehensive language, animations, and it will be administered via user friendly platforms or websites.
224298842|NCT00821002|DRUG|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
224298843|NCT02923414|DEVICE|Standard escalating shocks|125 J, 150 J, 200 J
224298844|NCT02923414|DEVICE|High energy shock protocol|360 J, 360 J, 360 J.
224298845|NCT00369382|DRUG|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
224298846|NCT00369382|DRUG|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
224298847|NCT01839630|DRUG|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
224298848|NCT01957566|PROCEDURE|APS|
224298849|NCT03554603|BEHAVIORAL|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
224298850|NCT03110601|DEVICE|Control - Conventional SCS|Conventional SCS Parameters
224298851|NCT03110601|DEVICE|Test - Stimgenics SCS|Stimgenics SCS Parameters
224298852|NCT00469768|DRUG|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
224298853|NCT00469768|DRUG|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
224298854|NCT00469768|OTHER|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
224298855|NCT01363804|DRUG|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
224298856|NCT03870113|BIOLOGICAL|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
224298857|NCT04083586|OTHER|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
224298858|NCT00732420|DRUG|topotecan|Topoisomerase I inhibition.
224298859|NCT00732420|DRUG|pazopanib|Tyrosine kinase inhibitor
224298860|NCT00646620|DRUG|budesonide/formoterol (Symbicort)|
224298861|NCT00646620|DRUG|fluticasone/salmeterol (Advair Diskus)|
224298862|NCT00646620|DRUG|albuterol (Ventolin)|
224298863|NCT00577902|OTHER|Observation|Head and neck cancer patients receiving chemoradiation
223562704|NCT00367718|DRUG|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
223562705|NCT01521871|PROCEDURE|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
223562706|NCT01521871|PROCEDURE|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
224035546|NCT06120582|GENETIC|ANB-002, dose 2|Adeno-associated viral vector carrying the FIX gene single infusion at dose 2.
224035547|NCT06120582|GENETIC|ANB-002, dose 3|Adeno-associated viral vector carrying the FIX gene single infusion at dose 3.
224298864|NCT03594695|DIAGNOSTIC_TEST|HSCRP and NLR|hs-CRP levels and NLR values will be studied from routine blood samples.
224298865|NCT03764436|BEHAVIORAL|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
224298866|NCT02268266|DEVICE|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
224298867|NCT00609466|DRUG|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
224298868|NCT00609466|DRUG|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
224298869|NCT00609466|DRUG|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
224298870|NCT04684303|PROCEDURE|Lumbar medial branch radiofrequency ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
224298871|NCT04684303|PROCEDURE|Lumbar medial branch cryo ablation neurotomy|Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
224298872|NCT03512262|DRUG|Abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
224298873|NCT03512262|DRUG|Placebo|Abaloparatide-matched placebo.
224298874|NCT00453427|DRUG|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (\> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
223562707|NCT05667584|DEVICE|hypotension prediction index derived from non-invasive arterial pressure waveforms|The Hypotension Prediction Index (HPI) is an algorithm based on the complex analysis of features in high-fidelity arterial pressure waveform recordings developed to observe subtle signs that could predict the onset of hypotension in surgical and intensive care unit patients. HPI is a unitless number that ranges from 1 to 100, and as the number increases, the likelihood of a hypotensive event (MAP \<65 mm Hg for more than 1 minute) occurring in the near future increases. In a validation study on HPI conducted in patients under general anesthesia, the algorithm, at its optimal value, predicted hypotension with both sensitivity and specificity of 86% 5 minutes before the event. Measurement of the arterial pressure waveforms using a finger cuff (ClearSight) is well established.
223562708|NCT05667584|DEVICE|non-invasive arterial pressure waveforms|ClearSight is a non-invasive hemodynamic monitoring device using digital-cuff and volume-clamp technology to obtain a continuous arterial blood pressure waveform. Continuous finger blood pressure measurement is established by wrapping the cuff around the middle phalanx of a finger. The area under the waveform curve is analyzed using a unique algorithm that serves to calculate the arterial blood pressure, stroke volume (SV) and CO.
223562709|NCT06907680|DIETARY_SUPPLEMENT|M-Gard|One capsule containing 250mg of M-Gard Particulate EW is taken twice daily for 14 days.
223562710|NCT06907680|OTHER|Placebo|One capsule containing 250mg of MCC (Microcrystalline Cellulose) is taken twice daily for 14 days.
223562711|NCT06889779|DIETARY_SUPPLEMENT|MIX 1|Humiome® Post LB postbiotic 300 mg , Human Milk Oligosaccharides 2'-Ofucosyllactose 300 mg 1 capsule per day Orally
223562712|NCT06889779|DIETARY_SUPPLEMENT|MIX 2|Humiome® Post LB postbiotic 100 mg Human Milk Oligosaccharides 2'-O-fucosyllactose 500 mg 1 capsule per day Orally
224035548|NCT06296875|DIETARY_SUPPLEMENT|Vegetable oil|mixed vegetable oil
224035549|NCT06296875|DIETARY_SUPPLEMENT|Krill oil|Krill oil
223420985|NCT05727566|OTHER|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency|visual pain scale (VASpain/fatigue), Beck depression index (BDI), the sexuality-importance score, sexual intercourse frequency
223420986|NCT05207657|DRUG|Lentiviral vector transduced CD34+ cells|Gene therapy for p47 AR-CGD will be performed by introduction a normal copy of the NCF-1 gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient
223420987|NCT06612242|PROCEDURE|early tracheostomy (less than 7 days from intubation)|Early tracheostomy (less than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
223420988|NCT06612242|PROCEDURE|Late tracheostomy (more than 7 days from intubation)|Late tracheostomy (more than 7 days from ventilation) in mechanically ventilated patients with Guiilain-Barre syndrome
223562713|NCT06889779|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose 1 capsule per day Orally
223562714|NCT07079267|DRUG|Olpasiran|
223562715|NCT05756166|PROCEDURE|Biopsy|Undergo tumor biopsy
223562716|NCT05756166|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223562717|NCT05756166|DRUG|Celecoxib|Given PO
223562718|NCT05756166|PROCEDURE|Computed Tomography|Undergo CT scan
223562719|NCT05756166|BIOLOGICAL|Interferon Alpha-2|Given IV
223562720|NCT05756166|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223562721|NCT05756166|BIOLOGICAL|Pembrolizumab|Given IV
223562722|NCT05756166|DRUG|Rintatolimod|Given IV
224137568|NCT02245451|DRUG|Methadone|
224137569|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
224137570|NCT01551134|PROCEDURE|Fundoplication|Primary fundoplication
224137571|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
224137572|NCT00071422|DRUG|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
224137573|NCT00071422|DRUG|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
224137574|NCT00976950|DRUG|Tipranavir|
224137575|NCT00976950|DRUG|ritonavir|low-dose
224137576|NCT04722484|DRUG|Vericiguat (BAY1021189)|Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
224137577|NCT04195100|DRUG|Pilocarpine Ophthalmic Solution|"1. low dose pilocarpine = 3 x 2.0 mg = 3 x 2 drops of pilocarpine 20.0 mg/ml (2%) per day~2. high dose pilocarpine = 3 x 5.0 mg = 3 x 5 drops of pilocarpine 20.0 mg/ml (2%) per day"
224137578|NCT00126789|DRUG|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
224137579|NCT02674672|DEVICE|VenaTech® (VenaTech Retrievable Filter)|
224137580|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to starchy meal|
224137581|NCT02168296|DIETARY_SUPPLEMENT|Plant-based ingredient added to liquid|
224137582|NCT02168296|DIETARY_SUPPLEMENT|No Plant-based ingredient|
224137583|NCT04008901|DRUG|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
224137584|NCT04008901|DRUG|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
224137585|NCT04325945|DEVICE|Low level laser therapy|808nm low level laser therapy on acupuncture points
224137586|NCT00304915|BEHAVIORAL|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
224137587|NCT00160992|BIOLOGICAL|Melan-A analog peptide|
224137588|NCT03411577|OTHER|Behavioral Intervention|
224137589|NCT06271928|DRUG|Yijing Keli|Once enrolled, participants will be administrated Yijing Keli
223420989|NCT01098760|DRUG|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
223420990|NCT04872894|OTHER|Observational study. No intervention is performed|Descriptive study in participants with clinical and biochemical suspicion of FHH. Comparison between genotype-negative and genotype-positive participants with clinical and biochemical suspicion of FHH.
223420991|NCT00045370|BIOLOGICAL|recombinant interferon alfa|
223420992|NCT00045370|DRUG|temsirolimus|
223420993|NCT01582178|PROCEDURE|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
223420994|NCT01582178|PROCEDURE|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
223420995|NCT04092946|DEVICE|Digital intervention|"Individuals included will be offered a program based on three pillars: education, cognitive-behavioural therapy (CBT) and therapeutic exercise.~The therapeutic exercise component will be delivered in the form of exercise sessions to be performed independently by the individual at home using SWORD Phoenix. These programs will have a duration of between 8 and 12 weeks, according to the condition, following pre-defined protocols. These protocols can be adapted to the needs, performance and progress of each individual by their assigned physical therapist. Individuals will be asked to perform at least 3 exercise sessions per week, in different days, but will not be excluded in case of lower adherence.~In addition to the exercises, the individuals will also have access to educational articles written by the clinical team, as well as to a CBT program delivered through a combination of written articles and pre-recorded audio sessions."
223420996|NCT00137475|PROCEDURE|Intensity-Modulated Radiation Therapy|
223420997|NCT03156179|DIAGNOSTIC_TEST|calcium isotope analysis|A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample \[(42Ca/48Ca) / (44Ca/48Ca)\] is the fractional calcium absorption.
224035550|NCT00105950|DRUG|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
224035551|NCT04633707|DEVICE|adjunctive bright white light therapy in the morning|the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.
223739664|NCT00061698|BEHAVIORAL|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
224035552|NCT04633707|DEVICE|adjunctive bright white light therapy in the afternoon|the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
224035553|NCT04633707|DEVICE|adjunctive dim red light therapy in the afternoon|the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.
224035554|NCT06236347|BEHAVIORAL|Smoking cessation e-visit|Electronic visits (e-visits) for smoking cessation
224035555|NCT06236347|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
224137590|NCT05984810|PROCEDURE|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101|Fluorescence-guided surgery using CEA-targeted fluorophore SGM-101
224137591|NCT05282446|DRUG|INV-202|tablet
224137592|NCT05282446|DRUG|Placebo|matching tablet
224137593|NCT01853111|BIOLOGICAL|Interleukin-2|
224137594|NCT04124042|BIOLOGICAL|XT-150|plasmid DNA
224137595|NCT04124042|DRUG|Placebo|Placebo is a sterile phosphate-buffered saline
224137596|NCT04895605|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
224137597|NCT04895605|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
224137598|NCT02662985|DRUG|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose was administered as 2 × PFS injections."
224137599|NCT02662985|DRUG|Placebo|Secukinumab placebo was provided in a 1 mL PFS for s.c. injection.
224137600|NCT01807715|OTHER|survey|Survey before procedure to obtain demographic information and contraceptive information
224137601|NCT02628249|DIETARY_SUPPLEMENT|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
224137602|NCT02628249|DIETARY_SUPPLEMENT|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
224137603|NCT02628249|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
224137604|NCT02628249|DIETARY_SUPPLEMENT|Essential amino acids|Essential amino acids modeled after egg protein.
224137605|NCT02628249|DIETARY_SUPPLEMENT|Non essential amino acids|Non essential amino acids modeled after egg protein.
224137606|NCT02143193|BEHAVIORAL|Skin-to-Skin Contact|
224137607|NCT00139139|BIOLOGICAL|Hepatitis A vaccine|
224137608|NCT04172753|RADIATION|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
224137609|NCT04172753|DIAGNOSTIC_TEST|Imaging on the MR Linac|Only imaging performed on the MR Linac
224137610|NCT01228942|DEVICE|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
224137611|NCT03676153|OTHER|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
223420998|NCT03500783|DRUG|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
223420999|NCT03500783|OTHER|Standard CPB|Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
223421000|NCT05645640|COMBINATION_PRODUCT|Village doctor-led tailored health management|"Investigators will sketch features of cardiovascular risk factor combinations for the high-risk subjects and accordingly set tailored promotion targets for them. Subjects will receive individualized consultation about their cardiovascular risk profile and tailored health management led by village doctors. They will receive tailored health text messages pushed by village doctors 3 times a week, including contents in physical activity, healthy diet, smoking abstinence, responsible alcohol drinking, sleep, and medication adherence. They will be provided with a smart band, and supposed to daily wear the smart band to collect health data. The progress of tailored promotion targets will be evaluated every 3 months, and feedback will be given in the form of virtual rewards and punishments: completed (a virtual golden egg) and failed (a virtual bomb). According to the number of virtual golden eggs, participants could redeem project gift in real life."
223421001|NCT06332274|DRUG|Tislelizumab|"Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
223421002|NCT06332274|OTHER|Blood sampling|Blood sampling for analyses of MRD (Molecular Residual Disease)
223421003|NCT06332274|DRUG|Placebo|"Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV."
223421004|NCT01964144|DRUG|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
223421005|NCT06316193|OTHER|Diary|The diary is the tool through which the experiences and experiences of the parents of infants admitted to Neonatal Pathology and included in the study and the health care personnel who decide to participate will be collected and analyzed. This tool is given to the parents of infants included in the study in the first few days of the infant's stay (by the third day after admission), subject to the parents' written consent, accompanied by a brief letter of introduction to the diary itself, written by the nurses on the ward. This tool has been part of current clinical practice since January 2023.
223421006|NCT05119322|DIAGNOSTIC_TEST|GlutenDetect home urine test|GFD compliance self-asessment using a home rapid test for GIP detection in urine.
223421007|NCT06721559|BEHAVIORAL|Empower@Home: An online cognitive-behavioral therapy self-care program for geriatric depression|Empower@Home is an online self-help intervention based on cognitive behavioral therapy principles designed to treat depressive symptoms in older adults. The intervention has three components: 9 interactive self-paced online sessions, printed workbook that goes along the online sessions for exercises and homework, and telephone coaching by a trained staff from a social service agency serving older adults. The online sessions contain entertainment elements in the form of a character-driven story of a homebound older adults, video-based psycho-educational content, voice-over instructions, interactive exercises, and weekly home practice assignments.
223421008|NCT06721559|OTHER|Telephone friendly visits|Participants in the waitlist control group will receive attention control through biweekly telephone-friendly visitors. Trained project staff will call participants to provide companionship, emotional support, and a friendly conversation. In addition, the callers will conduct a biweekly assessment of depressive symptoms using the patient health questionnaire (PHQ-9), to mirror the biweekly in-app PHQ-9 assessments with the experimental group.
223421009|NCT05193071|DRUG|Aspirin 100mg; Clopidogrel 300mg|Aspirin 100mg plus Clopidogrel 300mg will be orally administrated after randomization
223421010|NCT00671528|DRUG|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
223421011|NCT00671528|DRUG|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
223421012|NCT00671528|DRUG|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
223421013|NCT05039814|OTHER|postoperative acute kidney injury|patients suffered postoperative acute kidney injury
223421014|NCT05039814|OTHER|none postoperative acute kidney injury|patients did not suffered postoperative acute kidney injury
223421015|NCT00352222|DEVICE|stent implantation|
224137612|NCT03676153|OTHER|Integrative medicine treatment program|Integrative medicine treatment program
224137613|NCT02480179|DEVICE|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
224298875|NCT05203666|OTHER|percutaneous removable interspinous process|percutaneous removable interspinous process spacer a neurologic intermittent clauditation due to a degenerative lumbar spinal stenosis.
224298876|NCT04001920|OTHER|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
224298877|NCT02198326|DRUG|BIBN 4096 BS- in single rising doses|
224298878|NCT02198326|DRUG|Placebo|
223421016|NCT06720584|BEHAVIORAL|Health coach-led, online support program for people living with lupus|"The health coach-led online support and education program for people living with lupus. It includes 8 group sessions and 2 individual sessions with the health coach to set individual goals. Each program group will include up to 10 participants.~Program Session Structure (\~60-75 minutes): educational component presented using a slide set, discussion questions interspersed, mindfulness activities, goal check-ins.~Associated Materials: Notebook, expert videos available."
223421017|NCT04172259|DRUG|Doxorubicin liposome|PLD
223421018|NCT04172259|DRUG|Cyclophosphamide|CTX
223562723|NCT04294498|DRUG|Durvalumab|Entecavir treatment for chronic hepatitis B will be started within one week before initiation of durvalumab treatment for advanced hepatocellulcar carcinoma
223562724|NCT04368091|DEVICE|Xtreme Touch - Neo sirolimus coated PTA balloon catheter|The Xtreme Touch (Magic Touch PTA) - Neo Sirolimus PTA Balloon Catheter is the world's first sirolimus coated PTA balloon. The purpose of the X-TOSI all-comers registry is to collect short and long-term clinical performance data on the Xtreme Touch (Magic Touch PTA) -Neo sirolimus PTA balloon catheter in the treatment of atherosclerotic disease in the infrainguinal arteries in an all-comers patient population in real world daily clinical practice.
223562725|NCT01090934|DEVICE|High Resolution EEG|High Resolution EEG
223421019|NCT04172259|DRUG|Trastuzumab|H
223562726|NCT01090934|DEVICE|Stereo-electroencephalography|SEEG
223562727|NCT03165123|DRUG|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
223562728|NCT03165123|DRUG|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
223562729|NCT03724981|DRUG|Dulaglutide Pen|Injected on a practice pad.
223562730|NCT03724981|DRUG|Semaglutide Pen|Injected on a practice pad.
223562731|NCT05346146|DRUG|Sintilimab; Gemcitabine; Albumin-paclitaxel|Sintilimab: 200mg IV Q3W D1; Gemcitabine: 1000mg/m2 IV Q3W D1,8; Albumin-paclitaxel：125mg/m2,IV,D1,D8,Q3W
223562732|NCT03727022|DRUG|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
223562733|NCT03727022|DRUG|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)
223562734|NCT04796103|PROCEDURE|Dextrose Prolotherapy|In the patients in the prolotherapy injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of 5% dextrose, 1 ml each, will be applied periarticularly. In addition, home exercise program will be given to this group.
223562735|NCT04796103|PROCEDURE|Serum Physiological Group (placebo control group)|In the patients in serum physiological injection group, at the 1st, 4th and 7th weeks, the insertion points of the ligaments and tendons that are sensitive with pressure around the knee (medial collateral ligament (2), lateral collateral ligament (2), quadriceps tendon (1) and patellar tendon (1)) A total of 6 ml of saline will be applied periarticularly. In addition, home exercise program will be given to this group.
223739665|NCT00061698|BEHAVIORAL|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
224137614|NCT01947959|DRUG|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors (20 mg rivaroxaban \[od\], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\])."
224137615|NCT01947959|DRUG|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
223421020|NCT04172259|DRUG|Docetaxel|DOC
223421021|NCT04172259|DRUG|Epirubicin|EPI
223421022|NCT04172259|DRUG|Pertuzumab|P
223421023|NCT04172259|DRUG|Paclitaxel|paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week
223421024|NCT04172259|DRUG|Paclitaxel-albumin|albumin-bound paclitaxel 260 mg/m2 or albumin-bound paclitaxel 100 mg/m2 every week
223421025|NCT06730594|DIETARY_SUPPLEMENT|VL-BK-02 (25 billion CFU/Capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
223421026|NCT06730594|DIETARY_SUPPLEMENT|Placebo (Microcrystalline Cellulose - 375 mg/capsule)|One capsule per day consumed orally before breakfast Duration: 84 days (12 weeks)
223739666|NCT00003147|BIOLOGICAL|Ad5CMV-p53 gene|
223739667|NCT02499250|DEVICE|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
224137616|NCT01486004|DRUG|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
224137617|NCT01486004|DRUG|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
223421027|NCT06737432|OTHER|RKP Monitoring Software|Use of RKP alerting and monitoring software.
224035556|NCT05731050|DRUG|NM8074|"NM8074 will be administered as an intravenous infusion. All enrolled subjects will receive a dose of 15 mg/kg NM8074 once every two weeks for a total of 6 doses from Day1 to Day 84.~For Soliris-treated PNH subjects, admission and dosing of NM8074 on Day 1 should be scheduled to coincide with the next scheduled dose of Soliris (i.e., 14 ± 2 days after the last Soliris dose). Soliris should NOT be administered on Day 1 or at any time thereafter during course of the study.~Subjects in the treatment groups will receive a dose of 15 mg/kg of NM8074 on Day 1, which will be administered during the study visit by the site staff. During the remainder of the treatment period, subjects will be given another 15 mg/kg dose every two weeks at approximately the same time. On days of scheduled study visits at the Investigation Site, the dose must be administered after blood work is completed."
224035557|NCT02719847|PROCEDURE|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
224035558|NCT06046040|DRUG|TmPSMA-02 CAR T Cells|TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
224035559|NCT05402332|DRUG|AVTX-801|D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)
224137618|NCT02056717|DRUG|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
224137619|NCT02056717|DRUG|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
224137620|NCT05572827|BEHAVIORAL|Breathing exercises|Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
224137621|NCT06382363|PROCEDURE|POC-cHbA1c testing|The point-of-care HbA1c instrument employed in this study will be the Cobas b 101 (Roche Diagnostics, Switzerland) diagnostic test system. A capillary blood sample will be obtained by dermal puncture of a fingertip using a disposable lancet and resorbed in the specially marked area of the Cobas b 101 test disc. The disc will be inserted in the autoanalyzer. Test results displayed in both % and mmol/l will be available within 10 minutes.
224137622|NCT04782037|DRUG|L-Methylfolate Calcium|Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
223421028|NCT04858061|BEHAVIORAL|Virtual Reality Cue Exposure Therapy|Exposure to alcohol-related cues within virtual environments
223421029|NCT04858061|BEHAVIORAL|Treatment-as-usual|Pharmacotherapy and psychotherapy
223421030|NCT06784895|BEHAVIORAL|Women only Cardiac Rehab program|"This is a 12-week program and will include 36 sessions 3 times a week. This group will also have Women-Only Education sessions. Participants will also have a 24-week follow-up visit from the time of entry.~This group orientation prior to starting CR will allow additional time for enhanced story telling among patients, provide a more detailed description of what to expect in CR, and allow additional time to address participant concerns or worries prior to starting CR. Women-specific education content will be provided monthly in addition to the standard weekly mini-teaches. This education content will be developed and delivered by experience health care professionals that are experts in women's health."
223421031|NCT06784895|BEHAVIORAL|Standard of Care (mixed-sex) rehab program|This is a 12-week program and will include up to 36 sessions 3 times a week. Participants will also have a 24-week follow-up visit from the time of entry. Exercise classes are medically supervised, and each program is individualized based upon medical history, cardiac risk factors, goals, and initial fitness level. Educational programs are arranged in a continuing series, with sessions taught by experts in nutrition therapy, stress reduction therapy, and exercise.
223421032|NCT05280444|DRUG|Idarubicin Hydrochloride for Injection|The initial dose of idarubicin is 10 mg and the maximum tolerated dose is 20 mg. Idarubicin is first dissolved in water for injection to make a solvent of 2mg/ml, which is then mixed with lipiodol to make an emulsion with a ratio of 1:2. Lipiodol-idarubicin emulsion is slowly injected, followed by embolization with embolic agents.
223421033|NCT03364400|DRUG|VT1021|Peptide
223421034|NCT00556933|DRUG|rabbit anti-thymocyte globulin - single dose|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
223421035|NCT00556933|DRUG|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
223421036|NCT00556933|DRUG|rabbit anti-thymocyte globulin - 4 doses|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
223421037|NCT00556933|DRUG|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
223421038|NCT00556933|DRUG|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
223421039|NCT00755599|PROCEDURE|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
223421040|NCT00755599|PROCEDURE|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
223421041|NCT00602459|DRUG|Cyclophosphamide|Given IV
223421042|NCT00602459|DRUG|Fludarabine Phosphate|Given IV or PO
223421043|NCT00602459|OTHER|Laboratory Biomarker Analysis|Correlative studies
223421044|NCT00602459|DRUG|Lenalidomide|Given PO
223421045|NCT00602459|BIOLOGICAL|Rituximab|Given IV
224035560|NCT05402332|DRUG|Placebo|placebo equivalent
223421046|NCT00005777|PROCEDURE|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (\>52 mm Hg)
223421047|NCT00005777|PROCEDURE|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target \<48 mm Hg)
223421048|NCT00005777|DRUG|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
223421049|NCT00005777|DRUG|Placebo|The infants in the placebo groups received equal volumes of saline.
223562736|NCT00434603|BEHAVIORAL|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
223562737|NCT01360372|DRUG|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
223562738|NCT01360372|DRUG|Saline injection|Saline 0.4 to 0.8 ml injection
223562739|NCT02108717|DEVICE|Remote CT reading using the iPhone|
223562740|NCT02108717|DEVICE|CT reading using LCD monitor|
223562741|NCT01255007|OTHER|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
223562742|NCT00130143|DRUG|Ethyol (Amifostine)|
223562743|NCT03359707|OTHER|survey|no intervention just survey
223562744|NCT00197145|DRUG|GW873140|400 mg twice daily
224035561|NCT01166893|DEVICE|Modulated Imaging and Laser Speckle Imaging|wound healing
224035562|NCT06138132|BIOLOGICAL|KYV-101 anti-CD19 CAR-T cell therapy|KYV-101 anti-CD19 CAR-T cell therapy
224035563|NCT06138132|DRUG|Standard lymphodepletion regimen|Standard lymphodepletion regimen
223562745|NCT01794078|DRUG|Aminophylline 400 mg|Xanthine derivative
223562746|NCT01794078|DRUG|Ambrisentan 5 mg|Endothelin receptor antagonist
223562747|NCT01794078|OTHER|Placebo|
223562748|NCT03886870|BEHAVIORAL|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
224137623|NCT04301687|PROCEDURE|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
223421050|NCT06343467|DEVICE|Generic Volar Locking Plate|Application of a generic volar locking plate is done in the generic implant arm compared to the other commonly used implants by surgeons in the conventional implant arm.
223421051|NCT06343467|DEVICE|Conventional Volar Locking Plate|Application of a conventional, brand name volar locking plate is done in the conventional implant arm compared to the generic implant arm.
223421052|NCT04057482|DRUG|D|treatment of BV with dequalinium chloride vaginal tablets
223421053|NCT06346444|OTHER|Diagnostic test and behavioral|Questionnaires (CGI, RSBQ) and Outcome measurements (Neuroscope, EEG, Brain MRI, Bone densitometry, X-ray of thoracic and lumbosacral spine Blood biomarkers-RNA, proteins, other metabolites-)
223421054|NCT02523976|DRUG|Dasatinib|Second-generation tyrosine kinase inhibitor
223421055|NCT02523976|DRUG|prednisone|
223421056|NCT02523976|DRUG|cyclophosphamide|
223562749|NCT03886870|BEHAVIORAL|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
223562750|NCT00898300|OTHER|biologic sample preservation procedure|
223562751|NCT00898300|PROCEDURE|biopsy|
223562752|NCT00018330|BEHAVIORAL|Weight Loss|
224035564|NCT05471700|DRUG|Azacitidine|Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
224035565|NCT05471700|DRUG|Venetoclax|Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
224035566|NCT04263909|DRUG|Sublingual Tablet|sufentanil SL 30mcg administered sublingually to patients undergoing spine surgery before extubation and during recovery
224035567|NCT06963034|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
224035568|NCT06963034|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
224035569|NCT06961565|DRUG|PAS-004 Tablets|A mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MAPK/ERK kinase, or MEK) 1/2 inhibitor presented in 1m and 4mg strength tablets, intended for oral administration once daily.
224035570|NCT04477330|OTHER|Transcranial direct current stimulation (tDCS)|1 mA tDCS
224035571|NCT04477330|OTHER|Ankle motor training|Visuomotor target tracking task
223421057|NCT02523976|DRUG|daunorubicin|
223562753|NCT01174277|OTHER|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
223562754|NCT00678535|DRUG|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m\^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m\^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
223562755|NCT00678535|DRUG|Capecitabine|Capecitabine 1000 mg/m\^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
223562756|NCT00678535|DRUG|Cisplatin|Cisplatin 80 mg/m\^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
223562757|NCT05392790|OTHER|Progressive resisted exercise training|Progressive resisted exercises will be started with the 8 maximum repetition test (8 RM) performed at progressive intensities. The subject will perform the 8 RM test at the beginning and the end of each cycle over the two-month training period. Each training session lasts sixty minutes and will be performed three times per week on alternate days.
223562758|NCT05392790|DRUG|Calcium and Vit D|Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
223562759|NCT05392790|OTHER|Aerobic exercises|Aerobic exercises will be applied at 70 - 80% of their maximum heart rate. Trained health professionals supervised the exercise program. Each exercise session will begin with a 5-10-minute warm-up, will be followed by 20 -30 minutes of aerobic activity, and will be concluded with a 5-10-minute cool-down period.
224035572|NCT04477330|BEHAVIORAL|High intensity interval speed based treadmill training (HIISTT)|Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
224035573|NCT04992325|DIAGNOSTIC_TEST|Anterior segment-optical coherence tomography|Each subject underwent anterior segment -optical coherence tomography to evaluate the total corneal, epthelium and stromal thicknesses.
224035574|NCT01349881|DRUG|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
224035575|NCT01349881|DRUG|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
224035576|NCT01349881|DRUG|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
224035577|NCT01349881|DRUG|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
224035578|NCT05173597|DRUG|Follitropin delta|REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
224035579|NCT06506565|DRUG|Ketamine|Infusion during wound care
224035580|NCT06506565|DRUG|0.9% NaCl|Infusion during wound care
224035581|NCT05614323|OTHER|Interview and determining taste and smell with taste strips and Sniffin' Sticks|The Patient-Generated Subjective Global Assessment (PG-SGA) Short Form will be filled in by the participants. Next, a semi-structured in-depth interview will be performed in a quiet environment. The interview will take a maximum of one hour and will take place once. Topics that will be discussed are eating-related problems, the taste and smell of the offered hospital food, the choice in hospital food, the ambience during the eating moments, the use of protein-enriched snacks, the difference between eating at home and at the hospital, personal tips- and-tricks to maintain adequate nutritional intake, and how patients' think that food enjoyment can be improved in the hospital. The interview will be recorded. At last, taste and smell will be objectively determined with respectively taste strips and Sniffin' Sticks.
223421058|NCT02523976|DRUG|vincristine|
223562760|NCT02578680|BIOLOGICAL|Pembrolizumab 200 mg|IV infusion
223562761|NCT02578680|DRUG|Cisplatin|IV infusion
223739668|NCT02499250|DRUG|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
224035582|NCT04823299|PROCEDURE|Cryoballoon ablation|Cryoballoon pulmonary vein isolation ablation
224035583|NCT04823299|PROCEDURE|Radiofrequency catheter ablation +EPS guided trigger and substrate ablation|RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation
224137624|NCT04301687|PROCEDURE|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
224137625|NCT03442829|BEHAVIORAL|Sweet food consumption|Sweet food consumption at breakfast
224137626|NCT03442829|BEHAVIORAL|Non-sweet food consumption|Non-sweet food consumption at breakfast
224137627|NCT05279989|OTHER|Seated Tai Chi Qigong|Participants will receive seated Tai Chi Qigong videos.
224137628|NCT05279989|OTHER|Health Information Videos|Participants will receive videos of health information.
224137629|NCT02011126|DRUG|Imetelstat Sodium|Given IV
223421059|NCT02523976|DRUG|cytarabine|
223421060|NCT02523976|DRUG|mercaptopurine|
223421061|NCT02523976|DRUG|methotrexate|
223421062|NCT02523976|DRUG|dexamethasone|
223421063|NCT02523976|DRUG|mitoxantrone|
223421064|NCT02523976|DRUG|etoposide|
223421065|NCT02523976|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223421066|NCT02523976|PROCEDURE|autologous hematopoietic stem cell transplantation|
223421067|NCT00445497|DRUG|amoxicillin-clavulanate potassium|
223421068|NCT00445497|DRUG|ciprofloxacin|
223421069|NCT00445497|PROCEDURE|psychosocial assessment and care|
223421070|NCT00445497|PROCEDURE|quality-of-life assessment|
223421071|NCT01295827|BIOLOGICAL|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
223562762|NCT02578680|DRUG|Carboplatin|IV infusion
223562763|NCT02578680|DRUG|Pemetrexed|IV infusion
224137630|NCT02011126|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223421072|NCT01668173|DRUG|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
223421073|NCT00688662|PROCEDURE|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
223421074|NCT00688662|PROCEDURE|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
223421075|NCT01174706|BEHAVIORAL|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
223421076|NCT01240577|DRUG|IPdR|
223421077|NCT02300662|DEVICE|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
223421078|NCT02300662|OTHER|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
223421079|NCT01883726|DEVICE|Grayson's presurgical nasoalveolar molding|Grayson NAM
223421080|NCT01883726|DEVICE|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
223421081|NCT00944086|OTHER|Recruitment Manoeuvre|Recruitment Manoeuvre
223421082|NCT06235021|OTHER|Saffron|"Saffron powder (purchased from Moayeri Copmany2 in Oman, prepared from the stigma of Crocus sativus L.).~Total of 10 mg of saffron powder will be added to 100 ml of distilled water. Then, it will be incubated on a shaker for 24 h. The material will be passed through several layers of muslin cloth. The extracts will then be poured into a round bottom balloon and placed in the freezer at a temperature of -80°C. After freezing, the extracts were placed in a freeze-dryer.~In vacuum, the solvent will be removed and saffron powder will be obtained. After preparing the initial concentration, serial dilution with ratios of one-half and one-third will be performed in sterile vials and one-half of the final concentration will be discarded.~After the preparation of extract, the 0.2% saffron mouthwash will be prepared by mixing the following ingredients: 1. propylene glycol (5 g) 2. saffron extract (0.2 g) 3. polysorbate 80 (1.8 g) 4. sodium benzoate (0.2 g) 5. water (91 g)."
223421083|NCT06235021|OTHER|chlorhexidine mouthwash|commercial product of 0.2% chlorhexidine mouthwash.
223421084|NCT00746564|DEVICE|SJM Confirm|All patients in this study will receive the SJM Confirm device.
223421085|NCT03318497|DRUG|3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT|Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
223421086|NCT03318497|PROCEDURE|Computed Tomography|Undergo PET/CT
223421087|NCT03318497|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223421088|NCT03318497|OTHER|Laboratory Biomarker Analysis|Correlative studies
223421089|NCT03059745|PROCEDURE|Cholecystectomy|Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
223421090|NCT06578598|DEVICE|Igelplus|Intubation with Igelplus laryngeal mask
223421091|NCT00077298|BIOLOGICAL|cetuximab|Given IV
223421092|NCT00077298|BIOLOGICAL|bevacizumab|Given IV
223421093|NCT00077298|DRUG|irinotecan hydrochloride|Given IV
223421094|NCT00077298|OTHER|laboratory biomarker analysis|Correlative studies
223421095|NCT03732482|DRUG|Temozolomide capsules|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
223421096|NCT03732482|DEVICE|radiotherapy|Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
223421097|NCT02921880|OTHER|Cardiac Rehabilitation|
223421098|NCT00907491|DEVICE|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
223421099|NCT04836962|DRUG|normal saline|2cc of normal saline is administered to patient instead of dexamethasone.
223421100|NCT04836962|DRUG|dexamethasone|dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
223421101|NCT02842580|DRUG|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
223421102|NCT02842580|DRUG|acide folinique|200 mg/m² if Elvorine
223739669|NCT04072211|BIOLOGICAL|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
223739670|NCT05952024|DRUG|Acalabrutinib|Patients will receive acalabrutinib orally with dosing schedule of X.
223739671|NCT05952024|BIOLOGICAL|Rituximab|Patients will receive rituximab via IV infusion on Cycle 1 Day 15 and via SC injection on Day 1 of Cycle 2 through Cycle 8.
223739672|NCT00003573|BIOLOGICAL|filgrastim|
223739673|NCT00003573|DRUG|cisplatin|
224035584|NCT06300957|OTHER|Help Wanted Prevention Intervention|"The intervention includes an introductory welcome place, five training sessions that deliver core intervention content, and a resources page that provides links to external sources of support.~The Help Wanted Prevention Intervention is a free, online, self-help course to address the needs of people with a sexual attraction to children. Help Wanted aims to provide knowledge, skills, and resources to support help-seekers' commitments to living safe, healthy, and fulfilling lives."
224035585|NCT06300957|OTHER|Waitlist Control|Participants will be provided with information on how to access alternative resources and help lines to support mental health, suicide prevention, and child sexual abuse prevention. After one month, they will be granted access to Help Wanted.
224035586|NCT06801886|DRUG|Silymarine supplementation|900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.
223421103|NCT02842580|DRUG|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
223562764|NCT02578680|DIETARY_SUPPLEMENT|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
224035587|NCT06801886|OTHER|Placebo Supplementation|Placebo supplementation during the early post-transplant period (30 days) under standard treatment
223421104|NCT02842580|DRUG|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
223421105|NCT02842580|DRUG|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
223421106|NCT02842580|DRUG|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
223421107|NCT05972408|PROCEDURE|percutaneous nephrlolithotomy|Endoscopic removal of renal stones
223421108|NCT05972408|GENETIC|VDR gene, CASR gene|checking possible mutations of VDR and CASR genes
223562765|NCT02578680|DIETARY_SUPPLEMENT|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
223562766|NCT02578680|DRUG|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
224035588|NCT06078878|DEVICE|HF-OCT Imaging System with Vis-M Micro-Imaging Catheter|Subjects undergo HF-OCT imaging of the desired intravascular segement
224035589|NCT04288778|DRUG|Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration. The study Treatment duration will be of 24 weeks.
224035590|NCT03945747|DIAGNOSTIC_TEST|Blood draw|Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.
224035591|NCT03945747|DIAGNOSTIC_TEST|Urine sample collection|Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.
224035592|NCT03945747|DIAGNOSTIC_TEST|DXA scan|Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.
224035593|NCT00006332|DRUG|Tetrathiomolybdate|
224137631|NCT01134757|BIOLOGICAL|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
224137632|NCT01066195|DRUG|iressa|iressa 250mg per day every day
223421109|NCT01130441|BEHAVIORAL|psychotherapy|short problem-solving skills therapy intervention
223421110|NCT02640677|BIOLOGICAL|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
223421111|NCT01516008|DRUG|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
223421112|NCT01516008|DRUG|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
223421113|NCT01516008|DRUG|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
223421114|NCT05704998|OTHER|Physiotherapy|Posture exercises, myofascial release techniques, sternocleidomastoideus and upper trapezius kinesio taping, trigger point ischemic compression, suboccipital release technique, cervical traction, deep neck flexors endurance exercises, massage
223421115|NCT04393480|OTHER|Robotic therapy|ReoGo™ - Motorika robotic therapy - upper extremity robotic rehabilitation system
223562767|NCT02578680|DRUG|Saline solution|IV infusion
223562768|NCT00970723|BEHAVIORAL|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
223562769|NCT00970723|BEHAVIORAL|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
223562770|NCT00970723|BEHAVIORAL|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
223562771|NCT00073411|DRUG|duloxetine|
223562772|NCT00073411|DRUG|escitalopram|
223562773|NCT00073411|DRUG|placebo|
223562774|NCT03581149|DRUG|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
224035594|NCT00621647|DRUG|Quetiapine Fumarate|
224035595|NCT00621647|DRUG|Quetiapine Fumarate|
224137633|NCT01066195|DRUG|alimta|alimta 500mg/m2 every 3 weeks
224137634|NCT02862223|DIETARY_SUPPLEMENT|Neoprinol|
224035596|NCT00621647|DRUG|Placebo|
224035597|NCT02645188|OTHER|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
224298879|NCT03407430|DRUG|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
223421116|NCT04393480|OTHER|Conventional therapy|Range of Motion (ROM) exercises, muscle strengthening, balance and mobility training, exercises for enhancing activities of daily life, neurophysiological exercises, turnings, bed movements, bridge building, sitting and transfer training, gait training, proprioceptive exercises, balance exercises on the balance board of those affected by the cerebellar system, occupational therapy, cognitive rehabilitation by the relevant psychologist given to those with cognitive impairment
223421117|NCT06458582|DEVICE|High-Flow Nasal Cannula|The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
224298880|NCT03407430|DRUG|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
223421118|NCT02036840|DRUG|Antibiotic|
223421119|NCT05284591|BIOLOGICAL|Daratumumab|intravenous or subcutaneous
223421120|NCT04287231|DEVICE|Transcranial direct current stimulation|This instrument will be used to induce post-stroke motor recovery, two different monocephalic montages are typically used to restore excitability in the lesioned hemisphere and to down regulate excitability of the non-lesioned hemisphere and rebalance Interhemispheric inhibition. each participant will undergo a 20-minute period of tDCS, applied at 2 mA through a pair of saline-soaked surface sponge electrodes (35 cm2).
223562775|NCT03581149|DRUG|2L polyethylene glycol/ascorbic acid|"* First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
223562776|NCT04654169|PROCEDURE|Ultrasound-guided IAI|Ultrasound-guided IAI was applied with a posterior glenohumeral joint in-plane injection technique.
223562777|NCT04654169|PROCEDURE|Ultrasound-guided SSNB|Ultrasound-guided SSNB was carried out with a supraspinatus fossa level in-plane injection technique
223562778|NCT05427136|DIAGNOSTIC_TEST|Lung function measurements|"All lung function tests are non-invasive and last about 60 minutes per child:~* Multiple Breath Washout: The nitrogen multiple-breath-washout test (N2MBW) measures ventilation inhomogeneity of the lung that occurs when smaller airways are damaged.~* Spirometry/Bodyplethysmography/DLCO: Spirometry measures dynamic air flows to quantify airway obstruction of large airways and pulmonary restriction. Plethysmography assesses static lung volumes. Diffusing capacity of the lung for carbon monoxide (DLCO) evaluates diffusion deficits."
223739674|NCT00003573|DRUG|cyclophosphamide|
223421121|NCT05504538|PROCEDURE|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope|arthroscopic fixation of Acute acromioclavicular joint injury using tight rope
223739675|NCT00003573|DRUG|etoposide|
223739676|NCT00003573|DRUG|vincristine sulfate|
224035598|NCT02624765|DRUG|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
224035599|NCT02624765|DRUG|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
224035600|NCT02624765|DRUG|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
224035601|NCT02624765|DRUG|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
224035602|NCT02624765|DRUG|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
223421122|NCT05504538|DEVICE|Tight rope|Adjustable button device from Arthrex Naples USA
223421123|NCT02932527|BEHAVIORAL|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
223421124|NCT02932527|PROCEDURE|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
223421125|NCT02932527|PROCEDURE|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
223421126|NCT03960489|DRUG|Roxadustat|Participants will receive single dose of 100 mg azo dye free tablet or mini tablet suspension or solid mini tablet or dye containing tablet.
223421127|NCT06683430|DIETARY_SUPPLEMENT|High Potassium, Low Sodium Diet|Daily intake of 3500 mg K and 1500 mg Na for 14 days.
223421128|NCT06683430|DIETARY_SUPPLEMENT|Standard Diet|Daily intake of 1700 mg K and 2000 mg Na for 14 days.
223421129|NCT00004647|DRUG|mexiletine|
223421130|NCT03699280|OTHER|Virtual Reality|Oculus Go VR device
223421131|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform acts of kindness to others
223421132|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform acts of kindness to self
224035603|NCT02624765|DRUG|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
224035604|NCT05058625|DEVICE|Dry Needling plus normal volleyball training|Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
224035605|NCT05058625|OTHER|Control Group|Normal volleyball training
224035606|NCT02973074|DIETARY_SUPPLEMENT|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
224035607|NCT05482152|BEHAVIORAL|Nurse-led care by a nurse specialist in pain|A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
224035608|NCT05987397|DRUG|idebenone 30 mg for 14 days|The patient received oral idebenone 30 mg three times a day after stroke for a total course of 14 days (acute phase).
224298881|NCT01953939|OTHER|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
224298882|NCT06168435|OTHER|eIMPAQc|e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
223421133|NCT03319342|BEHAVIORAL|Behavioral Intervention|Perform self-kindness meditation
223421134|NCT03319342|BEHAVIORAL|Behavioral Intervention|Keep track of daily activities
223421135|NCT03319342|OTHER|Questionnaire Administration|Ancillary studies
223421136|NCT03270852|DEVICE|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
223421137|NCT03270852|OTHER|No Enhanced reality|Identical rehabilitation without enhanced reality
224035609|NCT05987397|DRUG|idebenone 30 mg for 3 months|The patient will be treated with oral idebenone 30 mg three times a day after stroke for a total course of 3 months.
224035610|NCT05042518|BEHAVIORAL|Experiment|breathing control and self-talk with objectives
223421138|NCT04604392|PROCEDURE|Rapid Maxillary Expansion Treatment|The patients were treated with KBME, Hyrax and MIDME maxillary expansion appliances, respectively. All expansion appliances containing a Hyrax expansion screw positioned parallel to the second premolars and were used to correct the posterior crossbite. In the MIDME group, two mini-screws with a diameter of 1.6 mm and a length of 10 mm are located on the right and left sides between the roots of the 2nd premolar and 1st molar teeth with 60-70° angle. KBME and Hyrax expansion appliances were cemented with glass ionomer cement and MIDME was cemented with using the light-cured composite. Same protocol was applied to all patients during RME treatment. Expansion screws in all groups were activated by two turns a day.
223421139|NCT01733290|DRUG|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
223421140|NCT01733290|DRUG|Normal saline instillation|Normal saline instillation
223421141|NCT02842710|DEVICE|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
224035611|NCT05042518|OTHER|Control|The participant in the control group will receive consultations by a sport psychologist for goal setting and positive thinking. The duration is similar to the training group (4-5 minutes in each session, 4 sessions per week for 1 month)
224035612|NCT01324323|DRUG|Romidepsin|14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.
223421142|NCT05806632|OTHER|Prognostic model|Risk assessment and risk stratification
223421143|NCT03963232|DRUG|Galcanezumab|Administered SC
223562779|NCT05427136|DIAGNOSTIC_TEST|Breath Analysis|Patients will exhale into a secondary electrospray-ionization-mass spectrometry (SESI-MS) breath analysis platform. SESI-MS allows real-time breath-printing by detection of both volatile and non-volatile trace components.
223739677|NCT00003573|RADIATION|radiation therapy|
223739678|NCT05896293|DRUG|kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)
223739679|NCT05896293|DRUG|leuprolide acetate|Single SC bolus
224035613|NCT01324323|DRUG|Rifampin|600 mg oral once daily on Days 4-8
224035614|NCT05023343|DRUG|Ropivacaine|30 mL Ropivacaine 0,75% administered as a unilateral TQL block
224137635|NCT01486784|DRUG|Birinapant|IV formulation to be given weekly 3 weeks out of 4 week cycle or 4 weeks our of a 4 week cycle as a 30 minute infusion
224298883|NCT04445779|DIETARY_SUPPLEMENT|Coenzyme Q10|Patients will receive per-orally 10 mg/kg of body weight of coenzyme Q10 in form of Myokinon (PharmaNord, Denmark) in three divided doses. They will receive therapy for at least 10 days before surgical procedure.
224298884|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
223421144|NCT03963232|DRUG|Placebo|Administered SC
223421145|NCT05510570|GENETIC|The research does not require interventions|We use Whole-exome sequence (WES) to analyze if there is any gene mutations for DLD(developmental language disorder) children.
223421146|NCT03563352|OTHER|Interview|Attend an interview
223421147|NCT03563352|OTHER|Survey Administration|Ancillary studies
223421148|NCT00792792|DEVICE|Modulated Imaging|Modulated Imaging Spectroscopy
223421149|NCT03617770|BEHAVIORAL|Sleep Opt-In|8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
223421150|NCT03617770|BEHAVIORAL|Healthy Living|8-week intervention that includes weekly telephone counseling on healthy living.
223421151|NCT04921826|OTHER|online survey|online survey
223421152|NCT00356135|DRUG|prasugrel 10 mg|10 mg tablet taken orally
223421153|NCT00356135|DRUG|clopidogrel|75 mg tablet taken orally
223562780|NCT05427136|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Functional MRI scan assessing regional fractional lung ventilation and relative perfusion, followed by a morphological MRI scan. This technique allows simultaneous assessment of all affected lung components, the airways, alveoli and pulmonary vasculature.
223562781|NCT05427136|OTHER|Standardized interview to assess respiratory symptoms|Short questions on current airway symptoms, recent colds, exercise-related respiratory symptoms, and passive smoking exposure will be assessed. The interview takes about 10 minutes.
224035615|NCT05023343|OTHER|Quadriceps muscle strength|Quadriceps muscle strength is assessed using a hand-held dynamometer. Each participant is tested pre block administration and 60 minutes after
224035616|NCT05023343|OTHER|Timed Up and Go|To test mobilisation the standardised Timed Up and Go test is used. Each participant is tested pre block administration and 60 minutes after
224035617|NCT05023343|OTHER|Single-leg 6 meter timed hop test|To test muscle strength and power the single-leg 6 meter jump test is used. Each participant is tested pre block administration and 60 minutes after
224035618|NCT05023343|OTHER|Temperature discrimination|Dermatomal evaluation of cold and warm discrimination of the thoracic and lumbar dermatomes Approximately 60 minutes after block administration
224035619|NCT05023343|OTHER|Pinprick test|"Dermatomal evaluation of pinprick/sharp sensation of the thoracic and lumbar dermatomes.~Approximately 60 minutes after block administration"
224035620|NCT05023343|DIAGNOSTIC_TEST|Blood samples|As a substudy the maximum serum concentration of ropivacaine is analyzed. Blood samples are taken at 0, 15, 30, 45 and 60 minutes after block administration
223421154|NCT00356135|DRUG|prasugrel placebo|oral, as blinding mechanism.
223421155|NCT00356135|DRUG|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
223421156|NCT00356135|DRUG|clopidogrel placebo|oral, as blinding mechanism
223421157|NCT03475862|DRUG|PTI-821 capsule Manipulated|PTI-821 (oxycodone) 40 mg extended release capsule
223421158|NCT03475862|DRUG|PTI-821 Non-manipulated|PTI-821 (oxycodone) 40 mg capsule extended release capsule
223421159|NCT03475862|DRUG|OxyContin|Crushed OxyContin (oxycodone) extended-release 40 mg tablet
223421160|NCT03475862|OTHER|Placebo|Matching placebos for PTI-821 and oxycodone IR
223421161|NCT03475862|DRUG|Oxycodone|Crushed oxycodone 40 mg immediate release tablet
223421162|NCT04965311|BIOLOGICAL|Botulinum Toxin Type A|Given via endoscopic injection into intraduodenal sphincter of Oddi segment
223421163|NCT03512210|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily with or without food.
223421164|NCT03512210|OTHER|Minimal Monitoring (MINMON) Strategy|"MINMON Strategy:~1. No pre-treatment HCV genotyping~2. Entire treatment course (84) tablets of SOF/VEL administered to participants at study entry~3. No scheduled on-treatment laboratory monitoring or clinic visits~4. Remote contact with participants at week 4 and week 22"
223421165|NCT02898428|DEVICE|Continuous glucose monitoring (CGM)|
223421166|NCT03138759|DRUG|Pexidartinib|Orally, on Day 2
223421167|NCT03138759|DRUG|Probenecid|Orally, on Day 2
223421168|NCT04143854|DRUG|MBA-P01(Botulinum toxin A)|Intramuscular injection; Dose varies by group
223421169|NCT04143854|DRUG|Placebo|Intramuscular injection; normal saline
223421170|NCT02586038|DRUG|MLN9708|
223562782|NCT05427136|OTHER|Data collection for assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and HSCT|Assessment of clinical parameters and cumulative doses to chemotherapy, radiation, surgery and hematopoietic stem cell transplantation (HSCT). Data on cumulative doses of pulmotoxic chemotherapy (carmustine, lomustine, busulfan, bleomycin, methotrexate and cyclophosphamide, fludarabine, ifosfamide, melphalan and thiotepa) and radiation therapy at the region of the chest from patient's hospital charts will be collected. Information on chest wall and lung surgery will be retrieved from the surgical reports. Information about conditioning regimens including cumulative chemotherapy doses and total body irradiation of patients undergoing HSCT will be collected. Further information on the health state of the patient and interventions (e.g. development of pneumonia, antibiotic treatment) will be collected from the hospital charts.
223421171|NCT02586038|DRUG|Dexamethasone|
223421172|NCT02586038|DRUG|Cyclophosphamide|
223562783|NCT05427136|OTHER|Collection of genetic samples|Germline DNA is collected (e.g. through saliva or buccal cell sampling) for later analysis on genetic risk factors for pulmonary complications.
223562784|NCT02833090|PROCEDURE|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
223421173|NCT02586038|DRUG|Thalidomide|
223421174|NCT01927549|PROCEDURE|Immediate multivessel PCI|
223421175|NCT01927549|PROCEDURE|Culprit Lesion only PCI|
223421176|NCT05172440|DRUG|tislelizumab combined with axitinib|Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
223421177|NCT06937060|BIOLOGICAL|semaglutide|Semaglutide is act as an adjunct to a reduced calorie diet and increase physical activity for chronic weight management in adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
223421178|NCT04638764|OTHER|Aerobic interval training combined with high intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 70 %- 80 % of one repetition maximum (1-RM)).
223421179|NCT04638764|OTHER|Aerobic interval training combined with low intensity resistance training|Patients enrolled in arm of the study will perform 12 weeks of combined aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing) combined with high intensity resistance training (3 sets of leg press at the intensity of 30 %- 40 % 1-RM).
224298885|NCT03531190|DIETARY_SUPPLEMENT|Nutritional supplement (Protein)|Protein supplement as needed
224298886|NCT00192855|DRUG|Entacapone|Entacapone 600mg BID
224298887|NCT02794155|DRUG|HDV Insulin Lispro|HDV Insulin Lispro: \~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
223421180|NCT04638764|OTHER|Aerobic interval training|Patients enrolled in arm of the study will perform 12 weeks of aerobic interval training (5 intervals of cycling at the intensity of 50 %-80% of peak power obtained at baseline cardiopulmonary testing).
223421181|NCT04725955|OTHER|Enriched wheat bread|Either 50g of glucose dissolved in 250mL water or white wheat bread or wheat bread enriched with 5mg a-cyclodextrin or wheat bread enriched with a 5mg mixture of a-cyclodextrin and encapsulated hydroxytyrosol (per 50g of available carbohydrates).
223562785|NCT01234740|DRUG|bafetinib|Given orally
224298888|NCT02794155|DRUG|Insulin LISPRO|Insulin Lispro: no bound insulin
223421182|NCT01547260|DRUG|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
223421183|NCT01547260|DRUG|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
223421184|NCT04649840|DIAGNOSTIC_TEST|Humoral and cellular immunity|Humoral (IgG) and cellular (antigen-specific cells) immunity
223421185|NCT04199169|BIOLOGICAL|HeV-sG-V|A Hendra virus soluble glycoprotein vaccine formulated in phosphate buffer and adjuvanted with aluminum hydroxide. Placebo is normal saline.
223421186|NCT04199169|BIOLOGICAL|Normal Saline Placebo|0.9% Saline
223421187|NCT03660774|OTHER|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
223421188|NCT01590069|BIOLOGICAL|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
223421189|NCT01590069|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223421190|NCT03285867|PROCEDURE|TACE|transcatheter arterial chemoembolization
223421191|NCT03642964|DRUG|CTC-501|pramipexole IR, given with ondansetron
223421192|NCT02169141|OTHER|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
223421193|NCT06434805|OTHER|sex workers and sexual minorities education workshop|The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
223421194|NCT04691986|DIETARY_SUPPLEMENT|Nicotinamide Riboside|Nicotinamide Riboside is a form of vitamin B3 and is naturally occurring in humans.
223421195|NCT04691986|OTHER|Placebo|Placebo pills contain micro cellulose powder.
223421196|NCT03725761|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
223421197|NCT05839847|DEVICE|Low-intensity focused ultrasound|A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can reduce reactions to sensory stimuli.
223421198|NCT05839847|DEVICE|Low-intensity focused ultrasound - sham|A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
223562786|NCT01234740|PROCEDURE|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
223421199|NCT05555615|DRUG|Pimavanserin|Pimavanserin given once daily, as capsule of 10, 20, or 34 mg dose strength, respectively, according to the patient's age
223562787|NCT01234740|OTHER|pharmacological study|Correlative studies
223562788|NCT01234740|OTHER|liquid chromatography|Correlative studies
223421200|NCT06405347|BEHAVIORAL|Inpatient Whole Health Bundle|Hospitalized patients on the intervention units will be offered participation in the Inpatient Whole Health Bundle, which is comprised of a variety of offerings aimed at improving the wellbeing of the patient. They can choose to use any or none of the bundle elements.
223421201|NCT04707703|DRUG|Isavuconazonium Injection [Cresemba]|Intravenous isavuconazonium sulfate 372 mg every 8 hours for 6 doses followed by intravenous isavuconazonium sulfate 372 mg once daily for up to 28 days
223421202|NCT04707703|DRUG|Placebo|Intravenous placebo every 8 hours for 6 doses followed by intravenous placebo once daily for up to 28 days
223421203|NCT04606485|OTHER|Acupressure|Acupressure is accepted as a non-invasive application that can easily be applied by trained nurses, which increases the quality of the medical care administered and contributes to physical and psychological recovery.
223421204|NCT02195622|DEVICE|Lumenis VersaCut Morcellator|
223562789|NCT01234740|OTHER|mass spectrometry|Correlative studies
223562790|NCT01234740|OTHER|laboratory biomarker analysis|Correlative studies
223421205|NCT02195622|DEVICE|Wolf Piranha Morcellator|
223421206|NCT03190668|DRUG|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
223421207|NCT03190668|DRUG|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
223421208|NCT03190668|DEVICE|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
223421209|NCT03190668|DEVICE|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
223421210|NCT04569422|DRUG|Benoxyl|reduce pain
223421211|NCT02836236|DRUG|TAF|TAF 25 mg tablet administered orally once daily
223421212|NCT02836236|DRUG|TDF|TDF 300 mg tablet administered orally once daily
223421213|NCT02836236|DRUG|TAF Placebo|TAF placebo tablet administered orally once daily
223421214|NCT02836236|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
223562791|NCT01234740|GENETIC|protein expression analysis|Correlative studies
223562792|NCT01234740|GENETIC|western blotting|Correlative studies
223562793|NCT01234740|OTHER|immunohistochemistry staining method|Correlative studies
223562794|NCT01234740|PROCEDURE|therapeutic conventional surgery|debulking craniotomy
223562795|NCT00451009|DEVICE|Viacell's product Media Kits|
223562796|NCT01292980|DEVICE|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
223562797|NCT02879591|OTHER|Social Skills training with Avatar therapist|
223562798|NCT03161912|DRUG|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion.
224035621|NCT05023343|DIAGNOSTIC_TEST|Non-invasive blood pressure measurement|Non-invasive blood pressure is measured prior to block administration and 30 minutes after block administration
224035622|NCT01148966|DRUG|aminolevulinic acid|Given PO
224035623|NCT01148966|OTHER|laboratory biomarker analysis|Correlative studies
224035624|NCT01148966|PROCEDURE|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
224035625|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
224035626|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
224035627|NCT00669487|DRUG|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
224035628|NCT04910646|DRUG|orange peel fermentation|To evaluate whether the fermented orange peel enzyme has the effect of reducing body fat.
223421215|NCT02222363|DRUG|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
223421216|NCT04546529|DEVICE|Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing real TsMS with coil
223421217|NCT04546529|DEVICE|Sham Trans-spinal Magnetic Stimulation (TsMS)|Patients undergoing placebo TsMS with coil
223421218|NCT05601622|PROCEDURE|Fluid loading|Intravenous administration of 10ml/kg of crystalloids over 10 minutes
223421219|NCT05601622|DIAGNOSTIC_TEST|Transthoracic echocardiography|Transthoracic echocardiographic measurement of stroke volume index
223421220|NCT05601622|DIAGNOSTIC_TEST|PVI, RPVI|Continuous measurement of pleth variability index and Rainbow pleth variability index
223421221|NCT05601622|PROCEDURE|Tidal volume change|Changing tidal volume for mechanical ventilation as 6, 8, 10 ml/kg
223421222|NCT05068778|BEHAVIORAL|Artificial Intelligence Application|AI application through smart phone
223562799|NCT03596047|DEVICE|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
223562800|NCT03596047|DEVICE|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
223562801|NCT05789823|PROCEDURE|Mechanical thrombectomy combined with ischemic post-conditioning|Ischemic post-conditioning will be applied after successful recanalization of the culprit artery achieve by thrombectomy. Ischemic post-conditioning consists of briefly repeated 4 cycles × 2 minutes of occlusion and reperfusion (equal duration) of the initially occluded artery using a balloon.
223562802|NCT05789823|PROCEDURE|Mechanical thrombectomy alone|Successful recanalization was achieved by mechanical thrombectomy without subsequent ischemic post-conditioning.
223562803|NCT04244981|DRUG|Prothrombin Complex Concentrate, Human|A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.
223562804|NCT04244981|DRUG|Fresh Frozen Plasma|When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
223562805|NCT05187884|DRUG|Darovasertib|Oral Darovasertib 300 mg tablets twice daily
223562806|NCT04770545|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
223562807|NCT06458920|BEHAVIORAL|Social regulation|Participants will regulate emotion with the help of a friend
223421223|NCT06492265|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
223421224|NCT06492265|COMBINATION_PRODUCT|Standard stroke unit adherent to guidelines|The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
223421225|NCT05678244|DRUG|Acetaminophen|IV acetaminophen will be added to standard of care opioid based pain regimes.
223562808|NCT06458920|BEHAVIORAL|Cognitive regulation|Participants will regulate emotion on their own
223562809|NCT00709176|BEHAVIORAL|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
223562810|NCT00709176|BEHAVIORAL|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
223562811|NCT01633632|BEHAVIORAL|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
223562812|NCT01633632|BEHAVIORAL|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
223562813|NCT00332384|DRUG|brimonidine/timolol fixed combination|
223562814|NCT02290691|BIOLOGICAL|Influenza Vaccine|Influenza Vaccine
223562815|NCT04324541|DIAGNOSTIC_TEST|PET scan of the brain with Flortaucipir|PET scan of the brain with non FDA approved Radio tracer.
224035629|NCT04910646|DRUG|Placebo|Placebo without orange peel fermentation
224035630|NCT03153137|DRUG|Macitentan 10 mg|film-coated tablet; oral use
224035631|NCT03153137|DRUG|Placebo|film-coated tablet; oral use
224035632|NCT01821378|DRUG|Lurasidone|Lurasidone 20 mg once daily
223421226|NCT05678244|DRUG|Placebo|In control group placebo will be added to standard of care opioid based pain regimes.
223421227|NCT03136341|DRUG|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
223421228|NCT03136341|OTHER|Placebo|Dosing will be determined at each study visit based upon muscles involved
223421229|NCT05716256|DRUG|Ulinastatin|The CIS-ULI group received ulinastatin 5000U/kg followed by cisatracurium 0.1 mg/kg The CIS-NS (control) group received normal saline 0.1ml/kg followed by cisatracurium 0.1 mg/kg. The ROC-ULI group received ulinastatin 5000U/kg followed by rocuronium 0.6 mg/kg The ROC-NS (control) group received normal saline 0.1ml/kg followed by rocuronium 0.6 mg/kg
223421230|NCT05716256|PROCEDURE|TOF monitoring|The acceleromyograph TOF-Watch® SX (Organon, Ireland) is used for TOF monitoring. When the Narcotrend™ index is below 50 and level of anesthesia assessed as deep enough, TOF stimulation is started at 50 mA amplitudes and the setup is checked for any problem concerning the electrodes impedance and local hand temperature. After 1 minute, TOF stimulation is stopped and a tetanic stimulation (each electrical stimulus of 200μs duration and 50 mA amplitude) is delivered at a frequency of 50Hz for 5 seconds. After this procedure the alignment of sensors are checked to see if they are intact and readjust to their initial position if necessary. A no stimulation pause is observed during 3 minutes.
223421231|NCT04097795|OTHER|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
223421232|NCT05533957|OTHER|Application of different dosages of oxygen therapy|To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
223421233|NCT05034861|DEVICE|cCTG|Self-applied home computerized CTG device used twice weekly instead of standard Doppler assessment once weekly.
223421234|NCT05034861|DIAGNOSTIC_TEST|Doppler|Standard Doppler assessment provided once weekly in case of late FGR with positive end diastolic flow in the umbilical artery.
223421235|NCT04563871|DRUG|80mg Osimertinib|One tablet of 80mg Osimertinib for oral administration per day
223421236|NCT02287285|DRUG|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
223421237|NCT01106677|DRUG|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
223421238|NCT01106677|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
223421239|NCT01106677|DRUG|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
223421240|NCT01106677|DRUG|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
223421241|NCT02014233|DIETARY_SUPPLEMENT|Omega-3|
223421242|NCT02014233|DIETARY_SUPPLEMENT|Olive oil|
223421243|NCT06392139|BEHAVIORAL|Specific Therapy Program for Personality Disorders|The program was founded in 1999; since then, it has provided a wide range of different treatment interventions (outpatient, inpatient and day care). The interventions are psychoanalytically oriented and specifically for patients with Borderline Personality Disorder. Most of them are in the form of group psychoanalytic psychotherapy. The program consists of two steps: 1) an initial reception outpatient clinic where patients are followed after the referral to the Program, for a period of 6-8 months. This first step consists of monthly psychodynamically oriented sessions, monthly psychiatric appointments and application of psychological assessment instruments. The intervention focuses on crisis management and construction of the treatment plan for every patient. 2) The second step consists of long-term psychodynamic psychotherapy interventions, in combination with psychiatric treatment when it is is needed.
223562816|NCT05896098|OTHER|Ultrasound|Measurement of the airway by ultrasound in obese patients.
223562817|NCT05081167|DRUG|REL-1017|REL-1017 tablet
223421244|NCT06392139|OTHER|Treatment As Usual (TAU) Group|"The TAU group receives the common practice treatment in the two Specific Outpatient Clinics for BPD patients:~The Outpatient Clinic for Borderline Personality Disorder Patients of the 2nd Psychiatric Clinic at the Medical School of National and Kapodistrian University of Athens called Attikon General University Hospital and The Outpatient Clinic for Borderline Personality Disorder Patients of the Psychiatric Clinic of Sismanogleion General Hospital.~Treatment As Usual (TAU) The TAU includes the psychiatric management, consultation and pharmacotherapy if needed in the two Specific Outpatient Clinics for BPD patients. TAU provides one thirty minutes session per month. In case of crisis management patients contact their psychiatrist during the working hours, or after that they leave a message on the telephone answering machine and if needed make a visit in the Emergency Department of the Hospital on Duty."
223421245|NCT03540004|DEVICE|MolecuLight i:X Imaging Device|The i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
223421246|NCT06620601|DIAGNOSTIC_TEST|Portable Polysomnography|Research assistants set up the portable polysomnography (Prodigy) for the overnight sleep study.
223421247|NCT06620601|DEVICE|Treatment|Based on the decision aid, patient preference, and CADTH recommendations, the sleep physicians will recommend the participant to use Auto-CPAP or MAD for six months.
223739680|NCT06084546|DEVICE|geko™ X-W3|The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
223739681|NCT03371628|DEVICE|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
223562818|NCT05081167|DRUG|Placebo|Placebo tablet
223562819|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
223562820|NCT00962533|DRUG|telbivudine|telbivudine, 600mg, oral, daily
223562821|NCT03341364|BEHAVIORAL|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
224298889|NCT05314894|BEHAVIORAL|Education|Giving training to the students in the initiative group to quit smoking in three sessions, sending messages via whatsapp program and telephone counseling
224298890|NCT04216758|DRUG|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223421248|NCT06620601|OTHER|Questionnaires|Participants will complete eleven questionnaires: Stop-Bang, Insomnia severity index, Epworth sleepiness score (ESS), quality of life (FOSQ-10), Beck Depression Inventory (BDI), Chalder Fatigue Scale (CFQ), primary care post-traumatic stress disorder (PTSD) scale (PC-PTSD-5), Asthma control questionnaire (ACQ), OHIP-14, and Participant demographics. The RA will help the participants complete the questionnaires (\~one and a half hours in total).
223421249|NCT04248140|OTHER|radio frequency electromagnetic field|Exposure system delivers emissions comparable to those from WiFi access point close to the bed or sham (nor exposure)
223421250|NCT03937908|DRUG|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
223421251|NCT03937908|DRUG|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
223421252|NCT03122743|PROCEDURE|Biospecimen Collection|Undergo collection of serum samples
223421253|NCT03122743|OTHER|Laboratory Biomarker Analysis|Correlative studies
223421254|NCT03122743|OTHER|Questionnaire Administration|Ancillary studies
223562822|NCT03341364|BEHAVIORAL|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
223562823|NCT01842035|DRUG|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
223562824|NCT05108272|PROCEDURE|Microneedling|Derma Pen is an electric device, used for microneedling. Derma pen has a Cartridge which has microneedles fitted. These needles penetrate the skin upto 2mm
223562825|NCT05108272|PROCEDURE|Percutaneous Collagen Induction|It is self-adhesive sheet made from medical graded Silicone. It has micropore technology which entraps moisture where it is needed on scared skin.
223562826|NCT03441997|OTHER|Mind-body exercise|Exercise program.
223562827|NCT03441997|OTHER|Light mobility exercises|Modified mind-body program.
223562828|NCT00734604|DRUG|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
223562829|NCT00734604|DRUG|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
223421255|NCT05740189|DEVICE|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
223562830|NCT00734604|DRUG|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
223562831|NCT02482597|DEVICE|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
224035633|NCT01821378|DRUG|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
224035634|NCT01821378|DRUG|Placebo|Once Daily
223562832|NCT01678573|DRUG|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
224035635|NCT02367326|OTHER|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
223562833|NCT01678573|DRUG|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
223562834|NCT01678573|DRUG|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
223562835|NCT04310982|DEVICE|The G-Walk sensor system (G-Walk)|The G-Walk is a wireless sensor device which is placed on an elastic belt and worn on the waist of the person being evaluated. The device is placed with the center of the device at the fifth lumbar vertebrae and the patient is completely free to walk, run and jump wearing this device. The gait and jump performance of the participants was assessed with the participants wearing this device two times to investigate the test-retest reliability. The second being 7 days after the first.
223562836|NCT06552975|OTHER|Infection|Pathogens such as bacteria and viruses invade the human body, grow, and proliferation, triggering an immune response.
223562837|NCT03490591|BEHAVIORAL|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
223562838|NCT03907865|DRUG|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
223562839|NCT00426816|DRUG|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
223562840|NCT00426816|DRUG|Placebo|Placebo to match SB-649868
224035636|NCT02888665|DRUG|Doxorubicin Hydrochloride|Given IV
224035637|NCT02888665|OTHER|Laboratory Biomarker Analysis|Correlative studies
224035638|NCT02888665|BIOLOGICAL|Pembrolizumab|Given IV
224035639|NCT04921007|PROCEDURE|Sacral ESP block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed longitudinally to the midline of the sacrum. The median sacral crests and erector spinae muscle will be visualized, then a 22-gauge, 50 mm needle will be advanced from cranial to caudal direction until its tip touch the sacral crest.
223421256|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (pre-treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 1-56
223421257|NCT05919472|BIOLOGICAL|COVID-19 vaccine|Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
223421258|NCT05919472|BIOLOGICAL|MenACWY vaccine|MenACWY vaccination given on day 28 to all participants
223421259|NCT05919472|DIETARY_SUPPLEMENT|Oral iron supplementation (simultaneous treatment)|Iron supplements as 200 mg oral iron as FeSO4 given on alternate day on days 28-56
223421260|NCT05919472|BIOLOGICAL|Typhim Vi vaccine|Typhim Vi vaccination given on day 28 to all participants
223421261|NCT03326349|OTHER|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
223421262|NCT03326349|OTHER|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
223562841|NCT01428037|DRUG|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
223562842|NCT01428037|DRUG|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
223562843|NCT05974618|DIAGNOSTIC_TEST|Ultrasound|"A standardised transvaginal (supplemented with transabdominal if transvaginal is not sufficient) examination is performed. When a colour Doppler ultrasound examination is performed, the pulse repetition frequency should be 0.3-0.6 KHz. The colour Doppler gain should be increased until colour Doppler artefacts appear and then lowered until just below the reappearance of colour Doppler artefacts. Ultrasound frequency and priority (grey scale or colour/Power Doppler) must also be optimised when using colour/power Doppler. Doppler ultrasound should be used with all masses included, irrespective of gestational age."
223562844|NCT00053976|BIOLOGICAL|Daclizumab|
223739682|NCT06493396|DRUG|Opioid-free Analgesics|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
223421263|NCT05524818|DIAGNOSTIC_TEST|the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)|The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (\< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
223421264|NCT03337945|DRUG|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
223421265|NCT06485440|DRUG|Dysport 300 UNT Injection|300 UNITS of BTA (Dysport) injected to lateral abdominal muscles prior to abdominal wall reconstruction (4 weeks before surgery)
223421266|NCT01764789|OTHER|questionnaire administration|Ancillary studies
223421267|NCT01764789|PROCEDURE|quality-of-life assessment|Patients will participate in a quality life assessment.
223421268|NCT01764789|PROCEDURE|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
223421269|NCT01764789|BEHAVIORAL|behavioral intervention|Participate in multi-component biobehavioral intervention
223562845|NCT00053976|DRUG|methylprednisolone|
223562846|NCT00053976|DRUG|Placebo|
223562847|NCT02589665|DRUG|Mirikizumab|
223562848|NCT02589665|DRUG|Placebo|
223562849|NCT00978380|DRUG|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
223562850|NCT05148442|DRUG|IBI322|Recombinant anti-human CD47/PD-L1 bispecific antibody
223562851|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 30 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
223562852|NCT06437613|PROCEDURE|Passive Static Stretching exercises for 60 seconds|"Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)"
223562853|NCT05865340|BEHAVIORAL|oral health + MED diet|oral health + MED diet education
223562854|NCT05865340|BEHAVIORAL|oral health|oral health education
223562855|NCT05865340|BEHAVIORAL|MED diet|MED diet education
223562856|NCT02450383|DRUG|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
224035640|NCT04921007|PROCEDURE|Caudal block|A high-frequency ultrasound linear probe covered with a sterile sheath will be placed on to the sacrococcygeal region. The dura mater, epidural space, conus medullaris, sacral cornua, and sacrococcygeal ligament will be identified. Using the in-plane technique, a 22-gauge, 50 mm needle will be introduced to reach the sacral epidural space.
223562857|NCT02450383|PROCEDURE|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
223421270|NCT01764789|OTHER|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
223421271|NCT01764789|OTHER|educational intervention|Participate in multi-component biobehavioral intervention
223421272|NCT04384861|BEHAVIORAL|Mayo Clinic SMART program (Stress Management and Resilience Training)|The SMART program included a workshop and ongoing eLearning Support. The learning objectives of the workshop are: (1) learn the neuroscience and behavioural aspects of human experience, particularly with respect to stress, resiliency, performance and wellness and (2) learn practical approaches to enhance engagement and emotional intelligence and thereby decrease stress and anxiety, increase resilience, enhance performance, and improve relationships. The goal of the eLearning support is to support and reinforce the messages and techniques delivered in the 2-hour workshop.
223421273|NCT02790359|OTHER|Air|Group of patients who would receive air insufflation
224035641|NCT04921007|DRUG|Bupivacaine Hydrochloride|Following negative aspiration, a precalculated dose (0.5 ml/kg) of 0.25% bupivacaine will be injected.
224035642|NCT05197023|DRUG|SHR-1819 injection or placebo|Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
224035643|NCT04045951|OTHER|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
223421274|NCT02790359|OTHER|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
223421275|NCT05142150|OTHER|Questionaire|"Patient questionaires collecting data on quality of life, illness management, communication and decision making. Patient report data of end of life care ( i.e administration of chemotherapy, surgical interventions, palliative care involvement, hospital admissions) through as self reported diary.~Carer for patients questionnaires their satisfaction with care. 5-7 weeks after patient deceased carer completes bereavement questionnaire and quality of death and dying."
223421276|NCT05780970|OTHER|No intervention|Non-treated children and caregivers complete assessments only. The primary (treated) parent / adolescent dyad participate in family based weight management treatment through the main trial. In the main trial, families are randomized to either TEENS+Parents as Coaches (parent skills training) or TEENS+Parent Weight Loss (parent behavioral weight loss).
223421277|NCT04738097|DRUG|Ticagrelor 90mg|ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.
223421278|NCT04738097|DRUG|Clopidogrel 75 mg|ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
223421279|NCT00784238|DRUG|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
224298891|NCT04216758|DRUG|Gemcitabine|Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223421280|NCT01047826|PROCEDURE|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
223421281|NCT01047826|PROCEDURE|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
223421282|NCT03693612|DRUG|feladilimab|feladilimab is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
223421283|NCT03693612|DRUG|Tremelimumab|Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
223421284|NCT03693612|DRUG|Docetaxel|Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m\^2).
223421285|NCT03693612|DRUG|Paclitaxel|Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m\^2.
223562858|NCT05069714|DRUG|MTX-hold|Temporary discontinuation of methotrexate for 1 or 2 weeks
223421286|NCT03693612|DRUG|Cetuximab|Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m\^2 followed by 250 mg/m\^2 once weekly.
223562859|NCT05484531|DEVICE|CLEAR|Reduction or elimination of myopia from -0.50 D to -10.00 D, with astigmatism of 0 D to -5.00 D or without astigmatism, and MRSE of -0.50 D to -12.50 D in the eye to be treated in patients who are 18 years of age or older with documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude
223562860|NCT04449952|OTHER|Listerine Cool Mint|Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
223562861|NCT04449952|OTHER|5% Hydroalcohol Mouth Rinse|Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
223562862|NCT04449952|OTHER|Colgate Cavity Protection Toothpaste|Participants used Colgate cavity protection toothpaste for brushing teeth twice daily.
223562863|NCT04449952|OTHER|Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula|Participants use 20 mL of AFEO mouth rinse lead formula for 30 sec after brushing.
224035644|NCT02876666|BEHAVIORAL|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
224035645|NCT00400309|BIOLOGICAL|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
224035646|NCT00400309|BIOLOGICAL|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
224035647|NCT01728051|DRUG|Melphalan|
224035648|NCT01728051|DEVICE|Percutaneous Hepatic Perfusion|
224035649|NCT00993915|DRUG|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
223421287|NCT04669873|RADIATION|Active Comparator: Standard|Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks
223421288|NCT04669873|RADIATION|Experimental 1: Hypofractionated radiotherapy|Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week
223421289|NCT04669873|RADIATION|Experimental 2: Accelerated Partial Breast Irradiation|Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
223421290|NCT05262309|DRUG|Pamrevlumab|"Pamrevlumab dosing, 30 mg/kg IV, will be administered at day 1, day 7 and day 14.~Based on Investigator's decision, treatment may be continued every 3 weeks after day 14, up to 11 weeks."
223562864|NCT04449952|DEVICE|Concept Curve Winter Series Toothbrush|Participants will brush teeth at least one minute with provided bristled toothbrush.
223562865|NCT04449952|DEVICE|Listerine Cool Mint Floss|Participants will use marketed fluoride-containing dentifrice, floss.
224035650|NCT05151848|DRUG|Adalimumab Injection|Adalimumab Injection injected subcutaneously every other week for 78 weeks
224035651|NCT05151848|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 78 weeks
224035652|NCT00295360|BEHAVIORAL|no intervention, pathophysiological study|
223562866|NCT03990415|BEHAVIORAL|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
223562867|NCT03258281|DRUG|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
223562868|NCT03258281|DRUG|Placebo|Patients will receive placebo administered subcutaneously
224035653|NCT00714597|DRUG|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
224035654|NCT00714597|DRUG|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
224035655|NCT02225496|PROCEDURE|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
224137636|NCT04886193|DRUG|FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU), Treprizumab, Tiggio capsule (S-1)|"* FLOT: Docetaxel 50mg/m2 ivd d1 + oxaliplatin 85mg/m2 ivd d1 + leucovorin 200mg/m2 ivd d1 + 5-FU 2600mg/m2 civ 24h Q2W~* Treprizumab 3mg/kg, intravenously administered on the first day of each cycle, Q2W~* Tiggio capsule (S-1) 40-60mg (BSA\<1.25 m2: 40mg, 1.25 m2≤BSA≤1.5 m2: 50mg, BSA\> 1.5 m2: 60mg) po bid d1-14 Q3W, continuous treatment for 1 year;~* Teriprizumab 240mg, intravenously, given on the first day of each cycle, Q3W, continuous treatment for 1 year."
224035656|NCT02225496|PROCEDURE|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
224035657|NCT02225496|BEHAVIORAL|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
223421291|NCT05013151|DIETARY_SUPPLEMENT|Dates|Consumption of 6 dates a days until 41 weeks of gestation
223421292|NCT05013151|DIETARY_SUPPLEMENT|Castor oil|One time consumption of 60 CC Castor oil
223421293|NCT05900869|OTHER|FSFI|Female Sexual Function Index questionnaire
223421294|NCT05900869|OTHER|BES|Body Esteem Scale questionnaire
223421295|NCT03784209|DIAGNOSTIC_TEST|The diagnosis of Artificial Intelligence and endoscopist|When suspected lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
223421296|NCT04376944|OTHER|Survey|questionnaire on their symptoms and their exposures
223421297|NCT05318092|DEVICE|AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE|The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
223421298|NCT04815265|DRUG|Remimazolam|Remimazolam is used for sedation
223421299|NCT04815265|DRUG|Dexmedetomidine|Dexmedetomidine is used for sedation
223421300|NCT01914146|OTHER|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
223421301|NCT01914146|OTHER|No Insulin|Study session will occur prior to initiation of insulin therapy.
223421302|NCT02241083|DRUG|Dopamine|
223421303|NCT02241083|DRUG|Norepinephrine|
223421304|NCT02241083|OTHER|no medication|
223562869|NCT02419196|OTHER|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
223562870|NCT01357824|PROCEDURE|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
224035658|NCT02092974|PROCEDURE|tDCS|
224035659|NCT02092974|DRUG|Citalopram|
224035660|NCT02092974|OTHER|sham-tDCS + placebo|
224035661|NCT02785224|DRUG|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
224035662|NCT00189566|DRUG|Paclitaxel|
224035663|NCT00189566|DRUG|Topotecan|
224035664|NCT00189566|DRUG|Carboplatin|
224035665|NCT00769860|DRUG|Arimoclomol|Arimoclomol 100 mg TID for 4 months
224035666|NCT00769860|OTHER|Placebo|Placebo for 4 months
224035667|NCT05424913|OTHER|research-specific blood sample|blood sample of 50 ml maximum levels of serum Insulin Regulated Amino Peptidase, lipidome markers and inflammation markers
224035668|NCT00969046|DRUG|EPO906 (patupilone)|
224035669|NCT01603082|DRUG|Ticagrelor|180 mg loading dose
224035670|NCT01603082|DRUG|Clopidogrel|600 mg loading dose
224035671|NCT02498496|DRUG|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
224035672|NCT02498496|DRUG|Placebo|Administration of 100 mL of Normal Saline
223421305|NCT00102375|DRUG|Topotecan|
223421306|NCT00048802|DRUG|Lithium|
223421307|NCT00048802|DRUG|Olanzapine|
223421308|NCT00048802|DRUG|Divalproex|
223421309|NCT00048802|DRUG|Risperidone|
223421310|NCT00048802|DRUG|Quetiapine|
223421311|NCT00048802|DRUG|Ziprasidone|
223421312|NCT00048802|DRUG|Aripriprazole|
223421313|NCT03638999|DRUG|Ketorolac Trometamol 30Mg/1mL Injection|Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
223421314|NCT03638999|DRUG|Normal saline|Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
223421315|NCT03075345|BEHAVIORAL|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
223421316|NCT03075345|BEHAVIORAL|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
223421317|NCT04434469|DRUG|RO7297089|RO7297089 will be given via intravenous (IV) infusion
223421318|NCT05622058|DRUG|ALRN-6924|ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
223562871|NCT02947854|DRUG|Fimaporfin (Photosensitizer)|
223562872|NCT02947854|BIOLOGICAL|Hiltonol (Poly-ICLC)|
224035673|NCT02528565|DEVICE|Adhesix Bioring|
224035674|NCT06266819|OTHER|chewing gum|In addition to the routine treatment plan, mint-flavored gum will be chewed for an average of 15 minutes at least 4 hours after the antiemetic application.
224035675|NCT01522105|DRUG|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
224035676|NCT00852592|DEVICE|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
224035677|NCT00852592|DEVICE|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
223421319|NCT05622058|DRUG|TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)|TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
223421320|NCT03146689|DRUG|Topical NSAID|Applied four times daily
223421321|NCT03146689|DRUG|Topical Capsaicin|Applied four times daily
223421322|NCT03554863|DEVICE|Nasal High Flow Oxygen|Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
223421323|NCT03554863|DEVICE|Facial Mask|Preoxygenation with facial mask
223421324|NCT02991729|OTHER|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
223421325|NCT02991729|OTHER|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
223421326|NCT01154296|BEHAVIORAL|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
223421327|NCT02464475|OTHER|osteopathic manipulative treatment|
223421328|NCT02464475|OTHER|sham osteopathic treatment|
223421329|NCT04518098|OTHER|Strength and balance exercise|The exercise program consists of muscle strengthening and balance training exercises that progress in difficulty. After completion of the baseline assessment and randomization, IG participants will receive orientation and learn the exercise routines (in the Cancer Rehabilitation Clinic within the Faculty of Rehabilitation Medicine at the University of Alberta). The duration of training is 3 months (40-50 minutes per scheduled session, three times a week) at home, with a minimum of one live group session supervised by the CEP, a minimum of one independent home session supported by the Active Living module of the HEAL-ME application; (the third session can be a live session or independent session at the participant's discretion).
223421330|NCT01793480|DRUG|Methadone|
223421331|NCT06317714|OTHER|questionnaires|"o Quality of life questionnaires EORTC QLQC-30 and EQ-5D-5L~° questionnaires NCI- PRO-CTCAE"
223421332|NCT02759055|OTHER|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
223562873|NCT02947854|BIOLOGICAL|HPV E7 (Human Papilloma Virus E7) peptides|
223562874|NCT02947854|BIOLOGICAL|KLH (Keyhole Limpet Hemocyanin)|
223562875|NCT03470324|DEVICE|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
223562876|NCT03470324|DEVICE|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
223562877|NCT03470324|BEHAVIORAL|Swallowing therapy|Swallowing therapy with speech therapist
223562878|NCT00062023|DRUG|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
223562879|NCT00062023|DRUG|Sulindac|Patients receive oral sulindac twice daily for 12 months.
223562880|NCT00062023|DRUG|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
224035678|NCT04806698|DEVICE|Menicon Z Night|Children wearing Menicon Z Night orthokeratology contact lenses
224035679|NCT04806698|DEVICE|Control|Children wearing distance single-vision glasses or distance single-vision soft contact lenses
224035680|NCT00196872|DRUG|Epirubicine|Epirbubicne is given
223421333|NCT06623812|OTHER|Behavioral: Post- meal satiety and subsequent ad-libitum meal energy intake|Investigate differences in post meal satiety and subsequent post meal energy intake after consuming fixed portion meals with different protein source and/ or different protein quality
223421334|NCT01865201|DRUG|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
224035681|NCT00196872|DRUG|Cyclophosphamide|Cyclophosphamide is given
224035682|NCT00196872|DRUG|Taxol|Taxol is given
223421335|NCT01865201|OTHER|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
224035683|NCT00196872|DRUG|Xeloda|Xeloda is given
224035684|NCT00196872|DRUG|Ibandronat|Ibandronat is given
224035685|NCT00283257|BEHAVIORAL|Patients and caregivers are taught problem solving skills|
224035686|NCT06441084|BIOLOGICAL|NCR300 injection|Subjects will receive at least 1 cycle of NCR300 injection.
224035687|NCT04854629|OTHER|Spinomed active|Wearing of the orthosis 2-3 h/twice a day for 16 weeks Supplementation of a maximum of 1000 mg/d calcium and 800 IE/d vitamin D
224035688|NCT05467774|BEHAVIORAL|Operant RF H-reflex conditioning|Operant down-conditioning of rectus femoris H-reflex
224035689|NCT01849666|DRUG|phenprocoumon|6 mg oral single dose
224035690|NCT01849666|DRUG|vemurafenib|960 mg bid orally
224035691|NCT04607525|DRUG|Dexmedetomidine|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group D: Patients received 0.5 µg/kg/h of Dexmedetomidine. Dexmedetomidine dosage was diluted in 50 ml syringe of normal saline Group C: Patients received equal volume and rate of normal saline as Group D.~This dosing regimen was in accordance with existing guidelines \[5\] \[6\] \[7\]."
224035692|NCT04607525|DRUG|normal saline|"On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D."
224035693|NCT05051137|BIOLOGICAL|Infliximab|Initiation of infliximab in any dose and frequency of administration. Could be discontinued for safety reasons and replaced by etanercept.
224035694|NCT05051137|DRUG|Sulfasalazine + Hydroxychloroquine|Initiation of sulfasalazine and hydroxychloroquine not more than 180 days apart, in any dose and frequency of administration. Any one of the two drugs could be discontinued. while continuing the other, or both could be replaced by cyclosporine, for safety reasons.
224035695|NCT01019317|DRUG|Cytarabine|0.5 grams/m\^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients \> 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 3).
224035696|NCT01019317|DRUG|Fludarabine|15 mg/m\^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients \> 65 years and 3 days in patients with PS \> 3).
224035697|NCT04777253|OTHER|Biofeedback method|"Patients in the study group will participate in training with visual biofeedback, aimed to improve motor function of the arm. The exercise will be performed using a Biometrics device. The biofeedback training will be carried out for 30 minutes per day.~Health-resort based rehabilitation The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy."
224035698|NCT04777253|OTHER|Health-resort based rehabilitation|"The patients will participate in a three-week rehabilitation program (from Monday to Friday), with the treatments and therapies continued for up to two hours per day.~The program will include: group and individual exercise (active and assisted exercises, manipulation exercise, PNF-based practice, balance and breathing exercise), manual massage, physical treatments, such as: laser, whirlpool therapy, mud compress therapy, carbonic acid therapy, TENS therapy, BIO-V lamp, and localized cryotherapy"
224035699|NCT00695253|DEVICE|Talent Endoluminal Spring Graft System|Endovascular repair for patients with AAA who meet the inclusion criteria for the study
224035700|NCT02652650|DRUG|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
224035701|NCT02652650|DRUG|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
224035702|NCT02652650|DRUG|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
224035703|NCT05049278|DRUG|Norepinephrine|"* Continuous drug: norepinephrine 4mg \* 1@ + D5W 200 mL (20 μg/mL)~* Range: 0.03 \~ 0.09 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
224035704|NCT05049278|DRUG|Phenylephrine|"* Continuous drug: phenylephrine 10mg \* 5@ + D5W 200 mL (250 μg/mL)~* Range: 0.42 \~ 1.26 μg/kg/min (= 0.1 \~ 0.3 mL/kg/h)"
223421336|NCT00109681|DRUG|Iloprost Inhalation Solution (Ventavis)|
223421337|NCT01037595|DRUG|turmeric|turmeric 500 md tid orally for 8 weeks
223562881|NCT00062023|OTHER|Sulindac Placebo|Oral sulindac placebo twice daily.
224035705|NCT03442049|OTHER|Physiotherapy - Study group|Study group : In addition to home program spinal stabilization exercises
224035706|NCT03442049|OTHER|Physiotherapy - control group|Home exercise program
224035707|NCT04265560|OTHER|Progressive Resistance Training|Progressive resistance training programme for individuals following spinal cord injury.
224035708|NCT03294109|DRUG|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
224035709|NCT03212430|DRUG|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
223421338|NCT01037595|DRUG|placebo|placebo 3 time orally for 8 weeks
223421339|NCT01037595|DRUG|turmeric|500 mg tid orally for 8 weeks
224035710|NCT04430465|DIETARY_SUPPLEMENT|Grain products high in wholegrains from oat and rye|A selection of grainproducts high in wholegrain from oat and rye, including cereals, bread, rolls, and pasta is replacing habitual grain products
223421340|NCT02877095|DRUG|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
223421341|NCT02327338|DEVICE|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
223421342|NCT02327338|DRUG|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
223421343|NCT03812770|DRUG|Sorafenib|Oral Sorafenib, 400mg, Bid
223421344|NCT03812770|DRUG|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223421345|NCT03812770|DRUG|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
223421346|NCT06616675|DRUG|Darifenacin|Anticholinergic drug therapy for OAB treatment - Darifenacin, 15mg/day
223421347|NCT06616675|DEVICE|Neuromodulation - Sacral nerve stimulation|Neurodyn Portable TENS FES neuromuscular stimulation device in an outpatient clinic. Two self-adhesive electrodes (5x9cm) were used, positioned one in each gluteal region, below the iliac spine to apply low-frequency biphasic current with 10 Hz. Pulse duration of 0.5 milliseconds was applied for 40 minutes with continuous stimulation, 3 times a week, for 20 sessions.
223421348|NCT06257342|PROCEDURE|6 minutes walk|A 6 minutes walk test
223421349|NCT05923242|BEHAVIORAL|Computerized Intervention Authoring Software (CIAS)|CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
223562882|NCT03735199|DEVICE|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
223562883|NCT03735199|DEVICE|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
223562884|NCT04465032|OTHER|Gut microbiome transplantation|Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
224035711|NCT04430465|DIETARY_SUPPLEMENT|Grain products low in wholegrains|A selection of grainproducts low in wholegrain, including cereals, bread, rolls, and pasta is replacing habitual grain products
224035712|NCT04744285|OTHER|Cigarette packaging|receive normal packet cigarette
223421350|NCT02935504|BEHAVIORAL|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~1. Engage clinic leaders and staff~2. Identify leadership group and prepare for change~3. Assess readiness to implement PRISM~4. Identify steps to achieve goals~5. Implement PRISM components into the clinic~6. Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
223421351|NCT02935504|BEHAVIORAL|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
223562885|NCT00588172|DRUG|Metformin|1000mg bid for 1 week
224035713|NCT04744285|OTHER|Data capture|Attend video sessions
224035714|NCT04744285|OTHER|Questionnaire administration|Ancillary studies
224035715|NCT00124098|DRUG|Aranesp® (darbepoetin alfa)|
224035716|NCT00597441|BIOLOGICAL|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
224035717|NCT00906919|BEHAVIORAL|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
223562886|NCT02332772|OTHER|Data Collection|Data collected from endoscopy procedures.
223562887|NCT05235347|BIOLOGICAL|Sotrovimab|500mg IV
224035718|NCT00906919|BEHAVIORAL|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
224035719|NCT02535663|DIETARY_SUPPLEMENT|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
223421352|NCT05313022|BIOLOGICAL|ZR-202-CoV|Adjuvanted Recombinant SARS-CoV-2 S-protein Subunit Vaccine
223421353|NCT05313022|OTHER|Placebo|Normal saline solution
223562888|NCT01773343|PROCEDURE|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
224035720|NCT02535663|DIETARY_SUPPLEMENT|Placebo|Same product without RG
224035721|NCT04410250|BEHAVIORAL|oral hygiene|Mothers will be instructed on the oral hygiene of the newborn
223421354|NCT05444725|OTHER|Stage of Decision Making|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
223421355|NCT05444725|OTHER|Choice framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
223421356|NCT05444725|OTHER|Opportunity Framing|Investigating preferences and attitudes towards breast cancer screening information, invitation, and decision making as well as barriers for breast cancer decision making. This will be done by using different framing of information (choice framing vs. opportunity framing), question about stage of decision making, and general questions about screening information and invitation.
223421357|NCT00545246|DRUG|aflibercept (AVE0005)|intravenous infusion
223421358|NCT00545246|DRUG|docetaxel|intravenous infusion
223421359|NCT00415116|DRUG|carboplatin|
223421360|NCT00415116|DRUG|docetaxel|
223421361|NCT00415116|DRUG|lenalidomide|
223421362|NCT02807012|OTHER|Nursing educational intervention|"The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.~The control group could have ou not the usual care guidelines provide by health services that have access."
223421363|NCT01070095|OTHER|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
223421364|NCT06440330|DEVICE|continuous glucose monitoring|continuous glucose monitoring will be used during the first 14 days post-transplantation
223421365|NCT00869284|DRUG|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
223421366|NCT00869284|PROCEDURE|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
223421367|NCT06667193|OTHER|Cold Water Immersion (CWI) - Cold Tub Immersion (CI)|Once thermoneutral procedures are complete, participants in the CI group will be seated in the cold tub and submerged into the water (10º C). The sternal notch of each participant will be used as the anatomical marker to mark submersion point. Participants will sit with both arms outstretched underwater with their backs not touching the sides of the tub. Participants with a shorter stature will be provided an underwater cushion to meet the submersion requirements. The 4-minute timer will begin once confirmation of the participants submersion level and posture is determined. Once completed, the participant will be instructed to slowly exit the tub and allowed to dry and change as necessary.
223421368|NCT06667193|OTHER|Cold Water Immersion (CWI) - Cold Shower (CS)|Once thermoneutral procedures are complete, participants in the CS group will be instructed to enter the research shower area in Gunter 1610. Within the shower area, the walls of the shower will be numbered from 1 to 4, with 1 defined as facing the faucet, 2 defined as 90° to the right of side 1, 3 defined as 180° from the faucet, and 4 defined as 270° to the right or 90° C to the left from side 1. Participants will be instructed to turn 90° to the right cycling through sides 1 to 4 and then back to 1 every 15 seconds prompted by the researcher. This will allow the participant to complete three full rotations in the shower during the 4-minute intervention time. The shower faucet is modified and oriented in a way where it only produces cold water (10º C) when turned on. Once completed, the participant will be instructed to slowly exit the shower and is allowed to dry and change as necessary.
223421369|NCT02796352|DRUG|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
223421370|NCT03992170|DRUG|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
223421371|NCT02070731|DEVICE|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
223421372|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 5 MBq/kg (D0)
224035722|NCT03057314|DRUG|Amorphous Calcium Carbonate|"Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
224035723|NCT01774084|DIETARY_SUPPLEMENT|Experimental: PreOp, NutriciaNordica AB|
224298892|NCT04216758|DRUG|tegafur|Patients secondly receive tegafur Body surface area \< 1.25 m\^2, 60 mg/d;Body surface area ≥ 1.25 m\^2 to \< 1.5 m\^2, 80 mg/d;Body surface area ≥ 1.5 m\^2, 100 mg/d (po) on days 1-21 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
223421373|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 10 MBq/kg (D0)
223421374|NCT04481230|DRUG|99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg|1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
223421375|NCT06347055|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Continuous theta burst rTMS
223421376|NCT06649136|DRUG|Methotrexate|comparison between oral and subcutaneous methotrexate dosis of 25mg
223421377|NCT04062032|DRUG|Aspirin 81 mg|ASA 81mg taken daily
223421378|NCT04062032|DRUG|Aspirin 325mg|ASA 325mg taken daily
223421379|NCT02429388|DRUG|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
223421380|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
223421381|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
223421382|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
223421383|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (next highest dose)
223421384|NCT01322594|BIOLOGICAL|MEDI2338|MEDI2338 single IV dose (highest dose)
223421385|NCT01322594|OTHER|Placebo|Placebo single IV dose
223421386|NCT04070690|PROCEDURE|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
223562889|NCT01451229|DRUG|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
223421387|NCT05742139|OTHER|Non intervention|Non intervention
223421388|NCT04676958|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2
223421389|NCT04676958|DIETARY_SUPPLEMENT|Micro-crystalline cellulose|Micro-crystalline cellulose
223421390|NCT05838339|BEHAVIORAL|Healthy Sleep Intervention|The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
223421391|NCT00124202|BEHAVIORAL|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
223421392|NCT03743103|DRUG|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
223421393|NCT03743103|DRUG|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
223421394|NCT03638284|DEVICE|Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
223421395|NCT05454384|OTHER|Medical Record Examination|The patients' demographic features, related management and treatment process, the responses given to the consultations by OMFS clinic, the physicians' recommendations, the patient management, and the treatments applied by dentistry clinics were classified and recorded for statistical analyses.
223421396|NCT05218356|DRUG|Covidir injections|administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)
223421397|NCT05218356|DIAGNOSTIC_TEST|Quantitative PCR SARS-CoV-2|detection of viral RNA in nasopharyngeal and oropharyngeal samples by the Real Time Protein Chain Reaction technique.
223421398|NCT05218356|DIAGNOSTIC_TEST|IgM and IgG dosage|lood collection for dosage of Anti SARS-CoV-2 antibodies.
223562890|NCT06259006|DRUG|Dexamethasone Oral|Dexamethasone suspension (1mg/ml) 20mg/m2/day (maximum dose 24mg/day) given in three divided doses
223562891|NCT06259006|DRUG|Placebo|Matching capsules taken orally three times daily for three days
223562892|NCT02509468|DRUG|Sirolimus|"* each patient will be followed during a 12-month-period~* each patient will start by an observational period and end being treated by sirolimus~* at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
223421399|NCT05218356|DIAGNOSTIC_TEST|Screening Blood tests|omplete blood count, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubins and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides); coagulogram (TP, aPTT); D-dimer; C-reactive protein; HIV, HBV, HCV serology; Ferritin; troponin, fibrinogen,Coagulogram (TP, aPTT); D-dimer, Pregnancy test for non-sterile women.
223421400|NCT05218356|DIAGNOSTIC_TEST|Electrocardiogram|valuation by the principal investigator or assistant physician with a complete physical examination
223421401|NCT05218356|OTHER|NEWS-2 score|assessment of the participant by the NEWS-2 score.
223421402|NCT05218356|OTHER|WHO score|assessment of the participant by the score of the World Health Organization.
223421403|NCT05218356|OTHER|Physical examination|evaluation by the principal investigator or assistant physician
223421404|NCT05218356|OTHER|COVID-19-Related Symptoms assessment|will be completed by the study staff member based on patient status and answers.
223421405|NCT04283682|BEHAVIORAL|Early skin-to-skin combined with breast-feeding|Premature infants in the intervention group have access to skin-to-skin once a day for 1 hour at least once no ventilation support needed. During the skin-to-skin period,the breastfeeding is encouraged for about 5-10 minutes. The whole intervention stop until the baby achieve the full oral feeding.
223421406|NCT06181292|BIOLOGICAL|PHH-1V81|booster of PHH-1V81
223421407|NCT06181292|BIOLOGICAL|Comirnaty Omicron XBB1.5|booster of Comirnaty Omicron XBB1.5
223421408|NCT03692325|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
224035724|NCT01774084|DIETARY_SUPPLEMENT|Placebo Comparator: Water|
223421409|NCT03087422|BEHAVIORAL|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
223421410|NCT03961386|BEHAVIORAL|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
223421411|NCT03961386|BEHAVIORAL|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
223421412|NCT04456868|BEHAVIORAL|Electroencephalogram|Electroencephalogram will be done for P300 wave assessment
223421413|NCT04456868|BEHAVIORAL|walking test|8-Meter walking test will be done for gait parameter assessment
223421414|NCT04456868|BEHAVIORAL|Quality of life questionnaire|Starkstein Apathy Scale, DSM-5 criteria, Montgomery-Åsberg Depression Rating Scale, Perseverative Thinking Questionnaire, classification of Hoehn \& Yahr
223421415|NCT04456868|PROCEDURE|Position emission tomography|Position emission tomography will be done for
223421416|NCT04083469|BEHAVIORAL|Peer-Led Peer-Elected Intervention|The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
223421417|NCT04083469|BEHAVIORAL|Adult-Led Intervention|The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
223421418|NCT04083469|BEHAVIORAL|Peer-Led Non-Elected Intervention|The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
223421419|NCT06620718|PROCEDURE|coronectomy|The inferior alveolar nerve and buccal nerve were blocked with maxicaine anaesthetic solution (articaine hydrochloride 40 mg, epinephrine hydrochloride 0.006 mg). Incisions were applied uniformly across all patients, and a triangular flap technique was employed. After elevating the flap and exposing the bone, the bone overlying the crown of the tooth was removed using a bone round bur to fully visualize the tooth\&#39;s crown. Once the crown was fully exposed, the crown preparation was initiated at the enamel-dentin junction using a fissure bur. The crown preparation was completed without leaving any sharp edges, and the crown was extracted. Then, the exposed pulp was washed with sterile serum without any further intervention. The surgical area was sutured using 5/0 silk. Analgesic (25 mg of dexketoprofen trometamol twice a day) and antibiotic (125 mg clavulanic acid, 875 mg amoxicilin twice a day) drugs were described.
223421420|NCT01928342|DRUG|Coenzyme A|Coenzyme A 400mg per day
223421421|NCT01928342|DRUG|Placebo|Capsule without coenzyme A.
223421422|NCT06623513|DRUG|Parecoxib Sodium|Parecoxib Sodium 40 mg administered intravenously 30 minutes before the ERCP procedure.
223421423|NCT06623513|DRUG|Indomethacin suppository|Indomethacin suppository 100 mg administered rectally 30 minutes before the ERCP procedure.
224035725|NCT06459193|DRUG|Trimetazidine|Trimetazidine 35 mg tab once daily
223421424|NCT06317142|DRUG|Acipimox 250 mg Oral Capsule|A subset of prediabetes individuals (first 10 IFG and 10 IGT subjects enrolled) will receive a 4-day Acipimox treatment (3x 250mg capsules for three days (one with breakfast,one with lunch and one with snack) and 1x 250mg in the morning of day 4.
223421425|NCT01099501|DIETARY_SUPPLEMENT|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
223421426|NCT01099501|DIETARY_SUPPLEMENT|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
223421427|NCT01099501|DIETARY_SUPPLEMENT|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
223421428|NCT00922467|DRUG|NaCl 9/00|Same volume as in the esmolol group
223421429|NCT00922467|DRUG|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
223421430|NCT02140528|BIOLOGICAL|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
223421431|NCT02140528|BIOLOGICAL|Placebo|
223421432|NCT01202370|DRUG|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).
223421433|NCT01470651|DRUG|Armodafinil|50mg - 250mg pills, taken each morning, for 14 weeks
223421434|NCT01470651|DRUG|Sugar Pill|Inactive pill, matched to look like active medication
223421435|NCT03586674|DRUG|Lipanthyl|Tablet
223421436|NCT03586674|DRUG|Ursogal|suspension
223421437|NCT00496275|DRUG|Zactima (ZD6474)|
223421438|NCT00496275|DRUG|Vinorelbine plus cisplatin|
223421439|NCT00496275|DRUG|Gemcitabine plus cisplatin|
223421440|NCT00562289|DRUG|aspirin|during the follow up
224035726|NCT06459193|DRUG|Placebo|Placebo once daily
224035727|NCT03655379|DEVICE|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
223421441|NCT00562289|DRUG|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
224035728|NCT00416169|DRUG|galantamine hydrobromide|
224035729|NCT00821431|DEVICE|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
224137637|NCT00156910|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
224298893|NCT01411865|OTHER|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
224298894|NCT01411865|OTHER|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
224035730|NCT00821431|DEVICE|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
224035731|NCT06248931|DRUG|Valproic acid|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
224137638|NCT00156910|OTHER|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
224137639|NCT06804304|BEHAVIORAL|Music-based telerehabilitation|The music-based telerehabilitation program is a 10-week multicomponent intervention which includes (1) rhythm-based training of motor and cognitive (attention, working memory, executive function) functions, (2) singing-based training of speech production (using singing and melodic intonation therapy training), (3) playing-based training of upper-extremity motor functions (using instrumental training with a xylophone), and (4) music listening for enhancement of mood, attention, and memory. Training is done using a tablet computer and an online platform comprising a collection of short (3-5 min) training videos for each of the 4 training modules, which the patients are instructed to train with at home for 4 days / week (60 min/day). Additionally, the patients participate in a remote (online) music therapy session led by a music therapist for 1 day/week (60 min).
224137640|NCT06809933|OTHER|Digital Health Mobile App|"A digital health technology (DHT) called Move by Sword Health, which utilizes a mobile app displaying tailored and recommended exercise options, wearable technology (Move wearable or equivalent), and a web-based platform monitored by a physical therapist who will provide individual support"
224137641|NCT06809933|OTHER|Virtual Support Group|An institutional, virtual peer support group session will include a maximum of 5 participant per group
224137642|NCT06809933|OTHER|Health Coaching|The facilitated group and discussions sessions will be led by a University of California, San Francisco (UCSF) certified health coach (CHC), following a pre-specified agenda and provided virtually
224137643|NCT06809933|OTHER|Wearable Activity Tracker|A wearable device to track participant activity
224298895|NCT01547949|DIETARY_SUPPLEMENT|tart cultivar Montmorency cherry juice|
224298896|NCT01547949|DIETARY_SUPPLEMENT|placebo cherry fruit drink|
224298897|NCT05808673|BIOLOGICAL|Post-change CMAB807X|for subcutaneous injection only
224298898|NCT05808673|BIOLOGICAL|Pre-change CMAB807X|for subcutaneous injection only
224298899|NCT05808673|BIOLOGICAL|Xgeva®|for subcutaneous injection only
224298900|NCT03627741|DRUG|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
224298901|NCT05665920|RADIATION|Ultra-hypofractionated whole breast radiotherapy|Ultra-hypofractionated whole breast radiotherapy, 26 Gray (26Gy) in 5 fractions for one week
224298902|NCT05665920|RADIATION|Standard Radiation|Standard Radiation: Whole Breast Irradiation, at 40 Gy, in 15 fractions and drainage
224298903|NCT06880783|OTHER|manual diaphragm release technique|The participant should be supine with relaxed limbs, and the therapist should position themselves at the head, making manual contact with the pisiform, hypothenar region, and fingers. The therapist should gently pull the contact towards the head, deepen it during exhalation, and gradually increase the depth.
223421442|NCT00562289|DEVICE|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
223421443|NCT01413789|DRUG|Dermatix|1 application of Dermatix
223421444|NCT01413789|DRUG|Kelocote|1 application of Kelocote
223421445|NCT01413789|DRUG|BAP scar gel|1 application of BAP scar gel
223421446|NCT01413789|DRUG|Alhydran|1 application of Alhydran
223421447|NCT01413789|DRUG|Bap Scar Care T|1 application of BAP Scar Care T
223421448|NCT01413789|DRUG|Bap Scar Care S|1 Application of Bap Scar Care S
223421449|NCT01413789|DRUG|Mepiform|1 application of Mepiform
223421450|NCT01413789|DRUG|Scar Ban Elastic|1 application of Scar Ban Elastic
223562893|NCT04536480|BEHAVIORAL|Time Limited Eating|The TLE intervention arm will involve instructing participants to consume their usual kind and amount of food and beverages (all calories) within a pre-specified 8-hour period, fasting for the remaining 16-hours. They will be free to divide their food and beverage intake into as many meals or snacks as desired during the 8-hour period. Participants will be allowed to consume non-caloric beverages (water, tea, coffee) during the fasting period. No energy restriction will be required.
223421451|NCT04694950|PROCEDURE|Usual care|Intravenous morphine according to clinician´s discretion.
223421452|NCT06597565|DRUG|Gemcitabine|Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368.
223421453|NCT06597565|DRUG|ACR-368|ACR-368 is an experimental drug.
223421454|NCT02461524|DEVICE|Endurant Evo AAA Stent Graft System|
223421455|NCT02461524|PROCEDURE|Endovascular aneurysm repair (EVAR)|
223421456|NCT06621134|OTHER|AI Chatbot|Participants will be required to provide consent for randomization when they first access our system. Users can ask questions covered by the question bank, as well as specific questions not covered by the bank, through an AI chatbox. The aim is to understand the significant difference between using AI chatbots and telephone hotlines to assist parents, as well as the effectiveness of AI chatbots compared to telephone hotlines.
223421457|NCT06621134|OTHER|Telephone hotline|Participants will be asked to consent to randomization on their first access to our system. Users ask questions covered by the question bank and specific questions not covered by the question through a telephone hotline.
223421458|NCT02071862|DRUG|CB-839|CB-839 monotherapy
223421459|NCT02071862|DRUG|Pac-CB|CB-839 in combination with standard dose paclitaxel
223739683|NCT06493396|DRUG|Opioid group|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
223421460|NCT02071862|DRUG|CBE|CB-839 in combination with standard dose everolimus
223739684|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-087|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-087 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
223739685|NCT05603559|DRUG|1.1 GBq (30 mCi) of 177Lu-P17-088|All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
224035732|NCT06248931|DRUG|Topiramate 50 MG|The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
224035733|NCT01349023|OTHER|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
224035734|NCT00243360|BEHAVIORAL|diagnostic and treatment clinical algorithms|
224035735|NCT03595592|DRUG|Trastuzumab|Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
224035736|NCT03595592|DRUG|Pertuzumab|Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
224035737|NCT03595592|DRUG|Carboplatin|Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
224035738|NCT03595592|DRUG|Paclitaxel|Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
224298904|NCT06880783|OTHER|deep breathing exercises|Participants in a crook laying position are instructed to inhale through the nose, lift the abdomen, and let out through the mouth, breathing six breaths per minute for 30 minutes.
224298905|NCT06723639|PROCEDURE|A new two-layer surgical technique|A new double row suturing technique attempting to restore the length of the distinct soleus and gastrocnemius portions of the Achilles tendon.
224298906|NCT06723639|OTHER|Standard non-surgical treatment|Standard non-surgical treatment
224298907|NCT01469260|OTHER|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
224298908|NCT02156141|OTHER|Supervised high intensity training|8 weeks of supervised training
223421461|NCT02071862|DRUG|CB-Erl|CB-839 in combination with standard dose erlotnib
223421462|NCT02071862|DRUG|CBD|CB-839 in combination with standard dose docetaxel
223739686|NCT05407675|DRUG|BMS-986408|Specified dose on specified days
223739687|NCT05407675|BIOLOGICAL|Nivolumab|Specified dose on specified days
223739688|NCT05407675|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223739689|NCT05407675|BIOLOGICAL|Platinum-doublet chemotherapy|Specified dose on specified days
223421463|NCT02071862|DRUG|CB-Cabo|CB-839 in combination with standard dose cabozantinib
223421464|NCT01506765|DRUG|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
223421465|NCT01470781|BEHAVIORAL|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
223739690|NCT05407675|DRUG|Rabeprazole|Specified dose on specified days
223739691|NCT03420651|OTHER|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
224035739|NCT03595592|DRUG|Doxorubicin|Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
223739692|NCT03420651|OTHER|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
224035740|NCT03595592|DRUG|Cyclophosphamide|Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
224035741|NCT03595592|DRUG|Atezolizumab|Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
224035742|NCT03595592|PROCEDURE|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
224035743|NCT02281929|DRUG|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
224035744|NCT02281929|DRUG|Placebo|Placebo in three daily doses during 30 days
224035745|NCT02281929|DRUG|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
224035746|NCT04056065|DRUG|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
224035747|NCT04056065|DRUG|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
224035748|NCT00294385|DRUG|Docetaxel|
224035749|NCT00294385|DRUG|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
224035750|NCT00294385|DRUG|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
224035751|NCT03475810|DEVICE|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
223421466|NCT01470781|BEHAVIORAL|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
223421467|NCT00765895|DRUG|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
223421468|NCT00765895|DRUG|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
223421469|NCT01171781|DRUG|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
223421470|NCT01171781|DRUG|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
223421471|NCT01936181|DRUG|Remicade (infliximab)|
223421472|NCT01936181|DRUG|SB2 (proposed biosimilar to infliximab)|
223421473|NCT00478010|OTHER|counseling intervention|
223421474|NCT00478010|OTHER|study of socioeconomic and demographic variables|
223421475|NCT00478010|PROCEDURE|psychosocial assessment and care|
223421476|NCT00478010|PROCEDURE|quality-of-life assessment|
223421477|NCT02810470|DIETARY_SUPPLEMENT|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
223421478|NCT02810470|DIETARY_SUPPLEMENT|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
223421479|NCT03360006|DRUG|ABBV-744|Tablet, oral
223421480|NCT05545631|OTHER|no intervention|no intervention in this study
223421481|NCT02817516|DRUG|TAK-828|TAK-828 solution.
223739693|NCT05095597|PROCEDURE|Injection of hUC-PRP by hysteroscopy|PRP previously frozen at -80ºC (6±2 mL) will be defrozen after checking donor-receptor compatibility and viral safety study. PRP (4±2 mL) will be activated with 5% CaCl2 and immediately injected (4±2 mL) in the sub-endometrial wall via hysteroscopy.
224035752|NCT03475810|DRUG|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
224035753|NCT05217303|DRUG|HL-085|HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
224035754|NCT01491217|DRUG|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
224035755|NCT05208801|DRUG|Percutaneous injection|A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics
224035756|NCT05208801|DRUG|Morphine|Intrathecal injection of morphine 400mcg
224035757|NCT05208801|DRUG|Morphine+Bupivacaine|Intrathecal injection of 5mg of 0.5% bupivacaine chloride
224137644|NCT06809933|OTHER|Handouts|A handout with exercise recommendations for those with cancer in accordance with national guidelines
224137645|NCT01021852|DRUG|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
223421482|NCT02817516|DRUG|Placebo|TAK-828 placebo-matching solution.
223562894|NCT04536480|BEHAVIORAL|Components Common to All Study Arms.|All participants will receive two hours of standard nutrition counseling recommended for adolescents living with T2D. No specific caloric restriction will be recommended. All participants will maintain their usual lifestyle, including physical activity and sleep patterns. Physical activity and sleep recommendations consistent with the American Academy of Pediatrics guidelines for adolescents will be encouraged but not formally prescribed.
223562895|NCT04536480|BEHAVIORAL|Control|Participants assigned to the control arm will be instructed to consume food over a 12-h or more eating window. No energy restriction will be required.
223562896|NCT04536480|DEVICE|Continuous Glucose Monitor|All participants will be trained to wear a blinded continuous glucose monitor sensor using manufacturer educational materials under the supervision of research staff. Participants will be asked to wear the CGM for the duration of the study. During each study visit, the CGM reader will be connected to the site database to create an individual participant report. Participants will be provided enough sensors to replace the sensor every 14 days. The participants and guardians will be educated on how to use the CGM and receive 1:1 coaching on how to change the sensor, which will be completed either independently or under study team guidance. At each weekly phone meeting, study staff will monitor any challenges related to CGM wear, including participant discomfort, skin adherence, and other issues.
223562897|NCT03853850|BEHAVIORAL|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (\*\*\*) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
223562898|NCT03090659|BIOLOGICAL|LCAR-B38M CAR-T cell injection|
223562899|NCT01681069|DIETARY_SUPPLEMENT|IQP-VV-102|
223421483|NCT04962724|DRUG|Radiolabelled Xevinapant 200 mg (Oral Solution)|\[14C\]-Xevinapant 200 mg administered as an oral solution on Day 1 of Part 1, containing approximately 100 microcurie (μCi) \[3.7 megabecquerel (MBq)\] in fasted conditions.
223421484|NCT04962724|DRUG|Radiolabelled Xevinapant 100 μg (IV Solution)|100 μg \[14C\]-xevinapant single dose administered as an IV bolus on Day 1, containing approximately 0.2 μCi \[7.4 kilobecquerel (kBq)\].
223421485|NCT04962724|DRUG|Xevinapant 200 mg (Oral Solution)|Xevinapant 200 mg administered as an oral solution on Day 1 of Part 2 in fasted conditions
223421486|NCT02620241|OTHER|sitting position|
223421487|NCT00664859|DRUG|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
223562900|NCT01681069|OTHER|Placebo|
223562901|NCT00763191|OTHER|examination of ocular movements|
223562902|NCT00763191|OTHER|MATTIS test|
223562903|NCT00763191|OTHER|UPDRS test|
223562904|NCT00763191|OTHER|CRST test|
223562905|NCT03831516|DIAGNOSTIC_TEST|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
224035758|NCT04694872|OTHER|Telerehabilitation Based LSVT BIG Exercise Protocol|Lee Silverman Voice Treatment-LOUD therapy is a protocol involving intensive speech therapy, which was initiated at the Lee Silverman Parkinson Center between 1987-1989 to heal hypophonia in individuals with PD. LSVT-BIG, on the other hand, is a protocol derived from LSVT-LOUD, used in neurorehabilitation, consisting of focused large-amplitude functional movements performed with great effort. Maximal Daily exercises consist of seven standard exercises. Functional component tasks, on the other hand, will be created for movements in which the patient has difficulty in daily life activities selected individually based on his complaints. In hierarchical tasks, daily life activities with difficulties will be studied with large amplitudes. Exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week, 60 minutes a day, 4 weeks protocol respectively.
223421488|NCT06485349|DIETARY_SUPPLEMENT|Olive Leaf Extract (OLE)|Daily dose of 750mg OLE consumed with water after breakfast without any modification of their dietary patterns for 90 days.
223421489|NCT06485349|OTHER|Placebo|100mg microcrystalline cellulose
223421490|NCT03777813|DRUG|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
223562906|NCT03150004|DRUG|Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen|"Subjects will be started on CLAG-M regimen, which consists of the following:~* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5~* Mitoxantrone 10 mg/m\^2 IV on days 1-3;~* G-CSF at a dose of 300 μg on days 0-5."
223562907|NCT03150004|DRUG|Cladribine and Cytarabine (CLLDAC) Regimen|"* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;"
223562908|NCT05336929|OTHER|Roy adaptation model-based nursing education|
223562909|NCT03883165|OTHER|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
223562910|NCT03883165|OTHER|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
223739694|NCT05095597|DRUG|Oestraclin|Patients will receive estrogenic therapy, based on estradiol, for 10±2 days (oestraclin, topical cream, 5µg daily for 10±2 days).
223421491|NCT03777813|COMBINATION_PRODUCT|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
223421492|NCT03706859|PROCEDURE|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
223421493|NCT03911986|DEVICE|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
223421494|NCT06621433|OTHER|T-PRF with CAF|Blood sample will be obtained from the patient, conveyed into a titanium tube and immediately centrifuged at 2700 rpm for 12 mins at room temperature using fixed angle centrifuge (PRF Process, Tangkula800-1, China). The fibrin clot will be collected and placed in the PRF compression device (PRF GRF box) and condensed to produce a uniform T-PRF membrane which will be inserted over the recession area and covered by the coronally advanced flap.
223421495|NCT06621433|OTHER|SECTG with CAF|Sub epithelial connective tissue graft will be obtained from the donor site (hard palate), placed into recipient site and secured by sutures, then covered by a coronally advanced flap.
223421496|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
223421497|NCT02123615|DRUG|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
223421498|NCT02123615|DRUG|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
223421499|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
223421500|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
223421501|NCT02123615|DRUG|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
223421502|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
223421503|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
223421504|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
224035759|NCT04694872|OTHER|Telerehabilitation Based Functional Balance and Mobility Exercise|"These exercises will be applied simultaneously with the physiotherapist over the Zoom application, 4 days a week and 60 minutes a day for 4 weeks.~Exercises will get harder with each passing week and its progression will be adjusted to the patient."
223421505|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
223421506|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
223421507|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
223421508|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
223421509|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
223421510|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
224137646|NCT01021852|DRUG|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
223421511|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
223421512|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
223421513|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
223421514|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
224137647|NCT03985072|DRUG|Andes-1537 for Injection|Andes-1537 administered subcutaneously five days per week.
224137648|NCT04137133|DIAGNOSTIC_TEST|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
224137649|NCT04693442|OTHER|taking of blood, urine and blood samples and objective scar assessment|blood, urine and skin tissue sampling \& scar assessment questionnaires
224137650|NCT00776399|DEVICE|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
224137651|NCT01763463|DRUG|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
224035760|NCT04600479|DIAGNOSTIC_TEST|Evaluation of the prevalence of HCV, HBV and HIV viral infections|"1. Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~   In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~2. Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up."
224137652|NCT01763463|DRUG|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
224137653|NCT03631862|DRUG|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
223421515|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
223421516|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
223421517|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
223421518|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
223421519|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
223421520|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
223421521|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
223562911|NCT01350752|BEHAVIORAL|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
223562912|NCT01350752|BEHAVIORAL|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
224035761|NCT04201405|DRUG|Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene|Autologous CD34+ haematopoietic stem cells from MPS IIIA patients will be genetically modified ex vivo using CD11b.SGSH Lentiviral vector (LV), a self-inactivating LV expressing the SGSH gene codon optimized for human use and regulated by a human CD11b myeloid-specific promoter. Cells will be cryopreserved prior to patient administration.
224035762|NCT03681886|DEVICE|Harmoni Modular Intraocular Lens|Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag.
224137654|NCT03631862|DRUG|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
224137655|NCT01740037|OTHER|Specialized outpatient AF Clinic|
224137656|NCT01740037|OTHER|Usual Care|
224137657|NCT02493426|DRUG|Intranasal Oxytocin|
224137658|NCT02493426|DRUG|Placebo|
223421522|NCT02123615|DRUG|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
223421523|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
223421524|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
223421525|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
224137659|NCT03491553|DRUG|Selgantolimod|Tablet(s) administered orally once weekly
224137660|NCT03491553|DRUG|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
224137661|NCT03491553|DRUG|Hepatitis B virus (HBV) OAV Therapy|"Commercially available HBV OAV therapy could include one of the following:~Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®)"
223421526|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
223421527|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
223421528|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
223421529|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
223421530|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
223421531|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
223421532|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
223421533|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
223421534|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
223421535|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
223421536|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
223421537|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
223421538|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
223421539|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
223421540|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
223421541|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
223421542|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
223421543|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
223421544|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
223421545|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
223421546|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
223421547|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
223421548|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
223421549|NCT02123615|DRUG|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
223421550|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
223421551|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
223421552|NCT02123615|DRUG|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
223421553|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
223421554|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
223421555|NCT02123615|DRUG|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
223421556|NCT01389570|PROCEDURE|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
223421557|NCT01943851|DRUG|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
223421558|NCT01950559|OTHER|Oral food challenge|Oral food challenge to determine allergy to soy
223421559|NCT00900757|DRUG|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
223421560|NCT00832442|DRUG|Beta blocker|as determined by individual study
223421561|NCT00832442|OTHER|Placebo|in addition to usual care
223562913|NCT01350752|BEHAVIORAL|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
223562914|NCT04478071|DRUG|vadadustat|Participants will receive vadadustat once daily for 14 days.
223421562|NCT00039494|DRUG|erlotinib hydrochloride|Given orally
223421563|NCT00039494|RADIATION|3-dimensional conformal radiation therapy|
223421564|NCT00039494|DRUG|temozolomide|Given orally
223421565|NCT04766489|PROCEDURE|Complete Decongtestive Therapy|Patients will be given complete decongestive therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise, for 5 days a week and for a mean of 20 sessions. Each session will be of 1 hour duration for compressive therapies(Short stretch bandages will be left on for 23 hours a day), 30 minutes of manual lymphatic drainage, and decongestive exercises 3 times a day for 15 minutes each time.
223421566|NCT01567566|OTHER|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
223421567|NCT04982692|DRUG|intravaginal prasterone|6.5 mg of Intravaginal prasterone once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
223421568|NCT04982692|DRUG|Placebo ovules|Placebo ovules once daily at bedtime with a finger to insert the vaginal suppository into the vagina for a treatment cycle of 12 weeks.
223421569|NCT03358589|DIAGNOSTIC_TEST|FDG-PET/CT|Scans
223421570|NCT05969366|PROCEDURE|Total hip arthroplasty|
223421571|NCT00748189|DRUG|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
223421572|NCT00748189|DRUG|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
223421573|NCT02784626|DRUG|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
223421574|NCT02784626|DRUG|Propofol|Intraoperative sedation using propofol
223421575|NCT01287091|DRUG|GDC-0980|Oral tablet dose
223421576|NCT01287091|DRUG|GDC-0980|Oral capsule dose
223421577|NCT01287091|DRUG|GDC-0980|Oral tablet dose in fed state
223421578|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fasting state
223421579|NCT01287091|DRUG|GDC-0980|Oral repeating dose in fed state
223421580|NCT01287091|DRUG|GDC-0980|Oral tablet in a fasting state
223421581|NCT01287091|DRUG|rabeprazole|Oral repeating dose
223421582|NCT02128425|DRUG|FOLFOXIRI|"irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients"
223421583|NCT02128425|DRUG|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
223421584|NCT04105946|DRUG|Dexmedetomidine|dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
223421585|NCT04105946|DRUG|Remifentanil|remifentanil administration intraoperatively in combination with other drugs used in TIVA
223421586|NCT00492596|DEVICE|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
223421587|NCT00492596|PROCEDURE|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
223421588|NCT00058968|DRUG|Duloxetine hydrochloride|
223421589|NCT00058968|DRUG|placebo|
223421590|NCT03320850|DRUG|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
223421591|NCT03320850|DRUG|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
223421592|NCT05961410|DRUG|Eltrombopag olamine|Patients will receive eltrombopag 75 mg/day from ESHAP D6 until end of stem cell harvest.
223421593|NCT06344533|DRUG|JMKX003142 Injection|JMKX003142 Injection will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
223421594|NCT06344533|DRUG|Placebo|Matching placebo will be administered intravenously once in SAD cohorts and once daily in MAD cohorts for 5 consecutive days.
223421595|NCT05754580|RADIATION|High Dose Brachytherapy|This technique involves transient insertion of a stronger (i.e. more active) source (Ir-192) into the prostate, with dose delivery over the course of several minutes followed by immediate removal.
223562915|NCT04478071|DRUG|placebo|Participants will receive matching placebo once daily for 14 days.
223421596|NCT05754580|RADIATION|Stereostatic Body Radiation Therapy|ultra-hypofractionation radiation therapy.
223739695|NCT05095597|PROCEDURE|Umbilical cord blood collection|The SCU will be collected using a blood collection bag containing anticoagulant. This step will be performed by the medical and nursing staff of the obstetrics service of the HUP La Fe. The blood collection bags will be the following, or similar: Cord Blood Collection Bags from MACOPHARMA; CPD Umbilical Cord Bag from GRIFOLS.
224035763|NCT03681886|PROCEDURE|Optic Exchange|Removal of one optic and replacement with another for the purpose of improving refractive outcomes
224298909|NCT02156141|OTHER|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
223421597|NCT00616980|BIOLOGICAL|CD34-positive cells|
223421598|NCT00616980|BIOLOGICAL|CD34-positive cells|
223421599|NCT00616980|BIOLOGICAL|Saline and 5% autologous plasma|
223421600|NCT04481191|BIOLOGICAL|RotaTeq (V260)|Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution
223421601|NCT04481191|BIOLOGICAL|IPV|0.5 mL dose IPV (Sabin strain based), administered via IM injection
223421602|NCT01335880|BEHAVIORAL|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
223421603|NCT01335880|BEHAVIORAL|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
223421604|NCT02168374|OTHER|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
223421605|NCT02742116|GENETIC|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.~A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.~Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
223421606|NCT00546117|DRUG|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing \>30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
223421607|NCT00546117|DRUG|placebo|Placebo Solutab in 15 and 30 mg dosages.
223421608|NCT06642155|BEHAVIORAL|RESPONSIBLEPLAY© MTM-Based Intervention|Participants in this group will receive a theory-based intervention using the Multi-theory Model (MTM) of health behavior change. The intervention includes participatory dialogue, behavioral confidence-building, and strategies to modify the physical and social environments. It also incorporates emotional transformation and practice for change. Sessions will be delivered in-person over three weeks, focusing on promoting responsible gambling behaviors.
223421609|NCT06642155|BEHAVIORAL|Knowledge-Based Intervention|Participants in this group will receive a knowledge-based intervention that provides information on gambling risks and responsible gambling strategies. The intervention consists of lectures and reading materials delivered in-person over three weeks. It focuses on raising awareness of gambling risks but does not include the behavioral change strategies used in the MTM-based intervention.
223421610|NCT01424514|DRUG|SB-705498|12mg intra nasal
223421611|NCT01424514|DRUG|Placebo|Placebo intra nasal
223421612|NCT00079586|DRUG|Heparin|Unfractionated Heparin per institutional practice
223421613|NCT00079586|DRUG|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
223421614|NCT06624241|PROCEDURE|Lipo-Curcumin gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.
223421615|NCT06624241|PROCEDURE|Lipo gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.
223421616|NCT06624241|PROCEDURE|Discharged Gel + SRP|The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.
223421617|NCT06624241|PROCEDURE|SRP alone|The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.
223421618|NCT02638675|BEHAVIORAL|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
223421619|NCT02638675|DEVICE|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
223421620|NCT02638675|BEHAVIORAL|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
223421621|NCT02670733|PROCEDURE|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
223421622|NCT06207149|BEHAVIORAL|ASISTIR|This will be a 24 hour advocacy program focused on adult disability services.
223421623|NCT04178642|DRUG|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
223421624|NCT04178642|PROCEDURE|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
223421625|NCT00996411|DRUG|Salvinorin A|This is an initial dose ranging study
223421626|NCT00373009|BEHAVIORAL|Traditional Army training|As usual training for Soldiers
223421627|NCT00373009|BEHAVIORAL|Core stabilization exercise only|Core stabilization exercise
223421628|NCT00373009|BEHAVIORAL|Psychosocial education class only|Psychosocial education class
223421629|NCT00373009|BEHAVIORAL|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
223421630|NCT02487771|DRUG|DHA|600 mg DHA capsule
223421631|NCT02487771|DRUG|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
223421632|NCT02653170|OTHER|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services."
223421633|NCT02653170|OTHER|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~1. Contact list of care team members.~2. Access to hospital patient portal.~3. Stroke education materials, resources, and guidelines.~4. Access to Michigan 2-1-1 services.~5. Medication information and adherence tools.~6. Patient and Caregiver support networks."
223421634|NCT02043951|DEVICE|Lutonix Drug Coated Balloon Catheter|
223421635|NCT00451295|DRUG|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
223421636|NCT00451295|DRUG|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
223421637|NCT01439022|BEHAVIORAL|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
223421638|NCT01439022|BEHAVIORAL|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
223421639|NCT02147522|BEHAVIORAL|Self-care management|AHH behavioral intervention is provided by promotoras
223421640|NCT04319081|DRUG|PCSK9 inhibitor|Patients are included after PCSK9 inhibitors prescription , at the first dispensation
223421641|NCT04002999|DEVICE|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, \[24\] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
223421642|NCT04002999|DEVICE|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
223421643|NCT04002999|DEVICE|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
223421644|NCT06648577|PROCEDURE|Ultrasound imaging|The participants are scanned with an ultrasound scanner
223421645|NCT06623851|OTHER|Intraoral scanner|"* The digital impressions will be made with the intraoral scanner following the procedure reported by the manufacturer.~* The intraoral scanning process is divided into the lower jaw scan, upper jaw scan, and bite scan stages"
223421646|NCT06623851|OTHER|Alginate impression|Conventional impressions of both arches will be made according to the manufacturer's instructions, using steel impression trays and alginate
223421647|NCT03710070|DEVICE|Amplatzer vascular plug 4|See above
223421648|NCT03710070|OTHER|Sham Control|Angiography of the IMA without occlusion
223421649|NCT05984264|DRUG|lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.|Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.
223421650|NCT06130891|OTHER|Cognitive sensory motor relearning|"Cognitive Exercises:~* Orientation: Checking awareness of date, time, and weather.~* Attention: Tasks like connecting dots or spotting differences.~* Shape Sorting: Sorting objects by size, color, etc.~* Calculation Training: Counting money, beads, basic arithmetic.~* Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
223421651|NCT06130891|OTHER|Sensory motor relearning|"Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
223421652|NCT06130891|OTHER|Motor Relearning|"Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks."
223421653|NCT02312453|PROCEDURE|Posterior approach|We adopted the technique as described by Hebbard et al.
223421654|NCT06017817|DEVICE|Lumoral Treatment|Anti-infective photodynamic therapy for plaque-induced oral conditions
223421655|NCT06017817|PROCEDURE|Standard oral hygiene instructions|Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use
223421656|NCT06017817|PROCEDURE|Scaling and root planing (SRP|non-surgical anti-infective treatment by scaling and root planing
223421657|NCT06017817|PROCEDURE|surgical anti-infective peri-implantitis treatment|surgical anti-infective peri-implantitis treatment
223421658|NCT04574934|OTHER|aquatic therapy|Aquatic therapy refers to water-based treatments or exercises of therapeutic intent, in particular for relaxation, fitness, and physical rehabilitation. Treatments and exercises are performed while floating, partially submerged, or fully submerged in water. Many aquatic therapy procedures require constant attendance by a trained therapist and are performed in a specialized temperature-controlled pool. Rehabilitation commonly focuses on improving the physical function associated with illness, injury, or disability
223421659|NCT04409535|OTHER|WHOQOL-BREF survey|Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
223421660|NCT05901350|DRUG|Levodopa|Some patients did not reduced the dose of levodopa after STN-DBS comparing to some without reducing the dose.
223421661|NCT03675295|DRUG|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
223421662|NCT03675295|DRUG|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
223421663|NCT01539395|OTHER|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
223421664|NCT05588869|OTHER|observation of the adverse outcomes of Cyclosporine in steroid dependent and frequent relapsing nephrotic syndrome in children|The interventions that will be done include collection of the following data : age at disease onset, disease duration, type of steroid response, age at the start of CsA treatment, dose and duration of CsA treatment, mean values of the maintenance doses of CsA and their trough blood levels and observation of the side effects. serum creatinine at regular intervals before and after CsA treatment and renal biopsy for those who are on CsA for more than 2-3 years would be done.
224298910|NCT02156141|OTHER|Control period|8 weeks with no training.
223421665|NCT05039567|BEHAVIORAL|optimal heart team protocol|Heart teams in the experimental group will be established and trained based on the optimal heart team implementation protocol. The protocol included instructions on specialist selection, specialist training, team composition, team training and formal implementation precess.
223562916|NCT06205563|BEHAVIORAL|high-intensity interval training|High-intensity interval training (to significantly faster breathing, a significant increase in breathing depth, a significant increase in heart rate, sweating, and the need to stop exercising and adjust your breathing before you can speak; Energy expenditure (METy ≥6.00 in children) : Participants randomly assigned to HIIT will perform a 10-minute warm-up at 60-70% of their maximum heart rate (HRmax). After this, they will walk, run, or bike at 85-95% of their maximum heart rate for four sessions of four minutes each, with three minutes of active recovery (50-70% of their maximum heart rate) in between. The participants were given a five-minute cooling-off period at the end, for a total of 40 minutes of exercise. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
224035764|NCT01691391|BEHAVIORAL|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two \[18F-\]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
223562917|NCT06205563|BEHAVIORAL|moderate intensity continuous training|Moderate intensity continuous training (rapid breathing, rapid heart rate, slight sweating, but still able to talk easily; Energy expenditure (children METy) 3.00 to 5.99) : Participants randomly assigned to the MICT group will walk, run, or cycle continuously for 40 minutes at 60-70% HRmax. Participants will be required to participate in supervised exercise classes at least five times and up to seven times a week for 12 weeks. Each participant will be free to wear a smart electronic sports bracelet, which can be used to punch in sports.
223562918|NCT04400019|DRUG|Hydroxychloroquine Only Product in Oral Dose Form|The dose to be used as chemoprophylaxis will be 800mg of HCQ on the first day and 400mg for the following four days.
224035765|NCT01317225|DRUG|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
223421666|NCT01968356|DRUG|3M CHG/IPA Prep Colorless|Apply topically.
223562919|NCT03716778|OTHER|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
223562920|NCT01697423|DRUG|platelet-rich plasma|
223562921|NCT01697423|DRUG|durolane|
223562922|NCT05033587|DRUG|Anlotinib|Anlotinib a multi-target receptor tyrosine kinase inhibitor.
223562923|NCT05033587|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
223562924|NCT05033587|RADIATION|Radiotherapy|The radiotherapy regimen delivered 2.0Gy once a day, five days a week to a total dose of 60Gy.
224035766|NCT01317225|DRUG|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
224035767|NCT01050907|DRUG|Miltefosine|2.5 mg/kg/day for 28 days
224035768|NCT00279630|PROCEDURE|Orthoses and Exercise|orthrose and exercise - daily
224035769|NCT03508167|DEVICE|Thermal Band|Thermal Band used 8 hours per day
224035770|NCT03508167|DRUG|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
224137662|NCT05673863|BEHAVIORAL|Psychological Resilience Program|The psychological resilience program was applied to the children in the intervention group twice a week for a total of 5 weeks. Each session consisted of 90 minutes of structured practice. The application is carried out using narrative therapy, cognitive behavioral therapy, psychodrama and analogy techniques, self-assessment and didactic teaching techniques. In addition, participants were engaged in self-regulation exercises and positive imagery activities. Each session includes practices on empathy, stress management, resilience, realistic and unrealistic thinking, optimism and pessimism, autonomy and humor related to resilience.
223421667|NCT01968356|DRUG|3M CHG/IPA Prep Tint|Apply topically.
223421668|NCT01968356|DRUG|ChloraPrep|Apply topically.
223421669|NCT01968356|DRUG|Saline|Apply topically.
223421670|NCT03133091|DRUG|PIEB: Patient Intermittent Epidural Boluses|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
223421671|NCT03133091|DRUG|PCEA: Patient Controlled Epidural Analgesia|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
224035771|NCT03508167|DRUG|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
224035772|NCT05817253|BEHAVIORAL|Portrait|In the context of audit and feedback interventions, Portrait is document produced by the physician organization 'Therapeutics Initiative' that provides personalized prescribing feedback for BC family physicians (FPs). Portraits are used as a practice resource tool for reflection on prescribing patterns. Each Portrait topic provides data of individual physician's prescribing practice, alongside the mean and median levels of their peers (other BC physicians), a succinct review of the best-available evidence on the topic, and recommendations for future action.
224035773|NCT05817253|BEHAVIORAL|Therapeutics Letter|The Therapeutics Letter is a standalone publication that details identified problematic therapeutic issues in a brief, simple and practical manner. Therapeutics letters include a systematic literature review on a clinical topic, and help provide reference for the data presented in the Portraits.
224298911|NCT02156141|OTHER|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
224298912|NCT06745102|DIETARY_SUPPLEMENT|Xanthohumol|Participants receive a study drink supplemented with Xanthohumol (0 mg = Placebo or 0.75 mg soluble Xanthohumol)
223421672|NCT04775498|BEHAVIORAL|Face-to-face psychoeducation group|All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency. For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient. Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
223421673|NCT04775498|BEHAVIORAL|SIMPLe mobile application|The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience. The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition. The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm \& Vieta ; 2015). Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion. During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
223421674|NCT04533243|DRUG|2.5ug/h transdermal fentanyl|2.5ug/h transdermal fentanyl administers for opioid-naive patients with moderate cancer pain very 3 days
223562925|NCT04713345|OTHER|Virtual Reality Observations|If the patient is included in the Virtual Reality group, they will be asked to observe 1 time per day for 9 days for 5 minutes Virtual Motor Actions (avatar moving in a virtual environment) using a headset. Virtual Reality, followed by 5 minutes of relaxation performed using soothing music played through headphones.
223562926|NCT04713345|OTHER|Relaxation|If the patient is included in the Relaxation group, they will be offered 10 minutes of relaxation performed using soothing music played through headphones once a day for 9 days.
223562927|NCT00245050|DIETARY_SUPPLEMENT|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
223562928|NCT00245050|DRUG|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
223562929|NCT00245050|DRUG|doxorubicin HCL liposome|IV, 40mg/m2
223421675|NCT04533243|DRUG|Oral immediate-released morphine|5mg immediate-released morphine every 4 hours, double dose before sleep.
224035774|NCT02039804|DRUG|Corticosteroids|Intra-bursal injection
224137663|NCT02581319|PROCEDURE|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
224137664|NCT03108651|OTHER|Case|Motivational message will be administrated.
223421676|NCT01619540|OTHER|Valsalva maneuver|
223421677|NCT03863704|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
223562930|NCT01140100|DRUG|propofol|
223562931|NCT01140100|DRUG|thiopental,propofol|
223562932|NCT01604577|BEHAVIORAL|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
223562933|NCT03940638|OTHER|Data collection|Data collection
223562934|NCT04370483|DRUG|Leflunomide|Gievn PO
223562935|NCT04370483|OTHER|Quality-of-Life Assessment|Ancillary studies
224137665|NCT06450691|PROCEDURE|biopsy|skin biopsy and blood sampling
223562936|NCT02776462|DEVICE|EyeBox CNS|
223562937|NCT04848519|DRUG|Pembrolizumab|Given IV as first line for locally advanced or metastatic urothelial carcinoma who are not eligible for platinum-based chemotherapy; or second line for locally advanced or metastatic urothelial carcinoma after progression on platinum-based chemotherapy
223562938|NCT04848519|DRUG|Propranolol Hydrochloride|Given PO for patients on the ICI plus propranolol arm
223562939|NCT04848519|DRUG|Nivolumab|Given IV as adjuvant treatment of urothelial carcinoma in high risk of disease recurrence after undergoing radical resection
223562940|NCT04848519|DRUG|Avelumab|Given IV as maintenance treatment in locally advanced or metastatic urothelial carcinoma following no progression on first-line platinum-containing chemotherapy
223562941|NCT00222235|DRUG|d-cycloserine|
223562942|NCT00222235|DRUG|glycine|
223562943|NCT00222235|DRUG|placebo|
223562944|NCT03967028|PROCEDURE|cesarean section|lower segment cesarean section either elective or emergency
223562945|NCT03155529|PROCEDURE|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
223562946|NCT00425698|DRUG|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
223562947|NCT00425698|DRUG|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
223562948|NCT02704702|DRUG|Fimasartan|
223562949|NCT02704702|DRUG|Rosuvastatin|
223562950|NCT02704702|DRUG|Fimasartan + Rosuvastatin|
223562951|NCT02340247|OTHER|Water|
223562952|NCT02340247|DRUG|Ursodeoxycholic Acid|
223562953|NCT02340247|DRUG|Chenodeoxycholic Acid|
224035775|NCT02039804|DEVICE|Hyaluronic acid|Intra-bursal injection
224035776|NCT05981911|DEVICE|XIENCE Skypoint™ stent|Percutaneous coronary intervention with Xience-Skypoint™ stent
224035777|NCT00301223|DRUG|Pregabalin|
224035778|NCT05944042|OTHER|Observational Transplant Analysis|Identify more accurate predictive models of transplant risk
224035779|NCT00684229|PROCEDURE|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
224035780|NCT00684229|DRUG|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
224137666|NCT02408796|DRUG|OTO-201|
224298913|NCT06745102|DIETARY_SUPPLEMENT|Iso-alpha Acids|Participants receive a study drink supplemented with Iso-alpha Acids (0 mg = Placebo or 45 mg Iso-alpha Acids)
223421678|NCT03469180|OTHER|Treadmill training|Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
223421679|NCT03469180|OTHER|Whole body vibration training|Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
223421680|NCT04076423|DRUG|Dual Therapy|DTG + 3TC
223421681|NCT04076423|DRUG|Triple therapy|BIC / FTC / TAF
223562954|NCT04806776|OTHER|24hrs dressings change|The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).
223562955|NCT04806776|OTHER|7days dressings change|The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
223562956|NCT04533971|OTHER|Whole body cryotherapy|The WBC procedure consisted of 2-3 min walk in the cryogenic chamber at -110℃. Immediately before the WBC procedures, the patients were provided with a special treatment suit, they were instructed as to how to protect the parts of the body that are particularly vulnerable to frostbite, on the proper way of moving and breathing during the treatment. Excluding Saturdays and Sundays, the WBC treatments were performed daily for the next four weeks. Each time after the WBC the subjects participated in 15-minute kinesitherapy exercises conducted in groups of 5-6 people. The exercises were of general improvement nature and took into account the mobility of the subjects.
223562957|NCT02885740|OTHER|Quantification assay of adenosine and methionine cycle metabolites|
223562958|NCT02885740|GENETIC|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
224035781|NCT05332301|OTHER|High-fat test meal|Ingestion of a mixed macronutrient breakfast meal providing 846 kcal, of which 58% is fat, 29% is carbohydrate and 13% is protein.
224035782|NCT05921396|PROCEDURE|Nasal patency - rhinomanometry|Nasal patency before and after the pituitary adenoma surgery will be assessed using rhinomanometry.
224035783|NCT05921396|PROCEDURE|Nasal patency - nasal inspiratory peak flow|Nasal patency before and after the pituitary adenoma surgery will be assessed using nasal inspiratory peak flow..
224035784|NCT04526197|DRUG|ALXN1840|ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.
224035785|NCT04526197|DRUG|Celecoxib|Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
224035786|NCT00372385|DRUG|Ribavirin|tablet
224035787|NCT00372385|DRUG|Pegylated Interferon Alfa 2a|Solution for injection
224298914|NCT06745102|DIETARY_SUPPLEMENT|Xanthohumol + Iso-alpha Acids|Participants receive a study drink supplemented with Xanthohumol and Iso-alpha Acids (0 mg = Placebo or 0.75 mg + 45 mg soluble Xanthohumol + Iso-alpha Acids)
223421682|NCT04875026|DRUG|5-fluorouracil 4% (Tolak)|Application of Tolak once daily in the evening for 4 weeks
223562959|NCT02885740|OTHER|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
223562960|NCT02885740|BIOLOGICAL|Blood sample|
223562961|NCT03275246|DEVICE|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
224035788|NCT00372385|DRUG|Placebo|tablet
224035789|NCT00372385|DRUG|Telaprevir|tablet
224035790|NCT01744223|BIOLOGICAL|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
223421683|NCT04875026|DEVICE|Dexeryl|Application of Dexeryl once daily in the morning for 8 weeks
223421684|NCT01859052|OTHER|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
223421685|NCT01859052|OTHER|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
223421686|NCT01859052|OTHER|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
223421687|NCT01433068|DEVICE|NBTXR3|One intratumor implantation by injection
223421688|NCT03291470|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1
223421689|NCT03291470|BIOLOGICAL|Placebo Control|2 mL normal saline intraarticular injection
224035791|NCT01744223|DRUG|Rimiducid|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
224035792|NCT01744223|BIOLOGICAL|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
224035793|NCT01744223|BIOLOGICAL|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
224035794|NCT01744223|BIOLOGICAL|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
224035795|NCT01744223|PROCEDURE|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
224035796|NCT01558895|RADIATION|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
224035797|NCT01558895|OTHER|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
223421690|NCT04984278|DRUG|Nabiximols|oromucosal spray
224035798|NCT01699789|OTHER|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
224035799|NCT01699789|BEHAVIORAL|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
224035800|NCT01699789|BEHAVIORAL|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
223421691|NCT04984278|DRUG|Placebo|oromucosal spray
223421692|NCT04305925|DEVICE|Focal Laser Ablation|Orion system to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy. MRI guidance will be achieved by MRI/ultrasound fusion, overlaying stored MRI images upon real-time ultrasound images. Interstitial laser treatments would be achieved by inserting the fiber into the cancerous regions guided by the Artemis image-fusion device. Applications of laser energy up to 15 watts of power will be used to treat the target region.
223421693|NCT05806996|DRUG|Magnesium|Intravenous infusion, load 50 mg/Kg with infusion of 15 mg/Kg/hour
223421694|NCT05806996|DRUG|Placebo|Equivalent volume of normal saline
223421695|NCT03750513|RADIATION|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Given LET optimized IMPT
223739696|NCT05095597|PROCEDURE|Endometrial biopsy|Biopsies will be taken by specialized medical personnel by aspiration with an intrauterine cannula (pipelle or cornier). Samples will be collected in 15 mL tubes (or in a larger capacity container if needed) containing PBS or RNA later until frozen at -80ºC, at the IVI Foundation facilities. Prior to freezing (in a 1.8-2 mL cryotube) the PBS will be removed and the sample cleaned in a Petri dish if needed.
224298915|NCT06281951|DRUG|Fentanyl - Inhalation by facial nebulization|3 administrations based on a weight-dependent threshold (40 µg per administration for a weight \< 70kg and 50 µg per administration for a weight ≥ 70kg).
224298916|NCT06281951|DRUG|Fentanyl - Nebulisation|3 administrations based on a weight-dependent threshold (20 µg/administration and for a weight \< 70kg and 30 µg/administration for a weight ≥ 70kg). The dose of each bolus will be distributed at equivalent volume in both nasal pits
223421696|NCT03750513|OTHER|Quality-of-Life Assessment|Ancillary studies
223421697|NCT03750513|OTHER|Questionnaire Administration|Ancillary studies
223421698|NCT06183307|DIETARY_SUPPLEMENT|Nattokinase|Participants will receive 1 capsule per day, providing the active nattokinase daily, at a dosage of 100mg, standardized at 2,000 Fibrinolytic Units for 2 months
223421699|NCT06183307|DIETARY_SUPPLEMENT|Placebo|The placebo group will receive 1 capsule per day with 100mg containing corn starch for 2 months.
223421700|NCT06052202|BEHAVIORAL|CRC mHealth|Participants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
223421701|NCT06052202|BEHAVIORAL|Control|Participants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
223421702|NCT05195684|OTHER|imaginal probe|trauma and nightmare imaginal probe/challenge for which psychophysiological and CNS responses are recorded
223421703|NCT06967467|BEHAVIORAL|Semi-structured interview|Interviews designed to obtain information about patient reasons for enrolling or declining participation in the RENEW Intervention
223421704|NCT06967467|BEHAVIORAL|Survey|Survey which will incorporate a series of closed-ended questions eliciting attitudes about the feasibility and acceptability of the intervention, allergy delabeling and future BL antibiotic use
223421705|NCT06967467|BEHAVIORAL|Ethnographic observation|Observations designed to identify communication and contextual barriers to the implementation of RENEW
223421706|NCT06967467|BEHAVIORAL|Survey|Survey instruments will measure knowledge,attitudes, and practices surrounding allergy delabeling and antibiotic stewardship in patients with HM and perceptions of the feasibility and acceptability of the RENEW intervention
223421707|NCT06967467|BEHAVIORAL|Semi-structured interview|Interviews designed to obtain information from clinicians about their perception of the implementation of the RENEW intervention
223421708|NCT06966609|PROCEDURE|Control Group|Conventional Physical Therapy ( 12 weeks intervention) 24 randomly allocated participants will get the conventional physical therapy that includes the stretching exercises (PNF technique) for 6 weeks; targeting all the affected lower limb muscles, strengthening exercises of all the weak lower limb muscles for 12 weeks along with gait training on parallel bars. Duration of session is 45 min.
223739697|NCT06406621|PROCEDURE|Laser hair depilation|"Laser hair depilation treatment with Nd:YAG laser every 4-6 weeks to obtain a total of 5 treatments. Similar to the control group, they will also receive the best recommended standard care including teaching on hair removal techniques and asked to perform either chemical or mechanical depilation as needed between treatments."
223739698|NCT00857220|DRUG|eszopiclone|One 2 mg tablet per day for 12 months
223739699|NCT00857220|DRUG|eszopiclone|one 3mg tablet per day for 12 months
224137667|NCT04716192|OTHER|Positional release technique|"Positional Release Technique The subject lies supine with therapist standing on the affected side; tender points are located along the upper fibres of the trapezius. Pressure will applied by pinching the muscle between the thumb and fingers. The subject's head is laterally flexed toward the side of tender point, then therapist grasps the subject's forearm and abducts shoulder to approximately 90° a slight flexion or extension is added to obtain fine-tune. The ideal position of comfort achieved is held for a period of 90 seconds and followed by a passive return of the body part to an anatomically neutral position continued for 5 minutes.~Mayofascial Release Technique Therapeutic Ultrasound"
224137668|NCT04716192|OTHER|Myofascial release technique & Ultrasound|"Myofascial Release Technique~* Position of the patient - sitting comfortably with supported back, elbow flexed with forearm placed on a pillow. A low load, long duration stretch is applied along the lines of maximal fascial restrictions. The fascia is palpated and the pressure is applied directly to the skin, into the direction of restriction just until resistance (tissue barrier) is felt. The pressure will be applied for 90 to120 seconds. This procedure will carried out without sliding over the skin or forcing the tissue until the fascia complex starts to yield and a sensation of softening is achieved.~* Therapeutic ultrasound with the frequency of 3Mhz , with continuous mode and an intensity of 0.1-1.5 W/cm2 for a duration of 5 min will given with the patient position back rest."
224298917|NCT05762484|PROCEDURE|Nd:YAG laser hair removal|Using the Nd:YAG laser (cynergy), hair of the axillae will be removed.
223421709|NCT06966609|PROCEDURE|Experimental Group|Conventional Physical Therapy and Cuevas Medek Exercises ( 12 weeks intervention) 24 randomly allocated participants will get the conventional physical therapy that includes the stretching exercises (PNF technique) for 6 weeks; targeting all the affected lower limb muscles, strengthening exercises of all the weak lower limb muscles for 12 weeks along with gait training on parallel bars.Along with conventional physical therapy, experimental group participants will get Cuevas Medek Exercises that includes antigravity exercises, specefic types of stretchings and balancing exercises. Types of exercises that will be performed on the patient out of 100 exercises,will depend on the patient's need that is affecting his or her gross motor proficiency.Total duration of session is 90 min.
223421710|NCT06969157|PROCEDURE|Surgery|Minor or major surgeries were performed depending upon the primary diagnosis. Major surgery was defined as one done under general anesthesia while minor was one done under local anesthesia.
223421711|NCT06968039|DEVICE|Neuroelectrics StarStim 32|Using the advanced Neuroelectrics StarStim 32 device from Spain, individualized imaging modeling systems are employed to precisely target the frontal and parietal cortex. Personalized EEG-guided electrical stimulation protocols are selected. The stimulation parameters are as follows: a current intensity of 2 mA, a duration of 21 minutes per session for one time with EEG monitoring conducted before and after electrical stimulation.
223421712|NCT06968039|DEVICE|Neuroelectrics StarStim 32|Sham stimulation is performed using the same device and procedures as the neuromodulation group. The stimulator automatically shuts off after 30 seconds, while maintaining the device's connection. This design creates an initial sensation similar to actual stimulation while preserving the double-blind nature of the study.
223421713|NCT06966908|OTHER|Facilitate the referral of in-hospital chronic hepatitis B patients and provide treatment and follow-up in the infectious disease department.|After visiting the hospital, high-risk HBV patients are prescribed HBsAg testing by their primary physician. If HBsAg positivity is detected in patients from non-infectious disease departments, their lab reports will include a reminder to visit the Hepatitis B Health Clinic. Some primary physicians may also request an infectious disease consultation or recommend patient referral. Additionally, within two weeks, the Hepatitis B Specialist Assistant will contact the patients by phone to provide referral recommendations. Once referred to the Hepatitis B Health Clinic, physicians will conduct health education, complete liver function and virological assessments, and develop individualized treatment and follow-up plans.
223421714|NCT03697512|DRUG|Ibrutinib|capsules for oral intake in a dosage of 560 mg (four capsules) daily
223562962|NCT06072144|OTHER|Validity and reliability study|Test-retest method will be used to assess reliability. For this purpose, participants will be re-evaluated one week later with the Smart Speed device. For validity assessment, concurrent validity and agreement between measurements will be evaluated. Concurrent validity will be assessed by correlation analysis and agreement between measurements will be assessed by Bland Altman.
223562963|NCT05806541|BEHAVIORAL|laughter therapy|Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
223562964|NCT02292082|DRUG|Bupivacaine|
223562965|NCT02292082|DRUG|Morphine|
223421715|NCT03697512|DRUG|Rituximab|Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.
223421716|NCT03652220|BEHAVIORAL|Meditation Based Lifestyle Modification|8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
223562966|NCT02292082|DRUG|Methylprednisolone|
224298918|NCT05762484|DRUG|Clindamycin 1 % Topical Lotion|Clindamycin 1% lotion if needed
223421717|NCT03652220|OTHER|Minimal treatment|Drug continuation under medical supervision
223421718|NCT03652220|OTHER|Multimodal specific treatment:|Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
223421719|NCT02055989|RADIATION|Dose-escalated radiotherapy level 1|
223421720|NCT02055989|RADIATION|Sequential dose-escalated radiotherapy level 2|
223562967|NCT02292082|DRUG|Cefazolin|
223739700|NCT04221542|DRUG|AMG 509|AMG 509 administered as an IV infusion (Parts 1, 3, 4 and 5) or SC injection (Part 2).
223739701|NCT04221542|DRUG|Abiraterone|Abiraterone administered as oral tablets.
223739702|NCT04221542|DRUG|Enzalutamide|Enzalutamide administered as oral tablets.
223739703|NCT04644289|DRUG|olaparib|Olaparib tablets are administrated orally 300 mg twice daily.
223739704|NCT04644289|DRUG|durvalumab|Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
223739705|NCT01787084|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
223739706|NCT03698994|OTHER|Pharmacokinetic Study|Ancillary studies
223739707|NCT03698994|DRUG|Ulixertinib|Given PO
223421721|NCT04298814|OTHER|severe covid-19 pneumonia with ET|severe covid-19 pneumonia undergoing endotracheal intubation
223421722|NCT06333067|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
223421723|NCT01905202|DRUG|Secretrol|
223421724|NCT04512196|DRUG|Superoxidized Water|Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
223421725|NCT04512196|DRUG|Normal Saline|Normal saline contains 0.9% sodium chloride.
224035801|NCT03905161|OTHER|6-minute walk test|The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
223421726|NCT04304235|DEVICE|Pediatric Rapid Sepsis Trigger (PRST) tool|The digital platform consists of a mobile application integrating a pulse oximetry sensor attached to this device, with embedded smart algorithms that predict a critically ill state, or level of risk (below) in a child presenting at the hospital. The platform also includes an interactive dashboard located in strategic locations (e.g., laboratory, consultation rooms), which connects to the mobile application through a secure local network and displays the triage data to provide real-time monitoring for the physicians who manage the patients.
223421727|NCT04304235|OTHER|Emergency Triage and Treatment (ETAT) guidelines|These are the triage guidelines currently applied in the study hospital sites. This will be the comparator group.
223421728|NCT04377425|DIAGNOSTIC_TEST|COVID-19 swap test PCR|COVID-19 swap test PCR performed according to hospital standard operating procedures
223421729|NCT04240717|BEHAVIORAL|Patient Decision Aid|The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e. response to therapy, risk of side effects).
223421730|NCT04400864|OTHER|Dietary intervention|dietary counseling based on the principals pf the dietary intervention group.
223421731|NCT00546065|DRUG|esomeprazole treatment|concomitant esomeprazole treatment
223421732|NCT02234830|DEVICE|Exoseal closure device|Closure device for femoral artery access closure
223421733|NCT02234830|DEVICE|Angioseal closure device|Closure device for femoral artery access closure
223421734|NCT03815877|DIETARY_SUPPLEMENT|Nescafe Gold ® coffee|"Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~\- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
224035802|NCT00703144|DRUG|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
224035803|NCT00703144|PROCEDURE|Pharmacokinetic|
224035804|NCT04025463|BEHAVIORAL|HHMB|Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
223421735|NCT03815877|DIETARY_SUPPLEMENT|Nescafe Gold DECAF® coffee|"Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
223421736|NCT01132248|DRUG|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
223421737|NCT01132248|DRUG|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
223421738|NCT03813901|OTHER|Samalochana Counselling|Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.
223421739|NCT03813901|OTHER|Wait list control|Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
223421740|NCT06665893|DEVICE|Digi-physical treatment tool|A support tool named Evira will be used to provide behavioral treatment. Through daily weightings at home using a special designed scale, which sends data directly to an application on the parents phone and to a clinic homepage, the child's weight development can be easily monitored.
223421741|NCT02907528|BIOLOGICAL|Bone|Furcation defect regenerated with bone graft material
223421742|NCT02907528|BIOLOGICAL|EMD|Furcation defect regenerated with EMD
223421743|NCT04251793|OTHER|Observation|Soft tissue implant measurements and radiographs
224035805|NCT02638935|DEVICE|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
223562968|NCT02292082|DRUG|Normal saline|
223562969|NCT02292082|DRUG|Midazolam|
223562970|NCT02292082|DRUG|Propofol|
223562971|NCT02292082|DRUG|Dexamethasone|
223562972|NCT02292082|DEVICE|8 MHz. Chiba needle, 22 G / 4 inches|
223562973|NCT00822627|DRUG|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
223562974|NCT00822627|BEHAVIORAL|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
223562975|NCT06379802|BEHAVIORAL|Individualized physical activity and diet|Precision health
224035806|NCT02902627|DEVICE|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
224298919|NCT04994938|OTHER|Diet Intervention|Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.
224298920|NCT04994938|OTHER|Exercise Intervention|Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
223421744|NCT02202993|DRUG|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
223421745|NCT04447001|BEHAVIORAL|Tai-chi prime (TCP)|TCP is a 6-week twice-weekly simplified tai chi class of 1.5 hr per session with two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
223421746|NCT02657213|DEVICE|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
223421747|NCT02657213|DEVICE|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
223421748|NCT00277303|DRUG|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
223421749|NCT02401490|DRUG|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
223421750|NCT02401490|DRUG|Placebo|
223421751|NCT04558606|DEVICE|Sonic Toothbrush|Sonic Toothbrush (Philips Sonicare Flexcare Platinum Toothbrush®)
223421752|NCT04558606|DEVICE|Manual Toothbrush|Manual brushing (Technique Pro - GUM® Sunstar Italiana SRL)
223421753|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
223562976|NCT03139643|OTHER|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
223562977|NCT03139643|OTHER|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
223562978|NCT03139643|OTHER|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
223562979|NCT04689906|OTHER|surgery|This is a retrospective study that includes patients operated for suspicion of acute appendicitis
223562980|NCT03913026|BIOLOGICAL|Transplant with an expanded ECT-001 cord blood|"1. Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~2. The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~3. Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
223562981|NCT01414023|BEHAVIORAL|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
224137669|NCT05300243|DIAGNOSTIC_TEST|HPV integration test|The stratified analysis by the level of HPV DNA integration in HSIL and cervical cancer will be drawn to explore whether the status of HPV integration makes any difference in the progression of cervical cancer. The purpose of the research is to reduce the miss of cervix lesions and prove that HPV integration detection is sensitive in cervical cancer precise screening.
223562982|NCT01414023|BEHAVIORAL|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
223562983|NCT00742989|OTHER|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
223562984|NCT00742989|OTHER|Sham OLT|Therapeutic massage performed
223562985|NCT00198393|DRUG|Gefitinib|250 mg/day, until progression
223421754|NCT00425061|BIOLOGICAL|IMA-638|SC Injection, 12 weeks
223421755|NCT00425061|OTHER|placebo|placebo
223421756|NCT02793401|DEVICE|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
223421757|NCT02793401|DEVICE|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
223421758|NCT02793401|DEVICE|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
223421759|NCT02793401|DEVICE|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
223562986|NCT00198393|DRUG|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
223562987|NCT00198393|DRUG|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
223562988|NCT03806556|DRUG|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
223562989|NCT03806556|DRUG|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
224035807|NCT06220903|OTHER|Complex Decongestive Therapy|"1. Manual Lymph Drainage: Cervical region lymph drainage and abdominal region lymph drainage (especially combined with abdominal breathing) were applied.~2. Skin Care: Moisturizing creams with a pH of 5.5 were applied to the extremities before bandaging.~3. Multilayer Bandaging: Short pull bandage application was applied in a gradient manner.~4. Exercise: Joint range of motion exercises, breathing exercises (abdominal breathing), decongestive exercises, and self-drainage techniques were taught.~5. Compression Stocking: After the decongestion phase was over, flat knit compression stockings were recommended according to the patient's extremity."
223421760|NCT02793401|OTHER|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
223421761|NCT02793401|OTHER|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
223421762|NCT06136182|PROCEDURE|Pericardial Closure Using Gentrix Following Cardiac Surgery|To determine feasibility and effectiveness of Gentrix for cardiac use, and if this product is patient population specific.
224137670|NCT04195269|DRUG|Test Article|10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
223562990|NCT02803177|BIOLOGICAL|BMC2012|
224035808|NCT01906346|DRUG|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
224035809|NCT01906346|DRUG|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
224035810|NCT03328533|DRUG|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
223562991|NCT02803177|DEVICE|beta-TCP Chronos® Synthes|
223562992|NCT01847066|DEVICE|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
223562993|NCT01847066|DEVICE|Erbium 2940 plus cosmetics|laser
224137671|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
223421763|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification and autotransplantation of anterior lens capsule|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification with autotransplantation of anterior lens capsule.
223421764|NCT05906212|PROCEDURE|Non-penetrating deep sclerectomy and phacoemulsification|This group will be undergoing nonpenetrating deep sclerectomy and phacoemulsification alone.
223421765|NCT00093418|DRUG|tipifarnib|Given orally
223421766|NCT06084949|DEVICE|Nordic walking or inspiratory muscle training|Nordic walking is a form of low-impact aerobic exercise that incorporates the use of walking poles. And inspiratory muscle training is a type of exercise that provides resistance during the inhalation phase.
223562994|NCT03109093|DRUG|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
223421767|NCT06180369|OTHER|GC Fuji Triage ® GC America Inc., Alsip, Illinois )|Fissur Sealent application
223562995|NCT01709422|DRUG|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
223562996|NCT01709422|DRUG|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
223562997|NCT01709422|DRUG|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
224137672|NCT00987233|DRUG|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
224137673|NCT00987233|DRUG|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
224298921|NCT06928948|PROCEDURE|Femur replacement|Reconstruction using the Limb Preservation System™ for segmental resection of the distal femur.
224298922|NCT06927843|DEVICE|point of care test|DPP Syphilis Screen and Confirm antibody point-of-care-test (POCT)
224298923|NCT06846242|OTHER|Assessment|The group in which the assessments will be made.
223421768|NCT06180369|OTHER|BeutiSealant (Shofu, Kyoto, Japonya)|Fissur Sealent application
223421769|NCT00187681|DRUG|Metformin|2 doses of Metformin Day 1 1000mg, Day 2 850 mg
223421770|NCT00312832|DRUG|switching; dose reduction|
223421771|NCT05406115|DRUG|AMG 786|Oral tablet
224298924|NCT03596931|DRUG|Statins (Cardiovascular Agents)|Prescribed with statins
223421772|NCT05406115|OTHER|Placebo|Oral tablet
223421773|NCT04720911|BEHAVIORAL|In-person TASCS|In-person clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
223562998|NCT00051012|DRUG|ONTAK|
224035811|NCT03328533|DRUG|Norepinephrine|Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
224035812|NCT03328533|DRUG|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
224035813|NCT02460666|BEHAVIORAL|Tai-Chi-Chih (TCC)|
224035814|NCT02460666|BEHAVIORAL|Health Education and Wellness Classes (HEW)|
223421774|NCT04720911|BEHAVIORAL|Telehealth TASCS|Telehealth clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.
223421775|NCT04720911|BEHAVIORAL|Self-administered TASCS|Self-administration of the intervention, including the Safety Planning Intervention, facilitated by the TASCS ED Patient App.
223421776|NCT04720911|BEHAVIORAL|Follow-up care|Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
223421777|NCT00491309|BEHAVIORAL|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
223421778|NCT05620732|BIOLOGICAL|Claudin18.2 CAR-T cells|patients treated with Claudin18.2 CAR-T cells
223421779|NCT06664905|OTHER|Resistance Exercise|10 Repetition Maximum (RM)
223421780|NCT06664905|OTHER|Placebo|No exercise
223421781|NCT04444193|DRUG|Durvalumab|Anti-PD-L1 Monoclonal Antibody
224035815|NCT04483986|PROCEDURE|Rectus muscle re-approximation|Study group: we are going to re-approximate rectus muscle wirth minimum 3 stiches.
224035816|NCT04168684|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
224035817|NCT04168684|BEHAVIORAL|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
224035818|NCT00373750|PROCEDURE|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
224035819|NCT01258335|DIETARY_SUPPLEMENT|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
224035820|NCT01258335|OTHER|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
224035821|NCT02172339|DRUG|Tiotropium, solution ampoules|
224035822|NCT05939466|DRUG|Bedrocan®-type cannabis (22% THC, <1% CBD)|Decoction with 100 mg of Bedrocan®-type cannabis (22% THC, \<1% CBD)
224137674|NCT04650958|PROCEDURE|Deep brain stimulation|Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
224137675|NCT00731848|DIETARY_SUPPLEMENT|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
224298925|NCT06929039|DRUG|Abatacept|Test Product (A) (Kashiv's Abatacept): KSHB002 (Abatacept) Injection, 125 mg/mL - Manufactured by: Kashiv Bioscience's LLC, USA.
223421782|NCT04444193|DRUG|Lenvatinib Oral Product|Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT
223421783|NCT02918474|OTHER|Decision Aid|Use decision making tool
223421784|NCT02918474|OTHER|Questionnaire Administration|Ancillary studies
223421785|NCT00090220|BIOLOGICAL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
223421786|NCT00090220|BIOLOGICAL|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
223421787|NCT05399862|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17648 probiotic|Lactobacillus reuteri DSM 17648 is a single-strain probiotic used as adjunct treatment in H.pylori infection
223421788|NCT05399862|OTHER|Placebo|Placebo capsule with no microbial cell preparation
223421789|NCT05926973|OTHER|Enhanced cardiac arrest bundle|"* Delivering shocks with the LUCAS mechanical CPR device running~* After 5 shocks have been delivered placing new pads in the Anterior Posterior (AP) position~* Delivering shocks using the TVAA Tempus Pro defibrillator rather than the Ambulance Service defibrillator."
223421790|NCT01167673|DIETARY_SUPPLEMENT|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
223421791|NCT01167673|DIETARY_SUPPLEMENT|Placebo|placebo
223421792|NCT02137850|DRUG|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
224035823|NCT01487356|OTHER|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
224035824|NCT00246428|BEHAVIORAL|Individual Motivational Interview (IMI)|Individual counseling sessions with emphasis in personal responsibility, exploration of motivation for drinking and review of potential negative consequences. will be evaluated 6, 9, and 12 months
224035825|NCT00246428|BEHAVIORAL|Individual Motivational Interview + Family Check-Up|One hour videotaped session of family assessment
224035826|NCT05606133|DIAGNOSTIC_TEST|NavDx(R)|NavDx® is a blood test that utilizes digital droplet PCR in order to quantify fragments of tumor-specific DNA shed by HPV-associated cancer cells in the blood. The technology has the ability to distinguish tumor-tissue modified virus particles present in the plasma cell-free DNA from non-cancer associated sources of HPV DNA.
224035827|NCT06075238|DRUG|blinatumomab|The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
224035828|NCT00227890|BEHAVIORAL|MI/CBT|
224035829|NCT00227890|BEHAVIORAL|RT/TU|
224035830|NCT03688607|PROCEDURE|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
224035831|NCT02484339|DRUG|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
224137676|NCT03707964|OTHER|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
224137677|NCT03707964|OTHER|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
224137678|NCT00135837|DRUG|Verteporfin for injection|
223421793|NCT04080557|OTHER|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
224035832|NCT02484339|OTHER|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)-\>-\>conventional or high dose radiotherapy
224137679|NCT02074774|DEVICE|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
224137680|NCT02074774|OTHER|Manual control|Standard practice of manually titrating FiO2 as needed.
223421794|NCT00537316|BIOLOGICAL|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
223562999|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged \> 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
224137681|NCT01453309|PROCEDURE|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
223563000|NCT03720041|DRUG|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
224035833|NCT05292820|OTHER|Validated and non-validated questionnaire for exploration of sexuality and satisfaction after surgical procedure|Validated questionnaire : Female Sexual Function Index (FSFI), Female Genital Self-Imaging Scale (FGSIS), Body Image Scale (BIS), Non-validated questionnaire exploring post-surgery satisfaction, self-esteem scale, sexology.
224035834|NCT01323621|DRUG|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
224137682|NCT01453309|PROCEDURE|No Cell Saver|Cell Saver will not be available during surgery
224137683|NCT05008588|BIOLOGICAL|Conditioned Medium|Intranasal of 3 cc of conditioned medium each, for 3 days in a row
223421795|NCT00537316|DRUG|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
223421796|NCT00537316|DRUG|Placebo to Azathioprine|Placebo to AZA tablet orally every day
224035835|NCT01323621|DRUG|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
224035836|NCT01323621|DRUG|Double-dummy placebo|inhalation powder
224137684|NCT05008588|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|Intra-parenchymal transplantation of 20x10\^6 UC-MSCs
224137685|NCT05008588|PROCEDURE|Neurologic and Neutrophic Drugs|Such as clopidogrel, piracetam, citicoline
224137686|NCT02377271|DRUG|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
224137687|NCT02377271|DRUG|placebo|treatment by bosentan or placebo is randomized
224137688|NCT06293664|OTHER|α-MSH infusion|Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
224137689|NCT06293664|OTHER|Placebo solutions|Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
224137690|NCT02660333|DIETARY_SUPPLEMENT|Placebo|Maltodextrin - 11g/day
224137691|NCT02660333|DIETARY_SUPPLEMENT|Prebiotic|Fructooligosaccharide - 11g/day
224137692|NCT02660333|DIETARY_SUPPLEMENT|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
224137693|NCT00305851|PROCEDURE|Music Therapy|Undergo therapeutic music video therapy
223421797|NCT00537316|DRUG|Placebo infusion|Placebo to IFX intravenous (IV) infusion
223421798|NCT05764616|PROCEDURE|PARASTERNAL BLOCK|After induction of general anesthesia, an ultrasound-guided Parasternal Block will be performed with 20 mL of ropivacaine 0.5 % per side.
223421799|NCT05764616|PROCEDURE|LOCAL INFILTRATION OF DRAINAGE EXIT SITES|At the end of surgery, a local infiltration of drainage exit sites will be performed with 10 mL of ropivacaine 0.25% per side
223421800|NCT05764616|PROCEDURE|RECTUS SHEATH BLOCK|At the end of surgery, a rectus sheath block will be performed with 10 mL of ropivacaine 0.25% per side.
223421801|NCT02651155|DRUG|Lubiprostone|Lubiprostone capsules
223421802|NCT02651155|DRUG|Placebo|Lubiprostone placebo-matching capsules
223421803|NCT06684912|OTHER|High-intensity interval exercise|The number of bouts of exercise-recovery for each participant was tailored to achieve the desired EE. For example, a participant with a peak oxygen uptake (V̇O2) peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
224137694|NCT00305851|PROCEDURE|Psychosocial Assessment and Care|Undergo books on tape therapy
224137695|NCT00305851|OTHER|Quality-of-Life Assessment|Ancillary studies
224035837|NCT01323621|DRUG|Salbutamol as needed|inhalation powder
224137696|NCT03348852|DEVICE|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
224137697|NCT03420716|DIETARY_SUPPLEMENT|yogurt|
224137698|NCT04735367|DRUG|palbociclib plus letrozole|palbociclib plus letrozole
224137699|NCT01595737|DRUG|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
224137700|NCT01595737|DRUG|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
224298926|NCT06929039|DRUG|Abatacept|Reference Product (B) (US-licensed ORENCIA): 'ORENCIA' (abatacept) injection 125 mg/mL - Manufactured for: Bristol-Myers Squibb Company Princeton, NJ 08543 USA.
224137701|NCT01726920|DRUG|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
224137702|NCT01726920|DRUG|naratriptan|Tablets containing naratriptan 2,5 mg
224137703|NCT01726920|DRUG|naproxen|Tablets containing naproxen 500 mg
224137704|NCT02804880|BEHAVIORAL|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
224137705|NCT02804880|BEHAVIORAL|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
224137706|NCT02804880|BEHAVIORAL|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
224137707|NCT02804880|OTHER|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
224137708|NCT02804880|OTHER|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
224137709|NCT02804880|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
223421804|NCT06684912|OTHER|Moderate continuous exercise|Energy expenditure of exercise conditions (HIIE and MICE) were matched for energy expenditure. A participant with a V̇O2 peak of 30 mL.kg-1.min-1, weighing 80 kg, would need 6 bouts to match the target EE, assuming 1L of O2 uptake equals 5 kcal.
224035838|NCT03732508|DRUG|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
224035839|NCT03732508|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
224137710|NCT02804880|OTHER|12-page booklet|12-page smoking cessation self-help booklet
224137711|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review.
224137712|NCT00906074|PROCEDURE|Elective or emergency abdominal surgery|Clinical record review
224137713|NCT02840058|OTHER|Biological samples|blood and tumor tissue samples
224137714|NCT02840058|DRUG|Anti PD1/PDL1 treatment|
224137715|NCT03513965|BEHAVIORAL|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
224137716|NCT03513965|BEHAVIORAL|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
224137717|NCT02328989|DEVICE|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
224137718|NCT00235339|BEHAVIORAL|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
224137719|NCT00235339|BEHAVIORAL|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
224137720|NCT03720730|OTHER|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
224298927|NCT06929039|DRUG|Abatacept|Reference Product (C) (EU-authorized ORENCIA): 'ORENCIA' 125 mg solution for injection (abatacept) - Marketing Authorization Holder: Bristol-Myers Squibb Pharma EEIG, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland.
224298928|NCT06779292|DIAGNOSTIC_TEST|Large Language Model Diagnosis|Using the large language model for diagnosing emergency neurology conditions.
224298929|NCT01195272|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
224035840|NCT03732508|DRUG|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
224298930|NCT06923332|OTHER|High Fiber bar with Inulin|Bar with inulin - high fiber
224298931|NCT06923332|OTHER|Low fiber bar - no inulin|Bar without inulin - low fiber
223421805|NCT05087810|BEHAVIORAL|Psychological stress induction|Subjects will undergo acute psychological stress induction by performing mental arithmetic tasks.
223421806|NCT05087810|OTHER|Accelerated oral hydration|Participants will drink 2L of fluid in a short period of time to force diuresis and urine production.
223421807|NCT00890708|DRUG|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
223421808|NCT04579835|OTHER|External Cephalic Version|External Cephalic Version Twin A
223421809|NCT02233296|DRUG|Lasmiditan|2 discrete doses separated by 6 days.
223421810|NCT06683716|OTHER|Training in presence of the instructor|The instructor gives the trainee instructions for the examination while he/she is present in the examination room.
223421811|NCT06683716|OTHER|Telemedically training by an instructor|The trainer gives instructions to the trainee through a telemedical connection to the examiner using SmartGlasses
223421812|NCT01609543|DRUG|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
223421813|NCT05578716|DIETARY_SUPPLEMENT|Partially hydrolysed formula|Partially hydrolysed formula
223421814|NCT06277323|BEHAVIORAL|Monthly report card intervention|The investigators will increase the frequency (monthly instead of quarterly) and enhance the content of the performance feedback emails sent to cardiologists (i.e., behaviorally-informed).
223421815|NCT06277323|BEHAVIORAL|Storyboard intervention|The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.
223421816|NCT04116658|BIOLOGICAL|Multiple dose of EO2401|Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
223421817|NCT05778435|DEVICE|wireless fetal monitoring system|The wireless fetal monitoring system shortens the period of labor by enabling the woman to be more mobile during the intrapartum period.
223421818|NCT00507819|DRUG|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
223421819|NCT00507819|DRUG|Placebo|One placebo capsule will be taken by mouth three times-a-day.
223421820|NCT00111319|DRUG|bortezomib|
223421821|NCT03807219|DIETARY_SUPPLEMENT|Magnox Comfort|Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).
223421822|NCT03807219|OTHER|Placebo|placebo
224137721|NCT01795222|DRUG|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
224137722|NCT01795222|DRUG|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
224137723|NCT02643186|DRUG|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
224137724|NCT02643186|PROCEDURE|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
224137725|NCT05755334|DRUG|Ropivacaine|Administration of Ropivacaine
224298932|NCT06237803|OTHER|storage of biological samples|collect and store biological samples
223421823|NCT05377554|DRUG|Bevonescein|Bevonescein will be infused during the pre-operative period.
223421824|NCT05377554|OTHER|Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay|Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.
223421825|NCT05377554|OTHER|Intra-operative Visualization using White Light Reflectance (WLR)|Intra-operative real time nerve visualization will be undertaken using WLR.
223421826|NCT01472016|DRUG|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
223421827|NCT01472016|DRUG|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
223421828|NCT01472016|DRUG|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
223421829|NCT01472016|DRUG|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
223421830|NCT01472016|DRUG|erlotinib|Erlotinib will be taken orally daily.
223421831|NCT01472016|DRUG|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
223421832|NCT00004235|DRUG|docetaxel|
223421833|NCT00004235|DRUG|irinotecan hydrochloride|
223421834|NCT05508035|DRUG|Sacubitril / Valsartan|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
223421835|NCT05508035|DRUG|Ramipril|The participants will be randomized to either ramipril 5 mg twice daily plus placebo for sacubitril / valsartan 200 mg twice daily or sacubitril / valsartan 200 mg twice daily plus placebo for ramipril 5 mg twice daily in 1: 1 ratio using the IT randomization module. All patients eligible for randomization will receive their first dose of double-blind drug plus placebo the day after randomization visit. After assigning a randomized treatment, patients will continue at the target dose and attend a 2-week telephone follow-up followed by site visits after one month, four months, eight months and in the final visit after 12 months.
223421836|NCT06683833|DRUG|Egyptian MTA|"* Complete caries removal from the cavity.~* The liquid of Egyptian MTA (Toothmate) will be mixed with powder according to the manufacturers' instructions.~* The capping materials will be placed with the passive application on the deepest part of the cavity. Only light pressure will be applied on the MTA mixture using a wet cotton pellet to ensure adaptation of the material onto the dentin.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
224298933|NCT00018811|BEHAVIORAL|Relaxation training & thermal biofeedback|
224298934|NCT00018811|BEHAVIORAL|Surface EMG biofeedback|
224298935|NCT01489618|BIOLOGICAL|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
223421837|NCT06683833|DRUG|Biodentine|"* Complete caries removal from the cavity.~* Gently tapping a capsule of Biodentine (Septodont) on a hard surface to loosen the powder, then opening the capsule, Detaching a single-dose container of liquid and gently tapping on the sealed cap to force all the liquid down the container, Twisting cap to open, Then Pouring 5 drops from the single-dose container into the capsule, Then Closing the capsule and Placing it on a mixing device for 30 seconds, Then Collecting Biodentine with the instrument supplied in the box.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
223421838|NCT06683833|DRUG|Calcium Hydroxide (Ca(OH)2)|"* Complete caries removal from the cavity.~* According to the manufacturers' instructions, Dispensing equal volumes of base and catalyst pastes on the parchment paper pad provided. Using a Dycal (Dentsply) Liner applicator, stirring immediately to mix thoroughly until a uniform color is achieved, complete mixing occurs within 10 seconds, using the ball-pointed Dycal Liner applicator or similar instrument, the mix will be placed directly on the cavity.~* The capping materials will be placed with the passive application on the deepest part of the cavity.~* A light-cured glass ionomer cement base will be applied in the cavity .~* Selective enamel etching will be applied on enamel only.~* The one-bottle universal adhesive system bond will be applied on enamel and dentine.~* A Nano hybrid composite resin material will then be incrementally inserted into the cavities."
223421839|NCT04684459|BIOLOGICAL|Dual-targeting HER2 and PD-L1 CAR-T cells|HER2-positive solid tumor serosal cavity infusion
223421840|NCT01098500|DRUG|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
223421841|NCT05161975|DIETARY_SUPPLEMENT|Vitamin K2|Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.
223421842|NCT02157649|DRUG|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
223421843|NCT02157649|DRUG|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
223421844|NCT02157649|DRUG|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
223421845|NCT04072393|PROCEDURE|Home-based cardiac rehabilitation|-Patients will be evaluated by the clinical team at The Heart Care Institute (HCI). They will receive a heart rate monitor, blood pressure monitor, and weight scale that they will take home with them. They will receive training on how to use the heart rate monitor and blood pressure monitor. They will receive training on how to record their exercises and weights in the teleHeart application by an exercise physiologist from HCI. Within 6 weeks of completion of standard of care radiation therapy or cytotoxic chemotherapy (whichever is last), they will be prescribed a course of home-based CR by a cardiologist at HCI and be instructed on the regimen by an exercise physiologist from HCI.
223421846|NCT03452488|DRUG|BIO101|Oral capsules
223421847|NCT03452488|DRUG|Placebo|Oral capsules
223421848|NCT00965978|DRUG|ONO-5920 / YM529|oral
223421849|NCT01187771|PROCEDURE|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
223421850|NCT01187771|PROCEDURE|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
223421851|NCT06682507|OTHER|No Intervention: Observational Cohort|No Intervention: Observational Cohort
223421852|NCT06666478|OTHER|Exercise protocol at workspace|"The exercise protocol at Workspace begins in a sitting position with spinal mobility exercises that mobilize the hips, lumbar spine, thoracic spine, and cervical spine, accompanied by progressive activation of the peripheral joints in the upper limbs. This is followed by multiaxial functional exercises for the trunk and upper limbs, which combine various movements (e.g., lateral bending and twisting) that simulate the positions employees assume while working.~Subsequently, exercises are performed in an upright position, focusing on stretching and mobilizing the joints and nervous tissue to promote relaxation and release. Coordination, fluid movement, and controlled breathing are emphasized to help workers develop and maintain a stable core while on the job. These principles are essential for workers who are frequently exposed to stressors and physical exertion, as they seek to improve the quality of their movements-namely, smoothness, rhythm, and appropriate speed-while at work."
223421853|NCT00899171|GENETIC|DNA analysis|
223421854|NCT00899171|GENETIC|DNA methylation analysis|
223421855|NCT00899171|GENETIC|RNA analysis|
223421856|NCT00899171|GENETIC|gene expression analysis|
223421857|NCT00899171|GENETIC|reverse transcriptase-polymerase chain reaction|
223421858|NCT00899171|OTHER|laboratory biomarker analysis|
223421859|NCT02222311|OTHER|Blood Samples|
223421860|NCT01065870|DRUG|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
224137726|NCT05314218|DEVICE|Electrophysiology catheters and cables|"The Xtrem electrophysiology catheter was developed for diagnosis of cardiac arrhythmias. Their function is to collect by contact, electrical signals generated by the heart muscle.~Xtrem are inserted via femoral vena cava or via artery and can be used in two occasions:~* Exploration procedures for diagnosis alone~* Diagnosis before ablation procedure An extension cable is used to connect the catheter to a stimulation/ recording device."
223421861|NCT01065870|DRUG|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
223563001|NCT03720041|DRUG|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
223563002|NCT03720041|DRUG|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
223421862|NCT00653770|BIOLOGICAL|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10\^7 pfu)
223421863|NCT00653770|BIOLOGICAL|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10\^7 pfu)
223421864|NCT06684067|BEHAVIORAL|Patient navigation|Participants will receive online educational material, hospital site navigation guidance and direct contact with the patient navigator, in addition to standard instructions on the colonoscopy procedure.
223421865|NCT05484440|OTHER|Psychological|
223421866|NCT06122012|DRUG|HSK16149 20mg BID|HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；
223421867|NCT00565643|DEVICE|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
223563003|NCT02925078|DEVICE|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with \<2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
223563004|NCT02516098|DRUG|hyoscine butylbromide|
223563005|NCT00234871|DRUG|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
224035841|NCT06419751|BEHAVIORAL|Regular exercise|Based on the study participant's status and exercise assessment, the investigators prescribe moderate-intensity aerobic exercise combined with resistance exercise. Before each exercise, preparatory activities (10min), 20-30min moderate-intensity aerobic exercise, finishing activities (10min) at the end, 5 days/week, for 12 weeks, and at the same time, choose non-consecutive 3 days of resistance training in 5 aerobic training sessions to increase resistance training (choose 1\~2 muscle groups each time, 4\~5 movements, repeat each action 8\~12 times, repeat 2\~3 sets)
224035842|NCT06419751|BEHAVIORAL|Baduanjin|A professional therapist instructed the participants to learn and train Baduanjin before the intervention, and a standardized Baduanjin exercise program included eight postures, each training time was about 50 minutes (including 10 min of warm-up, 2 times of Baduanjin, and 10 min of relaxation), 5 days/week, a total of 12 weeks
224035843|NCT02648750|BEHAVIORAL|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
224035844|NCT04896138|OTHER|Interstitial Lung Disease|Not applicable - this is not an interventional trial
224035845|NCT00737919|DIETARY_SUPPLEMENT|Plant Stanol|Plant stanols in margarines daily 2 grams
224035846|NCT00737919|DIETARY_SUPPLEMENT|Plant Sterol|Plant sterols in margarines daily 2 grams
224035847|NCT04226833|DRUG|entrectinib|1x100 milligram (mg) capsule given with approximately 240 milliliter (mL) of water within 30 minutes of consumption of a standardized meal
224035848|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 1 for 48 weeks
224137727|NCT00062114|BIOLOGICAL|rituximab|
224137728|NCT00062114|RADIATION|yttrium Y 90 ibritumomab tiuxetan|
223421868|NCT00565643|DEVICE|Placebo|Routine abdominal closure without placement of adhesion barrier
223421869|NCT01671995|PROCEDURE|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
223563006|NCT00234871|DRUG|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
224035849|NCT04957550|DRUG|SHR0302 tablets、Placebo|SHR0302 tablets dose 2 for 48 weeks
224035850|NCT04957550|DRUG|Placebo|SHR0302 tablets blank preparation for 24 weeks then SHR0302 tablets dose 1/dose 2 for 24 weeks
224035851|NCT02774551|BEHAVIORAL|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
224035852|NCT01230853|DRUG|Active Comparator: A|Lecanemab Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
224035853|NCT01230853|DRUG|Placebo Comparator B|Placebo Matching Placebo Infusion
224137729|NCT00469755|DRUG|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
224137730|NCT00469755|DRUG|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
223563007|NCT00873041|DRUG|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
224035854|NCT01230853|DRUG|Active Comparator B|Lecanemab Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
223421870|NCT01671995|PROCEDURE|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
223421871|NCT06666023|DEVICE|Device|Use of the device in groups to test its ability to diagnose infections.
223421872|NCT01782417|BEHAVIORAL|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
223421873|NCT06355258|DRUG|Troxerutin|Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
223421874|NCT06355258|DRUG|Placebo|Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
223421875|NCT06355258|DRUG|placebo + low molecular weight heparin|2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
223421876|NCT06355258|DRUG|troxerutin + low molecular weight heparin|2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
223421877|NCT00003416|BIOLOGICAL|filgrastim|
223421878|NCT00003416|BIOLOGICAL|recombinant interferon alfa|
223421879|NCT00003416|DRUG|dexamethasone|
223421880|NCT00003416|DRUG|melphalan|
223421881|NCT00003416|PROCEDURE|peripheral blood stem cell transplantation|
223421882|NCT05830734|OTHER|injection of freshly collected adipose cells|"A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.~Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.~The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested."
223421883|NCT05830734|PROCEDURE|Bascoms Cleft lift procedure|The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
223421884|NCT01254318|OTHER|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
223421885|NCT02780141|DRUG|roxadustat|Oral
223421886|NCT05311436|BEHAVIORAL|Experimental - Intensive nutrition counselling for pregnant, adolescent and under2 children|"Pregnant women: Intensive dietary counseling using diet chart for locally available food, and to attend antenatal care services from local ANC providers, daily Iron, folic acid, and calcium supplementation.~Adolescent girls: Group sessions in the nutrition centers with the adolescent girls will be conducted twice monthly for 6 months. Iron and folic acid (200 mg ferrous fumarate and 400 μg folic acid); once weekly for 3 months; zinc 10 mg daily for 1 month.~Children \<2 years: Behavioral counseling sessions through monthly home visits on Infant and Young Child feeding, Growth monitoring and promotion, and water sanitation and hygiene, and food safety.~Intensive WASH counselling: Intensive WASH counseling will be provided to separate group of child participants twice a month for 6 months.~Severely stunted children: 1 egg supplementation for 3 months and 1 sachet of multiple micronutrient powder (1 RDA of vitamin A and C, iron-folic acid, and zinc) daily for 2 months."
223421887|NCT02775149|OTHER|Collection of saliva samples|Collection of saliva samples
223421888|NCT02775149|OTHER|Visual detection of BEWE-index|Visual detection of BEWE-index
223421889|NCT05833113|DEVICE|Placebo-Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~The control group will also receive the TENS-pants electrodes, connected to TENS treatment. In the placebo-TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. However, the TENS treatment to the control group will be set so that no electricity will reach the patient.~A multimodal analgesia regimen will be applied postoperatively"
223563008|NCT00873041|DRUG|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
223563009|NCT04271748|OTHER|Time Restricted Feeding|The counseling on the regimen will involve instructing the subjects on study compliance and fasting times. Subjects will be instructed to choose an eight-hour eating window (e.g., 11:00am - 7:00pm) during which the patient will be able to eat his/her normal diet. During the 16-hour fasting window (e.g., 7:00pm - 11:00am), the participant will be able to drink regular water and black coffee.
223563010|NCT05587231|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The experimental group will have the Dextenza Insert implanted immediately after surgery
223563011|NCT05587231|DRUG|Topical Fluorometholone|Steroid drops will be administered by the subject according to the standard of care taper
223563012|NCT03582865|DRUG|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
224035855|NCT01230853|DRUG|Placebo Comparator A|Placebo Matching Placebo Infusion
224035856|NCT02088788|DEVICE|Board|Also has radio-dense pelvic shielding
224035857|NCT02088788|DEVICE|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
224137731|NCT00469755|DRUG|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
224137732|NCT04076150|DEVICE|Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System|Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
224137733|NCT03927508|DRUG|r-tPA|Pulse spray and infusion
223739708|NCT06123546|OTHER|Patient oriented discharge summary|"The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge."
223739709|NCT03233347|DRUG|Brentuximab Vedotin|Given IV
223739710|NCT03233347|DRUG|Dacarbazine|Given IV
223563013|NCT05462444|OTHER|Skin prick test|Skin prick test with a standard pallete of inhalational and nutritional allergens
223563014|NCT05825534|OTHER|EIT monitoring|EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
223563015|NCT02526563|PROCEDURE|ropivicaine|Blood draws to measure serum ropivicaine
223563016|NCT02352454|DEVICE|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
223563017|NCT02522585|OTHER|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
223563018|NCT00144469|DRUG|peginterferon alfa-2a|
223563019|NCT00144469|DRUG|rivavirin|
223563020|NCT06232850|OTHER|Position sense and manual dexterity evaluate|Position sense and manual dexterity evaluate
223563021|NCT00406874|DRUG|omega 3 fats|1,000 mg daily
223563022|NCT00406874|DRUG|folic acid|800 micrograms daily
223563023|NCT02559934|DRUG|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
223563024|NCT05210517|DRUG|Empagliflozin 25 MG|25 once daily one week treatment
223563025|NCT05210517|DRUG|Benzbromaron|100 mg once daily 1 one week treatment
223563026|NCT05210517|DRUG|Empagliflozin 25 MG + benzbromarone 100 mg|combined treatment once daily for one week
223563027|NCT00346606|DRUG|Denosin® and Xyzal®|
223563028|NCT05556135|DIAGNOSTIC_TEST|level of serun adiponectin|estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
223563029|NCT00592163|DRUG|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
223563030|NCT03418649|DRUG|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
223563031|NCT03418649|DRUG|Placebo Oral Tablet|PO once daily for 10 days
223739711|NCT03233347|DRUG|Doxorubicin|Given IV
223563032|NCT01520701|DEVICE|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
224298936|NCT01489618|BIOLOGICAL|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
224298937|NCT05397548|DIAGNOSTIC_TEST|Measurement of levels of circulating exosomal lncRNA-GC1|Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
223563033|NCT01520701|DRUG|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
223563034|NCT05829447|DEVICE|G-EYE 760 R endoscope|The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
223739712|NCT03233347|OTHER|Laboratory Biomarker Analysis|Correlative studies
223739713|NCT03233347|BIOLOGICAL|Nivolumab|Given IV
223739714|NCT03233347|DRUG|Vinblastine|Given IV
223739715|NCT04290689|DRUG|Botulinum Toxin-A injection|Botulinum Toxin-A injection to be administered by the surgeon to the subject's calf muscle as per normal clinical protocol to help improve muscle tone.
223563035|NCT03831191|DRUG|LY3375880|Administered SC
223563036|NCT03831191|DRUG|Placebo|Administered SC
223563037|NCT02300558|DRUG|Eleclazine|Tablets administered orally
223563038|NCT02300558|DRUG|Eleclazine placebo|Tablets administered orally
223563039|NCT05474781|DRUG|Epclusa|HCV treatment
223563040|NCT01491386|DEVICE|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
223563041|NCT01491386|DEVICE|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
223563042|NCT01932320|DRUG|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
223739716|NCT04290689|PROCEDURE|Serial casting stretching|Stretching cast intervention to be carried out in clinic as per normal clinical protocol.
223421890|NCT05833113|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|"Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~In the TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. TENS device will be applied 4 times a day with treatment periods of 30 minutes.~A multimodal analgesia regimen will be applied postoperatively"
223421891|NCT02691819|DEVICE|single stent and embedded balloon angioplasty|
223421892|NCT05500638|BEHAVIORAL|Virtual Reality|At this stage, trainings were given for epileptic seizures. Parents were asked to wear SG glasses and they were trained on the correct approach to seizures over the Focal to bilateral tonic-clonic seizure scenario integrated into the SG glasses. The clinic and process of focal to bilateral tonic-clonic seizure and the training of what to do and not to do during the seizure were given again through SG glasses. Parents interfered with the patient scenario many times during their free work time and had the chance to interfere with the seizure again and again by restarting the seizure.
224035858|NCT05452590|PROCEDURE|Ultrasound-guided wire-in-needle technique for central venous catheter placement|The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
224035859|NCT02423239|DRUG|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
223421893|NCT04336319|BIOLOGICAL|Fecal Microbial Transplantation|"1. At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~2. FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline)."
223421894|NCT03374501|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)
223421895|NCT03374501|DIETARY_SUPPLEMENT|Soft drink|Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
223421896|NCT05449301|OTHER|Rhythmic Auditory Stimulation|The participants will receive RAS on regular treadmill for balance and gait improvement. one session per day, 3 session per week for consecutively 12 weeks.
223421897|NCT05449301|OTHER|Treadmill Training|participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.
223421898|NCT05449301|OTHER|Unilateral Step Training|Patients will be trained on regular treadmill for both paretic and non paretic lower extremity. Single session per day, 3 session per week for consecutively 12 weeks.
223421899|NCT03285568|DRUG|Palbociclib|Observe patients receiving palbociclib for dose adjustment and lab monitoring
223421900|NCT05919225|PROCEDURE|Risk stratification before decision-making about patient hospitalization or discharge|Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.
223421901|NCT06249347|PROCEDURE|PROMISED|CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Roof linear ablation: linear ablation in the left atria roof; Anterior septal linear ablation: linear ablation in the anterior septal linear which coursed from the middle of the right superior and inferior pulmonary veins or the middle of the right superior pulmonary vein to the mitral valve annulus; Mitral isthmus linear ablation: linear ablation in the mitral isthmus; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
223421902|NCT06249347|PROCEDURE|CPVI and LAAC|CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
223421903|NCT06249347|DEVICE|Radiofrequency ablation catheter|Device： Radiofrequency ablation catheter
223421904|NCT06249347|DEVICE|left atrial appendage occlusion device|Device： left atrial appendage occlusion device
223421905|NCT02793674|DEVICE|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
223421906|NCT02793674|DEVICE|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
223739717|NCT00003443|DRUG|bryostatin 1|
224035860|NCT02423239|DRUG|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
224035861|NCT02423239|DRUG|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
224035862|NCT02423239|DRUG|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
224035863|NCT04288895|DRUG|Vortioxetine|5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
223421907|NCT05536024|DIAGNOSTIC_TEST|Prediction of glioma grading and molecular subtype|Prediction of WHO grading(II/III/IV), IDH gene mutation status, ATRX deletion status, 1p/19q deletion status, CDKN2A/B homozygous deletion status, TERT gene mutation status, epidermal growth factor receptor (EGFR) mutation status, chromosome 7gain and chromosome 10 less status, H3F3A G34 (H3.3 G34) mutation status, H3 K27M mutation status
223421908|NCT02846116|OTHER|Prosthetic crown|
224035864|NCT02701738|DIETARY_SUPPLEMENT|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (\~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
224137734|NCT03927508|DEVICE|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
223421909|NCT02117908|DEVICE|RESMED AUTOSET S9|Continuous positive pressure during surgery
223421910|NCT00644176|DRUG|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
223421911|NCT00644176|OTHER|placebo|placebo
223421912|NCT00644176|DRUG|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
223421913|NCT00644176|OTHER|placebo|placebo
223421914|NCT05353244|DEVICE|PrTMS|Each participant will receive a personalized rTMS treatment based on their individual alpha frequency.
223563043|NCT01932320|DRUG|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
223421915|NCT05353244|DEVICE|Sham|Using a sham coil that looks and sounds like an actual TMS coil, each participant will receive sham rTMS treatments.
223421916|NCT02804139|OTHER|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
223421917|NCT02804139|OTHER|Standard Care|Standard Care after C-section with no additional physical therapy.
223421918|NCT01871181|PROCEDURE|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
223421919|NCT01871181|PROCEDURE|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
223421920|NCT00804102|DEVICE|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
223421921|NCT00804102|DEVICE|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
223421922|NCT05461521|OTHER|Family members of patients admitted to the ICU|"At inclusion:~* Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~* Venous blood sampling at 350 relatives~* Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~  3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~  6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU."
223421923|NCT05461521|OTHER|Health care professionals|All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
223421924|NCT05461521|OTHER|Patients|Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
223563044|NCT01932320|DRUG|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
223563045|NCT01932320|DRUG|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
223563046|NCT04302701|OTHER|Dichoptic treatment using virtual reality|Dichoptic visual training will be performed with the patient wearing his spectacles using the computer game included in Vivid Vision (Vivid Vision, San Francisco, USA) which will be run in the Oculus Rift OC CV1 virtual reality head mounted display (Oculus VR, Menlo Park, California, USA). Each subject will have 20 treatment sessions, divided into 1 hour-sessions performed twice a week for 10 weeks. Each session will be 60 minutes. Adherence to the treatment regimen will be assessed by the number of hours spent in training at the end of 5th week.
224035865|NCT04462341|DEVICE|Water Flosser|Device that uses water under pressure to clean around teeth and under the gums
224035866|NCT04462341|DEVICE|Manual Toothbrush|Plastic handle with nylon bristles to clean teeth
224035867|NCT01115972|DRUG|ASP1585|oral
224035868|NCT01115972|DRUG|valsartan|oral
224035869|NCT00730431|DRUG|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
224137735|NCT03482323|BEHAVIORAL|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
224137736|NCT03482323|BEHAVIORAL|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
224137737|NCT04788108|DRUG|Dydrogesterone|Dydrogesterone tablet
224035870|NCT00730431|DRUG|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
224137738|NCT04788108|DRUG|Placebo|Placebo tablet
223421925|NCT04264390|BEHAVIORAL|Movement-to-music|Movement-to-music is a physical activity program that was developed onsite at a state-of-the-art adapted fitness facility. The program includes movements that are coupled with music to enhance muscular strength, cardiorespiratory capacity, flexibility, and balance. For this study, the program will be packaged into playlists of exercise videos that will be given to participants. Participants will be instructed to complete the prescribed videos 3 times per week. Participants will also be asked to attend 4 behavioral coaching calls with a telecoach. The goals of the behavioral coaching calls will be to address issues with the technology components of the program and promote physical activity participation within the community and adherence to the movement-to-music videos.
223421926|NCT00330343|DRUG|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
223421927|NCT01595464|BEHAVIORAL|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
223421928|NCT05622318|DRUG|Cyclophosphamide|25 mg/kg by IV on Days +3 and +4.
224035871|NCT02876835|DRUG|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
224035872|NCT02876835|DRUG|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
224035873|NCT02876835|DRUG|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
224035874|NCT02876835|DRUG|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
223421929|NCT05622318|DRUG|Tacrolimus|Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level \[IV:PO ratio = 1:4\]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.
223421930|NCT05622318|DRUG|Mycophenolate Mofetil|15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.
223421931|NCT05622318|DRUG|Ruxolitinib|5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.
223421932|NCT01992653|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
223421933|NCT01992653|DRUG|Doxorubicin|Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
223421934|NCT01992653|DRUG|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
223739718|NCT03084874|BEHAVIORAL|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
223739719|NCT05592782|BEHAVIORAL|Virtual Reality Based Mindfulness meditation|Participants will undergo a guided VR meditation using a commercial VR application. The meditation will last approximately 15 minutes. Prior to starting and on upon completion of each VR meditation session, participants' state pain, anxiety, depression, and stress will be assessed. For each participant enrolled, baseline and monthly assessments using the DASS-21 and PPI-SFI3a will be performed for three consecutive months.
224035875|NCT00198549|DRUG|Vitrase (ovine hyaluronidase) Lyophilized|
224035876|NCT03321487|DEVICE|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
224035877|NCT04537169|PROCEDURE|Levator resection|Eyelid crease incision Dissection of the levator aponeurosis to the level of Whitnall ligament. Assessment of the structure of Whitnal ligament. Resection of a calculated part of the aponsurosis. re-attachment of the aponeurosis to the tarsus Incision closure with crease formation
224035878|NCT03510988|DIAGNOSTIC_TEST|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
224035879|NCT05383404|DIAGNOSTIC_TEST|blood and urine samples|complete blood count, blood glucose, blood gases, serum bicarbonates, serum electrolytes, serum albumin ,serum creatinine. blood urea nitrogen, urine analysis.
224035880|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
224035881|NCT00860821|DRUG|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
224035882|NCT02540538|BIOLOGICAL|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
224035883|NCT02540538|BIOLOGICAL|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
224137739|NCT02734719|DEVICE|Bonestim|Bonestim is the multipad electrical stimulation device.
224137740|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
224137741|NCT02340988|DRUG|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
223421935|NCT01992653|DRUG|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
223421936|NCT01992653|DRUG|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
223421937|NCT01992653|DRUG|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
223421938|NCT01992653|DRUG|Rituximab|Rituximab will be administered at 375 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
224035884|NCT03552861|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
223421939|NCT05764538|DRUG|DAOIB|The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation
223421940|NCT00356356|DRUG|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
223421941|NCT05326347|DRUG|OPC-34712FUM/ Brexpiprazole fumarate|The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
223421942|NCT02308423|RADIATION|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
223421943|NCT00288600|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin
223421944|NCT00288600|DRUG|Normal saline solution|Normal saline solution 10 ml/Kg
224035885|NCT04331041|DEVICE|Adaptive stereotactic body radiation therapy|"* Will be administered using MRIdian and Ethos~* 50 Gy in 5 fractions"
223421945|NCT01654120|DRUG|Liraglutide|SC, 1.8mg,QD, six months to one year
223421946|NCT01654120|DRUG|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
224035886|NCT04331041|DRUG|Defactinib|-Oral drug 400 mg twice a day
223421947|NCT02913404|PROCEDURE|ACL Reconstruction|standard surgical procedure
223421948|NCT02913404|PROCEDURE|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
223421949|NCT06618079|DRUG|HUC2-565-A, HUC2-565-A and HUC2-565-B|Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.
223421950|NCT06618079|DRUG|HUC2-565-B, HUC2-565-A and HUC2-565-B|Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
223421951|NCT01585662|PROCEDURE|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
223421952|NCT04110561|DEVICE|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
223421953|NCT06362993|OTHER|Bundling|Education on and screening for diabetes and hypertension offered together with education and screening for breast cancer.
224035887|NCT04331041|PROCEDURE|Tumor biopsy|-Baseline and 12-14 weeks after end of SBRT (or at time of surgery)
223421954|NCT06362993|OTHER|MEGH|Education on breast cancer and discussion sessions to male partners to change men's gender attitudes and behaviors.
224035888|NCT04331041|PROCEDURE|Research blood draw|-Baseline, 6-8 weeks after the end of SBRT, and 12-14 weeks after the end of SBRT
224035889|NCT01794585|BEHAVIORAL|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
223421955|NCT03846154|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"1. A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~2. Access to schools and school material~3. Family visits~4. Their parents received training regarding agriculture and microcredit projects, and financial assistance~5. FORNET if affected by trauma-related symptoms, and/or acting aggressive~6. If needed medical assistance /.) If needed, legal assistance"
223421956|NCT04793490|PROCEDURE|Sphenopalatine ganglion block|Patients will receive the SPGB via the transnasal approache by a cotton tipped applicator soaked in lignocaine 2% with 4 mg dexamethasone
223421957|NCT04793490|DRUG|paracetamol|patients will receive paracetamol 1 g thrice daily intravenously
223421958|NCT00657488|DRUG|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
223421959|NCT04266587|BIOLOGICAL|Blood sampling|blood sampling is done on healthy volunteers
223421960|NCT00327028|DRUG|Diphenine|
223421961|NCT03601312|BEHAVIORAL|Exposure and Response Prevention|Exposure and response prevention is an evidence-based behavioral treatment that primarily focuses on exposures, in which the child faces OCD-related fears in a methodical manner and acquires more adaptive coping strategies.
223421962|NCT03601312|BEHAVIORAL|OC-Go|OC-Go is a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices. Individuals receiving this intervention will receive exposure and response prevention with OC-Go.
223421963|NCT01803217|OTHER|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
223421964|NCT03150511|DRUG|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
223421965|NCT00771017|BIOLOGICAL|GVAX prostate cancer vaccine|Given intradermally
223421966|NCT00771017|DRUG|bicalutamide|Given orally
223421967|NCT00771017|DRUG|goserelin|Given intramuscularly
223421968|NCT00771017|DRUG|leuprolide acetate|Given intramuscularly
223421969|NCT05405361|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
223421970|NCT05405361|OTHER|Placebo|Intravenous administration of placebo
223421971|NCT06920303|DEVICE|transcranial colour coded duplex|transcranial colour coded duplex is good non invasive tool in detect velocity and obstructions of intracranial arteries
223421972|NCT00001460|BEHAVIORAL|inpatient evaluation and management|
223739720|NCT05542264|DRUG|SEP-363856|SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
224035890|NCT01794585|BEHAVIORAL|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
224035891|NCT03773822|COMBINATION_PRODUCT|Hydrocortisone + Flucortac|Low dose steroids
223421973|NCT02964208|DEVICE|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
223421974|NCT01989325|DRUG|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
223421975|NCT01989325|DRUG|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
223421976|NCT01989325|DRUG|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
223421977|NCT01989325|DRUG|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
223421978|NCT06680687|BEHAVIORAL|Educational Program (video, information booklet, Survivorship Card)|"Caregivers will be invited to attend an educational group session. Each session will be organized weekly to monthly. A maximum of ten caregivers can be present at a session.~First a video will be displayed in which healthcare providers explain medical aspects of survivorship. Caregivers of survivors and young adult survivors discuss experiences after completing cancer treatment in the video.~Secondly, the present healthcare provider will hand over an information booklet 'Life after childhood cancer' to the caregivers. The booklet covers similar topics as presented in the video.~Lastly, a Survivorship Card will be shared with the caregivers. The card contains a record of the patient's cancer and treatment history and the expected follow-up appointment schedule. The survivor and family take one card home and a duplicate copy of the card remains in the medical file."
223421979|NCT06680687|BEHAVIORAL|Follow-Up Program (form and healthcare provider training)|"Healthcare providers will attend a training session of approximately 90 minutes, in which investigators will discuss the same topics as covered in the educational group session supported by PowerPoint slides.~A Follow-Up Form will be introduced to be used by healthcare providers in the outpatient follow-up clinic. The form will include questions referring to symptoms specific for certain late effects. Specific questions will be included per subcategory: hematological malignancies, solid tumors or central nervous system (CNS) tumors."
223421980|NCT04996316|OTHER|Electronic Health Record Review|Health record reviewed
223421981|NCT04996316|OTHER|Interview|Participate in interview
223421982|NCT04996316|OTHER|Media Intervention|Use MammoScreen
223421983|NCT04996316|OTHER|Survey Administration|Complete survey
223421984|NCT04996316|OTHER|Training and Education|Undergo training
223563047|NCT04302701|OTHER|Patching|Patients in the control group will be instructed to continue wearing spectacles if required. Patients will be prescribed two continuous hours of daily patching with at least one hour of near activities during patching. Adhesive skin patches will be provided by the study. The parent/patient will be instructed to spend at least one of the hours of patching time each day performing eye-hand coordination activities at near.
224035892|NCT03773822|OTHER|Placebo|Placebo
224035893|NCT02506478|OTHER|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
223421985|NCT05665075|DRUG|QN-023a|NK cell therapy
223421986|NCT05665075|DRUG|Cyclophosphamid|Lympho-conditioning Agent
223421987|NCT05665075|DRUG|Fludarabine|Lympho-conditioning Agent
224035894|NCT01885325|OTHER|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
224035895|NCT02216487|DRUG|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
224035896|NCT00408603|DRUG|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
224137742|NCT00334932|DRUG|bortezomib|
223421988|NCT05665075|DRUG|Cytarabine|Lympho-conditioning Agent
223421989|NCT05665075|DRUG|VP-16|Lympho-conditioning Agent
223563048|NCT02471274|DRUG|sotagliflozin|single 400 mg dose
223421990|NCT06879717|DRUG|roginolisib|tablet, 40mg tablet strength
223421991|NCT06879717|DRUG|Dostarlimab|500 mg administered as IV infusion
223421992|NCT06879717|DRUG|Docetaxel|75 mg/m2 administered over 1 hour as IV infusion
223421993|NCT06882577|OTHER|observational only- no intervention|observational only- no intervention
223421994|NCT01483729|DRUG|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
223421995|NCT01483729|DRUG|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
223421996|NCT01483729|DRUG|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
223421997|NCT01483729|DRUG|ritonavir|Test Formulation 1, single oral dose
223421998|NCT01483729|DRUG|ritonavir|Test Formulation 2, single oral dose
223563049|NCT03575845|BEHAVIORAL|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
223563050|NCT01059682|DRUG|Dalcetrapib|Dalcetrapib 600 mg orally once daily
223563051|NCT01059682|DRUG|Placebo|Placebo orally once daily
224035897|NCT01209312|OTHER|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
224035898|NCT00364156|DRUG|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
224035899|NCT00364156|DRUG|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
224035900|NCT04626817|DEVICE|Isokinetic device (Biodex System 4)|The measurement of muscle strength with isokinetic device
224137743|NCT00334932|DRUG|melphalan|
224137744|NCT00334932|DRUG|pegylated liposomal doxorubicin hydrochloride|
224035901|NCT04612387|BEHAVIORAL|Mind-body therapy|Online yoga, meditation and nutrition tips.
224035902|NCT04775251|OTHER|Upward rotation exercise|Treatment for correction of depressed scapular Alignment by exercise ( Upward Rotation Exercises) for 6 weeks.
224035903|NCT01561222|DRUG|Calcitriol|0.25 ug per day for one year
224035904|NCT01561222|DRUG|placebo|one pill per day
223421999|NCT01483729|DRUG|ritonavir|Reference Formulation, single oral dose
223422000|NCT06667570|PROCEDURE|SALFOAM 3%|"* Drug: Polidocanol 3%~* Device: Lidstop®"
223422001|NCT06667570|PROCEDURE|Control Group|"* Drug: Polidocanol 3%~* Device: Standard compression with dental roll and elastic stockings"
223422002|NCT06729554|OTHER|Education & Care in RARE|Education \& Care in RARE (https://www.youtube.com/watch?v=R3fr-q-6JIw) is a short-term, structured, resource-oriented and child-friendly psychoeducation program for children and adolescents with rare diseases. It promotes knowledge and competence on rare diseases in children in order to reduce the psychosocial rare disease burden and to improve individual self-competence in managing the rare disease and to improve their quality of life. Education \& Care in RARE can be used for all pediatric rare diseases. This has the great advantage that users only need to be trained in the use of one program.
223422003|NCT06729450|DEVICE|DispersinB Acne Cleanser|DispersinB Acne Cleanser, strength: 80 ug/g, topical gel
223422004|NCT06296927|OTHER|Emotional Freedom Technique|The researcher will apply the Emotional Freedom Technique to women in the intervention group who apply for mammography screening for 30-40 minutes before the screening.
223422005|NCT02913274|DEVICE|Paclitaxel (Taxol) eluting angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
223422006|NCT02913274|DEVICE|high-pressure angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
223422007|NCT02913274|DEVICE|low-pressure balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
223422008|NCT06405828|BEHAVIORAL|ACCESS Supportive Care|"ACCESS Supportive Care includes:~1. Coaching sessions: 6 one-hour weekly Community Navigator led supportive and early palliative care health coaching sessions. Sessions will be hybrid (in-person or virtual) per participant preference.~2. Monthly check-in: Monthly check-ins (\~5-10 minutes) about their supportive care and social determinants of health needs over 16 weeks.~3. Scheduling of outpatient supportive oncology appointment if interested.~4. Community linkage: Warm hand offs and connection to community resources to enhance access to support groups, educational workshops, and healthy lifestyle services."
223422009|NCT06405828|BEHAVIORAL|Phone sessions|6 weekly phone sessions, approximately 10 minutes in length each, to review breast cancer and supportive and palliative care resources in NYC and online. The 6 weekly phone sessions will include the topics discussed in the intervention arm but will be informational in nature. The phone sessions will be followed by monthly check-ins (\~5 minutes) to review and answer questions about the resources for the duration of 16 weeks.
223422010|NCT03530605|DEVICE|Optune TTF device|portable device which produces electrical fields
224035905|NCT05419089|PROCEDURE|Robotic surgery|Transoral robotic surgical resection of the tumor with negative intraoperative frozen section margins.
223422011|NCT06826807|OTHER|Regular monitoring with transient elastography|MASLD patients were received their liver fat and fibrosis status regularly using transient elastography
223422012|NCT06756984|PROCEDURE|Partial Cyst Wall Resection with Nerve Root Sleeve Plasty|Surgical technique involving partial removal of the cyst wall to decompress the nerve root, followed by plasty of the nerve root sleeve to restore nerve function and prevent recurrence.
223422013|NCT06756984|PROCEDURE|Partial Cyst Wall Resection with Nerve Root Sleeve Reinforcement and Reconstruction:|Advanced surgical technique combining partial cyst wall removal with additional reinforcement and reconstruction of the nerve root sleeve to provide enhanced support and reduce the risk of cyst recurrence.
223422014|NCT06756984|PROCEDURE|Autologous Fat/Muscle with Fibrin Glue Microscopic Cyst Filling|Minimally invasive surgical technique where autologous fat or muscle tissue is used to fill the cyst cavity, and fibrin glue is applied to seal the defect, aiming to obliterate the cyst and prevent cerebrospinal fluid leakage.
223422015|NCT04986410|DIAGNOSTIC_TEST|CCTA, CT-MPI, CT-FFR, SPECT-MPI|Subjects undergo CCTA, CT-MPI, CT-FFR or SPECT-MPI
224035906|NCT05255081|DEVICE|Adspray|Application of AdSpray™ over all organs under the laparotomy incision at the end of operation
224035907|NCT05255081|PROCEDURE|Placebo-control|Spray with saline would be applied to organs under incision
223422016|NCT05390242|DIAGNOSTIC_TEST|Radiographic study|Candidates undergo a radiographic study (Orthopantomography and Implant periapical radiography)
223563052|NCT05669755|DRUG|Cagrilintide|Participants will receive cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
223563053|NCT05669755|DRUG|Semaglutide|Participants will receive semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 219 weeks.
223563054|NCT05669755|DRUG|Placebo|Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
224035908|NCT03318939|DRUG|Poziotinib|"The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.~* Cohorts 1-3: 16 mg QD~* Cohort 4: 8 mg BID~* Cohort 5: randomized to 8 mg BID or 6 mg BID or 10 mg QD~* Cohorts 6 and 7: 8 mg BID"
224035909|NCT04338828|DRUG|Nitric Oxide Gas|Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
224035910|NCT04338828|OTHER|Inhaled Supplemental Oxygen|2 L/min oxygen therapy
224035911|NCT02320955|PROCEDURE|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
224035912|NCT06165614|DRUG|Artesunate pessary|Subjects will self-administer 200 mg of Artesunate pessary (vaginal insert) daily for 5 days, on weeks 1, 3, 5, 7.
224035913|NCT06165614|PROCEDURE|Colposcopy|Colposcopy is a procedure that allows close examination of the cervix, vagina, and vulva, performed on weeks 8 and 14.
223422017|NCT04180852|OTHER|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
223422018|NCT06767306|RADIATION|Stereotactic Body Radiotherapy (extracranial) concurrent with immunotherapy|A minimum SBRT biologically effective dose (BED) of 48Gy10 to all sites of extracranial metastatic disease should be administered between cycle 1 and cycle 3 of standard of care immunotherapy.
223422019|NCT06767306|DRUG|Immunotherapy alone|All patients will receive standard of care 1st line immunotherapy as decided by the treating clinician and in accordance with the current listing on the Australian Register of Therapeutic Goods (ARTG) or applicable international regulatory agency.
223422020|NCT00796952|BEHAVIORAL|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
223422021|NCT00796952|BEHAVIORAL|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
223422022|NCT00796952|BEHAVIORAL|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
223422023|NCT06532864|BEHAVIORAL|Practice Mawangdui Guiding Technique|Nursing staff with experience in teaching Mawangdui Daoyin Exercise conducted the operation instruction on different floors. A feasibility assessment of the older adults was carried out by the nursing staff at the end of the teaching, and only after passing this assessment could the experimental part begin. The treatment group participated in five Mawangdui Daoyin Exercise sessions per week, each lasting approximately 45 minutes, and the exercises continued for 12 weeks.
223422024|NCT05314127|DRUG|Tazarotene 0.1% Gel,Top|once daily topical application at night with a cotton tipped applicator on every lesion
223422025|NCT05314127|DRUG|Imiquimod|Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.
223422026|NCT05314127|DRUG|Fluorouracil Cream|5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
223563055|NCT00574041|DRUG|Interferon beta-1a|injected, once a week
224137745|NCT02776657|OTHER|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
223422027|NCT05314127|DRUG|Petrolatum|applied once daily at night
223422028|NCT01375972|DRUG|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
223422029|NCT01375972|DRUG|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
223422030|NCT01466504|PROCEDURE|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
223422031|NCT05887440|BEHAVIORAL|isokinetic strength training of knee extensor and flexor muscles|"Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)"
223422032|NCT06809777|DRUG|Topical 25% podophyllin|25% podophyllin applied topically once weekly for 4 weeks
223422033|NCT06809777|PROCEDURE|Cryotherapy|cryotherapy of 10 sec freeze cycle applied twice weekly for 4 weeks
223422034|NCT00264745|BEHAVIORAL|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
223422035|NCT00264745|BEHAVIORAL|Attention Control|Minimal intervention beyond initial hospital visit.
223422036|NCT01743560|DRUG|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
223422037|NCT01743560|DRUG|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
223563056|NCT05223023|OTHER|questionnaire|"All of the therapists who works in the pediatric rehabilitation area were assessed with the scale of 50 questions named Opinions of Physiotherapists Working in the Area of Pediatric Rehabilitation on Treatment Types, Efficiency and Training"
223563057|NCT05925283|DRUG|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
223563058|NCT05925283|DRUG|Esketamine|intranasal esketamine 1mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
223563059|NCT05925283|DRUG|midazolam and esketamine|oral midazolam 0.3mg/kg and intranasal esketamine 0.6mg/kg approximately 30-40 mins before surgery using a computer-generated random number table.
223422038|NCT03226769|DEVICE|TrueTear™|Intranasal application of TrueTear™ device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear™ per participant guide.
223422039|NCT03226769|DEVICE|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions.
223563060|NCT02570724|DRUG|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
223422040|NCT03296644|DEVICE|Class II correction using PowerScope2|
223422041|NCT03296644|DEVICE|Class II correction using Forsus|
223422042|NCT05581784|OTHER|Pain neuroscience education|"PNE sessions will be led by an experienced physical therapist certified in PNE in 35-minute face-to-face group sessions. Here elements of the neurophysiology of pain are addressed, as well as the different psychosocial dimensions that influence it. The distribution of themes will be carried out as follows:~Week One: Coping with Pain. Week 2: Pain and Cognition Week 3: Your security system Week 4: Altered Alarm System (extra sensitive). Week 5: The defense system is in distress. Week 6: Fatigue, anxiety, and stress Week 7: Current Models of Treatment Week 8: Achievements and goals Week 9: Pain emphasis and differentiation This group remains with pharmacological treatment and the usual guidelines given by the doctor."
223422043|NCT05581784|OTHER|Conventional management or Usual care|This group will only have pharmacological treatment and the usual guidelines given by the doctor. Without educational intervention.
223563061|NCT02570724|BIOLOGICAL|blood patch|
224035914|NCT01891721|BEHAVIORAL|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
224035915|NCT01891721|BEHAVIORAL|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
224035916|NCT01891721|BEHAVIORAL|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
224035917|NCT00005002|DRUG|Lamivudine/Zidovudine|
224035918|NCT00005002|BIOLOGICAL|HIV-1 Immunogen|
224035919|NCT00005002|DRUG|Nelfinavir mesylate|
224035920|NCT02233283|OTHER|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
223422044|NCT00004237|DRUG|cyclophosphamide|
223422045|NCT00004237|DRUG|doxorubicin hydrochloride|
223422046|NCT00004237|DRUG|epirubicin hydrochloride|
223422047|NCT00004237|DRUG|mitoxantrone hydrochloride|
223422048|NCT00004237|DRUG|vinorelbine tartrate|
224035921|NCT02233283|OTHER|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
223422049|NCT00004237|PROCEDURE|conventional surgery|
223422050|NCT00004237|RADIATION|radiation therapy|
223422051|NCT06529445|DRUG|High Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
223422052|NCT06529445|DRUG|Median Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
223422053|NCT06529445|DRUG|Low Dose VC004 Capsules|VC004 Capsules qd per period, for two periods
223422054|NCT06576141|OTHER|Kaleidoscope|The participation of patients in this group in the study will take approximately 15-20 minutes.
223422055|NCT06576141|OTHER|Virtual Reality|The participation of patients in this group in the study will take approximately 15-20 minutes.
223422056|NCT06576141|OTHER|control|The participation of patients in this group in the study will take approximately 5-10 minutes.
223422057|NCT04535869|DRUG|Sofosbuvir 400 MG plus Daclatasvir 200mg|This group which receive sofosbuvir and daclatasvir for 14 days plus standard therapy
223422058|NCT04808063|PROCEDURE|Prophylactic mesh implantation|Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
224035922|NCT02233283|OTHER|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
223422059|NCT03200314|OTHER|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
223422060|NCT02695550|DRUG|CT-707|
223422061|NCT01167933|DRUG|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
223422062|NCT06461299|DRUG|Seysara Oral Product|"Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four."
223563062|NCT00284505|DRUG|thalidomide|
223563063|NCT00969644|DRUG|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
223563064|NCT00969644|DRUG|Pegvisomant|s.c. injections once daily (10-15 mg/day)
224035923|NCT02233283|OTHER|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
223422063|NCT04589936|PROCEDURE|Prone positioning|Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
223422064|NCT03565159|BIOLOGICAL|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
223422065|NCT03565159|OTHER|Sodium Chloride 0.9%|Placebo
223422066|NCT02203227|DIETARY_SUPPLEMENT|Placebo|
223422067|NCT02203227|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
223563065|NCT03076216|DEVICE|OncoSil™|The implantation of OncoSil™ under EUS
223563066|NCT02018848|BEHAVIORAL|Attention Training Program|
223563067|NCT04793724|DEVICE|Simeox|"A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are;~* clearance of the upper airways before the physiotherapy session~* correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece~* slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax~* step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs~* comfortable, relaxed sitting position with straightened spine~* controlled cough, which will be encouraged only when it is productive"
223563068|NCT04793724|DEVICE|PARI O PEP|"ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be:~* horizontal;~* low;~* transition of the device from the low position to the horizontal position;~* upside down.~The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform huffing with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum."
223563069|NCT00086801|DRUG|doxorubicin hydrochloride|given IV
224035924|NCT02827136|DRUG|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
224035925|NCT02827136|DRUG|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
224137746|NCT02776657|DEVICE|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
223563070|NCT00086801|DRUG|gemcitabine hydrochloride|given IV
223563071|NCT00086801|DRUG|vinblastine|given IV
223563072|NCT00086801|PROCEDURE|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
223563073|NCT00086801|PROCEDURE|CT scan|
224035926|NCT05358951|BEHAVIORAL|STEP-YA with Coaching|Online instruction on behavioral changes to improve sleep with 2 additional individually coached session
224035927|NCT05358951|BEHAVIORAL|STEP-YA without Coaching|Online instruction on behavioral changes to improve sleep without additional individually coached session
224035928|NCT03460379|DRUG|Escitalopram|Patients are tested for their normal prescription escitalopram medication
224035929|NCT04536610|BEHAVIORAL|Providing structured osteoporosis education|The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
224035930|NCT04536610|BEHAVIORAL|Giving informative leaflet|Leaflets containe the same information as the OP education program
224035931|NCT01655927|DRUG|Tranexamic Acid|
224035932|NCT01655927|DRUG|Placebo: Saline|
224035933|NCT02992483|DRUG|MIK665|MIK665
224035934|NCT06179329|PROCEDURE|Coronary artery bypass graft|Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.
224035935|NCT00137813|DRUG|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
223422068|NCT02203227|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
223422069|NCT02203227|DIETARY_SUPPLEMENT|MaQxan|
223422070|NCT04993638|DEVICE|hip arthroplasty|Hip prosthesis surgery
223422071|NCT03048292|OTHER|Acute Endovascular Stroke Treatment|
223563074|NCT01575093|OTHER|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
223563075|NCT06162494|BIOLOGICAL|Recombinant Zoster Vaccine|After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine
223739721|NCT05542264|DRUG|Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)|PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
224035936|NCT00137813|DRUG|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
224035937|NCT06239298|DRUG|ZG005 Powder for Injection|intravenous infusion(IV), once every 3 weeks
224137747|NCT02776657|PROCEDURE|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
224137748|NCT01441921|DIETARY_SUPPLEMENT|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
224137749|NCT01441921|OTHER|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
223563076|NCT06135350|DRUG|Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day|"Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
224137750|NCT02128763|DRUG|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
224035938|NCT06239298|DRUG|Donafenib Tosilate Tablets|The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
224035939|NCT04343248|DRUG|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for six weeks
224035940|NCT04343248|DRUG|Placebo|Placebo administered orally twice daily for six weeks
224137751|NCT02128763|DRUG|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
224137752|NCT02242825|DRUG|Micardis®|
224137753|NCT02242825|DRUG|MicardisPlus®|
224137754|NCT06281782|OTHER|topical retinoids and platalet rich plasma|We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
223422072|NCT06028685|DEVICE|Acupoint stimulation|The experimental group will receive low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3). The stimulation will be administered three times per week for a duration of six weeks.
223422073|NCT06028685|DEVICE|Acupoint stimulation(placebo)|The control group will receive sham low-level laser stimulation on seven acupoints, including Shenmen (HT7), Neiguan (PC6), Hegu (LI4), Zusanli (ST36), Yanglingquan (GB34), Sanyinjiao (SP6), and Taixi (KI3), without emitting laser beams.The stimulation will be administered three times per week for a duration of six weeks.
223422074|NCT02236845|DEVICE|Lacrima Medical Device and sham comparator|
223422075|NCT00940823|DEVICE|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
223422076|NCT00940823|DEVICE|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
223422077|NCT04205331|DEVICE|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients|Assessing validity of ultrasound as regards correlation to Cormack-Lehane grading in obese patients
223422078|NCT03211780|DEVICE|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
223739722|NCT03646682|PROCEDURE|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
223739723|NCT02855034|OTHER|Blood samples|Blood samples for dosage: copeptin and protein S100B
224035941|NCT04343248|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
224137755|NCT05198752|DRUG|Neoantigen mRNA Personalised Cancer SW1115C3|Subcutaneous Injection
224137756|NCT00575952|DRUG|Cisplatin|Given IV or IP
224137757|NCT00575952|DRUG|Doxorubicin Hydrochloride|Given IV
224137758|NCT00575952|BIOLOGICAL|Filgrastim|Given SC
224137759|NCT00575952|DRUG|Paclitaxel|Given IV or IP
224137760|NCT00575952|BIOLOGICAL|Pegfilgrastim|Given SC
224137761|NCT03319615|BEHAVIORAL|Dietary energy restriction|
224137762|NCT05595785|BEHAVIORAL|Physical-Based Yoga Practice|Physical-based yoga classes emphasized Bishnu Ghosh lineage hatha yoga. The 50 minute yoga classes were twice per week for four weeks. The yoga instructor had certifications in both Bikram and Amrit yoga practices and training in Bishnu Ghosh lineage hatha yoga as taught by Mary Jarvis
224137763|NCT05595785|BEHAVIORAL|Mindfulness-Based Yoga Practice|The mindfulness-based yoga classes included all elements of the physical-based yoga classes with the addition of mindfulness cues. The mindfulness cues included body scan, mindful movement, and yoga nidra. Certification of the instructor included the Integrative Amrit Method of Yoga Nidra that was inclusive of the use of mindfulness cues that coincided with the physical postures of yoga.
224137764|NCT01892098|DIETARY_SUPPLEMENT|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
224137765|NCT01892098|DIETARY_SUPPLEMENT|Placebo|Cellulose pill given as placebo
224137766|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
223422079|NCT05484856|BIOLOGICAL|Autologous adipose tissue derived stromal cells|autologous adipose tissue derived stromal cells is recovered as pellet after non enzymatic processing with sonication using ultrasound . This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ , the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC,2-- 20%), plus a wide number of CD34+ hematopoietic cells (40%)
223422080|NCT04463420|DRUG|PHR160 Spray|One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
223422081|NCT04463420|DRUG|Placebo|participants will receive a placebo spray every hour. This process will continue for 10 days.
223422082|NCT04463420|DRUG|Standard treatment|: Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
224137767|NCT03396250|DRUG|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
223563077|NCT06135350|OTHER|Placebo|"Placebo arm patients will receive placebo:~* 4 tablets twice a day for the first 2 days and;~* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days."
223563078|NCT05824923|PROCEDURE|Pulmonary arterial denervation|"Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55 ℃ for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.~For non-atrial fibrillation patients, dual antiplatelet therapy for 1 month after PADN is recommended. Patients with atrial fibrillation should continue new oral anticoagulants and patients who underwent metal valve replacement should continued oral warfarin anticoagulation according to guidelines, which could determined by the physician."
223563079|NCT05824923|DRUG|Guideline-directed medical therapy (GDMT) for heart failure|"GDMT medication recommendation including:~* Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blocker (ARB) or angiotensin receptor-neprilysin inhibitor (ARNI)~* Beta-receptor blocker (BB)~* Mineralocorticoid receptor antagonist (MRA)~* Sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Diuretics~The medication regimen (type and dosage) will be the investigator's discretion in accordance with the 2023 ESC Guidelines for Heart Failure. The type and dosage of all GDMT medications (except for diuretics) should remain unchanged through follow-up duration (at 12-month visit), unless the participant's conditions need adjust of GDMT regimens. Dosage and single or combination of diuretics are all left at physician's discretion."
223563080|NCT05230667|OTHER|PRP injection (PRP group)|Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.
223563081|NCT05230667|OTHER|Corticosteroid injection (CS group)|Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.
223563082|NCT05230667|OTHER|Normal saline injection (NS group)|Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
223563083|NCT05292092|DRUG|Essential pro|Patients in whom treatment with (Essential Pro) has been attempted
223563084|NCT03159169|DEVICE|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
224137768|NCT06553066|DRUG|Deep neuromascular blockage|"maintenance of a deep neuromuscular block with rocuronium, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale(Leiden scale : 1 indicates extremely poor conditions, 2 poor conditions, 3 acceptable conditions, 4, good conditions and 5 optimal conditions)"
224137769|NCT06553066|DRUG|Moderate neuromascular blockage|maintenance of a moderate neuromuscular block with rocuronium, titrated to maintain a TOF count of 1-2
223563085|NCT05407012|OTHER|Application of the barrier enhancing preparation.|Application of the barrier enhancing preparation around 30 minutes before application of the peanut protein extract +/- massage after extract application;
223563086|NCT01054560|DEVICE|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
223563087|NCT01054560|DEVICE|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
223563088|NCT02522182|BEHAVIORAL|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
223739724|NCT05379829|DRUG|Ziltivekimab|Participants will be administered 3 doses subcutaneously (s.c.) every four weeks (Q4W).
223739725|NCT05379829|DRUG|Placebo|Participants will be administered 3 doses s.c. Q4W.
224035942|NCT04438031|BEHAVIORAL|Navigation Intervention Prenatal 1.0 (intervention discontinued, modified to 2.0. Data will not be used)|This program recruits mothers in OB/GYN (prenatal) offices, provides up to three Navigation visits (using prenatal navigation version 1.0), establishes connections between the family and primary health care or other community providers, and then follows up one month later to confirm these referrals. Navigators will assess and support family needs across multiple developmentally-appropriate domains at each age. Prenatally, the domains include support for (1) health and access to healthcare, (2) adjustments to pregnancy, (3) household and material needs, and (4) family safety. At 12, 24, and 36 months, the domains include support for (1) child basic needs, (2) parenting and child behavior, (3) child health and development, and (4) parent health and well-being.
224137770|NCT03926767|OTHER|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
223739726|NCT05649306|OTHER|Additional Education|Study-Specific Patient Handouts, Treating-Provider led counseling, Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and referrals for additional support services
223739727|NCT05649306|OTHER|Questionnaires|Female Sexual Function Index, Demoralization Scale-II
223739728|NCT05649306|OTHER|Attendance Diary|Attendance Diaries for the Women's Bladder Cancer Support Group, Women's Bladder Cancer Educational Series, and additional educational and support services utilized
223739729|NCT04720534|DRUG|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
223422083|NCT04801680|DEVICE|Mpact 3D metal cup|Subjects, among those whose clinical condition makes them eligible for a primary total hip arthroplasty, will be invited to participate to the study during preoperative visit. They'll receive the Mpact 3D metal cup device
223422084|NCT01758731|DRUG|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
223422085|NCT01758731|DRUG|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
223422086|NCT01758731|RADIATION|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
223422087|NCT04280744|OTHER|Music therapy|Patient preferred song will be provided in a sedative manor (e.g., 60-80 beats per minute) using live music (singing with guitar accompaniment) by a board certified music therapist.
223422088|NCT02615431|OTHER|MitraClip Intervention|
223422089|NCT06188455|DRUG|Fluzoparib Capsules|Oral administration of 100 mg, 2 capsules/time (50 mg/capsule), twice daily
223422090|NCT06188455|DRUG|Apatinib Mesylate Tablets|Oral administration of 250 mg each time, 1 tablet/time (250 mg/tablet)
223422091|NCT02715362|DRUG|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
223422092|NCT06137131|BEHAVIORAL|Straw phonation in air|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in air
223422093|NCT06137131|BEHAVIORAL|straw phonation in water|Phonation (/u/ vowel) through a stirring straw (3 mm diameter, 20cm length) in 2 cm or 5 cm water
223422094|NCT06137131|BEHAVIORAL|/u/ phonation|/u/ phonation without a straw, control condition
223422095|NCT05263856|DEVICE|laser acupuncture|The parameter setting of 810nm wavelength laser acupuncture device in 1) ear were irradiated with a 4mm probe, adjusted to Nogier A frequency for acute treatment, and the pulsed mode was irradiated with an emission frequency of 200mW for 10seconds, each acupoint provided 1 joule of energy with total of 12joules,and 2) myofascial trigger point were irradiated with a 10mm probe, adjusted to Nogier C frequency for muscle treatment, and the pulsed mode was irradiated with an emission frequency of 500mW for 20 seconds, each acupoint provided 5 joule of energy with total of 50 joules, providing a total of 62 joules of one intervention session.
224035943|NCT04438031|BEHAVIORAL|Control Intervention|Brief information will be provided about pregnancy prenatally and child development at 12, 24, and 36 months.
224035944|NCT04438031|BEHAVIORAL|Navigation Intervention Prenatal 2.0|This program recruits mothers in OB/GYN offices. Mothers are offered visits from a Navigator prenatally and postnatally (12-, 24-, and 36-months). During visits, the Navigator works with the mother to identify family needs, establishes connections between the family and community providers, and follows up one month later to confirm these referrals. Navigators assess and support family needs across 13 factors: caregiver health, infant health, healthcare plans, childcare plans, parent-child relationship, management of infant crying/behavior, household safety/material supports, family/community violence, history of parenting difficulties, parent well-being, substance use, parent emotional support, and other needs not related to first 12 factors. Navigation 2.0 is a revision of 1.0 in which adjustments to the protocol were made to improve guidance for Community Navigators and aid their assessments of family needs.
224035945|NCT06518239|DEVICE|Peep Belt|Belt will be placed on the nipple line of the patient prior to the surgery start in the operating room. Data will be collected prior to the initial incision after the patient has been intubated, and then at the end of surgery before the patient has been extubated.
224035946|NCT05045157|PROCEDURE|Percutaneous A1 Pulley Release Under Ultrasound Guidance|the A1 pulley is cut off with Ultrasound guidance by a percutaneous insertion of the small needle under local anaesthesia.
224035947|NCT05045157|DRUG|Corticosteroid injection|corticosteroid injection is performed
224137771|NCT03926767|OTHER|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
223422096|NCT02731937|DEVICE|GE Healthcare Revolution CT Scanner (CT Scanner)|Raw CT Scan Data
223422097|NCT06925464|DRUG|CD7 CAR-T cells infusion|Approximately 3-5 days prior to CD7 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
223422098|NCT06904807|DRUG|LIFE-001|Single dose of LIFE-001 between 10mg and 300mg administered subcutaneously
223422099|NCT06904807|DRUG|Placebo|Single dose of placebo comparator administered subcutaneously
223422100|NCT06904807|DRUG|LIFE-001|Four doses of LIFE-001 between 50mg and 300mg administered subcutaneously seven days apart
223422101|NCT06904807|DRUG|Placebo|Four doses of placebo comparator administered subcutaneously seven days apart
223563089|NCT02522182|BEHAVIORAL|Usual Treatment|Information related to intervention description have been already included in arm/group description
224035948|NCT04047186|DRUG|Tislelizumab Injection|Patients in the experimental group receive Tislelizumab Injection
223422102|NCT06841419|PROCEDURE|surgical reconstruction of a soft tissue defects by a pedicled flap|harvesting of a fasciocutaneous flap from the anterolateral aspect of thigh based on a perforators from the descending branch of lateral femoral circumflex artery to reconstruct a neighboring soft tissue defect.
223422103|NCT01253005|BEHAVIORAL|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
223563090|NCT03066960|PROCEDURE|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
223563091|NCT03066960|PROCEDURE|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
223563092|NCT01532076|PROCEDURE|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
223422104|NCT02497443|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
223422105|NCT02551770|PROCEDURE|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
224035949|NCT06777524|BEHAVIORAL|skin-to-skin contact education|For the intervention group, additional education on the importance and clinical benefits of mother-infant skin-to-skin contact will be provided (including an educational video). They will be instructed to engage in a minimum of 6 hours of skin-to-skin contact per day with the infant's and mother's chests exposed for at least 15 minutes per session, and to keep a record of the contact time, as well as the time spent holding the clothed infant and a daily feeding diary.
224137772|NCT03926767|OTHER|Orofacial Exercises|Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
223422106|NCT02551770|PROCEDURE|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
224137773|NCT03926767|OTHER|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
224137774|NCT01683110|DRUG|cabozantinib|
223422107|NCT02551770|DEVICE|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
223422108|NCT05669131|OTHER|Motor imagery training|Participants imagine themselves through their own eyes performing submaximal elbow flexion contractions.
224137775|NCT00747838|PROCEDURE|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
223422109|NCT04328129|PROCEDURE|Human biological samples|"* Blood sample~* Nasopharyngeal swab."
223563093|NCT01532076|PROCEDURE|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
223563094|NCT01947621|OTHER||
223563095|NCT05636046|PROCEDURE|transseptal catheterization|puncture of interatrial septum at the level of fossa ovalis, using transseptal needle.
223563096|NCT03049358|OTHER|Physiologic Testing|Undergo UPSIT smell test
223563097|NCT03049358|OTHER|Quality-of-Life Assessment|Ancillary studies
223739730|NCT04720534|DRUG|Placebo|calculated volume to match active treatment by sc injection
224137776|NCT06128590|DEVICE|Photobiomodulation|"Photobiomodulation was applied before the procedures at an infrared wavelength of 808nm, at a power of 100mW, 1 point with a total energy of 8J, time of 80s, irradiance of 3.33W/cm² and radiant exposure of 266.66 J/cm2. The application point was on the retromolar region where the needle was inserted to perform the anesthetic, in a single application before the procedure.~The patient and operator were properly protected with goggles in both the control and experimental groups."
223422110|NCT06947460|DRUG|CD19-BCMA CAR-T cells infusion|Approximately 3-5 days prior to CD19-BCMA CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
223422111|NCT04089904|DRUG|Pembrolizumab Injection|Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
223422112|NCT03721263|BIOLOGICAL|ASLAN004|Single Dose
223422113|NCT02531477|DRUG|propofol|intracarotid propofol as an anesthetic agent
223422114|NCT04320693|DRUG|IMMU-132|IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
223422115|NCT03287362|BEHAVIORAL|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
224035950|NCT05607095|BIOLOGICAL|Lifileucel (LN-144/LN-145)|Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.
223563098|NCT03049358|PROCEDURE|Sham Intervention|Undergo sham training
223563099|NCT03049358|PROCEDURE|Therapeutic Procedure|Undergo olfactory training
223563100|NCT03049358|OTHER|rose essential oil|patient smells rose oil in vial
223563101|NCT03049358|OTHER|lemon essential oil|patient smells lemon oil in vial
223563102|NCT03049358|OTHER|clove essential oil|patient smells clove oil in vial
223563103|NCT03049358|OTHER|eucalyptus essential oil|patient smells eucalyptus oil in vial
223563104|NCT03049358|OTHER|canola oil placebo|patient smells canola oil in vial
223739731|NCT05206227|BEHAVIORAL|Aerobic Exercise|Subjects will complete a single bout of aerobic exercise.
223739732|NCT05206227|DRUG|alpha-FMH|Subjects will undergo either local heating with diathermy or whole body heating with far-infrared sauna.
223739733|NCT05206227|BEHAVIORAL|Resistance and Aerobic Exercise|Subjects will complete bouts of resistance and aerobic exercise.
224035951|NCT05057806|DRUG|Empagliflozin 25 MG|Empagliflozin 25MG will be administered orally once per day for 3 months
224035952|NCT05057806|DRUG|Placebo|The placebo will be administered orally once per day for 3 months
224035953|NCT03140423|DRUG|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
224035954|NCT03140423|DRUG|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
223422116|NCT03287362|BEHAVIORAL|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
223422117|NCT03287362|BEHAVIORAL|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
223422118|NCT02843776|OTHER|Questionnaires completion|
223422119|NCT02482480|OTHER|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
223422120|NCT02482480|OTHER|Control|Dietary and general recommendations
223422121|NCT00321698|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
223422122|NCT00321698|DRUG|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
223422123|NCT05270395|BEHAVIORAL|mPal|"mPal's patient content includes a multi-component web-based tool with the following: (1) a brief educational video that seeks to educate patients about palliative care; (2) and assessment of palliative care knowledge; (3) assessment of palliative care needs; and (4) an assessment of whether patients would like to meet with palliative care or discuss palliative care and their palliative care needs with their oncology provider.~The provider-level component includes provider education on palliative care. The system-level component includes electronic health record modifications to facilitate palliative care discussions and referrals."
223422124|NCT05258279|DRUG|Pembrolizumab|IV infusion Q3W
223422125|NCT05258279|DRUG|Lenvatinib|Oral capsule once daily
223422126|NCT05258279|DRUG|Carboplatin|IV infusion Q3W
223422127|NCT05258279|DRUG|Pemetrexed|IV infusion Q3W
223422128|NCT05844020|BEHAVIORAL|Educational materials|Trauma-informed intimate partner violence screening, brief interventions, and referrals to treatment by providers
223422129|NCT05152758|DEVICE|PARx|Prescription Physical Activity Programming Application
224035955|NCT03404505|BEHAVIORAL|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
224035956|NCT03404505|BEHAVIORAL|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
224035957|NCT04641143|DRUG|Troriluzole|Troriluzole - 2 100mg capsules QD for the first two weeks.
223422130|NCT05139212|PROCEDURE|Optimum time for intravenous cannulation in children premedicated with dexmedetomidine|The optimum time for intravenous cannulation after the induction of anesthesia with sevoflurane, oxygen, and nitrous oxide in children with intranasal dexmedetomidine premedication will be searched in children undergoing elective surgery.
223422131|NCT05342077|BEHAVIORAL|Virtual Reality-Reward Training (VR-RT)|Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
223422132|NCT05342077|BEHAVIORAL|Virtual Reality-Memory Training (VR-MT)|Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.
223422133|NCT04302454|RADIATION|Radiotherapy|Radiotherapy
223563105|NCT03287934|DEVICE|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
224035958|NCT04641143|DRUG|Placebo|Matching placebo - 2 140mg capsules QD from week two through week ten.
224035959|NCT05268601|DRUG|Bamlanivimab|Administration of monoclonal antibody against SARS-CoV-2
223422134|NCT04302454|DRUG|Leuprorelin|Hormonal therapy
223739734|NCT05206227|DRUG|Antihistamine|Subjects will complete a single bout of aerobic exercise under placebo vs antihistamine conditions.
223739735|NCT05070403|DRUG|Afatinib 40 MG|Participants will receive 40 mg Afatinib, once daily.
224035960|NCT05268601|DRUG|Bamlanivimab and Etesevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
224035961|NCT05268601|DRUG|Casirivimab and Imdevimab Drug Combination|Combined administration of monoclonal antibodies against SARS-CoV-2
224035962|NCT05268601|DRUG|Sotrovimab|Administration of monoclonal antibody against SARS-CoV-2
224035963|NCT05277883|RADIATION|CT scan|CT of the lower limb
224035964|NCT00329485|DRUG|CORvalen (D-Ribose)|
224035965|NCT01313650|DRUG|62.5/25mcg|GSK573719/GW64244
224035966|NCT01313650|DRUG|62.5mcg|GSK573719
224035967|NCT01313650|DRUG|25mcg|GW642444
224035968|NCT01313650|DRUG|Placebo|Placebo
223422135|NCT06265649|OTHER|NOM|Non-operative management (NOM) for ALCD consists of lab test monitoring, fluid therapy, antibiotic therapy, abscess drainage if \>4cm, restoring a regular diet
223422136|NCT06621368|OTHER|Exercise|the RT program will consist of eight exercises for different body segments, namely: vertical bench press, horizontal leg press, low row, leg extension, scott curl, leg curl, triceps pulley and seated calf raise. Every 12 weeks of training, the program will be restructured with changes in the order in which the exercises are performed, the number of sets, the number of repetitions or the training system in an attempt to avoid a supposed adaptive plateau. The protocols in each stage will follow the recommendations for prescribing RT for the elderly, aiming at improving strength and hypertrophy, namely: a combination of single-joint and multi-joint exercises (free weights and machines), slow or moderate execution speed (ratio 1:2 for concentric and eccentric muscle actions, respectively), one to three sets of multiple repetitions, 8-12 RM or 10-15 RM, with recovery intervals between sets of one to two minutes, and a training frequency of two to three weekly sessions, on alternate days.
223422137|NCT06621368|OTHER|Control-no treatment|Participants will maintain their daily activities.
223422138|NCT06622564|DRUG|Before CPB Tranexamic Acid|Tranexamic acid 1 to 10 g (10 to 100 mL) administered intravenously as per standard care at the induction of anesthesia as a bolus and/or continuous infusion (i.e., before CPB).
223422139|NCT06622564|DRUG|After CPB Tranexamic Acid|Tranexamic acid 5 g (50 mL) administered after heparin reversal (i.e., after CPB).
223422140|NCT06622564|DRUG|Before CPB Placebo|Placebo (10 to 100 mL saline) administered intravenously at the induction of anesthesia as a bolus and/or continuous infusion.
223422141|NCT06622564|DRUG|After CPB Placebo|Placebo (50 mL saline) administered after heparin reversal.
223422142|NCT04948541|COMBINATION_PRODUCT|osa treatment|different treatments can be included
223422143|NCT04948541|OTHER|no treatment|no treatment was undergone
223422144|NCT06435325|BEHAVIORAL|Precision diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
223422145|NCT06435325|BEHAVIORAL|Control diet|After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
223422146|NCT03196661|BIOLOGICAL|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
223422147|NCT01862263|DRUG|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
223422148|NCT01862263|DRUG|Insulin|Long- acting human insulin analog indicated to improve glycemic control
223422149|NCT01862263|DRUG|Placebo|Matching placebo of vildagliptin
223422150|NCT04194320|PROCEDURE|Ultrasound (US) guided supraclavicular brachial plexus block|Using 8 mg dexamethasone or 10 mg nalbuphine as adjuvants to (Lidocaine 2% + bupivacaine 0.5% 1:1 mixture) in ultrasound (US) guided supraclavicular brachial plexus block
223422151|NCT00071656|BEHAVIORAL|Psychosocial (behavioral) Intervention|
223422152|NCT04622514|OTHER|Village doctor-led telemedicine integrated care|1\. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
223422153|NCT04622514|OTHER|Enhanced usual care|1\. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
223422154|NCT02618837|PROCEDURE|Downstream strategy|"At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~* Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~* Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel\* daily for at least 12 months~  * If subject is \>75 years old or \<60 kg, daily dose of prasugrel should be 5mg"
224035969|NCT03275103|DRUG|Cevostamab|Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
224035970|NCT03275103|DRUG|Tocilizumab|Tocilizumab will be administered as premedication during Cycle 1.
224035971|NCT04209790|RADIATION|Neoadjuvant chemoradiation|Intensity modulation radiation therapy (IMRT) with a simultaneous integrated boost with Fixed-gantry IMRT, helical tomotherapy, or Vesicular Modulated Arc Therapy (VMAT) can be used. All photon treatments shall be delivered with megavoltage machines of a minimum energy of 6 Megavolt (MV) photons. Selection of the appropriate photon energy(ies) should be based on optimizing the radiation dose distribution within the target volume and minimizing dose to non-target normal tissue.
224035972|NCT04209790|DRUG|Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|During Concomitant Radiation Therapy on the same day as the first fraction of radiotherapy. Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days. The drug will be administered orally daily during radiotherapy, as best tolerated by the patient. During weekends without radiotherapy (Saturday and Sunday), the drug will be taken in the morning. The dose will be determined using actual body surface area (BSA) as calculated in square meters at the beginning of the concomitant treatment. The BSA will be calculated from the height obtained at the pretreatment visit. Capsules of temozolomide are available in 5, 20, 100, 140, 180, and 250 mg. The daily dose will be rounded to the nearest 5 mg.
223563106|NCT03287934|DEVICE|digital light processing(dlp)|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with digital light processing technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
223422155|NCT02618837|PROCEDURE|Upstream strategy|"At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
224137777|NCT06128590|DRUG|Mepivacaine hydrochloride in combination with epinephrine|"The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure."
224298938|NCT05250674|DEVICE|CEM-guided biopsy|"The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation."
224298939|NCT03295318|BIOLOGICAL|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
223422156|NCT02068781|DIETARY_SUPPLEMENT|Low-sodium diet|50 mmol NaCl per 24h
223422157|NCT02068781|DIETARY_SUPPLEMENT|High-sodium diet|250 mmol NaCl per 24h
223422158|NCT05177926|DRUG|antiviral prophylaxis with Tenofovir Alafenamide Fumarate|All participants will receive antiviral prophylaxis with Tenofovir Alafenamide Fumarate for preventing of Mother-to-child transmission of HBV
223422159|NCT05128630|DRUG|Durvalumab|Patients will receive 1500 mg durvalumab via IV infusion q3w concomitant with chemotherapy (Cisplatin/carboplatin plus etoposide) for up to a maximum of 3 cycles, then via IV infusion at the same interval during sequential radiotherapy and then every 4 weeks for up to a maximum of 12 months or until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
223422160|NCT03622398|PROCEDURE|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
223563107|NCT02083848|OTHER|7T MRI|Ultra high field magnetic resonance imaging
223563108|NCT05875636|OTHER|Esophagogastroduodenoscopy|All patients will undergo an esophagogastroduodenoscopy per standard of care, as scheduled.
224035973|NCT04209790|PROCEDURE|Surgery post Radiation and Temozolomide (benzolamide)|Surgical resection of GBM will be done after radiation and Temozolomide treatment.
224035974|NCT05393037|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
224035975|NCT05393037|BIOLOGICAL|Placebo|Saline in each 0.5 mL sterile solution
224035976|NCT05393037|BIOLOGICAL|PCV15|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
224035977|NCT05393037|BIOLOGICAL|PPSV23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
224035978|NCT05393037|BIOLOGICAL|PCV15 - Part B|Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
223422161|NCT03622398|PROCEDURE|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
223422162|NCT03902717|PROCEDURE|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
223422163|NCT02809105|DRUG|linaclotide|Oral administration once daily
223422164|NCT02809105|DRUG|Placebo|Oral administration once daily
223563109|NCT04599023|DEVICE|MSPT|The MS Performance Test (MSPT) software tool and accompanied hardware is an iPad®-based assessment tool, developed via collaboration between Biogen and the Cleveland Clinic Mellen Center, and designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders.These assessment modules of the MSPT are self-administered by MS patients at the point of care and incorporate and expand upon previously validated measures of the MSFC.
223563110|NCT01127464|DRUG|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
223563111|NCT01127464|DRUG|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
223563112|NCT01127464|DRUG|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
223563113|NCT00151684|DRUG|Diazoxide|
223739736|NCT04959968|DEVICE|eye patch and earplug|The use of eye patch and ear plugs in post-operative intensive care in craniotomy cases.
223422165|NCT06209398|BIOLOGICAL|Enterovirus Type 71 Vaccine, inactivated ( Human Diploid Cell )|Used for EV71 virus susceptible individuals aged 6 months to 5 years. Each bottle (bottle) contains 0.5ml of neutralizing antibody with a potency of no less than 3.0EU for the inactivated 71 type intestinal disease vaccine. Intramuscular injection into the deltoid muscle of the upper arm. The immunization program consists of 2 doses with 1-month interval.
223422166|NCT06209398|BIOLOGICAL|Recombinant Hepatitis B Vaccine|Each vaccine bottle (tube) is 0.5ml, containing 10ug of HBsAg and inject into the upper deltoid muscle. The immunization program consists of three doses, administered at 0, 1, and 6 months respectively. Newborns are given the first dose within 24 hours after birth, with one dose of vaccine administered each time.
223422167|NCT06209398|BIOLOGICAL|Group A meningococcal polysaccharide vaccine|This product is made by lyophilizing the purified polysaccharide antigen obtained from Group A meningococcus liquid culture. The vaccination targets children aged 6 months to 15 years old, and the initial immunization age starts from 6 months old. Infants and young children aged 6 to 12 months old are vaccinated with 2 doses of 30 micrograms, with an interval of 3 months. Subcutaneously inject 0.5ml into the lateral deltoid muscle of the upper arm at a dose of 30 μg of polysaccharide antigen (0.5ml).
223422168|NCT06666777|BEHAVIORAL|Intervention focused on intersubjective prelinguistic and socio-communicative skills|"The intervention consists of 8 45-minute, weekly sessions over two months. These sessions may take place in various settings, such as free play, snack time, or structured activities. The speech therapist will use these settings to help parents observe intersubjective and social-communicative behaviors, providing guidance and strategies to support them.~The following topics will be addressed: Attention; Multisensory Stimulation and Integration: Sensitivity and Responsiveness; Communicative Codes and Preference/Discrimination; Gestures; Intentionality and Communicative Styles.~These topics are not structured into rigid levels for each session. Instead, several topics may be addressed within the same session and revisited across multiple sessions. This flexibility allows the speech therapist to adapt the intervention based on observations, interactions with the child, and discussions with the parent."
223422169|NCT06666777|BEHAVIORAL|Standard speech therapy intervention|The standard speech therapy intervention, as typically conducted in rehabilitation centers, consists of 8 weekly sessions, each lasting 45 minutes, over a two-month period (same as the experimental intervention). During these sessions, the therapist may provide various stimulations aimed at enhancing the child's vocalization, verbal comprehension, and speech production. While the therapist may offer guidance to parents on how to continue these stimulations in daily routines, they will not be directly involved in the sessions unless strictly necessary.
223422170|NCT01351480|BIOLOGICAL|abatacept|Abatacept administered SC weekly at 125 mg dose
223422171|NCT00199797|DRUG|Oxaliplatin|Oxaliplatin was administered at 85 mg/m2 on day 2 of every 2 week regimen.
223422172|NCT00199797|DRUG|5-Fluorouracil|The dose of 5-FU was 400 mg/m2 IV bolus followed by continuous IV infusion at 600 mg/m2 over 22 hours on day 2 and day 3 of every 2 week regimen.
223422173|NCT00199797|DRUG|Leucovorin|Leucovorin was administered at a dose of 200mg/m2 on day 2 and day 3 of every 2 week regimen.
223422174|NCT00199797|DRUG|huA33|huA33 was administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2.
223422175|NCT01684098|DRUG|Tc 99m EC20|
223422176|NCT05789784|OTHER|mymobility Physical Therapy|Physical therapy protocol administered at home through the mymobility application.
223422177|NCT05789784|OTHER|Standard Office-based Physical Therapy|Physical Therapy protocol administered through exercise handouts and formal office-based therapy directed by physical therapist.
223422178|NCT03429751|DRUG|30 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
223422179|NCT03429751|DRUG|10 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
223422180|NCT01103453|BEHAVIORAL|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
223422181|NCT05738551|OTHER|stress ball|Applicable to group 1
223422182|NCT05738551|OTHER|chewing gum|Applicable to group 2
223422183|NCT02121015|BEHAVIORAL|Share|
223422184|NCT02121015|BEHAVIORAL|Self-Directed|
223422185|NCT03677323|DEVICE|Virtual reality|"The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete."
223422186|NCT03677323|DRUG|Droleptan|Venous administration of 1.25 mg of Droleptan
223422187|NCT03677323|DRUG|Propofol|Venous administration of 20 mg of Propofol
223422188|NCT03677323|DRUG|Sufentanyl|Venous administration of 5 μg of Sufentanyl.
223422189|NCT02338297|PROCEDURE|TACE|Transarterial chemoembolisation (TACE)
223422190|NCT02338297|DRUG|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
223563114|NCT02429492|DEVICE|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
223422191|NCT02338297|DRUG|PVA|Occlude arterioportal shunts(APS) with PVA
223563115|NCT03397394|DRUG|Rucaparib|Rucaparib will be administered daily.
223563116|NCT05382468|OTHER|Intradialytic exercise|Intradialytic exercise comprised of a set warm up, aerobic, active,passive \& cool down activities performed by patients during dialysis for a period of 30 min twice or thrice a week regularly for one month \& supervised by principle investigator.
223563117|NCT02135029|DRUG|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
223563118|NCT02135029|DRUG|Atorvastatin|Atorvastatin PO QD
224035979|NCT06322043|DEVICE|Adipearl|Injection of the investigational device in subcutaneous tissue.
223422192|NCT06619925|BEHAVIORAL|after-school extended sports service|Impact of voluntary participation in different types (e.g. outdoor physical activities, indoor physical activities, ball games, calisthenics, etc.), intensity and duration of after-school extended physical education services on children\&#39;s myopia and other physical and psychological well-being
223422193|NCT06619925|BEHAVIORAL|non-after school extended sports service|Students in the same grade as the exposure group but participating in after-school non-physical education extended services (e.g., homework help, static activities such as calligraphy, chess, etc.) served as a control group, aiming to maximise the control of the influence of potential factors other than physical activity on the results of the study.
223422194|NCT06649422|DRUG|Blinatumomab|The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.
223422195|NCT06618495|DRUG|Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)|Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 4 weeks.
223422196|NCT02556619|BEHAVIORAL|Early Palliative Care/Symptom Control|"1. Establish palliative care goals~   1. Determination of Medical Power of Attorney~  2. Discuss/plan code status/advance directives~  3. Document palliative care goals~2. Symptom Assessment and Control~   1. Pain-treatment with opioid and non-opioid medications~  2. Itching-H2 blockers, steroids~  3. Nutrition-appetite stimulated with Megace, review low sodium diet~  4. Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~  5. Nausea- treated with anti-emetics~  6. Jaundice and Body Image- counselling regarding symptoms~3. End-of-Life Care~   1. Discuss religious preferences~  2. Assess for distress- ensure interaction with Cancer Resource Center~  3. Hospice- charity Hospice options for select patients."
223422197|NCT03356119|DEVICE|RemovAid device|The contraceptive implants of the subjects in this arm are removed by the new IMD.
223422198|NCT01843114|DEVICE|FDOCT|Measurement of retinal blood velocities
223422199|NCT01843114|OTHER|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
223422200|NCT00771251|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
223563119|NCT02135029|OTHER|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
223563120|NCT02135029|OTHER|Placebo for atorvastatin|PO QD
223563121|NCT00712725|DRUG|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
223563122|NCT00712725|DRUG|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
223563123|NCT00712725|DRUG|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
224035980|NCT06483204|DRUG|Medrol 4 MG Oral Tablet Includes Medrol Dosepak|Medrol tapered dosepak given to experimental arm patients to determine if there is a significant difference in pain, nausea, edema and ecchymosis outcomes in the postoperative period after a functional rhinoplasty procedure.
223422201|NCT00771251|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
223422202|NCT01892111|OTHER|Structured exercise program.|
223422203|NCT02925715|PROCEDURE|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
223422204|NCT05773651|OTHER|Data collection|The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature
223422205|NCT05970588|BEHAVIORAL|Standing Promotion Intervention|Participants will be provided with a standing desk converter to set on top of their existing desk for 4 weeks.
223422206|NCT03717051|DRUG|Nicotine replacement therapy (NRT) sampling|1-week free NRT samples (patch or gum)
223422207|NCT03717051|BEHAVIORAL|Medication counseling|Medication counseling
223422208|NCT01004224|DRUG|BGJ398|
223422209|NCT02416648|BEHAVIORAL|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
223422210|NCT04432090|DRUG|Placebo|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
223422211|NCT04432090|DRUG|Study Medication (MBX-2982)|Each group will receive either a pill that contains the study medication (MBX-2982) or a pill that does not contain the medication (placebo)
223422212|NCT04432090|OTHER|No medication for this group|This group will be studied to establish the norm of the measurement that will be performed to obtain the study outcomes.
223422213|NCT04378959|DRUG|Lidocaine patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
223422214|NCT04378959|DRUG|Placebo patch|Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
223563124|NCT00712725|DRUG|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
223563125|NCT00712725|DRUG|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
223563126|NCT00712725|DRUG|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
223422215|NCT00928941|BEHAVIORAL|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
223422216|NCT00928941|BEHAVIORAL|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
223422217|NCT04250350|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
223422218|NCT05735990|DEVICE|Intraocular lens|Aspheric hydrophilic acrylic IOL for implantation into the capsular bag
223422219|NCT03926390|DIETARY_SUPPLEMENT|Bovine colostrum|bovine colostrum for first 2 weeks
223422220|NCT00784550|DRUG|Tiotropium Bromide|Long-acting muscarinic antagonist
223563127|NCT00712725|DRUG|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
223422221|NCT00784550|DRUG|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
223422222|NCT03711149|OTHER|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
223422223|NCT00772824|DIETARY_SUPPLEMENT|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
223422224|NCT00772824|DIETARY_SUPPLEMENT|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
223422225|NCT04796883|DEVICE|Hanita Glaucoma shunt Ver.3.2|The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
223422226|NCT02358785|DEVICE|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
223422227|NCT02425761|PROCEDURE|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
223422228|NCT06356974|DRUG|Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)|Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
223422229|NCT05705115|DRUG|Ringer acetate|Ringer acetate 5 ml/kg.
223422230|NCT05705115|OTHER|Lower body negative pressure|Lower body negative pressure, 40 mmHg. Experimental hypovolemia.
223422231|NCT04900844|DEVICE|CGuard Carotid Stent implantation|Implantation of CGuard carotid stent in the eligible patients
223422232|NCT05901194|DRUG|Lenvatinib|Lenvatinib will be administred orally and daily at the usual dose ( 8 or 12 mg per day depending on the weight \< or ≥ 60kg) in the 25 patients of the study from TACE failure until LT
223422233|NCT04822636|BEHAVIORAL|Family-based mental health navigation|Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
223563128|NCT02543866|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
223563129|NCT00657293|BEHAVIORAL|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
223563130|NCT00657293|BEHAVIORAL|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
224035981|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
223422234|NCT05987553|OTHER|e-learning program|All participants participate in this intervention: an e-learning program about the recognition of actinic keratosis. The program exists of 30 cases. Each case exists of a question and thorough explanation including references to various sources.
223422235|NCT03737708|DRUG|tacrolimus|Administered orally
223422236|NCT03737708|DRUG|methotrexate|Administered orally
223422237|NCT03737708|BIOLOGICAL|adalimumab|Administered as subcutaneous injection
223422238|NCT03737708|BIOLOGICAL|tocilizumab|Administered by intravenous injection
223422239|NCT03737708|BIOLOGICAL|abatacept|Administered by intravenous injection
223422240|NCT00546676|DRUG|Telithromycin|
223422241|NCT04502147|PROCEDURE|Laparoscopic Splenectomy|Laparoscopic splenectomy by ligating the splenic artery
223422242|NCT05608369|DRUG|Cisplatin|Cisplatin100 mg/m2 every 3 weeks or 40 mg/m2 weekly
223422243|NCT05608369|RADIATION|Radiation therapy|Radiation therapy (70 Gy) for total of 7 weeks
223422244|NCT05608369|DRUG|Vorinostat|Pre-treatment; 300 mg every other day and ends with the dose closest to the last fraction of radiation (total of 8 weeks)
223563131|NCT03466099|DRUG|KVD001 Injection|Intravitreal KVD001 Injection
223563132|NCT03466099|OTHER|Sham Procedure|Sham Procedure
223563133|NCT02829736|PROCEDURE|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
223563134|NCT02829736|PROCEDURE|Standard post-operative chest tube|A regular chest tube is left in the pleura.
223563135|NCT02829736|PROCEDURE|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
223563136|NCT00048022|DRUG|Dual Integrin Antagonist|
223422245|NCT03582800|DRUG|STS|"M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~* Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~* Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation."
223422246|NCT03665675|BIOLOGICAL|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
223422247|NCT03665675|BIOLOGICAL|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given intravenously
223422248|NCT05924815|DRUG|Aficamten|Oral Tablet
223422249|NCT05924815|DRUG|Aficamten-matching Placebo|Oral Tablet
223422250|NCT05924815|DRUG|Moxifloxacin|Oral Tablet
223422251|NCT01098656|DRUG|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
223422252|NCT04270864|DRUG|Ipilimumab|20mg (4mL) IT
223422253|NCT04270864|DRUG|Nivolumab|360mg IV then 480mg IV
223422254|NCT04270864|DRUG|Tilsotolimod|8 mg (2mL) IT
223422255|NCT00688701|DRUG|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
223422256|NCT00688701|DRUG|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
223422257|NCT00688701|DEVICE|Pen auto-injector|
223422258|NCT05094765|BIOLOGICAL|FMT|Fecal Microbiota Transplantation
223422259|NCT00029536|BIOLOGICAL|Progesterone Lozenges|200mg Progesterone Lozenges
223422260|NCT00029536|OTHER|Matched Placebo Lozenges|Matched Placebo Lozenges
223422261|NCT00743730|OTHER|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
223422262|NCT00743730|OTHER|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
223422263|NCT00743730|OTHER|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
223422264|NCT00095641|DRUG|capecitabine|
223422265|NCT00095641|PROCEDURE|adjuvant therapy|
223422266|NCT00095641|PROCEDURE|chemotherapy|
223422267|NCT03892577|DRUG|Precision oncology including targeted therapy and immunotherapy|Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
223422268|NCT03410407|OTHER|Observation of CNS involvement|AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
223422269|NCT04596709|DIETARY_SUPPLEMENT|Vitalose|dissolved in water
223422270|NCT04596709|DIETARY_SUPPLEMENT|isomaltulose|dissolved in water
224035982|NCT04540133|DRUG|dexamethasone 0.5mg/5ml solution in Mucolox™|Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
224035983|NCT05746624|BEHAVIORAL|keypresses|benign behavioral intervention-- keypresses
223422271|NCT04596709|DIETARY_SUPPLEMENT|sucrose|dissolved in water
223422272|NCT04596709|DIETARY_SUPPLEMENT|glucose|dissolved in water
223422273|NCT06032052|DRUG|Single drug chemotherapy plus immunotherapy|The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine. Paclitaxel or pemetrexed are available for monotherapy for non-squamous and non-small cell lung cancer. Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on
223422274|NCT04183738|DRUG|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
223422275|NCT04183738|DRUG|Darunavir|800mg tablet by mouth once daily for 96 weeks.
223422276|NCT04183738|DRUG|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
223422277|NCT04183738|DRUG|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
223422278|NCT06640985|DEVICE|EDX110 wound dressing system|EDX110 is a dressing system comprising two layers that allows the generation of nitric oxide (NO) in situ, enables adequate moisture management and facilitates debridement
223422279|NCT00283855|BEHAVIORAL|Online Self-Management|Online Self-Management
223422280|NCT00102648|DRUG|Lonafarnib|Given PO
223422281|NCT00102648|DRUG|Temozolomide|Given PO
223422282|NCT06623825|DEVICE|teleconsultation by Augmented Reality smart glasses|The device operated on Android 9.0 and it connected to 5G connection with a bandwidth speed 30-mbps delivering a very low latency. The device supported real time screen sharing and therefore the data were collected from smart glasses including visual and audio with real-time two-way communications. Physicians at the hospital can access the information and video via a mobile app, enabling continuous monitoring of patients. The features facilitate healthcare providers at SRRSH and medical personnel in the HAG2022 polyclinic to discuss the patient's condition, exchange, and deliberate on the pre-hospital medical examinations of the patient.
224035984|NCT06559150|DRUG|Nebulized Ensifentrine Suspension; 3 mg|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
223422283|NCT06623825|DEVICE|teleconsultation by two-way radio connection.|adhering to the standard conventional triage process without the AR tool, only using a two-way radio connection.
224035985|NCT06559150|DRUG|Nebulized Placebo Solution|Administered by a standard jet nebulizer, twice daily for a minimum of 24 weeks and up to a maximum of 156 weeks (3 years)
223422284|NCT01168908|DRUG|Sildenafil|20mg tablet three times daily
224137778|NCT06128590|DEVICE|Photobiomodulation simulation|The participants will be treated in the same manner as in group A. The person responsible for the application of FBM will simulate the irradiations by placing the device in the same location described for the experimental group, but the equipment will remain turned off. To prevent the participant from identifying their group, the activation sounds of the devices (beeps) will be recorded to simulate the device's operation.
224137779|NCT06015802|OTHER|diagnosed and treated reasonably according to the clinical guidelines and clinical pathways|The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
223422285|NCT00166257|DEVICE|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
223422286|NCT00166257|DRUG|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
223422287|NCT00418366|DRUG|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
223422288|NCT01393509|DRUG|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
223422289|NCT05018767|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
223422290|NCT06341543|DIAGNOSTIC_TEST|Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).|The QF-CMV will be performed in all participants.
223422291|NCT06341543|OTHER|Communication of the result of the QF-CMV to the clinician in charge|"The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge."
223422292|NCT01765777|PROCEDURE|Osteopathic Manipulative Medicine|
224035988|NCT03975959|OTHER|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
224035989|NCT03153111|DRUG|Macitentan|macitentan 10 mg; film-coated tablet; oral use
224035990|NCT03153111|DRUG|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
223422293|NCT01765777|PROCEDURE|Phototherapy|
223422294|NCT03653351|DEVICE|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
223422295|NCT03653351|DEVICE|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
223422296|NCT03150654|DEVICE|Laser pan-retinal photocoagulation|Green laser photocoagulator
223422297|NCT04288921|DIAGNOSTIC_TEST|Swab|Swab samples for diagnostic test
224137780|NCT04873284|DRUG|fosaprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV"
224137781|NCT04873284|DRUG|aprepitant|"Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg)."
224137782|NCT04873284|DRUG|Granisetron plus dexamethasone|Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
224137783|NCT02137590|DIETARY_SUPPLEMENT|Spanish Black Radish product|
223422298|NCT02567734|PROCEDURE|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
223422299|NCT02416128|DRUG|Euphrasia|1 drop in the treated eye QID X 10 days
223422300|NCT02416128|DRUG|Prednisolone acetate|1 drop in the treated eye QID X 10 days
223422301|NCT05753267|DRUG|Mesalamine|Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
224035991|NCT02258165|DEVICE|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
224035992|NCT05647772|BEHAVIORAL|UseIt! App|The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.
223422302|NCT05753267|DRUG|Fenofibrate 160mg|Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
223422303|NCT01969786|OTHER|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
223422304|NCT06665880|OTHER|Routine clinical treatment|Routine clinical treatment is based on the latest international guidelines for DRE.
223422305|NCT03875092|BIOLOGICAL|Pembrolizumab|IV infusion
223422306|NCT03875092|DRUG|Paclitaxel|IV infusion
223422307|NCT03875092|DRUG|Carboplatin|IV infusion Carboplatin dose should not exceed 900 mg.
223422308|NCT03875092|DRUG|Saline placebo for pembrolizumab|IV infusion
223422309|NCT03205761|DRUG|Olaparib|Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
223422310|NCT04420585|DRUG|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
223422311|NCT01513109|BIOLOGICAL|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
223422312|NCT06430502|BIOLOGICAL|Tumor Treatment Vaccine; PD-1/L1 inhibitors|Before and after the patient's treatment period using PD-1 inhibitors，patients will receive tumor treatment vaccine(TTV), which would be given deep subcutaneously in the arm or near the tumor.The initial dose is 1ml each time, if the reaction isn't obvious, the dose can be appropriately increased to 2.5-4.0ml each time.The interval between injections can be shortened or extended depending on the patient's condition and response.
223422313|NCT02444364|DRUG|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
223422314|NCT00065637|DRUG|Teriparatide|Synthetic human parathyroid hormone
223422315|NCT00065637|DRUG|Placebo teriparatide|Placebo injections
223422316|NCT02756780|OTHER|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
223422317|NCT04277650|OTHER|Machine learning algorithm|machine learning directed identification of radiotherapy or chemoradiotherapy patients at high-risk for emergency department acute care and/or hospitalization
223422318|NCT03808350|PROCEDURE|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
224137784|NCT03509337|DIAGNOSTIC_TEST|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
223422319|NCT03808350|OTHER|Placebo/Control|Family members will not be invited to remain in the ICU room
223563137|NCT01142869|DRUG|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
223422320|NCT01374932|DEVICE|CPAP|Continuous positive airways pressure (CPAP)
224137785|NCT00764959|DEVICE|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
224137786|NCT04108585|PROCEDURE|HFO therapy|HFO therapy from mechanical ventilation
224137787|NCT04108585|PROCEDURE|CPAP therapy|CPAP therapy from mechanical ventilation
224137788|NCT03251287|DRUG|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
224137789|NCT03251287|DRUG|Placebo|Single dose of oral matching placebo
223422321|NCT04599725|DRUG|medical abortion|medical abortion
223422322|NCT02163226|RADIATION|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
223422323|NCT02163226|RADIATION|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
223422324|NCT02163226|BEHAVIORAL|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
223422325|NCT06232057|OTHER|Virtual Reality|Women in the intervention group will be given a pre-test (STAI) before cesarean. Then, they will be shown a relaxing video (video with nature views accompanied by nature sounds) through virtual reality glasses for a maximum of 20 minutes. After a cesarean, women's anxiety levels (STAI) will be evaluated within the first 4 hours postoperatively. Pain levels (VAS) will be assessed postoperatively at the 2nd, 4th, and 6th hours.
223422326|NCT04114357|DRUG|Acetylated and Butyrylated High Amylose Maize Starch|Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner for 4 weeks
223422327|NCT05435625|PROCEDURE|FCO2|Fractional Carbon dioxide laser
223422328|NCT05435625|PROCEDURE|FRF|Fractional Microneedling Radiofrequency
223563138|NCT06049225|BEHAVIORAL|High-Tech|Access to technological platform and weekly health coaching
223563139|NCT06049225|BEHAVIORAL|Low-Tech|Weekly email with educational content and weekly health coaching
223563140|NCT06049225|BEHAVIORAL|Attention Control|No technology access or health coaching
223563141|NCT05448573|DIAGNOSTIC_TEST|Fatigue Screening and assessment|(Newly) diagnosed cancer-patients from any cancer entity. No intervention.
223563142|NCT01766739|BIOLOGICAL|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
223563143|NCT02693080|DEVICE|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
223422329|NCT05489991|BIOLOGICAL|TmPSMA-02|Intravenous administration of genetically modified autologous T-cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) with a lentiviral vector to express anti-PSMA scFv, CD2 co-stimulatory domain and dually armored with a dominant negative TGFβ receptor and PD1.CD28 switch, will be infused intravenously on Day 0 as a single flat dose following standard lymphodepleting (LD) regimen.
223422330|NCT04958148|DIETARY_SUPPLEMENT|Salt pills|Subjects will supplement salt pills with meals.
223422331|NCT04958148|DIETARY_SUPPLEMENT|Placebo pills|Subjects will supplement placebo pills with meals.
223422332|NCT06618508|PROCEDURE|Manual debridement|Traditional technique which consists of scraping off the irregular epithelium to allow a new layer to form.
223739737|NCT02828618|PROCEDURE|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
224035993|NCT05647772|BEHAVIORAL|Coach|The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.
224035994|NCT05647772|BEHAVIORAL|SmilingMind App|The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
223422333|NCT06618508|PROCEDURE|Phototherapeutic keratectomy|New technique which has been increasingly used and which consists of a 193nm excimer laser that breaks molecular bonds between cells on the epithelial surface.
223422334|NCT03558152|DRUG|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
223422335|NCT03558152|DRUG|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
224035995|NCT04421833|BEHAVIORAL|TOVERTAFEL|"The TOVERTAFEL is a small box that can be attached to the ceiling. Inside the box is a high-quality projector, infrared sensors, a speaker, and a processor that work together to project games onto the table. Because the colored objects respond to the movements of the hands and arms, the residents can play with the light itself.~The planned activities provide cognitive, social and physical stimulation through light projections and can all be used individually or in groups with the presence of a caregiver or facilitator. Sixteen play activities are offered."
224137790|NCT03251287|DIAGNOSTIC_TEST|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
224137791|NCT03251287|DIAGNOSTIC_TEST|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
224137792|NCT00002833|BIOLOGICAL|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
224137793|NCT00002833|DRUG|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
224137794|NCT00002833|DRUG|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
223422336|NCT03558152|DRUG|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
223422337|NCT03558152|DRUG|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
223422338|NCT00522535|PROCEDURE|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
223422339|NCT00522535|DEVICE|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
224035996|NCT04421833|BEHAVIORAL|USUAL activities|"patients can participate in cooking workshops, cinema activities (screening of old films or documentaries on a large screen, in a cozy atmosphere), walks in the garden and the visit of a dog trained in assisted therapy by the animal."
224035997|NCT02762253|DRUG|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
224137795|NCT00002833|DRUG|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
224137796|NCT00002833|DRUG|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
224137797|NCT00002833|DRUG|Idarubicin|IV Days -6, -5 and -4.
224137798|NCT00002833|DRUG|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
224137799|NCT00002833|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
224137800|NCT00004038|BIOLOGICAL|Ad5CMV-p53 gene|
223422340|NCT03018496|DIETARY_SUPPLEMENT|Beta-Hydroxy-Beta-Methylbutyrate|
223422341|NCT03018496|OTHER|Placebo|
223422342|NCT01335217|PROCEDURE|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
223739738|NCT02828618|PROCEDURE|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
223739739|NCT02828618|PROCEDURE|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
224137801|NCT00004038|DRUG|chemotherapy|
224137802|NCT00426517|DRUG|Campath 1H|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
224137803|NCT00426517|DRUG|Busulfan|Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
224137804|NCT00426517|DRUG|Horse Anti-human Thymocyte Globulin (h-ATG)|Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
224137805|NCT00426517|DRUG|Total Body Irradiation (TBI)|TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
224137806|NCT00426517|DRUG|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
224137807|NCT00077519|DRUG|tipifarnib|
224137808|NCT00077519|RADIATION|radiation therapy|
224035998|NCT02749656|DRUG|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
223422343|NCT00166543|DRUG|TAS-108|
223422344|NCT02872974|OTHER|GDM|Exposure to GDM during fetal life
223422345|NCT02422966|DRUG|Paracetamol|
223422346|NCT02422966|DRUG|Ibuprofen|
223422347|NCT02219581|DRUG|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
223422348|NCT02219581|DRUG|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
223422349|NCT02219581|DRUG|Standard multimodal pain management regimen|"The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~* Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~* Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~* Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. The dose is 15 mg for older patients or if creatinine clearance (CrCl) is low.~Postoperative~* Tylenol: 1000mg po q 8hr (scheduled)~* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~* IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~* Morphine patient-controlled analgesia (PCA): only for failure of the above~* Morphine Sulfate (MS) Contin: Use as backup prn pain"
223563144|NCT02693080|DRUG|Isovue-200|Contrast agent
224035999|NCT02749656|DRUG|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
224036000|NCT02749656|DRUG|Placebo|apply on the scalp psoriasis lesion twice a day
224036001|NCT02902003|BEHAVIORAL|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
224036002|NCT05652686|DRUG|Peluntamig (PT217)|A bispecific antibody (bsAb) against DLL3 and CD47.
224036003|NCT05652686|DRUG|Carboplatin + Etoposide|Administered per Standard of Care.
224036004|NCT05652686|DRUG|Paclitaxel.|Administered per Standard of Care.
224036005|NCT05652686|DRUG|Atezolizumab|Administered per Standard of Care.
224036006|NCT02612753|PROCEDURE|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
224036007|NCT02612753|DEVICE|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
224036008|NCT02612753|DEVICE|tDCs|
224137809|NCT01608724|DRUG|Saxagliptin|oral, 5 mg once a day (Q.D.)
224137810|NCT00873808|DRUG|clodronate disodium|
224137811|NCT00873808|DRUG|demeclocycline hydrochloride|
223422350|NCT02219581|DRUG|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
223563145|NCT02693080|RADIATION|Computed Tomography Perfusion Imaging|
223563146|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo|Low Repeat Dose
223563147|NCT04681833|DRUG|Recombinant Respiratory Syncytial Virus Vaccine (BARS13)|High Repeat Dose/High Repeat Multiple Dose
223563148|NCT04681833|DRUG|Placebo|Liquid diluent/Lyophilised Powder
223563149|NCT05723536|PROCEDURE|Partial Left Atrial Isolation|Partial electrical isolation of the left atrium endo-epicardially (pulmonary veins, posterior wall and left atrial appendage) and left atrial appendage isolation using Atriclip (Atricure, Mason OH, USA) in a single procedure in patients with persistent atrial fibrillation.
223563150|NCT05723536|PROCEDURE|Catheter Ablation|Catheter Ablation of Atrial Fibrillation
224036009|NCT01276431|DRUG|Buprenorphine transdermal patch|
224036010|NCT02314767|BEHAVIORAL|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
224036011|NCT02314767|BEHAVIORAL|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
224036012|NCT01439919|DRUG|SSR411298|"Form: tablet~Route: oral administration with food"
224036013|NCT01439919|DRUG|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
224036014|NCT01389765|DRUG|LY2216684|Administered orally
224036015|NCT03565120|RADIATION|Aggressive Thoracic Radiotherapy|The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
224036016|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
224036017|NCT01689220|DRUG|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
224036018|NCT02753140|DRUG|Cetuximab|
224036019|NCT02753140|RADIATION|radiation|
224036020|NCT02753140|DRUG|Docetaxel|
224036021|NCT02753140|DRUG|Cisplatin|
224137812|NCT00873808|DRUG|ibandronate sodium|
224137813|NCT00873808|DRUG|tetracycline hydrochloride|
224137814|NCT00873808|DRUG|zoledronic acid|
224137815|NCT00873808|OTHER|laboratory biomarker analysis|
224137816|NCT00873808|PROCEDURE|adjuvant therapy|
224137817|NCT00873808|PROCEDURE|computed tomography|
224137818|NCT00873808|PROCEDURE|dual x-ray absorptiometry|
224036022|NCT03450967|DRUG|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
223422351|NCT04594226|PROCEDURE|EA combined with medication|"Primary acupoints include Ashi points, Jiaji acupoints and Xi-cleft points. Jiaji points on the ipsilateral side will be selected according to the corresponding ganglia involved by HZ. Xi-cleft points will be selected based on the distribution regions of PHN. For pain sites that mainly distributed in the gallbladder meridian, GB36 will be selected. For pain sites that mainly distributed in the stomach meridian, ST34 will be selected. For pain sites that mainly distributed in the gallbladder meridian, BL63 will be selected. For pain sites that mainly distributed in the large intestine meridian, LI7 will be selected. Supplementary acupoints will be chosen based on TCM syndrome differentiation.~Operation: Two paired of acupoints are connected to the EA apparatus. EA parameter is selected as 2/100Hz wave. EA intensity is selected according to the patients' endurance. Needles will be retained and EA will last for 30 mins for each session."
223422352|NCT04594226|DRUG|Medication|The dosage of gabapentin starts from 100mg Tid. 100mg-300mg can be increased every 3-7 days and taken in three doses, but the total amount is not more than 1800mg/day. The dosage of gabapentin will be adjusted according to the patient's condition until his pain is effectively controlled. After maintaining the medication for two weeks, the dosage can be gradually reduced and 100mg can be reduced every 3-7 days.
223422353|NCT01785511|RADIATION|UVA Radiation|UVA radiation exposure for 20 minutes
223422354|NCT03914261|DRUG|Risankizumab|Tablet
223422355|NCT02153671|BIOLOGICAL|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
223422356|NCT02153671|BIOLOGICAL|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
223422357|NCT05481528|DRUG|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
223422358|NCT05481528|DRUG|Elinzanetant (BAY3427080)|Single oral dose of elinzanetant
223422359|NCT05481528|DRUG|Placebo|Single oral dose of placebo
223422360|NCT06459349|OTHER|exteroceptive and proprioceptive sensory stimulation training|Patients in this group will receive intervention exteroceptive and proprioceptive sensory stimulation for 50 minutes per session, 03 times a week, for 06 weeks
223422361|NCT06459349|OTHER|sensorimotor therapy group|Patients will receive sensorimotor therapy for 50 minutes per session, 03 times a week, for 06 weeks
223422362|NCT00063791|DRUG|Bortezomib|
223422363|NCT05630521|BEHAVIORAL|Medication Adherence Problem Solving for Hypertension|The MASH program is a 12-week intervention containing two components: (1) four education modules on HTN causes, risks, treatment, and barriers to treatment; and (2) telehealth visits every 2 weeks with a registered nurse to deliver evidence-based managed problem solving strategies tailored on patients' responses to assessments of HTN beliefs, medication beliefs, and barriers impacting their medication adherence.
223422364|NCT04274504|DIAGNOSTIC_TEST|Osteopontin|Serum osteopontin (OPN) was measured by ELIZA and osteopontin gene mutation was analyzed by sequencing and correlated with clinicopathological criteria, response, PFS and OS.
223422365|NCT02794701|OTHER|People with silicosis|
223422366|NCT00002104|DRUG|Thalidomide|
223422367|NCT01300338|DEVICE|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
224137819|NCT00211718|DRUG|intra-articular botulinum toxin type a|
224137820|NCT04837534|BEHAVIORAL|Counseling group|In this group after the children have been examined, treatment plan and follow up schedule been advised by a pediatric ophthalmologist, parents/guardians along with the child will receive counseling from a trained counselor as per the set counseling protocol in every follow-up visits and will also be provided with the disease-specific information leaflets as an additional information material before the child is discharged from the department.
223422368|NCT01300338|DEVICE|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
224036023|NCT04598048|BEHAVIORAL|Questionnaire|Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
224137821|NCT04837534|BEHAVIORAL|SMS and phone call reminder group|In this group after the children have been examined, treatment plan, and the follow-up schedule been advised, they will be discharged from the department but later they will receive reminders through short messaging text (SMS) and phone calls as per the set protocol.
223422369|NCT02668809|OTHER|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
223422370|NCT02668809|OTHER|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
223422371|NCT02668809|OTHER|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
223422372|NCT02668809|OTHER|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
223422373|NCT02668809|OTHER|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
224036024|NCT06223204|OTHER|Controlled euglycemia, hypoglycemia and hyperglycemia|EIT measurements are collected in different glycemic states (euglycemia, hypoglycemia and hyperglycemia). Venous blood glucose is measured using a gold-standard glucose analyzer.
224137822|NCT06146296|BIOLOGICAL|Local Vitamin C injection|An injection of 1-1.5 ml of L-ascorbic acid, locally introduced in relation to the keratinized gingival tissues, with extension to the whole target region successively. The injected area will be massaged for equal distribution of the injected vitamin. Injections will be performed on the first day of retainer delivery (T0), after 1 month (T1), after 3 months (T2), and after 6 months (T3). Hence, a total of 4 local Vit-C injections will be performed over the study period.
223422374|NCT02668809|OTHER|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
223422375|NCT02668809|OTHER|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
223422376|NCT02668809|OTHER|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
223422377|NCT06620887|OTHER|Evaluate the impact of HEMAGO program on maternal morbidity and mortality in sickle cell disease patients during their pregnancies.|"HEMAGO pregnancy monitoring is a joint consultation program between the sickle cell disease hematologist and an obstetrician. This program was implemented in April 2016 at the Croix-Rousse maternity Hospital. This program offers close, complete and personalized pregnancy monitoring for each patient with major sickle cell syndrome.~These are follow-up consultations once a month until 24 weeks then every 15 days until delivery. At each consultation, doctors evaluate a general and obstetric clinical examination. The team establishes a precise schedule adapted to each patient for pregnancy monitoring : monthly blood tests, monthly ultrasounds with maternal and fetal Doppler, adaptation of basic treatment, transfusion exchange program according to eligibility criteria, and organization of childbirth."
223422378|NCT04001894|DRUG|Ticagrelor 90mg|Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
223422379|NCT04001894|DRUG|Clopidogrel 75mg|Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
223422380|NCT04888429|DRUG|Camrelizumab|Patients received camrelizumab 200 mg every 3 weeks
223422381|NCT04888429|DRUG|Famitinib|Patients received Famitinib 20 mg once per day
223422382|NCT05856994|DRUG|Tacrolimus ointment|For the active comparator group, the wound(s) will be cleaned and bacitracin ointment will be applied to the wound. External dressings on all treated wounds will be placed based on the current standard of care. For the control group, the wound(s) will be cleaned and a hydrocolloid Dressing will be affixed to the burn and treated area. For the treatment group, the wound(s) will be cleaned and tacrolimus (0.03%) ointment will be applied over the burn. Hydrocolloid Dressing will be affixed to the burn and treated area. External dressings on all treated wounds will be placed based on the current standard of care.
223563151|NCT06355609|DRUG|sunvozertinib in combination with Anlotinib|Sunvozertinib 300 mg once daily (QD) with Anlotinib 8mg once daily （QD in Day 1-14），21 days in one cycle.
223563152|NCT03861416|DRUG|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
223563153|NCT03861416|DRUG|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
224137823|NCT06146296|BIOLOGICAL|Oral Vitamin C supplement|Patients will be prescribed a daily oral (systemic) Vit-C supplement to be taken over the follow up period.
224137824|NCT04387136|DRUG|Sublingual Sufentanil|15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
223422383|NCT05031650|PROCEDURE|openCPAP|Randomized to : Individualized high level CPAP between 8-10 cmH2O pressure
223422384|NCT05031650|PROCEDURE|standardCPAP|Randomized to : Standard level CPAP between 6-8 cmH2O pressure
223422385|NCT00878150|BEHAVIORAL|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
223422386|NCT00878150|BEHAVIORAL|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
223422387|NCT05885295|DIAGNOSTIC_TEST|MRI brain, Blood tests, cognitive assessments|observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
223563154|NCT03861416|DRUG|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
223563155|NCT03149354|OTHER|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
223563156|NCT06278506|PROCEDURE|Ablation|Microwave ablation, Radiofrequency ablation, Cryo ablation
223563157|NCT06278506|PROCEDURE|Surgery|Partial or total nefrectomy
223563158|NCT02973295|DRUG|Silymarin|Capsules contains 100 mg of silymarin
223563159|NCT02973295|OTHER|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
223563160|NCT02664168|DEVICE|Aquacel Ag Surgical Dressing|
224137825|NCT00815906|DRUG|SBI-087|IV, Single dose
224137826|NCT00815906|DRUG|SBI-087|IV, Single dose
224137827|NCT00815906|DRUG|SBI-087|SC, Single dose
223563161|NCT02664168|DEVICE|Single-Use Negative Pressure Wound Therapy (PICO)|
223563162|NCT03754127|DEVICE|tDCS|Transcranial direct current stimulation
223563163|NCT03754127|DEVICE|sham tDCS|Sham transcranial direct current stimulation
223563164|NCT04891718|BIOLOGICAL|MVC-101|Intratumoural microdose injection by the CIVO device.
224137828|NCT00815906|DRUG|SBI-087|SC, Single dose
224137829|NCT04255836|DRUG|Durvalumab|Durvalumab 1500mg q3w combined with chemotherapy for 4 cycles, then 1500mg q4w combined with SBRT, then 1500mg q4w for PD or up to 24 months
224137830|NCT04255836|DRUG|the first line chemotherapy for metastatic NSCLC|paclitaxel+carboplatin or pemetrexed+cisplatin
224137831|NCT04255836|RADIATION|stereotactic body radiotherapy (SBRT)|SBRT total doses of 50-60Gy/≤10F
223422388|NCT00970632|DRUG|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
223422389|NCT00970632|DRUG|Placebo tablet|Placebo tablet po QD for 12 weeks
223422390|NCT00970632|DRUG|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
223422391|NCT00970632|DRUG|Placebo capsule|Placebo capsule po QD for 12 weeks
223422392|NCT05817487|BEHAVIORAL|high-intensity interval training (HIIT)|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.
223422393|NCT05817487|BEHAVIORAL|crossover point(COP) exercise training|Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
223422394|NCT03811327|BEHAVIORAL|Zero-time Exercise|A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
223422395|NCT04055376|DEVICE|GENUS device (Active Settings)|"Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
223422396|NCT04055376|DEVICE|GENUS device (Sham Settings)|"Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 or 9 months. After 6 or 9 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 or 9 months.~Note: Due to the COVID-19 pandemic, participants who have not yet reached the 6-month mark will have their 6 month visit postponed to 9 months."
223563165|NCT04891718|BIOLOGICAL|Nivolumab|Intratumoural microdose injection by the CIVO device.
224137832|NCT00717366|DRUG|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
224137833|NCT02381496|DRUG|ACT-453859 1 mg|Capsule
224137834|NCT02381496|DRUG|ACT-453859 3 mg|Capsule
224137835|NCT02381496|DRUG|ACT-453859 10 mg|Capsule
224137836|NCT02381496|DRUG|ACT-453859 30mg|Capsule
224137837|NCT02381496|DRUG|ACT-453859 100 mg|Capsule
224137838|NCT02381496|DRUG|ACT-453859 300 mg|Capsule
223422397|NCT03272659|DRUG|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
223422398|NCT04766957|DEVICE|Idracare|Treatment will last 3 months (12 weeks). The treatment will be applied 2 times a week, preferably at night before going to bed.
223422399|NCT01940315|BIOLOGICAL|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
223422400|NCT01940315|BIOLOGICAL|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
223422401|NCT00672386|DRUG|JNJ16269110|5 mg twice daily for 12 weeks
223422402|NCT00672386|DRUG|JNJ16269110|10 mg twice daily for 12 weeks
223422403|NCT00672386|DRUG|JNJ16269110|15 mg twice daily for 12 weeks
223422404|NCT00672386|DRUG|Placebo|twice daily for 12 weeks
223422405|NCT00672386|DRUG|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
223422406|NCT00672386|OTHER|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
223422407|NCT02085616|BEHAVIORAL|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
223563166|NCT04891718|COMBINATION_PRODUCT|MVC-101 + Nivolumab|Intratumoural microdose injection by the CIVO device.
223563167|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
223563168|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
223563169|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
223739740|NCT02828618|PROCEDURE|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
223739741|NCT02828618|DRUG|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
224137839|NCT02381496|DRUG|ACT-453859 800 mg|Capsule
224137840|NCT02381496|OTHER|Placebo|Matching ACT-453859 placebo capsule
224137841|NCT02381496|DRUG|Setipiprant 500 mg|Capsule
224137842|NCT02381496|DRUG|Setipiprant 1000 mg|Capsule
224137843|NCT03936816|OTHER|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
224137844|NCT00605410|DRUG|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
224137845|NCT00605410|DRUG|placebo|Matched placebo
224137846|NCT00235690|PROCEDURE|Blood draws|PK samples obtained around a clinical dosing of colistin
224137847|NCT00235690|OTHER|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
224137848|NCT04727502|DRUG|Duloxetine|duloxetine
224137849|NCT04727502|DRUG|Pregablin|Pregablin
223422408|NCT02085616|BEHAVIORAL|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
223422409|NCT05759429|OTHER|BWRP|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
223422410|NCT05759429|OTHER|BWRP + melatonin|Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
223422411|NCT03343717|OTHER|Rehabilitation|physical therapy exercise
223422412|NCT03343717|OTHER|Chest physical therapy|chest physical therapy exercise
223422413|NCT04458025|OTHER|Standard rehabilitation program|Standard rehabilitation will start 4 weeks after surgery according to the standard of cre
223422414|NCT04458025|OTHER|Early rehabilitation program|Early rehabilitation program will start 2 weeks
223422415|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
223422416|NCT02062710|DRUG|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
223422417|NCT02062710|DRUG|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
223422418|NCT02062710|DRUG|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
223422419|NCT02062710|DRUG|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
223422420|NCT02062710|DRUG|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
223422421|NCT01950104|OTHER|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
223422422|NCT01950104|OTHER|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
223422423|NCT04955665|PROCEDURE|bone block procedure|a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.
223422424|NCT04955665|PROCEDURE|Reattachment of the superior peroneal retinaculum|two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
223422425|NCT00297531|DEVICE|PerioWave|
223422426|NCT00297531|PROCEDURE|Scaling and Root Planing|
223422427|NCT01702194|DRUG|TD-1211 IV [C14]|
223422428|NCT01702194|DRUG|TD-1211 PO [C14]|
223563170|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
223739742|NCT02067299|DRUG|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
224137850|NCT02141802|BEHAVIORAL|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
224137851|NCT02141802|BEHAVIORAL|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
223422429|NCT04376086|PROCEDURE|Epidural anesthesia|Segmental epidural analgesia
223422430|NCT04376086|PROCEDURE|general anesthesia|general anesthesia
223422431|NCT03091881|DRUG|Granisetron 0.1 MG/ML|Granisetron 0.1 MG/ML Will be given 10 min before spinal block
223422432|NCT03091881|DRUG|Placebos|Placebos will be given 10 min before spinal block
223422433|NCT03048123|PROCEDURE|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
223422434|NCT03048123|PROCEDURE|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
223422435|NCT03048123|DRUG|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
223422436|NCT03048123|DRUG|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
223422437|NCT01670734|DRUG|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
223422438|NCT02002533|BEHAVIORAL|Brief Behavioral Therapy|Undergo BBT intervention
223422439|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo BBT intervention
223422440|NCT02002533|OTHER|Educational Intervention|Undergo HEAL
223422441|NCT02002533|BEHAVIORAL|Telephone-Based Intervention|Undergo HEAL
223422442|NCT00241124|DRUG|valsartan|
223422443|NCT00241124|DRUG|lisinopril|
223422444|NCT02351908|DRUG|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
223422445|NCT02351908|DRUG|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
224137852|NCT03696303|OTHER|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
224137853|NCT01879956|OTHER|Craft Activities|There is no intervention method used to perform the task.
224137854|NCT01879956|BEHAVIORAL|OGI Method|metacognitive approach to assess executive functions.
224036025|NCT02292368|BEHAVIORAL|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
223422446|NCT02351908|DRUG|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
223422447|NCT02362776|OTHER|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
223422448|NCT00101036|DRUG|lapatinib ditosylate|Given PO
223422449|NCT00101036|OTHER|laboratory biomarker analysis|Correlative studies
223422450|NCT04761549|PROCEDURE|Adolescent Idiopathic Scoliosis|Adolescent Idiopathic Scoliosis
223422451|NCT02823392|OTHER|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 \< 95%).
223422452|NCT06667895|OTHER|respiratory gated taVNS|Electrical stimulation will be delivered in bursts during expiration
223422453|NCT06667895|OTHER|random burst stimulation|Electrical stimulation will be delivered in bursts at random timepoints during the breathing cycle
223422454|NCT06667895|OTHER|continuous stimulation|Electrical stimulation will be delivered continuously for 30sec followed by a 30sec break.
223422455|NCT06667895|OTHER|Sham stimulation|Electrical stimulation will be identical to the taVNS, but the electrodes will be placed at a different position on the ear
223422456|NCT06619145|DRUG|Low dose Oliceridine|Low dose Oliceridine
223422457|NCT06619145|DRUG|High dose Oliceridine|High dose Oliceridine
224036026|NCT02292368|PROCEDURE|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
224036027|NCT02292368|PROCEDURE|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
223422458|NCT06649188|DEVICE|Magnesium Sulphate Iontophoresis|"Iontophoretic drug delivery system (phoresors II auto model PM850 IOMED) The phoresors II auto model PM850 IOMED allows the user to deliver a specific dose from 0 to 80 mA/min, control the current from 0 to 4 mA and automatically calculates required time for the selected dose. Current ramp-up and down, shut-off, error messages and safety checks are also performed automatically. The builtin option for manual current shut-off is an added safety feature (Teslim et al., 2013).~* Electrodes: Active-Anode (Drug Delivery).~* Drug Used: MgSO4 Aqueous Solution.~* Drug Ion Polarity: Positive Polarity."
223422459|NCT06649188|OTHER|traditional physical therapy program|Deep friction massage, stretching and pressure therapy.
224036028|NCT02960841|OTHER|Intracavitary Manual Lymphatic Drainage|
223422460|NCT05136144|DRUG|SM-020|Topical Akt Inhibitor SM-020 Gel
223422461|NCT00340106|BEHAVIORAL|Counseling|
223422462|NCT06523543|PROCEDURE|Inclusion (Visit 1 - Week 7-16)|Extraction of cervico-vaginal sampling
223422463|NCT06523543|DIAGNOSTIC_TEST|Second semester of pregnancy (Visit 2 - Week 20-24)|Ultrasound examination (determination of chromosomal sex)
223563171|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
224036029|NCT02960841|OTHER|Conventional treatment|
224137855|NCT03661489|DRUG|Remimazolam|For induction and maintenance of general anesthesia
223422464|NCT06523543|DIAGNOSTIC_TEST|Third semester of pregnancy (Visit 3- Week 34)|Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
223739743|NCT02067299|OTHER|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
223739744|NCT06444880|DRUG|Ubamatamab|Given by IV
224036030|NCT02882087|DRUG|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
224036031|NCT02882087|DRUG|RC18 160 mg plus MTX|
224036032|NCT04497194|OTHER|not applicable (observational study)|not applicable (observational study)
224137856|NCT03661489|DRUG|Propofol|For induction and maintenance of general anesthesia
224137857|NCT01182389|PROCEDURE|Robotic VT Ablation|Robotic VT Ablation
223422465|NCT03683927|COMBINATION_PRODUCT|Bacillus clausii|The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
223422466|NCT03683927|OTHER|Sterile water|The placebo group will receive sterile water 4 times a week
223422467|NCT01749709|BEHAVIORAL|Music listening|
223422468|NCT01749709|BEHAVIORAL|Audiobook listening|
223422469|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
223422470|NCT03184337|BEHAVIORAL|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
223422471|NCT00731718|DEVICE|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
223422472|NCT00657033|DRUG|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
224137858|NCT01182389|OTHER|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
224036033|NCT04637477|BEHAVIORAL|Virtual ELM|Participants will attend 1.5-hour virtual group-based sessions for 12 weeks. The program includes physical activity, cooking demonstrations, and group discussions. All sessions are led by a registered dietitian and health psychologist.
224036034|NCT02455219|DEVICE|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
224036035|NCT05223465|OTHER|Survey|Google form distributed for students and faculties
224036036|NCT03877432|DEVICE|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
224036037|NCT01110811|PROCEDURE|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
224036038|NCT06249373|DEVICE|Low intensity pulse ultrasound （LIPUS） intervention for arteriovenous fistula anastomosis|The LIPUS intervention group for arteriovenous fistula should receive forearm wearable portable low-intensity pulse ultrasound （LIPUS） intervention at the anastomotic site no more than 3 days after suture removal two weeks after the fistula surgery. If the ultrasound examination indicates the presence of stenosis in the outflow tract, the intervention should also be performed at the same time. It belongs to non-invasive extracorporeal intervention, with three times a week （during dialysis） for 20 minutes each time. The sound intensity is 350mW/cm2, the pulse frequency is 1MHz, the pulse repetition frequency is 100Hz, the pulse frequency is 100 times, and the treatment period is 12 weeks.
224036039|NCT01299987|RADIATION|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
224137859|NCT01446601|DEVICE|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
224137860|NCT00910429|DRUG|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
223422473|NCT00657033|DRUG|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
223422474|NCT05542628|OTHER|No intervention included|No intervention included
223422475|NCT04756193|DIAGNOSTIC_TEST|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound|Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
224137861|NCT01167465|OTHER|Moussik Diaper Rash Mousse|To be used as instructed
224137862|NCT01167465|OTHER|Desitin Creamy Ointment|To be used as instructed
224137863|NCT05672966|BIOLOGICAL|Human papillomavirus (HPV) Vaccine|0.5mL, Intramuscular
224137864|NCT05672966|BIOLOGICAL|Placebo|0.5mL, Intramuscular
223422476|NCT06394466|OTHER|Non Applicable|Non Applicable
223422477|NCT03268759|OTHER|fMRI|Observation of neural markers of reward processing
223422478|NCT04349059|OTHER|Animal based diet|Food will be provided by Montefiore-Einstein Food Services
223422479|NCT04349059|OTHER|Plant based diet|Food will be provided by Montefiore-Einstein Food Services
223422480|NCT04499300|OTHER|Data collection from medical files|Data collection from medical files
223422481|NCT00555126|DEVICE|Forced Air Warming|Warming after Randomization
223422482|NCT00555126|DEVICE|Warming with endovascular catheter + forced air warming|Warming after Randomization
223422483|NCT00112528|BIOLOGICAL|bevacizumab|
223422484|NCT00112528|DRUG|gemcitabine hydrochloride|
223422485|NCT00112528|DRUG|oxaliplatin|
223422486|NCT05863507|DIETARY_SUPPLEMENT|Grape powder supplementation|The participants will be willing to consume the grape powder dissolve in water daily for 6 weeks
223422487|NCT05863507|DIETARY_SUPPLEMENT|Placebo|The participants will be willing to consume the placebo powder, similar to the grape powder, dissolve in water daily for 6 weeks
223422488|NCT04236661|DEVICE|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
223422489|NCT02103192|OTHER|Anti-Oxidant Drink|
223422490|NCT03822663|DIETARY_SUPPLEMENT|Caffeine supplementation|The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 70 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
223422491|NCT03822663|DIETARY_SUPPLEMENT|Placebo treatment|The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 70 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
223422492|NCT05231746|BIOLOGICAL|hSTC810|hSTC810 will be administered as an intravenous infusion (IV)
223563172|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
223739745|NCT06444880|DRUG|Cemiplimab|Given by IV
223422493|NCT04685772|DRUG|Methylprednisolone|"The Methylprednisolone dose pack (Medrol Dose Pack) is pre-packaged with dosing instructions. This dose pack is tapered over 7 days and administration will be the following for all patients:~Day 1 (total 24 milligrams (mg)) - 8mg before breakfast, 4mg after lunch and dinner, and 8mg at bedtime Day 2 (total 20mg) - 4mg before breakfast, after lunch and dinner, and 8mg at bedtime Day 3 (total 16mg) - 4mg before breakfast, lunch, dinner, and at bedtime Day 4 (total 12mg) - 4mg before breakfast, after lunch, and at bedtime Day 5 (total 8mg) - 4mg before breakfast and at bedtime Day 6 (total 4mg) - 4mg before breakfast Day 7 (total 0mg) - Completed"
223422494|NCT03123835|PROCEDURE|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
223422495|NCT01046058|DRUG|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
223422496|NCT00976820|BIOLOGICAL|GSK2340274A|Two intramuscular injections
223422497|NCT00976820|BIOLOGICAL|GSK2340273A|Two intramuscular injections
223422498|NCT06572748|OTHER|10-week programme|"1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments."
223422499|NCT06110754|BEHAVIORAL|I-STRONG for SCD|I-STRONG for SCD is a group-based, multi-component intervention that includes mind-body, cognitive-behavioral, and neuromuscular movement training. The intervention includes 16 sessions that occur over 8 weeks. Adolescents attend every session and parents attend 6 of the 16 sessions.
223422500|NCT03741751|DEVICE|rTMS|Participants will receive either active or sham bilateral rTMS over the dorsolateral prefrontal cortex (DLPFC) for 12.5 min per side.
223422501|NCT03741751|BEHAVIORAL|Computerized cognitive training|All participants will receive computerized cognitive training for 40 min after each rTMS session.
223422502|NCT01698242|BEHAVIORAL|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
223563173|NCT02583685|DRUG|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
223563174|NCT02583685|DRUG|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
223739746|NCT05556720|BIOLOGICAL|Pfizer Bivalent COVID-19 Vaccine|One or Two doses three months apart, per manufacturer's recommendations.
223739747|NCT05556720|BIOLOGICAL|Moderna Bivalent mRNA vaccine|One or Two doses three months apart, per manufacturer's recommendations.
224036040|NCT04038853|DRUG|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
224036041|NCT04038853|DRUG|Placebo|Placebo identical to the study intervention drug
224036042|NCT01998126|DRUG|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
224036043|NCT01998126|DRUG|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
224036044|NCT01998126|DRUG|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
224137865|NCT03378726|DIETARY_SUPPLEMENT|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
224036045|NCT01998126|DRUG|Nivolumab|
224036046|NCT04758182|DEVICE|High intensity laser therapy|Device: HIRO 3.0 device high peak power (3kW), a wavelength of 1064 nm
224036047|NCT04758182|DEVICE|Ultrasound therapy|Device: Chattanooga intellect mobile ultrasound device frequency of 1 MHz, an intensity of 2 W/cm2 and a duty cycle of 100%
224036048|NCT06378411|DEVICE|Music Game Intervention|Use of music to induce improvements in cognitive and motor outcomes.
224137866|NCT03378726|BEHAVIORAL|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
224137867|NCT03378726|BEHAVIORAL|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
224137868|NCT03378726|DIETARY_SUPPLEMENT|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
224137869|NCT03378726|BEHAVIORAL|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
223422503|NCT01698242|BEHAVIORAL|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
224036049|NCT05512637|DIAGNOSTIC_TEST|Step 1 - Screening ; Step 2 - Clinical interview|"Step 1: screening is performed by online parental questionnaires (SRS-2, Identidys scale, DCDQ, parental concerns questionnaire ) via a web platform. Parents and registered doctors will be informed by mail in case of negative screening; In case of positive screening, they will be called by phone in order to give them the results and to invite them for a clinical and semi-structured interview.~Step 2: The semi-structured interview will be performed by a psychologist specialized in NDD in order to clinically confirm the results of the screening and refer the child to care and interventions, by mail to the registered doctor. Around 12 months after this interview, parents will be called by phone to collect a description of the referral and their satisfaction about the screening process."
224137870|NCT04846348|COMBINATION_PRODUCT|Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.|Combination of ingredients includes 2 agents which target mast cell mediators and one agent which globally reduces mast cell degranulation combined in an emollient cream base (Vanicream).components: Vanicream: Over the counter emollient cream Diphenhydramine Antihistamine Trolamine salicylate Prostaglandin inhibitor, antiinflammatory Cromolyn Sodium Mast cell degranulation inhibitor
223422504|NCT01949012|OTHER|Capnography|Capnography waveform and capnometry readings
223422505|NCT01719913|OTHER|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
223422506|NCT01719913|OTHER|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
223422507|NCT03261674|BEHAVIORAL|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
223422508|NCT03261674|BEHAVIORAL|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
223422509|NCT02901743|OTHER|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
223422510|NCT03159234|RADIATION|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
223422511|NCT03159234|RADIATION|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
223422512|NCT03159234|RADIATION|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
223422513|NCT02119689|OTHER|Diabetic Patients|measuring CD34 cell function in relation to diabetic retinopathy status
223422514|NCT02119689|OTHER|Healthy Controls|measuring CD34 cell function
223422515|NCT04013360|OTHER|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
223563175|NCT03709277|BEHAVIORAL|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
223563176|NCT00708591|DRUG|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
223739748|NCT05020340|PROCEDURE|External cephalic version|In the intervention group, ECV will be performed by two operators with one of them having experience of ≥ 5 successful ECV. The procedure will be performed by the first operator under real time continuous ultrasonographic guidance. The fetal head and buttock will be grasped by both hands and attempt to rotate the fetus to a longitudinal lie either in a clockwise or anti-clockwise fashion. The second operator will perform the ECV if the first operator fails the procedure.
224036050|NCT03365050|OTHER|No Intervention Given|No Intervention to be given
223739749|NCT03987061|DEVICE|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
224036051|NCT00174265|DRUG|asenapine|5-10 mg sublingually twice daily for 26 weeks
224036052|NCT00174265|DRUG|olanzapine|5-20 mg by mouth once daily for 26 weeks
224036053|NCT01473160|DEVICE|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
224036054|NCT01473160|DEVICE|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
224137871|NCT04417725|OTHER|Not applicable - this is a non-interventional, observational study.|Not applicable - this is a non-interventional, observational study.
223422516|NCT04013360|OTHER|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
223422517|NCT04126915|GENETIC|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
224036055|NCT01798277|PROCEDURE|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
224036056|NCT01798277|DRUG|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
224036057|NCT02211352|DRUG|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
224036058|NCT02211352|DRUG|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
224036059|NCT04575480|PROCEDURE|Shock Wave Lithotripsy for renal stone.|The following protocol will be applied for all patients in study groups. SWL will be performed using the Dornier Gemini lithotripter (Dornier MedTech, Wessling, Germany) . A total of 3 000 shocks will be delivered at 80 shocks/min. The patient will receive 1 mg/kg pethidine i.v. for analgesia. Treatment will begin at machine power step 1, which will deliver 49 MPa focal pressure and 0.35 mJ/mm2. Power will be gradually increased by one step for each 200 shocks up to step 4, which deliver 70 MPa and 0.7 mJ/mm2. The maximum session number will be 3 session. Patient treated with \<2 sessions will be excluded from the analysis
224036060|NCT06503562|OTHER|central nervous system focused treatment program|Pain neuroscience education, breathing exercises and relaxation exercises with guided imagery
223422518|NCT05325489|DRUG|Nebulized Budesonide|use 0.5mg/2ml Pulmicort Respules BIS QD and oral montelukast sodium chewable tablets 4mg QD
223422519|NCT05325489|DRUG|Intranasal Budesonide Spray|nasal spray 100μg QD and oral montelukast sodium chewable tablets 4mg QD
223422520|NCT00576160|BEHAVIORAL|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
223422521|NCT02952092|DRUG|roxadustat|Oral
223422522|NCT02952092|DRUG|Darbepoetin alfa|Intravenous
223422523|NCT03108768|DEVICE|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
223422524|NCT03108768|DEVICE|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
223422525|NCT04560972|DRUG|Atezolizumab|Given IV
223422526|NCT04560972|DRUG|Carboplatin|Given IV
223422527|NCT04560972|DRUG|Etoposide|Given IV
223422528|NCT04560972|DRUG|Protein Phosphatase 2A Inhibitor LB-100|Given IV
224036061|NCT06503562|OTHER|Classical Physiotherapy|All participants will receive conventional physiotherapy five days a week for one month. Transcutaneous electrical nerve stimulation, 15 min hotpack will be applied to the neck and back. Afterwards, mobilisations to the cervical and thoracic spine joints and myofascial release to the upper trapezius muscle will be applied. The patient will be given 3X10 neck active range of motion exercises to do at home every day and self stretches to the muscles in the neck region (SCM, upper trapezius, scalene and pectoral) according to the patient's condition. After the first week, strengthening exercises with isometric and resistive isotonic exercises will be given to the neck and upper back muscles gradually increasing. Patients will not be given any medication and will be asked not to use any medication.
224036062|NCT02795416|DRUG|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
224036063|NCT05187156|BEHAVIORAL|Behavioral Activation and Social Engagement|brief, PCMHI-based psychotherapy using behavioral activation principles and focused attention on enhancement of social support
223422529|NCT00623935|DRUG|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
223422530|NCT00623935|DRUG|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
223422531|NCT00623935|RADIATION|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
223422532|NCT00623935|PROCEDURE|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
223422533|NCT03628339|DRUG|Midazolam|Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.
223422534|NCT03628339|DRUG|Tepotinib|Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.
223422535|NCT06665152|DEVICE|ProTaper File System|A rotary file system
223422536|NCT06665152|DEVICE|WaveOne File System|A reciprocating file system
223422537|NCT01172496|DRUG|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
223422538|NCT01665885|DEVICE|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
223422539|NCT01665885|DEVICE|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
223422540|NCT03986788|OTHER|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
223422541|NCT05342051|OTHER|balneotherapy|immersion in radon, calcium, natrium, bicarbonate content 42 ℃ thermal-mineral water 15 times in 3 weeks, plus usual care. The total mineral substance of the water is 1530 mg/l. The suggested daily time spent in water is 20 minutes altogether with breaks.
223422542|NCT05318248|DRUG|Clonidin|0,15mg Clonidin orally versus placebo pill
223422543|NCT05318248|DRUG|Placebo|placebo pill
223422544|NCT05189301|DIAGNOSTIC_TEST|first pass study|Radionuclide assessment of ventricular performance was performed (Symbia T2, Germany)
223422545|NCT05189301|DIAGNOSTIC_TEST|cardiopulmonary exercise testing|to measured (mL/min, STPD), CO2 output ( ) (mL/min), and minute ventilation ( ) (L/min, BTPS) breath by-breath (MasterScreen CPX™, Germany)
223422546|NCT02735512|OTHER|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
223422547|NCT02735512|OTHER|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
223422548|NCT05069025|OTHER|music|In the music group, music chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
223422549|NCT05069025|OTHER|no-music|Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
223422550|NCT04878484|BIOLOGICAL|TCRT-ESO-A2|TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1.
223422551|NCT02845960|BEHAVIORAL|rapid recovery|rapid recovery
223422552|NCT04611191|OTHER|Team Sports|The intervention involves team sports in sports clubs in local municipalities
223422553|NCT04611191|OTHER|Control|The intervention involves a control condition with participants continuing their normal way of living
223563177|NCT00708591|DRUG|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
223563178|NCT01811589|DEVICE|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
223563179|NCT01811589|OTHER|Free-hand|Ventricular catheter placement without a guidance (free-hand)
224036064|NCT05187156|BEHAVIORAL|Treatment as usual|treatment as usual in PCMHI includes participation in any other skills-based groups or brief individual psychotherapy and medication management offered in PCMHI
224036065|NCT05539833|DRUG|KSH01 injection|TCR-T cell injection
224036066|NCT03040622|DEVICE|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
224036067|NCT01572922|DEVICE|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
224036068|NCT01572922|DEVICE|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2\*-UTE scans will be performed.
224036069|NCT01572922|PROCEDURE|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
224036070|NCT06335862|OTHER|Randomisation between the PPT- and no-PPT-group|Randomisation is performed between two possible treatment options for tracheomalacia in OA patients; the PPT or the wait-and-see policy (no-PPT).
224036071|NCT06335862|PROCEDURE|Primary Posterior Tracheopexy|The PPT involves fixating the posterior membrane of the trachea to the spinal ligament with sutures, to prevent the trachea from collapsing.
224137872|NCT03976115|DRUG|DDO-3055|Oral
223422554|NCT02263391|BEHAVIORAL|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
223422555|NCT02263391|BEHAVIORAL|Focus Group|Study participants will be invited to participate in a focus group discussion.
223422556|NCT04736446|DEVICE|I-gel® supraglottic device|Use of an i-gel® supraglottic device to deliver ventilations
223422557|NCT04736446|DEVICE|Face mask ventilation|Use of a face mask to deliver ventilations
223422558|NCT03718481|OTHER|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training \[1\]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
223422559|NCT04590508|DRUG|Xanthohumol|The xanthohumol supplement will be administered in a capsule and taken orally.
223422560|NCT04590508|OTHER|Placebo|The placebo will be administered in a capsule and taken orally.
223563180|NCT00543933|DRUG|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
223563181|NCT00703274|BEHAVIORAL|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
223563182|NCT05781945|DIETARY_SUPPLEMENT|probiotics|supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
223563183|NCT05781945|OTHER|standard therapy|standard therapy for sars-cov-2
224137873|NCT03976115|DRUG|Placebos|Oral
224137874|NCT02121756|DRUG|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
224036072|NCT06335862|DIAGNOSTIC_TEST|Preoperative tracheobronchoscopy|Prior to OA correction, a flexible and a rigid tracheobronchoscopy will be performed, in addition to a flexible tracheobronchoscopy through the endotracheal tube. Preoperative evaluation of TM through a tracheobronchoscopy is part of standard care for all participating centres.
224036073|NCT06335862|DIAGNOSTIC_TEST|Intraoperative tracheobronchoscopy|After the PPT is performed, or in case of the no-PPT group at the stage of the surgery when the PPT would usually be performed, a flexible tracheobronchoscopy through the endotracheal tube is carried out. This tracheobronchoscopy is routine care for all patients undergoing a PPT, and is additional for patients in the no-PPT-group.
224036074|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy through the endotracheal tube during extubation|A postoperative flexible tracheobronchoscopy is performed in the neonatal or pediatric intensive care unit (ICU), through the endotracheal tube during extubation. This procedure is a study intervention.
224036075|NCT06335862|DIAGNOSTIC_TEST|Postoperative tracheobronchoscopy after 2-6 months|Two to six months after OA correction, a follow-up flexible and a rigid tracheobronchoscopy will be performed, under general anesthesia in the surgical theatre. This postoperative evaluation of TM through a tracheobronchoscopy is part of standard care for the Karolinska University Hospital and Great Ormond Street Hospital. At the University Medical Centre Utrecht and Erasmus Medical Centre Rotterdam, this tracheobronchoscopy is performed on indication in approximately half of patients. For the other half of patients, this is a study intervention.
224036076|NCT01802489|DRUG|Amiloride|
224036077|NCT01802489|DRUG|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
223422561|NCT06968715|DIETARY_SUPPLEMENT|Experimental 1: low-breath hydrogen|Hydrogen-rich water (1.0 L/day)
223422562|NCT06968715|DIETARY_SUPPLEMENT|Experimental 2: high-breath hydrogen|Hydrogen-rich water (1.0 L/day)
223422563|NCT06968715|DIETARY_SUPPLEMENT|Experimental 3: low-breath hydrogen|Placebo water (1.0 L/day)
223422564|NCT06968715|DIETARY_SUPPLEMENT|Experimental 4: high-breath hydrogen|Placebo water (1.0 L/day)
223422565|NCT00747474|DRUG|Lipotecan|Lipotecan IV day 1, 8, 15
223422566|NCT01532843|DRUG|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
223422567|NCT05170100|BEHAVIORAL|NUIG OAB App|An interactive software-delivered 8-week intervention accessed through the patients' mobile device. It provides best-practice behavioural therapy, and delivers evidence-based dietetics, physiotherapy and psychology treatments to reduce the symptoms of overactive bladder.
223422568|NCT00694252|DRUG|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
223422569|NCT04447352|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
223422570|NCT04447352|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
223422571|NCT04447352|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
223422572|NCT04447352|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
223563184|NCT00613327|DRUG|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
223563185|NCT03208660|DRUG|Fycompa|Oral suspension
223563186|NCT04679506|DRUG|Cladribine|CLAE regimen (cladribine + cytarabine + etoposide) for reinduction of R/R T-ALL/LBL
223563187|NCT02745678|DRUG|Thermosensitive gel rectal formulation|
223563188|NCT00565162|DRUG|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
223563189|NCT04351399|OTHER|questionnaire assesment|The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
223563190|NCT03203824|DIETARY_SUPPLEMENT|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
223563191|NCT03203824|OTHER|non dark chocolate|No dark chocolate will be given to this group during the procedures.
223563192|NCT02024360|BEHAVIORAL|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
224036078|NCT00809081|PROCEDURE|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
224036079|NCT00160381|DRUG|Asoprisnil|10mg Tablet, oral Daily for 12 months
224036080|NCT00160381|DRUG|Asoprisnil|25 mg Tablet, oral Daily for 12 months
224036081|NCT00160381|DRUG|Placebo|Tablet, oral Daily for 12 months
224036082|NCT00445068|DRUG|LBH589|
224036083|NCT05651750|DRUG|Montelukast|receiving 2 months treatment with Montelukast once a day
223422573|NCT04447352|DRUG|Cisplatin|intraoperative: 75mg/m² intraabdominal solution over 1 hour and 30 minutes
223422574|NCT05511532|OTHER|Orthopaedic treatment|"Female and male patients aged between 6 and 12 years are included in the study. Initially, the values of dorsiflexion of the tibio-fibular-talar joint and dorsiflexion of the first metatarsophalangeal joint will be measured to rule out hallux rigidus and ankle equinus, respectively.~Those patients who do not present hallux rigidus or equinus ankle, will be included in the study and will have their computerized foot pressures taken."
223563193|NCT02286804|DEVICE|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
223563194|NCT00118248|DRUG|tanespimycin|Given IV
223563195|NCT03832322|PROCEDURE|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
223563196|NCT03832322|PROCEDURE|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
223563197|NCT02574884|PROCEDURE|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
223422575|NCT06648070|PROCEDURE|Neuromuscular reeducation technique|"5 repetitions of neuromuscular reeducation technique i.e. deep pressure along muscles origin to insertion with active movement of that muscle with 10 seconds rest of each repetitions.~Control group will receive 3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds."
223422576|NCT06648070|PROCEDURE|Post Facilitation Stretch|3- 5 repetitions of Post Facilitation stretch to the tight muscles of UCS i.e. 20% maximal isometric contraction of the muscles to be stretched for 5-10 seconds followed by a rapid stretch ( through the new barrier) of 10 seconds. After stretch muscle is allowed to relax in mid range for 10 seconds.
223422577|NCT03975556|BEHAVIORAL|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
223422578|NCT03975556|BEHAVIORAL|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
223422579|NCT01558856|PROCEDURE|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
223422580|NCT01558856|PROCEDURE|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
223422581|NCT06244056|PROCEDURE|Stellate Ganglion Block|A stellate ganglion block is performed by a medical professional in a sterile setting. Firstly Position of patient: Semi-lateral decubitus position, with the neck turned contralateral. Using Probe of ultrasound: Linear 6-13 MHz to guide the needle to the stellate ganglion , The skin at the injection site is cleaned with an antiseptic solution to reduce the risk of infection. A local anesthetic is injected into the skin and deeper tissues to numb the area. Needle:25G 1.5 inch or 22G 3.5 inch is inserted through the skin and deeper tissues until it reaches the stellate ganglion.Once the needle is in the correct position, 3-5 mL of local anesthetic (0.25-0.5% bupivacaine) The procedure typically takes about 15-20 minutes.
223563198|NCT01255176|PROCEDURE|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
223563199|NCT02704975|DEVICE|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
223563200|NCT02704975|DEVICE|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
223739750|NCT01329302|PROCEDURE|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
224036084|NCT05651750|DRUG|Fluticasone Furoate|receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
223422582|NCT00972556|DRUG|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
223739751|NCT04493853|DRUG|Capivasertib|400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
224036085|NCT04335383|BIOLOGICAL|Isolation of anti-Pseudomonas antibodies from type B lymphocytes|Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.
224036086|NCT04829929|DEVICE|Omega™LAA Occluder implantation|Left Atrial Appendage closure for patients with non-valvular atrial fibrillation (NVAF) and high bleeding risk by Omega™LAA Occluder using Omega™ Delivery System
224036087|NCT00207805|PROCEDURE|autologous PBSC transplant|optimal timining of a second autologous transplant
224036088|NCT05826574|DRUG|Brensocatib|Oral tablets.
224036089|NCT05826574|DRUG|Rifampin|Oral capsules.
224036090|NCT05826574|DRUG|Esomeprazole|Oral capsules.
224036091|NCT02561533|OTHER|BRAF detection on fine needle aspiration biopsy (FNAB)|
224036092|NCT06029725|DEVICE|radiofrequency microneedling combined with 1927 nm thulium laser|"1. session: radiofrequency microneedling + 1927 nm thulium laser~2. session: 1927 nm thulium laser monotherapy~3. session: 1927 nm thulium laser monotherapy"
223422583|NCT00972556|DRUG|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
223422584|NCT01675570|DRUG|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
223422585|NCT01675570|DRUG|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
223422586|NCT00890084|DRUG|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
223422587|NCT01760967|DRUG|Dexmedetomidine|intervention to administer dexmedetomidine or not
223422588|NCT01388244|OTHER|Screening|Screening by risk factor assessment (FRAX) followed by DXA
223422589|NCT01388244|OTHER|Control|Observation by use of register data
223422590|NCT01891565|BEHAVIORAL|Feedback|
223422591|NCT03340220|DRUG|XPF-008|Capsule filled with XEN1101
223422592|NCT03340220|DRUG|Microcrystalline Cellulose|Placebo capsule
223422593|NCT03340220|DRUG|XPF-010|Capsule filled with XEN1101
223422594|NCT03340220|DRUG|Itraconazole 400mg|Oral
223422595|NCT05987904|DEVICE|LynxPatch|Measurements with the LynxPatch device are conducted.
223422596|NCT01323595|DRUG|Celecoxib|Celecoxib 200mg PO BID x 6 days
223422597|NCT01323595|DRUG|Sugar Pill|Sugar pill PO BID x 6 days
223422598|NCT06277635|DRUG|Silymarin|Silymarin is randomly assigned to the participants for 12 weeks during study.
223422599|NCT06277635|DRUG|Placebo|Placebo is randomly assigned to the participants for 12 weeks during study.
223422600|NCT03592537|DRUG|Fentanyl|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into three groups of 30 children
224036093|NCT06029725|DEVICE|radiofrequency microneedling monotherapy|1 session: radiofrequency microneedling monotherapy
224036094|NCT06841536|DRUG|Atorvastatin 80mg|"Daily intake of 80 mg of the approved drug Atorvastatin. Starting at dose 40 mg with 40 mg weekly increment reaching the maintenance dosage of 80 mg on week two, which is the approved maximum dosage of Atorvastatin. Participants who don't tolerate this fast up-titration may have prolonged tritation protocol (up to four weeks).~Under special circumstances, participants with intolerable side-effects may stay at a lower dose (40 mg/day).~The dosage and applied up-tritation is based on recommendations from trained cardiologists at the National Hospital of the Faroe Islands."
224137875|NCT02121756|DRUG|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
224137876|NCT01200615|BEHAVIORAL|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
223422601|NCT03592537|DRUG|Midazolam|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
223422602|NCT03592537|DRUG|Bupivacaine Hydrochloride|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care, or in data collection. Children will be randomly allocated into three groups of 30 children
223422603|NCT06623864|OTHER|meaningful activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
223422604|NCT06623864|OTHER|other activities|The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
223422605|NCT00482404|BEHAVIORAL|Romantic kissing|
223422606|NCT01760486|BEHAVIORAL|Shape Up Rhode Island|
223422607|NCT01760486|BEHAVIORAL|Shape Up Rhode Island + Professional Coach + Incentives|
223422608|NCT01760486|BEHAVIORAL|Shape Up Rhode Island + Peer Coach + Incentives|
223422609|NCT00616616|PROCEDURE|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
223422610|NCT05670041|BEHAVIORAL|Intensified follow-up|Early, intensified follow-up after discharge from TAVI-procedure.
223422611|NCT03796416|DRUG|Misoprostol|used at a rate of 25 mcg Q4hours for cervical ripening.
223422612|NCT02588716|DRUG|Terlipressin|Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
223422613|NCT02588716|DRUG|normal saline|Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
223422614|NCT02091596|DRUG|PluroGel N|Study Drug
223422615|NCT02091596|DRUG|PluroGel|PluroGel Vehicle Placebo Comparator
223422616|NCT04671381|BEHAVIORAL|Hearing Evaluation|Behavioral thresholds for pure tones will be conducted along with speech perception measures.
223422617|NCT04671381|DEVICE|Over-the-Counter Hearing Aid (OTC HA) Fitting and Orientation|Study participants will be fitted with binaural OTC HAs in addition to receiving information on how to use and care for their devices.
223422618|NCT04671381|BEHAVIORAL|Four Weeks of Aural Rehabilitation|Participants will receive four weeks of information sessions to help them adjust to their over-the-counter hearing aid and their hearing loss.
223422619|NCT04671381|DEVICE|Provision of Over-the-Counter Hearing Aids|Study participants will receive binaural OTC HAs. Participants will fit their OTC HAs based on manufacturer guidelines without the help of an audiologist.
223422620|NCT04432714|DRUG|Lenalidomide|Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
223422621|NCT04432714|DRUG|Rituximab|Rituximab 375 mg/m2，IV, d0
223422622|NCT04432714|DRUG|Etoposide|Etoposide 50 mg/m2/day CI24h d1-d4
223422623|NCT04432714|DRUG|Doxorubicin|Doxorubicin 10 mg/m2/day CI24h d1-d4
223422624|NCT04432714|DRUG|Vincristine|Vincristine 0.4mg/m2/day CI24h d1-d4
223422625|NCT04432714|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m2/day IV d5
223422626|NCT04432714|DRUG|Prednisone|Prednisone 60 mg/m2/bid oral or IV d1-d5
223422627|NCT03705650|DIAGNOSTIC_TEST|Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance, feedback and interpretation assistance to users during image acquisition. For this study, CMAs will use EchoGPS to perform point-of-care echocardiogram examinations.
224036095|NCT06841536|BEHAVIORAL|Exercise|Exercise will be performed as aerobic interval training sessions on cycling ergometers lasting \~45 min, four times weekly for 12 weeks. All exercise sessions will be supervised. Participants will wear HR monitor system during all sessions (Polar Electro Oy, Kempele, Finland) and the Borg 6-to-20 scale will also be used to assess the rate of perceived exertion during exercise sessions. A 4-week ramp-up phase will be applied, consisting of two sessions in weeks 1 and 2, three sessions in weeks 3 and 4 after which participants will complete 4 sessions a week from weeks 5 to 12.
223422628|NCT03016481|BEHAVIORAL|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
223422629|NCT03016481|BEHAVIORAL|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
223422630|NCT02331550|PROCEDURE|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
223739752|NCT04493853|OTHER|Placebo|matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
223739753|NCT04493853|DRUG|Abiraterone Acetate|Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
224036096|NCT06139185|OTHER|Data collection|Data collection
223422631|NCT02331550|PROCEDURE|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
223422632|NCT03886519|PROCEDURE|BRAP (Bevel/rotate/advance procedure)|Trichiasis surgery using the BRAP procedure
224036100|NCT06981962|OTHER|Pressure ulcer prevention program|Interventions will consist of proper positioning, frequent change of patients' posture to limit or decrease pressure over the skin, skincare, such as maintaining adequate hydration, keep skin clean, prevent excessive dryness of skin, prevent message over bony prominence, and control moisture.
223422633|NCT03886519|PROCEDURE|Trabut|Trichiasis surgery using the Trabut procedure
223739754|NCT05023746|DIAGNOSTIC_TEST|Genetron lung cancer panel|Follows the principle of synchronous blinding. The enrolled cases are coded, and the enrolled samples are detected with Genetron lung cancer panel and comparison methods. The detection results are compared, and the samples that are inconsistent with the detection results of similar products on the market are reviewed by the the Sanger sequencing method, when the site detection results compared with Sanger sequencing method are inconsistent, Sanger's detection results are recognized. The results were determined independently according to the cutoff values or interpretation requirements provided by each method, and relevant statistics were used to evaluate clinical application performance of Genetron lung cancer panel.
223739755|NCT05185258|DRUG|Enstilar|Topical foam
223739756|NCT05185258|DRUG|Placebo-vehicle|Topical foam
224036101|NCT06983496|BEHAVIORAL|Post-ICU Telehealth Follow-up|The post-ICU clinic follow-up will be conducted by a pharmacist via a telehealth visit. A collaborating physician (i.e. intensivist) will provide clinical support and oversight as needed. The appointments will be 30-60 minute telephone/video calls. Participants be assessed for PICS and recommended interventions to improve their care.
224137877|NCT02749877|BEHAVIORAL|Working Memory Training|(Training Details already described above)
223422634|NCT04157114|DRUG|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
223422635|NCT04157114|DRUG|Placebo|Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
223422636|NCT04157114|BEHAVIORAL|Standardized behavioral counseling|Subjects receive manually-guided counseling 1 time per week for a 6 week duration
223422637|NCT01232881|PROCEDURE|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
223739757|NCT06645873|DEVICE|Continuous glucose monitoring (CGM) device|All included study participants recieve a CGM sensor (Dexcom G7) to monitor blood glucose. The treatment team is blind for the CGM values; the gold standard for glucose control (POC interval measures) will be followed.
224036102|NCT01685190|RADIATION|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
224036103|NCT01685190|RADIATION|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
224036104|NCT03834038|DRUG|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
224036105|NCT06656338|OTHER|Higher HEI-2020 diet followed by lower HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
224137878|NCT02749877|BEHAVIORAL|Physical Training|(Training Details already described above)
224137879|NCT03120481|OTHER|no intervation|no intervention
224137880|NCT00154167|DRUG|NV-101 (phentolamine mesylate solution)|
224137881|NCT01322646|DEVICE|CarChipPro|On board driving monitor
223422638|NCT01232881|PROCEDURE|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
223422639|NCT01345981|DRUG|Lidocaine|dosage 20 mg and 40 mg
223422640|NCT02175134|OTHER|Blood and Ascites ELISPOT|
223422641|NCT06078358|OTHER|Resistance exercise training|Traditional linear periodization resistance training.
223422642|NCT01628796|OTHER|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
223422643|NCT04530058|DRUG|Metformin|Metformin 500 mg twice a day, administered orally or via gastric tube.
223422644|NCT04530058|DRUG|Placebos|Placebo twice a day, administered orally or via gastric tube.
223422645|NCT03701841|DRUG|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
223422646|NCT02050919|DRUG|Epirubicin Hydrochloride|Given IV
223422647|NCT02050919|RADIATION|External Beam Radiation Therapy|Undergo EBRT
223422648|NCT02050919|DRUG|Ifosfamide|Given IV
223422649|NCT02050919|OTHER|Laboratory Biomarker Analysis|Correlative studies
223422650|NCT02050919|DRUG|Sorafenib Tosylate|Given PO
223422651|NCT02050919|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical resection
223422652|NCT01435096|DRUG|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
223422653|NCT02691936|DEVICE|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
223422654|NCT02691936|DRUG|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
223422655|NCT06062602|DRUG|TAK-676|Intratumoral microdose injection by the CIVO device.
223422656|NCT06062602|DRUG|Carboplatin|Intratumoral microdose injection by the CIVO device.
223422657|NCT06062602|DRUG|5-FU|Intratumoral microdose injection by the CIVO device.
223422658|NCT06062602|DRUG|Paclitaxel|Intratumoral microdose injection by the CIVO device.
223422659|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin|Intratumoral microdose injection by the CIVO device.
223422660|NCT06062602|COMBINATION_PRODUCT|Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
223422661|NCT06062602|COMBINATION_PRODUCT|Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
223422662|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin + 5-FU|Intratumoral microdose injection by the CIVO device.
223739758|NCT01966965|DRUG|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
223422663|NCT06062602|COMBINATION_PRODUCT|TAK-676 + Carboplatin + Paclitaxel|Intratumoral microdose injection by the CIVO device.
223422664|NCT01878084|OTHER|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
223422665|NCT01878084|OTHER|empty extraction socket|Extraction socket will be left empty
223422666|NCT00749684|BIOLOGICAL|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
223422667|NCT06092827|BEHAVIORAL|Non weight-bearing physical activity program|12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
223422668|NCT00921102|DRUG|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
223422669|NCT00921102|DRUG|Morphine|200 µg of a 200 µg/ml solution, intrathecally
223422670|NCT00921102|DRUG|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
223422671|NCT00921102|DRUG|Atropine|"100 µg of a 1 mg/ml preservative-free solution~* intrathecally in group Intrathecal Atropine~* intravenously in group IV Atropine"
223422672|NCT03024684|DRUG|Atorvastatin|Atorvastatin 10mg daily
223422673|NCT03024684|DRUG|Placebo Oral Tablet|Placebo one tablet daily
223422674|NCT06631521|DRUG|Darolutamide|600 mg (two 300 mg tablets) taken orally twice daily.
223422675|NCT06631521|DRUG|Relugolix|A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.
223422676|NCT06631521|PROCEDURE|Radical Prostatectomy|Performed at least 48 hours and within 2 weeks after the completion of neoadjuvant therapy.
223422677|NCT03376308|DIAGNOSTIC_TEST|Pain Score|"Four poin scala 0=No Pain~1. mild~2. intermediate~3. severe"
223422678|NCT03376308|DIAGNOSTIC_TEST|Withdrawal movement score|"Withdrawal movements~1. no movement response~2. movement limited to the wrist~3. movement limited to the elbow/shoulder,~4. generalized movement response."
223422679|NCT03376308|DIAGNOSTIC_TEST|hemodynamic response|Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
223422680|NCT05970549|DEVICE|IRRAflow® Active Fluid Exchange System|"All patients in the prospective arm of the study who met the study criteria and consent will be enrolled in the IRRAflow with Active Fluid Exchange arm.~Insertion of the IRRaflow catheter will be performed by neurosurgical attendings and residents who are privileged to place external ventricular drains and who have be instructed on how to appropriately connect the inserted IRRAflow catheter to the system. The on-site IRRAflow instructor will be present and available at all time to assist with any issues or questions should they arise."
223422681|NCT05970549|DEVICE|Traditional extraventricular drain|The retrospective analysis will be performed on the last 60 traditional external ventricular drains.
223739759|NCT01966965|DRUG|NEDAX|AS SPECIFIED AT THE LEAFLET
223739760|NCT06096116|DRUG|Human plasma derived antithrombin|A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma
223739761|NCT06096116|DRUG|Placebo|Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ
224137882|NCT01322646|BEHAVIORAL|Driver's Education|10 Session License to Learn Program.
223422682|NCT05970549|PROCEDURE|Non-contrast head CTs|Non-contrast head CTs will be performed at least every 48 hours to document effectiveness. This frequency is standard, if not more frequent as necessary, for patients with external ventricular drainage and intraventricular hemorrhage. Scans are routinely obtained at this frequency to evaluate, for example: evacuation of hemorrhage, admission pathology, post-placement of catheters, any change in neurological exam, or after elevations in intracranial pressure. With these common CT scans we will be able to assess the efficacy of the IRRAflow catheter on the specified parameters. These scans are routinely performed due to this pathology and as such are covered as a necessity of the hospitalization by the insurance companies. MRI may be used in place of a CT scan if medically indicated as determined by the neurosurgical attending or neurocritical care attending according to standard of care for treatment of the neurological pathology.
223422683|NCT01328106|DRUG|GSK1120212|Repeating oral dose
223422684|NCT02039518|DRUG|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
223422685|NCT02039518|OTHER|observation group|observation group
223422686|NCT04000542|OTHER|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
223422687|NCT04725942|DRUG|Oral Posaconazole tablets|Posaconazole tablets (300 mg Q12h D1) taken orally on the day of transplantation, and followed by 300mg Qd, until 90 days after transplantation.
223422688|NCT02103959|DRUG|CMX-2043|Slow bolus IV administration of CMX-2043
223422689|NCT02103959|DRUG|Placebo comparator|Slow bolus IV administration of PBS
223422690|NCT01620775|OTHER|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
223422691|NCT01620775|OTHER|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
223422692|NCT02647970|BEHAVIORAL|PUFA-Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
223422693|NCT02647970|BEHAVIORAL|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
223422694|NCT02643849|DEVICE|The Spanner Temporary Prostatic Stent|
223422695|NCT04888442|BIOLOGICAL|pCAR-19B cells|Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223422696|NCT02993952|DEVICE|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
224036106|NCT06656338|OTHER|Lower HEI-2020 diet followed by higher HEI-2020 diet|Controlled feeding study of HEI-2020 diet. Crossover feeding study of two, 7-day feeding periods with higher HEI-2020 and lower HEI-2020 diets completed in random order.
223422697|NCT02993952|DEVICE|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
223422698|NCT02437500|BIOLOGICAL|SER-109|SER-109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
223422699|NCT00372606|BEHAVIORAL|Online MiDieta Diet and Weight Management Program for Hispanics|
223422700|NCT01645878|BEHAVIORAL|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
223422701|NCT01645878|BEHAVIORAL|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
223422702|NCT01645878|BEHAVIORAL|routin breast feeding education|
223422703|NCT02319174|DEVICE|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
223739762|NCT03625921|BEHAVIORAL|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
223739763|NCT03625921|BEHAVIORAL|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
223739764|NCT03914794|DRUG|Pemigatinib|Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
224036107|NCT06629077|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and a simulated postural change task.
224036108|NCT06629077|DRUG|Prazosin|A dose of prazosin will be administered based on body weight.
224036109|NCT06629077|DRUG|Placebo|Oral placebo
224036110|NCT06651970|DRUG|Acalabrutinib|Acalabrutinib Monotherapy
224036111|NCT06651970|OTHER|Investigator's choice of treatment|control arm treatment type will be defined by the PI prior to randomisation
224036112|NCT06984783|COMBINATION_PRODUCT|The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band.|The new type of filtering glasses can efficiently filter out narrow-band high-energy blue and green light.
224036113|NCT06984783|COMBINATION_PRODUCT|The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band.|The new type of filtering glasses can efficiently filter out narrow-band high-energy blue and green light.
223422704|NCT06293989|DRUG|Diazepam 5mg|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam 5 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
223422705|NCT06293989|DRUG|Diazepam 10 mg|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam10 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
223422706|NCT06293989|DRUG|Placebo|For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.
223422707|NCT04798989|DRUG|CY6463|CY6463 Oral Tablet
224036114|NCT06652113|DRUG|hydroxychloroquine and levothyroxine|Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
224036115|NCT06652113|DRUG|Levothyroxine|Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.
223422708|NCT04798989|DRUG|Placebo|Placebo Oral Tablet
223422709|NCT05219292|OTHER|Active music therapy|"Active music therapy is not a musical learning process. The restrictive character of classical respiratory rehabilitation will be alleviated by the playful aspect and the pleasure generated by the sessions, which will facilitate the commitment of the patients in their post-transplant respiratory rehabilitation.~The recorder was chosen among other wind instruments for several reasons:~* Its use is simple,~* It acts as an oscillating exhalation resistance device that generates a positive expiratory pressure (auto-PEP) produced by this wind instrument allows to obtain conditions similar to the treatment performed by a flutter (classical respiratory rehabilitation), a pressure on the expiratory flow with the obtaining of an oscillating effect during the trills, an increase of the respiratory capacities,~* The characteristics of the sound it produces (duration, intensity, timbre and frequency) will generate auditory feedback allowing patients to become aware of their breathing patterns."
223422710|NCT05219292|OTHER|Questionnaires|"We chose the HAD (Hospital Anxiety and Depression Scale) to assess anxiety and depression. This test is a reference test, often used in studies of transplant patients. The results obtained in previous studies allowed us to create our hypotheses.~To measure pain we chose the visual analogue scale (VAS). This reference test is often used in pain studies. It has the advantage of being simple to perform and easy to understand.~Quality of life will be assessed using the SF-12 (Short Form 12 Health Survey Questionary). We consider it to be simple and easy for patients to understand."
223422711|NCT05748392|DEVICE|Wound and per-wound assessments While using Device|3D imaging and wound and per-wound skin characteristics will be conducted initially, at dressing changes and at end of treatment/study.
223563201|NCT01997606|OTHER|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
223563202|NCT01997606|OTHER|placebo|
224036116|NCT04067375|OTHER|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
224036117|NCT06979453|DRUG|Deucravacitinib|Specified dose on specified days
224036118|NCT06979453|OTHER|Placebo|Specified dose on specified days
223563203|NCT04445207|BIOLOGICAL|Convalescent Plasma|One to two 200 mL units of Convalescent plasma per infusion, up to 6 total units within a 3-week period.
223563204|NCT03540589|DEVICE|Buzzy specific vibration device|It is a device that produces vibration
224036119|NCT03591302|BIOLOGICAL|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from living donor.
224036120|NCT03591302|RADIATION|Total Lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
224036121|NCT06986798|OTHER|Local standard medical care|No investigational study interventions will be administered in this study. Participants will undergo therapeutic and diagnostic procedures as per local standard medical care and as deemed appropriate by the treating physicians. Collection of blood and of available clinical data are the only activities performed in addition.
224036122|NCT04059016|OTHER|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
223422712|NCT02556294|BEHAVIORAL|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
223563205|NCT03540589|BEHAVIORAL|Distraction|The distraction will be obtained through tablet with videos
223563206|NCT03652363|DRUG|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
223563207|NCT04252313|OTHER|Music|Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
223563208|NCT03734640|OTHER|Low-intensity monitoring strategy|Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment
223563209|NCT03734640|OTHER|Guideline recommended standard monitoring|Post-tpa patients will be monitored in the usual care monitoring environment
223563210|NCT05394597|OTHER|Repellent lotion|lotion of the repellent active ingredient IR3535
223739765|NCT06151223|OTHER|Bio-specimen Collection: Blood|At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.
224137883|NCT01322646|BEHAVIORAL|STEER Program|8-session behavioral parent training and teen social skills/communication training program
223422713|NCT02556294|BEHAVIORAL|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
223422714|NCT01913431|DRUG|Baracle Tab.®|
223422715|NCT01913431|DRUG|Baraclude Tab.®|
223422716|NCT02892422|DRUG|Lu AF35700|"Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study"
223422717|NCT02544425|DRUG|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
223422718|NCT02544425|DRUG|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
223422719|NCT02544425|DRUG|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
223422720|NCT02544425|DRUG|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
223422721|NCT02544425|DRUG|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
223422722|NCT02544425|DRUG|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
223422723|NCT05521334|DEVICE|micropulse transscleral cyclophotocoagulation|glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
223563211|NCT05394597|OTHER|Repellent Wipe|wipe of the repellent active ingredient IR3535
223563212|NCT05040503|BIOLOGICAL|Blood sampling at inclusion|"Sampling of 2 tubes of 3 ml:~* patient: H0: 0-6h post-admission~* healthy volunteer: at inclusion"
223563213|NCT05040503|BIOLOGICAL|Blood sampling at 24 hours|Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)
223563214|NCT05040503|OTHER|Data collection|clinical and biological medical data for patients and general health data for healthy volunteers
223563215|NCT06164652|DEVICE|walking with Ceriter Stride One|Subjects walk on the GAITRite with the CSO insole in their shoes.
224137884|NCT01322646|OTHER|Driving Simulator Practice|Practice Driving on a driving simulator
224137885|NCT00283530|PROCEDURE|Tumor biopsy|
224137886|NCT02047630|DRUG|Generic latanoprost|
224137887|NCT02047630|DRUG|Brand-name latanoprost|
224137888|NCT02049801|DRUG|MEK inhibitor MEK162|Given PO
224137889|NCT02049801|DRUG|idarubicin|Given IV
224137890|NCT02049801|DRUG|cytarabine|Given IV
224137891|NCT02049801|OTHER|pharmacological study|Correlative studies
224137892|NCT02049801|OTHER|laboratory biomarker analysis|Correlative studies
223422724|NCT01064258|DEVICE|CPAP|CPAP at 4 cm H2O
224036126|NCT06661122|DRUG|Darolutamide (BAY1841788) + docetaxel + ADT|Follow clinical practice/administration. ADT=androgen deprivation therapy.
223422725|NCT01064258|DEVICE|autoCPAP|autoCPAP working between 4 and 15 cm H2O
223422726|NCT04058535|BIOLOGICAL|Eylea|Aflibercept
223422727|NCT04058535|BIOLOGICAL|ALT-L9|Aflibercept biosimilar
223422728|NCT03676296|DRUG|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
223422729|NCT03676296|DRUG|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
223422730|NCT04033341|DRUG|LY3214996|Administered orally
223422731|NCT04033341|DRUG|[14C]-LY3214996|Administered orally
223422732|NCT05890352|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood
223422733|NCT05890352|PROCEDURE|Computed Tomography|Undergo PET/CT and CT
223422734|NCT05890352|DRUG|Lenalidomide|Given PO
223422735|NCT05890352|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223422736|NCT05890352|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223422737|NCT05890352|OTHER|Quality-of-Life Assessment|Ancillary studies
223422738|NCT05890352|OTHER|Questionnaire Administration|Ancillary studies
223422739|NCT05890352|BIOLOGICAL|Tafasitamab|Given IV
223422740|NCT05890352|DRUG|Tazemetostat|Given PO
223422741|NCT05890352|DRUG|Zanubrutinib|Given PO
223422742|NCT05081700|DRUG|All patients in the study will be treated with ocrelizumab|300 mg of OCR IV infusion will be given on Day 0 followed by a second dose of 300 mg OCR 14 days later ± 2 days, and then 600 mg of OCR as a single infusion will be given every 24 weeks thereafter per standard medical care.
223422743|NCT00032188|BIOLOGICAL|aldesleukin|Given subcutaneously
223422744|NCT00032188|DRUG|bryostatin 1|Given IV
223739766|NCT06151223|OTHER|Bio-specimen Collection: Pancreatic Juice|This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.
224036127|NCT01115790|DRUG|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
223422745|NCT00032188|OTHER|laboratory biomarker analysis|Correlative studies
223422746|NCT03065088|BEHAVIORAL|aLIFE|The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
223422747|NCT03065088|BEHAVIORAL|eLIFE|The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
224036128|NCT00780754|DRUG|dutasteride|0.5mg
223422748|NCT03065088|BEHAVIORAL|control|The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
223422749|NCT01023256|DRUG|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
223422750|NCT01023256|DRUG|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
223422751|NCT01023256|DRUG|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
223422752|NCT04018456|OTHER|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
223422753|NCT04018456|OTHER|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
223422754|NCT03155178|DRUG|3M CHG/IPA Prep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
223422755|NCT03155178|DRUG|ChloraPrep|Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
223422756|NCT04760509|OTHER|In this study, the short-term follow-up of patients with neural tube defects in the neonatal intensive care unit will be evaluated retrospectively.|there is no intervention. It is retrospective study.
223422757|NCT03200756|BEHAVIORAL|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
223422758|NCT03200756|BEHAVIORAL|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
223422759|NCT03241628|DEVICE|Dressing Glove|Viscose dressing glove
223422760|NCT01077609|DRUG|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
223422761|NCT01077609|DRUG|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
223422762|NCT00330109|PROCEDURE|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
223422763|NCT00330109|PROCEDURE|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
223422764|NCT00330109|PROCEDURE|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
223422765|NCT03089697|BIOLOGICAL|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
223422766|NCT03089697|OTHER|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
223422767|NCT05565040|PROCEDURE|Circumcision in concealed penis|comparison of three surgical techniques (as described in the arms) in the management of concealed penis in pediatrics
223422768|NCT03655912|DEVICE|Red/green glasses|The use of red/green glasses and electronic devices for two hours a day during 4 months.
223422769|NCT03655912|DEVICE|Electronic Tablet|The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
223422770|NCT03655912|DEVICE|Eye patch|The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
223422771|NCT01128101|DRUG|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
223422772|NCT05209126|DIETARY_SUPPLEMENT|Beetroot juice|Acute effects of beetroot juice ingestion on neuromuscular performance in female rugby players
223422773|NCT06644469|DEVICE|Dynatronics VF5 Model vibration platform|The Dynatronics VF5 Model vibration platform is a specialized therapeutic device designed for rehabilitation and wellness applications. Utilizing advanced vibration technology, it provides whole-body vibration therapy that can enhance muscle strength, improve flexibility, and promote overall physical well-being. The platform features adjustable frequency and amplitude settings, allowing customization based on individual needs. Its user-friendly interface and robust, durable design make it suitable for both clinical and mobile therapy settings. Additionally, the compact and portable nature of the VF5 facilitates easy storage and transport, while safety features such as non-slip surfaces ensure user protection.
224036129|NCT00780754|PROCEDURE|prostate biopsy|prostate biopsy
224036130|NCT06817382|GENETIC|INS1201|Suspension for IT injection.
224036131|NCT06605391|BEHAVIORAL|Caregiving While Black-LIVE|Caregiving while Black-LIVE is a psychoeducation program that aims to intensify the development of caregiver mastery by integrating the online learning assets of the fully asynchronous Caregiving while Black program with synchronous, group-based opportunities for interactivity and active learning. The Caregiving while Black course includes topics of navigating the healthcare system, managing home life, and caregiver self-care. Once enrolled in the course, participants will be provided instructions for accessing the weekly sessions and course online, and supplemental course materials will be mailed to them. The Canvas platform enables the research team to monitor each individual's movement in the cohort through the asynchronous part of the course. Nudges and reminders to view these materials are sent twice a week via text or email with participant's consent. Synchronous sessions are conducted on a videoconferencing platform.
224036132|NCT03144804|DRUG|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
224036133|NCT02100397|BIOLOGICAL|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
224137893|NCT03627858|DRUG|beclomethasone / formoterol / glycopyrronium|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
224137894|NCT00204334|DRUG|darbopoeitin|
224137895|NCT04813536|OTHER|the Standard Shiftwork Index questionnaire|"1. Biographical information: This includes personal data (e.g., age, sex, marital status, and domestic situations), shift details (e.g., shift start and end times), organization of shiftwork, and general job satisfaction~2. Sleep and fatigue: Measures the effect of shiftwork on perceived sleep quality and quantity and fatigue"
223422774|NCT06644469|DEVICE|Placebo Dynatronics VF5 Model vibration platform|Placebo intensity with vertical vibration of 0.2 mm
223422775|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
223422776|NCT02768116|PROCEDURE|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
223422777|NCT06653608|DRUG|Nano-reinforced calcium hydroxide medicament|Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)
223422778|NCT06653608|DRUG|Calcium hydroxide without nanoparicles|Group B ( Calcium hydroxide medicament without nanoparticles)
223422779|NCT05484349|DRUG|Tizanidine Hydrochloride|Tizanidine Hydrochloride 1 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
224036134|NCT06514326|BEHAVIORAL|DPT-TP|"This intervention includes all the ingredients of DPT-STD, but with additional features that correspond to the conceptual model of therapeutic persuasiveness. Each theme in the program comprises a learning phase followed by a 1-2 week focusing phase.~Accordingly, the program utilizes the following features:~1. Call to action: Parents receive timely triggers via text messages that are related to the specific goals and therapeutic activities of the modules they have completed.~2. Monitoring and ongoing feedback of user state: Specific practices currently taught are documented within the system through a brief daily report, on which parents receive feedback.~3. Adaptation to user state: Parents' reports on their activities are used to acknowledge their success and to suggest additional actions based on the specific goals reported by parents. Effort related to desired therapeutic activities is adapted based on graded tasks."
224036135|NCT06514326|BEHAVIORAL|DPT-STD|"This intervention is similar in its features to other programs that deliver DPT, and is suitable for use on computers or on mobile devices. An icon is positioned on the mobile device home screen in order to enable quick access to the program. The DPT-STD comprises seven 10- to 25-minute modules, each corresponding to one of the themes mentioned above. Each module's content includes videos and texts guiding the parent through the training process, and interactive features, such as multiple-choice questions with direct feedback. Additional features embedded within the platform include downloadable materials and a questions and answers section that contains frequently asked questions."
224036136|NCT03278730|DRUG|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
223422780|NCT05484349|DRUG|Tizanidine Hydrochloride|Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
223422781|NCT05484349|DRUG|Tizanidine Hydrochloride Placebo|Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
223422782|NCT04323306|DRUG|MMV688533|Investigational medicinal product
223739767|NCT06151223|DIAGNOSTIC_TEST|MRI|"A research MRI with contrast that includes a Magnetic Resonance Cholangiopancreatography (MRCP) will be offered to patients in the Tier 2 cohort at baseline and at 3-year intervals if not done as standard of care. Gadolinium based intravascular contrast will be administered for this procedure. Sedation for claustrophobia/anxiety per clinical protocol will be an option if the patients requested. Subject would be notified of any concerning results. A safety questionnaire will be completed by the study team before ordering the MRI.~Clinically indicated MRIs for the TIER 1 participants will be used and collected as part of the registry.~If a clinical MRI/MRCP has been performed between 0 to 3 months before obtaining consent, the prior clinical MRI/MRCP could be used to obtain baseline imaging data."
223739768|NCT03282266|PROCEDURE|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
224137896|NCT04813536|OTHER|complete blood picture|5ml blood to estimate changes of total leucocytic count, Hemoglobin, eosinophilic, monocyte
223422783|NCT06411600|DRUG|Encorafenib|Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.
223563216|NCT03482648|DRUG|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
223563217|NCT03482648|DRUG|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
223563218|NCT03482648|DRUG|Placebo|Placebo matched to BBT-401-1S, oral capsule
223422784|NCT06411600|DRUG|Cetuximab|Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².
223563219|NCT02921217|DIETARY_SUPPLEMENT|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
223739769|NCT03282266|PROCEDURE|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
223422785|NCT06411600|DRUG|Bevacizumab|Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
223422786|NCT00707278|RADIATION|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
223739770|NCT05511792|PROCEDURE|TAVR for BAV Using Down Sizing with the Evolut Pro platform|Down sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
223739771|NCT05511792|PROCEDURE|TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform|Traditional sizing strategy in Type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement with self-expanding valves
223422787|NCT00707278|DRUG|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
223422788|NCT00707278|DRUG|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
223563220|NCT02921217|DIETARY_SUPPLEMENT|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
223563221|NCT02921217|DIETARY_SUPPLEMENT|Control|Placebo: 300 mg maltodextrin.
223563222|NCT03992716|DRUG|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
223563223|NCT03992716|DRUG|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
223563224|NCT04867720|DRUG|Everolimus|\- Oral intake, BID - After first dose 1mg(total 2mg daily), check the blood concentration of everolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8mg/mL.
223563225|NCT00695916|PROCEDURE|Breast MRI|
223563226|NCT06552949|PROCEDURE|Emergent laparoscopic cholecystectomy guided by ICG cholangiography (ELC-ICGC)|Emergent conventional laparoscopic cholecystectomy
223422789|NCT06043778|BEHAVIORAL|Community care for People with Schizophrenia in India (COPSI)|This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
223422790|NCT06043778|BEHAVIORAL|mindLAMP Mobile Application|Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
224036137|NCT03278730|DRUG|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
224036138|NCT06616324|DEVICE|Virtual Reality|Participants in the intervention group will undergo ESWL according to standard treatment but with the addition of Virtual Reality and ANC-headphones as a supplement.
224036139|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
224036140|NCT01458223|DRUG|Antibiotic|Ancef or Vancomycin
224036141|NCT01786187|BEHAVIORAL|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
224036142|NCT01786187|OTHER|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
224036143|NCT07013708|DEVICE|Laser|High frequency laser device
224036144|NCT07013708|OTHER|Placebo|Same device but without pressing the ON button
224036145|NCT07021092|OTHER|Interventions will be developed in aim 2 of the study.|Person-centred package that connects patients to service delivery, builds rapports and improves engagement in care leading to sustained viral load suppressions
223422791|NCT06523881|PROCEDURE|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey)|Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) is a medication used during anesthesia. It is administered by inhalation with an anesthesia device.
223422792|NCT06523881|PROCEDURE|Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey)|Propofol is a drug used during anesthesia. It is administered intravenously using an infusion pump during surgical procedures.
223422793|NCT05787535|DRUG|Fludarabine + Cyclophosphamide|Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
223422794|NCT05787535|BIOLOGICAL|HRYZ-T101 TCR-T Cell|On day 1, the TCR-T cells will be administered one time.
223422795|NCT06623708|DEVICE|SMARTCLOTH|The intervention consists of using SMARTCLOTH. This device makes it possible to monitor dietary intake throughout the day and record it in a database that, through a website, allows to track it. SMARTCLOTH is a digital tablecloth consisting of a scale, several buttons and a screen. The device allows weighing the food to be consumed and recording its nutritional value (macronutrients in grams, macronutrient servings and kilocalories). The latter is achieved because SMARTCLOTH allows the patient to select to which food group the food being weighed belongs, increasing the accuracy of the nutritional estimation.
223422796|NCT04660500|OTHER|PD Drivers Using AV Technologies On-road|All drives will include events to assess the impact of in-vehicle information systems (IVIS) and advanced driver assistance systems (ADAS) on the driving performance (driving errors) of drivers with PD. For IVIS the investigators will include options to assess errors with lane maintenance (with and without the lane departure warning system) and signaling (with and without blind spot detection). For ADAS the investigators will include conditions to assess errors in speeding (with and without adaptive cruise control) and lane exceedances (with and without lane keeping assist).
223422797|NCT01729000|OTHER|Gloves|All staff must wear gloves for subjects that are in the experimental group.
224036146|NCT07019025|OTHER|Therapeutic patient education on the use of a insulin bolus calculator app|Therapeutic patient education on the use of a insulin bolus calculator app
224036147|NCT07020377|DRUG|Dapagliflozin (DAPA)|dapagliflozin 10mg tab once daily for NAFLD patient
223422798|NCT03207542|DRUG|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
223422799|NCT04346901|DRUG|Thiamazol|All new hyperthyroid with melasma patients were recruited and their mMASI were calculated All subjects were given thiamazole by Internist based on their clinical hyperthyroidism After 3 months of taking hyperthyroid drugs (thiamazole), mMASI were recalculated and compared
224036148|NCT07020377|DRUG|Placebo|placebo
224036149|NCT07020377|OTHER|Negative control|Baseline sample serum without either drug or placebo
224036150|NCT07020949|DRUG|THDBH120 injection|Participants received THDBH120 by subcutaneous injection.
224036151|NCT07020949|DRUG|Placebo of THDBH120 injection|Participants received placebo by subcutaneous injection.
224036152|NCT07021183|BEHAVIORAL|Sleep Course|The Sleep Course previously developed and evaluated in Australia will be delivered to clients meeting participation criteria tailored to PSP. The Sleep Course has been slightly adapted for PSP by including relevant statistics and literature pertaining to sleep disturbance in PSP. The Sleep Course has four lessons and includes optional therapist support for up to 8 - 12 weeks. Should clients request support, clients will be contacted by their therapist by secure emails on their designated check-in dates. The therapist also reviews client progress in the Course and emails clients on a designated check in date. Sometimes the therapist will call the client. Phone calls are typically made if a client is not logging in or if the therapist feels that a phone call would be a helpful way to provide support.
224036153|NCT06901895|COMBINATION_PRODUCT|Hylorunic acid|Hylorunic acid (hylo) eye drop is prescribed and check the curative effect after phacoemulsification after 2nd and 4th week.
224036154|NCT06901895|DIAGNOSTIC_TEST|Lipid coated carbomer gel|Lipid coated carbomer gel (visole)is prescribed and check yhe curative effect after phacoemulsification in diabetic patients post operatively in 2nd and 4th week.
223563227|NCT05764005|BEHAVIORAL|web-based tool (MAP- Management of Active surveillance in Prostate Cancer)|A web-based tool with modules on active surveillance education, team based active surveillance care delivery and the role of the PCP, and self-management for cancer anxiety and worry. {may need more detail}
223563228|NCT05764005|BEHAVIORAL|MUSIC website|Standard of care educational materials {add more detail}
223563229|NCT04974346|RADIATION|Paraaortic prophylactic irradiation and pelvic definitive concurrent chemoradiation|The para-aortic area, from left renal vein level to abdominal aorta bifurcation level，will be prophylactic irradiation. The other intervention is the same as control arm.
223563230|NCT04974346|RADIATION|Pelvic definitive concurrent chemoradiation|Pelvic definitive concurrent chemoradiation, including external beam radiotherapy, concurrent chemotherapy and brachytherapy.
223563231|NCT00797264|DRUG|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
223563232|NCT00797264|DRUG|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
224036155|NCT04091451|BIOLOGICAL|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of HZ/su vaccine were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
224036156|NCT04091451|DRUG|Placebo|2 doses of Placebo were administered intramuscularly according to a 0,2 months vaccination schedule, at Day 1 and Month 2.
223739772|NCT05301998|OTHER|Skin and thickness measurement/breast MRI|"Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital"
223422800|NCT06313086|DRUG|DP303c|intravenous injection
223422801|NCT06313086|DRUG|trastuzumab emtansine|intravenous injection
223422802|NCT03785912|BEHAVIORAL|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
223422803|NCT00834639|DRUG|divalproex sodium|delayed-release 500 mg tablet
223422804|NCT00834639|DRUG|Depakote®|delayed-release 500 mg tablet
223422805|NCT01406145|DRUG|ASP0777|oral tablet
223563233|NCT00797264|DRUG|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
224036157|NCT06334302|OTHER|"Omega Galil Hazelnut Chocolate Spread O'Sweet Spread"|Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
223563234|NCT00491270|DEVICE|VS Sense|An applicator to diagnose pH increase above 5.2
223739773|NCT04830202|DRUG|Telisotuzumab vedotin|Intravenous Infusion
224036158|NCT06334302|OTHER|Active Control-Nutella hazelnut cocoa spread|Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
224036159|NCT06733792|BEHAVIORAL|CBT-based intervention|"* 1st week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health consequences, motives for cannabis use reduction/quitting, psychoeducation concerning withdrawal symptomatology, therapist's recommendation (progressive reduction of cannabis use).~* 2nd week: Daily self-report on cannabis and tobacco use, myths regarding cannabis use and its health and behavioral consequences, identification of triggers, alternatives to cannabis use, therapist's recommendation (progressive reduction of cannabis use).~* 3rd week: Daily self-report on cannabis and tobacco use benefits from quitting cannabis, behavioral activation, diaphragmatic breathing, training in social abilities, strategies to prevent smoking, therapist's recommendation (progressive reduction of cannabis use).~* 4th week: Daily self-report on cannabis and tobacco use (i.e., nº of joints/cigarettes), high-risk situations for relapse, lapse vs. relapse, coping strategies, relapse prevention plan."
224036160|NCT06733792|BEHAVIORAL|Self-help guide|Psychoeducation on cannabis.
223563235|NCT03551405|RADIATION|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
223422806|NCT01406145|DRUG|Placebo|oral tablet
223422807|NCT05129137|DRUG|nefopam hydrochloride 30mg X2|nefopam hydrochloride 30mg X2
223422808|NCT05129137|DRUG|paracetamol 500 mg X2|paracetamol 500 mg X2
223422809|NCT05129137|DRUG|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2|Combination Product: nefopam hydrochloride 30mg / paracetamol 500mg X2
223422810|NCT03367546|PROCEDURE|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
223422811|NCT01684982|DEVICE|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
223422812|NCT01684982|DEVICE|sirolimus eluting stent|control arm of a comparison between drug eluting stents
223422813|NCT04429204|PROCEDURE|Biospecimen Collection|Undergo collection of tissue
223422814|NCT04429204|PROCEDURE|Cryosurgery|Undergo cryoablation
224036161|NCT06902064|DEVICE|Transcranial temporal interference stimulation|Transcranial temporal interference stimulation (tTIS) is a novel neurostimulation technique that utilizes two or more electric fields of specific frequencies to modulate the oscillations of neurons at the desired spatial location in the brain. The physics of tTIS offers the advantage of non-invasively regulating deep brain structures and minimally stimulating the overlying cortex outside the selected target.
223422815|NCT06621550|OTHER|High Intensity Interval Training|Participants will receive a single session of HIIT, which last for 19 minutes in duration. During the HIIT session, participants will complete 2 minutes stretching warm-up exercise, followed by a video of exercises which will be projected on the screen to facilitate the participants to follow. The exercise in the video involves various combinations of aerobic and core resistance exercise such as squat jump, jump lunge, push up, burpee, mountain climber etc. The exercise involved bodyweight or minimal basic equipment only, the workout to rest ratio is 45 secs: 15 secs. Participants' heart rate will be kept surveillance and to maintain their respective heart rate attained 85% of aged predicted maximal heart rate during the workout period.
223422816|NCT05093530|DRUG|Neumifil|Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
223422817|NCT05093530|DRUG|Placebo|Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
223422818|NCT03374930|PROCEDURE|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
223422819|NCT06648941|PROCEDURE|Muscle release|supraspinatus muscle release
223422820|NCT06623916|DEVICE|Endometrial Cancer Survivors|strain sonoelastograghy method has not been studied before in endometrial cancer as a prognostic factor. we compared well known pathologic prognostic factors with elastographic methods.
223422821|NCT02317835|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
223422822|NCT05877417|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine supplementation for 8 weeks, 5g daily. A 5 day loading phase will be implemented with 20g daily for 5 days.
223422823|NCT05877417|DEVICE|Blood Flow Restriction|Blood Flow Restriction Cuffs applied during exercise
223422824|NCT05877417|OTHER|Exercise|Participants will exercise
223422825|NCT06619548|OTHER|Auricular magnet with a magnetic strength of 1800 Gauss|Auricular magnets with a magnetic strength of 1800 Gauss are used as the experimental group.
224036162|NCT06902064|DEVICE|sham tTIS|"The sham tTIS is enabled by checking the Pseudo-Stimulation option on the screen. After the rising phase, the current will drop directly to 0mA, imitating the sensation of a real stimulation."
224036163|NCT06903143|BEHAVIORAL|Screening, brief intervention, and referral to treatment (SBIRT)|The intervention will consist of a 30 minute alcohol brief intervention based on CETA' substance use reduction element; if warranted, referral will be made for the full CETA intervention, which consists of 6-12 weekly cognitive behavioral therapy-based sessions.
224036164|NCT07179367|OTHER|Escape Room-Based Teaching Method on Patient Safety|Intervention Description: This intervention is a patient safety-themed escape room simulation specifically designed for nursing students. The activity consists of three phases structured in accordance with INACSL standards: pre-briefing, escape room simulation, and post-briefing assessment. Working in small groups, students solve knowledge- and skill-based patient safety tasks in three different rooms (patient safety, mother-baby room, and adult intensive care unit). Correct answers ensure progress, while post-briefing assessment using the PEARLS method supports reflection and learning. Unlike traditional teaching, this innovative method emphasizes teamwork, active participation, and experiential learning to increase self-efficacy and satisfaction with patient safety practices.
223422826|NCT06619548|OTHER|Auricular magnet with no magnetic strength|Auricular magnets with no magnetic strength are used as placebo control.
223422827|NCT04979195|OTHER|Patients with stable normal kidney function|Covid-19 patients with stable kidney function will represent group 1.
223422828|NCT04979195|OTHER|Patients with unstable kidney function|Covid-19 patients with unstable kidney function will represent group 2.
223422829|NCT01136889|OTHER|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
223422830|NCT01609439|DRUG|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
223563236|NCT04633070|BEHAVIORAL|Gamification|Gamification (including, but not limited to a ranking system, badges and achievements, points, social media interaction, and leveling up) within mobile and web-based applications (also referred to as 'apps') for lifestyle modification (diet, physical activity, smoking cessation etc).
224036165|NCT07182019|BEHAVIORAL|Connecting Today|Connecting today is a facilitated remote visiting program for people living with moderate to severe dementia in care homes. The program offers residents up to 60 minutes of scheduled contact with a family member, friend or volunteer by video call. An onsite facilitator supports the video calls which are delivered via ipad/zoom.
224037853|NCT05506072|OTHER|Standard Physical Thearapy|"Participants will be randomized into their assigned group of receiving standard therapy without BFR by a blinded therapist within the study using a computer generated randomization formula Participants will then visit the clinic for study testing at six weeks, 12 weeks, and six months after their surgery. During each of these visits, they will be asked to complete a survey, and then their shoulder strength and flexibility will be measured. Each study visit will last approximately 30 minutes. Participants will also attend 12-18 shoulder rehabilitation sessions in the clinic over six weeks from the six week to 12 week mark (about two to three sessions per week). Each rehabilitation session will last approximately 30 minutes and consist of standard rehabilitation exercises without BFR.~Between the 12-week follow-up and 6-month follow-up, participants will receive standard post-surgical rehabilitation for their specific shoulder surgery without Blood Flow Restriction training."
223563237|NCT06325241|OTHER|No intervention|There is no intervention. This is an observational study.
223563238|NCT04176874|PROCEDURE|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
223563239|NCT03069248|DRUG|Rituximab|
223563240|NCT03069248|DRUG|Alpha Interferon|
224036166|NCT07181447|DIAGNOSTIC_TEST|Pelvic Floor Muscle Assessment by Near-Infrared Spectroscopy|This study will develop and test an instrument to establish a normal range for near infrared spectroscopy (NIRS) optical changes associate with pelvic floor exercise in adult women based on the test-to test (intra-day) reliability of oxygen kinetics related to contraction of the pelvic floor muscle. We will establish the relationship between the quantitative NIRS data, the condition of Myofascial pelvic musculature and the symptomatology of MPP and related comorbidities. We will also evaluate prospectively the effectiveness of these data in predicting effective treatment modalities. Finally, we will optimize a training regime for non-specialists to allow this technique to be used in a variety of settings. The development of this device and validation of its relevance to diagnosis and treatment of MPP will provide effective care sooner and at a lower cost than current procedures. It will also reduce inequities in the availability of care to underserved populations.
223422831|NCT01609439|DRUG|Placebo|Placebo
223422832|NCT06191393|DIAGNOSTIC_TEST|Aptitude Medical Systems Metrix COVID/Flu Test|The Metrix COVID/Flu Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2, Influenza A, and Influenza B via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result, detection of the Flu A gene target will produce a positive Flu A result, and detection of the Flu B gene target will produce a positive Flu B result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
223422833|NCT01894659|OTHER|24% oral sucrose|
223422834|NCT01894659|OTHER|30% oral glucose|
223422835|NCT05229952|DIETARY_SUPPLEMENT|Low-oxalate controlled diet|Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
223422836|NCT05229952|OTHER|Primed, continuous intravenous infusion of 13C2-oxalate|Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
224036167|NCT07188584|RADIATION|Reduced-Target Radiotherapy|Experimental group: GTVnx: 69.96 Gy/33 Fr/2.12 Gy; GTVnd: 69.96 Gy/33 Fr/2.12 Gy; CTV1: 60.60 Gy/33 Fr/1.82 Gy; GTV2: No prescription dose (only delineated, actual dose is scattered dose).
224036168|NCT07188584|RADIATION|Conventional Full-Target Radiotherapy|Control group: GTVnx: 69.96 Gy/33 F/2.12 Gy; GTVnd: 69.96 Gy/33 F/2.12 Gy; CTV1: 59.4 Gy/33 F/1.8 Gy; CTV2: 54 Gy/33 F/1.64 Gy.
224036169|NCT07187609|PROCEDURE|Immediate implant with bovine drived hydroxyapatite xenograft.|patients will undergo immediate implant with bovine drived hydroxyapatite xenograft.
224036170|NCT07187609|PROCEDURE|immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft|patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft
224036171|NCT07189377|DRUG|Entecavir|Recipients will receive 1mg administered orally, beginning pre-transplant as soon as the patient arrives to the hospital for surgery, and then 1mg post-operatively administered orally or via nasogastric tube once daily for 28 days.
224036172|NCT07189377|BIOLOGICAL|HBIG|Recipients will receive 4500 IU intravenously pre-transplant and then at day 3 and 7 post-transplant (3 doses total).
224036173|NCT07189377|DEVICE|EVLP UV Light Treatment|UV light therapy will be administered to the organ during EVLP prior to transplantation. For minimum 2 hours, maximum 6 hours (duration determined by time clinically required for EVLP based on standard clinical assessment of lung).
224036174|NCT07187986|OTHER|Sound acupuncture|Best medical therapy + soundpuncture
223422837|NCT03750669|DRUG|AG regimen|Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
223422838|NCT03750669|DRUG|mFolfirinox|Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
223563241|NCT00272155|BEHAVIORAL|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
223563242|NCT00272155|BEHAVIORAL|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
223422839|NCT02697526|OTHER|Terumo|
223563243|NCT01378702|DRUG|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
223563244|NCT00568763|BIOLOGICAL|sargramostim|
223563245|NCT00568763|OTHER|immunoenzyme technique|
223422840|NCT02697526|OTHER|Tensoplast|
223422841|NCT03382834|DRUG|Tamoxifen|20 mg orally
223422842|NCT03382834|DRUG|Vorinostat|400 mg orally
223422843|NCT03382834|DRUG|Antiretroviral drugs|Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
223563246|NCT00568763|OTHER|immunohistochemistry staining method|
223563247|NCT00568763|OTHER|immunologic technique|
223563248|NCT00568763|OTHER|laboratory biomarker analysis|
223563249|NCT00568763|PROCEDURE|biopsy|
223563250|NCT00568763|PROCEDURE|cryosurgery|
223563251|NCT00568763|PROCEDURE|radiofrequency ablation|
223422844|NCT02387957|DRUG|Fovista®|
223422845|NCT02387957|DRUG|bevacizumab|
223563252|NCT02531425|BIOLOGICAL|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
223563253|NCT03504540|PROCEDURE|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
223563254|NCT03867266|PROCEDURE|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
224036175|NCT07189013|DEVICE|Mechanical infusion pump|Patients with earlier experience on electronic infusion pumps will crossover to the mechanical infusion pump for three month's period
223422846|NCT02387957|DRUG|ranibizumab|
223422847|NCT02387957|DRUG|aflibercept|
223422848|NCT04150796|PROCEDURE|Ventral Hernia Repair|Participants will undergo robotic ventral hernia repair according to the assigned treatment arm.
223422849|NCT05510115|DRUG|Empagliflozin|Empagliflozin: The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-\[4-chloro-3-\[\[4-\[\[(3S)-tetrahydro-3furanyl\]oxy\]phenyl\]methyl\]phenyl\]-, (1S). Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene. Empagliflozin power will be added in white and bovine origin gelatin capsules. Each capsule of empagliflozin will contain 10 mg or 25 mg of empagliflozin (free base) and the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
224036176|NCT01278251|PROCEDURE|Distal Biceps Re-Insertion|
224036177|NCT06181136|DRUG|DNL126|intravenous repeating dose
224036178|NCT04121468|DRUG|Metformin|Each tablet contains 500mg of metformin hydrochloride
224036179|NCT04121468|OTHER|Placebo|Each tablet contains no active drug ingredient
224036180|NCT06439056|DRUG|NEX-22A, a prolonged release formulation of liraglutide|NEX-22A, a prolonged release formulation of liraglutide
224137897|NCT04813536|OTHER|lipid profile|5ml blood to estimate changes of plasma triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and HDL-C
224137898|NCT04982159|OTHER|There is no intervention. This is an observational study.|There is no intervention. This is an observational study.
224137899|NCT04147871|DRUG|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
224137900|NCT04147871|DRUG|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
224137901|NCT06168500|PROCEDURE|Test group|3.0mm diameter implant
223422850|NCT05510115|DRUG|Placebo|Placebo capsules will be matched in size and color to empagliflozin capsules. Each placebo capsule will contain the following inactive ingredients: microcrystalline cellulose magnesium, stearate, dicalcium phosphate, and silicone dioxide.
223422851|NCT02034981|DRUG|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~* 280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~* 165 mg/m² twice daily for ALCL patients aged from 1 to 17."
223422852|NCT06253390|BEHAVIORAL|Metacognitive training|Metacognitive training therapy
223422853|NCT06253390|BEHAVIORAL|control|management technique as usual
223422854|NCT06346821|DEVICE|Optune® (Tumor Treating Fields)|TTFields at 200 kHz to the brain using the Optune® System
223422855|NCT01259349|PROCEDURE|one percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
223422856|NCT01259349|PROCEDURE|40 percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
223563255|NCT03721484|DIAGNOSTIC_TEST|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
223563256|NCT01781650|OTHER|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
223563257|NCT01781650|OTHER|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if \>3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
224036181|NCT05648825|DEVICE|Transapical beating-heart septal myectomy|We have invented a beating-heart myectomy device. Using this device, myectomy could be performed in the beating heart via a mini-thoractomy approach. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. We are now conducting the study to explore the feasibility, the safety, and the efficacy of transapical beating-heart myectomy for the treatment of apical hypertrophic cardiomyopathy.
224036182|NCT06678659|DRUG|REC-1245|Oral
224036183|NCT06317285|DRUG|GSK3915393|GSK3915393 will be administered.
224036184|NCT06317285|DRUG|Placebo|Placebo will be administered.
224036185|NCT06819956|DRUG|Ketorolac|Ketorolac 15 mg IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The ketorolac will be diluted in a 0.9% normal saline 10 mL syringe.
224137902|NCT06168500|PROCEDURE|Control group|4.0 diameter implant + guided bone regeneration
224137903|NCT03309267|PROCEDURE|Intercostal block|Intercostal block +patient controlled analgesia
224137904|NCT03309267|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
224137905|NCT05601024|BEHAVIORAL|Laughter Therapy|The first component of intervention is the laughter therapy that is a combination of warm up exercise, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy with whatsapp group call. Each group will consist of at least 5 people. Each session of laughter therapy will be offered one a weekly and 30-40 minutes each time.
224137906|NCT00321425|PROCEDURE|brachial plexus block|
224137907|NCT00321425|PROCEDURE|ultrasound guidance|
224137908|NCT00321425|PROCEDURE|electrical nerve stimulation|
224137909|NCT00255086|DRUG|Memantine|10mg Memantine
224137910|NCT00255086|DRUG|Placebo pill|10mg placebo pill
224137911|NCT03878524|DRUG|Abemaciclib|Given PO
224137912|NCT03878524|DRUG|Abiraterone|Given PO
224137913|NCT03878524|DRUG|Afatinib|Given PO
223422857|NCT03613649|DRUG|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
223422858|NCT03613649|DRUG|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
223422859|NCT03613649|OTHER|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
223563258|NCT01781650|OTHER|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
223563259|NCT05489354|OTHER|mHealth psychoeducational intervention|The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
224036186|NCT06819956|DRUG|Placebo|Matching placebo IV q6h for a maximum of 3 days total or discharge from ICU (whichever comes first). The matching placebo will be diluted in a 0.9% normal saline 10 mL syringe.
224036187|NCT06060717|DEVICE|F&P Caramel|Nasal mask
224036188|NCT06831383|BEHAVIORAL|STOP-HPV-Online|Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-Online intervention.
224036189|NCT06831383|BEHAVIORAL|STOP-HPV-LC|Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-LC intervention.
224036190|NCT02935257|BIOLOGICAL|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
224036191|NCT03882229|DEVICE|MED-EL CI systems|• Cochlear Implant (CI) and external audio processor
224036192|NCT06089421|OTHER|Genetic Information Assistant|Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
223422860|NCT03546036|DEVICE|Weighted metal chain blanket|Use of a weighted metal chain blanket of 8 kg
223563260|NCT03303170|DEVICE|Sebacia Microparticles|Topical microparticle suspension
223563261|NCT03303170|DEVICE|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
223422861|NCT03546036|DEVICE|Control plastic chain blanket|A blanket with light plastic chains
223422862|NCT06447597|DRUG|B007|B007 high dose and low dose： Subcutaneous injection was administered on days 1 and 15
223563262|NCT02216968|BEHAVIORAL|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
224036193|NCT06089421|OTHER|Telegenetics with UVA genetic counselor|Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.
224036194|NCT06030570|OTHER|Rehabilitation program (Revita)|Multidisciplinary programs in an outpatient hospital setting are coordinated by specialists in Physical and Rehabilitation Medicine. These programs combine a physical part (e.g., specific exercises, manual techniques) with at least one other element (psychological, social, educational or occupational intervention). In a multidisciplinary spine rehabilitation program, a maximum of 36 sessions over a maximum time period of 6 months is offered. Afterwards, a (monodisciplinary) follow-up trajectory (K15) is possible, consisting of maximum 104 sessions a year.
224036195|NCT04750928|DRUG|Abemaciclib|Abemaciclib is to be administered orally on Days 1 through 28 of each 28-day cycle
224036196|NCT06146621|BEHAVIORAL|Low-touch text messaging|To address families' lack of awareness of the Earned Income Tax Credit (EITC) and the ways they may benefit from filing taxes, one study arm will receive low-touch text messages. These act in part by increasing awareness of programs and eligibility rules and in part as reminders to overcome limited attention to filing. Study participants receiving this intervention will receive behavioral science-informed text messages in English or Spanish from WIC that inform them about the EITC throughout tax season (i.e., January-April) 2024. We will personalize message contents (e.g., EITC benefit size mentioned in message based on participant income, marital status, and number of dependents) due to suggestive evidence that a tailored, individualized text message has the potential to be effective
224037854|NCT04600336|DRUG|Oxybutynin Chloride|Given PO
223563263|NCT01129713|DRUG|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
224037855|NCT04600336|DRUG|Placebo Administration|Given PO
224137914|NCT03878524|BIOLOGICAL|Bevacizumab|Given IV
223422863|NCT06447597|DRUG|Placebo|B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
223422864|NCT00299897|DRUG|SP01A|
224037856|NCT04600336|OTHER|Quality-of-Life Assessment|Ancillary studies
224037857|NCT04600336|OTHER|Questionnaire Administration|Ancillary studies
224037858|NCT05327452|BEHAVIORAL|Supervised Home-Based Exercise|Online supervised aerobic and resistance exercise
224037859|NCT05327452|BEHAVIORAL|Unsupervised Home-Based Exercise|Unsupervised aerobic and resistance exercise (UNSUP)
224037860|NCT05327452|BEHAVIORAL|Attention Control|Stretching Program
223563264|NCT01129713|DRUG|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
223563265|NCT00139542|OTHER|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
223563266|NCT00139542|OTHER|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
223422865|NCT05882305|BIOLOGICAL|Autologous monocyte-derived DCs pulsed withEBV-associated antigen|Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
223422866|NCT05335395|BEHAVIORAL|SUNRISE radio campaign|"The SUNRISE radio campaign will be promoting responsive caregiving and providing opportunities for early learning to support child development during the first 3 years of life.~The SUNRISE campaign will follow DMI's established intervention approach with:~1. 60-second radio spots, tailored to increase awareness, knowledge, motivation, skills and opportunity regarding the target behaviours, will include scripted dramas and modelling of responsive parent-child interactions. Each spot will be broadcast 10 times a day for a week; the content of the spots will be changed on a weekly basis. This weekly cycle will continue for three years.~2. Long format 60-minute programmes broadcast 2-3 times a week, incorporating longer dramas, real life testimonials and practical 'how to' advice, with space for listeners to call in, express opinions and uncertainties and ask questions."
223563267|NCT02138305|DEVICE|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
223563268|NCT02138305|PROCEDURE|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
223563269|NCT03750760|DRUG|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
223739774|NCT02763917|DEVICE|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
223739775|NCT02763917|DEVICE|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
223739776|NCT04562870|DRUG|Selinexor|Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral
224037861|NCT06809985|PROCEDURE|Hamilton maneuver|The Hamilton maneuver is performed by inserting one or two fingers through the internal cervical os and carefully producing a circumferential rotational movement through the uterine segment in order to separate the fetal membranes from the decidua. This maneuver is recommended in order to reduce the need for formal induction.
224037862|NCT01998009|OTHER|fecal occult blood tests|
224037863|NCT00002123|DRUG|Delavirdine mesylate|
224037864|NCT00002123|DRUG|Didanosine|
223563270|NCT03750760|DRUG|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
223563271|NCT03750760|DRUG|Ezetimibe 10mg|Cholesterol absorption inhibitor
223563272|NCT01267110|OTHER|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
223563273|NCT01267110|OTHER|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
223563274|NCT03181217|OTHER|water 0|300 ml tap water at 0 ºC
223563275|NCT03181217|OTHER|water 22|300 ml tap water at 22 ºC
223563276|NCT03181217|OTHER|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
223563277|NCT03181217|OTHER|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
223563278|NCT06379035|DIAGNOSTIC_TEST|ELISA / PCR|"Multiplex PCR for confirmation of diagnosis of Blastocystis and Cryptosporidium infection.~Enzyme linked immunosorbent assay (Elisa) for detection of :~Different cytokines level in Colorectal cancer patients that may be involved in the tumor progression due to Blastocystis and Cryptosporidium infection."
223563279|NCT02687555|BEHAVIORAL|Cognitive Bias Modification of Appraisals (CBM-App)|
223563280|NCT02687555|BEHAVIORAL|Peripheral Vision Task (control condition)|
223563281|NCT00382421|DRUG|bisoprolol|
223563282|NCT00382421|DRUG|amlodipine|
223563283|NCT00382421|DRUG|molsidomine|
223563284|NCT00382421|DRUG|acetylsalicylic acid|
223563285|NCT01408550|DRUG|NPB-01|Intravenous immunoglobulin
223563286|NCT01408550|DRUG|Placebo|Physiological saline
223563287|NCT04103307|PROCEDURE|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
223563288|NCT00404755|DRUG|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
223563289|NCT00404755|DRUG|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
224037865|NCT06592677|BEHAVIORAL|Condensed internet-delivered prolonged exposure (CIPE)|'Condensed Internet-delivered Prolonged Exposure' (CIPE) is an intervention designed for victims with symptoms of post-traumatic stress disorder (PTSD) soon after a traumatic incident. CIPE is a therapist-supported intervention that consists of four modules delivered over the internet. Central CIPE-interventions include psychoeducation of normal post-traumatic reactions, in-vivo exposure, imaginary exposure, and a breathing exercise.
223422867|NCT06684392|OTHER|Inspiratory muscle training|Subjects will train only inspiratory muscle strength if they do not achieve VP or definitive disconnection of MV, and, when they already achieve these VP or definitive disconnection, the new EMI regimen that combines strength and resistance training will begin to be applied. Inspiratory muscle training guideline (EMI). On the day that, according to the EMI guideline, the Pimax evaluation corresponds, the training time will be replaced by the evaluation to avoid overloading the subjects with ventilatory work, training them only once a day.
223422868|NCT03937440|DRUG|Deep neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
223422869|NCT03937440|DRUG|Moderate neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
223422870|NCT03132064|PROCEDURE|total knee arthroplasty|surgical repair for end stage of knee osteoarthritis.
223422871|NCT00093587|BIOLOGICAL|anti-thymocyte globulin|
223422872|NCT00093587|DRUG|busulfan|
223422873|NCT00093587|DRUG|cyclophosphamide|
223422874|NCT00093587|DRUG|cyclosporine|
223422875|NCT00093587|PROCEDURE|allogeneic bone marrow transplantation|
223422876|NCT00093587|PROCEDURE|peripheral blood stem cell transplantation|
223422877|NCT00093587|RADIATION|radiation therapy|
223563290|NCT00404755|DRUG|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
223563291|NCT03163693|DRUG|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
223422878|NCT01334671|DRUG|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
223422879|NCT00675428|DRUG|BG00002 (natalizumab)|
223422880|NCT02064842|DRUG|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
223422881|NCT02064842|DRUG|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
223422882|NCT02064842|DRUG|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
223422883|NCT02064842|DRUG|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV \[80 mg/mL strength\]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
223422884|NCT04144348|BIOLOGICAL|mRNA-1653|Sterile liquid for injection
223422885|NCT04144348|BIOLOGICAL|Placebo|Sterile liquid for injection
223422886|NCT00120562|PROCEDURE|Gastric Bypass Surgery|
223563292|NCT03163693|OTHER|normal saline|receive equal volume of normal saline
224137915|NCT03878524|DRUG|Bicalutamide|Given PO
223422887|NCT00319592|BIOLOGICAL|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
223422888|NCT00319592|BIOLOGICAL|JE-VAX® vaccine|1.0 mL, subcutaneously
223422889|NCT06205901|DEVICE|PET-CT, MRI|whole body MRI and PET-CT for cancer patients with distant metastasis
223422890|NCT05747898|PROCEDURE|cannula- based subcision|Insertion of a needle into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
223422891|NCT05747898|PROCEDURE|common- needle based subcision|Insertion of a cannula into the base of a cutaneous scar to cut fibrous tissue and help new collagen formation.
223422892|NCT03244540|PROCEDURE|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
223422893|NCT03244540|PROCEDURE|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
223422894|NCT03244540|DEVICE|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
223422895|NCT03244540|DRUG|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
223422896|NCT03244540|DRUG|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
223422897|NCT03244540|PROCEDURE|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
224137916|NCT03878524|PROCEDURE|Biospecimen Collection|Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
223422898|NCT03244540|PROCEDURE|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
223422899|NCT03244540|DRUG|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
223422900|NCT03244540|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
223422901|NCT03244540|DRUG|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
223422902|NCT01707355|BEHAVIORAL|intervention - poster|
223422903|NCT01497964|DRUG|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
223422904|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223422905|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223563293|NCT03393819|DRUG|DuraPrep|DuraPrep surgical solution
223563294|NCT03393819|DRUG|ChloraPrep|ChloraPrep surgical solution
223563295|NCT02603601|BEHAVIORAL|Mind-body lifestyle intervention|
223563296|NCT02603601|BEHAVIORAL|Standard lifestyle intervention|
223563297|NCT00350870|DRUG|disulfiram|250mg per day of Disulfiram plus CBT
223563298|NCT00350870|DRUG|Placebo|Placebo plus CBT
223563299|NCT00350870|BEHAVIORAL|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
223563300|NCT00350870|DRUG|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
223422906|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223422907|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223563301|NCT01969383|OTHER|Heated pool training|
224036197|NCT06146621|BEHAVIORAL|Personal tax filing support|Participants randomized to this intervention will be connected with a human assistor who will work with them to ensure they access resources to help them file taxes and apply for the EITC. The English- and Spanish-speaking assistors will be study team staff trained to provide personalized support to help families access resources for which they are eligible. The assistor will be available by text or phone to talk with people if they encounter barriers and will call to follow-up on a mutually agreed upon schedule.
224036198|NCT06146621|BEHAVIORAL|Information about free tax-filing support|Basic information about where to find free tax filing support in their community will be provided to all participants by email once upon enrollment.
224036199|NCT06146621|BEHAVIORAL|Financial assistance|Participants randomized to this intervention will receive a $100 cash incentive for tax filing, designed to offset the time, hassle, and resources spent on tax preparation and filing, as well as psychological frictions like inattention that prevent some people from filing. This will be provided to recipients as soon as they show proof of tax filing, to provide a more immediate reward relative to the delays in receiving a federal tax refund. We will test the feasibility of delivering this via gift card, check, or other modalities, in addition to evaluating the framing and incentive amount.
224036200|NCT03470675|DRUG|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
224036201|NCT03470675|DRUG|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
224036202|NCT03470675|DRUG|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
224036203|NCT05798403|DEVICE|electroacupuncture|"All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used."
224036204|NCT05798403|DRUG|Solifenacin Succinate Tablets|"During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out."
224036205|NCT04993690|DRUG|LP-168 tablet|Subjects to take LP-168 orally with 240mL water, without food, Once daily or twice daily
224036206|NCT04354246|DRUG|Dose escalation: COM902 monotherapy.|COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
224036207|NCT04354246|COMBINATION_PRODUCT|Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)|Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
224036208|NCT04354246|DRUG|Cohort expansion: COM902 (RDFE) monotherapy.|COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
224036209|NCT04354246|DRUG|Cohort expansion: COM902 in combination with COM701 (both at the RDFE).|COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
224036210|NCT04354246|COMBINATION_PRODUCT|Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.|Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
224036211|NCT02445222|GENETIC|Previously treated CAR-T patients|Lentiviral-based CAR-T cell therapy
224036212|NCT04720157|DRUG|177Lu-PSMA-617|administered intravenously once every 6 weeks (1 cycle) for 6 cycles
224137917|NCT03878524|DRUG|Bortezomib|Given IV
224137918|NCT03878524|DRUG|Cabazitaxel|Given IV
224137919|NCT03878524|DRUG|Cabozantinib|Given PO
224137920|NCT03878524|DRUG|Capecitabine|Given PO
224137921|NCT03878524|DRUG|Carboplatin|Given IV
224137922|NCT03878524|DRUG|Celecoxib|Given PO
224137923|NCT03878524|DRUG|Cobimetinib|Given PO
224137924|NCT03878524|DRUG|Copanlisib|Given IV
224137925|NCT03878524|DRUG|Dabrafenib|Given PO
224137926|NCT03878524|DRUG|Dacomitinib|Given PO
224137927|NCT03878524|DRUG|Darolutamide|Given PO
224137928|NCT03878524|DRUG|Dasatinib|Given PO
223422908|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223422909|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223422910|NCT00856869|DRUG|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
223422911|NCT01512446|DRUG|Alendronate|70 mg per week
223422912|NCT01512446|DRUG|Placebo|1 pill per week
224137929|NCT03878524|DRUG|Doxorubicin|Given IV
224137930|NCT03878524|BIOLOGICAL|Durvalumab|Given IV
224137931|NCT03878524|DRUG|Enasidenib|Given PO
224137932|NCT03878524|DRUG|Entrectinib|Given PO
224137933|NCT03878524|DRUG|Enzalutamide|Given PO
224137934|NCT03878524|DRUG|Erlotinib|Given PO
224137935|NCT03878524|DRUG|Everolimus|Given PO
224137936|NCT03878524|DRUG|Fluorouracil|Given IV
224137937|NCT03878524|DRUG|Idelalisib|Given PO
224137938|NCT03878524|DRUG|Imatinib|Given PO
224137939|NCT03878524|BIOLOGICAL|Ipilimumab|Given IV
224137940|NCT03878524|DRUG|Lenvatinib|Given PO
224137941|NCT03878524|DRUG|Leucovorin|Given IV
224137942|NCT03878524|DRUG|Lorlatinib|Given PO
224137943|NCT03878524|DRUG|Losartan|Given PO
224137944|NCT03878524|DRUG|Nab-paclitaxel|Given IV
224036213|NCT04720157|DRUG|68Ga-PSMA-11|Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
223422913|NCT05938829|OTHER|Ultrasound following the SMFM guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery. This information will be captured in our ultrasound reporting software, Viewpoint.
223422914|NCT05938829|OTHER|Ultrasound following the ISUOG guidelines|Patients will be followed with weekly ultrasound. During these scans, the patient will have a biophysical profile, a non-stress test (if the gestational age is over 32 weeks), and a Doppler interrogation of the fetal umbilical artery, middle cerebral artery, and ductus venosus. This information will be captured in our ultrasound reporting software, Viewpoint.
223422915|NCT00750139|DRUG|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
224036214|NCT04720157|DRUG|ARDT|Administered orally on a continuous basis as per package insert and guideline
224036215|NCT04720157|DRUG|ADT|ADT are administered as per physician order
224036216|NCT06007924|DRUG|Avutometinib|Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off
224036217|NCT06007924|DRUG|Defactinib|Defactinib 200 mg twice daily 3 weeks on/1 week off
224036218|NCT05809128|OTHER|surgery for breast cancer and imaging test evaluations|At the time of surgery, having completed the evaluation extemporaneous of the surgical piece, tissue samples will be collected to be stored from the material exceeding the completion of the patients' diagnosis. In addition, paramenters that can be extracted from radiodiagnostic images will be evaluated
224036219|NCT01034293|DIETARY_SUPPLEMENT|low feeding frequency (3x)|3 meals a day
224036220|NCT01034293|DIETARY_SUPPLEMENT|High feeding frequency (14x)|14 meals a day
224036221|NCT05954780|DRUG|Selinexor|Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC
224036222|NCT06769945|BEHAVIORAL|Nursing Care Based on Kolcaba's Comfort Theory|In practice, patient education, pain management, emotional support, appropriate environmental arrangements and individualised care come to the fore. Studies show that with this approach, patients' physical comfort increases, anxiety levels decrease and overall satisfaction improves. It is stated that nursing care based on Kolcaba's theory offers an effective model to improve the quality of life of postoperative patients.
224036223|NCT01141348|BEHAVIORAL|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
224036224|NCT01141348|BEHAVIORAL|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
224036225|NCT06332508|DEVICE|Pulsed electromagnetic fields (PEMFs)|"Device: PEMFs~PEMFs treatment can be delivered up to 7 days prior to day of surgery (dose levels 1-2) or anthracycline-based chemotherapy (dose levels 3-4) to allow subject flexibility of timing and decrease the need for multiple visits. A research staff will be assigned to be with subject during the duration of PEMFs to monitor for any side effects during treatment."
224036226|NCT06332508|DRUG|Anthracycline-based chemotherapy|"Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy."
224137945|NCT03878524|DRUG|Neratinib|Given PO
223422916|NCT00750139|DRUG|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
223422917|NCT00750139|DRUG|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
223422918|NCT00750139|DRUG|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
223422919|NCT00429936|DRUG|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
223422920|NCT00186836|BIOLOGICAL|Engerix-B and Twinrix|
223422921|NCT05499221|DEVICE|Carriere motion appliance|The CMA will be bonded on the permanent maxillary canine and first molar, and the correct size is chosen according to the manufacturer's instructions.
223422922|NCT02385838|BEHAVIORAL|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
223739777|NCT04562870|OTHER|Physician's Choice Treatment|Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.
224036227|NCT05794113|DEVICE|Mobile app - CanImmunize|Using a mobile app
224036228|NCT05794113|DEVICE|Web based notification|Using a web-based version of a survey
224036229|NCT00056511|DRUG|Fresh garlic or garlic supplements|
224036230|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
224036231|NCT01856166|DEVICE|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
224036232|NCT01856166|DRUG|Levobupivacaine|
224036233|NCT01856166|DRUG|Sufentanil|
224036234|NCT01398293|DRUG|danoprevir|100 mg single dose orally
224036235|NCT01398293|DRUG|danoprevir|400 mg single dose orally
224036236|NCT01398293|DRUG|danoprevir placebo|single oral dose
224036237|NCT01398293|DRUG|moxifloxacin|400 mg single dose orally
224036238|NCT01398293|DRUG|moxifloxacin placebo|single oral dose
224036239|NCT01398293|DRUG|ritonavir|100 mg single dose orally
224036240|NCT01398293|DRUG|ritonavir placebo|single oral dose
224036241|NCT02823756|PROCEDURE|Physical Therapy|Exercise, education, spinal manipulation
224137946|NCT03878524|BIOLOGICAL|Nivolumab|Given IV
224137947|NCT03878524|DRUG|Olaparib|Given PO
224137948|NCT03878524|DRUG|Oxaliplatin|Given IV
224137949|NCT03878524|DRUG|Palbociclib|Given PO
224137950|NCT03878524|DRUG|Panobinostat|Given PO
224137951|NCT03878524|BIOLOGICAL|Pembrolizumab|Given IV
224137952|NCT03878524|BIOLOGICAL|Pertuzumab|Given IV
224137953|NCT03878524|DRUG|Ponatinib|Given PO
224137954|NCT03878524|OTHER|Quality-of-Life Assessment|Ancillary studies
224137955|NCT03878524|DRUG|Regorafenib|Given PO
224137956|NCT03878524|DRUG|Ruxolitinib|Given PO
224036242|NCT01317212|DRUG|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
223422923|NCT02385838|BEHAVIORAL|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
223422924|NCT02385838|BEHAVIORAL|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
223422925|NCT02385838|BEHAVIORAL|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
223422926|NCT06287164|OTHER|Data collection|Data collection on heart failure therapy and follow up
223422927|NCT05849883|DRUG|Omeprazole 20 mg Capsules|Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production
223422928|NCT00002059|DRUG|Inosine pranobex|
224036243|NCT02598557|DRUG|Exemestane|Given PO
224036244|NCT02598557|OTHER|Laboratory Biomarker Analysis|Correlative studies
224036245|NCT02598557|OTHER|Pharmacological Study|Correlative studies
224036246|NCT02598557|OTHER|Placebo Administration|Given PO
224036247|NCT02598557|OTHER|Quality-of-Life Assessment|Ancillary studies
223422929|NCT00798343|BIOLOGICAL|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
223422930|NCT00798343|BIOLOGICAL|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
223422931|NCT04310709|DRUG|Regorafenib/Nivolumab|Combination of regorafenib and nivolumab
223422932|NCT03127735|DRUG|BAY1436032|"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
223422933|NCT04365504|DIAGNOSTIC_TEST|Dual energy X ray absorbtiometry|The primary clinical application of dual-energy x-ray absorptiometry (DXA or DEXA) is the measurement of bone mineral content (BMC, g) and bone mineral density (BMD, g/cm2) of the lumbar spine and proximal femur to assess risk for osteoporosis.
223422934|NCT03600194|DEVICE|PowerSleep Stim|The PowerSleep Stim device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. Soft audio tones (below 65dB) will be administered via the speakers system during deep sleep as determined by the functionality of the device. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
224036248|NCT02598557|OTHER|Questionnaire Administration|Ancillary studies
224036249|NCT02598557|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224036250|NCT03970551|OTHER|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
224036251|NCT03970551|OTHER|Stress Test|Stress test involving submerging your hand in ice water or performing mental arithmetic to increase sympathetic activity.
223422935|NCT03600194|DEVICE|Northwestern Stim|The Northwestern Stim Device will function similarly to the PowerSleep device, but stimulation will be provided using a standard PC (computer) setup at the bedside using standard PSG electrodes. EEG will be monitored and slow wave sleep (SWS) identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves and to control acoustic stimulation in a phase-locked manner (targeting the up phase of the slow wave). Acoustic stimulation will be provided by headphones with an audible soft volume that do not result in arousals.
223422936|NCT03600194|DEVICE|PowerSleep Sham|The PowerSleep Sham device is a wearable and non-invasive device, consisting of a headband with 2 electrodes (one forehead and one mastoid) and speakers covered by foam over each ear. The headband is connected via a tether cable to a user interface which houses the EEG amplifier and electronics of the device. The headband is adjusted via Velcro closure. The device also includes a right mastoid electrode EEG will be recorded by the PowerSleep device. There are no audio tones played in the Sham condition. The version being used for this study is considered investigational as this is an earlier version which allows the study team will be able to review EEG data recorded by the PowerSleep device in real time.
224036252|NCT03970551|OTHER|Functional Electrical Stimulation|A mild electrical stimulus to passively induce a leg muscle contraction with minimal sympathetic activation.
224036253|NCT02328287|DRUG|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
224036254|NCT05629650|BEHAVIORAL|Tai Chi for memory|The adapted form of TCM will be provided at 60 minutes per session, twice a week for 12 weeks by a certified Tai Chi instructor who had experience in teaching older adults with cognitive impairments.
224036255|NCT00269568|DRUG|mifepristone and misoprostol|
224036256|NCT05055986|DEVICE|Semiautomatic segmentation of open-source software|Semiautomatic segmentation of open-source software is accurate as of the manual segmentation of commercial software.
224036257|NCT04058379|RADIATION|CT scan|3 ct scans : D0, D1 and D3
224298940|NCT03295318|BIOLOGICAL|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
224298941|NCT03295318|BIOLOGICAL|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
223422937|NCT03600194|DEVICE|NorthWestern Sham|The Northwestern Sham device is set up will function similarly to the PowerSleep prototype. EEG will be monitored and SWS identified using a standard PSG channels (international 10-20 system: Fpz, F3, F4, C3, C4, P3, P4, O1, O2) referenced to left mastoid. Electro-oculogram (EOG) will be recorded using 2 electrodes placed lateral to each eye and chin electromyogram (EMG) was recorded using 3 chin electrodes. The full EEG data set will be collected using Brain Vision Recorder software (Brain Products GmBH) and stored for off-line analysis and sleep scoring. A Matlab script (R2014b, MathWorks, Natick, MA) was developed for online detection of slow-waves. Participant will wear headphones but no audio tones played in the Sham condition.
223422938|NCT04439214|BIOLOGICAL|Nivolumab|Given IV
223563302|NCT04418869|OTHER|Exercise bouts|Each subject performed three bouts with 45 minutes of exercise (continuous exercise, intermittent exercise and resistance exercise) in a randomized order. In addition a control session were performed where the subjects sat on a chair for 45 minutes.
223563303|NCT05923827|DEVICE|Omnipod 5 System|The Omnipod 5 system is a tubeless patch pump that receives glucose values and trend data from the glucose sensor every 5 minutes, automatically calculates insulin dose, and sends delivery commands to the Pod for the delivery of insulin.
223563304|NCT03194568|DEVICE|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
224036258|NCT01343589|DIETARY_SUPPLEMENT|milk fat|39 g milk fat per day in 12 weeks
224036259|NCT00149422|DEVICE|NT-proBNP measurements|
224036260|NCT03483558|OTHER|Control|A standardized diet without any vegetables was provided.
224036261|NCT03483558|OTHER|Spinach|A standardized diet with 200g spinach was provided.
224036262|NCT03483558|OTHER|Celery|A standardized diet with 200g celery was provided.
224137957|NCT03878524|DRUG|Sirolimus|Given PO
224137958|NCT03878524|DRUG|Sorafenib|Given PO
224137959|NCT03878524|DRUG|Sunitinib|Given PO
223422939|NCT02611271|OTHER|Monitoring of antibiotic drug removal|No study specific intervention will be performed
223422940|NCT02166736|DEVICE|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
223422941|NCT02166736|DEVICE|FFR|Intervention guided by Fractional Flow Reserve
223563305|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet A|Healthy, balanced diet following Eatwell Guide recommendations
223563306|NCT05627570|DIETARY_SUPPLEMENT|Healthy, balanced Diet B|Healthy, balanced diet following Eatwell Guide recommendations
223563307|NCT05627570|BEHAVIORAL|Behavioural support intervention|Participants will work with a behavioural scientist to create a personal plan to eat a healthier diet and be more physically active. This support will last for 6 months, with ongoing monthly telephone/video calls with the research team.
223739778|NCT04378790|OTHER|Patching|Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
223739779|NCT04378790|OTHER|Glasses|Eye Glasses are created and worn by patient to improve vision
224036263|NCT03483558|OTHER|Onion|A standardized diet with 200g onion was provided.
224036264|NCT03483558|OTHER|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
224036265|NCT04586517|OTHER|Heavy-load resistance training|Supervised heavy-load resistance training during chemotherapy treatment
224036266|NCT04586517|OTHER|Control|Activity as usual during chemotherapy
224036267|NCT05717426|OTHER|Open chain exercises|An open chain exercise is one that allows the furthest part of the chain to move freely. For example, picking up a glass of water is an open-chain exercise. The hand affects the elbow and the shoulder as it is not fixed in place. However, it does not effect the rest of your body.
224036268|NCT05717426|OTHER|Closed kinetic chain exercises|Closed Kinetic Chain (CKC) exercises or closed chain exercises are exercises or movements where the distal aspect of the extremity is fixed to an object that is stationary.
224036269|NCT04469166|PROCEDURE|tourniquet|Use of tourniquet
224036270|NCT04469166|PROCEDURE|No tourniquet|No use of tourniquet
224036271|NCT02656498|DRUG|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
224036272|NCT00796848|DEVICE|Navigator Continuous Glucose Monitor|
224036273|NCT01117454|DRUG|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
224036274|NCT01117454|DRUG|Placebo|placebo, similar in appearance to flecainide
224036275|NCT01117454|DRUG|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
224036276|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
224036277|NCT00389857|BIOLOGICAL|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
224036278|NCT06326957|OTHER|SELF-BREATHE|SELF-BREATHE is on online supportive self - management intervention for individuals living with chronic breathlessness due to respiratory disease. SELF-BREATHE provides user with educational resources about breathlessness and self - management techniques such as breathing exercises, goal setting which aims to help with their breathlessness.
224036279|NCT00278460|DRUG|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
224036280|NCT00278460|DRUG|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
224036281|NCT06459323|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
224137960|NCT03878524|DRUG|Trametinib|Given PO
224137961|NCT03878524|BIOLOGICAL|Trastuzumab Emtansine|Given IV
224137962|NCT03878524|DRUG|Tretinoin|Given PO
224137963|NCT03878524|DRUG|Vemurafenib|Given PO
224137964|NCT03878524|DRUG|Venetoclax|Given PO
224137965|NCT03878524|DRUG|Vismodegib|Given PO
224137966|NCT03878524|DRUG|Vorinostat|Given PO
224137967|NCT04741334|DRUG|direct anticoagulant|exposure to direct anticoagulant
224137968|NCT04741334|DRUG|antiplatelet drugs|exposure to antiplatelet drugs
224137969|NCT04741334|DRUG|Dicumarols|exposure to dicumarols
223422942|NCT06627309|DRUG|Dara IV|The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
223422943|NCT06627309|DRUG|Bortezomib (drug)|Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles
224036282|NCT04276766|OTHER|Crossover intervention|"Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study."
224036283|NCT06287723|BIOLOGICAL|Blood sample/Liquid biopsy|ctDNA analysis
224298942|NCT06579261|OTHER|Core Shamanism|Each Shamanic intervention session, led by the shamanic practitioner, will include classical music as a control, followed by repetitive drumming and/or rattling music which the participant and shamanic practitioner will listen to for 15-30 mins. Following listening to drumming, the patient will then talk with the shamanic practitioner to debrief the experience of each session. Participants will also listen to classical music as a control stimulus.
223422944|NCT06627309|DRUG|Dexamethasone|Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
223422945|NCT06627309|DRUG|Cyclophosphamide (CTX)|Some patients may receive cyclophosphamide orally or intravenously at a dosage of 300 mg/m2 weekly.
223422946|NCT06627309|DRUG|Dara SC|The treament follow the clinical routine practice, as daratumumab 16mg/kg iv qw OR dara SC 1800mg initially. The treatment schedule involve weekly administrations during cycles 1 to 2, following by biweekly administrations during cycles 3 to 6. Subsequently, monthly administrations are given as monotherapy.
223422947|NCT06258720|DRUG|Lu AF82422|Lu AF82422 solution for intravenous infusion
223422948|NCT04811092|DRUG|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
223422949|NCT04811092|OTHER|Placebo|Placebo
223422950|NCT03556501|DIAGNOSTIC_TEST|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
223422951|NCT03191461|DIAGNOSTIC_TEST|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
224036284|NCT00647751|DRUG|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
224036285|NCT00647751|DRUG|Lamictal® Tablets 25 mg|2x25mg, single dose fed
224036286|NCT00888433|DEVICE|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
224036287|NCT04536454|DRUG|[18F]FPyGal|Radiotracer for PET-imaging
224036288|NCT06196983|OTHER|Rhythmic aerobic exercises|The experimental group's pattern of functional movements includes both right and left foot movements. To improve muscle strength and the capacity to maintain balance, exercises including running in place, side steps, walking while eating, and turning in place can also be used. The rhythmic aerobic group linked their motions to the rhythmic auditory stimuli in order to perform in a rhythmic manner.
224036289|NCT06196983|OTHER|Control group, strength and balance exercises|The control group engaged in strength and balance exercises where they stood with weight on one leg and raised the other leg to the side or back. In a tandem stance, place your foot heel directly in front of your toe. Get out of a chair, then take a seat without using your hands.
223422952|NCT04553471|RADIATION|Stereotactic body radiotherapy|Treatment will take approximately 2 weeks.
224036290|NCT04655404|DRUG|Larotrectinib|"1. Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
224036291|NCT04655404|PROCEDURE|Larotrectinib surgical|"1. Surgical cohort: Larotrectinib x 3-5 days prior to definitive surgery followed by Larotrectinib monotherapy x2 cycles followed by disease evaluation~2. Larotrectinib with or without chemotherapy backbone"
224298943|NCT04319718|COMBINATION_PRODUCT|MK-2048 High Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)"
224298944|NCT04319718|COMBINATION_PRODUCT|MK-2048 Low Eudragit Vaginal Film|"2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)"
223422953|NCT04553471|PROCEDURE|Research blood draw|-Baseline, immediately after radiotherapy completion (fraction 5), 14 days after radiotherapy, and 30 day follow-up
223422954|NCT05917834|BIOLOGICAL|Nipple sparing mastecomy with different incision placements|Nipple sparing mastectomy was performed using Radial/Peri-areolar incision or imframammary incision
223422955|NCT04399135|DIAGNOSTIC_TEST|Orthopantomogram X-ray view|taking an X-ray to determine bone loss level and attachment loss level for periodontitis classification
223422956|NCT04399135|DIAGNOSTIC_TEST|Endo-Ice|Included teeth will be dried with 4x4 gauze then tested with a cold test using Endo-Ice.
223422957|NCT04399135|DIAGNOSTIC_TEST|Electric Pulp Tester (EPT)|Included teeth will be dried with 4x4 gauze then tested with an Electric test using electric pulp tester (EPT).
223422958|NCT04155229|OTHER|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
223422959|NCT01259804|DIETARY_SUPPLEMENT|Peanut oral immunotherapy|Daily doses of peanut flour
223422960|NCT01886209|DRUG|Prednisone|
223422961|NCT01886209|DRUG|VX-509|
223563308|NCT06450964|OTHER|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and the mitochondrial DNA mutation heterogeneity level was determined.|Biological samples such as blood, urine, oral epithelial cells and nails of carriers were collected, and some granulosa cells, trophoderm cells, embryo culture fluid, embryo biopsy fluid, and embryo trophoblast cells were collected. Placenta and umbilical cord blood samples of some fetuses were collected after delivery, and the mitochondrial DNA mutation heterogeneity level was determined.
223563309|NCT06826690|PROCEDURE|Group 1: ultrasound guided wrist block with bupivacane alone|Ultrasound guided wrist block with 15 ml volume of bupivacane.25%
223563310|NCT06826690|PROCEDURE|Group 2 : ultrasound guided wrist block with bupivacane and dexamethasone|Group 2 : patients receive ultrasound guided wrist block with bupivacane.25% and 8 mg dexamethasone.. 15 ml volume totally
223563311|NCT06826690|PROCEDURE|Group 3: ultrasound guided wrist block with bupivacane and dexametmiodine|Group 3 will receive ultrasound guided wrist block with bupivacane.25% and 50 mcg dexametmiodine... 15 ml volume totally
223563312|NCT06826690|PROCEDURE|Group 4: patients will receive ultrasound guided wrist block with bupivacane and dexamethasone and dexametmiodine|Group 4 patients will receive ultrasound guided wrist block with bupivacan.25%e and 8 mg dexamethasone and 50 mcg dexametmiodine
223563313|NCT06572891|OTHER|Maxillary obturator|conventional acrylic obturator
224036292|NCT06288321|DRUG|Microdrop Mydrin-P|Microdrop Mydrin-P consists of around one third of the standard Mydrin-P drop size. Drop volume measurement was performed using a precision weight scale (Sartorius) with accuracy up to 0.001g. The microdrop administration was conducted via attachment of a 16 gauge needle to a 1ml syringe.
223422962|NCT01886209|DRUG|Methylprednisolone|
223422963|NCT03045432|OTHER|video-teaching|By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
223563314|NCT06572891|OTHER|Implant supported obturator|"Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made"
223563315|NCT04850196|DEVICE|TEAS|TEAS treatment was performed for 30 mins before anesthesia on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints . And TEAS treatment for 30 mins was also performed on bilateral side by an experienced acupuncturist at the Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints at the end of surgery as well as on the each night before sleeping after surgery until discharged from the hospital
223422964|NCT03045432|OTHER|oral-teaching|The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
223422965|NCT03045432|OTHER|regular rehabilitation program|Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
223422966|NCT06522698|DEVICE|Smart Pill Bottle|Patients in the intervention group will have their opioid medication consumption monitored through a smart pill bottle that records medication usage and streamlines the data into an online platform accessible by the medical staff. This group will also fill out surveys delivered through the smart pill bottle's online platform.
224036293|NCT06288321|DRUG|Standard Mydrin-P|Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
224036294|NCT01500850|DRUG|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
224036295|NCT01500850|DRUG|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
223422967|NCT02194712|OTHER|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
224036296|NCT01500850|DRUG|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
223422968|NCT01681680|DRUG|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
223422969|NCT00323791|DRUG|gemcitabine hydrochloride|
223422970|NCT00323791|DRUG|imatinib mesylate|
223422971|NCT00323791|GENETIC|gene expression analysis|
223422972|NCT00323791|GENETIC|protein expression analysis|
223563316|NCT04850196|OTHER|control group|Patients in the Control group received electrical stimulation at a non-acupoint which was located 2 cm interior to the bilateral Neiguan (PC6), HT7 (Shenmen), ST36 (Zusanli) and LI4 (Hegu) acupoints similar to patients in group TEAS
223563317|NCT05521854|BEHAVIORAL|DynamiCare app (app-based contingency management)|Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
223563318|NCT05521854|BEHAVIORAL|Sham control|Participants get access to the DynamiCare app but will not be provided with financial incentives.
223563319|NCT05447650|DEVICE|i-Lumen(TM) AMD|Transpalpebral microcrurrent stimulation
223563320|NCT05447650|DEVICE|i-Lumen(TM) AMD Sham|Transpalpebral sham stimulation
223563321|NCT04916353|DRUG|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain
223422973|NCT00323791|OTHER|immunohistochemistry staining method|
223422974|NCT00323791|OTHER|laboratory biomarker analysis|
223422975|NCT03641326|DRUG|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
223422976|NCT03641326|DEVICE|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
223422977|NCT01529788|DRUG|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
223422978|NCT01529788|DRUG|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL \[7.5 units\] per injection point) divided among 4 injection points (0.05mL \[2.5units\]) on Day 0 of the study
223422979|NCT01872065|DRUG|ARC-520|
223563322|NCT04916353|DRUG|Triamcinolone Acetonide.|Triamcinolone Acetonide 40mg/1ml injection
223563323|NCT05465070|DEVICE|Leg heat therapy|A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.
223563324|NCT05465070|DEVICE|Sham Control|A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
223563325|NCT06292195|OTHER|Exposure|Maternal vitamin D levels during pregnancy (serum 25-hydroxyvitamin D levels)
223563326|NCT02291783|DRUG|HTL0009936|Single dose
223563327|NCT02291783|DRUG|HTL0009936 placebo|Placebo single dose
223563328|NCT06407128|BIOLOGICAL|Collection of biological samples|Collection of biological samples (blood sample + valve tissue sample + saliva, periodontal and feces sample)
223563329|NCT03982784|PROCEDURE|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
223563330|NCT03982784|DRUG|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
223563331|NCT00517348|BIOLOGICAL|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
223563332|NCT04683549|DIAGNOSTIC_TEST|HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy|"Locally advanced non-operable newly diagnosed FIGO stage IB-IVA cervical cancer patients planned for definitive radiochemotherapy will be accrued to study and will have:~1. FDG PET Scan before treatment and 3 months after treatment~2. Pre- treatment DNA from the neoplastic time preserved in the form of paraffin blocks to determine HPV status~3. Blood sample to measure HPV DNA at time point baseline (before treatment), in the middle of treatment and at the end of definitive radiochemotherapy,~4. \[F-18\] - FDG PET scan before treatment and 3 months post completion of radiochemotherapy."
223563333|NCT01453205|DRUG|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
224036297|NCT01500850|DRUG|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
224036298|NCT04628468|DEVICE|moveUp|Mobile application for use in the rehabilitation of primary knee and hip arthroplasty
224036299|NCT04628468|OTHER|Predefined number of traditional physiotherapy sessions|exercises with a physiotherapist being physically present
224036300|NCT05629195|DEVICE|tunneled PICC|PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
224036301|NCT01681628|BEHAVIORAL|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
224036302|NCT00375557|DRUG|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
223422980|NCT01872065|DRUG|Placebo|
223422981|NCT01017523|BEHAVIORAL|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
223422982|NCT01017523|OTHER|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
223422983|NCT02211482|DRUG|dolutegravir, lamivudine|single arm
223422984|NCT04505072|BEHAVIORAL|PR-ESSENCE|Manual-based training of mutual problem-solving
223422985|NCT04505072|BEHAVIORAL|Treatment as usual|General support in daily structure and activities that is given to all youth staying at the treatment homes
223422986|NCT05274854|BEHAVIORAL|a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing|Pre consultation interventions consist of one of four intervention a)standardised dietician supervised intervention, b) exercise intervention, c) internet delivered cognitive behavior therapy or d) nothing
223422987|NCT05274854|BEHAVIORAL|a) consultant-led outpatient clinic or b) a integrated care clinic|Consultation intervention consists of one of two interventions a) consultant-led outpatient clinic or b) a integrated care clinic
224036303|NCT00375557|DRUG|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
223563334|NCT01453205|DRUG|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
223563335|NCT01453205|DRUG|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min \[800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
223563336|NCT01453205|DRUG|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
223563337|NCT01453205|PROCEDURE|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
223563338|NCT01453205|DRUG|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
223563339|NCT00724685|DRUG|Naropeine (Ropivacaine)|
223563340|NCT00724685|DRUG|Placebo|saline
223563341|NCT04105920|DEVICE|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
223422988|NCT06668727|DRUG|HepB mAb19|"The study has two parts:~Part A will involve administering a single ascending dose of HepB mAb19 or placebo using a randomized, double-blind method in Groups 1-3 at dose levels of 3, 10, and 30 mg/kg. Participants enrolled in Groups 1-3 will be randomized at a 3:1 ratio to receive HepB mAb19 or placebo. Part B will assess the maximum tolerated dose (MTD) in Group 4 in an openlabel fashion. Participants will receive HepB mAb19 at MTD."
223422989|NCT06530680|BEHAVIORAL|Hippotherapy|Two 1-hour sessions of hippotherapy for eight weeks.
223563342|NCT05274971|OTHER|Active dietary management and aerobic exercise training.|Active dietary management and aerobic exercise training.
223563343|NCT05849207|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.
223563344|NCT05021133|BEHAVIORAL|Tele-Navi LCS|Tele-Navi of LCS includes: telehealth coaching from a Tele-Navigator for patients undergoing LCS using a video or telephone call
223563345|NCT03332199|OTHER|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
224036304|NCT02762825|BEHAVIORAL|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
223563346|NCT03880370|BEHAVIORAL|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
224036305|NCT02762825|BEHAVIORAL|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
224036306|NCT02794454|OTHER|HeezOn Ultra-1|
224036307|NCT02794454|OTHER|HeezOn Ultra-2|
224036308|NCT02794454|OTHER|Placebo|
223563347|NCT03880370|DIAGNOSTIC_TEST|Ultrasound imaging|Rectus abdominis dominant side \& non-dominant side external oblique dominant side \& non-dominant side internal oblique dominant side \& non-dominant side transversus abdominis dominant side \& non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side \& non-dominant side
223563348|NCT03880370|DIAGNOSTIC_TEST|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
223563349|NCT03880370|DIAGNOSTIC_TEST|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
223563350|NCT00467194|DRUG|Rapamycin|
223563351|NCT00467194|DRUG|Bevacizumab|
223563352|NCT01186926|DEVICE|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
224036309|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
224036310|NCT02010606|BIOLOGICAL|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
224036311|NCT01810692|DEVICE|Group1:Spiriva® Respimat®|COPD patients using Respimat®
224036312|NCT01810692|DEVICE|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
224036313|NCT00227565|DRUG|carboplatin|
224036314|NCT00227565|DRUG|pemetrexed disodium|
224036315|NCT00227565|RADIATION|radiation|
223422990|NCT00589381|DRUG|fenretinide lipid matrix|
223422991|NCT03207464|DRUG|[C-11]Methylreboxetine|8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
223422992|NCT05404256|OTHER|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface|Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
223422993|NCT05404256|OTHER|Radical gastrectomy +D2 lymphadenectomy|Radical gastrectomy +D2 lymphadenectomy
223422994|NCT01868698|OTHER|high-voltage electrical stimulation|
223422995|NCT01868698|OTHER|Kinesiotherapy|
223422996|NCT01868698|OTHER|shortwave diathermy|
223422997|NCT04754958|DEVICE|Immersion in virtual reality using Nordic Neurolab(™) Visual System|In addition to the standard MRI procedure, the VR intervention group will be looking at stereoscopic computer generated images through a pair of head-coil-mounted googles (Nordic Neurolab ™ Visual System). Two markers (color balls) will be fixed on their knees to capture their movement (camera tracking from the outside of the MRI room). The VR scenario will consist in showing a replication of the actual MRI examination room, as seen from the point of view of the participant lying on the MRI bed, but without the MRI tunnel. Participant can see themselves in the large room (a simplified gender-matched avatar), and an entertaining video can be displayed.
223422998|NCT05608291|DRUG|Fianlimab|Fianlimab will be administered by intravenous (IV) infusion every (Q) 3 weeks
223422999|NCT05608291|DRUG|Cemiplimab|Cemiplimab will be administered by IV infusion Q 3 weeks
223423000|NCT05608291|DRUG|Pembrolizumab|Pembrolizumab will be administered by IV infusion Q 3 weeks
223423001|NCT05608291|DRUG|Placebo|Matching placebo co-infused with pembrolizumab IV, will be administered by IV infusion Q 3 weeks
223563353|NCT04418492|BEHAVIORAL|Skills for Adaptive Functioning through Executive training (SAFE; tentative title)|An intervention program to improve adaptive skills and executive functions in young adults with high-functioning autism spectrum disorder was administered weekly for 10 weeks to the participants. The participants also completed pre-, mid- and post-intervention assessments.
223423002|NCT06174298|DRUG|Granulocyte Colony-Stimulating Factor (Filgrastim)|"Intervention Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Intervention Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media supplemented with GCSF. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
223563354|NCT06039436|DRUG|Anti-Thymocyte Globulin (Rabbit)|Indications for trial stopping: subjects occur pregnancy events, severe organ function impairments, or emergency events related or unrelated to treatment; or subjects are unwilling to continue participating in the clinical trial.
223563355|NCT03614481|GENETIC|Sampling|Sampling
223563356|NCT00123279|DRUG|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
223563357|NCT02034682|DRUG|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
223563358|NCT02034682|DRUG|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
223563359|NCT05699993|DRUG|Itraconazole|Itraconazole was administered orally
223563360|NCT05699993|DRUG|IBI351|IBI351 was administered orally
223563361|NCT05699993|DRUG|Dextromethorphan|Dextromethorphan was administered orally
223563362|NCT00500058|DRUG|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
223563363|NCT00500058|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered by IV infusion.
223563364|NCT05329480|DIETARY_SUPPLEMENT|Creatine Monohydrate|Creatine Monohydrate powder, 4 separate 5g doses per day for 7 days.
223563365|NCT05329480|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin powder, 4 separate 5g doses per day for 7 days.
223423003|NCT06174298|OTHER|Standard Embryo Transfer Media|"Control Group Fresh Embryo Transfers: On day 5 or 6 of culture, viable embryos will be transferred into a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the embryo transfer (ET) procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician.~Control Group Frozen Embryo Transfers: Cryopreserved embryos will be thawed according to the Kitazato thawing protocol and will be subsequently transferred to a center-well dish containing 1 mL of embryo transfer media. The embryos will be cultured in this medium for approximately 3 hours before the ET procedure. During the ET procedure, the same media will be used to fill the ET syringe and catheter that will be used to deposit the embryos into the uterus by the physician."
223423004|NCT03470012|DEVICE|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
223563366|NCT01120860|DEVICE|MRI|MRI - routine imaging sequences, designed for anatomical quantification
223563367|NCT06282406|OTHER|Transcutaneous Electrical Stimulation|Electrical pulse trains applied to the skin overlying putative sites of auricular vagal innervation.
223563368|NCT06282406|OTHER|Sham|Electrodes placed on the skin overlying putative sites of auricular vagal innervation but no current administered.
223563369|NCT06811103|OTHER|patient reported outcome|after enrollment, patient will have to answer to several patient reported outcome (PRO) to evaluate their pain, and well being. They will also answer to the MacCatT PRO to assess their understanding, reasoning, appreciation and choice expression
224036316|NCT06211192|OTHER|retrospective data collection|retrospective data collecting from medical records
224036317|NCT00846651|OTHER|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
224036318|NCT00846651|OTHER|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
224036319|NCT00846651|DRUG|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
224036320|NCT05809310|PROCEDURE|Percutaneous intervention (stent) for PA stenosis|Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries
224036321|NCT03786159|OTHER|No intervention|No intervention
224036322|NCT00181584|DRUG|Zoledronic acid|Given intravenously once.
224036323|NCT00181584|OTHER|Placebo|Given intravenously once.
224036324|NCT00315081|DRUG|Bromocriptin|
224036325|NCT02261038|OTHER|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
224298945|NCT06483347|DRUG|ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab|"This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks."
223423005|NCT00641576|DEVICE|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.~Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
223423006|NCT00854425|DRUG|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
223423007|NCT01048060|PROCEDURE|Bone marrow specimen banking|
223423008|NCT05491525|DRUG|Vibegron|Participants will be administered Vibegron orally, once daily (QD)
224036326|NCT01768897|DRUG|CPI-613|Given IV
224036327|NCT01768897|DRUG|cytarabine|Given IV
224036328|NCT01768897|DRUG|mitoxantrone hydrochloride|Given IV
224036329|NCT01768897|OTHER|laboratory biomarker analysis|Optional correlative studies
223423009|NCT00477750|DRUG|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
223423010|NCT00477750|DRUG|melphalan|"Phase I - dose escalating: 5mg/m\^2 dose level -1, 5 mg/m\^2 dose level 0, 8 mg/m\^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m\^2 orally days 1-4 every 28 days until progression"
223423011|NCT00477750|DRUG|prednisone|60mg/m\^2, orally days 1-4 every 28 days until progression
223423012|NCT05277142|OTHER|oral motor training|they received oral motor training for 40 minutes 3 times/week for twelve successive weeks.
223563370|NCT06655532|BEHAVIORAL|Exercise Program|Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
223563371|NCT06655532|BEHAVIORAL|Usual Care|Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
224036330|NCT01768897|OTHER|pharmacological study|Correlative studies
224036331|NCT06572111|DRUG|BI 1839100 (C-14) formulation 1|BI 1839100 (C-14) formulation 1
224036332|NCT06572111|DRUG|BI 1839100|BI 1839100
224036333|NCT06572111|DRUG|BI 1839100 (C-14) formulation 2|BI 1839100 (C-14) formulation 2
224036334|NCT06429384|DRUG|Y-3 Injection/Y-3 blank injection|The first dose should be completed as soon as possible after randomization; The time from the second dose to the first dose shall not be less than 12h, but not more than 24h+1h; The time interval of each subsequent administration is 24h±1h;
224036335|NCT04450654|DRUG|Gamunex-C|Gamunex-C IVIG will be given at week 0 and week 4
224036336|NCT04450654|DRUG|Albumin|1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4
224036337|NCT01468220|OTHER|Endurance training|Endurance training three times per week over six weeks
224036338|NCT03670706|BEHAVIORAL|Exercise|Package of care
224036339|NCT03670706|OTHER|analgesic optimisation|optimisation
224036340|NCT02423304|GENETIC|blood samples collected from all patients|blood samples collected from brachial pluxes
224036341|NCT05774444|DIETARY_SUPPLEMENT|Krill oil|Krill oil will be supplemented to see if they can gain strength and/or muscle mass following supplementation.
224036342|NCT05774444|DIETARY_SUPPLEMENT|Krill protein|Krill protein will be given to the participant following a resistance exercise bout.
224036343|NCT05774444|DIETARY_SUPPLEMENT|Vegetable oil|This will be the control against the Krill oil
224036344|NCT05774444|DIETARY_SUPPLEMENT|Carbohydrate|This will be the control for the Krill protein
224036345|NCT03459599|DRUG|Prophylactic antibiotics|Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
224036346|NCT03459599|OTHER|No prophylaxis (Amox-clav withheld)|Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
224036347|NCT03685864|OTHER|Suture Embedding Acupuncture|Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
224036348|NCT03685864|OTHER|Sham Acupuncture|Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
224036349|NCT01937936|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
224036350|NCT01937936|BEHAVIORAL|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
224036351|NCT05187052|OTHER|Tracheal intubation|Video-assisted intubation technique
224137970|NCT04260334|OTHER|Preoperative Education|The first two hours after the hospitalization of the patient will be met and the aim of the study will be explained. On the same day, the patient will be given breathing and relaxation exercises and explained why it is important. On the second day after the hospitalization, the patient will be evaluated and the previous day's exercises will be repeated and leg exercises will be performed. The importance of mobilization will then be highlighted. the same day gradual relaxation exercise and surgical relaxation will be administered to the patient three times. The patient will be evaluated on the first postoperative day.
223423013|NCT05277142|DEVICE|Neuromuscular Electrical Stimulation|They received the same Oral motor training program of Group A for 20 minutes in addition to Neuromuscular Electrical Stimulation (NMES) at intensity ranged from (3-5mA) duration for 20 minutes and frequency of 80 HZ 3 times/week for twelve successive weeks
223423014|NCT06621901|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
223423015|NCT06621901|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
223423016|NCT06682585|OTHER|Individualised dietary intervention|"* Energy Intake: Caloric needs will be calculated based on the patient's age, weight, and activity level, taking into account the potential impact of corticosteroid therapy on energy expenditure.~* Protein Intake: Protein requirements will be met through a balanced diet, aiming to optimize muscle protein synthesis.~* Calcium and Vitamin D Intake: Adequate intake of these nutrients will be emphasized to support bone health and prevent osteoporosis.~* Fluid Intake: Fluid intake will be monitored to prevent dehydration and constipation.~* Carbohydrate Intake: A low-glycemic index diet will be recommended to manage blood glucose levels and insulin resistance, especially in patients on corticosteroid therapy.~* Sodium Intake: Sodium intake will be restricted to minimize fluid retention and hypertension."
223423017|NCT00136136|PROCEDURE|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
223423018|NCT03513809|DEVICE|Thoracic electrical impedance tomography|Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
223423019|NCT05678868|PROCEDURE|MitraClip procedure|MitraClip is surgical procedure to repair the mitral valve in your heart. During the procedure, the doctor will access the mitral valve using a thin tube (called a catheter) that is guided through a vein in your leg to reach your heart. A small implanted clip is attached to the mitral valve to reduce the leaking across the valve and to reduce symptoms and stress on the heart.
223423020|NCT01214369|PROCEDURE|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
223423021|NCT00476268|DRUG|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
223423022|NCT00476268|DRUG|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
223423023|NCT00476268|DRUG|Formoterol powder 12 µg/unit dose|2 inhalations bid
223423024|NCT00177853|DRUG|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
223423025|NCT00177853|DRUG|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
223423026|NCT00177853|PROCEDURE|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
223423027|NCT03109353|DRUG|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
224137971|NCT02176590|BEHAVIORAL|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
223423028|NCT03247153|DIAGNOSTIC_TEST|Echocardiography|Imaging of the heart using ultrasound
224036352|NCT06010498|BEHAVIORAL|eye mask|"* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
224137972|NCT02176590|OTHER|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
224137973|NCT02619318|BEHAVIORAL|Balancing Everyday Life (BEL)|
224137974|NCT02619318|BEHAVIORAL|Care as usual (generally standard occupational therapy)|
223423029|NCT02383368|DRUG|ASP4132|oral
223423030|NCT00601172|DRUG|Casopitant|Experimental NK-1 receptor antagonist
223423031|NCT00601172|DRUG|Dexamethasone|Standard antiemetics
223423032|NCT00601172|DRUG|Placebo|Placebo to match IV casopitant
223423033|NCT00601172|DRUG|Ondansetron|Standard antiemetics
223423034|NCT02661269|DEVICE|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
223423035|NCT02661269|DEVICE|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
223423036|NCT04158674|DRUG|Levosimendan|Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
223423037|NCT04158674|DRUG|Cernevit|mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
224036353|NCT06010498|BEHAVIORAL|standart care|"Control group (n)~* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled"
224036354|NCT04500808|DRUG|Macitentan Dose 1|Participants will receive Dose 1 of macitentan tablet in Part 1.
224036355|NCT04500808|DRUG|Macitentan Dose 2|Participants will receive Dose 2 of macitentan tablet in Part 1.
224036356|NCT04500808|DRUG|Macitentan Dose 3|Participants will receive Dose 2 of macitentan tablet in Part 1 and 2.
224036357|NCT04500808|DRUG|Placebo|Participants will receive matching placebo from Day 1 up to Day 13.
224036358|NCT06333288|BEHAVIORAL|PST-APPLE Watch group|PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.
224036359|NCT06333288|BEHAVIORAL|Education-only control group|Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
224036360|NCT06845319|DRUG|Carboplatin|Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).
224036361|NCT06845319|DRUG|Paclitaxel|80mg/m2 weekly
224036362|NCT06845319|DRUG|Pembrolizumab|200 mg every 3 weeks for 4 cycles
224036363|NCT04424979|DEVICE|High power prisms|High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
224036364|NCT06560294|DRUG|Micronized purified flavonoid fraction (Daflon ®)|Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
224036365|NCT06560294|OTHER|Glue embolization|Patients will receive transcatheter glue embolization.
224036366|NCT06580938|BIOLOGICAL|PF-07921585|IL-12 mutein, solution, administered once every 3 weeks intravenously or subcutaneously
224036367|NCT06580938|BIOLOGICAL|Sasanlimab|Anti-PD1 antibody solution, administered once every 3 weeks subcutaneously
224036368|NCT03312348|DEVICE|Infrared imaging|Infrared image image acquisition of study participants
224036369|NCT03549000|OTHER|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
224036370|NCT03549000|OTHER|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
224036371|NCT03549000|DRUG|NIR178|NIR178 Specified dose on specified days, Orally
224036372|NCT06095713|DRUG|Pegunigalsidase-alfa|Standard of care
224036373|NCT06528210|DRUG|Gonadotropin Releasing Hormone Agonists and Antagonists|Given PO, IM, Sub-Q injection or Sub-Q implant
224036374|NCT06528210|DRUG|Bicalutamide|Given PO
224036375|NCT06528210|PROCEDURE|Biopsy Procedure|Undergo prostate biopsy
224036376|NCT06528210|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224137975|NCT05534204|PROCEDURE|Silk suture|Patients with bilateral impacted lower third molars will have operations for both sides. On one side for primarily closure after operation silk suture will be used.
224137976|NCT05534204|PROCEDURE|Polyester suture|Patients with bilateral impacted lower third molars will have operations for both side. On one side for primarily closure after operation polyester suture will be used.
223423038|NCT05437874|DRUG|Natural Water|"355 ml of regular coke, diet coke or mineral water should be drunk.~* Salivary pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Dental biofilm pH will be determined at 0, 5, 10, 15, 30, 45 and 60 minutes later~* Streptococcus mutans dental biofilm formation ( Colony Forming Units) will be conducted at 0 and 120 minutes later"
223423039|NCT05330364|DRUG|Chidamide|Chidamide 30mg/d p.o. begin at day 1, twice per week, during a 28-days cycle.
224036377|NCT06528210|PROCEDURE|Computed Tomography|Undergo CT scan
224036378|NCT06528210|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224036379|NCT06528210|BIOLOGICAL|Pembrolizumab|Given IV
224036380|NCT06528210|OTHER|Questionnaire Administration|Ancillary study
224036381|NCT06528210|RADIATION|Radiation Therapy|Undergo radiation therapy
224036382|NCT06528210|PROCEDURE|Bone Scan|Undergo bone scan
224036383|NCT00108186|DRUG|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
224036384|NCT06135714|DRUG|Systemic therapy for 12 weeks after primary registration|"* Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib"
224036385|NCT06135714|PROCEDURE|Radiation therapy (SBRT/conventional RT)|Brain: 18-24Gy/1Fr. or 27Gy/3Fr. or 30Gy/5Fr. Lung: 42Gy/4Fr.(peripheral) or 50Gy/8Fr.(central) or 60Gy/25Fr.(ultra central) Liver/Adrenal: 40Gy/5Fr. Bone: 35Gy/5Fr. Distant lymph node: 45/10Fr. or 60Gy/25Fr.
224036386|NCT06135714|PROCEDURE|Surgery|Surgery for the oligometastases
224137977|NCT03783052|DEVICE|SmartPill in fasted state|SmartPill administration in fasted state
224137978|NCT03783052|DEVICE|SmartPill in fed state|SmartPill administration in fed state
224137979|NCT03783052|OTHER|Aspiration|Aspiration of gastrointestinal samples in fasted and fed state
224137980|NCT03783052|OTHER|Gastric emptying scintigraphy|Gastric emptying scintigraphy in fed state
224137981|NCT02640352|DIETARY_SUPPLEMENT|Probi Defendum|
224137982|NCT02640352|DIETARY_SUPPLEMENT|Placebo|
224036387|NCT06135714|DRUG|Same systemic therapy after secondary registration|"* Luminal BC~  1. Denovo stage IV~     Premenopausal(PRE): Aromatase inhibitor(AI) + CDK4/6 inhibitor(CDK) +LHRH agonist, or Fulvestrant(FUL) + CDK4/6 inhibitor +LHRH agonist~     Postmenopausal(POST): AI + CDK~ 2. Recurrence after completion of postoperative endocrine therapy~     PRE: AI + CDK +LHRH agonist, or FUL + CDK +LHRH agonist~     POST: AI + CDK, or FUL + CDK~ 3. Recurrence during postoperative endocrine therapy~     PRE: FUL + CDK +LHRH agonist, or AI + CDK +LHRH agonist~     POST: FUL + CDK~* HER2-positive BC~Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)~・Triple negative BC.~1. PD-L1 negative - following a) or b)~   1. Taxane (naive for taxane)~  2. S-1 or Capecitabine or Eriblin (previously treated with taxane)~2. PD-L1 positive - following a) or b)~   1. Pembrolizumab + Gemcitabine + Carboplatin~  2. Atezolizumab + Nab-paclitaxel~3. BRCA-mutation positive Olaparib"
224036388|NCT04241172|DEVICE|Experimental: Immersive Virtual Reality (HIVR)|"the HIVR exercises will be performed using Nirvana system, a medical device based on virtual reality specifically designed to support motor rehabilitation, by projecting aquatic scenarios on the floor that simulates the movement and the noise of the water due to the motor exercise execution by the patient. In particular, the following virtual reality scenarios will be used:~* Swimming pool: the environment represents a swimming pool (water and edge). The patient must perform exercises by moving the lower limbs while sitting on a chair. The virtual environment gives the sensation of having the lower limbs immersed in water above the knees;~* Water metal: the environment gives the feeling of being immersed in water up to the waist. The subject interacts with the virtual water performing walking exercises and receiving a visual and auditory biofeedback."
224036389|NCT04241172|PROCEDURE|Traditional Hydrotherapy (TH)|"The TH group exercises will be performed in a swimming pool suitable for hydrotherapy treatments. In particular, patients will perform:~* exercises with a patients sitting on the swimming pool edge with lower limb immersed in the water;~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* water walking exercises."
224036390|NCT04241172|PROCEDURE|Traditional Rehabilitation (TR)|"The TR group exercises will be performed in the gym with a physiotherapist. In particular, patients will perform:~* exercises with a patient sitting on a chair (3 minutes per exercise):~* flexion-extension of the knee;~* leg and hip circling;~* flexion-extension of the ankle;~* triple flexion;~* walking (with and without aids)."
223423040|NCT05330364|DRUG|Cladribine|Cladribine 5mg/m2/d i.v. d1-5, once per day, during a 28-days cycle.
224036391|NCT04954820|DRUG|Lutathera|2 additional infusions of Lutathera®
224137983|NCT02072720|DRUG|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
223423041|NCT04187625|BIOLOGICAL|endothelial progenitor cell|Kidney-derived endothelial progenitor cells will be delivered percutaneously to the kidney blood supply.
223423042|NCT02056366|DRUG|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
223423043|NCT03715972|DRUG|Hydroxyurea|info included in arm group
223423044|NCT03715972|DRUG|Acetazolamide|Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
223423045|NCT06665139|DIAGNOSTIC_TEST|muscle thickness|Pain intensity will be measured with visual analog scale, sonographic severity grade of shoulder impingement syndrome, muscle thickness of serratus anterior muscle, upper trapezius and middle trapezius with USG in patients diagnosed with impingement and meeting the criteria and healthy volunteers.
223423046|NCT03030989|DRUG|Chlorhexidine Gluconate 2% Wipe|
223423047|NCT03030989|DRUG|Placebo Wipe|
223423048|NCT06559865|BEHAVIORAL|Breathing exercises|as per group description
223423049|NCT01826890|OTHER|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
223423050|NCT02872610|BEHAVIORAL|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
224137984|NCT00583440|BEHAVIORAL|12-step facilitation|12 weekly individual 12-step facilitation sessions
224137985|NCT00583440|BEHAVIORAL|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
223423051|NCT02706886|DRUG|Lumasiran|Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
223423052|NCT02706886|DRUG|Placebo|Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
223423053|NCT02083055|DRUG|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
223423054|NCT02083055|DRUG|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
223423055|NCT00090701|DRUG|AG2037|
223423056|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-1800 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-1800 (10 sessions of iTBS1800 with 50 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine).
223423057|NCT04653337|COMBINATION_PRODUCT|Robot-assisted accelerated iTBS-600 combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of robot-assisted accelerated iTBS-600 (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
223423058|NCT04653337|COMBINATION_PRODUCT|Sham accelerated iTBS combined with serotonin-norepinephrine reuptake inhibitors(SNRIs)|Subjects will receive a 5-day trial of sham accelerated iTBS (6 sessions of iTBS600 with 30 min interval per day over 5 consecutive days) combined with SNRIs（Venlafaxine or Duloxetine）
224036392|NCT05490121|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
224036393|NCT05842512|DRUG|ADI-PEG20|Treatment for NASH
224036394|NCT05842512|OTHER|Placebo|Treatment for NASH
223739780|NCT06263075|PROCEDURE|Intraoperative monitoring|"ANESTHESIOLOGICAL MANAGEMENT accords to usual practice. Participants underwent preoperative fasting (3 h for breast milk, 4 h for formula milk, and 1 h for clear liquids), no premedication, induction and maintenance by sevoflurane, fentanyl boluses for analgesia, mechanical ventilation (PEEP 4 cm H2O, target tidal volume 6-8 ml/Kg, end tidal CO2 32-40 mmHg), 10 ml/Kg/h of intraoperative fluids. Scalp block is performed before surgery.~MONITORING DURING SURGERY: monitor devices routinely used are connected to the participant: Dräger Infinity Delta XL®, Masimo® for pulse oximetry (Rainbow SET), regional cerebral oximetry (O3TM), and (optional) brain function monitoring (Masimo® SedLine). Arterial blood gas test is sampled at the anesthesiologist's discretion. After the artery catheterization, the MostCare® system is simultaneously connected to the patient monitoring devices. Data are collected every 3 minutes, 6 minutes for the noninvasive blood pressure measurement."
224036395|NCT05814575|BEHAVIORAL|NEXUS intervention|During the fetal ultrasound protocol, the NEXUS intervention is added for the component of 'attachment promotion' as it is a natural extension to share with the pregnant person the behavioral and social strengths of their unborn child. As the participant observes the fetus on the monitor (a second external monitor is set up for easy viewing by the mother), she may also feel fetal movement simultaneously in the womb (after 23 weeks gestation), creating a visual and sensory link between the mother and fetus. A trained nurse or ultrasonographer shares observations of fetal behavior with the mother and others if present. The nurse is also trained in motivational interviewing techniques to use the strengths of the mother and those attributed to her fetus to explore readiness to change and other motivational factors that may be barriers to health promotion.
224036396|NCT05814575|BEHAVIORAL|Standardized Non-Medical fetal ultrasound|A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.
224036397|NCT06452654|DRUG|Comirnaty Injectable Product|Vaccination
224036398|NCT06452654|DRUG|Sodium Chloride 0.9% Inj|Vaccination
224036399|NCT06675357|RADIATION|FAPI|5 +/- 2 mCi of Ga-FAPI-46
224036400|NCT06675357|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET scan
224036401|NCT06675357|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
224036402|NCT06490432|DEVICE|Transient elastography|Device that measures stiffness of liver tissue
224036403|NCT06078579|DIAGNOSTIC_TEST|Leptin|Assessment of salivary and serum leptin levels in oral lichen planus patients and healthy controls
224036404|NCT05598814|BIOLOGICAL|Mepolizumab Injection|All patients in both the intervention group and the control group will be treated with Mepolizumab injections every month.
224036405|NCT05598814|PROCEDURE|Functional Endoscopic Sinus Surgery (FESS).|The Functional Endoscopic Sinus Surgery will be performed 2 weeks after the first injection of Mepolizumab in the intervention group.
224036406|NCT06616389|DRUG|ODX (Osteodex)|Multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX.
224036407|NCT04033263|OTHER|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
224036408|NCT04033263|OTHER|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
224036409|NCT04033263|OTHER|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
224137986|NCT03719482|DRUG|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-1054 injection and PET scan.
224137987|NCT03420326|BEHAVIORAL|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
224137988|NCT00854178|DRUG|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
224137989|NCT04580251|PROCEDURE|Targeted axillary dissection|The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
224036410|NCT04033263|OTHER|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
224137990|NCT04365998|DEVICE|BUBOLight® Device|1 session of phototherapy with BUBOLight® device during 4 hours.
224137991|NCT01789853|BEHAVIORAL|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
224137992|NCT01789853|BEHAVIORAL|Conventional Physical Therapy|Regular physical therapy for 8 weeks
224137993|NCT00661245|DEVICE|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
224137994|NCT00661245|DEVICE|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
224137995|NCT02990897|BEHAVIORAL|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
224137996|NCT00016198|DRUG|FOLFOX regimen|
224137997|NCT00016198|DRUG|fluorouracil|
224137998|NCT00016198|DRUG|leucovorin calcium|
224137999|NCT00016198|DRUG|oxaliplatin|
224138000|NCT05246176|DEVICE|nephrostomy set|insertion of the nephrostomy set through the skin to obtaining good external drainage of bile in case of malignant obstructive jaundice.
223423059|NCT03862794|BEHAVIORAL|new social norm feedback letter with bar chart|letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
223423060|NCT03862794|BEHAVIORAL|standard social norm feedback letter|social norm feedback letter used as standard practice, without specific information about the prescribing percentile
223423061|NCT05681468|OTHER|Keto-SAT|"Nutrition counselling focused on Keto diet (saturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
223423062|NCT05681468|OTHER|Keto-CAN|"Nutrition counselling focused on Keto diet (unsaturated fat).~10% TE as carbohydrate (mainly from vegetables and whole grain products), protein between 20-30% TE and fat between 60-70%."
223423063|NCT05681468|OTHER|LFD|"Nutrition counselling focused on low-fat diet.~30% total energy (TE) as fat, 50% TE as carbohydrates (primarily whole grains) and 17-20% TE protein (mainly lean sources)."
223423064|NCT05269875|OTHER|ACP|The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
223423065|NCT00123617|PROCEDURE|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
223423066|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Healthcare workers will receive standard PPE and a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at the beginning of their shift, in the middle, and at the end of their shift.
223423067|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Patients will receive standard of care treatment and a pre- and post-study nasal spray COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle shortly after admission or preoperatively.
223423068|NCT04364802|DRUG|Povidone-Iodine Nasal Spray and Gargle|Community members will receive a pre- and post-study nasal swab COVID19 test. Additionally, they will receive povidone-iodine nasal spray and gargle (10% diluted 1:30) to use at home.
223563372|NCT06655298|DEVICE|US guided block|"Group Q; (28 patients) Quadratus lumborum block group; patients will receive general anesthesia initially then bilateral QLB type III (anterior subcoastal approach) with a volume of 30 mL of bupivacaine 0.25% for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg) \[9\].~✓ Group E; (28 patients) Erector spinae plane block; patients will receive general anesthesia initially then bilateral ESPB with a volume of 30 mL of bupivacaine 0.25 % for each side taking care that the patient does not receive a local anesthetic dose higher than the maximum allowed (2.5 mg/kg"
223563373|NCT06267872|BIOLOGICAL|CD4BS CH505M5 Pr-NP1|A ferritin NP expressing 8 copies of an HIV-1 Env protein trimer. To be administered intramuscularly (IM).
223563374|NCT06267872|BIOLOGICAL|CH505TF chTrimer|A stabilized chimeric SOSIP Env trimer protein with the N-terminal sequence of CH505 TF gp120 Env transplanted into the BG505 SOSIP sequence. To be administered IM.
223563375|NCT06267872|BIOLOGICAL|3M-052-AF (labeled as AP 60-702)|An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.
223563376|NCT06267872|BIOLOGICAL|Aluminum Hydroxide Suspension (Alum)|Alum to be administered IM as 500 mcg (aluminum content) admixed with 3M-052-AF (5 mcg) along with CD4BS CH505M5 Pr-NP1 and CH505 TF chTrimer.
223563377|NCT06267872|BIOLOGICAL|ACU-026-001-1 (labeled as empty LNP)|An AF consisting of 4 lipid components.
223563378|NCT06604546|DRUG|hyaluronidase|150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm)； D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg)； D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back)； 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
223739781|NCT06238596|PROCEDURE|rehabilitation|The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
223739782|NCT05564169|DRUG|Placebo|treatment per os
223739783|NCT05564169|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
223739784|NCT05564169|DRUG|Standard of care|Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
223739785|NCT05558904|DRUG|Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Given IV
223739786|NCT05558904|PROCEDURE|Computed Tomography|Undergo PET/CT
224036411|NCT06339450|OTHER|walk tours|"* During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break."
224036412|NCT05537740|DRUG|BAY3375968|Intravenous (IV) infusion
224036413|NCT05537740|DRUG|Pembrolizumab|IV infusion
224036414|NCT02076750|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
224036415|NCT06112613|OTHER|Electronic Health Record Review|Ancillary studies
223423069|NCT01669174|DRUG|Placebo|
223423070|NCT01669174|DRUG|BYM338|BYM338
223423071|NCT01115920|DRUG|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
223423072|NCT04353167|OTHER|observational evaluation|Patients will be evaluated only observationally without intervention
223423073|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
223423074|NCT00650117|DRUG|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
224036416|NCT06112613|OTHER|Health Promotion and Education|Receive access to educational materials
224036417|NCT06112613|PROCEDURE|Health Telemonitoring|Utilize the WiseBag medication dispenser
224036418|NCT06112613|OTHER|Interview|Complete an interview
224036419|NCT06112613|BEHAVIORAL|Patient Navigation|Receive healthcare provider follow ups as part of the CONCURxP program
223423075|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
223423076|NCT00650117|DRUG|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
223423077|NCT00650117|DRUG|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
224138001|NCT02472691|DRUG|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
223423078|NCT00650117|DRUG|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
223423079|NCT05046379|OTHER|Lipidomics|Lipidomics is the large-scale study of lipids (fats and fat-like molecules) within biological systems. It involves identifying and quantifying the wide variety of lipids in cells, tissues, or organisms to understand their roles in metabolism, signaling, and disease. Lipidomics is a subfield of metabolomics and uses advanced analytical techniques, like mass spectrometry, to profile lipid molecules. It helps in studying how lipids contribute to cellular functions, disease development, and responses to therapies.
224138002|NCT02472691|DRUG|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
224138003|NCT02472691|BIOLOGICAL|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10\^6 CD3/kg (1st DLI), 1-5x10\^6 CD3/kg (2nd DLI) and 5-15x10\^6 CD3/kg (3rd DLI).
224138004|NCT02725827|OTHER|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
223423080|NCT04582929|DRUG|Neuronox ® Injection|Neuronox ® 50 or 100 unit intramuscular injection
223423081|NCT03274141|OTHER|Non-Interventional|Non-Interventional
223423082|NCT05537441|BEHAVIORAL|Text messaging|Patients will receive up to 3 text messages reminding them about the importance of influenza vaccination during the 2022-2023 flu season.
223423083|NCT05528107|PROCEDURE|Lap IPOM plus|Participants will undergo Lap IPOM plus repair according to the assigned treatment arm.
224036420|NCT06112613|OTHER|Survey Administration|Ancillary studies
224036421|NCT06112613|OTHER|Text Message-Based Navigation Intervention|Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
224036422|NCT04998916|DEVICE|Real TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses of continuous theta burst stimulation with the active sham coil (double blinded using the integrated active sham system).
224036423|NCT04998916|DEVICE|Sham TBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the integrated active sham system). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the scalp. The electrodes are placed on the left frontalis muscle under the coil for both the real and sham stimulation sessions.
224138005|NCT02725827|OTHER|Control medium|The usual embryo transfer medium used in the study centres.
224298946|NCT02739945|PROCEDURE|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
224298947|NCT01288053|BIOLOGICAL|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
223423084|NCT05528107|PROCEDURE|eTEP|Participants will undergo eTEP repair according to the assigned treatment arm.
223423085|NCT01264237|DRUG|Etoricoxib|90mg Tablet QD at 10:00a.m.
223423086|NCT01264237|DRUG|Placebo|One tablet QD at 10:00a.m.
223423087|NCT03697759|OTHER|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
223423088|NCT06621147|PROCEDURE|Surgery|Surgery
223423089|NCT04164251|OTHER|Screening mammography|The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
224036424|NCT03289897|DIAGNOSTIC_TEST|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
224036425|NCT03681197|DRUG|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
224036426|NCT03681197|DRUG|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
224036427|NCT03681197|DRUG|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
223423090|NCT02819180|BIOLOGICAL|Butantan Influenza Trivalent, Fragmented and Inactivated vaccine|
223423091|NCT02849860|DRUG|IDP-121 Lotion|Lotion
223423092|NCT01641497|RADIATION|3D conformational radiation|25 \* 1.8 Gy in 5 weeks (=45 Gy)
223423093|NCT01641497|RADIATION|IMRT|25 \* 1.8 Gy in 5 weeks (=45 Gy)
223423094|NCT04310397|DRUG|Dabrafenib|Given PO
223423095|NCT04310397|BIOLOGICAL|Spartalizumab|Given IV
223423096|NCT04310397|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223423097|NCT04310397|DRUG|Trametinib|Given PO
223423098|NCT03397329|DRUG|AG-348 Sequence A|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
223423099|NCT03397329|DRUG|AG-348 Sequence B|"1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
223423100|NCT00985998|DRUG|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4\~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4\~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12\~18 weeks)."
223423101|NCT05613998|OTHER|GPR Group|"6-week treatment using the GPR method. 1 weekly session (45 min) with frog on the ground and sitting postures + daily home self-postures (10 min)"
223423102|NCT05613998|OTHER|Aerobic Exercice Group|6-week nonspecific aerobic exercise treatment. Participants will take a daily walk (20 min)
223423103|NCT05012904|BEHAVIORAL|parent involvement application|A parent was involved in the procedure. The parent held the children in their arms and holding the extremity from which the blood was drawn, holding the hands of children and communicating with their children in the child's room, and in this way the parent was involved in the procedure.
223563379|NCT06604546|DRUG|Placebo|150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
223423104|NCT05595564|DEVICE|Photobiomodulation therapy|A previous application of photobiomodulation therapy was offered or not, for possible performance enhancement.
223423105|NCT04231929|DEVICE|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved."
223423106|NCT01383629|BEHAVIORAL|Counselling|Preoperative counselling
223423107|NCT00723255|BIOLOGICAL|bevacizumab|Given IV
223423108|NCT00723255|DRUG|temsirolimus|Given IV
223563380|NCT05810571|PROCEDURE|preoperative remifentanil consumption|continuous remifentanil infusion will applied for peroperative analgesia
223563381|NCT05810571|PROCEDURE|postopeartive controlled anlagesia with morphine|postoperative morphine patient controlled analgesia will be applied for postoperative analgesia
223563382|NCT06811675|DRUG|Dexamethasone and N-acetylcysteine (NAC)|Dexamethasone 10mg IV STAT +QD for 3 days+NAC IV 200mg/kg over 4 hours, then 100 mg/kg over 16 hours
223563383|NCT06811675|DRUG|Placebo|Placebo
223563384|NCT06652386|OTHER|Telemedicine Group|"* Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request."
224036428|NCT03413371|DRUG|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
224036429|NCT03413371|DRUG|0,5 % bupivacaine with of 2% lidocaine|in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
223423109|NCT00614523|DRUG|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
223563385|NCT02601638|OTHER|Demographics and Health History Questionnaire|
223563386|NCT02601638|OTHER|Pre-Class Laryngectomy Survey|
223563387|NCT02601638|BEHAVIORAL|Counseling session with speech pathologist|
223563388|NCT02601638|BEHAVIORAL|Total Laryngectomy Preoperative Education Class|
223563389|NCT02601638|OTHER|Day of Hospital Discharge Laryngectomy Survey|
224036430|NCT03413371|DRUG|1 % Ropivacaine|in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
224036431|NCT03413371|DRUG|0,5 % bupivacaine|in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
224036432|NCT05531786|DRUG|Pacritinib|Pacritinib will be given as 100 mg or 200 mg tablets to be taken orally twice daily (12 hours apart) on days 1-28 of a 28 day cycle. Morning and evening should be taken at approximately the same time of day.
224036433|NCT01410136|PROCEDURE|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
224036434|NCT04823520|DRUG|TCA|All patients will receive 6 sessions at 2 weeks intervals,the half face which will recieve MDA and TCA,MDA will be done before appling TCA.
224036435|NCT05311098|DEVICE|cryoablation|Treatment of atrial fibrillation with cryoablation catheters
223563390|NCT02601638|OTHER|Day of Discharge Practicum|
223563391|NCT02601638|OTHER|Laryngectomy Education Study Exit Survey|
224036436|NCT05907291|DRUG|atumelnant (CRN04894)|Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
224036437|NCT04337333|DEVICE|Two-in-one stent|Endoscopic placement of a Two-in-one metal stent into extrahepatic bile duct
224036438|NCT01594866|DRUG|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
223423110|NCT00614523|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
223423111|NCT01249924|DEVICE|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
224036439|NCT01594866|DRUG|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
224036440|NCT01637623|DRUG|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
224036441|NCT01637623|DRUG|Allopurinol|Allopurinol 300 mg daily for 6 weeks
224036442|NCT01637623|DRUG|Placebo|Placebo capsule daily for 6 weeks
224036443|NCT01647750|DRUG|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
224036444|NCT01647750|DRUG|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
224036445|NCT06420895|OTHER|Clinical follow-up|Clinical follow-up of patients
224036446|NCT06420895|OTHER|Transthoracic Echocardiogram (TTE)|Transthoracic Echocardiogram
224036447|NCT06420895|OTHER|Magnetic resonance imaging (MRI)|Magnetic resonance imaging
224036448|NCT06420895|OTHER|Transesophageal echocardiogram (TEE)|Transesophageal echocardiogram
224036449|NCT05104008|OTHER|Lateral wedge insoles with home exercises group(Group 1)|In this group, participants were advised to use lateral wedge insole during walking and long-standing. Non customized full-length lateral wedge insoles of 7mm made of silicon material with 5 degrees angulation (because greater wedging is associated with foot discomfort) was used. Full-length wedge extends under the lesser metatarsal heads which increases the lever arm for rearfoot eversion and thus can prevent subtalar joint rotation. The evaluations were performed every week till fourth week.
224036450|NCT05104008|OTHER|Traditional physiotherapy with home exercises group (Group 2)|Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
224036451|NCT02029820|DEVICE|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
223423112|NCT01249924|DEVICE|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
224036452|NCT05968287|DIAGNOSTIC_TEST|The Leukocyte ImmunoTest™ (LIT™)|The baseline LIT scores was performed for two parallel groups. The sequential LIT score was also performed for patients with various infection conditions with/without sepsis.
224036453|NCT03829709|OTHER|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
224036454|NCT06079489|OTHER|Brochure-Based Exercise Program|Simple posture exercises
224036455|NCT06079489|OTHER|Telerehabilitation-Based Structured Exercise Program|Progressive physical fitness and posture exercises
224036456|NCT01777087|OTHER|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
224036457|NCT05737966|OTHER|evaluation of professional practices|Evaluation of professional practices : evaluation of the case management carried out in a program for early psychosis in France using a checklist according good practices guidelines
224036458|NCT05993949|DRUG|Dasatinib|3 pulses of oral dasatinib (100 mg daily) beginning on Day 4 (+up to 2 days) for 3 days (with 4 days off), repeated weekly. The weekly 3-day pulse schedule of dasatinib may continue for up to 3 months in subjects who continue to meet the dasatinib eligibility criteria and who do not meet off treatment/off study criteria
224036459|NCT05577078|PROCEDURE|Transcatheter edge-to-edge repair (TEER)|Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
224036460|NCT00701207|DRUG|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
223423113|NCT05565001|DRUG|Levcromakalim|Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
224036461|NCT06637917|DEVICE|OxySoftN™ Neonatal-Adult SpO2 Sensor with N600X Nellcor™ Patient Monitoring System|The Nellcor™ N-600x Pulse Oximetry System with N-600X Pulse Oximeter and Nellcor™ Sensors and Cables with OxiMax technology is indicated for prescription use only for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin and PR. The N-600x Pulse Oximeter is intended for use with neonatal, pediatric, and adult patients during both no motion and motion conditions and for patients who are either well or poorly perfused, in hospitals, hospital-type facilities, intra-hospital transport, and home environments.
223739787|NCT05558904|OTHER|Laboratory Biomarker Analysis|Correlative studies
223739788|NCT05558904|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224138006|NCT03896880|DIAGNOSTIC_TEST|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~1. Isolation of microorganisms:~2. Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~1. Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~2. Culture on Brilliance Candida differential agar"
223423114|NCT06342219|BEHAVIORAL|Neurofeedback Mindfulness|The participants will use a portable EEG headband (MUSE) which is a noninvasive tool for collecting EEG data. They will receive real-time EEG data given an audio feedback while doing their daily mindfulness practice.
223423115|NCT06342219|BEHAVIORAL|Attention Task|The participants in this arm will use the portable EEG while listening to an audiobook. They will receive a summary of their brain activities after task completion on each day.
223423116|NCT03500458|BEHAVIORAL|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
223423117|NCT02000336|DRUG|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
223423118|NCT02000336|DRUG|Placebo|
223423119|NCT03635905|DRUG|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
223423120|NCT03635905|DRUG|Placebo|Methylcellulose placebo capsule
223423121|NCT00776113|DRUG|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
223423122|NCT04220749|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
223423123|NCT04220749|PROCEDURE|Trans-Oral Surgery (TOS) + Neck Dissection|Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
223423124|NCT03310801|PROCEDURE|ACP or Watchman|Left atrial appnedage occlusion using ACP or Watchman
223423125|NCT02130804|DRUG|Salsalate (4 g/day)|Given orally twice daily
223423126|NCT02130804|DRUG|Placebo (4 g/day)|Given orally twice daily
223423127|NCT02339350|DRUG|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
223423128|NCT02339350|DRUG|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
223423129|NCT03224416|OTHER|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
223423130|NCT03224416|OTHER|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
223563392|NCT02221635|PROCEDURE|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
223563393|NCT02221635|DRUG|Risperidone|Risperidone (2-4 mg) was took orally.
223563394|NCT06657391|DRUG|recombinant humanized anti-CD25 monoclonal antibody|The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
223739789|NCT06481592|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
223739790|NCT05670080|BEHAVIORAL|Motor Imagery|Motor imagery is the imagining of action without its physical execution and motor imagery elicits activity in brain regions that are normally activated during actual task performance. The brain perceives real experiences and the visualization process as similar. For this reason, imagery is considered a mental exercise
223739791|NCT05670080|BEHAVIORAL|Physical Therapy|Electrotherapy (TENS), cold pack therapy, joint range of motion exercises, and strengthening exercises for the muscles around the shoulder.
224298949|NCT04201886|OTHER|serum calprotectin|serum calcium binding leucocyte protein
224298950|NCT06316648|DIETARY_SUPPLEMENT|whey intake group|It was prepared at the bedside by the first investigator for the patients in the oral whey intervention group by mixing 54 grams of 70% demineralized whey powder taken from the herbalist into 600 ml of drinking water six hours before the surgery, and the patients were given 400 ml six hours before the surgery and 200 ml two hours before the surgery. They were given ml and allowed to drink.
224298951|NCT06316648|PROCEDURE|control group|The patients were left fasting after 00:00.
223423131|NCT03224416|OTHER|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
223423132|NCT05038501|OTHER|To study comorbidities in patients undergoing Oncosurgeries|In the Preoperative Anaesthesia checkup we will study prevalence of comorbidities as Coronary artery Disease, Hypertension, Diabetes Mellitus , Hypothyroidism and prior Corona Virus Infection in patients undergoing Oncosurgeries
223563395|NCT06656650|BEHAVIORAL|Commensality groups|Participants will attend at least 3 out of 6 commensality groups over the course of 6 months.
223563396|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the Left DLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).
223563397|NCT06658795|DEVICE|Transcranial direct current stimulation (tDCS) on the right VLPFC|The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)
223563398|NCT06658795|DEVICE|Sham stimulation group|The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
223563399|NCT06661174|PROCEDURE|Bariatric surgery|Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function
223563400|NCT06661174|OTHER|Non-surgical therapy|Diet management，exercise，metformin，GLP-1 receptor agonists and other drugs which can lose weight.
223563401|NCT06660524|DRUG|Sevelamer|Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
223563402|NCT06660524|DRUG|Calcium carbonate|Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
223739792|NCT06385015|BEHAVIORAL|Tailored DPP Intervention|The intervention includes 19 sessions (18 in-person and 1 on-demand) covering 24 DPP modules; each session is approximately an hour in length and will be moderated by a trained lifestyle coach. Lifestyle coaches are accessible, collaborative, and culturally competent diabetes care and education specialists trained and certified in the CDC's National DPP curriculum to provide effective guidance and support for program participants. Each group will meet regularly during the academic year, with six in-person sessions delivered per 10-week quarter (for each of three quarters) to allow for breaks during final exams and scheduled school recess (e.g., spring break). It will take place on UCLA campus.
223739793|NCT04643444|DIAGNOSTIC_TEST|Blood sampling|Testing for the presence of SARS-CoV-2 antibodies
224036462|NCT06637917|DEVICE|LNCS® NEO SpO2 Sensor with RAD-97™ Pulse CO-Oximeter|The Masimo Rad-97™ and accessories are indicated for the continuous non-invasive monitoring of functional oxygen saturation of arterial hemoglobin, PR, carboxyhemoglobin saturation (SpCO), methemoglobin saturation (SpMet), total hemoglobin concentration (SpHb), and/or acoustic respiratory rate (RRa). The Masimo Rad-97™ and accessories are indicated for use with adult, pediatric, and neonatal patients during both no motion and motion conditions, and for patients who are well or poorly perfused. In addition, the Masimo Rad-97™ and accessories are indicated to provide the continuous non-invasive monitoring data obtained from the Masimo Rad-97™ and accessories for functional oxygen saturation of arterial hemoglobin and PR to multi-parameter devices for the display on those devices.
224036463|NCT06637917|DEVICE|1041PTS (or similar) Kendall™ Neonatal Electrodes with IntelliVue MP5 Portable Patient Monitor|Market-released ECG monitoring system
224036464|NCT01475578|DRUG|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
224036465|NCT01475578|DRUG|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
224036466|NCT03696615|OTHER|Tabata Kettlebell Swing Workout|See description of experimental arm.
224036467|NCT03696615|OTHER|Control|see description of control arm
223423133|NCT05743101|DRUG|Levofloxacin|Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
223423134|NCT05743101|DRUG|Levofloxacin simulant|Levofloxacin simulant is placebo.Endovascular thrombectomy is one of the treatments for acute ischemic stroke.
223423135|NCT06623175|DEVICE|Acupuncture needles|See arm description
223423136|NCT01084200|DRUG|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
223423137|NCT01084200|DRUG|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
223423138|NCT01084200|DRUG|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
223423139|NCT00318500|DRUG|ERB-041|
223423140|NCT05514587|BEHAVIORAL|Meaning of Life Questionnaire (MLQ)|Completion of questionnaires at crisis centre entry and 3 months later.
223423141|NCT06428552|DEVICE|Mobile Application|Daily rehabilitation program of 40 minutes duration using a mobile application to be completed 6 days per week for 12 weeks
223423142|NCT05530200|RADIATION|Hypofractionated radiotherapy|24Gy/8Gy/3f
223423143|NCT05530200|DRUG|PD-L1 inhibitor|q3w
223423144|NCT05530200|DRUG|GM-CSF|200μg, D1-D7
223423145|NCT05530200|DRUG|IL-2|at a dose of 2 million IU, D8-D14
223423146|NCT03966924|DEVICE|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
223423147|NCT05887570|BEHAVIORAL|Educational intervention|intervention through extra education, modules, instruction on models
223423148|NCT05887570|OTHER|Control - Regular Instruction|participants receive usual training
223423149|NCT05603195|DRUG|REGN7508 (IV)|Administered sequential, ascending single intravenous (IV) dose
223423150|NCT05603195|DRUG|REGN7508 (SC)|Administered sequential, ascending single subcutaneous (SC) dose
223423151|NCT05603195|DRUG|Matching Placebo (IV)|Administered sequential, ascending single intravenous (IV) dose
223423152|NCT05603195|DRUG|Matching Placebo (SC)|Administered sequential, ascending single subcutaneous (SC) dose
223423153|NCT04184362|DEVICE|Empower Neuromodulation System Transcutaneous Electrical Nerve Stimulation|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
224036468|NCT00538304|DRUG|bimatoprost eye drops|1 drop in each eye daily for 1 month
224036469|NCT00538304|DRUG|placebo|1 drop in each eye daily for 1 month
224036470|NCT00960960|DRUG|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
223423154|NCT05115422|BEHAVIORAL|'Coping with Brain Fog' program|The proposed intervention is an 8-week 'Coping with Brain Fog' program for cancer survivors, adapted for AYAs with cancer, with one 90-minute group session per week. The intended group size for the program is 8-12 participants. The program was developed to be delivered in person, however for the purposes of this study it will be conducted in a virtual setting. The overall goals of the program are to educate participants about cancer-related brain fog and enhance their cognitive function and wellbeing. To accomplish this, the program is segmented into three main components: memory skills, task management, and psychological wellbeing. For each component, participants are systematically introduced to evidence-based strategies to cumulatively build a repertoire of cognitive tools designed to reduce the impact of cancer-related brain fog. The program uses a manual and participant materials that are copyrighted by Maximum Capacity Inc.
223423155|NCT05911828|DRUG|ZY19489 + Ferroquine (FQ)|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
223423156|NCT05911828|DRUG|Placebo|ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
223423157|NCT02726438|DRUG|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
223423158|NCT06010238|DEVICE|Short term variation|Short term variation in computer software analysis
223423159|NCT06010238|DEVICE|Visual interpretation|Visual interpretation of cardiotocography
223423160|NCT00735137|DEVICE|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
223423161|NCT00868491|DRUG|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
223423162|NCT00868491|RADIATION|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
223423163|NCT00868491|DRUG|cetuximab, cisplatin|"* cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
223423164|NCT04512599|OTHER|Prebiotic Bar|The prebiotic bar is a proprietary formula created by the study co-investigators, who will not be involved in participant recruitment, selection or outcome measures.The prebiotic bars will be shipped and stored at room temperature prior to consumption.
223563403|NCT06659809|BEHAVIORAL|Tele-care video-feedback intervention (TVFI)|The TVFI 6 weekly sessions are organized in two subsequent phases: 4 sharing the focus sessions and 2 integration sessions. Sharing the focus sessions are dedicated to the discussion between the psychologist and the mother of specific themes related to parenting and parent-infant interaction: physical stimulation, responsiveness, teaching, and parenting experience. The goal of the sharing the focus sessions is to develop insights about the infants' behavioral signals, the best ways to provide stimulations and get in touch, strategies to promote emotion regulation, and to sustain cognitive and behavioral achievements. In the subsequent two integration sessions, the mother plays with the infant while the psychologist provides guidance based on topics previously discussed during the first four sessions. The goal is to promote a pragmatical translation of the insights developed during the sharing the focus sessions into the interactive exchanges between the mother and the infant.
224036471|NCT00960960|DRUG|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
224036472|NCT00960960|DRUG|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
224036473|NCT00960960|DRUG|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle.
224036474|NCT00960960|DRUG|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
224036475|NCT05712200|BIOLOGICAL|Abelacimab|Abelacimab provided as liquid in vial (150 mg/mL)
224036476|NCT05712200|DRUG|Placebo|"Dosage Formulation: Liquid (in vial)~Dose Strength: Placebo to Abelacimab"
224138007|NCT03896880|OTHER|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
224298952|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
223563404|NCT06658054|DRUG|Adjuvant analgesia|Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.
223563405|NCT06658054|DRUG|Control (Standard treatment)|Patient will receive standard ESPB with bupivacaine and normal saline
224036477|NCT03992469|DRUG|EBFAHF-2|EBFAHF-2 is a 0.55g capsule that is easy to swallow. The quality, safety and consistency of EBFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 capsules bid) and full dose (maximum of 5 capsules bid). Weight based dosing will ensure an equivalent amount is given to each individual.
224036478|NCT03992469|DRUG|Placebo|Placebo capsules made of cornstarch
224036479|NCT02698969|DRUG|Sugammadex|
224036480|NCT02698969|DEVICE|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
224138008|NCT03896880|OTHER|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
224138009|NCT03896880|OTHER|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
224138010|NCT02027168|OTHER|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
224036481|NCT02698969|DRUG|Neostigmine|
224036482|NCT02698969|DRUG|Atropine|
224036483|NCT02698969|DEVICE|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
224036484|NCT02698969|DRUG|Rocuronium|Rocuronium will be administered 0.6 mg\*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg\*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
224036485|NCT02698969|DRUG|Fentanyl|Fentanest will be administered 2 mcg\*kg-1 at the induction of general anesthesia and titrated 0.5 mcg\*kg-1 every 30 minutes
224036486|NCT02698969|DRUG|Propofol|Propofol will be administered 2 mg\*kg-1 at the induction of general anesthesia
224036487|NCT02698969|DRUG|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
224036488|NCT03426254|BIOLOGICAL|Injections Subcutaneously Talazoparib|Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
224036489|NCT03426254|DRUG|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28.
224036490|NCT05561829|BEHAVIORAL|Sleep Optimization|Automated digital administration of a sleep optimization module via mobile or web application, lasting approximately six weeks. Based on the participant's situation and needs, sleep restriction, sleep compression, or circadian-rhythm normalization is advised and conducted. The aim is to optimise the participant's sleep efficiency.
224036491|NCT05561829|BEHAVIORAL|Stimulus Control Therapy|Automated digital administration of a stimulus control therapy module via mobile or web application, lasting approximately six weeks. The aim is to strengthen associations between sleep and the sleep environment and to eliminate conditioning of non-sleep behavior and the sleep environment.
224036492|NCT05561829|BEHAVIORAL|Relaxation Training|Automated digital administration of a relaxation training module via mobile or web application, lasting approximately six weeks. The aim is to reduce somatic tension and limit intrusive thought processes that interfere with sleep.
224036493|NCT05561829|BEHAVIORAL|Cognitive Therapy|Automated digital administration of a cognitive therapy module via mobile or web application, lasting approximately six weeks. The aim is to identify, challenge, and modify dysfunctional beliefs about sleep.
223423165|NCT06333574|OTHER|Family weight self-measurement and remote follow-up management based on wechat.|On the basis of routine outpatient management, patients or their family members were subjected to remote follow-up management based on wechat, and the follow-up time was 6 months. Specific methods: Same as the control group, the information of weight and blood pressure of the patients was registered at the end of dialysis, and the purpose, role and importance of weight management were informed to the patients. On this basis, a special wechat signal is set up to add patients or patients' family members as wechat friends and establish a wechat interaction platform with patients. In the interdialysis period, remind patients to weigh themselves through wechat (the time of each weighing is fixed, preferably consistent with the time of weighing in the hemodialysis center), control the weight gain during the interdialysis period not to exceed 4.5% of dry weight, and inform patients again about the purpose, role and importance of weight management.
223563406|NCT04613492|BIOLOGICAL|MEDI9253|Participants will receive either single or multiple dose of MEDI9253; sequentially or concurrent with Durvalumab
223739794|NCT04643444|OTHER|Online Questionnaire|Questions on working place, risk profiles and PPE
223739795|NCT05860257|BEHAVIORAL|PeerLearning.net|PeerLearning.net provides an easy-to-use, scalable, and widely accessible means to support teachers in effectively designing and delivering high-fidelity Cooperative Learning (CL) lessons and, in turn, it has the potential to amplify the positive effects of CL found in previous research. Using PeerLearning.net, teachers design their lesson by selecting from among a set of typical CL lesson templates (e.g., jigsaw, peer tutoring, group projects) which they can customize and populate with their own curriculum and materials. These design templates represent the optimal, high-fidelity design that is required in order for CL to be successful. During lesson delivery, PeerLearning.net manages membership in learning groups, distributes instructional materials, directs student activities according to a pre-specified timetable, supports teacher observations of student behavior, and delivers post-lesson group activities and reviews.
223739796|NCT06534060|BIOLOGICAL|Genetic: MB-105|MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.
223739797|NCT05958342|DRUG|Calcium Gluconate|1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes
223739798|NCT05958342|DRUG|Vasopressin|4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours
224036494|NCT05561829|BEHAVIORAL|Sleep Hygiene Education|Automated digital administration of a sleep hygiene education module via mobile or web application, lasting approximately six weeks. The aim is to identify and modify environmental and lifestyle factors that may interfere with sleep.
224036495|NCT02170389|OTHER|Laboratory Biomarker Analysis|Correlative studies
224036496|NCT02170389|PROCEDURE|Nephrectomy|Undergo partial or radical nephrectomy
223423166|NCT06333574|OTHER|Routine care|The dialysis doctor registered the information of the patient's weight and blood pressure at the end of dialysis, and informed the patient of the purpose, role and importance of weight management.
223423167|NCT04763655|DIAGNOSTIC_TEST|clinical and neuropsychological testing|Patients are monitored with Brief Psychiatric Rating Scale (BPRS) weekly and structural and functional MRI and MATRICS battery before and at the end of the course of the study
223423168|NCT00508287|DRUG|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
223423169|NCT00508287|DRUG|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
223563407|NCT04613492|BIOLOGICAL|Durvalumab|Participants will receive durvalumab treatment sequentially or concurrently with MEDI9253
223739799|NCT05958342|DRUG|saline placebo|saline placebo volume matched to prehospital or in hospital phase
224036497|NCT02170389|BIOLOGICAL|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
224036498|NCT00190632|DRUG|Duloxetine|
224036499|NCT00171574|DRUG|Valsartan|
224036500|NCT00171574|DRUG|Valsartan plus HCTZ|
224036501|NCT00171574|DRUG|Lisinopril|
224138011|NCT00234572|DRUG|Lanreotide (Autogel formulation)|
224138012|NCT00002386|DRUG|Indinavir sulfate|
224138013|NCT00002386|DRUG|Lamivudine|
224138014|NCT00002386|DRUG|Stavudine|
224138015|NCT00002386|DRUG|Zidovudine|
224138016|NCT00002386|DRUG|Zalcitabine|
224138017|NCT00002386|DRUG|Didanosine|
224298953|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
224036502|NCT04780308|PROCEDURE|Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires|The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
224036503|NCT05009745|PROCEDURE|PGT-A Strategy|PGT-A strategy involves trophectoderm biopsy, comprehensive chromosome screening (CCS) using Next Generation Screening (NGS), freezing of embryos and replacement in a frozen-thawed embryo transfer cycle.
224036504|NCT03252275|OTHER|Peer learning|Peer learning plus HBB and ECEB
224036505|NCT01285466|DRUG|BEZ235 + paclitaxel|
224036506|NCT01285466|DRUG|BKM120 + paclitaxel|
224036507|NCT01285466|DRUG|BEZ235 + paclitaxel + trastuzumab|
224036508|NCT01285466|DRUG|BKM120 + paclitaxel + trastuzumab|
224036509|NCT01008696|DRUG|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
224036510|NCT01008696|DRUG|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
224036511|NCT02929797|BIOLOGICAL|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
224036512|NCT02929797|DRUG|Gemcitabine|gemcitabine
224036513|NCT04874181|DEVICE|Silverfit 3D|Virtual reality game used for rehabilitation of stroke patients
224036514|NCT06565455|BEHAVIORAL|Growing Healthy Children and Families in Rural Arkansas|The intervention will consist of seven healthy eating culturally developed modules, which will be implemented/delivered in the participants home and two cooking demonstration/tasting workshops for the participants in the intervention group (mothers in the church setting and individual and collective goal settings for the intervention group.
224036515|NCT05097911|DRUG|MTL-CEBPA|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
224138018|NCT01527019|DRUG|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
224138019|NCT01527019|DRUG|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
224138020|NCT01527019|DRUG|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
224138021|NCT05294211|DEVICE|M•care™ System|The M•care™ System will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
224138022|NCT05294211|DEVICE|Cardiotocography (CTG)|A standard of care CTG device will be applied for monitoring of fetal heart rate (FHR), maternal heart rate (MHR) and uterine activity (UA)
224138023|NCT05759845|DRUG|Topiramate 25Mg Tab|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
224138024|NCT05759845|DRUG|Amitriptyline 25 Mg Oral Tablet|Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
224138025|NCT05759845|DRUG|topiramate 25mg plus amitriptyline 25mg|topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
224298954|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
224298955|NCT00144781|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
224298956|NCT02068092|DRUG|Hydroxytyrosol|
224298957|NCT03684187|BEHAVIORAL|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
224298958|NCT04786548|DRUG|Celecoxib|Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks.
224298959|NCT06424067|DRUG|Fingolimod 0.5 milligram (mg) [Gilenya]|Oral fingolimod will be administered at a dose of 0.5 mg once a day.
224298960|NCT04196972|OTHER|Communication Intervention|Receive ECHO telementoring intervention
224298961|NCT04196972|OTHER|Questionnaire Administration|Ancillary studies
224298962|NCT04196972|OTHER|Waiting List|Placed on wait-list
224298963|NCT03607708|OTHER|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
223423170|NCT00508287|DRUG|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
223423171|NCT03357575|BIOLOGICAL|Mesenchymal Stem Cells from adipose|inject mesenchymal Stem Cells from adipose
223423172|NCT03357575|BIOLOGICAL|Hyaluronic Acid|inject hyaluronic acid
224036516|NCT05097911|DRUG|Atezolizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
223563408|NCT06654284|OTHER|quality of life questionnaires|"All patients will receive a combination of quality of life questionnaires aimed at predeifined time points (baseline, 3 months, 1 year, 3 year, 6 year, 9 year and 12 year) collecting a complete overview of different aspects of quality of life, including: - Florida patient acceptance score (FPAS) - Short Form Health Survey (SF-12) - Kansas City Cardiomyopathy Questionnaire (KCCQ-12) - Hospital Anxiety and Depression Scale (HADS) - Florida Shock Acceptance score (FSAS) - Steinke Sexual Concerns Inventory - the Good Death questionnaire"
223563409|NCT04254653|BEHAVIORAL|American Indian and Alaska Native What Can I Eat?|Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
223563410|NCT06607224|DEVICE|Experimental (Decision making guided by CGM)|Patients use FSL2 and a smartphone. Libreview app will be used to assess interstitial glucose, alarms, and trend arrows, and LibreLinkUp app for research team. Concurrently, CG will be performed using the FreeStyle Optium Neo glucometer from Abbott. The nursing staff will be trained to manage and respond to alarms and trend arrows according to established protocols. The basal insulin adjustment protocol establishes with fasting and premeal targets between 140-180 mg/dL. For prandial insulin, corrective guidelines set according to each patient sensitivity factor, with additional adjustments for the intervention group based on trend arrows. The hypoglycemia alarm sets below 85 mg/dL. If activated, nursing staff will confirm the value via CG. If values are below 70 mg/dL, follow hypoglycemia protocol and if below 100 mg/dL with a descending trend arrow, 15 grams of slow-acting carbs. The hyperglycemia alarm will be set above 300 mg/dL and nurse inform investigators to make decisions.
223563411|NCT03684603|BEHAVIORAL|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
223563412|NCT03684603|BEHAVIORAL|melody only during motor training|sequence of tones which are presented to the patient using earphones
224036517|NCT05097911|DRUG|Bevacizumab|The starting dose will be at dose level 1. For cycle 1 only, there will be a lead-in period whereby patients will receive one dose of MTL-CEBPA, 7 days prior to cycle 1 day 1. MTL-CEBPA is then administered on Day 1 and 8 of each cycle, atezolizumab is administered on Day 1 of each cycle and bevacizumab is administered on Day 1 of each cycle. One cycle of treatment consists of 21 days.
224036518|NCT01318954|BIOLOGICAL|Allergen immunotherapy|
224036519|NCT04630847|BIOLOGICAL|Fecal Microbiota Transplant|FMT utilizing stool from first degree relatives
224036520|NCT03537859|OTHER|Augmented Reality|Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
224036521|NCT03537859|OTHER|Non Augmented Reality|Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
224036522|NCT03549533|OTHER|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
224036523|NCT02743377|OTHER|Brain PET Imaging with 11C Rolipram|Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
224298964|NCT03607708|OTHER|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
223423173|NCT02870816|PROCEDURE|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
223423174|NCT02870816|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
223423175|NCT02870816|PROCEDURE|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
223423176|NCT06617910|RADIATION|SBRT by Cyberknife|The patients with sinonasal maliganacy receive curative surgery then receive adjuvant RT by the method of SBRT by Cyberknife.
223423177|NCT02542241|DRUG|Sodium Chloride [3%]|Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
223423178|NCT02542241|DRUG|Sodium Chloride [0.9%]|Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
223423179|NCT01763723|DEVICE|IPL-home use device|A light based home use device for hair removal
223423180|NCT04598451|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
223423181|NCT04598451|OTHER|Placebo|Subcutaneous injection of placebo
223423182|NCT04598451|DRUG|prednisone|Oral prednisone tablets
223423183|NCT01311518|DRUG|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
223423184|NCT01311518|DRUG|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
223423185|NCT03338543|DEVICE|PENS|percutaneous electrical nerve stimulation
223423186|NCT03338543|DEVICE|TENS|transcutaneous electrical nerve stimulation
223423187|NCT05383092|OTHER|Adapted Physical Activity Strong|Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
223423188|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
223423189|NCT01264848|PROCEDURE|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
223423190|NCT00722566|DRUG|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
223423191|NCT00722566|DRUG|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
223423192|NCT04621526|DRUG|dexmedetomidine- ketamine|patients will receive combination of ketamine 1mg/kg and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and ketamine 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
223423193|NCT04621526|DRUG|dexmedetomidine- propofol|patients will receive combination from 0.5 mg/kg propofol and dexmedetomidine 1ug/kg diluted in 10 ml 0.9% saline infused over 10 min together as an intravenous bolus dose then a maintenance of 0.5ug/kg/h dexmedetomidine and propofol 0.5 mg/kg/h continuous infusion in two separate syringes pump to achieve modified Observer's Assessment of Alertness and sedation score (OAA/S) 3 and the infusion will stopped by finishing the skin suture.
223423194|NCT06619223|DIAGNOSTIC_TEST|Duplex Ultrasound|The primary intervention in this study is the use of ankle Doppler waveform assessment for post-revascularisation surveillance in patients with Peripheral Arterial Disease (PAD). This technique utilises continuous-wave Doppler (CWD) and pulsed-wave Doppler (PWD) to assess the blood flow in the key ankle arteries, including the dorsalis pedis artery (DPA) and posterior tibial artery (PTA).
223423195|NCT01570569|DRUG|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
223563413|NCT00753103|BIOLOGICAL|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
223563414|NCT00753103|DRUG|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
224036524|NCT02743377|DRUG|Whole Body PET Baseline with 11C Rolipram|Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
224036525|NCT02743377|DRUG|Whole Body PET Blocked with Roflumilast|Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
224036526|NCT05987852|DEVICE|Hyperbaric Oxygen Therapy|"Participants enrolled in the active intervention group receiving HBOT will undergo compression to 2.4 Atmospheres Absolute (ATA; 100% O2) for 90 minutes with two 5-10 minute air breaks (breathing room air at the 2.4 ATA) during the session. This is done once a day for 5 days."
224036527|NCT05987852|OTHER|Sham Hyperbaric Air|"This control arm will undergo compression to 1.34 ATA for monoplace chambers and 2.4 ATA for multiplace chambers for the full 90-minute session but 21% oxygen instead of 100% oxygen being administered. These participants will also have two 5-10 minute air breaks to mimic the treatment protocol. Multiplace sham sessions will have modified air breaks to avoid decompression sickness. This will happen once a day for 5 days."
224036528|NCT06469346|OTHER|Nordic Hamstring Eccentric Exercise Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~Nordic eccentric exercise protocol:~* Week 1: 2 sets x 5 repetitions~* Week 2: 2 sets x 6 repetitions~* Week 3: 3 sets x 6 repetitions~* Week 4-6: 3 sets x 8 repetitions"
224036529|NCT06469346|OTHER|Passive Hamstring Static Stretching Training|"Warm up: stationary bycicle at 50 watts and 60 bpm Mobility exercises for hip and knee joint~* Week 1-2: 1 set x 2 repetitions of 30 seconds~* Week 3: 1 set x 3 repetitions of 30 seconds~* Week 4-6: 1 set x 3 reps of 40 seconds"
224298965|NCT05948592|BIOLOGICAL|TP-102|Patients randomised to TP-102 will receive 1 (one) mL of IP solution, applied topically per cm3 of target ulcer. The titre of each bacteriophage in TP-102 is 1x109 PFU/mL (\>1x108 PFU/mL and \<1x1010 PFU/mL). All patients randomised to TP-102 will receive the same concentration per mL. TP-102 will be applied to the target ulcer using a syringe without a needle. The volume of TP-102 to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
223423196|NCT01570569|DRUG|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
223423197|NCT01570569|DRUG|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
223423198|NCT01570569|DRUG|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
223423199|NCT01570569|DRUG|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
223563415|NCT00753103|DRUG|Prednisolone|Daily oral 1mg/kg tapered over 12 months
223563416|NCT00753103|DRUG|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
223563417|NCT00753103|PROCEDURE|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine \> 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
224036530|NCT06469346|OTHER|Control Group|No intervention
224036531|NCT03953443|OTHER|Not interventional|
223423200|NCT01570569|DRUG|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
223423201|NCT00854919|DRUG|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
223423202|NCT00854919|BEHAVIORAL|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
223423203|NCT05967923|RADIATION|Shock wave therapy|Patients in this group will receive shock wave therapy once a week for four weeks in addition to routine physical therapy program.
223423204|NCT05967923|RADIATION|Low level lazer therapy|Patients in this group will receive low level lazer therapy three times a week week for four weeks in addition to routine physical therapy program.
223423205|NCT05967923|OTHER|Routine physical therapy program|Patients in this group will receive only routine physical therapy program three times a week for four weeks.
223423206|NCT03504306|OTHER|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
223423207|NCT04885400|BEHAVIORAL|iJobs|During the program, the participants will learn and exercise successful job search strategies. The web-based adaptation of the Jobs program will allow self-administration. After each session, they will receive written feedback from trainers on the platform.
223423208|NCT06730737|OTHER|Video preventive education|Interactive video that teaches the subject about the overall importance of prevention, smoking cessation, proper diet, exercise, and sleep.
223423209|NCT06517043|BEHAVIORAL|Balance Training|Complex balance task involving static and dynamic weight shifting and coordinated stepping
223423210|NCT06517043|DEVICE|Spinal Active tsDCS|Active tsDCS over lumbar regions
223563418|NCT00753103|DRUG|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
223563419|NCT00753103|DRUG|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
223563420|NCT02373956|DEVICE|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
224036532|NCT02076113|PROCEDURE|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
224036533|NCT02076113|PROCEDURE|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
224036534|NCT02076113|PROCEDURE|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
224036535|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
224036536|NCT03027154|BIOLOGICAL|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
224036537|NCT04908605|DRUG|Mirtazapine|Every patient will be given mirtazapine 30 mg tablet
223423211|NCT06517043|DEVICE|Spinal Sham tsDCS|Sham tsDCS over lumbar regions
223423212|NCT03225755|DRUG|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
223423213|NCT06965556|OTHER|Medical Humanities-based Patient Education Strategy|Medical Humanities-based Patient Education with Comic-based Medical Education Materials for Breast Cancer Patients during Perioperative Hospitalization Stage
223423214|NCT04185428|BEHAVIORAL|Integrative Therapy|still meditation, meditative movement, relaxation techniques, and massage therapy
223423215|NCT05675904|PROCEDURE|Colon oncological resection|Scheduled colon cancer surgery
223423216|NCT06967077|OTHER|Virtual reality head set.|Tennis game exercise using virtual reality head set
223423217|NCT06968858|DIAGNOSTIC_TEST|NIMBLE test|Non-invasive assessment of ISR with the NIMBLE System (Microwave Interferometry)
223423218|NCT05579197|DEVICE|Lower-limb robotic intervention|"The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.~Specifically, the tasks involve walking, sit to stand, balance and stair climbing.~During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:~* The Optogait system; for a markerless gait analysis;~* The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.~Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients."
223563421|NCT02373956|PROCEDURE|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
223563422|NCT06659731|OTHER|Quantitative Sensory testing (QST)|The QST protocol (Rolke et al., 2006; Blankenburg et al., 2010), implies the administration of 7 short sensory test in order to measure up to 13 parameters, which can be grouped as follows: thermal detection thresholds for the perception of cold, warm and paradoxical heat sensations, thermal pain thresholds for cold and hot stimuli, mechanical detection thresholds for touch and vibration, mechanical pain thresholds and sensitivity for pinprick and blunt pressure, vibration detection threshold and pressure pain threshold.
223423219|NCT01482065|DEVICE|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI\> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
223423220|NCT05590416|DRUG|Adalimumab|Adalimumab is administered subcutaneously at an initial loading dose of 80 mg, followed by a 40 mg dose every other week (q2w) starting from the second week. Therapy will be continued 6 months after the disappearance of active ocular inflammation. Then, injection will extend for 3 days until withdrawal after 40 days apart.
223423221|NCT04923581|BEHAVIORAL|Oral Health Behavioral Interventions|The study will use a factorial design to evaluate the efficacy of three distinct intervention components: Motivational interviewing, storytelling videos and oral health promotion messages, in enhancing mothers' brushing of their preschool children's teeth using fluoridated toothpaste.
223423222|NCT02942381|DRUG|Hydroxychloroquine Sulfate|200mg Bid (eGFR\>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
223423223|NCT02942381|DRUG|Placebo|
223423224|NCT04321369|DIAGNOSTIC_TEST|Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals|This is an operational project. Patients will collect a sample from the tongue, nasal cavity and MT and then clinicians will collect a NP sample from the nostril corresponding to each participant's dominant hand.
223423225|NCT04884113|DEVICE|Motorized Spiral enteroscopy|Small-bowel enteroscopy for diagnosis and intervention
223423226|NCT00384748|BEHAVIORAL|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
223423227|NCT00384748|BEHAVIORAL|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
223423228|NCT00384748|BEHAVIORAL|Usual care|Routine VA care.
223563423|NCT06659731|OTHER|EEG|EEG recording at rest and while receiving heat stimuli to study cortical processing of salient thermal stimuli. Up to 30 painful thermal stimuli, will be delivered to the patients' hand dorsum in order to register contact heat evoked potentials (CHEPs).
223563424|NCT06659354|BEHAVIORAL|Pregnant Body Project (PBP)|The Body Project is typically delivered as four 1-hour weekly sessions consisting of written, verbal, and behavioral exercises. The sessions aim to induce cognitive dissonance by encouraging participants to challenge the thin-ideal, a theoretically and empirically supported component of ED prevention. This adapted version of the Body Project (the Pregnant Body Project; PBP) consists of 6 1-hour, weekly group sessions delivered via Zoom. Since the target population consists of individuals with histories of an ED or disordered eating behaviors, PBP also includes elements from a treatment intervention (i.e., the Body Project Treatment 8.0 manual). PBP was adapted iteratively with a needs assessment, expert stakeholder input, and participant feedback following a mock trial with individuals with lived experience (i.e., individuals with histories of an ED who have given birth). This condition will be peer-delivered by facilitators with lived experience.
224036538|NCT04908605|DRUG|Melatonin|Every patient will be given melatonin 5 mg tablet
224036539|NCT04908605|DRUG|Placebo|Every patient will be given a matching placebo tablet
224036540|NCT06568939|DRUG|Telisotuzumab Vedotin|Intravenous (IV) Infusion
224036541|NCT06199466|DRUG|Gemcitabine|Given by IV
224036542|NCT06199466|DRUG|Nab-paclitaxel|Given by IV
224036543|NCT06199466|DRUG|YL-13027|Given by PO
224036544|NCT00692302|BEHAVIORAL|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
224036545|NCT00692302|BEHAVIORAL|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
224036546|NCT00498134|DRUG|Triple therapy for H. pylori infection|
224036547|NCT00498134|DRUG|Cox-2 inhibitor|
224036548|NCT05147623|PROCEDURE|Any surgery/procedure|Any surgery/procedure in all adult patients that were performed in an operating room
223423229|NCT06011395|DEVICE|Smartwatch|Activity tracker (step count, calories burned), heart rate monitor
223423230|NCT06011395|DEVICE|Imperial Healthy Hearts app|Digital cardiac rehabilitation smartphone application. Represents smart watch data and source of educational materials for cardiac rehabilitiation programme.
224036549|NCT00710827|DRUG|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
224036550|NCT00710827|DRUG|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
224036551|NCT04852263|OTHER|Group I|Oral fiberoptic intubation was carried out using lingual traction without nasopharyngeal airway.
224036552|NCT04852263|OTHER|Group II (NPA group)|Oral fiberoptic intubation was carried out using lingual traction plus modified nasopharyngeal airway.
224036553|NCT03080688|DEVICE|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
224036554|NCT06518174|DIAGNOSTIC_TEST|MRI, SWE, and US evaluation|"We will perform SWE and MRI sampling of the uterus from fundus to lower uterine segment with at least two points each from the upper, mid, and lower thirds of the uterus. SWE and MRI will be performed at time of study recruitment. US procedures will be transabdominal. When possible, we will also collect transvaginal US. MRI images will also be sampled from existing pretreatment studies performed as standard of care. All images will be evaluated for the presence and degree of fibrosis. We will compare SWE and MRI post-treatment. We will also compare pre-and post-treatment MRI.~We will perform US and estimate uterine volumes and arterial resistance. Use descriptive statistics to compare values to age-matched controls"
223423231|NCT05320783|OTHER|music|Classical music pre-selected was started to the patients with individual comfortable volume.
223423232|NCT05320783|OTHER|control|music player was not started.
223423233|NCT02158468|DEVICE|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
224036555|NCT06836375|DIAGNOSTIC_TEST|Spirometry test with bronchodilation|this test measures how much air you can breathe in and out of your lungs, as well as how easily and fast you can then blow the air out of your lungs
223423234|NCT02158468|DEVICE|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
223423235|NCT01337713|OTHER|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
223423236|NCT01337713|OTHER|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
223423237|NCT01405417|PROCEDURE|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
223423238|NCT06147947|DIAGNOSTIC_TEST|Diagnostic Test: Transient elastography (TE) and 2D-shear wave elastography (2D-SWE)|"Index test: TE examination will be completed by experienced nurses, requiring fasting for more than 4 hours before the examination and an interval of no more than 1 week from the abdominal ultrasound and 2D-SWE examination. The report will be considered highly reliable only if IQR/med is ≤ 30%, at least 10 successful acquisitions are obtained, and the success rate is at least 60%. Abdominal ultrasound and 2D-shear wave elastography (2D-SWE) will be completed by a sonographer, the interval between ultrasonic examination and laboratory tests should be less than a week, and the patients should fast for at least 4 hours before the examination.~Reference standard: Hepatic venous pressure gradient (HVPG) will be conducted by experienced interventionists. There should be a maximum interval of no more than 1 week between the HVPG and ultrasound examination, and patients should fast for at least 2 hours before undergoing HVPG."
223423239|NCT00000861|DRUG|Indinavir sulfate|
223423240|NCT02860975|OTHER|Inhaled Nitrogen|"To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.~Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask."
223423241|NCT05204160|BIOLOGICAL|Pembrolizumab|Given IV
223423242|NCT03933644|DEVICE|Gastric Tube|SGA is inserted with a gastric tube as guide for insertion
223423243|NCT03933644|DEVICE|No gastric Tube|SGA is inserted without a gastric tube as guide for insertion
224036556|NCT06836375|DIAGNOSTIC_TEST|Methacholine challenge|test used to diagnose asthma where the patient breaths in methacholine
224036557|NCT06836375|DIAGNOSTIC_TEST|impulse oscillometry|test that uses sound waves to measure how much resistance there is to the normal movement of air in and out of your lungs when you are breathing at rest
223423244|NCT02848365|DEVICE|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
223423245|NCT03358771|OTHER|COPD discharge care bundle|As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
224036558|NCT06836375|OTHER|Measurement of the exhaled FeNO fraction|Measure the level of nitric oxide in parts per billion (PPB) in the air the patient slowly exhales
224036559|NCT04910321|OTHER|diet, physical activities, sleep|lifestyle factors
224036560|NCT03509896|OTHER|Non-Interventional|Non-Interventional
223563425|NCT06659354|BEHAVIORAL|Pregnancy Health Education (PHE)|This time- dose- and attention- matched control condition accounts for the potential effects of time spent and support from group members and facilitators. Participants assigned to the PHE group will also be asked to attend 6, 1-hour, weekly group sessions via Zoom. During the sessions participants receive psychoeducation on body image and disordered eating during pregnancy but will not engage in any dissonance-inducing exercises. Participants will also receive lifestyle education specific to pregnancy (e.g., proper nutrition, sleep, physical activity), tied back to body image and disordered eating.
223739800|NCT06262269|OTHER|Home-based adapted physical activity program supervised by an APA teacher via individual video conference.|Participants will follow a 12-week tele-rehabilitation programme involving high-intensity interval training (HIIT) adapted to their AIS. The programme includes three 45-minute individual sessions per week. The exercises are selected from a database designed for AIS patients. The APA teacher will systematically document the patient's presence or absence at each tele-rehabilitation session, thus assessing their adherence to the programme.
224036561|NCT03399409|BEHAVIORAL|Motivational Interviewing|Motivation techniques
224036562|NCT03399409|BEHAVIORAL|Anti-inflammatory Information|Provision of information on anti-inflammatory products
224036563|NCT04500665|DRUG|Colchicine|Colchicine
224036564|NCT04500665|DRUG|Placebo|Placebo
223423246|NCT03358771|OTHER|COPD discharge care bundle & coordinator|The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
223423247|NCT02161484|PROCEDURE|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
223563426|NCT06658223|OTHER|Exercise with virtual reality|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person's condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
223563427|NCT06659081|PROCEDURE|socket shield technique|partial extraction therapy : sectioning the root and keeping part of it in contact with labial plate of bone
223563428|NCT06659081|PROCEDURE|subepithelial connective tissue graft|A connective tissue graft harvesting from maxillary tuberosity area
223563429|NCT06659081|PROCEDURE|implant placement|implant placement
223563430|NCT05691062|DEVICE|Titanium Fusion Device|Titanium fusion device will be utilized for one-level lumbar fusion.
223563431|NCT05691062|DEVICE|PEEK Fusion Device|PEEK fusion device will be utilized for one-level lumbar fusion.
223563432|NCT05434065|DRUG|Celecoxib 200mg|Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
223563433|NCT00772915|DRUG|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
223563434|NCT00772915|DRUG|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
224036565|NCT06560996|OTHER|Very low calorie diet with low protein content (VLCD-LP group)|Very low calorie diet (850 kcals per day) with low protein content (10%)
224036566|NCT06560996|OTHER|Very low calorie diet with high protein content (VLCD-HP group)|Very low calorie diet (850 kcals per day) with high protein content (30%)
224036567|NCT01621230|DRUG|Epidural Bupivacaine plus fentanyl|The subjects will receive 0.125% bupivacaine with fentanyl 2 mcg/mL at a rate of 10 mL/hr.
224036568|NCT01621230|DRUG|Epidural fentanyl|The subjects will receive epidural fentanyl 10 mcg/mL with the rate of 10mL/hr.
224036569|NCT04285242|OTHER|Observational assessments|Clinical assessments
224036570|NCT04899661|DRUG|Molidustat (Musredo, BAY85-3934)|Tablets, administered orally at the discretion of investigators
224036571|NCT01054144|DRUG|Lenalidomide|"* Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~* Dose Level -4: Discontinue"
224036572|NCT01054144|DRUG|Prednisone|"* Starting Dose: 100 mg PO days 1-5 every 28 days;~* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~* Dose level -3: Discontinue"
224036573|NCT01054144|DRUG|Dexamethasone|"* Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~* Dose level -3: Discontinue"
224036574|NCT03997266|DRUG|Ampicillin|Intravenous ampicillin
223423248|NCT02161484|PROCEDURE|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
223423249|NCT02161484|DRUG|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
223423250|NCT02161484|DRUG|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
224298966|NCT05948592|OTHER|Placebo|Patients randomised to placebo, the volume calculated to be administered will be determined from the wound volume assessment at the previous visit through an automated wound measurement system (Silhouette), except on the first day of treatment where the amount applied will be determined based on the wound volume determined at that time using the automated wound measurement system (Silhouette).
223563435|NCT06607653|DEVICE|Olfactory training|Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
223563436|NCT06608082|DIAGNOSTIC_TEST|indocyanine green injected intravenously|During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
223563437|NCT04420598|DRUG|Trastuzumab deruxtecan|"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowed"
224036575|NCT03997266|DRUG|Gentamycin|Intravenous gentamycin
223423251|NCT02259192|DEVICE|MED-EL Maestro Cochlear Implant|cochlear implant
223423252|NCT02005692|DEVICE|DynaSense sensor|
224036576|NCT03997266|DRUG|Normal saline|Intravenous normal saline
224036577|NCT06518564|DRUG|Avelumab|Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.
224036578|NCT06518564|DRUG|M1774|Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.
224036579|NCT04265547|BEHAVIORAL|Breast Cancer Risk Reduction Household Intervention|This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
223423253|NCT01054274|DEVICE|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
224036580|NCT04981509|BIOLOGICAL|Atezolizumab|Given PO
224036581|NCT04981509|BIOLOGICAL|Bevacizumab|Given IV
224036582|NCT04981509|PROCEDURE|Biopsy Procedure|Undergo biopsy
224036583|NCT04981509|PROCEDURE|Biospecimen Collection|Undergo blood collection
224036584|NCT04981509|PROCEDURE|Bone Scan|Undergo bone scan
224036585|NCT04981509|PROCEDURE|Computed Tomography|Undergo CT without contrast
224036586|NCT04981509|PROCEDURE|Computed Tomography with Contrast|Undergo CT with contrast
224036587|NCT04981509|DRUG|Erlotinib|Given PO
224036588|NCT04981509|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223423254|NCT01054274|DEVICE|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
223423255|NCT01895270|DRUG|Isradipine|Isradipine extended release formulation
223423256|NCT01895270|DRUG|Placebo|Placebo will consist of microcrystalline cellulose.
224036589|NCT04981509|PROCEDURE|Positron Emission Tomography|Undergo PET
224036590|NCT04981509|DRUG|Sodium Fluoride F-18|Given F-18 sodium fluoride
224036591|NCT05719415|OTHER|Measurement of pulmonary functional capillary surface area|Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro
224036592|NCT05575492|BIOLOGICAL|mRNA-1647|Sterile liquid for injection
223423257|NCT01892709|DRUG|Hydromorphone|
223423258|NCT06166537|OTHER|Graduated compression stockings|Graduated compression stockings are standard care (control)
223423259|NCT06166537|OTHER|No Graduated compression stockings|No Graduated compression stockings is the intervention
223423260|NCT02091375|DRUG|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
223423261|NCT02091375|DRUG|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
224036593|NCT05575492|OTHER|Placebo|0.9% sodium chloride injection (normal saline)
224036594|NCT06331078|OTHER|Square Stepping Exercise training|The experimental group will have Square Stepping Exercise training.
224036595|NCT06331078|OTHER|Aerobic Exercise Training|Individuals in the aerobic control cohort will partake in a treadmill walking session.
224036596|NCT06530563|DRUG|Oliceridine Injection [Olinvyk]|"Oliceridine fumarate injection, specifications: 1mg/1mL, 2mg/2 mL, 10mg/10 mL; Stored in the dark, 15-30 ℃, not frozen; Jiangsu Nhwa pharmaceutical co., LTD. Production.~Dexmedetomidine, specifications: 200ug/2ml; Ondansetron, specifications: 8mg/4ml."
224036597|NCT06530563|DRUG|Sufentanil Citrate|"Sufentanil Citrate injection, specification: 50 ug/ml, 1 ml; Avoid light seal; Yichang humanwell pharmaceutical co., LTD.~Dexmedetomidine, specifications: 200ug/2ml; Ondansetron, specifications: 8mg/4ml."
224036598|NCT04507074|DEVICE|lumbar traction therapy|The application of traction forces on the traction table (ST6567P-SEERSMEDICAL) will last 30 minutes a day for 4 weeks (continuous traction mode with a maximum strength of 30% of the patient's body weight).
224036599|NCT05050682|DRUG|PF-07304814|PF-07304814 is an anti-viral, formulated for intravenous delivery
224036600|NCT05136131|PROCEDURE|Electrical cardioversion|"Shocks are delivered as per the Ottawa Cardioversion Protocol in the shock arm. 1) 200J shock delivered using self-adhesive electrodes in an anteroposterior configuration. 2) 200J shock delivered using self-adhesive electrodes in an anterolateral configuration while applying pressure over the electrodes with disconnected standard handheld paddles. 3) 360J shock delivered using the same technique as in (2). 4) As per the treating physician's discretion."
224036601|NCT05136131|OTHER|Sham electrical cardioversion|No shock is delivered in the sham procedure arm.
224036602|NCT04979052|DRUG|Interferon Gamma-1B|100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.
224036603|NCT04532424|DEVICE|Transcranial magnetic stimulation|Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
224036604|NCT03918681|OTHER|Therapeutic Intervention|Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
224036605|NCT04928846|BIOLOGICAL|Telisotuzumab Vedotin|Intravenous (IV) Infusion
224036606|NCT04928846|DRUG|Docetaxel|IV Infusion
224036607|NCT03801902|RADIATION|Accelerated Hypofractionated Radiation Therapy|160 Gy given as one 4 Gy fraction per day, 5 days per week for 15 fractions.
224036608|NCT03801902|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224036609|NCT03801902|PROCEDURE|Computed Tomography|Undergo brain CT and chest CT
224036610|NCT03801902|BIOLOGICAL|Durvalumab|Administered intravenously (IV) as a 1500 mg fixed dose over 60 minutes for 13 cycles (1 cycle = 4 weeks), until disease progression or toxicity or death, whichever comes first.
224036611|NCT03801902|PROCEDURE|Magnetic Resonance Imaging of the Brain with and without Contrast|Undergo brain MRI
224036612|NCT03801902|BIOLOGICAL|Monalizumab|Administered IV as a 1500 mg fixed dose over 60 minutes (+/- 10 minutes)
224036613|NCT03801902|BIOLOGICAL|Oleclumab|Administered IV 3000 mg over 60 minutes (+/- 10 minutes)
223423262|NCT03625765|DEVICE|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
223423263|NCT01741792|DRUG|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
223423264|NCT06576960|DRUG|Nano silver fluoride varnish and tri calcium phosphate varnish|Fluoride varnishes
223423265|NCT04609774|OTHER|Severe Acute Respiratory Syndrome CoronaVirus 2 detection|Severe Acute Respiratory Syndrome CoronaVirus 2 Detection by Real-Time Polymerase Chain Reaction and cell culture
223423266|NCT04164173|DEVICE|EzPAP|Patient will receive 10 min EzPAP 4 times daily
223563438|NCT06598540|BEHAVIORAL|Kindness-focused|This mindset intervention frames food choices as an opportunity to practice self-kindness. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session delivered via the Stanford Zoom platform. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include sharing their experiences about considering food choices as an act of self-kindness with other study participants or writing an encouraging letter to a study participant and physician colleague through the private and secure message board of a web-based educational platform.
224036614|NCT03801902|RADIATION|Radiation Therapy|60 gy given as one 2 Gy fraction per day, 5 days per week for 30 fractions
224036615|NCT05132543|DEVICE|High density micro-electrocorticography for neural speech prothesis|ECoG electrodes are thin, high-density, flexible electrode arrays used for recording electrophysiological signals from the brain.
224036616|NCT06505044|PROCEDURE|aerobic exercise|"aerobic exercise.~* Intensity: according to heart rate (60-75% of maximum heart rate) MHR=220-age.~* Heart rate: determined by the sensor of a treadmill.~* Duration: 40-50 min per session. Each session consisted of 5-10 minutes of warming up exercise on a treadmill without increasing speed or intensity and the same for the cooling down phase. There was 30 minutes of conditioning exercise including increasing the treadmill speed till reaching (60-75%) of the maximum heart rate.~* Frequency: 3 times/week for 12 weeks in addition to their usual daily calcium intake."
224036617|NCT06505044|PROCEDURE|resistance exercise|resisted exercise program for 12 weeks
223423267|NCT04164173|DEVICE|Metaneb|Patient will receive 10 min Metaneb 4 times daily
223423268|NCT04164173|DEVICE|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
223423269|NCT03511040|DEVICE|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
224036620|NCT05363280|DRUG|AL8326 low dose group|Taken AL3826 at low dose orally
224036621|NCT05363280|DRUG|AL8326 middle dose group|Taken AL3826 at middle dose orally
224036622|NCT05363280|DRUG|AL8326 high dose group|Taken AL3826 at high dose orally
224036623|NCT05796362|DRUG|Azithromycin Oleogel (Oral and Rectal)|"Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)"
224036624|NCT05664763|DRUG|[18F]FPEB with PET|radioactive tracer \[18F\]FPEB administered by bolus infusion over up to 2 hours with PET performed in the last 30 minutes of infusion with Positron emission tomography (PET) neuroimaging
224036625|NCT05664763|BEHAVIORAL|Cannabis abstinence|Motivational enhancement and contingency management (CM) to promote and maintain cannabis abstinence after the baseline scan.
224036626|NCT03720262|COMBINATION_PRODUCT|Mesh reinforcement|Reinforcement of the abdominal wall with Ultrapro Advanced.
224036627|NCT03720262|OTHER|No reinforcement|Suturing the abdominal wall without mesh reinforcement
224298967|NCT06499831|DIAGNOSTIC_TEST|0-(2-18F-Fluoroethyl)-L-Tyrosine|0-(2-18F-Fluoroethyl)-L-Tyrosine positron emission tomography (FET) is an amino acid agent derived from tyrosine that is able to cross the blood brain barrier. It has been studied primarily in diagnosis and detection of tumor recurrence in glioblastomas with emerging evidence for its use in brain metastases. Compared to conventional MRI, FET-PET has been shown to delineate geographically distinct tumor volume in newly diagnosed GBM suggesting the complementarity of the two modalities.
224138026|NCT00064350|DRUG|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
224138027|NCT00064350|DRUG|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
223423270|NCT06684795|DRUG|FG001 prior to surgery|Patients will receive a single intravenous injection of 36 mg FG001 administered the day before surgery.
224036628|NCT05940662|PROCEDURE|Immediate Implant Placement|"The extraction of the failing tooth will be carried out. Subsequently, immediate implant placement and bone grafting of the intra-alveolar space by the means of a well-documented xenogeneic bone substitute will be carried out, will be conducted all in one single surgical intervention.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
224036629|NCT05940662|PROCEDURE|Early Implant Placement|"The extraction of the failing tooth will be carried out. Within a healing period of 4-16 weeks, the extraction socket will be completely covered by soft tissues.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
224036630|NCT05940662|PROCEDURE|Late Implant Placement|"The extraction of the failing tooth and a socket grafting procedure using a well-documented xenogeneic bone substitute will be carried out. Within a healing period of at least 16 weeks, the extraction socket will be completely covered by soft tissues and complete bone healing is anticipated.~Implant placement and bone grafting by the means of guided bone regeneration using locally harvested autogenous bone and a well-documented xenogeneic bone substitute will be carried out.~After a healing period of at least 8 weeks, implant reopening takes place (conventional loading protocol)."
224036631|NCT02993523|DRUG|Azacitidine|Solution for subcutaneous or intravenous administration.
224036632|NCT02993523|DRUG|Venetoclax|Tablet
224036633|NCT02993523|DRUG|Placebo|Matching placebo tablet
224036634|NCT06631339|OTHER|Light Intervention|LEDs mimicking the spectrum of sunlight (4000K) administered daily for 1 academic year, every school day, for the entire school day. The light levels generated by these LEDs will fluctuate throughout the day but will remain under 1000 lux.
224036635|NCT06631339|BEHAVIORAL|Digital Intervention|Smart-phone application (LightUP) will be synced daily to a child-worn light and activity sensor and will allow parents to track their children's outdoor time and exposure to brighter light levels across the day. The application will also nudge parents to increase their child's exposure to light (e.g., increase time outdoors, or sitting next to a window indoors) after school hours for better myopia prevention and control. i-LightUP aims to gradually assist parents in helping their children reach the ultimate goal of spending at least 2 hours per day in brighter light conditions (e.g., above 1000 lux).
224036636|NCT06631339|OTHER|Control Group|Standard Classroom Lighting + Sham LightUP phone application
224036637|NCT06561425|GENETIC|GLPG5101|Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
224036638|NCT05180097|DRUG|Gemcitabine|1000mg/m2 IV, 30 mins D1, D8
224036639|NCT05180097|DRUG|Dexamethasone|40mg daily PO, D1-D4
224036640|NCT05180097|DRUG|Cisplatin|75mg/m2 IV, 1 hour, D1
224036641|NCT05180097|DRUG|Brentuximab vedotin|1.8 mg/kg IV, 30 mins, Q21 days
224138028|NCT03751592|DRUG|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
223423271|NCT01883817|DRUG|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
223423272|NCT01883817|DRUG|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
223423273|NCT01571999|DRUG|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
224036642|NCT05180097|DRUG|Pembrolizumab|200mg IV, 30 mins, Q 21 days
224036643|NCT06397313|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
224036644|NCT06397313|DRUG|Ruxolitinib|Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
224036645|NCT06770452|DRUG|HRS-4642|HRS-4642 is a KRAS G12D inhibitor
224036646|NCT06770452|DRUG|Nimotuzumab|Nimotuzumab is a humanized IgG 1 monoclonal antibody targeting EGFR
224036647|NCT06770452|DRUG|gemcitabine + nab-paclitaxel|Albumin paclitaxel 125mg/m2 intravenous infusion, gemcitabine 1000mg / m2, D1,8, a cycle every 3 weeks
224036648|NCT04380649|DEVICE|New headset prototype|creation of a new headset prototype for using the P300 Speller, comfortable to use in everyday life by people with disabilities.
223423274|NCT01571999|DRUG|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
223423275|NCT05036577|DRUG|Orelabrutinib|"Orelabrutinib will be given as 150 mg/d or 200 mg/d orally 72h after MTX infusion or MTX clearance, every 21 days for 6-8 cycles during combination induction treatment.~Daily Orelabrutinb with dose in last cycle of induction will be administered as maintenance treatment for up to 1 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first)."
223423276|NCT05036577|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 21 days for 6-8 cycles during combination induction treatment.
223423277|NCT05036577|DRUG|Methotrexate (MTX)|high-dose Methotrexate 3.5 g/m2 or 5g/m2 intravenous infusion (3h) d2, every 21 days for 6-8 cycels during combination induction treatment.
223423278|NCT05036577|DRUG|Dexamethasone|Dexamethasone 10-15 mg, iv, d1-4, every 21 days for 6-8 cycles during combination induction treatment.
223423279|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
223423280|NCT03961061|BEHAVIORAL|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~1. a mobile-enabled website,~2. diet and physical activity tracking apps and physical activity tracker~3. tailored self-monitoring feedback~4. caregiver podcasts~5. animated videos for adolescent patients~6. social support via social media."
223423281|NCT06685523|PROCEDURE|Subgingival debridement|To be applied 1 times (0. days)
223423282|NCT06685523|PROCEDURE|Er:YAG laser decontamination|To be applied 3 times
223423283|NCT06685523|PROCEDURE|Diyot laser decontamination|To be applied 3 times
223563439|NCT06598540|BEHAVIORAL|Health-focused|Brief education intervention framing food choices as a component of a healthy lifestyle. Individuals randomized to this arm will participate in a 15-20-minute live virtual educational session. The recording of the session will be available for 7 days on a private and secure educational web-based platform. After participating in the initial educational session, participants will have the option to engage in brief (less than 10-minute) web-based activities on their own time during weeks 2 and 5. Examples of such activities include writing a brief statement about their perspective on the usefulness of healthy eating and sharing it with physician colleagues in their group through the private and secure message board of a web-based educational platform.
223563440|NCT01051531|DRUG|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
223563441|NCT00487942|DRUG|armodafinil|50 mg/day armodafinil
223563442|NCT00487942|DRUG|armodafinil|100 mg/day armodafinil
223563443|NCT00487942|DRUG|armodafinil|200 mg/day armodafinil
223563444|NCT00487942|DRUG|placebo|placebo
223739801|NCT06262269|OTHER|First period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet of specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
224036649|NCT05197881|DEVICE|Varian Ethos Adaptive Radiation Therapy|Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
224036650|NCT02647294|DIETARY_SUPPLEMENT|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
224036651|NCT02647294|OTHER|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
224036652|NCT03963687|OTHER|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
224036653|NCT03963687|OTHER|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
224036654|NCT00202566|DRUG|Ivabradine|
224036655|NCT06802536|DEVICE|Biodentine (calcium silicate-based cement) (Septodont, Saint Maur de Fossés, France)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.
224036656|NCT06802536|DEVICE|NeoPutty (calcium silicate-based cement) (Avalon Biomed, Bradenton, USA)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material.
224036657|NCT03995797|PROCEDURE|Laser therapy|Erbium YAG laser
224036658|NCT04557605|OTHER|Progressive cycling exercise test to exhaustion|Progressive step cycling exercise test to exhaustion
224036659|NCT00334347|DRUG|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
224036660|NCT00334347|DRUG|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
224036661|NCT02404974|BEHAVIORAL|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
224138029|NCT00608439|DRUG|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
224138030|NCT00608439|OTHER|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
224138031|NCT02927340|DRUG|Lorlatinib|
224138032|NCT03769324|DIAGNOSTIC_TEST|Osmolarity Test|Osmolarity Test
224138033|NCT00838916|BIOLOGICAL|albiglutide|albiglutide weekly injection
223423284|NCT01354743|DRUG|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
223423285|NCT01354743|DEVICE|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
223423286|NCT01188824|DRUG|Cilostazol|100 mg, bid p.o.
223423287|NCT01188824|OTHER|placebo|1 tablet, bid
223423288|NCT03308591|DRUG|NACT|Platin based chemotherapy
223423289|NCT03308591|PROCEDURE|RT+PLND|radical hysterectomy+pelvic lymphadenectomy
223423290|NCT03308591|DRUG|Adjuvant chemotherapy|Platin based chemotherapy
223423291|NCT02056457|BEHAVIORAL|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
223423292|NCT02056457|BEHAVIORAL|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
223423293|NCT03417232|PROCEDURE|CAF|The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
223563445|NCT06828029|BEHAVIORAL|Problem-Solving|The problem-solving training consists of five modules, blending theory and practice. Module 1 covers the basics of problem-solving, including key steps like identification, analysis, and evaluation, with group activities for hands-on practice. Module 2 focuses on creative techniques, such as brainstorming and mind mapping, to develop innovative solutions. Module 3 teaches decision-making and prioritization, using tools like SWOT analysis and decision trees, with applied exercises. Module 4 emphasizes teamwork and communication, highlighting conflict resolution and effective collaboration through team-based problem-solving activities. Module 5 integrates all techniques, applying them to real-life scenarios, particularly clinical cases, with group discussions and solution evaluations. The training incorporates interactive learning, simulations, and structured feedback, aiming to enhance problem-solving and leadership skills. Evaluation includes self-assessment and performance observation
223563446|NCT05544227|DRUG|SV-102|SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.
223739802|NCT06262269|OTHER|Second period of the home-based adapted physical activity program with an exercise booklet.|Participants will receive a self-programme in the form of a booklet containing specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
223739803|NCT03665831|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
224036662|NCT02215460|PROCEDURE|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036663|NCT02215460|PROCEDURE|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036664|NCT02215460|DRUG|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
223423294|NCT04507256|COMBINATION_PRODUCT|AZD7442|Participants randomized to AZD7442 will be administered dose 1, each in Cohort 1a (IM) and Cohort 1b (IV). Participants in Cohort 2 and 3 will receive AZD7442 (IV) doses 2 and 3, respectively. Participants in Cohort 4 will receive AZD7442 (IV) dose 4.
223423295|NCT04507256|OTHER|Placebo|Participants randomised to placebo will receive the same volume of solution as participants on active treatment.
223423296|NCT04025411|DEVICE|Intensive Visual Simulation 3 (IVS3) device|"Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand."
223423297|NCT04025411|DEVICE|traditional Mirror Therapy (TM)|Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
223423298|NCT04025411|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be performed during the 1st, 6th, 11th, 16th and 20th session of their programme will be made in order to evaluate brain activity.
223423299|NCT06247007|PROCEDURE|Electroacupuncture|LI-4, LI-11, GV-14, GV-20 acupuncture points were needled bilaterally.
223423300|NCT01814293|DEVICE|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) \& control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
224036665|NCT02215460|DRUG|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036666|NCT02215460|DRUG|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036667|NCT02215460|DRUG|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
223423301|NCT04008771|DEVICE|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
223423302|NCT06281210|PROCEDURE|Omission of surgical treatment|Omission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy
223423303|NCT00631410|DRUG|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
223423304|NCT00631410|DRUG|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
223423305|NCT03755869|DRUG|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
223423306|NCT00316615|BIOLOGICAL|influenza vaccine|
224036668|NCT02215460|DRUG|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
223423307|NCT04762485|BIOLOGICAL|Humanized CD7 CAR-T cells|Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (0.5-10)x10\^6 CD7 CAR-T cells/kg
223423308|NCT00504699|PROCEDURE|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
223563447|NCT07011082|OTHER|Stress preventative measures|These studies will address fundamental gaps in our current knowledge and establish a scientific framework to investigate the long-term effects of early childhood adversity, physical or emotional trauma, child maltreatment, or other adverse experiences in early childhood, as well as the preventive and protective effects of loving, nurturing, and consistent caregiving offered to young children during their early childhood
224036669|NCT02215460|DRUG|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036670|NCT02215460|DRUG|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036671|NCT02215460|DRUG|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
224036672|NCT01859780|OTHER|Visual distractor|
224036673|NCT00587353|OTHER|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
224036674|NCT03118674|DRUG|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
224138034|NCT00838916|DRUG|insulin glargine|insulin glargine
223739804|NCT05507424|PROCEDURE|Prone Positioning|Newborn will be prone position for 30-60 seconds during delayed umbilical cord clamping
223739805|NCT05507424|PROCEDURE|Supine Positioning|Newborn will be supine position for 30-60 seconds during delayed umbilical cord clamping
223739806|NCT05799755|DRUG|Nintedanib|Nintedanib 150 mg BID
223739807|NCT05799755|DRUG|Placebo|Placebo comparator
223423309|NCT02413385|BEHAVIORAL|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
223423310|NCT00000161|DRUG|Aspirin|
223423311|NCT00000161|DRUG|Beta-Carotene|
223423312|NCT00000161|DRUG|Vitamin C|
223423313|NCT00000161|DRUG|Vitamin E|
223423314|NCT02233101|DRUG|Oral Tranexamic Acid|patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
223423315|NCT02233101|DRUG|Intravenous Tranexamic Acid|Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
223423316|NCT04726644|PROCEDURE|hernia repair|different methods for hernia repair
223423317|NCT04306744|DEVICE|Vorso PROTECT System|The Vorso PROTECT System is designed to deliver targeted, imperceptible, non-invasive stimulation to the ear to treat the signs and symptoms (e.g., tender and swollen joints, pain, synovitis) of patients with rheumatoid arthritis.
223423318|NCT04306744|DEVICE|Vorso PROTECT System - Sham (OFF)|Identical device to experimental arm, but the device will not deliver stimulation
223423319|NCT04633629|OTHER|Lung ultrasound|We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
223423320|NCT03330262|DEVICE|BALCAP prosthesis|The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
223423321|NCT06093646|BEHAVIORAL|Ebola+D intervention|Ebola+D intervention will include psycho-education, Problem Solving Therapy, antidepressant medication and referral to a supervising specialist mental health worker.
223423322|NCT00020046|DRUG|docetaxel|
223739808|NCT05799755|DRUG|Standard of Care|Maximum of 2 standard of care immunosuppressant (IS) drugs are allowed, one being a glucocorticoid (GC) and the other being a non-GC IS drug OR 2 non-GC IS drugs in the event that the patient is not on a GC). The patient should be on the IS drug(s) for at least 12 weeks (at least 4 weeks or more for GC) before the screening. The doses should be stable for at least 4 weeks (at least 2 weeks for GC) before the screening visit.
223423323|NCT00020046|DRUG|thalidomide|
223423324|NCT00619567|BEHAVIORAL|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
223423325|NCT05024240|DIAGNOSTIC_TEST|Stabilometry|Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
223423326|NCT05024240|DIAGNOSTIC_TEST|Stroop test|There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
223423327|NCT05024240|DIAGNOSTIC_TEST|Backward counting test|In this counting test probands are given number from interval \<180-200\> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
223423328|NCT05098912|OTHER|Manual acupuncture|Manual acupuncture using filiform needle
223423329|NCT05098912|OTHER|Thread embedding acupuncture|Thread Embedding acupuncture using Polydioxanone thread
223423330|NCT01197625|BIOLOGICAL|Dendritic cell vaccine|Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
223423331|NCT02554058|DEVICE|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
223423332|NCT05959096|DRUG|LY3437943|Administered SC
223423333|NCT05959096|DRUG|LY3437943|Administered IV
223423334|NCT02980341|DRUG|Patritumab Deruxtecan|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
223423335|NCT01647516|DRUG|Ozanimod|Ozanimod capsules by mouth daily.
223423336|NCT01647516|DRUG|Placebo|
223423337|NCT04028427|BEHAVIORAL|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston \& Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
223423338|NCT04028427|BEHAVIORAL|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
223423339|NCT01065376|PROCEDURE|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
223423340|NCT01065376|PROCEDURE|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
223423341|NCT01844180|DRUG|ONO-2952|
223423342|NCT01844180|DRUG|ONO-2952 Matching Placebo|
223739809|NCT03888651|OTHER|Quality-of-Life Assessment|Complete quality of life assessment
223739810|NCT03888651|OTHER|Questionnaire Administration|Complete questionnaire
223739811|NCT02981498|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223739812|NCT02981498|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
224298968|NCT02842333|OTHER|Additional biological samples|Blood samples
223423343|NCT04424082|OTHER|Removal of dead space filter|Dead space filters will be removed and Vcap parameters (VCO2 ml/min, PaCO2 kPa, alveolar dead space in ml) recorded before and after removal
223423344|NCT03177031|DEVICE|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
223423345|NCT03177031|DEVICE|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
223423346|NCT02630329|PROCEDURE|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
223423347|NCT02630329|PROCEDURE|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
223563448|NCT07014891|DEVICE|Intelligent Visual Feedback Motor Control Training|Patients receive motor control training using the intelligent training system (Monitored Rehab Systems B.V., 2031 CW Haarlem, The Netherlands). The Monitored Rehab Systems-Functional Squat is selected for lower - limb motor control training. The patient assumes a supine position, with both feet fixed at the correct position on the pushing - training board. The relative position of the patient can be displayed on the computer screen. The system represents the degree of joint flexion and extension and the duration of muscle contraction through the height, length, and size of images, while the speed of moving images reflects the speed of joint movement during exercise. Patients complete various simulated actions through interactive video games. During the training, the load of exercise training can be adjusted according to the patient's functional status and tolerance. The training is conducted once a day, 20 minutes per session, five times a week, for a total of four weeks.
223423348|NCT01354665|BIOLOGICAL|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
223423349|NCT02997644|BEHAVIORAL|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
223563449|NCT07014891|DEVICE|Bobath Ball Training|Bobath Ball Training Specific operations include: ① In the supine position, the heel controls the ball to move back and forth; ② In the supine position, both feet step on the ball to perform stepping movements, etc. The training is conducted 1 session daily, 20 minutes per session, 5 days per week, for a total of 4 weeks.
223739813|NCT05777928|PROCEDURE|Sleeve gastrectomy|Sleeve gastrectomy involves vertical resection of a major part of the stomach, and a tubular remnant is retained along the lesser curvature.
223739814|NCT05777928|PROCEDURE|OverStitch™ Endoscopic Suturing System|Overstitch endoscopic procedure makes a review of gastro-jejunal anastomosis reducing surgical complications
224298969|NCT06084832|BIOLOGICAL|blood microsampling|blood microsampling for the measure of Phosphatidylethanol
223423350|NCT02997644|BEHAVIORAL|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
223423351|NCT02375594|OTHER|Exercise in park equipment|
223423352|NCT00215696|GENETIC|BioBypass®|
223739815|NCT05142592|DRUG|IPG7236|The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
223739816|NCT04324554|DIAGNOSTIC_TEST|MRI of the right knee|An MRI of the right knee will be done to define the role of imaging in the diagnosis of early femoro-patellar osteoarthritis.
223739817|NCT00987077|DEVICE|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
223739818|NCT05608746|OTHER|Physical Exercise|Home-based individualized training, consisting of unsupervised aerobic exercise and resistance exercise, with moderate intensity. The pt. receives an exercise manual and exercise videos online, through an APP.
223739819|NCT05608746|OTHER|Pelvic Floor exercise|Patients will be assessed by a physiotherapist and instructed in a pelvic floor exercise program, accessed through the APP. Furthermore, the pt. is provided with general information about pelvic floor anatomy and muscle function.
223739820|NCT05608746|OTHER|Sexual counseling|Patients will be provided with 1 video-consultation with a clinical sexologist, during the prehabilitation period. The patients will be instructed in strategies to improve postoperative communication regarding, sex, realistic expectations, erectile dysfunction and the use of aids.
223739821|NCT05608746|DIETARY_SUPPLEMENT|Nutritional supplement|Patients are systematically screened for malnutrition to assess the nutritional status. Patients are given recommendations with dietary advice online, through the APP. If the patient is at nutritional risk, the patient is provided with a nutritional supplement.
223739822|NCT05608746|OTHER|Stress management|Patients are systematically screened for anxiety and depression. If patients are at risk of anxiety or depression, they are referred to a consultation with a nurse, who will provide information and strategies to handle the uncertainties they may experience.
223739823|NCT05608746|OTHER|Standard pre-surgical preparation and pt. information.|One week preoperatively the usual regime for the presurgical preparation and information will be followed.
223739824|NCT01317745|OTHER|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
223739825|NCT01317745|DRUG|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
223739826|NCT01317745|BIOLOGICAL|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
224298970|NCT06287801|OTHER|Annual Wellness Visit|Completion of a structured Annual Wellness Visit (AWV) questionnaire administered by an assigned practice staff member for Medicare beneficiaries deemed by study algorithm as high-risk. Those responses will then be used by the primary care team to place any needed referrals and offer any indicated personal health advice and create a care plan for the coming year. Routine usual care from the primary care practice will occur.
223423353|NCT03134846|DRUG|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
223423354|NCT04567368|DIAGNOSTIC_TEST|Xpert MTB/XDR|Cepheid Xpert MTB/XDR assay for detection of resistance to INH, FQ and SLID
223423355|NCT05245916|DRUG|IBI397|IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
223423356|NCT05245916|DRUG|IBI397+Sintilimab|IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
223423357|NCT05245916|DRUG|IBI397+Rituximab|IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
224036675|NCT01353625|DRUG|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
224036676|NCT00482924|OTHER|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
224036677|NCT06320613|OTHER|Acupuncture therapy|After disinfecting (alcohol or 0.9% Normal saline) the skin at the acupuncture point, use small tweezers to clip the handle of the needle, remove the adhesive tape and stab the acupuncture point at a perpendicular angle, and then press the thumb with moderate pressure on the snap-needle embedded needle site in order for the patient to feel localized soreness and distension as appropriate. The snap-needle was removed after 24 hours, and the pressing time point remained unchanged.
224036678|NCT06320613|OTHER|Ginger Acupuncture Point Patch|Ginger was thinly sliced and then cut into 2-3cm diameter ginger discs according to a circular mold and covered with a sterile circular dressing. The ginger compress was removed within 6 hours.
224036679|NCT04261023|DRUG|Orencia 125 MG Per 1 ML Prefilled Syringe|Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
224036680|NCT05073237|OTHER|Placebo|Daily placebo tablet
224036681|NCT05073237|DRUG|conjugated estrogens/bazedoxifene (CE/BZA)|Participants assigned to CE/BZA will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20mg.
224036682|NCT00528866|DRUG|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
224036683|NCT00528866|DRUG|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
223563450|NCT06773130|DRUG|HRS-4642|HRS-4642 will be administrated per dose level in which the patients are assigned.
223563451|NCT06773130|DRUG|Nimotuzumab|400mg，ivgtt，d1，qw
223563452|NCT04291105|BIOLOGICAL|VV1|VV1 is to be administered on Day 1 and every 3 weeks as long as there is clinical benefit
223563453|NCT04291105|BIOLOGICAL|Cemiplimab|Cemiplimab should be given on Day 8 of Cycle 1 (28 days) and then Day 1 of each subsequent 21-day cycle.
223563454|NCT06076551|DIAGNOSTIC_TEST|Adenosine stress echocardiography|Transthoracic echocardiographic assessments will be performed using an ultrasound device (Vivid E95, General Electric Healthcare, Liestal, Switzerland). Color Doppler flow of the distal left anterior descending artery was examined from the modified apical four-chamber view of the anterior interventricular groove. Pulsed-wave Doppler registered blood ﬂow velocity patterns using a sample volume (2-3.0 mm) placed on the color signal. The ultrasound beam was aligned parallel to the vessel ﬂow. The velocity scale of color Doppler was set to 0.21 m/s. Coronary ﬂow Doppler images were acquired at baseline and at 1, 2, and 3 min after adenosine infusion in the same part of the artery. Anti-anginal medications, including calcium channel blockers, were discontinued before the study.
223563455|NCT07022405|DRUG|Pramipexole Immediate Release|The intervention involves taking pramipexole immediate release (IR) for 8 weeks followed by 2 weeks of down titration and follow up.
223563456|NCT07029217|RADIATION|Radiation (Standard)|24 Gy in 12 fractions
223563457|NCT07029217|RADIATION|Radiation (Very low dose)|4 Gy in 1-2 consecutive daily fractions
224036684|NCT00528866|DRUG|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
224036685|NCT00528866|DRUG|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
224036686|NCT00528866|RADIATION|3-dimensional conformal radiation therapy|
224036687|NCT00528866|RADIATION|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
224036688|NCT05474586|OTHER|Collavant n2 40 mg/day|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
224036689|NCT05474586|OTHER|Glucosamine hydrochloride & Chondroitin sulfate|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
224036690|NCT05474586|OTHER|Microcrystalline cellulose|2 capsules in the morning before breakfast and 2 capsules at night before going to bed for 180 days
224036691|NCT00082303|BEHAVIORAL|Music Imagery|
223423358|NCT05771896|DRUG|Darolutamide|"Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (\>56 days between cycles). Any participant requiring dose interruption \>28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly."
223739827|NCT04718467|BIOLOGICAL|Recombinant COVID-19 vaccine (Sf9 cells)|Three doses of Recombinant COVID-19 vaccine (Sf9 cells) (40μg) at the schedule of day 0, 21, 42.
223739828|NCT04718467|BIOLOGICAL|Placebo|Three doses of Placebo (1.0ml) at the schedule of day 0, 21, 42.
223739829|NCT01019642|DRUG|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
224036692|NCT02887872|OTHER|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
224036693|NCT04589182|DEVICE|MHSL- SleepBand|The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
224036694|NCT04589182|DEVICE|Sham|Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
224036695|NCT02690779|OTHER|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
224036696|NCT02690779|OTHER|Routine Care Instructions|patients will follow routine care and instructions
224036697|NCT05931835|DEVICE|VERAFEYE System|The VERAFEYE System will be used during standard of care, catheter-based treatments for atrial flutter or atrial fibrillation; or left atrial appendage/atrial septal defect closure procedures.
223739830|NCT01019642|DRUG|placebo|no active principles given.
223739831|NCT00412022|DRUG|tamoxifen|20 mg daily for 5 years
223739832|NCT00412022|DRUG|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
223739833|NCT00412022|DRUG|letrozole|2.5 mg daily for 5 years
224036698|NCT06511063|DRUG|tenofovir disoproxil/emtricitabine|Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
224036699|NCT06511063|DRUG|Selzentry|Participants will take Selzentry for 90 days.
224036700|NCT06511063|DRUG|Placebo|Matching placebo.
224298971|NCT06287801|OTHER|Geriatric Resources and Assessment for the Care of Elders|The practice will initiate the Geriatric Resources and Assessment for the Care of Elders (GRACE) program for Medicare beneficiaries deemed by study algorithm as high-risk and meeting other study criteria (see below). After completion of the in-home structured annual wellness visit (AWV) and GRACE assessment by the NP/SW team, responses will be reviewed and applied to construct an individualized care plan using the GRACE protocols inclusive of advance care planning, health maintenance, medication management, assistance with any difficulty walking, falls, dementia, depression, chronic pain, malnutrition, weight loss, urinary incontinence, visual impairment, hearing impairment, or caregiver burden.
224298972|NCT01870882|BEHAVIORAL|Attentional retraining|
224298973|NCT01870882|BEHAVIORAL|Control condition|
224298974|NCT01045421|DRUG|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
224298975|NCT06196021|OTHER|Intra-articular hyaluronic acid injection|"Hyaluronic acid was injected into the symptomatic knees of the patients a total of 3 times, once a week for 3 weeks.~Injections were administered by the physician using a lateral approach with the patient lying on his back and the knee in full extension.~After each injection, patients were warned to apply cold to avoid possible local reactions and not to overload for 24 hours.~Hyaluronic acid preparation was in the form of 2.5 ml solutions obtained biotechnologically, containing 10 mg sodium hyaluronan in each milliliter.~The hyaluronan in solution was of medium molecular weight (0.9 million daltons) but still lower molecular weight than the hyaluronan in normal healthy synovial fluid."
224298976|NCT04922684|BEHAVIORAL|Mimic facial expressions|16 times (4 times a week, last 4 weeks) of mimicking facial expressions.
224298977|NCT00207779|DEVICE|heparin impregnated central venous catheters|
224298978|NCT03340753|DRUG|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
224298979|NCT03340753|DRUG|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
224298980|NCT06454942|DIETARY_SUPPLEMENT|Nutrient-fortified egg|Consumption of nutrient-fortified eggs with habitual diet
224298981|NCT06454942|DIETARY_SUPPLEMENT|Regular egg with habitual diet|Consumption of regular egg with habitual diet
224298982|NCT00146406|BEHAVIORAL|Project Connect|
224298983|NCT04551911|DRUG|Rayaldee|30 mcg calcifediol Extended-Release (ER) Capsule
224298984|NCT04551911|DRUG|Placebo|0 mcg calcifediol Extended-Release (ER) Capsule
224036701|NCT06001918|DRUG|Nectero EAST System|Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
224036702|NCT06191471|OTHER|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis|Laparoscopic cholecystectomy for hepatitis A induced acute acalculous cholecystitis
224298985|NCT03971149|BEHAVIORAL|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
224298986|NCT00354250|DRUG|ispinesib|Given IV
224298987|NCT03044041|DRUG|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
224298988|NCT00885521|OTHER|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
224298989|NCT01030341|DEVICE|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
223739834|NCT00412022|DRUG|zoledronic acid|4 mg every 6 months
223739835|NCT03127774|DRUG|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
223423359|NCT05771896|DRUG|Radium-223|"Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption \>28 consecutive days (\>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice."
223423360|NCT02247596|DRUG|Resveratrol|1g tds 2 weeks
223423361|NCT02247596|DRUG|Placebo|Sugar pill 1g tds for 2 weeks
223423362|NCT06149650|DEVICE|Shockwave Medical IVL System|Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.
223423363|NCT05447819|PROCEDURE|Reverse shoulder arthroplsaty|Patients with the diagnosis of rotator cuff arthropathy (degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon) or degeneration of the glenohumeral joint with severe posterior wear with an indication of a reverse total shoulder arthroplasty
223423364|NCT03216590|DEVICE|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
223423365|NCT03193801|DEVICE|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
223423366|NCT00831974|DRUG|masitinib (AB1010)|3 mg/kg/day
223423367|NCT00831974|DRUG|masitinib (AB1010)|6 mg/kg/day
223423368|NCT03875274|DRUG|Ropivacaine, Morphine|Morphine added to ropivacaine for fascia iliaca compartment block
224036703|NCT00559585|DRUG|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
223563458|NCT07026539|DRUG|Finerenone (BAY 94-8862)|Patients with an eGFR of 25-60 ml/min/1.73m2 will receive an initial dose of 10 mg finerenone/placebo once daily and those with an eGFR of at least 60 ml/ in/1.73m2 will receive an initial dose of 20 mg finerenone/placebo once daily. From 4 weeks the target dose is 20 mg finerenone/placebo once daily. An increase in dose from 10 to 20 mg once daily will be encouraged after 4 weeks provided the plasma potassium level is 4.8 mmol/L or less and the eGFR stable. If eGFR is reduced with \>30 % compared to the previous measurement, we will not increase the dose of finerenone/placebo. Plasma potassium and eGFR will be measured 4 weeks after any initiation, re-start or increase in dose. A decrease in dose from 20 to 10 mg is allowed at any time after initiation of finerenone or placebo. Patients in the placebo group will undergo sham adjustment of the dose. Finerenone or placebo will be withheld if potassium concentrations exceed 5.5 mmol/L and restarted if potassium levels fall to 5.0 mmol/L
224036704|NCT00559585|DRUG|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
224138035|NCT00939224|DEVICE|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
224298990|NCT02063243|PROCEDURE|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
224298991|NCT03880435|DEVICE|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
223563459|NCT07026539|DRUG|Placebo|Placebo tablets matching BAY94-8862 are administered orally.
223739836|NCT03127774|DRUG|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
223423369|NCT03875274|DRUG|Ropivacaine, Saline|Normal saline added to ropivacaine for fascia iliaca compartment block
223423370|NCT00387140|DRUG|MK2295|
223423371|NCT03316469|DRUG|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
223423372|NCT03316469|DIAGNOSTIC_TEST|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
223423373|NCT04964544|COMBINATION_PRODUCT|5 mg rosuvastatin calcium with a Web App (combination product)|The combination product will be a Drug (Rosuvastatin calcium 5 mg) and Software as a Medical Device (Web App that features a Technology-Assisted Self-Selection (TASS) tool). Rosuvastatin calcium 5 mg will be taken orally, 1 tablet daily to use for lowering cholesterol, a key risk factor that can lead to heart disease.
223423374|NCT03993574|OTHER|Self- management program|"The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks"
223563460|NCT07033182|DRUG|Levornidazole Disodium Phosphate for Injection|Single dose, IV
224138036|NCT04696458|DIETARY_SUPPLEMENT|Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)|Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).
224138037|NCT04696458|OTHER|Placebo Comparator: Placebo|Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.
224138038|NCT04961099|DRUG|HY01|low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
223423375|NCT03993574|OTHER|Standard care|"All stroke patients being discharged from the acute hospital receive the following care:~1. 1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~2. A stroke clinic appointment that is set to occur 90-days post discharge.~3. A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~4. Information on local support groups.~5. Referrals to start physical, occupational or speech therapy, if recommended by their physician."
223423376|NCT01098201|DRUG|Certolizumab|Subcutaneous administration on a monthly basis for six months
223423377|NCT06419686|OTHER|Placebo (saline)|Intravenous saline during experimental days.
223423378|NCT06419686|DRUG|GIP|Intravenous GIP administration during experimental days.
223423379|NCT06419686|DRUG|Alanine|Intravenous alanine administration during experimental days.
223423380|NCT06419686|DRUG|GIP + alanine|Intravenous administration of GIP and alanine during experimental days.
223423381|NCT02350686|DRUG|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
223423382|NCT02350686|DRUG|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
223423383|NCT00874835|DEVICE|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
223423384|NCT01613222|DEVICE|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
223423385|NCT02205008|PROCEDURE|surgery|Total or subtotal gastrectomy with D2
224298992|NCT04453098|BEHAVIORAL|3-week residential program based on a tryptic (diet,|"3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education)."
223423386|NCT02205008|DRUG|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (\<1.25m2:40mg, 1.25-1.5m2:50mg, \>1.5m2:60mg, bid)
223423387|NCT02205008|DRUG|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
223423388|NCT01550081|OTHER|Rate of perceived exertion|Exercise intensity controlled by Borg scale
223423389|NCT01550081|OTHER|Heart rate monitor|Exercise intensity controlled by heart rate monitors
223423390|NCT05524896|DEVICE|ElucidVivo|Plaque morphology characterization for predicting non-invasive fractional flow reserve (FFR)
223423391|NCT06647719|OTHER|Educational Videos|Subjects in the experimental group will be provided with 3 links to videos to be watched after CTR surgery. These videos will be available through YouTube, Twitter, Facebook, Instagram, TikTok, or MyChart. Videos will be available to watch multiple times at the subjects choice.
223423392|NCT01348308|DRUG|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
223423393|NCT01348308|DRUG|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
223423394|NCT03696108|DRUG|Gefapixant|Gefapixant 15 mg or 45 mg tablet administered orally BID
223423395|NCT03696108|DRUG|Placebo|Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
223423396|NCT05123664|OTHER|Capsule|1 cap daily at same time of the day with or without food for 4 weeks
223423397|NCT04109287|DEVICE|REVITIVE® device|The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
223563461|NCT07033104|OTHER|us guided Transversalis fascia plane block|addition of calcitonin to pubivacaine
223739837|NCT03127774|PROCEDURE|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
223739838|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with VR-IOMSs|Learning Orientation and Mobility skills from virtual-reality-based, automated, intelligent computer training programs - VR-IOMSs
223739839|NCT04639531|BEHAVIORAL|Orientation and Mobility Training with COMS|Learning Orientation and Mobility skills from human Certified Orientation and Mobility Specialists (COMS)
223423398|NCT02209142|OTHER|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
223423399|NCT02209142|OTHER|psychometric data collection|
223423400|NCT03505593|DEVICE|ENVUE System|The ENvizion Medical™ ENVUE™ System is designed to aid qualified operators in the placement of the ENvizion Medical™ Enteral Feeding Tube™ into the stomach or small intestine.
223423401|NCT04513080|BEHAVIORAL|Video-chat psychotherapy (VCP)|Video Chat Only (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.
223739840|NCT04639531|BEHAVIORAL|No Orientation and Mobility Training|No Orientation and Mobility training. Watch low vision education videos and discuss low vision issues not related to O\&M with COMS
223739841|NCT05901545|BIOLOGICAL|Panitumumab|Given by IV
224298993|NCT00614809|DRUG|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
224298994|NCT00507286|DRUG|combination of various doses of sildenefil and alprostadil|
224036705|NCT04664010|DRUG|Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C|Atomized inhalation of 5 million U α-interferon and 2 mL sterilized water, twice a day; 0.2 g arbidol, three times a day, treatment course no more than 10 days; intravenous administration of ribavirin 500 mg, once every 12 hours, treatment course no more than 10 days; intravenous administration of 10 g immunoglobulin C, once a day, 3-5 days. Anti-bacterial infection treatment is given to the patients who have yellow sputum and increased levels of procalcitonin and other bacterial infection specific indicators.
224036706|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose|Buzhong Yiqi plus and minus formula: 1 dose once, twice a day, taking with warm water. Huhuang Detoxicity Paste: One dose once, twice a day, taking with warm water; Baimu Qingre Jiedu Paste: One dose once, twice a day, taking with warm water; Fumigation/inhalation of Chinese herbs and vitamin C: 30-40 minutes once, 3-7 times a day. Patients take vitamin E capsule and folic acid every day. plus invention 1
224298995|NCT03400072|OTHER|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
223423402|NCT04513080|BEHAVIORAL|Message-based psychotherapy (MBP)|Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.
223423403|NCT04513080|BEHAVIORAL|Message-based psychotherapy with monthly video chat (Premium Plan)|The Premium plan allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care will be based on CBT, PST or IPT.
223423404|NCT04513080|BEHAVIORAL|Message-based psychotherapy with weekly video chat (Ultimate Plan)|The Ultimate Plan allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT.
223423405|NCT04692480|BEHAVIORAL|Breastfeeding Video Education|"Video entitled Breastfeeding in the First Hour, It's in Your Hands"
223423406|NCT04692480|BEHAVIORAL|Breastfeeding PDF education|PDF of standard breastfeeding education handouts
223423407|NCT00704444|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets
223423408|NCT00704444|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
223423409|NCT05120466|BEHAVIORAL|AD IT UP media literacy intervention|AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.
223423410|NCT05120466|BEHAVIORAL|Usual health education curriculum|The school's regular health education curriculum includes classroom lectures, hands on activities and group work.
223423411|NCT00528060|DRUG|Atazanavir|2pills/day
223563462|NCT07032441|DEVICE|PSG|"Polysomnography (PSG) is a comprehensive test used to assess sleep disorders and monitor sleep quality. PSG is typically conducted in specialized sleep laboratories and can simultaneously record various physiological parameters to help doctors diagnose different types of sleep disorders, such as obstructive sleep apnea, insomnia, and periodic limb movement disorder.~The monitored components of PSG usually include:~Electroencephalogram (EEG): Records the electrical activity of the brain to determine different sleep stages.~Electrooculogram (EOG): Records eye movements to identify rapid eye movement (REM) sleep stages.~Electromyogram (EMG): Records muscle activity, typically monitoring the muscles of the jaw or legs.~Electrocardiogram (ECG): Monitors the electrical activity of the heart. Respiratory flow monitoring: Records the flow and frequency of breathing. Oxygen saturation monitoring: Monitors blood oxygen levels using a pulse oximeter."
223563463|NCT07034378|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation of pulmonary veins
223563464|NCT07034378|PROCEDURE|Extended cryoballoon ablation|Cryoablation of pulmonary veins + posterior wall isolation
223739842|NCT05901545|OTHER|Indium In 111 Panitumumab|Given by IV
223739843|NCT05901545|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT/CT
223423412|NCT00528060|DRUG|Ritonavir|1 pill/day
223423413|NCT00528060|DRUG|Tenofovir/emtricitabine|1 pill/day
223423414|NCT02861326|DEVICE|Gracey Curettes|
223423415|NCT04016922|OTHER|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\\U ratio.~\* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~* As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
223423416|NCT00003134|DRUG|irinotecan hydrochloride|
223739844|NCT05901545|PROCEDURE|Computed Tomography|Undergo SPECT/CT
223739845|NCT05901545|PROCEDURE|Surgical Procedure|Undergo standard of care surgery
223739846|NCT05901545|OTHER|Imaging agent|Receive local injection of optical dye
223739847|NCT05901545|PROCEDURE|Intraoperative Imaging|Undergo Intraoperative Imaging
223423417|NCT05246059|OTHER|Olfactory Training|Sniffin' Sticks (Duft-Quartett, Burghart Messtechnik, GmbH, Germany)
223423418|NCT02611570|OTHER|LDCT|LDCT at enrollment, annually for two years and biennially for 6 years if no lung cancer is detected
223423419|NCT04217837|DEVICE|Transcranial Magnetic Stimulator|Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
223423420|NCT00880061|DRUG|IL13-PE38QQR|
223423421|NCT02584127|BEHAVIORAL|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
223423422|NCT02584127|BEHAVIORAL|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
223423423|NCT03608657|DRUG|Apremilast|Apremilast
223423424|NCT03632629|OTHER|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
223423425|NCT04042766|PROCEDURE|laser vaginal treatment|Er:YAG laser
223423426|NCT01748617|OTHER|Controlled diet|1 week of controlled diet
223423427|NCT02449317|OTHER|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~* extracellular water/total body water \< 0.36 : 4 ml/kg/hr~* extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~* extracellular water/total body water \> 0.4 : 1 ml/kg/hr"
223423428|NCT02449317|OTHER|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
223423429|NCT03596281|DRUG|Pembrolizumab|200mg Q3W IV
223423430|NCT03596281|DRUG|Bevacizumab|400 or 300 mg Q3W IV
223423431|NCT03596281|DRUG|pegylated liposomal doxorubicin (PLD)|15 or 20 or 30 mg/m² Q3W IV
223563465|NCT07034378|PROCEDURE|Standard cryoballoon ablation|Standard cryoablation of pulmonary veins
223563466|NCT07034118|RADIATION|Proton radiotherapy|Patients enrolled would receive proton radiotherapy with chemoimmunotherapy.
224036707|NCT04664010|DRUG|Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment|invention 1 plus invention 2 plus 100 mL of 5% glucose containing vitamin C (10 g/60 kg body mass) is intravenously administered twice a day.
224037866|NCT06592677|BEHAVIORAL|Treatment-as-usual (TAU)|There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
224037867|NCT06601686|DEVICE|Transcranial electrical stimulation (TES)|TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.
224037868|NCT06601686|DEVICE|Transcranial electrical stimulation with temporal interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
223423432|NCT03805217|DEVICE|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
223423433|NCT01623843|PROCEDURE|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
223423434|NCT01623843|PROCEDURE|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
223423435|NCT01899742|DRUG|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
223423436|NCT01899742|DRUG|Tiotropium 18 mcg|Inhalation Powder
223423437|NCT01946893|BEHAVIORAL|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
223423438|NCT01946893|BEHAVIORAL|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
223423439|NCT00089778|DRUG|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
223563467|NCT07034118|DRUG|Immune Checkpoint Inhibitors|Patients enrolled would receive proton radiotherapy and chemoimmunotherapy
223563468|NCT07035041|DRUG|D-2570|Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
223563469|NCT07035041|DRUG|Placebo|Subjects will then be randomized in a 1:1:1 ratio to D-2570 or placebo . They will enter the study treatment period and take the assigned investigational product once daily for 12 consecutive weeks.
223739848|NCT05901545|PROCEDURE|Near Infrared Imaging|Undergo Near Infrared Imaging
223739849|NCT05901545|PROCEDURE|Electrocardiography|Undergo Electrocardiography
224037869|NCT06601686|DEVICE|Sham stimulation|TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current. It will also include periods with no stimulation and a ramping up period followed by no stimulation.
224036708|NCT06435754|PROCEDURE|Intervention group Vestibular Socket Preservation|After atraumatic extraction Vestibular access horizontal incision will be made at the socket site, at the mucco-buccal fold. Subperiosteal tunnel will be created from the facial aspect of the socket orifice and extending apically until the extent of the vestibular access incision. A cortical shield will be introduced from the vestibular incision through the tunnel and the Socket will be filled by xenograft . Apical cut will be made at the palatal aspect to free the pedicle flap connective tissue and the pedicle flap will be raised using periosteal elevator and rotated and rolled occlusally to seal the socket and sutured using interrupted sutures . The primary palatal flap will be sutured in place over the donor site palatally using interrupted sutures.
224036709|NCT06435754|PROCEDURE|Control Group ice cream cone technique|After atraumatic extraction Collagen barrier membrane will be shaped as an ice cream cone and placed in the extraction socket lining the buccal tissues. The socket will be filled with Demineralized Bovine Bone Matrix DBBM.The upper part of the membrane will be used to cover the socket and will be stabilized by interrupted sutures using prolene sutures of size 6-0
224036710|NCT00800787|BIOLOGICAL|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~\< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are \<150 IU/ML \> 75 Kg: 1,000 IU weekly"
223423440|NCT00089778|DRUG|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
224036711|NCT05044026|OTHER|Jakavi|Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
223423441|NCT00089778|OTHER|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
223423442|NCT06452199|DIETARY_SUPPLEMENT|B. infantis|1000 newborn children are randomized 50/50 to receive either B. infanits or placebo in a dietary supplement, for daily oral administration in three weeks from 7 days of age.
223423443|NCT06452199|DIETARY_SUPPLEMENT|Placebo|Identical looking placebo (without any probiotics/B. infantis) for double-blinded daily oral administration in three weeks from 7 days of age.
223423444|NCT02195310|DEVICE|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
223423445|NCT02195310|DEVICE|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
223423446|NCT02141568|OTHER|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
223423447|NCT02830958|DEVICE|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
223563470|NCT07035080|OTHER|interferential therapy|Thirty hemophilic males (type A and B) children with unilateral hemarthrosis, age ranged from 8 to 12 years participated in this study. They were selected from the outpatient clinic. Faculty of physical therapy, kafrelsheik university. The patients were divided randomly into two groups of equal number , control and study groups, 15 patients each . the control group (7 left and 8 right hemarthrosis) received traditional treatment program for one hour per session includeing (ultrasound stretching and strengthening exercise ) , while the study group (6 left and 9 right hemarthrosis) received interferential therapy in addition to the same treatment program given to the control groups.
223739850|NCT05901545|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223739851|NCT01422772|BIOLOGICAL|VM202-0.5 mg|0.5 mg intramyocardial injection
224036712|NCT02789527|DRUG|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
224036713|NCT02789527|GENETIC|Genotyping|DNA sampling from a saliva sample
224036714|NCT03506685|OTHER|Dry needling and STM|dry needling and soft tissue mobilization
224298996|NCT03400072|OTHER|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
224298997|NCT01752686|DRUG|carboplatin|carboplatin as adjuvant chemotherapy
223423448|NCT02830958|OTHER|No intervention|No intervention. Uses of an ordinary tape
223423449|NCT04843124|DEVICE|Remote HA adjustment|The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
224298998|NCT02731417|OTHER|acupuncture|Acupuncture for women with post partum urinary retention
223423450|NCT04843124|OTHER|Traditional hearing aid|Traditional hearing aid
223423451|NCT02723903|DRUG|Deanxit|we use Deanxit for the patient with anxiety
223423452|NCT02723903|DRUG|Prozac|we use Prozac for the patient with depression
223423453|NCT02723903|PROCEDURE|coronary artery disease treatment|including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
223423454|NCT04613661|OTHER|Australian Spasticity Assessment Scale|Australian Spasticity Assessment Scale is a clinical measure to assess the severity of spasticity
223423455|NCT06149065|DRUG|Testosterone|Masculinizing hormone therapy (testosterone) is used in female-to-male transgenders for medical reason.
223423456|NCT06031935|BEHAVIORAL|Yoga|The patients will receive links to two yoga videos. They will do each of these videos at home for 4 weeks.
223423457|NCT01154088|BIOLOGICAL|Mencevax ACWY|One dose, Subcutaneous injection
223423458|NCT01154088|BIOLOGICAL|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
223423459|NCT00534885|BIOLOGICAL|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
223423460|NCT00534885|BIOLOGICAL|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
223423461|NCT00534885|BIOLOGICAL|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
223423462|NCT00534885|BIOLOGICAL|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
223423463|NCT01122407|DRUG|L-NMMA|L-NMMA 250 ug/Kg/min
223423464|NCT01122407|DRUG|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
223423465|NCT02491372|BEHAVIORAL|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
223423466|NCT01104246|DRUG|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
223423467|NCT04128722|DRUG|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
223423468|NCT04042350|OTHER|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
223423469|NCT03367052|PROCEDURE|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
223423470|NCT03367052|PROCEDURE|Hybrid|The hybrid method will be used in one group of patients.
223423471|NCT01475851|DRUG|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
223423472|NCT05400070|DRUG|Neoadjuvant therapy 1|Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.
223423473|NCT01576276|RADIATION|Integrated MR-PET scan|Integrated MR-PET scan using \[11C\]diprenorphine
223423474|NCT01576276|DRUG|Ketorolac|3 administrations of ketorolac over course of study
223423475|NCT05161520|PROCEDURE|phacoemulsification combined with IOL and CTR implantation|Device: CTR (276001G； OPHTEC BV, Netherlands) Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, a capsular tension ring is implanted in the capsular bag and then IOL is implanted.
223423476|NCT05161520|PROCEDURE|phacoemulsification combined with IOL implantation|Device: IOL (920H; Rayner Intracular Lenses Limited，Hove，East Sussex，UK) All patients undergo uneventful phacoemulsification by a 3.0 mm temporal transparent corneal incision using Centurion Vision System (Alcon Laboratories, Fort Worth, TX, USA). After the nucleus and cortex are removed, IOL is implanted in the capsular bag.
224138039|NCT05038033|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
224138040|NCT05038033|BEHAVIORAL|Cognitive Behavioral Theory (CBT)|The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
224138041|NCT01842607|BIOLOGICAL|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
224138042|NCT04558788|DIAGNOSTIC_TEST|Immunohistochemistry on intestinal biopsies|Immunohistochemistry will be performed on human intestinal biopsies
224138043|NCT04134585|OTHER|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
224138044|NCT02518152|PROCEDURE|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
224298999|NCT02731417|DEVICE|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
223423477|NCT01867294|DRUG|Doxycycline|Given PO
223423478|NCT01867294|PROCEDURE|Management of Therapy Complications|Moisturizer given topically
223739852|NCT01422772|BIOLOGICAL|VM202-1.0 mg|1 mg intramyocardial injection
223739853|NCT01422772|BIOLOGICAL|VM202-2.0 mg|2 mg intramyocardial injection
223739854|NCT06965257|OTHER|Continuous non-invasive blood pressure monitoring|Addition prior to anaesthetic induction of the non-invasive monitoring device (digital sleeve available at the investigation site) for blood pressure measurement on the side ipsilateral to the arterial catheter
223423479|NCT01867294|OTHER|Placebo|Given topically
223423480|NCT01867294|OTHER|Questionnaire Administration|Ancillary studies
223423481|NCT01867294|DRUG|Spironolactone|Given topically
223423482|NCT01867294|DRUG|Sunscreen|Given topically
223423483|NCT01867294|DRUG|Therapeutic Hydrocortisone|Given topically
223423484|NCT04255732|DEVICE|extent of retinal area viewing Optos, Daytona, Optos PLC, Dunfermline, UK|Comparison of the extent of retinal periphery view between two wide field imaging devices.
223423485|NCT04255732|DEVICE|extent of retinal area viewing Clarus, 500 Carl Zeiss, Meditec AG, Jena, Germany|Comparison of the extent of retinal periphery view between two wide field imaging devices.
223423486|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Abdominal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
223423487|NCT02447497|OTHER|Normal Saline - Abdominal Region|0.9% sodium chloride applied with foam applicator
223423488|NCT02447497|DRUG|3M CHG/IPA Surgical Skin Preparation - Inguinal Region|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
223423489|NCT02447497|OTHER|Normal Saline - Inguinal Region|0.9% sodium chloride applied with foam applicator
223423490|NCT04642677|OTHER|healthcare provider's recommended communication with sympathy and printed paper|"Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation."
223563471|NCT07035080|OTHER|tradional physical therapy|Thirty hemophilic males (type A and B) children with unilateral hemarthrosis, age ranged from 8 to 12 years participated in this study. They were selected from the outpatient clinic. Faculty of physical therapy, kafrelsheik university. The patients were divided randomly into two groups of equal number , control and study groups, 15 patients each . the control group (7 left and 8 right hemarthrosis) received traditional treatment program for one hour per session includeing (ultrasound stretching and strengthening exercise ) , while the study group (6 left and 9 right hemarthrosis) received interferential therapy in addition to the same treatment program given to the control groups.
223563472|NCT04415749|BIOLOGICAL|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine
223563473|NCT04415749|OTHER|Placebo|Normal saline
223563474|NCT07034859|DRUG|Cabergoline 0.5 MG|Cabergoline (Dostinex ®) 0.5 mg/tablet. Cabergoline will be given orally 1mg/week (Day1-14), 2mg/week (Day15-end of the study).
223563475|NCT07034742|DRUG|Intraperitoneal chemotherapy PLUS systemic chemotherapy|Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)
223739855|NCT04130997|BIOLOGICAL|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
223739856|NCT04745559|BIOLOGICAL|Pneumococcal conjugate vaccine (PCV13)|Licensed heptavalent pneumococcal conjugate vaccine (PCV13, Pneumococcal 13-valent conjugate vaccine
224138045|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
224138046|NCT02518152|PROCEDURE|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
224138047|NCT02880397|DRUG|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
224138048|NCT02880397|DRUG|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
224138049|NCT04224428|DRUG|Fexofenadine Pill|fexofenadine tablets 60 mg once daily will be taken for six months
224138050|NCT04224428|DRUG|Placebo oral tablet|lactose oral tablet
224299000|NCT05154630|DRUG|TQB2858 injection|TQB2858 is a Programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β(TGF-β) double antibody.
224036715|NCT00762749|DRUG|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
224299001|NCT04738474|BEHAVIORAL|Promoting Resilience in Stress Management (PRISM)|"Develops personal resilience resources through 1:1 sessions with a PRISM coach."
224299002|NCT04738474|OTHER|Usual Care|No additional study-specific interaction with subjects. Subjects continue to receive usual medical care.
224036716|NCT04614662|BEHAVIORAL|SPARK Symptom Screening Linked to Feedback to Providers|Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.
224036717|NCT02782546|PROCEDURE|Graft cell infusion|-Day 0
224036718|NCT02782546|DRUG|Tacrolimus|-GVHD prophylaxis
224036719|NCT02782546|DRUG|Mycophenolate mofetil|-GVHD prophylaxis
223423491|NCT05797415|PROCEDURE|Sentinel Lymph Node Biopsy|"* Injection of 99mTc-labeled nanocolloids~* Preoperative lymphoscintigraphy~* Intraoperative gamma probe search of the sentinel lymph node~* Sentinel lymph node biopsy~* Excisional biopsy of the neoformation in cases not undergoing excision before SLN biopsy.~* If the SLN is histologically positive, the multidisciplinary team will consider whether to refer the patient for parotidectomy and excision of the lymph node chain and/or adjuvant radio/chemotherapy."
223423492|NCT06645353|DEVICE|MSOT Multispectral Optoacoustic Tomography|MSOT Multispectral Optoacoustic Tomography, single-wavelength, HbT, Hb, HbO2, collagen and mSO2 (700-1.100 nm wavelength range, in 10 nm increments) in the tibialis anterior and flexor hallucis brevis, at multiple time-points before, during and after interventional LER Lower Extremity Revascularization .
223423493|NCT02873572|BEHAVIORAL|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
224036720|NCT02782546|DRUG|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
224036721|NCT02782546|PROCEDURE|CIML NK cell infusion|-Day +7
223423494|NCT02873572|BEHAVIORAL|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~* psychiatric assesment and~* registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
223423495|NCT02017912|BIOLOGICAL|Nurown MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
223423496|NCT02017912|BIOLOGICAL|Placebo|Excipient administration by combined intramuscular and intrathecal administration
223423497|NCT02231281|DRUG|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
224036722|NCT02782546|DRUG|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
224036723|NCT02782546|PROCEDURE|Leukapheresis|-Day +6
224138051|NCT06317077|OTHER|PAP therapy setting|Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated
223423498|NCT02231281|PROCEDURE|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
223423499|NCT05292417|RADIATION|hypofractionation Radiotherapy|Patients will receive radiation to the target lesion at a dose of 5Gy, 5 fractions a week, or a dose of 8Gy, 3 fractions a week. The course last once or twice depending on the investigator.
223423500|NCT05292417|DRUG|sintilimab|200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
223423501|NCT05292417|DRUG|GM-CSF|200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
223423502|NCT05292417|DRUG|Fruquintinib|Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
223423503|NCT05015621|DRUG|Surufatinib plus Toripalimab|Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
223423504|NCT05015621|DRUG|5-fluorouracil, Calcium folinate and Irinotecan|Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.
223423505|NCT03285503|DRUG|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
223423506|NCT00307632|DRUG|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm\^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
223563476|NCT07032883|OTHER|Benson relaxation technique|"It will be performed every day, twice daily (in the morning and evening), for 4weeks, the Benson relaxation technique instruction included these steps.~1. Sit in a comfortable position.~2. Close their eyes.~3. Relax all their muscles beginning from the soles of the feet, moving forward up, and relax all parts of their body.~(4 ) Breath through their nose, pay attention to the sound of their breathing, and say the word ''one'' quietly to themselves when the breath is out.~(5) Continue for 20 min. the patients were instructed to check the time by opening their eyes. However, using an alarm was prohibited. The training sessions were held during the patients hospitalization period after one week from surgery, the technique continued during the hospitalization and after discharge from the hospital."
223563477|NCT07032883|OTHER|Routine physiotherapy program|The participants will receive routine physical therapy program (gentle stretching, manual therapy, mobility and strengthening exercises and posture training) for 40 minutes , for 4 weeks.
223739857|NCT04745559|BIOLOGICAL|CD19 targeted CAR T Cell Therapy|This is a personalized therapeutic approach that entails removal of T cells from patient's peripheral blood, genetic modification, activation and expansion in vitro to retarget cells against CD19 protein on the surface of B cells, and infusion of the genetically engineered cells back into the patient. CD19 is a surface protein that is expressed on B cells starting from early pre-B cells to mature fully differentiated B cells. Therefore, CD19-targeted CAR T cell therapy can effectively treat refractory B cell lymphomas.
223739858|NCT04639050|DRUG|RO7126209|RO7126209 will be administered intravenously as specified in each treatment arm.
223739859|NCT04639050|DRUG|Placebo|RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
223739860|NCT06511908|DRUG|(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)|Arm 1 and 2 Experimental Intervention
224036724|NCT04549025|DRUG|Pimivalimab|Specified dose on specified days
224036725|NCT04549025|DRUG|Vopratelimab|Specified dose on specified days
224036726|NCT03135171|DRUG|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
224036727|NCT03135171|DRUG|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
224036728|NCT03135171|DRUG|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
224138052|NCT06317077|OTHER|exclusive use of Löwenstein Medical full face masks|Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
224138053|NCT01398033|DEVICE|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
224138054|NCT01398033|DEVICE|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
223423507|NCT05811052|OTHER|Suboccipital Release Technique|The suboccipital release technique was applied to the participants in the experimental group by an experienced practitioner who had received osteopathy training. The individual lay in the supine position, and the practitioner applied the relaxation technique by placing his hands on the patient's nape-atlantooccipital joint. The application was continued until the relaxation of the muscles under the hand of the practitioner.
223423508|NCT05811052|OTHER|Sham Suboccipital Release|The participants in the control group were given a sham application by touching the hands of the therapist on the nape of the neck and waiting for a while.
223423509|NCT04706806|DIETARY_SUPPLEMENT|apple cider vinegar|2 tablespoons diluted in water taken twice daily with meals
223423510|NCT04706806|DIETARY_SUPPLEMENT|vinegar pill|one pill taken daily
223423511|NCT04553640|OTHER|Group A/Intervention Curriculum|Virtual patient cases and feedback
223423512|NCT04553640|OTHER|Group B/Control Curriculum|Online articles on dizziness and emergency department clinical experience
223423513|NCT01301781|DRUG|BLI801|BLI801 laxative - oral solution
223423514|NCT01301781|DRUG|Placebo|BLI801 placebo - oral solution
224138055|NCT01945333|BEHAVIORAL|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
224138056|NCT02547116|DRUG|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
223423515|NCT02453217|BEHAVIORAL|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
223423516|NCT02453217|OTHER|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
223423517|NCT02553785|DEVICE|Revivent TC|
223423518|NCT02900417|DRUG|Sitagliptin|All the patients will receive sitagliptin 100mg daily
223423519|NCT06027918|PROCEDURE|Infraclavicular brachial plexus block|In the application of infraclavicular brachial plexus blocks (coracoid approach); 1.5mg/kg dose of bupivacaine and 1mg/kg lidocaine mixture will be applied around the axillary artery in the 6 o'clock position under US guidance.
223563478|NCT07032883|DRUG|Medications|"the participants will receive the following medications:~1. Antibiotic: Ancef 1 g intravenous (IV) ( cefazolin) intravenous post-surgery every 8 hours for 24 hours. If allergic to ampicillin /cephalosporins clindamycin IV 600\_900 mg every 8 hours for 24 hours. Then continue oral with keflex 1g tablets (cephalexin) twice daily for 7 days.~2. Anti-inflammatory:~   Adolor ( ketorolac) 15\_30 mg IV every 6 hours up to 5 days post-operation ( not exceed 120 mg/day) then followed by oral celecoxib 200 mg once or twice daily till pain subsides.~3. paracetamol 500\_1000 mg I.V every 6 hours for 5 days (Not exceed 4000 mg / day) Then followed by oral paracetamol tablets till pain subsides.~4. Zurcal 40 mg IV (pantoprazol) then followed by oral zurcal tablets."
223563479|NCT07034547|PROCEDURE|Botulinum toxin infiltration|Botulinum toxin is a medication that is injected directly into the muscles selected by a physiatrist, based on a clinical evaluation. The doses are determined according to the clinical condition of the spasticity, the patient's age, and weight. The procedure is performed under deep sedation and uses ultrasound and electrostimulation to ensure greater safety and precision.
223563480|NCT06721689|DRUG|PEEL-224|PEEL-224 (PEG-\[SN22\]4) is a novel topoisomerase I inhibitor
223563481|NCT06721689|DRUG|Vincristine|Vincristine is an inhibitor of microtubular formation which is approved by the Food and Drug Administration (FDA) and is commercially available.
223563482|NCT06721689|DRUG|Temozolomide (TMZ)|Temozolomide is an alkylating agent which is approved by the FDA and is commercially available.
223563483|NCT06732141|BEHAVIORAL|Personalized Telephone-Based Psychological Support|"This intervention involves weekly, individualized 30-minute telephone sessions conducted over 8 weeks. The sessions are designed to address anxiety and improve adherence to inhaled corticosteroid (ICS) therapy in asthma patients. The intervention comprises four core components:~1. Medication Education: Detailed guidance on the benefits, mechanisms, and safety of ICS therapy, aiming to address misconceptions and reduce fears about side effects.~2. Lung Rehabilitation Guidance: Instructions for breathing exercises and tailored physical activity to improve respiratory health and overall well-being.~3. Motivational Interviewing (MI): A patient-centered approach that identifies barriers to adherence, enhances self-efficacy, and motivates behavior change.~4. Progressive Muscle Relaxation (PMR): A systematic relaxation technique to alleviate physical and emotional stress, tailored to each patient's anxiety levels."
223563484|NCT06732141|BEHAVIORAL|Standard Care with Weekly Follow-Up Calls|Participants receive weekly telephone follow-up calls for 8 weeks. These calls include health status assessments, symptom monitoring, and general medication inquiries but exclude psychological or educational components.
223563485|NCT06890676|OTHER|Comprehensive Oral Evaluation|A thorough check-up of teeth, gums, and surrounding tissues, including medical and dental history, to assess overall oral health and identify any infections.
224036729|NCT02615821|BEHAVIORAL|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
224036730|NCT04143399|PROCEDURE|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
224036731|NCT04143399|PROCEDURE|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
223423520|NCT02449382|PROCEDURE|continuous venovenous hemofiltration|If the serum sodium concentration \>150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
223739861|NCT06511908|DRUG|Placebo|Arm 1 and 2 Control Intervention
223739862|NCT03244020|DRUG|Aspirin 325mg|Aspirin 325 mg by mouth once daily
223739863|NCT03244020|DRUG|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
223739864|NCT06083636|OTHER|Single extra blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) additional to regular blood draw will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
224036732|NCT03773198|OTHER|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
224036733|NCT03773198|OTHER|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
224036734|NCT02716467|OTHER|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
223423521|NCT02449382|DRUG|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
223423522|NCT02754271|OTHER|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
223423523|NCT03550755|BIOLOGICAL|V3-Cervix|Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
224036735|NCT02716467|RADIATION|Radiotherapy|All participants will receive treatment by radiotherapy
224036736|NCT03952494|GENETIC|Genomind®Professional PGx Express TM|The current test includes the analysis of fifteen pharmacodynamic genes and nine pharmacokinetic genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), bipolar disorder, Posttraumatic Stress Disorder (PTSD), autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
224036737|NCT03841682|BEHAVIORAL|I-CARE2|"I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity."
224036738|NCT03376607|OTHER|HBCP programme|The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.
224036739|NCT03376607|BEHAVIORAL|mobile health application|"HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material."
223423524|NCT00002837|BIOLOGICAL|Filgrastim (G-CSF)|
223423525|NCT00002837|DRUG|Cyclophosphamide|
223423526|NCT00002837|DRUG|Doxorubicin Hydrochloride|
223423527|NCT00002837|DRUG|Paclitaxel|
223423528|NCT00002837|PROCEDURE|Peripheral Blood Stem Cell Transplantation|
223423529|NCT04538833|DRUG|monosialic gangliosides|The experimental group received 80 mg of monosialic gangliosides (GM1) on days -1, 1, and 2 of albumin-bound paclitaxel(GM1 is a single infusion).
223423530|NCT04538833|OTHER|Placebo|The control group received placebo on days -1, 1, and 2 of albumin-bound paclitaxel (placebo as a single infusion)
223563486|NCT06890676|OTHER|Intraoral Complete Radiographic Series|A series of x-rays of the whole mouth intended to display the, teeth, roots, periapical areas, bone, and areas without teeth.
223563487|NCT06890676|OTHER|• Teledentistry-synchronous and asynchronous|The delivery or coordination of care for a patient using synchronous; real-time or aysnchronous communication between care providers or between care providers and a patient.
223563488|NCT06890676|PROCEDURE|Periodontal Therapy|A therapeutic procedure designed to remove plaque and calculus (hardened plaque) causing gum infections that can lead to tooth loss and other medical complications.
223563489|NCT06890676|PROCEDURE|Periodontal Maintenance Procedure|A periodic evaluation and therapeutic support procedure for patients with a history of gum infections.
223739865|NCT06083636|OTHER|Single blood draw and completion of single questionnaire|Single blood draw of 3 tubes (20 mL) will be performed. All participants will complete a single questionnaire that will be 5-10 minutes time-consuming.
224036740|NCT00642382|DEVICE|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
224036741|NCT00642382|DEVICE|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
224036742|NCT02361151|BEHAVIORAL|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
224036743|NCT02361151|BEHAVIORAL|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
224036744|NCT01379391|DRUG|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
224037870|NCT06602765|OTHER|Tooth brushing, tooth paste containing 1450ppm fluoride|brushing with fluoride toothpaste, dietary counselling for caries prevention and application of fissure sealant compound on first permanent t molars.
224037871|NCT05317481|BEHAVIORAL|BE-SMART-DR|Therapy that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk
223423531|NCT01869205|DEVICE|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
223423532|NCT06436950|DEVICE|transcutaneous electrical phrenic nerve stimulation (TEPNS)|TEPNS is conducted twice a day for consecutive 5 days. Electrodes are applied to bilateral neck skin which phrenic nerve runs underneath.
223423533|NCT03718520|OTHER|no intervention, this is a purely observational study|No intervention
223423534|NCT02626130|PROCEDURE|Cryosurgery|Undergo cryoablation
223423535|NCT02626130|OTHER|Laboratory Biomarker Analysis|Correlative studies
223423536|NCT02626130|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223423537|NCT02626130|BIOLOGICAL|Tremelimumab|Given IV
223423538|NCT01510795|DRUG|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
223423539|NCT02173678|DRUG|COMBIVENT® HFA-MDI|
223423540|NCT02173678|DRUG|COMBIVENT® CFC-MDI|
223423541|NCT02173678|DRUG|Placebo HFA-MDI|
223563490|NCT06890676|PROCEDURE|Application of Caries Arresting Medicament|Topical application of decay arresting or inhibiting medicament.
223739866|NCT04017299|OTHER|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
224036745|NCT03446729|BEHAVIORAL|Guided Self-Help Behavioral Weight Loss|Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
224036746|NCT01087931|DRUG|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
224036747|NCT01087931|OTHER|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
224036748|NCT05021523|OTHER|Hot ambient conditions exposures|Participants rest or exercise for 40min to 1h daily in hot ambient conditions
224036749|NCT05021523|OTHER|Immobilization|Participants are wearing a walking boot (with crutches) for 2 weeks
224036750|NCT03767582|RADIATION|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
224036751|NCT03767582|DRUG|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
224036752|NCT03767582|DRUG|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
224036753|NCT03767582|DRUG|GVAX|Vaccine (5x10\^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
224037872|NCT05317481|BEHAVIORAL|psychoeducational control comparator condition (CC)|Structured sessions, matched for BE-SMART-DR session number and time, that will emphasize established strategies to manage health and well being
224037873|NCT02132546|DRUG|Chlorhexidine|
224037874|NCT04726566|PROCEDURE|Tendon graft|Anatomical surgery for chronic lateral ankle instability under arthroscopy with tendon graft
224138057|NCT00379262|DRUG|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
224138058|NCT00379262|DRUG|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
223423542|NCT06685627|OTHER|Open water wetsuited swimming.|All swimmers used their own well-fitting wetsuits (5 mm maximum thickness in accordance with World Triathlon guidelines7) and were free to supplement additional neoprene hats, gloves and booties as desired. A safety paramedic attended all swims. Swim distance was self-determined
223423543|NCT01490073|DRUG|Insertion of nitroglycerin ointment|Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
223423544|NCT01490073|DRUG|Insertion of placebo ointment|Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
223423545|NCT03242876|OTHER|Control|Control will be 109 g white bread to be consumed together with 200 mL water
223423546|NCT03242876|OTHER|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
223423547|NCT06684548|PROCEDURE|Hip/shoulder width ratio|the effect of hip/shoulder-width ratio on sensory blockade level in patients undergoing intrathecal anesthesia for subumbilical herniorrhaphy
223423548|NCT03902184|BIOLOGICAL|IPH4102|Patients will receive a flat dose of 750mg
223423549|NCT03404947|DIETARY_SUPPLEMENT|Ethanol|For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
223423550|NCT01923298|DRUG|Estradiol|
223423551|NCT04880798|DIAGNOSTIC_TEST|124I PET/CT|The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.
223423552|NCT05209776|BIOLOGICAL|Peripheral immunological assessment on venous blood|Peripheral immunological assessment carried out as part of the research, on venous blood at the puncture point necessary for the electrophysiological examination: 1 heparin tube and 1 EDTA tube
223423553|NCT05209776|BIOLOGICAL|Immunological assessment carried out on intracardiac material|Immunological assessment carried out as part of the research, on intracardiac material taken during the electrophysiological examination: 1 EDTA tube
223423554|NCT06840587|BEHAVIORAL|Connect-Home ADRD|Connect-Home ADRD will introduce new structure and processes to support SNF staff delivery of transitional care for transitions to home, assisted living, or long-term care, and post-discharge transitional care by the Dementia Caregiving Specialist.
223423555|NCT00186966|DRUG|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
223423556|NCT00186966|DRUG|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
223423557|NCT00186966|PROCEDURE|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
223563491|NCT06890676|OTHER|Oral Hygiene Assistance|Dental procedures aimed at educating patients on, and assisting patients with ,proper oral hygiene practices removing food debris, germ-laden plaque, and soft tartar using cloth wipes, toothbrush, floss, and using oral hygiene aids.
224037875|NCT04726566|PROCEDURE|Suture with biological reinforcement|Anatomical surgery for chronic lateral ankle instability under arthroscopy by suture with biological reinforcement
224037876|NCT06352047|OTHER|The effect of positioning on respiratory functions of preterm infants after extubation.|Position changes and the direction of the position (supine, prone, side lying) are recorded in the nurse observation form.
224138059|NCT00379262|DRUG|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
224138060|NCT01884857|DRUG|Metoprolol Succinate ER Tablets 50 mg|1\* 50 mg tablet once a day
224138061|NCT01884857|DRUG|'TOPROL-XL®' ER Tablets 50 mg|1 \* 50 mg tablet per day
224138062|NCT00972127|DRUG|Neramexane|25 mg or 2x25mg tablets
223423558|NCT00186966|RADIATION|Total body irradiation|See Detailed Description section for details of treatment interventions.
224036754|NCT02044211|BEHAVIORAL|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
223423559|NCT00052052|DRUG|interferon-gamma 1b|200 mcg, SQ, 3x per week
223423560|NCT06186427|DIAGNOSTIC_TEST|68Ga-DOTA-GPFAPI-04 PET/CT|The same group of patients underwent 68Ga-DOTA-GPFAPI-04 PET/CT and FDG PET/CT examinations respectively
223423561|NCT01986127|DRUG|Adalimumab|single intralesional administration during endoscopy process
223423562|NCT01986127|DRUG|placebo|single intralesional administration during endoscopy
224036755|NCT02044211|BEHAVIORAL|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
224036756|NCT01207726|DRUG|Azacitidine|Given SC
224036757|NCT01207726|DRUG|Entinostat|Given PO
224036758|NCT01207726|OTHER|Laboratory Biomarker Analysis|Correlative studies
224138063|NCT02034474|DRUG|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
223423563|NCT06682676|DEVICE|Nasal ventilation function test and cold and dry air nasal provocation test|The visual analogue scale (VAS) of nasal symptoms, rhinoconjunctivitis quality of life questionnaire (RQLQ), total nasal symptom score (TNSS), total nasal volume (TNV), minimum cross-sectional area (MCA), peak inspiratory flow (PNIF), and total nasal resistance (TNR) at 75Pa were recorded before and after nasal ventilation function test and CDA nasal provocation test.
223563492|NCT06890676|PROCEDURE|Referral for Treatment of Acute Oral Infection|Diagnosis and treatment of oral infection outside the scope of a dental hygienist or Expanded Function Dental Assistant.
223563493|NCT06895668|OTHER|None (cohort study)|None (cohort study)
223563494|NCT06896071|BEHAVIORAL|Project SOLVE|"Project SOLVE is a 30-minute self-guided online activity that includes an introduction to problem solving and which types of problems might be most appropriate for this skill; a description of how the brain facilitates problem solving; vignettes demonstrating how older adolescents have solved their problems; scientific evidence that problem solving can work; practice exercises; and activities to encourage the use of problem solving in daily life. The intervention teaches students how to solve problems via the SOLVE framework (i.e., Saying what the problem is; One goal to aim for; Listing some solutions; Voting for the best solution; Exploring what works)."
223563495|NCT06896071|BEHAVIORAL|Project Success|Project Success is comparable to Project SOLVE in format and length (i.e., a 30 minute online, self-guided intervention) and teaches young people three strategies to reach their academic goals: how to take effective notes, how to break big assignments down into smaller tasks, and how to ask trusted others for help.
223563496|NCT06895278|DRUG|Methotrexate|Prevalent use of methotrexate in pediatric age
223563497|NCT06895278|DRUG|Biological Drug|Prevalent use of biological drugs in pediatric age
224138064|NCT02034474|DRUG|Placebo|intravenously via iv drip over 60 min
223423564|NCT04119076|OTHER|Classroom-based physical activity|
223423565|NCT04119076|OTHER|Control Group|
223423566|NCT04183582|BEHAVIORAL|Behavioural Activation|"Behavioural Activation is a treatment for depression, the current programme has been adapted to suit the needs of postnatal women Session 1: Getting Started Session 2: Identifying Triggers, Reactions and Avoidance Patterns (TRAPs) Session 3: Turning TRACs in to Triggers, Reactions and Alternative Coping (TRACs) Session 4: Support and Communication Session 5: Being a Good Enough Mum Session 6: Staying Well"
223563498|NCT06896305|COMBINATION_PRODUCT|CDED (Crohn's Disease Exclusion Diet) in addition to anti-TNF therapy|"Patients in the experimental group will receive professional dietary advice on how to adhere to CDED for 12 weeks, in addition to anti-TNF therapy while patients in the control group will receive only anti-TNF therapy for the entire duration of the study.~Diet adherence is completely voluntary and is not enforced in any way. CDED is divided into 3 phases, the first two, grouped as the induction phase, with 6 weeks of strict diet and 6 weeks to gradual food reintroduction, followed by 12 weeks of patients follow-up.~Five foods (chicken, eggs, potatoes, apple and bananas) are permitted at the start of the diet; the patient can then choose to consume a range of permitted foods at will, the variability of which increases after the first six weeks"
223563499|NCT06896305|DRUG|Anti-TNF Therapy|The control group will receive only anti-TNF therapy as per standard of care. This therapy is recommended by guidelines and is the cornerstone of treatment of Crohn's disease and ulcerative colitis.
223423567|NCT02496091|DEVICE|ATLANTIS Abutment|
223423568|NCT03951974|BEHAVIORAL|Social Emotion Regulation Strategy Development|Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.
223423569|NCT03951974|BEHAVIORAL|Control|Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
223423570|NCT06621160|OTHER|Observation|After the participants\&#39; physical and sociodemographic characteristics were recorded, they were asked to fill out the Constipation Severity Scale and 7- Day Stool Diary to determine their constipation levels. The individuals\&#39; anthropometric characteristics were assessed with triceps, subscapula, suprailiac and calf skinfold thickness, humerus and femur epicondyle diameter, biceps and calf circumference measurements, spinal postures were assessed with the Spinal Mouse, and physical activity levels were assessed with the International Physical Activity Questionnaire-Short Form UFAA-KF and pedometer.
223423571|NCT03174873|PROCEDURE|laparoscopy|Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
223423572|NCT04275921|DIAGNOSTIC_TEST|MRI scan|MRI analysis using TWIST and HASTE
223563500|NCT06845579|PROCEDURE|Renal sympathetic denervation|All procedures will be carried out by highly experienced interventional cardiologists, each having performed a minimum of 20 RDN prior to treating study patients. All interventions will be performed with the CE-marked Symplicity SpyralTM (Medtronic, Minneapolis, MN, USA) renal denervation system following current treatment standards. Procedures will be performed as stated in the IFU. The specific ablation points will be determined by the discretion of the interventionalist.
223563501|NCT06880042|DRUG|Tacrolimus|Tacrolimus is calcineurin inhibitor that will act as immunomodulator
224036759|NCT03851614|BIOLOGICAL|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
223563502|NCT06880042|DRUG|Calcipotriol|Calcipotriol is a vitamin D analogue that will act as immunomodulator
223563503|NCT06896773|OTHER|Impact of Normobaric Hypoxia on Cardiac Biomarkers in trained men|The intervention will consist of three series differing in terms of simulated altitude: S1 (normoxia), S2 (2000 m a.s.l.), and S3 (3000 m a.s.l.). Each research series will consist of one day of the measurements. All participants will perform two ergocycle tests (the graded exercise test GXT and constant-workload exercise test CXT at the individual lactate threshold workload (WRLT) until volitional exhaustion) with 10 minutes of active recovery break in different environment (S1, S2, S3- 3000). The order of the series will be randomized across all participants. The fraction of inspired oxygen (FIO2) will depend on the series and will be as follows: S1 (normoxia) = 20.9%; S2 (2000 m a.s.l.) = 16,5%; S3 (3000 m a.s.l.) = 14.4%. The hypoxic environment will be maintained using AirZone climate technology (AirSport). Between the series, there will be a one-week active rest break excluding exposure to hypoxia and performance of high-intensity exercise.
223563504|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the IHT group|The participants in IHT group will live in normoxic conditions, but part of their training will be performed in normobaric hypoxia in a hypoxic chamber. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
223563505|NCT06896773|OTHER|Effects of Hypoxic Strength Training on Cardiac Biomarkers in the NRT group|The participants in the NRT group will perform resistance training in normoxia. The experiment will consist of two series of testing (S1 and S2), performed in a laboratory. S1 will involve baseline testing, while S2 will be performed after three weeks of training after 3 days of rest. Each research series will consist of three measurement days. The testing protocol and blood sampling will be the same as in the first and second stages of the research. After next 72h of rest, all participants will have their muscle strength assessed using the one-repetition maximum (1RM) test in normoxia environment. The tests will be conducted in two exercises: a barbell bench press and a barbell squat.
223739867|NCT06024928|DEVICE|Control-IQ use in Type 2 Diabetes under basal insulin injections|Testing the safety and feasibility of using Automated Insulin Delivery (AID) in people with Type 2 Diabetes under basal insulin injections to achieve safe and fast basal insulin titration.
223739868|NCT05840211|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
223739869|NCT05840211|DRUG|Paclitaxel|Administered intravenously
223739870|NCT05840211|DRUG|Nab-paclitaxel|Administered intravenously
223739871|NCT05840211|DRUG|Capecitabine|Administered orally
223739872|NCT05378880|BEHAVIORAL|Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission|The study teams will work with communities and authorities to develop, implement and evaluate a multifaceted intervention bundle that will optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission, by targeting the general public (including farmers) and medicine stores.
224138065|NCT06250894|DRUG|PD-1inhibitor|Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
223423573|NCT04275921|DIAGNOSTIC_TEST|4D MRI|4D MRI alongside 4D CT in lung cancer
223423574|NCT05908123|BEHAVIORAL|The Blank Center CARE Model(TM) for Individuals who Stutter|The over-arching goal of the Blank Center CARE Model is to ensure individuals who stutter communicate effectively, advocate for themselves in a manner that maintains agency, and ensure their quality of life does not depend on producing, or attempting to control, stuttered speech.
223423575|NCT06061523|DRUG|Sotorasib|Oral Tablet
223423576|NCT06459050|OTHER|Dominant Limb Overcoming Isometric Conditioning Activity|Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by the dominant limb.
223423577|NCT06459050|OTHER|Non-dominant Limb Overcoming Isometric Conditioning Activity|Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by non-dominant limb.
223739873|NCT03176329|OTHER|Nursing 1 : INTELLIVENT-ASV|
223739874|NCT03176329|OTHER|Nursing 2 : INTELLIVENT-ASV|
223739875|NCT03176329|OTHER|Nursing 1 : Conventional mode|
223423578|NCT06685614|DEVICE|orthodontic bracket bonding|compare the effectiveness of different bonding methods including traditional direct bonding, traditional indirect bonding, indirect bonding using 3D-printed transfer tray, and indirect bonding using vacuum-formed transfer tray made with 3D-printed models
223423579|NCT06674655|BEHAVIORAL|Motor Imagery Plus Therapeutic Exercise|This group will perform three days of lumbo-pelvic motor control exercise intervention along with a motor imagery intervention program during active breaks between exercises.
223423580|NCT06674655|BEHAVIORAL|Therapeutic Exercise|This group will perform a lumbo-pelvic motor control exercise program for three consecutive days.
223423581|NCT06674655|BEHAVIORAL|Minimal intervention|This group will carry out a therapeutic counseling and minimal education intervention during a one-day intervention.
223423582|NCT02272842|DIETARY_SUPPLEMENT|Vitamin B12|Vitamin B12 in a multivitamin paste.
223423583|NCT05769400|OTHER|Patient Participation Form|A form that consists of revised osteoporosis knowledge test, osteoporosis self-efficacy scale, and osteoporosis health belief scale.
223423584|NCT04540159|DIAGNOSTIC_TEST|Flow-cytometric analysis|Measuring the level of sCD25 (IL-2Ra), 4-1BB, B7.2 (CD86), Free Active TGF-β1, CTLA-4, PD-L1, PD-1, Tim-3, LAG-3, Galectin-9 in the intraabdominal ascites
223423585|NCT00922506|DRUG|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
223423586|NCT04339647|BEHAVIORAL|The SIMS programme|The intervention targets 5-6-year-old preschool children and their parents. Apart from the usual care, 5-6-year-old children receive oral health lessons and supervised daily tooth brushing (1000ppm F) at school over a period of 6 months, as well as home tooth brushing supervision by parents for 6 months. Parents/guardians attend a meeting with a DT team at school to discuss on child's oral health status, receive OHE and free toothbrush and fluoride toothpaste (1000ppm F) for child home tooth brushing, and receive 10 oral health infographic messages from DT over a period of 5 months (with printed versions available).
223423587|NCT04482998|OTHER|No intervention - retrospective study|No intervention - retrospective study
223423588|NCT05832905|BEHAVIORAL|Mobile and Wearable-assisted Case Management|The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
223423589|NCT02255305|BIOLOGICAL|FMT|Patients in the FMT group will receive \~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
223423590|NCT02255305|DRUG|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
223423591|NCT03687398|DIAGNOSTIC_TEST|genetic testing with nanoclonal technique|endometrial sampling
223423592|NCT05590897|PROCEDURE|Teeth Brushing|All 52 participants were instructed through a lecture on how to perform toothbrushing with a fluoridated toothpaste (Colgate T®) and dental flossing three times per day after meals for 30 days. The Bass technique was taught, by which the bristles should be positioned at an approximate angle of 45º to the gingival pocket on both the free and proximal faces, with the performance of short, slightly circular vibrating movements.
223423593|NCT05590897|PROCEDURE|Dental Flossing|All 52 participants were instructed to floss, 3 times a day after meals for 30 days.
223423594|NCT05590897|PROCEDURE|Tongue Scraping|Tongue scraping was performed by the same operator for all participants. Posteroanterior movements were performed with the scraper on the dorsum of the tongue, followed by the cleaning of the scraper with gauze. The procedure was performed ten times on each participant to standardize mechanical removal.
223423595|NCT05590897|RADIATION|Antimicrobial Photodynamic Therapy (aPDT)|"One session of aPDT was performed. The annatto photosensitizer was mixed at a concentration of 20% (Fórmula e Ação®, Brazil) in spray form, applied with a sufficient quantity to coat the middle third of the dorsum of the tongue (five sprays) and left for two minutes for incubation. The excess was removed with an aspirator. \|The surface of the tongue remained moist with the photosensitizer itself without the use of water. Six points were irradiated with a distance of 1 cm between points, considering the spread of the light and effectiveness of aPDT. The device was previously calibrated at a wavelength of 395-480 nm. Light was irradiated to ensure a beam area of 2 cm in diameter per point. Energy was 9.6 J and exposure time was 20 seconds per point."
223423596|NCT00138398|BIOLOGICAL|Commercial TriValent Split Influenza Virus|
223423597|NCT02396420|DEVICE|Embosphere Microspheres|
223423598|NCT02330367|DRUG|AC0010|"Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D."
223423599|NCT06069076|DIAGNOSTIC_TEST|cathepsin S and chromogranin A|Diagnostic value of serum Cathepsin S and Chromogranin A
223423600|NCT05033262|OTHER|Our Memory Care Wishes|Our Memory Care Wishes is a web-based advance care planning platform designed for persons living with dementia in nursing homes to discuss and document healthcare and daily life preferences with the help of shared decision-makers. Penn researchers meet via Zoom with PLWD and their SDMS and nursing home staff to facilitate website completion.
223423601|NCT00172601|PROCEDURE|mobilization|
223423602|NCT00569673|BIOLOGICAL|filgrastim|
223563506|NCT06896773|OTHER|Impact of Normobaric Hypoxia on Cardiac Biomarkers in untrained men|The intervention will consist of three series differing in terms of simulated altitude: S1 (normoxia), S2 (2000 m a.s.l.), and S3 (3000 m a.s.l.). Each research series will consist of one day of the measurements. All participants will perform two ergocycle tests (the graded exercise test GXT and constant-workload exercise test CXT at the individual lactate threshold workload (WRLT) until volitional exhaustion) with 10 minutes of active recovery break in different environment (S1, S2, S3- 3000). The order of the series will be randomized across all participants. The fraction of inspired oxygen (FIO2) will depend on the series and will be as follows: S1 (normoxia) = 20.9%; S2 (2000 m a.s.l.) = 16,5%; S3 (3000 m a.s.l.) = 14.4%. The hypoxic environment will be maintained using AirZone climate technology (AirSport). Between the series, there will be a one-week active rest break excluding exposure to hypoxia and performance of high-intensity exercise.
223739876|NCT03176329|OTHER|Nursing 2 : Conventional mode|
223423603|NCT00569673|BIOLOGICAL|pegfilgrastim|
223739877|NCT00622479|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
223739878|NCT04667767|OTHER|WASH kit|WASH kit containing a plastic container and a supply of Aquatabs® (effervescent chlorine tablets) and training in their use and associated hygiene practices.
223739879|NCT04667767|OTHER|Standard treatment|National standard outpatient treatment for uncomplicated severe acute malnutrition
223423604|NCT00569673|DRUG|docetaxel|
223563507|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the LHTL group|The participants from the LHTL group will be exposed to normobaric hypoxia (FIO2 = 14.4%, corresponding to an altitude of 3000 m a.s.l.) in a hotel room for 11 to 12 hours a day (evenings and nights). Participants in this group will perform interval training under normoxic conditions. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
223563508|NCT06896773|OTHER|Effects of Hypoxic Endurance Training on Cardiac Biomarkers in the Control group|The participants in the C group will live and train in normoxic conditions. The experiment will consist of two series of testing: S1 (baseline) and S2 (after 3 weeks of training and 3 days of rest). All participants will perform the same testing protocol as in stage 1-albeit in a normoxic environment and after 72h of rest, all testing procedures will be repeated in a hypoxic environment.
223563509|NCT06896773|OTHER|Effects of Hypoxic Strength Training on Cardiac Biomarkers in the HRT group|The participants in the HRT group will perform resistance training in normobaric hypoxia (FIO2 = 14.4%, 3000 m a.s.l.). The experiment will consist of two series of testing (S1 and S2), performed in a laboratory. S1 will involve baseline testing, while S2 will be performed after three weeks of training after 3 days of rest. Each research series will consist of three measurement days. The testing protocol and blood sampling will be the same as in the first and second stages of the research. After next 72h of rest, all participants will have their muscle strength assessed using the one-repetition maximum (1RM) test in normoxia environment. The tests will be conducted in two exercises: a barbell bench press and a barbell squat.
223563510|NCT06895785|DEVICE|Exalt Model D|Exalt Model D single-use duodenoscope will be used in ERCP
223563511|NCT06895785|DEVICE|Reusable|Standard reusable duodenoscope will be used in ERCP
224036760|NCT03851614|DRUG|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
223423605|NCT00569673|DRUG|trabectedin|
223423606|NCT00334529|DRUG|Oseltamivir|
223423607|NCT05002673|DEVICE|DENTAL LOCAL ANESTHESİA|doing local and topical anesthesia with two different device
223423608|NCT06137573|DRUG|[14C]TNP-2198|600mg suspension containing 150μCi of \[14C\] TNP-2198
223563512|NCT06896097|PROCEDURE|Ridge preservation|extraction of non restorable tooth in a traumatic way and socket preservation with the selected group
223563513|NCT06000683|BEHAVIORAL|Patient education|Patients will be sent information (in preferred language) on lung cancer risk, lung cancer screening (LCS) benefits, harms, false positive rates, recommendations of follow-up for positive results, and exam insurance coverage.
223739880|NCT04817488|OTHER|Prehospital emergency ultrasound with tele-supervision|Prehospital emergency ultrasound with tele-supervision in patients with acute dyspnoea
224036761|NCT03851614|DRUG|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
224036762|NCT04325308|PROCEDURE|Protein-enriched human milk diet|1.2 g of human-based protein will be added to each 100 ml of human milk administered
224036763|NCT04325308|PROCEDURE|Usual human milk diet|Human-based protein will not be added to the human milk administered.
224036764|NCT01174654|BEHAVIORAL|Contingency management|A 12-week contingency management intervention
224036765|NCT06296745|DRUG|Pemetrexed|Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
224037877|NCT05585853|OTHER|virtual reality|Virtual reality glasses application is a method without any side effects. Patients will be treated for an average of 10 minutes. Data will be collected before, during, immediately after the application, at the 15th and 30th minutes.
224037878|NCT06992544|OTHER|Pistachio-enriched diet|1 packet/day of approximately 1.25 oz (35 g) of dry roasted, unsalted, shelled pistachio kernels
224037879|NCT06992544|OTHER|Usual diet|Usual diet (while abstaining from pistachio consumption and limiting other nut consumption to ≤1 serving/week)
223423609|NCT02050217|PROCEDURE|Neurally Adjusted Ventilatory Assist|
223423610|NCT06131684|DEVICE|Intrauterine pressure catheter (IUPC) present|Amniotic fluid will be analyzed every 3 hours for the duration of labor for patients who require an IUPC through the standard of care.
223423611|NCT06131684|DEVICE|Intrauterine pressure catheter (IUPC) absent|Patients that do not require an IUPC through the standard of care will not have amniotic fluid analyzed.
223423612|NCT03518619|BEHAVIORAL|PFIcope+EMI|The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
223423613|NCT01812317|PROCEDURE|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
223423614|NCT01812317|PROCEDURE|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
223423615|NCT04068012|OTHER|Ventilator protocol|open loop ventilator management by a computer based protocol
224036766|NCT05486559|OTHER|ECMO-free protocol|"All patients randomized to the ECMO-Free Protocol Group will receive a protocolized daily assessment of readiness for liberation from VV-ECMO, which will be initiated between 6:00 AM local time and 10:00 AM local time. If the patient is enrolled after 10:00 AM local time the ECMO-free protocol will begin the following calendar day.~The ECMO-Free Protocol is a 3-step process of assessing readiness for liberation from VV-ECMO: a safety screen (Phase 1: ECMO-Free Safety Screen), titration of the non-ECMO fraction of inspired oxygen (Phase 2: Non-ECMO respiratory support titration), and a trial of cessation of sweep gas flow (Phase 3: ECMO-Free Trial)."
223423616|NCT03193112|DRUG|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
223423617|NCT01273623|DEVICE|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
223423618|NCT02238912|DRUG|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
223423619|NCT06240702|OTHER|Telerehabilitation Group|Unlike the control group, the experimental group will be given a phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Within the scope of the Phase II telerehabilitation program, breathing exercises and calisthenic exercises will be performed at increasing intensity according to the patient's tolerance, 3 days a week for 3 weeks. In addition, walking training will be continued over increasing distances. In addition, it will be aimed to increase sleep quality by giving a sleep hygiene education brochure to the patients in the experimental group. During the sessions, the vital signs and clinical status of the patients will be monitored according to the severity level determined by the finger pulse oximeter device, digital blood pressure monitor, perceived difficulty level (Borg Scale) and maximum heart rate. In addition, patients will be kept in a diary to monitor their compliance with the treatment program.
223423620|NCT01640379|BEHAVIORAL|Technology Enhanced Community Health Nursing|"* Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)~* Enhanced community health nursing visit on day 3-5, includes evidence-based STI/HIV prevention component (Sister to Sister Teen)"
223423621|NCT04016038|OTHER|a psycho-social investigation|The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
223423622|NCT01493284|DEVICE|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
223423623|NCT00325156|BIOLOGICAL|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
223423624|NCT00519428|DRUG|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
223423625|NCT00519428|DRUG|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
223423626|NCT00519428|DRUG|escitalopram + bupropion|same dosing schedule as for monotherapy
223423627|NCT02949193|DRUG|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
223423628|NCT02949193|DRUG|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
223423629|NCT05792332|OTHER|Telemonitoring|Patients are followed up by a nurse specialist in parkinsonism who interacts with the treating neurologist and a multidisciplinary team
223423630|NCT05792332|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
223423631|NCT04064411|COMBINATION_PRODUCT|abaloparatide|Abaloparatide is a synthetic peptide that is a potent and selective activator of the parathyroid hormone 1 receptor signaling pathway.
224036767|NCT05486559|OTHER|Usual Care|All patients randomized to the Usual Care Group will undergo assessments of readiness for liberation, weaning, and decannulation at the discretion of the treatment team.
224036768|NCT04994665|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy is a surgical weight-loss procedure, about 80% of the stomach is removed
224036769|NCT04994665|PROCEDURE|sleeve gastrectomy with omentopexy|After sleeve gastrectomy procedure, the omentopexy involves suturing the omentum back to the greater curvature of the stomach in several locations, depending on the length of the greater curvature
223423632|NCT04064411|COMBINATION_PRODUCT|abaloparatide solid microstructured transdermal system|Abaloparatide-sMTS is a drug-device combination product consisting of the drug abaloparatide coated onto a sMTS array for transdermal administration of abaloparatide.
223423633|NCT06664697|DEVICE|Cochlear Implantation with Robotic-Assisted Insertion System|The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.
223423634|NCT01598233|DEVICE|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
223423635|NCT03449654|DRUG|Liraglutide|Liraglutid
223423636|NCT03449654|DRUG|Placebo (for liraglutide)|Placebo (for liraglutide)
223423637|NCT05507476|DRUG|Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray|The patient will receive two puffs of desmopressin acetate 10 µg/puff in the side of the nasal cavity ipsilateral to the obstructed lacrimal duct (20 μg totally) 60 minutes before surgery.
223423638|NCT05507476|DRUG|Epinephrine topical 1:100,000 Nasal Packs|The patient will receive topical 1:100,000 epinephrine in the side of the nasal cavity ipsilateral to the obstructed lacrimal gland via 3 soaked packs placed in the middle meatus for 5 minutes immediately before the start of surgery.
223423639|NCT05045027|PROCEDURE|Biospecimen Collection|Undergo collection of tissue samples
223423640|NCT05045027|PROCEDURE|Diagnostic Imaging|Undergo multinuclear metabolic imaging
223423641|NCT05045027|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223423642|NCT05970276|DEVICE|Deep Sleep (N3) Enhancement with TES|As participants sleep, their sleep EEG will be measured and automatically scored by the computer to determine stage of sleep. When slow wave sleep is detected, low-level current (.5-1 mA total) will be applied through pre-set electrodes.
223423643|NCT00296946|DRUG|ipratropium bromide (drug)|
223423644|NCT05144308|PROCEDURE|Images of the operated eye (s)|Through the operating microscope or a slit lamp, dilated pupil. Taken on the day of surgery (D0) and at 1 week, 1 month and 3 months post-op
223563514|NCT06000683|BEHAVIORAL|Referral to financial navigation resources|Patients who self-report needing help with health-related social risks at baseline will be sent a brochure (in preferred language) from patient advocate foundation (PAF), a national non-profit financial navigation organization, where patients can self-refer.
223563515|NCT06000683|BEHAVIORAL|Patient Reminders|Within 2 weeks prior to primary care appointment, patients will receive a text message or a phone call (if not having a phone that receives text messaging) encouraging patients to discuss the LCS with their provider.
223563516|NCT06000683|BEHAVIORAL|Provider Reminers|Within 2 weeks prior to primary care appointment, providers will be notified of their patient's eligibility for LCS.
223423645|NCT02114450|BEHAVIORAL|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
223423646|NCT02114450|BEHAVIORAL|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
223423647|NCT06668038|OTHER|Multidisciplinary and multicenter validation of re-irradiation with curative intent|"Validation in multidisciplinary and multicenter meeting of re-irradiation indication after review of technical data (images, structures and doses) of 1st irradiation and recent diagnosis images of the lesion to be irradiated, merged using MIM.~In case of re-irradiation validation, validation in multidisciplinary and multicenter meeting of cumulated doses after review of EQD2 doses summation using MIM."
223563517|NCT01777503|DRUG|prasugrel|prasugrel 5 mg o.d.
223563518|NCT01777503|DRUG|Clopidogrel|75 mg o.d.
223563519|NCT06755632|DIAGNOSTIC_TEST|TROD (rapid diagnostic orientation test) and FibroScan®|"Fast-track appointment at the hepatology consultation at Avicenne Hospital (Bobigny) or the hepatology consultation at Jean Verdier Hospital (Bondy) for any patient :~* with Fibroscan® ≥ 9.6 KPa or~* positive hepatitis C serology or~* HBsAg positive"
223563520|NCT06897280|DEVICE|SCS Device Program Setting|A Pulse Dose setting specifies a brief duration of stimulation 'on' and stimulation 'off' durations, applied in a continuously cycled manner
224138066|NCT05231174|OTHER|A self-evlaution tool based on Large Language Model|"Following the baseline assessment, participants will be guided to use a self-evaluation tool independently to assess their risk of diabetic retinopathy (DR). This tool is a fusion of a conversational AI system based on LLM and an existing logistic diagnostic model.~The AI system is designed to collect clinical variables, including age, duration of diabetes, Body Mass Index (BMI), and insulin usage. Additionally, clinical test data such as mean arterial pressure, HbA1c, serum creatinine, and microalbuminuria will be extracted from a local dataset using the patient's name and ID. Once collected, these data will be transmitted to a server-based diagnostic model for further analysis to determine the presence of DR."
223423648|NCT02117921|BEHAVIORAL|One-on-one interview and educational sessions. Reading material for educational series provided.|A one-on-one interview with the patient and the principal investigator and group educational sessions.
223423649|NCT04729179|DRUG|Cannabidiol|Participants will start with 10 mg of cannabidiol daily and the dose will be escalated every third day until the maximum dosage of 50 mg is reached (after two weeks). The participants be on the 50 mg dosage of cannabidiol for 24 weeks.
223423650|NCT04729179|DRUG|Placebo|Placebo is administered as tablets of 10 mg that are identical in appearance, taste, and smell to the Cannabidiol tablets.The participants will be on the 50 mg dosage of placebo for 24 weeks.
223423651|NCT03395184|DRUG|PF-06651600 Placebo|12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
223423652|NCT03395184|DRUG|PF-06651600|200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
223423653|NCT03395184|DRUG|Placebo PF-06700841|12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
223423654|NCT03395184|DRUG|PF-06700841|60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
223423655|NCT02057484|DRUG|Tacrolimus|oral
223423656|NCT05698979|DRUG|BOTOX INJECTION|"The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2)."
223739881|NCT04817488|OTHER|Prehospital emergency ultrasound without tele-supervision|Prehospital emergency ultrasound without tele-supervision in patients with acute dyspnoea
223423657|NCT01960270|DEVICE|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
223563521|NCT06896747|BIOLOGICAL|Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes|"Mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) are isolated from umbilical cord-derived mesenchymal stem cells (UCMSCs) subjected to mechanical stress conditioning during in vitro expansion. This process enhances exosome yield, bioactivity, and regenerative capacity. The exosomes are purified via ultracentrifugation and characterized for size, protein markers, and RNA content.~In this study, ME-UCMSC-Exo is administered via intra-endometrial injection under hysteroscopic guidance. Each participant in this intervention group will receive 1-1.5 mL of exosome solution (containing approximately5\*10\^10 particles/mL) per injection site during the proliferative phase (Day 3-7 of the menstrual cycle). The aim is to enhance endometrial thickness, receptivity, and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions."
223739882|NCT06032533|DEVICE|Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
223739883|NCT06032533|DEVICE|Sham Remote Ischemic Conditioning with Automatic Tourniquet Device|"5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged.~Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment."
223423658|NCT06045403|BEHAVIORAL|Issuing health risk warning for a heat or cold|Whenever a health risk warning for a heat or cold is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.
223423659|NCT06045403|DEVICE|A digital heat or cold health risk early warning tool|A WeChat mini-program provides real-time updates on early warnings and health advisories.
223423660|NCT06045403|BEHAVIORAL|Perform daily self-monitoring of their BP and ECG|Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.
223423661|NCT06045403|DEVICE|Self-monitoring blood pressure and ECG device|Devices for self-monitoring blood pressure and electrocardiography (ECG).
223423662|NCT03507764|OTHER|Use of the treadmill workstation at work|"During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions."
223423663|NCT02433821|OTHER|Pilates|
223423664|NCT05494008|PROCEDURE|Korean herbal medicine treatment|Korean herbal medicine treatment is a treatment using complex extract of medicinal herbs prescribed by a Korean medicine doctor who has completed specialized education to diagnose the health condition and symptoms of patients with post-traffic accident syndromes.
223423665|NCT05494008|PROCEDURE|Non-Korean herbal medicine treatment|acupuncture, pharmacoacupuncture, cupping, chuna
223423666|NCT05685264|DRUG|Ponsegromab|Participants will receive one subcutaneous injection
223423667|NCT05685264|DRUG|Ponsegromab|Participants will receive four subcutaneous injections
223423668|NCT02522156|BEHAVIORAL|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
223423669|NCT02522156|BEHAVIORAL|Control|Neutral guided imagery scenarios making no reference to smoking.
223423670|NCT06301607|DEVICE|Intermittent Oro-esophageal Tube Feeding|The group is given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223423671|NCT06301607|DEVICE|Nasogastric Tube|The group is given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223423672|NCT06301607|BEHAVIORAL|comprehensive rehabilitation therapy|"Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223563522|NCT06896747|BIOLOGICAL|Umbilical cord mesenchymal stem cell-derived exosomes|Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) are obtained from standard cultured UCMSCs without mechanical stress preconditioning. These exosomes undergo identical purification and characterization procedures as ME-UCMSC-Exo but lack biomechanical priming. UCMSC-Exo is also administered intra-endometrially via hysteroscopic injection at a dose of 1-1.5 mL (5\*10\^10 particles/mL) per site.
223423673|NCT05452499|OTHER|Pain neuroscience education and therapeutic exercise|Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).
223423674|NCT02779699|DRUG|AL2846|AL2846 p.o. qd
223423675|NCT03069599|PROCEDURE|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
223739884|NCT03643640|BEHAVIORAL|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
223423676|NCT01290978|DRUG|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
223423677|NCT01290978|DRUG|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
223423678|NCT06662487|BEHAVIORAL|Resistance Training|Participants in the experimental group will perform free weight resistance training sessions focused on push, pull, and leg movement patterns. The program will last for 10 weeks, progressively increasing in load and intensity. The intervention will be designed to improve the participants' physical strength and observe how these changes affect their cognitive performance.
223739885|NCT03643640|OTHER|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
223739886|NCT04379882|DEVICE|Digital Sedation (Silva)|Use of Digital Sedation (virtual reality associated with psychological interventions) for preoperative anxiety management
223563523|NCT06896747|BIOLOGICAL|platelet-rich plasma|"Platelet-rich plasma (PRP) is an autologous biological preparation obtained from centrifuged whole blood. It contains a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), which promote endometrial regeneration.~In this study, PRP will be administered via hysteroscopically guided intra-endometrial injection at a dose of 1-1.5 mL per injection site, following standard PRP preparation protocols. This group serves as a positive control for evaluating the efficacy of exosome-based therapies."
223563524|NCT06898502|DEVICE|Electrotherapy ( TENS, hot pack, and therapeutic ultrasound )|"Each participant will receive electrotherapy treatment three times a week for four weeks. Each treatment session will consist of 20 minutes of TENS, 20 minutes of hot pack, and 6 minutes of ultrasound therapy. Twelve weeks after the treatment, participants will be contacted by phone and asked about their improvement using the Global Rating of Change Scale (GRC). Pain intensity and disability level will be reassessed through phone interviews using the Numeric Pain Scale, the Oswestry Disability Index for low back pain, and the Neck Disability Index for neck pain at the 12th week. Thus, it will be evaluated whether there is any difference in patient satisfaction, pain intensity, and disability at the 12th week between participants who selected electrotherapy as the most effective method and those who chose other treatments."
223563525|NCT06895655|DEVICE|MRI and Ultrasound Elastography|transcutaneous ultrasound elastography and MRI abdomen with diffusion to evaluate pancreatic mass as regard of probability of mass to be malignancy ,size of the mass ,relation to pancreatic duct and bile duct evaluation with their result will be compared to the pathologic finding.
223563526|NCT06895434|OTHER|Balneotherapy with physical therapy|"Balneotherapy applied in the thermal pools to patients for 20 minutes, at a temperature of 38-40°C. After resting for 30 minutes,physical therapy was applied.~A physical therapy program (5 days a week for 2 weeks, a total of 10 sessions) was applied to the painful area, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity."
223563527|NCT06895434|OTHER|Physical therapy|A physical therapy program (5 days a week for 2 weeks, a total of 10 sessions) was applied to the painful area, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.
223563528|NCT06896214|OTHER|Standardised nursing care intervention|Standardised nursing care intervention
223563529|NCT05920811|OTHER|conventional obturator|restoration of midline maxillary defect with obturator made of cast metal , heat cure acrylic resin
223563530|NCT05920811|OTHER|3 d printed obturator|restoration of midline maxillary defect with obturator made of SLM metal , 3 d printed resin
223423679|NCT03215511|DRUG|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
223423680|NCT05629611|DEVICE|Vi-Sealer|using Reusable device, Vi-Sealer
223423681|NCT05629611|DEVICE|Ligasure|using Ligasure
223423682|NCT05629611|DEVICE|Other AHD|Using other AHDs such as Thunderbeat, Harmonic scalpel, Caiman®, Enseal, etc. except Ligasure
223563531|NCT05325736|PROCEDURE|sleeve gastrectomy surgery|participants undergoing sleeve gastrectomy surgery
223563532|NCT05325736|PROCEDURE|gastric bypass surgery|participants undergoing gastric bypass surgery
223563533|NCT05325736|PROCEDURE|control|cholecystectomy
223563534|NCT05325736|PROCEDURE|Pancreatectomy|Collecting a sample of an unidentified healthy pancreas to extract insulin-secreting beta cells from the sample
223563535|NCT06751602|DRUG|Belumosudil 200 mg QD|Belumosudil 200 mcg oral daily
223563536|NCT06751602|DRUG|Placebo|Placebo (once daily)
223563537|NCT06893549|DIETARY_SUPPLEMENT|Lactobacillus plantarum GKK1 Probiotic|Participants in the probiotic group will receive a daily oral supplementation of Lactobacillus plantarum GKK1 probiotic capsules for 28 days. Each capsule contains 50 billion CFU, with a total daily intake of 100 billion CFU. The probiotic strain Lactobacillus plantarum GKK1 has been selected for its potential benefits in reducing exercise-induced fatigue and enhancing physical performance. The supplementation period will be followed by an exhaustive exercise test to assess physiological and biochemical changes.
224036770|NCT05532748|DEVICE|Respiratory exercise protocol with the modified Pachon's incentive|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a slow, deep breath, fully stretching the condom, and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe for 3 minutes at a gentle intensity through your nose without extra effort.~All these instructions will be explained through a video."
223423683|NCT01182597|DRUG|Pantoprazole (Pantoloc)|Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
223423684|NCT01182597|DRUG|Lansoprazole (Takepron OD)|Lansoprazole (Takepron OD) 30mg q12h PO
223423685|NCT02342197|DRUG|Decapeptyl|half the dose of Gn agonist
223423686|NCT00286780|DRUG|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
223423687|NCT01881204|DIETARY_SUPPLEMENT|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
223563538|NCT06893549|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will receive a daily oral supplementation of placebo capsules for 28 days. The placebo capsules are identical in appearance, taste, and weight to the probiotic capsules but contain only microcrystalline α-cellulose, magnesium stearate, and silicon dioxide. The supplementation period will be followed by an exhaustive exercise test to assess physiological and biochemical changes.
223563539|NCT03203941|BIOLOGICAL|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
223563540|NCT03950544|DRUG|Fosfomycin|Fosfomycin and meropenem
223563541|NCT03950544|DRUG|Tigecycline|Tigecycline and meropenem
223423688|NCT01881204|DIETARY_SUPPLEMENT|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
223423689|NCT01881204|DIETARY_SUPPLEMENT|Control|Cookies without Hesperidin or Calcilock added.
223423690|NCT03088046|DRUG|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
223423691|NCT05173168|DIETARY_SUPPLEMENT|Probiotic Dietary Supplement|Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts
223563542|NCT03950544|DRUG|Polymyxin B|Polymyxin B and meropenem
223563543|NCT06896227|DIAGNOSTIC_TEST|transthoracic echocardiography|Each study patient will undergo transthoracic echocardiography, transesophageal echocardiography, and cardiac magnetic resonance imaging following transcatheter aortic valve replacement.
223563544|NCT02204046|DRUG|BIWA 4|
223563545|NCT00082368|DRUG|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
223563546|NCT00082368|DRUG|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
223563547|NCT00050206|DRUG|Olanzapine|
223563548|NCT00050206|DRUG|Placebo|
223563549|NCT07081893|OTHER|Conventional care with semi-structured interviews and focus groups|In semi-structured individual interviews, employees of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. This makes it possible to gather in-depth insights. This approach will mainly be used when surveying e.g. board members, managers, representatives of patient organisations. In addition, focus groups (6 to 8 people) will be organised. This is especially valuable when surveying doctors, paramedics and nurses. Focus groups make it possible to survey several respondents at the same time, encourage spontaneous conversations and share experiences. The interaction between participants can also ensure that additional perspectives and insights are covered.
223563550|NCT07081893|OTHER|In-depth interviews with patients and relatives|The objective is to thoroughly understand what PEC means in rehabilitation. Although PEC can be understood as 'being responsive to the unique wishes and needs of the individual person', there still is a lack of consensus about its exact conceptualization in the rehabilitation context (Yun and Choi 2019). Prior work often only considers PEC in terms of shared decision making and goal setting, while the holistic perspective on the patient as a whole person is largely neglected (Yun and Choi 2019). This qualitative phase thus focuses on understanding PEC, its dimensions and the unique wishes and needs of patients in rehabilitation services. In addition, we gather insights regarding the potential enhancement of PEC in rehabilitation. The interviews are based on the Trajectory Touchpoint Technique (TTT; Sudbury-Riley et al. 2020a; 2020b) which allows us to uncover the unique experiences of respondents (i.e., patients, relatives, informal caregivers). The TTT is especially suited fo
223739887|NCT00647790|PROCEDURE|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
223739888|NCT00002433|DRUG|Interferon gamma-1b|
223739889|NCT00753558|DRUG|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin \& polymyxin E, gentamicin \& polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
224036771|NCT05532748|DEVICE|"Respiratory exercise protocol with Branded respiratory incentive, Triflo II®"|"With the participant sitting on a chair, with their back against the backrest, they will hold the device with the hand that is most comfortable for them and place the mouthpiece in their mouth, ensuring a correct seal with their lips.~You will be asked to take a smooth deep breath lifting as many spheres as you can and hold your breath for at least 5 seconds. Expiration will be performed passively through the device without removing it from the mouth and without performing any forced maneuver.~There will be 3 series of 10 breaths with a 1-minute rest between series. The total number of breaths for the entire session will be 30; the maneuver will end once the series and repetitions are finished. You will be asked to remove the mouthpiece from your mouth and breathe gently through your nose for 3 minutes without extra effort.~All these instructions will be explained through a video."
224036772|NCT04028908|DIAGNOSTIC_TEST|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
223739890|NCT04177342|DRUG|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
223739891|NCT04177342|DRUG|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
224036773|NCT02906839|OTHER|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI \>15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
224036774|NCT06226831|OTHER|Structured interview|In-person structured interviews will be performed by the investigators.
224036775|NCT00279110|BEHAVIORAL|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
224036776|NCT01313403|OTHER|Antidepressant (SSRI)|
223423692|NCT03053063|DRUG|SEL|Tablets administered orally once daily
223423693|NCT03053063|DRUG|Placebo to match SEL 6 mg|Tablets administered orally once daily
223423694|NCT03053063|DRUG|Placebo to match SEL 18 mg|Tablets administered orally once daily
223739892|NCT00681655|OTHER|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
223739893|NCT00681655|OTHER|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
223739894|NCT01170455|DEVICE|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
223739895|NCT01170455|DEVICE|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
223423695|NCT03477747|DEVICE|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
223563551|NCT07081893|OTHER|Semi-structured interviews and focus groups|In semi-structured individual interviews, employees of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. This makes it possible to gather in-depth insights. This approach will mainly be used when surveying e.g. board members, managers, representatives of patient organisations. In addition, focus groups (6 to 8 people) will be organised. This is especially valuable when surveying doctors, paramedics and nurses. Focus groups make it possible to survey several respondents at the same time, encourage spontaneous conversations and share experiences. The interaction between participants can also ensure that additional perspectives and insights are covered.
223563552|NCT07081893|OTHER|Conventional care with additional focusgroups|In semi-structured individual interviews, students of healthcare organisations are asked about their experiences, opinions and knowledge on person-centredness. The focus groups will be supported by the Lego® Serious Play (LSP) will be used to collect in-depth insights from students. This design allows flexibility in questioning, while still following a consistent structure to explore common themes across focus groups. The use of Lego encourages participants to think in new ways.
223563553|NCT07079748|DIETARY_SUPPLEMENT|Yeast Postbiotics|Participants in the intervention group will take two capsules of yeast postbiotics daily after meals, with each capsule containing 250 mg of yeast postbiotics, along with maltodextrin and silicon dioxide.
223563554|NCT07079748|DIETARY_SUPPLEMENT|Placebo|Participants in the placebo group will take an equal number of placebo capsules, identical in dosage form, taste, appearance, and packaging. The placebo contains only maltodextrin and a small amount of silicon dioxide. All participants will take two capsules once daily, swallowed with warm water after meals.
223563555|NCT07079280|OTHER|Low Intensity Aerobic Exercise with Blood Flow Restriction (LIAE+BFR)|"In the LIAE+BFR condition, participants will walk on a treadmill for 20 minutes at 30-40% of heart rate reserve (HRR), with a pneumatic cuff inflated to 1.3 times the individual's ankle systolic blood pressure, using a 5cm wide x 75cm long commercial cuff around each upper thigh.~Treadmill speed will be adjusted dynamically to maintain target intensities, while the incline remains at 1%. Heart Rate, the Modified Borg Rate of Perceived Exertion scale, and the Rating of perceived discomfort will be continuously monitored throughout both exercise sessions to ensure adherence to the prescribed intensity levels."
223563556|NCT07079280|OTHER|High Intensity Interval Exercise (HIIE)|"In the HIIE condition, participants will perform a 20 minutes treadmill-based HIAE, alternating between 60-seconds high-intensity intervals at 60-89% HRR and 60-second active recovery intervals at 40-50% HRR.~Treadmill speed will be adjusted dynamically to maintain target intensities, while the incline remains at 1%. Heart Rate, the Modified Borg Rate of Perceived Exertion scale, and the Rating of perceived discomfort will be continuously monitored throughout both exercise sessions to ensure adherence to the prescribed intensity levels."
223563557|NCT01311115|BEHAVIORAL|Group commitment contract|"1. Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~2. The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~3. Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
223563558|NCT01311115|BEHAVIORAL|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
223563559|NCT03044119|BIOLOGICAL|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
223563560|NCT03044119|BIOLOGICAL|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
223563561|NCT07080593|BEHAVIORAL|Novel Physical Activity Program|A structured phase and a self-directed phase, involving both in center and out-of-center exercise. Our novel intervention provides patient's the autonomy to choose the types of physical activity and exercise that they are willing and able to participate in. In brief, it involves working one-on-one with patients to develop an activity prescription that aligns with the participants' goals and motivations to increase physical activity levels.
223563562|NCT07080593|BEHAVIORAL|Standard of Care Physical Activity Program|"Those in the control group will undergo a variety of exercises including intradialytic cycling and resistance (strength training)"
223739896|NCT03487757|OTHER|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
223739897|NCT03487757|OTHER|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
223739898|NCT00197041|BIOLOGICAL|RTS,S/AS02A|
223423696|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
224036777|NCT05015946|BEHAVIORAL|Small-sided team handball training|60 minutes small-sided team handball training. Initial 20 minutes of warm-up including exercises for strength, aerobic, balance, coordination, and mobility. Hereafter 20 minutes of handball specific exercises including dribbling, running and shooting. Final 20 minutes of small-sided handball matches.
223423697|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
223423698|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
224036778|NCT04830956|OTHER|FID123238|Lubricant applied to the ocular surface
223423699|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
223563563|NCT05474638|DEVICE|Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)|Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
223563564|NCT04659499|DRUG|Nab-paclitaxel in combination with pyrotinib|Nab-paclitaxel I.V. 260mg/m2 every 3 weeks for 12 weeks plus pyrotinib oral 240mg daily for one year
223563565|NCT03143907|BEHAVIORAL|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
223563566|NCT03319953|DRUG|TAK-041|TAK-041 suspension
223563567|NCT03319953|DRUG|Placebo|TAK-041 placebo-matching suspension
223739899|NCT02369003|PROCEDURE|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with PD undergoing deep brain stimulation (DBS) surgery.
223739900|NCT02543645|DRUG|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
224036779|NCT04830956|OTHER|Systane Hydration|Drops applied to the ocular surface
224036780|NCT05049746|OTHER|Discussion|Participate in discussion
224036781|NCT05049746|OTHER|Interview|Participate in interview
224138067|NCT04966884|DRUG|JAK Inhibitor|"1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. Tofacitinib 5 mg twice daily for 12 months."
224138068|NCT00003817|DRUG|dolasetron mesylate|
224036782|NCT05049746|OTHER|Questionnaire Administration|Complete questionnaire
224036783|NCT02407184|OTHER|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
224036784|NCT00827762|DRUG|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
224138069|NCT00003817|DRUG|granisetron hydrochloride|
224138070|NCT00003817|DRUG|ondansetron|
224299003|NCT05376709|DIETARY_SUPPLEMENT|Short-Term Calorie Reduction|Align with the R-CHOP regimen, patients in the experimental group will first perform water fast 24 hours before (day 0) and during the first day of R-CHOP (day 1) when they receive Rituximab, Vincristine, Doxorubicin, cyclophosphamide, and prednisolone. On day 2, they will resume normal calorie intake until the day before the next cycle of chemotherapy. While each cycle of R-CHOP takes 21 days, most patients will receive a total of 6-8 cycles over four to six months.
223423700|NCT02208284|DRUG|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
223423701|NCT02208284|DRUG|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
223423702|NCT02341495|DRUG|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
223423703|NCT02341495|DRUG|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
223423704|NCT02341495|DRUG|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
223423705|NCT03633162|OTHER||
223423706|NCT04374162|PROCEDURE|PEEP|different PEEP set on the anesthetic machine
223423707|NCT02151734|DRUG|KALOMIN™ Tab.|
223423708|NCT02151734|DRUG|Umckamin syrup|
223423709|NCT03183713|BEHAVIORAL|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
224138071|NCT00003817|DRUG|tropisetron|
224138072|NCT00003817|PROCEDURE|quality-of-life assessment|
224138073|NCT01858610|DRUG|Irbeasartan/hydrochlorothiazide|
224138074|NCT01858610|DRUG|Irbesartan|
224138075|NCT01858610|DRUG|Hydrochlorothiazide|
223423710|NCT03183713|BEHAVIORAL|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
223423711|NCT00199706|DRUG|7.2% NaCl in 6% hydroxyethyl starch solution|
223423712|NCT01970475|BIOLOGICAL|ABP 501|Solution for subcutaneous injection in pre-filled syringe
223423713|NCT01970475|BIOLOGICAL|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
223423714|NCT01000220|DRUG|Omeprazole|
223423715|NCT01000220|DRUG|Placebo|
223423716|NCT00536627|BIOLOGICAL|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
223423717|NCT00570427|BEHAVIORAL|Problem Solving Therapy (PST)|Counseling
223423718|NCT00570427|BEHAVIORAL|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
223563568|NCT03319953|DRUG|Second Generation Antipsychotics (SGA)|Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
223563569|NCT02696733|DEVICE|Ultrasound|Ultrasound-guided obturator nerve localization
223563570|NCT02696733|DRUG|lidocaine 2%|local anesthetic used to block the obturator nerve
224036785|NCT00809523|DEVICE|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
223423719|NCT02824601|DEVICE|Laser|1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
223423720|NCT02824601|DRUG|Calcium hydroxide|2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
223423721|NCT04182269|OTHER|Measurement of functional exercise capacity|The Glittre Activities of Daily Living (ADL) Test was used to evaluate functional exercise capacity.
223423722|NCT03828552|OTHER|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
223423723|NCT04174183|DEVICE|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
223563571|NCT02696733|DRUG|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
223423724|NCT05496959|DRUG|Lutetium Lu-177 PNT2002|Given IV
223423725|NCT05496959|OTHER|Quality-of-Life Assessment|Ancillary studies
223423726|NCT05496959|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223423727|NCT01188876|DRUG|carboplatin|Given intravenously on Day 1 of each 28-day cycle
223423728|NCT01188876|DRUG|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
223563572|NCT05682287|DEVICE|448kHz capacitive resistive monopolar radiofrequency|Capacitive resistive monopolar radiofrequency (CRM) treatment is a type of medical procedure that uses radiofrequency energy to heat the targeted tissue.
223563573|NCT05682287|OTHER|Proprioceptive Neuromuscular Facilitation|Proprioceptive neuromuscular facilitation (PNF) is a type of physical therapy that uses techniques such as stretching and strengthening exercises to improve muscle function and movement patterns.
223563574|NCT03524963|DRUG|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
223563575|NCT03524963|DRUG|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
223563576|NCT06837961|DIETARY_SUPPLEMENT|LC-Plasma|1 tablet containing 50mg LC-Plasma is taken daily for 4 weeks
223563577|NCT06837961|OTHER|Placebo|1 tablet containing 50mg MCC is taken daily for 4 weeks
223563578|NCT06894719|DRUG|tranexamic acid Oral-Short Arm|1.95g Tranexamic acid daily for post op days 1 to 3
223563579|NCT06894719|DRUG|tranexamic acid Oral-Long Arm|1.95g tranexamic acid daily post op days 1-7
223563580|NCT06894719|DRUG|Control group placebo|Placebo for 3 days post-op
223563581|NCT00633373|DRUG|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
224036786|NCT00809523|DEVICE|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
224036787|NCT04195581|DEVICE|comfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
224036788|NCT04195581|DEVICE|fanfilcon A|Subjects were randomized to wear each lens and solution combination for a month.
224036789|NCT06107881|BEHAVIORAL|Low Vision Rehabilitation|Evaluation and training with magnification or visual assistive devices for visually-impaired adults
224036790|NCT03712189|DEVICE|LifeFlow|The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
224138076|NCT01795287|PROCEDURE|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
224138077|NCT01795287|PROCEDURE|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
224138078|NCT05651893|BEHAVIORAL|re-examination|During colonoscopy, the left colon was examined a second time in the forward view.
223423729|NCT01188876|DRUG|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
224036791|NCT04858854|OTHER|Sulforaphane, administered as Broccoli sprout extract|Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.
224036792|NCT01237340|DRUG|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
224036793|NCT03598322|PROCEDURE|Dextrose 1mL injection|Dextrose 1mL injection and hydrodissection for CTS
224036794|NCT03598322|PROCEDURE|Dextrose 2mL injection|Dextrose 2mL injection
224036795|NCT03598322|PROCEDURE|Dextrose 4mL injection|Dextrose 4mL injection
224036796|NCT01012479|DRUG|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
223423730|NCT01188876|DRUG|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
223423731|NCT02224027|DEVICE|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
223423732|NCT02224027|DEVICE|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
223739901|NCT02042248|BIOLOGICAL|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
223739902|NCT06120920|OTHER|Assigned Interventions|Conventional physical therapy consists of hot pack application and transcutaneous electric stimulation (TENS) and routine knee strengthening exercises in addition with core stability exercises in three sessions per week for 4 weeks. Core stability exercises include bent knee hollow hold, bridging, supine toe tap and knee strengthening exercises include knee flexion strengthening exercises and knee extension isometric exercises.
224036797|NCT01205997|DRUG|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
223423733|NCT02224027|DEVICE|i-gel|In i-gel group, i-gel is inserted by novices.
224036798|NCT01205997|DRUG|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
223423734|NCT00941499|DRUG|HAI Oxaliplatin|140 mg/m\^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
223423735|NCT00941499|DRUG|5-FU|900-1750 mg/m\^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
223423736|NCT00941499|DRUG|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
223423737|NCT00941499|DRUG|Cetuximab|Loading dose of 250-500mg/m\^2 and Maintenance dose of 125-250 mg/m\^2 by vein on Day 1 of 21 day cycle.
223423738|NCT00941499|DRUG|Leucovorin|200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.
223423739|NCT00941499|DRUG|5-FU|300-400 mg/m\^2 bolus + 600-1000 mg/m\^2 infusion over 22 hours on Days 1-2 of each cycle.
223423740|NCT00941499|DRUG|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
223423741|NCT00206687|BIOLOGICAL|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
223423742|NCT00206687|PROCEDURE|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
223423743|NCT01985087|RADIATION|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
224138079|NCT05651893|BEHAVIORAL|extended withdraw time|During colonoscopy, the left colon was examined with double basic withdrawal time in the forward view.
224138080|NCT01965236|DIETARY_SUPPLEMENT|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
224138081|NCT01965236|DIETARY_SUPPLEMENT|Placebo|
223423744|NCT01985087|DRUG|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
223423745|NCT06315881|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral mucosa sample collection
223423746|NCT06315881|DRUG|Cigarette|Smoke usual brand cigarette
223423747|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN R/S ONP
223423748|NCT06315881|DRUG|Nicotine Oral Pouch|Insert low FBN \> 99% S ONP
223423749|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high R/S ONP
223423750|NCT06315881|DRUG|Nicotine Oral Pouch|Insert high FBN \> 99% ONP
223423751|NCT06315881|DRUG|Smokeless Tobacco|Insert ST
223423752|NCT06315881|OTHER|Survey Administration|Ancillary studies
223423753|NCT06315881|OTHER|Text Message-Based Navigation Intervention|Receive text with a link to daily diary surveys
224036799|NCT01205997|DRUG|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl\[25microgram\] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
223423754|NCT06796036|OTHER|Combat Medic Decision-Making with and without artificial intelligence assistance|Participants will complete 10 simulated Tactical Combat Casualty Care (TCCC) scenarios, with 5 scenarios conducted using AI assistance (GPT-4) and 5 without AI. In AI-assisted scenarios, participants will use GPT-4 to query and optimize ventilator settings based on patient data, while non-AI scenarios rely solely on their clinical judgment.
223423755|NCT05946785|DRUG|Acetylcholine|acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
223423756|NCT05946785|DRUG|insulin aspart|insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
223423757|NCT04628390|DEVICE|Laser|The laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
223563582|NCT07080008|DEVICE|Lumitrace|Administered as a bolus intravenous injection over 30 - 60 seconds
223563583|NCT07080008|DEVICE|KARL STORZ POWER LED BLUE System|Imaging will be acquired within 30 minutes post Lumitrace administration. Following the initial endoscopic surgical incision, the surgeon will record the image assessments based on Likert Scales.
223739903|NCT06120920|OTHER|Conventional Physical Therapy and Routine Knee Exercises with Hip Strengthening Exercises.|Conventional physical therapy consists of hot pack application, Tens and routine knee exercise program same as group A and in addition with hip strengthening exercises. Hip strengthening exercises include hip flexion and extension strengthening exercises and hip internal rotation and external rotation and hip adduction and abduction strengthening exercises.C
223739904|NCT01857388|BEHAVIORAL|ParentCorps|
223739905|NCT04891783|DEVICE|ultrasonography|The Carotid US examination will be performed by a radiologist, according to the same protocol in the different participating hospitals. It will include the measurement of cIMT in the common carotid artery and the detection of focal plaques in the extracranial carotid tree following the Mannheimconsensus\[26\]. Plaque is defined as a focal protrusion in the lumen at least cIMT\>1.5 mm, protrusion at least 50% greater than the surrounding cIMT, or arterial lumen encroaching \>0.5 mm \[26\]. The cIMT will be determined as the average of three measurements in each common carotid artery. The final cIMT is the largest average cIMT (left or right). Patients with carotid plaques will be considered as having very high CV .
224036800|NCT06425276|DRUG|Melphalan Hydrochloride for Injection|During the Study Period, patients will receive Melphalan HCl for Injection dosed at 100 mg/m2 on Day -3 and Day -2.
224036801|NCT06254911|BIOLOGICAL|Atezolizumab|Given IV
223423758|NCT04628390|OTHER|Placebo|Simulation laser application will be carried out only once, immediately after the cementation of the orthodontic appliance.
223423759|NCT06815783|DEVICE|Ultrasound guidance|Use of ultrasound in group 2
223423760|NCT06815783|DEVICE|Fluoroscopy guided|Conventional techniques for implanting LBBAP lead
223423761|NCT04940754|PROCEDURE|osteosynthesis|Closed reduction, internal fixation
223423762|NCT04021537|DEVICE|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
223423763|NCT05692531|BEHAVIORAL|A Story Within A Story|"The intervention is the screening via Zoom of A Story Within A Story, two dramatized scenarios. The first depicts a reinforcing feedback loop connecting internalized, anticipated and enacted HIV stigma and serosorting within the Black SGL/MSM community. Set during the COVID-19 pandemic, it depicts a Zoom call among three generations of Black SGL/MSM, a chosen family. In this scene, the oldest member of the family, not knowing that the youngest has just tested positive for HIV, describes how they would never partner with someone who was living with HIV because of what they saw at the beginning of the HIV epidemic. The middle-aged member attempts to mitigate the damage done by this, while the youngest member describes what kind of support he needs. The second scenario depicts a Telehealth visit between a young Black gay man and his sexual health provider; his older lover joins the call at one point and the focus is on sexual communication and PrEP use."
223423764|NCT01840150|PROCEDURE|breath test|Undergo NA-NOSE breath test
223423765|NCT01840150|OTHER|laboratory biomarker analysis|Correlative studies
223423766|NCT03144271|DRUG|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
223423767|NCT03144271|DRUG|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
223423768|NCT01514838|DRUG|ASP1941|oral
223423769|NCT01514838|DRUG|acarbose|oral
223423770|NCT01514838|DRUG|Placebo|oral, used only during placebo run-in period
223563584|NCT03626688|DRUG|Ralinepag|Active
223563585|NCT03626688|DRUG|Placebo|Placebo
223563586|NCT06821061|BIOLOGICAL|Investigational Influenza Vaccine|Investigational Influenza Vaccine
223563587|NCT06821061|BIOLOGICAL|Investigational COVID-19 Vaccine|Investigational COVID-19 Vaccine
223563588|NCT06821061|COMBINATION_PRODUCT|Investigational Influenza and COVID-19 Combination Vaccine|Investigational Combined Influenza and COVID-19 Vaccine
223563589|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 1|Licensed Influenza Vaccine 1
223423771|NCT04875728|DRUG|Cefazolin|Given IV
223563590|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 2|Licensed Influenza Vaccine 2
223563591|NCT06821061|BIOLOGICAL|Licensed Influenza Vaccine 3|Licensed Influenza Vaccine 3
223563592|NCT06821061|BIOLOGICAL|Licensed COVID-19 Vaccine|Pfizer-BioNTech COVID-19 Vaccine
223563593|NCT06066918|DRUG|Pregabalin 75mg|Pregabalin 75 mg twice a day
223563594|NCT06828185|PROCEDURE|Radical inguinal orchiectomy|External oblique fascia will be incised during orchiectomy
223563595|NCT06828185|PROCEDURE|Radical external oblique fascia sparing orchiectomy|External oblique fascia will be spared during orchiectomy
224036802|NCT06254911|PROCEDURE|Transoral Surgery with cervical lymphadenctomy (neck dissection)|Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck
224036803|NCT06254911|PROCEDURE|Computed Tomography|Undergo CT scan
223563596|NCT01877525|PROCEDURE|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
223563597|NCT02631174|DRUG|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
223423772|NCT04875728|PROCEDURE|Resection|Undergo standard of care surgical resection
223423773|NCT04905602|DRUG|SHR-1905/placebo|"Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose"
223563598|NCT01766349|BEHAVIORAL|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
223563599|NCT00569309|BIOLOGICAL|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
223563600|NCT00569309|OTHER|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
223563601|NCT00569309|OTHER|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
223563602|NCT05889442|DRUG|Levcromakalim|Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
223563603|NCT05889442|OTHER|Placebo|Continuous intravenous infusion of 20 mL isotonic saline over 20 minutes
223563604|NCT04736368|OTHER|EDIP Diet Suggestions|CD participants will receive EDIP diet suggestions after random allocation.
224036804|NCT06254911|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223423774|NCT03114527|DRUG|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
223423775|NCT03114527|DRUG|Everolimus|mTOR inhibitor
223423776|NCT02718170|PROCEDURE|Buried Intramedullary K-wire Fixation|
223423777|NCT02718170|PROCEDURE|Plate and Screw Fixation|
223423778|NCT05521529|OTHER|no intervention, as this is an observational study|no intervention
223423779|NCT04829617|BEHAVIORAL|PP-MI Intervention|The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and promoting adherence to physical activity, diet, and medications (through MI). Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to monitor health behavior adherence, resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in health behaviors.
223563605|NCT04736368|OTHER|diet guidance|Control group will be given diet guidance according to routine experience under the participant's request.
223563606|NCT02243618|DRUG|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
223563607|NCT02243618|DRUG|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
223563608|NCT05834088|OTHER|Myofascial release techniques|12 treatment sessions will be given in 12 weeks
223563609|NCT05834088|OTHER|Thiele massage|12 treatment sessions will be given in 12 weeks
223563610|NCT00790868|DRUG|d-cycloserine|50mg
223563611|NCT00790868|DRUG|placebo|50mg
223563612|NCT01380535|DRUG|ECP Methoxsalen|Methoxsalen delivered by ECP
223563613|NCT01380535|DRUG|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
223563614|NCT05381441|BEHAVIORAL|Safety Action Feedback and Engagement (SAFE) Loop|Nursing units randomized to the intervention arm will undergo the SAFE Loop intervention, which involves five Key Attributes: (1) obtaining input from nurses on which problems to address; (2) focusing on selected high-priority events, (3) prompting nurses to report the high-priority events for a designated period and write more informative reports; (4) following standardized investigative procedures to integrate information from sources internal and external to CSMC, and (5) providing feedback to nurses about safety problems and mitigation plans. During all phases, the SAFE Loop Team collaborates with frontline nurses and Unit Managers.
223739906|NCT06431854|BEHAVIORAL|ED-MINERVA Program|ED-MINERVA Program aims to improve ED symptoms and related difficulties of the patient and provide tools to enhance the family's management (nutritionally, emotionally, and behaviorally) in their natural environment. The treatment consists of four phases with a gradually decreasing therapeutic intensity, ranging from total hospitalization, family treatment apartment, to home treatment and subsequent linkage with specialized local facilities. The ED-MINERVA program uses various aspects of family-based treatment, cognitive behavioral therapy, dialectical behavioral therapy, and systemic family therapy.
223739907|NCT05713045|DIETARY_SUPPLEMENT|Konakion|Comparing 4 different regimen of Vitamin K administration in newborn
224138082|NCT03600714|DRUG|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.
223563615|NCT05452954|BEHAVIORAL|Brief behavioral parent training|In the newly developed intervention, both stimulus control and contingency management techniques will be offered in a brief behavioral parent training consisting of two intervention sessions and one booster session.
223563616|NCT01845584|DRUG|NPB-01|
223563617|NCT00672087|GENETIC|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
223563618|NCT04178993|DRUG|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
223563619|NCT04178993|DRUG|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
223563620|NCT04178993|DRUG|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
223563621|NCT04178993|DRUG|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
224138083|NCT03600714|DRUG|Lonafarnib|Oral prenylation inhibitor
223423780|NCT04829617|BEHAVIORAL|MI-alone Intervention|The time- and attention-matched MI-alone intervention focuses on providing education about heart failure (HF) and promoting adherence to physical activity, diet, and medications. Each week, participants will independently complete an activity related to HF education or adherence to a health behavior, then complete a phone session with a study trainer. HF educational topics will include the causes and types of HF, risk factors for cardiovascular disease, methods for monitoring risk factors and symptoms, and the importance of adherence to physical activity, diet, and medications. For each health behavior, study trainers will assist participants to monitor adherence, identify realistic behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) that provide education and encourage engagement in health behaviors.
223423781|NCT06847438|BEHAVIORAL|Optimized version of the EPIC-HF Checklist|The EPIC-HF checklist is a 1-page patient activation tool that contains approved and guideline-recommended medications and target doses for HFrEF. The EPIC-HF checklist allows patients to see recommended doses and categories of GDMT, which they can compare to their current medications and dosing. The EPIC-HF checklist has been refined and updated to include GDMT prescription and has been optimized for delivery through electronic medical record (EMR) systems. The checklist is being used as a patient activation/ discussion tool only and data entered on the checklist will not be collected for purposes of this study.
223423782|NCT06847438|BEHAVIORAL|Clinician-facing Decision Support|Information regarding GDMT (including target doses and medications) analogous to what is contained in the checklist will be provided to clinicians in intervention clinics. This information will be visible at the time of the encounter.
223423783|NCT06847438|BEHAVIORAL|Standard of Care|Patients of clinics that are not implementing EPIC-HF checklist will not have the checklist available to them through the electronic medical record (EMR).
223423784|NCT02686866|DEVICE|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
223423785|NCT02686866|DEVICE|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
223423786|NCT02686866|DEVICE|hand grip strength|
224138084|NCT03600714|DRUG|Ritonavir|Booster of lonafarnib action
223423787|NCT04773184|PROCEDURE|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
223423788|NCT04773184|PROCEDURE|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing. This is like a moving x-ray of the swallow.
223423789|NCT04773184|PROCEDURE|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
223423790|NCT04773184|PROCEDURE|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
223423791|NCT04773184|PROCEDURE|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
223423792|NCT04773184|PROCEDURE|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
223423793|NCT04773184|OTHER|Voicing Tasks|Voicing tasks will be completed to assess vocal ability.
223423794|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac) off-label use gadolinium contrast (IND exempt)|Clinical MRI
223423795|NCT03340233|DIAGNOSTIC_TEST|MRI (cardiac)|MRI without contrast
223423796|NCT05129293|BEHAVIORAL|Prospective Memory Intervention|Cognitive remediation focusing on prospective memory
223423797|NCT05129293|BEHAVIORAL|Educational|Psychoeducation
223563622|NCT04268329|OTHER|Educational website|A website is used to educate patients and family members about head and neck cancer.
223563623|NCT03424967|BEHAVIORAL|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
223563624|NCT00024024|DRUG|rebimastat|
223563625|NCT04140695|DRUG|Tradipitant|BID
223563626|NCT04140695|DRUG|Placebo|BID
223563627|NCT06403306|DRUG|Ferric Sulfate (Viskostat; Ultradent, Utah, USA)|Widely used in pulpotomy treatment of primary teeth, provides hemostasis through a chemical reaction with blood. The metal-protein complex, formed due to contact with blood, creates a mechanical plug; thus, hemostasis occurs without clot formation.
223739908|NCT02955485|OTHER|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
223739909|NCT04566354|OTHER|Repeated 30-s sprint exercise|Analyze of Interleukin-6 concentration before and after repeated 30-s sprint exercise
224138085|NCT00675103|DRUG|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
224138086|NCT02366754|DEVICE|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
224138087|NCT02366754|DEVICE|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
224138088|NCT03230474|DRUG|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
223423798|NCT03805451|BEHAVIORAL|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
223423799|NCT03692975|OTHER|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
223423800|NCT03692975|OTHER|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
223423801|NCT03692975|OTHER|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
223563628|NCT06403306|DRUG|Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)|Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
224036805|NCT05117697|OTHER|lateral subcutaneous sphincterotomy|"Patients of the main group are treated with a crack by performing a lateral subcutaneous sphincterotomy.~In the control group, the fissure is excised in combination with a lateral subcutaneous sphincterotomy."
224036806|NCT00183768|BEHAVIORAL|Cognitive Behavioral Therapy|
223423802|NCT03692975|DEVICE|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
223423803|NCT04908904|DIETARY_SUPPLEMENT|Cafestol|Capsule with 12 mg cafestol
223423804|NCT04908904|DIETARY_SUPPLEMENT|Placebo|Placebo capsule without cafestol
223423805|NCT01397786|DRUG|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
223423806|NCT00621595|DIETARY_SUPPLEMENT|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
223423807|NCT06797297|BIOLOGICAL|IBI363|a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade.
223423808|NCT06797297|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a humanized monoclonal anti-PD1 antibody
223423809|NCT05782270|DRUG|Warfarin|dual antiplatelet therapy combined with warfarin
223423810|NCT05782270|DRUG|DAPT|Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)
223423811|NCT05782270|OTHER|CE+CABG|Coronary endarterectomy combined with coronary artery bypass grafting
223423812|NCT06037161|PROCEDURE|Mandibular Incisor root coverage procedure|Mucogingival procedure to cover mandibular incisor tooth with receded gums
223423813|NCT06666660|DIETARY_SUPPLEMENT|Multivitamin/Mineral supplements|Each participant will be given 180 MVM tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally daily, in the morning before food. Participants will be asked to return the remainder of dispensed MVM tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm.
223423814|NCT06666660|OTHER|Placebo|Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.
223423815|NCT05523479|BEHAVIORAL|Traditional online education|A 30-60 minute, online, interactive, educational video that is customized to each provider type and offered with provider-specific continuing education credits
223423816|NCT05523479|BEHAVIORAL|Interprofessional education|Interprofessional education (IPE) consists of both classroom-based IPE and just-in-time IPE. In classroom-based IPE, a trained physician educator with content expertise who works in the ICU leads a 60-to-90-minute, in-person, IPE workshop consisting of a 30-minute didactic session and a 30-to-60-minute small group session, during which participants work together to apply the content to authentic cases. The workshops, which are designed according to modern principles of adult learning and IPE, present the rationale and evidence supporting the preventive, post-extubation therapies. They are specifically designed to foster authenticity, reinforce role identity, and relate the content to life experience. In just-in-time IPE, trained local champions meet with the interprofessional ICU team each morning to identify eligible patients and, as needed, briefly review the evidence supporting proper use of the assigned preventive, post-extubation strategy.
224036807|NCT00183768|BEHAVIORAL|Psychopharmacology|
223423817|NCT05523479|BEHAVIORAL|Clinical protocol|"An adequately explicit protocol provides specific rules for use of the preventive, post-extubation therapy based on patient data. A ready-to-customize version of the protocol with instructions to work with key local stakeholders to revise the protocol, accounting for local needs and resources, is provided. After local customization, a local champion then disseminates the protocol based on local practices."
223423818|NCT05523479|OTHER|Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation NIV for high-risk patients and preventive post-extubation HFNC for low-risk patients
223739910|NCT03251079|DEVICE|Continuous glucose monitoring system|Implanted continuous glucose monitoring system
223739911|NCT04554329|PROCEDURE|bandage contact lens|bandage contact lens
223739912|NCT00951808|BIOLOGICAL|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
223739913|NCT00951808|BEHAVIORAL|Standard care|Participants will receive standard care for ACS while in the hospital.
224036808|NCT02802930|DRUG|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
224036809|NCT02802930|DRUG|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
224036810|NCT02802930|DRUG|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
223423819|NCT05523479|OTHER|Preventive post-extubation high-flow nasal cannula oxygen (HFNC)|Preventive post-extubation HFNC for all eligible patients (without risk stratification)
223423820|NCT06483048|BIOLOGICAL|Autologous MUC1-activated T-cells|Given IV
224036811|NCT02802930|DRUG|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
224036812|NCT03088722|OTHER|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
224036813|NCT03590015|OTHER|Old invitation letter|Invitation Letter written by researchers/doctors
224036814|NCT03590015|OTHER|New invitation Letter|Invitation Letter written in simple sentences and a sequential structure of basic information in the rewritten information Letter
224036815|NCT02959567|DEVICE|Aqueduct 100 dilation|
224036816|NCT01843218|OTHER|Evaluation of erectile dysfunction|Assessment (at night) of erctile dysfunction using R/P recording (RIGISCAN® PLUS / polysomonography)
224036817|NCT01136811|DEVICE|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
224036818|NCT05062902|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
224036819|NCT05062902|DRUG|Botulinum Neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
224036820|NCT03628365|DIETARY_SUPPLEMENT|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
224036821|NCT03769012|DIETARY_SUPPLEMENT|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
223423821|NCT06483048|DRUG|Bendamustine|Given IV
223423822|NCT06483048|PROCEDURE|Biospecimen Collection|Undergo blood and possible ascites sample collection
223423823|NCT06483048|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223423824|NCT06483048|DRUG|Cyclophosphamide|Given IV
223423825|NCT06483048|PROCEDURE|Echocardiography|Undergo ECHO
223423826|NCT06483048|PROCEDURE|Leukapheresis|Undergo leukapheresis
223423827|NCT06483048|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224036822|NCT03769012|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
224036823|NCT00151736|DRUG|Chlorambucil|Chlorambucil 2mg tablets
223423828|NCT06483048|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223423829|NCT06483048|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223423830|NCT00264069|DRUG|antipsychotic|as prescribed
223423831|NCT00264069|DRUG|antidepressants|as prescribed
223423832|NCT03509428|BEHAVIORAL|SRETP|SRETP will involve short periods of exercise at a high intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session. Exercise intensities during the interval exercise-training program are specific to each patient and derived from CPET. Moderate intensity exercise is below the anaerobic threshold (AT). Patients will exercise at 80% of oxygen uptake (VO2) obtained at the anaerobic threshold (80%AT) for moderate intensity exercise - 3 minutes. Severe exercise intensity is recognised as 50% of the difference between the VO2 AT and VO2 Peak (50%∆) - 2 minutes.
223423833|NCT03509428|BEHAVIORAL|Psychological support|Support sessions will be patient-centred, giving the patient an opportunity to raise any issues/concerns they are having, this may include (but will not be limited to) ways of coping with their reactions to cancer, family and relationship issues, exploring personal issues and dealing with practical issues. Patients will have access to other resources available at the cancer centres including but not restricted to further information about their condition and how to access financial support. These processes reflect the best practice currently being delivered by cancer support centre staff in the Wessex region. Any patient deemed at risk (i.e. from suicidal ideation or self harm) will be reported to their GP, followed up by a letter.
223423834|NCT03945370|DIETARY_SUPPLEMENT|β-hydroxybuturate esters|Oral dietary supplement product containing β-hydroxybuturate esters
223423835|NCT03945370|DIETARY_SUPPLEMENT|Placebo drink|Oral placebo drink
223423836|NCT03527810|PROCEDURE|Sleeve Gastrectomy Without Interrogation of Hiatus|Weight-loss procedure to reduce the stomach.
224036824|NCT00151736|DRUG|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
224036825|NCT00177983|BEHAVIORAL|(relapse rate)|
224036826|NCT02949089|DRUG|ACH04|The subjects will receive the study medication in each group
224036827|NCT00822588|DEVICE|Sangvia® System|Sangvia® Intra- and Post-op System
223423837|NCT03527810|PROCEDURE|Sleeve Gastrectomy With Interrogation of Hiatus|Weight-loss procedure to reduce the stomach with hiatal repair.
223423838|NCT01953874|DEVICE|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
223423839|NCT01953874|DRUG|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
223423840|NCT00811785|DRUG|Copper Histidine|Daily subcutaneous injections for three years
224036828|NCT05532397|DRUG|QPOP category 1|combination regimens with published data in the setting of gliomas
224036829|NCT05532397|DRUG|QPOP category 2|combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
224036830|NCT02500381|DRUG|SRP-4045|SRP-4045 solution for IV infusion
224036831|NCT02500381|DRUG|SRP-4053|SRP-4053 solution for IV infusion
224036832|NCT02500381|DRUG|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
224036833|NCT06392477|DRUG|DR-0201|DR-0201 is a bispecific antibody
224036834|NCT03829319|BIOLOGICAL|Pembrolizumab|IV infusion Q3W
224036835|NCT03829319|DRUG|Carboplatin|IV infusion Q3W
224036836|NCT03829319|DRUG|Cisplatin|IV infusion Q3W
224036837|NCT03829319|DRUG|Pemetrexed|IV infusion Q3W
224036838|NCT03829319|DRUG|Lenvatinib|Oral capsule once daily
224036839|NCT03829319|DRUG|Placebo matching lenvatinib|Oral capsule once daily
224036840|NCT05440825|DEVICE|VRelax|Virtual Relaxation relaxation, VRelax, includes a collection of high quality 360° degrees videos of nature environments with 3D audio and interactive elements, created for relaxation, stress-reduction and improving sleep. When activated, the participant can choose specific 360° videos from a menu. The 360° videos include among other things a coral reef with an interactive game element of popping air bubbles, a scuba diving experience with dolphins, a mountain meadow with cows, and a session of Tibetan sound bowls.
223423841|NCT04649736|OTHER|Respiratory and psychological rehabilitation|"Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies."
223423842|NCT03339726|DRUG|New Formulation Phenylephrine HCl|2 doses of one tablet 12 hours apart
223423843|NCT03339726|DRUG|Marketed Phenylephrine HCl|4 doses of one capsule 4 hours apart
223423844|NCT03339726|DRUG|Placebo|4 doses of placebo capsule and tablet taken 4 hours apart
223423845|NCT01275755|DRUG|Placebo|
223423846|NCT01275755|DRUG|ADL5945 0.25 mg|
223423847|NCT05288595|DEVICE|CliniMACS Plus Instrument|Miltenyi Biotec's CliniMACS Plus Instrument is to be used to TCRαβ CD19 deplete products utilized in this protocol. The CliniMACS Plus is an automated cell separation platform which is functionally closed, maintaining a sterile system for cell depletion and enrichment utilizing a magnetic separation column. Reagents and supplies are to be used for research only but are manufactured and tested under a quality system certified to ISO 13485. Should CD34 selection be required to augment stem cell dose, Miltenyi Biotec's CliniMACS® Plus CD34 Reagent System is FDA approved as a Humanitarian Use Device (HUD). The approved indication was the treatment of patients with acute myeloid leukemia (AML) undergoing myeloablative transplant from matched related allogeneic donors. The CliniMACS® Plus reagent system was approved to obtain an enriched CD34+ cell population for hematopoietic reconstitution without the need for GVHD prophylaxis.
223423848|NCT02010281|DEVICE|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
223423849|NCT00006398|DRUG|Timolol Maleate|
223739914|NCT03729856|BEHAVIORAL|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
223739915|NCT03729856|OTHER|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
223739916|NCT03729856|OTHER|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
224036841|NCT05440825|OTHER|Relaxation exercises|Relaxation exercises consisting of audio-guided breathing exercises, muscle relaxation exercises, and body scan exercises
224036842|NCT05121974|DRUG|Tebipenem Pivoxil|Tebipenem (brand name: Orapenem) is a broad-spectrum orally administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics.
224138089|NCT03230474|DRUG|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\\ kg naloxone in 0.5 ml volume (total volume 2mL).
224138090|NCT02518308|BEHAVIORAL|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
224138091|NCT02999568|OTHER|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
223423850|NCT00006398|DRUG|Placebo|
223423851|NCT01885702|BIOLOGICAL|DC vaccination|DC vaccination
223423852|NCT05592015|DRUG|Ruxolitinib|Given PO
223423853|NCT05892939|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
223423854|NCT05892939|DRUG|intranasal Placebo|Administration of intranasal Placebo
223423855|NCT04624490|DRUG|Hyperpolarized Xe129|During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
223423856|NCT00979589|DRUG|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
223423857|NCT00979589|DRUG|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
223423858|NCT04792840|DRUG|Femara Pill|study effect on bone
224036843|NCT05121974|DRUG|Azithromycin|Oral Azithromycin antibiotic (Macrolides)
224036844|NCT05121974|DRUG|Ceftriaxon|IV Ceftriaxone (Cephalosporin)
223423859|NCT03754634|DRUG|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
223423860|NCT03871738|OTHER|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
223423861|NCT04136977|DEVICE|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
223423862|NCT03048695|BEHAVIORAL|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
223423863|NCT00196339|DRUG|Cyproterone acetate 5|Cyproterone acetate 5 mg
223423864|NCT00196339|DRUG|Placebo|Matching placebo
224036845|NCT04498832|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
224138092|NCT04453904|OTHER|"sequential radiochemotherapy in a sanwich mode"|Patients will randomized into two different modalities of radiochemotherapy.
224138093|NCT03894774|BEHAVIORAL|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
224138094|NCT03894774|OTHER|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
224299004|NCT00687089|OTHER|Sexual, cognitive functional tests and measurement weight|
223423865|NCT00196339|DRUG|Cyproterone acetate 15|Cyproterone acetate 15 mg
223423866|NCT00196339|DRUG|Cyproterone acetate 25|Cyproterone acetate 25 mg
223423867|NCT01318590|DRUG|EUS procedure with drug injection|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
223423868|NCT01318590|OTHER|EUS procedure|EUS procedure without any drug injection
223423869|NCT02210247|DRUG|EXPAREL|
223423870|NCT01621451|DRUG|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
223423871|NCT01621451|DRUG|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
223423872|NCT06252051|DRUG|Trivalent Influenza Vaccine|We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
224036846|NCT04498832|BIOLOGICAL|Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
223423873|NCT05791630|OTHER|the labour care guide (LCG)|The labour care guide is a tool to be used for assessing labour progression and monitoring care in labour
223423874|NCT02161237|DRUG|Advagraf®|oral
223423875|NCT05113888|DRUG|Qizhi weitong granules(High）|take orally before meals, 1 bag each time, 3 times a day.
223423876|NCT05113888|DRUG|Qizhi weitong granules(Low）|take orally before meals, 1 bag each time, 3 times a day.
223423877|NCT05113888|DRUG|Placebo|take orally before meals, 1 bag each time, 3 times a day.
223423878|NCT05848492|DRUG|Fluconazole|Fluconazole will be given for prevention of invasive candidiasis in preterm and very low birthweight babies.
224138095|NCT00003466|DRUG|temozolomide|
223423879|NCT05848492|DRUG|Saline|0.9% Saline 2cc intravenous will be given to preterm babies in placebo group.
223739917|NCT02120729|OTHER|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
223739918|NCT00768807|DEVICE|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
224138096|NCT06131125|OTHER|Plyometric training exercises|This includes plyometric training exercises thrice a week for 6 weeks
224138097|NCT06131125|OTHER|Explosive strength training exercises|this includes explosive strength training exercises thrice a week for 6 weeks
224299005|NCT02454660|BEHAVIORAL|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
224299006|NCT05340543|PROCEDURE|Confocal optical coherence tomography - OCTAVE|"An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function"
224299007|NCT00256984|PROCEDURE|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
224036847|NCT04369066|DIAGNOSTIC_TEST|Blood samples (collection of 5 mL of blood in a dry tube)|"A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.~The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The serum samples will be extracted and collected prospectively from the blood samples.~For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie."
224138098|NCT06170801|BEHAVIORAL|Kiesler Circle Training (KCT)|Kiesler Circle Training is a transdiagnostic modular group treatment, which comprises a baseline module and four additional independent modules (nonverbal communication, verbal communication, conflict training and empathy and corrective interpersonal experiences). KCT is based on a heuristic model to explain and anticipate interactions developed by Donald Kiesler and other representatives of the interpersonal theory. The circumplex model arranges the variety of interpersonal behaviors in terms of a circular continuum allocated on two orthogonal axes: The vertical axis addresses interpersonal control (agency), the horizontal axis addresses interpersonal communion. The model further allows illustrating complementary action tendencies to anticipate other's reactions and to guide own behavior to achieve interpersonal goals. KCT is designed for increasing the awareness of such interpersonal action tendencies and for improving interpersonal behavioral flexibility.
224138099|NCT06170801|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy is based on the interrelationships of thoughts, actions and feelings. Presumably, individual CBT will address intrapersonal therapeutic foci such as behavioral activation, identification of dysfunctional thoughts, overcoming fears by exposure, etc. Individual CBT may also include interpersonal functioning as therapeutic foci. Disorder-specific treatment manuals are available for all diagnoses included in the study. Of note, state-of-the-art CBT does not necessarily mean, that individual CBT-sessions strictly adhere to a manual. However, because both study sites are CBT training institutes, which guarantee supervision at least every four hours, it can be estimated that state-of-the-art CBT is realized.
224138100|NCT06441851|PROCEDURE|Videolaparoscopic Partial Nephrectomy|Videolaparoscopic partial nephrectomy
224138101|NCT06441851|PROCEDURE|Robot-assisted Partial Nephrectomy|Robot-assisted partial nephrectomy
224138102|NCT03596658|DRUG|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
224138103|NCT00004929|BIOLOGICAL|MUC-2-KLH vaccine|
224138104|NCT00004929|BIOLOGICAL|QS21|
223423880|NCT03681990|DRUG|3M CHG/IPA Prep|Apply topically to intact skin
223423881|NCT01865669|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
223423882|NCT03452046|OTHER|IVC diametres|
223423883|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 1|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
223423884|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 1|Preparation of PRP Concentrate via sterile Terumo-Harvest System
223423885|NCT04238143|PROCEDURE|Tissue Stromal Vascular Fraction (tSVF) Arm 2|Harvesting subcutaneous tSVF with sterile, disposable microcannula system
223423886|NCT04238143|BIOLOGICAL|PRP Concentrate Arm 2|Preparation of PRP Concentrate via sterile Terumo-Harvest System
223423887|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 2|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
223423888|NCT04238143|PROCEDURE|Cellular Stromal Vascular Fraction (cSVF) Arm 3|Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)
223423889|NCT04238143|DRUG|Sterile Normal Saline (IV Solution)|Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
223423890|NCT05431023|DRUG|Lactoferrin|Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection
223423891|NCT05431023|DRUG|Pneumonia treatment|Antibiotics for pneumonia
224299008|NCT02124941|DRUG|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
223423892|NCT05044936|DRUG|Cannabidiol Oil|"The dose that will be used for each administration of CBD will be 0.5mg/kg of body mass. As there are no recommendations for CBD from the FDA or through previous research in humans, and especially for CBD cream, the dosage is based on the United Kingdom's governing body recommending maximal amounts of CBD ingestion being 1 mg/kg per day. Further, the practical amount that companies recommend is anywhere from a pea size to a handful, which can range from high and low amounts. Using 0.5mg/kg of body mass allows for a moderate use of the lotion, as well as leaving extra quantities throughout the day should people want to use CBD outside of their post-workout recovery strategies outside of a laboratory setting. To convert the amount of CBD to the amount of lotion, we will divide the amount of CBD (0.5 mg/kg) by 4.85 (the amount of mg of CBD per gram of lotion). This will calculate the amount (in grams) of lotion each participant will receive."
223423893|NCT05044936|OTHER|Resistance Exercise|Participants will complete eccentric-based leg press (4-s lowering phase and 1-s upward phase) for 10 sets of 8 repetitions at 70% 1RM in order to induce muscle damage using a leg press machine. Three minutes of rest will be permitted between sets. Following the 10th leg press, participants will complete 4 sets of 20 consecutive plyometric lunges using only their body weight. Two minutes of rest will be permitted between sets. The muscle damaging protocol will be done upon completion of the 4th set of plyometric lunges.
223423894|NCT03133273|OTHER|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
224299009|NCT02124941|DIAGNOSTIC_TEST|[18F]FDG PET scan|All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
224299010|NCT02124941|DIAGNOSTIC_TEST|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
223423895|NCT02416531|DRUG|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
223423896|NCT02416531|RADIATION|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
223423897|NCT02416531|RADIATION|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
223423898|NCT05264792|OTHER|Enhanced Implementation Support|"This support package will include:~1. one-on-one remote (phone/web-based) technical assistance sessions (every two weeks) between the facility team and the study team Implementation Support Coaches. These sessions will involve a discussion on successes and challenges in integrating depression screening with routine care and developing strategies to improve screening, using the PDSA (Plan Do Study Act) cycle model.~2. remote peer learning community (peers include ANMs and Nurses who administer screening) through a cross-facility WhatsApp group moderated by the study team Coaching Support Team.~3. virtual peer learning network conferences (quarterly) moderated by the Coaching Support Team focused on lessons learned in improving depression screening.~The 9-month intervention duration is informed by the Institute of Healthcare Improvement's Breakthrough Series guidelines."
223423899|NCT05264792|OTHER|Routine Implementation Support|This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
223423900|NCT01073228|DRUG|EVP-6124|
223423901|NCT01073228|DRUG|Placebo|
223423902|NCT03350061|DEVICE|SENSY|The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
223423903|NCT03541954|OTHER|Sensory testing of lower urinary tract.|Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
223423904|NCT03541954|OTHER|Sensory testing of lower rectal tract|Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
223423905|NCT03541954|OTHER|Sensory testing of vulva muscles|Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
223423906|NCT03541954|OTHER|Sensory testing of pelvic muscles|Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
223423907|NCT00636194|DEVICE|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
223423908|NCT00636194|DEVICE|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
223423909|NCT01088880|DRUG|Canakinumab|
223423910|NCT02449135|PROCEDURE|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
223423911|NCT05144789|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
223423912|NCT05144789|DEVICE|Active TBS-DMPFC|"Participants in the active stimulation group will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
223563629|NCT06403306|DEVICE|Er,Cr:YSGG laser (Waterlase MD, Biolase, USA)|Alternative technique introduced to clinical practice in recent years to provide hemostasis in vital pulp treatment is the usage of lasers in various wavelengths. Using lasers in pulpotomy provides many advantages such as tissue vaporization and coagulation, maintenance of a blood-free working field due to its property to close small blood vessels, minimal clot formation, and sterilization of the wound surface. Furthermore, laser systems were reported to induce cellular biostimulation. Er,Cr:YSGG lasers which belong to the Erbium laser family are the laser systems with the highest absorption rate by water, having a wavelength of 2780 nm. Besides, Erbium lasers manifest bactericidal effects.
223563630|NCT01007929|DRUG|14C-AZD1236|Oral solution 1mg/mL
223563631|NCT05422365|DRUG|Intravenous immunoglobulin (IVIG), 10% solution for infusion|The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.
223739919|NCT02314650|OTHER|acupoint stimulation|stimulation was given at acupoints
223739920|NCT02314650|OTHER|non-acupoint stimulation|stimulation was given at non-acupoints
223739921|NCT02314650|OTHER|electrodes attached|electrode were attached to skin
223739922|NCT02654483|DRUG|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
223739923|NCT02654483|OTHER|Placebo|Matching tablets to VPD-737 tablets without active drug
223739924|NCT05212012|DRUG|Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)|Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)
223739925|NCT01643811|PROCEDURE|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
223739926|NCT01643811|PROCEDURE|Endoscopic submucosal dissection|endoscopic submucosal dissection
223739927|NCT03968302|DRUG|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
223739928|NCT03968302|DRUG|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
224036848|NCT04369066|DIAGNOSTIC_TEST|Nasopharyngeal swabs|"The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.~The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).~For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.~The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total."
224036849|NCT05833087|BEHAVIORAL|Schema therapy|30 sessions of schema therapy. The therapy was developed by Jeffrey Young and others and encompasses elements from cognitive behavioral, psychodynamic, and gestalt therapies, as well as attachment theory.
224036850|NCT05833087|BEHAVIORAL|Other psychotherapy|In this arm, psychotherapy can be psychodynamic, cognitive behavioral, interpersonal or other evidence-based psychotherapies, aimed at changing cognitions, behavior, improve social relations and uncover unconstructive psychological patterns.
224036851|NCT05833087|OTHER|Standard care package content|"Standard care packages: The patient is offered prescription and monitoring of psychopharmacological treatment of up to 5 hours by a psychiatrist, when appropriate.~Additionally, patients have up to 3 hours of preparatory and diagnostic sessions and up to 4 hours of meetings with the participation of next-of-kin and/or collaboration partners in other public instances.~Expanded package: In one center, specialized treatment is offered for difficult-to-treat depression. Up to 9 months of psychotherapy is offered, as well as close follow-up on adjustment in medicine."
224036852|NCT05865457|DEVICE|BUFY02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
224036853|NCT05865457|DEVICE|TRB02 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
224036854|NCT05961592|DRUG|R-2487 DP|Probiotic
224036855|NCT05381038|DEVICE|QPOP|QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.
224036856|NCT05381038|DEVICE|CURATE.AI|"CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months."
224036857|NCT05381038|DRUG|Azacitidine + docetaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
224036858|NCT05381038|DRUG|Azacitidine + paclitaxel|"Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days."
224036859|NCT05381038|DRUG|Azacitidine + irinotecan|"Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days."
224036860|NCT05824273|BEHAVIORAL|LungTalk|LungTalk is a 10-15 minute long computer-tailored health communication and decision-making tool.
224036861|NCT05824273|BEHAVIORAL|Non-tailored intervention - Standard of practice|ACS Lung Screening Informational Video
224036862|NCT04483245|BIOLOGICAL|Blood sampling|Blood sampling
224036863|NCT06263283|OTHER|session of Kine-Yoga|"Daily performance of a Kine-Yoga-PEP intervention supervised by a physiotherapist of the department trained in the Kine-Yoga-PEP intervention at J2, J3 and J4 of uterovaginal brachytherapy.~Possibility for the patient to practice this session in autonomy (using PEP tools given to the Shared Educational Check-up) according to her wish during the duration of the treatment and up to 15 days post treatment"
224138105|NCT02300896|OTHER|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
224138106|NCT03449316|BEHAVIORAL|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
224138107|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
224138108|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
224138109|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
224138110|NCT01573013|DIETARY_SUPPLEMENT|iron fortified biscuits|control biscuit on a daily basis for 8 months
224138111|NCT02006264|DRUG|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
223563632|NCT04753658|DRUG|lorlatinib|Oral
223563633|NCT05515588|DRUG|BI 690517 (C-14)|BI 690517 (C-14)
223563634|NCT05515588|DRUG|BI 690517|BI 690517
223563635|NCT00306293|DRUG|valacyclovir|valacyclovir
223423913|NCT05144789|DEVICE|Sham TBS-DLPFC or DMPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223423914|NCT05482464|DIETARY_SUPPLEMENT|Casein glycomacropeptide (CGMP)|Casein glycomacropeptide (CGMP) supplementation for 3 weeks
224138112|NCT02006264|DRUG|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
223423915|NCT06107270|DEVICE|pressure biofeedback|uninﬂated pressure sensor will be kept below the neck suboccipital
223423916|NCT06107270|DEVICE|therapeutic ultra sound|continuous US waves of 1 MHz frequency and 1-1.5 W/cm2 power
223423917|NCT06107270|DEVICE|infra red radiation|(R 125, 250watt, Philips)
223423918|NCT06107270|OTHER|post isometric relaxation|sustained contraction followed by relaxation
223423919|NCT04412200|DEVICE|Hyperbaric oxygen chamber (HBOC)|HBOC group will receive 100% oxygen at 2 ATA for 90 min with 5 min air breaks every 20 min at each session. Intensive management period includes 60 daily sessions, 5 days per week within 12 weeks,
223423920|NCT01537874|BEHAVIORAL|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
223423921|NCT01537874|BEHAVIORAL|Usual best practices|Standard care delivered using informational materials
223423922|NCT05462223|COMBINATION_PRODUCT|Alucent Vessel Restoration System for AVF|"Alucent Vessel Restoration System for AVF (VRS-AVF) consists of the following components:~1. VRS 10-8-10 Dimer Coated Balloon Catheter for AVF~2. VRS Light Fiber~3. VRS Light Source"
223423923|NCT00828724|DRUG|Lorcaserin 10mg|
223423924|NCT03126162|PROCEDURE|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
223423925|NCT03126162|PROCEDURE|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
223423926|NCT06033430|OTHER|True dry needling|Prior to the procedure, participants will be given a detailed explanation of the dry needling technique. Afterward, the specific area will be thoroughly cleaned using an alcohol pad. In the true dry needling group, along with routine physiotherapy, a sterile filiform acupuncture needle, measuring 2 cm in length and designed for single-use, will be inserted at a 15-degree angle relative to the skin's surface, directly into the scar tissue. Once inserted, the needle will be gently rotated to aid in separating tissue adhesions along the path of the scar. Routine physiotherapy includes the application of kinesiology taping, in addition to a 20-minute session of infrared therapy positioned 30 cm away from the scar tissue. A total of six treatment sessions will be administered to the patients, with three sessions per week scheduled over a two-week period.
223423927|NCT06033430|OTHER|Sham dry needling|The sham group participants will be positioned in a similar manner to those in the experimental group, with a minor exception. Instead of inserting the 2-cm single-use sterile filiform acupuncture needle into the scar tissue, it will be superficially inserted at a point further away from the scar tissue and removed after 20 minutes. Moreover, routine physiotherapy administered to the participants in the sham group will be identical to that of the experimental group, ensuring consistency between the two groups.
223423928|NCT06682936|PROCEDURE|ambulatory chest drain and talc pleurodesis|a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis
223423929|NCT01745224|DEVICE|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
223423930|NCT01745224|DEVICE|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
223423931|NCT01826136|DEVICE|Acapella device|
223423932|NCT05876624|OTHER|Blood Pressure measurement|Blood Pressure measurement
223423933|NCT04015921|OTHER|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
223423934|NCT06490380|DRUG|PARPi|Poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi)
223423935|NCT00441376|DRUG|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
223423936|NCT00246272|DRUG|risperidone|
223423937|NCT02621489|DRUG|Bydureon|2 mg Once Weekly
224138113|NCT00261170|DRUG|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
224138114|NCT00261170|OTHER|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
223423938|NCT02621489|DRUG|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
223423939|NCT02621489|DRUG|Metformin|Metformin 1g BID
223423940|NCT00278122|BIOLOGICAL|sargramostim|
223423941|NCT00278122|DRUG|paclitaxel|
223423942|NCT04833270|OTHER|KM non-pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. Non-pharmacological treatment including Korean medicine, such as acupuncture, electroacupuncture and chuna, etc, will be chosen by professional physician according to the medical condition of each subject.
223423943|NCT04833270|OTHER|Pharmacological treatment group|This is a pragmatic setting, and specific intervention is not determined prior to the study. The pharmacological treatment will be chosen by professional physician according to the medical condition of each subject.
223423944|NCT01246349|BEHAVIORAL|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
223423945|NCT01246349|BEHAVIORAL|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
223423946|NCT02000700|DRUG|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
223423947|NCT02000700|DRUG|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
223563636|NCT00232284|DRUG|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
223563637|NCT00232284|BEHAVIORAL|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
223739929|NCT00743327|DRUG|Pioglitazone|45mg capsule, once daily for 1 year
223739930|NCT06386133|DEVICE|MS Boost|remote monitoring digital tool based on functional tests (walking, dexterity, vision and cognition). These digital tests may be combined with a fatigue assessment via questionnaires and, if needed, a telerehabilitation program. This program includes an algorithm comprising fatigue management advice and/or physical activity recommendations personalised to the patients, aimed at improving fatigue-related symptoms. The patient can use the telerehabilitation program without supervision
223739931|NCT06386133|OTHER|Standard of care|General fatigue tips are given to patients who suffering from chronic fatigue such as stop smoking, eat a healthy diet...
223739932|NCT02014883|DRUG|GLUT1 DS|
224036866|NCT05026983|DRUG|Binimetinib|Given PO
224138115|NCT02117596|DRUG|Sirolimus|"1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
223423948|NCT02000700|DRUG|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
223739933|NCT05655858|OTHER|Management of allergic rhinitis|Collection of patient data in real-life
223739934|NCT06972979|BEHAVIORAL|Text Message Gamification and Remote Support|Participants in the intervention arm consists of several components: (I) medication check-ins with the ability to set the time(s) for daily medication reminders, (II) a gamification experience to drive behavior change, (III) ability to identify a support partner who receives weekly updates on the patient's game status; (IV) access to an RN team for clinical questions and care coordination, and (V) patients' providers can see real-time progress within an electronic health record (EHR) integrated application.
223739935|NCT06973928|DEVICE|Measures of jaw activity using the Jawac|At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements of jaw activity. Patients will undergo adenotonsillectomy during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires.
223739936|NCT03797378|OTHER|eM2M|The eM2M intervention involves three 60-minute sessions per week for 12 weeks. All sessions are delivered remotely in real-time through videoconferencing technology. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
223423949|NCT02000700|DRUG|Placebo|One matching placebo tablet orally administered at baseline phase.
223423950|NCT04025437|PROCEDURE|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
223423951|NCT04025437|RADIATION|Neoadjuvant radiotherapy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
223563638|NCT00218634|BEHAVIORAL|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
223563639|NCT00218634|BEHAVIORAL|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
223563640|NCT05243745|OTHER|3% PVM/MA + 5% KNO3 Combination|Toothpaste containing 3% PVM/MA + 5% KNO3 as combination will be used as test product.
223563641|NCT05243745|OTHER|3% PVM/MA only|Toothpaste containing 3% PVM/MA only will be used as comparator 1 product.
223563642|NCT05243745|OTHER|5% KNO3 Only|Toothpastes containing 5% KNO3 only will be used as comparator 2 product.
223563643|NCT05243745|OTHER|Regular Fluoride|Toothpaste containing regular fluoride will be used as negative control.
223563644|NCT01120236|DRUG|Bicalutamide|Given PO
223563645|NCT01120236|BIOLOGICAL|Cixutumumab|Given IV
223563646|NCT01120236|DRUG|Goserelin Acetate|Given SC
223563647|NCT01120236|OTHER|Laboratory Biomarker Analysis|Correlative studies
223563648|NCT01120236|DRUG|Leuprolide Acetate|Given IM
223563649|NCT01120236|OTHER|Pharmacological Study|Correlative studies
224036867|NCT05026983|DRUG|Encorafenib|Given PO
224036868|NCT05026983|OTHER|Questionnaire Administration|Ancillary studies
224036869|NCT01012739|DRUG|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
224036870|NCT01012739|DRUG|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
224036871|NCT01012739|DRUG|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
224036872|NCT01012739|DRUG|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
224036873|NCT05829863|BEHAVIORAL|educational message exposure|Exposing African American young adult vapers to persuasive anti-vaping public service announcements (PSAs) with the goal of reducing their subsequent e-cigarette use.
224036874|NCT04113668|DRUG|BMS-986165|Specified Dose on Specified Days
224036875|NCT04113668|DRUG|diflunisal|Specified Dose on Specified Days
224036876|NCT00640055|OTHER|Coordinator|Coordinator (non-physician) assigned cause of death
224036877|NCT00640055|OTHER|Physician-assigned cause of death|Physician (gold standard) cause of death
224036878|NCT01810237|DRUG|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
224036879|NCT02217189|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
223423952|NCT00024037|PROCEDURE|management of therapy complications|
223423953|NCT01579045|DEVICE|senofilcon A|bilateral daily use soft contact lens
223423954|NCT01579045|DEVICE|etafilcon A|bilateral daily use soft contact lens
223423955|NCT01579045|DEVICE|nelfilcon A|bilateral daily use soft contact lens
223423956|NCT01579045|DEVICE|Filcon II 3|bilateral daily use soft contact lens
223423957|NCT01579045|DEVICE|Filcon II 3|bilateral daily use soft contact lenses
223423958|NCT01772745|PROCEDURE|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
223423959|NCT01772745|PROCEDURE|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
223423960|NCT01566942|DRUG|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
223423961|NCT01566942|DRUG|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
223423962|NCT01472653|DRUG|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
224036880|NCT04026061|BEHAVIORAL|FMA group|A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
223423963|NCT01472653|RADIATION|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
223423964|NCT01472653|DRUG|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
223423965|NCT04673747|PROCEDURE|Total Hip Arthroplasty|Total replacement of the head, femoral neck and acetabulum of the hip joint with specialized implants
223423966|NCT04673747|PROCEDURE|Manual correction of the sacroiliac joint|Manual correction of the iliosacral displacement of the sacroiliac joint in total hip arthroplasty is performed in the operating room after anesthesia just before total hip arthroplasty. It is carried out according to the methodology developed by us.
223423967|NCT05637047|PROCEDURE|pulsed radiofrequency|ultrasound-guided intramuscular and interfascial pulsed radiofrequency ablation
223423968|NCT05637047|PROCEDURE|Dry needling|ultrasound-guided intramuscular and interfascial dry needling
223563650|NCT03732495|DRUG|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
223563651|NCT01073397|BEHAVIORAL|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
224036881|NCT04026061|BEHAVIORAL|Control group|Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
224036882|NCT05378126|OTHER|Neurological assessment|"No specific procedure is planned for the study other than the neurological examination by a neurologist of all patients. The patient will be taken care according to current recommendations.~In addition, a study-specific, non-injected brain CT scan will be performed systematically in patients undergoing cardiac surgery to evaluate postoperative hemorrhagic transformation."
224036883|NCT04908176|DRUG|Avapritinib|avapritinib tablets
224036884|NCT04908176|DRUG|midazolam|midazolam syrup
224036885|NCT06037096|OTHER|Attend-PE model|A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
223423969|NCT00438243|DRUG|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
223423970|NCT00438243|DRUG|Refresh Plus|1 drop in the affected eye twice daily
223563652|NCT00146419|BEHAVIORAL|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
223563653|NCT03156686|PROCEDURE|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
223739937|NCT05442086|BEHAVIORAL|Music and Theta Auditory Beat Stimulation|Participants will listen to calm music with theta auditory beat stimulation for 24-27 minutes
224036886|NCT05520281|BEHAVIORAL|Short-term psychodynamic psychotherapy for patients with serious physical illness (ORPHYS)|A short-term psychodynamic therapy that focuses on the special inner and outer situation of patients with a serious physical illness, especially with regard to the importance of relationships in a limited lifetime.
224036887|NCT05394714|BIOLOGICAL|Magicell-NK contains NK cells suspended in 100 mL normal saline|Eligible subjects will be assigned into one of the three dose escalating cohorts (3+3 subjects/cohort) according to the time sequence enrolled
224138116|NCT00391417|DRUG|estradiol gel|
223423971|NCT05551546|BEHAVIORAL|Functional Medicine Health Coaching for Elimination Diet for Elimination Diet|"All participants will receive 5 coaching sessions to support them through the elimination diet.~First session: The foundation session is where the coach and participant begin to develop rapport and outline the participant's goals. This occurs before the start of the Elimination Diet for motivation, expectations, education, and preparation.~Second session: This can occur during week 1 of the elimination diet to support working through the implementation.~Third session: This session is recommended to occur during week 3 of the diet to prepare for the reintroduction of foods.~Fourth session: A session is recommended while the participant is reintroducing foods as this is typically the most difficult part of the diet as participants may be experiencing symptoms to reactive foods.~Fifth session: A wrap up session is recommended after all of the food re-introductions to support the participant with maintenance, goals to move forward, and reflection."
223423972|NCT05551546|BEHAVIORAL|Self-guided Elimination Diet|"The Elimination Diet course materials include self-guided materials designed to guide participants through all phases of a comprehensive elimination diet, including preparation, elimination, and reintroduction phases.~All participants in this wait-list control group will be presented via email with the opportunity to receive the five sessions of coaching (described above) at the conclusion of the study."
223423973|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
223423974|NCT03962790|DEVICE|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
224036888|NCT05585528|PROCEDURE|Functional or surgical management in 1st intention|Proportion of patients after rupture of the anterior cruciate ligament of the knee, who will have functional or surgical management in 1st intention
224036889|NCT06039306|DIETARY_SUPPLEMENT|Immunonutrition oral nutrition supplementation|Participant will prescribed with 2 servings of immunonutrition supplement 5 days before surgery and 7 days after surgery
224036890|NCT05937347|BEHAVIORAL|TAU + UP4H|Group treatment protocol of 8 weeks (approximately 105 minutes per week, 75 of face-to-face and 30 of virtual intervention).
224036891|NCT05937347|BEHAVIORAL|TAU + M4H|Group treatment protocol of 8 weekly 75 minute sessions (face-to-face intervention).
224036892|NCT05937347|BEHAVIORAL|TAU + CT|Group treatment protocol of 8 weekly 60 minutes sessions (virtual intervention).
224036893|NCT05937347|OTHER|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to children with ADHD.
224138117|NCT04127734|PROCEDURE|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
224138118|NCT00657124|DIETARY_SUPPLEMENT|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
223423975|NCT00745238|OTHER|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
223423976|NCT02781753|BIOLOGICAL|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
223423977|NCT02781753|BIOLOGICAL|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
223423978|NCT03780465|DRUG|Oral idronoxil suspension|Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
224036894|NCT05254938|BEHAVIORAL|The Halland Obesity Municipal Effort for children|A comprehensive, intensive lifestyle intervention for the children with the greatest need of intensive treatment.
224036895|NCT05165537|DEVICE|NIMM_MRS|evaluation of new MRS methods
224036896|NCT06731335|DRUG|Psilocybin|PSILOCYBIN (PEX010) 25 mg PO single dose
224036897|NCT06731335|DRUG|Active Placebo|Dextromethorphan 400 mg PO single dose
224036898|NCT02938793|DRUG|Durvalumab|intravenous administration
224138119|NCT00657124|DIETARY_SUPPLEMENT|Placebo|placebo
224036899|NCT02938793|DRUG|Tremelimumab|intravenous administration
224036900|NCT06390956|DRUG|Pirtobrutinib|Administered once daily as an oral medication.
224036901|NCT06390319|DRUG|Dexamethasone|Given orally (PO) or intravenously (IV).
223423979|NCT03780465|DRUG|NOX66 (A)|Idronoxil formulated in suppository base A
224036902|NCT06390319|DRUG|Vincristine|Given IV.
224036903|NCT06390319|DRUG|Daunorubicin|Given IV.
224036904|NCT06390319|DRUG|Calaspargase pegol|Given IV.
224036905|NCT06390319|DRUG|Dasatinib|Given PO
224036906|NCT06390319|DRUG|Venetoclax|Given PO (ETP, near-ETP, and MPAL only).
224036907|NCT06390319|DRUG|Bortezomib|Given IV (T-LLy only).
224036908|NCT06390319|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Given Intrathecal (IT), Age adjusted.
224036909|NCT06390319|DRUG|Cyclophosphamide|Given IV.
224036910|NCT06390319|DRUG|Cytarabine|Given IV or IT.
224036911|NCT06390319|DRUG|Mercaptopurine|Given PO.
223423980|NCT03780465|DRUG|NOX66 (B)|Idronoxil formulated in suppository base B
223423981|NCT06483243|DRUG|Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG|At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
223423982|NCT02312869|OTHER|No intervention|not applicable, observational study
223423983|NCT02548000|OTHER|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
224036912|NCT06390319|DRUG|Nelarabine|Given IV
224036913|NCT06390319|DRUG|Methotrexate|Given IT, IV, PO or intramuscular (IM).
224036914|NCT06390319|DRUG|Thioguanine|Given PO (participants intolerant to mercaptopurine).
224138120|NCT04961918|PROCEDURE|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)|Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL)
224138121|NCT05846295|OTHER|ESTIMATE|An online educational module consisting of a video tutorial and feedback during a questionnaire
224138122|NCT06366295|DEVICE|subgingival mechanotherapy with perioscopy|Subgingival mechanotherapy using a machine scaler, curettes and a perioscope
224138123|NCT06366295|DEVICE|classical subgingival mechanotherapy|Subgingival mechanotherapy using a machine scaler and curettes
224138124|NCT00609219|BIOLOGICAL|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 2 x 10\^7 cells/m2~Group Two:~Day 0 - 2 x 10\^7 cells/m2 Day 14 - 1 x 10\^8 cells/m2~Group Three:~Day 0 - 1 x 10\^8 cells/m2 Day 14 - 2 x 10\^8 cells/m2"
224299011|NCT02124941|DIAGNOSTIC_TEST|[11C]APP311 PET scan|All subjects will undergo \[11C\]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
224036915|NCT06081010|BEHAVIORAL|Community Health Worker Intervention|Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
224036916|NCT03073226|DEVICE|Olympus Elite|New generation Olympus endoscope
224036917|NCT03073226|DEVICE|Olympus Spectrum|Current generation Olympus endoscope
224036918|NCT04452994|DRUG|JNJ-68284528|JNJ-68284528 will be administered as a single intravenous (IV). The target dose will be the recommended Phase 2 dose (RP2D) of 0.75\*10\^6 chimeric antigen receptor (CAR)-positive viable T cells per kilogram (cells/kg) (range: 0.5 to 1.0\*10\^6 CAR-positive viable T cells/kg).
224036919|NCT05396105|DRUG|deucrictibant selected dose|deucrictibant soft capsule for oral use
224299012|NCT01164345|DRUG|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
223423984|NCT02548000|OTHER|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
223423985|NCT03764228|BIOLOGICAL|hAECs|Human amniotic epithelial cells（hAECs）
223423986|NCT02900495|DEVICE|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
223423987|NCT03043157|DRUG|rocuronium|intravenous rocuronium infusion
223423988|NCT02579343|DEVICE|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
223423989|NCT02579343|DRUG|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
223423990|NCT02889250|DEVICE|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
223423991|NCT00035295|DRUG|MK0869, aprepitant|
223423992|NCT00035295|DRUG|Comparator: placebo|
223423993|NCT00381238|DRUG|rosiglitazone|Extended Release Tablets
223423994|NCT01976468|OTHER|SCC metastasis|occurrence of SCC metastasis
223423995|NCT00061373|DRUG|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
223423996|NCT00061373|DRUG|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
223423997|NCT00061373|DRUG|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
223423998|NCT02968667|BEHAVIORAL|Empowerment|6 weeks of empowerment program and supported face to face discussion
223423999|NCT02086448|DEVICE|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
224299013|NCT01783249|OTHER|Stationary Exercise cycling|Stationary exercise cycling
224299014|NCT01956695|DRUG|Lenalidomide|
224299015|NCT01956695|DRUG|Rituximab|
224299016|NCT00300625|PROCEDURE|Application of the San Francisco Syncope Rule|
224299017|NCT01374126|DRUG|Artesunate|Artesunate alone
223424000|NCT02086448|DEVICE|sham-CPAP|
223424001|NCT02086448|OTHER|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
223424002|NCT05027048|DRUG|Calcium chloride|See arm description above
223424003|NCT05027048|DRUG|Saline placebo|see arm description above
223424004|NCT00344591|BEHAVIORAL|Structured Ecosystems Therapy (SET)|
223424005|NCT00344591|BEHAVIORAL|Individually tailored intervention|
223424006|NCT01310556|OTHER|ogtt for patients with coronary artery disease|75 g OGTT
223424007|NCT02068170|DRUG|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
223424008|NCT01029171|BEHAVIORAL|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
223424009|NCT01029171|BEHAVIORAL|control; usual care|Usual care as prescribed by geriatrician.
223424010|NCT03651687|OTHER||
223424011|NCT01895348|DRUG|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
223424012|NCT01895348|DRUG|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
223424013|NCT01895348|DRUG|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
224036920|NCT06269081|BEHAVIORAL|Supportive-Expressive Peer Social Support Group Intervention|The social support group intervention involves weekly virtual support group meetings for 8 consecutive weeks. The groups, facilitated by trained research staff, will last approximately 90 minutes each week and include 5-12 individuals per group. Groups will follow pre-determined topic areas, with participants encouraged to explore their feelings about the difficulties associated with normal aging, being HIV-positive, and living with HIV/AIDS as an older adult. Facilitators will encourage mutual support among group members, promote greater openness and emotional expressiveness, and help participants to improve their social and family support and enhance their quality of life. This intervention is an adaptation of Telephone Supportive-Expressive Group Therapy.
224138125|NCT05782166|BEHAVIORAL|Betel Quid Educational Booklet|"Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
224138126|NCT05782166|BEHAVIORAL|Betel Quid Cessation Intervention Module|"All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained.~An interactive, educational talk will be given regarding the content of the educational booklet.~Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others.~Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour."
224138127|NCT05107349|PROCEDURE|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
224138128|NCT02451436|BEHAVIORAL|Sleep and Media Use Intervention|
224138129|NCT02451436|BEHAVIORAL|Study Skills Control Group|
223424014|NCT02982616|DIETARY_SUPPLEMENT|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
223424015|NCT02982616|BEHAVIORAL|Positive emotion|Positive emotion induced by facial expressions and classic music.
223424016|NCT02982616|DIETARY_SUPPLEMENT|saline|saline
223424017|NCT02982616|BEHAVIORAL|neutral emotion|Neutral emotion induced by facial expressions and classic music.
223563654|NCT02918396|DEVICE|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
223739938|NCT05442086|BEHAVIORAL|Pink Noise (control)|Participants will listen to pink noise for 24 minutes
223739939|NCT04370704|DRUG|INCAGN02385|INCAGN02385 administered intravenously
223424018|NCT04682262|PROCEDURE|Cervical dilatation|Patients undergo to cervical dilatation prior to the hysteroscopy under general anaesthesia with using Hegar dilator (no.10)
223424019|NCT00369200|DRUG|AFP464|Given IV
223424020|NCT00369200|OTHER|laboratory biomarker analysis|Correlative study
223424021|NCT00369200|OTHER|pharmacological study|Correlative study
223739940|NCT04370704|DRUG|INCAGN02390|INCAGN02390 administered intravenously
223739941|NCT04370704|DRUG|INCMGA00012.|INCMGA00012 administered intravenously
223739942|NCT06771479|BIOLOGICAL|MVA strain monkeypox attenuated live vaccine (low dose)|Low dose MVA strain monkeypox attenuated live vaccine
223739943|NCT06771479|BIOLOGICAL|MVA strain monkeypox attenuated live vaccine (high dose)|High dose MVA strain monkeypox attenuated live vaccine
223424022|NCT05382195|OTHER|hospital anxiety and depression scale|questionare on patients with multiple sclerosis
223424023|NCT00421824|DRUG|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
223739944|NCT06771479|OTHER|Placebo|Vaccine excipient
223739945|NCT06975423|DEVICE|Active lower-limb neuroprosthesis|Walkasins sensory neuroprosthesis provides real-time sensory input by delivering vibrotactile stimuli to the lower limbs above the ankle
223739946|NCT06975423|DEVICE|Inactive lower-limb neuroprosthesis|Walkasins sensory neuroprosthesis does not provide real-time sensory input by delivering vibrotactile stimuli to the lower limbs above the ankle
223739947|NCT06620289|BEHAVIORAL|Dental Desensitization Clinic|The goal of offering desensitization visits is to reduce the dental anxiety and distress of patients and enhance their cooperation during future appointments. The specifics of the desensitization are individualized to meet the unique needs of each patient based on information provided by the parent/caregiver. A standard desensitization visit involves providing the patient the opportunity to sit in the exam chair; touch the toothbrush and rubber prophy cup, mouth mirror, fluoride applicator brush, air-water syringe tip and saliva ejector tip; gain exposure to the dental lights and sounds commonly experienced in the dental visit; practice opening their mouth; and tolerate toothbrush and rubber prophy cup, mirror, explorer, fluoride applicator brush, air-water syringe, and salvia ejector in the mouth. If the child is unable or unwilling to participate, these activities are modeled on the parent or by the CCLS.
223739948|NCT02007044|DRUG|Ibrutinib|Given PO
223424024|NCT00421824|DRUG|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
223424025|NCT05497232|PROCEDURE|simultaneous pancreas-kidney transplantation|"Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases."
223424026|NCT03535194|DRUG|Mirikizumab|Administered SC
223424027|NCT03535194|DRUG|Placebo|Administered SC
223424028|NCT03535194|DRUG|Secukinumab|Administered SC
223424029|NCT00382590|DRUG|5-Azacytidine|75 mg/m\^2 daily for 7 days (days 1-7) via subcutaneous injection.
223424030|NCT00382590|DRUG|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
223424031|NCT00382590|DRUG|Valproic Acid (VPA)|50 mg/m\^2 orally daily days 1-7.
223424032|NCT06666842|BEHAVIORAL|Noom Weight|Participants assigned to Noom Weight will be provided access to the app-based program for 16 weeks. This program offers access to self-monitoring features, psychoeducational articles, one-on-one coaching from health experts, and group support. The app includes a robust database of foods, allowing users to track their energy intake. Self-monitoring via the app enables users to review and monitor behavior and weight change patterns. Daily articles review principles of behavior change, nutrition, exercise, etc.
223424033|NCT06666842|BEHAVIORAL|Educational Control|Participants assigned to the educational control will receive 16 brief (5-10 minute read) weekly newsletters outlining information on developing and maintaining a healthy diet and lifestyle adapted from the 2015-2020 Department of Health and Human Services (HHS) and Department of Agriculture (USDA) Dietary Guidelines for Americans. Newsletters include detailed information on topics such as nutrition fundamentals (e.g., calorie limits; healthy eating), food groups and dietary guidelines (e.g., importance of vegetables, fruits, and grains), and tips for habit change (e.g., reducing added sugar and saturated fats). Each week includes prompts for individuals to try new strategies (e.g., make a conscious decision about everything you eat; try to eat at your calorie budget).
223424034|NCT01226498|PROCEDURE|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
223424035|NCT03375671|DRUG|Ketalar|single administration of 5 mg/kg, IM
223424036|NCT03375671|DRUG|Midazolam injection|single administration of 5 mg, IM
223424037|NCT03375671|DRUG|Haloperidol|single administration of 5 mg, IM
223424038|NCT05756803|DEVICE|Low-intensity acoustic shockwave therapy|The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.
223424039|NCT00757965|GENETIC|polymorphism analysis|
223424040|NCT00757965|OTHER|laboratory biomarker analysis|
223424041|NCT00757965|OTHER|questionnaire administration|
223424042|NCT03104062|DIAGNOSTIC_TEST|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
223739949|NCT02007044|OTHER|Quality-of-Life Assessment|Ancillary studies
223739950|NCT02007044|OTHER|Questionnaire Administration|Ancillary studies
223739951|NCT02007044|BIOLOGICAL|Rituximab|Given IV
223739952|NCT05587842|PROCEDURE|Early Weightbearing management post operation|Subjects will be instructed to be weightbearing, as tolerated, on their ankle starting at two weeks post operation.
223739953|NCT05587842|PROCEDURE|Delayed Weightbearing management post operation (Traditional)|Subjects will be instructed to be non-weightbearing on their ankle until at least 6 weeks. After 6 weeks, the subject will be instructed to be weightbearing as tolerated.
223739954|NCT05133427|DEVICE|TOOsonix system ONE-M|All selected BCC areas will be treated by high intensity focused ultrasound
224138130|NCT03079349|OTHER|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
223424043|NCT03104062|DIAGNOSTIC_TEST|Platelet Aggregability|Obtained using Multiplate Analyzer
223424044|NCT03104062|DIAGNOSTIC_TEST|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
223424045|NCT05222152|DRUG|Chronocort|Hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg
223424046|NCT05222152|DRUG|Plenadren|Hydrocortisone modified-release tablets for oral administration - 5mg and 20mg
223424047|NCT00991471|BEHAVIORAL|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
223424048|NCT00991471|BEHAVIORAL|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
223424049|NCT01847781|BIOLOGICAL|Prevenar13|
223424050|NCT06141122|OTHER|A recipe booklet|A recipe resource with visuals in line with the low-residue diet recommendations given to patients before colonoscopy, including cooking instructions for the meals in the diet list.
223424051|NCT06011356|DEVICE|Smartwatch|Activity tracker (step count, calories burned), measures heart rate, heart variability and other physiological variables.
223424052|NCT04333407|DRUG|Aspirin 75mg|• If patient not on aspirin, add aspirin 75mg once daily unless contraindicated.
223424053|NCT04333407|DRUG|Clopidogrel 75mg|• If patient not on clopidogrel or equivalent, add clopidogrel 75mg once daily unless contraindicated
223424054|NCT04333407|DRUG|Rivaroxaban 2.5 MG|"* If patient not on an anticoagulation, add rivaroxaban 2.5mg bd unless contraindicated~* If patient on DOAC then change to rivaroxaban 2.5mg unless contraindicated"
223424055|NCT04333407|DRUG|Atorvastatin 40mg|• If patient not on a statin, add atorvastatin 40mg once daily unless contraindicated
223424056|NCT04333407|DRUG|Omeprazole 20mg|• If patient not on a proton pump inhibitor, add omeprazole 20mg once daily.
223739955|NCT02927041|DEVICE|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
223424057|NCT06582407|OTHER|Mathematical Prediction of unforseen patient reorientation|The goal of this project is to develop models to predict in the preoperative period which patients will require hospital admission after ambulatory surgery or unforeseen hospital discharge after surgery
223424058|NCT03603470|OTHER|EOS imagery|Whole body EOS imaging in seated and standing position
223424059|NCT02682823|DEVICE|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
223424060|NCT02682823|DRUG|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
223424061|NCT06237413|DRUG|ZG2001 Tosilate Tablets|ZG2001 will be administered orally once or twice daily in a continuous regimen
224036921|NCT06269081|BEHAVIORAL|Individual Strengths-Based Case Management Intervention|The strengths-based case management (SBCM) intervention helps participants address the multiple structural barriers faced by rural older people living with HIV. This intervention, delivered by trained research staff, includes two 60-minute telephone- or video-based SBCM counseling sessions, with shorter follow-up sessions to check-in on progress and help patients navigate identified barriers. The case manager will provide tailored sessions based on individually-identified needs and proximal life stressors. Capitalizing on participants' personal strengths, case managers will help empower participants to navigate issues related to employment, insurance, mental health, housing, or transportation. This may include assistance understanding, applying for, and accessing benefits or programs.
223424062|NCT06622213|OTHER|mucoadhesive film with Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
223424063|NCT06622213|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Apply ¼ inch on ulcer 3 times per day (after meals)
223424064|NCT06622213|OTHER|mucoadhesive film without Acmella oleracea extract|Apply 1 patch on ulcer 3 times per day (after meals)
223739956|NCT05483868|DRUG|AU-011|Administration of AU-011 intratumorally and intramurally
223739957|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Adminstration|AU-011 Intratumorally and Intramurally
224036922|NCT06667609|OTHER|Any treatments regimen|Participants may receive any treatments in accordance with standard clinical practice, based on physicians' recommendations and patients' preferences.
224036923|NCT05794958|DRUG|Axicabtagene Ciloleucel|Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
223739958|NCT05483868|COMBINATION_PRODUCT|AU-011 in Combination with Medical Laser Administration|AU-011 Intratumorally
223739959|NCT04742751|DRUG|Metformin|To begin week 12 for participants who remain prediabetic after 12 week lifestyle run-in. Dosage and Route of Administration: 500 mg dose/ day to be taken orally, increased to 1000 mg dose/ day at week 14 through week 24. The dose should be taken immediately following the evening meal and at approximately the same time daily
224036924|NCT04282187|DRUG|Decitabine|Given IV
224036925|NCT04282187|DRUG|Ruxolitinib|Given PO
224036926|NCT04282187|DRUG|Fedratinib|Given PO
224036927|NCT04282187|OTHER|Questionnaire Administration|Ancillary studies
224036928|NCT04282187|DRUG|Pacritinib|Given PO
224036929|NCT04282187|PROCEDURE|Biospecimen Collection|Undergo collection of blood and bone marrow samples
224138131|NCT03079349|OTHER|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
223424065|NCT06193811|DRUG|Avenciguat (BI 685509) (intended commercial formulation (iCF))|Avenciguat (BI 685509) (intended commercial formulation (iCF))
223424066|NCT06193811|DRUG|Avenciguat (BI 685509) (trial formulation 2 (TF2))|Avenciguat (BI 685509) (trial formulation 2 (TF2))
223424067|NCT06193811|DRUG|esomeprazole|esomeprazole (Nexium mups)
223424068|NCT01938430|DRUG|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
223424069|NCT01938430|DRUG|RBV|RBV tablets administered orally in a divided daily dose
223424070|NCT05120518|OTHER|Collection of post mortem tissue donation|Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.
223424071|NCT06665282|DEVICE|Pulsed high intensity laser therapy|"The study employs a BTL-6000 high-intensity laser therapy (12 W) to apply high intensity laser therapy to deep tissues. high intensity laser therapy therapy uses powerful beams (\>500 mw) to penetrate deeper, delivering high multi-directional energy in a short time. Pulsed laser therapy, a form of high intensity laser therapy therapy, enhances cell metabolism without disrupting it.~High-intensity laser therapy is a safe treatment method consisting of three phases. The first phase involves fast scanning around the wrist, hand, and fingers, with fluencies set at 510, 610, and 710mJ/cm2. The second phase involves holding the handpiece vertically to 90° on 10 fixed points around the metacarpophalangeal and interphalangeal joints, each radiated for 15 seconds, and a total dose of 1500 J. The third phase is the same but at a slower rate, with a total energy of 300 J."
223424072|NCT06665282|DEVICE|sham pulsed high intensity laser therapy|Patients in the control group will receive sham high-intensity laser therapy, where all parameters will be set up without switching on the start button and high intensity laser therapy machine is switched on with a visible light beam only
223424073|NCT06665282|OTHER|Routine physical therapy program|All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
224036930|NCT06976216|DRUG|KarXT|Specified dose on specified days
224036931|NCT06976216|DRUG|KarX-EC|Specified dose on specified days
224036932|NCT06976216|OTHER|Placebo|Specified dose on specified days
224036933|NCT06976203|DRUG|KarXT|Specified dose on specified days
224036934|NCT06976203|DRUG|KarX-EC|Specified dose on specified days
224036935|NCT06976203|OTHER|Placebo|Specified dose on specified days
223424074|NCT03692793|OTHER|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
224036936|NCT06806046|DRUG|M9140|M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, then M9140 will be escalated to the high dose level.
224036937|NCT06805825|DRUG|NN3201|A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.
224138132|NCT05164679|BEHAVIORAL|multimodal training (MMT)|Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
223424075|NCT00979875|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
223424076|NCT00979875|DRUG|Insulin lispro|
223424077|NCT00979875|DRUG|Insulin glulisine|
223424078|NCT00979875|DRUG|Insulin aspart|
223424079|NCT02606006|BEHAVIORAL|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
224036938|NCT02271477|DEVICE|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
224036939|NCT01118689|DRUG|MLN0128|MLN0128 administered orally once daily for 28 days
224138133|NCT05780593|OTHER|Manual Therapy|After the baseline assessment, each intervention group will be given physical therapy treatment. The group A will receive Manual Mobilization of the Lumbosacral Spine followed by passive stretching of the hip abductors of both sides of the body. The patient then will be asked to stand on the inclined board for 01 minute with feet 3 to 4 inches apart hands placed on the wall at the level of shoulder joints. After 01-minute patient will be asked to leave the inclined board. The patient will be advised to do this 01-minute inclined board standing for three times a day at home. All the patients in Group A will receive this treatment regime for two weeks.
224138134|NCT05780593|OTHER|Inclined Board Standing|The patients in Group B will be asked to stick to their medications if advised and stand on the inclined board for 01 minute. Inclined boards will be provided to all patients and will be advised to follow the inclined standing for 01 minute for three times a day at home for two weeks. After two weeks at the completion of intervention, they will be assessed through self-reporting questionnaires of the study.
224138135|NCT00234728|DEVICE|Occlusive dressing|
224138136|NCT01079429|GENETIC|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
224138137|NCT02687750|DEVICE|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
224138138|NCT00004278|DRUG|ganciclovir|
224138139|NCT01244191|DRUG|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
223424080|NCT02606006|BEHAVIORAL|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
223424081|NCT03644485|DRUG|Tacrolimus immediate-release formulation|oral
223424082|NCT03644485|DRUG|Tacrolimus prolonged-release formulation|oral
223424083|NCT03644485|DRUG|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
224138140|NCT01244191|DRUG|Placebo|Tivantinib Placebo tablets given twice a day
224138141|NCT01244191|DRUG|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
224138142|NCT03160664|DEVICE|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
223424084|NCT03644485|DRUG|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
223424085|NCT03644485|DRUG|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
223424086|NCT03251261|DEVICE|illumigene CMV assay, illumipro-10|CMV assay for detection of CMV
223424087|NCT03184194|DRUG|nivolumab-daratumumab|nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
223424088|NCT03184194|DRUG|nivolumab-daratumumab with low-dose cyclophosphamide|nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
223424089|NCT05715489|PROCEDURE|Comparison of pre and postoperative POP-Q values of the patients|Pectopexy Without Using Mesh will be applied to the patients and POP-Q values will be compared pre and postoperatively
223563655|NCT02918396|DEVICE|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
223563656|NCT02918396|DEVICE|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
223563657|NCT00063895|DRUG|erlotinib hydrochloride|Given PO
223563658|NCT00063895|OTHER|pharmacological study|Correlative studies
223563659|NCT00063895|OTHER|pharmacogenomic studies|Correlative studies
223563660|NCT00063895|OTHER|laboratory biomarker analysis|Correlative studies
223424090|NCT05715489|PROCEDURE|Comparison of pre and postoperative PISQ-12 scores of the patients|Pectopexy Without Using Mesh will be applied to the patients and PISQ-12 scores will be compared pre and postoperatively
223424091|NCT06620029|DRUG|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates. BMX-001 (7-28 mg) will be given by subcutaneous (s.c.) injection starting on Day 1, Day 8, Day 15, and Day 22 of each 28-day PTX treatment cycle.
223424092|NCT06620029|DRUG|Paclitaxel (Taxol)|Paclitaxel will be given via IV infusion at a dose = 80 mg/m2 on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle and will be sourced from standard commercial sources. Appropriate pretreatment prior to PTX will be given as per institutional standards. PTX management for any adverse event (AE) in any cycle, reasonably attributed to the chemotherapy agent that requires dose interruption should be managed per package insert, and/or institutional guidelines. Dose modification recommendations are provided in protocol to provide general consistency with dosing. Study Treatment dosing BMX-001 should continue even if the PTX is omitted. The subject may continue on PTX if the AE does not prohibit dosing per institutional practice. Grade 3 or higher infusion PTX reactions or recurrent infusion reactions may require permanent discontinuation of PTX. PTX may be continued in select patients using institutional desensitization protocol.
223424093|NCT00205868|DEVICE|Precision Spinal Cord Stimulation System|Stimulation on throughout study
223424094|NCT03572725|PROCEDURE|Gas tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
223424095|NCT03572725|PROCEDURE|Air tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
223424096|NCT03355157|DRUG|Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)|Drug intervention
223424097|NCT04053140|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
223424098|NCT04053140|DEVICE|Microneedle array and closed-loop control of penicillin delivery|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
224036940|NCT04382274|PROCEDURE|Quadratus Lumborum Block|transducer will be placed at the level of the anterior superior iliac spine and moved cranially until the three abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border will be visualized leaving underneath the internal oblique muscle, like a roof over the QL muscle. The probe will be tilted down to identify a bright hyperechoic line that represented the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of 20 mL of 0.25% bupivacaine will be applied
224036941|NCT04382274|PROCEDURE|Dual Transversus Abdominis Plane and Ilioinguinal/Iliohypogastric Nerve blocks|the probe will be located between the iliac crest and the lower costal margin in the anterior axillary line at the level of umbilicus, and the layers of abdominal wall will be identified (external oblique, internal oblique, and transverse abdominis muscles). In-plane technique will be used and the tip of the needle was inserted between the internal oblique and transverse abdominis muscles. After negative aspiration (to exclude intravascular injection), 20 mL of 0.25% bupivacaine will be injected. Then abdomen will be scanned through anterior superior iliac spine (ASIS)-umbilicus line. Ilioinguinal nerve can be visualised between the internal oblique and transverse or external oblique muscles and within 1 to 3 cm from the ASIS. The iliohypogastric nerve lies immediately adjacent. After negative aspiration (to exclude intravascular injection), 10 mL of 0.25% bupivacaine will be injected. The same technique will be performed on the other side.
223424099|NCT04053140|DRUG|Penicillin G_1200mg|Benzylpenicillin IV 1200mg administered every 4 hours.
224138143|NCT03160664|DEVICE|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
224138144|NCT03160664|OTHER|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
223424100|NCT04053140|DRUG|Penicillin G_2400mg|Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
223424101|NCT04053140|DRUG|Penicillin G_600mg/hr|Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
223424102|NCT04151160|DIAGNOSTIC_TEST|Point of care ultrasound measurements|i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.
223424103|NCT06322095|DRUG|PD-1|Previous PD-1
223424104|NCT06322095|DRUG|MET inhibitor|Previous MET inhibitor
223424105|NCT06322095|DRUG|ALK inhibitor|Previous ALK inhibitor
223424106|NCT06322095|DRUG|BRAF Inhibito|Previous BRAF inhibitor
223424107|NCT06322095|DRUG|EGFR Monoclonal antibody|Previous EGFR Monoclonal antibody
223424108|NCT06322095|DRUG|GH21|Oral, 15mg BIW or 6mg QD
223424109|NCT06322095|DRUG|MEK Inhibitor|Previous MEK Inhibitor
223424110|NCT04782895|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)|Three doses administered intramuscularly at 0, 45 day and 6 month.
223424111|NCT04782895|BIOLOGICAL|Gardasil®9|Three doses administered intramuscularly at 0, 45 day and 6 month.
223424112|NCT06434220|DIAGNOSTIC_TEST|Baseline model|Model prediction of patient disposition including feature importance scores driving prediction.
223424113|NCT06434220|DIAGNOSTIC_TEST|Fairness-aware model|Model prediction of patient disposition including feature importance scores driving prediction. This model has been tuned to minimize subgroup calibration errors.
223424114|NCT05082558|OTHER|No intervention, as this was retrospective study.|No intervention performed. Participants were entolled retrospectively and medical records were accessed for data.
223424115|NCT01008956|BIOLOGICAL|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
223424116|NCT03855020|DIAGNOSTIC_TEST|Plasma EBV DNA|Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate
223563661|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
223563662|NCT02314065|BEHAVIORAL|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
223563663|NCT03438955|DRUG|Omacor|Omacor soft capsule 4000mg for 16days
223563664|NCT03438955|DRUG|Pritor|Pritor tablet 40mg for 7days
224036942|NCT03723876|BEHAVIORAL|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
224036943|NCT04029935|BEHAVIORAL|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
223563665|NCT03438955|DRUG|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
224036944|NCT04029935|BEHAVIORAL|Control|time-matched task (sitting on the bike without pedalling)
224036945|NCT03049735|DRUG|Relugolix|Relugolix (40 mg) tablet administered orally once daily.
224036946|NCT03049735|DRUG|Estradiol/norethindrone acetate|E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
224036947|NCT03049735|DRUG|Estradiol/norethindrone acetate placebo|E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
224036948|NCT03049735|DRUG|Relugolix placebo|Relugolix (0 mg) placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.
224036949|NCT05520255|DRUG|18F-PSMA-1007|18F-PSMA-1007 intravenous injection
223563666|NCT03438955|DRUG|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
223563667|NCT01766492|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
223563668|NCT00952445|DRUG|T0903131 Besylate|Once daily, oral
223563669|NCT00952445|DRUG|Placebo|Once daily, oral
223563670|NCT05037448|BEHAVIORAL|Me & My Wishes|Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
223563673|NCT05563883|OTHER|event occurence|occurence of an event of interest: (AF, cancer, thromboembolism, bleeding, mortality...
223563674|NCT04051710|DRUG|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
223563675|NCT04051710|DRUG|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
223563676|NCT04051710|DRUG|Placebo|Placebo Product
223563677|NCT00693823|PROCEDURE|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
223563678|NCT00693823|DEVICE|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
223563679|NCT04918953|DRUG|methylprednisolone|The patients were treated with three protocols: (1) oral methylprednisolone, 40 mg for 3 days, 20 mg for 3 days, and 8 mg for 6 days; (2) oral methylprednisolone, 20 mg for 3 days, 10 mg for 3 days, and 4 mg for 6 days. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
224138145|NCT06270693|PROCEDURE|Endodontic treatment|Root canal treatment
223424117|NCT02372929|PROCEDURE|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
223424118|NCT05697029|DRUG|Tetrandrine|tetrandrine TID for 28 days
223424119|NCT01051544|DRUG|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
223424120|NCT01051544|DRUG|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
223424121|NCT04811612|DIAGNOSTIC_TEST|Warmed heel stick|One heel will be warmed before sampling with the other heel will not be warmed
223424122|NCT02619110|OTHER|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
223424123|NCT02619110|OTHER|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
223424124|NCT06111196|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection|100mg/4ml;single dose;intravenous injection
223424125|NCT06111196|DRUG|Pembrolizumab injection|100mg/4ml;single dose;intravenous injection
223424126|NCT00196066|DEVICE|Peripheral Vessel Stenting|
223424127|NCT06616714|OTHER|Observtional Study|Observtional Study
223563680|NCT04918953|DRUG|budesonide atomization suspension|(3) budesonide atomization suspension (AstraZeneca Trading Co., Ltd, AU.) inhaled through the nose atomized with an air compression atomizer for 4 weeks, 2 mg for the first 2 weeks and reduced to 1 mg for the last 2 weeks. At the same time, all patients received olfactory training for 12 weeks as proposed by Hummel et al
223563681|NCT01746121|GENETIC|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
223563682|NCT04588012|BEHAVIORAL|The online self-help Program OurRelationship developed by prof. Brian Doss and prof. Andrew Christensen.|The OurRelationship program is developed by prof. Brian Doss and prof. Andrew Christensen.
223563683|NCT04588012|BEHAVIORAL|"The off line self-help course Pas på Parforholdet."|"The book Pas på parforholdet is written by Mattias Stølen Due."
223563684|NCT03905031|DEVICE|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD\>0.2 is abnormal and suggestive of intracranial hematoma.
223563685|NCT04963140|OTHER|Optimized self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) if an increased risk of asthma exacerbations is detected by the home monitoring device
223563686|NCT04963140|OTHER|Conventional self-management of asthma|Short-term increase of asthma medication (as prescribed by the study doctor at enrolment) is based on subject's self-perception of symptoms
223563687|NCT01971463|OTHER|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
224036950|NCT06574620|GENETIC|Genetic testing|Analyses of the deoxyribonucleic acid (DNA), ribonucleic acid (RNA), proteins, and other molecules in the sample.
224036951|NCT06574620|PROCEDURE|Optional biopsy|Optional collection of tumour tissue and normal tissue after the last dose of treatment.
224036952|NCT06574620|PROCEDURE|Tissue collection|Collection of tumour tissue and normal tissue from biopsy or standard resection surgery prior to the first dose of treatment.
224036953|NCT06090539|DRUG|BMS-986458|Specified dose on specified days.
224036954|NCT06090539|DRUG|Rituximab|Specified dose on specified days.
224036955|NCT06090539|DRUG|Glofitamab/Obinutuzumab|Specified dose on specified days
224036956|NCT06090539|DRUG|Mosunetuzumab|Specified dose on specified days
224036957|NCT04003818|DRUG|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
223563688|NCT04879394|OTHER|Hypnosis|4 weekly hypnosis sessions, aiming at pain control and distress management. The 90 min. sessions will be conducted in group format by a doctorate-level psychologist trained in hypnosis. Contents will be detailed on hypnosis protocols to ensure standardization.
223563689|NCT00301600|DRUG|Mycophenolate mofetil|MMF,1.0g/d
223563690|NCT02581956|BEHAVIORAL|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
223563691|NCT02581956|BEHAVIORAL|No walking exercise|no exercise
223563692|NCT03018418|RADIATION|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
223563693|NCT03018418|DRUG|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
224036958|NCT02802969|PROCEDURE|Surgery|"The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.~The surgery can be macroscopically complete or incomplete."
224036959|NCT02802969|RADIATION|Protontherapy|Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
224036960|NCT02802969|DRUG|18F FAZA|FAZA PET/CT, in order to target the hypoxic zones
224036961|NCT04534504|PROCEDURE|SG-JJB|Base on SG-JJB procedure, the jejunum was not transected, only 200-cm jejunum 20-cm distal to Treiz ligament was measured and side-to-side jejunojejunal anastomosis was made. And the jejunum 3-5cm distal to the anastomosis was ligated with 10# suture.
224036962|NCT04046718|DEVICE|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
224036963|NCT04600362|DRUG|Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Subcutaneous
224036964|NCT01893437|DRUG|RO6799477|Single doses of RO6799477
223424128|NCT04629781|DRUG|Docetaxel micellar|There will be three dose levels, 1-3, with each level consisting initially of a cohort containing 3 patients. One additional dose level, dose level -1, shall be allowed in the event that dose level 1 is considered too toxic
223424129|NCT06570343|DRUG|Fentanyl-Morphine|Intrathecal injection of bupivacaine, fentanyl and morphine
223424130|NCT06570343|DRUG|Morphine|Intrathecal injection of bupivacaine and morphine
223424131|NCT05845905|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by the inflation of an automated cuff to the pressure rising by 20 mmHg from baseline systolic pressure. RIC will be conducted twice daily for 7 days.
223424132|NCT05845905|PROCEDURE|Sham remote ischemic conditioning|Sham-RIC is performed in the same way as the treatment group except that the blood pressure cuff is inflated to 60 mmHg, which produces mild pressure sensations but has no blocking impact on blood flow.
223424133|NCT02662764|DRUG|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
223424134|NCT05398952|DIAGNOSTIC_TEST|Laboratory investigations|Laboratory investigations correlated with symptoms and imaging results
223424135|NCT02852200|OTHER|SEGAm|
223424136|NCT00372710|DRUG|Zoledronic acid|
223424137|NCT05307016|DIAGNOSTIC_TEST|Two dimensional ultrasonography power and color doppler|"transabdominal and transvaginal two-dimensional power Doppler ultrasound volumes of the placental bed were obtained according to a predefined protocol with the participant in a semi-recumbent position and a full bladder using a RAB4-8-D 3D/4D curved array abdominal transducer (4-8.5 MHz) on a Voluson E8. Predetermined machine settings were used. To allow for differences in attenuation of the power Doppler signal resulting from variation in placental site and maternal adiposity.~Intraoperative staging of degree of placental invasion will be done according to clinical grading system by Collins et al., 2015.~Specimens obtained from patients who underwent hysterectomy or resection of segment of anterior uterine wall in cases with anterior placenta previa will be immersed in formalin 10% concentration and will be sent for histopathological evaluation that will be done by the same pathologist."
223424138|NCT01783600|DEVICE|NanoCross .014 balloon catheter|
223424139|NCT04123106|PROCEDURE|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
223424140|NCT04123106|PROCEDURE|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
224036965|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: caplet Route of administration: oral
224036966|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 1 tablets Route of administration: oral
224036967|NCT04748926|DRUG|rilzabrutinib SAR444671|Pharmaceutical form: Oral Formulation 2 tablets Route of administration: oral
224036968|NCT00390910|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
223424141|NCT02493010|DEVICE|Arousal-based biofeedback system|
223424142|NCT05905666|BEHAVIORAL|health education and counseling|In the control stage, participants only received standard nursing care. In the experimental stage, intervention measures (health education and counseling) were implemented. The baseline data were the pretest data collected in the control stage. Four weeks later, a posttest was performed, namely the pretest of the experimental stage. Subsequently, 4 weeks of health education and counseling were introduced to smokers according to different stages. After 4 weeks of intervention, participants were asked to fill out the posttest questionnaire again to measure the stages of change for smoking cessation, smoking decisional balance, and self-efficacy of smoking cessation.
223424143|NCT02937142|BEHAVIORAL|cognitive behavior group therapy|1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
223424144|NCT02937142|OTHER|Treatment as usual|Education on ADHD, and ADHD medication if indicated
223424145|NCT01191775|DRUG|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
223424146|NCT06617182|DRUG|Thalidomide|Patients in thalidomide group took thalidomide orally at a dose of 100mg once a day for 8 weeks.
223424147|NCT06617182|DRUG|Glutamine|In the glutamine group, two capsules of glutamine were taken orally 3 times a day for 8 weeks.
223424148|NCT06617182|DRUG|Thalidomide+Glutamine|Patients in thalidomide combined with glutamine group took thalidomide orally at a dose of 100mg once a day and two capsules of glutamine were taken orally 3 times a day for 8 weeks.
224036969|NCT00390910|BIOLOGICAL|Infanrix hexa|Intramuscular injection, 3 doses
224036970|NCT04531215|DRUG|ultrasound guided Retrolaminar Block|ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
224036971|NCT04531215|DRUG|ultrasound guided Erector Spinae Plane|ultrasound guided Erector Spinae Plane Block (ESPB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side.
224138146|NCT06150690|OTHER|No intervention|The participants did not receive any study-specific intervention
224138147|NCT02164513|DRUG|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
223424149|NCT06617871|PROCEDURE|Mechanical Alignment (MA)|Primary TKA with the Medacta SpheriKA, utilizing either MA methodology.
223424150|NCT06617871|PROCEDURE|Kinematic Alignment (KA) Interventions:|Primary TKA with the Medacta SpheriKA, utilizing either KA methodology.
223424151|NCT06141616|OTHER|Asthma Rehabilitation Program|The group will receive free physiotherapy treatment with aerobic exercises, 3x/week, 60 minutes a day, lasting 3 months, in addition to educational sessions in a playful way.
223424152|NCT05178641|DEVICE|Ninjamas Pyjama Pants|Disposable, absorbent underwear-like pyjama pant specifically designed to manage nocturnal enuresis in children by absorbing involuntary urine loss overnight and keeping the child's bed and clothing dry.
223424153|NCT05178641|OTHER|Participant's Overnight Current Standard of Care|Any disposable or reusable absorbent diaper or pant product available on the US market that is used to absorb involuntary urine loss for children who are wetting the bed at night.
223424154|NCT05022524|DIETARY_SUPPLEMENT|Acetate (Apple Cider Vinegar)|Consumer-grade apple cider vinegar (ACV) capsules will have extra enteric coating applied for delivery further into the GI tract.
223424155|NCT00811824|BEHAVIORAL|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
223424156|NCT01869699|DRUG|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
223424157|NCT01869699|DRUG|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
224036972|NCT04585776|DRUG|LY900014|Administered SC
224036973|NCT04585776|DRUG|Insulin Degludec|Administered SC
224036974|NCT02159560|DEVICE|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
224036975|NCT05282615|DEVICE|Emanate Tray|Emanate Tray, a personalized dental tray set (upper and lower) with PVA hydrogel containing 0.05% w/w chlorhexidine gluconate
224036976|NCT01620112|DRUG|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
224036977|NCT01620112|DRUG|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
224138148|NCT02164513|DRUG|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
223424158|NCT01993589|DRUG|comparison of pain relievers during curattage|
223424159|NCT01993589|DRUG|comparison of pain relievers|
223424160|NCT01993589|DRUG|comparison of pain relievers during curattage|
223424161|NCT01993589|DRUG|comparison of pain relievers during curattage|
223563694|NCT05273021|DIAGNOSTIC_TEST|TAPS|all participants are investigated by the Dutch TAPS tool (Tobacco, Alcohol, Prescription medication and other Substances-tool). A screener and short assessment of possible substance use problems
223563695|NCT00420004|DRUG|LY2216684|3-mg and 6-mg tablets
223563696|NCT00420004|DRUG|Placebo|
223563697|NCT00420004|DRUG|Escitalopram|10-mg capsules
224036978|NCT01620112|DRUG|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
224036979|NCT01620112|DRUG|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
224036980|NCT00713726|DRUG|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
224036981|NCT00713726|DRUG|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
224036982|NCT04727086|DRUG|BP1.3656|BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
224299018|NCT01374126|DRUG|Azithromycin + Artesunate|Combination of azithromycin + artesunate
223424162|NCT01993589|DRUG|comparison of pain relievers during curattage|
223563698|NCT03929653|OTHER|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
223563699|NCT05081947|BEHAVIORAL|COMPASS|COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.
223563700|NCT05778084|DRUG|Empagliflozin 10 MG|Blood samples will be collected as a baseline to test for N-terminal Pro-B-type Natriuretic Peptide, followed by administration of empagliflozin for 6 months, and then another blood samples will be collected after 6 months.
223563701|NCT00362583|DRUG|Fentanyl|
223563702|NCT05989087|DIAGNOSTIC_TEST|CSF|Early-onset Alzheimer's disease patients underwent routine laboratory tests to obtain CSF samples. Also, all participants underwent structural MRI examinations and neuropsychological tests.
223563703|NCT04902404|OTHER|First Pathways Game|The First Pathways Game is a free, online parenting education program. Parents watch short videos (approximately 30 seconds) on the First Pathways Game website to receive neuroscience knowledge and ideas for age-appropriate game ideas to play with their child. The game ideas employ common household items, such as measuring cups and paper.
224036983|NCT04727086|DRUG|Placebo|Administered once daily in tablet form.
224036984|NCT00516243|OTHER|placebo|Given PO
223424163|NCT06648083|OTHER|Food autonomy|Determine the age of acquisition of full oral feeding in extremely premature infants hospitalised in a neonatal unit where that applies a strategy of specific and individualized stimulation of orality.
223424164|NCT03521297|DRUG|Probiotic|UDCA combined probiotic
224036985|NCT00516243|OTHER|quality-of-life assessment|Ancillary studies
223424165|NCT03521297|DIETARY_SUPPLEMENT|Placebo|UDCA combined placebo
223424166|NCT06261060|DRUG|Sirolimus|Given by PO
223424167|NCT01653860|BEHAVIORAL|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
223424168|NCT01653860|BEHAVIORAL|Ordinary group treatment|group treatment 8 weeks (16 hours)
223424169|NCT06622681|OTHER|No intervention|No intervention
223424170|NCT02289781|DEVICE|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
223424171|NCT01022294|DRUG|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
223563704|NCT03452904|DEVICE|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
223563705|NCT03452904|DEVICE|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
223563706|NCT00309140|DRUG|enzastaurin|500 milligrams (mg), oral, daily, six 42-day cycle and subsequent cycles or until participants met study discontinuation criteria of progressive disease or unacceptable toxicity
223563707|NCT00733772|DIETARY_SUPPLEMENT|flaxseed|30 grams/day of flaxseed for 12 weeks
223563708|NCT00733772|BEHAVIORAL|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
223563709|NCT00998673|DEVICE|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
223563710|NCT00998673|DEVICE|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
223563711|NCT05908071|DRUG|SHEN26 capsule|Capsule administered orally after meals.
223563712|NCT05908071|DRUG|SHEN26 placebo|Capsule administered orally after meals.
223563713|NCT00441649|DRUG|Methylphenidate|
223563714|NCT00591149|DRUG|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
224036986|NCT00516243|PROCEDURE|questionnaire administration|Ancillary studies
224036987|NCT00516243|PROCEDURE|laboratory biomarker analysis|Correlative studies
223424172|NCT01022294|DRUG|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
223424173|NCT05587868|BIOLOGICAL|COVID-19 Vaccine|Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
223424174|NCT03105986|DRUG|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
223424175|NCT03105986|DRUG|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
224036988|NCT00516243|DRUG|defined green tea catechin extract|Given PO
224036989|NCT02642510|OTHER|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
224036990|NCT02642510|OTHER|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
223424176|NCT04085224|DRUG|Somatropin|LG Somatropin
223424177|NCT00732758|DIETARY_SUPPLEMENT|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
223424178|NCT00732758|DIETARY_SUPPLEMENT|Placebo Tablet|Placebo Tablet once daily for 6 months
223424179|NCT02918435|BEHAVIORAL|WE CARE|The WE CARE (Well-child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
223424180|NCT03373058|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.
223424181|NCT03373058|PROCEDURE|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
224036991|NCT02802709|DEVICE|SB-061|delivered via intra-articular injection
224036992|NCT02802709|OTHER|Placebo|Placebo
224036993|NCT06151054|DIAGNOSTIC_TEST|Measure of aortic inflammation|Standard Uptake Value (SUV) measures of aortic wall
224036994|NCT01474863|DRUG|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
224036995|NCT01474863|DRUG|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
224036996|NCT01474863|DRUG|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
224036997|NCT01119326|PROCEDURE|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
224036998|NCT03231943|DRUG|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
224036999|NCT03231943|DRUG|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
223424182|NCT03373058|DRUG|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group."
223424183|NCT02205905|DRUG|14C PER977|Open-label, single dose
223424184|NCT03228316|PROCEDURE|superior hypogastric plexus block|nerve plexus block
223424185|NCT03228316|RADIATION|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
223424186|NCT05214586|PROCEDURE|Follow up of the clinical stage|Pain, Swelling, Infection, Patient satisfaction and recurrence of the disease will be measured
223424187|NCT01844206|DRUG|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
223424188|NCT01844206|DRUG|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
223424189|NCT05583292|OTHER|ASA-PS|The American Society of Anesthesiologists classification of physical status (ASA PS) is a scale consisting of 6 classes showing the preoperative comorbidity of the patient.
223424190|NCT05583292|OTHER|SORT|Surgical outcome risk tool (SORT) is a scale used to estimate patient preoperative mortality/ morbidity, measured from sortsurgery.com.
223424191|NCT05583292|OTHER|Sarcopenia|Sarcopenia represents a loss of muscle strength and mass in older individuals and people who have tumors. Sarcopenia score is valuable in predicting preoperative mortality/ morbidity
223563715|NCT00591149|DRUG|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
223563716|NCT00591149|DRUG|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
223563717|NCT05568914|DEVICE|Indirect Calorimetry|Indirect Calorimetry (Q-NRG Metabolic Monitor, COSMED) is performed to determine the Resting Energy Expenditure before hemodialysis.
224037000|NCT04710888|DRUG|use of basil extract gel in treatment of aphthus ulcer|This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
224037001|NCT04710888|OTHER|muco adhesive placebo gel|mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
224037002|NCT04710888|OTHER|no treatment|(i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
224037003|NCT02810899|DRUG|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
224037004|NCT02810899|DRUG|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
224037005|NCT02944994|OTHER|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
224037006|NCT02944994|OTHER|Routine Care|This arm will reflect typical care received in routine mental health care
224037007|NCT04687150|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation from a tested general donor, frozen and thawed from a fecal bank
224037008|NCT04687150|OTHER|Colored water|Colored water (placebo)
223424192|NCT06366139|PROCEDURE|Radiofrequency thermocoagulation of the trigeminal ganglion|The patient is placed in the supine position and the foramen ovale is identified medial to the coronoid process of the mandible by giving the head a submental oblique position under fluoroscopic guidance. A 20-gauge, 5 mm active type, and 100 mm radiofrequency cannula is inserted 2 cm lateral to the commissura labialis and advanced towards the foramen. After entering the foramen ovale with a lateral fluoroscopic image, the radiofrequency cannula is connected to the radiofrequency generator and sensory and motor stimulations are performed to confirm the target maxillary and mandibular nerves. The radiofrequency lesion is applied at 60°C, 65°C and 70°C for 60-seconds periods. The patient is observed for side effects for 1 hour after the procedure.
223424193|NCT06366139|PROCEDURE|Maxillary/Mandibular nerve pulsed radiofrequency|The patient is placed in the lateral decubitus position with the affected side up. A 5-12 MHz linear ultrasound probe is placed in the infrazygomatic area above the maxilla at a 45° inclination in both the frontal and horizontal planes. The probe position allows visualization of the pterygopalatine fossa, which is limited to the maxilla anteriorly and the greater wing of the sphenoid posteriorly. Real-time ultrasound guidance allows direct localization of the internal maxillary artery and identification of the needle tip. The radiofrequency cannula was connected to the radiofrequency generator and PRF was applied at 42°C for 240 seconds after confirming the localization of the maxillary and mandibular nerve by obtaining appropriate responses to sensory and motor stimulation.
223424194|NCT05798013|BEHAVIORAL|Digital health management|The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.
223424195|NCT05085106|DRUG|Felbinac trometamol eye drop|Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
224037009|NCT00121693|BEHAVIORAL|Music therapy (listening to specific music)|Listening to Music
224037010|NCT02577601|DRUG|Ulipristal Acetate|
224037011|NCT02577601|DRUG|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
224037012|NCT03728413|BIOLOGICAL|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
224037013|NCT04818424|DEVICE|Soft exosuit|A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
224037014|NCT04818424|BEHAVIORAL|Gait training without exosuits|Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
224037015|NCT00372021|PROCEDURE|optic nerve neurotomy|
224037016|NCT03341351|OTHER|Instructional video|Instructional video using the modified beef tongue model
224037017|NCT03341351|OTHER|Instructional workshop|Instructional workshop using the modified beef tongue model.
224138149|NCT02164513|DRUG|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
224037018|NCT05138991|PROCEDURE|Echocardiogram Recording|Undergo assessment via echo
224037019|NCT05138991|OTHER|Questionnaire Administration|Ancillary Studies
224138150|NCT00245193|BEHAVIORAL|Motivationally-Enhanced Interpersonal Psychotherapy|
224138151|NCT00945074|OTHER|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
224138152|NCT00945074|OTHER|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
224138153|NCT00945074|OTHER|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
223424196|NCT05085106|DRUG|Placebo eye drop|Placebo eye drop: 0.0%, 1 drop will be instilled as instructed over one day in single-dose study; 0.0%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
223424197|NCT02991716|OTHER|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
223424198|NCT04127032|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly support, or monitored optional support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their access to therapist support by an additional 8 weeks (i.e., up to 16 weeks in total).
223424199|NCT03408249|DIAGNOSTIC_TEST|IBDoc calprotectin test|Patients are asked to perform a single IBDoc calprotectin home test.
223424200|NCT03408249|OTHER|questionnaire|Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
223424201|NCT04240457|COMBINATION_PRODUCT|Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.
223424202|NCT02673268|PROCEDURE|Mastectomy|
223424203|NCT02673268|DEVICE|Da Vinci Robot Xi|
224037020|NCT05138991|PROCEDURE|Stress Cardiac Magnetic Resonance Imaging|Undergo assessment via CMR
224037021|NCT05138991|DEVICE|Wireless Synchronized Cardiac Function Monitoring Device|SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
224138154|NCT03984331|DEVICE|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
224138155|NCT03984331|DEVICE|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
223424204|NCT02271399|DRUG|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
223424205|NCT02271399|DRUG|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
223424206|NCT04722029|BIOLOGICAL|Adenovirus Specific T lymphocytes|ADV-VSTs is being proposed for the treatment of refractory ADV infection and/or disease in these populations using haploidentical donors for ease of donor selection, antiviral immunity, coupled with a high-throughput antigen stimulation/IFN-γ capture system (Miltenyi Biotec, CliniMACS Prodigy® System) for rapid and less costly isolation of ADV-VSTs.
223424207|NCT03845491|DEVICE|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
223424208|NCT06679569|DRUG|rocuronium 0.2 mg/kg/hr continuous infusion|To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.
223424209|NCT06679569|DRUG|rocuronium 0.6 mg/kg/hr continuous infusion|To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
223424210|NCT03406559|OTHER|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
223563718|NCT05568914|DEVICE|Bio-electrical Impedance Analysis (BIA)|Bio-electrical Impedance Analysis (BIA101/BIVA, Akern) is used to analyse the body composition (Fat Mass, Fat Free Mass, Phase Angle).
223563719|NCT05568914|OTHER|Nutritional assessments|The Nutritional assessments consist of a dietary anamnesis and a 3-day nutritional diary to determine the nutritional (caloric and protein) intake of the participants.
223563720|NCT00470093|BIOLOGICAL|recombinant interferon-α|
224138156|NCT00006248|DRUG|cisplatin|
224138157|NCT00006248|DRUG|fluorouracil|
223563721|NCT00470093|BIOLOGICAL|recombinant interleukin-6|
223563722|NCT02596373|DRUG|Mitoxantrone Hydrochloride Liposome Injection|
223563723|NCT01610440|BIOLOGICAL|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
223424211|NCT01590043|OTHER|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
223424212|NCT04670952|OTHER|Low Pressure Laparoscopic Cholecystectomy|Low Pressure Laparoscopic Cholecystectomy (10mmHg) is set as the experimental group.
223563724|NCT05901363|PROCEDURE|Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy|laparoscopic removal of gallbladder and endoscopic extraction of common bile duct stones
223563725|NCT05901363|PROCEDURE|aparoscopic common bile duct exploration and laparoscopic cholecystectomy|laparoscopic removal of gallbladder and laparoscopic extraction of common bile duct stones
223563726|NCT01381003|GENETIC|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
223563727|NCT04205851|DRUG|KIN-1901|KIN-1901 is a fully human monoclonal antibody (mAb).
223563728|NCT04205851|DRUG|Placebo|Saline
223563729|NCT00989521|DRUG|PUR003|PUR003 for inhalation
224037022|NCT04231266|DRUG|ManNAc|Oral N-acetyl-D-mannosamine monohydrate (ManNAc)
224037023|NCT04231266|OTHER|Placebo|Placebo
224037024|NCT02906787|BEHAVIORAL|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
224138158|NCT00006248|DRUG|paclitaxel|
224138159|NCT02969434|OTHER|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
223424213|NCT04670952|OTHER|Standard Pressure Laparoscopic Cholecystectomy|Standard Pressure Laparoscopic Cholecystectomy (14mmHg) is set as the control group.
223424214|NCT02322658|DRUG|Eszopiclone Tablets 3 mg|
224037025|NCT02906787|BEHAVIORAL|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
223424215|NCT01680159|DRUG|TA-650|
223424216|NCT06683313|COMBINATION_PRODUCT|combination femoral nerve and popliteal sciatica block|Combination of femoral nerve and popliteal sciatica block performed after knee surgery
223424217|NCT06683313|COMBINATION_PRODUCT|combination adductor canal and IPACK block|Combination of adductor canal and IPACK block performed after knee surgery
223424218|NCT03633305|DRUG|Hypnotics|Medication used 1 to 7 nights/week for 6 to 8 weeks.
223424219|NCT03633305|BEHAVIORAL|Online CBT|Internet self-help program for insomnia with 6 cores.
223424220|NCT03633305|BEHAVIORAL|Face-to-face CBT|Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
223424221|NCT02200536|OTHER|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
223424222|NCT02200536|OTHER|Infant oral health pamphlet|Infant oral health pamphlet
223424223|NCT04936802|DEVICE|Transcatheter tricuspid valve repair system (Trialign)|To assess the Trialign System to treat subjects with moderate to severe tricuspid regurgitation
223424224|NCT00380289|DRUG|Thiazide and beta blocker|
223424225|NCT00061867|DRUG|pegylated liposomal doxorubicin hydrochloride|
224037026|NCT03715088|BEHAVIORAL|Resistance Training Intervention|Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
224037027|NCT05880277|DIAGNOSTIC_TEST|POCUS|Point of Care Ultrasound
224037028|NCT05106608|DEVICE|Energy density photobiomodulation (7.5)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
224037029|NCT05106608|DEVICE|Energy density photobiomodulation (3)|A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.
224037030|NCT05106608|DEVICE|Sham placebo|In addition, a mobile health application (LAXER) will be provided.
224037031|NCT02818920|DRUG|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 \& 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
224037032|NCT05425706|OTHER|application of SNAGs technique|in experiment group, the SNAGs technique was applied to 16 participants in addition to conventional therapy.
224138160|NCT06233734|DEVICE|The Lokomat (Hocoma, Zurich, Switzerland).|The Lokomat is a device which can be used to implement robot-assisted gait training safely within disabled stroke populations. The robot-assisted gait training group will receive training via the Lokomat. Involvement in the study will not influence the duration or frequency of robot-assisted gait training sessions they receive. The amount of training they receive via the Lokomat will be determined (as per standard care) by the care team at the stroke ward.
224138161|NCT01667393|DEVICE|IDEV SUPERA Stent|
224138162|NCT01667393|DEVICE|Percutaneous Transluminal Angioplasty|
224138163|NCT04786041|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
223424226|NCT00061867|PROCEDURE|hyperthermia treatment|
223424227|NCT06682767|DIETARY_SUPPLEMENT|FMD1 (LNT22-017-1)|FMD is a plant-based ketogenic diet that provides essential nutrients while maintaining hypo-caloric content. FMD is administered cyclically with 3-5 consecutive days of the diet followed by resumption of normal eating.
223424228|NCT03745690|PROCEDURE|Image-Guided Surgery|Undergo near-infrared image guided surgical resection
223424229|NCT03745690|DRUG|Indocyanine Green Drug|Given IV
223424230|NCT01148303|DRUG|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
223424231|NCT01148303|DRUG|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
223424232|NCT01148303|DRUG|Placebo|Placebo
223424233|NCT05909878|DEVICE|Virtual Reality|The pre-procedural IVR game preparation (IMAGINE) was developed by Paperplane Therapeutics® (intervention development team). IMAGINE is an immersive virtual reality simulation aiming to reduce the anxiety and phobic reactions of young patients and to better prepare them for this exam. Since the game is a preparation, it is a no success game and is independent of the ability and previous experience of the child with video games. It offers an immersive and fun simulation that aims to desensitize young patients to MRI and transform an anxiety-inducing experience into a fun play session. The participant will learn about the main principles of magnetic resonance imaging and experience a very realistic simulation of the MRI exam. This will allow children to prepare for the MRI scanner by enabling them to experience the process of undergoing an MRI exam beforehand.
223563730|NCT00989521|DRUG|Placebo|Normal saline for inhalation
223563731|NCT03263468|PROCEDURE|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
223563732|NCT03263468|PROCEDURE|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
223563733|NCT01801176|OTHER|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
223424234|NCT05909878|OTHER|Standard Protocol|The usual care group will only receive the standard preparation, which comprises of an explanation of the MRI procedure given by the radiology technician as per the radiology department's protocol. Specifically at the hospital (HSJ), standard care also includes access to a television mounted near the MRI playing videos.The research nurse will be able to complete any information should they find it incomplete or substandard.
223424235|NCT02388815|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
223424236|NCT02179970|DRUG|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
223424237|NCT00310752|DEVICE|DermaStream(tm) application and Streaming of Saline|
223424238|NCT00005889|DRUG|alanine|
223563734|NCT05325749|GENETIC|Screening|Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
224037033|NCT06895005|DEVICE|Transcutaneous auricular vagus nerve stimulation + rehabilitation therapy|Transcutaneous auricular vagus nerve stimulation using INPULSE 3 times a week for six consecutive weeks. The stimulation parameters will be a frequency of 30Hz with a pulse width of 300 us and a stimulation time of 1.5 seconds for each respiratory cycle. The electrical current will be gradually increased to a maximum of 5 mA (0.25-mA increments) to allow adaptation to the stimulation until a comfortable tolerance level is achieved. Patients will receive physical rehabilitation therapy during stimulation, which will include reaching and grasping exercises, gross movements, turning objects, simulating specific tasks, inserting objects, opening and closing containers.
224037034|NCT06895005|OTHER|sham stimulation + rehabilitation therapy|Patients will receive physical rehabilitation therapy during placebo stimulation (No electrical stimulation), including reaching and grasping exercises, gross movements, turning objects, simulating specific tasks, inserting objects, opening and closing containers.
224037035|NCT06885151|OTHER|Evidence-based IVF website content|The Evidence-based IVF website has been developed through a robust co-design process with IVF patients and clinicians, and the information about effectiveness and safety of add-ons was produced following established systematic review methodology of Cochrane (including risk of bias, GRADE, and TRACT assessment). They will view information about one of the following IVF add-ons: Endometrial receptivity array (ERA test), EmbryoGlue, or intralipid.
224037036|NCT06885151|OTHER|Control|Participants will view information that has been generated by combining information from the top 3 websites retrieved on Google search of the add-on name. They will view information about one of the following IVF add-ons: Endometrial receptivity array (ERA test), EmbryoGlue, or intralipid.
224037037|NCT05671419|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
224037038|NCT05772156|DRUG|Methylergonovine|Methylergonovine 200mcg Intramuscular (IM)
224037039|NCT05772156|DRUG|Placebo|Matching saline placebo
224037040|NCT07178223|PROCEDURE|Arthroplasty CMC-1|Touch Touch® dual-mobility Arthroplasty CMC-1 joint (Kerimed). Dorsal approach. Conical cup. Soft dressing 3 weeks. Loading allowed after 2 months.
224037041|NCT07184385|BIOLOGICAL|REGENECYTE|HPC, Cord Blood
224037042|NCT07184385|BIOLOGICAL|Placebo|Normal Saline
224299019|NCT04996563|OTHER|Video|A brief educational video, approximately 9 minutes in duration, on pelvic organ prolapse is sent electronically to patients to view prior to their initial visit in order to provide early access to information. The video was created to educate patients on the following key components of prolapse: the clinical condition, associated symptoms, common risk factors, evaluation and diagnosis, non-surgical treatment options, and surgical treatment options. Simple drawings and animations are included as visual aids to enhance the ability to conceptualize prolapse and its management options.
224299020|NCT01301586|DRUG|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
224299021|NCT01301586|DRUG|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
223424239|NCT00005889|DRUG|amino acids|
223424240|NCT00005889|DRUG|glucagon|
223424241|NCT00005889|DRUG|glucose|
223424242|NCT00005889|DRUG|glutamine|
223424243|NCT00005889|DRUG|glycerol|
223424244|NCT00005889|DRUG|insulin|
223424245|NCT00005889|DRUG|leucine|
223424246|NCT00005889|DRUG|lipids|
223424247|NCT00005889|DRUG|urea|
223424248|NCT04676451|DEVICE|Femto-AK|Astigmatic Keratotomy / Arcuate Incisions for the correction of astigmatism
223424249|NCT06120569|DEVICE|Soleus ms exercise|Soleus muscle exercise before and after eating by half an hour
223424250|NCT04225429|DRUG|Tazemetostat|800mg/dose taken orally twice every day.
223424251|NCT00168272|DEVICE|Transcranial Magnetic Stimulation|
223424252|NCT03204929|DRUG|Cu(II)ATSM|copper-containing synthetic small molecule
223424253|NCT01252563|DRUG|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
223424254|NCT03025139|OTHER|Educational Intervention|Attend survivorship education
223424255|NCT03025139|OTHER|Laboratory Biomarker Analysis|Correlative studies
223424256|NCT03025139|PROCEDURE|Meditation Therapy|Attend mindfulness meditation
223424257|NCT03025139|OTHER|Questionnaire Administration|Ancillary studies
223424258|NCT02537002|DRUG|PF-05230907|A single intravenous dose of 3 μg/kg
223424259|NCT02537002|DRUG|PF-05230907|A single intravenous dose of 5 μg/kg
223424260|NCT02537002|DRUG|Placebo|A single intravenous dose of matched placebo
223563735|NCT05325749|GENETIC|Family history record|Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
224299022|NCT00634881|BIOLOGICAL|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
223424261|NCT06028802|DIAGNOSTIC_TEST|CT Clock Tool measurement|Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
223424262|NCT02497963|PROCEDURE|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
223424263|NCT02497963|PROCEDURE|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
223424264|NCT01068886|PROCEDURE|External pancreatic stent|stent through pancreatic anastomosis
223424265|NCT02825758|DIETARY_SUPPLEMENT|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
223424266|NCT02223936|OTHER|group exposed|Assessment by Brunet Lezine scale
223424267|NCT02223936|OTHER|Control|Not exposed group
223424268|NCT04293913|BEHAVIORAL|illustrated communication material|Illustrated communication material was introduced to the patients in the intervention group. In the process (intensive care) that patients received mechanical ventilation support after the operation, agitation and sedation levels were monitored by the intensive care nurse who was to communicate with the patient using the Richmond Agitation Sedation Scale (RASS). According to this scale, having minimum -2 and maximum +2 points was accepted as the starting criteria for communication (Sessler et al., 2002). Communication was established with the illustrated communication material.
223424269|NCT04701229|GENETIC|somatic cytogenetic and genetic characterization|investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
223424270|NCT03429244|DIAGNOSTIC_TEST|68Ga-PSMA-11 PET-MRI|Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.
223424271|NCT01246869|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer
223424272|NCT01246869|DRUG|1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole|Brain scan with radiopharmaceutical imaging tracer that directly assesses tumor hypoxia
223424273|NCT01246869|DRUG|[15O]water|Brain scan with imaging tracer used for measuring tumor blood flow/perfusion
223424274|NCT01246869|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Brain scan to assess tumor size and tumor blood flow/perfusion
223424275|NCT03421145|DEVICE|3M™ Oral Rinse|The Investigational Rinse contains a sugar-based surfactant using a proprietary formula. The intended use of the product is to help prevent and reduce plaque accumulation on the teeth and related gum-tissue inflammation (gingivitis).
223424276|NCT03421145|OTHER|Vehicle Control Oral Rinse|The Placebo Comparator oral rinse is similar to the Experimental Oral Rinse only it does not contain the active ingredient.
223739960|NCT04742751|BEHAVIORAL|Digital Intervention|"Lifestyle Change Digital Intervention - This is a digital platform that will include a core curriculum focused on diet, exercise, and behavioral strategies for goal setting and self-monitoring to improve diet including a weight loss On Day 1, participants will begin their digital lifestyle intervention using their smart-phone application with their lifestyle coach and peer group.~On day 14, participants will be contacted by phone (+/- 4 days, day 10 to 18) and adherence assessed using virtual pill counts via phone calls.~At weeks 4, 8, 16 and 20 a phone-based pill count for adherence and adverse event symptom log will be completed and study medication dispensed.~At week 12 (interim assessment) and 24 (study-end), the participant will return to St. Jude Children's Research Hospital (SJCRH) for an in-person assessment.~The digital lifestyle change program will complete at week 24."
224299023|NCT00634881|BIOLOGICAL|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~* Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~* Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~* Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
223424277|NCT03421145|DEVICE|PerioShield™ Oral Health Rinse|PerioShield™ Oral Health Rinse (0.2% delmopinol hydrochloride) is marketed in the US and was purchased for use in this study.
223424278|NCT03421145|OTHER|Water|Purified bottled water containing no active ingredients.
223424279|NCT06429345|DRUG|Coenzyme Q10 100 Milligrams Oral Capsule|Patients will be randomly divided into two groups using a computer generated random number chart Coenzyme Q10 group will receive 400 milligrams coenzyme Q10 preoperative and 400 milligrams coenzyme Q10 for 3 days post operative in addition to the standard preventive measures.
223424280|NCT06429345|DRUG|Placebo|placebo group will receive only the standard preventive measures (as proper hydration pre and post operative)without the coenzyme Q10.
223424281|NCT03627338|DIAGNOSTIC_TEST|questionaire, interview|questionaire, interview
223424282|NCT04502225|OTHER|Tilt|Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
223424283|NCT04502225|OTHER|Elevated trunk|Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
223424284|NCT04502225|OTHER|Tilt - In home|Tilt of the whole bed so that the head is elevated by 8 inches overnight.
223424285|NCT04502225|OTHER|Elevated Trunk - In home|Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
223424286|NCT02773212|DRUG|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
223424287|NCT02773212|BEHAVIORAL|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
223424288|NCT02773212|DRUG|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
223424289|NCT01062243|BEHAVIORAL|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
223424290|NCT06093737|BEHAVIORAL|COPE: Communities Organizing for Power through Empathy|A three session brief group psychoeducational intervention. Session 1 is 4 hours, Session 2 and 3 are 1.5 hours. It is delivered in groups of 8-15 people with sessions spaced 1 month apart.
223424291|NCT05573477|DRUG|ATB-1011|Oral tablet
223424292|NCT05573477|DRUG|ATB-1012|Oral tablet
224138164|NCT02582580|OTHER|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
224138165|NCT02582580|DEVICE|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
223424293|NCT05573477|DRUG|ATB-1013|Oral tablet
223424294|NCT05573477|DRUG|ATB-1011 placebo|Placebo matched to ATB-1011
223424295|NCT05573477|DRUG|ATB-1012 placebo|Placebo matched to ATB-1012
223424296|NCT05573477|DRUG|ATB-1013 placebo|Placebo matched to ATB-1013
223424297|NCT04901351|PROCEDURE|Smear|In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
223424298|NCT03843632|BIOLOGICAL|VARIVAX™|VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).
223424299|NCT06619873|DRUG|HRS-8080|"Medication regimen A~Drug:~600mg, Old process tablets，NPO~Medication regimen B~Drug:~600mg, New process tablets，NPO~Medication regimen C~Drug:~600mg, New process tablets，PC.，low-fat diet~Medication regimen D~Drug:~600mg, New process tablets，PC.，high-fat diet"
223424300|NCT04167631|RADIATION|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
223424301|NCT02716831|BEHAVIORAL|Nutritional Counseling & Acceptance-based Therapy|
223424302|NCT02716831|BEHAVIORAL|Cognitive Behavioral Therapy for Eating Disorders|
223563736|NCT05325749|OTHER|Questionnaire survey|Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
223424303|NCT00774553|DRUG|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
223424304|NCT00774553|DRUG|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
223424305|NCT01820572|DRUG|Belatacept|
223424306|NCT01820572|DRUG|Tacrolimus|
223424307|NCT01820572|DRUG|Cyclosporine|
223424308|NCT01279122|DEVICE|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
223424309|NCT00004422|DRUG|immune globulin|
223424310|NCT03404726|DRUG|BAY2402234|BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
223424311|NCT03134534|PROCEDURE|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
223563737|NCT05325749|GENETIC|Diagnostic|The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
223563738|NCT05325749|GENETIC|Selective screening|The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
223563739|NCT02429713|PROCEDURE|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
223563740|NCT02429713|PROCEDURE|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
223563741|NCT05132257|PROCEDURE|Severe ROP|The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.
223424312|NCT03134534|PROCEDURE|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
223424313|NCT01609634|OTHER|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
224037043|NCT07188363|PROCEDURE|Ligament reconstruction|Retensioning involves restoring the tension in a ligament or soft tissue that has become lax, often due to injury or joint instability. This technique is typically used for ligaments that do not require complete reconstruction but have lost their functional tension. Ligament reconstruction is a surgical procedure to replace or repair a damaged ligament, often using grafts (autografts or allografts). It aims to restore joint stability and function, particularly in cases of significant ligament damage or rupture. Syndesmosis surgery involves repairing or reconstructing the fibrous joint between two bones (e.g., the tibia and fibula). It may involve screw fixation, suture-button devices, or grafts to restore the alignment and stability of the syndesmosis.
223424314|NCT01609634|OTHER|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
223424315|NCT01609634|OTHER|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
223424316|NCT06622343|DRUG|Antivenom Serum|Intravenous administration of 6000 IU of antivenom serum was given to patients envenomed by pit vipers. This treatment was based on Chinese guidelines for the management of snakebites. Additionally, patients received supportive treatments, including antibiotics to prevent infection, antihistamines for allergic reactions, and magnesium sulfate for localized swelling and pain relief.
224138166|NCT02582580|OTHER|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
223424317|NCT06622343|PROCEDURE|Wound Debridement|Patients who did not develop necrotizing skin infections received wound management, including multiple punctures using a three-edged needle for toxin drainage, along with standard wound care and debridement as necessary to prevent infection and promote healing.
223424318|NCT04675957|OTHER|cardiac rehabilitation|stationary or ambulatory cardiac rehabilitation
223424319|NCT01863316|DEVICE|I gel|
223424320|NCT01863316|DEVICE|LMA Supreme|
223424321|NCT05036668|BIOLOGICAL|Cryptosporidium parvum oocysts (ABO809)|ABO809 3x10\^6 CE/3mL concentrate for oral suspension, single dose at Day 1
223424322|NCT02105246|BEHAVIORAL|Referral to home-based cardiac rehab|Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
223424323|NCT02105246|BEHAVIORAL|Referral to center-based cardiac rehab|Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
223424324|NCT04025775|DEVICE|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~* Glooko/Diasend cloud upload system to monitor CGM/insulin data."
223424325|NCT04025775|OTHER|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
223424326|NCT00658775|DRUG|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
223424327|NCT00658775|DRUG|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
223424328|NCT04091100|PROCEDURE|Electroacupuncture|An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
223424329|NCT04091100|PROCEDURE|Myofascial Release|longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
223424330|NCT02368743|DRUG|mesalazine|
223424331|NCT00588211|BEHAVIORAL|Interviews|45-minute individual interviews after the conclusion of their dental appointment
223424332|NCT00588211|BEHAVIORAL|focus group|A focus group of the preliminary cancer-related risk perception item pool.
223424333|NCT00588211|BEHAVIORAL|Survey|Quantitative item analysis of the final item pool.
223424334|NCT00588211|BEHAVIORAL|Survey|A second confirmatory factor analysis.
224138167|NCT00810719|DRUG|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
223424335|NCT05108142|OTHER|Dietary intervention|fresh, hot pasta and re-heated pasta
223424336|NCT03001349|PROCEDURE|Computed Tomography|Undergo PET/CT
223424337|NCT03001349|DRUG|Gallium Ga 68-Edotreotide|Given IV
223424338|NCT03001349|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223424339|NCT05525988|PROCEDURE|Hemi-Hamate Transfer for Proximal Pole Scaphoid Reconstruction|"Surgical Technique:~The participants will be positioned in the supine decubitus on the surgical table with the operated upper limb put on a C-arm (Mobile fluoroscopy device) compatible surgical arm-board. After anesthesia, a pneumatic tourniquet will be placed with a cuff pressure raised to 250 mmHg, then the limb is draped in the regular sterile fashion. Through a dorsal approach to the wrist joint, the proximal pole of scaphoid bone will be assessed before resectioning for confirmation that it cannot be preserved. The hamate bone will be exposed through capsulotomy and the measurements of the resected scaphoid will be transferred. The harvested H-H autograft will be placed and fixed to the distal scaphoid segment. Wound closure is then performed in layers in the usual fashion, and the wound will be covered by a sterile gauze, then a short-arm thumb spica splint will be put on."
223424340|NCT00387010|DRUG|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
223424341|NCT04586634|DEVICE|Peristeen cone catheter|The active intervention is the Peristeen cone catheter device. The comparator in this investigation is current standard of care for patients with LARS which is conservative bowel management.
223424342|NCT06651801|BEHAVIORAL|Group Medical Visits|Group medical visits occur every 2 weeks virtually (via Zoom) for 6 months. Each group consists of 45 minutes of group time and 5 minute individual check-in appointments. The group time consists of psychoeducation, group support, and medication follow-up.
223424343|NCT00949819|OTHER|Active surveillance|Serial, long term data collection and active surveillance
223424344|NCT06656702|DRUG|Psilocybin|Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
223424345|NCT06036810|OTHER|Shared Medical Decision Tool|standard of care
223424346|NCT06036810|BEHAVIORAL|Engaging Patients in Decision Making|standard of care
223424347|NCT06036810|BEHAVIORAL|Literacy Spanish Language|standard of care
223424348|NCT06683625|DIAGNOSTIC_TEST|6K Max Effort Erg Test|"6K Max Effort Erg Test, involves participants completing a 6000-meter rowing distance on an ergometer as quickly as possible. This test is designed to measure peak endurance and performance under controlled conditions and will serve as a primary assessment of each athlete's physical output and adaptive capacity."
223424349|NCT03048318|PROCEDURE|Arterial Flushing|
223424350|NCT03048318|PROCEDURE|Portal Flushing|
223424351|NCT02589990|BEHAVIORAL|Strength training|see arm description
223424352|NCT00789256|DRUG|Melphalan|Melphalan: 2mg orally, once daily
223424353|NCT00789256|DRUG|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
223424354|NCT00789256|DRUG|Melphalan and bortezomib|
223424355|NCT01453478|DRUG|GSK1325756|CXCR2 antagonist
223424356|NCT00191347|DRUG|pemetrexed|
223424357|NCT00191347|DRUG|gemcitabine|
223424358|NCT06478433|DEVICE|Munatoril Aerosol Combo|"Munatoril® Aerosol Combo is a Medical Device that contains:~5 ml single-dose vials of sterile, 3% hypertonic, near-neutral pH bromine-iodine saline solution, based on Cervia integral sea salt, salso-bromo-iodine saline mother water from the Cervia Thermal Baths and hyaluronic acid with high molecular weight.~Lavonase® syringe with blue nebulizer valve (microsol), 10 ml, Medical Device for the administration of solutions in nebulized form within the nasal cavities and nasopharynx."
223424359|NCT06478433|DEVICE|Iperclenny|Hypertonic and Isotonic solution present on market in italy.
223424360|NCT06181305|DRUG|estradiol valerate and letrozole|hormone replacement therapy by estradiol valerate plus letrozole incorporation .
223424361|NCT06181305|DRUG|letrozole 2,5 mg tablet|mild ovarian stimulation
223424362|NCT03064100|OTHER|Observational Study|Exclusion from the study
224138168|NCT00810719|DRUG|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
223424363|NCT05306314|DIETARY_SUPPLEMENT|TREATAPROST|oral administration before meals 30 minutes
223424364|NCT02963428|BEHAVIORAL|Enhanced Care|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
223424365|NCT06665854|BEHAVIORAL|Rhythmic Song Group|The rhythmic song group will first click on the start button on the mobile application. When starting the application to stimulate the baby, a bell will ring, and the baby movements will be coded as present/absent via the mobile application; then they will sing a rhythmic song and recode the baby movements as present/absent via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
223563742|NCT05978076|OTHER|data collection|data collection : mechanism of injury, associated injury, length of stay, maximal lipase level, nutritional care and local complications.
223563743|NCT01431937|DRUG|GSK2018682|Active Drug
223563744|NCT01431937|DRUG|Placebo|Placebo
223563745|NCT05752227|PROCEDURE|Transthoracic biopsy|Us guided transthoracic biopsy
223563746|NCT05752227|RADIATION|CT chest|Computed tomography
223563747|NCT01938508|DRUG|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
223563748|NCT04113174|OTHER|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
223563749|NCT00153829|BEHAVIORAL|Multifaceted outreach facilitation for chronic illness care|
223563750|NCT00664560|DRUG|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
223563751|NCT00664560|DRUG|celebrex|200 mg celecoxib qd
223563752|NCT00664560|DRUG|Placebo|sugar pill bid
223563753|NCT00664560|DRUG|Rescue Antacid|Antacid Tablets
223563754|NCT02456636|BEHAVIORAL|Fee-for-Service Model (FFS, In clinic individual visits)|To be performed by participant's doctor or other healthcare professional in their doctor's office.
223563755|NCT02456636|BEHAVIORAL|Patient Centered Medical Home (PCMH, In clinic group visits)|To be performed by a registered dietitian, a nurse or other healthcare professional in their local setting.
223424366|NCT06665854|BEHAVIORAL|Rhythmic Instrument Group|The Rhythmic Instrument Group will first click on the start button on the mobile application. Then, they will ring a bell to start the application to warn the baby, and they will code the baby's movements as present/absent via the mobile application; then they will play a rhythmic instrument and code the baby's movements as present/absent via the mobile application again. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
223424367|NCT06665854|BEHAVIORAL|Control Group|"Control Group will first code Start via the mobile application. Then, a bell will ring to warn the baby, they will code the baby's movements as present/absent via the mobile application again and will only rest. When the application is over, all pregnant women will code Finish via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week."
223424368|NCT04529785|PROCEDURE|SVC only|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC alone
223424369|NCT04529785|PROCEDURE|SVC isolation with substrate modification and vein of Marshal ethanol infusion|Patients allocated to this arm will receive an RF ablation with the isolation of the SVC, substrate modification and vein of Marshal ethanol infusion
223424370|NCT03195725|OTHER|Review of notes|No intervention will occur
223424371|NCT02808728|DRUG|Pain Cocktail with Exparel|pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.
223563756|NCT02456636|BEHAVIORAL|Disease Management (DM, Phone group visits)|To be performed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling via telephone.
223563757|NCT05557552|RADIATION|standar thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with standard dose thoracic radiotherapy of 60 Gy/30Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
223563758|NCT05557552|RADIATION|decreased thoracic RT dose|All the enrolled patients will be patients with NSCLC who did not have PD (determined as per the RECIST v1.1) after 4-6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, those enrolled patients would be treated with decreased thoracic radiotherapy of 50Gy/25Fx concurrently with PD-1/PD-L1 maintenance therapy, and the total maintenance therapy time should at least more than 6 months.
223563759|NCT02834117|OTHER|natural cycle|Ovulation is not induced by drugs
223563760|NCT02834117|DRUG|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
223563761|NCT00999635|DEVICE|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
223739961|NCT06521736|DEVICE|AAC-BCI device|Participants without speech and severe movement disorders will be trained on the augmentative and alternative communication, brain-computer interface (AAC-BCI) system, using it for at least 10 hours per week in their homes for communication and other control functions. Participants will have daily support for using the AAC-BCI from trained caregivers along with intervention support from consultants and speech language pathologists.
223739962|NCT03709043|DRUG|Standardized kudzu|Standardized kudzu
223739963|NCT03709043|OTHER|Placebo|Placebo
223739964|NCT03709043|DIAGNOSTIC_TEST|Sexually transmitted infection testing:|At baseline and month 3 visits, all participants will be tested for syphilis (serum RPR), Neisseria gonorrhea and Chlamydia trachomatis (urine, pharyngeal swab, and rectal swab nucleic acid amplification \[NAAT\]) through an established protocol that has been validated by our Public Health Laboratory (PHL) and others.
223739965|NCT03709043|BEHAVIORAL|Medical Management (MM) counseling for alcohol use:|MM has been used in a targeted pharmacotherapy trial and our team has successfully used MM in AUD trials. MM is a low-intensity supportive program designed to increase problem recognition and enhance motivation to change maladaptive alcohol use patterns. Participants will receive individual 20 minute MM sessions weekly from trained staff supervised by a clinical psychologist.
223739966|NCT03709043|DIAGNOSTIC_TEST|Urinalysis for novel alcohol biochemical markers for recent alcohol use:|Urine samples will be collected at Enrollment, Month 1, Month 2 and Month 3 visits and tested for ethyl glucuronide (EtG) to determine recent alcohol consumption in the past three days. EtG is a relatively novel, highly sensitive indicator for recent alcohol consumption; this alcohol biomarker is detectable in urine for approximately 72 hours.
223739967|NCT03709043|DIAGNOSTIC_TEST|Dried Blood Spot (DBS) Testing for PEth:|DBS samples will be collected at enrollment, weeks 12, and post-treatment visits at month 3. Samples will be dried overnight using standardized methods. PEth testing of DBS samples will be conducted at the United States Drug Testing Laboratories in Des Plaines, IL using liquid chromatography-tandem mass spectrometry system following extraction into methanol.
223739968|NCT03709043|BEHAVIORAL|Behavioral survey measurements:|Standardized and validated behavioral measures will be assessed using audio computer administered surveys (ACASI) to minimize underreporting of risk activities and standardize data collection.To minimize potential social desirability bias, staff will not have access to data during the trial.
223739969|NCT03709043|BEHAVIORAL|Ecological Momentary Assessment procedure:|Participants will receive daily SMS texts to collect data on alcohol consumption, number of drinks on drinking days, targeted medication administration prior to anticipated drinking sessions, and sexual risk behaviors
223739970|NCT06078020|OTHER|Interview|Semi-structured interview to assess understanding and acceptability at 3+/-2 and 14+/-7 days after consent
223739971|NCT06973668|DRUG|Mycophenolate Mofetil|15 mg/kg/dose (max: 1,000mg/dose) IV/PO three times daily
223739972|NCT06973668|DRUG|Ruxolitinib|5 mg PO every 12 hours
223739973|NCT05099965|BIOLOGICAL|CMV-MVA Triplex|5 x 108 plaque-forming unit (pfu) ±0.5 x 108 pfu of MVA Vaccine
223739974|NCT05099965|BIOLOGICAL|Placebo|7.5% Lactose in phosphate-buffered saline \[PBS\]
224138169|NCT01185145|RADIATION|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
223424372|NCT02808728|DRUG|Pain Cocktail with Ropivacaine|pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
223424373|NCT05110846|DRUG|Placebo|Placebo
223424374|NCT05110846|DRUG|CT-868|CT-868
223424375|NCT01931956|DEVICE|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
223424376|NCT00431028|DEVICE|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
223424377|NCT03283293|RADIATION|Target Volume Delineation after NACT|The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
223424378|NCT02076503|PROCEDURE|PET-MR 18f-FACBC|
224037044|NCT07186270|BEHAVIORAL|Positively framed FOP labels (present versus absent) x Price (high versus low)|"The intervention combines either a front-of-pack (FOP) label that frames high nutrition or no FOP label with price variation. Products are randomly assigned to either receive a positively-framed FOP label or no label, and to either a high or a low price.~This yields four experimental arms:~1. Positively framed FOP label with high price~2. Positively framed FOP label with low price~3. No label with high price~4. No label with low price"
224037045|NCT07186270|BEHAVIORAL|Graded FOP labels (no label vs. high rating (grade A) vs. low rating (grade D)) x Price (average vs. premium)|"The intervention combines either a graded front-of-pack (FOP) labelling or no FOP labelling with price variation. Products are randomly assigned to either receive a graded label or no label, and to either a premium or an average price.~This yields six experimental arms:~1. High grade (A) with premium price~2. Low grade (D) with premium price~3. No label with premium price~4. High grade (A) with average price~5. Low grade (D) with average price~6. No label with average price"
224138170|NCT01185145|RADIATION|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
224138171|NCT04344379|DRUG|hydroxychloroquine|200 mg BID per day
224138172|NCT04344379|DRUG|azithromycin|250 mg per day
224138173|NCT04344379|DRUG|hydroxychloroquine placebo|200 mg BID per day
223424379|NCT02076503|PROCEDURE|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
224138174|NCT00598715|DEVICE|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
224138175|NCT00598715|DEVICE|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
223424380|NCT04257032|DRUG|Rosuvastatin|Tablet
223424381|NCT04257032|DRUG|Rosuvastatin + BI 1323495|Tablets
223424382|NCT04257032|DRUG|Dabigatran etexilate|Capsule
223424383|NCT04257032|DRUG|Dabigatran etexilate + BI 1323495|Capsule and tablets
223424384|NCT02847494|DRUG|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
223424385|NCT02847494|DRUG|Dexamethasone|dexamethasone 10mg intramuscular injection
223424386|NCT02847494|DRUG|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
223424387|NCT01901653|DRUG|Rovalpituzumab tesirine (SC16LD6.5)|
223424388|NCT02468154|DEVICE|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
223424389|NCT02468154|OTHER|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
223424390|NCT06898580|OTHER|sacral massage with tennis ball|When the cervical dilatation in labor is 5-6 cm, 7-8 cm and 9-10 cm, the woman will be asked to mark the intensity of the pain she feels on the VAS scale before starting the procedure. Then, the researcher explains sacral massage to the pregnant woman. While performing this application, the researcher will apply pressure to the sacral area with a tennis ball in a circular motion so that the patient can feel but not feel pain. The application will be applied to the pregnant woman for a total of 3 contractions. 30 minutes after each procedure, the woman will be asked to mark the intensity of the pain she feels on the VAS scale and mark the Birth Comfort Scale. The research will end when a total of 70 experimental groups and 70 control groups are reached.
223424391|NCT06760572|DEVICE|Airway insertion|Tube will be inserted into the trachea to make airway data measurements.
223739975|NCT04415944|PROCEDURE|Second look laparoscopy reassessment surgery (SLLRS)|Performed less than 12 weeks after intravenous chemotherapy cycles are completed.
224138176|NCT03503149|OTHER|no intervention|observational study
224138177|NCT00176670|DRUG|midazolam or GameBoy or parental presence|
224138178|NCT04316663|BEHAVIORAL|Well-Being Intervention|The main aim of the well-being intervention is to reduce levels of distress through the promotion of psychological well-being. Key components of the intervention are self-monitoring of instances of well-being and what leads to their interruption (i.e., thoughts and behaviors), cognitive restructuring of interfering thoughts, and homework assignments to address dysfunctional behaviors and increase exposure to optimal experiences. Participants will become aware of their functioning based on six different dimensions of psychological well-being (i.e., self-acceptance, positive relations with others, autonomy, environmental mastery, purpose in life, and personal growth), and will be guided in finding a balance within each dimension.
224138179|NCT04316663|BEHAVIORAL|Sleep Hygiene|The main aim of sleep hygiene education is to provide participants with a set of behavioral and environmental recommendations intended to promote healthy sleep. During the intervention, participants will become aware of their own sleep patterns, will learn about healthy sleep habits, and will be encouraged to follow a set of recommendations to improve their sleep. Key components of the intervention are sleep hygiene and education.
223424392|NCT04074681|BEHAVIORAL|Gambling Internet-based Protocol|Gambling Internet-based protocol is a multimedia interactive and self-help program for problem and pathological gamblers, which will allow individuals to learn and practice adaptive ways to cope with this problem. The main therapeutic modules included in this program are: 1) Motivational for change; 2) Psychoeducation; 3) Stimulus control (e.g. self-prohibition and blocking of usual gambling websites with therapist confirmation) and responsible return of debts; 4) Cognitive restructuring; 5) Emotion regulation; 6) Planning of significant activities; 7) Coping skills and exposure with response prevention; 8) Relapse prevention.
223424393|NCT02646540|DRUG|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
223424394|NCT02646540|DRUG|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
223424395|NCT02646540|DRUG|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
224037046|NCT07187804|DRUG|Intravitreal faricimab injection|"* Initial loading injections : every 4 weeks by 12weeks~* Treat and extend injection(\~76 week) : Week 20 - Week 76~TAE is initiated with a minimum injection interval of 8 weeks. If no recurrence is observed, the interval is extended by 2 weeks at a time, up to a maximum of 16 weeks. In the event of recurrence, the injection interval is reduced to 8 weeks, regardless of the previous schedule. The minimum injection interval remains 8 weeks."
224037047|NCT07188688|DEVICE|Musculoskeletal Ultrasound Device|Musculoskeletal Ultrasound assessment by LOGIQ P10 from General Electric (GE) Healthcare, each patient will be evaluated by grey scale, power doppler MSUS and Shear Wave Elastography (SWE)
223424396|NCT00058929|DRUG|treprostinil sodium|
223424397|NCT03992027|BEHAVIORAL|CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis|CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
223424398|NCT03992027|BEHAVIORAL|Waitlist Control|Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
224037048|NCT07188701|BEHAVIORAL|Telerehabilitation Exercise Program|"1. Telerehabilitation Exercise Program~   Intervention Description:~   A 6-week structured telerehabilitation exercise program delivered via Zoom under the supervision of a physiotherapist. Sessions were conducted 4 days per week, approximately 20-30 minutes each. Exercises focused on posture correction, cervical stabilization, mobility, and pain management strategies.~2. Home Exercise Program~Intervention Description:~A 6-week home exercise program for chronic non-specific neck pain. Exercises were demonstrated once weekly via Zoom by a physiotherapist, and participants performed them independently at home on the remaining days. Each session lasted 20-30 minutes and included stretching, strengthening, and posture training."
224037049|NCT07188350|OTHER|Conventional Physical Therapy|Individualized physical therapy including progressive mobility (e.g., bed exercises, sitting on the edge of the bed, standing, transfers, and ambulation) and respiratory therapy tailored to the patient's clinical condition. Delivered daily by trained professionals.
224037050|NCT07188350|DEVICE|Neuromuscular Electrical Stimulation (NMES)|NMES will be applied to both lower limbs once or twice daily for 20 consecutive days. Electrodes will be positioned on the vastus lateralis, vastus medialis, tibialis anterior, hamstrings, and gastrocnemius muscles. The stimulation protocol includes progressive parameters to induce visible and effective muscle contractions.
224037051|NCT07189026|DIAGNOSTIC_TEST|Airway opening pressure|Airway opening pressure will be measured within one hour of intensive care unit admission (using a standardized low-flow insufflation maneuver flow 5-6 LPM). The inflection point on the pressure-time or pressure-volume waveform- depending on ventilator model-will define the airway opening pressure.
224037052|NCT07187895|DRUG|XTR004|"At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi."
224138180|NCT03082495|BEHAVIORAL|Exercise|Supervised high-intensity interval training (HIIT) during NACRT followed by unsupervised moderate-to-vigorous intensity continuous exercise training after the completion of NACRT and before surgery
223424399|NCT03002948|OTHER|Orgasm|"clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score"
223424400|NCT00751504|DRUG|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
223424401|NCT02686463|PROCEDURE|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
223424402|NCT02686463|PROCEDURE|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
223424403|NCT03998384|PROCEDURE|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
224138181|NCT04614116|OTHER|External cooling|water-circulating cooling/warming sleeves connected to a medical cooling device (Hilotherm Clinic®, Hilotherm GmbH, Germany) will be placed around the subject's abdomen and lower back. Initially the temperature of the water will be set to 25°C. A mild cold stimulus will be applied by reducing the temperature of the circulating water by approximately 1°C every 2 minutes to a minimum of 10°C.
223424404|NCT03998384|PROCEDURE|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
223424405|NCT01829100|BEHAVIORAL|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
223424406|NCT03792100|DRUG|SmofKabiven emulsion for infusion|Total Parenteral Nutrition
223424407|NCT03792100|DRUG|"Hospital compounded All in one emulsion"|Total Parenteral Nutrition
223424408|NCT02270047|DIETARY_SUPPLEMENT|Orange nectar|Orange nectar
223424409|NCT02270047|DIETARY_SUPPLEMENT|Orange Nectar with fibre|
223424410|NCT01017133|RADIATION|fludeoxyglucose F 18|Given IV
223424411|NCT01017133|RADIATION|Fluorine F 18 EF5|Given IV
223424412|NCT01017133|PROCEDURE|Positron emission tomography|Undergo scan
223424413|NCT02841280|DRUG|Chlorthalidone|This is a forced-titration study and the study drug will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
223424414|NCT02841280|DRUG|Placebo|This is a forced-titration study and placebo will be increased if goal BP is not achieved.
223424415|NCT02246179|DEVICE|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
223424416|NCT02246179|DRUG|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
223424417|NCT02246179|DRUG|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
223424418|NCT00077142|DRUG|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
223424419|NCT05322889|DRUG|Telmisartan tablets|12 weeks treatment
223424420|NCT02027987|DRUG|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
223424421|NCT01357070|DIETARY_SUPPLEMENT|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
223424422|NCT01357070|DIETARY_SUPPLEMENT|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
224037053|NCT07189325|DRUG|Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons)|"Patients randomized in the experimental group will be treated with platform therapies (Dimethyl Fumarate, Diroximel Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) according to treatments' authorization from the day of randomization to M36 described below.~Patients will receive appropriate information and recommendation for the initiation of the chosen platform treatment as mention in the SmPC by treating neurologist or a member of the investigating team. If therapies are not tolerated, a therapeutic switch to other platform therapies will be possible. Any switch to a disease modifying therapy not listed as platform therapy will be considered as a major protocol deviation (see statistics).~Patients are allowed to switch from any platform DMT to another platform DMT."
223424423|NCT00323570|DRUG|activated recombinant human factor VII|
223424424|NCT06452849|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
223424425|NCT05277051|DRUG|GSK4381562|GSK4381562 will be administered.
223424426|NCT05277051|DRUG|Dostarlimab|Dostarlimab will be administered.
223424427|NCT05277051|DRUG|Belrestotug|Belrestotug will be administered.
223424428|NCT05277051|DRUG|Nelistotug|Nelistotug will be administered.
223424429|NCT05277051|DRUG|GSK5764227|GSK5764227 will be administered.
223424430|NCT03448731|DRUG|Doxycycline 50Mg Tablet|Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
223424431|NCT04350437|DRUG|induction of labor|Giving drugs to facilitate uterine contractions and fasten the process of delivery
223424432|NCT02026791|DEVICE|I-gel|"* The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted."
223424433|NCT02026791|DEVICE|Supreme-LMA|"* The patient was monitored at 1-5 minute intervals.~* While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~* After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~* Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted."
223424434|NCT06665360|OTHER|The high speed bur was used to mill the cancellous cortical bone of the lamina|The high speed bur was used to mill the cancellous cortical bone of the lamina
223424435|NCT06242392|GENETIC|homologous recombination deficiency|Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
223424436|NCT02298062|DRUG|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
224037054|NCT07189325|DRUG|Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab)|"Patients randomized in the control group will be treated every 6 months (or at previous extended interval dosing) for patients with anti-CD20 (Ocrelizumab, Rituximab) or every 4 weeks for patients with subcutaneous anti-CD20 (Ofatumumab) from the day of randomization to M36. If therapies are not tolerated, a therapeutic switch to other anti-CD20 therapy will be possible. Any switch to a disease modifying therapy not listed as anti-CD20 therapy will be considered as major protocol deviation (see statistics).~Patients are allowed to switch from any anti-CD20 to another anti-CD20."
224037055|NCT07188168|DEVICE|Miller mobility measurement|Tooth mobility at different levels of mobility was assessed using Miller, Periotest and Osstell, and was evaluated both subjectively and objectively.
224037056|NCT07188376|DEVICE|Intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation (iTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each iTBS session includes 600 pulses delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), in 2 sec on / 8 sec off cycles at 110% resting motor threshold (RMT). Stimulation is ramp-up from 80% to 110% RMT (\~90 pulses). Two iTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
224037057|NCT07188376|DEVICE|Continuous Theta Burst Stimulation|Continuous Theta Burst Stimulation (cTBS) is then delivered to the left DLPFC using a MagVenture TMS device. Each cTBS session includes 2 bouts of 1800 pulses separated by a 1 minute rest period. Each bout is delivered in 3-pulse bursts at 50 Hz, every 200 ms (5 Hz), continuously for \~120 seconds at 110% resting motor threshold (RMT). Stimulation is ramped up from 80% to 110% RMT over the first 30 seconds. Two cTBS sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
224037058|NCT07188376|DEVICE|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation (TMS) is delivered to the left DLPFC using the sham side of a MagVenture TMS coil, paired with synchronized scalp electrodes to mimic the sensation of real TMS. The sham procedure matches the timing and auditory cues of either iTBS or cTBS protocols, depending on random assignment. Two sham stimulation sessions are given per visit, separated by 30 minutes. The second session is timed to correspond to the peak BAC.
224138182|NCT04614116|DIAGNOSTIC_TEST|FDG PET/CT|o 75 MBq 18F-FDG will be injected through the intravenous line on the scanner manually (bolus injection) with a simultaneous start of dynamic FDG-PET/CT scan for 45 minutes and a partial body scan from head to the abdomen after 45 minutes. Total scan time 60 minutes.
224037059|NCT07187323|OTHER|Saliva sampling|Unstimulated, whole saliva was collected from all participants across the six study groups following a detailed explanation of the procedure. Initially, individuals were asked to rinse their mouths with filtered water and remain seated in a relaxed position for five minutes. Then, they were instructed to passively drool into a sterile collection tube over a 10-minute period.31 The collected saliva samples were then centrifuged at 3000 ×g for 10 minutes to remove debris and prepare them for storage at -80°C .
224037060|NCT07187323|OTHER|Amino Acid Analysis|Saliva samples were deproteinized by mixing with 6% sulfosalicylic acid in a 1:1 ratio, followed by incubation at room temperature for 5 minutes. The mixtures were then centrifuged at 15,000 rpm for 5 minutes. A 10 µL aliquot of the resulting supernatant was diluted with 800 µL of 2 mM tridecafluoroheptanoic acid containing 0.375 M glucosaminic acid and internal standards. The prepared solutions were transferred into autosampler vials for analysis. Calibration standards were generated by combining known concentrations of amino acid standards.
223424437|NCT02298062|DRUG|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
223563762|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
224037061|NCT07188545|DRUG|Intervention|"GLP-1RA and/or SGLT2i adult users with ≥1 prescription for the intervention GLP-1RA or SGLT2i medications (including combination drugs or mixed therapies with comparator medications).~GLP-1RAs include: Exenatide, Liraglutide, Semaglutide, Dulaglutide, Lixisenatide, Albiglutide, Tirzepatide.~SGLT2is include: Canagliflozin, Dapagliflozin, Bexagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin."
224037062|NCT07188545|DRUG|Active Comparator|"DPP4i or Oral Obesity Agent adult users with ≥1 prescription for the comparator DPP4i or Oral Obesity Agent medications AND no intervention GLP-1RA or SGLT2i prescriptions in first 30 days of follow up.~DPP4is include: Alogliptin, Saxagliptin, Linagliptin, Sitagliptin.~Oral Obesity Agents include: Orlistat, Naltrexone-bupropion, Phentermine-topiramate, Phentermine, Diethylpropion, Bupropion (off-label), Topiramate (off-label)"
224138183|NCT04614116|DIAGNOSTIC_TEST|13C-Glucose injection|0.5 g 13C-Glucose i.v. infusion over 5 minutes, after termination of FDG injection
224138184|NCT06692569|OTHER|Conventional Physical Therapy|The conventional Physical Therapy, the treatment will be based on the client's capabilities. It included functional reeducation, muscle strengthening and stretching, muscle tone regulation methods, and training for activities of daily living
223424438|NCT06663540|OTHER|Exercise & Abacus|"Features two main interventions: physical exercise sessions and abacus training activities.~Physical Exercise Sessions aim to enhance fitness and cognitive function through activities like aerobic exercises and team sports. Research indicates that regular physical activity can improve memory, attention, and problem-solving skills essential for academic success.~Abacus Training Activities focus on developing mathematical skills and cognitive abilities. Children learn to manipulate the abacus for calculations, which enhances numerical understanding and memory retention, positively impacting academic performance.~The program's innovative dual approach suggests that integrating physical and cognitive training can lead to greater improvements in academic performance and emotional resilience than either intervention alone."
224037063|NCT07187622|OTHER|examine the impact of education|The mothers in the study group were given education about neonatal jaundice and were trained to increase the mothers' knowledge level and to prevent neonatal jaundice.
224037064|NCT07188766|DRUG|Sodium Chloride (NaCl) 0.9 %|Keep vein open rate
223424439|NCT02727777|DRUG|TAK228|Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
223424440|NCT02727777|OTHER|Blood Sugar Testing|Participant given a glucometer to check pre-dose blood sugar levels at home every day.
223424441|NCT00957268|DRUG|Alogliptin|Alogliptin tablets
223424442|NCT05152966|DEVICE|Ablation|Ablation using the FARAPULSE™ Cardiac Ablation System Plus
223424443|NCT01738503|DRUG|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
223424444|NCT01738503|DRUG|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
223424445|NCT00005944|DRUG|chemotherapy|
223424446|NCT00005944|DRUG|fluorouracil|
223424447|NCT00005944|DRUG|leucovorin calcium|
223563763|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative delta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223563764|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223563765|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative theta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
224037065|NCT07188766|DRUG|Sodium Chloride (NaCl) 0.9 %|IV bolus of 20 mL/kg of normal saline over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements
224037066|NCT07179627|DEVICE|Ankle exoskeleton|The ankle exoskeleton provides bilateral torque assistance at the ankle joints during common functional tasks such as level-ground walking, stair and ramp ascent, and other daily activities, thereby reducing the mechanical workload and supporting more effective community ambulation. In particular, the device is designed to address drop-foot on the paretic side by delivering bidirectional assistance, which helps improve toe clearance during swing as well as push-off during stance. As a wearable assistive device, assistance is applied only while the device is worn.
224037067|NCT07179627|OTHER|Baseline (no ankle exoskeleton)|The intervention will serve as a baseline where participants will be asked to perform the tasks without wearing an ankle exoskeleton.
223424448|NCT00005944|DRUG|mitomycin C|
223424449|NCT00005944|PROCEDURE|conventional surgery|
223424450|NCT00005944|PROCEDURE|laparoscopic surgery|
223424451|NCT05052372|DRUG|Balversa|BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery
223424452|NCT02787421|DEVICE|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
223424453|NCT03925038|BEHAVIORAL|Augmented Care: Electronic Media Dashboard|A participant-specific dashboard that highlights patterns of patient electronic communication usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
223424454|NCT03925038|BEHAVIORAL|Treatment as Usual|Participants will receive psychotherapy as treatment as usual.
223424455|NCT06685354|DRUG|hepatic arterial infusion of recombinant human type 5 adenovirus|Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101). The H101 treatment regimen consists of 3 cycles or until a specific treatment discontinuation event occurs as outlined in the protocol. The H101 administration method is as follows: if the sum of the largest diameters of lesions is ≤10 cm, the total dose is 1.0×10\^12 vp (2 vials); if the sum of the largest diameters is \&gt;10 cm, the total dose is 1.5×10\^12 vp (3 vials). Treatment cycles are every 3 weeks.
223424456|NCT03732352|OTHER|Fludeoxyglucose F-18|Given IV
223424457|NCT03732352|DRUG|Osimertinib|Given PO
223424458|NCT03732352|PROCEDURE|Positron Emission Tomography|Undergo fludeoxyglucose F-18 PET scan
224037068|NCT07188129|DEVICE|Test Algorithm and Test Device|Test Algorithm analysis of 24-hour ECG Data collected with a Test Device
224037069|NCT07187557|OTHER|A self-compassion based birth preparation program|A self-compassion based birth preparation program
224037070|NCT07187427|PROCEDURE|Spinal analgesia|"All procedures performed will be standardized. When neuraxial analgesia is required, an non-implicated anesthesiologist will performe the technique (not blind) The procedure will involve two steps. The first will involve an intraspinal injection of the solution using a 25-gauge Whitacre needle, while the second will be administered through the epidural catheter.~STEP 1: Intraspinal SPINAL Group: Bupivacaine 0.25% Isobaric 1 ml + Fentanyl 15 mcg, (0,3ml)~STEP 2: Epidural SPINAL group: 0.9% NaCl 2 ml."
224037071|NCT07187427|PROCEDURE|Epidural Analgesia|"All procedures performed will be standardized. When neuraxial analgesia is required, an non-implicated anesthesiologist will performe the technique (not blind) The procedure will involve two steps. The first will involve an intraspinal injection of the solution using a 25-gauge Whitacre needle, while the second will be administered through the epidural catheter.~STEP 1: Intraspinal EPI Group: Bupivacaine 0.25% Isobaric 1 ml + NaCl 0.9% 0.3 ml~STEP 2: Epidural EPI group: Fentanyl 100 mcg, (2 ml of a concentration of 50 mcg/ml)"
224037072|NCT07187869|DRUG|Cabozantinib|Given by IV
224037073|NCT07187869|DRUG|Nivolumab|Given by IV
224037074|NCT04286516|DEVICE|Transcranial Magnetic Stimulation|Paired pulse transcranial magnetic stimulation
224037075|NCT02413840|BEHAVIORAL|Baduanjin qigong|
224037076|NCT05400590|PROCEDURE|Peripheral venous blood sample|2.5% of body weight
224037077|NCT05400590|PROCEDURE|Conjunctival impression|Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
224037078|NCT03620890|DRUG|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
224037079|NCT03620890|DRUG|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
224037080|NCT05976087|DEVICE|SensoExo|combination of sensory feedback and the use of soft exoskeleton
223424459|NCT01794182|DRUG|Glyburide for Injection|Administered as specified in the treatment arm.
223424460|NCT01794182|DRUG|Placebo|Administered as specified in the treatment arm.
223424461|NCT03005327|DRUG|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
224037081|NCT04358263|DEVICE|Continuous Glucose Monitoring Guardian Connect Mobile system (real-time continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
224037082|NCT04358263|DEVICE|Continuous Glucose Monitoring FreeStyle Libre Flash system (intermittently-scanned continuous glucose monitoring)|rtCGM and isCGM are used in Type 1 diabetic patients to improve glucose control and to minimize or avoid severe hypoglycaemia.
224299024|NCT03249974|DEVICE|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
223424462|NCT01340027|DRUG|Mirabegron|oral
223424463|NCT01340027|DRUG|Solifenacin succinate|oral
223424464|NCT01340027|DRUG|Placebo|oral
223424465|NCT01987739|DRUG|200 mg almorexant|
223424466|NCT01987739|DRUG|400 mg almorexant|
223424467|NCT01987739|DRUG|1000 mg almorexant|
223424468|NCT01987739|DRUG|20 mg zolpidem|
223424469|NCT01987739|DRUG|40 mg zolpidem|
223424470|NCT01987739|DRUG|placebo|
223424471|NCT04683692|DEVICE|Magnetic Resonance Imaging (MRI)|Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
223424472|NCT04683692|OTHER|Laboratory Testing|Laboratory blood testing to include high sensitivity CRP (hs-CRP), interleukin-6 (IL-6), NT-proBNP and high sensitivity troponin prior to and post-ablation
224037083|NCT02537418|DRUG|durvalumab|
224037084|NCT02537418|DRUG|tremelimumab|
224037085|NCT06018844|OTHER|NUDGE|NUDGE is a brief mHealth text messaging intervention designed to promote activity in adolescents by allowing them to set, monitor, and receive feedback on daily PA goals through text message.
224037086|NCT05163210|BEHAVIORAL|AO+VR|The experimental treatment will consist of 15 hours (min. 15, max. 20), and will be carried out 4 days/week for a total duration of 5 weeks. During the rehabilitation sessions, the patient will be instructed to carefully watch videos lasting about 1.5 minutes, presented on Liquid Crystal Display (LCD) monitor, consisting in unimanual or bimanual actions performed by an actor, from a lateral perspective. Subsequently, the patient will be asked to imitate the actions presented for at least 3 consecutive times, within a time window of 3 min., using the same objects observed in the video, in a virtual scenario (VR), through the Khymeia Virtual Reality Rehabilitation System (VRRS).
224299025|NCT01006226|DRUG|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
224299026|NCT03572166|DIAGNOSTIC_TEST|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
223424473|NCT01377740|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
223424474|NCT06411730|DRUG|BMS-986368|Specified dose on specified days
223424475|NCT00335569|DRUG|hCG-IBSA|
223424476|NCT03359668|DIAGNOSTIC_TEST|Use of IV contrast during head and neck CT|Use of IV contrast during head and neck CT
223424477|NCT05076669|OTHER|stoma follow-up|delivery and enhanced follow-up by the FSK HHN provided, in particular, by stomal therapy nurse consultants and patient-relation experts during in-person or remote appointments in addition to the routine care delivered and prescribed by the sites
223424478|NCT05076669|OTHER|standard of care|routine management of stoma
223424479|NCT04523272|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223424480|NCT04523272|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
223424481|NCT04523272|DRUG|Sunitinib|A multi-target receptor tyrosine kinase inhibitor.
223424482|NCT04687072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection with efgartigimod PH20 SC
223424483|NCT04687072|OTHER|Placebo PH20 SC|Subcutaneous injection with placebo PH20 SC
223424484|NCT06257927|BEHAVIORAL|Tuko Pamoja|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
223424485|NCT06003374|DEVICE|Ultrasound|"At international protocol U/S examination is performed from an anterior approach, with the transducer in a sagittal plane parallel to the femoral neck. The patients are positioned supine with the hips in neutral position. Also a coronal view is performed from the lateral approach. Establish a new protocol in the MSK unit to perform hip US,~* adductor view: flexion, abduction and lateral rotation of the hip joint with viewing the hip via adductor muscle group.~* gluteal view: posterior approach of the hip joint via gluteal region with the patient lying on the contralateral examined hip.~Psoas and thigh views: US examination of psoas and quadriceps muscles to exclude the presence of absecess .~-finally US guided aspiration under complete a septic condition."
223424486|NCT05933174|OTHER|Prompt-sheet|Simple prompt sheet with which participants will encouraged to use to guide a conversation with their provider at their next visit for routine diabetes care. These questions are based on recommendations from the Agency for Healthcare Research and Quality's Question Builder App and also on recommendations from the Canadian Deprescribing Network which specifically addresses SU use.
223424487|NCT05933174|OTHER|Usual education|Control group patients will be sent an information brochure with content from the NIDDK about diabetes medications (https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments).
223424488|NCT00915876|DRUG|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
223424489|NCT00915876|DRUG|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
223424490|NCT06665529|OTHER|28-day mortality prediction by ICU staff and mortality scores|28-day mortality prediction by ICU staff (three senior physicians and ICU nurse) and mortality scores (APACHE 2, MPM 2 and MODS).
223424491|NCT06682260|DRUG|Nitroglycerin (NTG)|Infusion of intravenous nitroglycerin beginning at 2 microgram/kg/min (2 ml/hour) and titrated with the aim of a MAP reduction of 20-30%. Infusion rate will not be increased after the first 30 minutes and is limited to 0.1 µg/kg/min to 5 µg/kg/min.
223424492|NCT04619329|DEVICE|GSMs-TACE|TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm)
223424493|NCT04619329|PROCEDURE|Surgical Resection|Surgical Resection of HCC
223424494|NCT01883180|DRUG|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
223424495|NCT02782065|OTHER|Not an interventional study|
223424496|NCT02130089|BEHAVIORAL|Intensive Tailored Education|
223424497|NCT01662791|DRUG|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
223424498|NCT05303298|DEVICE|Anti-reflux oesophageal stent|Fully covered self-expanding metal stent with anti-reflux mechanism
223563766|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223563767|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative slow alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223424499|NCT05303298|DEVICE|Conventional oesophageal stent|Fully covered self-expanding metal stent without an anti-reflux mechanism
223424500|NCT02074098|DEVICE|Macintosh laryngoscope|Direct Laryngoscope
224299027|NCT03572166|DIAGNOSTIC_TEST|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
223424501|NCT02074098|DEVICE|Glidescope|Videolaryngoscope-1
223424502|NCT02074098|DEVICE|Airwayscope|Videolaryngoscope-2
223424503|NCT02807298|DRUG|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
223424504|NCT02807298|DRUG|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
223424505|NCT02807298|DRUG|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
223424506|NCT00037947|PROCEDURE|Hearing in Multiple Sclerosis|
223424507|NCT02572076|DEVICE|Motus Cleansing System|
223424508|NCT03008265|OTHER|Postoperative fascial dehiscence|
223424509|NCT05016401|DEVICE|KONTACT PERIO LEVEL (KPL)|The Kontact™ Perio Level is an implant with a transgingival neck that facilitates one-step surgery.
223424510|NCT02591901|DRUG|Uro vaxom|Prevention of recurrent symptomatic lower urinary tract infections
223424511|NCT02591901|OTHER|Placebo comparator|Placebo comparator
223424512|NCT01068067|OTHER|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
223563768|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223563769|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative fast alpha power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223563770|NCT04467658|DIAGNOSTIC_TEST|electroencephalography absolute beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
224037087|NCT05163210|BEHAVIORAL|CO+VR|Patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist. Thus, the general setting for carrying out the rehabilitation sessions will be identical to that of the experimental treatment, except for the fact that the control group will not be involved in action observation before preforming the exercises. Thus, the control treatment is not based on action imitation, but on purely motor execution.
224037088|NCT05818436|PROCEDURE|Procedure: prosthetic functioning|Prosthetic reline and occlusal stabilization through repair of missing pieces and recovery of occlusal contacts
224037089|NCT05818436|DEVICE|Conventional dental prosthesis|: conventional prosthetic treatment new prosthesis
224037090|NCT03633747|DRUG|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
224037091|NCT06957756|DRUG|BI 1584862|BI 1584862
224037092|NCT06457997|DRUG|PHN-010|PHN-010 is an ADC
224037093|NCT05995964|DRUG|PF-07275315|subcutaneous injection
224037094|NCT05995964|DRUG|PF-07264660|subcutaneous injection
224037095|NCT05995964|OTHER|Placebo|subcutaneous injection
224037096|NCT03769181|DRUG|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224037097|NCT03769181|DRUG|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
224037098|NCT02087748|DRUG|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
224037099|NCT02087748|DRUG|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
224037100|NCT01674751|OTHER|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
224138185|NCT06692569|OTHER|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy (mCIMT) which involves trunk constraint along with conventional Physical Therapy treatment. Under the attentive guidance of a physiotherapist, the patient engages in specific hand activities aligned with personalized goals. These activities encompass tasks such as picking up marbles, flipping cards, stacking blocks, combing hair, writing, and other actions relevant to daily life. The difficulty level is dynamically adjusted according to the patient's abilities and progress during the training sessions.Tasks may vary from one patient to another, and each session introduces fresh, goal-oriented challenges to further enhance rehabilitation outcomes, along with the conventional physical therapy treatment. The patients were wearing a trunk west which had a Velcro strap on the non-effected side part of the west, and it was attached to the Velcro straps on the non-affected part on the back support of the treatment chair.
223424513|NCT01068067|DRUG|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
223424514|NCT06078267|DEVICE|CardioPumlonary Management System (CPM)|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
223424515|NCT00883467|PROCEDURE|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
223424516|NCT00883467|PROCEDURE|no preconditioning|no preconditioning
223424517|NCT04525768|DIAGNOSTIC_TEST|JAK2 mutation test|Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
223424518|NCT04287946|DEVICE|Ablation|Ablation of a single-side of the greater splanchnic nerve
223563771|NCT04467658|DIAGNOSTIC_TEST|electroencephalography relative beta power|We used MATLAB 7.0.1 (Math Works, Natick, MA, USA) and the EEGLAB toolbox to pre-process and analyze the EEG recordings. First, the EEG data were down-sampled to 250 Hz. Next, the EEG data were detrended and mean-subtracted to remove the DC component. A 1-Hz high-pass filter and a 60-Hz notch filter were applied to remove eye and electrical noise. Next, independent component analysis (ICA) was performed to remove the well-defined sources of artifacts. ICA has been shown to reliably isolate artifacts caused by eye and muscle movements and heart noise (23). Finally, clinical psychiatrists and EEG experts visually inspected the corrected EEGs. For the analysis, we selected more than two minutes of artifact-free EEG readings from the three-minute recordings
223563772|NCT04467658|DIAGNOSTIC_TEST|Korean ADHD rating scale|The KARS is a standardized screening tool for ADHD in Korean children and rating scale completed by the parents.
223563773|NCT04467658|DIAGNOSTIC_TEST|Korean Version of Diagnostic Interview Schedule for Children Version IV|The DISC-IV is a structured diagnostic tool that was developed for use in epidemiological studies in children and adolescents
223739976|NCT04415944|DRUG|HIPEC with Carboplatin|"Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~* Extraperitoneal disease noted at the time of the second look procedure~* Macroscopic intraperitoneal disease which is not resectable to R1~* Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~* Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research."
224037101|NCT06493981|DRUG|Eltrombopag|Treatment with eltrombopag in a dose of (50-150mg/d)
224037102|NCT05640466|DEVICE|Reduction and fixation of metatarsal neck fracture by metaizeau's technique|Reduction and fixation of metatarsal neck fracture by metaizeau's technique
224037103|NCT04260451|OTHER|ventilation|"Driving Pressure Limited Ventilation~Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 10 to 2 cmH2O during one-lung ventilation.~1\. Lung recruitment: stepwise increase of positive end expiratory pressure 5,10,15 cmH2O with tidal volume 5mL/kg, inspiratory:expiratory 1:1, respiratory rate 10. and driving pressure up to 20 cmH2O. Then decremental PEEP titration is performed using a volume-controlled ventilation until the lowest driving pressure (plateau pressure minus PEEP) is found. This individualized PEEP is adjusted during one-lung ventilation."
224037104|NCT01508546|PROCEDURE|axillary dissection|Conservative breast surgery with or without axillary dissection
224037105|NCT01611064|DRUG|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
224037106|NCT01611064|DRUG|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
224037107|NCT00444392|BEHAVIORAL|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
224037108|NCT06198751|DRUG|6.0 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.
224138186|NCT06693323|DRUG|AHCC®capsules|Given PO
224138187|NCT06339333|BEHAVIORAL|ACT Now GAIN Later|ACT Now GAIN Later is a Psychologist Guided Self Help Parenting Programme. This has been developed by HSE Senior psychologist,. Dr. Michelle Howard to help parents manage challenging behaviors in their children. Parents of children who are referred to HSE Psychology Services with behavioural difficulties are invited to participate in this 7 week programme.
224138188|NCT06339333|OTHER|Control Group|Waitlist Group
224138189|NCT06467604|BEHAVIORAL|Surveys|Participants will be provided electronic surveys at 3 timepoints throughout study.
223424519|NCT04778943|OTHER|Surgery(OLIF and MIS-TLIF)|oblique lateral interbody fusion (OLIF); minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF)
223424520|NCT01280032|RADIATION|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
223563774|NCT00590174|DRUG|Aspirin|stopping clopidogrel at 1 year after DES implantation
223563775|NCT00590174|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
223563776|NCT03462017|DRUG|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
223563777|NCT03462017|DRUG|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
224037109|NCT06198751|DRUG|7.5 mg/kg of TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.
224037110|NCT03078907|DRUG|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
224037111|NCT03078907|DRUG|Placebo|Matching film coated tablets
224138190|NCT06467604|OTHER|Indirect Calorimetry|Participants will receive indirect calorimetry at 3 time points throughout the study.
224138191|NCT06467604|OTHER|Body composition|Participants will receive body scans using bioelectrical impedence seca mBCA 554 digital body composition analysis scale 3 time points throughout the study.
224138192|NCT06467604|OTHER|Anthropometrics|Participants will have their Height, weight, waist circumference, and calculated BMI performed at 3 time points throughout the study.
224138193|NCT01883323|DRUG|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
224138194|NCT01883323|DRUG|Fludarabine|i.v., 25mg/m2 per day for 5 days
224138195|NCT01883323|BIOLOGICAL|Tumor-Infiltrating Lymphocytes|i.v., 1x10\^10 - 1.6x10\^11 cells
224138196|NCT01883323|BIOLOGICAL|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
223424521|NCT06249737|BEHAVIORAL|Training|Each participan will train the kinematic control of each degree of freedom, according to each arm, playing a videogame using an inertial sensor.
223424522|NCT04304482|DRUG|ANAVEX2-73 oral liquid|Liquid oral solution
223424523|NCT04304482|DRUG|Placebo oral liquid|Liquid oral solution
223424524|NCT02714088|OTHER|Novel high-intensity interval training|
223424525|NCT02648854|DRUG|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
224037112|NCT05193240|DIAGNOSTIC_TEST|preliminary swallowing test|"Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research."
223424526|NCT02648854|DRUG|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
223424527|NCT02663102|OTHER|Data collection|Safety monitoring and evaluation: - Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. - Recording of SAEs throughout the study period for each subject.
223424528|NCT01443338|DRUG|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
223424529|NCT01443338|DRUG|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
223424530|NCT00533702|BIOLOGICAL|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
223424531|NCT00533702|DRUG|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
223563778|NCT03462017|DRUG|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
223424532|NCT00811902|DRUG|Nerispirdine|tablet, oral administration
223424533|NCT00811902|DRUG|placebo|tablet, oral administration
223563779|NCT03462017|DRUG|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
223563780|NCT03267667|DIAGNOSTIC_TEST|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
223563781|NCT03350035|DRUG|IV Ganaxolone active|IV
223563782|NCT03350035|DRUG|IV Placebo, non-active|IV
223563783|NCT02973347|OTHER|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
223563784|NCT02973347|OTHER|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
224037113|NCT03122275|OTHER|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
224037114|NCT03122275|OTHER|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
223424534|NCT03901833|BEHAVIORAL|Telemedicine Support|Telemedicine intervention
224037115|NCT03122275|OTHER|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
224138197|NCT01510808|PROCEDURE|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
224138198|NCT05841602|OTHER|descriptive|This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.
224138199|NCT00440427|DRUG|Desvenlafaxine Sustained Release (DVS SR)|
223424535|NCT03901833|OTHER|Standard of Care|Standard of Care
223563785|NCT01900171|DRUG|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
223563786|NCT01900171|DRUG|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
223424536|NCT06665243|BEHAVIORAL|Technology-enhanced horticultural activities|The indoor technology-enhanced horticultural activities will be delivered to people with dementia and their family caregivers through a smart grower. The smart grower is a hydroponic indoor grower that creates a controllable environment with auto optimization for growing healthy plants, fresh vegetables, herbs, and fruits. A mobile app will be connected to the grower for controlling the growing environment (e.g., lighting, watering), tracking the progress of the plants, and guiding the older people with dementia and their family caregivers in conducting the horticultural activities. The program will consist of eight face-to-face (F-T-F) horticultural activity training sessions for groups of 6-8 participants. The indoor program contains various horticultural, cognitive, and multisensory stimulation activities, such as asking PWD and family caregivers to record the sense of touch and odor when caring for the plants and to observe the various changes in the plants using the smart grower.
223424537|NCT01919684|DRUG|LGD-6972|
223424538|NCT01919684|DRUG|Placebo (Captisol®)|
223424539|NCT05971511|OTHER|Questionnaire|Questionnaire
223563787|NCT00150319|DRUG|Vfend®; I.V.|
223563788|NCT02269176|DRUG|Low dose of telmisartan|
223563789|NCT02269176|DRUG|High dose of telmisartan|
223563790|NCT02269176|DRUG|Low dose of losartan|
223563791|NCT02269176|DRUG|High dose of losartan|
223563792|NCT02606981|DEVICE|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
223563793|NCT02606981|DEVICE|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
223563794|NCT05828394|PROCEDURE|DFGG|Depithelised free gingival graft harvesting technique
223563795|NCT05828394|PROCEDURE|SCTG|Subepithelial connective tissue graft harvesting technique
223563796|NCT02041975|DIETARY_SUPPLEMENT|Nutriose FB06|Wheat dextrin soluble fibre
223424540|NCT04500483|DIAGNOSTIC_TEST|indirect calorimetry|measurement of resting energy expenditure using indirect calorimetry
223424541|NCT03224611|DEVICE|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
223424542|NCT04245540|DIETARY_SUPPLEMENT|Pau d' Arco|Encapsulated herbal Pau d' Arco.
223424543|NCT01746420|DRUG|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
224037116|NCT03122275|OTHER|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
223424544|NCT01746420|DRUG|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
223424545|NCT00517140|PROCEDURE|Repeat Caesaen section|
223424546|NCT00517140|PROCEDURE|vaginal delivery|
223424547|NCT06601569|DIAGNOSTIC_TEST|balance and range of motion|"* Spinal alignment and range of motion measure scale (SAROMM): is a measure of spinal alignment and range of motion using standard physical therapy techniques scored on a 5-point ordinal score of 0 (normal alignment and range with active correction) to4 (severe ﬁxed deformity) (Bartlett ey al., 2005)~* Modified Ashworth scale (MAS): is a measure of muscle motion and scoring the perceived resistance to movement on a scale of 1 (no increase in tone) to 5 (rigid in ﬂexion or extension) (Clopton et al., 2005).~* Early clinical assessment of balance (ECAB) scale: Is a 13-item test that estimates postural stability for children with CP across all levels of functional ability (Jeffries etal., 2016).~* Functional strength assessment scale: Therapists completed a functional strength assessment (FSA) to obtain an estimate of strength for major muscle groups including the neck and trunk ﬂexors and extensors, and hip extensors, knee extensors, and shoulder ﬂexors bilaterally."
223424548|NCT05296044|DRUG|JT-003|Subjects take the investigational products once a day for 24 weeks.
223424549|NCT05296044|DRUG|JT-003 Placebo|Subjects take the investigational products once a day for 24 weeks.
223424550|NCT03743324|PROCEDURE|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
223424551|NCT03743324|PROCEDURE|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
224037117|NCT03122275|OTHER|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm."
224138200|NCT06866314|DIETARY_SUPPLEMENT|Tea infusion VitalPLANT - Active comparator|Consumation of 200 mL of tea infusion (VitalPLANT) in the morning 30 min before breakfast for one week
224138201|NCT06866314|DIETARY_SUPPLEMENT|Tea infusion VitalPLANT + Helichrysum Italicum - Experimental product|Consumation of 200 mL of tea infusion VitalPLANT + Helichrysum Italicum in the morning 30 min before breakfast for one week
224138202|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results available|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
224138203|NCT05299840|DIAGNOSTIC_TEST|Oncogramme results unavailable|in vitro analysis of each patient's tumor cells in order to compare the responses of the tumor cells to the different molecules and therapeutic combinations available
223424552|NCT03743324|RADIATION|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
223424553|NCT02578121|DRUG|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
223424554|NCT02578121|DRUG|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
223424555|NCT02578121|DRUG|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
223424556|NCT04391738|OTHER|Patients admitted to Intensive Care Unit with SARS-CoV2|Patients admitted to Intensive Care Unit with SARS-CoV2
223424557|NCT04311749|GENETIC|Expanded panel cell free DNA testing (non-invasive prenatal testing)|Maternal blood sampling
223424558|NCT04311749|GENETIC|Placental biopsy|Post-delivery placental sampling
223424559|NCT04311749|GENETIC|Umbilical cord blood|Post-delivery umbilical cord blood sampling
223424560|NCT05154500|OTHER|Iron biofortified potato|A non-blinded randomized cross-over design with multiple meal feedings will be used to quantify iron bioavailability from iron biofortified and non-biofortified potatoes. Women volunteers will consume biofortified ('A') and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p\<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p\>0.05). Based on this study design, every woman is her own control.
223563797|NCT02041975|DIETARY_SUPPLEMENT|Placebo|
223563798|NCT02490995|OTHER|Movie|Besides the anesthesist explanations the children will have a movie explanation.
223563799|NCT02872896|PROCEDURE|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
223563800|NCT02192060|OTHER|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
223563801|NCT02192060|OTHER|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
223739977|NCT04415944|OTHER|FACT-O Quality of Life Questionnaire|Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
223424561|NCT05154500|OTHER|Zinc biofortified potato|A crossover study will be used to compare zinc bioavailability of biofortified and non-fortified potatoes. Nutritional pre-screening is not required as there are no major systemic influences on zinc absorption.Volunteers will be randomly assigned to consume first either the biofortified or the non-biofortified potato, and consume the second potato-type 30 days later. Zinc absorption from two meals of biofortified or non-fortified potato will be measured using the double stable isotope technique.
223424562|NCT03587883|OTHER|Cocoa flavanols I|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
223424563|NCT03587883|OTHER|Control I|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
223424564|NCT03587883|OTHER|Cocoa flavanols II|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
223424565|NCT03587883|OTHER|Control II|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
223424566|NCT04285424|BIOLOGICAL|Fecal Microbiota Transplantation|The fecal collection produced from a single healthy donor, unrelated to the patients
223563802|NCT01739686|OTHER|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
223563803|NCT04347213|BEHAVIORAL|Regular lifestyle in different circumstances|Participants' lifestyle will be followed over the years.
223739978|NCT05010122|DRUG|Decitabine and Cedazuridine|Given PO
224037118|NCT06224309|DIAGNOSTIC_TEST|18F-BL40 PET/CT|Vital signs will be recorded prior to the BL40 injection. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the 18F-BL40 from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
224037119|NCT06224309|DIAGNOSTIC_TEST|18F-FDG PET/CT|"The patient will return on another day for the 18F-FDG PET/CT scan. A fasting period of 6 hours is required before this scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
224037120|NCT06224309|DIAGNOSTIC_TEST|Routine Blood Draw - Phase 1 only|Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after 18F-BL40 administration.
224037121|NCT03338192|OTHER|QST|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
224037122|NCT05003713|DRUG|CORT125236|CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
223424567|NCT05663645|BEHAVIORAL|Health insurance educational guide|The educational guide includes 4 content areas: 1) Definition of key insurance terms; 2) premiums, deductibles across the five 2023 health plans; 3) Summary of how premiums and deductibles can affect out of pocket costs; 4) Guide to finding in-network IVF providers and facilities.
223424568|NCT03861299|PROCEDURE|Awake craniotomy|Awake craniotomy
223424569|NCT03861299|PROCEDURE|Craniotomy under general anesthesia|Craniotomy under general anesthesia
223739979|NCT05010122|DRUG|Gilteritinib|Given PO
223424570|NCT06468800|DEVICE|TRACMOTION|Patients already scheduled for ESD will undergo an ESD procedure with the aid of the Tracmotion device
223424571|NCT03008863|OTHER|Education|
223424572|NCT04115995|DIAGNOSTIC_TEST|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
223424573|NCT04693377|PROCEDURE|Cryosurgery|Undergo cryoablation
223424574|NCT04693377|OTHER|Quality-of-Life Assessment|Ancillary studies
223424575|NCT04693377|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
223424576|NCT01740752|BEHAVIORAL|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
223424577|NCT01740752|BEHAVIORAL|CBT|"weekly manualized higher dose of individual CBT"
223739980|NCT05010122|DRUG|Venetoclax|Given PO
223739981|NCT05563948|DRUG|Cannabis|Vaporized cannabis will be administered 3x/day for 15 days.
223739982|NCT02851706|OTHER|No Treatment|Survey or Questionnaire Completion with or without Sample Submission
223739983|NCT07128550|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
223739984|NCT07128550|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
223739985|NCT07128550|DRUG|Bulevirtide|Bulevirtide administered by subcutaneous injection
223739986|NCT05365035|DRUG|Cladribine|Given by Vein (IV)
223739987|NCT05365035|DRUG|Cytarabine|Given under the skin; subcutaneous injection (SQ)
223739988|NCT05365035|DRUG|Venetoclax|Given by PO
223739989|NCT05365035|DRUG|Azacitidine|Given by IV or subcutaneous injection (SQ)
223739990|NCT06655155|COMBINATION_PRODUCT|Efgartigimod PH20 SC|Subcutaneous efgartigimod PH20 SC given by prefilled syringe
223739991|NCT06655155|OTHER|Placebo PH20 SC|Subcutaneous placebo PH20 SC given by prefilled syringe
224037123|NCT05003713|DRUG|Placebo matching CORT125236|Placebo matching CORT125236 Lipid Capsule Formulation 10-60 mg for oral administration
224037124|NCT05003713|DRUG|Prednisone|Prednisone tablet 25 mg (20 mg + 5 mg tablets) for oral administration
224037125|NCT00222573|DRUG|clopidogrel and metoprolol|
224037126|NCT02991508|DRUG|Placebo|
224037127|NCT02991508|DRUG|Adrecizumab|
224037128|NCT00244127|DRUG|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
224037129|NCT03808688|DRUG|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
224037130|NCT00528983|DRUG|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
224037131|NCT00528983|DRUG|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
224037132|NCT00528983|DRUG|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
224037133|NCT03329196|DRUG|MT-6548|Oral tablet
223424578|NCT06059261|DRUG|Envafolimab and recombinant human endostatin combined with chemoradiotherapy|Induction treatment phase: Envafolimab administered by subcutaneous injection on day 1 every 3 weeks at 300 mg for 3 cycles, cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles, gemcitabine was administered by intravenous infusion on days 1 and 8 of each cycle at 1 g/m2 every 3 weeks for 3 cycles, recombinant human endostatin was administered on day 1 every 3 weeks at 210 mg for 3 cycles. Concurrent treatment phase: Cisplatin was administered by intravenous infusion on day 1 of each cycle at 100mg/m2 every 3 weeks for 2 cycles. Adjuvant treatment Phase: Envafolimab was administered on day 1 every 3 weeks at 300 mg for 8 cycles as a subcutaneous injection. Intensity-modulated radiotherapy: 69.96Gy/33fractions/7 weeks,5 fractions/week, 1 fraction/day.
223424579|NCT06253637|DRUG|Daratumumab plus chemotherapy according to the national treatment program|"Daratumumab is a human IgG1қ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein which is expressed in several hematological malignancies including multiple myeloma (MM) and ALL. Daratumumab induces lysis of CD38-expressing tumor cells by several mechanisms. Intravenous daratumumab has been approved first as a single agent and then in combinations in the MM setting and in AL amyloidosis.~The activity of daratumumab in ALL is being explored in the DELPHINUS trial, in which the drug was combined with chemotherapy in pediatric and young adult patients with relapsed/refractory T-cell ALL or lymphoblastic lymphoma (LL).~In the present trial, daratumumab will be administered to adult Very high risk T-lineage ALL weekly in induction and early consolidation (C1-C2), and the first day of each of the following intensive cycles up to C8."
223424580|NCT03467061|DIETARY_SUPPLEMENT|Nitrate-rich beetroot juice|concentrated beetroot juice
223424581|NCT03467061|DIETARY_SUPPLEMENT|Nitrate-depleted beetroot juice|concentrated beetroot juice
223424582|NCT03467061|OTHER|Mouthwash|2 x 10 mL antibacterial mouthwash per day for 14 days
223424583|NCT03014297|DRUG|everolimus|everolimus
223424584|NCT03014297|DRUG|fosbretabulin|fosbretabulin
223424585|NCT03689907|OTHER|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
224037134|NCT03329196|DRUG|Darbepoetin alfa|Subcutaneous
224037135|NCT04401163|DIAGNOSTIC_TEST|Imaging of the lungs|After hospital admissions with COVID19 patients will come for two clinical visits to complete a number of questionnaires, pulmonary function testing, six-minute walk test, blood sampling and imaging of the lungs.
224037136|NCT00627029|BEHAVIORAL|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
224138204|NCT01987388|OTHER|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
223424586|NCT04323618|DEVICE|Breathe Well|
223563804|NCT01610557|DRUG|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
224037137|NCT01509326|OTHER|chiropractic treatment|12 sessions over 4 weeks
224037138|NCT01509326|DEVICE|Dr. Zaxx pillow|Daily use of an acupressure pillow
224037139|NCT03974399|DIETARY_SUPPLEMENT|Bacopa Monnieri|subjects will take Bacopa Monnieri daily for 3 months
224037140|NCT01992120|OTHER|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
224037141|NCT01992120|OTHER|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
224037142|NCT03248583|OTHER|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
224037143|NCT03248583|OTHER|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
224138205|NCT01987388|OTHER|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
224037144|NCT03248583|OTHER|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
224037145|NCT02198625|OTHER|Moderate FiO2 and Protective Lung Ventilation Using|
224037146|NCT01178320|DRUG|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
224037147|NCT01191372|DRUG|placebo control|sterile saline for injection
224037148|NCT01191372|DRUG|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
224037149|NCT04612036|DEVICE|Journey II Bi-Cruciate Stabilized TKA|Total Knee Arthroplasty System
224037150|NCT04612036|DEVICE|Journey II Cruciate Retaining TKA|Total Knee Arthroplasty System
224037151|NCT04612036|DEVICE|Journey II Bi-Cruciate Retaining TKA|Total Knee Arthroplasty System
224037152|NCT01460095|OTHER|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
224037153|NCT02014415|PROCEDURE|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
224037154|NCT04041089|BEHAVIORAL|Recognition of objects|"* Name of shapes / colors / images / objects~* Classification of shapes / colors / images / objects"
224037155|NCT04041089|BEHAVIORAL|Location of objects|"* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~* Hit/catch a stationary/mobile target as quickly as possible"
223563805|NCT01610557|DRUG|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)\* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~\*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
224037156|NCT04041089|BEHAVIORAL|Manipulation of objects|"* Storage of shapes/objects~* Use of everyday objects (pen, cutlery, etc.)"
224037157|NCT00526409|DRUG|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
224037158|NCT00526409|DRUG|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
224037159|NCT00526409|DRUG|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
224037160|NCT00526409|DRUG|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
223563806|NCT05617066|BEHAVIORAL|Cognitive behavioral therapy|With the cognitive behavioral therapy will work on different aspects for coping and tools psychological stress.
224138206|NCT01987388|OTHER|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
224138207|NCT01987388|OTHER|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
224037161|NCT00526409|DRUG|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
224037162|NCT00526409|DRUG|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
224138208|NCT03201952|DRUG|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
224138209|NCT03201952|DRUG|Placebos|Ileostomy administration of 5cc saline placebo once
224138210|NCT00092066|DRUG|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
224138211|NCT03308981|DEVICE|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
224138212|NCT03308981|OTHER|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
224138213|NCT01628250|PROCEDURE|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
224138214|NCT01628250|PROCEDURE|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
224138215|NCT03754283|DEVICE|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
224037163|NCT00526409|DRUG|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
224037164|NCT04091022|DRUG|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months
224138216|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in ODT form|15 mg as 1 x 15 mg orally disintegrating tablet (ODT)
224138217|NCT04511637|DRUG|Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form|15 mg as 1 x 15 mg film-coated tablet
223424587|NCT06366087|DRUG|Atropine Sulfate Ophthalmic Solution USP, 1%|Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.
223424588|NCT06366087|DRUG|Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)|Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
223424589|NCT03474744|DRUG|Copanlisib|Solution for IV infusion
223424590|NCT03474744|DRUG|Rituximab|Solution for IV infusion
223424591|NCT01515462|GENETIC|TLT003|TLT003 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
223424592|NCT06793527|DRUG|Celiac Plexus Block|During general anesthesia, a celiac plexus block will be performed intraoperatively (20 ml of 0.5% ropivacaine). The patient will not feel discomfort due to general anesthesia.
223424593|NCT06793527|DRUG|ESP block|Before the procedure, a block of the erector spinae (ESP) compartment will be performed with approximately 20 ml of 0.25% ropivacaine at the Th4 level. The patient will be informed about the possibility of short-term discomfort if the block is performed before full induction of anesthesia.
223424594|NCT06793527|DRUG|Lidacaine|Instead of a regional block, an intravenous infusion of lidocaine will be used.
223563807|NCT04187794|OTHER|Interview patient|to investigate an association between literacy level and medication adherence in patients with rheumatic diseases.
223563808|NCT01938924|DEVICE|GekoTM|electrical neuromuscular stimulation
223563809|NCT00592228|DEVICE|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~1. FFR group: if FFR\<0.75~2. Routine DES group"
223563810|NCT01023555|OTHER|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
223563811|NCT03729258|DRUG|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
223424595|NCT06248359|DRUG|L-Arginine hydrochloride|Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI
223424596|NCT05810506|OTHER|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.|In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
223424597|NCT00860249|BEHAVIORAL|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
223424598|NCT00860249|BEHAVIORAL|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
223424599|NCT03817957|DRUG|Polyglucoferron|intravenous administration
223424600|NCT03817957|DRUG|Ferric carboxymaltose|intravenous administration
223424601|NCT03817957|DRUG|Ferrous Sulfate|oral administration
223424602|NCT04935801|BIOLOGICAL|LD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
223424603|NCT04935801|BIOLOGICAL|LD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
223563812|NCT03729258|DRUG|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
224138218|NCT01019772|BIOLOGICAL|LBVH0101 (Hib vaccine)|
223563813|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate|Prosciutto/pancetta/Parma ham/salami (all derived from pork) prepared by a commercial butcher with the sodium nitrate and nitrite as an additive.
223563814|NCT05045807|DIETARY_SUPPLEMENT|Meat with added nitrate plus vegetables|"The same intervention as of intervention meat with added nitrate consumed together with mixed vegetables."
223563815|NCT00346450|PROCEDURE|Cultivated conjunctival transplantation|
223739992|NCT06655337|DEVICE|Smartphone Application for Post-Discharge Symptom Monitoring|This intervention involves the use of a smartphone application designed for symptom monitoring. The app enables participants to log daily health data, including symptoms and vital signs, for 7 days following discharge. It provides automated prompts and guidance for self-management, including when to seek medical assistance. The app does not provide direct medical intervention but facilitates remote symptom tracking to reduce readmissions and emergency hospitalizations. Follow-up consultations are conducted at day 7 and day 28.
223739993|NCT05027997|DRUG|Dipraglurant|Oral tablet
223739994|NCT05027997|DRUG|Placebo|Oral matching placebo tablet
224138219|NCT01019772|BIOLOGICAL|Hiberix™ Vaccine|
224138220|NCT00078988|BIOLOGICAL|filgrastim|Given IV
224138221|NCT00078988|DRUG|carboplatin|Given IV
224138222|NCT00078988|DRUG|etoposide|Given IV
224138223|NCT00078988|DRUG|isotretinoin|Given IV
224138224|NCT00078988|DRUG|thiotepa|Given IV
223424604|NCT04935801|BIOLOGICAL|HD vehicle-GNP|Two intradermal injections in the upper arm spaced 21 days apart
223424605|NCT04935801|BIOLOGICAL|HD PepGNP-Dengue|Two intradermal injections in the upper arm spaced 21 days apart
223424606|NCT00432796|DRUG|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
223424607|NCT00432796|OTHER|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"
223424608|NCT03574142|DRUG|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
223424609|NCT04481581|OTHER|Electronic Alerts|When FiO2 remains =\>0.4 and SpO2 =\>94% for more than 45 minutes, an electronic health record based alert will be sent to respiratory therapists to titrate oxygen per decision support tool.
223563816|NCT06475209|DRUG|Adebrelimab combined with Apatinib|Each treatment cycle spans 3 weeks. Sequential medication administration begins on the first day of each cycle: Atezolizumab is administered at a dosage of 1200mg on day 1, every 3 weeks, while Apatinib is given orally at a dosage of 250mg daily from day 1 to day 14, every 3 weeks, with a one-week hiatus following two weeks of continuous intake. Administration timing allows for a window of ±5 days. Subjects are required to undergo comprehensive assessments, including vital signs monitoring, anthropometric measurements, physical examinations, laboratory analyses, and performance status evaluations, to assess treatment tolerability for continuation.
223739995|NCT06368947|BEHAVIORAL|Therapeutic Play|Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
224037165|NCT06781801|OTHER|Intervention|"The intervention group follows a structured flowchart for annual health check-ups, focusing on assessing the cardiometabolic profile, considering sex and ethnicity. This assessment includes tracking changes in cardiometabolic parameters, alongside overall cardiometabolic risk using SCORE2 and if the criteria for metabolic syndrome are met.~Lifestyle habits are evaluated based on health status, illness, and benefits of quitting unhealthy behaviors. Education sessions educate participants and families on the link between psychotic disorders, lifestyle choices, and cardiometabolic health.~Gradual lifestyle changes are tailored to individual needs, addressing stress and cognitive challenges, and follow national health guidelines with personalized advice and motivational tools. Regular follow-ups assess progress, while motivational tools body composition analyzer and QRISK3 enhance engagement. Contact with internal and external resources is based on the assessment and motivational work."
224037166|NCT04337177|DRUG|VAL-413|a flavored preparation of orally administered irinotecan
224037167|NCT04337177|DRUG|Temozolomide|alkylating oral chemotherapy agent used to treatment brain cancers
224037168|NCT04104529|OTHER|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
224037169|NCT04104529|OTHER|tumor collection|Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
224037170|NCT01059136|DRUG|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
224037171|NCT06798454|DRUG|PVT201|"Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor.~PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells.~IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections.~PVT201 will be administered intravenously."
224037172|NCT06798454|OTHER|Placebo|Participants randomized to placebo will be administered normal saline IV.
224037173|NCT04450836|DRUG|Regorafenib then Trifluridine/Tipiracil|"REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle."
224037174|NCT04450836|DRUG|Trifluridine/Tipiracil then Regorafenib|"TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off."
224037175|NCT02703220|OTHER|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
224037176|NCT02703220|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
224138225|NCT00078988|PROCEDURE|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
223739996|NCT06980025|DRUG|162mg Aspirin|"Two 81mg aspirin tablets in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."
223739997|NCT06980025|DRUG|81mg Aspirin|"One 81mg aspirin tablet in an over-encapsulated capsule filled with microcrystalline cellulose.~Study intervention will be packaged into bottles (35 capsules per bottle)."
223739998|NCT05367960|DRUG|Zatolmilast/ BPN14770|25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
223739999|NCT06628622|DRUG|BI 1356225|BI 1356225
223740000|NCT06628622|DRUG|Placebo|Placebo
224037177|NCT02703220|DRUG|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
224037178|NCT05433675|DRUG|Macitentan|Macitentan dispersible and film-coated tablets will be administered orally as per assigned treatment sequence.
224037179|NCT05781152|DRUG|Anti-TNF therapy|Use of anti-TNF therapy for children and adolescents with newly diagnosed Crohn's disease guided by a clinical decision support tool
224037180|NCT05839756|DRUG|budesonide|2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively
224037181|NCT05839756|DRUG|normal saline|5 ml normal saline will be nebulized preoperatively
224037182|NCT02960113|DRUG|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
224037183|NCT02960113|DEVICE|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
224037184|NCT04165590|OTHER|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.
224037185|NCT02090153|DRUG|S-1|40\~60mg bid，d1\~7 q2W
224037186|NCT02090153|DRUG|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
224037187|NCT04202952|DRUG|HEC110114 Tablet|administered orally once daily
224037188|NCT04202952|DRUG|Sofosbuvir Tablet|administered orally once daily
224037189|NCT02513186|DRUG|lenalidomide|Pharmaceutical form: tablet Route of administration: oral
224037190|NCT02513186|DRUG|bortezomib|Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
224037191|NCT02513186|DRUG|cyclophosphamide|Pharmaceutical form: tablet Route of administration: oral
224037192|NCT02513186|DRUG|dexamethasone|Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
224037193|NCT02513186|DRUG|isatuximab SAR650984|Pharmaceutical form: solution for infusion Route of administration: intravenous
224037194|NCT00485160|DRUG|Continuous indomethacin|
223424610|NCT06078748|BEHAVIORAL|EX|"EX involves 2.5hrs of moderate intensity aerobic and resistance exercise per week. EX will be instructed by a clinical exercise physiologist (CEP) or registered kinesiologist (RKIN). The EX session will include a 5min warm-up, 20-30min of moderate intensity aerobic exercise, 20-30min of moderate intensity resistance training, and a 5min cool down. The virtual video session will be pre-recorded, have similar composition, and will be led by the same instructor as the group sessions. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on exercise in order to overcome barriers and increase maintenance of lifestyle changes."
223424611|NCT06078748|BEHAVIORAL|DIET|"DIET involves one session per week of diet education delivered by a Registered Dietitian. The DIET session will be 90 minutes during months 1-4, and 30 minutes in months 5 and 6. DIET was developed by our team, emphasizing foods identified as supporting executive function, memory, and other cognitive abilities. This group will also receive the Adult Strategies Put Into Real World Environments (ASPIRE) goal strategy training, with goals focused on diet in order to overcome barriers and increase maintenance of lifestyle changes."
224037195|NCT00485160|DRUG|ibuprofen|
224037196|NCT04916041|DEVICE|Cataract surgery with bilateral implantation of the same type of intraocular lens|Cataract surgery with bilateral implantation of the same type of intraocular lens
223424612|NCT06078748|BEHAVIORAL|STRETCH|STRETCH sessions will be time/frequency-matched to EX sessions (2.5hrs/week: 1.5hr in virtual group sessions; 1hr virtual video session) to control for social aspects and placebo effects of EX.Each STRETCH session will include a 5min warm-up, 5min of balance exercises, and 50min of stretching. Difficulty will not be progressed. STRETCH sessions will also be led by a CEP/RKIN instructor and video sessions will be pre-recorded by the same instructor.
224037197|NCT03638934|OTHER|Videos about ACP|Three videos about advanced care planning are provided for self-education.
224037198|NCT03638934|OTHER|Brochure about Life-Sustaining Treatment Act|Brochure about Life-Sustaining Treatment Act are provided for self-education.
224037199|NCT02864420|OTHER|Home hospitalization|
224037200|NCT02864420|OTHER|Inpatient Hospitalization|
224037201|NCT02183532|DRUG|BI 1356 BS|single dose
224037202|NCT02183532|DRUG|BI 1356 BS|multiple doses
224037203|NCT03434353|DRUG|Inarigivir Soproxil|Administered orally once daily one hour before or one hour after a meal
224037204|NCT03434353|DRUG|TAF|Administered orally once daily with food
224037205|NCT01572701|DRUG|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
224037206|NCT03665896|DEVICE|intubation with VivaSight double-lumen tube|
224037207|NCT03665896|DEVICE|intubation with standard double-lumen tube|
224037208|NCT03665896|PROCEDURE|fiberoptic bronchoscopy|
224037209|NCT03255837|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
224037210|NCT05092633|DEVICE|Miniscrew|Application of laser on miniscrew
223424613|NCT06078748|BEHAVIORAL|ED|ED sessions designed to be of equal intensity and social engagement to the DIET intervention. Participants will engage in group discussion and receive information on the brain and cognitive processes, the effect of age on cognition, and tips to promote healthy aging. This will include lectures, watching documentaries and participating in various games.
223424614|NCT03614260|DEVICE|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
223424615|NCT03614260|PROCEDURE|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
223424616|NCT01714843|DRUG|linaclotide|oral
223424617|NCT01714843|DRUG|placebo|oral
223424618|NCT06645782|BEHAVIORAL|Virtual, Group CF-CBT|Virtual, group CF-CBT is an online, tailored CBT program for adults diagnosed with CF. Participants will attend eight weekly sessions (90 minutes each) delivered online. The sessions include: Introduction to CBT; Relaxation Skills; Depression in CF: What Helps?; Adaptive Thinking Skills, Part 1; Adaptive Thinking Skills, Part 2; Taking Charge of My Health; Anxiety in CF: What Helps?; and Maintaining Positive Changes.
223424619|NCT06189729|BEHAVIORAL|Text reminder|Participants will receive trimonthly text reminders through instant messaging mobile applications or short message service.
223424620|NCT06189729|BEHAVIORAL|HIV self-test|Participants will receive trimonthly text messages asking them to choose a pickup point run by the delivery company to collect the free HIV self-test. Upon receiving the delivery instruction, the self-test kit with bilingual (Chinese and English) instructions would be delivered to the designated location.
223424621|NCT00174967|DRUG|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
223424622|NCT00174967|DRUG|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
223424623|NCT00174967|DRUG|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
223424624|NCT00174967|DRUG|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
224037211|NCT00551109|DRUG|placebo|placebo, oral administration, once daily for 8 weeks
224037212|NCT00551109|DRUG|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
223424625|NCT06234592|DRUG|Angiotensin II|Angiotensin II infusion
223424626|NCT06234592|DRUG|Vasopressin|Vasopressin infusion
224037213|NCT00551109|DRUG|SA4503 High|High dose, oral administration, once daily for 8 weeks
224037214|NCT06794996|DRUG|Inaxaplin|Tablets for Oral Administration.
223424627|NCT06234592|DRUG|Norepinephrine|Standard care vasopressor therapy, norepinephrine infusion
223424628|NCT03625635|OTHER|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
223424629|NCT04250532|OTHER|Drowning|Measurement of pulse oximetry, after lifeguard immersion during their morning training
223424630|NCT02004821|DIETARY_SUPPLEMENT|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
223424631|NCT06046625|OTHER|Regular care with additional administration of a semi-structured interview|"Patients receiving regular care. In addition, a semi-structured interview is conducted.~The semi-structured interviews take place once after completion of the care pathway (after all appointments for check-ups associated with the treatment). The interview contains questions about the experience of patients with the care, the needs in this care, the experiences with the information received, the support/guidance, the turnaround time, the treatment received and areas for improvement."
223424632|NCT02539966|DEVICE|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
223424633|NCT02938403|BEHAVIORAL|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
223740001|NCT03564873|DRUG|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
224037215|NCT01538563|DRUG|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
224037216|NCT03932825|DRUG|Nitrous Oxide|An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
224037217|NCT03932825|DRUG|Placebo|An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration \~50%)
224037218|NCT03138811|DRUG|CSJ117|inhaled once daily dose
224037219|NCT03138811|DRUG|Placebo Comparator|inhaled once daily dose
224037220|NCT00530868|OTHER|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
224037221|NCT00530868|DRUG|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
224037222|NCT01990534|DRUG|Brentuximab Vedotin|Brentuximab vedotin IV infusion
224037223|NCT01580033|BIOLOGICAL|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
224037224|NCT01580033|BIOLOGICAL|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
223424634|NCT02938403|BEHAVIORAL|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
223424635|NCT06054061|BEHAVIORAL|Experimental: experimental wellbeing promotion group (Think and Cope Positively)|"Session 1: Welcome. 2: Identifying and amplifying positive emotions. 3: Experiencing positive emotions. 4: Identifying my negative trap thoughts. 5: Transforming my automatic thoughts into positive ones. Session 6: Experiencing my positive thoughts I. 7: Experiencing my positive thoughts II. 8: Learning to be kinder to myself. 9: Identifying a life project (Individual appointment).10: Identifying coping strategies I. 11: Identifying coping strategies II. 12: Identifying adaptive coping strategies linked to well-being. 13: Building my life purpose with my environment. 14: Helping me to build my life purpose? 15: Multi-family session, farewell and closing."
223563817|NCT06251661|OTHER|Cognitive multi-sensory Rehabilition|Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
223563818|NCT06251661|OTHER|selected traditional physical therapy program.|The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
223563819|NCT04924894|OTHER|no intervention|no intervention
223563820|NCT00978055|DRUG|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
224299028|NCT01957072|BEHAVIORAL|Behaviour change intervention|"The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
223424636|NCT06054061|BEHAVIORAL|TAU|The usual treatment in the intervention of people affected by severe mental disorder in the network of public and subsidized centers in Spain consists of improving psychosocial functioning. To this end, and depending on the characteristics of the user, work is done in groups and individually on social skills, psychoeducation about the disease, adherence to pharmacological treatment, improvement of daily living activities, promotion of independent leisure, support to families in the process of relapse prevention, and training for labor market insertion.
223424637|NCT02947204|OTHER|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
223424638|NCT02947204|OTHER|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
223424639|NCT03382301|DRUG|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
223424640|NCT03382301|DRUG|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
223424641|NCT05073029|OTHER|nutrition program and modification of physical activity|nutrition program developed by a gastroenterologist-nutritionist and modification of physical activity (8000-10000 steps daily)
223563821|NCT00978055|DRUG|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
223563822|NCT03593343|BEHAVIORAL|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
223563823|NCT06355596|OTHER|Virtual teaching|Virtual teaching of laparoscopic skills
223563824|NCT05687812|DIETARY_SUPPLEMENT|Cephalaria Syriaca flour-added bread|100g of test bread (consisting of 0.2% Cephalaria Syriaca flour bread) containing 50g of carbohydrates (KH).
223563825|NCT00134992|DRUG|Prednisolone acetate|
224037225|NCT01580033|BIOLOGICAL|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
223563826|NCT02813096|DRUG|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
223563827|NCT02813096|OTHER|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
224037226|NCT01580033|BIOLOGICAL|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
224037227|NCT02030756|DEVICE|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
224037228|NCT02030756|DEVICE|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
224037229|NCT04778969|DEVICE|drug-eluting stent|A group of percutaneous coronary intervention (PCI) using drug-eluting stents (DES)
224037230|NCT04778969|DEVICE|drug-coated balloon|A group of percutaneous coronary intervention (PCI) using drug-coated balloon (DCB)
224037231|NCT05087160|OTHER|mitigation measures against COVID 19|no intervention
224037232|NCT00234494|DRUG|Cisplatin|Cisplatin 70 mg/m2, day 1
224299029|NCT04243434|DRUG|Vincristine Sulfate Liposome|Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
223563828|NCT04277858|DRUG|Docetaxel|Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
223563829|NCT05430191|OTHER|Cascade Screening|FH is a genetic condition that causes high LDL cholesterol starting at birth. When one individual with FH is diagnosed, it is important that biological family members are also screened, since there is a 50% chance that each first-degree relative will have also inherited FH. More distant relatives may also have inherited FH. This evidence-based process is known as cascade screening.
223563830|NCT04360512|PROCEDURE|Posteriorization of the talus|Three sets of a 30-s grade IV mobilization
223563831|NCT02715024|DRUG|Tamsulosin|Oral
223563832|NCT02715024|DRUG|Solifenacin|Oral
223740002|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
224037233|NCT00234494|DRUG|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
224037234|NCT00234494|DRUG|Bevacizumab|Bevacizumab 15mg/kg, day 1
224037235|NCT01774851|DRUG|MM-111|MM-111 (IV)
224037236|NCT01774851|DRUG|Paclitaxel|Paclitaxel (IV)
223424642|NCT05073029|DIETARY_SUPPLEMENT|synbiotic (Fructooligosaccharides+Lactobacillus rhamnosus GG ATCC 53103, 4.0х109 colony forming units - CFU)|one synbiotic sachet (3g), BID, for 3 month traetment
223424643|NCT05073029|DIETARY_SUPPLEMENT|vitamin D3|vitamin D3, oral, 2000IU BID, for 3 month treatment
223424644|NCT02066818|DRUG|Lidocaine/tetracaine patch|
223424645|NCT02066818|DRUG|1% lidocaine|
223424646|NCT01668524|DRUG|ATS907|Single dose of each of three increasing concentrations
223424647|NCT06112652|DEVICE|4 session rTMS|Participants will receive 4 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223424648|NCT06112652|DEVICE|6 session rTMS|Participants will receive 6 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223424649|NCT06112652|DEVICE|8 session rTMS|Participants will receive 8 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223424650|NCT06112652|DEVICE|10 session rTMS|Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days. Individualized targets will be generated using the pBFS method.
223424651|NCT06112652|DEVICE|sham rTMS|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223424652|NCT03552224|PROCEDURE|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
223424653|NCT05592561|OTHER|mental stress task|The stress protocol used for this experiment utilized a cognitive challenge and a previously studied virtual reality active shooter drill (VR-ASD). The cognitive challenge included a modified version of the Stroop challenge (2 min) and mental arithmetic calculations (2 min) presented to the subject via e-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh, PA, USA). Immediately upon completion of the cognitive challenge, the subjects completed the VR-ASD scenario (\~2 min) followed by the same cognitive challenge with different questions (another 4 min). The total duration was \~10 min.
223424654|NCT01275651|OTHER|laboratory biomarker analysis|Correlative studies
223424655|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:~* Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~* Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~* Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
223424656|NCT01585350|BIOLOGICAL|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
223424657|NCT04934189|BEHAVIORAL|Empowerment Self Defense Training|We have contracted with Prepare, Inc., the New York City chapter of IMPACT International to deliver the tailored ESD violence prevention intervention. IMPACT is an international ESD violence prevention organization with chapters across the United States. Prepare, Inc. will provide facilitators who have completed IMPACT's nationally standardized ESD violence prevention program requirements that include receipt of over 100 hours of training. IMPACT training is open to trans and cisgender women. The extensive training of IMPACT facilitators promotes intervention efficacy, while the risk of potential bias conferred by their experience with a pre-existing curriculum is mitigated by our community-engaged approach (i.e.,TW community members, service providers, and scientists \[PI and Co-I\] collectively shape the content of the final tailored ESD intervention, and TW co-facilitators will be present in every training session).
223424658|NCT05295979|DRUG|Inflammatory skin disease formula|ISDF granules (10.85g twice daily) for 12 weeks
223424659|NCT05295979|DRUG|Placebo|Placebo granules (10.85g twice daily) for 12 weeks
223424660|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
223424661|NCT03191136|DRUG|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
223424662|NCT04615806|DRUG|Indocyanine green solution|ICG solution was endoscopically injected into the esophageal submucosa at the four quadrants around the tumor.
223424663|NCT01210196|PROCEDURE|MRI|Cardiac MRI after 12 and 24 months.
223424664|NCT04326296|DRUG|PD-L1 Monoclonal Antibody Combined With Lenalidomide|PD-L1 monoclonal antibody was administered by intravenous drip every 3 weeks.Lenalidomide was administered orally, 25mg once a day on days 1-21 of each repeat cycle of 28 days.
223424665|NCT01532336|DRUG|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
223424666|NCT01532336|DRUG|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
223563833|NCT04696367|PROCEDURE|Emergency laparotomy|Midline laparotomy for acute intra-abdominal pathology
224037237|NCT01774851|DRUG|Trastuzumab|Trastuzumab (IV)
224037238|NCT03641053|OTHER|Honey|Substance is given topically after the wound has been sutured
223563834|NCT04251767|OTHER|washed microbiota transplantation|"Washed microbiota suspension (5u) delivered through nasogastric tube, nasojejunal tube or oral.~Dose and frequency: 5u, once."
223563835|NCT04251767|OTHER|placebo|"Placebo (edible suspension of the same color as the washed microbiota suspension，5u) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy.~Dose and frequency: 5u, once."
223563836|NCT06399510|OTHER|Sterofundin fluid therapy|Sterofundin is known as balanced solution which has similar electrolytes content as per human plasma.
223563837|NCT02845622|DIETARY_SUPPLEMENT|Hazelnut|This dietary supplement contains 30 g of hazelnut.
223563838|NCT02845622|DIETARY_SUPPLEMENT|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
223563839|NCT02845622|DIETARY_SUPPLEMENT|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
223563840|NCT02845622|DIETARY_SUPPLEMENT|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
223740003|NCT03564873|DRUG|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
223740004|NCT03564873|DRUG|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
223740005|NCT04657081|DRUG|Decitabine and Cedazuridine (ASTX727)|Route of administration: oral in the form of a tablet
223740006|NCT04657081|DRUG|Venetoclax|Route of administration: oral in the form of a tablet
224138226|NCT00078988|PROCEDURE|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
223740007|NCT04573140|BIOLOGICAL|Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)|RNA-LP vaccines will be administered intravenous. Three RNA-LP vaccines will be administered every 2 weeks followed by 12 cycles of adjuvant monthly RNA-LP vaccines for a total of 15 vaccines.
224037239|NCT03641053|OTHER|Povidone-iodine|Substance is given topically after the wound has been sutured
224037240|NCT03641053|OTHER|Paraffin gauze|Substance is given topically after the wound has been sutured
224037241|NCT01831544|DEVICE|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
224037242|NCT04486157|DRUG|IN-A012|The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.
224037243|NCT04486157|DRUG|Akynzeo 300Mg-0.5Mg Capsule|The subjects will be administrated Akynzeo by Orally with water.
224138227|NCT05349942|DEVICE|Intraoral scanning and data acquisition|Intraoral scanner data acquisition, 3 scans are taken for each participant. Data will be exported from dedicated software (Planmeca, Romexis) and imported into GOM surface analysis software. Sample comparisons and sample preparation are performed here. The results are collected in excel spreadsheets and analyzed in SPSS statistical software.
223424667|NCT03911661|OTHER|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
223424668|NCT03911661|OTHER|Usual care|Historical management of warfarin by patient's usual care providers
223424669|NCT00908791|DRUG|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
223424670|NCT00880581|DRUG|PF-3512676|18 mg injection
223424671|NCT00880581|RADIATION|Local radiotherapy|2 gray (2 Gy) on each of Days 1 and 2
223424672|NCT06006494|OTHER|aerobic|"We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; includes activities such as walking, cycling, jogging, aerobic dancing, swimming.~An average of 50 minutes of exercise per day will be required, 3 days a week."
223424673|NCT06006494|OTHER|resistant|Resistance exercises are the whole of the exercises in which effort is made against the weight and the weight is lifted. Exercises with therabands, dumbbells or body weight will be given. The exercises will be done 2 days a week for an average of 30-40 minutes.
223424674|NCT06006494|OTHER|yoga|Yoga is basically breathing exercises, warm-up exercises, relaxation, It is a session consisting of movements and relaxation exercises.movements are performed by standing in a fixed posture for 15 seconds to 2 minutes in a certain posture, they are postures for both strengthening, stretching and balance. Yoga practice will be done 2 days a week for an average of 40 minutes.
223424675|NCT00564837|PROCEDURE|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
223424676|NCT00564837|PROCEDURE|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
223563841|NCT02845622|DIETARY_SUPPLEMENT|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
223563842|NCT05940363|COMBINATION_PRODUCT|Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies|To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
223563843|NCT03155919|DIETARY_SUPPLEMENT|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
223424677|NCT03716843|OTHER|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
223424678|NCT02558621|DEVICE|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
223424679|NCT02170896|DRUG|BIBR 1048 MS Capsule A|
223424680|NCT02170896|DRUG|BIBR 1048 MS Capsule B|
223424681|NCT02170896|DRUG|BIBR 1048 MS Capsule C|
223424682|NCT02170896|DRUG|BIBR 1048 MS Capsule D|
223424683|NCT02170896|DRUG|BIBR 1048 MS tartaric acid solution|
223424684|NCT02170896|DRUG|Pantoprazole|
223424685|NCT06441032|OTHER|No patient treatment is associated with the study|No patient treatment is associated with the study.
223424686|NCT03192995|DRUG|lorcaserin|lorcaserin 20 mg tablet
223424687|NCT03192995|DRUG|Placebo Oral Tablet|placebo 20 mg. tablet
223424688|NCT03192995|BEHAVIORAL|Substance use counseling|Manual-driven psychosocial substance use counseling program using cognitive behavioral therapy and motivational interviewing techniques and incorporating the Stages of Change Model.
223424689|NCT03192995|BEHAVIORAL|ACASI|Audio-computer assisted self-interviews (ACASI) is a self-administered standardized questionnaire on substance and alcohol use, substance use treatment, sexual risk behavior, partnership sexual risk, and
223424690|NCT03192995|DIAGNOSTIC_TEST|Cocaine metabolites|Rapid qualitative urine test Medtox Verdict II (Medtox Diagnostics, Burlington, NC) and tamper-evident sweat patches (PharmChek®, PharmChem, Inc., Fort Worth, Tx)
223424691|NCT03192995|BEHAVIORAL|Ecological Momentary Assessment (EMA)|EMA are questions sent to the participant 4-5 times a day to determine real-time behavior and participant experiences.
223424692|NCT03192995|BEHAVIORAL|Balloon Analogue Risk Task (BART)|BART is a computerized measure of risk taking behavior. The BART models real-world risk behavior through the conceptual frame of balancing the potential for reward versus loss. This is a test for impulsivity.
223424693|NCT03192995|BEHAVIORAL|Qualitative Exit Interview|The qualitative exit interview assessed acceptability measures and included questions on attitudes about trial participation, level of satisfaction with trial procedures, and trial medication.
223424694|NCT03506568|DEVICE|Devers Drop Device (D3) app|A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
223424695|NCT01286168|DEVICE|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
223424696|NCT01286168|DEVICE|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
223424697|NCT01286168|PROCEDURE|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
223424698|NCT01286168|DEVICE|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
223424699|NCT01768975|DRUG|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
223424700|NCT01768975|OTHER|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
223424701|NCT04630249|BEHAVIORAL|Listening to Women and Pregnant and Postpartum People|Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to telemedicine mental health and substance use disorder treatment services.
223424702|NCT05165199|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
223424703|NCT04476342|DEVICE|minimal invasive cardiopulmonary bypass (MICPB) system|The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
223424704|NCT00492882|DRUG|usual administration of exogenous recombinant FSH|
223424705|NCT04175782|PROCEDURE|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
223424706|NCT01596153|DIETARY_SUPPLEMENT|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
223424707|NCT02893553|DRUG|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
223424708|NCT02893553|DRUG|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
223424709|NCT02893553|DRUG|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
223424710|NCT02893553|OTHER|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
223424711|NCT01443091|OTHER|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
223424712|NCT01443091|OTHER|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
223563844|NCT03155919|DIETARY_SUPPLEMENT|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
223563845|NCT01679548|PROCEDURE|Single-port LAVH|LESS LAVH was performed using a commercially available four-channel, single-port system. A rigid, 0-degree, 5 mm laparoscope was used.
223563846|NCT01679548|PROCEDURE|Three-port LAVH|Conventional LAVH was performed using three ports; a 12, 10, and 5-mm port was placed in the umbilicus, left lower quadrant, and suprapubic area, respectively. A rigid, 0-degree, 12 mm laparoscope was introduced through 12mm port of umbilicus.
223563847|NCT02039219|DRUG|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
223563848|NCT02039219|DRUG|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
223740008|NCT06982300|OTHER|[68Ga]Ga-DOTA-TOC PET imaging|"Patients will undergo \[68Ga\]Ga-DOTA-TOC PET imaging before and 3 weeks after start of standard of care treatment with induction chemotherapy or CRT, unless the baseline scan shows no tracer uptake in the tumor, in that case the scan will not be repeated.~Patients will receive 120 MBq \[68Ga\]Ga-DOTA-TOC intravenously and will be scanned up to 20 minutes, 60 minutes after tracer injection, after acquisition of a low dose CT for attenuation correction.~The investigators will use archival tissue of the diagnostic biopsy for SSTR2 staining. If there is not sufficient tumor tissue available, a new biopsy will be performed after the baseline PET scan.~Blood samples will be drawn before the start, during and after finishing therapy at 3 or 4 different time points, depending on the treatment schedule."
223740009|NCT04425421|OTHER|OBSERVATIONAL|OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE
224037244|NCT04563364|OTHER|Interdisciplinary hospital-home intervention|The intervention will start in NICU and to be continued at home with the support of ICT. The NICU intervention will have theoretical and practical components, the theoretical one will be about motor development in premature infants, and practical one will have strategies for motor early intervention, it will be demonstrated with pediatric simulator and parents should be demonstrate it with a infant: 1Sensorial motor stimulation, visual and auditory follow-6up; Tactile integration 3Extension muscle activation 4Middle line integration 5Alignment reaction stimulation in prone position 6Flexor muscle activation with transition to lateral position 7Flexor muscle activation with transition to sitting position 8Facilitation of reciprocal flexion and extension lower limbs. All parents will receive a motor sensorial kit that will include roller, visual tags, blankets and rattles, it will be for apply the strategies for motor early intervention, and will be supported by ICT
224037245|NCT04563364|OTHER|Convencional treatment|Control group will receive a conventional treatment given by the institutions
224037246|NCT05539859|PROCEDURE|Endoscopic surgery|Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management
224138228|NCT04616495|PROCEDURE|Liver transplantation|Chemotherapy and liver transplantation
224138229|NCT00369967|DRUG|NuvaRing|Initiation of NuvaRing for contraception
224138230|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
224138231|NCT03536598|DRUG|Amlodipine 10 mg + Valsartan 160 mg|
224138232|NCT03536598|DRUG|Valsartan 160 mg + Rosuvastatin 20 mg|
224138233|NCT03424577|DRUG|H3B-6527|Oral capsule
223424713|NCT04317924|DEVICE|Polyglycolic acid felt|Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
223424714|NCT04317924|OTHER|Standard of care|Standard of care after air leak post lung resection
223424715|NCT01899716|OTHER|Exercise|
223424716|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
224299030|NCT04243434|COMBINATION_PRODUCT|CHOP|CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
224299031|NCT04243434|COMBINATION_PRODUCT|R-CHOP|R-CHOP to be administered on Day 1 on Cycle 1 \& 2 ( 21-day Cycle) \& prednisone administration on Days 2 to 5 on Cycle 1 \& 2 ( 21-day Cycle)
223424717|NCT03615716|BEHAVIORAL|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
223424718|NCT03578016|OTHER|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
223424719|NCT03578016|OTHER|Treatment as Usual|TAU consists of clinical assessment and treatment.
223424720|NCT00083941|BIOLOGICAL|TroVax|1ml intramuscular injection
223424721|NCT00083941|BIOLOGICAL|Interleukin-2|Intravenous IL-2
223424722|NCT05809258|PROCEDURE|Supraclavicular block|brachial plexus nerve block by supraclavicular route
223424723|NCT05809258|PROCEDURE|Axillary block|brachial plexus nerve block by axillary route
223563849|NCT05447195|DRUG|CAN008|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given CAN008 + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the CAN008+TMZ maintenance therapy period in which subjects in both groups are given CAN008+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given CAN008 IV infusion weekly until disease progression.
223563850|NCT05447195|DRUG|Placebo|Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
224037247|NCT05539859|OTHER|Medical management|Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.
224037248|NCT00609843|OTHER|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
224037249|NCT05114915|DRUG|Albumin-bound docetaxel|Albumin-bound docetaxel by intravenous infusion
224037250|NCT00148954|DEVICE|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
224037251|NCT00148954|DEVICE|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
224138234|NCT05496218|DIAGNOSTIC_TEST|Blood samples|At study entry, we will collect morning blood samples from fasting women. participants will be asked with an interview on demographic and lifestyle characteristics, health-related behaviours, the existence and duration of infertility, medical history, and history of hormonal or surgical treatments for endometriosis. Pain symptoms before surgery will be evaluated through a 10 cm long one-dimensional visual-analogue scale (VAS). In addition, women will be asked to report about their usual weekly food consumption in the previous year. Information on the diet will be based on a reproducible and valid food frequency questionnaire. Energy and mineral and macro-and micronutrient intakes will be estimated using the most recent update of an Italian Food Consumption Database.
223424724|NCT01373112|PROCEDURE|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
223563851|NCT01242696|PROCEDURE|Coronary artery stenting|Coronary artery stenting with drug eluting stents
223563852|NCT00834470|DRUG|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
223563853|NCT02537587|OTHER|Control 1|67g of control bar
223563854|NCT02537587|OTHER|Control 2|86g of control bar
223563855|NCT02537587|OTHER|15/0|66g of experimental bar 15/0
223563856|NCT02537587|OTHER|15/0LS|84g of experimental bar 15/0LS
224037252|NCT06514235|OTHER|Observational study (Non-interventional study)|This is an observational study.
224037253|NCT04235270|COMBINATION_PRODUCT|FDC of Macitentan and Tadalafil|Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.
224037254|NCT04235270|DRUG|Macitentan|Macitentan 10 mg tablet will be administered orally as free combination.
223424725|NCT01373112|PROCEDURE|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
223424726|NCT06514755|PROCEDURE|GNA followed by GAE|Participants in the experimental arm will undergo genicular nerve ablation (GNA), a minimally invasive procedure targeting the genicular nerves to interrupt pain transmission. One month after undergoing GNA, participants will receive geniculate artery embolization (GAE), which targets the geniculate arteries to reduce inflammation and pain.
223563857|NCT02537587|OTHER|15/5|75g of experimental bar 15/5
223563858|NCT02537587|OTHER|10/5|72g of experimental bar 10/5
224037255|NCT04235270|DRUG|Tadalafil|Tadalafil 40 mg tablet will be administered orally as free combination.
224037256|NCT05028829|DRUG|Atorvastatin 20mg|Oral administration of atorvastatin 20 mg
224037257|NCT05028829|DRUG|Placebo|Oral administration of placebo
224037258|NCT00421473|DRUG|Atovaquone / Proguanil|
224037259|NCT04175808|DRUG|Omecamtiv Mecarbil (OM)|Oral solution
224037260|NCT04175808|DRUG|Placebo|Placebo oral solution
224037261|NCT04175808|DRUG|Moxifloxacin|400 mg moxifloxacin oral tablet
224037262|NCT05706896|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
224037263|NCT04883671|OTHER|Standard of Care|Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
224037264|NCT04883671|RADIATION|SBRT|SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
224037265|NCT06493812|PROCEDURE|Fascia lata|This intervention involves the harvesting of fascia lata from the thigh and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left thigh, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
224138235|NCT03807076|OTHER|GIP-A|GIP-A
224138236|NCT03807076|OTHER|Placebo|Placebo
224138237|NCT01005056|DRUG|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
224138238|NCT03682939|BIOLOGICAL|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
224138239|NCT03682939|BIOLOGICAL|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
224138240|NCT04560140|BEHAVIORAL|Narrative and Skills-building Intervention|The intervention is grounded in Narrative Theory and Bandura's principles of Self-efficacy and Outcome Expectation. It will consist of eight individual sessions over six months delivered by a facilitator. Participants will be facilitated to narrate their survival experiences and rebuild core life skills.
224138241|NCT02829866|DEVICE|AMIStem-H|
224138242|NCT02344420|PROCEDURE|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
223424727|NCT06514755|PROCEDURE|GAE alone|Participants in the active comparator arm will receive geniculate artery embolization (GAE) alone, a minimally invasive procedure targeting the geniculate arteries to reduce inflammation and pain, without prior genicular nerve ablation (GNA).
224037266|NCT06493812|PROCEDURE|Temporal fascia|This intervention involves the harvesting of temporal muscle fascia from the temporal region of the head and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left temporal region, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
223424728|NCT03097055|PROCEDURE|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
223424729|NCT03097055|PROCEDURE|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
223424730|NCT01671150|DRUG|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
223424731|NCT03410212|DRUG|Ketorolac Tromethamine|The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
224037267|NCT03912272|BEHAVIORAL|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
224037268|NCT03912272|BEHAVIORAL|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
224037269|NCT05205382|OTHER|5% nicotine|Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
224037270|NCT05205382|OTHER|3% nicotine|Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
224037271|NCT05205382|OTHER|0% nicotine|Effects of e-cigarette pods (SREC) with 0% nicotine concentration
224037272|NCT04229472|DIAGNOSTIC_TEST|High density electrophysiological mapping|Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
224037273|NCT04229472|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
224037274|NCT01017068|DRUG|OME|4g/100ml) dose: п gutt tid x 1/52
224037275|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
224037276|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
224037277|NCT01017068|DRUG|OME|(4g/100ml) dose: п gutt tid x 1/52
224037278|NCT01017068|DRUG|OME|(2g/100ml) dose: п gutt tid x 1/52
224037279|NCT01017068|DRUG|OME|(1g/100ml) dose: п gutt tid x 1/52
224037280|NCT02843685|DRUG|Drotrecogin alfa activated|
224037281|NCT05577286|OTHER|regular care|the regular medical treatment without change of their daily activity routine
224037282|NCT05577286|OTHER|plyometric training|designed plyometric training program for 30 minutes, three times a week for two successive months
224037283|NCT03594344|PROCEDURE|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
224037284|NCT04516707|OTHER|clinical database|"The various clinicam database will be collected solely to meet the objectives of the study.~All data collected to create the database for this project will be anonymized"
224037285|NCT02021292|DRUG|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
224138243|NCT02344420|BEHAVIORAL|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
224037286|NCT02021292|DRUG|Placebo|Matching placebo oral tablet, to be taken once daily.
224037287|NCT04959175|DRUG|Mycophenolate Mofetil|15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
224037288|NCT04959175|PROCEDURE|Allogeneic HSCT|Stem cell transplant
224138244|NCT02344420|PROCEDURE|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
223424732|NCT03410212|BEHAVIORAL|Sham injection|In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
223424733|NCT00002701|DRUG|busulfan|
223424734|NCT00002701|DRUG|cyclophosphamide|
223424735|NCT00002701|DRUG|cytarabine|
223424736|NCT00002701|DRUG|etoposide|
223424737|NCT00002701|DRUG|idarubicin|
223424738|NCT00002701|DRUG|mercaptopurine|
223424739|NCT00002701|DRUG|methotrexate|
223424740|NCT00002701|DRUG|mitoxantrone hydrochloride|
223424741|NCT00002701|DRUG|thioguanine|
223424742|NCT00002701|DRUG|tretinoin|
224037289|NCT04959175|DRUG|Fludarabine|30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
224037290|NCT04959175|DRUG|Sirolimus|Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
224037291|NCT04959175|DRUG|Filgrastim|begins on day +5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously, until the absolute neutrophil count is \> 1,000/mm3 over the course of three days or \> 5,000/mm3 on one day. Rounding to the nearest vial is allowed. G-CSF may be stopped early or not administered if required by the clinical circumstance. Additional G-CSF may be administered as warranted.
224037292|NCT04959175|DRUG|Cyclophosphamide|Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
224037293|NCT04959175|DRUG|Mesna|25 or 35 mg/kg (equal to the cyclophosphamide dose) as IV infusion concomitant with cyclophosphamide. Mesna may or may not be given with the pre-transplant cyclophosphamide depending on institutional practice.
224037294|NCT04959175|PROCEDURE|Total Body Irradiation (TBI)|400 centigray (cGy) to be delivered in 2 fractions as 200 cGy per fraction twice daily. Pre-Transplant Day -1 (or Day 0 prior to graft administration)
224037295|NCT05726227|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
224037296|NCT05726227|DRUG|Placebo|Placebo will be administered subcutaneously once-weekly.
224037297|NCT06012149|BEHAVIORAL|Braining|A 12 week program where participants are encouraged to participate in physical exercise at the psychiatric unit.
224037298|NCT06012149|BEHAVIORAL|Structured advice on physical activity|A 12 week program where participants are encouraged to engage in physical exercise
224037299|NCT04171310|DRUG|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
224037300|NCT03263351|BEHAVIORAL|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
224037301|NCT03263351|BEHAVIORAL|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
224037302|NCT00022048|BIOLOGICAL|bevacizumab|
224037303|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)|Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive generic/regular PSAs that address vaping harms more broadly; during the second six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products.
224037304|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)|Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products; during the second six months, they will receive generic/regular PSAs that address vaping harms more broadly.
224037305|NCT05447325|BEHAVIORAL|Exposure to Anti-Vaping Messages (no message exposure)|Participants will not receive any message intervention in this arm.
224037306|NCT04464603|DEVICE|InterFACE (mHealth tool)|"Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support."
224037307|NCT04464603|OTHER|Conventional methods|"Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool."
224138245|NCT02344420|BEHAVIORAL|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
223424743|NCT00002701|PROCEDURE|allogeneic bone marrow transplantation|
223424744|NCT00002701|PROCEDURE|autologous bone marrow transplantation|
224037308|NCT04669158|DRUG|Idebenone|Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.
223424745|NCT00002701|RADIATION|radiation therapy|
223424746|NCT01758107|OTHER|Withdraw cyclosporine|
223424747|NCT00560287|DEVICE|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
223424748|NCT00560287|DEVICE|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
224037309|NCT04669158|DRUG|Placebo|Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
224037310|NCT05870748|DRUG|Luveltamab tazevibulin|Luveltamab tazevibulin is an antibody-drug conjugate targeting FOLR1. It consists of an IgG1 antibody (SP8166) conjugated to cleavable 3-3-aminophenyl hemiasterlin drug-linkers at 4 sites. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death.
224037311|NCT05870748|DRUG|Pegfilgrastim|Pegfilgrastim or pegylated G-CSF is approved and used to decrease the incidence of infection in patients receiving myelosuppressive anti-cancer drugs. It increases the proliferation and differentiation of neutrophils.
224037312|NCT05870748|DRUG|Gemcitabine|Gemcitabine is a chemotherapy regimen used for treating platinum-resistant ovarian cancer. It inhibits ribonucleotide reductase and DNA polymerase, hindering tumor cell growth and promoting cell death.
224037313|NCT05870748|DRUG|Paclitaxel|Paclitaxel is a chemotherapy regimen approved for treatment of previously treated ovarian cancer. It stabilizes microtubules, inhibiting tumor cell replication.
224037314|NCT05870748|DRUG|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin is a chemotherapy regimen approved for treating platinum-resistant ovarian cancer. It inhibits DNA and RNA synthesis by intercalating between base pairs, obstructing tumor cell division.
224138246|NCT05336006|OTHER|High-intensity aerobic training with high protein diet|"High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d), as prescribed by a qualified nutritionist."
223424749|NCT01237249|DRUG|Melphalan|
223424750|NCT01237249|DRUG|Prednisone|
223424751|NCT01237249|DRUG|Velcade|
223424752|NCT01237249|DRUG|Revlimid|
223424753|NCT01237249|DRUG|Dexamethasone|
223424754|NCT00843037|DRUG|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
223424755|NCT06162845|BEHAVIORAL|A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions|Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
223424756|NCT06162845|BEHAVIORAL|Paper-based home exercise program for pelvic floor muscle exercise|Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
223424757|NCT04112160|DRUG|Ketorolac|IM injection of either normal saline or Ketorolac
223424758|NCT04112160|DRUG|normal saline|normal saline
223563859|NCT02537587|OTHER|10/10|80g of experimental bar 10/10
223424759|NCT04889196|DRUG|Silver diamine fluoride|Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
223424760|NCT04889196|DEVICE|hall technique|The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
223563860|NCT04552210|DIAGNOSTIC_TEST|blood sample|Whole blood was collected on EDTA (1mg/ml) to prevent clotting and DNA degradation.
223563861|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous (SC) injection
223563862|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
223563863|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
224037315|NCT05870748|DRUG|Topotecan|Topotecan is a chemotherapy regimen approved for treatment of metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy. It binds to topoisomerase I inducing DNA breaks and subsequent tumor cell apoptosis.
224037316|NCT06334120|DRUG|Darolutamide (Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
224037317|NCT06129864|DRUG|volrustomig|volrustomig
224037318|NCT05499130|DRUG|TEV-48574|Subcutaneous infusion
223563864|NCT02974855|BIOLOGICAL|PF-06741086|PF-06741086 SC injection
223563865|NCT03695627|BEHAVIORAL|Meditation|10 minute a day, 8 week digital meditation
223563866|NCT05186103|OTHER|observation|The assessment combined a parent-reported questionnaire (the Participation in Childhood Occupation; PICO) alongside the Pediatric Evaluation of Disability Inventory (PEDI self-care) and a Performance-based task, the Washing Hands Structured Observation (WashHO).
223563867|NCT00129701|PROCEDURE|Telephone consultation|
224037319|NCT05499130|DRUG|Placebo|Matching Placebo
223424761|NCT03055468|BEHAVIORAL|Peer support|Peer support and antidepressant medications
223424762|NCT03121924|PROCEDURE|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
223424763|NCT06372418|OTHER|Breastfeeding peer support intervention|In addition to support as currently recommended by the World Health Organization (WHO) and National IMAM guidelines, care givers will receive a homebased individualized face to face support provided by breastfeeding peer supporters and phone call support upto 7 weeks post hospital discharge.
224037320|NCT04733027|COMBINATION_PRODUCT|Dose escalation, first-in-human phase I clinical trial with an Expansion phase|PEP-010 will be administered on days 1, 2 and 3 every week, as a 3-hour intravenous infusion. Treatment will be administered until disease progression, unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Each cycle will be of 21 days duration.
224037321|NCT06625190|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
224037322|NCT06625190|DRUG|Zoledronic acid|"All subjects will receive zoledronic acid intravenously on days +28, +56, +84, +112, and +140.~Dosing in the phase Ib portion of the study will follow a 3 + 3 design where the first 3 subjects will receive the expected phase II dose of 1.25 mg/m2 (dose level 1). If no dose-limiting toxicities (DLTs) occur in these subjects, dose level 1 will be the maximum tolerated dose. However, if at least 1 DLT is observed in the first 3 patients, 3 additional subjects will be enrolled at dose level 1. If more than 2 DLTs are observed in these 6 subjects, then dose de-escalation to 0.8 mg/m2 (dose level 0) will occur and 3-6 additional subjects may be enrolled.~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase Ib portion."
224037323|NCT05972733|BIOLOGICAL|HIL-214|HIL-214
224037324|NCT04662151|BIOLOGICAL|AT-100|reconstituted AT-100 for intratracheal administration
224037325|NCT04662151|PROCEDURE|Air-sham|room air for intratracheal administration
224037326|NCT04395118|BEHAVIORAL|Mailed Outreach|The investigators will randomize elevated LFT patients (\~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
224037327|NCT00982215|DRUG|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
224037328|NCT00982215|DRUG|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
224037329|NCT00747630|OTHER|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
224037330|NCT04680351|PROCEDURE|phrenic stimulation|measurements of the hemodynamic effects of phrenic stimulation
224037331|NCT05745844|OTHER|activity sessions|77 activity sessions ; muscle strengthening, testing or unloading
224037332|NCT04987658|DRUG|OLZ/SAM|Olanzapine and Samidorphan taken once daily over a max period of 21 days
224037333|NCT01685710|DRUG|GTN patch|
224138247|NCT05336006|OTHER|Control group|This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
224037334|NCT01685710|DRUG|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
224037335|NCT06431880|OTHER|External oblique intercostal plane block|Patients will receive external oblique intercostal plane block
223424764|NCT06372418|OTHER|Standard Care|Caregivers will receive post-discharge support as currently recommended by the World Health Organization (WHO) and national IMAM guidelines.
223424765|NCT04685668|BEHAVIORAL|The PartoMa guidelines and training|"All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~1. Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~2. Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars."
223424766|NCT06467994|OTHER|Cashew oral immunotherapy|Cashew Flour (boiled/ roasted) that is prepared under food manufacturing regulations
224037336|NCT06431880|OTHER|Thoracic paravertebral block|Patients will receive thoracic paravertebral block
224037337|NCT02415465|PROCEDURE|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
224037338|NCT02415465|PROCEDURE|General|General Intraoperative Anesthesia
224037339|NCT02415465|PROCEDURE|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
224037340|NCT02415465|PROCEDURE|Spinal|Spinal Intraoperative Anesthesia
224037341|NCT00601991|BIOLOGICAL|VEGF Trap|Drug under investigation
224037342|NCT00601991|PROCEDURE|Bone marrow biopsy|To determine response to treatment
224037343|NCT00601991|PROCEDURE|bone marrow aspiration|To determine response to treatment
224138248|NCT03117530|DRUG|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
223424767|NCT06467994|OTHER|Placebo oral immunotherapy|Placebo oral immunotherapy consists of corn flour with food colouring that has similar appearance, taste and smell to the active product
223424768|NCT02679989|BEHAVIORAL|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
223424769|NCT02679989|BEHAVIORAL|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
223563868|NCT03576066|DRUG|ABI-H0731|Participants will receive ABI-H0731 300 mg tablets orally once daily (QD).
223563869|NCT03576066|DRUG|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
224037344|NCT00601991|PROCEDURE|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
224037345|NCT01157013|OTHER|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (\^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
224037346|NCT00000913|DRUG|Ritonavir|
224037347|NCT00000913|DRUG|Nelfinavir mesylate|
224037348|NCT00000913|DRUG|Saquinavir|
224037349|NCT03492788|OTHER|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
224037350|NCT03492788|OTHER|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
223563870|NCT03576066|DRUG|Placebo Oral Tablet|Participants will receive placebo matching ABI-0731 tablets orally QD.
223563871|NCT03120260|OTHER|Diet|Intervention 'Diet+ short sleep versus normal sleep
224037351|NCT02869555|OTHER|Data collection|
224037352|NCT05740657|DRUG|Fentanyl|The drugs were administered in the course of a surgery or for pain management.
224138249|NCT04973891|DRUG|Canagliflozin combined with metformin|"Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS."
224138250|NCT04973891|DRUG|metformin|Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
224138251|NCT05289206|OTHER|Vaccine - ChAdOx1-S/nCoV-19 [recombinant]|ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
224138252|NCT02562872|DRUG|DSM265|DSM265 400 mg single oral dose
223424770|NCT02091960|DRUG|Enzalutamide|Capsules for oral administration
223563872|NCT00616382|DRUG|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
224037353|NCT02734394|BEHAVIORAL|Exercise|Cardiovascular and resistance exercise training
224138253|NCT02562872|DRUG|Placebo|Placebo to match DSM265, single oral dose
224138254|NCT02562872|BIOLOGICAL|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
223740010|NCT04171440|PROCEDURE|robotic pancreaticoduodenectomy|The robotic pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
224138255|NCT02562872|BIOLOGICAL|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
223740011|NCT06605924|OTHER|Tobacco-free|Ad contains baseline language + language that product is tobacco-free
224037354|NCT05845866|BEHAVIORAL|Modified Body Project|The Body Project, an evidence-based body image intervention developed for young women at risk for eating pathology, was adapted for use among adult women with high weight and shape concern and high body weight who want to lose weight.
224138256|NCT05723458|COMBINATION_PRODUCT|Cream|A cream containing Turmeric, Black Seeds, Flaxseed, and Medicago Sativa
224138257|NCT05723458|DRUG|Placebo|Placebo cream containing vaseline
224138258|NCT05295745|BEHAVIORAL|Cognitive remediation therapy and multidisciplinary intervention|"The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included"
224138259|NCT00944216|DRUG|Salkera Emollient Foam|application of the Salkera emollient foam twice a day during the 12 week study period.
224037355|NCT05845866|BEHAVIORAL|Facts about obesity, myths about weight loss|This intervention is designed to help individuals prepare for weight loss and is focused on facts about obesity, myths about weight loss, and the importance of a varied diet.
224037356|NCT05845866|BEHAVIORAL|Lifestyle intervention for weight loss|This 24-week behavioral weight management program is based on the Look AHEAD and Diabetes Prevention Program manuals. It is designed to facilitate 7-10% weight loss of initial body weight through dietary and physical activity changes with use of behavioral strategies to support lifestyle changes over time.
224037357|NCT04225078|DRUG|Loperamide|Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.
224037358|NCT04225078|OTHER|Placebo|Matching loperamide placebo capsules will be administered orally.
224037359|NCT04225078|DRUG|Moxifloxacin|Moxifloxacin tablets will be administered orally.
224037360|NCT04285476|DIAGNOSTIC_TEST|Signature of microRNA for patients with bethesda classification 3, 4 or 5|If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
224037361|NCT03957954|BIOLOGICAL|cLSC|Transplantation of cLSC
223424771|NCT02091960|DRUG|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
223424772|NCT00687843|DRUG|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
223424773|NCT00687843|DRUG|Krestin (PSK)|3 g, PO from day 1 to day 336
223424774|NCT02794792|DRUG|Ipragliflozin L-proline|Oral
223424775|NCT02794792|DRUG|Metformin|Oral
223424776|NCT02794792|DRUG|Placebo|Oral
223424777|NCT03460405|BIOLOGICAL|Vi-DT Vaccine|1 dose of Vi-DT Vaccine
223424778|NCT03460405|BIOLOGICAL|Vi Polysaccharide Vaccine|1 dose of Vi Polysaccharide Vaccine
224037362|NCT03957954|DEVICE|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
224037363|NCT03865940|DRUG|Lidocaine|6 mL of 1% lidocaine
224037364|NCT03865940|DRUG|Guanfacine|250 mcg
224037365|NCT06338670|DEVICE|Cochlear Osia 3 Sound Processor|Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +
224037366|NCT06338670|DEVICE|Cochlear™ Osia® 2 Sound Processor|Osia® 2 Sound Processor
224037367|NCT06345833|DRUG|1%Tranexamic acid with standard local|1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control.
224037368|NCT06345833|DRUG|3% TXA|3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control.
224037369|NCT06345833|DRUG|1% TXA with local plus 3% TXA-soaked pledgets|1% TXA with local plus 3% TXA-soaked pledgets with saline as the control.
223424779|NCT03460405|BIOLOGICAL|IPV Vaccine|1 dose of IPV Vaccine
223424780|NCT06793943|DRUG|Zasocitinib|Zasocitinib tablets specified doses on specified days.
223424781|NCT06793943|DRUG|COC|COC tablets (containing LNG and EE) specified doses on specified days.
223424782|NCT06793943|DRUG|Metformin|Metformin tablets specified doses on specified days.
223424783|NCT06793943|DRUG|Digoxin|Digoxin tablets specified doses on specified days.
223424784|NCT06793943|DRUG|Esomeprazole|Esomeprazole capsules specified doses on specified days.
223424785|NCT01579084|DRUG|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
223424786|NCT01579084|DRUG|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
223424787|NCT01579084|DRUG|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
223424788|NCT01579084|DRUG|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
223424789|NCT03892174|OTHER|Treatment protocol with adsorption|Adsorption while patients are in the OR on the extracorporeal circuit
223424790|NCT06012448|DRUG|Dupilumab|"Patients will start by getting dupilumab 600 milligram (mg) subcutaneously at week 0, followed by 300 mg every 2 weeks starting at week 2. The last dose will be given at week 24.~In addition, participants will have visits at the research site for examinations, provide health information, laboratory draws, skin biopsies (at certain time points). Participation in the study will last approximately 28 weeks."
223424791|NCT05691335|PROCEDURE|Standard CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 30 minutes.
223740012|NCT06605924|OTHER|Discrete|Ad contains baseline language + language that product is discrete
224037370|NCT01205256|DRUG|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
224037371|NCT04982588|DEVICE|Medtronic CoreValve™ Evolut™ PRO System|"The system comprised of the following three components:~1. CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)~2. EnVeo™ PRO Delivery Catheter System (DCS)~3. EnVeo™ PRO Loading System (LS)"
223424792|NCT05691335|PROCEDURE|Accelerated CXL|Epithelium-off CXL performed by removal of corneal epithelium, instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
223424793|NCT05691335|PROCEDURE|Transepithelial CXL|Epithelium-on CXL performed by instillation of riboflavin onto the cornea followed by UVA corneal irradiation for 5 minutes.
223424794|NCT06821347|DRUG|NanO2TM|Intravenous NanO2 0.17ml/kg (three doses given over 4.5 hours)
223424795|NCT06821347|OTHER|Sodium Chloride 0.9% Intravenous|Placebo
223424796|NCT03992989|DEVICE|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
223424797|NCT03992989|DEVICE|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
223424798|NCT03727126|PROCEDURE|Robotic esophagectomy|Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
223424799|NCT03727126|PROCEDURE|Thoracolaparoscopic esophagectomy|Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
223424800|NCT05021458|OTHER|Gong's mobilization|Ten patients will be treated with Gong's mobilization.
223424801|NCT05021458|OTHER|SNAG|: Ten patients will be treated with SNAGs
223424802|NCT06622473|DEVICE|hand dexterity assessement|Each participant will perform the VET, with their most affected hand, followed by the VET with the less affected hand.
223424803|NCT03066245|BIOLOGICAL|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
223424804|NCT00462592|DRUG|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning \& 1 puff evening.
223740013|NCT06605924|OTHER|Convenient|Ad contains baseline language + language that product is convenient
223740014|NCT00050596|DRUG|MDX-010 / MDX-010 + Docetaxel|
224037372|NCT05995678|BEHAVIORAL|STEP-Home-SP|This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.
224138260|NCT03363217|DRUG|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
224138261|NCT05994586|DIETARY_SUPPLEMENT|AP029 mix|Polyphenol-rich plant extracts Twice a day
223424805|NCT00462592|DRUG|montelukast|montelukast 5 mg ( \< 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
223424806|NCT00462592|OTHER|placebo|placebo
223424807|NCT06366516|DIAGNOSTIC_TEST|Methylation Test|"Participants who aged 25-65 years with high-risk HPV infection are recruited.To start with,cervical exfoliated cells are collected, coded (according to the actual enrollment sequence), and stored in the pathology department where methylation testing is performed.In addition,patients will underwent colposcopy and biopsy.~Patients are followed up by cytology, high-risk HPV and methylation tests at 6 and 12 months after enrollment.Cervical conization and hysterectomy will be taken if necessary according to histopathological results. The clinical endpoint is reached when CIN2+ is confirmed by histopathological result."
223424808|NCT04026893|PROCEDURE|Uterine Transplant from Deceased Donor|The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
223424809|NCT01287949|BIOLOGICAL|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
223424810|NCT04519320|DIAGNOSTIC_TEST|Pulmonary function testing|"D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan~* Pulmonary function testing (PFT)~* 6-minute walk test (6MWT)~* MOS SF-36 Questionnaire~* HADS scale~* Ventilatory polygraphy~M6: D0 + 6 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~M12: D0 + 12 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan (If anomaly found at M3)~* PFT~* Pulmonary Exercise Stress Test~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO \<LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale"
223424811|NCT06503783|DRUG|BL-M17D1|Administration by intravenous infusion for a cycle of 3 weeks.
223424812|NCT02738879|DRUG|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
223424813|NCT02738879|DRUG|Placebo to sitagliptin|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
223424814|NCT02738879|DRUG|Metformin|At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
224037373|NCT05995678|BEHAVIORAL|Transition Assistance Program|Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
224138262|NCT05994586|OTHER|Placebo|Twice a day
224138263|NCT01743872|PROCEDURE|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
224138264|NCT01743872|PROCEDURE|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
223424815|NCT02738879|DRUG|Metformin XR|At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
223424816|NCT02738879|DRUG|Insulin glargine|Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
224138265|NCT01743872|PROCEDURE|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
224138266|NCT01743872|PROCEDURE|Heparinized Normal Saline Injection|Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.
224138267|NCT04777578|OTHER|Dry needling|Dry needling based on fast-in fast-out technique in the teresa major muscle
223740015|NCT04975347|DRUG|Naloxone|One bolus and one infusion of naloxone
224037374|NCT05995678|BEHAVIORAL|VA Solid Start|VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
224037375|NCT04386343|DRUG|CH1701 for prevention and treatment of radiation burns.|Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.
224037376|NCT04386343|DRUG|Safety assessment of CH1701|Safety assessment of CH1701 after 14 days of use on volunteers
224037377|NCT04386343|DRUG|Placebos|The placebo was used on patients as a control for the doses of CH1701
224037378|NCT01025024|GENETIC|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
224138268|NCT01221688|PROCEDURE|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
224138269|NCT01221688|PROCEDURE|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
224138270|NCT04851002|PROCEDURE|Application of concentrated growth factor with dental implants|Concentrated growth factor(CGF) liquid applied to the implant cavity also CGF membrane covered socket and implant
223563873|NCT00616382|DRUG|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
223424817|NCT01438294|OTHER|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
223424818|NCT01438294|OTHER|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
223424819|NCT01302444|DRUG|Tadalafil|Tadalafil 40mg for 12 weeks
223424820|NCT01302444|DRUG|Placebo|Placebo for 12 weeks
223424821|NCT04241744|DRUG|Vancomycin 125 MG po BID|prevention to develop CDI during hospitalization
223424822|NCT01346189|BEHAVIORAL|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
224037379|NCT02366728|BIOLOGICAL|Unpulsed DCs|Patients in Group I will receive 1 x 10\^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
224037380|NCT02366728|BIOLOGICAL|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
224037381|NCT02366728|BIOLOGICAL|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10\^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
224037382|NCT02366728|BIOLOGICAL|111In-labeled DCs|111In-labeled DCs are 2 x 10\^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10\^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
224037383|NCT02366728|DRUG|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
224037384|NCT02366728|DRUG|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
224037385|NCT02366728|DRUG|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
224037386|NCT00980681|DRUG|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
224138271|NCT04851002|PROCEDURE|Application of advanced platelet rich fibrin with dental implants|Advanced platelet rich fibrin (A-PRF) liquid applied to the implant cavity also A-PRF membrane covered socket and implant
223424823|NCT04188431|DRUG|Dexamethasone|Is usually commercialized as dexamethasone phosphate as solution for injection
223424824|NCT04188431|DRUG|Sodium chloride|prepared in the same intravenous volume to mimic experimental arm
223424825|NCT06484348|BEHAVIORAL|Monitoring of eating behaviors|Overall eating behaviors will be assessed from pictures of consumed food and drinks taken by the participants with their smartphones. A complete assessment of eating habits will be carried out daily for 4 days. For each photo, the participants will indicate the reasons why they ate by completing analogical scales (hunger, craving, sleepiness, stress, negative emotion) and an open question (other reason). These data will be used to determine the reason and timing of food intake and the number of calories ingested for each food category. Eating behaviors specifically related to sugar intake will be monitored using the FREESTYLE PRO® sensor. This small device is used routinely for diabetes care and is placed on the back of the arm. The system is designed to measure glucose levels in the interstitial fluid every 15 minutes for up to 14 days. The recorded data can be downloaded by an investigator using the FREESTYLE LIBRE PRO® reader.
223424826|NCT06484348|BEHAVIORAL|Monitoring of sleep/wake rhythm|"The sleep-wake rhythm will be measured continuously during the 5 days, both subjectively (sleep diary) and objectively, using the GT9X LINK ACTIGRAPH."
223424827|NCT06484348|BEHAVIORAL|Measure of nocturnal sleep parameters|The quality and quantity of the participants' sleep will be recorded using the SOMFIT® device. This non-invasive portable device will allow the determination of sleep architecture as well as sleep EEG microstructure.
223424828|NCT06484348|BEHAVIORAL|Measure of sleepiness|Sleepiness will be assessed by the Karolinska Sleepiness Scale (KSS) at the initiation of food intake and 30 min and 2 hours afterwards, and by analysis of EEG activity recorded by the SOMFIT® over a time window surrounding food intake. Indeed, participants will also be asked to wear the device as much as possible during the day when they are at home in order to explore sleepiness markers during wakefulness.
223424829|NCT01730534|DRUG|Dapagliflozin 10 mg|Oral dose (od)
223424830|NCT01730534|DRUG|Placebo tablet|Oral dose (od)
223563874|NCT02750345|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
223563875|NCT02750345|DRUG|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
223563876|NCT02750345|DRUG|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
223563877|NCT03521232|DRUG|Niclosamide|enema given twice daily for 6 weeks
224138272|NCT04851002|PROCEDURE|Control side of concentrated growth factor study group|Traditional implant methods applied
224138273|NCT04851002|PROCEDURE|Control side of advanced platelet rich fibrin study group|Traditional implant methods applied
224138274|NCT02733406|OTHER|Target Controlled Infusion|
224138275|NCT02733406|OTHER|Velocity Controlled Infusion|
224138276|NCT03353753|DRUG|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
224138277|NCT03353753|DRUG|Placebo Oral Tablet|Placebo
224138278|NCT02858154|OTHER|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
224037387|NCT00980681|OTHER|Time of Flight|Each subject will undergo a TOF MRA
223424831|NCT04540341|OTHER|Mulligan mobilization|Mulligan mobilization technique will be apply.
223424832|NCT04540341|OTHER|Core stabilization|Core stabilization technique will be apply.
223563878|NCT01215617|BEHAVIORAL|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
223563879|NCT01215617|BEHAVIORAL|Control|Standard medical treatment
223563880|NCT00149695|BEHAVIORAL|Weekly home delivery of milk products|
223563881|NCT00006164|DRUG|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight \<75 kg, \>75 kg) daily in two divided doses for 24 weeks
223563882|NCT00006164|DRUG|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
224037388|NCT01704833|BEHAVIORAL|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
224037389|NCT04381455|DEVICE|OSSIX Bone|subjects will be implanted with OSSIX Bone during sinus elevation surgery
224037390|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
223424833|NCT04540341|OTHER|Conventional therapy|Conventional therapy exercise will be apply.
223740016|NCT06660667|BIOLOGICAL|SAR402663|Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
223563883|NCT05271032|DIAGNOSTIC_TEST|use of Trasnpulmonary termodiluetion technique|All the patients underwent to invasive hemodynamic monitoring through the transpulmonary thermodilution technique (PiCCO, PULSION medical system. Gettinge; Solna, Sweden). Briefly, the technique consists in the administration of a cold saline bolus in superior vena cava while monitoring the corresponding temperature variation through a femoral arterial catheter equipped with a tip thermistor. Accordingly, a 5 French catheter equipped with a tip thermistor was inserted into the femoral artery.
224138279|NCT02858154|OTHER|Low flow oxygen by nasal cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to manage sleep apnea
224138280|NCT02979301|DRUG|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
224138281|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared calcium hydroxide in to the root canals|Calcium hydroxide (Merck, Darmstadt, Germany): prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.
224299032|NCT01673243|OTHER|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
223563884|NCT00849615|DRUG|Docetaxel|50mg/m2 qd15
223740017|NCT06660667|DRUG|Diluent|Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
224138282|NCT05581706|COMBINATION_PRODUCT|Place the freshly prepared double antibiotic paste in to the root canals|Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in airtight containers. The same amount of each drug powder (1:1) was mixed and the mixed samples were combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.
224299033|NCT00226421|DRUG|Oxymorphone Extended Release|
223740018|NCT06662162|DEVICE|i-Lumen AMD|i-Lumen AMD transpalpebral microcurrent stimulation system
223424836|NCT04369131|DEVICE|Functional electrical stimulation|Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
223424837|NCT04814550|DIAGNOSTIC_TEST|FFR|FFR measured by pressure wire, AccuFFRangio computed by coronary angiographic images
223424838|NCT01895608|BEHAVIORAL|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
223563885|NCT00849615|DRUG|5-Fluorouracil|2600mg/m2 qd15
223563886|NCT00849615|DRUG|Oxaliplatin|85mg/m2 qd15
223563887|NCT00849615|DRUG|folinic acid|200mg/m2 qd15
223740019|NCT05247229|BEHAVIORAL|Middle school education program|The intervention assessed the impact of a middle school education program (implemented as an after school program in Sitka, AK and Juneau, AK and during school hours as an elective in Hoonah, AK) on shellfish and toxin knowledge and clam harvesting planned behaviors. The intervention took place weekly during the school year. The curriculum centered around teaching children about local traditional ecological knowledge and traditional harvesting and gathering practices.
224037391|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
224037392|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
224037393|NCT00992511|BIOLOGICAL|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
224037394|NCT02091583|DIETARY_SUPPLEMENT|Butter, sunflower and safflower oil|
224037395|NCT02091583|DIETARY_SUPPLEMENT|High Oleic Canola Oil and DHA (HOCO-DHA)|
224037396|NCT02091583|DIETARY_SUPPLEMENT|Barley beta-glucan|
224037397|NCT02091583|DIETARY_SUPPLEMENT|HOCO-DHA and Barley beta-glucan|
224037398|NCT01747304|DEVICE|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
224037399|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
223424839|NCT01895608|BEHAVIORAL|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
223424840|NCT01895608|BEHAVIORAL|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
223424841|NCT01895608|BEHAVIORAL|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
223424842|NCT05855174|DIETARY_SUPPLEMENT|Whey protein|Weight protein provided in a shake with carbohydrate and water
223424843|NCT00405522|DRUG|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
223563888|NCT03892083|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
223563889|NCT01447485|DRUG|Valsartan (VAL489)|
223563890|NCT02947178|PROCEDURE|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
223563891|NCT02947178|BEHAVIORAL|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
223563892|NCT02947178|BEHAVIORAL|Pill Count|Patient reported as needed (prn) pain medication usage
223563893|NCT02947178|DRUG|Bupivacaine|
223563894|NCT02947178|DRUG|Liposomal Bupivacaine|
223563895|NCT02642393|DRUG|Inosine|capsules containing 500 mg of inosine
224138283|NCT05581706|DIAGNOSTIC_TEST|Taking standart periapical radiography with film holder|"Post-operative periapical radiographs were obtained with Digora Optime SPP system (Soredex Corp., Tuusula, Finland) using intraoral film holders to keep the plates parallel to the long axis of the teeth. A size #2 SPP was used for all exposures. SPPs were exposed with a Gendex Oralix DC dental x-ray unit (Gendex Dental Systems, Milan, Italy) operating at 60 kVp, 7 mA, 0.25 sec. and the plates were scanned immediately after exposure. The clinical and radiographical follow up was performed on 12th months.~Image-J program (version 1.47, National Institutes of Health, Bethesda, MD) with TurboReg plug-in (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) was used to determine the increase in root length, root width, and radiographic root area at 12th month follow up."
223424844|NCT00405522|DRUG|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
223563896|NCT02642393|DRUG|Placebo|capsules containing \~500 mg of lactose and appearing indistinguishable from inosine capsules
223563897|NCT02966093|DRUG|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
223563898|NCT02966093|DRUG|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
223740020|NCT05281471|BIOLOGICAL|olvimulogene nanivacirepvec|Olvi-Vec is an engineered oncolytic vaccinia virus
224299034|NCT06151496|DRUG|Alpha-Agonist|The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
224299035|NCT06151496|DRUG|α-adrenergic receptor agonist|The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
223424845|NCT05174858|DEVICE|Hemostatic dressing ETIK COLLAGENE|The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
223424846|NCT05174858|OTHER|Comparator|The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
223563899|NCT00633074|BIOLOGICAL|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
223424847|NCT02855359|DRUG|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
223563900|NCT00633074|BIOLOGICAL|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
223563901|NCT04477382|DIETARY_SUPPLEMENT|holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.|Subjects suffering from house dust mite (HDM) allergic rhinoconjunctivitis who are reacting positively to chamber exposure with HDM are reevaluated in the exposure chamber 3 months after taking food supplements.
223563902|NCT03088436|DEVICE|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
223563903|NCT04983836|PROCEDURE|Serratus anesthesia technique|locoregional anaesthesia allowing analgesia of the hemi-thorax by ultrasound guided single injection of naropeine 5mg/ml
223563904|NCT04983836|PROCEDURE|Paravertebral anesthesia technique|Ultrasound guided single injection of of naropeine 5mg/ml dose into the paravertebral space next to the thoracic spine
223740021|NCT05281471|DRUG|Platinum chemotherapy: carboplatin (preferred) or cisplatin|Administered according to local practice
223563905|NCT02204605|BEHAVIORAL|Video-based Consensus Opinion|
224037400|NCT04498169|DRUG|Netarsudil Ophthalmic|Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
224037401|NCT05030103|DEVICE|Reading glasses, +2.0 diopters|The participants in the glasses-group are asked to wear the reading glasses during near-work.
224037402|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
224037403|NCT03163979|BIOLOGICAL|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
224299036|NCT03275636|BIOLOGICAL|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
224299037|NCT04267107|OTHER|Individual Managing Fatigue Program|The Individual Managing Fatigue Program includes six weekly sessions that focus on sleep, communication and body mechanics, activity stations, priorities and standards, and balancing daily schedule. Each session includes three parts: 1) a pre-session activity 2) in-session activities/information and 3) homework. Prior to coming to each session, participants will be asked to complete activities that will help them prepare for the in-session discussions. During each session participants will discuss and practice the topics most important to them. Based on their discussions, participants and therapists will decide on activities to complete during each session and as homework. The therapist will help the participant begin the homework at the end of each session, and the participant will finish it outside of the session at home. At the beginning of the following session, the therapist and participant will review the homework.
224299038|NCT02422771|OTHER|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
224299039|NCT04746911|DRUG|ARQ-151 cream 0.3%|ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
224299040|NCT04069871|DEVICE|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
224299041|NCT04069871|DEVICE|Sham TENS|Patients in the control group will receive sham TENS.
224299042|NCT00266071|BEHAVIORAL|Cutaneous response|
224299043|NCT05874583|DRUG|Combined route administration of Tranexamic acid|tranexamic acid in topical route administration
224299044|NCT05874583|DRUG|Intravenous route Tranexamic acid injection|Intra venous route administration
224299045|NCT04551833|DRUG|Levobupivacaine|Tramadol versus Dexamethasone as adjuvant to Levobupvacain
224299046|NCT00684489|DRUG|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
224299047|NCT00684489|DRUG|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
224299048|NCT02648295|PROCEDURE|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
224299049|NCT03596151|DEVICE|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
224299050|NCT05802251|DIAGNOSTIC_TEST|Ultrasonographic parameters|cervical length. placental thickness. distance placental edge from internal os of the cervix
224299051|NCT04094376|OTHER|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
224299052|NCT00222989|DRUG|PPI|
224299053|NCT03420664|DEVICE|Orthosis VACOped|Orthosis for lower limb immobilisation
224299054|NCT03420664|DEVICE|Below knee cast|Below knee cast for lower limb immobilisation
224299055|NCT05948514|OTHER|The complications related to central venous access device|The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
224299056|NCT02514850|DRUG|Biochaperone Combo|Injection of BioChaperone Combo
224299057|NCT02514850|DRUG|Humalog Mix25|Injection of Humalog Mix25
224299058|NCT02514850|DRUG|Humalog|Injection of Humalog
224299059|NCT02514850|DRUG|Lantus|Injection of Lantus
224299060|NCT02514850|DRUG|Placebo|Injection of saline 0.9% solution
223424848|NCT02855359|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
223424849|NCT02855359|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
224037404|NCT03163979|BIOLOGICAL|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
224037405|NCT03163979|BIOLOGICAL|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
224037406|NCT03730441|DEVICE|Colonoscopy|Endoscopic examination of large bowel
224037407|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC|"FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
223424850|NCT02855359|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
223424851|NCT02855359|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
223424852|NCT02855359|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
223424853|NCT01619137|DRUG|water and soap|water and soap for 6-8 hours per day.
223424854|NCT01619137|DRUG|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
223424855|NCT05290909|OTHER|The protocol of blended and problem-based learning|The protocol of blended and problem-based learnin: The online platforms used in this research are the school's iLMS platform, online digital learning, and online opinion exchange platform. It will use online resources (Google, open educational resources, YouTube copyrighted medical micro-movies, and audio-visual materials), and the theme will be elderly care or emerging Multimedia resources on infectious themes, as well as real-time interaction with kahoot or Slido electronic whiteboards, will be uploaded to the office3655The One website. Drive is provided by the school (the school account is used to store course resources) and the system of digital theoretical course concepts in advance. Broadcasting, video (such as: values and conflicts; ethics and morality; patient rights and responsibilities; nurses' rights and responsibilities; ethical theory; basic ethical principles; ethical dilemmas and ethical decision-making; etc.), pre-recorded and stored on the Internet Road platform iLMS.
223424856|NCT05290909|OTHER|The traditional problem-oriented teaching model|The traditional problem-oriented teaching model: There will be two PBL case introductions throughout the semester, with face-to-face teaching in physical classrooms.
223424857|NCT02184585|DRUG|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
224037408|NCT04546568|DEVICE|Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM|"FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care."
224138284|NCT05581706|OTHER|Sample collection for immunofluorometric assay|Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
223424858|NCT02184585|DRUG|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
223424859|NCT02184585|DRUG|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
223424860|NCT06004856|DRUG|Orelabrutinib|Orelabrutinib once daily (QD)
223424861|NCT06004856|DRUG|Placebo|Placebo once daily (QD)
224037409|NCT00844207|DRUG|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
223424862|NCT00877409|DRUG|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
223424863|NCT00877409|DRUG|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
223424864|NCT02833844|DRUG|Evolocumab|Dose of subcutaneous evolocumab QM
223424865|NCT02833844|DRUG|Placebo|Dose of matching placebo QM
224037410|NCT00844207|DRUG|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
224037411|NCT03442790|PROCEDURE|Agitated Saline Method|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
223424866|NCT06386068|BEHAVIORAL|Values-based Cognitive Behavioral Therapy (V-CBT)|The intervention offers a 10-session treatment for chronic Whiplash-Associated Disorder (WAD). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants' lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
223424867|NCT02704572|BIOLOGICAL|Zostavax|Zostavax will be administrated by subcutaneous injection.
223424868|NCT00065104|DRUG|DHEA|
223424869|NCT06498622|DRUG|Donafenib + Envafolimab|"Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI"
223424870|NCT03231540|DIETARY_SUPPLEMENT|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
223424871|NCT03369067|DEVICE|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].
223424872|NCT03369067|DEVICE|Dexcom CGM G5|"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
223424873|NCT03369067|DEVICE|Continuous Subcutaneous Insulin Infusion|Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
223424874|NCT02952846|OTHER|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
223424875|NCT04828265|BIOLOGICAL|Aldafermin|Single dose of aldafermin
223424876|NCT02312596|DEVICE|PRP Concepts Fibrin Bio-Matrix|Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
223424877|NCT02312596|OTHER|Usual and Customary Practice|Usual and customary care for non-healing wounds
223424878|NCT06665295|BEHAVIORAL|THRIVE-CAR-T|The intervention will begin several weeks prior to CAR-T cell therapy and will continue up until 30 days post CAR-T cell therapy. THRIVE-CAR-T is an educational and interactive digital application on an iPad for patients as they navigate receiving CAR-T. THRIVE-CAR-T is self-administered and provides education about the CAR-T cell therapy process, with several features to promote coping skills training informed by various well-established supportive psychotherapy strategies (e.g., cognitive behavior therapy, mindfulness, positive psychology), engagement, and health behavior change including gamification strategies, videos of patients who received CAR-T, and optional content.
223424879|NCT05451550|PROCEDURE|Brachial plexus block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
224037412|NCT03442790|PROCEDURE|chest x-ray|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
223424880|NCT05451550|PROCEDURE|General anesthesia|General anesthesia were performed according to clinical routine: induction drugs: propofol, sufentanil, rocuronium, maintenance drugs: propofol, sevoflurane and remifentanil, Laryngeal mask ventilation.
223563906|NCT02591667|PROCEDURE|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
224037413|NCT03858790|DEVICE|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
224037414|NCT02281279|BIOLOGICAL|rituximab|Given IV
224037415|NCT02281279|DRUG|lenalidomide|Given PO
224037416|NCT02281279|DRUG|romidepsin|Given IV
224037417|NCT02281279|OTHER|laboratory biomarker analysis|Correlative studies
223563907|NCT02591667|DRUG|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
223740022|NCT05281471|DRUG|Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin|Administered according to local practice
223740023|NCT05281471|DRUG|Bevacizumab (or biosimilar)|Administered according to local practice
223740024|NCT06980428|DRUG|AZD4954|AZD4954 will be administered orally.
223740025|NCT06980428|DRUG|Placebo|Placebo will be administered orally.
224037418|NCT05719558|DRUG|ASP1002|intravenous (IV) infusion
224037419|NCT01979224|OTHER|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
224037420|NCT04879641|BEHAVIORAL|Exposure|Participants are instructed to plan and track in vivo exposures using an exposure diary. Participants are also instructed to reduce safety behaviors, which are overt or covert acts such as avoiding eye contact or rehearsing sentences to prevent a feared outcome.
224037421|NCT04879641|BEHAVIORAL|Attention Training|Participants are trained to reduce self-focused and biased attention. Various audio exercises are introduced in which participants learn to intentionally direct the attention away from themselves (i.e., less private self-consciousness), and to be less alert to potentially dangerous external social stimuli (i.e., less public self-consciousness).
224037422|NCT04879641|BEHAVIORAL|Cognitive Restructuring|Participants are instructed to identify and modify dysfunctional and negatively biased assumptions. It includes a thought diary to track negative beliefs in daily routine, alongside with exercises to formulate helpful and adaptive thoughts.
224037423|NCT04879641|BEHAVIORAL|Psychoeducation|Participants are delivered detailed evidence-based information on SAD with a focus on maintaining processes (e.g., the vicious circle of negative thoughts and emotions, cognitions, and behaviors associated with the maintenance of SAD). Based on the information provided, participants are encouraged to develop an individual model of their social anxiety symptoms.
223424881|NCT05451550|PROCEDURE|Suprascapular nerve block|An additional ultrasound-guided suprascapular nerve block(0.375% ropivacaine) were performed before general anesthesia induction in general anesthesia combined with brachial plexus block group
224037424|NCT06489340|DRUG|2HPβCD|2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.
223424882|NCT04403503|DRUG|Gelatin Sponge;Thrombin, Bovine 5000 IU Multiple Routes Kit [GELFOAM-JMI SPONGE KIT]|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group)
224037425|NCT04304976|DEVICE|ROBERT®|Robotic Rehabilitation intervention ROBERT®, designed for early, and supplementary therapy of patients.
224037426|NCT04014036|DEVICE|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
224138285|NCT05207306|PROCEDURE|Type of interfascial plane block|"In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way."
224138286|NCT05670405|OTHER|The Trauma PORTAL|"Participants will have 9 weeks to complete the 8 modules which each take on average 45 minutes to complete. Each module consists of psychoeducational handouts, videos, interactive exercises, and discussion topics that has been adapted from the R\&R curriculum. The participants will also receive a pdf of the handouts from the modules, which can be used to take notes or refer back to in the future.~There will be an optional 60-minute weekly virtual group session for participants to engage with other participants in their group and for group facilitator providers to discuss the materials covered and answer any questions. Participants will join a Zoom video group visit to access the group. Each weekly group will be facilitated by 2 clinicians specializing in trauma-focused therapy within the WCH TTP who have extensive experience with in-person and virtual synchronous R\&R."
224138287|NCT03444194|PROCEDURE|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
224138288|NCT00709917|DRUG|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
223424883|NCT04403503|DRUG|Cyanoacrylate, Isobutyl|Donor site was closed either with GS (Spongostan®, Ethicon, Somerville, USA) (GS group) and GS covered with high viscosity CY (PeriAcryl®, Glustitch Inc., Delta, Canada) (GS+CY group).
223424884|NCT01245543|DRUG|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
223424885|NCT01245543|DRUG|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
223424886|NCT05013879|DEVICE|Kinesio(R)Tape for edema control|Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
223563908|NCT02591667|PROCEDURE|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
223563909|NCT04147390|DRUG|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
223563910|NCT04147390|DRUG|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
223563911|NCT00365105|DIETARY_SUPPLEMENT|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
223563912|NCT00365105|DIETARY_SUPPLEMENT|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
224037427|NCT03499236|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
224138289|NCT04536649|RADIATION|Radiotherapy|Multimodal brain imaging-guided radiotherapy using different beams
224138290|NCT03148626|OTHER|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
223424887|NCT05153200|DRUG|Upadacitinib|15 mg po daily
223424888|NCT05153200|DRUG|Adalimumab|40 mg sc every other week
223424889|NCT06499233|DRUG|Trimethoprim/Sulfamethoxazole|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
223424890|NCT02377479|DRUG|Clomiphene|Taken for controlled ovarian hyperstimulation.
223424891|NCT02377479|DRUG|Letrozole|Taken for controlled ovarian hyperstimulation
223424892|NCT00630175|DRUG|zolpidem-MR (modified release)|
223424893|NCT00630175|DRUG|zolpidem (SL800750)|
223424894|NCT00630175|DRUG|placebo|
223424895|NCT05531578|DEVICE|INOVARE® Transcatheter Valve, NexusCath Delivery System, Aureus Expandable Introducer, Balloon Catheter for Pre-Dilation and Compression Device (Crimper)|Transfemoral implantation of the INOVARE® transcatheter valve
223424896|NCT05482321|DRUG|Definity Suspension for Injection|"* DEFINITY is administered as per manufactures instructions~* 1 vial of DEFINITY is allowed to warm to room temperature and activated by 45s shaking on a VIALMIX~* Withdraw the activated milky white suspension using the provided Dispensing Pin, PINSYNC or 18-20 gauge syringe needle, from the middle of the liquid in the inverted vial.~* Deliver a dose of 10 μl/kg of 'milky white suspension' IV as a bolus, delivered over 30seconds.~* Following imaging, provide a 10 mL flush of preservative-free saline~* Wait at least 30minutes until second dose (if provided)."
223563913|NCT00365105|DRUG|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
223563914|NCT00365105|DRUG|Sm-153|Single dose intravenously 1 mCi/kg body weight.
223563915|NCT00365105|RADIATION|Sr-89|Single dose intravenously 4 mCi.
223424897|NCT01864915|DRUG|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
223424898|NCT01864915|PROCEDURE|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
223424899|NCT05132712|DRUG|Losartan Potassium|ACE inhibitor
223424900|NCT05132712|DRUG|multi-vitamins|placebo drug
223424901|NCT03408470|DRUG|TD-1473 oral capsule|(Intervention description included in arm description)
223424902|NCT03408470|DRUG|[14C]-TD-1473 IV bolus|(Intervention description included in arm description)
223424903|NCT03408470|DRUG|[14C]-TD-1473 Oral Capsule|(Intervention description included in arm description)
223424904|NCT03963050|OTHER|Exercise Training|The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
223424905|NCT03963050|OTHER|Exercise Training + Cognitive Training|"ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts."
223424906|NCT03963050|OTHER|Control|NO changes in lifestyle
223424907|NCT03676114|DRUG|ketamine|0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
223563916|NCT00608023|DRUG|Tesamorelin|
223563917|NCT00608023|DRUG|Placebo for Tesamorelin|
223563918|NCT06428565|DIAGNOSTIC_TEST|Low-level laser therapy (LLLT) or cold laser therapy|Low-level laser therapy (LLLT) or cold laser therapy
223563919|NCT03075722|DEVICE|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
223563920|NCT03069287|BEHAVIORAL|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
223740026|NCT04782375|DRUG|Stop group|discontinue antiviral treatment
223740027|NCT05725057|DRUG|AX-158|Subjects randomized to this arm will receive AX-158 treatment for 28 days with a 30 day safety follow-up period.
224037428|NCT03499236|OTHER|Control|Right heart catheterization, invasive echocardiography.
224037429|NCT05603793|BEHAVIORAL|Knowledge, Attitude & Practices|The objective the of the KAP intervention is to explore key aspects related to child health and nutrition to better understand the community's knowledge, perception and practices. In addition to child health, we are also tracking the transition of health from urban to rural areas in terms of the prevalence of adult non-communicable diseases.
224037430|NCT05317884|BEHAVIORAL|Reminder|Email
224037431|NCT04791969|DRUG|Naltrexone Hydrochloride|Intermittent Oral Naltrexone, 50 mg
224037432|NCT04791969|DRUG|Placebo|Intermittent Oral Placebo
224037433|NCT04791969|BEHAVIORAL|Ecological Momentary Intervention|"Receive ecological momentary intervention if ecological momentary assessment reports meth craving, stress, not taking study drug, or antecedents detected for high risk meth use."
223424908|NCT03676114|DRUG|Normal saline|Same volume of normal saline will be administrated
223424909|NCT01692249|OTHER|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
223424910|NCT05824052|OTHER|Ozone injection|Ozone injection is a process where ozone gas is injected into a substance or system for various purposes. Ozone gas (O3) is a highly reactive form of oxygen that can be generated through the use of specialized ozone generators. Ozone injection can be used in a variety of applications, including water treatment, air purification, and medical therapy.
223424911|NCT02197286|DRUG|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
223424912|NCT02197286|DRUG|Placebo|Daily dose of a single gelatin placebo capsule.
223424913|NCT03768011|COMBINATION_PRODUCT|transdermal cream and or patch|transdermal cream and/or transdermal patch(s) with or without oral medication
223424914|NCT00558662|DEVICE|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
224037434|NCT05581667|OTHER|post isometric relaxation|PIR is performed by first passively lengthening the muscle, then having the patient lightly contract (10-20% of maximum) against resistance for 5 seconds passively before exhaling and relaxing the muscle and repeated. The clinician then takes up the slack within the muscle and repeats the technique 3 to 5 times
224037435|NCT05581667|OTHER|Swedish Massage|classic Swedish massage for the cervical and upper thoracic region. Massage is a method that is applied to superficial soft tissues such as muscles, skin, ligaments and fascia and structures located under the superficial tissues and aims to relax.
224037436|NCT00182390|PROCEDURE|Red blood cell transfusion|
224138291|NCT03148626|OTHER|Control|Usual Education
223424915|NCT00558662|DEVICE|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
223563921|NCT04299503|DRUG|Crisaborole Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
223563922|NCT04299503|DRUG|Placebo Topical Ointment|For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
223740028|NCT05725057|DRUG|Placebo|Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
224037437|NCT04615247|OTHER|Yoga Program|The yoga program is designed to maximize women's awareness of and control over the pelvic floor, promote relaxation, and improve physical function.
224037438|NCT04615247|OTHER|Physical Conditioning Program|The physical conditioning program will focus on a core set of exercises designed to improve physical function and emotional well-being in order to improve management of chronic pain.
224037439|NCT03260231|DIETARY_SUPPLEMENT|Milled seed mix|Dietary intervention with or without seed mix
224037440|NCT00247377|PROCEDURE|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
224037441|NCT00247377|PROCEDURE|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
224037442|NCT05020431|OTHER|Biological measuring of collagen fragments biomarker during orthodontic tooth movement|Biological measure the levels of type I collagen fragments ICTP and CTX levels in the GCF and saliva during initial leveling and alignment in adolescent patients treated with fixed orthodontic appliances.
224037443|NCT00004051|DRUG|irinotecan hydrochloride|
224037444|NCT04577196|OTHER|Trauma dashboard|A large dashboard available to all, providing a framework for synthesizing and displaying relevant information about the arriving critical patient, to be filled in by the trauma leader.
224037445|NCT02075268|DRUG|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
224037446|NCT04085627|DRUG|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg\& Amlodipine 5mg
224037447|NCT04500431|BIOLOGICAL|Targeting CD269 chimeric antigen receptor engineered T cells|Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
224037448|NCT02942238|PROCEDURE|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
224037449|NCT02942238|PROCEDURE|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
224037450|NCT00014326|RADIATION|radiation therapy|
224037451|NCT03113253|DRUG|Tranexamic Acid|
224037452|NCT03113253|DRUG|Placebo|0.9% sodium chloride to mimic tranexamic acid
224037453|NCT04682977|OTHER|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning)|IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning) is an intervention designed to be delivered in primary care settings by an on-site occupational therapist. Based on the premise of preventing the physical and cognitive decline that is associated with aging and chronic disease, the 12-week intervention includes a comprehensive assessment of ADL functioning and ten intervention sessions addressing disease management, physical activity and executive functioning.
224037454|NCT04682977|OTHER|Usual primary care services|Usual primary care services might include monitoring of vitals and other relevant laboratory testing, prescription of medications for chronic disease management, as well as counseling for lifestyle changes.
224037455|NCT03558594|BEHAVIORAL|Hypnosis|Behavioral Condition
224037456|NCT03558594|BEHAVIORAL|Mindfulness|Behavioral Condition
224037457|NCT06072781|DRUG|avutometinib|Avutometinib: administered orally
224037458|NCT06072781|DRUG|Defactinib|Defactinib: administered orally
224037459|NCT06072781|DRUG|Pegylated liposomal doxorubicin|administered intravenously
224037460|NCT06072781|DRUG|Paclitaxel|administered intravenously
224037461|NCT06072781|DRUG|Letrozole|administered orally
224037462|NCT06072781|DRUG|Anastrozole|administered orally
224037463|NCT05793918|OTHER|Therapeutic Percutaneous Electrolysis an neuromodulation|Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
224138292|NCT04535154|OTHER|No interventions|No interventions
224138293|NCT01830816|DRUG|Ixazomib|Ixazomib capsules
223740029|NCT01013727|RADIATION|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
224037464|NCT05793918|OTHER|Conventional group|Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
224037465|NCT00212628|DRUG|Minodronic acid hydrate|
224037466|NCT06611241|BEHAVIORAL|Hazard Anticipation Program for Parents of Teen Drivers|Parents and teens who receive the intervention will complete a web-based training that provides parents with guidance on how to teach their teen to identify potential hazards on the roadway. The program begins by providing background on teens' difficulty learning this skill and the motivational interviewing techniques that are being used in the course. Parents then engage with a series of hazard videos. For each hazard, parents watch the hazard unfold, provide an example of what they might say to their teen in that, and are provided with examples of how to coach their teen through the hazard before it becomes a critical event. Parents and teens then jointly watch 12 videos depicting hazards unfolding on the roadway. Teens are asked to identify the hazard without parental input by pressing a spacebar. Teens must also indicate what they believe was the key event that caused the hazard. Then parents and teens are given an opportunity to replay the video and discuss the hazard together.
224037467|NCT05395481|DRUG|LY3849891|Administered SC
224037468|NCT05395481|DRUG|Placebo|Administered SC
224138294|NCT04173871|DEVICE|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
224138295|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
223563923|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
223424916|NCT06499168|DRUG|neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery|"In locally advanced breast cancer patients who will receive neoadjuvant chemotherapy formalin fixed paraffin embedded tissue specimen of the baseline TCNB of locally advanced breast cancer will be obtained from pathology laboratory, Pathology Department, Assiut University.~* Histological diagnosis of H\&E stained sections will be confirmed.~* Immunohistochemical staining for CD10 .~* Baseline clinicopathological features of patients who will receive neoadjuvant chemotherapy will be collected from patients' records.~* Correlation between CD10 expression and the baseline clinicopathological features with the response to neoadjuvant chemotherapy."
223424917|NCT01070667|DRUG|Dronedarone|400mg orally once per day for 3 months
223424918|NCT01070667|DRUG|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
223424919|NCT02541669|DRUG|TAK-491|TAK-491 tablets
223740030|NCT06863142|BIOLOGICAL|VRC-FLUMOS0116-00-VP|The VRC-FLUMOS0116-00-VP (FluMos-v2) vaccine is composed of de novo engineered pentamer assembled with de novo engineered trimeric domains to an icosahedral core, projecting 20 HA ectodomain trimers from influenza strains: Influenza A (H1-H3) and Influenza B (Victoria lineage and Yamagata lineage)
223424920|NCT02541669|DRUG|TAK-491 placebo|TAK-491 placebo-matching tablets
223424921|NCT04086212|DRUG|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
223424922|NCT04086212|DRUG|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
223424923|NCT06668610|DEVICE|StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS|Real multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 20 minutes.
223424924|NCT06668610|DEVICE|StarStim 32, Neuroelectrics, Spain - Sham multifocal tDCS|Sham multifocal tDCS will be delivered with an intensity of 2.0 mA over 8 electrodes positioned over the frontal and temporal areas in the left hemisphere according to the international 10/10 EEG system. The overall duration of stimulation will be set at 30 seconds.
223424925|NCT06668610|BEHAVIORAL|Cognitive treatment|During the two cycles, all participants will undergo traditional cognitive stimulation therapy, involving paper-and-pencil exercise and computerised activity on several cognitive domains including memory, attention, and executive functions (duration 30-40 minutes) .
223424926|NCT03580434|DEVICE|V-STRUT|Minimally invasive implantation of V-STRUT
223424927|NCT06668675|OTHER|A serious game known as the 'Happy Heart' will be used as the intervention.|"The serious game known as 'Happy Heart' is a mobile game used for educational purpose in addition to entertainment. It focuses on healthy habits for the heart and is aimed at improving knowledge on diet and physical activity among school-going adolescents.~The game is developed in collaboration with the game development team from the School of Informatics, University of Skövde and the health team from Kathmandu Medical College, Nepal."
223424928|NCT02284659|DEVICE|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
223424929|NCT02284659|DEVICE|FES- Sham|
223424930|NCT04558775|OTHER|Observational|no intervention
223424931|NCT01138358|OTHER|medical chart review|
223424932|NCT01138358|OTHER|study of socioeconomic and demographic variables|
223424933|NCT01138358|OTHER|survey administration|
223424934|NCT01138358|PROCEDURE|quality-of-life assessment|
223424935|NCT04651049|DRUG|propranolol|This retrospective study included 128 patients treated with oral propranolol at a dose of 2.0 mg/kg per day.
223424936|NCT04651049|DEVICE||
223424937|NCT06622603|DRUG|Febuxostat|The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.
223424938|NCT00124007|BIOLOGICAL|VRC-HIVADV014-00-VP|
223424939|NCT00124007|BIOLOGICAL|VRC-HIVDNA016-00-VP|
223424940|NCT04433715|DIAGNOSTIC_TEST|ICIQ-SF|All participants completed ICIQ-SF,
223424941|NCT04433715|DIAGNOSTIC_TEST|UDI-6|All participants completed UDI-6
223424942|NCT04433715|DIAGNOSTIC_TEST|IIQ-7|All participants completed IIQ-7
223424943|NCT02737631|DEVICE|"Chameleon Personal Lubricant"|
223424944|NCT05172869|PROCEDURE|Suprainguinal Performed FICB|Linear ultrasound probe places above inguinal ligament sagittally, close to the femoral crease and superior-lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
223424945|NCT05172869|PROCEDURE|Infrainguinal Performed FICB|Linear ultrasound probe places below inguinal ligament transversally, close to the femoral crease and lateral to the femoral artery. It is aimed to spreading local anesthetics under the fascia iliaca medial-laterally
223424946|NCT02191722|BEHAVIORAL|reading comics booklet|
223424947|NCT03912714|PROCEDURE|Laparoscopic appendectomy|Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (\>20).
223424948|NCT03912714|PROCEDURE|Endoscopic appendix biopsies|Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
223424949|NCT06648616|OTHER|EBT|Elastic Band Resistance Training
223424950|NCT00752258|DRUG|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
223424951|NCT01118624|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
223740031|NCT06863142|OTHER|ALFQ|The ALFQ adjuvant is a sterile suspension that contains monophosphoryl 3-deacyl Lipid A \[3D-PHAD(R)\] and QS-21
223740032|NCT05251207|DIETARY_SUPPLEMENT|L-carnitine|L-carnitine-L-tartrate
223740033|NCT05251207|DIETARY_SUPPLEMENT|L-leucine|L-leucine
224037469|NCT03257020|DIAGNOSTIC_TEST|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
224037470|NCT06832306|DEVICE|Phrenic Nerve Stimulation|During controlled MV when patients are not breathing, continuous diaphragm neurostimulation-assisted ventilation (DNAV) will be delivered in synchrony with each ventilator-delivered breath.
224037471|NCT06736574|DRUG|Omecamtiv Mecarbil (OM)|Oral Tablet
224037472|NCT06736574|DRUG|Placebo|Oral Tablet
224037473|NCT06076486|DRUG|Elagolix|Elagolix 200 mg tablets administered orally BID
224037474|NCT06076486|DRUG|Elagolix placebo|Elagolix placebo administered orally BID
224037475|NCT01383161|DRUG|Curcumin|Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
223740034|NCT05251207|BEHAVIORAL|Change of the circadian cycle|Reducing sleep at night for four consecutive days (enabling sleep between 8:00 and 17:00)
224037476|NCT01383161|OTHER|Placebo|Six capsules per day for 18 months.
224037477|NCT05873946|DIAGNOSTIC_TEST|intraoperative ultrasound|Use of 2D non-navigated intraoperative ultrasound as an operative adjunct
224037478|NCT05713188|DEVICE|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream. Healthy volunteers will undergo filtration for 5 hours.
224037479|NCT05903872|OTHER|aromatherapy massage|aromatherapy massage was applied using essential oils
224037480|NCT05903872|OTHER|back massage|back massage was applied using only almond oil
224037481|NCT01736085|BEHAVIORAL|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
224037482|NCT01736085|BEHAVIORAL|Voucher|"Subjects will receive a voucher for nicotine patches.~Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date."
223424952|NCT01118624|DIETARY_SUPPLEMENT|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
223424953|NCT01118624|DIETARY_SUPPLEMENT|Folic Acid|"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
223424954|NCT00690196|BEHAVIORAL|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
223424955|NCT00690196|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
223424956|NCT06621342|BIOLOGICAL|PRP Experimental|All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.
223424957|NCT05053048|DEVICE|SL-PLUS-Stem for total hip arthroplasty|Patients undergoing primary total hip arthroplasty are randomly assigned (1:1) to receive either an uncemented NT-SL-PLUS Stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) or a matching uncemented STD-SL-PLUS stem (Smith\&Nephew Orthopaedics AG, Aarau, Switzerland) in a blinded fashion.
223740035|NCT06870617|OTHER|Practical Geriatric Assessment|The PGA will be administered via the electronic health record (EHR), available for patients to complete independently prior to an initial medical oncology visit, or during the visit with staff assistance. Results from the PGA will be shared automatically with clinical teams via the EHR, including a Best Practice Alert highlighting any identified geriatric impairment(s) and ASCO's recommendation for PGA-adapted care.
223424958|NCT04799548|DRUG|Transcatheter Arterial Chemoembolization|"Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid."
223424959|NCT04799548|DRUG|Tislelizumab|PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
223424960|NCT05591612|BEHAVIORAL|Salt replacement seasoning (50% salt and 50% MSG) mix|Individuals in this group were provided a seasoning that replaced 50 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 50/50 MSG Mix to be added to vegetables in diet.
223424961|NCT05591612|BEHAVIORAL|Salt replacement seasoning (70% salt and 30% MSG) mix|Individuals in this group were provided a seasoning that replaced 30 % regular salt with a reduced-sodium MSG substitute. This study assessed the vegetable intake using the intervention of 70/30 MSG Mix to be added to vegetables in diet.
223424962|NCT05591612|BEHAVIORAL|NaCl (sodium chloride/table salt)|Individuals in this group were asked to use normal seasoning of regular salt. This study assessed the vegetable intake using table salt to be added to vegetables in diet.
223424963|NCT01783639|PROCEDURE|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
223424964|NCT00902343|PROCEDURE|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
223424965|NCT00902343|PROCEDURE|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
223424966|NCT02774122|DEVICE|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
223424967|NCT02774122|DEVICE|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
223424968|NCT05267925|DIETARY_SUPPLEMENT|CuraLin|"CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~* Mormordica charantia (fruit) - 300mg~* Gymnema sylvestre (leaf) - 80mg~* Trigonella foenum-Graecum (seed) - 100mg~* Curcuma longa (rhizome) - 100mg~* Phyllanthus embilica officinalis (fruit) - 100mg~* Swertia chiraytia (leaf) - 80mg~* Syzgium Cumini (seed) - 100mg~* Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~* Cinnamoum verum/zeylanicum - 40 mg~* Hydroxypropyl methylcellulose~* Rice Flour"
223424969|NCT03748576|BEHAVIORAL|telemedicine: management through WeChat group chat|Patients in intervention group received additional WeChat group management when conducted standard clinic prenatal care
223424970|NCT02085668|DEVICE|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
223424971|NCT03783130|BIOLOGICAL|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.
223424972|NCT03783130|OTHER|Alum Adjuvant|Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.
223424973|NCT05657600|BEHAVIORAL|Sociodemographic profile, quality of life, sleep, fatigue, physical function and balance assessments|Respiratory functions are assessed with a portable spirometer according to the criteria of the American Thoracic Society and European Respiratory Society. Measures the physical, mental, social, and environmental well-being were tested to understand the quality of life. The quality of sleep, delayed sleep, sleep disorders, usage of sleeping pills, and loss of functionality during the day were assessed. The balance and static standing capability of the participants were tested. The functional reach of participants were tested by expecting them to lean forwardly as far as they can without taking a step, nor rising their heels. The fatigue feeling of the participants as everyday life were assessed. The posture of the participants was assessed on 13 regions at anterior, posterior and lateral views.
223424974|NCT05657600|OTHER|Video-based yoga|Video-based yoga
224037483|NCT01736085|DRUG|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
224037484|NCT06193863|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|At the discretion of the treating physician, based on the recommendations written in the local product information.
224037485|NCT03942406|COMBINATION_PRODUCT|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
224037486|NCT04377828|DEVICE|Pigment laser|one to two session of pigment laser (532 nm)
223424975|NCT05657600|OTHER|Face-to-face yoga|Face-to-face yoga
223424976|NCT05657600|OTHER|physical exercise|physical exercise
223424977|NCT00396552|DEVICE|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
223424978|NCT00396552|DEVICE|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
223424979|NCT06431399|DRUG|JLP-2004 qd|Group I(Peroid I-JLP-2004 FAST, Peroid II-JLP-2004 FED), Group II(Period I-JLP-2004 FED, Period II-JLP-2004 FAST)
223424980|NCT00655733|DRUG|HMPL-004|HMPL-004 1200 mg/d
223424981|NCT00655733|DRUG|Placebo|Placebo 1200 mg/d
223424982|NCT03440307|BEHAVIORAL|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
223424983|NCT03440307|BEHAVIORAL|Email Only|Participants received health and fitness education.
223424984|NCT03149289|DRUG|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
223424985|NCT03070340|DIAGNOSTIC_TEST|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
223424986|NCT03070340|DIAGNOSTIC_TEST|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
223424987|NCT00662662|BEHAVIORAL|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
223424988|NCT01881880|DEVICE|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
223424989|NCT04446195|BEHAVIORAL|Individualized Intervention|In this study, patients with the risk factors of insufficient intestinal preparation were treated with individualized intervention (mainly from the following aspects: chronic constipation, intestinal preparation not strictly in accordance with the requirements, body mass index \> 25 kg / m2, age \> 70 years old, with other diseases such as diabetes, Parkinson's disease, history of stroke or spinal cord injury, etc., application of tricyclic antidepressants or anesthetics).
223424990|NCT05990348|OTHER|difficult weaning patients|intercostal thickening fraction values during PSV and NAVA modalities in patients with difficult weaning from MV admitted in ICU.
223563924|NCT06422364|DEVICE|Weighted Wearable Blanket provided by Dreamland Baby Co.|All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete an overnight polysomnogram.
223424991|NCT05567432|PROCEDURE|thyroidectomy|use diathermy or ligasure for homeostatic during thyroidectomy
223424992|NCT02847143|DRUG|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
223424993|NCT02847143|DEVICE|fMRI|FMRI during emotional image visualization
223424994|NCT02847143|BEHAVIORAL|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
223424995|NCT02847143|BEHAVIORAL|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
223424996|NCT06418477|DRUG|Dara-CyBorD|"Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis."
224037487|NCT06106828|DRUG|Satralizumab|Satralizumab will be administered by SC injection.
223424997|NCT04873453|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
223424998|NCT04873453|DRUG|Placebo|Placebo arm
223424999|NCT06618768|DIETARY_SUPPLEMENT|Consumption of an aronia-mixture to prevent Urinary Tract Infections in female patients|The present pilot study will assess the feasibility of methods and procedures to be used in a larger study and contribute to establish power calculations required to conduct a randomised clinical trial which will examine whether consumption of 1 dL aronia-mixture/day for six months will reduce prevalence of symptomativ UTi episodes among adult women with a recent history of uncomplicated, recurrent UTIs.
223563925|NCT05964530|PROCEDURE|Surgery|Surgery procedures include LAR+ anal preservation or APR
223563926|NCT04093323|BIOLOGICAL|Alpha-type-1 Polarized Dendritic Cells|Given ID
223740036|NCT06870617|OTHER|Correlation of body composition PGA and step count with outcomes|Monitoring of step counts (measured via FitBit) and body composition (measured via standard abdominal CT scans)
223563927|NCT04093323|DRUG|Celecoxib|Given PO
223563928|NCT04093323|DRUG|PD-1 Ligand Inhibitor|Given IV
223563929|NCT04093323|DRUG|PD1 Inhibitor|Given IV
223563930|NCT04093323|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given IV
223563931|NCT04093323|DRUG|Rintatolimod|Given IV
224037488|NCT06106828|DRUG|Placebo|Placebo will be administered by SC injection
224037489|NCT06390462|BEHAVIORAL|Interpersonal counseling|A structured psychotherapeutic intervention to prevent depression or treat mild to moderate depression. IPC-A is a brief, individual-based intervention (3-8 sessions). The focus is on interpersonal relations as a factor of resilience in depressive symptoms. IPC-A is a shorter form of IPT-A, developed by prof. Myrna Weissman and team.
224037490|NCT06390462|BEHAVIORAL|Treatment as usual|Any other behavioral or medical support or depression indicated by depressive symptoms or depression. This is based on adolescent, caretaker and professional's report.
223425000|NCT03410472|BEHAVIORAL|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
223425001|NCT01226368|OTHER|Biological Sample collection|Cervix cells
223425002|NCT06647563|BIOLOGICAL|Toripalimab|Specified dose on specified days
223425003|NCT06647563|BIOLOGICAL|Cetuximab|Specified dose on specified days
223425004|NCT06647563|DRUG|Albumin-Bound Paclitaxel|Specified dose on specified days
223425005|NCT06647563|DRUG|Carboplatin|Specified dose on specified days
223425006|NCT06647563|DRUG|Cisplatin|Specified dose on specified days
223425007|NCT06647563|RADIATION|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
223425008|NCT06647563|RADIATION|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
223425009|NCT06647563|RADIATION|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
223425010|NCT02236806|DRUG|Bisoprolol|5 mg daily
223425011|NCT02236806|DRUG|Ramipril|5 mg daily
223425012|NCT02236806|DRUG|Placebo|1 capsule daily
223425013|NCT00101075|DRUG|Capecitabine|
223425014|NCT00101075|DRUG|Oxaliplatin|
224037491|NCT06390462|OTHER|No support, intervention or other treatment|The group will comprise those adolescents who report sustained depression but do not seek or receive support over 6 months of follow-up based on adolescent and caretaker's report
223425015|NCT03242187|PROCEDURE|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
223563932|NCT05128786|BIOLOGICAL|CCT301-38|Blood will be collected from subjects to isolate peripheral blood mononuclear cells for the production of CCT301-38. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion followed by a single or multiple dose of CCT301-38 via intravenous injection.
224037492|NCT02067442|DRUG|oral acetaminophen|1000 milligrams given orally before surgery
223425016|NCT03242187|PROCEDURE|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
223425017|NCT02122770|DRUG|MLN4924|MLN4924 intravenous solution.
223425018|NCT02122770|DRUG|Fluconazole|Fluconazole tablets.
223425019|NCT02122770|DRUG|Itraconazole|Itraconazole oral solution.
223425020|NCT02122770|DRUG|Docetaxel|Docetaxel intravenous solution.
223425021|NCT02122770|DRUG|Carboplatin|Carboplatin intravenous solution.
223563933|NCT05082012|DEVICE|Treatment of Hallux Valgus|Patients 14 years through 58 years with symptomatic hallux valgus will be eligible to participate based on the inclusion/exclusion criteria established in the study protocol. Anticipated subject duration will be 2 years post index procedure.
223563934|NCT00648427|DRUG|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
224037493|NCT02067442|DRUG|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
223425022|NCT02122770|DRUG|Paclitaxel|Paclitaxel intravenous solution.
223425023|NCT03089671|OTHER|Vitamin B (riboflavin, vitamin B2)|Vitamin B is a natural health product approved as a colouring agent.
223425024|NCT03089671|OTHER|5% Dextrose in Water (D5W)|5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
223425025|NCT06312111|BEHAVIORAL|recommendation to increase physical activity|education on the benefits of physical activity in PAH from the first visit and doctor's recommendation to increase physical activity above 5,000 steps a day in inactive patients and above 5,000 steps per person in active patients
223425026|NCT06443398|OTHER|There is no intervention in the study|There is no intervention in the study
223425027|NCT06619262|DEVICE|Transcutaneous Electrical Nerve Stimulation|TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.
223425028|NCT06619262|DEVICE|Neuromuscular and Muscular Electrical Stimulation|Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.
223425029|NCT06619262|OTHER|Exercise program|Specific exercise program for patients with lower extremity hemiparesis after stroke
223425030|NCT01740128|DEVICE|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
223425031|NCT01740128|OTHER|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
223425032|NCT06631482|DEVICE|Maintain HPI < 85|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
223425033|NCT06631482|DRUG|Maintain MAP>=73|Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
223425034|NCT02474589|DRUG|tecovirimat|Study is based on Animal Regulatory Rule
223425035|NCT02474589|OTHER|Placebo|Does not apply
223425036|NCT00036491|DRUG|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m\^2
223425037|NCT04108494|PROCEDURE|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
223563935|NCT00648427|DRUG|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
223563936|NCT06444555|DIETARY_SUPPLEMENT|BEP supplement|The BEP supplement used in Burkina Faso is a fortified medium-quantity lipid-based nutrient supplement called Plumpy'Doz. The product is a peanut and milk-based ready-to-use nutritional formulation produced by Nutriset. A peanut-based BEP formulation with a trademark Plumpy'Sup produced by Hilina Enriched Foods PLC will be used in Ethiopia.
223425038|NCT06385691|OTHER|myDIET software tool|"The tool is based on self-questionnaires completed by the patient. They are mainly filled in using visual analogue scales (from 0-10) or grades of symptoms/toxicities (Grades 0 to 4), based on the CTCAE V5. These scales will cover the following themes: food intake, weight changes, digestive symptoms, taste disorders, pain and fatigue. The system will be able to monitor data changes and the response given will be adapted according to the severity of symptoms:~* No signs of seriousness: general prevention or treatment documents/advice: toxicity management, nutritional advices targeted on symptoms, on digestive problems, on appropriate physical activity.~* Presence of signs of seriousness: action to be taken and alert to the coordinating nurse, oncologist or dietician.~In case of an alert, the coordinating nurse will call the patient back and either manage the symptom, schedule a nutritional consultation to initiate nutritional management, or refer the patient to the oncologist."
223425039|NCT00809640|BEHAVIORAL|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
223425040|NCT06623604|BEHAVIORAL|Experimental: Physical activity program|"In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;#39; classes would not be disrupted.~The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week.~During the program, students did a total of 180 hours of physical activity."
223425041|NCT01223469|DEVICE|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
223563937|NCT06444555|DIETARY_SUPPLEMENT|Multiple Micronutrient supplement|The MMN formulation is based on the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP). The formulation contains 15 minerals and vitamins and is administered as a tablet.
223425042|NCT02719912|DEVICE|mitral valve replacement|transcatheter mitral valve replacement
223425043|NCT03455010|OTHER|Increased load|Participants walk with 120% body weight achieved with a weight vest
223425044|NCT03455010|OTHER|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
224037494|NCT04620551|DEVICE|Sub-clinical stimulation|The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
224037495|NCT03976349|DRUG|BIIB094|Administered as specified in the treatment arm.
224037496|NCT03976349|DRUG|Placebo|Administered as specified in the treatment arm.
223425045|NCT03664310|OTHER|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
223425046|NCT03664310|OTHER|Control|Physical health control
223425047|NCT06621381|BEHAVIORAL|Concentrated exposure and response prevention|The intervention consists of: Psychoducation for the patients (1 session, 2-3h in group format), psychoeducation for the legal guardians (1 session, 3h in group format), exposure and response prevention (3-4 sessions, 9-12h over the course of one week, individual format), group reunions for sharing experiences, motivational work and relapse prevention ( 2 sessions, 3h)
223425048|NCT01692210|DRUG|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
223425049|NCT02012738|BEHAVIORAL|FORNET|"8 individual sessions:~* 1 lifeline~* 6 exposure sessions~* 1 outlook"
223425050|NCT02012738|BEHAVIORAL|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
223425051|NCT02012738|OTHER|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
223425052|NCT02012738|OTHER|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
223425053|NCT00132938|DRUG|telithromycin|
223563938|NCT01591837|BIOLOGICAL|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
223425054|NCT01734538|DIETARY_SUPPLEMENT|Omega-3 Complete|
223425055|NCT01734538|DIETARY_SUPPLEMENT|Placebo capsule|
223425056|NCT02396017|DEVICE|Capsule endoscopy|Endoscopic device
223740037|NCT02472795|DRUG|Matching placebo|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
223425057|NCT02396017|DRUG|Polyethylene Glycol|Bowel purgative
223740038|NCT02472795|DRUG|Cenerimod|One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
224037497|NCT05628285|DEVICE|Sentio 1|Sound processor
224037498|NCT05733546|DRUG|Psilocybin|COMP360 Psilocybin administered under supportive conditions
224037499|NCT04720209|OTHER|CARE|CARE is a 16-week, supervised, periodized AE and RE program performed in a circuit fashion 3 days/week on-site
224037500|NCT04720209|OTHER|TARE|TARE is a 16- week, supervised AE and RE program consisting of three sessions per week on-site
224037501|NCT04720209|OTHER|Home-Based Stretching|This group will perform a home-based program of the same stretches utilized in the CARE and TARE groups.
224037502|NCT06644937|DRUG|TACE combined with Acoradine|"Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) ."
224037503|NCT05481879|DRUG|DYNE-101|Administered by IV infusion
224037504|NCT05481879|DRUG|Placebo|Administered by IV infusion
224037505|NCT06312358|BEHAVIORAL|Building Capacity for Infant Achievements in Child Care|All teacher participants will be assigned to the professional development intervention consisting of an interactive workshop and weekly coaching sessions.
223563939|NCT06552793|BIOLOGICAL|autogenous partially demineralized dentin graft|tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
223563940|NCT06552793|BIOLOGICAL|Xenograft|Cortico-cancallous Bovine powder
223563941|NCT05925452|DRUG|GenaKumab|GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
223563942|NCT06339502|BEHAVIORAL|Jigsaw Technique|The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
223563943|NCT04022226|DRUG|Ketamine|Induction agent that suppresses infra-slow waves
223563944|NCT04022226|DRUG|Methohexital|Induction agent that does not suppress infra-slow waves
223740039|NCT04780256|PROCEDURE|Endoscopic resection|"The endoscopic resection is the procedure that allows to remove cancerous or precancerous conditions of digestive tract. Endoscopic resection can be preformed by several techniques:~1. Endoscopic mucosal resection (EMR): it allows to remove mucosal lesions~2. Endoscopic submucosal dissection: it allows to remove mucosal lesions that involved submucosal layer and large lesions~3. Full-thickness resection: it allows to remove infiltrating lesions by the resection of a little piece of the entire gastrointestinal wall"
223740040|NCT06871969|DIAGNOSTIC_TEST|Dry electrode EEG|"A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. EEG data will be acquired with Strokepointer (TrianecT B.V., Utrecht, The Netherlands).~StrokePointer is a portable EEG acquisition and analysis device. The device consists of three parts: (1) StrokePointer headset with dry electrodes to measure EEG data, (2) Portable StrokePointer suitcase that contains a mobile computing device (Android phone), CE-marked (IIa) EEG amplifier and storage compartments and (3) Software to acquire, analyse and upload EEG data."
224037506|NCT06127979|PROCEDURE|core needle biopsy|Pre-Endocrine Therapy core needle biopsy. The pre-treatment research biopsy will require a biopsy marker clip to document that the cancer lesion was biopsied
224037507|NCT06127979|OTHER|blood draw|blood draw
224037508|NCT05906758|PROCEDURE|Angiography|Coronary angiography with less than 20cc of contrast materials
223425058|NCT02658734|DRUG|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
224037509|NCT00552201|DRUG|Tacrolimus|Administration Twice a day after adjustment to blood level
224037510|NCT06515093|OTHER|PelloGraft|dual layer amnion/chorion-derived allograft
224037511|NCT06515093|OTHER|SanoGraft|single layer amnion-derived allograft
224037512|NCT06510309|DRUG|Venetoclax|B-cell lymphoma inhibitor, tablets taken orally per protocol.
224037513|NCT06510309|DRUG|Rituximab|Anti-CD20 monoclonal antibody, 10mL or 50 mL single-use vials, via intravenous (into the vein) infusion per protocol.
224037514|NCT05735730|OTHER|Blood draw|The study intervention consists of a blood draw for genetic analysis.
224037515|NCT02042430|DRUG|Epacadostat|Given PO
224037516|NCT02042430|OTHER|Laboratory Biomarker Analysis|Correlative studies
224037517|NCT02042430|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224037880|NCT05215327|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
223425059|NCT00236158|DEVICE|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
223425060|NCT04902313|BEHAVIORAL|Awareness and insight Modules (AiM)|12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
223425061|NCT03647735|OTHER|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
223425062|NCT05409313|BEHAVIORAL|EBP training|The EBP training program was modified by the 5A-steps EBP teaching model that which aimed to enhance nurses' EBP competencies and application. A 12-hours EBP training consisted of lectures, hand-on practice, group and individual consulting, group presentations and reflections, and disseminating findings to publish.
223425063|NCT05409313|BEHAVIORAL|SDM training|A 10-hour SDM training program included lecture 4 hours and workshops 6 hours, with focused on 3-talk model for SDM skills, 4-habit model for communication skill, and how to use Ottawa personal decision guide. Teaching strategies included lectures, clinical scenarios role play, and post-scenario debriefing. The major contents were SDM concepts and essential steps, SDM tools, strategies for the clinical implementation, the concept and purpose of choosing wisely campaign, and patient-centered communication skills.
223425064|NCT04342741|DEVICE|Foley catheter cervical ripening|Participants were assessed when labour was established or the following morning.
223425065|NCT00688935|BIOLOGICAL|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
223425066|NCT01944618|DRUG|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
224037518|NCT04118283|BEHAVIORAL|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
224037519|NCT04118283|BEHAVIORAL|Health and Wellness|Health \& Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
223425067|NCT04933084|BEHAVIORAL|Pre-operative Opioid Education|"The pre-operative education in the text handout and pre-recorded video will include the topics of:~1. Description of expected postoperative pain after robotic prostatectomy and typical opioid consumption after RARP.~2. Efficacy of non-opioid multimodal analgesia and recommendation to take nonopioid alternatives prior to prescribed opioids.~3. Adverse short- and long-term effects of opioids including nausea, vomiting, sedation, hypoventilation, hypotension, dizziness, constipation, depression, and addiction."
223425068|NCT04247464|PROCEDURE|Fasting|Food intake restriction
224037520|NCT04151264|DEVICE|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
224037521|NCT06387966|DRUG|Flonoltinib Maleate Tablets|Day 1 will be used for drug administration, and Day 1\~Day 7 will be used for experimental data collection.
224037522|NCT06387966|DRUG|Flonoltinib Maleate Tablets placebo|Day 1 will be used for drug administration, and Day 1\~Day 7 will be used for experimental data collection.
224037523|NCT02853019|OTHER|Electroencephalogram|electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
224037524|NCT02853019|BEHAVIORAL|Cognitive tasks|\- clinical scales and subjective assessments of emotional and motivational stimuli
224037525|NCT02853019|BEHAVIORAL|subjective evaluation scales|\- clinical scales and subjective assessments of emotional and motivational stimuli
224037526|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after oncological surgery.|In patients who will undergo oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
224037527|NCT06635551|DIAGNOSTIC_TEST|Ultrasonographic evaluation of vascular catheter-related thrombosis after non-oncological surgery.|In patients who will undergo non-oncological surgery and have a central venous catheter, the presence of thrombosis, its duration of occurrence and its dimensions will be evaluated by ultrasonography.
223425069|NCT04586218|BEHAVIORAL|Computer guided vasopressor infusion|automated titration of vasopressor infusion to maintain a mean arterial pressure \> 65mmHg
223425070|NCT04586218|BEHAVIORAL|Manual control of vasopressor infusion|manual adjustments of noradrenaline infusion
223425071|NCT04113408|OTHER|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
223425072|NCT02965196|DRUG|IV Dexamethasone Therapy|
223425073|NCT02965196|OTHER|IV Normal Saline (NaCl 0.9%)|
223425074|NCT03108599|OTHER|Enhanced Cab|The enhanced cab intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep program.
223425075|NCT03108599|BEHAVIORAL|Fit4Sleep|The behavioral sleep program includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The behavioral sleep program includes an optional body weight management component. The intervention arm will receive the behavioral sleep program in combination with the enhanced cab intervention.
223425076|NCT02658006|PROCEDURE|Cardiac surgery|All cardiac surgery procedures
223425077|NCT05839106|DRUG|PM1032 injection|Subjects will receive PM1032 by intravenous administration.
223425078|NCT00459706|DEVICE|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
223425079|NCT00459706|DEVICE|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
223425080|NCT00189306|DRUG|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
223425081|NCT06078449|DEVICE|Therapeutic Ultrasonic|Ultrasound is a therapeutic modality that has been used by physical therapists to achieve therapeutic benefits. It is alternating compression and rarefaction of sound waves with a frequency of \>20,000 cycles/second. Therapeutic ultrasound frequency will be used by 0.7 to 3.3 MHz. Maximum energy absorption in soft tissue will be 2 to 5 cm. Intensity decreases as the waves penetrate deeper. It is applied using a round headed wand or probe that is put in direct contact with the patient's skin. Ultrasound gel must be used on all surfaces of the head as a conducting medium in order to assist in the transmission of the ultrasonic waves \& to reduce friction.
223425082|NCT06078449|DRUG|Hyaluronan intra-articular injection|The type of Hyaluronan injection that will be used in this study consists of High Molecular Weight Hyaluronic acid (High MW HA 3000 kDa), will be given by the orthopedic surgeon.
223425083|NCT01577849|DRUG|Vitamin D3|administration of Vitamin D3 24,000 IU
223425084|NCT01577849|DRUG|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
223425085|NCT00001111|DRUG|Nevirapine|
223740041|NCT06688955|PROCEDURE|Colonoscopy with Bacteriological Controlled Water|Patient with coloscopy which used Bacteriological Controlled Water : Collection of 250 ml of bacteriologically controlled water from the wash bottle at the end of each water-assisted colonoscopy to test for enterobacteria and fecal streptococci
223425086|NCT00001111|DRUG|Zidovudine|
223425087|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
224037528|NCT03694418|BEHAVIORAL|We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth|N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epidemiology Team to enhance the coordination and implementation of SRH services at Fort Peck.
224037529|NCT05528653|DRUG|Descovy|HIV infection pre-exposure prophylaxis
224037530|NCT06380842|OTHER|Necrotizing Pancreatitis patients' organ dysfunction progression|Study the dynamic nature of organ dysfunction
224037531|NCT06085092|BEHAVIORAL|Open weighing|The open-weighing intervention aims to challenge beliefs about weight gain. The study coordinator (SC) will explain open weighing, discuss any concerns you have about your weight, and construct a weight graph with the number of weeks on the x-axis and weight in pounds on the y-axis. The SC will help identify beliefs about gaining weight, which will be written on a Feared Outcomes Form. The SC will ask you to predict your weight, mark the weight prediction on the graph, weigh you on a standing scale, record your weight, and discuss your responses to seeing your weight, including any reasons for a difference between your predicted and actual weight. Each week, the SC will graph your actual and predicted weights over time and discuss anything that you are learning from this process. The SC will ask you to complete the Feared Outcomes Form once per day over the next week, review it each week, and talk to you about what you are learning from this process.
224037532|NCT06085092|BEHAVIORAL|Blind weighing|The blind weighing intervention aims to help you see self-weighing as an eating disorder symptom that you should stop, and that weight is not important to your identity or self-esteem. To do this, the study coordinator will explain why blind weighing might be helpful. You will then be asked to step backwards on a standing scale. The study coordinator will record your weight but will not share your weight information with you. The study coordinator will discourage you from thinking or talking about your weight.
224037533|NCT03768986|BEHAVIORAL|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
224138296|NCT00537264|OTHER|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
224138297|NCT03106948|DRUG|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
224138298|NCT03106948|DRUG|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
224138299|NCT03106948|DRUG|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
224138300|NCT06118164|BEHAVIORAL|pursing- lip breathing combined with aerobic walking exercise|pursing- lip breathing combined with aerobic walking exercise
224138301|NCT06118164|BEHAVIORAL|pursing- lip breathing|pursing- lip breathing
223425088|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
223425089|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
223425090|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
223425091|NCT04913337|DRUG|NGM707 plus pembrolizumab (KEYTRUDA®)|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."
223425092|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
223425093|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
223425094|NCT04913337|DRUG|NGM707|"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."
223425095|NCT04448132|BIOLOGICAL|IPV-Al|adjuvanted reduced dose inactivated polio vaccine
223740042|NCT07009899|DRUG|Linvoseltamab|Linvoseltamab is a human IgG4-based bsAb that binds to CD3, a T-cell antigen associated with the TCR complex, and BCMA, which is expressed on the surface of malignant MM B-lineage cells, as well as late-stage B cells and plasma cells.
223425099|NCT00074997|OTHER|Placebo|Single intravenous infusion of placebo.
223425100|NCT00074997|GENETIC|OZ1|Single intravenous infusion of OZ1.
223425101|NCT00074997|GENETIC|CD34+ cells|Autologous CD34+ cells.
223425102|NCT06617728|PROCEDURE|Intervention 1: Regional Analgesia|Regional analgesia techniques like epidural or peripheral nerve blocks.
223425103|NCT06617728|DRUG|Intervention 2: Intravenous (IV) Analgesia|IV medications used for pain control, including opioids and non-opioid analgesics.
223425104|NCT02638571|OTHER|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
223425105|NCT05073328|OTHER|COVID-19 required hospitalisation|Patients who contracted a COVID19 required hospitalisation
223425106|NCT05390528|DRUG|HLX301|HLX301 will be administered as a single intravenous (IV) infusion on Day1 in each 14-day cycle.
223425107|NCT06072677|BEHAVIORAL|Healthy Minds Program|The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
223425108|NCT05642260|OTHER|fall prevention programe|Patients in the experimental group will receive a comprehensive fall prevention program (guided by the post-TKR protocol followed at Al-Razi Orthopedic Hospital) into the conventional physiotherapy treatment
223425109|NCT06265701|BEHAVIORAL|Derailment-Focused Reflective Journaling|Experimental group aimed at decreasing anxiety symptoms
223425110|NCT06265701|OTHER|Everyday Tasks Reflective Journaling|Control group
223425111|NCT02434172|OTHER|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
223425112|NCT04982068|BIOLOGICAL|202-CoV low adjuvant dose|standard dose of 202-CoV with low dose CpG / alum adjuvant
223425113|NCT04982068|BIOLOGICAL|202-CoV low antigen dose|low dose 202-CoV with CpG / alum adjuvant
223425114|NCT04982068|BIOLOGICAL|202-CoV standard dose|standard dose 202-CoV with CpG / alum adjuvant
223425115|NCT04982068|OTHER|Placebo|Normal saline solution
223425116|NCT02160522|DEVICE|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
223425117|NCT04933916|DRUG|EMB-001|Combination product metyrapone and oxazepam
223563945|NCT05894304|DEVICE|Suspension system|suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
223563946|NCT05894304|OTHER|Scapular training exercises|Scapular muscle strength by resistance
223563947|NCT03130439|DRUG|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
223563948|NCT05775549|OTHER|None (Observational Study)|Not Applicable since observational study
223563949|NCT06157697|BEHAVIORAL|Social Transfer|Social transfers are defined as a cash or in-kind transfer. Based on previous social transfer programs in Brazil, we will offer gift packages for mothers at 6 months. The options include: diapers, hygiene products, child developmental toys, transport vouchers, or a combination of these.
223740043|NCT06691971|DEVICE|AeviceMD|The AeviceMD device will be placed on the patient to detect the presence of wheeze and perform auscultation.
223740044|NCT03721822|DRUG|[18F]NOS|\[18F\]NOS is an investigational radiotracer which each subject will have one \[18F\]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
223740045|NCT06683742|DRUG|EYP-1901|Intravitreal Injection
224037534|NCT03768986|BEHAVIORAL|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
224037535|NCT03768986|BEHAVIORAL|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
224037536|NCT02310672|DRUG|Macitentan|All patients take open-label macitentan 10mg o.d.
223425118|NCT03640481|DRUG|Belumosudil (KD025)|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
223425119|NCT06511323|DIAGNOSTIC_TEST|dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases|at baseline prior to stereotactic radiation, at 10 weeks after treatment, and at first concern for progression at treated lesion or 12 months post-treatment, whichever comes earlier.
223425120|NCT06311435|DIAGNOSTIC_TEST|RNA Biomarker Blood Test|Blood will be collected into a PaxGene Blood tube for processing by sponsor
223425121|NCT03990935|OTHER|ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
223425122|NCT05248113|DEVICE|Electrical stimulation of cochlear nerve|Intraoperative electrical stimulation of the cochlear nerve in patients undergoing surgery for resection of vestibular schwannoma. Activation of the auditory system monitored with scalp recording of auditory brainstem response.
223425123|NCT00311519|DRUG|Hylenex|
223425124|NCT05470621|BEHAVIORAL|PlayOn! playground curriculum|A staff and student training to implement a playground curriculum in after-school and recess settings
223425125|NCT03395717|DEVICE|Exoskeleton-Assisted Gait Training|
223425126|NCT00311636|DRUG|cyclophosphamide|
223563950|NCT06044233|DRUG|STI-1558|STI-1558 test preparation and reference preparation
223563951|NCT04506593|OTHER|no intervention|
223563952|NCT04019106|DRUG|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
223563953|NCT01038479|DIETARY_SUPPLEMENT|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
223563954|NCT01038479|BEHAVIORAL|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
223740046|NCT06683742|DRUG|Aflibercept (2.0 mg)|Intravitreal Injection
223740047|NCT06712316|DRUG|Pumitamig|Intravenous infusion
223740048|NCT06712316|DRUG|Pembrolizumab|Intravenous infusion
223740049|NCT06712316|DRUG|Carboplatin|Intravenous infusion
224037537|NCT03258554|BIOLOGICAL|Cetuximab|Given IV
224037538|NCT03258554|BIOLOGICAL|Durvalumab|Given IV
224037539|NCT03258554|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224037540|NCT03258554|OTHER|Laboratory Biomarker Analysis|Correlative studies
223563955|NCT05511727|DEVICE|single versus double Foley's catheter in pre-induction cervical ripening|The single balloon catheter (i.e. Foley catheter \[FC\]) and Cook cervical ripening balloon have been the most commonly used mechanical method
223563956|NCT01109121|DRUG|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
223563957|NCT01109121|DRUG|Allopurinol|Allopurinol 400 mg, QD
223563958|NCT01109121|DRUG|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
223563959|NCT01463696|DRUG|MK-8242|10 mg, 100 mg and 150 mg capsules
224037541|NCT03258554|OTHER|Quality-of-Life Assessment|Ancillary studies
224037542|NCT03258554|OTHER|Questionnaire Administration|Ancillary studies
224037543|NCT06135402|DEVICE|Treatment with Monalisa Glide Laser|3 fractional laser treatment-sessions with Monalisa Glide
224037544|NCT06135402|DRUG|Treatment with Clobetasol|Application of Clobetasol twice per week
224037545|NCT06629090|DEVICE|MRI|Participants will undergo an MRI scan while performing breathing and simulated postural change tasks.
224037546|NCT06629090|DRUG|Prazosin|A dose of prazosin will be administered based on body weight
224037547|NCT06629090|DRUG|Placebo|Oral placebo
224138302|NCT06118164|BEHAVIORAL|aerobic walking exercise|aerobic walking exercise
224138303|NCT00131677|DRUG|tenofovir disoproxil fumarate|study product taken daily
224138304|NCT00131677|DRUG|placebo|study product taken daily
224138305|NCT00280319|BEHAVIORAL|interpersonal psychotherapy for groups|psychotherapy
223425127|NCT00311636|DRUG|docetaxel|
223425128|NCT00311636|DRUG|doxorubicin hydrochloride|
224138306|NCT00280319|BEHAVIORAL|creative play therapy|consisted of play activities
223425129|NCT00311636|DRUG|epirubicin hydrochloride|
223425130|NCT00311636|DRUG|fluorouracil|
223425131|NCT00311636|DRUG|methotrexate|
223425132|NCT00311636|DRUG|paclitaxel|
223425133|NCT00311636|DRUG|triptorelin|
223425134|NCT00311636|PROCEDURE|adjuvant therapy|
223425135|NCT03081806|DRUG|X0002|Subjects will complete 22 weeks of double-blind treatment and then enter into 30 weeks open-label treatment.
223425136|NCT03944369|OTHER|KB109|KB109 is a novel glycan
223425137|NCT03944369|OTHER|No intervention|No intervention
223425138|NCT05492487|DRUG|Mirena|Mirena Intrauterine System (Mirena-IUS) is a levonorgestrel-releasing intrauterine system. Mirena consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a white or almost white cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. Mirena is approved for intrauterine contraception and in 2009 to treat heavy periods for women who choose intrauterine contraception. Mirena is often used off-label for the treatment of endometrial hyperplasia. Levonorgestrel is a progestogen used in a variety of contraceptive products. Low doses of levonorgestrel can be administered into the uterine cavity with the Mirena intrauterine delivery system. Mirena has mainly local progestogenic effects in the uterine cavity.
223563960|NCT03322046|BEHAVIORAL|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
223563961|NCT06334159|PROCEDURE|Horizontal GBR with the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being fixed with non-resorbable pins (Test Group).
224037548|NCT05645575|DEVICE|Open-label TMS|Customized, Open-Label Transcranial Magnetic Stimulation
224037549|NCT04782466|BEHAVIORAL|Physical Activity (PA) Intervention|The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).
224037550|NCT04782466|BEHAVIORAL|Waitlist attention-control|For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
224037551|NCT02523560|OTHER|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
224037552|NCT06418971|BEHAVIORAL|CarePair|This study will pilot test the feasibility and acceptability of a digital self-assessment and referral tool using machine learning models to enhance service use and address unmet needs in ADRD caregivers.
224037553|NCT04294563|DIETARY_SUPPLEMENT|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
224037554|NCT04294563|OTHER|Standard Care by Surgeon and Physical Therapist|Patient will receive standard care from treating physicians and physical therapists pre- and post-operatively
224037555|NCT03489174|OTHER|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
224037556|NCT03489174|OTHER|Usual Care|Usual care.
224037881|NCT05215327|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
224138307|NCT06183632|BIOLOGICAL|blood sampling|3 x 7mL EDTA blood tubes
223425139|NCT05492487|DRUG|Megace|Megestrol acetate (Megace) is a synthetic derivative of the natural occurring steroid hormone, progesterone. It is licensed for the treatment of anorexia, cachexia or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS) and palliative treatment of advanced breast or endometrial cancer. Megace is often used off-label for the treatment of endometrial hyperplasia. While the precise mechanism by which Megace produces its antineoplastic effects against endometrial carcinoma and endometrial hyperplasia is unknown at the present time, inhibition of pituitary gonadotrophin production and resultant decrease in estrogen secretion may be factors. There is evidence to suggest a local effect as a result of the marked changes brought about by the direct instillation of progestational agents into the endometrial cavity.
223425140|NCT00727844|DRUG|Immediate Start Linezolid|
223425141|NCT00727844|DRUG|Delayed Start Linezolid|
223425142|NCT06619340|DRUG|Exparel|20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded. An 18-gauge bevel needle will be introduced through the capsular pocket at 1 to 2cm proximal to the adductor tubercle at the proximal border of the posteromedial femoral condyle. The needle will be angled proximally and posteriorly, and then advanced to contact the posteromedial capsule. A 20mL bolus of the study drug admixture will be administered. The remaining 20mL of the study drug admixture will be administered to the anterior and lateral knee structures with approximately 1 to 1.5mL administered with each stick to the intended area.
223563962|NCT06334159|PROCEDURE|Horizontal GBR without the use of non-resorbable pins for the stabilization of the collagen membrane|Horizontal Guided Bone Regeneration, with a mixture of xenograft (Cerabone®) and allograft (Maxgraft®), on a 50-50 mixture ratio, grafted in the area required to be augmented, and then covered by a collagen membrane (Jason® membrane), being left unfixed (Control Group).
223563963|NCT03981887|DRUG|Nafithromycin|Nafithromycin 200 mg as IV infusion
224037557|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Dietary supplement I (WPowDSI)|The WPowDSI group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding supplementation, participants were randomly assigned to receive their daily dose.
224037558|NCT06620666|DIETARY_SUPPLEMENT|Water-based power resistance training + Placebo (WPowPl)|The WPowCr group will perform 8 repetitions per exercise (arm fly and swing, small and big kick, and a combined upper and lower limb exercise). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition) was recorded, accorded to an adaptation of the OMNI-RES scale in water in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase as fast as possible; eccentric phase 2s). Devices were used according to individual needs. Regarding placebo, participants were randomly assigned to receive their daily dose.
224037559|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Dietary supplement I (EBPowDSI)|The EBPowDSI group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 12-16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
224037560|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based power resistance training + Placebo (EBPowPl)|The EBPotPl group will perform 8 repetitions per exercise (militar press, squat, upright row, lunge, and push-press). Regarding the perceived exertion rating, a value of 4 (1º repetition,) and 7 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 90s of active recovery (slow rhythmic swinging of the extremities) between sets and 90s of rest between exercises. The speed of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: as fast as possible; eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
224037561|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII)|The EBEccDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
224138308|NCT05189158|DIAGNOSTIC_TEST|Hypercapnic hyperoxic ventilatory response|"The hypercapnic ventilatory response (HCVR) described by Read in 1967 (Read's rebreathing method) is a clinical way to assess the central and peripheric sensitivity to CO2, using a small bag (4-6 l) to achieve prompt equilibrium between the apparatus compartments and the lungs.~By rebreathing a hyperoxic mixture with an initial composition of 70% O2, 7% CO2 and 23% N2, this equilibrium is assumed to be achieved after 15 seconds of rebreathing, when the relationship between VE and PetCO2 has become linear."
223563964|NCT03981887|OTHER|Placebo|placebo administered as IV infusion
223563965|NCT00515606|DRUG|helium:oxygen|
223563966|NCT04149470|DRUG|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
223563967|NCT00351767|DRUG|placebo|Topically applied
223563968|NCT00351767|DRUG|telbermin|Topically applied
224299061|NCT04190719|OTHER|multimodal prehabilitation|"Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics"
224299062|NCT01700036|DRUG|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
224299063|NCT00062543|PROCEDURE|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
224299064|NCT00062543|DEVICE|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
224299065|NCT04390295|DRUG|Placebo|Once daily, 24 weeks
224299066|NCT04390295|DRUG|SHR3824|Once daily, 52 weeks
224299067|NCT04390295|DRUG|metformin|Three times daily, 52 weeks
224299068|NCT04166448|OTHER|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
224299069|NCT00679926|DRUG|Once daily|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
224299070|NCT01103726|DRUG|PF-02545920|1 and 5 mg tablets, 6 mg single dose
224299071|NCT01103726|DRUG|placebo|matching placebo tablets, single dose
224299072|NCT01103726|DRUG|PF-02545920|1 mg tablets, 3 mg single dose
224299073|NCT01103726|DRUG|PF-02545920|5 mg tablets, 15 mg single dose
224299074|NCT01103726|DRUG|Placebo|matching placebo tablets, single dose
224299075|NCT00299026|DEVICE|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
223425143|NCT01905501|DRUG|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
224299076|NCT04342468|OTHER|non-interventional|No intervention
224299077|NCT03827746|OTHER|Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale|"Tampa Kinesiophobia Scale: The TSK is a 17-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury.~Berg-Balance Test: 14-item scale designed to measure balance of the older adult in a clinical setting.~International Physical Activity Questionnaire-Short Form: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.~Falls Efficacy Scale: A 16- item self-administered questionnaire designed to assess fear of falling in mainly older population"
224299078|NCT00604123|DRUG|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
224299079|NCT00604123|DRUG|Placebo|Placebo nasal spray twice daily for 2 weeks.
224299080|NCT00258050|DRUG|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
224299081|NCT00258050|DRUG|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
224299082|NCT04602910|DEVICE|a web-based shared decision-making tool|Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
224299083|NCT02603718|OTHER|Rehabilitation treatment|
224299084|NCT02261350|DIETARY_SUPPLEMENT|Food fortification|
224299085|NCT02261350|DIETARY_SUPPLEMENT|Oral Nutritional Supplements|
223425144|NCT01905501|DRUG|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
223425145|NCT04944810|PROCEDURE|Magnetic Gastric Bypass|Perform a gastric bypass with the magnetic grasper to do the liver retraction, upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb and perform the section of the limb and finish the gastric bypass
223425146|NCT04944810|PROCEDURE|Magnetic Sleeve Gastrectomy|Perform a sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach
223425147|NCT04944810|PROCEDURE|Revisional Bariatric Surgery|Perform liver retraction and also steps of the surgery like upper retraction of the stomach, upper retraction of the jejuno-jejunal anastomosis, upper retraction of the mesocolon to close petersen defect or the jejuno-jejunal anastomosis to close the intermesenteric defect also to do the retraction of the omega limb, upper retraction of the stomach
223425148|NCT04944810|PROCEDURE|Nissen/Sleeve Gastrectomy with Magnetic Assistance|Perform a nissen-sleeve gastrectomy with the magnetic grasper performing the liver retraction and the upper retraction of the stomach, retraction of the stomach to close the hiatal defect and perform a nissen funduplication before do the sleeve gastrectomy
223425149|NCT04944810|PROCEDURE|Mangetic General Surgery|Use the magnetic grasper to do the gallbladder retraction in cholecystectomies and upper retraction of the stomach to close the defect on hiatal hernia cases.
223425150|NCT05261334|PROCEDURE|contour augmentation|early implant placement with contour bone augmentation
223425151|NCT05212324|PROCEDURE|widening of first web space|widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
223425152|NCT00373958|BIOLOGICAL|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
223425153|NCT00373958|BIOLOGICAL|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
223425154|NCT02743390|BIOLOGICAL|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
223425155|NCT02743390|OTHER|Saline|Saline for 2 hours (250mL)
223425156|NCT01726387|BEHAVIORAL|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
223425157|NCT01726387|BEHAVIORAL|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
223563969|NCT06029868|DIETARY_SUPPLEMENT|Black seed oil capsule|700 mg black seed soft gel capsule once a day from Gorgan Essential Oil Pharmaceutical Company,
224037562|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based eccentric resistance training + Placebo (EBEccPl)|The EBEccPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). The exercises were performed at maximum intensity until the point where stability or technique was lost, prior the stretching of the band. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric phase: until reaching the stretching of the band; eccentric phase: 5s). Regarding placebo, participants were randomly assigned to receive their daily dose.
224037563|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII)|The EBMaxDSII group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding supplementation, participants were randomly assigned to receive their daily dose.
224037564|NCT06620666|DIETARY_SUPPLEMENT|Elastic band-based maximum strength resistance training + Placebo (EBMaxPl)|The EBMaxPl group will perform 6 repetitions per exercise (lunge, chest press, hiptrust and standing row). Regarding the perceived exertion rating, a value of 7 (1º repetition,) and 9 (last repetition), according to an adaptation of the OMNI-RES EB scale in the remaining 16 weeks. The number of sets throughout the entire intervention was 4 sets per exercise, with 120s of active recovery between sets and 90s of rest between exercises. The pace of execution of the exercises was controlled using a metronome marking the cadence (concentric-eccentric phase: 2s). Regarding placebo, participants were randomly assigned to receive their daily dose.
224037565|NCT06620666|DIETARY_SUPPLEMENT|Control + Placebo (CPl)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding placebo, participants were randomly assigned to receive their daily dose.
224037566|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement I (CDSI)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
223425158|NCT03375879|DEVICE|Bandage contact lens|Bandage contact lens
223425159|NCT01385488|BEHAVIORAL|self-monitor arm volume|bioelectrical impedance
223563970|NCT06029868|DIETARY_SUPPLEMENT|Placebo Black seed oil capsule|Placebo Black seed oil capsule
223563971|NCT06098911|DEVICE|MI varnish|delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
223563972|NCT04150146|DRUG|Rebamipide SR 150mg after high-fat meal|Test Drug
224138309|NCT05189158|DIAGNOSTIC_TEST|Hypoxic eucapnic ventilatory response|The hypoxic eucapnic ventilatory response (HOVR) is a clinical way to assess the peripheric chemosensitivity to O2, using a small bag (4-6 l) to rebreathe a gas mixture initially composed of 20% O2, 0% CO2 and Δ% N2. Eucapnia is achieved by the activation of a CO2 reabsorption cell during the course of the test.
224138310|NCT05491655|DEVICE|High Intensity His Bundle pacing|All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
224138311|NCT01192217|PROCEDURE|Modified thoracoscopic technique|Two-port thoracoscopic technique
224138312|NCT01192217|PROCEDURE|Axillary mini-thoracotomy|Axillary mini-thoracotomy
223425160|NCT01552915|DRUG|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
223740050|NCT06712316|DRUG|Pemetrexed|Intravenous infusion
223740051|NCT06712316|DRUG|Paclitaxel|Intravenous infusion
223425161|NCT01552915|DRUG|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
223425162|NCT01552915|DRUG|Placebo|Daily oral dosing in the AM for 8 weeks
223425163|NCT06315478|DRUG|Omeprazole 20 MG Oral Tablet|standard triple therapy for 14 days Bid for each drug
223425164|NCT06315478|DRUG|Amoxicillin 500Mg Tab|Quadruple regimen for 14 days Bid for each drug
223425165|NCT06315478|DRUG|Clarithromycin 500Mg Tab|Hybrid regimen, PPI and Amoxicillin for first 7 days then adding clarithromycin and metronidazole for the second 7 days
223425166|NCT00005072|BIOLOGICAL|Leuvectin|1000 ug of Leuvectin injected intratumorally
223425167|NCT01983072|DIETARY_SUPPLEMENT|Infant formula|
224138313|NCT00319228|DRUG|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
224037567|NCT06620666|DIETARY_SUPPLEMENT|Control + Dietary supplement (CDSII)|Participants randomized into the control group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet. Regarding supplementation, participants were randomly assigned to receive their daily dose.
224037568|NCT06620666|DIETARY_SUPPLEMENT|Active Comparator: Aerobic training + Placebo (AerPl)|The group will perform aerobic exercise for 20-40 minutes with easy execution exercise. Regarding placebo, participants were randomly assigned to receive their daily dose.
224138314|NCT03071705|DRUG|Metformin|500 mg PO BID
224138315|NCT03071705|DRUG|TKI|standard dose
224037569|NCT02691260|BEHAVIORAL|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
224138316|NCT04922749|BEHAVIORAL|MULTI+|MULTI+ is a multidisciplinary, multicomponent treatment which aims to improve lifestyle factors through a holistic lifestyle approach, by focusing on 10 core components. The MULTI+ will be integrated into daily treatment to promote uptake and sustainability.
224138317|NCT01518712|DRUG|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
224138318|NCT01518712|DRUG|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
224138319|NCT06290947|DEVICE|BFR Cuffs for Intervention Group|"The intervention consists of supervised treadmill sessions incorporating specialized BFR cuffs, branded as H+ Curve, tailored for Blood-Flow Restriction Walk Training (BFRw). These cuffs are strategically positioned on the upper portion of the lower limbs to induce muscle adaptations and~improve metabolic health outcomes. The innovative protocol is designed to probe the potential benefits of BFRw in ameliorating insulin sensitivity and enhancing aerobic capacity, thus presenting a pioneering exercise approach for individuals with Type 2 Diabetes."
223425168|NCT01983072|OTHER|Breastfeeding|Breastfeeding
223425169|NCT01902758|DRUG|ambrisentan and theophylline|
223425170|NCT01902758|DRUG|placebo|placebo for comparison group
223425171|NCT02987517|OTHER|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
224037570|NCT02691260|BEHAVIORAL|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
224037571|NCT02691260|BEHAVIORAL|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
224037572|NCT03865823|PROCEDURE|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
224138320|NCT06290947|OTHER|Standard Walking Training Program|"The control group will engage in a standard walking training regimen, consisting of supervised treadmill sessions without the application of BFR cuffs. This protocol serves to uphold the scientific rigor of the study by offering a comparison group for the BFRw intervention.~Purpose:~To evaluate the impact of a typical exercise routine on insulin sensitivity and aerobic capacity, thereby establishing a control benchmark to contrast with the effects of the BFRw intervention."
224138321|NCT02750904|BEHAVIORAL|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
224138322|NCT02750904|BEHAVIORAL|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
223425172|NCT02987517|OTHER|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
223425173|NCT02987517|OTHER|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
223425174|NCT02346110|DRUG|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
223425175|NCT02346110|DRUG|Dexamethasone|4 mg
223425176|NCT02346110|OTHER|Sodium chloride|1 mL of sodium chloride solution as placebo
223425177|NCT00525941|DRUG|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
223563973|NCT04150146|DRUG|Rebamipide SR 150mg under fasting condition|Reference Drug
223563974|NCT00579618|OTHER|Saliva or Blood samples|Extracting sample of saliva or blood only once.
223563975|NCT00005841|BIOLOGICAL|MART-1 antigen|
223563976|NCT00005841|BIOLOGICAL|gp100 antigen|
223563977|NCT00005841|BIOLOGICAL|incomplete Freund's adjuvant|
223563978|NCT00005841|BIOLOGICAL|progenipoietin|
223563979|NCT00005841|BIOLOGICAL|tyrosinase peptide|
223563980|NCT02193737|PROCEDURE|Early oral fluid recovery.|
223563981|NCT02193737|PROCEDURE|Delayed oral fluid recovery.|
224037573|NCT00139087|BEHAVIORAL|Telephone Outreach for Therapy|
223563982|NCT01273116|OTHER|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~* will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~* a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~* will be discussed at least once in a multidisciplinary meeting;~* a structured medication review will be carried out by a geriatrician;~* is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~* may receive a consult of a geriatrician, if judged necessary;~* will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
223563983|NCT05052814|OTHER|root canal medicament-calcium hydroxide|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
224037574|NCT02904434|OTHER|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
224037575|NCT06339619|DRUG|Adebrelimab|20mg/kg ivgtt D1 Q3W
224037576|NCT06339619|DRUG|Apatinib|250mg PO QD
224037577|NCT06339619|DRUG|Tegafur|dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA\>1.5m2, 60mg，PO QD D1-21 Q3W
224037578|NCT02018367|DRUG|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
224037579|NCT01601847|DIETARY_SUPPLEMENT|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
224037580|NCT01601847|DRUG|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
224037581|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
224037582|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
224037583|NCT01284062|BIOLOGICAL|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
224037584|NCT01284062|OTHER|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
224037585|NCT00711256|OTHER|sunscreen MATAS sunlotion SPF 8|
224037586|NCT00711256|RADIATION|UVB light|duration 4 times 1 minute radiation on the trunk.
224037587|NCT04333654|DRUG|Hydroxychloroquine SAR321068|Pharmaceutical form:Tablet Route of administration: Oral
224037588|NCT04333654|DRUG|Placebo|Pharmaceutical form:Tablet Route of administration: Oral
224037589|NCT02234323|BIOLOGICAL|rFVIIIFc|Administered as specified in arm description
223425180|NCT02831985|PROCEDURE|general practice follow-up|Post-surgery follow-up by general practitioner
223425181|NCT02831985|PROCEDURE|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
223425182|NCT05026047|OTHER|HPV self-sampling|HPV self-sampling in HIV-positive women
223425183|NCT05725265|DEVICE|Large-area low-level laser therapy(Venusure)|The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
224037590|NCT02886767|OTHER|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
224037591|NCT00670189|DRUG|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
224037592|NCT01060826|OTHER|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
223425184|NCT05725265|DEVICE|Conventional low-level laser therapy|The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
223425185|NCT02691429|OTHER|Acai dye 10%|dye to be used during chromovitrectomy in humans
223425186|NCT01196689|DRUG|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
223425187|NCT06621992|OTHER|Skills to Enhance Positivity|
223425188|NCT06621992|OTHER|Treatment as Usual|Participants received treatment as usual
224037593|NCT01060826|DRUG|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
224037594|NCT01060826|DRUG|somatostatin|Intravenous bolus 250 micrograms
224037595|NCT00725634|BIOLOGICAL|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
224037596|NCT00725634|BIOLOGICAL|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
223425189|NCT05267990|DIAGNOSTIC_TEST|Multi-Detector Computed Tomography|Coronary angiography calcium score via Multi-Detector Computed Tomography
223425190|NCT04944303|DRUG|Sugammadex|Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
224037597|NCT00019084|BIOLOGICAL|aldesleukin|
224037598|NCT00019084|BIOLOGICAL|mutant p53 peptide pulsed dendritic cell vaccine|
224037599|NCT00019084|BIOLOGICAL|ras peptide cancer vaccine|
224037600|NCT00019084|BIOLOGICAL|sargramostim|
224037601|NCT00019084|BIOLOGICAL|therapeutic autologous lymphocytes|
224037602|NCT00019084|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
224037603|NCT05150652|DRUG|Anastrozole 1mg|Participants will take 1mg of anastrozole once daily, orally, for up to six cycles of 28 days.
224037604|NCT05150652|DRUG|Letrozole 2.5mg|Participants will take 2.5mg of Letrozole once daily, orally, for up to six cycles of 28 days.
224037605|NCT05150652|DRUG|Exemestane 25 mg|Participants will take 25mg of Exemestane once daily, orally, for up to six cycles of 28 days.
224037606|NCT05150652|DRUG|Tamoxifen|Participants will take 20mg of Tamoxifen once daily, orally, for up to six cycles of 28 days.
224037607|NCT02644941|BIOLOGICAL|Human Acellular Vessel (HAV)|HAV-tissue-engineered vascular conduit (6mm diameter)
224037608|NCT02644941|DEVICE|ePTFE graft|One of two commercially available comparators (Bard Impra® and Gore PROPATEN®)
224037609|NCT05398887|RADIATION|Low radiation dose CT|Underwent low dose chest CT with 30% lower radiation dose
224037610|NCT05398887|RADIATION|Underwent ultra dose chest CT|Underwent ultra dose chest CT with 90% lower radiation dose
223425191|NCT04944303|DRUG|Normal saline|Equal doseage of normal saline was injected to reverse the NMB.
223425192|NCT04289909|OTHER|Adaptive Optics Ophthalmoscopy (AOO)|AOO will permit to detect and quantify retinal perivascular inflammation in patients with MS in comparison to Healthy volunteers (control group)
223425193|NCT06492733|DEVICE|FastWire System - Peripheral|The Investigator can use the FastWire System during the procedure to cross CTO Caps and/or to cross multiple lesions.
223425194|NCT01880086|DRUG|Clomiphene citrate|
223425195|NCT01880086|DRUG|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
223425196|NCT02458768|DRUG|IVF-M HP Inj.|
223425197|NCT02458768|DRUG|Menopur® Inj.|
223425198|NCT00987870|DRUG|BFH772|
223425199|NCT00987870|DRUG|Placebo|
223425200|NCT00987870|DRUG|BFH772|
223425201|NCT00987870|DRUG|Placebo|
223425202|NCT00987870|DRUG|calcipotriol/betamethasone|
223425203|NCT04756570|OTHER|Control|Individuals in this group will be randomly recruited from hospitalized stroke volunteers. Since these individuals receive routine rehabilitation 5 days a week, they will be evaluated at the beginning and end of 18 sessions over a total period of 6 weeks. Conventional physiotherapy will include normal joint movements, muscle strengthening exercises, balance and mobility exercises, and exercises to improve daily life activity.
223425204|NCT04756570|OTHER|Robotic Group 1|Individuals in this group will receive one session of robotic rehabilitation in addition to conventional therapy each week
224037611|NCT05398887|OTHER|Artificial Intelligence based model|Deep-learning based contrast boosting algorithms
224037612|NCT00471796|BEHAVIORAL|Biofeedback|
224037613|NCT02047825|OTHER|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
224037614|NCT02047825|OTHER|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
224037615|NCT03027375|DRUG|Qishen Granules|The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
224037616|NCT03027375|DRUG|Placebo|The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
224037617|NCT06113237|DRUG|Epidiolex|Oral solution
224037618|NCT04111042|DEVICE|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
224037619|NCT02147665|OTHER|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
224037620|NCT04998019|BEHAVIORAL|PositiveLinks|"The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB)."
224037621|NCT05166785|OTHER|DPP Tailored for Older Adults and delivered via Telehealth|Diabetes Prevention Program (DPP) Tailored for Older Adults and delivered via Telehealth (DPP-TOAT) will be composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions
224037622|NCT05166785|OTHER|In-Person Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP) is composed of 16 60-minute weekly sessions followed by six 60-minute monthly support sessions over 12 months in person approved by the Centers for Disease Control and Prevention (CDC)
224037623|NCT06348264|DRUG|Rezvilutamide|Rezvilutamide 240 mg (3\*80mg tablets) will be administered orally once daily with or without food.
224037624|NCT06348264|DRUG|Leuprolide Acetate|The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.
224037625|NCT05066477|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
224037626|NCT05066477|OTHER|Placebo|Pure maltodextrin
224037627|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
224037628|NCT02141789|BEHAVIORAL|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
224037629|NCT06117098|DEVICE|Mobile application|Individual lifestyle intervention via an mobile application
224037630|NCT06117098|BEHAVIORAL|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"|"Group-based lifestyle intervention at a Healthy Lifestyle Centre + mobile application"
223563984|NCT05052814|OTHER|root canal medicament-chlorhexidine gel|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
224037631|NCT06117098|BEHAVIORAL|Group-based lifestyle intervention|Group-based life style intervention at a Healthy Lifestyle Centre (ususal care)
224037632|NCT00132613|PROCEDURE|Observation alone after pericardial drainage|
224037633|NCT00132613|DRUG|Pericardial instillation of bleomycin after drainage|
224037634|NCT04608669|DRUG|Paracetamol|Give paracetamol or placebo and compare temperature
224037635|NCT01562171|OTHER|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
224037636|NCT01562171|OTHER|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
224037637|NCT00730561|BIOLOGICAL|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
224037638|NCT02329665|DEVICE|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
224037639|NCT00286884|PROCEDURE|Monitoring of heart rate variability|
224037640|NCT00842881|DEVICE|Healingstone navel belt|6\~8hours/day for 3months
224037641|NCT01633814|DRUG|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
224037642|NCT01633814|DRUG|Placebo|placebo patch.
224037643|NCT01372670|DRUG|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID"
224037644|NCT01372670|DRUG|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
224037645|NCT01372670|OTHER|Placebo|Placebo given 3 times per day
224037646|NCT04706351|OTHER|IdFAI questionnaire|The Identification of Functional Ankle Instability (IdFAI) is a newly published questionnaire that was specifically designed to detect whether individuals meet a minimum criteria necessary for inclusion in an FAI population. The IdFAI is intended to give both researchers and clinicians a simple and effective tool to determine an individual's ankle stability status
224037647|NCT01717768|DRUG|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
224037648|NCT05548296|DRUG|ACR-368|ACR-368 is an experimental drug
224037649|NCT05548296|DRUG|Gemcitabine|Sensitization of tumor cells is provided through administration of ULDG
224037650|NCT05548296|DIAGNOSTIC_TEST|OncoSignature|Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy
224037651|NCT00448435|DRUG|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
224037652|NCT00448435|DRUG|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
224037653|NCT01881581|BIOLOGICAL|Saline Solution|Saline Solution is used as control in all arms.
224037654|NCT01881581|BIOLOGICAL|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
224037655|NCT01881581|BIOLOGICAL|M-GPE|M-GPE is used in Arm D,E,F,G and H
224037656|NCT03965078|DRUG|topical (eye drop) anti-inflammatories|Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
224037657|NCT00446238|BEHAVIORAL|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
223425205|NCT04756570|OTHER|Robotic Group 2|Individuals in this group will receive two sessions of robotic rehabilitation in addition to conventional therapy each week
223425206|NCT05929729|DRUG|Ferric derisomaltose|Refer to arm/group descriptions
223425207|NCT05929729|DRUG|NovaFerrum|Refer to arm/group descriptions
223425208|NCT04724629|BIOLOGICAL|Ixekizumab|80 mg of IL-17 inhibitor
223563985|NCT05052814|OTHER|root canal medicament-calcuim hyroxide &chlorhexidine ge|Two different root canal medicaments and their combination were placed into the root canals following the removal of previous root canal fillings and re-instrumentation. Afterward, postoperative pain scores were recorded at 6 and 12 hours and at 1, 2, 3, 4, 5, 6, and 7 days using the visual analog scale (VAS). Sensitivity on percussion, spontaneous pain, swelling, and antibiotic and analgesic requirements of the patients were married during clinical examinations performed postoperatively after 2 and 7 days.
223563986|NCT03905265|DRUG|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
223563987|NCT02493803|BEHAVIORAL|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
223563988|NCT01683747|DRUG|Tranexamic Acid|
223563989|NCT01683747|DRUG|Control Intervention (Carrier fluid only)|
223563990|NCT03726918|PROCEDURE|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
224138323|NCT02488616|OTHER|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
223425209|NCT04724629|BIOLOGICAL|Aldesleukin|1.5 million IU (low-dose) of IL-2
223425210|NCT04724629|DRUG|Colchicine|0.5 mg of indirect IL-6 inhibitor
223425211|NCT04724629|DRUG|Standard of care (SOC)|Active comparator (Corticoids and antiretrovirals)
223425212|NCT00055770|DRUG|erlotinib hydrochloride|Given orally
223563991|NCT05804656|DRUG|CKDB-501A|Intramuscular injection CKDB-501A
223563992|NCT05804656|DRUG|Botox®|Intramuscular injection Botox®
223563993|NCT02554149|RADIATION|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
223563994|NCT02130687|DRUG|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
223425213|NCT00055770|DRUG|docetaxel|Given IV
223425214|NCT00055770|OTHER|laboratory biomarker analysis|Correlative studies
223425215|NCT00055770|OTHER|pharmacological study|Correlative studies
223425216|NCT00271011|DRUG|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
223425217|NCT00271011|DRUG|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
223425218|NCT00271011|DRUG|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1\*28 allele will receive irinotecan 110 mg/m2.
223425219|NCT03403751|DRUG|Reltecimod 0.5 mg/kg|Single IV infusion of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL) over approximately 10 minutes
223425220|NCT03403751|DRUG|Placebo|Single IV infusion of 0.5 mL/kg of 0.9% saline (volume equivalent to Reltecimod dosing schema) over approximately 10 minutes
223425221|NCT05853549|DEVICE|optical surface monitoring system|An optical surface monitoring system (OSMS) could achieve continuous monitoring of patient position through a nonradiographic and noninvasive technology, which has been widely applied to many sites of radiation therapy, including breast, intracranial, head and neck, abdomen, and extremities
223425222|NCT00266643|DRUG|duloxetine hydrochloride|
223425223|NCT02411058|BEHAVIORAL|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
223563995|NCT02130687|DRUG|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
223563996|NCT02130687|DRUG|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
223563997|NCT02130687|OTHER|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
223563998|NCT01057576|DIETARY_SUPPLEMENT|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
223563999|NCT01057576|OTHER|Placebo|capsule, daily dosage
223564000|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #1|Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
223564001|NCT04707989|OTHER|Ketone- Promoting Food Ingredient #2|Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
223564002|NCT04707989|OTHER|Ketone Free Placebo|Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
223564003|NCT04571424|DRUG|BIIB133 (Dapirolizumab pegol)|Administered as specified in the treatment arm
224037658|NCT00446238|BEHAVIORAL|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
224037659|NCT01387230|DRUG|GSK573719|62.5 mcg
224037660|NCT01387230|DRUG|GSK573719|125mcg
224037661|NCT01387230|OTHER|Placebo|Placebo
224037662|NCT05515120|DRUG|Rivaroxaban 20 MG [Xarelto]|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
224037663|NCT05515120|DRUG|Aspirin 300mg|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
224037664|NCT05515120|DRUG|Acenocoumarol Oral Tablet|It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
224138324|NCT02488616|OTHER|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
223425224|NCT02411058|BEHAVIORAL|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
223425225|NCT00896181|DRUG|docetaxel|Given IV
223425226|NCT00896181|DRUG|cisplatin|Given IV
223425227|NCT00896181|DRUG|carboplatin|Given IV
223425228|NCT00896181|DRUG|fluorouracil|Given IV
223425229|NCT00896181|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
223425230|NCT00896181|RADIATION|intensity-modulated radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
223425231|NCT05761210|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection
223425232|NCT03319264|OTHER|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
223425233|NCT03319264|OTHER|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
223425234|NCT03319264|RADIATION|DXA measurement|DXA measurement will be performed to assess patient's body composition
223425235|NCT03319264|OTHER|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
223425236|NCT03319264|BEHAVIORAL|Life habits Questionnaire|Life habits Questionnaire
223425237|NCT00351741|DEVICE|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
223425238|NCT00351741|DEVICE|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
223425239|NCT01539551|OTHER|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
223425240|NCT02947256|PROCEDURE|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
223425241|NCT02947256|PROCEDURE|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
224037665|NCT02977117|OTHER|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
224037666|NCT02977117|OTHER|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
224037667|NCT04632472|DEVICE|Active fixation bipolar lead versus passive fixation quadripolar leads in Cardiac Resynchronization Therapy|Cardiac resynchronization therapy trial comparing types of leads.
224037668|NCT04693260|DEVICE|Visual Acuity with a Hand-held Device Supported by Mobile App.|The Insight will be compared to a standard ETDRS eyechart
224037669|NCT03731260|DRUG|Avapritinib|Avapritinib tablet
224037670|NCT03731260|DRUG|Placebo|Placebo tablet
224037671|NCT01382264|OTHER|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
224037672|NCT01831830|BEHAVIORAL|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
224138325|NCT02488616|DEVICE|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
224138326|NCT02488616|DEVICE|Continuous glucose monitoring system|Enlite sensor®, Medtronic
224138327|NCT02488616|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
224138328|NCT03337555|DEVICE|McGrath|McGrath videolaryngoscope
224138329|NCT03337555|DEVICE|Pentax|Pentax videolaryngoscope
224138330|NCT03337555|DEVICE|Macintosh|Macintosh direct laryngoscope
224138331|NCT02093234|BEHAVIORAL|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
224138332|NCT02093234|BEHAVIORAL|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
224138333|NCT02093234|BEHAVIORAL|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
224138334|NCT03019224|PROCEDURE|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
223425242|NCT06620978|PROCEDURE|Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..|"Low pressure: Operative hysteroscopy without anesthesia with normal Saline medium in low pressure..~Operative hysteroscopy without anesthesia using normal Saline as medium with different pressure according to the arm allocated. The procedure is done for endometrial polyp removal, retained products of conception removal, intrauterine adhesyolisis and intrauterine device removal."
223425243|NCT06620978|PROCEDURE|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium in High pressure.|High pressure: Operative hysteroscopy without anesthesia with normal Saline medium at high pressure.
223425244|NCT00520481|DRUG|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
223425245|NCT00871442|OTHER|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
223425246|NCT00871442|OTHER|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
223425247|NCT00871442|DRUG|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
223425248|NCT01739218|DRUG|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula (\[participant's glomerular filtration rate + 25\] multiplied by the target area under the concentration-time curve \[AUC\] of 5 milligrams per milliliter per minute \[mg/mL/min\]), as intravenous \[IV\] infusion over 30-60 minutes \[min\] every 3 weeks).
223425249|NCT01739218|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared \[mg/m\^2\] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m\^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
223425250|NCT01739218|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram \[mg/kg\] as IV infusion over 30-90 min every 3 weeks.
223425251|NCT06602050|OTHER|HG and NIF|In mechanically ventilated patients, handgrip strength, the Negative Inspiratory Force (NIF) value obtained via the ventilator, and physical function through various tests will be assessed.
223425252|NCT00778284|DRUG|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
223425253|NCT02710253|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224037673|NCT03951779|DIAGNOSTIC_TEST|Exercise cardiac magnetic resonance imaging|Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
223425254|NCT02710253|OTHER|Laboratory Biomarker Analysis|Correlative studies
223425255|NCT02710253|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223425256|NCT01118793|DRUG|Clopidogrel|150 mg dosage of Clopidogrel for 7 to 10 days.
223425257|NCT04896346|OTHER|Punch biopsy|punch biopsies will be used for histologic analysis and biochemical assays
223425258|NCT04896346|OTHER|non-invasive photography, assessments, and measurements|photography, scar questionnaires, pain and itch assessments, and non-invasive measurements of scar including color, stiffness, and elasticity
223425259|NCT05905653|DRUG|STN1012600 ophthalmic solution 0.002%|1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
223425260|NCT03381079|PROCEDURE|Posterior scleral reinforcement|Posterior scleral reinforcement (pPSR) is a procedure applied with autologous or biological material or synthetic materials reinforcing pole of the sclera after eyeball, in order to prevent or alleviate myopic development.
223425261|NCT04455191|PROCEDURE|Thawing Embryos in Advance|Thaw Embryos one day in Advance
223425262|NCT04455191|PROCEDURE|Thawing Embryos on the Day of Transfer|Thaw Embryos on the morning of transfer day.
223425263|NCT00589758|DIAGNOSTIC_TEST|Echocardiography|2D and 3D echocardiography
223425264|NCT00589758|OTHER|Biomarker evaluation|Blood and urine collected
223425265|NCT06219824|DRUG|premixed Bio-ceramic MTA|pulpotomy treatment will be done and the premixed bioceramic MTA will be applied in the pulp chamber
223425266|NCT06219824|DRUG|Conventional MTA|pulpotomy treatment will be done and powder and liquid MTA will be mixed and applied in the pulp chamber
223425267|NCT05314842|DRUG|Formocresol|dressing agents in pulpotomized primary molas using formocresol in cariously exposed vital primary molars
223425268|NCT05314842|DRUG|Premixed bioceramic MTA|dressing agents in pulpotomized primary molas using premixed bioceramic MTA in cariously exposed vital primary molars
223425269|NCT02952131|PROCEDURE|Lipoaspiration|Closed Syringe Harvesting Autologous Subdermal Fat
223425270|NCT02952131|PROCEDURE|AD-cSVF|Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
223425271|NCT02952131|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
223425272|NCT03942068|DRUG|albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
223425273|NCT03942068|DRUG|Apatinib|a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
223425274|NCT04829032|PROCEDURE|Hartmann's procedure|Hartmann's procedure
223425275|NCT06038461|DRUG|Surufatinib Combined With Temozolomide and S-1|"Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D"
223425276|NCT04441957|DEVICE|Endovenous Mechano- Chemical Ablation|The Flebogrif™ catheter (Balton® Sp. z o.o., Warsaw, Poland) represents endoluminal Non Thermal Non Tumescent devices designed to cause occlusion (fibrosis) of the target vein through the combined mechanical and chemical damage to its endothelial lining with retractable cutters and foamed sclerosant.
223425277|NCT06666101|DIETARY_SUPPLEMENT|Long chain polyunsaturated Omega-3|2 capsules of fatty acids in the morning and 2 capsules in the evening except the first day, 4 soft gels in a single administration in the morning, ± 2,6 g/d
223425278|NCT06666101|DIETARY_SUPPLEMENT|Placebo|Olive oil
223425279|NCT04848779|DRUG|Alglucosidase alfa GZ419829|"Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous"
224037674|NCT05160441|BIOLOGICAL|Platelet Rich Plasma Injection|"Minimum 2cc Leukocyte Poor Platelet Rich Plasma~The PRP will be prepared by drawing 60cc blood from the participant through venipuncture, spinning the blood sample in a centrifuge and then injecting the platelet rich plasma (approximately 2-5cc or max collected) into the study shoulder using ultrasound guidance. This sample will be prepared by the study provider (physician assistant or physician). Any leftover blood will be safely discarded per standard protocols."
223564004|NCT04571424|DRUG|Placebo|Administered as specified in the treatment arm
223425280|NCT05709951|OTHER|Functional Exercises|The patients were requested to perform these functional exercises for 4 days per week three times for 20 min (8 weeks).
223425281|NCT05709951|OTHER|Core Stability Exercises|The patients were requested to perform 4 core strengthening exercises for 4 days per week three times for 20 min (8 weeks)
223425282|NCT02408289|DIETARY_SUPPLEMENT|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
223425283|NCT02408289|DIETARY_SUPPLEMENT|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
223564005|NCT01895439|BIOLOGICAL|Autologous Mesenchymal Stem Cells|
223564006|NCT01424891|DRUG|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
223564007|NCT01424891|DRUG|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
223564008|NCT01424891|DRUG|Placebo|treatment with placebo over 8 weeks
223564009|NCT01320319|OTHER|Placebo|Capsule form, 960 mg to be taken three times a day.
223564010|NCT01320319|DIETARY_SUPPLEMENT|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
223564011|NCT00974441|DRUG|Divalproex Sodium|500 mg Extended Release Tablet
224037675|NCT05160441|BIOLOGICAL|Corticosteroid Injection|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
223564012|NCT00974441|DRUG|Depakote®|500 mg Extended Release Tablet
223564013|NCT04883125|DRUG|Pioglitazone 15mg|pioglitazone (7.5-30 mg) once daily plus imatinib 400 mg 6 months
224138335|NCT03019224|PROCEDURE|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
224138336|NCT03019224|PROCEDURE|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
223425284|NCT02408289|DIETARY_SUPPLEMENT|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
223425285|NCT02408289|DIETARY_SUPPLEMENT|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
223425286|NCT04406584|PROCEDURE|Injection into olfactory cleft|Already stated above.
223425287|NCT00868725|OTHER|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
223564014|NCT05952765|PROCEDURE|Immediate implant|"* Local anesthesia Septanest special® will be administered prior to the procedure.~* Teeth extraction will be initiated by intrasulcular incision via 15 C blade without flap elevation.~* The tooth to be extracted will be luxated atraumatically using periotomes and thin straight elevator and delivered using forceps.~* The socket will be inspected for integrity, using a UNC graduated periodontal probe.~grafting material either experimental or control will be used to graft jumping gap."
223564015|NCT06214130|DRUG|Sodium valproate 500 MG|oral intake
223564016|NCT06214130|DRUG|Valproic Acid 500 MG|oral intake
223564017|NCT05099354|DIAGNOSTIC_TEST|autonomic nervous system testing|"* Autonomic tests, including heart rate variability (HRV) and baroreceptor sensitivity (BRS), are performed with a 10min ECG with non-invasive or invasive blood pressor measuring during rest. During the time at the stroke unit, this data will be calculated using the existing continuous monitoring.~* Valsalva maneuver during continuous ECG and blood pressure monitoring. The patient will be instructed to exhale against a mouthpiece with a defined resistance for 15 seconds.~* Assessment of the cerebrovascular reserve capacity will be done with continuous transcranial duplex sonography (TCD) and breath holding index (BHI). The patient will be instructed to hold his breath for 30 seconds, 4 times in a row with intervals of 4 minutes. This test will be performed only in responsive and compliant patients."
223564018|NCT00149136|DRUG|imatinib|
223564019|NCT03558334|DRUG|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
224037676|NCT05160441|BIOLOGICAL|Delayed Platelet Rich Plasma Injection After Corticosteroid Injection Failure|Participants randomized to the corticosteroid injection (CSI) group who report no improvement in their pain level at the 6 week post-CSI visit will be unblinded to their study injection (CSI) and will be offered the option to stay in the study and receive Platelet Rich Plasma injection.
223564020|NCT03558334|DRUG|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
223564021|NCT06077955|PROCEDURE|Mini-gastric bypass with stapled anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler."
223564022|NCT06077955|PROCEDURE|Mini-gastric bypass with hand-sewn anastomosis|"the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture."
223564023|NCT01973387|DRUG|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
223564024|NCT01973387|DRUG|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
224037677|NCT04280536|DRUG|Cohort A|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
223425288|NCT03560726|BEHAVIORAL|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
223425289|NCT04272944|DRUG|10 mg/kg Q2W|10 mg/kg MSB2311 every two weeks
223425290|NCT04272944|DRUG|20 mg/kg Q3W|20 mg/kg MSB2311 every three weeks.
223425291|NCT05029128|BEHAVIORAL|Endurance exercise intervention|All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.
223425292|NCT02091986|DRUG|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
223425293|NCT02091986|DRUG|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
223564025|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides
223564026|NCT05786937|BIOLOGICAL|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides|Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides
223564027|NCT05786937|OTHER|Commercial ringer´s lactate solution|Placebo
223564028|NCT00139295|DEVICE|Hylastan|
223564029|NCT01676753|DRUG|Dinaciclib|Given IV
223564030|NCT01676753|DRUG|Pembrolizumab|Given IV
223564031|NCT04277663|DRUG|IBI310+IBI308|In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
224138337|NCT03019224|PROCEDURE|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
224138338|NCT03019224|PROCEDURE|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
223425294|NCT02091986|OTHER|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
223425295|NCT01558440|DIETARY_SUPPLEMENT|Infant Formula|A diet that is being fed to the young infants.
223425296|NCT01558440|DIETARY_SUPPLEMENT|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
223425297|NCT01558440|DIETARY_SUPPLEMENT|Diluted F-100|300 ml of water is added to 1000 ml of f-100
223425298|NCT06574945|DRUG|intravenous injection of propofol only|Propofol was administered intravenously 2 mg/kg
223425299|NCT06574945|DRUG|intravenous injection of propofol +esketamine|intravenous injection of 0.5 mg/kg ESK followed by 1.5 mg/kg of propofol or intravenous injection of 0.25 mg/kg ESK followed by 1.5 mg/kg of propofol
223425300|NCT04616573|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
223425301|NCT04616573|DEVICE|iStent inject|Trabecular meshwork implantation
223425302|NCT02537431|BIOLOGICAL|burosumab|solution for subcutaneous injection
223425303|NCT03148860|DRUG|Methotrexate|subjects will receive once weekly 15 mg (3 capsules) MTX
223564032|NCT04277663|DRUG|IBI308|In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
223564033|NCT04277663|DRUG|High-dose recombinant interferon a-2B|In this group, subjects will be given 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
223564034|NCT05878886|DIETARY_SUPPLEMENT|Emergency Food Product|Each subjects of treatment group consumed 50 g food bar during 15 days. Monitoring of compliance undertaken by home visit to recall daily food consumption three days a week and to record the food bar stocks at home during study, and also weekly weight measurement.
223564035|NCT06279364|DRUG|SKB264|IV Infusion
223564036|NCT06279364|DRUG|Paclitaxel|IV Infusion.
223564037|NCT06279364|DRUG|Nab-paclitaxel|IV infusion.
223564038|NCT06279364|DRUG|Capecitabine|Tablet. Oral route of administration.
223564039|NCT06279364|DRUG|Eribulin|IV infusion.
223564040|NCT06279364|DRUG|Carboplatin|IV infusion.
223564041|NCT03027856|DEVICE|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
223564042|NCT00167609|DRUG|dehydroepiandrosterone 100 and 400 mg|
223564043|NCT02084706|PROCEDURE|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
223564044|NCT02084706|DRUG|2% Lidocaine|
223564045|NCT02084706|DRUG|Triamcinolone (20 g)|
223564046|NCT02084706|PROCEDURE|J-tip lidocaine administration|
223564047|NCT02084706|PROCEDURE|Triamcinolone (20 g) Injection over the A1 pulley.|
223564048|NCT01215110|DRUG|TMC207|
223564049|NCT01215110|DRUG|Rifafour e-275 mg|
223564050|NCT06636318|DIAGNOSTIC_TEST|Blood Sample Collection|"To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses."
223564051|NCT06636318|DEVICE|Actigraph (GT9X-BT) Monitor|Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
224037678|NCT04280536|DRUG|Cohort B|Oral FTD/TPI at RP2D will be administered until disease progression, intolerable toxicity or patient withdrawal.
223425304|NCT03148860|DRUG|Ustekinumab|subject will receive Ustekinumab open-label over a treatment period of 52 weeks
223425305|NCT03148860|OTHER|Placebo|subjects will receive once weekly 3 capsules PLC to MTX
223425306|NCT04881227|DEVICE|Chatbot on COVID-19 vaccine hesitancy|This intervention will provide to participants information on COVID-19 vaccine hesitancy consisting of the possibility of accessing a long series of questions and answers online about this vaccination.
223425307|NCT04881227|OTHER|Control intervention|This control intervention will provide to participants a brief text decribing the way vaccines works.
223425308|NCT00919373|PROCEDURE|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
223425309|NCT00919373|PROCEDURE|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
223425310|NCT00919373|PROCEDURE|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
224037679|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone"
224138339|NCT03019224|DRUG|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
223425311|NCT00107965|DRUG|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
223425312|NCT00107965|DRUG|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
223425313|NCT00107965|DRUG|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
223564052|NCT06636019|DEVICE|Myopia control contact lens|Myopia control contact lens is placed on the study eye.
223740052|NCT04166513|DEVICE|Targeted Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the targeted region.
224037680|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Indian Costus|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Indian Costus supplements"
224037681|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Quinine pills|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Quinine supplementation (1g Quinine)"
224037682|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Anise seed capsule|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Anise seed supplementation (450mg anise seed)"
224037683|NCT04553705|DRUG|Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice|"Omega-3 supplementation 1000mg contains (300-400mg EPA \& 200-300mg DHA)~Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone~Deglycyrrhizinated Licorice 800 mg"
224037684|NCT04553705|DRUG|Active Comparator|Standard protocol care of COVID-19 infection
224138340|NCT03019224|PROCEDURE|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
223425314|NCT00107965|DRUG|PEP005|Vehicle Gel (Day 1,2 application)
223425315|NCT00107965|DRUG|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
223425316|NCT00107965|DRUG|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
223425317|NCT00107965|DRUG|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
223425318|NCT00107965|DRUG|PEP005|Vehicle Gel (Day 1,8 application)
223425319|NCT03887026|DRUG|Norketotifen|Norketotifen oral capsule
223425320|NCT03887026|DRUG|Placebo|Placebo oral capsule
223425321|NCT00794040|DRUG|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
223425322|NCT00794040|DRUG|Add-on placebo following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
223425323|NCT00836381|DRUG|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
223425324|NCT00836381|DRUG|Placebo|Identical Placebo once daily
224037685|NCT04978311|BEHAVIORAL|Mirror therapy (MT) priming with task-specific training|In the regimen, participants will perform MT first followed by task-specific training. After completion of MT, participants will practice task-specific training that emphasizes on restoration of essential skills for daily activities. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
224037686|NCT04978311|BEHAVIORAL|Mirror therapy priming with impairment-oriented training|In the regimen, participants will perform MT first followed by impairment-oriented training. After completion of MT, participants will practice impairment-oriented training that emphasizes on restoration of movement. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
224037882|NCT06665685|DEVICE|BioButton Device|BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will be the patient wearing the device during their Nursing Home stay for 30-days.
224037687|NCT04978311|BEHAVIORAL|Control therapy|The control group will receive therapeutic training equivalent in duration to the two experimental groups. The control intervention will include practice of gross/fine motor activities, training of activities of daily living, practice to increase range of motions, muscle strengthening, as well as use of adaptive or compensatory technique to alleviate functional deficits. After that, the contents of home practice will be designed corresponding to treatment principles of the clinic-based intervention.
224037688|NCT06374368|PROCEDURE|jejuno-ileal diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
224037689|NCT06374368|PROCEDURE|jejuno-colic diversion|The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).
224037690|NCT01127945|DRUG|statin|"1. adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~2. acute heart failure therapy"
224037691|NCT02371122|DEVICE|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
224037692|NCT02371122|DEVICE|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
224037693|NCT02371122|DEVICE|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
224037694|NCT02371122|DEVICE|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
224037695|NCT05683535|DRUG|Atropine Sulfate|0.01%, 0.03%, or 0.05% atropine eye drops made from compounding pharmacies.
223425325|NCT00392743|PROCEDURE|pet/spect scan|
223425326|NCT02375308|BEHAVIORAL|HDT|20 sessions, individual psychotherapy
223425327|NCT02375308|BEHAVIORAL|ACDT|20 sessions, individual psychotherapy
223425328|NCT06669884|OTHER|Cardiodynamicsgram (CDG)|Cardiodynamicsgram (CDG) technique
223425329|NCT06372587|OTHER|genetically encoded engineered proteins|using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss
223425330|NCT04448457|DRUG|Sufentanil Sublingual Tablet|15 mcg with lockout interval of 20 min
223425331|NCT04448457|DRUG|Oxycodone oral tablet and oxycodone extended-release oral tablet|Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
223425332|NCT02348801|BEHAVIORAL|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of \~90 min duration 15 min warm-up of flexibility exercise, followed by \~30 min of aerobic exercise, and, after a brief rest period, \~30 min of resistance training, and finally \~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
223425333|NCT02348801|BEHAVIORAL|Healthy lifestyle|Diabetes support and education
223425334|NCT02094976|DEVICE|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
223425335|NCT02094976|DEVICE|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
223425336|NCT02094976|DEVICE|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
223425337|NCT06666920|RADIATION|laser irradiation|Immediately after applying the bleaching agent, the gel on the left upper and lower hemiarches (teeth 21-25 and 31-35) was irradiated using an Er,Cr:YSGG laser (2780 nm). Specifically, an Er,Cr:YSGG solid-state laser device (Waterlase MD Turbo, BIOLASE, Irvine, CA, USA) equipped with a Z-type glass tip (MZ8) measuring 800 μm in diameter and 6 mm in length was used. This tip was attached to the laser system's gold handpiece. The laser parameters for the treatment included an average output power of 1.25 W, a pulse duration of 700 μs (S-mode), and a pulse repetition rate of 10 Hz, without water or air flow, according to a previous study. Each tooth received two 15-s irradiation intervals, one for each 20-min session (totaling 30 s), while maintaining the laser handpiece approximately 2.5 cm from the tooth surface, perpendicular to the enamel. The gel was irradiated using a scanning mode, with the handpiece moved slowly in both horizontal and vertical directions at a speed of 2 mm/s.
223425338|NCT01990131|OTHER|Cognitive Anxiety Sensitivity Treatment|
223425339|NCT01990131|OTHER|Physical Health Education Training|
223425340|NCT03181269|OTHER|Intervention education|An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
223425341|NCT03181269|OTHER|Placebo Education|An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
223425342|NCT06668129|BEHAVIORAL|Back care intervention program|"The back care intervention consists of:~1. Nine oral presentations. Include Programa Suma't programme developed by the Provincial Council of Majorca.~2. Multisubject Teaching Unit.~3. Information campaign widespread by the school (i.e. posters, triptychs, school website, social networks, etc.)~4. The Back Care Day at school."
223425343|NCT05236374|OTHER|Beef protein|Animal protein source
223425344|NCT02393807|DRUG|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
223425345|NCT02393807|DRUG|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
223425346|NCT03626363|BEHAVIORAL|Stress Management|An eight week stress reduction course.
223425347|NCT03368885|OTHER|Maternal dietary diversity|Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition
223425348|NCT03368885|OTHER|Diet diversity in complementary feeding|Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
223740053|NCT04166513|DEVICE|Active Control Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes, and stimulation will be applied to the active control region.
223740054|NCT04166513|BEHAVIORAL|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
224037696|NCT06534411|DRUG|Cagrilintide|Participants will receive once-weekly cagrilintide subcutaneously.
224037697|NCT06534411|DRUG|Semaglutide|Participants will receive once-weekly semaglutide subcutaneously.
224037698|NCT06534411|DRUG|Tirzepatide|Participants will receive once-weekly tirzepatide subcutaneously.
224037699|NCT02315599|DRUG|anti-CD19 CAR|
224037700|NCT04026841|DRUG|PD-1 antibody Sintilimab|Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
224037701|NCT03015441|OTHER|Milk product fermented by lactic bacteria or not fermented|2 pots of 125g consumed daily during 28 days
224037702|NCT04473183|DIAGNOSTIC_TEST|Specimen Collection|"Blood: Two tubes of blood (up to 10 ml each) will be drawn from participants and will be collected by experienced phlebotomists.~Nasal, oral, and rectal swabs: Nasal, oral, and rectal swabs are optional specimens that patients may be asked to donate. If prospective consent is provided, swabs will be self-collected by participants after receiving clear instructions from the team and collected in the dedicated container.~Saliva: Saliva is an optional specimen that patients may be asked to donate. If prospective consent is provided, whole saliva samples will be self-collected by participants using a pad placed between the cheek and gum for 2-5 minutes or collecting the saliva directly to a sterile container."
224037703|NCT04473183|DIAGNOSTIC_TEST|Surveys|Participants will be asked to fill out a brief online survey that will investigate symptoms consistent with SARS-CoV-2 infection in the past 3 months and the geographic location of the clinic(s) they work in (if a resident of a medical school) and their comorbidities related to SARS-CoV-2.
224037704|NCT02575820|PROCEDURE|Old red blood cells transfusion|Red blood cells (shelf life \> 14 days) transfusion during the operation (total hip replacement arthroplasty)
224037705|NCT02575820|PROCEDURE|New red blood cells transfusion|Red blood cells (shelf life =\< 14 days) transfusion during the operation (total hip replacement arthroplasty)
224037706|NCT05972629|DRUG|SAR444836|Infusion pump, intravenous infusion (IV)
224037707|NCT06042010|DRUG|Oral zinc supplement|patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
224037708|NCT06042010|DRUG|triamcinolone acetonide Oral paste|patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
223425349|NCT03368885|OTHER|Exclusive Breast Feeding|Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
223425350|NCT03368885|OTHER|Community mobilization|Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding
223425351|NCT03368885|OTHER|Capacity Building|Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
223425352|NCT03368885|OTHER|Use of existing platforms VHSND|Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding
223425353|NCT03368885|OTHER|Strategic use of data|Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
223425354|NCT01893060|DRUG|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
223425355|NCT01893060|DRUG|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
223425356|NCT01893060|DRUG|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
224037883|NCT06665685|DEVICE|Providing Clinical Care with BioButton Device|BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will provide care for patients wearing the BioButton device during their Nursing Home stay for 30-days.
223425357|NCT01893060|OTHER|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
223740055|NCT04166513|BEHAVIORAL|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
223740056|NCT07033845|DEVICE|Phenylephrine|Topical Phenylephrine
224037884|NCT06855537|PROCEDURE|PCI strategy|-In the intervention group, vulnerable plaque lesions (quantitative flow ratio, QFR \>0.8) to be treated at the operator's discretion using second-generation drug eluting stent (DES).
223425358|NCT04410120|OTHER|Interview|Semi-structured 45 minute interviews regarding impact of asthma attacks
223425359|NCT05261724|DIAGNOSTIC_TEST|MRI|In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.
223425360|NCT05872867|BIOLOGICAL|WM-A1-3389|Anti-IGSF1 (Immunoglobulin superfamily member 1)
223425361|NCT05872867|BIOLOGICAL|Pembrolizumab|Anti-PD-1(Programmed cell death protein 1)
223425362|NCT06903559|DRUG|Roxadustat|Intervention Description: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Administered orally three times per week. Dosage will be initiated and adjusted according to prescribing guidelines for the treatment of anemia associated with chronic kidney disease in patients on dialysis, based on hemoglobin levels.
223425363|NCT06903559|DRUG|Conventional Anemia Management|Standard of care treatment for renal anemia, typically involving administration of erythropoiesis-stimulating agents (ESAs, e.g., epoetin, darbepoetin) and/or intravenous iron supplementation. Dosing and specific agents used are per standard clinical practice at the study site and adjusted based on hemoglobin levels and iron status according to prevailing guidelines.
223425364|NCT06487338|OTHER|Low-level laser therapy|Is a form of medicine that applies low-level (low-power) lasers that relieve pain.The effects appear to be limited to a specified set of wavelengths
223425365|NCT06487338|OTHER|Shock wave Therapy|is a non-invasive treatment that stimulates the body's natural healing process. It can relieve pain and promote healing of injured tendons, ligaments, and other soft tissues
223425366|NCT01945853|DEVICE|7 Tesla MRI|
223425367|NCT02600845|DEVICE|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
223425368|NCT00489905|DRUG|Zolderonic acid (Zometa)|
223564053|NCT05688202|PROCEDURE|Simultaneous combination of fractional CO2 laser and subcision|"Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
223740057|NCT04616547|OTHER|Questionnaire Administration|Ancillary studies
224037709|NCT03199937|BEHAVIORAL|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
224138341|NCT02942316|DEVICE|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~* after induction, before opioid administration~* after opioid administration, steady state~* surgical incision~* end of procedure"
223740058|NCT04616547|RADIATION|Tin Sn 117m Pentetate|Given IV
224138342|NCT00286130|DRUG|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
224138343|NCT00286130|DRUG|FOLFOX 6|"FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
224138344|NCT00286130|DRUG|FOLFIRI|"FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
224138345|NCT04258046|DRUG|Trametinib tablet|Drug is supplied in 0.5 mg and 2 mg tablets
223425369|NCT04837508|DRUG|MRG002|Administrated intravenously
223425370|NCT05941143|OTHER|mindfulness-based intervention|8 weekly group 2-hour sessions program adapted from mindfulness-based stress reduction and mindfulness-based cognitive therapy protocols. It was specifically tailored to older adults.
223425371|NCT03845582|DRUG|ALK-001 oral capsule|Daily administration for 24 months
223425372|NCT03845582|DRUG|Placebo oral capsule|Daily administration for 24 months
223425373|NCT06489327|DRUG|melatonin (Circadin ®) 0.2 mg/kg|Patients will receive oral melatonin at a dose of 0.2 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
224138346|NCT01690169|DRUG|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
223425374|NCT06489327|DRUG|melatonin (Circadin ®) 0.4 mg/kg|Patients will receive oral melatonin at a dose of 0.4 mg/kg as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
223425375|NCT06489327|DRUG|placebo group|Patients will receive oral placebo as premedication in the morning of the surgery, 90 minutes before the induction of anesthesia, with a maximum dose of melatonin set at 10 mg.
223425376|NCT06287827|PROCEDURE|Simplified protocol|"MUAC-based dosing:~* SAM \[MUAC \<115mm or WHZ \<-3 or oedema (+/++)\] = Two 92g sachets Ready to use Therapeutic Food (RUTF)/day (Approx. 1000 kcal/day).~* MAM \[MUAC 115mm\<125mm or WHZ \<-2\] = One 92g sachet RUTF/day (Approx. 500 kcal/day)."
223425377|NCT06287827|PROCEDURE|Standard protocol|"Weight-based dosing~* SAM: Mid-upper-arm circumference (MUAC) \<115mm or Weight-Height/length Z Score \<-3 or mild or moderate bipedal oedema: 150-185 kcal/kg/day is offered using RUTF until the patient passes to MAM and then the dose is reduced to 100 -130 kcal/kg/day using RUTF until recovery.~* MAM: MUAC 115-\<125mm or Weight-Height/length Z Score \<-2: 100-130 kcal/kg/day is offered using RUTF until recovery."
223425378|NCT00352092|DRUG|calcineurin inhibitor|
223425379|NCT00352092|DRUG|sirolimus|
223425380|NCT00352092|DRUG|mycophenolate mofetil|
223740059|NCT05415020|BEHAVIORAL|Lifestyle Behavior Protocol|Virtual training on building a skillset to improve lifestyle behavior that reduces migraine attacks
223740060|NCT05415020|BEHAVIORAL|Sham Behavior Protocol|Virtual training on the disease of migraine and how migraine can progress to chronic migraine.
223740061|NCT06808516|DRUG|Oxytocin nasal spray|24 IU
223740062|NCT06808516|DRUG|Placebo|0.9% NaCl
223425381|NCT04084834|OTHER|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
223425382|NCT05897086|DRUG|Polyethylene Glycol 3350|Topical irrigation with approximately 2 ccs of a 190 mM solution of 50% PEG 3.35 kD in sterile water
223564054|NCT05688202|PROCEDURE|Sequential combination of fractional CO2 laser and subcision|"Fractional CO2 laser conducted two weeks after subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap."
223564055|NCT05688202|DEVICE|Fractional CO2 laser|Fractional CO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) on both sides of the face sequentially with a two-week interval between sessions for each face's side by a single physician, with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes. At the first pass, only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density in the static operating mode. At the second pass, the whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density in the static operating mode with less than 10% overlap.
224037710|NCT03199937|OTHER|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
223425383|NCT02409563|DRUG|Budesonide nasal spray (100 mcg bid)|
223425384|NCT02409563|DRUG|Budesonide nasal spray (50 mcg bid|
223425385|NCT02529124|DIETARY_SUPPLEMENT|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
223425386|NCT02529124|DIETARY_SUPPLEMENT|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
224037711|NCT03197363|OTHER|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
224037712|NCT00014313|DRUG|cisplatin|
224037713|NCT00014313|DRUG|etoposide|
224037714|NCT04959955|DIAGNOSTIC_TEST||
224037715|NCT05583201|BIOLOGICAL|KD-496|Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
223425387|NCT02529124|BEHAVIORAL|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
223425388|NCT04416867|DEVICE|splint and home exercise|Each patient will be given a home exercise program of wrist range of motion, wrist stretch, wrist isometric strengthening and median nerve glide exercises to be performed daily for the duration of the study
223425389|NCT04416867|DEVICE|RESWT|RESWT at a pressure of 4 bars, a frequency of 5Hz and 2000 hits in total will be applied 2cm proximal to the median nerve, with the probe directed towards the palm, diffusely over the pisiform.
223425390|NCT04416867|DEVICE|physical therapy|20 minutes of liquid paraffin treatment of the hand, 1.5watt/cm2 therapeutic ultrasound applied to the volar surface of the wrist for 5 minutes and 20 minutes of transcutaneous electrical nerve stimulation (TENS) on five consecutive days of the week for a total of fifteen sessions over 3 weeks
224037716|NCT00003741|BIOLOGICAL|monoclonal antibody HeFi-1|
224037717|NCT00403754|DRUG|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
224037718|NCT00403754|DRUG|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
224037719|NCT00403754|DRUG|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
224138347|NCT01690169|DRUG|placebo|A single dose of oral placebo administered.
224138348|NCT00789269|DRUG|rhubarb|14 days of rhubarb
224138349|NCT00789269|DRUG|placebo|14 days of placebo
224138350|NCT05883553|DEVICE|Usability and added value of device within sexual activity|Participants and there partners will be asked to use the device over the course of 4 months, during which both will provide answers to questionnaires on quality of relation and sexual life, and detailed questions on the usability and the added value of the used device during sexual activity along with overall satisfaction with the device.
224138351|NCT03284255|DEVICE|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
223564056|NCT05688202|PROCEDURE|Subcision|Subcision is operated in all participants using an 1812G Nokor needle (BD Nokor™ Admix Needles, Becton, Dickinson and Company, New Jersey, United States). The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine. After obtaining appropriate anesthesia, a Nokor needle is inserted into the skin close to the depressed scars and progressed until it lays precisely under the scar. The insertion depth is at the dermal-hypodermal junction. Initially, the subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue. Once the fibrous mass has been sufficiently fractured, the needle is slid in a direction parallel to the skin's surface in order to detach the scar from its tethers. For densely fibrous scars, several needle insertion sites are used to undermine the defect from various angles.
223564057|NCT05688202|DRUG|Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream|Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
223564058|NCT05688202|DRUG|Paracetamol|A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
223564059|NCT05688202|DRUG|Lidocaine 2% Injectable Solution|The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
223564060|NCT02580123|BEHAVIORAL|Intervention taught by trained educators|
223564061|NCT05501210|DEVICE|WBV|Whole body vibration (WBV) therapy
223564062|NCT05501210|DEVICE|PEMF|Pulsed electromagnetic fields (PEMF)
223564063|NCT00120081|BIOLOGICAL|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
223564064|NCT00120081|BIOLOGICAL|Saline placebo|Inactive saline placebo control
223740063|NCT07071727|RADIATION|Preoperative radiotherapy|preoperative radiotherapy
224037720|NCT03139825|OTHER|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
224037721|NCT00947778|OTHER|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
224037722|NCT00947778|OTHER|1 training session|20 sessions of 30 minutes by week during 24 semaines
224037723|NCT02979925|DEVICE|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
223425391|NCT02531776|DEVICE|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson \& Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated."
224037724|NCT02979925|DEVICE|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
224037725|NCT06092554|DIETARY_SUPPLEMENT|LactoLevure|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The probiotic capsules look identical to the placebo capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
224037885|NCT06855537|DRUG|OMT strategy|"* Lifestyle modifications and intensive medical therapy (based on current guideline-directed secondary prevention).~* Both groups to receive statin or other therapies to achieve LDL-C \<1.4 mmol/L and decrease by 50% compared to the baseline.~* Lifestyle and risk factor management to include smoking cessation, nutritional optimization, physical activity, adherence to prescribed medications, and control of diabetes and hypertension."
223425392|NCT01080469|DRUG|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
223425393|NCT06668662|DEVICE|Endoactivator|Endoactivator is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
223425394|NCT06668662|DEVICE|Conventional irrigation|Conventional irrigation is an irrigation technique which will help to reduce post-operative pain in patients following endodontic treatment.
223425395|NCT02289547|DRUG|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
223425396|NCT06022276|DRUG|Nimotuzumab|Nitozumab injection 400mg/cycle, every 21 days/cycle, until disease progression, intolerable toxicity or death, or subject decision to withdraw from the study.The molecular testing results of the patient are analyzed and interpreted by the MTB team, and appropriate combination therapy(Nitozumab+) strategies are proposed based on the patient's previous treatment history, physical condition, drug accessibility, and economic status.
223425397|NCT03145961|DRUG|Pembrolizumab|200mg intravenous infusion
223425398|NCT06929624|DRUG|SHR-A1912 Injection|SHR-A1912 injection.
223425399|NCT06929624|DRUG|Rituximab Injection|Rituximab injection.
223425400|NCT06929624|DRUG|Gemcitabine Hydrochloride for Injection|Gemcitabine hydrochloride for injection.
223425401|NCT06929624|DRUG|Oxaliplatin Injection|Oxaliplatin injection.
223425402|NCT06922747|OTHER|Group exercising|Weekly, supervised exercise sessions in groups
223425403|NCT06922747|OTHER|Somatic tracking|A psychological intervention aiming to learn the brain to reinterpret pain signals.
223425404|NCT06922747|OTHER|General activity recommendaitons|General recommendaitons for physical activity and healthy lifestyle
223564065|NCT05523609|DRUG|Letrozole 2.5mg|20 patients will receive Letrozole only for 12 weeks
223740064|NCT06194799|DRUG|ACP-204|ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
224037886|NCT06610110|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
224037726|NCT06092554|OTHER|Placebo|Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The placebo capsules contain a powdered glucose polymer that is unharmful for the patient and will be provided by the sponsor. The placebo capsules look identical to the probiotic capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.
224037727|NCT05680558|DRUG|UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|Extracorporeal Photopheresis (ECP)
224037728|NCT05680558|DEVICE|THERAKOS® CELLEX photopheresis system|THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
224037729|NCT01548924|DRUG|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
224037730|NCT01548924|DRUG|Dovitinib + Paclitaxel|"* Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~* Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
224037731|NCT05464030|DRUG|M9140|M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.
224037732|NCT05464030|DRUG|M9140|M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.
224037733|NCT05464030|DRUG|Bevacizumab|Bevacizumab will be administered intravenously as per standard of care.
224037734|NCT05464030|DRUG|Capecitabine|Capecitabine will be administered orally as per standard of care.
224037735|NCT05464030|DRUG|5-fluorouracil (5-FU)|5-FU will be administered intravenously as per standard of care.
224037736|NCT05464030|DRUG|Folinic acid|Folinic acid will be administered intravenously as per standard of care.
224037737|NCT05326308|DRUG|Zanubrutinib|according to the Summary of Product Characteristics (SmPC).
224037738|NCT05326308|DRUG|Obinutuzumab|according to the Summary of Product Characteristics (SmPC).
224138352|NCT03284255|DEVICE|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
223425405|NCT04195620|OTHER|High self-disclosure|"The high self-disclosure condition involves individuals asking and answering a series of questions that are more personal in nature and involve sharing or receiving information that is likely to be emotionally laden and information that is not readily shared in typical conversations. An example of a question from this condition includes If you were to die today without the chance to speak with anyone, what would you most regret not having said to someone? Why haven't you said it yet?"
223425406|NCT04195620|OTHER|Low self-disclosure|"The low self-disclosure condition involves individuals asking and answering a series of questions that are not personal in nature and involve sharing or receiving information that is shared in very casual conversations. An example of a question from this condition includes What did you do to celebrate Halloween last year?"
223425407|NCT03726294|DRUG|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
223425408|NCT01904292|DRUG|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
223425409|NCT03096678|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance Imaging|Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
223425410|NCT03546426|DRUG|Pembrolizumab|200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
223425411|NCT03546426|BIOLOGICAL|Autologous dendritic cells|Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
223425412|NCT03546426|DRUG|Interleukin-2|3 MU s.c. from day +2 to day +6 after each DC administration
223425413|NCT03139006|DEVICE|Dual-layer spectral detector CT|A dual energy CT approach
223425414|NCT04413552|DRUG|INDV-2000|INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
223425415|NCT04413552|DRUG|Placebo|Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
224037739|NCT05900037|DEVICE|GATT-Patch|"GATT-Patch is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location.~GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver."
224037740|NCT05900037|DEVICE|SURGICEL® Original|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is indicated for use in surgical procedures to assist in the control of capillary, venous and small arterial hemorrhage when ligation or other conventional methods of control are impractical or ineffective.
224037741|NCT01729455|BIOLOGICAL|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
224037742|NCT01729455|OTHER|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
224037743|NCT00614705|DRUG|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
224037744|NCT00614705|DRUG|Placebo|oral capsule form, once daily for 28 days
224037745|NCT03938701|DRUG|Adalimumab-800CW|Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
224037887|NCT06610110|DIETARY_SUPPLEMENT|Placebo|Placebo (3 mg/kg maltodextrin)
224037888|NCT02778243|BIOLOGICAL|steroids concentrations determination|
224138353|NCT00091845|DRUG|AVI-4020 Injection|
224138354|NCT05638763|DRUG|Dasatinib Pill|Patients will receive half pill of dasatinib 50mg (25mg/day, orally) for one year
223564066|NCT05523609|DRUG|Letrozole + vitamin D3 and calcium|20 patients will receive Letrozole in addition to 2000 IU vitamin D3 per day for 12 weeks.
223564067|NCT03118856|DIAGNOSTIC_TEST|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
224037746|NCT03938701|DEVICE|Fluorescence Imaging|"Rheumatoid arthritis: a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals open-air by using a black-box.~Inflammatory bowel disease: a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
224037747|NCT05849181|DEVICE|Moona Device|Moona Device pillow pad
224037748|NCT05849181|DEVICE|Inactive Moona Device|Inactive Moona Device pillow pad
224037749|NCT05483296|OTHER|Dim light condition|"During the Dim light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
224037750|NCT05483296|OTHER|Moderate light condition|"During the Moderate light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
224037751|NCT05483296|OTHER|Bright light condition|"During the Bright light condition, the four-hour afternoon light exposure at the participants' eye level will be dim (\>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level."
224037752|NCT05090995|BEHAVIORAL|Behavioral Self-Management and Feedback|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
224037753|NCT05090995|BEHAVIORAL|Behavioral Self-Management|Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
224037754|NCT05701189|DRUG|Efgartigimod Alfa-Fcab|Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
224037755|NCT05701189|DRUG|Intravenous Immunoglobulin (IVIg)|IVIg is the standard-of-care treatment for GBS. Brand of IVIG used may vary per institutional standards
224037756|NCT04260217|DRUG|APG2575 400 mg|APG2575 400 mg
224037757|NCT04260217|DRUG|APG2575 600 mg|APG2575 600 mg
224037758|NCT04260217|DRUG|APG2575 800 mg|APG2575 800 mg
224037759|NCT05256238|OTHER|comprehensive supervised exercise program (CSEP)|"The CSEP starts as soon as possible after cancer diagnosis and lasts for 12 weeks:~* week 1-6 (during cancer treatment): 2 supervised sessions at the exercise room of the University Hospital Leuven in connection to the radiotherapy treatment session and one additional session at home. Patients will receive equipment to perform the program at home, e.g. weights, therabands,…~* week 7-12 (after cancer treatment): 1 supervised session at the exercise room of University Hospital Leuven in connection to the follow-up consultations (once a week) with the oncologist and two additional sessions at home~* maintenance program (from week 13), patients will exercise at home with a monthly teleconsultation"
224037760|NCT05016323|DRUG|HR19042 Capsules|HR19042 Capsules
224037761|NCT05016323|DRUG|Placebo|Placebo
224037762|NCT06602856|OTHER|Point-of-care ultrasound examination|We are investigating the extent to which pre-hospital point-of-care ultrasound examination influences the further deployment tactics, medical treatment and choice of destination hospital for patients.
224037763|NCT01202214|DRUG|1440115|
224037764|NCT01202214|DRUG|Placebo|matching placebo
224037765|NCT02020070|DRUG|Degarelix|
224037766|NCT02020070|DRUG|Ipilimumab|
224037767|NCT02020070|PROCEDURE|Radical Prostatectomy|
224037768|NCT02499770|DRUG|Carboplatin|
223425416|NCT06772987|DEVICE|Accelerated rTMS treatment|1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.
223425417|NCT02070627|DRUG|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
223425418|NCT02070627|DEVICE|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
223425419|NCT05711186|OTHER|Structured SDM|The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR
223425420|NCT05711186|OTHER|Usual Care|Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure.
223425421|NCT03675165|BEHAVIORAL|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
223425422|NCT04693832|DEVICE|5inD|Interactive Mobile Application which is includes five different game (mandala, puzzle, tetris, music, breath exercise)
223425423|NCT06576388|DRUG|EXG001-307 injection|Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.
223425424|NCT01993953|OTHER|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
223564068|NCT05527587|OTHER|Nature Connections Intervention|10 PLWD and their 10 caregivers will be examined for the effects of a park visit program on their behaviour and mood symptoms, cognition, and quality of life over the period of 8-weeks. If participants meet the study criteria, an initial education session on the health benefits of nature will be provided to the them. Participants will then be invited to participate in the park visit program which will have them visiting local parks or outdoors spaces with their caregivers. They will be encouraged to allocate approximately 120 minutes each week to outdoor park activities for 8 weeks. Participants will be provided with a visit passport to record a log of activities completed during the park visits. During the 8 weeks of intervention, participants will also participate in a weekly check-in meeting with other participants to discuss about their experiences with the park visits.
223564069|NCT05605275|DIAGNOSTIC_TEST|PCT levels|All patients will have their serum PCT level recorded on the day of the positive blood culture and in the next three days.
223564070|NCT05605275|DIAGNOSTIC_TEST|CRP levels|All patients will have their serum CRP level recorded on the day of the positive blood culture and in the next three days.
223564071|NCT05605275|DIAGNOSTIC_TEST|White blood cell count|All patients will have their white blood cell (WBC) count recorded on the day of the positive blood culture and in the next three days.
223564072|NCT05605275|DIAGNOSTIC_TEST|Platelet count|All patients will have their platelets count recorded on the day of the positive blood culture and in the next three days.
223564073|NCT01190761|DRUG|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
223564074|NCT01190761|DRUG|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
223564075|NCT02512874|OTHER|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
223564076|NCT02512874|DEVICE|Dynamometer|Grip Test
223564077|NCT02512874|RADIATION|DEXA|Body Composition Testing
223564078|NCT02512874|OTHER|Gait Speed Test|15 foot walk test
223564079|NCT02512874|DEVICE|Activity Monitor|Measures energy expenditure and activity
223564080|NCT02512874|OTHER|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
223564081|NCT02854488|DRUG|Yervoy|
223564082|NCT03888235|PROCEDURE|Immediate corrective exercises|The sacroiliac forward flexion test (SIFFT) finds the position of each innominate bone. Subjects learn 1 of 3 exercises. To correct anterior rotation, flex the thigh hard against the ilium, pushing it backwards. To correct posterior rotation, hyperextend the thigh to pull the ilium forward. 1.Genuflect, anterior foot and posterior knee on the floor hands on the floor on either side of the foot, sliding the knee backwards to hyperextend the thigh. 2. Supine, anterior foot on an assistant's sternum, posterior thigh hyperextended. Assistant leans forward, forcing the anterior thigh against the ilium and pushing down on the posterior thigh. 3. For anterior rotation alone: anterior foot on a chair seat, pulling up hard with both hands, leaning back, forcing the thigh against the ilium. Hold position for 2 minutes. Use as needed for pain control. They are reassessed one month later when they receive the pelvic support belt. Both treatments used together will be assessed one month after.
223564083|NCT03888235|DEVICE|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their sacroiliac joints. The belt is fitted tightly around the pelvis, over the sacrum and below the anterior superior iliac spines (ASISs) to prevent opening the joint. (The upper part of the innominate bones flares out so pushing them inwards will move the lower part outwards, away from the sacrum, opening the sacroiliac joints, increasing their instability). They will use this belt for activities which have in the past precipitated back pain. They will be reassessed one month later.~At that time they will be given the exercises to correct their sacroiliac malrotation and the concurrent use of both treatments will be assessed at their last visit one month later."
223564084|NCT03888235|OTHER|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month. At their one-month visit, they will be taught how to assess the direction of sacroiliac malrotation and how to do the corrective exercise. They will also be fitted for a pelvic stabilization belt.
224037769|NCT02499770|DRUG|Placebo|
223564085|NCT05441605|OTHER|Effects of Chlorhexidine Solutions with Different Concentrations in Preventing Peripheral Venous Catheter-Associated Infections|Chlorhexidine solution in different concentrations (1%, 2%, 4%) will applied to the 3 determined experimental groups, and 70% alcohol solution will applied to the control group. Its effects in preventing peripheral venous catheter-associated infection will compared.
223564086|NCT00666653|DRUG|pramipexole|
223564087|NCT05282108|DRUG|Carcemia|Generic Imatinib
223564088|NCT05282108|DRUG|Glivec|Imatinib
223564089|NCT06401746|DEVICE|Gastric Alimetry|The Gastric Alimetry™ System is intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of various gastric disorders.
223564090|NCT05530863|BEHAVIORAL|Assisted Therapy|The participant will receive coaching calls and support
223564091|NCT05530863|BEHAVIORAL|Sleep Hygiene|Standard Sleep Hygiene instructions.
224037770|NCT02499770|DRUG|Trilaciclib|
224037771|NCT02499770|DRUG|Etoposide|
224037772|NCT06079684|DEVICE|Intermittent vacuum therapy|"Data on demographics and clinical conditions was gathered. The investigators collect the next features: sex, age, level of education, occupation, environment, degree of functional deficit, body mass index and Kellgren-Lawrence classification.~Also, scores for the Knee Injury and Osteoarthritis Outcome Score, the Western Ontario and McMaster Universities Osteoarthritis Index, the Functional Independence measurement, the Fall Risk Score, and the Visual Analogue Scale were recorded at baseline and after 10 days.~A blinded expert used a 7-15 MHz linear probe to take ultrasonographic measurements of Baker Cyst at baseline and after 10 days."
223425425|NCT01993953|OTHER|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
223425426|NCT01993953|OTHER|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT's from group B will also serve as training instructors.
223425427|NCT05237102|PROCEDURE|Cerebrospinal fluid shunt|"The procedure is designed to reduce the amount of cerebrospinal fluid in a patient's brain by draining it through a shunt tube:~①V-P shunt is suitable for most types of hydrocephalus; ②L-P shunt is suitable for traffic hydrocephalus and positive pressure hydrocephalus, and patients with lower cerebellar tonsil hernia are contraindications; ③ Common terms of ventriculoatrial (V-A) shunt are not suitable for V-P shunt (abdominal infection, serious respiratory and circulatory diseases are contraindications); ④ The third ventriculostomy is suitable for patients with non-traffic and partial traffic hydrocephalus （infants and patients with severe ventricular enlargement should be cautious, and patients with shunt tube cannot be placed due to ventricular conditions）; ⑤Other shunt methods include septum pellucidum fistula and Torshunt （ventriculo-occipital cistern shunt after tumor resection）"
223425428|NCT06507839|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
223425429|NCT06507839|OTHER|Placebo|Matching placebo
223425430|NCT06943937|DRUG|YTS109 cell injection|Subjects will receive YTS109 Cell Injection(1E6 STAR+T cell/kg or 2E6 STAR+T cell/kg) once in this study.
223425431|NCT06939335|DEVICE|Disposable PEEP Valve set at 5 cm H20.|Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 and a 22 mm disposable PEEP Valve set at 5 cm H20.
223425432|NCT06939335|DEVICE|Controle|Ventilation during cardiac arrest with an adult Resuscitation Bag with a pressure relief valve set at 40 cm H20 without a disposable PEEP Valve.
223425433|NCT01442311|OTHER|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
223425434|NCT01442311|OTHER|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
223425435|NCT02700373|DRUG|PDC-APB|
223425436|NCT02700373|DRUG|Placebo|
223564092|NCT06806241|DRUG|Tranexamic acid|in the study group, a combination of two ampules of Tranexamic acid solution mixed with saline will be used. Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
223425437|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
223425438|NCT00251082|DRUG|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
223740065|NCT06823752|DRUG|Lemborexant 10 MG|An orally ingested tablet containing 10mg Lemborexant taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
223425439|NCT00251082|DRUG|Placebo|Placebo
223740066|NCT06823752|DRUG|Placebo|Placebo tablets will contain similar excipients without the active ingredient (Lemborexant) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.
224037773|NCT02475486|DEVICE|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
224037774|NCT05530590|OTHER|Training to Serve (TTS) in person training|Participants receive in person training.
224037775|NCT05530590|OTHER|Training to Serve online training (eTTS)|Participants receive online training.
224037776|NCT02089841|DRUG|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
223425440|NCT06433622|DIAGNOSTIC_TEST|Repeat Thromboelastography with Platelet Mapping|Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
223425441|NCT03277469|DEVICE|MRI|Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
223425442|NCT03277469|RADIATION|Brachytherapy|Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
223425443|NCT03277469|DEVICE|MRI Tracker|The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
223425444|NCT04852679|DRUG|Lanreotide autogel|Administered as deep subcutaneous (SC) injections
223564093|NCT06806241|DRUG|saline irrigation|In control group, saline will be used for irrigation.Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.
223564094|NCT03314974|BIOLOGICAL|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
224037777|NCT03267693|DIAGNOSTIC_TEST|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
224037778|NCT00047320|DRUG|carboplatin|Given IV
224037779|NCT00047320|DRUG|etoposide|Given IV
224037780|NCT00047320|DRUG|ifosfamide|Given IV
224037781|NCT00047320|DRUG|thiotepa|Given IV
224037782|NCT00047320|PROCEDURE|adjuvant therapy|
223425445|NCT04183413|OTHER|DSD|This intervention consist of three Differentiated Service Delivery Models in which stable clients can be enrolled. The fast-track model gives preferential treatment to enrolled clients. Clients arrive at clinics, usually early in the morning, and can see the nurse as well as collect their medication without queuing. This model mainly targets the working population. The facility-based treatment clubs consist of bimonthly meetings where clients meet in groups of approximately 20 members. They receive health counselling, risk factor screening and medication prescription. This model mainly targets clients living close to the facility. The community advisory groups consist of groups of up to six clients. Groups are equipped with a point of care blood pressure and blood glucose measurement devices. They take turns in collecting the medication for the entire group and meet on a monthly basis. This model targets clients in hard-to-reach areas.
223425446|NCT04183413|OTHER|CDP|Community Distribution Points are set up on a monthly basis in communities linked to the clinic. Healthcare staff sets up a temporary point of contact where clients can obtain screening for diabetes and hypertension, health counselling, referral to primary or tertiary facilities, and medication.
223425447|NCT00795080|PROCEDURE|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
223425448|NCT03466606|BEHAVIORAL|pre-habilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
223425449|NCT06453928|DEVICE|Hybrid Closed Loop Insulin Pump System|Patients will be started on an automated insulin delivery system.
223425450|NCT04604444|BEHAVIORAL|Multimodal Intensive Rehabilitation of Aphasia and Apraxia of Speech|Intensive Comprehensive Aphasia (ICAP) and Apraxia of Speech Program
223740067|NCT07072845|BEHAVIORAL|Enhanced Brief Cognitive Behavioral Therapy (E-BCBT) for Suicidal Inpatients|"E-BCBT is a brief, structured cognitive behavioral therapy designed for psychiatric inpatients at risk of suicide. The primary goals are to reduce the risk of suicide attempts after discharge, improve problem-solving and coping with recent stressors related to suicidal crises, and help patients shift from maladaptive suicidal modes to more adaptive cognitive and behavioral patterns. The intervention consists of five individual sessions (approximately 50-60 minutes each) delivered during hospitalization. It includes two sessions on crisis management, two sessions on cognitive and behavioral strategies, and one relapse prevention session. Each session incorporates psychoeducation, skill-building, and worksheet-based self-practice to enhance self-regulation and promote continued use after discharge."
223740068|NCT07072845|OTHER|Treatment as Usual (TAU)|TAU is based on a short-term inpatient stabilization model and includes 24-hour multidisciplinary care provided by the psychiatric ward. Individualized treatment may involve pharmacotherapy, occupational therapy, and supportive psychotherapy, depending on patient needs and hospital protocols.
223740069|NCT06769048|DRUG|Placebo-matching BI 1584862|Placebo-matching BI 1584862
223740070|NCT06769048|DRUG|BI 1584862|BI 1584862
223740071|NCT06780215|DRUG|Varenicline Tartrate Tablets|"Participants in treatment group take varenicline tartrate tablets according to the following regimen:~Days 1-3: 0.5 mg/dose, once daily. Days 4-42: 0.5 mg/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 0.5 mg/dose, once daily."
223740072|NCT06780215|DRUG|Placebo|"Days 1-3: 1 tablet/dose, once daily. Days 4-42: 1 tablet/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 1 tablet/dose, once daily."
223740073|NCT06781879|DRUG|Mitomycin c|Chemoablation
223740074|NCT06855563|BEHAVIORAL|Community-based intervention packages|"Community-based intervention packages~* Intervention packages are expected to consist of multiple specific activities tailored to the local context. All intervention packages will be designed to be (i) multi-level (i.e. targeting at least two of individual, external and structural environments), (ii) multi-component (i.e. targeting both healthy diet and physical activity), (iii) co-created with local communities in which they are implemented and (iv) health equity oriented in terms of both access and improvement. The exact package of interventions will differ by country and is expected to evolve pragmatically over time.~* The intervention group in each country will be made up of (children in) neighbourhoods where intervention packages are implemented."
224037783|NCT00047320|PROCEDURE|conventional surgery|
224037784|NCT00047320|PROCEDURE|neoadjuvant therapy|
223425451|NCT01294696|DRUG|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
223425452|NCT05210101|DRUG|Sotrovimab|Two intravenous (IV) doses of sotrovimab were administered over the study period, the first 500mg, and the second 2000mg, in light of the reduced antiviral neutralization of sotrovimab against the BA.2 subvariant.
223425453|NCT02641886|DRUG|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
224037785|NCT00047320|PROCEDURE|peripheral blood stem cell transplantation|
224037786|NCT00047320|RADIATION|radiation therapy|craniospinal irradiation
224037787|NCT02882932|PROCEDURE|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
224037788|NCT00510523|DEVICE|Whole Body Vibration machine|
224037889|NCT04369989|OTHER|No intervention|No intervention
224138355|NCT05638763|DRUG|Ketoconazole Pill|Patients will receive ketoconazole 200mg two times a day, orally, for one year.
224138356|NCT02462941|DRUG|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
223425454|NCT02641886|OTHER|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
223425455|NCT02481271|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
223425456|NCT02481271|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
223425457|NCT01882881|OTHER|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (\~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
223564095|NCT03314974|BIOLOGICAL|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
224037789|NCT04396314|BEHAVIORAL|Basic Body Awareness Therapy|Basic Body Awareness Therapy (BBAT), a health oriented, multi-perspective and person-centred approach with a focus on the patient's resources. It is a movement awareness training approach in physiotherapy, aiming to promote movement quality in daily life through self-exploration and self-experience enabling the learning of new movement habits
224037790|NCT04396314|BEHAVIORAL|Psychological treatment|Cognitive-behavioural therapy, cognitive processing therapy, cognitive therapy and prolonged exposure therapy
224037791|NCT04597814|OTHER|No Intervention|No Intervention
224037792|NCT05740020|DEVICE|virtual reality glasses|A specialized VR glasses will be used and VR games application in spider cage
224037793|NCT05740020|OTHER|The traditional exercise program|"The selected physical therapy program:~1. Neurodevelopmental approach: aims to facilitate typical motor development and function and to prevent secondary impairments (figure 4).~2. Approximation: aims to control spasticity and stimulate the joint mechanoreceptors (figure 5).~3. Stretching exercise: aims to maintain length and flexibility of shorten muscles (figure 6).~4. Strengthening exercise: aims to improve the functional ability (figure 7).~5. Spider suspension exercise for 30 minutes (figure 8).~5\. Gait training activities: aims to improve balance (figure 9). 6. Balance training program: aims to improve balance (figure 10)."
224037794|NCT00551902|PROCEDURE|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
224037795|NCT00551902|PROCEDURE|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
224037796|NCT03435016|DIAGNOSTIC_TEST|Diagnostic work-up|Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
224037797|NCT05564299|DIAGNOSTIC_TEST|Rapid 30-minute Desktop Assay|"Participants will undergo routine evaluation and specimen collection per current clinic protocols. Specimens will be processed by the rapid 30-minute desktop assay. Concurrently, specimens will be used to create a point-of-care gram stain, to be read by the clinician following the clinical encounter.~Treatment for urethritis and cervicitis will be provided based on results from the 30-minute assay.~Specimens will also be plated for Gonorrhea culture and sent to the Massachusetts Department of Public Health for additional Gonorrhea and Chlamydia polymerase chain reaction testing, as per clinic protocols."
224037798|NCT04586062|DRUG|Plasminogen|Human Plasminogen
224037799|NCT04824521|BEHAVIORAL|Mindfulness-Oriented Recovery Enhancement|MORE is a mindfulness-based intervention.
224037800|NCT05636891|BIOLOGICAL|Stimus|"* NNG-DEPO (Darbepoetin alfa 10 mcg/0.4 mL, 20 mcg/0.5 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL) is available as a prefilled syringe in a sterile, colorless, glass tube.~* Aranesp® (Darbepoetin alfa 10 mcg/ 0.4 mL, 20 mcg/ 0.5 mL, 40 mcg/ 0.4 mL, 60 mcg/ 0.3 mL) is manufactured by Amgen, as a pre-filled syringe in a sterile, glass tube, colourless.~Storage: 2-8ºC, not frozen. The process of transporting and storing the drug must ensure the temperature in the range of 2-8ºC.~NNG-DEPO/Aranesp is administered subcutaneously (or intravenously for patients with PK-PD in the previous IV group), at a dose of 0.75 g/kg initially, every 2 weeks at the second visit.~IPs will be prepared according to standard procedure (SOP). Dosage adjustment guideline:~Patients will have hemoglobin levels monitored every 2 weeks. The investigators will evaluate and adjust the dose of Darbepoetin alfa to maintain the Hb levels within the target range (10 - 12 g/dL)"
224037801|NCT02323763|OTHER|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
224037802|NCT00447382|DRUG|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
224037803|NCT00447382|DRUG|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
224037804|NCT00447382|DRUG|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
224037805|NCT00523120|DRUG|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
224037806|NCT00523120|DRUG|dexotc|aural drops
224037807|NCT02673619|DRUG|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm\^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
224138357|NCT02462941|PROCEDURE|Cardiac catheterization|(non-experimental) standard procedure
224138358|NCT01806636|DEVICE|PneumRx Coil System|
224138359|NCT04574388|OTHER|open label placebo|open label placebo pill
224138360|NCT03225716|DRUG|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
224138361|NCT03225716|DRUG|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
224138362|NCT03665428|DRUG|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
224138363|NCT03665428|DRUG|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
223564096|NCT06409871|OTHER|Physiotherapy treatment.|-Physiotherapy treatment will consist of joint mobilisation, proprioceptive neuromuscular facilitation and manual therapy.
223425744|NCT06337916|BEHAVIORAL|Cervical Standard Exercise Group|The patients in cervical standard exercise group will receive conventional cervical exercise for 6 weeks, 3 days a week, 1 session a day. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
223425745|NCT05045781|DRUG|Eptinezumab|single iv infusion
223425746|NCT02449304|DEVICE|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
223425747|NCT04324346|DRUG|FEC75 (or EC90) x 6|Type of Chemotherapy
223425748|NCT04324346|DRUG|FEC100 + Taxotere (EC90 + Taxotere) 3+3|Type of Chemotherapy
223425749|NCT04324346|DRUG|Paclitaxel|Type of Chemotherapy
223425750|NCT05193617|DRUG|GP+Penpulimab+Anlotinib|GP combine with penpulimab and anlotinib neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
223425751|NCT05193617|DRUG|GP+Penpulimab|GP combine with penpulimab neoadjuvant therapy+CCRT+penpulimab adjuvant therapy
223425752|NCT02691013|DRUG|Ramelteon|
223564302|NCT06658691|OTHER|Multidisciplinary approach|"The study investigated a multidisciplinary approach consisting of an endocrinologist, a diabetes specialized nurse, and a clinical pharmacist to assess and improve diabetic foot care by systematic screening, patients' risk categorization, therapy optimization, and tailored education.~Risk of Diabetic Foot Ulcer (DFU) occurrence was assessed and evaluated by the endocrinologist, and the nurse based on the 2019 International Working Group on Diabetes Mellitus (IWGDF). At that point, only the clinical pharmacist knew about patients' allocations.~According to risk stratification, the clinical pharmacist provided intervention patients with educational sessions and tailored materials during scheduled three months follow-up interviews at Jordan University Hospital (JUH) DFU-related clinics.~Moreover, the study evaluated the impacts of the multidisciplinary approach on health-related Quality of Life (QoL) at baseline and at the end of the study. Economic impacts were also further analyzed."
223425753|NCT02691013|DRUG|Placebo|
223425754|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
223425755|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
223425756|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
223425757|NCT02150733|DRUG|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
223744762|NCT06159140|DEVICE|MRI|In vivo MRI
224139011|NCT05863494|DEVICE|Transcranial Direct Current Stimulation (tDCS) sham|"TDCS is a non-invasive brain stimulation that uses electrical currents to stimulate specific areas of the brain. A constant, low-intensity current passes through two to four electrodes, which can be placed on various locations on the head, to modulate neuronal activity. tDCS can administer anodal and cathodal stimulation to excite (depolarization) or inhibit (hyperpolarization) neuronal activity, respectively. Using low-amplitude direct currents applied via scalp electrodes to alter cortical excitability is not a novel concept. This non-pharmacological approach has held promise for decades as a way to treat a plethora of neurological and psychiatric disorders.~The sham group will receive 1 minute from 0.0mA to no more than 0.5mA at the initiation of the treatment after which the current will be turned off. This is to maintain a blind trial. 0.5mA is negligible current, but mimics treatment with an initial small tingle."
223425758|NCT04550975|OTHER|Advanced Cognitive Stimulation Therapy|An adapted version of Cognitive Stimulation Therapy for people with moderate to severe dementia.
223425759|NCT01363752|DRUG|Advagraf|oral
223425760|NCT01363752|DRUG|Mycophenolate Mofetil|oral
223425761|NCT01363752|DRUG|Sirolimus|oral
223425762|NCT01363752|DRUG|Corticosteroids|i.v. and oral
223425763|NCT06017752|BEHAVIORAL|STAC Teacher Module|"The STAC Teacher Module is a 30-minute presentation that includes normative feedback, didactic information, a review of the student STAC strategies and corresponding strategies teachers can use to support students who act as defenders, and information about perceptions vs. facts about bullying."
223425764|NCT04130542|BIOLOGICAL|LVGN6051|IV infusion once every 3 weeks (Q3W).
224163407|NCT03050307|DRUG|TAK-438|TAK-438 tablets
224163408|NCT03050307|DRUG|Lansoprazole|Lansoprazole capsules
223425765|NCT04130542|BIOLOGICAL|KEYTRUDA® (pembrolizumab)|IV infusion once every 3 weeks (Q3W).
223425766|NCT05169437|DRUG|Niraparib|Eligible participants will receive daily dosing of Niraparib.
223425767|NCT02357706|DEVICE|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
223425768|NCT02357706|DEVICE|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
223425769|NCT03544099|DRUG|Pembrolizumab|Pembrolizumab 200mg Intravenous Solution
223425770|NCT03539770|PROCEDURE|Posterior spinal fusion|Surgical procedure that involves placement of spinal rods to correct spinal curvature
223425771|NCT05248256|OTHER|Evidence-based radiation dose limitation to the vertebral bone marrow|The only intervention that will occur during the radiation treatment planning process will be the application of evidence-based radiation dose limitations to the vertebral bone marrow during treatment plan optimization in order to attempt to limit Grade 3 Lymphopenia (G3L) toxicity.
223425772|NCT02111785|DRUG|Dexamethasone|Treatment with a short course of oral dexamethasone
223744763|NCT06460649|OTHER|Progressive relaxation techniques|Participants received Progressive muscle relaxation along with Benson relaxing 3 times a week for 12 weeks. 36 sessions overall
224163409|NCT03050307|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
223425773|NCT02111785|PROCEDURE|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
224037890|NCT06999239|PROCEDURE|laser therapy in TMD|"In this study patients will receive the Low-level laser therapy with a 635 nm wavelength diode laser (Lasotronix, Diode Laser DiodeLX model SMART M; Zytnia, Piaseczno, Poland) with 200 mW in a continuous mode, using a handpiece with a cylindrical applicator with a diameter of 8 mm in contact mode extra-orally, fiber-optic applicator with a diameter of 8 mm in contact mode intraorally, with a power density of 400 mW/cm2, delivering 10-12 J/cm2 on each application point, over a period of 20 sec.~There are two methods for examination of lateral pterygoid muscle: digital palpation and functional manipulation.~For digital palpation of lateral pterygoid muscle, we place our index finger or tip of our little finger in the vestibular area adjacent to the maxillary third molar.~Functional manipulation of the inferior head of lateral pterygoid muscle: It is best accomplished by having the patient make a protrusive movement against resistance to contract it since this muscle is the primary pro"
224037891|NCT06684613|DEVICE|PrEP Decision Aid|Patient-facing decision-aid on PrEP that will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of counseling.
224037892|NCT06684613|OTHER|Generic Information|"Participants will be asked to watch a CDC-produced video, PrEP (Pre-Exposure Prophylaxis (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid."
224037893|NCT07019415|DRUG|Vitamin D 5000 IU+ placebo|vitamin D 5000 IU + placebo in the experimental group
224037894|NCT07019415|DRUG|Placebo : calcium carbonate 500 mg, microcrystalline cellulose, magnesium stearate, sodium starch glycolate|this placebo group receive placebo tablet ( calcium carbonate 500 mg, microcrystalline cellulose, magnesium stearate, sodium starch glycolate )
224037895|NCT06067438|DRUG|Amiodarone Hydrochloride|Given IV and via feeding tube
224037896|NCT06067438|OTHER|Saline|Given IV
224037897|NCT06506448|DIAGNOSTIC_TEST|CT Coronary Angiography|CTCA for anatomical, physiological, plaque composition and inflammatory assessment of coronary arteries
224037898|NCT05472714|OTHER|Educational Video|Investigators will develop an informational video to be presented within one week of diagnosis of a tumor to those referred for tumor normal paired genetic testing.
224037899|NCT04962607|OTHER|Neo-Putty® as dressing agents in pulpotomized primary molars|"Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with Vitrebond® and with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).~In the control group, a cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM"
224037900|NCT07112339|DRUG|Insulin icodec|Insulin icodec will be administered as subcutaneous injection.
224037901|NCT07112339|DRUG|Basal insulin analogues|Basal insulin analogues will be administered as subcutaneous injection.
224037902|NCT06914518|OTHER|viscoelastic gel containing a fixed combination of natural origin PN (10 mg/ml, 1%) and HA with molecular weight > 1500 kDa (10 mg/ml, 1%)|At the end of the standardized peri-implant non-surgical therapy a viscoelastic gel containing a fixed combination of natural origin PN (10 mg/ml, 1%) and HA with molecular weight \> 1500 kDa (10 mg/ml, 1%) (REGENFASTe, Mastelli S.r.l., Sanremo, Italy) will be injected in the peri-implant sulcus.
224037903|NCT06914518|PROCEDURE|Non-Surgical Intervention|Standardized peri-implant non-surgical therapy will be performed as follows: local anaesthesia (articaine 4% and adrenaline 1:100,000), debridement of the implant surfaces with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the H3 dental ultrasonic scaler (H3, Satelec Acteon; Olliergues, France), curettage of the bone defect (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) and supra- and submucosally cleaning using an air polisher with sub- gingival tip (EMS Air-flow® with erythritol-based powder containing
224037904|NCT06920004|BIOLOGICAL|empasiprubart|Intravenous infusion of empasiprubart
224037905|NCT06920004|BIOLOGICAL|IVIg|Intravenous infusion of IVIg
224037906|NCT06920004|OTHER|empasiprubart-placebo|A placebo resembling the empasiprubart treatment
224037907|NCT06920004|OTHER|IVIg-placebo|A placebo resembling the IVIg treatment
224139012|NCT06824064|DRUG|RBS2418|RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
224139013|NCT06824064|DRUG|Placebo|Placebo to Match RBS2418
224139014|NCT04008407|PROCEDURE|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
224139015|NCT04008407|PROCEDURE|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs =\> 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
224163410|NCT03050307|DRUG|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
224163411|NCT03050307|DRUG|Bismuth-Containing Quadruple Therapy|1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
224163412|NCT00470977|DRUG|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
223425774|NCT04193956|OTHER|Standard-of-care procedures|Patients receive standard of care anti-PD-1 treatment as monotherapy or in combination with other checkpoint inhibitors. Related assessments, as laboratory assessments, CT-thorax-abdomen and FDG-PET will be performed according to clinical routine procedures.
223425775|NCT04193956|OTHER|Study procedures|Patients will undergo tumor biopsies, venous blood sampling and feces sampling in combination with a food questionnaire before, during and at the end of standard of care anti-PD-1 treatment.
223425776|NCT01844661|BIOLOGICAL|CELYVIR|
223425777|NCT03790228|DRUG|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
224037908|NCT04757532|DRUG|Bupropion|300 mg of bupropion hydrochloride (1 tablet) administered orally in a single dose.
223425778|NCT04743193|OTHER|2.5 %sevoflurane|for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
223425779|NCT04743193|OTHER|8% sevoflurane low flow anesthesia|For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
223425780|NCT00154778|DRUG|Taxol, UFT,Leucovorin|
223425781|NCT03645746|DRUG|REGN5069|REGN5069 will be administered by IV infusion or SC injection
223425782|NCT03645746|DRUG|Placebo|Placebo-matching REGN5069
223425783|NCT00682370|DRUG|saline solution|intravenous infusion, single dose
223425784|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~0.3 mg/kg heme arginate"
223425785|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~1 mg/kg heme arginate"
223425786|NCT00682370|DRUG|heme arginate|"intravenous infusion, single dose~3 mg/kg heme arginate"
223425787|NCT02976779|DRUG|OWC MGC cream|Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
223425788|NCT02976779|DRUG|OWC Control Cream|Topical Cream without active ingredients
223425789|NCT05243485|DIAGNOSTIC_TEST|PreHEART|"The PreHEART score is validated for use in the pre-hospital setting.The score can be calculated based on five different elements: history, ECG, age, gender, and a Point-of-Care (POC)-Troponin. A minimum of 0 points and a maximum of 2 points can be scored in each element, the total PreHEART can contain a maximum of 10 points. The score of the history is based on the symptoms of the patient in accordance with the symptoms of a myocardial infarction. Based on the suspicion of ischemia on the ECG. Age will be based on the date of birth. Compared to the female gender, the male gender has higher risk of developing myocardial infarction and will be scored higher. The biomarker Troponin will be collected via intravenous access and measured using a POC-analyzer I-Stat from Abbott industries. In total 17 µl of blood is required to fill a cardiac Troponin I (cTnI) cartridge. Analyzing the blood will take approximately 10 minutes."
223425790|NCT06620679|BIOLOGICAL|Lipopolysaccharide (LPS)|Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight
223425791|NCT06620679|OTHER|Placebo|Normal saline, single i.v. bolus, in equal volume to intervention
223425792|NCT06243367|OTHER|Placebo drink|Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
223425793|NCT06243367|DIETARY_SUPPLEMENT|Carbohydrate|Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
223425794|NCT05587829|OTHER|• Diaphragmatic breathing technique|In supine position, the participant inhales through the mouth for 5 s to expand the abdomen to the maximal level, minimizing movement of the thorax, and performs a long exhalation to maintain a lower abdominal contraction and retroversion of the pelvis
223425795|NCT05587829|OTHER|basic breathing technique|Deep Breathing for 15 minutes
224037909|NCT04757532|DRUG|Anastrozole|1 mg of anastrozole (1 tablet) administered orally in a single dose.
224037910|NCT04757532|DRUG|Testosterone cyclopentylpropionate|100 mg of testosterone cyclopentylpropionate (equivalent to 70 mg of testosterone) administered via intramuscular injection in a single dose (2 mL).
224037911|NCT04757532|DRUG|Danazol|200 mg of danazol (1 capsule) administered orally in a single dose.
223425796|NCT01607060|DRUG|Lactulone|Patients will receive lactulone to daily laxation
223425797|NCT03199482|DRUG|Dexamethasone Oral Tablet|single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
223425798|NCT03199482|DRUG|Placebo|Placebo will be administrated 30 minutes before start of root canal treatment
223425799|NCT00904865|PROCEDURE|SPA cholecystectomy|SPA cholecystectomy
223425800|NCT00904865|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
223425801|NCT05631691|BEHAVIORAL|Support for Students exposed to Trauma Program|Support for students exposed to trauma program (SSET) is a school-based intervention program for students who have been exposed to traumatic events and exhibit signs of post-traumatic stress disorder (PTSD). (Jaycox, Langley, \& Dean, 2009; Jaycox, Langley, Stein et al., 2009). SSET is specifically designed for school teachers, school counsellors, and other non-clinical staff. SSET program is a series of 10 structured lessons designed to reduce post-traumatic and depressive symptoms and improve functioning in school children exposed to traumatic events. it includes psycho-education, relaxation, cognitive restructuring, social problems solving and behavioral exposure.
223425802|NCT02360631|DRUG|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
223425803|NCT02360631|DRUG|Placebo|Health education counseling will be provided to all participants.
223425804|NCT00786331|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
223425805|NCT00786331|DRUG|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
224037912|NCT04757532|DRUG|Chlorthalidone|50 mg of chlorthalidone (1 tablet) administered orally in a single dose.
224037913|NCT00703898|DRUG|nevirapine|200 mg/day twice a day
224037914|NCT07155148|OTHER|observational study|Observational registry without clinical interventions
224037915|NCT07173660|OTHER|Delphi study|A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
224037916|NCT07174297|DRUG|Acotiamide|Both these drugs are used for the management of PDS type of FD
224163413|NCT04949633|DRUG|Prostaglandins|Second cervical ripening lasting a maximum of 24 hours
224163414|NCT04949633|DRUG|Oxytocin|Induction of labor with oxytocin.
224163415|NCT04849195|OTHER|No intervention|No intervention
224163657|NCT05419284|OTHER|Observation of GAPP+Care|Healthcare workers in the geriatric rehabilitation ward will be interviewed on their opinions on GAPP+Care
224163658|NCT02439866|DRUG|placebo|gelatinous capsules filled with sugar as placebo
223425806|NCT04704492|DRUG|Biological: SM03|Biological: SM03 600 mg or 900 mg intravenous (IV) on week 0,2
224037917|NCT07173205|BEHAVIORAL|AYA Survivors Coping and Emotional Needs Toolkit (ASCENT)|Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
224037918|NCT07175233|DRUG|SIM0278 injection|SIM0278 injection
224037919|NCT07175233|OTHER|Placebo|placebo
224037920|NCT07179003|PROCEDURE|Standard of care breast abscess drainage|All subjects will receive ultrasound-guided percutaneous abscess drainage in a procedure room. The site will be prepared and dressed following standard of care sterile procedure, and a needle/catheter will be advanced under ultrasound guidance into the abscess. The abscess will be drained by syringe aspiration, and the cavity will be flushed with sterile saline. Aspirated abscess fluid will be delivered to the Clinical Microbiology Laboratory for processing, including bacterial identification and antibiotic susceptibility testing.
224037921|NCT07179003|DRUG|Methylene Blue|Following standard of care breast abscess drainage, for subjects randomized to the photodynamic therapy arm, sterile, clinical-grade methylene blue will be infused into the abscess cavity at a concentration of 100 µg/mL via the same needle/catheter used for drainage. The volume introduced will be matched to the amount of abscess material aspirated during the standard of care drainage. After a 10-minute incubation interval, methylene blue will be aspirated and the cavity flushed with sterile saline to remove methylene blue that has not been taken up by microbes.
224037922|NCT07179003|DRUG|Lipid Emulsion|For subjects randomized to the photodynamic therapy arm, immediately prior to illumination a lipid emulsion will be administered directly to the abscess through the drainage needle/catheter at a concentration of 0.1%. This lipid emulsion will be either Intralipid or Nutrilipid. The lipid emulsion serves to gently distend the cavity, and through light scattering, homogenize the light dose to the walls of the cavity. The volume administered will be matched to the amount of abscess material aspirated during the standard of care drainage. Following laser illumination, the lipid emulsion will be aspirated and the cavity flushed with sterile saline.
224037923|NCT07179003|DEVICE|Insertion of optical fiber|For subjects randomized to the photodynamic therapy arm, a sterile, single-use optical fiber will be advanced to the approximate center of the abscess cavity via the same needle/catheter used for abscess drainage under ultrasound guidance. This will be connected to the clinical laser system via SMA connector for delivery of treatment light.
224037924|NCT07179003|DEVICE|Laser illumination|For subjects randomized to the photodynamic therapy arm, laser illumination for photodynamic therapy will be delivered by a laser system operating at 665 nm (ML7710, Modulight, Tampere, Finland) at a fluence rate of 20 mW/cm\^2. The laser power required to achieve this fluence rate will be calculated based on abscess size. Illumination will be delivered for \~20 minutes, resulting in a total delivered fluence of 25 J/cm\^2.
224037925|NCT07179003|PROCEDURE|Photodynamic therapy|For subjects randomized to the photodynamic therapy arm, the photodynamic therapy procedure comprises the methylene blue, lipid emulsion, insertion of optical fiber, and laser illumination interventions.
224037926|NCT07187661|DRUG|Intra-articular Bevacizumab|This clinical trial investigates the intra-articular injection of Bevacizumab, a recombinant humanized monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF). The intervention functions by binding to and neutralizing VEGF-A, thereby blocking the pathogenic angiogenesis and vascular permeability that characterizes chronic hemophilic synovitis. For administration, the first four patients will receive a dose of 20 mg in 0.8 mL per injection, and if this is well-tolerated without major toxicities, the dose for all subsequent patients will be increased to 40 mg in 1.6 mL. Each injection will be administered directly into the target joint (knee, elbow, or ankle) once every 28 days for a total of four doses. Crucially, all injections will be performed only after appropriate prophylactic factor replacement to mitigate any procedure-related bleeding risk.
223425807|NCT05035667|OTHER|Questionnaire Administration|Complete questionnaires
223425808|NCT03734146|BEHAVIORAL|Aerobic Exercise|180 minutes of moderate-vigorous intensity aerobic exercise per week
224037927|NCT07189156|OTHER|Immediate Weight Bearing Pelvis|Patient with a pelvis fracture may be randomized to be immediately weight bearing as tolerated after surgery.
224037928|NCT07189156|OTHER|Delayed Weight Bearing Pelvis|Patient with a pelvis fracture may be randomized to be delayed weight bearing as tolerated (either non-weight bearing, foot flat, or toe touch weight bearing per surgeon discretion) for 6-12 weeks after surgery.
224037929|NCT07189156|OTHER|Immediate Weight Bearing Acetabulum|Patient with an acetabulum fracture may be randomized to be immediately weight bearing as tolerated after surgery.
224163659|NCT02439866|DRUG|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
224163660|NCT02439866|DRUG|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
223425809|NCT03734146|BEHAVIORAL|Resistance Exercise|180 minutes of resistance exercise per week
223425810|NCT03734146|BEHAVIORAL|Combined aerobic and resistance exercise|180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
223478231|NCT05056207|OTHER|Cohort II (patients followed intensively for lymphedema)|patients who have recently undergone ALND
223478232|NCT06443827|DRUG|Amantadine Sulfate|intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
223564303|NCT06605768|DIETARY_SUPPLEMENT|Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.|"Biotin, Collagen \&amp;amp; Keratin Beauty Complex 25,000 mcg, 60 capsules, oral route of administration."
223425811|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at high intensity (HI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 85% of the one-repetition maximum per exercise (high load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
223425812|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate-high intensity (MHI-bands)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
223425813|NCT06618469|BEHAVIORAL|Elastic band-based resistance training program at moderate intensity (MI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic bands equivalent to 65-70% of the one-repetition maximum per exercise (moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase).
223425814|NCT06618469|BEHAVIORAL|Elastic tubes-based resistance training program at moderate-high intensity (MHI-tubes)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance squat, lunge, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform 6 submaximal repetitions using elastic tubes equivalent to 75-80% of the one-repetition maximum per exercise (high to moderate load/intensity training sessions). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9 . The number of sets per exercise progressed from 3 to 4. The speed of execution of the exercises was controlled using a metronome marking the cadence (2s of concentric and eccentric phase)
223425815|NCT06618469|BEHAVIORAL|Water-based resistance training program at moderate intensity (WMI)|The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance leg extension and flexion, hip flexion and extension, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform in the poll the concentric and eccentric movements of each exercise at maximal velocity during 40 seconds (equivalent to working around 10 repetitions /75% 1RM each exercise). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4.
223425816|NCT01955772|DRUG|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
223425817|NCT00857168|DRUG|Testosterone MD-Lotion|
223425818|NCT04603768|OTHER|Theraband exercises|Group A performed theraband exercises for 6 weeks.In the first 2 weeks theraband with low resistance was used to perform exercises and then we proceeded gradually with higher resistance therabands.Theraband exercises was performed for Shoulder Flexion,Shoulder Extension Strengthening, Shoulder Internal Rotation Strengthening, Shoulder External Rotation Strengthening, Shoulder Abduction, Empty Can Exercise \& Rowing Exercise with 8-10 reps, 3sec hold and 2-3 sets With each of these exercises
223425819|NCT04603768|OTHER|Co-contraction exercises|"Muscle co-contraction is the simultaneous contraction of the muscles acting around a joint. Subject stood upright \& contracted both the groups (agonist and antagonist) simultaneously without bringing movement at shoulder joint with 6-8 reps , 3sets \& 5- 15 seconds duration of sustained self-arm bracing or stiffening was maintained.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
223564304|NCT06605768|DIETARY_SUPPLEMENT|Placebo product|Placebo, 60 capsules, oral route of administration
224037930|NCT07189156|OTHER|Delayed Weight Bearing Acetabulum|Patient with an acetabulum fracture may be randomized to be delayed weight bearing as tolerated (either non-weight bearing, foot flat, or toe touch weight bearing per surgeon discretion) for 6-12 weeks after surgery.
224037931|NCT07188662|PROCEDURE|group (B) Prehabilitation care combine with ERAS post-operative care|intervention will includes receiving prehabilitation care combine with ERAS post-operative care.
224037932|NCT07188948|DEVICE|Skin conditions|Participants with skin conditions such as AK or participants without any skin conditions (healthy skin)
224037933|NCT07188948|DEVICE|Skin Condition|Participants with Skin conditions or participants without any skin conditions (Healthy)
224037934|NCT07187830|DRUG|Semaglutide (1 Mg Dose)|standard of care treatment
224037935|NCT07187375|DRUG|Crinecerfont|Oral solution
224037936|NCT05249426|DRUG|BI 765063|BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
224037937|NCT05249426|DRUG|Ezabenlimab|Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
224037938|NCT05249426|DRUG|BI 836880|BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
224037939|NCT05249426|DRUG|Cetuximab|Cetuximab
224037940|NCT05249426|OTHER|Investigator´s Choice Chemotherapy|Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
224037941|NCT05103943|OTHER|SPECT MPI|SPECT MPI including dynamic acquisitions for stress, rest MBF and MFR
224037942|NCT00210301|DRUG|Provigil (modafinil)|
224037943|NCT06088862|DRUG|Nicoderm|21mg nicotine patch daily; maximum usage 9 weeks
223425820|NCT04603768|OTHER|Isometric exercises|"Isometric exercises of shoulder were performed in subjects for 6 weeks which included isometric Shoulder flexion, shoulder abduction isometric exercise, isometric shoulder external rotation, isometric shoulder internal rotation \& isometric shoulder extension with 8-10 reps, 5 sec hold and 2 sets.~On eligible participants baseline assessment was done,3 session were given 3days per week, post intervention assessment was taken at 3rd and 6th week"
223425821|NCT01341340|DEVICE|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
224037944|NCT06088862|DRUG|Nicorette 4Mg Chewing Gum|4mg Nicorette gum (flavors - cinnamon surge, fruit chill, and mint); as needed maximum usage 9 weeks
223425822|NCT06664840|OTHER|MDR diet assessment|Participants will record their dietary intake on the MyRareDiet (MRD) app and nutrient content will be assessed to validate MRD compared to a traditional interviewer assessed 24 hour recall.
224037945|NCT06088862|DRUG|Nicorette Lozenge Product|4mg Nicorette mint lozenge; as needed maximum usage 9 weeks
224037946|NCT06088862|OTHER|BIDI e-cigarette|BIDI e-cigarette (flavors - Classic, Arctic, and Solar); as needed for maximum of 5 weeks
224139016|NCT06897631|DEVICE|Robot-Assisted Tai Chi Training|This intervention involves robot-assisted Tai Chi training for upper limb rehabilitation, delivered in a seated position to ensure participant safety and comfort. Each 60-minute session consists of a 5-minute warm-up/preparation phase, followed by three 15-minute segmented functional training phases incorporating Tai Chi-inspired movements to target upper limb coordination, range of motion, and strength recovery, interspersed with two 5-minute rest intervals. The protocol is administered 5 times per week over 4 weeks, with robotic assistance tailored to guide functional upper limb trajectories while minimizing compensatory movements.
224139017|NCT06897631|BEHAVIORAL|Conventional rehabilitation training|This intervention follows evidence-based clinical guidelines for post-stroke upper limb rehabilitation, focusing on therapist-guided task-oriented training that integrates activities of daily living (ADL) such as table wiping and clothes hanging. Sessions emphasize progressive functional integration, with exercises adjusted weekly based on patient performance. Training is delivered in 60-minute sessions (1 session/day), 5 days per week over 4 weeks, under direct therapist supervision to ensure proper movement patterns and safety.
224139018|NCT03699852|RADIATION|Membracel and LED photobiomodulation|Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
223425823|NCT06664840|OTHER|24 hour recall|A trained nutritionist will conduct a telephone multi-pass 24 hour diet recall on 3 randomized nonconsecutive days. The dietary intake will be analyzed using NDSR and metabolic pro and nutrient intake will be compared to the nutrient intake assessed with the MRD app.
223425824|NCT02689869|DRUG|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research \& Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
223425825|NCT02689869|DRUG|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
224139019|NCT03699852|OTHER|Membracel|This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
224139020|NCT06898489|COMBINATION_PRODUCT|Yu-Tone Music Intervention|SLE patients undergo a structured Yu-tone music listening program (30 minutes daily, 5 days per week, with each cycle lasting 8 weeks, for a total of 3 cycles
223425826|NCT03166540|OTHER|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
224037947|NCT06088862|OTHER|on!|4mg on! Nicotine Pouch (flavors - Berry, Mint, and Original); as needed for maximum usage 5 weeks
224037948|NCT01544699|DEVICE|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
224037949|NCT04593888|BEHAVIORAL|Gluten reduced diet|Dietary advice focusing on reducing gluten intake in children
224037950|NCT03564743|DIAGNOSTIC_TEST|Evaluation of ASAS criteria|Perform ASAS criteria at the time of physician diagnosis of chronic low back pain in rheumatological practice.
224037951|NCT00000387|BEHAVIORAL|Self-management therapy|Behavioral
224037952|NCT00000387|BEHAVIORAL|Self-management therapy|
224037953|NCT04070755|DRUG|FMX-101|
224037954|NCT04264429|DEVICE|Infrapatellar strap|Orthotic device which is positioned over the patellar tendon
224037955|NCT04264429|OTHER|Elastic band|Orthotic device which is positioned over the patellar tendon
224037956|NCT02685098|BIOLOGICAL|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2+ and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at 7 days before amputation.
224037957|NCT05299775|DIAGNOSTIC_TEST|World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)|"WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected."
223425827|NCT03166540|OTHER|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
223425828|NCT02002312|DRUG|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
224139021|NCT06898489|DRUG|Conventional pharmacotherapy|Standard SLE medications (e.g., hydroxychloroquine, glucocorticoids).
224139022|NCT03637842|DRUG|Lorcaserin|Lorcaserin XR 20mg per day
223425829|NCT04117672|DIETARY_SUPPLEMENT|Salovum|Active egg yolk powder
223425830|NCT04117672|DIETARY_SUPPLEMENT|Placebo egg yolk powder|Normal egg yolk powder
223425831|NCT05186246|DRUG|Combination cream|Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate Cream combination (10 gram), were applied on one side of the face twice daily by participants.
223425832|NCT05186246|DRUG|Placebo cream|Cream that is identical looking were given to subjects to be applied on the other side of the face twice daily
223425833|NCT01075646|DRUG|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
223425834|NCT01075646|DRUG|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
223425835|NCT02048566|DEVICE|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
224037958|NCT06391554|OTHER|PRT|An initial 12-week exercise intervention, consisting of 1-hour group sessions of progressive resistance training supervised by a physiotherapist 2 times per week. The sessions consist of a 10-minute submaximal warm up on an exercise bike followed by 50 minutes of PRT with exercises targeting the muscles of the hip and knee joints; leg press, hip extension, hip abduction, hip flexion and knee extension. The progression will be in line with guidelines provided by the American College of Sports Medicine. The intensity will follow repetition maximum (RM) targets, from 12 RM for the first week towards 8 RM for the last weeks. After the 12 weeks, participants will receive 8 booster sessions and are given a membership to a fitness center where they will be encouraged to continue the exercise program on their own.
224037959|NCT06391554|OTHER|EDU|Three EDU sessions provided by a trained physiotherapist involving important disease-specific information. The sessions will address knowledge of OA, treatment options with a specific focus on physical activity recommendations, advice on self-management and more. All three sessions will emphasize on engaging the participants actively and sharing experiences with each other.
223564305|NCT01202188|DRUG|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
223564306|NCT01202188|DRUG|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
223564307|NCT01202188|DRUG|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
223564308|NCT01202188|DRUG|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
223564309|NCT01202188|DRUG|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
224037960|NCT04221763|DEVICE|His-bundle pacing.|Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
224037961|NCT06178445|DRUG|SOC plus trastuzumab and pembrolizumab|SOC treatment with gemcitabine/cisplatin in combination with trastuzumab and pembrolizumab
224139023|NCT03637842|DRUG|Placebo oral capsule|Placebo
224139024|NCT02860533|DEVICE|cuff device|Measurement of blood pressure during stress testing with cuff device
224139025|NCT02860533|DEVICE|iphone|Measurement of blood pressure during stress testing with iPhone
224139026|NCT00002344|DRUG|Azithromycin|
224139027|NCT01594294|DEVICE|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
224139028|NCT01594294|DEVICE|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
224139029|NCT01594294|DEVICE|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
224139030|NCT01594294|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
224139031|NCT01594294|DEVICE|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
224139032|NCT01422278|OTHER|Rehabilitation|Three weeks of rehabilitation in Hospital.
224163661|NCT04443257|OTHER|assessment of the sequelae after hospitalization for Sars-COV-2|the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
224037962|NCT04436237|OTHER|Virtual reality foot placement training|The training is conducted in sitting and standing, and involves both the affected and unaffected foot placement. In the total immersive virtual environment, a target will be presented and the participants are required to move one foot to the target. The location of the moving foot is not seen by the participant in this training.
224037963|NCT00754143|DRUG|FG-3019|Placebo every 2 weeks IV for all infusions
224037964|NCT00754143|DRUG|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
224037965|NCT00754143|DRUG|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
224037966|NCT02367235|PROCEDURE|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
223425836|NCT02048566|DEVICE|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
223425837|NCT02048566|OTHER|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
223425838|NCT02048566|OTHER|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
223425839|NCT00330330|DRUG|ISIS 113715|
223425840|NCT00416130|DRUG|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
223425841|NCT02064322|DEVICE|SImmetry Implant|"The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
223425842|NCT02228239|DRUG|Esketamine|Esketamine 84 milligram (mg) \[3\*1 of spray in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
224037967|NCT02367235|PROCEDURE|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
223425843|NCT02228239|DRUG|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
223425844|NCT02228239|DRUG|Placebo (Matched to Esketamine)|Placebo \[3\*1 in each nostril\] will be administered intranasally on Day 1 in one of the treatment periods.
223425845|NCT02228239|DRUG|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
223425846|NCT02089958|PROCEDURE|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
223425847|NCT04624958|DRUG|Zanubrutinib and Rituximab|Zanubrutinb 160mg PO BID d1-28; Rituximab 375mg/m2 iv.drip d1.
223425848|NCT04624958|DRUG|R-DHAOx|Rituximab 375mg/m2 iv.drip d1; Dexamethasone 20mg iv.drip d1-4; Cytarabine 2000mg/m2 (1000mg/m2 for patients aged over 65) iv.drip d2,3 Oxaliplatin 130mg/m2 iv.drip d1.
223425849|NCT04624958|DRUG|Zanubrutinib Maintenance|Zanubrutinb 160mg PO BID.
223425850|NCT04410016|OTHER|Staff Wellbeing Centres|2 Centres (rooms) accessible to staff for rest and relaxation, work breaks, supports advice and signposting. They are manned by support workers called Wellbeing Buddies.
223425851|NCT01520558|BIOLOGICAL|CNDO-109-AANK Cells|Single dose, infusion
223425852|NCT05988463|DRUG|Artesunate Oral Product|Artesunate capsules administered orally twice daily beginning at 10 mg for 4 weeks, followed by 20 mg for 4 weeks, and then 30 mg for 4 weeks.
224037968|NCT06316531|DRUG|BL-M07D1|Administration by intravenous infusion for a cycle of 3 weeks.
224037969|NCT06316531|DRUG|T-DM1|Administration by intravenous infusion for a cycle of 3 weeks.
224037970|NCT00292656|PROCEDURE|NAET|
224037971|NCT04985305|BEHAVIORAL|Teaching material|The GPs receive a power-point slide show to use at the nursing home. The slide show includes a description of BPSD symptoms, what the mechanism, effect and adverse events of antidepressants and a rationale for deprescribing.
224037972|NCT04985305|BEHAVIORAL|Pre-visit reflection tool|The GPs receive a checklist and an email template to ensure; 1) The home visit is planned on a day where the staff at the nursing home that knows the patient best is at work. 2) The staff at the nursing home contacts the relevant relatives and informs about the home visit. 3) The symptom assessment scale is complete by the nursing home staff and returned to the GP prior to the home visit
224037973|NCT04985305|BEHAVIORAL|Dialogue tool|The dialogue tool includes a list of questions to help the GP explore the nursing home staffs', patients' and relatives' concerns and views on deprescribing antidepressants, as well as information on when to contact the GP. The intervention has been developed during a tailoring process involving GPs, nursing home staff, interviews with patients and other experts in the field.
223425853|NCT01676896|BEHAVIORAL|Asthma in-school class|
224163662|NCT06118008|DRUG|HS-20094 5mg|Administrated by subcutaneous injection
224163663|NCT06118008|DRUG|HS-20094 10mg|Administrated by subcutaneous injection
224163664|NCT06118008|DRUG|HS-20094 15mg|Administrated by subcutaneous injection
223425854|NCT01676896|BEHAVIORAL|Asthma Day Camp|
223425855|NCT01676896|BEHAVIORAL|Health Promotion in-school class|
224163665|NCT06118008|DRUG|HS-20094 20mg|Administrated by subcutaneous injection
223425856|NCT02394496|DRUG|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
223425857|NCT02394496|DRUG|Lapatinib|1500mg (TBD) O.S. qd
223425858|NCT02394496|DRUG|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
223425859|NCT02394496|DRUG|Placebo Lapatinib|1500mg (TBD) O.S. qd
223425860|NCT00863473|PROCEDURE|Surgical treatment with LCP|
223425861|NCT04114331|OTHER|Manual therapy and exercise|Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
223425862|NCT05705882|OTHER|Malnutrition|For the diagnosis of malnutrition, the investigators adopted the Global Leadership Initiative on Malnutrition (GLIM) scheme based on three phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present in patients with nutritional risk.
223425863|NCT02256982|DRUG|Gemcitabine|
223425864|NCT02256982|DRUG|Cisplatin|
223425865|NCT02256982|PROCEDURE|Surgery|Surgical Resection and Lymphadenectomy
223425866|NCT02256982|RADIATION|Radiation|Radiation Therapy
223425867|NCT01775982|OTHER|Psychiatric evaluation|"This evaluation is carried out in several stages:~* Assessment of cognitive functioning;~* Interview with a relative;~* Interview with caregivers;~* Evaluation of the presence of delirium according to DSM-IV criteria;~* Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~* Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
223425868|NCT01775982|OTHER|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
223425869|NCT01735344|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
223425870|NCT01735344|DRUG|Lisinopril|40 mg tablet once a day
223425871|NCT00514644|OTHER|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
223425872|NCT00514644|OTHER|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
223425873|NCT01943968|OTHER|Blood test|
223425874|NCT00639444|DIETARY_SUPPLEMENT|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
223425875|NCT01120080|BEHAVIORAL|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
224037974|NCT04985305|BEHAVIORAL|Educational session for GPs|Before randomization all participating GPs receive a ½-day course on the evaluation and treatment of neuropsychiatric symptoms that occur in patients with dementia. Elaborate information about antidepressants to this population and reasons to discontinue use. A sSpecialists in general practice, pharmacology and geriatrics/gerontopsychiatrics teaches the course. The course is mandatory for the participating GPs, but voluntary for the staff at the GPs office. The course is preferably held with actual attendance, but may be converted to an online meeting due to the COVID-19 pandemic.
224037975|NCT04985305|BEHAVIORAL|Symptom assessment scale|An email template containing 12 screening questions from the Neuropsychiatric Inventory Nursing Home Edition is given to the GPs to distribute to the nursing home prior to the home visit and 1 month after the home visit
223425876|NCT01120080|BEHAVIORAL|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
223425877|NCT06356844|DIETARY_SUPPLEMENT|Resolvin supplement|Transforaminal steroid injection will be administered to patients who are being followed up due to inflammatory low back pain. Patients will receive resolvin supplements for 6 months postoperatively.
223425878|NCT05730244|DRUG|Cassia alata extract|1 ml Cassia alata extract
223425879|NCT05730244|DRUG|Placebo|1 ml placebo solution
223425880|NCT03494062|BEHAVIORAL|Exercise|Home-based exercise training
223425881|NCT03545295|PROCEDURE|Quadratus Lumborum Block type 2|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
223425882|NCT03545295|PROCEDURE|Quadratus Lumborum Block type 3|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
223425883|NCT00672581|DRUG|ZD4054|10mg, Oral tablet, single dose
223425884|NCT05285995|OTHER|Music Intervention|Before the operation, subjects were asked to choose their favorite music to listen so as to reduce the anxiety before the operation and before the induction of anesthesia.
223425885|NCT05285995|OTHER|The animation intervention|Before surgery, subjects were asked to choose their favorite cartoons to watch to reduce anxiety before surgery and induction of anesthesia.
223425886|NCT00031681|DRUG|7-hydroxystaurosporine|Given IV
223425887|NCT00031681|DRUG|irinotecan hydrochloride|Given IV
223425888|NCT00031681|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223425889|NCT02458339|PROCEDURE|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
223425890|NCT02458339|DRUG|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
223425891|NCT01072435|DEVICE|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
223425892|NCT01072435|DEVICE|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
223425893|NCT00402558|DRUG|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
223425894|NCT00402558|DRUG|Busulfan|130 mg/m\^2 By Vein Over 3 Hours x 4 Days
223425895|NCT00402558|DRUG|Fludarabine|40 mg/m\^2 By Vein Over 30 Minutes x 4 Days
223425896|NCT00402558|PROCEDURE|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
223425897|NCT00402558|DRUG|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is \> 500 x 109/L for 3 consecutive days.
224037976|NCT06503029|DEVICE|Invisalign Cleaning Crystals|Invisalign Cleaning Crystals are used as a cleaning method for orthodontic clear aligners. It includes Sodium Sulfate as an active ingredient.
224037977|NCT06503029|DEVICE|Fittey Dent Cleaning Tablet|Fittey Dent Cleaning Tablet is used as a cleaning method for orthodontic clear aligners. It includes Sodium Perborate as an active ingredient.
224037978|NCT06503029|DRUG|Listeren Mouthwash|Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
224037979|NCT06503029|DEVICE|Toothbrush and Water|Toothbrush and water is used as a cleaning method for orthodontic clear aligners that as recommended by the aligner manufacturer.
224037980|NCT05212454|DRUG|Capecitabine|capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
224037981|NCT03157232|DEVICE|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
224037982|NCT05388877|DRUG|Dabrafenib|Given PO
224037983|NCT05388877|DRUG|MEK-1/MEKK-1 Inhibitor E6201|Given IV
224037984|NCT05388877|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224037985|NCT05388877|PROCEDURE|Computed Tomography|Undergo CT
224037986|NCT05388877|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224037987|NCT04849182|DIETARY_SUPPLEMENT|Vertistop D|Food supplement containing alpha-lipoic acid, carnosine, zinc, vitamin D3 and vitamins of group B, 1 tablet/day before meals
224037988|NCT04849182|DIETARY_SUPPLEMENT|Vertistop L|Food supplement containing alpha-lipoic acid, carnosine, zinc and curcumin, 2 tablets/day (morning and evening)
224037989|NCT01521897|BIOLOGICAL|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
223425898|NCT00402558|DRUG|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
223425899|NCT00402558|DRUG|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
223425900|NCT00402558|DRUG|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
223425901|NCT06097624|OTHER|synchronized tele-exercise|All evaluations and exercise interventions will be performed by via Google Meet, a video-conferencing application. The participation link will be sent to the individual by the researcher before each session. In case of any technological disruption, the session will be postponed to the nearest available time by phone. All interventions will be run by a blinded researcher.
223425902|NCT03194750|OTHER|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of \< 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
224037990|NCT04090853|DEVICE|Venus Bliss|The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
224037991|NCT00257686|DRUG|Pitavastatin|
224037992|NCT00257686|DRUG|Pravastatin|
223425903|NCT03194750|OTHER|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
223564310|NCT04448392|DRUG|Valacyclovir|Upon completion of standard of care acyclovir for treatment of neonatal HSV disease, valacyclovir oral suspension (per ASHP recipe), 20 mg/kg every 8 hours, to be given for 2 (up to 7) days
223564311|NCT06660576|PROCEDURE|Cholecystectomy and histochemical analysis of Gallbladder stones|Cholecystectomy and histochemical analysis of Gallbladder stones
223564312|NCT06661408|BEHAVIORAL|Intervention group 1|The women assigned to this group will be shown the newborn bath application video prepared by the researchers in groups of 2-4 people in the form of a projection presentation.
224037993|NCT06206512|DRUG|Extended release torsemide|This is an extended-release formulation of torsemide
224037994|NCT06206512|DRUG|Immediate release torsemide|This is the generic, immediate release formulation of torsemide
224037995|NCT06206512|DRUG|Extended release torsemide placebo|Placebo of extended release torsemide
224037996|NCT06206512|DRUG|Immediate release torsemide placebo|Placebo of immediate release torsemide
223425904|NCT03683693|DIAGNOSTIC_TEST|Procalcitonin group|"The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT \< 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT \< 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion."
224139033|NCT06383104|OTHER|Intervention|Three myofascial release techniques will be performed with low load and long duration stretching to the myofascial complex to restore optimal length, decrease pain and improve function. In the development of the deep myofascial techniques, respiratory synchronisation with the patient will be performed. Proprioceptive neuromuscular facilitation techniques will be performed by executing diagonal spiral movements against resistance, several times, through a full range of motion. Three sets of three repetitions with 6-second contractions and a 30-second rest between sets shall be performed.
223425905|NCT01687465|PROCEDURE|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
223744764|NCT06460649|OTHER|Benson relaxation techniques|Participants received Benson relaxation techniques 3 times a week for 12 weeks. 36 sessions overall.
224037997|NCT05211310|OTHER|High-Activity Arthroplasty Score (HAAS)|The questionnaire developed by Talbot et al. in 2010 consists of 4 sub-dimensions. 0-18 points can be obtained from the survey. High scores are associated with higher functional ability.
224037998|NCT05211310|OTHER|Western Ontario and McMaster Universities osteoarthritis score (WOMAC)|It is used to evaluate disability in patients with hip and knee osteoarthritis. Each sub-dimension is standardized within the range of 0-100 points, with high scores indicating poor health.
224037999|NCT05211310|OTHER|The Knee injury and Osteoarthritis Outcome Score (KOOS)|It is calculated between 0 and 100 points. 0 points indicate severe knee problem, 100 points no knee problem
224038000|NCT05211310|OTHER|The Forgotten Joint Score-12 (FJS-12)|It evaluates how much an individual can forget an artificial joint during activities of daily living. A total of 100 points can be obtained. A high score is associated with the ability to forget.
224038001|NCT05211310|OTHER|EQ-5D-5L|It is a questionnaire evaluating the quality of life. The higher the total score, the higher the quality of life.
224139034|NCT05136248|PROCEDURE|intraarticular injection|Ultrasound-guided intraarticular injection
224139035|NCT05136248|PROCEDURE|peng block|Ultrasound-guided PENG block
224139036|NCT01869166|BIOLOGICAL|CART-EGFR|
224139037|NCT02623036|DRUG|Equivalent dose enalapril|Chronotherapy with enalapril.
224139038|NCT02623036|DRUG|Equivalent dose lisinopril|Chronotherapy with lisinopril
224139039|NCT02509494|BIOLOGICAL|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5\*10\^10 viral particles.
224139040|NCT02509494|BIOLOGICAL|MVA-BN-Filo|MVA-BN-Filo- is a non-replicating vaccine, 0.5 mL IM injection of 1\*10\^8 Infectious Unit (Inf. U.).
224139041|NCT02509494|BIOLOGICAL|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
224139042|NCT02509494|BIOLOGICAL|Placebo|0.9% saline for injection.
224139043|NCT06039917|OTHER|AI based automatic surveillance (AS) system (ENDOANGEL-AS)|An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.
224139044|NCT06039917|OTHER|Manually remind the patients|Medical staff remind patients to review manually.
224139045|NCT01511107|DRUG|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
224038002|NCT05211310|OTHER|Numerical pain scale (NPS)|It is the numerical expression of perceived pain intensity. It is rated from 0-10 points. 10 points indicate the highest pain intensity, 0 points the absence of pain.
224038003|NCT05843643|DRUG|Upadacitinib|Oral Tablets
224038004|NCT05843643|DRUG|Placebo|Oral Tablet
224139046|NCT01511107|DRUG|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
224139047|NCT04900480|OTHER|Direct access to publicly subsidized physiotherapy|This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
224139048|NCT01106482|OTHER|Serology blood draw|Blood draw only, no vaccine
224139049|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
224139050|NCT03163108|DEVICE|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
224139051|NCT02533661|OTHER|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
224139052|NCT03969836|DEVICE|NeurOS system|NeurOS system pads will be placed on patients' head for monitoring.
224139053|NCT02020460|DEVICE|Subdural trial lead|
224139054|NCT02020460|DEVICE|Epidural trial lead|
224139055|NCT05533333|BEHAVIORAL|Falls prevention exercises|A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
224139056|NCT01812486|RADIATION|dose de escalation|
224139057|NCT01812486|RADIATION|standard dose|
223425906|NCT01687465|PROCEDURE|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
223425907|NCT01220765|DEVICE|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 \> 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
223425908|NCT00395941|DRUG|Pioglitazone|
223425909|NCT00395941|DRUG|Acitretin|Acitretin
223425910|NCT05380544|DEVICE|Extracorporeal Shockwave Therapy|ESWT will be given at 0.1mJ/mm2, 5 pulses/second and penetration of 5mm. Each intervention will be delivered in 3x30minute sessions over 7 days.
223425911|NCT02989779|DRUG|NK1 Antagonist|
223425912|NCT02989779|DRUG|Placebo Oral Capsule|
223425913|NCT05367284|DRUG|Testosterone|Testogel 16.2 miligrams/ gram (mg/g) gel
223425914|NCT03395470|DRUG|PXL770|MAD
223425915|NCT03395470|DRUG|Placebo|MAD
223425916|NCT03395470|DRUG|Rosuvastatin|DDI
223425917|NCT03142542|DRUG|ZYDENA TAB.75mg(Udenafil 75mg)|ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
223425918|NCT03142542|DRUG|Placebo Oral Tablet|Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
223425919|NCT02822573|DRUG|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
223425920|NCT02822573|DRUG|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
223425921|NCT00893165|BEHAVIORAL|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
223425922|NCT04971148|OTHER|HFNC flow set at patient peak tidal inspiratory flow|HFNC flow will be set at the level equal to patient peak tidal inspiratory flow
223425923|NCT04971148|OTHER|HFNC flow set at 1.33 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.33 times of patient peak tidal inspiratory flow
223425924|NCT04971148|OTHER|HFNC flow set at 1.67 times of patient peak tidal inspiratory flow|HFNC flow will be set at 1.67 times of patient peak tidal inspiratory flow
224038005|NCT04919525|DEVICE|TrainPain|Participants will use gamified sensory perceptual training technology once daily for 28 days. This will involve participants completing a 15 minute sensory training session using the provided technology and viewing a 5 minute web based pain management lesson; additionally, participants will receive daily text messages. The device used in this study has two components. The first is a video game that can be downloaded onto any smartphone device. The second component is two vibrational devices that can be attached to the arms, legs, upper back, and lower back.
224139058|NCT00241163|PROCEDURE|Fibrinogen (human) + thrombin (human) (TachoSil)|
223425925|NCT04971148|OTHER|HFNC flow set at 2 times of patient peak tidal inspiratory flow|HFNC flow will be set 2 times of patient peak tidal inspiratory flow
223425926|NCT05465265|BEHAVIORAL|Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs)|Cases: Navigation of PWID into PrEP-Navigation into prEP by use of PrEP-UP intervention (provision of PrEP information through 5 counselling sessions, peer support, booking of appointments for PWIDs) Control group: Provision of PrEP information to PWID through pamphlets on PrEP uptake, adherence and retention among PWID.
223425927|NCT04201158|DIAGNOSTIC_TEST|Exercise Capacity|Modified Shuttle Walk Test
223425928|NCT03275675|DRUG|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
223425929|NCT00797628|BEHAVIORAL|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
223425930|NCT00797628|BEHAVIORAL|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
223425931|NCT01864876|BIOLOGICAL|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
223425932|NCT01864876|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
224038006|NCT02467348|DRUG|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
224038007|NCT02467348|DRUG|Ascitic fluid|
224139059|NCT01619592|DEVICE|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
223425933|NCT01864876|BIOLOGICAL|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
223425934|NCT00775840|DRUG|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
223425935|NCT00775840|DRUG|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
223425936|NCT05901012|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
223425937|NCT05901012|DRUG|Placebo|DMT will be administered using a vaporizer device in a placebo-controlled, double-blind, randomized, monocentric clinical trial design.
223425938|NCT01469832|BIOLOGICAL|MA09-hRPE|"* Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells"
223425939|NCT06339411|DRUG|Cerebrolysin|Cerebrolysin post-mechanical thrombectomy, initiated within 24 hours of stroke onset and continued for 14 days. The study assessed neurological, neuropsychological, and biomarker outcomes at multiple time points post-stroke to evaluate the effects of Cerebrolysin on recovery.
223425940|NCT00003764|DRUG|cyclophosphamide|
223425941|NCT00003764|DRUG|fludarabine phosphate|
223425942|NCT04202913|BEHAVIORAL|Coaching|Child will receive 1:1 coaching with health coach.
223425943|NCT06365008|DRUG|Sintilimab+irinotecan+leucovorin folinate+fluorouracil|sintilimab 3mg/kg for patients with body weight\<60kg or 200mg for patients with body weight ≥ 60kg, plus irinotecan 180mg/m2 intravenous infusion, leucovorin folinate 400mg/m2 intravenous infusion and fluorouracil 400mg/m2 intravenous injection followed by 2400mg/m2 intravenous infusion for 48 hours, repeated every two weeks.
224038008|NCT04471948|DEVICE|Fractional picosecond 1064 nm laser|The parameter of laser was 8 mm spot size, 0.8 mJ/CM2, 750 ps, 5 Hz, 2 passes The treatment was done in every 4 weeks for 3 sessions.
224038009|NCT03560947|OTHER|Manual Therapy and Exercise (Physiotherapy Intervention)|Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.
224038010|NCT03560947|OTHER|Usual Care (Physiotherapy Intervention)|Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
224038011|NCT03433495|OTHER|Melodic Intonation Therapy|
224038012|NCT05962047|OTHER|Games of WonderTree Augmented Reality|Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
224038013|NCT05962047|OTHER|Traditional therapy|Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
224038014|NCT02194062|DRUG|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
224038015|NCT02194062|DRUG|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
224038016|NCT02194062|DRUG|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
224038017|NCT05599295|DRUG|Orbactiv|Solution for IV infusion
224038018|NCT05599295|DRUG|Kimyrsa|Solution for IV infusion
224038019|NCT04434599|DEVICE|Fluoroscopically guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
223425944|NCT06410703|DRUG|CAN1012|CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W
223564313|NCT06661408|BEHAVIORAL|Intervention group 2|In groups of 2, the researcher will first explain the stages of newborn bathing application by the researcher in the form of a projection presentation, and then the pregnant women will be provided to perform the newborn bathing application on the newborn bathing model and tools simultaneously with the researcher.
223425945|NCT04212208|DEVICE|IV cannulation|IV cannulation in the preoperative period
223425946|NCT01044290|OTHER|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
223425947|NCT01044290|OTHER|Attention Control|Subjects listened to a non-guided relaxation CD
223425948|NCT02733354|DEVICE|watch viedo|
223425949|NCT00387751|BIOLOGICAL|Bevacizumab|Given IV
223425950|NCT00387751|OTHER|Laboratory Biomarker Analysis|Correlative studies
223425951|NCT00387751|OTHER|Pharmacological Study|Correlative studies
223425952|NCT00387751|DRUG|Sorafenib Tosylate|Given orally
223564314|NCT06658392|OTHER|cognitive tasks|no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
223744765|NCT03084588|DRUG|methadone|Patients will be given methadone at induction of anesthesia
224038020|NCT04434599|DEVICE|Contact force guided ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
224038021|NCT04434599|DEVICE|Local impedance guide ablation|Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
224038022|NCT06261333|OTHER|Questionnaires|No Intervention
224038023|NCT02704546|DRUG|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
224038024|NCT02704546|DRUG|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
224038025|NCT00719550|DRUG|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
224038026|NCT00719550|DRUG|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
224038027|NCT00719550|DRUG|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
224038028|NCT00719550|DRUG|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
224038029|NCT00719550|DRUG|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
224038030|NCT06583733|BEHAVIORAL|KOKU Bladder|"In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
224038031|NCT06583733|BEHAVIORAL|recommendations|"In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.~After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires."
224038032|NCT04870125|DRUG|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%)|Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%) for up to 90 minutes daily for 3 days.
224038033|NCT04870125|OTHER|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
224038034|NCT02276872|DRUG|oral treprostinil|
224038035|NCT06847191|DRUG|NE3107|20 mg Capsule
224038036|NCT06847191|DRUG|Placebo|placebo capsule
224038037|NCT05584670|DRUG|SAR445877|Concentrate for solution for infusion
224038038|NCT05584670|DRUG|Cetuximab|Solution for infusion
224038039|NCT05888493|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel is a solution for infusion of 0.6 to 6 x 10\^8 CAR-positive viable T-cells taken intravenously (i.v.).
224038040|NCT05888493|DRUG|Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.|Lenalidomide 20 mg daily on days 1-21 for up to 12 cycles Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 2-5
224139060|NCT03342937|DRUG|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~1. Safety validation part: all Cycles are 21 days in length.~2. Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
223425953|NCT04874233|DRUG|HU6|HU6 is active study drug
223425954|NCT04874233|DRUG|Placebo|Non-active study drug N = 20
223425955|NCT04303533|DEVICE|Neuro-Feedback EFP|Neurofeedback (NF) - is a treatment method based on learned self-modulation of neural activity in response to feedback of neural signal. Amygdala-EFP (EEG-finger-print, EFP) is an EEG-NF application that modulates amygdala response.
223425956|NCT01901354|OTHER|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
223425957|NCT01901354|OTHER|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
223425958|NCT03081559|BEHAVIORAL|Healthy Divas|Peer-based counseling to improve medication adherence and engagement in care
223425959|NCT06158659|DIETARY_SUPPLEMENT|Feihe Investigational Formula|Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
223425960|NCT06158659|DIETARY_SUPPLEMENT|Control Formula|Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
223425961|NCT06158659|OTHER|Breastfeeding|Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
223425962|NCT00759785|DRUG|dalotuzumab (MK0646)|Single intravenous infusion
223425963|NCT00720512|BIOLOGICAL|bevacizumab|Given IV
223425964|NCT00720512|DRUG|fluorouracil|Given IV
224139061|NCT03372629|DRUG|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
224139062|NCT03372629|DRUG|Placebo oral capsule|Placebo capsules matching ID-085 capsules
224139063|NCT01543139|DRUG|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
224139064|NCT01543139|DRUG|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
224139065|NCT01543139|DRUG|Valproate|Valproate: Week0-8: 300mg/day
223425965|NCT00720512|DRUG|irinotecan hydrochloride|Given IV
223425966|NCT00720512|DRUG|leucovorin calcium|Given IV
223425967|NCT00720512|DRUG|oxaliplatin|Given IV
223425968|NCT05735314|OTHER|consultation with a specialist|The intervention consists of consultation with a specialist, use of a nurse navigator to help patients with appointments and help them understand their condition, and use of a data query of the electronic health record (EHR) to identify abnormal test results to make sure they are appropriately addressed.
223425969|NCT05735314|OTHER|Usual care|Usual care involves primary care physicians ordering additional tests and referrals to evaluate patients with new anemia and decreased glomerular filtration rate (GFR) .
224139066|NCT05365009|DIAGNOSTIC_TEST|Multidisciplinary aproach|regular tests
224139067|NCT05962918|OTHER|Perinal massage|"Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum."
223425970|NCT06051123|DIETARY_SUPPLEMENT|Probiotic|Participants will be taking 1 sachet a day.
223425971|NCT06051123|DIETARY_SUPPLEMENT|Placebo|Participants will be taking 1 sachet a day.
224139068|NCT03256734|OTHER|Policy intervention|Incentive payment for physicians
224139069|NCT04437030|DEVICE|MSOT Acuity Echo device|The MSOT acutiy Echo device can take ultrasound recordings in addition to photoacoustic recordings.
224139070|NCT05043246|BIOLOGICAL|SARS-COV-2 VACCINE|the antibody titer and adverse reactions were observed.
224139071|NCT00484549|PROCEDURE|Blood sample|Ischemic stroke hospitalized
224139072|NCT02539355|OTHER|Diet A|12-week diet
223425972|NCT06424990|OTHER|balance training with TENS|children will receive Biodex balance training with TENS for 30 minutes a day, 5 days per week for 4 weeks
223425973|NCT06424990|OTHER|Balance training with placebo TENS|children will receive Biodex balance training with placebo TENS for the same period.
223425974|NCT02032381|OTHER|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
223425975|NCT05127850|BEHAVIORAL|Consultation audio recording app|Smartphone or tablet mobile application which allows for voice recording
223425976|NCT01646021|DRUG|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
223425977|NCT01646021|DRUG|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
223425978|NCT02589249|DIETARY_SUPPLEMENT|AyuFlex|Active product
223425979|NCT02589249|DIETARY_SUPPLEMENT|Placebo|Placebo
223425980|NCT05888441|OTHER|Obstacle characteristics|"In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast."
224139073|NCT02539355|OTHER|Diet B|12-week Diet
224139074|NCT00511953|DRUG|Gabapentin Extended Release tablets|1800mg
223425981|NCT03268824|DEVICE|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
223425982|NCT03268824|DEVICE|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
223425983|NCT03268824|OTHER|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
223425984|NCT06577519|DRUG|Vicagrel|Vicagrel loading followed by Maintenance dose
223425985|NCT06577519|DRUG|Clopidogrel|Clopidogrel loading followed by Maintenance dose
223425986|NCT04305249|DRUG|ATG-017|Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
223425987|NCT04305249|DRUG|ATG-017+Nivolumab|With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
223425988|NCT03256058|PROCEDURE|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
223425989|NCT03256058|PROCEDURE|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
223425990|NCT06540664|OTHER|Auricular Acupuncture needles|Auricular Acupuncture needles 5 days in 2 weeks
223425991|NCT06540664|OTHER|Sham Auricular Acupuncture needles|Sham Auricular Acupuncture needles 5 days in 2 weeks
224038041|NCT05888493|DRUG|Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles|Rituximab 375 mg/m2 i.v. on day 1 Cyclophosphamide 750 mg/m2 i.v. day 1 Doxorubicin 50 mg/m2 i.v. day 1 Vincristine 1.4 mg/2 (capped at 2 mg) i.v. day 1 Prednisone or prednisolone 40 mg/m2 PO days 1-5
224038042|NCT05888493|DRUG|Lymphodepleting chemotherapy|"Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) OR Cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).~OR Bendamustine 90 mg/m\^2 i.v. daily for 2 days (If there was previous grade IV hemorrhagic cystitis with cyclophosphamide, or the participant demonstrated resistance to a previous cyclophosphamide-containing regimen)"
224038043|NCT05888493|OTHER|Corticosteroids and/or Radiation (Bridging therapy)|Corticosteroids and/or Radiation
224038044|NCT06847815|OTHER|Sweet corn|Fresh and processed sweet corn
224038045|NCT06847815|OTHER|Glucose Tolerance Drink|Beverage providing 50 g of glucose
224038046|NCT03588182|OTHER|Virtual Reality Experience|Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
223425992|NCT00559403|BEHAVIORAL|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
223425993|NCT00559403|BEHAVIORAL|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
223425994|NCT02220179|BEHAVIORAL|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
223425995|NCT01663779|PROCEDURE|Ultrasound guided radial artery catheterization.|Radial artery catheters will be placed with the assistance of bedside ultrasound.
223425996|NCT01663779|PROCEDURE|Blind insertion of radial artery catheterization|Radial artery catheters will be placed by the palpation technique only.
223744766|NCT03084588|PROCEDURE|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
224038047|NCT05249634|DRUG|Jatenzo Pill|oral tablet daily
224139075|NCT00511953|DRUG|Gabapentin|1800mg
224139076|NCT06481657|OTHER|train with oxygen and without oxygen enrichment (placebo).|The experimental group will train with oxygen goggles in the aerobic part of the training The control group will train with oxygen goggles without oxygen enrichment (placebo).
224139077|NCT05186909|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
224038048|NCT01753583|DEVICE|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
224038049|NCT01753583|OTHER|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
224038050|NCT04147234|DRUG|BI 1387446 50 μg|Participants received 50 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
224038051|NCT04147234|DRUG|BI 754091|Participants received BI 754091 (ezabenlimab) intravenously at a dose of 240 mg once every 21-day cycle.
224038052|NCT04147234|DRUG|BI 1387446 100 μg|Participants received 100 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
224139078|NCT05186909|OTHER|Placebo|Placebo
224038053|NCT04147234|DRUG|BI 1387446 200 μg|Participants received 200 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
223425997|NCT05182359|OTHER|SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test|The SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) test is used to predict the four-year likelihood of myocardial infarction, stroke, hospitalization for heart failure or death. It will be provided to the participant's ordering provider.
223425998|NCT01460654|DRUG|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
223425999|NCT01460654|DRUG|Alendronate|Alendronate (Fosamax) 70mg every week.
223426000|NCT01460654|DRUG|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
224038054|NCT04147234|DRUG|BI 1387446 400 μg|Participants received 400 μg BI 1387446 intratumorally based on tumor diameter, on Day 1 of a 21-day cycle. Injections were administered under visual inspection for skin tumors or imaging guidance.
224038055|NCT06439394|DRUG|Optive MEGA-3 (OM3)|Eye Drops
223426001|NCT01460654|DRUG|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
224038056|NCT06149390|DRUG|consolidation with ASCT|high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
224038057|NCT05453032|DEVICE|NeuroConn|A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
224038058|NCT06834685|DEVICE|Photobiomodulation sessions|The treatment will be administered by an ATP38 device delivering a power of 4 Joules/cm2 at wavelengths of 620 and 820 nm
224038059|NCT01245075|OTHER|Deep brain stimulation|Deep brain stimulation on
224038060|NCT01245075|OTHER|Placebo|deep brain stimulation off
224038061|NCT02596620|DRUG|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
224038062|NCT02596620|DRUG|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
224038063|NCT02596620|DRUG|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
224038064|NCT02596620|DRUG|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
224038065|NCT00411125|DRUG|Oral salmon calcitonin|
224038066|NCT01717963|DRUG|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
224038067|NCT01717963|DRUG|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
224038068|NCT02323633|DEVICE|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
224038069|NCT02323633|DEVICE|Sham|No transcranial Pulsed Current Stimulation (tPCS)
223426002|NCT02465879|OTHER|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
223426003|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.1%|IVW-1001 Ophthalmic Eyelid Wipe 0.1%
224038070|NCT03892512|DRUG|Esmolol Hydrochloride|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
224038071|NCT03892512|DRUG|Dexmedetomidine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
224038072|NCT00695851|DRUG|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
224038073|NCT00695851|DRUG|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
224038074|NCT05558176|DRUG|Sildenafil citrate|The same brand of sildenafil citrate (VIAGRA, manufactured by Fareva Amboise Zone Industrielle, 29 route des Industries, 37530 Poce Sur Cisse, France, under authority of Pfizer Inc, NewYork, NAFDAC Reg NO: 04 - 1509, Batch No: 477209; Exp date: 11 - 2024) will be used in the course of the study.
224038075|NCT02039791|BIOLOGICAL|Nimotuzumab|200mg/w,weekly, 6 weeks
223426004|NCT06400459|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|IVW-1001 Ophthalmic Eyelid Wipe 0.2%
223426005|NCT06400459|DRUG|IVW-1001 Placebo|IVW-1001 Placebo
223426006|NCT06618742|PROCEDURE|Cryotherapy|Focal cryoballoon ablation, 1-3 treatments with an interval of 1-3 weeks
223426007|NCT00046852|BIOLOGICAL|filgrastim|
223426008|NCT00046852|BIOLOGICAL|pneumococcal polyvalent vaccine|
223426009|NCT00046852|BIOLOGICAL|therapeutic autologous lymphocytes|
223426010|NCT00046852|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223426011|NCT00046852|DRUG|carmustine|
223426012|NCT00046852|DRUG|cyclophosphamide|
223426013|NCT00046852|DRUG|melphalan|
223426014|NCT00046852|PROCEDURE|bone marrow ablation with stem cell support|
223426015|NCT00046852|PROCEDURE|peripheral blood stem cell transplantation|
223426016|NCT00875199|BEHAVIORAL|contingency management|Prize-based contingency management for weight loss
224038076|NCT02039791|DRUG|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
224038077|NCT02039791|DRUG|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
224038078|NCT04876534|DRUG|Tocilizumab 20 Mg/mL Intravenous Solution|Intravenous administration
224038079|NCT04876534|DRUG|MethylPREDNISolone Injectable Solution|Intravenous administration
224038080|NCT00867113|DRUG|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
224038081|NCT00897143|GENETIC|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
224038082|NCT00897143|GENETIC|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
224038083|NCT00897143|OTHER|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
224038084|NCT00897143|OTHER|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
223426017|NCT00875199|BEHAVIORAL|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
223426018|NCT02581475|PROCEDURE|Extending withdrawal time in the proximal colon|
223426019|NCT02581475|PROCEDURE|Segmental examination twice of the proximal colon|
223426020|NCT01967706|OTHER|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
223426021|NCT01967706|OTHER|mCC|Single use of subject's own menthol cigarette (mCC)
223426022|NCT01967706|OTHER|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
223426023|NCT01570270|DIETARY_SUPPLEMENT|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
223426024|NCT03108170|OTHER|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
223426025|NCT03108170|OTHER|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
223426026|NCT03108170|OTHER|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
223426027|NCT03450785|OTHER|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
223426028|NCT02777970|DRUG|Tramadol Hydrochloride/Dexketoprofen Trometamol|
223426029|NCT02777970|DRUG|Tramadol Hydrochloride/Paracetamol|
223426030|NCT02777970|DRUG|Placebo|
223426031|NCT02347891|DRUG|Belimumab|Randomized phase: Week 0 - Week 40
223426032|NCT02347891|DRUG|Placebo|Randomized phase: Week 0 - Week 40
224038085|NCT04147325|DRUG|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
223426033|NCT02319967|BEHAVIORAL|CAPE|Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
223426034|NCT02319967|BEHAVIORAL|CHW home visits|Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
224038086|NCT02209155|DRUG|R-verapamil 75 mg tablet|
224038087|NCT02209155|DRUG|Placebo|
224038088|NCT06400498|BEHAVIORAL|Prompted Palliative Care Consult|When a patient is randomized to the Palliative Care Consultation Prompt Group, a clinical decision support tool in the electronic health record will inform the treating clinician of the patient's serious illness and the results of the Surprise Question and prompt the treating clinician to consider a palliative care consultation. If the treating clinician feels a palliative care consultation would be indicated for the patient, the clinical decision support tool will facilitate the placement of a palliative care consultation by the treating clinician. If the treating clinician feels that a palliative care consultation would not be indicated, then the clinical decision support will record a reason it is not indicated.
224038089|NCT03426826|BIOLOGICAL|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
224038090|NCT00633165|DRUG|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
224038091|NCT01886313|DRUG|Civamide Nasal Spray|
224038092|NCT01886313|DRUG|Placebo|
223426035|NCT01685489|DRUG|Docetaxel, PSK®|
223426036|NCT01685489|DRUG|Docetaxel, Placebo|
223426037|NCT00538044|DRUG|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
223426038|NCT00226668|DRUG|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
223426039|NCT00226668|DRUG|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
223426040|NCT03861312|BEHAVIORAL|Neck Laterality|"Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
223426041|NCT03861312|BEHAVIORAL|Foot Laterality|"Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
223426042|NCT06420934|OTHER|Drying procedure after surgical handwashing|Participants will dry their hands with one surgical towel
223426043|NCT00000864|DRUG|Abacavir sulfate|
223426044|NCT00000864|DRUG|Zidovudine|
223426045|NCT06622915|DEVICE|Tissue Doppler imaging and Conventional Echocardiography|non-invasive cardiac imaging technique which measures the velocity of the longitudinal motion of the mitral annulus, tricuspid annulus and the basal part of interventricular septum
223426046|NCT00463762|DRUG|CP-75385-02 Cefoperazone/sulbactam|
223426047|NCT04775901|OTHER|CT-guided lung biopsy|Percutaneous transthoracic lung biopsy was conducted stepwise under the real-time guidance of CT scan. This kind of modality served as an effective method for diagnosing peripheral lung lesions (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
223744767|NCT00720057|DRUG|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
224038093|NCT00697879|DRUG|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
224038094|NCT06033781|BEHAVIORAL|Cognitive Behavioral Therapy for Nightmares in Children|The Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC) is a brief, five-session manualized therapy designed to treat children ages 6-17. The manualized CBT protocol is five session that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
224038095|NCT05804279|DRUG|BPDO-1603|donepezil/mematine
224038096|NCT01207232|BEHAVIORAL|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
223426048|NCT04775901|DEVICE|Template-guided lung biopsy|A three-dimensional model consisting of participant's thoracic image information was initially reconstructed based on the CT scan data. Afterwards, a navigational template was customized, which accommodated well to the anatomical landmarks of the participant. The template was then printed by means of stereolithography from photopolymer material. Participants would receive navigational template-guided percutaneous transthoracic lung biopsy (all of the participants received fine-needle aspiration, some of them received coaxial needle biopsy as well, according to the pulmonologist's instruction).
223426049|NCT04558567|DRUG|Vogelxo|50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)
223426050|NCT05965635|OTHER|Ixodus scapularis nymphs|Tick challenge
223426051|NCT00247078|BIOLOGICAL|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
223426052|NCT00247078|BIOLOGICAL|Placebo|
223426053|NCT02728583|DIETARY_SUPPLEMENT|Margarine enriched with plant sterols and fish oil|
223426054|NCT02728583|DIETARY_SUPPLEMENT|Placebo margarine|
223426055|NCT05010512|DEVICE|Delefilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
223426056|NCT05010512|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses used as indicated
223426057|NCT06178731|DEVICE|rTMS|3 min rTMS delivery with iTBS to the left DLPFC
223426058|NCT06178731|OTHER|Virtual Reality|2-15 min VR viewing, 15 min descriptive and imaginal recounting
223426059|NCT05698472|OTHER|questionnaire|"Use the Questionnaire on physical exercise of the elderly in Beijing community to collect the related information of the elderly."
223426060|NCT03310658|DEVICE|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
224038097|NCT01207232|BEHAVIORAL|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
223426061|NCT02155517|DRUG|Evaluation of propofol effect|"The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
223426062|NCT02155517|DRUG|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
223426063|NCT03308136|PROCEDURE|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1\) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
223426064|NCT03308136|PROCEDURE|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2\) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3\~4ml of local anesthetics to the muscle layer along the expected needle pathway.
223426065|NCT03308136|DRUG|1% Lidocaine|1% Lidocaine
223426066|NCT00422344|DRUG|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
223426067|NCT05002894|OTHER|Pilates exercises|Pilates exercises for flexibility and stability
223426068|NCT05002894|DIETARY_SUPPLEMENT|medical standard care for fatigue|supplements and medical care
223426069|NCT06618560|DEVICE|Enamel Matrix Derivative application|After submarginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush), implant surfaces will be conditioned for 2 min with 24% ethylene-diaminetetraacetate EDTA (PrefGel®, Institut Straumann AG). Then, the sites will be completely rinsed with saline solution and thoroughly dried with air. Repeated irrigation and air-drying will be done in the area until complete bleeding control with sterile gauzes. Then EMD (Emdogain®, Institut Straumann AG) will be gently applied with a blunt-tipped sterile syringe until overflowing from the mucosal margin.
224038098|NCT03882905|DRUG|Ezetimibe|10 mg tablet, oral, once daily
224038099|NCT03882905|DRUG|Placebo|one tablet, oral, once daily
224038100|NCT03882905|DRUG|Simivastatin|Once daily administration at dose to be determined
224038101|NCT03882905|DRUG|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
224038102|NCT02771314|DRUG|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
224038103|NCT00006098|DRUG|bortezomib|
224038104|NCT02914691|DRUG|Dapagliflozine 10 mg once daily tablet treatment|
224038105|NCT02914691|DRUG|Placebo identical once daily tablet treatment|
224038106|NCT03024177|DRUG|Vapendavir|Vapendavir Tablets, 264 mg
224038107|NCT03024177|DRUG|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
224038108|NCT04066790|DRUG|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
224038109|NCT04066790|DRUG|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
224038110|NCT04066790|DRUG|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
224139079|NCT03054987|PROCEDURE|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
223426070|NCT06618560|DEVICE|Hyaluronic Acid (HA)|After submarginal instrumentation of the implant surface (i.e., titanium curettes plus oscillating chitosan brush), the cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) will be will be implemented to the peri-implant pockets.
223426071|NCT06618560|PROCEDURE|Control|Implants allocated to the control group will be treated with the same sub-marginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush). Implant surface will be irrigated with with sterile saline.
223426072|NCT04417192|DRUG|Olaparib|Olaparib will be administered at a dose of 300mg as oral dose, twice a day.
223426073|NCT04417192|DRUG|Pembrolizumab|Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
223426074|NCT05668143|BEHAVIORAL|Virtual reality|The Patient Information Form and the State Anxiety Scale will be administered to the patients just before the surgery. The researcher will measure the patient's respiratory, blood pressure, pulse and oxygen saturation values on the monitor just before the start of the operation and every 15 minutes after the operation, and the vital signs will be recorded in the follow-up form. Virtual reality glasses will be put on the patient immediately after anesthesia is given to the patient by the anesthesiologist. Glasses will be worn during the total knee replacement surgery. Total knee replacement surgery takes an average of 60 minutes. During the surgery, patients will be shown nature and landscape images with virtual reality glasses. Virtual reality glasses will be removed immediately after the operation and the State Anxiety Scale and vital signs follow-up form will be applied before the patient is sent to the service from the operating room.
223426075|NCT04913350|OTHER|Russian current|One of the preferred common neuromuscular electrical stimulation techniques for muscle strengthening is the Russian current (RC) It stimulates almost all muscle motor units to contract synchronously, resulting in a greater muscle hypertrophy.
223426076|NCT04913350|DEVICE|elbow support|tennis elbow brace is recommended to decrease pain and improve function by restricting the movement of the forearm or relieving loads on the origin of the muscles of the extensor
223426077|NCT01846481|DRUG|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
223426078|NCT01846481|DRUG|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
223426079|NCT01846481|DRUG|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
223426080|NCT01846481|DRUG|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
224038111|NCT04066790|DRUG|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
224038112|NCT04066790|PROCEDURE|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
224038113|NCT05810337|DIETARY_SUPPLEMENT|Splenda drink|4.5g Splenda containing 1% sucralose, 95% maltodextrin, dissolved in 250ml water and consumed with a high carbohydrate breakfast.
224038114|NCT05810337|DIETARY_SUPPLEMENT|Maltodextrin drink|4.5g maltodextrin dissolved in 250ml water and consumed with a high carbohydrate breakfast.
224038115|NCT05810337|DIETARY_SUPPLEMENT|High carbohydrate breakfast|Meal consisting of 30g cereal with 100ml skimmed milk, 1.5 slices white toast with 12g margarine, providing 386kcal, 61.4g carbohydrate, 10.4g protein and 10.1g fat.
224038116|NCT00263744|BIOLOGICAL|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
224038117|NCT00263744|OTHER|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
224038118|NCT00037791|DRUG|(PN-152,243)/PN-196,444|
224038119|NCT03706339|OTHER|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
224038120|NCT03706339|DRUG|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
223426081|NCT01071486|DRUG|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
223426082|NCT00866086|OTHER|questionnaire administration|
223426083|NCT00866086|PROCEDURE|computed tomography|
223426084|NCT00866086|RADIATION|radiation therapy treatment planning/simulation|
223426085|NCT03359486|BEHAVIORAL|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
223426086|NCT03359486|BEHAVIORAL|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
223426087|NCT03028857|DRUG|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
223564315|NCT06987604|DEVICE|High-dose continuous renal replacement therapy|Continuous renal replacement therapy administered at an effluent dose of 45-55 mL/kg/h using standard equipment and protocols for critically ill patients with ALF or ACLF and hyperammonemia.
224038121|NCT03706339|DRUG|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
224139080|NCT03054987|PROCEDURE|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
224139081|NCT01372371|BIOLOGICAL|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
224038122|NCT03613285|DEVICE|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
223426088|NCT03028857|DRUG|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner. Increased awareness into the benefits of choline by obstetricians and pregnant women, as well as our recently published results from an observational study showing a wide distribution of serum choline concentrations in pregnant women, suggest that serum choline concentration is a more apt independent variable for analyses.
223426089|NCT00122122|BEHAVIORAL|Enhanced Pharmacy Care|
223426090|NCT01885286|PROCEDURE|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
223426091|NCT05555225|OTHER|Methylome|Epigenetic study : analysis of DNA methylation
223426092|NCT00864825|DRUG|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
223426093|NCT02952625|OTHER|Imaging|Single arm Imaging (PET/MR) study
223426094|NCT00549913|BIOLOGICAL|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
224038123|NCT03613285|DEVICE|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
224038124|NCT03613285|DEVICE|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
224139082|NCT01372371|BIOLOGICAL|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
224139083|NCT01372371|BIOLOGICAL|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
224139084|NCT00363051|DRUG|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
223426095|NCT00549913|PROCEDURE|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
223426096|NCT06528535|OTHER|Health promotion intervention|Health promotion activities on nutrition with distribution of baskets of fresh fruits and vegetables
223426097|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
223426098|NCT03726203|DEVICE|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
224139085|NCT00363051|DRUG|Octreotide Depot|
223426099|NCT04724902|OTHER|Elastic bandage compression|The compression will be applied with the volunteer in the supine position on a stretcher, with both lower limbs extended and relaxed. The intervention in the Compression group will be with elastic bandages involving the entire surface of the knee, positioned considering anatomical aspects: femoral condyles and the anterior tibial tuberosity. The level of compression must be maintained between 30 mmHg and 60 mmHg, according to the researched literature. The variations within these values will be stipulated according to the volunteer's self-report (comfortable and painless compression). The Shan Group will have the bandage wrapped around the knee without any compression force being exerted. The intervention will be carried out for 20 minutes, once a day, for 4 consecutive days. The Control group will be composed of volunteers who make up a study waiting list and will carry out the evaluations at the same time intervals as the other groups, but will not receive any type of intervention.
223426100|NCT04636385|OTHER|Observational study no intervention|No intervention
224038125|NCT06522750|OTHER|7-day ambulatory caloric restriction intervention using the Buchinger-Wilhelmi method|Buchinger-Wilhelmi method, will be administered in an ambulatory setting under physician guidance. It involves an initial bowel cleanse followed by 7-day fasting period. The initial bowel cleanse will be performed according to the standard procedure commonly used for colonoscopy preparation. During the fasting period, subjects will be provided with a dietary energy supply of a maximum of 350 kcal per day, primarily consisting of vegetable broths as well as fresh vegetable juices. Patients will only be allowed to consume calorie-free and unsweetened water or tea in addition to the prescribed diet.
224038126|NCT06191770|PROCEDURE|Morphine,|Nalbuphine along multimodal analgesia(Paracetamol and Ketamine)
224038127|NCT00482196|DRUG|MK0493|
224038128|NCT05325697|COMBINATION_PRODUCT|Intervention consisting of a multicomponent exercise program combined with an oral nutritional supplement|The multicomponent exercise program to prevent frailty and risk of falls (Vivifrail) was developed by a European expert group co-funded by the ERASMUS+ programm of the European Union. The program consists of a screening and a subsequent 12-week exercise program. The screening classifies individuals into four categories: disabled, frail, pre-frail, or robust and the difficulty of the program's exercises is adapted to the categories and it includes endurance, balance, and resistance training as well as stretching exercises. This exercise program will be combined with an oral nutritional supplement (Moltein®Plus), which was specifically designed to promote muscle health in elderly people. Moltein®Plus is completely balanced oral nutrition supplement made from whey protein fortified with leucine. Enriching dietary protein with leucine allows to maximize muscle protein synthesis rates without calling for very high protein doses, which are difficult to ingest for older individuals.
224038129|NCT03765411|PROCEDURE|Proctectomy|Resection of the rectum
224139086|NCT02028585|DIETARY_SUPPLEMENT|Low-fat milk group|
223426101|NCT03598920|DEVICE|AsspireAssist|Endoscopic bariatric procedure using the AsspireAssist device
223426102|NCT03598920|OTHER|Nutritional consulting|Nutritional consulting provided by a specialized consultant.
224163666|NCT06085703|DRUG|Henagliflozin|Henagliflozin will be initiated and maintained at 5mg/day every morning. If necessary, the dose can be increased to 10mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
223426103|NCT00343785|DRUG|cyclophosphamide|Given IV
223426104|NCT00343785|BIOLOGICAL|anti-thymocyte globulin|Given IV
224038130|NCT04910022|DRUG|NMS-03305293|Route of administration: Oral
224038131|NCT04910022|DRUG|Temozolomide|"Route of administration: Oral~Commercially available temozolomide"
224038132|NCT00688831|DRUG|AZD1305|Solution for iv infusion , single dose
224038133|NCT00688831|DRUG|Placebo|NaCl solution for iv infusion, single dose
223426105|NCT00343785|DRUG|cyclosporine|Given IV or PO
223426106|NCT00343785|PROCEDURE|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
224038134|NCT01236105|DRUG|LY2624803|Administered orally (po), once.
224038135|NCT01236105|OTHER|Activated Charcoal|Administered po
224038136|NCT02393274|DEVICE|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
224038137|NCT04098965|OTHER|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
224038138|NCT04098965|OTHER|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
224038139|NCT05115604|BEHAVIORAL|cognitive behavioural intervention|Six sessions of cognitive behavioural and psychoeducational therapy will be conducted to treat insomnia.
224038140|NCT04086433|DEVICE|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
224038141|NCT05798533|BIOLOGICAL|Neo-T|Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.
224038142|NCT05798533|COMBINATION_PRODUCT|Toripalimab|"3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks.~Toripalimab is recommended for patients with Melanoma."
224038143|NCT05798533|COMBINATION_PRODUCT|Tislelizumab|"200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks.~Tislelizumab is recommended for patients with NSCLC or other tumor types."
224038144|NCT02309060|BEHAVIORAL|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
224038145|NCT05192304|DRUG|TPN-672|single dose of TPN-672 maleate tablet
224038146|NCT00634010|DRUG|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
224038147|NCT00634010|DRUG|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
224038148|NCT04052568|DRUG|Psilocybin|Participants will undergo up to four moderate to high dose psilocybin sessions. Dosing at the first session will be 20 mg. For subsequent sessions participants will either remain at their previous dose, or increase by increments of 5 mg up to a maximum of 30 mg.
224139087|NCT02411383|DEVICE|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
224038149|NCT01303263|BEHAVIORAL|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
223426107|NCT00343785|DRUG|methotrexate|Given IV
223426108|NCT00343785|GENETIC|DNA analysis|Correlative studies
223426109|NCT00343785|OTHER|flow cytometry|Correlative studies
223426110|NCT00343785|GENETIC|polymorphism analysis|Correlative studies
223426111|NCT00343785|OTHER|laboratory biomarker analysis|Correlative studies
223426112|NCT00828074|DRUG|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
223426113|NCT00828074|DRUG|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
223426114|NCT04430231|OTHER|Wait list time|
223426115|NCT02512081|OTHER|No intervention applied|No intervention applied
223426116|NCT03937401|DRUG|Oxytocin|Oxytocin infusion during MRI-HIFU treatment
223426117|NCT06682312|DEVICE|Non-invasive blood pressure|"Manual blood pressure via sphygmomanometer~Or~Non invasive blood pressure via earlyvue VS30 Monitor"
223426118|NCT06451289|DIAGNOSTIC_TEST|Head computered tomography|Retrospective data collecting from medical records
224038150|NCT05247138|DEVICE|BioRootTM RCS|BioRoot™ RCS is a hydrophilic mineral root canal sealer prepared from the mixture of a powder part and a liquid part. BioRoot™ RCS is a class III implantable medical device. This device is intended to be used in dentistry for permanent obturation of root canals of permanent and mature teeth with adjunction of gutta-percha points. Exposure to the sealer BioRootTM RCS starts from the day when the root canal treatment is performed until the end of individual observational period or the removal of the sealer in case of extraction or retreatment, if this event occurs before the end of individual observational period.
224038151|NCT00758056|GENETIC|polymorphism analysis|
224038152|NCT00758056|OTHER|laboratory biomarker analysis|
224038153|NCT00758056|OTHER|questionnaire administration|
224038154|NCT02934022|DRUG|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
224038155|NCT00567216|DRUG|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
224038156|NCT00385372|PROCEDURE|elimination diet|
224038157|NCT00385372|PROCEDURE|provocation diet|
224038158|NCT05103696|DRUG|Remimazolam Besylate|Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
224038159|NCT05103696|DRUG|etomidate combined with propofol|Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
223426119|NCT01305889|BEHAVIORAL|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
223426120|NCT01305889|DRUG|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
223426121|NCT00224146|DRUG|oxybutynin transdermal delivery system (Oxytrol(r))|
223426122|NCT03747068|DRUG|Anti-TNF Drug|
224038160|NCT03030235|DRUG|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10Mg Oral Tablet
223426123|NCT03219359|PROCEDURE|Autologous stem cell transplant|Hematopoietic stem cell transplantation
223426124|NCT03219359|DRUG|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal
223426125|NCT03219359|DRUG|Cyclophosphamide|Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
224038161|NCT03030235|DRUG|Dapagliflozin matching placebo|Dapagliflozin matching placebo
224038162|NCT04970043|DRUG|Camrelizumab+ pemetrexed + platinum|"Induction period: (4-6 cycles) Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Carboplatin: AUC = 4-5, given on the first day, every 3 weeks as a cycle; After 4-6 cycles of treatment, the patients entered the maintenance treatment period of carrizumab combined with pemetrexed.~Maintenance treatment period:~Camrelizumab: a fixed dose of 200 mg, intravenous drip for 30-60 minutes, the first day, every 3 weeks as a cycle.~Pemetrexed: 500 mg / m2, given on the first day, every 3 weeks as a cycle; Every 3 weeks is a treatment cycle, and the drug is maintained until the following conditions occur: disease progression, intolerable toxicity, or receiving immunotherapy for no more than 35 cycles (2 years)."
224038163|NCT05781568|DIAGNOSTIC_TEST|Biomarker dosage|The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
224038164|NCT05339321|GENETIC|SCG101|SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.
224038165|NCT05339321|BIOLOGICAL|PD1/PD-L1 checkpoint inhibitor|Commercially approved for HCC treatment.
224038166|NCT03417518|DRUG|Desflurane Inhalant Product|General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
224038167|NCT03417518|DRUG|Propofol|General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
224038168|NCT00006159|BEHAVIORAL|lifestyle (exercise, diet, and family and community support)|
224038169|NCT05506501|PROCEDURE|unilateral epidural anesthesia|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
224038170|NCT05506501|PROCEDURE|Ultrasound guided femoro/ sciatic nerve block|Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
224038171|NCT06430944|PROCEDURE|Placing a hip spica cast for patients with femur fractures|Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
224038172|NCT05823025|OTHER|PWV measurement|Patient will have its PWV measured with the reference (the SphygmoCor) and by stepping on Withings bathroom scales WBS08 and WBS12.
224038173|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
223426126|NCT03219359|DRUG|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
223426127|NCT03219359|DRUG|Methylprednisolone|Day -3 to -1: 1 gram prior to each ATG dose
224038174|NCT01306422|OTHER|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
224038175|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
224038176|NCT01306422|OTHER|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
224038177|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
224038178|NCT01306422|OTHER|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
224139088|NCT06024213|PROCEDURE|Sentinel lymph node identification|Intervention description: Intraoperative identification of sentinel lymph node
224139089|NCT06024213|DRUG|indocyanine green|Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route
224139090|NCT06024213|DRUG|methylene blue|1%), 2-5 mL administered by periareolar or peritumoural route
223426128|NCT03219359|DRUG|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
223426129|NCT05225675|BIOLOGICAL|ARGX-117|Intravenous administration of ARGX-117
223426130|NCT05225675|OTHER|Placebo|Intravenous administration of placebo
223426131|NCT01011166|DRUG|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
223426132|NCT01011166|DRUG|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
223426133|NCT01011166|BIOLOGICAL|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
223426134|NCT01011166|DRUG|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
223426135|NCT01264666|DIETARY_SUPPLEMENT|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
223426136|NCT01264666|DIETARY_SUPPLEMENT|Chinese Meijiao liquor|
223426137|NCT01264666|DIETARY_SUPPLEMENT|Water control|
223426138|NCT00858299|DRUG|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
224139091|NCT06024213|DRUG|Technetium (99mTc)|(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route
224139092|NCT02720653|PROCEDURE|Endoscopic sinus surgery|
223426139|NCT05481593|BEHAVIORAL|Scheduled Coaching + Gamified Rewards|Participants will receive scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
224038179|NCT03605563|PROCEDURE|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
224038180|NCT03605563|PROCEDURE|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction."
224038181|NCT01561781|DRUG|Digoxin|Oral tablets 0.25mg, single dose
224038182|NCT01561781|DRUG|Vandetanib|Oral tablets, 300 mg, single dose
224038183|NCT02646748|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
224038184|NCT02646748|DRUG|itacitinib|Itacitinib tablets administered orally once daily.
224038185|NCT02646748|DRUG|INCB050465|INCB050465 tablets administered orally once daily.
224038186|NCT05175313|RADIATION|transthoracic ultrasonography|"1. lung ultrasonography~2. Diaphragm and respiratory muscle ultrasound~3. inferior vena cava ultrasound"
224038187|NCT05175313|DEVICE|spirometry|pulmonary function test : FVC, FEV1, FEV1/FVC will be measured.
224038188|NCT00372749|BEHAVIORAL|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
224038189|NCT05189262|OTHER|Blood and urine collection|No intervention - Biological specimen collection
224038190|NCT02066051|DEVICE|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
224038191|NCT02066051|PROCEDURE|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
224038192|NCT02257957|DRUG|PRP injection|
224038193|NCT02257957|DRUG|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
224038194|NCT06583980|BEHAVIORAL|Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact|A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.
224038195|NCT04561765|DEVICE|iCanCope|The iCanCope mobile and web-based self-management program has been empirically evaluated for multiple painful diseases
224038196|NCT04561765|DEVICE|iCanCope+Contingency Management|In addition to the iCanCope-NF activities outlined above, individuals will be rewarded with incentives (contingency management) such as points that are redeemable for prize-based gift card vouchers. Points will be accrued through access to new sections, daily check-ins, and engagement of the mobile application. Based on research, the total amount of money that can be earned by the patient over the course of the two months is 50 dollars USD.
223426140|NCT05481593|BEHAVIORAL|Scheduled Coaching Calls + Independent Rewards|Participants will receive scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
224038197|NCT02576236|OTHER|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
224038198|NCT02576236|OTHER|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:~* If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~* If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
224038199|NCT03027557|DRUG|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
224038200|NCT03027557|DRUG|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
224038201|NCT03027557|OTHER|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
224038202|NCT03027557|OTHER|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
224038203|NCT05066698|BIOLOGICAL|ST266|Topical ocular application: one drop four times a day for eight weeks
224038204|NCT05066698|OTHER|0.67% Sodium Chloride Ophthalmic Solution|Topical ocular application: one drop four times a day for eight weeks
224038205|NCT05066698|BIOLOGICAL|Open-label ST266|Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
224038206|NCT04721821|DRUG|Tofacitinib|Patients who received Tofacitinib for RA
224139093|NCT04509804|OTHER|non-interventional|non-interventional
223426141|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Gamified Rewards|Participants will not have scheduled coaching calls and receive gamified rewards (i.e., earning points over time and converted to monetary gifts)
223426142|NCT05481593|BEHAVIORAL|No Scheduled Coaching Calls + Independent rewards|Participants will not have scheduled coaching calls and receive fixed rewards (i.e., non-increasing)
223426143|NCT01028638|OTHER|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
224038207|NCT04649268|DEVICE|Group B|The C2 CARE C2 Physio 2019.2 has been developed for physiotherapy rehabilitation purposes including vestibular disorders. Virtual reality environments will be provided via the VR Oculus Quest headset as part of the OKS exposure incorporated within a customised VRT programme. Participants will attend 45 minute individualised supervised sessions once weekly for 8 weeks. Participants in this rehabilitation group will also have a home-based exercise programme to practise on days not attending clinic. The home-based programme will incorporate customised VRT exercises with exposure to VR environments using the VR Oculus Quest headset.
224038208|NCT04649268|OTHER|Group A|Optokinetic stimulation treatment delivered through visual motion DVDs. Individualised 45 minute supervised sessions will occur for this group also once weekly for 8 weeks together with a home-based customised VRT programme incorporation the DVD to practise on days not attending clinic. Participants will have to use the OKS DVD for their exercises at home daily for 8 weeks as part of the prescribed home exercise programme.
224038209|NCT04289740|BEHAVIORAL|7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals|Patients assigned to the experimental group will receive 7 sessions (1.5 hr/session) in groups of approximately 8-10 individuals over a 12 week period
224038210|NCT04289740|BEHAVIORAL|a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure plus same number of sessions as the experimental intervention.|The control group will receive a progressive muscle relaxation group intervention, based on the Bernstein and Borkoveck procedure. This intervention will have the same number of sessions as the experimental intervention and last anywhere from 60 to 90 minutes, depending on the session.
224038211|NCT02155036|OTHER|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) \~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
224038212|NCT00565383|PROCEDURE|Combined spinal-epidural analgesia|Combined spinal-epidural
224038213|NCT00565383|PROCEDURE|Intravenous fentanyl (50mcg)|Intravenous fentanyl
223426144|NCT01152359|BEHAVIORAL|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
223426145|NCT01152359|BEHAVIORAL|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
223426146|NCT01914575|DEVICE|Mapping with the Acutus Medical System followed by Ablation|
223426147|NCT03419598|PROCEDURE|Opening wedge high tibial osteotomy|Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia. Since this is a virtual trial, the virtual patients were duplicated and enrolled into both arms
223426148|NCT03419598|DEVICE|Personalised subject specific custom HTO plate|Subject specific custom plate for stabilizing an open wedge HTO
223426149|NCT03419598|DEVICE|Generic HTO plate|Generic plate for stabilizing an open wedge HTO
223426150|NCT02945397|BEHAVIORAL|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
223426151|NCT02945397|BEHAVIORAL|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
224139094|NCT03711877|DEVICE|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
224038214|NCT01610687|DRUG|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
224038215|NCT00486876|DRUG|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
224139095|NCT03711877|DEVICE|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
224139096|NCT00648141|DRUG|Celecoxib|200 mg oral capsule once daily for 12 weeks
224139097|NCT00648141|DRUG|Celecoxib|200 mg oral capsule twice daily for 12 weeks
224139098|NCT00648141|DRUG|Diclofenac|75 mg oral capsule twice daily for 12 weeks
224139099|NCT02384772|OTHER|Survey|
224139100|NCT03768895|RADIATION|MRI|"The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI."
224038216|NCT06428981|OTHER|degenerative cervical diseases|Including herniation of the intervertebral disc, ossification of the posterior longitudinal ligament, and spinal stenosis, resulting in cervical radiculopathy, or degenerative cervical myelopathy, and were scheduled to undergo anterior discectomy with fusion surgery.
224038217|NCT01615380|BEHAVIORAL|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
224038218|NCT01615380|BEHAVIORAL|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
224038219|NCT03836807|DRUG|OKITASK®|A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
224038220|NCT03836807|OTHER|Placebo|A single oral dose of matching Placebo was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained Placebo. The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
224038221|NCT00365898|DRUG|Hydromorphone Hydrochloride Extended-Release|
224038222|NCT03629743|DEVICE|EEG|EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
224038223|NCT03629743|DEVICE|ECOG|ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
224038224|NCT02765880|OTHER|fMRI|Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.
223426152|NCT06298695|BEHAVIORAL|Individual Schema Therapy|"Schema therapy focuses on adapting maladaptive schemas (i.e., core representations of oneself, others or the world) and dysfunctional personality traits, while also incorporating exposure therapy. It consists of a maximum of 40 sessions within one year."
223426153|NCT06298695|OTHER|TAU|Treatment As Usual according to the Dutch Multidisciplinary Guidelines Anxiety Disorders and the Dutch Quality Standard for Anxiety Disorders. TAU often consists of a continuation of Cognitive Behavioral Therapy (CBT) and (different) medications, sometimes in a more treatment-intensive format. There are no restrictions to TAU, except that it may not be schema therapy. The actual content of TAU will be tracked.
224038225|NCT02765880|OTHER|EEG|link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
224038226|NCT02679339|DRUG|CNTX-2022 (lidocaine gel, 40%)|
224139101|NCT06051825|DIAGNOSTIC_TEST|Blood specimen collection for C-reactive protein (CRP) and WBC (white blood cells). Saliva specimen collection for analysis of CRP levels|Blood analysis of CRP and WBC levels Saliva analysis of CRP levels
223426154|NCT05186038|DIAGNOSTIC_TEST|iVYCHECK GIP Urine|To determine the presence of Gluten Immunogenic Peptides (GIP) in urine samples using the immunochromatographic test iVYCHECK GIP Urine (Biomedal S.L).
224139102|NCT03053726|PROCEDURE|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
224139103|NCT02433860|BEHAVIORAL|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately \> 36 weeks gestation or at delivery."
224139104|NCT06348953|OTHER|selective caries removal and conventional non-bioactive restorative system|conventional dental restorative adhesive and resin based composite
224139105|NCT06348953|OTHER|selective caries removal and bioactive restorative system|bioactive dental restorative resin based system
223426155|NCT05186038|DIAGNOSTIC_TEST|CeliacDetect|To determine the presence of IgA anti-tTG antibodies in blood samples using the immunochromatographic test CeliacDetect (Biomedal S.L).
223426156|NCT03470558|OTHER|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits before surgery and at 2, 6, and 12 months after surgery.
224038227|NCT02679339|DRUG|Placebo|
224038228|NCT01019291|OTHER|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
224038229|NCT01019291|OTHER|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
224038230|NCT02430051|BEHAVIORAL|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
224038231|NCT06027125|OTHER|Action observation Therapy|The patients in the AOT group will be required to observe the upper limb movements or functional actions in video clips and to execute what they had observed to the best of their ability.
224038232|NCT06027125|OTHER|Mirror Therapy|The patients will be seated in front of a mirror box placed at their midsagittal plane to perform the movements. The affected arm of the participants was placed inside of the mirror box, and the unaffected arm was infront ofthe mirror.
224038233|NCT04780490|OTHER|liberal fluid management|10 ml/ kg/ hr Ringer's lactate solution
224038234|NCT04780490|OTHER|restrictive fluid management|2 ml/ kg/ hr Ringer's lactate solution with 2 mcg / kg / hr norepinephrine infusion
224038235|NCT01272947|DRUG|Diclofenac sodium|Topical gel 1%- 4 times daily
224038236|NCT01272947|OTHER|Placebo|Topical gel - 4 times daily
224038237|NCT03045042|DRUG|Enzyme Replacement Agent|Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
224038238|NCT01961661|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10\^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month"
224038239|NCT01961661|DIETARY_SUPPLEMENT|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
224038240|NCT03272763|DEVICE|F&P Toffee mask|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
224038241|NCT05803304|BEHAVIORAL|PATH Intervention|The PATH intervention guides participants in making changes in their lifestyle and PA habits to support long-term adherence to the minimum threshold of PA Guidelines (150 MVPA minutes per week). The health coach provides participants with access the PATH website and a detailed orientation on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA by about 10 minutes per week. The PA prescription process begins by identifying a suitable PATH level for each participant. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week. The coach also guides participants to select activities with intensity to help them progress along the PA continuum (i.e., from inactive to light PA and then MVPA).
224038242|NCT05803304|BEHAVIORAL|Attention Control Intervention|"A health coach will have a zoom meeting with each control group participant where they will be provided with an electronic copy of the Be Active Your Way booklet, developed by the Centers for Disease Control and Prevention (CDC) to help individuals integrate PA into their daily lives. The coach will orient the participant to the key strategies used in the booklet and encouraged them to use it regularly and to self-monitor PA using the Fitbit during the entire course of the study. In addition, the group will be introduced to www.health.com, a jargon free website that focuses on general health topics and latest medical news. At the end of the meeting, the participants will be asked to provide a schedule for zoom meetings the study team twice per month during the 6 month study. The meetings will focus on their progress in using the Be Active Your Way handout and the health.com website."
224038243|NCT05803304|OTHER|Physical activity tracker|Participants will be asked to wear Fitbit Charge 5 on their non-dominant hand for the entire duration of the study using a 24hr wear protocol.
224038244|NCT05803304|BEHAVIORAL|Dietary education|Diet quality and barriers to healthy eating will be evaluated at baseline, and then all study participants will be provided with educational materials that are curated to promote diet quality. Participants will receive a monthly email with a brief PDF addressing a diet component focused on improving diet quality to reduce CVD risk and improve general health.
224038245|NCT04315987|BIOLOGICAL|NestaCell®|A dose of 2x10\^7 cells (20 million cells) will be administered IV on days 1, 3, 5 and 7 in all subjects.
224038246|NCT04315987|BIOLOGICAL|Placebo|Matching Placebo will be administered IV on days 1, 3, 5 and 7 in all subjects.
224038247|NCT04193878|DRUG|Inhaled budesonide and formoterol|aerosolized doses of budesonide (1.0 mg/2 ml) and formoterol (20 mg/2 ml) twice daily for up to 5 days
224038248|NCT04193878|DRUG|Inhaled placebo|aerosolized saline (4 ml of 0.9% saline) twice daily for up to 5 days
224038249|NCT04048265|DEVICE|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
224038250|NCT02019420|DRUG|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
224038251|NCT02019420|DRUG|Linezolid|Linezolid IV 600 mg twice daily
223426157|NCT04569968|OTHER|Expiratory muscle training|For training group first maximum expiratory pressure measurement will be assessed with portable expiratory measurement device. Measurement will be taken while the patient in a sitting position. Three measurement values with 5% variation will be taken an average of these values recorded as a maximum expiratory pressure of the patient. After the maximum expiratory pressure of the patient is measured 50% percent of the related value will be set on the expiratory muscle trainer. Then patient will be informed about how to use the trainer. Trainer will be used daily for four weeks with 50 repetitions. At the end of every week pressures will be measured again for re-calibration of the trainer.
224038252|NCT02510560|DRUG|NTRA-2112|
224038253|NCT02510560|DRUG|Placebo|
223744768|NCT00720057|DRUG|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
224038254|NCT02630732|BEHAVIORAL|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
224038255|NCT02630732|BEHAVIORAL|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
224038256|NCT05520541|OTHER|Exercise|Both groups will receive exercise-based training
224038257|NCT04978181|DRUG|Alteplase Injection|thrombolytic therapy for acute ischemic stroke in time window
224038258|NCT00132496|DRUG|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
223426158|NCT02370667|OTHER|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
223426159|NCT02370667|OTHER|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
223426160|NCT02370667|OTHER|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
223426161|NCT05884424|BEHAVIORAL|PARO Therapy Robot|"Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~1. Welcome and presentation.~2. Main activity with PARO.~3. PARO cleaning.~4. End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2)."
223426162|NCT04339803|OTHER|rehabilitation intervention|we use lower limb mirror therapy after stroke for two weeks
223426163|NCT00051441|DRUG|Benzydamine Hydrochloride 0.15% Oral Rinse|
223426164|NCT01023841|DRUG|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
223426165|NCT01023841|DRUG|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
223426166|NCT03347344|DRUG|Riluzole|50 mg will be administered (per os) twice a day
223426167|NCT03347344|DRUG|Placebo|50 mg will be administered (per os) twice a day
223426168|NCT05021289|BEHAVIORAL|guided imagery|guided imagery
223426169|NCT03518970|OTHER|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
223426170|NCT01447875|OTHER|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
223426171|NCT01447875|DRUG|propofol or mexmedetomidine|
223426172|NCT04647656|DEVICE|Hyperbaric oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
223426173|NCT04647656|DEVICE|Sham|Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
223426174|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
223426175|NCT00976209|DRUG|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
224038259|NCT05743504|DRUG|Tiragolumab|Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery
223426176|NCT02097797|OTHER|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
223426177|NCT02097797|OTHER|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
223426178|NCT03083431|DRUG|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg/d in 4 divided dosages)
223426179|NCT03083431|DRUG|Placebo|Oral solution containing the same excipients as propranolol solution
223426180|NCT00916968|DEVICE|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
224038260|NCT03645265|BEHAVIORAL|Auditory|Use of auditory cues to improve speech production
224038261|NCT03645265|BEHAVIORAL|Gestures|Use of gestures to improve speech production
223426181|NCT00916968|DEVICE|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
224139106|NCT02409056|BEHAVIORAL|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
223426182|NCT00250536|DRUG|nandrolone decanoate|
223426183|NCT00250536|BEHAVIORAL|resistance exercise training|
223426184|NCT01733043|DRUG|Dexmedetomidine|
223426185|NCT01733043|DRUG|Placebo|
223426186|NCT06730243|PROCEDURE|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"|"Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction"
223426187|NCT06730243|PROCEDURE|Standard Robot-Assisted Radical Prostatectomy|Standard Robot-Assisted Radical Prostatectomy
223744769|NCT02208856|DRUG|BIBR 796 BS|
224139107|NCT02409056|BEHAVIORAL|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
224139108|NCT04169685|PROCEDURE|bronchoscopy|during flexible bronchoscopy
224139109|NCT03342456|DRUG|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g\*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
223426188|NCT06730243|PROCEDURE|Laparoscopic Radical Prostatectomy|Laparoscopic Radical Prostatectomy
223426189|NCT03488849|DEVICE|SureCRIC|SureCRIC is intended to be used as an accessory to cricothyrotomy and tracheotomy devices, helping to identify and stabilize anatomical landmarks for establishing an airway.
223426190|NCT03488849|OTHER|Freehand|Freehand palpation approach to identification of the cricothyroid membrane
223426191|NCT02444975|DIETARY_SUPPLEMENT|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
223426192|NCT02444975|OTHER|Coaching program|Coaching program to support increased water intake
223426193|NCT02444975|OTHER|No intervention|No intervention
223426194|NCT03197870|DRUG|AKB-9778|Subcutaneous AKB-9778 15mg
223426195|NCT03197870|DRUG|Placebo|Subcutaneous Placebo
223426196|NCT05737017|DEVICE|ClearCoajet|The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure.
223426197|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
223426198|NCT00630084|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
223426199|NCT05542706|OTHER|Accompanying caregivers by paramedical team|At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.
224038262|NCT02780050|OTHER|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
223426200|NCT00832845|BEHAVIORAL|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 36 weeks.
223426201|NCT00832845|BEHAVIORAL|Treatment as usual (TAU)|Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
223426202|NCT05660005|OTHER|Muscle Stretching|Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.
223426203|NCT05660005|OTHER|Self Myofascial Release|The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).
223426204|NCT05660005|OTHER|home exercises|The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
223426205|NCT00819598|PROCEDURE|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
223426206|NCT00819598|PROCEDURE|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
224038263|NCT03059927|PROCEDURE|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith \& Nephew, Cruciate Retaining design
223426207|NCT03451097|RADIATION|echocardiography|cardiac ultrasound
223426208|NCT06444269|RADIATION|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
223426209|NCT06444269|DRUG|microbubble CEUS Contrast Enhanced Ultrasound (CEUS)|Microbubble Contrast non-FDA approved for route of administration
223426210|NCT00214149|RADIATION|brachytherapy|breast brachytherapy to 34 Gy
223426211|NCT00552981|PROCEDURE|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
223426212|NCT00552981|PROCEDURE|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
224038264|NCT03059927|PROCEDURE|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Anterior Stabilized design
224038265|NCT03059927|PROCEDURE|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith \& Nephew, Posterior Stabilized design
224038266|NCT00025454|DRUG|tipifarnib|
223426213|NCT01961895|PROCEDURE|Continuous lumbar plexus (LP) block analgesia|
223426214|NCT01961895|DRUG|Intravenous patient-controlled analgesia|
223426215|NCT02315495|DRUG|Saxagliptin|
223426216|NCT02315495|DRUG|Acarbose|
223426217|NCT01323010|DRUG|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (\> 15 to 20 kg), 1500 mcg (\> 20 to 25 kg) and 1800 mcg (\> 25 kg).
223426218|NCT01323010|DRUG|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (\> 25 kg)
223426219|NCT00978250|DRUG|5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.
223744770|NCT02208856|DRUG|Placebo|
224038267|NCT00197808|BIOLOGICAL|menjugate|men C conjugate vaccine
224038268|NCT00197808|BIOLOGICAL|Men C conjugate vaccine|men C conjugate vaccine
224038269|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
224038270|NCT00197808|BIOLOGICAL|Men C Conjugate|men C conjugate vaccine
224038271|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
224038272|NCT00197808|BIOLOGICAL|Men C conjugate|men C conjugate vaccine
224139110|NCT03342456|DRUG|Amoxicillin Capsules|group 2,0.5g\*24 capsules/box, produced by United Laboratories（Zhuhai）
223426220|NCT03826628|DRUG|rapamycin|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
223426221|NCT03826628|DRUG|placebo|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
224139111|NCT03342456|DRUG|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg\*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
223426222|NCT03973918|DRUG|Encorafenib|450mg QD 28 day cycle
223426223|NCT03973918|DRUG|Binimetinib|45mg BID 28 day cycle
223426224|NCT03973918|BIOLOGICAL|Research Bloods|Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
223426225|NCT03973918|BIOLOGICAL|Tumor Tissue|at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
223426226|NCT02357095|PROCEDURE|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
223426227|NCT01134679|BEHAVIORAL|Multi-disciplinary disease management approach|Follow up with phone calls
223426228|NCT01330394|DEVICE|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
223426229|NCT06668298|DRUG|Oliceridine|The formula for postoperative analgesia pump is oliceridine 0.4mg · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
223426230|NCT06668298|DRUG|Sulfentanil|The analgesic regimen for the sufentanil group is sufentanil 2 µ g · kg-1+tropisetron 10mg, mixed with physiological saline to 100ml.
223426231|NCT02951533|DRUG|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
223426232|NCT02951533|DRUG|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
223426233|NCT05335447|DRUG|GLPG3667 capsule|On Day 1, participants will receive a single oral dose of GLPG3667
223426234|NCT05335447|DRUG|[14C]-GLPG3667 solution for infusion|On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion
223744771|NCT02208856|OTHER|high fat standardized breakfast|
223744772|NCT02735551|DRUG|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
223744773|NCT02735551|OTHER|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
224038273|NCT02592512|OTHER|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
224038274|NCT02592512|OTHER|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
224038275|NCT02374398|DRUG|Tranexamic Acid|see arm/group descriptions
224038276|NCT02374398|DEVICE|Aquamantys System|see arm/group descriptions
224038277|NCT02374398|OTHER|Control|Standard Electro-cautery and Saline
224038278|NCT02238951|OTHER|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
224038279|NCT02238951|OTHER|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
224038280|NCT01093625|DEVICE|Narafilcon B Contact Lens|
224038281|NCT01093625|DEVICE|Spectacles|spectacle wearers
224038282|NCT04567667|DRUG|[14C] BMS-986278|Specified dose on specified days
224038283|NCT04567667|DRUG|Kinevac®|Specified dose on specified days
224038284|NCT04722250|DEVICE|Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems|TAVR treatment with Medtronic Evolut PRO, PRO+ System or Evolut FX System (where commercially available)
224139112|NCT03342456|DRUG|Furazolidone Tablets|group 1 and group 2,0.1g\*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
224139113|NCT03342456|DRUG|Potassium Citrate Tablets|group 1 and group 2,110mg\*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
223426235|NCT05335447|DRUG|[14C]-GLPG3667 capsule|On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667
223426236|NCT05174949|DEVICE|Transcranial direct current stimulation (high-definition)|"Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham"
223426237|NCT03141229|BEHAVIORAL|Mindfulness based stress reduction|
223426238|NCT02029989|DEVICE|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
223426239|NCT02029989|DEVICE|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
223426240|NCT02029989|DEVICE|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
223426241|NCT02029989|DEVICE|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
223426242|NCT02029989|DEVICE|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
223426243|NCT02029989|BEHAVIORAL|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
223426244|NCT04351373|DRUG|Fluorescein Sodium|Intravenous administration 1 mg/kg initial dosing if insufficient additional doses of 1 mg/kg may be administered.
223426245|NCT04351373|DEVICE|YELLOW560 filter|Integrated fluorescence module serves to make fluorescent areas visible to assist in visualizing tumor during the resection.
223426246|NCT05306782|DEVICE|transcranial Electrical Stimulation|transcranial Random Noise Stimulation, transcranial Direct Current Stimulation, or Sham are administered (by means of surface electrodes) on associative motor regions during speech therapy sessions (20 minutes, in the initial part of the sessions; 1.5 mA).
224038285|NCT04722250|DEVICE|Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems|TAVR treatment with Edwards SAPIEN 3 or SAPIEN 3 Ultra System
224038286|NCT00472173|DRUG|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
223426247|NCT05306782|BEHAVIORAL|Speech Therapy|Speech Therapy is associated to transcranial electrical stimulation or sham, during stimulation sessions. Total duration of the single session: 45 minutes
223426248|NCT03376451|OTHER|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
223426249|NCT03101826|BEHAVIORAL|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
223426250|NCT01075230|PROCEDURE|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
223426251|NCT01629810|DEVICE|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
223426252|NCT05685134|DEVICE|Radiofrequency catheter ablation|Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome
223426253|NCT05685134|DEVICE|Sham procedure|Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
223426254|NCT03581734|BIOLOGICAL|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
223426255|NCT03581734|BIOLOGICAL|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
224038287|NCT00472173|DRUG|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
224038288|NCT00437671|DRUG|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
224038289|NCT00437671|BIOLOGICAL|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
224038290|NCT03521414|DEVICE|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
224038291|NCT03521414|DRUG|Sevoflurane|we used sevoflurane drug at inoperative
224038292|NCT06330883|DIAGNOSTIC_TEST|Prognosis|survival/mortalite
224038293|NCT04549519|OTHER|No intervention|No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
224038294|NCT00573599|DRUG|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
224038295|NCT00573599|DRUG|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
224038296|NCT04853355|DRUG|Spironolactone 50 mg|Add Spironolactone 50 mg to previous regimen
224038297|NCT04263012|OTHER|collection of patient data|assess mortality rate, rehospitalization and survival rate of patients after receiving an artificial heart implant
224038298|NCT03769064|DRUG|Placebo|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
224038299|NCT03769064|DRUG|Methylphenidate 60 mg|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
224038300|NCT03769064|DRUG|Treatment Phase Sequence 4213|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
224038301|NCT03769064|DRUG|Treatment Phase Sequence 2134|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
223426256|NCT02683057|OTHER|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
223426257|NCT03091036|OTHER|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
223426258|NCT02683252|OTHER|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
223426259|NCT05855590|DRUG|Tranexamic acid|10mg/kg intravenous single dose
223426260|NCT05855590|OTHER|0.9% isotonic saline solution|100 ml intravenous single dose
223426261|NCT03338803|DRUG|Linagliptin|drug
223426262|NCT01528397|PROCEDURE|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
223426263|NCT06630078|DEVICE|Wevosys acoustic analysis|Recording of voice signal of subjects enrolled
223426264|NCT06619301|DRUG|Insulin glargine|Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.
223426265|NCT06619301|DRUG|insulin NPH|Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
223426266|NCT05970770|DEVICE|Hypotension Prediction Index|in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA; internal memory 60 gigabyte, 10 gigabyte used for operating system) with ClearSight non-invasive hemodynamic monitoring and with the Hypotension Prediction Index software enabled. They will not receive preventive vasopressors but only norepinephrine boluses if Hypotension Prediction Index \>85
223426267|NCT05970770|DRUG|Norepinephrine|Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
223426268|NCT02071810|DRUG|BIA 9-1067|
223426269|NCT02071810|DRUG|Placebo|
223564316|NCT06987604|DEVICE|Conventional-dose continuous renal replacement therapy|Continuous renal replacement therapy administered at an effluent dose of 25-35 mL/kg/h using standard equipment and protocols for critically ill patients with ALF or ACLF and hyperammonemia.
223426270|NCT06523075|OTHER|Tumor Necrosis Factor|This study is a retrospective observational study, with Tumor Necrosis Factor being one of the exposure factors under investigation.
223426271|NCT06523075|OTHER|Interleukin-1β|This study is a retrospective observational study, with Interleukin-1β being one of the exposure factors under investigation.
223426272|NCT06523075|OTHER|Interleukin-12|This study is a retrospective observational study, with Interleukin-12 being one of the exposure factors under investigation.
223426273|NCT06523075|OTHER|Interleukin-18|This study is a retrospective observational study, with Interleukin-18 being one of the exposure factors under investigation.
223426274|NCT06523075|OTHER|Complement C3|This study is a retrospective observational study, with Complement C3 being one of the exposure factors under investigation.
223426275|NCT06523075|OTHER|Complement C5|This study is a retrospective observational study, with Complement C5 being one of the exposure factors under investigation.
223426276|NCT03069261|DEVICE|Indocyanine green angiography|
223426277|NCT03867487|DRUG|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
223564317|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility, plus specific training of the inspiratory muscles, 3 times a week, at a load between 50 and 80% of the maximum inspiratory pressure of each participant, after re-education of their diaphragmatic ventilation.
224139114|NCT03678376|OTHER|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
223564318|NCT06611969|PROCEDURE|Exercise|The training programme will consist of 5 weekly sessions of aerobic work, strength and mobility.
224139115|NCT00129792|DRUG|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
223426278|NCT03867487|DRUG|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
223426279|NCT02958280|BEHAVIORAL|Fit&Sober App|Fit\&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
223426280|NCT02958280|BEHAVIORAL|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
223426281|NCT03724877|DRUG|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
223426282|NCT03724877|DRUG|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
223744774|NCT02735551|OTHER|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
223564319|NCT06608134|BIOLOGICAL|Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection|Direct injection of biologic into the knee joint.
223564320|NCT06857214|DRUG|GNC-038|Administration by intravenous infusion. Once a week (IV, QW), twice in total.
223744775|NCT04222569|PROCEDURE|T-piece|Spontaneous breath trial with a T-piece
224038302|NCT03769064|DRUG|Treatment Phase Sequence 1342|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
224038303|NCT03769064|DRUG|Treatment Phase Sequence 3421|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
223426285|NCT02438605|DEVICE|Nellix|
223426286|NCT04323033|DEVICE|PERS stent|"PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1)."
223426287|NCT04323033|DEVICE|NEPTUN C stent|Neptun C is balloon-expanding cobalt-chromium stent.
223426288|NCT00742508|DRUG|SK&F-105517-D 10 mg capsule|1 capsule once a day
223426289|NCT00742508|DRUG|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
223426290|NCT00742508|DRUG|SK&F-105517-D 20 mg capsule|1 capsule once a day
223426291|NCT00742508|DRUG|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
223426292|NCT00742508|DRUG|Carvedilol-IR 10 mg tablet|1 tablet twice a day
223426293|NCT03633149|BEHAVIORAL|Computer tablet-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
224038304|NCT00533026|DRUG|Duloxetine|
224038305|NCT00533026|DRUG|Warfarin|
224038306|NCT00148265|DRUG|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
224038307|NCT05426642|OTHER|E-health Video KaSEH|The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
224038308|NCT05426642|OTHER|Brochure|The brochure contain the information regarding cervical cancer and its screening
223426294|NCT03633149|BEHAVIORAL|Person-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
223426295|NCT03633149|BEHAVIORAL|Brief Advice|Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
224038309|NCT04394481|DRUG|Dexmedetomidine|IV injection (1 µg/kg - 100 mL) before anesthetic induction
224038310|NCT04394481|DRUG|Ropivacaine|Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)
223426296|NCT06667934|DRUG|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night|Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
223426297|NCT06667934|DRUG|Methalazine suppository was given rectally once a day|Methalazine suppository was given rectally once a day
224038311|NCT04394481|DRUG|Dexamethasone|IV injection (0.15 mg/kg) during anesthetic induction
223426298|NCT03376256|DEVICE|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
223426299|NCT02229175|DRUG|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
223426300|NCT02229175|DEVICE|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
223426301|NCT01850147|DRUG|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
224038312|NCT06085027|PROCEDURE|Labor analgesia|Perform epidrual analgesia for parturients between 18 to 45 year-old
224038313|NCT01069250|OTHER|There are no interventions in this study|
224038314|NCT00555490|DIETARY_SUPPLEMENT|Soy protein|35 % of protein from soy protein for 4-years
224038315|NCT05436535|BIOLOGICAL|Dupilumab|Adult dupilumab-naïve topical steroid non-responder (EASI \>7) participants beginning treatment with dupilumab will initially receive a loading dose of two 300 mg subcutaneous injections. The two injections will be administered at different sites in the abdomen, thighs, or upper arms. Pediatric dupilumab-naïve topical steroid non-responder participants beginning treatment with dupilumab will receive a loading dose, according to their weight. Dupilumab-naïve topical steroid non-responsive participants will continue use of dupilumab on a schedule determined by their age and weight until their penultimate scheduled visit (Day 140-196).
223426302|NCT00438737|BIOLOGICAL|bevacizumab|
223426303|NCT00438737|BIOLOGICAL|cetuximab|
223426304|NCT00438737|DRUG|fluorouracil|
223426305|NCT00438737|DRUG|leucovorin calcium|
223426306|NCT00438737|DRUG|oxaliplatin|
223426307|NCT00438737|PROCEDURE|adjuvant therapy|
223426308|NCT00438737|PROCEDURE|conventional surgery|
223426309|NCT00438737|PROCEDURE|neoadjuvant therapy|
223426310|NCT04696354|DIAGNOSTIC_TEST|IVUS|Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.
224038316|NCT05436535|DRUG|Vanicream- Dupilumab-naïve|Dupilumab-naïve AD participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at their penultimate visit (Day 140-196) through the End of Study Assessment.
224139116|NCT00129792|BEHAVIORAL|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
224163667|NCT06085703|DRUG|Gliclazide|Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
224163668|NCT03482362|DRUG|Vinorelbine Tartrate|Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
224038317|NCT05436535|DRUG|Triamcinolone Acetonide|"On Day 7, all dupilumab-naïve AD participants will begin applying triamcinolone 0.1% ointment (provided by the study) twice daily to the specified target area. Additionally, dupilumab-naïve AD participants will apply triamcinolone 0.1% ointment twice daily to active lesions on non-sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply triamcinolone 0.1% ointment (provided by the study) once or twice daily, per clinician discretion, to the specified target area. Additionally, participants will apply triamcinolone 0.1% ointment once or twice daily, per clinician discretion, to active lesions on non-sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply triamcinolone 0.1% ointment as needed to active lesions on non-sensitive, non-target skin."
223426311|NCT04696354|OTHER|Continued Compression Therapy/Stockings|Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
223426312|NCT04647396|OTHER|"Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)"|"Implementation of the KDIGO bundle for at least 12 hours~1. discontinuation of all nephrotoxic drugs when possible~2. optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring)~3. close monitoring of serum creatinine, fluid balance and urinary output~4. avoidance of hyperglycemia~5. considerations of alternatives to radiocontrast agents~6. discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~7. avoidance of HES, gelatin, and chlorid-rich solutions"
223426313|NCT03734302|DRUG|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
224038318|NCT05436535|DRUG|Hydrocortisone|"On Day 7, all dupilumab-naïve AD participants will apply hydrocortisone 2.5% ointment twice daily to active lesions on sensitive, non-target skin.~Between Day 35 and Day 140, dupilumab-naïve AD topical steroid responsive (EASI ≤ 7) participants will apply hydrocortisone 2.5% ointment once or twice daily, per clinician discretion, to active lesions on sensitive skin body wide.~Between Day 35 and Day 140, dupilumab-naïve topical steroid non-responder (EASI \>7) participants may apply hydrocortisone 2.5% ointment as needed to active lesions on sensitive, non-target skin."
223426314|NCT01081444|DEVICE|rTMS|effective and active cortical magnetic stimulations
223426315|NCT01081444|DEVICE|Placebo rTMS|non active cortical magnetic stimulation
223426316|NCT00381732|DRUG|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
223426317|NCT00381732|DRUG|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
223426318|NCT06619808|PROCEDURE|Hyperbaric oxygen therapy|Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).
223426319|NCT03565042|PROCEDURE|Arthroscopy|Arthroscopy of swollen joint (ankle/knee)
223426320|NCT06256692|OTHER|Pulse oximeter|No real intervention, but all study participants will have an additional pulse oximeter attached, to measure oxygen saturation.
223426321|NCT05140629|OTHER|Baobab fruit aqueous extract|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
223426322|NCT05140629|OTHER|Placebo OGTT|After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water. Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
223426323|NCT04684628|DRUG|68Ga-PSMA PET/CT|Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
223426324|NCT06585527|BIOLOGICAL|TS-2021|The participants meeting the criteria will undergo TS-2021 oncolytic virus (5×1011PFU/ml) intratumoral injection using stereotactic technique under MR Localization.
224038319|NCT05436535|DRUG|Vanicream- Active|Non-AD control participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
224038320|NCT05436535|DRUG|Vanicream- Experienced Dupilumab|Long-term dupilumab participants will apply Vanicream at least twice daily to the specified target skin area over two time periods during the study. First, they will apply starting at Day 0 through Day 7. They will resume application starting at Day 140 through the End of Study Assessment Visit.
224038321|NCT02472379|BEHAVIORAL|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
224038322|NCT02472379|OTHER|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
223426325|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood sample collection|Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
223564321|NCT06857214|DRUG|Placebo|The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
224038323|NCT03234166|OTHER|Non interventional study|Only data will be taken of patient's file.
224038324|NCT02307864|DRUG|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
224163669|NCT04935567|OTHER|Statistical model for the prediction of VNS efficacy|statistical model for the prediction of VNS efficacy based on a mathematical and statistical analysis of scalp EEG data
224163670|NCT04574869|DRUG|RLS-0071 10 mg/kg|Single dose IV infusion of 10 mg/kg RLS-0071
224163671|NCT04574869|DRUG|RLS-0071 40 mg/kg|Single dose IV infusion of 40 mg/kg RLS-0071
223426326|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood draw|Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
223426327|NCT06667063|OTHER|Nasal swab/Nasopharyngeal swab/Blood draw|Visit 1/2/3：Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing
223426328|NCT06348433|OTHER|Ketogenic diet|Ketogenic diet is a formula diet with high fat, low carbohydrate, proper amount of protein and other nutrients.
223426329|NCT04982211|DRUG|Propranolol|Oral propranolol hydrochloride capsules, dosed per participant weight
223426330|NCT04982211|DRUG|Placebo|Oral placebo capsules, dosed per participant weight
223426331|NCT06451562|DRUG|Lidocaine|a local anesthetic drug of the amino amide type
223426332|NCT05837104|DRUG|Magnesium vitamin B6|Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
223426333|NCT05837104|DRUG|Placebo|Placebo tablet, three times daily for four weeks.
223426334|NCT00900549|DEVICE|CRT on|12 months
224038325|NCT02307864|DRUG|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
224038326|NCT02307864|DRUG|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
224038327|NCT02307864|DRUG|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
224038328|NCT01431534|DRUG|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
224139117|NCT03746808|BEHAVIORAL|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
223426335|NCT00900549|DEVICE|CRT off|12-month
223426336|NCT06934174|BEHAVIORAL|WeSafe (myPlan Thailand: Friends and Family)|WeSafe, a Web-Based App (myPlan Thailand) is a culturally tailored web-based app designed to empower and support friends and family of IPV survivors. It gathers key data on survivors' demographics, relationship status, living situation, and children's ages to personalize the safety support plan. The app delivers comprehensive IPV information through text, videos, images, and illustrations, addressing culturally specific issues. It guides users in setting priorities through pairwise comparisons and includes a risk assessment tool adapted from Danger Assessment (DA)-Thailand. Based on the inputs, myPlan Thailand provides a tailored plan with supportive strategies, communication scripts, advocacy tips, self-care resources, and child safety strategies, enhancing overall safety and well-being.
223426337|NCT06934174|BEHAVIORAL|DV learning|Control group. The control condition will be the publicly-available Thai-language DV learning launched in 2019.49 This app screens users for Domestic violence (physical, psychological, and sexual violence), and provides information about 6 modules include 1. Understanding situation of domestic violence 2. Key principles of helping survivors 3. Guideline for helping survivors 4. Case management and working with multi professionals 5. Legal Proceedings and Justice System Processes for Domestic Violence and Intimate Partner Violence Cases 6. Selfcare for providers. This platform put the knowledge from understanding the basic situation through practical intervention for providers and other people who are interested in. It is optional to get the certificate if participants have 80% pass rate on quizzes.
223426338|NCT05629494|DRUG|Ibuprofen 400 mg, TID|Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.
223426339|NCT05629494|DIAGNOSTIC_TEST|PSA test|PSA test will be repeated in 6 weeks
223426340|NCT05203848|PROCEDURE|Community Dance Intervention|The main dance instructor for the CDP is Yarra Ileto, who is the Artistic Director for NUS Dance Synergy. Yarra was trained at LASALLE College of the Arts, graduating with a First Class BA (Hons) Dance in 2008. Also, she has experience with crafting and conducting Community Dance Programs (CDP) for Seniors. Yarra will be developing the dance lesson plan and also training selected students from NUS Dance Synergy to guide the seniors during the dance sessions. Older adults will learn and practice the basic steps together for the first few weeks. Then, the student dance instructors will start teaching the dance formation. During each session, participants will need to warm up first to prevent injuries before practicing dance steps. Small group practicing is reserved for older adults to interact with each other. All the participants will do relaxation exercises before ending the session to cool down their bodies and release muscle tensions.
223426341|NCT05203848|OTHER|Control group|Control group
223426342|NCT05117554|DRUG|casdatifan|Capsule
223426343|NCT05117554|DRUG|Placebo|Capsule
223426344|NCT05117554|DRUG|Midazolam|Syrup solution
223426345|NCT06453876|DEVICE|Ultrasound assisted Thrombolysis|Please see Arms
223426346|NCT06453876|DEVICE|Percutaneous Embolectomy|Please see arms
223426347|NCT06453876|DRUG|Heparin|Active comparator
224038329|NCT03595839|PROCEDURE|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
224038330|NCT03595839|PROCEDURE|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
223426348|NCT00514826|OTHER|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
223426349|NCT04829110|OTHER|ETOH|Participants will consume Vodka
223426350|NCT04829110|OTHER|Sucrose|Participants will consume sucrose in solution with water
224038331|NCT06154213|BEHAVIORAL|Building Habits Together|"Private, hidden Facebook group Building Habits Together includes 24 weeks on content based on the Diabetes Prevention Program and the Habit app."
224038332|NCT06154213|BEHAVIORAL|Getting Healthy Together|"Private, hidden Facebook group Getting Healthy Together includes 24 weeks on content based on the Diabetes Prevention Program and the MyFitnessPal app."
224038333|NCT06497127|DRUG|BW-00112|BW-00112 or volume-matched placebo on Day 1 and Day 90
224038334|NCT05267860|DEVICE|Prophylactic Drain|We want to put a prophylactic drain after cholecystectomy.
224139118|NCT00830115|DRUG|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
224139119|NCT00139607|DRUG|Paracoxib|
223426351|NCT02715700|DRUG|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
223426352|NCT02715700|DRUG|Doravirine|Doravirine 100 mg oral tablet once per day.
223426353|NCT06405789|OTHER|yoga practice|The researcher has a yoga certificate before the study. The intervention group participated in 15 weeks of yoga/awareness activities led by the researcher. The yoga curriculum for the use of yoga in the classroom had been previously studied with nursing students and permission was obtained for its use in this study \[11\]. The course content consists of 1.5 hours/per week (theoretical: 30 minutes; practical: 60 minutes) Each yoga session includes 5 minutes of breathing (pranayama) and warming up, 40 minutes of postures (asanas), 5 minutes of breathing (pranayama), 5 minutes of corpse pose (shavasana).In addition, to develop mindfulness, after the class, students were offered daily practices that enable a mindfulness-based approach to life events. The students participated in activities such as yoga practice, breathing and relaxation exercises, meditation practices with instructor notes and resources.
223426354|NCT02263248|DRUG|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
223426355|NCT02263248|DRUG|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
223426356|NCT02263248|DRUG|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
223564322|NCT06606522|DIAGNOSTIC_TEST|Clinical model|Clinical model: a clinical model based on basic demorgraphic information and commonly executed laboratory tests to differentiate different pathological types of intrinsic AKD.
223564323|NCT06606522|DIAGNOSTIC_TEST|Urinary biomarkers|Urinary biomarkers: biomarkers help differentiate different pathological types of intrinsic AKD.
223564324|NCT06861010|OTHER|Placebo|Placebo tablets will have the same look and appearance of ondansetron.
223564325|NCT06861010|DRUG|Ondansetron|ondansetron is commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea
224038335|NCT02981654|DEVICE|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
224038336|NCT02737839|OTHER|Stepping On Education Program|
224038337|NCT02737839|OTHER|Home visit|
224038338|NCT02737839|OTHER|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
224038339|NCT02737839|OTHER|Mini-Balance Evaluation Systems Test|"* The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~* Balance testing will take approximately 15 minutes."
223426357|NCT06066697|BEHAVIORAL|SOVA Ambassador|"The SOVA Ambassador intervention includes:~adolescents will have access to the website specifically for adolescents: sova.pitt.edu These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion.~Participants that receive this intervention will contribute monthly articles and regular comments."
223426358|NCT06066697|BEHAVIORAL|Self-Reflection|Participant will be given an article from the sova.pitt.edu website and a prompt to write about privately.
223426359|NCT06356480|BIOLOGICAL|1% Acetic acid dressing|1% acetic acid dressing in chronic diabetic foot and wounds to see early epithelialization and later on graft application.
223426360|NCT03014128|OTHER|Clinical examination and data processing of questionnaires|xy
223426361|NCT04857814|DEVICE|ADAMM- RSM Device|All participants will wear the ADAMM- RSM device for a 6 month period
223426362|NCT05536895|DIAGNOSTIC_TEST|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
223426363|NCT05536895|DIAGNOSTIC_TEST|Multi-detector Computed Tomography|Conventional, standard of care perfusion imaging for AIS
223426364|NCT02730377|DRUG|liraglutide|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223426365|NCT02730377|DRUG|alpha-glucosidase inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223426366|NCT02730377|DRUG|DPP-4 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223426367|NCT02730377|DRUG|meglitinides|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223426368|NCT02730377|DRUG|SGLT-2 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223426369|NCT02730377|DRUG|sulphonylurea|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223426370|NCT02730377|DRUG|thiazolidinediones|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
223564326|NCT06865768|DRUG|Flotufolastat F-18 Gallium|Given IV
223564327|NCT06865768|PROCEDURE|Magnetic Resonance Imaging|Undergo TRUS-MR fusion biopsy
224139120|NCT01861145|DEVICE|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
224163672|NCT04574869|DRUG|Placebo|The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
223426371|NCT06292585|PROCEDURE|MMA embolization plus medical therapy|Patients assigned to the intervention group will receive endovascular embolization treatment within 2 hours after enrollment. Patients will receive the best conservative treatment recommended by the guidelines after MMA, and conservative treatment will be the same in both groups
223426372|NCT06292585|DRUG|Medical therapy alone|Patients will receive the best conservative treatment recommended by the guidelines, and conservative treatment will be the same in both groups. Conservative treatment includes medication and general treatment. Drug therapy can be divided into hemostatic treatment, antihypertensive treatment, and symptomatic treatment. Specific local clinical diagnosis and treatment standards shall prevail or refer to corresponding clinical guidelines.
223426373|NCT01701297|DRUG|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
223426374|NCT01701297|DRUG|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
223426375|NCT01701297|DRUG|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
223426376|NCT04439305|DRUG|Dasatinib|Given PO
223426377|NCT00860041|BEHAVIORAL|pain questionnaires|
223426378|NCT01069237|DEVICE|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
223426379|NCT01069237|DEVICE|Clear Care|Lens Care Solution for contact lenses
223426380|NCT06022042|DEVICE|On1 two-stage abutment and one-stage abutment|the On1 two-stage abutment has a smooth collar with a height of 1.75-2.5mm, and the Nobel implants have a smooth neck design ranging from 0-0.75mm to protect the connective tissue around the implant.
223426381|NCT05563012|DRUG|Sintilimal Injection|Sintilimal (200mg) will be given i.v. on day 1 of each 3-week cycle.
223426382|NCT05654090|DRUG|cefoperazone sodium and sulbactam sodium|Pharmacokinetic study under fasting conditions
223426383|NCT00302484|DRUG|Zoledronate|
224038340|NCT02737839|OTHER|GAITRite|"* Gait will be assessed using the 4.87-m GAITRite~* The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
224038341|NCT02737839|OTHER|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up \& Go, 3) Dual Timed Up \& Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
224038342|NCT01068353|BIOLOGICAL|Etanercept|50 mg given as a once weekly subcutaneous injection
223426384|NCT00697541|DRUG|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
223426385|NCT00697541|DRUG|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
223426386|NCT00697541|DRUG|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
223426387|NCT00697541|DRUG|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
223426388|NCT00005768|DRUG|Estrogen|
223426389|NCT04045132|BEHAVIORAL|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
223426390|NCT04045132|BEHAVIORAL|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
223426391|NCT03180658|PROCEDURE|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
223564328|NCT06865768|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
224038343|NCT01068353|OTHER|Placebo|Placebo injection given once weekly
223426392|NCT03180658|PROCEDURE|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
223426393|NCT05809024|DRUG|letrozole|Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
223426394|NCT04463056|BIOLOGICAL|Elizaria®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
223426395|NCT04463056|BIOLOGICAL|Soliris®|Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
223426396|NCT03796442|DEVICE|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
224038344|NCT03251196|OTHER|No Intervention, and Observational Study|Observational Study
223426397|NCT03796442|DEVICE|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
223426398|NCT05487287|DEVICE|Kinematic computational analysis of the hand (Leap Motion device)|"Kinematic computational analysis exercises:~1. Finger extension~2. Wrist extension~3. Finger separation~4. Finger clamp"
224038345|NCT00182351|PROCEDURE|D-dimer|
224038346|NCT00182351|PROCEDURE|Serial Compression Ultrasound|
224038347|NCT03502954|BIOLOGICAL|ABY-039|ABY-039
224038348|NCT03502954|BIOLOGICAL|Placebo|Placebo
224038349|NCT00911794|OTHER|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
224038350|NCT00911794|OTHER|Neutral (Sham) Writing|Patients write about neutral subjects
224038351|NCT06044402|OTHER|group L (Vt 6 ml/kg)|low tidal volume ventilation (tidal volume was set to 6 ml/kg)
223426399|NCT04995653|DRUG|Vancomycin Pre-Treatment|Four times daily dosing with Vancomycin
224038352|NCT06044402|OTHER|group I (Vt 8 ml/kg)|intermediate tidal volume ventilation (tidal volume was set to 8 ml/kg)
224038353|NCT01009554|DEVICE|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
223426400|NCT04995653|DRUG|Vancomycin Placebo|Four times daily dosing with Vancomycin Placebo
223426401|NCT04995653|DRUG|SER-155|Once daily dosing with SER-155
223564329|NCT06865768|PROCEDURE|Positron Emission Tomography|Undergo PET
224038354|NCT01009554|DRUG|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
224038355|NCT01492530|BEHAVIORAL|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
224038356|NCT01492530|BEHAVIORAL|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
224038357|NCT03753633|OTHER|Speech therapy|Oropharyngeal exercises will be performed under the supervision of a speech therapist.
224038358|NCT03753633|OTHER|Control|Inspiratory and expiratory exercises recruiting diaphragmatic muscles
223426402|NCT04995653|DRUG|SER-155 Placebo|Once daily dosing with SER-155 placebo
223426403|NCT05096260|BEHAVIORAL|Motivational Interviewing based SMS/MMS and web content|Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
223426404|NCT02607852|DEVICE|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
223426405|NCT01552148|OTHER|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
223426406|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
223426407|NCT01552148|DRUG|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
223426408|NCT04142320|DEVICE|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
223426409|NCT04142320|DEVICE|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
223426410|NCT04142320|DEVICE|sham rTMS|Delivers placebo magnetic stimulation
223426411|NCT02143791|PROCEDURE|Burst and Tonic stimulation|
223564330|NCT06865768|PROCEDURE|Transrectal Ultrasonography Guided Biopsy|Undergo TRUS-MR fusion biopsy
224038359|NCT00186641|PROCEDURE|high dose chemo and auto hematopoietic cell transplant|
224038360|NCT01605253|DRUG|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
224038361|NCT01605253|DRUG|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
224038362|NCT04258436|PROCEDURE|Serratus anterior block|Serratus anterior block will be performed using an ultrasound guided transducer to inject 2mg/kg of 0.2% ropivacaine
224038363|NCT05100485|DIAGNOSTIC_TEST|Esophagogasrtoduodendoscopy|Esophagogasrtoduodendoscopy was used to detech the presence of varices.
224038364|NCT05100485|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|A method used to eveluate the portal pressure
224038365|NCT02032303|PROCEDURE|Assessment of coronary flow reserve|
224038366|NCT02032303|PROCEDURE|Percutaneous Coronary Intervention|
224038367|NCT02032303|DRUG|Ticagrelor loading|
224038368|NCT02032303|DRUG|Prasugrel loading|
224163673|NCT04574869|DRUG|RLS-0071 10 mg/kg|Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
223426412|NCT06623760|DEVICE|Desk and chair adaptation interventions|Adjustment of the height of tables and chairs to the height of each pupil in accordance with Functional sizes and technical requirements of chairs and tables for educational institutions (GB/T 3976--2014）, with a duration of intervention of one year。
223426413|NCT05768191|DRUG|premix insulin human isophane suspension and insulin human|Sequence (Premix first, then Humulin N + Humulin R): Subjects randomized to this sequence will receive premix insulin, twice per day for 16 weeks. After the first 16 weeks, subjects will cross over to the Humulin N plus Humulin R sequence for a further treatment of 16 weeks
223426414|NCT05768191|DRUG|Humulin N plus Humulin R|Sequence (Humulin N + Humulin R first, then Premix): Subjects randomized to this sequence will receive basal bolus insulin scheme with Humulin N (twice daily) and Humulin R (before meals) for 16 weeks. After the first 16 weeks, subjects will cross over to the Premix sequence for a further treatment of 16 weeks
223426415|NCT00401544|DRUG|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
223426416|NCT00401544|DRUG|IV iron dextran|Administered by intravenous (IV) injection.
223426417|NCT02564445|BEHAVIORAL|Gamification|All participants will be entered with their teammate into a game that includes points and levels
223426418|NCT02564445|BEHAVIORAL|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
223426419|NCT02564445|BEHAVIORAL|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
223426420|NCT02564445|BEHAVIORAL|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
223426421|NCT01429064|DRUG|ODM-201|ODM-201 administered orally daily
223564331|NCT07009418|DIAGNOSTIC_TEST|Coronary CT Angiography (CCTA)|In the surveillance by CCTA group, patients will be evaluated by CCTA at 1 year from index hospitalization. CCTA will be done according to current acquisition guidelines. Downstream management according to the results from CCTA will be performed under recommendations from current guidelines.
223564332|NCT06504329|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT) + Subepithelial Connective Tissue Graft (SCTG)|The modified coronally advanced tunnel (MCAT) technique is performed to prepare a recipient site. A subepithelial connective tissue graft (SCTG), harvested from the palate, is inserted into the tunnel using guiding sutures and stabilized. The flap is advanced coronally to completely cover the graft and achieve primary closure.
223564333|NCT06504329|PROCEDURE|Modified Coronally Advanced Tunnel (MCAT) + Enamel Matrix Derivative (EMD)|This intervention involves the application of enamel matrix derivative (EMD; Emdogain, 0.15 ml gel form) in conjunction with the modified coronally advanced tunnel (MCAT) technique. Following tunnel preparation, EMD is applied to the exposed root surface to enhance periodontal tissue regeneration.
223564334|NCT07011654|DRUG|Sacituzumab govitecan|Given by IV
223564335|NCT07011654|DRUG|Naxitamab|Given by IV
223564336|NCT07012772|DEVICE|The COMBO Endoscopy Oropharyngeal Airway|Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.
223564337|NCT07012954|DRUG|Cetuximab (Erbitux, C225)|cetuximab 500 mg/m² repeated every two weeks.
223564338|NCT07012954|DRUG|trifluridine/tipiracil|Trifluridine/tipiracil 35 mg/m² (orally for 5 days, followed by 9 days off)
223564339|NCT07012954|DRUG|Bevacizumab ( Avastin)|bevacizumab 5 mg/kg
223426422|NCT06057714|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
223426423|NCT02847923|OTHER|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
223426424|NCT02847923|OTHER|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
223426425|NCT02847923|OTHER|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
223426426|NCT02847923|OTHER|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
223426427|NCT03359330|OTHER|Degradable Conduit Small Gap Tublization|Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
223426428|NCT05561907|PROCEDURE|Surgical gastrojejunostomy (SGJ)|Laparoscopic gastrojejunostomy
223426429|NCT05561907|PROCEDURE|Endoscopic gastrojejunostomy (EGJ)|Endoscopic ultrasound (EUS) guided gastrojejunostomy
223564340|NCT07016386|PROCEDURE|Group A: will receive an ultrasound-guided interscalene block (ISB)|Group A: will receive an ultrasound-guided interscalene block (ISB) using a 15ml mixture of lidocaine (7.5ml 2%) and bupivacaine (7.5ml 0.5%).
223564341|NCT07016386|PROCEDURE|Group B:will receive an ultrasound-guided infraspinatus-teres minor (ITM) interfacial plane block|Group B:will receive an ultrasound-guided infraspinatus-teres minor (ITM) interfacial plane block using a 15ml mixture of lidocaine (7.5ml 2%) and bupivacaine (7.5ml 0.5%).
223564342|NCT03111550|DEVICE|Investigational Intraocular Lens Device #1: TECNIS Model ZHR00|Intraocular lens replaces the natural lens removed during cataract surgery.
223426430|NCT06282224|DEVICE|Performing endoscopic transnasal skull base surgery with AR-integrated endoscope|To explore how to use augmented reality technology (AR) to highlight important anatomical structures in the neuroendoscopic field of view, optimize the endoscopic surgical field of view, make up for the shortage of simple endoscopic field of view, make it easier for surgeons to distinguish deep anatomical structures, and reduce the intraoperative and postoperative complications of transnasal endoscopic surgery.
223426431|NCT04623879|DRUG|Lumacaftor, Ivacaftor Drug Combination|
223426432|NCT04306159|PROCEDURE|Subcostal TAP|Subcostal transversus abdominis plane block
223426433|NCT04306159|PROCEDURE|Modified RSB|Rectus Sheath Block under the guidance of surgical incision
223426434|NCT04306159|OTHER|General anesthesia|Traditional general anesthesia management
223426435|NCT02856607|OTHER|determine the prognosis of threated patients according to the clinical care pathway.|
223426436|NCT00401713|PROCEDURE|Transplantation of autologous RPE|RPE cell suspension
224038369|NCT01210989|DRUG|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
224038370|NCT01210989|DRUG|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
224038371|NCT01405937|DRUG|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
224038372|NCT01405937|BIOLOGICAL|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
224038373|NCT01405937|DRUG|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
224038374|NCT02554903|DRUG|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
224038375|NCT02554903|DRUG|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
224038376|NCT05803590|DRUG|Green tea mouthwash|effictive against caries and periodontal diseases
224038377|NCT05803590|DRUG|Chlorhexidine mouthwash|the gold standard against which other anti-plaque and gingivitis agents are measured
224038378|NCT03537950|DRUG|PLC|Single oral dose of PLC.
224038379|NCT03537950|DRUG|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
224038380|NCT03537950|DRUG|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
224038381|NCT01764048|DRUG|Fix protocol|Please see arm description
224038382|NCT01764048|DRUG|medications following demand protocol|Please see arm description
224038383|NCT05679856|RADIATION|Hypofractionated single vocal cord irradiation|Only the affected vocal cord with additional margin to account for motion and setup errors will receive 58.08Gy/16 fractions using IMRT/VMAT technique
224038384|NCT05679856|RADIATION|Whole laryngeal radiotherapy|The whole larynx from lower border of hyoid bone to lower border of cricoid cartilage will receive 63Gy/28 fractions using IMRT/VMAT technique
224038385|NCT04527120|OTHER|indigenously developed ultrasound phantom (IDUP)|Ultrasound phantom model developed in the department of Emergency Medicine of Jubilee Mission Medical College, to train vascular access.
224038386|NCT00243750|DRUG|Methotrexate|
224038387|NCT04888520|DEVICE|Adhesive elastic bandage|"The base of the tape should be applied 5 cm below the origin of the rectus femoris (lower anterior iliac spine), going towards its insertion (base of the patella, through supra-patellar ligament), without tension in this part of the tape (2 to 3 cm initial) in order to avoid discomfort. The application mode will be in I (I-strip). The participants will be in the supine position, with the hip flexed at 30° and the knee flexed at 60°. The applications of the tape will be carried out every Monday, before the first day of running training of the week and should remain until Friday, when it will be removed by the researcher after the last day of running training of the week. If the elastic bandage unstuck alone from the skin before this period, the event should be immediately reported to the therapist."
223426437|NCT00401713|PROCEDURE|Translocation of autologous RPE and Choroid|RPE patch
223564343|NCT03111550|DEVICE|Investigational Intraocular Lens Device #2: TECNIS Model ZQR00|Intraocular lens replaces the natural lens removed during cataract surgery.
223564344|NCT03111550|DEVICE|TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00|Intraocular lens replaces the natural lens removed during cataract surgery.
224038388|NCT00366704|DRUG|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
224038389|NCT00366704|DRUG|risperidone|4mg, QD, 8 week treatment
224038390|NCT01217268|BEHAVIORAL|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
224038391|NCT00364026|DRUG|darusentan|
224038392|NCT00109720|BEHAVIORAL|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
224038393|NCT00109720|BEHAVIORAL|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
224038394|NCT03408782|PROCEDURE|Insertion of drainage|
224038395|NCT04173065|DRUG|VK2809|Capsule
224038396|NCT04173065|DRUG|Placebos|Capsule
224038397|NCT06061016|OTHER|No intervention|No intervention
224038398|NCT00395148|DRUG|rHDL|
224038399|NCT02730364|DRUG|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
224139121|NCT01861145|DRUG|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
223426438|NCT02327403|DRUG|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
223744776|NCT04222569|PROCEDURE|PSV 7 and PEEP 0|Spontaneous breath trial with a pressure support ventilation of 7 cmH2O and no positive end expiratory pressure
224038400|NCT01562951|DRUG|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
224038401|NCT01562951|DRUG|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
224038402|NCT01387048|DRUG|skinoren|gel 15%, twice daily, 36 weeks
224139122|NCT02928380|DEVICE|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
223426439|NCT04510246|BEHAVIORAL|Enhanced case management|"The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~* Further testing advice~* Awareness that treatment can be prescribed by the general practitioner~* Conducting pre-treatment work-up assessment~* DAA prescription guidelines, including linkage to specialist consultation~* Providing treatment support~* Advising on testing process for cure~* Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~* Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP."
223426440|NCT00880230|DEVICE|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
223426441|NCT04318522|DEVICE|Transcranial Direct Current Stimulator|Transcranial Direct Current Stimulation (tDCS) is a non-invasive brain stimulation device that can excite or inhibit the brain activity depending on the stimulation protocol. It has mainly two variants including conventional c-tDCS and High-Definition HD-tDCS.
223426442|NCT04310631|DRUG|Ranibizumab Injection|Ranibizumab Injection (0.5 mg/0.05 ml): Three monthly intravitreal injections
223426443|NCT02729038|DRUG|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
223426444|NCT02002039|DRUG|Erythropoietin|500 units /kg /day every other day for 5 doses
223426445|NCT06375746|OTHER|Personalized video|After enrollment and assignment to the intervention group, patients will receive a link to a personalized video describing the different induction methods by a text message.
223426446|NCT05489263|OTHER|No intervention|No intervention
223426447|NCT00851916|RADIATION|CyberKnife Radiosurgery|CyberKnife Radiosurgery
223426448|NCT06112158|BEHAVIORAL|Education Intervention|"The BSE training program for the early diagnosis of breast cancer will be offered to students in two ways: face-to-face and via web support.~Content of training Session 1: Topics such as the structure of the breast, the definition of breast cancer, its prevalence, risk factors and symptoms Session 2: Teaching the importance of early diagnosis in breast cancer, the importance and benefits of BSE, the technique of performing BSE, the obstacles to the application of BSE.~Session 3: Teaching the risk factors that cause breast cancer. Session 4: Discussion of case reports of patients diagnosed with breast cancer. Supporting education with web support"
223426449|NCT01915667|DRUG|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
223426450|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
223426451|NCT01915667|DRUG|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
223426452|NCT01921192|DRUG|Folic Acid, vit B6 and B12|
223564345|NCT07013656|OTHER|L-tryptophan|L-tryptophan, an aromatic amino acid and one of the building blocks of protein, is a part of our daily diet. The load of L-tryptophan (0.1 kcal/minute) is based on our previous study, in which L-tryptophan represented a submaximal load.
224038403|NCT01387048|DRUG|differin|0.1% gel, once daily in the evening
223426453|NCT01921192|DRUG|Placebo|
223426454|NCT04253639|OTHER|Questionnaires|"Patients must fill questionnaires to collect socio-demographics, aetiology and characteristics of pain, efficacy and tolerance regarding the TENS.~Study sites must fill questionnaires to collect information regarding the type of pain management centre, the characteristics of the clinician, the characteristics of the TENS prescribed."
223426455|NCT03562286|PROCEDURE|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
223426456|NCT02683655|DRUG|Apatinib|Apatinib 500mg qd p.o.
223426457|NCT02683655|DRUG|Apatinib|Apatinib 750mg qd p.o.
223426458|NCT03829618|DRUG|Topical lidocaine|1% lidocaine topically applied in 4 mL aliquots
223426459|NCT03829618|DRUG|Nebuliser solution|2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
223426460|NCT03829618|DRUG|Nebuliser Suspension|2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
223426461|NCT06667102|BEHAVIORAL|Strategic and Interactive Signing Instruction|SISI centers on deaf children producing sign language compositions to communicate their messages with identified audiences, and teachers utilizing strategic and interactive approaches to bring attention to target sign language skills by consciously monitoring and manipulating language to create desired meanings grounded in socially shared understandings.
223426462|NCT01906021|PROCEDURE|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
223426463|NCT01906021|PROCEDURE|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
224038404|NCT01387048|DRUG|skinoren|12 weeks treatment, the following 24 months only observation
223426464|NCT00642096|DRUG|Metoprolol Succinate|
223426465|NCT00642096|DRUG|Hydrochlorothiazide|
223426466|NCT01129349|DRUG|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
223426467|NCT02275780|DRUG|Doravirine|Doravirine 100 mg tablet administered p.o. q.d.
223426468|NCT02275780|DRUG|Darunavir|Darunavir 800 mg tablet administered p.o. q.d.
224038405|NCT01975818|DRUG|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
224038406|NCT01975818|BIOLOGICAL|Epoetin alfa/beta|
224038407|NCT01400789|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
224038408|NCT05275712|OTHER|Audiological evaluation|Questionnaire for parents about their children behavior after implantation, audiological evaluation and speech perception test .
224038409|NCT04974515|DEVICE|eXciteOSA|eXciteOSA is a device for improving genioglossus endurance through electrical stimulation
224139123|NCT02928380|DEVICE|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
223426469|NCT02275780|DRUG|Ritonavir|Ritonavir 100 mg tablet administered p.o. q.d.
223426470|NCT02275780|DRUG|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
223426471|NCT03960866|DRUG|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
223426472|NCT03960866|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
223426473|NCT02190032|DEVICE|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
223426474|NCT02190032|DEVICE|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
223426475|NCT04430842|DRUG|QBS10072S|QBS10072S targets cancers with high LAT1 expression.
223426476|NCT00738881|DRUG|Erlotinib Hydrochloride|Given PO
224038410|NCT04566627|BEHAVIORAL|"Yo Sé Lo Que Quiero programl"|"Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis."
224038411|NCT04427553|DEVICE|Percutaneous Peripheral Nerve Stimulation|Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.
224038412|NCT04427553|OTHER|Control Group|No intervention
224038413|NCT04910477|DRUG|Dexmedetomidine|ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
224038414|NCT04910477|DRUG|Neostigmine/atropine|nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
224038415|NCT04910477|OTHER|Saline placebo|nebulization of saline placebo in 4 ml) twice daily for three days.
224038416|NCT04962789|DIAGNOSTIC_TEST|transvaginal ultrasound on the uterus|"Transvaginal ultrasound measurement to record endometrial thickness 2 times in each cycle:~In case of fresh cycles: 1)Day of ovulation triggering 2)Day of embryo transfer In case of frozen thawed cycles : 1)End of estrogen phase 2)Day of embryo transfer"
224038417|NCT00690235|DRUG|Pramlintide|180mg subcutaneous injections, twice daily
224038418|NCT00690235|DRUG|Placebo|180mg subcutaneous injections, twice daily
224038419|NCT00560053|DRUG|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
224139124|NCT04779632|DIETARY_SUPPLEMENT|Experimental: Fish Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 1000 mg twice a day (in total 5.2 mg/day of long-chain n-3 fatty acids hereof 2400 mg of eicosapentaenoic acid and 1600 mg of docosahexaenoic acid) for 4 weeks.
224139125|NCT04779632|DIETARY_SUPPLEMENT|Comparator: Safflower Oil|Participants are provided with fish oil capsules and asked to take 4 capsules of 500 mg twice a day (containing \~ 3000 mg of linoleic acid) for 4 weeks.
223426477|NCT00738881|DRUG|Pemetrexed Disodium|Given IV
223426478|NCT00348790|DRUG|vatalanib|
223426479|NCT02809859|DEVICE|Fisher & Paykel Healthcare CPAP Device|Fisher \& Paykel Healthcare CPAP Device
223426480|NCT06646159|BEHAVIORAL|REThink Intervention|"At its core, the REThink game consists of seven levels, each focusing on a specific emotion-regulation skill crucial for emotional health. The game's story is based on the RETMAN character which helps the player fight the power of the Irrationalizer who personalizes irrational beliefs. The game is based on cognitive-behavioral psychotherapy - the unified protocol (Barlow et al., 2004) and well-supported Rational Emotive Behavioral Therapy (Ellis, 1995). Each level is composed of three sublevels, increasing in difficulty, and also has an embedded validated assessment system (composed of a sublevel for each level; David, Tomoiaga \& Fodor, 2024), and can function as a standalone intervention."
223426481|NCT06022614|DRUG|Use Bupivacaine 0.25% Injectable Solution|Group A Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml normal saline.
223426482|NCT06022614|DRUG|Bupivacaine 0.25% Injectable Solution plus Dexmedetomidine|Group B Patients receiving 20 ml Bupivacaine 0.25% added to 1 ml dexmedetomidine
223744777|NCT04222569|PROCEDURE|PSV 0 and PEEP 0|Spontaneous breath trial without pressure support ventilation and positive end expiratory pressure, with a patient intubated and connected to the ventilator
224038420|NCT00560053|PROCEDURE|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
224139126|NCT00352950|DRUG|AMG 954/Panitumumab|
224163416|NCT04545931|DEVICE|Posterior tibial nerve stimulation|34-gauge stainless steel needle is inserted about three finger breadths cephalad to the medial malleolus. In children, previous administration of a topical anesthetic agent (e.g. lidocaine) can help to reduce pain and fear associated with needle insertion. The goal is to place the tip of the needle close to the PTN without actually touching it. The negative electrode is placed on the same leg near the arch of the foot. The needle and the electrode are connected to a low voltage (9 V) stimulator
224163417|NCT04545931|DRUG|Desmopressin Acetate|0.2 mg, single evening dose ) for 12 weeks, tapering to half of the dose daily for two weeks before discontinuation
223426483|NCT04586738|PROCEDURE|non-perforating deep sclerectomy surgery|Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
223426484|NCT03074435|DEVICE|Indoor residual sprayings|Houses will be spayed with this formulation containing Pyrimiphos methyl.
223426485|NCT03074435|DEVICE|Larvicide|Larval breeding sites will be treated with larvicide
223426486|NCT03074435|BEHAVIORAL|BCC|
223426487|NCT03074435|BIOLOGICAL|Ivermectin|
223426488|NCT04712019|DEVICE|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric at 125mmHg of continuous negative pressure on a closed surgical incision
223426489|NCT04712019|DEVICE|Standard Silver-containing Dressing|A standard silver-containing dressing applied to a closed surgical incision
223426490|NCT01282164|PROCEDURE|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
223426491|NCT01282164|PROCEDURE|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh \>90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
223426492|NCT00485043|BEHAVIORAL|Modified T'ai Chi: T'ai Chi for Arthritis|
223426493|NCT04521621|BIOLOGICAL|Gebasaxturev|Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.
223426494|NCT04521621|DRUG|Pembrolizumab|Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
223426495|NCT04525079|DRUG|CT-P59|CT-P59 will be administered
223426496|NCT04525079|DRUG|Placebo|Placebo-matching CT-P59
223426497|NCT00438100|DRUG|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
223426498|NCT00438100|DRUG|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
223426499|NCT03140332|OTHER|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
223426500|NCT02316899|DRUG|linaclotide|Oral administration once daily
223426501|NCT02316899|DRUG|Placebo|Oral administration once daily
223426502|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, blood glucose monitor for personal use|measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)
223426503|NCT05091736|DIAGNOSTIC_TEST|blood glucose measurement, laboratory reference device|measurement of the blood glucose concentration using a laboratory reference device
223426504|NCT04001387|PROCEDURE|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
223426505|NCT03585153|OTHER|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
223426506|NCT05845567|DRUG|Givinostat|ITF2357 Givinostat 10mg/mL. Dose: 10 mg/mL; Dosage form: oral suspension.
223426507|NCT05845567|DRUG|Clarithromycin|Clarithromycin 500 mg immediate-release oral film-coated tablet (Klacid®) was administered twice a day, in the morning and in the evening.
223426508|NCT06098872|DRUG|Trametinib tablet|Drug is supplied in 2mg and 0.5 mg tablets
223426509|NCT01757912|PROCEDURE|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
223426510|NCT04424212|BEHAVIORAL|Intervention group CoronaCope|Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
223426511|NCT00725608|DRUG|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
223426512|NCT00004087|BIOLOGICAL|filgrastim|as prescribed by physician
223426513|NCT00004087|PROCEDURE|autologous bone marrow transplantation|1-2 weeks before treatment
223426514|NCT00004087|PROCEDURE|peripheral blood stem cell transplantation|1-2 weeks before treatment
223426515|NCT00004087|RADIATION|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
223426516|NCT00004087|RADIATION|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
223426517|NCT04697004|DEVICE|Investigational Arm: SMR Stemless Reverse|The SMR Stemless Reverse is intended for total, primary shoulder joint replacement by reducing pain and restoring shoulder articular mobility function.
223426518|NCT04697004|DEVICE|Control Arm: SMR Reverse Shoulder System|Conventional stemmed shoulder prostheses are commonly used in the clinical practice.
223426519|NCT06623539|DRUG|Pemafibrate high dose|Pemafibrate 0.1 mg tablets shall be administered orally twice daily, two tablets per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 2 tablets 1 or 0.4 mg for 1 tablet 1 can be substituted.
223426520|NCT06623539|DRUG|Pemafibrate low dose|Pemafibrate 0.1 mg tablets shall be administered orally twice daily, one tablet per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 1 tablets 1 can be substituted.
223426521|NCT06623539|DRUG|Fenofibrate|Fenofibrate 53.3 mg tablets shall be administered orally once daily, one tablet per dose, after breakfast. Thereafter, the dose may be carefully increased to two tablets per dose at the physician\&amp;#39;s discretion.
224038421|NCT00560053|DRUG|Maintenance|"At 3 months of transplantation or with \>1.500 neutrophiles/ \> 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
224038422|NCT00560053|PROCEDURE|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
224038423|NCT00560053|PROCEDURE|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
224038424|NCT01143103|DEVICE|Cough assist (Philips,respironics)|
223426522|NCT04402996|OTHER|Saliva|"individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
223426523|NCT04402996|OTHER|gingival crevicular fluid|"GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC."
223426524|NCT03409107|DRUG|Daprodustat (GSK1278863)|Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
223426525|NCT03409107|DRUG|Placebo|Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
223426526|NCT03409107|DRUG|Iron therapy|Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
223426527|NCT00169715|PROCEDURE|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
223426528|NCT04842188|PROCEDURE|L-PRF with aPDT|surgical open flap debridement followed by L-PRF with aPDT
223426529|NCT04842188|PROCEDURE|L-PRF|surgical open flap debridement followed by L-PRF alone
223426530|NCT00675168|RADIATION|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
223426531|NCT05234086|COMBINATION_PRODUCT|InbioDerm + C plus advanced healing|For patients who are assigned to experimental treatment with InbioDerm+C plus advanced healing a section of skin tissue and peripheral venous blood will be taken. From the skin section, through an enzymatic process and cell proliferation for a period of approximately fourteen days, the cells that are integrated in the InbioDerm+C will be obtained and used to treat the foot ulcer.
223426532|NCT05234086|PROCEDURE|Advanced healing|Patients who are assigned to active comparator correspond to the control treatment, which will be received advanced healing.
223426533|NCT06002139|BEHAVIORAL|Immersive Virtual Reality Therapy|"8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation."
223426534|NCT06002139|BEHAVIORAL|Conventional rehabilitation|"Four weeks of conventional rehabilitation including:~* Two hours of kinesiotherapy (120 minutes, including gait training).~* Thirty minutes of ergotherapy.~* Three physical therapy procedures (i.e. laser therapy, magnetic therapy, electrotherapy) tailored to individual ailments and needs."
223426535|NCT00136435|DRUG|prednisone|Induction Phase: Given orally on days 1-28
223426536|NCT00136435|DRUG|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
223426537|NCT00136435|DRUG|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
223426538|NCT00136435|DRUG|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
223426539|NCT00136435|DRUG|asparaginase|Induction: Given into the muscle on day 5
223426540|NCT00136435|DRUG|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
223426541|NCT00136435|RADIATION|cranial radiation|Given in 10 daily treatments during CNS therapy phase
223740100|NCT06483620|DIAGNOSTIC_TEST|Neuropathy - and Foot Ulcer - Specific Quality of Life instrument (Neuro Qol)|The NeuroQoL questionnaire is a valid, reliable, and self-reported questionnaire. It has 35-items with six domains namely, painful symptoms and paresthesia (items 1-7), reduction or loss of ability to feel (items 8-10), unsteadiness while walking/standing/diffuse sensory-motor symptoms (items 11-13), limitation in daily living (items 14 - 16), interpersonal problems (items 17-20), emotional distress (items 21- 27) and end with an overall assessment of quality of life or satisfaction with experiences in the above six domains \[1 item in each domains, i.e. additional 6 items (items 28-33)\]. The two final items (items 34-35) assess overall impact of neuropathy on QoL \[5\]. The scoring of the questionnaire is according to a five-point Likert scale, all the time, most of the time, some of the time, occasionally, never. Each domain has a maximum score 5 and minimum 1, where 5 means that the QoL is affected all the time because of the foot problem while 1 means never it affects their QoL
223740101|NCT07076186|DRUG|Trabectedin|Given by IV Infusion
223740102|NCT07076186|DRUG|Doxorubicin Hydrochloride|Given by IV Infusion
223740103|NCT06578247|DRUG|Quizartinib|Participants will receive quizartinib at 60 mg/day orally once daily
223740104|NCT06578247|DRUG|Placebo|Participants will receive placebo at 60 mg/day orally once daily
224038425|NCT01143103|OTHER|Usual respiratory therapy|
224038426|NCT00839943|OTHER|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
224038427|NCT00768391|BIOLOGICAL|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
224038428|NCT02750098|OTHER|Glucose measurement|"1. Elective cataract surgery~2. Blood glucose measurement - glucometer~3. Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~4. Perioperative Hemoglobin A1c level - blood laboratory test"
224038429|NCT00569816|DRUG|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
223426542|NCT00136435|DRUG|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
223426543|NCT00136435|DRUG|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
223426544|NCT00136435|DRUG|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
223426545|NCT00136435|DRUG|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
223426546|NCT00136435|DRUG|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
223426547|NCT06621303|BIOLOGICAL|Diabetic foot ulcer treatment|The trial is designed to last up to 26 weeks, including a screening period of 1 week, a treatment period of 1 week, and an observation period of 24 weeks. According to the inclusion criteria, 10 diabetic patients with ulcers will be clinically screened, and after signing the informed consent form, they will be assigned a number. Post-injection of OPM cells, wound assessments are conducted weekly, with physical examinations and vital signs (pulse, blood pressure) recorded at weeks 4, 8, 12, 16, 20, and 24. Clinical laboratory tests (routine blood tests, tumor markers, etc.) are performed at week 12. Vascular CTA and immune cell count in wound lavage fluid are conducted at week 24 post-cellular intervention, followed by a final examination at week 24.
223426548|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
223426549|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
223426550|NCT02971436|DEVICE|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
223426551|NCT02971436|DEVICE|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
223426552|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
223426553|NCT02971436|DEVICE|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
223426554|NCT00567385|DRUG|somatropin|
223426555|NCT00312065|DEVICE|Application of reflective heat shield to thermistor probe|
223426556|NCT05221268|OTHER|Level walking exercise|treadmill exercise with 0 inclination
223426557|NCT05221268|OTHER|Downhill exercise|treadmill exercise with -20 inclination
223426558|NCT05784974|DRUG|Cadonilimab|15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
223426559|NCT04987099|DIETARY_SUPPLEMENT|550 mg/day Choline|Choline chloride (550 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
223426560|NCT04987099|DIETARY_SUPPLEMENT|25 mg/day Choline|Choline chloride (25 mg) is a water soluble choline salt that will be provided in a grape juice cocktail solution to participants for daily consumption.
223426561|NCT00258349|DRUG|vorinostat|Given orally
223426562|NCT00258349|DRUG|trastuzumab|Given IV
223426563|NCT04205409|BIOLOGICAL|Nivolumab|Given IV
223426564|NCT03179293|DRUG|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
223426565|NCT03179293|DRUG|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
223426566|NCT02999529|OTHER|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
223426567|NCT05685862|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging device|Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
223426568|NCT04388904|DRUG|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)|Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.
223426569|NCT06471946|DRUG|Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT|"Patients were treated by VA Conditioning Regimen Allo-HSCT:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9"
223426570|NCT03254212|DEVICE|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to \> 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to \< 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
223426571|NCT01684579|BEHAVIORAL|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
223564346|NCT07013656|OTHER|Combination of L-tryptophan + Ca-500|Calcium, an essential mineral and a key component of dairy products, is a regular part of our daily diet. In this condition, both L-tryptophan and calcium will be administered as 'active'. Recent studies have shown that calcium in a dose of 500 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'lower dose'.
223564347|NCT07013656|OTHER|Combination of L-tryptophan + Ca-1000|In this condition, both L-tryptophan and calcium will be administered. In our study calcium in a dose of 1000 mg enhances the effects of L-tryptophan to stimulate gut functions and reduce energy intake. This dose of calcium will be considered 'higher dose'.
223426572|NCT01684579|BEHAVIORAL|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
223426573|NCT01684579|BEHAVIORAL|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
223426574|NCT01735968|DRUG|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
223426575|NCT01048112|BIOLOGICAL|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
223426576|NCT02835950|DEVICE|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
223426577|NCT06646510|OTHER|traditional exercises|strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand
223426578|NCT06646510|OTHER|sensory electrical stimulation|The stimulated muscles included the flexor carpi radialis (FCR), extensor carpi radialis (ECR), and flexor carpi ulnaris (FCU). Rectangular surface electrodes (Ag/AgCl; 50mm \_ 50mm size) were attached on the motor point of each muscle, i.e., at four fingerbreadths from biceps tendon of FCR, at two fingerbreadths distal from lateral epicondyle for the ECR, at two fingerbreadths volar to ulna at the junction of the upper and middle thirds of the forearm for FCU.14 Portable stimulators will use with the following stimulation settings: constant current (0.2 mA step), 100 Hz stimulation frequency, biphasic pulse, and 300 \_s pulsewidth.
223426579|NCT01329718|OTHER|Blood Sample|Blood sample collection
223426580|NCT06579937|DRUG|Esketamine hydrochloride|During anesthesia induction, a 0.2 mg/kg esketamine bolus was administered intravenously.
223426581|NCT06579937|DRUG|normal saline|During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
223426582|NCT02004899|DRUG|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
223426583|NCT01250132|OTHER|Biological and behavioral explorations|"Blood dosages:~* biochemistry~* pituitary gland~* somatotropic axis~* corticotropic axis~* gonadotropic axis~* thyrotropic axis~* antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
223426584|NCT00535847|DRUG|Telaprevir|Tablet
223426585|NCT00535847|DRUG|Ribavirin|Tablet
223426586|NCT00535847|DRUG|Pegylated interferon alfa 2a|Solution for Injection
223426587|NCT05454540|DEVICE|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|"daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.~Other Name: RTMS"
223426588|NCT04911335|COMBINATION_PRODUCT|Faringel plus and oral hygiene|The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
223426589|NCT04887636|OTHER||
223426590|NCT02129790|BEHAVIORAL|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
224038430|NCT05295316|OTHER|Life Stressor Checklist Revised (LSC-R) (Appendix 1)|Evaluation of stress factor as risk factor for fibromyalgia development
224038431|NCT01868139|DEVICE|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
224163418|NCT02158000|OTHER|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
224038432|NCT02960373|OTHER|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
224038433|NCT02960373|OTHER|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
224163419|NCT01048164|PROCEDURE|Massage|Chair Massage
224163420|NCT02094196|OTHER|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
224163674|NCT04574869|DRUG|RLS-0071 40 mg/kg|Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
224038434|NCT02960373|OTHER|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
223426591|NCT06268405|GENETIC|Liquid Biopsy|Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
223426592|NCT06268405|DEVICE|Positron Emission Mammography (PEM)|PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
223426593|NCT03482076|DIAGNOSTIC_TEST|transferrin receptor concentration|Sandwich radio-imunoassay
223426594|NCT03694444|DRUG|AMY-101|C3 complement inhibitor
223426595|NCT03694444|OTHER|Water for injection|Placebo
223426596|NCT04221620|DEVICE|Zengar Electroencephalogram (EEG) Neurofeedback device|Electroencephalogram (EEG) Neurofeedback is a noninvasive way to allow the central nervous system to self regulate and calm the brain enough to allow the frontal cortex to function in an ideal state, which is the part of the brain that controls important functions including behavior, problem solving, memory, language, emotions, and judgment. EEG Neurofeedback is performed via a musical medley that lasts for about 34 minutes, with baseline numbers taken at the beginning and after the music finishes. During this time, the participant will wear headphones, sensory clips on the ears (3 total), and two sensors on their head while receiving traditional occupational therapy services.
223426597|NCT04218292|DEVICE|Micro Plug Set|The Micro Plug Set is indicated for arterial embolization in the peripheral vasculature.
223426598|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
223426599|NCT03129191|DEVICE|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
223426600|NCT00423189|DRUG|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
223426601|NCT00423189|DRUG|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
223426602|NCT05551520|DEVICE|Normative|ImPACT will be administered at baseline testing
223426603|NCT05551520|DEVICE|Reliability|ImPACT will be administered again within 60 days of baseline test
223426604|NCT01671566|BEHAVIORAL|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
223426605|NCT00278226|BEHAVIORAL|smoking cessation intervention|
223426606|NCT00278226|OTHER|educational intervention|
223426607|NCT02546791|DRUG|Dasatinib|
223426608|NCT00483210|DRUG|Fenofibrate|
224038435|NCT02960373|OTHER|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
224038436|NCT03425981|OTHER|Whole-Body Electromyostimulation Training|"The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D)."
224163421|NCT05376241|BEHAVIORAL|Decision aid|Mammography screening decision aid for women in their 40s with information about screening guidelines, breast cancer mortality reduction, false positives, overdiagnosis, and a personal breast cancer risk estimate.
224163422|NCT03760562|DRUG|Glucocorticoids|Oral Glucocorticoids.
223426609|NCT03407703|DRUG|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|HCV treatment
223426610|NCT02028403|DRUG|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
223426611|NCT02028403|DRUG|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
223426612|NCT03826810|RADIATION|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
223426613|NCT03826810|PROCEDURE|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
223426614|NCT05028413|BEHAVIORAL|Participants Shown their Breath Alcohol Content Measurement|Each time a Breath Alcohol Content (BrAC) Measurement is taken by the research team, the participant is shown the measurement before completing the paper visual analog scale scale (the Self-Reported intoxication Survey) on their perceived fitness to drive.
223426615|NCT01818206|OTHER|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
223426616|NCT00994695|BIOLOGICAL|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
223426617|NCT03170466|BEHAVIORAL|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
223426618|NCT01040936|DRUG|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
223426619|NCT01040936|DRUG|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
223426620|NCT01459718|DRUG|Deferasirox|20-40 mg/kg/day orally, once daily
223426621|NCT01459718|DRUG|Deferoxamine (DFO)|40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week
223426622|NCT03912818|DRUG|Carboplatin|Given IV
223426623|NCT03912818|DRUG|Cisplatin|Given IV
224139127|NCT05720273|DRUG|palicalcitol|This study does not interfere with the clinical medication of the researchers, and the usage and dosage of the drugs will be recorded according to the actual use. The recommended starting dose of palicalcitol may be based on body weight, baseline iPTH, or combined with prior medication. Dose adjustment should be determined according to pre-dialysis iPTH, Ca and P. iPTH levels should be maintained at 150-300pg/ml, while Ca and P levels should be closely monitored. If hypercalcemia occurs, the dose should be reduced or medication should be discontinued until these parameters return to normal; Subsequently, the dose of palicalcitol should be restarted at a lower dose. If PTH levels decrease as a result of treatment, the dose of medication may need to be reduced accordingly. The dose adjustment interval is 2-4 weeks, and the dose can be adjusted immediately for safety reasons.
223426624|NCT03912818|PROCEDURE|Cystectomy|Undergo cystectomy
223426625|NCT03912818|DRUG|Doxorubicin|Given IV
223426626|NCT03912818|BIOLOGICAL|Durvalumab|Given IV
223426627|NCT03912818|DRUG|Gemcitabine|Given IV
223426628|NCT03912818|DRUG|Methotrexate|Given IV
223426629|NCT03912818|DRUG|Vinblastine|Given IV
223426630|NCT00691899|DRUG|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
223426631|NCT00691899|DRUG|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
223426632|NCT00006066|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
223426633|NCT00006066|BIOLOGICAL|Diphtheria and Tetanus Toxoids Adsorbed|
223426634|NCT00006066|BIOLOGICAL|Tetanus and Diphtheria Toxoids Adsorbed|
223426635|NCT00006066|DRUG|Bacteriophage phi X 174|
223426636|NCT00006066|DRUG|Aldesleukin|
223426637|NCT06621225|DEVICE|Artificial Intelligence|Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.
223426638|NCT06621225|DEVICE|Mucosal Exposure Device|The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
223426639|NCT00715728|DEVICE|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
223426640|NCT00715728|DEVICE|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
223426641|NCT05876793|DRUG|Remimazolam tosilate|The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
223426642|NCT01930344|DEVICE|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
223426643|NCT01930344|DEVICE|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
223426644|NCT04690725|DRUG|TQB3525|TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
223426645|NCT01772186|DEVICE|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
223426646|NCT05353972|DRUG|IMG-007 or placebo|intravenously administered
223426647|NCT03541330|OTHER|semi-directive interview|semi-structured interview conducted by a clinical psychologist
223426648|NCT02938624|DRUG|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
223426649|NCT02938624|DRUG|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
223426650|NCT02938624|DRUG|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
223426651|NCT02938624|DRUG|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
223426652|NCT02938624|PROCEDURE|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
223426653|NCT02526875|DRUG|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
223426654|NCT06463418|DEVICE|Ekoskeleton (Intervention)|Exoskeleton walking three times per week for 12 weeks.
223426655|NCT06463418|OTHER|Relaxation (Comparator)|Relaxation three times per week for 12 weeks.
223564348|NCT07013656|OTHER|Control|An isotonic solution containing 2.5 g of NaCl, dissolved in 225 mL of distilled water.
224038437|NCT05399121|BEHAVIORAL|Piano Learning then Free Improvisation|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~The patient will then be asked to perform exercise 2. Exercise 2: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically. The therapist will use various MT accompaniment techniques.~Both exercises will be performed for the same amount of time (5 minutes each)."
224038438|NCT05399121|BEHAVIORAL|Free Improvisation then Piano Learning|"During all 15 sessions (one session per patient) all patients will be asked to perform two piano playing exercises:~Exercise 1: Free Improvisation exercise -The patient will be instructed to use separate finger movement while playing freely on the piano while the therapist musically interacts with them. The therapist will use various MT accompaniment techniques.~The patient will then be asked to perform exercise 2. Exercise 2 - Piano Learning exercise - The music therapist will guide the patient to use separate finger movement and to play a brief extract from a familiar song. The therapist guiding techniques may include (but not restricted to) demonstrating to the patient which keys to press (turn- taking), playing the same notes with them in synchronization, or harmonizing the patient's playing.~Both exercises will be performed for the same amount of time (5 minutes each)."
223426656|NCT03840551|OTHER|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
223426657|NCT01258075|DRUG|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
223426658|NCT01258075|DRUG|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
223426659|NCT02387775|DEVICE|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
223564349|NCT07035002|BIOLOGICAL|transfusion of 5×10^8 PD-1 knockout TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
223564350|NCT07035002|BIOLOGICAL|transfusion of 1×10^9 PD-1 edited TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
223564351|NCT07035002|BIOLOGICAL|transfusion of 2×10^9 PD-1 edited TILs per kg body weight|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
223564352|NCT07035002|BIOLOGICAL|transfusion of maximum dose without side effects among group A, B and C|Obtaining individual tumor tissue via surgery resection or biopsy, and then isolating TILs in the tumor under GMP conditions, and further using gene editing technology to knockout PD-1 to finally obtain gene-edited TILs-T cells, and transfusing them back to the patient.
224038439|NCT06186245|OTHER|Early feeding with an oral diet|Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.
224038440|NCT01238289|BEHAVIORAL|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
224038441|NCT01238289|BEHAVIORAL|Control|This group continues with standard care at the community health center
224038442|NCT06124053|BEHAVIORAL|Group Voice Therapy|"The group voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. Each group is composed of three participants. The session durations are planned to be 45-60 minutes each."
223426660|NCT01200732|DRUG|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
223426661|NCT02413242|OTHER|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
223426662|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (2/ week)
223426663|NCT04587349|OTHER|Neurorehabilitation|Neurorehabilitation - 2 years-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training. (3/ week)
223426664|NCT04587349|OTHER|Physiotherapy|Physiotherapy 2-years-long (3/week)
224038443|NCT06124053|BEHAVIORAL|Individual Voice Therapy|"The individual voice therapy intervention consists of a total of eight sessions. The session contents include both direct and indirect voice therapy approaches. The session durations are planned to be 45-60 minutes each."
224038444|NCT06124053|BEHAVIORAL|Vocal Hygiene Education|Regarding vocal hygiene training, information related to voice production and respiratory characteristics will be provided, and guidance on correct and incorrect voice use will be given.
223426665|NCT06057493|OTHER|Retinal Imaging with Optina4C Camera|"The study consists of 2 visits and 8 Imaging sessions:~The participant will go through four (8) imaging sessions in two visits with the Optina-4CTM cameras to get pictures of your retina. These imaging sessions will be done by three qualified operators who have been trained on the study device by Optina Diagnostics."
223426666|NCT01899807|DEVICE|OssDsign AB|
223426667|NCT03367559|BIOLOGICAL|ROTAVAC®|Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
223426668|NCT03897114|DIETARY_SUPPLEMENT|Cocoa group|Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
223426669|NCT03897114|DIETARY_SUPPLEMENT|Placebo group|The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
223426670|NCT00651534|DRUG|Ronacaleret|
223426671|NCT00556634|DRUG|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
223426672|NCT00760370|DRUG|Zoledronic Acid|4 mg intravenous (iv), one treatment
223426673|NCT04568525|DIAGNOSTIC_TEST|Passive Microwave Radiometry|The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
223426674|NCT01591551|DRUG|Natalizumab (Tysabri)|300 mg IV every 4 weeks
223426675|NCT05274542|OTHER|high intensity with blood flow restriction|Participants in high intensity with blood flow restriction group (n=12) will be given high-intensity resistance exercise training that restricts blood flow. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. A blood pressure cuff will be used to restrict blood flow. By applying the cuff to the proximal of the muscle, the blood flow will be restricted with a pressure of 150 mmHg and the muscle will be exercised in this way. After the exercise, the cuff will be removed and evaluations will be made after 2 minutes of rest.
223426676|NCT05274542|OTHER|high intensity without blood flow restriction group|Participants in high intensity without blood flow restriction group (n=12) will be given high-intensity resistance exercise training. Open kinetic chain rectus femoris resistance exercise training will be given with free weights, 80% of 1 RM with 8 repetitions, 2 sets and 3 minutes rest between sets. The exercises will be performed in a single session accompanied by a physiotherapist. After the exercise, after 2 minutes of rest, evaluations will be made.
223426677|NCT00460707|DRUG|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
223426678|NCT00460707|DRUG|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
223426679|NCT00460707|DRUG|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
223426680|NCT00460707|DRUG|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
223426681|NCT00460707|DRUG|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
223426682|NCT03098056|OTHER|PROG2|"Nutritional Supplements to be administered:~* Protein Shakes: one shake po twice daily~* Phytosterol supplement: one capsule po twice daily~* Cinnamon: one tablet twice daily~* Fiber supplement; one shake twice daily~* Antioxidant supplement: 2 capsules daily with dinner~* Fish Oil supplement: 1 capsule twice daily with food~* Probiotic supplement: 1 capsule twice daily with food"
223426683|NCT06545630|BIOLOGICAL|Tumor antigen-sensitized DC vaccine|subcutaneous administration
223426684|NCT00313365|PROCEDURE|Surgical Lavage (Arthrotomy)|
223426685|NCT00313365|PROCEDURE|Arthrocentesis (Serial needle aspiration)|
223426686|NCT03294291|PROCEDURE|Quadratus lumborum block|Postoperative pain procedure
223426687|NCT03294291|PROCEDURE|Caudal block|Postoperative pain procedure
224038445|NCT02400450|DIETARY_SUPPLEMENT|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
223426688|NCT00807391|PROCEDURE|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
223426689|NCT03725774|OTHER|GRIP (Getting Research into Practice) model|"The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles."
223426690|NCT06511362|PROCEDURE|Functional stabilization training|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
223426691|NCT06511362|PROCEDURE|perturbation exercises|At the start of the study, a formal education session, lasting about 30 minutes will be given. whole treatment plan will be given for 8 weeks. Pre and post intervention measurements will be taken by using measuring tools.
223426692|NCT05304689|DIAGNOSTIC_TEST|test for quantitative index of interleukins in the oral fluid|collection of oral fluid and determination of the content of cytokines by test systems in patients with postoperative wound
224038446|NCT02400450|DIETARY_SUPPLEMENT|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
224038447|NCT06536062|PROCEDURE|Intravitreal injection of CB-PRP|The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
223426693|NCT01570634|DRUG|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
223426694|NCT01618019|DIETARY_SUPPLEMENT|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
223426695|NCT01618019|DIETARY_SUPPLEMENT|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
223426696|NCT03380104|DEVICE|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
223426697|NCT03380104|BEHAVIORAL|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
223426698|NCT01542034|DRUG|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
223426699|NCT01542034|DRUG|Placebo|Phosphate buffered saline placebo for injection
223426700|NCT05020418|OTHER|Chart Review|Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
223426701|NCT06342583|OTHER|Advanced social relations training with technical device|15 participants from the experimental group will undergo a first part in which they will be guided through social stories to construct an appropriate conversation repertoire. In the first phase the participants will see 8 social stories with scenes from everyday life and after learning the correct mode of interaction and communication they will be asked to interact in the group by playing the roles previously seen in the social stories. These will be shown on a technological device. Participants will have the opportunity to choose the correct mode of interaction by selecting it directly on the technological device. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media. Slides will be shown to explain risks and correct use and the operator will show on the technological device (Smartphone) all the practical steps to be taken (e.g. privacy settings).
224038448|NCT05627206|BEHAVIORAL|Problem Management + For Moms|Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
223426702|NCT06342583|OTHER|Advanced social relations training without technical device|15 participants from the control group will undergo a first part in which they will be guided through social stories to build an appropriate conversation repertoire. In the first phase, the participants will see eight social stories illustrating scenes from everyday life and, after learning the correct modes of interaction and communication, they will be invited to interact in the group by playing the roles previously seen in the social stories. These will be shown in traditional mode (flashcards). Participants will have the opportunity to choose the correct mode of interaction by touching the card showing the appropriate mode. Each selected alternative will refer to the next scenario in relation to the selected answers. In the second phase participants will be instructed on the correct use of social media (facebook, instagram, TikTok, Whatsapp, YouTube). The trainer will show images on paper related to risks and correct use of social media.
223564353|NCT07034573|OTHER|context adapted air filtration system for operating theatre|"This observational pilot study combines a retrospective design (technical data) and a prospective design (microbial data) to evaluate a new air filtration system adapted to the context. For this research, the technical data of the system concerning air velocity, temperature, etc. will be used retrospectively. Microbial sampling in the operating theatre will be carried out prospectively.~No patient contact will take place."
224038449|NCT04801134|OTHER|Education|as per previous description
224038450|NCT00522912|PROCEDURE|Trichiasis surgery|Posterior lamella tarsal rotation
224038451|NCT00522912|PROCEDURE|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
224038452|NCT06147570|DRUG|HS-10365 capsules|HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
224038453|NCT06245889|DRUG|Paclitaxel|chemotherapy
224038454|NCT06245889|DRUG|Carboplatin|chemotherapy
224038455|NCT06245889|DRUG|Pembrolizumab|immunotherapy
224038456|NCT06245889|DRUG|Doxorubicin|additional chemotherapy - neoadjuvant or adjuvant rescue
224038457|NCT06245889|DRUG|Cyclophosphamide|additional chemotherapy - adjuvant rescue
224038458|NCT06245889|DRUG|Olaparib|adjuvant rescue
224038459|NCT06245889|DRUG|Capecitabine|adjuvant rescue
224038460|NCT04795934|PROCEDURE|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION|LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
224038461|NCT05752123|BIOLOGICAL|ET-01|Recruited participants will receive ET-01 IV infusion after conditioning.
224038462|NCT06238778|DRUG|HDV-Lispro|HDV-L will be used as the mealtime insulin
224038463|NCT06238778|DRUG|Lispro|Lispro will be used as the mealtime insulin
224163675|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
224038464|NCT03951220|OTHER|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
223426703|NCT04823793|DIAGNOSTIC_TEST|Stool DNA methylation detection|Stool specimens are collected from participants in the outpatient department or the inpatient department. Both FIT and stool DNA real-time PCR are performed simultaneously. To improve the sensitivity and specificity of the colorectal cancer screening, this study enrolls multiple candidate genes to distinguish whether the participant has a high risk of colorectal cancer.
223426704|NCT02612610|DRUG|Gefapixant|Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
223426705|NCT02612610|DRUG|Placebo (for gefapixant)|
223426706|NCT05801900|DRUG|Ketorolac group|30 min preoperatively then every 8 hours postoperatively
223426707|NCT05801900|DRUG|Ibuprofen group|30 min preoperatively then every 8 hours postoperatively
223426708|NCT01801280|DRUG|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
223426709|NCT01801280|DRUG|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
224038465|NCT03951220|OTHER|DXA scan|Used to assess bone density
223426710|NCT01801280|DRUG|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
223426711|NCT02149823|DRUG|Syntocinon 24 Intranasal Units (IU)|
223426712|NCT02149823|DRUG|Syntocinon 40 Intranasal Units (IU)|
223426713|NCT02149823|DRUG|Intranasal Placebo|
223740105|NCT06578247|DRUG|Chemotherapy|Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).
224038466|NCT03951220|OTHER|Bloods and urine|Samples will be taken to assess bone biomarkers
224038467|NCT05620901|DRUG|Dextenza 0.4Mg Ophthalmic Insert|DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use
224038468|NCT05620901|DRUG|Pred Forte|To treat perioperative ocular inflammation and pain;
224038469|NCT05671874|BEHAVIORAL|Web/mobile/tablet-based digital decision aid + communication (DA+C) tool|The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
223426714|NCT00176644|DRUG|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
223426715|NCT01612637|BEHAVIORAL|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
223426716|NCT01612637|BEHAVIORAL|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
223740106|NCT06795906|DRUG|AZD8630|AZD8630 will be administered via dry powder inhalation (DPI).
223740107|NCT06795906|OTHER|Placebo|Placebo will be administered via DPI.
224038470|NCT05877521|BEHAVIORAL|MORE treatments|MORE participants will also be asked to engage in 15 minutes/day of skill practice at home, and complete daily diaries of mindfulness practice time
224038471|NCT05877521|OTHER|Standard of Care for Pain Management|Participants in the WLC group continue to receive their standard medical care and pain management as prescribed by their physicians or other health care providers.
224139128|NCT04826913|DEVICE|Organoids|"Use of an innovative device to improve the management of patients with NSCLC for precision medicine.~The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device."
223426717|NCT05236894|BEHAVIORAL|Cigarette Smoking|Smoke preferred brand of cigarette
223426718|NCT05236894|DRUG|Nicotine Oral Pouch|Given lower dose nicotine pouch
223426719|NCT05236894|DRUG|Nicotine Oral Pouch|Given higher dose nicotine pouch
223426720|NCT05236894|OTHER|Questionnaire Administration|Ancillary studies
223426721|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
223740108|NCT06795906|DEVICE|Saphira device|AZD8630 or placebo will be administered to participants via Saphira device.
223426722|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
223426723|NCT05236894|DRUG|Nicotine Oral Pouch|Given 3mg nicotine pouch (Aim 2)
223426724|NCT02456389|OTHER|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
223426725|NCT02456389|OTHER|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
223426726|NCT02456389|OTHER|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
223426727|NCT02456389|OTHER|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
223426728|NCT02456389|OTHER|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
223426729|NCT02456389|OTHER|Standard postoperative care|Routine postoperative care, as medically indicated
223426730|NCT05384002|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients who underwent MRI with confirmed pathology data (either biopsy or prostatectomy)
223426731|NCT06014697|DIAGNOSTIC_TEST|Optical Coherence Tomography|Assessment of the lesion with a non-invasive OCT scan according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
223426732|NCT06014697|OTHER|Clinical assessment|Clinical assessment of the lesion by a dermatologist according to a confidence scale (5-point Likert scale: 1 Definitely not invasive, 2 Probably not invasive, 3 Unknown invasive or non-invasive, 4 Probably invasive, 5 Definitely invasive)
223426733|NCT04261413|DRUG|RS-0139|RS-0139 will be administered for the indication of solid tumors.
223426734|NCT02463344|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
223426735|NCT02783729|DRUG|Lemborexant|Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
224038472|NCT05649657|OTHER|Cyclic aerobic and resistance training|Two options for the participants to choose from. First, a home-based program. The participant will be requested to wear a heart rate recorder during home exercise. Second, a hospital-based program. The participants visit the rehabilitation center twice weekly to receive supervised exercise therapy. The exercise prescription comprises aerobic and resistance training. The intensity is set initially at ventilatory anaerobic threshold and gradually titrated up to respiratory compensatory point based on the breath-by-breath cardiopulmonary exercise testing. The duration is 25\~35 minutes per session plus a 5-minute warm-up and 5-min cool-down. The frequency is 2\~3 sessions per week and about 70 sessions in total.
224038473|NCT04598477|BIOLOGICAL|efgartigimod PH20 SC|Subcutaneous injection of efgartigimod using rHuPH20 (PH20) as a permeation enhancer
224139129|NCT05897112|DRUG|Group A received cryotherpay|Group A were subjected to weekly cryotherapy with a cotton stick dip ped in Liquid Nitrogen for 02 Freezes and Thaw Cycle of 07 seconds with each cycle 10 seconds apart for 3 weeks
223426736|NCT02783729|DRUG|Lemborexant|Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
223426737|NCT02783729|DRUG|Lemborexant-matched placebo|Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
223426738|NCT02783729|DRUG|Zolpidem tartrate|Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
223426739|NCT02783729|DRUG|Zolpidem-matched placebo|Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
223426740|NCT03400709|DRUG|N Acetylcysteine|Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
223426741|NCT03400709|DRUG|Placebo Oral Tablet|Placebo treatment
223426742|NCT02693171|DRUG|Dinutuximab|Unituxin was administered along with cytokines according to the prescribing information
223426743|NCT05127304|DEVICE|Trelegy Ellipta|Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol
223426744|NCT05127304|DEVICE|Stiolto Respimat|Stiolto Respimat with Tiotropium Bromide/Olodaterol
223426745|NCT05127304|DRUG|Furoate/Umeclidinium/Vilanterol|Furoate/Umeclidinium/Vilanterol
223426746|NCT05127304|DRUG|Tiotropium Bromide/Olodaterol|Tiotropium Bromide/Olodaterol
223426747|NCT03583060|BEHAVIORAL|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
223426748|NCT02310425|DRUG|S. boulardii|50 mg/kg twice daily
223426749|NCT02310425|DRUG|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
223426750|NCT06666803|OTHER|FNB sampling|A supplementary FNB will be performed during the EUS procedure. Sample will be processed to obtain organoids and assess their morphological, proliferative and genetics characteristics.
223426751|NCT06666803|BIOLOGICAL|blood sampling|A blood withdrawal will be performed during the EUS procedure. Sample will be processed to assess organoids morphological, proliferative and genetics characteristics.
224163867|NCT02950311|DRUG|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
223426752|NCT01421186|DRUG|MOR03087 phase 1 dose escalation|"Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1."
223426753|NCT01421186|DRUG|MOR03087|MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
223426754|NCT01421186|DRUG|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
223426755|NCT01421186|DRUG|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
223426756|NCT01421186|DRUG|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
223426757|NCT03858725|DRUG|D569 Tab.|D569 Tab. 1T single oral administration under fasting condition
223426758|NCT03858725|DRUG|CKD-374 5mg Tab.|CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
223426759|NCT00301301|DRUG|Gemcitabine|
223426760|NCT00301301|DRUG|Cisplatinum|
224038474|NCT04598477|DRUG|prednisone|Oral prednisone tablets
224038475|NCT04468841|DIAGNOSTIC_TEST|cfDNA testing|peripheral blood samples collected before initiation of standard therapy, after 2 cycles of therapy, at the completion of 6-8 cycles of induction therapy, and then every 6 months for a total of 2 years from the initiation of therapy using a cfDNA assay. For retrospective patients, blood samples will be collected once.
223426761|NCT00301301|DRUG|Rituximab|
223426762|NCT03261726|DEVICE|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
223426763|NCT01866657|DRUG|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
223426764|NCT01866657|OTHER|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
223426765|NCT01866657|OTHER|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
223426766|NCT01866657|OTHER|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
223426767|NCT01866657|DRUG|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
224038476|NCT04468841|OTHER|sample of saliva or fingernail clipping|collected in clinic one time
224038477|NCT04468841|DIAGNOSTIC_TEST|pre-treatment test specimen|From bone marrow, blood, lymph node, or alternate site to identify tumor-specific mutations. For retrospective patients initial tumor tissue (if available).
224038478|NCT04468841|DIAGNOSTIC_TEST|PET/CT, CT, or MRI testing|PET/CT scans are required at baseline and at the patient's end-of-treatment visit. The other standard-of-care scan timepoints can be performed using PET/CT, dedicated CT, or MRI per the treating investigator's discretion.
224038479|NCT02520986|DEVICE|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
224038480|NCT02520986|DEVICE|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
224038481|NCT04434040|DRUG|Atezolizumab|Atezolizumab is a type of antibody and is administered intravenously.
224038482|NCT04434040|DRUG|Sacituzumab govitecan|Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously
224038483|NCT05514132|DRUG|Ceralasertib|Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol 3-kinase-related kinase family members.
224038484|NCT05514132|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells.
224038485|NCT05829031|BEHAVIORAL|Targeted music listening|Participants listen to self-selected relaxing music. They can choose between a duration of either 10 minutes or 20 minutes.
224038486|NCT05595837|OTHER|Standard organ transplant|Standard organ transplant procedures and follow up care
224038487|NCT06222450|BEHAVIORAL|Vestibular Rehabilitation Therapy (VRT)|customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training
224139130|NCT05897112|DRUG|Group B received 10% Potassium Hydroxide Solution|Group B applied 10% potassium hydroxide aqueous solution twice daily with the help of a cotton tip applicator until lesion showed signs of inflammation or clearance for 3 weeks
224163868|NCT02950311|OTHER|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
223426768|NCT01866657|BIOLOGICAL|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
223426769|NCT01866657|DRUG|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
223426770|NCT06662526|DRUG|Trace lithium dose plus treatment as usual|Subjects assigned to the active arm will receive 50 mg of lithium per day, for five years
223426771|NCT06662526|DRUG|Placebo pill plus treatment as usual|Patients will receive a placebo pill plus treatment as usual by their clinical providers
224038488|NCT02876302|DRUG|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
224038489|NCT02876302|DRUG|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
224038490|NCT02876302|DRUG|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
224038491|NCT02876302|DRUG|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
223426772|NCT03830957|DRUG|Ivabradine|7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg
224038492|NCT05557331|DEVICE|PIMPmyHospital (mobile app)|After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
224038493|NCT05579990|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company supplemented by remote weekly behavioral support with study staff.
224038494|NCT02530463|DRUG|Azacitidine|Given IV
224038495|NCT02530463|BIOLOGICAL|Ipilimumab|Given IV
224038496|NCT02530463|OTHER|Laboratory Biomarker Analysis|Correlative studies
224038497|NCT02530463|BIOLOGICAL|Nivolumab|Given IV
224038498|NCT02731716|BEHAVIORAL|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
223426773|NCT03830957|DRUG|Metoprolol|5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg
223426774|NCT00621166|DRUG|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
223426775|NCT03366766|BIOLOGICAL|Nivolumab|Given IV
223426776|NCT03366766|DRUG|Cisplatin|Given IV
223426777|NCT03366766|DRUG|Pemetrexed Disodium|Given IV
223426778|NCT03366766|DRUG|Gemcitabine Hydrochloride|Given IV
223426779|NCT04528212|DRUG|Glimepiride Tablets|Glimepiride (4 mg) per Day
224038499|NCT02731716|BEHAVIORAL|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
224038500|NCT02731716|BEHAVIORAL|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
224038501|NCT06289673|DRUG|Dexamethasone|Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
224139131|NCT03050216|BIOLOGICAL|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
224139132|NCT03310437|PROCEDURE|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
224139133|NCT06060756|OTHER|questionnaires completion|"Patients will complete the following questionnaires at 3, 6 and 12 months after start of the treatment for Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS):~* Pain-related questionnaire~* Endometriosis-specific questionnaire~* Hospital Anxiety and Depression scale~* Questionnaire McGill on Quality Of Life~* Insomnia-related questionnaire"
223426780|NCT04528212|DRUG|glimepiride plus fenofibrate|Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
223426781|NCT04528212|DRUG|glimepiride plus curcumin|Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
223426782|NCT05522322|OTHER|COPD scoring ststems in ICU|SAPS \& APACH scoring systems in COPD ICU pts
223426783|NCT06621836|DRUG|ICPB H|"ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group H will receive 10 ml 0.25 % bupivacaine he technique will be repeated on the opposite side"
223426784|NCT06621836|DRUG|ICPB - L|"ICPB technique The patient's head will be rested on a pillow and turned to the opposite side. A linear probe with higher frequencies will be placed transversely over the midpoint of the SCM muscle. The carotid artery will be identified and traced upwards to its bifurcation. the probe will be then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle will be advanced underneath the investing fascia of SCM muscle and above the interscalene groove until feeling the pop on piercing the investing fascia. The patient will be then randomly allocated into two groups (H \& L) using computer-generated random numbers that will be concealed in opaque envelopes. Group L will receive 10 ml 0.125% bupivacaine. The technique will be repeated on the opposite side"
223426785|NCT05274841|OTHER|Support of relatives|Screening of the support needs of relatives
223426786|NCT01185743|DRUG|olanzapine|olanzapine 10mg od + placebo od
223426787|NCT01185743|DRUG|ziprasidone|ziprasidone 40mg td
223426788|NCT01185743|DRUG|placebo|placebo td
223426789|NCT05600270|DEVICE|Angled guidewire|Cannulation of the common bile duct using an angled-tip guidewire during ERCP
223426790|NCT05600270|DEVICE|Straight guidewire|Cannulation of the common bile duct using an straight-tip guidewire during ERCP
224038502|NCT06289673|DRUG|Vincristine|Intravenously (IV) for 1 dose on Day 1 or 2
224038503|NCT06289673|DRUG|Daunorubicin|Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
224038504|NCT06289673|DRUG|Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
224038505|NCT06289673|DRUG|Methotrexate|Given IT as part of Intrathecal triple therapy.
224038506|NCT06289673|DRUG|Cytarabine|Given IT as part of Intrathecal triple therapy.
224038507|NCT06084299|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocytes|Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.
224139134|NCT01207388|DRUG|Blinatumomab|Continuous intravenous infusion
224139135|NCT01885078|DRUG|Baricitinib|Administered orally
224139136|NCT01885078|DRUG|Placebo|Administered orally
224139137|NCT04146571|DRUG|Ensartinib|Oral, ALK inhibitor
223426791|NCT03634995|DRUG|BMS-986256|Specified dose on specified days
223426792|NCT03634995|OTHER|Placebo|Specified dose on specified days
223426793|NCT03107689|OTHER|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
223426794|NCT02126267|PROCEDURE|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
223426795|NCT02126267|PROCEDURE|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
223426796|NCT02126267|DRUG|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
223426797|NCT02126267|DRUG|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
223426798|NCT02126267|DRUG|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
223426799|NCT01095900|PROCEDURE|conservative lateral internal sphincterotomy|
223426800|NCT01095900|PROCEDURE|Intra-sphincteric Botulinum-toxin injection|
223426801|NCT03777332|DRUG|PEGCETACOPLAN (APL-2)|Complement (C3) Inhibitor
223426802|NCT04360174|DRUG|OTX-TIC|OTX-TIC implant is injection in the anterior chamber of the eye
223426803|NCT03374592|RADIATION|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
223426804|NCT03374592|RADIATION|Conventional Radiotherapy|Conventional radiotherapy technique
223564354|NCT07032662|DRUG|IMVT-1402|Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)
223564355|NCT07032662|DRUG|Placebo|Matching placebo SC QW for 24 weeks (Period 1)
223426805|NCT06684730|PROCEDURE|Hand Function Assessment Scales|The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), The Box and Block Test (BBT) and Action Research Arm Test (ARAT) will be used as hand function assessment scales.
223426806|NCT06684730|OTHER|Prosthesis Satisfaction Scale|The Quebec Assistive Technology User Satisfaction Assessment (Q-YTKMD) Questionnaire will be used.
223426807|NCT06684730|OTHER|Quality of Life Scale|5Q-5D-5L will be used as quality of life scale.
223426808|NCT06684730|PROCEDURE|Kinematic Analysis|Kinematic analysis of shoulder abduction, elbow flexion, and cervical flexion will be performed during simulated tasks of drinking water from a glass and filling glass of water.
223426809|NCT06684730|PROCEDURE|Parkour Completion Time|A 10-item daily living activities parkour will be prepared for the participants. During the parkour, the participant will be given the following tasks: opening and closing 10 jar lids, slicing a 20cm cylindrical dough into 10 pieces, simulating drinking soup from a bowl 15 times with a spoon (standard bowl 150 ml, standard tablespoon 10 ml), simulating eating meatballs from a plate with a fork 10 times (approximately 6-10 meatballs per serving), simulating pouring water from a pitcher into a glass 10 times, simulating drinking water from a glass 10 times, simulating brushing teeth for 2 minutes, opening 10 clothespins attached to the edge of a cardboard box and attaching them to the other side, simulating opening and closing a zipper, and putting on shoes and tying shoelaces. The course completion time will be recorded.
223426810|NCT06684730|PROCEDURE|Fatigue Scale|A pre- and post-parkour will be employed, including a 5-point Likert scale for fatigue assesment, hand function assessment scales and kinematic analysis to participants. The results before and after the parkour will be compared.
223426811|NCT06269380|PROCEDURE|Esophagogastroduodenoscopy|During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.
223426812|NCT06269380|PROCEDURE|Endoscopic biopsy sampling|The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.
223426813|NCT02288091|DRUG|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
223426814|NCT02979912|BIOLOGICAL|Platelet Lysate|Eye drops of Platelet Lysate
223564356|NCT07035028|DIAGNOSTIC_TEST|Digital fetal scalp stimulation dFSS|Digital fetal scalp stimulation will be performed for a period of 30 seconds, prior to obtaining the fetal blood sample. Digital fetal scalp stimulation will be performed by vaginal touch with a gauze pad and rubbing the fetal scalp with pressure for 30 to 60 seconds.
223564357|NCT05844098|DEVICE|K-wire|K-wire No. 2.0 insertion was done additionally from arthroscopic assisted CC-stabilization by inserting K-wire from acromion process to distal clavicle.
223564358|NCT06894407|DEVICE|Device: Targeted Hyperthermia Therapy|Intra-tumoral gold nanorods (SivaRods) exposed to Near Infrared Light (860 +/- 10nm) mediated targeted hyperthermia therapy.
224038508|NCT05726864|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 admixed with ELI-002 Amph-Peptides 7P administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing)
224163676|NCT03766113|OTHER|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
223426815|NCT00901017|DEVICE|Straumann BoneCeramic|Bone augmentation procedure performed with Bone Ceramic
223583970|NCT06667713|BEHAVIORAL|ENTRUST - substance use and HIV counseling and goal setting with economic empowerment and photovoice training|The ENTRUST intervention consists of an adapted counseling intervention based on motivational interviewing techniques and goal setting (SBIRT-T); Economic skill building using a tailored app (WorthIt for ENTRUST); and, Photovoice Activities with an optional photo exhibit
223583971|NCT06667713|BEHAVIORAL|SBIRT-T only|An adapted screening brief intervention and referral to treatment intervention to link transgender women to substance use and HIV services
223426816|NCT00901017|DEVICE|Bio-Oss|Bone Augmentation procedure performed with Bio Oss
223426817|NCT02891434|DEVICE|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
223426818|NCT02891434|DEVICE|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
223426819|NCT02891434|DEVICE|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
223426820|NCT00676312|DRUG|PTH134|
223426821|NCT04081025|OTHER|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
223426822|NCT04021121|DRUG|LZD|LZD 1200 mg daily
223426823|NCT04021121|DRUG|High dose RIF|RIF 35 mg/kg/day
223426824|NCT04021121|DRUG|Standard dose RIF|RIF 10 mg/kg/day
223426825|NCT04088279|DIAGNOSTIC_TEST|MRI|Oxygen enhanced and fourier decomposition MRI
224070827|NCT05955625|OTHER|TIMELY|The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
223426826|NCT06480721|OTHER|Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan|"Patients in the investigational arm will undergo the extra FET-PET scan, with use of the O-(2-~¹⁸F-fluoroethyl)-L-tyrosine (¹⁸F-FET) tracer. FET-PET scanning will be performed according to the joint European Association of Nuclear Medicine (EANM)/European Association of Neuro-Oncology (EANO)/Response Assessment in Neuro-oncology (RANO) guidelines. In most patients, a static scan (20-40 minutes post-injection) will performed. If the logistics of the research site allow for a dynamic scan (0-60 minutes post-injection), this will be performed. Interpretation will be done by an experienced nuclear medicine physician from the local center according to current European guidelines. Central review will be performed by a panel of nuclear medicine physicians from the study team. Clinical management is based on the index MRI and this additional \[¹⁸F\] FET PET scan."
224139138|NCT01885858|BEHAVIORAL|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
224139139|NCT01885858|BEHAVIORAL|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
224139140|NCT06191120|RADIATION|[18F]-ALF-FAPI-74 PET/CT scan|Participants will receive up to three \[18F\]-ALF-FAPI-74 PET/CT scans. \[18F\]-ALF-FAPI-74 is a PET tracer with high binding specificity and selectivity to FAP-expressing cells.
223426827|NCT06666634|DRUG|Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan|Sentinel node biopsy with either ICG-99mTc-nanoscan or 99mTc-nanoscan
223426828|NCT01665222|DRUG|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
223426829|NCT02222233|DRUG|BI 671800 HEA delayed release (enteric coated) tablet|
223426830|NCT02222233|DRUG|BI 671800 HEA solution|
223426831|NCT02222233|DRUG|BI 671800 HEA particulate|
223426832|NCT03538977|PROCEDURE|Hydrotherapy|A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.
223426833|NCT03538977|PROCEDURE|Conventional Physiotherapy|Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
223426834|NCT04064970|BEHAVIORAL|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
223426835|NCT03876366|OTHER|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
223426836|NCT03876366|OTHER|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
223426837|NCT04537910|DRUG|LY3819253|Administered SC.
223426838|NCT04537910|DRUG|Placebo|Administered SC.
223426839|NCT03887507|OTHER|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
224070828|NCT03036293|DRUG|Tenoten|Tablet for oral use.
224038509|NCT05423158|BEHAVIORAL|d-Coaching|"MOVN mobile app: Each participant will be assigned a secure login account that does not include personal information for research only. Participants will be trained on how to access and use the MOVN private social network group.~Annie text messaging: Participants will be registered in the Annie VA text messaging program to receive tailored, interactive push messages with a combination of 1 and 2-way tailored messages on goals, barriers, self-management, etc. (based on data collected in real-time from the Fitbit and barriers identified at baseline).~Fitbit wearable device \& mobile app: The intervention group will be instructed to use the Fitbit for step counts and maximizing the Fitbit mobile app/desktop platform to track all PA, sharing one's Fitbit profile with others (optional leaderboard), and use of all available features."
224038510|NCT03960840|BIOLOGICAL|Rapcabtagene autoleucel single agent|Single infusion of rapcabtagene autoleucel
224038511|NCT03960840|DRUG|Ibrutinib|Tablets or capsules for oral daily use
224038512|NCT06334393|BIOLOGICAL|VLA1601|0.45mL (milliliter), Day 1 and 29
224038513|NCT06334393|BIOLOGICAL|CpG 1018®|CpG 1018® will be investigated in combination with VLA1601 Low dose
224038514|NCT06334393|BIOLOGICAL|3M-052-AF|3M-052-AF will be investigated in combination with VLA1601 Low dose
224038515|NCT05999929|BEHAVIORAL|Memory Support System|The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
224038516|NCT06840899|DRUG|CBD|Twice daily 100mg cannabidiol (CBD)
224038517|NCT04649229|DRUG|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
224038518|NCT04649229|DRUG|Placebo|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
224038519|NCT04649229|DRUG|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
224038520|NCT04649229|DRUG|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
224038521|NCT04649229|DRUG|Aprepitant|Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
224038522|NCT05745883|DRUG|DISC-0974|DISC-0974 is administered subcutaneously
223426840|NCT03887507|OTHER|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
223426841|NCT06387706|OTHER|Gamified web-based pain management Program|"Gamified Program Development: The project aims to create a Gamified web-based pain management Program (GAP) tailored for older adults with chronic pain, enhancing engagement through gaming elements.~Inclusive Design Process: Older adults with chronic pain will actively participate in developing GAP, providing valuable feedback throughout the process.~Pilot Study Design: A pre and post study design will be employed, with a small pilot group of 4 participants to offer diverse perspectives in the program's development.~Educational Content \& Activities: GAP will feature interactive educational content on pain effects, medication, non-drug treatments, and exercises, delivered through a mobile-friendly web platform."
223426842|NCT05755607|PROCEDURE|laparoscopic pancreaticoduodenectomy|The laparoscopic group will perform the surgical procedure using laparoscopic instruments, with three surgeons involved throughout the procedure.
223426843|NCT05755607|PROCEDURE|Robot Pancreaticoduodenectomy|The robotic team will perform the surgery using the latest generation Da Vinci robotic surgical system, with an additional surgeon assisting in the procedure.
223426844|NCT01623037|DEVICE|The Zeltiq System|Non-invasive cooling is applied to the each flank with a defined cooling rate and duration.
223426845|NCT02782299|OTHER|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
223426846|NCT05686161|BIOLOGICAL|SW-BIC-213;SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
223583972|NCT04436068|DEVICE|Hyperfine MRI scan|Participants receive a Hyperfine low field strength brain MRI scan in addition to a regularly scheduled standard clinical CT or MRI scan.
223744778|NCT06448559|OTHER|Semi-directive interview|Semi-directive interviews are individual interviews used in a qualitative approach to collect information in order to perform a thematic analysis
224038523|NCT05745883|DRUG|Placebo|Placebo is administered subcutaneously
224038524|NCT05913973|DRUG|Pvs230D1-EPA/Matrix-M|Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris. The synthetic gene sequence was optimized for P. pastoris expression and cloned into the expression vector pPICZ(alpha)A, which also encodes a pre-prosecretory alpha-factor sequence.
224038525|NCT06263582|DRUG|Artesunate pessary|Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
224070829|NCT03036293|DRUG|Placebo|Tablet for oral use.
224070830|NCT00510627|DEVICE|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
224070831|NCT00510627|DRUG|Chemotherapy|Standard of care chemotherapy regimen
224070832|NCT02562742|DRUG|SOF|SOF 400 mg tablets administered orally once daily
223426847|NCT05686161|BIOLOGICAL|Sinopharm (BIBP);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
223426848|NCT05686161|BIOLOGICAL|Pfizer(BNT162b2);SARS-Cov-2.|"The study will be performed in people receiving two doses of Sinopharm vaccine over 180 days (± 30 days) after the second dose prior to enrollment. The three study groups who will receive the booster dose will be assigned as follows:~Subjects (N≈600) Group 1: (N≈200) - Stemirna(SW-BIC-213) Group 2: (N≈200) - Pfizer(BNT162b2) Group 3: (N≈200) -Sinopharm (BIBP) Study groups: There will be three study groups. Study Group Assignment: Randomization (1:1:1) will be applied for subjects to account for the different number of doses per vial for different vaccines and short shelf life."
223426849|NCT04198285|PROCEDURE|Retrograde bladder filling|The bladder will be filled with a large syringe through the urinary catheter (which is left in place for the surgery) with 200mL of sterile saline, and then the catheter will be removed.
223426850|NCT01203826|BIOLOGICAL|Asfotase Alfa|
223426851|NCT04576065|OTHER|WFIT|access to nurse practitioner for telehealth visits and activity monitor for 6 months after hospital discharge
223426852|NCT04473820|DRUG|Vapocoolant spray|The spray will be applied continuously from 25 cm distance for less than 5 seconds to the cannulation site.
224038526|NCT06263582|DIAGNOSTIC_TEST|blood draws for pharmacokinetics of the study drug|On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
224038527|NCT06965699|DIETARY_SUPPLEMENT|ProSauce|10g additional protein from ProSauce
224038528|NCT06965699|DIETARY_SUPPLEMENT|low-protein sauce|Commercially available standard low-protein sauce
223426853|NCT04473820|DRUG|Lidocaine-Prilocaine cream|A finger tip (0.5 gr) of the cream will be applied in 4 square cm at cannulation site and will be covered with closed dressing for 45 minutes.
223426854|NCT00968058|PROCEDURE|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
223426855|NCT03344575|PROCEDURE|Conventional defect closure|Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
223426856|NCT03344575|PROCEDURE|Peritoneal bridging|Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
223426857|NCT06643416|DRUG|Timolol 0.5% eye drops and betamethasone valerate 0.1% cream|Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
223426858|NCT06643416|DRUG|Betamethasone valerate 0.1% cream|The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.
223426859|NCT02788370|DEVICE|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
223426860|NCT02788370|OTHER|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (\>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) \>80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)"
223426861|NCT00091637|DRUG|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
223426862|NCT00091637|DRUG|Placebo infusion|bolus infusion over a 10 minute period once
223426863|NCT04761406|DIETARY_SUPPLEMENT|Phaeosol group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
223426864|NCT04761406|DIETARY_SUPPLEMENT|Placebo group|"In a double blind, randomized manner, 40 pre-menopausal females will ingest one of the following for 12 weeks:~Treatment 1 -Placebo (218 mg/d of 100% sunflower Oil) Treatment 2 - PhaeoSOL (218 mg/d)~Supplements will be prepared in softgel capsules for double blind administration by the sponsor."
223426865|NCT01513811|DRUG|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
223740111|NCT06914375|OTHER|Goya Foods - Canned Chickpeas|Whole-cooked, canned chickpeas supplied by Goya Foods. Provided to participants on a weekly basis in amounts specific to DGAs 2020-2025 and the participant's gender.
224038529|NCT03021460|DRUG|Ibrutinib|Given PO
224038530|NCT03021460|OTHER|Laboratory Biomarker Analysis|Correlative studies
224038531|NCT03021460|BIOLOGICAL|Pembrolizumab|Given IV
224038532|NCT03376152|BEHAVIORAL|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
224038533|NCT06219356|DRUG|GLB-002|Administered orally according to the assigned treatment schedule.
224038534|NCT05718869|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224038535|NCT05718869|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224038536|NCT05718869|PROCEDURE|Computed Tomography|Undergo CT scan
224038537|NCT05718869|BIOLOGICAL|Tafasitamab|Given IV
224038538|NCT05718869|DRUG|Zanubrutinib|Given PO
224038539|NCT06851039|DIETARY_SUPPLEMENT|Potato starch supplementation|Participants will receive potato starch supplement, undergoing gut microbial fermentation and acting as an endogenous source of the short-chain fatty acids, including butyrate. Effects of these compounds on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
223426866|NCT01513811|DRUG|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
223426867|NCT01513811|DRUG|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
223426868|NCT02491801|OTHER|Dietary intervention|All arms are given to all participants, in a randomized order
223426869|NCT00718484|DRUG|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
223426870|NCT00718484|DRUG|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
223426871|NCT02630849|PROCEDURE|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
223426872|NCT02630849|PROCEDURE|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
223426873|NCT05336292|BEHAVIORAL|Meaningful life-focused intervention|The intervention works different skills to increase the meaningful life in the general population and specifically in the army.
223426874|NCT05336292|BEHAVIORAL|Meaningful life and emotional regulation-focused intervention|The intervention works different skills to increase the meaningful life and emotional regulation in the general population and specifically in the army.
223426875|NCT05336292|BEHAVIORAL|Control Group|This group does not do any intervention
224038540|NCT06851039|DIETARY_SUPPLEMENT|Sodium butyrate supplementation|Participants will receive sodium butyrate supplement, acting as an exogenous source of the short-chain fatty acid butyrate. Effects of such compound on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
224038541|NCT06851039|DIETARY_SUPPLEMENT|Accessible starch supplementation|Participants will receive the accessible (digestible) waxy maze starch as placebo.
224038542|NCT05413850|DRUG|Lutetium (177Lu) rhPSMA-10.1 Injection|Therapeutic cycles of 177Lu-rhPSMA-10.1
223426876|NCT03099694|PROCEDURE|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.
223426877|NCT03099694|PROCEDURE|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
223426878|NCT05691959|DRUG|Placebo|Patients randomized to placebo group will receive Normal Saline 50ml IV.
223426879|NCT05691959|DRUG|Calcium|Patients randomized to the study group will receive Calcium 2gm in Normal Saline 50ml IV.
223426880|NCT05994911|BEHAVIORAL|Mindfulness Training|"The application is planned as 8 sessions and one session per week. Each session corresponds to one lesson hour and is approximately 30-40 minutes. In the content of the application, the individual's attention, mind, attitude, intention, thought; It has basic concepts such as the separation and merging process of thoughts in our minds, the deep processes of awareness, staying in the moment, values, focusing process, self-compassion, integration of awareness with other situations in life, meditation practices developed with practice, and the content summarized around these concepts. It is a program that tries to enable individuals to focus on the moment they live in, within the framework of these basic concepts. The program is divided into session titles such as Introduction to Mindfulness, Mind Awareness, Body Awareness, Emotion and Behavior Awareness, Self Compassion, Stress Awareness, Eating Awareness."
223426881|NCT03832790|OTHER|observation|observation
223426882|NCT06771622|DRUG|HCB101|QW
223426883|NCT06771622|DRUG|Trastuzumab|8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days;
223426884|NCT06771622|DRUG|Pertuzumab|840 mg IV on Day 1, cycled every 21 days;
223426885|NCT06771622|DRUG|Oxaliplatin|130 mg/m2 IV on Day 1, cycled every 21 days
223426886|NCT06771622|DRUG|Capecitabine|1000 mg/m2 PO BID on Days 1-14, Cycled every 21 days
223426887|NCT06771622|DRUG|Ramucirumab|8 mg/kg IV on Days 1 and 15, Cycled every 28 days
223426888|NCT06771622|DRUG|Paclitaxel|80 mg/m2 IV on Days 1, 8, and 15, Cycled every 28 days
223426889|NCT06771622|DRUG|Bevacizumab|5 mg/kg IV on Day 1, Repeat every 2 weeks; or 7.5 mg/kg IV on Day 1, Repeat every 3 weeks.
223426890|NCT06771622|DRUG|Cetuximab|400 mg/m2 first infusion, followed by 250 mg/m2 IV weekly; or 500 mg/m2 IV over 2 hours on Day 1 every 2 weeks;
223426891|NCT06771622|DRUG|Irinotecan|180 mg/m2 IV over 30-90 minutes on Day 1 every 2 weeks
223426892|NCT06771622|DRUG|Leucovorin|400 mg/m2 IV on Day 1 every 2 weeks
223426893|NCT06771622|DRUG|5-FU|400 mg/ m2 IV bolus on Day 1, followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks
223426894|NCT06771622|DRUG|Toripalimab|240 mg/kg IV on Day 1 Cycled every 21 days
223426895|NCT06771622|DRUG|Albumin-bound paclitaxel|125 mg/m2 IV on day 1 and Day 8 Cycled every 21 days
223426896|NCT06771622|DRUG|Pembrolizumab|200 mg IV day 1; given every 21 days
223426897|NCT06771622|DRUG|Gemcitabine|1000 mg/m2 IV days 1 and 8
223426898|NCT06595446|PROCEDURE|Early Stent removal|Ureteral JJ stents removed 5-7 days after radical cystectomy and ileal conduit formation
223426899|NCT06595446|PROCEDURE|Late Stent removal|Ureteral JJ stents removed 4-6 weeks after radical cystectomy and ileal conduit formation
224038543|NCT05413850|DIAGNOSTIC_TEST|18F-rhPSMA-7.3 injection (in phase 1 only)|18F-rhPSMA-7.3 (in phase 1 only) at an administered activity of 296 MBq (8 mCi) for PET/CT scan to ascertain whether the subject has PSMA-positive disease.
224038544|NCT04912765|BIOLOGICAL|Neoantigen Dendritic Cell Vaccine|10 doses of the vaccine will be administered via intra-dermal injection concurrently with adjuvant nivolumab.
223426900|NCT02856724|DRUG|PGE2|10 mg PGE2 vaginal ovul(Propess)
223426901|NCT04255680|DIAGNOSTIC_TEST|Buccal Swabs and Blood Draws|Buccal Swabs - Frataxin \& specific RNA markers Blood Draws - Lipid panel, Uric Acid, Protein Marker Analysis and PAX Gene RNA Analysis
223426902|NCT04507919|DRUG|Dabrafenib|150 mg
223426903|NCT04507919|DRUG|Trametininb|2.0 mg
223426904|NCT03424902|DIAGNOSTIC_TEST|cardiac computed tomography and cardiac catheterization|assesment of certain predictors with CT and fluroscopy for paravalvular leakage
223426905|NCT06330792|OTHER|bio-mechanical awareness|Biomechanical awareness advices for physiotherapists during session: consist of group of awareness advices and McKenzie extension part method exercises to help physiotherapist working in correct position and consume his energy.
223426906|NCT06330792|OTHER|core stability exercises|Core stabilization exercise Program: The procedure for core stabilization exercises to improve core muscles in lumbar area
223426907|NCT04699513|DEVICE|Mechanical Ventilation Mode (airway pressure release ventilation )|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that alternates between two levels of continuous positive airway pressure (CPAP) support and allows spontaneous respiratory effort at either CPAP level. It is considered as an alternative, life-saving modality in patients with acute respiratory distress syndrome (ARDS) that struggle for oxygenation.
223426908|NCT06159556|OTHER|Peanut intake|Participants will consume 2 ounces of peanuts/peanut butter for 12 weeks
223426909|NCT05870956|DRUG|Nintedanib|Nintedanib
223426910|NCT00471718|DRUG|ABT-751|"Phase I:~Cohort \| Number of Patients \|Dose (mg) ABT-751 (BID)~* -1 \| 3-6 \|100 mg BID~* 1 \| 3-6 \|125 mg BID~* 2 \| 3-6 \|150 mg BID~* 3 \| 3-6 \|175 mg BID~* 4 \| 3-6 \|200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
223426911|NCT05798741|PROCEDURE|Hardware removal|The surgery of hardware removal after an ORIF of an ankle fracture
223426912|NCT02006797|OTHER|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
223426913|NCT05731037|OTHER|Resistance training for knee extensors|The exercise will be started at 60% of 1 repetition maximum (RM) and progressed to 75% of 1 RM during the first 3 weeks and maintained throughout the intervention period. The exercise will be performed slowly (6 s/ repetition).
223426914|NCT01148160|DRUG|voriconazole|intravenous, oral administration
223426915|NCT05566834|DRUG|Minnelide|at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.
223426916|NCT03287284|DEVICE|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
223426917|NCT03287284|BEHAVIORAL|Resistance Training|Resistance Training
223426918|NCT03287284|DEVICE|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
223426919|NCT02683395|DRUG|PLX51107|
223426920|NCT06333275|BIOLOGICAL|Vaccines against: Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b, varicella and measles|"First immunization course (6±1 months post CAR-T treatment):~1. Diphtheria, tetanus, pertussis, polio, haemophilus influenza type b (as by the Swiss guidelines\[FOPH\] all of these are administered in one combined vaccine; INFANRIX DTPa-IPV+Hib Inj Susp®; GlaxoSmithKline)~2. Hepatitis B (Engerix B®, GlaxoSmithKline)~3. 13-valent Streptococcus pneumonia vaccine (Prevenar-13®; Pfizer)~4. Herpes zoster vaccine in patients with documented prior seropositivity or known varicella-infection in patient history (as by The Swiss guidelines; Shingrix®; GlaxoSmithKline)~5. Tick-borne encephalitis (as by The Swiss guidelines; FSME Immun CC®; Pfizer or Encepur N®, BavarianNordic; these vaccines can be used interchangeably)~Second immunization course (12±1 months post CAR-T treatment):~1. Mumps, measles, rubella (Priorix®, GlaxoSmithKline)~2. Varicella zoster vaccine (as by guidelines; Varilrix®, GlaxoSmithKline) If seronegative/patient history negative"
223426921|NCT02880865|BIOLOGICAL|Live attenuated SA 14-14-2 Japanese Encephalitis vaccine|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
223426922|NCT02880865|BIOLOGICAL|Measles, mumps, rubella vaccine|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
223426923|NCT02971475|PROCEDURE|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
223426924|NCT02971475|PROCEDURE|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
223426925|NCT02971475|DRUG|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
223426926|NCT06166745|DEVICE|Sensi-IP toothpaste|Brushing daily with the Sensi-IP toothpaste for 14 days for dentinal hypersensitivity.
223426927|NCT06166745|DEVICE|Sodium Fluoride Toothpaste|Brushing daily with the Sodium Fluoride toothpaste for 14 days for dentinal hypersensitivity.
223426928|NCT05546346|DEVICE|wearable magnet tracking system|In this group, wearable magnet tracking system was used.
223426929|NCT01117675|OTHER|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
223426930|NCT01117675|OTHER|Standard of Care|Standard of Care
223426931|NCT05982483|PROCEDURE|Erector Spinae plane block using 20 ml of bupivicaine 0.25%|"Utilizing the in line approach, a 22 gauge 3.5 spinal needle was guided the the tip of the transverse process corresponding to the area of maximal tenderness or central to the reported area of spasm. 1% lidocaine with epinephrine was used for skin anaesthesia and for hydro-localization of the needle tip on approach to the tip of the transverse process. Once the needle tip made contact with the transverse process, 2-3 ml of 1% lidocaine with epinephrine was injected to open the ESP plane. If there was no reported tachycardia after approximately 45 seconds, 20 ml of 0.25% bupivicaine was injected into the ESP plane."
223426932|NCT05982483|DRUG|Usual care|Analgesia as dictated by the treating emergency physician
223426933|NCT02224820|BIOLOGICAL|IdeS|Doses are administered in ascending doses
223426934|NCT02591095|DRUG|ABT-263|
223426935|NCT05674123|PROCEDURE|Colonoscopy|Undergo colonoscopy
223426936|NCT05674123|PROCEDURE|Endoscopic Ultrasound|Undergo rectal endoscopic ultrasound
223426937|NCT05674123|OTHER|Medical Chart Review|Ancillary studies
223426938|NCT05674123|OTHER|Medical Device Usage and Evaluation|Undergo resection with the Flex Robotic System
223426939|NCT05674123|PROCEDURE|Resection|Undergo resection with the Flex Robotic System
223426940|NCT01446237|OTHER|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
223426941|NCT06684236|OTHER|transcutaneous electrical stimulation|electrical stimulation is given through electrodes attached to the skin
223426942|NCT06684236|OTHER|electrodes attachment|electrodes are attached to the skin area of Neiguan acupoint, which is located on 3cm above the transverse crease of the wrist
223426943|NCT00611845|DRUG|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
223426944|NCT06666153|BIOLOGICAL|EBV immunological agent|"27 participants with will be enrolled in the study and divided into three groups, including EBV-LPD (Adults group), EBV-LPD (Children group) and PTLD (Adults group） each with 9 people.The participants will be divided into three different dose groups, and a 3+3 dose escalation design is used. The low dose is 5.0×10\^5, the medium dose is 2.0×10\^6 and the high dose is 5.0×10\^6 for children and low dose is 5.0×10\^6, the medium dose is 2.0×10\^7 and the high dose is 5.0×10\^7 for adults. Only one dose will be administered to each participant with EBV immunological agent combined with Toripalimab 240mg."
223426945|NCT04737798|OTHER|oil pulling with coconut oil|using oil pulling therapy with coconut oil
223426946|NCT04737798|OTHER|oil pulling with sesame oil|using oil pulling therapy with sesame oil
223426947|NCT04535531|DRUG|SB206 10.3% berdazimer|Topically once daily
223426948|NCT04535531|DRUG|vehicle gel|Topically once daily
223426949|NCT04724343|DRUG|Triptorelin acetate|0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
223426950|NCT04724343|DRUG|Cetrorelix|0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
223426951|NCT04724343|DRUG|recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin|Dosage adjustment according to the ovarian response.
223426952|NCT04724343|DRUG|Human Chorionic Gonadotropin (hCG)|Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
223426953|NCT00630721|OTHER|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
223564359|NCT06896357|PROCEDURE|Limbal relaxing incisions|A fixed depth diamond-guarded knife (Gemcision LRI 600 Microns Blade, Katalyst Surgical, chesterfield, MO, USA) will be used to create a paired circumferential corneal incision, following the limbal curvature, 1-1.5mm anterior to the limbus centered on the steep corneal meridian. The incision arc length will be ninety degree according to the Nichamin Age and Pachymetry Adjusted (NAPA) nomogram.
224038545|NCT04912765|DRUG|Nivolumab|9 doses of 240mg IV nivolumab as a 30 minutes infusion will be administered in combination with NA DC vaccine starting from the second vaccine dose. Upon completion of 10 doses of NA DC vaccine, 480mg IV nivolumab will be administered as a 30 minutes infusion for a maximum of 9 doses.
223426954|NCT00591617|OTHER|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
223426955|NCT06339164|OTHER|skills and learning quality in breech delivery|evaluation of different skill retention and learning quality after different learning methods
223426956|NCT05703880|DRUG|Finerenone (Kerendia, BAY948862)|Retrospective cohort analysis using United States Optum EHR data and OM1 RWDC databases.
223426957|NCT01190267|DRUG|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
223426958|NCT04203992|BEHAVIORAL|Videogame|"True Champion is an educational, values-based game that aims to empower young athletes to make informed decisions to avoid doping.~Participants engaging in the videogame sessions will encounter a series of thought-provoking situations and knowledge tests. Players will help their assigned character navigate through these curriculum-rich scenarios in order to reach their performance goals in a healthy and ethical way."
223426959|NCT04203992|BEHAVIORAL|Control|Participants will be given an anti-doping booklet prepared by UNESCO. This booklet is considered standard educational material, i.e. what might be presented to young athletes as part of their regular sports curriculum.
223426960|NCT01662921|DRUG|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
223426961|NCT01662921|DRUG|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
223564360|NCT06896409|COMBINATION_PRODUCT|PuraStat® combined with Adrenaline|PuraStat® application (mL) combined with Adrenaline injection (mL)
223564361|NCT06896409|COMBINATION_PRODUCT|Standard of Care|Adrenaline injection + second hemostasis modality (contact thermal, mechanical therapy, or injection of a sclerosing agent).
223564362|NCT06896851|OTHER|Su Jok|a type of acupressure includs hand massage
224038546|NCT06315829|DEVICE|Spasm Vision|Machine learning software developed to analyze videos and accurately distinguish infantile spasms from visually similar movements.
224038547|NCT04664829|DRUG|Bexarotene|Administered orally once a day. Starting dosage: 200mg/m\^2
224038548|NCT04664829|DRUG|Capecitabine|Administered orally twice a day. Dosage: 1000mg/m\^2
223426962|NCT01662921|DRUG|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
223426963|NCT06500065|PROCEDURE|Computed Tomography|Undergo dPET/CT
223426964|NCT06500065|RADIATION|Gallium Ga 68-HA-DOTA-TATE|Given IV
223426965|NCT06500065|PROCEDURE|Positron Emission Tomography|Undergo dPET/CT
223426966|NCT01056198|DRUG|Santyl|2 mm Santyl applied once daily.
223426967|NCT01056198|PROCEDURE|Control|Daily gauze and optional sharp debridement
223426968|NCT06618456|BEHAVIORAL|VR dive (with Hypnosis)|Participants experience a VR dive through a friendly underwater world. They get a trance induction via audio.
223426969|NCT06618456|BEHAVIORAL|VR dive (without Hypnosis)|Participants experience a VR dive through a friendly underwater world. They are informed that this part of the VR is a familiarization phase to the VR and they do not get a trance induction.
223564363|NCT06896851|OTHER|Sham point using|unrelated point using for acupressing
223426970|NCT06618456|BEHAVIORAL|Height exposure|The participants go through a height exposure. They start at the ground level of a virtual city and move upwards in 3 meter steps until they reach a height of 60 meters. Participants focus on a yellow spot on a balcony in front of them, so that they can recognise the depth perimeter.
223426971|NCT01952119|OTHER|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
223426972|NCT03481374|DIAGNOSTIC_TEST|autonomic function testing|"autonomic function testing, ergospirometry, three questionnaires~Other Names:~* The autonomic function tests consist of five tests:~  * The Valsalva maneuver~ * The isometric handgrip test~ * The deep breathing test~ * The cold pressor test~ * A short head-up tilt test~* A maximal ergospirometry~* Three questionnaires:~  * EQ-5D-3L: quality of life~ * IPAQ: capacity to do physical activities"
223426973|NCT04017832|DRUG|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
223426974|NCT04017832|DRUG|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
223426975|NCT04017832|DRUG|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
223426976|NCT04017832|DRUG|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
223426977|NCT06620783|BEHAVIORAL|exercise|Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
223426978|NCT06620783|BEHAVIORAL|yoga|The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.
223426979|NCT06620783|BEHAVIORAL|active self-care|The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
223426980|NCT06668766|DEVICE|10-cm Single Lumen Mildine|Arm Description: The BD Powerglide Pro Midline catheter is currently approved for use by the FDA and by Albany Medical Center. This 18-gauge or 20-guage MC is distinct in that it is a standard 10-cm, does not require premeasurement or trimming of the catheter prior to placement, and features an accelerated Seldinger technique, meaning that it has a built-in deployable internal wire system. Additionally, because it is only 10-cm, it does not require a confirmatory chest x-ray prior to use. The provider will use standard aseptic technique for placing the MC (e.g., chlorhexidine prep, sterile probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number from the randomization packet to allow for vessel depth and size measurement.
223426981|NCT06668766|DEVICE|4.78 cm Long Peripheral Intravenous Catheter|The BD Insyte Autoguard 4.78 cm 18- or 20-gauge needle with self-retraction is currently approved for use by the FDA and by Albany Medical center. The long PIV will be placed using standard aseptic technique (e.g., chlorhexidine prep, sterile gloves, sterile ultrasound probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number in the comments section of the QPATH worksheet to allow for vessel depth and size measurement. Operators will be instructed to use standard techniques in US-guided vascular access.
223426982|NCT06684600|DRUG|Dalpiciclib + Pyrotinib|Dalpiciclib Isethionate tablets, 125mg, oral administration on days 1 to 21, followed by a 7-day drug holiday, every 4 weeks; Pyrotinib Maleate tablets, 320mg, oral administration once daily on days 1 to 28, every 4 weeks; Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, or the investigator determines that the subject should discontinue study treatment.
223426983|NCT06187961|PROCEDURE|HAIC|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks.
223426984|NCT06187961|DRUG|Lenvatinib plus cadonilimab|lenvatinib (8mg, qd) plus cadonilimab (10mg/kg, q3w)
223426985|NCT06620796|DRUG|Arm 1|Ivonescimab combined with Cadonilimab plus EC
223426986|NCT06620796|DRUG|second-line group|AK112+AK104+paclitaxel
223426987|NCT05019846|DRUG|Triptorelin Embonate|single administration before SRT starting
223426988|NCT05019846|DRUG|Bicalutamide 50 mg|1 dose each day, 7 days before LHRH until 10 days after LHRH administration
223426989|NCT02141815|DIETARY_SUPPLEMENT|Arabinoxylan-oligosaccharides|
223426990|NCT02141815|DIETARY_SUPPLEMENT|Maltodextrine|
223426991|NCT03634436|DRUG|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
223426992|NCT03634436|DRUG|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
223740112|NCT06914375|OTHER|Goya Foods - Canned Lentils|Whole-cooked, canned lentils supplied by Goya Foods. Provided to participants on a weekly basis in amounts specific to DGAs 2020-2025 and the participant's gender.
223426993|NCT02046395|DRUG|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
223426994|NCT05928559|OTHER|OMRON BF511 Body Composition Monitor|The OMRON BF511 Body Composition Monitor is a digital scale and participants' body compositions will be evaluated with this device. The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test and the maximum oxygen consumption levels will be calculated with the help of the formula with the data obtained from this test. The trunk extensor muscle endurance of the participants will be evaluated with the Biering-Sorensen Test and the trunk flexor endurance will be evaluated with the Kraus-Weber Test. Participants' M. Quadriceps, M. Hamstring, M. Biceps Brachii and M. Triceps Brachii muscle strengths will be evaluated with MicroFET® 2 hand dynamometer.
223740113|NCT06914375|OTHER|Control|Participants in the Control condition (CTL) will be asked to consume their standard diet while avoiding any and all pulse intake.
223740114|NCT05327010|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223740115|NCT05327010|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224038549|NCT01701596|PROCEDURE|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
224038550|NCT01701596|PROCEDURE|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
224038551|NCT04721132|BIOLOGICAL|Atezolizumab|Given IV
223426995|NCT06886048|DIETARY_SUPPLEMENT|barley green|Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
223426996|NCT06724900|BIOLOGICAL|KB304|Genetically modified herpes simplex type 1 virus
223426997|NCT06724900|DRUG|0.9% Normal Saline (NS)|Placebo
223426998|NCT06076018|DRUG|Group morphine|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
223426999|NCT06076018|OTHER|Group placebo|Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
223427000|NCT02166411|PROCEDURE|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
223427001|NCT02166411|PROCEDURE|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
223427002|NCT05238870|OTHER|Interviews for the needs analysis. No intervention.|To develop the education and training package, a needs-analysis is necessary. The clinicians' training needs will be established through interviews.
223740116|NCT05327010|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223427003|NCT03005223|DRUG|Co-administration of DWC20155/DWC20156|
223427004|NCT03005223|DRUG|DWC20163|
223427005|NCT00940680|DRUG|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
223427006|NCT00940680|DRUG|Losartan|losartan 100mg q.d.
223427007|NCT01300299|RADIATION|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (\> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within \<2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
224038552|NCT04721132|BIOLOGICAL|Bevacizumab|Given IV
224139141|NCT00155454|PROCEDURE|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
224139142|NCT04622085|DEVICE|ANIMERS Chiara LA|20mg/SciVision Biotech Inc.
223427008|NCT06373393|OTHER|STABILISE|"STABILISE technique: Stent assisted balloon induced intimal disruption and relamination in aortic dissection repair"
223427009|NCT04316442|BIOLOGICAL|STI-6129|Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
223427010|NCT02294175|DEVICE|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
223740117|NCT05327010|PROCEDURE|Diagnostic Imaging Testing|Undergo diagnostic imaging
223740118|NCT05327010|DRUG|Talazoparib|Given PO
223740119|NCT02048033|DEVICE|Regular endoscopy + endogastric suturing|Patients will get the usual endoscopy used for diagnosis. In addition, they will receive an endoscopic surgery using the APOLLO Endosuregery technique. The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
223740120|NCT02048033|DIAGNOSTIC_TEST|Regular endoscopy|Patients will get the usual endoscopy used for diagnosis.
223740121|NCT06425159|DRUG|BHV-7000|BHV-7000 75mg. Participants will take blinded investigational product (IP) once daily
223740122|NCT06425159|DRUG|Placebo|Matching placebo taken once daily
224038553|NCT04721132|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224038554|NCT04941222|OTHER|"With robotic seal PARO"|The PARO robot will be made available to the patient by the caregiver in charge of the patient for 5mn before a toilet and during the duration of the care (about 10mn), at the frequency of twice a week for 16 weeks
224038555|NCT04685616|RADIATION|Involved site radiotherapy|"Involved site radiotherapy as per International Lymphoma Radiation Oncology Group (ILROG) guidelines.~Recommended dose 30Gy"
224038556|NCT04685616|DRUG|Doxorubicin|See arm description
224038557|NCT04685616|DRUG|Bleomycin|See arm description
224038558|NCT04685616|DRUG|Brentuximab vedotin|See arm description
224038559|NCT04685616|DRUG|Vinblastine|See arm description
224038560|NCT04685616|DRUG|Dacarbazine|See arm description
224038561|NCT04685616|DRUG|Haematopoietic growth factor|See arm description
224139143|NCT04622085|DEVICE|JUVÉDERM VOLUMA®|20mg/Allergan, Inc.
224139144|NCT03115112|DRUG|Bexagliflozin|tablets containing 20 mg bexagliflozin
224139145|NCT03115112|DRUG|Sitagliptin|tablets containing 100 mg sitagliptin
224038562|NCT06969664|DRUG|SHR7280 Tablet|Oral SHR7280 tablet.
223427011|NCT02294175|PROCEDURE|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
223427012|NCT06142877|BEHAVIORAL|Social Media Use Reduction|Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
223427013|NCT06617247|DRUG|Intervention1: Cannabidiol|Os cuidadores randomizados para esta intervenção usarão CBD oral 300 mg (ou seja, 150 mg, duas vezes ao dia) por quatro semanas. A substância será fornecida gratuitamente pela empresa Ease Labs e será administrada em cápsulas para promover o cegamento. Esta posologia foi baseada no estudo, no qual o CBD nesta dosagem e forma de apresentação provou ser seguro e eficaz na redução de indicadores de burnout em profissionais de saúde da linha de frente da COVID-19. A segurança do uso do CBD também foi relatada em estudos anteriores conduzidos com humanos. Os efeitos colaterais do uso do CBD são raros, incluindo sintomas leves e toleráveis (por exemplo, tontura, sonolência, fadiga, letargia, náusea, dor de cabeça, febre e alterações sensoriais).
223427014|NCT06617247|DRUG|Intervention 2: Placebo|In this group, the subjects will receive placebo intervention. For blinding purposes, caregivers in this group will use the vehicle of oral CBD 300mg (
223427015|NCT01718834|BIOLOGICAL|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
223427016|NCT01718834|BIOLOGICAL|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
223427017|NCT00792688|DRUG|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
223427018|NCT00792688|DRUG|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
223427019|NCT00792688|DRUG|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
223427020|NCT05040607|OTHER|Data Collection|"The first stage of the study:~Retrospective data collection of pulmonary function, respiratory muscle strength, exercise capacity, physical fitness, and activities of daily living (ADL).~The second stage of the study~-Retrospective data of pulmonary function, respiratory muscle function, functional capacity before and after supervised inspiratory muscle training with POWERbreathe K5 device using tapered flow resistive loading and airway clearance techniques performed for 6 weeks in PCD with decreased respiratory muscle strength."
223427021|NCT05040607|OTHER|Data Collection|-Retrospective data collection of pulmonary function, respiratory muscle function, exercise capacity, physical fitness, and activities of daily living (ADL).
223427022|NCT01921712|DRUG|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
223427023|NCT01921712|DRUG|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
223427024|NCT01921712|DRUG|Active comparator|Randomized single dose of inhaled active comparator product
223427025|NCT01945437|DRUG|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
223427026|NCT06860984|DRUG|Duloxetine|Duloxetine, a non-opioid neuromodulator, has been widely used to manage neuropathic pain. It possesses dual central and peripheral analgesic properties
223427027|NCT06860984|OTHER|Placebo capsule|Placebo will have the same look and appearance of active comparator
223427028|NCT05655286|DRUG|38% SDF treatment|Children with active caries will receive 38% silver diamine fluoride treatment
223427029|NCT05655286|BEHAVIORAL|not to rinse for at least 30 minutes after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
223427030|NCT05655286|BEHAVIORAL|rinse mouth immediately after SDF treatment|After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
223427031|NCT04447391|OTHER|Combined exercise program|Combined exercise programme, consisting of warm-up, aerobic exercise, resistance training, and cool-down, 3 days a week after school for 50 minutes from 17;30 under supervision by a trainer plus 300 kcal deficit diet
223427032|NCT04447391|OTHER|Control|300 kcal deficit diet only
223427033|NCT06604689|DRUG|third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)|EGFR-mutated NSCLC patients with brain metastases who met the inclusion and exclusion criteria, would receive first-line third-generation EGFR-TKI treatment (monotherapy or combined with upfront cranial radiotherapy)
223427034|NCT05352672|DRUG|Fianlimab|Intravenous (IV) infusion
223427035|NCT05352672|DRUG|Cemiplimab|IV infusion
223427036|NCT05352672|DRUG|Pembrolizumab|IV infusion
223427037|NCT05352672|DRUG|Placebo|IV infusion
223427038|NCT06648356|OTHER|Neuromuscular electrical stimulation (NMES)|Neuromuscular electrical stimulation (NMES) is applied during an isometric contraction. The NMES uses a symmetrical biphasic rectangular pulse (50Hz frequency and 300 µs phase width) delivered through an Enraf Nonius TensMed S82 electrostimulator. Two 5x9 cm electrodes are placed on the hamstrings, and participants adjust the current to a moderate-strong, yet painless, contraction level. During the intervention, one researcher maintains the stretch position while another researcher controls the current intensity and monitors the timing of both stretching and contractions.
223564364|NCT06897098|BIOLOGICAL|Implantation of autologous cartilage mini-grafts (Cartibeads)|"1. st surgery: cartilage biopsy harvest by minimally invasive surgery (arthroscopy or mini arthrotomy).~2. nd surgery: Implantation of autologous cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant)."
224038563|NCT06969664|DRUG|SHR7280 Placebo Tablet|Oral SHR7280 placebo tablet.
224038564|NCT05704647|DRUG|BMS-986213 (Relatlimab-Nivolumab FDC)|Given by IV (vein)
224038565|NCT05704647|DRUG|Nivolumab|Given by IV (vein)
224038566|NCT05704647|DRUG|Relatlimab|Given by IV (vein)
224038567|NCT03964233|DRUG|BI 907828|Film-coated tablets
224038568|NCT03964233|DRUG|ezabenlimab|Solution for infusion
224038569|NCT03964233|DRUG|BI 754111|Solution for infusion
224038570|NCT06411925|DRUG|Atock Dry Syrup with placebo patch|Atock Dry syrup (TID) with placebo patch (QD)
224038571|NCT06411925|DRUG|Tulobuterol patch with placebo dry syrup|Tulobuterol patch (QD) with placebo dry syrup (TID)
224038572|NCT05025423|DRUG|Venetoclax Oral Tablet [Venclexta]|Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8
224038573|NCT05632315|DRUG|PMT|Fecal Microbiota for Transplant, enema product (PMT-001) or Fecal Microbiota for Transplant, suspension product (PMT-002)
224038574|NCT00285935|OTHER|Standard Clinical Care with an SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)"
224038575|NCT01052922|OTHER|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
224139146|NCT03115112|DRUG|Placebo for sitagliptin|inactive tablets to match the appearance of sitagliptin tablets
224304936|NCT06616896|DEVICE|vibration|Each participant will randomly receive four different vibration conditions (2 frequencies × 2 vibration modes = 4 conditions) in a different order. Considering that the current research range of local vibration frequency is 10 to 150 Hz the frequencies with low and high frequencies (30/60Hz) will be selected. The location chosen for this study is the quadriceps muscle belly. Two-minute vibrations will improve muscle strength without any fatigue side effects. Two vibration modes include providing a two-minute continuous vibration intervention and only providing vibration during the rest position before executing the functional test.
223427039|NCT06648356|OTHER|Contract-Relax PNF (crPNF)|The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
223427040|NCT00502892|DRUG|Topotecan|0.5 mg/m\^2 IV Daily x 3 Days
223427041|NCT00502892|DRUG|Ifosfamide|1.8 grams/m\^2 IV Over 1 Hour x 5 Days
223427042|NCT00502892|DRUG|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days \[for patients \> 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days\]
223427043|NCT00965341|DRUG|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
223427044|NCT00965341|DRUG|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
223427045|NCT02807506|DEVICE|Mobile Service Robot|The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
223427046|NCT02807506|OTHER|Survey|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot.
223427047|NCT03548142|BEHAVIORAL|provision of relevant information|caregivers are provided with brochure that informs about end-of-life issues for persons with advanced dementia
223427048|NCT04010929|PROCEDURE|Partial pulpotomy with laser+MTA|After removing caries, laser+MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
223740123|NCT01568671|OTHER|Room temperatures|Room temperature of metabolic chamber set between 16C and 31C
223740124|NCT06911632|DEVICE|ECG-based AI Device - Results Returned to Investigator|An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.
223740125|NCT06911632|PROCEDURE|Echocardiogram and Right Heart Catheterization|Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart
223740126|NCT06911632|DEVICE|ECG-based AI Device - Results Not Returned to Investigator|An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.
223740127|NCT07105891|OTHER|Thawing protocol|Standard thwaing
223740128|NCT07105891|OTHER|thawing protocol|Fast thawing
223740129|NCT07105891|OTHER|thawing protocol|Ultrafast thawing
224038576|NCT01052922|OTHER|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
224038577|NCT01052922|OTHER|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
224038578|NCT05606068|DEVICE|Paxman Limb Cryocompression System (PLCS)|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Cryocompression will be applied during every cycle of chemotherapy for a duration of up to 4 hours. All chemotherapy patients will receive 30 minutes pre-infusion cooling and 30 minutes post-infusion cooling. Cryocompression for each cycle will not exceed 4 hours. Chemotherapy and concomitant limb cryocompression are performed for 12 cycles and may be continued further in consultation with the PI. Overall, limb cryocompression will be administered for no longer than four hours."
224038579|NCT03824483|DRUG|Zanubrutinib|zanubrutinib (160mg by mouth BID)
224038580|NCT03824483|DRUG|Obinutuzumab|"obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter)."
224139147|NCT03115112|DRUG|Placebo for bexagliflozin|inactive tablets to match the appearance of bexagliflozin tablets
224139148|NCT05027256|DEVICE|Entia Liberty|Home Monitoring solution
224139149|NCT02466568|DRUG|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
224139150|NCT02466568|BIOLOGICAL|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
224139151|NCT05415345|BIOLOGICAL|Cecolin|Bivalent HPV Vaccine
224139152|NCT05415345|BIOLOGICAL|Hecolin|Hepatitis E vaccine
223427049|NCT04010929|PROCEDURE|Partial pulpotomy with MTA|After removing caries, MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
223427050|NCT04778462|DEVICE|extracorporeal shock wave and conventional treament|"Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band will be applied as low energy 2 sessions per week for 2 weeks The will be used as a radial type of shock wave therapy.~Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
223427051|NCT04778462|DEVICE|high pain threshold ultrasound and conventional treatment for myofascial pain syndrome trigger points|"will be applied in continuous mode, with the probe placed directly on the TrP and held motionless. To elicit threshold pain, the US probe will be kept static on the TrP. Intensity gradually will be increased to the level of maximum pain the patient could bear. It will be kept at that level for 3 to 4 seconds, then will be reduced to the half-intensity level for another 15 seconds. This procedure was repeated 3 times.the intensity of US will be dependent on the patient's level of pain. intensity will be applied in the range of 0.5 to 2.0 Watt per/cm2. Patients continually report their pain level and its localization and nature High-power pain threshold US will be applied 4 times, with a 3-day interval 2 sessions per week for 2 weeks .~1)Isometric neck extensor exercise2)Isometric neck flexor exercise3)Isometric neck side bending muscle exercise,Stretching exercise:Passive stretching for the neck extensor muscles ,stretching of the neck side-bending muscles,Ischemic compression"
223427052|NCT04778462|OTHER|conventional treatment for myofascial pain trigger point|"Strengthening, stretching exercises and ischemic compression:~1. Isometric neck extensor exercise:~2. Isometric neck flexor exercise:~3. Isometric neck side bending muscle exercise:~Stretching exercise:~Passive stretching for the neck extensor muscles:~Passive stretching of the neck side-bending muscles:~Ischemic compression"
223427053|NCT02925182|DEVICE|Er,Cr:YSGG Laser|
223427054|NCT02898727|OTHER|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
223427055|NCT00963027|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
223427056|NCT00963027|DRUG|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
223427057|NCT00355576|DRUG|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
223427058|NCT00355576|DRUG|Creatine|10 g BID for either study arm
223427059|NCT00355576|DRUG|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
223427060|NCT06667791|OTHER|Computer guided sodium hyaluronate injections|Patients will be treated with Computer guided sodium hyaluronate injections in superior TMJ space
223427061|NCT06667791|OTHER|conventional sodiumhyaluronate injections|Patients will be treated with conventional sodium hyaluronate injections in superior TMJ space
223427062|NCT00003829|DRUG|cyclophosphamide|
223427063|NCT00003829|DRUG|fludarabine phosphate|
223427064|NCT06407557|BEHAVIORAL|Accelerometer|Use of prompts to enable activity in older adults.
223427065|NCT03108586|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
223427066|NCT03108586|PROCEDURE|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
223427067|NCT03097367|DIAGNOSTIC_TEST|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at \<2 cm below SMSP, and Level -2: bladder neck at \>2 cm below SMSP.
223740130|NCT07113093|OTHER|Augmented Reality|Gait training will be conducted using the AR applications Stepping Stones, Reactive Stones, Obstacles, Speed Adjustment, Slalom, Tandem, and Monster Game for 45 minutes.
224038581|NCT03824483|DRUG|Venetoclax|Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
224038582|NCT01644110|DRUG|INCB018424/CC-4047|"Cohort 1: For patients (1-41) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.~Cohort 2: For patients (42-90) the starting dose of ruxolitinib in this trial is 10 mg twice daily po; the starting dose of pomalidomide is 0.5 mg po once daily."
224304937|NCT06577532|DRUG|ABO2102|mRNA encoding mutant KRAS neoantigens, administrated intramuscularly
223740131|NCT07113093|OTHER|Virtual Reality|Gait training will be conducted using the VR applications Nature Island, Italian Apps, and Soccer for 45 minutes.
223427068|NCT01077739|DRUG|fluorouracil (5FU)|standard FOLFOX regimen
223427069|NCT01077739|DRUG|leucovorin|standard FOLFOX regimen
223427070|NCT01077739|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
223427071|NCT01077739|DRUG|capecitabine [Xeloda]|standard XELOX regimen
223427072|NCT01077739|DRUG|oxaliplatin|standard XELOX or FOLFOX regimen
223427073|NCT00960986|DRUG|Duloxetine hydrochloride|po, QD
223427074|NCT04864340|DEVICE|CE marked medical device|Tetanic stimulation
223427075|NCT04864340|DEVICE|Algometer|Pressure stimulation
223427076|NCT04864340|PROCEDURE|Comparator|Non-nociceptive procedure (fine touch)
223427077|NCT00539149|DRUG|Amoxycillin|50 mg/kg/day twice daily
223427078|NCT00539149|DRUG|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
223427079|NCT01766752|DEVICE|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
223427080|NCT05523193|OTHER|Formal treatment model|Formal treatment model , no further surgery or minimally invasive treatment was performed
223427081|NCT06276777|PROCEDURE|Tooth varnish (PRG Barrier Coat from Shofu)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
223427082|NCT06276777|PROCEDURE|Tooth varnish (Clinpro white varnish 3M)|Treatment of cervical dentin hypersensitivity with tooth desensitizers.
223427083|NCT03229447|BEHAVIORAL|eLearning Modules|All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
223427084|NCT03229447|BEHAVIORAL|Change Team Intervention|Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
223427085|NCT05189327|OTHER|No intervention|Non-interventional study
223427086|NCT00110227|BEHAVIORAL|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
223427087|NCT00110227|BEHAVIORAL|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
223427088|NCT02964754|DEVICE|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
223427089|NCT02964754|PROCEDURE|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
223427090|NCT06450054|DIAGNOSTIC_TEST|Aerobic Exercise in diabetic post-stroke patients|The experimental group's members will use the treadmill for a five-minute warm-up and cool-down. Over 12 weeks, they will attend three 40-minute weekly sessions in groups of two to four. They will then perform aerobic exercise for thirty minutes at a heart rate reserve of 60% to 80%. Those with a low exercise tolerance will first be given small workouts lasting at least ten minutes, interspersed with rest periods until they can perform 30 minutes of exercise. They will progress to longer, continuous workouts punctuated by shorter rest periods as their tolerance to exercise grows. The degree of treadmill training intensity will be adjusted step-by-step according to each person's tolerance, heart rate, blood pressure responses, and perceived effort rate. If they exercise beyond their cardiovascular conditioning zone, participants will be instructed to raise their treadmill speed until they achieve it
223427091|NCT06450054|OTHER|Aerobic Exercise in Non diabetic post-stroke patients|Group B will be managed aerobic exercise in non-diabetic post-stroke patients. Participants in the control group will walk outside comfortably while maintaining a heart rate reserve of less than 40%. They will be instructed to reduce their pace until their training zone reaches ≤40% if their heart rate reserve exceeds 40%. If the efficacy is demonstrated, participants in the control group will receive the experimental intervention
223427092|NCT04116827|DRUG|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
223427093|NCT04464720|BEHAVIORAL|Cooking Ventilation Intervention|An educational video presentation for the families regarding the importance of ventilation use during and after cooking, and strategies for improving the ventilation during cooking, has been created by Dr. Holm, with input from Youth Research Assistants (YRAs) The youth involvement will help to ensure that the information is presented in a way that will resonate with the local community and will also provide the youth with exposure to developing health education tools. The educational video will be shown to families at the time of the intervention visit and they will receive printed reminder materials of what they have learned.
223427094|NCT02389569|PROCEDURE|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
223427095|NCT02389569|PROCEDURE|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
223427096|NCT02511314|DEVICE|TENA Identifi|TENA Identifi
223427097|NCT00342563|DRUG|mecamylamine|mecamylamine 10mg/day
223427098|NCT00342563|DRUG|Placebo|Placebo
223564365|NCT06762626|OTHER|Frozen embryo transfer according to endometrial receptivity analysis result|Frozen embryo transfer will be arranged according to endometrial receptivity analysis result, which will be shown in the form of P+X hours
223564366|NCT06086873|DEVICE|Implant Type|"Patients enrolled in the study will be allocated to one of three implant groups:~* Group 1: NGA Implant (NobelActive TiUltraNP, Nobel Biocare AG, Switzerland)~* Group 2: BLX implant (BLX) modSLA Surface (BLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)~* Group 3: TLX implant (TLX) modSLA Surface (TLX, SLActive, Roxolid, Institut Straumann AG, Switzerland)."
224070833|NCT02562742|DRUG|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (\< 60 kg = 600 mg , \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
223564367|NCT06895395|BEHAVIORAL|High intensive combined phonetic-phonological intervention|High intensity speech intervention 5 times 30' per week for 2 times 4 weeks
223564368|NCT06895395|BEHAVIORAL|Low intensive combined phonetic-phonological intervention|low intensity speech intervention 2 times 30' per week for 20 weeks
223564369|NCT06896487|OTHER|Surface EMG Biofeedback Muscle and Relaxation Training|We think that 6 weeks of superficial EMG Biofeedback muscle training and relaxation training given to the participants in this study will improve the patient's upper trapezius activation and voluntary contraction performance.
223564370|NCT06896487|OTHER|Conventional Rehabilitation|The conventional rehabilitation group of this study received ultrasound, TENS and hot pack application 3 days a week for 6 weeks.
223564371|NCT06897787|PROCEDURE|manuel positioning group|As Prof. Reyneke does, mandibular base and proximal segment leveling are performed first, followed by fixation.
223564372|NCT06897787|PROCEDURE|mandibular basis osteotomy|After the mandibular sagittal split, secure the proximal segment in its preoperative position and remove the bone piece for leveling. After that, fixation is performed.
223583973|NCT03681678|DEVICE|fCO2 Laser Therapy Group|Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
223427099|NCT04818606|OTHER|Mindfulness Oriented Recovery Enhancement|Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings.
223427100|NCT04531254|BEHAVIORAL|Wearing a face mask at all times|Children in this group will be asked to wear a face mask in the classroom and common areas during the simulation
223427101|NCT05537792|DEVICE|Robotic Knee/Ankle Prosthesis|The intervention is an experimental robotic knee/ankle prosthesis that has been previously developed by the team. It is used to improve walking gait performance.
223427102|NCT06629298|OTHER|5Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 5 Hz."
223427103|NCT06629298|OTHER|2 Hz Stochastic Resonance Whole-Body Vibration Training|"Both the experimental group and the control group performed their training on an SRT Zeptor® Medical plus noise device (Frei Swiss AG, Zurich). The device featured two independent foot plates that vibrated stochastically in all three dimensions, resulting in multidimensional movement. During the training, participants were instructed to stand on the foot plates with both feet, keep their arms relaxed at their sides, maintain a slight bend in their knees, and focus their gaze on a fixation cross on the wall. Following the protocol used in Faes et al. (2018), each training session consisted of three series, each comprising one minute of vibration training followed by one minute of rest.~The vibration frequency for the intervention group was set at 2 Hz."
223427104|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (test product)|One tablet of Test
223427105|NCT01600274|DRUG|Dienogest-Ethinyl Estradiol (reference product)|One tablet of Reference
223427106|NCT06329960|OTHER|Ultrasound-guided injection combined with needle release|Ultrasound-guided PIT using D5W HD for dorsal scapular nerve combined with needle release of major and minor rhomboideus
223427107|NCT04913727|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging before the procedure|CMR image acquisition with previously mentioned analysis
223427108|NCT04913727|PROCEDURE|Transcatheter mitral edge-to-edge repair.|Included patients will undergo Transcatheter mitral edge-to-edge repair.
223427109|NCT05123092|OTHER|Ultrasound guided lumbar erectae spinae block|One group by using ultrasound for making erectae spinae block
223427110|NCT05123092|OTHER|Intrathecal Morphine injection|Injecting intrathecal morphine
223427111|NCT03150992|DIETARY_SUPPLEMENT|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars \& sweeteners.
223427112|NCT06509750|OTHER|Carob-meal|A meal with carob-beverage
223427113|NCT06509750|OTHER|Non-carob-meal|A meal with orange-beverage
223427114|NCT01376466|OTHER|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
223427115|NCT00033202|DRUG|Gimatecan® (ST-1481)|
223427116|NCT00319384|DEVICE|Ultrafiltration therapy|
223427117|NCT01636154|DRUG|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
223427118|NCT01636154|DRUG|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
223427119|NCT01636154|DRUG|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
223427120|NCT04614038|DIAGNOSTIC_TEST|DETEC® pH|DETEC® pH is a disposable diagnostic device that is used to indicate the alkalinity of the wound by testing wound exudate adsorbed onto wound dressing.
223427121|NCT01522287|BEHAVIORAL|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
223740132|NCT07113093|OTHER|Self Directed Exercises|"Patients will be taught exercises including walking on a flat surface, walking with varying step lengths, walking over obstacles, and walking at different speeds. They will be instructed to perform these exercises for 45 minutes per day."
223740133|NCT07113093|OTHER|Others|The treatment duration is 60 minutes. Based on the patient's needs, the following exercises will be performed: scapular and thoracolumbar mobilization; upper and lower extremity exercises (range of motion, stretching, and strengthening); bed mobility and transitional movements such as rolling, coming to a sitting position, and standing up; core activation exercises such as bridging and functional reaching; weight shifting and balance training; gait training (e.g., walking between parallel bars, walking in different directions, and walking over obstacles); and cycling on a bicycle ergometer.
223740134|NCT07103278|DRUG|AD-116|AD-116 Oral Tablet
223740135|NCT07103278|DRUG|AD-1161|AD-1161 Oral Capsule
224070834|NCT04032210|OTHER|dual Zinc plus Arginine based toothpaste (Colgate total)|Regimen using dual Zinc plus Arginine based toothpaste (Colgate total)
223427122|NCT03763461|DEVICE|HFNC|High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
223427123|NCT03763461|DEVICE|Oxygen Mask|Application of oxygen during conscious sedation
223740136|NCT07108439|OTHER|Administration of intra-osseous local anesthesia before the extraction of a first permanent molar under general anesthesia|Intra osseous administration of articain 4% 1/100 000 during general anesthesia for the extraction of a first permanent molar. The administration will be done with Quicksleeper 5.
224038583|NCT03588507|COMBINATION_PRODUCT|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
224038584|NCT05742737|OTHER|Frailty Index|The mFI-5 scoring system used in the current study was developed by Saxton and Velanovich by comparing the five variables in the original CSHA-FI with NSQIP database
224038585|NCT04017325|OTHER|no intervention (post study follow up)|No intervention (post study follow up)
224038586|NCT05771909|OTHER|NeurodigitX|"The NeurodigitX Group receiving this program will follow the recommendations for a period of three months (2 sessions of 2 minutes per day)."
223427124|NCT03677336|DRUG|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
223564373|NCT04696276|OTHER|ERAS protocol|special approaches in three phases preoperatively, intraoperatively and postoperatively, by an interdisciplinary team comprising of the surgeon, the anesthesiologist and the nurse. The combination of these techniques reduces the reaction to postoperative stress, relieves acute postoperative pain, restores the patient immediately to their original feeding and mobilization habits, thus reducing the time required for their complete recovery.
223564374|NCT06895876|PROCEDURE|Deep parasternal intercostal plane block|The block is performed bilaterally in the 4th intercostal space. The probe is placed in the latero-median axis and a needle is placed latero-medially between the intercostal and transverse thoracic muscle. The solution is then injected under ultrasound control
224038587|NCT05771909|OTHER|Control|"The Control Group does not receive the NeurodigitX application."
224038588|NCT02564926|DRUG|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
224139153|NCT03662633|DIAGNOSTIC_TEST|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
223583974|NCT05100836|DEVICE|Impella 5.5|Impella 5.5 mechanical circulatory support
224038589|NCT02564926|DRUG|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
224038590|NCT05052554|DRUG|QR-504a|Intravitreal (IVT) injection
224038591|NCT02628301|DIETARY_SUPPLEMENT|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
224038592|NCT02628301|OTHER|Normocaloric diet|Normocaloric diet
224038593|NCT05877378|DEVICE|Single-use negative pressure therapy (PICO)|PICO system will be applied to patients in the intervention group with diabetic foot ulcers, venous leg ulcers or pressure ulcers. This device will be changed every 7 days, until the wound is closed, or until a set period of study duration, approximately 12 weeks.
224038594|NCT01351753|DRUG|Metformin|
224038595|NCT01351753|DRUG|Orlistat|
224038596|NCT01351753|DRUG|Topiramate|
224038597|NCT01351753|DRUG|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
224038598|NCT00770835|DRUG|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
224038599|NCT00770835|DRUG|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
224038600|NCT02038920|DRUG|Vedolizumab|Vedolizumab IV injection
224038601|NCT02038920|DRUG|Vedolizumab placebo|Vedolizumab placebo-matching IV infusion
224038602|NCT00866697|DRUG|Pazopanib|Pazopanib 800 mg tablet daily for 104 weeks (24 months)
224038603|NCT00866697|DRUG|Placebo|Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
224038604|NCT04165993|DRUG|Concurrent chemotherapy and KN026|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
224038605|NCT04165993|DRUG|KN026 monotherapy|30 mg/kg Q3W KN026
224038606|NCT04165993|DRUG|KN026 combination|30 mg/kg Q3W KN026 5 mg/kg Q3W KN046
224304938|NCT06577532|DRUG|Toripalimab|Anti-PD-1 antibody, administered intravenously
223427125|NCT03677336|DRUG|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
223583975|NCT05717062|DRUG|Varespladib intravenous form|This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
224038607|NCT00496795|OTHER|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
224038608|NCT05555667|DRUG|Remimazolam besylate|Sedation drug
224038609|NCT05555667|DRUG|Propofol|Propofol. Sedation drug
224139154|NCT03662633|DIAGNOSTIC_TEST|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
223427126|NCT03677336|DRUG|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
223427127|NCT03677336|DRUG|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
223427128|NCT06334653|OTHER|exercise|acute exercise bout
223427129|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
223427130|NCT00846677|DIETARY_SUPPLEMENT|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
223583976|NCT05717062|DRUG|varespladib-methyl- oral form|Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
223583977|NCT05717062|DRUG|Placebo intravenous form|The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
223427131|NCT05073341|OTHER|Nurse-led family intervention|Nurse-led family intervention having three components first is infarmation about the patient's condition and guidance will be given to solve there queries and the emotional support will be given to the primary caregivers of CLD patient's admitted in HDU
223427132|NCT03955081|DEVICE|Deep enteroscopy|A deep enteroscopy conducted with the new medical device PowerSpiral.
223427133|NCT00954512|DRUG|Carboplatin|
223427134|NCT00954512|DRUG|Epirubicin|
223427135|NCT00954512|BIOLOGICAL|Trastuzumab|
223427136|NCT00954512|DRUG|Everolimus|
223427137|NCT00954512|DRUG|Gemcitabine|
223427138|NCT00954512|BIOLOGICAL|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
223427139|NCT00954512|BIOLOGICAL|Cetuximab|
223427140|NCT00954512|DRUG|Paclitaxel|
223427141|NCT00954512|DRUG|Cisplatin|
223427142|NCT00954512|DRUG|5-FU|
224038610|NCT04376060|DEVICE|Gen-Os®; The soft lamina (OsteoBiol®)|"The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects."
223427143|NCT00954512|DRUG|Erlotinib|
223427144|NCT00954512|DRUG|Irinotecan|
223427145|NCT00954512|DRUG|Folinic Acid|
223427146|NCT01751334|DEVICE|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
223427147|NCT01751334|DEVICE|total knee arthroplasty|Fixed Total Knee Arthroplasty
223427148|NCT03531528|OTHER|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
223427149|NCT04398485|DRUG|ION251|ION251 administered by IV infusion
223427150|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
223427151|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
223427152|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
223427153|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
223427154|NCT01117233|DRUG|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
223427155|NCT01794793|DRUG|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
223564375|NCT06895889|DEVICE|EB-OC Graft Implantation|The implantation of the EB-OC graft is completed via an arthrotomy, which is categorized as a minor surgery and is done on an outpatient basis, which means you can go home the same day. It is completed under general anesthesia and may last between one to two hours.
223564376|NCT06895889|PROCEDURE|Abrasion chondroplasty|Abrasion chondroplasty is a minimally invasive procedure in which the surgeon uses a rotary burr to scrape off the bone tissue from the surface of the joint.
224038611|NCT04275297|BEHAVIORAL|Psychosocial Treatment|The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.
224038612|NCT04275297|BEHAVIORAL|Attention Control|The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
224038613|NCT04760886|OTHER|Type of hospital (rural DGH vs Urban MTC)|In this small cohort study, the hospital in which the patients were treated was the intervention. One was in a rural area and was a district general, whereas one was in an urban enviroment and was a major trauma centre.
224038614|NCT02887027|BEHAVIORAL|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
224038615|NCT06554418|BEHAVIORAL|Communities Care|Communities Care is a violence prevention program targeting social norms and behavioral change
224038616|NCT05612347|DIAGNOSTIC_TEST|FIT|Annual FIT
224038617|NCT05612347|DIAGNOSTIC_TEST|Colonoscopy|One time surveillance colonoscopy
224070835|NCT04032210|OTHER|Zinc based toothpaste (Crest complete)|Regimen using Zinc based toothpaste (Crest complete)
223427156|NCT01794793|DRUG|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
223427157|NCT01794793|DRUG|Pasireotide LAR|Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
223427158|NCT03495154|DEVICE|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
223427159|NCT05599139|BEHAVIORAL|Low iodine diet|Before ablation and possible subsequent therapy with 131I, patients have to follow a low iodine diet (LID), reducing the iodine intake \< 50 mcg per day and thereby depleting the overall iodine store in the body.
223427160|NCT05685732|DRUG|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)|Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
223427161|NCT05685732|OTHER|placebo|matching placebo
223427162|NCT02640404|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
223427163|NCT02640404|BIOLOGICAL|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
223427164|NCT05250102|DEVICE|Pulse oximeter sensors|Pulse oximeter reading will be compared to CO-oximeter reading.
224038618|NCT02989948|DEVICE|Physician-modified aortic endograft|Use of physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
224038619|NCT05305131|DRUG|cisplatin and gemcitabine|Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2
224038620|NCT05305131|DRUG|induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.|Day -7 (+/-1 day): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2+ IV pembrolizumab 200mg over 30 minutes Day 8: IV Gemcitabine 1000mg/m2 Day 15 (for cycles 1 and 2 only): IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes
224038621|NCT07128758|BEHAVIORAL|Music Group Implementation Before surgery, children were asked whether they enjoyed listening to music and what styles of music they liked.|"All procedures required for developing a music pool to be used for music listening intervention in children undergoing appendectomy were completed and are outlined as follows:~* Children were asked about their music preferences.~* Songs were selected from the Ministry of National Education's music books.~* Music with proven effectiveness was selected from music platforms.~* A music pool was created by the researcher based on these inputs.~* Expert opinions were obtained from 12 academicians and 10 healthy children regarding the music pool.~* Necessary revisions were made in line with expert feedback, and the final version of the music pool was determined.~* A pilot application was conducted (data from the pilot were not included in the main data set).~* Children were randomly assigned to the music and control groups using randomization (https://www.random.org).~* A neutral observer (not the researcher/a blinded observer) was trained to administer the scales after the music intervention"
224139155|NCT03554070|PROCEDURE|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
223427165|NCT05244044|OTHER|Pulmonary rehabilitation in primary care|Pulmonary rehabilitation consists breathing exercises, exercise capacity, muscle strength and change towards an active lifestyle.
223427166|NCT05354102|DRUG|BMC128|A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
223427167|NCT05354102|DRUG|Nivolumab|A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
223427168|NCT05397171|DRUG|AZD8853|Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
223427169|NCT05397171|DRUG|Zirconium-89 crefmirlimab berdoxam|CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
224139156|NCT03554070|DEVICE|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
224139157|NCT00624728|RADIATION|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (\>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (\> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
223427170|NCT04973540|DEVICE|Iron Bioresorbable Scaffold System (IBS Angel)|Subjects in this arm will be implanted with IBS Angel.
223427171|NCT04971200|DRUG|Tildrakizumab|2 100mg subcutaneous injections Q4W
223427172|NCT06914986|PROCEDURE|Performed flexible and navigable suction ureteral access sheath combined with needle perc|Patients are performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL
223427173|NCT06914986|PROCEDURE|PCNL|Patients were performed flexible and navigable suction ureteral access sheath combined with needle perc or PCNL
223427174|NCT06914999|PROCEDURE|Computed Tomography|Undergo PET/CT
223427175|NCT06914999|OTHER|Fludeoxyglucose F-18|Given F-18 FDG
223427176|NCT06914999|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
223427177|NCT06914999|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223427178|NCT06914999|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223427179|NCT06914999|DRUG|Sodium Fluoride F-18|Given IV
223427180|NCT06915012|DEVICE|Tesla BioHealing(R) Biophoton Generators|Biophoton generators have been reported to reduce severe chronic pain significantly. This is to determine its efficacy.
223427181|NCT02720263|DRUG|ASP4345|Oral
223427182|NCT02720263|DRUG|Matching Placebo|Oral
223564377|NCT00780143|DRUG|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
223564378|NCT06895733|DRUG|Pazopanib Oral Tablet|Orally administered once daily (100mg)for 21 consecutive days, followed by a 7-day cessation of medication; Every 28 days is a treatment cycle.
223564379|NCT06895733|DRUG|Palbociclib|Oral treatment once a day, with a cycle of 28 days. In the safety introduction section, the initial dose of pazopanib is 400mg, and in the dose escalation queue, the dose of pazopanib is 600mg.
223427183|NCT06667635|DIAGNOSTIC_TEST|Artificial intelligence|Artificial intelligence (AI) tools developed through the training of large amounts of image data can assist with the analysis and interpretation of neuroimaging data of cerebral small vascular disease（CSVD）.
224038622|NCT06655623|BEHAVIORAL|Schema therapy|Schema therapy is a form of psychotherapy invented to address more complex clinical cases. It consists of elements from Cognitive Behavioral Therapy as well as psychodynamic, emotion-focused and gestalt therapies, with a distinct focus on experiential interventions. A therapy manual was developed for use in this study.
224038623|NCT00915733|DRUG|cilostazol|100 mg twice daily for at least 1 month
224038624|NCT00915733|DRUG|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
224038625|NCT00915733|GENETIC|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G\>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G\>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
224038626|NCT00915733|DRUG|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
224038627|NCT00538889|DRUG|Lecozotan SR|
224038628|NCT00538889|DRUG|Citalopram|
224038629|NCT06988124|DRUG|Dexamethasone Palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
223427184|NCT02100670|DRUG|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
223427185|NCT02100670|DRUG|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
223427186|NCT02100670|DRUG|3% menthol|To be applied four times daily for 10 days.
223427187|NCT02100670|DRUG|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
223740137|NCT06919744|DRUG|Best medical care|Acetazolamide will be introduced at the time of papilledema discovery. Weight loss will be recommended.
224038630|NCT06988124|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
224038631|NCT06655766|PROCEDURE|socket-plug technique with putty bone|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* putty bone is injected into the socket up to the crest of the bone.~* Collagen plug or sponge is adapted over the graft to occlude the socket~* The plug is then stabilized with absorbable suture material."
224038632|NCT06655766|PROCEDURE|Ice cream cone technique|"* Atraumatic extractions after careful surgical preparation of the soft and hard tissues using periotomes sulcular incision may be done with the aid of number 15c scalpel to dissect the crestal fibers and avoid trauma to soft tissue, care should be taken not to raise the flap.~* Careful curettage and debridement of the socket is performed with hand instruments to remove granulation tissue.~* The socket walls are then inspected for the presence of buccal defects.~* A Collagen barrier membrane is then shaped as an ice-cream cone and placed in the extraction socket lining the buccal tissues.~* The socket is then filled with particulate bone graft.~* The upper part of the membrane is then used to cover the socket.~* Absorbable suture is then used to close the socket and stabilize the barrier membrane"
224038633|NCT05573906|COMBINATION_PRODUCT|Cognitive behavioral therapy for anxiety plus benzodiazepine taper|11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiazepine taper. This will be added to a gentle, 12-week benzodiazepine taper. CBT will be initiated for two sessions prior to the benzodiazepine taper initiation.
224038634|NCT05573906|COMBINATION_PRODUCT|Health education control plus benzodiazepine taper|11 sessions of individual therapy control consisting of psychoeducational topics related to health and well-being, along with the gentle, 12-week benzodiazepine taper.
224038635|NCT06991179|DRUG|LY4064809|Administered orally
224038636|NCT06990997|BEHAVIORAL|Aphasia identification (ID) card|Participants will view an aphasia ID card for a speaker with aphasia. The card will disclose the speaker's aphasia, define aphasia, and request time to communicate.
224038640|NCT06346405|OTHER|Subthreshold Micropulse Laser Treatment|Subthreshold micropulse laser treatment consists in 33 spots of 100 microns, distance among each spot of 2.50 microns, duration of 200 sec, power of 250 milliwatt (mW) duty cycle 5%.
224038641|NCT06611267|OTHER|Pain without cream on|Participants will be inflicted with pain without cream on.
224038642|NCT06611267|OTHER|Pain with cream on|Patients are inflicted with pain after getting a cream on, which has previously had pain-relieving effects
224038643|NCT03459014|OTHER|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
224038644|NCT03459014|OTHER|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
224038645|NCT06996756|BIOLOGICAL|AAV8hAAT(AVL)|AAV8hAAT(AVL) gene transfer vector
223427188|NCT04096638|DRUG|SB 11285|SB 11285 2mg lyophilized powder for IV infusion
223427189|NCT04096638|DRUG|Atezolizumab|1680 mg every 4 weeks
223564380|NCT02326168|DRUG|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
224070836|NCT04032210|OTHER|Fluoride based toothpaste (Signal)|Fluoride based toothpaste (Signal)
224139158|NCT04689672|DIAGNOSTIC_TEST|Lung ultrasound|Bedside lung ultrasound
224139159|NCT00992732|DRUG|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
224163869|NCT01191138|PROCEDURE|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
224038646|NCT05139069|BEHAVIORAL|Trauma-Informed Toolkit|Staff in this intervention will be trained to conducting intimate partner violence screening, and providing support to women through referrals to local community resources; to help African American women identify and understand HIV risk factors (e.g., unprotected condom less sex with a male partner who is HIV-positive or unknown HIV status); and to communicate with their African American women patients in a respectful way in order to build trust and facilitate shared decision making.
223427190|NCT02955095|DEVICE|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
223427191|NCT06173037|DRUG|RC88|2.0 mg/kg Q3W IV
223427192|NCT02234596|DRUG|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
223427193|NCT05374187|DEVICE|Active eTNS|Participants will receive active trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. Participants deemed to be positive responders to blinded active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
223427194|NCT05374187|DEVICE|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (eTNS) administered by the Monarch eTNS system nightly during sleep for 4 weeks. At conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open active eTNS treatment. Participants deemed to be positive responders to open active treatment will be invited to continue open nightly eTNS in a 12 month extension period.
223427195|NCT05206955|DRUG|Tadalafil|10 mg once daily orally week 1, 20 mg once daily orally during week 2, and 40 mg once daily orally during weeks 3 through 52
223427196|NCT05206955|DRUG|Placebo|Looks exactly like the study drug, but it contains no active ingredient
223427197|NCT06951425|DRUG|TH-CART-027|3+3 dose escalation design: Dose Level 1: 0.3×10\^6 CAR+ T cells /kg; Dose Level 2: 1.0×10\^6 CAR+ T cells /kg; Dose Level 3: 3.0×10\^6 CAR+ T cells /kg
224038647|NCT06617793|BIOLOGICAL|rapcabtagene autoleucel (YTB323)|CAR-T cell suspension for intravenous infusion
223427198|NCT05630040|DEVICE|Non-invasive vagus nerve stimulation|Participants will take the VNS device home and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for 6 weeks.
223427199|NCT05630040|DEVICE|Sham Intervention|Participants will take a placebo device home for 6 weeks and use daily.
223427200|NCT05633992|BIOLOGICAL|V116|Sterile 0.5 mL solution in prefilled syringe containing 4 μg of each pneumococcal polysaccharide (PnPs) antigen 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B.
223427201|NCT05633992|BIOLOGICAL|PPSV23|Sterile 0.5 mL solution in prefilled syringe containing 25 μg of each PnPs antigen 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
223427202|NCT04801147|BIOLOGICAL|Dendritic Cells Vaccine|"Right after the surgical resection of the tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Immunotherapy will follow radiochemotherapy and will comprise 4 vaccinations every second week (injections I, II, III, IV), 2 further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) 2 months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only. In correspondence to the third vaccine injection (week 13), mTMZ will start.~Vaccine doses will be injected in the forearm of the patient."
223427203|NCT03634033|BEHAVIORAL|MiCAP with IF (Main Study)|"Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
223427204|NCT03634033|BEHAVIORAL|MiCAP with IF and EF (Main Study)|"Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed.~CAPABLE is a multi-component intervention used to enhance older adults ability to function at home independently."
223427205|NCT03634033|BEHAVIORAL|MiCAP with IF and Caregiver Engagement (Administrative Supplement)|A pilot study to examine use of informal caregiver engagement to provide CAPABLE to beneficiaries with Alzheimer's Disease or other Dementia using MiCAP with Internal Facilitation (implementation strategies from the (Main Study). External facilitator will be Champion, clinician, and an early adopters of CAPABLE.
223427206|NCT06516094|DRUG|Celecoxib+Pregabalin+Vitamin B fixed dose|One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day
223427207|NCT06516094|DRUG|Celecoxib + Vitamin B fixed dose|One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
223740138|NCT06919744|DEVICE|Intervention (stenting)|Transverse venous sinus will be stented by neuro-radiological intervention
223740139|NCT06915454|DEVICE|Intra-op PET/CT Specimen Scanner|Once the tumor or cancer is resected, it will then be imaged with the XEOS Aura 10 PET/CT Imaging Device. Imaging will be obtained utilizing a XEOS AURA 10 scanner in real time while in the operating room with the surgery team still present.
224038648|NCT07002086|PROCEDURE|Total knee replacement|"* Is a surgical procedure to resurface a knee damaged by arthritis. Metal and plastic parts are used to cap the ends of the bones that form the knee joint, along with the kneecap.~* In the surgical procedure of these surgeries, cement is used to fix the prosthesis."
223427208|NCT06516094|DRUG|Pregabalin + Vitamin B fixed dose|One capsule of 150 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
224038649|NCT07129265|OTHER|Working group|Participants will: 1) take a 10-min demographic survey; 2) join 3 x 60-min working group meetings in which they will review preliminary results, collaborate on curriculum design, and provide feedback; and 3) respond to prompts in 3 emails (approx 5-10 mins each).
224038650|NCT07129265|OTHER|Focus group|Participants will take a 10-min demographic survey and join 1 x 30-min focus group meeting in which they will provide feedback on the curriculum in development.
224139160|NCT00992732|DRUG|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
224139161|NCT01546285|DEVICE|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
223427209|NCT06397365|OTHER|medical hypnosis|"The first hypnosis session (V2) consists of a safe place suggestion. Through this type of suggestions, patients will safely experience the dissociative state, and will be given tools (recordings of sessions) to perform self-hypnosis at home between the visits. The suggestions will help the patient to visualize an imaginary place where they feel well and safe, a protective place to rest. In this first session, CPAP treatment will be introduced during hypnosis, with specific suggestions relating to the use of this treatment.~The second session (V3) The second session will also use the safe place. We will adapt the suggestions according to the experience reported by the patient on the day of the visit. During this session, we'll focus on changes in the patient's perception of the CPAP machine.~Patients will also be given the recording of each session to perform self-hypnosis at home between the visits."
223427210|NCT05434182|PROCEDURE|Intradermal Suture|Skin closure with an intradermal suture using Monosyn® (Braun®) 4/0 absorbable monofilament.
223427211|NCT05434182|PROCEDURE|Metallic Staples|Skin closure with metallic stapling using Visistat® (Weck®) 35W skin stapler.
223427212|NCT05342636|BIOLOGICAL|Pembrolizumab|200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
223427213|NCT05342636|BIOLOGICAL|Coformulation favezelimab/pembrolizumab|800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
223427214|NCT05342636|BIOLOGICAL|MK-4830|800 mg administered via IV infusion Q3W
223427215|NCT05342636|DRUG|Lenvatinib|20 mg administered via oral capsules each day
223427216|NCT05342636|DRUG|Irinotecan|180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.
223427217|NCT05342636|DRUG|Paclitaxel|80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
223427218|NCT05461677|DEVICE|SAIRE smart walker|Participants will walk along the 10-meter walkway 5 times using the SAIRE smart walker
223427219|NCT05461677|DEVICE|Standard 4-wheeled walker|Participants will walk along the 10-meter walkway 5 times using a standard 4-wheeled walker
223427220|NCT05461677|OTHER|No walking aid|Participants will walk along the 10-meter walkway 5 times without using a walking aid
223427221|NCT04501406|DRUG|Pioglitazone|An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.
223564381|NCT06440954|DRUG|Intrathecal pemetrexed|Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
223564382|NCT05610618|OTHER|Visual stimulation|Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
223564383|NCT06036017|OTHER|Earplugs|There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).
223740140|NCT07111598|BIOLOGICAL|Blood test at D0|Six extra blood collection tubes (28 mL) will be drawn during the visit (D0), in addition to the routine blood samples, at the blood collection center
224038651|NCT07130773|DEVICE|Second-generation FARAWAVE Nav catheter without the use of pre-ablation CT|"FARAWAVE Nav without pre-ablation CT (Intervention Group, n = 29)~Description of the investigation-specific intervention:~Participants in the intervention group will undergo pulmonary vein isolation (PVI) using the second-generation FARAWAVE Nav pulsed field ablation (PFA) catheter without the use of pre-ablation CT imaging. The FARAWAVE Nav catheter integrates magnetic navigation and electroanatomical mapping capabilities, allowing real-time visualization of left atrial anatomy and electrical signals. Energy delivery is based on non-thermal pulsed electric fields (irreversible electroporation), specifically targeting myocardial tissue while sparing surrounding structures."
224139162|NCT01755312|DEVICE|Medication reminder|Medication reminder
224139163|NCT05843071|DEVICE|Nasal sprays with sea salts|Nasal sprays for nasal congestion and dryness
224139164|NCT05353101|DRUG|Cyclosporine 0.05% eye drops|Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
224139165|NCT05353101|DRUG|Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%|Corticosteroids can inhibit the release of mast cells, block the chemotaxis of inflammatory cells, and reduce the number of mast cells and eosinophils in the conjunctiva. At the same time, it can inhibit phospholipase A2 and quickly alleviate symptoms and signs.
223427222|NCT04501406|OTHER|Placebo|Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
223427223|NCT00815815|BEHAVIORAL|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
223564384|NCT06036017|OTHER|Music Therapy|Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).
224139166|NCT03979027|DIETARY_SUPPLEMENT|Breakfast: ready-to-eat-cereal and milk|
223427224|NCT00318851|DEVICE|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
223427225|NCT05092295|DEVICE|Head and Intraocular Trauma Tool|HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
223427226|NCT05092295|DIAGNOSTIC_TEST|SCAT-5|Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
223427227|NCT02326116|OTHER|Trachael Preparation Education|
223427228|NCT01296542|DRUG|Moxifloxacin Ophthalmic|
223427229|NCT01296542|DRUG|Besifloxacin Ophthalmic|
223427230|NCT03243344|DEVICE|Surgiflo|using device during the endonasal surgery.
223427231|NCT03243344|DEVICE|Floseal|using device during the endonasal surgery.
223427232|NCT03243344|DEVICE|Algosteril|using device during the endonasal surgery.
223427233|NCT01045083|DRUG|RO4917523|Oral single dose
223427234|NCT01045083|DRUG|escitalopram|Oral single dose
223427235|NCT01045083|DRUG|methylphenidate|Oral single dose
223427236|NCT01045083|DRUG|placebo|Oral single dose
223427237|NCT01649648|BIOLOGICAL|Autologous cord blood|Baby's own umbilical cord blood
223427238|NCT02819245|PROCEDURE|posterior correction and fusion|
223427239|NCT05451433|DRUG|Saccharomyces Boulardii 250 MG|Normagut capsule twice a day
223427240|NCT05451433|DRUG|Placebo|Placebo capsule twice a day
223427241|NCT01668953|OTHER|Platelet Rich Plasma (PRP) Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~4. Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~5. The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
223427242|NCT01668953|OTHER|Whole Blood Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. 6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~4. Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~5. The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
223427243|NCT01668953|OTHER|Dry Needle Fenestration|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. A 22-gauge needle will then be placed into the tendon.~4. 15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
223427244|NCT01668953|OTHER|Sham Injection|"1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
223427245|NCT02134002|DRUG|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
223427246|NCT02134002|DRUG|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
223427247|NCT03931317|DRUG|Latanoprostene bunod 0.024% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
223427248|NCT03931317|DRUG|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
223427249|NCT01643733|DEVICE|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
223427250|NCT01944670|DEVICE|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
223740141|NCT07111598|BIOLOGICAL|Blood test at D+3 months|six extra blood collection tubes (28 mL) will be drawn during the visit (D+3 months) for group 3 patients, in addition to the routine blood samples, at the blood collection center
223740142|NCT05870787|DIAGNOSTIC_TEST|Swede score colposcopy|New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
223740143|NCT07118241|DRUG|Recombinant Human Proteoglycan 4|rhPRG4 450ug/ml
223740144|NCT07118241|DRUG|Vehicle Control|PBS based Vehicle Conrtol
223427251|NCT02804906|BEHAVIORAL|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
224139167|NCT03317249|DIAGNOSTIC_TEST|ECG|12-lead electrocardiogram
224038652|NCT07130773|DEVICE|FARAPULSE with pre-ablation CT|"FARAPULSE with pre-ablation CT (Control Group, n = 29)~Description of the investigation-specific intervention:~Participants in the control group will undergo pulmonary vein isolation (PVI) using the first-generation FARAPULSE pulsed field ablation (PFA) catheter. All patients in this group will undergo pre-procedural cardiac CT imaging to evaluate pulmonary vein anatomy and assist in procedural planning. The FARAPULSE catheter delivers non-thermal pulsed electric fields for selective myocardial ablation, aiming to achieve electrical isolation of the pulmonary veins."
224038653|NCT07129018|DRUG|Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Overexpression BTC|Subjects received treatment with Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w) and Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w) in combination with Pertuzumab (initial dose 840 mg, iv, followed by 420 mg, iv, d1, q3w). Study treatment continued until the occurrence of a protocol-specified treatment discontinuation event. Following the end of treatment, subjects will continue to undergo safety follow-up and survival follow-up. For subjects who discontinued treatment for reasons other than disease progression, periodic tumor imaging assessment follow-up will also continue after treatment cessation.
224038654|NCT07129018|DRUG|Trastuzumab-rezetecan + Pertuzumab + Iparomlimab and Tuvonralimab for HER2 Moderate/Low BTC|Subjects received treatment with Iparomlimab and Tuvonralimab (5.0 mg/kg, iv, d1, q3w) and Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w) in combination with Pertuzumab (initial dose 840 mg, iv, followed by 420 mg, iv, d1, q3w). Study treatment continued until the occurrence of a protocol-specified treatment discontinuation event. Following the end of treatment, subjects will continue to undergo safety follow-up and survival follow-up. For subjects who discontinued treatment for reasons other than disease progression, periodic tumor imaging assessment follow-up will also continue after treatment cessation.
224038655|NCT05902819|BEHAVIORAL|Imagery|Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
224038656|NCT05902819|DRUG|Minocycline|Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
224038657|NCT05902819|DRUG|Placebo|Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
224038658|NCT07008495|PROCEDURE|varicocelectomy|to detect testicular sperm retrieval rate after varicocelectomy in men with non obstructive azoospermia.
224038659|NCT07010601|BEHAVIORAL|Experimental Tobacco Marketplace|This study will have three different scenarios in the Experimental Tobacco Marketplace (ETM) for participants who reported being cigarette and/or e-cigarette users. These will consist of hypothetical purchase scenarios where a variety of different tobacco products are available to purchase. The three ETM scenarios will be adjusting price cigarettes, adjusting price e-cigarettes, and both adjusting price cigarettes and e-cigarettes.
224038660|NCT07010601|BEHAVIORAL|Hypothetical Novel Nicotine Product Purchase Tasks|This study will have a set of hypothetical demand tasks for novel nicotine products. These tasks consist of different novel hypothetical products (combusted, oral, and vaporized) of differing nicotine content (high and low), and different flavors (preferred alcoholic flavor, no characterizing flavor) where likelihood to try is assessed at a variety of price points.
224038661|NCT06674109|DRUG|Empagliflozin 10 mg|For the empagliflozin arm, participants will take 10 mg daily.
224038662|NCT06674109|DRUG|Placebo|Participants in the placebo arm will take a placebo daily.
224038663|NCT04469621|DRUG|SAR443122|Pharmaceutical form:capsule Route of administration: oral
224038664|NCT04469621|DRUG|Placebo|Pharmaceutical form:capsule Route of administration: oral
224038665|NCT05731492|DRUG|Macitentan|Macitentan will be administered orally.
224038666|NCT06625151|BEHAVIORAL|Perfectionism and Coping Processes Model - Explanatory Feedback Intervention (PCPM-EFI)|The PCPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and coping processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in perceived criticism, self-blame, perceived control, avoidant coping, and event stress are connected to increases negative affect; (b) how changes in perceived social support, positive reinterpretation, perceived control, avoidant coping, and problem-focused coping are linked to increases in positive affect; (c) how self-critical perfectionism and maladaptive stress and coping tendencies explain enduring mood problems; (d) how healthy striving, adaptive appraisal, and coping tendencies can identify personal strengths; and, most important, (e) what the person needs to do to manage and improve his or her mood.
224038667|NCT06625151|BEHAVIORAL|Perfectionism and Emotion Regulation Processes Model - Explanatory Feedback Intervention (PERPM-EFI)|The PERPM-EFI provides individualized explanatory feedback of daily diary data demonstrating how stress and emotion regulation processes for each participant trigger and maintain their negative and positive mood. The feedback consists of five separate modules: (a) how changes in event stress, mindfulness, self-compassion, experiential avoidance, and rumination are connected to increases in negative affect, (b) how changes in event stress, mindfulness, reappraisal, self-compassion, and experiential avoidance are linked to increases in positive affect, (c) how self-critical perfectionism and maladaptive stress and emotion regulation tendencies explain enduring mood problems, (d) how healthy striving, adaptive appraisal, and emotion regulation tendencies can identify personal strengths, and, most important, (e) what the person needs to do to manage and improve his or her mood.
224038668|NCT06628310|DRUG|ABBV-400|Intravenous (IV) Infusion
224038669|NCT06628310|DRUG|Budigalimab|IV Infusion
224139168|NCT03317249|DIAGNOSTIC_TEST|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
224139169|NCT03317249|DIAGNOSTIC_TEST|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
224139170|NCT03317249|DIAGNOSTIC_TEST|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
224139171|NCT03317249|OTHER|Echocardiogram|optional (for non-IST participants only)
223583978|NCT05717062|DRUG|Placebo - oral form|Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
223427252|NCT02804906|BEHAVIORAL|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
223427253|NCT01267084|DRUG|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
223427254|NCT01267084|DRUG|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
223427255|NCT01267084|DRUG|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
223427256|NCT05850390|OTHER|Respiratory-Responsive Vocal Biomarker application|"A smartphone app that allows participants to receive a respiratory-responsive vocal biomarker (RRVB) score by recording a 6-second held ahh vowel elicitation. The applications returns the RRVB score which has previously been validated to correspond to the likelihood that the user's voice is similar to those of people diagnosed with asthma. This study will examine if the RRVB scores correlate with respiratory function and symptoms in asthma patients."
223427257|NCT05194995|DRUG|JAB-21822|JAB-21822 administered orally as a tablet.
223427258|NCT05194995|DRUG|Cetuximab|Cetuximab administered as an intravenous (IV) infusion.
223427259|NCT00289406|DRUG|S-amlodipine gentisate|
223427260|NCT00289406|DRUG|Amlodipine besylate|
223427261|NCT01167556|BEHAVIORAL|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
223427262|NCT00743288|DRUG|Melphalan|Same as above
223427263|NCT00743288|DRUG|Panobinostat|
223427264|NCT05310318|PROCEDURE|Surgical treatment with and without fertility-sparing procedures|Patients accepted surgeries for LGESS and relevant adjuvant therapy if indicated.
223427265|NCT03060967|BEHAVIORAL|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
223427266|NCT05582044|OTHER|Lower-body Negative Pressure (-25 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
223427267|NCT05582044|OTHER|Lower-body Negative Pressure (-15 mmHg)|The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
223427268|NCT05582044|OTHER|Lower-body Neutral Pressure (0 mmHg)|In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
223427269|NCT05903924|DRUG|Tradipitant|Oral Capsule
223427270|NCT05903924|DRUG|Placebo|Oral Capsule
223427271|NCT03443765|DIAGNOSTIC_TEST|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
223427272|NCT03443765|DIAGNOSTIC_TEST|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at -20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
223427273|NCT03290534|DEVICE|CivaSheet|implanting CivaSheet for localized radiation dose delivery
223427274|NCT06331871|PROCEDURE|Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence.|Intervention performed by needling in the vicinity of the peripheral nerves of the shoulder under ultrasound-guided control.
223427275|NCT06331871|PROCEDURE|Manual physiotherapy protocol based on available evidence.|Physiotherapy treatment based on the best scientific evidence available, based on manual therapy and passive and active kinesitherapy
223427276|NCT06411002|DRUG|DAXXIFY|Intramuscular injection of daxibotulintoxinA-lanm
223427277|NCT06162169|DRUG|JAB-21822|JAB-21822 was administered orally
223427278|NCT06162169|DRUG|Itraconazole|Itraconazole was administered orally
223427279|NCT06162169|DRUG|Omeprazole|Omeprazole was administered orally
223427280|NCT06162169|DRUG|Midazolam , Rosuvastatin calcium and digoxin|Midazolam , Rosuvastatin calcium and digoxin was administered orally
223427281|NCT06162169|DRUG|Rifampicin|Rifampicin was administered orally
223427282|NCT05494684|OTHER|Multisensoral Nature-based Intervention|The intervention includes a multi-sensory nature experience using natural materials and a virtually created natural environment.
223427283|NCT02988362|DRUG|HL068 16/10mg|Candesartan 16mg and Amlodipine 10mg
223427284|NCT02988362|DRUG|Candesartan 16mg and Amlodipine 10mg|
223427285|NCT05175196|DIAGNOSTIC_TEST|CandyCollect|The CandyCollect device is a novel, micro-engineered, lollipop-inspired platform. It has functionalized open microchannels for pathogen capture and concentration. It also has time-controlled flavoring release to make the platform more patient-centric.
223427286|NCT05175196|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Child participants are instructed to suck on the swab for 10 seconds, as they would suck on a lollipop. Participant will be asked to take this test twice."
223427287|NCT05486104|DRUG|Hemay005 tablets|Hemay005 tablets (15mg/tablet）will be orally administered twice daily.
223427288|NCT05486104|DRUG|Hemay005 placebo tablets|Hemay005 placebo tablets will be orally administered twice daily.
223740145|NCT02156817|OTHER|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
224038670|NCT06628310|DRUG|Fluorouracil|IV Infusion; IV Injection
224038671|NCT06628310|DRUG|Leucovorin|IV Infusion; IV Injection
224038672|NCT06628310|DRUG|Oxaliplatin|IV Infusion
224038673|NCT07018401|DRUG|Pomalidomide|Oral pomalidomide up to 4 mg daily
224038674|NCT07020065|DRUG|Cemiplimab|cemiplimab IV 350 mg, day 1
224038675|NCT07020065|DRUG|Carboplatin|carboplatin IV AUC 3 day 1
224038676|NCT07020065|DRUG|Pemetrexed & Gemcitabine|pemetrexed IV 300 mg/m2 day 1 gemcitabine IV 600 mg/m2 day 1, d8
223427289|NCT04565210|OTHER|Music exposure|Participants will be offered individual sessions of music. They will be exposed for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
223427290|NCT04565210|OTHER|Silence|Participants in this group will be offered individual silence session for 10 minutes per day, 3 days per week for a period of 2 weeks using a headphone.
223427291|NCT05887843|DRUG|Mometasone + Azelastine|Mometasone + Azelastine, 50 μg/140 μg (per actuation) liquid, nasal spray, two actuations administered in each nostril
223427292|NCT05887843|DRUG|Mometasone Furoate|Mometasone Furoate 50 μg (per actuation) nasal spray, two actuations administered in each nostril
223427293|NCT05887843|DRUG|Azelastine Hydrochloride|Azelastine Hydrochloride 140 μg (per actuation) nasal spray, two actuations administered in each nostril
223427294|NCT06668233|RADIATION|CT|CT Brain
223740146|NCT06923839|BIOLOGICAL|Test bacterial peptide: RUCILP|The naturally occuring gut peptide RUCILP synthesized by the commensal gut bacterium Ruminococcus torques
224139172|NCT05889351|DRUG|Vehicle gel, 4 + 4 applications or 4 + 2 applications|Control arm/placebo
224139173|NCT05889351|DRUG|LTX-109 3% gel, 4 + 4 applications|Cohort 1 active treatment
224139174|NCT05889351|DRUG|LTX-109 3% gel, 4 + 2 applications|Cohort 2 active treatment
224139175|NCT04019795|DEVICE|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
224139176|NCT04019795|DEVICE|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
224163870|NCT01191138|PROCEDURE|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
223427295|NCT06668233|RADIATION|CT scan|Neuroimaging in case with delayed development , focal neurological symptoms or seziures
223427296|NCT00465803|DRUG|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
223427297|NCT00465803|DRUG|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
223427298|NCT00465803|DRUG|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
223427299|NCT03185715|BEHAVIORAL|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
223427300|NCT06622980|OTHER|Education|"The educational intervention will take the form of a video explaining both general ergonomic principles and specific advice for laparoscopic surgeons. This video will be shown to surgeons at a time of their convenience and the research team will be available to answer any further questions at this time.~The educational video will cover both ergonomics principles and specific advice for laparoscopic surgeons. The principles will be relevant to any situation, including those outside the medical field. The laparoscopic-specific section will include tips for optimisation of operating theatre set-up and advice on posture and body position. The video content will be reviewed by experts experienced in surgical ergonomics education to ensure it covers all useful information and is in line with best practice."
223427301|NCT00180492|DEVICE|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
223427302|NCT05098119|DRUG|Sintilimab, Nab-paclitaxel, Carboplatin|Neoadjuvant Therapy
223427303|NCT05098119|PROCEDURE|Surgical resection|Standard of care
223427304|NCT05098119|DRUG|Sintilimab|Adjuvant Therapy
223740147|NCT06923839|OTHER|Placebo|Placebo is identical to the active intervention except for the absence of the RUCILP molecule.
223740148|NCT01312649|BEHAVIORAL|Experimental psychology methods (computer tests)|
223744779|NCT06335069|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI|All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
224038677|NCT07020065|DRUG|Paclitaxel|paclitaxel IV 50 mg/m2 day 1, d8
224038678|NCT07020611|DEVICE|Cygnum Aneurysm Sac Management Device (ASMD)|Cygnum ASMD, adjunctive to EVAR, lines the aneurysmal wall to prevent type II endoleaks
224038679|NCT07019987|OTHER|PEEP Titration Using Electrical Impedance Tomography (EIT)|"EIT will be used to guide individualized PEEP titration in mechanically ventilated patients with AHRF. Each subject will receive mechanical ventilation at two PEEP levels:~PEEP\_CLIN (set by the treating clinician)~PEEP\_TIT (identified using EIT to minimize alveolar collapse and overdistension)~Both levels will be maintained for 30 minutes in each body position, with continuous physiologic data collected during each phase."
224038680|NCT07019987|PROCEDURE|Body Positioning: Supine and Prone|Each subject will be ventilated in both the supine and prone positions. Positioning will follow institutional protocols and be coordinated with clinical staff to ensure safety. After supine assessments are completed, the patient will be transitioned to prone, followed by a recruitment maneuver to standardize lung volume history. The PEEP titration protocol will then be repeated in the prone position.
224038681|NCT06112379|DRUG|Dato-DXd|Experimental drug IV infusion
224038682|NCT06112379|DRUG|Durvalumab|Experimental drug IV Infusion
224038683|NCT06112379|DRUG|Pembrolizumab|IV Infusion Active comparator
224038684|NCT06112379|DRUG|Doxorubicin|IV infusion Experimental/Active Comparator
224038685|NCT06112379|DRUG|Epirubicin|IV Infusion Experimental/Active Comparator
224038686|NCT06112379|DRUG|Cyclophosphamide|IV infusion Experimental/Active Comparator
224163871|NCT05155839|DRUG|MRG001|Administrated intravenously
224163872|NCT03067064|OTHER|no intervention|Clinical examination
223427305|NCT02983149|DEVICE|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
223427306|NCT02983149|DEVICE|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
224038687|NCT06112379|DRUG|Paclitaxel|IV infusion Experimental/Active Comparator
223427307|NCT02983149|DEVICE|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
223427308|NCT00026442|DRUG|capecitabine|
223427309|NCT04338269|DRUG|Atezolizumab|Atezolizumab 1200 mg will be administered at a fixed dose on Day 1 of each 21-day cycle by IV infusion every 3 weeks.
223427310|NCT04338269|DRUG|Cabozantinib|Cabozantinib 60 mg (three 20-mg tablets) administered orally once daily.
223427311|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 1)|1 week of consecutively consuming oral placebo (1 time/day)
223427312|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 1)|1 week of consecutively consuming oral probiotics (1 time/day)
223427313|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 2)|1 week of consecutively consuming oral placebo (1 time/day)
223427314|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 2)|1 week of consecutively consuming oral probiotics (1 time/day)
223427315|NCT05195047|DIETARY_SUPPLEMENT|1 week placebo(Week 3)|1 week of consecutively consuming oral placebo (1 time/day)
224038688|NCT06112379|DRUG|Carboplatin|IV infusion Experimental/Active Comparator
224038689|NCT06112379|DRUG|Capecitabine|Tablet Oral route of administration Experimental/Active Comparator
224038690|NCT06112379|DRUG|Olaparib|Tablet Oral route of administration Experimental/Active Comparator
224038691|NCT03425279|BIOLOGICAL|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
224163873|NCT03878043|OTHER|Follow-up Care|Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
223427316|NCT05195047|DIETARY_SUPPLEMENT|1 week of probiotics(Week 3)|1 week of consecutively consuming oral probiotics (1 time/day)
223427317|NCT06064825|OTHER|2 year follow-up of neurodevelopment using a parental questionnaire|A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
223427318|NCT04838756|OTHER|AI screening modality|Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.
223427319|NCT04838756|OTHER|Conventional screening modality|Screen exams will be read by two radiologists without the support of AI.
223427320|NCT06409468|PROCEDURE|Subperiostal tunnel in conjunction with Novomatrix|An intrasulcular incision on the tooth with recession and on each adjacent tooth. Subperiosteal pouches dissected apically for about 6-8 mm facial to the 3 teeth and connected by extension of the subperiosteal dissection into the interdental areas to create a tunnel. NovoMatrix trimmed to a vertical dimension of 7-8 mm and a horizontal length to completely over the exposed roots and extend laterally to the root line angles of the adjacent teeth. The graft inserted into the tunnel and aligned. Both the overlying tissue and graft positioned 1mm coronally to the level of the cementoenamel junction and secured with a 6-0 resorbable sling suture.
223427321|NCT06061185|DEVICE|Multimodal CT|Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
223427322|NCT02454010|BIOLOGICAL|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
223427323|NCT06038591|BEHAVIORAL|Sleep Tight|The sleep intervention focuses on enhancing young children's sleep by providing parents with behavioral strategies and support. Interventionists will work with parents on establishing consistent soothing bedtime routines; behavioral regulation to manage bedtime resistance and nighttime wakings; goal setting, problem solving, and action planning; self-monitoring via daily sleep logs; and stimulus control of child's sleep environment.
223427324|NCT05288205|DRUG|JAB-21822|KRAS G12C inhibitor
223427325|NCT05288205|DRUG|JAB-3312|SHP2 inhibitor
223427326|NCT04659707|DRUG|Hyperpolarized Xe129|Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
223427327|NCT04775342|DEVICE|smartphone|modern technology
223427328|NCT06391541|PROCEDURE|modified thoracolumbar interfacial plan block (mTLIP)|Injecting local anesthetic at L3 vertebral level between the longisimus and iliocostalis muscles within the erector spinae muscles.
223427329|NCT06391541|PROCEDURE|Intertransverse process block (ITP)|injection of local anesthetic on the superior costotransverse ligament between the transverse process and the pleura.
223427330|NCT02988440|DRUG|PDR001|PDR001 will be administered intravenously
223427331|NCT02988440|DRUG|Sorafenib|Sorafenib is formulated as a tablet.
223427332|NCT04722367|BEHAVIORAL|Art Pedagogy and Mindfulness|Each participant will take part in four 1-hour sessions. Study activities include guided meditation, close looking, drawing, writing, and storytelling. Each session will begin with a guided meditation that is followed by an exercise inspired by two works of art, and end with an opportunity for students to reflect on the experience.
223427333|NCT06219291|OTHER|Observational|Observation of the natural course of the disease
224038692|NCT03425279|BIOLOGICAL|PD-1 inhibitor|PD-1 inhibitor
224038693|NCT07029581|DRUG|ACP-204|Provided as 1 capsule, to be taken orally once daily
224163874|NCT01807494|DEVICE|Total hip replacement components|All patients will receive the same implants
224038694|NCT07029581|DRUG|Placebo|Provided as 1 capsule, to be taken orally once daily
224038695|NCT04915768|BIOLOGICAL|CH505 TF chTrimer|Combined with adjuvants 3M-052-AF and Alum. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
224038696|NCT04915768|BIOLOGICAL|3M-05-AF|Combined with CH505 TF chTrimer and Alum adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.
224038697|NCT04915768|BIOLOGICAL|Aluminum hydroxide suspension|Combined with CH505 TF chTrimer and 3M-052-AF adjuvant. Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle
223427334|NCT05269420|PROCEDURE|SAS-J|Single Anastomosis Sleeve Jejunal Bypass
223427335|NCT03868748|DIETARY_SUPPLEMENT|Beta-arbutin|Beta-arbutin capsules
223427336|NCT03868748|OTHER|Placebo|Placebo capsules containing non-medicinal ingredients
223427337|NCT00217074|OTHER|acupuncture|
223427338|NCT02562638|OTHER|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
223583979|NCT04619004|DRUG|Patritumab Deruxtecan (Fixed dose)|Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
223583980|NCT04619004|DRUG|Patritumab Deruxtecan (Up-Titration)|Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
224038698|NCT07132645|PROCEDURE|Computed Tomography|Undergo CT scan
224038699|NCT07132645|DRUG|Gallium Ga 68-DOTA-FAPI-04|Given IV
223583981|NCT06966791|OTHER|No intervention will be performed as part of this study. However, regardless of the study, all participants will have breast cancer surgery|No intervention will be performed as part of this study. However, regardless of the study, all participants will have breast cancer surgery and other breast cancer treatments.
224038700|NCT07132645|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224038701|NCT07131787|DEVICE|Blood flow restriction training (smart-cuff pro device)|This group will undergo low load strength training consisting of calf, thigh, glute and core exercises. A Blood flow restriction cuff will be added during selected exercises in rehabilitation program (targeting quadriceps and calf muscles)
224038702|NCT07131787|OTHER|Standardised strength training|This group will undergo standard, traditional strength training consisting of calf, thigh, glute and core exercises.
224038703|NCT07105098|DRUG|NBI-1117568|NBI-1117568 will be administered per schedule specified in the arm description.
224038704|NCT07105098|DRUG|Placebo|Placebo will be administered per schedule specified in the arm description.
224038705|NCT07106554|BEHAVIORAL|holotropic breathwork|participants will engage in holotropic breathwork
224139177|NCT04019795|DEVICE|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
224139178|NCT04019795|DEVICE|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
224139179|NCT05396313|DEVICE|CRT/ICD|The patients received implantation of CRT/ICD.
224139180|NCT06436729|PROCEDURE|Splinting|The joining of two or more teeth into a rigid unit by means of a fixed or removable restorations/devices
224139181|NCT06436729|PROCEDURE|MINST alone|Minimally invasive non surgical therapy alone
224139182|NCT03492645|BEHAVIORAL|Telephone-and technology-facilitated treatment protocol|"1. 8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~2. Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~3. Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
224139183|NCT03492645|BEHAVIORAL|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
224139184|NCT04430660|OTHER|13C-MRS procedure/Acetate infusion|Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples.
224139185|NCT04430660|DEVICE|Continuous glucose monitoring|Participants will wear blinded continuous glucose monitoring devices (dexcom, G6) for approximately 4 weeks. Sensors will be replaced every 7-10 days.
224139186|NCT02667548|PROCEDURE|PCI|percutaneous coronary intervention
224139187|NCT04315493|DRUG|pyrotinib maleate fasted in P1, low-fat diet in P2|pyrotinib maleate administration in fasted condition in period 1, pyrotinib maleate administration after low-fat diet in period 2
224139188|NCT04315493|DRUG|pyrotinib maleate low-fat diet in P1, fasted in P2|pyrotinib maleate administration after low-fat diet in period 1, pyrotinib maleate administration in fasted condition in period 2
224139189|NCT02567214|DRUG|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
224139190|NCT02567214|DRUG|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
224139191|NCT02658201|DEVICE|MRI|Ultrafast MRI to assess constipation
224139192|NCT01204697|DRUG|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
224139193|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
224139194|NCT01204697|DRUG|erlotinib [Tarceva]|150 mg/day orally as monotherapy
224139195|NCT01471860|DEVICE|BAROSTIM NEO System|
224139196|NCT01471860|DRUG|Medical Management|
224139197|NCT02333591|DRUG|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
223427339|NCT05341336|PROCEDURE|total surgical excision|"patients will be operated under general anesthesia. Pressure is applied along the incision line while staying away from the palpable margin of the AVM lesion and used Raney clips to control bleeding.~Once the skin flap was raised, the lesion could be seen through the galea. The galea around the lesion is incised, and the lesion will be separated from the underlying skin using a combination of bipolar diathermy and sharp dissection.~The nidus is often located in galeal aponeurosis. Dilated arteries and veins extended into subcutaneous tissue, which was separated with special care to prevent accidental nidus rupture and avoid excessive cauterization to prevent postoperative scalp necrosis.~Ligation is applied on feeder arteries, then applied to veins with total excision of the lesion.~After excision of the lesion, the skin flap was replaced with interrupted stitches.~The wound was allowed to heal primarily along with intravenous administration of antibiotics."
223427340|NCT03322865|DRUG|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15\*~\*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
224139198|NCT02333591|DRUG|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
224139199|NCT02333591|DRUG|Saline|Infused intravenously for 2,5 hours.
224139200|NCT01205451|DRUG|Botulinum toxin type A|Botulinum toxin type A
224139201|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
224139202|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
224139203|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
224139204|NCT00721422|DRUG|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
224139205|NCT04003753|OTHER|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
224139206|NCT01170702|DRUG|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
224139207|NCT01170702|DRUG|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
224139208|NCT01170702|DRUG|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
223583982|NCT03714503|DEVICE|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
224038706|NCT06919588|BEHAVIORAL|comedy therapy|Before the transplant surgery, the patients were shown 10-minute Turkish comedy films prepared by the researchers.
224038707|NCT07141381|DRUG|VRN110755|VRN110755 is an investigational EGFR inhibitor administered as an 80 mg oral capsule. It will be given to all participants under fasted, fed, and PPI pre-treated conditions across three periods in a crossover design.
224038708|NCT07141381|DRUG|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 5 days prior to VRN110755 dosing in Period 3. This is to assess the effect of increased gastric pH (via proton pump inhibition) on the pharmacokinetics of VRN110755.
224038709|NCT06936670|DEVICE|Inspiratory Muscle Strength Training (IMST)|A novel form of physical training that uses the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device, generating large negative intrathoracic pressures. The device can be set to different levels of resistance, meaning the intervention and sham groups will undergo the same training, but at 75% and 15% of their maximal inspiratory pressure respectively.
224038710|NCT06936670|DEVICE|Sham Training|The same training regiment but at much lower resistance, offering little to strength training impact.
224038711|NCT06944626|DEVICE|tDCS|tDCS will be applied to the dorsalateral prefrontal cortex with a current of 2 mA for 30 minutes on 3 consecutive days.
224038712|NCT06944626|DEVICE|Sham tDCS|The tDCS application will be increased to 2 mA for the first 30 seconds and will be reduced to 0 mA within 30 seconds after receiving current for 15 seconds. The electrodes will remain on the patient's head for the rest of the time (30 min in total).
224038713|NCT06944626|OTHER|Conventional physiotherapy|"Within the scope of conventional physiotherapy, respiratory control training, diaphragmatic breathing exercise, puckered lip breathing, relaxation exercises will be started 10 minutes after the start of tDCS or sham tDCS application.~While tDCS or sham tDCS application continues, 10 repetitions will be performed in order and with time for rest between exercises."
223744780|NCT05578495|OTHER|Accelerometer data|Patients will wear an accelerometer 3 times a year for 5 days (3 weekdays and 2 weekend days), the data will be collected
223427341|NCT03580408|DRUG|Nivolumab|240 mg
223427342|NCT03580408|DRUG|Vinblastin|6mg/m²
223427343|NCT03290755|BEHAVIORAL|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
223427344|NCT00670293|RADIATION|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
223427345|NCT00670293|DRUG|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
223427346|NCT00670293|PROCEDURE|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
223427347|NCT04387734|DRUG|Ocrelizumab|Ocrevus will be administered following the FDA's regulations.
223427348|NCT04387734|DRUG|Platform|The applications of the platform DMTs will follow the FDA-approved regulations.
223427349|NCT06580613|OTHER|New model of Hypertension Management|Hypertension management based on cardiovascular risk assessment. For details see description of study arm intervention.
223427350|NCT06580613|OTHER|Control|Hypertension Management as usual
223427351|NCT03378414|PROCEDURE|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)
223427352|NCT03378414|PROCEDURE|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)
223427353|NCT03378414|BIOLOGICAL|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
224038714|NCT07147725|DEVICE|AI Stethoscope|"Patients attending routine echocardiography who satisfy the inclusion and exclusion criteria will be approached before their echocardiography appointment to obtain informed consent to participate in the study. On providing informed consent, each patient will receive a non-invasive, external examination with a smart stethoscope that records a 3-lead electrocardiogram (ECG) and phonocardiogram (PCG) waveforms. This examination will require only one study visit (during routine echocardiography) and no additional visits. The stethoscope is a fully CE-marked device.~In addition to echocardiography parameters and smart stethoscope waveforms, baseline demographics, clinical and medication history will be recorded. These data points will be re-examined at 24 months following enrolment (via chart review)."
224139209|NCT01170702|DRUG|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
224139210|NCT02590887|DIETARY_SUPPLEMENT|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (14, and 28 days) drinking the beverage.
223427354|NCT06444308|OTHER|CommCare with Mobile Clinical Decision Support (CDS) Application|For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
223427355|NCT06444308|OTHER|Remote Supervision by Physicians|teleconsultation with a supervising physician
223427356|NCT06444308|OTHER|CommCare Application without CDS|The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
223427357|NCT05486117|DRUG|Delgocitinib|Cream for topical application 20 mg/g
223427358|NCT06163898|DRUG|Alnuctamab|Specified dose on specified days
223427359|NCT06163898|DRUG|Mezigdomide|Specified dose on specified days
223427360|NCT06163898|DRUG|Dexamethasone|Specified dose on specified days
223427361|NCT01942044|DEVICE|Promus element, Xience prime, and Nobori|
223427362|NCT05099614|COMBINATION_PRODUCT|Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system|1.2 mg of naloxone hydrochloride is administered to healthy adults using the SmartDose wearable auto injector and the mobile respiratory sensing system.
223427363|NCT05670223|OTHER|Fit&Strong Exercise Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
223583983|NCT05644041|DRUG|gemcitabine + docetaxel|The study drugs, Gemcitabine and Docetaxel, will be administered intravesically at 1000 mg and 40 mg, respectively.
223583984|NCT04979910|DRUG|Ixekizumab|a monoclonal antibody (mAb) against interleukin 17A (IL-17A)
223583985|NCT06017258|BIOLOGICAL|CD371-specific/YSNVz/I-18 CAR T cells|Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.
223744781|NCT01679002|DRUG|BIA 2-093|
223744782|NCT01679002|DRUG|Oxcarbazepine|
223583986|NCT05235061|BEHAVIORAL|Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PTE is an adaptation of the HOBSCOTCH program for people with a traumatic brain injury and post-traumatic epilepsy that incorporates education about TBI, PTE, and cognition into the education module.
223427364|NCT04916743|OTHER|Intradialytic exercise group|Participants will do concurrent exercise (a combination of aerobic exercise and resistance training) for 30-60 minutes during the second hour of their routine hemodialysis sessions. To determine the intensity of the prescribed exercise, maximum heart rate is used for aerobic workout and 5 Repetitions Maximum (5RM) for resistance protocols. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg RPE Scale). All protocols are tailor-made based on each individual's needs and physical abilities.
223427365|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
223427366|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
223427367|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
223427368|NCT00102141|DRUG|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
223427369|NCT00102141|DRUG|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
223427370|NCT06322953|DRUG|Direct-Acting Oral Anticoagulants (used as per local standard practice)|Direct-acting oral anticoagulants to be prescribed as per local standard practice at either 1 or 4 weeks.
223427371|NCT02142361|DEVICE|enfilcon A|Silicone hydrogel toric lenses.
223427372|NCT05346211|DIETARY_SUPPLEMENT|Curcumin|Curcumin Supplementation
223564385|NCT06036017|OTHER|Presence of Family After Extubation:|According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
223564386|NCT04607213|PROCEDURE|Advancement-rotation approach based on Millard' for repairing lip defect.|"patients were treated using Millard technique is the downward rotation of the medial part of the flap, and lateral advancement of the flap to close and fill the defect. if more lip height is needed; cut- as- you-go by adding a back-cut incision at the end of his rotation incision down toward the philtral ridge of non-clefted side. Moreover; C-flap is used to close nasal sill."
223564387|NCT04607213|PROCEDURE|Straight-line approach|"patients were treated using Straight-Line design based on Fisher modification. C-shaped flap extend from the proposed nasal sill to the origin of philtral column of medial flap as a straight incision to the planned top of the cupid's bow. In addition, to the previous mentioned incision, small inlate incision is needed to length the cleft side on the medial flap.~On the other hand, on the lateral flap; two connected triangular incisions are used; one on the vermillion border at Noordhoff's point. And the other one just above the cutaneous margin to improve aesthetic outcome and diminish formed scar."
223564388|NCT02438384|BEHAVIORAL|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
223564389|NCT02438384|BEHAVIORAL|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
223564390|NCT00771706|DRUG|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
223564391|NCT00771706|DRUG|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
223583987|NCT05235061|BEHAVIORAL|HOBSCOTCH-PTE for Caregivers|Select components of the HOBSCOTCH-PTE program delivered to caregivers consist of session 1 of the HOBSCOTCH-PTE (virtual) program (education module), guidance and instructions on utilizing quick relaxation, and session 8 of the HOBSCOTCH-PTE program (program wrap-up and maintenance planning).
224038715|NCT07141342|DEVICE|The Fast In-Bed Tracking System (FIT) Weight Scale|It is hypothesized that wheelchair users who are randomized into the FIT Weight Scales group will lose a significantly greater percent of body weight over time (6 months, 12 months) than wheelchair users randomized to the control group.
224070385|NCT05517941|OTHER|active cycle breathing|The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation
223427373|NCT02076737|DEVICE|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
223427374|NCT04932824|BIOLOGICAL|SCB-2019|a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
224139211|NCT03777202|PROCEDURE|High-flow nasal oxygen|High-flow nasal oxygen will be applied to the patients using Optiflow system through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
223427375|NCT05727787|RADIATION|Stereotactic Body Radiation Treatment|Single fraction SBRT 27 Gy
223427376|NCT03792529|OTHER|detect gene mutations of ctDNA and ctRNA|Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
223427377|NCT02610829|DIETARY_SUPPLEMENT|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
223427378|NCT05800587|DRUG|Carboplatin|Standard of care chemotherapy regimen
223427379|NCT05800587|DRUG|Pemetrexed|Standard of care chemotherapy regimen
223427380|NCT05800587|DRUG|Paclitaxel|Standard of care chemotherapy regimen
223427381|NCT05800587|DRUG|Nab paclitaxel|Standard of care chemotherapy regimen
223427382|NCT05800587|DRUG|Docetaxel|Standard of care chemotherapy regimen
223427383|NCT05800587|DRUG|Gemcitabine|Standard of care chemotherapy regimen
223427384|NCT05800587|DRUG|Etoposide|Standard of care chemotherapy regimen
223427385|NCT05800587|DRUG|Irinotecan|Standard of care chemotherapy regimen
223427386|NCT05800587|DRUG|Topotecan|Standard of care chemotherapy regimen
223427387|NCT05800587|DRUG|Lurbinectedin|Standard of care chemotherapy regimen
223427388|NCT04752761|BEHAVIORAL|Extrambulatory digital PROMs detection|An alternative PROMs evaluation method will be used in which the questionnaire will be administered to the patient digitally (Google Forms) in an outpatient environment
223427389|NCT02128347|OTHER|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
223427390|NCT02203851|DRUG|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
223427391|NCT06263270|BIOLOGICAL|CYT-108, a recombinant protease inhibitor|"CYT-108 is a recombinant alpha-2-macroglobulin (A2M) variant engineered with increased potency against A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) substrates while possessing strong activity against Matrix Metalloproteinases (MMPs) and serine proteases. This A2M variant was engineered with amino acid modifications to the bait region (i.e., protease-binding region) of the A2M protein to make the variant at least two fold more effective in inhibiting ADAMTSs compared to wt-A2M without affecting its inhibitory activity toward other proteases (see Investigator Brochure). CYT-108 is not expected to cure osteoarthritis (OA), but it is expected to be the first treatment to slow disease progression by inhibiting cartilage breakdown, resulting in clinically significant outcomes such as pain reduction and improvement in mobility. This hypothesis is supported by our preliminary findings in multiple safety and efficacy studies conducted in rat and canine models of OA."
223427392|NCT06263270|OTHER|Phosphate Buffered Saline (PBS)|Phosphate Buffered Saline (PBS)
223427393|NCT01055405|DRUG|Sildenafil|Sildenafil 20mg TID orally
223427394|NCT01055405|OTHER|Placebo|Placebo TID orally
223427395|NCT03523143|OTHER|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
223583988|NCT05394064|GENETIC|SBT101|SBT101 Treatment
223583989|NCT05394064|PROCEDURE|Imitation Procedure|Procedure that mimics SBT101 infusion, but contains no drug administered
224139212|NCT03777202|PROCEDURE|Low-flow nasal oxygen|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
224139213|NCT02729948|OTHER|Survey Administration|Ancillary studies
224139214|NCT02729948|DEVICE|Tethered Capsule Endoscope|Undergo TCE
224139215|NCT05279105|BEHAVIORAL|Program support|The intervention to be evaluated in this study is program design and selection considerations by humanitarian organisations. It will comprise of factors that motivate organisations to chose certain delivery models in providing health care in conflict-affected settings
224139216|NCT01499719|BEHAVIORAL|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
224139217|NCT02732353|DIETARY_SUPPLEMENT|Minced beef|Cow meat protein supplement
224139218|NCT02732353|DIETARY_SUPPLEMENT|Hydrolyzed beef|Cow meat protein supplement
224139219|NCT04107558|DEVICE|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
224139220|NCT03798184|PROCEDURE|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime\&Bond Active in self-etch or selective-etch mode with or without bioglass
224139221|NCT01677507|DRUG|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
224139222|NCT03409419|DRUG|[18F] CFA|pilot study to evaluate the bio-distribution of \[18F\] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
224139223|NCT02762019|DEVICE|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
224139224|NCT02762019|DEVICE|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
224139225|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
223564392|NCT06108193|DRUG|topical minoxidil in Acne Vulgaris|Split face: 2% or 5% topical minoxidil solution applied and no treatment Description: Subjects will apply the 2% or 5% topical minoxidil solution to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face twice a day for 4 weeks.
223564393|NCT05208515|OTHER|independent obsteric operating center|send emergency cesarean section needing women from labor room to independent obstetric operating center
223564394|NCT05208515|OTHER|general operating center|send emergency cesarean section needing women from labor room to general operating center
224038716|NCT07141342|BEHAVIORAL|Group Lifestyle Balance Adapted for Individuals with Impaired Mobility (GLB-AIM) intervention|The GLB-AIM is a direct adaptation of the Diabetes Prevention Program (DPP) - Group Lifestyle Balance (DPP-GLB) which has successfully yielded an average 6 percent weight loss at 12 months and reduced diabetes risk over 2.8 years by 58 percent, which was 39 percent lower than participants randomized to the metformin group. The GLB-AIM which has been proven feasible and effective in a pilot study and a randomized control trial (RCT) with 67 mobility impaired individuals randomized to the intervention group or a waitlist control group. There were significant between group differences in weight loss at 6 months (-1.7 kg loss vs 0.05 kg gain, p \<0.05) and combined results from both groups after receiving the intervention revealed an average weight loss at 12 months of 3.3 percent of their starting weight. Notably, the average loss was lower than the 5 to 7 percent achieved by diverse participants in the DPP-GLB trials.
224038717|NCT07162805|DRUG|Propofol|The initial dose is 1.5 mg/kg, adjusted in increments or decrements of 0.1 mg/kg according to the modified Dixon's up-and-down method. Additional rescue doses of 0.25-0.5 mg/kg are titrated if insertion is unsuccessful.
223427396|NCT03523143|OTHER|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
223564395|NCT05286476|COMBINATION_PRODUCT|Whole Body Vibration|vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform
223564396|NCT05286476|OTHER|pelvic floor exercises and static abdominal exercises in addition to diet instructions|"During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times."
224038718|NCT07179133|PROCEDURE|Craniocervical Flexion Training alone|"10-minute hot pack treatment before starting the protocol. Week 1: Muscle Activation, • Hold for 5-10 seconds.~* Perform in supine with a sphygmomanometer device.~* Nod head gently as if saying yes, aiming for 20-22 mmHg. Week 2: Endurance Training Goal: • Hold for 10-15 seconds. Increase holding time and precision.~Exercise:~• Maintain the contraction at 24-26 mmHg on the device. Week 3: Strength and Postural Training •Hold for 15 seconds.~Exercise:~* Perform CCFT in sitting or standing. Week 4: Functional Integration~* Maintain contraction during functional tasks (e.g., desk work).~* Hold for 15-20 seconds.~* Sets/Reps: 3 sets of 8-12 repetitions."
224139226|NCT02131545|DRUG|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
223427397|NCT03161002|GENETIC|detection of genotype|detection of genotype by next generation sequencing
223427398|NCT03250481|DRUG|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
223427399|NCT00402532|DRUG|Everolimus|Initial dosage 2 x 0.75 mg/d
223427400|NCT00402532|DRUG|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
223427401|NCT05288387|PROCEDURE|Spinal cord stimulation|High-frequency stimulation with modulated current via skin patches captures posterior horns of the spinal cord and this activation leads to blood pressure elevation.
223427402|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention + Phone Coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week.~During the phone coaching calls, the participant will be able to troubleshoot any technical difficulties and ask any questions about the material being taught in the intervention."
223427403|NCT05581472|BEHAVIORAL|Online Acceptance and Commitment Therapy Intervention without phone coaching|"The intervention has 8 modules. The modules Away Moves and Letting Go of Control, help to establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. The modules Noticing Hooks and Stepping Back focus on diffusion, self as context, and mindfulness. While mindfulness is overtly addressed in the module Stepping Back, it is weaved through each module. The modules Your Values and How You Want to Act focus on helping participants identify their values. The modules Goal Setting and Making Commitments focus on committed action. Each module has a practice assignment which participants are asked to engage in over the next week."
223427404|NCT04169672|DRUG|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
223427405|NCT04169672|DRUG|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
223427406|NCT03198832|PROCEDURE|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
223427407|NCT04519788|DRUG|AT-301B|Nasal Spray
223427408|NCT04519788|DRUG|AT-301A|Nasal Spray
223427409|NCT04264117|PROCEDURE|FlexAbility (Mesh-like irrigated tip catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. 30 sec ablation in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 13mL/min~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
223427410|NCT04264117|PROCEDURE|TactiCath (Contract force monitoring catheter) group|"1. AF catheter ablation (PV isolation and linear ablations)~2. contact force \>10g, target force-time integral 400 in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines"
223427411|NCT03203408|DEVICE|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
223427412|NCT03203408|DEVICE|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
223427413|NCT01632150|BIOLOGICAL|Elotuzumab|Powder for solution, 400-mg vials, for infusion
223564397|NCT06929806|DRUG|Ferric Derisomaltose|100 mg/mL
223564398|NCT04028167|DRUG|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
223564399|NCT06942429|BEHAVIORAL|Internet-delivered cognitive-behavioral therapy|Internet-delivered cognitive behavioral therapy (ICBT) is a 12-module intervention delivered over a maximum of 14 weeks. Two age-specific versions are available: \[1\] for children aged 8-12 years and \[2\] for adolescents aged 13-17 years. Both versions share the same core content, but the texts, illustrations, videos, and exercises are adapted to be developmentally appropriate. Each version focuses on exposure, along with psychoeducation, coping strategies, and relapse prevention. Caregivers have access to a parallel program that mirrors the structure of the youth program. Both patients and caregivers engage with a therapist through a secure digital platform, communicating via text messages similar to emails. Two scheduled telephone or videoconference calls are conducted approximately 3-4 and 7-8 weeks into treatment, respectively, to follow up on adherence and address questions related to the intervention. Additional telephone support will be available on demand.
223740149|NCT06919835|DRUG|Cilostazol 100 mg|Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.
223427414|NCT01632150|BIOLOGICAL|Thalidomide|50-mg capsules administered orally
223427415|NCT01632150|BIOLOGICAL|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
223427416|NCT01632150|BIOLOGICAL|Cyclophosphamide|50-mg tablets administered orally
223427417|NCT04288141|OTHER|Acquisition of blood samples and tumour tissue samples (biopsies)|Acquisition of blood samples and tumour tissue samples (biopsies) in a sequential manner as participants proceed through HER2-directed therapy as prescribed by their oncologist.
223427418|NCT05171244|BEHAVIORAL|virtual reality training|training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care
223427419|NCT05171244|BEHAVIORAL|usual care|usual program of interventions in usual care
223427420|NCT06620991|DRUG|Phentolamine|A loading dose of 1-5 mg IV bolus over 1 minute is given followed by an IV infusion of a rate of 0.1-2 mg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over a volume of 10ml
223427421|NCT06620991|DRUG|Esmolol|A loading dose of 1 mg/kg IV infused over 1 minute is given followed by an IV infusion of 0.15-0.3 mg/kg/min according to patient desired target mean arterial pressure (MAP) 50-60 mmHg over total volume of 10ml
223427422|NCT04890977|BEHAVIORAL|Talking Story|A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
223427423|NCT05605639|DRUG|Bupivacaine|The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
223427424|NCT05605639|OTHER|Placebo (physiological saline serum infiltration)|The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
223427425|NCT00598611|DRUG|desloratadine|singel dose, oral, 20 mg
223427426|NCT00598611|DRUG|desloratadine|single dose, oral, 5 mg
224070837|NCT04780269|DEVICE|Induction of labor with Foley catheter|A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
223427427|NCT06133946|GENETIC|Genetic screening test (Deafness gene variant detection array kit)|Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
223427428|NCT01131884|DRUG|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
223427429|NCT01131884|DRUG|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
223427430|NCT02057913|DRUG|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
223427431|NCT04062071|OTHER|no intervention|no intervention
223427432|NCT03391232|BIOLOGICAL|PolyPEPI1018 CRC Vaccine|Colorectal Cancer Vaccine
223427433|NCT05276011|BIOLOGICAL|TG-C|2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
223427434|NCT05276011|BIOLOGICAL|Placebo Control|2 mL normal saline injection
223427435|NCT00535782|DRUG|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
223427436|NCT00535782|DRUG|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
223427437|NCT00535782|DRUG|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
223427438|NCT05679531|OTHER|intervention|After filling out the patient information form, the patients who met the research criteria were chewed gum for an average of 15 minutes.
223427439|NCT04830384|DEVICE|Fully Active|7 subjects will be dispensed active treatment devices with light and music fully functional
223427440|NCT04830384|DEVICE|LLLT Only|7 subjects will be dispensed active treatment devices with only light functional
223427441|NCT04830384|DEVICE|Music Only|7 subjects will be dispensed placebo comparator devices with only music functional
223427442|NCT04830384|DEVICE|Placebo|7 subjects will be dispensed placebo or sham devices with no light or music functional
223427443|NCT04751786|DRUG|PRECIOUS-01|Subjects will be enrolled in one of three dosing cohorts (three subjects per cohort for the planned dose escalation with a planned extension to a total of six subjects for the two highest dosing cohorts for the evaluation of the pharmacodynamic effects of PRECIOUS-01 for determination of the RP2D, if MTD is not reached).
223427444|NCT04562831|DIETARY_SUPPLEMENT|EH301 (Nicotinamide Riboside/Pterostilbene)|Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.
223427445|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
223427446|NCT00731562|DRUG|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
223427447|NCT00220324|DRUG|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
223583990|NCT05487885|DEVICE|Continuous theta burst stimulation (cTBS)|a form of transcranial magnetic stimulation, to dorsomedial prefrontal cortex (dmPFC)
223744783|NCT05699343|PROCEDURE|InterOss Collagen (Bone xenograft) and InterOss Collagen Guide (Collagen membrane)|Group will receive InterOss Collagen and InterOss Collagen Guide during surgical intervention visit.
224038719|NCT07179133|PROCEDURE|Semispinalis Cervicis strengthening with Craniocervical Flexion Training:|"Craniocervical flexion training will be same as given to group A.~Week 1: Semispinalis Cervicis Activation:~* Patient sits upright with neutral spine.~* Therapist applies gentle manual resistance at C2 vertebra while the patient resists backward motion.~* Hold for 3-5 seconds, then relax.~Week 2: Progressive Activation with Increased Resistance:~* Apply moderate manual resistance at C2.~* Hold for 5 seconds, focusing on controlled movement.~Week 3: Strength and Functional Coordination with Dynamic Resistance:~* Introduce light movement (e.g., slight backward head tilt) under resistance.~* Therapist adjusts resistance dynamically.~Week 4: Advanced Endurance and Functional Integration with Functional Movements:~* Combine resistance training with controlled head rotations or slight lateral flexion.~* Maintain resistance and stability.~* Reps/Sets: 3-4 sets of 12 reps."
224038720|NCT07172958|BIOLOGICAL|Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells|Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
224139227|NCT02131545|DRUG|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
224139228|NCT02131545|DRUG|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
223427448|NCT03641625|DEVICE|Muscular tissue oxygen saturation guided care|Muscular tissue oxygen saturation monitored at flank and arm will be maintained \> 70% (absolute measurement) and \> baseline throughout the entire procedure.
224139229|NCT04562545|DEVICE|Modified Twin Block|a modified twin block design including jack screws to facilitate incemental advancement
224139230|NCT04562545|DEVICE|Twin Block Appliance set to maximum bite|a traditional twin block set to maximum bite advancement at start of treatment
223427449|NCT02630225|BEHAVIORAL|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
223427450|NCT02630225|OTHER|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~1. All necessary medical care and scheduled follow-ups with subspecialty services~2. Evaluation by social work with referral to appropriate community services~3. Screening for alcohol use~4. Discharge planning services~5. Financial counseling"
224139231|NCT02825147|DRUG|Pegaspargase|
224139232|NCT02825147|DRUG|Methotrexate|
224139233|NCT02825147|DRUG|Dexamethasone|
224139234|NCT02825147|DRUG|Etoposide|
224139235|NCT02825147|RADIATION|radiotherapy|
223427451|NCT02630225|BEHAVIORAL|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
223427452|NCT02630225|OTHER|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
223427453|NCT06018896|DRUG|Ascorbate|For patients with baseline serum Vitamin C concentration \< 65 μmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol/L, continuously 900 mg/day, three times a day, orally.
223427454|NCT00451893|PROCEDURE|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
223427455|NCT00451893|PROCEDURE|Lichtenstein operation with a light-weight mesh|Johnson\&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
223427456|NCT03648671|DRUG|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
223427457|NCT03648671|DRUG|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
223427458|NCT03648671|DRUG|rasagilina mesilato (12 weeks)|rasagilina mesilato
223427459|NCT03648671|DRUG|rasagilina mesilato (12 weeks)|rasagilina mesilato
223427460|NCT03078296|OTHER|survey respondents|all survey participants will be asked to complete a questionnaire
223427461|NCT04737824|PROCEDURE|"An adaptation of the balloon-blowing exercise"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
223427462|NCT04737824|PROCEDURE|"An adaptation of the balloon-blowing exercise for seven weeks, three times a week, at home"|The participants were positioned in supine, on a semi-rigid surface, with the upper limbs placed above the level of the head, at rest. Their feet were also placed at a resting position on a wall and with their hips and knees at 90o of flexion. The cervical was placed in a neutral position and the pelvis was maintained in a posterior pelvic tilt, both structures corrected by the researcher. The participants were asked to contract the adductors, maintaining a bilateral and symmetric pressure between 10 and 15 mmHg on two sphygmomanometers placed between the knees. Also, an isometric contraction of the hamstrings and gluteus was requested. A Threshold®, with a minimum resistance of 5 cmH2O, and they were instructed to close their lips around the mouthpiece, to avoid air leaks. To start the exercise, it was transmitted to the participants to make a maximum inspiration through the nose, for two seconds. Subsequently, a maximum exhalation throughout the threshold was made for three seconds.
223427463|NCT06014619|PROCEDURE|Mohs surgery|Treatment of a skin disease by Mohs micrographic surgery technique (frozen sections).
223427464|NCT06014619|PROCEDURE|Slow Mohs surgery|Treatment of a skin disease by Slow Mohs technique (formalin fixation and paraffin-embedded sections).
223427465|NCT06621888|DRUG|NTI164|This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
223427466|NCT06194747|OTHER|Quality improvement bundle|(1) standardizing BZD default to intranasal or buccal midazolam; (2) targeting initial BZD treatment within 10 minutes of seizure onset; (3) relocating and bundling all administration items needed to the hospital unit medication room; (4) utilizing basic seizure first aid in the initial patient assessment; (5) developing and implementing SE-specific EHR documentation; (6) multidisciplinary QI teams
223427467|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles with central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles with central data and methods support.
223427468|NCT06194747|OTHER|Quality improvement bundle and local PDSA cycles without central support|Sites will implement both the standard QI bundle as well as site-specific PDSA cycles without central data or methods support.
223427469|NCT06440356|OTHER|laser therapy|low level laser therapy applied
223427470|NCT06604962|PROCEDURE|IMES using IEP|First group (n=12) received IMES using inverse electrode placement. The needle electrode inserted into the paraspinal region was connected to the active or cathode pole of the electrical stimulator. The reference or anode pole of the electrical stimulator was connected to the electrode that was inserted into the MTrP area of the UT muscle. The muscle was stimulated for 10 min with a tolerable intensity in a single session to induce muscle relaxation
223427471|NCT06604962|PROCEDURE|IMES using CEP|Second group (n=12) underwent IMES with conventional electrode placement. In this group, the cathode pole of the stimulator was connected to the needle inserted into the UT muscle, and the anode pole was connected to the needles of the paraspinal region of the cervical spine. Needle electrodes were connected using alligator clip connectors. The muscle was stimulated for 10 min with a tolerable intensity in a single session to induce muscle relaxation.
223427472|NCT06604962|OTHER|Sham-IMES|Third group (n=12) received sham-IMES. Similar to the experimental intervention groups, the cathode pole of the stimulator was connected to the needle inserted into the UT muscle, and the anode pole was connected to the needles of the paraspinal region of the cervical spine. However, the delivered IMES was very minimal intensity
223427473|NCT06472531|DRUG|INR101|• 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT
223427474|NCT06472531|DRUG|INR101|"* 9±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT~* 7±1 mCi of INR101 will be injected intravenously prior to perform the PET/CT"
223427475|NCT06470035|DEVICE|Active VeNS Device|Battery powered non-invasive neurostimulation device
223427476|NCT06470035|DEVICE|Sham VeNS Device|Placebo comparator sham device (no active stimulation)
223427477|NCT02853669|PROCEDURE|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
223427478|NCT02853669|PROCEDURE|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
223427479|NCT04738617|BEHAVIORAL|Inter and intra-individual variation in acute responses to two different warm-up types|Comparison of the acute effects of two different warm-up protocols on subsequent performance.
224038721|NCT07181551|BEHAVIORAL|Forward to Quit (F2Q)|A mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. Delivered via a secure website accessible by smartphone or tablet.
224038722|NCT07179770|DRUG|Belzutifan|120 mg orally daily for 28 days
223427480|NCT04998279|DRUG|Granulocyte Colony-Stimulating Factor|Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
224038723|NCT07179770|DRUG|89Zr-DFO-girentuximab|10 mg single slow intravenous (IV) administration
224038724|NCT07179770|DEVICE|89Zr-DFO-girentuximab PET|89Zr-DFO-Girentuximab PET before and after 4 weeks of treatment with standard-of-care (SOC) belzutifan.
224038725|NCT07179861|OTHER|AI Suggestions (Anonymized 5-tool panel)|"What: Display of AI-generated suggestions for each vignette, aggregated from five large language model tools (names not shown to participants).~When/Who: Shown only in Group 2, after the physician's initial answer and confidence score.~Purpose: Measure AI performance (primary) and quantify the effect of AI suggestions on physicians' answers (secondary).~Applies to: Group 2."
224038726|NCT07179861|OTHER|Confidence Rating Task (1-10 Likert)|"What: Self-rated confidence for the initial answer on a 1-10 scale. When/Who: Group 2 before viewing AI suggestions. Purpose: Quantify confidence changes pre- vs post-AI and relate confidence to correctness.~Applies to: Group 2."
224038727|NCT07182162|OTHER|Remote supervision + simulation|teacher use remote supervision to assist peer training Hospital-at-Home scenario simulation
224038728|NCT07179354|DEVICE|Rapid Maxillary Expansion with Face Mask (RME/FM)|A tooth- and tissue-borne rapid maxillary expansion appliance with an expansion screw was used to achieve transverse maxillary expansion, followed by Petit-type face mask therapy. Expansion protocol: two quarter-turns per day for 10-14 days, then one quarter-turn per day until cusp-to-cusp relationship was achieved. Face mask elastics applied 16 hours/day at 350-500 g per side, with a 30° downward and forward vector relative to the occlusal plane.
224038729|NCT07179354|DEVICE|Mini Maxillary Protractor (MMP)|An intraoral mini maxillary protraction appliance was used to advance the maxilla. Force was applied through intraoral elastics connected to intraoral anchorage units. The protocol was designed to deliver orthopedic forward traction of the maxilla without an external face mask.
224038730|NCT07179354|DEVICE|Modified Splint with Elastics and Chin Cup (Modified SEC III)|A modified splint appliance combined with intraoral elastics and an orthopedic chin cup was used to achieve skeletal mandibular retrusion and Class III correction. The appliance applied orthopedic forces through combined vertical and horizontal components, promoting backward positioning of the mandible while maintaining transverse maxillary relationships.
224038731|NCT07172594|DRUG|Lactium|Lentra sachet (containing 150 mg Lactium) will be totally dissolved in 100 ml water and 50 ml will be given to cases, 2 hours before surgery.
224038732|NCT07172594|OTHER|Placebo control|50 ml water added to it powdered vanilla flavor will be given to cases 2 hours before surgery.
224038733|NCT07180472|DRUG|Cilostazol|Oral administration of cilostazol
224038734|NCT07180472|DRUG|Aspirin|Oral administration of Asprin
223427481|NCT04998279|OTHER|placebo|mock test without injection of G-CSF
223427482|NCT01054300|DRUG|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
223427483|NCT01054300|DRUG|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
223427484|NCT01054300|DRUG|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
224038735|NCT07180472|DRUG|Clopidogrel|Oral administration of Clopidogrel
224038736|NCT07182097|DRUG|Fentanyl 2 µg/kg IV bolus + 1-2 µg/kg/h infusion during anesthesia|Patients will receive fentanyl 2 µg/kg IV bolus at induction, followed by a continuous infusion of 1-2 µg/kg/h during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.
224038737|NCT07182097|DRUG|Remifentanil 1 µg/kg IV bolus + 0.1-1 µg/kg/min infusion during anesthesia|Patients will receive remifentanil 1 µg/kg IV bolus at induction, followed by a continuous infusion of 0.1-1 µg/kg/min during maintenance of anesthesia. Standard anesthesia will be provided with propofol, rocuronium, and sevoflurane.
224038738|NCT07182227|GENETIC|PS-002|Adeno-associated viral vector containing the human Complement Factor I (CFI) gene
224139236|NCT01040338|DRUG|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
223427485|NCT01054300|DRUG|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
224038739|NCT07180810|DRUG|Dexmedetomidine infusion low dose|low dose dexmedetomidine infusion at rate 0.6mcg/kg/hour rate .
224038740|NCT07180810|DRUG|Group B receiving normal saline|Normal saline infusion at rate 0.6mcg/kr/hour rate
224038741|NCT07176767|DEVICE|Positive airway pressure therapy|Initiation of continuous or bilevel positive airway pressure therapy
224038742|NCT07187505|DRUG|Venetoclax|Venetoclax is a selective BCL-2 inhibitor administered orally once daily. The dose will be adjusted according to the study protocol and patient tolerance.
224038743|NCT07187505|DRUG|All-trans retinoic acid|All-Trans Retinoic Acid (ATRA) is administered orally, twice daily, as part of standard induction and consolidation therapy for acute promyelocytic leukemia.
224139237|NCT04859972|DIAGNOSTIC_TEST|Diagnosis of IBS|Diagnosis of IBS according to ICD-10
223427486|NCT01054300|DRUG|Placebo|Placebo to ertugliflozin administered as a single dose
223427487|NCT04749654|OTHER|The Salivary pH measured|The saliva samples were obtained at 10-12 a.m. from all children. The saliva was collected into plastic cylinders and the salivary pH was measured with a pH meter (Compact pH meter B-212 twin pH, HORIBA, Osaka, Japan).
223427488|NCT04749654|OTHER|The saliva flow rate was measured|The saliva flow rate was estimated by during the first 30 s of paraffin chewing. The saliva was collected into plastic cylinders for a period of 5 minutes. Afterward, the saliva were weighed with a in a precision balance (Mettler PC 400, Zurich, Switzerland) and the flow rate was computed in gms/ml.
223427489|NCT04749654|OTHER|Streptococcus mutans and Lactobacillus counts in saliva were measured|The saliva samples were obtained according to described above. Numbers of colony-forming units (CFU) of S. mutans were counted on TSY20B agar and Lactobacilli were counted on Rogosa agar.
223427490|NCT00981045|DRUG|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
223427491|NCT00981045|DRUG|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
223427492|NCT01241877|DIETARY_SUPPLEMENT|astaxanthin|astaxanthin
223427493|NCT01241877|DIETARY_SUPPLEMENT|placebo|placebo
223427494|NCT05129475|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332 300 mg (2 × 150 mg tablets)/ritonavir 100 mg under fed or fasted conditions at 0 hour on Day 1
223427495|NCT05129475|DRUG|Ritonavir|Single oral dose of ritonavir 100 mg at -12 hours prior to PF-07321332/ritonavir dosing, and ritonavir 100 mg will be dosed at 12 hours after PF-07321332/ritonavir dosing.
223427496|NCT00308087|DRUG|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
223427497|NCT00308087|DRUG|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
223427498|NCT01000532|DEVICE|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
223427499|NCT01000532|DEVICE|Pacemaker therapy|Pacemaker therapy
223427500|NCT01000532|DEVICE|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
223427501|NCT00962975|DRUG|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
223740150|NCT07127809|BEHAVIORAL|Mindfulness Practice|Participants in this group will engage in a structured mindfulness practice program delivered via a custom-developed mobile app. The intervention includes guided mindfulness exercises such as meditation, breathing techniques, and body awareness, designed to be practiced daily alongside routine nursing duties. The program aims to enhance psychological capital and reduce job burnout symptoms over a 40-day intervention period, with follow-up assessments at 2 and 4 months post-intervention.
223740151|NCT07140016|DRUG|gilteritinib|Oral
224038744|NCT07187505|DRUG|Arsenic Trioxide (ATO)|Arsenic Trioxide (ATO) is administered intravenously once daily, in combination with ATRA and venetoclax, during induction and consolidation therapy.
224038745|NCT07188389|BEHAVIORAL|Acute exercise-moderate intensity|30 minutes of cycling exercise at moderate (90% of first ventilatory threshold)
224038746|NCT07188389|BEHAVIORAL|Acute effects-heavy intensity|Participants will cycle 30 minutes at heavy (110% of first ventilatory threshold) intensity
224038747|NCT07187570|DRUG|Dapagliflozin 10 mg once daily|Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.
223427502|NCT02977611|DRUG|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
223427503|NCT01321138|PROCEDURE|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
223427504|NCT01321138|PROCEDURE|PCA morphine|Postoperative analgesia with self-administration iv morphine
223427505|NCT03700333|DRUG|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if\<1.5m2; 75mg, twice a day, morning and night,if \>1.5m2 )chemotherapy after finishing first-line therapy(\>21 days).
223427506|NCT03700333|DRUG|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(\>21 days).
223427507|NCT00200109|DEVICE|Occipital Nerve Stimulation|Each group had a different plan
223427508|NCT00177307|DRUG|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
223427509|NCT00177307|DRUG|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
223427510|NCT00177307|DRUG|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
223427511|NCT00895128|DRUG|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
223427512|NCT00895128|DRUG|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
223427513|NCT00622661|OTHER|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
223427514|NCT00622661|OTHER|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
223427515|NCT03845361|PROCEDURE|Radial artery cannulation|Radial artery cannulation
223427516|NCT06621693|DEVICE|Transcutaneous electrical diaphragmatic stimulation intervention|It will be applied on diaphragm, 30 min per session ,3 days/week for 4 weeks at a stimulation frequency of 30 Hz, pulse width of 400 μs, the intensity was gradually increased until visible muscle contraction was observed.
223740152|NCT06507657|DRUG|empagliflozin|"intake of a 10mg empagliflozin oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
224038748|NCT07187440|OTHER|No intervention|This is a non-interventional study
224038749|NCT07187973|DRUG|DISC-3405|DISC-3405 is administered subcutaneously.
224038750|NCT07188090|DRUG|Plerixafor|Plerixafor is an antagonist of chemokine receptor-4 (CXCR4) receptor that can release stem cells from the bone marrow niche into the peripheral blood circulation
224038751|NCT07188090|DRUG|Gcsf|All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.
223427517|NCT06621693|OTHER|traditional physiotherapy program|The participants will receive traditional physiotherapy ( postural drainage, percussion , diaphragmatic breathing, phase 1 cardiac Rehabilitation and balance training ) three times per week for 4 weeks
223427518|NCT01878812|BIOLOGICAL|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
223427519|NCT00279617|DRUG|levetiracetam|open label levetricetam
223427520|NCT02523924|DRUG|18F-DCFPyL|18F-DCFPyL PET/CT
223427521|NCT02677038|DRUG|Olaparib|Given PO
223427522|NCT06647602|DRUG|Euthyrox (levothyroxine)|Euthyrox (levothyroxine sodium tablets; L-T4) is a thyromimetic synthetic drug identical to T4. Patients will recieve levothyroxine (euthyrox) in a dose of 2 μg × kg body weight / day.
223427523|NCT06647602|DRUG|Cytomel (liothyronine)|Cytomel (liothyronine sodium tablets; L-T3) is a thyromimetic synthetic drug identical to T3. The pharmacoequivalent ratio of L-T3 to L-T4 is 1:3. The L-T4-cohort receive doses of 2 μg × kg body weight / day. The pharmacoequivalent L-T3 dose would be 1/3th of that namely: 0.67 μg × kg body weight / day. Cytomel will be given trice daily and available dosages are 5, 12.5 and 25 μg.
223427524|NCT03671564|DRUG|Milademetan|Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
223427525|NCT02078375|DIETARY_SUPPLEMENT|Protein|whey protein plus casein protein
223427526|NCT02078375|DIETARY_SUPPLEMENT|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
223427527|NCT02078375|OTHER|Resistance Exercise Program|All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
223427528|NCT04294706|DIETARY_SUPPLEMENT|Hemp arm|Hemp oil
223427529|NCT06411951|OTHER|Participation in the INTUK care offer at Klinik Zugersee|Person-centered treatment and care tailored to the individual patients needs by a team consisting of a senior physician, a nurse, social workers and peers.
223427530|NCT05502744|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis due to the advantages of small wounds, less use of abdominal drains , less need for antibiotics and analgesics and less postoperative hospital stay time.Laparoscopic cholecystectomy in acute cholecystitis may be performed as soon as begging of the symptoms called emergency or urgent and maybe scheduled in advance after controlling acute attack after 6-8weeks called elective.
223427531|NCT03590535|DIAGNOSTIC_TEST|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
223427532|NCT03590535|DIAGNOSTIC_TEST|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
224070838|NCT04780269|DRUG|Induction of labor with PGE2|PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
224139238|NCT00900445|DRUG|Daunorubicin Hydrochloride|Given IV
224139239|NCT00900445|OTHER|Pharmacological Study|Correlative studies
223427533|NCT01176695|DRUG|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
223427534|NCT01176695|DRUG|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
223427535|NCT05913635|BEHAVIORAL|Consumption of lunch and dinner, with no breakfast|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-breakfast intervention day, participants are instructed to fast and only be allowed to consume water until 1.00 p.m. and consume the above-designed lunch and dinner at 1.00 p.m. and 8.00 p.m. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. the following day.
223427536|NCT05913635|BEHAVIORAL|Consumption of breakfast and lunch, with no dinner|The day before intervention day, all participants will be provided with 3 nutritionally balanced meals which are designed by the investigators. On the no-dinner intervention day, participants are instructed to consume the above-designed breakfast and lunch at 7.30 a.m. and 1.00 p.m., and no dinner. Additionally, all participants are informed that they are only allowed to consume water between meals and before receiving breakfast at 7.30 a.m. on the following day.
223427537|NCT06621706|DEVICE|Gastric ultrasonography|"Women will be requested to fast 2 hours for clear drinks, 6 hours for a light meal, and 8 hours for a meal high in fried or fatty content prior to their next antenatal clinic visit.~On the day of assessment, fasting and dietary compliance will be confirmed individually with each woman and Gastric ultrasonography will be performed after sex and eight hours of fasting food.~Women will be first scanned in a semi-recumbent (45 degrees head up) supine position, followed by a semi-recumbent (45 degrees head up) right lateral position (RLP). In both positions the gastric antrum will be identified in the sagittal plane with its internal anatomical landmarks identified, i.e. the left lobe of the liver anteriorly and the abdominal aorta posteriorly."
223427538|NCT00655148|BIOLOGICAL|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
223427539|NCT00655148|BIOLOGICAL|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
223427540|NCT03775122|DEVICE|TAES|TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
223427541|NCT03347734|BEHAVIORAL|Eye exercises group|"* 20 times hot water, 20 times cold water washing face in the morning and evening.~* Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~* 20 blinks~* Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
223740153|NCT06507657|DRUG|Placebo tablet|"intake a placebo oral tablet~At visit 1, after randomization, participants will be provided with bottles containing enough study pills for 3 months duration at 1 tablet daily. Participants will start the study drug on the morning following Visit 1. At the 3 month follow up visit, participants will be provided with enough study pills to complete the remaining 6 months of the study."
224139240|NCT00900445|DRUG|Prednisolone|Given orally
223427542|NCT03347734|BEHAVIORAL|Convergence exercise group|"* Close eyes for 15 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 20 ft away for 10 s,~* Close eyes for 5 s,~* Focus on a point 1 to 1.5 ft away for 10 s,~* Blink for 5 s,~* Close eyes for 5 s."
223740154|NCT05633966|DRUG|Kisspeptin 112-121|SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)
223740155|NCT07142577|OTHER|Mandala coloring|Mandala coloring activities will be carried out by the certified researcher 3 days a week for 8 weeks.
223740156|NCT05184764|BIOLOGICAL|AP-SA02|Bacteriophage administered via intravenous bolus infusion
224038752|NCT07188883|OTHER|Birth Education|The population consisted of all pregnant women between 24-36 weeks of gestation residing in Izmir province, and the study was completed with a total of 80 pregnant women, 40 pregnant women as intervention and 40 as control in line with the snowball sampling method. Ege Birth Perception Scale, Risk Assessment Form, Individual Introduction Form, Prenatal Self-Assessment Scale, Birth Education Evaluation Form were used to collect the data. Pregnant women who agreed to participate in the study were randomly divided into intervention and control groups; the intervention group received nine hours of online training, while the control group did not receive any intervention.
223427543|NCT03347734|BEHAVIORAL|Oculomotor Exercise Group (OMEG)|"* The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~* The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~* The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~* The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
223427544|NCT02779335|OTHER|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
223427545|NCT06648369|OTHER|MAX-ICH care bundle|The MAX-ICH care bundle is a comprehensive treatment approach for intracerebral hemorrhage (ICH). Patients receive 72 hours of care in a high-dependency unit like an ICU or hyperacute stroke unit. Intensive blood pressure control is used if systolic blood pressure exceeds 140mmHg, with rapid reduction to below 140mmHg within 60 minutes, and maintenance at or above 110mmHg for at least 75% of the time, with variability kept under 20%. The protocol includes rapid reversal of anticoagulation within 60 minutes, administration of tranexamic acid (1g bolus within 60 minutes, followed by 1g over 8 hours), and neurosurgical evaluation within 60 minutes. Additionally, family counseling is provided to avoid Do-Not-Resuscitate orders during the first 72 hours.
223427546|NCT06648369|OTHER|Standard of care|The control group will be treated according to the hospital's standard protocol for patients with spontaneous intracerebral hemorrhage, based on the guidelines of the European Stroke Organisation (ESO). The ESO develops evidence-based recommendations for the optimal care of stroke patients. The recommended immediate measures include: immediate stabilization and assessment, blood pressure control and reduction, brain imaging, surgical intervention for large hemorrhages, coagulation control, and monitoring of intracranial pressure. The specific application of these measures varies depending on the hospital and the treating physicians.
223427547|NCT03698838|DEVICE|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
223427548|NCT05831839|DEVICE|RehaCom|computerized cognitive training
223427549|NCT01505738|OTHER|bacterial samples|bacterial samples taken
223427550|NCT03640975|OTHER|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
223427551|NCT03270475|OTHER|exercise training|subjects complete 4-5 weeks of training
223564400|NCT06942429|BEHAVIORAL|Personalized in-person cognitive-behavioral therapy|Personalized in-person cognitive-behavioral therapy (CBT) follows a manual drawing on previously published protocols and meta-analyses on effective components of CBT for pediatric anxiety disorders and results from our pilot study. It consists of 12 weekly one-hour sessions delivered over a maximum of 14 weeks. It follows a disorder-specific CBT approach, with a strong emphasis on therapist-led exposure tailored to the patient's principal anxiety disorder. Participants receive workbooks containing information on anxiety disorders, the treatment rationale, and the rationale for exposure therapy. The intervention has three phases: \[1\] 1-2 sessions of psychoeducation and symptom identification, \[2\] 8-10 sessions of therapist-led exposure with homework, and \[3\] 1-2 sessions of relapse prevention planning. Caregiver involvement is tailored to the individual needs of each participant, with a maximum of 2 additional hours allocated for caregivers beyond the standard treatment time.
223740157|NCT05184764|OTHER|Placebo|Inactive Placebo administered via intravenous bolus infusion
223740158|NCT06935500|PROCEDURE|endoscopic ureteric lithotripsy|2 different sizes of ureteroscopes, 4.5/65f and 7.5/9.5f, will be used in the study.
223740159|NCT06938412|DEVICE|Physical Activity Intervention Using FitBit Wearable Device|The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device.
224038753|NCT07188246|RADIATION|Radiation|Stereotactic body radiation therapy to the breast
223427552|NCT00515359|PROCEDURE|Intermittent Propofol Sedation|Intermittent versus continuous dosage
223427553|NCT00515359|PROCEDURE|Continuous Propofol Sedation|intermittent vs continuous dosage
223740160|NCT06941363|RADIATION|SBRT|Eligible patients are those with (1) persistently detectable PSA post-operatively or (2) developing biochemical recurrence after prostatectomy with initially undetectable PSA, without evidence of macroscopic local relapse and/or regional and distant metastases at restaging, proposed for receiving up to 15 Gy in a single session to the prostate bed.
223740161|NCT06943521|DRUG|MT-4561|i.v.
224038754|NCT07188246|DRUG|Pembrolizumab (KEYTRUDA®)|Two injections
224070386|NCT05517941|OTHER|incentive spirometer|Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
224070387|NCT03957772|PROCEDURE|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
223427554|NCT06623552|OTHER|Neck Pain and Disability Scale (NPDS)|"The Turkish version of the Neck Pain and Disability Scale (NPDS), developed by Wheeler et al., was used for individuals with neck pain. The severity of neck pain is evaluated on a 5-point Likert scale; where 0 indicates no pain and 4 indicates very severe pain. The score is higher in those with upper extremity symptoms.The cut-off value of this scale was set to 15 to detect disability-related neck pain.The cut-off value is mandatory to evaluate a patient or a particular group of patients for clinically significant neck pain by distinguishing it from insignificant pain"
224038755|NCT07188597|BEHAVIORAL|Cognitive Behavior Therapy for those at risk of first episode psychosis|Participants will receive a culturally adapted manualised Cognitive Behavioural Therapy (CBT) for those at risk of first episode psychosis (FEP). The intervention aims to reduce symptoms, normalise psychosis-like experiences, and prevent catastrophic appraisals that may lead to delusions. It integrates psychoeducation, behavioural experiments, and techniques addressing cognitive biases. By reframing unusual experiences as perceptual or reasoning biases, distress and emotional arousal are reduced, lowering the chance of fixed, frightening beliefs. Homework tasks further support coping. CBT for At-Risk Mental States has shown effectiveness in reducing transition to psychosis and improving recovery. This study will adapt and field test the manual, with potential for remote delivery via phone, video, or AI tools to enhance accessibility.
224038756|NCT07187726|DEVICE|XAINET AI tool|The AI-based prediction of arm lymphedema risk is communicated to the patient and treating physician.
224038757|NCT07188480|DIAGNOSTIC_TEST|bronchial lavage for NGS analysis|NGS analysis conducted on bronchoscopic cytological samples in patients with NSCLC
224038758|NCT07188792|OTHER|HORTICULTURAL THERAPY|"* Introduction~* Explanation of the training content for horticultural activities using visual materials~* Explanation of the program's scope, duration, and expected participant roles and responsibilities"
224038759|NCT07186946|DRUG|THRV-1268|THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
224038760|NCT07186946|DRUG|Placebo|Placebo
224038761|NCT07189143|DIETARY_SUPPLEMENT|Belinal® (Abies alba branch extract)|Belinal® capsules, 900 mg/day (4 × 225 mg), orally for 14 consecutive days.
224038762|NCT07189299|DRUG|LSD 10 μg every Day|Participants will receive 10 μg LSD every day during the luteal phase
224038763|NCT07189299|DRUG|LSD 10 μg every other day|Participants receive 10μg LSD every second day during the luteal phase
224038764|NCT07189299|DRUG|Placebo|Participants receive inactive placebo during the luteal phase
224038765|NCT07187674|DRUG|Iparomlimab and tuvonralimab combined with olaparib and paclitaxel|The main objective of this study is to evaluate the tpCR of early high-risk TNBC with HRD positive treated with Iparomlimab and tuvonralimab combined with olaparib and paclitaxel as neoadjuvant therapy
224139241|NCT00900445|DRUG|Prednisone|Given orally
223427555|NCT06623552|OTHER|Fonseca Anamnestic Index (FAI)|It is a questionnaire consisting of 10 questions, including pain during the period, parafunctional habits, movement restriction, clicking, malocclusion, emotional stress.In this study, clinical signs relevant to each severity category of Fonseca's anamnestic index were used to detect the frequency of symptoms and to characterize the symptoms and clinical findings of TMD.The Turkish version of Fonseca's Anamnestic Index (FAI) questionnaire was used to assess the symptom severity.
223427556|NCT06623552|OTHER|Evaluation of Jaw Functional Limitation|The Jaw Functional Limitation Scale (JFLS) was developed as an 8-item scale for general functional limitation in the jaw. In the light of the obtained items and supporting psychometric data, it has been expanded and re-developed to include the verbal and non-verbal communication limitations that occur in a 20-item tool16 JFLS-20 is a tool with three structure contents (chewing, vertical mobility of jaw state and emotional and verbal statement) to evaluate functional state.Difficulty performing a determined task is graded from 0 (without limitation) to 10 (severe limitation). Higher scores are a more serious sign of functional limitation.
223427557|NCT06620692|DRUG|5% GM-XANTHO [GM-XAN003]|5% GM-XANTHO \[GM-XAN003\]
223427558|NCT06620692|DRUG|Placebo|The placebo
223427559|NCT03042169|DRUG|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
223427560|NCT03042169|PROCEDURE|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
223427561|NCT03042169|DRUG|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
223427562|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223427563|NCT00380081|DRUG|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223427564|NCT00380081|DRUG|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223427565|NCT06622395|DIAGNOSTIC_TEST|Remote diagnosys|Remote Diagnostic Arm (Teleconsultation): First Teleconsultation (V1): A child psychiatrist or psychologist specializing in ASD conducts the ADI-R (short version) interview with the parents or legal guardian via teleconsultation. The professional will score the items from the algorithm. After the consultation, the professional completes a questionnaire assessing the technical aspects of the remote interview (e.g., video quality, connection stability). Second Teleconsultation (V2): During the BOSA remote assessment, the professional sends the parent/caregiver instructions and a video link. The parent watches the video and follows guidance on how to position themselves and the child for optimal visibility. The parent then carries out the BOSA activities under supervision. The professional observes the child's behavior and provides time guidance. Two questionnaires are completed: one on the technical aspects of the consultation and the second on parent-child interaction.
223427566|NCT02916394|RADIATION|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
223427567|NCT00904202|DRUG|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
224038766|NCT07189221|BEHAVIORAL|Life Style Intervention|"The intervention consists of seven related components:~I. A Bluetooth-enabled weighing scale that syncs with the app to facilitate self-monitoring of weight.~II. Synchronous coaching sessions conducted on a 1:1 basis between the mHealth coach and participants. There will be 2 synchronous sessions, the first at enrolment and the second between 6-8 weeks postpartum. These sessions typically last 45-50 minutes in length with a follow-up summary video message of the goals discussed and, at the beginning of the mother's journey, the establishing of a change agreement. This is mediated through the live-video feature in the B2B\&Me+ mHealth coaching app, but the length and thus number of these sessions is determined by the woman. If the woman is diagnosed with GDM, there will be an opportunity for a third 15-minute synchronous coaching session to review and adjust any lifestyle goals to align with the individual's diabetes management plan.~III. Asynchronous mHealth coaching that uses a combi"
224038767|NCT07189078|PROCEDURE|Restrictive intubation strategy|"Endotracheal intubation is recommended only if at least one of the following criteria persists for more than 5 minutes:~1. Respiratory rate \> 40/min, persistent use of accessory muscles, or thoracoabdominal paradox.~2. SpO₂/FiO₂ \< 88.~3. Neurological or systemic impairment attributable to hypoxemia, defined as: altered higher brain functions without another identifiable cause, Glasgow Coma Scale ≤ 12, uncontrolled hemodynamic instability, or rising lactate levels."
224038768|NCT07189078|PROCEDURE|Liberal intubation strategy|"Endotracheal intubation is recommended if SpO₂/FiO₂ \< 110 for more than 5 minutes.~In addition, intubation is also recommended in the liberal strategy if any of the restrictive strategy criteria occur and persist for more than 5 minutes."
224038769|NCT07187934|DEVICE|AI algorithm|iDAScore® is a deep learning-based tool that provides fully automated analysis of embryo time-lapse images. It automatically generates a score (1-9.9) for each embryo in the patient's embryo cohort, which correlates to the likelihood of achieving a fetal heartbeat (clinical pregnancy).
223427568|NCT00904202|DRUG|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
223427569|NCT00904202|DRUG|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
223427570|NCT00904202|DRUG|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
223427571|NCT00904202|DRUG|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
224299322|NCT06389643|PROCEDURE|Four-point scleral fixation of Akreos AO60 IOL|Intrascleral tunnels were marked at a distance of 2 mm from the corneal limbus, 6 mm apart (4 in number) after retrobulbar anesthesia. Next corneal incisions were performed. An artificial lens was then implanted into the anterior chamber. The 6-0 polypropylene suture was introduced into the anterior chamber through openings in the cornea. The next stage was to perform a sclerotomy using a 30G needle. Then the needle was passed through the hole in the haptic and 6-0 polypropylene suture was inserted into the needle hole and guided outside. The other end of the suture, passed through the opening in the haptic, was placed in the lumen of the needle and carried out through another sclerotomy and then externalised. This maneuver was repeated with another haptics as well. Correct position of the IOL in the eye was achieved by pulling on the ends of the monofilament. The ends of sutures were trimmed and cauterized. The melted tips of the sutures were then fixed subconjunctivally.
224299323|NCT06389643|PROCEDURE|Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique|The surgery was performed under retrobulbar anesthesia. The first step of the procedure was to mark the locations of the intrascleral tunnels (2 mm from the corneal limbus) and locate them at a distance of 180° from each other to prevent the lens from tilting in the eyeball. Openings in the cornea were done. Three-piece IOL was implanted into the anterior chamber. The first sclerotomy was performed through the conjunctiva using a 30G needle 2 mm from the limbus. One of the haptics was inserted into the needle lumen and then brought out. Same procedure was performed with another haptic at a distance of 180°. The next step was to perform cautery of the tips of the haptics, obtaining a 0.3 mm collar that prevents the risk of the haptic coming out of the tunnel and displacing the lens inside the eyeball. The tips of the haptics were finally gently inserted into the scleral canals and covered with conjunctiva.
224299324|NCT05668078|DIAGNOSTIC_TEST|Rapid Antigen Testing (RAT) for COVID-19|COVID-19 RAT intervention done among the school students to see if RAT test can play a role in reducing absenteeism. School type-1-only for symptomatic participants, School type-2-Serial testing at three days interval for all participants and School type-3 got no testing.
223427572|NCT00904202|DRUG|Gabapentin 1800 mg/day + Lidoderm patch|
223427573|NCT02892604|DEVICE|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
223427574|NCT04747067|DEVICE|BIOPURE 260HF dialyzer|Dialyzer with effective surface area 2.6 m2, High-flux polyethersulfone hollow fiber with steam sterilization, myoglobin sieving coefficient (SC) 0.7, membrane cutoff 40,000 Daltons (Allmed Medical Gmbh)
223740162|NCT06940830|DRUG|Efanesoctocog alfa|Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.
223740163|NCT07105280|DEVICE|Conventional DBS|Treatment for a minimum of 2 to a maximum of 7 days with the patient's original conventional DBS (cDBS) settings.
224038770|NCT07189286|BEHAVIORAL|PAVE intervention|The commercial virtual reality app that will be used for the intervention, Supernatural, provides participants a trainer as they use their arms and legs (e.g., seated knee strikes) to smash targets to 500+ musical tracks. In this manner, this study employs fun as a motivator for exercise commencement and adherence while hospitalized. The research assistant will implement the intervention using the four-step approach including: (1) patient mobility screen, (2) orientation to the technology and intervention, (3) goal setting for physical activity, and (4) ongoing assessment, adaptation, and motivation.
224038771|NCT07189286|BEHAVIORAL|Education control|"Education control participants will receive and physical activity education using the NIH Get Fit for Life booklet."
224038772|NCT07188909|DRUG|Patient-Donor Derived Probiotics|To clinically evaluate the efficacy of patient- and/or donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.
224038773|NCT07189065|DRUG|Rocbrutinib|200mg qd PO. The treatment will continue until progressive disease, unacceptable toxicity, etc.
224038774|NCT07189065|DRUG|Bendamustine|Participants will receive a total of 6 cycles (a cycle being 28 days) 90 mg/m2 Bendamustine (IV infusion) on Days 1 and 2 of Cycles 1-6.
224038775|NCT07189065|DRUG|Rituximab|Participants will receive a total of 6 cycles (a cycle being 28 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.
224038776|NCT07189065|DRUG|Lenalidomide|20mg qd PO day 1-21
223427575|NCT05997823|OTHER|kinesiotape|The button hole technique was used for area correction during the KT application (Figure 1). Two I-tapes were applied, one from the medial epicondyle to the proximal phalanx on the palmar side and the other from the lateral epicondyle to the proximal phalanx on the dorsal side. The area where the phalanges are located was marked, and two hole was drilled in the center.After cleaning the skin with alcohol, the tape to be applied to the palmar side was passed over the 3rd and 4th fingers, and the patient was asked to perform radial deviation and wrist extension
223427576|NCT05997823|OTHER|home exercises|home exercises
223427577|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
223427578|NCT01489124|DRUG|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
223427579|NCT01489124|DRUG|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
223427580|NCT00591058|DRUG|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
223427581|NCT05007041|BIOLOGICAL|FLUAD® Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
223427582|NCT05007041|BIOLOGICAL|Fluzone® High-Dose Quadrivalent|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
223427583|NCT05007041|BIOLOGICAL|SHINGRIX®|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
224038777|NCT07188740|DRUG|Metformin|Start at 500 mg twice daily, titrate to 2000 mg/day for 6 months
224139242|NCT00900445|DRUG|Vincristine Sulfate|Given IV
223427584|NCT06622551|DIETARY_SUPPLEMENT|Iron-folic acid supplement|The major thing distinguishing this clinical study from another clinical trial is that we differentiate intervention based on nutritional status as we want to observe whether different nutritional status, especially overweight/obese will diminish the effect of IFA supplementation.
223427585|NCT00443664|DEVICE|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
223427586|NCT05540041|OTHER|Bubble breathing play therapy group|The efficacy of bubble breathing play therapy in the preoperative anxiety children and their parent.
223427587|NCT05540041|OTHER|Tell-show-do play therapy group|The efficacy of tell-show-do play therapy in the preoperative anxiety children and their parent.
224038778|NCT07189182|DEVICE|Origin Intubation System|This device leverages self-deploying geometry to guide intubation.
224038779|NCT07188064|PROCEDURE|Post radical prostatectomy nerve restoration procedure (PRP-NR)|Somatic to autonomic nerve grafting procedure which uses a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
224038780|NCT07188155|BEHAVIORAL|Exposure Therapy for Anorexia (Exp-AN)|"Exp-AN is specifically designed to target anxiety about weight gain. Exp-AN helps participants identify their specific feared consequences of weight gain (e.g., I will permanently hate myself if I gain weight), and combines in vivo (i.e., in real life) and imaginal (i.e., mental) exposure exercises to address these fears."
224038781|NCT07187791|DEVICE|CT scan|All Patients will undergo CT KUB cyst evaluation Qualitatively regarding Gross Picture in Imaging and Quantitavely using Hausfield units then patients will undergo Abdomianl ultrasound
224070388|NCT03957772|PROCEDURE|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
224070389|NCT03709173|BEHAVIORAL|FuRST 2.0|Round 2 of cognitive pre-testing for a new functional rating scale
224070390|NCT05284123|OTHER|Self-compassion workshop|The self-compassion workshop instructs participants to reflect on a source of shame, connect with their suffering related to it, and then direct feelings of support and understanding towards their suffering via a few brief writing tasks. This workshop also provides participants with basic information about mental health resources.
224139243|NCT00002545|DRUG|carmustine|
224299325|NCT01780987|DRUG|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
223427588|NCT05540041|OTHER|No intervention|Routine nursing care
223427589|NCT05899075|OTHER|xylitol wipes|group A will receive xylitol wipes and group B will receive placebo wipes
223427590|NCT05899075|OTHER|placebo wipes|group A will receive xylitol wipes and group B will receive placebo wipes
223427591|NCT01815606|PROCEDURE|biopsy with 19 gauge needle|biopsy with 19 gauge needle
223427592|NCT01815606|PROCEDURE|biopsy with 25 gauge needle|biopsy with 25 gauge needle
223740164|NCT07105280|DEVICE|Optimized conventional DBS|Treatment for a minimum of 2 to a maximum of 7 days with a previously optimized version of the patient's original conventional DBS (O-cDBS) settings.
223740165|NCT07105280|DEVICE|Optimized adaptive DBS|Treatment for a minimum of 2 to a maximum of 7 days with previously optimized adaptive DBS (O-aDBS) settings.
223740166|NCT06946485|BIOLOGICAL|Universal anti-CD70 CAR-T (CHT101)|Universal anti-CD70 CAR-T (CHT101) cell therpy
224139244|NCT00002545|RADIATION|low-LET photon therapy|
224139245|NCT02655445|PROCEDURE|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
224139246|NCT02655445|PROCEDURE|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
224139247|NCT02655445|PROCEDURE|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
224139248|NCT00530530|DRUG|ASP8825|oral
224139249|NCT00530530|DRUG|Placebo|oral
224299326|NCT01780987|DRUG|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
224038782|NCT07187739|OTHER|Mediterranean diet|All individuals in the intervention group will be instructed to adhere to Mediterranean diet recommendations for a period of three months following the activation of the deep brain stimulation device. Nutritional training sessions focusing on the Mediterranean diet will be provided and reinforced during monthly follow-up interviews. In line with these recommendations, olive oil will be promoted as the primary dietary fat. Participants will be encouraged to consume a minimum of 300-400 grams of vegetables daily and 450 grams of fresh fruit or alternatively, 300 grams of fresh fruit and 30 grams of dried fruit. The consumption of bakery products, sugary snacks, and carbonated beverages will be discouraged. White meat will be favored over red meat in meal planning. Participants will also be advised to include 450 grams of fish, 30 grams of oilseeds, and 180 grams of legumes in their weekly diets. There is no routine Mediterranean diet recommendation after STN DBS.
224038783|NCT07188272|DIETARY_SUPPLEMENT|DASH diet|Eating vegetables, fruits, and whole grains Including fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils Limiting foods that are high in saturated fat, such as fatty meats, full-fat dairy products, and tropical oils such as coconut, palm kernel, and palm oils Limiting sugar-sweetened beverages and sweets
223427593|NCT03896711|BEHAVIORAL|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
223427594|NCT03896711|OTHER|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
223427595|NCT01266785|DRUG|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
223427596|NCT04889157|DRUG|PF-06882961|Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
223427597|NCT04889157|DRUG|Placebo|3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
223427598|NCT03873415|DRUG|BMS-986165|Oral administration
223427599|NCT05720026|DRUG|SYSA1901|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
223427600|NCT05720026|DRUG|Pertuzumab|loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle
223427601|NCT05720026|DRUG|Trastuzumab|loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle
223427602|NCT05720026|DRUG|Docetaxel|75 mg/m\^2 IV, q3w/cycle, total 4cycle
223427603|NCT04258540|BEHAVIORAL|Yoga group|The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).
223427604|NCT04258540|BEHAVIORAL|yoga course|yoga course
224038784|NCT07188272|PROCEDURE|High Intensity Interval Training|High Intensity Interval Training
224038785|NCT07188441|DRUG|Teniposide Injection|teniposide 300mg/m2 for 5 days, cisplatin 75mg/m2 for 5 days
224038786|NCT04942795|DEVICE|Compliant balloon|Use of a compliant balloon when ADAPT fails to reach the clot site
223427605|NCT01546168|DEVICE|esophageal deviation with IDE device|esophageal deviation during AF ablation
223427606|NCT02850016|DRUG|3BNC117|Intravenous Infusion of 3BNC117
223427607|NCT02850016|DRUG|Romidepsin|Intravenous Infusion of Romidepsin
223427608|NCT02034396|PROCEDURE|Blood Draw|One blood draw at enrollment
223427609|NCT05919914|OTHER|Exercise with Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.
223427610|NCT05919914|OTHER|Exercise without Blood Flow Restriction (BFR)|Wrist extensor exercise (concentric - eccentric)
223427611|NCT02946814|DRUG|essential oils|
223427612|NCT02946814|DRUG|essential oils without mouthwash|
223427613|NCT02946814|DRUG|sterile water|
223427614|NCT05959408|PROCEDURE|Collection of throat swab|Introduction of a cotton swab for self-collection
223427615|NCT05959408|PROCEDURE|Collection of anal swab|Introduction of a cotton swab for self-collection
223427616|NCT05959408|PROCEDURE|Collection of first void urine|first void urine collected on urine pot
223427617|NCT00157911|DRUG|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
224038787|NCT04629963|OTHER|Pain Evaluation and BPISF|Current diagnostic approaches guide evaluators to use the United Nations Istanbul Protocol (UNIP) for the assessment of torture survivors. The proposed investigation offers a novel diagnostic paradigm by which participants are evaluated by the UNIP and a validated pain screen (Brief Pain Inventory Short Form).
224038788|NCT04629963|OTHER|Surveys, a fingerstick blood sample, EMAs, and a digital wearable device|The following surveys: BPI-SF, RHS-15, RTHC, SOIS-SF, RPMS, WHOAQ, QVSFS, a fingerstick blood sample, EMAs, and a digital wearable device
224139250|NCT03368131|DRUG|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
224139251|NCT03368131|DRUG|Capecitabine|825\~1000mg/m2 bid d1-14
223427618|NCT00157911|DRUG|Comparator: simvastatin / Duration of Treatment: 12 weeks|
223427619|NCT02954653|BIOLOGICAL|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
223427620|NCT02954653|DRUG|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
223427621|NCT02954653|DRUG|Daunorubicin|60-90 mg/m2 daily for 3 days
223427622|NCT02954653|DRUG|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
224038789|NCT05594199|BEHAVIORAL|Virtual Smoking Cessation Program|"This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided."
224038790|NCT06396897|OTHER|Indiana University Health Hospital at Home Program|Structure of Care in IUH H@H Program: The IUH H@H program allows patients to be cared for at home using home remote monitoring devices, travel laboratory services and both in-person and virtual rounding by the health care team. The team includes registered nurses (RN), advanced practice provider (APP, nurse practitioner and physician assistants) and hospitalist physician. Care at home is divided into 4 consecutive phases after initial hospitalization: (1) evaluation/planning, (2) acute, (3) recovery, and (4) rehabilitation. All patients are sent home with a RPM tablet used to obtain vital signs, send messages between patient and RN, \& perform video visits. The device is Bluetooth enabled and does not require WiFi or a phone line. All data obtained is automatically pulled into the electronic medical record. The RN uses a device which enables remote physical exams, i.e., obtain heart, lung and bowel sounds, pictures (wounds, lines, etc.) for review by APP/MD.
224038791|NCT04012437|DEVICE|Sphincter Control Training (SCT)|The SCT + device consists of 8 different exercises and an educational session into a app using a masturbation electronic aid device
224038792|NCT04012437|BEHAVIORAL|Sphincter Control Training (SCT)|The SCT consists of 4 different exercises and an educational session into a app using a masturbation electronic aid device
224139252|NCT03368131|DRUG|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
224139253|NCT03368131|RADIATION|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
224139254|NCT00870285|RADIATION|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
224139255|NCT01333306|PROCEDURE|Transcranial direct current stimulation (tDCS)|
224139256|NCT02791880|PROCEDURE|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
224139257|NCT04343209|DIAGNOSTIC_TEST|Myocardial Perfusion Imaging Study|Evaluation of myocardial perfusion via PET imaging agent
224139258|NCT04343209|DRUG|AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]|Cardiac PET imaging agent
224139259|NCT03773926|DEVICE|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
224139260|NCT01707329|DRUG|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
224299327|NCT01780987|DRUG|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
223427623|NCT02954653|DRUG|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
223427624|NCT01032421|PROCEDURE|IVF procedure|
223427625|NCT05308784|OTHER|Cellworks Singula and Ventura reports|Personalized drug match reports based on patients' genomic aberration.
223427626|NCT04875390|OTHER|Erector spina plane block|After the surgery is completed, intraoperative Erector spina plane block will be performed
224139261|NCT01707329|DRUG|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
224139262|NCT04995471|BEHAVIORAL|In presence RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
224163677|NCT03766113|OTHER|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
224163875|NCT00312728|DRUG|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
223427627|NCT04875390|OTHER|local infiltration|After the surgery is completed, intraoperative local infiltration will be performed
223427628|NCT02211690|DRUG|dolutegravir 50 mg (one tablet daily)|
223427629|NCT02211690|DRUG|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
223427630|NCT00711828|DRUG|Bortezomib|Given IV
223427631|NCT00711828|BIOLOGICAL|Rituximab|Given IV
223427632|NCT00711828|DRUG|Cyclophosphamide|Given PO
223427633|NCT00711828|DRUG|Dexamethasone|Given PO
223427634|NCT00711828|OTHER|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
223427635|NCT00711828|OTHER|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
223427636|NCT06439628|DRUG|Rimegepant|patients take rimegepant to treat migraine attack as needed
223427637|NCT01825174|BEHAVIORAL|Ball games program|twice a week different ball games 90min
224299328|NCT05765630|BIOLOGICAL|BLOOD SAMPLES|BLOOD SAMPLES
223427638|NCT01825174|BEHAVIORAL|Nutrition counseling|9 units of 90min each of nutrition counseling
223427639|NCT06260267|DRUG|Microbiota suspension|Microbiota suspension
223427640|NCT06260267|DRUG|Microbiota capsule|Microbiota capsule
223427641|NCT06260267|DRUG|Placebo suspension|Placebo suspension
223427642|NCT06260267|DRUG|Placebo capsule|Placebo capsule
223427643|NCT01890226|BEHAVIORAL|Mobile Personal Health Record App.|
223427644|NCT02286648|DRUG|Formocresol|pulpotomy with formocresol
223427645|NCT02286648|DRUG|Mineral Trioxide Aggregate|pulpotomy with MTA
223427646|NCT01659346|PROCEDURE|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
223427647|NCT01659346|DRUG|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
224299329|NCT03698448|DRUG|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
224038793|NCT05467878|OTHER|The anesthesia and analgesia technique preferred by the anesthetist will be recorded.|In the study, the anesthesia method applied by blind anesthesiologists in the peroperative period, the drugs or techniques used for analgesia will be recorded and their effects on the postoperative period and hospital stay will be examined.There will be no intervention in the perioperative and postoperative process.
224038794|NCT06629441|DIETARY_SUPPLEMENT|Probiotic group|taking 10 billion CFU probiotic one sachet one time, lasting 56 days.
224038795|NCT06629441|DIETARY_SUPPLEMENT|Placebo group|taking maltodaxtrin one sachet one time, lasting 56 days.
224038796|NCT06362798|OTHER|Financial Transfers|"Mothers assigned to the intervention group will be informed that they are eligible to receive financial transfers $160/week on a debit-card with a one-time label or scripted message that states: This money is intended to help you to spend more time visiting and caring for your infant(s) in the NICU. Financial transfers will begin 1 week after birth or when the mother is discharged (whichever comes later) until the infant is discharged, except in cases where the hospitalization lasts beyond 42 weeks corrected age."
224038797|NCT06526351|DEVICE|Early implant placement with immediate provisional restoration|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Immediate provisional restoration will be delivered.
224038798|NCT06526351|DEVICE|Early implant placement with delayed loading|Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Delayed loading protocol followed.
224038799|NCT00398970|DEVICE|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
224038800|NCT02858830|OTHER|High fat mixed meal|
224038801|NCT04356248|BEHAVIORAL|Endurance Training|Treatment in both arms consists of specific endurance exercise modalities (HIIT or ST). Treatments differ in the applied training intensities. Participants in both arms will exercise 3 times per week over a period of 3 weeks on a bicycle ergometer. Exercise sessions will be supervised by a trained physical therapist. Exercise intensity will be heart rate monitored based on the maximum heart rate (HRmax) assessed during the initial cardiopulmonary exercise test. Exercise sessions in both arms will include a warm-up and a cool-down period at low intensity (50% HRmax) for 3 min each.
224038802|NCT04356248|BEHAVIORAL|Education|Treatment in both arms consists of specific energy management education interventions (IEME or PMR). Treatments differ in the applied education approaches. Participants in both arms will exercise 2 times per week over a period of 3 weeks.
224038803|NCT03182166|DRUG|Golimumab (Optimization)|"Increase dose of golimumab.~* For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~* For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
224038804|NCT03182166|DIAGNOSTIC_TEST|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
224038805|NCT03182166|BIOLOGICAL|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
224038806|NCT05334017|DRUG|Xylometazoline 0,1%|1 ml of 0,1% xylometazoline diluted with 1 ml of 0,9% isotonic saline solution given as a nasal spray
224038807|NCT05334017|DRUG|Cocaine 4%|2 ml of 4% cocaine given as a nasal spray
224038808|NCT06414681|DRUG|Tagraxofusp|Tagraxofusp Patients will receive 12 micrograms/kg of Tagraxofusp (TAG) by IV infusion once daily for 3 consecutive days.
224038809|NCT06414681|DRUG|Pacritinib|Pacritinib Pacritinib (PAC) will be given orally, 200 mg twice per day starting at C2D4 and administered continuously (Subsequent cycles start on Day 1 of the Cycle).
224038810|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Sharkskin Forceps|25g Grieshaber Sharkskin ILM Forceps with Reflex Handle
224038811|NCT06536569|DEVICE|Internal limiting membrane (ILM) Peeling with Standard Forceps|25g Grieshaber Standard ILM Forceps
224038812|NCT06342284|RADIATION|Proton Beam Radiation with or without concurrent chemotherapy|Curative-intent fractionated proton beam thoracic radiotherapy, with or without concurrent chemotherapy
224038813|NCT06371287|BEHAVIORAL|Treinamento Auditivo Musical|Auditory training with a focus on musicality. The skills trained will be: figure-ground for instrumental sounds, sequential figure-ground, directed listening, duration of sounds, frequency of sounds, rhythm (temporal structuring), auditory closure and audiovisual memory, with a focus on temporal processing, working memory and attention selective on an increasing scale of difficulty. The frequency ranges of instrumental sounds are from 200 to 4000 Hz, composed of the following instruments: guitar, vibraphone, piano, flute and drum.
224038814|NCT06371287|BEHAVIORAL|Placebo|"This placebo approach will be to demonstrate the influence of musical exposure without exercises with structuring auditory skills and compare with the TAM group.~The song Sonata for two pianos in D major, K448, by Mozart, will be used. The films selected were: Cirque Du Soleil, entitled The Journey of Man; Chaplin collection with the following films: Modern Times, The Great Dictator, In Search of Gold and Footlights. The choice of the order of the films will be random, as proposed by Freire (2009)."
224038815|NCT04914143|OTHER|broken Ganoderma lucidum spore powder|The experimental group was treated with broken Ganoderma lucidum spore powder after chemotherapy
224038816|NCT04914143|OTHER|placebo|the control group was treated with placebo after chemotherapy
224038817|NCT01161901|PROCEDURE|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
224299330|NCT02547155|PROCEDURE|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
224299331|NCT02547155|PROCEDURE|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
224299332|NCT00920517|BIOLOGICAL|rDEN2/4delta30(ME) vaccine|10\^3 PFU dose
224299333|NCT00920517|BIOLOGICAL|Placebo|placebo for rDEN2/4delta30(ME) vaccine
224299334|NCT00296634|DRUG|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
223740167|NCT06948786|DRUG|Pirtobrutinib|Given PO
223427648|NCT01471717|DRUG|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
223564401|NCT06943781|DIAGNOSTIC_TEST|Fecal Helicobacter pylori gastric cancer susceptibility gene test|In the early stage of the study, the team used genome-wide association analysis (GWAS) to identify H. pylori specific SNP that are significantly associated with gastric cancer in gastric cancer patients and controls; according to the mutation or not of the SNP loci, the strains were categorized into the high-risk group of gastric cancer (mutated group) and the low-risk group (un-mutated group). The mutation status of the SNP locus was detected in portable and non-invasive fecal samples from patients using molecular biology assays for early non-invasive screening and risk assessment of gastric cancer in H. pylori infected patients.
223564402|NCT06943794|DRUG|recommendations for eradication treatment|"A high-risk Hp subtype guidance group consisting of the receiving physician + trial-related personnel conducts individualized assessment based on Hp infection, SNP test results, gastric mucosa condition, medical history and other factors, and provides subjects with medical explanations and recommendations for eradication treatment.~Eradication group protocol: standard quadruple therapy for H. pylori eradication program (PPI + bismuth + two antibiotics)~1. Omeprazole (or esomeprazole): 20mg, 2 times/day~2. Bismuth citrate: 220mg, 2 times/day~3. Metronidazole: 400mg, 3 times/day~4. Tetracycline: 500mg, 3 times/day~5. Treatment cycle: 10-14 days Eradication success was assessed after 1 month by urea breath test (UBT) or Hp fecal antigen test."
223564403|NCT06943768|DIAGNOSTIC_TEST|fecal methylation site-based testing and fecal Helicobacter pylori gastric cancer susceptibility gene-based testing|To establish an early diagnostic test system for gastric cancer based on the methylation site detection technology in feces, with or without the combination of Helicobacter pylori gastric cancer susceptibility gene detection, and then to evaluate the clinical diagnostic value of this test system.
223564404|NCT06950125|OTHER|Placebo|Bottle of 15 mL liquid (non-effective product) will be taken once a day for 12 weeks.
223564405|NCT06950125|OTHER|JUICE HA® supplement|Bottle of 15 mL JUICE HA® supplement will be taken once a day for 12 weeks.
223564406|NCT06949657|OTHER|the conventional treatment group|Patients received conventional mental health education once weekly for 6 weeks, covering schizophrenia symptoms, treatment, and prognosis. Standard nursing care and antipsychotic medications (e.g., olanzapine, quetiapine) were maintained without additional psychological interventions.
223564407|NCT06949657|OTHER|the ACT group|"Patients received ACT-based nursing interventions tailored to risk factors (e.g., age ≥70, long disease duration), including:~ACT modules: Acceptance, cognitive defusion, mindfulness, values clarification, and committed action.~Adjunct strategies: Family therapy, Tai Chi, and crisis planning. Frequency: Daily practice + 1-2 group sessions/week for 6 weeks. Goal: Enhance psychological flexibility, reduce stigma, and improve cognitive function."
223740168|NCT06948786|BIOLOGICAL|Mosunetuzumab|Given IV
223740169|NCT06948786|PROCEDURE|Biospecimen Collection|Undergo blood sample and oral swab and/or rectal swab collection
223740170|NCT06948786|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
223564411|NCT06950775|OTHER|Residence in Agrihood Neighborhood|We are examining the effects of individuals who move into an agrihood neighborhood.
223564412|NCT06954584|DRUG|Bevacizumab|Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 15 months
223564413|NCT06954584|DRUG|Fluzoparib Monotherapy|150 mg orally bid (50 mg/capsule, 3 capsules/dose)
223564414|NCT06954584|BEHAVIORAL|Dietary Intervention|Control carbohydrate intake in the daily diet
223564415|NCT06360614|OTHER|Hand massage application|2 sessions of hand massage every day, 2 days a week (Monday and Friday) for 4 weeks
223564416|NCT06360614|OTHER|routine monitoring and nursing care|Routine monitoring and nursing care for 4 weeks
223564417|NCT06525896|DEVICE|NSSD|A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.
223564418|NCT06525896|DEVICE|Sham NSSD|A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
223564419|NCT06518655|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
223564420|NCT06470204|DRUG|Ropivacaine|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2ml 0.9% NaCl)
223564421|NCT06470204|DRUG|Ropivacaine+Dexamethasone|Ultrasound-guided iPACK block + ACB - 2 x (20ml 0,2% ropivacaine + 2mg Dexamethasone)
223583991|NCT05487885|BEHAVIORAL|Positive Affect Training|Psychosocial add-on intervention that could enhance the effects of TBS. PA Therapy (Craske et al., 2016) is an innovative cognitive and experiential technique developed to address anhedonia specifically and, ideally, change altered patterns of frontostriatal function. Standing in contrast to Cognitive Behavioral Therapy, PA training has efficacy for enhancing positive affect and reducing negative affect (Craske et al., 2018). This treatment can be easily applied, and we propose that it will enhance neural circuit-level changes elicited by TBS.
223740171|NCT06948786|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
224038818|NCT04027231|OTHER|analysis of the synovial fluid|Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
224038819|NCT01423812|DRUG|Twice-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to remain on regimens containing combination Darunavir 600mg plus Ritonavir 100mg twice-daily
224038820|NCT01423812|DRUG|Once-daily combination Darunavir and ritonavir|Subjects randomized 1:1 to switch to from combination Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to the experimental combination Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
223427649|NCT01471717|DRUG|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
223427650|NCT01471717|DRUG|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
223427651|NCT01471717|DRUG|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
223427652|NCT01471717|DRUG|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
223427653|NCT01471717|DRUG|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
223427654|NCT00431665|DRUG|NG-monomethyl-L-Arginine (L-NMMA)|
223427655|NCT00431665|DRUG|triglycerides (Intralipid 20%)|
223427656|NCT00431665|DRUG|heparin|
223427657|NCT00431665|DRUG|somatostatin|
223427658|NCT00431665|DRUG|insulin|
223564422|NCT05064176|OTHER|Usual care|"Home physical therapist performs usual care and educates the patient to perform self-management~Usual care:~M1-6: 6 months of maintenance decongestive lymphatic therapy (DLT) (by patient and home physical therapist):~* week 1-2: no physical therapy; patient performs limb elevation, muscle contractions and wears the bandage (intervention group)/ compression garment (control group)~* week 3-4: start physical therapy, 2 days/ week: exercises, skin care \& manual lymph drainage (MLD), education; self-management by patient and wearing compression garment 14-16h/day (4 sessions) M2-6: 1 day/ week physical therapist: exercises, skin care \& MLD, and self-management by patient and wearing compression garment 14-16h/day (20 sessions)~M7-12: 6 months of maintenance DLT by patient (self-management) and home physical therapist:~\- 1 day/week physical therapist: skin care, MLD, exercises (26 sessions) Month 13-18: 6 months of maintenance DLT by patient Month 19-36: 18 months of follow-up"
223564423|NCT05064176|PROCEDURE|Reconstructive lymphatic surgery|"For the procedure of LVA:~\- Aim: making anastomoses of lymph vessels at the capillary level with a diameter of 0.3 to 0.8 mm, to redirect lymph to venous stream directly~For the procedure of LNT:~\- Aim:~1. Placed lymph nodes act as sponge to absorb lymphatic fluid and direct it into the vascular network;~2. Placed lymph nodes induce lymphangiogenesis"
223564424|NCT02640625|DIETARY_SUPPLEMENT|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
223564425|NCT01567501|DRUG|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
224038821|NCT00799279|BEHAVIORAL|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
223564426|NCT01567501|DRUG|Levocetirizine Dihydrochloride|5 mg tablet once in a day
223564427|NCT03511625|DRUG|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
224299335|NCT00296634|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
224299336|NCT06168786|DRUG|Fruquintinib|Fruquintinib:5mg ,qd,po, d1-d14, q3w
224299337|NCT06168786|DRUG|Cadonilimab|Cadonilimab:10mg/kg, ivgtt, d1, q3w
224299338|NCT06168786|RADIATION|SBRT|SBRT:8-10Gy×5F，qod， in 10 days
223427659|NCT00431665|DRUG|glucose|
223564428|NCT03511625|DRUG|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
223564429|NCT01086956|DRUG|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
224299339|NCT00179816|DRUG|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
224299340|NCT03499210|DEVICE|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
223427660|NCT00431665|DRUG|inulin|
223427661|NCT00431665|DRUG|paraamino hippurate (PAH)|
223427662|NCT04398186|DIAGNOSTIC_TEST|Anogenital distance measurement|Measurements of AGD and perineal muscle strength
223427663|NCT03841539|BEHAVIORAL|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
223427664|NCT03841539|DIETARY_SUPPLEMENT|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
223427665|NCT03841539|BEHAVIORAL|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
223427666|NCT01200459|BEHAVIORAL|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
223427667|NCT01206413|DIETARY_SUPPLEMENT|Low glycemic index diet|
223427668|NCT01206413|DIETARY_SUPPLEMENT|High glycemic index diet|
223427669|NCT01206413|OTHER|Home-based exercise intervention|
223427670|NCT01206413|OTHER|Non-exercisers|
224038822|NCT00799279|BEHAVIORAL|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
224038823|NCT04248582|DEVICE|Cryotherapy|LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
224038824|NCT04440787|PROCEDURE|Three point cuff palpation technique|the ETT is finally positioned according to the Three point cuff technique.
224038825|NCT01619111|DRUG|standard chemo- or endocrine therapy|"standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
224038826|NCT01619111|DRUG|standard chemo- or endocrine therapy + Lapatinib|"Lapatinib~\+ standard chemo- or endocrine therapy:~* Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~* Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
224038827|NCT02748018|DEVICE|670G and 770G Insulin Pump|Medtronic 670G and 770G Hybrid Closed Loop Systems
224038828|NCT02748018|DEVICE|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
224038829|NCT05334420|BEHAVIORAL|Healthy Dads Healthy Kids|Group based lifestyle behavioral intervention for weight loss for fathers and increased physical activity for their child. The program meets weekly 90-minute sessions over 10 weeks. Mothers/partners are invited to one session (Week 4). Each meeting consisted of a brief review session with Dads and Kids together (15 minutes), separate break-out discussion for Dads (Dad's Club) and Kids (Kid's Club) (30 minutes); and a joint physical activity component for Dads and Kids (Sports Club) (45 minutes). Each week covers different topics for fathers and a corresponding session for kids. The program encourages fathers to be healthy, positive role models for their children, and teaching fathers weight loss strategies, authoritative parenting strategies and to encourage healthy behaviors in their kids. Fathers and kids are encouraged to eat healthy, reduce their screen time and be more active. If the COVID pandemic prevents in-person meetings, the program will be delivered virtually.
224038830|NCT05334420|OTHER|Standard of care control|Families will receive handouts on healthy eating, physical activity and screen media use to promote healthy weight status. Fathers will attend one group session with a focus on dietary changes and increased physical activity to promote healthy weight loss.
224038831|NCT06563583|OTHER|Group 1 will include patients aged 18-40 years|Group 1 will include patients aged 18-40 years.
224038832|NCT06563583|OTHER|Group 2 will include patients aged 40-64 years|Group 2 will include patients aged 40-64 years, and finally.
224038833|NCT06563583|OTHER|Group 3 will include patients aged 65-85 years|Group 3 will include patients aged 65-85 years.
224139263|NCT04995471|BEHAVIORAL|In presence RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
224038834|NCT05264428|DIETARY_SUPPLEMENT|Honey|Participants need to drink honey every day for four weeks.
224038835|NCT05264428|DIETARY_SUPPLEMENT|Water|Participants need to drink water every day for four weeks.
224038836|NCT00537485|DRUG|SPM 962|transdermal application, 1 time per day
224038837|NCT00537485|DRUG|placebo|transdermal application, 1 time per day
224038838|NCT04029350|DRUG|Anlotinib Combined With Osimertinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
224299341|NCT04168190|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
224299342|NCT04168190|BIOLOGICAL|Pneumovax™23|Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
224299343|NCT02637635|PROCEDURE|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
224299344|NCT02637635|PROCEDURE|Expander prosthesis|breast reconstruction with expander prosthesis.
224299345|NCT00992524|DRUG|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
224299346|NCT00992524|DRUG|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
224299347|NCT02841813|OTHER|No intervention|No intervention
223427671|NCT03589963|BEHAVIORAL|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
223564430|NCT02524015|OTHER|Novel physical therapy|
223564431|NCT02524015|OTHER|Standard physical therapy|
224038839|NCT04080791|DEVICE|Virtual Reality (VR) System|The participants will undergo daily 30-minute sessions for 8 days of Virtual Reality (VR) with a VR system using commercially available default programs in addition to traditional intensive therapy regimen provided during inpatient rehab.
224038840|NCT04080791|PROCEDURE|Standard of care|Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.
224038841|NCT06503094|DRUG|CD19&CD20 bispecific CAR-T cells|Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
223427672|NCT06254508|BEHAVIORAL|Online program that includes exercise guided by the FITT-VP principle and dietary advice|"1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance."
223427673|NCT06254508|BEHAVIORAL|Conventional in-clinic nutrition and exercise advice and self-control|Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
223427674|NCT02941796|DRUG|HCP1105|
223427675|NCT02941796|DRUG|HCP0918|
223427676|NCT02941796|DRUG|HCP0816|
223427677|NCT02062996|DRUG|Oxymetazoline|
223564432|NCT01025349|DRUG|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
223564433|NCT05034315|OTHER|Whole egg consumption|The participants in the whole egg group consumed two whole eggs immediately after exercise.
224038842|NCT05341700|BEHAVIORAL|Impact Load Exercises|Participants will complete 50-65 min running protocol on treadmill and 5 sets of 10 jumping exercises for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
224038843|NCT05341700|BEHAVIORAL|No Impact Load Exercises|Participants will complete only a 50-65 min running protocol on treadmill for 5 consecutive days. Participants will also be provided all meals and snacks to induce a energy-restricted state for the 5-day period.
224299348|NCT06155318|DIAGNOSTIC_TEST|68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included|Patients meeting the inclusion criteria will undergo 68Ga-DOTATOC PET(PET/MRI or PET/CT) as part of their routine work-up, according to the referral clinicians' indication.PET/MRI will be performed on a 3.0T time of flight PET/MRI. Simultaneous PET/MRI will start approximately 60 minutes after the injection of 68Ga-DOTATOC.
223427678|NCT00070018|BIOLOGICAL|rituximab|250 mg/m\^2, as part of Zevalin regimen
224038844|NCT03327116|DRUG|Methotrexate|oral, 15 mg per week, 24 weeks
224038845|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
223427679|NCT00070018|DRUG|Cyclophosphamide|750 mg/m\^2
223427680|NCT00070018|DRUG|doxorubicin hydrochloride|50 mg/m\^2
223427681|NCT00070018|DRUG|prednisone|100 mg
223427682|NCT00070018|DRUG|vincristine sulfate|1.4 mg/m\^2
223427683|NCT00070018|RADIATION|radiation therapy|4000-5000 cGy total
223427684|NCT00070018|BIOLOGICAL|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
223740172|NCT06948786|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224038846|NCT00312221|DRUG|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
224038847|NCT00312221|DRUG|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
224038848|NCT05590936|DRUG|Dimenhydrinate Tablets|2 hours preoperative per os administration of 50 mg dimenhydrinate
224038849|NCT05590936|DRUG|Ondansetron iv|Intraoperative intravenous administration of 4 mg ondansetron
224038850|NCT06057675|DRUG|Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.
224038851|NCT06057675|DRUG|Control (1% lidocaine with 1:100,000 epinephrine)|Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
224038852|NCT01893892|DIETARY_SUPPLEMENT|levocarnitine|Given PO
224038853|NCT01893892|OTHER|placebo|Given PO
224038854|NCT01893892|OTHER|questionnaire administration|Ancillary studies
224038855|NCT01003990|DRUG|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
224038856|NCT01003990|DRUG|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
224038857|NCT01003990|DRUG|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
224038858|NCT01003990|DRUG|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
224038859|NCT02812901|PROCEDURE|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
223427685|NCT00070018|BIOLOGICAL|Indium-111 ibritumomab tiuxetan|5 mCi
223427686|NCT02086825|DRUG|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
223427687|NCT02086825|DRUG|Lactulose|20g dose titrated
223427688|NCT02400866|DRUG|Olanzapine|
223427689|NCT02939716|OTHER|Rhubarb|300gm rhubarb
223427690|NCT02939716|OTHER|Bread|2 slices bread
223427691|NCT02939716|OTHER|Lettuce|300g lettuce
223740173|NCT06948786|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223740174|NCT06948786|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
223740175|NCT06948786|OTHER|Questionnaire Administration|Ancillary studies
223427692|NCT03343249|BEHAVIORAL|Smart Phone Based Smoking Cessation|The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
223427693|NCT03202537|DRUG|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
223427694|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
224038860|NCT02812901|PROCEDURE|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
224038861|NCT03889431|DIETARY_SUPPLEMENT|Iodine capsule|225 µg of iodine daily as a capsule of potassium iodide
224038862|NCT03889431|OTHER|Iodized Salt|450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
224038863|NCT00151554|BEHAVIORAL|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
224038864|NCT03690141|DRUG|eFT508|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
224038865|NCT01922479|DRUG|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
224038866|NCT01922479|DRUG|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
224038867|NCT04989699|DRUG|OTX-TKI/Sham|OTX-TKI is one dose so subsequent visits will be sham to maintain the mask
224038868|NCT04989699|DRUG|Aflibercept/Sham|Aflibercept administered every 8 weeks
224038869|NCT05212896|DRUG|BC006|BC006 monoclonal antibody injection
224038870|NCT01807923|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
224038871|NCT01807923|DRUG|Ivacaftor|Film-coated tablet
224038872|NCT01807923|DRUG|Placebo|Matching placebo tablet
224038873|NCT02403622|DRUG|Fecal Microbiota Preparation|Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
224038874|NCT04611620|BEHAVIORAL|Cognitive Dysfunction|To fully characterize factors associated with cognitive dysfunction in BCS and CRC survivors that have cognitive concerns and (2) to fully characterize factors associated with psychoneurological symptom cluster in BCS and CRC survivors.
224038875|NCT03531788|DEVICE|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
224038876|NCT03531788|DEVICE|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
224038877|NCT05149365|DRUG|Sitagliptin + Standard Prophylaxis|Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
224038878|NCT05149365|DRUG|Standard Prophylaxis|Standard prophylaxis regimen for GVHD of Alternative Donor HSCT, include Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin
223564434|NCT04463628|BEHAVIORAL|Questionnaire|"The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown"
224038879|NCT01647529|DRUG|Ganciclovir|Treatment with topical ganciclovir ointment
224038880|NCT05913310|DRUG|Kui-Yuan Chewable Tablets|Kui-Yuan chewable tablets are the optimal ingredients found in sunflower dish that can reduce uric acid and anti-gout, including flavonoids, Coumarin (including scopolamine) and phenolic acids.
224038881|NCT05913310|DRUG|Placedo of Kui-Yuan Chewable Tablets|Placedo of Kui-Yuan Chewable Tablets are composed of L-arabinose, food starch and a few auxiliary materials.
224038882|NCT02693769|DRUG|fluticasone propionate/formoterol fumarate breath actuated inhaler|
224038883|NCT02693769|DRUG|Indacaterol maleate / glycopyrronium bromide capsules|
224038884|NCT02673606|DRUG|Estradiol 2Mg Tablet|one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
223427695|NCT00570349|DRUG|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
224038885|NCT02673606|DRUG|Estradiol 4Mg Tablet|two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
224038886|NCT02673606|DRUG|Placebo Pills|inactive placebo pills
224038887|NCT02014740|DRUG|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
224038888|NCT02014740|DRUG|Metformin|
224038889|NCT02992314|DEVICE|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
224038890|NCT02992314|DEVICE|Placebo|Placebo formulation with out the active ingredients
224038891|NCT03173079|OTHER|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
224038892|NCT04614441|DRUG|OFEV®|nintedanib
223427696|NCT00570349|DRUG|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
223427697|NCT02543892|BIOLOGICAL|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
223427698|NCT02543892|BIOLOGICAL|Placebo|Normal Saline
223427699|NCT00371644|BEHAVIORAL|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
223427700|NCT00371644|BEHAVIORAL|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
223427701|NCT06355089|DIETARY_SUPPLEMENT|Placebo Comparator|Low-protein milk product
223427702|NCT06355089|DIETARY_SUPPLEMENT|Whey protein hydrolysate milk product|Milk product with whey protein hydrolysate
223427703|NCT06355089|DIETARY_SUPPLEMENT|Postbiotic and whey protein hydrolysate milk product|Milk product with whey protein hydrolysate and Lacticaseibacillus rhamnosus GG
223427704|NCT01252862|DEVICE|iStent|Implantation of two iStents through a small temporal clear corneal incision
223427705|NCT06731426|BEHAVIORAL|CBM-TAF|CBM-TAF aims to modify TAF by training participants to adopt an interpretation style that is inconsistent with TAF (i.e., having unwanted thoughts is not morally equivalent to acting upon them and/or having unwanted thoughts does not increase the likelihood of feared events happening in real life). To personalize the training, CBM-TAF is designed to address 4 subtypes of OCD (as defined by Dimensional Obsessive-Compulsive Scale; Abramowitz et al., 2010), each of which targets either TAF-moral or TAF-likelihood. Participants will indicate two OCD subtypes that are most relevant to their experiences and only complete scenarios that correspond to their chosen subtypes. For each scenario, participants are instructed to enter a missing letter in a fragmented word and resolve its emotional ambiguity. After then, participants will answer a True/False question related to the given scenario to verify their comprehension and consolidate their acquisition of healthier interpretation style.
223427706|NCT06731426|BEHAVIORAL|CBM-SMP|CBM-SMP is a comparable intervention to CBM-TAF (Siwiec et al., 2023), which aims to provide general education about stress and stress management techniques. It is identical to CBM-TAF in terms of its administration, except for the content of scenarios included in training sessions. For each scenario, participants are instructed to enter a missing letter in a fragmented word. After then, participants will answer a True/False question related to the given scenario in order to verify their comprehension.
223427707|NCT00598546|BEHAVIORAL|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
224038893|NCT04272541|BEHAVIORAL|Psychoeducation program|Intervention program consisted of psychopharmacology + psychoeducation. This will be executed during 3 months, distribuited in several sessions.
223427708|NCT00821223|PROCEDURE|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
223427709|NCT00821223|PROCEDURE|manual small incision surgery|
223427710|NCT00821223|PROCEDURE|phacoemulsification|cataract surgery
223427711|NCT01500213|DRUG|Rolapitant|200 mg PO
223427712|NCT01500213|DRUG|Granisetron|10 mcg/kg IV
223427713|NCT01500213|DRUG|Dexamethasone|20 mg PO and 8 mg PO
223427714|NCT01500213|DRUG|Placebo|(4 X 0 mg capsules) o mg PO
224038894|NCT04272541|DRUG|Psychopharmacology intervention|Intervention program consisted of psychopharmacology. This will be executed during 3 months.
224038895|NCT03404284|BEHAVIORAL|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
223427715|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
223427716|NCT00785213|DRUG|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
223427717|NCT00785213|DRUG|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
223427718|NCT00525902|DRUG|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
224038896|NCT02608541|OTHER|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
223427719|NCT02468128|DRUG|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
223427720|NCT02468128|DRUG|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
223427721|NCT02180997|DRUG|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
223427722|NCT02180997|DRUG|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
223427723|NCT02180997|DRUG|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
223427724|NCT03667417|OTHER|Questionnaires|standardized data collection and 10-year prospective follow-up
223427725|NCT02172586|DRUG|Telmisartan|
223427726|NCT02172586|DRUG|Losartan|
223427727|NCT02172586|DRUG|Hydrochlorothiazide|
223427728|NCT00985959|DRUG|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
223427729|NCT00985959|DRUG|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
223427730|NCT00985959|DRUG|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
223427731|NCT00985959|DRUG|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
223427732|NCT00985959|DRUG|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
223427733|NCT00383175|OTHER|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
223427734|NCT06726837|OTHER|Postoperative pain - 6th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 6th hour.
223427735|NCT06726837|OTHER|Postoperative pain - 24th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 24th hour.
223427736|NCT06726837|OTHER|Postoperative pain - 48th hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 48th hour.
223427737|NCT06726837|OTHER|Postoperative pain - 72nd hour|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 72nd hour.
223427738|NCT06726837|OTHER|Postoperative pain - 7 day|Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 7 day.
223427739|NCT00392470|BIOLOGICAL|cetuximab|
223427740|NCT00392470|DRUG|irinotecan hydrochloride|
223427741|NCT00392470|PROCEDURE|conventional surgery|
223427742|NCT00392470|PROCEDURE|neoadjuvant therapy|
223427743|NCT00392470|RADIATION|3-dimensional conformal radiation therapy|
223427744|NCT00392470|RADIATION|intensity-modulated radiation therapy|
223427745|NCT01656278|PROCEDURE|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28\>3.2 AND/OR MRI-detected bone marrow oedema score \> 0 (RAMRIS-score)"
223427746|NCT01656278|OTHER|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28\>3.2"
223427747|NCT04373798|DIAGNOSTIC_TEST|C-reactive protein|Measurement of CRP value from blood sample taken at covid19 check point (baseline).
223427748|NCT04756128|DRUG|Colchicine 0.6 mg|"Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)"
223427749|NCT04756128|DRUG|Naltrexone|"Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension."
223427750|NCT01777568|DRUG|30% oxygen|Inspired oxygen will be maintained at 30%.
223427751|NCT01777568|DRUG|80% oxygen|Inspired oxygen will be maintained at 30%.
223427752|NCT03851146|BIOLOGICAL|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
223427753|NCT05008393|DRUG|PJS-539 Dose 1|Patients will receive PJS-539 dose 1 daily for 10 days.
223427754|NCT05008393|DRUG|PJS-539 Dose 2|Patients will receive PJS-539 Dose 2 daily for 10 days.
223427755|NCT05008393|DRUG|Placebo|Patients will receive placebo daily for 10 days.
223564435|NCT04463628|BEHAVIORAL|Interview|Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
223564436|NCT00511433|DRUG|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
223564437|NCT00511433|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
223564438|NCT00531076|BIOLOGICAL|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
223427756|NCT03579628|DRUG|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
224038897|NCT04308525|BEHAVIORAL|Early ambulation|Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
224038898|NCT04308525|BEHAVIORAL|Early oral feeding|To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
224038899|NCT04308525|OTHER|Multimodal opioid-sparing analgesia|"On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day."
224038900|NCT04308525|PROCEDURE|Goal-directed fluid therapy|Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
224139264|NCT04995471|BEHAVIORAL|Tele-RRT - prototype software|Rhythmic Reading Training (RRT) is a prototype software which includes reading exercises presented simultaneously with a rhythmic stimulation with gradually increasing speed.
223427757|NCT03760328|DEVICE|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
223427758|NCT00103493|BEHAVIORAL|Motivational interviewing|
223427759|NCT00103493|BEHAVIORAL|Targeted DVD-based educational program|
223427760|NCT02744482|DRUG|risedronate|risedrante tablet (75 mg)
223427761|NCT02744482|DRUG|placebo|risedrante placebo tablet (75 mg)
223427762|NCT00844480|DRUG|zoledronic acid|zoledronic acid, 5mg, iv
223427763|NCT00844480|DRUG|placebo|iv
223427764|NCT06730880|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction (abbreviated PCR) is a laboratory technique for rapidly producing (amplifying) millions to billions of copies of a specific segment of DNA, which can then be studied in greater detail.
223427765|NCT02858180|DRUG|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
223427766|NCT00526331|DEVICE|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
223427767|NCT00526331|DEVICE|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
223427768|NCT06193148|DRUG|Jaktinib|Participants will receive Jaktinib orally for single dose
223427769|NCT06193148|DRUG|Placebo|Participants will receive Placebo orally for single dose
223427770|NCT02490748|PROCEDURE|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
223427771|NCT02490748|BIOLOGICAL|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
223427772|NCT05600062|DRUG|Racecadotril 100 milligram (MG) Oral Capsule|Licensed NEP inhibitor
223427773|NCT05600062|DRUG|Placebo|Placebo capsule
223427774|NCT03229148|PROCEDURE|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
223427775|NCT03229148|PROCEDURE|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
223427776|NCT03907930|PROCEDURE|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
223564439|NCT06162195|DEVICE|The H1 Implant|Patients allocated to The H1 Implant arm will be implanted with the H1 Implant which is a cementless, ceramic hip resurfacing device.
223564440|NCT06162195|DEVICE|Cementless total hip replacement|Patients allocated to cementless total hip replacement arm will be implanted with a cementless ceramic-on-poly or ceramic-on-ceramic total hip replacement
223427777|NCT01028248|DRUG|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
223427778|NCT06242418|DRUG|FOLFOXIRI|Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
223427779|NCT06242418|DRUG|XELOX|Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
223427780|NCT00574249|BIOLOGICAL|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
223427781|NCT00574249|DRUG|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
224038901|NCT04308525|PROCEDURE|CAD/CAM system for reconstructive plates|Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
224038902|NCT04308525|OTHER|Functional discharge criteria|Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
224038903|NCT04308525|OTHER|Standard/historical postoperative regimen|Non-formalised historical peri- and postoperative regimen.
224038904|NCT00800943|BIOLOGICAL|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
224038905|NCT03594851|BEHAVIORAL|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
224038906|NCT03594851|BEHAVIORAL|Sleep diary|A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
223427782|NCT00574249|DRUG|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
223427783|NCT00669552|PROCEDURE|Percutaneous coronary intervention|PCI previously electively scheduled.
223427784|NCT03684824|DRUG|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
223427785|NCT03684824|DRUG|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
223427786|NCT03084068|OTHER|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
223427787|NCT03084068|OTHER|Placebo|Open rotator cuff surgery with standard suture repair
223427788|NCT01036659|DRUG|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
223427789|NCT03079037|DEVICE|Stimulation|Traditional deep brain stimulation
223427790|NCT02827435|DRUG|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
223427791|NCT02219789|DRUG|Alisertib|Given PO
223427792|NCT02219789|DRUG|Fulvestrant|Given IM
223427793|NCT02219789|OTHER|Laboratory Biomarker Analysis|Correlative studies
223427794|NCT05969964|BEHAVIORAL|Avoid second resection after initial complete resection|Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.
223427795|NCT01295463|OTHER|questionnaire administration|
223427796|NCT01295463|OTHER|study of socioeconomic and demographic variables|
223427797|NCT01295463|PROCEDURE|assessment of therapy complications|
223427798|NCT01295463|PROCEDURE|fertility assessment and management|
223427799|NCT01295463|PROCEDURE|psychosocial assessment and care|
223427800|NCT01295463|PROCEDURE|quality-of-life assessment|
223427801|NCT06619288|DRUG|B/F/TAF|Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.
223427802|NCT06619288|DRUG|TDF+3TC+EFV|Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).
223427803|NCT06619288|DRUG|DTG/3TC|Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
223427804|NCT06318052|DEVICE|The FemTouch delivery system|The FemTouch delivery system is used in conjunction with the AcuPulse CO2 laser system and the AcuScan120 microscanner to provide fractional treatments in gynecology
223427805|NCT06318052|DRUG|Gynomunal gel treatment|hormone/free, vaginal moisturizing gel for women with vaginal dryness
223564441|NCT01740089|DRUG|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
223427806|NCT02094222|DRUG|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
223427807|NCT01729052|DEVICE|Acupuncture|
223427808|NCT06618781|PROCEDURE|Sedation|Preoperatively, 2 mg intravenous midazolam was administered to the patients. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and when the Vizel analog score was \>4, intravenous 0.1-1 mcg/kg remifentanil was administered.
223427809|NCT06618781|PROCEDURE|Sedation + Quadratus Lumborum Block|Before the procedure, the patient was placed in the left lateral position and a Quadratus Lumborum Block was applied at the thoracic 8-10 level. A total of 20 cc blocking fluid consisting of 14 cc of 0.5% bupivacaine and 6 cc of 2% lidocaine was used for the block. A minimum of 30 minutes was waited after the block. 2 mg of intravenous midazolam was administered before being taken to the operating room. Intravenous 0.5 mg/kg propofol and 0.5 mcg/kg fentanyl were used for induction. Intravenous 0.5-1 mg/kg propofol was administered to provide an intraoperative bispectral index of 40-60, and intravenous 0.1-1 mcg/kg remifentanil was administered when the Vizel analog score was \>4.
223427810|NCT04295057|OTHER|Non-intervention|Non-intervention
223427811|NCT01712867|OTHER|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
223427812|NCT01712867|OTHER|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
223427813|NCT01639404|PROCEDURE|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
223427814|NCT01639404|OTHER|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
223427815|NCT02212990|OTHER|Acetaminophen Arm|Blinded Therapy
223427816|NCT02212990|OTHER|Placebo Arm|Blinded Therapy
224038907|NCT03594851|BEHAVIORAL|Katz Index of Independence in Activities of Daily Living|Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
224038908|NCT03594851|BEHAVIORAL|Lawton Instrumental Activities of Daily Living|"Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers."
224038909|NCT03594851|BEHAVIORAL|Neuropsychiatric Inventory (Cummings)|"Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease."
223427817|NCT02212990|OTHER|Ibuprofen Arm|Open Label Therapy
223564442|NCT01740089|DRUG|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
224038910|NCT03594851|BEHAVIORAL|Mini Zarit Caregiver Burden Scale, for the caregiver|Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
224038911|NCT03594851|BEHAVIORAL|Mini Mental state examination|"It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975"
223427818|NCT01222754|DRUG|Lenalidomide|"1. With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~2. Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
223427819|NCT01222754|RADIATION|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
223427820|NCT03266458|PROCEDURE|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
223427821|NCT02501954|DRUG|Cisplatin|Given IV
223427822|NCT02501954|DRUG|Carboplatin|Given IV
223427823|NCT02501954|DRUG|Paclitaxel|Given IV
223427824|NCT02501954|RADIATION|Radiation Therapy|Undergo Radiation Therapy
223427825|NCT01931943|DRUG|selatinib ditosilate tablets|
223427826|NCT01683851|DEVICE|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
223427827|NCT00347919|DRUG|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
223564443|NCT01740089|DRUG|Ribavirin|800-1400 mg/day orally
223564444|NCT01338077|DRUG|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
223564445|NCT01338077|DRUG|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
223564446|NCT00006078|DIETARY_SUPPLEMENT|lycopene|
223564447|NCT05332249|PROCEDURE|Surgery|Patients who undergo spinal surgery for degenerative spinal disease
223427828|NCT00347919|DRUG|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
223427829|NCT00347919|DRUG|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
223427830|NCT00347919|DRUG|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
223427831|NCT05263765|PROCEDURE|utilization of AO in the acute resuscitation of trauma and acute care surgery patients in shock.|AO to facilitate the acute resuscitation of trauma and acute care surgery patients in shock.
223427832|NCT02059668|BIOLOGICAL|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
223427833|NCT05665972|OTHER|Mandala coloring|Each participant will be given 12 colored felt-tip pen paint sets and 12 mandala coloring pages by the researchers. Participants will be asked to dye for 3 menstrual cycles, 14 days before the start of menstruation, 1 day a week, at any time of the day and for an average of 20-30 minutes each time.
223427834|NCT02097251|DRUG|UX003|Open Label
223427835|NCT00383695|BIOLOGICAL|cetuximab|
223427836|NCT00383695|DRUG|capecitabine|
223740176|NCT07147764|OTHER|Physiotherapy|Physiotherapy treatment programs include therapeutic ultrasound, muscle relaxation techniques, range of motion exercises, and joint and soft tissue mobilization.
224038912|NCT03594851|BEHAVIORAL|Cornell Scale for Depression in Dementia|The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
224070391|NCT05284123|OTHER|Mental health literacy workshop|The mental health literacy workshop provides participants with information about the symptoms and treatment of common mental disorders, and asks participants to reflect on what they learned through a couple brief writing tasks. This workshop also provides participants with basic information about mental health resources.
223427837|NCT00383695|DRUG|oxaliplatin|
223427838|NCT00383695|PROCEDURE|adjuvant therapy|
223427839|NCT00383695|PROCEDURE|conventional surgery|
223427840|NCT00383695|PROCEDURE|neoadjuvant therapy|
223427841|NCT00383695|RADIATION|radiation therapy|
223427842|NCT03173742|DRUG|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
223427843|NCT03173742|DRUG|T1,T3,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
223427844|NCT03173742|DRUG|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
223427845|NCT03173742|DRUG|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
223427846|NCT03173742|DRUG|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
223427847|NCT03173742|DRUG|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
223427848|NCT06164847|BEHAVIORAL|AERO Program|HEP, identification of barriers for exercise using the COM-B model. Interventions for these barriers: Review of HEP, review of method of delivery, cues, reminders, discussion of barriers and problem solving, motivational interviewing, decision balance sheets, behavioural contract, goal setting reviews, monitoring calls (detailed description in the link below).
223427849|NCT06164847|OTHER|Standard Care|home exercise programs, mobilisations, soft tissue techniques, or training with gym equipment
223427850|NCT02874079|OTHER|Blood sample and cotton skin swabs|
223427851|NCT06668753|DRUG|Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab|SGLT-2 inhibitors
223427852|NCT00483197|DEVICE|VentrAssistTM Left Ventricular Assist Device|
223427853|NCT02481401|BEHAVIORAL|Intensive Individual Intervention Program|
223427854|NCT02481401|BEHAVIORAL|Peer-To-Peer Program Intervention|
223427855|NCT03492398|DRUG|HY209|6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.
223427856|NCT05213884|DRUG|Camrelizumab|200 mg, intravenous infusion over 30 minutes (Q3W); 1\~3 cycles of camrelizumab before radiotherapy and camrelizumab are maintained for 16 cycles (1 year) after the end of radiotherapy.
223427857|NCT05213884|DRUG|Concurrent cisplatin chemotherapy|cisplatin is given at a dose of 40 mg/m2 via intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy every week for 6 cycles.
223427858|NCT05213884|RADIATION|Intensity-modulated radiotherapy (IMRT)|70 Gy/ 35 fractions/7 weeks, 5 fractions/week, 1 fraction/day.
223427859|NCT02269410|DIETARY_SUPPLEMENT|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
223427860|NCT02269410|DIETARY_SUPPLEMENT|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
223427861|NCT02269410|DIETARY_SUPPLEMENT|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
223427862|NCT02269410|DIETARY_SUPPLEMENT|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
223744784|NCT05699343|PROCEDURE|InterOss Collagen (Bone xenograft)|Group will only receive InterOss Collagen during surgical intervention visit.
223744785|NCT06172621|PROCEDURE|Spinal Cord Associative Plasticity (SCAP)|Paired non-invasive brain and spinal cord stimulation.
223427863|NCT00852215|DEVICE|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
223427864|NCT00852215|DEVICE|Vision stent|Stenting with VISION coronary stent system for coronary lesions with \> 50% diameter stenosis with ischemic symptoms or positive functional study, or \> 70% diameter stenosis without ischemic symptoms or positive functional study
223427865|NCT01512069|BEHAVIORAL|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
223427866|NCT01512069|BEHAVIORAL|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
223427867|NCT06623929|DRUG|Etofenamat|E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.
224070392|NCT05284123|OTHER|Control workshop|The control workshop provides participants with basic information about mental health resources.
224070393|NCT05290025|DRUG|Nicotine patch|\> 20 cigarettes per day: 21 mg nicotine/ 24 hours 10-20 cigarettes per day: 14 mg nicotine/ 24 hours 5-10 cigarettes per day: 7 mg nicotine/ 24 hours
224070394|NCT05290025|DRUG|Nicotine gum|Nicotine chewing gum will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 chewing gums per day
223427868|NCT06623929|DRUG|Diclofenac|Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
223427869|NCT03530813|OTHER|Ebook Asthma First Aid in School Training|Technology assisted, self-directed learning eBook resource
223427870|NCT03530813|OTHER|Face-To-Face Asthma First Aid in Schools Training|School Asthma First Aid Management Program 3 Hour Face to Face Training
223427871|NCT01382225|DRUG|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
223427872|NCT01382225|OTHER|Vehicle|Inactive ingredients used as run-in and placebo comparator
223427873|NCT04159649|DRUG|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
223427874|NCT04159649|DRUG|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
223427875|NCT04159649|PROCEDURE|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
223427876|NCT04859153|DIAGNOSTIC_TEST|central nerve sensory, motor control and various muscle mechanical characteristic and sport-related fitness test|To explore the sports performance of the adolescent sprinters, including analyzing the correlations between the results and central nerve sensory, and also between motor control and various muscle mechanical characteristic and sport-related fitness factor.
223564448|NCT05000268|OTHER|Progressive Myofascial Relaxation Exercise|"Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed."
223564449|NCT03703310|DRUG|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
223564450|NCT03703310|DRUG|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
223564451|NCT00906724|PROCEDURE|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
223564452|NCT05945732|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC."
223564453|NCT05209295|DRUG|Onureg|Specified dose on specified days
223564454|NCT06052878|OTHER|"Parental telephone interview with standardized parental questionnaire from the Behaviour Rating Inventory of Executive Function (BRIEF)"|"The Behaviour Rating Inventory of Executive Function (BRIEF) is a parental questionnaire that assesses the executive functions of children aged 5 to 18 years old. It consists of 86 questions grouped into 8 scales: inhibition, flexibility, emotional control, initiation, material organization, working memory, planning/organization, and monitoring. It provides information on a global scale (score) regarding subtle and subclinical changes in various executive functions."
223564455|NCT06052878|OTHER|Parental questionnaire about their child's cognitive functioning in their daily life and medical history.|Standardized questionnaire includes : The child's medical history and cognitive functioning (at school, parental home, and during extracurricular activities), home environment, parent's child socioeconomic status and emotional climate.
223564456|NCT05087927|BEHAVIORAL|Gain framing plus demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
223564457|NCT05087927|BEHAVIORAL|Loss framing plus demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of women of multiple races."
223564458|NCT05087927|BEHAVIORAL|Gain framing plus not demographically targeted photos|"Gain framing: Participant feels PrEP puts her in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
224038913|NCT03594851|BEHAVIORAL|Quality of Life in Alzheimer's Disease|The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses \& includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
224038914|NCT02939248|DRUG|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
223427877|NCT01852201|DEVICE|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
223427878|NCT01063270|DRUG|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
223427879|NCT01063270|PROCEDURE|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
223427880|NCT06148428|PROCEDURE|Laser in situ keratomileusis (LASIK)|"Patients were planned to undergo laser in situ keratomileusis. Local anesthesia was achieved by preservative-free oxybuprocaine hydrochloride 0.4% drops (a commonly used topical anesthetic due to its effectiveness in alleviating pain and ocular surface discomfort during the procedure). During surgery, the lights of the operating room were dimmed as much as possible and the surgeons spoke to the patients in a calm voice and explained what was happening. They also reassured the patients that the surgery was going as planned and would be over soon.~For patients undergoing (Microkeratome) MK-LASIK, a Moria 2 Microkeratome (Moria SA, Antony, France) was used to create the flap. For patients undergoing Femtosecond LASIK (FS-LASIK), the Allegretto Wave Light FS-200 femtosecond Laser (Alcon labs, Fort Worth, TX, USA) was used for flap creation.~Laser ablation was performed using WaveLight EX500 Excimer Laser (Alcon labs, Fort Worth, TX, USA) with a planned post-operative emmetropia."
224299349|NCT01796613|DEVICE|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
224304939|NCT05122377|DRUG|3M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
223427881|NCT03480191|DRUG|Daptomycin|Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
223427882|NCT03624062|DRUG|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
223427883|NCT05710991|BEHAVIORAL|Sleep Hygiene Workshop|Psychoeducation on the perinatal period and sleep difficulties including principles of sleep hygiene conducive environment for sleep, bedtime routine, food, beverage, and stimulant consumption, exercise
223427884|NCT05710991|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia Workshop|The CBT-I workshop group contains empirically supported strategies for insomnia modified to target the transitions and concerns faced by perinatal individuals. Content includes Sleep drive, stimulus control, sleep restriction, counter-arousal techniques, cognitive restructuring
223427885|NCT00494052|BEHAVIORAL|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
223427886|NCT00494052|BEHAVIORAL|Physician Education Session|A physician education session will be included in the program.
223427887|NCT00737347|BEHAVIORAL|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
223564459|NCT05087927|BEHAVIORAL|Loss framing plus not demographically targeted photos|"Loss framing: Without PrEP, participant feels less in control~Participants (majority of whom will be African American) will be shown an image of an African American woman."
223564460|NCT01034566|RADIATION|Proton Beam Radiation Therapy|
223744786|NCT06172621|PROCEDURE|Upper extremity task-oriented exercise|Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
223427888|NCT00746707|DEVICE|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
223427889|NCT00746707|PROCEDURE|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
223427890|NCT01198288|OTHER|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
223427891|NCT01198288|OTHER|Standard Care|As describe in the standard care arm
223744787|NCT05861856|OTHER|Manual therapy|Mobilization for the spine, mobilization and relaxation methods for the soft tissues around the spine will be performed.
224038915|NCT02939248|DRUG|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
224038916|NCT01759212|BIOLOGICAL|Allogeneic stem cells implantation|
224038917|NCT03575455|BEHAVIORAL|Exercise|HR-controlled treadmill walking
224038918|NCT01241097|DRUG|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
223427892|NCT03951064|DEVICE|Esophageal balloon|All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed \>30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
223427893|NCT03951064|PROCEDURE|Intervention Spontaneous Breathing Trial (SBT) and Extubation|Patients in the Intervention group will undergo an SBT regardless of their PEEP level. The PEEP that generates a Ptp of 0 will be considered their optimal PEEP, and this will not be lowered for the SBT. The Intervention Group SBT will consist of a trial of a pressure support of 5 cm H2O and Optimal PEEP.
223427894|NCT03951064|PROCEDURE|Control Spontaneous Breathing Trial and Extubation|Patients in the Control group will undergo an SBT when they reach a PEEP ≤8 cm H2O. This is the current standard of care based on the SBT protocol at UNC Hospitals. SBT and extubation prior to meeting these criteria will be based on primary medical team's discretion and will be recorded for analysis and safety tracking.
223427895|NCT03951064|PROCEDURE|Intervention Weaning after Tracheostomy|Based on the use of optimal PEEP in this group, and the experience in the previous study protocol, the investigators will place patients in the Intervention group on Tracheostomy Collar Trial only with a speaking valve. This simulates the normal process of utilizing the upper airway to maintain lung inflation that is performed automatically when a patient does not have an artificial airway.
223427896|NCT03951064|PROCEDURE|Control Weaning after Tracheostomy|The control group will be placed on Tracheostomy Collar Trial with no requirement for speaking valve. They may utilize a speaking valve if tolerated and desired, but there is no requirement as there is in the Intervention group.
223427897|NCT00796705|DRUG|Adalimumab|40 mg injection of adalimumab administered subcutaneously
224038919|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI)-Standard of Care|"Standard care involves behavioral intervention delivered during admission Intensive Multidisciplinary Intervention. Patients admitted to the program will participate in four therapeutic meals per day, five days per week (Monday through Friday). The behavioral intervention involves a standard sequence of reinforcement techniques, bite persistence (a.k.a., contingency contacting, escape extinction), and stimulus fading/antecedent manipulation protocols. Parent training will be the central method for structuring meals and transferring treatment gains from the clinic to the home setting. The sequence and steps for parents training will follow a sequential, proficiency-based process, with caregivers transitioning to serve as the primary feeder by discharge.~Management of tube wean in our standard of care involves reducing tube feeding calories based on oral intake at a 1:1 ratio."
224038920|NCT05053438|BEHAVIORAL|Intensive Multidisciplinary Feeding Intervention (IMFI) standard of care + rapid tube weaning|The experimental arm combines standard care with a rapid tube wean. On day 1, the dietitian will meet with the caregiver to determine the usual tube feeding schedule. The dietitian will then create a tube feeding plan that meets 70% of the child's caloric needs (a 30% reduction).On day 3, if a patient has moved past a rice size bite volume in therapeutic meals, the patient's tube feedings will be further reduced to meet 50% of needs. All schedules and documents will be updated accordingly. After the 50% tube wean cut, the dietitian will use a regular tube wean sheet to provide credit for oral intake for the remainder of admission.
223427898|NCT00796705|DRUG|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
224038921|NCT02993653|RADIATION|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
224139265|NCT04995471|BEHAVIORAL|Tele-RRT - online platform|"RRT is a web application with a client-server structure developed in javascript/php language using open-source support libraries. The server-side system uses a LAMP stack (Linux, Apache, Mysql, Php) on Server Cloud. The application can also be activated as a desktop application through portable web server installation systems, available for linux, windows and OS operating systems. In this form, the application can also be used in contexts without an Internet connection. The system is also accessible from tablets. RRT consists of a module of progressive reading exercises. The exercises are organized according to different types (syllables, words, non-words, short texts) and accompanied by a rhythmic-melodic stimulation, which is coordinated with a visual cue. Both remote (Rhythmic Reading Tele-Training, RRTT) and in presence administration (RRT) are available."
224139266|NCT02941341|DRUG|r-hFSH|As per standard practice
224299350|NCT01796613|DEVICE|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck \& Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
224299351|NCT05268068|DRUG|Risankizumab|Intravenous (IV) Infusion
224299352|NCT05268068|DRUG|Risankizumab|Subcutaneous (SC) Injection
223427899|NCT00796705|DRUG|Etanercept|50 mg dimeric fusion protein administered subcutaneously
223427900|NCT02046083|DRUG|arachid|
223427901|NCT06666790|DEVICE|Scan with elastic scattering spectroscopy device to assess risk of malignancy|Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
224299353|NCT02322463|DRUG|Arab children|Treatment with Oxycodone
224299354|NCT00202423|DRUG|Sativex|
223427902|NCT00464516|DRUG|placebo|once daily for 14 days orally
223427903|NCT00464516|DRUG|Estetrol|once daily for 14 days orally
223564461|NCT01579565|DRUG|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
224299355|NCT04605003|DEVICE|Novel rig-S|A new device created to hold the high level disinfectant and automatically indicate when sterilisation process has been completed
223427904|NCT06712966|OTHER|EngageRx_SMBP|Patients in the EngageRx\_SMBP arm will be automatically registered in the CareSimple system and mailed a device they can use at home. They may also choose to install a smartphone application from CareSimple that will provide reminders about measuring their BP. The clinician will then manage the patient's hypertension according to the standard of care. The SMBP measurements from CareSimple will be available through EngageRx for them to use, and they will receive a weekly staff message to check EngageRx if there are new SMBP measurements for them to review. The clinician will also be able to indicate when they would like to stop using the CareSimple system.
223564462|NCT01579565|DRUG|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
223564463|NCT02179736|DEVICE|Restylane|
223564464|NCT03040011|DRUG|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
223564465|NCT03040011|DRUG|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
223564466|NCT03040011|PROCEDURE|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
223740177|NCT07147764|BEHAVIORAL|Pain Neuroscience Education|"PNE sessions will be conducted in addition to physiotherapy programs for intervention groups. PNE sessions will occupy half of each session during the first two weeks. Physiotherapists trained in PNE will deliver sessions using a combination of metaphors, animated videos, and scientifically accurate descriptions. The same physiotherapist will lead both sessions with the same patient.~Active learning techniques will include:~Connecting new information with prior knowledge. Operationalizing key pain concepts into individual contexts. Facilitated problem-solving and critical reflection."
224038922|NCT03700749|DRUG|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
224038923|NCT03700749|DRUG|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
224038924|NCT03700749|DRUG|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
224038925|NCT03700749|DRUG|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
224139267|NCT00790179|PROCEDURE|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
224139268|NCT01949727|OTHER|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
224139269|NCT02331524|BEHAVIORAL|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
224299356|NCT04605003|DEVICE|Conventional Autoclave machine|The gold standard device to clean all medical instruments
224299357|NCT04300283|BEHAVIORAL|Hypnosis|See previous description
223740178|NCT07149038|DEVICE|Cerogrin|Participants in this arm will receive transcutaneous auricular vagus nerve stimulation using the Cerogrin device. This device non-invasively delivers electrical stimulation to the vagus nerve located on the outer ear, aiming to improve cognitive function.
223740179|NCT07149038|DEVICE|Sham Device|Participants in this arm will use a sham device. This device is identical in appearance to the active Cerogrin device but delivers no electrical stimulation or therapeutic effect. The sham device serves as a control to compare outcomes with the active treatment group.
223740180|NCT07150845|DRUG|EVO756|Dose 1
223740181|NCT07150845|DRUG|EVO756|Dose 2
223740182|NCT07150845|DRUG|EVO756|Dose 3
223740183|NCT07150845|DRUG|Placebo control|Placebo control
223740184|NCT07142811|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
223740185|NCT07142811|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
223740186|NCT07142811|DRUG|Bulevirtide|Bulevirtide administered by subcutaneous injection
223740187|NCT05611931|DRUG|Selinexor|Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
223740188|NCT05611931|DRUG|Matching Placebo for selinexor|Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
223740189|NCT07157696|DEVICE|High-Flow Nasal Cannula (HFNC) Oxygen Therapy|"Type: Device / Procedure~Description: Humidified high-flow nasal cannula oxygen therapy delivered via a home device. Provides warmed (37°C), humidified air and supplemental oxygen at ≥30 L/min, titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use the device for ≥8 hours per day, preferably overnight.~Special Features: Integrated remote monitoring system that automatically records flow, FiO₂, SpO₂, heart rate, and usage time, transmitting data to a secure cloud platform for clinical follow-up."
224038926|NCT04561752|DRUG|ZN-c5|ZN-c5 is the study drug.
224038927|NCT02742766|DRUG|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
223427905|NCT03404349|BEHAVIORAL|Mindfulness for Adolescence Course|There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.
223427906|NCT05372055|OTHER|Semi-structure interviews|Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
223427907|NCT00224458|DRUG|Truvada|
223427908|NCT00224458|DRUG|efavirenz|
223427909|NCT03136458|PROCEDURE|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
223427910|NCT03136458|DRUG|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
223427911|NCT00154232|DRUG|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
223427912|NCT05545384|DRUG|Immediate Azathioprine (1st attack)|"Patients randomized in Immediate Azathioprine group will benefit from immediate treatment with azathioprine. Treatment will be started at 2mg/kg or at 1mg/kg if the patient has a partial activity which would be increased slowly according the 6-TGN activity and clinical and biological tolerance at Week 2 for patient with partial activity or M1 for patient without TPMT activity deficit.~Only for patient with partial deficit and whose 6-TGN activity is low, azathioprine would be increased at 3mg/kg/d at Week 6 and without exceeding a total daily dose of 150 mg."
223427913|NCT05545384|DRUG|Immediate Rituximab (1st attack)|"Patients randomized in Immediate Rituximab group will benefit from immediate treatment with rituximab. Rituximab 375mg/m2 IV will be given at D1 and D15 and repeat every 6 months for 2 years.~Once the inclusion criteria are validated, the first injection will be performed according to the injection protocol (Annex 4). Fifteen day later, the second injection will be performed.~The next visit during a consultation with PI or his collaborators will be scheduled 1 week ± 2 days later, and patients will be advised to contact the PI if any neurologic symptoms or symptoms of adverse event occurs in the meantime."
223427914|NCT05545384|DRUG|Standard of care|Patients in this group will be treated according to standard care
223427915|NCT04210388|DRUG|AZD5718 tablet, Formulation A|Volunteers will receive single doses of AZD5718 tablet, Formulation A under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
223427916|NCT04210388|DRUG|AZD5718 tablet, Formulation B|Volunteers will receive single doses of AZD5718 tablet, Formulation B under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
223427917|NCT04210388|DRUG|AZD5718 tablet, Formulation C|Volunteers will receive single doses of AZD5718 tablet, Formulation C under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
223427918|NCT04210388|DRUG|AZD5718 tablet, Formulation D|Volunteers will receive single doses of AZD5718 tablet, Formulation D under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
223427919|NCT04210388|DRUG|AZD5718 film-coated tablet, Reference treatment|Volunteers will receive single doses of AZD5718 film-coated tablet, Reference treatment under fasted conditions. The dose will be administered with 240 mL (8 fluid ounces) of non-carbonated water after an overnight fast of at least 10 hours.
223427920|NCT02548351|DRUG|Obeticholic Acid|
223427921|NCT02548351|DRUG|Placebo|
223740190|NCT07157696|DEVICE|Oxygen therapy|"Type: Device / Procedure~Description: Standard long-term oxygen therapy delivered through conventional low-flow systems (e.g., nasal cannula or mask). Oxygen is titrated to maintain oxygen saturation (SpO₂) ≥92%. Patients are instructed to use oxygen for ≥8 hours per day, preferably overnight.~Special Features: No humidification, high-flow delivery, or remote monitoring capabilities."
223740191|NCT07160439|BEHAVIORAL|Digital Micro-Interventions|Digital Micro-Interventions are brief interventions that target specific behavioral and cognitive mechanisms of mental health, designed for brief periods of engagement.
223740192|NCT07156916|DRUG|Tamsulosin (0.4 mg/j)|Prolonged-release tablets 0.4 mg (Synthon Hispania SL, Spain)
223740193|NCT07156916|DRUG|Tamsulosin (0.4 mg/j)|Prolonged-release, film-coated tablets (Astellas Pharma B.V., the Netherlands)
223740194|NCT07168915|BIOLOGICAL|V118E|IM administration
223740195|NCT07168915|BIOLOGICAL|PREVNAR 20™|IM administration
224139270|NCT02331524|OTHER|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
224139271|NCT00282269|PROCEDURE|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
224299358|NCT01775969|OTHER|Text Message|A text message with instructions is sent to the patient
224299359|NCT01775969|OTHER|Voicemail|A voicemail with instructions is sent to the patient
224299360|NCT06205472|RADIATION|Adjuvant SIB radiotherapy|Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
223740196|NCT07168915|BIOLOGICAL|Saline|IM administration
223427922|NCT06808074|DRUG|Inhaled amikacin|Dosage of amikacin: 20 mg/kg based on ideal body weight, with a maximal dose of 2 g, once daily for 3 consecutive days.
223740197|NCT07173088|OTHER|Ankle Muscle Power (AMP) program|The AMP program targets various aspects of muscle power development through a program that takes the participant through 3 different stages of training over the course of their rehabilitation. This portion of the program is in addition to receiving standard rehabilitation exercises as well.
223427923|NCT06808074|DRUG|Placebo|The equivalent volume of saline solution (0.9% sodium chloride \[NaCl\]) will be administered once daily for three consecutive days
223427924|NCT06857825|BEHAVIORAL|Implementation of Infection Control Link Nurses (ICLNs)|"Infection Control Link Nurses (ICLNs) are clinical nurses, working in direct nursing care, with an interest and expertise on infection control practice. They work with constant and direct support by the IPC hospital team, and they are required to follow a training course with numerous scheduled meetings about IPC-related issues.~They will be selected via spontaneous application or identified by their Head Nurses. All ICLNs activities are to be completed during working hours, they still maintain their clinical nursing role, but in addition they implement and translate IPC-measures into clinical practice by observing, monitoring and analyzing data on compliance with hand hygiene, compliance with standard and isolation precautions, healthcare-associated infections and other IPC-related issues"
223427925|NCT06896630|DRUG|Tenofovir Disoproxil Fumarate (TDF)|ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B VIRUS INFECTION
223427926|NCT01247051|PROCEDURE|Precoating|preoperative filling of heart lung machine with patients blood
223427927|NCT01247051|PROCEDURE|Standard priming|preoperative filling of heart lung machine with colloids
223427928|NCT00125242|BEHAVIORAL|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
223427929|NCT00606554|DEVICE|Computer-assisted weaning program|Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
224038928|NCT02742766|DRUG|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
224038929|NCT02518022|DRUG|Insulin|Insulin for beer
224038930|NCT00691886|DRUG|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
224038931|NCT02628756|PROCEDURE|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
224038932|NCT04144504|DEVICE|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
224038933|NCT04144504|DEVICE|Plastic stenting|Use of plastic stents
224038934|NCT04427501|DRUG|LY3819253|Administered IV
224299361|NCT00629265|DEVICE|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
224299362|NCT03651466|DRUG|Gx-G6|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
223427930|NCT00606554|BEHAVIORAL|Standard of Care weaning|Evidence-based standard of care weaning process.
223427931|NCT01664949|DRUG|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
223427932|NCT01664949|DRUG|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
223427933|NCT04654754|DEVICE|high-flow high humidity oxygen device with tracheostomy adapter|This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
223427934|NCT02496351|DEVICE|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
223740198|NCT07173088|BEHAVIORAL|Standard of Care|Standard rehabilitation program
223740199|NCT07181694|DRUG|Adalimumab (BCD-057) 100 mg/mL|Single subcutaneous injection
223740200|NCT07181694|DRUG|Adalimumab (BCD-057) 50 mg/mL|Single subcutaneous injection
223740201|NCT07181694|DRUG|Adalimumab (Humira) 100 mg/mL|Single subcutaneous injection
224038935|NCT04427501|DRUG|LY3832479|Administered IV
223740202|NCT07176728|DRUG|BAY 3389934|Solution for intravenous infusion
224038936|NCT04427501|DRUG|LY3853113|Administered IV
224038937|NCT04427501|DRUG|Placebo|Administered IV
224038938|NCT01973946|OTHER|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
224038939|NCT00999713|DRUG|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
224038940|NCT00999713|OTHER|Air placebo|Endotracheal air administration
224038941|NCT00238667|DRUG|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
224038942|NCT00238667|DRUG|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
224038943|NCT02084641|OTHER|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
224038944|NCT03674125|BIOLOGICAL|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
224038945|NCT01567982|DEVICE|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
224299363|NCT03651466|DRUG|Placebo|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
224299364|NCT01917448|DRUG|Morphine|spinal morphine 0.15 mg
223427935|NCT00618943|BEHAVIORAL|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
223427936|NCT04104217|BEHAVIORAL|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
223427937|NCT04104217|BEHAVIORAL|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
223427938|NCT00991757|DRUG|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
223427939|NCT00003407|DRUG|amifostine trihydrate|
223427940|NCT00003407|DRUG|cytarabine|
223427941|NCT00003407|DRUG|mitoxantrone hydrochloride|
223427942|NCT05220462|DRUG|Remimazolam|As per Remimazolam arm
223427943|NCT05220462|DRUG|Midazolam|As per Midazolam arm
223427944|NCT05577169|BEHAVIORAL|Mind-body skills|The purpose of mind-body medicine is to use conscious thoughts and actions to positively impact autonomic responses from the brain as well as coping mechanisms for life's stresses. Examples of mind-body skills include deep breathing exercises, meditation, drawing, guided imagery, journaling, affirmations, and biofeedback.
223427945|NCT05577169|BEHAVIORAL|Diabetes education|When children and adolescents are diagnosed with diabetes, education is typically focused on the parents; as our older adolescents prepare to transition to adult care with full responsibility of their health, the goal of short education sessions is to review the basics of T1D along with addressing each individual's needs and questions as they make this transition.
223427946|NCT02683278|BEHAVIORAL|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
223427947|NCT02683278|BEHAVIORAL|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
223427948|NCT02683278|OTHER|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
223427949|NCT04831827|OTHER|IVR Reminder|Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
223427950|NCT04831827|OTHER|Phone call from research team|Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
223427951|NCT04831827|OTHER|EHR Portal message|Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
223427952|NCT02414360|OTHER|Shortened Format|Shortened format of a systematic review
223427953|NCT02414360|OTHER|Full Length|Full length systematic review
224038946|NCT00893646|BEHAVIORAL|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
223427954|NCT03003494|DRUG|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
223427955|NCT04687943|COMBINATION_PRODUCT|PELOID therapy, kinesio tape, exercise|126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
223427956|NCT03804229|DRUG|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
223427957|NCT03804229|DRUG|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
223740203|NCT07176728|DRUG|Matching Placebo / Diluent|Solution for intravenous infusion
223744788|NCT05861856|OTHER|Virtual reality|Virtual reality supported core stabilization exercises will be performed.
223427958|NCT06260423|PROCEDURE|Experienced dentist using lateral compaction with bioceramic sealer.|Root canal treatment using bioceramic sealers.
223427959|NCT06260423|PROCEDURE|Unexperienced dentist using lateral compaction with bioceramic sealer.|Root canal treatment using bioceramic sealers.
223427960|NCT06260423|PROCEDURE|Experienced dentist using Single cone with bioceramic sealer.|Root canal treatment using bioceramic sealers.
223427961|NCT06260423|PROCEDURE|Unexperienced dentist using Single cone with bioceramic sealer.|Root canal treatment using bioceramic sealers.
223427962|NCT04542421|DIAGNOSTIC_TEST|Lung ultrasound use in patients hospitalized with COVID|Hospitalists will be taught to use lung ultrasound in the management of their patients with COVID
223427963|NCT01911481|OTHER|hydration|
223427964|NCT06682884|DRUG|Lorlatinib 100 mg|Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
223427965|NCT03107364|OTHER|Hospital stay|Collection of hospital lengths of stay and readmissions
223427966|NCT01131143|BEHAVIORAL|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
224038947|NCT01482663|BEHAVIORAL|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
224038948|NCT00124371|BEHAVIORAL|a nurse led home-based education and support programme|
224038949|NCT05285488|OTHER|"focused attention group"|"focused attention group: adult subjects practicing focused attention meditation.~contemplation group: adult subjects practicing contemplation meditation."
223427967|NCT01131143|BEHAVIORAL|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
224038950|NCT01677351|DRUG|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
224038951|NCT01677351|DRUG|placebo|
224038952|NCT05093725|DEVICE|flow cytomery|take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth
224038953|NCT00639223|DIETARY_SUPPLEMENT|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
223427968|NCT00099684|DRUG|Ezetimibe|
223427969|NCT04898764|DRUG|Mometasone Furoate|Mometasone furoate nasal spray suspension, 50µg/actuation
223427970|NCT05231733|BIOLOGICAL|SPX-101|Subjects will receive SPX-101 on Day 1 of the first cycle, and will be evaluated for DLTs in the following 3 weeks. After the first cycle, subjects will continue treatment at dosing intervals as determined by safety and PK results. All patients will continue treatment until disease progression, development of unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion (maximum duration: 2 years).
223427971|NCT04991077|BIOLOGICAL|analyse of angiogenic, vasoactive and VEGF systems|the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.
223740204|NCT07179601|PROCEDURE|Hemorrhoidal artery embolization|Hemorrhoidal artery embolization (HAE) involves the deliberate blockage of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve symptoms related to internal hemorrhoids, especially bleeding.
224038954|NCT00639223|DRUG|Pravastatin|One 20mg capsule twice daily for 12 weeks
224038955|NCT00639223|BEHAVIORAL|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
224038956|NCT05612763|DEVICE|Self fitting hearing device|comparison of outcomes when device is fit by clinician or self fit
224038957|NCT04936841|DRUG|NKTR-214|Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)
224299365|NCT01917448|OTHER|control|Patient receive only local infiltration without spinal analgesia
224299366|NCT01913925|OTHER|Tyrosine-Containing Food Bar|
224299367|NCT01913925|OTHER|Placebo Bar|
224038958|NCT04936841|DRUG|anti-PD-1 therapy|immunotherapy drug, monoclonal antibody
223427972|NCT05969977|DRUG|PPI-1011|PPI-1011 is a liquid oil with light yellow to amber color, clear to slightly opalescent and flows readily at room temperature. It is insoluble in water and miscible with dichloromethane and liquid coconut oil. It is a synthetic glycerolipid derivative, comprised of an assembly of naturally-occurring products including glycerol backbone, an ether-linked hexadecyl group at sn1 position, an all-cis-4, 7, 10, 13, 16, 19-docosahexaenoyl group at sn2 position, and a lipoyl group at sn3 position. It was designed as a plasmalogen precursor and is similar in structure to naturally occurring alkyl-diacyl lipids with the primary difference being the presence of a lipoic acid moiety at the sn3 position. PPI-1011 is formulated in liquid coconut oil containing 0.1% 1-thioglycerol as an antioxidant.
223427973|NCT05969977|DRUG|Placebo|Placebo
223427974|NCT03668847|DRUG|DM-CHOC-PEN|DM-CHOC-PEN administration by IV infusion
223427975|NCT05238025|BIOLOGICAL|MVA-BN-RSV vaccine|One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
223427976|NCT05238025|BIOLOGICAL|Tris Buffered Saline (TBS)|One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
224038959|NCT04936841|RADIATION|Palliative Radiation|radiation to relieve symptoms
224038960|NCT03926156|DRUG|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food
224070395|NCT05290025|DRUG|Nicotine lozenge|Nicotine lozenges will be available in 1 and 2 mg strengths. Patients may individually choose which strength to use. Maximum 12 lozenges per day
224070396|NCT05290025|BEHAVIORAL|Smoking cessation counselling|Once a week patients are asked about progress in cessation attempt. Sigaretts smoked the last week are recorded. Goal is set for the next week. Information on typical nicotine withdrawal symptoms and ameliorating techniques.
224070397|NCT05290025|OTHER|Screening for use of tobacco products|At the initiation of the trial screening questions about cigarett use for the last day and week.
224070398|NCT05290025|OTHER|Screening for interest in smoking cessation|At the initiation of the trial all smoking participants are asked if the are interested in changing their smoking habits. They are given three alternatives: will make cessation attempt; will make reduction attempt; not certain.
224070399|NCT01026831|DRUG|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
224299368|NCT00999648|OTHER|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
224299369|NCT00999648|OTHER|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
224299370|NCT00996138|BIOLOGICAL|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
224299371|NCT04465630|DEVICE|OMNI® Surgical System|Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
224299372|NCT04276844|DIAGNOSTIC_TEST|Ultrasonography using the two-dimensional (2D) mode|Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.
224299373|NCT04276844|DIAGNOSTIC_TEST|Respiratory Functional Explorations|Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
224299374|NCT06332729|DEVICE|universal exercis unit|Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
224299375|NCT06332729|DEVICE|functional electrical stimulation|Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
224299376|NCT02363608|OTHER|standard post surgery care|
224299377|NCT02363608|BEHAVIORAL|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
224299378|NCT02363608|BEHAVIORAL|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
224299379|NCT05476107|DRUG|AMT-126|Single or daily dosing at doses A, B, C, D, E, F; G, H, and I
224299380|NCT05476107|DRUG|Placebo|Single or daily dosing at doses A, B, C, D, E, F; G,H, and I
224299381|NCT05476107|OTHER|Radioactive Tablet (Part 2 Only)|Single dose in two periods in Part 2 (optional)
224299382|NCT04972123|DRUG|CPC - Capsaicin, Phenylephrine, Caffeine|CPC is a combination of Capsaicin, Phenylephrine and Caffeine
224299383|NCT04972123|DIAGNOSTIC_TEST|Tilt Table Test|Participant will undergo tilt tablet testing using the Italian protocol (see reference section). The Italian protocol includes 20 minutes of passive tilt at 70 degrees (Passive Phase) followed by nitroglycerin (NTG) administration and tilt testing for another 15 minutes (NTG Phase).
224299384|NCT04972123|DRUG|Placebo|Placebo for CPC
223427977|NCT03040804|RADIATION|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
224299385|NCT02032706|DEVICE|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
224070400|NCT01026831|DRUG|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
224299386|NCT03903809|DRUG|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
224299387|NCT03903809|DRUG|ESPO|Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
224299388|NCT00895947|DRUG|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
224299389|NCT00895947|OTHER|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
224299390|NCT00192244|BIOLOGICAL|CAIV-T, Liquid|
224299391|NCT01531829|DRUG|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
224299392|NCT01531829|DRUG|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
224299393|NCT02001220|PROCEDURE|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
223427978|NCT04546139|OTHER|footwork|six-point footwork
223427979|NCT01559350|PROCEDURE|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
223427980|NCT01559350|PROCEDURE|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
223427981|NCT02280746|OTHER|Gluten challenge|Intervention will be continued for at least 6 months
223427982|NCT01902810|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization
223427983|NCT01902810|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization
223427984|NCT04331977|DEVICE|Maxillary Expansion|2 appliances to expand the maxillary arch
223427985|NCT01265576|DRUG|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
223427986|NCT01265576|DRUG|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)\[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID\]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
223427987|NCT01265576|DRUG|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
223427988|NCT01263782|DRUG|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
223427989|NCT01263782|DRUG|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
223427990|NCT01263782|DRUG|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
223427991|NCT01263782|DRUG|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
223427992|NCT03628131|DRUG|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
223427993|NCT03628131|DRUG|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
223427994|NCT03628131|DRUG|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
223427995|NCT03628131|DRUG|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
223427996|NCT01730027|DRUG|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
223427997|NCT01730027|DRUG|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
223427998|NCT01730027|DRUG|montelukast|montelukast for 12 weeks
223427999|NCT01154348|DRUG|S-707106|Tablet, taken once daily with morning meal
223564467|NCT03040011|PROCEDURE|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
223564468|NCT03040011|DRUG|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
223564469|NCT02867813|BIOLOGICAL|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
224304940|NCT05122377|DRUG|1M GnRHa|This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
223744789|NCT03064191|COMBINATION_PRODUCT|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
223744790|NCT03064191|OTHER|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
223428000|NCT01154348|DRUG|Placebo|Placebo tablet, taken once daily with morning meal
223428001|NCT01154348|DRUG|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
223744791|NCT02414334|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|
223744792|NCT03141242|BEHAVIORAL|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
223744793|NCT03141242|BEHAVIORAL|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
223744794|NCT00002091|DRUG|Pentoxifylline|
223428002|NCT01154348|DRUG|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
223428003|NCT02339480|OTHER|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
223428004|NCT04545567|DEVICE|RocketAP|Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal
223428005|NCT04545567|DEVICE|USS Virginia|Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion
223428006|NCT02776891|DRUG|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
223428007|NCT02038855|BEHAVIORAL|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
223428008|NCT00141245|DRUG|Pregabalin|
223428009|NCT00003762|DRUG|docetaxel|
223428010|NCT00003762|DRUG|gemcitabine hydrochloride|
223428011|NCT02754674|PROCEDURE|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
223428012|NCT03651427|DRUG|Estradiol|Induced hypogonadism and re-institution of CSHT
223428013|NCT00738790|RADIATION|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
223428014|NCT00738790|RADIATION|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
223428015|NCT03814720|BIOLOGICAL|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/1999 (H1N1) genetically fused to the ferritin protein from H. pylori. Purified H1ssF\_3928 particles display eight well-formed HA trimers that antigenically resemble the native H1 stem viral spikes.
223428016|NCT01257763|DEVICE|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
223428017|NCT01257763|DEVICE|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
223428018|NCT05721872|COMBINATION_PRODUCT|D-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)|"After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I.~Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day).~Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients."
223428019|NCT05721872|DRUG|FOLFOX/FOLFIRI regimen|"FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days~FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks"
223428020|NCT01107808|DRUG|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
223428021|NCT01107808|DRUG|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
223428022|NCT03418584|DEVICE|HybridAPC|HybridAPC is a device which combines submucosal fluid injection with APC
223428023|NCT03891043|DIETARY_SUPPLEMENT|Selenium|A 100 micrograms of Selenium was given to be taken twice a day.
223428024|NCT03891043|OTHER|Placebo|Placebo pill of 100 micrograms of starch was given to be taken twice a day.
223428025|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
223428026|NCT02135107|DRUG|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
223428027|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
224038961|NCT03926156|DRUG|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
224038962|NCT03963752|DRUG|Ziyinxiehuo Granules Herbs|1 pack of Ziyinxiehuo granules Herbs is administered after dissolved, 2 times per day after a meal.
224038963|NCT03963752|DRUG|Megestrol Acetate Tablet|the dose is 6-8mg/d, three times per day after meals.
223428028|NCT02135107|DRUG|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
223428029|NCT01193465|DEVICE|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
223428030|NCT01193465|DEVICE|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
223428031|NCT01193465|DEVICE|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
224038964|NCT03963752|DRUG|Leuprorelin Acetate 3.75mg Injection|Usage： 80μg/kg by subcutaneous injection, every 4 weeks
223428032|NCT01193465|DEVICE|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
223564470|NCT03263728|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
223564471|NCT01018472|DIETARY_SUPPLEMENT|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
224038965|NCT02873273|DRUG|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
223428033|NCT01846429|DRUG|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
223428034|NCT00489229|DRUG|Rosiglitazone|
223428035|NCT00489229|DRUG|Ramipril|
223428036|NCT06422104|DEVICE|Repetitive transcranial magnetic stimulation|10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session
223428037|NCT02401516|DEVICE|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
223428038|NCT02062073|DRUG|Abametapir Lotion 0.74% w/w|
223428039|NCT02062073|OTHER|0.1% sodium lauryl sulfate|
223428040|NCT02062073|OTHER|saline 0.9%|
223428041|NCT02062073|OTHER|Vehicle Lotion|
223428042|NCT01959763|BEHAVIORAL|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
223428043|NCT03197324|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
223428044|NCT03197324|DRUG|Digoxin|2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
223428045|NCT03308435|DIAGNOSTIC_TEST|Geriatric assessment|the assessment includes functional tests (hand grip strength, SPPB (Short Physical Performance Battery)) and questionaires Euro-QoL 5D, LUTS, GDS, ADL, iADL, dietary recall).
223428046|NCT03308435|DIAGNOSTIC_TEST|Psychiatric assessment|Psychiatric assessments includes HAMD-17 as well as Beck depression inventory, hospital anxiety and depression scale, SF36, PTSS-10
223428047|NCT03308435|DIAGNOSTIC_TEST|Inflammatory assessment|analysis will include arginase, ADMA, SDMA, homoarginine, aminoacids + metabolites, tryptophan, kynurenine, kynurenine acid, cortisol, ACTH, Metanephrine, myeloperoxidase,
223428048|NCT03308435|DIAGNOSTIC_TEST|Cardiological assessment|ECG, echocardiography
223428049|NCT02957435|DRUG|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
223428050|NCT01630863|PROCEDURE|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
223428051|NCT05641285|DEVICE|The OtoSight Middle Ear Scope|The OtoSight Middle Ear Scope is intended for use as an imaging tool for real-time visualization of the human tympanic membrane and fluid or air within the middle ear space. In the presence of middle ear fluid, the OtoSight Middle Ear Scope is used to visualize the fluid density. The OtoSight Middle Ear Scope is also used to provide surface images of the ear canal and tympanic membrane. It is indicated for use in children and adults.
223744795|NCT01673451|DRUG|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
223428052|NCT04025931|DRUG|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
223428053|NCT01510600|GENETIC|DNA analysis|
223428054|NCT01510600|GENETIC|polymerase chain reaction|
223428055|NCT01510600|OTHER|laboratory biomarker analysis|
223428056|NCT01510600|OTHER|medical chart review|
223428057|NCT00927511|DRUG|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
223428058|NCT06620393|DRUG|Dexmedetomidine|DEX 4 mcg/100 ml at a starting dose of 0.6 mcg/kg/hour and increased by 0.2 mcg/kg/hour every 30 minutes up to final dose of 1.4 mcg/kg/hour.
223428059|NCT06620393|DRUG|Placebo|NaCl 0.9% 100ml
223478233|NCT06682416|PROCEDURE|In the context of epidural analgesia, the temperature of the local anesthetic solution is elevated to 37°C utilizing a blood transfusion and infusion warmer.|"For the observation group, after reactivating the analgesic pump's exhaust procedure to clear the air from the tubing, the output tubing of the analgesic pump is first connected to the epidural catheter. Following this, a blood transfusion and infusion warmer (manufactured by Barkey GmbH \& Co. KG., Germany, model S-line, with the national medical device registration number 20182450063) is used to preheat the output tubing of the analgesic pump until it reaches the predetermined temperature of 37°C.~For the control group, after reactivating the analgesic pump's exhaust procedure to remove air from the tubing, the output tubing of the analgesic pump is connected to the epidural catheter without preheating the output tubing using a blood transfusion and infusion warmer, maintaining room temperature (23°C)."
224070401|NCT03916211|BIOLOGICAL|MSCs treatment|intramuscular injection of adipose stem cells treat diabetic foot
224070402|NCT01180660|DRUG|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
224070403|NCT01180660|DRUG|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
224070404|NCT02790151|BEHAVIORAL|Standard Therapy|Learning and practicing Memory strategies
223428060|NCT06354361|BEHAVIORAL|Trauma-Informed Goal Management Training (TI-GMT)|"Trauma Informed-Goal Management Training (TI-GMT) is a modified version of Goal Management Training (GMT), a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours. TI-GMT enhances the standard GMT protocol with the addition of several trauma-informed adaptations and content that is sensitive and specific to public safety personnel with PTSD.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
223428061|NCT06354361|BEHAVIORAL|Goal Management Training (GMT)|"Goal Management Training (GMT) is a cognitive remediation program that emphasises mindfulness and practice in planning and completing goal-oriented behaviours.~Participants are trained to interrupt ongoing disruptive behaviours through the resumption of executive control to help define goal hierarchies and monitor goal achievement. Mindfulness meditation helps develop attentional control and the skill of bringing one's mind to the present. Real-life examples are incorporated to illustrate goal attainment failures and successes, and participants practice solving complex, real-life tasks in sessions.~Sessions include instructional material, interactive tasks, discussion of real-life deficits, and homework/practice activities."
223428062|NCT02232828|PROCEDURE|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
223428063|NCT02232828|PROCEDURE|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
223428064|NCT00877071|DRUG|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
223428065|NCT01984892|DRUG|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
223428066|NCT06621940|OTHER|High Protein Diet|Individuals will be placed on a high protein diet for 10 days.
223428067|NCT06621940|OTHER|Normal Protein Diet|Individuals will be placed on a normal protein diet for 10 days.
223428068|NCT05120531|OTHER|Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia|Use of an Ambulatory Monitoring System from Vuije University (VU-AMS) to record autonomic and cardiovascular activity of patients undergoing otolaryngologic surgery with anesthesia. This monitoring device will provide data of ANS activity and normoxic bradycardia among patients with Down Syndrome. This data will be compared to data from patients without Down Syndrome.
223428069|NCT05407974|PROCEDURE|pleurectomy|"All patients will undergo resection of apical blebs with simultaneous pleurectomy or pleural abrasion.~Chest tube will be inserted in the pleural cavity and maybe connected on low-grade suction for first 24 h according to type of pneumothorax \& surgeons' preference, after which the suction is disconnected.~Post Operatively both groups will be compared regarding the postoperative drainage amount, persistence of air leak (chest tube removal time), length of hospital stay, mortality and risk of recurrence.~Follow up Chest x-ray will be done immediate postoperatively, then each patient will be followed up after 6 months."
223428070|NCT04158882|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
223428071|NCT03886779|DRUG|Bromfenac|0.7 MG/ML \[Prolensa\]
223428072|NCT03886779|DRUG|Nepafenac|3 MG/ML \[Ilevro\]
223428073|NCT04973631|GENETIC|Sex, Age|Evaluate the effect of sex and age on the incidence and survival of GC.
223428074|NCT03568682|BEHAVIORAL|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
223428075|NCT04827082|OTHER|Diacutaneous fibrolysis|Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
223428076|NCT02156895|DRUG|Axitinib|based on Axitinib approval
224304941|NCT00388076|DRUG|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
224304942|NCT00388076|DRUG|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
224304943|NCT00388076|DRUG|paclitaxel|in combination with pazopanib
223428077|NCT05994521|PROCEDURE|ERCP alone|"ERCP with biliary stenting will be performed alone. ERCP is part of standard of care for biliary drainage. An endoscope is advanced to the small intestines and a metal stent is inserted through the tumor instead of bypassing the tumor to effectively drain the biliary system under x-ray guidance.~Management of MGOO will be on a wait-and-see approach, using endoscopic interventions performed only if obstruction is clinically diagnosed"
223428078|NCT05994521|PROCEDURE|ERCP +ProEUS-GE|ERCP is performed as described above. following the ERCP, the scoped is switched for an echoendoscope which is advanced to the stomach. A stent is then placed between the stomach and the small intestines, creating a connection (ProEUS-GE).
223428079|NCT05723328|BEHAVIORAL|Group Music Therapy Advocacy Recording Intervention (MTAR)|Music Therapy Advocacy Recording Intervention (MTAR) is a sequence of group music therapy song-writing and recording sessions framed as a mental health awareness project to be shared with the general public.
223428080|NCT03805373|OTHER|Diet Assessment Survey|Participants will complete 2 different diet assessment tools separated by at least 1 week.
223428081|NCT03476174|DRUG|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
223428082|NCT03476174|DRUG|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
223428083|NCT06272136|DEVICE|Clinical Demo 2.0|During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)
223428084|NCT01056991|OTHER|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
223428085|NCT01056991|OTHER|warming blanket|
223428086|NCT03410082|DEVICE|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
223428087|NCT03410082|DIAGNOSTIC_TEST|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
223428088|NCT03055494|BIOLOGICAL|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
223428089|NCT03055494|BIOLOGICAL|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
223428090|NCT06346847|DIETARY_SUPPLEMENT|Postbiotic|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
223428091|NCT06346847|DIETARY_SUPPLEMENT|Placebo|1 capsule a day, 15 minutes before breakfast with a glass of water for 12 weeks
224139272|NCT05743751|DEVICE|Normothermic machine perfusion|XVIVO (perfusion company, Gothenburg, Sweden), functions to be included in perfusion equipment, cardiopulmonary bypass machine and neonatal cardiopulmonary bypass machine, including polyethylene pipeline, heating equipment (perfusion temperature 37 ℃), venous pool (venous pressure is 0 mmHg, adjust the height of perfusion pool), centrifugal pump (arterial pressure is set at initial 75 mmHg, maintain 65 mmHg). The perfusion solution contains 215ml of dextran/albumin solution and 400ml of hematocrit, 2ml of 10% calcium gluconate, 1300u/L heparin and 400mg of cefazolin sodium. The oxygen/carbon dioxide ratio is (95%/5%, 2L/min) for continuous perfusion, and pO2 is maintained at 650mmHg during perfusion. During perfusion, continue to use verapamil, amino acid, glucose and insulin. Lactic acid Ringer solution (10ml/h) was used to supplement the lost circulation volume due to urine production during perfusion.
224304944|NCT00388076|DRUG|carboplatin|in combination with pazopanib
223428092|NCT04190368|OTHER|Team Clinic Care|"Participants attend quarterly visits (1 visit every 3months). Appointments scheduled for Telehealth (TH) (1 in-person visits) as decided by provider/patient.~Selected providers will be trained in the Team Clinic Care protocol for completing medical appointments. Team Clinic Care key components:~(1) Shared decision making: Providers, AYA, parent/caregiver will mutually agree on priorities for each medical visit using a shared decision making tool (2) Autonomy supportive care: Providers will be trained in skills building, patient centered key elements, intervention bites, reviewing plans, designed to support AYA autonomy and intrinsic motivation. AYA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach AYA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate. (4) Fidelity Review and process for self-assessment"
223428093|NCT04190368|OTHER|Standard Care|Participants attend quarterly visits (1 visit every 3 months) and see their diabetes care provider. They do not participate in Team Clinic group visits but if they need diabetes education or supportive services they will be referred for necessary care per usual methods.
223478234|NCT07017946|DRUG|MTP-101C|MTP-101C is a freeze-dried encapsulated formulation of fecal microbiota purified from the stool of healthy donors.
223478235|NCT02298972|BEHAVIORAL|Nurse support and selfmanagement intervention|
223478236|NCT05678361|BEHAVIORAL|Sleep/Nap|Participants sleep after a maximum of three sessions of exposure therapy.
223478237|NCT01884597|DRUG|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
223478238|NCT01884597|DRUG|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
223478239|NCT01585883|BEHAVIORAL|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
223478240|NCT00860275|DRUG|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
223428094|NCT06847906|OTHER|Iteratively designed (new) clinical decision support tool for virtual visits|The new, iteratively designed clinical decision support tool includes the traditional CDS along with links to supportive tipsheets, which include one for providers on how to add an order for patients to upload vitals in their electronic health record, and one that walks patients through how to upload vitals on their own.
223428095|NCT06847906|OTHER|Traditional clinical decision support tool|The traditional CDS tool is the usual care intervention, and does not include links to tipsheets to support virtual patient care.
223428096|NCT05940402|DRUG|Emraclidine|Oral tablets
223428097|NCT04016896|BEHAVIORAL|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
223428098|NCT04016896|OTHER|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
223428099|NCT03848663|BEHAVIORAL|Traditional Remapping|Shifting text outside of scotoma
223428100|NCT03848663|BEHAVIORAL|Personalized Remapping|Shifting text based on individual letter-based perimetry
223428101|NCT04488419|DRUG|ATH-1017|Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
223428102|NCT04488419|DRUG|Placebo|Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
223428103|NCT06320457|OTHER|Brief case management intervention|"The brief case management intervention aims to support patients during the difficult phase of involuntary hospitalisation and reduce the impact of this short-term event on their long-term recovery process. The intervention starts during the hospital stay, at the latest one week after admission, and lasts for a maximum of one month after discharge. The intervention consists of five sessions, the order of which may vary according to the specific needs of the patient:~1. Personal account of involuntary hospitalisation and its consequences~2. Presentation of the personal recovery model and the tools to promote it and prevent coercion~3. Introduction to the personal recovery plan~4. Network meeting and discussion on dignity of risk~5. Personal recovery plan"
223428104|NCT03976336|DIETARY_SUPPLEMENT|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
223428105|NCT03976336|OTHER|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
223428106|NCT01320345|DRUG|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
223428107|NCT01320345|DRUG|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
223428108|NCT06649396|DIAGNOSTIC_TEST|Dried Blood Spot|Comparing analysis results between dried blood spot and plasma
223428109|NCT06649396|DIAGNOSTIC_TEST|Analysis on plasma|Analysis on plasma
223428110|NCT04166591|BEHAVIORAL|Overheard Speech|New words are introduced with the child as an observer rather directly taught.
223428111|NCT04166591|BEHAVIORAL|Addressed Speech|New words are introduced directly to the child by an experimenter.
223428112|NCT05969548|DEVICE|active 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223428113|NCT05969548|DEVICE|active 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223428114|NCT05969548|DEVICE|active 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223740205|NCT07176793|OTHER|Implementation mapping to develop a multilevel health system strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes|Conduct implementation mapping to develop a multilevel health system breastfeeding support strategy for patients with GDM at UC Davis Health in Sacramento, California, a large academic medical center. The study design for this mapping process will include five steps in this 1-year proposal: (1) conduct a needs and assets assessment and identify implementers; (2) identify implementation outcomes and determinants; (3) choose mechanisms of change and design implementation strategies; (4) produce implementation protocols and materials; and prepare for the final step, (5) evaluate implementation outcomes, by selecting outcome measures for a future trial . This disciplined and systematic approach to intervention development will directly inform my future directions: a mixed methods feasibility trial to pilot the implementation strategy developed here, followed by a full-scale randomized trial to test the strategy's effectiveness in reducing diabetes risk.
223740206|NCT07178912|DRUG|Blinatumomab|Given by Iv
223740207|NCT07178912|DRUG|olverembatinib|Given by PO
223428115|NCT05969548|DEVICE|sham 1200-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223428116|NCT05969548|DEVICE|sham 2400-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1200-pulse cTBS stimulations per day, parted by a 30-minute rest period (a total of 2400 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223428117|NCT05969548|DEVICE|sham 3600-pulse continuous Theta Burst Stimulation|Each patient will receive two sham 1800-pulse cTBS stimulations per day, parted by a 50-minute rest period (a total of 3600 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223428118|NCT03337360|DIETARY_SUPPLEMENT|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
223428119|NCT03337360|OTHER|Placebo|Inactive ingredients, placebo
223428120|NCT02616965|DRUG|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
223428121|NCT02616965|DRUG|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
223428122|NCT04233346|DRUG|Ponatinib 30mg OD|Ponatinib 30mg OD
223428123|NCT04233346|DRUG|Ponatinib 45mg OD|Ponatinib 45mg OD
223740208|NCT03270839|DRUG|Bonine 25Mg Chewable Tablet|Motion sickness drug
223740209|NCT03270839|DRUG|Kwells|Motion sickness drug
223740210|NCT03270839|DRUG|Placebo Oral Tablet|No active substance in the tablet
223428124|NCT05234593|DIETARY_SUPPLEMENT|EmpowerPlus Lightning Sticks|multinutrient supplement containing vitamins, minerals, amino acids and antioxidants taken one Stick daily by dissolving the powder on or under the tongue
223428125|NCT06621355|OTHER|Physical fitness test: Progressive intervalic test|"An incremental interval test of 4\&#39; of work for 1\&#39; of rest will be performed at an individual intensity below the aerobic threshold. At the end of the rest minute, the load shall be increased slightly. In order to be as adjusted and individualised as possible, the subjective physical condition level stated by the patient during the sociodemographic data collection shall be taken as a reference for the establishment of the initial load, being a value of power (W) in cycle ergometer and speed (km/h) in treadmill. Never less than 50W or 6 km/h, respectively.~The minimum incremental values will be 25W or 0.5km/h until you are unable to complete a full interval. An incomplete interval shall also be recorded and analysed.~During the one minute rest period, as will have been well emphasised during the explanation of the test, no part of the body may be moved at all, so at the end of the 4 minutes of work, the evaluator will count down for the patient to get ready and remain stil"
223428126|NCT05234125|BEHAVIORAL|Better|It is a nonpharmacologic sleep intervention to improve maternal glucose metabolism in African American Pregnant Women (AAPW). Sleep BETTER is composed of sleep hygiene practices and cognitive-behavioral principles.
223428127|NCT05234125|BEHAVIORAL|Birth Prep|The intervention involves training about pregnancy-related issues, and follow up
223428128|NCT06422312|DEVICE|Cystoscopy with RedPine flexible disposable cystoscope|Use of a disposable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents.
223428129|NCT06422312|DEVICE|Cystoscopy with standard of care flexible reusable scope|Use of a reusable flexible cystoscope to visualize the urethra and bladder, take biopsies, and remove stents
223428130|NCT05935891|DRUG|CBD-dominant|product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
223428131|NCT05935891|DRUG|THC dominant|contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.
223428132|NCT04797949|DRUG|Low-dose aspirin|Women will be prescribed 81 mg of aspirin to take daily during pregnancy.
223428133|NCT06145698|DEVICE|Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device|Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.
223428134|NCT02441270|DRUG|Cyclophosphamide|
223428135|NCT02441270|RADIATION|Stereotactic body radiotherapy|
223428136|NCT05224960|BIOLOGICAL|UC-MSCs|3 doses of UC-MSCs intravenously at day 1, day 8, day 15.
224139273|NCT05743751|DEVICE|Hypothermic machine perfusion|LifePort Kidney Transporter is designed to integrate with the clinical environment by using readily available supplies, requiring minimal user intervention, and by being easy to use. LifePort Kidney Transporter is a portable, isolated kidney perfusion and transport system, designed to support a donated kidney and to maintain the organ in a near-normal physiologic state under hypothermic aseptic conditions. An insulated plastic housing encloses the kidney and perfusate within a LifePort Kidney Transporter Disposable Perfusion Circuit. LifePort Kidney Transporter components include an Ice Container, Pump Deck, Control Panel, Outer Display, Bubble Detectors, External Connections Panel, sensors, and four lithium-ion batteries. Two handles make the unit easy to lift and carry
223428137|NCT05224960|BIOLOGICAL|Placebo(solution without UC-MSCs)|3 doses of placebo intravenously at day 1, day 8, day 15.
223428138|NCT02889198|BEHAVIORAL|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
223428139|NCT02111746|DRUG|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
223428140|NCT02111746|DRUG|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
223428141|NCT02111746|DRUG|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
224038966|NCT01236651|DRUG|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
224038967|NCT01236651|DRUG|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
224038968|NCT03230656|OTHER|Early cognitive-communication therapy|
224038969|NCT01444209|RADIATION|Iodine Implants|Interstitial Radioactive Iodine Implants
224038970|NCT04640389|OTHER|Cross-sectional study/no intervention|Cross-sectional study/no intervention.
224038971|NCT02016833|PROCEDURE|Blood Sampling|Sampling of 80mL of whole blood
223428142|NCT01618851|RADIATION|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
223428143|NCT03164473|DRUG|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
223428144|NCT03164473|DRUG|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
223428145|NCT03164473|DRUG|Placebo-rituximab|4 infusions for 18 months
223428146|NCT03164473|DRUG|Placebo-azathioprine|oral tablets for 24 months
223428147|NCT00331513|DRUG|vorinostat|Given orally
223428148|NCT00331513|DRUG|idarubicin|Given IV
223428149|NCT00331513|OTHER|laboratory biomarker analysis|Correlative studies
223428150|NCT00331513|OTHER|pharmacological study|Correlative studies
223428151|NCT04390672|DEVICE|SUPRAFLEX Cruz|Percutaneous Coronary Intervention for multivessel disease
223428152|NCT04390672|DEVICE|SYNERGY|Percutaneous Coronary Intervention for multivessel disease
223428153|NCT04161079|DEVICE|Medtentia Annuloplasty Ring (MAR)|Mitral valve repair using the MAR performed in clinical investigation 2010-040
223428154|NCT00046917|DRUG|alvocidib|Given IV
223428155|NCT00046917|DRUG|irinotecan hydrochloride|Given IV
223428156|NCT00046917|DRUG|cisplatin|Given IV
224070405|NCT02790151|BEHAVIORAL|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
223428157|NCT02535234|DEVICE|Novel System|A Novel full Continuous Positive Airway Pressure (CPAP) system - Prototype Device, Mask + Accessories
223428158|NCT02535234|DEVICE|Traditional System|A Traditional full Continuous Positive Airway Pressure (CPAP) system- Released Device + Accessories, Prototype Mask
223428159|NCT06179732|COMBINATION_PRODUCT|Mesh - spatial repellent impregnated with transfluthrin (2500mg)|"Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only."
223428160|NCT06179732|BEHAVIORAL|Information and Education Campaigns (IEC)|IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
223428161|NCT06179732|DIAGNOSTIC_TEST|test and treat malaria cases|All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
223428162|NCT05872100|BEHAVIORAL|MINDFULNESS BASED APPLICATION|"* The effectiveness of mindfulness practices in the field of health~* Breathing exercise~* Discussing and sharing about exercise~* Introduction of informal and formal mindfulness practices~* Communication exercise with conscious awareness~* Sounds and thoughts meditation~* The concept of compassion~* Biological foundations of compassion~* Self-compassion~* Barriers to compassion~* Coping with compelling emotions~* Coping with the intensity of compassion~* Compassionate mindfulness attitudes~* Admission stages and improving acceptance~* Compassion Meditation~* Courtesy Meditation~* My partner activity~* Body Scan~* Mindfulness Sitting Meditation~* Receiving feedback on the development of mindfulness skills and the content of the training program~* Integration of conscious awareness exercises in daily life for the future"
223428163|NCT01157000|DRUG|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
223428164|NCT02515994|DEVICE|senofilcon C|Investigational contact lens
223428165|NCT02515994|DEVICE|comfilcon A|Marketed Monthly Replacement Lens (Control)
223428166|NCT02642003|DRUG|Granulocyte Colony Stimulating Factor|
224070406|NCT04983914|DEVICE|Transcorneal Electrostimulation via OkuStim System|Transcorneal electrostimulation, usually applied once per week for 30 min (home-use).
223428167|NCT04943302|DRUG|Bendamustine Hydrochloride|To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles
223428168|NCT04943302|DRUG|Isatuximab|To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1
223428169|NCT01624857|DRUG|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
223428170|NCT01624857|DRUG|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
223428171|NCT00326781|DRUG|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
223428172|NCT00326781|DRUG|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
223428173|NCT00327743|DRUG|larotaxel|IV infusion on Day 1 of a 21-day cycle
224070407|NCT03505229|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
224304945|NCT04487938|OTHER|No intervention utilised|No intervention utilised
223428174|NCT00327743|DRUG|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
223428175|NCT02768441|DRUG|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
223428176|NCT00192101|DRUG|gemcitabine|
223428177|NCT00192101|DRUG|cisplatin|
223428178|NCT00606840|BEHAVIORAL|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
223428179|NCT00606840|BEHAVIORAL|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
223428180|NCT05160038|DEVICE|Embodied virtual reality|An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
223428181|NCT02189655|PROCEDURE|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
223428182|NCT04489849|DRUG|Apixaban 2.5 MG|apixaban 2.5mg BID for 3 months in experimental group
223428183|NCT04489849|OTHER|Active Control|Medication other than anticoagulation
223428184|NCT00393263|DRUG|pimecrolimus and clobetasol|
223428185|NCT00393263|DRUG|clobetasol 0.05% cream|twice daily for three months
223428186|NCT00900640|PROCEDURE|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
223428187|NCT00219570|DRUG|clindamycin|
223428188|NCT00219570|DRUG|nadifloxacin|
223428189|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (RhinAdvil(R))
223428190|NCT01170637|DRUG|Ibuprofen|200 mg oral administration (BI product)
223428191|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (BI product)
223428192|NCT01170637|DRUG|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
223428193|NCT06620900|OTHER|Integrated Model of Care|The Integrated Model of Care was developed and piloted by the study team provide support for individuals seeking care in an interdisciplinary intensive outpatient program for mild traumatic brain injury to receive support for co-occurring substance use-related needs.
223428194|NCT04516382|DRUG|PTG-300|Active drug
223428195|NCT04477044|OTHER|Study Group|GoPro Hero4 to be mounted on the participant's forehead while performing intubation on a manikin.
224038972|NCT03228381|DEVICE|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
224038973|NCT03298321|OTHER|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
223428196|NCT04308980|DIETARY_SUPPLEMENT|Specialized product for medical nutrition (SPP-1)|"Patients randomly allocated to this group will use specialized product for medical nutrition (SPP-1). This product contains: soy protein, whey protein concentrate, microcapsulated rapeseed oil, maltodextrin, inulin, Polydextrose, soy lecithin, potassium citrate, magnesium lactate, ω-3 PUFA (docosahexaenoic acid), sweetener mixture (stevia extract, erythritol), natural flavor Yogurt-vanilla, calcium carbonate, betaine hydrochloride, natural flavor raspberry, vitamin premix (vitamins a, e, C, D3, B1, B2, B6, B12, PP, folic acid, Pantothenic acid, K1, Biotin), beet juice concentrate, carrageenan, mineral premix (iron, zinc, copper, manganese, iodine, selenium, molybdenum, chromium), alpha-lipoic acid. The product is packed in approved by sanitary rules bags by 30 g. The instant drink obtained by the mixture of the bag content with warm (30-60C) water should be used immediately after being prepared. The daily dose is 1 pack TID"
223428197|NCT04308980|BEHAVIORAL|individualized diet|All the patients enrolled to the study will be provided with recommendations on diet. Individualized requirements will be calculated based on the results of indirect calorimetry (resting energy expenditures) and measurements of urea in daily urine
223428198|NCT00276185|DRUG|Time delay treatment of botulinum toxin|
223428199|NCT00888602|DIETARY_SUPPLEMENT|3.4 g psyllium|3.4 g psyllium served with meal
223428200|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium served with a meal
223428201|NCT00888602|DIETARY_SUPPLEMENT|6.8 g psyllium|6.8 g psyllium
223428202|NCT00888602|OTHER|Meal|meal
223428203|NCT02787018|DRUG|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
223428204|NCT02787018|DRUG|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
223428205|NCT02787018|DRUG|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
223428206|NCT05571202|PROCEDURE|General anesthesia plus local infiltration|The eligible patients underwent anorectal surgery under general anesthesia (GE, GM, IVG) plus locally injected analgesics.
223428207|NCT05571202|PROCEDURE|Spinal anesthesia|The eligible patients underwent anorectal surgery under spinal anesthesia alone.
223428208|NCT05024981|BEHAVIORAL|Videographic feedback|Twice a week during his classic re-education sessions, the patient will be filmed for 1 minute. After transferring the video to a tablet, he will watch the video once and decide what he wants to correct. During the second viewing, he will analyse his walk, the therapist being present to provide additional information. Finally, the patient will apply his analysis while being filmed and will compare the possible differences between the 2 videos. Depending on the time available, the patient may have to repeat the recordings, analyses and exercises.
223428209|NCT05024981|BEHAVIORAL|Classic reeducation|The patient will benefit twice a day for 30 minutes from re-education sessions.
223428210|NCT02537834|DRUG|Tofogliflozin|
223428211|NCT02537834|DRUG|GLP-1 analogue|
223428212|NCT02322450|DRUG|QGC001|
223428213|NCT02322450|DRUG|Placebo|
223428214|NCT02954185|OTHER|WellClub|
223428215|NCT02954185|BEHAVIORAL|Standard Therapy|
223428216|NCT04927871|BEHAVIORAL|Total Diet Replacement (TDR)|The nutritionist will provide a total diet replacement (TDR) with Low-Energy Liquid-Diet (LELD - 811 kcal/day, 64 g protein, 132 g carbohydrate, 6 g fat) and the food reintroduction for two months.
223428217|NCT04927871|BEHAVIORAL|Medical Nutritional Therapy (MNT)|The nutritionist will provide Medical Nutritional Therapy (MNT) using the transcultural Diabetes Nutritional Algorithm (tDNA) Toolkit adapted for Venezuela for four months.
223428218|NCT04927871|BEHAVIORAL|Diabetes Prevention Program 4 months|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 4-months.
223744796|NCT01673451|DRUG|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
223428219|NCT04927871|BEHAVIORAL|Diabetes Prevention Program|The coach will provide a group-based Diabetes Prevention Program (DPP) version in weekly encounters during 6-months.
223428220|NCT04616105|DRUG|REGN6490|Single dose of REGN6490
223428221|NCT04616105|DRUG|Placebo|Placebo matching single dose of REGN6490
223428222|NCT03950141|DRUG|Apatinib and S-1|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
223428223|NCT02454374|PROCEDURE|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
223428224|NCT02454374|PROCEDURE|Routine Physiotherapy Care|Routine Physiotherapy Care
223428225|NCT03541434|DIAGNOSTIC_TEST|Complete Blood Count|White blood cell subgroups count
223428226|NCT03541434|DIAGNOSTIC_TEST|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
223428227|NCT03541434|PROCEDURE|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
223428228|NCT02719834|DRUG|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
223428229|NCT02719834|OTHER|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
223428230|NCT01402505|PROCEDURE|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
223428231|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech Implant EV Profile (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Placement healing abutment~4. Suturing the wound tightly"
223428232|NCT06404944|PROCEDURE|implantation|"1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech OsseoSpeed® TX dental implant (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Guided bone regeneration with xenogeneic bone material Bio-oss® (Geistlich Pharma AG, Sweden) and collagen membrane Bio-Gide® (Geistlich Pharma AG, Sweden)~4. Suturing the wound tightly"
223428233|NCT03566056|OTHER|Complications to Whipples procedure|Patients undergoing the Whipple procedure often tend to have a lot of complications. This study aims to investigate what complications these patients experience
223428234|NCT05919849|BEHAVIORAL|Brief online writing intervention|Participants will be instructed to write for 20 minutes across 3 consecutive days. They will be writing based on the prompts given to them.
223428235|NCT05919849|OTHER|Control condition|Participants will be instructed to write in order to control for time and writing engagement.
223428236|NCT05597917|DRUG|Trabectedin|Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
223478241|NCT00860275|DRUG|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
223478242|NCT00860275|DRUG|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
223478243|NCT00860275|DRUG|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
223478244|NCT00860275|DRUG|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
223478245|NCT04078009|DIAGNOSTIC_TEST|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
223478246|NCT04078009|DIAGNOSTIC_TEST|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
223478247|NCT04670120|DRUG|Pyrifazimine (TBI-166)|"The new drug pyrifazimine (previous name: TBI-166) is obtained by retaining the key skeleton of the lead drug clofazimine which can exert its efficacy and modification by introducing moderate polar groups structural. While the drug has strong activity against tuberculosis-sensitive bacteria and drug-resistant bacteria in vivo and in vitro, its pharmacokinetic properties and skin staining side effects have been significantly improved compared with the lead drugs, so that the drug can achieve the goal that reducing fat solubility, accelerating metabolism in the body, reducing skin staining and reducing side effects.~In November 2016, the new anti-drug-resistant tuberculosis drug pyrifazimine and its tablets obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
223478248|NCT06115460|DRUG|oral sitagliptin supplementation|oral sitagliptin supplementation for three months
223478249|NCT06448962|DRUG|AD-2021|PO, Once daily(QD), 8weeks
223478250|NCT06448962|DRUG|AD-2022|PO, Once daily(QD), 8weeks
223478251|NCT06448962|DRUG|AD-2021 Placebo|PO, Once daily(QD), 8weeks
223478252|NCT06448962|DRUG|AD-2022 Placebo|PO, Once daily(QD), 8weeks
223428237|NCT05597917|BIOLOGICAL|tTF-NGR|Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 of tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 9 am and on the following day, q d 22 x until disease progression or contraindications against further application.
223428238|NCT04178824|BEHAVIORAL|Discount Intervention|15% or 30% discount on fruits and vegetables
223428239|NCT06146010|OTHER|No intervention|Once the patient or their legal guardian has given their written consent, a patient is included in the leptomeningeal disease register. Due to the rapid course of the disease and potential rapid deterioration, the documentation of the course of the disease of the individual patients is to be carried out retrospectively from the data recorded during the course of the clinical routine for the entire duration of the study or until the death of the participating patients after the written consent of the patients. The registry's data sources are the diagnostic findings made at the center and doctors' letters from routine clinical practice. The participating centers carry out the assessment of the participants' performance status so that the patients do not have to complete any study-related questionnaires.
223428240|NCT05651438|OTHER|Assessment|Assessment of pain, fatigue, sleep quality, and e-sports-specific features
223428241|NCT00419601|DRUG|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
223428242|NCT00419601|DRUG|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
223428243|NCT06188442|DRUG|DoxyODPrEP|Participants in the DoxyODPrEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally 2-24 hours before sex, and one 100mg capsule each 24 and 48 hours after loading dose. If they have sex within 48 hours after the loading dose, they would be asked to continue a daily 100mg until two days after the last sex
223564472|NCT01018472|OTHER|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
223564473|NCT02359357|DRUG|FDL169|
223564474|NCT02359357|DRUG|Placebo|
223564475|NCT05022199|DEVICE|SPY fluorescent angiography|This group has had SPY fluorescent angiography used intraoperatively during urinary diversion. To be compared with historic controls who did not.
223564476|NCT00532025|DRUG|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
223564477|NCT03217877|DIAGNOSTIC_TEST|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
223564478|NCT03217877|DIAGNOSTIC_TEST|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
223564479|NCT01301521|DRUG|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
223564480|NCT01588262|OTHER|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
224038974|NCT02479334|OTHER|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
224038975|NCT02479334|OTHER|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
223428244|NCT06188442|DRUG|DoxyPEP|Participants in the DoxyPEP arm would be instructed to take two doxycycline hyclate 100mg capsules orally within 24 hours and up to 72 hours after each sex.
223428245|NCT01014897|DEVICE|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
223564481|NCT06357871|OTHER|No intervention|No intervention
224038976|NCT02479334|OTHER|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
224139274|NCT02449408|OTHER|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
223564482|NCT04022785|DRUG|Azacitidine|Given IV or SC
223564483|NCT04022785|DRUG|BRD4 Inhibitor PLX51107|Given PO
223564484|NCT05539560|OTHER|Olfactory training with essential oils|Olfactory training twice daily with essential oils from Urtegaarden Aps with scents of orange, lavender, clove and peppermint. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
223564485|NCT05539560|OTHER|Olfactory training with fragrance-free oils|Olfactory training twice daily with fragrance-free oils from Urtegaarden Aps in the same four containers as the intervention group. The olfactory training is performed every morning and evening, by smelling each of the oils for 30 seconds.
223428246|NCT01617772|DRUG|Atorvastatin|Atorvastatin 20 mg
223428247|NCT01617772|DRUG|L-Carnitine|1000mg L-carnitine
223428248|NCT01617772|DRUG|Placebo|Identically looking placebo
223428249|NCT02472743|DEVICE|Custom-built phototherapy lamp|Described in the arm description
223428250|NCT02262598|DRUG|Telmisartan|
223428251|NCT02262598|DRUG|Hydrochlorthiazide (HCTZ)|
223428252|NCT02262598|DRUG|Telmisartan/HCTZ fixed dose|
223428253|NCT06388863|DRUG|Healthy donor-derived FMT capsule|Participants will be treated with healthy donor-derived fecal microbiota transplantation in the form of oral capsules.
223428254|NCT06388863|DRUG|Placebo capsule|Capsules whose appearance and smell are identical as FMT capsules but contain milk powder
223428255|NCT05525585|DIETARY_SUPPLEMENT|Early HMF|Mom's milk or donor milk will be fortified between postnatal day 4 and 7
223428256|NCT05525585|DIETARY_SUPPLEMENT|Delayed HMF|Mom's milk or donor milk will be fortified between postnatal day 10 and 14
223428257|NCT06550011|DRUG|ABI-110 Low Dose|Low dose. lower than the safety factor of 10 as recommended by the FDA
223428258|NCT06550011|DRUG|ABI-110 Medium Dose|Medium dose
223428259|NCT06550011|DRUG|ABI-110 High Dose|High Dose
223428260|NCT05622071|DRUG|Tislelizumab|Tislelizumab 200 mg will be administered every 3 weeks IV for a maximum of 2 years
223428261|NCT05674916|DIAGNOSTIC_TEST|Point-of-care ultrasound-driven diagnostic pathway|Focused lung ultrasound will include 8 zones (anterior and lateral) and evaluate pneumothorax, interstitial syndrome, lung consolidation, and pleural effusion. Focused cardiac ultrasound will include four views (subxiphoid four-chamber view, parasternal long-axis view, parasternal short-axis view, and apical four-chamber view) and evaluate pericardial fluid, right ventricle dilation, and left ventricular systolic contractility.
223428262|NCT03575299|BIOLOGICAL|The adoptive treatment of allogeneic γδT cells|Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
223428263|NCT03575299|OTHER|Control|No allogeneic γδT cells will be administered to patients with MDR-TB.
223428264|NCT03575299|DRUG|Conventional treatment|Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
223428265|NCT04735692|OTHER|Full mouth or quadrant SRP|Full mouth or quadrant SRP
223740211|NCT07205406|BEHAVIORAL|group based-parenting training|The group received approximately three hours of parenting training once a week for 5 weeks that focused on understanding children with ID in the first week, practical parenting skills in the second week, and how to provide emotional support and regulate parental emotions in the third week. Knowledge and skills were reinforced in the fourth and fifth weeks. The intervention group received training in small groups, each consisting of only 10 participants. The training involved experts in mental health counseling, pediatric nurses, special school teachers, and a motivator.
224038977|NCT02479334|OTHER|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
223428266|NCT04754438|BEHAVIORAL|e-CBT|Electronically delivered cognitive behavioural therapy
223428267|NCT04754438|BEHAVIORAL|Mental Health Coaching|Electronically delivered mental health coaching
223428268|NCT01354392|DRUG|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
223428269|NCT03007290|OTHER|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
223428270|NCT06522555|DRUG|polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide|"Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
223428271|NCT06522555|DRUG|zanubrutinib, rituximab and lenalidomide|"Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years."
224038978|NCT03739437|BEHAVIORAL|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
224070408|NCT06454253|DEVICE|Da Vinci Robot Surgical System|Performing surgery on right colon cancer patients using the da Vinci robotic surgical system or laparoscopic surgical system
223428272|NCT01178879|BEHAVIORAL|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
223428273|NCT04181983|OTHER|Personalized exercise program|Home-based personalized exercise program using a smart phone app
223428274|NCT04181983|OTHER|WHO exercise guidelines|Standard exercise counselling according to WHO guidelines
224070409|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
224070410|NCT00717938|DRUG|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
224070411|NCT03576937|DIAGNOSTIC_TEST|GUARDANT360|GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.
224070412|NCT04401176|DRUG|Heparin & Alkalinized Lidocaine Bladder Instillation|Bladder instillation instilled via catheter and to dwell for minimum of 30 minutes prior to spontaneous void
224070413|NCT04401176|DRUG|Onabotulinum Toxin A|Intradetrusor onabotulinumtoxinA injection (0.5mL x 20 sites)
223428275|NCT05702242|PROCEDURE|IUD removal with no visible strings|Removal with either alligator forceps or MVA
223428276|NCT05702242|DEVICE|Alligator forceps|IUD removal with alligator forceps
223428277|NCT05702242|DEVICE|Manual Vacuum Aspirator|IUD removal with MVA
223428278|NCT00135798|DRUG|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was \<0.5 ug/kg, PEGIFN was permanently discontinued."
223428279|NCT04186806|DEVICE|3M Dry Mouth Moisturizing Spray to Biotene Moisturizing Mouth Spray|20 ml bottle
223428280|NCT04186806|DEVICE|Biotene Moisturizing Mouth Spray to 3M Dry Mouth Moisturizing Spray|44.3 ml bottle
223428281|NCT03348475|BEHAVIORAL|Binge Focused Therapy (BFT) Intervention|The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
223428282|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
223428283|NCT02416193|DRUG|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
223428284|NCT00286923|DRUG|Topiramate|
223428285|NCT05274581|OTHER|A new type of ultrasound course|All participants will receive the educational intervention. The educations intervention consists of three teaching seminars over three months, a curriculum of 10 point-of-care ultrasound applications, an online learning platform providing educational support before, during and after the teaching sessions.
223428286|NCT03819595|OTHER|Supervised exercise|a free 12-week, small-group (\~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
223428287|NCT03819595|OTHER|Personalized Program PVS|"a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record."
223428288|NCT03928808|BIOLOGICAL|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
223428289|NCT02609100|PROCEDURE|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
223428290|NCT02609100|PROCEDURE|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
223428291|NCT02609100|DEVICE|1.0 X 2.5 cm 'pill' containing a camera|
223428292|NCT02339116|DRUG|fluoruracil|
223428293|NCT02339116|DRUG|Oxaliplatin|
223428294|NCT02339116|DRUG|Irinotecan|
223428295|NCT02339116|DRUG|Bevacizumab|
223428296|NCT05923775|PROCEDURE|Impacted third molar surgey|The surgery was performed using the classic technique: ten minutes after anesthesia administration, a horizontal and sulcular incision was performed, and a mucoperiosteal envelope flap was elevated. The bone covering the impacted third molar tooth was removed with the use of a surgical handpiece and rotary instrument. During the operation, saline water was applied to the surgical drill with a second hand to protect the bone from developing a high temperature. After extraction of the third molar, the cavity was treated with curettage, irrigated with saline, and sutured.
223428297|NCT00702442|DRUG|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
223428298|NCT00702442|DRUG|Saline solution|Saline solution administrated i.v 30 min prior surgery
223428299|NCT03703011|DEVICE|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
223428300|NCT05365646|DEVICE|Hearing aids equipped with motion sensing abilities|Participants will wear hearing aids that will assess their movement, and fall risk.
223740212|NCT07205172|OTHER|Orthodontic and periodontal analysis|Intraoral digital impression aimed at orthodontic analysis and periodontal evaluation using a dedicated periodontal probe, as part of the routine dental examination.
223428301|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
223428302|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
223428303|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
223428304|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
223428305|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
223428306|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
224070414|NCT00671021|OTHER|Platelet aggregation|Platelet aggregation TxA2 formation
223428307|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
223428308|NCT01240980|DRUG|Placebo|Solution, Oral, 0 mg, once daily, 1 day
223428309|NCT01240980|DRUG|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
223428310|NCT01240980|DRUG|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
223428311|NCT01240980|DRUG|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
223428312|NCT01240980|DRUG|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
223428313|NCT01240980|DRUG|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
223428314|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
223428315|NCT01240980|DRUG|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
224139275|NCT04646473|BEHAVIORAL|SweetGoals app|App offers goal setting and feedback
223428316|NCT05860439|PROCEDURE|Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)|Patients previously treated were reassessed for long-term follow-up.
223428317|NCT01917812|DEVICE|Digital Activity Tracker|
223428318|NCT01917812|OTHER|Smart Text Messaging|
223428319|NCT05249322|OTHER|Follow-up alternating between face-to-face consultation and teleconsultation every three months.|"The intervention will be an alternate follow-up every three months with:~* A tele-consult: with paramedical consult (with assistance for home-spirometry) and medical consult for about 1h30 in total, make with a HCL platform for telemedicine.~* An usual in-hospital consult of about 1h30 with paramedical and medical consult."
224038979|NCT03739437|BEHAVIORAL|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
223428320|NCT04739722|DIAGNOSTIC_TEST|ColoSense|"ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.~A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals."
224038980|NCT04586582|DIAGNOSTIC_TEST|ST-segment resolution <40.15%|Forty-two STEMI patients with single-branch coronary artery stenosis or occlusion were enrolled. ST-segment elevations were measured at emergency admission and at 24 h after PCI. Late gadolinium-enhanced cardiac magnetic resonance imaging (CMR-LGE) was performed 7 days after PCI to evaluate myocardial scars.
224038981|NCT02798263|OTHER|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
224038982|NCT02798263|OTHER|Acupuncture|30 minutes of classical acupuncture using predefined points.
224038983|NCT02798263|OTHER|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
224038984|NCT01846325|DIETARY_SUPPLEMENT|vitamin E|
224139276|NCT04646473|BEHAVIORAL|Coaching|Web health coaching
223428321|NCT06666751|PROCEDURE|Cataract plus Microstent surgery|Both the Hydrus microstent and iStent Inject W are used in combination with cataract surgery, in order to help lower intraocular pressure for patients with open-angle glaucoma. The microstent is a small flexible device that is inserted into the eye during cataract surgery in order to improve the outflow of fluid from the eye.
223428322|NCT02684409|DRUG|PROT-CL-NP101-015.01|
223428323|NCT01021761|DRUG|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
223428324|NCT01021761|DRUG|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
223428325|NCT01021761|DRUG|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
223478253|NCT04559113|DRUG|Methylprednisolone Injectable Product|"1. 0.5mg to 1mg/Kg methylprednisolone or equivalent dexamethasone dose (to a maximum of 20mg) given daily x 5 to 7-days or~2. Methylprednisolone 1 mg/kg daily IV for 5 days followed by 40 mg daily x 3 days, followed by 10 mg daily x 2 day."
223478254|NCT06417970|DIAGNOSTIC_TEST|Shoulder Proprioception, Palmar Touch Sensation and Psychometric Parameters|"Shoulder Proprioception: Proprioception will be measured with isokinetic device. The measurement reference angles are 30° and 60°.~Palmar Touch Sensation: Palmar tactile sensation will be measured with the Semmes-Weinstein Monofilament.~Psychometric Parameters: Athlete Psychological Strain Questionnaire, Tampa kinesiophobia questionnaire"
223564486|NCT06300723|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
224038985|NCT01846325|DIETARY_SUPPLEMENT|DHA|
224038986|NCT01846325|OTHER|placebo|
224038987|NCT04145544|DEVICE|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
224038988|NCT04145544|DEVICE|Implantation of other commercial suturable dural substitute|Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
224038989|NCT04803136|PROCEDURE|spine surgeries|all spine surgeries including stabilization and fusion surgeries
223478255|NCT03685604|DRUG|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
224139277|NCT04646473|BEHAVIORAL|Incentives|Financial incentives for meeting goals
224139278|NCT02858973|DRUG|Q203|
224139279|NCT02858973|DRUG|Placebo|
224139280|NCT02430428|DEVICE|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
224139281|NCT01666691|DRUG|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
224139282|NCT01666691|DRUG|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
224139283|NCT05533255|OTHER|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Composite resin at room temperature is used.
224038990|NCT01800422|DRUG|telapristone acetate|Given orally
223428326|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
223428327|NCT03047720|DEVICE|Lully Sleep Guardian|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
223428328|NCT00614120|DRUG|liraglutide|0.6 mg/day, s.c. (under the skin) injection
223428329|NCT00614120|DRUG|placebo|Glimepiride placebo, capsules
223428330|NCT00614120|DRUG|liraglutide|1.2 mg/day, s.c. (under the skin) injection
223428331|NCT00614120|DRUG|liraglutide|1.8 mg/day, s.c. (under the skin) injection
223428332|NCT00614120|DRUG|glimepiride|Capsules, 4.0 mg/day
224038991|NCT01800422|OTHER|placebo|Given orally
224038992|NCT01800422|PROCEDURE|therapeutic conventional surgery|Undergo surgical resection
224038993|NCT01800422|OTHER|laboratory biomarker analysis|Correlative studies
224038994|NCT01800422|OTHER|questionnaire administration|Ancillary studies
223428333|NCT00614120|DRUG|metformin|Tablets, 1.5-2.0 g/day
223428334|NCT00614120|DRUG|placebo|Liraglutide placebo, s.c. (under the skin) injection
223428335|NCT06622174|RADIATION|Pulse radiotherapy|Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle
223428336|NCT06523907|OTHER|Intervention Basic Nursing skills|Evaluating the effectiveness of the education program in improving paramedics' knowledge of essential nursing care principles, such as hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
223428337|NCT06523907|OTHER|Control Present Knowledge about basic nursing skill|Assess the current and baseline knowledge status of the participants about the hygiene practice, infection control, safe administration of injection, blood draw, vital sign monitoring, respiratory rate
223428338|NCT01185509|DRUG|trastuzumab|
223428339|NCT01185509|DRUG|vinorelbine|
223428340|NCT03687372|DRUG|A-101|hydrogen peroxide topical solution 45%
223428341|NCT03687372|OTHER|vehicle|vehicle as a topical solution
223428342|NCT04884425|DEVICE|Pulsed Electromagnetic Frequency Device (Energy5)|A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
223428343|NCT00227630|DRUG|cisplatin|
223428344|NCT00227630|DRUG|pemetrexed disodium|
223428345|NCT00227630|PROCEDURE|adjuvant therapy|
223428346|NCT00227630|PROCEDURE|conventional surgery|
223428347|NCT00227630|PROCEDURE|neoadjuvant therapy|
223428348|NCT00227630|RADIATION|radiation therapy|
223428349|NCT04892212|DRUG|Sirolimus|The daily dose of sirolimus is divided twice.
223428350|NCT00536224|BEHAVIORAL|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
223428351|NCT00536224|BEHAVIORAL|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (\<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
223428352|NCT00022243|DRUG|batabulin sodium|
224038995|NCT00086034|DRUG|Motexafin gadolinium|
224038996|NCT02618824|DRUG|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
224070415|NCT03861559|DRUG|mometasone furoate nasal spray|intranasal administration
224070416|NCT03861559|DRUG|placebo nasal spray|intranasal administration
224070417|NCT00005613|DRUG|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
224070418|NCT00005613|DRUG|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
224070419|NCT00005613|DRUG|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
224070420|NCT00501787|DRUG|Metformin|
224070421|NCT00002689|DRUG|dexamethasone|
224070422|NCT00002689|DRUG|fluorouracil|
224070423|NCT00002689|RADIATION|brachytherapy|
224070424|NCT00002689|RADIATION|phosphorus P32|
224070425|NCT00002689|RADIATION|radiation therapy|
224070426|NCT04456309|OTHER|No intervention,|pure observational study
223428353|NCT03555864|DEVICE|infrared transluminescent device|use of infra red for venous access for second intravenous access
223428354|NCT03380702|PROCEDURE|whitening photoactivation gel|35 subjects in active comparator group
223428355|NCT03380702|PROCEDURE|placebo|35 subjects in placebo comparator group
224038997|NCT02618824|OTHER|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
224038998|NCT04438161|BEHAVIORAL|PERCCS: Personalized Education Regarding Clinical and Community Supports|A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
224038999|NCT02138721|PROCEDURE|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
224039000|NCT01052688|OTHER|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
223428356|NCT05028075|BEHAVIORAL|Cobalt +|Participants will complete baseline surveys at enrollment and then complete subsequent surveys (depression, anxiety, well-being, satisfaction with access to care, work productivity) at enrollment; 0 months and then again at 6 months. The primary endpoint is assessed at 6 months. A secondary endpoint of persistence of effect is measured 3 months later-9 months post initiation. The intervention group receives usual Cobalt plus: 1) monthly automated text messaging reminders and links to Cobalt resources 2) intermittent mental health assessments which triage individuals to an appointment based on their results.
223428357|NCT02012933|DRUG|3,4-diaminopyridine|10mg tablets for up to 100mg per day
223428358|NCT00108485|DRUG|Extended release niacin|Extended release niacin 1500-2000mg once daily
223428359|NCT00108485|OTHER|Placebo|Placebo tablets
223428360|NCT01932736|OTHER|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
223428361|NCT04789291|DRUG|BI 1595043|Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
223428362|NCT06426862|OTHER|Otago Exercise Program|"Otago exercise program~Strengthening Exercise Knee extensor, Hip adductors, heel and toe raising~Balance exercise Sit to stand, Knee bending, one leg standing, tandem stance, side walk, walk and turn around, tandem walk, backward walk, heel and toe walk, stair climbing"
224039001|NCT01172509|DRUG|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
224039002|NCT03056911|DRUG|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
224039003|NCT03600623|DRUG|Folfirinox|SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
224039004|NCT03600623|DRUG|Gemcitabine nab-Paclitaxel|SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
223428363|NCT06426862|OTHER|Control Group|Routine physiotherapy like strengthening, stretching, postural awareness, gait and balance training.
223428364|NCT05288894|DIAGNOSTIC_TEST|Cardiac magnetic resonance imaging|A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.
223428365|NCT04790162|BEHAVIORAL|Heartfulness Meditation|Heartfulness meditation with a trainer provided virtually
223428366|NCT04403646|DIETARY_SUPPLEMENT|ARBOX|dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg
223428367|NCT04403646|OTHER|PLACEBO|Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
223428368|NCT03067688|DRUG|Temisartan+Amlodipine+Rosuvastatin (Combination drug)|PO, Once daily(QD), 8weeks
223428369|NCT03067688|DRUG|Temisartan+Amlodipine|PO, Once daily(QD), 8weeks
223428370|NCT03067688|DRUG|Temisartan+Rosuvastatin|PO, Once daily(QD), 8weeks
223428371|NCT05015140|OTHER|musıc therapy|calm music with nature sounds set by the music therapist
223428372|NCT00878969|DRUG|valsartan (ARB)|
223428373|NCT00878969|DRUG|ramipril (ACE inhibitor)|
223428374|NCT00878969|DRUG|Placebo|
223428375|NCT02350946|DRUG|Oxytocin|
223428376|NCT02350946|DRUG|Placebo|
223428377|NCT00978939|OTHER|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
223428378|NCT00978939|OTHER|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
223428379|NCT04336449|DRUG|Eptinezumab|Eptinezumab - single intravenous infusion
223428380|NCT04336449|DRUG|Placebo|Placebo - single intravenous infusion
223428381|NCT03729570|OTHER|ePrEP|Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit consists of surveys, specimen collection, and a telemedicine consultation.
223428382|NCT02289287|BEHAVIORAL|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
223478256|NCT03685604|DRUG|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
223478257|NCT03429101|DRUG|Poziotinib|Poziotinib is a tablet for oral administration.
223478258|NCT03429101|DRUG|T-DM1|T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
223428383|NCT02289287|BEHAVIORAL|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
223428384|NCT00805870|DRUG|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
223428385|NCT00805870|DRUG|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
224299394|NCT02001220|PROCEDURE|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP \< to 5 cm H2 O or PS \< 8 cm H2 O with PEEP \< 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
223428386|NCT05131087|DEVICE|Cadence implant|CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
223428387|NCT01701193|DRUG|L-Alanyl/L-Glutamine|Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection. It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery. The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
223428388|NCT01701193|DRUG|Physiologic saline|Placebo
223428389|NCT05735262|DEVICE|active iTBS|Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
223428390|NCT05735262|DEVICE|sham iTBS|Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
223428391|NCT06016569|DIAGNOSTIC_TEST|Exhaled breath condensate sampling|Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed.
223428392|NCT06016569|DIAGNOSTIC_TEST|Blood sampling|A venous blood sample will be taken for further biomarker analysis.
223428393|NCT06016569|PROCEDURE|LDCT|LDCT scan will be performed.
223428394|NCT06016569|DIAGNOSTIC_TEST|Vital signs|Blood pressure, weight, height, pulse, oxygen saturation will be measured.
223428395|NCT06016569|DIAGNOSTIC_TEST|Spirometry|Spirometry will be performed.
223428396|NCT00278148|DRUG|carboplatin|AUC2 weekly x 3 weeks
223428397|NCT00278148|DRUG|Erlotinib|Daily
223428398|NCT00278148|DRUG|paclitaxel|50mg/m2/weekly x 3 weeks
223740213|NCT07207018|BEHAVIORAL|CFTSI (Child and Family Traumatic Stress Intervention)|CFTSI is a family-centered intervention lasting five to eight sessions, aiming to strengthen parental support for the child by facilitating the identification of the child's typical responses to traumatics events, improving communication between the child and the parent, and teaching coping strategies and behavioral interventions to both parents and children to reduce acute post-traumatic reactions.
224070427|NCT03527121|OTHER|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
223428399|NCT00278148|PROCEDURE|conventional surgery|conventional surgery
223428400|NCT00278148|RADIATION|radiation therapy|150 cGy bid
223428401|NCT03499457|DRUG|Amoxicillin|chalange test of 50 mg, and after an hour 500 mg
223428402|NCT02120820|BEHAVIORAL|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
223428403|NCT02120820|BEHAVIORAL|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
223428404|NCT02120820|OTHER|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
223428405|NCT02120820|BEHAVIORAL|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
223428406|NCT02181322|DRUG|Meloxicam - low dose|
223428407|NCT02181322|DRUG|Meloxicam - medium dose|
223428408|NCT02181322|DRUG|Meloxicam - high dose|
223428409|NCT02407457|DEVICE|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
223428410|NCT02407457|DEVICE|FDA Approved EVAR AAA Graft Systems|
223478259|NCT01093846|DRUG|AIN457|300mg every 4 weeks
223478260|NCT01093846|DRUG|AIN457|300mg every 2 weeks
223478261|NCT01093846|DRUG|Placebo AIN457|Placebo to AIN457
223478262|NCT04079504|PROCEDURE|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
223478263|NCT04079504|PROCEDURE|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
223478264|NCT03082729|DRUG|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
223428416|NCT06098703|BEHAVIORAL|CARD (Comfort Ask Relax Distract)|CARD is a vaccine delivery framework/protocol to plan and deliver vaccinations
223428417|NCT03873909|OTHER|Fruit Smoothie|Fruit Smoothie with 150-200 g mamey sapote fruit
223428418|NCT03873909|OTHER|Matrix-Free Shake|Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
223428419|NCT00245297|DRUG|Kogenate FS, reconstituted in a suspension of liposomes|
223428420|NCT05386277|DEVICE|TufTex Single Lumen Embolectomy Catheter|The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
223428421|NCT06275711|BEHAVIORAL|Therapeutic communication methods|Drawing pictures, story completion, breathing and relaxation exercises
223428422|NCT06619795|DEVICE|Anodal tDCS|In addition to anodal tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
223428423|NCT06619795|DEVICE|Sham tDCS|In addition to Sham tDCS stimulation, participants simultaneously underwent motor or cognitive therapy, depending on their assigned group.
223428424|NCT02467257|DIETARY_SUPPLEMENT|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
223428425|NCT05977075|OTHER|ApisMela protocol|The activities and games proposed by this protocol are offered in a sequence characterized by increasing complexity. The same function is stimulated with varied tasks because the repetitiveness of the same task negatively affects skill generalization. ApisMela training teaches to focus on the purpose of the task, check that you understand it, and make explicit the procedures to be implemented. Language plays a crucial role, participants are encouraged to use speech as a tool for attention regulation and cognitive processing. It's divided into 20 sessions: a weekly group meeting of one hour and thirty.
223428426|NCT05977075|OTHER|"Unstuck and on Target protocol"|The protocol teaches people to be more flexible, skillful in planning and goal-oriented. It is useful for moving more easily from one topic to another and from one task to another, considering new ideas or another person's point of view, generalizing skills learned across contexts so that teachers, parents and therapists can focus more on educational aspects and less on behavioral management. It is divided into 20 sessions: a weekly group meeting of one hour and thirty minutes. A homework sheet is provided for each session to consolidate the skill learned and generalize it outside the work setting. Parents have an active role in performing the task.
223428427|NCT03721042|DEVICE|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
223428428|NCT00638742|DRUG|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
223428429|NCT02083185|DRUG|Relugolix|Relugolix tablets
223428430|NCT02083185|DRUG|Leuprorelin|Leuprorelin subcutaneous injection
223428431|NCT01609309|PROCEDURE|Laparoscopic gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
223744797|NCT06543069|DRUG|Sintilimab, Bevacizumab , Pemetrexed , Cisplatin|Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
224039005|NCT04221386|BEHAVIORAL|Melodic Intonation Therapy (MIT)|Subjects will receive at least 6 MIT sessions in group of 3-5 subjects. In the sessions, experimenter will sing songs with the subjects. Songs used in the intervention are familiar to elderly and are rewritten and embedded with everyday phrases and vocabularies. The whole intervention will span 3-4 weeks.
224039006|NCT01395316|DRUG|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
224039007|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
224039008|NCT01920386|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
224039009|NCT03359590|DRUG|Sitagliptin 100 mg|The treatment consists of sitagliptin tablets (100 mg/day) for up to 24 weeks.
224039010|NCT03359590|DRUG|Placebo|The treatment consists of placebo tablets for up to 24 weeks.
224039011|NCT05974592|OTHER|Education|Diabetic Foot Self-Management Training Program will be implemented.
224039012|NCT02128451|DRUG|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
224139284|NCT05533255|OTHER|Preheated composite resin (3M™ Filtek™ Z350 XT Universal Restorative)|Conventional composite resin (3M™ Filtek™ Z350 XT Universal Restorative) is preheated to a temperature of 57 degrees Celsius using a composite warmer for 10 minutes is used.
223478265|NCT00576511|DRUG|prucalopride|4 mg o.d.
223478266|NCT00576511|DRUG|placebo|Placebo o.d.
223478267|NCT02323074|PROCEDURE|Brain Computer Interface|
223478268|NCT05750758|DRUG|rivaroxaban|rivaroxaban 2.5mg bid for 1m
223478269|NCT04724746|BEHAVIORAL|Written Exposure and Cognitive Behavioral Therapy|Intervention involves writing details about a recent sexual assault and coping skills for substance use.
223478270|NCT03311867|OTHER|Ethibond Suture|Cerclage placement with ethibond
223478271|NCT03311867|OTHER|Prolene Suture|Cerclage placement with prolene
224039013|NCT02128451|DRUG|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
223428432|NCT01609309|PROCEDURE|Open gastrectomy|"* After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~* The type of reconstruction will be selected according to the surgeon's experience."
223428433|NCT02952989|DRUG|SGN-2FF|SGN-2FF oral daily dosing.
223428434|NCT02952989|DRUG|pembrolizumab|200 mg every 3 weeks by IV infusion
224039014|NCT05332444|DRUG|susceptibility-guided tailored therapy (Group A)|"Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1\. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days."
224039015|NCT05332444|DRUG|guidelines-recommended empiric therapy (Group B)|bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
223428435|NCT04341831|DRUG|Teicoplanin|We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
223428436|NCT01041976|BEHAVIORAL|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
223428437|NCT01041976|BEHAVIORAL|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
223428438|NCT04018040|OTHER|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
223564487|NCT00842439|BEHAVIORAL|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
223564488|NCT00842439|DIETARY_SUPPLEMENT|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
224039016|NCT02846532|DRUG|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
224039017|NCT02846532|DRUG|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
224039018|NCT06132425|BEHAVIORAL|Exposure|All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.
224039019|NCT06132425|BEHAVIORAL|Rehearsal|After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
224039020|NCT05602142|DRUG|[11C]CPPC PET ligand|Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).
224039021|NCT05556824|DRUG|MHS-1031|Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)
224039022|NCT05556824|OTHER|Placebo|Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.
224039023|NCT05183360|DRUG|BI 706321|BI 706321, tablet, oral use
224039024|NCT05183360|DRUG|Placebo|Placebo, tablet, oral use
224039025|NCT05512364|DRUG|Elacestrant|400mg QD orally on a continuous dosing schedule
224039026|NCT05512364|DRUG|Tamoxifen|20 mg QD orally on a continuous dosing schedule
223564489|NCT04140955|PROCEDURE|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
223564490|NCT06054516|DIAGNOSTIC_TEST|13C-enriched pyruvate|Before starting the hyperpolarization injection procedure, the patient will be scanned using the standard MR imaging defined in the clinical protocol and 13C prescriptions and a pre-scan will be completed. The clinical investigator will mount the administration syringe in the MR compatible power-injector with pre-adjusted injection volume calculated according to body weight (0.43 ml /kg bw). This setting is checked by the scanning operator and clinical investigator. The injection valve is set for agent delivery, and agent injected at a rate of 5 ml/s. The timings are monitored using a stopwatch on the SPINLAB. Following injection of hyperpolarized \[1-13C\]-Pyruvate , 20 ml of sterile saline in a separate syringe, already attached to the patient line, will be used to flush the IV line at the same injection rate (5 ml/s).
223744798|NCT02555033|OTHER|Resistance training|traditional resistance training
224039027|NCT05512364|DRUG|Letrozole 2.5mg|2.5 mg QD orally on a continuous dosing schedule
224039028|NCT05512364|DRUG|Anastrozole 1mg|1 mg QD orally on a continuous dosing schedule
224039029|NCT05512364|DRUG|Exemestane 25 MG|25 mg QD orally on a continuous dosing schedule
224039030|NCT06253494|BIOLOGICAL|AdHER2DC vaccine|AdHER2DC vaccine is given by intradermal injections on Day 1 of cycles 1-3 (priming) followed by optional boost doses (up to 3), on Day 1 of cycles 6, 9, 12
223428439|NCT03186534|BEHAVIORAL|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
223428440|NCT03186534|BEHAVIORAL|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
223428441|NCT02062424|OTHER|DIPI|
223428442|NCT03867149|OTHER|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
223428443|NCT03867149|OTHER|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
223428444|NCT03573219|RADIATION|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
223428445|NCT02026817|DRUG|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
223428446|NCT02026817|DRUG|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
223428447|NCT02026817|DRUG|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
223428448|NCT03054064|DEVICE|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
223428449|NCT03787303|DRUG|Triiodothyronine (T3)|Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
223428450|NCT04895813|BEHAVIORAL|Education|The patient will be given pre-colonoscopy training and guidance by telephone.
223428451|NCT02712021|OTHER|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
223428452|NCT02712021|OTHER|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
223428453|NCT05870449|DEVICE|tunneled PICC|Tunneled PICC is a type of PICC catheterization technique that involves establishing a subcutaneous tunnel to keep the outlet of the catheter away from the puncture site
223428454|NCT05870449|DEVICE|routine PICC|Peripherally inserted central venous catheterization is a technique that involves inserting PICC through the peripheral vein and infusing drugs into the central vein through a catheter.
224039031|NCT06253494|BIOLOGICAL|Pembrolizumab|Pembrolizumab is given by IV infusion on Day 8 of cycle 1 and Day 1 of cycles 2-16
223428455|NCT00228319|DIETARY_SUPPLEMENT|Oral Ascorbic Acid|4 grams per day for 12 months
223428456|NCT00228319|DRUG|Paclitaxel|Six cycles
224039032|NCT06253494|BIOLOGICAL|N-803|N-803 is given by subcutaneous injections on Day 1 of cycles 1-16
223428457|NCT00228319|DRUG|Carboplatin|Six cycles
223428458|NCT00228319|DRUG|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
223428459|NCT00228319|DIETARY_SUPPLEMENT|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
223428460|NCT00228319|DIETARY_SUPPLEMENT|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
223428461|NCT03502018|DRUG|Bupivacaine liposome|A long-acting liposomal bupivacaine
223428462|NCT03502018|DRUG|Saline|Saline injection used as control
223428463|NCT06620822|DRUG|IBI363|IBI363 is the worlds first PD-1/IL-2α bispecific antibody fusion protein with an IL-2 arm that has been designed and modified to retain CD25 (IL-2Rɑ) activity to maximize efficacy and high selectivity, and to reduce binding to IL-2Rβγ to reduce systemic toxicity, whereas the PD-1 binding arm allows for blockade of PD-1 and selective delivery of IL-2. Therefore, IBI363 has the ability to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, which can more effectively activate tumor-specific T cells. IL-2, as an important cytokine for activating tumor-specific CD8+ T cells, is mechanistically complementary to immune checkpoint inhibitors, and can reverse T-cell depletion, thereby overcoming immune resistance.
223428464|NCT06620822|DRUG|LM-108+Sintilimab|LM-108 is a humanized monoclonal antibody targeting the human chemokine CC receptor 8 (CCR8) and is able to modulate the tumor microenvironment by specifically removing tumor-infiltrating regulatory T cells (Treg) through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Treg.
223478272|NCT04950400|DRUG|Carrelizumab + chemotherapy + apatinib|Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
223478273|NCT02523352|PROCEDURE|Non-Invasive Ventilation|Progressive increase in airway pressure to open lungs atelectatic regions.
223478274|NCT02523352|PROCEDURE|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
223744799|NCT02555033|OTHER|Instability resistance training|training under unstable conditions
223744800|NCT04429893|DRUG|magnesium sulphate|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
224039033|NCT06253494|DRUG|Lenvatinib|Lenvatinib is taken orally on Days 8-28 on cycle 1 and every day of cycles 2-16
224039034|NCT06253494|DEVICE|PATHWAY HER2 (4B5) assay|Used during screening to estimate eligibility
224039035|NCT02363400|DRUG|MEP|Adjuvant Chemotherapy
224039036|NCT06852820|DRUG|Lu-PSMA-617|Given IV
224070428|NCT03527121|OTHER|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
224070429|NCT01905280|PROCEDURE|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
224039037|NCT05245851|DEVICE|Opportunistic screening for low BMD|"Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician."
223428465|NCT06620822|DRUG|IBI310+Sintilimab|The principle of CTLA-4 combined with PD-1 therapy is to fully relieve the inhibition of T cells by blocking both CTLA-4 and PD-1 immune checkpoints simultaneously.CTLA-4 inhibitors mainly work in the initial immune response stage by blocking the binding of CTLA-4 to B7 and enhancing the activation and proliferation of the initial T cells; whereas PD-1 inhibitors restore the anti-tumor activity of activated T cells by blocking the binding of PD-1 to its ligand PD-L1/PD-L2 and restoring their anti-tumor activity. and its ligand PD-L1/PD-L2 binding, lifting the functional inhibition of activated T cells and restoring their anti-tumor activity. Combination therapy can fully activate T-cells, improve the immune system\&amp;#39;s ability to recognize and attack tumors, enhance the anti-tumor immune response, and overcome the drug resistance of single therapy, thus improving the therapeutic effect.
223428466|NCT06620822|DRUG|Sintilimab|Sindilizumab (Sintilimab) is a humanized anti-PD-1 monoclonal antibody that has demonstrated promising anti-tumor activity in several cancer types. It works by blocking the binding of PD-1 to its ligands, PD-L1 and PD-L2, thereby lifting the inhibition of T-cells and restoring the immune system\&#39;s killing function against tumor cells.
223428467|NCT02824536|DRUG|3BNC117|Intravenous Infusion of 3BNC117
223428468|NCT02824536|DRUG|10-1074|Intravenous Infusion of 10-1074
223428469|NCT02824536|DRUG|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
223428470|NCT04324736|OTHER|no interventional study|no interventional study
223564491|NCT06036329|DEVICE|Group A : provided with 1 Whitsundays Nasal mask without a spare mask cushion|Group A will be provided with 1 Whitsundays Nasal mask without a spare mask cushion (replacement cushions will only be provided when requested)
223564492|NCT06036329|DEVICE|Group B : provided with 1 Whitsundays Nasal mask with 2 spare mask cushions|Group B will be provided with 1 Whitsundays Nasal mask with 2 spare mask cushions
224039038|NCT06206837|DRUG|vepdegestrant|Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
224070430|NCT01905280|PROCEDURE|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
223428471|NCT06726902|DEVICE|GBT and SI with erythritol powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy~   * Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system.~  * Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with erythritol powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only."
223428472|NCT06726902|OTHER|GBT and SI with glycine powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with glycine powder.~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
223428473|NCT06726902|OTHER|GBT and SI with trehalose powder|"Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with trehalose powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only"
223564493|NCT01777555|DRUG|CVT-301|
223564494|NCT01777555|DRUG|Placebo|
223564495|NCT01068951|BIOLOGICAL|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
223564496|NCT03018470|OTHER|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
223564497|NCT01760473|DRUG|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
223564498|NCT06467669|OTHER|Wrist denervation procedure|To summarize, a Wagner incision is made starting over the junction of the glabrous and non-glabrous skin overlying the thumb CMC joint extending toward the distal wrist crease. The branches of the superficial radial nerve are identified as lying perpendicular to the plane overlying the fascia of the thenar muscles. The branches of the lateral antebrachial cutaneous nerve are identified and resected within the anatomic snuffbox deep to the first compartment. Finally, the thenar muscle fibers are divided at their proximal origin to identify the articular branches of the posterior cutaneous branch of the median nerve.
223564499|NCT00689000|DRUG|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
223564500|NCT01463111|DRUG|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
223564501|NCT01463111|DRUG|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
223564502|NCT01463111|DRUG|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
224070431|NCT02751502|DEVICE|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
224070432|NCT02984046|DRUG|Protein CC16|
224039039|NCT06206837|DRUG|PF-07220060|Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
224039040|NCT05533515|DIAGNOSTIC_TEST|CTC Blood Test|We will draw blood to measure the level of Circulating Tumour Cells
224039041|NCT03193788|DRUG|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
224039042|NCT03193788|DRUG|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
223564503|NCT01561547|BEHAVIORAL|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
223428474|NCT06726902|OTHER|SRP and SI|conventional scaling and root planning (SRP) with subgingival instrumentation only will be performed
223428475|NCT01384019|DEVICE|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
223428476|NCT01384019|PROCEDURE|c-PCI|conventional PCI without Guard wire
223428477|NCT03784118|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children
223428478|NCT03784118|DIAGNOSTIC_TEST|perfusion index|measurement of perfusion index immediately after arterial catheterization until surgery end, in arterial catheterization site and contralateral site.
223428479|NCT00766285|BIOLOGICAL|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
223428480|NCT00766285|BIOLOGICAL|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
223428481|NCT04631328|OTHER|Growing Together|Growing Together is a suite of free, online research-informed professional development modules to help early childhood educators promote deeper family engagement and enrich teacher-parent interactions.
223428482|NCT01914211|DRUG|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
223428483|NCT01914211|PROCEDURE|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If \> 5Kg draw 20% of circulating blood volume without PRBC replacement)
223428484|NCT00215371|DRUG|Formoterol Fumarate|
223428485|NCT03639805|OTHER|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
223564504|NCT01561547|DIETARY_SUPPLEMENT|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
223564505|NCT01134406|DEVICE|Hydros Joint Therapy|Single intra-articular injection.
223564506|NCT01134406|DEVICE|Hydros-TA Joint Therapy|Single intra-articular injection
224039043|NCT03193788|DRUG|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
224039044|NCT03193788|DRUG|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
223428486|NCT03639805|OTHER|standard care of vaso-occlusive crises|administration of standard care only
223428487|NCT06649474|BIOLOGICAL|assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy|assess the serum HMGB1 concentrations
223428488|NCT01695330|DRUG|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
223428489|NCT06263881|DRUG|Raphamin|Tablet for oral use.
223428490|NCT06263881|DRUG|Placebo|Tablet for oral use.
223428491|NCT03259672|DRUG|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
223428492|NCT03259672|DRUG|Desflurane|Desflurane was used as a maintenance anesthetic agent.
223428493|NCT00767039|DRUG|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
223564507|NCT01134406|DEVICE|Synvisc-One|Single intra-articular injection.
223564508|NCT03285958|BEHAVIORAL|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
223564509|NCT04376840|OTHER|Blood sample and data record|Blood sample and data record
223744801|NCT04429893|DRUG|bupivicaine|assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy
224039045|NCT03006354|DEVICE|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
224039046|NCT03006354|DEVICE|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
224039047|NCT05750537|BEHAVIORAL|EMPACT-Us|A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
224039048|NCT00132223|DRUG|Contrast agent|
224039049|NCT01019980|DRUG|Diclofenac potassium|Diclofenac potassium
224039050|NCT01019980|DRUG|Acetaminophen|Acetaminophen
224039051|NCT06119009|OTHER|non interventions|
224039052|NCT01554488|DRUG|Inhaled Fluticasone Propionate|Inhaled corticosteroid
224039053|NCT04293289|OTHER|CICS-1 (investigational device),SPM-011(investigational drug)|Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
223428494|NCT00767039|DRUG|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
223428495|NCT04502238|OTHER|Fluid restriction|Study participants will refrain from drinking fluids overnight to facilitate 1-2% fluid loss from baseline
224039054|NCT00012298|BIOLOGICAL|rituximab|Given IV
224039055|NCT00012298|BIOLOGICAL|yttrium Y 90 ibritumomab tiuxetan|Given IV
224039056|NCT00012298|BIOLOGICAL|indium In 111 ibritumomab tiuxetan|Given IV
224039057|NCT00012298|BIOLOGICAL|oprelvekin|Given subcutaneously
224039058|NCT00012298|BIOLOGICAL|filgrastim|Given subcutaneously
224039059|NCT02383589|DRUG|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
224039060|NCT02383589|DRUG|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
224039061|NCT02383589|DRUG|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
224039062|NCT02383589|DRUG|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
224039063|NCT00450905|DEVICE|PRIMA Device|
224039064|NCT02900534|OTHER|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
224039065|NCT03050151|DRUG|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
224139285|NCT00664755|DRUG|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
223428496|NCT00772122|DRUG|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
224039066|NCT03050151|DEVICE|Auto-injector Device|Delivery of Dupilumab by auto-injector device
224039067|NCT03050151|DEVICE|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
224039068|NCT06378437|DRUG|GLB-001|Administered orally according to the assigned treatment schedule
224039069|NCT03002519|BIOLOGICAL|PLX-R18|Intramuscular (IM) administration of PLX-R18
224039070|NCT04849624|OTHER|No Intervention|This is an observational study and involved no intervention
224139286|NCT00664755|DEVICE|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
224139287|NCT04094766|DRUG|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
223428497|NCT00772122|DRUG|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
224039071|NCT07129499|DRUG|Shenbai Granules|10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.
224039072|NCT07129499|DRUG|Placebo|10 g/bag, two bags each time, twice a day, monthly for 30 days for 6 months.
224139288|NCT04574921|OTHER|Light Therapy System (LTS): Active setting|Exposure for 1 hour á day for consecutive days.
224139289|NCT04574921|OTHER|Light Therapy System (LTS): Sham setting|Exposure for 1 hour á day for consecutive days.
224139290|NCT01841957|PROCEDURE|ISBCS|same-day cataract surgery
224139291|NCT01841957|PROCEDURE|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
223428498|NCT01826370|DRUG|Linagliptin|tablet
223428499|NCT01332279|DRUG|everolimus|Given PO
223428500|NCT01332279|DRUG|erlotinib hydrochloride|Given PO
223428501|NCT01332279|PROCEDURE|biopsy|Correlative studies
223428502|NCT01332279|OTHER|laboratory biomarker analysis|Correlative studies
224039073|NCT07128966|OTHER|Observation|This is non-interventional, observational only
224039074|NCT04225806|DEVICE|BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)|The BlueLeaf System is a single-use, disposable device designed to modify the vein wall to form one or more functional autogenous valves to improve the hemodynamics of the deep venous system treated.
224039075|NCT06605534|BEHAVIORAL|LungTalk|Tailored lung screening intervention
224039076|NCT06605534|OTHER|Non-tailored lung screening|Non-tailored lung screening. It involves the addition of education to Social Determinants of Health (SDOH) screening and referral with patient navigation. Patients will be identified, and screened for SDOH needs using the UniteUs SDOH screener that is embedded in the Electronic Health Record (EHR), and connected to geographically-tailored resources (as described above under Arm 1). Participants will then be sent a non-tailored lung screening educational brochure via email to review that details lung cancer risk, lung screening facts, benefits, and potential harms. Within 48 hours, the Community Outreach and Engagement (COE) Patient Navigator will contact the patient to answer questions and provide navigation services as described above in Arm 1.
224039077|NCT05553470|DRUG|Miricorilant|600 mg miricorilant
224039078|NCT06593912|PROCEDURE|Early Functional Training|Early functional training after 3 weeks using Air Stirrup compared to cast (standard protocol) after peroneal tendon surgery.
224039079|NCT06593912|PROCEDURE|Standard protocol|Cast 6 weeks after peroneal tendon surgery (standard protocol)
224039080|NCT00805038|BEHAVIORAL|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
224039081|NCT00805038|BEHAVIORAL|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
224039082|NCT06995898|PROCEDURE|Biospecimen Collection|Undergo blood collection
224039083|NCT06995898|DEVICE|Device Usage|Evaluation of MCD tests
224039084|NCT06995898|OTHER|Electronic Health Record Review|Obtain health data
224039085|NCT06995898|PROCEDURE|Multi-Cancer Detection Test|Undergo Shield MCD test
224139292|NCT00799344|DEVICE|Catania Stent|coronary stent implantation
224139293|NCT04841720|DRUG|HSK16149|HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
223428503|NCT01332279|OTHER|immunohistochemistry staining method|Correlative studies
223428504|NCT01332279|GENETIC|polyacrylamide gel electrophoresis|Correlative studies
224039086|NCT06995898|PROCEDURE|Multi-Cancer Detection Test|Undergo Avantect MCD test
224039087|NCT06995898|OTHER|Questionnaire Administration|Study specific questionnaires
224039088|NCT06997419|DRUG|Dexamethasone Palmitate|Patients in the dexamethasone palmitate group will be assigned to receive intravenous injection of dexamethasone palmitate 8 mg (contains 5mg dexamethasone) after anesthesia induction and before surgical incision.
224039089|NCT06997419|DRUG|Dexamethasone|Patients in the dexamethasone group will be assigned to receive intravenous injections of dexamethasone 5 mg after anesthesia induction and before surgical incision.
224039090|NCT05903196|DEVICE|Mygen V-1000 RF system|The Mygen V-1000, a microprocessor-based generator of RF Medical Co., Ltd., provides up to 140 watts of radio-frequency (RF) energy to be used for coagulation \& ablation of vessel, tissue \& bone
224039091|NCT06999122|DIAGNOSTIC_TEST|Brain Scan|"The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head.~The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues."
224039092|NCT05039840|DRUG|SAR441344 IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
224039093|NCT05039840|DRUG|SAR441344 SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
224039094|NCT05039840|DRUG|Placebo IV|Pharmaceutical form: solution Route of administration: Intravenous infusion
224039095|NCT05039840|DRUG|Placebo SC|Pharmaceutical form: solution Route of administration: subcutaneous injection
224039096|NCT06287502|DIETARY_SUPPLEMENT|β-hydroxy β-methylbutyrate (HMB)|Ensure NutriVigor, a nutritional supplement, was provided to subjects according to the manufacturer's recommendation of two servings per day. Each serving consists of 54.1g of powder which provides \~231kcal, 8.61g protein, 1.21 g β-hydroxy β-methylbutyrate, 130 IU vitamin D and 0.29 g omega-3 fatty acid.
224039097|NCT06287502|BEHAVIORAL|Resistance, aerobic, flexibility and balance exercise training|The exercise intervention consists of 75-minutes sessions delivered by physiotherapists at the Integrated Rehabilitation Day Centre (IRDC) in Kowloon Hospital, twice per week for 12 weeks with a total of 24 supervised sessions. Each exercise session consists of 5 minutes of warm up, 30 minutes of resistance training, 20 minutes of aerobic training, 15 minutes of balance or neuromuscular exercises and 5 minutes of cool down.
224039098|NCT06996496|OTHER|Postpartum educational tool after hypertensive pregnancy|postpartum educational tool for patients having experienced a hypertensive disorder of pregnancy
224039099|NCT06999005|PROCEDURE|Fluoride Varnish Application (Preventive Protocol)|Single application of Duraphat® fluoride varnish on permanent molars and incisors, repeated every 3 months.
224039100|NCT06999005|PROCEDURE|Fluoride Varnish for Active Enamel Lesions|Weekly fluoride varnish applications for 4 weeks, followed by quarterly maintenance applications.
224039101|NCT06999005|PROCEDURE|Atraumatic Restorative Treatment (ART) Sealant|Sealant placement with high-viscosity glass ionomer using the ART technique, with quarterly fluoride varnish.
224039102|NCT06999005|PROCEDURE|Atraumatic Restorative Treatment (ART)|Manual caries removal and cavity restoration with glass ionomer cement, followed by fluoride varnish every 3 months.
224039103|NCT04542382|DRUG|Rosuvastatin|"Rosuvastatin will be administered as follows:~Day 1: single dose of 10 mg Rosuvastatin tablet."
224039104|NCT04542382|DRUG|Rosuvastatin (Inhibitor arm)|"Rosuvastatin will be administered as follows:~Day 8: single dose of 10 mg Rosuvastatin tablet."
224039105|NCT04542382|DRUG|Eltrombopag|"Eltrombopag will be administered as follows:~Day 8: single dose of 75 mg Eltrombopag tablet."
224039106|NCT07004023|DIETARY_SUPPLEMENT|AlphaWave® L-Theanine|Study staff will provide participants with a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water.
224039107|NCT07004023|OTHER|Placebo|Study staff will provide participants with a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water.
224039108|NCT06999187|DRUG|DR-0202|DR-0202 is a bispecific antibody
224039109|NCT04536337|DRUG|ALG-000184|Single or multiple doses of ALG-000184
224039110|NCT04536337|DRUG|Placebo|Single or multiple doses of Placebo
224039111|NCT04536337|DRUG|Entecavir|multiple doses of Entecavir
224139294|NCT04841720|DRUG|Metformin Hydrochloride tablet|Metformin hydrochloride tablets for single use: D9-D11 oral metformin hydrochloride tablets 500 mg BID, D12 only take 500 mg metformin hydrochloride tablets in the morning on an empty stomach; wash-out period is about 4 days (D12-D15);
224039112|NCT05435300|OTHER|PET Scan|Participants will undergo two PET scans throughout the study.
224039113|NCT06364137|OTHER|Teleo|Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.
224039114|NCT06364137|OTHER|Standard videoconferencing|Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform
224139295|NCT04841720|DRUG|HSK16149+Metformin（phase 3）|Combined use of HSK16149 capsules and metformin hydrochloride tablets: D16-D19 oral metformin hydrochloride tablets 500 mg BID, D16-D19 oral HSK16149 80 mg BID; D20 oral metformin hydrochloride tablets 500 mg and HSK16149 capsules 80 mg in the morning on an empty stomach.
223428505|NCT01332279|OTHER|pharmacological study|Correlative studies
223428506|NCT01332279|RADIATION|external beam radiation therapy|Undergo EBRT
223428507|NCT01332279|GENETIC|microarray analysis|Correlative studies
223428508|NCT01575275|DRUG|aminolevulinic acid|Given PO
223428509|NCT01575275|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223428510|NCT04939675|DRUG|Zonisamide 100mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
224039115|NCT06102577|DIETARY_SUPPLEMENT|1gr. Vitamine C|Take 1g. of vitamin C at the end of an osteopathic manual treatment
224039116|NCT06102577|OTHER|1gr Placebo|ake 1g. of placebo at the end of an osteopathic manual treatment
224039117|NCT06102577|OTHER|control group|control
224039118|NCT00528255|DRUG|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
223428511|NCT04939675|DRUG|Levetiracetam 500mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
223428512|NCT04939675|DRUG|LamoTRIgine 50mg|Only one ASM will be used. The drug choice depends on patients tolerance and basic condition. Twice daily
223428513|NCT06622018|PROCEDURE|Seashell Nanoparticles and Gluma Desensitizer|Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times
223428514|NCT04416737|DRUG|Ultra-rapid insulin|Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.
223428515|NCT03332628|DEVICE|Microneedle patch|Each patch contains 50 microneedles.
224039119|NCT02126943|DRUG|Opsumit (macitentan)|10 mg tablets
224039120|NCT06917885|BIOLOGICAL|CUE-102|A WT-1-pHLA-IL2-Fc fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.
223428516|NCT01821209|PROCEDURE|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
223428517|NCT02851056|BIOLOGICAL|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10\^6 cells. A minimum of 1 x 10\^6 cells and a maximum of 20 x 10\^6 cells will be administered."
223428518|NCT02851056|PROCEDURE|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
223428519|NCT02851056|BIOLOGICAL|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
223428520|NCT02851056|DRUG|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
224039121|NCT06586892|BEHAVIORAL|Radiotherapy followed by chemotherapy|"Researchers would like to test the accuracy of the MRI data being used for this study. If you agree, you will have 2 additional MRI scans within 2 weeks before Visit 1.~The first 90 participants who agree will be selected to have the following scans:~* 35 participants will be scanned 2 times on one MRI device (Device #1).~* 35 participants will be scanned 2 times on another MRI device (Device #2).~* 20 participants will be scanned 1 time on both MRI devices (Device #1 and #2). If you agree and you are chosen, the study doctor will tell you if you will have scans on~  1. or 2 MRI devices."
224039122|NCT04480723|OTHER|Blood Sample|Blood samples will be taken and analyzed to evaluate the presence of PH.
224039123|NCT04480723|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI will be performed to evaluate the presence of PH.
224039124|NCT07102212|BEHAVIORAL|mHealth Intervention|Participants are randomized to the FOCUS app or Information Control section of the app and will have six weeks to complete the app. Randomization, via the app, is stratified by geographic location (rural vs other), cancer type, and demographics so experimental arms are equivalent. Participants will complete 5 assessments online over a 12-mo period. The participants will have weekly telehealth professional support during the six-week intervention. Participants wear GeneActiv watches for sleep/activity recording for 7 days and provide blood and saliva samples at baseline, 6 and 12 weeks, and 6 and 12 months.
224039125|NCT07129148|OTHER|Device: No specific devices|Routine doctor-patient interaction.
224039126|NCT07129148|OTHER|Device: CGM,CGM management platform|Wearable monitoring + CGM management platform-assisted administration
224039127|NCT07129148|OTHER|"Device: Professor Tang WeChat Mini-program"|Mini-program-assisted health management
224039128|NCT07129148|OTHER|"Device: CGM, Smart Bracelet, Professor Tang WeChat Mini-program"|Wearable monitoring + mini-program integrated management
224139296|NCT03668535|PROCEDURE|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
224139297|NCT03668535|PROCEDURE|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
223428521|NCT01472757|DRUG|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
223428522|NCT01472757|DRUG|Placebo|Placebo delivered via a new dry powder inhaler
223428523|NCT02619396|PROCEDURE|Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
223428524|NCT02619396|PROCEDURE|Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
223428525|NCT02619396|PROCEDURE|Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
223428526|NCT02619396|PROCEDURE|Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
223478275|NCT04606758|PROCEDURE|PCNL under fluoroscopic control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under fluoroscopic guidance
223428527|NCT06614296|PROCEDURE|Crenel Lateral Interbody Fusion|The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.
223428528|NCT06614296|PROCEDURE|Crenel lateral interbody fusion plus second stage surgery|The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.
223428529|NCT06253741|PROCEDURE|PARAVERTEBRAL BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes
223428530|NCT06253741|PROCEDURE|RHOMBOID INTERCOSTAL AND SUBSERRATUS PLANE BLOCK|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
223428531|NCT06253741|PROCEDURE|PLACEBO|Hemodynamic data (mean arterial pressure, heart rate, oxygen saturation) will be recorded for all patients every 30 minutes during the intraoperative period, along with the amount of opioids used throughout the surgery. A patient-controlled analgesia device (PCA) will be connected to each patient 15 minutes before awakening, prepared with a 1mg/ml morphine solution, with a bolus dose of 2 ml and a lockout period of 15 minutes.
224039129|NCT07128680|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224039130|NCT07128680|PROCEDURE|Bone Scan|Undergo bone scan
224039131|NCT07128680|PROCEDURE|Computed Tomography|Undergo CT
224039132|NCT07128680|DIETARY_SUPPLEMENT|Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01|Given PO
224039133|NCT07128680|BIOLOGICAL|Ipilimumab|Given IV
224039134|NCT07128680|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224139298|NCT02271867|PROCEDURE|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
223428532|NCT01751581|BEHAVIORAL|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
223428533|NCT01751581|BEHAVIORAL|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
223428534|NCT04489381|DRUG|Nitazoxanide|Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
224039135|NCT07128680|BIOLOGICAL|Nivolumab|Given IV
224039136|NCT07130903|DRUG|Fruquintinib|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class
224039137|NCT07130903|DEVICE|TheraBionic P1|TheraBionic P1 is a amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device
224039138|NCT07128979|DRUG|Neoven 225 mg capsules|Patients in this group will only use Neoven 225 mg capsules orally. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. A total of 378 mg of total ruscogenin (ruscogenin/neoruscogenin mixture obtained by extraction method) will be taken orally using one Neoven capsule orally with meals twice a day. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.
224039139|NCT07128979|DRUG|Placebo|Patients in this group will only receive an oral placebo capsule designed for this study. There will be no signs or inscriptions on the capsules regarding their contents. The duration of the study is determined as 42 days. During this period, one placebo capsule will be taken orally twice a day with meals. A total of 84 capsules will be given to the patients, and their use will be questioned by phone on the 7th and 14th days of the treatment and the number of uses will be checked at the end of the treatment. Failure to use all of the capsules will be considered as a criterion for exclusion from the study.
224070433|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.
224139299|NCT01926847|DRUG|Riociguat (Adempas, BAY63-2521)|
223428535|NCT04489381|DRUG|Placebo|Two placebo tablets administered orally twice daily with food for 5 days
224070434|NCT00737659|DRUG|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
224139300|NCT01926847|DRUG|Placebo|
224139301|NCT01115075|OTHER|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
224139302|NCT01115075|BEHAVIORAL|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
224139303|NCT02943018|OTHER|anovaginal distance variation|Kappa calculation
224139304|NCT01309867|DEVICE|Investigational Toric Lens|Bausch \& Lomb investigational toric contact lens worn on a daily wear basis for 2 weeks.
223428536|NCT04489381|DIETARY_SUPPLEMENT|Vitamin Super B-Complex|Vitamin Super B-Complex administered orally twice daily to maintain the blind
223428537|NCT05143008|BEHAVIORAL|SMART Intervention|Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
223478276|NCT04606758|PROCEDURE|PCNL under ultrasound control|Patients receive standard of care treatment for their urolithiasis using standard PCNL under US guidance
224039140|NCT07130006|PROCEDURE|PENG and LFCN peripheral nerve blocks with spinal anesthesia|"At first, one needs to detect hyperechogenic iliopsoas notch and psoas tendon, between anterior inferior iliac spine and iliopubic eminence. Then needle needs to be inserted in-plane and 20mL of levobupivacaine 0.25% administered along the fascial plane. Additionally, after identification of sartorius muscle, 5mL of levobupivacaine 0.5% need to be administered in a space between sartorius and tensor fascia latae muscles where lateral femoral cutaneous nerve can be identified as a hyperechoic structure. Single shot needle, with bevel up, will be visible all the time, in plane technique will be used. The spread of the local anesthetic will appear hypoechoic on ultrasound. Curvilinear probe will be used.~For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle."
224039141|NCT07130006|PROCEDURE|FN and LFCN peripheral nerve blocks with spinal anesthesia|"At first, one needs to detect both femoral artery and vein medial to it. Then needle needs to be inserted in-plane and 15mL of levobupivacaine 0.5% need to be administered underneath fascia iliaca, lateral to femoral nerve. Additionally, after identification of sartorius muscle, 5mL of levobupivacaine 0.5% need to be administered in a space between sartorius and tensor fascia latae muscles, where lateral femoral cutaneous nerve can be identified as a hyperechoic structure. Single shot needle, with bevel up, will be visible all the time, in plane technique will be used. The spread of the local anesthetic will appear hypoechoic on ultrasound. Linear probe will be used.~For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle."
224039142|NCT07130006|PROCEDURE|FIC peripheral nerve block with spinal anesthesia|Suprainguinal approach will be performed. At first, one needs to detect anterior inferior iliac spine, sartorius and internal oblique muscles creating a bow-tie. Deep circumflex iliac artery will be seen between transversus abdominis and iliacus muscle. Then needle needs to be inserted in-plane and 40mL of levobupivacaine 0.25% administered along the fascial plane so that fascia separates from iliacus muscle. The needle is inserted from caudal to cranial, to achieve the widest possible spread of local anesthetic under the fascia, to the cranial side, as this reaches both lateral femoral cutaneous nerve and femoral nerve. The spread of anesthetic will appear hypoechoic on ultrasound. For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle.
224039143|NCT07130006|PROCEDURE|Fentanyl (IV) with spinal anesthesia|A total dose of 2 mcg/kg of fentanyl will be given to patients before positioning to spinal. For spinal anesthesia levobupivacaine will be placed in the subarachnoid space at lumbar vertebrae 3/4 level using 25 G spinal needle.
224039144|NCT07128836|OTHER|proprioceptive training exercise and receive insole vibrator|The treatment for the participants in the experimental group includes; 5 minutes warm up, 30 minutes proprioceptive training exercise, 20 minutes walk with in-sole vibrator, 5 minutes cool down. The duration of each session will be 60 minutes. All the participants will receive 36 sessions (3 times per week over 12 week's period).
224039145|NCT07128836|OTHER|proprioceptive training exercise along with simple insoles without vibration|The treatment for the participants in the control group includes; 5 minutes warm up, 30 minutes proprioceptive training exercise, 20 minutes walk with non-vibrating insole, 5 minutes cool down. The duration of each session will be 60 minutes. All the participants will receive 36 sessions (3 times per week over 12 week's period).
224139305|NCT01309867|DEVICE|PureVision Toric Lens|Currently marked Bausch \& Lomb PureVision Toric Lens worn on a daily wear basis for 2 weeks.
224139306|NCT04731623|DRUG|ION904|ION904 will be administered by SC injection.
224139307|NCT04731623|DRUG|Placebo|Placebo (0.9% sterile saline) will be administered by SC injection.
224139308|NCT00943488|BIOLOGICAL|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
224139309|NCT03915912|BEHAVIORAL|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
224139310|NCT06317922|DEVICE|Thealoz Duo;|THEALOZ DUO is a solution containing trehalose (3%), sodium hyaluronate (0.15%), sodium chloride, trometamol, hydrochloric acid, and water for injections; Hydraback is a solution containing a sodium chloride 0.9 %, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, water for preparations for injection.
224139311|NCT06317922|DEVICE|sham (Hydrabak)|Hydrabak is an ophthalmic solution containing: sodium chloride 0.9%, sodium dihydrogen phosphate dihydrate, sodium phosphate dodecahydrate, and water for injectable preparations
224139312|NCT01560442|DRUG|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
224139313|NCT04668092|OTHER|Functional dry needling|functional dry needling applied to hamstring for 1 minute and post interventional data collected
224139314|NCT00712933|DRUG|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
224139315|NCT06335498|DEVICE|ECG co-measurement|Measure ECG with 12 lead device at same time that AFGen1 is monitoring ECG
224139316|NCT06335498|DEVICE|Periodic ECG triggered measurement|Subject triggers AFGen1 to perform an extended measurement during wear period
224139317|NCT06168370|RADIATION|CT guided strategy|"1. With signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI are switched from SAPT to apixaban. Patients fulfilling the dose reduction criteria according to the drug label, or with a Clinical Frailty Scale ≥4 will receive 2.5mg bid, patients not meeting these criteria will receive a standard dose of 5mg bid.~2. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI, without another indication for antiplatelet therapy stop their SAPT.~3. Without signs of subclinical valve thrombosis on 4D-CT at 3 months after TAVI with another indication for antiplatelet therapy continue life-long SAPT."
224139318|NCT00047307|DRUG|alvocidib|Given IV
224139319|NCT00047307|DRUG|gemcitabine hydrochloride|Given IV
224139320|NCT00047307|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
224139321|NCT00047307|OTHER|laboratory biomarker analysis|Correlative studies
223428538|NCT02833935|BEHAVIORAL|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
223428539|NCT03768024|DRUG|GRT0151Y 50 mg capsule|GRT0151Y 50 mg capsule
223428540|NCT03768024|DRUG|Hydromorphone IR 4 mg|Hydromorphone IR 4 mg tablet (encapsulated)
224039146|NCT07008209|BEHAVIORAL|Reconstrual Strategy Training|"Participants receive training in the reconstrual strategy, which involves recognizing and reinterpreting initial negative appraisals of emotionally challenging situations. The training guides participants to:~Identify the situation and their initial negative interpretation.~Generate alternative, balanced explanations that reduce negative emotional impact.~The goal is to help participants view events from a different, realistic perspective to decrease negative emotions by modifying how they interpret situations."
224299395|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+virtual reality+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.frequency:Stimulation perform for 30 minutes per day for 4 weeks .~duration 600 pulses (intratrain pulse) frequency =20 Hz ; Pulse duration =0.3ms ,lasting 30 seconds each time ,stimulating once every 5 minutes"
223428541|NCT03768024|DRUG|Matching placebo|Matching placebo
223428542|NCT03157739|BEHAVIORAL|MigraineManager: Individualized Self-Management Tool|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
223428543|NCT01194635|GENETIC|fluorescence in situ hybridization|
223428544|NCT01194635|GENETIC|gene expression analysis|
223428545|NCT01194635|GENETIC|polymerase chain reaction|
223428546|NCT01194635|GENETIC|protein analysis|
223428547|NCT01194635|GENETIC|protein expression analysis|
223428548|NCT01194635|OTHER|enzyme-linked immunosorbent assay|
223740214|NCT07207018|BEHAVIORAL|non-specific psychological support therapy|non-specific psychological support therapy, focused on the child rather than the family, and aimed at supporting the child and strengthening their daily adaptation. This support therapy is already integrated into the standard practice of the CRPOCC, but will be conducted by psychotherapists from the Montpellier University Hospital who are not trained in CFTSI, to ensure a consistent format that facilitates comparisons between the two groups. The number of sessions may be increased to a total of eight sessions if the clinician determines that additional aspects need to be addressed during the sessions.
224039147|NCT07008209|BEHAVIORAL|Repurposing Strategy Training|"Participants receive training in the repurposing strategy, which involves adjusting or replacing personal goals to better align with the current situation. The training guides participants to:~Identify the situation and the original goal that was not met.~Develop alternative, realistic goals or modify existing ones to reduce the emotional impact of unmet expectations.~This approach helps participants manage negative emotions by creating meaningful, adaptable goals that fit the reality of the situation."
224039148|NCT07008209|BEHAVIORAL|Active Control|Participants are asked to carefully copy a neutral descriptive passage without making any changes, focusing solely on transcription accuracy. This task serves as an active control by engaging participants in a cognitive task that requires attention and effort, but does not involve emotion regulation strategies. The task controls for the effects of engagement and time spent on a task without influencing participants' emotional processing.
224039149|NCT07003321|DRUG|HRS-4508 tablet|HRS-4508 tablet
224039150|NCT07007533|DRUG|DA-5223-R|once a day
224039151|NCT07007533|DRUG|DA-5223|once a day
224039152|NCT07129863|DIETARY_SUPPLEMENT|Placebo: Mouth rinse with plain water|Placebo: Mouth rinse with plain water, containing no caffeine, serving as the control condition.
224039153|NCT07129863|DIETARY_SUPPLEMENT|Experimental: Low mouth rinse caffeine concentration (1%)|Arm Description: Low caffeine concentration: Mouth rinse containing 1% caffeine solution (based on weight/volume).
224039154|NCT07129863|DIETARY_SUPPLEMENT|Moderate caffeine concentration (2% caffeine solution weight/volume).|Moderate caffeine concentration: Mouth rinse containing 2% caffeine solution (weight/volume).
224039155|NCT07129863|DIETARY_SUPPLEMENT|High caffeine concentration (3% caffeine solution weight/volume).|High caffeine concentration: Mouth rinse containing 3% caffeine solution (weight/volume).
223428549|NCT01194635|OTHER|immunohistochemistry staining method|
223428550|NCT01194635|OTHER|laboratory biomarker analysis|
223428551|NCT02266290|PROCEDURE|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
223428552|NCT02266290|DEVICE|Sport tex® kinesiotape|
223428553|NCT02266290|DEVICE|Pretape Cramer®|
223428554|NCT04444128|DIAGNOSTIC_TEST|Cardiac Imaging|Subjects undergo CMR study with contrast agent (gadobutrol 0.1 mmol/kg; mapping, volumes, function, strain and LGE); transthoracic echocardiography and blood testing.
223428555|NCT01094652|DIETARY_SUPPLEMENT|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
223428556|NCT01094652|DIETARY_SUPPLEMENT|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
223428557|NCT02961062|DRUG|SAF312|
223428558|NCT02961062|DRUG|Placebo|
223428559|NCT03861871|DRUG|Fenfluramine Hydrochloride|Oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 2.5 mg/mL. Manufactured by Andersonbrecon, Inc. on behalf of Zogenix International Limited.
223428560|NCT03567512|BEHAVIORAL|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
223428561|NCT03567512|BEHAVIORAL|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes)."
223428562|NCT01590732|DRUG|Carboplatin|Given IV
223740215|NCT07206823|DRUG|Romiplostim N01|"Romiplostim N01 will be administered via subcutaneous injection once weekly for a total treatment duration of 12 weeks. The starting dose is set at 3 μg/kg. Weekly dose adjustments will be guided by platelet counts measured immediately prior to administration, as follows:~For a platelet count below 50 × 10⁹/L, the dose will be increased by 1 μg/kg.~For a platelet count between 50 and 200 × 10⁹/L, the current dose will be maintained as the minimum therapeutic dose for bleeding risk reduction.~For a platelet count between 200 and 400 × 10⁹/L, the dose will be decreased by 1 μg/kg.~For a platelet count exceeding 400 × 10⁹/L, the administration will be withheld. It is stipulated that dosing will resume at a reduction of 1 μg/kg from the previous dose once the platelet count returns to 200 × 10⁹/L or below.~Under no circumstances shall the dose exceed the maximum allowable limit of 10 μg/kg per week."
224139322|NCT03494426|PROCEDURE|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~1. antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~2. oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~3. the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
224139323|NCT03494426|DRUG|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
224139324|NCT03934710|DRUG|Placebo|Drug will be administered in solution form
224139325|NCT03934710|DRUG|Serotonin agonist - 13ug|13ug lysergic acid diethylamide
224139326|NCT03934710|DRUG|Serotonin agonist - 26ug|26ug lysergic acid diethylamide
223428563|NCT01590732|DRUG|Etoposide|Given IV
223740216|NCT07206823|DRUG|Rituximab|Rituximab will be administered in accordance with the Chinese guidelines for the diagnosis and management of adult primary immune thrombocytopenia (2020 edition). The dosage will be 375 mg/m² per infusion, administered via intravenous infusion once weekly for a total of four weeks.
223740217|NCT07204964|BIOLOGICAL|Flu mRNA (Formulation B1)|One dose of Flu mRNA (Formulation B1) received intramuscularly.
223740218|NCT07204964|BIOLOGICAL|Flu mRNA (Formulation B3)|One dose of Flu mRNA (Formulation B3) received intramuscularly.
223428564|NCT01590732|DRUG|Ifosfamide|Given IV
223428565|NCT01590732|DRUG|Romidepsin|Given IV
223428566|NCT02951039|DRUG|Edoxaban|Prescribed according to approved label
223740219|NCT07204964|BIOLOGICAL|Flu mRNA(Formulation A)|One dose of Flu mRNA (Formulation A) received intramuscularly.
223740220|NCT07204964|COMBINATION_PRODUCT|Comparator 1|One dose of Comparator 1 received intramuscularly.
223740221|NCT07204964|COMBINATION_PRODUCT|Comparator 2|One dose of Comparator 2 received intramuscularly.
223740222|NCT07204964|COMBINATION_PRODUCT|Comparator 3|One dose of Comparator 3 received intramuscularly.
223740223|NCT07206368|OTHER|Fall prevention exercise|Participants will attend a virtual exercise-based group fall prevention class that focuses on movement and obstacle negotiation 3 times per week for 3 months.
223740224|NCT07206368|OTHER|Health promotion education|Participants will attend a virtual group health promotion education class that focuses on reasons to maintain a healthy lifestyle and local resources to support them in this. The sessions will take place 1 time per week for 3 months.
223740225|NCT07205913|OTHER|25 ml blood sample|A 25-ml blood sample
223740226|NCT07205913|OTHER|Urine sample|A 10-ml urine sample
223740227|NCT07205913|OTHER|Stools|10-g stools
223740228|NCT07205913|OTHER|40 ml blood sample|A 40-ml blood sample
223740229|NCT07206199|BEHAVIORAL|exposure therapy in virtual reality|Participants complete five 30-40-minute sessions of exposure therapy administered via a virtual reality headset once a week. The exposure involves exposure to various symptom-provoking scenarios in the virtual house environment. Scenarios can be adjusted to distinct OCD dimensions: contamination/cleaning, fear-of-harm/checking symmetry/ordering, and also to symptoms of hoarding. Stimuli can be also freely combined across different dimensions, so that the scenarios fit the individual needs.
223740230|NCT07206199|OTHER|Wait list|The patients are assigned to a waitlist period for 5 weeks. During this period they are not allowed to change any treatment (phramacotherapy and/or psychoterapy as usual) started prior to the trial.
223740231|NCT07205705|DIETARY_SUPPLEMENT|Millet|Wheat + Barnyard millet/ Wheat +Barley/ wheat+ Bengal gram flour
223740232|NCT07206134|PROCEDURE|Modified Omega bone plate for fixation of mandibular fractures in mental foramen region|Reflection of vestibular flap without dissection around mental bundle and fracture reduction and fixation with 3D Modified Omega bone plate
223428567|NCT01866267|DRUG|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
223428568|NCT05563402|DEVICE|Atalante|Atalante Gait training: Using the Atalante System (self-reliant walking system), participants will be secured with the appropriate sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5 minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute).
223428569|NCT04305106|DRUG|Bevacizumab|Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
223428570|NCT04305106|OTHER|Placebo|Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
223428571|NCT04305106|OTHER|Standard care|Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
223428572|NCT01734252|DRUG|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
223428573|NCT03449394|OTHER|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
223428574|NCT04940520|BIOLOGICAL|Drug recommended by the Brazilian Society of Dermatology|Using a drug recommended by the Brazilian Society of Dermatology, twice a day.
223428575|NCT04940520|COMBINATION_PRODUCT|Alpha bisabolol product and laser|Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.
223428576|NCT04940520|BIOLOGICAL|Alpha bisabolol product|Using alpha bisabolol-based product twice a day
223428577|NCT04636294|DIAGNOSTIC_TEST|SARS-CoV-2 PCR|SARS-CoV-2 PCR of nasopharyngeal lysate.
223428578|NCT00392522|DRUG|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
223428579|NCT02604355|OTHER|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
223428580|NCT02604355|DRUG|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
223428581|NCT00008775|DEVICE|Pressure support ventilation|
223428582|NCT01259375|DRUG|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
223428583|NCT03334318|OTHER|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223428584|NCT03334318|OTHER|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223428585|NCT03334318|OTHER|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223428586|NCT03334318|OTHER|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223428587|NCT03334318|OTHER|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223428588|NCT03334318|OTHER|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223740233|NCT07206134|PROCEDURE|Conventional miniplates for fixation of mandibular fractures|Reflection of vestibular flap with dissection around mental bundle and fracture reduction and fixation with 2 miniplates
224139327|NCT06015412|DIAGNOSTIC_TEST|Radiographic classification|disease stages ranged from 1 to 4 according to the Kellgren-Lawrence radiographic classification system
223428589|NCT03334318|OTHER|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223428590|NCT03334318|OTHER|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223744802|NCT03192592|OTHER|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
223428591|NCT03334318|OTHER|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
223744803|NCT00463749|DRUG|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
224139328|NCT01758965|OTHER|PPI|monotherapy of PPI
224139329|NCT01758965|OTHER|H2RA and surgicel|combination therapy of H2RA and surgicel
223428592|NCT03334318|DRUG|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
223428593|NCT03334318|DRUG|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
223428594|NCT03124121|DRUG|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
223428595|NCT02311556|DEVICE|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
223428596|NCT01330056|PROCEDURE|FOPS|"* Functional organ preservation (FOPS) as a first-line treatment modality~* Postoperative RT or CRT may be included for the patients of this group."
223428597|NCT01330056|RADIATION|CRT|"* Concurrent chemoradiotherapy as a first-line treatment modality~* Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
223428598|NCT05009407|BIOLOGICAL|Immunohistochemistry and clinical analyses on patients and corneas|Immunohistochemistry and clinical analyses on patients and corneas
223428599|NCT02999724|DRUG|Gabapentin|Gabapentin 300-600 mg 1 hour preop
223428600|NCT02999724|OTHER|placebo|placebo capsule(s) 1 hour preop
223428601|NCT02470819|GENETIC|Genetic profiling|genetic profiling
223428602|NCT02832141|PROCEDURE|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
224039156|NCT07130305|OTHER|whole body vibration plus usual care|Familial mediterranean fever (20 FMF adolescent girls ) will be in this vibration group who will receive vitamin D and their traditional colchicine doses daily for six months. vibration group will also receive three sessions of 20-min whole body vibration in the week for 6 months
223428603|NCT02832141|PROCEDURE|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
223428604|NCT04808232|BEHAVIORAL|progressive muscle relaxation exercise|"We used the muscle relaxation audio CD produced by the Turkish Psychologists Association. The CD consists of three parts; the 10-min first part includes definition and purpose of relaxation, and points to take into consideration during relaxation, the 30-min second part includes instructions with river sounds, and the 30-min third part includes only relaxing music without instructions. We used the second part of the audio record in this study. Following the instructions on the CD, the students tensed each muscle group from hands to feet, and then, all muscles in their face and body for approximately 10 s. The women breathed in, tensed a specific muscle group, and then relaxed it while breathing out. The relaxation step took 10-20 s before tensing the next muscle group. Thus, the women relaxed by tensing and relaxing the muscle groups in hands, arms, neck, shoulder, chest, stomach, hips, foot and fingers, and all muscles in the face and body."
223428605|NCT05827575|DEVICE|Transcutaneous Auricular Vagal Nerve Stimulation|stimulation on both ear within different area for 4 weeks；parameter：2s on，3s off,0.5ms，25hz
223428606|NCT05280899|OTHER|Weight-bearing As Tolerated|The WBAT group will be instructed to bear weight as tolerated immediately following their surgical procedure. The rehabilitation protocols provided will be identical beyond the initial weightbearing recommendations. Following the initial protection phase (three weeks), whereby the two weightbearing interventions will be provided, patients will progress through standardized phases including mobility and neuromuscular retraining, muscle balance and strengthening, functional training, and finally, advanced training for return to work and sport.
223428607|NCT05280899|OTHER|Partial Weight-bearing|"The PWB group will be instructed to bear weight to a maximum of 20 lbs of bodyweight on the operative limb for the initial three weeks (termed toe touch), with graduated return to full weightbearing thereafter."
223428608|NCT00478699|DRUG|Docetaxel/Cisplatin control|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
223428609|NCT00478699|DRUG|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
223428610|NCT00478699|DRUG|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
223428611|NCT00478699|DRUG|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
223428612|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
223428613|NCT01075906|DRUG|colchicine sprinkle capsules|0.3 mg
223428614|NCT00508937|OTHER|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
223428615|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
223428616|NCT00508937|OTHER|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
223428617|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
224039157|NCT07130305|OTHER|usual care|Familial mediterranean fever (20 FMF adolescent girls ) will be in this control group who will receive vitamin D and their traditional colchicine doses daily for six months.
224039158|NCT07129551|PROCEDURE|preop virtual 3D model|Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively
224039159|NCT07129551|PROCEDURE|postop 3D model|Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated
224039160|NCT07130851|PROCEDURE|vestibular schwannoma resection|Vestibular schwannoma resection leads to partial or combined acute unilateral peripheral or combined vestibular lesion.The organism responds with the process of central vestibular compensation.
224039161|NCT07130578|DIAGNOSTIC_TEST|urine tumor DNA/RNA testing|The test analyzes DNA and RNA fragments shed by urothelial carcinoma cells into urine, detecting tumor-specific genetic and epigenetic alterations.
224039162|NCT05462951|RADIATION|Standard|Radiation then brachytherapy
224039163|NCT06868628|DRUG|Foralumab Nasal|Foralumab is an anti-CD3 monoclonal antibody administered as a nasal spray. Participants will complete eight 3-week dosing cycles over the study. During each cycle, Foralumab will be administered intranasally three times per week for the first two weeks, with no administration in the third week.
224039164|NCT06868433|BIOLOGICAL|Autologous Tumor Membrane Vesicles Vaccine|Given intradermally
224039165|NCT06868433|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224039166|NCT06868433|PROCEDURE|Computed Tomography|Undergo CT
224039167|NCT06868433|PROCEDURE|Echocardiography|Undergo echocardiography
224039168|NCT06868433|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224039169|NCT06868433|BIOLOGICAL|Pembrolizumab|Given IV
224039170|NCT06868433|PROCEDURE|Positron Emission Tomography|Undergo PET
224039171|NCT06868433|PROCEDURE|Surgical Procedure|Provide tissue from standard of care surgery
224039172|NCT06870383|DRUG|Erector spinae plane block|The block will be done under ultrasound guidance using 20 ml bupivacaine 0.25% that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose.
224039173|NCT06870383|DRUG|Combined Pecto-intercostal and recto-intercostal fascial plane block|The blocks will be done under ultrasound guidance using 10-15 ml of 0.25% bupivacaine that will be injected for each side ensuring not to exceed the maximal 2 mg/kg bupivacaine dose..
224039174|NCT07010965|DEVICE|NyokAssist™|The NyokAssist™ Ventricular Assist Device can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta .
223428618|NCT00508937|OTHER|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
223428619|NCT04060199|DRUG|Viltolarsen|IV infusion
223428620|NCT04060199|DRUG|Placebo|IV infusion
223428621|NCT00914706|OTHER|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
223428622|NCT01005888|BIOLOGICAL|C1 esterase inhibitor [human] (C1INH-nf)|
223428623|NCT01005888|DRUG|Placebo (saline)|
223428624|NCT00044707|DRUG|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
223428625|NCT04993599|DEVICE|Social robot interaction|The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
223428626|NCT02371564|DEVICE|High flow humidified oxygen|
223428627|NCT02371564|DEVICE|Standard flow humidified oxygen|
223428628|NCT04850573|OTHER|equine assisted activities|Participants interact with the horse and learn how to safely handle the horse.
223428629|NCT04115410|DRUG|PD-1 inhibitor|PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
223428630|NCT04115410|DRUG|Chemotherapy Drugs, Cancer|Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
223428631|NCT03669718|BIOLOGICAL|ISA101b|Every 3 weeks for a total of 3 times
223428632|NCT03669718|DRUG|Cemiplimab|Every 3 weeks for up to 24 months
224039175|NCT07010965|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide coronary flow
224039176|NCT06624462|OTHER|Treatment in the Meta Care Clinic|"* Consultations by medical doctors with specific metabolic training from the metabolic clinic located at Centre for Addiction and Mental Health in Toronto, Canada, and an exercise physiologist.~* Evaluation of their psychopharmacotherapy with consultation and detailed recommendations to the patients' treating psychiatrist and/or general practitioner regarding dosage reductions or switching of psychotropics if this is clinically feasible to reduce the metabolic burden.~* Lifestyle interventions~* Pharmacotherapy with evidence to support use to mitigate antipsychotic-induced weight gain~* Treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and diabetes in close collaboration with recognized specialists in endocrinology.~* Assessment of plans at conferences with participation of the sponsor, the primary investigator as well as recognized specialists in endocrinology and psychiatry.~* Qualitative interviews will be conducted post-intervention."
223428633|NCT03669718|OTHER|Placebo|Every 3 weeks for a total of 3 times
223428634|NCT00669019|DRUG|saracatinib|
223428635|NCT02947906|OTHER|No intervention|No intervention
223428636|NCT05921149|DIETARY_SUPPLEMENT|Fasting Mimicking Diet (Xentigen by L'Nutra)|L-Nutra Xentigen is a product which will provide all the food to be consumed by subjects during 3 days prior to chemotherapy and for 24 hours after chemotherapy. Xentigen is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients that are generally regarded as safe (GRAS) and comprises proprietary vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. The FMD consists of a 4-day regimen that provides approximately 1100 kilocalories for the first day and approximately 500 kilocalories per day for the second to the fourth day. Subsequently, a day 5 of transition diet (approximately 800 kilocalories) is provided to avoid the refeeding syndrome.
223428637|NCT05921149|DRUG|Carboplatin|Given IV
223428638|NCT05921149|DRUG|Paclitaxel|Given IV
223428639|NCT05921149|DIETARY_SUPPLEMENT|Standard diet|Normal diet
223428640|NCT06027307|DRUG|Enavogliflozin|All study patients will receive enavogliflozin in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
223428641|NCT06027307|DRUG|Placebo|All study patients will receive placebo in addition to their prior medications. They will receive optimal medical treatment for their underlying disease such as hypertension, diabetes, arrhythmia and/or coronary artery disease.
223428642|NCT05166720|BEHAVIORAL|NIDCAP care|NIDCAP care was performed according to the best evidence of NIDCAP
223428643|NCT02846870|OTHER|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
223428644|NCT02846870|OTHER|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
223428645|NCT05109637|DEVICE|Konectom NMD Application|Administered as specified in the treatment arm.
224070435|NCT03064737|OTHER|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use."
224070436|NCT02678390|DIETARY_SUPPLEMENT|MCT|A 5 day consecutive MCT intake of 30 g/day.
224070437|NCT02678390|DIETARY_SUPPLEMENT|MCT+ aerobic exercise|A 5 day consecutive MCT intake of 30 g/day in combinaison with 30 minutes of aerobic exercise (70% to 80% HRR) per day for the five days.
223428646|NCT04855214|OTHER|Qualitative Analysis|Mixed methods analysis of the user's experience with upper limb prosthetics.
223428647|NCT01629290|DEVICE|Enamel Pro|Varnish treatment containing 5% NaF
223428648|NCT01629290|DEVICE|Duraphat|Varnish treatment containing 5% NaF
223428649|NCT01629290|DEVICE|Vanish|Varnish treatment containing 5% NaF
223428650|NCT01629290|DEVICE|Placebo|Bland varnish containing no NaF
223428651|NCT03783403|DRUG|CC-95251|Specified dose on specified days
224070438|NCT02678390|DIETARY_SUPPLEMENT|Aerobic exercise|A single period of 30 minutes of aerobic exercise (70% to 80% HRR).
224070439|NCT02678390|DIETARY_SUPPLEMENT|Control day|No MCT or aerobic exercise
223428652|NCT03783403|DRUG|Rituximab|Specified dose on specified days
223428653|NCT03783403|DRUG|Cetuximab|Specified dose on specified days
223428654|NCT02538887|DEVICE|Radio Frequency Surgical Detection|
223428655|NCT02047656|DRUG|LFF269|LFF269 capsules twice daily (b.i.d)
223428656|NCT02047656|DRUG|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
223428657|NCT01123941|BIOLOGICAL|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
223428658|NCT01123941|BIOLOGICAL|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
223428659|NCT01463592|BIOLOGICAL|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
223428660|NCT01463592|DRUG|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
223428661|NCT01463592|BIOLOGICAL|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
223428662|NCT03841968|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
223428663|NCT03841968|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
223428664|NCT03337581|DRUG|Dexmedetomidine|see arms
223428665|NCT06012955|DEVICE|Target-controlled infusion (TCI) systems|Target-controlled infusion (TCI) with propofol and remifentanil was used for anesthesia induction and maintenance
223428666|NCT04601103|DRUG|No SLS toothpaste|Toothpaste no Sodium Lauryl Sulfate
223428667|NCT04601103|DRUG|Medium SLS toothpaste|Less than or equal to X ppm Sodium Lauryl Sulfate
223428668|NCT04601103|DRUG|High SLS toothpaste|More than or equal to X ppm Sodium Lauryl Sulfate
223428669|NCT04601103|DEVICE|Anti-plaque|Rinse prevents bacterial adherence to teeth
223428670|NCT01044511|BEHAVIORAL|Home visits|home visits by specialist nurse 2 times and 1 phonecall
223428671|NCT01044511|BEHAVIORAL|standard|hotline
223428672|NCT05497388|OTHER|Serious Game|using Serious Game for HCV education
223428673|NCT05960448|OTHER|Transcutaneous Spinal Cord Stimulation (TSCS)|This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.
223428674|NCT05960448|OTHER|Sham Transcutaneous Spinal Cord Stimulation|This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
223428675|NCT03147859|BIOLOGICAL|Vedolizumab (brand name Entyvio)|IV infusion
223428676|NCT06011161|BEHAVIORAL|Brief Relationship Checkup (BRC)|"The investigators are using the three 30-minute session protocol developed for Air Force Primary Care (Cigrang et al., 2016). Although it is simply referred to as the Marriage Checkup in that manuscript, the investigators use the name BRC to distinguish it from many other versions of Dr. James Cordova's Marriage Checkup (Cordova, 2014) adapted for different settings. Sessions in this version are briefer than other versions (30 mins vs. 60-90 mins) and this trial does not have any eligibility restrictions based on marital status."
223428677|NCT01454154|DRUG|Glyburide|Administered as specified in the Treatment Arm.
223428678|NCT01454154|DRUG|Placebo|Administered as specified in the Treatment Arm.
223744804|NCT00463749|DRUG|Placebo|NaCl as placebo
223428679|NCT04368039|DEVICE|Normobaric Oxygen|40% FiO2 for 4 weeks
223428680|NCT04368039|DEVICE|Placebo|21% FiO2 for 4 weeks
223428681|NCT06666894|OTHER|Intermittent fasting|subjects consumed 100 % of their energy needs in an 8-h period of time each day, with their caloric intake divided into three meals consumed at 1 p.m., 4 p.m., and 8 p.m. The remaining 16 h per 24-h period made up the fasting period. Subjects in the ND group consumed 100 % of their energy needs divided into three meals consumed at 8 a.m., 1 p.m., and 8 p.m. all patients will be subjected to 30 minutes mild aerobic exercise on treadmill.
223428682|NCT06666894|OTHER|Dietary approach to stop hypertension (DASH)|The USDA's 2015-2020 Dietary Guidelines for Americans recommend a healthy eating pattern, including a variety of vegetables, fruits, whole grains, fat-free dairy, protein, and oils. Limit saturated fats, trans fats, added sugars, and sodium to less than 10% daily calories, 10% saturated fat daily calories, and 2,300 mg sodium per day.
223428683|NCT05230004|DEVICE|iFIT prosthesis|An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.
223428684|NCT04755413|OTHER|Medical/Behavioral therapy|"* Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~* Overweight/Obese: Advise calorie reduction, dietician consultation.~* Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~* High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~  b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~  d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of \<55mg/dl in diabetes~* Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~* Diabetes management: HbA1c goal 6.5%"
223428685|NCT04755413|OTHER|Standard of Care|Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.
223428686|NCT04755413|OTHER|Registry|Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
223428687|NCT03489018|BIOLOGICAL|PCV10|Experimental arms will receive a lower dose of the intervention than the marketed dose.
223428688|NCT03489018|BIOLOGICAL|PCV13|Experimental arms will receive a lower dose of the intervention than the marketed dose.
223428689|NCT03099213|DRUG|RAMIPRIL HOE498|Pharmaceutical form:Tablet Route of administration: Oral
223744805|NCT01788670|DIETARY_SUPPLEMENT|Ethanol|
223744806|NCT01788670|OTHER|Water|
224070440|NCT02300701|DRUG|Xolair|According to manufacturer's instructions
224070441|NCT02300701|DRUG|Placebo|Placebo
224070442|NCT06548984|OTHER|diaphragmatic exercises|Perform controlled and supervised diaphragmatic exercises
224070443|NCT06548984|OTHER|Respiratory muscle training|Perform respiratory muscle training with controlled and supervised devices
223428690|NCT02349919|DRUG|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
223428691|NCT02349919|DRUG|Placebo|Placebo twice daily for 4 weeks
223428692|NCT01802736|BEHAVIORAL|Motivational intervention counselling plus SPP|
223428693|NCT06604143|BEHAVIORAL|Quality Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training focuses on specific aspects of finger movement, and participants will receive feedback related to their playing. They will wear a wrist brace for support, and their hand and arm positions will be monitored to ensure proper technique.
223428694|NCT06604143|BEHAVIORAL|Goal Training|Participants will engage in piano playing tasks using their affected hand and fingers. The training emphasizes learning to play and producing music. Feedback will be provided on various aspects of performance such as speed and accuracy, but specific details about finger movement or technique will not be given. The use of a wrist brace and monitoring of hand and arm positions will be consistent with standard practice.
223428695|NCT00381043|DRUG|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
223428696|NCT04197102|DRUG|CBD Isolate|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD isolate oil will be taken once daily for 8 weeks for participants randomized to the CBD Isolate arm.
224039177|NCT06624462|OTHER|Standard care with general practitioner and/or outpatient clinics|"Following measurements after 12 months, patients will receive individualized lifestyle recommendations from an exercise physiologist and a MD will offer to send recommendations regarding the following potential post-trial interventions to the patient's general practitioner and/or outpatient clinic prepared in close collaboration with recognized specialists in psychiatry and endocrinology:~* Suggestions regarding relevant psychotropic medication adjustments or switches if this is found relevant and clinically feasible to reduce the metabolic burden.~* Suggestions regarding potential add-on of weight reducing pharmacotherapy.~* Suggestions regarding pharmacological treatment of other cardiovascular risk factors such as dyslipidaemia, hypertension, smoking and type 2 diabetes."
223428697|NCT04197102|OTHER|CBD Broad Spectrum|A fixed dose of 300-mg of a hemp-derived formulation of purified 99.9% CBD Broad Spectrum oil will be taken once daily for 8 weeks for participants randomized to the CBD - Broad Spectrum arm.
223428698|NCT04197102|OTHER|Placebo oil|Placebo solution will be taken once daily for 8 weeks by participants randomized to the placebo arm.
223428699|NCT05625945|BEHAVIORAL|Physical activity monitoring|Physical activity patterns will be measured using the activPAL3 micro monitor
223428700|NCT06442098|BEHAVIORAL|CAMP SMART Literacy Summer Camp|Multimodal approach to reading intervention
223428701|NCT04065451|DRUG|Epinephrine|Epinephrine in the submucosal injection fluid
223428702|NCT02704520|DIAGNOSTIC_TEST|High resolution MRI scan|MRI reporting of tumour but not mrTRG in the control arm = standard of care
223428703|NCT02704520|DIAGNOSTIC_TEST|mrTRG assessment|Watch and wait offered for good responders Consider further treatment for poor responders
223428704|NCT02688998|DEVICE|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
223744807|NCT02391155|PROCEDURE|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
223744808|NCT02391155|PROCEDURE|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
224139330|NCT03696706|RADIATION|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
224139331|NCT03696706|RADIATION|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
224139332|NCT00259441|DRUG|Simvastatin|
224139333|NCT00947752|DRUG|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
224139334|NCT00947752|DRUG|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
223428705|NCT06126835|DRUG|Ozanimod|Women with UC exposed to ozanimod during pregnancy
223428706|NCT06126835|DRUG|Conventional therapy|Women with UC exposed to conventional therapy (aminosalicylates, azathioprine, or mercaptopurine) during pregnancy
223428707|NCT06126835|DRUG|Advanced therapy|Women with UC exposed to advanced therapy (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib, cyclosporine, or tacrolimus) during pregnancy
223428708|NCT01457586|BIOLOGICAL|Blood transfusion|Blood transfusion in perioperative period.
223428709|NCT01457586|BIOLOGICAL|No blood transfusion|No transfusion in the perioperative period.
223428710|NCT01978470|DEVICE|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
223428711|NCT00536549|DEVICE|Guardian RT|
223428712|NCT00536549|BEHAVIORAL|Education about the self monitoring blood glucose|
223428713|NCT02585817|DEVICE|Remote CIED Management|Information Technology
223428714|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
223428715|NCT03045276|BEHAVIORAL|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
223428716|NCT04278651|DRUG|Ferumoxytol|510mg infusion x 2 doses 3-8 days apart
224039178|NCT02408861|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224039179|NCT02408861|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224039180|NCT02408861|PROCEDURE|Computed Tomography|Undergo CT scan
224039181|NCT02408861|BIOLOGICAL|Ipilimumab|Given IV
224039182|NCT02408861|BIOLOGICAL|Nivolumab|Given IV
224039183|NCT02408861|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224039184|NCT06173661|DRUG|Fremanezumab|The intervention will be active medication.
224039185|NCT06173661|OTHER|Placebo|The intervention will be placebo injection.
224039186|NCT06685185|DRUG|NNC0363-1063|NNC0363-1063 will be administered subcutaneously.
224039187|NCT06685185|DRUG|Placebo|Placebo will be administered subcutaneously.
224039188|NCT06685185|DRUG|Insulin degludec|Insulin degludec will be administered subcutaneously.
224039189|NCT06685185|DRUG|Insulin detemir|Insulin detemir will be administered subcutaneously.
224039190|NCT07012031|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224139335|NCT04973410|DIAGNOSTIC_TEST|Coronary Physiology|Invasive coronary physiology measurements during diagnostic CAG with thermodilution method with the CoroFlow® (Coroventis, Uppsala, Sweden)
224039191|NCT07012031|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224039192|NCT07012031|PROCEDURE|Computed Tomography|Undergo CT
224039193|NCT07012031|PROCEDURE|Echocardiography Test|Undergo ECHO
224039194|NCT07012031|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224039195|NCT07012031|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224039196|NCT07012031|DRUG|Sotorasib|Given PO
224039197|NCT07012031|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
224039198|NCT07019558|OTHER|Neurological assessment|Collect retrospective and current clinical data and assess motor impairment
224139336|NCT04973410|DIAGNOSTIC_TEST|15O-H2O-PET scan|Myocardial blood flow (MBF) measured with oxygen-15 (O-15) labelled water used as a tracer molecule with positron emission tomography (PET)
223428717|NCT04278651|DRUG|Ferrous Sulfate|325mg oral twice daily
223744809|NCT05688189|DEVICE|different starting temperature setting of HFNC|The humidification temperature will be set based on the enrollment arm (37°C vs 34-37°C vs 31-34-37°C)
223744810|NCT05662566|PROCEDURE|Epidural replacement|"Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter"
223744811|NCT00778011|DRUG|Ondansetron|dosage
223744812|NCT00778011|DRUG|Ondansetron|4 mg
223744813|NCT00778011|DRUG|Metoclopramide|10 mg IV
224039199|NCT07019558|DIAGNOSTIC_TEST|Ophthalmological assessment|Ophthalmological assessment of possible optic nerve or retinal damage.
224039200|NCT07020026|DRUG|[18F]PI-2620|All participants will undergo PET imaging using the \[18F\]PI-2620 tau-binding tracer.
224039201|NCT07020806|DRUG|[68Ga]Ga DOTA-5G|Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection.
224039202|NCT07019961|DEVICE|the GMA-TULIP laryngeal mask|insert GMA-TULIP laryngeal masks after anesthesia induction
224039203|NCT07019961|DEVICE|the i-gel laryngeal mask|insert i-gel laryngeal masks after anesthesia induction
224039204|NCT07021105|PROCEDURE|ESP Plane block|Group E (n=20): Bilateral erector spinae plane (ESP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) at the T12 level, approximately 3-4 cm laterally from the midline, in the neurofascial plane between the transverse processes and the erector spinae muscle.
224039205|NCT07021105|PROCEDURE|QLB plane block|Group Q (n=20): Bilateral quadratus lumborum block (QLB) will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side), placed between the psoas major and quadratus lumborum muscles under US guidance, between the iliac crest and the 12th rib.
224039206|NCT07021105|PROCEDURE|TAP Block|Group T (n=20): Bilateral transversus abdominis plane (TAP) block will be performed with 40 ml of 0.25% bupivacaine (20 ml on each side) in the neurofascial plane between the internal oblique and transversus abdominis muscles.
224039207|NCT07021105|OTHER|No intervention|Group C (Control group, n=20): No block will be applied, only the standard intravenous patient-controlled analgesia (PCA) protocol will be used.
224039208|NCT07018908|DIETARY_SUPPLEMENT|supplementation with 5 g dehydrated nopal powder from highly mature cladodes|Group I received 5 g of dehydrated Opuntia ficus-indica cladodes plus the standard normocaloric diet for dyslipidemia.
224039209|NCT07018908|DIETARY_SUPPLEMENT|supplementation with 15 g dehydrated nopal powder from highly mature cladodes|Group II received 15 g plus the diet, and Group III followed only the diet.
224039210|NCT07018908|OTHER|Control Group (only diet)|No dehydrated nopal or placebo. Diet: 30 g of fiber per day Normocaloric diet Carbohydrates 55%, Lipids 25% and Proteins 20%
224039211|NCT07014670|OTHER|Validation and Reability study|Validation and Reability study
224039212|NCT07020533|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224039213|NCT07020533|OTHER|Electronic Health Record Review|Ancillary studies
224039214|NCT07020533|PROCEDURE|Haploidentical Hematopoietic Cell Transplantation|Undergo HCT
224039215|NCT07020533|DRUG|Letermovir|Given IV or PO
224039216|NCT07020533|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
224039217|NCT07020533|PROCEDURE|Myeloablative Conditioning|Receive myeloablative conditioning
224039218|NCT07020533|PROCEDURE|Pheresis|Undergo apheresis
224039219|NCT07020533|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Given G-CSF
224039220|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
224039221|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
224039222|NCT07019779|BIOLOGICAL|CM518D1|CM518D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.
224039223|NCT03716739|DRUG|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
224039224|NCT03716739|DRUG|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
224139337|NCT04154696|PROCEDURE|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
224039225|NCT06690424|DRUG|Remimazolam|remimazolam 0.2mg / kg was injected IV during the induction of anesthesia，and remimazolam 0.3-0.5mg / kg / h was administered IV during anesthesia maintenance.
224039226|NCT06690424|DRUG|Propofol|Propofol 1.5-2mg / kg was injected IV during the induction of anesthesia，and Propofol 2-3mg / kg / h was administered IV during anesthesia maintenance.
223428718|NCT01597375|DRUG|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
223428719|NCT01597375|DRUG|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh \>60kg or 5 mg by mouth daily if they weigh \<60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
223428720|NCT01549561|BEHAVIORAL|Parent Training|16 weeks of parent training led by a trained group facilitator
223428721|NCT01549561|BEHAVIORAL|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
223428722|NCT05062824|BEHAVIORAL|Baby Feed|Baby Feed web portals can (1) Quickly and easily evaluate infant diet using a validated Infant Food Frequency Questionnaire (infant FFQ) developed by our group14. \[Parental FFQ portal\]; (2) Provide automatic results to healthcare professionals on nutrients and foods/beverages consumed above or below the recommended levels to discuss with parents for improving the infant's diet. Also, to provide recommendations for amounts of foods/beverages that the infant should be consuming by age \[Clinician Portal\]; (3) Give online access to parents to these diet recommendations to implement at home, with an easy tracking component \[Parent's Portal\].
223428723|NCT04611737|BEHAVIORAL|Interviewing|Self-Determination Theory within motivational interviewing
223428724|NCT01258062|DRUG|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
223428725|NCT01258062|DRUG|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
223428726|NCT04819503|DRUG|Spinal anaesthesia (sub-study 1)|We will conduct two sub-studies on the same patient group. Sub-study 1 is an observational study where patients with phantom and/or residual limb pain after lower limb amputation will be given spinal anaesthesia with 1% Chloroprocaine in an open label manner to investigate whether the peripheral nervous system is a necessary driver of their pain.
223428727|NCT04819503|DEVICE|Repetitive transcranial magnetic stimulation (sub-study 2)|After sub-study 1, the same patients will enter sub-study 2 where they are randomly assigned to receive either first active rTMS (10 days over 2 weeks), and then after a 9 week washout period, sham rTMS (10 days over 2 weeks), or they first receive sham rTMS, and then after 9 weeks of washout, active rTMS. Thus, patients undergo stimulation with deep rTMS in a double blinded randomised controlled trial with a 2 x 2 cross-over design, receiving both active and placebo stimulation
223564510|NCT03831906|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra (Ultra)|"The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available."
223428728|NCT06328816|BEHAVIORAL|routine rehabilitation treatment|The routine rehabilitation treatment included intervention for risk factors (such as blood pressure, blood lipids, and blood glucose control, restriction of smoking and alcohol, exercise, etc.) Besides, the patients with stable vital signs were scheduled for specialized rehabilitation training upon enrollment, and targeted rehabilitation programs were selected, conducted by experienced rehabilitation therapists.
223428729|NCT06328816|BEHAVIORAL|Computer-assisted Cognitive Function Training|Based on the patient's cognitive impairment assessment results, the training content includes Attention game training, Executive function program training, Logical reasoning training, Agility training, Memory training. The training is conducted seven days a week, once a day, for a duration of 30-45 minutes per session
223428730|NCT02235051|BEHAVIORAL|exercise intervention|Undergo Curves exercise program
224039227|NCT06698744|BIOLOGICAL|UF-KURE-BCMA CAR T-cells|"Experimental anti-BCMA CAR T-cells manufactured with a proprietary ultrafast process. Patients will receive a single dose of CAR T-cells at one of three potential doses:~* Dose -1: 3x10\^6 cells~* Dose 1: 10x10\^6 cells~* Dose 2: 15x10\^6 cells"
224039228|NCT06698744|DRUG|Cyclophosphamide|Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m\^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
224039229|NCT06698744|DRUG|Fludarabine|Patients will receive 3 days of IV fludarabine 30 mg/m2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.
224039230|NCT07024979|BEHAVIORAL|Music Therapy Songwriting Intervention|The music therapy songwriting intervention is an active, client-centered music therapy approach in which the participant collaboratively create an original song with a professional music therapist. This evidence-based method combines: 1) lyric writing: the participant can express personal experience/emotions through guided lyric creation; 2) musical composition: the participant will choose or improvise their favorite melody, harmony, and rhythm with a music therapist; 3) therapeutic processing: discussion of song meaning and emotional connections between the participant and music therapist.
223564511|NCT04599270|OTHER|PREVENTURE Program|Adolescents will be follow PREVENTURE program (2 session of 90 min).
223564512|NCT04599270|OTHER|Routine care|Adolescents will be follow routine care
223564513|NCT03615872|DEVICE|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
223744814|NCT01768481|DRUG|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
223744815|NCT01768481|DRUG|sugar pill|placebo controlled arm receives similarly looking placebo.
224070444|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate|iron (100 mg) supplement in form of ferrous fumarate
224139338|NCT02418533|DRUG|menotropin|Menopur is used for controlled ovarian stimulation (COH)
224039231|NCT04528693|BEHAVIORAL|Circuit training (combination of strength and endurance exercises)|The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
223428731|NCT02235051|OTHER|laboratory biomarker analysis|Correlative studies
223428732|NCT02235051|OTHER|questionnaire administration|Ancillary studies
223428733|NCT02235051|OTHER|quality-of-life assessment|Ancillary studies
223428734|NCT04159428|DIAGNOSTIC_TEST|HHIE-S survey score|"First, the patient will fill in the French translation of the HHIE-S questionnaire in the observation book.~* Secondly, he will perform the audiometry in silence test: for the tonal test in silence, we will test the frequencies 500, 1000, 2000 and 4000 hertz in each ear with pure tone sound. For the vocal in silence test, we will use the dissyllabic lists of words (Fournier's lists) at the intensities of 20, 30, 40, 50 and 60 decibels. This test will be in free-field conditions testing both ears.~* Thirdly, he will perform the speech in noise audiometry test that consists in repeating sentences pronounced at an equal intensity (60 decibels) while the intensity of the noise is increasing. This test will be in free-field conditions testing both ears."
223428735|NCT02118142|DIETARY_SUPPLEMENT|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
223428736|NCT02118142|DIETARY_SUPPLEMENT|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
223428737|NCT02226705|PROCEDURE|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
223428738|NCT00002038|DRUG|Fluconazole|
223428739|NCT00582504|BIOLOGICAL|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
223428740|NCT03178240|BEHAVIORAL|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
223428741|NCT00624195|DRUG|FDA Approved Antiretroviral Therapy (see list below)|"Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
223428742|NCT01040195|DRUG|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
223428743|NCT01040195|DRUG|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
223428744|NCT06368895|PROCEDURE|Fecal microbiota transplantation delivery through colonoscopy|Patients will receive 4 L of macrogol and salts solution the afternoon before FMT and remain fasting the night before the scheduled treatment. During colonoscopy, about 350 mL of donor fecal preparation will be infused in the cecum.
223428745|NCT06368895|DRUG|Fecal microbiota transplantation delivery through oral capsules|Intestinal gastro-resistant capsules (capacity 0.91 mL, overall 10\^8-9 bacteria per capsule) will be filled with the fecal slurry. From each donation weighing 100 g, it is expected to obtain 150 cps, which will be promptly frozen and stored at -80°C. At each monthly visit, the patient will receive 60 capsules, to be stored at -20°C at home. Capsules will be administered orally at the dose of 1 cps twice a day from month 1 post-colonoscopy to patients in the FMT group 1 (colonoscopy plus capsules), and from day 1 to patients in the FMT group 2 (capsules only).
223428746|NCT06622447|DIETARY_SUPPLEMENT|βGluCnCs intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into βGluCnCs intervention (N=40).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
223428747|NCT06622447|DIETARY_SUPPLEMENT|Placebo intervention|"The intervention trial consisted of a prospective, randomized, two parallel arms, double-blinded, single-center study with 16-week of duration.~Individuals were subjected to a 2 weeks run-in period. Following this, the population was randomly allocated into placebo intervention (N=20).~During the intervention period, study participants received βGluCnCs product daily for a total of 12 weeks."
223428748|NCT01567345|DEVICE|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
223428749|NCT01567345|DEVICE|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
223428750|NCT01576445|PROCEDURE|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
223428751|NCT01576445|PROCEDURE|medial parapatellar approach|medial parapatellar approach
223428752|NCT00602498|DRUG|Clarithromycin|
223428753|NCT05498103|DRUG|Methazolamide 25 MG|25 mg tablets
223740234|NCT07206459|OTHER|Healthy Patients|"RESEARCH DESIGN AND METHODS This will be a physiological observational study~Study design. Participants will breathe on CPAP with a ventilator. The investigators will deliver the PNS at PEEP levels of zero cmH2O (baseline EELV), zero cmH2O + an abdominal binder (to reduce lung volume), five cmH2O and ten cmH2O. The abdominal binder will be used to achieve an EELV lower than at baseline. At the end of the protocol another PNS at zero cmH2O (baseline EELV) will be performed. Healthy participants will be exposed to the different levels of PEEP from 2 to 5 minutes before each PNS is performed.~At every PEEP level, relative changes in EELV (∆z) will be measured with Electrical Impedance Tomography (EIT) to record relative changes in EELV and the electrical activity of the costal diaphragm will be measured using surface electromyography"
224039232|NCT05869513|DIETARY_SUPPLEMENT|Vegetable oil|Mixed vegetable oil
224039233|NCT05869513|DIETARY_SUPPLEMENT|Krill oil|Superba Krill Oil
223428754|NCT05498103|DRUG|Methazolamide 50 MG|50 mg tablets
223428755|NCT04697420|PROCEDURE|Thoracic paravertebral block|Thoracic paravertebral block is a technique in which , the local anesthetic agent is injected in the paravertebral space to anesthetise the spinal nerves after emerging from the vertebral canal in order to provide analgesia in the thoracic and upper abdominal area .
224039234|NCT05869513|OTHER|Home-based resistance exercise|Home based resistance band and body weight exercise
224070445|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g GOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
223428756|NCT04697420|PROCEDURE|Transversus abdominis plane block|Transversus abdominis plane block is a technique is mostly done under ultrasound guidance to identify the transversus plane between the internal oblique muscle and the transverses abdominis muscle , the space in which the neurovascular supply of the anterior abdominal wall is present , and hence the injection of local anesthetic agent in this space results in anesthesia of the anterolateral aspect of the abdominal wall.
224070446|NCT04194255|DIETARY_SUPPLEMENT|ferrous fumarate + 15 g FOS|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g FOS)
223428757|NCT00161642|DRUG|CMD-193|
223478277|NCT04913831|DRUG|Cerebrolysin|Cerebrolysin 20ml + physiological saline 80ml, 8-35 days, once/day, intravenous administration
223478278|NCT04913831|DRUG|Placebo|physiological saline 100ml, 8-35 days, once/day, intravenous administration
223478279|NCT05689359|DRUG|Hydroxychloroquine|Hydroxychloroquine will be administered at 600 mg po BID for 3 days prior to starting chemotherapy, continued during the course of chemotherapy, and for 7 days after chemotherapy.
223478280|NCT02832778|DRUG|Efavirenz|Efavirenz 400mg
223478281|NCT02832778|DRUG|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
223478282|NCT02832778|DRUG|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
223478283|NCT02832778|DRUG|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
223478284|NCT02832778|DRUG|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if \<50kg.)
223478285|NCT04328987|PROCEDURE|cold snare polypectomy|Resection of colorectal polyp using cold snare polypectomy method. The polyp will be resected by mechanical force of snare without electrical cautery.
223478286|NCT02023827|BEHAVIORAL|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
223478287|NCT01683461|BEHAVIORAL|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
223478288|NCT01683461|BEHAVIORAL|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
223478289|NCT03434483|PROCEDURE|Assessment of the atherosclerotic plaque in a moderate lession.|"In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function."
223478290|NCT03434483|GENETIC|Gene variants in atherosclerosis|From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
223478291|NCT03434483|OTHER|Microbiota analysis|From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
223478292|NCT03434483|OTHER|Immunological analysis|A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
223478293|NCT03434483|OTHER|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
223478294|NCT01537172|DRUG|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
223478295|NCT01537172|DRUG|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
223478296|NCT00584389|DRUG|rimonabant|20mg/d (oral) once daily for 12 weeks
223478297|NCT00584389|BEHAVIORAL|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
223478298|NCT00313872|DRUG|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre \& Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre \& post hydration (if Mg \<WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
224039235|NCT07031245|BEHAVIORAL|Evidence-based quality improvement (EBQI)|Evidence-based quality improvement (EBQI) is a multi-level implementation strategy that aids in the development and implementation of evidence-based interventions to reduce burnout. Preliminary survey, interview, and systematic review data on burnout, turnover intent, burnout drivers, and burnout interventions will be presented to an expert panel for each intervention site. These panels will collectively decide on the top categories of burnout drivers to target and burnout interventions to implement. These top drivers and intervention categories will be presented to site-level providers and staff and proposals will be solicited for quality improvement (QI) interventions to reduce burnout that reflect these categories and address these drivers. The expert panels will then choose one or more of these QI interventions to implement and evaluate at each intervention site.
224039236|NCT06690710|BIOLOGICAL|allogeneic engineered Gingival Fibroblasts (aeGF)|single intra-articular injection of the study drug (aeGF) in the knee joint
223428758|NCT00744549|DIETARY_SUPPLEMENT|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
223428759|NCT00744549|DRUG|Placebo|Twice a day with meals.
223740235|NCT07206459|OTHER|Critically Care Patients|"RESEARCH DESIGN AND METHODS This will be a physiological observational study~Study design. For patients. The investigators will perform PNS at the patients own mode of ventilation at their clinical level of PEEP (baseline EELV), PEEP of zero cmH2O (if acceptable for 5 minutes), clinical PEEP ± 2 - 4 cmH2O. At the end of the protocol, another stimulation at the clinical level of PEEP (baseline EELV) will be performed. Patients will be exposed to the different levels of PEEP from 2 to 5 minutes before each PNS is performed."
224039237|NCT06687395|OTHER|Skill training on different models|Skill training on different models (medium/high fidelity vs. self-made model)
224039238|NCT06711718|OTHER|Qualitative interview (patients)|Qualitative interviews to be carried out by an experienced researcher with patients who have had their diabetes diagnosis reviewed as a result of the running of the tool.
224039239|NCT06711718|OTHER|Qualitative interview (staff)|Qualitative interviews to be carried out by an experienced researcher with practice staff who have run the tool and reviewed patients flagged by the tool.
224039240|NCT06712823|DRUG|atumelnant (CRN04894)|Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) receptor antagonist.
223428760|NCT01508052|DEVICE|sequential compression device|applying sequential compression device during the surgery
223428761|NCT01508052|DEVICE|elastic stockings|applying elastic stockings during the surgery
224039241|NCT06714357|DRUG|irinotecan|Administered at the dosage of 180 mg/m2 over 60 minutes
224039242|NCT06714357|DRUG|panitumumab|Administered as 60 minutes, or 90 minutes for doses over 1000 mg, intravenous infusion at the dosage of 6 mg/kg
224039243|NCT06714357|DRUG|Valproic Acid (VPA)|"VPA will be administered in each patient with a titration strategy to improve the compliance for the treatment, looking for a target serum level between 50 and 100 μg/mL that represents the recommended values for the treatment of epilepsy and also a useful concentration to produce the desired synergistic effect with chemotherapy based on preclinical studies.~Administrated at the dosage of 500 mg/three times a day (after 7 days of gradual dose escalation)."
224039244|NCT07031531|COMBINATION_PRODUCT|AI-Enabled Stratified Management System|After discharge, participants install SMART-CHD, sync their EHR data, and complete a 10-minute orientation. They then use the app's OCR-assisted surveys to report lifestyle, lab, and event data, while paired wearables stream continuous vitals. AI voice calls and a CRC-managed WeChat group deliver reminders and support. The app's embedded predictive models stratify them into risk tiers and generate tier-specific follow-up schedules. Personalized lifestyle modification guidance, dietary plans, and medication adjustment recommendations are generated by the platform's module. Automated alerts and teleconsultation options are triggered upon detection of high-risk signs or abnormal results, ensuring timely clinical intervention and enhanced secondary prevention.
224039245|NCT07031531|COMBINATION_PRODUCT|Usual Post-Discharge Care|Usual discharge protocol comprising verbal and printed discharge instructions addressing medication schedules, follow-up timelines, and lifestyle optimization strategies.
224039246|NCT05884242|DRUG|Adalimumab|Adalimumab will be administered subcutaneously.
224039247|NCT05884242|DRUG|Lipopolysaccharide (LPS)|LPS will be administered intravenously.
224039248|NCT07037004|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224039249|NCT07037004|DRUG|Clostridium butyricum CBM588 Strain|Given PO
224039250|NCT07037004|PROCEDURE|Computed Tomography|Undergo CT
224039251|NCT07037004|BIOLOGICAL|Pembrolizumab|Given IV
224039252|NCT07035730|DEVICE|Unilateral hip exoskeleton|Unilateral hip exoskeleton assisted gait training. Gait training will consist of overground walking with the exoskeleton SHAJA for 30-40 minutes.
223428762|NCT05989074|DEVICE|ALLEGRA TAVI System TF|Patients receive ALLEGRA TAVI System TF. Patient will receive medication according to routine practice of the hospital
223428763|NCT05989074|DEVICE|Ballon-expandable valve system|Patients receive any kind of CE-marked balloon expandable valve system, used at the hospital. Patient will receive medication according to routine practice of the hospital.
223428764|NCT03839290|PROCEDURE|Early neonatal cheiloplasty|
223428765|NCT03992573|PROCEDURE|CGF application|CGF application into post-operative soft tissue and bone defects
223428766|NCT03781258|DRUG|Warfarin|Anti-thrombotic monotherapy (ASA)-Warfarin withdrawal.
223428767|NCT05104801|DRUG|sitravatinib|sitravatinib 100mg QD PO
223428768|NCT05104801|DRUG|tislelizumab|tislelizumab 200mg Q3W IV
223428769|NCT04713592|DRUG|Placebo for Risankizumab|Subcutaneous (SC) Injection
223428770|NCT04713592|DRUG|Risankizumab|Subcutaneous (SC) Injection
223428771|NCT03098498|PROCEDURE|Subgingival Debridement|Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
223428772|NCT02225366|BIOLOGICAL|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
223428773|NCT02225366|OTHER|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
223428774|NCT02835651|DIETARY_SUPPLEMENT|Palmitic acid|Experimental products are enriched with C16:0
223428775|NCT02835651|DIETARY_SUPPLEMENT|Stearic acid|Experimental products are enriched with C18:0
224039253|NCT07035730|BEHAVIORAL|Conventional gait training|Conventional gait training will consist of overground walking without the exoskeleton SHAJA for 30-40 minutes.
224039254|NCT07039422|BIOLOGICAL|Ianalumab|Concentrate for solution for infusion for intravenous use
224039255|NCT06884332|RADIATION|Sparing irradiation|"For Sparing irradiation arm the Clinical Target Volume (CTV) = Growth Tumor Volume (GTV) + entire vertebra opposite."
224039256|NCT06884332|RADIATION|Conventional spinal irradiation|"For conventional spinal irradiation arm, Clinical Target Volume (CTV ) = Growth Tumor Volume (GTV) + entire vertebra opposite + 1 vertebra above and below."
223428776|NCT00321880|PROCEDURE|therapeutic touch|administration of healing touch in 30 minute sessions
223428777|NCT06376565|OTHER|Best Practice|Receive standard care
223428778|NCT06376565|OTHER|Communication Intervention|Complete clinic EHR interventions
223428779|NCT06376565|OTHER|Communication Intervention|Receive scheduling reminders
223428780|NCT06376565|OTHER|Communication Intervention|Receive reminders and pending EHR orders
223428781|NCT06376565|OTHER|Interview|Complete interview
223428782|NCT06376565|OTHER|Interview|Ancillary studies
223740236|NCT07205016|BEHAVIORAL|Dual task exercise|The intervention group will conduct the same multicomponent intervention than the control group, but adding the dual cognitive task while performing the therapeutic physical activity, which may include counting numbers backwards, in 2s, mentioning names of animals, food, countries and others. The objective of this additional condition is to stimulate cognitive and functional capacity simultaneously, increasing the complexity of the activity and the transfer to daily life activities.
224039257|NCT07037966|DEVICE|MRI|Standard 3T MRI Scan
224039258|NCT07037966|DEVICE|MRI|Low-field MRI scan using the NextMRI prototype
224039259|NCT04732273|OTHER|Physical examination, diagnostic tests, laboratory tests|Physical examination, diagnostic tests depending on examined organ system (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels).
224039260|NCT04732273|OTHER|Personal history, questionnaire|Personal history and focused questionnaires per organ system including symptoms, medication use, physical activity, and general wellbeing.
224039261|NCT06883500|BEHAVIORAL|Energy diary|A prospective observational study is conducted at two German rehabilitation centers in a co-design approach with repeated feedback loops (expert consensus, patient interviews). Daily energy-changes will be analyzed and validated using the Multidimensional Fatigue Inventory-20 (MFI-20).
224039262|NCT06725420|OTHER|Ultrasound-guided local Injection|Ultrasound-Guided steroid injection and splinting in patients with carpal tunnel syndrome
224039263|NCT06725420|OTHER|Intramuscular Steroid Injection|Intramuscular gluteal steroid injection and Splinting in Patients With Carpal Tunnel Syndrome
224039264|NCT06725420|DEVICE|Splinting|wrist night splint
224039265|NCT07042295|DRUG|Amivantamab and Recombinant Human Hyaluronidase|Given SC
224039266|NCT07042295|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224039267|NCT07042295|BIOLOGICAL|Cetuximab|Given IV
224039268|NCT07042295|PROCEDURE|Computed Tomography|Undergo CT scan
224039269|NCT07042295|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224039270|NCT07045766|DIETARY_SUPPLEMENT|FibreGum chewing gum|Chewing gum containing galactooligosaccharides (GOS), delivering a total daily dose of 3 g of dietary fiber.
223428783|NCT06202664|PROCEDURE|Erector Spinae Block|Erector Spinae block under ultrasound guidance will be administered bilaterally at T6 level. The block will be administered after induction of general anesthesia with 1mg of IV Midazolam, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. After induction patient will be placed in lateral position and then under ultrasound guidance Erector Spinae Block will be administered at T6 level. Drugs administered in the block will include 30ml of 0.25% Bupivacaine and 10ml of 1% Lignocaine (bilaterally). Skin incision for trocar insertion will be given 15 mins after administration of Erector Spinae Block.
223428784|NCT06202664|DRUG|Opioid Analgesic|This group of patient will receive general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium. 1g of IV paracetamol and 30 mg of IV Ketorolac will be given if intra-operative course suggest inadequate analgesia (Rise in Heart rate ± Blood Pressure by more than 20% from baseline).
223428785|NCT01310634|BEHAVIORAL|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
223428786|NCT05050734|BEHAVIORAL|Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)|Behavioral treatment for persistent tic disorders.
223428787|NCT03277053|DEVICE|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
223428788|NCT03277053|OTHER|Control.|Patient receive an ipad with no application.
223478299|NCT00313872|DRUG|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
223478300|NCT04650737|DRUG|single shot ESBP with dexmedtomidine|Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
223478301|NCT04650737|DRUG|continous ESPB|Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
223478302|NCT03321721|PROCEDURE|Suture for wound repair|Repair of wound with suture
223478303|NCT03321721|DEVICE|Suture for wound repair|Repair of wound with suture
224039271|NCT06716502|DEVICE|Portable CPAP efficacy|The device will be tested in providing a PEEP comprised between 4-7,5 cmH2O
224039272|NCT06716502|DEVICE|Portable CPAP usability assessment|The device usability will be evaluated in individual's self-experience tests, i.e., in conditions where the volunteer will self-apply the device.
224039273|NCT06925789|DRUG|Ropivacaine|The nerve block is performed when the patients are admitted to the hospital with diagnosed hip fractures. And another nerve block with catheter is performed for post-operative pain control in geriatric population with 0.25% Ropivacaine 30mls.
223428789|NCT05709353|BEHAVIORAL|Prolonged exposure therapy|"COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure.~COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist."
224039274|NCT07044596|DEVICE|Functional near-infrared spectroscopy (fNIRS)|fNIRS is a non-invasive imaging technique which takes advantage of the light scattering and absorption differences between oxygenated (HbO) and de-oxygenated hemoglobin (HbDO) to characterize changes in cerebral hemodynamics in response to a given task or stimulus.
224039275|NCT07044596|DEVICE|V1 stimulation electrodes|The V1 electrodes will be placed on the forehead with some gel and held in place with a headband or cap (a conductive adhesive gel may be placed under the electrodes to help with stimulation). Participants will receive short electrical stimulations through these electrodes that will differ in intensity.
224039276|NCT07044596|DEVICE|Magnetic Resonance Imaging (MRI)|Participants will undergo 2 90-minute MRI sessions
224039277|NCT07045935|DRUG|Cabergoline (Dopamine Agonist)|Cabergoline is available in tablet form, with doses of 0.5 mg per tablet. The standard dosing for hyperprolactinemia typically starts at 0.25 mg to 0.5 mg per week, which can be gradually increased based on the patient's response, with a usual range of 0.25 mg to 2 mg per week. The dose required to achieve the target prolactin levels (pre- defined for each intervention arm) may vary between patients, so a fixed dose is not specified. This allows for individualized treatment based on each patient's response.
224039278|NCT06632847|OTHER|IMT based Resistance training|IMT with device group is trained twice daily, with the morning session and afternoon session. The intensity will increase progressively in this group, starting at 60% Maximal Inspiratory Pressure (MIP) and reaching 75% by the end of study. POSITION: Patient will be in sitting position. FREQUENCY: 4 TO 5 times per week. INTENSITY: 60 to 75% of MIP (gradually increment the load by 10%every 2 weeks to reach 75 to 80 %MIP). Time: 15 to 20 minutes.
224039279|NCT06632847|OTHER|Theraband Resistive training|IMT training is form of exercise designed to strengthen the muscle that are involve in inhalation, primarily the diaphragm and intercostal muscles. Thera-band resistive training perform twice daily, with morning and afternoon session. Training will be perform 3 times per week. POSITION: patient will be in standing position. INTENSITY: moderate intensity (black and green thera-band used to provide medium resistance). Time: 15 to 20 minutes
223428790|NCT05709353|DRUG|MDMA|Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose.
223428791|NCT05709353|DRUG|Niacin|Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions.
223428792|NCT01292694|DRUG|Losartan|Oral, single-dose, 50 mg tablet
223428793|NCT01292694|DRUG|Captopril|Oral, single-dose, 50 mg tablet
223428794|NCT01292694|DRUG|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
224039280|NCT06716814|DRUG|Efanesoctocog alfa|Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
224039281|NCT06732323|DRUG|ESG401|IV infusion on day 1,8, and 15 of each 28 day cycle
224039282|NCT06732323|DRUG|Investigator's Choice Chemotherapy|Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
224039283|NCT07049926|DRUG|Belzutifan|Oral Tablet
224139339|NCT02418533|DRUG|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
223428795|NCT06618482|PROCEDURE|Kinesiotaping|Low back kinesiotaping
223428796|NCT06618482|PROCEDURE|Kinesiotaping|Transversus abdominis kinesiotaping
223428797|NCT03782298|DEVICE|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|"PEEK Suture Anchors, which include:~* SPYROMITE™ 2.0 PK Suture Anchor with Needles~* DYNOMITE™ 2.0 PK Suture Anchor with Needles~* RAPTORMITE™ 3.0 Suture Anchor with Needles~* FOOTPRINT™ Ultra PK SL Suture Anchor"
223428798|NCT03118141|PROCEDURE|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
223428799|NCT03118141|PROCEDURE|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
223428800|NCT03118141|PROCEDURE|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
224139340|NCT03265743|OTHER|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
223428801|NCT05100368|OTHER|patients|Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis
223428802|NCT05665166|GENETIC|Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII|Autologous CD34+ haematopoietic stem cells from MPS II patients will be genetically modified ex vivo using CD11b.IDS-ApoEII Lentiviral Vector (LV), a self-inactivating (SIN) LV expressing the human codon-optimized IDS gene tagged with ApoEII and regulated by a human CD11b myeloid-specific promoter. These transduced CD34+ HSCs will then be cryopreserved until the time of infusion back to the patients
223428803|NCT03475199|DEVICE|FabLife|"* A personnalized dietary program depending on the patient's phenotype and genotype~* The daily intake of a dietary supplement, developped in the context of male infertility."
223428804|NCT06488209|DRUG|LAD191|LAD191 SC injection.
223428805|NCT06488209|OTHER|Placebo|Matching placebo SC injection.
223428806|NCT05658055|DRUG|Vonoprazan|Potassium-competitive acid blocker
223428807|NCT05658055|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
223428808|NCT05658055|DRUG|probiotics|Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
224039284|NCT07049926|DRUG|Zanzalintinib|Oral Tablet
224039285|NCT07050719|PROCEDURE|Peripheral Oxygen Saturation (SpO₂) Group|FiO₂ adjusted based on pulse oximetry to maintain SpO₂ ≥98%
223428809|NCT00785434|DRUG|escitalopram|Dose ranging up to 50mg
223428810|NCT02012465|BIOLOGICAL|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~* Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~* The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
223428811|NCT06622811|OTHER|Students' Knowledge about Virtual Reality Questionnaire|"Part I: Personal Characteristics of Nursing Students:~It covers; age and gender.~Part II: Students' Knowledge about Virtual Reality Questionnaire:~This part will used to assess students' knowledge related to virtual reality that includes a definition of virtual reality, history of virtual reality, advantages and disadvantages of virtual reality on nursing education and equipment used for virtual reality and the effect virtual reality on future of education~Scoring system:~Respondents' answers will be scored (0) for incorrect answers, and (1) for correct answers. The overall items scores will be summed up and categorized according to the total percentages of unsatisfactory (\<60%) and satisfactory (≥60%)."
223428812|NCT06622811|OTHER|California Critical Thinking Disposition Inventory (CCTDI)|"It will consist of 24 items classify into 7 dimensions grouped as follows; truth-seeking (3 items); open-mindedness (4 items); analyticity (3 items); systematicity (4 items); critical thinking self-confidence (4 items); inquisitiveness (3 items); and cognitive maturity (3 items).~Scoring system:~Students asked to respond to all items with six points Likert scale as follows; strongly disagree = 1, disagree= 2, neutral = 3, sometimes agree = 4, agree = 5, and strongly agree= 6. The overall items scores will be summed up and categorized according to the total percentages of satisfactory critical thinking (≥75%) and unsatisfactory critical thinking (\<75%)."
223428813|NCT03273725|OTHER|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
223428814|NCT01797081|BIOLOGICAL|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
223428815|NCT01797081|BIOLOGICAL|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
223428816|NCT01797081|OTHER|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
223428817|NCT00697736|PROCEDURE|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
223428818|NCT02426749|DEVICE|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
223428819|NCT02426749|DEVICE|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
223428820|NCT05731869|OTHER|epicondylitis band|An off-the-shelf lateral epicondylitis tape in S-M-L dimensions was used distal to the lateral epicondylitis.
223428821|NCT05731869|OTHER|wrist orhosis|Wrist orthosis of the shelf was used in sizes S-M-L, covering the hand and wrist.
223428822|NCT01498224|DEVICE|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
224039286|NCT07050719|PROCEDURE|Peripheral Oxygen Saturation and Oxygen Reserve Index (SpO₂-ORI) Group|FiO₂ adjusted using both SpO₂ and ORI to maintain ORI between 0-0.3
224039287|NCT07049679|BEHAVIORAL|ActiveHeal Diabetes (AHD) Program|Biweekly phone/Zoom calls to support physical activity and dietary behavior change, focused on history, experience, benefits and adaptation
224039288|NCT07049939|DRUG|MK-3543|Capsule for oral administration
224039289|NCT07043725|DRUG|TQB2102 for injection|TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
224039290|NCT07043725|DRUG|Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection|TCbHP is a commonly used chemotherapy scheme for HER2 positive breast cancer. H represents Trastuzumab injection, P represents Pertuzumab Injection, T represents Docetaxel injection and C represents Carboplatin injection.
224039291|NCT04012879|COMBINATION_PRODUCT|CD19 CART|CD19 CART
223428823|NCT01498224|PROCEDURE|Sutures|
223428824|NCT05463237|DIAGNOSTIC_TEST|oral glucose tolerance test|oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation
223428825|NCT05463237|DIAGNOSTIC_TEST|Blood sample|Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes
223428826|NCT05517824|PROCEDURE|microinsulated needle radiofrequency|A single treatment using a microinsulated needle radiofrequency device
223740237|NCT07205016|BEHAVIORAL|Otago exercise|The proposed intervention is a multicomponent program designed to address frailty in community-dwelling older adults. It integrates three evidence-based domains: therapeutic physical activity, cognitive psychological intervention, and nutritional support.
224039292|NCT06743516|PROCEDURE|Pancreaticojejunostomy with external stent|Inserting ureteric stent at the pancreaticojejunostomy site
224039293|NCT06743516|PROCEDURE|Pancreaticojejunostomy without external stent|Only Pancreaticojejunostomy without inserting external stent
224039294|NCT06894108|DIETARY_SUPPLEMENT|Proprietary Blend of Botanical Extracts|Participants consumed 2.4ml of the supplement each night before bed.
224039295|NCT06894108|DIETARY_SUPPLEMENT|Melatonin|Participants consumed 1mg melatonin each night before bed.
223428827|NCT02511054|DRUG|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
223428828|NCT02511054|DRUG|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
223428829|NCT02511054|BIOLOGICAL|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
223428830|NCT00604942|PROCEDURE|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
223428831|NCT00604942|PROCEDURE|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
223428832|NCT00604942|DRUG|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
223428833|NCT00604942|DRUG|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
223428834|NCT04174664|DIAGNOSTIC_TEST|1-minute sit to stand test|Childrens will complete 1-minute sit to stand test and 3 minute step test and quality of life questionnaire.
223428835|NCT00342381|DRUG|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
223428836|NCT00342381|DRUG|Placebo|Single dose placebo treatment
223744816|NCT04263701|OTHER|Therapeutic exercises|Conventional physiotherapy exercises for children with cerebral palsy
223744817|NCT04263701|OTHER|Dual Task Training|Dual task training in addition to conventional physiotherapy exercises for children with cerebral palsy
224039296|NCT07052266|GENETIC|MyRisk Hereditary Cancer Test|Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.
224070447|NCT04194255|DIETARY_SUPPLEMENT|labelled iron as ferrous fumarate + 15 g acacia gum|iron (100 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g acacia gum)
224070448|NCT03499028|OTHER|JointCOACH|Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
223428837|NCT02513498|DRUG|Ixazomib Citrate|Given PO
223428838|NCT02513498|OTHER|Laboratory Biomarker Analysis|Correlative studies
223428839|NCT02513498|OTHER|Quality-of-Life Assessment|Ancillary studies
223428840|NCT02513498|OTHER|Questionnaire Administration|Ancillary studies
223428841|NCT03657524|OTHER|echocardiography|Speckle tracking echocardiography
223428842|NCT00760695|DRUG|dronabinol|tablets, twice daily, for 4 weeks
223428843|NCT00760695|DRUG|placebo|tablets, twice daily, for 4 weeks
223428844|NCT06018298|OTHER|Treatment as usual (TAU)|the components of treatment as usual (TAU) are summarised and assessed by the items of the DUNDRUM-3: physical health, mental health, substance misuse, problem behaviours, self care and activities of daily living, education occupation and creativity, family and intimacy.
223428845|NCT06101017|DIAGNOSTIC_TEST|Optical Coherence Tomography|Non-invasive imaging test that use light waves to take cross-section pictures of the eye.
223428846|NCT03762928|DRUG|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
223428847|NCT03762928|DRUG|midazolam|single administration of midazolam 2 mg oral solution
223428848|NCT03762928|DRUG|efavirenz|single administration of efavirenz 50 mg capsule
223428849|NCT04868851|BEHAVIORAL|Here for Health Only|Patients will complete the Here for Health Healthy Lifestyle intervention designed by the Paediatric Diabetes Dietitians at Oxford University Hospitals NHS Foundation Trust.
223428850|NCT04868851|BEHAVIORAL|mHealth technology assisted exercise counselling|Patients will complete the Here for Health intervention before completing a 3 month exercise and physical activity intervention supported by mHealth technology
223428851|NCT05077176|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
223428852|NCT05077176|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
223428853|NCT02767492|DEVICE|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
224070449|NCT00498173|DRUG|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
224070450|NCT00498173|DRUG|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
224070451|NCT00750633|DRUG|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
224070452|NCT00750633|DRUG|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
224070453|NCT00750633|DRUG|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
223428854|NCT02767492|DRUG|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
223428855|NCT01177709|DRUG|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
223428856|NCT06481111|DRUG|supplementary treatment with vitamin D|observational design
223428857|NCT03762863|DEVICE|Tourniquet application skill retention|Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
223428858|NCT03722953|OTHER|Control|"1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
223428859|NCT03722953|OTHER|Aerobic Exercise|"1. Ultrasound~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation"
223428860|NCT01171703|DEVICE|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
223428861|NCT01171703|DEVICE|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
223428862|NCT02409745|PROCEDURE|endometrial scratch|local injury to the endometrium by Pipelle
223428863|NCT02484651|DRUG|Sugammadex|Reversal of deep neuromuscular block
223428864|NCT02484651|DRUG|Rocuronium|Maintenance of deep neuromuscular block
223428865|NCT02770404|DRUG|Nafithromycin|100, 200, or 400 mg of nafithromycin
224039297|NCT07052474|BEHAVIORAL|Intensive trauma-focused treatment|"The treatment program includes components of Trauma focused cognitive behavioral therapy (TF-CBT), Eye Movement Desensitization and Reprocessing Therapy (EMDR), physical activity, as well as parent sessions. The intensive treatment largely follows the Dutch intensive trauma treatment program Korte Intensieve Traumabehandeling (KIT) (Albisser et al., 2024).~The intensive treatment incorporates core components from TF-CBT for children and adolescents (Cohen \& Mannarino, 2008) as well as the standard EMDR protocol (Shapiro, 2018)."
224039298|NCT07054463|OTHER|FSN Therapy Combined with Rehabilitation Training|"Prior to treatment, blinding will be ensured through the use of eye masks. Based on the affected muscle theory, all forearm muscles within the splint-immobilized area will be considered as an affected muscle group and further subdivided into flexor and extensor subgroups according to functional anatomy.~Two needle insertion points will be selected approximately 5 cm distal to the cubital crease, corresponding to the flexor and extensor muscle groups.~Following standard disinfection of the insertion device and sites, a disposable FSN needle will be inserted subcutaneously into the superficial fascial layer, with the needle tip directed toward the affected muscle group. The needle core will then be retracted into the soft tube, ensuring no tip exposure, and the tube base will be secured within the handle slot. A 30° fan-shaped sweeping motion will be performed bilaterally at a frequency of 100 sweeps/min for 2 minutes."
224070454|NCT00750633|DEVICE|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
223428866|NCT02770404|DRUG|Placebo|IV matching placebo
223428867|NCT03922737|PROCEDURE|In-person office visit|Post-operative visit to occur in-person with provider
223428868|NCT03922737|PROCEDURE|Teleheath visit|Post-operative visit to occur via telehealth software platform with provider
223428869|NCT06038058|DRUG|BRY812 for injection|BRY812 for injection will be administered by intravenous drip, tentatively once per cycle spanning 3 weeks on D1 of each cycle until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation or withdrawal from the study. The dose of each administration will be calculated based on the weight measured prior to such administration. The dosing regimen (dosing frequency and interval) for subsequent study may be adjusted based on prior data. The intravenous drip should last for ≥ 90 min for the first dose and may be adjusted to ≥ 30 min for subsequent doses if the first dose is tolerable.
223428870|NCT06664047|PROCEDURE|OTT ACLR|Patients in this group will undergo a reconstruction with the OTT technique which includes an intra-articular component and an extra-articular one, functioning as a LET.
223428871|NCT06664047|PROCEDURE|ACLR LET|Patients in this group will undergo a reconstruction with the conventional ACL technique accompanied by a routine LET, obtained from the iliotibial band.
223428872|NCT00831545|DRUG|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
223428873|NCT02251106|DEVICE|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
224070455|NCT01681264|DRUG|Morphine|
224070456|NCT01681264|DRUG|Guanfacine 1mg|
224070457|NCT01681264|DRUG|Guanfacine 2mg|
224070458|NCT01681264|DRUG|Placebo|
224070459|NCT00299208|DRUG|Artesunate|
224070460|NCT00299208|DRUG|Azithromycin|
223428874|NCT05565443|DEVICE|Blood Brain Barrier Disruption - Functional|Delivery of GCase across the BBB to form a disease modifying strategy for patients with Parkinson's Disease
223428875|NCT02375555|DRUG|Lenalidomide|
223428876|NCT02375555|DRUG|Elotuzumab|
223428877|NCT02375555|DRUG|Bortezomib|
223428878|NCT02375555|DRUG|Dexamethasone|
223428879|NCT02375555|PROCEDURE|Stem Cell Mobilization|
223428880|NCT04926103|OTHER|Fecal Microbiota transplant (FMT)|Patients will come once a week for FMT for 8 weeks. FMT is the administration of the supernatant component of stool and water mixture from a healthy relative or an unrelated donor. The donor's stool and blood is rigorously screened to exclude known communicable diseases. Those that achieve remission with FMT will have the option of continuing FMT once per month for 3 years
223428881|NCT05253716|OTHER|ONS|Immunonutritional supplement
223428882|NCT03809468|OTHER|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
223428883|NCT02267772|DRUG|IV Acetaminophen|IV Acetaminophen
223428884|NCT02267772|DRUG|IV Morphine|IV Morphine
224070461|NCT00299208|DRUG|Quinine|
223428885|NCT03111472|OTHER|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
223428886|NCT05030909|BEHAVIORAL|transdiagnostic group treatment|The individual and group sessions will integrate core principles from Motivational interviewing (provide information, address barriers), Cognitive Behavioural Therapy (psychoeducation regarding emotions, enhancing emotional awareness, cognitive restructuring, behavioural experiments, relaxation) , Acceptance Commitment Therapy (mindfulness, grounding, emotional and body awareness, enhancing cognitive flexibility), and aspects of Islamic psychology.
223428887|NCT04805580|PROCEDURE|unilateral intrathecal block|Quadratus lunborum block
223428888|NCT03065959|DRUG|reldesemtiv|oral
223428889|NCT03065959|DRUG|Placebo|oral
223428890|NCT01565369|DRUG|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
223428891|NCT06505915|DIETARY_SUPPLEMENT|Pre op Carbohydrate drink|Lemon flavoured clear carbohydrate drink
223564514|NCT05988294|OTHER|Pilates exercises|One-hour Pilates exercise program was given by a certified trainer to patients three times per week for 12 weeks. The exercise program followed the basic principles of the Pilates method. Our protocol comprised the following components of Pilates-based exercises: strength and stabilization, flexibility and range of motion, proper body alignment, balance, coordination, and body awareness. Resistance bands and 26 cm Pilates balls were used as supportive equipment. The exercise sections consisted of 5 minutes breathing, 10 minutes warm-up, 35 minutes conditioning phase and 10 minutes cool-down.
223564515|NCT05988294|OTHER|Conventional physical therapy exercise program|Diaphragmatic deep breathing exercises, bronchial hygiene techniques, assisted cough, stretching exercises and ROM exercises for both upper and lower limbs for 45 minutes, 3 days/ week for 12 weeks.
223564516|NCT03817463|DRUG|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
223564517|NCT03817463|DRUG|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
223564518|NCT05519501|DEVICE|SyntrFuge System|Microsized Adipose Tissue
223564519|NCT05519501|PROCEDURE|Standard of Care|Offloading
223564520|NCT04756999|BEHAVIORAL|massage therapy|Reflexology is massage therapy used to maintain and improve health, as well as relieve some symptoms.
223564521|NCT01766063|DRUG|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
223564522|NCT01468948|DRUG|Octanoic Acid|
224070462|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
224070463|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the first cycle of induction.
224139341|NCT02789605|DRUG|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
223428892|NCT06505915|OTHER|Clear fluid as per sip til send policy|clear fluid such as water
224070464|NCT05801835|DRUG|(cytarabine: daunorubicin) liposome for injection|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
224070465|NCT05801835|DRUG|Vyxeos|Be given intravenously at 65U/m\^2 on days 1 and day3 of the second cycle of induction.
223428893|NCT06563544|DEVICE|FCV|90 minutes of FCV
223428894|NCT06124755|DEVICE|Viabahn endoprosthesis group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.
224139342|NCT02789605|DRUG|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
223428895|NCT06124755|DEVICE|Drug-coated balloon group|Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
223428896|NCT01996410|DEVICE|Acupuncture|
223428897|NCT05380284|OTHER|Senior Driving Simulation Training|The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .
223428898|NCT05380284|OTHER|Waiting list control|The control group is waiting list control. They will also receive the (Senior Driving Simulation Training) after all research is done.
223428899|NCT05161208|DRUG|OC-01 (varenicline 0.6mg/ml) Nasal Spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
223564523|NCT06481371|DRUG|zuojinwan|In the Chinese medicine combination group, 3g of Zuojinwan was added to the western medicine group twice a day for 4 weeks.
223564524|NCT06481371|DRUG|Rabeprazole sodium enteric-coated tablets|For epigastric pain syndrome
223564525|NCT06481371|DRUG|mosapride citrate|Postprandial discomfort syndrome
223564526|NCT05962632|DRUG|Fluoride based varnish (Dentkist Charm Fill Varnish )|topical Fluoride varnish administrated professionally every 3 months in the clinic
223564527|NCT05962632|DRUG|pro care gel remineralizing agent|topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
223564528|NCT05962632|DEVICE|Mobile application|examine the impact of Mobile application on caries prevention
223564529|NCT05962632|COMBINATION_PRODUCT|tooth brushing/fluoridated toothpaste over the counter 1450 ppm, interdental cleaning,fluoride rinse OTC|interdental cleaning(dental floss),fluoride rinse OTC (B-FRESH MOUTH WASH )
223564530|NCT02645877|PROCEDURE|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
224070466|NCT03595553|DRUG|Ridinilazole|ridinilazole (200 mg bid)
224070467|NCT03595553|DRUG|Vancomycin|vancomycin (125 mg qid)
223428900|NCT05161208|DRUG|Placebo (vehicle) nasal spray|Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
224039299|NCT07054463|OTHER|Sham FSN Therapy Combined with Rehabilitation Training|"Patients randomized to this group will undergo the sham intervention in the same predetermined anatomical region. Prior to the procedure, eye masks will be applied to ensure blinding. The Sham FSN device, featuring a blunt tip, will generate a pricking sensation upon spring-loaded actuator deployment without actual skin penetration, maintaining parallel alignment to the epidermal surface.~Following standard aseptic preparation, the acupuncturist will stabilize the needle body with the non-dominant hand while simulating insertion motions with the dominant hand, replicating the authentic FSN technique by retracting the stylet to the locking groove. The practitioner will then perform sweeping manipulations (ensuring continuous dermal contact during the procedure). Both the operational protocol and treatment course will be identical to those of the genuine FSN intervention group."
224039300|NCT07053085|PROCEDURE|Lumpectomy or mastectomy|Resection of the primary breast tumor (ie. lumpectomy when possible or mastectomy when breast conservation not possible). Surgical resection of the primary breast tumor is to be performed per standard guidelines as applied to localized disease. Breast conserving surgery (ie. lumpectomy) is allowable per patient preference when supported by standard surgical practice. Mastectomy is preferred when breast conservation is declined by the patient, or if breast conservation would otherwise not be feasible in the early-stage setting (e.g. large tumor:breast volume ratio, inability to achieve negative margins with breast conservation, etc)
224070468|NCT02355561|DRUG|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
224070469|NCT02355561|DRUG|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
224070470|NCT02355561|DRUG|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
223428901|NCT04907643|DEVICE|PICO G2 4k|Participants will use the Pico G2 4K VR audio and visual head-mounted device. The Pico G2 4K is a standalone VR headset that comes with an orientation-tracked controller. It does not require a smartphone or personal computer to operate. The device supports 3 degrees of freedom (3DOF) head tracking, has best-in-class optics, and a wide field-of-view.
223428902|NCT02559791|BIOLOGICAL|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
223428903|NCT02559791|DRUG|Placebo|Matching placebo once monthly for 2 months
223428904|NCT02973113|BIOLOGICAL|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
223428905|NCT02973113|BIOLOGICAL|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
223428906|NCT01744184|DRUG|Entonox|Entonox arm
223428907|NCT01744184|DRUG|Midazolam|up to 5mg midazolam as appropriate
223428908|NCT02857244|DRUG|Duloxetine|Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
223428909|NCT02857244|DRUG|Donepezil|Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
223428910|NCT02857244|DRUG|Modafinil|Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil \& duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
223428911|NCT02336360|DRUG|Flortaucipir F18|No flortaucipir administered in this study. Subjects received flortaucipir in an Avid-sponsored study.
223428912|NCT01864369|BEHAVIORAL|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
223428913|NCT05301179|OTHER|Protein quantity and quality|Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
223428914|NCT06327087|OTHER|No intervention|Observational study in the late follicular and mid-luteal phase
223428915|NCT03586505|DEVICE|Light exposure|"The 6 lights used randomly are :~* 482nm =standard blue light illumination,~* 650nm,~* 675nm,~* 700nm,~* 750nm~* 800nm"
223428916|NCT06668844|PROCEDURE|Endoscopic direct Draf IIa|Endoscopic direct Draf IIa (Carolyn' window approach) frontal sinusotomy
223428917|NCT06668844|PROCEDURE|Endoscopic angled Draf IIa|Group BFrontal sinusotomy using angled endoscopeand instruments
223428918|NCT01095978|DRUG|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
223428919|NCT05523011|DRUG|Exosome ointment|100 µg MSC exosomes/g ointment
223428920|NCT06323746|DEVICE|Denneroll cervical traction orthodontic|The duration of each session will start at approximately three minutes and increase by one minute per session until reaching the goal of 20 minutes per session. The intervention will be repeated three times per week for 10 weeks in the supervised setting.
223428921|NCT06667986|OTHER|artificial intelligence models (YOLO and Mask-RCNN)|machine learning model will used to detect secondary caries around restorations by comparing the results with digital bitewing radiography
223428922|NCT02266472|DRUG|metformin|single dose of metformin given as tablets
223428923|NCT02266472|DRUG|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
223428924|NCT02266472|DRUG|empagliflozin|single dose of empagliflozin given as tablet
223428925|NCT00808639|DRUG|Methotrexate|intravenously 30mg/m2 over 30 minutes
223428926|NCT00808639|DRUG|Doxorubicin|intravenously 30mg/ms over 15 minutes
223428927|NCT00808639|DRUG|vinblastine|intravenously 3mg/m2 over 30 minutes
223564531|NCT04692649|OTHER|pragmatic posterior capsular stretch|pragmatic posterior stretch is used to increase the length of the posterior capsule
224139343|NCT04683107|OTHER|Eccentric protocol|Participants in this arm will perform progressive eccentric exercise protocol
223428928|NCT00808639|DRUG|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
223428929|NCT00808639|DRUG|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
223428930|NCT00432224|PROCEDURE|photodynamic therapy|
223428931|NCT01585753|DRUG|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
223428932|NCT01585753|DRUG|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
223428933|NCT01585753|DRUG|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
223428934|NCT00409968|PROCEDURE|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
223428935|NCT00288067|DRUG|fenretinide|Given PO
223428936|NCT00288067|DRUG|rituximab|Given IV
223428937|NCT04635124|BEHAVIORAL|Dog visit|An visitor visits the participant with a dog
223428938|NCT04635124|BEHAVIORAL|Encourage to engage in activity|In each visit the visitor invites the participant to engage in an activitty
223428939|NCT06414824|DEVICE|Intermittently Scanned Continuous Glucose Monitoring|FreeStyle Libre, 4 weeks
223428940|NCT06414824|DEVICE|Standard Blood Glucose Monitoring|Standard blood glucose monitoring with glucose meters
223428941|NCT06204471|DEVICE|Helite hip protector|hip protector
224139344|NCT04683107|OTHER|Isometric protocol|Participants in this arm will perform progressive isometric exercise protocol
223564532|NCT04692649|OTHER|cross body stretch|crossbody stretch performed by an individual
223564533|NCT03116828|DRUG|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
223564534|NCT03116828|DRUG|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
223428942|NCT06204471|DEVICE|Wolk hip protector|Hip protectdor
223428943|NCT04894552|PROCEDURE|Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma|Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.
223740238|NCT07206563|DRUG|Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer|"Intervention: Penfluridol, an oral antipsychotic drug, is used as monotherapy. It targets DRD2, inhibits glycolysis, and induces apoptosis.~Dosing Schedule:~Phase Ib: 3+3 dose-escalation design. Initial dose 20 mg weekly, escalating to 40 mg, then 60 mg until recommended Phase II dose (RP2D) is determined based on 21-day DLT assessment.~Phase II: Expansion cohort at RP2D to further evaluate safety and estimate ORR. Duration: Treatment continues until progression, unacceptable toxicity, withdrawal, or investigator decision.~Monitoring: Regular AE/SAE monitoring using NCI-CTCAE v5.0. Assessments include weekly vital signs, biweekly blood tests, and ECGs every 2 weeks. Tumor response evaluated by RECIST 1.1 criteria with imaging every 2-3 cycles.~Dose Modification: Adjustments made for EPS, QTc prolongation, and proteinuria. Rationale for Single-Arm Design: Chosen due to the ultra-rare patient population and lack of established comparators. Efficient for determining RP2D and ORR."
224139345|NCT03084718|DRUG|CHF 718 pMDI|Dose Response: Test one of three different doses of CHF 718 pMDI
224139346|NCT03084718|DRUG|Placebo pMDI|Placebo Control
224139347|NCT03084718|DRUG|Beclomethasone Dipropionate (BDP)|Active Control
224139348|NCT02196987|OTHER|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
224139349|NCT02196987|OTHER|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
223428944|NCT04779580|PROCEDURE|Lateral Cutaneous Nerve Of The Thigh Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The lateral cutaneous nerve of the thigh will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
223428945|NCT04779580|PROCEDURE|Subcostal Nerve Block Using Local Anaesthetic|Currently accepted aseptic conditions will be met. The subcostal nerve will be identified on ultrasound (Sonosite X-Porte) and 5mL of 1% lidocaine will be administered around the nerve using a 50mm Stimuplex needle. The area of anaesthesia will be demarcated using ice.
223428946|NCT04737395|DEVICE|"upper extremity training program (Meditouch,MSQUARE)"|40 hours of therapy with the Hand Tutor (MediTouch) device and a wearable vest (EkssoUE, Ekso Bionics) for arm rehabilitation
223428947|NCT05040672|BEHAVIORAL|questionare online application|questionare online application
224039301|NCT07053085|RADIATION|Radiotherapy|"Radiotherapy will be delivered using external beam radiation per the guidelines.Radiotherapy will be delivered using external beam radiation per the guidelines set forth below, targeting two main compartments:~1. Patients will undergo radiotherapy to the breast/chest wall, and regional nodal basins (including the axilla, supraclavicular fossa and internal mammary chain) per the standard adjuvant approach for locally advanced disease, and~2. Patient will undergo stereotactic body radiotherapy (SBRT) or similarly-ablative approaches to sites of distant disease, including all observable foci and those that may have since resolved radiographically during systemic therapy"
224039302|NCT07053085|DRUG|Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs|Continue to receive the standard treatment you have already started, which includes trastuzumab, pertuzumab, paclitaxel, or a combination of these drugs. This treatment is not part of the study and will be decided by your regular treating physician.
223428948|NCT04497376|PROCEDURE|upgraded '2C3L'|Patients randomized to the upgraded '2C3L' arm will first undergo EI-VOM, followed by the '2C3L' ablation step. The details include: (1). EI-VOM procedure: An 8.5-French-long sheath or a steerable long sheath is sent to the coronary sinus (CS) via the femoral vein. A JR4.0 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a BMW wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated with 6 to 8 atm in the VOM. A selective venogram of the VOM is obtained by slowly injecting 1 mL of contrast medium. Then, ethanol is slowly injected into the VOM and selective venography of the VOM is repeated. (2) . After EI-VOM, radiofrequency ablation was performed to achieve bilateral pulmonary vein isolation and bidirectional block of mitral isthmus line, roof line, and cavotricuspid isthmus line. (3). Any organized AT observed during the procedure will be targeted as well.
223428949|NCT04497376|PROCEDURE|pulmonary vein antral isolation|After reconstructing the left atrial geometry, PVI will be performed (the right PV antrum (PVA) will be ablated first, followed by the left PVA. ) in a wide area circumferential pattern. Complete PVI will be achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished. The endpoint of the circumferential PVA ablation procedure is to achieve electrical bilateral PV isolation, that is, the PV potentials associated with atrial electrical activity cannot be recorded during sinus rhythm or CS pacing (entrance block). A waiting period of at least 20 min (after the last PV is isolated) will be used during which spontaneous PV reconnection will be related. , and tDemonstration of exit block (he by pacing in the PV cannot be and proving the absence of transmitted conduction to capture the atrium) may be performed but is not mandatory. Any organized AT observed during the procedure will be targeted as well.
223428950|NCT05743062|BEHAVIORAL|Virtual Reality|Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.
223428951|NCT05743062|OTHER|Control|For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.
223428952|NCT05984173|DRUG|Vitamin E application|patients received vitamin E inside the socket after extraction
223428953|NCT05907031|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
223428954|NCT05907031|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive days each week.
223428955|NCT00662428|OTHER|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
223428956|NCT00662428|OTHER|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
223428957|NCT04692324|PROCEDURE|Biospecimen Collection|Undergo collection of CSF samples
223428958|NCT04692324|OTHER|Electronic Health Record Review|Review of medical records
223428959|NCT04692324|OTHER|Survey Administration|Ancillary studies
223428960|NCT03953027|OTHER|Survey Administration|Ancillary studies
223428961|NCT05732116|OTHER|PTSD|Series scales, including GHQ-12, PCL-6, and CAPS-5 will be used to screen and diagnose the development of PTSD in surgeons and anesthesiologists at 3 time points, baseline (time 0), 3 m, and 6 m.
223428962|NCT06337786|DEVICE|Digital app RB4.1|Standard care and the digital app RB4.1
223428963|NCT06337786|OTHER|Control arm|Standard care alone
223428964|NCT06065007|OTHER|No intervention|This is a cross-sectional observational study, no intervention will be implemented or exposure studied. Data for outcomes of interest will be collected via questionnaires
223428965|NCT05878925|OTHER|Aroma|The study intervention is an olfactory stimulation with vanilla or strawberry aroma. The aroma will be applied to the inner surface of the nCPAP mask of preterm infants using designated scent pens every 3-4 hours over a period of 12 hours. The two aromas will be applied in blocks of 5 consecutive infants (5 infants vanilla, 5 infants strawberry, and so forth).
223428966|NCT05878925|OTHER|Placebo|During the control intervention, identically looking placebo pens will be used to apply a colored carrier solution (without aroma) to the inner surface of the nCPAP mask of preterm infants in the same manner.
223428967|NCT06280066|OTHER|Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers|The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.
223564535|NCT00882583|DRUG|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
223564536|NCT00882583|DRUG|Dasatinib|Oral Dasatinib Days 8 through 64.
223564537|NCT00882583|DRUG|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
224039303|NCT06807086|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia|The Survivorship Sleep Program is a virtual program based on cognitive behavioral therapy for insomnia (CBT-I), which teaches evidence based skills to improve sleep-related behaviors, expectations, and environment, to promote relaxation, and to reduce worry. It also involves reducing the time spent in bed in order to improve the quantity and quality of sleep over time. The Survivorship Sleep Program is delivered in 4 weekly sessions by a trained facilitator and includes considerations specific to managing insomnia after cancer diagnosis and treatment. Additionally, 1 booster session is offered at week 6.
223428968|NCT03605771|OTHER|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
224039304|NCT06807086|BEHAVIORAL|Enhanced Usual Care|A sleep hygiene handout and a referral for CBT-I offered through MGH or community partners.
224039305|NCT06891456|DEVICE|RFA Ablation|RFA ablation of VT substrate using FlexAbility or ThermoCool ST catheter
224039306|NCT06891456|DEVICE|PFA Ablation|PFA ablation of VT substrate using FARAPOINT catheter
224039307|NCT06761677|DRUG|Brincidofovir|Phase 1b part is dose escalation study evaluating three dose levels of BCV, and participants will be assigned to a dose schedule in the order of study entry. In Phase 2 part, participants will receive BCV BIW at the RP2D (determined in the Phase 1b part).
224039308|NCT06773117|DRUG|Susu Xiao'er Zhike Granules|Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
224039309|NCT06773117|DRUG|Extremely-low dose Susu Xiao'er Zhike Granules|Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
224039310|NCT07054853|DEVICE|Induced rotator cuff fatigue by isokinetic biodex|"Each subject will undergo two separate fatigue protocols from distinct shoulder abduction angles (30° and 90°), referred to as Protocol A and Protocol B, respectively.~Fatigue will be induced using the Biodex System 4 Pro Isokinetic .Participants will be seated with the tested arm positioned at the designated shoulder abduction angle and elbow flexed at 90°. The arm will be secured using a shoulder adapter to ensure standardized positioning. Hand Grip strength will be assessed using a Jamar Plus+ Digital. Participants will perform three maximal grip trials, each lasting 3 seconds, with verbal encouragement provided. The average of the three trials will be used as the maximum voluntary contraction"
224039311|NCT03989492|OTHER|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
224039312|NCT06861153|BEHAVIORAL|Pulses 1.5 cups Group|Participants will receive 1.5 cup-equivalents of pulses per week.
224039313|NCT06861153|BEHAVIORAL|Pulses 3 cups Group|Participants will receive 3 cup-equivalents of pulses per week.
224039314|NCT06861153|BEHAVIORAL|My Plate Group (Control)|Participants will continue with their usual dietary practices, receiving no additional pulses. They are encouraged to follow My Plate general recommendations.
224039315|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 1|For each participant only 1 eye will receive a low dose (\>= 0.8 to \< 2.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
224039316|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 2|For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
224039317|NCT06891885|DRUG|DSP-3077 Retinal Sheet Cohort 3|For each participant only 1 eye will receive a high dose (\>= 2.4 to \< 6.4 mm2) of single subretinal injection of DSP-3077 using the DSP-3077-delivery device on Day 1
224039318|NCT06550791|BEHAVIORAL|Anticancer Learning Circle|All participants will partake in the Anticancer Learning Circle, a lifestyle modification program. All participants will complete web-based learning modules focused on improving diet, lowering stress, increasing fitness, and reducing exposure to toxins in the home environment. Each week, all participants will meet as a group to discuss the learning topic of the web-based learning module for the week.
224039319|NCT06237452|BIOLOGICAL|VE303|VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.
224139350|NCT03841487|DEVICE|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
224139351|NCT03341923|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
224139352|NCT03341923|DEVICE|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
223428969|NCT03383081|BIOLOGICAL|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);
223428970|NCT03383081|BIOLOGICAL|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)
223428971|NCT03383081|PROCEDURE|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
224139353|NCT01809925|DIETARY_SUPPLEMENT|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
224139354|NCT01809925|DIETARY_SUPPLEMENT|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
224139355|NCT00740324|DRUG|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
224139356|NCT00740324|DRUG|NPO-11|NPO-11 after administration of NPO-11
224139357|NCT00740324|DRUG|NPO-11|1 mg glucagons after administration of NPO-11
224139358|NCT00799500|OTHER|Screening|Weekly vaginal pH
223428972|NCT04867967|BEHAVIORAL|Iyengar Yoga|Classical Iyengar Yoga intervention, especially designed for headache patients. Note: First administered face-to-face, due to Covid-restrictions changed to online classes
223428973|NCT04867967|BEHAVIORAL|Mindfulness-based stress reduction|Standardazied Mindfulness-based stress reduction intervention Note: First administered face-to-face, due to Covid-restrictions changed to online classes
223428974|NCT04220814|RADIATION|MRI|MRI protocol is different, a little bit longer than MRI in routine for patients. For healthy volunteer, a specific MRI for this study is done
223428975|NCT04220814|OTHER|Electrophysiology|Electrophysiology will be done during routine visits for patients and during inclusion visit to healthy volunteers
223428976|NCT05201144|DRUG|Sildenafil Oral Suspension|Sildenafil citrate is a highly selective PDE-5 inhibitor found in pulmonary vascular smooth muscle cells. Sildenafil acts by increasing cGMP levels in the nitric oxide pathway, leading to smooth muscle relaxation and an anti-proliferative effect within the pulmonary vasculature.
223428977|NCT05201144|OTHER|Placebo|Equal volume of placebo
223428978|NCT04104412|BIOLOGICAL|human umbilical cord mesenchymal stem cell|2\*10\^7
223428979|NCT01109628|DIETARY_SUPPLEMENT|Protein drink|Twice a day during 6 months
223428980|NCT01109628|DIETARY_SUPPLEMENT|Placebo drink|Twice a day during 6 months
223428981|NCT05342753|DEVICE|Restylane Kysse|Hyaluronic Acid: Injectable gel for lip augmentation and the correction of upper perioral rhytids
223428982|NCT06796335|OTHER|RIGht|The final intervention consists of five components; 1) education of nurses 2) a dialog tool used in a single session intervention and follow- up 3) a relative- to- relative list 4) video material 5) guidelines on how to document the relative involving plan in the patient's electronic journal.
223428983|NCT00197002|BIOLOGICAL|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
224039320|NCT06237452|BIOLOGICAL|Placebo|Placebo capsules contain microcrystalline cellulose. Placebo capsules are visually identical to and not discernible from VE303 capsules. Placebo capsules will not contain any VE303 drug product.
223428984|NCT00197002|BIOLOGICAL|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
223428985|NCT02017717|BIOLOGICAL|Nivolumab|specified dose on specified days
223428986|NCT02017717|BIOLOGICAL|Bevacizumab|specified dose on specified days
223428987|NCT02017717|BIOLOGICAL|Ipilimumab|specified dose on specified days
223428988|NCT05635227|DRUG|Dexamethasone phosphate|See description of arms
223428989|NCT05635227|DRUG|Isotonic sodium chloride (0.9%)|See description of arms
223428990|NCT05635227|DRUG|Olanzapine 10 MG|Olanzapine tablet pre-hidden in capsule identical to the placebo tablet
223428991|NCT05635227|DRUG|Placebo capsule|capsule identical to capsule containing olanzapine
223428992|NCT05635227|PROCEDURE|Flow-targeted hemodynamic management|See description of arms
224039321|NCT07060235|OTHER|fascial exercise home brochure|Fascia exercises are taught by the physiotherapist in the clinical setting and if the exercises are performed incorrectly, intervention is made and the correct exercise is taught. At home, the individual is motivated and monitored with an exercise diary. He/she remembers the exercises from the home brochure.
223428993|NCT05635227|PROCEDURE|Pressure-targeted hemodynamic management|See description of arms
223428994|NCT05635227|PROCEDURE|Low tidal-volume ventilation|See description of arms
223428995|NCT05635227|PROCEDURE|No ventilation|See description of arms
223428996|NCT05687747|DRUG|Radiolabelled tracer, 68Gallium-FAPI-46 PET/MRI|68Gallium-FAPI-46 PET/MRI is a novel radioactive diagnostic tracer used with Positron Emission Tomography imaging. It defects Fibroblast Activation Protein positive cancer cells and cancer associated fibroblasts.
223428997|NCT05956886|BEHAVIORAL|sleep chatbot|Personalized intervention algorithms will be developed based on CBT-I guidelines, focus group data, individual sleep baseline information and self-reported prioritized sleep goals. The CBT-I intervention will focus on principles of sleep restriction and stimulus control, with other CBT-I components used as on-demand content. The sleep chatbot system will facilitate sleep goal-setting with the participant and communicate weekly behavioral prescriptions and educational modules. After baseline data collection, the research coordinator will provide intervention orientation and set up the first-week sleep modification goal during the in-person/Zoom meeting. Sleep modification goals in the remaining weeks will be developed through the participant-chatbot interaction. The Chatbot system will send sleep-related information and behavioral reminders/feedback based on the interactive conversation with participants. Participants will also complete a sleep diary prompted by a chatbot.
223428998|NCT05371496|DRUG|Semaglutide|3.0 mg/ml (titrated to 2.4 mg) subcutaneous once weekly for 12 months
223428999|NCT05371496|DRUG|Placebo|Matched placebo with no active drug once weekly for 12 months
223429000|NCT05371496|BEHAVIORAL|Counselling on healthy lifestyle intervention|All participants will receive counselling on healthy lifestyle intervention including limiting consumption of salt, red meat, saturated or trans fats, sweets, and sugar-sweetened beverages, and how to restrict calorie intake (500 kcal/day deficit) in consultation with a trained study dietician. Regular physical activity \>150 minutes per week will be encouraged.
223429001|NCT03527264|DRUG|Nivolumab induction|2 doses Nivolumab 240mg IV
223429002|NCT03527264|DRUG|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
224070471|NCT03462407|BEHAVIORAL|DAID|"The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it."
224070472|NCT03462407|BEHAVIORAL|Dog walking|Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
224070473|NCT01110200|DRUG|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
224070474|NCT01110200|DRUG|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
224070475|NCT03910556|DRUG|Propofol|intraoperative factors
223429003|NCT03527264|RADIATION|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
223429004|NCT03527264|DRUG|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
223429005|NCT03527264|DRUG|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
223429006|NCT04236414|DRUG|Olaparib|Patients will receive a single dose of olaparib on Day 1, followed by initiation of bd continuous dosing from Day 2 onwards. Olaparib should be taken at the same time each day (morning and evening), approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. 25 and 100 mg tablet strengths available for ages ≥3 to \<18 years. AAF available for ≥0.5 to \<6 years; The AAF is a sprinkle capsule formulation, available in dose strengths of 15 mg and 19.5 mg. The sprinkle capsules contain 1.5 mg granules which are to be dispersed onto a food vehicle prior to dosing.
224039322|NCT07060235|OTHER|Fascial exercise based mobile application|Fascia exercises are taught by the physiotherapist in the clinical setting and if the exercises are performed incorrectly, intervention is made and the correct exercise is taught. At home, the individual is motivated and monitored with an exercise diary. Performs the exercises by watching videos on the mobile application. The physiotherapist intervenes in motivation with instant notifications via the mobile application.
223429007|NCT05276726|DRUG|JAB 21822|Administered orally
223429008|NCT05470283|DRUG|OBX-115|Given by IV
223564538|NCT00882583|RADIATION|Radiation Therapy|Standard Radiation Therapy.
223564539|NCT02964559|BIOLOGICAL|Pembrolizumab|Given IV
223564540|NCT01215643|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
223564541|NCT01215643|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
223564542|NCT01215643|DRUG|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
223564543|NCT01009437|DRUG|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
223564544|NCT01009437|PROCEDURE|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
223429009|NCT05470283|DRUG|Acetazolamide|Given by PO
223429010|NCT05470283|DRUG|Cyclophosphamide|Given by IV
223564545|NCT01689025|DRUG|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
223564546|NCT01689025|DRUG|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
223564547|NCT02821442|DEVICE|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
223429011|NCT05470283|DRUG|Furosemide|Given by IV
223429012|NCT05470283|DRUG|Mesna|Given by IV
224139359|NCT05501288|DRUG|Huashi Baidu granule|Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
223429013|NCT05470283|DRUG|Fludarabine Phosphate|Given by IV
223429014|NCT05669352|DRUG|CA-4948|Subjects on both the phase I and phase II portions will take 200 mg CA-4948 orally two times daily.
223429015|NCT05669352|DRUG|Pembrolizumab|Subjects on both the phase I and phase II portions will receive 400 mg pembrolizumab intravenously once every six weeks.
223429016|NCT06158568|OTHER|Percutaneous Electrical Nerve Stimulation|Application of a electrical current percutaneously (at the motor response intensity) targeting the suprascapular and axillar nerves
223429017|NCT06158568|OTHER|Placebo Percutaneous Electrical Nerve Stimulation|Application of sham electrical current (no intensity) percutaneously targeting the suprascapular and axillar nerves
223429018|NCT06158568|OTHER|Exercise|Application of three weeks of progressive exercises targeting the shoulder musculature
223429019|NCT05527847|BEHAVIORAL|Peers LEAD|Two group session focusing on beliefs about medicines and diabetes, discrimination/mistrust, and communication with providers, and 2 peer-based phone calls from Ambassadors to occur weekly for weeks 3-8, then bi-weekly for weeks 9-12.
223429020|NCT05527847|BEHAVIORAL|HLWD|Weekly group sessions for two months. Sessions will last up to 2.5 hours and focus on a different diabetes self-management topic.
223429021|NCT02013570|DRUG|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
223564548|NCT02821442|DEVICE|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
223564549|NCT03900949|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic SCT
223564550|NCT03900949|DRUG|Cytarabine|Given IV
223564551|NCT03900949|DRUG|Daunorubicin Hydrochloride|Given IV
223564552|NCT03900949|DRUG|Gemtuzumab Ozogamicin|Given IV
223564553|NCT03900949|DRUG|Midostaurin|Given PO
223564554|NCT05888467|OTHER|supervised infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. During the exercise session, the participant is assigned to an individual 'sport cabin' in which they are standardly exposed to infrared light.
223564555|NCT05888467|OTHER|supervised non-infrared exercise group|Participants of the intervention group will be asked to perform 1-3 exercise sessions per week at the Infraligne center of Genk, Hasselt or Maasmechelen for a total duration of 12 weeks. Participants assigned to the supervised non-infrared exercise group will exercise in the sport-cabin with the infrared light turned off.
223564556|NCT05888467|OTHER|Control group|Participants of the control group are advised to perform moderate intensity aerobic exercise at least 3 days per week for an average of 30-50 minutes per session and a total duration of 12 weeks.
224070476|NCT03318146|DEVICE|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
224070477|NCT03318146|DRUG|XALATAN®|one drop in the affected eye(s) once daily in the evening
224039323|NCT07060235|OTHER|lumbal stabilizasyon home brochure|"Participants assigned to the intervention group will receive a structured home-based lumbar stabilization exercise program designed to improve spinal stability, core muscle control, and functional performance. The program will target deep trunk stabilizer muscles, including the transversus abdominis and multifidus, through low-load, motor control-based exercises.~The intervention will last for 14 days, with exercises to be performed 3 times for everyday, Each session will last approximately 20-30 minutes and consist of:~Warm-up (1 minutes): Breathing exercises and gentle mobility~Core Stabilization (15-20 minutes): Exercises such as abdominal hollowing, bridging, bird-dog, side plank, and dead bug - progressing from static holds to dynamic movements as tolerated~Cool-down (1 minutes): Light stretching and relaxation"
223429022|NCT04253405|DEVICE|High Flow Nasal Catheter|"HFNC will be delivered through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize the patient´s comfort and SpO2"
224039324|NCT04047654|DRUG|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
224039325|NCT07067034|BEHAVIORAL|Ridikullus Nursing İntervention|A one-session, nurse-led psychosocial intervention designed to reduce anxiety in university students. Participants identified personal metaphors related to their anxiety and were guided to reconstruct them into less distressing, humorous, or calming mental images. The intervention was delivered in a structured format by an academic nurse trained in therapeutic communication
224139360|NCT05501288|DRUG|compound pholcodine oral solution|Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
224139361|NCT04929613|BEHAVIORAL|Mindfulness-Based Resilience Training|2.5-day intensive MBRT training sessions.
224139362|NCT01742078|DRUG|LY2541546 - IV|Administered IV
224139363|NCT01742078|DRUG|LY2541546 - SC|Administered SC
224139364|NCT01742078|DRUG|Placebo|Administered IV or SC
224139365|NCT00467025|DRUG|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
224139366|NCT00467025|DRUG|Sorafenib|400 mg PO BID
224139367|NCT00467025|DRUG|AMG 386 placebo IV|AMG 386 placebo IV
224139368|NCT03083509|OTHER|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
224139369|NCT03083509|OTHER|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
223429023|NCT04253405|DEVICE|Noninvasive positive pressure ventilation (NIPPV)|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 according to the protocol.
223429024|NCT03572400|DRUG|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
223429025|NCT03572400|DRUG|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
223429026|NCT00623597|DRUG|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
223429027|NCT00623597|DRUG|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
223429028|NCT03309826|DEVICE|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
223429029|NCT03309826|DEVICE|Nasal Dilator Strip|Nightly use of nasal dilator strip
223429030|NCT06284395|DRUG|Bortezomib|Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
223429031|NCT03132870|OTHER|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
223429032|NCT03653949|OTHER|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
223429033|NCT03653949|OTHER|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
223429034|NCT05392439|DEVICE|taVNS|transcutaneous auricular vagal nerve stimulation
223429035|NCT05392439|DEVICE|sham-taVNS|transcutaneous stimulation at the elbow area
223478304|NCT00666237|PROCEDURE|Tube shunt surgery|The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.
224039326|NCT06770569|DRUG|HRS-3802|HRS-3802
224039327|NCT06770439|DRUG|IBI343|IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate
224039328|NCT06770439|DRUG|Gemcitabine+Albumin-bound paclitaxel|Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer
224039329|NCT06344884|PROCEDURE|Early catheter removal|Catheter removal the day after surgery as opposed to standard of care (3 to 4 days after surgery)
223429036|NCT03203226|OTHER|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
223429037|NCT05548998|OTHER|General anesthesia with low fresh gas flow|General anesthesia with a fresh gas flow lower than 1L/min for the maintenance phase of anesthesia
223429038|NCT05548998|OTHER|General anesthesia with high fresh gas flow|General anesthesia with a fresh gas flow equal to or higher than 1L/min for the maintenance phase of anesthesia
223429039|NCT05548998|DIAGNOSTIC_TEST|Mini mental state examination|6 category and 30-point test to inquire patient's cognitive function
223429040|NCT05548998|DIAGNOSTIC_TEST|Visual Analogue Scale|The patient's self-reported pain intensity according to a visual scale between 0 and 100
223429041|NCT03051516|OTHER|Laboratory Biomarker Analysis|Correlative studies
223429042|NCT03051516|OTHER|Placebo Administration|Given IM
223429043|NCT03051516|OTHER|Questionnaire Administration|Ancillary studies
223429044|NCT03051516|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
223429045|NCT05262712|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the feet of participants via C2 tactors (diameter: 3.05 cm, height: 0.79 cm, operating frequency: 200-300 Hz see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
223429046|NCT05262712|OTHER|Placebo Control|Devices mounted, no stimulation
223429047|NCT03621540|DEVICE|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
223429048|NCT03621540|DEVICE|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
223429049|NCT03621540|BEHAVIORAL|Adaptive working memory training|Adaptive spatial n-back training.
223429050|NCT04156945|BEHAVIORAL|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
223429051|NCT04156945|DIAGNOSTIC_TEST|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
223744818|NCT05882799|PROCEDURE|Ultrasound-guided dry needling|Ultrasound-guided dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle while monitoring the needle's progress with real-time ultrasound imaging. In this technique, a trained practitioner visualizes the piriformis muscle and the surrounding structures using an ultrasound machine, and then inserts the needle through the skin and into the muscle tissue, guided by the ultrasound image.
223429052|NCT00204503|DRUG|Depakote ER|
223429053|NCT04106362|BIOLOGICAL|Cetuximab|Given IV
223429054|NCT04106362|DRUG|Cisplatin|Given IV
223429055|NCT04106362|OTHER|Quality-of-Life Assessment|Ancillary studies
223429056|NCT04106362|OTHER|Questionnaire Administration|Ancillary studies
223429057|NCT04106362|RADIATION|Radiation Therapy|Undergo radiation therapy
223429058|NCT04587739|COMBINATION_PRODUCT|Surgery with Neoadjuvant stereotactic body radiation therapy|Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
223429059|NCT02232854|BEHAVIORAL|Depression training/supervision program|"The intervention will be composed of:~* Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~* After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~* Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~* Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
223429060|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
223429061|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
223429062|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
223429063|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
223429064|NCT01238562|DRUG|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
223429065|NCT05976308|DRUG|Bushen Huatan Decoction|The treatment group used Bushen Huatan Decoction, including Tusizi (the seed of Chinese dodder), Fupenzi (Raspberry), Bajitian (Morinda officinalis), Duzhong (Eucommia ulmoides), Shudi (prepared Rehmanniaroot), Fuling (Tuckahoe), Zelan (Aconitum gymnandrum), Zexie (Rhizoma alismatis), Guizhi (Cassia twig), Zhebeimu (Thunberg Fritillary Bulb), Taoren (Peach kernel) and Chuanxiong (Ligusticum wallichii). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
223429066|NCT05976308|DRUG|Placebo|The treatment group used Caramel pigment, Ku Ding Cha Extracts, Maltodextrin, Starch and 5% Bushen Huatan Decoction.
223429067|NCT04511195|DIETARY_SUPPLEMENT|Standardized extract of Sphaeralcea angustifolia|Each patient will be treated topically with a gel containing the Sphaeralcea angustifolia extract three times a day for 4 weeks. Sphaeralcea angustifolia extract is standardized in its active compounds content: Sphaeralcic acid and scopoletin
223429068|NCT04511195|DRUG|Diclofenac Sodium Gel|Each patient will be treated topically with a gel containing 2% diclofenac three times a day for 4 weeks.
223429069|NCT01272141|DRUG|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily"
223429070|NCT00572052|DEVICE|NovoFine® needle 6 mm|
223429071|NCT00572052|DEVICE|Ultra-Fine needle 12.7 mm|
223429072|NCT01819753|PROCEDURE|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
223429073|NCT05574803|DEVICE|Active-tDCS|Active-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (20 minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program.
223429074|NCT05574803|DEVICE|Sham-tDCS|Sham-tDCS (1 mA) over the supplementary motor area (SMA) for 5 sessions (one minutes per session, weekly), along with behavioural therapy of speaking tasks (i.e., story narration and conversation) using the minimum prolongation technique based on the Camperdown Program. Participants will receive initial stimulation for one minute, eliciting a tingling sensation on the scalp then it will be discontinued.
223429075|NCT04543721|DEVICE|24-h-ABPM|24-h- blood pressure measurement and pulse wave analysis
223429076|NCT02935582|DRUG|Enstilar® aerosol foam|Treatment according to local labelling
223429077|NCT02935582|DRUG|Other topical|Treatment according to local practise
223429078|NCT05556564|DRUG|observational study|No intervention, observational study
223564557|NCT06528418|OTHER|Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system|Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
223564558|NCT01454128|BEHAVIORAL|exercise|36 session supervised exercise intervention
223564559|NCT02845479|OTHER|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
223564560|NCT00804752|DRUG|Adding vitamin D|Adding 1000IU/Vitamin D daily
223564561|NCT00804752|DRUG|Vitamin D|Addition of 1000IU/day Vitamin D
223564562|NCT00002705|DRUG|topotecan hydrochloride|
224039330|NCT05556954|PROCEDURE|Wound debridement|"Participant that are having usual care visits for management of diabetic foot ulcers will be enrolled into this study. The procedure is done as part of standard of care. Tissue from the samples will be analyzed for this study.~Aliquoting and Deoxyribonucleic acid (DNA) extraction will be done on the specimens. Bacterial DNA from biospecimens will be isolated, quantified, amplified, and sequenced."
224039331|NCT06780449|DRUG|Cagrilintide|Participants will receive cagrilintide subcutaneously.
223429079|NCT03350308|OTHER|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
223429080|NCT02758444|DIETARY_SUPPLEMENT|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
223429081|NCT02758444|DIETARY_SUPPLEMENT|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
223429082|NCT02758444|DIETARY_SUPPLEMENT|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
223564563|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS plus GOS|
223564564|NCT03469518|DIETARY_SUPPLEMENT|β-Cx plus PS|
223564565|NCT04011566|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
224039332|NCT06780449|DRUG|Semaglutide|Participants will receive semaglutide subcutaneously.
223564566|NCT05160168|DRUG|THE-630|Oral THE-630 administered once daily in a continuous regimen
223564567|NCT01762735|OTHER|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
223564568|NCT01762735|OTHER|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
223564569|NCT05042323|BEHAVIORAL|TF-CBT-Short|Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
223564570|NCT04543266|PROCEDURE|Surgery|Resection of tumors
223429083|NCT02758444|DIETARY_SUPPLEMENT|MNP without Zn|Same as above except MNP will not contain Zn
223429084|NCT02339155|BIOLOGICAL|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
223429085|NCT02339155|BIOLOGICAL|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
223429086|NCT02339155|DRUG|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
223429087|NCT00162149|DRUG|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
223429088|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
223429089|NCT00162149|DRUG|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
223429090|NCT00162149|DRUG|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
223429091|NCT00842075|DRUG|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
223429092|NCT01214252|DEVICE|Permacol Surgical Implant|Permacol Surgical Implant
223429093|NCT05610800|DRUG|Exenatide 2 milligram (mg) Injection|Exenatide will be purchased commercially as Bydureon for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 14 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.
223429094|NCT05610800|DRUG|Placebo|Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered 2 mg subcutaneously using insulin syringes.
223429095|NCT05610800|DRUG|Nicotine patch|"Nicotine patches will be purchased commercially and dispensed during clinic visits for one week of use.~Participants who smoke \>10 cigarettes/day will receive 21 mg patches for the first 12 weeks, 14 mg patches for week 13, and 7 mg patches for week 14.~Participants who smoke 5-10 cigarettes per day will receive 14 mg patches for the first 12 weeks and 7 mg patches for weeks 13 and 14."
223429096|NCT05610800|BEHAVIORAL|Smoking Cessation Counseling|Participants will receive brief individual behavioral smoking cessation counseling that consist of weekly in-person sessions and 2 brief (10-15 min) supportive phone calls (once pre-quit and again 3-days post-quit), spanning the 14-week active treatment phase. Counseling will be provided by master's level clinicians who will receive at least 8 hours of initial training.
224039333|NCT06780449|DRUG|Placebo cagrilintide|Participants will receive placebo matched to cagrilintide subcutaneously.
224039334|NCT06780449|DRUG|Placebo semaglutide|Participants will receive placebo matched to semaglutide subcutaneously.
224039335|NCT06739785|OTHER|SCAT6-tr|"Step 1: Initial Translation At this stage, two independent bilingual translators whose native language is Turkish will translate the content into Turkish. Step 2: Integration of Translations~A single translation will be created by comparing the two Turkish versions of SCAT 6.~Step 3: Back-translation The Turkish version will be translated into English by 2 bilingual colleagues who are blind to the original version. The Turkish version will be translated into English by 2 bilingual colleagues who are blind to the original version. These two English versions will be compared, differences will be resolved by consensus and a new combined version will be created. If consensus cannot be reached, a third person will be asked for help. Step 4: Expert Evaluation"
224039336|NCT07071194|PROCEDURE|OMT|Patients in the treatment group will undergo OMT using sub-occipital release, rib raising, doming the diaphragm, thoracic inlet release and myofascial techniques.
223429097|NCT02703506|OTHER|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
223429098|NCT02703506|OTHER|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
223429099|NCT03250585|DIAGNOSTIC_TEST|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
223429100|NCT03250585|DIAGNOSTIC_TEST|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
223429101|NCT05008809|DRUG|mFOLFOX6|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: (optional: 400 mg/m² bolus, 2-5 min IV infusion), 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
223429102|NCT05008809|DRUG|mFOLFOXIRI|Oxaliplatin: 85 mg/m², 2h IV infusion on d1 Irinotecan: 150 mg/m², 90 min IV infusion on d1 Folinic acid: 400 mg/m², 1-2 h IV infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles are administered.
223429103|NCT05008809|DRUG|FOLFIRI|Folinic acid: 400mg/m², 1-2h IV Infusion on d1 5-FU: 2400 mg/m², 46 h IV infusion on d1 Irinotecan: 180 mg/m², 90-120 min IV infusion on d1 Cycles are repeated on day 15. A total of up to 12 cycles is administered.
223429104|NCT05008809|DRUG|CAPOX|Capecitabine: 1000 mg/m², oral 1-0-1 on d1-14 Oxaliplatin: 130 mg/m², 3h IV infusion on d1 Cycles are repeated on day 22. A total of up to 8 cycles isadministered.
223429105|NCT00360815|BEHAVIORAL|Insulin|
223429106|NCT01827878|DRUG|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
223429107|NCT01827878|DRUG|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
223429108|NCT02176083|BEHAVIORAL|Text message management prompts|
223429109|NCT02036671|DEVICE|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
223429110|NCT02957045|PROCEDURE|Cough pressure measurement|
223429111|NCT02957045|DEVICE|Pcough|
223429112|NCT04327661|DRUG|Tradipitant|Oral Capsule
223429113|NCT04327661|DRUG|Placebo|Oral Capsule
223429114|NCT02817698|DRUG|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
224039337|NCT07071194|OTHER|Light touch|Patients in the control group will undergo light touch in similar locations to OMT.
224039338|NCT07071623|DRUG|MK-8527|Oral tablet
224039339|NCT07071623|DRUG|Emtricitabine/tenofovir disoproxil (FTC/TDF)|Oral tablet
224039340|NCT07071623|DRUG|Placebo matched to MK-8527|Placebo oral tablet matched to MK-8527
223429115|NCT03427268|DRUG|PM060184|"PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle)."
223429116|NCT03702491|DRUG|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
223429117|NCT03702491|DRUG|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
223429118|NCT02320682|DEVICE|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
223429119|NCT02671825|DRUG|PUR0200|PUR0200 dry powder inhalation
223429120|NCT02671825|DRUG|Reference Product|Dry Powder Inhalation Reference Product
223740239|NCT07205198|DRUG|SIBP-A10|"SIBP-A10 injection. Strength: 0.5, 1.5, 3, 5, 7, 10 and 15 mg/kg. Intravenous infusion administration, with a treatment cycle of every 21 days, administered once on the first day of each cycle. The dose escalation stage,0.5 mg/kg group was subjected to accelerated titration, where the safety was evaluated within 21 days after the first administration to one subject. If unacceptable toxic reactions occurred, the traditional 3+3 dose escalation method was immediately switched. If unacceptable toxic reactions do not occur, the next dose group will be explored. The third stage will use RP2D for further exploration."
224039341|NCT07071623|DRUG|Placebo matched to FTC/TDF|Placebo oral tablet matched to FTC/TDF
224039342|NCT07069699|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224039343|NCT07069699|PROCEDURE|Biospecimen Collection|Undergo CSF and blood sample collection
223429121|NCT01542905|DIETARY_SUPPLEMENT|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
223429122|NCT01542905|OTHER|Placebo|Placebo Capsule (1g/day) for 8 Weeks
223429123|NCT01813734|DRUG|Ponatinib|28 day cycle
223429124|NCT03357900|DEVICE|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
223429125|NCT00345878|BIOLOGICAL|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223429126|NCT00345878|BIOLOGICAL|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
223429127|NCT02498509|DRUG|CKD-342|treatment for 4 weeks after randomization
223429128|NCT02498509|DRUG|Mometasone furoate|treatment for 4 weeks after randomization
223429129|NCT02498509|DRUG|Levocabastine HCL|treatment for 4 weeks after randomization
223429130|NCT05848323|BEHAVIORAL|4-week Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
223429131|NCT05848323|BEHAVIORAL|4-week Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
223478305|NCT00666237|PROCEDURE|Trabeculectomy|The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.
223478306|NCT00666237|DRUG|Mitomycin C|A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes
223478307|NCT04102137|BIOLOGICAL|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
223478308|NCT04102137|BIOLOGICAL|Boostagen (TDaP BioNet)|"Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
223478309|NCT04102137|BIOLOGICAL|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
223478310|NCT05767983|OTHER|Fat-free milk|Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).
223478311|NCT05767983|OTHER|Fat-free yogurt|Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).
223478312|NCT05767983|OTHER|Low-fat cheese|Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).
223429132|NCT05848323|BEHAVIORAL|4-week Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
223429133|NCT05390723|BEHAVIORAL|Communciation intervention|The investigators cannot reveal the manipulated communication as this might influence participant outcomes.
223429134|NCT05393934|OTHER|High dense nutrients formula|High dense nutrients formula: Powder based Infant formula with High Nutrients' Density with energy density of 100 kcal/100ml and for Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
223429135|NCT05393934|OTHER|Pediatric Nutrition Care (PNC)|Pediatric Nutrition Care: A medical service to understand nutritional status, problems related to the feeding process and clinical diagnosis of the patient.
223429136|NCT00002030|DRUG|Pentamidine isethionate|
223429137|NCT00507351|BEHAVIORAL|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
223429138|NCT00148655|DEVICE|Decision Board|Decision board that explains the risks and benefits of treatment options
223429139|NCT06851663|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
223429140|NCT06851663|DRUG|[68Ga]Ga-NOTA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
223429141|NCT06851663|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
223429142|NCT06851663|DRUG|[18F]F-RESCA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
223429143|NCT01622205|OTHER|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
223429144|NCT01622205|OTHER|Ordinary rehabilitation|Ordinary rehabilitation
223429145|NCT06272760|OTHER|Home-based hand-arm bimanual intensive training (Tele-HABIT)|Hand-Arm Bimanual Intensive Therapy (HABIT) is a therapeutic approach designed to improve the motor skills and functional use of both arms in individuals with conditions such as cerebral palsy. The core principle of HABIT is to encourage voluntary exercise by actively engaging the affected side, which may be weaker or partially paralyzed, in various activities. This approach aims to reduce physical and mental discomfort while maximizing the effectiveness of the training. HABIT has been adapted into a home-based format by ZOOM, referred to as Home-Based HABIT (H-HABIT).
223429146|NCT05756231|BEHAVIORAL|SIHT-16|a pencil-paper assessment tool.
223429147|NCT06330311|OTHER|Physiotherapy|Evidence-based multimodal physiotherapy treatment based on learning and motor control
223429148|NCT02179606|DEVICE|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
223429149|NCT02179606|DEVICE|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
223429150|NCT04927377|BEHAVIORAL|AI4DM|Those in the AI4DM intervention arm will receive weekly and bi-weekly calls for six months, access to home and online technology, diabetes-related multimedia educational content, a technology package including a voice-assistive device, wireless glucometer, and wrist-worn activity monitor
223478313|NCT05767983|OTHER|Fruit juice|Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).
224039344|NCT07069699|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224039345|NCT07069699|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224039346|NCT07069699|DRUG|Pidnarulex|Given IV
224039347|NCT07069699|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224039348|NCT04491175|DEVICE|M-Stim|"The casing for the device is a 54 belt with 3-button haptic controller for on-off, therapy cycles(8) and intensity(5) levels."
224039349|NCT04491175|DEVICE|TENS|LG SMART TENS stimulator is a portable electrotherapy devcie featuring transcutaneous electrical nerve stimulation (TENS) therapeutic device, which is used for pain relief. The stimulator sends a gentle electrical current to underlying nerves and muscle groups via electrodes applied on the skin. The parameters of the device are controlled by buttons on a controller with an adjustable intensity level.
224039350|NCT07070232|DRUG|BNT326|Intravenous (IV) infusion
224039351|NCT07070232|DRUG|BNT327|IV infusion
224039352|NCT07070232|DRUG|Itraconazole|Oral administration
224039353|NCT07070232|DRUG|Paroxetine|Oral administration
224039354|NCT06802549|DEVICE|Biodentine (calcium silicate-based cement) (Septodont, Saint Maur de Fossés, France)|It will be placed on the exposed pulp with the help of a carrier and the exposed pulp will be covered with material
224039355|NCT06802549|DEVICE|Theracal PT (resin modified calcium silicate-based cement) (Bisco Inc., Schaumburg, IL, USA)|It will be placed on the exposed pulp with the help of its injection tip and the exposed pulp will be covered with material
223429151|NCT04927377|BEHAVIORAL|Attention-control|Those in the Attention-control Group will receive telecoaching calls at the same frequency of the Intervention Group. Coaching calls will focus on general wellbeing, rather than diabetes-related topics. The Attention-control Group will serve as an untreated comparison group for the Intervention Group.
223429152|NCT04810247|BEHAVIORAL|Body Project|The Body project is a dissonance based intervention designed to target negative body image among adolescent females. The intervention is delivered in small groups of 5-10 individuals over 4, one-hour group sessions. This program will be iteratively revised for use among adult women with weight/shape concern and higher body weight.
223429153|NCT03611231|DRUG|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
223429154|NCT04094272|DIAGNOSTIC_TEST|transthoracic doppler-echocardiography (TTE)|Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
223429155|NCT01995175|PROCEDURE|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
223429156|NCT01995175|PROCEDURE|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
223429157|NCT01995175|OTHER|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
223429158|NCT04773652|DIAGNOSTIC_TEST|speckle tracking echo|Two-dimensional and 3D Speckle tracking echocardiography and feature tracking CMR will be performed twice: within 48 hours of admission and 3 months following the index event.
223429159|NCT01877551|DRUG|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
223429160|NCT01877551|OTHER|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
223429161|NCT06042361|BEHAVIORAL|Smokefree Implementation Framework and Toolkit|"Framework and toolkit that includes Implementation Guide, Action Plan, and Implementation Checklist that supports the needs of Permanent Supportive Housing communities."
223429162|NCT04932746|DRUG|Dexmedetomidine|"Infusion syringes are supplied with a concentration of 0.25 mcg / mL (dexmedetomidine or placebo) either 80 mcg / 20 mL, 200 mcg / 50 mL, or 400 mcg / 100 mL.~It begins with infusion of 4 ml within 10 minutes and then continues infusion, depending on the child's weight, at 1.6 ml / kg / h.~All injections will be prepared randomly by a doctor who did not participate in the study, and then placed in unmarked infusion pumps, given to an anesthesiologist (more than 10 years experience in pediatric anesthesia) without knowledge of the infusion content. The randomization process is carried out via sealed envelope technique.~The injections in both groups will be stopped before the skin is closed. Both patients and anesthesiologists blinded the study drug (dexmedetomidine or placebo) by infusion of solution (dexmedetomidine or placebo). Depending on the size in ml, to ensure that there is no bias and blindness to the medical team about what the drug is."
223429163|NCT04932746|DRUG|Placebo|The same anesthesia, the same amount of Saline solution will be administered, instead of dexmedetomidine, with the same protocol
223429164|NCT00984061|DRUG|colchicine|0.6mg tablet administered at 9am on Day 1
223564571|NCT06339242|DRUG|Furmonertinib|After completion of all screening activities, eligible patients were confirmed to enter the study. All patients will receive study treatment, Furmonertinib tablets 160mg, oral, once daily, lateral ventricular chemotherapy with Ommaya capsule technique until disease progression, intolerable toxicity, death, withdrawal of informed consent.
223429165|NCT00984061|DRUG|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
223429166|NCT00984061|DRUG|colchicine|0.6 mg tablet administered at 9am on Day 29
223429167|NCT04853342|DRUG|Drug: Furmonertinib 80 mg|The initial dose of Furmonertinib 80 mg once daily
223429168|NCT04853342|DRUG|Furmonertinib 80 mg placebo|The initial dose of Furmonertinib 80 mg once daily
223429169|NCT05838742|DRUG|GSK3858279|GSK3858279 will be administered.
223429170|NCT05838742|DRUG|Placebo|Placebo will be administered.
223564572|NCT00606541|DRUG|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
224039356|NCT06388083|DRUG|Tinlarebant|5 mg tablet
224039357|NCT06388083|DRUG|Placebo|Placebo tablets
223564573|NCT00606541|DRUG|Placebo|Placebo
223564574|NCT00176488|DRUG|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
224039358|NCT05356000|OTHER|Special low-oxalate diet followed by all-day visit to University of Chicago research clinic|"Active participation in this study will last for around one week. For the first two days, participants will be asked to eat a special diet at home. From Days 3-5, they will eat special meals that will be delivered to their home from a research clinic at the University of Chicago. They will also collect urine at home on Days 4 and 5.~On Day 6, subjects will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. They will receive a special liquid that contains oxalate, and will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect their urine and blood throughout the day. We will draw blood 4 separate times."
224039359|NCT06841991|BEHAVIORAL|Teach Back Education|The relatives of patients who will undergo colonoscopy will be trained with the teach-back technique.
223429171|NCT05896553|DRUG|intranasal Oxytocin(24IU)|Administration of intranasal Oxytocin(24IU)
223429172|NCT05896553|DRUG|intranasal Placebo|Administration of intranasal Placebo
223429173|NCT02697890|DEVICE|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
223429174|NCT02697890|DEVICE|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
223429175|NCT06652438|DRUG|Revumenib|day 1- 28 per cycle
223429176|NCT06652438|DRUG|Placebo|day 1- 28 per cycle
224039360|NCT06889389|BEHAVIORAL|Education|The intervention consists of 20 minutes of pain neuroscience education, focused on concepts related to movement-related fear and the benefits of exercise for managing pain. Specific exercises, mentioned in the generic part of the procedure, will be discussed during this session. This intervention aims to modify the subjects' beliefs regarding exercises and their neck pain.
224039361|NCT06889389|OTHER|Excercise|The exercise intervention includes performance tests and variations of these tests used as exercises, such as the Closed Kinetic Chain Upper Extremity Stability Test, Single Arm Military Press, and Seated Medicine Ball Throw. Variations of these performance tests will be implemented, with adjustments made to the load or execution time until the participant reports a perceived fatigue of 4-6 (moderate to strong) on the modified Borg scale.
224039362|NCT06889389|OTHER|Placebo|The placebo intervention involves the application of a TENS device, which will be placed on the participant and kept turned off for 15 minutes. Subjects will be informed that the device is working at a very low intensity, too weak to be perceived. This intervention aims to simulate the experience of treatment without delivering any therapeutic effect.
224039363|NCT06890260|OTHER|Electroacupuncture combined with Microneedle Knife|The patient takes the supine position, the acupoints take bilateral Yingxiang acupoints and upper Yingxiang acupoints, the tip of the needle is stabbed obliquely towards the root of the nose for 5-10mm, to the extent that there is a feeling of soreness and distension in the nose, and perform the flat tonic and flat cathartic method, the waveform of electroacupuncture is selected as sparse and dense wave, the frequency is 2/100Hz, the strength of the current is taken as the degree that the patient can tolerate it, and the time of energizing is 30min; and then the patient takes the seated position, with his head hanging down low on the therapeutic pillow, and the therapeutic point of occipitocervical segment is selected, Then the patient is placed on the therapeutic pillow in a sitting position with the head hanging low, the treatment point of the occipitocervical segment is selected, the treatment point of the cervicothoracic junction is marked, and the micro-needle knife cuts and loose
223429177|NCT06157164|OTHER|UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)|Simultaneous UroLift™ and Holmium Laser Enucleation of the Prostate (HoLEP) for the Treatment of BPH in Men with Prominent Median Lobe Desiring Preservation of Ejaculation
223429178|NCT04695262|PROCEDURE|EUS-FNB|Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB)
223429179|NCT02659514|DRUG|Poziotinib|8 mg oral tablets, administered QD.
223429180|NCT05803213|OTHER|Virtual Reality 360 interactive video|Clinical scenarios revised and presented with 360 video, and interactive design on the learning platform that is available anytime and anywhere to the medical students
223429181|NCT05803213|OTHER|Traditional mini-lecture|Clinical scenario described according to the script as a mini-lecture to the medical students
224139370|NCT03083509|OTHER|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
224139371|NCT03930641|DRUG|RTH258|6 mg in prefilled syringe
224139372|NCT03849976|BEHAVIORAL|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
223429182|NCT01380717|DRUG|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
223429183|NCT01380717|DRUG|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
223429184|NCT03828110|DEVICE|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
223429185|NCT03828110|PROCEDURE|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
223429186|NCT04869319|BEHAVIORAL|MyChart message|Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
223429187|NCT05245721|DRUG|Nalbuphine|Caudal nalbuphine injection in pediatrics undergoing infra-umbilical surgeries
223429188|NCT05245721|DRUG|Bupivacain|Caudal bupivacaine in pediatrics undergoing infra-umbilical surgeries
223429189|NCT03823079|DRUG|rhTPO|rhTPO 300u/kg, subcutaneous injection, qd
223429190|NCT03823079|DRUG|irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
223429191|NCT03823079|DRUG|Raltitrexed|3mg/m2 q3w
223429192|NCT03823079|RADIATION|radiotherapy|in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
223429193|NCT03823079|DRUG|rhIL-11|rhIL-11 50ug/kg, subcutaneous injection, qd
223429194|NCT00455559|DRUG|Perifosine|
223429195|NCT00455559|DRUG|Imatinib Mesylate|
223429196|NCT06608875|BEHAVIORAL|Hyper-personalized feedback (HPF intervention)|For lower limb motor rehabilitation, the investigator will employ real-time continuous feedback for movement aspects that are specific to each participant's motor deficit. The feedback will be adapted and tailored to each participant.
223478314|NCT05767983|OTHER|Snack skipping|Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
223429197|NCT06608875|BEHAVIORAL|Targeted auditory stimulation during sleep (TASS verum intervention)|The investigator aim to reactivate rehabilitation- related memories through the presentation of auditory stimuli during sleep with the goal of promoting motor memory consolidation into stable motor commands
223429198|NCT06608875|BEHAVIORAL|Control targeted auditory stimulation during sleep (TASS sham intervention)|Identical auditory presentation during the motor rehabilitation training, but not during the night (sham promotion memory reactivation)
224039364|NCT06890260|DRUG|Cetirizine hydrochloride tablets combined with nasal budesonide spray.|Cetirizine hydrochloride tablets (specification: 10mg\*24 tablets, Suzhou Sinochem Pharmaceutical Industry Co., Ltd., State Pharmaceutical License: H20030447) shall be given, 1 tablet daily. At the same time, nasal budesonide spray (specification: 64μg\*120 sprays, AstraZeneca Pharmaceuticals Co., Ltd, State Pharmaceutical License: J20090079) shall be used: the starting dose shall be 2 sprays in each nostril twice a day, and after 3 days, it shall be reduced to 1 spray in each nostril twice a day, and then changed to 1 spray once a day after 1 week, which shall be used as the maintenance dose. The dosage will be increased or decreased at the patient's discretion according to the symptomatic condition during the course of treatment for a total of 4 weeks of treatment and observation. No other drugs for allergic rhinitis will be used during the treatment period.
224039365|NCT06809309|OTHER|Positive pressure ventilation during cardiopulmonary resuscitation|"The primary exposures of interest are the observed ventilation rate, tidal volume and minute ventilation during cardiopulmonary resuscitation.~Ventilation data are obtained by inspiratory and expiratory air flow measurements using the EOlife (Archeon, Besançon, France) to which healthcare providers are blinded."
224039366|NCT07072481|BEHAVIORAL|Activities|"Activities include the implementation of the three main components of 4YBY that include;~1\) provision of HIV self-testing bundles and navigation to youth-friendly clinical sites for sexually transmitted infection screening to recruited youth participants; 2) use of trained community health workers to implement the HIV self-testing bundles and STI screening services to recruited youth participants; and 3) peer-to-peer support and supervision on what works or does not work with implementing 4YBY services among recruited youth participants."
224039367|NCT07072481|BEHAVIORAL|Benefits|The benefits are conceptualized at the individual, community and CBO levels. At the individual level, at-risk youth gain access to HIV prevention services and educational materials. Community outreach will tailor educational materials to local needs, enhancing the overall impact. CBOs will form academic-community partnerships, receive training, and access resources to sustain 4YBY. A quarterly learning collaborative will also promote effective implementation.
224039368|NCT07072481|BEHAVIORAL|Capacity|Following a baseline assessment, CBOs will receive initial training on 4YBY through live videoconferences, with options for self-study for those unable to attend. Training will cover research evidence, implementation procedures, and necessary tools. Refresher training will occur every six months, ensuring ongoing support. Young people will engage in educational meetings to improve program uptake, assess quality, and enhance long-term retention.
223429199|NCT00006007|DRUG|gemcitabine hydrochloride|
223429200|NCT00006007|DRUG|pemetrexed disodium|
223429201|NCT01504607|PROCEDURE|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
223429202|NCT03387228|OTHER|Pain education|"Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes."
223429203|NCT03387228|OTHER|Control group|"The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking."
223429204|NCT01628653|DEVICE|U-SMART|4-weeks' training
223429205|NCT05390151|PROCEDURE|Laser treatment of anal fistula|using a radial laserprobe to treat transsphincteric fistula
223429206|NCT05390151|PROCEDURE|RAF|current golden standard in transsphincteric fistula surgery
223429207|NCT03352193|DIETARY_SUPPLEMENT|Wheat spaghetti|Wheat oral immunotherapy
223429208|NCT04560283|DRUG|Vaginal gel HYALOGYN®|Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks
223429209|NCT04560283|BEHAVIORAL|Expectant management|Expectant management for 12 consecutive weeks
223478315|NCT03783065|DRUG|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
223478316|NCT03783065|PROCEDURE|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
223478317|NCT03783065|PROCEDURE|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
223478318|NCT04433104|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells transplantation|Patients assigned to UC-MSC administration groups will receive two administrations at a dose of 1 million cells/kg patient body weight via the IV route with a 3-month intervening interval
223478319|NCT04433104|DRUG|drug therapy according to Vietnamese MOHS procedure|Salbutamol, Terbutaline
223478320|NCT05441189|PROCEDURE|Resection|radical R0 resection of pancreatic adenocarcinoma
223478321|NCT01416571|BIOLOGICAL|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
223478322|NCT03184246|DEVICE|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
223478323|NCT03184246|DEVICE|Direct laryngoscopy|direct laryngoscopy will be used for intubation
223478324|NCT05502029|BEHAVIORAL|Extended translation|Translation extended beyond the preoperative area
223429210|NCT02092480|BEHAVIORAL|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
223429211|NCT00742872|DRUG|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
223429212|NCT00742872|DRUG|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
223429213|NCT06667323|OTHER|Integrated health service delivery for very young adolescent girls|The proposed HPV-VISION intervention will aim to increase girl-centered access to HPV vaccination and other VYA services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health post level.
223429214|NCT03264781|DRUG|Cyclofem|Intramuscularly injection 0.5 ml of Cyclofem or placebo
223429215|NCT02455258|OTHER|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
223429216|NCT02455258|OTHER|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
223429217|NCT06215924|OTHER|Reverse Kegel exercise|In addition to the training given by the physician, patients will be taught the 'Reverse Kegel' exercise. The 'Reverse Kegel' exercise is an exercise that is used to relax the pelvic floor muscles. To practice the exercise, patients will be asked to lie in a supine position with a support under the knees. In this position, patients will be asked to relax the pelvic floor muscles while breathing through their nose, maintain this movement for 5 seconds, and tighten the pelvic floor muscles while exhaling. Patients will be advised to do this exercise for 5 sets, 10 repetitions during the day. On the day of the training, initial evaluations will be made to the patients before the exercise training is given. Evaluations will be repeated at the end of the second and fourth week.
223429218|NCT06215924|OTHER|Postisometric Relaxation Technique|In addition to training given by the physican, internal digital Postisometric Relaxation method will be applied to the patients in this group from the anal region. Application will be made to the muscles where muscle spasm, movement restriction and pain are detected. The patient will be asked to perform a contraction against the digital resistance with maximum force and maintain this contraction for 5 seconds, actively relax after 5 seconds. During relaxation, stretching will be applied for 30 seconds by digitally supporting the movement of the pelvic floor muscles. The process will be performed with 5 repetitions. The application will be made 2 days a week for 4 weeks. On the day of the training, initial evaluations will be made to the patients before the exercise training is given.Evaluations will be repeated at the end of the second and fourth week.
223478325|NCT05502029|BEHAVIORAL|Standard translation|Translation in the preoperative area
223478326|NCT03795415|BEHAVIORAL|Gundo So|"Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools."
223478327|NCT03353220|DRUG|Belviq|Belviq is an oral drug
223478328|NCT03353220|DRUG|Placebo|The placebo is made to mimic Belviq, but does not contain any active drug
223478329|NCT01001741|OTHER|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
223740240|NCT07205614|OTHER|pain consultation, biopsychosocial pain education + usual care|"Participants will receive a link to a digital pain education program. The program will include standard information about endometriosis, but will also introduce a biopsychosocial understanding of pain including influence of psychological factors such as excessive worry, stress, sleep disturbance and emotional distress. Self-management strategies including physical activity, relaxation and breathing techniques, cognitive techniques, psychosocial support and appropriate use of pain medication and supplemental treatment (e.g. physical therapy, TENS, heat), will be introduced.~Participants will then attend a single good pain consultation, a patient-centered consultation with a clinician associated with the project, in which content from the educational package will be reinforced. The consultation will provide the opportunity to address the biopsychosocial factors including anxiety, previous trauma, emotional distress etc. Shared decision-making regarding preferred self-management strat"
223478330|NCT03680027|DIETARY_SUPPLEMENT|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
223478331|NCT02615886|OTHER|Observational Control|Participants will be observed and not provided any dietary supplementation.
223478332|NCT02615886|DIETARY_SUPPLEMENT|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
223429219|NCT06621108|OTHER|Focus group session|Participants will take part in a focus group, which includes sharing their experience of the four-week feeling tone mindfulness course in an online group session. The focus group session will be led by trained moderator, and attended by several other course participants who completed the four-week feeling tone mindfulness course. The session will be audio-recorded as the research team will analyze the qualitative feedback offered by participants.
223429220|NCT02353494|DRUG|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
223429221|NCT04197674|OTHER|Dialysis modality|This is a observational cohort study, and there is no intervention for all participants. Our aim is to evaluate dialysis modality (PD and HD) on patient survival
223429222|NCT03578458|OTHER|subjects will install a mobile app for use|novel mobile application
223429223|NCT05069142|OTHER|Rehabilitation|Pre- and post-operative exercise and education.
223429224|NCT05026099|OTHER|Boxing training|Boxing training: warm-up. Mitt hitting, sandbag hitting, in sitting, cool down, Assessment after 4 weeks boxing training: warm-up. Mitt hitting, sandbag hitting, below hips, cool down, Assessment after 6 weeks Boxing training: warm-up. Mitt hitting, sandbag hitting, both inn sitting and standing, cool down, Post assessment
223429225|NCT05026099|OTHER|Task Oriented Training|Task-oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 4 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Assessment after 6 weeks Task oriented training: 6 tasks in sitting and standing position for both upper and lower limb Post assessment
223429226|NCT00003913|BIOLOGICAL|anti-thymocyte globulin|
223429227|NCT00003913|BIOLOGICAL|filgrastim|
223429228|NCT00003913|DRUG|busulfan|
223429229|NCT00003913|DRUG|cyclophosphamide|
223429230|NCT00003913|DRUG|methylprednisolone|
223429231|NCT00003913|PROCEDURE|umbilical cord blood transplantation|
223429232|NCT00003913|RADIATION|radiation therapy|
223429233|NCT06620497|PROCEDURE|stress free implant bar|SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.
223429234|NCT06620497|PROCEDURE|milled bar|bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
223429235|NCT03289598|BEHAVIORAL|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~1. Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~2. The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
223429236|NCT01968707|DRUG|ChloraPrep Hi-Lite Orange|Apply topically.
223429237|NCT01968707|DRUG|Normal saline|Apply topically.
223564575|NCT00176488|DRUG|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
223564576|NCT00372372|DRUG|risedronate|
223564577|NCT01980836|BIOLOGICAL|Seasonal influenza vaccine|
223740241|NCT07205614|OTHER|Usual Care|Usual follow up at the department of gynecology
224039369|NCT07072481|BEHAVIORAL|Activities-S|Activities include the implementation of the three main components of 4YBY that include; 1) provision of HIV self-testing bundles and navigation to youth-friendly clinical sites for sexually transmitted infection screening to recruit youth participants; 2) use of trained community health workers to implement the HIV self-testing bundles and STI screening services to recruited youth participants; and 3) peer-to-peer support and supervision on what works or does not work with implementing 4YBY services among recruited youth participants.
224039370|NCT07072481|BEHAVIORAL|Benefits-S|The benefits are conceptualized at the individual, community, and CBO levels. At the individual level, at-risk youth gain access to HIV prevention services and educational materials. Community outreach will tailor educational materials to local needs, enhancing the overall impact. CBOs will form academic-community partnerships, receive training, and access resources to sustain 4YBY. A quarterly learning collaborative will also promote effective implementation.
223429238|NCT01968707|DRUG|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
223429239|NCT01968707|DRUG|3M CHG/IPA Prep Tint 26-mL|Apply topically
223740242|NCT07206589|OTHER|Cancer Screening|Undergo BE-SOS test
223740243|NCT07206589|OTHER|Computer-Assisted Intervention|Undergo BE risk assessment using AI powered BE Risk Tool
223429240|NCT06664320|PROCEDURE|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
223429241|NCT06664320|DRUG|hydroxyethyl starch (HES 130/0.6)|hydroxyethyl starch (HES 130/0.6)
223429242|NCT02395237|DRUG|: Amaryl® M IR 2/1000|
223429243|NCT04736927|DRUG|GLPG3667|From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
223429244|NCT04736927|DRUG|Midazolam|On Day 1 and Day 7 as liquid formulation, orally in fed state.
223429245|NCT00916344|DEVICE|EVIA Pacemaker|patient has standard indication for pacemaker therapy
223564578|NCT01081704|DRUG|ustekinumab|Single dose of 45 mg subcutaneous injection
223564579|NCT01081704|DRUG|ustekinumab|Single dose of 90 mg subcutaneous injection
223564580|NCT03130621|DIAGNOSTIC_TEST|Gene detection|Next-generation sequencing
223564581|NCT04355442|PROCEDURE|Facial fractures reduction or osteosynthesis|Facial fractures reduction or osteosynthesis
223740244|NCT07206589|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
223740245|NCT07206589|BEHAVIORAL|Health Risk Assessment|Undergo manual BE risk assessment
223740246|NCT07206589|OTHER|Navigation|Receive RN navigation
224039371|NCT07072481|BEHAVIORAL|Capacity-S|Following a baseline assessment, CBOs will receive initial training on 4YBY through live videoconference, with options for self-study for those unable to attend. Training will cover research evidence, implementation procedures, and necessary tools. Refresher training will occur every six months, ensuring ongoing support. Young people will engage in educational meetings to improve program uptake, assess quality, and enhance long-term retention.
224039372|NCT07072481|BEHAVIORAL|People|Sustainability teams will be established in CBOs to lead the implementation of their sustainability blueprint for 4YBY. These teams will train staff, monitor goals, and provide feedback on performance and progress over time
224039373|NCT07072481|BEHAVIORAL|Learning Meetings|CBOs will participate in bi-weekly collaborative meetings to enhance their sustainability efforts, share lessons learned, and support one another. These meetings will focus on creating a supportive learning environment and reinforcing leadership that promotes continuous learning.
224039374|NCT07072481|BEHAVIORAL|Adaptation Monitoring|CBOs will adapt best practices for their sustainability plans using the FRAME-IS framework to ensure that strategies meet local needs while documenting the modifications and maintained elements over time.
224039375|NCT07072481|BEHAVIORAL|Nurturing Coaches|Trained coaches will provide individualized support to CBOs, holding weekly office hours to assist with their sustainability plans, monitor progress, and address site-specific barriers to change.
224139373|NCT02181010|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
224139374|NCT02060318|DRUG|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
224139375|NCT02767856|DEVICE|IO-therapy Glasses|
224139376|NCT04611178|DEVICE|Mechanical thrombectomy|Stent retriever for treatment of cerebral arterial occlusions
224139377|NCT03537352|PROCEDURE|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
224139378|NCT03537352|DRUG|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
223429246|NCT03663465|OTHER|Hawthorn|Hawthorn tablet
223429247|NCT03663465|DRUG|SGAs|SGAs tablet
223429248|NCT05912231|RADIATION|Accelerated Proton Beam Radiation Therapy (PBT)|per protocol
223429249|NCT05912231|RADIATION|Accelerated Photon Radiation Therapy (XRT)|per protocol
223429250|NCT02946073|DRUG|buprenorphine|
223429251|NCT02946073|OTHER|Placebo|
223429252|NCT03544931|PROCEDURE|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
224139379|NCT00424294|DRUG|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
224139380|NCT00424294|DRUG|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States \[US\] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
224139381|NCT00424294|DRUG|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
223429253|NCT03544931|DEVICE|EMD Application|Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
223429254|NCT03936465|DRUG|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
223429255|NCT03936465|DRUG|BMS-986378|BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
223429256|NCT04495504|DRUG|Ropivacaine|Administration of a bolus dose of 10 ml of ropivacaine 7, 5 mg/mL in each catheter Continuous infusion of ropivacaine 2 mg/ml in a rate of 3 mL/h during the first 48 hours postoperatively.
223429257|NCT02529904|BIOLOGICAL|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
223429258|NCT02454712|DRUG|PF614|PF614 is an oxycodone prodrug
223429259|NCT02454712|DRUG|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
223429260|NCT02454712|DRUG|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
223429261|NCT01679067|PROCEDURE|colonoscopy with endoscopic biopsies|
223429262|NCT04376125|OTHER|Suboccipital inhibition in tension headache|Deep maneuver of myofascial induction in the suboccipital muscles
223429263|NCT05342922|PROCEDURE|Ultrasound group|"In the operating room, all of the patients will receive standard monitoring. Scans will be made in logiditunal parasagittal and transverse midline views with ultrasound. Needle entry sites in the L2-L3 and L3-L4 intervals will be determined as the intersection of the longiditunal and transverse lines.~When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine."
223429264|NCT05342922|PROCEDURE|Landmark group|In the Landmark group, the injection site will be determined using the traditional method of palpating the posterior superior iliac spine.When the spinal puncture operator is outside the room, Needle entry sites were marked for both groups.After skin marking, the pregnant woman will be asked to remain still and a subarachnoid puncture will be performed immediately. Spinal anesthesia will be administered with injection of intrathecal bupivacaine.
223429265|NCT02614222|DEVICE|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
223429266|NCT05803096|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-45%) for the duration of prostate biopsy.
223429267|NCT05803096|OTHER|Oxygen|Oxygen will be administered at 10 Liters/min for the duration of prostate biopsy.
223429268|NCT04211532|OTHER|Surgery|Surgical risk is calculated according to the surgery performed.
223429269|NCT01655849|DRUG|z160|
223429270|NCT01655849|DRUG|Placebo|
223429271|NCT06124248|BEHAVIORAL|RISE intervention|"The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention."
223429272|NCT01588457|DRUG|Lithium|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain Li of ≥0.5mEq/L (milliequivalents per liter).
223429273|NCT01588457|DRUG|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
223429274|NCT01588457|DRUG|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
223429275|NCT01588457|DRUG|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
223429276|NCT05333939|DIETARY_SUPPLEMENT|Moringa leaf powder|capsule ingestion
223429277|NCT05333939|OTHER|Placebo|capsule ingestion
223429278|NCT03205735|DIAGNOSTIC_TEST|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
223429279|NCT00984139|BIOLOGICAL|Engerix™-B Kinder|Intramuscular, one dose.
223429280|NCT02721524|PROCEDURE|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
223429281|NCT06213896|DRUG|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
224039377|NCT06765434|OTHER|Music ( Dmitri Shostakovich's Jazz Waltz Suite)|Music
223429282|NCT06213896|PROCEDURE|Color Fundus Photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
223429283|NCT06213896|DEVICE|EyeCheckup v2.0|Screening for existence of eye diseases
223429284|NCT06506019|DRUG|Psilocybin|25 mg psilocybin
223429285|NCT06506019|DEVICE|Functional MRI|The fMRI involving resting state measures and a facial affect task will be conducted one-day and one-month after the dosing session.
223429286|NCT03991013|DRUG|Dolutegravir 50 mg|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
223429287|NCT03991013|DRUG|Placebo|Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
223429288|NCT04690790|PROCEDURE|Thoracoscopy|Patients who are indicated for thoracoscopic nodulectomy.
224039378|NCT06765434|OTHER|Music( Personalized music)|Music
224070478|NCT04011020|COMBINATION_PRODUCT|Stem Cell Educator therapy|Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
223429289|NCT02527759|BEHAVIORAL|Survey|
223740247|NCT07206589|OTHER|Questionnaire Administration|Ancillary studies
223740248|NCT07206108|PROCEDURE|modified endocrown|Combining the advantages of post-core crown and endocrown, an modified endocrown was designed
223429290|NCT05803070|DRUG|Topical Cetirizine 1 %|topical cetirizine belongs to anti histamines group
223429291|NCT05803070|DRUG|Topical betamethasone valerate 0.1%|topical betamethasone valerate belongs to corticosteroids group
223429292|NCT02673801|OTHER|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
223429293|NCT03442478|OTHER|2D/3D Tomosynthesis|
223429294|NCT02956369|DIETARY_SUPPLEMENT|Control|Control granulates (maize starch and long-chain fatty acids) with powder
223429295|NCT02956369|DIETARY_SUPPLEMENT|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
223740249|NCT07205133|OTHER|Whole Body Vibration Training|Information already included in arm/group descriptions.
223740250|NCT07205133|OTHER|Otago Exercise|Usual Care
223429296|NCT02062944|DRUG|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
223429297|NCT05107791|DRUG|Stulln Eyedrops|Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.
223429298|NCT05107791|DRUG|Thera Tears|The eyedrops will be used in the identical manner as Stulln eyedrops.
223429299|NCT00420277|DRUG|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
223429300|NCT00420277|DRUG|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
223429301|NCT05331768|COMBINATION_PRODUCT|banding ligation plus terlipressin infusion|Subjects were randomly allocated to banding ligation plus terlipressin infusion for 24 hours (24-h group) or banding ligation plus terlipressin infusion for 72 hours (72-h group) using a blocked allocation strategy. The 72-h group received the standard treatment with administration of intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) with an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 72 hours. Terlipressin was administered blinded after endoscopic treatment and infused as a 5 ml bolus in a pre-prepared syringe. The 24-h group received intravenous terlipressin (Glypressin® Ferring Pharmaceuticals) as an initial intravenous bolus of 2 mg (10 ml) and thereafter every 6 hours for a period of 24 hours.
223429302|NCT03813186|DRUG|ASTX727 + Day 2 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
223429303|NCT03813186|DRUG|ASTX727 + Day 4 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
223429304|NCT03824886|OTHER|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
223429305|NCT03998163|DRUG|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
223429306|NCT00043030|PROCEDURE|psychosocial assessment and care|
223429307|NCT00095186|DRUG|Recombinant Human Lactoferrin|
223429308|NCT01088243|DRUG|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
223429309|NCT01088243|DRUG|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
223429310|NCT00716352|BEHAVIORAL|Educational intervention programme|
223429311|NCT06622200|BEHAVIORAL|Mindfulness-based Intervention|"In the present research, the standardized, theory based MBI was introduced to the experimental group (Smith, 2005). This 30-minute protocol involves a series of activities, including paying attention to and being aware of breath, body sensations, thoughts, and sounds without judgment. This protocol is a widely recognized and utilized method due to its simplicity and accessibility, making it an ideal choice for this study.~Participants in the experimental group completed three weekly sessions of MBI for five weeks during their hemodialysis treatments (Alhawatmeh et al., 2022). Participants were provided with audio recordings of the MBI protocol, which they could practice during hemodialysis sessions. These recordings were delivered via email and WhatsApp, depending on their preference. This audio recording was developed based on the Smith's protocol by a certified study researcher who had a higher degree in nursing and extensive experience in practicing and delivering MBIs."
223429312|NCT02763332|OTHER|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
223429313|NCT02763332|OTHER|Global trunk group (GTG)|This bandage was placed globally along the back
223429314|NCT02340442|OTHER|Obstetrical care parameters|
223429315|NCT02340442|OTHER|DVA measurements|
223429316|NCT02340442|OTHER|Fundus photographs|
223429317|NCT02119832|DEVICE|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
223429319|NCT00483106|DRUG|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
223429320|NCT00483106|DRUG|Placebo|taken orally twice a day for 7 consecutive days
223429321|NCT00028899|DRUG|asparaginase|
223429322|NCT00028899|DRUG|cytarabine|
223429323|NCT00028899|DRUG|gemtuzumab ozogamicin|
223429324|NCT00028899|DRUG|mitoxantrone hydrochloride|
223429325|NCT05672407|DRUG|Tranexamic acid|100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
224039379|NCT07072468|DRUG|VMD-3866 Gel|"Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose).~Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home."
223429326|NCT05672407|DRUG|Placebo|Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
223429327|NCT03814512|BEHAVIORAL|Extended Sleep Intervention|Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
223429328|NCT03679338|DEVICE|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
224039380|NCT07072468|DRUG|Placebo Gel|Each participant will have 2 treatment periods, separated by a washout of at least 7 days. Participants will be randomized 1:1 to receive VMD-3866 gel in one period, and placebo gel in the other. Before the start of each treatment period, participants will have a Run-in period lasting 7 days, during which they will record NPRS scores each morning in a trial diary. Participants will continue to record NPRS scores in the trial diary during treatment periods 1 and 2 (about 1 h after each dose). Participants will be screened within 45 days before their first treatment period. Eligible participants may attend an outpatient visit up to 14 days before their first dose of VMD-3866 or placebo, for baseline QST and, in ≥ 8 participants, a skin biopsy. Participants will visit the site for their first and last doses (Days 1 and 8) in each treatment period. All other doses they will self-administer at home.
224039381|NCT07130955|DEVICE|Six-channel RF Renal Denervation System|DSA-guided percutaneous renal sympathetic denervation using a six-channel RF renal denervation system-comprising the six-channel radiofrequency generator (specification model: 25D1G, software release version: SRG-V1) and the ultra-guiding radiofrequency denervation catheter (specification model: 25C6W127F115T)
223564582|NCT04860557|OTHER|cognitive skill, dual task and physical activity assessment|Montreal Cognitive Assessment Test, Trail Making Test (TMT) A \& B sections and Stroop test for cognitive ability assessment, 10 meter walking test (single-double task) for dual task, Time up and Go test (single-double task), physical International Physical Activity Questionnaire was used for activity and The Exercise Benefit / Barriers Scale was used for exercise perception.
223564583|NCT00258232|DRUG|capecitabine|
224139382|NCT05698121|DEVICE|CapriXpress|The app is a digital, tailored intervention aimed at activating patients during their waiting period between discharge from hospital and start of their cardiac rehabilitation by providing certainty and guidance. The goal of the intervention is to reach the end-goal: the start of the rehabilitation. Progression towards this end-goal is made automatically as time advances. The intervention provides guidance by providing the patient with a set of daily messages. These messages are pre-made by representatives of different disciplines within cardiac rehabilitation. The messages contain discipline-related information and suggestions as well as a perspective on peer experiences. Each day, the patient is free to choose which and the number of messages to engage with.
223429329|NCT01437917|OTHER|20% amylose bread|20% amylose bread
223429330|NCT01437917|DIETARY_SUPPLEMENT|10% amylose bread|10% amylose bread
223429331|NCT01437917|DIETARY_SUPPLEMENT|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
223564584|NCT00258232|DRUG|celecoxib|
223429332|NCT05645419|BEHAVIORAL|personalized chronoprevention|Chronobiological variables: dynamic and static position of the planets of the solar system, moon, sun, constellations; angles/degrees of celestial objects above/below the horizon; angular interactions between celestial objects; the moment/time of the patients' birth; moment/time of MI occurrence; latitude / longitude of the place of birth of the patients, as well as the occurrence of MI (event); the degree of influence of celestial objects in relation to the constellations, where they were at a particular personal event / points of the patient.
223429333|NCT05207618|DIETARY_SUPPLEMENT|ARBOX (QUEBRACHO AND CHESNUT EXTRACT)|ARBOX TWICE A DAY FOR 60 days
223429334|NCT02231879|DRUG|Plerixafor|Twice daily low dose injection for 14 months.
223429335|NCT02231879|DRUG|G-CSF|Twice daily low dose injection for 14 months.
223429336|NCT05203549|PROCEDURE|Tumor biopsy|Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy
223564585|NCT00258232|DRUG|irinotecan hydrochloride|
224139383|NCT01464788|DRUG|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
224139384|NCT01464788|DRUG|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
224139385|NCT01464788|DRUG|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
224139386|NCT03411772|PROCEDURE|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
224139387|NCT03411772|PROCEDURE|Bariatric surgery|Bariatric surgery will be conducted
224139388|NCT03346447|OTHER|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
223429337|NCT04653753|DEVICE|kneeSOFT500|At least 30 patients (15 patients in the orthosis group and 15 patients in the control group) will be included. Patients included in the orthosis group will use the device during sports sessions while patients included in the control group will not use a knee support device.
223429338|NCT03165760|PROCEDURE|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
223429339|NCT03667872|PROCEDURE|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
223429340|NCT02587572|BIOLOGICAL|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
223429341|NCT03714646|DIETARY_SUPPLEMENT|beta glucan and resistant starch|12g per day the day before the CID Resistant starch 7.5 g
223429342|NCT03714646|DIETARY_SUPPLEMENT|Placebo|isocaloric maltodextrin before the CID
223564586|NCT01044745|DRUG|rituximab|Given IV
223564587|NCT01044745|DRUG|mycophenolate mofetil|Given IV or PO
223564588|NCT01044745|DRUG|tacrolimus|Given IV
223564589|NCT01044745|DRUG|anti-thymocyte globulin|Given IV
223564590|NCT01044745|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
223564591|NCT01044745|OTHER|laboratory biomarker analysis|Correlative studies
223564592|NCT01044745|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
223564593|NCT01044745|DRUG|cyclophosphamide|Given PO or IV
223564594|NCT01044745|DRUG|fludarabine phosphate|Given IV
223564595|NCT01044745|DRUG|busulfan|Given IV
223564596|NCT01044745|RADIATION|total-body irradiation|Undergo TBI
223564597|NCT01044745|BIOLOGICAL|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
224139389|NCT01404026|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm\^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
224139390|NCT02763293|OTHER|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
223429343|NCT03714646|DIETARY_SUPPLEMENT|beta gluten|12 g beta gluten there day before the CID
223429344|NCT06623838|DIAGNOSTIC_TEST|Evolutionarily informed case conceptualization|Case conceptualization of personality functioning of a few transcripts of initial sessions and report of psychometric measures of patients diagnosed with personality disorder.
223429345|NCT03269084|OTHER|No intervention. DIPP is an observational study.|
223429346|NCT01156649|DEVICE|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
223429347|NCT01156649|DEVICE|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
223429348|NCT04346212|DIAGNOSTIC_TEST|Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)|We will assess dysphagia, nutritional status and needs of compensatory treatment (fluid and nutritional adaptation) in patients with COVID-19 disease. We will also collect clinical data, information about swallowing and nutritional status and needs through the electronical medical history of the patients and by telephone call at 3 and 6 months follow-up, as well as clinical complications.
223429349|NCT04167124|BEHAVIORAL|multi-sensor lifestyle intervention|
223429350|NCT01949441|BIOLOGICAL|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
223429351|NCT01949441|BIOLOGICAL|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
223429352|NCT03714854|DEVICE|transcranial magnetic stimulation|TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
223429353|NCT04662788|DRUG|NK cells/Combined Monoclonal Antibodies|Each subject receive NK cells/Combined Monoclonal Antibodies
223429354|NCT03249597|DIAGNOSTIC_TEST|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
223429355|NCT00522704|OTHER|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
223429356|NCT00750412|BEHAVIORAL|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
223429357|NCT01759810|BIOLOGICAL|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
223429358|NCT01759810|BIOLOGICAL|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
223564598|NCT01044745|BIOLOGICAL|immunosuppressive therapy|Undergo immunosuppressive therapy
223564599|NCT00116701|DRUG|Aranesp®|
223564600|NCT03290417|DIETARY_SUPPLEMENT|Vitamin D|5000 IU/cap; One cap by mouth daily
223564601|NCT03290417|DIETARY_SUPPLEMENT|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
223564602|NCT03290417|DIETARY_SUPPLEMENT|Turmeric|250mg/cap; two capsules by mouth 4 times per day
223564603|NCT03892668|DRUG|Tranexamic Acid|Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.
223564604|NCT03892668|DRUG|oxytocin|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.
223564605|NCT03892668|DRUG|placebo|An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation
223564606|NCT02890303|DEVICE|Zepto System|Anterior Capsulotomy using the Zepto System.
223564607|NCT05210582|DRUG|Afamelanotide|Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
223564608|NCT06486493|OTHER|Conventional treatment|Conventional medical treatment by their physicians, following the Clinical Practice Guideline for the Prevention and Diagnosis of Overweight and Obesity in Children and Adolescents (SS-025-08) and the Guideline for the Diagnosis, Treatment, and Prevention of Overweight and Obesity in Adults (IMSS 46-08), over six months, with a follow-up of 18 months post-intervention.
223564609|NCT06486493|OTHER|Playful Family Education Strategy|"Workshop based on national and international guidelines for managing overweight and obesity in school-aged children, by the Food and Agriculture Organization (FAO). Monthly sessions over six months for parents and children, followed by an 18-month post-intervention follow-up.~For parents:~* First session focuses on raising awareness about childhood obesity through counseling and nutritional advice, promoting water consumption over sugary drinks.~* Subsequent sessions use 'case study' technique to discuss common food and nutrition challenges.~For children:~* Sessions follow the 'Nutritional Guidance Intervention Guide' by the National System for Integral Family Development (DIF).~* First session encourages healthy eating habits through activities and educational games.~* Later sessions emphasize healthy eating patterns and physical activity."
223740251|NCT07206238|DIAGNOSTIC_TEST|Positron Emission Tomography / Magnetic Resonance Imaging|FDG PET/MRI with Black Blood sequences of the head and neck area.
223740252|NCT07205289|BIOLOGICAL|Gamma-PN|Killed whole-cell pneumococcal vaccine
223740253|NCT07205510|OTHER|nothing|This is an observational study.
223429359|NCT01112410|OTHER|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
223429360|NCT01112410|OTHER|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
223429361|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
223429362|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
223429363|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
223429364|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
223429365|NCT01168310|DRUG|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
223429366|NCT01168310|DRUG|Formoterol Fumarate|Inhalation Solution
223429367|NCT01168310|DRUG|Placebo|Inhalation Solution
223740254|NCT07205367|DEVICE|Zio Monitor|The Zio monitor is a long-term continuous ambulatory patch ECG monitor which adheres to the patient's left pectoral region.
223740255|NCT07206017|OTHER|prebiotic dried chicory root (WholeFiber)|Supplementing with WholeFiber for 6 weeks two times a day (10 g per portion).
223740256|NCT07205159|DRUG|FB102|Route of administration- Intravenous (IV)
224039382|NCT07130955|PROCEDURE|Parallel controln with sham operation(there is no rade and/or generic name,It is a blank control sham operation)|Sham procedure including femoral artery puncture and selective renal angiography; the six-channel radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.
224039383|NCT07130539|OTHER|MIND HIIT|4 week intervention consisting of the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in combination with 3 days per week of High-Intensity Interval Training (HIIT) exercise
224039384|NCT03354741|OTHER|laser therapy|stimulation of the acupuncture point P6 by laser therapy
224039385|NCT03773965|DRUG|Baricitinib|Administered orally.
224039386|NCT06832722|DRUG|AK1967 (Procizumab)|DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)
224039387|NCT06832722|DRUG|Placebo|Application of placebo
224039388|NCT05843864|DEVICE|Photobiomodulation Therapy with Standard Physical Therapy|Photobiomodulation Therapy (PBMT) will be provided by a trained individual in addition to standard physical therapy. Treatment will be delivered for approximately 10-16 minutes. Participants will then be instructed to rest for 5 minutes after the treatment.
224039389|NCT05843864|OTHER|Sham Photobiomodulation Therapy with Standard Physical Therapy|Sham Photobiomodulation Therapy (PBMT) will be provided by a trained to the some location and with the same contact time and frequency as the active intervention (PBMT) in addition to standard physical therapy. Participants will then be instructed to rest for 5 minutes after the treatment.
224039390|NCT06659341|DRUG|BAY3498264|Oral
224039391|NCT06468228|DRUG|Lutikizumab|Subcutaneous injection
224039392|NCT06468228|DRUG|Placebo|Subcutaneous injection
223429368|NCT05410041|BIOLOGICAL|CAR-NK-CD19 Cells|CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5\~D-3), determined by tumor burden at baseline.
224039393|NCT05566795|DRUG|Tovorafenib|Oral Tablet Powder for Oral Suspension
223429369|NCT06620341|BEHAVIORAL|drug education|"* Training: Train emergency doctors every month on how to use antibiotic infusion reasonably; The prescription, cancellation, or method of use of antibiotics is decided by doctors.~  * Implementation of intervention cards: When the C-reactive protein (CRP) of patients is exceed 10mg/L, the doctor should determine whether to use antibiotics based on the clinical status of patients.~    * Promotion: Promote reasonably use of intravenous antibiotics through public accounts and posters.~      * Patient education: Distribute educational flyers to patients about how to use antibiotics reasonably."
223429370|NCT04399408|DEVICE|Obstetrics Ultrasound (non invasive)|Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.
223429371|NCT04228757|DIETARY_SUPPLEMENT|phytoestrogen herbal blend|phytoestrogen herbal blend
224039394|NCT05566795|DRUG|Chemotherapeutic Agent|Intravenous solution for injection
223429372|NCT04228757|OTHER|Placebo|Tablet without active ingredients
223429373|NCT06505135|BIOLOGICAL|Stem-cell treatment|"In the cell treatment group of patients, injection of the cell suspension will be performed at the end of the surgical procedure. Fluid is carefully aspirated via the anterior outflow cannula, and autologous micro-fragmented adipose tissue is injected in dry arthroscopy conditions from the lateral portal while maintaining a subacromial view from the posterior portal.~10 mL of the stem cells suspension will be injected into the supraspinatus muscle at four predefined sites at the musculo-tendinous junction of the supraspinatus muscle. For each injection site, 1.5 mL of the suspension will be injected using an 18-gauge syringe."
223740257|NCT07205159|DRUG|Placebo|Route of administration- Intravenous (IV)
223740258|NCT07205497|DRUG|QL1706+TC|Participants will take eparbrutinib (QL1706) alongside cisplatin and albumin-bound paclitaxel (TC) every three weeks for three cycles. If the lesion was reduced to less than or equal to 2cm, conectomy was performed; if the pathological results indicated no high-risk factors, total hysterectomy was performed, and QL1706+TC was treated after surgery. If the lesion is larger than 2cm, a type III hysterectomy is performed and adjuvant treatment is determined according to sedlis criteria after surgery.
223740259|NCT07205302|DEVICE|flow diverter|the treatment of intracranial non-saccular aneurysms with flow diverter
223740260|NCT07206290|DRUG|Survodutide (BI 456906)|0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg s.c. weekly
223740261|NCT07206290|DRUG|Placebo|Placebo matching survodutide
223740262|NCT07206381|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR) Group Therapy|Sessions conducted in groups with one therapist and one co-therapist; each session follows the EMDR standard protocol.
223740263|NCT07207239|DEVICE|repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol|Theta-burst rTMS treatment stimulates the left Dorsolateral Prefrontal Cortex (DLPFC). The TBS parameters the investigators adopted follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. The investigators plan to deliver 1800 stimuli to the left DLPFC daily in 9.5-minute blocks for four weeks.
224139391|NCT00731393|BIOLOGICAL|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
223429374|NCT06505135|OTHER|Standard care|Standard treatment also includes intravenous injection preoperatively of 2 g of Cloxacillin In case of allergy 1.5 g of Cefuroxim is chosen. Tendon suture is performed arthroscopically under regional anaesthetic blockage and light sedation with standard double row technique using suture anchors
223429375|NCT05909813|BEHAVIORAL|Individualized Piano Keyboard Instruction|"During weeks two through seven, participants will receive a once a week, hour long, in-person individualized piano keyboard instruction as follows:~1. Warm-up~   1. Scales and Chords: Consisting of scales on seven major keys (C, D, E, F, G, A and B), chord progressions on I, IV, V, I. Two different keys will be learned every week.~  2. 5-finger exercises will be completed four times per week.~2. Piano Theory and Music~   1. Piano Theory: Playing through Alfred's Basic Adult All-in-One Course, Book 1, to be completed at the ability level of participant, with a least two new pages per lesson.~  2. Chosen Piece: Playing through an instrumental piece chosen by the participant.~Participants will be asked to practice homework from this lesson daily for 20 minutes per day, until their next weekly lesson."
223429376|NCT01210495|DRUG|Axitinib (AG-013736)|Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
223429377|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
223429378|NCT01210495|DRUG|Placebo|Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
223429379|NCT01210495|OTHER|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
223429380|NCT04504266|BEHAVIORAL|POWER|This intervention consists of a motivational interview and a mobile-app based coaching program to encourage patients to exercise and adopt a Mediterranean diet in the 3+ weeks prior to surgery.
223429381|NCT00065650|DRUG|Vedic Medicine|
223429382|NCT00065650|BEHAVIORAL|Vedic Medicine|
223429383|NCT00648934|DRUG|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
223429384|NCT00648934|DRUG|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
223429385|NCT00751257|DRUG|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
224039395|NCT05866419|DEVICE|ThecaFlex DRx System|The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
223429386|NCT00751257|DRUG|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
223429387|NCT06602349|DRUG|Lidocaine 10 MG/ML|administration of lidocaine in posterior perineal block infiltration
223429388|NCT06602349|DRUG|Saline|administration of salin solution in posterior perineal block infiltration
223429389|NCT02189018|OTHER|Active Exercise|Active exercise on a treadmill
223429390|NCT02189018|OTHER|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
223429391|NCT02189018|OTHER|Weight loss and active exercise|Weight loss and active exercise on a treadmill
223429392|NCT02189018|OTHER|Ad lib activity at home|Ad lib activity at home
223429393|NCT00454818|GENETIC|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
223429394|NCT00454818|PROCEDURE|Placebo Infusion|Saline; epicardial coronary artery infusion
223429395|NCT00454818|GENETIC|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
223429396|NCT01791946|PROCEDURE|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
223429397|NCT01791946|PROCEDURE|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
223429398|NCT04151485|BEHAVIORAL|Mind/Body Program for Fertility (Domar et al., 2011)|see Arm Description
223429399|NCT04151485|BEHAVIORAL|Fertility Support Program|see Arm Description
223429400|NCT00001783|DRUG|0-15 Water|
223429401|NCT00640653|BEHAVIORAL|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
223740264|NCT07205887|DRUG|EYE103|EYE103 is a humanized antibody formulated for intravitreal administration
224039396|NCT07078448|OTHER|Foam Roller|FR will be applied to each hamstring muscle for 3 minutes per leg, totaling 6 minutes. The pressure was self-regulated by participants, who are instructed to apply as much body weight as tolerable. The rolling frequency is maintained at approximately 0.5 Hz, corresponding to one complete rolling cycle every 2 seconds. Before the intervention, participants will receive verbal and visual instructions to ensure correct execution.
223429402|NCT00640653|BEHAVIORAL|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
223478333|NCT04005768|DRUG|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
223429403|NCT00640653|BEHAVIORAL|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
223429404|NCT00640653|BEHAVIORAL|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
223429405|NCT00640653|BEHAVIORAL|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
223429406|NCT03257878|OTHER|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
223429407|NCT00273468|DRUG|Granisetron|
223429408|NCT04723563|DRUG|Heparin|25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
223429409|NCT04723563|DRUG|0.9%sodium chloride|5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
223429410|NCT04380012|DRUG|Pyrotinib|Pyrotinib as interventions were used in patients with HER2-positive advanced colorectal cancer
223429411|NCT04380012|DRUG|Pyrotinib in combination with trastuzumab|Pyrotinib in combination with trastuzumab as interventions were used in patients with HER2-positive advanced colorectal cancer
223429412|NCT03843424|BEHAVIORAL|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
223429413|NCT03843424|BEHAVIORAL|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
223429414|NCT02505334|DRUG|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
223429415|NCT04007224|DRUG|Intranasal oxytocin|daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
223429416|NCT04007224|BIOLOGICAL|Autologous umbilical cord blood|patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
223429417|NCT01835275|BEHAVIORAL|Enhanced Audio|
223429418|NCT01835275|BEHAVIORAL|Audio|
223429419|NCT00667186|OTHER|Targeted Screening|Selection method for screening is based on risk
223429420|NCT00667186|OTHER|Routine Screening|Selection method for screening is not based on risk
223429421|NCT06339216|DRUG|Adebrelimab+Apatinib+Paclitaxel for Injection(Albumin Bound)|"Adebrelimab injection：Intravenous infusion, fixed dose 1200 mg, Day 1, Q3W. Until disease progression or intolerable toxicity occurs, the infusion should be administered over 30 to 60 minutes and over a maximum of 2 hours. When adalimumab is administered in combination with chemotherapy, Adebrelimab should be administered as an intravenous infusion first, followed by chemotherapy at least 30 minutes apart.~Apatinib mesylate：Administered orally, 250 mg/time, once daily, orally, half an hour after meals (the time of daily administration should be as same as possible), with warm boiled water, the missed dose of Apatinib during the course of treatment cannot be supplemented.~Paclitaxel for Injection(Albumin Bound)：Intravenous infusion, 250 mg/m2, day 1, Q3W, intravenous drip over 30 minutes."
223429422|NCT03685292|BEHAVIORAL|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
223429423|NCT03685292|DRUG|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
223740265|NCT07205887|DRUG|Aflibercept 2.0 mg|Aflibercept 2.0 mg is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with Neovascular Age-Related Macular Degeneration (NVAMD). Aflibercept 2.0 mg is only administered to 2 cohorts of Incomplete Responders (IR) with NVAMD in combination with Low Dose or High Dose EYE103.
223429424|NCT03685292|DEVICE|Behavioral Division|This study is relative to minimal contact control (MCC).
223429425|NCT04308915|BEHAVIORAL|Game-based cognitive training|A suite of 5 games is presented to the participants for training working memory
223429426|NCT01864213|DRUG|Ametop cream|
223429427|NCT00581542|DRUG|moxifloxacin|1-2 drops three times a day for 8-10 days.
223429428|NCT00581542|DRUG|polytrim|1-2 drops four times a day for 8-10 days.
223429429|NCT04341350|DRUG|Propofol + analgesic drug|sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
223478334|NCT04005768|DRUG|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
223740266|NCT07207005|DEVICE|ECIMA CORIN|Mobile cup (Corin) made of highly cross-linked PE doped with vitamin E (ECIMA, Corin).
223429430|NCT04341350|DRUG|Isoflurane + analgesic drug|sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
223429431|NCT06552962|DEVICE|Whole body vibration|The aim of this study is to reveal the effect of exercises performed with WBV on the myofascial tissue of the lumbar region and the tone of superficial back muscles, as well as to investigate the effects on pain, function, muscle strength, balance, proprioception and endurance parameters, compared to the exercise-only group.
223429432|NCT06552962|BEHAVIORAL|lumbar stabilization exercises|The control group will undergo lumbar stabilization exercises twice a week for 6 weeks.
223429433|NCT00656851|DRUG|Pioglitazone|30mg/day for 16 weeks
223740267|NCT07207005|DEVICE|CORIN|Mobile cupule (Corin) is made of conventional PE
223740268|NCT07205068|DEVICE|Shockwave M5 IVL Catheter|The Shockwave M5 IVL Catheter is a balloon catheter designed to modify calcified arterial plaque using intravascular lithotripsy prior to vascular access
223429434|NCT00656851|BEHAVIORAL|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
223429435|NCT01391195|DEVICE|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
223429436|NCT00041106|DRUG|gemcitabine hydrochloride|Given IV
223429437|NCT00041106|DRUG|cisplatin|Given IV
223429438|NCT00041106|DRUG|gefitinib|Given PO
223429439|NCT00041106|OTHER|laboratory biomarker analysis|Correlative studies
223429440|NCT02348151|OTHER|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
223429441|NCT02348151|OTHER|Corridor|The volunteers will perform the shuttle walk test on the corridor
223429442|NCT06601322|OTHER|Pacemaker Interrogation and Electrocardiogram (ECG):|Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.
223429443|NCT06601322|OTHER|Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR|Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.
223429444|NCT06601322|OTHER|Continuous pacemaker telemetry (CPT)|CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.
223429445|NCT03234517|DRUG|Vaginal Clindamycin Cream|Vaginal Clindamycin Cream
223429446|NCT03234517|DRUG|Vaginal Probiotic|Vaginal Probiotic
223429447|NCT05667974|BIOLOGICAL|PIKA Rabies Vaccine (Vero Cell) for Human use, Freeze-dried|PIKA rabies vaccine
223429448|NCT05667974|BIOLOGICAL|Chirorab|Active Comparator
223429449|NCT01058616|DRUG|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
223429450|NCT06452745|PROCEDURE|Colonoscopy|Colonoscopy performed as a regular practice during colorectal cancer screening.
223429451|NCT06452745|OTHER|Urine and FOBT collection|After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
223740269|NCT07205068|PROCEDURE|Modified Seldinger Technique|Standard of care for femoral access in patients with calcified femoral arteries
223740270|NCT07205068|PROCEDURE|Modified Seldinger Technique|Standard femoral artery access using the modified Seldinger technique without any prior vessel preparation or plaque modification.
223740271|NCT07204938|DRUG|navenibart|Navenibart will be administered as a subcutaneous injection.
223740272|NCT07205601|BIOLOGICAL|RB-ADSC|RB-ADSC is an investigational an ex-vivo expanded autologous adipose-derived stem cell product
223740273|NCT07205601|OTHER|Placebo|0.9% NaCl USP
223744819|NCT05882799|PROCEDURE|Blinded dry needling|Blinded dry needling is a minimally invasive technique that involves inserting a sterile acupuncture needle into trigger points of a muscle without using real-time imaging guidance. In this technique, the practitioner relies solely on their palpation skills to locate the trigger points of the piriformis muscle and inserts the needle through the skin and into the muscle tissue.
223429452|NCT01838434|DRUG|lenalidomide|given PO
223429453|NCT01838434|DRUG|idelalisib|given PO
223429454|NCT03411980|DRUG|Vilaprisan (BAY1002670)|Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
223429455|NCT02291601|DRUG|Chlorhexidine Gluconate|comparison with other CHG products
223429456|NCT02291601|OTHER|Vehicle|Excipients of CHG product only.
223744820|NCT03713203|DEVICE|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
224070479|NCT03268915|DIAGNOSTIC_TEST|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
224070480|NCT02877342|OTHER|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
223429457|NCT02291601|DRUG|DynaHex-2|2% CHG solution
223429458|NCT03137901|DEVICE|Capstesia|Picture of the arterial waveform taken with a smartphone
223429459|NCT03809767|DRUG|CS1003 monoclonal antibody|CS1003 will be administered intravenously every 3 weeks.
223429460|NCT00196729|DRUG|Thyrogen + Radioiodine (131I)|
223429461|NCT05262088|OTHER|video recording of general movements|"Video recording of general movements of children aged 3-5 days, then 4-5, 8-9, 12-13, 16-17, 20-22 weeks of life.~At the age of 12 weeks of life, an assessment will be made on the Motor Optimality Scale (MOS)."
223429462|NCT04995250|OTHER|corrective exercise training for knee|All patients received 12 weeks (3 days per week) physiotherapy sessions with hot pack, TENS and Ultrasound session for 10 mints and knee isometric, quad strengthening, adductor and abductor strengthening, calf stretch, hamstring stretch, Maitland mobilization, Unconventional Corrective knee exercise protocol treatment: standing on one extremity, up and down on bosu exercise, walking to lateral direction, walking to anterio-posterior direction, walking to anterio-posterior and lateral for 20 mints. Data were collected at baseline, at week 4 and at post treatment (week 12).
223429463|NCT00000753|DRUG|Atevirdine mesylate|
223429464|NCT00000753|DRUG|Zidovudine|
223564610|NCT06486493|OTHER|Reinforced Playful Family Education Strategy|The previosuly created and INDAUTOR registered workshop, will be reinforced through two-week technological algorithms, such as videogames, educational videos, and digital challenges, for the children, that they must complete through their smartphone of tablet. Followed by an 18-month post-intervention follow-up.
223564611|NCT04014881|BIOLOGICAL|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
223564612|NCT04388319|DRUG|Zonisamide|Zonisamide (100 mg/daily) for 12 weeks.
224039397|NCT06665399|OTHER|Observation|"In this study, the definition of observation is that participants cannot receive the following treatments currently considered to have a clear efficacy for NL-GLM/PDM, including surgical treatments (minimally invasive excision or open excision, incision and drainage), ultrasound-guided aspiration, oral corticosteroid therapy, antibiotic treatment, anti-tuberculosis therapy, or ductal lavage therapy. As symptomatic management for pain, the use of NSAIDs is permitted. Additionally, for patients with fistulas or skin lesions, routine wound care is also allowed. These two interventions are not considered as receiving treatment intervention in this study."
223564613|NCT04388319|DRUG|Bupropion|Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 12 weeks.
223564614|NCT04388319|OTHER|Halo G6 e-cigarette|G6 e-cigarette for ad libitum use for two weeks prior to complete switch day.
223564615|NCT04086693|DEVICE|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
223564616|NCT04086693|DEVICE|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
224039398|NCT06453720|PROCEDURE|Colonoscopy|A colonoscopy will be performed as part of routine clinical care for all participants, with the study not requiring any additional scheduling commitments outside of routine care.
223429465|NCT00000753|DRUG|Zalcitabine|
223429466|NCT00000753|DRUG|Didanosine|
223564617|NCT01159171|DRUG|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
223564618|NCT01159171|DRUG|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
223564619|NCT01159171|DRUG|oxaliplatin|40 mg/m2 iv weekly
223564620|NCT05124652|DEVICE|Auto Adjusting Prosthesis|Participants will test the auto adjusting prosthesis. The prosthesis will be able to move up to 3 panels built into the socket walls to expand or tighten the socket's fit. The auto adjustments will take place during periods of sitting, standing, or walking. Manual adjustments will also be possible either via the researcher controlling the prosthesis or via the key fob developed in the first aim.
223564621|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
224039399|NCT03843463|DRUG|Escitalopram 10mg|Escitalopram tablet
224039400|NCT03843463|DRUG|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
224070481|NCT01616407|DRUG|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
223429467|NCT03360851|DIAGNOSTIC_TEST|low-dose CT|see arm/group description
223429468|NCT03360851|DIAGNOSTIC_TEST|PoC-PCR|see arm/group description
223429469|NCT01999998|RADIATION|Radiotherapy|
223429470|NCT03379753|OTHER|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
223429471|NCT05001516|DRUG|LM-302|All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.
223429472|NCT00155766|BIOLOGICAL|HPV16 E7 peptide-pulsed autologous DCs|
223429473|NCT01032239|DRUG|intrathecal baclofen|ITB test, implant, 6 months follow-up
223429474|NCT06618170|DIAGNOSTIC_TEST|Tissue surface analysis with the device|Usage of the device to analyse the presence or absence of tumoral membrane marker at the surface of the removed tumoral specimen
223429475|NCT05284708|DEVICE|Atalante|Powered Exoskeleton
223429476|NCT04688528|RADIATION|Dose de-escalation and / or Volume de-escalation|The dose de-escalation and/or volume de-escalation strategy will be individually adapted in function of the draining pattern of sentinel lymph nodes on the contralateral side of the neck.
223429477|NCT02738255|DEVICE|Varnum mouthpiece|An adhesive mouthpiece with a central opening applied during sleep
223429478|NCT01940900|DRUG|E10030|
223429479|NCT01940900|DRUG|ranibizumab|
223429480|NCT01940900|DRUG|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
223429481|NCT00654992|DRUG|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
223429482|NCT00654992|DRUG|Normal Saline|300 IU/kg of normal saline intravenously before surgery
223429483|NCT06514053|PROCEDURE|Full pulpotomy|A full pulpotomy will be performed by removing the entire roof of the pulp chamber and the remaining pulp tissue will be covered by Biodentine.
223429484|NCT06514053|PROCEDURE|Root canal treatment|The regular procedure of root canal treatment will be performed on teeth with irreversible pulpitis
223429485|NCT06648551|DIAGNOSTIC_TEST|CONUT|It is a scale that uses albumin, lymphocytes, and cholesterol for the diagnosis of malnutrition
223429486|NCT00140270|BEHAVIORAL|PEP program|
223429487|NCT02293759|PROCEDURE|HoLEP|Holmium laser enucleation of the prsotate
223429488|NCT02293759|PROCEDURE|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
223429489|NCT00516191|DRUG|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
223429490|NCT01753661|BEHAVIORAL|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
223429491|NCT01753661|BEHAVIORAL|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
223429492|NCT01753661|BEHAVIORAL|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
223429493|NCT00510016|DRUG|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
223429494|NCT00533689|PROCEDURE|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
223429495|NCT01433445|DRUG|panobinostat|Given 3 times a week, every other week in 28-day cycles.
223429496|NCT01433445|DRUG|ruxolitinib|Given twice daily in 28-day cycles.
223429497|NCT03785509|DRUG|DAPT, Statin|Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
223429498|NCT05097092|PROCEDURE|Orthopedic immobilization|Orthopedic immobilization will be performed with a sling and swathe.
223429499|NCT05097092|OTHER|Unilateral resistance training|Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.
223429500|NCT05097092|OTHER|Bilateral resistance training|Bilateral resistance training will be performed by both arms in both groups during Phase 2.
223564622|NCT01327079|DRUG|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
223564623|NCT01461928|DRUG|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
223564624|NCT01461928|DRUG|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
223564625|NCT03263858|DEVICE|Stent|Implantation of coronary stent in de novo coronary artery lesions
223429501|NCT01775358|DRUG|ALRN-5281 0.015 mg/kg|
223564626|NCT04112797|BIOLOGICAL|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
223564627|NCT06046612|DRUG|Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment|The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.
223564628|NCT00461149|DRUG|Octreotide-LAR|
223564629|NCT00963716|DEVICE|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
224039401|NCT03843463|BEHAVIORAL|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
223429502|NCT01775358|DRUG|ALRN-5281 0.05 mg/kg|
223429503|NCT01775358|DRUG|ALRN-5281 0.15 mg/kg|
223429504|NCT01775358|DRUG|Placebo 0.015 mg/kg|
223429505|NCT01775358|DRUG|Placebo 0.05mg/kg|
223429506|NCT01775358|DRUG|Placebo 0.15mg/kg|
223429507|NCT04917458|DRUG|Cholecalciferol 4000 IU Oral Capsule, Liquid Filled|-Vitamin D 25 (OH) or Cholecalciferol 4000 IU capsules, each capsules contain Vitamin D3 tablet @ 1000 IU Patients included into the study will be randomized into two groups and receive placebo (as control group) or cholecalciferol administered orally for 3 months.
223564630|NCT00963716|DEVICE|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
223564631|NCT00886886|DRUG|MDMA|125 mg, single dose
223564632|NCT00886886|DRUG|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
223429508|NCT04917458|DRUG|Placebo|Placebo will be given to control group. It would be administrated orally, one capsule once a day for 30 days of study period
223429509|NCT01788189|DRUG|Lenalidomide|
223429510|NCT04972968|DRUG|ABBV-154|Subcutaneous Injection
223429511|NCT04972968|DRUG|Placebo|Subcutaneous Injection
223429512|NCT04972968|DRUG|Glucocorticoid|Oral Tablet
223429513|NCT06452147|OTHER|Nerve block+standard anesthesia|"1. Receive nerve block as soon as possible after randomization;~2. Ultrasound-guided nerve block is recommended, with the iliacfascia block recommended as the blocking site;~3. It is recommended to use 1.33% bupivacaine liposome (long-acting), and the maximum dose should not exceed 133mg; or regular local anesthetic (bupivacaine or ropivacaine, etc.) with electronic analgesic pumping infusion; or multiple single injections of regular local anesthetics should be used to maintain the continuity of nerve block effect."
223429514|NCT06452147|DRUG|Intravenous lidocaine+standard anesthesia|"1. Subjects randomly assigned to Lidocaine Group (Group L) will be given ECG monitoring, oxygen saturation monitoring, blood pressure monitoring and an open intravenous route on the morning of the surgery. It is recommended to start the infusion of Lidocaine as soon as possible in the ward.~2. It is recommended to use portable electronic infusion pump for drug delivery. The loading dose is 1mg/kg, and the maintenance dose range is 1\~2mg/kg/h. The specific dosage is determined by the anesthesiologist based on the patient's condition. The infusion ends when the patient leaves the Post-anesthesia care unit after surgery, and the infusion time and total amount should be recorded."
223429515|NCT06452147|DRUG|Bupivacaine liposome|1.33% bupivacaine liposome
223429516|NCT06452147|DEVICE|Ultrasound-guided nerve block|Ultrasound-guided nerve block
223429517|NCT02622763|BIOLOGICAL|Tolerogenic Dendritic Cells|Intralesional administration
223429518|NCT01698879|DRUG|Mylotarg|"Cohort 1 version 1.0. GO: 6mg/m\^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m\^2, SC, days 0 to 7. GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
223564633|NCT00886886|DRUG|Placebo|capsules identical to MDMA or Reboxetine
223564634|NCT01018134|DRUG|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
223564635|NCT01018134|DRUG|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
223429519|NCT06056882|OTHER|CLE-guided cryobiopsy|During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
223429520|NCT04637581|BEHAVIORAL|Wraparound|Wraparound is a 12-month family-driven intensive care coordination model.
223429521|NCT03596606|PROCEDURE|Manual Treatment|"The manual treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~* Soft tissue techniques.~* Articulatory techniques applied at cervical level~* Osteopathic manipulation techniques applied at the affected jaw/s.~* Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
223429522|NCT03596606|PROCEDURE|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
223429523|NCT00569647|DEVICE|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
223429524|NCT00569647|DEVICE|Placebo|no use of device
224039402|NCT06788535|DRUG|I-124 evuzamitide|I-124 evuzamitide, single dose imaging agent, administered intravenously.
224039403|NCT04532645|DRUG|Olaparib|Olaparib
223564636|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
223564637|NCT01018134|DRUG|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
223564638|NCT01018134|DRUG|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
224039404|NCT06575192|DEVICE|ARTIA Reconstructive Tissue Matrix|Surgical Implant
223564639|NCT01018134|DRUG|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
223564640|NCT04110951|BEHAVIORAL|Pranayama Breathing Technique|Yogic Breathing Technique
223564641|NCT04110951|BEHAVIORAL|Relaxation technique|Progressive relaxation technique
223564642|NCT00121524|DRUG|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
223564643|NCT00121524|DEVICE|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
224039405|NCT06575192|OTHER|No Intervention|No ADM
224039406|NCT04844606|DRUG|Mirikizumab|Administered SC
224039407|NCT04844606|DRUG|Mirikizumab|Administered IV
223429525|NCT04614610|DRUG|Lidocaine Iv|Lidocaine 1.5mg/kg (Max dose: 200mg) in Dextrose 5% 100mL over 10 minutes
223429526|NCT04614610|DRUG|Placebo|Dextrose 5% 100mL over 10 minutes
223429527|NCT00200876|PROCEDURE|Hypertonic saline|To elicit pain
223564644|NCT00121524|DRUG|Atropine|Atropine 3 mg iv in initial systole
224039408|NCT06764303|DRUG|NTQ5082 100mg qd|NTQ5082 100mg qd
224039409|NCT06764303|DRUG|NTQ5082 200mg qd|NTQ5082 200mg qd
224039410|NCT04617834|OTHER|Quality Surveillance Data Collection|Data will be retrospectively collected through EHR queries
224039411|NCT07093307|BEHAVIORAL|Docudrama|Participants at docudrama sites will watch a 30-minute docudrama (two episodes of 15 minutes each) immediately after blood donation while waiting to recover and to be refreshed.
224070482|NCT01616407|DRUG|Methylphenidate|40 mg per os, single dose
224070483|NCT01616407|DRUG|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
223429528|NCT00200876|PROCEDURE|Isotonic saline|Non-painful control
223429529|NCT03907527|BIOLOGICAL|PRGN-3005 UltraCAR-T cells|Given IP
223429530|NCT03907527|BIOLOGICAL|PRGN-3005 UltraCAR-T cells|Given IV
223429531|NCT05476627|DIAGNOSTIC_TEST|Biomarkers|Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
223429532|NCT06682182|DRUG|Tislelizumab+SOX|"OX: S-1 dosing based on body surface area (BSA): \<1.25m², 40 mg bid orally, 1.25-\<1.5m², 50 mg bid orally, ≥1.5m², 60mg bid orally, days 1-14; Q3W; Oxaliplatin 130mg/m² IV day 1, for a total of 6 cycles.~Tislelizumab: 200mg IV, day 1, Q3W, for a total of 6 cycles. HIPEC: Docetaxel 75mg/m² in 3500ml normal saline, at 43°C for 60 minutes."
223429533|NCT06482294|DRUG|Salbutamol|One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
224039412|NCT07093307|BEHAVIORAL|Control|"Participants randomized at control sites will receive the standard NBSG communications for blood donors: 1) a thank you phone call and 2) and a reminder phone call two-weeks prior to when they are due for their next blood donation."
224039413|NCT07090135|DEVICE|Transcranial electrical stimulation with Temporal Interference (TES-TI)|TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
224039414|NCT06908928|DRUG|bulumtatug fuvedotin|given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 1
224039415|NCT06908928|DRUG|bulumtatug fuvedotin|given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 2
223429534|NCT06482294|DRUG|Fluticason either Beclometasone or Budesonide|One arm is a combination of salbutamol and an ICS as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
223429535|NCT02381730|DRUG|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
223429536|NCT05768230|DRUG|levosimendan|Levosimendan 12.5mg was injected intravenously in a 5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
223429537|NCT05768230|DRUG|5% glucose injection|5% glucose injection 50ml configuration at a rate of 2ml/h for 24 hours.The injection was performed at a constant rate of 2ml/h. If there was no significant hypotension or tachycardia, the injection was completed within 24h
224039416|NCT06908252|DRUG|Pre-Exposure Prophylaxis (PrEP)|Oral Pre-Exposure Prophylaxis (PrEP) pills
224039417|NCT07096362|DRUG|5-Fluorouracil|Participants will be administered 2400 mg/m\^2 of 5-Fluorouracil via continuous intravenous infusion over a 46-hour period beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
224039418|NCT07096362|DRUG|Oxaliplatin|Participants will be administered 85 mg/m\^2 of Oxaliplatin via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
224039419|NCT07096362|DRUG|Leucovorin|Participants will be administered 400 mg/m\^2 of Leucovorin via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
224039420|NCT07096362|DRUG|Irinotecan|Participants will be administered 150 mg/m\^2 of Irinotecan via intravenous infusion beginning on Day 1 of each two-week cycle of standard of care (SOC) modified Folfirinox combination therapy.
224139392|NCT00731393|BIOLOGICAL|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
223429538|NCT04381689|BIOLOGICAL|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Teratect Prefilled Syringe Inj. 0.5mL
223429539|NCT04381689|BIOLOGICAL|Fluarix Tetra Pre-filled Syringe|Fluarix Tetra Pre-filled Syringe 0.5mL
223429540|NCT04742712|DEVICE|CoronaCheck Device|All participants breath normally into the device for up to 6 minutes
223429541|NCT01877967|DIETARY_SUPPLEMENT|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
223429542|NCT01877967|DIETARY_SUPPLEMENT|placebo|
223429543|NCT03979807|DRUG|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
224139393|NCT04397718|DRUG|Degarelix|Degarelix is an FDA-approved drug for prostate cancer
224139394|NCT04397718|OTHER|Saline|09% Saline
224139395|NCT01693055|DEVICE|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
224139396|NCT03714906|PROCEDURE|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
223429544|NCT03979807|DRUG|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
223429545|NCT04060277|DRUG|Letermovir|Given as SOC
223429546|NCT04060277|BIOLOGICAL|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
223429547|NCT04060277|OTHER|Placebo Administration|Given IM
223478335|NCT06307262|DEVICE|T-TEER|T-TEER using the PACAL or TriClip device
223564645|NCT00121524|DRUG|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
224039421|NCT07096362|DRUG|Gemcitabine|Participants will be administered 1000 mg/m\^2 of Gemcitabine standard of care (SOC) via intravenous infusion on days 1, 8 and 15 of each four-week treatment cycle.
224039422|NCT07096362|DRUG|Nab Paclitaxel|Participants will be administered 125 mg/m\^2 of Nab Paclitaxel standard of care (SOC) by intravenous infusion on days 1, 8 and 15 of each four-week treatment cycle.
224139397|NCT00679718|DRUG|diquafosol tetrasodium (INS365) ophthalmic solution|
224139398|NCT01797965|DRUG|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
223429548|NCT02644720|PROCEDURE|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
223429549|NCT02644720|PROCEDURE|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
223429550|NCT02644720|DRUG|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
223429551|NCT02644720|DEVICE|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
223429552|NCT02644720|DEVICE|monofocal intraocular lens (IOL) (Tecnis ZCB)|
224039423|NCT07096362|DIAGNOSTIC_TEST|Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay|"ctDNA will be measured in participants in person via blood samples during Screening/Baseline and at the following intervals during treatment and follow-up:~* Every weeks 2 beginning at weeks 2, 4, 6 and 8 of standard of care therapy.~* Every 4 weeks beginning at week 10 of standard of care therapy until disease progression.~ctDNA will be measured to obtain participant tumor methylation scores (TMS)."
224039424|NCT07098286|OTHER|high intensity home-based rehabilitation|Whereas standard home healthcare would include 1-3 visits per week of therapy services after a stroke, the HIHR intervention will include at least therapy visits per week. Between occupational, physical, and speech therapy, the frequency for each will match individual patient needs based on the type and severity of their stroke-related deficits.
224039425|NCT06140797|COMBINATION_PRODUCT|Multimodal prehabilitation combined with perioperative ERAS care（PREERAS）|Pre-admission risk assessment and targeted intervention provided by multidisciplinary team
224039426|NCT07091500|BEHAVIORAL|Exercise training|Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.
224039427|NCT07091500|DRUG|Semaglutide|semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling
224039428|NCT07098182|PROCEDURE|Clamping and restauration of arterial blood of the inferior mesenteric artery|"* Injection of Indocynianine green (INFRACYANINE 25mg diluted in 10 mL solvent, IV injection of 3ml at a concentration of 2.5 mg/mL or 7.5 mg), (excluding NaCl), purge 10ml NaCl,~* Camera model (STORZ)~* Camera/target distance: 5cm~* Camera recording time (since Indocynianine green injection): 2 to 5 min with temporal identification of the injection time.~Extracorporeal evaluation (by mini laparatomy extraction in colorectal surgery minimally invasive, by laparotomy in case of ovarian cancer with lights of the room switched off (laparotomy)"
224039429|NCT06880835|DEVICE|Control IQ + sleep activity with TI|TI for meal bolus with Control IQ + sleep activity pump setting
224039430|NCT04776434|DEVICE|SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)|This study will capture data from the use of the SELUTION SLR according to its approved labelling.
224039431|NCT05838508|BEHAVIORAL|Exercise intervention|Research participants will be assigned to two exercise conditions.
224039432|NCT04135066|OTHER|Refine grain breakfast|After wearing continuous glucose monitoring device (CGM) on baseline, participants will be provided with breakfast A on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast A is pseudorandom. Breakfast A contains white bread (100g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
223429553|NCT05874427|PROCEDURE|Multimedia informed consent|A standard consent form on paper to explain the procedure, with an additional video to explain the procedure and risks.
223429554|NCT05874427|PROCEDURE|Standard informed consent|A standard consent form, written on paper, used to explain a procedure to a patient face-to-face by a physician.
223429555|NCT05379270|OTHER|Diet soda|Participants will be asked to drink 24 ounces of a commercially-available diet beverage sweetened with sucralose and acesulfame-potassium.
223429556|NCT05304793|OTHER|Best Practice|Receive usual management of dyspnea
223429557|NCT05304793|BEHAVIORAL|Cognitive Behavior Therapy|Receive TAB treatment
223429558|NCT05304793|OTHER|Questionnaire Administration|Ancillary studies
223429559|NCT04056845|DEVICE|Valgus knee brace (Medex K39-OA Corrector)|Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
223429560|NCT04056845|OTHER|Physiotherapy and oral analgesic (diclofenac and panadol)|Physiotherapy and oral analgesic (diclofenac and panadol)
223429561|NCT04570527|PROCEDURE|PCI|percutaneous coronary intervention
223429562|NCT05351879|BIOLOGICAL|GAD-alum (Diamyd) 40 μg/mL|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) adsorbed to Alhydrogel at a concentration of 40 μg/mL and is given as a sterile solution for intralymphatic injection
223429563|NCT05128890|PROCEDURE|Resection techniques for pancreatic and liver tumors|to compare open versus minimally invasive pancreatic resection techniques and analyze the different outcome variables from the clinical standpoint
223429564|NCT00270270|DRUG|epoetin alfa|
223429565|NCT05981261|OTHER|inducement of experimental pain|Inducement of experimental pain
223429566|NCT05408871|DRUG|adnectin 18F-BMS-986192 Head and Neck Cancer|Head and Neck Cancer: PET imaging will be performed after initial diagnosis and within 2 weeks of MRI or CT of the neck done as standard of care. MRI will include T1 weighted pre and post gadolinium spin echo, diffusion weighted imaging, and T2 weighted imaging. CT of the head and neck with contrast will be performed per standard clinical protocol. Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
223478336|NCT07086820|DRUG|Tuberculosis window prophylaxis with weekly rifapentine and isoniazid for 12 weeks|Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided to all participants.
223478337|NCT07086820|DRUG|Standard of care tuberculosis prophylaxis with weekly rifapentine and isoniazid for 12 weeks|Weekly isoniazid and rifapentine for 12 weeks (3HP regimen) will be provided only to participants with a positive IGRA result at baseline.
223478338|NCT06906809|DRUG|BGB-16673|Administered orally
223478339|NCT06906809|DRUG|Itraconazole|Administered orally
224039433|NCT04135066|OTHER|Whole grain breakfast|After wearing CGM on baseline, participants will be provided with breakfast B on two consecutive days in a whoe 14-day monitoring period. The appearance of breakfast B is pseudorandom. Breakfast B contains plain oats (70g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.
224039434|NCT04135066|OTHER|Oral Glucose Tolerance test (75g 2-hour)|75 g pure glucose with 300 mL water per time per person is applied. In the following 3 hours, participants are advised to rest in a seated position, avoiding unnecessary walking or exercise. Energy-giving food items were still prohibited within this interval.
224039435|NCT05460273|DRUG|Datopotamab Deruxtecan (Dato-DXd)|Dato-DXd is an antibody-drug conjugate (ADC) that binds to TROP2.
224039436|NCT07105111|DRUG|Valbenazine|Valbenazine capsules for oral administration.
224039437|NCT06912867|BEHAVIORAL|Blood Flow Restriction (BFR) Exercise Program|Participants performed supervised low-load resistance training with BFR using KAATSU C3 equipment twice a week for 8 weeks.
224039438|NCT06689891|DEVICE|Pelvic Floor Muscle Therapy Website|8-week video-based, self-directed PFMT course
224039439|NCT05952167|OTHER|Intensive cervical traction protocol|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
224039440|NCT05952167|OTHER|Intensive cervical traction protocol - placebo|2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
224039441|NCT04759586|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223429567|NCT05408871|DRUG|adnectin 18F-BMS-986192 Brain Metastases|Brain Metastases: Recruited patients will undergo standard clinical MRI within 2 weeks prior to PET, including T1 weighted pre- and post-gadolinium spin-echo and gradient-echo imaging, diffusion weighted imaging, susceptibility weighted imaging (2D SWI), T2 weighted imaging, 3D FLAIR, and combined DCE and dynamic susceptibility contrast (DSC) perfusion (DCE perfusion will be performed first, DSC perfusion will utilize T2 spin echo images). DCE perfusion will be processed on syngo Tissue 4D software (Siemens). DSC perfusion will be processed with syngo MR Perfusion Engine (Siemens). Patients will get one intravenous line and one radial artery line placed prior to imaging and up to 5.5mCi (204MBq) of \[18F\] PDL192 tracer will be administered intravenously, as a bolus, once the patient is positioned on the scanner. 42 PET data will be acquired at single bed position and in list mode for 120 min after the start of tracer administration. Samples will be drawn from radial artery line.
224039442|NCT04759586|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224039443|NCT04759586|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224039444|NCT04759586|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224039445|NCT04759586|DRUG|Cyclophosphamide|Given IV
224039446|NCT04759586|DRUG|Doxorubicin Hydrochloride|Given IV
224039447|NCT04759586|PROCEDURE|Echocardiography Test|Undergo ECHO
224039448|NCT04759586|DRUG|Etoposide Phosphate|Given IV
224039449|NCT04759586|BIOLOGICAL|Filgrastim|Given SC
224039450|NCT04759586|PROCEDURE|Lumbar Puncture|Undergo LP
224039451|NCT04759586|BIOLOGICAL|Nivolumab|Given IV
224039452|NCT04759586|BIOLOGICAL|Pegfilgrastim|Given SC
224039453|NCT04759586|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224039454|NCT04759586|DRUG|Prednisolone|Given PO
224039455|NCT04759586|DRUG|Prednisone|Given PO
224039456|NCT04759586|RADIATION|Radiation Therapy|Undergo radiation therapy
224039457|NCT04759586|BIOLOGICAL|Rituximab|Given IV
224039458|NCT04759586|BIOLOGICAL|Rituximab and Hyaluronidase Human|Given SC
224039459|NCT04759586|DRUG|Vincristine Sulfate|Given IV
224039460|NCT06488716|DRUG|RO7759065|Specified dose on specified days
224039461|NCT06488716|DRUG|Atezolizumab|Specified dose on specified days
224039462|NCT04880265|DEVICE|Vivalink wearable life sensors|Collection of EKG data
224039463|NCT06915480|BEHAVIORAL|Reminder message and patient navigation|This study will evaluate the combination of pre-appointment messages and patient navigation services.
224039464|NCT07111130|OTHER|12-week Lifestyle Intervention|Eligible participants within the existing ELEGANCE cohort will undergo a structured 12-week lifestyle intervention comprising a low-carbohydrate, high-fibre dietary plan and a prescribed physical activity program targeting at least 150 minutes of moderate-intensity exercise per week. Standardized meal provision and wearable fitness tracking devices will be used to support adherence throughout the intervention period.
224039465|NCT04106102|DEVICE|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
224039466|NCT04106102|DEVICE|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
224039467|NCT07105605|BEHAVIORAL|Intervention Group|pediatric nursing student
224039468|NCT05845047|BEHAVIORAL|PICTURE-IT|"The speech-language pathologist (SLP) will provide one of the following stimuli hierarchically:~1. Single words depicted in the picture, then with written and spoken labels~2. 2-word phrases depicted in the picture and then with written and spoken word~3. Subject-Verb-Object sentence depicted in the picture and then with written and spoken sentences~4. Two-sentence event, depicted with photos and subsequently with two written and spoken sentences~5. Short story depicted with a video clip and subsequently with printed and spoken narrative.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
224039469|NCT05845047|BEHAVIORAL|CoDeLT|"The speech-language pathologist (SLP) will facilitate the computer-delivered naming treatment, consisting of a picture/seen and heard spoken word verification task.~A picture will be presented for two seconds on a laptop computer screen and will be immediately followed by an audio-visual display of a speaker's mouth saying a noun, phrase, or sentence. The spoken word, phrase, or sentence either will or will not fit the preceding picture, and the participant must indicate whether the picture and video match or do not match. The computer will provide immediate visual feedback following a response.~Sessions will be completed online with a speech-language pathologist using video conferencing software, using a laptop and a hot spot the investigators will provide if needed. Participants in both groups will receive the same 15 45-minute sessions of a PICTURE-IT."
224070484|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
224039470|NCT07113912|DEVICE|counterforce forearm brace|a flexible band that fits around the proximal forearm, applying pressure to underlying tissues during activity to potentially reduce acceleration forces and alleviate pain associated with conditions like lateral epicondylitis.
224039471|NCT07113912|PROCEDURE|thoracic immobilization|the methods and devices used to restrict movement of the thoracic spine, which is the upper and middle part of the back.
224039472|NCT06921200|PROCEDURE|Cryotherapy|Cryotherapy is one of the non-pharmacological pain-relieving techniques, which involves chilling specific body areas with ice packs, ice cubes, ice water, or ethyl chloride sprays. The present study intervention will be conducted on 50 post-partum women to assist in relieve episiotomy pain. The researchers will assess the baseline level of episiotomy pain for each woman then the researchers will instruct women to perform perineal care. After cleaning the perineum, the researchers will ask the women to maintain her knee more flexed and apply ice gel pad against the episiotomy line for about 20 minutes then remove it and keep it in the freezer for reusing and assess the level of episiotomy pain using the Numeric Rating Scale for Pain after two hours from delivery. Ice gel pad will be applied for the second time after the episiotomy.
224039473|NCT05640843|OTHER|Whole Foods Plant-based Diet|The meals will have a low glycemic index and contain legumes, vegetables, whole grains, and plant-based fats that have undergone minimal processing. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to education materials. Patients will also receive dietary education and counselling from a research dietitian every 4 weeks for the 12-week intervention period. They will have access to the team for questions and support as needed
224039474|NCT05640843|DIETARY_SUPPLEMENT|Algae Omega 3 + Curcumin|For 52 weeks on the supplement arm, patients will be given algae omega 3 supplements and curcumin supplements (Sabinsa pharmaceuticals) twice daily
224039475|NCT05640843|OTHER|Placebo supplements|For 25 weeks on the placebo arm, patients will be given placebo supplements twice daily (Veggie Doctor/M and M pharmaceuticals and Sabinsa pharmaceuticals).
224039476|NCT07123350|DRUG|Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care|This study does not include any subject enrollment or randomization. This is a retrospective cohort review of patients referred to start subcutaneous vedolizumab from a VUMC IBD provider.
224039477|NCT07127185|DIAGNOSTIC_TEST|LS/MS|Quantitative determination of ceftobiprole concentrations in plasma and urine was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
224039478|NCT07126990|BIOLOGICAL|Novel oncolytic virus Ad-TD-nsIL12|Ommaya capsule was placed for intratumoral injection at a dose of 1×10\^10vp
224070485|NCT01437397|DRUG|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
224070486|NCT01437397|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
223429568|NCT01344993|BIOLOGICAL|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
223429569|NCT05757427|DEVICE|Wavelia #2|Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an OBCD scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.
223429570|NCT04009668|DRUG|adalimumab|Adalimumab will be dosed based on weight
223429571|NCT06522282|COMBINATION_PRODUCT|Emergency Stroke Unit based on 0.23-T MRI|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
223429572|NCT06522282|COMBINATION_PRODUCT|Standard stroke unit|The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
223429573|NCT03103373|DEVICE|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
223478340|NCT06906809|DRUG|Phenytoin|Administered orally
223478341|NCT05862012|DRUG|ISB 2001|Participants will receive escalating doses of ISB 2001
223478342|NCT05862012|DRUG|ISB 2001|Participants will receive injection of ISB 2001 as determined in Part 1.
223478343|NCT06908317|OTHER|floor rise training using backward chaining method|"Each session lasts for 40 minutes starting with a five minutes warming-up including flexibility exercises and ends with a five minutes cooling-down consisting of stretching and breathing exercises. Warming-up is followed by the practicing of getting up floor taught with BMC involving the following 7 steps:~Step 1: descending from a standing position to half kneeling on a wedge pillow. Step 2: descending from a standing position to half kneeling on the floor. Step 3: Like step 2, then descending both knees to the floor into a high kneeling position. Step 4: Like step 3, then descending both hands to the floor one at a time, to come to a prone kneeling position. Step 5: Like step 4, then descending of the body to half sitting. A pillow can be positioned under the hip to soften the floor surface. Step 6: Like step 5, then descending of the body to side lying position. Step 7: Like step 6, then turning from side-lying to supine"
223478344|NCT02868567|DRUG|dalfampridine|Pill open label
223478345|NCT01533259|DRUG|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
223478346|NCT05553405|DRUG|Intralipid Infusion|Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids. It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection. In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
223478347|NCT02996383|DEVICE|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
223478348|NCT02996383|DEVICE|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
223478349|NCT06315283|DRUG|TV-44749|Administered subcutaneously (sc)
223478350|NCT06315283|DRUG|Oral olanzapine|Administered orally
224039479|NCT07133139|DEVICE|Dry Needling|"The examiner will use the repeated tapping technique of Travel and Simmons in the active condition in the painful tender points and TPs. In the sham treatment, the needle tip retracts when pushed against the skin (like a ballpoint pen), and the subject feels a pointy object on their skin, which does not penetrate. Prior studies have shown that this is a credible placebo condition. Prior studies have also shown that one dry needling session is effective at least temporarily for 1-2 weeks, AND that US correlates of TPs improve as well"
224039480|NCT07133139|DEVICE|Sham Dry Needling|Half of the subjects will receive a sham needle instead which puts pressure on the skin but does not penetrate the skin (like a ballpoint pen with the tip retracted pushing on the skin). Since manual pressure over myofascial tender and trigger points is also an accepted treatment, the sham procedure could also be therapeutic, although we do not think it will be very effective.
224039481|NCT07133139|OTHER|NUN Biomarker|"A NUN biomarker measurement means checking the level of a certain substance (the NUN biomarker) in your body that can give investigators clues about your condition.~Measuring the NUN biomarker helps investigators see if a treatment is working or if your condition is changing."
224039482|NCT07128953|DRUG|Solution of Zuoqing San for fumigation and washing of the postoperative wound of anal fistula|Left Qing San Decoction (25g of Cai Yin + 30g of Eucommia + 25g of Sophora flavescens + 25g of Anemarrhena asphodeloides + 15g of Lithospermum erythrorhizon, prepared in the Pharmacy Department of Anhui University of Traditional Chinese Medicine), add 1000mL of water, boil, then steam and wash the wound surface. The temperature is 40 ± 2℃. Do it once a day, for 15 minutes each time, for 7 consecutive days.
224039483|NCT07128953|OTHER|Equal-volume placebo inhalation rinse|Equal-volume placebo inhalation rinse
224039484|NCT03827460|BEHAVIORAL|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
224039485|NCT03827460|BEHAVIORAL|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
224039486|NCT03827460|DRUG|Intravenous Alcohol|During the laboratory alcohol infusion sessions, alcohol is infused through an indwelling catheter.
224039487|NCT06832189|DRUG|Everolimus|"The starting dose of EVR will be based on the maintenance TAC dose of the subject at study entry:~1. EVR 1 mg PO BID if TAC dose is \<=2 mg BID~2. EVR 2 mg PO BID if TAC dose is 2.5-7 mg BID~3. EVR 3 mg PO BID if TAC dose is \>7 mg BID~The dosage will be adjusted as needed to achieve and maintain EVR trough concentration of 5-8 ng/mL."
224039488|NCT06832189|DRUG|Epoetin alfa|The dose used in this study is 10,000 units SC every 8 weeks (at study weeks 16, 24, 32, 40 and 48) for five doses
224039489|NCT04124614|DRUG|Brexpiprazole|3 mg pill
224039490|NCT04124614|DRUG|Sertraline|150 mg pill
224039491|NCT04124614|OTHER|Placebo|Pill
224139399|NCT00656734|BIOLOGICAL|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
224139400|NCT05862558|DEVICE|Shockwave Balloon|Intravascular lithotripsy (IVL) performed with the Shockwave balloon (Shockwave Medical Inc) enables treatment of calcified stenosis of the peripheral arteries by using sonic pressure waves to selectively disrupt superficial and deep calcium without impacting healthy tissue
224139401|NCT05044585|OTHER|Remote Automated Monitoring System|The subject will be monitored with conventional monitoring devices as well as the MultiSense patch.
223429574|NCT03103373|DEVICE|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
223429575|NCT01826565|PROCEDURE|Rotational technique|90 degree rotation
223429576|NCT06126029|DRUG|Metformin 500 Mg extended release Oral Tablet|34 patients of experimental group will get metformin 500mg extended release oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
223429577|NCT06126029|DRUG|Placebo oral tablet|34 patients of placebo group will get placebo oral tablet once daily with evening meal along with standard of care (ibuprofen 400mg and rabeprazole 20mg twice daily) for 8 weeks as prescribed by the physician.
223429578|NCT06569173|DEVICE|LaiKai anti-reflux ureteral stent|Ureteral stents are serving to support the ureter and facilitate urine drainage with an anti-reflux valve.
223429579|NCT06569173|DEVICE|LaiKai Ureteral Stent|Ureteral stents are serving to support the ureter and facilitate urine drainage.
223429580|NCT03573531|OTHER|Laboratory analysis|Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
223429581|NCT00847769|OTHER|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
223429582|NCT00847769|OTHER|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
224039492|NCT05726890|BEHAVIORAL|bedtime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime. These changes are expected to foster the infant's ability to fall asleep independently at bedtime. It is also expected that after 1-2 weeks, these changes would lead to self-soothing also during the night.
224039493|NCT05726890|BEHAVIORAL|bedtime and nighttime intervention for early childhood insomnia|The intervention focuses on providing parents with skills on how to modify and limit their sleep-related interactions with their infant at bedtime and during the night. These changes are expected to foster the infant's ability to fall asleep independently at bedtime and to resume sleep independently during the night.
224039494|NCT05670379|COMBINATION_PRODUCT|Exenatide Implant|Exenatide Implant is a drug:device combination that delivers steady levels of exenatide, a glucagon-like peptide-1(GLP-1) receptor agonist, for an extended period of time following subdermal insertion.
223429583|NCT00847769|OTHER|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
223429584|NCT02329067|OTHER|walnuts|consumption of 43 g walnuts per day
223429585|NCT05935163|PROCEDURE|Conventional therapy for hamstring tightness|Conventional Physical therapy will include TENS , hot pack , Hamstring self stretch , Calf self stretching , bridging exercise , piriformis stretch , prone on hands and prone on elbows.
223429586|NCT05935163|PROCEDURE|Bowen Technique|"Bowen Technique:~1. The patient will assume a full prone-lying position on the plinth.~2. Sequence of short gentle moves will be applied over hamstrings. Firstly, the thumbs will be placed on top of the hamstrings muscle and the tightness is assessed.~3. Then, the muscle will be hooked by the thumbs from its lateral edge. Then, gentle pressure will be applied to the point of resistance to challenge the muscle in medial direction, as the thumbs will be flattened in medial direction, the muscle will pluck under the thumbs.~4. First with the thumbs, then will be followed by the fingers. Often, the hands are placed with a distance of inch of space between the thumbs and fingers so that the hands performed the technique on the muscle easily.~5. The whole procedure will be repeated again. The treatment time for each session will be 20 minutes for each side."
223564646|NCT01064102|DRUG|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
223564647|NCT06209138|DRUG|5 fluorouracil|5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
223564648|NCT06209138|OTHER|Saline|Normal saline solution contains 0.9 percent sodium chloride (salt)
223564649|NCT01461265|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
223564650|NCT05292911|DRUG|ALT-801|Injected subcutaneously (SC)
223564651|NCT05292911|OTHER|Placebo|Injected subcutaneously (SC)
223564652|NCT03047356|BEHAVIORAL|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
223564653|NCT03047356|OTHER|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
223564654|NCT02977936|DIETARY_SUPPLEMENT|Cartimotil Fort|1 to 4 capsules per day during 90 days
223564655|NCT02222909|OTHER|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
224039495|NCT05670379|DRUG|Bydureon BCise (exenatide extended release)|glucagon-like peptide-1 (GLP-1) receptor agonist
223429587|NCT05935163|PROCEDURE|Dynamic Soft Tissue Mobilization (DSTM):|"1. To access the hamstring muscle group, the subject will be asked to attain prone position and deep longitudinal strokes will be applied to the entire muscle group. Once the specific area of hamstring muscle tightness will be located, the remaining treatment will be limited to this target area.~2. To execute the dynamic intervention, the subject will be requested to move in the supine position with the hip and knee flexed to 90 degree.~3. Deep longitudinal strokes will be applied in a distal to proximal direction to the area of hamstring tightness and the leg will be passively moved to knee extension. Five strokes will be applied and 20 seconds of shaking is performed at the completion of this technique.~4. This treatment will be given for 20 minutes on each side."
224039496|NCT05670379|DRUG|Semaglutide, 1.0 mg/mL|glucagon-like peptide-1 (GLP-1) receptor agonist
224039497|NCT04522765|DIAGNOSTIC_TEST|Assessment of 24 hour blood pressure and arterial stiffness|Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device
224039498|NCT07145957|OTHER|Prehabilitation|subjects randomized to the IRTx cohort will also be instructed by a Physical or Occupational Therapist to perform the exercises described in the RSA IR Prehab Exercise Protocol handout, 5-7 times per week for 6 weeks.
223564656|NCT02242435|BIOLOGICAL|4 mL injection of Ampion|4 mL injection of Ampion
223564657|NCT02242435|DRUG|4 mL Injection of Placebo|
223564658|NCT01981863|DRUG|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
223564659|NCT01981863|DRUG|Placebo|Placebo administered in same volume as in experimental arm.
224039499|NCT06947031|DEVICE|AHCL|The downloaded data will be analyzed prior to the surgical procedure. In accordance with standard clinical practice, a TBR time-under-range % (\<54 mg/dL) or TBR time-under-range % (\<70 mg/dL) greater than 4% will be identified, and the target glucose will be increased by 10 mg/dL relative to the previously established value. This is intended to reduce the risk of perioperative hypoglycemia.
224039500|NCT06946225|BIOLOGICAL|IMA203|Following non-myeloablative chemotherapy for lymphodepletion (LD) with fludarabine (FLU) and cyclophosphamide (CY), participants will receive a single infusion of IMA203 on Day 1 and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion.
224070487|NCT01437397|DRUG|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
223564660|NCT03366558|DIAGNOSTIC_TEST|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
224070488|NCT01437397|DRUG|Placebo|Inhaled dose-matched placebo, twice per day
223564661|NCT03366558|DIAGNOSTIC_TEST|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
223564662|NCT06236542|DEVICE|NextGen automated tracheostomy suctioning device|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctionings using an automated robotic suctioning device.
224070489|NCT00001386|DRUG|PCLUS 3-18 MN|
223564663|NCT06236542|DEVICE|NextGen mixed-reality tracheostomy tube change system|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy tube changes using the mixed reality tracheostomy tube change system.
224039501|NCT06946225|BIOLOGICAL|mRNA-4203|mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.
224039502|NCT04024748|DEVICE|PET/CT imaging|Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
223429588|NCT05146544|OTHER|Heart Rate Recording|During the APA session, HR was digitized at 1Hz (using custo guard, Custo Med GmbH). The ratio between the APA session HR and exercise test HRpeak was used to assess the intensity of effort.
223429589|NCT02419612|DRUG|Saxagliptin|
223429590|NCT02419612|DRUG|Dapagliflozin|
223429591|NCT02419612|DRUG|Glimepiride|
223429592|NCT02419612|OTHER|Placebo|
223429593|NCT04427163|GENETIC|Blood sample analysis|Nucleic acids sequencing, presence of proteins and metabolites.
223429594|NCT04427163|OTHER|Health status|Health status will be examined by a physician and subject will complete a health status questionnaire.
223429595|NCT04427163|OTHER|Race and ethnicity|Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
223429596|NCT06647667|OTHER|HIITS|"Frequency: HIIT will be in 2 supervised sessions per week for 12 weeks on the treadmill.~session duration from 30-40 min including the waming up and cooling down Intensity: HIIT included 4 minute intervals aiming 60-85% of heart rate reserve"
223429597|NCT06647667|OTHER|MICT|"Frequency: Moderate continuous training is scheduled 2 times per week for 12 weeks.~Intensity: exercise had been applied on the treadmill with 40%-59% of heart rate reserve) session duration from 30-40 min including the warming up and cooling down"
223429598|NCT01033955|DRUG|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
223429599|NCT01033955|DRUG|Placebo|identical appearing encapsulated placebo.
223429600|NCT04210908|OTHER|Visual biofeedback|Patient will observe the descent of the fetal head as they push during contractions
223429601|NCT02827019|OTHER|questionnaire|a questionnaire made puerperium the 2nd day of life during the interview with the parents on the basis of a semi-structured interview about the progress of the birth and the immediate postpartum period using the memories of parents
223429602|NCT01740908|OTHER|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
223429603|NCT06664138|DRUG|Remimazolam|Remimazolam is a recently approved medication used for the induction of general anesthesia and maintenance of sedation. There have been no prior studies using remimazolam for the induction of anesthesia in ECT, and this research aims to investigate the feasibility of using remimazolam as an induction agent for ECT.
223429604|NCT06664138|DRUG|Etomidate|Etomidate is widely used in ECT due to its rapid onset, stable hemodynamic profile, and quick recovery. In this study, remimazolam will be used as the experimental group, while etomidate will serve as the control group.
223429605|NCT04411979|OTHER|treatment-as-usual plus aerobic walking|aerobic walking
223429606|NCT00474045|DRUG|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
224039503|NCT06946355|OTHER|In-hospital food support intervention|The in-hospital food support intervention will provide two meals for up to two parents per day.
224039504|NCT06946355|OTHER|Post-discharge food support intervention|The post-discharge intervention will provide families with grocery gift cards and frozen meals at the time of discharge.
224039505|NCT06953336|OTHER|Fruit and Vegetable Voucher Support Program|Participants will receive a monthly food voucher in the form of an Electronic Benefit Transfer (EBT) card, mailed to their home and refilled each month for 6 months. The EBT cards are provided and managed by an external community-based organization in partnership with the research team. The intervention is designed to supplement household food purchases, reduce food insecurity, and support nutritional well-being among pediatric and young adult kidney transplant recipients who have recently screened positive for food insecurity. Pre- and post-intervention surveys will be used to assess food security status and dietary quality.
224039506|NCT07147231|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224039507|NCT07147231|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224039508|NCT07147231|BIOLOGICAL|Cemiplimab|Given IV
224039509|NCT07147231|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224039510|NCT07147231|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224039511|NCT07147231|DRUG|Pidnarulex|Given IV
224039512|NCT07147231|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224039513|NCT06951698|DRUG|KarXT|Specified dose on specified days
224039514|NCT06951698|OTHER|Placebo|Specified dose on specified days
224039515|NCT06954987|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Given IV
224039516|NCT06954987|PROCEDURE|Biospecimen Collection|Undergo blood, urine and buccal swab collection
224039517|NCT06954987|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224039518|NCT06954987|DRUG|Busulfan|Given IV
224039519|NCT06954987|PROCEDURE|Chest Radiography|Undergo chest x-ray
224039520|NCT06954987|PROCEDURE|Computed Tomography|Undergo CT scan
224039521|NCT06954987|PROCEDURE|Echocardiography Test|Undergo echocardiography
224039522|NCT06954987|DRUG|Fludarabine|Given IV
224039523|NCT06954987|DRUG|Melphalan|Given IV
224039524|NCT06954987|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224039525|NCT06954987|DRUG|Placebo Administration|Given PO
224039526|NCT06954987|PROCEDURE|Positron Emission Tomography|Undergo PET scan
224139402|NCT03925194|DRUG|Anakinra|Application of Anakinra once daily for 28 days
224139403|NCT02660619|OTHER|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
224139404|NCT00598169|BIOLOGICAL|rituximab|375mg/m2 on Day 1
224139405|NCT00598169|DRUG|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
224039527|NCT06954987|RADIATION|Total-Body Irradiation|Undergo total body irradiation
224039528|NCT06954987|DRUG|Venetoclax|Given PO
224039529|NCT06951269|BEHAVIORAL|Live entrained music therapy|This study will use live, improvised, entrainment-based music. The music will be applied to synchronize with the newborns' breathing patterns, adapting the tempo to the breathing rate, with characteristics that seek to induce a state of relaxation in the patient: moderate volume (below 65 dB; this measure will be validated using the ambient noise indicator of the neonatal intensive care unit), simple harmonic sequences (tonic-subdominant-dominant), melodies that avoid large intervals (beyond a third), medium registers, and a stable pulse. Once the music therapist synchronizes the pulse of the music with the newborn's breathing, the music will be gradually become slower (approximately 10-15%), the volume will be adjusted, and the complexity of the music will be reduced until the patient can transition to a state of greater relaxation. The music therapy session will last 10 minutes, after which the music therapist will leave the room.
224039530|NCT07147023|OTHER|LLM SIC Summary Email|"A Large Language Model-based platform is integrated with the Health Vision Platform, a HIPAA-compliant, electronic health record data management system. Real-time summaries of prior SIC with be sent to clinicians caring for participants in the intervention arm.~An email will be sent to the inpatient attending and responding clinician encouraging the team to review the SIC summary, discuss care preferences with the patient and ensure care is aligned with preferences and goals. If no SIC documentation is found, the email will instead encourage the outpatient oncologist to share information regarding undocumented SICs that may have occurred, as well as prompt inpatient and outpatient teams to engage the patient in SIC.~For patients with no SIC documentation who are still admitted 72 hours later, the RA will send an additional email prompting SIC or asking the clinician to indicate that an SIC is not appropriate. Patients will also receive standard of care."
223744821|NCT00205426|DRUG|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
224039531|NCT07146750|COMBINATION_PRODUCT|SAR445229|Single dose
224039532|NCT07152197|OTHER|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training Supervised (RET) focusing on lower limbs. Warm-up (5 min cycling), followed by 5 sets of leg press, leg extension, leg curl, and weighted dorsiflexion. Cool-down with flexibility exercises. Load progression from 60% to 80% of 1Repetition Maximum across 8 weeks. Participants must complete ≥80% of sessions. Evaluators of pre- and post-intervention outcomes will be blinded.
224039533|NCT07151937|DRUG|LAD191|LAD191 subcutaneous injection.
224039534|NCT07151937|OTHER|Placebo|LAD191 Placebo subcutaneous injection.
223429607|NCT00474045|DRUG|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
224039535|NCT07151937|DRUG|Adalimumab|Adalimumab subcutaneous injection.
224039536|NCT07154654|DRUG|Mexiletine|Non interventional
224039537|NCT07158112|DRUG|Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
224039538|NCT07158112|DRUG|Test Stannous Fluoride Dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
224039539|NCT07158112|DRUG|Sodium monofluorophosphate dentifrice|Each subject will be randomly assigned to one of three treatment products and will be asked to brush 2x a day (1 minute per brushing) for 3 months.
224039540|NCT07155421|OTHER|Early Cardiopulmonary Rehabilitation|An individualized CPR program including positioning, deep breathing exercises (diaphragmatic and segmental breathing exercises), pursed-lip breathing exercises, breathing exercises using incentive spirometry, and progressive mobilization exercises (in-bed range of motion exercises, sitting, standing, and walking exercises)
224039541|NCT07155421|OTHER|Routine in-hospital care|Routine in-hospital care for acute decompansated heart failure
224039542|NCT07152249|OTHER|AW-D Clinical Decision Support Tool|The AW-D Clinical Decision Support Tool will test the automatic delivery of best practice advisories for antiemetic medications at critical timepoints in the perioperative period.
224039543|NCT07155707|OTHER|Teleo|Therapist-led psychotherapy sessions implemented within the Teleo virtual therapy platform.
224039544|NCT07155707|OTHER|Standard Videoconferencing|Therapist-led psychotherapy sessions implemented in standard (non-Teleo) video platform.
223429608|NCT00474045|DRUG|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
223429609|NCT03083561|DRUG|LY3337641|Administered orally.
224039545|NCT07161011|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.2%|Low dose
224039546|NCT07161011|DRUG|IVW-1001 Ophthalmic Eyelid Wipe 0.4%|High dose
224039547|NCT04900792|DRUG|Ferumoxytol injection|Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
224039548|NCT04900792|DRUG|Pharmacological ascorbate|Intravenous ascorbate
224070490|NCT00001386|DRUG|PCLUS 6.1 MN|
224070491|NCT01776073|BEHAVIORAL|Patient Navigation|
224070492|NCT05543473|OTHER|Vestibular Rehabilitation Therapy|an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
224070493|NCT00903175|DRUG|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
224070494|NCT00903175|DRUG|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
224070495|NCT00987038|DRUG|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
224070496|NCT00987038|DRUG|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
224039549|NCT04900792|RADIATION|External beam radiation therapy|Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
223429610|NCT03083561|DRUG|Placebo|Administered orally.
223429611|NCT01754961|DRUG|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
223429612|NCT01754961|DRUG|Placebo|Placebo given orally on Day 1
223429613|NCT06666933|BEHAVIORAL|Time restricted eating|TRE (eating is allowed from 8am to 4pm without limitation in calories) with metformin 1g bid po for 6 weeks
223429614|NCT06666933|DRUG|Metformin|Taking metformin 1g bid po only for 6 weeks as control
223429615|NCT02009397|DRUG|Ipilimumab|
223429616|NCT02009397|DRUG|GM-CSF|
223429617|NCT00581347|OTHER|outreach services|Tracking/reminder/recall/home visit strategy.
223429618|NCT01312168|DEVICE|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
223429619|NCT01312168|DEVICE|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure \<3 cmH2O, daily use at sleep, six months
223429620|NCT05839782|PROCEDURE|Mitral valve repair (PLM)|A mitral valve plasty is performed to treat mitral regurgitation
223429621|NCT05839782|PROCEDURE|Mitral valve replacement|A mitral valve replacement with a prosthesis is performed to treat mitral regurgitation
223429622|NCT02987374|BIOLOGICAL|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
223429623|NCT05221346|DIETARY_SUPPLEMENT|Plant food supplement|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
224039550|NCT04900792|DRUG|Temozolomide|Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
224039551|NCT07163182|BIOLOGICAL|CHF6467 Part 1 (SAD)|Intranasal administration of single ascending doses of CHF6467 in 4 different cohorts
224039552|NCT07163182|BIOLOGICAL|CHF6467 Part 2 (MAD)|Intranasal administration of multiple ascending doses of CHF6467 in 3 different cohorts
223429624|NCT05221346|DIETARY_SUPPLEMENT|Maltodextrin|Food supplements are consumed during 3 weeks by hypercholesterolemic volunteers
223429625|NCT03280082|OTHER|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
223429626|NCT03280082|OTHER|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
224039553|NCT07163182|DRUG|Placebo|Intranasal administration of matched-placebo of CHF6467 in Part 1 and Part 2
223429627|NCT02278120|DRUG|Ribociclib|Ribociclib (600 mg, in three 200 mg hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
223429628|NCT02278120|DRUG|Tamoxifen|Tamoxifen (20 mg, tablets) was administered orally on a continuous daily schedule (days 1-28 of each 28-day cycle)
223429629|NCT02278120|DRUG|Letrozole|Letrozole (2.5 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
223429630|NCT02278120|DRUG|Anastrozole|Anastrozole (1 mg, tablets) was administered orally once daily on a continuous daily schedule (days 1-28 of each 28-day cycle)
223429631|NCT02278120|DRUG|Goserelin|Goserelin (3.6 mg, subcutaneous implant) was administered on day 1 of every 28-day cycle
223429632|NCT02278120|DRUG|Placebo|Placebo (hard gelatin capsules) was administered orally once daily on Days 1-21 of each 28-day cycle.
223429633|NCT00920127|DIETARY_SUPPLEMENT|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
223429634|NCT00287989|DRUG|Carboplatin|
223429635|NCT00287989|DRUG|erlotinib hydrochloride|150mg
223429636|NCT00287989|DRUG|Paclitaxel|200mg/m2
223429637|NCT00287989|DRUG|erlotinib hydrochloride|1500mg
223429638|NCT02441127|DEVICE|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
223429639|NCT02441127|PROCEDURE|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
223429640|NCT02262689|DRUG|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
224039554|NCT07161219|DEVICE|inspiratory muscle training|inspiratory muscle training for intervention group
224070497|NCT00964977|RADIATION|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
223429641|NCT02262689|DRUG|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
223429642|NCT00254176|DIETARY_SUPPLEMENT|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
223429643|NCT00254176|DIETARY_SUPPLEMENT|Placebo - added premasol|Premasol 121 mg per kg per day
223429644|NCT00006280|DRUG|Tobramycin for Inhalation|
223429645|NCT03545594|OTHER|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts before the Corona pandemic and eight sessions with up to six of them video delivered if necessary during the Corona pandemic ) delivered over a 4-month period in three phases
223564664|NCT06236542|DEVICE|NextGen Tracheostomy Toolkit|Providers will be trained on tracheostomy care using multiplayer virtual reality educational modules and participants will receive tracheostomy suctioning using the robotic suctioning device; and tracheostomy tube changes using the mixed reality tracheostomy tube change system.
224039555|NCT07162493|BEHAVIORAL|ATTACH|"ATTACH(TM) is a manualized, 10-session, mentalizing/reflective functioning-based parenting program, with one 45-60-minute weekly session. It is conducted individually with one parent focusing on one child throughout the program; however, a co-parent/parental support person will participate in session 7 and session 9. A session includes three components to facilitate parental reflective functioning: 1)Video-review of parent-child interaction, 2) reflection on a hypothetical situation (pre-defined for each session), and 3) reflection on a mildly stressful situation from the parent's everyday life with the child. The parent's reflective process is supported by handouts, e.g., emotion cards. All material used in the sessions have been translated into Danish, and the wording have been modified to fit with the cultural context, based on feedback from two pilot studies. ATTACH is facilitated by professionals employed at the family centers, who have been trained and certified in ATTACH."
224039556|NCT07162493|BEHAVIORAL|Treatment as Usual (TAU)|Treatment As Usual (TAU) consists of the standard services and support typically offered to families by the local social- and healthcare systems within each municipality. These services vary depending on individual needs, risk assessment of the family, and municipal practices, but often include individual and/or group-based parenting support or therapeutic services at the trial site and/or in the parent's home. TAU may also involve referrals to additional resources or interventions deemed necessary by social authorities or healthcare providers (e.g., psychiatric treatment in the region). The control group will not receive the ATTACH™ program but will have access to all relevant standard care options available within their municipality. TAU can be delivered by different professionals, such as health visitors, social workers, family therapists/counsellors or clinical psychologists. For more details on TAU services at each trial site, see the attached project protocol.
224039557|NCT07161713|BEHAVIORAL|Oncology-informed yoga|8 weekly sessions of cancer informed-yoga incorporating light movement, breathing techniques, and some meditation practices
224039558|NCT07161713|BEHAVIORAL|SMART|SMART, developed by the Impact Foundation, is an adaptation of Mindfulness-based Stress Reduction (MBSR) approach that incorporates other elements like mindful self-compassion, emotional literacy, and positive psychology principles to address the unique stressors faced by teachers.
224139406|NCT00598169|DRUG|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x \[creatinine clearance + 25\]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
224139407|NCT00598169|DRUG|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
224139408|NCT00598169|DRUG|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
224139409|NCT00598169|DRUG|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
224139410|NCT00598169|GENETIC|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
224139411|NCT00598169|GENETIC|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
224139412|NCT03882346|COMBINATION_PRODUCT|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
223429646|NCT03545594|OTHER|Control|Usual follow-up in the municipality
223429647|NCT01486901|DRUG|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
223429648|NCT05071040|BEHAVIORAL|Home-based physical activity|Participants will follow a strength exercise program
223429649|NCT01966068|OTHER|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
223429650|NCT06667024|DRUG|Hyperbaric bupivacaine|Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
223429651|NCT06667024|DRUG|Dexmedetomidine and Hyperbaric bupivacaine|Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
223564665|NCT03895086|OTHER|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
223429652|NCT06173635|DEVICE|Maxi Move 5|4 comparative devices will be used to evaluate the MM5 device
224039559|NCT07167589|PROCEDURE|Cataract surgery with implantation of a single-piece microincisional IOL|
223429653|NCT02009124|BIOLOGICAL|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
223429654|NCT05781516|DRUG|Prednisolone|Oral prednisolone 0.6-0.8mg/kg daily for 4 weeks, then tapered and withdrawal in 4 months.
223429655|NCT05781516|DRUG|Baricitinib|Oral Baricitinib 2mg daily for 12 months.
223429656|NCT04430764|PROCEDURE|non-surgical periodontal treatment|Non-surgical periodontal treatment program was as following: First, motivation and oral hygiene instructions were given to all participants with periodontitis. The modified-Bass tooth brushing technique with a given dentifrice and toothbrush twice a day, and dental flossing/ interdental brushing once a day was advised to all patients with periodontitis. Second, scaling using an ultrasonic device and root planning by hand instruments under local anesthesia was performed.
223429657|NCT00020943|BIOLOGICAL|filgrastim|5 ug/kg subQ daily day 4 until ANC \>10,000 (or ANC\> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
223429658|NCT00020943|BIOLOGICAL|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 \& 12 Tx 3, and weekly for 2 doses Tx 5
223429659|NCT00020943|DRUG|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
223429660|NCT00020943|DRUG|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
223564666|NCT03895086|BEHAVIORAL|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
223564667|NCT05617924|PROCEDURE|Physical Therapy|Therapy methods using physical agents in treatment
224039560|NCT07168772|DIETARY_SUPPLEMENT|Lactibane Iki|Patients will receive a probiotic sachet twice a day for six months. The probiotic, Lactibiane iki (Pileje; Paris, France), is composed of Bifidobacterium lactis LA 304, Lactobacillus acidophilus LA 201, and Lactobacillus salivarius LA 302 and contains 4x10E10 CFU/sachet.
223429661|NCT00020943|DRUG|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
223429662|NCT00020943|DRUG|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1\& 2
223429663|NCT00020943|DRUG|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
223429664|NCT00020943|DRUG|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
223429665|NCT00020943|DRUG|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
223429666|NCT00020943|DRUG|prednisone|100 mg/sq m PO Days 3-7, Tx 1 \& 2
223429667|NCT00020943|DRUG|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 \& 2
223429668|NCT00020943|PROCEDURE|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
223429669|NCT00207558|DRUG|folic acid|
223429670|NCT05303766|DEVICE|Radio-frequency ablation|Radiofrequency thermocoagulation of the genicular nerves
223429671|NCT05303766|DRUG|Intra-articular steroids|Intra-articular steroids for Knee osteoarthritis
223429672|NCT05303766|DEVICE|Pulsed Radio-frequency|Intraarticular Pulsed Radiofrequency of the knee
223429673|NCT05793450|DRUG|IBI362|2.0mg, SC, single dose
223429674|NCT01151202|DRUG|AG NPP709syrup|
223429675|NCT00004406|DRUG|human parathyroid hormone|
223429676|NCT05043597|PROCEDURE|Thrombus aspiration|Thrombus aspiration
223429677|NCT01187498|BEHAVIORAL|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
223429678|NCT01187498|DRUG|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
223564668|NCT04875507|BEHAVIORAL|Positive Psychology|This intervention aim to examine the effectiveness of PPI in reducing depressive symptoms, enhancing self-esteem, and promoting quality of life among Chinese children who are living in poverty. Participants in the experimental group will receive a 1.5 hour workshop on 4 positive psychology techniques, including (1) gratitude visit/letters, (2) 3 good things, (3) you at your best, and (4) using signature strengths. A booster intervention will be given at 1-week follow-up.
223564669|NCT00002938|PROCEDURE|conventional surgery|Salvage prostatectomy
223564670|NCT00117715|PROCEDURE|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
223564671|NCT05258214|OTHER|Mulligan Bent Leg Raise|Mulligan's bent leg raise, as well as the extreme Straight Leg Raise, can be used to relieve Low Back Pain. It can be used to treat leg discomfort that is above the knee. Bent Leg Raise methods are used where there is a restricted range of motion in the hip flexion joint, as well as low back pressure with or without referred leg pain.
224039561|NCT07168772|OTHER|Placebo|Patients will receive a placebo (starch) sachet twice a day for six months.
224039562|NCT07162428|BEHAVIORAL|Art Therapy|"The art therapy sessions will be conducted by a certified art therapist who has completed a two-year training program, together with a psychiatric nurse who has completed a 4-hour training course on Severe Personality Disorders and Therapeutic Interventions - Art Therapy. A clinical nurse and a psychiatry resident will also participate as observers. The therapist will deliver the intervention through semi-structured sessions, following a predefined content and method. These sessions are referred to as Semi-Structured Art Therapy Sessions."
224070498|NCT03466177|DIAGNOSTIC_TEST|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
223429679|NCT01720498|DRUG|remifentanil|The effect site concentration of remifentanil
223429680|NCT00041977|DRUG|doxycycline hyclate 20 mg twice daily|
223564672|NCT05258214|OTHER|Mulligan Traction Straight Leg Raise|Mulligan traction leg raise exercises are a non-invasive treatment that has been shown to help people with low back pain and reduced hip flexion range. Conservative sciatica therapy focuses on pain relief, but increasing Straight Leg Raise range will help restore normal mobility and reduce the severity of low back disability.
224039563|NCT07157865|DEVICE|Prism adaptation training combined with TENS|Subjects in the experimental group will receive both prism adaptation training and TENS to identify affects on USN. To date there are no published studies combining these treatments to minimize USN.
223564673|NCT05258214|OTHER|Neural Mobilization|These techniques are designed to mobilize a nerve with as little pressure down, resulting in a larger longitudinal excursion than techniques that actually lengthen the nerve bed, such as tensioning procedures.
224039564|NCT07157865|OTHER|PAT only|Subjects will receive prism adaptation training (PAT) only wearing prism goggles during a functional reaching task during occupational therapy.
224039565|NCT07173634|OTHER|Speaking Valve Trial|The speaking valve group ascertains a patient's eligibility for decannulation following the results of the speaking valve test. A patient who can endure a 4-hour trial with a speaking valve, maintaining a pulse oxygen saturation (SpO₂) of at least 95%, a breathing rate (RR) below 20 per minute, and exhibiting no signs of distress throughout the trial, qualifies for decannulation.
224039566|NCT07173634|OTHER|Capping Trial|The capping valve group determines a patient's eligibility for decannulation based on the results of the capping test. A patient who can tolerate 48 hours of capping with a pulse oxygen saturation (SpO₂) of ≥95%, a breathing rate (RR) of \<20/min, and no signs of distress during the 48-hour trial, is eligible for decannulation.
224039567|NCT07167316|DRUG|DMTN|Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine by inhibiting activity in the locus coeruleus, a key brain region involved in arousal and stress responses. In this study, dexmedetomidine will be administered as an oro-dispersible tablet applied buccally, allowing for rapid absorption through the oral mucosa.
224039568|NCT07167316|OTHER|Auditory Stimulation|Auditory tones will be presented throughout the night at individually calibrated intensities, adjusted to each participant's hearing threshold, in order to induce controlled sleep fragmentation without full awakenings.
224039569|NCT07167316|DRUG|Placbo|Oro-dispersible placebo tablet identical in appearance and packaging to the active Dexmedetomidine tablet.
224039570|NCT07172152|BEHAVIORAL|HRV Biofeedback Training|Participants will be trained to use HRV biofeedback through paced breathing exercises (6 breaths per minute) twice daily over a four-week period.
224039571|NCT07182045|OTHER|Temporary clamping of uterine and ovarian vessels|Surgeon will temporarily clamp uterine and ovarian vessels.
224039572|NCT07182188|DEVICE|Vascular Interventional Robotic System|The cerebral angiography will be performed by using the vascular interventional robotic system
223564674|NCT00243451|OTHER|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
223564675|NCT06485973|OTHER|Modified Dental Anxiety Scale (MDAS)|The MDAS is described as a scale to provide a more comprehensive assessment of dental anxiety. The MDAS has shown favorable psychometric properties with acceptable reliability and validity.
223564676|NCT02104596|DEVICE|Xylitol|
223564677|NCT03504982|DRUG|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat
223564678|NCT03504982|DRUG|Moxifloxacin|D: 400 mg moxifloxacin
223564679|NCT03504982|DRUG|Placebo|A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
223564680|NCT01971749|PROCEDURE|Coronary stent procedure (CSP)|
223564681|NCT01971749|PROCEDURE|Coronary-artery bypass grafting (CABG)|
224039573|NCT07179224|DEVICE|Treatment with EXOMIND (BTL-699-2)|Transcranial magnetic stimulation with the EXOMIND (BTL-699-2) device will be delivered across various stimulation locations. The intensity will be carefully adjusted based on subject feedback, but it should not exceed 70% of the motor threshold.
223429681|NCT01717482|DRUG|Metformin|
223429682|NCT01717482|OTHER|Placebo Comparator|Standard of Care Observation
223429683|NCT00191282|DRUG|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
223429684|NCT00191282|DRUG|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \>8.0%
223429685|NCT00191282|DRUG|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
223429686|NCT00191282|DRUG|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
223564682|NCT03218072|DRUG|HLX01|a potential rituximab biosimilar
223564683|NCT04271371|OTHER|Not yet developed|A prototype intervention will be developed over Phase 1 \& 2 and piloted in Phase 3 of this study.
223564684|NCT02703012|OTHER|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
223564685|NCT04861467|DRUG|Camrelizumab|IV
223429687|NCT00191282|DRUG|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \>8.0%.
224039574|NCT07174622|DEVICE|Renal Denervation (Symplicity Spyral™)|Symplicity Spyral™ multi-electrode renal denervation system
224039575|NCT07175402|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|The Online version of Acceptance and Commitment Therapy (iACTforDGBI) intervention will include 8 weekly sessions of around 20 minutes each, and will comprise ACT-consistent informative texts, audio exercises, and videos. The intervention is expected to have the following overall structure: Session 0: Individual videoconference meeting, introduction. Session 1: Creative hopelessness and mindfulness. Session 2: The body, acceptance, and values. Session 3: Compassion. Session 4: Cognitive defusion and committed action. Session 5-7: Personalised content (in-depth material and tasks based on individual difficulties assessed with diary). Session 8: Summary of intervention.
224039576|NCT07175402|OTHER|Psychoeducation|Participants in the active control group will be asked to complete 8 weekly 20-minute sessions of an online course for education on DGBIs. This course will be delivered through a similar platform than the one delivering the online ACT for DGBI intervention, via the same website. The intervention platform will have similar designs and structure, and will be developed by the same web development company. Session 0: Individual session, introduction. Session 1-8: The content will be based on the IBS school intervention (e.g., Ringström et al., 2009), in particular its online version (Lindfors et al., 2021), developed by members of the current research team. This education intervention was based on the biopsychosocial model of DGBI and was originally developed and tested as a face-to-face group intervention with six 2-h sessions held weekly. IBS school generally aims at increasing disease knowledge in people with IBS and covers a wide spectrum of issues related to IBS.
224039577|NCT07177430|DEVICE|Inspiratory Muscle Training|"Participants will perform inspiratory muscle training using a respiratory muscle trainer. The initial training load will be set at 30% of PImax.~The intervention will last for 8 weeks and will be carried out 5 days per week, twice daily, in 3 sets of 10 repetitions.~The training load will be increased in the 2nd, 4th, and 6th week of the program, each time by an additional 10% relative to the initial PImax."
224039578|NCT07177430|DEVICE|Inspiratory Muscle Training (Sham)|"The training intervention in the Sham Group will differ from the experimental group only in terms of training load.~This load will remain constant at 15% PImax, which does not cause any changes in the functioning of the inspiratory muscles.~All other training parameters will be identical to those in the IMT group."
224039579|NCT07187492|DRUG|Bacillus coagulans|"Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Bacillus coagulans 1050 mg three times daily.~Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Bacillus coagulans 1050 mg three times daily."
224039580|NCT07187492|DRUG|placebo|"Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Bacillus coagulans (with identical dosage and frequency).~Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Bacillus coagulans (with identical dosage and frequency)."
224039581|NCT07188636|OTHER|No Intervention: Observational Cohort|Participants underwent non-cardiac surgery and were followed retrospectively without any experimental intervention. Data were collected from electronic medical records and national death registry to assess postoperative mortality outcomes.
224070499|NCT05903846|OTHER|Oketani massage|"The part between the breast and the base of the lower pectoral muscle is called the oketani. It is a manual massage technique developed to encourage breastfeeding in breastfeeding problems such as insufficient milk production and mastitis. It is a massage that stimulates the breast, relaxes it and is painless."
224070500|NCT01687712|DRUG|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
224070501|NCT01687712|DRUG|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
224139413|NCT02982538|BEHAVIORAL|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
223429688|NCT04794374|OTHER|Telerehabilitation|Telerehabilitation will consists of physiotherapist-guided exercises. Exercises will be designed by physiotherapists for COVID-19 survivors using the current guidelines. Exercise brochure will be prepared and will be sent to participants. Repetitions and sets of exercises will be modified according to the patients.
223429689|NCT01736774|OTHER|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
223429690|NCT01736774|OTHER|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
223429691|NCT00102531|DRUG|Cisplatin liposomal|
223429692|NCT03004170|BEHAVIORAL|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
223429693|NCT03004170|BEHAVIORAL|Telephone-Administered Coping Effectiveness Training|
223429694|NCT03494400|OTHER|Aerobic Training Presential|The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days, more follow-up.
223429695|NCT03494400|OTHER|Aerobic Training Home-based|The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities, more follow-up.
223429696|NCT06163742|DEVICE|Product X|The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.
224039582|NCT07188714|PROCEDURE|VATs decortication|"A long thoracoscopic instruments are to be used for dissection, evacuation of pus and removal of the visceral peel at the surface of the lung. Instruments will be introduced below the lens in cases of uniportal procedure. Two ports VATS will be used early in this series by adding another 3-4 cm incision in the 3rd or 4th intercostal space anterior axillary line, scope will be introduced through the lower port and instruments will be introduced through the other.~Irrigation with warm saline is to be done; breaking up the fine adhesions, the surgeon will take off the thick visceral peel over the lung surface, opening the fissures using combination of blunt and sharp dissection leaving the parietal pleura."
224039583|NCT07188714|PROCEDURE|VATs debridement|"Removal of pus, debris, granulation tissue is to remove as much as possible of the empyema biofilm while freeing the lung from any loculations.~Following debridement and flushing the pleural cavity by warm saline, the attending anaesthiologist is to modify the ventilatory settings to attain the maximally allowed degree of lung expansion (TV criteria/peak/plateau/PV curve). Then, instillation of saline to obliterate the pleural cavity until saline leaks back from the operating port. If leakage starts after instillation of ≤200 cc. (obliteration of the whole pleural cavity including the cost phrenic angle will be assumed, lung is to be considered sufficiently expanded, and VATS will be withheld at debridement step. On the other hand, if leakage starts after instillation of ≥ 200 cc, lung entrapment and failure of expansion will be assumed, and surgery will proceed to VATS decortication to achieve reasonable lung expansion"
224039584|NCT07189234|BEHAVIORAL|Time-restricted eating (TRE) + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hour eating window for the course of the study as well as receive nutritional counseling from the study dietician.
223429697|NCT06163742|DEVICE|Standard-of-Care|The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
224039585|NCT07189234|BEHAVIORAL|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt the 10-hour eating window.
224039586|NCT07188116|OTHER|COVID-19|The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.
224039587|NCT07188753|OTHER|transcranial magnetic stimulation by accelerated & high-dose theta-burst, functional imaging guided, i|Participants will then be treated with 1,800 pulses of iTBS (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) per session at 90% resting motor threshold and depth-adjustment to the personalized functional target. Each session will last 10 min followed by a 50-minute intersession interval. Ten sessions will be applied per day (18,000 pulses/day) for 5 consecutive days (90,000 total pulses).
224039588|NCT07187908|DRUG|Efbemalenograstim alfa Injection|The patients with solid tumor who were at high risk for febrile neutropenia or intermediate risk of chemotherapy regimens associated with other risk factors in febrile neutropenia would be injected Efbemalenograstim alfa for primary/secondary prevention.
224139414|NCT02982538|BEHAVIORAL|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
223429698|NCT05468242|DRUG|Neoadjuvant chemo-immunotherapy|The neoadjuvant chemo-immunotherapy before radiotherapy comprised of chemotherapy plus Tislelizumab \[200 mg, once every 3 weeks (Q3W)\].
223429699|NCT05468242|DRUG|Bevacizumab|The Bevacizumab was administrated concurrently with neoadjuvant chemo-immunotherapy (7.5mg/kg) once every 3 weeks (Q3W).
223429700|NCT05468242|RADIATION|Radiotherapy|Definitive radiotherapy to the thoracic lesions.
224039589|NCT07188051|DIETARY_SUPPLEMENT|Ovolux brand eggshell membrane powder|Unhydrolyzed eggshell membrane powder
224039590|NCT07188051|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
224039591|NCT07188844|DRUG|Batoclimab|Batoclimab 340 mg SC QW
223429701|NCT05468242|DRUG|Tislelizumab|Tislelizumab consolidation (200 mg) is performed once every 3 weeks after the neoadjuvant therapy and concurrent chemo-radiotherapy, and will continue on a Q3W schedule for a maximum duration of 12 months.
223429702|NCT05462132|DRUG|SYNB1353|SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
223429703|NCT06370871|DRUG|Brigimadlin|Brigimadlin
223564686|NCT01089413|DRUG|bevacizumab [Avastin]|As prescribed by physician
223564687|NCT02383420|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
224039592|NCT07188974|PROCEDURE|Arthrocentesis (lavage only)|A minimally invasive procedure in which the temporomandibular joint (TMJ) space is washed with sterile solution to remove inflammatory mediators and improve joint mobility.
223429704|NCT06370871|DRUG|Ezabenlimab|Ezabenlimab
223429705|NCT06370871|DRUG|Gemcitabine|Solution for infusion
223429706|NCT06370871|DRUG|Docetaxel|Solution for infusion
223429707|NCT02288078|OTHER|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
223429708|NCT02288078|OTHER|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
223429709|NCT02288078|OTHER|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
223564688|NCT01905345|PROCEDURE|Training|
223429710|NCT02288078|OTHER|Clinical findings|"* Blood and lymphatic system disorders: febrile neutropenia~* Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~* General disorders and administration site conditions: fatigue and malaise~* Immune system disorders: allergic reaction~* Metabolism and nutrition disorders: anorexia~* Nervous system disorders: dysgeusia and peripheral sensory neuropathy~* Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~* Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~* Vascular disorders: hypertension~* Symptomatic pancreatitis"
224039593|NCT07188974|PROCEDURE|Arthrocentesis + Injectable Platelet-Rich Fibrin (i-PRF)|Autologous platelet-rich fibrin prepared by centrifugation of the patient's blood and injected intra-articularly into the TMJ following arthrocentesis. i-PRF contains platelets, leukocytes, and growth factors, which may promote tissue regeneration and healing.
223429711|NCT02288078|OTHER|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
223564689|NCT01480804|OTHER|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
223564690|NCT02513485|DRUG|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
223564691|NCT02513485|DRUG|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
223564692|NCT01088165|DRUG|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
224039594|NCT07188779|DEVICE|RADA16 hydrogel|Application of 2.5% RADA16 hydrogel to the tonsillar fossae following tonsillectomy using a sterile syringe tip applicator. The gel will be spread into a thin layer within the tonsillar fossae. The gel will be left to sit for 60 seconds. A suction device will then be used to remove any excess RADA16 hydrogel, leaving a thin layer of RADA16 over the tonsillar fossae.
224039595|NCT07188142|DRUG|Drug/Agent: Gluma Desensitizer|Gluma desensitizer applied to prepared tooth surface, followed by universal bonding agent and composite restoration. Application done during the first visit of restorative treatment. Post-operative sensitivity measured at baseline, 1 week, 1 month, and 3 months.
224039596|NCT07188142|DRUG|Drug/Agent: No desensitizer (Control)|Universal bonding agent applied followed by composite restoration without prior use of Gluma desensitizer. Post-operative sensitivity measured at baseline, 1 week, 1 month, and 3 months.
224039597|NCT07187635|PROCEDURE|Second Transurethral Resection of Bladder Tumor (re-TURBT)|Participants with NMIBC who have undergone initial TURBT will not receive utDNA testing and will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery, in accordance with current clinical guidelines.
224039598|NCT07187635|DIAGNOSTIC_TEST|utDNA Testing (Urine Tumor DNA Detection)|"Participants with NMIBC who have undergone initial TURBT will receive urine tumor DNA (utDNA) testing.~If utDNA is positive, the patient will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery.~If utDNA is negative, re-TURBT will be omitted and patients will proceed to guideline-based adjuvant therapy or surveillance."
224039599|NCT07187882|PROCEDURE|Autologous Non-cultured Epidermal Cell Suspension transplantation|"1. Thin split thickness skin grafts were taken from the donor site (anterolateral thigh) after application of topical anaesthesia under complete aseptic precautions.~2. The cell suspension was prepared by the cell sorting kit (Primcell, Jiangsu Repatec Life Science Co.,Ltd).~3. Then the recipient skin was uniformly dermabraded using an electrical dermabrader set at 10,000 to 20,000 rpm until punctate bleeding points appeared.~4. The cell suspension was applied onto the dermabraded recipient area.~5. The recipient site was then fixed firmly with dressings and elastic bandage. The dressings were removed 10 days after transplantation."
224039600|NCT07189195|DRUG|TR-002|Weekly intravenous infusion
224039601|NCT07188038|PROCEDURE|Low positive end-expiratory pressure|Low (4 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
224039602|NCT07188038|PROCEDURE|Medium positive end-expiratory pressure|Medium (10 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
224039603|NCT07188038|PROCEDURE|High positive end-expiratory pressure|High(16 cmH2O) positive end-expiratory pressure (PEEP) will be applied during pressure support ventilation. The PEEP level will be kept for 10 minutes prior to data acquisition.
224139415|NCT03327753|BEHAVIORAL|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
223744822|NCT06490263|DRUG|Experimental: Mulberry Twig Alkaloids Tablets 126 mg single dose in healthy subjects|Part One: Administered by chewing with meals or swallowing after meals, with a dosage of 126 milligrams, given as a single dose only.
223744823|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with single dose in healthy subjects|Parts Two: Administered by swallowing after meals with four distinct dosage groups.
223429712|NCT02288078|OTHER|Coagulation and fibrinolysis system|international normalized ratio (INR)
223429713|NCT02288078|OTHER|Urinalysis|Proteinuria (qualitative)
224039604|NCT07189351|OTHER|Bowen Therapy|Participants received a hot pack, followed by Bowen Therapy performed in prone lying position on a plinth. Bowen moves were applied to soft tissues and muscles of the neck and upper back, aiming to reduce muscle tension and pain. Sessions lasted 15-20 minutes, administered on alternate days for 6 weeks. Assessments were conducted at baseline, 3rd week, 6th week, and at 3-week follow-up.
224039605|NCT07189351|OTHER|Muscle Energy Technique (Post-Isometric Relaxation)|Participants received a hot pack applied over the neck and upper back area for 7-10 minutes, followed by Muscle Energy Technique in supine lying position. Post-isometric relaxation was used for upper trapezius, levator scapulae, scalenus, and sternocleidomastoid muscles. A moderate isometric contraction was held for 5 seconds, followed by 3 seconds of relaxation, with 5 repetitions per muscle. Sessions were given on alternate days for 6 weeks. Assessments were performed at baseline, 3rd week, 6th week, and at 3-week follow-up.
224039606|NCT07187752|DRUG|Trastuzumab|Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks)
224039607|NCT07187752|DRUG|Pertuzumab|Pertuzumab (loading dose 840 mg, followed by 420 mg every 3 weeks)
223429714|NCT02288078|OTHER|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
223429715|NCT02288078|OTHER|Adverse event|CTCAE ver.4.0
224039608|NCT07187752|DRUG|Chemotherapy|Chemotherapy chosen by the investigators.
223429716|NCT02288078|OTHER|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
224039609|NCT07187752|PROCEDURE|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
224039610|NCT07187843|OTHER|Clinical assessments|standardized neurological examination, motor and non-motor symptom scales, cognitive testing, and autonomic symptom questionnaires.
223429717|NCT02288078|OTHER|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
223429718|NCT02288078|OTHER|Brain MRI|If any symptom of brain metastasis is suspected
223429719|NCT02288078|DRUG|Dexamethasone|Capsule filled with dexamethasone and lactose
223429720|NCT02288078|DRUG|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
223564693|NCT01088165|DRUG|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
223564694|NCT01088165|OTHER|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
223744824|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in healthy subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
224039611|NCT07187843|OTHER|Phenotypic classification|patients will be stratified into Brain-First and Body-First phenotypes based on the presence of RBD and instrumental findings.
224039612|NCT07187778|DRUG|Pembrolizumab|Oral administration
224039613|NCT07187778|DRUG|Belzutifan|Oral administration
224039614|NCT07187388|DEVICE|Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS|"TENS intervention will be administered using a current-controlled TENS device that produces charge-balanced, symmetrical biphasic rectangular pulses. Participants will be seated and skin cleaned prior to applying 2 self-adhesive round surface electrodes (25mm) on each side of the face. One electrode (anode) will be placed over the masseter muscle belly, while the other (cathode) will be positioned over the TMJ. Electrode placement will be confirmed by palpation of the TMJ and Masseter. This set up will be mirrored on the opposite side. Once all 4 electrodes are in place, the TENS unit will be turned on.~Participants will remain seated. The TENS unit will be set to manual mode to deliver the stimulation at a frequency of 50 Hertz (Hz) and a pulse width of 200 microseconds (µseconds). Stimulation amplitudes will be gradually increased from 0 milliamps (mA) to each participant's tolerance level. The 30 minute TENS intervention will then take place."
224039615|NCT07188558|BIOLOGICAL|rondecabtagene autoleucel|An autologous, dual-targeting CD19/20 CAR T-cell candidate.
224039616|NCT07188558|BIOLOGICAL|axicabtagene ciloleucel|An autologous CD19 CAR T-cell therapy
224039617|NCT07188558|BIOLOGICAL|lisocabtagene maraleucel|An autologous CD19 CAR T-cell therapy
223429721|NCT02288078|DRUG|Placebo|Capsule filled with lactose
224163876|NCT00312728|DRUG|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
223429722|NCT02288078|DRUG|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
223429723|NCT00596128|BEHAVIORAL|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
223429724|NCT04756154|DRUG|CHG/IPA Surgical skin preparation|Apply topically to the inguinal region for 2 minutes
223429725|NCT04756154|DRUG|Normal saline|Apply topically to the inguinal region for 2 minutes
223429726|NCT05599087|BIOLOGICAL|Acellular system|Regenerative Endodontic Procedure Tissue engineering procedure
223429727|NCT02694354|DRUG|BI 685509|
223429728|NCT02694354|DRUG|Placebo|
224039618|NCT07188961|OTHER|kinesiologic taping|This intervention is distinguished from other studies by its combined assessment of trunk and extremity kinesiology taping in children with both hemiplegic and diplegic cerebral palsy over a four-week period.
224039619|NCT07188311|DRUG|Pucotenlimab ,Lenvatinib|A total of 24 cases are planned to be enrolled. All subjects will receive Pucotenlimab (3mg/kg, on Day 1, with a maximum dose not exceeding 200mg) once every 3 weeks (Q3W), in combination with Lenvatinib and Irinotecan. The chemotherapy regimen is fixed: Lenvatinib capsules 7mg/m2 (maximum 12mg) orally from Day 1 to 21 and Irinotecan 50mg/m2 from Day 1 to 5. Chemotherapy will be administered for 2 to 4 cycles, once every 3 weeks (Q3W).
224039620|NCT07187531|DRUG|High Dose SAB-142|High Dose SAB-142
224039621|NCT07187531|DRUG|Low Dose SAB-142|Low Dose SAB-142
223429729|NCT05028127|DRUG|Bimekizumab|Subjects will be receiving bimekizumab at pre-specified time-points.
223744825|NCT06490263|DRUG|Mulberry Twig Alkaloids Tablets with multiple dose in overweight or obese subjects|Part Three: Administered by swallowing after meals with two distinct dosage groups, taken three times daily.
224039622|NCT07187531|OTHER|Placebo|Placebo
224039623|NCT07189000|BEHAVIORAL|App-based prehabilitation program|A lightweight mobile/web application delivering a patient-centered prehabilitation program from randomization until surgery. Features include: weekly home six-minute walk tests (6MWT) logged in the app; brief daily check-ins for exercise performed, simple nutrition targets, and mood/stress; push reminders; short educational video/handout content; and CSV export for analysis. The app provides standardized instructions and safety prompts for the home 6MWT and basic validity checks (continuous 6 minutes, pause limits, outlier flags). No additional study-specific clinic visits are required beyond routine preoperative admission and one routine postoperative outpatient visit.
224139416|NCT03327753|BEHAVIORAL|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
224139417|NCT01947608|DRUG|LDK378|750 mg. orally
224139418|NCT06365671|OTHER|autologous stem-cell transplantation|high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT)
224139419|NCT06365671|DRUG|Relmacabtagene autoleucel (relma-cel)|relma-cel (CD19 CAR-T cell)infusion on day 3(±1d) after ASCT with a fixed dose of 100X10\^6.
223429730|NCT00454220|OTHER|Placebo|33 patients to placebo + 131-I arm
223429731|NCT00454220|DRUG|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
223429732|NCT00454220|DRUG|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
223429733|NCT02562222|PROCEDURE|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
223429734|NCT02562222|PROCEDURE|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
223429735|NCT02562222|PROCEDURE|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
223429736|NCT02562222|PROCEDURE|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
224039624|NCT07189000|OTHER|Usual care (ERAS-standard perioperative care)|Standard perioperative counseling/education and routine mobilization per institutional ERAS practice. No study app is provided and no remote 6MWT logging is required. Outcome assessments are collected at routine preoperative admission (including in-hospital 6MWT per protocol) and at one routine postoperative outpatient visit (≈3 or 6 months per unified site policy). No additional study-specific clinic visits are required.
224039625|NCT07188207|DRUG|Oxytocin|"Intravenous oxytocin administered per hospital protocol immediately after delivery of the baby and placenta (example regimen: 10 IU slow IV bolus followed by infusion e.g., 20 IU in 500-1000 mL isotonic crystalloid run over 2-4 hours; actual dosing adjusted per anesthesiologist/obstetrician and hospital policy). Document exact time, dose, and infusion rate in each case.~Single rectal dose of misoprostol 600-1000 µg (select dose based on patient risk profile; e.g., 600 µg for routine prophylaxis, 800-1000 µg for high-risk cases) inserted into the rectum immediately after delivery of the baby and placenta. No dilution required."
223429737|NCT02562222|PROCEDURE|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
223429738|NCT02562222|PROCEDURE|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
223429739|NCT02562222|PROCEDURE|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
223429740|NCT04641663|DIETARY_SUPPLEMENT|Multi-target Dietary Supplement (MTDS)|"The Multi-Target Dietary Supplement (MTDS) is comprised of 51 ingredients designed to simultaneously target and support the cellular processes implicated in the progression of the aging phenotype (oxidative stress, inflammatory processes, insulin resistance, and membrane and mitochondrial deterioration). The MTDS is unique in that it was specifically designed as a multi-target intervention to support the complex cellular perturbations associated with aging. Components of the formulation were chosen based on scientific consensus of documented effectiveness for one or more of the targeted processes, long-term evidence of safety, and synergistic or additive interactions between components.~The MTDS is divided into morning and evening doses to maximize availability of the components to the peak activity level of the cellular processes that require those components."
223429741|NCT01790828|DRUG|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
223429742|NCT03349554|OTHER|body-scan meditation|15 minutes audio-guided body-scan meditation
223429743|NCT03349554|DIAGNOSTIC_TEST|Psychological evaluation|"NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation"
223429744|NCT00525811|OTHER|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
223429745|NCT00525811|OTHER|patient information|Information on acute low back pain, information on depression
223429746|NCT04973371|DIAGNOSTIC_TEST|Home-based point-of-care (POC) TB testing using GeneXpert device + MTB/RIF test|Those who screen positive for TB using the standard 4-question screener will be offered a GeneXpert® \[Cepheid, Sunnyvale, CA\] MTB/RIF test in their home with referral for clinic-based TB treatment initiation for those who receive a positive MTB/RIF test result.
223429747|NCT04648982|OTHER|Admission to inpatient psychiatric unit|All persons in the study are hospitalized at the only inpatient mental health hospital in Rwanda - Ndera. Data will be collected when the person is being discharged.
223429748|NCT04054973|DRUG|L-arginine|6000mg of L-arginine daily for 14 days
223429749|NCT04054973|DRUG|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
223429750|NCT03109665|DIAGNOSTIC_TEST|SD-OCT Angiography|SD-OCT Angiography
223429751|NCT03109665|DIAGNOSTIC_TEST|SD-OCT|SD-OCT
224039626|NCT07188025|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX). Duration of treatment will be 3 months (12 weeks).
224039627|NCT07187401|DRUG|ALN-CFB|Administered as defined in the protocol
224039628|NCT07187401|DRUG|Placebo|Administered as defined in the protocol
224039629|NCT07187960|DRUG|TQB2825 Injection|TQB2825 is a Cluster of Differentiation 3 (CD3) × Cluster of Differentiation 20 (CD20) bispecific antibody.
224039630|NCT07187960|DRUG|Rituximab Injection|Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA, Dexamethasone)
223429752|NCT02101931|DRUG|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
223429753|NCT06463392|OTHER|No Intervention: Observational Cohort|No intervention is scheduled for this observational study.
223429754|NCT02855229|DRUG|Methylphenidate|cross-over, single-dose intervention
224039631|NCT07188831|OTHER|Agarwood Aromatherapy Inhalation|The experimental group will receive agarwood essential oil sachets as the aromatherapy intervention, and participants will place the sachet 60 cm from the nose during sleep for one week.
224039632|NCT07189208|DRUG|Benzathine penicillin 2.4 million units|IM injection of BPG
223429755|NCT04271319|DEVICE|BEST™ HVPC microcurrent electrical stimulation PRO-SPORT Ultra® Device|"Participants will receive treatment with an active electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief"
223429756|NCT04271319|DEVICE|Sham PRO-SPORT Ultra® Device|"Participants will receive treatment with a sham electrical stimulation device for 7 in-clinic treatments over 2 weeks.~Sham PRO-SPORT Ultra® device will be used. The built in electrodes and the accessory port for connecting the lead wire to the electrode pads will be disconnected internal to the device. The device will power on with the same sounds and indications."
223429757|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
223429758|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
223429759|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
223429760|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
223429761|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
223429762|NCT06522945|DRUG|TQD3524|Polymyxin antibiotics
223429763|NCT02814227|DEVICE|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
223429764|NCT03589976|DRUG|Sirolimus 2 MG|Dose will be adjusted throughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose will be 6mg/day.
223429765|NCT03589976|OTHER|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
223429766|NCT06083727|OTHER|rate of cesarean section|rate of primary cesarean section in primigravida and multigravida
223429767|NCT01833624|DIETARY_SUPPLEMENT|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
223429768|NCT01833624|DIETARY_SUPPLEMENT|Sondalis® HP|
223429769|NCT01780402|BEHAVIORAL|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
224039633|NCT07189208|BEHAVIORAL|Counseling and intensified testing.|Brazilian Ministry of Health guidelines for the prevention and diagnosis of maternal syphilis consist of counseling about STI prevention and syphilis testing at the first pre-natal consultation, at a subsequent consultation during or after 28 weeks of pregnancy, at delivery, and in case of abortion or stillbirth. In this study, intensified testing refers to treponemal and non-treponemal tests once every four weeks beginning as of the 28th week of pregnancy.
224039634|NCT07188103|DRUG|Ivonescimab+Radiotherapy|Short-course hypofractionated radiotherapy was administered to progressive lesions after first-line treatment, with a prescribed dose of 20 Gy in 5 fractions (95% PTV). The monoclonal antibody was initiated within 1 week after completing the radiotherapy regimen, at a dose of 20 mg/kg. Ivonescimab was administered every three weeks until disease progression, intolerable toxicity, or patient refusal.
224039635|NCT07188415|DEVICE|Ankle-foot Orthoses|Group 1 will consist of individuals who have CMT and have undergone surgical correction (OP) and Group 2 will be AFO users who have CMT but have not undergone major surgical correction (NonOP).
224039636|NCT07188402|OTHER|Prevalence of sleep disturbances in patients with bullous pemphigoid|Use of a questionnaire assessing the Insomnia Severity Index (ISI)
224039637|NCT07188402|OTHER|Prevalence of sleep disturbances in healthy volunteers without bullous pemphigoid|Use of a questionnaire assessing the Insomnia Severity Index (ISI)
224039638|NCT07189169|DRUG|QA108 granules|Take the medication as required for 24 weeks
223429770|NCT04567927|OTHER|Ultrasonography|Venous compression ultrasonography using real-time B-mode and colour doppler in transverse and longitudinal views
223429771|NCT04015076|DRUG|Inzomelid|Active Drug
223429772|NCT04015076|DRUG|Placebo|Placebo to Match
223429773|NCT00468754|DEVICE|Insulin pumps|
224039639|NCT07189169|DRUG|QA108 granules placebo|Take the medication as required for 24 weeks
224139420|NCT06061887|OTHER|Fall evaluation|Evaluation of the frequency of falls in patients with acute stroke and determining the risk factors associated with recurrent falls within the first six months after stroke
224139421|NCT04694547|OTHER|There is no intervention, as this is a survey study|Survey
223429774|NCT03721835|DEVICE|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
223429775|NCT04198584|BEHAVIORAL|VC-CBCS|A 14-module stress management and lifestyle group-based intervention delivered via videoconferencing WebEx technology to participants who have/had chronic hepatitis C and experience symptoms, stress or lifestyle requirements to promote liver health.
224139422|NCT05725382|DEVICE|The NOL monitor (Pain Monitoring Device monitor-PMD200™)|NOL-guided perioperative remifentanil administration
224139423|NCT01821820|OTHER|Pistachios|
224039640|NCT07189338|PROCEDURE|Apneic oxygenation|"* Preoxygenation will be performed using NIV for 3-5 min With nasal cannulas placed in standby beneath the patient's chin (with HFNO on and set with a flow at 60-70L.min-1, FiO2 1.0)~* Rapide sequence induction~* Hypoventilation phase will be continue for 1 min using NIV~* At the time of laryngoscopy :~After removing the facemask, the nasal cannulas of HFNO will be placed in the patient's nares then the laryngoscopy will be performed.~\* Use of capnography to confirm the success of procedure"
224039641|NCT07189338|PROCEDURE|Usual Care|"* Preoxygenation will be performed using NIV for 3-5 min without HFNO~* Rapide sequence induction~* Hypoventilation phase will be continue using NIV for 1min~* At the time of laryngoscopy :~After removing the facemask, laryngoscopy will be performed without oxygen.~\* Use of capnography to confirm the success of procedure"
224139424|NCT05430711|DRUG|Dinoprostone|After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
223429776|NCT06408064|OTHER|Music therapy|Music therapy is a non-pharmacological therapeutic intervention that will be implemented through two modalities: live and pre-recorded instrumental lullabies music.The volume control will be conducted within the groups through the use of a decibel regulator, with a maximum volume of 70 dB. During the intervention and for a period of 30 minutes following its conclusion, singing will be prohibited by the music therapist or the parents. Both live and pre-recorded music will be instrumental in nature, lacking any lyrics.
224039642|NCT07188454|BEHAVIORAL|Mindfulness-Based Digital Intervention (AIZEN Program)|The intervention consisted of a 5-week mindfulness program designed for caregivers. Participants attended one live, instructor-led online class each week (90 minutes per session) delivered via Microsoft Teams. Between classes, they were asked to complete at least 10 minutes of daily guided mindfulness practice using the AIZEN digital platform. To encourage adherence, participants also received automated daily reminders through the LINE messaging service.
224039643|NCT07187544|DRUG|Calcium Chloride|Intravenous calcium chloride 10% (1g) will be administered in 100ml normal saline, over 10 minutes.
223740274|NCT07207343|DEVICE|Haifu Focused Ultrasound tumor therapeutic System|Haifu Focused Ultrasound tumor therapeutic System is a tumor ablation technique developed in recent years that allows for non-invasive treatment of solid tumors using High-Intensity Focused Ultrasound (HIFU). This method works by physically focusing ultrasound energy at a single point within biological tissue, creating a focal zone of high-power, low-frequency ultrasound that induces mechanical fragmentation (histotripsy) and cavitation effects, dissolving the tissue into fragments and destroying tumor cells. Under real-time ultrasound imaging guidance, various scanning treatment protocols are used to move the focal point throughout the treatment zone, effectively ablating the tumor tissue. The destroyed tumor tissue is gradually absorbed by the body. Since this technique does not require needle puncture, electrode insertion, radiation, or thermal effects, it is minimally invasive and holds the potential to overcome the limitations of existing ablation technologies.
223740275|NCT07206667|PROCEDURE|T1 GRE GADO MRI sequence|Addition of a T1 gradient echo sequence with gadolinium (T1 TFE GADO) during the two MRI scans performed in routine practice before and after neurosurgery.
224039644|NCT07187544|OTHER|Placebo|Intravenous administration of 100ml normal saline, over 10 minutes.
224039645|NCT07187544|DRUG|Carbetocin|50 mcg intravenous carbetocin.
224039646|NCT07189364|BEHAVIORAL|Peer Comparison Feedback Report|The intervention will be an electronic, individualized, peer-comparison feedback report on the participant's antimicrobial prescribing practices, combined with a knowledge toolkit focused on optimizing antimicrobial use.
223429777|NCT02744027|OTHER|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories \[TWIST\]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
224039647|NCT07188233|DEVICE|Transcatheter Mitral Valve Repair|Mitral valve repair with the CathHELIX Transcatheter Mitral Annuloplasty System in subjects with functional Mitral Regurgitation
224039648|NCT07187713|DRUG|ACE Reno|1 ml sublingual 4 times daily for 12 weeks
224039649|NCT07187947|DRUG|Feminizing GAHT|Before gender-affirming surgery, the regimen consists of an antiandrogen (cyproterone acetate or leuprorelin or triptorelin) plus estradiol (estradiol or estradiol valerate), whereas after an oophorectomy, estradiol/estradiol valerate can be administered alone.
224039650|NCT07187947|DRUG|Masculinizing GAHT|Before and after gender-affirming surgery, the regimen consists of the administration of testosterone or its esters (testosterone undecanoate, testosterone enanthate)
224039651|NCT07188519|OTHER|expressive writing|Each of the four rounds consisted of three consecutive days of writing followed by a gap week.
224039652|NCT07188532|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224139425|NCT04261387|DRUG|LUT014 Gel|Topical application qd for 28 days
224139426|NCT04261387|DRUG|Placebo for LUT014 Gel|Matching placebo for qd topical application for 28 days
224139427|NCT04629612|PROCEDURE|Regional anesthesia|Regional anesthesia such as paravertebral block, pectoral block, superficial cervical plexus block, etc applies according to institution protocol
224139428|NCT05171582|PROCEDURE|Surgery 1 (Test group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
223429778|NCT02744027|OTHER|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
223429779|NCT02744027|OTHER|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
224039653|NCT07188532|DRUG|Chemotherapy|Given chemotherapy
223429780|NCT01726036|DEVICE|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
223429781|NCT01726036|DEVICE|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
223740276|NCT07207044|BEHAVIORAL|Exercise - Strength + Cardio|Supervised strength training 2x/week + self-administered cardio training 2x/week.
224039654|NCT07188532|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224039655|NCT07188532|PROCEDURE|Conventional Radiotherapy|Undergo conventional radiotherapy
224039656|NCT07188532|PROCEDURE|Definitive Surgical Resection|Undergo definitive surgical resection
224039657|NCT07188532|RADIATION|Dose-escalated Radiation Therapy|Undergo hypofractionated or conventional radiotherapy
224039658|NCT07188532|OTHER|Electronic Health Record Review|Ancillary studies
224039659|NCT07188532|RADIATION|External Beam Radiation Therapy|Undergo definitive radiotherapy
224039660|NCT07188532|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
223429782|NCT00779532|DRUG|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
223429783|NCT00779532|DRUG|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
223429784|NCT00779532|DRUG|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
223429785|NCT00779532|DRUG|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
223429786|NCT02763397|DEVICE|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
223429787|NCT02763397|DEVICE|DBS|DBS will be switched off
223429788|NCT05519059|DRUG|Pelareorep|Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle
223429789|NCT05341206|DRUG|Herbal gargle|The treatment group receive Herbal gargle 150ml and are instructed to hold the gargle in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
223429790|NCT05341206|OTHER|Normal saline|The control group receive Normal saline 150ml and are instructed to hold the normal saline in the mouth for 30s and then expectorate it twice a day, 5 days a week for 8 weeks.
223429791|NCT02343445|DRUG|P-1037|P-1037 is a novel ENaC inhibitor
223429792|NCT02343445|DRUG|Hypertonic Saline|4.2% saline solution
223429793|NCT02343445|DRUG|Saline|0.17% saline solution
223429794|NCT01190358|DIETARY_SUPPLEMENT|Placebo|Sugar pill containing maltodextrin.
223429795|NCT01190358|DIETARY_SUPPLEMENT|Grape seed extract|Meganatural Gold® contains 300mg of grape seed extract.
223429796|NCT02057029|BEHAVIORAL|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
223429797|NCT06605989|PROCEDURE|Nasotracheal intubation|For nasotracheal intubation, the nasal RAE tube will be first inserted through the left nostril for patients in the left nostril side arm. For nasotracheal intubation, the nasal RAE tube will be first inserted through the right nostril for patients in the right nostril side arm.
223740277|NCT07207044|BEHAVIORAL|Time-restricted feeding|Time-restricted feeding in a 16/8 regimen - 16 hours of fast and 8 hours of eating per day.
224039661|NCT07188532|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224039662|NCT07188532|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224039663|NCT07188532|OTHER|Questionnaire Administration|Ancillary studies
224039664|NCT07188532|RADIATION|Radiation Therapy|Undergo hypofractionated or conventional standard radiotherapy
224039665|NCT07187336|PROCEDURE|Shoulder MSAT Group|"Shoulder Motion Style Acupuncture Treatment (MSAT) involves inserting acupuncture needles into specific points around the shoulder joint, then guiding or assisting the patient's shoulder movements while the needles remain in place. This combined technique is intended to maximize acupuncture effects by stimulating both the needles and the joint motion.~In this study, MSAT will be performed once daily for three consecutive days (hospital days 2-4), in addition to standard integrative Korean medicine treatment (acupuncture, pharmacopuncture, Chuna manual therapy, and herbal medicine). Each MSAT session lasts about 10-20 minutes.~This distinguishes the intervention from the comparator arm, which receives integrative Korean medicine treatment only, without MSAT."
224039666|NCT07187336|PROCEDURE|Integrative Korean Medicine Only Group|"Participants in this group receive only standard integrative Korean medicine treatments, without MSAT. Treatments include acupuncture (6-10 points, 15-20 minutes per session), pharmacopuncture (injection of herbal extracts at acupuncture points), Chuna manual therapy (10-15 minutes daily), and herbal medicine (oral decoction extracts taken twice daily).~This arm serves as the comparator to distinguish the additional effects of MSAT, since both groups receive the same integrative Korean medicine but only the experimental arm includes Shoulder MSAT."
224039667|NCT06464562|BEHAVIORAL|LiveWell: Adapted Dialectical Behavioral Therapy Skills Training|An adapted dialectical behavioral therapy skills training intervention
224039668|NCT05490004|OTHER|Violence, Evidence, Guidance, Action Project (VEGA) Education Intervention|VEGA is a novel education intervention that has the potential to improve the preparation of healthcare and social service providers (HHSPs) to be able to effectively recognize and respond to intimate partner violence (IPV) and related forms of family violence, including child maltreatment (CM), in their clinical encounters. VEGA was developed based on systematic reviews and consultation with individuals belonging to 22 national healthcare and social service organizations, including the Royal College of Physicians and Surgeons of Canada. VEGA follows a competency-based framework and a participatory, encounter-based curriculum that includes four learning modules: (a) the epidemiology of IPV and CM; (b) strategies for safely recognizing and responding to (i) IPV and (ii) CM; and (c) principles for ensuring safe clinical encounters for IPV and CM discussions.
224039669|NCT07188610|BIOLOGICAL|T cell injection targeting CD7 chimeric antigen receptor|After signing the informed consent form, eligible subjects will undergo a single nucleated cell collection for the preparation of CAR-T cells, followed by lymphodepletion pretreatment and a single infusion of PA3-17 injection.
224039670|NCT05868811|BEHAVIORAL|Music Together|The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.
224039671|NCT05868811|BEHAVIORAL|Play Group|The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
224039672|NCT05773885|DEVICE|VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)|"The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
224139429|NCT05171582|PROCEDURE|Surgery 2 (Control group)|After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
224139430|NCT01016691|DRUG|High Dose Drug Device|device inserted for 4 days
224139431|NCT01016691|DRUG|Low Dose Drug Device|device inserted for 4 days
224139432|NCT01016691|DRUG|Placebo Device|device inserted for 4 days
224139433|NCT01016691|DRUG|bimatoprost 0.03%|one drop in each eye on one day only
223429798|NCT01390428|DRUG|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
223429799|NCT05079750|BIOLOGICAL|ChAdOx1 biEBOV|ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)
223429800|NCT02800915|OTHER|Service innovation with focus on multidisciplinary collaboration|The follow-up is performed via telemedicine (videoconference) to the patient in his or her own home, and in cooperation with the district nurses.
223429801|NCT06354920|BEHAVIORAL|Bonding Bundle|Doctors in the intervention arm will be asked to use suggested approaches while meeting with their hospitalized patients. The goal of these strategies is to improve the relationship and interactions between patients and physicians.
223429802|NCT06315517|OTHER|Conventional lactose-free cow's milk|"Participants will receive conventional lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
223429803|NCT06315517|OTHER|Nonconventional (A2) cow's milk|"Participants will receive nonconventional (A2) cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
223429804|NCT06315517|OTHER|Nonconventional (A2) lactose-free cow's milk|"Participants will receive nonconventional (A2) lactose-free cow's milk as follows:~On Day 1, participants will receive 50mg casein/kg/bw (\~125ml milk). On Day 3, participants will receive 100mg casein/kg/bw (\~250ml milk). On Day 5, participants will received 200mg casein/kg/bw (\~500ml milk). During test phases, breath hydrogen and methane will be measured every thirty minutes for three hours, and blood glucose will be measured every thirty minutes for two hours. Gastrointestinal symptoms will be assessed with visual analog scales for the following 24 hours. There will be a 7-10 day wash out period in between test phases."
223429805|NCT05961930|BEHAVIORAL|Questionnaire|Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
224039673|NCT05773885|OTHER|Conventional rehabilitation|"The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week."
224039674|NCT03188562|OTHER|PET/CT|Positron Emission Tomography (PET/CT)
224039675|NCT03188562|PROCEDURE|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
224039676|NCT03188562|PROCEDURE|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
224039677|NCT06179576|BEHAVIORAL|Connect to Baby|"To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention."
224039678|NCT06393504|DRUG|Daridorexant|Daridorexant received during or shortly prior to pregnancy.
224039679|NCT06393504|DRUG|Non-orexin receptor antagonist insomnia medication|Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
224039680|NCT06393504|OTHER|No insomnia medication|No insomnia medication received during or shortly prior to pregnancy.
223429806|NCT05399043|OTHER|Multidisciplinary Conventional Neuromotor Rehabilitation|Patients will receive conventional treatment consisting of two daily one-hour session (4 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to patient's medical diagnosis, disability severity, and to the consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, speech therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
223429807|NCT05399043|DEVICE|Technology-based Rehabilitation|"According to their individualized rehabilitation project, patients will undergo RAT or non-immersive VR-based rehabilitation.~RAT will consist of three times a week one-hour session (4 weeks) and will be conducted by the implementation of an exoskeleton device for the upper limbs (Armeo-Spring™) or for the lower limbs (Lokomat™).~VR-based rehabilitation will consist of one daily one-hour session (4 weeks) and will be conducted by the implementation of a single non-immersive VR device among the Riablo™ (Corehab, Italy), the ProKin 252™ (TechnoBody SRL, Italy), the D-Wall™ (TechnoBody SRL, Italy), the Walker View™ (TechnoBody SRL, Italy).~Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants."
223429808|NCT05897827|BEHAVIORAL|PLANTS|PLANTS intervention is an online-delivered training program, including asynchronous and synchronous activities. This intervention was informed by the Information-Motivation-Behavior theory to target skills, self-efficacy, knowledge, and outcome expectations. There are 3 asynchronous online modules that cover a variety of topics including lessons on LGBTQ+ terminology, names and pronouns, resources, antibullying, gender neutral bathrooms, student confidentiality, active empathic listening, and school policies. Module include recorded presentations, student testimonials, activities, and downloadable resources for future reference. Every month, 7-9 lessons are opened. There are 2 synchronous group events delivered via Zoom and are 1.5 hours each.
223429809|NCT05897827|BEHAVIORAL|EMAILS|The active control arm is an email-based intervention, EMAILS, in which existing public resources for supporting, affirming, and protecting LGBTQ+ students are emailed to participants.
223429810|NCT05999318|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive two 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223429811|NCT05999318|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive two sham 600-pulse cTBS stimulations per day, parted by a 15-minute rest period (a total of 1200 pulses daily), for 3-week treatment, with 5 consecutive workdays each week.
223564695|NCT02502227|BEHAVIORAL|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
223564696|NCT03811847|DRUG|Methylphenidate Extended Release Oral Capsule|"Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg"
224039681|NCT04890054|OTHER|Fecal Immunochemical Test|Patients due for CRC screening are mailed a FIT test by the clinic or health plan
224039682|NCT04890054|OTHER|Interview|Participate in interviews to evaluate the implementation of the mailed FIT and patient navigation programs by the clinics and regional organizations
224039683|NCT04890054|BEHAVIORAL|Patient Navigation|Clinic staff are trained in Navigation, patients with an abnormal FIT are contacted about colonoscopy by patient navigators
223429812|NCT06069154|DEVICE|Cryoneurolysis|Active cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or for the Varian: 5.5-minute \[all but 5 participants\] or 3-minute \[5th - 12th participants; changes based on new laboratory and subsequently clinical data\] argon activation (2000 psi starting at 100% power but decreased to keep return gas flow temperature warmer than -100C) followed by a 30-second helium defrost. For the active comparator, the gas will be deployed to the tip where a drop in temperature will result in cryoneurolysis.
223429813|NCT06069154|PROCEDURE|Local anesthetic peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks. The injectate through the introducer will depend on the treatment group: for participants of the control group, ropivacaine 0.5% or bupivacaine 0.375% (both with epinephrine 1:400,000) will be injected (volume determined by institutional standard-of-care). This will provide a peripheral nerve block for the control group.
224039684|NCT03531736|DRUG|Antithymocyte globulin (Rabbit)|ATG (2 mg/kg/d IV on days-8 through -7)
224039685|NCT03531736|DRUG|fludarabine|fludarabine (30 mg/m2/d on days -5 through -2)
223429814|NCT06069154|DEVICE|Sham Cryoneurolysis|Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or for the Varian: 1 cycle of 5.5 minutes \[all but 5 participants\] or 3 minutes \[5th - 12th participants; changes based on new laboratory and subsequently clinical data\] of argon and 30 seconds of helium. However, for the sham comparator, the gas will NOT be deployed to the tip, there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
224039686|NCT03531736|RADIATION|total body irradiation|TBI 200 cGy (days -2 and -1) given post stem cell infusion
224039687|NCT03531736|DRUG|cyclophosphamide|cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)
223429815|NCT06069154|PROCEDURE|Sham peripheral nerve block|Due to the pragmatic design of this trial, study participation will not alter an institution's current practice. Examples of peripheral nerve blocks include paravertebral, erector spinae plane, and serratus anterior nerve blocks: for participants allocated to the cryoneurolysis group (experimental group), normal saline will be injected for the peripheral nerve block. This will result in a sham/placebo nerve block for the experimental group.
223429816|NCT05441033|OTHER|Fetal Heart Sounds (FHS) Listening Intervention|Pregnant women and their partners listened to fetal heart sounds (also referred to as angel sounds) for 20 minutes before bedtime on three consecutive nights using a fetal heart rate monitoring device. The intervention aimed to enhance prenatal attachment and reduce anxiety by increasing awareness of the fetus through auditory stimulation.
223429817|NCT05441033|OTHER|Guided Imagery Technique (GIT) Intervention|Pregnant women and their partners listened to guided imagery audio recordings for 20 minutes before bedtime on three consecutive nights. The recordings were developed to support bonding with the baby, reduce anxiety, and improve sleep quality. The intervention was delivered via audio files prepared by the research team based on structured imagery scripts.
223429818|NCT05199662|DRUG|Intravenous tenecteplase|Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).
223429819|NCT05199662|DRUG|Placebo|Placebo matching IV TNK
223429820|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Bangladesh|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
223429821|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in Uganda|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
224039688|NCT03531736|DRUG|Rituxan|Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia
224039689|NCT03531736|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
224039690|NCT06018363|BIOLOGICAL|Allogenic B7-H3 CAR-γδT cell(QH104)|"Dose escalation (3+3) : dose 1 (1 × 10\^7 CAR+cells) , dose 2 (3 × 10\^7 CAR+cells), dose 3 (6× 10\^7 CAR+cells), once every 4 weeks via an Ommaya reservoir or intrathecal administration.~Dose expansion 1: dose of RP2D, once every 4 weeks via an Ommaya reservoir or intrathecal administration.~Dose expansion 2: 3 × 10\^7 CAR+cells, every two weeks for three consecutive months, then changed to once every 4 weeks via an Ommaya reservoir or intrathecal administration."
224039691|NCT06261567|DRUG|Biologic treatment|Patients receiving treatment with any biologic treatment for severe asthma which is approved within the UK NHS. These include omalizumab, mepolizumab, reslizumab, benralizumab and/or dupilumab
224039692|NCT05333328|DRUG|Ovarian function suppression with endocrine treatments|"* Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients."
224039693|NCT06399289|BIOLOGICAL|Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)|Lyophilized powder for solution for intravenous injection
224039694|NCT04624126|DEVICE|3D-Erect|3D-printed erectile device for intercourse
224039695|NCT06185530|DIAGNOSTIC_TEST|Detection of obstructive coronary disease|Detection of obstructive coronary disease
224039696|NCT06957743|BEHAVIORAL|Mindfulness Meditation|The Mindfulness Meditation trainings will teach participants Shamatha Vipassana, which is the specific form of Mindfulness Meditation typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Participants will be invited to lie flat on their back (i.e., to mimic conditions in the MRI scanner) and will listen to the clinician read a standardized Mindfulness Meditation script.
224039697|NCT06957743|BEHAVIORAL|Self-Hypnosis|In the Self-Hypnosis group, participants will relax with their eyes closed and, as with Mindfulness Meditation, will lie flat on their lack and will listen to the clinician read a standardized hypnotic script. The Self-Hypnosis practice will include an induction followed by suggestions for decreased pain and improvement in comorbid symptoms (e.g., mood).
223429822|NCT06452004|DIAGNOSTIC_TEST|Validation of AI-DSS in India|VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
223429823|NCT02548559|DRUG|Full-Spectrum Cannabidiol|Full-Spectrum Cannabidiol; total daily dose of 30 mg.
223429824|NCT02548559|DRUG|Single-Compound Cannabidiol|Single-Compound Cannabidiol; total daily dose of 30 mg.
223429825|NCT02548559|DRUG|Placebo|Placebo solution.
223429826|NCT06072430|DRUG|VBI-S|VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
224039698|NCT05180578|OTHER|Goat milk diet|Elimination of cow milk from diet . Goat milk containing diet.
224039699|NCT05591274|DEVICE|SmileyScope Virtual Reality Headset|The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
224039700|NCT04112654|PROCEDURE|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
223429827|NCT05920941|DRUG|[14C]JAB-21822|Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach
223429828|NCT06527287|OTHER|Neurocognitive Ankle Training for Instablity to Optimize Neuromusculoskeletal outcomes (NATION)|The NATION rehabilitation protocol will serve as the true intervention group. NATION is a 6-week evidence-based chronic ankle instability (CAI) rehabilitation protocol that incorporates neurocognitive exercises. Participants will complete up to 18 unsupervised home sessions and up to 12 supervised sessions. Treatment volume and exercises may vary based on participant progress and study team member guidance.
223429829|NCT06527287|OTHER|Evidence-Based|The Evidence-Based rehabilitation protocol will serve as the active comparator group. The Evidence-Based protocol will be similar to the intervention (i.e., NATION protocol), but the exercises will exclude the neurocognitive tasks. Participants assigned to the Evidence-Based protocol will complete up to 18 unsupervised home sessions and up to 12 supervised sessions over the course of 6-weeks. Treatment volume and exercises may vary based on participant progress.
223429830|NCT05962164|BEHAVIORAL|Passive Heat Therapy|The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
223429831|NCT05962164|BEHAVIORAL|Sham Immersion|The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
223429832|NCT05684055|DRUG|First-line antihypertensive single-pill combination (SPC)|In intervention villages, participants diagnosed with aHT are offered pharmacological treatment (eHealth supported prescription of first-line antihypertensive single-pill combination (SPC)) and treatment monitoring in the villages by CC-VHWs guided by the ComBaCaL app.
223429833|NCT05684055|OTHER|Standardized counselling and referral to the closest health facility|In control villages, participants diagnosed with aHT receive a standardized counselling by the CC-VHW and are referred to the closest health facility for initiation or continuation of antihypertensive treatment.
223429834|NCT02984566|DEVICE|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
223429835|NCT06579755|BIOLOGICAL|TDV|TDV SC injection.
223429836|NCT06579755|OTHER|Placebo|Placebo SC injection.
224039701|NCT04112654|PROCEDURE|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
223429837|NCT04367857|OTHER|COVID-19 Serology|Quantitate Serology enzyme-linked immunosorbent assay (ELISA) for COVID-19
223429838|NCT04367857|BEHAVIORAL|Health Care Worker Survey|The purpose of this survey is to assess how healthcare workers are experiencing and coping with the COVID-19 crisis.
223429839|NCT05380687|DIAGNOSTIC_TEST|Inspiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of inspiration. It is used to asses expiratory force generation (maximal expiratory pressure, MEP) and frequently used in clinical practice.
223429840|NCT05380687|DIAGNOSTIC_TEST|Expiratory hold|A short period (\< 30 seconds) during which both inspiratory and expiratory valves of the ventilator circuit are closed at the end of expiration. It is used to asses static PEEP and inspiratory force generation (maximal inspiratory pressure, MIP \& occlusion pressure, ∆Pocc) and is frequently used in clinical practice.
223429841|NCT05380687|DIAGNOSTIC_TEST|Ultrasound of respiratory muscles|Ultrasound of the diaphragm, parasternal intercostal muscle and internal oblique muscle will be performed during each block. Thickening fractions, calculated as thickness at end-inspiration minus thickness at end-expiration divided by thickness at end-expiration, are used to assess the contribution of the muscle to the tidal volume. A median over 5 breaths will be calculated.
223429842|NCT05380687|OTHER|PEEP 10|Positive End-Expiratory Pressure of 10cmH2O for 30 minutes
223429843|NCT05380687|OTHER|PEEP 5|Positive End-Expiratory Pressure of 5cmH2O for 30 minutes
223429844|NCT05380687|OTHER|PEEP 0|Positive End-Expiratory Pressure of 0cmH2O for 30 minutes
223429845|NCT04642430|DRUG|Apixaban|Refer to Apixaban group
223429846|NCT04642430|DRUG|Rivaroxaban|Refer to Rivaroxaban group
223564697|NCT03811847|OTHER|Placebo|Placebo comparator MPH Matched Placebo Tablet
224039702|NCT04700046|DRUG|Mexiletine 167 mg|Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.
223429847|NCT01089933|PROCEDURE|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
224039703|NCT04700046|DRUG|Placebo|The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
224039704|NCT02018757|DRUG|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
223429848|NCT01089933|PROCEDURE|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
223429849|NCT04652908|BIOLOGICAL|Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix|As in the current standard fetal surgery, under sonographic guidance, initial uterine entry will be accomplished by uterine stapling device or similar. The fetus will be given an intramuscular injection of pain medications and paralytic. The myelomeningocele will be closed in a standardized manner under magnification. As in the standard fetal operation, the spinal cord will be dissected from surrounding tissue and allowed to drop into the spinal canal. The PMSC-ECM product will then be tailored to the size of the spinal cord and applied topically, cell side down. The PMSC-ECM product will be sutured in place to the dura. Finally, the fetal skin will be closed in the standard fashion. The amniotic fluid volume will be replaced and antibiotics will be added. The uterus will be closed. The abdominal fascial layer and skin will be closed in routine fashion.
223429850|NCT04652908|OTHER|Untreated contemporaneous cohort|The addition of a non-PMSC treated cohort, the untreated contemporaneous cohort, has been added at the request of the FDA to provide contemporaneous patients for validation of the continued relevance of use of the outcomes of the MOMS trial as the comparison arm for the Phase 2a portion of the study.
223429851|NCT02999230|OTHER|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
224039705|NCT02018757|DRUG|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
223429852|NCT02999230|OTHER|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
223429853|NCT02999230|OTHER|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
223429854|NCT02999230|OTHER|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
223429855|NCT00177281|DRUG|S CKD602|
223429856|NCT05199194|DRUG|Tenecteplase|Intravenous thrombolysis with tenecteplase 0.25mg/kg
224039706|NCT03658746|DRUG|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
224039707|NCT03658746|DRUG|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
224039708|NCT03658746|DRUG|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
224039709|NCT05061563|DRUG|Elinzanetant (BAY3427080)|Elinzanetant given orally as single dose capsule and intravenous as single dose in Period 1. Elinzanetant given orally as single dose capsule in Period 2.
224039710|NCT05061563|DRUG|Esomeprazole|Esomeprazole given orally once daily for 5 days in Period 2.
224039711|NCT02296151|OTHER|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
224039712|NCT02296151|OTHER|iliotibial band stretches|Iliotibial band stretches
223429857|NCT05199194|DRUG|Placebo|Intravenous administration of placebo, matching the volume of tenecteplase 0.25mg/kg
223429858|NCT06467656|OTHER|Individualized, periodized endurance training for ultra-endurance triathlon.|Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
224039713|NCT01944735|DRUG|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
224039714|NCT01944735|DRUG|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
224039715|NCT05649033|OTHER|data collection|Work-related stress evaluation
224039716|NCT01310803|DRUG|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
224039717|NCT01310803|OTHER|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
224039718|NCT04160143|PROCEDURE|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
224039719|NCT02198612|OTHER|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
223429859|NCT06467656|OTHER|Time-Aligned Control|Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
223429860|NCT06620263|OTHER|Pre-education period (PreEd)|No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).
223429861|NCT06620263|OTHER|Post-education period (PostEd)|In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
223429862|NCT00663897|DRUG|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
224039720|NCT04907747|DRUG|Vonoprazan|Potassium-competitive acid blocker
224039721|NCT04907747|DRUG|Esomeprazole|Proton pump inhibitor
224039722|NCT04907747|DRUG|Colloidal bismuth pectin|Gastric mucosal protective drug with anti-H. pylori effect
224039723|NCT04907747|DRUG|Amoxicillin|Antibiotic for H. pylori eradication
224039724|NCT04907747|DRUG|Furazolidone|Antibiotic for H. pylori eradication
224039725|NCT02378454|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
223429863|NCT00663897|DRUG|mosapride|mosapride, 5 mg, thrice daily for 14 days
223564698|NCT00795548|DRUG|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
223564699|NCT00269269|DRUG|antihypertensive drug|
224039726|NCT01306890|BIOLOGICAL|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
224039727|NCT05102084|DEVICE|Listening to music with a bluetooth headset to patients receiving CPAP support|Listening to music with a bluetooth headset during the CPAP application to the patients and checking the compatibility on the CPAP device.
224039728|NCT03219320|DRUG|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
224039729|NCT03219320|DRUG|Placebo|Matching Placebo capsules.
224039730|NCT03774160|BEHAVIORAL|Generacion Actual|See description in arm description.
224039731|NCT00652392|DRUG|budesonide/formoterol|
224039732|NCT00652392|DRUG|budesonide and placebo|
223429864|NCT05197985|BEHAVIORAL|IECD Intervention|The Nurturing Care curriculum contains: 1) responsive caregiving, 2) the important role everyone plays in raising a child, 3) maternal health and nutrition, 4) responsive feeding and good nutrition, 5) how children grow and develop, 6) hygiene, 7) language development, 8) the importance of play, 9) managing the stress of parenting, 10) protecting your child from harm. Modules will be delivered through group sessions for caregivers, individualized home visits and Social Behavior Change Communication. IECD will build families' capacity to grow and raise healthy food to consume themselves, and connect them to agricultural markets. Specifically, IECD will provide agriculture technical training to Village Model Farms and households, and will facilitate linkages to markets by identifying buyers and connecting them to the farmers. IECD will train and support volunteers to conduct disability screening, and train disability interventionists to provide appropriate therapies and support services.
223429865|NCT06062199|PROCEDURE|Training in the A-DIVA scale and its failure prediction score|Nurses are trained in the A-DIVA scale and its predictive failure score. This score enables them to adapt their approach to peripheral venous line insertion.
223564700|NCT00269269|BEHAVIORAL|placebo|
223564701|NCT00803257|OTHER|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
223564702|NCT03626636|DRUG|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
223564703|NCT03626636|OTHER|Sham|Sham injection
223564704|NCT01472783|DRUG|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
223564705|NCT02120170|PROCEDURE|Colon polypectomy|
223564706|NCT00182780|DIETARY_SUPPLEMENT|American ginseng|
223564707|NCT00182780|OTHER|Placebo|
223564708|NCT01587261|DRUG|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
224039733|NCT06475391|DIETARY_SUPPLEMENT|L-arginine|2 grams iof L-arginine will be ingested before an acute testing bout of exercise tasks in 250 mL of cranberry juice.
224039734|NCT06475391|DIETARY_SUPPLEMENT|Placebo|Placebo
224039735|NCT04697043|PROCEDURE|Systemic therapy followed by surgery if the disease is not progressive|Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The systemic therapy followed by surgery if the disease is not progressive.
224039736|NCT06104202|OTHER|Early Maladaptive Schemas|"Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory"
224039737|NCT04066803|DRUG|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
223740278|NCT07207044|BEHAVIORAL|Time-restricted feeding + Exercise|Strength and cardio exercise 2x/week each combined with time-restricted feeding in a 16/8 regimen.
223740279|NCT07206992|DRUG|24 hours antibiotics|Antibiotic therapy will start 24 hours before urological surgery
223740280|NCT07206992|DRUG|48 hours antibiotics|Antibiotic therapy will start 48 hours before urological surgery
224039738|NCT04066803|DRUG|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
224039739|NCT04066803|DRUG|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
223429866|NCT05339841|OTHER|Mobile health application|The mHealth app delivers a personalized support program of digital health. Specifically, using ad hoc designed algorithms which uses the data self-reported by the subject and/or collected by the recruiter at baseline, the App delivers periodic messages with advice, motivational reminders and support to improve lifestyle habits and risk factor control.
224039740|NCT01865396|BEHAVIORAL|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
224039741|NCT01865396|BEHAVIORAL|Standard oncologic care|Patients will receive standard oncologic care.
224039742|NCT04206995|OTHER|Solid Phase Microextraction (SPME)|A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
224039743|NCT04206995|OTHER|Absorptive patch|An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
224039744|NCT03047551|PROCEDURE|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
224039745|NCT03047551|PROCEDURE|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
224039746|NCT05214417|DRUG|Ketamine Injectable Solution|2 IM ketamine sessions with psychotherapy, spaced 9-15 days apart
224039747|NCT05214417|OTHER|Naturalistic Control|Continuation of pre-existing conventional treatment
224039748|NCT00257829|DRUG|Methazolamide|
224039749|NCT00257829|DRUG|Cisplatin|
224163877|NCT00312728|DRUG|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
223478351|NCT07136441|DIAGNOSTIC_TEST|Lower Limb Neurodynamic Test (LLNT) with Shear Wave Elastography|"Participants underwent sciatic nerve stiffness assessment using shear wave elastography during two distinct sequences of the lower limb neurodynamic test. Each participant received:~Proximal-to-distal sequence: Starting with hip flexion, followed by knee extension, then ankle dorsiflexion with toe extension.~Distal-to-proximal sequence: Starting with ankle dorsiflexion and toe extension, followed by knee extension, then hip flexion."
223478352|NCT06928116|BEHAVIORAL|Heat therapy|At home lower body heat therapy
223478353|NCT06928116|BEHAVIORAL|Sham Control|Sham Thermoneutral
223478354|NCT06928116|BEHAVIORAL|Walking|Walking intervention
223478355|NCT06928324|PROCEDURE|Erector Spinae Plane block|The Erector Spinae Plane Block (ESPB) is a technically simple and safe form of regional anesthesia that can provide effective analgesia for 12 hours in patients with acute postoperative pain
223478356|NCT06928324|PROCEDURE|Control|No intervention
223478357|NCT07095075|BIOLOGICAL|LUCAR-DKS1 NK cells|Prior to the infusion of the LUCAR-DKS1 cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
223478358|NCT02707042|DRUG|Amoxicillin|7-day therapeutic oral course of twice daily amoxicillin
223478359|NCT02707042|DRUG|Azithromycin|5-day oral course of once-daily azithromycin
223478360|NCT02707042|OTHER|Control|A group of volunteers will receive no antibiotics and will serve as study controls.
223478361|NCT06908707|DRUG|LAE102 SC|A single dose of LAE102 will be administered subcutaneously
223478362|NCT06908707|DRUG|Placebo SC|A single dose of placebo administered subcutaneously
223478363|NCT06908707|DRUG|LAE102 IV|A single dose of LAE102 administered intravenously
223478364|NCT06908707|DRUG|Placebo IV|A single dose of placebo administered intravenously
223478365|NCT06649409|DRUG|Vamorolone|vamorolone 20 mg/kg single dose on Day 2
223478366|NCT06649409|DRUG|Eplerenone|Eplerenone 200 mg single dose on Day 2
223478367|NCT06649409|DRUG|Fludrocortisone|"Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm."
223478368|NCT02062138|OTHER|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
223478369|NCT02062138|OTHER|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
224039750|NCT06426043|DRUG|Lusutrombopag|Administer lusutrombopag at 3mg/qd orally for 12 weeks (lusutrombopag starting dose is 3mg, once daily. After 2 weeks of continuous administration, the dose can be increased by 3mg every 2 weeks based on the platelet count and safety of the subject. The dose can be gradually increased to 9mg/d over a total of 12 weeks). The course should be at least 3 months. When the platelet increase is \<20×109/L, the daily dose can be increased by 3mg up to a maximum of 9mg/day; when the platelet increase is ≥50×10\^9/L and ≤200×10\^9/L, the dose can be maintained; when the platelet count is ≥200×10\^9/L and ≤400×10\^9/L, the daily dose can be reduced by 3mg; when the platelet count is \>400×10\^9/L, the drug can be suspended and resumed when the platelet count decreases to \<200×10\^9/L, with the daily dose reduced by 3mg. In this case, if the lowest dose of 3mg/day is used, the drug can be suspended. Responders continue treatment until 6 months.
224039751|NCT00726622|PROCEDURE|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
224039752|NCT00726622|PROCEDURE|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
224039753|NCT00228397|DRUG|CCI-779|
224039754|NCT05653323|DRUG|VX-993|Suspension for oral administration.
224039755|NCT05653323|DRUG|Placebo|Suspension for oral administration.
224039756|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
224039757|NCT01135680|DRUG|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
224039758|NCT01135680|DRUG|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
224039759|NCT01135680|DRUG|Moxifloxacin|single oral 400-mg dose on study Day 3
224039760|NCT01135680|DRUG|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
224039761|NCT01135680|DRUG|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
224039762|NCT00238173|BIOLOGICAL|filgrastim|
224039763|NCT00238173|DRUG|acetylcysteine|administered i.v. over 30 to 60 minutes
224039764|NCT00238173|DRUG|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
224299396|NCT06632665|OTHER|transcutaneous vagus nerve stimulation+routine physical therapy|"Transcutaneous vagus nerve stimulation Location The left auricular branch vagus nerve will be stimulated by the modified dot -like electrodes will be fitted to the cymba conchae.Stimulation perform for 30 minutes per day for 4 weeks .~Routine physical therapy Stretching Areas :upper chest ,neck flexors ,shoulder flexor and adductors ,elbow and wrist flexors 10 minute per session,and stretches will held for 10s -30swith four repetition of each.30 minutes per day for 4 weeks Upper extremity Proprioception ,coordination,speed and agility increase such as followReach and grasp Handle turning simulated eating task Inserting object Opening bottle strenghtening exercise Muscles biceps brachii brachialis Coracobrachialis triceps brachii wrist extensors 10 minute per session for 4 weeks"
223478370|NCT02062138|OTHER|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
224039765|NCT00238173|DRUG|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
224039766|NCT00238173|DRUG|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
224039767|NCT00238173|DRUG|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
224039768|NCT00238173|DRUG|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
224039769|NCT05137496|DRUG|Ruxolitinib|0.3mg/kg/d, iv.gtt, for at least 2 weeks
224039770|NCT05137496|DRUG|methylprednisolone|2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
224039771|NCT01545570|DRUG|GSK2376497|GSK2376497 Active Comparator
224039772|NCT01545570|DRUG|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
223478371|NCT06188208|DRUG|VVD-130850|Oral tablets
224039773|NCT05222607|DRUG|IncobotulinumtoxinA|IncobotulinumtoxinA injections for aesthetic indications.
223478372|NCT06188208|DRUG|Pembrolizumab|IV infusion
223478373|NCT06842485|OTHER|Telerehabilitation|The experimental group will be given a tailored program of telerehabilitation consisting of stretching and strengthening exercises for six weeks (three times per week)
223478374|NCT06842485|OTHER|Patient education|Patient education will be given to both the experimental and control groups. Patient education and telerehabilitation will be given to the experimental group. To the control group, patient education alone will be provided
224039774|NCT04682171|OTHER|Low level laser therapy|"* Gallium aluminium arsenide laser device will be used with wavelength of 850nm, power 100 mW, spot size of 1.0 mm and energy of 6J/point for 60seconds. Total 8 points will be irradiated. It will take 20 minutes.~* Patient will receive treatment in supine position with the affected knee(s) slightly flexed supported by the pillow or rolled towel.~* On the affected knee the laser probe will placed with full contact with skin at 8 points. Three points at medial side of the knee, three points at lateral side and two points at the medial edge of the bicep femoris muscle tendon and semitendinosus muscle tendon in the popliteal fossa"
224039775|NCT04682171|OTHER|Conventional Exercise Therapy|"1. Quadriceps isometric strengthening exercises.~2. Range of motion and active stretching exercises applied to hamstring and quadriceps muscle.~3. Hamstring muscle isometric exercises~4. Active ankle pump.~5. Short arc terminal extension exercises for the knee joint.~6. Static and dynamic strengthening exercises for the hip abductors, adductors and extensor group of muscles.~7. Non-weight bearing progressive resistance exercises with weighted cuffs, with progression to closed chain exercises as patient's pain allows.~8. Isometric exercises were applied with 6 second contractions and rest period of 2 seconds. Isotonic exercises were started as 10 repetitions with half of weight of 10 RM, 10 repetitions with three fourth of this weight and 10 repetitions with whole 10 RM"
224039776|NCT02926131|OTHER|Blood sampling|"* One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~* An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
224039777|NCT01940354|DEVICE|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
224039778|NCT01940354|DEVICE|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
224039779|NCT03855553|BEHAVIORAL|Family Based Treatment|"10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status."
224039780|NCT03855553|BEHAVIORAL|Enhanced Cognitive Behavioral Therapy|10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
224039781|NCT01486953|DRUG|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
224039782|NCT01486953|DRUG|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
223429867|NCT05930886|OTHER|Focus Group|Black or Hispanic/Latino parents, caregivers or family members of children with ADHD symptoms and/or emotional dysregulation, will discuss: (1) impact of child's mental health, treatments, care received; (2) perceived and actual barriers to future study participation, including discussion about acceptability of bio-specimen collection methods for urine and blood. Each group will comprise individuals who self-identify as Hispanic/Latino, Black, or mixed race. Groups are anticipated to comprise individuals who identify with one or the the other race/ethnicity in order to create space to hear perspectives that may differ between these broadly defined groups.
223429868|NCT05488509|DRUG|Cannabis|Participants will inhale vapor from cannabis containing either 20mg THC or 40mg THC.
223429869|NCT05488509|DRUG|Placebo|Participants will inhale vapor from a placebo product.
223429870|NCT06838416|DRUG|Finerenone|Treatment will continue for 48 weeks.
223429871|NCT06480227|DEVICE|Solyx Single-incision Sling|Minimally invasive mesh device placed to treat stress urinary incontinence.
223429872|NCT06480227|DEVICE|Bulkamid Transurethral Bulking Agent|Minimally invasive bulking agent injections used to bulk up the tissue surrounding the urethra to treat stress urinary incontinence. Up to 2 treatments within 12 months are allowed
223429873|NCT06100770|DEVICE|Aveir AR Leadless Pacemaker|This study will utilize real-world data from patients implanted with the Aveir AR Leadless Pacemaker. No device intervention is required in this study.
223429874|NCT06100770|DEVICE|Single-chamber atrial transvenous pacemaker|This study will utilize real-world data from patients implanted with a single-chamber atrial transvenous pacemaker as a comparator to the Aveir AR LP study arm. No device intervention is required in this study
223564709|NCT01587261|DRUG|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
224039783|NCT01538953|OTHER|handwashing|participants received weekly in-home handwashing promotion and soap as needed
224163878|NCT00028964|DIETARY_SUPPLEMENT|Chinese herbs|
224163879|NCT00028964|DRUG|cyclophosphamide|
223429875|NCT06485427|PROCEDURE|Selective Intra-arterial Cooling Infusion (IA-SCI)|"Pre-recanalization: During the procedure, the micro-catheter is advanced over a micro-guide wire, traveling up through the neck until it reaches beyond the clot. A 50 mL cold 0.9% saline (4 ℃) is infused intro into the ischemic territory at a rate of 10 mL/min via the micro-catheter. This enables the cold solution to infuse into the ischemic territory prior to revascularization.~Post-recanalization: After recanalization, cold 0.9% saline (4 ℃) is reinfused into the vessel via the catheter at a rate of 22 mL/min for 10 min, repeated twice with a 10-minute interval between infusions."
223429876|NCT05756894|DEVICE|Neurostimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
224163880|NCT00028964|DRUG|doxorubicin hydrochloride|
224163881|NCT00028964|PROCEDURE|adjuvant therapy|
224163882|NCT02868151|DRUG|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
224163883|NCT02868151|DRUG|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
224163884|NCT01718366|DRUG|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
224163885|NCT06177223|BEHAVIORAL|Cognitive Behavioral therapy|CBT-based treatment plan would be designed to address PTSD and associated problems.
224163886|NCT06059274|OTHER|Topical serum|Participants are asked to apply the topical serum twice daily for 84 days.
223429877|NCT05756894|OTHER|Repiratory training|Respiratory exercises will be completed immediately after completing neurostimulation. Respiratory exercises will involve inspiratory muscle training performing four sets of 6-10 breaths per day with two minutes of rest.
223429878|NCT05299333|OTHER|Exercise|High repetition muscle endurance and strengthening exercises Walking
224299397|NCT05637619|DEVICE|Monolithic Zirconia|Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants
223429879|NCT04330664|DRUG|MRTX849|KRAS G12C Inhibitor
223429880|NCT04330664|DRUG|TNO155|SHP2 Inhibitor
223429881|NCT06160258|BEHAVIORAL|Ready to Eat (RTE)|Participants will be provided precooked and individually packaged whole grains in the ready-to-eat (RTE) condition for reheating and consumption at home.
223429882|NCT06160258|BEHAVIORAL|Dried|Participants will be provided with dried whole grains for home preparation and consumption
223429883|NCT00005005|DRUG|PTH|
223429884|NCT00005005|DRUG|Alendronate|
223429885|NCT05348837|PROCEDURE|Deep brain stimulation|Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
224299398|NCT05637619|DEVICE|Hybrid-Acrylic|Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;
223429886|NCT06275074|PROCEDURE|Dry Needling|Insertion of filiform needles into cervicothoracic multifidi, upper trapezius, and suboccipital muscles
223429887|NCT06275074|OTHER|Therapeutic Exercise|Therapeutic exercise program provided to all participants with the aim of addressing periscapular strength and postural edurance.
223429888|NCT05553223|BEHAVIORAL|Microdoses of activity|Short bouts of low-intensity exercise (walking) will be used to break up prolonged sitting.
223429889|NCT06003023|BEHAVIORAL|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to participants in both arms.
223429890|NCT06003023|BEHAVIORAL|Tailored Exercise Prescription|Participants in both arms will receive the results of their exercise stress test, which includes information on the duration, frequency, and intensity of their physical activity.
223429891|NCT06003023|BEHAVIORAL|Healthy Lifestyle Education|Participants in both arms will receive information on healthy living, including topics such as physical activity, sleep, stress management, and diet.
223429892|NCT06003023|BEHAVIORAL|Physical Activity Lifestyle Intervention Informed by the Theory of Planned Behavior|Participants randomized to the CHD-PAL arm will receive coaching to: 1) change attitudes towards physical activity; 2) increase perceptions of other people's approval of physical activity; 3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance and will be accompanied by goal-setting.
223429893|NCT04483284|DRUG|TACE combined with Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
223429894|NCT04483284|PROCEDURE|TACE plus Camrelizumab|Camrelizumab(200mg q3w ivgtt) combined with TACE
224039784|NCT01538953|OTHER|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
224039785|NCT01538953|OTHER|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
224039786|NCT01708239|OTHER|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
224039787|NCT05083338|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224299399|NCT05637619|BEHAVIORAL|Dentate Patients|Dentate Patients with natural dentition or tooth supported crowns
224299400|NCT00173550|PROCEDURE|Hysterectomy and Bilateral salpingo-oophorectomy|
223429895|NCT06372899|OTHER|E-cigarettes|Participants randomized to ECIGS are instructed to switch from smoking combustible cigarettes to using e-cigarettes for 6 weeks. They will be provided with an e-cigarette device and nicotine pods.
223429896|NCT06372899|OTHER|Oral nicotine pouches|Participants randomized to ONPS are instructed to switch from smoking combustible cigarettes to using nicotine pouches for 6 weeks. They will be provided with nicotine pouches.
223429897|NCT00462176|PROCEDURE|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
223429898|NCT00462176|OTHER|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
223429899|NCT01190059|DRUG|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
223429900|NCT05573672|COMBINATION_PRODUCT|Dietary Counselling combined with Omega-3 Supplementation|"Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal."
223429901|NCT03570372|BEHAVIORAL|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
223429902|NCT03570372|BEHAVIORAL|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö \& Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
224039788|NCT05083338|PROCEDURE|Pain Assessment|Undergo pain assessment
224039789|NCT05083338|OTHER|Questionnaire Administration|Complete questionnaires
224039790|NCT03891303|OTHER|Allogenic blood transfusion (ABT)|During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
224039791|NCT04721093|DEVICE|Photobiomodulation device|In this study, PBM was applied using a machine made to be attached to the subject in the form of a probe. In this clinical trial, a low-intensity irradiation device (Color-DNA-WSF U) from Color seven was used to deliver visible light (610nm± 10nm wavelength, 3.0mW/㎠±20%) irradiation. PBM was applied 5 times a week for 8 weeks, 30 minutes per session.
224039792|NCT00594126|DRUG|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
224039793|NCT03736161|DRUG|Group A- Tofacitinib|Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
224039794|NCT03736161|DRUG|Group B- Methotrexate|Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
224039795|NCT03993197|BEHAVIORAL|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 6 or 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~* First week a session of Body Strategy ©~* Second week a psychological session with group of speech (Photolanguage ©).~* Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
224039796|NCT00002790|DRUG|cyclosporine|
224039797|NCT00002790|DRUG|methotrexate|
223429903|NCT05957445|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
223429904|NCT05957445|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a series of stimulation sequences，including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
223429905|NCT05515887|DRUG|Shenqu Xiaoshi Oral liquid|The dosage was determined by age: 3-4 years old, 5 ml/dose; 5-14 years old 10 ml/dose. Taken half an hour after meals, three times a day.
223564710|NCT04268875|DEVICE|Optical Coherence Tomography (OCT)|"The OCT fibre is an optical fibre catheter containing a lens located at its extremity and positioned distal to the arterial segment to be examined. This is an intracoronary, very high-resolution section technique based on absorption and reflection of close infrared light by stents and tissues.~OCT analysis is performed during a usual coronary angiography procedure. It is a common technique already used and recommended for intrastent restenosis to establish the mechanism of the process. No new product is being tested. The examination performed is the same."
224039798|NCT00002790|DRUG|sirolimus|
224039799|NCT05273957|OTHER|Case Manager|Patients are followed up by a nurse specialist in parkinsonism (case manager) who interacts with the treating neurologist and a multidisciplinary team
224039800|NCT05273957|OTHER|Standard-of-care|Patients are managed only by the neurologist according the institution's clinical practice
223429906|NCT05613868|DRUG|TPN-101|100 mg/ day up to 400mg/day of TPN-101
223429907|NCT04542499|DRUG|Tavapadon|Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
224039801|NCT05887453|DEVICE|Magnetocardiography|Magnetocardiography is a device used to exam the dynamic magnetic map of the heart for the diagnosis of some heart diseases
224039802|NCT03837314|DEVICE|"Bioinduction Picostim Deep Brain Stimulation system"|Neurostimulation of the subthalamic nucleus region.
224039803|NCT04492345|OTHER|Isokinetic reeducation|Conventional rehabilitation session and isokinetic during 7 weeks
224039804|NCT04492345|OTHER|Conventional reeducation|Conventional rehabilitation session during 7 weeks
224039805|NCT03872453|DRUG|Zavegepant|A single dose of zavegepant
224039806|NCT03872453|DRUG|Zavegepant matching placebo|A single dose of placebo matched to zavegepant
224139434|NCT01974726|OTHER|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
223564711|NCT02715882|DRUG|CBLB502|
223564712|NCT02715882|DRUG|Placebo|
224039807|NCT03872453|DEVICE|Intranasal Aptar Pharma Unit Dose System|A single-dose intranasal device
224039808|NCT00352885|DRUG|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
224039809|NCT00352885|DRUG|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
224039810|NCT00352885|DRUG|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
223429908|NCT04542499|DRUG|Placebo|Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
223429909|NCT05863520|BEHAVIORAL|Zones of Regulation|ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.
223429910|NCT05863520|BEHAVIORAL|Facing Your Fears - School Based|FYF-SB is a CBT program for managing anxiety in autistic youth.
223429911|NCT04381195|DIAGNOSTIC_TEST|REALS Development|Complete drafting of an item pool (adults with ASD, parents, adult service providers); Assign items to all parts of our conceptual framework to ensure sufficient construct coverage across employment, social, and independent living domains; and Conduct cognitive interviews with 25 caregivers of adults with ASD and 25 self-reporting adults with ASD.
223429912|NCT04381195|DIAGNOSTIC_TEST|REALS Testing|A national sample of proxy reporters (e.g., parents, clinicians, group home staff) for 1000 autistic adults and self-reporting autistic adults and adults with other IDD will complete the REALS draft items and a co-calibration battery to establish psychometrics, generate short-forms, and ensure applicability across adults with ASD.
223429913|NCT04281784|BEHAVIORAL|EHR-based Clinician Jumpstart|The Jumpstart Guide is a communication-priming intervention for clinicians that addresses hospitalized patients' goals of care. The intervention's goal is to prompt clinicians to provide standard of care which includes a discussion with patients or their legal surrogate decision-maker about their goals of care. The one-page Jumpstart Guide provides information to the clinician about prior advance care planning documentation and code status derived from the EHR. The Jumpstart Guides includes tips to improve goals-of-care communication.
223429914|NCT05998161|BEHAVIORAL|reviga|Participants will receive access to the digital health intervention reviga in addition to TAU.
223429915|NCT05711381|DRUG|HM15912|Singe subcutaneous administration of HM15912 0.5 mg/kg
223429916|NCT05957354|DEVICE|active continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
223429917|NCT05957354|DEVICE|sham continuous Theta Burst Stimulation|Each patient will receive a combination of stimulation sequences, including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
223429918|NCT05868226|DRUG|ALX148|CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.
223429919|NCT05868226|DRUG|Fam-Trastuzumab Deruxtecan-Nxki|Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor
223429920|NCT05868226|DRUG|Zanidatamab|Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
224039811|NCT01377077|PROCEDURE|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
224039812|NCT01377077|PROCEDURE|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
224039813|NCT03811639|PROCEDURE|Radio-frequency ablation|Ablation for atrial fibrillation
224039814|NCT03811639|PROCEDURE|Cryoballoon ablation|Ablation for atrial fibrillation
224039815|NCT03873493|DRUG|Venetoclax|Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
224039816|NCT03873493|DRUG|Ibrutinib|Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
224039817|NCT00863109|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
223429921|NCT05868226|DRUG|Tucatinib|Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
223429922|NCT05651022|DRUG|Decoy20|Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy.
223429923|NCT05651022|DRUG|Tislelizumab|Tislelizumab is a PD-1 inhibitor.
223429924|NCT04335487|BEHAVIORAL|PSP PTSD Course|A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
223478375|NCT04207671|PROCEDURE|Complete omission of chest tube|No chest tube implacement
223478376|NCT04207671|PROCEDURE|Improved drainage strategy|A two-lumen central venous catheterization along the midclavicular line, second intercostal space for remedial gas-remove
223478377|NCT04224974|OTHER|Usual Care|The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial
223564713|NCT01429428|OTHER|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
223564714|NCT01429428|OTHER|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
223564715|NCT02526524|DRUG|Met DR|metformin delayed-release tablets
223564716|NCT02526524|DRUG|Met IR|metformin immediate-release tablets
223564717|NCT02526524|DRUG|Placebo|
224039818|NCT00863109|DRUG|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
224039819|NCT05245409|OTHER|Chiropractic adjustment using an activator|Chiropractic adjustment using an activator
224039820|NCT01616433|BEHAVIORAL|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
223429925|NCT04335487|BEHAVIORAL|PSP Wellbeing Course|A tailored ICBT intervention designed to treat symptoms of depression, anxiety, or PTSD will be delivered to public safety personnel. Clients will be offered once a week support, but support can be increased to twice a week support if PSP request extra support. The intervention is designed to be completed in 8 weeks, but clients will be able to extend their treatment by an additional 8 weeks (i.e., up to 16 weeks in total).
223429926|NCT04322539|DRUG|Fruquintinib|Oral VEGFR inhibitor
223429927|NCT04322539|DRUG|Placebo|Placebo capsule
223429928|NCT06052748|DRUG|AD-223A|PO, Once daily(QD), 8weeks
224039821|NCT01616433|BEHAVIORAL|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
224039822|NCT03756350|DEVICE|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
224039823|NCT05185986|BEHAVIORAL|Home-Based Pilates exercise|The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.
224039824|NCT05185986|OTHER|Home-based Cognitive Rehabilitation|Home-based Cognitive Rehabilitation is the 3 sessions per week and 8 weeks of cognitive rehabilitation exercises at home. Each session consists of two Pen and paper exercises. Exercises are active in the areas of planning, cognitive organization, cognitive flexibility and working memory. Each session will take 30 to 45 minutes.
224139435|NCT01974726|OTHER|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
224139436|NCT01974726|OTHER|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
224139437|NCT01974726|OTHER|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
223429929|NCT06052748|DRUG|AD-223B|PO, Once daily(QD), 8weeks
223564718|NCT02034175|DEVICE|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
223564719|NCT02034175|DEVICE|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
224039825|NCT05185986|OTHER|waiting list group|This group act as the control group and will maintain their physical and cognitive activities as the preintervention. Following the 8 weeks of intervention the home-based pilates and cognitive rehabilitation exercises will be provided to them for their own use.
223429930|NCT06052748|DRUG|AD-223C|PO, Once daily(QD), 8weeks
223429931|NCT06052748|DRUG|AD-223A Placebo|PO, Once daily(QD), 8weeks
223429932|NCT06052748|DRUG|AD-223B Placebo|PO, Once daily(QD), 8weeks
223429933|NCT06052748|DRUG|AD-223C Placebo|PO, Once daily(QD), 8weeks
223564720|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
223564721|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
223564722|NCT01503606|DRUG|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
223564723|NCT01503606|DRUG|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
224039826|NCT04123314|DRUG|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
224039827|NCT04283981|DEVICE|Control group without use of VSP|The control group will include patients that undergo mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) in standard fashion (without virtual surgical planning assistance and occlusal splint)
223429934|NCT02228304|DRUG|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
223429935|NCT02228304|DRUG|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
223429936|NCT05519332|PROCEDURE|percutaneous vertebral-disc plasty|percutaneous vertebroplasty combined percutaneous cement discoplasty
223429937|NCT05899491|PROCEDURE|ARMA|Patients will be instructed to fast for 6 hours pre-ARMA, the Procedure will be performed under propofol-based sedation. Patients will be in the left lateral decubitus position. The stomach will be insufflated with CO2 to visualize the cardia in retroflex view.
224039828|NCT04283981|DEVICE|Treatment Group with use of VSP|The treatment group corresponds to patients undergoing mandibular reconstruction via open reduction internal fixation (intraoral or extraoral approach) utilizing virtual surgical planning via 3D Systems, bite registration and fabrication of occlusal splint via intraoral digital scanner, and mandibular hardware
224039829|NCT01099423|PROCEDURE|timing of surgery|
224039830|NCT01099423|GENETIC|gene expression analysis|
224039831|NCT01099423|OTHER|biologic sample preservation procedure|
224039832|NCT01099423|OTHER|laboratory biomarker analysis|
224039833|NCT01099423|PROCEDURE|therapeutic conventional surgery|
224299401|NCT01415765|DRUG|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
224299402|NCT01415765|DRUG|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
223429938|NCT05899491|PROCEDURE|UGI Endoscopy|"UGI Endoscopy will be performed under propofol based sedation with scope kept inside for atleast 5 minutes.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry, reflux questionnaire."
223429939|NCT04393064|DEVICE|fiberoptic endoscopic evaluation of swallowing|"intreventions name :-Fiberoptic endoscopic evaluation of swallowing(FEES) will be performed on all infants enrolled in this study.~interventions type: flexible nasopharyngeal laryngoscope 3,5 mm in size with portable camera \& light source \& video recording system will be used. Procedure will be done without anesthesia~."
223429940|NCT00800813|BEHAVIORAL|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
223429941|NCT05627310|OTHER|Diagnostic|Training dataset was used to train the deep learning model, which was validated and tested by external dataset.
223429942|NCT00079300|DRUG|imiquimod|
223564724|NCT05486000|DEVICE|Atrial shunt implant system|"Patients with chronic left heart failure who meet the conditions of the clinical trial undergo interventional surgery with the Atrial Shunt Implant System"
223564725|NCT02908646|PROCEDURE|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
224039834|NCT00696982|DRUG|sitagliptin|sitagliptin 100 mg once daily for 3 months
224039835|NCT00696982|DRUG|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
224039836|NCT06101953|BEHAVIORAL|Stress management|It spanned 12 weeks, with three hours per week (comprising two hours of theoretical content and one hour of practical application) and employed diverse teaching methods, including lectures, interactive learning, research, fieldwork, hands-on practice, and question-answer sessions. The primary objective of this course was to enhance students' awareness of stress by helping them identify its sources, symptoms, and effects. Also interception and resilience. Furthermore, it aimed to teach students how to assess stress and apply stress-management techniques effectively in their daily lives.
224039837|NCT00561496|DRUG|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
223429943|NCT00079300|PROCEDURE|conventional surgery|
223429944|NCT00072540|DRUG|celecoxib|
223429945|NCT00072540|PROCEDURE|anti-cytokine therapy|
223429946|NCT00072540|PROCEDURE|antiangiogenesis therapy|
223429947|NCT00072540|PROCEDURE|biological therapy|
223429948|NCT00072540|PROCEDURE|cancer prevention intervention|
223429949|NCT00072540|PROCEDURE|chemoprevention of cancer|
223429950|NCT00072540|PROCEDURE|enzyme inhibitor therapy|
223429951|NCT00072540|PROCEDURE|growth factor antagonist therapy|
224039838|NCT00256334|DRUG|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
224039839|NCT05048420|PROCEDURE|surgery|ACL reconstruction and RAMP lesion repair
224299403|NCT01415765|DRUG|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
223429952|NCT04743583|DEVICE|Endosonography B-mode examination|Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
223429953|NCT04401761|DRUG|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
223429954|NCT04401761|DRUG|Acetylsalicylic acid|75 - 100 mg once daily at the discretion of the investigator
223429955|NCT06431685|RADIATION|Whole Brain Low Dose Radiotherapy|Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: Group 1: 4 Gy/2f of one cycle; Group 2: 4 Gy/2f of two cycles (Q3w); Group 3: 4 Gy/2f of three cycles (Q3w). WB-LDRT will be administered in a 4 Gy of 2 fractions over two days, starting from Day 1 in the first cycle (a daily dose of 2 Gy, 4 Gy/2f for one cycle, once per three weeks, at minmum in one cycle and maximum in four cycles in total).
223564726|NCT02908646|PROCEDURE|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
224039840|NCT03592290|DIAGNOSTIC_TEST|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
224039841|NCT04656509|OTHER|4-s sprint inertial load training|A program employing 30 bouts of 4s inertial load sprint training with progressively reduced recovery time (30 to 15 s) between sprints is effective for improving blood volume, VO2peak and maximal power.
224299404|NCT01415765|DRUG|Vincristine|CIV on days 1-4 of every 21 day cycle
224299405|NCT01415765|DRUG|Cyclophosphamide|IV on day 5 of each 21 day cycle
224299406|NCT01415765|DRUG|Doxorubicin|CIV on days 1-4 of each 21 day cycle
224299407|NCT01415765|DRUG|Rituximab|IV on day 1 of each 21 day cycle
224299408|NCT01415765|DRUG|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
224039842|NCT00440700|BEHAVIORAL|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
224039843|NCT00440700|BEHAVIORAL|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
224039844|NCT00440700|BEHAVIORAL|Control 2: Standard of Care|Usual ICU nursing care.
224039845|NCT04405700|OTHER|Pharmacovigilance surveillance program|The pharmacovigilance (PV) surveillance program will prospectively monitor for adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated with the International Epidemiology Databases to Evaluate consortium (IeDEA).
224039846|NCT00514761|DRUG|AZD6244|oral vial
224039847|NCT00514761|DRUG|Capecitabine|oral tablet
224039848|NCT05584228|DRUG|Azathioprine + infliximab|Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
224039849|NCT05584228|PROCEDURE|Intestinal resection|Ileocolonic or small bowel resection
223429956|NCT06431685|DRUG|Pemetrexed|Pemetrexed, 30 mg, intrathecal injection, once per three weeks, 4 cycles in total
224039850|NCT05906342|OTHER|20% fat meal|Provided to participants once throughout duration of study, contains 20% fat
224039851|NCT05906342|OTHER|40% fat meal|Provided to participants once throughout duration of study, contains 40% fat
224039852|NCT05906342|OTHER|60% fat meal|Provided to participants once throughout duration of study, contains 60% fat
224039853|NCT05906342|OTHER|80% fat meal|Provided to participants once throughout duration of study, contains 80% fat
224039854|NCT00109499|DRUG|AdGVPEDF.11D|
224039855|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus MIND diet|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.
223429957|NCT06431685|DRUG|Sintilimab|PD-1 inhibitor (Sintilimab, dose as recommended in the instruction manual), intravenous infusion, once per three weeks, 4 cycles in total
224039856|NCT05472831|BEHAVIORAL|BAILAMOS dance program plus Health Education|The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
224039857|NCT05428137|DIETARY_SUPPLEMENT|Probiotic|Live bacteria strain in a form of a capsule daily for 16 weeks
224039858|NCT05428137|DIETARY_SUPPLEMENT|Postbiotic|Heat treated bacteria strain in a form of a capsule daily for 16 weeks
224039859|NCT05428137|OTHER|Placebo|Placebo in a form of a capsule given for 16 weeks
224039860|NCT00597077|OTHER|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
224039861|NCT00597077|OTHER|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
224039862|NCT05713279|DRUG|SOC|"In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator."
224039863|NCT04678323|DRUG|Lifestyle Management|Participants in this group will receive lifestyle management.
224039864|NCT01096342|DRUG|dinaciclib|Given IV
224039865|NCT01096342|OTHER|laboratory biomarker analysis|Correlative studies
224139438|NCT01974726|OTHER|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
224163887|NCT03058263|DRUG|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
224163888|NCT05714254|DRUG|MEDI0618|Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.
224163889|NCT05714254|DRUG|Placebo|Four doses of IV placebo or SC placebo administered once every two weeks.
223429958|NCT06431685|DRUG|Chemotherapy|Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
223429959|NCT03203928|BEHAVIORAL|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
223429960|NCT00743938|DRUG|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
223429961|NCT00743938|DRUG|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
223564727|NCT04915118|OTHER|Decompensation event|NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
223564728|NCT03018795|PROCEDURE|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
223429962|NCT03873441|OTHER|Computer Games-Aided Balance Training Protocol|"1\) Sitting Balance exercises while playing the interactive computer games starting with bi manual object placed in hands for controlling the games, then using the head rotation movements to control the games progressing to use of trunk motions to control games while balancing on the compliant surfaces in order to progress by increasing the balance costs.~(2) Standing Balance exercises progressing from a fixed support surface to uneven, compliant surfaces like progression from standing over ground to sponge to air bladder as child tolerates increased balance costs.~(3) Progression then to balancing while performing the visuomotor and visuospatial game tasks such as playing the games starting with bi-manual object placed in hands for controlling the games, then using the head rotation movements to control the games and then progressing to use of trunk motions to control games while balancing on compliant surface.~(4) Progression to single-leg stance and stepping activities."
223429963|NCT03873441|OTHER|Conventional Balance Training Protocol|"The following is a summary of the conventional physical therapy balance training protocol:~1. Active-assisted stretching exercises for lower limb musculature focusing on postural control and improvement in dynamic stability,~2. Balance and weight bearing exercises with multi-directional reach outs associated with trunk movements on fixed surface gradually progressing to unstable movable and compliant surfaces,~3. Weight transfer exercises with multi-directional reach outs and~4. Stepping exercises in different directions on variety of surfaces."
224039866|NCT02614534|DRUG|MITOMYCIN-C 30 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
224039867|NCT02614534|PROCEDURE|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
224039868|NCT04767737|OTHER|Topically Administered Lavender Aromatherapy|3 puffs (0.3 ml) of 100% lavender (Lavandula Angustifolia) essential oil to the topical lavender oil group were sprayed on the arms of the patients.
224039869|NCT04767737|OTHER|Topically Administered Water|3 puffs (0.3 ml) of topical distilled water to the placebo group were sprayed on the arms of the patients.
224039870|NCT02350179|DRUG|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
224039871|NCT02350179|DRUG|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
224039872|NCT01834196|DEVICE|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
224039873|NCT02284048|DRUG|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
224039874|NCT00142051|DRUG|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
224039875|NCT00142051|DRUG|oxygen|oxygen fi02 21% (room air)
224039876|NCT02014155|OTHER|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
224039877|NCT02014155|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
224039878|NCT05207735|DRUG|Sintilimab|"* Sintilizumab, 200 mg, intravenous infusion, a treatment cycle every 3 weeks, administration on the first day of each cycle, 6 cycles.~* Capecitabine: 1250 mg/m2, orally, twice a day, 1-14 days, one treatment cycle every three weeks, 8 cycles."
224039879|NCT02106754|BEHAVIORAL|Brief Intervention|
223429964|NCT02407132|BEHAVIORAL|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
223564729|NCT05254405|DRUG|Brexanolone Injection [Zulresso]|Continuous infusion of brexanolone over 60 hours titrated to a maximal dose of 90 mcg/kg/hr.
223564730|NCT03411252|DRUG|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
223564731|NCT03411252|DRUG|Placebo|Sugar pill manufactured to mimic Mirabegron
223564732|NCT04371640|DRUG|Sirolimus 1 MG/ML|Oral solution
223564733|NCT04371640|DRUG|Placebo|Oral solution
223564734|NCT01411358|BIOLOGICAL|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
223564735|NCT01411358|BIOLOGICAL|elderly aged over 60|one dose of 0.5mL AdimFlu-S
224039880|NCT02106754|BEHAVIORAL|Brief Intervention with Coaching|
224039881|NCT02106754|BEHAVIORAL|Treatment as Usual|
224039882|NCT06787937|BEHAVIORAL|VLNC messages|Participants will be exposed to messaging about VLNCs and reduced nicotine policy through multiple formats, including inserts placed in cigarette packs, printed advertisements, and video materials presented during their weekly visits.
224039883|NCT06787937|BEHAVIORAL|Control message|Participants will be exposed to control messages, such as advertisements for bottled water, during their weekly visits.
224039884|NCT04317950|OTHER|Vojta|Reflex locomotion stimulus
224039885|NCT04317950|OTHER|Sham|sham stimulus
224039886|NCT03298568|DIETARY_SUPPLEMENT|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
224039887|NCT06402981|OTHER|High risk prediction model for liver injury|Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
224039888|NCT00125879|BIOLOGICAL|Myozyme|20 mg/kg qow or 40 mg/kg qow
224039889|NCT00419718|DRUG|inhaled human insulin|
224039890|NCT01449877|DRUG|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
224039891|NCT01580150|OTHER|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
224039892|NCT01580150|OTHER|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
223429965|NCT02407132|BEHAVIORAL|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
223429966|NCT01031745|BEHAVIORAL|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
223429967|NCT01031745|OTHER|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
223429968|NCT01702532|DRUG|Nicotine|Comparison of different dosage forms of nicotine
223429969|NCT03617861|DRUG|Human Secretin|Injected once over one minute
223564736|NCT05281536|OTHER|Ppostural change from 45° to 10° in supine position|The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
223564737|NCT03303859|DIAGNOSTIC_TEST|Bacterial vaginosis|
223564738|NCT04077294|OTHER|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
223564739|NCT04077294|OTHER|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
223564740|NCT03346265|OTHER|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
224039893|NCT04906616|BEHAVIORAL|Mlambe|A combined economic and relationship-strengthening intervention at the couple level to redirect funds spent on alcohol into financial investments (e.g., education, income-generating business) and to improve couple relationships and adherence to ART.
224039894|NCT00244972|OTHER|Laboratory Biomarker Analysis|Correlative studies
224039895|NCT00244972|DRUG|Sorafenib Tosylate|Given PO
224039896|NCT00244972|DRUG|Tipifarnib|Given PO
224039897|NCT03739762|BEHAVIORAL|i-STAND|Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions. (As of 3/31/2022 Re-randomizations are no longer taking place)
224039898|NCT03739762|OTHER|Healthy Living control|In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
224299409|NCT05934955|DRUG|BI 1839100|BI 1839100
223429970|NCT03617861|DRUG|Placebo|Injected once over one minute
224039899|NCT04774770|BEHAVIORAL|HED-Start|The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
224039900|NCT04358510|DEVICE|COViage|The COViage machine learning algorithm is designed to predict mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
224039901|NCT02872077|OTHER|Auricular acupuncture|
224039902|NCT06494709|OTHER|photographs|"Standardized photographs presenting 10 control subjects (class I) and patients with dentofacial deformities (10 class II and 10 class III) before and after surgery - from the front and from the side - will be used to form an approximately 10 min video sequence using the Tobii Pro Lab® software (Tobii Pro AB, Danderyd, Sweden). The naive participants will look at the percept during which the faces of the controls and the patients will alternate, with the only instruction being free visual exploration of the percept.~The fixation duration in the defined areas of interest (eyes, nose, mouth, chin) will be recorded with a Tobii® Pro X3-120 eye-tracking device and the results will be processed with the Tobii Pro Lab® software."
224039903|NCT04793269|OTHER|No intervention|no intervention
224039904|NCT06512272|OTHER|Video recorded shared using a mobile application|"The routine hospital discharge explanation is video recorded \[up to three minutes\].~The video is uploaded by to a mobile app for the patient and patient/ relatives can review the advice multiple times"
224039905|NCT04321980|DRUG|OP-101|Subcutaneous injection of OP-101 in healthy volunteers
224039906|NCT01889303|DRUG|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
224163890|NCT05249803|COMBINATION_PRODUCT|Patients with COVID-19 Pneumonia|Patients were offered with usual care of COVID-19 in ICU and we did retrospective study
224163891|NCT03884127|DRUG|Ezetimibe 10mg|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
224163892|NCT03884127|DRUG|Orlistat 120 MG|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
224163893|NCT02251028|BEHAVIORAL|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
224163894|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
223429971|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for banking
223429972|NCT05770531|PROCEDURE|Computed Tomography|Undergo CT
223429973|NCT05770531|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223429974|NCT05770531|PROCEDURE|Biospecimen Collection|Undergo blood sample collection for ctDNA evaluation
223429975|NCT05770531|BIOLOGICAL|Sacituzumab Govitecan|Given by IV
224163895|NCT02084875|DRUG|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
224039907|NCT01889303|DRUG|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
224039908|NCT01889303|RADIATION|radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons in both Arm A and Arm B. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
224039909|NCT03431181|BEHAVIORAL|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
224039910|NCT03431181|BEHAVIORAL|Usual care|Patients in the control arm will receive usual care (as per local practices).
223429976|NCT04030260|DRUG|Regorafenib and PD-1 antibody in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and PD-1 antibody
224039911|NCT02112435|DEVICE|Somnyx ®|Active mandibular advancement splint
224039912|NCT02112435|DEVICE|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
224039913|NCT03581201|DIAGNOSTIC_TEST|Laboratory measurements|"Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~* Hormone analysis~* Clinical chemistry~* Complete blood count~* Adipokines~* Glucose and HbA1c-levels~* Urinary Chemistry"
224163896|NCT04726436|OTHER|Dextrose 5% in water|One hour before operation, patients were given dexrose 5%100/hour only for 2 hours to end at about middle of surgery
223429977|NCT04030260|RADIATION|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
223429978|NCT04549376|DRUG|Povidone-Iodine 0.4% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.4%
223429979|NCT04549376|DRUG|Povidone-Iodine 0.5% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.5%
223429980|NCT04549376|DRUG|Povidone-Iodine 0.6% NI|Povidone iodine (PVP-I) nasal irrigation at concentration of 0.6%
223564741|NCT03346265|OTHER|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
223564742|NCT02913430|DRUG|Fulvestrant|500mg IM Q28 days
223429981|NCT04549376|DRUG|Povidone-Iodine 0.5% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.5%
223564743|NCT02913430|DRUG|Tamoxifen|20mg PO Qdaily
223564744|NCT02913430|DRUG|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
224163897|NCT04726436|OTHER|Dextrose 10%|One hour before operation, patients were given dexrose 10 %100/hour only for 2 hours to end at about middle of surgery
224163898|NCT04726436|OTHER|Saline placebo|One hour before operation, patients were given normal saline100/hour only for 2 hours to end at about middle of surgery
224299410|NCT05934955|DRUG|Placebo matching BI 1839100|Placebo matching BI 1839100
223429982|NCT04549376|DRUG|Povidone-Iodine 0.6% NS|Povidone iodine (PVP-I) nasal spray at concentration of 0.6%
223429983|NCT04549376|OTHER|Placebo comparator: DW-NI|Nasal irrigation will be provided by Distilled water
223429984|NCT04549376|OTHER|Placebo comparator: DW-NS|Nasal spray will be provided by Distilled water
223429985|NCT05103436|OTHER|TENS|Electrical nerve stimulation
223429986|NCT03790618|DRUG|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
223429987|NCT03790618|DRUG|methamphetamine|Please see above.
223429988|NCT03751436|DRUG|Enzalutamide|Given PO
223429989|NCT03751436|DRUG|Venetoclax|Given PO
223429990|NCT04222842|DRUG|CM082|Subjects will receive CM082 orally for two weeks followed by two weeks off in four-week cycles.The total treatment period is tentatively set at 3 cycles (12 weeks).
223429991|NCT05258799|DRUG|rhTPO|decitabine (15 mg/m2 daily, days 1-5); low-dose cytarabine (10 mg/m2 q12 h, days 3-9); rhTPO (15,000 U daily, days 2, 4, 6, 8, and 10-24 or until a platelet count \> 50 × 109/L was observed); aclarubicin (14 mg/m2 daily, days 3-6); and G-CSF (300 μg daily, days 2-9).
223429992|NCT03384784|DRUG|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
223429993|NCT03384784|DRUG|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
223564745|NCT01628484|OTHER|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
224039914|NCT03581201|DIAGNOSTIC_TEST|Stool samples|For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.
224039915|NCT03581201|DIAGNOSTIC_TEST|Bioimpedance analysis|The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.
224039916|NCT02464228|DRUG|Tipifarnib|oral
224039917|NCT04560569|DRUG|Albuvirtide|Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
224039918|NCT04560569|DRUG|3BNC117 Antibody|Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
224039919|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
224039920|NCT01809535|DEVICE|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
224039921|NCT05013853|PROCEDURE|Restoration teeth|Remove caries and restore with resin composite
224039922|NCT05737043|DIAGNOSTIC_TEST|prenatal diagnose|we will do a fetal echo in pregnant women with polyhidramnios
223429994|NCT01849068|DRUG|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
223429995|NCT01849068|DRUG|Placebo|Placebo for 12 weeks
224039923|NCT04830150|BEHAVIORAL|Supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).|This study was conducted to determine the effects of supportive interventions on the stress levels of mothers of infants hospitalized in the Neonatal Intensive Care Unit (NICU).
224039924|NCT04258371|DRUG|Dapagliflozin 10 MG|Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
224039925|NCT04258371|DRUG|Placebo oral tablet|Placebo once daily for 12 weeks
224039926|NCT06335992|OTHER|Exercise regime|Exercise
224039927|NCT03597971|DRUG|HMPL004-6599|For each cohort, 6 subjects will receive HMPL004-6599
224039928|NCT03597971|DRUG|Placebo|For each cohort, 2 subjects will receive placebo
224039929|NCT04159766|DRUG|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
224039930|NCT04159766|DRUG|Placebo|normal saline
224039931|NCT01695577|OTHER|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
224039932|NCT01695577|OTHER|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
224039933|NCT01873716|DRUG|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
224139439|NCT01974726|OTHER|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
223429996|NCT06457360|DRUG|tranexamic acid|Application of sterile gauze after extraction for hemostasis
223429997|NCT06457360|DRUG|Ankaferd Blood Stopper|Application of sterile gauze after extraction for hemostasis
223429998|NCT06457360|DRUG|Chitosan|Application of sterile gauze after extraction for hemostasis
223429999|NCT06537076|DRUG|AR1005|AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.
223430000|NCT06537076|DRUG|Placebo|Matching placebo for AR1005 to be administered BID for 20 weeks
224039934|NCT00003653|DRUG|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
224039935|NCT00003653|DRUG|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
224163899|NCT02384928|PROCEDURE|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
223430001|NCT06537076|DRUG|Rivastigmine 3 mg|3mg Rivastigmine will be administered BID for both active and placebo groups
223430002|NCT02210286|DIETARY_SUPPLEMENT|Magtein|
223430003|NCT02533102|DRUG|E7050|100 mg tablet administered orally
223430004|NCT01846221|DRUG|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
223430005|NCT01846221|DRUG|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
223430006|NCT02920541|DRUG|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
223430007|NCT02967913|PROCEDURE|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
223430008|NCT04606992|PROCEDURE|CELS|CELS resection for early colon cancer is a compromised resection performed in frail patients
223430009|NCT01668966|DRUG|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
224039936|NCT00003653|DRUG|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
224039937|NCT00003653|DRUG|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
223430010|NCT01609166|DRUG|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
223430011|NCT01609166|DRUG|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
223430012|NCT06649526|OTHER|endotracheal intubation with videolaryngoscope|The present study will compare the images of two different VLs with Macintosh blades (the McGrath videolaryngoscope and the Hugemed videolaryngoscope) in both indirect (screen images) and direct (images viewed through the mouth) laryngoscopy.
223430013|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
223430014|NCT01639066|DRUG|Entecavir|Entecavir 1 mg daily Oral
223430015|NCT01639066|DRUG|Tenofovir|Tenofovir 300mg daily Oral
223430016|NCT06309420|DEVICE|Cryogenic treatment of warts (Pixie CO2)|Treatment of common and plantar warts by cryotherapy treatment.
223430017|NCT06309420|DEVICE|Cryogenic treatment of warts (Wortie®)|Treatment of common and plantar warts by cryotherapy treatment.
223564746|NCT01628484|OTHER|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
224139440|NCT01974726|OTHER|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
224163900|NCT02384928|DEVICE|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
224299411|NCT03494335|OTHER|Online surveys|The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
224299412|NCT05472662|DRUG|Placebo 152a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 152a propellant
224299413|NCT05472662|DRUG|Placebo 134a|Placebo pressurised metered-dose inhaler (pMDI) formulated with the 134a propellant
223564747|NCT01628484|OTHER|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
223564748|NCT03855046|DRUG|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
223564749|NCT03855046|PROCEDURE|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
223564750|NCT01040091|DRUG|Emtricitabine (FTC)|200 mg once a day
223564751|NCT01040091|DRUG|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
223430018|NCT06620081|OTHER|Performance Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
223430019|NCT06620081|OTHER|Functional Tests|Three functional tests were performed: the six-minute walk test, incremental lower limb test with arterial blood gas analysis, and lower limb endurance test with inspiratory capacity measurement. Each test was conducted on different days with different devices: HFNC and conventional oxygen therapy, totaling six test days. The inspired oxygen fraction (FiO2) was titrated to maintain normoxia between 90% to 96% and was kept constant for both interfaces.
223430020|NCT02712762|OTHER|Cross-sectional study|
223564752|NCT01040091|DRUG|Efavirenz (EFV)|600 mg once a day
223564753|NCT01040091|DRUG|Truvada|200 mg emtricitabine + 300 mg TDF once a day
224039938|NCT00003653|DRUG|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
224039939|NCT00003653|DRUG|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
223430021|NCT04146675|DEVICE|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
224039940|NCT00003653|DRUG|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
224039941|NCT06074003|OTHER|Seated Rest (Non-exercise control)|Sitting for 30 minutes
224039942|NCT06074003|OTHER|High-intensity interval exercise|Performing a single session of high-intensity interval exercise on a cycle ergometer
223430022|NCT04146675|DEVICE|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
223430023|NCT04326868|DRUG|Benzimidazole Anthelmintic|The participants diagnosed positive will be randomly assigned to one of the following treatment arms of the study. Parents or guardians of eligible children will be asked to bring them to the CERMEL (clinic). after a brief clinical examination child fulfilling inclusion criteria will be randomly assigned to one of the following treatment regimens of the study.
223430024|NCT03652233|DRUG|Nivolumab|Given by vein every 14 days for up to 12 months
223430025|NCT03652233|DRUG|Afatinib|Taken by mouth daily for up to 12 months
223430026|NCT02879994|OTHER|Laboratory Biomarker Analysis|Correlative studies
224139441|NCT01974726|OTHER|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
223430027|NCT02879994|BIOLOGICAL|Pembrolizumab|Given IV
223430028|NCT02741791|DRUG|AXS-05|AXS-05 taken daily for 6 weeks.
223430029|NCT02741791|DRUG|Bupropion|Buproprion taken daily for 6 weeks.
223430030|NCT02750605|DEVICE|DEB|Intervention with drug eluting balloon.
223430031|NCT02750605|DEVICE|POBA|Intervention with old technology as comparison
223430032|NCT04132089|BEHAVIORAL|capABILITY|All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
223564754|NCT05552794|DIAGNOSTIC_TEST|Optic nerve Sheath Diameter (ONSD)|ONSD and rSO2 monitoring will perform when the patients arrived in ICU.
223564755|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
223430033|NCT01712893|DRUG|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
223430034|NCT04096898|DEVICE|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
223430035|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
223430036|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
223430037|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
224039943|NCT05925166|DRUG|rhTNFR-Fc|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
224039944|NCT05925166|DRUG|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
224039945|NCT04103697|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
224039946|NCT04103697|DRUG|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
224039947|NCT04103697|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
223430038|NCT02909881|DIETARY_SUPPLEMENT|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
223564756|NCT00420940|DEVICE|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
224039948|NCT04103697|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
224039949|NCT04103697|PROCEDURE|Rectal cancer surgery|Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
224039950|NCT04354805|DRUG|Chlorpromazine|(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
224139442|NCT01974726|OTHER|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
224139443|NCT00057460|DRUG|Talampanel|
224139444|NCT05497895|BIOLOGICAL|5% thymoquinone (TQ) gel|Mode of Administration In Group I patients, the lipid based TQ gel (5%) will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performing the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior and after its application. The patients will be instructed to not eat for 30 minutes following its application.
224139445|NCT05497895|BIOLOGICAL|SRP and placebo|In Group II patients, the placebo gel will be applied topically to the affected areas, twice daily for two weeks following SRP. The investigator performs the treatment of gingivitis based on the patient's response to therapy. For home care, the patients will be instructed to clean and dry the affected area prior to the gel application and hands will be washed prior to and after its application. The patients will be instructed to not eat for 30 minutes following its application
224139446|NCT05497895|PROCEDURE|Only SRP-one stage prophylaxis|The Group III patients will be subjected to one-stage oral prophylaxis.
223430039|NCT02909881|BEHAVIORAL|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
223430040|NCT06077149|BIOLOGICAL|RSV vaccine|"All participants will get either the Pfizer RSV vaccine (RSVpreF (ABRYSVO)) or the GSK RSV vaccine (RSVpreF (AREXVY)) at 120 ug of the RSV prefusion F antigen intramuscularly in the the non-dominant deltoid muscle.~Long-term care facility residents will get whichever vaccine is available at the facility as part of standard of care. Community cohort will be matched proportionally"
223430041|NCT03568032|DIAGNOSTIC_TEST|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
223430042|NCT03568032|DIAGNOSTIC_TEST|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
223430043|NCT03568032|DIAGNOSTIC_TEST|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
223430044|NCT03568032|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|Cognitive assessment
223430045|NCT03568032|OTHER|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
223564757|NCT03752346|OTHER|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~1. a warm-up with 10 minutes of stretching exercises.~2. A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~3. Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
223564758|NCT04293510|PROCEDURE|renal biopsy and blood sampling|renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
224039951|NCT02801903|DRUG|SB204 4%|Topically Once Daily (AM)
224039952|NCT03436706|OTHER|exposure|exposure to chronic stress
224039953|NCT04182503|OTHER|No intervention|This is a multi-city observational cohort study without intervention.
224039954|NCT03579849|DIAGNOSTIC_TEST|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
224039955|NCT05754554|PROCEDURE|Atlas occipital decompression lateral joint release combined with occipital-neck fusion|A. Chiari malformation combined with type II Basilar invagination showed that the slope spinal canal angle decreased, and the position of the dentition moved up. The yellow fusion device in the picture is C1/2 lateral inter-articular Cage (the patent granted by the applicant for this project); B. After atlanto-occipital decompression, C1/2 lateral inter-articular release is performed, and a fusion device is implanted to move down the position of the tip of the tooth process to reduce the compression of the cervical medulla oblongata; C. Implantation of the posterior neck nail rod system; D. Improve the angle of the sloped spinal canal by posterior compression rod technique (Cantilever) to further reduce the compression on the superior cervical medulla oblongata.
224039956|NCT00390611|DRUG|Sorafenib|
224039957|NCT00390611|DRUG|Paclitaxel|Paclitaxel
224039958|NCT00390611|DRUG|Carboplatin|Carboplatin
223430046|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
223430047|NCT01594398|DRUG|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
223430048|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
223564759|NCT05312632|DRUG|Safinamide Mesilate|Safinamide Mesilate oral tablets.
224039959|NCT04691999|BEHAVIORAL|Intermittent Fasting|16-18 hour fasting period four times per week
224039960|NCT00006036|DRUG|cisplatin|
224039961|NCT00006036|DRUG|lurtotecan liposome|
224039962|NCT02193360|DRUG|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
224039963|NCT06168136|OTHER|protein diet|this group of patients will receive high protein intake (target: 1.8 g protein/kg BW/d)
224039964|NCT06168136|OTHER|Normal protein diet|this group of patients will receive normal protein intake (target: 1.2 g protein/kg BW/d)
224039965|NCT06401564|DEVICE|Virtual Reality Therapy|Each participant will receive one or two 20 minute VR sessions during their admission. Participants are able to pause or discontinue at any time. During each VR session, participants will use the REAL Immersive VR system and be equipped with a VR headset and 6 sensors attached to the torso, waist, and upper extremities. Patient will then undergo various virtual challenges guided by the physical or occupational therapist facilitating movements of the upper extremity, core, head, and neck.
224039966|NCT06167603|DIAGNOSTIC_TEST|FDG-PET|Among other neuroimaging techniques, FDG-PET represents a unique tool to study the early metabolic alterations associated with neurodegeneration, both at the group and individual subject level.
224039967|NCT06167603|DIAGNOSTIC_TEST|Blood test and clinical examination.|baseline, 12-months and 24 months.
224039968|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid
224039969|NCT01710683|BEHAVIORAL|Care program|Care program with multimodal pain treatment including epidural steroid.
224139447|NCT01226212|DIETARY_SUPPLEMENT|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
224139448|NCT01226212|DIETARY_SUPPLEMENT|Placebo|maltodextrose
223430049|NCT01594398|DRUG|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
224139449|NCT02615067|DRUG|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
224139450|NCT02615067|DIAGNOSTIC_TEST|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
223564760|NCT04779567|DRUG|Acetaminophen|Acetaminophen 1 gr iv 4 times a day
223564761|NCT04779567|DRUG|Placebo|100 ml saline 0.9% iv 4 times a day
224039970|NCT02080351|BEHAVIORAL|Simple cognitive task|
224039971|NCT02248948|DIETARY_SUPPLEMENT|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
224039972|NCT02248948|DIETARY_SUPPLEMENT|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
224039973|NCT05759065|BEHAVIORAL|Tele-Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.
224039974|NCT05759065|BEHAVIORAL|Tele-Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
224039975|NCT00385203|DRUG|AZD2171|45 mg oral tablet once daily dose
224039976|NCT04541056|BEHAVIORAL|Goal Management Training (GMT)|The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.
224139451|NCT04504435|DRUG|GSK3494245|Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
224139452|NCT04504435|DRUG|Placebo|Matching placebo capsules will be provided
224139453|NCT04278508|DRUG|Progesterone|To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
223430050|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
223430051|NCT01594398|DRUG|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
223430052|NCT00361166|DRUG|ACP-103|
223430053|NCT00348426|DRUG|Botulinum AntiToxin|
223430054|NCT00348426|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
223430055|NCT00348426|PROCEDURE|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
223430056|NCT02491125|DIETARY_SUPPLEMENT|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
223430057|NCT02491125|DIETARY_SUPPLEMENT|Placebo|12 weeks daily intake of 15g of maltodextrin
223564762|NCT01948765|DRUG|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
223564763|NCT01948765|DRUG|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
223564764|NCT04786704|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|A diagnostic device measuring syndecan 2(SDC2) methylation status in stool DNA to detect colorectal cancer
223564765|NCT04786704|DIAGNOSTIC_TEST|quantitative Fecal immunochemical test|A diagnostic device using immunoturbidimetric methods to measure fecal hemoglobin concentration
223564766|NCT03100240|PROCEDURE|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
224139454|NCT05534035|BIOLOGICAL|PTX-COVID19-B|The vaccine product, PTX-COVID19-B, is a preservative-free, sterile mRNA-lipid nanoparticle (mRNA-LNP) dispersion in an aqueous cryoprotectant buffer intended for IM injection.
224139455|NCT05534035|BIOLOGICAL|Vaxzevria®|The AstraZeneca COVID-19 Vaccine is a colorless to slightly brown solution, clear to slightly opaque with a pH of 6.6. One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 1010 viral particles (vp) (corresponding to not less than 2.5 × 108 ifu).
224139456|NCT03805581|DRUG|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
223430058|NCT00998348|BEHAVIORAL|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
223430059|NCT02226926|DRUG|Aggrenox|
223430060|NCT02226926|DRUG|Persantin Retard|
223430061|NCT02226926|DRUG|Acetylsalicylic acid|
223430062|NCT03955965|OTHER|Medication reconciliation|No intervention was performed other than collecting data on patients' medical files
223430063|NCT03864666|DRUG|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
223430064|NCT03864666|DRUG|PMR 200 mg|Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
223430065|NCT00939406|DEVICE|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
223430066|NCT05588999|PROCEDURE|Cryotherapy Alone|"Patients in Group A were subjected to Cryotherapy Alone with liquid nitrogen and received maximum of four treatments given two to three weeks apart .~The liquid nitrogen was applied with a spray or a probe"
223430067|NCT05588999|COMBINATION_PRODUCT|Cryotherapy plus Salicylic Acid|Patients in Group B were subjected to cryotherapy plus with 50% salicylic acid to be properly applied for a maximum of eight weeks The liquid nitrogen was applied with a spray or a probe
223430068|NCT02160028|OTHER|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
223564767|NCT01663116|GENETIC|Stem cells|"1. first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~2. second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~3. third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
223564768|NCT01663116|GENETIC|Placebo|"1. first cohort: 20 ml administered at days 1, 8 and 15~2. second cohort: 40 ml administered at days 1, 8 and 15~3. third cohort: 80 ml administered at days 1, 8 and 15"
224039977|NCT04541056|BEHAVIORAL|Brain Health Workshop (BHW)|BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.
224139457|NCT01398072|DRUG|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
224139458|NCT01398072|DRUG|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
223430069|NCT02160028|OTHER|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
223430070|NCT00552032|DRUG|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
223430071|NCT00552032|DRUG|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
223564769|NCT01029990|OTHER|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
224039978|NCT05500755|DEVICE|Implant Treatment|Surgical placement of a DS Prime Taper implant and its posterior prosthesis.
224039979|NCT03819881|BIOLOGICAL|STMC-103H|Live bacterial product
224039980|NCT03819881|BIOLOGICAL|Placebo|Inactive placebo substance
224039981|NCT02801955|PROCEDURE|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
224039982|NCT02801955|PROCEDURE|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
224039983|NCT00135239|PROCEDURE|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
224039984|NCT00135239|PROCEDURE|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
224139459|NCT01398072|DRUG|Doxycycline|An oral dose of 100 mg once daily.
224139460|NCT01398072|DRUG|Placebo|Oral dose of one table once daily.
224139461|NCT04404010|OTHER|Immersive Virtual Reality|Participants randomized to the iVR simulator utilizes a head-mounted display producing 3D visuals with haptic controllers for an immersive operating room experience. The module produced consists of the key steps in performing a reverse shoulder arthroplasty using virtual versions of the equipment used in the real procedure. Prior to initiation, participants will be provided with a safety and training demonstration on the use of the VR module by study personnel. Participants will be provided as much time as they require to watch the video, including repetition if desired, which they will be timed for completion.
224039985|NCT05993936|DEVICE|mobile application|A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
224039986|NCT03308942|DRUG|Niraparib|Niraparib is an orally available, potent, highly selective poly adenosine diphosphate- ribose (poly ADP-ribose) polymerase-1 (PARP-1) and PARP-2 inhibitor. It will be available as 100 milligrams (mg) capsules and will be administered as 2 X 100 mg capsules (200 mg per day) orally once daily (QD).
224039987|NCT03308942|BIOLOGICAL|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G-4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands (PD-L1 and PD-L2). It will be available as 50 mg lyophilized powder single-use vials or 100 mg/4 milliliters (mL) (25 mg/mL) solution in a single-dose vial. It will be administered at a dose of 200 mg intravenous (IV) using a 30-minute IV infusion
224039988|NCT03308942|BIOLOGICAL|TSR-042 (Dostarlimab)|TSR-042 (Dostarlimab) is a humanized mAb of the IgG4/kappa isotype that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. It will be administered at a dose of 500 mg for every 3 weeks (Q3W) for first 4 cycles followed by 1000 mg for every 6 weeks (Q6W) for all subsequent cycles using a 30-minute IV infusion. TSR-042 (dostarlimab) will be supplied as a solution of 160 mg (20 mg/mL) or 500 mg (50 mg/mL) in a single-dose vial.
224039989|NCT04296279|DRUG|FMP014|Falciparum Malaria Protein-14
224139462|NCT04404010|OTHER|Surgical Technical Instructional Video|Participants will be provided as much time as they require to watch the instructional video, including repetition if desired, which they will be timed for completion.
224139463|NCT05242445|DRUG|Cetrelimab|Cetrelimab (Dose 1 and Dose 2) will be administered via SC injection or as an IV infusion.
224139464|NCT05242445|DRUG|Placebo|Placebo will be administered via SC injection or as an IV infusion.
224039990|NCT04296279|DRUG|ALFQ|ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
224039991|NCT01131351|DRUG|Delamanid|OPC-67683 film-coated tablets
224139465|NCT06067412|DRUG|Levetiracetam|Efficacy in fits
224139466|NCT06067412|DRUG|Phenytoin|Efficacy in fits
224139467|NCT00133835|PROCEDURE|Extracorporeal shock wave lithotripsy|
224139468|NCT00133835|PROCEDURE|Endoscopic drainage of the main pancreatic duct|
224139469|NCT02120157|DRUG|Cyclophosphamide|Chemotherapy administration
224139470|NCT02120157|RADIATION|TBI|Radiation Therapy
224139471|NCT02120157|DRUG|Busulfan|Chemotherapy Administered
224139472|NCT02120157|OTHER|Unmanipulated Bone Marrow|Bone Marrow Transplant
224139473|NCT02120157|DRUG|Tacrolimus|Immunosuppressive Drug Administered
224139474|NCT02120157|DRUG|Mycophenolate mofetil|Immunosuppressive Drug Administered
224139475|NCT03528889|PROCEDURE|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
224139476|NCT03482141|DEVICE|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
224039992|NCT01131351|DRUG|Optimized Background Regimen (OBR)|OBR was selected at the discretion of the study investigator and included at least 2 anti-TB medications based on World Health Organization (WHO's) guidelines for the programmatic management of drug-resistant TB. Study investigator could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
224039993|NCT02079090|DRUG|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
224039994|NCT02079090|DRUG|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
224039995|NCT01903070|DRUG|Linagliptin|
224139477|NCT03472599|OTHER|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
224139478|NCT06113497|DRUG|Cocktail injection|Morphine 5 mg, ropivacaine 150 mg, tramadol 40 mg, epinephrine 1 mg, ketorolac 60 mg, and ketamine 1 g will be mixed with normal saline to prepare a total volume of 60 ml
224139479|NCT02635152|BEHAVIORAL|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
224139480|NCT02635152|BEHAVIORAL|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
224139481|NCT04368455|BEHAVIORAL|Virtual Immersive Communication Training on Recommending Immunizations (VICTORI)|An intervention that includes a self-directed app based curriculum and virtual reality simulations, designed to increase the strength and consistency of HPV vaccine recommendations among clinicians.
224139482|NCT04368455|BEHAVIORAL|HPV Same Way Same Day App|An intervention that includes a self-directed app based curriculum
224139483|NCT04753047|OTHER|No intervention|No intervention
224139484|NCT00780702|DRUG|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
224139485|NCT00780702|DRUG|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
224139486|NCT05432102|DIAGNOSTIC_TEST|Pulse oxymetry|Diagnostic intervention to diagnose OSA.
224139487|NCT05432102|DIAGNOSTIC_TEST|Respiratory polygraphy|Diagnostic intervention to diagnose OSA.
224299414|NCT04620135|DRUG|Netarsudil ophthalmic solution 0.02%|Topical sterile ophthalmic solution Other Name: Rhopressa®
224039996|NCT02294682|DRUG|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
224039997|NCT04180748|OTHER|fluorescence imaging with 405nm light|Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
224039998|NCT00715195|BEHAVIORAL|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
223430072|NCT00533052|BEHAVIORAL|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
224039999|NCT01747967|OTHER|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
224040000|NCT05476042|DRUG|Prescription of placebo|Normal saline
224040001|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 3000 units in normal saline
223430073|NCT02384109|BEHAVIORAL|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
223430074|NCT02384109|OTHER|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
223564770|NCT01029990|OTHER|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
223564771|NCT02379221|DRUG|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
223564772|NCT02379221|DRUG|Topical|4% Topicaine gel
224139488|NCT03354702|OTHER|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
224139489|NCT03354702|OTHER|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
224139490|NCT01238406|DEVICE|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
224139491|NCT01238406|DEVICE|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
224139492|NCT05931185|OTHER|low frequency transcutaneous electrical stimulation and Therapeutic Ultrasound|patients will receive low-frequency transcutaneous electrical stimulation for 15 minutes and therapeutic Ultrasound for 10 minutes as a treatment and patients will receive a total of 12 treatment sessions (3 sessions per week for 4 weeks and then follow-up will be done for the next 2 weeks) and the total duration of each session will be of 25 minutes.
223564773|NCT00100997|DRUG|tanespimycin|
223564774|NCT02660671|BEHAVIORAL|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
223564775|NCT02660671|BEHAVIORAL|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
223564776|NCT02660671|BEHAVIORAL|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
223564777|NCT06197191|DEVICE|Fukuda Denshi Cardimax ECG device model FCP-7101|ecg and holter will be done one day before and one day after then after 1,6,12 month after transcatheter closure of ASD
223564778|NCT00584090|DRUG|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
223564779|NCT00584090|DRUG|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
224040002|NCT05476042|DRUG|Erythropoietin prescription|Erythropoietin 6000 units in normal saline
224040003|NCT06466031|OTHER|MRI & PET fusion|MRI+T1C in fusion with MET-PET will be used for tumor resection and/or radiotherapy planning. Resection will be terminated after removal of PET-assigned tumor margin or in case any neuromonitoring-based indications regarding neurological damage occur.
224040004|NCT06466031|OTHER|MRI+T1C|MRI+T1C will be used for tumor resection and radiotherapy planning. Resection will be terminated after removal of contrast-enhancing part regardless of 5-ALA fluorescence or in case any neuromonitoring-based indications regarding neurological damage occur.
224040005|NCT04202770|OTHER|Exosomes|Focused ultrasound delivery of intravenously-infused exosomes
224040006|NCT01595984|DRUG|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
224040007|NCT01595984|DRUG|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
224040008|NCT03010306|OTHER|CASITA|
224139493|NCT05931185|OTHER|Therapeutic Ultrasound|patients will receive a therapeutic ultrasound for 10 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
224139494|NCT05931185|OTHER|Low frequency transcutaneous electrical stimulation|participants will receive low-frequency transcutaneous electrical stimulation for 15 minutes three times a week for 4 weeks and then follow-up will be done for the next 2 weeks
224299415|NCT04620135|DRUG|Ripasudil hydrochloride hydrate ophthalmic solution 0.4%|Other Name: Glanatec®
224299416|NCT02452983|DRUG|Sertraline|
224299417|NCT02452983|PROCEDURE|Bone Marrow Aspirate/Biopsy|
224299418|NCT00835965|DRUG|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
224040009|NCT04080284|DRUG|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
224139495|NCT03263156|BEHAVIORAL|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
224139496|NCT04509323|DRUG|Huperzine A for Injection|Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days
224040010|NCT00298129|DEVICE|Ambulatory blood pressure monitoring|
224040011|NCT03901573|DRUG|NT-I7|"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"
224040012|NCT03901573|DRUG|atezolizumab|"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"
224040013|NCT04114266|OTHER|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
224040014|NCT00162864|DRUG|montelukast sodium|
224040015|NCT01281007|DRUG|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
224040016|NCT01281007|DRUG|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
224040017|NCT05112198|DEVICE|Use of Noona web- based symptom tracking tool|Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
224040018|NCT05028725|DEVICE|EsophaCap Sponge|Non-invasive strategy to sample esophageal tissue
224040019|NCT05028725|PROCEDURE|Chromoendoscopy|Lugol's iodine chromoendoscopy is a technique that is used to identify mucosal abnormalities of the esophagus
224040020|NCT05028725|DEVICE|EsoCAN assay|Biomarker Test
224040021|NCT03099668|OTHER|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
224040022|NCT00347672|BIOLOGICAL|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
224139497|NCT06081673|DRUG|Penpulimab injection|Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2)； 200mg,D1, IV(21 days/cycle).
224139498|NCT06081673|DRUG|cisplatin|Cisplatin :75mg/m2, D1, IV(21 days/cycle)
223430075|NCT01796314|BEHAVIORAL|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~1. Knowledge of the disease~2. Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~3. Crisis situations. Prevention of caregiver's exhaustion~4. Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
224040023|NCT02461030|DRUG|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
224040024|NCT02461030|DRUG|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
224139499|NCT06081673|DRUG|albumin-paclitaxel|albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)
224139500|NCT05005091|DIETARY_SUPPLEMENT|Oral carbohydrate|100 ml oral carbohydrate two hours ago preoperatively
224299419|NCT00835965|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
224299420|NCT00835965|DRUG|Placebo Dexamethasone|
223430076|NCT02519816|OTHER|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
224040025|NCT02461030|PROCEDURE|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
224040026|NCT02545621|OTHER|RAGE TXNIP Inflammasome axis|
223740281|NCT07205536|DRUG|Mecapegfilgrastim injection|After enrollment, a single subcutaneous dose of mecapegfilgrastim should be administered 24 hours following completion of each chemotherapy cycle. The recommended dose is a fixed 6 mg, or an individualized 100 μg/kg based on the patient's body weight. If neutrophil counts remain below 0.5 × 10⁹/L for more than 24 hours after mecapegfilgrastim administration, short-acting G-CSF may be used as rescue therapy at the investigator's discretion until neutrophil levels return to normal.
224040027|NCT03981471|BEHAVIORAL|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
224139501|NCT00239837|BEHAVIORAL|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
224040028|NCT06341608|BEHAVIORAL|Telehealth for opioid use disorder treatment delivery|A multi-component patient and provider facing strategy to be designed in Aim 2. Components will likely include 1) a user-friendly telehealth platform for performing all medication induction and maintenance visits, 2) integrated case management, 3) text message scheduling reminders, 4) mailed saliva drug screening tests
224040029|NCT03422172|DRUG|Oral CAB|CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
223430077|NCT06712186|DRUG|Dexmedetomidine Group / Group D|In this study, the intervention involve administrating 0.5 mcg/kg of Inj dexmedetomidine intravenously over 10 min to patients in intervention group/group D 2 minutes prior to Endotracheal intubation using laryngoscopy aiming to asses its efficacy in attenuating the pressor response to laryngoscopy.
224139502|NCT01153893|BIOLOGICAL|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
224139503|NCT01153893|BIOLOGICAL|InfanrixTM|Intramuscular injection, 1dose
224139504|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
224139505|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
223430078|NCT06712186|OTHER|Normal Saline (Placebo)|The Placebo group / group C will be administer Normal Saline without any active medication over 10 min to patients, 2 minutes prior to Endotracheal intubation using laryngoscopy to compare its effect to those of Dexmedetomidine in attenuating the pressor response to laryngoscopy.
224040030|NCT03422172|DRUG|CAB LA|CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
224139506|NCT01645085|DRUG|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
224139507|NCT01645085|DRUG|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
223430079|NCT05551689|DRUG|Psychostimulant|All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)
223430080|NCT05551689|DEVICE|FOCUS ADHD App|FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)
223430081|NCT04010864|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
223430082|NCT00223730|DRUG|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
223430083|NCT00223730|DRUG|Placebo|
223430084|NCT01844973|DRUG|M518101|Proper quantity twice a day
223564780|NCT01322399|PROCEDURE|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
224040031|NCT04332224|DEVICE|Blanketrol cooling device and water-perfused blankets|Blanketrol and water-perfused blankets
224040032|NCT04332224|DEVICE|Blanketrol and Kool Kit|Blanketrol cooling device with water-perfused vest, hood and lower body blanket
224040033|NCT04332224|DEVICE|Arctic Sun|Arctic Sun cooling device with gel cooling pads
224040034|NCT04166604|DRUG|Trifluridine/Tipiracil|"After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery"
224139508|NCT05939271|PROCEDURE|lower extremity amputation|"persons are defined as having a lower extremity amputation when an operation with removal of an extremity below the hips took place.~To identify those people with diabetes who underwent amputation, the following DBC's claims were extracted from the system: 038590; amputation upper leg, 038690; amputation lower leg, 038691; exarticulation of the lower leg, 038790; amputation of the tarsus, 038791; amputation or exarticulation of a toe, 038793; exarticulation of the foot, 038794; Chopart exarticulation, Lisfranc, respectively trans metatarsal amputation. Amputations were categorized into minor (038790, 038791, 038793, 038794) and major (038590, 038690,038691) amputations"
223430085|NCT01844973|DRUG|Vehicle|Proper quantity twice a day
223430086|NCT01123772|DRUG|INO-8875|eye drops for 14 days in one eye
224139509|NCT03056807|OTHER|25° head-up position|Angle person is positioned for procedure.
224139510|NCT03056807|OTHER|55° head-up position|Angle person is positioned for procedure.
224139511|NCT01838590|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
224139512|NCT01838590|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224139513|NCT03162341|PROCEDURE|ultrasonography|The tophus volume will be assess using ultrasonography.
224139514|NCT03162341|PROCEDURE|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
224139515|NCT00219388|DRUG|Levosimendan|
223430087|NCT01123772|OTHER|Placebo control|Matched placebo
224040035|NCT05460507|DRUG|Retreatment Rhenium Liposome|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
224040036|NCT06023641|DRUG|Vincristine|"Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15"
224040037|NCT06023641|DRUG|Dactinomycin|"Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1"
224040038|NCT06023641|DRUG|Cyclophosphamide|"Low-risk Administer by IV infusion over 30-60 minutes on Day 1, 91) dose, Mesna and hydration will be given with IV cyclophosphamide according to institutional standards.~Intermediate-risk Administer by IV infusion over 30-60 minutes, 1 dose, day 1 High-risk Administer by IV infusion over 30-60 minutes, 1 dose, day1"
224040039|NCT06023641|PROCEDURE|Surgical Resection|Low, Intermediate and High-risk
224040040|NCT06023641|PROCEDURE|Proton beam radiation or external beam radiation or brachytherapy|Low, Intermediate and High-risk
224040041|NCT06023641|DRUG|Liposomal irinotecan|Intermediate and High-risk Administer by IV infusion over 90 minutes, 1 dose on day 1 Liposomal irinotecan should be premedicated with dexamethasone (or an equivalent corticosteroid) if not contraindicated. Premedication with diphenhydramine and an H2 receptor antagonist (i.e., famotidine) are also encouraged.
224040042|NCT06023641|DRUG|Vinorelbine|Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
224040043|NCT06023641|DRUG|Temozolomide|High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
224040044|NCT06023641|DRUG|Filgrastim, peg-filgrastim|"Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy."
224040045|NCT03946514|DRUG|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
224040046|NCT03946514|DRUG|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
224040047|NCT00589498|DIETARY_SUPPLEMENT|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
224040048|NCT04053634|BIOLOGICAL|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
224040049|NCT04053634|BIOLOGICAL|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
224040050|NCT06170736|PROCEDURE|Doppler-Guided Haemorrhoidal Artery Ligation|The principle consists of locating the signal emitted by the haemorrhoidal arteries using a Doppler probe. Once identified, the arteries are ligated in order to remove the arterial vascularization of the haemorrhoidal bundles. The treatment of the prolapse is reinforced by a folding of the mucosa of the lower rectum, called mucopexy.
224040051|NCT06170736|PROCEDURE|Radiofrequency ablation|The principle consists of inserting a metal probe under the mucosa of the anus, in contact with the haemorrhoidal bundles to be treated. A source of radiofrequency is then delivered through this probe in contact with the haemorrhoidal veins which will be sclerosed. The procedure is repeated for each haemorrhoidal bundle to be treated.
224040052|NCT06293625|DRUG|Folfox|Folfox chemotherapy (folinic acid, fluorouracil and oxaliplatin) for 6 weeks (3 courses) before surgery.
224040053|NCT06293625|PROCEDURE|Surgery|Experimental arm: Surgery should take place 21 days after the last dose of neoadjuvant chemotherapy Control arm: upfront surgery as soon as possible
224040054|NCT05132387|OTHER|ECMO assisted CPR in out-of-hospital cardiac arrest|Patients included in the registry will be transferred during LUCAS assisted CPR by the Wroclaw Emergency Medical Services to the Emergency Department of the Wroclaw University Hospital where blood gasses will be assessed. If two or more of the following: end-tidal carbon dioxide (CO2) \> 10 mm Hg, arterial partial pressure of oxygen (PaO2) \>50 mm Hg or oxygen saturation \>85%, and lactic acid \<18 mmol/L will be fulfilled patient will be further transferred to the Cardiac Catheterization Laboratory for V-A ECMO implantation followed by coronary/pulmonary artery angiography and intervention.
223430088|NCT01643798|PROCEDURE|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
223430089|NCT01643798|PROCEDURE|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
224040055|NCT06548269|DIAGNOSTIC_TEST|Cardiologic work-up|Noninvasive prolonged ECG monitoring with a duration of 7 days measuring AF burden； Echocardiography measuring LA volume or volume index, LA diameter or diameter index； Cardiac CTA measuring LAA morphologies, cardiac thrombus.
224040056|NCT05329935|BIOLOGICAL|Cultured Thymus Tissue|Product will be surgically administered into the quadriceps
224040057|NCT02022085|DEVICE|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
223430090|NCT06347445|OTHER|There is no intervention.|There is no intervention.
223430091|NCT02144636|DIETARY_SUPPLEMENT|herbalife protein shake|
223430092|NCT06471855|DEVICE|Multidisciplinary Conventional and Technology-based Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. According to their individualized rehabilitation project, patients will undergo non-immersive VR-based rehabilitation. VR-based rehabilitation will consist of one daily session (3 weeks) and will be conducted by the implementation of a single non-immersive VR device among the D-WallTM (TechnoBody SRL, Italy). Part of the duration of the whole treatment will be dedicated to the use of the device, resulting in the same amount of rehabilitation for all participants.
223478378|NCT04224974|BEHAVIORAL|EASE-psy|"All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT).~-EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms."
223478379|NCT04709276|DRUG|Nivolumab|360 mg intravenously every 3 weeks
223478380|NCT04709276|DRUG|Ipilimumab|1 mg/kg intravenously every 6 weeks
224040058|NCT05576350|BEHAVIORAL|Smartphone Based Alcohol Monitoring (SAM)|Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
224040059|NCT05576350|BEHAVIORAL|Tracking and Reducing Alcohol Consumption (TRAC)|The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of alcohol consumption, which will be discussed during intervention sessions.
224040060|NCT05576350|BEHAVIORAL|TRAC-ER|Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
224040061|NCT05853965|DRUG|Belantamab mafodotin, Venetoclax|Belantamab mafodotin (IV) Venetoclax (PO)
224040062|NCT03457545|BEHAVIORAL|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
224040063|NCT03457545|OTHER|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
224040064|NCT05039099|DRUG|AP-101|Participants receive AP-101 by intravenous infusion (IV).
224040065|NCT05039099|DRUG|Placebo|Participants receive placebo by IV.
224040066|NCT00140231|DRUG|r-metHuLeptin|recombinant human leptin
224040067|NCT00140231|OTHER|placebo|placebo (no active drug)
224040068|NCT03111693|OTHER|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
224040069|NCT00884338|OTHER|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
224040070|NCT00884338|OTHER|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
224040071|NCT00905138|DRUG|GLPG0259|single ascending doses, oral solution
224040072|NCT00905138|DRUG|placebo|single dose, oral solution
224040073|NCT00905138|DRUG|GLPG0259|multiple dose, oral solution, 5 days
224040074|NCT00905138|DRUG|placebo|oral solution, 5 days
224040075|NCT01939054|DRUG|Nimotuzumab|
224040076|NCT01939054|DRUG|docetaxel|
224040077|NCT01939054|DRUG|capecitabine|
224040078|NCT04864509|DRUG|Melatonin 10 MG|Nightly dose
224040079|NCT04864509|DRUG|Placebo|Nightly dose
224040080|NCT01753154|DRUG|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
224040081|NCT01753154|DRUG|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
224040082|NCT00556153|DRUG|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
224040083|NCT04295980|PROCEDURE|Surgical removal of the BAVMs|Resection the BAVM nidus by microsurgery.
224040084|NCT03304353|OTHER|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
224040085|NCT03304353|OTHER|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
224040086|NCT03329443|DRUG|Spironolactone|each patient will receive 200 mg of spironolactone as per his/her angiography premedications
224040087|NCT03329443|DRUG|Placebo Oral Tablet|Each patient will receive a placebo tablet as per his/her angiography premedications
224040088|NCT03831425|DIETARY_SUPPLEMENT|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
224040089|NCT03831425|OTHER|Placebo|6 week trial of either treatment with Placebo
224040090|NCT05594823|OTHER|Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide|Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
224040091|NCT05594823|OTHER|Ambulatory heart failure management with fixed dose furosemide|Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
224040092|NCT03819010|DRUG|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
224040093|NCT03819010|DRUG|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
223430093|NCT06471855|OTHER|Multidisciplinary Conventional Rehabilitation|Patients will receive conventional treatment consisting of two daily sessions (3 weeks) and including traditional rehabilitation activities like range of motion exercises (passive, active assisted, and active), progressive resistive exercises, balance and strength training, and aerobic conditioning. The intervention procedures will follow the routine multidisciplinary clinical practice of the Institute where the study will be carried out. Procedures will be adapted according to the patient's medical diagnosis, disability severity, and to consequent rehabilitation objectives in favor of an individualized rehabilitation project and program. If necessary, patients might therefore undergo parallel rehabilitation activities (ie, occupational therapy, cognitive stimulation) that will be kept under control throughout data collection and analyses.
223430094|NCT06129136|OTHER|Nature-based exposure by biodiversity component in lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
224040094|NCT02709590|DRUG|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
224040095|NCT02709590|DRUG|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
224040096|NCT03913975|OTHER|Neuromuscular training|The novel training program with real-time biofeedback added consists of 2 sets of 10 repetitions per session with a progression in exercise intensity (Squat: 40 repetitions during week 1; Squat Jump: 80 repetitions during weeks 2-3; Tuck Jumps: 120 repetitions during weeks 3-6) over the 6-week training period.
224040097|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 75 mg BID
224040098|NCT06637514|OTHER|Placebo|Placebo Tablet: BID
224040099|NCT06637514|DRUG|JNT-517 Tablet|JNT-517: 150 mg BID
224040100|NCT06246617|DEVICE|da Vinci SP Surgical System for Single-Port Thoracic Surgeries|Subjects who have received or plan to receive pulmonary lobectomy/segmentectomy, mediastinal tumor resection (including thymectomy), radical resection of esophagus cancer or other surgeries with the SP single-port robot.
224040101|NCT03100799|PROCEDURE|Arthroscopy|Arthroscopy of the target knee
224139516|NCT06120309|DIAGNOSTIC_TEST|CRS scoring|For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H\&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines
224139517|NCT06120309|DIAGNOSTIC_TEST|Routine blood laboratory testing before treatment|The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
224040102|NCT03100799|PROCEDURE|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
224040103|NCT03100799|DIAGNOSTIC_TEST|MRI|MRI with and without a gadolinium-based contrast agent
224040104|NCT03932734|OTHER|survey|Face-Q conversion table
224139518|NCT02469727|BEHAVIORAL|Fitbit|Participants will use the FitBit device to track their physical activity
224139519|NCT02469727|BEHAVIORAL|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
224139520|NCT01229241|DRUG|local anesthetic|"postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
224040105|NCT05390359|OTHER|High-intensity and short-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a high intensity current (3 mA), that will be applied for 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
224040106|NCT05390359|OTHER|Low-intensity and long-duration|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a low intensity direct current (0.1 mA) during 90 seconds, with 3 seconds rests between pulses and 1 second of pulses ramp.~The total treatment time will be 366 seconds."
224040107|NCT05390359|OTHER|High-intensity, short-duration and 20 Hz|"The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 pulses of a high intensity compensated biphasic current (3 mA), during 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp. The alternating frequency will be of 20 Hz and the pulse width of 50 microseconds.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds."
224139521|NCT02683304|BIOLOGICAL|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
224139522|NCT02683304|DEVICE|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
224139523|NCT01697904|PROCEDURE|Titration of oxygen during newborn resuscitation in delivery room|
223430095|NCT06129136|OTHER|Placebo group using colored lotion.|Lotion is used at minimum three times per week and at least to arms. No restrictions to normal life and self-care. Atopy medicines and lotions are allowed when needed, only the usage amount is followed.
223430096|NCT06116552|BEHAVIORAL|More Social Stories|Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
223430097|NCT06116552|BEHAVIORAL|Less Social Stories|Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
223430098|NCT06838871|BEHAVIORAL|Inspiratory Muscle Training (IMT) with Abdominal Drawing-In Maneuver (ADIM) training|"ADIM aims to enhance trunk stability by selectively activating the transversus abdominis. Participants begin in a supine position and practice drawing in their abdomen toward the spine while maintaining a stable trunk and pelvis. A therapist provides verbal instructions and manual guidance to ensure proper muscle activation.~IMT is performed using the Threshold RMT device (IMT, GH INNOTEK, Busan, South Korea). Participants wear a nose clip and start with 30% of Maximal Inspiratory Pressure (MIP), gradually increasing by 10% per week to reach 60% MIP by the final week. Each session consists of five sets of 10-15 repetitions, with a one-minute rest between sets."
223430099|NCT06838871|BEHAVIORAL|Sham Inspiratory Muscle Training (IMT) with Abdominal Drawing-In Maneuver (ADIM) training|Sham IMT with ADIM training performs the same ADIM protocol as the IMT with ADIM training but undergoes IMT with minimal resistance (0 cmH₂O) to prevent actual muscle strengthening. This design ensures that the effects observed can be attributed to IMT rather than ADIM.
223430100|NCT05045391|DIAGNOSTIC_TEST|Aspergillus IgG detection|Aspergillus IgG will be detected among pulmonary tuberculosis patients. 5 ml of vein blood will be collected for ELISA.
223430101|NCT04516343|DEVICE|Robotic Ankle Assist Device (RAAD)|The RAAD (Robotic Ankle Assist Device) is an intelligent, powered ankle device designed to increase independence, mobility, and deliver gait training to children with movement disorders, such as CP
223430102|NCT05565781|DEVICE|ECG smartwatch|Testing ECG smartwatch to detect AF or potential signs of AF
224139524|NCT04467632|OTHER|Validation of the mobility assessment by IMU wearable sensors|"The validity of the mobility assessment by IMU wearable sensors will be verified in Work Package 3.~It will be defined as the accuracy of the machine learning algorithm to predict patients' motor status compared to the motor status assessed at clinical examination by means of the MDS-UPDRS-III scale and the Fit test. Prediction by machine learning will be compared with the MDS-UPDRS-III total score and with the 3.14 item (global clinical impression of mobility) of the same scale.~The patients will be asked to perform all the motor tasks of the MDS-UPDRS-III scale and the finger tapping test (Fit test) with both hands wearing the IMU system. A subset of minimal motor tasks allowing good prediction of the patient's motor status by the machine learning algorithm will then be selected for Work Package 4."
224139525|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Baseline Phase B1: Observation phase: 1-week wrist actigraphy and sleep diary to assess habitual activity/rest routines.~B2: Nocturnal sleep consolidation phase: 2 weeks: timed light exposure, constant sleep/wake routine and sleep restriction of 1 hour/night (based on habitual activity)."
223430103|NCT05565781|DEVICE|Insertable Cardiac Monitor (ICM)|Gold-standard cardiac monitor for comparison of testing device (ECG smartwatch)
223740282|NCT07205536|DRUG|Oral or short-acting granulocyte-stimulating agents|In the first cycle after enrollment, patients will be followed for changes in neutrophil counts. Should the neutrophil level fall below 1.5 × 10⁹/L, the investigator may, based on clinical judgment, decide whether to intervene with leucogen tablets or other granulocyte-boosting agents. If the count remains below 1.0 × 10⁹/L, short-acting G-CSF may be administered as a rescue therapy.
223740283|NCT01234545|DRUG|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
224040108|NCT05390359|OTHER|Sham electrolysis|The control ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon, without electrical stimulation during 366 seconds.
224040109|NCT00404066|DRUG|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
224040110|NCT00404066|DRUG|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
224040111|NCT00404066|DRUG|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
224040112|NCT00404066|DRUG|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
224040113|NCT00404066|DRUG|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
224040114|NCT00404066|DRUG|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
224040115|NCT00404066|DRUG|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
224040116|NCT00404066|DRUG|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
224040117|NCT06412484|BEHAVIORAL|Pain Free Session|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail): clinical exam, QST, SSRs, CPM, rsMRI, lumbar MRI, MRS, and blood sample.
224040118|NCT06412484|BEHAVIORAL|Low Back Pain Session (= clinically relevant pain)|On a day in which patients have an ongoing typical low back pain episode of an intensity of 3 or more (on a numerical rating scale of 0-10), they will undergo all the study measures (see primary outcome measures for detail), except the lumbar MRI: clinical exam, QST, SSRs, CPM, rsMRI, MRS, and blood sample.
224040119|NCT06412484|BEHAVIORAL|Experimental Pain Session (= clinically irrelevant pain)|On a day in which participants don't have any pain or a pain ranging from 0-2 (on a numerical rating scale of 0-10), an experimental pain state will be induced using a high concentration (8%) Qutenza patch, containing capsaicin. All the study measures will be performed (see primary outcome measures for detail), except the lumbar MRI and blood sample: clinical exam, QST, SSRs, CPM, rsMRI, MRS.
224040120|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose A|TD-0903 Dose A
224040121|NCT05091723|DRUG|Nezulcitinib (TD-0903) Dose B|TD-0903 Dose B
224040122|NCT03815643|DRUG|Avelumab|Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
224040123|NCT05766709|DRUG|NNC0194-0499|NNC0194-0499 will be administered subcutaneously once weekly.
224040124|NCT05766709|DRUG|Semaglutide|Semaglutide will be administered subcutaneously once weekly.
224040125|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/3.20 mg/mL)|NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
224139526|NCT04467632|OTHER|Testing in real-life conditions at patients' home in a small group of subjects|"Intervention phase~* Phase A (11 days): subjects will receive one hour of morning and afternoon light exposure twice a day:~  * Day #1: baseline assessment of outcome measures;~ * Days #2 to #6: bright light in the morning (active treatment) + dim light in the afternoon (placebo), to progressively advance circadian phase of 30' per day (phase advance of 2.5 hours obtained at day 6);~ * Days #7 to #11: dim light in the morning + bright light in the afternoon to revert the circadian phase to the baseline of 30' per day.~* Washout: 6 days. No intervention during this phase, to stabilise the reverted circadian rhythm to baseline, for phase B to be held at the same conditions as phase A.~* Phase B (11 days): similar as in phase A:~  * Day #1: similar as in phase A;~ * Days #2 to #6: reverted conditions compared to phase A.~ * Days #7 to #11: reverted conditions compared to phase A."
223430104|NCT05565781|DEVICE|External ECG Monitoring|Regular cardiac monitor for diagnosis of AF
223430105|NCT03991923|DEVICE|XVIVO heart preservation devices|The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
223430106|NCT03991923|DEVICE|Standard ICSS|Cold static preservation using standard preservation solution
224040126|NCT05766709|DRUG|NNC0194-0499/Semaglutide A (40/0.33mg/mL)|NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
224040127|NCT05197517|DRUG|Rosuvastatin 10 mg|Film Coated Tablets products containing 10 mg Rosuvastatin
224040128|NCT06737783|OTHER|Thoracic mobility exercises + Conventional therapy|mobility exercises comprises of Cat and camel stretch (On hands and knees (supported with knee braces), alternating between arching the back up and dropping it down to stretch thoracic spine), Thoracic rotations in side lying (side lying on the side with knees bent, rotating the upper body to increase thoracic mobility alternatively), Thoracic extension at wall using body weight (Standing with back to wall, gently pushing the upper back into extension while keeping the lower back stable), half kneeling chop thrust (Kneeling on one knee (supported with knee braces), rotating the torso while keeping the pelvis stable to mobilize the thoracic spine) , Thoracic extension with a foam roller (Lying on the back with foam roller along thoracic spine, rolling gently to extend the thoracic spine in supine position). Adopt these positions with 5 secs hold and 15-20 reps will be performed for 2 sets and 10 reps per set.
224040129|NCT06737783|OTHER|Self myofascial release with foam roller, T6- T7 Maitland mobilization + Conventional therapy|Hamstring Self myofascial release with foam roller (Sitting with one leg extended, roll the foam roller along the hamstring while applying pressure to tender spots) 3 sets with 30 to 120 secs rolling duration per second for 5 mins T6-T7 grade 3 Maitland mobilization (Lying on the back, the therapist applies a sustained, posterior-to-anterior force on T6-T7 in prone position) 30 repetitions, with 1 min rest between 4 sets for 15 mins. Conventional therapy includes Hot pack/Cold pack + tens = 15 mins, Frequency 80 Hz, Pulse duration: 100 microseconds, Static quads (10 reps, 10 second hold, 2 sets), Active knee flexion and extension ROMs (10 reps, 5 secs hold, 2 sets), Long Axis Knee traction (5 reps, 30 secs hold, 10sec rest in b/w 2 sets), Kaltenborn Knee Glides Ant and Post direction ( 5 reps, 30 secs hold,10 sec rest interval in b/w 2 sets), Calf stretches (10 reps, 5 secs hold , 2 sets).
224040130|NCT04644380|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
224040131|NCT05054595|BEHAVIORAL|Standard Pain Management|Nurses will provide psychoeducation about pain along with common pain coping strategies, such as rest, ice, and elevation, for use any time they experience intense pain or take pain medication before and after surgery.
223430107|NCT02928783|BEHAVIORAL|Home-based cardiac rehabilitation|
223430108|NCT05542797|DRUG|Duphastone|dydrogesterone hormone
223430109|NCT05848882|DEVICE|Elastodontic Device|Removable device that embraces two dental archs
223430110|NCT03794661|DEVICE|Clinician programmer electrode screening mode tool|Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
223430111|NCT06653465|DRUG|Acetaminophen|Acetaminophen, which has similarly effects with NSAIDs in terms of inhibition of cyclooxygenase COX1, COX2 and COX3, is widely used as adjuvant for perioperative multimodal analgesia.
223430112|NCT06653465|DRUG|Saline|Saline, a kind of crystalloid widely used in clinical treatment.
223430113|NCT05935007|DEVICE|Aveir DR Leadless Pacemaker System|This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention will be conducted in this study.
223430114|NCT04236518|BEHAVIORAL|Diets with either predominantly animal protein sources.|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
223430115|NCT04236518|BEHAVIORAL|Diets with predominantly plant protein sources|20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
224040132|NCT05054595|BEHAVIORAL|Audio-Recorded Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then have them listen to a very brief (1 minute 30 second) guided mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
224040133|NCT05054595|BEHAVIORAL|Nurse-Led Mindfulness-Based Intervention|Nurses will read patients a brief (1 minute) scripted, introduction to mindfulness and then guide them through a very brief (1 minute 30 second) mindfulness practice validated in our prior research to encourage focused attention on breath and body sensations and open monitoring and acceptance of discursive thoughts, negative emotions, and pain. Finally, patients will be given an audio recording of the mindful pain management technique for use any time.
224040134|NCT05443087|OTHER|Blood sampling to build population pharmacokinetics model|"Determine for each drug plasmatic exposure (Css, trough) through the PopPK model.~Concentrations measured at the following time points:~* 1 month after the first treatment administration~* 2 months after the first treatment administration~* In case of progression~* In case of severe toxicities (AESI) related to the drug received"
224040135|NCT01091597|PROCEDURE|usual PV ablation|usual PV ablation, per above
224040136|NCT01091597|PROCEDURE|Box isolation of pulmonary veins|as above
224040137|NCT04330846|PROCEDURE|Surgical resection|The type of endoscopic treatment will be initially with EBD and if a failure treatment occurred then a SEMS will be placed.
224040138|NCT05740085|OTHER|Patient information form|Patients will be asked to fill out a patient information form and an osteoporosis awareness form
224040139|NCT04844450|DRUG|JNJ-75220795|JNJ-75220795 will be administered subcutaneously.
224040140|NCT04844450|DRUG|Placebo|Matching placebo will be administered subcutaneously.
224040141|NCT01119482|BIOLOGICAL|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
224040142|NCT01978860|DEVICE|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
224040143|NCT05034536|DRUG|Pembrolizumab|Intravenous infusion
223430116|NCT00268567|DRUG|leflunomide combined with prednisone|
223430117|NCT06439966|DRUG|ABBV-787|Intravenous (IV) Infusion
223430118|NCT06619158|PROCEDURE|Crown modification|Zirconia glaze removal and polish after crown removal to reduce roughness and prohibit plaque adhesion
223430119|NCT05296954|PROCEDURE|high resolution cartography|High-resolution electro-anatomical mapping will be performed in each group with the RHYTHMIA HDx system to obtain an activation and voltage map of the Koch triangle and surrounding areas.
223430120|NCT02075528|DRUG|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
223430121|NCT03030144|OTHER|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
223430122|NCT03825835|DRUG|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
224040144|NCT05034536|DRUG|Infliximab|Intravenous infusion
223430123|NCT03825835|DRUG|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
223430124|NCT03096769|OTHER|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
223430125|NCT03891472|DRUG|Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.|mFOLFIRINOX \> SBRT \> mFOLFIRINOX \> Surgical Intervention
223430126|NCT04865549|PROCEDURE|SNB + TAD + Lymphadenectomy|Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
223430127|NCT04448067|BEHAVIORAL|Dietary Lentil Intake|Dietary intake of moderate or high dose of lentils at midday meals
223430128|NCT04448067|BEHAVIORAL|No Dietary Lentil CONTROL|Dietary intake of meals without lentils and matched to dietary lentil meals for total energy and protein
224040145|NCT05034536|DRUG|Placebo|Intravenous infusion
224040146|NCT05034536|DRUG|Relatlimab|Intravenous infusion
224040147|NCT05034536|DRUG|Nivolumab|Intravenous infusion
224040148|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
224040149|NCT02183636|DRUG|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
224040150|NCT02183636|DRUG|Linagliptin tablet|5 mg
224040151|NCT02183636|DRUG|pioglitazone tablet (Actos®)|45 mg
224040152|NCT04635683|DRUG|Lenalidomide|Given PO
224040153|NCT04635683|BIOLOGICAL|Ublituximab|Given IV
223430129|NCT03602391|BEHAVIORAL|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
223564781|NCT01322399|PROCEDURE|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
224040154|NCT04635683|DRUG|Umbralisib|Given PO
224040155|NCT05794750|DRUG|AK104 injection|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
224139527|NCT05190536|PROCEDURE|Ho:YAG lasers|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um Ho:YAG laser fiber was used for lithotripsy.Kidney stones were fragmented by Ho:YAG lasers, and sucked out by the suction sheath.
224139528|NCT05190536|PROCEDURE|TFL|Under the guidance of B-ultrasound or X-ray, the appropriate target calyx was punctured with an 18G puncture needle.Percutaneous tract was established with 18Fr suction sheath. 12Fr nephroscope and 360um TFL fiber was used for lithotripsy.Kidney stones were fragmented by TFL, and sucked out by the suction sheath.
224139529|NCT05843305|DRUG|BPI-452080|Subjects will receive BPI-452080 until disease progression
224040156|NCT05794750|PROCEDURE|TME surgery|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
224040157|NCT05794750|DRUG|Capecitabine|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
224139530|NCT00753961|OTHER|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
224139531|NCT00753961|OTHER|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
224139532|NCT02399904|OTHER|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
223430130|NCT00293124|DRUG|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
223564782|NCT01657890|DRUG|isavuconazole|oral
223564783|NCT01349361|PROCEDURE|Daylight mediated photodynamic therapy|
223564784|NCT01598558|DRUG|Cu-64 Rituximab|Up to 14 mCi, iv
223564785|NCT05529277|OTHER|Dementia Care Management|Comprehensive assessment of health care needs of person with cognitive impairment and caregiver followed by algorithm-/ and person-based support in health care planning, implementing and monitoring
224139533|NCT05218057|PROCEDURE|Ureteroscopic lithotripsy|Ureteroscopic lithotripsy is one of the surgical procedure options for ureteric stone less than 1.5 cm. While many energy systems has been used for stone fragmentation during ureteroscopy, laser energy is the most commonly used approach for stone fragmentation.
224139534|NCT00694694|DRUG|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
224139535|NCT00694694|DRUG|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
223430131|NCT06622382|PROCEDURE|Bariatric endoscopic antral myotomy|A mucosal incision is performed using a triangle-tip knife J at the level of the incisura along the level of the greater curvature. Submucosal tunneling is then performed and stopped immediately proximal to the pylorus. Two parallel lines of partial thickness myotomy are then performed from the distal to proximal antrum using the same endoscopic knife. The myotomy is stopped approximately 2 cm distal to the mucosal incision site. Finally, the mucosal incision is closed using endoclips after haemostasis is confirmed.
223430132|NCT00559780|BEHAVIORAL|Resistance training|12 weeks of resistance training (3/week)
223430133|NCT00559780|BEHAVIORAL|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
223430134|NCT00559780|BEHAVIORAL|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
223430135|NCT05387460|DIAGNOSTIC_TEST|radiomics|Radiomics refers to high-throughput mining of quantitative image features from medical imaging. Radiomics derived data, when combined with other pertinent clinicopathological features, can produce accurate and robust evidence-based decision-making systems. Multimodal radiomics can provide more imaging feature information than single modal radiomics, which showed better diagnostic performance in previous study of kinds of cancer diseases.
223430136|NCT02101372|BEHAVIORAL|treatment as usual|case management
223430137|NCT02101372|BEHAVIORAL|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
223430138|NCT06523023|BEHAVIORAL|An integrated online program|Our integrated online program combines validated psychoeducational materials on dissociation with components of strucutred writing therapy.
223430139|NCT00372723|DRUG|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
223430140|NCT04564469|DRUG|Furosemide|A number of different protocols exist in terms of the timing of furosemide injection, (F+0) protocol in which furosemide is injected at the same time of radiotracer administration \&( F - 15)protocol in which furosemide is administered 15 min before tracer administration
223430141|NCT01097421|DRUG|Pramipexole Extended Release|
223430142|NCT00122538|DRUG|Efavirenz (EFV)|
223430143|NCT00122538|DRUG|Lamivudine (3TC)|
224040158|NCT05794750|DRUG|Oxaliplatin|Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
224040159|NCT00409253|DRUG|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
224040160|NCT00409253|DRUG|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD \>105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
224040161|NCT02890758|BIOLOGICAL|Natural Killer (NK) Cells|Dose escalation of Natural Killer (NK) Cells from two infusion of starting at Dose Level 1 (1x10\^7 cells/kg), dose Level-1 (1x10\^6 cells/kg) if 2 of 6 patients at Level 1 develop DLTs. Escalation to dose level 2 (2.5X10\^7) and Dose level 3 (5X10\^7) is dependent on DLT
224040162|NCT02890758|BIOLOGICAL|ALT803|given at 6mcg/kg weekly for four weeks
224040163|NCT05716750|DIETARY_SUPPLEMENT|Vitamin D|50,000 IU vit D treatment for 8 weeks
224040164|NCT05439434|OTHER|Fear of Pain Questionnaire for Children Short Form|administering the questionnaire twice, one week apart.
224040165|NCT05400642|DEVICE|THRIVE|Apneic ventilation
223430144|NCT00122538|DRUG|Didanosine (ddI)|
223430145|NCT01013844|BEHAVIORAL|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter \> or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
223430146|NCT02018172|DRUG|somatropin|
223430147|NCT03249246|OTHER|No intervention|
223430148|NCT05212701|DRUG|Reparixin|The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
223430149|NCT05212701|DRUG|Placebo|The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
223430150|NCT02634268|BEHAVIORAL|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
223430151|NCT02685501|OTHER|no intervention|
224139536|NCT05239312|DRUG|Antimicrobial|Implementation of antimicrobial protocol for empirical treatment which will be done according to the results of antibiotic susceptibility
223430152|NCT02381301|BIOLOGICAL|Venous blood sampling prior to CCTA.|
223430153|NCT05102825|DIAGNOSTIC_TEST|1H and Xe-129 MRI|Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).
223430154|NCT05146986|DEVICE|Non surgical and Surgical|"For non-surgical group, patients will receive non-surgical treatment (analgesia and symptomatic management treatment).~For surgical group, patients will receive surgical treatment using RibFix Blu Thoracic Fixation System."
223430155|NCT03479359|BEHAVIORAL|Routine review of DRE results by attending doctors|Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
223430156|NCT05523232|OTHER|Vibration training with 42 Hz|Vibration exposure was given using a handheld vibration device.
223430157|NCT05523232|OTHER|Vibration training with 63 Hz|Vibration exposure was given using a handheld vibration device.
223430158|NCT02985606|OTHER|Caffeine powder -60|
223430159|NCT02985606|OTHER|Caffeine powder -30|
223430160|NCT02985606|OTHER|Caffeine powder 0|
223430161|NCT02985606|OTHER|Placebo powder -60|
224040166|NCT05400642|DEVICE|mechanical ventilation|mechanical ventilation in Positive Pressure
224040167|NCT06267157|DEVICE|virtual reality training|Group that will receive breastfeeding training with virtual glasses, in the metaverse universe.
224040168|NCT06267157|OTHER|theoretical breastfeeding training|Classic 2-hour theoretical breastfeeding training with ppt
224040169|NCT06027190|DEVICE|Repetitive transcranial magnetic stimulation|"Intervention Name and Specification~1. Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~2. 70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced."
224040170|NCT06027190|DEVICE|Sham|Placebo coil (Magstim Company, Whitland, UK):
224040171|NCT00382603|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
224040172|NCT02685553|DEVICE|NIR|Laparoscopic use of NIR
224139537|NCT03666975|DEVICE|LIV 30 Hz|LivMD LIV platform
224139538|NCT02492685|DEVICE|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
224139539|NCT00671814|DRUG|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
224139540|NCT00671814|DRUG|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
224139541|NCT00671814|DRUG|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
224139542|NCT06553846|DRUG|Lutetium [177Lu]-FAP-75|Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
224139543|NCT04791033|PROCEDURE|Hysterectomy|Elective procedure with hysterectomy due to benign gynecological condition
224139544|NCT02240745|OTHER|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
224139545|NCT03110198|DRUG|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
224139546|NCT03110198|DRUG|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
224139547|NCT03110198|DRUG|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
224139548|NCT03365804|DEVICE|3D Printed Brace|All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
224139549|NCT00160576|DRUG|Levetiracetam|
224139550|NCT04148599|DRUG|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
224299421|NCT04414462|OTHER|exergaming training|"* HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)"
223430162|NCT02985606|OTHER|Placebo powder -30|
224040173|NCT01054651|DRUG|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
224040174|NCT01054651|DRUG|Praziquantel|
224040175|NCT05138523|COMBINATION_PRODUCT|Sofosdac®|Once daily fixed-dose combination of 400 mg Sofosbuvir and 60 mg Daclatasvir
224040176|NCT02479945|OTHER|Obtaining biospecimen|
224040177|NCT04317560|PROCEDURE|Arthrocentesis|2 guiding points have been created on the skin. The first one is 10 mm in front of the tragus and 2 mm below the tragus line. The second guide point is on the same line, 20 mm in front of the tragus and 6 mm below. After the auriculotemporal nerve block was made, the first 20 gauge needle was inserted from the first point. 2mL Ringer's Lactate solution is injected into the temporomandibular joint area, and then a second 20 gauge needle is entered from the second guide point determined before and pressurized washing is performed with 100 mL of 5% lactate solution to enter the first needle and exit from the second needle.
224040178|NCT04317560|PROCEDURE|injectable platelet rich fibrin injection|2 tubes of blood were collected from the patients with the help of vacuumed 10 mL special liquid PRF tubes (Choukroun I-PRF Collection Tubes, Dr. Choukroun) after arthrocentesis. Blood tubes were centrifuged at 700rpm for 3 minutes. 3 mL of liquid PRF was obtained at the top of each tube. I-PRF was injected into the joint areas of all patients in the experimental group, with a maximum dose of 2 mL per joint.
224139551|NCT04148599|DRUG|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
224139552|NCT04148599|DRUG|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
223430163|NCT02985606|OTHER|Placebo powder 0|
223430164|NCT04908215|DRUG|INM-755 (cannabinol) cream|topical cream containing cannabinol for dermal application
224139553|NCT01017809|DRUG|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
224139554|NCT04727606|DRUG|Ure-Na|"* Participants in the study will receive Oral Urea (Ure-Na) treatment at a dose of 30 grams per day (2 x 15 gram pouches per day)~* Treatment will continue for approximately 1 month."
224040179|NCT06476574|DEVICE|Vacuum-formed retainer|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.~* The retainer will be finished and delivered to the patient.~* The patient will be instructed to wear the retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement; and he will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (before wearing of the retainer)."
224139555|NCT05084794|PROCEDURE|Internal fixation|Fixation of posterior malleolus with either plate or screws.
224139556|NCT01811901|OTHER|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
224139557|NCT04968340|PROCEDURE|conventional cs|opening the lower uterine segment with introduction of the surgeon hand below the fetal head during its extraction
224139558|NCT04968340|PROCEDURE|external pop out teqnique|support of lower uterine segment without introduction of the surgeon hand below the fetal head during its extraction
224139559|NCT06194981|DRUG|Oxaliplatin and capecitabine/ S-1 and capecitabine|Drug: capecitabine: 1000 mg/m² bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1; S-1: BSA\<1.25m², 40mg bid, 1.25m²≤BSA≤1.5m², 50mg bid, BSA\>1.5m², 60mg bid, po, d1-14, oxaliplatin: 130mg/m², iv drip for 2h, d1
224139560|NCT03537820|OTHER|questionnaire|questionnaire EVAN-G
224139561|NCT00736086|DEVICE|Vessel Closure (StarClose™)|
224139562|NCT02128620|BEHAVIORAL|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
224139563|NCT02787993|BEHAVIORAL|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
224139564|NCT00536978|DRUG|ARA-C|100 mg/m\^2 IV Daily Over 1 Hour for 4 Days
224139565|NCT00536978|DRUG|BCNU|300 mg/m\^2 IV Over 1 Hour for 1 Day
224139566|NCT00536978|DRUG|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
224139567|NCT00536978|DRUG|Cyclophosphamide|1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
224139568|NCT00536978|DRUG|Etoposide|100 mg/m\^2 IV Daily Over 3 Hours for 4 Days
224139569|NCT00536978|DRUG|Fludarabine|30 mg/m\^2 IV Daily Over 1 Hour for 3 Days
224139570|NCT00536978|DRUG|Melphalan|100 mg/m\^2 IV Over 30 Minutes for 1 Day.
224139571|NCT00536978|DRUG|Rituximab|375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.
224139572|NCT00536978|OTHER|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
224139573|NCT00536978|RADIATION|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
224139574|NCT00536978|DRUG|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
224139575|NCT00536978|DRUG|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
224139576|NCT00536978|PROCEDURE|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
224139577|NCT01085305|BEHAVIORAL|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
224139578|NCT01085305|BEHAVIORAL|TAU|Usual treatment for behavioral disorders
224139579|NCT02403193|DRUG|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
224139580|NCT02403193|DRUG|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
224139581|NCT02403193|DRUG|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
224139582|NCT02403193|DRUG|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
224139583|NCT02403193|DRUG|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
224139584|NCT02403193|DRUG|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
224139585|NCT02403193|DRUG|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
224139586|NCT02403193|DRUG|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
224139587|NCT02403193|DRUG|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
224139588|NCT02782871|DEVICE|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
224139589|NCT03215394|BEHAVIORAL|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
224040180|NCT06476574|DEVICE|Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.|"* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used \& it will be finished and delivered to the patient.~* The patient will be instructed to wear the Vacuum retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the bonded retainer; and will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0."
224040181|NCT06476574|DEVICE|Lingual bonded retainer from canine-to-canine|"* After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.~* The patient will be instructed to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the retainer.~* An alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (at the same visit of the delivery of the bonded retainer)."
224040182|NCT00813163|DRUG|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
224040183|NCT02627222|OTHER|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
224040184|NCT02627222|OTHER|White cassava|Conventional white cassava
224040185|NCT01165372|DRUG|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
224040186|NCT06041620|BIOLOGICAL|VGB-Ex01|CRISPR-Cas12b editing hematopoietic stem cells
224040187|NCT05385042|DIETARY_SUPPLEMENT|Sangobion and Thiamine Hydrochloride|"Prophylactic dietary supplements: 1 capsule of Sangobion + separate Thiamine Hydrochloride tablet 100mg per day for 12 weeks.~Then non-anaemic pregnant women will continue with prophylactic nutritional supplements until delivery."
224040188|NCT05385042|DIETARY_SUPPLEMENT|Sangobion, Thiamine hydrochloride and Vitamin B12|"Treatment dietary supplements: 3 capsules of Sangobion + separate Thiamine Hydrochloride tablet 100mg, Vit B12 100mcg per day for 12 weeks.~If experience a therapeutic increase of 3% Haematocrit within 28 days (responders), they will continue with prophylactic nutritional supplements until delivery.~If no affect in Haematocrit level within 28 days (non-responders; defined by trimester of diagnosis), they will be investigated for their serum ferritin and if this is low (\<15ng/mL) intravenous (iv) iron supplement (Venofer®) will be provided. The dose will be calculated for the individual concerned (required iron dose (mg) = (2.4 x (target Hb of 11g/dL (Ht 33%) x pre-pregnancy weight (kg) +1000mg for replenishment of stores). Doses will be administered by slow iv infusion 200 mg per dose (maximum of 3 doses per week).~Following treatment they will continue with prophylactic nutritional supplements."
224040189|NCT01179672|DRUG|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
224040190|NCT01179672|DRUG|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
224040191|NCT04345081|PROCEDURE|Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction|Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
224040192|NCT04345081|PROCEDURE|Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery|Classic Skin- Sparing Mastectomy
224040193|NCT00005036|DRUG|irinotecan hydrochloride|Given IV
224040194|NCT00005036|DRUG|oxaliplatin|Given IV
224040195|NCT00005036|DRUG|leucovorin calcium|Given IV
224040196|NCT00005036|DRUG|fluorouracil|Given IV
224040197|NCT00005036|PROCEDURE|quality-of-life assessment|Ancillary studies
224040198|NCT03089242|OTHER|observation of microRNA expression|no intervention
224040199|NCT01292447|DRUG|2% lidocaine gel|120mg lidocaine x 1
224040200|NCT01292447|DRUG|Placebo gel|Inert gel x 1
224040201|NCT03174418|PROCEDURE|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
224040202|NCT01755845|DRUG|paclitaxel|
224040203|NCT01755845|DRUG|cisplatin|
224040204|NCT01755845|RADIATION|radiotherapy|
224040205|NCT04922463|DEVICE|PLASOMA|Treatment with cold plasma device
224040206|NCT00238550|DRUG|Cannabis based medicine extract (CBME)|
224040207|NCT03410849|DIAGNOSTIC_TEST|Gastroscopy|in both arms intervention 'gastroscopy' will be carried out
224040208|NCT01187550|DRUG|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.
224040209|NCT00129623|DRUG|Placebo|po monthly for 1 year
224040210|NCT00129623|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
224040211|NCT06235450|DEVICE|iLIDS100|Subject applies iLIDS accessory to the iTEAR100 device. Applies to Eyelid margin similar to commercial products
224040212|NCT01855698|OTHER|Observation|
224040213|NCT04315545|DIAGNOSTIC_TEST|meal tolerance test|In addition to the standard oral glucose tolerance (which is normally performed between 24-28 weeks of pregnancy), is used to test the metabolic resilience capacity of glucose, we will provide our participants with a different diagnostic tool named 'meal tolerance test' in an earlier stage of pregnancy (12-16 weeks), mid pregnancy (24-28 weeks) and 3 months postpartum.
224040214|NCT05805943|DRUG|IMM0306|IMM0306 is an bi-specific antibody
223430165|NCT04908215|DRUG|Vehicle Cream|topical cream base for dermal application containing no active agent
224040215|NCT00117546|DRUG|alpha methyldopa|500 mg twice a day
224040216|NCT01686009|DRUG|Intra-nasal ketamine|
224040217|NCT01617590|DRUG|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
224040218|NCT01617590|DRUG|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
224040219|NCT02616614|DRUG|Onexton|Topical gel for treating acne
224040220|NCT02616614|DRUG|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
224040221|NCT02616614|DRUG|Placebo|Vehicle gel used as a placebo
224040222|NCT01085617|BIOLOGICAL|palifermin|
223430166|NCT00740909|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
223430167|NCT01608815|BIOLOGICAL|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
224040223|NCT01085617|BIOLOGICAL|rituximab|
224040224|NCT01085617|DRUG|cyclophosphamide|
224040225|NCT01085617|DRUG|cytarabine|
224040226|NCT01085617|DRUG|daunorubicin hydrochloride|
224040227|NCT01085617|DRUG|etoposide|
224040228|NCT01085617|DRUG|fludarabine phosphate|
224040229|NCT01085617|DRUG|imatinib mesylate|
224040230|NCT01085617|DRUG|melphalan|
224040231|NCT01085617|DRUG|mercaptopurine|
224139590|NCT03215394|BEHAVIORAL|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
223430168|NCT05526378|BEHAVIORAL|Sensory Interventions|"Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure."
223430169|NCT00368693|DEVICE|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
223430170|NCT01820507|DEVICE|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
224040232|NCT01085617|DRUG|methotrexate|
224040233|NCT01085617|DRUG|nelarabine|
224040234|NCT01085617|DRUG|pegaspargase|
224040235|NCT01085617|DRUG|vincristine sulfate|
224040236|NCT01085617|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224040237|NCT01085617|RADIATION|total-body irradiation|
224040238|NCT00004172|BIOLOGICAL|filgrastim|
224040239|NCT00004172|DRUG|carboplatin|
224040240|NCT00004172|DRUG|cyclophosphamide|
224040241|NCT00004172|DRUG|ifosfamide|
224040242|NCT00004172|DRUG|thiotepa|
224040243|NCT00004172|PROCEDURE|peripheral blood stem cell transplantation|
224040244|NCT00004172|RADIATION|radiation therapy|
224040245|NCT06849388|BEHAVIORAL|Heart Math program|Heart Math program is behavior intervention through several sessions
224040246|NCT03927040|DEVICE|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
224040247|NCT04638959|OTHER|collect gastric tissue and stool samples|collect gastric tissue and stool samples
224040248|NCT06411938|OTHER|Self-collection of vaginal swabs|Women will collect vaginal swabs for HPV testing, then undergo standard of care screening for cervical cancer
224040249|NCT06516900|DEVICE|OrthoFeet HandsFree Therapeutic Shoe|Patients with foot pain will be recruited for this study and will go for an intervention of wearing OrthoFeet therapeutic shoes for 6 weeks. Each patient will be evaluated and will participate in data collection before and after intervention.
224040250|NCT05674994|DRUG|Methylprednisone/Prednisone|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Glucocorticoids Group:~* Day 1, 2 and 3: Intravenous Methylprednisolone 10 mg/kg/d (without exceeding 1000 mg/d). Vials of injectable solution of methylprednisolone® are diluted in 100 ml of NaCl 0.9% or G5%. Perfusion duration is between 20 to 30 minutes.~* From day 4 to Day 30: Oral Prednisone slow tappering~  * 1 mg/kg/d for 7 days~ * 0.5 mg/kg/d for 7 days~ * 0.25 mg/kg/d for 7 days,~ * 10 mg/d until Day 30. For 10mg/kg, 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg; rounding to 5 decimal lower if decimal ≤ 7 and the top ten if decimal ≥ 8."
224040251|NCT05674994|OTHER|Placebo|"Patients will be enrolled during their hospitalization in pneumology department, as part of current practice, within 7 days of the screening visit. The investigator will perform randomization by connecting to the eCRF, randomization be stratified for the severity of IPF and the treatment with antifibrotic therapy (Nintedanib or Pirfenidone) (yes/no).~If patient is randomized in Placebo Group:~Day 1, 2 and 3: Intravenous Methylprednisolone-Placebo From Day 4 to Day 30: Oral Prednisone-Placebo The Methylprednisolone-Placebo corresponds to 100 ml of NaCl 0.9 % or G5%. Perfusion duration is between 20 to 30 minutes.~For the Prednisone-Placebo, the placebo was an oral solution formulated with a bittering agent (pharmaceutical excipient). Specifically, in place of prednisone, sucrose octaacetate (defined as a GRAS-'Generally Recognized as Safe' excipient by the EMA) was used at 5 mg/mL."
223430171|NCT01820507|DEVICE|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
224040252|NCT00977457|GENETIC|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
224040253|NCT00977457|GENETIC|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
224040254|NCT00977457|GENETIC|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
223430172|NCT00410020|BEHAVIORAL|Alpha-linolenic enriched diet|
223430173|NCT01619644|DRUG|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
223430174|NCT01619644|DRUG|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
223430175|NCT04282291|PROCEDURE|fascial block as postoperative analgesia|The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.
223430176|NCT04282291|DRUG|Morphine|The continuous (basal) dose
223430177|NCT04282291|DEVICE|PCA CADD Smith Medical pumps|perfusion
223430178|NCT02340260|BEHAVIORAL|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
223564786|NCT06239246|OTHER|Behavioral|"Psychotherapy: Cognitive-behavioral therapy (CBT), Internet-based cognitive-behavioral therapy (I-CBT), cognitive-behavioral therapy for insomnia (CBT-I), self-management education for heart failure, blended intervention; Drug treatment (cardiovascular drugs: aspirin, clopidogrel, ticagrelor, statins; psychiatric drugs: SSRIs, SNRIs, etc.);"
224040255|NCT00977457|GENETIC|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
224040256|NCT00977457|GENETIC|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
224040257|NCT00977457|OTHER|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
224040258|NCT00977457|PROCEDURE|therapeutic conventional surgery|
223430179|NCT02340260|BEHAVIORAL|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
223430180|NCT06622460|OTHER|Hand Dexterity Assessment|to evaluate the reliability and sensitivity of the VET in healthy. Their performance helps define normal thresholds and behaviors in grip force modulation and manual dexterity.
223430181|NCT01647191|BEHAVIORAL|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
223430182|NCT01647191|BEHAVIORAL|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
223430183|NCT00522691|PROCEDURE|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
223430184|NCT03246165|PROCEDURE|Cardiac surgery|Coronary bypass, heart valve replacement
223430185|NCT02417922|OTHER|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
223430186|NCT02417922|OTHER|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
223430187|NCT02035748|DRUG|Ocriplasmin|0.5 mg/0.2 mL solution for injection
223430188|NCT01945801|DRUG|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
223564787|NCT06345482|DRUG|MHB039A|a bispecific antibody
223564788|NCT00484393|DRUG|tetracaine 4% gel|tetracaine applied prior to 1 injection
224040259|NCT05945355|DEVICE|Pro2 - Low Dose - 40% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).
224040260|NCT05945355|DEVICE|Pro2 - High Dose - 75% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).
224040261|NCT05945355|DEVICE|Pro2 - SHAM - 15% of participant's MIP|Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
224040262|NCT02652455|DRUG|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
224040263|NCT02652455|PROCEDURE|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
224040264|NCT02652455|DRUG|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
224040265|NCT02652455|DRUG|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
224040266|NCT02652455|DRUG|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
224040267|NCT02652455|BIOLOGICAL|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
224040268|NCT02652455|DRUG|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
224040269|NCT05389462|DRUG|ADCT-601|Intravenous (IV) infusion
224040270|NCT05389462|DRUG|Gemcitabine|Intravenous (IV) infusion
224040271|NCT02315898|DRUG|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
223430189|NCT01945801|OTHER|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
223430190|NCT01945801|DRUG|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
223430191|NCT03275259|DEVICE|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
223430192|NCT03540303|DRUG|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
223478381|NCT04709276|DRUG|Carboplatin|"AUC 4 mg/ml per minute intravenously every 3 weeks for up to 10 cycles.~Subjects will also receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving carboplatin."
223564789|NCT00484393|DRUG|Placebo|placebo applied prior to 1 injection
223564790|NCT00519376|DRUG|GW642444M|drug
223564791|NCT00519376|DRUG|GW642444H|drug
224040272|NCT05882344|PROCEDURE|Device Implantation- Boston Scientific, VERCISE GENUS™ system|Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.
224040273|NCT05882344|DEVICE|DBS Stimulation - Boston Scientific, VERCISE GENUS™ system|Daily intermittent stimulation (60 Hz x 20s/min)
224040274|NCT03239483|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
224040275|NCT03239483|DRUG|Placebo gel|Universal HEC placebo gel; administered rectally
224040276|NCT06404086|DRUG|Modafinil|"Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks."
224040277|NCT06404086|DRUG|Modafinil Placebo|"The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.~Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
223430193|NCT05149352|BEHAVIORAL|Treatment as usual (TAU) for depression|TAU for depression will be largely determined by the Dutch multidisciplinary practice guideline on depression (Spijker et al., 2013). This means that patients with CT-related depression will receive good clinical care, e.g. evidence-based psychotherapeutic interventions, such as cognitive behavioral therapy (CBT) or interpersonal therapy (IPT) combined with/or pharmacotherapy. Therapists who give TAU are not allowed to provide a trauma-focused intervention aimed at CT during the 12-week intervention period.
223430194|NCT05149352|BEHAVIORAL|Trauma-focused therapy (TFT)|The content of TFT, delivered by another therapist than the therapist that will provide TAU, depends on the type of CT the patient reports. If the patient predominantly reports experiences of abuse, there are often clear memories of this abuse ('target images') present and Eye Movement Desensitization and Reprocessing (EMDR) is recommended as the treatment strategy. If the patient predominantly reports experiences of neglect, memories are often less identifiable, although these experiences can have a big impact on the development of maladaptive schemas. In this case, imagery rescripting (ImRs) is recommended as treatment strategy. If the patient reports both experiences of abuse and neglect, the therapist will discuss with the patient which type of CT has the greatest impact on the current depressive symptoms and starts with the indicated therapy. If indicated, the therapist can switch between EMDR and ImRs after a minimum of 4 sessions.
223430195|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) without effect to NaOCL|Finishing files of ProTaper Gold (F2) without effect to NaOCL
223430196|NCT05310500|DIAGNOSTIC_TEST|Finishing files of ProTaper Gold (F2) with effect to NaOCL|Finishing files of ProTaper Gold (F2) with effect to NaOCL
223430197|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
223430198|NCT05310500|DIAGNOSTIC_TEST|Finishing files of Dia-X ProTaper (D4) with effect to NaOCL|Finishing files of Dia-X ProTaper (D4) without effect to NaOCL
223430199|NCT01647984|DIETARY_SUPPLEMENT|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
223430200|NCT01647984|DIETARY_SUPPLEMENT|placebo|
223430201|NCT06478849|OTHER|QUESTIONNAIRES|QUESTINNAIRES / WEBINARS
223430202|NCT04446845|DRUG|Double Stimulation (Elonva+rFSH) in luteal /follicular phase|Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
223430203|NCT04446845|DRUG|Conventional Stimulation (Elonva+rFSH) in follicular phase|From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
223430204|NCT02895308|BEHAVIORAL|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
223430205|NCT02895308|BEHAVIORAL|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
223430206|NCT06424600|OTHER|Gingival Index|The G-I index ranging between 0.5-2 was used to calculate the occurrence of severe gingival issues in participants with smoking habits. The G-I index between 0.50-1.00 displayed light gingival inflammation, G-I between 1.10-2.00 revealed moderate gingival inflammation and G-I \> 2.00 confirmed severe gingival inflammation.
223430207|NCT02049840|DEVICE|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
223430208|NCT00813670|DRUG|XPF-001|Single oral dose, or 6 days of repeated oral doses.
223430209|NCT05896722|OTHER|Core muscle endurance|Trunk flexion, trunk extension, side bridge exercises and prone bridge test developed by McGill will be used to evaluate core muscle endurance.
223430210|NCT05896722|OTHER|Upper extremity muscle strength|Isometric muscle strength assessment of the shoulder, elbow and wrist muscles will be performed with a hand-held dynamometer.
223430211|NCT05896722|OTHER|Grip strength|Grip strength will be evaluated with a hand dynamometer in the position recommended by the American Association of Hand Therapists.
223430212|NCT05896722|OTHER|Pinch strength|Pinch strength will be evaluated with a pinchmeter in three positions.
223430213|NCT05896722|OTHER|Alternate hand-wall toss test|To measure hand-eye coordination, it is performed by changing hands by throwing and catching the ball against the wall.
223430214|NCT00175032|DRUG|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
223564792|NCT00519376|DRUG|placebo|
223564793|NCT00549263|DRUG|SB797620|
224040278|NCT06404086|DRUG|Solriamfetol|"The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.~Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase."
224139591|NCT03215394|OTHER|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
224299422|NCT04414462|OTHER|training - Group II|"* Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks."
223430215|NCT00175032|DRUG|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
223430216|NCT02662400|BIOLOGICAL|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
224040279|NCT06404086|DRUG|Solriamfetol Placebo|"The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.~Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators."
224040280|NCT06404086|DRUG|Melatonin|Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
224040281|NCT06404086|DRUG|Melantonin Placebo|Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
224040282|NCT06404086|DEVICE|Tailored lighting (TL) Active|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
224040283|NCT06404086|DEVICE|Tailored lighting (TL) Placebo|TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
224040284|NCT05090371|DRUG|Ofatumumab|3 loading doses followed by administration every 4 weeks as per label
224040285|NCT05090371|DRUG|Disease modifying treatment (DMT)|Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
224040286|NCT06309225|RADIATION|Modified dose and fields intensity modulated radiotherapy|Instead of standard bilateral or extensive neck fields, the current radiation fields will cover disease with only 3cm expansion. The clinical target volumes doses are biologically equivalent to the standard but given in a shorter hypofractionated approach.
224040287|NCT05014893|COMBINATION_PRODUCT|multi-modal targeted intervention (e.g., cognitive training, exercise, games)|The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
224040288|NCT06155331|DRUG|Fenofibrate|It is an approved drug for hypercholesterolemia, It lowers lipid levels by activating peroxisome proliferator-activated receptor alpha (PPARα).
224040289|NCT06155331|OTHER|Placebo|Placebo is made to look exactly like a real drug but is made of an inactive substance.
224040290|NCT06155331|DRUG|Doxorubicin|Anthracycline derived chemotherapy used in treatment of breast cancer
224040291|NCT06155331|DRUG|Cyclophosphamide|Alkylating agent used in treatment of breast cancer
224040292|NCT05677763|DRUG|OM-85|Subjects will be administered OM-85 3.5 mg capsules by mouth once daily. (10 days per month)
223430217|NCT05399017|DEVICE|EZVent|EZVent Ventilator System is designed for respiratory support in hospitalized mechanical ventilated patients. The Ventilator is designed to be used for adults patients. It is designed to be a stationary product suitable for service in hospitals, critical care situations to provide continuous positive pres- sure respiratory support to the patient. The ventilator met EDA, ISO 80601-2-12 requirements on essential performance of critical care ventilator and other applicable international standards.
224040293|NCT05677763|DRUG|Placebo|Subjects will be administered Placebo once daily. (10 days per month)
224040294|NCT05241444|BIOLOGICAL|CD4^LVFOXP3|"Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of:~i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood."
224040295|NCT05177107|BIOLOGICAL|Bacteriophage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
224040296|NCT05177107|OTHER|Placebo|Placebo (normal saline)
224040297|NCT05352048|DEVICE|Triggered Electromyography|Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.
224040298|NCT05352048|DEVICE|Mechanomyography|SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
224040299|NCT06361810|DRUG|Pembrolizumab|"Pembrolizumab will be administer at 400 mg IV every 6 weeks in combination with 177Lu-PNT2002 until the maximum tolerated dose of 177Lu-PNT2002 is reached during the dose escalation phase.~Pembrolizumab will be administer at 400 mg IV every 6 weeks for a maximum of 17 cycles (6 weeks in each cycle) during the dose expansion phase."
224040300|NCT06361810|DRUG|177Lu-PNT2002|"177Lu-PNT2002 given intravenously every 8 weeks will be administered at 3.4 GBq, 6.1 Gbq, or 6.8 Gbq in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks until the maximum tolerated dose is reached during the dose escalation phase.~177Lu-PNT2002 given intravenously every 8 weeks will be administered at the determined maximum tolerated dose for a maximum of 4 cycles in combination with the standard dose of pembrolizumab 400 mg given intravenously every 6 weeks for a maximum of 17 cycles."
224040301|NCT06361810|DRUG|(F-18)-DCFPyL|Patients will be administered 18F-DCFPyL as a single bolus intravenous radioactive dose injection of 333 MBq (9 mCi) at screening, week 12 and week 24.
224040302|NCT02412566|DRUG|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
224040303|NCT01660607|BIOLOGICAL|CD34+ Hematopoietic Progenitor Cells (HSPC)|Purified CD34+ hematopoietic progenitor cells used in transplantation.
224040304|NCT01660607|BIOLOGICAL|Regulatory T-Cells (Treg)|Highly purified CD4+CD25+CD127-FoxP3+ regulatory T cells to reduce graft-versus-host disease.
224040305|NCT01660607|BIOLOGICAL|Conventional T-Cells (Tcon)|Conventional CD3+ T cells used for immune reconstitution and graft enhancement.
224040306|NCT01660607|PROCEDURE|Myeloablative Conditioning Regimen|Chemotherapy or total body irradiation used before hematopoietic cell transplantation.
224040307|NCT03346772|BIOLOGICAL|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
224040308|NCT05586360|DRUG|Simvastatin 40mg|Simvastatin 40mg taken orally daily for 8 weeks
224040309|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 200 mg of bosutinib
223564794|NCT01398332|DEVICE|Stent graft (EXCLUDER)|Endovascular repair
224040310|NCT01233869|DRUG|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
224040311|NCT01233869|DRUG|Placebo|Once daily oral dose of placebo
224040312|NCT00312325|DRUG|Prednisolone|
224040313|NCT02887937|DRUG|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
224040314|NCT02315677|DEVICE|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
224040315|NCT02315677|DEVICE|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
224040316|NCT03383549|OTHER|Tele-rehabilitation|Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
224299423|NCT02343783|OTHER|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
223564795|NCT04850976|DEVICE|Endotracheal intubation|Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
223564796|NCT03785860|OTHER|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
224040317|NCT02967354|RADIATION|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
224070502|NCT04017260|PROCEDURE|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
224299424|NCT04021849|OTHER|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
223564797|NCT03785860|OTHER|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
223740284|NCT01365780|PROCEDURE|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
224040318|NCT05461482|OTHER|Pre-procedural consultation and audiovisual tools|In addition to the information provided by the referring physician, an interventional radiologist will assist the patient in a consultation before the intervention to inform him, explaining the objective of the intervention, its risks and benefits, and possible alternatives and doubts related to the intervention. In this group, educational videos will be used, one for each type of intervention, which will complement the explanations of the physician. The videos will aim to present in an understandable way the preparation for the intervention, its objective, the benefits and risks that derive from it and what you can expect once it has been carried out. Patients will have access to the videos before attending the consultation and will view them before being seen by the interventional radiologist.
224040319|NCT05141214|BEHAVIORAL|Virtual Reality Application|In VR application, Chaos Café, patients are immersed into a computer-generated kitchen environment. A humorous robotic chef serves children different food groups. Gameplay is advanced by choosing healthy foods, while eating unhealthy foods does not advance the application.
224040320|NCT01611753|OTHER|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
223740285|NCT03271879|DRUG|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
224040321|NCT00399386|PROCEDURE|EP|
224040322|NCT00399386|PROCEDURE|ICD|
224040323|NCT00399386|PROCEDURE|Ablation|
224040324|NCT05829707|DRUG|Diclofenac Sodium|"A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4"
224040325|NCT05829707|DRUG|Levobupivacaine bolus analgesia|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4."
224040326|NCT05829707|DRUG|Levobupivacaine PCA group|"The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain \>4 on the VAS, and meperidine 20-30 mg for VAS \>or = 4."
224040327|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
224040328|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.
224040329|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.
223740286|NCT04718220|DIAGNOSTIC_TEST|Antibody testing for SARS-CoV-2 IgG|Women enrolled into the unexposed (SARS-CoV-2 negative) cohort will undergo testing for SARS-CoV-2 IgG antibodies at enrollment, every trimester of pregnancy, and during delivery hospitalization.
224040330|NCT00930514|DRUG|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.
224040331|NCT00930514|DRUG|Rituximab|Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
224040332|NCT00324129|DRUG|MGCD0103|MGCD0103 given orally three times per week.
224139592|NCT03215394|BEHAVIORAL|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
224139593|NCT01694576|DRUG|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
224139594|NCT04200105|DEVICE|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 22G EBUS needle
224139595|NCT04200105|DEVICE|Acquire TBNB|Mediastinal and hilar lymph node sampling using the Acquire TBNB needle
224139596|NCT03039127|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
224139597|NCT03924791|DRUG|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
224139598|NCT03924791|DRUG|Methylprednisolone Acetate|In combination with lidocaine
224139599|NCT03924791|DRUG|Dexamethasone|In combination with lidocaine
224139600|NCT00538980|DRUG|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
224139601|NCT04705324|PROCEDURE|Operative Hysteroscopy|Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy
224139602|NCT04705324|PROCEDURE|D&C|Separation of the non-viable gestational sac from the uterine wall through dilation and curettage
224040333|NCT03267953|BEHAVIORAL|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
224040334|NCT03267953|BEHAVIORAL|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
224040335|NCT03267953|BEHAVIORAL|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
224040336|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
224040337|NCT01775839|DRUG|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
224040338|NCT05073679|DRUG|Naltrexone Hydrochloride|25mg x 3 days then 50mg a day thereafter
224040339|NCT05073679|OTHER|Control|Methylcellulose and gelatin capsule only
224040340|NCT03508258|OTHER|Non-interventional|Non-interventional
224040341|NCT03508258|OTHER|Non-Interventional|Non-Interventional
224040342|NCT01765868|DRUG|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
224040343|NCT05364268|DEVICE|Diagnostic Test: Diagnostic Software as Medical Device|AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses, specifically COVID-19 illness for this study.
224040344|NCT00533468|DRUG|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
224040345|NCT00533468|DRUG|Placebo|inactive placebo without LMX4
224040346|NCT00973154|DRUG|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
224040347|NCT02613351|DEVICE|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
224040348|NCT00301158|BEHAVIORAL|exercise intervention|
224040349|NCT00301158|OTHER|counseling intervention|
224040350|NCT00301158|OTHER|educational intervention|
224040351|NCT00301158|PROCEDURE|complementary or alternative medicine procedure|
224040352|NCT05696236|DEVICE|Transepidermal water loss (TEWL) monitor and stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will also be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers. If they numbers match the stopping rules, they will tell the doctor and the oral food challenge will be over.
224040353|NCT05696236|DEVICE|Monitor (TEWL) without stopping rules|The oral food challenge will be done as usual, and participants will wear the TEWL monitor. The research food allergy nurse and doctor will be looking for signs and symptoms of an allergic reaction. The research study coordinator will be watching the TEWL numbers, but the stopping rules will not be used to end the oral food challenge.
224040354|NCT00366483|DRUG|Lecozotan SR|
224040355|NCT01145495|OTHER|Laboratory Biomarker Analysis|Correlative studies
224040356|NCT01145495|DRUG|Lenalidomide|Given PO
224299425|NCT04021849|OTHER|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
224040357|NCT01145495|BIOLOGICAL|Rituximab|Given IV
224040358|NCT06073236|BEHAVIORAL|The healthy day-project|The content of the intervention will be based on what comes out of the cocreation sessions, which means that it is not yet possible to know what the intervention will exactly consist of. The idea is to compile two co-creation groups, both consisting of preschool teachers and preschoolers' parents. Within both co-creation groups, feasible and easy-to-use strategies to implement both at preschool and at home embedded within preschoolers' play-based learning will be the goal. Both co-creation groups will investigate and develop ways to incorporate play-based learning within health promotion throughout the day at home and at preschool.
224040359|NCT06159023|DEVICE|bronchial washing using a thin bronchoscope|For intervention, we plan to perform bronchial washing using a thin bronchoscope instead of bronchoalveolar lavage with the conventional thick bronchoscope to diagnose pulmonary TB.
224040360|NCT03216421|OTHER|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
224040361|NCT04668651|OTHER|antral ultrasound|Preoperative evaluation of gastric contents by antral ultrasound
224040362|NCT00593749|BEHAVIORAL|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
224040363|NCT00593749|BEHAVIORAL|Control|control group in study
224040364|NCT04512443|DRUG|Daflon|All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
224040365|NCT04029220|BEHAVIORAL|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
224040366|NCT01805167|OTHER|Electrophysiological study of the interindividual variability of vocal performance|
224040367|NCT00193869|DRUG|Dexamethasone|
224040368|NCT04674514|DRUG|APG-2575|APG-2575 orally once daily, every 28 days as a cycle.
224040369|NCT04674514|DRUG|Rd|Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.
224040370|NCT04431401|DEVICE|Magstim rTMS|The device is made in London,UK
224139603|NCT04705324|PROCEDURE|Operative Hysteroscopy - safety and feasibility|Operative hysteroscopy - safety and feasibility phase
224139604|NCT04505696|OTHER|Speech-Language Pathology Presentation|45 minutes presentation on Speech-Language Pathology introduction and scope Introduction to speech and language Introduction to a range of disorders The scope of practice
224139605|NCT05935904|OTHER|Exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
224139606|NCT05935904|OTHER|Non exposure|"Dietary habits:~Data collected using food frequency questionnaire~Risk factors associated with metabolic syndrome:~Data collected on nutritional status, biochemical indicators and other risk factors associated with metabolic syndrome progression during pregnancy~Pregnancy outcomes:~Adverse pregnancy and birth outcomes."
223430218|NCT04495816|DRUG|Omega-3 Fatty Acid Supplement|Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks. They will receive softgels containing 1,000 mg of omega-3 fatty acid. 1000 mg of omega-3 fatty acid blend including 683 mg Eicosapentaenoic Acid and 252 mg Docosahexaenoic Acid
223430219|NCT04495816|DRUG|Placebo/Control|Patients randomized to this arm will also be instructed to take two of the softgels they received per day for 6 weeks. They will receive placebo softgels that are indistinguishable from those containing fish oil.
223430220|NCT01778699|DIETARY_SUPPLEMENT|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
223430221|NCT05448287|BEHAVIORAL|Health and family planning|Promotion of health and family planning behaviors
223430222|NCT05448287|BEHAVIORAL|Nutrition|Promotion of maternal, infant, and young child feeding behaviors and nutrition
223564798|NCT02650128|DEVICE|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
223430223|NCT05448287|BEHAVIORAL|Agriculture and homestead food production|Promotion of knowledge and practices about homestead food production
223430224|NCT05448287|BEHAVIORAL|Water, sanitation, and hygiene|Promotion of behaviors to improve water, sanitation, and hygiene
223430225|NCT00428051|OTHER|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
223430226|NCT02707315|DRUG|Gemcitabine|
223430227|NCT02707315|RADIATION|Stereotactic Radiosurgery|
223564799|NCT01385111|PROCEDURE|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
224040371|NCT01560689|DRUG|Budesonide/formoterol|800 µg/j twice a day, every day
224040372|NCT01560689|DRUG|Placebo|Twice a day, every day
224040373|NCT02060721|DRUG|Macitentan|Macitentan 10mg, oral tablet, once daily
224040374|NCT00117507|DRUG|Deferasirox|
224139607|NCT06406686|PROCEDURE|Ablation of the Cavo-tricuspid isthmus for typical Atrial Flutter|Durable block across the cavotricuspid isthmus by radiofrequency ablation.
223430228|NCT03889470|DRUG|NTG 1 MG/ML Injectable Solution|administered after sheath placement
223564800|NCT01385111|PROCEDURE|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
224040375|NCT05105789|DIAGNOSTIC_TEST|BinaxNOW Test|diagnostic test for SARS-CoV-2
224040376|NCT05105789|DIAGNOSTIC_TEST|"Lollipop swab"|A lollipop swab, is an oral swab to collect saliva, sucked on like a lollipop for 20 seconds.
224139608|NCT03698513|DRUG|BMS-986177|BMS-986177 capsule
224139609|NCT03698513|OTHER|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
224139610|NCT03698513|DRUG|Clopidogrel|Clopidogrel tablet
224139611|NCT03698513|DRUG|Aspirin|Aspirin tablet
224139612|NCT01592890|DRUG|RO4917523|\[14C\]-labeled RO4917523, single oral dose
224139613|NCT01592890|DRUG|RO4917523|\[13C\]-labeled RO4917523, single intravenous tracer dose
223430229|NCT06477068|COMBINATION_PRODUCT|Mobile medical reminder application|"Experimental group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department, in addition to being supported through the telemedicine medication reminder app on smartphones.~Control group: Patients undergoing ovarian stimulation in the Infertility Department at Hung Vuong Hospital are prescribed and instructed to inject medication according to the current procedure of the department."
224040377|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 55% correction|HTO using PSI designed to achieve correction to 55% tibial width.
224040378|NCT06134050|PROCEDURE|Procedure: HTO using PSI aiming at 62% correction|HTO using PSI designed to achieve correction to 62% tibial width.
224040379|NCT04072289|DEVICE|Visumax spherocylindrical treatment|treatment of low cylinder (\<0.75D)
224040380|NCT00389233|DRUG|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
223430230|NCT02052596|BIOLOGICAL|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
223564801|NCT02553980|BEHAVIORAL|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
223564802|NCT02553980|OTHER|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
223564803|NCT03006029|DRUG|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
223564804|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|2.5 grams of PGX
224040381|NCT00389233|DRUG|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
224040382|NCT05928130|OTHER|plyometric training protocol|"The plyometric training program will last for 4 weeks, with three sessions per week. The plyometric exercises will be performed immediately after a warm-up. The program will incorporate bilateral, unilateral, acyclic, cyclic, horizontal, vertical, lateral, and diagonal movements involving both slow and fast movements.~Each session will include 4-5 plyometric exercises, with 2-10 sets per exercise and 1-10 repetitions per set. The training volume will progressively increase from the 1st to the 2nd week and then the intensity will increase while the volume decreases from the 3rd to the 4th week in both intervention groups. However, the final volume will vary by 50% between the groups."
224040383|NCT02005081|DEVICE|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
224040384|NCT02005081|DEVICE|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
224040385|NCT00198952|DRUG|DietPro|
223430231|NCT02052596|BIOLOGICAL|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
223430232|NCT06269016|OTHER|expremental pre and post test|effect of strengthening exercise of combined hip strengthening exercises and pelvic floor exercises
223430233|NCT00558896|DRUG|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
223564805|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|5.0 grams of PGX
223564806|NCT00935350|DIETARY_SUPPLEMENT|PolyGlycopleX (PGX)|0 grams of PGX
224040386|NCT00198952|DRUG|Placebo|
224040387|NCT01222637|DRUG|CetuGEX™|
224040388|NCT01538797|DRUG|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
223430234|NCT00558896|DRUG|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
223430235|NCT05964517|OTHER|Fascial Distortion Model|Facial Distortion is a manual therapy technique applied by model physiotherapists. It is a deep tissue massage to the fascial tissue.
223430236|NCT06119334|BEHAVIORAL|Online intervention|Phone counselling for 1 hour/week over 16 weeks and access to the online platform with health promotion materials (videos, text, audios)
223430237|NCT00150124|DRUG|MTZ+LT4|
223564807|NCT03846726|PROCEDURE|standard TME surgery|radical resection for rectal cancer
223564808|NCT00635739|DIETARY_SUPPLEMENT|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
223564809|NCT00635739|DIETARY_SUPPLEMENT|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
223564810|NCT03456791|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
223564811|NCT05250050|DRUG|Esomeprazole|20mg bid
223564812|NCT05250050|DRUG|Bismuth potassium citrate|0.6g bid
223564813|NCT05250050|DRUG|Metronidazole|0.4g qid
224040389|NCT01538797|DRUG|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
224040390|NCT05029960|DRUG|Brivaracetam|Dose of 50 mg twice daily for 6 months
224139614|NCT06011330|DRUG|Fruquintinib combined with anti-PD-1 antibodies|Fruquintinib (3-5mg once daily for 21 days on/7 days off) anti-PD-1 antibodies (including sintilimab, toripalimab, pembrolizumab, tislelizumab, and nivolumab).
224139615|NCT06156358|OTHER|No intervention|No intervention
224139616|NCT04129606|DIAGNOSTIC_TEST|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
223430238|NCT00150124|DRUG|Methimazole|
223430239|NCT00705718|DEVICE|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
223430240|NCT00497978|DIETARY_SUPPLEMENT|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
223430241|NCT00497978|DIETARY_SUPPLEMENT|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
223430242|NCT06620211|PROCEDURE|promontofixation, prolapse cure|Patient who underwent surgery to place the Sacromesh® medical device (promontofixation) for a prolapse cure, between 2009 and 2018
223430243|NCT06649461|PROCEDURE|ozone injections|Ozone injections (5 mL/10 μg/dL) were administered under aseptic conditions, with the wrist fixed in dorsiflexion, and with the insulin injector, a 23-gauge needle was inserted between the palmaris longus and flexor carpi radialis muscles at a 45-degree angle from the palmar distal line (Salutem/19147884379).
223430244|NCT06649461|OTHER|Splint|hand splint for night
223430245|NCT04669951|OTHER|uPAR immunohistochemistry|Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
223430246|NCT01881997|DRUG|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
223430247|NCT01881997|DRUG|Normal Saline|IM normal saline
223430248|NCT05562765|OTHER|Survey|A descriptive characteristics form, the General Comfort Scale and Quality of Life Index Cardiac Version-IV was used to collect data.
223430249|NCT02632240|OTHER|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
223430250|NCT03260517|DEVICE|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
223430251|NCT06041425|DRUG|Oxycodone|The patients were given 0.1mg/kg oxycodone 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
223430252|NCT06041425|DRUG|Sufentanil|The patients were given 0.1μg/kg sufentanil 15 minutes before transcatheter arterial chemoembolization (TACE). WBC count, neutrophil percentage, CRP, and IL-6 were used as inflammatory markers and measured before TACE (1 day before TACE) and 24 hours after TACE. Assess pain and side effects during TACE and within 24 hours after TACE. Pain was evaluated using the 11 point Numeric Rating Scale (NRS).
223430253|NCT02402634|OTHER|Mechanical ventilatory lung care|
224040391|NCT05291000|BEHAVIORAL|The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)|The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
224139617|NCT06017947|PROCEDURE|Music care|20 min music listening during transportation to hospital
224139618|NCT03586882|DEVICE|Spinal Cord Stimulation|Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
224139619|NCT05633134|PROCEDURE|Arteriography and precision preoperative embolization|Arteriography and transcatheter arterial embolization of pelvic tumors 0-24 hours prior to surgery.
223430254|NCT04855617|DRUG|Ocrelizumab|"Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion"
223430255|NCT02333721|PROCEDURE|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
223430256|NCT02333721|PROCEDURE|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
223430257|NCT00463216|BEHAVIORAL|A multidisciplinary diagnostic evaluation|
223430258|NCT06137703|DRUG|Zavegepant 100mg non-enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
223430259|NCT06137703|DRUG|Zavegepant 100mg immediate release tablet|Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
223430260|NCT06137703|DRUG|Zavegepant 2 x 100mg immediate release tablets|2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
223430261|NCT06137703|DRUG|Zavegepant 4 x 25mg enteric coated soft gel capsule|Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
223478382|NCT04709276|DRUG|Cabazitaxel|"20 or 25 mg/m2 intravenously every 3 weeks for up to 10 cycles.~Subjects will also take prednisone by mouth at a dose of 10 mg daily and receive granulocyte-colony stimulating factor (G-CSF) therapy while receiving cabazitaxel."
223478383|NCT07101445|DRUG|Acetaminophen|Given by mouth (PO).
223478384|NCT07101445|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223478385|NCT07101445|DRUG|Dexamethasone|Given intravenously (IV).
223478386|NCT07101445|OTHER|Electronic Health Record Review|Ancillary studies
223430262|NCT02161003|PROCEDURE|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
223430263|NCT02161003|PROCEDURE|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
223430264|NCT02160847|BEHAVIORAL|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
223430265|NCT04794205|DRUG|Low Dose Beta-Caryophyllene|5 mg BCP
223430266|NCT04794205|DRUG|Medium Dose Beta-Caryophyllene|30 mg BCP
223430267|NCT04794205|DRUG|High Dose Beta-Caryophyllene|150 mg BCP
223430268|NCT04794205|DRUG|Placebo|Placebo drug.
223430269|NCT02550392|BEHAVIORAL|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
223430270|NCT01971762|BEHAVIORAL|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
223430271|NCT01971762|BEHAVIORAL|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
223430272|NCT01729520|OTHER|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
223430273|NCT04329091|DRUG|Dexmedetomidine|All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.
223430274|NCT02594189|OTHER|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
223430275|NCT05473689|DEVICE|Continuous positive airway pressure (CPAP) therapy|Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
223430276|NCT04106089|BEHAVIORAL|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
223430277|NCT06620094|OTHER|diabetes education videos|In the initial meeting during the preparation phase, participants in the experimental group were informed about the notifications and diabetes education videos that would be sent to their phones. Afterward, the patients received three notifications daily, every day of the week. The first notification requested them to ;measure and record their fasting and postprandial blood sugar in the morning; The second notification instructed them to ;exercise for at least 30 minutes a day.; The third notification asked them to ;record the foods they consumed and their quantities, and to measure and record their evening fasting and postprandial blood sugar, as well as their blood sugar before going to bed.; Additionally, during their routine outpatient follow-ups, the results of their tests (A1C, BMI, total cholesterol, HDL, LDL, triglycerides), blood pressure, and weight measurements were recorded. Furthermore, three times a week, participants were asked to ;measure and record their blood pressur
223430278|NCT00741091|DEVICE|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
223430279|NCT00741091|DEVICE|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
224040392|NCT05162638|PROCEDURE|thoracic duct cannulation|"Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling."
224040393|NCT02797067|DRUG|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
224040394|NCT02797067|DRUG|Glycerin Suppository|30min before ESWL
223430280|NCT03837119|OTHER|pregnancy outcome|descriptive statistics of variables
223564814|NCT05250050|DRUG|Clarithromycin|0.5g bid
223564815|NCT05250050|DRUG|Levofloxacin|0.5g qd
223564816|NCT05250050|DRUG|Amoxicillin|1g bid
223564817|NCT05250050|DRUG|Tetracycline|0.5g qid
223564818|NCT06038526|PROCEDURE|Biospecimen Collection|Undergo buccal, nasal, and blood sample collection
223564819|NCT06038526|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
223564820|NCT06038526|BIOLOGICAL|Canakinumab|Given SC
223564821|NCT06038526|PROCEDURE|Carbon Monoxide Measurement|Undergo CO testing
224139620|NCT05633134|PROCEDURE|Arteriography|Arteriography of pelvic tumors 0-24 hours prior to surgery.
224139621|NCT00005612|BIOLOGICAL|filgrastim|
224139622|NCT00005612|DRUG|carboplatin|
224139623|NCT00005612|DRUG|cyclophosphamide|
224139624|NCT00005612|DRUG|etoposide|
224139625|NCT00005612|DRUG|paclitaxel|
224139626|NCT00005612|DRUG|topotecan hydrochloride|
224139627|NCT00005612|PROCEDURE|peripheral blood stem cell transplantation|
224139628|NCT05642013|PROCEDURE|Early prosthesis reimplantation|Early prosthesis reimplantation, within 16 to 30 days after implants removal
224139629|NCT05642013|OTHER|Retrospective analysis of medical records|Analysis of 50 records of operated patients managed with classical two-stage implant exchange
224040395|NCT01610362|BIOLOGICAL|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
224040396|NCT03943862|BEHAVIORAL|2Share|"The peer-led group program contains of three lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~* Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~* Lesson 3: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants will discuss their experiences with disclosure or non-disclosure."
224040397|NCT03995901|BIOLOGICAL|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
223430281|NCT04303936|DEVICE|SenseWear® armband device|"Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life, sleep"
224040398|NCT00323297|DRUG|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
223430282|NCT03122613|DIETARY_SUPPLEMENT|Curcumin|3g of Curcumin per day
223430283|NCT03122613|DRUG|Placebo|3g of Curcumin Placebo per day
224040399|NCT00323297|OTHER|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
224040400|NCT00323297|DRUG|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
224040401|NCT00323297|DRUG|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
224040402|NCT04823715|OTHER|TACE + hypofractionated EBRT|One cure of doxorubicin or DC Beads transarterial chemoembolization by a highly experienced interventional radiologist, followed 1 to 4 weeks later by hypofractionated external beam radiation therapy up to a total dose of 45-60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
224040403|NCT04823715|PROCEDURE|Surgical resection|Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma by a highly experienced liver surgeon
224040404|NCT04092062|DEVICE|ToothWave|RF-utilizing powered toothbrush for teeth whitening
224040405|NCT04092062|DEVICE|powered toothbrush|regular powered toothbrush with no RF
224040406|NCT05061784|PROCEDURE|Routine thymectomy, which has been performed|There is no intervention
224040407|NCT03047759|DEVICE|water flosser|Powered
224040408|NCT03047759|DEVICE|air floss|Powered
224040409|NCT00460057|DRUG|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
224040410|NCT05997862|DEVICE|HFFS|This study introduces a new way to exercise using a hip flexion feedback system (HFFS). The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. The HFFS monitors the subject's heart rate during the exercise using a standard heart rate monitor. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated by the HFFS based on real-time heart rate readings. Therefore, the HFFS can help people stay at a specific exercise intensity by controlling how high it tells them lift their knees during the exercise.
224040411|NCT06528639|BEHAVIORAL|HIIT|Three times a week, 10 sets each session, for 24 weeks of high-intensity interval training.
224040412|NCT01343485|BEHAVIORAL|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
223430284|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
223430285|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
223430286|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
223430287|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
223430288|NCT02566603|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
223564822|NCT06038526|OTHER|Survey Administration|Ancillary studies
224139630|NCT01290133|DRUG|GW597599|Single dose IV infusion
224139631|NCT01290133|DRUG|Placebo|Single dose IV infusion
224139632|NCT04389580|DRUG|Drug: Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days starting after three days of taking tamoxifen"
223430289|NCT06166043|BEHAVIORAL|NURSE FOLLOW-UP PROGRAM SUPPORTED WITH WEB-BASED EDUCATION|An online training consisting of 10 sessions in total for 5 weeks will be given to the patients in order to improve their fatigue management skills. In addition to this training, they will receive a nurse support program.
223430290|NCT01527487|DRUG|Eribulin|1.4 mg/m2 IV (Days 1 \& 8), given short (≤15 minute) IV infusion, per institutional standard
223430291|NCT01527487|DRUG|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
224139633|NCT04389580|DRUG|Aerosolized Isotretinoin plus Tamoxifen|"20 mg PO (by mouth) twice daily for 14 days~Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days starting after three days of taking tamoxifen"
223430292|NCT01527487|DRUG|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
223430293|NCT00108342|DRUG|Nicotine gum - 2 mg and 4 mg|
224040413|NCT02129153|BEHAVIORAL|LIFT (Parent Information)|"1. Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~2. Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
224040414|NCT01695915|PROCEDURE|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
224040415|NCT00114192|DRUG|docetaxel|
223430294|NCT00108342|DRUG|Nicotine lozenges - 2 mg and 4 mg|
223430295|NCT00108342|DRUG|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
224040416|NCT00114192|DRUG|thalidomide|
224040417|NCT04811638|OTHER|Validation of the Chelsea Critical Care Physical Assesment Tools|The validation of the CPAX tools will focus on the validity of constructs, internal consistency reliability and test-retest reliability. PFIT used for criterion validity.
224040418|NCT02160704|DRUG|Enclomiphene citrate|25 mg daily for 16 weeks
224040419|NCT02160704|OTHER|Placebo|placebo daily for 16 weeks
224139634|NCT04586868|BEHAVIORAL|An intervention development study|Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
224139635|NCT04586868|BEHAVIORAL|A randomized feasibility study|Feasibility of virtual reality environment for adolescents with psychosis
224139636|NCT04586868|BEHAVIORAL|A single-case study|The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
224040420|NCT01394471|DRUG|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
224139637|NCT03550131|BEHAVIORAL|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
224139638|NCT03550131|BEHAVIORAL|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
223430296|NCT00108342|OTHER|Computer learning|
223430297|NCT00292110|DRUG|Methadone|100 mg/day orally
223430298|NCT00292110|BEHAVIORAL|Contingency Management|Incentives given for cocaine abstinence
224040421|NCT01641809|DRUG|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
224139639|NCT00118027|DRUG|sulphadoxine-pyrimethamine intermittent preventive treatment|
224139640|NCT06288958|OTHER|Quality of Life and social participation in Italian children with CP|CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
224139641|NCT04540081|OTHER|Epic Healthy Planet Population Health Module|Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
224139642|NCT02008838|DIETARY_SUPPLEMENT|Synbiotic|
223430299|NCT00292110|DRUG|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
223430300|NCT00292110|BEHAVIORAL|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
223430301|NCT04147624|DRUG|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
223430302|NCT04147624|OTHER|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
223478387|NCT07101445|DRUG|Famotidine|Given by mouth (PO).
223478388|NCT07101445|DRUG|Loratadine|Given by mouth (PO).
223478389|NCT07101445|DRUG|Methylprednisolone|Given intravenously (IV).
223478390|NCT07101445|DRUG|Montelukast|Given by mouth (PO).
223478391|NCT07101445|DRUG|Motixafortide|Given subcutaneously (SC).
223478392|NCT07101445|PROCEDURE|Pheresis|Undergo apheresis
223478393|NCT07101445|OTHER|Questionnaire Administration|Ancillary studies
223478394|NCT07101445|BIOLOGICAL|Recombinant Granulocyte Colony-Stimulating Factor|Give Granulocyte Colony-Stimulating Factor (G-CSF).
223478395|NCT06410534|DRUG|nivolumab|Nivolumab will be dosed at 3 mg/kg and given as an IV over 30-60 minutes on day 1 of each cycle. It will be administered every 3 weeks (21 days) for up to 8 cycles
223478396|NCT06410534|DRUG|ipilimumab|Ipilimumab will be dosed at 1 mg/kg and given as an IV over approximately 30 minutes on day 1 of every other cycle (every 6 weeks or 42 days) for up to 4 doses
223478397|NCT06690281|BIOLOGICAL|KRAS TCR-Transduced PBL|Day 0: Cells will be infused intravenously (IV) over 20-30 minutes (2-4 days after the last dose of fludarabine)
224139643|NCT02008838|DIETARY_SUPPLEMENT|Placebo|
224139644|NCT06553950|DRUG|Botox injection|"Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle."
224139645|NCT06553950|DRUG|Mandibular stabilization splint|Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
224139646|NCT06553950|DRUG|Muscle relaxant|Patients will be treated by medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
223564823|NCT06305195|DIAGNOSTIC_TEST|heart rate variability test|"First, the patient is required to lie on their back to have a 5-minute continuous ECG recorded, without performing any maneuvers.~Following this, deep breath test, Valsalva and stand test are performed."
223564824|NCT04131205|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
224040422|NCT01641809|DRUG|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
224040423|NCT01641809|DRUG|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
224040424|NCT01641809|DRUG|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
224040425|NCT01641809|DRUG|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
224040426|NCT01641809|DRUG|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
224040427|NCT01641809|DRUG|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
224040428|NCT00146081|BEHAVIORAL|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
224040429|NCT01832363|DRUG|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
224040430|NCT01832363|OTHER|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
224040431|NCT05518864|DEVICE|IALURIL Prefill|GAG therapy (bladder instillations with glycosaminoglycans)
224040432|NCT05906823|OTHER|Detection of pleural effusion|Detection of pleural effusion
224040433|NCT00527254|DEVICE|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
224040434|NCT02257216|OTHER|Vayarin®|Medical Food
224040435|NCT02257216|OTHER|Placebo|Cellulose
224040436|NCT00036894|DRUG|lenalidomide|
224040437|NCT00361491|DRUG|SSR149415|
224040438|NCT00064389|DRUG|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
224040439|NCT00064389|DRUG|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
224040440|NCT01829399|DRUG|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
224040441|NCT01829399|DRUG|Normal Saline|
224040442|NCT03543696|RADIATION|Single Dose Radiotherapy (SDRT)|
224040443|NCT02435589|OTHER|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
224040444|NCT02435589|OTHER|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
224040445|NCT07129070|BEHAVIORAL|Interpersonal Psychotherapy-Adolescent Skills Training via Just-In-Time Training (JITT) implementation strategy|"IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships.~JITT-EBP integrates (a) self-directed, on-demand, online training modules for mentors and mentor supervisors, (b) synchronous evidence-based supervision strategies, and (c) an apprenticeship delivery model in which EBPs are co-led by an experienced mentor and a novice mentor, providing opportunity for in-the-moment training and support."
224040446|NCT07129070|BEHAVIORAL|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST) implemented via usual training|"IPT-AST is a group-based EBP that aims to prevent depression and support emotional well-being by helping youth develop skills to foster healthy relationships. Youth learn about the links between feelings and interpersonal interactions, and they learn communication strategies and interpersonal problem-solving skills that they can apply to their relationships.~Usual training involves (a) a one-day virtual training conducted by an IPT-AST expert prior to the beginning of the intervention, and (b) synchronous evidence-based supervision strategies."
224040447|NCT03672461|OTHER|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
224139647|NCT03321214|OTHER|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is \< 20 ppm or a wheat icon for \> 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
224139648|NCT01928043|DRUG|Curcumin|
223430303|NCT01967641|DRUG|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
223430304|NCT00723190|DRUG|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
224139649|NCT04680078|PROCEDURE|Placement of three interrupted sutures after Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. The sutures are removed 1 week after the surgery.
224139650|NCT04680078|PROCEDURE|Conventional Triangular Three-snip Punctoplasty of the lower punctum|A Nettelship dilator is used to enlarge the stenotic lacrimal punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is then removed .
224139651|NCT00005847|BIOLOGICAL|recombinant interferon alfa|
224139652|NCT00005847|DRUG|estramustine phosphate sodium|
224139653|NCT00005847|DRUG|isotretinoin|
224139654|NCT00005847|DRUG|mitoxantrone hydrochloride|
223430305|NCT06648902|DRUG|meldonium|500 mg (Arm A) or 1,000 mg (Arms B and C) orally daily, weeks 1-6
223430306|NCT04660318|DEVICE|Remote photoplethysmography for physiological parameters|physiological parameters will be acquired using the Remote photoplethysmography software simultaneously for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
224040448|NCT03672461|OTHER|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants."
224040449|NCT05386784|DRUG|Raloxifene plus cholecalciferol|Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily
224139655|NCT00005847|DRUG|paclitaxel|
224139656|NCT00005847|DRUG|vinorelbine ditartrate|
224139657|NCT01357304|BEHAVIORAL|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
224139658|NCT00191074|DRUG|somatropin, rDNA origin, for injection|
224299426|NCT05669183|PROCEDURE|Veno-arterial extracorporeal membrane oxygenation|Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
223430307|NCT04660318|DEVICE|standard acquisition system for physiological parameters|physiological parameters will be acquired using the standard acquisition system for the conventional parameters measurements (heart rate, respiratory rate, and oxygen saturation)
223430308|NCT02400567|DRUG|Fluorouracile|
223430309|NCT02400567|DRUG|Epirubicin|
223740287|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 RNA|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of placental tissue, umbilical cord blood, amniotic tissue, and neonates for SARS-CoV-2 RNA, as available.
224040450|NCT05386784|DRUG|Cholecalciferol|D3 oral base drop, 4 drops once daily (800 IU)
224139659|NCT02074306|DEVICE|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
224139660|NCT02074306|DEVICE|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
224299427|NCT04934449|DEVICE|Occlusal splint|Using occlusal splints during sleep for 2 months
224299428|NCT01805830|DRUG|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
223430310|NCT02400567|DRUG|Cyclophosphamide|
223430311|NCT02400567|DRUG|Letrozole|
223430312|NCT02400567|DRUG|Palbociclib|
223430313|NCT03181503|DRUG|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
224040451|NCT07130045|OTHER|Hybrid Endurance Strength Training|HybEST will be delivered three times weekly over eight weeks, with two supervised sessions at the center and 22 unsupervised sessions at home. The exercise characteristics of supervised HybEST and unsupervised HybEST are described. Monitoring methods for unsupervised HybEST include a wearable tracking device that collects data on patients' health parameters (arterial oxygen saturation (SpO2), heart rate, and blood pressure) and weekly phone calls. The unsupervised sessions will include video material on the home-based exercise program.
224040452|NCT07130045|OTHER|Usual Care|The UC group participants will participate in combined endurance and strength training similar to the intervention group's weekly center-based session over eight weeks.
224040453|NCT06892197|DRUG|Methylprednisolone (drug)|ATC code: H02AB06. Can be changed to Prednisolone 50 mg orally.
224040454|NCT06892197|DRUG|hydrocortisone|ATC-code: H02AB09. Can be changed to 50 mg x 4 daily orally if appropriate.
224040455|NCT06894888|OTHER|artifial intelligence education|With the start of the use of artificial intelligence in the field of nursing, we are trying to increase the skills of students by providing them with training in this field.
224040456|NCT07052682|DRUG|Ontamalimab|Ontamalimab SC injection.
224040457|NCT06895967|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
224040458|NCT06895967|BIOLOGICAL|HyQvia|Participants will receive SC infusion of HyQvia.
224040459|NCT06895967|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
224040460|NCT06895967|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer HyQvia to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
224040461|NCT07058155|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Fluoroscopically guided placement of a covered stent creating a portosystemic shunt between hepatic and portal veins. Goal: ≥ 50 % HVPG reduction or final HVPG \< 12 mmHg. Conducted 4-6 weeks (≤ 6 months allowed) before bariatric surgery; standard post-TIPS surveillance ultrasound and EGD to confirm patency and variceal resolution.
224040462|NCT07058155|PROCEDURE|Sleeve Gastrectomy|Longitudinal resection of \~80 % of stomach via laparoscopic or robotic approach, preserving pylorus. Performed after successful TIPS once portal pressures stabilize (\< 6 months post-TIPS). Standard peri-operative care, micronutrient supplementation, and bariatric follow-up per ASMBS guidelines.
224040463|NCT07058155|DRUG|Anti-Obesity Pharmacotherapy (Class Effect)|Clinician-selected, evidence-based anti-obesity medications (AOMs) used at the treating provider's discretion. Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine. Dosing and titration follow standard labeling; no specific drug is mandated. The study assesses the overall class effect of pharmacotherapy rather than any single agent.
224040464|NCT07058155|BEHAVIORAL|Lifestyle Counseling - Diet & Physical-Activity Program|Regular sessions with a registered dietitian or equivalent (in-person or virtual) focusing on adherence to a reduced-calorie diet, structured physical-activity regimen, and behavior-change strategies. Counseling occurs throughout the 6-month study period and is considered standard care for this patient population.
224040465|NCT06761976|DRUG|Sevabertinib|Sevabertinib is self-administered by the patient BID (twice a day) as tablets for oral administration
224040466|NCT04739059|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
224040467|NCT07129733|OTHER|Oral hygiene bundle|Implementation of the standardized oral hygiene bundle, which consists of the following key components: Standardization of materials used during the oral hygiene procedure, standardization of oral hygiene frequency, training of nursing staff involved in patient care on proper oral hygiene practices, discontinuation of routine application of chlorhexidine oral solution, and implementation of a standardized oral hygiene technique.
224040468|NCT07128433|PROCEDURE|milk expression|Following one-on-one antenatal manual colostrum expression instruction by a midwife at the breastfeeding clinic, participants will initiate twice-daily practice from 37 weeks gestation onward, performing 3-5 minutes of manual expression per breast per session (total duration ≤10 minutes per session).
224040469|NCT07128992|OTHER|Control visit interval|Study investigates whether it is safe to extend the interval of routine calendar-based follow-up visits from every 12 to every 24 months in patients with type 1 diabetes.
224040470|NCT07129941|BEHAVIORAL|Unified Protocol|The Unified Protocol is a transdiagnostic intervention for emotional disorders here delivered in a group format
224040471|NCT07130526|DEVICE|Intravascular Lithotripsy (IVL) plus DCB|"The device under investigation is the Peripheral Lithotripsy System (Shockwave Medical, Fremont, California). Miniaturized and arrayed lithotripsy emitters create a localized field effect at the site of the calcium. The Peripheral Lithotripsy System is CE-marked for peripheral arterial disease and for this study, will be used within its indication for use. This included the following: intended for lithotripsy-enhanced balloon dilatation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral and popliteal arteries.~The IVL catheter is delivered across a calcified lesion over an 0.014'' wire and the integrated balloon is expanded to 4atm to facilitate efficient energy transfer.~An electrical discharge from the emitters vaporizes the fluid within the balloon, creating a rapidly expanding and collapsing bubble that generates sonic pressure waves. The waves create a localized field effect that travels through soft vascular tissue,"
224040472|NCT07130526|DEVICE|POBA plus DCB|Standard of Care
224139661|NCT00539916|BEHAVIORAL|Regular orange juice consumption|600 mL /day.
224139662|NCT01670214|PROCEDURE|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
224139663|NCT03270150|DEVICE|BTL-899|BTL-899
224040473|NCT07130357|DEVICE|Collagen Scaffold|The bioinductive collagen scaffold will be placed over the repair site and secured with soft tissue anchors.
224139664|NCT05770050|OTHER|No intervention|No intervention
224139665|NCT04045236|OTHER|Registry|Data collection
224139666|NCT01428518|DRUG|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
224040474|NCT07130357|PROCEDURE|Achilles tendon repair|Upon diagnosis of an Achilles tendon rupture, the participant will receive a temporary slab and surgical repair will be scheduled, and the operation will be performed under general anaesthesia with the patient lying prone. The ruptured ends of the right Achilles tendon will be marked, and a 3 cm longitudinal skin incision will be made along the medial border of the tendon. A standardized end-to-end direct surgical repair using non-absorbable sutures in a 2-strand core in a krackow locking fashion will be performed. The surgical site will be closed in layers using 3-0 vicryl and 4-0 ethilon.
223430314|NCT03181503|DRUG|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
223430315|NCT04930042|DRUG|Stelara|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
223430316|NCT04930042|DRUG|AVT04|AVT04 or Stelara (45 mg/5ml) will be administered as a subcutaneous injection in the thigh or abdomen per the approved dosing regimen for moderate to severe chronic PsO for patients with a body weight ≤100 kg.11,12
223430317|NCT05451615|DRUG|Janus Kinase Inhibitor|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
223430318|NCT05451615|DRUG|Abatacept|One group of D2TRA subjects receive Janus Kinase Inhibitors combine Abatacept treatment, another group of D2TRA subjects receive Abatacept treatment only.
223430319|NCT02585271|DEVICE|Transanal decompression tube|22 Fr transanal decompression tube
223430320|NCT02585271|DEVICE|Stent|self-expandable colorectal nitinol alloys stent
223430321|NCT06730971|PROCEDURE|Total thyroidectomy|Post operative specimen after total thyroidectomy
223430322|NCT06730971|PROCEDURE|Total thyroidectomy|Remove of both thyroid lobes and isthmus
223430323|NCT02300350|DRUG|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
223430324|NCT02300350|DRUG|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
223430325|NCT02300350|DRUG|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
223430326|NCT01491750|BEHAVIORAL|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
223430327|NCT01491750|BEHAVIORAL|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
223430328|NCT06496022|DIAGNOSTIC_TEST|Frail scale|FRAIL scale for determining frailty (tired most of the time in the last 4 weeks; the presence of more than 5 diseases; difficulty or inability when climbing stairs and walking around the block; weight loss of more than 5% of the previous weight in the last 6 months).
224040475|NCT07129057|OTHER|MBSR program|The MBSR program lasts eight consecutive weeks (two months), with group sessions lasting two and a half hours each and an intensive 8-hour full-day practice session. At each session, the participants receive audio tracks for daily home practice.
223430329|NCT06496022|DIAGNOSTIC_TEST|Barthel scale|The Barthel scale is used to determine the degree of independence in daily life, the patient's household activity, the assessment of the quality of life and the necessary care.
223430330|NCT06496022|DIAGNOSTIC_TEST|SARC-F|The SARC-F scale is used to identify muscle dysfunction (difficulty lifting things over 4.5 kg, walking around the room, difficulty climbing from a chair and up 10 steps, whether the respondent has fallen in the last year).
224139667|NCT02977013|DIAGNOSTIC_TEST|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
223430331|NCT06496022|DIAGNOSTIC_TEST|FRAX|FRAX Scale (Kazakhstan platform) fracture and osteoporosis risk assessment on the website https://frax.shef.ac.uk/FRAX/tool.aspx?country=72
223430332|NCT06496022|DIAGNOSTIC_TEST|Mini-Cog scale|The Mini-Cog scale defines cognitive impairment (cognitive impairment - when scoring less than 3 points based on remembering three words and evaluating the task of drawing a clock).
223430333|NCT06496022|DIAGNOSTIC_TEST|dynamometry|carpal dynamometry (sarcopenia is exhibited at values below 26 units for men and below 16 units for women).
223430334|NCT02036658|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
223430335|NCT02036658|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
223430336|NCT01886742|DRUG|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
223430337|NCT01886742|DRUG|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
223430338|NCT00745511|DRUG|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
223430339|NCT00745511|DRUG|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
223430340|NCT01729533|OTHER|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
223430341|NCT01729533|OTHER|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei (\[1\] smooth, \[2\] symmetric, and \[3\] oval configuration) and \[4\] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies \<4% of the nuclear area) are selected for injection.
223430342|NCT05984693|BEHAVIORAL|Video Assisted Instruction|Video Assisted Instruction
224139668|NCT01906866|DRUG|Circadin 2/5/10 mg|Circadin 2/5/10 mg. Active arm
224139669|NCT01906866|DRUG|Placebo|Control arm
224139670|NCT02235987|DRUG|octreotide|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
224139671|NCT02235987|DRUG|DG3173|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
224040476|NCT07078500|DRUG|orelabrutinib combined with the Pola-R-CHP regimen|Enrolled patients will receive six cycles of orelabrutinib in combination with the Pola-R-CHP regimen, with each 21-day period being one cycle. At the end of the six cycles, an interim efficacy evaluation will be conducted. Patients with a response of CR or PR will receive an additional two cycles of orelabrutinib in combination with rituximab and undergo a final efficacy evaluation. Patients with a response of CR/PR after eight cycles of induction therapy will receive maintenance treatment with orelabrutinib for up to two years.
224040477|NCT06806150|BEHAVIORAL|INSPIRE Life Reflection|An 8-day web-based positive psychology intervention encouraging participants to reflect on positive aspects of their daily lives. Activities include gratitude exercises, self-compassion writing, and recognizing meaningful moments.
224040478|NCT06806150|BEHAVIORAL|INSPIRE Work Reflection|An 8-day web-based positive psychology intervention encouraging participants to reflect on positive aspects of their work experiences. Activities include gratitude exercises, self-compassion writing, and recognizing meaningful professional interactions.
223430343|NCT04695951|DIETARY_SUPPLEMENT|Renalof|A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
224040479|NCT06903221|DRUG|Tdap-IPV|intramuscular injection
223430344|NCT04695951|OTHER|Placebo|A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
223430345|NCT03672448|OTHER|Naturalistic observation|Naturalistic observation
223430346|NCT01058486|BEHAVIORAL|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (\<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
224040480|NCT06903221|DRUG|Td-IPV|intramuscular injection
224040481|NCT06902753|OTHER|Questionnaire and Physical Exam|"Neuropsychological assessment:~* Phase 1: MMS-LS (overall cognitive efficiency) + fluency tasks (verbal flexibility)~* Phase 2: MMS-LS (if the participant did not take part in phase 1), RL-RI LSF (verbal memory), Rey Complex Figure (visuospatial abilities and visual memory), Progressive Matrices, Symbols and Code (executive functions)"
224040482|NCT06901856|PROCEDURE|mEMR-C procedure|A transparent cap with an inner groove (MH-593; Olympus, Tokyo, Japan) was attached to the forward-viewing colonoscope. After the endoscope was inserted into the rectum, a crescent-shaped electrosurgical snare was passed through the sheath and looped along the inner groove of the cap. Submucosal injections were not required in this method. The tumor was suctioned into the cap and grasped by tightening the snare. After confirming the appropriate snare placement, both the tumor and overlying mucosa were resected using electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and the resected tumor was sent for pathological examination. Endoscopic examination was repeated without a transparent cap to evaluate the wound carefully in cases of perforation or bleeding and to ensure the absence of residual tumor tissues. If there was spurting or active bleeding, hot forceps were used to stop the bleeding.
224040483|NCT06901856|PROCEDURE|mEMR-L procedure|First, install the ligation device (provided by Jiangsu Gerrit) at the front end of the endoscope. After inserting the endoscope into the rectum, suck the lesion into the ligation device, release the ligator to ligate the lesion. Then, use a snare to resect the lesion below the ligator. Finally, uniformly suture the wound surface with metal clips.
224040484|NCT06901817|DRUG|Intraventricular Pemetrexed|Intraventricular injection of 30 mg pemetrexed via Ommaya reservoir, once every 4 weeks until disease progression.
224040485|NCT06901817|DRUG|Intraventricular Nivolumab|Intraventricular injection of 40 mg nivolumab via Ommaya reservoir, once every 4 weeks until disease progression.
224040486|NCT06901817|DRUG|Intraventricular Dexamethasone|Intraventricular injection of 5mg/2ml pemetrexed via Ommaya reservoir before injection of pemetrexed and nivolumab.
224040487|NCT06901518|DRUG|Galcanezumab-Gnlm|Subcutaneous injection
224139672|NCT06373042|DRUG|Intraarterial and intravenous tirofiban|Intraarterial and intravenous tirofiban after endovascular thrombectomy
223430347|NCT05137535|OTHER|Questionnaire|Family-based questionnaire
224139673|NCT06373042|DRUG|Intraarterial and intravenous placebo|Intraarterial and intravenous placebo after endovascular thrombectomy
224139674|NCT04729556|DEVICE|Sericin and chitosan cream|A novel film-forming cream containing sericin and chitosan
224139675|NCT02851433|DRUG|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
223430348|NCT00597506|DRUG|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
223430349|NCT00597506|DRUG|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
223430350|NCT00324142|DRUG|Oral tinidazole|
224139676|NCT02851433|DRUG|total intravenous anaesthesia with Propofol.|
224139677|NCT01911000|RADIATION|RT and hyperthermia after TACE|
224139678|NCT01364233|DEVICE|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
224139679|NCT01961843|DRUG|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
224139680|NCT01961843|DRUG|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
224040488|NCT07093463|DIETARY_SUPPLEMENT|Colon-delivered riboflavin|10 mg of colon-delivered riboflavin
224040489|NCT07093463|DIETARY_SUPPLEMENT|Conventional riboflavin|10 mg of conventional riboflavin
224040490|NCT07093463|OTHER|Microcrystalline Cellulose|10 mg microcrystalline cellulose
223430351|NCT04211974|DIAGNOSTIC_TEST|whole-exome sequencing|"Fresh frozen or formalin-fixed, paraffin-embedded samples were obtained from patients following resection along with matching peripheral blood samples.~whole-exome sequencing will be performed to identify mutations in tumor tissue and matching blood"
223430352|NCT03199612|DRUG|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
224139681|NCT05355727|OTHER|Clinical decision support tool recommended outcome|The PROSAIC-DS tool will take the variables and produce a suggested outcome. It will supply supporting evidence and best practice for its recommendations
224299429|NCT01805830|DRUG|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
223430353|NCT03199612|DRUG|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
223430354|NCT00154401|DRUG|liraglutide|
223430355|NCT05228925|OTHER|Maternal vitamin D status|Maternal vitamin D status (serum 25-hydroxyvitamin D) was collected during the GraviD study, while the woman was pregnant with the child now being followed-up in the GraviD-child study
223430356|NCT05359510|PROCEDURE|prophylactic mesh repair at different sites for prevention of incisional hernia after various abdominal incision versus primary abdominal suturing|before closure of the abdominal layers prophylactic mesh will be used for prevention of incisional hernia. another patient with abdominal incision , primary closure of abdominal layer will occur.
223430357|NCT02747849|DEVICE|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
223430358|NCT06238661|DIAGNOSTIC_TEST|Urology visit with Risk Calculator and MRI|Patients with PSA ≥3 ng/ml will undergo urology visit with risk calculator and MRI assessment of the prostate
223430359|NCT05702411|OTHER|Air Stacking Technique|Air Stacking lung reexpansion technique after aspiration with expiratory pause in a closed system.
223430360|NCT05702411|OTHER|No Air Stacking Technique|Aspiration technique in a closed system of aspiration with an expiratory pause of 10 seconds.
223430361|NCT01368107|DRUG|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
223430362|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
223430363|NCT01368107|DRUG|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
223430364|NCT01368107|DRUG|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
223430365|NCT02938949|DRUG|alirocumab|
223564825|NCT03546595|OTHER|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
223430366|NCT02938949|DRUG|placebo|
223430367|NCT01319240|DRUG|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
223430368|NCT01319240|DRUG|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
223430369|NCT01319240|DRUG|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
223564826|NCT03546595|OTHER|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
224040491|NCT06907043|DRUG|EIK1004-001 (IMP1707-001)|PARP1 selective inhibitor
224040492|NCT07099001|OTHER|Educational materials on the Alzheimer's disease assay|Between Round 1 and Round 2 virtual patient case administration, Intervention participants will receive educational materials describing the clinical validation and use cases of the Alzheimer's disease assay. These materials will approximate the type of information physicians would receive to introduce them to the Alzheimer's disease assay and may be comprised of a slide deck, fact sheet, sample test report, and/or example case scenarios.
224139682|NCT05522673|DRUG|11(R)-rolipram|Injected IV followed by PET scanning
224139683|NCT05739877|DRUG|DA-1229_01 2.5/500mg (Before)|single dose administration (one tablet once a day)
224139684|NCT05739877|DRUG|DA-1229_01 2.5/500mg (After)|single dose administration (one tablet once a day)
224139685|NCT06679517|PROCEDURE|TAVI|Clinical follow-up up to 10 years of patients undergoing TAVI
224139686|NCT00004363|DRUG|chlorpropamide|
224139687|NCT00004363|DRUG|desmopressin|
223430370|NCT03724266|DRUG|Chitosan|chitosan will be used as intracanal medication
223430371|NCT03724266|DRUG|Calcium Hydroxide|intracanal medication
223430372|NCT06288269|OTHER|Severity of Stroke and 1 year survival|Evaluated from NIHSS and clinical outcome 1 year survival death
223430373|NCT00081731|DRUG|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
223430374|NCT00081731|PROCEDURE|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
223430375|NCT02841566|OTHER|questionnaire|
224299430|NCT02666352|DRUG|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
224040493|NCT07099001|OTHER|Alzheimer's disease assay results|Within each of their virtual patient cases in Round 2 of case administration, Intervention participants will receive Alzheimer's disease assay results at the clinically appropriate point for each case.
223430376|NCT01241617|DEVICE|Duet TRS|Endo GIA stapler with integrated Duet TRS
224040494|NCT06163404|DEVICE|Implantation of Spirair Nasal Device using the Spirair delivery system.|The Spirair implant is designed to acutely correct cartilaginous septal deviation and maintain the cartilage in a corrected position for a duration sufficient to allow for cartilaginous remodeling.
223430377|NCT01241617|DEVICE|Endo GIA|Endo GIA stapler with Single Use Loading Units
223430378|NCT02096068|DRUG|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
224040495|NCT04667247|DRUG|FoTv|8 capsules three times a day for 14 consecutive days.
224040496|NCT06904625|OTHER|Taking blood samples before starting treatment|"For each patient included, a blood sample will be taken (37 mL in total) for the CTCs detection using the 3 techniques (CellSearch®, Parsortix® and SmartCatch®).~For 3 patients only, an additional blood volume (18 mL) will also be collected for tcDNA detection (exploratory analysis of 3 patients)."
224040497|NCT04613206|BIOLOGICAL|High Dose Quadrivalent Inactivated Influenza Vaccine|"Fluzone High-Dose (Influenza Vaccine) for intramuscular injection is an inactivated influenza vaccine, prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, octylphenol ethoxylate (Triton® X-100), producing a split virus. The split virus is further purified and then suspended in sodium phosphatebuffered isotonic sodium chloride solution. The Fluzone High-Dose process uses an additional concentration factor after the ultrafiltration step in order to obtain a higher hemagglutinin (HA) antigen concentration."
224040498|NCT04613206|BIOLOGICAL|Standard Dose Quadrivalent Inactivated Influenza Vaccine|Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses contained in the vaccine.
224040499|NCT04419766|OTHER|IR3535 (3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester) house spraying|The spraying will be performed monthly during the first 3 months, bimonthly during the next 6 months and then quarterly thereafter. The spraying will be carried out inside and outside the houses during the morning.
224040500|NCT04270058|DRUG|inotersen|TEGSEDI injection, for subcutaneous use
224040501|NCT07109024|DIAGNOSTIC_TEST|Generation of a comprehensive and single-lesion resistance profile|AI-supported image analysis of functional imaging (PET-CT) and previous imaging data and specialized molecular methods (next-generation sequencing) will be combined into a comprehensive resistance profile.
224040502|NCT05722041|PROCEDURE|Immediate dental implant placement|Placement of one dental implant immediately after tooth extraction.
223430379|NCT02096068|DRUG|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
223430380|NCT02948010|DEVICE|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher \& Paykel Healthcare CPAP Device
224040503|NCT07188571|DIAGNOSTIC_TEST|Gastric emptying scintigraphy|To assess gastric emptying rates in patients with simple obesity and diagnose the presence of gastric motility abnormalities.
224040504|NCT07189260|DEVICE|positive expiratory pressure|PEP therapy
224139688|NCT00302718|BEHAVIORAL|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
224299431|NCT02666352|DRUG|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
223430381|NCT02948010|DEVICE|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
223564827|NCT05385887|DRUG|Ciprofloxacin 500 mg|One tablet of 500mg Ciprifloxacine, twice a day
224040505|NCT07187583|DRUG|increased dosing interval of biological therapy|Increasing dosing interval of biological therapy for CRSwNP from every 4 weeks to every 6 weeks and if continued satisfactory response then to every 8 weeks.
224139689|NCT00302718|BEHAVIORAL|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
224299432|NCT02005887|DRUG|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
224299433|NCT02005887|DRUG|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
223430382|NCT02948010|DEVICE|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
223564828|NCT05385887|DRUG|Metronidazole 500 mg|One tablet of 500mg Metronidazole, three times a day
223564829|NCT05385887|DRUG|Placebo|Placebo tablets
223564830|NCT03232814|BEHAVIORAL|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
223564831|NCT06159881|PROCEDURE|Corneal Cross Linking|Total fluence adapted to thinnest point pachymetry
223564832|NCT01432340|BIOLOGICAL|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
224139690|NCT00302718|BEHAVIORAL|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
224299434|NCT02005887|DRUG|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
224299435|NCT00250900|BEHAVIORAL|Prescription Fill Status|
223430383|NCT02948010|DEVICE|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device
224040506|NCT07188649|BEHAVIORAL|oxygen deficiency|The aim of this study is to evaluate the effect of the Reverse Trendelenburg position on oxygenation (SpO₂/FiO₂ ratio) in the early postoperative period in patients undergoing laparoscopic surgery. In our study, obesity is considered as a comparative subgroup in terms of variability of this effect; additionally, the STOP-BANG score, which measures the risk of obstructive sleep apnea syndrome, is examined as an auxiliary indicator.
224040507|NCT07188012|GENETIC|mRNA|mRNA therapy delivered by extracellular vesicles (EVs)
224040508|NCT03462342|DRUG|Olaparib Pill|"For Cohorts A, B, and C: 300 mg twice daily by mouth which is taken continuously for 28 days, which is one cycle.~Cohort D 1-2: prescribed lower dose of olaparib (100-200mg daily for a 28-day cycle). Three to five dosing schedules will be evaluated. Dose Levels 1-3: olaparib 100 mg twice daily, Days 1-28. For Dose Levels 4-5: 100-200 mg twice daily, Days 1-28. Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
224040509|NCT03462342|DRUG|AZD6738|"For Cohorts A, B, and C: 160 mg orally once daily for first 7 days of every cycle (Days 1-7 of each 28-day cycle).~Cohort D 1-2: Prescribed higher dose of AZD6738 (120-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated.~Dose Levels 1-3: 120-160 mg twice daily, Days 1-14, in combination with olaparib twice daily, Days 1-28. Alternatively, AZD6738 at 160 mg once daily Days 1-14 with olaparib at 100-150 mg Days 1-28 may be evaluated.~Dose Levels 4-5: Alternative dosing schedule of AZD6738 at 80-160 mg once or twice daily, weekly intermittent schedule (Days 1-5, 8-12, 15-19) in combination with olaparib 100-200 mg twice daily, Days 1-28 may be evaluated. AZD6738 at 160 mg twice daily, Days 1-7 or 240 mg once daily Days 1-14 with olaparib 100-200 mg twice daily Days 1-28 may be evaluated.~Other dose levels may be considered and will not exceed AZD6738 160mg twice daily by mouth and olaparib 150mg twice daily by mouth."
224040510|NCT04285398|OTHER|Ophthalmic examinations|Slit-lamp examination, IntraOcular Pressure, Visual Acuity, Visual Field, Full-field Stimulus Threshold, Dark adaptometry, Color Vision testing, Optical Coherence Tomography, Fundus AutoFluorescence and Adaptive Optics imaging.
224040511|NCT04285398|OTHER|Mobility Test|Functional test to evaluate mobility and postural condition of patients
224040512|NCT00222053|DRUG|Thalidomide|Per os thalidomide
224040513|NCT00222053|DRUG|Biphosphonates|Biphosphonates
224040514|NCT01444651|DRUG|Tadalafil|20 mg Tadalafil taken once a day for 3 months
224040515|NCT01444651|DRUG|Placebo|Placebo tablet taken by mouth once a day for 3 months
224040516|NCT01436071|DRUG|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
224040517|NCT01436071|DRUG|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
224040518|NCT05679284|RADIATION|Low-dose X-ray of subcutaneous tissues|To identify needle fragment retentions, the radiologic imaging of all volunteers will be performed with X-ray using radiation doses as low as reasonably achievable (ALARA) and one projection per anatomic site.
224040519|NCT02941887|BEHAVIORAL|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
224040520|NCT01640210|DEVICE|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
224040521|NCT01611948|DRUG|Aprepitant|125mg/day for 8 weeks
224040522|NCT01611948|DRUG|Placebo|125mg/d placebo pill for 8 weeks
224139691|NCT04653818|DRUG|Velpatasvir/Sofosbuvir|sofosbuvir / velpatasvir will be given for 12 weeks aiming to eradicate HCV. Ribavirin will be added for Child-Pugh B patients or treatment will be extended for 24 weeks for those who are Ribavirin intolerant.
223564833|NCT02975999|DRUG|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
223564834|NCT02975999|DRUG|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
223564835|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
224040523|NCT01611948|BEHAVIORAL|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
224040524|NCT03707132|PROCEDURE|Tourniquet: Folley catheter in the low segment of the uterus|
224040525|NCT02791282|OTHER|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
224040526|NCT00175955|DRUG|Levetiracetam|
224040527|NCT01909648|OTHER|Blood withdrawal|
224040528|NCT01909648|GENETIC|Blood withdrawal|
224139692|NCT00819585|DRUG|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
224139693|NCT00819585|DRUG|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
224139694|NCT00819585|DRUG|Allopurinol|100-300 mg orally once daily for 24 weeks.
223430384|NCT02948010|DEVICE|CPAP with comfort feature A|CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
223430385|NCT02948010|DEVICE|CPAP with comfort feature B|CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
223430386|NCT02948010|DEVICE|CPAP with no comfort feature|CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
223430387|NCT02948010|DEVICE|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device
224139695|NCT00819585|DRUG|Placebo Matching Canakinumab|Subcutaneous injection.
224139696|NCT00819585|DRUG|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
223430388|NCT02948010|DEVICE|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
224040529|NCT01215175|BIOLOGICAL|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
224040530|NCT01215175|BIOLOGICAL|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
224040531|NCT01215175|BIOLOGICAL|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
224040532|NCT05732922|DEVICE|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.|A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants in the intervention arm to use during their telemedicine consultations with health care providers.
224040533|NCT00350922|BEHAVIORAL|Psychoeducation|
224040534|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: 3M 1522 & Nitto ST-2410WD|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
224040535|NCT05111847|DEVICE|Baseplates with two types of adhesives are tested: Amparo 130002 & 3M 2480|Baseplates with two different types of adhesives are placed behind the ears; One baseplate with one of the two types of the adhesive behind each ear
224040536|NCT00656123|BIOLOGICAL|Colon GVAX|Dose escalation: 1.4x10\^8 to 7x10\^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
224040537|NCT00656123|DRUG|cyclophosphamide|200 mg/m\^2 administered IV on Day 1 of Cycles 1-4
224139697|NCT06525545|PROCEDURE|early mobilizzation of the ankle|perform flexion-extension exercises of the operated ankle
224139698|NCT01108497|PROCEDURE|Bone Marrow Aspiration|
224139699|NCT01530438|OTHER|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~* Imaging : fMRI at rest and anatomical MRI~* Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
224139700|NCT02604862|OTHER|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
224139701|NCT02604862|OTHER|AZD1236|AZD1236 will be delivered at microdose concentrations and is thus considered to be unable to exert any pharmacologic effect outside the area of administration and unlikely to cause an adverse reaction.
223430389|NCT02356510|PROCEDURE|Primary PCI|
223430390|NCT03625310|DRUG|Sodium Fluoride|
224040538|NCT06603818|BIOLOGICAL|Tiragolumab|Tiragolumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
224040539|NCT06603818|BIOLOGICAL|Atezolizumab|Atezolizumab is given intravenously (IV) every 3 weeks (21-day cycles) for up to 2 years
224040540|NCT06603818|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will occur on Days 1, 3, and 5 of Cycle 1 only
224040541|NCT05937633|OTHER|Transformational Education Programme|"An evidence based targeted transformational leadership programme is designed to provide charge nurses an opportunity to develop transformational leadership knowledge and skill.~The programme includes a 2-day activity based educational training. A prereading booklet will be given prior to the educational activity aimed at enhancing the engagement of the participants. The educational programme comprises of the following contents: Concept of leadership and work engagement, transactional and transformational leadership styles, advantages, and disadvantages of transformational leaders. qualities of transformational leaders, 5- Practices of exemplary leadership practice, the 10 commitments of transformational leadership and developing transformational leadership skills."
224040542|NCT02612051|DRUG|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
224040543|NCT02612051|DRUG|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
224040544|NCT02612051|RADIATION|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
224040545|NCT00759733|PROCEDURE|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
224139702|NCT04171648|OTHER|Roasted Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.
224139703|NCT04171648|OTHER|Boiled Peanut Treatment|The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
223430391|NCT03625310|DRUG|Sodium Fluoride with TCP|
223430392|NCT03625310|DRUG|Sodium Fluoride with CXP|
223430393|NCT03625310|DRUG|Sodium Fluoride with CPP-ACP|
223430394|NCT04462523|DRUG|Dextenza 0.4Mg Ophthalmic Insert|The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
223430395|NCT04462523|DRUG|Topical Prednisolone|Standard of care topical drop treatment
224040546|NCT00759733|PROCEDURE|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
224040547|NCT05880940|DEVICE|Boost - Moveable Wheelchair Armrest|"The movable wheelchair arm rest device is a novel wheelchair armrest that quickly clicks into a manual wheelchair frame just like a conventional armrest. However, unlike a conventional armrest, the movable wheelchair arm rest device allows users to activate arm muscles in a way that is appropriate for the early stages of stroke recovery and consistent with the Feys et al. rocking chair approach: with biomechanical support of the shoulder, without high cognitive demand, and focusing on the out-of-synergy movement pattern that requires elbow extension. For the study, the investigators ask participants to exercise using Boost for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit."
224040548|NCT05880940|BEHAVIORAL|Electronic Arm and Hand Exercise Program|These exercises will be assigned to the participants electronically using a commercial home exercise program platform commonly used by hospital systems (i.e.: Medbridge). They will be encouraged to exercise for 30 min/day in addition to the regular rehabilitation therapy at ARU. These exercises will be monitored and supervised by therapists who have been trained in the study protocol. Once participants are discharged from the unit, they will be allowed to keep the electronic exercise program until their 3-month post stroke follow up visit, the last visit of the study. For this study, the investigators ask participants to exercise following this customized arm and hand exercise program for a 30-minute period per day for 5 times a week in addition to their regular therapy until their discharge from the unit.
224040549|NCT00174590|DRUG|risperidone|
224040550|NCT05258435|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
224040551|NCT01978795|OTHER|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
224040552|NCT01978795|OTHER|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
224040553|NCT03008954|DEVICE|GSP3|Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
224040554|NCT03008954|DIETARY_SUPPLEMENT|Avicel (modified Cellulose)|Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
224040555|NCT06000423|DRUG|Tranexamic acid|1300mg TXA taken three times per day for five days
224040556|NCT06000423|OTHER|Placebo|Placebo pills taken three times daily for five days.
224040557|NCT05250908|DEVICE|INTIBIA Therapeutic|INTIBIA implantable tibial nerve stimulator with therapeutic stimulation
224040558|NCT05250908|DEVICE|INTIBIA Non-Therapeutic|INTIBIA implantable tibial nerve stimulator with non-therapeutic stimulation for 3 months, then therapeutic stimulation
224040559|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
224040560|NCT00153647|PROCEDURE|Cap-assisted colonoscopy|Cap-assisted colonoscopy
224040561|NCT04526600|OTHER|Fidget ball|Access to a prototype 'smart' fidget ball with pressure sensors embedded, that produces touch traces and transmits real time data
224040562|NCT06804928|BEHAVIORAL|Virtual Reality Glasses|During the procedure, the patient will wear virtual reality glasses and watch a video. The video will be played through the virtual reality glasses throughout the entire procedure.
224040563|NCT06773871|OTHER|Exercise|Weekly supervised exercise for 12 weeks followed by 12 weeks of non-supervised exercise
224040564|NCT06773871|OTHER|Control|Remain usual activity level
224040565|NCT04951154|OTHER|Bronchoscopic Biopsy|Bronchoscopic biopsies will be used to evaluate biomarkers of tumor biology and immunology.
224040566|NCT04951154|OTHER|Blood Sample|Blood samples will be obtained to measure circulating biomarkers.
224139704|NCT01286948|DRUG|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
224139705|NCT05149248|BIOLOGICAL|Gardasil® [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant vaccine]|HPV vaccination in an alternative schedule for MSM of 1 dose (M0).
224139706|NCT05149248|BIOLOGICAL|Two dose|HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6)
224139707|NCT05149248|OTHER|Control group|HPV vaccination at 12 months
224139708|NCT05149248|BIOLOGICAL|2 dose vaccination over 6 month|2-dose HPV vaccination regimen over a 6-month period (M0,6)
224139709|NCT01333696|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
224139710|NCT00632541|DRUG|Sorafenib|Sorafenib 200mg po daily
224139711|NCT00632541|DRUG|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
224139712|NCT00632541|OTHER|Imaging|Imaging every third cycle
224139713|NCT05807386|BEHAVIORAL|Home-based exercise programme|A 12 week, online delivered, home-based exercise programme.
224139714|NCT05868096|OTHER|Structured holistic thinking course(2 hr)|The holistic thinking curriculum was designed as a structured program using mind maps, case-based discussions, and clinical observations to integrate physical, psychological, social, and spiritual aspects.
224139715|NCT05868096|OTHER|Clinical practice training|there is no holistic thinking curriculum.Using the holistic thinking case study form - introductory version self-study
224139716|NCT01260363|PROCEDURE|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
224139717|NCT01260363|PROCEDURE|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
223430396|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
223430397|NCT02258542|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously
223430398|NCT04353388|DIAGNOSTIC_TEST|CBC-DIFF Monocyte Volume Width Distribution (MDW)|MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
223430399|NCT00110916|DRUG|Intra-articular metHuIL-1ra (anakinra)|anakinra
224040567|NCT02782130|BEHAVIORAL|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:~1. Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~2. Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~3. A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~4. Users progress through Epic Allies' virtual world, creating allies with other users.~5. The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
224040568|NCT02782130|BEHAVIORAL|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
224040569|NCT05538273|OTHER|Early removal of urinary catheter postoperatively|removal of urinary catheter less than 24 hours after surgery
224040570|NCT05538273|OTHER|Late removal of urinary catheter postoperatively|removal of urinary catheter greater than 24 hours after surgery
224139718|NCT05636371|OTHER|Written Communication|Written patient care updates provided to families of ICU patients each day
223430400|NCT00110916|DRUG|placebo|placebo
223430401|NCT00134641|DRUG|gemcitabine|
223430402|NCT00134641|DRUG|vinorelbine|
223430403|NCT02947542|DEVICE|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
223430404|NCT02947542|DEVICE|Standard catheter|Coronary angiography will be performed using a standard catheter.
223430405|NCT03654105|DRUG|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
223430406|NCT03654105|DRUG|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
223430407|NCT03654105|OTHER|Diet Modification and Physical Activity Increase|"It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results."
223430408|NCT03654105|DIAGNOSTIC_TEST|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
223430409|NCT03654105|DIAGNOSTIC_TEST|spirometry with CO test|spirometry with CO test
223430410|NCT03654105|OTHER|anthropometic data collection|anthropometic data collection
223430411|NCT03654105|OTHER|blood test|blood test to assess the metabolic and inflammatory profile
223430412|NCT04150302|OTHER|Exploratory interviews|Exploratory interviews to generate an interview guide
223430413|NCT04150302|OTHER|Semi-directive interviews|Semi-directive interviews to collect qualitative data that will be used for questionnaire item generation
223430414|NCT04150302|OTHER|Delphi Process|Cotation of newly developed items pertinence on a 4 points likert scale.
223430415|NCT04150302|OTHER|Think aloud interviews|Debriefing session for the newly developed items: final possibility to adjust the tool before validating the psychometric proprieties of the questionnaire.
223430416|NCT04150302|OTHER|Psychometric validation|Psychometric properties study
223430417|NCT06154161|DIETARY_SUPPLEMENT|Whey protein supplement|A monthly supply of 35 g of whey protein isolate will be provided to participants in individual sachet packets with instructions of preparation. Every month, participants will come to the center to provide the standard monthly blood sample. At this time, the PI will have participants complete the quality-of-life instrument, ask if there have been any changes in their dietary habits, and collect weights for up to 6-months. Additionally, participants will indicate if they had consumed the protein daily and/or bring back their empty/full satchel packets. As this is a feasibility trial, it is necessary to determine the compliancy of consuming protein daily and the amount. Furthermore, understanding how protein markers may be affected by consumption of the protein daily vs less frequently throughout the week is important to establish improved recommendations for consumption of protein supplements.
223430418|NCT01110668|DRUG|Nilotinib|
223430419|NCT02979080|OTHER|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
223430420|NCT00392496|DRUG|sunitinib malate|Given orally
223430421|NCT01526876|DRUG|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
223430422|NCT04064255|OTHER|Practical Body Image (session 1 - 7)|Practical body image therapy
223430423|NCT04064255|OTHER|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
223430424|NCT05440435|DIAGNOSTIC_TEST|digital radiography (DR)|Patients with bone injury received routine and mobile DR sequential examination.
223478398|NCT06690281|DRUG|Aldesleukin|Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 3 doses)
223478399|NCT06690281|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 4 days
223478400|NCT06690281|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 30 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 7.5 mg/kg/day over 1 hour x 2 days
223478401|NCT04895436|DRUG|Venetoclax|Oral tablet
224040571|NCT02885090|PROCEDURE|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
224040572|NCT00010972|PROCEDURE|Acupuncture|
224040573|NCT03600857|OTHER|Home administration of misoprostol|First dose of misoprostol administration at home
224040574|NCT01662115|DRUG|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
224040575|NCT01662115|OTHER|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
224040576|NCT00998426|PROCEDURE|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
223430425|NCT06353126|PROCEDURE|DEB-TACE|"DEB-TACE, or Drug-Eluting Bead Transarterial Chemoembolization, is a minimally invasive interventional radiology procedure primarily used in the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This procedure combines two treatment modalities: transarterial chemoembolization (TACE) and the use of drug-eluting beads (DEB).~During DEB-TACE, tiny beads loaded with chemotherapy drugs are injected directly into the blood vessels supplying the tumor in the liver. These drug-eluting beads gradually release chemotherapy agents, delivering a targeted and sustained dose directly to the cancerous tissue while minimizing systemic side effects. Additionally, the beads themselves act as embolic agents, blocking the blood flow to the tumor and causing ischemia, which further contributes to the destruction of the tumor cells."
223430426|NCT06668272|BEHAVIORAL|Small Changes program|"Participants will be asked to track their compliance with their Small Changes diet plan using a simple checklist record . Participants will be asked to follow their diet plan every day. They are encouraged to create a diet plan that is as close to their current diet as possible. Meal options include make-from-scratch recipes, quick grab-and-go options,and restaurant options. There may be some time involved in learning the recipes and the routine of their new diet. It also may alter their grocery spending and habits somewhat"
223430427|NCT06668272|BEHAVIORAL|Standard behavioral therapy for weight loss|Participants will be provided guidance on cutting and counting calories, setting goals, reading labels, and portion sizes.
223430428|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
223430429|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
223430430|NCT05502146|DRUG|Noradrenaline Bitartrate|An intravenous bolus of norepinephrine 8 mcg will be administered for management of maternal hypotension.
223430431|NCT05502146|DRUG|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.5 mL)
223430432|NCT04281901|DRUG|Platelet- and extracellular vesicle-rich plasma|ear wick soaked in platelet- and extracellular vesicle-rich plasma
223430433|NCT04281901|DRUG|Standard conservative treatment|standard conservative measures, including antimicrobials, antiseptics and aural toilette for treating a chronically inflamed radical cavity.
223430434|NCT01841450|DEVICE|iStent|Implantation of one iStent in conjunction with cataract surgery
223430435|NCT01841450|PROCEDURE|Cataract surgery|Cataract surgery alone
223430436|NCT03584464|DEVICE|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm
223430437|NCT00732979|PROCEDURE|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
223430438|NCT00732979|PROCEDURE|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
223564836|NCT02342717|DRUG|Itraconazole|multiple doses of Itraconazole capsules
223564837|NCT02342717|DRUG|BI 425809|single dose BI 425809 tablet
223564838|NCT06303375|OTHER|Kinesio taping|"Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
223430439|NCT01292421|BIOLOGICAL|hepatitis B antigen peptide|Given PO
223564839|NCT06303375|OTHER|Conventional physical therapy|"10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week"
223564840|NCT04924530|DIETARY_SUPPLEMENT|Maltodextrin|Co-ingestion of maltodextrin with a high fat meal
223564841|NCT04924530|DIETARY_SUPPLEMENT|Sucrose|Co-ingestion of sucrose with a high fat meal
223564842|NCT04924530|DIETARY_SUPPLEMENT|Lactose|Co-ingestion of lactose with a high fat meal
223740288|NCT04718220|DIAGNOSTIC_TEST|Testing for SARS-CoV-2 IgM/IgG|Women in the exposed (SARS-CoV-2 positive) cohort will undergo testing of umbilical cord blood for SARS-CoV-2 IgG and IgM antibodies, as available.
223740289|NCT01028508|DRUG|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
224040577|NCT00998426|BIOLOGICAL|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
224040578|NCT04011228|DIAGNOSTIC_TEST|Blood sampling|After a fasting period over night blood samples will be taken.
224040579|NCT04011228|DIAGNOSTIC_TEST|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
224040580|NCT04011228|DIAGNOSTIC_TEST|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
224040581|NCT01584154|PROCEDURE|cryoablation|cryoablation with an 8mm-tip catheter
224040582|NCT01584154|PROCEDURE|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
224040583|NCT05641064|DRUG|Placebo|Continuous infusion of saline starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
224040584|NCT05641064|DRUG|Dexmedetomidine 0.5mcg/kg/h|Continuous infusion of dexmedetomidine in 0.5mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
224040585|NCT05641064|DRUG|Dexmedetomidine 1 mcg/kg/h|Continuous infusion of dexmedetomidine in 1mcg/kg/h dose starting after invasive monitoring placement before cardiopulmonary bypass (CPB) initiation up to surgery completion
223430440|NCT01292421|OTHER|placebo|Given orally (PO)
223430441|NCT01292421|OTHER|immunoenzyme technique|Correlative studies
223430442|NCT05163821|DIAGNOSTIC_TEST|Manchester Somali Cognitive Assessment Tool|Cognitive screen for dementia
223430443|NCT05163821|DIAGNOSTIC_TEST|ACE-III Somali Translation|Cognitive screen for dementia
223430444|NCT05168878|BEHAVIORAL|30-second BeSMART video|30 second video focused on education about child gun deaths and responsible gun storage
223430445|NCT05168878|BEHAVIORAL|3-minute BeSMART video|3-minute video focused on education about child gun deaths and responsible gun storage
223430446|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
223430447|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
223430448|NCT04476407|DRUG|benapenem|single-dose Benapenem 1.0mg(iv), 60min infusion
223430449|NCT06413056|DRUG|Micafungin|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B
224040586|NCT01432834|OTHER|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH \& Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
223430450|NCT06413056|DRUG|Amphotericin B|Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.
223430451|NCT01907061|DRUG|N-acetylcysteine|drug will be administered via IV,NG
223430452|NCT01907061|DRUG|Placebo|placebo or NAC will be given
223740290|NCT01028508|PROCEDURE|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
223430453|NCT03336268|BEHAVIORAL|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
223430454|NCT03183934|BIOLOGICAL|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
223430455|NCT03871816|OTHER|Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis|Saliva, blood, and/or archival tumor tissue will be collected from the participants with metastatic PC for genomic testing to confirm DRD status.
223430456|NCT05409079|DEVICE|Abilitech Assist|The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
223478402|NCT04895436|DRUG|Obinutuzumab|Intravenous (IV) infusion
223478403|NCT04138719|DRUG|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
223478404|NCT04138719|DRUG|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m\^2 on days 1, 8 and epirubicin given IV at 75 mg/m\^2 on days 1 every 21 days x 6 cycles；
223478405|NCT06662409|OTHER|Nature-based healing meditation (NBHM) intervention|6 nature-based healing meditation (NBHM) auditory modules available via the study website to facilitate bereavement (grief) recovery and assessed on parameters of directed attention, grief, and QOL (including parameters of depression/anxiety)
224040587|NCT01432834|OTHER|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
224040588|NCT03180749|OTHER|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
224040589|NCT01158651|DRUG|RAD001 (Everolimus)|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
224040590|NCT01296035|BIOLOGICAL|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
224040591|NCT00564785|DRUG|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
224040592|NCT00564785|OTHER|Placebo patch|placebo patch applied 20 minutes prior to epidural
223430457|NCT06619938|BEHAVIORAL|Mindfulness With Biofeedback|The intervention includes two weekly 90-minute sessions of brief mindfulness training, covering mindfulness practices, psychoeducation on caregiving, and group sharing. After the first session, participants receive a wearable device for biofeedback on RR, HR, HRV, EDA, and sleep patterns to support mindfulness practice and reduce stress. A 30-minute session teaches caregivers how to use the devices and understand the parameters. The study uses Fitbit Sense with Fitbit apps, employing PPG sensors. The Fitbit Sense connects to smartphones with the apps installed. Caregivers can: (1) view real-time RR, HR, HRV, and EDA on the device and trends on their phone; (2) receive mindfulness practice reminders; (3) access audio coaching; (4) set personal goals (e.g., 30 minutes of daily practice); (5) track practice duration; (6) rate daily stress; and (7) review sleep quality. After the second session, caregivers practice mindfulness for 30 minutes daily over eight weeks.
224040593|NCT06005389|PROCEDURE|cryotherapy|Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.
223478406|NCT07118046|DEVICE|Pulmonary vein isolation|Pulsed field ablation for pulmonary vein isolation in atrial fibrillation ablation
223478407|NCT06919991|DRUG|Casdatifan|Administered as a single dose in treatment Periods 1, 2, and 3
224040594|NCT06005389|DIAGNOSTIC_TEST|serum Galectin-3 assay|From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.
224040595|NCT00163423|DRUG|Ciclesonide|
224040596|NCT02970734|BEHAVIORAL|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
224040597|NCT02970734|BEHAVIORAL|Resource Webpage|Static webpage listing anxiety resources.
224040598|NCT01233453|DEVICE|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
224040599|NCT01233453|DEVICE|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
224139719|NCT04574609|DEVICE|Oncomfort® clinical virtual reality|"hypnotherapy arm, patients will receive in addition to the care provided by the usual :~* for PAC insertion: a 45-minute hypnotherapy session 2 hours before the procedure in a room of the outpatient surgery unit (UCA).~* during the entire duration of chemotherapy (and/or immunotherapy for HER2+ patients) : one hypnotherapy session before the first treatment and then every 3 weeks. One hypnotherapy session before the first treatment and then every 3 weeks. Thus, sessions will take place before each treatment for 3-week inter-course regimens and every 3 treatments for chemotherapy administered on a weekly. Each session will last 20 minutes."
223478408|NCT06919991|DRUG|Itraconazole|Administered as multiple doses in treatment Period 2
223478409|NCT06919991|DRUG|Phenytoin|Administered as multiple doses in treatment Period 3
223478410|NCT01408693|PROCEDURE|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
223478411|NCT01408693|PROCEDURE|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
223478412|NCT07117058|DIAGNOSTIC_TEST|New rapid screening tool for anxiety and depressive disorders|New rapid screening tool for anxiety and depressive disorders completed by patient during a regular follow-up consultation
223478413|NCT07117058|DIAGNOSTIC_TEST|SCARED-R-51 (Screen for Child Anxiety Related Emotional Disorders-Revised)|Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 7-14 years old.
223478414|NCT07117058|DIAGNOSTIC_TEST|HADS (Hospital Anxiety and Depression Scale)|Questionnaire completed by patient during a regular follow-up consultation : ONLY for patients 15-25 years old.
224040600|NCT04825769|DEVICE|LLLT（Low Level Laser Therapy）|2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
223430458|NCT06619938|BEHAVIORAL|Mindfulness Without Biofeedback|The control group will receive two weekly sessions of brief mindfulness training, the same as the intervention group. After the 1st brief mindfulness training, the control group will receive a 30-minute briefing session on goal setting for mindfulness practice. Each caregiver will be asked to develop an action plan for continuous mindfulness practice. A mindfulness therapist will also discuss the challenges and solutions for developing a habit of mindfulness practice with the caregivers in the second session. Caregivers in the control group will be advised to practice mindfulness daily for 30 minutes over the course of eight weeks.
224040601|NCT05961280|PROCEDURE|Mastectomy with sentinel lymph node biopsy|
223430459|NCT03279796|BIOLOGICAL|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
223430460|NCT03279796|DRUG|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
223430461|NCT03369028|OTHER|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
223430462|NCT02147951|DRUG|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
223430463|NCT00356902|PROCEDURE|titration of oxygen during resuscitation|
223430464|NCT06622707|OTHER|kinesio taping|Despite the increasing indications and new application techniques developed all over the world, it is believed that there is a need for evidence regarding the mechanisms of action and effectiveness of kinesio taping. As a result of the literature review, no study was found in which kinesio taping was applied for 72 hours as a non-pharmacological complementary method to reduce postoperative pain after cesarean section and increase postpartum comfort. In this study, it is planned to apply kinesiotaping for 72 hours after cesarean section.
223430465|NCT06622707|OTHER|Routine clinical care|As routine clinical care; Analgesic treatment protocol applied after cesarean section, postnatal care and discharge services are provided
223430466|NCT02433925|DIETARY_SUPPLEMENT|Resveratrol|
223564843|NCT06837935|DEVICE|Aluminum Foil Reflector|"The hyperbilirubinemia newborns will receive phototherapy with an Aluminum Foil Reflector around an incubator. The aluminum foil reflector, sewn inside a cloth that is 30 cm long and 3 mm thick, will be hung from the three sides of the phototherapy unit. The reflector will cover the whole incubator except for the foot part to allow infant observation during treatment. While receiving phototherapy, the lights will be continuously on, except during feeding, physical examination, and blood taking. All participants will dress only in nappies and eye masks during phototherapy treatment.~Serum bilirubin will be taken every 24 hours until phototherapy can be stopped according to AAP guidelines."
224040602|NCT02478723|DEVICE|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
224040603|NCT05659433|PROCEDURE|CEUS-guided percutaneous biopsy|A standard dose of SonoVue ultrasound contrast agent is injected prior to the biopsy, and the percutaneous biopsy is guided in real time, targeting the contrast-enhanced areas of the retroperitoneal tumors (viable, vascularized)
223430467|NCT02433925|DIETARY_SUPPLEMENT|Placebo|
223430468|NCT00250874|DRUG|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
223430469|NCT04500964|DEVICE|TAVR|Trancatheter aortic valve replacement
223430470|NCT05279976|OTHER|Visualized Education|The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.
223430471|NCT05279976|OTHER|Distraction|Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
223430472|NCT01177631|PROCEDURE|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
223430473|NCT06494410|PROCEDURE|High versus Low Fraction of Inspired Oxygen|to compare the effect of high oxygen fraction (FiO2 1.0) vs. low oxygen fraction (FiO2 0.4) on clinical outcome on intraoperative and postoperative atelectasis and PPC. We will asses the impact of FiO2, especially during RM, on atelectasis development, using modified LUSS in obese patients with atelectasis undergoing laparoscopic bariatric surgery.
223430474|NCT04373811|DIAGNOSTIC_TEST|Lung ultrasound|"Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.~Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded."
223430475|NCT04373811|DIAGNOSTIC_TEST|Muscle ultrasound|"Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.~Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe."
223430476|NCT03344692|DRUG|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
223430477|NCT03344692|OTHER|Placebo|prefilled pen containing 1 ml of solution without Praluent
223430478|NCT06482684|DRUG|KTE-X19|See description of treatment arms
224040604|NCT05659433|PROCEDURE|B-mode US-guided percutaneous biopsy|Standard of care (B-mode) ultrasound-guided percutaneous biopsy, without contrast enhancement
224040605|NCT01448122|OTHER|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
224139720|NCT02822911|BEHAVIORAL|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
224299436|NCT03409393|OTHER|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
223430479|NCT06482684|DRUG|Ibrutinib|See description of treatment arms
223430480|NCT02175082|OTHER|Cycling at Forced rate|
223564844|NCT04274049|GENETIC|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
224040606|NCT04359875|BEHAVIORAL|Phone-call screening and management by a medical student/general practitioner tandem|"Systematic phone contact of the patient by a medical student, under the indirect supervision of the general practitioner. This phone contact will be standardized with 3 questions to ask to the patient:~* How are you doing? (with a Likert scale from 1=very bad to 10=very well)~* Would you have made an appointment with your general practitioner if there had not been COVID19 epidemic and containment?~* Would you like an appointment with your doctor and / or has your doctor ever contacted you? In view of the answers to these 3 questions, the general practitioner will decide whether it is necessary to propose a consultation or a teleconsultation to the patient, taking into account his/her medical background."
224139721|NCT02822911|PROCEDURE|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
224139722|NCT02822911|PROCEDURE|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
224139723|NCT02822911|PROCEDURE|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
224139724|NCT02067091|DEVICE|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
224139725|NCT03946826|DRUG|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
224139726|NCT03946826|DRUG|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
224139727|NCT03946826|RADIATION|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
224299437|NCT03409393|OTHER|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
224299438|NCT02078336|DRUG|Midazolam Mylan|
224299439|NCT02078336|DRUG|Lorazepam Mylan|
224299440|NCT02078336|DRUG|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
224299441|NCT05284461|DEVICE|dental implant with transepithelial abutments manufactured by Galimplant Dental System (Spain)|Dental implants with transepithelial abutments with distinct morphology
223430481|NCT02175082|OTHER|Cycling at self-selected rate|
223430482|NCT05204173|DRUG|sintilimab, paclitaxel and S-1|Sintilimab 200mg intravenous (IV) infusion on day 1, PTX 50 mg/m2 IV and PTX 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days with one week rest.
223430483|NCT06262945|DIAGNOSTIC_TEST|Diagnoses|All of the patients withstand a radiological examination, including panoramic radiography, and all were handled by the same surgeon and assistant.
223430484|NCT06262945|PROCEDURE|traditional osteotomies|In all groups the flap incision was triangular in shape which avoids muscle involvement (Archer flap).
223478415|NCT01788761|DIETARY_SUPPLEMENT|Probiotic Supplemented Group|
223478416|NCT01788761|DIETARY_SUPPLEMENT|Control Group|
223478417|NCT07130786|DRUG|Levetiracetam (Keppra)|Patients will be randomized to receive levetiracetam/ASM or to receive no ASM therapy
223478418|NCT07129486|DEVICE|CPAP|Continuous positive airway pressure (CPAP) is the standard treatment for moderate to severe OSA in clinical practice.
223478419|NCT02728908|DEVICE|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
223478420|NCT06941610|DEVICE|Erchonia GVS Laser|405nm violet and 520nm green laser light therapy.
223478421|NCT07151469|OTHER|Kaltenborn mobilization|The therapist applies gentle traction to the mandible, maintained for approximately 20 to 30 seconds, to create space in the joint. This is done by pulling the jaw downward and slightly forward, which can help alleviate pressure and pain. This hand placement allowed the therapist to apply transverse force across the mandible as necessary, while at the same time allowing an anterior-inferior gliding force to the mandible on the side of restriction, while also controlling the unrestricted side inhibiting any excessive mandibular forward gliding with the other hand. The mobilization is then initiated with Grade I, which involves small-amplitude movements performed at the beginning of the range of joint play to reduce pain and muscle guarding. This is followed by Grade II mobilization, which consists of larger amplitude movements within the mid-range of joint play to enhance joint mobility and decrease pain without reaching the joint's full resistance barrier
223430485|NCT06262945|BIOLOGICAL|platelet rich fibrin|Platelet rich fibrin (PRF), is an example and popular procedure for accelerate healing of soft and hard tissue because of the presence of various growth factors.a blood sample was taken without anticoagulant in 10 mL glass-coated plastic tubes that were immediately centrifuged (Elektro-mag M415P) at 3,000 rpm for 10 min (approximately 400 g) (13). The platelet-poor plasma that accumulated at the top of the tubes was discarded.PRF was dissected approximately 2 mm below its contact point with the red corpuscles situated beneath, to include any remaining platelets that may have localized below the junction between the PRF and red corpuscles.
223430486|NCT06262945|DRUG|Antibiotics, Penicillin|Antibiotics are prescribed for the patients.
223430487|NCT06262945|DEVICE|low laser therapy, bicure laser|There are studies in the literature that low-energy lasers have positive effects on the biological and biochemical processes of wound healing. Acceleration of local circulation, increase in cell proliferation and collagen synthesis are among the various effects of laser application. B Cure Dental Pro Laser application will be applied to the patient for the first 3 days. Low dose laser application will be applied to the angulus area, covering the surgical area for 8 minutes. Before this laser procedure, the patient will be asked to fill out a pain scale. This pain scale and the number of analgesics used will be monitored for 3 days.
223430488|NCT06262945|DRUG|Analgesic|Analgesics are prescribed for the patients.
223430489|NCT02628457|PROCEDURE|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
223430490|NCT02429024|DEVICE|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
223430491|NCT02429024|DEVICE|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
223430492|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
223430493|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
224040607|NCT04464265|OTHER|Functional Magnetic Resonance Imaging (fMRI)|"Propofol will be administered by intravenous infusion. All anesthesia equipment, supplies, and drugs will be provided by anesthesiologists from the University of Michigan Health System. The researchers will manually control the infusion of propofol to achieve target effect-site concentrations which will be maintained for 4 minutes each.~Four types of music, including Jazz, Rock, Pop and Country, will be presented in a pseudo-randomized order. During the behavioral test period, participants will be asked to squeeze an Magnetic Resonance Imaging (MRI) compatible grip dynamometer (a rubber ball) for every 10-second periods (96 cycles in total). The beginning of each cycle will be cued with the spoken word squeeze."
223430494|NCT01144676|DRUG|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
223430495|NCT01144676|DRUG|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
223430496|NCT02345460|DRUG|Irinotecan Hydrochloride|Given IV
223430497|NCT02345460|DRUG|Oxaliplatin|Given IV
223430498|NCT02345460|DRUG|Leucovorin Calcium|Given IV
223430499|NCT02345460|DRUG|Fluorouracil|Given IV
223430500|NCT02345460|OTHER|Laboratory Biomarker Analysis|Correlative studies
223430501|NCT00639574|DRUG|Néfopam|"There are two groups :~* a group N : néfopam~* a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
223430502|NCT03186274|BEHAVIORAL|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
223430503|NCT03186274|BEHAVIORAL|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
223430504|NCT03430401|BEHAVIORAL|Perceptual-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
223430505|NCT03430401|BEHAVIORAL|Semantic-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
223430506|NCT03430401|BEHAVIORAL|Cognitive stimulation|The frequency, duration and the number of sessions will be consistent with the experimental interventions.
223430507|NCT03391544|PROCEDURE|V4c toric ICL implantation surgery|The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
224299442|NCT04016961|OTHER|AAT - Dog|therapy dog added to inpatient PT and OT session
224299443|NCT04016961|OTHER|TAU - No Dog|PT and OT as usual without the addition of therapy dog
223430508|NCT05393115|OTHER|Square wave breathing|difference in time to failure from the two breathing modes
223430509|NCT05115227|BEHAVIORAL|Education|The team will educate the patient about low back pain and how this can be self-managed.
223430510|NCT05115227|BEHAVIORAL|Exercise|The team will advice the patient to conduct relevant exercises and to stay physical active.
223430511|NCT02900105|DRUG|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
223430512|NCT00847782|PROCEDURE|Blood draw|1 day
223430513|NCT02133794|DEVICE|Tomosynthesis|
224040608|NCT04357145|OTHER|High Dosage Home Exercise Training|"By giving more exercise to the experimental group, exercise adherence, pain and functionality will be compared with the standard exercise group.~3 times more reputation than control~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
223430514|NCT06295627|OTHER|There were no interventions in retrospective analysis|A retrospective analysis method was used to analyze the causes of catheter-related urinary tract infection and the infecting bacteria of the two groups of patients. A single factor analysis was performed on various factors and other related factors, and corresponding nursing strategies were summarized and proposed.
223430515|NCT03794102|OTHER|Water|Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
223430516|NCT03794102|OTHER|Saline|0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
223430517|NCT02718690|DEVICE|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
223430518|NCT02718690|DEVICE|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
223430519|NCT02368379|OTHER|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
223430520|NCT02368379|OTHER|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
223430521|NCT03060343|BIOLOGICAL|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10\^5 cells/kg, Dose Level Two: 1.0×10\^6 cells/kg, Dose Level Three: 1.0×10\^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
223430522|NCT03755843|DIAGNOSTIC_TEST|PASSIVE LEG RISING|"Pasive Leg Rising: In the supine method, the legs are lifted passively from the horizontal position to a 30° to 45° elevation while the head of the bed is flat.~Fluid Challenge: Fluid responsiveness is generally defined as an increase in SV or CO of 10% to 15% in response to a 250 mL crystalloid fluid bolus"
224040609|NCT04357145|OTHER|Standard Dosage Home Exercise Training|"5-6 standard reputations for all exercises~Exercise Program to be Applied (0-3 Weeks):~Isometric knee extensor and adductor exercise~* Hamstring stretching exercise~* Terminal knee extension exercise~* Straight leg lifting exercise~Exercise Program to be Applied (3-12 Weeks):~* Stepping exercise~* Sit up and stand up without support~* Active knee flexion exercise~* Moving forward exercise"
224040610|NCT01063829|DRUG|60 mg AIC246|Oral administration
224040611|NCT01063829|DRUG|120 mg AIC246|Oral administration
224040612|NCT01063829|DRUG|240 mg AIC246|Oral administration
224040613|NCT01063829|OTHER|Placebo|Oral administration
224139728|NCT05657782|BIOLOGICAL|PanChol|PanChol is a new second generation live-attenuated oral cholera vaccine (OCV) that circumvents limitations of previous live-attenuated OCVs. In contrast to other live OCVs, PanChol is derived from a current circulating pandemic V. cholerae strain, thus eliminating the risk of vaccine-derived genes from extinct V. cholerae strains (such as CVD 103-HgR) recombining with circulating V. cholerae strains.
224139729|NCT04116450|PROCEDURE|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
224139730|NCT04822272|DEVICE|MRI thermometry|MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate
224139731|NCT03046940|OTHER|Patient-centered style of communication|Different doctor-patient communication
224139732|NCT03046940|OTHER|Doctor-centered style of communication|Different doctor-patient communication
223478422|NCT07151469|OTHER|active release technique|This deep tissue therapy technique is primarily used to break up adhesions and scar tissue on the surrounding muscle and ligaments. However, this technique has been proven to be a very effective method for treating TMD.While there are several muscles connected with the movement of the TMJ, it is thought that the major players are the digastricus, masseter, and lateral pterygoid muscles
224040614|NCT03272542|DIETARY_SUPPLEMENT|Prebiotic: soluble corn fiber|prebiotic
224040615|NCT03272542|DIETARY_SUPPLEMENT|Placebo: maltodextrin|placebo
224040616|NCT01782079|DIETARY_SUPPLEMENT|L. brevis|
224139733|NCT04212858|GENETIC|zinc-finger protein 217 gene|search for zinc-finger protein 217 gene in myeloma patients
223478423|NCT01931605|DEVICE|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
223478424|NCT04639440|OTHER|Adipose tissue|Adipose tissue sampling
223478425|NCT01950663|DEVICE|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
224040617|NCT04580862|OTHER|Non-surgical endodontic retreatment in single visit|Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
224040618|NCT06449950|BEHAVIORAL|Behavioral: Verbal Oral Hygiene Instructions|OHI-S index scores of patients who received verbal oral hygiene education were measured at baseline and final (in post-education).
224139734|NCT05381012|OTHER|Allodynia, quality of life, sleep, anxiety and depression, disability, and central sensitization|All patients will be evaluated for allodynia, quality of life, sleep, anxiety and depression, disability related to headache, and central sensitization.
224139735|NCT05381012|OTHER|Fibromyalgia syndrome|Patients who meet the diagnostic criteria for fibromyalgia syndrome will be evaluated with the Fibromyalgia Impact Questionnaire.
224139736|NCT05366270|DEVICE|WBH|Hyperthermia exposure using Heckel Hyperthermia Device
224040619|NCT06449950|BEHAVIORAL|Behavioral: Video-Based Oral Hygiene Instructions|OHI-S index scores of patients who received video-based oral hygiene education were measured at baseline and final (in post-education).
224040620|NCT02423018|DRUG|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
224040621|NCT02423018|DRUG|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
224040622|NCT00974090|DRUG|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
223430523|NCT01312233|OTHER|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12-week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self-management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti-inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
224040623|NCT00974090|DRUG|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
224040624|NCT03189862|BEHAVIORAL|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
224040625|NCT00665743|DRUG|PN400|naproxen 500 mg /esomeprazole 20 mg
224040626|NCT00665743|DRUG|naproxen|naproxen 500 mg tablet
224040627|NCT00665743|DRUG|naproxen|naproxen 500 mg
224040628|NCT05265910|DRUG|olopatadine hydrochloride ophthalmic solution 0.7%|Pataday® Once Daily Relief Extra Strength (eyedrop)
224040629|NCT05265910|DRUG|loratadine 10 mg|Claritin® Tablets 24-Hour (tablet)
224040630|NCT05265910|DRUG|Tears Naturale|Tears Naturale® II (eyedrop)
224040631|NCT05265910|DRUG|Placebo|Placebo tablet (tablet)
224040632|NCT06466863|OTHER|Validity and Reliability|"Participants were included in the study after obtaining consent from both the participants and their parents. Participants were informed about the study prior to the survey, and only those who volunteered were included in the study. The data collection process was conducted online via Google Forms. The assessment form was sent to the participants through social media platforms, messages, and emails. Participants completed the YAP-T twice, 7 days apart, and all measurements were taken on weekdays under similar conditions by the same evaluators (4 evaluators) in the same region (Istanbul).~Test-retest reliability will be determined by calculating the Intraclass Correlation Coefficient (ICC) between the total scores obtained from the two assessments."
223430524|NCT01312233|OTHER|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity-low amplitude or low velocity-variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
223564845|NCT04274049|OTHER|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
223564846|NCT06447779|BIOLOGICAL|Recombinant Zoster Vaccine (CHO Cell)|"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"
223564847|NCT06447779|BIOLOGICAL|NaCl solution Placebo|0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection
224139737|NCT05366270|DEVICE|Sham|Sham (mild heating) using Heckel Hyperthermia Device
224163901|NCT02384928|DRUG|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
223564848|NCT02172573|DRUG|Pramipexole|
223564849|NCT02172573|DRUG|Bromocriptine|
223564850|NCT02172573|DRUG|Placebo pramipexole|
223564851|NCT02172573|DRUG|Placebo bromocriptine|
223564852|NCT05294289|OTHER|Alpelisib|There was no treatment allocation. Patients administered alpelisib by prescription that were involved in Novartis' alpelisib managed access program were enrolled
223564853|NCT00678938|BEHAVIORAL|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
223564854|NCT00678938|BEHAVIORAL|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
224040633|NCT02939872|DRUG|aspirin and clopidogrel|at the discretion of investigator
224040634|NCT02939872|DRUG|Clopidogrel only|at the discretion of investigator
224040635|NCT02955576|DEVICE|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
224139738|NCT01149642|DIETARY_SUPPLEMENT|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
224040636|NCT02955576|DEVICE|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
224040637|NCT02955576|OTHER|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
224040638|NCT06313073|RADIATION|Neoadjuvant radiotherapy|The patient received synchronous radiotherapy and chemotherapy before surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
224040639|NCT06313073|RADIATION|adjuvant radiotherapy|The patient received radiotherapy after surgery. CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.CTV : 40Gy/15fx/3w, sequential GTV： 8.7-10Gy/3-4 Fx.
224040640|NCT00056862|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
224040641|NCT00056862|DRUG|Peginterferon alfa-2a|180 mcg/week
224040642|NCT00056862|DRUG|Ribavirin|800 mg/day
224040643|NCT03447366|DIAGNOSTIC_TEST|mitral doppler|Mitral doppler before and after vascular filling
224040644|NCT03902561|DEVICE|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
224040645|NCT00052039|DRUG|interferon-gamma 1b|This study was terminated prior to enrollment.
224040646|NCT00052039|DRUG|azathioprine|This study was terminated prior to enrollment.
224040647|NCT05953779|BEHAVIORAL|Clinician-administered Need-focused Single Session Intervention|All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
224139739|NCT01149642|DIETARY_SUPPLEMENT|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
224139740|NCT04398199|DRUG|Hypofractionated Radiation Therapy|The prescribed dose will be 70 Gy in 25 fractions. Participants will radiation therapy once a day for 25 days, Monday through Friday (around 5 weeks).
224139741|NCT04398199|RADIATION|Radiation Boost|Undergo simultaneous integrated boost (SIB) to treat both planned target volumes with daily image guidance. This approach allows daily confirmation of target localization and simultaneous delivery of lower dose per fraction to low risk areas while maintaining a high dose per fraction to the highest risk areas.
224139742|NCT04026854|BEHAVIORAL|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
223564855|NCT06407349|OTHER|Communication Board|communication board based on a functional communication picture of basic needs of categories ( food, clothes, object, and actions)
223564856|NCT06407349|OTHER|Traditional Therapy|Traditional Therapy
224040648|NCT01829360|BEHAVIORAL|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
224040649|NCT01622179|PROCEDURE|sewed indirectly|The epitenon was repaired and sewed indirectly.
224040650|NCT01622179|PROCEDURE|sewed directly|The epitenon was unrepaired and sewed directly.
224040651|NCT03388255|DRUG|Polydeoxyribonucleotides|"Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication."
224040652|NCT05987566|OTHER|Morning meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten after 1 hour of waking up in the morning
224040653|NCT05987566|OTHER|Evening meal challenge|A Western-style diet meal which will be individualized for caloric consumption by estimated total daily energy expenditure eaten within 1 hour of going to bed
224040654|NCT00034450|DRUG|L-carnitine|
224040655|NCT00201838|DRUG|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
224040656|NCT00201838|DRUG|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
224040657|NCT06298812|DEVICE|REFLECT Scoliosis Correction System|The REFLECT™ Scoliosis Correction System is designed for continued growth and mobility of the spine as well as straightening of the spine by holding the segments in a more natural anatomic position using non-rigid materials.
224040658|NCT06277102|OTHER|music listening|Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
224040659|NCT03198598|BEHAVIORAL|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
224040660|NCT03198598|BEHAVIORAL|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
224040661|NCT02347033|DRUG|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
224040662|NCT02347033|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
224040663|NCT05532436|OTHER|Breath Exercise|It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
224040664|NCT04379336|BIOLOGICAL|Bacille Calmette-Guérin (BCG)|BCG vaccine will be given intradermally in the upper arm after randomization.
224040665|NCT04379336|OTHER|Placebo Comparator|Placebo injection will be given intradermally in the upper arm after randomization.
224040666|NCT00028821|DRUG|2-methoxyestradiol|Given orally
224040667|NCT00028821|OTHER|pharmacological study|Correlative studies
224040668|NCT00028821|OTHER|laboratory biomarker analysis|Correlative studies
224040669|NCT02187614|DRUG|Diclofenac|
224040670|NCT02187614|DRUG|Morphine|
224040671|NCT02187614|DRUG|Paracetamol|
224040672|NCT02187614|DRUG|Placebos|
224040673|NCT04393025|DEVICE|Intracranial Stenting by Intracranial Stent Device|Large Intracranial Vessels with ICSD underwent catheter lab and IC stent is inserted
223430525|NCT01312233|OTHER|Shared Care|Participants allocated to Shared Care receive co-managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
223430526|NCT04662528|DRUG|Placebo|4 x 1g capsules/day
223430527|NCT04662528|DRUG|MAT9001 (omega-3 pentaenoic acid)|4 x 1g capsules/day
223430528|NCT06064838|DIETARY_SUPPLEMENT|Flavonoids|1 capsule every 12h for 90 days
223430529|NCT00774527|DRUG|Cyclophosphamide-fludarabine-anti thymocyte globulin|"* Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~* Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~* Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
223430530|NCT01601327|DRUG|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
223430531|NCT01601327|DRUG|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
223430532|NCT01601327|DRUG|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
223430533|NCT00163982|DRUG|Norfloxacin|
223430534|NCT03062527|OTHER|Dietary Intervention: Low vs. moderate glycemic index|
223430535|NCT01875627|DIETARY_SUPPLEMENT|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
223430536|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate and Konjac Noodles|
223430537|NCT01875627|DIETARY_SUPPLEMENT|Carbohydrate noodles|
224040674|NCT04393025|DRUG|Optimum medical treatment|Optimum Medical treatment
224040675|NCT04347850|OTHER|blood sample|Collection
224139743|NCT04914377|DRUG|TQ Formula/Tab|TQ Formula will be administered as an oral dose daily. The dose planned in this study is 3 g per day (3 500mg capsules to be taken twice daily).
223430538|NCT06621680|DRUG|Multivitamins|All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
223430539|NCT06621680|OTHER|Connective tissue massage|Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.
223430540|NCT02580669|OTHER|Neuropsychological assessment|A neuropsychological assessment is done
223430541|NCT02580669|OTHER|Neurologic consultation|A neurologic consultation is done
223430542|NCT02580669|OTHER|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
223430543|NCT01687569|OTHER|Control Cracker Snack|Base cracker snack
223430544|NCT01687569|OTHER|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
223430545|NCT01687569|OTHER|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
223430546|NCT03465501|RADIATION|Brachytherapy|Brachytherapy
224040676|NCT00859950|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
224040677|NCT00136409|DRUG|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
224040678|NCT03838198|BEHAVIORAL|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
224040679|NCT03838198|BEHAVIORAL|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
224040680|NCT03838198|BEHAVIORAL|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
224040681|NCT01159613|OTHER|Responders|Responders
224040682|NCT01159613|OTHER|Non Responders|Non Responders
224040683|NCT00283036|DRUG|Irbesartan|
224040684|NCT02378220|GENETIC|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
223430547|NCT01562301|DRUG|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
224040685|NCT00578786|DRUG|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
224040686|NCT05503550|DRUG|Talquetamab|Talquetamab will be administered subcutaneously (SC).
224040687|NCT01243697|DRUG|desogestrel|Tablets of 75 µg, once daily during 112 days
224040688|NCT00866723|DRUG|bevacizumab|
224040689|NCT05882097|OTHER|Transform program|International Care Ministries' (ICM) Transform is a 15-lesson, 15-week long values, health, and livelihood program that targets some of the poorest households in Uganda. The health dimension focuses on increasing health knowledge and behaviours on a range of health topics such as malnutrition, respiratory infection, lifestyle, sanitations, family planning and infant care. The livelihood dimension focuses on increasing the amount and sources of household income. Participants will learn about business ideas and farming techniques to diversify their income sources. Additionally, a savings group will be formed at the end of Transform to promote a sustainable strategy to reduce poverty among the participants. The values dimension will focus on relationships, personal character and decision making aspects of an individual.
224040690|NCT03045601|DIAGNOSTIC_TEST|CT-FFR|Invasive FFR and CCTA With CT-FFR
224139744|NCT05123651|BIOLOGICAL|Lactobacillus rhamnosus X253|Every two weeks, all volunteers were given the number of probiotic lozenges to be used within two weeks. Edible method: 3 times a day, 1 tablet every time (0.8g/tablet). Put the tablet in the mouth and keep it in the mouth for at least 2-3 minutes before swallowing. Take it once every 30 minutes after breakfast, lunch and dinner. Do not brush your teeth, eat foods, or rinse your mouth within half an hour of consumption. Maintain oral hygiene according to the original habits during consumption, and do not use fluoride toothpaste during consumption.
224163902|NCT02384928|PROCEDURE|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
223430548|NCT01562301|DRUG|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
223430549|NCT01562301|DRUG|Anvirzel|"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from"
223430550|NCT01562301|BEHAVIORAL|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
223430551|NCT00514904|BIOLOGICAL|Nimenrix|Single dose, intramuscular injection
223430552|NCT00514904|BIOLOGICAL|Mencevax|Single dose, subcutaneous injection
224040691|NCT03045601|DIAGNOSTIC_TEST|Stress echocardiography|Stress echocardiography and invasive FFR
224040692|NCT02182570|DRUG|WAL 801 CL dry syrup|
224040693|NCT01271803|DRUG|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
224040694|NCT01271803|DRUG|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
223430553|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
223430554|NCT00721344|DRUG|Moxifloxacin|Tablets 400mg
223430555|NCT00721344|DRUG|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
223430556|NCT00721344|DRUG|Placebo|Placebo cartridges
223430557|NCT06620484|DEVICE|Musculoskeletal Ultrasound with elastography|Musculoskeletal Ultrasound with elastography
223430558|NCT03820219|DEVICE|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
223430559|NCT03820219|OTHER|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
223430560|NCT06649513|DIAGNOSTIC_TEST|eye drops (Tropicamid)|Mydriatic + cycloplegic eye drops are given to measure refractive error and to image the full retina.
224040695|NCT06246708|OTHER|Self-help app with information for grieving Syrian Refugees|This study explores a self-help app for grieving Syrian refugees in Switzerland, featuring five chapters on grief, resources, space, negative thoughts, and future self-help. The Arabic app includes psychoeducational content, audio exercises, and videos. Users personalize it, save favorites, and set reminders. Tailored for Arabic-speaking refugees, it's accessible on iOS and Android, without invasive components. Participants complete one weekly chapter over five weeks. Data input is stored without manipulation. Accessible data includes completed chapters, subchapters, and feedback. The app promotes self-help, respecting cultural nuances for user engagement.
223564857|NCT03333096|DEVICE|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
224040696|NCT06246708|OTHER|Wait-list|Participants in the wait-list control group, receive access to the same intervention described above after a waiting period of 5 weeks.
224040697|NCT02302404|DRUG|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
224040698|NCT02302404|DRUG|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
224040699|NCT02302404|DRUG|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
224040700|NCT02302404|DRUG|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
223564858|NCT03333096|DIAGNOSTIC_TEST|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
224040701|NCT03428074|PROCEDURE|Surgeries|Minimally invasive surgeries of Ivor-Lewis and Mckeown
224040702|NCT00162890|BEHAVIORAL|Therapeutic exercise|
224040703|NCT03938077|DEVICE|Storytelling 4 Empowerment|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol \& drug use, HIV \& STIs, and tobacco prevention and cessation.
224040704|NCT04822623|DIAGNOSTIC_TEST|MRI|MRI examination
224040705|NCT00934804|DEVICE|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
224139745|NCT05405036|OTHER|simulated patient|In the last month of the Measurement and Evaluation course in Physiotherapy, a simulated patient session will be held four times (with disease in the cervical-lumbar-shoulder and knee region). Students will be evaluated by the methods they learned about patients. 10 days before and after the simulated patient sessions, the questionnaire will be applied in Turkish for validity and reliability, and then the questionnaire will be repeated after the simulated patient sessions are over, and the effect of the smile patient sessions on the perceived communication skills of the patient will be examined.
224139746|NCT05044260|PROCEDURE|Direct sinus lift with titanium reinforced PTFE membrane|Implants will be placed immediately after sinus lifting procedure and maintaining the sinus membrane in position using PTFE titanium reinforced membrane.
224139747|NCT02338791|DEVICE|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
223430561|NCT03837366|BEHAVIORAL|Activity tracker and health coaching|Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
223430562|NCT04186702|PROCEDURE|INTRAVITREAL RANIBIZUMAB INJECTION|interventions involving RANIBIZUMAB INJECTION 0.5 mg (0.05 mL of 10 mg/mL solution)
223430563|NCT06617156|OTHER|RSBI Value Evaluation|"Spirometer Measurement: The traditional method for calculating RSBI involves the use of a spirometer (Wright MK20; Ferraris Medical Ltd., Hertford, England), equipped with a disposable bacterial filter at the front end, connected to the artificial airway to measure the minute ventilation of the patient's spontaneous breathing over one minute.~Three Measurement Methods from the Ventilator: A. PSV at 5 cmH2O with PEEP at 5 cmH2O B. CPAP at 5 cmH2O C. CPAP at 0 cmH2O.~Electrical impedance tomography (EIT) will be secured around the patient's thorax using a silicone belt, positioned at the fifth or sixth intercostal space, with 16 evenly spaced electrodes. Measurement data will be obtained by passing a small electrical current around the chest, utilizing the principle of resistance."
223430564|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
223430565|NCT03747315|OTHER|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
223564859|NCT01235845|BIOLOGICAL|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
224040706|NCT01809184|DRUG|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
223430566|NCT06620354|DRUG|Selumetinib|Patients without indications for surgical excision were evaluated with 6 cycles of daily oral smetinib capsules (20-50mg bid) for 30 days, individually calculated based on patient body surface area (BSA)
224040707|NCT01809184|DRUG|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
224040708|NCT01809184|DRUG|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
224040709|NCT00320021|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
223430567|NCT03597009|DRUG|Talimogene laherparepvec (TVEC)|Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
224040710|NCT02623374|BEHAVIORAL|self-help CBT intervention (SHCBT)|See 'Arms' section
224040711|NCT06226311|OTHER|Data collection|Collection of sociodemographic, lifestyle and health data; Child anthropometry (weight, height and head circumference) at the ages of 3-4 and 5-6 years Child neurodevelopment scores at the ages of 3-4 and 5-6 years
224040712|NCT06226311|OTHER|Diagnostic Test: Urinary|Trichloro-pyridinol (TCPy) and 3-phenoxybenzoic acid (3-PBA) Environemental oligoelements including Lithium (7Li), Arsenic (75As), Cadmium (111Cd), Lead (208Pb) and Mercury (80Hg)
224040713|NCT03931733|OTHER|Music Therapy|Single thirty minute receptive music therapy intervention.
224040714|NCT05332405|DRUG|Indocyanine green|The subject will receive 3mL of ICG followed by 10 mL of sterile saline intravenously as per the Spy Elite protocol. Within minutes of the injection, the SPY machine will be turned on and focused on the nerve. The SPY machine gives a digital read out of the % fluorescence when the dye reaches the nerve. This number correlates with blood flow or vascularity.
223430568|NCT03597009|DRUG|Nivolumab|Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
224040715|NCT05367180|OTHER|MISOLRE prevention program on sun risks|Training of an ambassador class by a field coordinator Dissemination of the information by the ambassador class to the other classes of the school drawn by lot Transmission of an information document to parents on photoprotection to make them aware of the actions to adopt
224040716|NCT05367180|OTHER|"Vivre avec le Soleil prevention program on sun risks"|Program is delivered directly by the teachers through pedagogical books : 10 workshops over a period of 3 months
224040717|NCT05367180|OTHER|Sun protection equipment|Distribution of sunscreen, caps and sunglasses
224040718|NCT01554735|BEHAVIORAL|Exercise and diet|24 weeks of exercise and diet counselling
223430569|NCT00182598|PROCEDURE|computer-based psychoeducational intervention|
223430570|NCT00182598|PROCEDURE|community-based substance abuse counseling|
223430571|NCT06158997|DEVICE|EyePeace|EyePeace a commercially available for enhancing meibum expression. The flexible, handheld device is made of silicone and provides regulated vertical pressure on closed eyelids (https://www.eyepeace.de). EyePeace will be used to assess its usefulness in improving evaporative dry eye signs and symptoms.
223430572|NCT06158997|DEVICE|Heated Eye Mask|Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.
223430573|NCT05803447|OTHER|Interview questionnaire|"An Interview questionnaire concerning an assessment of the intensity suicidal behavior, M.I.N.I. 7.0.2 was used.~M.I.N.I. interview was conducted with each patient to verify the intensification of suicidal behaviour."
223430574|NCT05803447|DIAGNOSTIC_TEST|biochemical parameters|"The concentrations of the following parameters were determined from the:~* blood serum: vitamin D3, B12, folic acid, sodium, potassium, calcium, magnesium, chlorine, total cholesterol, LDL and HDL fractions, TG~* plasma: metabolites of the oxidative stress"
224040719|NCT01339741|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
223430575|NCT05803447|DIAGNOSTIC_TEST|cognitive function|The participants completing cognitive function were assessed using computer CogState Test. The following cognitive functions were assessed: psychomotor drive (DET), metastability of attention (IDN), verbal memory, retrieval of learned material (ISLR) and verbal learning and memory (ISL), visual learning and memory (OCL), processing speed (GMCT), visual memory including deferred retrieval (GMR), executive functions (SETS and GML), working memory (ONB, TWOB).
223430576|NCT02953106|DRUG|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
223430577|NCT02953106|DRUG|Placebos|Placebo nasal spray
223430578|NCT01845168|OTHER|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
223564860|NCT00123162|DRUG|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
224040720|NCT01339741|DRUG|Placebo|Placebo, oral route, 12 weeks
224040721|NCT02429622|RADIATION|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
224040722|NCT02429622|DRUG|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
224040723|NCT02429622|DRUG|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
224040724|NCT02429622|PROCEDURE|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
224040725|NCT04884763|DRUG|Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments|Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
224040726|NCT04884763|DRUG|Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments|Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
224040727|NCT00462189|DRUG|Immunotoxin therapy|
224040728|NCT00462189|DRUG|CAT-8015 Immunotoxin|
224040729|NCT00462189|PROCEDURE|Biological therapy|
224040730|NCT02616523|DRUG|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
224040731|NCT02616523|DRUG|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
224040732|NCT02616523|OTHER|placebo|The participants will be given infusion of normal saline intravenously.
224139748|NCT03195062|OTHER|Test meal|Liquid test meal (fructose+glucose)
224040733|NCT02616523|DRUG|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
224040734|NCT02178553|DRUG|Epidural|
224040735|NCT02178553|DRUG|Intercostal Bupivicaine (Exparel)|
223430579|NCT01845168|DEVICE|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
224040736|NCT04053530|OTHER|restorative materials|glass ionomer and bulk fill flowable composite
224040737|NCT05089409|DRUG|ATB1651, 2 mg/mL|The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
224040738|NCT05089409|DRUG|ATB1651, 5 mg/mL|The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
224040739|NCT05089409|DRUG|ATB1651, 10 mg/mL|The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
224040740|NCT05089409|DRUG|ATB1651, 20 mg/mL|The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
224040741|NCT05089409|DRUG|ATB1651, 30 mg/mL|The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
224040742|NCT05089409|OTHER|Placebo|The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
224040743|NCT00003251|DRUG|amifostine trihydrate|
224040744|NCT00003251|DRUG|cisplatin|
224040745|NCT00003251|DRUG|paclitaxel|
224040746|NCT00003251|RADIATION|radiation therapy|
224040747|NCT02187809|DRUG|Clobazam|
223430580|NCT01845168|DEVICE|Computer-alert|
223430581|NCT06618248|COMBINATION_PRODUCT|Sirolimus coated balloon angioplasty|This study involves the use of a Sirolimus-Coated Balloon (SCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The SCB is coated with sirolimus, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
223430582|NCT06618248|COMBINATION_PRODUCT|Paclitaxel coated balloon angioplasty|This study involves the use of a Paclitaxel-Coated Balloon (PCB) for the treatment of coronary artery disease, specifically targeting coronary bifurcation lesions. The PCB is coated with paclitaxel, an antiproliferative drug that helps to prevent restenosis by inhibiting smooth muscle cell proliferation. The balloon is inflated at the target lesion site, delivering the drug directly to the arterial wall. This intervention aims to achieve vessel dilation while reducing the risk of restenosis, providing a potential alternative to stent placement.
223430583|NCT06598384|DRUG|Venetoclax combined with Azacytidine|"Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5."
223430584|NCT03144843|DRUG|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
223430585|NCT03144843|DRUG|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
223430586|NCT01560533|BEHAVIORAL|Interviews|Interviews will be done with patients
224040748|NCT05085665|DRUG|Ivermectin|single dose, 150 ug/kg
224040749|NCT03559920|DRUG|Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery|The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.
224040750|NCT03559920|DRUG|Sedate using propofol.|Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
224299444|NCT01406392|DRUG|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
223430587|NCT02152553|DRUG|Hydrocortisone|
223430588|NCT02152553|DRUG|Placebo|
224040751|NCT01261754|RADIATION|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
224040752|NCT01261754|RADIATION|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
224040753|NCT02622880|DIETARY_SUPPLEMENT|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
224040754|NCT02622880|DIETARY_SUPPLEMENT|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
224040755|NCT03283280|OTHER|Ever X Posterior|Resin composite restoration can be made as a direct onlay
224040756|NCT04719767|DEVICE|visual laryngeal mask|After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
224040757|NCT02927743|BEHAVIORAL|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
224040758|NCT05638893|DRUG|Placebo Tablet|Placebo (tablet/12hr) + celecoxib (200mg/day) for three months.
224040759|NCT05638893|DRUG|Metformin Hcl 500Mg Tab|Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
224299445|NCT01406392|DRUG|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
223430589|NCT05738876|PROCEDURE|CORONARY ANGIOGRAPHY|coronary angiography by femoral or radial artery access
223430590|NCT05250687|PROCEDURE|MR- High intensity focused ultrasound|The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.
223430591|NCT05250687|RADIATION|External beam radiotherapy|Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
223430592|NCT03081143|DRUG|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
223430593|NCT03081143|DRUG|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
224040760|NCT00160355|PROCEDURE|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
224040761|NCT00160355|DEVICE|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
224040762|NCT00160355|DRUG|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
224040763|NCT03988322|OTHER|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
224040764|NCT03988322|OTHER|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
224040765|NCT02185209|DRUG|Placebo|Place capsule to mimic antibiotics
224040766|NCT02185209|DRUG|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
223430594|NCT03081143|DRUG|Paclitaxel|80 mg/m2 on day 1, 8, 15
223430595|NCT05461456|DRUG|Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)|"Intervention:~The amount of study lotion (OP2101) used is 11 grams per subject, equivalent to 22 fingertip units (FTU). The lotion is applied to the subject on back and front of the trunk, both hands (palm and back) and both arms. An SOP for handling and application of the lotion ensures the 11 grams covers 54% of the body surface area (BSA) evenly without residue.~Comment:~The treatment is single-dose and single-treatment. The FTU is used to standardize the amount of cream being applied in clinical research. It is also used in clinical practice and hence connects the objectiveness of the trial to the clinical situation."
223430596|NCT05636007|DEVICE|Huawei Watch|pulse rate variability measured by a smartwatch
223430597|NCT02042300|DEVICE|XIENCE Xpedition/Alpine/Sierra|
223430598|NCT06902532|BEHAVIORAL|coconut oil pulling with clove oil|Participants will swish 10 mL of coconut oil mixed with 2 drops of clove oil once daily for 4 weeks. This intervention is designed to assess its antimicrobial efficacy in reducing Streptococcus mutans levels in children and improving oral hygiene.
224139749|NCT02159469|COMBINATION_PRODUCT|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
224139750|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) low dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) low dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
223430599|NCT06902532|BEHAVIORAL|coconut oil pulling|Participants will swish 10 mL of pure coconut oil once daily for 4 weeks. This intervention aims to evaluate the effectiveness of coconut oil alone in reducing Streptococcus mutans levels and its potential role in maintaining oral health.
223564861|NCT00123162|DRUG|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
223564862|NCT01950793|DRUG|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
223564863|NCT01950793|DRUG|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
224139751|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) middle dose formulation vaccine|2 doses of 0.15 ml each of RSV (GSK3389245A) middle dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
224139752|NCT02927873|BIOLOGICAL|RSV (GSK3389245A) high dose formulation vaccine|2 doses of 0.5 ml each of RSV (GSK3389245A) high dose formulation vaccine administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
224139753|NCT02927873|DRUG|Placebo|2 doses (0.5 mL each for Placebo LD and Placebo HD groups and 0.15 mL each for Placebo MD group) of Placebo administered intramuscularly in the left anterolateral thigh or deltoid, at Day 1 and Day 31.
224040767|NCT02185209|DRUG|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
223430600|NCT06902532|DRUG|Fluoride Mouthwash|Participants will rinse with 10 mL of fluoride mouthwash three times daily for 4 weeks. This intervention serves as the active comparator, as fluoride mouthwash is a well-established method for reducing Streptococcus mutans levels and preventing dental caries.
223430601|NCT04787796|DEVICE|a 28-channel ECG (MECG) system|To test if a 28-channel ECG (MECG) system would efficiently differentiate the patients suspected to have CAD or ACS with acceptable sensitivity and specificity, and optimize this portable self-built-in multichannel ECG recorder system with various algorithms.
223430602|NCT04727034|DRUG|Remimazolam tosylate|Remazolam tosylate is an ultra-short-acting benzodiazepine drug, which has a mild inhibitory effect on the respiratory and circulatory systems and has anterograde amnesia. These advantages make remazolam tosylate very likely to replace propofol in painless gastroscopic anesthesia.
223430603|NCT04727034|DRUG|Propofol|Propofol is the most commonly used intravenous anesthetic for painless gastroscopy, but propofol significantly inhibits the respiratory and circulatory systems. Therefore, the incidence of intraoperative hypoxemia and hypotension is high.
223430604|NCT03635385|PROCEDURE|Apheresis technics|Blood draw will be performed for anti bodies dosages
223430605|NCT01399489|BEHAVIORAL|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
223430606|NCT04889599|DRUG|BH009 (Docetaxel injection)|75mg/m2
223430607|NCT04889599|DRUG|Docetaxel injection|75mg/m2
223430608|NCT05863793|OTHER|Acupuncture|The obligatory acupoints include Zhongwan (CV12), bilateral Weiwanxiashu (EX-B3), bilateral Ganshu (BL18), bilateral Pishu (BL20), bilateral Shenshu (BL23), bilateral Zusanli (ST36), bilateral Yanglingquan (GB34), bilateral Sanyinjiao (SP6), bilateral Taixi (KI3), and Bafeng (EX-LE10). Additional acupoints Baxie (EX-UE9) will be added when patients' symptoms appear not only in the lower limbs but also in the upper limbs. After skin disinfection, disposable, stainless steel acupuncture needles will be inserted into the skin of acupoint (approximately 10-20 mm depth), and then manipulations of twirling, lifting, and thrusting will be performed on all needles for at least 10 s to reach De qi (a compositional sensation including soreness, numbness, distention, and heaviness), which is believed to be an essential component for acupuncture efficacy. Needles will be retained in these acupoints for 20 min.
223430609|NCT05863793|OTHER|Sham Acupuncture|Patients in the SA group will receive sham acupuncture. The procedure and duration of treatment in the SA group will be identical in the MA group except the needles are blunt tip and there will be no skin penetration and needle manipulation for De qi.
223430610|NCT05404633|DEVICE|Ergogycle prototype testing for acceptability|The objective was to assess the acceptability of the ergogycle prototype (device) while used in a clinical settings by both the patients and the professionals.
223564864|NCT05716178|BEHAVIORAL|Maternal health education|The local religious leaders from each clustered kebele will be recruited based on religious educational status (educational status greater than or equal to diploma), acceptance by their followers and popularity, in collaboration with religious organization leaders, health extension workers, and kebele leaders. Then after the potential religious leaders are recruited, the two days training will be given for them. Recruited religious leaders are expected to give training on the topics (maternal health) for four sessions to promote healthy maternal behaviors for the members of their religion.
223564865|NCT00825942|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
223564866|NCT05922943|BEHAVIORAL|Harmony & Health program|Harmony \& Health program may help improve psychosocial wellbeing in participants and if improvements in physical activity and wellbeing can last after the program ends. Yoga combines gentle movements, breathing exercises, relaxation techniques, and meditation all tailored to the participant's needs.
223564867|NCT04227795|DEVICE|Artificial intelligence-Assisted real time colonoscopy|The colonoscopy was performed under artificial intelligence assistance
223564868|NCT01801436|DRUG|Bortezomib|Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
224040768|NCT02185209|DRUG|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
224040769|NCT02037646|OTHER|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
223430611|NCT02417961|BIOLOGICAL|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
223430612|NCT02624128|DRUG|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
223430613|NCT02624128|DRUG|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
223564869|NCT01497990|DRUG|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
223564870|NCT01974557|OTHER|Exercise|
223564871|NCT01885208|DRUG|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
223564872|NCT01885208|DRUG|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
223564873|NCT00673205|DRUG|Bicalutamide|150mg p.o. daily
223564874|NCT00673205|DRUG|Placebo|
223564875|NCT01213147|DRUG|clomiphene citrate|100 mg per day oral for 7 days
223564876|NCT01213147|DRUG|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
223564877|NCT06643234|PROCEDURE|Ventral hernia repair|Comparative between both techniques
223564878|NCT01184313|PROCEDURE|aortic valve surgery with CPB|elective aortic valve surgery with CPB
223564879|NCT04313374|DRUG|Morphine PCA 1 mg|PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
224040770|NCT02037646|OTHER|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
224040771|NCT02037646|PROCEDURE|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
224040772|NCT02037646|OTHER|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
223430614|NCT02624128|DRUG|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
223430615|NCT03765853|OTHER|Physiotherapy|Usual prevention methods (ergonomic education) and Stretching Postural® postures.
223478426|NCT03007940|OTHER|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
223564880|NCT04313374|DRUG|Morphine PCA 0,5 mg|PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
223564881|NCT04313374|DRUG|Placebo|the PCA will contain placebo
223564882|NCT02164357|PROCEDURE|EVT (endovascular treatment )|
224040773|NCT02037646|OTHER|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
224040774|NCT02037646|OTHER|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
224040775|NCT02862860|BIOLOGICAL|blood sample|
224040776|NCT02862860|BIOLOGICAL|urine sample|
224040777|NCT02862860|DEVICE|installation of Holter|
224040778|NCT00270478|DRUG|Erythropoietin and Hydroxyurea|
224040779|NCT02099903|DEVICE|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
224040780|NCT00168480|BIOLOGICAL|Botulinum Toxin Type A|100 U, repeated treatments at \> 4 month intervals up to Month 32, over a 36-month study period
224040781|NCT04677699|DIAGNOSTIC_TEST|Combined Risk Score|Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.
224040782|NCT04890678|DEVICE|22 residentsat risk for PU development|"mattress in bed~The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning."
224040783|NCT04890678|DEVICE|18 residents at least one PU category III-IV in the sacral area|"mattress in bed The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.~In the group of participants with a PU category III or IV, the Pressure Ulcer Scale for Healing Tool (PUSH) will be used to assess and measure change in PU status. The score on the PUSH-tool is defined by the surface area of the PU (length x width), the amount of exudate and the type of tissue in the wound bed."
224040784|NCT02583035|OTHER|Nurse telephone contact|Nurse will contact patient 3 days before consultation
224040785|NCT01243541|PROCEDURE|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
224040786|NCT01243541|OTHER|questionnaire administration|Ancillary studies
224040787|NCT01243541|PROCEDURE|quality-of-life assessment|Ancillary studies
224040788|NCT01243541|PROCEDURE|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
224139754|NCT05040789|BIOLOGICAL|CoVLP formulation|"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."
224163903|NCT02384928|BEHAVIORAL|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
224163904|NCT02044367|DRUG|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
223478427|NCT03007940|OTHER|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
223564883|NCT02164357|PROCEDURE|IVT (intravenous thrombolytic therapy)|
223564884|NCT00370760|DRUG|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
223564885|NCT00370760|DRUG|placebo|
223564886|NCT00877786|BEHAVIORAL|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
223564887|NCT03004261|BIOLOGICAL|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
223564888|NCT03004261|DRUG|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
223564889|NCT03004261|DRUG|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
223564890|NCT03134495|OTHER|all children with at least one prescription of PPI|all children with at least one prescription of PPI
223564891|NCT03134495|OTHER|all children with no prescription of PPI|all children with no prescription of PPI
223564892|NCT05291988|OTHER|Educational Intervention|Receive S2S education
223564893|NCT05291988|OTHER|Fecal Immunochemical Test|Receive FIT kit
223564894|NCT05291988|OTHER|Questionnaire Administration|Ancillary Studies
223564895|NCT05525091|OTHER|Feeding Evaluation|Feeding Evaluation with Device
223430616|NCT05645328|OTHER|Iowa Cancer Affiliate Network (ICAN)|Each hospital in the intervention has undergone interviews in which the investigators elicited program goals, challenges, and readiness for change. Prior to the intervention, the cancer centers will be provided a document specifying current status for meeting Commission on Cancer (CoC) accreditation standards, gaps identified, suggestions and resources for the next steps to meet goals, and progress toward fulfilling CoC accreditation standards. The hospitals will be offered support, expertise, and resources to facilitate them in achieving the CoC standards. Support will be offered in the form of education/training regarding the standards and provision of cancer services, regular in-person/zoom check-ins with hospital stakeholders to evaluate progress, and provision of documentation/educational resources regarding standard requirements. The intervention actions will be tailored to the needs of each hospital based on standards they currently do not meet and choose to work toward.
223430617|NCT03843645|PROCEDURE|general anesthesia|surgical procedure under general anesthesia
223430618|NCT03843645|PROCEDURE|regional anesthesia|surgical procedure under regional anesthesia
223430619|NCT04796350|DEVICE|AGN1 LOEP treatment|the implantation site is injected with the AGN1 implant material
224040789|NCT01243541|PROCEDURE|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
224040790|NCT03558022|DIETARY_SUPPLEMENT|Salt Pills|7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
224040791|NCT03558022|DIETARY_SUPPLEMENT|Placebo Pills|7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
223430620|NCT06652204|OTHER|questionnaire|Caregivers must reply to the French version of the QASCI questionnaire, the ZBI (Zarit Burden Interview) questionnaire, HADS (Hospital Anxiety and Depression Scale), and WHOQOL-Bref (World Health Organization Quality of Life Instrument - Short Form). After 15 days, they wil reply to the French version of the QASCI questionnaire (to asse the reliability).
223430621|NCT06539949|BEHAVIORAL|Rapid Planning Method (RPM)|RPM is a three day immersive seminar. Subjects will be exposed to a variety of mind-body exercises and psycho educational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
223430622|NCT06539949|BEHAVIORAL|Journaling|Subjects will be keeping a weekly to-do list.
223430623|NCT05354427|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with implantabale spacers.
223430624|NCT05397210|DEVICE|Infinity-Lock Button System|Infinity-Lock Button System
223430625|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
223430626|NCT00642603|DRUG|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
223430627|NCT00642603|DRUG|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
223430628|NCT00642603|DRUG|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
223430629|NCT00642603|DRUG|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
223430630|NCT06148337|DIETARY_SUPPLEMENT|unhydrolyzed eggshell membrane|an unhydrolyzed, minimally processed chicken eggshell membrane powder.
223430631|NCT06148337|DIETARY_SUPPLEMENT|Placebo|psyllium husk fiber powder
223430632|NCT04871308|DRUG|Dexmedetomidine|"Anesthesia is induced using midazolam or etomidate, and sufentanil. A target-controlled infusion of propofol and remifentanil is used for anesthesia maintenance.~From anesthesia induction before the initiation of cardiopulmonary bypass, dexmedetomidine is infused intravenously at a rate of 0.5 mcg/kg/hr after a loading dose infusion of 0.75 mcg/kg for 10 mins."
223430633|NCT04871308|DRUG|Control|During the same time window for dexmedetomidine, normal saline is infused at the same rate calculated for dexmedetomidine.
223430634|NCT05195398|DEVICE|Anodal transcranial Direct Current Stimulation (A-tDCS)|Participants randomized to tDCS will undergo 5 weeks of A-tDCS + CCT.
223430635|NCT05195398|DEVICE|Sham Intervention|Participants randomized to sham-intervention will undergo 5 weeks of sham + CCT.
223430636|NCT04851613|DRUG|Afuresertib|The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
223430637|NCT04851613|DRUG|Afuresertib/placebo|afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
223430638|NCT05172258|PROCEDURE|Biopsy Procedure|Undergo biopsy
223430639|NCT05172258|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223430640|NCT05172258|PROCEDURE|Computed Tomography|Undergo CT
224040792|NCT00154076|DRUG|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
224040793|NCT00154076|DRUG|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
224040794|NCT05432869|OTHER|ES and lifestyle advices|"The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.~External electrical stimulation will be applied for 30 minutes 3 days a week during 4 weeks. Electrodes were placed on the thighs."
224040795|NCT05432869|OTHER|Lifestyle advices|The lifestyle advices include fluid consumption, diet, weight control, constipation, smoking, etc.
224040796|NCT06137222|DEVICE|Tenex TXB MicroTip Ultrasound system plus SOC|Subcutaneous sharp debridement of the index DFU using standard technique (curettage or sharp blade debridement) plus wound care offloading. The index foot ulcer will be dressed with collagen alginate, gauze and roll gauze. Each subject will return for weekly wound assessment, serial sharp debridement if needed and repeat dressing changes. This care will occur for a duration of 12 weeks or until wound closure is confirmed. Defined as standard of care (SOC).
224040797|NCT06137222|OTHER|Standard of Care for diabetic foot ulcer|Use of standard of care for the treatment of a diabetic foot ulcer
224040798|NCT00778622|DRUG|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
224163905|NCT02044367|DRUG|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
224163906|NCT02044367|DRUG|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
224040799|NCT01460186|OTHER|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
224040800|NCT04008758|DIAGNOSTIC_TEST|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
224040801|NCT00901030|PROCEDURE|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
224040802|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with hysterectomy|After anesthesia, bladder stone removal patients undergo laparoscopic hysterectomy. The adnexa are coagulated and cut, and the bladder peritoneal reflection is opened. The uterus is removed transvaginally. Next, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the residual end.
224040803|NCT06418438|PROCEDURE|Laparoscopic uterosacral ligament suspension with cervical amputation|After anesthesia, bladder stone removal patients undergo cervical amputation surgery. The cervix is exposed and elevated using Allis forceps. A dilator is used to expand the cervix, and an incision is made on the anterior vaginal wall. The cervix is excised and shaped using the Sturmdorf method. Afterward, laparoscopic uterosacral ligament suspension is performed. The right and left uterosacral ligaments are freed and sutured to lift the uterus.
224040804|NCT01483833|DRUG|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
224040805|NCT01483833|DRUG|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
224040806|NCT02512198|BEHAVIORAL|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
224040807|NCT02471950|PROCEDURE|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
224040808|NCT03461874|BEHAVIORAL|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
223430641|NCT05172258|DRUG|Ipatasertib|Given PO
223430642|NCT05172258|BIOLOGICAL|Pembrolizumab|Given IV
223430643|NCT06417775|DRUG|Ubrogepant|Oral Tablets
223430644|NCT06417775|DRUG|Placebo for Ubrogepant|Oral Tablets
223430645|NCT05619653|DRUG|Prednisolone|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
223430646|NCT05619653|DRUG|Losartan|randomised double-blind, placebo-controlled clinical trial 1:1 randomisation
223430647|NCT04057352|DEVICE|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
223430648|NCT02823821|OTHER|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
223430649|NCT02823821|OTHER|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
223564896|NCT04527237|OTHER|acupressure|"The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application."
223564897|NCT04527237|OTHER|Placebo|Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
223430650|NCT06625320|DRUG|RMC-6236|Oral Tablets
223430651|NCT06625320|DRUG|Gemcitabine|intravenous (IV) infusion
223564898|NCT06230549|RADIATION|Adaptive Radiotherapy|Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
224163907|NCT06949280|DIETARY_SUPPLEMENT|Peanut Snack Experimental|Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
224163908|NCT06949280|DIETARY_SUPPLEMENT|Nut-free Snack|Subjects will receive a daily peanut snack and nutrition education-behavior modification instructions for weight loss
223430652|NCT06625320|DRUG|nab-paclitaxel|IV infusion
223430653|NCT06625320|DRUG|Irinotecan|IV infusion
223430654|NCT06625320|DRUG|Liposomal irinotecan|IV infusion
223430655|NCT06625320|DRUG|5-fluorouracil|IV infusion
223430656|NCT06625320|DRUG|leucovorin|IV infusion
223430657|NCT06625320|DRUG|Oxaliplatin|IV infusion
224163909|NCT06015568|DRUG|MCLA-129: 1500mg or 2000mg IV Q2W|Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
224163910|NCT06015568|DRUG|Befotertinib: 75 mg or 100 mg Po QD|"The initial dose of Befotertinib is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD.~Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs."
224040809|NCT03461874|BEHAVIORAL|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
224040810|NCT03461874|DRUG|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
224040811|NCT06360809|BEHAVIORAL|Prehabilitation exercise program|After the allocation, the intervention will consist of a prehabilitation program lasting 4 weeks. Each week, there will be three sessions, with one being face-to-face and the other two being unsupervised sessions but with online video-support. Face-to-face sessions will be organized in small groups, and each patient of the PEP group will have an individualized plan based on data obtained during the initial assessment. Each session will include a combination of strength training and moderate aerobic training in a circuit format with movements especially involving the upper body.
224040812|NCT04423913|OTHER|Administration of embolization beads|Patients will receive embolization beads, loaded with doxorubicin or not.
224040813|NCT00201435|DRUG|Paclitaxel weekly in combination with capecitabine|
224040814|NCT00201435|DRUG|Docetaxel every 3 week in combination with capecitabine|
224040815|NCT02642484|DRUG|Gabapentin|Gapapentin twice daily
224040816|NCT02642484|DRUG|Calcium Carbonate|calcium carbonate twice daily
224040817|NCT01521819|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
224040818|NCT01521819|DRUG|Lucentis|Intravitreal injection of Lucentis as needed.
224040819|NCT01463384|DRUG|Minocycline|50mg, twice daily for 6 months.
224040820|NCT04202250|PROCEDURE|CEMP (closed-ended multiport catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously.A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
224070503|NCT04017260|PROCEDURE|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
223430660|NCT00819208|BEHAVIORAL|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
223430661|NCT00819208|OTHER|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
223430662|NCT00819208|OTHER|educational intervention|Once at the beginning of the program
223430663|NCT00819208|OTHER|laboratory biomarker analysis|Every 12 months
223430664|NCT00819208|OTHER|questionnaire administration|Every 6 months
223430665|NCT00819208|OTHER|study of socioeconomic and demographic variables|Every 6 months
223430666|NCT00819208|PROCEDURE|fatigue assessment and management|Every 6 months
223430667|NCT00819208|PROCEDURE|quality-of-life assessment|Every 6 months
223430668|NCT00819208|OTHER|Educational Intervention|For Arm 2 just once at beginning of program.
223430669|NCT00819208|OTHER|Fitness testing|Objective fitness testing for both arms
223430670|NCT06300450|BEHAVIORAL|Computer Alert|On-screen alert-based decision support raising awareness of need for lipid-lowering therapy in patients with peripheral artery disease
223430671|NCT05729282|DRUG|Diazoxide oral suspension, 1 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 1 mg per kg per dose (total of 27 doses over 14 days).
223430672|NCT05729282|DRUG|Diazoxide oral suspension, 2 mg per kg per dose|Diazoxide oral suspension provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
224040821|NCT04202250|PROCEDURE|OESP (open-ended single port catheter) group|After sterile preparation and large inguinal crease draping, with the US probe in a sterile sleeve or cover , we will proceed to hydrolocalization with 5-10 mL 5% dextrose in order to open the space between the femoral nerve and the superior part of the ilio-psoas muscle. The Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the open-ended catheter will be then inserted under control and its position assessed between the femoral nerve and the superior aspect of the ilio-psoas muscle. Some aliquots of 5% dextrose will inject to confirm correct dispersal of the solution along the femoral nerve. The catheter will be tunnelled subcutaneously. A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
224040822|NCT01839721|DRUG|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
224040823|NCT01839721|OTHER|placebo|
224040824|NCT01251120|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
224139755|NCT02910544|DIETARY_SUPPLEMENT|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
224139756|NCT01519284|DRUG|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
224139757|NCT01519284|DRUG|Entacapone|Entacapone 200 mg
224139758|NCT01519284|DRUG|Placebo|placebo (four times a day)
224139759|NCT01519284|DRUG|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
224139760|NCT01519284|DRUG|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
224139761|NCT01519284|DRUG|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
223430673|NCT05729282|DRUG|Placebo|Flavor-approximate placebo consisting of peppermint extract in diet tonic water, thickened with xanthan gum, provided in label-obscured single-use oral syringes at 2 mg per kg per dose (total of 27 doses over 14 days).
223430674|NCT05729282|DEVICE|FreeStyle Libre Pro|All participants will wear a FreeStyle Libre Pro continuous glucose monitor (CGM) to track glycemic trends in response to study treatments. Investigators and participants will be blinded to CGM readings until after each participant has completed the trial.
223430675|NCT05729282|DRUG|Deuterated water (2H2O/D2O)|All participants will consume 32 aliquots of deuterated water (2H2O/D2O) 50 mL over 14 days to assess hepatic de novo lipogenesis. Tracer enrichment will be determined in blood and saliva.
223430676|NCT04759274|DEVICE|Diuretic Tuner|Mobile device application for diuretic dose titration
223430677|NCT05814016|DRUG|Danavorexton|Danavorexton IV infusion.
224139762|NCT06243341|DIETARY_SUPPLEMENT|Lepidium meyenii (MACA)|The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
224139763|NCT03629041|DEVICE|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
223430678|NCT05814016|DRUG|Placebo|Placebo matching danavorexton IV infusion.
223430679|NCT04412187|DIAGNOSTIC_TEST|[18F]-GE-180 PET|serial \[18F\]-GE-180 PET imaging to assess microglia activation
223430680|NCT04412187|DIAGNOSTIC_TEST|3T MRI|serial MR imaging (i) to determine infarct characteristics, (ii) to identify gray and white matter structures connected to the infarct, (iii) to detect incident lesions, and (iv) to quantify longitudinal changes e.g. of cortical thickness
223430681|NCT04412187|DIAGNOSTIC_TEST|immune cell profiling in blood|Cell-specific cytokine profiles, markers of activation, terminal differentiation as well as cytotoxicity will be assesses using flow cytometry.
223430682|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer without cycloplegia|Objective refraction without cycloplegia
223430683|NCT06524115|OTHER|Distance visual acuity check using objective refraction without cycloplegia|Distance visual acuity is checked, using objective refraction without cycloplegia
223430684|NCT06524115|DEVICE|Comparator device, Closed-field autorefractometer with cycloplegia|Objective refraction with cycloplegia
223430685|NCT06524115|OTHER|Distance visual acuity check using objective refraction with cycloplegia|Distance visual acuity is checked, using objective refraction with cycloplegia
223430686|NCT06092216|DRUG|Spesolimab|"900 mg of spesolimab intravenously (IV) administered every 4 weeks at Visits 2, 3, 4, 5, 6, 7, 8, 9.~If at visit 4 dosing schedule changes to every 3 weeks, Spesolimab will be administered at Visits 2, 3, 4, 5, 6, 8, 9, 10 and 11."
223478428|NCT03007940|OTHER|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
224139764|NCT03629041|DEVICE|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
224139765|NCT01262755|BEHAVIORAL|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
224139766|NCT03991364|OTHER|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
224139767|NCT03991364|OTHER|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
224139768|NCT06056349|DRUG|Midazolam oral solution|Buccal administration
224139769|NCT06056349|DRUG|ClonazePAM Oral Product|Orodispersable
224139770|NCT06056349|OTHER|Usual medication/ traditional|Medication that is usually used in the emergency department
223430687|NCT06246487|BEHAVIORAL|Occupational Therapy Intervention|Children randomized to the intervention condition will receive a sensory enriched intervention 2x's per week, 60-minutes per session, for 16 weeks. The intervention will follow a codified protocol developed by Dr. Bodison that is theoretically grounded in neurodevelopmental research. The interveners will be occupational therapists who will be trained by Dr. Bodison to deliver the codified, intervention protocol to provide a personally customized set of therapeutically guided environmental interactions. Because, at its core, the intervention emphasizes playful interaction with a sensory enriched environment, the intervention room will be equipped with swings, scooter boards, climbing equipment, bolsters, and large carpeted barrels. Within this setting, using the codified manual of intervention developed by Dr. Bodison, the intervener will structure activities to provide tactile and proprioceptive input to address the child's individualized areas of need.
223430688|NCT05299398|DRUG|Trazodone|Trazodone capsule once daily
224040825|NCT01251120|DRUG|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
224040826|NCT01822522|DRUG|Cabozantinib S-malate|Given PO
224040827|NCT01822522|OTHER|Laboratory Biomarker Analysis|Correlative studies
224040828|NCT01822522|OTHER|Pharmacological Study|Correlative studies
224040829|NCT04081584|DEVICE|ISS Device|The ISS Device (commercial and prototype) is used to measure tissue light scattering.
224040830|NCT02877940|DEVICE|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
224040831|NCT02877940|DEVICE|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
224040832|NCT02877940|DEVICE|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
224040833|NCT02821468|DRUG|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
224040834|NCT02821468|DRUG|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
224040835|NCT01605981|DRUG|AMN107|
224040836|NCT00890929|DRUG|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
224139771|NCT00393913|DEVICE|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
224139772|NCT03531333|PROCEDURE|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
224139773|NCT06303947|DEVICE|Intermittent Oro-esophageal Tube|The group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224040837|NCT00890929|DRUG|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
224040838|NCT01768988|DRUG|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
224040839|NCT01768988|DRUG|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3)."
224040840|NCT04231136|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
223430689|NCT05299398|DRUG|Placebo|Placebo capsule once daily
223430690|NCT03197467|DRUG|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
223430691|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|6 IU single dose
224040841|NCT04231136|DRUG|EAPA115|EAPA115
224040842|NCT04231136|DRUG|RAPA115|RAPA115
224040843|NCT01473316|DRUG|GDC-0980|Single oral dose
224040844|NCT01473316|DRUG|Ketoconazole|Repeating Oral Dose
224040845|NCT02558231|DRUG|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
224040846|NCT02558231|DRUG|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
224040847|NCT02558231|DRUG|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
224040848|NCT00004239|DRUG|Compound 506U78|
224040849|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
224040850|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
224040851|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
224040852|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
224040853|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
223430692|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|IN-OXT 6 IU three times a day for 2 weeks
224040854|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
224040855|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
224040856|NCT00356460|BIOLOGICAL|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
223430693|NCT04789148|DRUG|Placebo|Intranasal placebo three times a day for 2 weeks
223430694|NCT04789148|DRUG|Intranasal Oxytocin (IN-OXT)|24 IU single dose
223740291|NCT00817167|DEVICE|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
224040857|NCT05757115|BEHAVIORAL|Play Skills Training|"Each parent will be provided with play skills training that will support them to spend effective and meaningful time with their child. While planning the educational contents, an Occupational Therapy Model suitable for the parent and the child will be used. The process will be followed by giving unique recommendations to each parent. Recommendations given based on feedback will be revised."
224139774|NCT06303947|DEVICE|Nasogastric tube|The group is given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224139775|NCT06303947|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224139776|NCT04986020|DIAGNOSTIC_TEST|MRI|Identification of novel biomarkers from MRI
224139777|NCT04044092|OTHER|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
224139778|NCT04044092|OTHER|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
224139779|NCT03019744|DEVICE|MeCFES-assisted task-oriented upper limb rehabilitation|
224139780|NCT03019744|OTHER|Usual Care task-oriented upper limb rehabilitation|
224139781|NCT04448262|OTHER|data collection|collection of data about bronchial and systemic inflammation, quality of life, lung function
223740292|NCT00817167|DEVICE|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
224040858|NCT01006265|DRUG|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
224040859|NCT01006265|DRUG|Placebo|Matching placebo administered orally once daily
224040860|NCT01006265|DRUG|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
224040861|NCT01006265|DRUG|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
223430695|NCT04789148|DRUG|Placebo|placebo single dose
223430696|NCT06079970|DEVICE|Neelde Based Confocal Laser Endomicroscopy|Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)
223430697|NCT06079970|PROCEDURE|Conventional diagnostic bronchoscopy|Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
223430698|NCT02224781|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223430699|NCT02224781|PROCEDURE|Computed Tomography|Undergo CT
223430700|NCT02224781|DRUG|Dabrafenib Mesylate|Given PO
223430701|NCT02224781|PROCEDURE|Echocardiography Test|Undergo ECHO
223430702|NCT02224781|BIOLOGICAL|Ipilimumab|Given IV
223430703|NCT02224781|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
223430704|NCT02224781|BIOLOGICAL|Nivolumab|Given IV
223430705|NCT02224781|OTHER|Quality-of-Life Assessment|Ancillary studies
223430706|NCT02224781|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223430707|NCT05155163|BEHAVIORAL|SC-POWR|Patients assigned to SC-POWR receive 12 Cognitive Behavioral Therapy (CBT) sessions over 24 weeks.
223430708|NCT00006113|BIOLOGICAL|MART-1 antigen|
223430709|NCT00006113|BIOLOGICAL|aldesleukin|
223430710|NCT00006113|BIOLOGICAL|gp100 antigen|
224040862|NCT02033603|DRUG|Ropivacaine|30mls of 0.5% ropivacaine
224040863|NCT00565942|PROCEDURE|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
224040864|NCT00565942|PROCEDURE|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
224040865|NCT06396793|OTHER|no intervention because it is an observational study|it is an observational study thus there is no intervention
224040866|NCT05231486|BEHAVIORAL|Cognitive Orientation to daily Occupational Performance|CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
224040867|NCT04509960|DEVICE|direct laryngoskopy|Proseal Laryngeal mask inserted with direct laryngoskopy
224040868|NCT01464229|DRUG|Iloperidone|Iloperidone 1-8 mg for 4 weeks
224040869|NCT01464229|DRUG|Placebo|Placebo
224139782|NCT06068322|OTHER|Exercise training on a stationary bicycle|"Training is performed two to three times per week for a total of 30 sessions using a group format.~Both regimens start with a five-minute warm-up and ends with a five-minute cool-down, performed at an intensity corresponding to 30% of the maximal work rate achieved during a CPET (i.e., max aerobic power \[MAP\]) with a self-selected pedalling cadence of 50-70 revolutions per minute (RPM).~All exercise sessions will be held and supervised by an experienced health care professional, i.e. physiotherapists or other health professional.~The different types of exercise training is described under the specific arm.~Following the first 12-week training period, participants with COPD will enter a 21-month maintenance phase. They will continue to exercise using the same training modality (HIIT or MICT) as during the first 12-weeks but can select between three different settings to continue their training: Home, Outpatient, or Mix setting."
224139783|NCT00111150|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily|
223430711|NCT00006113|BIOLOGICAL|recombinant CD40-ligand|
223430712|NCT00006113|BIOLOGICAL|recombinant interferon gamma|
223430713|NCT00006113|BIOLOGICAL|recombinant interleukin-4|
223430714|NCT00006113|BIOLOGICAL|sargramostim|
223430715|NCT00006113|BIOLOGICAL|therapeutic autologous dendritic cells|
223430716|NCT00006113|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223430717|NCT00006113|BIOLOGICAL|tyrosinase peptide|
223430718|NCT00006113|RADIATION|Candida albicans skin test reagent|
223430719|NCT06229132|BEHAVIORAL|LGBTQ-affirmative CBT for transgender individuals|The intervention addresses unique stressors encountered by transgender individuals due to discrimination and lack of adequate and affirming healthcare resources.
223430720|NCT03666533|OTHER|Active transcranial Direct Current Stimulation|Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
223430721|NCT03666533|OTHER|Sham transcranial Direct Current Stimulation|Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
223430722|NCT05402033|BEHAVIORAL|Survey / Interview Group|Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
223430723|NCT05845996|DRUG|SAR441344|Solution for intravenous/subcutaneous injection
223430724|NCT05845996|DRUG|placebo|Solution for intravenous/subcutaneous injection
223430725|NCT05845996|BIOLOGICAL|Keyhole limpet hemocyanin|Subcutaneous Lyophilized powder for reconstitution
223430726|NCT04056884|BEHAVIORAL|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
223740293|NCT03443440|OTHER|Neurocognitive Testing|neurocognitive testing, computerized
224139784|NCT04084626|DRUG|PD1 antibody|2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).
224139785|NCT04084626|DRUG|lenalidomide|5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
224139786|NCT04564430|DRUG|Catapresan|The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
223430727|NCT04057898|DRUG|MN-166|Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
223430728|NCT04057898|DRUG|placebo|Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
223740294|NCT04171687|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg tablet
224139787|NCT04564430|OTHER|Saline|controlgroup receiving saline
223430729|NCT02159495|DRUG|cyclophosphamide|Given IV
223430730|NCT02159495|BIOLOGICAL|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
223430731|NCT02159495|OTHER|laboratory biomarker analysis|Correlative studies
223430732|NCT02159495|BIOLOGICAL|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
223430733|NCT02159495|DRUG|Fludarabine Phosphate|Given IV
223430734|NCT05892432|DRUG|Semaglutide 3 MG [Rybelsus]|Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.
223430735|NCT05892432|DRUG|Semaglutide 7 MG [Rybelsus]|Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.
223430736|NCT05892432|DRUG|Placebo|A medically inert placebo medication will be taken for 8 weeks.
224040870|NCT01249820|DRUG|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
224040871|NCT01249820|DRUG|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
224040872|NCT04233164|DRUG|Solu-Medrol 1mg/kg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
224040873|NCT04233164|DRUG|Solu-Medrol 250 mg|Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 250 mg of methylprednisolone.
224040874|NCT01840605|DRUG|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
224040875|NCT01840605|DRUG|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
224040876|NCT00399451|DRUG|Polidocanol Sclerotherapy|
224040877|NCT00195923|DRUG|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
224040878|NCT01326195|BEHAVIORAL|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
224040879|NCT01326195|BEHAVIORAL|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
223430737|NCT06633224|PROCEDURE|Blood Specimen Collection|Blood samples will be obtained throughout the course of the study
224040880|NCT04561804|PROCEDURE|laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)|"The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes"
224040881|NCT00180362|DEVICE|procedure|
224040882|NCT01884233|BEHAVIORAL|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
224040883|NCT01884233|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
224040884|NCT03553654|DIAGNOSTIC_TEST|low dose CT|CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
224040885|NCT03065023|DRUG|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
224040886|NCT05315453|BEHAVIORAL|Brief Cognitive Rehabilitation|5-session Cognitive Rehabilitation intervention that can be administered over telehealth.
223564899|NCT04215939|BEHAVIORAL|Cold environment participants with spinal cord injury|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
224040887|NCT01750541|DRUG|Haloperidol|
224040888|NCT01750541|DRUG|Valproate|
224040889|NCT04029961|OTHER|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
224040890|NCT04029961|OTHER|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
224040891|NCT02326714|OTHER|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
224040892|NCT02326714|OTHER|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
224040893|NCT04897269|PROCEDURE|Progesterone supplementation|This procedure is to add more progesterone on those who have low progesterone levels on the day of embryo transfer
224040894|NCT04895072|PROCEDURE|Standard group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a standard injection rate.
224040895|NCT04895072|PROCEDURE|Long group|Ultrasound-guided ESP block with 20 mL %0.375 bupivacaine will be administered at a long injection rate.
224040896|NCT03427125|DRUG|Tenapanor|Active Drug
224040897|NCT03427125|DRUG|Placebo|Inactive Drug
224040898|NCT03427125|DRUG|Sevelamer Carbonate|Active control
224040899|NCT04779190|DEVICE|Low-level laser therapy|Gallium-aluminum-arsenide diode laser device
224139788|NCT00757926|BIOLOGICAL|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
224139789|NCT00757926|OTHER|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
224139790|NCT00995670|DRUG|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
223740295|NCT04171687|DRUG|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
223430738|NCT06633224|OTHER|Stool Specimen Collection|Stool samples will be obtained throughout the course of the study
223430739|NCT06633224|OTHER|Quality of Life (QOL) Questionnaires|Surveys will be given throughout the course of the study.
223740296|NCT04171687|DRUG|RAPA113|RAPA113 tablet
224040900|NCT04779190|DEVICE|Therapeutic ultrasound|Therapeutic pulsed ultrasound with a frequency of 1 MHz
224040901|NCT04779190|OTHER|Home-based exercise|Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
224040902|NCT01167751|BIOLOGICAL|MNC|Implantation of BM derived MNC
224040903|NCT01167751|BIOLOGICAL|AC 133|Implantation of BM derived AC133
224040904|NCT01167751|BIOLOGICAL|Control|Injection of cell carrier
224040905|NCT02204384|OTHER|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
224040906|NCT02204384|DIETARY_SUPPLEMENT|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
224139791|NCT00995670|DRUG|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
224139792|NCT00995670|DRUG|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
224139793|NCT00995670|DRUG|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
223430740|NCT06369415|OTHER|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's)|"Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones. The ASQ-3 covers five developmental domains: communication, gross motor, fine motor, problem-solving and personal-social behaviour.~The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire for 2-17-year-olds. It exists in several versions to meet the needs of researchers, clinicians and educationalists. The SDQ asks about 25 attributes, some positive and others negative. These 25 items are divided between 5 scales: emotional symptoms, conduct problems; hyperactivity/inattention, peer relationship problems, and prosocial behaviour"
223430741|NCT01827969|PROCEDURE|ablathermy focused ultrasound|ablathermy focused ultrasound
224139794|NCT02001675|DEVICE|magnetic resonance imaging (MRI)|
224139795|NCT02001675|DEVICE|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
224139796|NCT00503542|DRUG|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
224139797|NCT00503542|DRUG|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
224139798|NCT00503542|DRUG|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
224139799|NCT00503542|OTHER|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
224139800|NCT05674500|OTHER|Educational Training on standardized coaching language|The faculty trainer participants in training groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The training video will demonstrate the use of recommended coaching language for endoscopy instruction (e.g., recommended 14 standard terms, need to refer to the screen when directing a trainee as opposed to their hands, use of a clockface analogy) and communication best practices (e.g., checking to ensure understanding, avoidance of cognitive overload, task deconstruction).
223430742|NCT06326190|DRUG|Local standard of Care|According to local standard practice, treatment or no treatment in the control arm is left to the investigator's discretion.
223430743|NCT06326190|DRUG|177Lu-DOTATATE|Intravenous injection of 177Lu-DOTATATE
223430744|NCT04655508|DRUG|Seretide|"For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~\- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber"
223740297|NCT00302874|BEHAVIORAL|Implementation of a protocol for treatment of hyperglycemia|
224040907|NCT02204384|OTHER|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
224040908|NCT06409585|DIAGNOSTIC_TEST|68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR|200MBq of the above named radiotracer will be administered for PET-MR
224040909|NCT06409585|DIAGNOSTIC_TEST|Echocardiogram|Echocardiogram at baseline and 1 year follow-up
224040910|NCT06409585|DIAGNOSTIC_TEST|Cardiac MRI|Cardiac MRI at 1 year
224040911|NCT05739123|DRUG|Relugolix-Containing Product|Any relugolix-containing therapy
224040912|NCT05330455|DRUG|GSK3965193|GSK3965193 will be administered
224040913|NCT05330455|DRUG|Placebo to match GSK3965193|Placebo to match GSK3965193 will be administered
224040914|NCT05330455|DRUG|Bepirovirsen|Bepirovirsen will be administered
224040915|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 375_B|Participants received 2 doses of 375\_B vaccine formulation by intramuscular injection in the non-dominant arm.
224040916|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 375_A|Participants received 2 doses of 375\_A vaccine formulation by intramuscular injection in the non-dominant arm.
224040917|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 750_B|Participants received 2 doses of 750\_B vaccine formulation by intramuscular injection in the non-dominant arm.
224040918|NCT05975840|BIOLOGICAL|FLU Q-PAN H5N8 750_A|Participants received 2 doses of 750\_A vaccine formulation by intramuscular injection in the non-dominant arm.
224040919|NCT06965452|DEVICE|Spinal angiography and embolization/ Embozene Microspheres|"Once consent is obtained the patient will be scheduled for spinal angiography and embolization. The patient will undergo the procedure at North Shore University Hospital. After embolization the patient will be monitored in recovery for 5 hours and then discharged to home.~The primary objective of this study is to examine the safety and feasibility of trans arterial embolization of the facet joint using Embozene Microspheres for the treatment of back pain from facet arthropathy and osteoarthritis."
224040920|NCT05956249|OTHER|Online group therapy|Online group therapy for the treatment of depression, anxiety and improvement of emotional well-being.The intervention will be carried out in 6 groups of 6 participants.
224040921|NCT05956249|OTHER|Control Group|Without intervention at the first moment, but the control group will receive the intervention after the reassessment of the scales by the scholarship holder was done.
224040922|NCT05180279|BEHAVIORAL|7-day sleep lab|Patients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
224040923|NCT06574893|OTHER|physical exercise|physical exercise
224040924|NCT05127434|DRUG|Placebo|0.9% sodium chloride (normal saline) injection
223430745|NCT04655508|DRUG|Placebo|For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
224040925|NCT05127434|DRUG|mRNA-1345|Sterile liquid for injection
224040926|NCT04508478|BEHAVIORAL|Aerobic training|Aerobic training
224040927|NCT04508478|BEHAVIORAL|Resistance training|Resistance training
224040928|NCT04508478|BEHAVIORAL|Control physical exercise|Control physical exercise
224040929|NCT04023825|DRUG|suprazygomatic maxillary nerve block|in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
224040930|NCT05501678|DRUG|Diphenhydramine|25mg (and up to 50mg) Diphenhydramine given orally
224040931|NCT05501678|DRUG|Placebo|Matching Placebo given orally
224040932|NCT06081283|DRUG|Phenobarbital Sodium Injection|"\*This drug can only be selected as part of the intervention for the subgroup of patients with a Glasgow Coma Score of 8 or less.~Loading dose 20 mg/kg intravenous. Max dose 1000mg Maintenance dose 4mg/kg/day. Max dose 300mg/day. Adult population Loading dose 20 mg/kg intravenous. Maintenance dose 4mg/kg/day."
224040933|NCT06081283|DRUG|Levetiracetam|Pediatric population Loading dose 60 mg/kg intravenous. Max dose 4000mg. Maintenance dose 40mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 2000mg-4000mg intravenous. Maintenance dose 1500mg to 3000mg/day.
224040934|NCT06081283|DRUG|Lacosamide Injectable Product|Pediatric population Loading dose 10 mg/kg intravenous, Max dose 400mg. Maintenance dose 4mg to 8mg/Kg/day. Max dose 300mg. Adult population Loading dose 200mg to 400mg intravenous. Maintenance dose 200mg to 400mg/day.
224139801|NCT05674500|OTHER|Educational Training on goal setting|The faculty trainer participants in the control groups will watch a 15-min long video between the two simulated endoscopy teaching encounters. The video link will be emailed to them 1 week before the second simulated encounter, and they can watch it in their own time. The video will be a 'dummy' colonoscopy training video which outlines how to set goals ahead of an endoscopy training session. The video will not discuss standardized coaching language and/or communication best practices.
223430746|NCT06226844|DEVICE|Music therapy walking program|In the experimental group (PEMA BeatMove), patients will benefit from an outpatient walking training program with app-based performance monitoring, combined with music therapy (BeatMove device). The program comprises 36 walking training sessions, with 30
223430747|NCT06470282|DRUG|Enfortumab Vedotin|Given intravenously (IV)
223430748|NCT06470282|BIOLOGICAL|Pembrolizumab|Given IV
224040935|NCT06081283|DRUG|Valproate Sodium|Pediatric population Loading dose 30mg/kg intravenous. Max dose 3000mg Maintenance dose 20mg to 30mg/Kg/day, Max dose 3000mg/day. Adult population Loading dose 30 mg/kg intravenous. Maintenance dose 20mg to 30mg/Kg/day
224040936|NCT06081283|DRUG|Phosphenytoin|Pediatric population Loading dose 20 mg PE/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day. Max dose 300mg PE/day. Adult population Loading dose 20 mg/kg intravenous. Max dose 1500mg PE Maintenance dose 4mg PE/Kg/day.
224040937|NCT04725617|DRUG|Varenicline|Standard smoking cessation treatment.
224040938|NCT04725617|BEHAVIORAL|Smoking Cessation Counseling|Standard smoking cessation treatment
224040939|NCT04725617|BEHAVIORAL|Health Approach 1 to Reduce Smoking|Behavioral health intervention option 1
224040940|NCT04725617|OTHER|Health Approach 2 to Reduce Smoking|Behavioral health intervention option 2
224040941|NCT04014361|DRUG|LY3154885 - Capsule|Administered orally.
224040942|NCT04014361|DRUG|Placebo - Capsule|Administered orally.
224040943|NCT04014361|DRUG|Itraconazole|Administered orally.
224139802|NCT02895256|DRUG|Any treatment for cluster headache|
224139803|NCT03771456|PROCEDURE|Colorectal resections|Colorectal resections
224139804|NCT03215082|OTHER|Vestibular-Visual Intervention|vestibular-visual exercises
224139805|NCT03215082|BEHAVIORAL|standard care|standard care
223430749|NCT06470282|RADIATION|Intensity Modulated Radiation Therapy (IMRT)|Undergo standard of care, IMRT
224040944|NCT04014361|DRUG|LY3154885 - Tablet|Administered orally.
224040945|NCT04757883|OTHER|Study of the synthesis of antibodies directed against SARS|Between 5 mL and 45 mL of additional blood will be collected to study the synthesis of antibodies against CoV-2 SARS and to investigate whether specialised immune cells also show an effective response against the virus.
224040946|NCT02170090|DRUG|Gemcitabine|Gemcitabine 1000mg/m2
224040947|NCT02170090|DRUG|Cisplatin|Cisplatin 25mg/m2
224040948|NCT02170090|DRUG|Capecitabine|Capecitabine 1250mg/m2
224040949|NCT05225103|BEHAVIORAL|SAFETY-Acute intervention|The trauma-informed brief suicide intervention based on the SAFETY-A (single crisis session in addition to follow-up caring contacts). Delivered in addition to usual care in facilities.
224040950|NCT06604026|DEVICE|BD PosiFlush™ SafeScrub|"Clinicians will be advised to use BD PosiFlush™ SafeScrub as per the Instructions for Use for the treatment arm of the study.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."
224139806|NCT04823767|OTHER|Single anastomosis sleeve jejunal bypass with hiatal repair|Single anastomosis sleeve jejunal bypass with hiatal repair
224139807|NCT03041909|DRUG|GBT440|Oral drug
224139808|NCT00822484|BIOLOGICAL|ILV-095|
224139809|NCT00822484|OTHER|Placebo|
224040951|NCT06604026|DEVICE|BD PosiFlush™|"Clinicians will be advised to follow and document the respective unit protocol, while using the standard pre-filled syringe (BD PosiFlush™ SP Syringe) and alcohol pad for scrubbing and flushing of NADs in the control arm of the study as the routine practice.~An independent nurse observer will observe and document any adverse events (e.g.~local skin reaction, or irritation, or allergic response, up to and including symptoms of anaphylaxis), compliance with needleless access device scrubbing before flushing, device success rate (encapsulation and removal) as well as the time requirements and number of steps for needleless access device scrubbing prior to catheter flushes during medication administration process."
223430750|NCT06470282|PROCEDURE|Transurethral Resection of Bladder Tumor|Undergo TURBT
224040952|NCT06974916|PROCEDURE|Staged bilateral Exablate thalamotomy|Staged bilateral Exablate thalamotomy in ET patients
224040953|NCT06974916|OTHER|Local standard medical treatment after previous Exablate unilateral thalamotomy.|Local standard medical treatment
224040954|NCT06163326|DRUG|Ritlecitinib|Ritlecitinib 50 mg capsule once daily
224040955|NCT06163326|DRUG|Ritlecitinib 100 mg|Ritlecitinib 100 mg capsule once daily
224139810|NCT00663455|DRUG|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
223430751|NCT06470282|PROCEDURE|Cystoscopy (CS)|Undergo cystoscopy
223430752|NCT06470282|PROCEDURE|Computed Tomography (CT)|Undergo CT imaging
223430753|NCT06470282|PROCEDURE|Magnetic Resonance Imaging (MRI)|Undergo MRI imaging
223430754|NCT06470282|PROCEDURE|Positron Emission Tomography (PET)|Undergo PET Scan, may be combined with CT (PET/CT)
223430755|NCT02389244|DRUG|Regorafenib|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
223430756|NCT02389244|DRUG|Placebo|For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
223430757|NCT04602026|OTHER|Best Practice|Receive standard of care
223564900|NCT04215939|BEHAVIORAL|Thermoneutral environment participants with spinal cord injury|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
224139811|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
224139812|NCT00383721|DRUG|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
224139813|NCT00383721|DRUG|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
224139814|NCT00383721|DRUG|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
224139815|NCT00383721|DRUG|Placebo|Placebo MDI twice a day for 26 weeks
224139816|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
224139817|NCT00469638|PROCEDURE|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
224139818|NCT06350565|DRUG|Dexamethasone|This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
224299446|NCT06654063|PROCEDURE|non-surgical periodontal therapy (SRP)|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage."
223430758|NCT04602026|BEHAVIORAL|Exercise Intervention|Complete home exercise intervention
223430759|NCT04602026|PROCEDURE|Physical Therapy|Undergo physical therapy
223740298|NCT02392962|PROCEDURE|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
224040956|NCT06163326|DRUG|Placebo|Matching capsule once daily
224040957|NCT05932251|DRUG|Metformin|All patients are diagnosed with gestational diabetes and treated with metformin (per routine clinical practice
224040958|NCT03189043|DEVICE|Antimicrobial Surface|Antimicrobial Surface
223430760|NCT04602026|OTHER|Questionnaire Administration|Ancillary studies
223430761|NCT06372015|OTHER|Nutritional Approach|Nutritional Approach
223430762|NCT06372015|OTHER|Surgery Approach|Bariatric surgery
223430763|NCT05502770|DIAGNOSTIC_TEST|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
223430764|NCT05502770|OTHER|Physical development and General Health|Physical development and General health examination
223430765|NCT05502770|DIAGNOSTIC_TEST|Developmental Red flags|Developmental Red flags Questionnaires
224040959|NCT04470609|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
224040960|NCT04470609|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
224040961|NCT04470609|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
224040962|NCT04470609|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
224139819|NCT04939025|PROCEDURE|Multi-interventional program|"1. Preoperative oral antibiotics and antibiotic enema of the rectal stump prior to the surgery~2. Routine and tailored lengthening measures of the mesentery~3. Intraoperative control of pouch vascularization using ICG~4. Early diagnosis and active assessment of the integrity of the anastomosis.~   1. Routine CRP-measurements at day 4 and 6 (after removal pouch catheter) in the non-diverted pouches with CT-scan with rectal contrast if any suspicion on a leak (elevated or rise in CRP. symptoms).~  2. Routine CRP-measurements at day 4 in the diverted pouches with endoscopy 10-14 days after pouch creation.~5. Endosponge vacuum assisted closure (EVAC) of the anastomotic defect aiming to close the defect within 10-14 days after diagnosis.~6. MRI assessment of the pouch after stoma closure preferably at one year to rule out chronic sepsis mimicking pouchitis or Crohn's disease."
223430766|NCT05565586|DIETARY_SUPPLEMENT|High-Fiber Diet (HFD)|Participants are assigned to the high fiber diet, all meals and snacks will be provided to participants during the study. This diet includes fruits, vegetables and whole grains, a maximum of 18 oz. cooked red meat (including beef, pork, and lamb) per week, and little or no processed meats or added sugars.
223430767|NCT05565586|DIETARY_SUPPLEMENT|Prebiotic Food-Enriched Diet (PreFED)|Participants are assigned to the prebiotic food enriched diet, participants will receive 2 prepared snacks and 1 meal component (a key prebiotic ingredient to incorporate into meals and simple recipes) each day. Participants will also receive a handout that includes key prebiotic foods to incorporate into your own diet.
223430768|NCT00626236|DRUG|SPN-810|1.67mg capsule taken TID
223430769|NCT00626236|DRUG|SPN-810|3.33mg capsule taken TID
223430770|NCT00626236|DRUG|SPN-810|5mg capsule taken TID
223430771|NCT00626236|DRUG|SPN-810|6.67 mg capsule taken TID
223430772|NCT06286748|DIETARY_SUPPLEMENT|Beetroot juice|Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.
223430773|NCT06286748|OTHER|Placebo|Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
223430774|NCT06008171|OTHER|Patient Decision Aid|A designed tool (by us) that help patients and providers talk and decide together about field-directed treatment options for actinic keratosis.
223430775|NCT05934253|DRUG|Chloroprocaine ophthalmic gel 3%|FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.
223430776|NCT02559856|DRUG|Apixaban|
223430777|NCT02559856|DRUG|Rivaroxaban|
224139820|NCT00000639|DRUG|Itraconazole|
223430778|NCT05709444|DRUG|Bremelanotide|Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).
223430779|NCT05709444|DRUG|RAAS inhibition therapy|RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.
223430780|NCT03547362|DIETARY_SUPPLEMENT|Casein|See arm description
223430781|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 1|See arm description
223430782|NCT03547362|DIETARY_SUPPLEMENT|Whey protein|See arm description
223430783|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 2|See arm description
223430784|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 3|See arm description
223430785|NCT03547362|DIETARY_SUPPLEMENT|Dairy protein blend 4|See arm description
224139821|NCT00000639|DRUG|Flucytosine|
224139822|NCT00000639|DRUG|Fluconazole|
224139823|NCT00000639|DRUG|Amphotericin B|
223430786|NCT04283292|DRUG|Capsaicin|Topical Capsaicin for the treatment of Cannabinoid Hyperemesis Syndrome
223430787|NCT04283292|DRUG|Placebo|Placebo cream that is applied once topically
223430788|NCT06612099|OTHER|Aerobic Exercise|Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
223430789|NCT06612099|OTHER|Mat Pilates Exercise|Individuals in this group will perform mat pilates exercises under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 exercise sessions. During the exercise sessions, individuals will undergo a 50-minute mat pilates exercise program. In addition to the mat pilates exercise group, on the days when he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.
223430790|NCT00077441|DRUG|bortezomib|Given IV
223430791|NCT00077441|OTHER|laboratory biomarker analysis|Correlative studies
223740299|NCT02392962|PROCEDURE|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
224040963|NCT02593786|DRUG|Nivolumab|
224040964|NCT03370848|DIETARY_SUPPLEMENT|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
224040965|NCT03370848|DRUG|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
224040966|NCT01507558|PROCEDURE|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
224040967|NCT04543604|BEHAVIORAL|Leatlet + visual aid (pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
223430792|NCT03978247|DIAGNOSTIC_TEST|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
224040968|NCT04543604|BEHAVIORAL|Leaflet + no visual aid (no pictogram)|The questionnaires were collected at baseline (at the end of the initial interview and once the patients assigned within the test groups declared to have read the leaflet) at 3- and 6-month follow-up. The questionnaire included demographic data such as age, gender, civil status, occupation (coded according to the CNO-11(2010), presence of systemic disorder, smoking and number of implants. Moreover, data concerning history of periodontal disease and type of prosthesis were further documented and added to demographics.
224040969|NCT00198627|DRUG|Co-Trimoxazole; TMP-SMZ|
224040970|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
224040971|NCT01130051|DRUG|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
224040972|NCT02898311|DEVICE|immediate loading of posterior implants with chairside CAD-CAM composite crown|
224040973|NCT00188422|PROCEDURE|low dose CT|
224139824|NCT01522625|DRUG|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
224139825|NCT01522625|DRUG|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
224139826|NCT05078073|DEVICE|Hyperbaric oxygen therapy|Patients with aGVHD treated with HBOT every two days
224139827|NCT00328965|DRUG|Lacidipine|Lacidipine 2, 4, 6mg
223430793|NCT06374277|OTHER|Med AAAction intervention|The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
223564901|NCT04215939|BEHAVIORAL|Warm environment participants with spinal cord injury|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
224040974|NCT02789735|DEVICE|Active laser therapy|Laser therapy at predetermined sites
224139828|NCT03935165|DRUG|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~\- Indocyanine Green is administered Intravenously"
224139829|NCT04674839|DRUG|MS-20|fermented soymilk product
224139830|NCT04674839|OTHER|Placebo|No active ingredient
224139831|NCT00211250|DRUG|Valproic Acid and Depakote ER|
224040975|NCT02789735|DEVICE|Sham laser therapy|Sham therapy at predetermined sites
224040976|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam tablet (reference - Treatment A) administered orally.
224139832|NCT03431701|OTHER|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
224040977|NCT05315947|DRUG|brivaracetam|Study participants will receive a single-dose of brivaractam dry syrup (test - Treatment B) administered orally.
224139833|NCT03431701|OTHER|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
224139834|NCT03431701|OTHER|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
224139835|NCT01568424|DEVICE|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
224139836|NCT01506050|DRUG|Desloratadine|Desloratadine ODT 5 mg
224139837|NCT03348241|DRUG|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
224139838|NCT03348241|DRUG|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
224139839|NCT03348241|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
224139840|NCT02612441|DEVICE|real Acupuncture Needles|Acupuncture needles
224040978|NCT02612025|BEHAVIORAL|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
224040979|NCT02767128|DRUG|Triferic|
224040980|NCT02767128|DRUG|Fer-In-Sol|
224040981|NCT02767128|DRUG|Shohl's solution|
224040982|NCT03998293|DRUG|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
224040983|NCT03398525|OTHER|usual care|usual care following local standard operational procedures
224040984|NCT03398525|OTHER|Musical intervention|Musical intervention using a marketed music program validated for music therapy
224040985|NCT02632565|DRUG|Lidocaine|
224139841|NCT02612441|DEVICE|sham Acupuncture Needles|sham Acupuncture Needles
224139842|NCT03519516|DRUG|PRO-174|"Pharmaceutical form: ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
224040986|NCT02632565|DRUG|Saline|
224040987|NCT06679205|BEHAVIORAL|Multidisciplinary and multimodal intervention|"The PAINDOC Program consists in:~* Therapeutic education: The therapeutic education block consists of 2 parts: a 2-hour education session called Empowered Relief® and 2 1-hour pain neuroscience education sessions.~* Psychotherapy: The psychotherapy part consists of 1 group session of 1 hour, face-to-face and with groups of up to 15 people.~* Therapeutic exercise: The therapeutic exercise module consists of 3 sessions of 1 hour each, face-to-face, with small groups of between 6 and 10 patients, and given by the physiotherapist of the pain unit."
224040988|NCT06679205|DRUG|Usual Care|The pharmacological treatment will be individualised according to pain intensity, contraindications and the appearance of adverse effects.
224040989|NCT04252287|DRUG|Canagliflozin 100 mg|Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
224040990|NCT04252287|DRUG|Placebo|Participants will receive matching placebo capsules orally once daily.
223430794|NCT03050541|DRUG|MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
223430795|NCT03050541|DRUG|Placebo|
223564902|NCT04215939|BEHAVIORAL|Cold environment healthy male participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
223564903|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy male participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
223564904|NCT04215939|BEHAVIORAL|Warm environment healthy male participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
223564905|NCT04215939|BEHAVIORAL|Cold environment healthy female participants|In a cold environment (15-17°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
224040991|NCT06574100|DRUG|Cannabidiol|Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
224040992|NCT06574100|DRUG|Cannabidiol|Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
224040993|NCT05871164|PROCEDURE|Pancreatic radiofrequency|Pancreatic radiofrequency is similar to a puncture under echoendoscopy. The lesion is located then punctured by transgastric or transduodenal route either using a 19 gauge needle with exchange of the stylet for a probe, or using a 19 gauge needle whose distal end of 5-10 mm corresponds to the active part, connected to a generator with an integrated cooling system.
224040994|NCT00632398|BEHAVIORAL|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
224040995|NCT00632398|BEHAVIORAL|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
224139843|NCT03519516|DRUG|Sophixín Ofteno®|"* Active substance: Ciprofloxacin 0.3%~* Pharmaceutical form: Ophthalmic solution~* Prepared by: Laboratorios Sophia, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: sterile multi-dose bottle"
223430796|NCT02104349|BEHAVIORAL|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
223430797|NCT04369040|DEVICE|High-flow nasal oxygen therapy using a specific nasal cannula|Patient in this arm will received high-flow nasal oxygen therapy ventilation during the ENT surgery
223430798|NCT04369040|DEVICE|Flow Controlled Ventilation using a laryngeal tri-tube|Patient in this arm will received a laryngeal tri-tube ventilation during the ENT surgery
224040996|NCT01217216|BEHAVIORAL|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
224040997|NCT01217216|BEHAVIORAL|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
224040998|NCT05359965|DEVICE|Positive Airway Pressure|Gentle and steady pressure (with or without supplemental oxygen) delivered to the airways of the lungs while subjects are sleeping.
224040999|NCT04612413|DRUG|Allocetra-OTS|Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
224041000|NCT04612413|OTHER|Placebo|Solution containing all excipients except for the Allocetra-OTS cells
224041001|NCT06650813|OTHER|Drépa-FACETS Program|Drépa-FACETS Program for Sickle Cell Disease
224139844|NCT02849314|DEVICE|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
224041002|NCT06267521|OTHER|Healthy Minds Program|Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.
224041003|NCT06267521|OTHER|Sham Meditation Didactic Material|Participants will listen to lessons from the Healthy Minds Program at home for four weeks, which will not include any actual meditation exercises.
224041004|NCT06267521|DEVICE|Sham Stimulation in Lab|On two nights each week during the four weeks of the intervention, participants will sleep in the lab and undergo sham TES-TI stimulation for approximately 10 hours per night
224041005|NCT06267521|DEVICE|Stimulation in Lab|Participants will sleep in the lab and undergo active TES-TI stimulation for approximately 10 hours per night.
224041006|NCT06267521|DEVICE|MRI Scanner|Imaging protocol will include: structural T1-weighted and T2-weighted images, resting-state functional MRI, task-based functional MRI, and multi-shell diffusion weighted MRI, total scan time will be approximately 2 hours
224041007|NCT02715466|DRUG|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
224041008|NCT02715466|DRUG|Balanced electrolyte solution|Sterofundin ISO
223430799|NCT05103176|DEVICE|TMS|A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be utilized to deliver brain stimulation. All participants will receive five consecutive days of stimulation. The 3-minute session of intermittent Theta Burst Stimulation (iTBS) will consist of 10 bursts of high-frequency stimulation (a 2 s train of 3 biphasic waveform pulses at 50 Hz repeated every 200 ms at 80% AMT) repeated every 10 s for a total of 190 s (600 pulses) to the target area. The target area will be located using BrainSight2 neuronavigation system. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
224041009|NCT04452487|BEHAVIORAL|decisions of limitations and stop processing|Compliance of the modalities of decisions of limitations and stop processing
224041010|NCT01395979|BEHAVIORAL|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
224041011|NCT01395979|BEHAVIORAL|Supportive Psychotherapy|Eight weekly sessions
224041012|NCT01395979|BEHAVIORAL|Sexual Risk Reduction Intervention|Two weekly sessions.
223430800|NCT05103176|BEHAVIORAL|Object directed grasping|"Subjects will perform a precision grip with the right hand towards either a small or large target object positioned in front of them. The illumination of an LED (green or red) will instruct the subject to plan a precision grip towards either a small or large target object positioned in front of them. After \~1 second, the LED will extinguish and cue subjects to execute the intended object-directed hand action. The presentation of the visual stimuli will be synchronized with the iTBS stimulation, which will occur 800ms before the onset of every GO cue in order to modulate cortical activity during both the planning and execution phase of the action."
223430801|NCT06210789|PROCEDURE|Surgical excision|Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
223564906|NCT04215939|BEHAVIORAL|Thermoneutral environment healthy female participants|In a thermoneutral environment (22-24°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
224139845|NCT02849314|BIOLOGICAL|NK immunotherapy|Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
223430802|NCT06052137|DEVICE|Active TBS-DLPFC|"Participants will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
224041013|NCT05475652|OTHER|Manual therapy|The manual therapy intervention is performed twice on the experimental group, once on day 0 (D0) and the second time on day 7 (D7). This intervention consists of a manual therapy protocol (base on myofascial release) applied to the cervical spine. Protocol consists of succession of techniques: suboccipital decompression, disengagement of Cervical 0-1-2,vibratory stimulation at C4 level and myofascial release technique of the cervical aponeuroses. Outcomes are evaluated before and after intervention.The same schedule will be reproduced on D7. On D21, only one assessment will be done at the beginning of the session.
224041014|NCT05475652|OTHER|Placebo intervention|"The Sham group receives placebo treatment twice (D0 and D7). This placebo treatment also called light touch treatment consists of applying light pressure with broad support from both hands on either side of the joint, in contact with the skin, without equal bone pressure or therapeutic intention, for a duration comparable to that of manual therapy. Outcomes are evaluation before and after placebo intervention. The same schedule will be reproduced at D7. On D21, only one assessment will be done at the beginning of the session and a manual therapy treatment on the cervical spine is provided to balance access to care in the two group"
224041015|NCT00464230|PROCEDURE|Bipolar hemiarthroplasty (Charnley/Hastings)|
224041016|NCT00464230|PROCEDURE|Internal fixation with two parallel screws (Olmed)|
224041017|NCT03523260|DEVICE|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
224041018|NCT01144767|BEHAVIORAL|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
224041019|NCT01144767|BEHAVIORAL|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
224139846|NCT01935336|DRUG|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
224139847|NCT01853436|DEVICE|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
223430803|NCT06052137|DEVICE|TBS-DMPFC|"Participants will receive intermittent TBS to DMPFC. The DMPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the DMPFC using a MagPro TMS system (MagVenture, Denmark)."
223430804|NCT03596671|DEVICE|RENOVA iStim™ System|Tibial implantable neuromodulation device
223430805|NCT03548961|DRUG|FOLFOX regimen|FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
224041020|NCT02852486|DRUG|Pioglitazone 30 Mg Oral Tablet|30 mg/day, orally, for 3 months, before imatinib discontinuation
224041021|NCT02852486|OTHER|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
224041022|NCT02936128|OTHER|TruSkin|
223430808|NCT02544295|BEHAVIORAL|Clinical interview|
223430809|NCT02544295|BEHAVIORAL|Virtual reality task|
223430810|NCT04291326|DIAGNOSTIC_TEST|Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound
223430811|NCT03606694|DRUG|Dihydromyricetin|The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.
223430812|NCT03606694|DRUG|Metformin|The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
223430813|NCT02824016|BIOLOGICAL|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
223430814|NCT02824016|RADIATION|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
223430815|NCT04991363|PROCEDURE|Bleaching|Digital images for each patient will be taken once with the camera fixed on the classic tripod and again when the camera was fixed on the ISD , then horizontal and vertical measurements of the canines will be recorded by using a computer software on the digital images, then bleaching will be fine for all patients, then a second set of images will be taken again with the tripod and then with ISD, then measurements will be repeated and compared with the first set of images
223430816|NCT00088959|DRUG|erlotinib hydrochloride|Given orally
223430817|NCT00088959|DRUG|celecoxib|Given orally
223430818|NCT00088959|OTHER|laboratory biomarker analysis|Correlative studies
223564907|NCT04215939|BEHAVIORAL|Warm environment healthy female participants|In a warm environment (33-35°C and 40-50% relative humidity), participants will stay in a sited position for 20 minutes in order to collect baseline data and to allow their blood flow and body temperature adapt to the exposing environmental condition. Immediately after the baseline period participants will immerse their left hand and foot in warm water (34-36°C) for five minutes for a consistent starting (hand and foot) temperature. Following that participants will immerse their hand and foot in cold water (8°C) for 40 minutes.
223564908|NCT01498575|BEHAVIORAL|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
224041023|NCT02936128|OTHER|Wound Cover|
223430819|NCT05450926|PROCEDURE|Ultrasound-guided selective cervical nerve root block|The volunteer will be placed in the lateral decubitus position with the examined side up and the ultrasonographic examination will be started. Using a high frequency 6-18 MHz linear transducer, scanning in the cephalad and caudal direction until the cervical tubercles are identified in the short axis of the vertebra at the cricoid level, the localization and number of the target nerve root and vascular structures in the foraminal opening between the anterior and posterior tubercles of the transverse process from C4 to C8. will be defined as Unlike healthy volunteers, local anesthetic and steroid injections will be administered to the target nerve.
223430820|NCT01825356|PROCEDURE|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
223430821|NCT01825356|PROCEDURE|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
223430822|NCT03219151|DEVICE|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
223430823|NCT03219151|OTHER|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
223430824|NCT01333358|DRUG|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
223430825|NCT02915536|OTHER|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
223430826|NCT02872857|DRUG|Placebo|Placebo will match drug capsules.
223430827|NCT02872857|DRUG|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
223430828|NCT02872857|DRUG|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
224041024|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
224041025|NCT02790580|DRUG|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
224041026|NCT05493085|PROCEDURE|Quadratus lumborum block|Ultrasound-guided quadratus lumborum block
224041027|NCT05493085|PROCEDURE|Caudal epidural injection|Single Caudal epidural injection
223430829|NCT05108740|DRUG|everolimus|Self-administered as a daily dose of 10mg orally
223430830|NCT03443310|PROCEDURE|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
223564909|NCT04587843|DRUG|Contrave 8Mg-90Mg Extended-Release Tablet|"Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.~Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a day)."
223564910|NCT04587843|DRUG|Placebo|Placebo tablets will be administered orally. Participants randomized to the control arm will be administered 4 placebo tablets a day for 1 year (2 tablets, taken twice a day).
223564911|NCT02694276|BEHAVIORAL|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
223564912|NCT03652857|DRUG|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
223564913|NCT06014606|DRUG|placebo|oral formulation
223564914|NCT06014606|DRUG|haloperidol 2mg|oral formulation
223564915|NCT06014606|DRUG|propranolol 40mg|oral formulation
223564916|NCT02293252|DEVICE|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
223564917|NCT01296633|BEHAVIORAL|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
223564918|NCT04282096|OTHER|native and non native casein|selected participant will test the 3 treatments in a random order
223564919|NCT02527226|BEHAVIORAL|Facial exercises|A series of self-administered facial movements and expressions.
223564920|NCT00918164|DRUG|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
224041028|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
223430831|NCT04142164|OTHER|MacInfo presentation|Presentation about intravitreal drug injection
223564921|NCT04124562|OTHER|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
223564922|NCT02420288|BEHAVIORAL|Exercise Group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
224041029|NCT00889018|DRUG|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
223430832|NCT04142164|OTHER|Placebo presentation|Placebo presentation
223430833|NCT02663752|PROCEDURE|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
223564923|NCT02899650|OTHER|exercise|acute downhill running
223430834|NCT02663752|DRUG|Deferasirox|Patients are already on commercial deferasirox before entering the study.
223430835|NCT01779167|DRUG|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \& 27)
224041030|NCT01080677|DRUG|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
224041031|NCT01080677|DRUG|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
224041032|NCT01739153|OTHER|Dietary intervention: CHEESE (High cheese intake)|
224041033|NCT01739153|OTHER|Dietary intervention: MEAT (High Meat intake)|
224041034|NCT01739153|OTHER|Dietary intervention: CARB (High Carbohydrate intake)|
223430836|NCT01779167|DRUG|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \& 28). Lenalidomide will be initiated at a starting dose of 5 mg.
223430837|NCT01779167|DRUG|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
223430838|NCT04392167|DEVICE|a/LCI-OCT imaging probe|a/LCI and OCT imaging measurements of several locations in the esophagus
223430839|NCT04392167|PROCEDURE|esophageal biopsy|biopsies of esophageal tissue imaged by a/LCI-OCT probe
224041035|NCT01096134|BIOLOGICAL|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
223430840|NCT06010420|DEVICE|insoles|Insoles are support devices that take the shape of the foot structure and enable the foot to press in a correct form.
223430841|NCT01644526|DEVICE|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
223430842|NCT01652326|DRUG|Diazepam|
223430843|NCT02395263|DRUG|Yuxintine|
223430844|NCT06095635|OTHER|Placebo Protocol|ingestion of 500 mg of starch following 30 minutes of exercise (treadmill)
223564924|NCT01608698|DRUG|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
224041036|NCT03719755|PROCEDURE|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
223430845|NCT06095635|OTHER|Protocol Beet|ingestion of 500 mg of beet extect following 30 minutes of exercise (treadmill)
223430846|NCT06095635|OTHER|Protocol Resveratrol|ingestion of 500 mg of resveratrol following 30 minutes of exercise (treadmill)
223430847|NCT06095635|OTHER|Protocol Beet and Resveratrol|ingestion 500 mg of beet extect and 500 mg of resveratrol following 30 minutes of exercise (treadmill)
223430848|NCT00955045|DRUG|istradefylline|
223430849|NCT04585399|BEHAVIORAL|Contingency management|Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
223564925|NCT01608698|DRUG|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
223564926|NCT00022360|DRUG|taurolidine|
224041037|NCT03719755|PROCEDURE|Normal Saline|Cystoscopic distention media of normal saline
224041038|NCT00835120|DRUG|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
224041039|NCT03813290|DEVICE|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
224299447|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Omega-3|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA)~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Patients will start taking Omega-3 supplements on the day of SRP procedure."
223430850|NCT01071239|DEVICE|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
223430851|NCT01071239|DRUG|Busulfan|Chemotherapy administered as a part of the HSCT conditioning regimen.
223430852|NCT01071239|DRUG|Fludarabine|Chemotherapy administered as a part of the HSCT conditioning regimen.
223430853|NCT01071239|DRUG|Cyclophosphamide|Chemotherapy administered as a part of the HSCT conditioning regimen.
223430854|NCT01071239|DRUG|ATG|Chemotherapy administered as a part of the HSCT conditioning regimen.
223430855|NCT02428803|OTHER|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
223430856|NCT05821790|OTHER|Surgical waste and Data collect|Samples required for the study will be obtained from surgical waste of patients who underwent meningioma resection. Data necessary for the study will be collected from the patient's medical records, MRI examinations, and data specific to the characteristics of the surgical waste.
223430857|NCT03251794|DIAGNOSTIC_TEST|three dimensional ultrasound|evaluation of the suprarenal glands
223430858|NCT03251794|DIAGNOSTIC_TEST|color Doppler|Doppler evaluation of the suprarenal artery
223564927|NCT02138409|DRUG|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
223564928|NCT02138409|DRUG|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
223564929|NCT04154449|DRUG|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
223430859|NCT05734950|OTHER|Translational study|Non-interventional, translational study
223430860|NCT05057117|DEVICE|Microwave thermolysis|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
223430861|NCT05057117|DRUG|Botulinum toxin A|Baseline treatment with microwave thermolysis in one axilla and botulinum toxin A in the contralateral axilla, as allocated by randomization
224041040|NCT05134051|DEVICE|Shockwave® Intravascular Lithotripsy System (Shockwave Medical Inc)|IVL is a novel balloon catheter-based device that utilises pulsatile mechanical energy to disrupt calcified lesions. IVL differs from other types of lithotripsy with respect to depth of penetration. It is a single-use, sterile, disposable balloon catheter. The emitters convert electrical energy into transient acoustic circumferential pressure pulses that disrupt both superficial and deep calcium within plaque. The balloon catheter is connected to the generator, which is programmed to deliver the specified dosage of pulses. The IVL balloon, sized 1:1 to the reference artery ratio, is inflated low pressure (4 atm) with 10 pulses of ultrasound energy of 10s delivered per balloon. The procedure is repeated to provide a minimum of 20 pulses in the target lesion, with interval deflation to allow distal perfusion. Each catheter can emit a max of 80 pulses at a rate of one pulse per second. If the lesion exceeds the 12mm balloon length, the balloon can be repositioned and the IVL repeated.
224041041|NCT05541432|OTHER|Supervised strength training (group 1)|Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of 10-12 repetitions at an intensity of \~70% of estimated 1 repetition maximum.
224041042|NCT05541432|OTHER|Supervised strength training (group 2)|Participants in this arm will complete twice weekly resistance training. They will focus on form initially, and then be progressed to 3 sets of \~4-6 repetitions at an intensity of 85% of estimated one repetition maximum, with a warm-up set of 8 repetitions at their estimated 70% estimated one repetition maximum to attempt to match the volume performed in the other resistance training group.
224041043|NCT05541432|OTHER|Home exercise|Participants in this arm will complete twice-weekly upper and lower body exercises at home, focused on posture and balance. Participants will meet 1:1 with an exercise physiologist who will select and prescribe exercises. Participants will also be invited to attend twice monthly virtual exercise and education sessions.
223430862|NCT04518969|DEVICE|CytoSorb|"CRRT with CytoSorb.Nevertheless , patients will be uniquely in CVVHD mode in order to measure only the CytoSorb Effect.~First 24 h : the CytoSorb should be changed after 12 h as we forecast a huge cytokine storm in the first 24 hours.~After the initial 24 h, cartridge change will occur every 24 hours up a maximum of 96 h in total in the inflammation storm persist."
224041044|NCT01843868|DRUG|Standard anti-emetics in conjunction with R-CHOP|
223430863|NCT05391581|OTHER|GIPR antagonist / study tool|Selective antagonist of the GIPR, GIP(3-30)NH2
224041045|NCT00617188|DRUG|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
224041046|NCT03230526|DRUG|[18F]DPA-714 PET scan|"One PET scan using \[18F\]DPA-714 is done at M2 between two \[123I\]FP-CIT scan (DaTscan) done at M1 and M23.~Neuropsychological assessment is done at M0, M18 and M24"
224041047|NCT04805554|OTHER|Joint Insights decision aid|The Joint Insights decision aid was developed by Dell Medical School faculty in collaboration with OM1, a health outcomes and predictive analytics company. This decision aid uses patient-report outcome measures (PROMs) - specifically, the PROMIS Global and the KOOS JR - along with patient clinical and demographic information (age, sex, race, ethnicity, chronic narcotic use, body mass index), in machine-learning-based predictive analytic models to provide personalized estimates of likely benefit or harm from total knee replacement surgery. The tool is designed to collect PROMs or pull in PROMs collected through other systems (e.g., an EHR or a third-party PROM platform). It also provides condition-specific education to patients with knee OA and allows a patient to reflect on and document their preferences and goals. The personalized risk/benefit report generated by the decision aid is meant to be discussed with the patient's provider to enhance shared decision making.
224041048|NCT00473421|PROCEDURE|Barium Sulphate and Zirconium Oxide|
224041049|NCT01298518|DRUG|PF-04620110|5 mg of PF-04620110 given once daily
223430864|NCT05391581|OTHER|GLP-2R antagonist / study tool|Selective antagonist of the GLP-2R, GLP-2(3-33)
223430865|NCT05391581|OTHER|Placebo|Saline
224041050|NCT01298518|DRUG|PF-04620110|2.5 mg of PF-04620110 given twice daily
223430866|NCT01831323|DIETARY_SUPPLEMENT|VSL#3|VSL#3
223430867|NCT01831323|DRUG|Rifaximin|Rifaximin
223430868|NCT01831323|DRUG|Mesalazine|Mesalazine
223430869|NCT01831323|DIETARY_SUPPLEMENT|Psyllium|psyllium
223430870|NCT06731738|DRUG|Gadoteric acid|A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.
223564930|NCT06130774|OTHER|Retro walking and conventional|Patient will start retro walking with first he/she will raise his/her one foot with toe off first then heel will be off from ground. swing phase of same leg would be done in backward direction with flexion on knee and extension will be performed on hip. Then patient will place the same foot on ground behind the other foot, with toe touch first on ground, and so this way patient would continue his retro-walk for 20 minutes
223564931|NCT06130774|OTHER|conventional therapy|Hot pack in supine lying (10min) TENS (10min ) Tibiofemoral mobilization (grade 1,2 ,3) (10rep) Static quadriceps exercise in supine (10rep x 3sec x2set) hip abduction in side lying(10repx 2set) knee bending exercise in prone lying ( 10rep x 2set) Hamstring stretch in supine ( 10 rep x 2 set)
223564932|NCT02294838|DEVICE|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
224041051|NCT01298518|DRUG|Placebo|Matching placebo giving for 4 weeks
223430871|NCT06731738|DRUG|Mangafodipir trisodium injection|Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.
223430872|NCT02165475|BEHAVIORAL|Biofeedback|
223430873|NCT02165475|DRUG|Loperamide|
223430874|NCT02165475|DRUG|Stool bulking agent (stericulia or isphagula husk)|
224041052|NCT02823808|DRUG|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
223430875|NCT02165475|OTHER|Combination of biofeedback and medical treatment|
223430876|NCT05597579|DIAGNOSTIC_TEST|DAPAR Tests (IQ equivalent test)|This study will compare DAPAR scores before and after the onset of the psychotic illness.
223430877|NCT04063657|PROCEDURE|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
223430878|NCT04063657|PROCEDURE|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
223430879|NCT04382144|DRUG|Liposomal bupivacaine|Patient will receive a single injection of a local anesthetic into the common extensor origin.
223430880|NCT03336723|DEVICE|Dental Implant|Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
223430881|NCT06454916|DEVICE|Small Bowel Anastomosis with Flexagon SFM Device with OTOLoc|This study will investigate one type of intervention: small bowel anastomosis creation in subjects undergoing laparoscopic small bowel surgery. Flexagon SFMs and OTOLoc devices will be delivered laparoscopically into two different sections of small bowel that are intended to be anastomosed. An OTOLoc device will be deployed into the small bowel wall in one section of the small bowel to provide access for the deployment of a Flexagon SFM into that section of bowel. The process is repeated at the second section of bowel. Once deployed, the Flexagon SFMs are approximated and positioned, after which the SFMs are couple together to form the anastomosis, with the OTOLoc devices allowing fluidic communication between the two sections of bowel until the anastomosis is fully formed.
223430882|NCT06528795|OTHER|Scenario-based high-reality hybrid simulation method|"Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario."
223430883|NCT05452733|BEHAVIORAL|differences of behavior between sleepwalking and non sleepwalking patient|movement registry done by camera when low intensity sound are send to patient during sleep.
224041053|NCT02823808|DRUG|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
224041054|NCT05001854|DRUG|Fludrocortisone|100 μg every 6 hours of fludrocortisone per os
224041055|NCT05001854|DRUG|Placebo|100 μg every 6 hours of placebo per os
224041056|NCT04338555|PROCEDURE|Transcutaneous electrical acupoint stimulation|TEAS group will receive electrical stimulation of acupoints at Neiguan and Shenmen points for 30 min every hour during the surgery.
224041057|NCT00006380|BIOLOGICAL|monoclonal antibody muJ591|
224041058|NCT00006380|RADIATION|iodine I 131 monoclonal antibody muJ591|
224041059|NCT01353456|DRUG|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
223430884|NCT03408444|DEVICE|EMO-114|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
223430885|NCT03408444|DEVICE|EMO-116|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
223430886|NCT03408444|DEVICE|EMO-118|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
223430887|NCT03408444|DEVICE|EMO-117|Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
223430888|NCT04984681|BEHAVIORAL|Mindfulness|The traditional mindfulness intervention consists of the following: (1) orientation; (2) a series of eight weekly session of 2.5 to 3 hours; (3) a silent retreat during the between weeks 4 and 6; (4) daily home assignments including formal and informal mindfulness practices; and (5) didactic presentations on stress and the consequences of stress.
223430889|NCT04984681|OTHER|Usual Care|The control condition will continue receiving usual care or standard of care.
223430890|NCT03141775|OTHER|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
223564933|NCT02294838|OTHER|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
223564934|NCT02294838|OTHER|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
224041060|NCT01353456|DRUG|Normal Saline|Same volume as dexmedetomidine given
224041061|NCT00583570|BEHAVIORAL|dietary education|dietary education
224041062|NCT02273726|DRUG|Epoetin Alfa|Epoetin alfa will be administered per dose and schedule specified in the arm.
224041063|NCT02273726|DRUG|Roxadustat|Roxadustat will be administered per dose and schedule specified in the arm.
224041064|NCT05197751|BIOLOGICAL|MSP3-CRM-Vac4All/ Alhydrogel®|The Investigational Medicinal Product (IMP) or in short Investigational Product (IP) is the MSP3-CRM-Vac4All/ Alhydrogel® vaccine
224041065|NCT06046755|OTHER|Very low calorie ketogenic diet (VLCKD)|Weight loss therapies in patients with excess body weight based on a ketogenic diet
224041066|NCT06046755|BEHAVIORAL|Group educational intervention program (IGOBE)|Balanced hypocaloric diet plus structured groupal program of habits change and exercise
224041067|NCT02407366|DRUG|Icotinib|Icotinib (125 mg ,Three times daily)
224041068|NCT02407366|DRUG|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
224041069|NCT02407366|DRUG|Carboplatin|Carboplatin (AUC，5) every 21 days
224041070|NCT02407366|RADIATION|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
224041071|NCT03610165|DEVICE|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
224041072|NCT03610165|DEVICE|Control|Arterial waveform and pressures
224041073|NCT05420883|OTHER|Acupressure|One minute after the Nonstress test recording starts, sequential pressure will be applied to the Zhi yin (BL67) acupuncture points simultaneously for 2 minutes. The process will be repeated a second time, with a three-minute rest period. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
223430891|NCT00357136|BEHAVIORAL|password usage|
224041074|NCT05420883|OTHER|Halojen ışık|One minute after the start of the Nonstress test recording, halogen light stimulation will be given from the mother's abdomen over the fetal head for 10 seconds and the procedure will be repeated after 10 minutes. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
224041075|NCT05420883|OTHER|Control|No application will be made to the control group. After the 20-minute Nonstress test procedure, the test will be evaluated by the researcher and her anxiety will be determined.
223564935|NCT04117581|DIETARY_SUPPLEMENT|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
223564936|NCT04117581|OTHER|Placebo|Inert filler capsules daily over 12 weeks (84 days)
224041076|NCT06072287|DIAGNOSTIC_TEST|Living with LTC Questionnaire|A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
224041077|NCT03125213|DRUG|AL-3778|AL-3778 tablets
224041078|NCT03125213|DRUG|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
224041079|NCT03125213|DRUG|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
224041080|NCT01568645|DRUG|Carvedilol|
224041081|NCT01568645|DRUG|Imatinib|
224041082|NCT05608902|OTHER|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection|Dynamic full-field optical coherence tomography analysis of skin biopsy or resection in the dermatology department before conventional histopathological analysis
224041083|NCT02921204|OTHER|Vitamin D status|There is no intervention in this study
224041084|NCT01301651|BEHAVIORAL|balance training|30 minute each time, 2 times per week for 6 weeks.
224041085|NCT00628303|BIOLOGICAL|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
224041086|NCT00628303|OTHER|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
224041087|NCT03653533|DEVICE|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
224041088|NCT03653533|DEVICE|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
224041089|NCT03653533|DEVICE|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
224041090|NCT04093427|OTHER|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
224041091|NCT04547673|DIAGNOSTIC_TEST|rigid nasal endoscopes|The endoscope is introduced through the nasal passage to observe, in sequence, the posterior nostril, superior and posterior walls of the nasopharynx, torus tubarius, pharyngeal opening of the auditory tube, and Rosenmu¨ller recess. The imaging light mode is set to conventional WLI and subsequently switch to NBI during the procedure, and representative images are collected and preserve for further analysis. All lesions, detected by either WLI or NBI, are biopsied.
223430892|NCT00960349|DRUG|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
223430893|NCT00960349|DRUG|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
223430894|NCT00960349|DRUG|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
223430895|NCT00960349|DRUG|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
223430896|NCT00960349|DRUG|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
223430897|NCT00001736|DRUG|Cysteamine|
223564937|NCT02049827|OTHER|participation in the study|
223564938|NCT05369520|DEVICE|TESCoN device - Thoracic stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the thoracic spinal cord (T7-T12, Group 1).
223564939|NCT05369520|DEVICE|TESCoN device - Lumbosacral stimulation|TCSCS will be delivered using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). The stimulation site will be over the lumbosacral spinal cord (L1 - L3, Group 2).
223564940|NCT02858986|PROCEDURE|3D laparoscopy|
223564941|NCT02858986|PROCEDURE|4K laparoscopy|
224041092|NCT02764450|DEVICE|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
224041093|NCT02764450|DEVICE|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
224041094|NCT02129205|DRUG|PF-06650808|Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
224041095|NCT02129205|DRUG|PF-06650808|Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
224041096|NCT00903656|DRUG|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
224041097|NCT00671554|BIOLOGICAL|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
224041098|NCT00184977|DRUG|N-acetylcysteine|
224041099|NCT00184977|DRUG|fluticasone propionate|
224041100|NCT02121496|BEHAVIORAL|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
224041101|NCT05196672|BEHAVIORAL|Virtual reality and eye mask|Adults will receive a virtual reality program 30 min before bedtime and then be placed on an eye mask during their sleep for consecutive 2 nights of ICU stay.
223430898|NCT03447600|BEHAVIORAL|Alternate Day Fasting|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
223430899|NCT03447600|BEHAVIORAL|Continuous dietary restriction|25% daily energy requirements every other day until study completion at \>/=5% weight loss which is an average of 12 weeks.
223430900|NCT02267213|DRUG|Lipotecan|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
223430901|NCT00568256|BEHAVIORAL|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
223430902|NCT00957749|DRUG|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
223430903|NCT01823172|PROCEDURE|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
223430904|NCT04628078|OTHER|Use of echocardiography guidance for LAAC|Since August 2015, the echocardiography is routinely used by majority of operators to guide LAAC
223430905|NCT01279564|DEVICE|ETview TVT endotracheal tube|intubation
223430906|NCT01279564|DEVICE|Endotracheal tube|Intubation
223430907|NCT00287391|DRUG|Rabeprazole|
223430908|NCT00782691|OTHER|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
223430909|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
223430910|NCT02847026|BIOLOGICAL|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
223430911|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
223430912|NCT02847026|BIOLOGICAL|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
223430913|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
223564942|NCT04446507|DRUG|Saroglitazar magnesium|1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
223564943|NCT02514694|DRUG|LEO32731|
223564944|NCT02514694|OTHER|Placebo|
223564945|NCT04783779|DEVICE|Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
223564946|NCT03469986|DEVICE|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
223564947|NCT01419613|BEHAVIORAL|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
223564948|NCT01419613|BEHAVIORAL|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
223564949|NCT00764387|DRUG|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
223564950|NCT00764387|DRUG|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
223564951|NCT03796390|BIOLOGICAL|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
223564952|NCT01126437|DRUG|tiotropium 18 mcg|HandiHaler
223564953|NCT01126437|DRUG|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
223564954|NCT01126437|DRUG|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
223564955|NCT03775343|DIAGNOSTIC_TEST|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
224299448|NCT06654063|DIETARY_SUPPLEMENT|non-surgical periodontal therapy (SRP)+ Vitamin D|"* The CAL PPD and mSBI will be measured for each patient and will be recorded at baseline and 6 weeks~* all patients will receive supragingival and sub-gingival plaque and calculus debridement (SRP) with an ultrasonic scaler (Various 350; NSK, Japan) and a manual universal curette (Gracey; Hu-Friday, Chicago, USA) where, conventional scaling and root planning (SRP) to the bottom of the pocket of 4 mm or more~* Subgingival saline irrigation will be performed adjunctively to Sub-gingival curettage.~* Serum vitamin D levels will be assessed at baseline and 6 weeks after intervention in all groups."
224299449|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
224041102|NCT03374098|BEHAVIORAL|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
224041103|NCT03374098|BEHAVIORAL|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~* Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~* Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~* Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
224041104|NCT02877927|DRUG|Omadacycline|po tablets
224041105|NCT02877927|DRUG|Linezolid|po tablets
224299450|NCT01615263|DEVICE|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
224299451|NCT02580084|PROCEDURE|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
223430914|NCT02847026|BIOLOGICAL|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
223430915|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
223430916|NCT02847026|BIOLOGICAL|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
223430917|NCT01473394|DRUG|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
223430918|NCT01473394|DRUG|Vilazodone|Vilazodone was supplied as tablets.
223430919|NCT03057223|DEVICE|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
223430920|NCT06215755|DRUG|VRG50635|"Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks."
223430921|NCT01538992|DEVICE|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
223430922|NCT02732405|DRUG|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
223430923|NCT03769597|DRUG|Iohexol Inj 300 MG/ML|After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
224041106|NCT04339114|OTHER|Breakfast: control meal|The breakfast meal includes a Taiwanese style pancake plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
223430924|NCT00546455|DRUG|Fenretinide|200 mg/day
223430925|NCT00546455|DRUG|Placebo|2 capsules/day
223430926|NCT00032422|PROCEDURE|Acupuncture|
223430927|NCT04577534|DRUG|iv Tocillizumab (TCZ)|Participants are randomized (2:1) to receive TCZ or Standard of Care
223430928|NCT05795205|BEHAVIORAL|Normal dinner|Participants will consume breakfast at 0830-0855 am, lunch at 1230-1255 pm, followed by dinner at 1800-1825 pm. Snacks will be consumed at 2130-2140 pm.
223430929|NCT05795205|BEHAVIORAL|Delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Dinner will be consumed at 21:30-21:55 pm.
224041107|NCT04339114|OTHER|Breakfast: Cinnamon meal|The breakfast meal includes a Taiwanese style pancake seasoned with grounded cinnamon plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
224041108|NCT04339114|OTHER|Breakfast: Italian herbs meal|The breakfast meal includes a Taiwanese style pancake seasoned with Italian herbs plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
223430930|NCT05795205|BEHAVIORAL|Exercise with delayed dinner consumption|Participants will consume breakfast at 08:30-08:55 am, lunch at 12:30-12:55 pm, followed by snacks at 18:00-18:10 pm. Participants will exercise for 45 min at moderate-intensity 45 min prior to the delayed dinner at 21:30-21:55 pm.
223430931|NCT02018978|BEHAVIORAL|Comprehensive Triaged HIV Prevention (CTHP)|"1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
223430932|NCT01482962|DRUG|Alisertib|Alisertib enteric coated tablets
223430933|NCT01482962|DRUG|Pralatrexate|Pralatrexate IV infusion
223430934|NCT01482962|DRUG|Gemcitabine|Gemcitabine IV infusion
223430935|NCT01482962|DRUG|Romidepsin|Romidepsin IV infusion
223430936|NCT05759520|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (multivalent conjugate)|the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
223430937|NCT05759520|BIOLOGICAL|Prevenar 13|the 2-month-old control group received the active control vaccine
223430938|NCT04393220|DRUG|Bevacizumab Injection|15mg/kg (Q3W)
223430939|NCT04393220|DRUG|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
224041109|NCT04339114|OTHER|Breakfast: pumpkin spice|The breakfast meal includes a Taiwanese style pancake seasoned with pumpkin spices plus a side of hash browns with ketchup. Every meal will be individualized to meet the 30% of the energy requirement of subjects based on the Harris benedict equation.
224041110|NCT02079012|BEHAVIORAL|10-week walking program|
224041111|NCT05447533|OTHER|Comprehensive geriatric assessment (CGA)|"Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~1. Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~2. High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe)."
224139848|NCT02719236|PROCEDURE|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
223430940|NCT04357912|BEHAVIORAL|Activity Tracker Group|In addition to the standard of care exercise education, participants in the activity tracker group will be provided a Fitbit physical activity tracker at no cost to the participants. They will be asked to download the Fitbit application (app) to their personal smartphone device to allow them to see their own data collected by the Fitbit. They will also be asked to download the Stridekick app for the purpose of sharing their activity tracker data electronically with the study team and having the opportunity to participate in fitness challenges through the app. App accounts will be created by the participants with usernames that do not contain the participant's identifiable personal information. Optional fitness challenges will be created once per month by the study investigators, and participants will also receive a weekly message of encouragement from the study team.
223430941|NCT04357912|BEHAVIORAL|Standard of Care Group|Participants will receive standard of care exercise education.
223430942|NCT01583075|PROCEDURE|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
223430943|NCT01583075|PROCEDURE|single ring pulmonary vein ablation|single ring pulmonary vein ablation
223430944|NCT03219606|OTHER|Organized education course of Modified Rodnan Skin Scoring|"1. Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~2. Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~3. Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
223430945|NCT01798407|DEVICE|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
223430946|NCT01798407|OTHER|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
223430947|NCT06299904|BEHAVIORAL|Modified Air-pulse Stimulation|Connected the oxygen humidification bottle to a fibreoptic endoscope, then inserted the terminal into the nasal cavity and the pulse sensation stimulation generated by oxygen was transmitted through the internal port of the fibreoptic endoscope to the anterior wall of the pyriform recess or to the folds of the arytenoepiglottis. (5 min once a day for 2 weeks)
224041112|NCT05447533|OTHER|Continued geriatric care|"Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured."
223430948|NCT06299904|BEHAVIORAL|Conventional air-pulse stimulation|The terminal airway of the air pulse was placed in the oral cavity, specifically in the patient's palatoglossal arch, pharyngeal posterior wall, tongue base, and other areas. The airbag was quickly squeezed to generate airflow and stimulate the mucosa.(5 min once a day for 2 weeks)
223430949|NCT01325116|BEHAVIORAL|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
224041113|NCT05447533|OTHER|Faecal microbiota transplantation (FMT)|When clinical indication for FMT, this will be delivered as 15-25 capsules (\~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.
223430950|NCT03111199|OTHER|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
223430951|NCT03111199|OTHER|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
223430952|NCT03111199|OTHER|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
223430953|NCT03111199|OTHER|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
223430954|NCT04892628|OTHER|Progressive resistance training|Resistance training of upper limb and lower limb muscles. Resistance will be increased on a weekly basis. Dumbbells and therabands will be used to provide resistance.
223430955|NCT04892628|OTHER|Aerobic training|The control group will be administered a standard physical therapy intervention program which will consist of active muscle stretching and aerobic exercises.
223430956|NCT02174913|DEVICE|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
223430957|NCT02174913|DRUG|Target controlled infusion of propofol|TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
223430958|NCT02174913|DRUG|Fentanyl|Fentanyl 1-2 mcg/kg iv for induction and then 0.5-1.0 mcg/kg/hr infusion is used for analgesic.
223430959|NCT02174913|DRUG|Atracurium|Atracurium 0.6 mg/kg is used for endotracheal intubation
223430960|NCT00897962|OTHER|Healthy Controls|One blood draw (2 teaspoons)
223430961|NCT00897962|OTHER|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
223744826|NCT06092099|DEVICE|TENA SmartCare Change Indicator|The TENA SmartCare Change Indicator is an accessory to absorbent incontinence products, intended for use on individual(s) with urinary incontinence who are dependent on one or more caregivers to change the absorbent incontinence product. The TENA SmartCare Change Indicator estimates the degree of urine saturation in the absorbent incontinence product and notifies the caregivers. This facilitates the caregiver's decision regarding when to change the absorbent incontinence product. As the current study is needed to validate the updated device, the full system will not be used, only the sensor part.
224041114|NCT05447533|OTHER|Standard care|Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
224041115|NCT05880550|OTHER|ultrasound cavitation in addition to aerobic ex|"Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes."
224041116|NCT05880550|OTHER|aerobic exercises.|the patients will do aerobic training for 40 minutes on a bicycle ergometer.
224041117|NCT04304781|DRUG|KSP/QRH dimer|Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
224041118|NCT00781820|DRUG|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
224041119|NCT00781820|DRUG|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
224041120|NCT03040310|OTHER|Back Rx program|The Back Rx program can be viewed via a smartphone app.
224041121|NCT01810016|BIOLOGICAL|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
224041122|NCT01810016|BIOLOGICAL|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
224041123|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
223430962|NCT00897962|OTHER|Non-cancer medical illness|One blood draw (2 teaspoons)
223430963|NCT02564640|DEVICE|videolaryngoscope|patients intubated by using the videolaryngoscope
224041124|NCT01810016|BIOLOGICAL|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
224041125|NCT05150496|BIOLOGICAL|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated|Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
224041126|NCT05150496|BIOLOGICAL|High-dose COVID-19 Vaccine(Vero Cell),Inactivated|High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
224041127|NCT05743322|DEVICE|Left atrial appendage closure|Left atrial appendage will be occluded using commercially available device
224041128|NCT05419843|OTHER|HSCT Arm group|"Conditioning regimen Stem cell source Only Bone Marrow With a minimal target dose of 4x108 nucleated cells/kg recipient ideal body weight. If the graft is less rich than the minimum target dose, it can be administered at the discretion to the physician.~GVHD Prophylaxis Prevention of EBV reactivation : Rituximab 150mg/m2 IV at Day+5 post HSCT."
224041129|NCT00708175|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
224041130|NCT00708175|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
223430964|NCT02564640|DEVICE|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
224041131|NCT05110274|PROCEDURE|Overnight Metabolic Flexibility|Participants will spend 13 hours (overnight) in a metabolic chamber where they will be fed a single high-fat supper meal. Energy expenditure, respiratory exchange ratio (RER), and 12-h oxidation of CHO, fat, and protein will be calculated and used to determine metabolic flexibility, i.e. change in RER from baseline.
224041132|NCT05110274|PROCEDURE|Clamp Metabolic Flexibility|Metabolic flexibility with be assessed during a 2-step hyperinsulinemic-euglycemic clamp procedure. The clamp will be performed for four hours, two hours at an insulin dose of 10 mU/m\^2/min and two hours at an insulin dose of 80 mU/m\^2/min. Resting metabolic rate will be determined via hood indirect calorimetry at baseline, before insulin onset, and during the final 30 min of each step of the clamp. Metabolic flexibility will be determined by comparing the resting metabolic rate during baseline and during the final 30 min of each step of the clamp.
224041133|NCT03641105|DIAGNOSTIC_TEST|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
224041134|NCT03196232|DRUG|Epacadostat|Given PO
223430965|NCT02678585|DRUG|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
224041135|NCT03196232|DRUG|Pembrolizumab|Given IV
224041136|NCT03217149|DRUG|heliox combined with MV|heliox combined with MV is given to infant with ARDS
224041137|NCT03217149|DRUG|MV|MV is given to infant with ARDS
224041138|NCT01578967|DRUG|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
223430966|NCT02678585|DRUG|Lidocaine|53 patients received intravenous regional lidocaine
224041139|NCT01578967|DRUG|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
224041140|NCT04744571|DRUG|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate- limiting medication (i.e. Beta- blocker or rate-limiting calcium antagonist) where appropriate. Anti- anginal therapy should be used if the patients have symptom.
223430967|NCT04891211|DIETARY_SUPPLEMENT|Vitamin D deficiency|Ocular significance of vitamin D deficiency in pediatric cases
223430968|NCT05642624|DRUG|Deoxycholic acid amphotericin B|Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.
223430969|NCT03932149|DEVICE|Intermittent Theta Burst Stimulation (iTBS)|The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
223430970|NCT03932149|DEVICE|Sham stimulation|The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
223564956|NCT03775343|DIAGNOSTIC_TEST|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
223430971|NCT04815499|DIETARY_SUPPLEMENT|Food supplement|ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
223430972|NCT04815499|DIETARY_SUPPLEMENT|Placebo|Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
223430973|NCT06623500|DIETARY_SUPPLEMENT|Iodine excess|Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L
223430974|NCT06623500|DIETARY_SUPPLEMENT|Iodine suitable|Iodine suitable areas：water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.
223430975|NCT06293118|DEVICE|Ischemic conditioning group|The ischemic conditioning protocol will consist of a period of 12 weeks (24 sessions) with a frequency of 2 weekly sessions lasting between 15 and 20 minutes each. Therapy will be performed bilaterally on the upper limbs. The ischemic conditioning group will perform 4 times, 8 cycles with 30 seconds of ischemia (80 - 200 mmHg) with 5 seconds of reperfusion in each cycle. Ischemia cycles are controlled by a device (KAATSU C3 - KAATSU GLOBAL / USA) with customized ischemia programs, partially restricting blood flow through special pressure cuffs that are internally valved, providing greater comfort and safety for these patients who typically have stiffness in the affected limb and localized muscle pain. In the first cycle, participants will be subjected to pressures of 80 to 150 mmHg. In the 3 subsequent cycles, pressures from 130 to 200 mmHg will be applied.
223430976|NCT06293118|DEVICE|Sham group|Participants in the control group (Sham) will perform 4 cycles of 5 minutes of ischemia (30 mmHg) with 4 subsequent cycles of reperfusion (rest) bilaterally in the arms with a sphygmomanometer
223430977|NCT03509870|BIOLOGICAL|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
223430978|NCT02378415|DRUG|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
223430979|NCT02378415|DRUG|Placebo|Normal Saline Infusion
223430980|NCT00182728|PROCEDURE|surgery|conventional
223430981|NCT00182728|PROCEDURE|therapy|neoadjuvant
223430982|NCT00182728|RADIATION|radiation therapy|intraoperative radiation therapy
223430983|NCT03023111|DRUG|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
223430984|NCT03023111|DRUG|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
223430985|NCT03023111|DRUG|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
224041141|NCT04744571|DEVICE|coronary wires. or coronary balloons|all species of coronary wires, or plain balloons
224041142|NCT04744571|OTHER|drug-coated balloon|Drug-coated balloon including all sizes and all brands
224041143|NCT04744571|DEVICE|drug-eluting stent|Drug-eluting stent including all sizes and all brands
223430986|NCT06622577|DIETARY_SUPPLEMENT|Cysteine|Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
223430987|NCT01440140|OTHER|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
223430988|NCT01440140|OTHER|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
223430989|NCT00250458|DRUG|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
224041144|NCT03722056|PROCEDURE|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
224041145|NCT02204566|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
224041146|NCT02626286|OTHER|HIV quarterly global care|
223744827|NCT06527131|DEVICE|pulsed electromagnetic field therapy|PEMF is regarded as an efficient physical therapy method that has been utilized clinically to treat a variety of orthopedic conditions, including delayed union and nonunion of fractures. According to studies, PEMF has been authorized for its biological effects, which include the mineralization of bone matrix, osteogenic differentiation of mesenchymal stem cells, and osteoblast proliferation
224041147|NCT04010773|OTHER|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
224041148|NCT05326113|OTHER|Physiotherapy|After POEM, patient underwent physiotherapy consisting of diaphragmatic breathing and dynamic stabilization exercises and PPIs
224041149|NCT05326113|DRUG|Control group|All patients will be treated with standard course of PPIs after POEM without physiotherapy.
224041150|NCT06044844|DRUG|Tofacitinib|tofacitinib efficacy
224041151|NCT04411927|OTHER|assessment of postural stability|assessment of postural stability
224041152|NCT00007813|BIOLOGICAL|filgrastim|
224041153|NCT00007813|DRUG|carboplatin|
224041154|NCT00007813|DRUG|cyclophosphamide|
224041155|NCT00007813|DRUG|etoposide|
224041156|NCT00007813|PROCEDURE|autologous bone marrow transplantation|
224041157|NCT00007813|PROCEDURE|peripheral blood stem cell transplantation|
224041158|NCT05686226|BIOLOGICAL|E7 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.
223430990|NCT00250458|DRUG|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
223430991|NCT01103102|DRUG|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
223430992|NCT01103102|DRUG|Placebo|Placebo
223430993|NCT05573490|DEVICE|Cognitive Training|Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
223430994|NCT05573490|BEHAVIORAL|Tai Chi- Qi Gong|Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
223744828|NCT06527131|DEVICE|Transcutanous electrical nerve stimulation|Electrical stimulation consider a safe and cost-effective method for pain management. It has no side effects and few contraindication in addition to no drug interaction . According to studies ,electrical stimulation decreases pain through reducing central transmission of pain signals because of nociceptive inhibition at the presynaptic level in the dorsal horn.
223744829|NCT06527131|DRUG|Vancomycin|medical antibiotics
224041159|NCT05686226|DRUG|Aldesleukin|Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV every eight hours will be administered for up to six doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
224041160|NCT04237922|DRUG|Prasugrel 10mg|Prasugrel 10mg dispensing claim is used as the exposure group
224041161|NCT04237922|DRUG|Clopidogrel 75mg|Clopidogrel 75 mg dispensing claim is used as the reference group
224041162|NCT04312464|OTHER|non|no intervention
224041163|NCT02150330|DRUG|Dehydroepiandrosterone (DHEAS)|
224041164|NCT02555696|DRUG|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
224041165|NCT04513704|DRUG|Oral Semaglutide|Participants will receive oral semaglutide tablet once daily for 10 days (3 mg for first 5 days and 7 mg for the next 5 days).
224041166|NCT04751760|BIOLOGICAL|collection of blood and urine|blood and urine will be collected during a blood test scheduled for the follow-up of the patient
224041167|NCT05777473|BEHAVIORAL|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The community health worker will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male community health workers will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
224041168|NCT05777473|BEHAVIORAL|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week. The husband groups will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
224041169|NCT05777473|BEHAVIORAL|Adopt-a-Friend|"The Adopt a Friend approach aims to promote the dissemination and discussion of new information and ideas among peers who are not directly involved in program activities. This involves asking each participant to choose a friend with whom she will share what she learns in home visits and her reflections. Adolescent girls will support each other in seeking sexual and reproductive health information or services if needed."
224041170|NCT01685424|DRUG|Etoricoxib|As per routine clinical practice in the United Kingdom
224041171|NCT00851123|BEHAVIORAL|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
224041172|NCT00851123|BEHAVIORAL|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
224041173|NCT00650572|DRUG|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
224041174|NCT04118517|OTHER|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing \>50% of the protein.
224041175|NCT03457883|DEVICE|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
224041176|NCT03457883|DEVICE|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
224041177|NCT01791647|DRUG|metformin 1500 mg|
224041178|NCT01791647|DRUG|myoinositol 1500 mg|
224139849|NCT02719236|PROCEDURE|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
223430995|NCT05573490|DEVICE|Brain Games|Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
224041179|NCT03228758|PROCEDURE|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
224041180|NCT00261404|DRUG|TNFerade™|
224041181|NCT00074022|BIOLOGICAL|GTI-2040|Given IV
224041182|NCT00074022|DRUG|docetaxel|Given IV
223430996|NCT05573490|BEHAVIORAL|Stretching|Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
223430997|NCT05051605|BIOLOGICAL|COVID-19 Vaccine|Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.
224041183|NCT00074022|OTHER|laboratory biomarker analysis|Correlative studies
224041184|NCT00074022|OTHER|pharmacological study|Correlative studies
224041185|NCT01974596|DIETARY_SUPPLEMENT|Probiotic tablets of Lactobacillus reuteri|
224041186|NCT01974596|DIETARY_SUPPLEMENT|Placebo tablets|
224041187|NCT02488889|DRUG|Varenicline|
224041188|NCT02488889|DRUG|Placebo pill (for varenicline)|
224041189|NCT02488889|DRUG|Alcohol|
224041190|NCT02488889|DRUG|placebo beverage (for alcohol)|
224041191|NCT03342248|OTHER|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
224041192|NCT05877183|DEVICE|Wearable device -'Smart Reminder'|The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 45-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
224041193|NCT05877183|DEVICE|Sham device|The sham device is also a wristwatch, which consists of an accelerometer, a gyroscope sensor, and a rechargeable battery that supports up to 72 hours of continuous use. The device will monitor the participant's arm activity, but it will not emit any reminders or be connected to a telerehabilitation system. The participants were instructed to perform the exercises from the pictorial handout for the recommended therapy dose and received a weekly therapy consultation as well.
224139850|NCT00735085|DRUG|SLV334|1000mg SLV334 as a single dose
224139851|NCT00735085|DRUG|SLV334|1000mg SLV334 b.i.d. for one day
224139852|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for one day
224139853|NCT00735085|DRUG|SLV334|2000mg SLV334 b.i.d. for three days
224139854|NCT00735085|DRUG|Placebo|SLV334 Placebo arm
224139855|NCT05321485|OTHER|MedicijnWijs|"The mobile phone app MedicijnWijs will guide the participants with their azathioprine therapy during 6 weeks. Information about azathioprine is given as well as general information about IBD, specified to disease modality (Crohn's Disease and Ulcerative Colitis). Contact details of the patient's pharmacy are listed, questions about the patient's symptoms are asked, and push notifications are added to remind the patients to take their medication.~At the beginning of the 6-weeks guidance, two validated questionnaires that are translated and validated in Dutch will have to be filled in: the MARS-5 and the IBD-KID2. After 6 weeks, the participants have to fill out the same questionnaires again to assess potential changes in the scores compared to baseline. Also, a number of questions will be asked to assess the ease of use of MedicijnWijs."
224139856|NCT05429554|DRUG|Vildagliptin|observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
224139857|NCT00592553|DRUG|Ataluren|Ataluren will be administered as per the dose and schedule specified in the respective arms.
224041194|NCT02978079|DEVICE|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
224041195|NCT03176563|DRUG|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
224041196|NCT03176563|DRUG|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
224041197|NCT03176563|DRUG|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
224041198|NCT03176563|DRUG|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
224041199|NCT03165318|DEVICE|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
224041200|NCT03165318|DEVICE|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
223430998|NCT01756105|DRUG|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
224041201|NCT05018260|BEHAVIORAL|Attention Bias Modification|Feedback according to participants' viewing patterns, in order to modify their attention bias to threat
224041202|NCT05018260|BEHAVIORAL|Attention Control|Feedback according to participants' viewing patterns, in order to strengthen their attention control
224041203|NCT03576703|OTHER|Exercise with and without SSB ingestion|Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
223430999|NCT01756105|DRUG|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is \> to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is \> 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is \> 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
223431000|NCT05666128|DRUG|HD-6277|HD-6277 100mg
223431001|NCT05666128|DRUG|HD-6277|HD-6277 50mg
224041204|NCT05574634|BEHAVIORAL|Tablet based adaptive multimodal attention practice program|An adaptive at-home tablet-based program that includes variants of the Flanker Task, the Stroop Task, and a Visual Tracking Task. Each session of practice will include up to ten minutes with each of these task types, and the tasks will increase in difficulty in a way that further taxes attention (such as through more distractors or more incongruent trials) as participant performance improves.
223431002|NCT05666128|DRUG|Placebo|Placebo
223431003|NCT05213793|DIAGNOSTIC_TEST|multi-delay arterial spin labeling|Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
223431004|NCT03051698|DRUG|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
223431005|NCT03051698|OTHER|Saline|0.9% NaCl
223431006|NCT03051698|DRUG|Antibiotics|vancomycin, ciprofloxacin, metronidazole
223431007|NCT00735293|DEVICE|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
223431008|NCT01972451|PROCEDURE|Colonoscopy with enhanced dye|
223431009|NCT02115074|DRUG|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
223431010|NCT02115074|DRUG|Celebrex|"Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (\> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
224041205|NCT05574634|BEHAVIORAL|Tablet based adaptive criterion task practice program|An adaptive, at-home tablet-based variant of the criterion task, that is, the selective attention/distraction task used during the scanning portion of the human participant portions of the study, that takes up to 25 minutes to complete each session.
224139858|NCT00592553|DRUG|Placebo|Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
224139859|NCT03326154|OTHER|No intervention, observational|Observation
224139860|NCT02085213|DRUG|Glyceryl Trinitrate|
224139861|NCT02085213|DRUG|Matched Placebo|Matched placebo
223431011|NCT02563262|OTHER|body angles measurements during weightlessness|
223431012|NCT03085992|DRUG|FOLFOXIRI plus Bevacizumab|"* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
223431013|NCT03085992|OTHER|Chemoradiotherapy plus Bevacizumab|"* FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~* BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
224139862|NCT00607568|DRUG|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
224139863|NCT01271387|DRUG|tasimelteon|20 mg tasimelteon capsules, PO single dose
224139864|NCT00251407|DRUG|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
224139865|NCT00251407|DRUG|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
224139866|NCT00251407|DRUG|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
224139867|NCT04068324|DIETARY_SUPPLEMENT|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
224139868|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
224139869|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
223431014|NCT00449943|PROCEDURE|Computed Tomographic Angiography|CT scan
224139870|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
224139871|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
224139872|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
224139873|NCT00703755|DRUG|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
224139874|NCT00703755|DRUG|Placebo|Placebo
224139875|NCT05614713|PROCEDURE|Selected physical therapy program|Gait training and balance training
224139876|NCT05614713|PROCEDURE|Modified physical therapy program to increase sensory input|Gait training and balance training using sensory stimulating matts
224139877|NCT04501198|DEVICE|moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
224139878|NCT04501198|DEVICE|Moxibustion combined with lifestyle intervention.|"1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks."
223564957|NCT01418703|DEVICE|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
224139879|NCT04501198|DEVICE|lifestyle intervention|All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
223431015|NCT00449943|PROCEDURE|Myocardial Perfusion Imaging Scan|SPECT
223431016|NCT01801358|DRUG|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
223431017|NCT01801358|DRUG|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
223431018|NCT04649918|OTHER|pulmonary rehabilitation|COVID 19 patients perform a standardized 3-week inpatient pulmonary rehabilitation program
223431019|NCT01985438|PROCEDURE|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
223431020|NCT01985438|PROCEDURE|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
223431021|NCT03059706|DEVICE|RegenoGel-OSP™|intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
223431022|NCT03059706|OTHER|saline|intra-articular injection of saline after arthroscopic surgery
223431023|NCT05631522|OTHER|foot reflexology|"Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body"
223431024|NCT01070836|DRUG|natalizumab|Administered as specified in the treatment arm
223564958|NCT01418703|DEVICE|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
224139880|NCT00828685|PROCEDURE|CRPP|Closed reduction, percutaneous pinning
224139881|NCT00828685|PROCEDURE|ORIF|Open reduction, internal fixation
224139882|NCT05643157|DEVICE|Adaptive Optics - Optical Coherence Tomography (AO-OCT) retinal imaging|AO-OCT used in this study is an investigational OCT imaging system. . In this instrument, ocular aberration sensing and correction is achieved with a Shack-Hartmann wavefront sensor (SHWS) and deformable mirror, respectively. A pupil camera and fixation target are used to position the participant's head and eye for scanning a particular retinal region within 15 degrees of the fovea. Data collected generally includes AO-OCT volume videos and SHWS measurements of ocular aberrations.
223431025|NCT02255136|OTHER|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
223431026|NCT02255136|OTHER|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
224139883|NCT01016548|BIOLOGICAL|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
223431027|NCT02283736|OTHER|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
223431028|NCT02283736|OTHER|Talc powder|Tablet containing talc powder
223431029|NCT02283736|PROCEDURE|Periodontal treatment|Scaling and root planning
223431030|NCT04970472|BIOLOGICAL|collection of blood, urines, stool and tumor samples|blood, urines, stool will be collected during routine cares. Tumor samples from surgery will also be stored.
223564959|NCT00163943|BEHAVIORAL|Dietary weight loss +/- aerobic exercise|
224041206|NCT05179642|OTHER|OPTIM-EHPAD tool|"This is a randomized, cluster stepped wedge study. Residents entering EHPAD during the pre-interventional inclusion period will be treated as usual in EHPAD. They will constitute the control group.~Residents entering EHPAD during the post-intervention inclusion period will have the optimization of their diagnostic and drug management, following a consultation between their referring physician and the coordinating physician based on the OPTIM-EHPAD method. They will constitute the intervention group.~The intervention is based on the utilization of the OPTIM-EHPAD method. It consists in training for coordinating physician and, optionally, for referring physician. It's a pedagogic tool proposing a rigorous methodology for reviewing prescriptions in chronological stages, associated with memos, constituting a form of clinical path for improving the quality and safety of prescriptions for EHPAD residents."
224041207|NCT05306457|BIOLOGICAL|CNS10-NPC-GDNF|Unilateral injections of CNS10-NPC-GDNF into the motor cortex
224041208|NCT00411281|DRUG|cytarabine|Given subcutaneously
223431031|NCT04042922|DEVICE|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
223431032|NCT04042922|DEVICE|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
223431033|NCT02326922|DEVICE|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
223431034|NCT06620913|OTHER|Description of clinical, immunological and tumor features of patients harboring CV2 Abs|This is a non-interventional study involving clinical data and biological samples (DNA and tumors block). Demographic and clinical data already collected in the database of the French Reference Center on PNS will be reviewed. The diagnostic tests performed to detect CV2-Abs in the patients already included in the database of the French Reference Center on PNS will be retrospectively analyzed.
223431035|NCT06615713|DEVICE|Steerable Ureteroscopic Renal Evacuation (SURE) with CVAC System|The CVAC Aspiration System is a sterile, single use, steerable ureteral catheter system with integrated vision, irrigation and aspiration for the treatment and removal of urinary stones (kidney stones, fragments, and dust).
223431036|NCT05547607|DIAGNOSTIC_TEST|advanced cardiac imaging|In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
223431037|NCT00001656|DRUG|Olanzapine|tablet; 5-20mg/day; 8 weeks
224139884|NCT04873076|DEVICE|Audiovisual distraction using 2d video glasses from HappyMed GmbH|Patients receive optical and acustical relaxing material during the procedure by using 2d video glasses from HappyMed GmbH
224139885|NCT03608891|DEVICE|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
224139886|NCT03608891|DEVICE|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
223431038|NCT00001656|DRUG|Clozapine|tablet; 12.5-900mg/day; 8 weeks
223431039|NCT04673656|DIETARY_SUPPLEMENT|BKR-017|Nutrient butyrate into a colon-targeted tablet formulation (BKR-017) is intended to stimulate secretion of GLP-1 from L-cells in the lower gut. Butyrate delivered to the colon in tablet form will not cause the side-effects seen with formation of butyrate by fermentation.
223431040|NCT00000207|DRUG|Buprenorphine|
223431041|NCT06620315|COMBINATION_PRODUCT|RBM|Resorbable Blast Media (RBM) implant surfaces can enhance osseointegration and implant stability
223431042|NCT06620315|COMBINATION_PRODUCT|sand blasted implant|sand blasted implant
223431043|NCT01523015|OTHER|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
223431044|NCT01523015|PROCEDURE|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
223564960|NCT00000593|PROCEDURE|blood transfusion|
223564961|NCT00615589|DRUG|Fludarabine/Busulfan x 4 days|"* Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~* Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
223564962|NCT00615589|PROCEDURE|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
223564963|NCT05971030|DEVICE|Cortical brain stimulation of mPFC and dlPFC|Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
223564964|NCT01220973|DRUG|atorvastatin calcium|
223564965|NCT01220973|DRUG|celecoxib|
223564966|NCT01220973|OTHER|laboratory biomarker analysis|
223564967|NCT02347553|OTHER|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
224041209|NCT00411281|PROCEDURE|observation|No intervention
224139887|NCT01279304|RADIATION|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
224041210|NCT06162000|OTHER|The group that will use the developed software in case studies|"In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups."
223431045|NCT06079307|OTHER|Oxygenated Mouthwash|Will be comparing the impact of using oxygenated mouthwash with other groups.
223431046|NCT06079307|OTHER|Oxygenated mouth foam|will be comparing the impact of using oxygenated foam to other groups.
224139888|NCT01279304|RADIATION|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
223431047|NCT03141983|DRUG|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
223431048|NCT03141983|DRUG|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
223431049|NCT06021756|DRUG|Intervention: Ketamine|Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
223431050|NCT03839771|DRUG|AG-120|250mg tablets
223431051|NCT03839771|DRUG|Placebo for AG-120|250mg tablets
223431052|NCT03839771|DRUG|AG-221|100mg tablets
223431053|NCT03839771|DRUG|Placebo for AG-221|100mg tablets
223431054|NCT00391157|DRUG|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
223431055|NCT00673725|DRUG|Locobase® REPAIR|emollient
223431056|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation|Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. No adjunctive therapies were applied in this group.
223431057|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and chlorhexidine irrigation|The participants in the mechanical instrumentation with chlorhexidine (MC) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were irrigated with 0.2% chlorhexidine digluconate solution for 1 minute.
223431058|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and ozone application|The participants in the mechanical instrumentation with ozone (MO) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, gaseous ozone was applied to the peri-implant pockets using an ozone-generating device and a specialized glass fiber probe. The ozone gas was delivered to four sites (mesial, distal, buccal, and lingual) for 15 seconds per site, resulting in a total application time of 1 minute per implant. The device operated at a power of 3 watts and 80% oxygen concentration, as recommended by the manufacturer.
223431059|NCT06730568|PROCEDURE|Submarginal mechanical instrumentation and air abrasion|The participants in the mechanical instrumentation with glycine powder air abrasion (MA) group were treated with conventional submarginal instrumentation using titanium curettes. Local anesthesia was applied before the procedure. The operator performed submarginal mechanical debridement until the implant surface was deemed adequately cleaned. Following mechanical instrumentation, the peri-implant pockets were treated with glycine powder-based air abrasion using an air-abrasion device (AIR-FLOW® handy 3.0 PERIO HANDPIECE, EMS, Nyon, Switzerland) and a flexible Perio-Flow® nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant.
223431060|NCT06730568|PROCEDURE|Air abrasion monotherapy|The participants in the glycine powder air abrasion monotherapy (A) group were treated exclusively with glycine powder-based air abrasion. Local anesthesia was applied before the procedure. The peri-implant pockets were instrumented with an air-abrasion device using glycine powder and a flexible nozzle. The nozzle was inserted into the pockets and guided in a circular motion from coronal to apical, parallel to the implant surface, in a non-contact mode as recommended by the manufacturer. The air-abrasion treatment was applied to four sites (mesial, distal, buccal, and lingual) for 5 seconds per site, resulting in a total application time of 20 seconds per implant. .
224139889|NCT01279304|RADIATION|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
224139890|NCT05820009|DEVICE|GORE® VIABIL® Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with the GORE® VIABIL® Biliary Endoprosthesis.
224139891|NCT05820009|DEVICE|GORE® VIABIL® Short Wire Biliary Endoprosthesis|Endoscopic treatment of benign biliary stricture secondary to Chronic Pancreatitis with GORE® VIABIL® Short Wire Biliary Endoprosthesis
224139892|NCT06041685|PROCEDURE|local warming|local warming on the site for arterial catheterization using forced air warmer
223431061|NCT06054243|BEHAVIORAL|CBT-I|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The treatment components aim to address the behavioural, cognitive and physiological factors perpetuating insomnia whilst considering the sleep and circadian features in adolescents and developmental context with the following key elements: psychoeducation about sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
224139893|NCT05594212|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
224139894|NCT04617899|DIAGNOSTIC_TEST|Intravascular imaging|Use of imaging catheter
224139895|NCT01812070|BEHAVIORAL|ACT|
224139896|NCT01812070|BEHAVIORAL|CBT|
223431062|NCT06054243|BEHAVIORAL|CBT-A|The intervention will consist of eight weekly group sessions (120-min, 5-8 adolescents in each group) delivered within a 10-week windows. The CBT-A treatment is modified from the Coping Cat programme, which incorporates psychoeducation and the core behavioural strategies and cognitive skills for managing anxiety (e.g. exposure, relaxation training, cognitive restructuring).
223431063|NCT04318639|COMBINATION_PRODUCT|Donepazil|"Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.~Cognitive remediation therapy (CRT): This study employs a computerized program (BrainHQ) for cognitive enhancement. Participants use their program for one hour per session, up to five sessions per week, over 13 weeks (maximum of 65 sessions). They may training on site or at another quiet location of their choice."
223431064|NCT05285722|BEHAVIORAL|Cognitive Behavioral Therapy form for dental anxiety|Message to Dentist form
223431065|NCT03785899|DEVICE|SPOCnew|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on."
223431066|NCT03785899|DEVICE|8s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 8s.
224139897|NCT03367442|OTHER|no intervention|no intervention
224139898|NCT00961870|PROCEDURE|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
224139899|NCT01146951|DRUG|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) \>= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
223431067|NCT03785899|DEVICE|SPOCold|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on."
223431068|NCT03785899|DEVICE|2s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 2s.
223431069|NCT02277158|DRUG|Chemoradiotherapy|S-1 CCRT
223431070|NCT00291772|DRUG|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
223431071|NCT04276610|BEHAVIORAL|Low Vision Reading Rehabilitation|Following Time 1, participants will receive the full complement of vision rehabilitation services available and deemed suitable by their clinical staff and rehabilitation professionals of either rehabilitation centre, according to the provision of assistive devices and services regulated by the Quebec Health Insurance (RAMQ). These services are include but are not limited to: a full optometric exam to determine functional vision, including refraction and the prescription of appropriate near and distance glasses and optical devices, an assessment by a low vision therapist and/or occupational therapist, the loan provision of hand-held optical magnification devices, electronic non-optical magnification devices (e.g., portable or table-top closed-circuit televisions), or computer software for screen content magnification (e.g., ZoomText), with appropriate training and follow-up sessions in the home, if required.
224139900|NCT01146951|DRUG|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
224139901|NCT04907422|DIAGNOSTIC_TEST|CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction|new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
224139902|NCT04907422|DIAGNOSTIC_TEST|non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction|conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
224139903|NCT05453448|DRUG|tenofovir alafenamide|Antiviral therapy
224139904|NCT05453448|DRUG|Entecavir|entecavir
224139905|NCT02299648|OTHER|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
224139906|NCT06376838|DEVICE|DLMR01|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
224139907|NCT06376838|DEVICE|Rejuran|Experimental and Acitve Comparator are applied 1 time to each of crow's feet on both sides of the subject.
224139908|NCT02967484|DEVICE|acupuncture|"1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
224139909|NCT04178135|DRUG|rLH|rLH supplement from day 1 of stimulation
224139910|NCT04178135|DRUG|rLH|rLH supplement from day 6 of stimulation
223431072|NCT03295123|OTHER|phone interview with the mother|it's a telephone survey about children's health
223431073|NCT02865590|DEVICE|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
223431074|NCT02865590|DEVICE|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
223431075|NCT06477835|BIOLOGICAL|SIM0718 Injection|Subjects who meet entry criteria will be randomized in a 1:1 ratio to receive either SIM0718 or matching placebo,Q2W, SC until Week 16. At the Week 16 visit, subjects in the placebo group will be transferred to SIM0718 300 mg Q2W after completing safety and efficacy assessments. Subjects who were originally treated with 300 mg Q2W of SIM0718 will continue on their original treatment regimen.
223431076|NCT02433041|DRUG|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
223431077|NCT02433041|DRUG|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
223431078|NCT02433041|DRUG|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
223431079|NCT02433041|DRUG|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
223431080|NCT01549041|DRUG|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
223431081|NCT01549041|DRUG|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
223431082|NCT03247764|OTHER||observational study
223431083|NCT05110521|BEHAVIORAL|PROMPTS|PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.
223431084|NCT05110521|BEHAVIORAL|MENTORS|MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
223431085|NCT02521779|OTHER|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
223431086|NCT02521779|OTHER|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
223564968|NCT05080855|PROCEDURE|modified Millard technique vs Tennison-Randall technique|evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
223564969|NCT01571128|OTHER|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
224139911|NCT03563261|DIETARY_SUPPLEMENT|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
224139912|NCT03563261|DIETARY_SUPPLEMENT|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
224139913|NCT01160861|DRUG|MEMP1972A|Repeating ascending dose
223431087|NCT02521779|OTHER|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
223431088|NCT02521779|OTHER|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
223431089|NCT00063479|DRUG|Zoledronic Acid|
223564970|NCT01571128|OTHER|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
223564971|NCT01571128|DRUG|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
224139914|NCT01160861|DRUG|placebo|Repeating ascending dose
223431090|NCT00210600|DRUG|PROCRIT (Epoetin alfa)|
223431091|NCT03409900|OTHER|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
223431092|NCT03409900|OTHER|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
223431093|NCT06494306|BEHAVIORAL|European Test of Olfactory Capabilities (ETOC)|Investigators will collect the ETOC score in patient of both arms
223431094|NCT06494306|BEHAVIORAL|Standardized Hedonicity Test|To smell 20 odorant solutions and for each odor and evaluate it along five dimensions: familiarity, hedonicity, edibility, desire to smell again, perceived intensity). Each dimension is assessed with a Likert scale (from 1 (not at all) to 9 (extremely))
223564972|NCT01571128|BEHAVIORAL|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
223564973|NCT01972308|BEHAVIORAL|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
223564974|NCT01972308|BEHAVIORAL|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
223564975|NCT00875238|BIOLOGICAL|trastuzumab|
224139915|NCT02915068|BEHAVIORAL|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
223431095|NCT06494306|BEHAVIORAL|Questionnaires|Patients with PTSD will have the following questionnaires : PTSD Checklist for Diagnostic and Statistical Manual (DSM)-V (PCL-5), Peri-trauma Dissociation Experience Questionnaire (PDEQ), Patient Health Questionnaire-9 (PHQ9), Snaith-Hamilton Pleasure Scale (SHAPS), Childhood Trauma Questionnaire (CTQ) and Apathy Evaluation Scale (AES)
223431096|NCT06494306|BEHAVIORAL|Odor / trauma association questionnaire|Patients with PTSD will have Odor / trauma association questionnaire
223431097|NCT00100191|PROCEDURE|uterine artery embolization|
223431098|NCT00100191|PROCEDURE|hysterectomy|
223564976|NCT00875238|DRUG|doxorubicin hydrochloride|
224041211|NCT05201937|DRUG|JNJ-64281802|JNJ-64281802 tablets will be administered orally as per the defined regimens.
224041212|NCT02427880|DRUG|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
224041213|NCT02427880|DRUG|Furosemide and Hydrochlorothiazide Followed by Furosemide|
224041214|NCT05619224|OTHER|Neurodevelopmental stimulation + Oral stimulation|"Neurodevelopmental intervention seeks to reduce abnormal postures and movement patterns in premature infants, allowing them to experience physiological postures in flexion and receive sensory stimulation. To this is added oral stimulation.~These stimulations are performed on alternate days."
224041215|NCT05619224|OTHER|Oral stimulation|This intervention consists of performing a sensorimotor stimulation of oral structures: stimulating for 7 minutes perioral structures( cheeks, lips and jaw)intraoral structures for 5 minutes and in the last 3 minutes non-nutritive suction stimulation with pacifier or finger.
224041216|NCT01703663|DEVICE|EPAP|
224041217|NCT05997849|BEHAVIORAL|Mobile application|A mobile application for the management of anxiety and depressive symptoms through self-applied emotional regulation tools.
224041218|NCT06173193|BEHAVIORAL|Multicomponent exercise regimen|"A multicomponent exercise regimen applied is comprised of the step-aerobic and resistance training programs alternating every two weeks. The trainees participate in supervised training sessions 3 times a week for 8 months. Each session will include a 10-minutes warm-up, 30-minutes of effective training part and a 10-minutes period for cooling down.~Step-aerobic: The program includes accelerating and decelerating through forwards and sideways movements with stops and turns to music. The degree of difficulty of movements and steps as well as training intensity will be gradually increased by increasing the height of the step benches.~Resistance training: The participants will undergo a progressive resistance training program. Resistance training will emphasize training of following muscle groups: Quadriceps and hamstrings, hip abductors, adductors and extensors, and calf muscles. In addition to lower limb exercises, trunk and upper body exercises will be applied at intervals."
224041219|NCT06173193|BEHAVIORAL|Standard rehabilitative management|The treatments that will be provided to the members of a reference group represent the standard rehabilitative management for knee OA patients. The home exercises focus on functional exercises maintaining lower extremity flexibility and muscle function. The home exercises are instructed to be carried out three times a week, each work-out lasting 30 minutes.
223431099|NCT02284763|OTHER|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
223431100|NCT01270386|DRUG|apatinib|Apatinib 750 mg p.o. once daily
223431101|NCT01270386|DRUG|placebo|placebo p.o. once daily
224041220|NCT05731414|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis (CBTp)|Individual formulation-based CBT will be delivered for one hour per week using a manual that has been validated in over 1000 individuals with schizophrenia-spectrum disorders across all stages of illness. This approach has demonstrated moderate to large improvements on symptoms and small to moderate effects on functioning. The first four sessions are devoted to building therapeutic rapport and developing collaborative treatment goals. The following phase focuses on developing formulations of why difficulties persist and using cognitive and behavioural change strategies. A longitudinal formulation is then offered to better understand how their difficulties developed. The final 2-4 sessions focus on consolidating the learning that occurred during treatment so that participants can maintain their improvement. Therapy homework is collaboratively assigned at the end of sessions to promote new learning in between sessions.
223431102|NCT01931241|DRUG|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
223431103|NCT03644836|DRUG|Amino Acids|Sweet taste cocoa flavored drink
223431104|NCT03644836|DRUG|Placebos|Sweet taste cocoa flavored drink
223431105|NCT05468749|DRUG|CTP-543|Single 12 mg oral dose administered on Day 1
223431106|NCT04754620|OTHER|real time online video visit|Participants have received an online visit by a smartphone application
223431107|NCT03266692|BIOLOGICAL|ACTR087|Autologous T cell product
223564977|NCT00875238|GENETIC|polymorphism analysis|
223564978|NCT00875238|OTHER|laboratory biomarker analysis|
223564979|NCT00875238|OTHER|questionnaire administration|
223564980|NCT00875238|PROCEDURE|assessment of therapy complications|
223564981|NCT00875238|PROCEDURE|magnetic resonance imaging|
223564982|NCT02816593|DRUG|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
223564983|NCT02816593|DRUG|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
224041221|NCT05731414|BEHAVIORAL|Cognitive Remediation Therapy (CR)|Action-based cognitive remediation (ABCR) will be delivered in group sessions one hour per week. ABCR was developed by Dr. Bowie (CI) and Dr. Best (PI) and has been found efficacious for schizophrenia-spectrum disorders in three clinical trials. ABCR involves practicing computerized training exercises with difficulty level dynamically titrated to improve neurocognitive abilities. Then participants engage in strategy discussions with other group members to develop new cognitive strategies. Finally, participants complete role-play simulations of real-world activities to practice their cognitive strategies in simulations of everyday life. ABCR is more effective for improving functioning than traditional approaches to CR. Homework consists of additional cognitive training and practicing cognitive strategies in everyday life.
224041222|NCT05731414|BEHAVIORAL|Befriending|Befriending will be delivered according to a manual validated to control for the non-specific effects of CBT, such as duration of therapeutic contact, client expectancy effects, therapeutic alliance, and therapist warmth. Befriending consists of 1-hour individual sessions once per week and involves a series of conversations similar to those one might have with a social acquaintance. These conversations involve discussion of neutral topics without problem-solving, coping strategies, or exploration of emotion. If emotional or mental health-related topics are brought up therapists redirect back to a neutral topic.
224041223|NCT05731414|BEHAVIORAL|Sham Cognitive Remediation|Sham CR was developed by Dr. Best and Dr. Bowie (CI) to control for the non-specific effects of CR such as computer practice and group discussion. Participants practice similar computerized exercises to ABCR, however, the exercises do not increase in difficulty. Participants then discuss enjoyment of the exercises but any discussion of cognitive strategies is redirected back to a neutral topic. We have previously found this condition to be an effective control for CR, with similar engagement to the active training group.
224041224|NCT06666192|OTHER|Cancer Screening|Undergo cancer screening
224041225|NCT06666192|OTHER|Discussion|Participate in discussions
223431108|NCT03266692|BIOLOGICAL|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
223431109|NCT03542591|OTHER|"Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet"|No active intervention, only survey as mentioned above.
223431110|NCT00201240|BIOLOGICAL|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ \>5 x 10\*6/kg and CD3+ \< 1 x 10\*5/kg
223431111|NCT01870674|DRUG|YH12852|
223431112|NCT01870674|DRUG|Prucalopride|
223431113|NCT01870674|DRUG|Placebo|
224041226|NCT06666192|OTHER|Educational Activity|Receive coaching calls
224041227|NCT06666192|OTHER|Educational Intervention|Receive educational materials
224041228|NCT06666192|BEHAVIORAL|Focus Group|Participate in focus group
224041229|NCT06666192|OTHER|Health Care Delivery|Integrate new activities into usual clinic processes
224041230|NCT06666192|OTHER|Health Promotion|Promote screening and wellness visits
224041231|NCT06666192|OTHER|Health Promotion and Education|Participate in educational sessions
224041232|NCT06666192|OTHER|Health Promotion and Education|Participate in early wave MLI
224041233|NCT06666192|OTHER|Health Promotion and Education|Participate in late wave MLI
223431114|NCT02182466|DEVICE|Colon capsule endoscopy|
223431115|NCT00909714|DEVICE|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
223431116|NCT00909714|DEVICE|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
223431117|NCT01135069|DRUG|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
223431118|NCT01135069|DRUG|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
223431119|NCT01135069|DRUG|placebo microsphere gel|treatment of acne vulgaris
223431120|NCT00829816|DRUG|Dimebon|
223431121|NCT00829816|DRUG|Placebo|
223431122|NCT03860714|DIAGNOSTIC_TEST|Neuropsychological tests|We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
223431123|NCT05240469|DEVICE|Automated sperm selection software|"The software measures both morphology and motility similar to an embryologist but provides a more accurate and consistent measure of sperm characteristics. Embryologists use their experience to qualitatively judge if an individual sperm is suitable for injection based on morphology and motility. Similarly, the software follows a two-step process: firstly, a computer vision algorithm measures characteristics of all sperm in a given field, including motility and morphology; secondly, the software algorithm then uses a set of quantitative criteria to categorize and identify the most developmentally competent sperm with normal characteristics. All the characteristics that the software calculate are defined by the WHO guidelines, and the software does not propose or define new parameters."
223431124|NCT03451110|DRUG|lemborexant|oral tablet
223431125|NCT03451110|DRUG|Loestrin|oral tablet
223431126|NCT03451110|DRUG|famotidine|oral tablet
223431127|NCT03451110|DRUG|fluconazole|oral tablet
223564984|NCT02816593|DRUG|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
223564985|NCT02709187|DRUG|DP-R208|Investigational product is prescribed to all of randomized subjects
224041234|NCT06666192|BEHAVIORAL|Health Risk Assessment|Incorporate risk assessments
224041235|NCT06666192|PROCEDURE|Implementation|Implement MLI
224041236|NCT06666192|OTHER|Informational Intervention|Review MLI materials
224041237|NCT06666192|OTHER|Internet-Based Intervention|Receive educational online materials
224041238|NCT06666192|OTHER|Interview|Participate in interview
224041239|NCT06666192|BEHAVIORAL|Outreach|Receive outreach activities
224139916|NCT05601908|OTHER|Virtual Reality Relaxation|Participants will undergo a 5-week course of 20-min sessions of VR relaxation. The VR device used will be the Oculus Quest wireless head mounted display (HMD) with two handheld controllers. The HMD and software have been provided by a Germany based company called Magic Horizons. Participants will be asked to wear the HMD and will wear headphones to hear audio. Each session will involve participants experiencing two virtual environments designed to promote relaxation, at least one of which will have a small interactive component to aid engagement. Environments will focus on nature and will be paired with soothing music or guided meditation. For example, scenes might include dolphins dancing underwater, a beach with rock pools, waterfalls, a rainforest, green meadows with flowers, mountains with lakes and/or a sandy desert. Participants will be seated throughout all sessions.
223431128|NCT04912219|DEVICE|Microneedling|"Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart"
224041240|NCT06666192|BEHAVIORAL|Patient Navigation|Receive access to CHW
224139917|NCT02541448|DEVICE|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar \& Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
224139918|NCT01187836|DRUG|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
224139919|NCT01187836|DRUG|Placebo|Placebo administered for 14 hours.
223431129|NCT00941694|BEHAVIORAL|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
223431130|NCT00941694|BEHAVIORAL|placebo group|3 phone calls not related to asthma self-management
223431131|NCT04217005|DEVICE|Sensory Feedback|Subjects will receive a sensory feedback provided by electrical stimulation
223431132|NCT05842564|OTHER|Blood samples|Blood sample of maximum 20ml (5 tubes of EDTA of 4ml or 5 tubes of EDTA of 2ml and a tube for the conservation of genomic DNA)
224041241|NCT06666192|OTHER|Survey Administration|Ancillary studies
224041242|NCT05045040|BEHAVIORAL|Mobile-based empathetic communication support program to promote ACP discussion|Patients in the intervention group are provided a mobile-based empathic communication support program-an app on a mobile phone. The app comprises a QPL (46 questions in eight categories) and questions about the patient's preferred treatment and end-of-life care based on their values and goals. Then, they proceed with the content themselves, at home or anywhere, at any time. Between app registration and the next outpatient visit, the patient is interviewed (by phone or in person) by a nurse or a clinical psychologist, who helps them prepare for the discussion with the physician and asks questions based on the patient's app responses for 30 minutes to an hour. During the outpatient visit, feedback is provided to patients and their physicians based on the interview. The duration between the start of app use and the next consultation is a minimum of one week and a maximum of four weeks.
224041243|NCT03823768|DRUG|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
224041244|NCT03823768|DRUG|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
224041245|NCT07130097|DRUG|PF-07220060|Cyclin-dependent kinase-4 inhibitor
224041246|NCT06809192|BEHAVIORAL|4-session Relaxation Training|A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, c) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, and autogenic relaxation, and d) goal setting and problem-solving barriers to integrate relaxation practices into daily routine.
224139920|NCT01329289|DRUG|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
224139921|NCT01329289|DRUG|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
224139922|NCT01329289|DRUG|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
224139923|NCT05518669|DEVICE|Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)|Subjects with biopsy of peripheral pulmonary nodule using electromagnetic navigation bronchoscopy and mobile cone-beam CT.
224139924|NCT00377585|BIOLOGICAL|Fluarix|
223431133|NCT05842564|OTHER|Biopsies|5 biopsies (one for each segment of the intestine explored: ileum, right colon, transverse colon left colon and sigmoid) will be taken during the ileocolonoscopy
223431134|NCT06482177|DRUG|Cyclosporine ophthalmic solution|Cyclosporine BID in the study eye
223431135|NCT06061055|DEVICE|Intubation with VentiBronc Anchor endobronchial double-lumen tube|Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
224139925|NCT00377585|BIOLOGICAL|adjuvanted influenza vaccine|
223431136|NCT06061055|DEVICE|conventional double-lumen intubation|Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
223431137|NCT06264674|DRUG|CHF5993 200/6/12.5 μg pMDI HFA-152a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
223431138|NCT06264674|DRUG|Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a|Pressurised Metered Dose Inhaler-2 inhalations twice daily
224041247|NCT06809192|BEHAVIORAL|4-session Behavioral Activation|A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
223431139|NCT02706171|RADIATION|CyberKnife|
223431140|NCT01794598|BEHAVIORAL|Receiving educational material of depression care|The educational material provides patients about depression management
223431141|NCT06148675|OTHER|No Intervention|No intervention,data collection
223431142|NCT05181254|BEHAVIORAL|health dialogue|The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
223431143|NCT03188068|DRUG|Sirolimus|Oral administration
223431144|NCT03188068|DRUG|Prednisolone|Oral administered with sirolimus
223431145|NCT01551719|BEHAVIORAL|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
223431146|NCT04989634|BEHAVIORAL|Intensive dietary and weight management|health education , nutritional analysis and individualized dietary guidance
223431147|NCT04989634|BEHAVIORAL|Standard care|Standard prenatal education on diet, nutrition and physical activity
223431148|NCT01633008|BEHAVIORAL|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
223431149|NCT00802061|BEHAVIORAL|Sleeping position in glaucoma patient|
223564986|NCT02709187|DRUG|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
223564987|NCT02709187|DRUG|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
223564988|NCT03691844|DRUG|AMZ001|diclofenac gel
223564989|NCT03691844|DRUG|Placebo|Placebo
224041248|NCT06809192|BEHAVIORAL|4-session Cognitive Therapy|A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, c) labeling thoughts as helpful, unhelpful, or neutral, d) using distraction to cope with unhelpful thoughts, e) challenging and changing unhelpful thoughts, f) problem-solving barriers to coping with or changing unhelpful thoughts.
224041249|NCT07129005|OTHER|No intervention (observational study)|No intervention (observational study)
224041250|NCT07128498|BEHAVIORAL|Tinker-Fun|A cognitive flexibility intervention revolves around a hands-on experience where participants design and build a craft or device. The process emphasizes active learning through observing, exploring, t
223431150|NCT02396303|DRUG|Carbetocin|
223431151|NCT01537068|DRUG|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
223431152|NCT01537068|DRUG|Placebo|Matching placebo pills
223431153|NCT00483704|DRUG|Telcagepant 140 mg|Telcagepant 140 mg tablets
223431154|NCT00483704|DRUG|Talcagepant 280 mg|Telcagepant 280 mg tablets
223431155|NCT00483704|DRUG|Placebo|Placebo tablets
223431156|NCT04442269|DRUG|dupilumab|Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
223431157|NCT04442269|DRUG|Placebo|Matching placebo
223431158|NCT01948583|DRUG|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
223431159|NCT00955981|DRUG|RDEA594|Uricosuric agent for the treatment of gout
223431160|NCT00955981|DRUG|Placebo|Matching placebo
223431161|NCT04108949|BEHAVIORAL|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
223431162|NCT04108949|BEHAVIORAL|Treatment as usual|See description included in arm/Group description.
223431163|NCT06136598|DRUG|Opevesostat|Tablets to be taken orally.
223431164|NCT06136598|DRUG|Dexamethasone|Tablets to be taken orally
223431165|NCT06136598|DRUG|Fludrocortisone|Tablets to be taken orally.
223564990|NCT03691844|DRUG|Comparator|diclofenac gel
223564991|NCT04991727|BEHAVIORAL|recruitment maneuvers|"Immediately after endotracheal intubation is completed~First RM (pulmonary retraction), maintain pressure at 40cmH2O for 30s, and then~Mechanical ventilation was maintained with 7cmH2O PEEP, and the RMS was repeated every 30 minutes until the end of surgery"
223564992|NCT01846663|DRUG|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
223564993|NCT01846663|DRUG|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
223431166|NCT06136598|DRUG|Hydrocortisone|Tablet to be taken orally as a rescue medication.
223431167|NCT03046901|DRUG|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
223431168|NCT01702675|DRUG|ACH15 50 mg|ACH15 50mg capsule
223431169|NCT01702675|DRUG|ACH15 250 mg|ACH15 250mg capsule
223431170|NCT01702675|DRUG|ACH15 500mg|ACH15 500 mg capsule
223431171|NCT01702675|DRUG|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
223431172|NCT01702675|DRUG|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
223431173|NCT01702675|DRUG|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
223431174|NCT01702675|DRUG|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
223431175|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
223431176|NCT01702675|DRUG|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
223431177|NCT01702675|DRUG|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
223431178|NCT01702675|DRUG|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
224041251|NCT07130487|BEHAVIORAL|Relational Agent ( RA) Alex|The intervention is an RA (chatbot) integrated into a genetic care delivery portal for primary care patients. The RA provides hereditary cancer education and risk evaluation through an interactive interface. Primary care patients will use the RA to complete questionnaires about their hereditary cancer risk, track their progress through the education component and assessment process, and obtain downloadable summaries of their cancer risk and family tree. Additionally, the chat feature stores past conversations, and a menu guides participants through key steps.
224041252|NCT06522035|DRUG|Allocetra|Intra-articular injecton of Allocetra into the target joint.
223431179|NCT04392388|BIOLOGICAL|Non applicable|to collect data from questionnaires and to collect serological samples
223431180|NCT01157650|OTHER|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~1. Liposuction procedure to obtain adipose tissue.~2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~3. ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
223431181|NCT02815124|OTHER|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
223564994|NCT02357693|DRUG|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
223564995|NCT02435290|BEHAVIORAL|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
223564996|NCT01690559|DRUG|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
223564997|NCT02087618|OTHER|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
223431182|NCT02815124|OTHER|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
223431183|NCT06498466|OTHER|myofascial release|Myofascial release therapy (MRT) is a manual therapy technique that involves gradual stretching by a therapist or the individual, acting on the muscles and surrounding fascia. Its effects include increasing joint range of motion and mobility of soft tissues, eliminating imbalances in muscle tone, reducing muscle pain, reducing stress on joints, and increasing neuromuscular efficiency.
223431184|NCT01630408|DRUG|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
223431185|NCT00005046|DRUG|chemotherapy|
223431186|NCT00005046|DRUG|paclitaxel|
223431187|NCT04144036|BIOLOGICAL|Neihulizumab, 3 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
223431188|NCT04144036|DRUG|Neihulizumab, 6 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
223431189|NCT04144036|DRUG|Neihulizumab, 9 mg/kg|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
223431190|NCT04144036|DRUG|Neihulizumab|This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
223431191|NCT05814536|DRUG|AB-218 capsule|Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
223431192|NCT01981343|DIETARY_SUPPLEMENT|A-F Betafood|
223564998|NCT02087618|OTHER|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
223431193|NCT01981343|OTHER|Placebo|
223431194|NCT06583447|BEHAVIORAL|Calorie-restricted diet (CRD)|"Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week."
223431195|NCT06583447|BEHAVIORAL|Time-restricted eating (TRE)|Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
223431196|NCT06375096|OTHER|evaluate bone mineral density|observation effect of graves' in bone mineral density in children
223431197|NCT02032862|DRUG|Sage extract, 3400 mg , DER 1:17|
223431198|NCT01793688|DRUG|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
224041253|NCT07118514|BEHAVIORAL|Progressive Resistance Training|A 12-week supervised resistance training program, performed twice weekly for 50 minutes per session. Exercises are based on 1-repetition maximum (1-RM) tests, using fixed machines and progressive loads (50-65% of 1-RM). Exercises include leg press, leg curl, knee extension, chest press, biceps/triceps curls, seated row, and lat pulldown.
224041254|NCT07118514|BEHAVIORAL|Stretching and Relaxation Activities|A 12-week supervised program focused on flexibility and relaxation, performed twice weekly for approximately 50 minutes. Includes static stretching of major muscle groups and guided breathing exercises aimed at reducing muscle tension and promoting mental relaxation.
223564999|NCT00883012|BIOLOGICAL|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus\*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms\*\*, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms\*\*, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms\*\* Two doses, one month apart"
223565000|NCT00883012|BIOLOGICAL|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
224041255|NCT02320929|PROCEDURE|Intraoperative flexor tendon sheath irrigation|
224041256|NCT02320929|PROCEDURE|Postoperative flexor tendon sheath irrigation|
224041257|NCT07123740|PROCEDURE|Intrathecal Morphine|"An intrathecal injection of morphine 300μg will be administered at the L3-L4 or L4-L5 level.~Additionally, in the postoperative period a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
224041258|NCT07123740|PROCEDURE|Bi-level Erector Spinae Plane Block|"Bi-level erector spinae plane block will be performed on the patients using a total of 40 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia."
224041259|NCT07123519|DRUG|YTS109 cell|Subjects will receive a single infusion of YTS109 cells. The dose groups are set to commence at 3E6 STAR-T cells/kg, employing a 3+3 escalation principle for dose titration.
224041260|NCT07122011|OTHER|Low-Intensity Resistance Training with BFR|"Warm-up: Five minutes of light-intensity cycling on a stationary bike.~Exercises:~1. Bilateral half squat (0°-90°)~2. Single-leg step-down from a 20 cm step~3. Knee extension (90°-0°) at 30% of one-repetition maximum (1RM)~4. Single-leg shallow squat (0°-45°)~Protocol: One set of 30 repetitions (or until volitional fatigue) followed by three sets of 15 repetitions for each exercise.~Rest periods: One minute between sets and two minutes between exercises.~BFR Application: Pneumatic cuff (The Occlusion Cuff Pro®) placed proximally on the dominant thigh, inflated to 60% of complete arterial occlusion (determined via Doppler ultrasound). The cuff remains inflated during sets and rest periods, and is deflated after completion of each exercise."
224041261|NCT06717854|OTHER|transanal irrigation|The enema is administered retrogradely via the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. the catheter is gently and slowly inserted 7-10 cm through the anus. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
224041262|NCT06717854|OTHER|antegrade enema|The enema is administered through the distal end of the ileocecal stoma, directed towards the anus. The enema commences one month post-operatively for patients with well-healed wounds, absence of stoma-related complications, and no evidence of anastomotic leakage upon digital examination, until ileostomy reversal. Using a disposable catheter, insert it about 20 cm. The initial irrigation volume is set at 500 ml and is gradually increased based on the patient's tolerance, up to a maximum of 1000 ml. 39-41°C warm water is the choice. Enemas are administered twice weekly, with each session limited to a duration of 30 minutes.
224041263|NCT07125235|BEHAVIORAL|reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention|The reSTART intervention integrates a mobile health application, a urine tenofovir point-of-care self-test, and adherence feedback with motivational messages to increase HIV medication intake, reduce stimulant use, and improve HIV virologic suppression.
224041264|NCT07125235|DEVICE|urine tenofovir point-of-care self-test|urine tenofovir point-of-care self-test
223740300|NCT04622839|OTHER|Tylenol and NSAIDS (Ibuprofen, diclofenac)|"This study will assess an aspect of perioperative care relating to pain control. Subjects will not be aware of which aspect is randomized, but will be given a list of possible aspects which will include the intervention (listed below):~* Agents used in nerve block (lidocaine vs ropivacaine)~* Location of injection for analgesic~* Use of over-the-counter pain management (including but not limited to acetaminophen, ibuprofen, naproxen, etc.)~* Type of initial opioid prescribed (including but not limited to oxycodone, tramadol, hydrocodone, etc.)~* Number of pills in the initial opioid prescription~* Instructions for sling wear (duration of use or type of sling)~* Ice usage (duration of use and frequency of use)~Blinding the participant to the randomized aspect of this study will help prevent bias in patient responses for outcome scores and medication usage."
223740301|NCT01851720|DRUG|Low dose fentanyl PCA|
223740302|NCT01851720|DRUG|Standard IV fentanyl bolus|
223431204|NCT05141916|PROCEDURE|Endoscopic Retrograde Cholagiopancreatography (ERCP)|Endoscopic procedure employed to manage biliary and pancreatic diseases
223431205|NCT02255318|DEVICE|Taurolock|
223431206|NCT02255318|DRUG|Placebo|
223431207|NCT04364113|OTHER|Usual Protein Diet|The usual protein diet contains 1.30 g/kg/day protein and 16-20 mg/kg/day of Phosphorus
223431208|NCT04364113|OTHER|Low Protein Diet|The low protein diet contains 0.575 g/kg/day protein and 5-10 mg/kg/day of Phosphorus
223565001|NCT00374569|PROCEDURE|Gymnastic Routine|A combination of gymnastic movements are performed
223565002|NCT05333666|OTHER|Data collection|This investigation aims to collect and analyze the data from a cohort. During the cohort development, all participants received venous puncturing for NOAC concentration measurement. However, the standard treatment protocol was not changed after study enrollment. In this retrospective cohort study, we only collect data from the cohort without further intervention to the participants.
223565003|NCT03546166|DRUG|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
223565004|NCT05501886|DRUG|Gedatolisib|Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
223565005|NCT05501886|DRUG|Palbociclib|Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
223565006|NCT05501886|DRUG|Fulvestrant|Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
223565007|NCT05501886|DRUG|Alpelisib|Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
223565008|NCT03414255|BIOLOGICAL|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
223565009|NCT03414255|DRUG|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
223565010|NCT04965948|OTHER|Novel food snack|Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks
223565011|NCT04965948|OTHER|Placebo snack|Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks
224041265|NCT07130240|DRUG|Neoadjuvant Chemotherapy Combined with Immunotherapy|"Drug: Neoadjuvant Chemotherapy paclitaxel, 135-175mg/m2, q3w, 2-3 cycles~Drug: Neoadjuvant Chemotherapy cisplatin, 75-80mg/m2, q3w, 2-3 cycles~Drug: Immunotherapy Ivonescimab, 20mg/kg, q3w, 2-3cycles~Procedure: Type A hysterectomy After 3 cycles of neoadjuvant therapy, patients who achieved CR/PR will undergo Type A hysterectomy + sentinel lymph node dissection / pelvic lymphadenectomy"
224041266|NCT07128810|OTHER|Parent Child Interaction Therapy|Parent was trained in a structured way during two phases of PCIT that are Phase 1: Child Directed Intervention and Phase 2: Parent Directed Intervention to encourage Language Development with frequency of sessions as 12 sessions; minimum 30 mins each day, 3x per week.
223431209|NCT04364113|OTHER|Very Low Protein Diet|The very low protein diet contains 0.28 g/kg/day or protein, mg/kg/day of Phosphorus and a keto acid mixture.
223431210|NCT04364113|DRUG|Medications needed to maintain usual blood pressure|The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
223431211|NCT04364113|DRUG|Medications needed to maintain low blood pressure|The MAP goal for the low blood pressure group is \<=92 mm Hg for ages 18-60 and \<=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
223431212|NCT02517242|DEVICE|Pens Device|
223431213|NCT02517242|DEVICE|Syringe|
223565012|NCT04404790|DRUG|Anfibatide 5 IU/60kg|5 IU/60kg IV administration of Anfibatide with 5 minutes
223565013|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.002 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
223565014|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.004 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
223565015|NCT04404790|DRUG|Anfibatide 5 IU/60kg +0.008 IU/kg/h|5 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
223740303|NCT01434238|OTHER|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
223431214|NCT02517242|OTHER|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
223431215|NCT03596723|DRUG|KPI-121 1%|eye drops
223431216|NCT03596723|DRUG|Prednisolone acetate|eye drops
223431217|NCT00865917|DRUG|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
223431218|NCT00865917|DRUG|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
223431219|NCT00865917|DRUG|Placebo|matching appearance
223431220|NCT06154395|PROCEDURE|OCT-guided PCI|The OCT guidance team routinely conducts OCT examinations on patients after standard angiography and/or thrombus aspiration. The OCT examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on OCT image features. After stent implantation, a follow-up OCT examination of the stent segment, as well as angiographic examination, is performed. Based on the OCT results, the operator decides whether post-dilation is necessary.
223431221|NCT06154395|PROCEDURE|60 MHz HD-IVUS-guided PCI|The IVUS guidance team routinely conducts IVUS examinations on patients after standard angiography and/or thrombus aspiration. The IVUS examination follows a standard procedure. The operator evaluates the stability of the lesion and decides whether to proceed with stent implantation therapy (with the option to choose the type of stent) or opt for conservative medical treatment. If a stent is implanted, the procedure is carried out according to guidelines and standard protocols, with the landing zone of the stent determined based on IVUS image features. After stent implantation, a follow-up IVUS examination of the stent segment, as well as angiographic examination, is performed. Based on the IVUS results, the operator decides whether post-dilation is necessary.
223431222|NCT06154395|PROCEDURE|Angiography-guided PCI|After routine angiography and/or thrombus aspiration, the operator assesses the lesion based on treatment standards to determine whether stent implantation is necessary. For patients undergoing stent implantation, a follow-up angiography is performed postoperatively, and the decision for post-dilation is made by the operator based on experience.
223431223|NCT03421314|DIETARY_SUPPLEMENT|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
223431224|NCT05838443|OTHER|Self-directed mindfulness utilizing a multi-sensor EEG-supported device with neurofeedback-assisted and technology-supported meditation|Neurofeedback-assisted, technology-supported mindfulness via EEG-supported device delivered individually without the need for a facilitator or travel to training site. The device allows noninvasive neural activity recording from frontal and posterior brain regions. A dedicated smartphone application uses the EEG data to provide real-time adaptive feedback-modulating natural sounds to prompt user awareness of mind-wandering and intentional return to present experience. A smartphone app will guide patients through attention and focus on breath exercises. Patients will hear their distracted mind as the wind. Wind becomes stronger if their mind wanders, prompting patient's awareness of their wandering mind and guiding the patient back to focusing on their breath without judgment of how they are doing. Patients will be asked to practice mindfulness using the device for 20 minutes per day for 4 sessions prior to surgery.
223431225|NCT05838443|OTHER|Provider-directed mindfulness|"Patients will receive mental health support by a licensed social work provider who is trained in mindfulness through four 20-minute telehealth sessions. Patients will be taught cognitive behavioral therapy (CBT) techniques to reduce pain catastrophizing and increase coping efficacy, the clinician will review patient's current sleep routine and teach concepts and strategies to improve sleep. Patients will be guided through mindfulness and meditation exercises to improve pain and mood coping. Mindfulness-based instructions takes patients through quieting their mind by focusing on breath, expanding focus (i.e., at the tip of their nose full flow of the breath), with emphasis on acknowledgement of arising thoughts/emotions without judgement or emotional reaction, and return attention back to breath sensation. Principles of CBT and mindfulness will be reiterated at subsequent sessions."
223431226|NCT05838443|OTHER|Conventional Care|Control group, as defined by our institution's standard preoperative care for given procedure, which does not include psychological preparation.
223431227|NCT06618937|OTHER|Treatment medication withdrawal strategy|The study aims to compare early biomarkers-guided versus conventional unguided drugs withdrawal strategy.
223565016|NCT04404790|DRUG|Anfibatide 7 IU/60kg|7 IU/60kg IV administration of Anfibatide with 5 minutes
223565017|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.002 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.002 IU/kg/h continuous intravenous infusion with 48 hours
223565018|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.004 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.004 IU/kg/h continuous intravenous infusion with 48 hours
224139926|NCT03296852|DIAGNOSTIC_TEST|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
224139927|NCT03296852|DRUG|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
224139928|NCT03181841|DRUG|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
224139929|NCT03181841|DRUG|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
224139930|NCT01747811|DEVICE|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
224139931|NCT01747811|DEVICE|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
224139932|NCT01299610|DRUG|GW870086 2.0%|White to slightly colored opaque cream
224139933|NCT01299610|DRUG|GW870086 0.2%|White to slightly colored opaque cream
224041267|NCT07128810|OTHER|Conventional Parent Led Therapy|Parent was trained in an unstructured way by using different language development strategies (Imitation, Focused Stimulations, Milieu Teaching, and others) to encourage Language Development with frequency of session as 12 sessions; minimum 30 mins each day, 3x per week.
224139934|NCT01299610|DRUG|FP 0.05%|White cream
224139935|NCT01299610|DRUG|Placebo|White to slightly colored opaque cream
224139936|NCT03393468|DRUG|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
224139937|NCT03012633|DEVICE|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
224299452|NCT02580084|PROCEDURE|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
224299453|NCT04026685|DRUG|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
223431228|NCT02550600|PROCEDURE|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P\_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P\_peak - PEEP) ≤15 cm H2O and P\_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
224139938|NCT04004377|OTHER|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
224299454|NCT04026685|DRUG|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
223431229|NCT02550600|PROCEDURE|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
223431230|NCT04450407|DRUG|LY3209590|Administered SC
223431231|NCT04450407|DRUG|Insulin Degludec|Administered SC
223565019|NCT04404790|DRUG|Anfibatide 7 IU/60kg +0.008 IU/kg/h|7 IU/60kg IV administration of Anfibatide with 5 minutes follow by the dose of 0.008 IU/kg/h continuous intravenous infusion with 48 hours
223565020|NCT05046717|DEVICE|ADAMTS13 Activity Assays|"In this study the measurement of ADAMTS13 activity will be assessed with three different commercial kits:~1. HemosIL AcuStar ADAMTS13 Activity Assay (Instrumentation Laboratory, Bedford, Massachusetts, United States)~2. ELISA, DG-EIA ADAMTS13 Activity (Diagnostic Grifols®, Spain)~3. FRETS-VWF73 for ADAMTS13 Activity Assay~Three kits will be used with all patients."
223565021|NCT00905762|DRUG|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
223565022|NCT00905762|DRUG|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
224041268|NCT07130565|DIAGNOSTIC_TEST|18F-92/AV45/TPZA/FT8, 11CPIB|Each subject receive a single intravenous injection of 18F-92/AV45/TPZA/FT8, 11C-PIB and undergo PET/CT or MRI imaging within the specificed time.
224139939|NCT00812240|DRUG|Masitinib|
224139940|NCT00812240|DRUG|Imatinib|imatinib 400 mg or 600 mg per day, per os
224139941|NCT05378022|COMBINATION_PRODUCT|LiveSpo Navax|In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
224139942|NCT05378022|DRUG|0.9% NaCl physiological saline|Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
224299455|NCT04535752|DRUG|ANX009|Single or multiple ascending dose
224139943|NCT01337167|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
224139944|NCT01337167|BIOLOGICAL|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
224139945|NCT01337167|BIOLOGICAL|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
224139946|NCT01337167|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
224299456|NCT04535752|DRUG|Placebo|Single or multiple ascending dose
223431232|NCT05644821|OTHER|complex intervention|"The intervention has several elements:~1. Regular symptom monitoring via ePROMs~2. Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4\) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist."
223431233|NCT05644821|OTHER|current clinical practice|current clinical practice
223431234|NCT03090724|DRUG|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
223431235|NCT04028622|OTHER|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
223431236|NCT05005585|PROCEDURE|immediate implant|immediate implant placement with VST technique versus early implant placement with contour augmentation technique
223431237|NCT03378297|DRUG|Metformin|Metformin tablets 850 mg x 2 orally
223431238|NCT03378297|DRUG|Acetylsalicylic acid|Acetylsalicylic acid tablets 160 mg x1 orally
223431239|NCT03378297|DRUG|Olaparib|Olaparib capsules 300 mg x 2 orally
223431240|NCT03378297|DRUG|Letrozole|Letrozol tablets 2.5 mg x 1 orally
223431241|NCT05916859|OTHER|Group 2 PDT (10 s)|\- Conventional endodontic treatment associated with PDT (10 s)
223431242|NCT05916859|OTHER|Group 3 PDT 20 s|Conventional endodontic treatment associated with PDAT (20 s)
223431243|NCT05916859|OTHER|Group 1. Placebo|Conventional endodontic treatment
223565023|NCT00905762|DRUG|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
223431244|NCT06622746|PROCEDURE|Endoscopic Hand Suturing|Endoscopic Hand Suturing is a technique of the wound closure after advanced endoscopic third-space resections I the upper and lower gastrointestinal tract. In this technique, the needle is held on the opposite side from the tip with the needle holder. The needle is pierced perpendicularly into the tissue at the side of the wound with an appropriate margin, then driven through the tissue with rotation and grasped at the bottom of the defect. The same steps are repeated from the middle of the wound to create a symmetrical structure.
223431245|NCT03579186|DEVICE|OKS|Optokinetic stimulation
223431246|NCT06342622|DIAGNOSTIC_TEST|Using routine clinical data and machine learning models.|This study used clinical data and machine learning model to screen young-onset colorectal cancer.
223431247|NCT04183140|PROCEDURE|primary percutaneous coronary intervention|primary percutaneous coronary intervention via transulnar or transradial access
223431248|NCT04483375|BIOLOGICAL|SCTA01|recombinant humanized anti-SARS-CoV-2 monoclonal antibody
223431249|NCT04483375|OTHER|Placebo|Placebo
223565024|NCT02444546|OTHER|Laboratory Biomarker Analysis|Correlative studies
223565025|NCT02444546|BIOLOGICAL|Sargramostim|Given SC
223565026|NCT02444546|BIOLOGICAL|Wild-type Reovirus|Given IV
224041269|NCT07128914|DRUG|GO306|"Part 1: A 3+3 single-dose escalation phase:~Low-dose cohort: 3.0E+07 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~Medium-dose cohort: 3.0E+08 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~High-dose cohort: 1.0E+09 PFU; Intratumoral or intracavitary injection of GO306; Cohort Size: 3 subjects; Dosing Schedule: Single initial administration.~Part 2: A multiple-dose expansion phase at the RP2D level to explore preliminary efficacy in specific tumor type:~RP2D; Intratumoral or intracavitary injection of GO306; Cohort Size: 20 subjects in specific tumor type; Dosing Schedule: QW or Q2W administration."
224041270|NCT07129564|OTHER|treatment react|Reverse remodeling of the LA was defined as at least a 15% reduction in the max LA volume after electrical or pharmacological cardioversion for 3 months
223565027|NCT02650271|DRUG|Entecavir|Patients will be received entecavir (10 mg/d) before liver resection.
224041271|NCT07129031|DRUG|low-titer O-group whole blood|Arm Description: During the emergency phase, administer 4 units of low-titer group O whole blood (anti-A/B IgM antibody titer \< 1:64); once the patient's blood type is determined, switch to type-specific whole blood.
224041272|NCT07129031|DRUG|1:1:1 component transfusion|"Following the Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition), implement the massive transfusion protocol (MTP) by transfusing type-specific blood components in a 1:1:1 ratio (red blood cells : plasma : platelets)."
224041273|NCT07129031|DRUG|ABO- and Rh-compatible whole blood|"Administer type-specific whole-blood transfusion in accordance with the Chinese Expert Consensus on Emergency Blood Support Models and Transfusion Strategies for Severely Injured Patients (2024 Edition)."
224041274|NCT07128797|DRUG|B1344|Subcutaneous injection
224041275|NCT07128797|OTHER|Placebo|Subcutaneous injection
224041276|NCT07129967|BEHAVIORAL|Orofacial myofunctional therapy|Orofacial myofunctional therapy consists of a set of oropharyngeal exercises to correct abnormal orofacial functions such as mouth breathing and a caudal tongue position, and strengthen upper airway muscles (e.g., muscles of the tongue and soft palate) that are involved in maintaining airway patency.
224041277|NCT07129707|OTHER|Exercise testing|Each participant performs a constant work-rate exercise test (70% peak work rate) under the 4 experimental conditions (referred as arms).
224041278|NCT07130617|DRUG|Low dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 312.5 mg/day, administered once daily (QD) for 7 consecutive days.
224041279|NCT07130617|DRUG|Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 625 mg/day, administered once daily (QD) for 7 consecutive days.
224041280|NCT07130617|DRUG|High dose of Megestrol Acetate Oral Suspension combined with standard therapy|A single dose of 937.5 mg/day, administered once daily (QD) for 7 consecutive days.
223565028|NCT02650271|DRUG|Tenofovir|Patients will be received tenofovir before liver resection.
223431250|NCT05688033|RADIATION|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy|dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
223431251|NCT05680051|DEVICE|Drug-eluting balloon|Drug eluting balloon was used in the experimental group
223431252|NCT05680051|DEVICE|Drug-eluting stent|Drug eluting stent was used in the control group
224041281|NCT07130617|DRUG|Megestrol Acetate Oral Suspension Placebo combined with standard therapy|A single dose of 5 mL/day, administered once daily (QD) for 7 consecutive days.
224041282|NCT07129161|DRUG|4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 2 cycles (Platinum-based doublet chemotherapy)|Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w
224139947|NCT01337167|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
223431253|NCT05622877|DRUG|Qushi Formula|Qushi Formula are decoction granules composed 8 traditional Chinese medicines, such as poria cocos, Macrocephalae Rhizoma, Polyporus, cassia twig, dried ginger and licorice, Etc.
223431254|NCT05622877|DRUG|Zhu's Wenban Formula|Zhu's Wenban granules are decoction granules composed of leech, panax notoginseng, Atractylodes Lancea and rhizome
223431255|NCT05622877|DRUG|placebo|The placebo was composed of dextrin, powdered sugar, starch, and liquid caramel in the same color as the other two groups.
223431256|NCT05622877|OTHER|Basic treatment|Basic diseases except hyperlipidemia were treated in accordance with the 2014 Chinese Guidelines for Secondary Prevention of Ischemic Stroke/Transient Ischemic Attack. Basic treatment includes conventional treatment such as comprehensive prevention and treatment (actively controlling basic diseases such as hypertension and diabetes and suggesting a good lifestyle), drug therapy (anti-inflammatory, lipid-regulating, anti-platelet aggregation, calcium channel blockers) and so on according to individual conditions of patients.
223431257|NCT05896462|OTHER|10% povidone iodine|The apposed skin edge was covered with 10% povidone iodine-soaked gauze dressing
223431258|NCT03628989|BEHAVIORAL|Use of Virtual Technology|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
224139948|NCT01337167|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
223431259|NCT00070382|DRUG|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
223431260|NCT00070382|DRUG|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
224139949|NCT01337167|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
224139950|NCT01337167|BIOLOGICAL|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
224139951|NCT03833817|BEHAVIORAL|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
224139952|NCT03713957|DRUG|GRF6021|GRF6021 for IV infusion
224139953|NCT03713957|OTHER|Placebo|Placebo for IV infusion
224139954|NCT04378257|BEHAVIORAL|Therapist Guided E-Therapy|"The participants in this group will be allocated weekly sessions with a trained aboard certified clinical psychologist via a web-based e-therapy platform.The link will direct the participant directly to a screen where they will be able to see and interact with the psychologist once a week. The sessions will be conducted in the Arabic or English languages.Following sessions would focus on psychological first aid based on the following interventional tools:~Cognitive Behavior Therapy (CBT)~* Acknowledging emotions and normalizing current stress~* Differentiate dysfunction versus distress (identify any debilitating thoughts/emotions if applicable)~* Behavioral Activation Acceptance and Commitment Therapy (ACT)~* Grounding, Breathing, Acceptance of emotions, and de-fusion"
223431261|NCT00790231|DEVICE|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
223565029|NCT03450694|DEVICE|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
223565030|NCT04493541|DRUG|BMS-986256|Specified Dose on Specified Days
224041283|NCT07129161|DRUG|4 cycles(Iparomlimab and Tuvonralimab 5mg/kg) + 4 cycles (Platinum-based doublet chemotherapy)|Iparomlimab and Tuvonralimab 5mg/kg：5mg/kg，q3W Platinum-based doublet chemotherapy：q3w
224041284|NCT06827470|BIOLOGICAL|Biological: Bordetella pertussis J820|Intranasal inoculation of Bordetella pertussis J820 in each naris on Day 1 of the study.
224041285|NCT05552209|DEVICE|Elbow MID 500|15 patients will be included in this group and will used the medical device Elbow MID 500 during sport practice (at least 2 sport sessions per week), for 6 weeks.
224041286|NCT05552209|OTHER|Control group Elbow MID 500|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow MID 500), for at least 2 sport sessions per week during 6 weeks.
224041287|NCT05552209|DEVICE|Elbow STRAP|15 patients will be included in this group and will used the medical device Elbow STRAP during sport practice (at least 2 sport sessions per week), for 6 weeks.
224041288|NCT05552209|OTHER|Control group Elbow STRAP|15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device Elbow STRAP), for at least 2 sport sessions per week during 6 weeks.
224041289|NCT05167123|DRUG|Light cured tri-calcium silicate base material|TheraCal (LC) (BISCO Inc., Schamburg, IL, USA) was introduced in (2011), are available commercially as flowable cement applicable via syringe
224041290|NCT04025567|DRUG|vancomycin|1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
224041291|NCT06807203|OTHER|Behavioral observation|Behaviors will be observed in children's natural environment. With a digital health assessment.
223565031|NCT04493541|OTHER|BMS-986256 Placebo|Specified Dose on Specified Days
224041292|NCT04435782|DRUG|JNJ-67896049|Participants will receive tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
224041293|NCT04924244|OTHER|Music Therapy|We will play music of the subject's choice of genre during the procedure.
224139955|NCT04378257|BEHAVIORAL|Self-Help Therapy|The participants in the control group will be supplied with an automatic weekly newsletter through E-mail containing self-help information and tips to cope with distress associated with COVID-19 in Oman. The information will mainly comprise of behavioral tips from principles of CBT and ACT focusing on positive cognitive reinforcement, strengthening relationships and mindfulness practice. The participants will be requested to use this information to manage any distress that they might experience. On the sixth week, the participants in the control group will be assessed on their mood and anxiety symptoms. Participants will also be requested to provide information on other self-help remedies that participants used to improve or manage their functionality (example, access to other websites, communication with close friends or family etc.)
224139956|NCT02567357|BEHAVIORAL|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
223431262|NCT04092673|DRUG|eFT226|eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
223431263|NCT04092673|DRUG|Sotorasib|Recommended dosage: 960 mg orally once daily
223431264|NCT04092673|DRUG|Fulvestrant|500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter
223431265|NCT04092673|DRUG|Abemaciclib|Dose in combination with fulvestrant: 150 mg twice daily
223431266|NCT04092673|DRUG|Trastuzumab|600 mg every 3 weeks
223431267|NCT06903585|DRUG|Naproxen (Proxen S)|Naproxen will be given for 5 days starting from the day subjects first receive palliative radiotherapy, it will be taken as an initial dose of 500mg then as 250mg every 8 hours for a total of 5 days.
223431268|NCT06903585|DRUG|Placebo|Placebo will be given for 5 days starting from the day subjects first receive palliative radiotherapy, it will be given every 8 hours for a total of 5 days.
223431269|NCT06903585|DRUG|Esomeprazole 20mg once daily|Esomeprazole will be given to all subjects as 20mg once daily starting from the day they start palliative radiotherapy and for a total of 5 days.
223431270|NCT03943264|DRUG|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
223431271|NCT05659979|OTHER|Comprehensive geriatric assessment|A detailed comprehensive geriatric assessment will be given to all the participants randomized to this group, including the administration of multidimensional prognostic index (MPI), a tool derived from the CGA and consisting of eight different domains.
223431272|NCT06506643|DRUG|Zinc-64 Aspartate|KLS-1 drug substance is Zinc Aspartate enriched with isotope Zinc-64 to 99.2% mass fraction of total Zinc. KLS-1 investigational medicinal product (IMP) is formulated as a solution, containing 25.64 mg of drug substance in 1 ml and inactive ingredients (water for injections, USP, EuPh).
223431273|NCT01574638|DRUG|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
223565032|NCT05439993|DRUG|Tepotinib plus paclitaxel|Paclitaxel 80mg/m2 on D1, 8, 15 tepotinib 250mg or 500mg daily on D1-28 Q 4weeks
223565033|NCT01562314|DRUG|GWP42003|1 to 5 50 mg capsules taken BID
223740304|NCT03927612|DEVICE|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
223565034|NCT01562314|DRUG|Placebo|1 to 5 matching capsules taken BID
223565035|NCT01062724|OTHER|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
223740305|NCT03927612|DEVICE|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
223740306|NCT03276689|DRUG|Duloxetine|The patients will take duloxetine for 8 weeks.
223740307|NCT03276689|DRUG|Pregabaline|The patients will take pregabaline for 8 weeks.
223740308|NCT03276689|OTHER|Placebo|The patients will take placebo for 8 weeks.
223740309|NCT00679185|BEHAVIORAL|expressive writing|four non-emotional writing assignments
223740310|NCT03862274|OTHER|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
224041294|NCT04924244|OTHER|No Music|No music will be played during the subject's interventional procedure
224041295|NCT06658899|DRUG|CRD-4730|Oral CRD-4730 in tablet form
224041296|NCT06658899|DRUG|Placebo|Placebo to match CRD-4730 in tablet form
224139957|NCT02567357|BEHAVIORAL|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
224139958|NCT04426994|DRUG|proton pump inhibitor use|Patients using long term proton pump inhibitor
224139959|NCT02504177|DRUG|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
224041297|NCT06824376|DEVICE|Manual acupuncture|After sterilisation, the sharp needles will be inserted into the deep tissue layers of acupoints. Acupuncturists will tried to elicit acupuncture de-qi sensation by the manual manipulation of needles. Within a 30-minute period, manual manipulation for each acupoint will last at least 10 seconds and wil repeated four times with intervals of 10-minute.
224041298|NCT06824376|DEVICE|Sham acupuncture|After sterilisation, Streitberger placebo needles with blunt tip will be used. It can be fixed on the surface of the sham points without piercing the skin. Within a 30-minute period, each point will undergo a simulated twisting motion of the needle for at least 10 seconds, and this will be repeated four times at 10-minute intervals.
224041299|NCT06744751|BIOLOGICAL|Fecal Microbiota Transplantation|Patients take the capsules twice daily, with a dose of 6 or 10 capsules per day, for a total of 6 days (72 or 120 capsules in total). Select the capsule dosage based on age. For children under 18 years old, take 10 capsules at a time. For adults aged 18 and above, take 6 capsules at a time. Both the FMT and placebo capsules are identical in appearance, size, color, form, weight, and taste, with the placebo containing starch as the main ingredient.
223565036|NCT02851797|DRUG|givinostat|"The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below:~Givinostat or placebo starting dose~* \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid~* \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid~* \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid~* \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid~* \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid~* \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid~* \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid~* \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid~* \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid"
224041300|NCT06744751|DRUG|Placebo|Manufactured by the same company, the placebo capsules contain starch as the main ingredient and are identical in appearance, size, color, dosage form, weight, and taste to the FMT capsules. They are administered twice daily, 6 or 10 capsules per dose (selected by age), for 6 days.
224041301|NCT06586723|BEHAVIORAL|PBIS|Positive Behavioral Interventions and Supports (PBIS) is an evidence-based, multi-tiered, problem-solving, and team-based framework designed to build a continuum of supports to promote all students' social emotional behavioral health.
223565037|NCT02851797|DRUG|placebo|The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.
224041302|NCT06586723|OTHER|HELM|Helping Educational Leaders Mobilize Evidence (HELM) is an implementation strategy for promoting building-level implementation leadership, implementation climate, and high-fidelity delivery of evidence-based practices
224041303|NCT06604741|OTHER|Assigned Interventions for LVIMT|"IMT is a form of exercise designed to strengthen the muscle involved inhalation, primarily the diaphragm and intercostal muscles.~The LVIMT group will perform IMT once daily, 5 days a week, maintaining 60% of maximal inspiratory pressure (MIP) throughout the 6-week intervention.~The intervals are typically longer in duration (e.g., 2-4 minutes) with a work-to-rest ratio of 1:1 or 1:0.5.~POSITION: rested and seated position. FREQUENCY: more frequency, once a day. 2-3 sessions per week. INTENSITY: Low resistance. Only 60%% MIP. TIME: shorter duration of 10-20 mint."
224139960|NCT02504177|DRUG|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
224139961|NCT02097485|DRUG|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
223565038|NCT00001766|DRUG|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
224041304|NCT06604741|OTHER|Assigned interventions for HVIMT|"The HVIMT group is trained twice daily, with the morning session matching the LV-IMT protocol, and an additional afternoon session. The HVIMT group also experienced a progressive increase in intensity, starting at 60% MIP and reaching 80% by the end of the study. LVIMT works for beginner or individuals with limited respiratory capacity while HVIMT is used for individual with high baseline respiratory fitness.~The intervals are typically shorter in duration (e.g., 30 seconds to 2 minutes) with a work-to-rest ratio of 1:1 or 1:2.~POSITION; Seated upright position. FREQUENCY: more frequency two session per week. 4-5 sessions per week. INTENSITY: high resistance. 60%-80% MIP.~(gradual increment the load by 10% every 2 weeks to reach 80% MIP)~TIME: longer duration 20-30 mint."
224041305|NCT05838586|BEHAVIORAL|prolonged SB|4 hours of prolonged SB
224041306|NCT05838586|BEHAVIORAL|SB broken 1|4 hours of SB broken up by 5 minutes of self-paced walking every hour
224139962|NCT02097485|DRUG|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
224139963|NCT03607474|OTHER|Questionnaires of life quality for patients|"* the WhoQoL~* a specific scale of Cushing's syndrome~* The Beck II scale~* HAD scale~* Rosenberg questionnaire~* Stunkard, Sorensen and Schlusinger (1983) figurines~* Brief Cope scale"
224139964|NCT03607474|OTHER|Questionnaires of life quality for caregivers|"* the WhoQoL~* The Beck II scale~* HAD scale"
224139965|NCT04374201|OTHER|2 zirconia FDPs|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
224139966|NCT04374201|OTHER|1 zirconia FDP|The United States Public Health Service criteria were used in order to examine technical and esthetic outcomes. Success and survival rates of the zirconia FDPs were calculated. The biological examination was performed analyzing both abutments and contralateral teeth.
224041307|NCT05838586|BEHAVIORAL|SB broken 2|4 hours of SB with one 20-minute bout of self-paced walking
224299457|NCT04467359|OTHER|ERAS|Optimize physical conditions; Fasting solid diet 6h before surgery, fasting clear fluid 2 h before surgery; If there is no chief complaint of dizziness, nausea or other discomfort after the operation, warm water (no more than 100ml) can be immediately drunk. Pain management; Encourage patients to engage in early activities under the premise of effective pain control; If no dural puncture and other complications occur, the patient has no chief complaints of headache, dizziness, nausea and other discomfort, and there is no need to lie supine, the comfortable position such as semi-supine lateral supine position can be taken immediately (avoid 90-degree upright position for patients with hip joint); Prevention of thrombosis; Prevention and treatment of nausea and vomiting; Follow-up was conducted at 4 weeks, 8 weeks and 12 weeks after the operation.
224299458|NCT04467359|OTHER|Perioperative routine rehabilitation nursing|Fasting and water deprivation at 12 o 'clock on the first day before surgery; Fasting water 6-8 hours after surgery; Lie flat on your pillow for 6 hours; Get out of bed activity 1 day after operation
224299459|NCT03971487|BEHAVIORAL|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
224299460|NCT03971487|BEHAVIORAL|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
224299461|NCT03971487|DIAGNOSTIC_TEST|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
224041308|NCT06615544|DEVICE|Placement of indirect dental restoration|The newly developed dual-cure adhesive will be used for the placement of indirect restorations.
224041309|NCT06996353|PROCEDURE|PTK-PRK refractive treatment|The PTK-PRK refractive treatment will be done according to routine clinical practice.
224041310|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring \& Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
224041311|NCT00315939|DEVICE|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring \& Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
224041312|NCT06672705|PROCEDURE|Biopsy|Undergo biopsy
224041313|NCT06672705|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224041314|NCT06672705|PROCEDURE|Computed Tomography|Undergo PET/CT
224041315|NCT06672705|BIOLOGICAL|Epcoritamab|Given SC
224041316|NCT06672705|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224041317|NCT06673524|PROCEDURE|Group T (Transversus Abmoninis Plane Block)|TAP Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position, the ultrasound (USG) probe is placed in an oblique position lateral to the xiphoid process at the lower border of the rib cage. The rectus abdominis muscle and its posterior sheath are visualized above the transversus abdominis muscle. At this level, only the aponeurosis of the internal oblique muscle can be seen between the transversus and external oblique muscles. By applying some pressure and tilt to the probe, the image of the myofascial planes is better optimized. Using a 22-25G, 50-100 mm block needle, an in-plane technique is applied, advancing either medially to laterally or vice versa. In the fascial plane between the rectus abdominis and transversus abdominis or between the internal oblique and transversus abdominis muscles, 20 ml of 0.25% bupivacaine is injected. The same procedure is then applied to the opposite side.
224041318|NCT06673524|PROCEDURE|Group R (Rectus-Intercostal Fascial Plane Block)|Rectus-Intercostal Fascial Plane Block: Aseptic conditions are ensured in the area where the block will be performed. With the patient in the supine position and under ultrasound (USG) guidance, a linear probe is placed 2-3 cm lateral and caudal to the xiphoid process to visualize the rectus abdominis muscle and the 6th-7th costal cartilages. Using an in-plane technique, the needle is advanced from caudal to cephalad. After confirming the target by hydrodissecting between the ribs and the rectus abdominis muscle, 20 ml of 0.25% bupivacaine is injected into the interfascial plane between the 6th-7th ribs and the rectus abdominis muscle using a 22-G, 80 mm block needle. The same procedure is then applied to the opposite side.
224299462|NCT03971487|BIOLOGICAL|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
224299463|NCT03077906|OTHER|Medical Files data extraction|Medical Files data extraction
224299464|NCT02138136|DRUG|Lubiprostone|12 or 24 mcg soft capsules for oral administration
224299465|NCT04192123|DEVICE|HM242|HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
224299466|NCT02593448|PROCEDURE|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~1. 30 minutes after anaesthesia induction,~2. directly after the sternotomy,~3. during CPB - 20 minutes after aortic cross-clamping ,~4. 40 minutes after aortic cross-clamping,~5. 20 minutes after the release of the aortic cross-clamp,~6. 45 minutes after weaning of CPB."
223431274|NCT05705154|BEHAVIORAL|Psychology interventions|"Based on clinical expertise and theory, it is anticipated the following elements may be included in the intervention:~* Progressive breathing pattern retraining, including education, self-observation, relaxation, body scanning, postural re-alignment~* Identifying the connections between body and mind to address anxiety and breathlessness~* Coping skills for managing anxiety using principles from narrative therapy and mindfulness~* Online materials to improve self-efficacy with home practice~* Social connection with other CYP for peer support, and resource sharing~* Activities to help CYP reconnect with their usual activities, skills, abilities, interests, support systems."
224041319|NCT07001046|OTHER|Mobile app-directed exercise program|The mobile app-guided exercise program initially asks the mother questions to collect information. These questions were about their motivation for exercise, the main exercise goal, and the area of focus in the exercise program
224041320|NCT07001046|OTHER|Traditional Abdominal Exercises|The traditional abdominal exercises program consisted of simple static abdominal exercises, graduated curl-ups, and corrected abdominal crunches with posterior pelvic tilting
224041321|NCT04693351|DRUG|Troriluzole|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
224041322|NCT04693351|DRUG|Placebo|Two 100mg capsules daily for first two weeks and then two 140mg capsules daily from week 2 through week ten.
224139967|NCT05317702|OTHER|Moderately Painful Massage|Participants will be seated in a chair with his or her shirt on. Participants will receive 60 seconds of manual pressure applied to the myofascial trigger point identified in the participant's upper back. The researcher's thumb or index finger will apply a deep manual pressure such that the participant rates the pain = 50/100 on a 101-point numeric pain rating scale with 0 indicating no pain and 100 indicating the most severe pain imaginable. The participant will be asked to rate his or her pain during the massage so the pressure may be adjusted to maintain the 50/100 related pain. Massage will be applied for 60 seconds, 4 times for a total contact time of 240 seconds. During each 30 second break in which manual pressure is released, Pressure Pain Threshold (PPT) to the foot will be examined. PPT will be assessed 2 times immediately after each of the 4 massage applications.
224139968|NCT02748122|OTHER|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
224139969|NCT05535101|DEVICE|Intermittent theta burst transcranial magnetic stimulation (iTBS)|The amphetamine users will undergo a one-month iTBS intervention. From Week 1 to Week 4, subjects will be treated five times a week.
223431275|NCT00129727|DRUG|Paclitaxel|Given intravenously
223431276|NCT00129727|DRUG|Carboplatin|Given intravenously
223431277|NCT00129727|DRUG|Bevacizumab|Given intravenously
223431278|NCT03128320|DRUG|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
223431279|NCT03128320|DRUG|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
223431280|NCT03128320|DRUG|Placebo|Single dose of placebo given in the fasted state
223565039|NCT00203918|BEHAVIORAL|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
223565040|NCT00203918|BEHAVIORAL|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
224041323|NCT06875778|OTHER|Pelvic Floor Exercises|Low intensity Warm Up Pelvic Floor Exercises and Cool down training
224041324|NCT05371548|DEVICE|SAM mobile application|See description of intervention group
223431281|NCT06144320|OTHER|Acupuncture|Acupuncture is performed using acupuncture points recorded in traditional Chinese medicine books as helpful for cognitive impairment.
223431282|NCT03931772|BEHAVIORAL|Automated Self-Hypnosis|Self-Hypnosis will be delivered through an interactive application administered through Amazon Alexa or Reveri.com.
223431283|NCT04483492|DRUG|Caffeine citrate|diaphragm contractility after administration
223431284|NCT05854303|BEHAVIORAL|Opioid cessation|opioid cessation will occur during pain rehabilitative program over approximately 3 weeks
223431285|NCT05854303|OTHER|No opioid cessation|Subjects will not stop taking opioids
223431286|NCT00346047|DRUG|Placebo|Corresponding placebo is applied for 12weeks
223431287|NCT00346047|DRUG|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
223431288|NCT06558747|PROCEDURE|Tooth Preperation|After the caries were removed, the teeth were prepared by shaving according to the manufacturer's recommendations for NuSmile ZR.
223431289|NCT06558747|PROCEDURE|Cementation|Pediatric zirconia crowns were placed on the prepared teeth with finger pressure, following the manufacturer's instructions for the luting cement to be used. For each cement, the recommended setting time was observed, and excess cement residues were removed accordingly.
223431290|NCT06624098|PROCEDURE|Early TIPS|TIPS was performed within 72 hours after the endoscopic hemostasis.
223565041|NCT01321918|OTHER|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
223431291|NCT02584894|DEVICE|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
223431292|NCT02584894|DEVICE|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
223431293|NCT02584894|BEHAVIORAL|psychoneurological assessment|psychoneurological assessment
223431294|NCT02584894|DEVICE|conductivity meter|electrodermal conductance measure
223431295|NCT02584894|DEVICE|electrocardiogram|heart rate measure
223431296|NCT00791362|OTHER|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
223431297|NCT03815591|DEVICE|smokeSCREEN web-based game|smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
224041325|NCT06894134|OTHER|Team-based learning|The intervention will include 4 two-hour modules assessing healthy diet, physical activity and screen time, regular sleep, and tobacco and alcohol use. Each module has specific learning objectives (attachment 1). The TBL is a structured active learning approach that fosters collaboration, critical thinking, and accountability. Each module will involve four key steps: (1) Preparation Phase, where students independently will review pre-class materials to build foundational knowledge; (2) Readiness Assurance Process (RAP), which assesses understanding through an individual quiz (iRAT), a team quiz (tRAT), and an instructor-led clarification session; (3) Application Activities
224041326|NCT05503797|DRUG|Plixorafenib|Oral tablets
224041327|NCT06750146|DEVICE|Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System|The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
224041328|NCT06739356|DEVICE|Fetal Treatment arm (FETO Group)|Participants will undergo FETO surgery at at 27 weeks 0 days - 29 weeks 6 days gestation.Balloon insertion into the fetal trachea will be performed. This will be followed by weekly \\ ultrasound monitoring and MRI at 3 weeks following FETO insertion and removal of the balloon which will be performed at at 34 weeks 0 days to 34 weeks 6 days. Planned delivery will occur after 37 weeks. The follow-up phase will be conducted from birth to 24 months of age
224041329|NCT06812377|OTHER|Maitland joint mbilization|Posteroanterior mobilization of the radial head in motion. This method is gliding over the radial head posteriorly to anteriorly while the patient executes (and relaxes) the painful action (e.g., clutching). Repeat the method six to ten times if there is a noticeable increase in your ability to grip without pain
224041330|NCT06812377|OTHER|mulligan mobilization|Using this approach, the patient performs (and relaxes) the painful action (e.g., clutching) while a lateral humeroulnar auxiliary glide is applied and maintained. If you notice a noticeable increase in your ability to grip without pain, repeat the method six to ten times. You can use a belt to help you glide.Three sets of it were performed, with a 30-second break in between
224139970|NCT05535101|DEVICE|Sham stimulation|Sham stimulation was delivered using the same protocol as active stimulation, but with the TMS coil rotated by 90 degrees with the edge of the coil touching the scalp.
224139971|NCT03836352|OTHER|DPX-Survivac|SubQ injection (q9w)
224139972|NCT03836352|DRUG|Cyclophosphamide|PO (BID)
224139973|NCT03836352|DRUG|Pembrolizumab|IV Infusion (q3w)
224139974|NCT02126670|DRUG|ACT01|
224139975|NCT02126670|DRUG|Comp01|
224139976|NCT02126670|DRUG|Comp02|
224139977|NCT02126670|DRUG|Comp03|
223431298|NCT01862939|DRUG|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
223431299|NCT01862939|DRUG|placebo|placebo to match part 2 DS-7309
223431300|NCT06514716|PROCEDURE|Geniculate Artery Embolization with Intra-articular Corticosteroid Injection (GAE with IACI)|Participants will undergo geniculate artery embolization (GAE) followed by an intraoperative intra-articular corticosteroid injection (IACI). This combination aims to alleviate post-procedural pain and improve early functional outcomes in patients with knee osteoarthritis (OA).
224139978|NCT02126670|DRUG|Comp04|
223431301|NCT06514716|PROCEDURE|Geniculate Artery Embolization alone (GAE alone)|Participants will undergo geniculate artery embolization (GAE) without the additional intraoperative intra-articular corticosteroid injection. This procedure aims to serve as a control to evaluate the effectiveness and safety of GAE with IACI in comparison.
224139979|NCT02700139|DEVICE|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
224139980|NCT02757092|OTHER|Home-based Pulmonary Rehabilitation|(1) breathing exercises (pursed-lip and diaphragmatic breathing) and coughing exercises, (2) aerobic exercises (upper and lower limb exercises and walking), (3) incentive spirometry training (Triflo-II), and (4) threshold load training of the inspiratory muscle. In the first stage (0-2 weeks), the aerobic exercise intensity was targeted to reach 10-11 points on the 20-point Borg rating of perceived exercise (RPE) scale. Patients raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min; in addition, they walked at a comfortable speed for 15 min twice per day. Incentive spirometry training (Triflo-II) was performed 8-10 times per hour. We used a threshold load trainer for inspiratory muscle training (30 breaths each time, twice per day) with the initial pressure set at 25%-30% of the maximum inspiratory pressure.
224139981|NCT03363919|DEVICE|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with Major Depressive Disorder (MDD) who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
224139982|NCT03363919|DEVICE|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
224139983|NCT00313248|DRUG|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
224139984|NCT00313248|DRUG|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
224139985|NCT01771536|OTHER|Decision Aid|
224139986|NCT01286116|DEVICE|Parachute Implant|Mechanical ventricular partitioning
224139987|NCT00989404|DRUG|Zanamivir|Rotahaler placebo 10mg BID 5 days
224139988|NCT00989404|DRUG|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
224139989|NCT00989404|DRUG|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
224139990|NCT03039920|OTHER|Electronic cigarette|Smoking of electronic cigarette
224139991|NCT03039920|OTHER|Conventional cigarette|Smoking tobacco cigarette
223431302|NCT03425266|OTHER|Interactive decision support tool|PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
224041331|NCT06812377|OTHER|radial nerve mobilization|The subjects will be placed in a reclining supine position. The arm will be internally rotated, the wrist, thumb, and fingers will be flexed, the shoulder girdle will be depressed, and the elbow will be stretched. Elbow flexion and wrist extension will be used to maintain shoulder depression after the radial nerve will be strained by these motions. Before beginning the gentle elbow extension test, the subject's wrist and fingers will be stabilized. The elbow will be then gently extended for about two seconds, just into the range where the participant felt tension but no pain, and then flexed. In a single session, three sets of six to eight oscillations will be executed
224041332|NCT07129668|BEHAVIORAL|Condition A|Condition A consists of performing the Finger Kazoo exercise without inducing oropharyngeal enlargement. In this condition, participants place the index finger vertically in front of the lips to partially occlude the vocal tract, producing a semi-occluded vocal tract configuration, but without modifying tongue position, soft palate height, or pharyngeal wall expansion to increase the oropharyngeal space.
224139992|NCT03842956|PROCEDURE|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
224139993|NCT03230617|DEVICE|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
224139994|NCT05862948|DEVICE|ENDO-Aid by Olympus|Colonoscopy assisted by ENDO-AID device
223431303|NCT01328899|DEVICE|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
223431304|NCT00468442|BIOLOGICAL|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
223431305|NCT00468442|BIOLOGICAL|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
223431306|NCT00468442|BIOLOGICAL|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
223431307|NCT00468442|BIOLOGICAL|Rituximab|Depletes transient B-cells
223431308|NCT00468442|DRUG|Sirolimus|Maintenance immunosuppressive therapy
223431309|NCT06602427|OTHER|Shoulder proprioception measurement using isokinetic dynamometer|A Cybex brand isokinetic dynamometer \[Cybex NORM®, Humac, CA, USA\] was used for shoulder proprioception assessment. Active Joint Position Sensation (AJPS) was evaluated to examine proprioception. AJPS was measured in the sitting position. The target angle was 30° external and 30° internal rotation. The participant was positioned with the elbow in 90° flexion and the wrist in the neutral position. The dynamometer was fixed at 0° to ensure the same starting position for each participant during trials and evaluations. Before starting the test, 3 trials were performed and then the participants were asked to find the target angle 3 times. The amount of error between the target angle and the angle found by the participant was used to describe the accuracy of the AJPS. The arithmetic mean of the result of the 3 tests was recorded for use.
223431310|NCT06124027|DEVICE|Monitoring tcPCO2 and mitoPO2|Monitoring tcPCO2 using SenTec and mitoPO2 using COMET
223431311|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 1. NovoRapid®, administered subcutaneously in dose 1.
223431312|NCT05737576|DRUG|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 1. HR011408 injection, administered subcutaneously in dose 1.
223431313|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 2. NovoRapid®, administered subcutaneously in dose 2.
223565042|NCT01321918|OTHER|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
223565043|NCT02791932|BEHAVIORAL|Exercise|See description above.
224139995|NCT01565434|OTHER|CR1 impact|
224139996|NCT01367314|DRUG|NVC-422|Dermal Gel applied 3 times per day for 7 days
224139997|NCT03717116|DIAGNOSTIC_TEST|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
223431314|NCT05737576|DRUG|NovoRapid®；HR011408 injection|NovoRapid®, administered subcutaneously in dose 2. HR011408 injection, administered subcutaneously in dose 2.
223431315|NCT05737576|DRUG|HR011408 injection; NovoRapid®|HR011408 injection, administered subcutaneously in dose 3. NovoRapid®, administered subcutaneously in dose 3.
223565044|NCT03655054|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
223565045|NCT03086291|DRUG|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
223431316|NCT05737576|DRUG|HR011408 injection; NovoRapid®|NovoRapid®, administered subcutaneously in dose 3. HR011408 injection, administered subcutaneously in dose 3.
223431317|NCT01003704|PROCEDURE|Lower extremity amputation|
223565046|NCT03897153|DEVICE|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
224139998|NCT02255617|BIOLOGICAL|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
224139999|NCT01051115|DRUG|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
223431318|NCT03385044|PROCEDURE|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
223431319|NCT03385044|PROCEDURE|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
223431320|NCT04441840|DIETARY_SUPPLEMENT|Active Probiotic Culture|Both conditions matched in appearance and serving size
223431321|NCT04441840|DIETARY_SUPPLEMENT|Inactive Probiotic Culture|Both conditions matched in appearance and serving size
223431322|NCT01486472|DRUG|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
223431323|NCT00001044|BIOLOGICAL|Aluminum hydroxide|
223431324|NCT00001044|BIOLOGICAL|QS-21|
223431325|NCT00001044|BIOLOGICAL|rgp120/HIV-1MN|
223431326|NCT02557204|PROCEDURE|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
223431327|NCT02557204|PROCEDURE|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
223431328|NCT02557204|PROCEDURE|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
223431329|NCT02557204|PROCEDURE|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
223431330|NCT03430895|DRUG|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
223431331|NCT04570852|OTHER|LiDCO|"We plan to elucidate the pathophysiology and molecular subtypes of acute pancreatitis in order to develop specific biomarkers and identify new drug targets. The evaluation will include an analysis of the impact of obesity and the metabolic profile during the disease course of acute pancreatitis.~Supportive treatments will be registered including an assessment of the fluid balance based on the fluid intake and loss and weight. Bioimpedance will be assessed at admission/day1, day 2, day 3,"
223431332|NCT01759849|OTHER|Allergen|Allergen extract is administered by inhalation.
223431333|NCT06622837|PROCEDURE|implant overdenture|With the assistance of these stereolithographic surgical guides and submerged surgical technique, 4 dental implants (IS III Active Implant, Neo BioTech) were placed in the canines and premolars regions of the maxillary arch, and 2 dental implants were placed in the canines region of the mandibular arch.
224041333|NCT07129668|BEHAVIORAL|Condition B|Condition B consists of performing the Finger Kazoo exercise with intentional oropharyngeal enlargement. In this condition, participants place the index finger vertically in front of the lips to partially occlude the vocal tract, producing a semi-occluded vocal tract configuration, while simultaneously modifying tongue position, elevating the soft palate, and expanding the pharyngeal walls to increase the oropharyngeal space.
223431334|NCT00260598|PROCEDURE|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
223431335|NCT01317797|DRUG|namilumab (MT203)|administered three times, subcutaneous in the abdomen
223431336|NCT01317797|DRUG|Placebo|administered three times, subcutaneous in the abdomen
223431337|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
223431338|NCT01378377|DRUG|Pimasertib|Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
223431339|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
223431340|NCT01378377|DRUG|Temsirolimus|Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
223565047|NCT02894957|DRUG|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
224041334|NCT06901557|COMBINATION_PRODUCT|Jing-Si Herbal Tea|The JSHT group will receive the standard medical treatment along with Jing-Si Herbal Tea, one packet daily for three months.
223431341|NCT01550705|DRUG|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
223431342|NCT01430780|DRUG|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
223431343|NCT01430780|DRUG|control group|placebo
224041335|NCT06901557|COMBINATION_PRODUCT|Placebo|The UC group will receive standard medical treatment, with one placebo packet daily for three months.
224041336|NCT06902428|DRUG|HSK44459|HSK44459, bid p.o.
224041337|NCT06902428|DRUG|Placebo|Placebo, bid p.o.
224041338|NCT07079228|DRUG|QLS31905|QLS31905 will be administered as an IV infusion.
224041339|NCT07079228|DRUG|Nab-paclitaxel.|Nab-paclitaxel will be administered as an IV infusion.
224041340|NCT07079228|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion.
224041341|NCT07079228|DRUG|Placebo for QLS31905|Placebo will be administered as an IV infusion.
224041342|NCT07079228|DRUG|Nab-paclitaxel.|Nab-paclitaxel will be administered as an IV infusion
224041343|NCT07079228|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion.
224041344|NCT06901492|DIAGNOSTIC_TEST|Prostate biopsy guided by PSMA PET/CT|The patient will undergo pelvic non-contrast CT imaging. After co-registration of the CT images with 68Ga-PSMA PET/CT data at corresponding anatomical levels, a percutaneous gluteal approach will be utilized for CT-guided prostate biopsy.
224041345|NCT06901492|DIAGNOSTIC_TEST|Prostate biopsy guided by mpMRI/US|The patient will undergo transrectal ultrasound (TRUS) prostate scanning. After co-registration and precise image fusion of TRUS findings with multiparametric MRI (mpMRI) data, a transperineal percutaneous approach will be employed to perform TRUS-guided prostate biopsy.
224140000|NCT02174016|DIETARY_SUPPLEMENT|Ketogenic diet|
224140001|NCT03357666|DRUG|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
224140002|NCT03357666|DRUG|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
223431344|NCT06624280|PROCEDURE|single-event multilevel surgery|surgical orthopedic approach where multiple deformities are corrected in one solution, often involving both lower limbs, to improve walking performance
223431345|NCT06590389|OTHER|mandala activity|A descriptive patient form, VAS and STAI-I were applied before surgery. After the surgery, VAS and STAI-I were applied before and after the mandala activity until the patient was discharged. The VAS form was applied every 4 hours until the patient was discharged. This process was repeated in the same way for the entire intervention group.
223431346|NCT01645891|DEVICE|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
223431347|NCT01645891|DEVICE|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
223431348|NCT01007331|BEHAVIORAL|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10\^10 colony forming units pr day of probiotics
223431349|NCT00754520|DEVICE|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
223431350|NCT00754520|DEVICE|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
223431351|NCT01594892|RADIATION|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
223431352|NCT03026530|PROCEDURE|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
223565048|NCT02808052|DRUG|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
224140003|NCT03357666|DRUG|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
223431353|NCT03026530|PROCEDURE|Laparoscopic bariatric surgery|
223431354|NCT03026530|DEVICE|Ventilator|
223431355|NCT00138073|DEVICE|Web-based waveform interpretation guide|Use of an educational website.
223431356|NCT00006357|DRUG|imatinib mesylate|
223431357|NCT05759624|DRUG|rhGH|Hormone replacement therapy with rhGH at a dose of 0.025-0.035 mg/kg of body weight per day (or 0.7-1.0 mg/m2 of body surface area per day).
223565049|NCT03804567|OTHER|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
223431358|NCT06090643|OTHER|Best Practice|Receive CRC screening usual care
223431359|NCT06090643|OTHER|Consultation|Receive consultation with clinic staff
223431360|NCT06090643|OTHER|Educational Intervention|Receive education and training on CRC screening
223431361|NCT06090643|OTHER|Electronic Health Record Review|Ancillary studies
223431362|NCT06090643|OTHER|Fecal Immunochemical Test|Receive FIT kit with culturally tailored instructions
223431363|NCT06090643|BEHAVIORAL|Feedback|Receive feedback on CRC screening
223431364|NCT06090643|BEHAVIORAL|Health Education|Receive CRC screening recommendations
223431365|NCT06090643|OTHER|Support Education Activity|Utilize clinical decision support tool
223431366|NCT06090643|OTHER|Text Message-Based Navigation Intervention|Receive text message reminders
223431367|NCT01239212|DRUG|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
223565050|NCT03804567|OTHER|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
223565051|NCT01581749|RADIATION|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
223565052|NCT03852992|DRUG|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
224041346|NCT06901492|DIAGNOSTIC_TEST|Systematic prostate biopsy|The patient will undergo systematic prostate biopsy under TRUS guidance.
224041347|NCT06902831|PROCEDURE|Endoscopic Carpal Tunnel Release|Release of carpal tunnel with endoscopic device
224041348|NCT06902831|PROCEDURE|Open carpal tunnel release|Release of carpal tunnel with open tecnique
224041349|NCT06902831|DRUG|Neurotrophic supplementation|Neurotrophic supplementation after surgery
224140004|NCT03357666|DRUG|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
224140005|NCT03357666|DRUG|Placebo|Vaginal administration, two tablets once a day for 7 days
224140006|NCT01646398|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
224140007|NCT01646398|BIOLOGICAL|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
224140008|NCT02726126|DRUG|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
224140009|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
224140010|NCT00255034|BIOLOGICAL|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
223431368|NCT03370575|DRUG|ethiodized poppyseed oil|Hysterosalpingography using ethiodized poppyseed oil
224041350|NCT06903676|DEVICE|TRP-2 Urine Dipstick|Urine dipstick testing for Trypsinogen-2
223431369|NCT03370575|DRUG|the second-generation non-ionic monomer contrast|Hysterosalpingography using the second-generation non-ionic monomer contrast
223431370|NCT02750475|DRUG|Sunscreen Sport Lotion (BAY987516)|50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
223431371|NCT02750475|OTHER|Untreated Skin|This site is patched without treatment as irradiated control
223431372|NCT05662059|DEVICE|RAVANS|Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation
223431373|NCT05662059|DEVICE|RAVANS-sham|RAVANS sham device
223431374|NCT01746498|PROCEDURE|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
223431375|NCT01746498|PROCEDURE|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
223431376|NCT01746498|PROCEDURE|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
223431377|NCT06395298|OTHER|Experimental group PIOMI|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)+PIOMI
223431378|NCT06395298|OTHER|Control group NIDCAP|A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)
223431379|NCT05977127|BIOLOGICAL|Comirnaty|Administration of Comirnaty vaccine
223431380|NCT03411694|OTHER|Survey|Survey in patients from the Jessa Hospital that are planned for elective surgery, both ambulatory and inpatient.
224041351|NCT06903429|PROCEDURE|Targeting of axillary lymph nodes using LuminoMark|This group used LuminoMark as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, comparing it to existing methods (charcoal staining, needle targeting, ultrasound-guided skin marking) to assess its safety and effectiveness, with procedural differences based on neoadjuvant chemotherapy status.
223431381|NCT05484076|OTHER|breastfeeding counseling|"A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training."
223431382|NCT03108404|OTHER|Validation of a diagnostic test|Validation of a diagnostic test
223431383|NCT02211963|DRUG|BI 44847|
223431384|NCT02211963|DRUG|Placebo|
223431385|NCT02010658|OTHER|Cognitive Aid|
223431386|NCT02744664|PROCEDURE|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
223740311|NCT03842384|BEHAVIORAL|iENDURE|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
224041352|NCT06903429|PROCEDURE|Targeting of axillary lymph nodes using conventional method|This group used conventional method (charcoal staining, needle targeting, ultrasound-guided skin marking) as a targeting method for axillary lymph nodes in breast cancer patients with suspected metastasis, with procedural differences based on neoadjuvant chemotherapy status.
224041353|NCT05433168|PROCEDURE|SHIATSU|The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
224140011|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
223431387|NCT02744664|DRUG|Icotinib|After Cryotherapy, subjects begin Icotinib administration
223431388|NCT05613608|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
223431389|NCT05613608|DRUG|Placebo|Placebo arm.
223431390|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on deepLive™ LC-OCT device|Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.
223431391|NCT06271603|DIAGNOSTIC_TEST|diagnosis based on skin biopsy|Control Arm: Standard management with an initial diagnosis based on skin biopsy
223431392|NCT05610384|DRUG|Ketorolac Injectable Solution|ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
224140012|NCT00255034|DRUG|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
223431393|NCT05610384|DRUG|Ibuprofen 800 mg|ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
223431394|NCT00519233|DRUG|AGS-1C4D4|IV
223431395|NCT00507078|PROCEDURE|Surgical treatment for OSA|
223431396|NCT06646328|PROCEDURE|Central venous access|Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein.
223431397|NCT06646328|DEVICE|Pump-assisted circuit|The pump-assisted circuit to be used will be Fresenius multiFiltrate (Fresenius Medical Care GmbH, Bad Homburg v.d.H., Germany). EMIC2® Fresenius Medical Care high-flux synthetic membrane will be used
224140013|NCT02185248|BEHAVIORAL|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
224041354|NCT05433168|PROCEDURE|DUMMY SHIATSU|Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
224041355|NCT07090642|OTHER|Digital escape room game|"Concurrent with the module training, the intervention group will be given the four-part escape room game M.E.R.C.I. The game's sections will be developed in parallel with the weekly topics of the disaster midwifery module training."
224140014|NCT03943108|DIAGNOSTIC_TEST|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
224140015|NCT04625361|DRUG|HEC122505MsOH|Part2：Mulltiple doses once daily, up to 8 days
223431398|NCT06646328|DRUG|Heparin sodium|Non-fractional heparin will be used in one arm with an initial dose of 500-1000 IU/hour with adaptation of the infusion to the patient and the clotting time.
223431399|NCT06646328|OTHER|Regional citrate anticoagulation|Regional citrate anticoagulation will be used in the other arm with an initial dose of 3 mmol/L and with a calcium reinfusion solution at an initial dose of 2 mmol/L, with adaptation of both infusions to the patient ionic calcium levels.
223431400|NCT06646328|PROCEDURE|Blood and ultrafiltrate samples|"Blood samples will be taken from the prefilter (inlet filter plasma concentration \[Ci\]) and postfilter (outlet filter plasma concentration \[Co\]) sites of the extracorporeal circulation circuit. The ultrafiltrate will be collected directly from the outlet of the hemofilter (ultrafiltrate concentration \[Cuf\]).~The samples will taken at the beginning of CRRT (T0) and at the following times: T0, Ci; after 60 min (T1) and after 24 hours (T2) of CRRT, Ci, Co and Cuf.~Venous access will be achieved with a 13 Fr double lumen catheter into the internal jugular or femoral vein."
223431401|NCT00773578|DEVICE|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
223431402|NCT00773578|DEVICE|Measurement of biomarkers of nasal inflammation|Nasal lavage
223431403|NCT04756583|OTHER|Notification system|Email and page notification sent to clinicians for patients at high-risk of mortality in 30 days and 6 months
223431404|NCT05484154|BIOLOGICAL|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given at 100 mL IV infusion
223431405|NCT05484154|OTHER|Placebo|Matching placebo, 0.9% sodium chloride in water, given at 100 mL IV infusion
223565053|NCT03852992|DRUG|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
223565054|NCT03852992|DEVICE|Laser|Fractional ablative, deep mode, 5% fractional coverage
224041356|NCT06902688|OTHER|ML-based intervention|A ML-based model will predict and identify participants that are at high-risk of receiving a targeted medication within three months after their hospital admission date.
224041357|NCT06902493|OTHER|No intervention|No intervention
224140016|NCT03125161|DRUG|HAI|HAI
224140017|NCT03125161|DRUG|chemotherapy ± target therapy|chemotherapy ± target therapy
224140018|NCT05459792|PROCEDURE|median nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
224140019|NCT05459792|PROCEDURE|radial nerve block|It will be given by one researcher using 5 ml 0.25% bupivacaine with 1% lidocaine for each nerve block after negative aspiration for blood so as to cover the nerve circumferentially
224140020|NCT05459792|PROCEDURE|local infiltration|intradermal infiltration followed by a subcutaneous injection with a total of 3 mL of 0.25% bupivacaine with1% lidocaine with a27- G needle
224140021|NCT01620697|PROCEDURE|Colorectal surgery|Colorectal surgery
224140022|NCT01039818|RADIATION|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
223431406|NCT06448533|OTHER|No intervention|No intervention
223431407|NCT00790998|DRUG|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
223431408|NCT00790998|DRUG|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
223431409|NCT00444041|DRUG|Bevacizumab|neoadjuvant therapy prior to elective surgery
223431410|NCT03909113|DIETARY_SUPPLEMENT|amino acid based formula|amino acid based formula
223431411|NCT06621082|DRUG|Selumetinib|After surgical resection，based on the patient's body surface area (BSA), the patient was given an oral dose of Simetinib bisulfate capsule (20-50mg bid) daily for 30 days for 6 cycles
223565055|NCT03852992|DRUG|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
223431412|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Tablet|1.5 grams/day
223431413|NCT06731582|DIETARY_SUPPLEMENT|Nicotinamide Placebo|2 tablets
223565056|NCT03852992|DRUG|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
223565057|NCT03852992|DRUG|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
223565058|NCT02439151|DEVICE|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
223565059|NCT02439151|DEVICE|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
223565060|NCT03182946|DIAGNOSTIC_TEST|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
224140023|NCT01039818|RADIATION|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
224140024|NCT04907864|COMBINATION_PRODUCT|Multi-modal intervention|Daily oral medications: ibuprofen 400 mg three times a day, omega-3-fatty acid 1 g twice a day, Bojungikki-tang 3.75g twice a day, oral nutritional supplement (HAMONILAN SOLN) 200 ml twice a day Weekly physical exercise by physiatrist (60 minutes per visit) Biweekly psychiatric intervention Nutritional counselling total four times during the study period
224140025|NCT02559557|OTHER|Educational Intervention|Participate in focus groups
224140026|NCT02559557|OTHER|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
224140027|NCT02559557|OTHER|Quality-of-Life Assessment|Answer questionnaires
224140028|NCT02559557|OTHER|Questionnaire Administration|Answer questionnaires
224140029|NCT02855645|DRUG|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
224140030|NCT02855645|DRUG|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
224140031|NCT06280612|OTHER|Pet therapy|The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.
224140032|NCT01144195|DRUG|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
224140033|NCT03327519|BEHAVIORAL|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
224140034|NCT03327519|BEHAVIORAL|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
224140035|NCT00369746|DRUG|citalopram|tablets, 60 mg maximum, daily, 12 weeks
224140036|NCT01913171|OTHER|Exercise|
224299467|NCT02593448|PROCEDURE|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
224299468|NCT02593448|PROCEDURE|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
224140037|NCT05494983|OTHER|Screening visit|The participants will be screened for inclusion and exclusion criteria and will be asked to fill the following questionnaires : Pittsburgh Sleep Quality Index, State and Trait Anxiety Questionnaire, Pain Catastrophizing Scale Fear of Pain Questionnaire, Perceived Stress Scale, Beck Depression Inventory, and questionnaires to assess their health status and the use of medications. A blood sample (to measure pro- and anti-inflammatory cytokines and perform metabolomic analyses) will be obtained. Enrolled participants will be given a wearable actimeter to assess daily total sleep duration during one week before the first experimental session. They will also be requested to complete daily a sleep diary during one week before each experimental session, and a food diary before the first experimental session. A fecal sample (to assess gut microbiota composition and perform metabolomic analyses) will be collected between the screening visit and the first experimental session.
224299469|NCT00590278|DRUG|Tomudex|
224299470|NCT00590278|PROCEDURE|Radiotherapy|
224299471|NCT00590278|PROCEDURE|Haematology|
223565061|NCT05305222|DRUG|Risankizumab|Intravenous (IV) Infusion
223565062|NCT05305222|DRUG|Placebo|Intravenous (IV) Infusion
223565063|NCT03386136|DRUG|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
223740312|NCT05868070|DEVICE|Conventional rehabilitation plus multimodal exercise|Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
223740313|NCT05349149|DRUG|Tocilizumab/Actemra® (Roche)|The infusion of tocilizumab will antagonize IL-6 signaling for the duration of the study, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
223740314|NCT05349149|DRUG|Saline 9%|The infusion of saline will serve as placebo for tocilizumab, allowing us to determine the role of IL-6 in regulating energy stores following acute exercise
223740315|NCT01870583|DRUG|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
223740316|NCT01870583|DRUG|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
223740317|NCT01870583|DRUG|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
224299472|NCT00590278|PROCEDURE|Biochemistry|
223565064|NCT00813865|DRUG|afegostat tartrate|
223565065|NCT01184638|DRUG|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
223565066|NCT01184638|DRUG|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
223565067|NCT01028768|DRUG|Teduglutide|10 mg, one-time subcutaneous
223565068|NCT03397745|DEVICE|BIS|All patients applied BIS on both side (Left and Right)
223565069|NCT02339142|RADIATION|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
223565070|NCT02339142|DRUG|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
223565071|NCT05664659|DRUG|Oxytocin + misoprostol|600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution
223565072|NCT05664659|DRUG|Carbetocin|100 micrograms carbetocin
223740318|NCT04160364|OTHER|qualitative study|qualitative research via guided interview
223740319|NCT04382131|OTHER|NaCl Solution|NaCl Solution prepared by participants at home using water and salt
223431414|NCT02520882|DRUG|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
224041358|NCT07128407|BEHAVIORAL|Protection Motivation Theory-Based Radiation Protection Training|A structured educational program designed according to Protection Motivation Theory (PMT). The program targets both threat appraisal (perceived severity and vulnerability) and coping appraisal (response efficacy, self-efficacy, and response cost) processes to improve nurses' knowledge, awareness, motivation, and safety behaviors regarding radiation protection.
224041359|NCT07130422|PROCEDURE|CABG surgery|CABG surgery
224041360|NCT06936722|OTHER|ELDOA + Conventional PT|"ELDOA, the protocol consists of 4 positions. Each position is maintained for 1 min with constant correction of posture throughout with 2 to 4 min rest within each position. The Exercise was performed in 10 to 25 mins. 4 positions of ELDOA are Decoarctation of C0/C1/C2, Decoarctation of C4/C5, Decoarctation of C5/C6, Decoarctation of C6/C7. All positions are attained in lying.~Hot pack 2. isometric strengthening exercises (Neck Flexion, Extension and Lateral Flexion) in 3x5 sets with 5 sec hold."
224041361|NCT06936722|OTHER|McKenzie Protocol + Conventional PT|Extension Dysfunction Retraction Retraction with patient overpressure Retraction with therapist overpressure Retraction with extension Lateral Flexion Dysfunction Lateral flexion: Lateral flexion with patient overpressure Lateral flexion therapist overpressure Rotation Dysfunction Rotation Rotation with patient overpressure Hot pack, isometric strengthening exercises (Neck Flexion, Extension and Lateral Flexion) in 3x5 sets with 5 sec hold Rotation with therapist overpressure
224041362|NCT01264653|DRUG|adrenalin|adrenalin 0.01%
224041363|NCT05608382|OTHER|sterile Phosphate Buffer Saline|control group
224041364|NCT05608382|OTHER|SGW13|active comparator
224041365|NCT06203405|PROCEDURE|Titrating sedation targeting both optimal P0.1 and appropriate arousal level|"* Sedation will be adjusted initially to target light sedation (RASS 0 to -2).~* Sedative drugs include IV fentanyl (25-75 mcg/h), midazolam (0.02- 0.1 mg/kg/h), propofol (5-50 mcg/kg/min), dexmedetomidine (0.2-0.7 mcg/kg/h).~* Deep sedation and neuromuscular blocking agents are allowed to facilitate mechanical ventilation adjustment in patients with refractory hypoxemia.~* Dose of cisatracurium is 0.15-0.2 mg/kg intravenous bolus, then continuous infusion at 5 -20 mg/h.~* Then sedation adjustment will be guided by P0.1 measurement.~* If P0.1 value of 1.5-3.5 cmH2O is achieved, no further adjustment is required.~* If P0.1 value \<1.5, sedation will be reduced.~* If P0.1 value \>3.5, sedation will be increased.~* If P0.1 value is still \>3.5 with deep sedation, cisatracurium will be allowed and titrated until P0.1 value \<3.5 cmH2O.~* The study protocol will be continued for 48 hours or until the patients are considered ready for weaning."
223431415|NCT02520882|DEVICE|PET/CT|
223431416|NCT03148457|DRUG|Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
223431417|NCT03148457|DRUG|Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
223431418|NCT03247491|BEHAVIORAL|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
223431419|NCT02464891|DRUG|CCX168|
223431420|NCT06174376|DEVICE|GORE Synthetic Cornea Device|Treatment with GORE Synthetic Cornea Device
224041366|NCT06203405|DRUG|Fentanyl|Continuous intravenous infusion of fentanyl 25-75 micrograms/hour
223431421|NCT03250091|PROCEDURE|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
223431422|NCT03250091|PROCEDURE|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
223431423|NCT03250091|PROCEDURE|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
223431424|NCT03250091|PROCEDURE|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
223431425|NCT00375050|DRUG|Riluzole|
223431426|NCT00375050|DRUG|Placebo|placebo
223431427|NCT00847392|PROCEDURE|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
223431428|NCT00478114|DRUG|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
224041367|NCT06203405|DRUG|Midazolam|Continuous intravenous infusion of midazolam 0.02 - 0.1 milligrams/kilogram/hour
223431429|NCT06429215|DEVICE|Multi-component Intervention (MC-I): VR Cognitive training and Psychoeducation on health and lifestyle|"In a period of 5 consecutive weeks, participants will receive:~* an interactive immersive virtual reality cognitive training for 30 minutes, 3 days per week. It consists in different tasks implemented in virtual real-like scenarios of daily living situations that target the following cognitive processes: long-term associative memory, relational binding, spatial pattern separation and pattern completion;~* an interactive immersive virtual reality health and lifestyle education program for 30 minutes, 1 day per week. It consists in 360° videos aimed at advancing awareness and knowledge of the various health conditions associated with an increased risk of cognitive decline and dementia and helping participants to develop a healthier lifestyle."
223565073|NCT04361409|DRUG|Rituximab|375mg/m2 on Day-14 and Day-7
223565074|NCT04361409|DRUG|Cisplatin|70mg/m2 on Day1
223565075|NCT04361409|DRUG|Gemcitabine|1000mg/m2 on Day8
223565076|NCT04820010|DRUG|Topical Insulin|Patients were administered eyedrops enriched with insulin
224041368|NCT06203405|DRUG|Propofol|Continuous intravenous infusion of propofol 5 - 50 micrograms/kilogram/minute
224041369|NCT06203405|DRUG|Dexmedetomidine|Continuous intravenous infusion of dexmedetomidine 0.2 - 0.7 micrograms/kilogram/hour
224041370|NCT06203405|DRUG|Cisatracurium|Continuous intravenous infusion of cisatracurium 5 - 20 milligrams/hour
224041371|NCT05051345|OTHER|Informational Intervention|Receive information on the services provided for pregnant women and smoking cessation
224041372|NCT05051345|OTHER|Informational Intervention|Receive tobacco cessation self-help materials
224041373|NCT05051345|OTHER|Informational Intervention|Receive Smoke-Free Homes mailings
224041374|NCT05051345|OTHER|Media Intervention|Download and use the Wellness app
224041375|NCT05051345|OTHER|Questionnaire Administration|Ancillary studies
224140038|NCT05494983|OTHER|Peripheral sensitization session|The extent of neurogenic inflammation induced by topical capsaicin will be used as a measure of the susceptibility to sensitize at peripheral level. A solution of capsaicin will be applied to the skin of the left or right volar forearm for 30 minutes. The capsaicin-induced neurogenic inflammation can be quantified by assessing the intensity, extent and duration of the capsaicin-induced cutaneous flare response using thermal infrared imaging. Using heat stimuli delivered to the treated skin and surrounding skin, the intensity and duration of the capsaicin-induced hyperalgesia will also be assessed. The experimental session will last approximately two hours.
224140039|NCT05494983|OTHER|Central sensitization session|The extent of secondary mechanical hyperalgesia induced by high-frequency electrical stimulation (HFS) of the skin of the left or right volar forearm will be used as a measure of the susceptibility to develop central sensitization. The stimulation will be delivered using a multi-pin electrode designed to preferentially activate epidermal free nerve endings. The strength, spatial extent and duration of the HFS-induced changes in pinprick sensitivity will be characterized by using calibrated mechanical pinprick stimuli. The experimental session will last approximately one hour.
224140040|NCT02522650|DRUG|Amiloride|5mg twice a day for 8 weeks
223431430|NCT06429215|DEVICE|Cognitive-only intervention (CO-I): VR Cognitive training (+ Psychoeducation active control)|"In a period of 5 consecutive weeks, participants will receive:~* the interactive immersive virtual reality cognitive training as described in the MC-I condition, for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for 30 minutes, 1 day per week."
223431431|NCT06429215|DEVICE|Active control intervention (AC-I): VR Cognitive active control + Psychoeducation active control|"In a period of 5 consecutive weeks, participants will receive:~* an active control of the immersive virtual reality cognitive training (participants will be requested to virtually carry out daily actions, in the same setting as those performed in cognitive immersive VR training, but they will follow prearranged instructions requiring very low cognitive demands) for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for about 30 minutes, 1 day per week."
223431432|NCT02351193|OTHER|transvaginal Ultrasound|
223431433|NCT00962091|DRUG|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
223431434|NCT01063920|DRUG|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
223431435|NCT01063920|DRUG|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
223431436|NCT02225327|BIOLOGICAL|Fluad alone|Fluad
223431437|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the different arms|Fluad and Prodiax
223565077|NCT04564807|BEHAVIORAL|Web-Based Insomnia Education Program|"Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data."
223740320|NCT03510156|BEHAVIORAL|Behavior analytic treatment|Function-based treatment
223740321|NCT00379496|PROCEDURE|Antidepressants|
223740322|NCT00379496|PROCEDURE|acupuncture|
224041376|NCT05051345|BEHAVIORAL|Smoking Cessation Intervention|Receive Smoke-Free Homes kit
224041377|NCT05051345|OTHER|Survey Administration|Ancillary studies
224140041|NCT02522650|DRUG|Triamterene|50mg twice a day for 8 weeks
224041378|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive telephone counseling sessions
223431438|NCT02225327|BIOLOGICAL|Fluad and PPV23 on the same arm|Fluad and Prodiax
223431439|NCT02225327|BIOLOGICAL|PPV23 alone|Prodiax
223431440|NCT04824391|BIOLOGICAL|ERUCOV-VAC 3 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
223431441|NCT04824391|BIOLOGICAL|ERUCOV-VAC 6 µg/0.5 ml Vaccine|Two IM applications on Days 1 and 28
223431442|NCT04824391|OTHER|Placebo|Two IM applications on Days 1 and 28
223431443|NCT03211923|DIAGNOSTIC_TEST|Transcranial magnetic stimulation (TMS)|Single pulse, monophasic transcranial magnetic stimulation
223431444|NCT02253771|DEVICE|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
223740323|NCT05150535|RADIATION|Hypofractionation Radiotherapy.|Patients will receive 40 Gy in 15 fractions to the entire breast and or chest wall over the course of 3 weeks.
223740324|NCT05150535|RADIATION|Ultra-hypofractionation radiotherapy|Patients will receive 26 Gy in 5 fractions to the entire breast and or chest wall over the course of one week.
223740325|NCT05423821|OTHER|Anesthesia efficacy in patients undergoing MRI|atropine will be administered when bradycardia develops, oxygen will be given if hypoxia develops
223740326|NCT05408416|PROCEDURE|preoperative group and intraoperative group|ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
224041379|NCT05051345|BEHAVIORAL|Telephone-Based Intervention|Receive a coaching call from a Baby Steps for Health counselor
224041380|NCT05051345|OTHER|Tobacco Cessation Counseling|Receive telephone counseling sessions
224041381|NCT06537921|DRUG|Minocycline 200mg|Dosage: 2x100mg/daily for 8 weeks
224041382|NCT02430350|DRUG|Compound Edaravone Injection|
224041383|NCT02430350|DRUG|Edaravone Injection|
224041384|NCT05427162|DRUG|Prostacyclin Receptor Agonist|Prostacyclin receptor agonist will be administered.
224041385|NCT05170958|DRUG|LBL-024 for Injection|LBL-024 was given every three weeks for treatment
224041386|NCT06525675|DRUG|Fulvestrant Injectable Product|500 mg fulvestrant on days 1, 14, 28, and once monthly thereafter, administered intramuscularly.
224041387|NCT06525675|DRUG|Letrozole 2.5mg|2.5 mg letrozole per day, administered orally (continuous treatment)
224041388|NCT06525675|DRUG|Palbociclib 125mg|orally administration 125 mg palbociclib per day (in cycles of 3 weeks of treatment followed by 1 week off)
224041389|NCT05866770|DEVICE|U8|The U8 Research System
223431445|NCT02253771|DEVICE|placebo shockwave therapy|sham shockwave therapy by an identically looking device without any function
224041390|NCT05866770|DEVICE|N8 sound processor|Nucleus 8 sound processor
223565078|NCT04564807|BEHAVIORAL|SHUTi Intervention|"Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention."
223565079|NCT03570918|BIOLOGICAL|MGD014|HIV-1 x CD3 bispecific DART molecule
224140042|NCT00005018|DRUG|Hydroxyurea|
223431446|NCT01979471|OTHER|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~  * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
223565080|NCT02330653|BIOLOGICAL|Fecal Microbiota Transplant (FMT)|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standard by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
223565081|NCT02330653|BIOLOGICAL|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
223565082|NCT05053815|OTHER|Pharmacogenomic Testing|Pharmacogenomic testing is done via buccal swab. As this study is retrospective, data from PGx testing has already been collected as a part of routine care.
223565083|NCT01404559|DEVICE|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
223565084|NCT01404559|DEVICE|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
223565085|NCT01404559|DEVICE|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
223565086|NCT02256384|DEVICE|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
223565087|NCT00742287|DIETARY_SUPPLEMENT|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
223565088|NCT00742287|DIETARY_SUPPLEMENT|Placebo|placebo
223565089|NCT02970006|DEVICE|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
223565090|NCT00943475|PROCEDURE|circumcision|circumcision by plastbell
223565091|NCT05173688|DRUG|Propofol|The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
223565092|NCT05928117|OTHER|Education|Pregnant women will be given training to cope with the fear of childbirth.
223740327|NCT03061110|BIOLOGICAL|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
224041391|NCT06956742|DEVICE|Active intermittent intrapulmonary deflation.|"Intermittent intrapulmonary deflation sessions will be performed using the SIMEOX device (SIMEOX, PhysioAssist, Aix-en-Provence, France), which will be delivered to the patient's home by a home healthcare provider. The device power setting (25%, 50%, 75%, or 100%) will be individualized according to the parameters determined during the familiarization visit by a trained physiotherapist. Patients will be instructed to perform tidal volume inspirations followed by passive expirations into the device through a mouthpiece, up to their maximal tolerance. The device will be activated by the patient during expiration using a manual remote control.~Each device usage cycle consists of 10 expirations, with oscillations generated at 12 Hz during the first 8 cycles and at 6 Hz during the last 2 cycles. Rest periods will be allowed during the session, and a mandatory pause will be imposed every 10 expirations. The session duration is fixed at 20 minutes, with patients performing one session in the"
224140043|NCT00005018|DRUG|Abacavir sulfate|
224140044|NCT00005018|DRUG|Efavirenz|
224140045|NCT00005018|DRUG|Didanosine|
224140046|NCT03549468|DEVICE|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
224140047|NCT04539691|DEVICE|Magnet|Magnet or Sham is worn by subject in close proximity to their described maximum pain site
224140048|NCT06338046|OTHER|Corthellus Shiitake(Mushroom) Extract|topical treatment with Corthellus Shiitake(Mushroom) Extract
224140049|NCT06338046|OTHER|Placebo|topical treatment with a placebo cosmetic formula
223431447|NCT02326298|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
223740328|NCT03061110|OTHER|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
223740329|NCT05425056|DRUG|Sirolimus|SeCI placed at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery.
224140050|NCT01109069|DRUG|PCI-32765|Dose based on parent protocol
224140051|NCT03947255|DRUG|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
224140052|NCT05151224|DIAGNOSTIC_TEST|microRNA 21|"Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment."
224299473|NCT04940949|DRUG|Lu AF90103|Lu AF90103 - powder for solution for infusion
224041392|NCT06956742|DEVICE|Placebo intermittent intrapulmonary deflation.|"Placebo intermittent intrapulmonary deflation sessions will be performed using the SIMEOX device (SIMEOX, PhysioAssist, Aix-en-Provence, France), which will be delivered to the patient's home by a home healthcare provider. Due to the physiological mechanism of action of the device (intermittent negative pressure with increasing intensity, inversely proportional to airflow resistance), it is assumed that device use under placebo conditions will be infra-therapeutic.~To ensure this, the device will be set to the same setting as the active intermittent intrapulmonary deflation session but an intentional air leak will be introduced into the circuit at the device's output (not visible to the participant) to prevent the generated negative pressure from exceeding t The validity of this placebo condition will be confirmed through bench tests.~All other conditions will remain identical to the active intermittent intrapulmonary deflation sessions. Patients will be instructed to perform tidal vo"
223431448|NCT02326298|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
223431449|NCT00312481|DRUG|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
223431450|NCT00312481|DRUG|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
223431451|NCT02650947|DIETARY_SUPPLEMENT|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
223431452|NCT02650947|DIETARY_SUPPLEMENT|Placebo|Consumption of empty capsule everyday for 4 weeks
223565093|NCT06479265|OTHER|Phyical/Cognitve Exercise|Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
223565094|NCT05828875|OTHER|questionnaire investigation|Conduct a questionnaire survey on patients' quality of life, nutrition, and psychology
223565095|NCT01620515|DRUG|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
223565096|NCT01620515|DRUG|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
224041393|NCT04532372|OTHER|Best Practice|Receive standard of care drugs
224041394|NCT04532372|DRUG|Leflunomide|Given PO
224041395|NCT04532372|DRUG|Placebo Administration|Given PO
224041396|NCT06165302|BEHAVIORAL|Exercise Intervention|12 weeks of prescribed exercise intervention.
224041397|NCT03435003|DRUG|Aprepitant 80 mg Oral Capsule|aprepitant 80 mg orally one hour prior to scheduled surgery
224041398|NCT03435003|DRUG|scopolamine transdermal|scopolamine transdermal patch one hour prior to scheduled surgery
224041399|NCT03435003|PROCEDURE|Total intravenous anesthesia|Maintenance of anesthesia without the use of inhaled anesthetics.
223565097|NCT05562674|BEHAVIORAL|Support group|"This is a group-based, peer specialist and clinician co-facilitated psychosocial intervention for Veterans with SMI, called Veteran Voices and Visions (VVV). VVV is an adaptation of a community-based support group model called the Hearing Voices (HV) approach. The approach facilitates group cohesion around and normalization of the common psychotic symptoms of SMI: hallucinations, delusions, and social isolation."
223565098|NCT01906385|DRUG|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
223565099|NCT04114643|BIOLOGICAL|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
223565100|NCT04114643|BIOLOGICAL|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
223565101|NCT05912881|OTHER|Olfactory training|Participants perform olfactory training using sticks filled with scented essential oils.
224041400|NCT03435003|DRUG|Dexamethasone|Dexamethasone 8 mg intraoperatively
224041401|NCT03435003|DRUG|Ondansetron|Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
224041402|NCT03435003|DRUG|Reglan|Postoperatively scheduled Reglan
224041403|NCT03435003|DRUG|Ondansetron|Postoperatively scheduled ondansetron
224041404|NCT03435003|DRUG|Compazine|Postoperatively as needed compazine for breakthrough PONV
224041405|NCT03435003|DRUG|Sugammadex|Reversal with sugammadex
224041406|NCT03435003|DRUG|Propofol|Intravenous anesthesia will be maintained through IV propofol
224041407|NCT03435003|DRUG|dexmedetomidine|maintenance of anesthesia in the intervention arm
223431453|NCT00583882|OTHER|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
223431454|NCT04323865|DIAGNOSTIC_TEST|fetal heart rate variability|No direct intervention, as the study is observational.
224041408|NCT03435003|DRUG|Fentanyl|intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
223431455|NCT03445234|DIETARY_SUPPLEMENT|Blueberry|26 g/day freeze-dried powder, 2 weeks duration
223431456|NCT03445234|DIETARY_SUPPLEMENT|Placebo|Placebo powder
224041409|NCT03435003|DRUG|Sevoflurane|inhalational anesthesia
224041410|NCT03435003|DRUG|Desflurane|inhalational anesthesia
224041411|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus extract|The participants are divided randomly into three groups，one of which are asked to Cyclocarya paliurus extract for three months .
223431457|NCT03445234|DIETARY_SUPPLEMENT|banana|Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
223431458|NCT03445234|DIETARY_SUPPLEMENT|No banana|water only
224041412|NCT04184440|DIETARY_SUPPLEMENT|Cyclocarya paliurus compounds|The participants are divided randomly into three groups，one of which are asked to take Cyclocarya paliurus compounds for three months .
224041413|NCT04184440|DIETARY_SUPPLEMENT|placebo|The participants are divided randomly into three groups，one of which are asked to take placebo for three months .
224041414|NCT06955702|DEVICE|cryotherapy for chemotherapy-induced madarosis|Application of temperature-controlled cold devices (-4°C to -7°C) to the supraorbital area (up to 3 cm above the eyelid margin), administered 15 minutes before chemotherapy infusion and maintained for 20 minutes post-infusion.
224041415|NCT01153802|DRUG|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
224140053|NCT01933204|OTHER|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
223431459|NCT04948034|RADIATION|Stereotactic Ablative Radiotherapy (SABR)|"We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience."
223431460|NCT04948034|DRUG|Fruquintinib|Starts within two weeks upon SABR completion: 5mg, d1-14, qd; Continued until disease progression, unacceptable toxicity or patient withdrawal.
223431461|NCT04948034|DRUG|Tislelizumab|Starts within one week upon SABR completion: 200mg, d1, q3w; the dosing will continue for up to two years until disease progression, unacceptable toxicity or patient withdrawal.
223431462|NCT01834716|BEHAVIORAL|Aerobic vs. Non-Aerobic exercise|
223431463|NCT05072964|DEVICE|FARAPULSE Pulsed Field Ablation System|A pulmonary vein isolation will be performed using catheter ablation
223431464|NCT03211143|DRUG|CKD-381|Test drug: CKD-381
223431465|NCT03211143|DRUG|Nexium|Reference drug: Nexium
223431466|NCT05708677|BIOLOGICAL|EB-101|This is non-interventional and follows patients treated with EB-101
223431467|NCT00659698|DEVICE|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
223431468|NCT03690973|DRUG|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
223431469|NCT03690973|DEVICE|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
223431470|NCT03690973|DEVICE|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
223431471|NCT03690973|DRUG|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
223431472|NCT06622733|BEHAVIORAL|Questionnaire|Attitude towards the concept of CS on demand
223565102|NCT05912881|OTHER|Placebo training|Participants perform olfactory training using sticks filled with unscented medium chain triglycerides.
223431473|NCT00203944|BEHAVIORAL|Behavioral, Development|
223431474|NCT06910917|BEHAVIORAL|Roy Adaptation-Based Nursing Interventions|"After the research groups were formed, a six-session interview program was created for the participants in the experimental group. Individual goals were set for the participants in the experimental group by combining the evaluations of the areas related to the psychosocial adaptation brought by the disease (physiological, self-concept, role function, interdependence) and the stimuli that would disrupt the adaptation (focus, affecting and possible) and nursing interventions were determined in line with these goals.~applied. In the sessions, nursing and psychiatric nursing interventions (psychoeducation, relaxation, awareness, effective coping) based on the Roy Adaptation Model were carried out for the negative situations caused by anxiety and anxiety experienced by individuals. It was applied to the participants as standard."
223431475|NCT02286570|DEVICE|Glidescope|videolaryngoscope used for endotracheal intubation
223431476|NCT02286570|DEVICE|Airtraq|videolaryngoscope used for endotracheal intubation
223431477|NCT02286570|DEVICE|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
223431478|NCT00703794|DEVICE|The AXIUM Progressive Coil System|Embolization of aneurysm
223431479|NCT04010747|BEHAVIORAL|Motivational Interviewing for Loved Ones (MILO)|4 sessions of behavioral coaching in motivational interviewing communication techniques
223431480|NCT04010747|BEHAVIORAL|Mental Health Services Consultation and Waitlist|1 session of individualized consultation on relevant mental health services for the IP and participating PCSO and 6 weeks on a waitlist, followed by opportunity to participate in MILO sessions.
223431481|NCT04229602|DRUG|Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
223565103|NCT04547907|DRUG|Nab-paclitaxel+ trastuzumab+ patuzumab|Nab-paclitaxel 125mg/m2 (days 1, 8, 15) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
223565104|NCT04547907|DRUG|Docetaxel+ carboplatin+ trastuzumab + patuzumab|Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) + Trastuzumab (initial loading dose of 8 mg/kg, subsequent maintenance dose of 6 mg/kg) + Pertuzumab (initial loading dose of 840mg, subsequent maintenance dose of 420mg), every 21 days constitute a cycle.
223565105|NCT03887988|PROCEDURE|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
223565106|NCT03887988|OTHER|Nonsurgical|Nonsurgical treatment of fracture
223431482|NCT04229602|DRUG|EFEXOR® XR|EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
223431483|NCT00634686|DIETARY_SUPPLEMENT|DHA/EPA|1.2 gram capsule daily for 6 months
223431484|NCT00634686|DIETARY_SUPPLEMENT|Placebo capsule|daily for 6 months
223431485|NCT00634686|DIETARY_SUPPLEMENT|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
223431486|NCT06531798|DRUG|Breztri Aerosphere|Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg
223431487|NCT04113421|DIAGNOSTIC_TEST|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
223565107|NCT03887988|PROCEDURE|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
223565108|NCT03887988|PROCEDURE|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
223565109|NCT04295681|DRUG|MMH-MAP|Oral administration
223565110|NCT04295681|DRUG|Placebo|Oral administration
223740330|NCT05256121|OTHER|AD Risk factors balance|"At baseline, participants in the intervention group will be asked to fill a daily risk-factor diaries (Risk factors log using the REDCap (Research Electronic Data Capture) software's survey).~In the Risk factors log, participants will need to answer shortly questions about their specific unbalanced risk factor.~In addition, during the 18-months intervention period, the study team will communicate with the participants by phone every 3-4 weeks to inquire about risk factors data. Before each phone call, participants' Risk factors log data since previous phone call will be analyzed. The team will propose alternative activities, and provide positive reinforcement and feedback."
223740331|NCT04925349|DIAGNOSTIC_TEST|Blood sample collection|blood sample collection
223740332|NCT05459571|BIOLOGICAL|Axicabtagene Ciloleucel|Administered intravenously
224140054|NCT01933204|DRUG|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
223431488|NCT06829615|DEVICE|Shen.AI|Contactless measurement of heart rate, heart rate variability, breathing rate, and blood pressure using Shen.AI software and reference methods.
223431489|NCT06519071|OTHER|Tryptophan Intake|Each hourly meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.7 Resting Energy Expenditure and adequate protein (at 1.5 g.kg.d), to maintain a metabolic steady state. The liquid shake contains protein-free powder orange-flavored drink crystals, corn oil, and water.
223431490|NCT06789666|BEHAVIORAL|ARTCan App|"The ARTCan App is an art therapy technology application program. The application can be accessed via the web (via computer, phone, or on a device such as an iPad). With the use of the application, participants complete weekly sessions that culminate in an art piece. Note that participants are not required to have expertise in drawing; developing art skills or assessing the quality of art pieces is not the focus of the ARTCan program.~Subjects will upload a photo of the art they created to this application to show proof of completion of art therapy. They will also answer questions specific to the art therapy theme for the week."
223431491|NCT06493578|DRUG|VYN201 Gel|VYN201 Gel is a topical formulation applied as a thin layer to affected areas.
223431492|NCT06493578|DRUG|Vehicle Gel|Vehicle gel (placebo) is matching in appearance to VYN201 gel and is to be applied in the same manner as VYN201 gel.
223431493|NCT04533698|OTHER|Assessment of reason for resternotomy|No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
223565111|NCT05718271|OTHER|Explicit instructions before extinction|"Shocks will no longer be administered during the next phase."
223565112|NCT05718271|OTHER|Explicit instructions after extinction|"Tomorrow no shocks will be administered."
223565113|NCT04402632|PROCEDURE|Surgical Management|SDH Evacuation (Control)
223565114|NCT04402632|DEVICE|Surgical Management + Treatment|SDH Evacuation + Onyx™ LES Embolization
223565115|NCT04402632|OTHER|No Treatment|Observation Only (Control)
223565116|NCT04402632|DEVICE|Treatment|Onyx™ LES Embolization
223565117|NCT06554535|DRUG|Serplulimab，Platinum-based Chemotherapy，Aspirin|Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
223565118|NCT01179828|DRUG|Oxycodone 15mg|15mg single administration p.o.
223565119|NCT01179828|DRUG|Clobazam|20mg single administration p.o.
223565120|NCT01179828|DRUG|Imipramine|75mg single administration p.o.
223565121|NCT01179828|DRUG|Tolterodine|1 mg single administration p.o.
223565122|NCT04353999|PROCEDURE|Socket sealing by diode laser photocoagulation|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed using 980 nm diode laser photocoagulation applied in a non-contact mode with a poer output of 1 watt in a continuous wave mode for 3-5 minutes
223565123|NCT04353999|PROCEDURE|socket sealing with dense polytetrafluroethylene membrane|tooth extraction followed by socket grafting with bovine bone xenograft and finally sealed by a non-resorbable dPTFE membrane that is stabilized by suturing to the soft tissue margins of the socket
223565124|NCT02806219|DEVICE|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
223565125|NCT02806219|DEVICE|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
223565126|NCT04966312|OTHER|Preoperative educational videos plus routine education|Mothers receiving routine education plus digital video disk before their children receiving congenital heart disease surgery. The content was the same as the routine education but was presented audio-visually, and the video was easy to understand by the general public.
223565127|NCT04966312|OTHER|Preoperative routine education|Mothers receiving routine education before their children receiving congenital heart disease surgery
224299474|NCT04940949|DRUG|Placebo|Placebo - powder for solution for infusion
224299475|NCT04882566|OTHER|Paleolithic Diet|Advice to follow Paleolithic Diet for Inflammatory bowel disease Patients
224041416|NCT04918238|OTHER|Conventional program|All the participants will receive the conventional physical therapy protocol per session as following: Infrared radiation on the low back area for 15 minutes, Ultrasound waves (Digi sonic device) for 10 minutes on the trigger areas of the low back, Myofascial release of the thoracolumbar fascia, Stretching of the Paraspinal muscles and the hamstrings, Mobilization of the lumbar and thoracic spine from a prone lying position and strengthening of abdominal muscles, multifidus and transversal's abdominal muscle.
224041417|NCT04918238|OTHER|Muscle energy technique|The patient was in the lateral recumbent position on the side opposite to his, her side-bending dysfunction while the physiotherapist stood facing the subject. The physiotherapist monitored the lumbar area with one hand while with the other hand flexed the subject's knees and hips until the barrier was engaged at the vertebral segment being treated.
223431494|NCT04533698|OTHER|Assessment of reason for avoidance of resternotomy|No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
223431495|NCT05965063|DIETARY_SUPPLEMENT|Bifidobacterium M-16V|Bifidobacterium M-16V was dosed at 10 billion colony forming unit (CFU) (equal to 6 drops)/day for 12 weeks.
224041418|NCT05470946|DEVICE|Double balloon enteroscopy|Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
224041419|NCT02665065|DRUG|Iomab-B|
224041420|NCT02665065|DRUG|Conventional Care|
224041421|NCT02665065|PROCEDURE|HCT|
224041422|NCT01557023|DRUG|barrier methods|
223431496|NCT05965063|OTHER|allergy food avoidance|strict avoidance of the specific allergenic food
223431497|NCT02459847|BEHAVIORAL|Mindfulness Training|
223740333|NCT05459571|DRUG|Cyclophosphamide|Administered intravenously
224299476|NCT03792360|DRUG|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
224041423|NCT01557023|DRUG|barrier methods|
224041424|NCT00186862|DRUG|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
224041425|NCT00646061|DRUG|buscopan|
224041426|NCT06476314|DEVICE|Virtual Reality Glasses Group|Apart from the routine clinic procedure, VR video scenes (contain nature views) will be watched for 5-10 minutes during the procedure.
224041427|NCT06476314|DEVICE|Stress Ball Group|Apart from the routine clinic procedure, it will be asked squeezing the stress ball for about 5-10 minutes (squeezing it once every time he counts to five)during the procedure.
224041428|NCT06267287|DIAGNOSTIC_TEST|Microbiological examination of the patient's biological material and determination of antibiotic resistance|Isolated microorganisms were identified based on growth in one or more cultures obtained from punctate synovial fluid, intraoperative tissues, and from removed implants (after their ultrasonic treatment). At least 4 samples of intraoperative material (tissue biopsies, joint aspirate, removed endoprosthesis components) were taken from patients for examination. The endoprosthesis components removed during surgery were placed in a sterile plastic container and delivered to the laboratory. In the laboratory, saline solution was added to the container and processed in an ultrasonic machine according to the author's method. Identification of isolated microorganisms and sensitivity to antibiotics was carried out using an automatic analyzer and a semi-automatic analyzer using kits, test systems. Sensitivity to antibacterial drugs was tested using the disk diffusion method and analyzer kits. Antibiotic sensitivity assessment was carried out in accordance with the criteria of EUCAST.
224041429|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - оnce at a dose of 10⁶ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
224299477|NCT06051565|DRUG|Polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.
224299478|NCT04982874|DRUG|Furosemide 40 mg|Administered with 240 mL of water
224299479|NCT04982874|DRUG|Lasix® 40 mg Tablet|Administered with 240 mL of water
223431498|NCT02459847|BEHAVIORAL|Sonographic Biofeedback|
223431499|NCT02459847|OTHER|Standard Care|
223431500|NCT04743804|BIOLOGICAL|Ravulizumab|Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
223431501|NCT04743804|OTHER|Placebo|Matching placebo
223431502|NCT04743804|OTHER|Best Supportive Care|Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
223431503|NCT01632904|DRUG|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
223431504|NCT01632904|DRUG|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
223431505|NCT01632904|DRUG|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
223740334|NCT05459571|DRUG|Fludarabine|Administered intravenously
223740335|NCT05459571|DRUG|Dexamethasone|Administered orally or intravenously
223740336|NCT06573658|BEHAVIORAL|Perturbation-based balance training (PBT)|It will be a two-session training with each session lasting for approximately an hour. Perturbations will be induced during treadmill walking. Participants will be instructed to recover their balance and continue walking after the perturbations.
224041430|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - once at a dose of 10⁷ PFU|15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
224041431|NCT05762523|BIOLOGICAL|VAC∆6 vaccine - twice at a dose of 10⁶ PFU|15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint
223431506|NCT01632904|DRUG|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
224041432|NCT05762523|BIOLOGICAL|Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine|15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
223431507|NCT00715104|BIOLOGICAL|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
223431508|NCT00715104|BIOLOGICAL|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
223431509|NCT04721704|DRUG|Clarithromycin+ Amoxicillin + Omeprazole|In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children
224041433|NCT05867459|DIAGNOSTIC_TEST|Serum creatinine|The test wil be measured for all pt in study to detect of their grade of CKD
224041434|NCT05867459|DIAGNOSTIC_TEST|Alb /creat ratio or 24h urine protein|Test will be measured to detect type and sevirity of proteinuria
224041435|NCT05867459|DIAGNOSTIC_TEST|Serum electrolyte|The test will be measured in all pt to detect renal tubular state
224041436|NCT05867459|DIAGNOSTIC_TEST|Urine analysis|It is mirror of kidney
224041437|NCT05867459|DIAGNOSTIC_TEST|Abdominal ultrasound|To detect the anatomy and any structural abnormality in kidneys
223565128|NCT00210353|DRUG|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
224041438|NCT05867459|DIAGNOSTIC_TEST|Renal biobsy|Is done but not for all pt but for pt that can do it and agree for it .the test is used for detection of type of CKD or type of glomerionephritis
224041439|NCT05867459|OTHER|Clinical assesment|"Clinical assessment:~age, kidney disease history, history of DM or HTN ,history of pregnancy during study, therapy in early pregnancy , body weight, body height, and . Mean arterial pressure (MAP) . Body mass index (BMI). According to age and Scr level, the estimated glomerular filtration rate (eGFR) was calculated by CKD-EPI Creatinine Equation (2021)~Evaluation of pregnancy outcomes :Adverse pregnancy outcomes included maternal death, severe preeclampsia ,eclampsia ,duration of hospital stay and type of care need, mode of delivery ,need of blood transfusion , gestational age during delivary for detet preterm birth early preterm or late preterm from or extremely preterm \> 28W, birth weigh for low birthweight ,very low birth weight , extremely low birth weight,NICU admission,IUGR, still birth ,abortion, and neonatal death."
224041440|NCT02410655|DRUG|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
224299480|NCT05770921|DEVICE|Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter|All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
223431510|NCT04721704|DRUG|Metronidazole +Amoxicillin + Omeprazole|Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
223431511|NCT05709119|DIAGNOSTIC_TEST|Quantification of human DNA retrieved and DNA fragmentation profile.|The sample will be analysed for material quality and have no impact on the patient's future care.
223431512|NCT01455246|DRUG|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of \> 30 ml/min and \< 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
223565129|NCT00210353|DRUG|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
223565130|NCT00210353|DRUG|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
223565131|NCT02450461|OTHER|no intervention|
223565132|NCT03957499|DRUG|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
223565133|NCT03957499|DRUG|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
223565134|NCT03957499|DRUG|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
223565135|NCT01541943|DRUG|Atorvastatin|Once daily, administered orally, 8 week
223565136|NCT01541943|DRUG|Losartan|Once daily, administered orally, 8 week
223565137|NCT01541943|DRUG|Placebo|Once daily, administered orally, 8 week
224041441|NCT02410655|DRUG|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
223431513|NCT01455246|DRUG|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of \>50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
223431514|NCT00427206|DRUG|acetaminophen (4g/day)|
223431515|NCT00427206|DRUG|placebo|
223431516|NCT05373992|BEHAVIORAL|Screen Time Restriction (ST-Restricted)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
223431517|NCT05373992|BEHAVIORAL|Aerobic Exercise (AE)|Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
223431518|NCT05373992|BEHAVIORAL|Screen-time restricted plus aerobic exercise (STR+AE)|Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
223431519|NCT05373992|BEHAVIORAL|Stretching Only|Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
223431520|NCT05575037|DRUG|Dupilumab|8-week trial of dupilumab (an anti-IL-4a) in patients with AERD.
223431521|NCT02059434|DRUG|LAS190792 Dose 1|
223431522|NCT02059434|DRUG|LAS190792 Dose 2|
223431523|NCT02059434|DRUG|LAS190792 Dose 3|
223431524|NCT02059434|DRUG|LAS190792 Dose 4|
223431525|NCT02059434|DRUG|LAS190792 Dose 5|
223431526|NCT02059434|DRUG|LAS190792 Dose 6|
223431527|NCT02059434|DRUG|LAS190792 Dose 1 (Part 2)|
223431528|NCT02059434|DRUG|LAS190792 Dose 2 (Part 2)|
223431529|NCT02059434|DRUG|Tiotropium 18 μg|
223431530|NCT02059434|DRUG|Indacaterol 150 μg|
223431531|NCT02059434|DRUG|Placebo|
223431532|NCT04965441|PROCEDURE|Computer-assisted surgery|Preoperative head and neck computed tomography (CT) and lower extremity CT angiography were acquired for all patients. In the CAS group, CT images (slice thickness\<1 mm) were imported into a 3D surgical planning software (Proplan, Version 2.0/3.0 Materialise, Leuven, Belgium). Virtual surgical planning was performed to determine the mandibular and fibular resection and cut margins with localization of the optimal angles for performing osteotomies. After that, surgical guides were designed utilizing a 3D designing software (3-Matic, Version 9.0-13.0, Materialise, Leuven, Belgium). The generated virtual templates were exported in Standard Tessellation Language (STL) format and printed with a professional 3D printer (Connex 350, Stratasys, Eden Prairie, MN, USA). The reconstructive plates were pre-bent on a 3D printed planned mandibular model.
223565138|NCT01541943|DRUG|HL-040XC|Once daily, administered orally, 8 week
223565139|NCT02529462|GENETIC|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
224041442|NCT04026139|OTHER|Elastic Band Resistance Exercise|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
224041443|NCT04026139|OTHER|active joint range-of-motion exercises and isometric contraction exercises|The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
224041444|NCT03839407|DEVICE|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
223565140|NCT02529462|DRUG|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
224041445|NCT00789867|DRUG|pGM169/GL67A|Received a nebulized dose via an breath-actuated nebulizer
224041446|NCT02774902|DRUG|TAK-438|TAK-438 tablets
224041447|NCT02774902|DRUG|Clarithromycin|Clarithromycin tablets
224041448|NCT00238628|DRUG|Bexarotene|
224041449|NCT00238628|DRUG|Iressa|
224041450|NCT01194453|DRUG|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
224041451|NCT01194453|DRUG|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
223431533|NCT03958214|BEHAVIORAL|Recipe 4 Success|Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
223431534|NCT03958214|BEHAVIORAL|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
223431535|NCT01877356|PROCEDURE|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
223431536|NCT01877356|PROCEDURE|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
223431537|NCT02956447|DRUG|Kisspeptin 112-121|0.313 ug/kg - 2 ug/kg IV or SC
223431538|NCT02956447|DRUG|GnRH|0.075 ug/kg IV
223565141|NCT00987428|PROCEDURE|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
223565142|NCT00987428|PROCEDURE|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
223565143|NCT02494518|BEHAVIORAL|Forced Exercise & Upper Extremity Repetitive Task Practice|
223565144|NCT02494518|BEHAVIORAL|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
223565145|NCT02494518|BEHAVIORAL|Stroke Education & Upper Extremity Repetitive Task Practice|
223565146|NCT05806034|OTHER|tractography MRI sequence protocol|tractography MRI sequence protocol does not require injection of contrast agent.
223565147|NCT00227669|DRUG|docetaxel|
223565148|NCT00227669|DRUG|gemcitabine hydrochloride|
223565149|NCT04962841|OTHER|Nutraceuticals|To observe the effect on cognitive and physical impairment.
224041452|NCT06117371|DRUG|BEBT-607Tablets|"PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle."
223431539|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
223431540|NCT00310206|BIOLOGICAL|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
223431541|NCT02634034|DRUG|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
223431542|NCT02634034|DRUG|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
223431543|NCT02634034|DRUG|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
223431544|NCT00771264|DEVICE|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
223431545|NCT06189391|DRUG|MK-1045|IV infusion
223565150|NCT03957421|OTHER|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
223565151|NCT04645654|BEHAVIORAL|Hypnosis|Three sessions of 30 minute hypnosis, based on standardised script, focused on pain management.
223565152|NCT00115479|DRUG|intensive insulin therapy to maintain normoglycemia|
223565153|NCT03791281|BEHAVIORAL|BASIS|
223565154|NCT03791281|BEHAVIORAL|Attention Control|
223565155|NCT04300361|GENETIC|Sequencing of DPYD gene|The DPYD gene of non-Western patients will be sequenced to identify DPYD variants that are possibly associated with an increased risk of developing severe fluoropyrimidine-related toxicity.
223565156|NCT03979014|BIOLOGICAL|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
224041453|NCT01877863|OTHER|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
223565157|NCT03354546|DIAGNOSTIC_TEST|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
223565158|NCT02713997|DRUG|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
224041454|NCT04727203|BEHAVIORAL|AHAA|Multi-component healthy lifestyle program
224041455|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
223431546|NCT05852574|DRUG|CP-101|"CP101 is an investigational oral microbiome drug designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent CDI.~CP101 contains live microbial communities, derived from rigorously screened human donor stool that is tested, stabilized, characterized, and formulated into capsules designed specifically for delivery into the small bowel for release, to avoid potential degradation by gastric acid."
223565159|NCT02713997|DRUG|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
223565160|NCT04363697|DRUG|Dapagliflozin|Dapagliflozin
223565161|NCT04363697|DRUG|Placebo|Matched placebo
223565162|NCT06503848|DRUG|Sumatriptan|Register the response to treatment and headache characteristics.
223565163|NCT06397703|DRUG|Leuprolide, Degarelix or Relugolix|Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
223431547|NCT05852574|DRUG|CP-101 + Placebo|The placebo in this trial will be presented in capsules that are identical in size, smell, texture, and appearance to those of the CP101 capsules. These will be produced by the BWH investigational drug service
223431548|NCT04355806|DRUG|PD-1/PD-L1 inhibitors|Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
223431549|NCT04355806|BIOLOGICAL|Inactivated trivalent influenza vaccine|Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
223431550|NCT03211442|RADIATION|Radiotherapy|Breast cancer patients treated with radiotherapy
223431551|NCT01004406|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
223431552|NCT01004406|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
223431553|NCT03393429|OTHER|DAVID assisted training|DAVID device assisted training under supervision
223431554|NCT03393429|OTHER|training recommendation|"training recommendation to stay active"
223431555|NCT06637423|DRUG|Sacituzumab tirumotecan|Intravesical administration
223431556|NCT06637423|DRUG|Rescue medication|Participants are allowed to take rescue medication for stomatitis or oral mucositis. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion or steroid mouthwash (dexamethasone or equivalent), antiemetic medications, oral nystatin suspension or antifungal medications, antidiarrheal agents, antiemetic agents, opiate and non-opiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
223431557|NCT06637423|DRUG|Supportive care measures|Participants are allowed to take supportive care measures for the management of adverse events associated with study intervention at the discretion of the investigator. Artificial tear drops or gel may be given as a supportive care for Ocular Surface Toxicity.
223740337|NCT06573658|BEHAVIORAL|Walking exercise (control)|It will be a two-session training with each session lasting for approximately an hour. The same training duration and format will be used as the PBT group, except that no perturbations will be induced during the treadmill walking.
223740338|NCT04937296|BEHAVIORAL|Physical activity|Participants will be asked to perform resistance exercises 3-times a week on alternating days for 12 weeks. Exercises will be performed with a TheraBand and will include the squat, lunge, press-up, cross body reach, reverse fly, lateral raise, biceps curl, triceps extension, frontal raise and bridge. In addition to the resistance exercises, the participants will perform aerobic exercise. They will be asked to download a specific exercise app to record the number of steps on day 1 of the intervention and participants who do not possess the required phone technology will be provided with a pedometer. They then will be asked to add 2000 steps on to their daily steps; this amount will then become their daily step goal. Once they have reached this goal on 4 out of 5 days, they will be asked to increase their new step step goal by an extra 500 per day.
223740339|NCT04937296|OTHER|Usual care|Usual care.
223740340|NCT00225160|DRUG|acetyl L-carnitine|
223740341|NCT01829581|OTHER|no intervention, only descriptive data analysis|
223740342|NCT03963791|OTHER|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
223740343|NCT03963791|OTHER|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
223740344|NCT05429190|RADIATION|Short MRI surveillance (SMS) protocol|Bi-annual, non-contrast agents, MRI screening consisting of Diffusion Weighted Imaging (b-values of 50 and 800 s/mm2), T2-weighted imaging and T1-weighted in- and out-of-phase imaging
223740345|NCT05429190|RADIATION|Bi-annual ultrasonography screening|Bi-annual ultrasonography for screening of HCC in high-risk patients
223740346|NCT04741074|DRUG|Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution|Dose will be started at 0.25 mg per week. Dose escalation will occur every 4 weeks to mitigate risk of gastrointestinal side effects to a maximum dose of 1.0 mg per week.
223740347|NCT04741074|DRUG|Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution|Matched placebo solution for injection will be provided by Novo Nordisk in a 1.5 ml pre-filled pen-injector for subcutaneous injection with the same instructions on dose escalation.
223740348|NCT00364884|DRUG|ketoaminoacid|
223740349|NCT02432846|BIOLOGICAL|Intuvax (INN: ilixadencel)|Therapeutic dose (10 million cells/dose): allogeneic, pro-inflammatory dendritic cells.
224041456|NCT00594516|DRUG|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
224041457|NCT00594516|DRUG|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
223431558|NCT02928770|DEVICE|Nastent|Use of the device while at home and in the sleep lab
223431559|NCT00631085|DRUG|gamma tocopherol|Maxi Gamma softgels 1200mg QD
223431560|NCT00403741|BEHAVIORAL|motivational interviewing|
223431561|NCT05936541|DIETARY_SUPPLEMENT|Probiotic Bifidobacterium Bifidum PRL2010|Probiotic supplement
223740350|NCT02432846|DRUG|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
224041458|NCT04540549|BEHAVIORAL|exercise|Jogging or cycling ≥5 days/week, 30-60 min/d
224041459|NCT01388231|BEHAVIORAL|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
224041460|NCT01388231|BEHAVIORAL|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
224041461|NCT05983549|PROCEDURE|fluid balance|patients will receive fluids with the aim to achieve a neutral balance
224299481|NCT05614557|DEVICE|Stratacel|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
224299482|NCT05614557|DEVICE|Stratamed|Silicone-based formulation registered as a European class IIa, TGA (Therapeutic Goods Administration) and FDA listed Class I medical device (wound dressing).
223740351|NCT01684631|DEVICE|Total Hip arthroplasty|
223740352|NCT01770379|BIOLOGICAL|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
223740353|NCT01770379|BIOLOGICAL|Placebo|
223740354|NCT00379626|DRUG|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
223740355|NCT03689998|DEVICE|immediate implant placement|immediate implant placement in freshly extraction socket
223740356|NCT03689998|DRUG|Melatonin|topical application of melatonin
223740357|NCT02400879|DRUG|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
223740358|NCT02400879|DRUG|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
223740359|NCT03045887|DRUG|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
223740360|NCT03045887|DRUG|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
223740361|NCT03045887|DRUG|Placebo|Lactose as powder for inhalation
223740362|NCT04219982|DRUG|DPI-386 Nasal Gel|Nasal gel
223740363|NCT04219982|DRUG|DPI-386 Placebo Nasal Gel|DPI-386 Placebo Nasal Gel
223740364|NCT04219982|DRUG|Transderm Scop®|Transderm Scop®
223740365|NCT05353127|DIAGNOSTIC_TEST|CPET/Cardiopulmonary Exercise Test|During CPET, a patient exercises against a progressively increasing work rate until volitional exhaustion, while breath-by-breath respiratory gasses are analyzed.
223740366|NCT04518514|DEVICE|TAPE-Software|Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
223740367|NCT05038527|DEVICE|ABM/P-15 bone graft|RCT (single blinded) where the patients will be randomized into two groups. One group receiving the standard bone graft which is a mix of locally autologous harvested bone and a morselized femoral head (allogenic) and the other group will receive bone graft of anorganic bovine bone mineral coated with a bioactive peptide (ABM/P-15).
223740368|NCT03839511|PROCEDURE|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
223740369|NCT03145025|DEVICE|Retisert|Intravitreal Implant
223740370|NCT03145025|DRUG|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
223740371|NCT02430675|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
223740372|NCT02430675|DEVICE|NanoKnife|
223740373|NCT05413707|PROCEDURE|Fixation of the posterior malleolus fractures|Fixation of the posterior malleolus fracture with screws and or plating.
223740374|NCT05413707|PROCEDURE|Fixation of lateral and/or medial malleolus fractures|Fixation with screws and/or plating
224041462|NCT00237822|BEHAVIORAL|Adherence Feedback (AF)|
224041463|NCT00237822|BEHAVIORAL|AF + Contingency Management (AF + CM)|
224041464|NCT00237822|BEHAVIORAL|AF + Motivational Enhancement Therapy (AF + MET)|
224041465|NCT01462136|DRUG|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
224041466|NCT04311892|DIAGNOSTIC_TEST|EMG of the hip abductor muscles|EMG will be carried out to examine the (superior gluteal nerve) SGN for all patients. The muscles will be evaluated according to the criteria of the American Academy of Electrophysiological Medicine for needle EMG. In order to exclude patients with polyneuropathy, radiculopathy, or plexopathy, nerve conduction studies of both lower extremities will be performed. Then, gluteus medius muscles will be assessed bilaterally to evaluate the SGN, the vastus medialis muscle for L4 root, tibialis anterior muscle for L5 root, and gastrocnemius muscle for S1 root.
224041467|NCT02462928|DRUG|Abicipar Pegol|Abicipar pegol intravitreal injection.
224041468|NCT02462928|DRUG|Ranibizumab|Ranibizumab intravitreal injection.
224299483|NCT03370874|BIOLOGICAL|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
224041469|NCT02462928|OTHER|Sham Procedure|Sham injection.
224041470|NCT02901496|BEHAVIORAL|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
224041471|NCT02901496|BEHAVIORAL|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
224041472|NCT02901496|BEHAVIORAL|No Exercise|Control to exercise
224041473|NCT02901496|DRUG|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
224299484|NCT03370874|PROCEDURE|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
224299485|NCT05007314|BEHAVIORAL|Biocriminological Evidence|Participants in each of the two main groups see a case with and a case without a neurobiological explanation for criminal offending.
224299486|NCT05120323|BEHAVIORAL|vDOT Intervention Group|The vDOT intervention group will submit video clips of doses of inhaled controller asthma medication via the Emocha® smartphone application with each prescribed dose of inhaled controller medication. Each video will include a date and time stamp of the medication dose. Participant videos will be evaluated by trained personnel using an inhaler technique checklist to score each dose and create a report detailing the steps that were taken to complete the medication dose.
224041474|NCT02901496|DRUG|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
224041475|NCT02954146|BEHAVIORAL|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
224041476|NCT01493557|DRUG|pantoprazole|40 mg q.a.m, p.o.
224041477|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
224041478|NCT01493557|DRUG|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
224140055|NCT04682678|PROCEDURE|Implantation of electrodes for Spinal cord stimulation|The implantation of electrodes for SCS at the epidural thoracic level connected to a neurostimulator at the abdominal level will be performed under general anaesthesia (hospitalization for 3 days in the Neurosurgery Department, CHUGA) in a maximum delay of 1 month following the preoperative assessment. During the first postoperative month, the optimization of SCS parameters will be performed by an experienced movement disorders neurologist.
224140056|NCT03246555|DRUG|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
224140057|NCT03246555|DRUG|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
224140058|NCT03457766|DEVICE|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
224140059|NCT04154995|DIAGNOSTIC_TEST|Venipuncture|Blood testing at 3, 6 and 12 months
224140060|NCT04154995|DIAGNOSTIC_TEST|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
223431562|NCT05936541|OTHER|Control group|No probiotic supplementation
223431563|NCT03201874|BEHAVIORAL|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
223431564|NCT03201874|BEHAVIORAL|Education|Education about sickle cell disease to increase disease knowledge
223565164|NCT06397703|RADIATION|Stereotactic body radiation therapy/radiosurgery (SBRT)|SBRT will be directed to the prostate and delivered with a prescription dose of 40 Gy in 5 fractions prescribed to the 95% isodose line encompassing the planning target volume. Intra-fraction motion targeting and target position corrections will be utilized for each of the 5 treatment fractions.
224140061|NCT01033604|PROCEDURE|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
224140062|NCT01033604|PROCEDURE|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
223431565|NCT00929474|DEVICE|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
223431566|NCT00929474|DEVICE|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
223431567|NCT01738841|BIOLOGICAL|Priorix-Tetra™|Single dose, subcutaneous injection
223431568|NCT01738841|OTHER|Safety data collection|Recording of adverse events, using diary cards
223565165|NCT06755034|DEVICE|c-SIMO|Placement of an implant in the mandibular canine area and using it to stabilize a pre-existing mandibular complete denture.
223565166|NCT06755034|DEVICE|m-SIMO|Placement of an implant in the midline of the mandible and using it to stabilize a pre-existing mandibular complete denture.
224041479|NCT01493557|DRUG|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
224041480|NCT00314678|DRUG|Topotecan|
224041481|NCT00314678|DRUG|Cisplatin|
224041482|NCT00314678|DRUG|Paclitaxel|
224041483|NCT03998176|DRUG|Bictegravir/emtricitabine/tenofovir alafenamide|B/F/TAF single tablet formulation
224041484|NCT02656420|DRUG|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
224041485|NCT02656420|DRUG|Placebos|Placebo as comparison to broccoli sprout-derived beverages
224041486|NCT00335465|DRUG|Insulin glargine|once a daily, sc injection, 100IU/ml
224041487|NCT01088464|BIOLOGICAL|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
224041488|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, every 2 weeks
224041489|NCT01088464|BIOLOGICAL|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
224041490|NCT01508104|DRUG|BEZ235|dose escalation 400mg- 1000mg per day
224041491|NCT01508104|DRUG|Everolimus|dose escalation 2.5 to 5 mg per day
224041492|NCT03629236|OTHER|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
224041493|NCT03629236|OTHER|Control|Debridement, dressing application, standard compression therapy
224041494|NCT00512746|OTHER|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
224041495|NCT00512746|OTHER|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
224041496|NCT00512746|PROCEDURE|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
224041497|NCT00512746|PROCEDURE|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
224041498|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
223431569|NCT03248518|BEHAVIORAL|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
223431570|NCT03248518|BEHAVIORAL|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
223431571|NCT03248518|BEHAVIORAL|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
223431572|NCT04857918|BEHAVIORAL|Virtual running group program|The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
223431573|NCT04857918|BEHAVIORAL|Attention Control: Fitness Application Strava|The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
223431574|NCT00436098|BEHAVIORAL|Motorpedagogic exercise|physical training
223431575|NCT05837728|BEHAVIORAL|Health promoting assessment of older adults living at home|Based on the results of the first assessment of the older person's health determinants, healthcare professionals will recommend and tailor measures to the individual's needs to reduce the risk of functional decline and maintain their health while living at home.
223565167|NCT03070223|DRUG|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
224041499|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
224041500|NCT05713773|DRUG|coated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
224041501|NCT05713773|DRUG|coated beads glucose (8 g)|After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
224041502|NCT05713773|DRUG|uncoated beads glucose (8 g) and caffeine anhydrous|After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
224041503|NCT01256151|DRUG|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
224041504|NCT01256151|DRUG|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
224299487|NCT01457261|DRUG|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
224299488|NCT00407693|DRUG|[C-11]PRB28|
223431576|NCT02428374|DRUG|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
223431577|NCT02428374|DRUG|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
223431578|NCT02428374|DRUG|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
223431579|NCT02428374|DRUG|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
223431580|NCT03440294|DIAGNOSTIC_TEST|resting standard spirometry|The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
223431581|NCT03440294|DIAGNOSTIC_TEST|maximum exercise testing|Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
223431582|NCT04205461|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation before pulmonary valve replacement. Voltage and activation mapping of right ventricle in a subset of patients.
223431583|NCT01651338|PROCEDURE|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
223431584|NCT01831505|DRUG|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
223431585|NCT01100216|OTHER|Nicotine Lozenge|4 mg for 12 days
223565168|NCT03070223|DRUG|Placebos|One tablet taken once daily, orally with or without food for the entire time participant was in REPRIEVE follow-up.
224041505|NCT03018587|DEVICE|TruSculpt|All subjects will receive 1 truSculpt radiofrequency treatment
223431586|NCT01100216|OTHER|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
223565169|NCT06315140|OTHER|Nutrition|The intervention will build on the 11-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity. Working with the Ramapough-leased Munsee Three Sisters Medicinal farm (growing produce/crops on clean soil) will provide the tribe with nutrition-rich foods and recipes for nutritious cooking. The interventions aims to return healthy soil on the farm allowing for healthy plant production.
224041506|NCT05837182|PROCEDURE|augmented fixation techniques|augmented fixation techniques like percutaneous transsarcal screws fixation, tension band plating, INFIX technique, triangular fixation and cement augmentation techniques
224041507|NCT01283230|DEVICE|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
224041508|NCT05199675|BEHAVIORAL|Digital Peer Support Training Program|The digital peer support training program will consist of bite size modules on the four active ingredients of youth mental well-being, which will be delivered through training workshops, simulation activities, and homework assignments. The training will be conducted over 8 sessions, each lasting for 45-60 minutes following the typical duration of a school lesson on Character and Citizenship Education. The training workshops will be conducted as part of the school's Character and Citizenship Education lessons. The proficiency of participants in applying these digital support skills will be evaluated through simulation and homework activities, in which they apply the four active ingredients in their responses to mock letters that are adapted from actual cases of peer emotional disclosure. At the end of the training, adolescents are expected to apply the four active ingredients to the homework assignments on peers' emotional experiences.
224041509|NCT03662139|OTHER|Dynamic Gait Index|Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
224041510|NCT04389190|OTHER|Fluoroscopy settings for image acquisition|X-ray radiation is routinely used for imaging in coronary cath labs. Intervention involves lowering patient and operators X-ray exposure by employing various setting on the fluoroscopy machine.
224041511|NCT06235814|PROCEDURE|Molecular Analysis for Thyroid Resection|"Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care."
224041512|NCT00749879|DRUG|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
224041513|NCT04824638|BIOLOGICAL|3 doses of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 D29 and M8, intramuscularly (participants without antecedent of SARS-CoV-2 infection)
223431587|NCT01100216|OTHER|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
223431588|NCT01100216|OTHER|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
223431589|NCT02427438|OTHER|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
223565170|NCT06651775|DEVICE|High intensity laser therapy|lumbosciatalgia mode of the HILT device
223565171|NCT06651775|DEVICE|Sham Comparator|sham mode of the HILT device
223565172|NCT05709704|DIAGNOSTIC_TEST|Self-palpation via telehealth|This will be used to determine if the participant has the diagnosis
223565173|NCT05709704|DIAGNOSTIC_TEST|Real-time Ultrasound|This will be used in a subgroup of participants to confirm/rule out a diagnosis
223431590|NCT02427438|OTHER|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
223431591|NCT06094101|BIOLOGICAL|Peptide vaccine IPX|"Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15."
223565174|NCT03219034|DEVICE|oral appliance - A ; washout; oral appliance B|Anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible. 1 week washout followed by anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
223431592|NCT05104879|OTHER|Biosketch Card|The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
223431593|NCT02907593|DRUG|Budesonide in Calfactant|Budesonide in Calfactant
223740375|NCT05413707|PROCEDURE|Syndesmotic fixation|Fixation of unstable syndesmosis with one or two 3.5 mm tricortical screws, or with a suture button.
223740376|NCT04434690|PROCEDURE|Simultaneous bilateral total knee arthroplasty|Two surgeons bilateral TKA group
223740377|NCT04434690|PROCEDURE|Sequenced bilateral TKA|Single surgeon bilateral TKA group
223740378|NCT01912287|BEHAVIORAL|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
224041514|NCT04824638|BIOLOGICAL|2 dose of BNT162b2 vaccine|Administration of BNT162 b2 vaccine (30µg in 0.3mL) at D1 and M8, intramuscularly (participants with antecedent of SARS-CoV-2 infection)
224041515|NCT02967081|PROCEDURE|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
224041516|NCT01249430|DRUG|Azacitidine|Given IV
224041517|NCT01249430|DRUG|Cytarabine|Given IV
224041518|NCT01249430|DRUG|Etoposide Phosphate|Given IV
224041519|NCT01249430|OTHER|Laboratory Biomarker Analysis|Correlative studies
223431594|NCT04139837|BEHAVIORAL|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
223431595|NCT00104065|DRUG|CG53135-05, velafermin|
223431596|NCT00322361|BIOLOGICAL|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
223431597|NCT00322361|BIOLOGICAL|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
223431598|NCT02071602|DRUG|CD-NP|Randomized 1:1:1
223431599|NCT04405284|OTHER|use and exposure to disinfectants during the coronavirus pandemic|The use of disinfecting products in deep house cleaning by women during the coronavirus lockdown.
223431600|NCT05963828|BEHAVIORAL|Post-hospital management based on WeChat applet|The brain and heart health manager uses the exclusive QR code in the WeChat applet to receive and manage patients. Patients can register and use the WeChat applet by scanning the QR code. The functions of WeChat applet include making medication plan for patients, daily medication reminder, targeted health education, health index monitoring, online consultation and so on.
223431601|NCT05963828|BEHAVIORAL|Routine post-hospital follow-up management|The brain and mental health managers routinely followed up the patients in the standard group for 1, 3, 6 and 12 months by telephone or outpatient follow-up, the main content of which was to inquire about the medication of patients and the management of stroke risk factors. Targeted health education was carried out according to the risk factors of patients.
223431602|NCT03941197|BEHAVIORAL|Ready and Healthy for Kindergarten Family Literacy program|Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
223478429|NCT03007940|OTHER|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
223565175|NCT03219034|DEVICE|oral appliance - B; washout; oral appliance A|Anti-snoring intra-oral appliance B that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs. 1-week washout followed by anti-snoring intra-oral appliance A that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
223565176|NCT02438683|DRUG|BI 409306|high dose, single dose, oral administration
223565177|NCT02438683|DRUG|BI 409306|low dose, single dose, oral administration
223565178|NCT02438683|DRUG|Placebo|single dose, oral administration
223565179|NCT00519324|DRUG|Everolimus|10 mg/day (2 tablets of 5 mg each)
224041520|NCT01249430|DRUG|Mitoxantrone Hydrochloride|Given IV
224041521|NCT01249430|OTHER|Pharmacological Study|Correlative studies
224041522|NCT06359366|PROCEDURE|perineal massage combined hip joint training|pregnant women take the lithotomy position, disinfect the vulva, and wear sterile gloves. Then thumbs, forefingers, and middle fingers dip massage oil to do a 2 minutes pressurized dilatation massage from inside to outside gently to loosen the fascia. Then rest 30s. All steps need to be repeated 2 to 3 times. When the pregnant women feel a slight sense of acidity and tingling sensation disappears, researchers sterilize the perineal body again. left side pelvic floor receives the same intervention as right. The whole process takes 15-20min, 5 times a week until delivery. Additionally, while using the pelvic floor fascia manipulation, pregnant women are instructed to perform specific movements of internal and external hip rotation, adduction and abduction, upward and downward.
224041523|NCT01235559|DRUG|Placebo|Oral doses, once a day for 52 weeks
224041524|NCT01235559|DRUG|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
224041525|NCT01235559|DRUG|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
224041526|NCT02435108|DRUG|crizotinib|crizotinib 250mg bid daily
224041527|NCT00613353|OTHER|Behavioral|Participants will be asked to wear an accelerometer
224041528|NCT05670769|OTHER|Education|The training module, which will be developed in line with the continuous midwifery care model, will include home care and counseling of pregnant women with gestational diabetes (glucose monitoring and control, diet, exercise, evaluation of fetal health, etc.).
224041529|NCT06460883|OTHER|eccentric cable leg curls|The players will undergo eccentric cable leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
223565180|NCT06606834|DIAGNOSTIC_TEST|sonoelastography|Elasticity is defined as the ability of an organ or tissue to return to its original shape after being deformed by an applied force or stress. Based on this principle, sonoelastography is a technique used to assess the elasticity of tissues and organs during ultrasonography. This assessment allows measurement of changes in stiffness of soft tissues following physiological or pathological processes.
224140063|NCT05369624|OTHER|Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)|"The strength training program included upper and lower limb exercises, initially with no weights but progressively adding weights once a week depending on symptoms, in 2 sets with 6-8 repetitions, for at least 5 days a week. The exercises recommended were the 'hanger' (which exercises the latissimus dorsi muscle), 'butterfly' (pectoralis major muscle), 'neck press' (triceps brachii and deltoids), leg flexion (biceps femoris and gastrocnemius) and leg extension (quadriceps femoris).~As resistance training, patients could choose between walking or cycling 3 to 5 days per week, for at least 20 minutes, increasing the duration of the exercise weekly, depending on their symptoms"
224299489|NCT01660334|DRUG|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
224299490|NCT04527653|DEVICE|Tixel|Non-invasive thermo-mechanical treatment
223431603|NCT05442606|OTHER|Ultrasound Therapy|Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses
223565181|NCT07034469|PROCEDURE|air|use of sterile air as a tamponade
224041530|NCT06460883|OTHER|eccentric banded leg curls|The players will undergo eccentric banded leg curls, completing 15 reps of 3 sets every other day with 30-45 seconds rest between sets, a total duration of 40 minutes conducted four days a week over a four-month training period.
224140064|NCT00848770|DRUG|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
224140065|NCT00848770|DRUG|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
224140066|NCT00848770|DRUG|manipulation of SAP|Esmolol or NPS or NOR
224140067|NCT03001336|OTHER|no intervention|This is a cross-sectional study
224140068|NCT04485117|DEVICE|Bispectral Index Monitor|Bispectral Index (BIS) sensor electrodes are applied over the patient's forehead after cleaning the forehead thoroughly with an alcohol swab.
224299491|NCT05757323|OTHER|infant formula based on hydrolyzed protein|infant formula based on hydrolysed protein
224299492|NCT05757323|OTHER|infant formula based on intact protein|infant formula based on intact protein
224299493|NCT02440113|DEVICE|Nellix|Nellix Implantation
223565182|NCT07034469|PROCEDURE|Gas SF6 (Sulfur Hexafluoride) and others|use of fluorinated gases such as SF6, C2F6 or C3F8 as a tamponade agent
224299494|NCT04153383|DRUG|Milrinone Injection|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
224299495|NCT01475058|BIOLOGICAL|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
224299496|NCT00971958|PROCEDURE|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
224299497|NCT00971958|DEVICE|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
224299498|NCT00971958|DEVICE|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
224299499|NCT00971958|DEVICE|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
223565183|NCT07033299|BIOLOGICAL|CAR-T Therapy|CT1192 cells infusion
223565184|NCT06887244|OTHER|Tele-consultation|Tele-consultation procedure is defined as a telephone consultation with the patient conducted by nursing staff with an appropriate level of experience in digestive endoscopy
223565185|NCT06895369|DRUG|Pucotenlimab|patients will receive 3 cycles of pucotenlimab combined with TP (cisplatin + docetaxel) as neoadjuvant therapy, followed by standard surgical treatment
224299500|NCT05142098|DRUG|Dexamethasone|Intramuscular
224299501|NCT05142098|DRUG|Etoricoxib 60 mg|Orally
223740379|NCT01912287|BEHAVIORAL|Stress Education|Active control group (12 sessions)
223740380|NCT01912287|BEHAVIORAL|Yoga|12 sessions, mindfulness components
224041531|NCT01453777|PROCEDURE|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
224041532|NCT01890148|DRUG|AZD5069|oral BD administration of 45 mg AZD5069
224041533|NCT06399874|BEHAVIORAL|Nightmare Deconstruction and Reprocessing|A psychotherapy that uses exposure to nightmare images for trauma activation in order to facilitate trauma memory reconsolidation
223431604|NCT05442606|OTHER|Manual Drainage Techniques|Manual Drainage Techniques for the frontal and maxillary sinuses
223431605|NCT05442606|OTHER|Self Sinus Massage Technique|Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
223431606|NCT05739942|DRUG|[177Lu]Lu-NeoB|Radiopharmaceutical solution for infusion
223431607|NCT05739942|DRUG|[68Ga]Ga-NeoB|Either provided as Kit for the radiopharmaceutical preparation of \[68Ga\]Ga-NeoB or as ready to use radiopharmaceutical solution for injection
223431608|NCT05739942|OTHER|Temozolomide|Capsules/ lyophilized powder in single-dose vial for reconstitution.
223431609|NCT04261959|OTHER|myoActivation|myoActivation is a novel, structured assessment and non-pharmacological therapeutic approach to both diagnosis and treatment of chronic myofascial pain. A detailed history of the timeline of lifetime trauma combined with a quick, structured and reproducible set of posture and movement tests help to easily identify myofascial components of chronic pain. The therapeutic component is delivered utilizing a needling technique, or myofascial release, focused to active myofascial trigger points, fascia in tension and tethered scars.
223431610|NCT05562141|BIOLOGICAL|Blood sample|Blood sample before induction, 1h after induction and 24h after the start of procedure
223431611|NCT02545361|DRUG|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
223431612|NCT05353582|DRUG|Preoperative systematic therapy|6 cycles of mFOLFOXIRI±Bev is administrated before CRS+HIPEC. Irinotecan165mg/m2 IV day 1, oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted. Bev will not be administrated in at the last two cycles for minimizing surgery complications.
223431613|NCT05353582|PROCEDURE|CRS+HIPEC|CRS+HIPEC aims to achieve CC0/CC1 resection. Oxaliplatin or mitomycin C is determined by the treating physician.
223431614|NCT05353582|DRUG|Postoperative chemotherapy|6 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
224041534|NCT06399874|DEVICE|NightWare|Wristband device that detects physiologic signals during sleep that indicate a possible nightmare and gently vibrates to rouse the sleeper without fully waking them.
224041535|NCT01678209|OTHER|fMRI scans|2 fMRI scans 6-8 weeks apart
223431615|NCT05353582|DRUG|Postoperative chemotherapy|12 cycles of mFOLFOX+Bev is administrated after CRS+HIPEC. Oxaliplatin 85mg/m2 IV day 1, leucovorin 400mg/m2 IV day , bevacizumab mg/kg IV day 1, 5-fluorouracil 400mg/m2 IV bolus day 1,5-fluorouracil 400mg/m2, continuous infusion over 46-48h. Dose reduction is permitted.
223431616|NCT03385304|DRUG|10% povidone-iodine (1% free iodine) in purified water|Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.
223431617|NCT03385304|DRUG|4% chlorhexidine gluconate (CHG) in purified water|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
223431618|NCT06605222|DRUG|SHR-7787 injection|Firstly Dose Escalation and Dose Expansion of SHR-7787 injection monotherapy should be conducted.
223431619|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (telehealth)|A 10-week, skills-based group eating intervention. Online/telehealth meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
223565186|NCT06896890|DRUG|CIS-DPI|"* Administration of cisplatin by inhalation (pulmonary route) using single-use RS01 capsule-based device and CIS-DPI hard capsules containing 2.5 mg, 5 mg, and 10 mg cisplatin.~* CIS-DPI, administered once-a-day, 5-days on followed by 2-days off. Daily dose to be administered will range from an initial dose of 2.5 mg cisplatin to a maximal theoretical dose of 30 mg (i.e., dose 1 to dose 7)."
223740381|NCT04094922|BEHAVIORAL|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
224041536|NCT01678209|DRUG|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
224041537|NCT01678209|DRUG|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
224041538|NCT03840694|OTHER|Smoking Abstinence|Participants will abstain from smoking for 24 hours.
224041539|NCT03840694|OTHER|Ad Lib Smoking|Participants will continue smoking as usual (i.e. ad lib) and smoke one cigarette of their own brand immediately prior to scanning.
224041540|NCT05529823|BEHAVIORAL|warm shower|A warm shower will be applied for 20 minutes to the pregnant woman whose cervical dilatation reaches 4-5 cm and 7-8 cm.
224041541|NCT00256880|DRUG|GW786034|
224041542|NCT03527914|OTHER|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
223431620|NCT05725408|BEHAVIORAL|Dialectical behavior therapy-informed group eating intervention protocol (in-person)|A 10-week, skills-based group eating intervention. In-person meetings will last approximately 1 hour each session, besides the first session (1.5 hours, orientation and assessments, online) and the final session (approx. 2-2.5 hours, session plus final assessments and exit interview).
223431621|NCT01120249|DRUG|everolimus|Given orally
223431622|NCT01120249|OTHER|placebo|Given orally
224041543|NCT03527914|OTHER|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
224140069|NCT04485117|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
224140070|NCT04485117|DRUG|Sevoflurane|Anesthesia is induced inhalationally by face mask with 8% sevoflurane in 100% oxygen, then decreased to 2-3% in 40% oxygen thoroughout the operation for maintenance of anesthesia.
224140071|NCT04485117|DRUG|Propofol|Anesthesia is induced by propofol (2mg/kg), then maintained using an infusion of fixed concentration (10-15 mg/kg/h) as titrated by the anesthesiologist .
223431623|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix|The 25g MCT-based nutrient mix will be consumed two hours after breakfast.
224041544|NCT01882218|DRUG|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
224041545|NCT01882218|DRUG|Standard Treatment|Standard liver surgery.
224041546|NCT00702845|DRUG|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
224041547|NCT00702845|DRUG|recFSH (follitropin beta)|150 IU recFSH SC injection
224041548|NCT00702845|DRUG|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
224041549|NCT00702845|DRUG|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
224041550|NCT00702845|BIOLOGICAL|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
224041551|NCT00702845|DRUG|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
224140072|NCT05175209|DIAGNOSTIC_TEST|EMG|Electromyelography
224140073|NCT00218426|DRUG|naltrexone implant|naltrexone implant is 1000 mg naltrexone
224140074|NCT00218426|DRUG|oral naltrexone|oral naltrexone 50 mg/day
223431624|NCT06511206|DIETARY_SUPPLEMENT|25g MCT-based nutrient mix + cofactors|The 25g MCT-based nutrient mix + cofactors will be consumed two hours after breakfast.
224041552|NCT00702845|DRUG|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
224140075|NCT00218426|DRUG|oral placebo naltrexone|oral placebo naltrexone resembles active medication
224140076|NCT00218426|DRUG|placebo implant|placebo implant resembles active medication
224140077|NCT02952703|BEHAVIORAL|brief pre-delivery smoking cessation counseling|
224140078|NCT02952703|BEHAVIORAL|additional pre-delivery smoking cessation counseling|
224140079|NCT02952703|BEHAVIORAL|post- delivery smoking cessation counseling|
224299502|NCT03726281|DRUG|Nivolumab|Nivolumab 240 mg, IV
224299503|NCT06469489|OTHER|Liver Disease of all etiologies|No intervention
223431625|NCT06511206|DIETARY_SUPPLEMENT|non-ketogenic control|The non-ketogenic control will be consumed two hours after breakfast.
223431626|NCT03238885|DIAGNOSTIC_TEST|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
223431627|NCT06602271|DRUG|PF614 capsule|Experimental oxycodone prodrug
223431628|NCT06602271|DRUG|Placebo|Inactive medication
223431629|NCT06602271|DRUG|Oxycodone HCl 10 mg|Active comparator
223431630|NCT02406300|PROCEDURE|Subarachnoid Anesthesia|
223431631|NCT02406300|PROCEDURE|PNB/GA|
223431632|NCT02406300|DRUG|ropivacaine|
223431633|NCT02406300|DRUG|sevoflurane or desflurane|
223431634|NCT02406300|DRUG|bupivacaine or levobupivacaine|
223431635|NCT01520142|DRUG|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
223740382|NCT02287558|DRUG|Pomalidomide|
223740383|NCT03294395|DRUG|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
223740384|NCT03294395|DRUG|Fosfomycin Oral Suspension|single dose 6g oral suspension
224041553|NCT00702845|BIOLOGICAL|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
224041554|NCT00682565|DRUG|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
224041555|NCT00682565|DRUG|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
224041556|NCT00682565|DRUG|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
224041557|NCT00682565|DRUG|CK-1827452 25mg capsule|25mg oral immediate release capsule
224041558|NCT00682565|DRUG|Placebo iv infusion|Matching placebo iv infusion
224041559|NCT00682565|DRUG|Placebo capsule|Matching placebo oral immediate release capsule
224041560|NCT02973425|BEHAVIORAL|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience \& Suite of mHealth motivational tools and mini-games.
224140080|NCT02952703|BEHAVIORAL|incentives|
224140081|NCT04080869|DRUG|retinyl palmitate|topical retinyl palmitate loaded ethosomes
224140082|NCT04080869|DRUG|Tretinoin|topical tretinoin
224140083|NCT04404023|BIOLOGICAL|UB-221|UB-221 (75 mg/ml)
224140084|NCT03989752|DEVICE|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
224140085|NCT00648661|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
224140086|NCT00648661|DRUG|Lexapro® Tablets 20 mg|20mg, single dose fed
224140087|NCT03585673|DRUG|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
224140088|NCT03585673|DRUG|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
224140089|NCT01684683|DRUG|Theophylline|Theophylline 0.1 bid
224140090|NCT01684683|DRUG|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
224140091|NCT03067194|DRUG|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
224299504|NCT04412148|DRUG|Triamcinolone Acetonide|intralesional injection of triamcinolone acetonide every 2 weeks for 6 sessions
224041561|NCT02973425|BEHAVIORAL|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
223431636|NCT01520142|DRUG|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
223431637|NCT01447446|DRUG|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
223431638|NCT01447446|DRUG|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
223431639|NCT01447446|DRUG|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
223431640|NCT01447446|DRUG|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
223431641|NCT01447446|DRUG|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
223431642|NCT03530787|OTHER|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
223431643|NCT03530787|OTHER|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
223431644|NCT05774795|PROCEDURE|Mitral valve surgery|Mitral valve repair or replacement to treat mitral regurgitation
223431645|NCT05774795|PROCEDURE|Aortic valve surgery|Aortic valve replacement to treat aortic regurgitation
223431646|NCT02961322|OTHER|lobo-isthmectomy assisted robot|
224041562|NCT00577850|DRUG|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
224041563|NCT00577850|DRUG|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
224041564|NCT03538353|OTHER|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
223431647|NCT02262000|RADIATION|Image Guided Stereotactic Ablative Radiotherapy|
224041565|NCT02454335|PROCEDURE|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
224041566|NCT05276557|COMBINATION_PRODUCT|PyloPlus Urea Breath Test System|System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.
224041567|NCT05276557|DIAGNOSTIC_TEST|Stool Antigen Test|An antigen test performed via a laboratory to test patients' stool for H. pylori
224041568|NCT00338663|DEVICE|knee immobilization splint|
223431648|NCT01007136|DEVICE|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
223431649|NCT01007136|DEVICE|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
223431650|NCT01329926|PROCEDURE|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
223431651|NCT05814692|DIAGNOSTIC_TEST|blood and urine samples|blood and urine samples
224041569|NCT05737134|OTHER|MA_PESAN MOBILE APPLICATION|The intervention group was given a mobile application consisting of video, and educational material that information was provided regarding the prevention of child sexual abuse.
224140092|NCT03067194|DRUG|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
224140093|NCT00216541|DRUG|epoetin alfa|
223431652|NCT06618404|OTHER|No intervention - cross-sectional cohort analysis|Observational
223431653|NCT01238718|DRUG|Lidocaine|lidocaine 1.5 mg/kg intravenously
223740385|NCT03294395|DRUG|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
223431654|NCT01238718|DRUG|Placebo|normal saline
223740386|NCT03294395|DRUG|Ceftriaxone|single dose 500mg intramuscular injection
223740387|NCT06201117|BEHAVIORAL|Preparatory information for ICU stay|Preparatory information for ICU stay after cardiac surgery via 12-minute digital media
223431655|NCT05136313|BEHAVIORAL|Time-restricted eating|16 weeks of TRE consisting of an 8-hour eating window.
223431658|NCT02273271|OTHER|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
223431659|NCT01892085|BEHAVIORAL|Early initiation|Initiation of breast milk expression \<1 hour following delivery.
223431660|NCT01892085|BEHAVIORAL|Intermediate expression|Initiation of milk expression 1-\<3 hours following delivery.
223431661|NCT01892085|BEHAVIORAL|Late initiation|Initiation of milk expression \>3-6 hours following delivery.
223740388|NCT06201117|BEHAVIORAL|Usual information|Preoperative information that is given to patients before having cardiac surgery
224041570|NCT01571765|OTHER|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
224041571|NCT03876171|BEHAVIORAL|Haitian youth family-based intervention study: family functioning|A weekly group therapy with the youth in presence of a parent or caretaker in the family.
224041572|NCT03876171|BEHAVIORAL|Haitian youth intervention study: youth psychoeducational|Weekly one and one psychoeducational module will be delivered to the youth.
224140094|NCT01753830|DEVICE|Durolane|4.5 mL
224140095|NCT01753830|DEVICE|PBS|4.5 mL
224140096|NCT01699412|DRUG|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
224140097|NCT01699412|DRUG|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
224140098|NCT02236741|DRUG|Mirapexin® (Sifrol®)|
224140099|NCT04060810|OTHER|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
223431662|NCT05659511|DIAGNOSTIC_TEST|MRI|MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
223431663|NCT02212548|DEVICE|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
223431664|NCT05205148|DEVICE|Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz|Patients treated with ultrathin coronary stents (namely stents with strut thickness \< 70 um) for specific coronary disease scenarios: unprotected left main stenosis; Bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm); Chronic total coronary occlusion; In-stent restenosis
223431665|NCT05074446|OTHER|stereotype threat manipulation|"Stereotype threat is the thought that a person will be negatively evaluated and judged regarding a negative stereotype that belongs to the group to which he/she belongs.~Stereotype threat manipulation will be performed on the intensivist and non-intensivist participants in the experimental group just before they are taken into the testing room. For manipulation, the following sentences will be said to the participants in the experimental group: We aim to compare the cardiopulmonary resuscitation performance between intensive care units and other branches. The other participants (Control Group) will not be given any prior information."
223431666|NCT04801472|OTHER|Optimisation of dental implant sites protection from irradiation|"Optimal treatment plan validation after two dosimetric computer-tomography scans (with or without radiological guide) and visualisation of virtual dental implants on scanner images.~Evaluation of toxicity, quality of life and dental implant survival rate"
224041573|NCT03876171|BEHAVIORAL|Haitian family-based intervention study: psychoeducational|Weekly psychoeducational module will be delivered to the adolescent to the youth in the presence of a family.
224041574|NCT03876171|BEHAVIORAL|Diversion Programs|Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
224041575|NCT00459966|PROCEDURE|Preoperative rehabilitation|
224041576|NCT02700204|DEVICE|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
224041577|NCT02700204|DEVICE|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
224041578|NCT00454532|DRUG|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
224140100|NCT03027388|DRUG|LB-100|LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
223431667|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 1
223431668|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 2
223431669|NCT01367496|DRUG|SC Methylnaltrexone (MNTX)|Dose 3
224041579|NCT05495139|DEVICE|Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease|This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
224041580|NCT03503513|DRUG|Gentamicin Sulfate|Gentamicin is compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Pharmacy mails participants treatment drug. Once received, participants will do daily instillations of 30 milliliters of solution after catheterizing their bladder at night.
224041581|NCT04495010|BIOLOGICAL|Nivolumab|Specified dose on specified days
224041582|NCT04495010|BIOLOGICAL|Ipilimumab|Specified dose on specified days
224041583|NCT03329222|OTHER|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
224041584|NCT03329222|OTHER|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
224140101|NCT00382213|DRUG|Olmesartan medoxomil|
224140102|NCT00382213|DRUG|Placebo|
224140103|NCT03028584|BEHAVIORAL|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
224140104|NCT00292747|DRUG|Drotaverine|
224140105|NCT00292747|DRUG|Drotaverine Placebo|
224140106|NCT00292747|DRUG|Ibuprofen|
224140107|NCT00292747|DRUG|Ibuprofen Placebo|
224140108|NCT03946293|DIETARY_SUPPLEMENT|White Bread|White bread made with commercial white flour with bran/fibre removed
224140109|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain bread|Wholegrain bread made with commercial wholegrain flour.
224140110|NCT03946293|DIETARY_SUPPLEMENT|Wholegrain Enzyme|Wholegrain bread made with enzyme-treated commercial wholegrain flour.
224140111|NCT00671723|DRUG|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
224299505|NCT04412148|OTHER|saline|intralesional injection of saline
223431670|NCT01367496|DRUG|IV Methylnaltrexone (MNTX)|
223478430|NCT03007940|OTHER|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
223478431|NCT00067340|DRUG|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
223478432|NCT00067340|OTHER|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
223478433|NCT03991975|DRUG|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
223478434|NCT03991975|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
223478435|NCT00389389|DRUG|AZD4877|intravenous infusion
223431671|NCT05276622|OTHER|Comprehensive Geriatric Assessment|"A modified Cancer and Aging Research Group (CARG) Geriatric Assessment that includes validated measures of 7 geriatric domains: functional status, comorbidity, cognition, psychological state, social activity, and support, nutritional status, and medications will be performed at baseline (pre-treatment), every 3 months for a total of 3 assessments. The modified comprehensive Geriatric Assessment includes patient-reported surveys and research staff assessments.~Cognitive Testing: The National Institutes of Health Toolbox Cognition Battery (objective) and PROMIS Short Form v2.0 - Cognitive function 8a (subjective)"
223431672|NCT05276622|OTHER|Qualitative patient-care partner interviews|Semi-structured Interviews: Baseline and again at 3 months.
224041585|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
224041586|NCT00298168|DRUG|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
223431673|NCT05276622|OTHER|Surveys on well-being and function|Care partner's Surveys on well-being and function: Baseline and again at 3 months
223431674|NCT05919095|DRUG|Carrilizumab plus GEMOX|"PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment."
223431675|NCT00274313|DRUG|552-02|
223565187|NCT06896461|DIAGNOSTIC_TEST|Cardiopulmonary exercise test|"The test consists of physical exertion performed on a stationary bike with a progressively increasing workload, continuing until specific electrocardiographic and/or clinical criteria are met or muscle fatigue occurs. The rate of workload increase (ramp) will be personalized and adjusted to ensure the exercise reaches its peak in approximately 10 minutes.~Throughout the test, a continuous electrocardiogram (ECG) will be recorded, and various physiological parameters will be measured. These include ventilation, oxygen consumption, carbon dioxide production, and related derived parameters, which will be assessed using a mouthpiece or a face mask through which you will need to breathe for the entire duration of the test. Blood pressure will also be measured at two-minute intervals."
224041587|NCT00298168|DRUG|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
224041588|NCT00929656|PROCEDURE|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
224140112|NCT00671723|DRUG|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
224140113|NCT00671723|DRUG|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
223431676|NCT00645125|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
223431677|NCT00645125|DRUG|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
223431678|NCT00881439|DRUG|Aliskiren|Oral, 300 mg, once daily, 6 months
223431679|NCT00881439|DRUG|Placebo|Matching Placebo once daily, 6 months
223431680|NCT03619759|DRUG|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
223431681|NCT01511718|DRUG|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
223431682|NCT01511718|DRUG|Ondansetron Hydrochloride|Zofran Tablets 8 mg
223431683|NCT05168163|BIOLOGICAL|Atezolizumab|Given IV
223431684|NCT05168163|DRUG|Cabozantinib|Given PO
223431685|NCT05168163|DRUG|Lenvatinib|Given PO
224041589|NCT00929656|PROCEDURE|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
224041590|NCT00929656|PROCEDURE|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
224041591|NCT02619968|OTHER|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
224140114|NCT01969942|BIOLOGICAL|allogeneic stem cell transplantation|
224140115|NCT01969942|DRUG|Clyclophosphamide|
224140116|NCT01969942|DRUG|Fludarabina|
224140117|NCT01969942|DRUG|Busulfan|
224140118|NCT01969942|DRUG|Melphalan|
224140119|NCT00390494|PROCEDURE|Hysterectomy|
224140120|NCT00390494|PROCEDURE|Myomectomy|
224140121|NCT00390494|PROCEDURE|Uterine Fibroid Embolization|
224140122|NCT00502528|DRUG|Placebo|Peri-interventional
223431686|NCT01255410|BIOLOGICAL|10^6 PFU rHMPV-Pa vaccine|Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally
223431687|NCT01255410|BIOLOGICAL|10^5 PFU rHMPV-Pa vaccine|Single dose of 10\^5 PFU rHMPV-Pa vaccine delivered intranasally
223431688|NCT01255410|BIOLOGICAL|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
223431689|NCT05783024|OTHER|Data collection|retrospective data collection
223431690|NCT03989934|BEHAVIORAL|The Mind in Action|Mindfulness program for adolescents
223431691|NCT03989934|BEHAVIORAL|Healthy Topics|Health education program for adolescents
224041592|NCT00607880|PROCEDURE|vascular access device placement|
224041593|NCT04144751|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
224140123|NCT00502528|DRUG|BQ-123|Peri-interventional
224140124|NCT01061736|DRUG|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224140125|NCT01061736|DRUG|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
224140126|NCT01061736|DRUG|Methotrexate|Same weekly dose as received prior to enrollment
224140127|NCT01061736|DRUG|Folic Acid|According to local standard
224140128|NCT04051476|OTHER|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
224041594|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered prolonged exposure|10 weeks of therapist-supported internet-delivered prolonged exposure
224041595|NCT05934162|BEHAVIORAL|Therapist-supported internet-delivered CBT|10 weeks of therapist-supported internet-delivered CBT
224140129|NCT04051476|OTHER|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
224299506|NCT04355663|BEHAVIORAL|Motor program activating therapy|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
224299507|NCT04355663|BEHAVIORAL|Vojta's reflex locomotion|Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
223431692|NCT03308318|PROCEDURE|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
223431693|NCT05583279|BEHAVIORAL|Dialetical Behavioral Therapy for Adolescents|DBT is an evidence-based treatment for individuals with complex clinical presentations, including borderline personality disorder (BPD), suicidality, and NSSI. Standard DBT (which includes individual therapy, skills group, between-session skills coaching, and peer consultation for therapists) is associated with symptom reductions in patients across a variety of domains, including BPD symptoms, SA, NSSI, hospitalizations, and social functioning. DBT focuses on teaching skills (e.g., emotion regulation) and facilitating the replacement of impulsive and/or ineffective behaviors (e.g., NSSI), with more effective/skillful behaviors.
223431694|NCT02440321|BEHAVIORAL|Parent-child interactive program|
223431695|NCT02440321|OTHER|written materials|
223431696|NCT06619002|PROCEDURE|Sentinel lymph node sampling|video analysis
223431697|NCT03047096|DRUG|hyaluronic acid|intra-Articular injection
223431698|NCT03047096|DRUG|hyaluronic acid and corticosteroids|intra-Articular injection
224041596|NCT03207113|BEHAVIORAL|Ned|Prostate cancer survivorship application.
224140130|NCT04051476|OTHER|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
223431699|NCT06295887|OTHER|Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation|Simulation program using VR or simulator that mimics patient's desaturation
223431700|NCT04972370|OTHER|Patients with Unilateral Cleft Lip with or without Cleft Palate|2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
223431701|NCT02089100|RADIATION|stereotactic body radiation therapy|
223431702|NCT02089100|RADIATION|Systemic treatment|
223431703|NCT05220059|DIETARY_SUPPLEMENT|Polyphenol extract|Single dose
223583992|NCT05487885|DRUG|Ketamine Injectable Solution|Ketamine is FDA-approved as an anesthetic agent that will be used off-label in this study. It is used routinely in both pediatric and adult patients and is considered extremely safe in substantially higher, anesthetic doses. The dose to be administered here (0.5 mg/kg) is a much lower, subanesthetic dose, and the administration route (intravenous) is the standard when used in anesthesia. Published studies and metaanalyses of this dose of intravenous ketamine as an off label use in depression show clearly that there are no increased risks in this population, including a recent study in adolescents (Dwyer et al, 2021, American Journal of Psychiatry). A single dose of ketamine will be used to determine if it alters the functioning of the anhedonia-related reward functioning and frontostriatal biomarkers assessed in this study.
224041597|NCT01170039|DRUG|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
224041598|NCT01170039|DRUG|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
224041599|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
224140131|NCT04051476|OTHER|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
224140132|NCT05682313|DIAGNOSTIC_TEST|Elastography arm|Renal ultrasound elastography to detect and classify the degree of fibrosis
224140133|NCT00002783|DRUG|cisplatin|
224140134|NCT00002783|DRUG|floxuridine|
224140135|NCT00002783|DRUG|fluorouracil|
223431704|NCT05220059|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223431705|NCT01622270|OTHER|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
223431706|NCT02636101|DRUG|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
223431707|NCT05236101|BEHAVIORAL|survey research|Children with dental treatment were asked to draw pictures.
223431708|NCT03284138|DEVICE|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
223431709|NCT03284138|DEVICE|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
224041600|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
224140136|NCT00002783|DRUG|leucovorin calcium|
224140137|NCT00002783|PROCEDURE|conventional surgery|
224140138|NCT03424317|BEHAVIORAL|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
224299508|NCT04355663|BEHAVIORAL|Functional electric stimulation|Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
224299509|NCT03164421|DRUG|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
224140139|NCT03424317|BEHAVIORAL|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
224041601|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
223431710|NCT01629823|DEVICE|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
223431711|NCT02034812|OTHER|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
224041602|NCT02101450|PROCEDURE|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
223431712|NCT04112095|DRUG|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
224041603|NCT03763851|RADIATION|Active PPP005|Group assigned to active PPP005 in the randomized placebo-controlled trial
223431713|NCT00239213|DRUG|catechin extracts (health food)|
224041604|NCT03763851|RADIATION|Radiotherapy|Palliative RadioTherapy to the symptomatic site
224041605|NCT00908583|DRUG|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
224041606|NCT00908583|DRUG|Bortezomib|Patients will receive bortezomib as described in protocol
224041607|NCT00908583|DRUG|Rituximab|Patients will receive rituximab as described in protocol
224041608|NCT00908583|DRUG|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
224041609|NCT04328779|OTHER|The multi-task overground walking training|The multi-task overground walking training group will undertake overground walking training while concurrently perform motor and cognitive tasks for 30 minutes per session, 3 times a week for 4 weeks.
223431714|NCT05914038|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex.
223431715|NCT03740321|DEVICE|Embolization with tri-acryl gelatin (Embosphere) particles|Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
223431716|NCT05742893|DIAGNOSTIC_TEST|Measurement of pragmatic and discourse test scores in the two scales.|The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .
223431717|NCT00027677|DRUG|halofuginone hydrobromide|
224041610|NCT04328779|DEVICE|The multi-task treadmill walking training|The multi-task treadmill walking training group will train the same set of motor and cognitive tasks while walking on the treadmill for 30 minutes per session, 3 times a week for 4 weeks.
224041611|NCT04328779|OTHER|Traditional rehabilitation|Traditional rehabilitation will train strength, balance, and gait for 30 minutes per session, 3 times a week for 4 weeks.
224041612|NCT00993954|PROCEDURE|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
224041613|NCT02722876|OTHER|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
224041614|NCT02722876|OTHER|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
224041615|NCT00617136|DEVICE|Intraoperative warming (Bair Hugger)|Intraoperative warming
224041616|NCT00617136|DEVICE|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
224041617|NCT00617136|DEVICE|Intraoperative warming (HotDog)|Intraoperative warming
224041618|NCT06142760|RADIATION|MR-guided radiation|Dayly artifical intelligence-based treatment adaptation under weekly offline MR-guidance
224041619|NCT02338011|DRUG|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
224041620|NCT02338011|RADIATION|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
224140140|NCT01768468|DRUG|LAYLA tablet|1 tablet twice a day
224140141|NCT01768468|DRUG|JOINS tablet|1 tablet at each time, 3 times a day
224299510|NCT03164421|DRUG|L-carnitine|L-carnitine in clomiphene resistant pcos women
224299511|NCT04390542|BEHAVIORAL|Psychoeducation|"6 sessions (in-person, videoconference, or phone delivery per the caregiver's choice) between the interventionist and caregivers. Topics covered in sessions include:~Session 1: Communication, Support, Self Care, Symptom Management~Sessions 2-4: Communication, Symptom Management, Support~Sessions 5-6: Self-Care, Symptom Management, Communication, Support, Future Planning"
224299512|NCT04593017|DIETARY_SUPPLEMENT|Active Probiotic|Lactobacillus Reuteri (DSM 17938 and ATCC PTA 4659
224299513|NCT04593017|OTHER|Placebo Probiotic|Placebo
223431718|NCT05615805|OTHER|OSDI questionnaire|Ocular Surface Disease Index
223431719|NCT05615805|OTHER|SPEEDII questionnaire|Standardized Patient Evaluation of Eye Dryness II questionnaire
223431720|NCT00006994|DIETARY_SUPPLEMENT|glutamine|20 cc three times daily for 60 days
223431721|NCT00006994|RADIATION|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
223431722|NCT00006994|DRUG|l-glutamine placebo|20 cc three times daily for 60 days
223431723|NCT04066296|DRUG|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
223431724|NCT02609724|OTHER|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
223431725|NCT02609724|OTHER|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
223431726|NCT02609724|OTHER|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
223431727|NCT02609724|OTHER|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
223431728|NCT02609724|OTHER|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
223431729|NCT02609724|OTHER|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
223431730|NCT03077659|DRUG|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
223431731|NCT06363032|DIAGNOSTIC_TEST|elastography|When routine renal ultrasound is arranged, patients will be invited to receive elastography at the same time.
223431732|NCT04940715|OTHER|Passive joint mobilization|Dosage: 5 sets of 2 minutes with 30 seconds of rest were applied, with a strong force (\>50% of maximum therapist strength), according to patient's irritability and severity.
223431733|NCT04940715|OTHER|Mobilization with movement|Dosage: 3 sets of 10 repetitions were performed, with 1-2 minutes of rest between sets.
223431734|NCT03069456|DEVICE|BIS|
223431735|NCT03069456|DEVICE|ADMS|
223431736|NCT01537978|OTHER|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
223431737|NCT00709007|BEHAVIORAL|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
224140142|NCT04992039|OTHER|WHO HEARTS technical package|"Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling."
224140143|NCT01362218|DRUG|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
223431738|NCT00709007|BEHAVIORAL|SAT|Participants take their HIV medications by themselves.
223431739|NCT04872556|DEVICE|Laser acupuncture device|The experiment group would arrange laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
223431740|NCT04872556|DEVICE|Pseudo-laser acupuncture|The experiment group would arrange Pseudo-laser acupuncture on day1 and day3 after Taxanes treatment. In the mean while, blood tests were performed with the C-Reactive protein, erythrocyte sedimentation rate, Interleukin-6 for each participants. Evaluation would be records on day1, day3, and day 8 after Taxanes treatment.
223431741|NCT00674856|DRUG|naproxcinod|750mg
223431742|NCT00874328|DRUG|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
223431743|NCT00874328|DRUG|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
223431744|NCT00874328|DRUG|TS-1 (S-1)|TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles
223431745|NCT03767556|PROCEDURE|Inspiratory muscle training|Powerbreathe® K5
223431746|NCT03957811|OTHER|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
223431747|NCT06153316|OTHER|School shooting incident|The school has experienced a gun shooting incident within the past 2 years of the study (for 3 case schools) and prior to 2 years (for 3 case schools). Incidents where a gun was displayed but no shot was fired, or where a shot was fired by police or security officer will not be included.
223431748|NCT02844907|DRUG|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
223431749|NCT02844907|DRUG|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
223431750|NCT02844907|OTHER|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
223431751|NCT01139099|BEHAVIORAL|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
224041621|NCT00860951|DEVICE|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
224041622|NCT04312373|OTHER|Ankle Foot Orthosis|"According to the SCED methodology, patients were fitted with ankle foot orthosis intermittently, during 4 phases, in the following order : without orthosis (A1), with orthosis (B1), again without orthosis (A2) and again with orthosis (B2).~All the phases were carried out over one day."
223431752|NCT04982978|BEHAVIORAL|PMT Threat Appraisal|"The first half of the PMT present video will include narration by Science Insider producer, Benji Jones, including dialogue regarding the risks associated with vaping by Chief Pediatric Pulmonology at the NYU Winthrop Hospital, Dr. Melodi Pirzada, and information on nicotine by the Director of Pediatric Pulmonology at NYU's Langone Hassenfeld Children's Hospital, Dr. Mikhail Kazachkov. The second half of the PMT present video will include personal experiences and narratives by students at the University of Utah with information regarding our current knowledge of vaping health effects through research by Dr. Sean Maddock and Dr. Sean Callahan from the University of Utah to highlight the susceptibility of vaping for a population of young adults in university."
223431753|NCT04982978|BEHAVIORAL|General Nutrition and Lifestyle|The first half of the PMT absent video will be presented by the Alliance for Aging Research, including an immersive video design, explaining the impact that nutrition may have as the participants age, reviewed by Dr. Steven Austad and Senior Nutritionist Johanna Dwyer. The second half of the PMT absent video will be presented by TED-Ed with narration by Addison Anderson, including a similar immersive video design, explaining how the food the participants eat may affect our brain and overall health. The nutrition and lifestyle information design will be administered as a control because it provides informative lifestyle choices regarding nutrition that can help promote the participants overall health without having an underlying link to vaping behaviour and its subsequent effect on the status of health.
223431754|NCT03024528|BEHAVIORAL|CPOT assessment|Polish version of Critical care pain observation tool validation.
223431755|NCT06720077|OTHER|Acupressure|"It will be applied for the experimental group only. Before starting the first treatment session, the participants will be instructed briefly about the nature of the treatment to gain their confidence and cooperation. Each participant in this group will be asked to lie in supine position and the acupressure will be applied by using the therapist's fingers on the following acupoints (san jio 6/ spleen 15/ stomach 25/ joining vally  intestine 4) 1 minute for each point with 3 repetitions on both sides (about 30 minutes as total time), 3 times per week for 6 weeks."
223431756|NCT06720077|OTHER|Diaphragmatic breathing exercises|A modified exercise will be used to achieve normal diaphragmatic breathing while the woman is lying on her back, with one hand placed on her abdomen and the other on her thorax. She will then be instructed to breathe in deeply, slowly, and gradually for 4 seconds, hold the air for 2 seconds, and exhale slowly through pursed lips for 6 seconds. Three series of ten repetitions will be completed with rest in between; the woman will be advised to rest longer if she feels dizzy or lightheaded. The patient will ensure the exercise is performed successfully if the hand placed on the abdomen shows greater mobility compared to minimal or no mobility of the hand on the thorax. From that point, the series of repetitions will begin.
223431757|NCT06720077|OTHER|General bowel care advise|All women in both groups will receive bowel care advice, including encouraging fiber intake (20-35 g/day) from sources like whole grains, fruits, vegetables, and legumes, with a focus on soluble fiber. They will be advised to limit meat, dairy, and low-fiber foods and avoid caffeine-containing products like chocolate and coffee. Adequate hydration (1.5-2.0 L/day) with water or juices will be recommended, along with daily exercise, such as 20-30 minutes of walking. Proper toilet posture will be emphasized, including sitting with knees higher than hips (using a stool if needed), leaning forward, placing elbows on knees, relaxing, and maintaining a straight spine.
223431758|NCT00550862|DRUG|INT-747|Once a day (QD) by mouth (PO)
223431759|NCT00550862|DRUG|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
224041623|NCT02645929|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
224140144|NCT01362218|DRUG|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
223431760|NCT00550862|DRUG|Placebo|Placebo
223431761|NCT03207074|DIAGNOSTIC_TEST|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
223431762|NCT00937248|DEVICE|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
224041624|NCT03234062|OTHER|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
224140145|NCT01680978|DRUG|aleglitazar|150 mcg orally daily, 6 weeks
224140146|NCT01680978|DRUG|placebo|orally daily, 6 weeks
224140147|NCT04735965|DRUG|Dexmedetomidine|Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
224140148|NCT04735965|DRUG|Meperidine|Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
224140149|NCT04735965|DRUG|Placeb|Equal volume of normal saline to dexmedetomidine and meperidine group.
224140150|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
224140151|NCT04641390|OTHER|Analysis of the seminal microbiome of the partners of women with altered vaginal microbiome not resistant to drug treatment|The analysis of the seminal microbiome will be carried out by massive genetic sequencing
224140152|NCT03817840|PROCEDURE|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
224140153|NCT05875389|OTHER|Virtual assessment|virtual assessment with a stroke neurologist/advanced practice nurse, with interdisciplinary support, to facilitate the care of patients admitted to primary stroke centres using existing tools for remote evaluation and review.
224140154|NCT04264767|PROCEDURE|Blood collection|Peripheral blood collection via routine venipuncture
223431763|NCT00937248|DEVICE|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
223431764|NCT03216148|DIAGNOSTIC_TEST|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
223431765|NCT02232152|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
223431766|NCT02232152|DRUG|fluorouracil|Given IV
223431767|NCT02232152|OTHER|pharmacological study|Correlative studies
223431768|NCT02232152|OTHER|laboratory biomarker analysis|Correlative studies
224041625|NCT03234062|OTHER|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
224041626|NCT03234062|OTHER|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
224041627|NCT06178965|PROCEDURE|Incisional Hernia Repair by Abdominal Wall Component Release with Contemporary Onlay Mesh Fixation|patients with incisional hernia will be operated by hernia reduction and sac closure followed by placement of onlay mesh after creating suitable flaps.
224041628|NCT00727649|DRUG|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
224041629|NCT00727649|DRUG|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
224041630|NCT01326208|PROCEDURE|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
223431769|NCT01675375|DEVICE|Eye Shield|one application following refractive surgery
223565188|NCT06896461|DIAGNOSTIC_TEST|Lung function|"Assessment of both static lung volumes (vital capacity, total lung capacity, functional residual capacity, and residual volume) and dynamic lung volumes (forced vital capacity and forced expiratory volume in one second, or FEV1).~Additionally, the flow-volume curve is measured, generated by continuously recording airflow and volume using an electronic spirometer during a foThe diffusion capacity for carbon monoxide (DLCO) can be measured using the single-breath method (DLCOSB). The patient inhales a small, known concentration of carbon monoxide (CO), holds their breath for 10 seconds, and then exhales. A sample of alveolar gas (from the end of expiration) is analyzed to determine the amount of CO absorbed during the breath, expressed in ml/min/mm Hg.~By repeating the test with inhalation of gas mixtures containing different oxygen concentrations (approximately 20%, 40%, and 60%), it is possible to assess the diffusion subcomponents: the membrane component and capillary blood volume."
223565189|NCT06896461|DIAGNOSTIC_TEST|Biomarkers evaluation|"Samples of plasma will be collected for bimarkers quantification in heart failure.~Speecifically, plasma levels will be quantitatively assessed using plasma obtained from venous blood. Blood will be collected in tubes containing 0.129 M Na-citrate (9 volumes of blood to 1 volume of Na-citrate), immediately centrifuged at 3000 g for 15 minutes at 4°C. Circulating levels of both immature and mature SP-B will be analyzed via Tricine gel electrophoresis followed by immunoblotting with an anti-SP-B antibody, allowing for the detection of all SP-B isoforms (proprotein 42 kDa, intermediate 23 kDa, and mature 8 kDa).~To validate potential heart failure biomarkers, a quantitative, scalable, and cost-effective method-Multiple Reaction Monitoring (MRM)-will be used. MRM, based on triple quadrupole mass spectrometry, enables precise quantification of proteins/peptides and their isoforms in complex biological samples."
223565190|NCT05949697|DIETARY_SUPPLEMENT|Dry Eye Drink|Dry Eye Drink is a dietary supplement containing electrolytes, vitamins and natural anti-inflammatories.
223565191|NCT06895694|OTHER|examine the impact of education|Children in the research group were trained to create a positive hospital perception.
224041631|NCT02921568|DEVICE|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
224041632|NCT02921568|DEVICE|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
224041633|NCT00765986|OTHER|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
223431770|NCT05040620|DRUG|Olive Oil Topical Oil|the effect of olive oil local application in decreasing orthodontic alighment phase
224041634|NCT00765986|OTHER|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
224041635|NCT06198842|DRUG|Treosulfan|Treosulfan 21mg/m2 (days -6, -5, -4)
224140155|NCT04102735|DEVICE|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
223431771|NCT06030830|BEHAVIORAL|SMaRT Mom|"SMaRT Mom intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention."
224041636|NCT02950402|OTHER|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
224041637|NCT02950402|OTHER|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
224041638|NCT03611283|OTHER|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
224041639|NCT03611283|OTHER|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
224041640|NCT03611283|OTHER|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
223431772|NCT05409430|DEVICE|Neurothrombectomy|"The ANA 5F device is intended to be inserted, be navigated to the neurovascular anatomy inside an outer catheter and be used as a conduit for insertion and guidance of intravascular catheters and retrieval devices into a selected blood vessel. The funnel is deployed by retracting the conduit catheter and is intended, when deployed, to provide temporary vascular flow restriction.~The device is indicated for the introduction of interventional devices into the neuro vasculature, during interventions for restoring blood flow in patients experiencing acute ischemic stroke due to large vessel occlusion."
224041641|NCT03611283|OTHER|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
224041642|NCT04480060|DIAGNOSTIC_TEST|COVID-19 diagnostic PCR|Nasopharyngeal swab samples will be analyzed by PCR for COVID-19 DNA existence.
224041643|NCT01681810|DRUG|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
224041644|NCT02618005|DIETARY_SUPPLEMENT|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
223431773|NCT00324389|DRUG|Interferon alpha|
223565192|NCT06895642|OTHER|Exercise|After all of the participants perform a symptom-limited cardiopulmonary exercise test, they included a single session high intensity interval exercise created according to test results. They randomized to two gorups as video and treadmill-based or only treadmill-based high intensity interval exercise.
223565193|NCT06895954|DIETARY_SUPPLEMENT|Genistein|Hyperlipidemia patients take a 125mg Genistein capsule daily, once a day.
223565194|NCT06896721|DRUG|Preoperative sedation with dexmedetomidine was administered nasal before surgery|Do not drink or fast before operation. Before entering the operating room, 2 sprits of dexmedetomidine were administered intranasally (1-2ug/kg) with conventional open venous access
224041645|NCT05940922|OTHER|No intervention. Retrospective observation only.|No intervention. Retrospective observation only.
224041646|NCT01726244|BEHAVIORAL|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
224041647|NCT04558463|DRUG|Favipiravir|"The favipiravir group received loading dose of 1600 mg twice a day (3200 mg/day) on the first day and continued with 600 mg twice a day (1200 mg/day) for the next 2nd - 7th day in addition to the standard therapy.~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
224041648|NCT04558463|DRUG|Oseltamivir 75mg|"The oseltamivir group was given twice a day of 75 mg of oseltamivir (150 mg/day) for 7 days in addition to standard therapy~Standard therapy: administration of azithromycin 500 mg/day or levofloxacin 750 mg/day for 5 days, chloroquine (either Sulphur-based chloroquine 600 mg/day or chloroquine phosphate 100 mg/day or hydroxychloroquine 400 mg/day) for 5-7 days, vitamin C, oxygen therapy according to the patients clinical condition, comorbid therapy and other symptomatic treatment such as antipyretic drug"
223565195|NCT06896721|DRUG|Preoperative sedation with normal saline was administered nasal before surgery|Do not drink or fast before operation. Before entering the operating room, 2 sprits of normal saline were administered intranasally (equal volume) with conventional open venous access
224041649|NCT02041208|PROCEDURE|kidney transplantation|kidney transplantation
224041650|NCT02931942|OTHER|blood withdrawn|venous blood sampling
224041651|NCT04030039|DRUG|Interferon|chronic hepatitis B patients with interferon therapy
224041652|NCT04030039|DRUG|nucleoside analogues|chronic hepatitis B patients with interferon therapy
224041653|NCT03226314|PROCEDURE|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
224041654|NCT03420794|OTHER|Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy|Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
224041655|NCT03823404|DRUG|COR388 capsule|BID (twice daily)
224041656|NCT03823404|DRUG|Placebo capsule|BID
224041657|NCT03035695|DEVICE|Axiostat®|
224140156|NCT04102735|DEVICE|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
223431774|NCT01683422|RADIATION|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
223431775|NCT01683422|RADIATION|Proton Radiation|
223431776|NCT00191425|DRUG|Teriparatide|
224041658|NCT03035695|DEVICE|Cotton Gauze|
223431777|NCT00191425|DRUG|Raloxifene|
223431778|NCT03774225|OTHER|Virtual Reality with Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
223431779|NCT03774225|OTHER|Virtual Reality with No Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
224041659|NCT05155787|DEVICE|Neurofeedback|Neurofeedback training as a method is going to let the brain producing the alpha signal (8-13 Hz).
224041660|NCT05155787|DEVICE|Shame neurofeedback|shame neurofeedback
224041661|NCT02529267|OTHER|Standard of care|
224041662|NCT05779202|OTHER|No intervention is planned.|No intervention is planned.
224041663|NCT04346498|OTHER|Chest-to-back|
224041664|NCT03498131|DRUG|3 mg Melatonin|3 mg melatonin once each day
224041665|NCT03498131|DRUG|5 mg Melatonin|5 mg Melatonin once each day
224041666|NCT03162887|OTHER|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
224041667|NCT03162887|OTHER|Counseling|Undergo a web-based decision counseling session
224041668|NCT03162887|OTHER|Informational Intervention|"Receive a next steps document"
224041669|NCT03383289|OTHER|R-REM training|three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
224041670|NCT02721745|BEHAVIORAL|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
223431780|NCT03774225|OTHER|Physical Therapy|Patients of the control group will be trained with balance exercises by a experient physiotherapist.
223431781|NCT03488225|DRUG|Cyclophosphamide|Given IV
223431782|NCT03488225|DRUG|Cytarabine|Given IT or IV
223431783|NCT03488225|DRUG|Dexamethasone|Given IV or PO
224041671|NCT02721745|DEVICE|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
224041672|NCT02721745|DEVICE|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
224041673|NCT05068518|OTHER|No intervention|no intervention
223431784|NCT03488225|DRUG|Doxorubicin Hydrochloride|Given IV
224041674|NCT01800357|DRUG|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
224041675|NCT01800357|DRUG|placebo|infusion of plabcebo once a day and for 14 days
224041676|NCT01800357|DRUG|aspirin|infusion of aspirin (100mg) once a day for days
223431785|NCT03488225|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
223431786|NCT03488225|OTHER|Laboratory Biomarker Analysis|Correlative studies
223431787|NCT03488225|DRUG|Leucovorin Calcium|Given IV
223431788|NCT03488225|DRUG|Mercaptopurine|Given PO
223565196|NCT06896864|PROCEDURE|cochlear implantation|After the surgery, patients typically undergo a period of recovery and healing. several factors including age at implantation, pre- and post-operative therapy, and parental involvement
223565197|NCT06896448|DIAGNOSTIC_TEST|Specialized sleep consultation and overnight recording using the APNEAL application|"A sleep consultation with a clinical examination. Completion of several questionnaires: Snoring and sleep quality questionnaire (AFSORL), EORTC Qulity of Life questionnary -C30, and H\&N35.~Providing the Apneal application pre-installed on a loaned smartphone for the patient to use at home for overnight recording."
224041677|NCT04652154|OTHER|Transitioning young patients' health care trajectories|New intervention where the patient with multi-referrals to specialist health service meet with a complementary professional team consisting of doctor, psychologist and physioterapist aiming clarify the child's condition through shared decison-making and agreeing upon treatment plans for the child
224041678|NCT06489756|OTHER|Echocardiography|Echocardiography will be performed according to clinical standards
223431789|NCT03488225|DRUG|Methotrexate|Given IT, IV or PO
223431790|NCT03488225|BIOLOGICAL|Ofatumumab|Given IV
224041679|NCT02884726|DRUG|BMS-986148|Specified dose on specified days
224041680|NCT05717478|COMBINATION_PRODUCT|rhBMP-2-BBM|Alveolar socket is filled with granules of bovine bone mineral (1.0-0.25 mm) loaded with human recombinant bone morphogenetic protein 2
224041681|NCT05717478|DEVICE|Bio-Oss+Bio-Gide|Alveolar socket is filled with granules of bovine bone mineral (Bio-Oss 1.0-0.25 mm) and covered with porcine collagen barrier membrane (Bio-Gide)
224041682|NCT00832117|DRUG|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
224041683|NCT00832117|DRUG|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
223431791|NCT03488225|DRUG|Prednisone|Given PO
223431792|NCT03488225|BIOLOGICAL|Rituximab|Given IV
223431793|NCT03488225|DRUG|Vincristine Sulfate|Given IV
223431794|NCT00061022|DRUG|NXY-059|
223431795|NCT00038896|DRUG|Venlafaxine ER|
223431796|NCT05680506|PROCEDURE|Pain neuroscience education|Pain neuroscience education will be given in form videos,pictures, stories and metaphors for 2 times per week for 4 weeks.
223431797|NCT05680506|PROCEDURE|Standard Therapy|Hot pack,TENS, Kaltenborn grade 1 and 2 mobilizations, stretchings and lumbar stabilization exercises
223431798|NCT03437876|OTHER|intestinal microbiota transplant|All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
223431799|NCT03203460|BEHAVIORAL|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
223431800|NCT04105894|DEVICE|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
223431801|NCT04105894|DIAGNOSTIC_TEST|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
223565198|NCT06885216|PROCEDURE|Anterior cervical discectomy and fusion/ posterior decompression|
224041684|NCT00832117|DRUG|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
224041685|NCT00832117|DRUG|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
224041686|NCT04439071|DRUG|PTC299|Oral tablets
224041687|NCT04439071|OTHER|SOC|As defined per local written policies or guidelines.
224041688|NCT04439071|DRUG|Placebo|Oral tablets
224041689|NCT00264524|PROCEDURE|venipuncture to withdraw patient's blood|
224041690|NCT06447818|OTHER|Change in airway markers|Mallampati and cormack lahane scores will be evaluated at the sixth postoperative month
224041691|NCT00498251|DRUG|inhalation of salbutamol (5 mg)|
224041692|NCT00498251|DRUG|ipratropium|
224140157|NCT02417467|OTHER|Nicotine E-Cigarette|
224140158|NCT02417467|OTHER|Non-Nicotine E-Cigarette|
224041693|NCT02241291|PROCEDURE|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
223431802|NCT04105894|DRUG|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
224041694|NCT04008147|DIETARY_SUPPLEMENT|100mg iron fumarate|100mg iron fumarate b.i.d. for 4 consecutive days
224041695|NCT04008147|DIETARY_SUPPLEMENT|Burgerstein Schwangerschaft & Stillzeit|contains 30 mg iron fumarate, given on 14 consecutive days
224041696|NCT00644553|DRUG|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
224041697|NCT00644553|DRUG|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
224041698|NCT01668407|DEVICE|Robot-Assisted Gait Training (RAGT)|Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
223431803|NCT05714475|PROCEDURE|Pancreas surgery|"Criteria~Inclusion Criteria:~* Isolated pancreatic metastases from Colorectal cancer~* Previous surgery for colorectal cancer~* Surgically manageable lesions: duodenal-pancreatectomy surgical removal of metastatic repetitions in pancreas~pancreaticoduodenectomy total-pancreatectomy distal-pancreatectomy other metastases resection"
223431804|NCT05724108|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224041699|NCT01668407|PROCEDURE|Treadmill Gait Training (TT)|"Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
224041700|NCT04571827|OTHER|Dry Needling|"Deep dry needling procedure~All subjects received a deep dry neddling technique on a latent myofascial trigger point of the upper trapezius muscle by isolating it by a pincer grasp with the thumb and index finger. This myofascial trigger point was previously found following the diagnostic criteria described by Travell \& Simons and Fernández-de-las-Peñas et al., and the deep dry needling intervention applied was based on the technique described by Hong.~The patients were placed in a prone position. Prior to the technique, the area was disinfected with an antiseptic solution. Fifteen incisions were made with a 0.26x40mm monofilament needle. The number of local twitch response made were noted. After removing the needle, at the end a soft compression was made with a cotton to reduce the possible appearance of bleeding."
224140159|NCT02417467|BEHAVIORAL|Counseling|
224140160|NCT02043405|BEHAVIORAL|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
224140161|NCT02043405|BEHAVIORAL|Weight loss Only Intervention|Weight loss Only Intervention
223431805|NCT05724108|PROCEDURE|Computed Tomography|Undergo CT
224041701|NCT00044551|DRUG|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
224140162|NCT02035150|DIETARY_SUPPLEMENT|Oatmeal|A breakfast consisting of oatmeal
224140163|NCT02035150|DIETARY_SUPPLEMENT|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
224140164|NCT02035150|DIETARY_SUPPLEMENT|No Breakfast|A breakfast consisting of plain water
224140165|NCT02875847|DIETARY_SUPPLEMENT|HMO1|
224140166|NCT02875847|DIETARY_SUPPLEMENT|HMO2|
224140167|NCT02875847|DIETARY_SUPPLEMENT|Dextropur|
224140168|NCT02168803|DRUG|Evacetrapib|Administered orally
224140169|NCT05904184|DRUG|Epoxy resin-based sealers (ERS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
223431806|NCT05724108|DRUG|Lutetium Lu 177 Dotatate|Given IV
223431807|NCT05724108|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224140170|NCT05904184|DRUG|Calcium silicate-based sealers (CSS)|All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
224299514|NCT02545647|DEVICE|BRYGB|65 patients undergo a banded RYGB
223431808|NCT05724108|DRUG|Triapine|Given PO
223431809|NCT00986986|DRUG|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
223431810|NCT02110030|DEVICE|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
223431811|NCT02110030|DEVICE|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
223431812|NCT01917357|BIOLOGICAL|Quinvaxem in Uniject|
223431813|NCT01917357|BIOLOGICAL|Quinvaxem in single dose vials|
223431814|NCT02370030|DIETARY_SUPPLEMENT|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
223431815|NCT06658886|OTHER|No intervention|No intervention
224041702|NCT06388681|DEVICE|The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography|The researchers will explain and demonstrate to the intervention group how to use the stress ball. Then, the patient will be asked to use the ball and it will be confirmed whether he/she uses it correctly. After angiography, it will be stated that the patients in the intervention group should count to 5 and squeeze it once for 10 minutes every hour and rotate with the right hand and left hand until they are mobilized.
224041703|NCT03177616|OTHER|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~* posture correction/spinal stabilization exercises~* soft tissue relaxation techniques~* spinal manipulation (i.e. chiropractic adjustment)/mobilization~* breathing and relaxing techniques~* stretches, self-care~* ergonomic modifications~* bracing and supports"
224041704|NCT00303420|DRUG|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
224041705|NCT00303420|DRUG|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
224041706|NCT01426516|DEVICE|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
224041707|NCT01524133|DRUG|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
224041708|NCT01524133|BEHAVIORAL|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
224041709|NCT04323839|OTHER|Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
224041710|NCT04323839|OTHER|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19|This is an observational study with no intervention
224041711|NCT06231576|OTHER|Prehabilitation|"* Nutritional optimization: A nutritionist will perform a structured interview, comprehensive nutrition assessment, and provide personalized dietary advice. The main goal is to ensure optimal protein intake to support exercise-induced anabolism. A daily protein intake of 1.2-2.0 g/kg will meet needs as outlined in surgical nutrition guidelines.~* Exercise: Based on current guidelines and instructed by a dedicated physiotherapist, for 1 hour per day preoperatively to increase muscle strength, aerobic capacity and physical endurance. Intensity will be based on the rate of perceived exertion using the Borg scale, a 15-graded scale ranging from very light to very hard. Resistance exercises will target upper/lower body, and abdominal muscles.~* Psychological coaching and support: Performed as one interview during inclusion, followed by weekly phone calls by a study nurse coordinator during the preoperative intervention."
224041712|NCT00862303|BIOLOGICAL|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
223431816|NCT05031637|BEHAVIORAL|treatment of BP by using night-time BP|titration of BP medications to target according to night-time SBP
224041713|NCT00862303|DRUG|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
224041714|NCT01878643|DRUG|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
224041715|NCT01878643|DRUG|Placebo|normal saline administered to patient via nebulization
224041716|NCT03619538|DRUG|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
223431817|NCT05031637|BEHAVIORAL|treatment of BP by using daytime BP|titration of BP medications to target according to daytime SBP
223431818|NCT02672007|DEVICE|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
223431819|NCT05156645|DRUG|SCTA01 and SCTA01C|Diluted by 0.9% normal saline
223431820|NCT05156645|DRUG|Placebo|Diluted by 0.9% normal saline
223431821|NCT04719130|OTHER|Multimodal circuit exercise|A structured and supervised multimodal exercise circuit twice a week, under 12 weeks program. The circuit workout program consists of 8 exercises, divided into motor coordination, balance, strength, and aerobic exercises. The exercises will be employed in a reserved room inside of the Basic Health Units. The sessions of exercises will last approximately 50 minutes,
223431822|NCT04719130|OTHER|Multidisciplinary lectures|Multidisciplinary lectures on pain and usual care provided by the Basic Health Units. A cycle of multidisciplinary lectures on pain will be offered by professionals in physical education, nursing, physiotherapy, medicine, psychology and social work that will take place in the Basic Health Units every 15 days.
223565199|NCT04548700|DRUG|Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (12 mg/m2, 15 mg/m2, 18 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28-day cycle."
224041717|NCT03619538|OTHER|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
224041718|NCT00786825|DRUG|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
224041719|NCT01920945|DRUG|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
223431823|NCT04809948|BIOLOGICAL|viral vector vaccine|AstraZeneca vaccine
223431824|NCT05890430|BIOLOGICAL|Blood draw, Urine draw|Collection of an additional volume of blood at each follow-up time in addition to the standard blood test performed during the patient's follow-up Collection of an additional volume of urine at each follow-up time
224041720|NCT04311567|DRUG|Tofacitinib|Open-label tofacitinib for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
224041721|NCT04311567|DRUG|Methotrexate|Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
223431825|NCT01537016|DEVICE|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
223431826|NCT01537016|DEVICE|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
223431827|NCT03404258|OTHER|Research Blood Sampling|Blood samples will be collected at specified time points and research assays will be performed.
223431828|NCT05949541|DRUG|Everolimus 10 mg|Everolimus is a kind of mTOR inhibitor which has been approved to use in several kinds of cancers, especially in metastatic breast cancer.
223431829|NCT05949541|DRUG|CDK4/6 Inhibitor SHR6390|Dalpiciclib (SHR6390) is a kind of CDK4/6 inhibitor that has demonstrated tolerability and preliminary clinical activity in patients with heavily pretreated hormone receptor-positive, HER2-negative advanced breast cancer.
223431830|NCT05949541|DRUG|Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors|Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line therapy for advanced luminal breast cancer. Investigators choose endocrine therapy including Letrozole, Anastrozole, Exemestane, and Fulvestrant. Postmenopausal participants should use Goserelin.
223431831|NCT04660708|BEHAVIORAL|manual physical therapy|Previously described in the arm description
223431832|NCT06338618|PROCEDURE|liver treatment protocol|The liver treatment protocol consists of performing twelve visceral manual techniques in an approximate time of 30 minutes twice a week for 4 weeks
223431833|NCT04886206|BIOLOGICAL|DLI|the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.
223431834|NCT01393132|DRUG|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
223431835|NCT01393132|DRUG|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
223431836|NCT02430103|DRUG|Goserelin 3.6 MG|In goserelin group, goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration.
224041722|NCT05861687|DRUG|Esomeprazole|Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
224041723|NCT05861687|DRUG|Lansoprazole|Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was \<30 kg, and 30 mg if it was \>30 kg
224041724|NCT05861687|DRUG|Amoxicillin|Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
223431837|NCT02476370|BEHAVIORAL|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
223431838|NCT02476370|BEHAVIORAL|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
223431839|NCT02003963|BEHAVIORAL|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
224041725|NCT05861687|DRUG|Clarithromycin|Administered twice a day per-oral with the dose of 7.5 mg/kg
224041726|NCT01156233|PROCEDURE|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
223431840|NCT04800614|DRUG|sitravatinib|100 mg sitravatinib on Day 1 of each of 3 periods
223431841|NCT01797159|RADIATION|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
223431842|NCT04294433|BIOLOGICAL|Infanrix-hexa, Twinrix-Junior|Vaccines administrated according to product monographs' recommendations
223431843|NCT01658449|OTHER|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
223431844|NCT01658449|OTHER|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
223431845|NCT01910220|DRUG|REGN1033 (SAR391786)|
224041727|NCT01156233|PROCEDURE|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
224041728|NCT02722382|OTHER|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
224041729|NCT01002456|OTHER|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
223431846|NCT01910220|OTHER|placebo|
223431847|NCT01273714|PROCEDURE|thyroid resection|bilateral subtotal versus total thyroidectomy
223431848|NCT05369494|OTHER|Hydrolyzed protein infant formula with oligosaccharides|Hydrolyzed protein infant formula with oligosaccharides
223431849|NCT06529172|OTHER|Resistance training|RG performed RT with an elastic band (yellow, force of 9-11 pounds when stretched twice the original length). They performed eight movements. Each movement was performed for 3-5 sets at 8 times/sets with 30 s of rest between groups. The movements included upright rows, reverse curls, standing shoulder rotations, neck-elbow extensions, elbow bends, downward lunges, standing leg lifts, side lifts and standing back kicks. All participants completed the RT movements according to the regular rhythm (1-2-1) provided by the experimenter, which ensured that all participants had similar movements completion rates.
223431850|NCT06529172|OTHER|Yijinjing|YG performed 12 movements . These movements included extending the hands upwards and slowly lowering them; extending the torso by stretching the hands straight up and bending the body to the left or right; squatting with the hands on the knees and standing up slowly; bending the body to the left or right side, extending the arms and waist; getting down on the knees, leaning forward, extending the hands forward and slowly pulling them back; bending forward, placing the hands around the knees and standing up slowly; placing the hands on the hips; and leaning back to stretch the back and waist.
223431851|NCT06529172|OTHER|Baduanjing|BG performed eight movements . These movements included holding the hands straight up, slowly bringing the hands down and turning the waist while in a standing position; bending the body to the left or right side and extending the arms; extending one hand straight up, placing the other hand on the waist, then switching arms and repeating the movement; tilting the head back and looking back while stretching the neck and back; squatting the body, swinging the head and hips from side to side and moving the spine and waist; bending the body forward, touching the hands to the toes and standing up slowly; making fists with the hands and moving the arms and shoulders; and gently bouncing the body to relax the whole body in a standing position.
223431852|NCT06529172|OTHER|Control|The CG group maintained their original lifestyle without engaging in regular exercise
223431853|NCT06482333|OTHER|Time for resumption of DOAC|Time for resumption of DOAC
223431854|NCT05867693|DIETARY_SUPPLEMENT|palmithoylethanolamide/polydatin|"Palmitoyl-ethanolamide, a saturated fatty acid amide of palmitic acid commonly found in egg yolk and peanuts, is chemically related to anandamide but exhibit low affinity for cannabinoid receptors, and participate in the control of inflammation and nociception mainly via down-regulation of mast cell activity. In addition, palmitoylethanolamide is able to reduce human colonic permeability both in vitro and in vivo. Interestingly, palmithoylethanolamide may act as mast cell modulator as a possible agonist for cannabinoid 2-like receptors; and as agonist for PPAR-α, transient receptor potential vanilloid type 1 (TRPV1), and 'orphan' G protein-coupled receptor 55.~For these reasons, palmithoylethanolamide has emerged as potential regulators of nociception. Polydatin, a resveratrol glucoside, is a common dietary component derived from grapes which may act synergistically with palmithoylethanolamide in reducing mast cell activation and local oxidative stress."
223431855|NCT05867693|DIETARY_SUPPLEMENT|placebo|After the screening phase, eligible patients will be randomly assigned to equivalent placebo
223431856|NCT01375582|DRUG|B & L Soothe Lubricant Eye Drops|Eye Drop
223431857|NCT01375582|DRUG|Liposic EDO|Eye Drop
223431858|NCT01375582|DRUG|OcuFresh Eye Wash|Saline drop
223431859|NCT05889208|DEVICE|Prophylactic pacemaker implantation|Pacemaker implantation prior the TAVI-procedure
223431860|NCT04610450|DEVICE|HEARO|Robotic system for otological procedures
223431861|NCT04610450|DEVICE|OTOPLAN|Otological surgical planning software
223565200|NCT04548700|DRUG|Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|"Drug: Liposomal mitoxantrone hydrochloride (at RP2D) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Cyclophosphamide (750 mg/m2) will be administered by an intravenous infusion on day 1 of each 28- or 21-day cycle.~Drug: Vincristine (1.4 mg/m2 with 2 mg as the maximum dose) will be administered by an intravenous injection on day 1 of each 28- or 21-day cycle.~Drug: Prednisone (100 mg/d) will be taken orally from day 1 to day 5 of each 28- or 21-day."
223431862|NCT03197740|DRUG|Donepezil patch|Treatment
223431863|NCT03197740|DRUG|aricept Tab|Comparator
223565201|NCT04739670|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.
223565202|NCT04739670|DRUG|Bevacizumab|Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
223565203|NCT04739670|DRUG|Gemcitabine|Gemcitabine is a type of chemotherapy drug
223565204|NCT04739670|DRUG|Carboplatin|Carboplatin is platinum based chemotherapy drug
223565205|NCT03241277|PROCEDURE|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
223565206|NCT00937742|DIETARY_SUPPLEMENT|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
223431864|NCT05020366|BEHAVIORAL|Promoting Health through Parent Empowerment and the Activation of Routines|Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.
223565207|NCT00003783|BIOLOGICAL|filgrastim|
223565208|NCT00003783|DRUG|asparaginase|
223565209|NCT00003783|DRUG|cyclophosphamide|
223565210|NCT00003783|DRUG|cytarabine|
223565211|NCT00003783|DRUG|daunorubicin hydrochloride|
223565212|NCT00003783|DRUG|dexamethasone|
223565213|NCT00003783|DRUG|etoposide|
223565214|NCT00003783|DRUG|idarubicin|
224041730|NCT01002456|OTHER|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
224140171|NCT04314479|BEHAVIORAL|Symptom Assessment and Health Coaching|The intervention condition will involve weekly symptom assessment and health coaching to manage symptoms and to meet the ACS cancer prevention guidelines provided over the telephone by trained health coaches. Participants will be completing the same forms/assessments throughout the study. The content will be built around the Symptom Management Toolkit. The coaching will be dictated by the symptoms the survivor or the support person is experiencing the week of the intervention call. All calls begin with the symptom assessments, only the intervention arm includes intervention coaching that focuses on physical activity, stress management, or eating a healthy diet to improve adherence to the ACS guidelines for cancer prevention. We anticipate coaching sessions will last approximately 20 - 45 minutes.
224140172|NCT04807036|DEVICE|Hypotension Prediction Index|HemoSphere Clinical Platform with Acumen Hypotension Prediction Index Feature
224140173|NCT03579550|PROCEDURE|office hysteroscopic metroplasty intervention arm|One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
223431865|NCT05020366|BEHAVIORAL|Enhanced Usual Care|For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
223431866|NCT01412892|DRUG|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
223431867|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
223431868|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
224041731|NCT03152279|DIAGNOSTIC_TEST|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
224140174|NCT02808741|DRUG|F901318 SDD|Pharmacokinetics area under curve
223431869|NCT04748848|DRUG|Azacitidine|Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
223431870|NCT04748848|DRUG|Venetoclax|Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
223431871|NCT04748848|DRUG|CC-90011|CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
223431872|NCT04686786|DRUG|CVL-865|Participants will receive 25 mg CVL-865 tablets orally BID during the treatment period. The dose may be decreased to 17.5 mg BID for tolerability.
223431873|NCT00055510|DRUG|BO-653|
223431874|NCT00563160|DRUG|gemcitabine, carboplatin|
223431875|NCT00563160|PROCEDURE|surgery|
223431876|NCT04315844|DEVICE|Ewata balloon guiding|The balloon guide catheter is coaxial cavity and reinforced braided catheter with varying stiffness echelon.The distal end is marked by an impermeable ray, the proximal end has a bifurcated ruhr interface, and the end is embedded with a compliance balloon.The product label indicates the size of the balloon guide catheter and the maximum volume of the balloon.
223565215|NCT00003783|DRUG|leucovorin calcium|
224140175|NCT02808741|DRUG|F901318 IR|Pharmacokinetics area under curve
224140176|NCT02808741|DRUG|F901318 IR Fasting|Pharmacokinetics area under curve
223431877|NCT00003394|DRUG|carboplatin|
223431878|NCT00003394|DRUG|endocrine-modulating drug therapy|
223431879|NCT00003394|DRUG|estramustine phosphate sodium|
223431880|NCT00003394|DRUG|goserelin acetate|
223431881|NCT00003394|DRUG|leuprolide acetate|
223431882|NCT00003394|DRUG|paclitaxel|
223431883|NCT03442699|BEHAVIORAL|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
223431884|NCT05995951|DEVICE|Deep Bran Stimulation (DBS)|Deep brain stimulation (DBS) surgery targeting the antero-medial Sub-Thalamic Nucleus (amSTN)
223431885|NCT05995951|DEVICE|Sham-stimulation|Deep brain stimulation (DBS) surgery - Sham stimulation
223565216|NCT00003783|DRUG|mercaptopurine|
223565217|NCT00003783|DRUG|methotrexate|
223565218|NCT00003783|DRUG|prednisone|
223565219|NCT00003783|DRUG|vincristine sulfate|
224041732|NCT03152279|DIAGNOSTIC_TEST|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
224041733|NCT05821530|DEVICE|HFIT|At least 1 hour daily for 4 weeks
224041734|NCT05821530|DEVICE|TENS|At least 1 hour daily for 4 weeks
223565220|NCT00003783|RADIATION|radiation therapy|
223565221|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|Adequate dairy (\> 3 standard daily servings)
223565222|NCT00686426|DIETARY_SUPPLEMENT|Dairy Foods|\< 1 standard dairy serving/day
224041735|NCT05821530|OTHER|Control|Users will continue to use the digital MSK program as needed
224041736|NCT05050942|DRUG|CAM2029|CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
224041737|NCT05050942|DRUG|Octreotide LAR|Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
224041738|NCT05050942|DRUG|Lanreotide ATG|Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
224140177|NCT02808741|DRUG|F901318 IR Fed|Pharmacokinetics area under curve
224140178|NCT01310816|DRUG|IPI-926|Oral
224140179|NCT01310816|DRUG|Placebo Arm|oral placebo
224140180|NCT00283998|PROCEDURE|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
224140181|NCT00120653|DRUG|Metoclopramide|
224041739|NCT05802992|DRUG|Colchicine|"The investigational drug colchicine was used at a daily dose of 0.5-1 mg. In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.~If the patient needs to be treated with the investigational drug colchicine on the day of dexamethasone administration, he should take dexamethasone orally within 3 hours before the administration of colchicine."
224041740|NCT05802992|DRUG|Lenalidomide|In every cycle, lenalidomide was administered at 10-25 mg (days 1-21). Dexamethasone 40mg (≤75 years old) or 20mg (\>75 years old) per week.If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day; If the weekly dose is 20mg or take the lower dose on the first day of each week.
224041741|NCT02136745|BEHAVIORAL|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
224140182|NCT00377910|DRUG|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
224140183|NCT03448861|DEVICE|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
224140184|NCT01114373|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
224140185|NCT01114373|DRUG|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
224140186|NCT02527122|DIAGNOSTIC_TEST|Allergen extracts|
224140187|NCT00934427|DRUG|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
223431886|NCT04079166|BIOLOGICAL|SCIB1 or iSCIB1+ DNA vaccine|"Participants receive up to 11 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.~Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment."
223431887|NCT04263480|DRUG|Carfilzomib + Ibrutinib|"Carfilzomib:~Cycle 1, day 1: 20 mg/m² i.v. Cycle 1, day 8, day 15: 70 mg/m² i.v. Cycle 2 - 12, day 1, day 8, day 15: 70 mg/m² i.v. Cycle 13 - 24, day 1, day 15: 70 mg/m² i.v.~Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
223431888|NCT04263480|DRUG|Ibrutinib|"Ibrutinib:~420 mg p.o daily until disease progression or non-tolerable toxicities"
223565223|NCT01655121|DIETARY_SUPPLEMENT|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
223431889|NCT05461898|OTHER|Inpatient Rehabilitation|Standard inpatient rehabilitation program with a interdisciplinary team that included a physiotherapist who ensured muscle strength, balance, aerobic and functional training, an occupational therapist who provided training of basic and instrumental activities of daily living and education of energy conservation techniques and a a speech and language therapist for swallowing training.
223431890|NCT05461898|OTHER|Inspiratory muscle training|Inspiratory muscle training protocol during 6 weeks with a electronic-controlled valve device
223565224|NCT00491946|DRUG|Actinomycin-D|
223565225|NCT00491946|DRUG|Vincristine|
223565226|NCT04448314|DIAGNOSTIC_TEST|PointCheck|This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
223565227|NCT03315793|DRUG|Duloxetine Hydrochloride|Administered orally
223565228|NCT03315793|DRUG|Placebo|Administered orally
223565229|NCT05355259|DEVICE|GECKO Active Guidewire|The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.
224041742|NCT03632109|DRUG|gentamicin 360mg IM|360mg IM of gentamicin
224041743|NCT00963833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
223431891|NCT05121168|DRUG|Active bupivacaine 0.25% via an erector spinae plane perineural catheter|Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
223431892|NCT05121168|DRUG|Placebo normal saline via an erector spinae plane perineural catheter|Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
223431893|NCT06257017|DRUG|gemcitabine|1,000 mg/m2 intravenous gemcitabine on day 1 and day 8
223565230|NCT04481061|GENETIC|Electronic Decision Tool|Adolescents and a parent, if applicable, will use an electronic decision tool to make categorical choices of types of diseases (treatable, preventable, adult-onset, and carrier status) they want to learn about the adolescent. Granular choices can be made within each category.
223565231|NCT01637363|BEHAVIORAL|Psychoeducation|6 x 2 hours of psychoeducation
224140188|NCT00934427|DRUG|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
224041744|NCT05575154|DEVICE|optical coherence tomography (OCT)|measuring retinal nerve fiber layer and neuroretinal rim thickness
224041745|NCT02885948|DRUG|Naloxone|used to block the effects of opioids, especially in overdose
224041746|NCT02885948|DRUG|Placebo|Placebo, ineffective control arm
224041747|NCT00966823|DEVICE|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~\- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
224041748|NCT00059839|DRUG|doxorubicin hydrochloride|Given IV
224140189|NCT05122195|OTHER|Compression therapy|Graduated elastic compression promote venous flow which is impaired by hormonal changes in the venous system during the gestational period and minimize the blocking effect of the gravid uterus.
224140190|NCT01396239|DRUG|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
224140191|NCT01396239|OTHER|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
224140192|NCT02484612|BEHAVIORAL|acute exercise|
224140193|NCT03110146|DEVICE|EnSite Precision|Ablation procedure
224140194|NCT05991674|DIAGNOSTIC_TEST|patch test for diagnosing allergic contact dermatitis|European Baseline Series (EBS) System of allergens
224140195|NCT01504386|PROCEDURE|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
224140196|NCT01504386|PROCEDURE|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
224140197|NCT03255993|DRUG|SPH3127 50mg|SPH3127 50mg
224140198|NCT03255993|DRUG|SPH3127 100mg|SPH3127 100mg
223431894|NCT06257017|DRUG|Cisplatin|70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
224140199|NCT03255993|DRUG|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
224140200|NCT03255993|DRUG|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
224140201|NCT05140395|DIAGNOSTIC_TEST|ABTEST card|Pre transfusional control with the referent ABTEST card and the in study ABDTEST Card
224140202|NCT03060083|OTHER|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
224140203|NCT03060083|OTHER|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
224140204|NCT03783728|DRUG|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
224140205|NCT03783728|DRUG|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
223431895|NCT03486678|DRUG|SHR-1210+GEMOX|28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
223431896|NCT05109832|DRUG|14C-IMP4297|14C marked IMP4297
223431897|NCT01727544|PROCEDURE|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
223431905|NCT03413956|PROCEDURE|Surgeries|Surgeries
224041749|NCT00059839|DRUG|mercaptopurine|Given by mouth
224041750|NCT00059839|DRUG|methotrexate|Given IV and intrathecally
224041751|NCT00059839|DRUG|prednisone|Given by mouth
224041752|NCT00059839|DRUG|vinblastine sulfate|Given IV
224041753|NCT00059839|DRUG|vincristine sulfate|Given IV
224041754|NCT00003181|BIOLOGICAL|aldesleukin|
224041755|NCT00003181|BIOLOGICAL|sargramostim|
224041756|NCT00003181|DRUG|vinblastine sulfate|
224041757|NCT01444014|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
224041758|NCT04866368|PROCEDURE|The ultrasound-guided Sacral Erector spinae plane block|postoperative pain procedure
224041759|NCT04866368|PROCEDURE|The dorsal penile block|postoperative pain procedure
224041760|NCT04888130|GENETIC|Phylogenetic Analysis|The phylogenetic analysis is carried out on a sample already taken in routine care (smear, culture on biopsy or PCR on swab).
224140206|NCT03783728|DRUG|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
224140207|NCT03444870|DRUG|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
224140208|NCT03444870|DRUG|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
224140209|NCT03555188|DRUG|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
224140210|NCT01608490|DEVICE|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
224140211|NCT04902534|DRUG|Naoqingzhiming Tablets (contains echinacoside 180mg)|Single dose escalation and multiple dose escalation
224041761|NCT04888130|OTHER|Data collection|Data will be collected using a standardized digital questionnaire, including clinical and microbiological features, treatments received details and training conditions and. Data will then be compared between patients with therapeutic success or failure.
224041762|NCT00648089|DRUG|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
224041763|NCT00807963|DRUG|rHuPH20|recombinant human hyaluronidase PH20 injection
224041764|NCT00807963|DRUG|zoledronic acid|subcutaneous injection
224041765|NCT01956734|PROCEDURE|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."
224041766|NCT01969097|DEVICE|tDCS|transcranial direct current stimulation (tDCS)
224041767|NCT01969097|BEHAVIORAL|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
224041768|NCT01693081|DRUG|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
224041769|NCT01693081|DRUG|placebo|
224041770|NCT04611438|DRUG|Cannabidiol|"Intervention schedule for each patient is as follows:~1. Baseline Phase (2 weeks) Baseline Phase starts from the screening visit, where the patient and caregiver write permission to the trial and goes through laboratory, electroencephalography, and neuropsychological tests.~2. Treatment Period: Titration (2 weeks) + stabilization period (10 weeks) + maintenance period (12 weeks)~   * Titration: The patient would start cannabidiol on 5mg/kg/mg for 1 week and titrate dosage up to 10mg/kg/day for second week with the caregiver monitoring the patient's tolerability~  * Stabilization: caregiver monitoring the patient's tolerability, with no change in medication dosage~  * Maintenance: no change in medication dosage"
224041771|NCT03106181|DEVICE|iStent inject®|Insertion of iStent inject®
224041772|NCT03106181|PROCEDURE|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
223431906|NCT01942356|PROCEDURE|TIVA - Hypotension|"Defined as: MAP \< 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1. Give 200 mL Fluid Bolus~2. If not successful, give ephedrine 5 mg bolus~3. Repeat from 1.) if even is not resolved after 3.)"
223431907|NCT01942356|PROCEDURE|TIVA - Hypertension|"Defined as: SBP \> 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered"
223431908|NCT01942356|PROCEDURE|TIVA - Bradycardia|"Defined as: Heart rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
223431909|NCT01942356|PROCEDURE|TIVA - Tachycardia|"Defined as: Heart Rate \> 90 beats/min~1. If associated with normal NIBP (MAP \> 60 mmHg and SAP \< 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~2. If associated with hypertension (SAB \> 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~3. If associated with hypotension (MAP \< 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol."
223431910|NCT01942356|PROCEDURE|INH - Hypotension|"Defined as: MAP \< 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. give a 200 ml fluid bolus (crystalloid).~2. If not successful, give ephedrine 5 mg bolus.~3. If not successful decrease volatile by 0.1 MAC.~4. Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations"
223431911|NCT01942356|PROCEDURE|INH - Hypertension|"Defined as: SBP \> 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~1. increase Sevoflurane by 0.1 MAC~2. If not successful after 3 minutes (SBP \>130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.~3. If still not successful (SBP \>130% of baseline), Labetolol 5mg IV will be administered."
223431912|NCT01942356|PROCEDURE|INH - Bradycardia|"Defined as: Heart Rate \< 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
223431913|NCT01942356|PROCEDURE|INH - Tachycardia|"Defined as: Heart rate \> 90 beats/min~1. if associated with normal NIBP (MAP \> 70% of baseline and SBP \<130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).~2. If associated with hypertension (SBP \>130% of baseline) : proceed with the management of the hypertension during maintenance protocol.~3. If associated with hypotension (MAP \< 70% of baseline) : proceed with the management of the hypotension during maintenance protocol."
224041773|NCT05545033|DEVICE|Virtual reality|5 to 15 minutes of virtual reality exposure
224041774|NCT00158873|DRUG|midazolam|
224041775|NCT00158873|DRUG|lorazepam|
224041776|NCT00158873|DRUG|fentanyl|
224041777|NCT00158873|DRUG|morphine|
224041778|NCT00158873|DRUG|remifentanil|
224041779|NCT00158873|DRUG|propofol|
224041780|NCT03842163|DIAGNOSTIC_TEST|Diagnosis of TTR amyloidosis cardiomyopathy|Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
224041781|NCT02675023|BIOLOGICAL|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
224041782|NCT01479114|DRUG|rh-GCSF|10 ug/kg/day intravenously for 3 days
224041783|NCT00395551|DRUG|ranibizumab|0.5mg intravitreal injection
224041784|NCT02575040|BIOLOGICAL|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
224041785|NCT04110548|PROCEDURE|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
224140212|NCT04902534|DRUG|placebo of Naoqingzhiming Tablets (without echinacoside)|Single dose escalation and multiple dose escalation
224140213|NCT06386809|DEVICE|TAVNS|TAVNS is a recently introduced treatment involving transcutaneous electrical stimulation of the auricular branch of the vagus nerve with VAGUSTIM device.
224041786|NCT04110548|PROCEDURE|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
224041787|NCT02700243|BEHAVIORAL|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
223431914|NCT04010526|COMBINATION_PRODUCT|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
223431915|NCT04010526|OTHER|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
223431916|NCT04050124|DEVICE|Promogran Prisma|Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
223431917|NCT04050124|DEVICE|Standard of care (SOC) dressings|standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
223431918|NCT04271839|COMBINATION_PRODUCT|fluticasone/formoterol k-haler (medium strength)|2 inhalations every 12 hours
223431919|NCT04271839|COMBINATION_PRODUCT|Standard of care (ICs/LABA high strength)|Depend of the ICs/LABA combination
223431920|NCT04669964|PROCEDURE|Intravenous Hydration|Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
223565232|NCT05420714|DEVICE|Dexcom Professional Continuous Glucose Monitoring|Patient will be asked to wear the Dexcom Pro-CGM device (small device that can be applied to either the arm or abdomen) for 10 days. They will have 30 minutes initial visit with CDCES to apply the device and review its use and 60 minute final session to review the blood sugar data from the CGM with CDCES and diabetes clinic provider.
224041788|NCT03415126|DRUG|ASN007: ascending doses|Oral drug for the treatment of advanced solid tumors
224041789|NCT03415126|DRUG|ASN007 RD|Oral drug for the treatment of advanced solid tumors
224041790|NCT03829241|DRUG|Troriluzole|100 mg capsule
224041791|NCT03829241|DRUG|Placebo|Placebo matched to troriluzole
223431921|NCT03119623|DRUG|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
223431922|NCT03119623|DRUG|Enalapril|enalapril 5mg, titrated up to 10mg po BID
223565233|NCT01356342|BIOLOGICAL|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"
223478436|NCT01855022|BEHAVIORAL|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
223478437|NCT01673386|DRUG|Tivozanib|
223478438|NCT01673386|DRUG|Sunitinib|
223565234|NCT05018806|DRUG|Placebo|Pharmaceutical form: Tablet Route of administration: Oral
224041792|NCT01418651|DRUG|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
224140214|NCT06386809|OTHER|Exercise program|Rocabado 6x6 exercises will be applied in our study. Rocabado exercise, which is the most commonly used exercise method in the literature, is a set of exercises for the craniocervical and craniomandibular system.
223565235|NCT05018806|DRUG|Rilzabrutinib|Pharmaceutical form: Tablet Route of administration: Oral
223565236|NCT05489653|BEHAVIORAL|mixed music|Learn about the effects of listening to music and doing activities with it on sleep.
224140215|NCT04037917|DEVICE|CorNeat EverPatch|Covering Ophthalmic Implants
223565237|NCT05814198|DIAGNOSTIC_TEST|HALP score|we will calculate the HALP score with the complete blood count and albumin values in FGR and SGA groups.
223565238|NCT01616940|BEHAVIORAL|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact."
224140216|NCT03998917|DIAGNOSTIC_TEST|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
224140217|NCT01969669|DRUG|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
224140218|NCT01969669|DRUG|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
224140219|NCT00326222|BEHAVIORAL|Lifestyle counseling|Self-management group education
224299515|NCT04206228|DRUG|Intravenous iron isomaltoside|"The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min)."
224041793|NCT01924013|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
224041794|NCT01924013|DIETARY_SUPPLEMENT|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
224041795|NCT04752020|DRUG|Netarsudil Ophthalmic|Use of netarsudil after Descemetorhexis without endothelial keratoplasty
224041796|NCT05290922|DIAGNOSTIC_TEST|DNA methylation testing|The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation.
224041797|NCT00469001|PROCEDURE|Treatment according NT Pro BNP level|
224041798|NCT00698451|DRUG|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
224041799|NCT06494215|OTHER|Pressure Support Variation and Calculation of Respiratory Mechanics|Patients will be submitted to different levels of pressure support (PS) in a randomly assigned order. First 30 minutes shall be recorded at the clinical PS. Next, blood gas samples shall be collected. Subsequently, three inspiratory pauses of at least 2 seconds shall be performed with an interval of at least 8 respiratory cycles between them. The same shall be performed with three expiratory pauses. Next, the PS shall be varied to 50% less or 50% more than clinical PS (based on randomization) and the same procedures shall be performed after 30 minutes of data recording (blood gas sample collection, inspiratory and expiratory pauses). All data shall be analyzed offline using a software that will be able to compare three different methods to calculate Pendelluft magnitude based on the literature. After completion of the protocol, ventilatory parameters shall be returned to the original settings. If the patient becomes tachypneic during lower PS, the protocol shall be interrupted.
224041800|NCT03525106|BEHAVIORAL|Booklet|Receive positive psychology manual
224041801|NCT03525106|BEHAVIORAL|Exercise Intervention|Complete positive psychology exercises
224041802|NCT03525106|OTHER|Quality-of-Life Assessment|Ancillary studies
224041803|NCT03525106|OTHER|Survey Administration|Ancillary studies
224041804|NCT03525106|BEHAVIORAL|Telephone-Based Intervention|Participate in phone sessions
224041805|NCT01899625|BEHAVIORAL|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
224041806|NCT01899625|BEHAVIORAL|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
224041807|NCT01447368|DRUG|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
224041808|NCT01447368|PROCEDURE|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
224041809|NCT04262050|DEVICE|transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS)|
224041810|NCT02224599|BIOLOGICAL|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10\^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
224041811|NCT02224599|DRUG|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
224041812|NCT02224599|DRUG|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
224041813|NCT06007742|OTHER|parent-administered pediatric tuina|"Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention."
224041814|NCT05197036|PROCEDURE|Total Knee Arthroplasty|A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.
224041815|NCT00868426|DRUG|Budesonide/Formoterol Batch 1|Single, inhaled dose
224041816|NCT00868426|DRUG|Budesonide/Formoterol Batch 2|Single, inhaled dose
224041817|NCT00868426|DRUG|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
224041818|NCT04973020|DRUG|SHR6390、efavirenz|SHR6390 tablet single dose；Efavirenz single dose.
224299516|NCT04206228|DRUG|Placebo|The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
223478439|NCT00534651|DRUG|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
223478440|NCT06209918|DEVICE|bioptron light therapy|patient will be sitting on comfortable chair with the hand placed on an armrest in an extended and supinated position. Firstly, the skin over the wrist area will be exposed and cleaned by alcohol to achieve maximal penetration of light. Then, the bioptron device will be held perpendicular to the surface of the treated area, at a distance of 10 cm.
223478441|NCT06209918|DEVICE|wrist brace|will keep the wrist in a neutral position, not bent back or bent down too far
224041819|NCT00733304|DRUG|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
224041820|NCT02041260|DRUG|Cabozantinib|
224041821|NCT01627002|BIOLOGICAL|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
224041822|NCT01627002|OTHER|Placebo|Subcutaneous
223431923|NCT06660745|OTHER|telenursing-based family empowerment program|"The intervention was conducted in two sections. The first part included a one-day educational workshop conducted through Skype for the child and their caregiver and was planned to introduce the members of the intervention group to each other and provide information on how to deliver and receive the content. In the second part of the intervention, the content was prepared based on a scheduled plan. It was in the form of a 5-10-minute audio file, video, or educational text and was uploaded on the SendBig website. Once the upload is complete, a link is provided to the user. The link was sent to the phone numbers of children with cystic fibrosis and their caregivers so that they could watch the weekly content over three months. Once it was confirmed that the link had been received (acknowledged in the Cystic Fibrosis Companions group) and the content had been viewed, remote follow-ups were scheduled twice a week, on Sundays and Tuesdays between 6:00 PM and 8:00 PM, using Skype messenger."
223431924|NCT01914159|DRUG|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
223431925|NCT01577615|BEHAVIORAL|Patterned Experience|"* The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~* Nonnutritive sucking will be offered to infants.~* Blood work will be collected for inflammatory cytokines.~* Saliva will be collected for genetic analysis~* Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~* All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~* Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~* Follow up visits will occur at 2,6and 24 months corrected age."
223431926|NCT04476121|PROCEDURE|PRF application|PRF application into post-operative wound.
223431927|NCT04476121|DRUG|Nipas application|Nipas application into post-operative wound.
223431928|NCT03576534|OTHER|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
223431929|NCT03688958|DRUG|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
223431930|NCT03688958|DRUG|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
223431931|NCT03688958|DRUG|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
223431932|NCT03688958|DRUG|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
223431933|NCT02574702|PROCEDURE|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
223431934|NCT04512313|DRUG|Rocuronium 0,3mg/kg|Rocuronium 0,3mg/kg at induction
224041823|NCT03155373|DIAGNOSTIC_TEST|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
224041824|NCT03155373|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
223431935|NCT04512313|DRUG|Rocuronium 0,9mg/kg|Rocuronium 0,9mg/kg at induction
223431936|NCT01664832|DEVICE|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
223431937|NCT05002517|DRUG|Tociliziumab group|Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.
224041825|NCT03155373|DIAGNOSTIC_TEST|Pulmonary function tests|Pre and post-operative pulmonary function tests
224041826|NCT03155373|DIAGNOSTIC_TEST|Cardiac MRI|Pre and post-operative cardiac MRI
223431938|NCT05002517|DRUG|Methylprednisolone group|Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
223431939|NCT02589353|DRUG|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
223431940|NCT05264519|OTHER|foot bath intervention|Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
223478442|NCT00000204|DRUG|Buprenorphine|
223478443|NCT02576600|DEVICE|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
223478444|NCT02576600|OTHER|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
223478445|NCT02576600|DRUG|Propofol|TCI
224041827|NCT03155373|OTHER|Quality of life survey|Pre and post-operative quality of life survey (SF36)
224041828|NCT03155373|PROCEDURE|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
224041829|NCT03155373|PROCEDURE|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
224140220|NCT05270642|PROCEDURE|Microwave Thermal guided by Plan for Microwave Thermal Field system|When HCC patients undergo microwave ablation, the doctor will refer to the ablation plan provided by the system.If the plan is consistent with what the doctor thinks, follow the plan provided by the system. If the protocol is not consistent with what the doctor thinks, the doctor will revise the protocol.
224299517|NCT05338021|PROCEDURE|Intrawound administration of vancomycin after closure of the arthrotomy|After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.
223478446|NCT02576600|DRUG|Remifentanil|TCI
223478447|NCT04326374|DRUG|TransCon hGH|Once weekly subcutaneous injection
223478448|NCT04326374|DRUG|daily hGH|Once daily subcutaneous injection
224041830|NCT04498208|BEHAVIORAL|Physical Prehabilitation|First, an evaluation of patient's aerobic capacity, functional mobility, functional strength, ambulation, fall risk, and overall mobility will be done by a trained member of the research team. Based on their functional level and preexisting conditions, therapeutic exercises will be recommended to optimize their strength, endurance, flexibility, and functional mobility in preparation for surgery. Decisions about the interventions are based on the assessment, individual patient characteristics, environmental factors, surgical type, and monitoring of the client's response and progress. Weekly sessions are 30-45 minutes long to monitor the client's response and progress their program. Based on their response to exercise (evaluated also by 2 apps: Timed Walk App and Smart Metronome \& Tuner App), re-evaluation via the assessments described above, change their plan of care (alter frequency, resistance, exercises) or discontinuation of treatment could be decided.
224041831|NCT04498208|BEHAVIORAL|Stress Reduction Prehabilitation|Participants will have the opportunity to learn techniques for mindfulness that have been established to reduce stress and assist with pain management with a member of the research team. Patients will be offered to listen to audio recording of relaxation sessions. Each session contains a relaxation technique that the patient practices while listening to the recording. Then the technique is used the next as a baseline to introduce a new technique more advanced. For some patients who struggle with the techniques the program will be adapted. Patients will choose 2 or 3 techniques and work on them.
224140221|NCT04387318|DEVICE|Multimodal training|"IMT will be performed using the POWERbreathe® Medic Plus inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. The IMT wil be performed two times per week for 8 weeks.~NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
224140222|NCT04387318|DEVICE|IMT + Pulmonary Rehabilitation|"IMT will be performed using the POWERbreathe® Medic Plus (POWERbreathe Medic Plus ®, SP, BR) inspiratory training device for five sets of 10 repetitions each, with a one-minute interval between each set. The initial load set will be 30% of maximal inspiratory pressure (MIP), during the first two weeks to allow for an adjustment period. After that, load increases occurred as follows: 35% of MIP in week 3, 40% of MIP in week 4, 45% of MIP in week 5, 50% of MIP at week 6, 55% of MIP in week 7, and 60% of MIP in weeks 8.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
223431941|NCT03968250|BEHAVIORAL|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
223431942|NCT03407183|PROCEDURE|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
223431943|NCT01647919|DIETARY_SUPPLEMENT|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
223431944|NCT01647919|DIETARY_SUPPLEMENT|Placebo|4 capsules of placebo identical to cogniVida™ once a day
223431945|NCT03152825|PROCEDURE|PCI|percutaneous coronary intervention attempt
223431946|NCT06731686|OTHER|Retrospective study|Collection of children's datas
223431947|NCT00430352|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
223431948|NCT05177900|DEVICE|Study Tool Computer|Nonconventional pulses delivered with custom-ware designed by Boston Scientific
223431949|NCT02290600|DEVICE|Continuous Glucose Monitor|CGM sensor calibration individualization
223431950|NCT04383340|BEHAVIORAL|Mother-Infant Transaction Program|Parent sensitivity training for mothers of premature infants
223431951|NCT04383340|BEHAVIORAL|Treatment as usual|Standard hospital care and parental support
223431952|NCT05805085|DEVICE|Lens A|Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
223431953|NCT05805085|DEVICE|Lens B|Silicone Hydrogel Daily Disposable Toric Contact Lens for 15 minutes
223431954|NCT05451784|DRUG|PD1+ TILs (NUMARZU-001) product infusion|"The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~* Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~* Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction)."
223431955|NCT00501124|DRUG|Clevudine|
223431956|NCT00501124|BIOLOGICAL|Purified hepatitis B surface antigen|
223478449|NCT04858464|OTHER|Survey study|Patients will complete the mentioned questionnaires.
223478450|NCT02963324|DRUG|Ivermectin|
223478451|NCT03126149|DRUG|PF-06667272|Single ascending dose of PF-06667272
223478452|NCT03126149|OTHER|Placebo|Single dose of placebo
223478453|NCT00357942|DRUG|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
223478454|NCT00357942|DRUG|Placebo|Placebo mouthwash
223478455|NCT00357942|DRUG|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
224140223|NCT04387318|DEVICE|NMES + Pulmonary Rehabilitation|"NMES will be applied using an calibrated electrical stimulator (Neurodyn High Volt, IBRAMED, São Paulo/São Paulo, Brazil). The following parameters will be used: 50 Hz frequency, pulse duration of 400 µs, work cycle of 5 seconds ON and 15 seconds OFF (first month) adjusted for 10 seconds ON and 30 seconds OFF (second month) and maximum intensity tolerated during 2 times per week for 8 weeks.~Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks."
224140224|NCT04387318|DEVICE|Pulmonary Rehabilitation|Pulmonary Rehabilitation The pulmonary rehabilitation will consist of aerobic and resistance exercise during 8 weeks.
224299518|NCT06502197|PROCEDURE|Silastic Stenting|Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.
223431957|NCT01772849|BEHAVIORAL|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
224140225|NCT04260919|PROCEDURE|Chest physiotherapy|
224140226|NCT02831842|DRUG|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
224140227|NCT02831842|DRUG|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
224140228|NCT02831842|DRUG|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
224140229|NCT04072185|OTHER|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
224140230|NCT04238884|DRUG|Voriconazole preemptive genotyping strategy|The patients who finally receives voriconazole will be randomized to receive the dose according to a pharmacogenetic algorithm including CYP2C19 genotype and clinical and demographic information.
224140231|NCT04238884|DRUG|Voriconazole clinical practice|The patients who finally receives voriconazole will be randomized to receive the dose according to clinical practice
224140232|NCT02310906|DRUG|Placebo|SRP-4053 placebo-matching solution for IV infusion.
224140233|NCT02310906|DRUG|SRP-4053|SRP-4053 (golodirsen) solution for IV infusion.
224140234|NCT05287607|DIAGNOSTIC_TEST|Urine sample for carbonic anydrase (I) levels|Point of care diagnostic device used routinely for non-invasive estimation of serum bilrubin level.
224140235|NCT06248697|BIOLOGICAL|αPD1/CTLA4-MSLN-CAR T cells|BZE2209 is prepared by non-viral vector technology consisting of autologous CD3+T cells expressing mesothelin-specific chimeric antigen receptor (CAR), PD1 nanoantibody and CTLA4 antibody with dimethyl sulfoxide as medium. It can be used for direct intravenous infusion. Autologous CD3+ T cells were transfected with plasmids expressing anti-mesothelin-specific CAR, anti-PD1 nanoantibody and anti-CTLA-4 antibody by electroporation in vitro. Mesothelin-specific CAR is a single-domain antibody (VHH) derived from alpaca, which is composed of a binding domain and a CD28 and CD3ζ chain signal transduction domain.
223431958|NCT00827749|DEVICE|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
223431959|NCT05926752|DEVICE|SoLá therapy|SoLá therapy is a photobiomodulation device that works by stimulating mitochondria, soothing tense muscles, and promotes healing.
223431960|NCT05926752|OTHER|Pelvic floor physical therapy|Physical therapy is manual myofascial release, muscles stretches, and exercises designed to help myofascial pelvic pain
223431961|NCT04466761|DIETARY_SUPPLEMENT|Monosaccharide Powder|Monosaccharide powder dissolved in water.
223431962|NCT04466761|OTHER|Placebo Comparator|Placebo (cellulose powder).
223431963|NCT00819780|DRUG|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
224140236|NCT02680587|RADIATION|SBRT|SBRT (1-5 fractions) will be administered.
224140237|NCT00111930|DRUG|DHEA|
224140238|NCT05668676|DRUG|Prednisone arm|2 tabs of 20 mg prednisone per day during 7 days added to usual care medications
224140239|NCT05668676|OTHER|Usual care|Usual care alone as per European guidelines, which includes oxygen in case of hypoxia, low dose furosemide (40mg or daily dosage), and iv nitrates if no contra-indication.
224140240|NCT02786108|PROCEDURE|left gastric artery embolization|
224140241|NCT02786108|BEHAVIORAL|healthy diet and exercise|
224140242|NCT03084289|BIOLOGICAL|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
224140243|NCT03084289|BIOLOGICAL|MVA ME-TRAP|The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
224140244|NCT03779633|DRUG|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
224041832|NCT04498208|BEHAVIORAL|Cognitive Prehabilitation|Cognitive prehabilitation will consist on the daily use of Lumosity training program, an already existing free app built to increase memory skills. The program proposed by Lumosity is tailored to each patient. The use of Lumosity will be monitored at each in-person session. Patients will be expected to complete at least three 5-minute sessions of Lumosity training per day.
224041833|NCT04498208|BEHAVIORAL|Nutrition Prehabilitation|Nutrition prehabilitation will involve transitioning the patient to the Mediterranean diet with targets regarding hydration and the proportion of fruits, vegetables, whole grains, and healthy fats the patient will consume in a given day. This nutritional program is flexible, and it allows for specific physician and nutritionist-recommended dietary needs to be incorporated. The patient is also given tools to encourage success in healthier eating, including recipes, sample menus, healthy restaurant options, meal kit options, and local CSA box options
224041834|NCT00943774|OTHER|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
223431964|NCT00819780|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
224041835|NCT00000491|DRUG|aspirin|
224041836|NCT04236882|OTHER|Focus Group|Attend focus group
224041837|NCT04236882|BEHAVIORAL|Health Education|Receive educational material on healthy homes
224041838|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based sleep intervention
224041839|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based health coaching sessions
224041840|NCT04236882|OTHER|Internet-Based Intervention|Receive web-based counseling sessions
224041841|NCT04236882|OTHER|Interview|Complete interview
224041842|NCT04236882|OTHER|Questionnaire Administration|Ancillary studies
224041843|NCT05178134|BIOLOGICAL|Etvax|"Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl)."
224041844|NCT05178134|BIOLOGICAL|Etvax|Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.
224041845|NCT00596934|DRUG|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
223431965|NCT00819780|DRUG|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
223565239|NCT01952665|DEVICE|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
224041846|NCT00636688|BEHAVIORAL|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
224041847|NCT00636688|BEHAVIORAL|Control - general information|General information about healthy food choices and exercise
224041848|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
223431966|NCT03326128|DRUG|Bupropion Hydrochloride|Antidepressant that is also effective in smoking cessation
223565240|NCT01952665|DEVICE|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
223565241|NCT01120314|DRUG|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
223565242|NCT01511328|OTHER|HPV testing|Testing for Human Papilloma Virus
224041849|NCT01479933|DIETARY_SUPPLEMENT|Placebo|Inactive placebo
224041850|NCT01479933|DIETARY_SUPPLEMENT|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
224041851|NCT03509636|DRUG|Fluzoparib|Fluzoparib capsule will be given twice daily orally
224041852|NCT05533242|DRUG|Lu-177 labeled 6A10-Fab-fragments|The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
224041853|NCT04582370|BEHAVIORAL|theater program|10-week theory-based theater program designed to improve their physical functioning and reduce emotional stress.
224041854|NCT06799338|DRUG|Lenacapavir Injection|"Patients will be included if they initiated LEN from 20 June 2023 to 30 June 2024.~All collected data are routinely reported by clinicians in medical records. All clinical decisions All collected data are routinely reported by clinicians in medical records, and will be collected using a dedicated electronic case report form (eCRF) created on this purpose, to ensure confidentiality of data."
224041855|NCT04504357|BEHAVIORAL|Tablet based U=U app|"Tablet based app focusing on TasP/U=U videos on: a) the science of TasP/U=U including risks, (b) benefits to self (e.g. psychological benefits, ability to have children), (c) benefits to partners (e.g. secondary prevention), (d) benefits to society (e.g. AIDS-free generation), and (e) TasP self-efficacy, including viral load (VL) literacy, disclosure, and couples testing."
224041856|NCT04504357|OTHER|Text messages|Monthly text messages reinforcing intervention content
224041857|NCT05467800|DRUG|Canakinumab|Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles.
224041858|NCT06339567|DIAGNOSTIC_TEST|Thrombotic profile|several thrombotic biological marker will be dosed in blood. (C protein, S protein, CRP us, Factor VIII, TFPI , nAPCsr, SHBG, nTMsr)
224041859|NCT04331054|DRUG|2: Usual practice + SYMBICORT RAPIHALER|2 puffs bid during 30 days by inhalation
224041860|NCT04331054|OTHER|1: Usual practice|Usual practice
224041861|NCT04778345|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging after 18F-FDG PET/CT scan during 2 days and 1 week.
223431967|NCT00150800|DRUG|Brivaracetam|"* Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 10 mg and 25 mg~* Route of Administration: Oral"
223431968|NCT02389790|DRUG|MT-1303|
224299519|NCT04978064|BEHAVIORAL|e-health psychological counselling|"Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application My Plan. The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.~Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study)."
223431969|NCT06099132|DIAGNOSTIC_TEST|Electromyographic measurements|HD and bipolar EMG were assessed from gastrocnemius medialis (GM), soleus (SO) and tibialis anterior (TA) at seated position, ankle at 0°, during isometric submaximal effort and maximal effort, knee flexed (90°) and knee extended (0°)
224299520|NCT05845294|PROCEDURE|Routine Care|Routine care for patients undergoing colorectal cancer stoma
224299521|NCT05845294|PROCEDURE|Short-term structured psychological Care|Short-term structured psychological care for colorectal cancer stoma patients based on conventional care
224299522|NCT00393120|DRUG|INCB009471|100mg SR (sustained release) orally once daily
224299523|NCT00393120|DRUG|INCB009471|300mg SR (sustained release) orally once daily
224299524|NCT00393120|DRUG|Placebo comparator|Orally once daily
224299525|NCT03096847|DRUG|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
224299526|NCT03096847|DRUG|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer were treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient began on Study Day 1 and continued until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occured first.
224299527|NCT03096847|DRUG|goserelin|Premenopausal patients additionally received goserelin 3.6mg as monthly implant
223431970|NCT06895252|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
223431971|NCT06895252|OTHER|Anti inflammatory diet|The modified diet plan will be given to each study participant
223431972|NCT06895252|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
223431973|NCT06895252|OTHER|Sham diet|Dietary counselling alone
224041862|NCT04648904|RADIATION|Radiotherapy|A total dose of 26 Gy in 5 fractions will be given once daily over 5 consecutive weekdays (or within 10 consecutive weekday to allow for treatment delays, interruptions, logistical problems, scheduling issues and weekends/holidays).
224299528|NCT05329298|DRUG|BPI-361175|Subjects will receive BPI-361175 until disease progression
224299529|NCT04203875|DRUG|Orencia® (Abatacept)|Orencia® (Abatacept) will be administered once a week for 6 months subcutaneously (injection under the skin) with an option to continue to receive Abatacept weekly injections for an additional 6 months, for a total of 12 months if there is a positive response.
224299530|NCT06031987|DEVICE|CareSens N (iSENS)|Control group is asked to perform SMBG (4 times or more per day).
224299531|NCT06031987|DEVICE|Freestyle Libre (Abbott)|CGM group is asked to scan CGM (4 times or more per day).
224299532|NCT05162651|BEHAVIORAL|Contingency-management|In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
224299533|NCT05162651|OTHER|Enhanced usual care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
224299534|NCT02931045|DRUG|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
224299535|NCT02931045|DRUG|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
224299536|NCT00466973|DEVICE|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
224299537|NCT00466973|DEVICE|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
224299538|NCT00466973|DEVICE|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
224299539|NCT00466973|DEVICE|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
224299540|NCT00466973|DEVICE|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
224299541|NCT00466973|DEVICE|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
224299542|NCT01381263|BEHAVIORAL|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
223431974|NCT01258179|OTHER|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
223431975|NCT06767748|DRUG|GZR4|GZR4 s.c., once-weekly，treat-to-target dose
223431976|NCT06767748|DRUG|insulin degludec|insulin degludec s.c.,once-daily，treat-to-target dose
223478456|NCT00357942|DRUG|Placebo|Placebo solution for injection every 3 hour for 24 hours
223478457|NCT06440512|OTHER|Dark chocolate Intervention|The intervention involves daily consumption of 50 grams of dark chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
223431977|NCT06618261|DIETARY_SUPPLEMENT|Caffeine + Resistance exercise|Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
224041863|NCT06181266|DRUG|ZH9|ZH9 is a live attenuated S. enterica serovar Typhi ZH9 \[Ty2 ΔaroC ΔssaV\]), a differentiated novel microbial immunotherapy.
224041864|NCT05589064|BEHAVIORAL|Experimental: Dietetic counseling|Patients will receive dietary counselling to increase caloric and nutrient intake, stabilize glycemia, and optimize hydration.
224041865|NCT05589064|DIETARY_SUPPLEMENT|Active Comparator: Omega-3, vitamin D3 and creatine monohydrate|Patients will be prescribed dietary supplements which will be taken daily for 8 weeks, as per the supplement protocol.
223431978|NCT06618261|DIETARY_SUPPLEMENT|Placebo + Resistance exercise|Acute placeb intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
224041866|NCT05589064|BEHAVIORAL|Other : Physiotherapy treatment|Patients will receive weekly physiotherapy treatment.
223431979|NCT04190498|DIAGNOSTIC_TEST|Nocturnal oximetry|Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
223431980|NCT06903923|DRUG|GLP-1 receptor agonist|Participants prescribed a GLP-1 receptor agonist (semaglutide) by their physician will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
223431981|NCT06903923|BEHAVIORAL|Lifestyle Management|Participants receiving usual lifestyle interventions will be enrolled in this arm of the study. All participants will receive study provided calcium \& vitamin D supplement to support bone health and to reduce this as a confounding factor in overall outcomes
224041867|NCT05602948|BEHAVIORAL|'Run, Jump & Fun' intervention|"The intervention can be designed e.g. to consist of morning sessions each schoolday (except days with PE) or with different time slots at different weekdays. Activities are mainly conducted by school personnel, but can be supplemented by activity sessions during recess once a week lead by older students. Further, to create variation and inspire teachers, external PA parties, for example instructors from local sports clubs are invited to conduct sessions for the students and deliver teaching materials.~To align with the aim of the Danish school system, activities must have a pedagogical purpose.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation (see Move \& Learn for more details).~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
224041868|NCT05602948|BEHAVIORAL|'Move & Learn' intervention|"The physical activities in Move \& Learn are closely linked to the subject curricula. The bodily integrating in the learning task can vary between high bodily engagement and less demanding activities.~Both the Run, jump \& fun and the Move \& learn interventions have a set of strategies underpinning implementation. These strategies include; 1) Initial workshops and follow-up courses for school personnel to ensure ownership, empowerment and knowledge in order to implement the interventions, 2) Teaching materials and resources, like posters, booklets etc., 3) A set of core principles for the two different interventions to ensure that the interventions are implemented as intended, and 4) Mandatory school meetings for staff and heads to ensure motivation.~Both interventions will be grounded in Self-Determination Theory and all activities will be designed to be motivating and enjoyable for all children including those neither particularly fit nor enthusiastic about PA."
224299543|NCT01381263|OTHER|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
223431982|NCT03185754|PROCEDURE|Sublobar resection|Sublobar resection
223431983|NCT03185754|PROCEDURE|lobectomy|lobectomy
223431984|NCT03087097|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with malnutrition (MAM or SAM) who are in the rehabilitation phase of treatment and have failed to respond to at least 4 weeks of standard therapy.
223431985|NCT01712165|DIETARY_SUPPLEMENT|ANMUM Materna|
223431986|NCT01712165|DIETARY_SUPPLEMENT|Control (milk powder)|
223431987|NCT00923182|DRUG|alemtuzumab|
223431988|NCT02683382|DEVICE|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
223565243|NCT01537081|DRUG|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
223565244|NCT01537081|DRUG|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
223565245|NCT01537081|DRUG|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
223565246|NCT01022359|DEVICE|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
223565247|NCT01022359|DEVICE|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
223431989|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
223431990|NCT00792246|DRUG|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
223431991|NCT01921244|OTHER|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
223431992|NCT03784144|DIAGNOSTIC_TEST|Biering-Sorensen Test and Prone Plank Test|All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
223431993|NCT01748422|DRUG|Qutenza|Transdermal patch
223565248|NCT06373926|BIOLOGICAL|blood withdrawal|blood withdrawal
223431994|NCT02188472|DRUG|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
224041869|NCT05466123|BEHAVIORAL|Virtual Reality|Simulated travel destination or activity of the participants choosing that would otherwise be inaccessible
224041870|NCT06802523|RADIATION|Actinium Ac 225 Lintuzumab|Given IV
224041871|NCT06802523|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223431995|NCT02188472|DRUG|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
223431996|NCT02188472|DRUG|Placebo|Placebo: 2 tablets should be taken twice daily
223431997|NCT05001295|PROCEDURE|Physical Activity|Following the guidelines of NICE, the program to be followed by the IG is designed so that the intervention lasts 5 weeks, divided into 4 levels of progressive intensity, in which sessions of 30 to 45 minutes of aerobic exercise will be carried out 2 days a week. week.
223431998|NCT02089334|DRUG|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
224041872|NCT06802523|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224041873|NCT06802523|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224041874|NCT06802523|DRUG|Decitabine and Cedazuridine|Given PO
223431999|NCT03177434|DRUG|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
224299544|NCT00876018|OTHER|Nutritional supplement|Fortified nutritional powder
223432000|NCT03177434|DRUG|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
223432001|NCT02215863|BIOLOGICAL|Fluad and Prevenar13|
223432002|NCT02215863|BIOLOGICAL|Fluad|
223432003|NCT02215863|BIOLOGICAL|Prevenar13|
223432004|NCT01604863|DRUG|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
223432005|NCT01604863|DRUG|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
223432006|NCT01604863|DRUG|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
223432007|NCT01179841|BEHAVIORAL|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
223432008|NCT01179841|BEHAVIORAL|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
223565249|NCT04976673|DRUG|Triamcinolone Acetonide|The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
223565250|NCT04976673|PROCEDURE|Photodynamic Therapy|the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
223478458|NCT06440512|OTHER|White chocolate Intervention|The intervention involves daily consumption of 40 grams of white chocolate for a period of two weeks. The dark chocolate is provided in tablet form, and participants are instructed to consume it daily.
223565251|NCT00283426|DRUG|Soluble beta-1,3/1,6-glucan|
223565252|NCT05345574|DRUG|dexmedetomidine infusion|dexmedetomidine as anaesthetic adjuvant
223478459|NCT05849805|PROCEDURE|Intracalvaria bone marrow injection|Intracalvaria bone marrow injection Y-3 (dose was given at 32 ug/kg), continuous medication for 3 days
223478460|NCT05849805|OTHER|Conventional treatment|standard treatment and management according to related guidelines
223478461|NCT00631293|DIETARY_SUPPLEMENT|lactisole|administration of lactisole followed by placebo
223478462|NCT00631293|OTHER|placebo|administration of placebo followed by lactisole
223478463|NCT04499885|DEVICE|Paraffin oil gastric lavage|Gastric lavage will be initiated with 50 mL of Paraffin oil and 50 mL of sodium bicarbonate solution
223478464|NCT04499885|DEVICE|Gastric lavage with saline and sodium bicarbonate 8.4%|Gastric lavage with saline and sodium bicarbonate 8.4%
224041875|NCT06802523|DRUG|Venetoclax|Given PO
224041876|NCT01526070|DRUG|Intravitreal injection of Aflibercept|
224041877|NCT01214187|DRUG|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
224041878|NCT01214187|OTHER|Oxygen|Room air oxygen concentrations will be administered as placebo
224041879|NCT04534556|DEVICE|Active Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
224299545|NCT00876018|OTHER|Placebo|Un-fortified nutritional powder
224299546|NCT02918747|DRUG|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
224299547|NCT02918747|DRUG|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
223432009|NCT01179841|BEHAVIORAL|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
224041880|NCT04534556|DEVICE|Placebo Vagus Nerve Stimulation|During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
223432010|NCT05546216|OTHER|Determination of the Effect of Raised Supine Position and Back Support on Back Pain, Anxiety and Comfort Level in Coronary Angiography Patients|The study was conducted between 01 September 2021 and 30 January 2022 as a randomized single-blind interventional study with a pre-test post-test control group. The sample of the study consisted of patients who underwent coronary angiography. Data; The patient information form was collected with the visual analog scale, state anxiety and immobilization comfort scale. Back support was provided to the intervention group with a pillow at the exit of the angiography and the head of the bed was raised 30 degrees. Back pain intensity at 0, 2 and 4 hours, anxiety and comfort level at 0 and 4 hours were measured. The control group was given routine nursing care.
223432011|NCT02613039|DRUG|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
224041881|NCT02308007|DRUG|Terconazole|
223432012|NCT06620705|DEVICE|Left bundle branch area pacing|Pacing of the left bundle branch area using a transvenous pacemaker lead
223432013|NCT06620705|DEVICE|Biventricular pacing|Pacing of the right and left ventricle using transvenous pacemaker leads
223565253|NCT05345574|DRUG|remifentanil infusion|remifentanil as anaesthetic adjuvant
223565254|NCT02834585|OTHER|Ultrasound|
224041882|NCT02308007|DRUG|Metronidazole|
224041883|NCT02308007|DRUG|Terconazole/metronidazole|
224041884|NCT05781633|DRUG|eutidrone etoposide bevacizumab|Eligible patients received a regimen of eutidrone(30mg/m2/d,iv,d1-5,21d/cycle), etoposide(30mg/m2/d,iv,d1-3,21d/cycle), and bevacizumab (10mg/kg,d1,21d/cycle).At least 4 to 6 cycles were administered, and if patients had a response or stable disease, bevacizumab was used as maintenance therapy until disease progression or intolerable toxicity.MRI of the brain with contrast enhancement was performed at baseline and every 6 weeks after enrollment; thereafter, patients with stable disease or a response could be assessed at a reduced frequency to every 9 weeks; central nervous system and noncentral nervous system lesions were assessed according to RANO-BM criteria and RECIST v1.1 criteria until disease progression, respectively.
224041885|NCT03498846|PROCEDURE|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
224041886|NCT03498846|PROCEDURE|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
224041887|NCT02231125|DRUG|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
224041888|NCT02231125|DRUG|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
224041889|NCT02724124|OTHER|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
224041890|NCT02724124|OTHER|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
224041891|NCT02724124|OTHER|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
224041892|NCT02724124|OTHER|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
224041893|NCT02724124|OTHER|Control|No intervention
224041894|NCT04287842|DRUG|Desflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest.
223432014|NCT01355198|DIETARY_SUPPLEMENT|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
223432015|NCT01355198|DIETARY_SUPPLEMENT|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
223432016|NCT05108077|BIOLOGICAL|cytokine-induced killer cells|Autologous cytokine-induced killer cells injected intravenously
223565255|NCT02596958|DRUG|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
223565256|NCT00355537|DRUG|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
223565257|NCT00355537|DRUG|0.9% saline|Saline injection intramuscular every 2 weeks
223565258|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
223565259|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
224041895|NCT04287842|DRUG|Sevoflurane|Desflurane anesthesia is introduced. This provides complete suppression of animal responses to pain, fixation, tracheal intubation and cardiac arrest. After fixation of the animal in the supine position trachea is intubated and mechanic ventlation with air using an animal respirator is performed. Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
224041896|NCT04287842|PROCEDURE|Cardiac arrest|Cardiac arrest is induced by intrathoracic clamping of the supracardiac bundle of vessels by means of a special hook. Period of cardiac arrest and absence of ventilation lasts 10 min. The animal is then resuscitated by means of chest compressions and mechanichal ventilation with air. Cardiac activity and systemic blood circulation recovers within 1 min; spontaneous respiration will be resumed after a period of 4-6 min.
224041897|NCT06494020|OTHER|Task Practice combined with Transcutaneous Spinal Cord Stimulation( TcSCS)|Hand rehabilitative tasks ( for gross hand movement, grasp and pinch tasks) will be done by participants during which time the participant will receive TcSCS. This will be done three times a week for 60 minutes.
224041898|NCT03678103|DEVICE|INVSENSOR00029|Noninvasive pulse oximeter sensor
224041899|NCT00486798|DRUG|Quetiapine|
223565260|NCT01559259|DRUG|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
223565261|NCT01559259|DRUG|Ibuprofen|Two caplets of ibuprofen 200 mg
224041900|NCT00486798|PROCEDURE|Rating Scales|
224041901|NCT00486798|PROCEDURE|Self Assessment Form|
224041902|NCT00486798|PROCEDURE|Blood and urine samples|
224140245|NCT03779633|OTHER|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
224299548|NCT02918747|DRUG|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
224041903|NCT00486798|PROCEDURE|Sleeping pattern|
224041904|NCT00650065|DRUG|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
224299549|NCT02918747|DRUG|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
224299550|NCT02918747|DRUG|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
223432017|NCT05108077|OTHER|Standard treatment according to the Clinical protocols|Standard treatment of bladder/renal cancer according to the Clinical protocols
223432018|NCT02510105|DEVICE|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
223432019|NCT02510105|DEVICE|CT scan|
223432020|NCT02510105|DEVICE|Servo-i|
223432021|NCT02510105|DEVICE|- Intubation|
223432022|NCT02510105|DEVICE|Ventilation ( with an ICU conventional ventilator)|
223432023|NCT01993498|PROCEDURE|blood sampling|blood samples collection
223432024|NCT06621927|OTHER|Diet|The Ideal Food Pyramid, which has not been applied before, is used to observe disease activities and especially changes in intestinal microbiota in rheumatoid arthritis.
223432025|NCT06621927|OTHER|Control (Standard treatment)|We chose a control group to show the effect of the intervention we would apply to the diet group and did not apply any intervention to the control group.
223432026|NCT00792376|DRUG|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
223432027|NCT00792376|DRUG|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
223432028|NCT05720494|DRUG|JZP441|Oral study drug administered for up to 4 weeks
223432029|NCT05720494|DRUG|Placebo|Oral placebo administered for up to 4 weeks
223432030|NCT02402023|BEHAVIORAL|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
223565262|NCT01559259|DRUG|Placebo|Two caplets of placebo
224041905|NCT00650065|DRUG|Zyrtec® Tablets 10 mg|10mg, single dose fasting
224041906|NCT05614310|OTHER|Magnetic Resonance Imaging (MRI)|Participants will be asked to lie in the MRI scanner while we collect 3D T1- and T2-weighted images and a 3D FLAIR image to exclude pathology (e.g. stroke). Participants will ingest a glucose solution (75 g Dextrose) so dynamic glucoCEST images can be acquired to measure glucose uptake and clearance.
224041907|NCT05614310|OTHER|Blood Glucose Assessment|A blood testing meter will be used to measure the blood sugar levels before and after the scans. Normal reading for a nondiabetic person after fasting is 70-99 mg/dl (3.9-6 mmol/L). If abnormal blood sugar levels are detected (sugar levels outside the above normal range), the participant will no longer be eligible for the study and they will be withdrawn.
224041908|NCT05614310|OTHER|Positron Emission Tomography (PET)|Participants will be administered a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG) through a canula inserted into a vein in the arm or hand and asked to sit quietly for 1 h. After 1 h they will be asked to lie quietly and without talking in the PET scanner and a PET brain scan will be performed.
224041909|NCT05614310|OTHER|Cognitive Assessment|Participants will be asked to undertake two cognitive tests (the Alzheimer's Disease Assessment Scale ADAS-cog test and the Mini Mental State Examination test - MMSE). These are standard clinical tests used to determine cognitive dysfunction in Alzheimer's disease.
224041910|NCT03165539|DEVICE|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
224041911|NCT02316184|BEHAVIORAL|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
224041912|NCT02316184|BEHAVIORAL|Brief Advice|
224041913|NCT05645835|BEHAVIORAL|intervention|the digital meditation app will be installed on participants iPad or android. Lonely older adults will use the app five days a week for six weeks total. Neuroimaging will be performed before and after the intervention.
224041914|NCT05645835|BEHAVIORAL|waitlist control|Participants in the waitlist group will have to wait six weeks after being screened before being able to use the meditation app after the assessment of primary and secondary endpoints
224140246|NCT03022513|OTHER|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
224299551|NCT02918747|DRUG|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
224299552|NCT02918747|DRUG|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
224299553|NCT02918747|DRUG|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
224041915|NCT05645835|OTHER|No Interventions|No intervention. Only baseline fMRI and EEG assessment.
224041916|NCT03331653|OTHER|Dry Needling and Ischemic Compression at the Trigger Point|The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
224041917|NCT03331653|OTHER|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point|The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
224041918|NCT01260727|BIOLOGICAL|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
224041919|NCT01260727|BIOLOGICAL|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10\^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
224041920|NCT01260727|BIOLOGICAL|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
224041921|NCT01260727|BIOLOGICAL|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
224041922|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
224041923|NCT02563093|BIOLOGICAL|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
224041924|NCT02563093|BIOLOGICAL|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
224041925|NCT02563093|BIOLOGICAL|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
224041926|NCT01241552|BIOLOGICAL|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
224041927|NCT01241552|BIOLOGICAL|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
224041928|NCT01241552|BIOLOGICAL|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
224041929|NCT01241552|BIOLOGICAL|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
224041930|NCT01241552|DRUG|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
224140247|NCT02382783|OTHER|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
224140248|NCT03827590|DRUG|Test|three times a day for five days
224140249|NCT03827590|DRUG|Active Comparator Control 1|three times a day for five days
224140250|NCT03827590|DRUG|Active Comparator Control 2|three times a day for five days
224140251|NCT03827590|DRUG|Placebo|three times a day for five days
224140252|NCT05644379|DRUG|Cadonilimab Injection|Cadonilimab Injection, 6mg/kg, intravenous drip ,q2w,
224140253|NCT05644379|DRUG|Regorafenib|Regorafenib 80mg, po, orally once daily
224140254|NCT01892449|OTHER|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
224140255|NCT01892449|OTHER|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
224140256|NCT03987334|OTHER|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
224299554|NCT02918747|RADIATION|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
224041931|NCT05949151|PROCEDURE|dental implants (K1 line conical connection double thread, OXY, Italy)|Six dental implants inserted on the edentulous mandible
224041932|NCT05949151|DEVICE|Occlusense (Bausch GmbH & Co. KG)|sensor used to evaluate the equilibration of occlusal forces.
224041933|NCT05949151|DEVICE|"electromyography (EMG) (Nemus II)."|EMG recordings were accomplished by a computer electromyography-based data acquisition system
224041934|NCT05949151|OTHER|oral health-related quality of life (OHRQoL)|Oral Health-related Quality of Life (OHRQoL) was estimated by employing the Oral Health Impact Profile questionnaire which comprises nineteen multiple questions that were translated into Arabic.
224041935|NCT03715023|DRUG|PC786|PC786 suspension for inhalation
224041936|NCT03715023|DRUG|Placebo|Placebo solution for inhalation
224041937|NCT03715023|DRUG|SOC|Standard treatment for RSV infection at study site
224041938|NCT05881980|DRUG|Terbinafine Tablets|Terbinafine 250 mg/day
224041939|NCT05881980|DRUG|Itraconazole|Itraconazole 200 mg/day
224041940|NCT04622033|BIOLOGICAL|Brodalumab|brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
224041941|NCT05671913|DRUG|Ketamine|Treatment arm
224041942|NCT05671913|DRUG|Placebo|Control arm
224041943|NCT00528567|DRUG|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
224041944|NCT00528567|DRUG|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
224140257|NCT03987334|OTHER|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
224041945|NCT01264367|DRUG|Clevudine|30mg,QD
224041946|NCT01264367|DRUG|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
224041947|NCT01869257|DEVICE|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
224041948|NCT01869257|DEVICE|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
224041949|NCT00331812|PROCEDURE|Mitochondrial functions and oxidative stress|
224140258|NCT06177119|PROCEDURE|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
224140259|NCT06177119|DRUG|Placebos during SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning with the first SRP session.
224041950|NCT03455192|DRUG|Synbiotic Supplement|
224140260|NCT06177119|DRUG|Placebos after SRP|Amoxicillin and metronidazole placebos thrice a day for 14 days, beginning after the last SRP session.
224140261|NCT06177119|DRUG|Metronidazole during SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning with the first SRP session.
224140262|NCT06177119|DRUG|Amoxicillin during SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning with the first SRP session.
224140263|NCT06177119|DRUG|Metronidazole after SRP|Metronidazole 400 mg, thrice a day for 14 days, beginning after the last SRP session.
224140264|NCT06177119|DRUG|Amoxicillin after SRP|Amoxicillin 500 mg, thrice a day for 14 days, beginning after the last SRP session.
224140265|NCT01010854|DRUG|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
224140266|NCT03222219|PROCEDURE|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
224140267|NCT05409768|PROCEDURE|Short axis out of plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance short axis visualisation out of plane approaches.
224140268|NCT05409768|PROCEDURE|Anteroposterior short axis in plane|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance anteroposterior short axis visualisation in plane approaches.
224140269|NCT00363441|PROCEDURE|Intensity Modulated Radiotherapy|
224140270|NCT02818140|PROCEDURE|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
224140271|NCT02818140|PROCEDURE|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
224140272|NCT02818140|DRUG|Ropivacaine|
224140273|NCT02818140|DRUG|Saline|
224140274|NCT02818140|DEVICE|Ultrasound|
224140275|NCT04532073|OTHER|Eurythmy Therapy|A mindfulness-oriented movement therapy
224140276|NCT04532073|OTHER|Tai Chi|A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics
224140277|NCT04532073|OTHER|Standard Care|Treatment process that a clinician should follow for a certain type of patient
224140278|NCT02500602|DRUG|doxazosin|active medication
224140279|NCT02500602|DRUG|placebo|placebo pill
224140280|NCT00347035|DRUG|brimonidine|
223565263|NCT06220591|PROCEDURE|Superior trunk block|"The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots."
224041951|NCT03455192|DRUG|Placebo Oral Tablet|
224041952|NCT04658459|PROCEDURE|Proximal Interphalangeal Joint Arthroplasty with the Tactys Prosthesis|
224041953|NCT04586998|DEVICE|"Exhaled drug monitor Edmon"|Taking samples of exhaled breath every minute during elective surgery in comparison to blood samples taken at predefined time points.
224041954|NCT03240913|BEHAVIORAL|Baseline and Follow-up Surveys|(completed online)
224041955|NCT03240913|OTHER|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
224041956|NCT03240913|OTHER|Pamphlet|(usual care)
224041957|NCT03352011|BEHAVIORAL|Primary Care Brief Mindfulness Training|Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
224041958|NCT03352011|BEHAVIORAL|PTSD Psychoeducational Class|"The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies."
224041959|NCT02505581|DRUG|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
224140281|NCT00098020|DRUG|Isotretinoin|
224140282|NCT02823600|DEVICE|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
224140283|NCT04975542|OTHER|Osteopathic Manipulative Medicine|Manipulative therapies based on Osteopathic principles.
224140284|NCT04975542|OTHER|Sham|Light touch techniques to mimic to osteopathic treatment.
224140285|NCT01840228|DRUG|Micronized progesterone suppository|
224140286|NCT04027101|DRUG|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
224041960|NCT02505581|PROCEDURE|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
224041961|NCT02505581|DRUG|Ciprofloxacin 750 mg oral|An oral antibiotic pattern of ciprofloxacin (750 mg / 12h, 2 doses) the day before surgery.
224041962|NCT02505581|DRUG|Metronidazole 250 mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
224041963|NCT02505581|DRUG|Cefuroxime 1.5 g Intravenous|An intravenous antibiotic pattern of cefuroxime 1.5 g during anesthetic induction.
224041964|NCT02505581|DRUG|Metronidazole 1 g Intravenous|An intravenous antibiotic pattern of metronidazole 1 g during anesthetic induction.
224041965|NCT01338129|DIETARY_SUPPLEMENT|vitamin c|1000 mg of vitamin c for 45 days
224140287|NCT04027101|DRUG|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
224140288|NCT03703271|DRUG|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
224140289|NCT03703271|PROCEDURE|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
224140290|NCT00386490|DRUG|larazotide acetate|capsule for oral administration
224140291|NCT01954888|PROCEDURE|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
223432031|NCT02402023|BEHAVIORAL|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
223432032|NCT06050655|DEVICE|Lingual aligners|orthodontic treatment with lingual aligners
223432033|NCT04507802|DEVICE|Non invasive ventilation via helmet|Patients requiring long hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet
223432034|NCT04490642|OTHER|Questionnaire|Final version Childhood Bladder and Bowel Dysfunction for 5-12 years old questionnaire in Korean language to patients who never encountered beforehand in other available languages (Dutch, English).
223432035|NCT02832375|DRUG|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
223432036|NCT02832375|DRUG|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
224140292|NCT01954888|PROCEDURE|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
224140293|NCT05331456|DEVICE|Unilateral alveolar cleft repair|Early secondary alveolar cleft repair is performed in children with a unilateral alveolar cleft using eirther autologous bone or a calcium phosphate based putty
224140294|NCT01790789|BEHAVIORAL|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
224140295|NCT01790789|OTHER|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
223432037|NCT00356252|DRUG|mixed carotenoids|
223432038|NCT06628752|DEVICE|Deep brain stimulation|Stimulation through a device implanted bilaterally into deep brain structures.
223432039|NCT05157542|DRUG|Durvalumab|Day 1 and 22, 1500mg
223432040|NCT05157542|DRUG|nanoparticle albumin bound paclitaxel|Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
223432041|NCT05157542|RADIATION|low dose radiation therapy|10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
224041966|NCT01338129|DRUG|placebo|placebo pills
224041967|NCT05326425|DRUG|lazertinib(YH25448)|\- lazertinib 240mg(3tablets, 80mg/1tablet), once a day, oral, before disease progression
224041968|NCT02920086|BEHAVIORAL|Nutrition Education Program|"* The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~* Nutritional education will be provided to ICU patents' families by a dietitian~* Tracking of nutritional information by family~* Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
224041969|NCT02920086|OTHER|Decision Support Program|"* Families will be provided with a web-based decision support tool (My ICU Guide)~* Families will meet with the ICU medical team early in ICU stay to review goals of care"
224041970|NCT01132066|OTHER|tDCS|tDCS will lead to an increase in cortical excitability
224041971|NCT01132066|OTHER|Sham|Sham will provide identical subjective sensation as tDCS
223432042|NCT03817411|DRUG|Telatinib|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
223432043|NCT03817411|DRUG|Capecitabine|1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
223432044|NCT03817411|DRUG|Oxaliplatin|130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
223432045|NCT03817411|DRUG|Placebos|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
223432046|NCT00201461|DEVICE|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
223432047|NCT00201461|DRUG|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
223432048|NCT05311228|DRUG|Azithromycin Powder|Azithromicyn intravena for 14 days
223432049|NCT06350461|OTHER|Discontinuation of hypertonic saline (HS)|Discontinuation of current hypertonic saline (HS) therapy during 6-week study period.
224041972|NCT00631189|DRUG|Rosuvastatin|5mg oral
224041973|NCT00631189|DRUG|Pravastatin|40mg oral
224041974|NCT00631189|DRUG|Atorvastatin|10mg oral
224041975|NCT06227208|DEVICE|Continuous vital sign monitoring|Wireless monitoring system that provided continuous, non-invasive collection of their vital signs, including peripheral oxygen saturation (SpO2) and respiratory rate (RR), for up to 92 hours following surgery or until discharge. The respiratory rate was monitored via FDA-approved Isansys Lifetouch electrocardiogram (ECG) patch, which was placed on the left side of the chest. SpO2 levels were continuously recorded using the Nonin WristOx 3150, a wrist-mounted finger oximeter.
224041976|NCT01132612|DRUG|AIN457|AIN457A 150 mg powder for solution
224041977|NCT01132612|DRUG|Placebo|Placebo to AIN457A 150 mg powder for solution
224041978|NCT06111482|DEVICE|Intense pulsed light.|The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
223432050|NCT06350461|OTHER|Continuation of hypertonic saline (HS)|Continuation of current hypertonic saline (HS) therapy during 6-week study period. Therapy is taken at least once daily according to each participant's pre-existing, clinically prescribed regimen (e.g., daily, twice daily). The concentration of HS is according to clinical prescription (e.g., 7% sodium chloride or 3.5% sodium chloride) and at least 3%.
223432051|NCT05407428|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including ALS patients
223432052|NCT02486640|DRUG|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
223432053|NCT02486640|DEVICE|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect autoinjector.
223740389|NCT04155632|DRUG|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
223740390|NCT04155632|DEVICE|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
223740391|NCT00000296|DRUG|Cotinine fumarate|
223740392|NCT03914326|DRUG|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
223740393|NCT03914326|DRUG|Placebo (semaglutide)|Placebo tablets to be taken with water at the same time every morning in a fasting state
223740394|NCT02929823|DRUG|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
223740395|NCT02929823|DRUG|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
223740396|NCT02929823|DRUG|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
223740397|NCT06117384|GENETIC|Biomolecular profiling|Molecular and functional analysis of biospecimens, including tumor-normal Whole-exome sequencing, bulk and single-cell RNAsequencing, spatial proteomics, functional testing.
223740398|NCT04017585|DIETARY_SUPPLEMENT|diet containing gluten|gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to placebo for another 7 days
223740399|NCT04017585|DIETARY_SUPPLEMENT|Diet containing placebo|Placebo will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten for another 7 days
223740400|NCT05971108|DIAGNOSTIC_TEST|Elecsys® GAAD|Elecsys® GAAD is a CE marked in vitro diagnostic (IVD) multivariate index assay, intended as an aid in the diagnosis of early-stage HCC. It provides a semi quantitative result by combining in an algorithm the quantitative measurements of Elecsys® AFP (alpha-fetoprotein) and Elecsys® PIVKA-II (protein induced by vitamin K absence II) levels in serum and plasma, with gender and age. Clinical evidence showed that Elecsys® GAAD had high performance in detecting HCC (sensitivity 86.5%), particularly early stage (sensitivity 78.9%), with 91.4% specificity for both early and all stages, out-performing current standard of care (Chan et al. 2021). Elecsys® GAAD may be integrated into current surveillance practice to increase early-stage HCC detection rate, reduce unnecessary onward investigations and patient anxiety.
223740401|NCT03758144|DRUG|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
223740402|NCT05268133|DIETARY_SUPPLEMENT|Aronia|As described in experimental arm
223740403|NCT05268133|DIETARY_SUPPLEMENT|Control|As described in placebo comparator arm
223740406|NCT03695562|PROCEDURE|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
223740407|NCT06181097|DEVICE|negative pressure wound therapy|The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.
223740408|NCT06181097|OTHER|standard dressing|The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
223740409|NCT00758082|DEVICE|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
223740410|NCT00758082|DEVICE|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
223740411|NCT05276570|DRUG|ARO-RAGE|single or multiple doses of ARO-RAGE by inhalation of nebulized solution
223740412|NCT05276570|DRUG|Placebo|calculated volume to match active treatment by inhalation of nebulized solution
223740413|NCT05855005|DEVICE|DTC Hearing Aids|DTC hearing aid programmed to the individual participant.
224140296|NCT02336139|DRUG|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
224140297|NCT03475901|OTHER|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
224140298|NCT05126940|DIAGNOSTIC_TEST|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis|Patients were placed in a semi-recumbent or supine position depending on their respiratory tolerance. For each side of the chest, 4 zones have to be assessed : 2 anterior and 2 lateral. The operator should calculate the number of B-lines when present .
223432054|NCT02247635|BEHAVIORAL|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
223432055|NCT06620224|DEVICE|Virtual Reality|we only use single group in this study, before the acupuncture treatment, let the participant wear the virtual reality to realize the course of the acupuncture treatment
223432056|NCT00084318|BIOLOGICAL|cetuximab|400 mg/m\^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m\^2 intravenously over 60 minutes in weeks 2 through 7.
223432057|NCT00084318|DRUG|cisplatin|30 mg/m\^2 intravenously infused over over 60 minutes in weeks 2 through 7.
223432058|NCT00084318|DRUG|docetaxel|15 mg/m\^2 intravenously infused over 30 minutes in weeks 2 through 7.
223432059|NCT00084318|RADIATION|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
223432060|NCT02290236|DEVICE|Pulseoximetry|Peripheral saturation will be recorded continuously
223432061|NCT04477590|DRUG|EXERCISE TRAINING WITH OR WITHOUT MEDICATION|A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
223432062|NCT06575179|DRUG|Dexmedetomidine low-dose|The low-dose dexmedetomidine group received a 75 μg/h loading dose over 15 minutes, followed by 60 μg/h maintenance infusion intravenously.
223565264|NCT06220591|PROCEDURE|Clavipectoral fascial plane block|"The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle."
223565265|NCT06442358|DEVICE|Pulsenmore ES home ultrasound device|Pulsenmore ES device is a portable home used ultrasound device which allow the patient to perform an ultrasound scan from the comfort of their home under the supervision of a healthcare provider
223565266|NCT06002555|DRUG|Apraglutide|Peptide analogue of GLP-2
223565267|NCT04191759|DIAGNOSTIC_TEST|Test-Retest reproducibility|Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
223565268|NCT04098432|DRUG|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
223565269|NCT04098432|RADIATION|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
223565270|NCT05969756|DRUG|Fluoride varnish|Thirty-eight permanent molars will receive 5% sodium fluoride varnish application every three months
223565271|NCT05969756|DRUG|Conventional etch and rinse sealant|Thirty-eight permanent molars will receive conventional etch and rinse sealant
223565272|NCT05969756|DRUG|Self-etch sealant|Thirty-eight permanent molars will receive self-etch sealant
223565273|NCT05142254|DRUG|Tadalafil|2.5-5 mg/day
223565274|NCT05142254|DRUG|Hydroxyurea|20 mg/kg/day
223565275|NCT05142254|DRUG|Placebo|identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.
223565276|NCT05949970|PROCEDURE|Radiofrequency denervation of the lumbar facet joint|Radiofrequency denervation of the medial branch of the dorsal ramus of the lumbar facet joint with a three-tined expandable needle.
223565277|NCT00113204|DRUG|IPI-504|
223565278|NCT01009944|DRUG|Lisinopril, Atenolol|once a day for 14 weeks
223740414|NCT04482842|DEVICE|Gene detection (CYP2C9*3, VKORC1)|Warfarin is administered at the recommended dose by detecting CYP2C9\*3 and VKORC1 gene polymorphismsand. The doctor adjusts the dosage according to the fluctuation of INR value in time.
223740415|NCT04482842|DRUG|Warfarin Sodium|Warfarin is administered at a gene-guided dose or at a regular dose.
223740416|NCT06441175|OTHER|Intubation device order|"D-V group: the group that performs direct laryngoscopy first and then videolaryngoscopy.~V-D group: the group that performs video laryngoscopy first and then directlaryngoscopy."
223740417|NCT06427603|BEHAVIORAL|physical activity|workshops and mobile apps: break sedentary behavior by activity breaks
223432063|NCT06575179|DRUG|normal Saline|The control group received volume-matched 0.9% saline infusions at identical rates.
224041979|NCT06111482|DEVICE|Radiofrequency microneedling device|The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
224041980|NCT06111482|DEVICE|Radiofrequency device|The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
224041981|NCT06111482|DEVICE|Combined energy devices|The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.
223432064|NCT06575179|DRUG|Dexmedetomidine high-dose|The high-dose dexmedetomidine group received a 150 μg/h loading dose over 15 minutes, followed by 120 μg/h maintenance infusion intravenously.
223432065|NCT00754208|DRUG|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
223432066|NCT04627532|DRUG|PF-07304814|Participants will receive PF-07304814
223432067|NCT04627532|DRUG|Placebo|Participants will recieve placebo
223432068|NCT03064854|DRUG|PDR001|Powder for solution for infusion
223432069|NCT03064854|DRUG|Cisplatin|Intravenous infusion
224041982|NCT00729781|DEVICE|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
224041983|NCT02252536|DRUG|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
224041984|NCT02252536|DRUG|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
224041985|NCT04608513|DRUG|ACT-1014-6470|Soft capsules for oral administration
224041986|NCT04608513|DRUG|Placebo|Soft capsules for oral administration
224041987|NCT03876990|DIAGNOSTIC_TEST|Multiplex PCR|Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
224041988|NCT03876990|DIAGNOSTIC_TEST|Current strategy alone|Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
224041989|NCT05942430|PROCEDURE|Autologous costal osteochondral transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Trim the autograft according to the size of the lesion;~5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;~6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
224299555|NCT05195866|DIAGNOSTIC_TEST|CRP POCT (C-reactive protein point of care test)|"CRP POCT equipment will be supplied at healthcare centers, along with a short training in use and interpretation supporting the clinical evaluation of the child. It will be communicated that CRP levels less than 10 indicate that the disease is not severe, and antibiotics is most likely not needed, if between 10 and 50, that antibiotics might be needed, and if more than 50 that it is likely that they are needed. With CRP between 10-50 the HCW are instructed to take the clinical picture into account together with the value of the test.~The training will also include knowledge of CRP pharmacodynamics and cases where a low CRP might need to be interpreted cautiously, e.g. a history of fever lasting less than 24 hrs. HCWs will be instructed to use CRP POCT for all patients in the intervention group and use the information to guide diagnosis and treatment choice. We will use Aidian (Copenhagen, Denmark) QuickRead go CRP POCT set-up."
223432070|NCT03064854|DRUG|Gemcitabine|Intravenous infusion
223432071|NCT03064854|DRUG|Pemetrexed|Intravenous infusion
223432072|NCT03064854|DRUG|Carboplatin|Intravenous infusion
223740418|NCT03226392|DRUG|QAW039|QAW039 once daily
224041990|NCT05942430|PROCEDURE|Autologous iliac osteoperiosteal transplantation|"Operating steps:~1. Arthroscopic examination of the size and location of the talar osteochondral lesion;~2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.~3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;~4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;~5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer."
224041991|NCT02777229|DRUG|Dolutegravir 50 mg|1 tablet once a day
224041992|NCT02777229|DRUG|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
223432073|NCT03064854|DRUG|Paclitaxel|Intravenous infusion
223432074|NCT03064854|DRUG|Canakinumab|Subcutaneous injection
223432075|NCT06667154|DRUG|Low-dose nivolumab combined with platinum-based doublet chemotherapy|Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
223432076|NCT01113645|PROCEDURE|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
223740419|NCT03226392|DRUG|Placebo|Placebo once daily
223432077|NCT03577977|DRUG|Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)|Betaferon was injected subcutaneously as prescribed by the treating physician.
223432078|NCT02893176|DRUG|macitentan|
223432079|NCT02893176|DRUG|placebo (for macitentan)|
224041993|NCT02777229|DRUG|Efavirenz 400 mg|1 tablets once a day
224041994|NCT04939519|BEHAVIORAL|Text-Messaging (TM)|"Participants in the TM condition will receive HIPAA-compliant bidirectional text messages. These texts will include a brief message alerting patients that they are eligible to receive the vaccine and asking participants if they would like to schedule a vaccine. Participants who reply yes will receive an additional message with information about how and where to register for the vaccine. This information will vary depending on local availability. Participants who reply no will receive a text requesting they contact their local clinic when they decide to receive the vaccine."
224041995|NCT04939519|BEHAVIORAL|Patient Navigation (PN)|Participants in the PN condition will receive a message alerting them that a Community Health Worker will contact them to assist with the process of scheduling a vaccine. At this time the participant has the option to opt-out of this follow up phone call. The patient navigation from the Community Health Worker includes practical advice in addressing barriers to vaccination such as logistics and transportation, as well as fear, skepticism, and hesitancy.
224041996|NCT05107804|OTHER|Exercise+CR|Exercise with caloric-restriction
224041997|NCT05107804|OTHER|Light Conditioning|Light Conditioning Exercise
224041998|NCT02236884|PROCEDURE|no-scar transanal total mesorectal excision(TME)|
224041999|NCT04044183|BEHAVIORAL|Active Brains 1|Active Brains uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The Active Brains sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal \& coping, and growth enhancement). The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a digital monitoring device (i.e., Fitbit) for recording of physical activity.
224042000|NCT04044183|BEHAVIORAL|Active Brains 2|"This active comparison condition controls for the effect of time spent, group member support/feedback, and interventionist support/feedback. The original HEP was adapted to provide population-specific information on chronic pain and MCI/MRP symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight, and Medical appointments). The HEP program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The HEP is conducted in the same format as Active Brains-Fitbit but are not taught the mind-body, walking, or cognitive-behavioral skills. HEP participants are encouraged to set lifestyle goals instead of quota-based walking goals aided by the Fitbit as in the Active Brains-Fitbit condition."
223432080|NCT03756727|DRUG|Ascorbic Acid|Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
223432081|NCT03756727|DRUG|Saline|Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
223432082|NCT02884557|OTHER|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
223432083|NCT00000592|PROCEDURE|blood transfusion|
223740420|NCT02963207|OTHER|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
224042001|NCT01438151|DRUG|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
224042002|NCT01486641|PROCEDURE|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
224042003|NCT05785572|PROCEDURE|supraescapular nerve radiofrequency|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
224042004|NCT05785572|PROCEDURE|interescalenic braquial plexus|supraescapular nerve radiofrequency or interescalenic braquial plexus for pain control in shoulder arthroplasty surgery
224042005|NCT00551551|OTHER|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
224042006|NCT00551551|OTHER|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
224042007|NCT05834686|BIOLOGICAL|HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-positive ABC
224042008|NCT04537273|OTHER|Descriptive and analytical|
224042009|NCT00706550|BIOLOGICAL|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
224042010|NCT00706550|BIOLOGICAL|Placebo|Placebo
223740421|NCT02963207|OTHER|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
223432084|NCT02339129|DRUG|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
223432085|NCT02339129|DRUG|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
223432086|NCT00212472|DRUG|Factor VIII concentrates|To be determined at the discretion of the investigator.
223432087|NCT00212472|OTHER|Low-dose treatment|50 FVIII u/kg three times a week.
223432088|NCT00212472|OTHER|High-dose treatment|200 FVIII u/kg per day.
224042011|NCT05671783|OTHER|Hemodynamic observation of the patients.|"For the purposes of this study, we defined intraoperative hypotension as a decrease in mean blood pressure of 30% from baseline for a minimum of 5 minutes, including induction and maintenance of anesthesia. The measuring blood pressure method (noninvasive or invasive) depended on the surgical intervention's invasiveness and the patient's cardiac performance.~As soon as the patients entered the PACU, the responsible nurses started the standard monitoring. Anesthesiologists constantly oversee all actions based on the patient's condition. Clinical observation for respiratory and gastrointestinal problems and all disorders were monitored. When in room air SO2 was \<94, we started oxygen treatment with a 4 liter/minute nasal cannula, and in cases of nausea antiemetic was administered. The Modified Aldrete Score was used to discharge the patent."
224042012|NCT02220309|DRUG|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
224042013|NCT00169520|DRUG|docetaxel|
224042014|NCT00169520|DRUG|SB-715992|
224042015|NCT01026142|DRUG|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
224042016|NCT01026142|DRUG|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
224042017|NCT01026142|DRUG|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
224140299|NCT04250376|DEVICE|Focused Transcranial Ultrasound|The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).
224299556|NCT01516866|PROCEDURE|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
224299557|NCT05009966|DRUG|SYSA1801 for injection|SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
224140300|NCT02476357|DEVICE|Harmonic scalpel|
224140301|NCT01295580|DEVICE|ARTZ|Hyaluronic acid (five 2.5 mL injections)
224140302|NCT01295580|DEVICE|DUROLANE|Hyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)
224299558|NCT00387920|DRUG|sunitinib malate|Given orally
223432089|NCT06590025|BEHAVIORAL|INtegral Cognitive REMediation program|This comprehensive functional remediation program includes a traditional CR component with a specialized therapist (based on the compensation model) and a CCT component adapted to the difficulties of each patient. The inclusion of both aspects allows adapting the intervention to the present difficulties by forming new strategies with compensation techniques and promoting translation to everyday life. Therefore, the intervention aims at improving cognitive functioning (beyond a mere training) so as to facilitate the improvement and maintenance of psychosocial functioning for patients with MDD.
224042018|NCT01026142|DRUG|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
224042019|NCT00846885|DRUG|Sumatriptan Succinate|100 mg Tablet
224042020|NCT00846885|DRUG|Imitrex®|100 mg Tablet
224042021|NCT06456996|COMBINATION_PRODUCT|Multi-component intervention package|"1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;~2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);~3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);~4. Health education to smokers for smoking cessation;~5. Health education to individuals with mental health issues;~6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;~7. To actively include individuals whose blood pressurei s higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;~8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;~9. Pay-for-population mechanism for medical practitioners."
224042022|NCT01549366|DEVICE|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
224140303|NCT02482441|DRUG|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
224140304|NCT02482441|DRUG|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
224299559|NCT00387920|OTHER|pharmacological study|Correlative studies
224140305|NCT01222572|RADIATION|Stereotactic boost|
224140306|NCT01222572|RADIATION|Conventional RT|
224140307|NCT01222572|DRUG|Etoposide|
224140308|NCT01222572|DRUG|Cisplatin|
224140309|NCT00303758|DRUG|cisplatin|
224140310|NCT00303758|DRUG|fluorouracil|
224140311|NCT00303758|DRUG|gemcitabine hydrochloride|
224140312|NCT00303758|DRUG|leucovorin calcium|
224140313|NCT01481090|PROCEDURE|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
224299560|NCT00387920|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
224299561|NCT00387920|OTHER|laboratory biomarker analysis|Correlative studies
224299562|NCT01774825|DIETARY_SUPPLEMENT|IQP-CL-101|2 softgels twice a day
224299563|NCT01774825|OTHER|Placebo|2 softgels twice a day
223432090|NCT06590025|BEHAVIORAL|Psychoeducation for depression|Psycho-education refers to educating individuals about depression and the various treatment options. It is a form of therapy that aims to provide individuals with the knowledge and skills to manage their mental health symptoms effectively.
224042023|NCT01549366|DEVICE|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
224042024|NCT03118349|DRUG|MVT-1075|MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
224042025|NCT03118349|DRUG|MVT-5873|MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
224042026|NCT01068925|DRUG|GSK1349572|"1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
223432091|NCT03140072|DRUG|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
223432092|NCT03140072|DRUG|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
223565279|NCT03542903|DEVICE|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
223565280|NCT03601039|DEVICE|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
223565281|NCT02150551|BIOLOGICAL|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; \<18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :\> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : \>34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
223565282|NCT05577377|BEHAVIORAL|Orgasmic Meditation|Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
223565283|NCT05683938|DEVICE|Intermittent self-catheterisation|GentleCath™ Air intermittent catheter
224042027|NCT05915897|DIAGNOSTIC_TEST|Specimen Donation|blood donation
224042028|NCT00816309|DEVICE|Acapella Physiotherapy|twice daily- around 20 minutes
224042029|NCT02761746|BEHAVIORAL|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
224042030|NCT02911090|OTHER|Data Registry|Data Registry
224042031|NCT04713202|DRUG|Telotristat ethyl|Telotristat Ethyl, 250mg
224042032|NCT04713202|DRUG|Peptide Receptor Radionuclide Therapy|Peptide Receptor Radionuclide Therapy
224042033|NCT04713202|OTHER|Placebo|Placebo
223565284|NCT06343818|OTHER|The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff|Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
223565285|NCT00907608|DRUG|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
223565286|NCT01147887|DRUG|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
223740422|NCT05766644|OTHER|Education|An 8-week program providing educational materials via a mobile app for chronic kidney disease management. Materials consist of videos, card news, and live online seminars with a Q\&A session. Topics are on general disease information, nutrition, and exercise.
223740423|NCT01358591|DIETARY_SUPPLEMENT|High calcium milk|High calcium milk (9 mg/kgBM)
223740424|NCT01358591|DIETARY_SUPPLEMENT|Control|Regular Milk
224042034|NCT05509985|BIOLOGICAL|ASKG315|Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
223432093|NCT04982458|DIAGNOSTIC_TEST|68Ga-FAPI|68Ga-FAPI injection is a radiopharmaceutical used for positron emission tomography (PET) diagnosis. This product is used for PET, qualitative and localized diagnosis and evaluation of abnormal expression of fibroblast-activated protein in focus-associated fibroblasts.
223432094|NCT03301740|OTHER|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
224042035|NCT03220087|OTHER|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
223432095|NCT03301740|OTHER|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
223432096|NCT06621043|DRUG|NTI164|Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC, administered orally starting with a dose of 5 mg/kg, titrated up to 20 mg/kg based on tolerance, followed by a maintenance phase at the maximum tolerated dose, and concluding with a gradual dose reduction.
223432097|NCT05496413|DEVICE|STARSTIM|In order to evaluate the working memory ability of schizophrenic participants, a task was designed that needs to be performed by them. Firstly, a stimulus of six different color circles of same size in a gray background would be given for 500ms. This would be followed by 2000ms delay phase and then a test array would be appeared. The test array would be exactly same to the stimulus array but with or without change in color of only one circle. The test array would appear on the screen till the participants record their response and they would be asked to respond if the test array matches to the stimulus or not.
223432098|NCT03707119|OTHER|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
223432099|NCT01869621|DRUG|Metformin|6 days treatment with metformin to steady-state
223432100|NCT00687349|BEHAVIORAL|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
223432101|NCT01852552|DEVICE|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
223565287|NCT02421406|BEHAVIORAL|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
223565288|NCT02421406|BEHAVIORAL|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
223565289|NCT01530035|OTHER|physical training|training
224042036|NCT05570474|DIETARY_SUPPLEMENT|Protein drink supplementation|Daily drink containing 20 grams of whey protein, dissolved in 200mL water.
223565290|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
223565291|NCT00185380|DRUG|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
223565292|NCT00185380|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
223565293|NCT00515658|DEVICE|theta-burst rTMS|
223565294|NCT00680355|DIETARY_SUPPLEMENT|golden rice|An acute dose of cooked golden rice containing \~ 1 mg of ß-carotene
223565295|NCT00680355|DIETARY_SUPPLEMENT|corn oil 0g|0 g of corn oil in the golden rice meal
223565296|NCT00680355|DIETARY_SUPPLEMENT|corn oil 10g|10g corn oil in the golden rice meal
223565297|NCT00680355|DIETARY_SUPPLEMENT|coren oil 5 g|golden rice meal with 5 g corn oil
223565298|NCT02199314|DRUG|Desflurane|
223565299|NCT03252444|OTHER|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
223565300|NCT03252444|OTHER|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
223565301|NCT05978388|DIAGNOSTIC_TEST|Analysis of coronary CT Angiography and CAC scoring at the time of catheter ablation|Analysis of coronary CT angiography and CAC scoring and initiation of relevant derived treatment at the time of catheter ablation.
223565302|NCT01368172|BEHAVIORAL|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
223565303|NCT04826848|DIAGNOSTIC_TEST|Lactate|We will evauate the lactate clearance of the patients in 6 hours period. Lactate clearance = \[(Initial lactate - 6th hour lactate) / Initial lactate\] \* 100
224042037|NCT05570474|DIETARY_SUPPLEMENT|Placebo|Daily placebo drink
224042038|NCT00334555|OTHER|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
224042039|NCT00334555|OTHER|partner delivered meds|patient given meds to give to her partner
224042040|NCT00334555|OTHER|field intervention|health worker finds partners
223432102|NCT01852552|PROCEDURE|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
224042041|NCT06558786|OTHER|EORTC QLQ-C30 questionnaire|"The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status/quality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) not at all, (2) a little, (3) quite a bit, and (4) very much, except for the global health status/quality-of-life scale, which has response options ranging from (1) very poor to (7) excellent. For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life."
224042042|NCT06558786|OTHER|QLQ-OGS25 questionnaire|The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.
224042043|NCT06027723|DRUG|Nicotine|Nicotine delivered through a vape
224042044|NCT06027723|OTHER|Placebo|Placebo nicotine-free vaping liquid delivered through a vape
224042045|NCT02896179|DEVICE|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
224140314|NCT04946799|BEHAVIORAL|Low-intensity training combined with blood flow restriction (LI-BFR)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve), with compression belts attached on both thighs, during exercise the belts are inflated with 50% of the participant's arterial occlusion pressure. Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. The compression belt is deflated during the rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
224140315|NCT04946799|BEHAVIORAL|High-intensity aerobic exercise (HI)|Participants (n=20) receives high intensity aerobic exercise intervention on a cycle ergometer (at 70% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
224140316|NCT04946799|BEHAVIORAL|Low intensity exercise (LI)|Participants (n=20) receives low intensity exercise intervention on a cycle ergometer (at 40% of heart rate reserve). Exercise is conducted during daytime, 3 times per week, for 12 weeks at Nanjing Maigaoqiao Community Health Service Center. Each exercise session contains 6 sections, each section lasts for 5 minutes, followed with a 1-minute rest period. At least two trained research assistants supervise the exercise in each session. Instant heart rate during exercise is measured with heart rate monitor for each participant.
224140317|NCT04353336|DRUG|Chloroquine or Hydroxychloroquine|Chloroquine or Hydroxychloroquine
224140318|NCT04733846|OTHER|data collection|Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
223432103|NCT01037127|DRUG|GSK1120212|Daily oral dosing
223432104|NCT05740176|DEVICE|Anterior Cervical Discectomy and Fusion|Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
223432105|NCT03440762|BEHAVIORAL|AF awareness education|Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
224140319|NCT00432094|DRUG|carboplatin|Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
224140320|NCT00432094|DRUG|etoposide|600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
224140321|NCT00432094|DRUG|ifosfamide|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
224140322|NCT00432094|DRUG|paclitaxel|225 mg/m\^2 intravenous over 3 hours on Day -7.
224140323|NCT00432094|DRUG|thiotepa|150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
224140324|NCT00432094|PROCEDURE|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (\< 4 x 10\^6 CD34+ cells/kg)
224140325|NCT00432094|DRUG|Mesna|2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
224140326|NCT00432094|BIOLOGICAL|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
223565304|NCT04540666|DRUG|Propofol|Targeted Controlled Propofol Infusion will be set at 1 micro gram/ml.
223565305|NCT03842969|DRUG|RO7234292 (RG6042)|Intrathecal injection
224140327|NCT05374148|BEHAVIORAL|health education|health education to prevent respiratory diseases among workers
224140328|NCT04315480|DRUG|Tocilizumab|single intravenous administration 8mg/Kg
223432106|NCT02622373|DEVICE|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
223432107|NCT03071731|DRUG|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
223432108|NCT03071731|DRUG|Placebos|Administration of a nebulized placebo before the administration of a functional test
223432109|NCT00826592|OTHER|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
223432110|NCT00274079|DRUG|SPIRIVA|
223432111|NCT00334633|DRUG|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
223432112|NCT00962364|BIOLOGICAL|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
223432113|NCT05930028|DRUG|Fimasartan|Subjects take the investigational products once a day for 8 weeks.
223432114|NCT05930028|DRUG|Ezetimibe/Atorvastatin|Subjects take the investigational products once a day for 8 weeks.
223432115|NCT05930028|DRUG|Fimasartan Placebo|Subjects take the investigational products once a day for 8 weeks.
223432116|NCT05930028|DRUG|Ezetimibe/Atorvastatin Placebo|Subjects take the investigational products once a day for 8 weeks.
223565306|NCT03347526|DRUG|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
223565307|NCT03347526|DRUG|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
223565308|NCT03347526|DRUG|Vigabatrin|oral
223565309|NCT05470179|DEVICE|Hybrid hyrax distalizer|class 2 Angle malocclusion
223565310|NCT05470179|DEVICE|Pendulum distalizer|class 2 Angle malocclusion
223565311|NCT02187276|DRUG|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
223565312|NCT00464373|DRUG|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
223432117|NCT05871398|DRUG|Tegoprazan|Novel, potent, and highly selective potassium-competitive acid blocker which was developed in Korea
223565313|NCT00464373|DRUG|Placebo|4ml NaCl 0.9%
223565314|NCT05979220|DRUG|Dalpiciclib combined with Letrozole|A multicenter, single arm, prospective Phase II clinical study
223565315|NCT00046293|DRUG|Reopro|
223565316|NCT00046293|DRUG|Retrovase|
223565317|NCT05296824|PROCEDURE|Cryoballoon ablation for the treatment of atrial fibrillation|Cryoballoon ablation for the treatment of atrial fibrillation
223565318|NCT01364883|BIOLOGICAL|Vaccination Schedule One|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
223565319|NCT01364883|BIOLOGICAL|Vaccination Schedule Two|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
223565320|NCT01364883|BIOLOGICAL|Vaccination Schedule Three|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
223565321|NCT01364883|BIOLOGICAL|Vaccination Schedule Four|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
223565322|NCT01364883|BIOLOGICAL|Vaccination Schedule Five|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
223565323|NCT01364883|BIOLOGICAL|Vaccination Schedule Six|Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
223565324|NCT01364883|BIOLOGICAL|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
224042046|NCT02896179|DEVICE|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
223432118|NCT05871398|DRUG|Placebo|Placebo
223432119|NCT03484936|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
223432120|NCT03484936|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
223432121|NCT02584998|OTHER|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
223432122|NCT02584998|OTHER|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
223432123|NCT06473454|OTHER|aerobic exercise and basic body awareness therapy ( exercise)|exercise
223432124|NCT02637713|DEVICE|Stretta|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter. It is approved for the management of GRED.
223432125|NCT02637713|PROCEDURE|Radiofrequency (RF) Energy to the LES (Stretta Procedure)|The Stretta procedure is performed endoscopically under moderate sedation or general anesthesia which uses radiofrequency (RF) energy applied to the lower esophagus over 14 minutes per FDA approved procedures.
223432126|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.
223432127|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions
223432128|NCT05923411|DRUG|Single dose of PF-07220060 as first Tablet Formulation|A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level
223432129|NCT05923411|DRUG|Single dose of PF-07220060 as second Tablet Formulation|A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level
223432130|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet Formulation|A single dose of PF-07220060 as a tablet formulation administered under fed conditions
223432131|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).
223432132|NCT05923411|DRUG|Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration|A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)
223565325|NCT04236180|OTHER|Specialised Paediatric Palliative Care (SPPC)|All services provided to children/families by a member of the multiprofessional SPPC team in Zurich according to local guidelines will be considered as study intervention. This includes direct consultation of the patient/family, as well as patient-/family-related consultation of the frontline care team. Bereavement support is considered an integrated part of SPPC and after the death of a child, follow-up bereavement support is routinely offered at the individual or group level as appropriate for parents and siblings.
224042047|NCT01087112|BEHAVIORAL|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
224042048|NCT01087112|BEHAVIORAL|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
224042049|NCT01499472|DEVICE|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
224042050|NCT01499472|DEVICE|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
224042051|NCT01499472|PROCEDURE|standard of care|regular care including debridement and bandaging.
224042052|NCT04720222|DEVICE|TENA-PROTO1|Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
224042053|NCT05429151|DRUG|Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen|"Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions."
224042054|NCT03726762|BEHAVIORAL|DBs at the end of the main meal + weight control program|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
224042055|NCT03726762|BEHAVIORAL|Water at the end of the main meal+ weight control program|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
224042056|NCT01959048|DRUG|fecal microbiota transplantation|
224042057|NCT04273256|DRUG|Myo-inositol|patients who will be supplemented with 2 grams of Myo-inositol daily for 3 months prior to their in-vitro fertilization cycle
224042058|NCT01351623|DRUG|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
224042059|NCT04201821|BIOLOGICAL|fecal microbial transplantation (FMT)|Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
224042060|NCT05564351|OTHER|eye mask and ear plug|black eye mask and silicon ear plug
223432133|NCT05923411|DRUG|Single dose of PF-07220060 as third tablet formulation|A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them
223432134|NCT02747797|DRUG|Lucitanib|10 mg orally daily
223565326|NCT02519894|BEHAVIORAL|Dietary Scanning Calculator|
223565327|NCT04164017|DEVICE|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
223565328|NCT04164017|DEVICE|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
224042061|NCT05516823|OTHER|Usage of drugs|Self-reported past usage of drugs belonging to different chemical groups.
224042062|NCT05097014|DRUG|CHF5993|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
224042063|NCT05097014|DRUG|CHF1535|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
224042064|NCT05097014|OTHER|Matched placebo|Pressurized metered dose inhaler (pMDI) 2 inhalations bid
224042065|NCT03920813|DRUG|Mercaptopurine|Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
224042066|NCT01484730|DEVICE|Multi-Spectral and Laser Speckle Imaging|Changes in skin tissue and blood flow.
223740425|NCT02834533|DEVICE|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
223740426|NCT02856633|DEVICE|Vitaliti|
224042067|NCT01130974|DEVICE|Bausch & Lomb contact lens|Bausch \& Lomb daily disposable cosmetic tint contact lens
224042068|NCT01130974|DEVICE|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
224042069|NCT00897351|GENETIC|mutation analysis|
224042070|NCT00897351|GENETIC|polymorphism analysis|
224042071|NCT00897351|GENETIC|protein expression analysis|
224042072|NCT00897351|OTHER|immunohistochemistry staining method|
224042073|NCT00897351|OTHER|laboratory biomarker analysis|
224042074|NCT00387764|DRUG|pazopanib|800 mg daily dosing continously until progression
224042075|NCT02636153|OTHER|normal diet|Diet containing 1500mg of phosphorus
224042076|NCT02636153|OTHER|restricted phosphate diet|Diet containing 500mg of phosphorus
224042077|NCT04062253|DIAGNOSTIC_TEST|HCV rapid test|Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
224042078|NCT04228809|DEVICE|tDCS|transcranial direct current stimulation
224042079|NCT02929745|PROCEDURE|Skin biopsy|Four 4-5 mm punch biopsies of the skin
224140329|NCT01261546|DRUG|Dexamethasone|"* Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~* Ranitidine 5 mg/kg IV, q.d. for 2 days~* Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
224042080|NCT02929745|PROCEDURE|Blood draw|Blood will be drawn to test for HLA-cw6 status
224042081|NCT05033652|OTHER|WARNING KD|"Within 48h of detecting an abnormal creatinemia value (GFR\<30 or AKIN2 and AKIN3), the biology laboratory will communicate the patient's information to the WARNING KD team. This team consists of one nephrologist and one clinical pharmacist who will trigger the initial management in the department and then, if the patient has a persistant warning signal during hospitalization, define the patient's course of treatment for discharge. Patients requiring special care will be oriented towards a nephrologist and the patient's GP will be alerted to the benefit of addressing the patient to a nephrologist for multidisciplinary management with a therapeutic project according to the recommendations for good therapeutic practices."
224042082|NCT00603655|OTHER|Low glycemic load diet|Low glycemic load diet
224042083|NCT00603655|OTHER|High glycemic load diet|High glycemic load diet
224042084|NCT06062433|DEVICE|AsthmaTuner|Phone application and spirometer for self-management of asthma
224042085|NCT06062433|OTHER|Asthma-Guidance and Prediction System|Artificial Intelligence (AI)-assisted clinical decision support system which extracts pertinent patient data related to asthma management from electronic health record
224042086|NCT02542384|DRUG|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
224042087|NCT02542384|DRUG|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
224042088|NCT02542384|DRUG|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
224042089|NCT01184053|DRUG|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
223432135|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Nut|
223432136|NCT03101852|DIETARY_SUPPLEMENT|Plumpy Sup|
223432137|NCT02191176|DRUG|Dextromethorphan syrup - low dose|
223432138|NCT02191176|DRUG|Dextromethorphan syrup - high dose|
223432139|NCT02191176|DRUG|Placebo|
223432140|NCT04921527|DRUG|chiauranib|50mg orally once daily
223432141|NCT04921527|DRUG|Placebo|50mg orally once daily
223432142|NCT04921527|DRUG|Paclitaxel|at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
223432143|NCT01537627|OTHER|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
223432144|NCT01537627|OTHER|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
223432145|NCT03273465|OTHER|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
223432146|NCT00215527|DRUG|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
223565329|NCT03789435|DIAGNOSTIC_TEST|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
223565330|NCT00052611|DRUG|Celecoxib|
223565331|NCT01892436|DRUG|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
223565332|NCT01892436|DRUG|Placebo|Placebo
223565333|NCT06488170|DRUG|Tildrakizumab|As provided in real world clinical practice.
223565334|NCT02021617|DEVICE|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver-a small battery-powered drill-and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
223565335|NCT03549676|BIOLOGICAL|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
223565336|NCT00583414|DEVICE|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
223565337|NCT01965769|OTHER|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
223565338|NCT00643786|DRUG|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
223565339|NCT00643786|DRUG|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
224042090|NCT02536573|OTHER|Radlink Surgical Positioning Software|
224042091|NCT02903082|BIOLOGICAL|Residue of blood further to NFS|
224042092|NCT02903082|BIOLOGICAL|Residue of blood further to preoperative workup|
224042093|NCT02903082|BIOLOGICAL|Bone marrow collected during a myelogram carried out for hematological pathology workup|
224042094|NCT02903082|BIOLOGICAL|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
224140330|NCT01261546|DRUG|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~* Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~* Ranitidine 5 mg/kg IV, q.d. for 2 days.~* Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
224140331|NCT01160653|DEVICE|FES-IM|implantable Functional Electrical Stimulation
223565340|NCT00733291|DEVICE|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
223565341|NCT00733291|DEVICE|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
223565342|NCT00733291|DEVICE|FID 107027 solution|Commercially marketed solution for contact lens disinfection
223565343|NCT00814697|DEVICE|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
223565344|NCT06354413|PROCEDURE|CABG during myectomy|To explore the effect of CABG during myectomy. No control group
223565345|NCT02759107|DRUG|Tirzepatide|Administered SC
224042095|NCT04418544|DEVICE|Device used to record voice for screening|voice recording
224042096|NCT03200340|DRUG|EC-18|Oral administration of EC-18 twice daily
224042097|NCT03200340|DRUG|Placebo|Placebo to match EC-18 capsule administration
224042098|NCT00179166|DRUG|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
224140332|NCT01160653|OTHER|Cognitive training|training of impaired cognitive processes
224140333|NCT05938777|BEHAVIORAL|Non-Stage-Matched Intervention|The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
224140334|NCT02022033|DRUG|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
224140335|NCT00200018|DEVICE|Enterra Therapy System (H9900014)|
224140336|NCT00889993|DIETARY_SUPPLEMENT|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
223565346|NCT02759107|DRUG|Placebo|Administered SC
224042099|NCT04399122|DRUG|acetaminophen/codeine vs acetaminophen/oxycodone|pain medications
224042100|NCT04557085|DRUG|Cenobamate|Cenobamate tablets
224042101|NCT04557085|DRUG|Placebo|Matching placebo tablets
224042102|NCT01083628|BEHAVIORAL|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
224042103|NCT01083628|BEHAVIORAL|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
224042104|NCT02536755|DRUG|Eliglustat, GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
224042105|NCT02086851|BEHAVIORAL|Lifestyle Intervention|
224042106|NCT02086851|BEHAVIORAL|Parent Motivational Interviewing|
224140337|NCT04591041|DEVICE|HoloSIM Software via Hololens 2|Medical students will train via a mixed reality simulated crisis scenario using the HoloSIM software on the Microsoft Hololens 2
223432147|NCT01461720|OTHER|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
223432148|NCT01461720|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
223432149|NCT02847182|BIOLOGICAL|Cord Blood Infusion|
223432150|NCT02847182|BIOLOGICAL|Placebo|
223432151|NCT06906536|OTHER|Acute Intermittent Hypoxia (AIH)|4 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals
223432152|NCT06906679|DEVICE|Experimental Group|"The EG will follow 20 sessions of robot-assisted therapy for the upper limb. Exercises will be performed using a handpiece to support the weight of the upper limb during therapy and to assist (or resist) movements according to the patient's needs. These modalities are presented to the patient through visual and motor feedback (force feedback).~The exercises will focus on rehabilitating upper limb performance, for example:~Elbow: flexion-extension; Shoulder: horizontal adduction/abduction, flexion-extension.~The software includes serious games for:~* Motor control (both movement control and force control);~* Coordination;~* Cognitive training;~* Simulation of daily activities. The exercises will be defined by specialized personnel based on the patient's characteristics. Each rehabilitation session lasts 45 minutes, including 5 minutes for device setup, 20 minutes for the right upper limb and 20 minutes for the left upper limb."
224042107|NCT06073379|OTHER|Korean manupuncture|Energy assessment on hands and body Correspondence point technique on hands Energy rebalancing with ki Maeks on hands Moxa technique on hands
224042108|NCT06073379|OTHER|Placebo session|Energy assessment on hands and body Correspondence point technique on the hands Energy rebalancing with ki Maeks on hands (use of Qi bong) Moxa technique on hands (placebo moxas)
224042109|NCT00187395|PROCEDURE|Randomized to either a 'less tight' group or a 'tight' group|
224042110|NCT01493258|OTHER|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
224042111|NCT01174238|DRUG|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
224042112|NCT01174238|DRUG|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
224042113|NCT01174238|DRUG|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
224042114|NCT02674191|DEVICE|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH\& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
224042115|NCT02674191|PROCEDURE|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
224042116|NCT02674191|PROCEDURE|Administration of , Mepivacaine-l|local anesthesia
223432153|NCT06906679|OTHER|control group|The CG will last 20 sessions (3 days/week) of conventional rehabilitative treatment without the use of technological devices for the upper limb. Each session will last 45 minutes. The motor exercises will focus on upper limb rehabilitation and will be performed with a therapist who will personalize the treatment based on the patient's characteristics and needs. Specifically, the upper limb treatment will include exercises for mobility (shoulder, elbow, wrist, and hand), coordination, and manual dexterity.
223565347|NCT02759107|DRUG|Dulaglutide|Administered SC
224042117|NCT02674191|PROCEDURE|BETADINE povidone-iodine 10%|a local disinfectant
224140338|NCT04591041|OTHER|Training by Mannequin Based Simulation|Medical students will train a via traditional mannequin based medical crisis scenario
223565348|NCT00000273|DRUG|opiates|prescription opioids
224042118|NCT02674191|DRUG|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
224042119|NCT02674191|DRUG|(Cataflam 25mg), are prescribed post-operatively|an analgesic
224140339|NCT02279121|DEVICE|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
224042120|NCT00557583|DRUG|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
224042121|NCT02301936|DRUG|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
224042122|NCT00000268|DRUG|Bupropion|
224140340|NCT02279121|DRUG|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
223565349|NCT02402894|OTHER|no intervention|
223565350|NCT01704729|PROCEDURE|group1|Non-cycloplegic self-refraction +conventional glasses
223565351|NCT01704729|PROCEDURE|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
223565352|NCT01704729|PROCEDURE|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
224042123|NCT00256425|BEHAVIORAL|Cognitive rehabilitation|
224042124|NCT01638091|BEHAVIORAL|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
224042125|NCT01638091|BEHAVIORAL|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
224042126|NCT01391585|OTHER|Text Message prompts|In this single armed intervention, patients will receive text message prompts
223432154|NCT02345889|DEVICE|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
223565353|NCT01704729|PROCEDURE|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
223565354|NCT01255813|DEVICE|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
223565355|NCT01255813|DEVICE|Stimulation (Full)|Stimulation applied above the perception threshold
223565356|NCT01255813|OTHER|Control|No stimulation applied
223565357|NCT04165655|BEHAVIORAL|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
223565358|NCT02428621|DEVICE|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
223740427|NCT05291247|DEVICE|Peripheral lithotripsy system (Shockwave Medical)|The combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device for calcified femoropopliteal disease.
224042127|NCT01416987|DRUG|Pergoveris®|Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
224042128|NCT01322984|BEHAVIORAL|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
224042129|NCT01322984|BEHAVIORAL|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
224042130|NCT05261971|DRUG|Etodolac 400 MG|Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.
223432155|NCT02345889|DEVICE|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
223432156|NCT02345889|DEVICE|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
223432157|NCT02345889|DEVICE|Standard Colonoscopy|Current standard of care colonoscopy
223565359|NCT02428621|DEVICE|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
223565360|NCT04840563|DEVICE|Kalifon A|Commercially available kalifilcon A lenses
223565361|NCT04840563|DEVICE|Dailies Total1|Dailies Total1
223565362|NCT04840563|DEVICE|Precision1|Precision1
223565363|NCT00003671|DRUG|asparaginase|
223565364|NCT00003671|DRUG|cyclophosphamide|
223565365|NCT00003671|DRUG|cytarabine|
223565366|NCT00003671|DRUG|daunorubicin hydrochloride|
223565367|NCT00003671|DRUG|dexamethasone|
223565368|NCT00003671|DRUG|leucovorin calcium|
223565369|NCT00003671|DRUG|mercaptopurine|
223565370|NCT00003671|DRUG|methotrexate|
223565371|NCT00003671|DRUG|thioguanine|
223565372|NCT00003671|DRUG|vincristine sulfate|
223565373|NCT01946672|PROCEDURE|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
223565374|NCT00116064|DRUG|intranasal lorazepam|
223565375|NCT00116064|DRUG|intramuscular paraldehyde|
223565376|NCT01353443|PROCEDURE|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
223565377|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
223565378|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
223565379|NCT02333682|DIETARY_SUPPLEMENT|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
223565380|NCT02333682|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
223740428|NCT05616156|DEVICE|Cre8™ BTK|Implant of Cre8™ BTK stent the treatment of infrapopliteal peripheral artery disease
223740429|NCT03808051|PROCEDURE|Physiological-based cord clamping|See Arm description.
223740430|NCT03808051|PROCEDURE|Time-based cord clamping|See Arm description.
224042131|NCT05261971|DRUG|Thiocolchicoside|Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
224042132|NCT01923116|DRUG|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
224042133|NCT01102803|BEHAVIORAL|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
224042134|NCT01102803|DRUG|D-Cycloserine|D-Cycloserine
224042135|NCT01102803|DRUG|Placebo|Sugar Pill
224042136|NCT05487339|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopy device
224042137|NCT05279209|PROCEDURE|catheter-directed sclerotherapy|Ovarian endometrioma is targeted under transvaginal/transabdominal ultrasound. A guidewire is inserted to the lesion and is exchanged for a catheter. The cystic content is thoroughly aspirated and then sclerotherapy is performed by injecting 99% ethanol.
224042138|NCT05279209|PROCEDURE|surgical resection|Surgical resection of the ovarian endometrioma is performed under general anesthesia. To preserve the residual ovarian function, enucleation is the primary surgical technique.
224042139|NCT01980420|PROCEDURE|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
224042140|NCT04688723|DRUG|Dabigatran + Ticagrelor|Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.
223432158|NCT00756392|PROCEDURE|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
223432159|NCT06328244|BEHAVIORAL|Simple swallowing training|"Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week."
223432160|NCT05908435|BEHAVIORAL|Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors|The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
223432161|NCT06153186|DRUG|Flunarizine Hydrochloride|Flunarizine tablet
223432162|NCT03333902|PROCEDURE|QLB|QLB, quadratus lumborum block.
223432163|NCT03333902|PROCEDURE|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
223432164|NCT03398512|PROCEDURE|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
223432165|NCT03398512|PROCEDURE|HIPEC|Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
223432166|NCT03398512|DRUG|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
223432167|NCT01173055|DRUG|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
224042141|NCT04688723|DRUG|Dabigatran + clopidogrel|Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
224140341|NCT00759746|BEHAVIORAL|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
223432168|NCT01173055|DRUG|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
223432169|NCT03335423|DRUG|Oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
223432170|NCT03335423|DRUG|Intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
223565381|NCT06415812|BEHAVIORAL|Evolutionary Systems Therapy|Evolutionary Systems Therapy is an individual form of psychotherapy (talk therapy) that has been previously tested trough a randomized controlled trial and a few cases series, confirming its feasibility and safety.
223565382|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
223565383|NCT00866034|DRUG|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
223565384|NCT04660825|OTHER|A resistance band exercise programme|A resistance band based exercise programme lasting six months
223565385|NCT04660825|OTHER|Control|Maintained usual physical activity
223740431|NCT01577147|OTHER|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
224042142|NCT04356911|OTHER|PLACEBO (Negative Control)|"The group received in-office bleaching. A 45-minute application of 35% hydrogen peroxide gel (Whiteness HP, FGM, Joinville, SC) was carried. After whitening therapy, a water-soluble placebo gel (KY®, Johnson \& Johnson, SP, Brazil) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the placebo gel for 20 seconds in each tooth surface. After washing the placebo gel, the laser tip was positioned at two points, apical and cervical, without emitting light (placebo), simulating the application of low-level laser therapy (LLLT).~This protocol was performed in 3 sessions, with an interval of seven days between them."
224042143|NCT04356911|OTHER|FBM|This group received photobimodulation with low level laser therapy (LLLT) of infrared spectrum with a wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), at two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. The laser was applied in 3 sessions with a time interval of seven days between them.
224042144|NCT04356911|OTHER|ESTRÔNCIO|After whitening therapy, a toothpaste with 10% strontium chloride (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of incisors, canines and premolars with the help of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. The desensitizer therapy was realized in 3 sessions with a time interval of seven days between them.
224042145|NCT04356911|OTHER|FBM+ESTRÔNCIO|After whitening therapy, a 10% strontium chloride toothpaste (Sensodyne Original, GSK, London, United Kingdom) was applied to the buccal surfaces of whitened teeth with the help of a Microbrush applicator applicator (Microbrush, 3M ESPE, São Paulo , Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a handpiece at low speed (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to rub the desensitizer for 20 seconds on each tooth , according to the manufacturer's specifications. After washing the desensitizer, the photobimodulation was realized with Low Level Laser Therapy (LLLT) of infrared spectrum with wavelength of 808 nm in its active environment AsGaAl (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil), in two points: cervical and apical region of the incisors, canines and premolars. 60 J / cm² was applied at each point for 16 seconds. This protocol was performed in 3 sessions, with an interval of seven days between them.
224042146|NCT03005951|OTHER|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
224042147|NCT03005951|OTHER|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
224042148|NCT05697731|DIAGNOSTIC_TEST|Vidiac Score|Vidiac score is a scoring system created according to the visibility of laryngeal structures under videolarnyngoscopy in patients with expected difficult intubation.
223432171|NCT03335423|DRUG|Oral codeine and oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
224042149|NCT00067951|DRUG|rosiglitazone/metformin|
224140342|NCT00759746|BEHAVIORAL|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
224140343|NCT00759746|BEHAVIORAL|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
224140344|NCT05669300|PROCEDURE|Yilmaz Suturation|uterine closure with Yilmaz Technique and single layer continue locked suturation
224140345|NCT05071352|DRUG|Nefopam|Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
223432172|NCT03335423|DRUG|Oral codeine and intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
223432173|NCT00456508|DRUG|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
223432174|NCT05994118|OTHER|NaCl 0.9% (normal saline)|Subcutaneous normal saline injection
223432175|NCT05994118|OTHER|Magnetized Normal Saline|Magnetized Normal Saline
223432176|NCT06623318|DEVICE|Remote therapeutic monitoring device|IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.
223432177|NCT05467618|PROCEDURE|Maxillofacial surgery|An incision on the skin over the mandible versus incision on the gingivae inside the mouth
223432178|NCT05922319|OTHER|Computerized cognitive training with different training doses|The training dose was defined as training frequency (number of training days per week) and average training duration per training day. The daily dose was divided into 13 categories with an interval of 5 minutes and the training frequency has 7 categories according to the number of training days per week.
223432179|NCT02021136|DEVICE|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
223432180|NCT02021136|OTHER|Control|Usual antalgic treatment + physical exercises recommendations
223432181|NCT00126100|DRUG|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
223432182|NCT00126100|OTHER|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
223432183|NCT03126006|PROCEDURE|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
224042150|NCT00613054|DRUG|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations."
223432184|NCT03126006|OTHER|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
223432185|NCT00743015|DRUG|BI 44370 TA tablet|
223432186|NCT02757937|BEHAVIORAL|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
224042151|NCT02877212|DRUG|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
224042152|NCT03976791|PROCEDURE|enlarged internal incision|enlarging the internal incision about 0.4mm
223432187|NCT02757937|OTHER|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
223432188|NCT06621628|OTHER|stretching, strengthening exercises and active exercises|Bioptron light therapy device, resisted exercises and stretching exercises
223432189|NCT01829178|DRUG|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
223432190|NCT01829178|DRUG|Placebo|placebo tablets: 420 mg in 3 divided dose
223432191|NCT01829178|DRUG|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
223432192|NCT06618833|OTHER|Collection of medical data|Collection of medical data focused on the history of atrial fibrillation by the principal investigator
223432193|NCT06618833|BEHAVIORAL|Collection of global health elements|Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient
223432194|NCT06618833|BEHAVIORAL|PROMIS global questionnaire|"The patient completes the global PROMIS questionnaire which collects data on their overall health.~The questionnaire consists of 10 questions about the patient\&#39;s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question:~Excellent to poor or Totally to not at all, or Always to never or None to very intense"
223432195|NCT06618833|BEHAVIORAL|Collection of sociological data|Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator
223432196|NCT04250233|DEVICE|Respiratory Monitor|All women receive a respiratory rate monitor after cesarean delivery. We anticipate that at least 30 women will receive standard dose neuraxial block, and aim to have a cohort of 20-30 women who receive non-standard dose (Group 20 in order to compare respiratory rates.
223432197|NCT06906588|DEVICE|Experimental|The experimental group (EG), in addition to the standard rehabilitation treatment, will perform one upper limb BRAT session per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system.. Each participant will perform a total of 16+/-3 treatment sessions with a frequency of 4 times a week for 4 consecutive weeks. During the first session, the device should be adjusted according to the patient's bilateral size and suspension angle. The selection of personalized exercises will be based on each patient's motor skills and the difficulty can be gradually increased during the treatment period. These modalities are shown to the patient with visual and motor feedback (force feedback). The duration of the single rehabilitation treatment is 45 minutes, of which 5 minutes are used for setting up the device, 10 minutes for assembly/disassembly, 10 minutes for unilateral treatment with the affected upper limb and 20 minutes for bilateral treatment.
223432198|NCT06906588|OTHER|Control|The control group (GC), in addition to the standard routine rehabilitation treatment, will follow 45 minutes of conventional rehabilitation of the upper limbs without the use of technological devices. Each participant will perform a total of 16+/-3 conventional upper limb treatment sessions with a frequency of 4 times a week for 4 weeks. The motor exercises will concern the rehabilitation of the upper limb and will be performed with a therapist who will personalize the treatment based on the clinical characteristics and needs of the patient. Specifically, the treatment of the upper limb will be characterized by motor exercises (shoulder, elbow, wrist and hand), coordination and manual dexterity. Each session will consist of passive, active-assisted and active exercises.
223432199|NCT04325698|DRUG|PF-06439535 (CN)|15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
223740432|NCT04788953|DRUG|Solriamfetol Oral Tablet|The administered drug is SUNOSI (solriamfetol) tablets for oral use. Initial U.S. Approval: 2019
223740433|NCT04788953|DRUG|Placebo|Control subjects will receive placebo tablets for oral use.
223740434|NCT06054230|DEVICE|Genomic Sequencer|Genomic Sequencing Device
224042153|NCT03976791|PROCEDURE|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
224042154|NCT02684279|DRUG|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
224042155|NCT05524987|BEHAVIORAL|ANDES INTERVENTION|ANDES intervention group will receive the ANDES implementation package consisting of health agent home visits for 12 consecutive months
224042156|NCT05319028|DRUG|Mivavotinib|oral tablet
224042157|NCT06033911|DEVICE|FoodFlip© App with no nutrition symbol|Intervention control: participants will have access to food information such as calories or the Nutrition Facts table through FoodFlip©
224042158|NCT06033911|DEVICE|FoodFlip© App with 'high-in' nutrition symbol|Intervention: Participants will have access to food information through FoodFlip© with Canada's 'high-in' NS
224042159|NCT07130435|BEHAVIORAL|Salutogenic Model-Based Healthy Aging Program|The Salutogenic Model-Based Healthy Aging Program is designed to enhance the sense of coherence and promote healthy aging among older adults aged 60-70. The program focuses on strengthening participants' internal resources, building resilience, and improving overall quality of life. It includes educational sessions, group discussions, and practical strategies for managing hypertension and diabetes, all while emphasizing physical, emotional, and mental well-being. The program aims to empower participants to make informed lifestyle choices and cope with the challenges of aging. Participants will receive regular follow-up assessments to track progress and ensure continued support throughout the study period.
224042160|NCT07128654|DRUG|CTL02|FDC tablet, single dose, oral administration
224042161|NCT07128654|DRUG|CTL0201|Nesina, tablet, single dose, oral administration
224042162|NCT07128654|DRUG|CTL0202|Jardiance, tablet, single dose, oral administration
224042163|NCT07129824|OTHER|Observation|Observe the effect of eating habits and food preferences on symptoms of chronic gastritis
224042164|NCT07130383|DRUG|MHB036C for Injection|Intravenous administration
224042165|NCT07130383|DRUG|MHB039A for Injection|Intravenous administration
224042166|NCT07129109|DIETARY_SUPPLEMENT|small-quantity lipid-based nutrient supplements (SQ-LNS)|All caregivers will receive 2 months of SQ-LNS in this cross-over design. Half of the participants will be randomized to receive the 7-day packaging first, and half will receive the 1-day packaging first.
224042167|NCT07128511|BEHAVIORAL|Multiple Inhalation Breathing Pattern|"This behavioral intervention involves a breathing pattern characterized by brief, rapid successive inhalations within each breath cycle. The timing of each short inhalation is coordinated with fast, cyclical auditory tones, providing a consistent rhythm for participants to follow. Visual cues are also displayed to reinforce the timing and sequence of breaths.~During training, participants first practice the breathing pattern without any cognitive task, followed by practice while performing the psychomotor vigilance task (PVT). The technique is then applied during the main experimental condition, where participants wear a chest wall force antagonistic device set at 25 cmH₂O to simulate the added work of breathing experienced underwater. The PVT lasts for 10 minutes, requiring participants to respond as quickly as possible to visual stimuli, allowing researchers to measure sustained attention and reaction time."
224140346|NCT05071352|DRUG|Standard of care in the ICU for assessment and management of pain, sedation, and delirium.|In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
224140347|NCT05689138|OTHER|Oral and Fecal Sample Collection|No interventions
224140348|NCT04991883|OTHER|case series review of clinical and histological data|We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.
224140349|NCT05364983|DEVICE|Juvene IOL|Cataract extraction and implantation of a posterior chamber IOL
224140350|NCT05364983|DEVICE|Tecnis® Monofocal (ZCB00, PCB00 or DCB00)|Cataract extraction and implantation of a posterior chamber IOL
224140351|NCT04779944|OTHER|other|questionnaire
224299564|NCT05622292|DEVICE|HARKIT I-Care Application|HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
223432200|NCT04325698|DRUG|Bevacizumab-EU|15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
223432201|NCT04325698|DRUG|Paclitaxel|175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
223432202|NCT04325698|DRUG|Carboplatin|AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
223432203|NCT00481260|PROCEDURE|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
223432204|NCT04206176|DRUG|Ticagrelor|Ticagrelor 45mg twice daily per oral administration
223432205|NCT04253782|OTHER|Team Intervention|"The Team will meet with participants (remotely/electronically and/or by phone) and will ask that they select one of three options that may help with opioid addiction:~1. treatment with buprenorphine/naloxone (BUP),~2. inpatient, 12-step, or methadone regimens, or~3. education only (materials provided by the CT Community for Addiction Recovery (CCAR)).~Throughout the study, participants may switch to any other option."
223432206|NCT03890627|DEVICE|Thoracic bio-reactance|Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
223740435|NCT03643094|DIETARY_SUPPLEMENT|Golden Black Seed|1 capsule per day for 8 weeks.
223432207|NCT05425043|BIOLOGICAL|Granulocytes|Receive granulocytes for 7 consecutive days after engraftment post transplant
223740436|NCT04246294|DEVICE|Continuous Positive Airway Pressure (CPAP)|"CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care."
223740437|NCT01404845|DIETARY_SUPPLEMENT|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
223740438|NCT01404845|DIETARY_SUPPLEMENT|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
223432208|NCT02939027|DEVICE|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
223432209|NCT02939027|DEVICE|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
223432210|NCT04216589|DRUG|Semaglutide|Administered subcutaneously
223432211|NCT04530591|OTHER|Survey|Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.
223740439|NCT03562104|OTHER|videofluoroscopy|Swallowing description in Minimally consciousness Patient
223740440|NCT03562104|OTHER|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
223740441|NCT00937157|DRUG|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
223740442|NCT00838058|DRUG|CE-224,535|one 250mg tablet, once in the morning in fasted state
223740443|NCT00838058|DRUG|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
223740444|NCT00838058|DRUG|CE-224,535|4x250mg tablets, once in the morning, in fasted state
223740445|NCT00838058|DRUG|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
223740446|NCT00838058|DRUG|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
223740447|NCT00838058|DRUG|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
223740448|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
223740449|NCT00838058|DRUG|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
223740450|NCT04063020|BEHAVIORAL|Psychological monitoring|"Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~* Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~* Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~* After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)"
223740451|NCT02943720|DRUG|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
223740452|NCT02943720|DRUG|placebo|placebo
223740453|NCT03892590|BIOLOGICAL|Gut microbiota|Status of microbiota
223740454|NCT05266755|OTHER|Fracture Territorial Liaison Service afert a Hip fracture|Give a diferent than the current one way of follow up to the patients with hip fracture
223740455|NCT05040854|GENETIC|HLA-DQA1*05 and DRB1|All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
223740456|NCT05766475|BEHAVIORAL|ROSE Program: In Person|In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
223740457|NCT05766475|BEHAVIORAL|ROSE Program: Virtual|Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
223740458|NCT00469092|DRUG|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
223740459|NCT00469092|DRUG|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
223740460|NCT00469092|DRUG|metformin|Tablets, 2550 mcg. Administered once daily.
223740461|NCT00469092|DRUG|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
223740462|NCT04699708|DEVICE|Carbon dioxide monitoring|Blinded recording of CO2 during preterm resuscitation.
223740463|NCT00002546|DRUG|cisplatin|
223740464|NCT00002546|DRUG|ifosfamide|
223432212|NCT04530591|OTHER|Interview|"Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device."
223432213|NCT00504491|DRUG|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
223432214|NCT06371729|PROCEDURE|DEEP mapping|"The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
223740465|NCT00002546|PROCEDURE|adjuvant therapy|
223740466|NCT00002546|RADIATION|radiation therapy|
223740467|NCT05888246|DIAGNOSTIC_TEST|Magnetocardiogram|Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
224299565|NCT03511274|BEHAVIORAL|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
223432215|NCT06371729|PROCEDURE|Activation Mapping|"VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)"
224042168|NCT07128511|BEHAVIORAL|Tactical Breathing Technique|"This behavioral intervention uses a slow, paced breathing cycle incorporating four distinct phases: inhale, hold, exhale, and hold. Each phase is precisely timed and synchronized with distinct auditory tones for inhalation, hold phase, and exhalation. Participants also receive visual cues to reinforce correct timing and ensure consistency throughout the exercise.~Training begins with participants practicing the breathing pattern without any cognitive task, followed by practice while completing the psychomotor vigilance task (PVT). The full experimental condition involves performing the 10-minute PVT while wearing a chest wall force antagonistic device set at 25 cmH₂O to simulate the restrictive breathing load experienced in underwater environments. The PVT requires quick responses to visual stimuli, allowing measurement of sustained attention and reaction time under load."
224042169|NCT06625697|BEHAVIORAL|Mindfulness Meditation|Participants will be instructed on how to wear the physiological monitoring equipment during the 14-unit mindfulness meditation curriculum. Participants will then complete 2-10 minute guided seated Equa training lessons on a laboratory smartphone device while physiological measures are tracked. After training lessons, a respiration biosignal feedback chart will appear on the smartphone screen. Participants will also complete a brief mindfulness survey before and after training lessons.
224042170|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 200J (® Zoll)|Cardioversion
224042171|NCT06556667|DEVICE|biphasic defibrillator with maximum energy of 360J (® Physio-Control)|Cardioversion
223432216|NCT04080674|OTHER|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
223432217|NCT03491631|DRUG|SHR9146+SHR-1210|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
223565386|NCT02019108|OTHER|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
224042172|NCT07020507|OTHER|Product gel RV3895A|The product is applied twice a day to the scar(s) under study, avoiding all contact with natural orifices (and avoiding ingestion by children in the case of application to the hands in particular). The product is applied using a specific massage technique developed for the product and which is explained by the investigator at visit 1. The product is applied in sufficient quantity to cover the application area.
224042173|NCT07013383|BEHAVIORAL|"I Recycle, I Protect the Environment, I Leave a Livable World as a Legacy Program"|The training program includes topics such as environmental pollution, recycling behaviors, and the protection of natural resources and ecosystems. In addition, the program incorporates activities such as games, puzzle, brainstorming sessions, and the creation of painted cloth bags.
224042174|NCT06696430|BEHAVIORAL|Educational Intervention on TENS Usage|"Educational sessions on TENS usage and support from designated superusers to increase knowledge and skills related to TENS for postoperative pain management."
224042175|NCT06696430|BEHAVIORAL|Nudging Intervention to Promote TENS Usage|Healthcare staff exposed to nudging strategies designed to enhance the use of TENS, which involves visual prompts, reminders, and environmental cues aimed at making TENS more salient and encouraging its use for postoperative pain management.
224042176|NCT07023822|DEVICE|Hyaluronic acid (HLA) Vaginal Moisturizer|Use of vaginal moisturizer every 3 days for weeks 1-8.
224042177|NCT07023822|DEVICE|Polycarbophil Vaginal Moisturizer|Use of vaginal moisturizer every 3 days for weeks 1-8.
224042178|NCT07023822|BEHAVIORAL|Hypnotic Relaxation|Listen to hypnotic relaxation audio files at least 3x/week for weeks 3-8.
224042179|NCT07023822|BEHAVIORAL|Progressive Muscle Relaxation (PMR)|Listen to PMR audio file at least 3x/week for weeks 3-8.
224140352|NCT02415764|BEHAVIORAL|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
223432218|NCT03491631|DRUG|SHR9146+SHR-1210+Apatinib|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
223432219|NCT03187067|DEVICE|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
223432220|NCT06559384|OTHER|Interviews|semi-structured individual interviews
223432221|NCT00003910|DRUG|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
223432222|NCT00003910|DRUG|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
223565387|NCT02019108|OTHER|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
224042180|NCT07030699|DRUG|Epcoritamab|Subcutaneous, once weekly in cycles 1-3; every 4 weeks cycles 4-12
224042181|NCT07030699|DRUG|Lenalidomide|Oral, daily on days 1-21 of a 28-day cycle
224042182|NCT07030699|DRUG|Tafasitamab|Intravenous, once weekly during cycles 1-3, then every 2 weeks during cycle 4-12
223432223|NCT00003910|DRUG|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
223432224|NCT01690910|DEVICE|Rifton Gait Trainer|
223432225|NCT01690910|DEVICE|Front Wheeled Walker|
223432226|NCT04875312|DEVICE|Ultrasound cavitation in group A|"Group A:~twenty obese infertile patients with PCO who will be treated by ultrasound cavitation, 2 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
223432227|NCT04875312|DEVICE|Electro acupuncture in group B|"Group B:~twenty obese infertile patients with PCO who will be treated by electroacupuncture, 3 times per week for 3 months with medical treatment and hypocaloric diet (1200 kcal/day)"
223565388|NCT03380546|DRUG|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
224042183|NCT07130747|OTHER|Myofascial release|The study involves women in both groups receiving myofascial release technique for twenty minutes three times per week for eight weeks. The technique requires the patient's skin to be dry and not oily, and all techniques must be applied at the barrier of tissue resistance. The technique involves gentle, sustained pressure held at the barrier for at least five minutes to allow the patient to respond to the treatment and relax. The technique involves skin stretching and desensitization around the scar, using up and down, side-to-side, and circular maneuvers.
224140353|NCT04357990|DEVICE|Viruxal Oral and Nasal Spray|Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf. The Device contains Omega3 Viruxide. The main components in Omega3 Viruxide are Neem oil and St. John's Wort oil. The Device is administered from a pressurized canister into the oral and nasal cavity, where it creates a physical barrier for temporary protection of the mucosal tissue.
224140354|NCT04357990|OTHER|Placebo|The placebo will be a similar spray containing saline only.
224140355|NCT02556424|DRUG|Dexamethasone|Intravitreal implant at D0
223565389|NCT03380546|DRUG|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
223565390|NCT01888536|DRUG|Limaprost|
223565391|NCT01888536|DRUG|Pregabalin|
223565392|NCT01888536|DRUG|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
223565393|NCT01888536|DRUG|Placebo(for Limaprost)|mimic Limaprost tablet
223565394|NCT02324140|OTHER|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
223565395|NCT01084278|DRUG|Colchicine|Colchicine tablets
223565396|NCT04569136|OTHER|Education|The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.
223565397|NCT04569136|OTHER|Therapeutic ultrasound|Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.
223565398|NCT04569136|OTHER|Sham ultrasound|Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.
223565399|NCT04569136|OTHER|Breast massage|Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.
223565400|NCT04569136|OTHER|Usual obstetric care|Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
223565401|NCT03122821|OTHER|Real Transcranial direct stimulation+Mental Imagery|"The subject will be practicing mental imagery along with mental imagery. A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
223565402|NCT03122821|OTHER|Sham Transcranial Direct Stimulation +Mental Imagery|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS \[2, 19-25\]. It employs a battery-driven stimulator to deliver weak direct currents (1.5 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 2 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 2 weeks"
223565403|NCT00611468|DRUG|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
223565404|NCT00611468|DRUG|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
223565405|NCT01466660|DRUG|Afatinib|afatinib once daily
223565406|NCT01466660|DRUG|gefitinib|Gefitinib once daily
223565407|NCT02694913|OTHER|Non Interventional|This is a non therapeutic, pilot study.
223565408|NCT01742910|PROCEDURE|intraocular lens implantation|
223565409|NCT06277986|OTHER|cachexia|Cachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.
223565410|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
224042184|NCT07130747|OTHER|Deep friction massage|Women in both groups (C) will receive a deep friction massage three times a week for eight weeks, applying a fingertip pad perpendicularly to post-cesarean scar tissue, moving across the band and back-and-forth motion along the scar tissue's length.
224042185|NCT07130747|OTHER|Routine daily scar care advices|Each woman in all groups (A, B, and C) will receive full instructions for daily post-cesarean-section scar care. Weekly revision for post-cesarean-section scar care will conduct by the researcher
224042186|NCT07130890|DEVICE|Health for All Mobile health application|This interventional study is implemented by using Health for All Mobile health application among pregnant women in the intervention group and in the control group pregnant women were those who took the routine ANC contact . The effect of the intervention is mainly depend on the women themselves.
223432228|NCT01768845|GENETIC|umbilical cord blood (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
223565411|NCT00191724|DRUG|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
223565412|NCT00191724|DRUG|Placebo|intravenous (IV), one infusion, over 12 hours
223565413|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
224042187|NCT06602076|BEHAVIORAL|ECHO (Empowering Our Community & Health Outcomes)|Additive intervention design wherein study participants receive remotely-delivered standard smoking cessation support (i.e., behavioral support plus nicotine replacement therapy) and engage in community-serving volunteer activities.
224042188|NCT05571735|BIOLOGICAL|Pfizer-BioNTech COVID-19 vaccine|Pfizer-BioNTech COVID-19 vaccine, Messenger RNA (mRNA) based vaccine encoding the viral spike glycoprotein (S) Formulation: Frozen concentrate before dilution with 0.9% sodium chloride solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.3 mL per dose) (at least 3 weeks apart)
224042189|NCT05571735|BIOLOGICAL|AstraZeneca vaccine|AstraZeneca vaccine, a replication-deficient simian adenoviral vector expressing the spike (S) protein of SARS-CoV-2 Formulation: Aqueous solution for injection Route of Administration: Intramuscular (IM) Dosing regimen: Two doses (0.5 mL per dose) (at least 12 weeks apart)
224042190|NCT05571735|BIOLOGICAL|Janssen Ad26.COV2.S COVID-19 vaccine|"Janssen Ad26.COV2.S COVID-19 vaccine, recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.~Formulation: Suspension for injection Route of Administration: Intramuscular (IM) Dosing regimen single dose (0.5 mL)"
224042191|NCT06738277|DRUG|Bmab 1200 (Biosimilar Ustekinumab)|Dosage Form: injection, Strength(s): 45 mg/ 0.5 mL Route of Administration: Subcutaneous Frequency and Dose: 45 mg, single dose
223565414|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
224042192|NCT07059000|BIOLOGICAL|Kedrion IVIG 10%|(Intravenous) Human Normal Immunoglobulin (IVIg) 10%
224042193|NCT06774404|DEVICE|Use of FreeStyle Libre 14 day Flash Glucose Monitoring System|Women with GDM in the intervention arm will use Flash Glucose Monitoring (FGM) from diagnosis until the end of pregnancy
224042194|NCT06774404|OTHER|No intervention|Only using SMBG
224042195|NCT06854718|BEHAVIORAL|Caregiver-Assisted Pain Coping Skills Training (CG-PCST)|Patient-caregiver dyads will receive five, forty-to-sixty-minute sessions over a six-to-eight-week period with a therapist to learn pain coping skills. These include training caregivers in strategies for assessing patient pain, including nonverbal pain behaviors (e.g., grimacing, bodily tension, labored breathing), which will become increasingly important as the patient's ability to express pain verbally decreases. The therapist will also train the caregiver to coach the patient in the use of the skills during activities that are challenging because of pain. We will focus on increasing positive patient-caregiver interactions and patient engagement in valued activities. Throughout the training, the therapist will help the patient and caregiver learn strategies for fostering regular home practice and application of the skills, identify challenges in using the skills, and find strategies for coping with challenges.
224042196|NCT05546554|DRUG|Suvorexant|5 mg (and up to 20 mg) Suvorexant given orally
223565415|NCT00191724|DRUG|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
223565416|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
223565417|NCT00803348|DRUG|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
223565418|NCT00803348|DRUG|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
224140356|NCT02556424|DRUG|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
223432229|NCT02008747|DRUG|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
223432230|NCT00855205|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
223432231|NCT01446276|DIETARY_SUPPLEMENT|Resveratrol|500 mg 3 times daily for six month
223432232|NCT01446276|OTHER|Placebo|1 placebo tablet 3 times daily for six month
223432233|NCT04751773|BEHAVIORAL|Exercise training|Perioperative exercise training
223565419|NCT02583100|BEHAVIORAL|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
223565420|NCT02583100|BEHAVIORAL|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
223565421|NCT00474864|DRUG|GW856553|
223432234|NCT01501773|BIOLOGICAL|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
223432235|NCT03191864|DRUG|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
223432236|NCT03191864|DRUG|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
223565422|NCT00461864|PROCEDURE|ultrasound examination of the hip|
223565423|NCT02430948|OTHER|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
223565424|NCT02430948|OTHER|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
223565425|NCT02430948|OTHER|Standard support|Screening recommendations presented in standard format
224042197|NCT05546554|DRUG|Placebo|Matching Placebo given orally
224042198|NCT07074392|DEVICE|Electrical Stimulation|Custom stimulator will deliver a 1hour stimulation protocol post-operatively at 20 Hz, with biphasic pulses (100 µs duration, 0-2mA amplitude range).
224042199|NCT07128784|OTHER|Aerobic exercise|continuous, moderate intencity aerobic exercise, 3 days a week, 30 minutes per day, 150/min per week for a total of 6 weeks
224042200|NCT06470893|BEHAVIORAL|OCD-NET|OCD-NET is bibliotherapy with coaching and its content is reflective of standard care for OCD. OCD-NET is a self-paced intervention that participants complete entirely online with the support of an assigned individual therapist. Most participants complete this treatment in up to twelve weeks. On average, participants are expected to spend between one to five hours per week during the first half of treatment. In the second half of treatment when participants begin regular exposure and response prevention (ERP) exercises, participants are expected to spend about one hour per day.
224042201|NCT06902727|DEVICE|VR-based exercise bike|For the intervention group, participations exercised on an immersive VR-based exercise bike for one hour, twice per week, for 4 weeks. Participants in the control group were asked to maintain their usual routine after the baseline test for 4 weeks. Participants were scheduled separately coming to lab for the post-test after 4 weeks and all participants received the identical assessments in aforementioned physiological and psychological outcomes.
224042202|NCT06902727|OTHER|Usual routine|Participants were asked to maintain their usual activities, without engaging in any other physical activity intervention during the 4-week study period.
224042203|NCT06902948|OTHER|upper limb function training|Intervention selection included stretching and mobilization exercise, strengthening exercise, electrical stimulation, acupuncture, functional or task specific training and mirror therapy.
224140357|NCT03398733|DEVICE|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
224140358|NCT06348810|BEHAVIORAL|Dual-task training|The dual-task training is a combination of cognitive tasks and motor tasks which is done simultaneously or at the same time.
224140359|NCT06348810|BEHAVIORAL|Cognitive training|Participants only receive cognitive tasks
224140360|NCT06348810|BEHAVIORAL|Motor training|Participants only receive motor tasks
224140361|NCT06348810|OTHER|Usual care|assist participants with activities of daily living, medication management, and social activities (such as singing, watching television).
223432237|NCT00534079|DRUG|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
223432238|NCT00534079|DRUG|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
223432239|NCT01908933|DEVICE|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
223432240|NCT01730651|RADIATION|Tomotherapy|"IMRT boost of gross LNs~1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
223432241|NCT06619054|DRUG|KP-001|Oral single dose 50mg.
223565426|NCT02430948|OTHER|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
223565427|NCT04143165|DRUG|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
223565428|NCT04758884|OTHER|Telemedicine|Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
223565429|NCT04880629|BEHAVIORAL|Baseline condition|In the baseline sleep condition, participants are instructed not to restrict their sleep on the night before completing an oral glucose tolerance test (OGTT). Participants are prescribed sleep-wake timings based on their preferred and averaged sleep durations measured over 2 weeks using a wearable sleep tracker. Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
223565430|NCT04880629|BEHAVIORAL|Sleep restriction condition|In the sleep restriction condition, participants are prescribed sleep timings to restrict their sleep by 1 to 2 hours on the night before completing an oral glucose tolerance test (OGTT). Sleep timings and durations on the 3 nights before the OGTT are verified using a sleep diary and sleep tracker.
223565431|NCT03896061|DEVICE|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
223565432|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
223565433|NCT02068690|DRUG|Placebo|Placebo
223565434|NCT02068690|DRUG|Placebo|Placebo
223565435|NCT02068690|DRUG|BI 425809 tablet|BI 425809 tablet
223565436|NCT02068690|DRUG|BI 425809 PfOS|BI 425809 PfOS
223565437|NCT00634725|DRUG|capecitabine|
223565438|NCT00634725|DRUG|erlotinib hydrochloride|
224140362|NCT02861755|BEHAVIORAL|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
224140363|NCT02861755|BEHAVIORAL|5-week Emotion Reporting|
224140364|NCT01595659|BEHAVIORAL|Passenger|Driving with risk accepting or risk averse passenger
224140365|NCT04000919|DRUG|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
224140366|NCT04000919|DRUG|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
224140367|NCT04000919|DRUG|Placebo oral tablet|Placebo
223432242|NCT00688311|DIETARY_SUPPLEMENT|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10\^10 each) combined with 4 types of dietary fiber (2.5g each).
224042204|NCT06901843|COMBINATION_PRODUCT|Mobilizations Exercises|Group A was treated with mobilizations exercises for 40 minutes for 3 sessions per week for 6 weeks. Patients received hip mobilizations. Therapist perform anterior posterior glide, caudal glide, posterior anterior glide with abduction, flexion and lateral rotation in 3 sets with 10 repetitions .Mobilization grades were performed according to patients tolerance level with duration 30-second rest .Hip strengthening exercises were performed 3 sets with 10 repetition with hip abduction in side lying, hip extension in prone position, sideway walk, hip abduction in a stand up position.
224042205|NCT06901843|COMBINATION_PRODUCT|Closed Kinetic Chain Exercises|Group B was treated with Closed Kinetic Chain Exercises for 40 minutes for 3 sessions per week for 6 weeks. Closed kinetic chain exercises were performed with 5 minute break between each exercise. Leg press in horizontal position ,Stationary bicycling and Stairmaster climbing.
223432243|NCT00688311|DIETARY_SUPPLEMENT|Placebo|Placebo
223432244|NCT01765829|DRUG|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
223432245|NCT01765829|DRUG|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
223432246|NCT03962231|OTHER|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
223432247|NCT03962231|OTHER|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
223432248|NCT03399682|DIAGNOSTIC_TEST|cystography|observationnal study
223432249|NCT04687020|DRUG|Viltolarsen|Received during weekly intravenous infusions
224140368|NCT04000919|DRUG|Carbidopa|Carbidopa (50mg)
224140369|NCT02813759|OTHER|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
224140370|NCT02813759|OTHER|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
223432250|NCT01563367|DRUG|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
223565439|NCT00634725|DRUG|gemcitabine hydrochloride|
224042206|NCT06903507|DEVICE|RT-Comfort Mattress|This dedicated RT-Comfort Mattress was newly developed (patent pending) for increasing comfort without compromising radiotherapy treatment quality.
223432251|NCT01563367|DRUG|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
223565440|NCT00634725|OTHER|laboratory biomarker analysis|
223565441|NCT00634725|RADIATION|radiation therapy|
223565442|NCT00620256|DRUG|AL-37807 ophthalmic suspension, 0.1%|
223565443|NCT00620256|DRUG|Timolol gel forming solution, 0.5%|
223565444|NCT00620256|OTHER|AL-37807 ophthalmic solution vehicle|
224140371|NCT03051724|OTHER|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
224140372|NCT01148563|DEVICE|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
224140373|NCT04184115|DRUG|DPI-386 Nasal Gel|1.5 mg reservoir of scopolamine to be delivered over a 72-hour period
224140374|NCT04184115|DRUG|Placebos|Placebo Nasal Gel and placebo patch
224140375|NCT04846166|DIAGNOSTIC_TEST|Periodontally healthy group|probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium
224140376|NCT04846166|DIAGNOSTIC_TEST|Periodontitis|: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
224140377|NCT00442676|DRUG|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
224140378|NCT00442676|DRUG|Placebo|Gelatin capsules of lactose
223432252|NCT01389479|BIOLOGICAL|Fluviral™|Intramuscular, single dose
223432253|NCT01389479|BIOLOGICAL|Fluzone®|Intramuscular, single dose
223432254|NCT02405975|OTHER|SCRIPT|An online tool designed to train doctors in all areas of prescribing
223432255|NCT03399903|DRUG|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
223432256|NCT02410083|DRUG|Clopirin 1|
223432257|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 1|
223432258|NCT02410083|DRUG|Clopirin 2|
223432259|NCT02410083|DRUG|Clopidogrel-Aspirin(co-administration) 2|
223565445|NCT00620256|DRUG|Latanoprost ophthalmic solution|
223565446|NCT03070639|BEHAVIORAL|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
223565447|NCT03070639|BEHAVIORAL|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
224140379|NCT05240638|DEVICE|TD Drainage|Image-guided percutaneous cannulation of the TD and drainage with an endovascular catheter (microcatheter)
224140380|NCT01879319|BIOLOGICAL|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
224140381|NCT01879319|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
224140382|NCT05129995|OTHER|Passive heat treatment|Participants will be subjected to an 8-week (3 x pw) passive heat treatment, by means of infrared sauna bathing, intervention.
224140383|NCT01933256|DRUG|HIP2B|
223432260|NCT02342548|DRUG|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
223432261|NCT05311566|COMBINATION_PRODUCT|Camrelizumab plus Concurrent chemoradiotherapy|Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy. After completing 6\~8weeks of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until disease progression or unacceptable toxicity.
223432262|NCT01725932|BEHAVIORAL|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
224042207|NCT06901986|DIETARY_SUPPLEMENT|Montmorency tart cherry|Montmorency tart cherry 60ml per day for 6 weeks.
224042208|NCT06901986|DIETARY_SUPPLEMENT|Placebo|Taste matched placebo.
223432263|NCT01047332|DEVICE|Partially Covered Wallstent|Partially covered wallstent
223432264|NCT01047332|DEVICE|Uncovered Wallstent|Uncovered wallstent
223432265|NCT00291161|BEHAVIORAL|Partners in Dementia Care|"Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient."
223432266|NCT01471509|OTHER|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
223432267|NCT00633776|DRUG|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
223565448|NCT03544476|BEHAVIORAL|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
223565449|NCT03544476|OTHER|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
224042209|NCT06902415|DEVICE|QDSA (Quantitative Digital Subtraction Angiography)|QDSA is a quantitative analysis technology based on DSA, used to assess hemodynamic characteristics and provide critical data support for the diagnosis and treatment of cerebrovascular diseases.
224042210|NCT06902311|RADIATION|Breast Radiotherapy|The tumor bed boost when given at the same time (called a simultaneous integrated boost, SIB) with whole breast irradiation (WBI).
224042211|NCT07092436|DEVICE|Robotic bilateral upper limb rehabilitation training|Bilateral upper limb rehabilitation using PhiCube, a modular robotic end-effector device with two motorized axes that can assist or resist patient movements. Treatment consists of 30 sessions over 3 months (3 sessions/week, 45 minutes each) combining motor training with gaming elements specifically designed for pediatric populations. The device's modular design allows customization for individual patient needs and bilateral coordination training. Sessions focus on improving range of motion, precision, dexterity, and movement fluidity through controlled, repetitive, high-intensity exercises in children aged 4-18 years with neuromotor disorders and developmental coordination disorder.
224140384|NCT01933256|DRUG|Placebo|
224140385|NCT03763903|OTHER|3D training|Skills (FLS tasks) training using 3D visualization
223565450|NCT03550443|DRUG|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
223565451|NCT03550443|DRUG|Placebo|Capsules containing an inert placebo
223565452|NCT04163861|DIAGNOSTIC_TEST|2d speckle tracking echocardiography|2d speckle tracking echocardiography
223565453|NCT04163861|DIAGNOSTIC_TEST|serum BNP level|serum BNP level of HFpEF study subjects
223565454|NCT03211611|BEHAVIORAL|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
223565455|NCT04974905|PROCEDURE|retrograde access for re-canalization of infra-inguinal arterial occlusive disease|after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
223565456|NCT02628431|DEVICE|Elfi tech monitor|
224042212|NCT00790465|DIETARY_SUPPLEMENT|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
224042213|NCT00790465|DIETARY_SUPPLEMENT|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
224140386|NCT03763903|OTHER|2D training|Skills (FLS tasks) training using 2D visualization
224140387|NCT05750134|OTHER|OBPLUS Clinical Database : data analysis|The data processed relates to patients cared for in the Hepato-gastroenterology and nutrition department of the Antoine Béclère Hospital at the Assistance Publique - Hôpitaux de Paris (AP-HP. All of the clinical and paraclinical data are collected during the visits and entered into the OBPLUS database (database registered in the AP-HP register). These data will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication.
224042214|NCT07130708|DEVICE|Telesurgery utilizing Microport Medbot Robotic Platform|A robotic surgery for prostate disease via telesurgery, where a highly trained surgeon performs the operation remotely using a secure internet connection.
224042215|NCT07131033|DRUG|Esketamine|Patients were given intravenous esketamine 0.25 mg/kg 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.
224042216|NCT07131033|DRUG|Magnesium sulfate|Patients were injected with 30 mg/kg of magnesium sulphate intravenously 10 min before the induction of anaesthesia, followed by continuous pumping at 10 mg/(kg-h) until the end of the operation.
224140388|NCT05750134|OTHER|"Biological collection Liver, bile ducts and pancreas: sample analysis"|"The samples (plasma, serum, saliva, stool) collected during the samples taken as part of the patient's care were the subject of a biological collection Liver, bile ducts and pancreas. These samples will be analyzed in order to identify the predictive factors of the effectiveness of the fundo-plication."
224140389|NCT02357797|DRUG|Vortioxetine|
224140390|NCT02357797|OTHER|Placebo|
224140391|NCT02611063|DRUG|fostamatinib|100mg qd, 150mg qd, or 100mg bid
224140392|NCT00854256|PROCEDURE|Canaloplasty|Canaloplasty surgery
224140393|NCT00854256|PROCEDURE|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
224140394|NCT00566449|DRUG|Placebo|one dose daily for 4 weeks
223432268|NCT03521817|OTHER|Alcohol|"The ethanol group will consume a 30% energy restriction diet that will also include \~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol."
223432269|NCT03521817|OTHER|No Alcohol|This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
223432270|NCT03702712|BEHAVIORAL|Aerobic Exercise and Relaxation|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
224042217|NCT07131033|DRUG|Esketamine and Magnesium sulfate|Patients received a simultaneous intravenous infusion of esketamine (0.25 mg/kg) and magnesium sulfate (30 mg/kg) over 10 minutes before anesthesia induction, followed by continuous infusion of esketamine at 0.25 mg/kg/h and magnesium sulfate at 10 mg/kg/h via separate channels until surgery completion.
224042218|NCT07131033|DRUG|Saline|Patients in the control group received an equivalent volume of normal saline infused intravenously over 10 minutes before anesthesia induction, followed by continuous saline infusion at a matched flow rate via a separate channel until surgery completion.
224140395|NCT00566449|DRUG|JNJ-31001074|10 mg daily for 4 weeks
224140396|NCT00566449|DRUG|JNJ-31001074|30 mg daily for 4 weeks
224140397|NCT05739760|BEHAVIORAL|Poem book about relational health|Poem book will consist of illustrations, poetry, and tips for parents on how to resolve their child's upset, their own upset, and to develop a stronger relationship. The study physician may read the book to the families at the visit. Then, families are instructed to read the book at least once, for as many times as the parent opts to.
224140398|NCT05739760|BEHAVIORAL|Poem book about physical health and safety|Poem book will consist of illustrations, poetry, and tips for parents on how to keep their child physically healthy and safe, and to avoid accidental injuries. The study physician may read the book to the families at the visit. Then families are instructed to read the book at least once, for as many times as the parent opts to.
224140399|NCT01164592|DEVICE|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
224140400|NCT00469846|PROCEDURE|L-arginine supplementation in a medical food|
224140401|NCT00469846|PROCEDURE|Vitamin C and E supplementation in a medical food|
224140402|NCT06259773|DIAGNOSTIC_TEST|knee stability test (DYNEELAX)|Each knee was tested under a force 120 Newtons in a posterior to anterior direction to create anterior tibial translation at 20 degrees knee flexion. Side-to-side difference of anterior/posterior tibial translation (mm) was measured from radiographs. Measurement of rotation and translation by DYNEELAX was also recorded.
224140403|NCT04392336|OTHER|Trust/Respect feedback|This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
224140404|NCT01500018|DRUG|TC-5214|Single oral dose of 2 mg
224140405|NCT01500018|DRUG|TC-5214 Placebo|Single oral dose
224140406|NCT01500018|DRUG|Ketamine|Single oral dose of 100 mg
224140407|NCT01500018|DRUG|Phentermine|Single oral dose of 45 mg
224140408|NCT01500018|DRUG|TC-5214|Single oral dose of 8 mg
224140409|NCT01500018|DRUG|TC-5214|Single oral dose of 16 mg
224140410|NCT01500018|DRUG|Phentermine|Single oral dose of 90 mg
224140411|NCT06119451|BEHAVIORAL|Traditional Music Therapy|Intervention using traditional music therapy as an alternative therapy for burnout syndrome
224140412|NCT00128583|BIOLOGICAL|polyvalent melanoma vaccine|
224140413|NCT02742857|BIOLOGICAL|BQ-A Peptide Extract|BQ-A Peptide Extract
224140414|NCT02742857|BIOLOGICAL|Mesenchymal Stem Cells|Mesenchymal Stem Cells
224140415|NCT02742857|DEVICE|Transcranial Laser Therapy|Transcranial Laser Therapy
224140416|NCT02742857|DEVICE|Median Nerve Stimulator|Median Nerve Stimulator
224140417|NCT01360762|DRUG|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
224140418|NCT00059618|DRUG|PS-341 (Bortezomib)|Starting dose 0.8 mg/m\^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
224140419|NCT00059618|DRUG|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
224140420|NCT03985748|DEVICE|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
224140421|NCT03985748|DEVICE|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
224140422|NCT04432844|PROCEDURE|Biplanar Ultrasound guided Internal Jugular Vein Cannulation|Using Philips EPIQ elite ultrasound system with a high-frequency 3D and 4D volume linear array transducer (USG XL 14-3) to obtain the biplanar imaging of Internal jugular vein cannulation.
223432271|NCT03702712|BEHAVIORAL|Aerobic Exercise Only|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
224042219|NCT07130929|OTHER|Functional Electrical Stimulation|Physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb, associated with functional electrical stimulation.
224042220|NCT07130929|OTHER|Conventional physiotherapy|Conventional physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb.
224042221|NCT07130396|DIETARY_SUPPLEMENT|Multivitamin and a Probiotic|The duration of trial intervention and participation for an individual participant is approximately 3 months (12 weeks). Screening, during which eligibility to participate in the trial is assessed, occurs at baseline. A fixed, orally administered, dose of the study products (PhytoMulti® Multivitamin, 2 tablets/day and UltraFlora® Balance Probiotic, 1 capsule/day) are taken daily with breakfast
224042222|NCT07129200|OTHER|Hot environment|Hot environment of 35 degrees Celsius
224042223|NCT07129200|OTHER|Thermoneutral environment|Thermoneutral environment of 18 degrees Celsius
224042224|NCT07130825|OTHER|8 hours simulated mental workday|During a simulated 8-hour mental work day, subjects will complete a set of cognitive tests (ANAM4, version 4; Vista Life Science, Norman, OK, USA) 8 times (1 session approximately 45 minutes), with a break of approximately 10 minutes after each session.
223432272|NCT03702712|BEHAVIORAL|Relaxation Only|This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
223432273|NCT03066856|OTHER|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~* reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~* reducing high glycemic index food and high insulinemic foods.~* reducing sources of saturated fat (red and processed meat, milk and dairy products).~* eating mostly food of plant origin, with a wide variety of seasonal products."
223432274|NCT03153982|DRUG|Ruxolitinib|Given orally
223432275|NCT05740683|DIAGNOSTIC_TEST|RT-QuiC|RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
223432276|NCT06084715|OTHER|Nutritional support|The hospitals in Benin already provide nutritional support for patients with pulmonary TB which will continue throughout the study.
223432277|NCT00082017|DRUG|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m\^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m\^2 Cycle 2: 45 mg/m\^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m\^2; Repeat cycles every 21 days."
223432278|NCT01848743|DRUG|Tenofovir|
223432279|NCT01848743|DRUG|lamivudine|
223432280|NCT03264378|BEHAVIORAL|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home-3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks-to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
223565457|NCT02876458|OTHER|Immediate coronary angiogram|An immediate coronary angiogram will be performed
223565458|NCT02876458|OTHER|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
223565459|NCT00280618|DRUG|Oxaliplatin|
224042225|NCT07130825|OTHER|Moderate intensity aerobic activity|In one of the conditions, subjects will perform moderate intensity aerobic activity (cycle veloergometer) for 30 min before 8 hours simulated mental workday and after.
224042226|NCT07130825|OTHER|Combined work model|In one of the conditions, subjects will perform cognitive test during 8 hours simulated mental workday applying combined work model (they will work standing and sitting on a balance ball).
224042227|NCT07130630|OTHER|Completion of Vietnamese Pain Self-Efficacy Questionnaire (PSEQ)|Participants completed the Vietnamese version of the Pain Self-Efficacy Questionnaire (PSEQ) to assess self-efficacy beliefs related to pain management.
224042228|NCT07129239|OTHER|Maintenance|Patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response
224140423|NCT01839175|BIOLOGICAL|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
224140424|NCT01839175|BIOLOGICAL|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
224140425|NCT01839175|BIOLOGICAL|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
224140426|NCT01839175|BIOLOGICAL|RotaTeq|2 mL oral administration at 2, 3 and 4 months
224140427|NCT01839175|BIOLOGICAL|Nimenrix|0.5 mL intramuscular injection at 12 months
224140428|NCT01839175|BIOLOGICAL|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
224140429|NCT01103778|DRUG|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
224140430|NCT04740099|OTHER|SOONER Video & Kit|A brief animated video including basic instructions for opioid overdose response accompanied by a Naloxone kit with an info graphic.
224140431|NCT04740099|OTHER|Standard of Care|A handout including a map and list of locations offering this service.
224042229|NCT07128563|DEVICE|piriform cortex-DBS|The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are biliteral piriform cortex.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
224042230|NCT05686187|OTHER|AR's platform for gender empowerment|The intervention of the experimental group is to accept the courses of the gender empowerment platform introduced by AR. The preliminary plan is 50-60 minutes each time. The content of the teaching plan course will adopt the course module design. Group content, and among the three module courses, there must be a core module course unit that is the workplace sexual harassment prevention unit
224042231|NCT07128537|PROCEDURE|Scheduled Oropharyngeal Suctioning Every 4 Hours|"The intervention in this study involves scheduled oropharyngeal suctioning every 4 hours, which distinguishes it from other oral care protocols used in clinical practice. In this arm, patients will receive systematic suctioning of the oropharyngeal area using a sterile suction catheter every 4 hours throughout their ICU stay, starting from the first day of mechanical ventilation. This frequent suctioning is designed to remove accumulated secretions that can harbor bacteria, reducing the risk of aspiration into the lungs, which is a major cause of early-onset Ventilator-Associated Pneumonia (VAP).~This intervention is not based on clinical need or visible signs of discomfort (as with traditional on-demand suctioning). Instead, it follows a standardized protocol of proactive, scheduled suctioning. The procedure will be performed by trained ICU staff and will involve suctioning for 10-15 seconds per session, ensuring adequate removal of secretions while minimizing patient discomfort. In"
224042232|NCT07128537|PROCEDURE|Standard Oral Care (Twice-Daily Brushing)|Participants in this group will receive standard oral care as part of ICU routine practice. This includes brushing of teeth, gums, and tongue twice a day to clear accumulated secretions and reduce bacterial growth. Additionally, on-demand suctioning will be performed if clinically indicated (e.g., when visible secretions or discomfort are observed). The control group will not receive the scheduled 4-hourly suctioning intervention, serving as a comparison to evaluate the effectiveness of regular suctioning in preventing VAP.
224042233|NCT07129915|BEHAVIORAL|Linguistic Nudging Training|Physicians receive 4-hour communication training to optimize shared decision-making using behavioral nudging techniques
224042234|NCT07129915|DEVICE|Medication Preference App|Patients use WeChat-based mini-program to record daily medication preferences and concerns
224042235|NCT07129915|OTHER|Standard Diabetes Care|Routine follow-up visits, HbA1c monitoring, and basic health education per hospital protocol
224042236|NCT06937372|DRUG|Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery.|Unlike low molecular weight heparin (LMWH), which requires daily subcutaneous injections, aspirin is taken orally, making it more comfortable and acceptable for patients, particularly the elderly or those with mobility issues. Aspirin is significantly less expensive than injectable anticoagulants like LMWH or newer oral anticoagulants, making it a potentially cost-effective alternative for thromboprophylaxis.
224042237|NCT06937372|DRUG|Low molecular weight heparin (LMWH)|"LMWH is administered via daily subcutaneous injection, typically starting shortly after surgery and continued for a defined period as per each hospital's local policy, often 14 to 28 days. LMWH has a proven track record of reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) after surgery.~However, it carries a risk of bleeding and may be challenging for some frail or elderly patients to tolerate, especially if self-injection is required post-discharge."
224042238|NCT06940505|OTHER|Telemedicine Follow-up|Oncological follow-up in a general hospital close to the patient, with aid of Telemedicine evaluation of the endoscopy video's by a Head and Neck surgeon in a specialised oncology centre
224042239|NCT06941545|DEVICE|Alimetry|High resolution gastric mapping of electrical gastric activity.
224140432|NCT04724733|BEHAVIORAL|Smoke Sense|Smoke Sense is a smartphone application (app). Smoke Sense participants will be asked to establish a profile which includes demographics, baseline health information and current beliefs about smoke and air pollution. In the Symptoms \& Smoke Observations tab, participants are asked to report their weekly observations of smoke, health symptoms, and exposure reduction behaviors. In the Fire \& Smoke Near Me tab, participants review the most recent AQ data measured at an AQ monitoring sites. Participants are asked to complete the AQ 101 module which test knowledge of AQ facts and provides correct answers. Badges are awarded for accomplishments within the app to promote certain desired behaviors: completing a user profile, launching the app weekly to check local AQ, reporting smoke and symptom observations, expanding AQ knowledge with AQ lessons, and exploring the map. Finally, participants can engage with other users by viewing cumulative statistics of symptoms and smoke observations.
223432281|NCT03970148|PROCEDURE|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
223432282|NCT00538512|BIOLOGICAL|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
223432283|NCT00538512|BIOLOGICAL|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
223432284|NCT00538512|OTHER|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
223432285|NCT06203210|DRUG|Ifinatamab deruxtecan|12 mg/kg intravenous dose on Day 1 of each 21-day cycle
223432286|NCT06203210|DRUG|Topotecan|Topotecan will be administered per local SoC.
223432287|NCT06203210|DRUG|Amrubicin|Amrubicin will be administered per local SoC.
223432288|NCT06203210|DRUG|Lurbinectedin|Lurbinectedin will be administered per local SoC
223432289|NCT06964087|DRUG|OPT101|Subcutaneous injection.
223432290|NCT06964087|OTHER|OPT101 Placebo to Match (PTM)|5% Dextrose (w/v)
224042240|NCT06941545|DEVICE|tVNS|Transcutaneous Auricular Vagal Nerve Stimulation, electrical stimulation to the ear.
224042241|NCT06941545|DEVICE|Gastroduodenal Manometry|Pressure catheter evaluating gastric and duodenal pressure profiles at rest and with certain stimuli applied
224042242|NCT04708613|DIAGNOSTIC_TEST|Cognitive/Neuropsychological Testing|Comprehensive testing of cognitive function and brain health.
224042243|NCT04708613|DIAGNOSTIC_TEST|Vestibular/Ocular-Motor Testing|A series of tests and questionnaires that asses vestibular function, balance, ocular-motor coordination, and reflexes.
224042244|NCT04708613|DIAGNOSTIC_TEST|Sleep Evaluation|A full assessment of sleep health, including insomnia (duration, frequency, daytime consequences) and other sleep disorders such as obstructive sleep apnea. Overnight sleep study is included.
223432291|NCT05390944|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
224042245|NCT04708613|DIAGNOSTIC_TEST|MRI, High-Resolution|A high-resolution MRI to provide qualitative and quantitative assessments of brain structure.
224042246|NCT04708613|DIAGNOSTIC_TEST|Health & Physical Exam|Participants will undergo an executive history and physical exam of all body systems.
224042247|NCT04708613|DIAGNOSTIC_TEST|Physical Function|These assessments will involve a series of tests and questionnaires that focus on physical function.
224042248|NCT04708613|DIAGNOSTIC_TEST|Blood Testing and Biomarker Analysis|"A blood draw will be performed to measure standard clinical labs as part of a full history and physical, as well as additional analysis of biomarkers indicative of brain health.~An optional lumbar puncture will be performed and CSF samples (20-30 mL) stored in the NCTC Biorepository until shipment to the CLIA-certified laboratory.~Both CSF and blood samples will be analyzed for t-tau, p-tau, and Aβ42 and stored for future testing,"
224042249|NCT04708613|DIAGNOSTIC_TEST|Applanation Tonometry|Hearth health is evaluated through testing of arterial stiffness and pulse wave reflections using a high fidelity applanation tonometer.
224042250|NCT04708613|DIAGNOSTIC_TEST|PET brain imaging|PET imaging of the brain using tau and amyloid ligands.
224042251|NCT04708613|DRUG|[C-11]6-OH-BTA-1|PET imaging of the brain using an amyloid ligand.
224042252|NCT04708613|DRUG|[F-18]AV-1451|PET imaging of the brain using a tau ligand.
224042253|NCT06950879|OTHER|Measurement|"A wooden construction was built consisting of two plates with dimensions of 35 x 29 cm: a bottom plate, with a measuring mat glued to it, a movable middle plate and a smaller top plate, allowing to mount a standardized overhead camera.~Participants were seated and placed one hand palm down on the measuring mat on the bottom plate. The hand was aligned with the midline of the body, lay flat with the fingers straight and lightly spread. First the actual landmarks were marked on the computer. Subsequently the participants hand was occluded by adding the middle plate. Participants were verbally cued to mark a certain landmark with their contralateral hand. These indicated points were marked on the computer. Before and after each trial, a picture was taken without the occluding board to ensure that the hand had not moved from its original position by digitally overlaying the images"
224042254|NCT07129954|BEHAVIORAL|Motor rehabilitation|Motor rehabilitation will be characterized by sessions of 45 minutes each with a patient (total sessions 36): physiotherapist ratio of 1:1. The rehabilitation project will be defined by the PM\&R specialist and the physiotherapist who will take charge of the patient. The treatment will focus on the maintenance of active and passive joint ranges, on the training of balance and gait, and on exercises of proprioception and scenic reinforcement. Specific devices (rehabilitation beds, verticalizer, posturography platform) will be used during motor treatment
224042255|NCT07129954|BEHAVIORAL|Motor Rehabilitation and Cognitive Behavioral Therapy|"1 session per week of 45 minutes of cognitive behavioral therapy and 2 sessions per week of 45 minutes of motor rehabilitation. The length of the treatment is the same as the control group: 12 weeks for 12 CBT sessions and 24 motor rehabilitation sessions (a total of 36 sessions).~Motor rehabilitation will be the same as that provided to the control group. In addition, participants will receive Cognitive-Behavioral Therapy (CBT), consisting of individual 45-minute sessions (one psychotherapist per patient).~The sessions will focus on the relationship between cognition, emotions, and behavior. Specifically, the therapist will work with the patient to identify and modify automatic thoughts, cognitive distortions, and underlying beliefs or patterns associated with the fear of falling."
224042256|NCT04256421|DRUG|Tiragolumab|Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
224042257|NCT04256421|DRUG|Atezolizumab|Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
224042258|NCT04256421|DRUG|Carboplatin|Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
224042259|NCT04256421|DRUG|Etoposide|Etoposide 100 mg/m\^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
224042260|NCT04256421|DRUG|Placebo|Placebo administered by IV infusion on Day 1 of each 21-day cycle.
224042261|NCT06789185|DRUG|0.1mg/kg esketamine|Intravenous injection 0.1mg/kg esketamine about 5min before the end of the surgery
224299566|NCT04919941|OTHER|A Guide to Conservative Care|The intervention is receipt of a patient decision aid on conservative care, entitled A Guide to Conservative Care. This is 12-page printed handout that provides an overview of conservative care. Participants assigned to the intervention group are mailed a copy of the Guide after their initial baseline visit (T1). Participants keep the Guide throughout the duration of the study.
224042262|NCT06789185|DRUG|0.2mg/kg esketamine|Intravenous injection 0.2mg/kg esketamine about 5min before the end of the surgery
224042263|NCT06789185|DRUG|0.1ml/kg normal saline|Intravenous injection 0.1ml/kg normal saline about 5min before the end of the surgery
224042264|NCT05999175|DEVICE|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.|the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days.
224299567|NCT01230892|DRUG|Nebivolol|10 mg PO qday
224299568|NCT01230892|DRUG|Atenolol|100 mg PO qday
224299569|NCT01687582|DRUG|GLP-1 analog|GLP-1 analog treatment
223432292|NCT05390944|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
223432293|NCT04762602|DRUG|HMPL-306|Administered orally QD in a 28-day continuous dosing treatment cycle
223432294|NCT06032143|BEHAVIORAL|Online educational phthalate course|This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
223740468|NCT06219447|DEVICE|VRRS Home Tablet or Medico Amico Kids APP|Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
223740469|NCT00344227|DRUG|Lucentis (Ranibizumab)|
223740470|NCT05160831|BIOLOGICAL|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cell injection is applied for treating knee OA patients.
223740471|NCT02237859|DRUG|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
223740472|NCT02237859|DIETARY_SUPPLEMENT|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
223740473|NCT02024867|DRUG|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
223740474|NCT02116400|OTHER|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
223740475|NCT02116400|OTHER|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
223740476|NCT02116400|BIOLOGICAL|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
223740477|NCT06037720|DEVICE|Coaguchek testing|Patients scheduled electively to undergo cardiac surgery with cardiopulmonary bypass at Hospital de Base in the Federal District.
223740478|NCT05331287|OTHER|Head position|Influence of different head position on nasal endotracheal intubation
223740479|NCT00047840|DRUG|ZD6474|
223740480|NCT00047840|DRUG|Placebo|
223740481|NCT00047840|DRUG|Docetaxel|
223740482|NCT05537402|DRUG|Atezolizumab and bevacizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle and Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle
223740483|NCT05537402|RADIATION|transarterial chemoembolization (TACE) or transarterial radioembolization (TARE|TACE cycles occur every 8 weeks +/- 7 days OR TARE cycles occur every 12 weeks +/- 7 days
223740484|NCT04561206|DRUG|Brentuximab Vedotin|Given IV
223740485|NCT04561206|BIOLOGICAL|Nivolumab|Given IV
223740486|NCT04695899|DEVICE|Dental Implant|"See Section Procedures."
223740487|NCT01571258|BEHAVIORAL|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
223740488|NCT03592147|OTHER|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
223740489|NCT03592147|OTHER|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
223740490|NCT03592147|OTHER|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
223740491|NCT03592147|OTHER|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
223740492|NCT03592147|OTHER|Music and Relaxation Light|The music and relaxation lighting were combined.
224042265|NCT05999175|DEVICE|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."|"the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial  Spazzolino tau-marin® 3 times a day after the main meals for 28 days."
224042266|NCT05999175|DEVICE|subjects of this group will use their routine oral hygiene products.|subjects of this group will use their routine oral hygiene products.
224042267|NCT04752475|DRUG|Furosemide|Furosemide 20 mg pill taken daily for 5 days
224042268|NCT04752475|OTHER|Placebo|Identical-appearing placebo pill taken daily for 5 days
224042269|NCT06143085|PROCEDURE|Root surface debridement|Periodontitis patients are treated non-surgically by supra- and subgingival debridement followed by root surface debridement for moderately deep periodontal pockets (4 to 6mm)
224042270|NCT02688673|BIOLOGICAL|adenovirus-transfected autologous DC vaccine plus CIK cells|
224042271|NCT01277770|DRUG|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
223432295|NCT06032143|BEHAVIORAL|Control environmental education|Participants in the control group will receive access to environmental exposures other than phthalates.
223432296|NCT06032143|BEHAVIORAL|Phthalate conversation|Participants in the intervention groups will be asked to engage in conversations about phthalates between doulas/pregnant individuals.
224042272|NCT01277770|OTHER|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
224042273|NCT01277770|DRUG|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
224042274|NCT02753790|RADIATION|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume \[PTV\] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
224042275|NCT02428010|DEVICE|TMVR Implant|Implantation of the Twelve TMVR System
224042276|NCT00893126|PROCEDURE|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
224042277|NCT02952391|OTHER|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer \[18F\]Fluoroethoxybenzovesamicol
224299570|NCT01983319|DEVICE|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
224299571|NCT01983319|DEVICE|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
224299572|NCT01983319|BEHAVIORAL|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
224299573|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
224299574|NCT06409650|DRUG|KX-826 dosed at 2.5mg|2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
224299575|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks
224299576|NCT06409650|DRUG|KX-826 dosed at 5 mg|5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks
224299577|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp once daily for 24 weeks
224299578|NCT06409650|DRUG|Matching placebo to KX-826|Placebo applied topically to scalp twice daily for 24 weeks
224299579|NCT03986450|OTHER|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
224299580|NCT00679913|PROCEDURE|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
223740493|NCT03592147|OTHER|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
224042278|NCT02827305|DRUG|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
224042279|NCT02827305|PROCEDURE|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
224042280|NCT00177138|DRUG|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
224042281|NCT00177138|DRUG|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)
224042282|NCT06261086|DIAGNOSTIC_TEST|evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)|2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
224042283|NCT03746951|DRUG|Ropivacaine Hcl 0.5% Inj Vil 20Ml|Anesthetic agent used in peripheral nerve block
224299581|NCT00679913|PROCEDURE|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
224299582|NCT06437106|BEHAVIORAL|A blanket impregnated with the mother's odor|Intervention group 1 consists of premature babies who receive a blanket impregnated with the mother's odor.
224299583|NCT06437106|BEHAVIORAL|blanket without mother's smell|Intervention group two consists of preterm infants who receive blanket without mother's odor.
224299584|NCT06437106|BEHAVIORAL|control group|The control group includes premature babies who are not subjected to any intervention and receive the usual care.
224299585|NCT01597219|PROCEDURE|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4
224299586|NCT01597219|PROCEDURE|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0
224299587|NCT05086718|OTHER|Endoscopic ear surgery|Endoscopic approach without posterior meatal flap elevation will be employed in the ear with dry chronic suppurative otitis media. Tympanoplasty utilizing composite cartilage-fascia graft will be performed. After three months of time period successful outcome will be taken as closure of air bone gap on pure tone audiometry.
224299588|NCT00287313|DRUG|Vitamin K|
224299589|NCT00000813|BIOLOGICAL|ALVAC-HIV gp160MN (vCP125)|
224299590|NCT00000813|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
224299591|NCT00000813|BIOLOGICAL|rgp120/HIV-1 SF-2|
223432297|NCT06032143|BEHAVIORAL|Environmental exposures conversation|Participants in the intervention groups will be asked to engage in conversations about environmental exposures (other than phthalates) between doulas/pregnant individuals.
224299592|NCT03560921|DIAGNOSTIC_TEST|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
223432298|NCT05523947|DRUG|YH32367|"Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8.~Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll 65 and 40 patients, respectively."
224042284|NCT04907110|DIETARY_SUPPLEMENT|Niagen|Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day
224042285|NCT04907110|OTHER|Exercise|During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.
224042286|NCT03146468|DRUG|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
224042287|NCT02901873|DEVICE|Electrical Impedance Spectroscopy|
224042288|NCT00182182|BEHAVIORAL|Primary care based disease management strategy|
224042289|NCT02113579|DEVICE|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
224042290|NCT02113579|OTHER|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
224042291|NCT02017041|DEVICE|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
224042292|NCT02017041|DEVICE|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
224042293|NCT03136419|DIETARY_SUPPLEMENT|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
224042294|NCT03136419|DIETARY_SUPPLEMENT|Placebo|Placebo supplementation for 8 weeks
224042295|NCT03765775|BIOLOGICAL|Sintilimab|Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
224042296|NCT03765775|DRUG|Anlotinib Hydrochloride|Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
224042297|NCT02871973|BEHAVIORAL|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
224042298|NCT02871973|BEHAVIORAL|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
224042299|NCT04283266|DIETARY_SUPPLEMENT|Synbiotic|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
224042300|NCT04283266|DIETARY_SUPPLEMENT|Placebo|Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
224042301|NCT00638560|DIETARY_SUPPLEMENT|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
224042302|NCT00638560|DIETARY_SUPPLEMENT|Antioxidant treatment|no treatment
224042303|NCT04035850|DRUG|Vortioxetine Tablets|Strength 5-20 mg
223432299|NCT05698147|DRUG|Selinexor|"Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death."
223432300|NCT05698147|DRUG|Rituximab|Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
223432301|NCT05698147|DRUG|Methotrexate|high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
223432302|NCT06282757|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
223432303|NCT06282757|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo stimulating verbal language.
223565460|NCT02301546|BEHAVIORAL|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
223565461|NCT01247025|OTHER|No intervention|This study will not contain a specific intervention
223565462|NCT01684696|BEHAVIORAL|Virtual experience|
223565463|NCT01684696|BEHAVIORAL|Videos|
224042304|NCT02567539|RADIATION|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
224042305|NCT02567539|DRUG|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
224042306|NCT03339869|OTHER|Blood sample|The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
224042307|NCT05935124|DIAGNOSTIC_TEST|WLE first, then B-NBI|
224042308|NCT05747508|COMBINATION_PRODUCT|INOpulse®|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
224042309|NCT05747508|COMBINATION_PRODUCT|Placebo|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
223432304|NCT06583941|DIETARY_SUPPLEMENT|Low Dose Virtiva Plus|Participants will consume a low dose of Virtiva Plus (120mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (120mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
224042310|NCT05747508|COMBINATION_PRODUCT|Long Term Follow Up|Patients will be treated by means of an INOpulse® device using an INOpulse® nasal cannula
224042311|NCT05060263|DRUG|HOT-1030|HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
223432305|NCT06583941|DIETARY_SUPPLEMENT|High Dose Virtiva Plus|Participants will consume a high dose of Virtiva Plus (240mg) twice daily, for 5 weeks. Prior to receiving their first study treatment, participants will undergo baseline assessments on all study variables. Including computerized cognitive assessment and survey questionnaires. After 4 weeks of supplementation, participants will take one serving of their treatment (240mg of Virtiva Plus) with a normal meal. Three hours later, participants will complete cognitive tests. On a separate day, the same procedure will be repeated, and subjects will take the survey tests.
223432306|NCT05328180|OTHER|Sodium bicarbonate|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5% is buffered with 7.5% sodium bicarbonate in 1:10.
223432307|NCT05328180|OTHER|Control arm|A 50/50 solution of lidocaine with adrenalin 1% and bupivacaine with adrenalin 0.5%.
223432308|NCT02567422|DRUG|Berzosertib|Given IV
223432309|NCT02567422|DRUG|Cisplatin|Given IV
223432310|NCT02567422|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223432311|NCT02567422|OTHER|Laboratory Biomarker Analysis|Correlative studies
223432312|NCT02567422|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223432313|NCT02567422|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224042312|NCT04828187|DIAGNOSTIC_TEST|Comparison of the proposed artificial network with the ground truth|"Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth."
224042313|NCT02217436|DEVICE|iPad|iPad with age-appropriate applications, videos, and music
224042314|NCT02217436|OTHER|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
224140433|NCT04724733|BEHAVIORAL|Smoke Sense Plus|Participants randomized to the Smoke Sense Plus intervention will be asked to do everything that the Smoke Sense intervention group does on a weekly basis, as well as: 1) Receive weekly push notifications that remind them to, for example, review their asthma action plan, refill any expired medications, take their daily controller medication, identify a clean air space in their home and community, 2) Monitor their lung function weekly via mobile spirometry, and 3) Subscribe to a social network to share strategies to minimize exposure.
224140434|NCT03420443|DIETARY_SUPPLEMENT|Oat bran|45 g oat bran.
223432314|NCT02567422|RADIATION|Radiation Therapy|Undergo radiation therapy
223432315|NCT04356677|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
223432316|NCT04356677|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
223432317|NCT05773781|OTHER|PuraBond|Application of PuraBond to surgical field
223432318|NCT05391048|DRUG|IMP4297(20mg)|Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
223432319|NCT05391048|DRUG|IMP4297(10mg)|Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
223432320|NCT05488691|BEHAVIORAL|EMDR|The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.
223432321|NCT05488691|BEHAVIORAL|TAU|treatment as usual for substance use disorders
223432322|NCT06091904|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
223432323|NCT06091904|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
223432324|NCT04240886|DRUG|fosmanogepix|IV and oral fosmanogepix
223432325|NCT03740139|OTHER|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
223740494|NCT02150954|DRUG|pitocin|
224042315|NCT01974089|OTHER|Dysphagia|Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
224042316|NCT01098981|DEVICE|Transcranial ultrasound as an adjunctive therapy to tPA|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with active insonation for 120 minutes"
224140435|NCT03420443|DIETARY_SUPPLEMENT|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
224140436|NCT03420443|DIETARY_SUPPLEMENT|No oral supplementation|No oral supplementation.
224042317|NCT01098981|DRUG|Standard of care tPA therapy for acute ischemic stroke|"* tPA per approved labeling administered over 60 minutes~* Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
224042318|NCT05510765|BEHAVIORAL|Transportation service|Improved transportation assets applied to all aspects of subjects life
224042319|NCT00830245|DRUG|Erlotinib|Erlotinib 150mg/day
224042320|NCT05195944|DRUG|Semaglutide Treatment|"The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day."
224042321|NCT05195944|DRUG|Sitagliptin 100mg|"participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period"
224140437|NCT01193140|DRUG|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
224140438|NCT01193140|DRUG|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
224140439|NCT01408667|DRUG|TRC150094|50 mg Tablets once a day
224140440|NCT01408667|OTHER|Placebo|Tablets once daily
224140441|NCT04266106|DRUG|SuperBio probiotic|One capsule po BID for 28 days
224042322|NCT05315362|DEVICE|solid microneedle skin patch|intradermal vaccination with a skin patch
224042323|NCT05315362|BIOLOGICAL|mRNA-1273|administration of mRNA-1273 vaccine
224299593|NCT01006564|OTHER|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
224299594|NCT01006564|OTHER|Other|Insertion of gold seeds into prostate for image registration.
224299595|NCT00725621|BIOLOGICAL|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
224299596|NCT00428779|PROCEDURE|running during 24 hours without sleep|patients running during 24 hours without sleep
224299597|NCT00428779|OTHER|no sleeping|patients without sleep during 24 hours
224299598|NCT05702879|DRUG|Ozanimod|Start of standard therapy
224299599|NCT05702879|DRUG|TNF Inhibitor|Start of standard therapy
224299600|NCT05702879|DRUG|Steroids|Start of standard therapy
223565464|NCT06166459|PROCEDURE|Drug-coated balloon combined with provisional drug-eluting stent implantation|(1) DCB combined with provisional DES implantation 1-2 mm distally to the ostium lesion whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the ostium lesions followed by DCB treatment (DES+DCB strategy).
223565465|NCT03053986|DIETARY_SUPPLEMENT|Apple polyphenols|1 tablet per day at evening before sleeping
224042324|NCT05315362|DEVICE|standard needle|intramuscular vaccination with a standard needle
224042325|NCT03511547|DEVICE|Pitch Patch|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ \[PP\]) augmentation.
224042326|NCT03511547|DEVICE|ArthroFlex|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® \[AF\]) augmentation.
224042327|NCT06070844|BEHAVIORAL|yoga nidra|Yoga Nidra is a guided meditation technique that involves listening to audio readings. Yoga nidra application will be started at the 6th postoperative hour and will be applied one time. Yoga nidra is expressed as yoga sleep or deep relaxation. In this practice, it will be ensured that the mother will mentally visualise all parts of her body with the commands to be given during controlled breathing and emotionally feel the body parts. The Yoga Nidra application will last 30 minutes.
224042328|NCT01410682|OTHER|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
224140442|NCT04266106|DRUG|Placebo|One capsule po BID for 28 days
224299601|NCT05702879|DRUG|Vedolizumab|Start of standard therapy
224299602|NCT05702879|DRUG|Ustekinumab|Start of standard therapy
224299603|NCT01189500|DRUG|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
224299604|NCT01189500|DRUG|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
224299605|NCT03939988|RADIATION|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
224299606|NCT03939988|RADIATION|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
224299607|NCT04691310|DEVICE|Kinesio Tex Gold|The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
224299608|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
224299609|NCT03330782|DRUG|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
224299610|NCT04560465|DRUG|Tranexamic acid|intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
224299611|NCT05028231|PROCEDURE|Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy|Each patient will complete 2 cycles of neoadjuvant therapy. After evaluating the curative effect, decide whether to operate or not. Patients with and without surgery enter the survival follow-up period.
224299612|NCT04999930|DEVICE|Aerochamber|efficacy and patients satisfaction
224299613|NCT04764630|DRUG|Four naloxone nasal spray doses (1 every 2.5 min)|Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min
224042329|NCT01410682|OTHER|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
224042330|NCT01667081|DRUG|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
224042331|NCT03034460|DRUG|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
224042332|NCT03034460|DRUG|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
224042333|NCT03034460|DRUG|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
224042334|NCT03034460|DRUG|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
224042335|NCT00914992|PROCEDURE|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
224042336|NCT00914992|OTHER|Squatting|Squatting
224140443|NCT03963713|RADIATION|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
224140444|NCT03963713|RADIATION|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
224140445|NCT00262977|BEHAVIORAL|Electronic prompt plus patient-directed intervention|
223432326|NCT03163056|BEHAVIORAL|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
224140446|NCT00262977|BEHAVIORAL|Electronic prompt to clinician to prescribe aspirin|
224299614|NCT04764630|DRUG|Four naloxone nasal spray doses (2 every 2.5 min)|Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)
224299615|NCT04764630|DRUG|Two naloxone nasal spray doses (1 every 2.5 min)|Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
224299616|NCT01319786|OTHER|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
224299617|NCT01319786|OTHER|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
224299618|NCT02540317|BEHAVIORAL|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
224299619|NCT02963402|DRUG|Tocilizumab|
224299620|NCT02963402|DRUG|Adalimumab|
224299621|NCT03323723|DEVICE|SUI Device|Pessary SUI device
224299622|NCT04131049|OTHER|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
224299623|NCT04131049|OTHER|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
223565466|NCT03053986|OTHER|Placebo|1 tablet per day at evening before sleeping
223565467|NCT00022204|DIETARY_SUPPLEMENT|vitamin E|
224042337|NCT00343616|PROCEDURE|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
224042338|NCT00343616|PROCEDURE|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
224042339|NCT00343616|PROCEDURE|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
224299624|NCT04131049|OTHER|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
224299625|NCT04131049|OTHER|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
224299626|NCT03415984|DIAGNOSTIC_TEST|Color retinography|Color retinography
224299627|NCT03415984|DIAGNOSTIC_TEST|Optical coherence tomography|Optical coherence tomography
224299628|NCT03415984|DIAGNOSTIC_TEST|Fundus autofluorescence imaging|Fundus autofluorescence imaging
223565468|NCT00022204|DRUG|pentoxifylline|
223565469|NCT00022204|PROCEDURE|quality-of-life assessment|
224299629|NCT02307643|DRUG|MT-1303 Low dose|
224299630|NCT02307643|DRUG|MT-1303 High dose|
224299631|NCT02021370|DRUG|BAY85-3934|25mg Tablet
224299632|NCT02021370|DRUG|Placebo|Matching placebo tablet
224299633|NCT01606059|DRUG|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
224299634|NCT01606059|DRUG|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
224299635|NCT01092078|BEHAVIORAL|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
224299636|NCT01092078|BEHAVIORAL|Patient Navigation|Patient navigation for colonoscopy.
224042340|NCT00343616|PROCEDURE|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
224042341|NCT01964261|DEVICE|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 3 NeuroPort Arrays (SIROF). The tip of the electrodes are sputtered iridium oxide film (SIROF). Each array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
224042342|NCT01821833|DIETARY_SUPPLEMENT|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
224042343|NCT01821833|DIETARY_SUPPLEMENT|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
224042344|NCT01821833|DRUG|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
224042345|NCT00520455|DRUG|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
224042346|NCT01798992|DRUG|Carvedilol|
224042347|NCT01798992|DRUG|Metoprolol succinate|
224042348|NCT01798992|DRUG|Metoprolol succinate + doxazosin|
223432327|NCT03163056|BEHAVIORAL|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
223432328|NCT03163056|BEHAVIORAL|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
223432329|NCT01942317|OTHER|Balneotherapy|
223740495|NCT02621242|PROCEDURE|Upper endoscopy|Upper endoscopy with biopsies
223432331|NCT06040502|BEHAVIORAL|The DICE Approach|Systematic guidance for care partners through assessment and management of the behavioral and psychological symptoms of dementia
223432332|NCT01232621|OTHER|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
223432333|NCT05994313|DIETARY_SUPPLEMENT|Habitual potato consumption|Potatoes are to be consumed in the evening meal, every evening for 12-weeks.
223740496|NCT02621242|PROCEDURE|Anoscopy|Anoscopy with biopsies
224042349|NCT04467944|OTHER|Pre-existing degenerative factors at adjacent segment|Pre-existing degenerative factors at adjacent segment, including disc factors and canal stenosis factors
224042350|NCT03809455|DRUG|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge…), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
224042351|NCT03809455|DRUG|Placebo|one intake of placebo (intranasal or buccal)
224042352|NCT03881228|BEHAVIORAL|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
224042353|NCT05525728|OTHER|Neurosensory|Physiological and neurophysiological investigations
224042354|NCT04853836|COMBINATION_PRODUCT|co-ultraPEALut|Olfactory rehab 10 minutes twice a day for all the observation period + co-ultraPEALut (700 PEA + 70 Luteolin) 1 dose daily.
224042355|NCT04853836|PROCEDURE|Olfactory Rehab|Olfactory Rehabilitation10 minutes twice a day for all the observation period
224042356|NCT04853836|DRUG|PEA-LUT 1 sachet|Only 1 sachet day of PEA-LUT no olfactory training
224042357|NCT04853836|DRUG|PEA-LUT 2 sachet day|2 sachets day of PEA-LUT no olfactory training
224140447|NCT05613842|DRUG|Copper-64 labelled SAR-Bombesin|radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
224140448|NCT06314165|OTHER|music medicine practice|Music medicine will be applied
224140449|NCT05108688|DRUG|Mirtazapine|Mirtazapine 30 mg tablet once daily for 3 successive days
224140450|NCT05108688|DRUG|Sumatriptan|Sumatriptan 50 mg tablet once daily for 3 successive days
224140451|NCT05108688|OTHER|Placebo|Placebo tablets once daily for 3 successive days.
224299637|NCT05195749|DRUG|101-PGC-005 ('005) + SOC|Three consecutive days of '005 administration
224140452|NCT03986190|BEHAVIORAL|Healthy Juntos|"Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in weekly 15-30 minute sessions regarding the family's progress throughout the intervention period."
224140453|NCT04511819|DRUG|Losmapimod oral tablet|Losmapimod will be administered with food when possible.
224140454|NCT04511819|DRUG|Placebo oral tablet|Placebo will be administered with food when possible.
224140455|NCT05194501|OTHER|Nine Hole Peg Test, Jamar dynamometer, pinchmeter|"Hand grip and pinch strengths: Hand grip strengths and tip pinch strengths were measured using a Jamar type hand dynamometer and pinchmeter available in our clinic.~The Nine Hole Peg Test (NHPT): Hand dexerities were evaluated with the NHPT available in our clinic."
223432334|NCT05994313|DIETARY_SUPPLEMENT|Habitual non-nutrient-dense staple consumption|White rice, white pasta or white couscous are to be consumed in the evening meal, every evening for 12-weeks.
223432335|NCT04427137|DEVICE|MagPro X100 Stimulator, B70 Fluid-Cooled Coil|Treatment will occur 8 times per treatment day (50 min pause between treatments). Each treatment session will consist of a single LFR treatment, with 360 pulses of LFR delivered in one continuous train of 6 minutes at 1Hz at 120% of the patient's resting motor threshold.
223432336|NCT04896437|PROCEDURE|non-centrifuge fat graft application to the wounds|Autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. Clinical observation and photograph records were used to follow the wounds.
223432337|NCT04497350|DEVICE|Transcranial Magnetic Stimulation|5,000 pulses (120-140% MT, continuous temperature of 24C) will be delivered per session (see Appendix A for timing parameters). Patients will have one TMS session per day, five days a week, until their treatment is completed (approximately four weeks).
223432338|NCT04497350|DEVICE|Theta Burst Stimulation|One session of iTBS will deliver 1,800 pulses (120-140% MT, continuous temperature of 22ºC) over an 9-minute-40-second period. The minimum break period between iTBS sessions is 25 minutes.
223432339|NCT02398370|BIOLOGICAL|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
223432340|NCT00098202|DRUG|Low phytic acid maize|
223432341|NCT00098202|DRUG|Zinc|
223432342|NCT01074723|DIETARY_SUPPLEMENT|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
223432343|NCT04508114|BEHAVIORAL|Technology-assisted Index|The participant will be informed the ATP testing result and explanation in pretest.
223432344|NCT04618471|DEVICE|Boston Scientific WaveWriter SCS System|WaveWriter SCS Programming
223432345|NCT05853211|COMBINATION_PRODUCT|Aligner and inter-arch elastics|Correction of class II malocclusion by class II elastics on clear aligners
223432346|NCT02376296|DRUG|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
223432347|NCT02376296|OTHER|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
223432348|NCT03859180|BEHAVIORAL|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
223432349|NCT05490823|DEVICE|A smartphone app for anemia screening|This app can achieve automatic detection of anemia based on patient-sourced images of fingernails and conjunctivae.
223565470|NCT06277414|OTHER|collection of laboratory test results, imaging results and symptoms|collection of laboratory test results, imaging results and symptoms
223565471|NCT04838054|DRUG|Stabilized chlorine dioxide oral rinse|Patients received stabilized chlorine dioxide rinse associated with periodontal basic therapy.
223565472|NCT04838054|OTHER|Placebo|Patients received a rinse containing no active ingredients and periodontal basic therapy.
223565473|NCT04894344|BEHAVIORAL|Education group|Is taught to choose low-sodium foods
223565474|NCT04404036|DEVICE|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
223565475|NCT03966963|BEHAVIORAL|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
223565476|NCT05970003|OTHER|Copenhagen exercises|"Group A performs copenhagen exercises~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
223565477|NCT05970003|OTHER|Holmich exercises|"The Holmich treatment protocol exercise includes static and dynamic and/or isometric and isotonic strengthening exercises for hip adductors and abductors and also for abdominal muscles.~There are 6 Different types of exercises were performed by players who were a participant with 3 sets of 10 repetitions with 15 sec recovery period.~Both groups will perform their routine warm ups and cool downs the total duration of the protocol is 6 weeks, 3 times a week the duration of each session 3 sets of 10 repetitions with 15 sec recovery period. Hip extensor and flexor stretching and strengthening."
223565478|NCT05809050|DIAGNOSTIC_TEST|BM aspirate|Bone Marrow aspiration \& Examination
223565479|NCT04054869|OTHER|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
223565480|NCT04054869|OTHER|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
223432350|NCT01080729|DRUG|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml \[22 micrograms/0.5 ml\]; 450 IU/0.75 ml \[33 micrograms/0.75 ml\]; or 900 IU/1.5 ml \[66 micrograms/1.5 ml\].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
223432351|NCT02800941|DRUG|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
224042358|NCT03486886|DIAGNOSTIC_TEST|PSMA -PET/CT scanning|"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."
223432352|NCT03129113|DRUG|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
223432353|NCT03129113|DRUG|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
223432354|NCT01229813|DRUG|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
223432355|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
223432356|NCT01229813|DRUG|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
223432357|NCT01229813|DRUG|low dose capecitabine|capecitabine 500 mg twice daily
223432358|NCT03954717|BEHAVIORAL|Shepherd CAN DO Program|CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
224140456|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter≥2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter≥2.00 mm)
224140457|NCT04953117|DEVICE|Restore DEB|subjects receiving Restore DEB
223432359|NCT01752634|DRUG|Secukinumab (AIN457)|Secukinumab (AIN457)
223432360|NCT01752634|DRUG|Placebo|Placebo PFS for s.c. administration.
223432361|NCT03071679|DRUG|Omiganan|Omignan 1%, 2.5%
223432362|NCT03071679|DRUG|Imiquimod|Imiquimod 15mg
223432363|NCT03071679|DRUG|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
223432364|NCT03071679|DRUG|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
223432365|NCT03071679|DRUG|Placebo|Vehicle
223432366|NCT00727987|DRUG|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
223432367|NCT00727987|DRUG|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
223432368|NCT00727987|DRUG|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
224042359|NCT06043115|OTHER|covid-19 survival cohort|consists of surviving patients
224042360|NCT06043115|OTHER|covid-19 mortality cohort|consists of deceased patients
224140458|NCT04953117|DEVICE|DCB of Lepu Medical(dimeter<2.00 mm)|subjects receiving DCB of Lepu Medical(dimeter\<2.00 mm)
224140459|NCT03957356|DEVICE|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
224140460|NCT01924156|BIOLOGICAL|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
224140461|NCT06006910|BEHAVIORAL|Column-based nudge in the EHR|The nudge is a column in EPIC that flags patients coming to the clinic as a new visit with documented ER+ breast cancer. The nudge flag can pop up when hovered over to remind surgeons of the Choosing Wisely criteria and to consider omission of SLNB.
223432369|NCT00516802|DRUG|KU-0059436 (AZD2281)(PARP inhibitor)|oral
223432370|NCT00516802|DRUG|dacarbazine|intravenous injection over at least 20 minutes
223432371|NCT01250171|BIOLOGICAL|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
223432372|NCT01250171|BIOLOGICAL|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
223432373|NCT01250171|BIOLOGICAL|Placebo|The placebo solution for infusion contained 5% glucose.
224140462|NCT06006910|BEHAVIORAL|No column-based nudge in the EHR|No intervention control period prior to nudge deployment.
224140463|NCT02116816|DIETARY_SUPPLEMENT|Polyphenol|Polyphenol
224140464|NCT03522701|BEHAVIORAL|CBTI|Refer to the arm description
224299638|NCT05195749|DRUG|Placebo + SOC|Three consecutive days of placebo administration
224299639|NCT04515537|DIETARY_SUPPLEMENT|Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),|Patient use 2 capsules 3 time a day by oral.
223432374|NCT02525302|DRUG|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
223432375|NCT01196936|DRUG|Tamoxifen Citrate|5 mg PO Daily
223432376|NCT01196936|DRUG|Placebo|1 tablet daily
223432377|NCT01196936|PROCEDURE|Digital mammography|Correlative studies
223432378|NCT01196936|OTHER|immunohistochemistry staining method|Correlative Studies
223432379|NCT01196936|OTHER|pharmacological study|Correlative Studies
223432380|NCT01196936|OTHER|laboratory biomarker analysis|Correlative Studies
223432381|NCT01196936|GENETIC|protein expression analysis|correlative studies
223432382|NCT01196936|OTHER|pharmacogenomic studies|correlative studies
223432383|NCT01196936|OTHER|questionnaire administration|Ancillary studies
223432384|NCT01196936|PROCEDURE|Fine needle aspiration|
223432385|NCT01196936|OTHER|Quality of Life Assessment|Ancillary Studies
223432386|NCT06556095|DRUG|Dexamethasone 4mg/ml solution|The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
223432387|NCT05748873|DRUG|SPVN06|AAV-RdCVF-RdCVFL
223432388|NCT06254898|BEHAVIORAL|Child life standard of care|Standard preparation and support provided to the participant by a Certified Child Life Specialist.
223432389|NCT06254898|BEHAVIORAL|Child life standard of care + incentives provided with conditional agreement.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. Before the procedure the child life specialist discusses earning a prize with the patient if they demonstrate the agreed upon coping goal (i.e. holding arm still, taking deep breaths, engaging in distraction.) At the end of the procedure the patient is provided with the prize if they earn the prize based on the agreed upon coping plan.
223432390|NCT06254898|BEHAVIORAL|Child life standard of care + incentive provided unconditionally.|Patient is provided standard preparation and support provided to the participant by a Certified Child Life Specialist. After the procedure is complete the patient is provided with a prize. The patient does not need to do anything to earn the prize.
223432391|NCT01110369|DIETARY_SUPPLEMENT|Protein drink|Protein drink twice a day during 6 months.
223432392|NCT01110369|OTHER|Resistance exercise training|Resistance exercise training twice per week during 6 months.
223432393|NCT01110369|DIETARY_SUPPLEMENT|Placebo drink|Placebo drink twice a day during 6 months.
223432394|NCT06104449|DRUG|Opevesostat|Tablets to be taken orally.
223432395|NCT06104449|DRUG|Dexamethasone|Tablets to be taken orally.
223432396|NCT06104449|DRUG|Fludrocortisone acetate|Tablet to be taken orally.
223432397|NCT06104449|DRUG|Hydrocortisone|Tablets to be taken orally as a recue medication.
223432398|NCT06581432|DRUG|Zongertinib|Zongertinib
223432399|NCT05015764|OTHER|Fluid Management|Removal of excess extracellular fluid using diuretics
223432400|NCT05015764|DEVICE|Reprieve Cardiovascular System|System with Fluid Management Module
223432401|NCT06474078|DRUG|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
223432402|NCT05242510|PROCEDURE|Patching|The subject will occlude the non-dominant eye for 24 hours.
223432403|NCT05242510|PROCEDURE|Prism Adaptation|The subject will undergo prism adaptation targeting the pre-occlusion distance angle for 1-2 weeks. • Fresnel prism(s) will be applied to the patient's spectacles equaling the distance angle between the two eyes. At the examiner's discretion depending on the size of the deviation, the prism(s) can be placed solely over the non-dominant eye, or split between the 2 eyes in some combination which results in equalization of the distance exotropia. If the distance angle calls for an amount of prism that cannot be exactly replicated with Fresnel prisms (e.g., 32 PD), the amount of prism used will be determined by rounding down to the nearest practical amount at examiner discretion.
224042361|NCT06244979|OTHER|Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)|100 MBq +/- 10% \[68Ga\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)
223432404|NCT05596318|DEVICE|Digital CBT-I|The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.
223432405|NCT05596318|DEVICE|Digital SHE|The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
223432406|NCT04523857|DRUG|Abemaciclib|Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
223432407|NCT04523857|DRUG|Hydroxychloroquine|Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
223432408|NCT06101940|DIAGNOSTIC_TEST|MRI scan|Brain MRI scan to evaluate the integrity of the nervous system; lower limb muscle MRI scan to evaluate fat infiltration in skeletal muscles of the lower limb
223432409|NCT06101940|DIAGNOSTIC_TEST|Electrocardiography|Standard 12-lead electrocardiography or Holter monitoring performed to assess cardiac conduction abnormalities and arrhythmias in patients with DM1.
223432410|NCT06101940|DIAGNOSTIC_TEST|Pulmonary function test|Comprehensive pulmonary function testing including spirometry to assess respiratory muscle weakness and restrictive lung disease in DM1 patients.
223432411|NCT04019964|DRUG|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
223432412|NCT04033081|DEVICE|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
223432413|NCT04478773|PROCEDURE|MRI|MRI with or without contrast
223432414|NCT06346509|DRUG|PORT-77|Healthy adult participants will receive a single oral dose of PORT 77.
223432415|NCT06346509|DRUG|Placebo|Healthy adult participants will receive matching placebo on Day 1.
223565481|NCT04802135|OTHER|Survey|directive questionnaire administered during an individual face-to-face interview
223565482|NCT01636063|DRUG|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
224042362|NCT00771641|PROCEDURE|conventional surgery|
224042363|NCT00771641|RADIATION|low-LET cobalt-60 gamma ray therapy|
224042364|NCT00771641|RADIATION|low-LET electron therapy|
224042365|NCT00771641|RADIATION|low-LET photon therapy|
224042366|NCT00771641|RADIATION|radiation therapy|
224042367|NCT00853398|PROCEDURE|surgical technique|
224042368|NCT03726359|RADIATION|Fractionated Stereotactic Radiation Therapy (FSRT)|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the Stereotactic Body Radiation Therapy (SBRT) schedule is completed within 1.5-2 weeks.
223565483|NCT01636063|DRUG|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
223565484|NCT00043355|DRUG|interferon gamma-1b|500 mcg, oral, three times weekly
223432416|NCT05317754|BEHAVIORAL|Mindful breathing|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
223432417|NCT05317754|BEHAVIORAL|Prostrations, according to Tibetan Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
223432418|NCT05317754|BEHAVIORAL|The Koan Mu, according to Zen Buddhist tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
223565485|NCT06138015|BEHAVIORAL|Exercise and Time-Restricted Eating|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks and a time-restricted eating following 16:8 protocol for 12 weeks.
223565486|NCT06138015|BEHAVIORAL|Exercise only|Moderate intensity circuit mixed endurance and resistance exercise programme two times per week for 55 minutes for 12 weeks only.
223565487|NCT04085458|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
223565488|NCT04549779|PROCEDURE|Low volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 5 ml levobupivacaine 0.25%
223565489|NCT04549779|PROCEDURE|Intermediate volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 10 ml levobupivacaine 0.25%
223565490|NCT04549779|PROCEDURE|High volume interscalene brachial plexus block|ultrasound-guided interscalene brachial plexus block with 15 ml levobupivacaine 0.25%
223565491|NCT00936533|DRUG|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
223565492|NCT00936533|DRUG|Placebo|Placebo preparation without active compound, administered as the active drug.
224042369|NCT05849480|DRUG|oxaliplatin|Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).
224042370|NCT05849480|DRUG|capecitabine|Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
224042371|NCT05849480|BIOLOGICAL|Keytruda|Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
224042372|NCT05849480|BIOLOGICAL|CDX-1140|CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
224042373|NCT05079464|OTHER|tDCS|All participants randomized to tDCS will receive active tDCS
224042374|NCT05079464|OTHER|Exercise|Participants will exercise at Toronto Rehab.
224042375|NCT05079464|OTHER|Sham stimulation|The same procedure for tDCS will be used for the sham condition, except without active current.
224042376|NCT05079464|OTHER|Treatment as usual|Exercise education/ treatment as usual will include routine advice about physical activity.
224042377|NCT02496897|BIOLOGICAL|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
223740497|NCT02621242|DRUG|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
223740498|NCT01206647|DRUG|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
224042378|NCT02496897|OTHER|Placebo|Placebo
224042379|NCT02496897|OTHER|IC31® Adjuvant|IC31® Adjuvant
224042380|NCT00931242|DRUG|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
224042381|NCT04322006|DRUG|TJ004309|Antibody to CD73
224042382|NCT04322006|DRUG|Toripalimab|Humanized monoclonal antibody to PD-1
224042383|NCT06270836|DRUG|Tarcocimab|Intravitreal injection
224042384|NCT06270836|OTHER|Sham injection|The sham injection is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It is performed to maintain masking of the study.
224042385|NCT00519155|DRUG|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
224042386|NCT00519155|PROCEDURE|Open flap debridement|Open flap debridement alone
224042387|NCT00346099|DRUG|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
224042388|NCT00346099|DRUG|Panitumumab with capecitabine and radiation|
224042389|NCT03281057|BEHAVIORAL|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
224140465|NCT06509711|OTHER|PLYOMETRICS jump training with HIIT (4 weeks,3 sessions per week)|First set of drills 6 x 40-cm hurdle jumps +5-s sprint\* at 130% of aerobic maximum speed. Second set of drills 6 x 30-cm hurdle jumps with extended legs + 5-s sprint at 130% of aerobic maximum speed. Third set of drills 6 x horizontal jumps + 5-s sprint at 130% of aerobic maximum speed. Fourth set of drills 3 right-leg and 3left-leg hops +5-s sprint at 130% of aerobic maximum speed. Each drills set was performed 2 times in a row. Afterwards, 10 seconds of rest were allowed. Thereafter, this sequence of effort-rest was repeated 8 times. After then, a 3-5 min recovery period was allowed before commencing the next drills set;
223432419|NCT05317754|BEHAVIORAL|The mirror exercise, according to Toltec tradition|"* Formal practice should take 30-60 minutes/day. It can be divided into as many as 4 sessions/day at times of participants' choosing, but the recommended times are after waking up in the morning and before going to bed at night.~* There is no limit to the number of times informal practice can be performed during the day.~* Use of a diary is necessary to record the time and duration of all formal and informal practices.~* The intervention will have a duration of 60 days. During this period, participants are to take part only in the intervention to which they have been randomized and no other. After this period of time and during the follow-up, participants will be able to practise any kind of meditation and at times of their choosing, but this information must always be recorded in their diary."
224042390|NCT05977296|DEVICE|CPAP|To use CPAP
224042391|NCT06038825|DEVICE|topical vibration|topical vibration (Aprilla brand, giving 6000 vibrations per minute) is a device for pain relief during injection of local anesthetic.
224140466|NCT06509711|OTHER|PLYOMETRICS JUMP TRAINING WITHOUT HIIT (4weeks, 3sessions Per week)|Plate pogo (4 reps, 3 sets) Broad jump( 4reps,3 sets)
224042392|NCT06228651|DEVICE|Tourniquet|
224042393|NCT06228651|OTHER|The leg without the tourniquet|
224042394|NCT02827123|DEVICE|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
224042395|NCT02827123|DRUG|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
224140467|NCT00602719|DRUG|Zolpidem|
224140468|NCT03756740|OTHER|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
224140469|NCT03756740|OTHER|control|subjects will receive the LBP exercises as printed pictures on paper
224140470|NCT00003225|DRUG|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
224140471|NCT00003225|DRUG|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
223432420|NCT05608772|PROCEDURE|revision surgery|revision procedure after failed sleeve gastrectomy
223432421|NCT06487403|RADIATION|Standard of care external beam radiotherapy (single integrated boost)|70Gy in 35 fractions, 56 Gy in 35 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
223432422|NCT06487403|RADIATION|Standard of care external beam radiotherapy (two-phase treatment)|70Gy in 35 fractions, delayed 40 Gy in 20 fractions. Oral Pimonidazole 200 mg and 300 mg tablets.
223432423|NCT04216784|DRUG|Furosemide Injection|Patient will receive furosemide intravenously
223432424|NCT04216784|DRUG|Albumin Human|Patient will receive albumin (25%) 12.5 gm intravenously
223432425|NCT05482880|OTHER|Regular care with additionally administration of questionnaires|"Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~1. after the multidisciplinary consultation, a baseline questionnaire\*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~2. 1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~\*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital."
223432426|NCT06660407|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223432427|NCT06660407|PROCEDURE|Computed Tomography|Undergo CT
223432428|NCT06660407|OTHER|Immunotherapy|Given immunotherapy
223432429|NCT06660407|RADIATION|Palliative Radiation Therapy|Undergo palliative radiation therapy
223432430|NCT06660407|RADIATION|Spatially-fractionated Radiation Therapy|Undergo grid radiation therapy
223432431|NCT02887040|RADIATION|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
223432432|NCT02887040|DRUG|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
223432433|NCT02887040|DRUG|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
223432434|NCT04159727|OTHER|stool and blood analysis|High throughput sequencing and quantitative PCR
223432435|NCT04977388|DRUG|Droxidopa|Subjects will self-administer capsules of Droxidopa by mouth twice daily for six weeks.
223432436|NCT04977388|OTHER|Placebo|Subjects will self-administer capsules of placebo by mouth twice daily for six weeks.
223432437|NCT06961370|DRUG|RO7669330|RO7669330 will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
223432438|NCT06961370|DRUG|Syfovre™|Syfovre™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
223432439|NCT06961370|DRUG|Izervay™|Izervay™ will be administered as an IVT injection in the study eye per the schedule specified in the respective arms.
224042396|NCT01679366|DRUG|Placebo|1 tablet 2 times daily
224042397|NCT01679366|DRUG|Probiotics|1 tablet twice daily
224140472|NCT02287701|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
224140473|NCT00084929|PROCEDURE|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
223432440|NCT06959394|OTHER|Ultrasound|Participants will receive ultrasound at 1.5 W/cm2 for 6 minutes (transmitter agent aquasonic gel) 5 sessions per week for 2 weeks.
223432441|NCT06959394|OTHER|Phonophoresis|Participants will receive ultrasound with 1.5 W/cm2, 6 min (transmitter diclofenac gel) for 5 sessions per week for 2 weeks.
223432442|NCT06959394|OTHER|Placebo|Participants will receive 0 W/cm2, 6 min ultrasound, 5 sessions per week for 2 weeks.
223432443|NCT00962949|DRUG|Angiotensin II|Angiotensin II infusion for 1 hour
223432444|NCT03155906|OTHER|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
223565493|NCT02447250|DRUG|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
224042398|NCT06386640|OTHER|Intervention Development|Phase I: Research to inform intervention design, Phase II: Co-design and production of intervention with relevant stakeholders, Phase IIa: Physical activity accelerometer data collection and analysis to develop an individualised rehabilitation programme, Phase III: Pilot and refine the intervention across to two NHS sites (University Hospitals of Leicester NHS Trust, Portsmouth Hospitals University NHS Trust).
224042399|NCT01434550|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
223432445|NCT06831461|RADIATION|Proton Beam Therapy|Patients randomized to the experimental arm will be treated with proton beam therapy.
223432446|NCT06831461|RADIATION|Photon Radiotherapy|Patients randomized to standard arm will be treated with photon therapy.
224042400|NCT01434550|RADIATION|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~1. Necrosis/apoptosis~2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1\. Aposense-PET imaging"
224042401|NCT00179504|BEHAVIORAL|Relaxation Response|Relaxation training
224042402|NCT04032691|DRUG|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
224042403|NCT01062139|DRUG|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
224042404|NCT01062139|DRUG|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
224042405|NCT05495711|BIOLOGICAL|human umbilical cord mesenchymal stem cell complex collagen|1 \* 10\^7 cells (2ml)
223432447|NCT06165341|DRUG|Fazirsiran Injection|Fazirsiran will be injected subcutaneously.
223565494|NCT03632993|DRUG|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (for example, dermal septa) at the site of injection and does not require systemic exposure to be effective.
223565495|NCT02657655|DEVICE|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
224042406|NCT05495711|PROCEDURE|intrauterine injection|intrauterine injection with human umbilical cord mesenchymal stem cell (19#iSCLife®-UT); total 1 time
224042407|NCT05011682|BEHAVIORAL|Regular diet|participant's usual diet during 2 weeks
224042408|NCT05011682|BEHAVIORAL|10-point nutrition plan|controlled portions of low glycemic index carbohydrates, avoidance of rapidly absorbed carbohydrates, adjustment of timing of meals and snacks, and attention to personal and cultural barriers to implementation
224042409|NCT03114007|BEHAVIORAL|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
224140474|NCT00513097|BEHAVIORAL|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
224140475|NCT00513097|BEHAVIORAL|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
224140476|NCT00513097|BEHAVIORAL|Survey|On-line evaluations and questionnaires
224140477|NCT00844649|DRUG|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m\^2 administered by intravenous infusion
223432448|NCT06165341|DRUG|Placebo|Fazirsiran matching placebo.
224042410|NCT03114007|BEHAVIORAL|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
224042411|NCT03114007|BEHAVIORAL|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
223432449|NCT06743191|BEHAVIORAL|Access Nourish|A total of 65 participants with hypertension and low access to high quality food will be enrolled to test the feasibility of using commercially available grocery delivery services, simultaneous to a robust behavioral intervention, to improve adherence to the DASH eating pattern. The behavioral intervention will include skills training, nutrient goal setting, self-monitoring via dietary tracking, personalized text message feedback, and adaptive health coaching. Participants will also receive a membership to Instacart+ and weekly grocery list recommendations from a health coach. Participants will be able to complete all intervention components via smartphone. The intervention period for participants will be 4 months.
223432450|NCT05904496|DRUG|BGB-30813|Specified dose administered on specified days
223432451|NCT05904496|DRUG|Tislelizumab|Specified dose administered on specified days
224042412|NCT00000820|DRUG|Aldesleukin|
224042413|NCT03496480|DIAGNOSTIC_TEST|Questionnaires|Psychological questionnaires: BTQ, IES-R, 7-items-short Screening scale, BDI, SF-36
224042414|NCT03552796|OTHER|Pharmacokinetic Study|Correlative studies
224042415|NCT03552796|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given intravesically
224042416|NCT06433804|DIAGNOSTIC_TEST|HER2 IHC|Immunohistochemistry for HER2
224042417|NCT04785339|BEHAVIORAL|intervention in adult Latinx immigrants|Participants will complete self-report outcome measures at pre (baseline) and post, and they will receive the intervention in-between these assessments. Thus, the time frame for data collection is 10 weeks.
224042418|NCT05252156|DEVICE|eXciteOSA|eXciteOSA
224042419|NCT06154551|DIAGNOSTIC_TEST|Paxillin biomarker|Paxillin used as a salivary biomarker
224042420|NCT00001333|DRUG|topotecan|
224042421|NCT05508750|OTHER|New Infant Formula|New infant formula fed daily ad libitum
224042422|NCT05508750|OTHER|Commercial Infant Formula|Commercially available infant formula fed daily ad libitum
224042423|NCT00226187|PROCEDURE|Supplement of fatty acid (DHA and AA)|
223432452|NCT06910423|BEHAVIORAL|Psychosocial intervention|Culturally relevant psychosocial intervention for people with insomnia
223565496|NCT02899507|DRUG|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
223565497|NCT01552551|BEHAVIORAL|Assessment and education|PA Healthy Steps program
223565498|NCT01552551|BEHAVIORAL|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
223565499|NCT01552551|BEHAVIORAL|Healthy Steps in Motion|Group exercise program
223565500|NCT02987361|DEVICE|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
223565501|NCT01372943|BIOLOGICAL|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
223565502|NCT02017938|PROCEDURE|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
223565503|NCT00059943|DRUG|docetaxel|
223565504|NCT05594927|DRUG|Icaritin|600 mg (6 x 100 mg capsules) icaritin administered orally twice daily (30 minutes after breakfast and dinner, respectively) until treatment discontinuation criteria are met.
223565505|NCT05594927|DRUG|Huachansu|1200 mg (4 x 300 mg tablets) huachansu administered orally three times a day (30 minutes after breakfast, lunch and dinner, respectively) until treatment discontinuation criteria are met.
224042424|NCT02221232|DRUG|Chloraprep|Apply topically.
224042425|NCT02221232|DRUG|ZuraPrep|Apply topically.
224042426|NCT02221232|DRUG|ZuraPrep Vehicle|Apply topically.
224042427|NCT03371758|OTHER|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
224042428|NCT01839162|PROCEDURE|Coronary angiography|Diagnostic coronary angiography
224042429|NCT01839162|PROCEDURE|PCI|Percutaneous coronary intervention
224042430|NCT01839162|PROCEDURE|Right approach|Right transradial access
224042431|NCT01839162|PROCEDURE|Left approach|Left transradial access
224042432|NCT00908063|DRUG|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
224042433|NCT00908063|DRUG|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
224042434|NCT01764126|DRUG|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
224042435|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
224042436|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
224042437|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
224042438|NCT01764126|DRUG|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
224042439|NCT04004429|DRUG|50 mg AP1189|50 mg AP1189 powder in bottle
224042440|NCT04004429|DRUG|AP1189|100 mg AP1189 powder in bottle
224042441|NCT04004429|DRUG|Placebo|Placebo powder in bottle
224042442|NCT03085758|BIOLOGICAL|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
224042443|NCT03085758|BIOLOGICAL|Placebo|Single i.v. dose of placebo (control group)
224042444|NCT01191541|DRUG|DNR:|DNR：45mg/m2 d1-3
224042445|NCT01191541|DRUG|Ara-c|DNR+ARA-C：DNR：45mg/m2 d1-3;Ara-C :1g/m2 d1-3
224042446|NCT02790125|DRUG|BMS-986166|
224042447|NCT02790125|DRUG|Placebo matching BMS-986166|
224042448|NCT04579744|OTHER|EuroQol 5D questionnaire|EuroQol questionnaire (EQ-5d) facilitates to obtain values of health in the physical, psychological, and social dimensions. It is a standardized non-disease specific instrument to describe and value the health-related quality of life.
224042449|NCT03601936|DEVICE|Evivo Infant Gut Bifidobacterium Screening Test|Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
224042450|NCT02643160|OTHER|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
223432453|NCT06909955|OTHER|Exercise|"Relaxation Exercises (Progressive Muscle Relaxation Exercises):~Progressive muscle relaxation exercises, one of the relaxation techniques, will be used in this study. Participants will be instructed to sit in a comfortable position on a chair during the exercises. Clear and precise instructions will be provided to ensure proper execution. The exercise program will be conducted for 8 weeks, 3 days a week, for 30 minutes, under the supervision of an expert physiotherapist."
223432454|NCT06912555|OTHER|Diet|The nutritional plan will be initially based on a protein intake of 1.3 to 1.5 g per kilogram of body weight. From this, the total daily calorie intake is calculated, with 30% of the calories allocated to fats. The remaining calories will be assigned to carbohydrates, depending on the protein intake. Protein distribution will be approximately 40% at breakfast and lunch, and 60% at dinner. Caloric restriction will be moderate, reducing the total energy expenditure by 30%-calculated individually-which translates to an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never provide less than 1200 kcal per day to ensure that the minimum nutritional requirements are met.
223432455|NCT06912555|OTHER|Diet|The macronutrient plan will include a protein intake of 1.3 to 1.5 g per kilogram of body weight. Based on this protein amount, the total daily caloric intake will be determined, allocating 30% of the calories to fat consumption. The remaining calories will be assigned to carbohydrates, proportional to the protein intake. Protein distribution will be approximately 85% during breakfast and lunch and 15% at dinner. The caloric restriction will be moderate, with a 30% reduction in total energy expenditure calculated individually, resulting in an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never contain fewer than 1200 kcal per day, ensuring that the participant's nutritional requirements are met.
224042451|NCT02390817|DRUG|Sugammadex|Administration of Sugammadex
224042452|NCT02390817|DRUG|Neostigmine|Administration of Neostigmine
224042453|NCT02626325|OTHER|High-carbohydrate or High-monounsaturated fat diets|
224140478|NCT00844649|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
223565506|NCT00788099|DRUG|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
224042454|NCT00849654|DRUG|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
224042455|NCT03519958|DIAGNOSTIC_TEST|Plasma-tissue testing|EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
224042456|NCT03778814|BIOLOGICAL|TCR-T cells|Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
224042457|NCT05798078|BEHAVIORAL|Cognitive Bias Modification for Interpretation (CBM-I)|The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
224042458|NCT05798078|BEHAVIORAL|Sham Training Control Condition|The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
224042459|NCT03274583|DIAGNOSTIC_TEST|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
224042460|NCT01122576|DEVICE|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
224042461|NCT01122576|DEVICE|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
224140479|NCT00664209|DRUG|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
224140480|NCT00664209|DRUG|placebo|placebo therapy
224140481|NCT06003257|OTHER|stainless steel crown|stainless steel full coverage crown for deciduous teeth
224140482|NCT06003257|OTHER|zirconia crown|zirconia full coverage crown for deciduous teeth
224140483|NCT06003257|OTHER|fiberglass crown|fiberglass full coverage crown for deciduous teeth
224042462|NCT01122576|DEVICE|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
223432456|NCT06912555|OTHER|Diet|The macronutrient plan will include a protein intake of 0.8 g per kilogram of body weight. From this protein amount, the total daily calorie intake will be calculated, with 30% of the calories allocated to fats. The remaining calories will be assigned to carbohydrates, depending on the protein intake. Caloric restriction will be moderate, reducing the total energy expenditure by 30%-calculated individually-which translates to an approximate decrease of 400 to 600 kcal per day compared to the participant's usual energy needs. It is important to note that the diet will never contain fewer than 1200 kcal per day, ensuring that the participant's nutritional requirements are met.
223432457|NCT06503159|BEHAVIORAL|Mindfulness-based Stress Reduction (MBSR) Program|The study intervention is a 9-week MBSR intervention once per week in-person or remotely (via an NIH approved remote platform used in compliance with policy, including HRPP Policy 303). The MBSR will be delivered to groups of 8-12 participants. Only the vaping adolescents will receive MBSR training.
223432458|NCT02338167|PROCEDURE|Blood sampling|A blood sample will be taken during a routine blood draw
223432459|NCT06359652|DEVICE|Prehabilitation Program (Apple Watch Series 6 with exercise flipbook)|We will evaluate whether use of a personal device (the Apple Watch) could help medical professionals assess patients' pre-surgery prehab state. It will also assess whether patients are willing to use a personal device and engage in prehab exercise and whether the device can enhance prehab uptake. The intervention is to also offer patients the Exercise Flipbook, to send them a reminder to exercise and to send them notifications to track their exercise.
223432460|NCT06387498|PROCEDURE|Testicular tissue biopsy and cryopreservation|Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy. However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option. The amount of testicular parenchyma removed will be at the discretion of the surgeon.
223432461|NCT06182332|OTHER|Electronic Health Record Review|Undergo medical record review
223432462|NCT06182332|OTHER|Internet-Based Intervention|Use AI algorithm
223432463|NCT06377098|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
223432464|NCT06377098|DRUG|Placebo Oral Tablet|Placebo table given orally every eight hours up to three times while mother is in labor
223432465|NCT04431895|DRUG|Tofacitinib 5 MG|tofacitinib 5 mg tablet administered twice a day for 6 months
223432466|NCT05409131|DEVICE|Omnipod 5 System|Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes.
223432467|NCT04783220|BEHAVIORAL|Comprehensive structured parent intervention|"1. Educational sessions and coaching on infants' behavior cues~2. Skills on motor stimulation~3. Written instructions for play and stimulation activities at discharge~4. Multidisciplinary follow-up~5. Developmental tracking and advice via a mobile app"
223565507|NCT00788099|DRUG|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
223565508|NCT01181999|DRUG|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
223565509|NCT01649674|DRUG|polyethylene glycole (PEG) solution|
223565510|NCT01649674|DRUG|sodium picosulphate and magnesium citrate solution|
223565511|NCT01345968|DRUG|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
223565512|NCT01345968|DRUG|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
223565513|NCT03135769|DRUG|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
223565514|NCT02367274|DEVICE|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
223565515|NCT06485856|BEHAVIORAL|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Evaluation of the pain level of patients who are followed in intensive care and cannot speak during the procedural procedure with 3 different methods.
223565516|NCT03224507|DRUG|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
223565517|NCT03224507|DRUG|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
223565518|NCT00262236|DRUG|Aliskiren|
223565519|NCT04916366|OTHER|Kinesio taping|Kinesio taping in a bandage to treat musculoskeletal pain.
223565520|NCT04916366|OTHER|Conventional bandage|It will be used a conventional bandage applicated in the same neck region than kinesio taping intervention.
223565521|NCT04506216|OTHER|cohort|"During a regular follow-up visit, the following data will be collected:~* questionnaires on lifestyle, eating custom (SCOFF-F, 5th question of the m-SCOFF) and physical activity (IPAQ)~* bio-electric impedance analysis~* insulin pump and sensor data collection"
224042463|NCT05029466|DRUG|Psilocybin|Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
224042464|NCT00564824|DRUG|Caffeine|Caffeine 200 mg tablet
224042465|NCT00564824|DRUG|Placebo|Placebo pills
224042466|NCT02740296|OTHER|No intervention|
224042467|NCT03836820|OTHER|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
224042468|NCT03836820|OTHER|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
224042469|NCT03836820|OTHER|Clinical Pilates and Aerobic Exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
224042470|NCT03265535|DIAGNOSTIC_TEST|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
223432468|NCT06109571|DEVICE|Connections App|The Connections app was developed for patients with substance use disorders or unhealthy substance use and adapted to include HIV support. For this study, it has been modified to provide additional resources to support patients engaged in HIV care. Connections' core features include agency-specific informational resources compiled in a resource center, patient self-monitoring through weekly check-in surveys, discussion rooms, and private messaging.
223565522|NCT04945278|OTHER|Double mirror device ALTER-EGO|"The patient and his matched healthy volunteer will be placed on each side of the double mirror device ALTER-EGO. Both sides will be lightened alternatively or at the same time by lights, so according to the light intensity, the subject will see himself in a mirror or the other person throw a classic window. The light intensity will vary from 0 to 100% and to 100% to 0% alternatively from each side of the mirror. At each 10% variation of one side, both patient and volunteer will have to answer that question : who do you see more : him/her or yourself ?"
224042471|NCT06416735|DRUG|Amiloride|administration of a single dose of 5 or 10 mg of Amiloride (based on body weight) After oral intake of the drug, the increase in sodium in the urine ends within 8 hours
223432469|NCT05564403|DRUG|Binimetinib|Given PO
223432470|NCT05564403|PROCEDURE|Biopsy Procedure|Undergo biopsy
223432471|NCT05564403|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223432472|NCT05564403|PROCEDURE|Bone Scan|Undergo bone scan
223432473|NCT05564403|PROCEDURE|Computed Tomography|Undergo CT
223432474|NCT05564403|PROCEDURE|Echocardiography Test|Undergo ECHO
223432475|NCT05564403|DRUG|Fluorouracil|Given IV
223432476|NCT05564403|DRUG|Leucovorin Calcium|Given IV
223432477|NCT05564403|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223432478|NCT05564403|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223432479|NCT05564403|DRUG|Oxaliplatin|Given IV
223565523|NCT04945278|OTHER|EASE test|The patient will have to answer the EASE test which is a specific test to detect patient with high risk of psychosis or schizophrenia
223432480|NCT03891784|DRUG|Abemaciclib|Given PO
223432481|NCT06103877|BIOLOGICAL|AZD1163|"In Part 1, Participants will receive AZD1163 through IV infusion or SC injection on Day 1.~In Part 2, participants will receive AZD1163 through SC injection on Days 1 and 15."
223432482|NCT06103877|OTHER|Placebo|"In Part 1, Participants will receive matching placebo through IV infusion or SC injection on Day 1.~In Part 2, participants will receive matching placebo through SC injection on Days 1 and 15."
223432483|NCT06075329|BEHAVIORAL|Contemplative Practice|Contemplative practice included Maitribodh Sambodh Dhyaan (MSD), which was designed to increase feeling of love and connection by including most of components of different contemplative practices such as breath watch, mantra or vibrational sound chant, focused meditation, and visualization followed by loving-kindness or a gratitude exercise at the end.
223432484|NCT06351566|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
223432485|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
223432486|NCT06351566|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
223432487|NCT06351566|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo, 10g per day.
223432488|NCT05880680|DEVICE|SEAL Device|Using standard interventional endovascular techniques, the device is navigated via the push wire delivery system through compatible neurovascular microcatheters to the aneurysm lumen or target site. The device is positioned into its target aneurysm lumen and is electrically detached by the operator with a hand-held, battery-powered detachment handle designed specifically for the SEAL Embolization System.
223432489|NCT01315041|DRUG|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
223432490|NCT01315041|DRUG|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
223565524|NCT02539199|DRUG|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
223565525|NCT02539199|DRUG|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
223565526|NCT00396006|BIOLOGICAL|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
223565527|NCT01736072|PROCEDURE|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
224042472|NCT02540863|OTHER|myofascial release protocol and Rocabado exercise therapy|
224042473|NCT02540863|OTHER|exercise therapy|
224042474|NCT05742503|OTHER|Depo-Provera|Injectable progesterone
224042475|NCT05742503|OTHER|Implanon|Etonogestrel implant
223432491|NCT02672332|DRUG|SB204 4%|Once daily
223432492|NCT02672332|DRUG|Vehicle Gel|Placebo comparator
223432493|NCT01451164|DRUG|OPC-34712|orally administered once daily
223432494|NCT01451164|DRUG|OPC-34712|orally administered once daily
223432495|NCT01451164|DRUG|OPC-34712|orally administered once daily
223432496|NCT01451164|DRUG|Placebo|orally administered once daily
223432497|NCT00297050|DRUG|Peramivir|
223432498|NCT05250531|BEHAVIORAL|multicomponent therapy|patient education,Exercise training,Private Psychotherapy,relaxation
223432499|NCT06229548|DRUG|SYH2053|subcutaneous injection
223432500|NCT06229548|DRUG|Placebo|subcutaneous injection
223432501|NCT02686242|PROCEDURE|spinal anesthesia|bupivacaine injected by spinal puncture
223432502|NCT02686242|PROCEDURE|general anesthesia|general anesthesia with intubation
223432503|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D2|Ergocalciferol vitamin D2
223432504|NCT01848236|DIETARY_SUPPLEMENT|Vitamin D3|Cholecalciferol vitamin D2
223432505|NCT02027662|DRUG|Osvaren Granules|
223432506|NCT02027662|DRUG|Osvaren film-coated tablets|
224042476|NCT05742503|OTHER|Norgestrel|Pill containing progesterone
224042477|NCT05742503|OTHER|Mirena|Levonorgestrel-releasing intra-uterine drug (IUD)
224042478|NCT02066623|DEVICE|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
224042479|NCT00072332|DRUG|cisplatin|
224042480|NCT00072332|DRUG|edotecarin|
224042481|NCT04636866|OTHER|NO intervention|NO intervention
223565528|NCT01736072|PROCEDURE|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
223565529|NCT04678986|OTHER|ER2|No intervention, data analysis only
223565530|NCT01984463|DRUG|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
223565531|NCT01984463|DRUG|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
223565532|NCT05215860|BEHAVIORAL|Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|WHO toolkit for Tobacco cessation (5A's and 5R's model)
224042482|NCT02169817|DRUG|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
224042483|NCT02169817|DRUG|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
223432507|NCT01308112|DIETARY_SUPPLEMENT|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
223432508|NCT06511570|DRUG|sabirnetug (ACU193)|sabirnetug by intravenous infusion
223432509|NCT06511570|COMBINATION_PRODUCT|Sabirnetug + rHuPH20|sabirnetug + rHuPH20 by subcutaneous injection
223432510|NCT04599933|DRUG|CSF-1|One drop bilaterally twice daily for approximately 2 weeks.
223432511|NCT04599933|DRUG|Vehicle|One drop bilaterally twice daily for approximately 2 weeks.
223565533|NCT05215860|OTHER|visual exposure to personal intraoral photographs of oral lesions at baseline and review|Chairside digital intraoral photographs of oral potentially malignant disorder with smart phone and showing the photograph to the participant explaining the abnormal areas of concern
223565534|NCT05887544|OTHER|Exposure: Plant-based diet pattern|From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.
223565535|NCT05887544|OTHER|Intervention: Fermented dairy products|1000g of the product to be consumed 1-2 days prior to spot urine sample.
223565536|NCT05887544|OTHER|Exposure: individual foods and food groups|From the dietary records, average intake of specific foods or food groups will be calcualted.
223565537|NCT01558362|DRUG|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections. All volunteers had a rest dose first followed by a stress dose.
224042484|NCT03518138|DRUG|Q-122|oral capsule of Q-122
224042485|NCT03518138|DRUG|Placebo|oral capsule of placebo
223565538|NCT00075946|BIOLOGICAL|rituximab|Given IV
224042486|NCT02906345|DEVICE|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
224042487|NCT05547282|RADIATION|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.|At the same time, the original regimen of immunomaintenance therapy was continued, according to the frequency of the original immunization regimen once every 3 weeks until progress.
224140484|NCT03641547|DRUG|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
223565539|NCT03162484|BEHAVIORAL|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
223565540|NCT00380029|DRUG|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
223565541|NCT00380029|PROCEDURE|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
223565542|NCT03913832|DEVICE|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions \& de novo lesions."
223565543|NCT03913832|DEVICE|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
223565544|NCT06321198|BIOLOGICAL|iMSC|Subjects will receive 4 or more times of iMSC injection
223565545|NCT03082183|DRUG|Rifampicin|once daily
223565546|NCT03082183|DRUG|BI 425809|once daily
223432512|NCT01424046|DRUG|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
223432513|NCT01424046|DRUG|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
223432514|NCT05366985|PROCEDURE|Socket shield technique with computer guided sectioning of the root|"A computer guide was used to section the root, leaving the coronal 2/3 of its labial part attached to the socket. An implant was then placed.~Preoperative and Postoperative (5 months later) intraoral scans were superimposed with a digital software to assess the dimensional changes of the labial alveolar ridge. Linear changes at 1,3 and 5 mm from the gingival margin and mean linear changes in a specified Area Of Interest (AOI) were measured"
223432515|NCT01289756|DRUG|Clomiphene|clomiphene once 100 mg oral
223432516|NCT01289756|DRUG|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
223432517|NCT01289756|DRUG|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
223432518|NCT05098067|DRUG|Capsaicin Topical Cream|5g 0.075% applied once
224042488|NCT04564144|DRUG|Meclizine Hydrochloride|A study will be conducted on the three tested orodispersible tablets and the commercial one (control). 6 volunteers are asked to cease any medication 7 days prior to blood sampling at least. Each volunteer will undergo 4 study sessions with one week of washout period in between (cross-overed to receive the other formulation). All volunteers are asked to fast overnight before taking the tablet. The tablet should be kept for 10 min in the mouth before swallowing without water. Just before taking the tablet, three milliliters of venous blood samples will be drown (predose, 0 h) and at 30, 60, 90, 120, 240, 360, 480, 720 min and 24 h postdose and stored in tubes coated with sodium heparin. Separation of plasma from Blood samples will be carried out by centrifuging at 5000 rpm for 10 min, then, it will be frozen at -20°C until analysis. By employing high-performance liquid chromatography (HPLC), the plasma concentration of MCZ will be assayed
224042489|NCT01558583|OTHER|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
224140485|NCT03641547|DRUG|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 \& B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
224140486|NCT03641547|DRUG|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
223432519|NCT05098067|DRUG|Metoclopramide|10mg IV once
223432520|NCT05098067|DRUG|Ondansetron|8mg IV once if needed
223432521|NCT05098067|DRUG|Lactated Ringers, Intravenous|1000cc once
223565547|NCT05392855|OTHER|Symptom driven performance of airway clearance|Perform symptom driven/intermittent airway clearance therapy with frequency based off of patient's daily symptoms including mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
223432522|NCT02411604|DRUG|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
223432523|NCT00072436|DRUG|gemcitabine hydrochloride|Given IV
223432524|NCT00072436|DRUG|alvocidib|Given IV
223432525|NCT00072436|OTHER|pharmacological study|Correlative studies
223565548|NCT05392855|OTHER|Continuous daily performance of airway clearance|Continue run-in protocol of twice daily airway clearance using twice daily mobilization therapy (high-frequency chest compression or vest device, intrapulmonary percussive ventilator, positive expiratory pressure device) and inhaled/nebulized therapies of albuterol, hypertonic saline and dornase alfa for the 12 week study period.
223432526|NCT00497848|BEHAVIORAL|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
223432527|NCT00497848|OTHER|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
223740499|NCT02276729|OTHER|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
223740500|NCT04535960|DRUG|Empagliflozin 25 MG + Liraglutide 1.8 MG|Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.
223740501|NCT04535960|DRUG|Liraglutide 1.8 MG + Empagliflozin 25 MG|Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
223740502|NCT06228040|OTHER|preanaesthetic teleconsultation|Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
224140487|NCT03641547|RADIATION|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
224299640|NCT04515537|PROCEDURE|Infiltrtion of SVf|After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
224299641|NCT03458637|BEHAVIORAL|LITE Program and Usual Care|Family based lifestyle Intervention
224299642|NCT03458637|BEHAVIORAL|Usual Care|Usual care consisting of 3 visits to weight management clinic
224299643|NCT02182128|DRUG|BIBF 1120|
224299644|NCT01589861|DRUG|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
223432528|NCT04281316|DEVICE|Nasal High Flow installation|"Participants randomized in NHF group will receive the nasal high flow (NHF) treatment delivered by myAirvo2.~Nasal High-Flow (NHF) is a treatment delivering heated, humidified, and optionally oxygen-enriched, air at high flow rates through a nasal cannula. The physiologic effects of NHF are an improvement in gas exchanges including a reduction in hypercarbia an optimization in breathing patterns with a reduction of work of breathing and high compliance as delivered via a comfortable nasal interface"
223432529|NCT04281316|DEVICE|Non Invasive Ventilation|Participants randomized in the Non Invasive Ventilation group will receive treatment as in their usual care.
223432530|NCT04281316|OTHER|Training session|The patients in the Nasal High Flow (MyAirvo) arm will receive two hours training adaptation session in the hospital
223432531|NCT04281316|OTHER|Education session|Participants randomized in the Non Invasive Ventilation group will receive an additional educational session of one hour for improving compliance.
224042490|NCT01558583|OTHER|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
224042491|NCT01558583|OTHER|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
224042492|NCT02785965|DEVICE|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
224140488|NCT00804375|DRUG|2PX|cutaneous solution to be applied twice daily for 84 days
223432532|NCT03722940|DRUG|Magnesium sulphate|Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
223432533|NCT03722940|OTHER|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
223432534|NCT01503398|DRUG|Olanzapine|Olanzapine Tablets, 5 mg
223432535|NCT04731025|DRUG|Gentamicin, Cefazolin and Vancomycin|The antibiotic solution will contain 1000 mg vancomycin, 80 mg gentamicin and 1000 mg cefazolin in a 500 mL isotonic saline solution. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
223432536|NCT04731025|OTHER|Placebo|500 mL of sterile isotonic (9%) saline. The solution will be used to wash the dissected implant pocket and the implant prior to insertion in the implant pocket.
224140489|NCT00804375|DRUG|Placebo|cutaneous solution to be applied twice daily for 84 days
223432537|NCT00050817|DRUG|clopidogrel (SR25990)|
223432538|NCT05507827|DRUG|Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)|CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
223432539|NCT05507827|DRUG|Treg CD34+HSPC (Orca-T)|Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
224140490|NCT00988260|DRUG|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
224140491|NCT00988260|DRUG|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
223565549|NCT05963412|OTHER|Meaning Centered Coping Program|"Meaning Centered Coping Program is a psychological intervention program developed for women diagnosed with breast cancer, based on the Meaning Making Model (Park, 2010; Park and Folkman, 1997) and Wong's (2010) principles of Meaning Therapy. Each weekly session had specific topics. These are:~Session 1: Guiding patients to tell the story of their breast cancer and psycho-education; Session 2: Encouraging patients to talk about the effects of breast cancer on their lives and learning to accept their difficult emotions; Session 3: Focusing on cognition through the meaning attributed to breast cancer; Session 4: Learning to take alternative perspectives and defusing their negative thoughts; Session 5: Exploring personal strengths; Session 6: İdentifying important life values and moving toward value-based actions; Session 7: Finding meaning in breast cancer and life; Session 8: Focusing on Future plans and hopes"
223565550|NCT04005508|DIAGNOSTIC_TEST|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
223740503|NCT06228040|OTHER|preanaesthetic classical physical consultation|Pre-anaesthetic classical consultation before teleconsultation implementation
224140492|NCT00988260|DRUG|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
224140493|NCT01398267|DRUG|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
223565551|NCT05898672|DRUG|Rosuvastatin|Single oral dose of rosuvastatin tablets
223740504|NCT00825747|DEVICE|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
224140494|NCT01398267|DRUG|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
224140495|NCT01398267|DRUG|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
224140496|NCT04286464|OTHER|No intervention|No intervention
224140497|NCT05239377|OTHER|IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator|Digital decision support
224140498|NCT00554892|PROCEDURE|bowel preparation|oral laxatives, retrograde enemas
224140499|NCT00554892|PROCEDURE|no preparation bowel|no preparation bowel
224140500|NCT00065442|BIOLOGICAL|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
224140501|NCT00065442|BIOLOGICAL|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
224140502|NCT03594253|BEHAVIORAL|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
223432540|NCT03652649|OTHER|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
223432541|NCT01903681|DRUG|Circadin 2 mg|First arm lower dose
223432542|NCT01903681|DRUG|Circadin 10 mg|Second arm higher dose
223565552|NCT05898672|DRUG|Nirmatrelvir/ritonavir|Twice daily oral doses of nirmatrelvir/ritonavir tablets
224042493|NCT02785965|BEHAVIORAL|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
224042494|NCT00931944|DRUG|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
224042495|NCT00850850|DRUG|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
224042496|NCT00850850|DRUG|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
224140503|NCT01594333|DRUG|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
223432543|NCT06647875|BEHAVIORAL|Complementary Feeding Education|"This training program has been designed in accordance withWHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age. The training will be delivered both in-person and via tablet, and will be supported by infographics and visuals created using WHO Guideline for Complementary Feeding of Infants and Young Children 6-23 Months of Age and the Basic Information for Families on Child Health and Safety in the First 5 Years booklet published by the Child Health Association, specifically the section on Healthy Eating. At the end of the training, participants will be provided with a booklet containing the Healthy Eating section of the Child Health Association's booklet."
223565553|NCT01229254|DRUG|Amiodarone|Patients on Amiodarone
223565554|NCT01229254|DRUG|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
223565555|NCT01229254|DRUG|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
223565556|NCT01229254|DRUG|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
223565557|NCT03853382|BEHAVIORAL|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
224042497|NCT03599037|OTHER|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
224042498|NCT00847184|DEVICE|Intubation|Intubation using the standard MacIntosh blade
224140504|NCT01594333|DRUG|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
223565558|NCT05610826|PROCEDURE|cytoreductive surgery|Cytoreductive surgery is an operation to remove as much tumor tissue as possible.
223565559|NCT05610826|DRUG|Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)|"PRRT is a form of targeted treatment (think of a lock and key) done by the use of a small molecule (Lutathera). Lutathera acts as a key to lock onto certain areas your tumor cells called receptors when injected into a vein and travels through blood."
223565560|NCT05610826|PROCEDURE|Peptide receptor radionuclide therapy (PRRT)|PRRT is a molecular targeted therapy used to treat neuroendocrine tumors (NET). Molecular targeted therapies use drugs or other substances to identify and attack cancer cells while reducing harm to healthy tissue. PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects.
223565561|NCT02231892|DEVICE|TMS|HAC coil (real rTMS or sham rTMS)
223565562|NCT00799227|DRUG|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
223565563|NCT01897350|OTHER|Cardiac magnetic resonance imaging|
223565564|NCT01755962|OTHER|Glycemic Load|
224042499|NCT00847184|DEVICE|Airtraq|Intubation with the use of the Airtraq technique
223565565|NCT01755962|OTHER|Resistance Training|
223565566|NCT05407649|RADIATION|Radiotherapy Combined with GM-CSF|Patients with stable or progressing metastatic thymic epithelial tumours, with at least two distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions or 60Gy in 30 fractions) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy).
224042500|NCT06313450|RADIATION|de-escalated radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with a tumor volume regression of 75% or more and no detectable EBV DNA will receive de-escalated radiotherapy for the primary tumor with 60 Gy. During radiotherapy, patients will receive Cisplatin 100 mg/m2 every three weeks for two courses and Toripalimab 240 mg every three weeks for three courses. If patients do not achieve complete remission at the end of radiotherapy, 6 Gy will be added to the residual lesions.
224140505|NCT01480557|PROCEDURE|liquefaction|Cataract extraction surgery type
224140506|NCT01480557|PROCEDURE|Torsional ip|A type cataract surgery using torsional ip technology
224140507|NCT05539586|OTHER|Tecartherapy|Patients will receive therapeutic exercise sessions for 7 weeks and 7 tecartherapy sessions.
223565567|NCT01557777|DRUG|Navitoclax|QD
224140508|NCT05539586|OTHER|Sham|Patients will receive therapeutic exercise sessions for 7 weeks and 7 sessions of simulated tecartherapy.
224299645|NCT00223353|OTHER|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
223432544|NCT03226678|DRUG|APL-2|Complement (C3) Inhibitor
224042501|NCT06313450|RADIATION|conventional radiotherapy|Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with tumor volume regression less than 75% or EBV DNA copy number higher than 0 receive conventional radiotherapy for the primary tumor with 70 Gy. Patients will receive Cisplatin 100 mg/m2, every three weeks for two courses during radiotherapy.
224042502|NCT02924298|BEHAVIORAL|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
224042503|NCT05514704|OTHER|Exercise Therapy via video conference|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
223432545|NCT00336388|DEVICE|Paracheck Device|
224042504|NCT05514704|OTHER|Exercise Therapy via mobile application|"The intervention will include the different levels of the following exercises that are given to the patient considering their functional level:~1. Straight leg raise (Level 1-2-3)~2. Quadriceps strengthening (Level 1-2-3)~3. Hip abductor/adductor strengthening (Level 1-2-3)~4. Hamstring stretch~5. Gastrocnemius stretch"
224042505|NCT04608760|DRUG|Meksibel|2 ml solution
224042506|NCT03989076|PROCEDURE|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
224042507|NCT02594423|DEVICE|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
224042508|NCT02594423|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
224042509|NCT02068365|DRUG|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
224042510|NCT06474910|OTHER|Connective tissue massage|In addition to the exercise program for hand rehabilitation, 15 patients in this group will receive connective tissue massage of the hand and forearm area. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
224042511|NCT06474910|OTHER|Exercise|Only exercise program will be applied to 15 patients in this group. The exercise program will include stretching exercises for the hand, strengthening exercises, normal joint movement exercises, functional exercises and tendon sliding exercises.
224042512|NCT02459769|BEHAVIORAL|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
224042513|NCT01188473|OTHER|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
224042514|NCT05070039|GENETIC|Expression of Cortactin anti body|assessment of Cortactin immunohistochemical expression in invasive and non-invasive urothelial carcinoma.
224042515|NCT00190710|DRUG|Gemcitabine|
224042516|NCT00190710|DRUG|Carboplatin|
224042517|NCT00684450|PROCEDURE|Titration protamine|10\. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
224042518|NCT00684450|DRUG|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
224042519|NCT01287364|DRUG|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
224042520|NCT01287364|DRUG|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
224042521|NCT04611854|BEHAVIORAL|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
224140509|NCT02985905|DIETARY_SUPPLEMENT|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
224140510|NCT05678075|BEHAVIORAL|Whole-food plant-based nutrition education|Participants will receive an educational intervention regarding the benefits of a whole food plant-based diet and how to incorporate more plant-based foods into their diets. The intervention will last 6 weeks.
224140511|NCT03522493|DEVICE|"Yaalom Katom"|Full face Gas mask
223432546|NCT00619164|DRUG|E5555|E5555, 50 mg (tablet), taken orally, once a day.
223432547|NCT00619164|DRUG|E5555|E5555, 100 mg (tablet), taken orally, once a day.
223432548|NCT00619164|DRUG|E5555|E5555, 200 mg (tablet), taken orally, once a day.
223432549|NCT00619164|DRUG|Placebo|Placebo tablet taken orally, once a day.
223432550|NCT02608008|DEVICE|Data analysis|data parameters Analysis
223565568|NCT02824770|BEHAVIORAL|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
223565569|NCT02824770|DRUG|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
223565570|NCT02824770|DRUG|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
223565571|NCT02824770|PROCEDURE|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
223565572|NCT06117969|DRUG|Tibolone|1.25mg po qd
223565573|NCT06117969|DRUG|Xiangshao granules|4g po tid
223432551|NCT05675514|OTHER|Myofascial Release Therapy|The increasing number of basketball players also increases the risk of sports-related injuries. Basketball has the highest injury risk of all sports because the game is so powerful and fast moving. Myofascial release therapy; ıt is a form of manual therapy applied on the muscle fascia complex to restore optimal length, reduce pain and improve functions. It is known to be effective in providing rapid relief of pain and tissue sensitivity. By restoring the length and health of the restricted connective tissue with the myofascial release therapy, it aims to relieve pressure on pain sensitive structures such as nerves and blood vessels, as well as improves sports performance.
223432552|NCT03182634|DRUG|Fulvestrant|
224042522|NCT04611854|BEHAVIORAL|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 8 lessons distributed across 8 weeks.
224042523|NCT01936909|DRUG|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
224042524|NCT01936909|DRUG|Anakinra (weeks 3-12)|
224042525|NCT01936909|DRUG|Placebo|
224042526|NCT02094833|BIOLOGICAL|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
223432553|NCT03182634|DRUG|Neratinib|
223432554|NCT03182634|DRUG|AZD5363|
223432555|NCT03182634|DRUG|Olaparib|
223432556|NCT03182634|DRUG|AZD6738|
223432557|NCT00865267|DRUG|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
223432558|NCT00574223|DRUG|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
223432559|NCT00574223|DRUG|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
223432560|NCT03117881|BEHAVIORAL|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
223432561|NCT03117881|BEHAVIORAL|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
224042527|NCT02094833|BIOLOGICAL|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
224140512|NCT02694211|BEHAVIORAL|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
223432562|NCT03117881|BEHAVIORAL|rDirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks by a therapist via videoconferencing technology. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
223432563|NCT04182438|DIETARY_SUPPLEMENT|Low potassium content vegetables|use low-potassium content vegetables
223432564|NCT05083052|OTHER|Propolis 15%|oothpaste formulation with 15% propolis.
224042528|NCT06439173|BIOLOGICAL|CAR-T cell therapy|Patients with diffuse large B-cell lymphoma undergoing consecutive commercial CAR-T therapy at the University Hospital of Salamanca
224042529|NCT05811715|OTHER|whole body stretching excercise|For the WBS group, each 30 minutes exercise class was run by a one trained physiotherapist to serve a maximum of 10 participants (10 x 3 = 30 participants) working in the hospital. Participants invited to attend the exercise class 3 times a week for 6 weeks in their hospital during lunch-break. During each session, participants asked to perform WBS exercise (Franco et al., 2008).
224042530|NCT05811715|OTHER|educational program|Participants received an education program which includes ergonomic principles, WRMSDs and their risk factors, as well as manual handling techniques(Bolbol et al., 2017).
224042531|NCT00686270|DRUG|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
223432565|NCT05083052|OTHER|Propolis 10%|Toothpaste formulation with 10% propolis.
223432566|NCT05083052|OTHER|Placebo|Formulation of toothpaste without active ingredient.
223432567|NCT03346304|OTHER|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
223432568|NCT02204358|PROCEDURE|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
223432569|NCT01027897|DRUG|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
223432570|NCT06730828|COMBINATION_PRODUCT|The intervention includes Amiodarone-Infused CardiaMend patches (70mg, 150mg and 300mg)|Intervention includes a topical, atrial-specific, amiodarone infused CardiaMend patch in the operating room and applied onto the epicardial surface biatrially
223565574|NCT06117969|DRUG|Tibolone plus Xiangshao granules|Tibolone 1.25mg po qd plus Xiangshao granules 4g po tid
224299646|NCT04013945|DIETARY_SUPPLEMENT|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
224299647|NCT04013945|DIETARY_SUPPLEMENT|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
223432571|NCT03870529|DRUG|Vitamin A Compound|Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
223432572|NCT03870529|PROCEDURE|Therapeutic Conventional Surgery|Participants randomized to this arm will receive surgical resection
223432573|NCT02045732|BIOLOGICAL|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
223432574|NCT02045732|BIOLOGICAL|Placebo|Bi-Weekly Subcutaneous Injections X 6
223432575|NCT02045732|BIOLOGICAL|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
223432576|NCT02045732|BIOLOGICAL|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
223432577|NCT05914389|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 for inducing chemotherapy on Day 1 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
223432578|NCT05914389|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the report in BJC (2018) 118:1322-1328.
223565575|NCT05553340|OTHER|Education for caregivers|The intervention will aim to equip the family caregiver to assist the elderly in activities of daily living after discharge, and will be carried out by two researchers, through an online course. The course includes the skills required and included in the scales that assess the caregiver's knowledge and performance. The course is divided into 12 modules that can be accessed as many times as needed by caregivers, in random order, according to the care needs of the elderly and the caregiver.
223565576|NCT00422630|BEHAVIORAL|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
224042532|NCT00992979|PROCEDURE|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
224140513|NCT02834234|GENETIC|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
223432579|NCT05914389|DRUG|Anti-PD-L1 Monoclonal Antibody|The incidence of adverse events with Anti-PD-L1 Monoclonal Antibodies is relatively low. Based on phase I clinical trial data of Envafolimab, a dose reduction design was conducted to minimize the incidence of adverse events while ensuring therapeutic efficacy. In the two cohorts of the efficacy-enhancing design, a reduced dose of 100mg/0.5ml IH QW will be used for 6 weeks. The PD-L1 monoclonal antibody (Envafolimab) dose adjustment was implemented according to the prescribing information.
223432580|NCT05914389|DRUG|Clostridium butyricum|Clostridium butyricum is treated with Miyarisan 588 powder, 160mg/day (4 packets/day) taken orally for a total of 6 weeks.There have been no reports of adverse reactions for Lactobacillus. There is no predetermined reduction plan.
223432581|NCT05914389|PROCEDURE|Colectomy|The specific surgical approach, whether it be laparoscopic or open surgery, is determined by the surgeon. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
223432582|NCT02265757|BEHAVIORAL|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
223565577|NCT00422630|BEHAVIORAL|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
224042533|NCT00992979|PROCEDURE|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
224042534|NCT00744211|DRUG|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
223432583|NCT02265757|BEHAVIORAL|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
224042535|NCT00744211|DRUG|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
224042536|NCT00744211|OTHER|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
224042537|NCT02959749|DRUG|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
224042538|NCT02959749|DRUG|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
224042539|NCT00000125|DRUG|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
224140514|NCT05656898|DEVICE|Piezocision+GaALAs diode laser|After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
224140515|NCT05656898|DEVICE|Piezocision|Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
224140516|NCT05656898|DEVICE|Orthodontic fixed appliance|Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
223432584|NCT02265757|BEHAVIORAL|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
223432585|NCT02265757|BEHAVIORAL|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
223432586|NCT02265757|BEHAVIORAL|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
223432587|NCT00473824|BIOLOGICAL|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
223432588|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|280 mg three times daily for four weeks
223432589|NCT00755950|DIETARY_SUPPLEMENT|Silymarin|420 mg three times daily for four weeks
223432590|NCT00755950|OTHER|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
223432591|NCT02795468|PROCEDURE|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
223432592|NCT02560623|PROCEDURE|Biopsy|Undergo biopsy
223432593|NCT02560623|PROCEDURE|Biospecimen Collection|Undergo collection of blood sample
223432594|NCT02560623|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
223432595|NCT02560623|DEVICE|Swallowable Sponge Cell Sampling Device|Undergo swallowable sponge cell sampling assessment
223432596|NCT05230745|DEVICE|ContraBand implants|Percutaneous implantation of the ContraBand devices by right heart catheterization
223432597|NCT06850116|PROCEDURE|Retzius-sparing robot-assisted radical prostatectomy|Retzius-sparing robot-assisted radical prostatectomy
223432598|NCT05737121|DRUG|VNX001|VNX001 (alkalinized lidocaine HCl and heparin sodium)
223432599|NCT05737121|DRUG|Placebo|Inactive placebo for VNX001
223432600|NCT05737121|DRUG|Lidocaine|Alkalinized lidocaine hydrochloride
224042540|NCT01788657|BEHAVIORAL|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
224042541|NCT01788657|BEHAVIORAL|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
224042542|NCT03881384|OTHER|ctDNA level during neoadjuant chemotherapy|Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
224042543|NCT06094751|BEHAVIORAL|ACT Guide for Insomnia|ACT Guide for Insomnia includes 2 modules. Module 1 will include sleep/insomnia education, ACT skills (acceptance, defusion), and behavioral change. Module 2 will include sleep restriction, sleep hygiene, ACT skills (values, committed action), and behavioral change.
224042544|NCT05315050|OTHER|Educational session and Information Pamphlet|"Each session will last for 50 minutes that will consist on lecturing, discussion about improving adolescent girls' menstrual knowledge, promoting a more positive attitude, encourage confidence, self-care behavior, physical activity and improve pain relief practice.~Exercise advice: The exercise protocol will include aerobic exercise such as jogging, which perform in the interventional group, three times a week, and for 10 to 30 min.~Stretching's advice: Piriformis stretching (5 repitition×20seconds), Cobra Pose. (5 repitition×20seconds), Adductor stretching. (5 repitition×20seconds), Sit up (10 repetition × 3 sets), Bridge exercise (10 repetition × 3 sets), Kegel exercise (10repetition × 3 sets), Pelvic eleva¬tion (10repetition × 3 sets), three times a week."
224140517|NCT02327221|DRUG|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
224299648|NCT03345394|BEHAVIORAL|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
224042545|NCT05315050|OTHER|Information Pamphlet|Pamphlets consist of information about primary dysmenorrhea its causes, symptoms (onset, duration, location, prognosis) and treatment strategies (taking hot bath, heating pad, yoga, exercise, maintaining hygiene, modifying life style) Emphasized on that menstruation is a not a disease it's a natural life experience.
224042546|NCT00470236|RADIATION|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
224042547|NCT00470236|RADIATION|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
224042548|NCT00470236|RADIATION|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
224042549|NCT00470236|RADIATION|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
224042550|NCT02336841|OTHER|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
224042551|NCT02336841|OTHER|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
224042552|NCT06524583|DRUG|Doxorubicin|60 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
224042553|NCT06524583|DRUG|Trabectedin|1.1 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
224042554|NCT06317818|OTHER|Mesenchymal Stem Cells|Suspension of mesenchymal stromal cells for intratissular injection
224042555|NCT06317818|OTHER|Comparative placebo|Cell-free cell suspension solution devoid of cells for intratissular injection
224042556|NCT03114865|DRUG|Blinatumomab 9ug|Cycle 1 - Days 1-7: 9 ug/day IV daily
224042557|NCT03114865|DRUG|Blinatumomab 28 ug|Cycle 1 - Days 8-28: 28 ug/day IV daily
224042558|NCT03114865|DRUG|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
224042559|NCT03114865|DRUG|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
224042560|NCT06419192|OTHER|dietary advice|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
224042561|NCT06419192|OTHER|dietary advice alone|Advise to eat 7 dates a day from 37SA until delivery. The food will not be provided.
224042562|NCT06419192|OTHER|food supplied|Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
224042563|NCT02577744|OTHER|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
224042564|NCT02577744|OTHER|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
224042565|NCT05446428|OTHER|study of IFNGS expression biomarkers|Blood tests for serum biomarkers, autoantibodies, cytokine profile etc.
224042566|NCT03612362|DEVICE|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence \& HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements \& suitably short follow-up period to decrease attrition."
224042567|NCT01053442|DIETARY_SUPPLEMENT|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
224042568|NCT01053442|DIETARY_SUPPLEMENT|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
224042569|NCT01316185|DRUG|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
224042570|NCT02104154|DEVICE|Samsung LABGEO PT10 Hepatic Panel|
224042571|NCT00002296|DRUG|Inosine pranobex|
223432601|NCT05737121|DRUG|Heparin|Alkalinized heparin sodium
223432602|NCT06096779|DRUG|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
223432603|NCT06096779|DRUG|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
223565578|NCT00422630|BEHAVIORAL|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
224042572|NCT04035226|OTHER|No intervention|No intervention will be administered as a part of this study.
224042573|NCT00440076|DRUG|Velcade|
223432604|NCT01412697|BEHAVIORAL|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
223432605|NCT05014815|DRUG|Ociperlimab|900 mg intravenously (IV) once every 3 weeks (Q3W)
223432606|NCT05014815|DRUG|Tislelizumab|200 mg IV Q3W
223432607|NCT05014815|DRUG|Carboplatin|Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle
224042574|NCT00113230|DRUG|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
224042575|NCT00113230|DRUG|Capecitabine|900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.
224042576|NCT00113230|RADIATION|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
224042577|NCT01087099|DRUG|Albendazole|Treatment with albendazole
224042578|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
224299649|NCT03345394|BEHAVIORAL|Standard treatment|Participants will receive the standard treatment offered at Unidade Recomeço Helvétia treatment program
224042579|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
224042580|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
224042581|NCT01921855|DRUG|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
224042582|NCT01921855|DRUG|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
224042583|NCT01358890|OTHER|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
223432608|NCT05014815|DRUG|Paclitaxel|75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle
223432609|NCT05014815|DRUG|Nab paclitaxel|100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle
223432610|NCT05014815|DRUG|Cisplatin|75 mg/m², administered intravenously on Day 1 of each 21-day cycle
223432611|NCT05014815|DRUG|Pemetrexed|500 mg/m² administered intravenously on Day 1 of each 21-day cycle
223432612|NCT05014815|DRUG|Placebo|Administered intravenously Q3W to match ociperlimab
223432613|NCT06261827|DRUG|Sham treatment|Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
223432614|NCT06261827|DRUG|200-ppm NO|NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
223565579|NCT00140283|PROCEDURE|Educational interactive intervention|
224042584|NCT01358890|OTHER|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
223565580|NCT03536780|DRUG|Avelumab and Gemcitabine|"* Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~* Gemcitabine: 1000 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle"
224042585|NCT02679599|OTHER|B-MOBILE-CARDIAC smartphone application|
224042586|NCT02679599|BEHAVIORAL|Cardiac rehabilitation as usual|
224042587|NCT00003757|BIOLOGICAL|rituximab|
224042588|NCT03054207|DRUG|Clopidogrel 300Mg Tablet|
224042589|NCT03054207|DRUG|Prasugrel 60Mg|
224042590|NCT04098042|DEVICE|Scaffold|implantation of a Magmaris scaffold
224042591|NCT01439542|RADIATION|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
224042592|NCT01439542|DRUG|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
224042593|NCT04042870|BEHAVIORAL|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
224042594|NCT01089920|OTHER|Green tea|Infusion (tea bags) from commercially available green tea
224042595|NCT01089920|OTHER|Coffee|Soluble coffee commercially available
224042596|NCT00112775|DRUG|dasatinib|
224042597|NCT00112775|DRUG|imatinib mesylate|
223432615|NCT04247880|BEHAVIORAL|Mentoring program|Apprentice-level female construction workers will be assigned to a mentor who has gone through a rigorous mentorship training. Participants will be asked to meet with a mentor at least 4 times/year in person to discuss the challenges of being a female in construction, learn coping mechanisms, and otherwise discuss the unique challenges of the job environment.
223432616|NCT00568997|DRUG|Pimecrolimus|Pimecrolimus 1% cream
224042598|NCT03714191|OTHER|Patient Outcomes|The intervention includes different versions of the BPA design and message.
224042599|NCT03714191|OTHER|Billing documentation|The intervention includes different versions of the BPA design and message.
224042600|NCT03714191|OTHER|Regulatory|The intervention includes different versions of the BPA design and message.
224042601|NCT05372653|DRUG|OPA-15406|0.3% or 1% ointment, topical, twice daily, for 52 weeks
224042602|NCT04328246|DEVICE|IES System|The IES system is composed of a stimulator and self-adhesive surface gel electrodes.
224042603|NCT04328246|OTHER|Standard of Care Therapy|Standard institutional practices for treating pressure injury.
224042604|NCT00465946|BEHAVIORAL|Salt Supplementation|
223432617|NCT06020612|OTHER|Assessment by dermatopathologists|Histological assessment of the cSCCs by eight dermatopathologists.
223432618|NCT05617716|RADIATION|Conventional external beam radiation therapy dose (EBRT)|Participants will undergo 8 Gray in 1 fraction of EBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
223432619|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy standard dose|Participants will undergo 24 Gray in 2 fractions of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
223432620|NCT05617716|RADIATION|Spine radiosurgery/stereotactic body radiation therapy high dose|Participants will undergo 19 Gray in 1 fraction of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.
223432621|NCT05962177|OTHER|Magnetic Resonance Imaging|Magnetic Resonance Imaging
223432622|NCT05962177|OTHER|Blood withdrawal|Blood withdrawal
223432623|NCT05962177|OTHER|Neuropsychological tests|Neuropsychological tests
223432624|NCT06303167|PROCEDURE|Biopsy Procedure|Undergo biopsy
223432625|NCT06303167|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223432626|NCT06303167|PROCEDURE|Echocardiography Test|Undergo ECHO
223432627|NCT06303167|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224042605|NCT03966261|OTHER|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
224042606|NCT01543724|DRUG|Lithium|10mg/kg/day for 12 weeks
224042607|NCT00890149|DRUG|Ondansetron|Ondansetron (4ug/kg bid),
224042608|NCT00890149|DRUG|Placebo|Placebo bid
224042609|NCT00890149|BEHAVIORAL|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking.
223432628|NCT06303167|DRUG|Osimertinib|Given PO
223432629|NCT06303167|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
223432630|NCT02716233|DRUG|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
223432631|NCT02716233|DRUG|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
223432632|NCT00532272|DRUG|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
223432633|NCT01276691|DRUG|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
223432634|NCT06619119|OTHER|Excape room simulation|"Application of Research:~Preparation and Implementation of the Escape Room The escape room game scenario prepared by the relevant faculty members consists of the subjects of Triage, Basic Life Support, Advanced Life Support and Traumas, which are included in the Emergency Nursing course curriculum. Students who will participate in the escape room game were given 30 minutes to solve the puzzles in the room, follow the clues, find the exit key and escape. To solve puzzles, unlock padlocks, and find specific objects in the escape room, students had to answer questions on Triage, Basic Life Support, Advanced Life Support, and Traumas and manage to exit the room in time."
223432635|NCT00376272|DRUG|Valsartan|
224042610|NCT03752099|DRUG|VERU-111|VERU-111
224042611|NCT04656314|DIAGNOSTIC_TEST|Functional MRI scan|Functional MRI scan: Phase contrast, BOLD, Arterial Spin Labeling, Diffusion weighted MRI, T1 mapping, T1rho mapping
224042612|NCT01381354|OTHER|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
223432636|NCT00376272|DRUG|Placebo|
223432637|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)|
224042613|NCT01381354|DEVICE|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
224042614|NCT01381354|OTHER|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
224042615|NCT01381354|DIETARY_SUPPLEMENT|Omega 3 fatty acids|4 grams daily by mouth.
224042616|NCT01381354|DIETARY_SUPPLEMENT|Full Spectrum vitamin|Two capsules daily.
224042617|NCT01381354|DIETARY_SUPPLEMENT|Essential - hydroxytyrosol|Two capsules twice daily.
224042618|NCT01381354|DIETARY_SUPPLEMENT|Maltodextrin fiber supplement|One scoop daily.
223432638|NCT02453282|BIOLOGICAL|MEDI4736 (Durvalumab)+Tremelimumab|
223432639|NCT02453282|DRUG|Paclitaxel + Carboplatin|Chemotherapy Agents
223432640|NCT02453282|DRUG|Gemcitabine + Cisplatin|Chemotherapy Agents
223432641|NCT02453282|DRUG|Gemcitabine + Carboplatin|Chemotherapy Agents
223432642|NCT02453282|DRUG|Pemetrexed + Cisplatin|Chemotherapy Agents
223432643|NCT02453282|DRUG|Pemetrexed + Carboplatin|Chemotherapy Agents
223432644|NCT02453282|BIOLOGICAL|Tremelimumab|
223432645|NCT03410732|BIOLOGICAL|activated DCs|autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
223432646|NCT03410732|PROCEDURE|radical surgery only|Only radical surgery is given to the control group
223432647|NCT01160835|PROCEDURE|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
223432648|NCT06338657|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224042619|NCT01381354|DIETARY_SUPPLEMENT|Mineral boost (magnesium)|Two capsules daily
224042620|NCT01381354|DIETARY_SUPPLEMENT|Niacinamide|500 mg daily
224042621|NCT01381354|DIETARY_SUPPLEMENT|Methyl B12|Methyl B12 1000 mcg daily
224042622|NCT01381354|DIETARY_SUPPLEMENT|Taurine|one gram daily
224042623|NCT01381354|DIETARY_SUPPLEMENT|creatine|one teaspoon daily
224042624|NCT01381354|DIETARY_SUPPLEMENT|thiamine|100 mg daily
224042625|NCT01381354|DIETARY_SUPPLEMENT|riboflavin|200 mg daily
224042626|NCT01381354|DIETARY_SUPPLEMENT|N acetylcysteine|1 gram daily
223432649|NCT06338657|PROCEDURE|Computed Tomography|Undergo CT scan
223432650|NCT06338657|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223432651|NCT06338657|DRUG|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
223432652|NCT06338657|PROCEDURE|Tumor Resection|Undergo surgical resection
223432653|NCT05227703|DRUG|CVL-231 15 mg|CVL-231 15 mg, oral (tablet), once per day for 6 weeks
223432654|NCT05227703|DRUG|Required CVL-231 30 mg|CVL-231 30 mg, oral (tablet), once per day for 6 weeks
223432655|NCT05227703|DRUG|Placebo|Matching placebo, oral (tablet), once per day for 6 weeks
223432656|NCT03813784|DRUG|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
223432657|NCT03813784|DRUG|Capecitabine|1000 mg/m\^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
223432658|NCT03813784|DRUG|Oxaliplatin|130 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle.
223432659|NCT03813784|DRUG|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
224042627|NCT01381354|DIETARY_SUPPLEMENT|alpha lipoic acid|300 mg twice daily
224042628|NCT01381354|DIETARY_SUPPLEMENT|L acetyl carnitine|500 mg twice daily
224042629|NCT01381354|DIETARY_SUPPLEMENT|methyl folate|1000 mcg one pill four times a week
224042630|NCT01381354|DIETARY_SUPPLEMENT|coenzyme Q|100 mg daily
224042631|NCT01381354|BEHAVIORAL|meditation|meditation 15 minutes daily
224042632|NCT01381354|BEHAVIORAL|self massage|self massage of hands, feet, ears 15 minutes daily
224042633|NCT01381354|BEHAVIORAL|learning|completing puzzles or learning 15 minutes daily
224042634|NCT01381354|DIETARY_SUPPLEMENT|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
224042635|NCT00711529|BEHAVIORAL|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
223432660|NCT06559137|DRUG|Ropivacaine 0.2% Injectable Solution|Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
224042636|NCT00711529|DRUG|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
224042637|NCT02083874|DRUG|CBD|
223432661|NCT05341947|BIOLOGICAL|Activated T cells|Activated T cells (ATC) administered intravenously at one timepoint
223432662|NCT06283992|OTHER|Digital Navigation|1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
223432663|NCT03902522|DRUG|PRO 140|2 injections of PRO 140 (2 X 2 mL/inj.) Subjects who were previously enrolled and receiving 350 mg dose had the option to move to the 700mg dose for the remainder of the trial.
223432664|NCT06037460|DRUG|Tocilizumab treatment|"* 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24"
223432665|NCT06037460|OTHER|questionnaires|HAQ, SF-36, FACIT-Fatigue score
223432666|NCT06037460|BIOLOGICAL|Blood samples|Additionnal blood samples for immunomonitoring
223432667|NCT06037460|PROCEDURE|18FDG PET scan|PETVAS calculation (to be performed between W0 and W8) (optional).
223432668|NCT04983667|DIETARY_SUPPLEMENT|Zn-AA|Oral supplementation of either 30 mg daily or Zinc-AA complex or placebo, from the study recruitment during first trimester of pregnancy, all through pregnancy and up to the sixth month after giving birth.
223432669|NCT05054361|DIAGNOSTIC_TEST|MAIT cells analysis|For FACS analysis, MAIT cells will be identified as CD3+ CD4- CD161high Vα7.2+ T cells. Surface markers will be analyzed to determine their activation status (CD25, CD69, CD44), their exhaustion (PD1, KLRG1, TIM3), their migration capacity (CCR6), and their proliferation and survival will be analyzed by Ki67 and BCL2 expression.
223432670|NCT05054361|DIAGNOSTIC_TEST|MAIT cytokines production analysis|Cytokine production will be assessed after PMA-ionomycin activation, followed by intracytoplasmic staining with antibodies against IL-2, IFN-γ TNF-α, IL-2, IL-4, IL-10, IL-13, IL-17 and granzyme B. To determine the capacity of MAIT cells to response to TCR stimulation (exhaustion), in vitro stimulation will be performed in the presence of specific bacterial ligands. Activation marker expression will be analyzed by FACS and cytokines released in the supernatant by Cytometry based assay.
223432671|NCT05054361|DIAGNOSTIC_TEST|Lactulose/Mannitol Test|After an overnight fast, the patients will drink 50 ml solution of 5 g lactulose and 2 g mannitol. Urine will be collected during before and 5 hours later.
223565581|NCT04917952|DEVICE|Blood Flow Restriction (BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, 80% at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the intervention group will receive an exercise protocol with blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Blood flow restriction will be applied at 80% by using pressure cuffs. The cuffs will be applied to the proximal thigh. Cuff pressure needed for a 100% vascular occlusion will be determined for each individual at a seated and relaxed position."
224042638|NCT04128345|DEVICE|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
223432672|NCT05054361|PROCEDURE|UGI Endoscopy|Duodenal biopsy collection and analysis. Biopsies will be analyzed by qPCR for the expression of key epithelial molecules such as the fucosyl transferase 2 (fut2), tight junction proteins (occludin, claudin4), antimicrobial peptides (Reg3, LL37) and mucus component (mucin 2). Immune cells function will also be assessed by q-PCR for key cytokines/molecules such as IL-23, IL-17, IL-22, Foxp3, IL-10, TGFb and CVB.
223432673|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Serology against CVB and CVB specific-qPCR measurement in gut microbiota samples will be performed in all patients of the three cohorts, and analysis of the gut mucosa by qPCR and immunochemistry with anti-CVB VP1 protein mAb will be performed on a subset of patients.
224042639|NCT03411460|DEVICE|FreeStyle Libre™ system|Measured non-invasively via scanner
223432674|NCT05054361|DIAGNOSTIC_TEST|Coxsackie virus B infection status|Stool samples are collected and directly kept under anaerobic condition. Within an hour the samples are processed: one fraction is aliquoted and frozen at -80°C and another fraction is used to prepared fecal supernatant for the bioassay of MAIT ligands, aliquoted and frozen. Bioassay to measure the presence of MAIT cell ligands by bioassays using WT3 cell line as well as plate bound MR117. 16S sequencing of all samples and according to the results obtained with the bioassay and 16S, 10 samples will be selected for metagenomic analysis.
223432675|NCT05889585|OTHER|quality of life questionnaire|EORTC-QLQ C-30 questionnaire The Impact of Events Scale (IES-R) Multi-Dimensional Fatigue Inventory The EORTC-QLQ C-30 Vers. 3
223432676|NCT02375490|BEHAVIORAL|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
224042640|NCT03411460|PROCEDURE|Finger prick|Blood test
224042641|NCT06238674|OTHER|indirect calorimetry and nitrogen balance|"nutrition therapy with energy guided by indirect calorimetry measurements and total protein guided by nitrogen balance with the maximum of 1.3 g/kg/d~, repeated indirect calorimetry if renal replacement therapy was initiated and follow up of urea nitrogen balance after 7 days of intervention to guarantee positive nitrogen balance"
224042642|NCT06238674|OTHER|Indirect calorimetry (Standard care nutrition arm)|indirect calorimetry measurements using the Q-NRG+ device will be conducted and urea nitrogen balance were measured . In the standard care nutrition arm, clinicians will be blinded to indirect calorimetry and urea nitrogen balance measurements
224140518|NCT02327221|DRUG|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
224140519|NCT06454851|BEHAVIORAL|Prosocial VR intervention|A four-week gamified prosocial VR intervention program based on literature review and relevance to the local contexts will be developed for the proposed project. The intervention will be expanded to include four weekly sessions, each lasting between 15 to 20 minutes. Each session will depict a different daily life scenario-campus, lecture hall, canteen, and library, respectively. During each session, participants will engage in a series of tasks that incorporate elements of prosocial behavior or helping actions within the scene. These tasks are designed to be more comprehensive and interactive, ensuring that participants are fully immersed in the experience for the entire duration of the session.
224140520|NCT06454851|OTHER|No intervention|The waitlist control group will not receive the intervention during the study.
224140521|NCT03743233|DEVICE|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
224042643|NCT02444481|DRUG|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
224042644|NCT03646500|PROCEDURE|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
224042645|NCT03646500|PROCEDURE|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
224042646|NCT00038727|BEHAVIORAL|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
224163423|NCT03161184|BEHAVIORAL|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
224299650|NCT00963079|PROCEDURE|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
224042647|NCT00038727|DRUG|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
224299651|NCT00963079|PROCEDURE|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
223432677|NCT01920737|DRUG|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
224042648|NCT00038727|BEHAVIORAL|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
224042649|NCT00038727|BEHAVIORAL|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
224299652|NCT02593435|GENETIC|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
223432678|NCT01920737|DRUG|Vincristine|
223432679|NCT01920737|DRUG|Prednisone|
223432680|NCT01920737|DRUG|PEG-Asparaginase|
223432681|NCT01920737|DRUG|Methotrexate|
223432682|NCT01920737|DRUG|6-MP (6-Mercaptopurine)|
223432683|NCT01920737|DRUG|Cyclophosphamide|
223432684|NCT01920737|DRUG|Cytarabine|
223432685|NCT01920737|DRUG|Leucovorin|
223432686|NCT01920737|DRUG|Dexamethasone|
223432687|NCT01920737|OTHER|Blood draw|
223432688|NCT01920737|DEVICE|CT/PET scans|PET or CT scan every 6 months for 3 years
223432689|NCT03606538|DRUG|Midomafetamine HCl|80 mg midomafetamine HCl
223432690|NCT06463652|PROCEDURE|Cervical cerclage|Cervical cerclage using the McDonald technique under anaesthesia.
223432691|NCT06463652|DRUG|Vaginal progesterone|Cyclogest® 200mg, Actavis, United Kingdom, applied once daily at bedtime.
223432692|NCT06621212|DRUG|mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day 1, every 4 weeks
223432693|NCT06621212|DRUG|Cytarabine|Cytarabine (100 mg/m\^2 ) on day 1-7, every 4 weeks
223432694|NCT06621212|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-8, every 4 weeks
223432695|NCT03364764|DRUG|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
223432696|NCT02836964|DEVICE|Crown placement|Dental implant
223432697|NCT00850304|DRUG|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
223432698|NCT00850304|DRUG|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
223432699|NCT01661933|BIOLOGICAL|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
223432700|NCT01661933|BIOLOGICAL|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
223432701|NCT06142942|OTHER|Exercise Intervention|Participants will complete an exercise intervention where they will exercise 2, 3, or 4 days per week for 4 weeks.
223432702|NCT05398185|DEVICE|CleverCap|The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
224042650|NCT06072443|BEHAVIORAL|Digital Health Companion (mobile App)|Participants will complete education modules, health literacy evaluations, and PRO assessments in the Digital Health Companion.
224042651|NCT01673568|DEVICE|ETO garments|patients wearing abdominal binder for 7 days postoperatively
224042652|NCT03279874|OTHER|Interviews|Semi-structured one-on-one interviews
224042653|NCT03740997|DRUG|Optison|Optison is administered intravenously
223432703|NCT02750007|DRUG|HS-20004|
224042654|NCT04251260|OTHER|Positioning in flexion|"The intervention group will be positioned in flexion (i.e. lower limbs in flexion, hand in midline) with an aid, the Snuggle up (Philips, USA). With positioning, the neonates bottom is tucked down in the snuggle up pocket, legs are aligned and gently flexed and hands towards midline and near the face.~Positioning will be demonstrated to the nursing staff of the Neonatal Intensive Care Unit (NICU). The intervention group will receive positioning during day and night throughout the intervention period."
224042655|NCT05924685|BIOLOGICAL|COVID-19 vaccination|Vaccination
224042656|NCT01993446|DRUG|DRM02|
224042657|NCT01993446|OTHER|Vehicle|
224042658|NCT00952172|BEHAVIORAL|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
224042659|NCT05087355|DIAGNOSTIC_TEST|PCR or antigen test for Covid 19 or Inluenza|PCR or antigen test for Covid 19 or Inluenza
224042660|NCT03570853|BEHAVIORAL|SMART-3RP|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
224042661|NCT04866654|DRUG|Nivolumab 10 MG/ML|Nivolumab, 100 mg, 10 mg/ml
224042662|NCT02042196|DRUG|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
223432704|NCT01752153|DRUG|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
223432705|NCT01752153|DRUG|Silymarin (Legalon)|
223432706|NCT05704335|OTHER|Questionnaire administration|A trained physician will administer a structured questionnaire
223432707|NCT00705458|PROCEDURE|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
223432708|NCT00705458|PROCEDURE|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
224042663|NCT02042196|DRUG|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
224042664|NCT02042196|DRUG|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
224042665|NCT02042196|DRUG|Climara|0.075mg/d transdermal patch will be placed on skin.
224042666|NCT02042196|DRUG|Placebo transdermal patch|Inactive transdermal patch
224042667|NCT04663100|OTHER|Patient-reported outcome measure|Participants will complete a patient-reported outcome measure for their oral anticancer agent at two timepoints over 2 months, to assess patient symptoms and adherence to their oral anticancer agent.
224299653|NCT04142008|DEVICE|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
224042668|NCT04663100|OTHER|Comprehensive Medication Review|Following the first patient-reported outcome measure, participants will be contacted by the community pharmacist for a Comprehensive Medication Review (CMR) for their chronic medications. A follow-up CMR will take place after the second patient-reported outcome measure.
224042669|NCT04663100|OTHER|Pharmacist communication|Throughout the study, the oncology and community pharmacists will communicate about medications through the electronic medical record.
224042670|NCT01829425|DRUG|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
224299654|NCT05084664|DEVICE|electrical stimulation|premodulated current+ exercises
224299655|NCT05084664|DEVICE|electrical stimulation|diadynamic current+ exercises
224299656|NCT01144364|DRUG|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
224042671|NCT01829425|BEHAVIORAL|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
224140522|NCT03743233|DEVICE|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
224140523|NCT03146221|OTHER|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
224140524|NCT00749164|PROCEDURE|MSC transplantation|1-2X10\^6 MSC per kg
224140525|NCT00589979|DRUG|Lidoderm (Lidocaine 5% Patch)|Topical Patch
224140526|NCT00589979|DRUG|Placebo Patch|Topical Patch
224140527|NCT00250991|DRUG|activase|
224140528|NCT00250991|DRUG|integrilin|
224140529|NCT02786940|DEVICE|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
223432709|NCT05449535|DRUG|JYB1904|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
223432710|NCT05449535|DRUG|Omalizumab|Dosage form: injection, powder, lyophilized, for solution； Usage and dosage matching:dose 1; single-dose; subcutaneous injection in the deltoid region of the upper arm.
224042672|NCT03210350|DIAGNOSTIC_TEST|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
224140530|NCT05865873|BEHAVIORAL|Health education|Health education will be delivered for six months, two times per month; one session will take one hour, and an overall 12 sessions will be conducted. One health education session consists of key messages on normal pregnancy and childbirths, ODS during pregnancy, delivery, and the postpartum period, the practice of BPCR, and the benefits of MHSU. The other actions executed by WDT facilitators will be the motivating mother and their families to utilize MHS. One hour will be allocated for each session, from this 20 minutes will be allowed for the pre-recorded an audio-based lecturer and the remaining 40 minutes will be allowed for raising questions and responses (discussion). After the session, some of the women will be selected to carry out role play which is basic to demonstrate the important messages and share experiences.
224140531|NCT00101621|DRUG|M40403|
224140532|NCT00355849|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
224140533|NCT00355849|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
224140534|NCT04771988|RADIATION|yttrium-90 radioembolization|selective/superselective treatment using resin microspheres labeled with Yttrium-90
224140535|NCT01756872|PROCEDURE|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
223432711|NCT05449535|DRUG|JYB1904 Placebo|Dosage form: injection, solution； Usage and dosage matching:dose 1, dose 2, dose 3, dose 4, dose 5; single-dose; subcutaneous injection in the deltoid region of the upper arm.
223432712|NCT01128218|DRUG|Tumor fluorescence|"Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2"
224042673|NCT05211739|DEVICE|Lehfilcon A toric contact lenses|FDA-cleared silicone hydrogel toric contact lenses used as indicated
224042674|NCT05211739|DEVICE|Comfilcon A toric contact lenses|Commercially available silicone hydrogel toric contact lenses used as indicated
224042675|NCT05211739|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
224042676|NCT01862640|DRUG|Brexpiprazole, OPC-34712|Once-daily, tablets
224140536|NCT05191355|BIOLOGICAL|blood test|Blood spot collection for sampling
224140537|NCT04599049|OTHER|six sessions of online classes and virtual training day camps through Zoom in two days|"The Smoke-free teens will join six sessions of online classes via an e-platform in October 2020 and followed by virtual training day camps through Zoom in two days in December 2020 organized by COSH. The online classes will educate students the knowledge on smoking hazards, tobacco control and smoking cessation. In addition, the teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model. After the online classes, the teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the online classes (T2), and 3 months later (T4). They will be asked to complete a process evaluation form immediately after the training camp (T3). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 months (T4), respectively."
224140538|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
224140539|NCT05583357|BIOLOGICAL|V-01D-351|One dose of V-01D-351 on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
224140540|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 2 doses of inactivated vaccine (CoronaVac) 6-15 months ago
224140541|NCT05583357|BIOLOGICAL|CoronaVac|One dose of CoronaVac on participants received 3 doses of inactivated vaccine (CoronaVac) 5-9 months ago
224140542|NCT04970394|BEHAVIORAL|Cervical Screening Reminder|Verbal reminder and if seen face-to-face, a written appointment booking slip.
224042677|NCT01862640|DRUG|Placebo Oral Tablet|Once-daily, tablets
224042678|NCT04178967|BIOLOGICAL|Lebrikizumab|Subcutaneous injection
224042679|NCT04178967|OTHER|Placebo|Subcutaneous Injection
224140543|NCT01497535|DRUG|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
224140544|NCT01497535|DRUG|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
224140545|NCT03061045|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
224140546|NCT02488525|DRUG|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
224299657|NCT04108247|DRUG|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
224299658|NCT06264791|OTHER|Stress|To manipulate stress, we follow the personalized imagery script procedure developed by Sinha and colleagues. Participants randomly assigned to the stress condition will be interviewed about one week prior to the lab session. They will share a detailed description of a stressful event from their life (last 12 months) with the interviewer. Based on this interview, the experimenter will write a script (\~500 words), that will then be audiotaped. Participants will listen to this personalized audiotape during the experiment, and will be asked to imagine this event as vividly as possible. Participants randomly assigned to the no stress condition will listen to a generic audiotape that describes a non-stressful event (\~500 words). They will not be interviewed. During the lab session, participants will first complete a 3-min color counting task. The participant will then listen to the audiotape (personalized stressful audiotape in stress condition, generic non-stressful audiotape in no stress c
224042680|NCT03681951|DRUG|GSK3145095|GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
224042681|NCT03681951|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
224042682|NCT04141254|OTHER|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
224042683|NCT04141254|OTHER|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
223740505|NCT01998633|BIOLOGICAL|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
224042684|NCT01975428|DEVICE|DM Pgm + device|"Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
224042685|NCT01975428|BEHAVIORAL|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
224042686|NCT00628251|DRUG|AZD2281|400mg Oral twice daily
224042687|NCT00628251|DRUG|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
224042688|NCT00628251|DRUG|AZD2281|200mg oral twice daily
224042689|NCT02129920|OTHER|This is an observational study|
224042690|NCT02715661|OTHER|exercise|six-month interval of exercise
224042691|NCT04069351|DIETARY_SUPPLEMENT|High-calorie mass gainer supplement|A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
224042692|NCT04069351|OTHER|Resistance Training|All participants will complete a 6-week supervised resistance training program.
224042693|NCT01020448|DRUG|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
224042694|NCT00728481|DRUG|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
224042695|NCT00728481|DRUG|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose \[Splenda-registered trademark\]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
224042696|NCT00378768|BIOLOGICAL|anti-thymocyte globulin|
224042697|NCT00629655|OTHER|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
224042698|NCT06414915|DRUG|Surufatinib|250 mg, po, qd, q3w
224042699|NCT06414915|DRUG|Tislelizumab|200mg, iv, q3w
224042700|NCT01824680|BEHAVIORAL|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
224042701|NCT00514657|DRUG|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
224042702|NCT00002951|DRUG|fluorouracil|
224042703|NCT00002951|DRUG|hydroxyurea|
224042704|NCT00002951|PROCEDURE|surgical procedure|
224042705|NCT00002951|RADIATION|radiation therapy|
224140547|NCT00217516|DRUG|selenium|Given orally
224140548|NCT00217516|OTHER|placebo|Given orally
224140549|NCT06122987|DRUG|Angiotensin II and hydrocortisone sodium succinate|Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
224042706|NCT01549782|DIETARY_SUPPLEMENT|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
224042707|NCT01549782|DIETARY_SUPPLEMENT|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
224042708|NCT00179725|DRUG|CC-5013|
224042709|NCT00179725|DRUG|liposomal doxorubicin|
224042710|NCT02545322|RADIATION|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
224042711|NCT05860023|OTHER|Exercise|Individuals in the experimental group will be asked to perform aerobic exercise or pelvic floor muscle strengthening exercises.
224042712|NCT06264778|DRUG|Dabrafenib|"Generic name: Dabrafenib mesylate capsules Dosage form: capsule Specifications: 50mg, calculated as C23H20F3N5O2S2 Usage: Orally The dose of dabrafenib is 150 mg twice daily (equivalent to a total daily dose of 300 mg), taken at least 1 hour before or 2 hours after a meal. If you miss a dose and it is less than 6 hours before the next dose, you should not take it.~Patients who undergo fenestrated decompression will be administered the drug for 8 weeks, with curettage performed between weeks 8 and 9. Patients undergoing curettage will continue to take dabrafenib preoperatively until a few hours before surgery, but ideally, patients will take dabrafenib within 12 hours before surgery."
224042713|NCT02748837|DRUG|ERY974|
224042714|NCT04846374|DEVICE|PowerPort|The study will compare pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
224042715|NCT01071135|DRUG|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
224042716|NCT00350805|PROCEDURE|EEG|One 20 minutes session
224042717|NCT00913250|DRUG|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
224140550|NCT05731232|DIETARY_SUPPLEMENT|Vivatlac Synbiotikum|Each capsule of Vivatlac® Synbiotikum contains a total of 4.5 x 10˄9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10˄8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10˄8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10˄8 CFU; Bifidobacterium breve Bb-03, 4.50 x 10˄8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10˄8 CFU; Streptococcus thermophiles St-21, 4.50 x 10˄8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10˄8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10˄8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10˄8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
224140551|NCT04562142|DEVICE|CAD-det|CAD-det test will be done on participants with suspected CAD clinically referred for ICA at a participating clinical investigation site.
223432713|NCT01230424|DRUG|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
223432714|NCT01230424|DRUG|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
223432715|NCT06623045|OTHER|Pelvic floor muscle training intervention|"The training program consisted of 12 weeks of PFM exercises, 3 times per week, with each session lasting between 10 and 15 minutes. The program followed different stages through the weeks: (1) proprioception of pelvic floor muscles activation and integration with diaphragmatic breathing, (2) stabilization and strengthening of the pelvic floor musculature through progressive overloading, and (3) transference of these exercises to FFT practice. During the 12 weeks, short contractions (2) were combined with longer ones (5 to 10), carrying out the progressive overload by increasing the number of contractions, the duration of the contraction, or by evolving the execution position towards more upright postures and sporting movements."
223432716|NCT06393257|DEVICE|Oscillation and Lung Expansion|A novel airway clearance technology
224140552|NCT03428256|DEVICE|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
224140553|NCT03428256|DEVICE|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
223432717|NCT06393257|BEHAVIORAL|Postural drainage|A type of physical therapy used to treat respiratory diseases by changing the patient's body position so that sputum is drained down the respiratory tract so that it can be more easily expelled from the body.
223432718|NCT06393257|DRUG|Anti-infective therapy|Antibiotics were used in these patients.
223432719|NCT06393257|DRUG|Mucolytic|Mucolytics were used in these patients.
223432720|NCT02813005|PROCEDURE|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
223740506|NCT00413192|DRUG|E7389|1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
223432721|NCT02813005|PROCEDURE|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
223432722|NCT04395612|DRUG|niraparib combined with brivanib|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Brivanib will be administered as a dose of 400mg orally every day.
223740507|NCT03755986|DEVICE|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
224042718|NCT00913250|DRUG|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
224042719|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
223740508|NCT01769833|DRUG|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
224042720|NCT02183922|DIETARY_SUPPLEMENT|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
223432723|NCT04395612|DRUG|niraparib combined with toripalimab|Drug：Niraparib will be administered as a dose of 200 mg orally every day. Drug：Toripalimab will be administered as a dose of 240mg Intravenously every 21days.
224140554|NCT02879981|DRUG|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
223432724|NCT06317844|BEHAVIORAL|Behavioral Writing Intervention|This behavioral intervention will require participants to write about certain aspects of their lives.
223432725|NCT05148403|DRUG|glibenclamide|Glibenclamide was given orally or by nasal feeding
223432726|NCT06521255|DRUG|Tafasitamab|Tafasitmab was infused intravenously
223432727|NCT06521255|DRUG|Lenalidomide|Lenalidomide orally
223432728|NCT06521255|DRUG|Gemcitabine|Gemcitabine was infused intravenously
223432729|NCT06521255|DRUG|Oxaliplatin|Oxaliplatin was infused intravenously
223432730|NCT06521255|DRUG|Rituximab|Rituximab was infused intravenously.
223432731|NCT00435435|DRUG|Disulfiram|
223432732|NCT00435435|DRUG|Acamprosate|
223432733|NCT00435435|DRUG|Naltexone|
223432734|NCT03536949|DRUG|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
223432735|NCT03536949|OTHER|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
223432736|NCT01425970|DRUG|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
224140555|NCT02879981|DRUG|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
224140556|NCT02879981|DRUG|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
224140557|NCT02557412|DEVICE|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
223432737|NCT01425970|DRUG|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
223432738|NCT01425970|DRUG|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
223432739|NCT01425970|DRUG|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
223432740|NCT01425970|BIOLOGICAL|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
223432741|NCT01425970|DRUG|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
223432742|NCT01425970|DRUG|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
223432743|NCT01425970|DRUG|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
223432744|NCT04058106|PROCEDURE|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
223432745|NCT02901275|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
223740509|NCT01769833|DRUG|Nucleosides|
224042721|NCT02183922|DIETARY_SUPPLEMENT|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
224042722|NCT04497909|BEHAVIORAL|Mindfulness|Mindfulness online training
224042723|NCT01891435|DRUG|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
224042724|NCT01891435|DRUG|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
223432746|NCT04888715|DRUG|DWN12088|Prolyl-tRNA synthetase (PRS) inhibitor
223432747|NCT04888715|DRUG|Pirfenidone|Pirfenidone
223432748|NCT04888715|DRUG|Nintedanib|Nintedanib
223432749|NCT03441607|DRUG|mHACMb|Active ingredient
223432750|NCT03441607|OTHER|placebo|inactive ingredient
223432751|NCT01721915|DRUG|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
223432752|NCT01721915|DRUG|Placebo|
223432753|NCT05471570|DEVICE|tDCS stimulation|The study examines the effect of excitatory stimulation of right inferior frontal gyrus (IFG) on naming abilities of people with aphasia (PWA) as compared to sham stimulation to examine the compensatory versus interference role of right hemisphere in language recovery after stroke.
223432754|NCT06648109|DEVICE|Electric Blanket|Participants were randomized to groups A and B. When the subject\&#39;s group cohort went through the intervention phase (instead of the control phase), they received a 7-day, 8-hour intervention with an electric blanket +5±1°C above room temperature.
223432755|NCT02063178|BEHAVIORAL|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
223432756|NCT02063178|BEHAVIORAL|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
223432757|NCT02063178|BEHAVIORAL|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
223740510|NCT03988192|DEVICE|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
223740511|NCT02589782|DRUG|Bedaquiline|
224042725|NCT01891435|DRUG|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
224042726|NCT00993135|DRUG|methotrexate|
224042727|NCT00993135|OTHER|medical chart review|
224042728|NCT00993135|PROCEDURE|assessment of therapy complications|
224042729|NCT04249414|DEVICE|PulmoVista 500|"Monitoring of Ventilation and Perfusion with the PulmoVista 500 during clinical routine.~No medical interventions required"
224042730|NCT00041067|BIOLOGICAL|filgrastim|
224042731|NCT00041067|BIOLOGICAL|trastuzumab|
224042732|NCT00041067|DRUG|docetaxel|
224042733|NCT00041067|DRUG|vinorelbine|
224042734|NCT04370288|DRUG|MCN (Methylene blue, vitamin C, N-acetyl cysteine)|A mixture of MCN will be injected to covid-19 patients.
224042735|NCT05593874|DIAGNOSTIC_TEST|Histones H3.1 blood levels|Measure of blood concentrations of histone subtype H3.1
224042736|NCT01266525|DRUG|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
224042737|NCT01266525|DRUG|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
224042738|NCT01266525|DRUG|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
224042739|NCT02749032|OTHER|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
224042740|NCT02749032|DRUG|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
224140558|NCT02557412|BEHAVIORAL|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
223432758|NCT02063178|BEHAVIORAL|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
223432759|NCT02063178|BEHAVIORAL|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
223432760|NCT02063178|BEHAVIORAL|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
223432761|NCT02063178|BEHAVIORAL|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
223432762|NCT02063178|BEHAVIORAL|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
223432763|NCT02063178|BEHAVIORAL|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
223432764|NCT02063178|BEHAVIORAL|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
224140559|NCT02557412|OTHER|Conventional treatment|Hygiene and diet recommendations on sleep
224140560|NCT00646841|DRUG|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
224140561|NCT01728883|DEVICE|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
224140562|NCT06678867|DRUG|5-ALA (Gliolan)|Gliolan 30 ml/mg powder for oral solution, Single dose 3-6 hours prior to surgery
224042741|NCT02749032|DRUG|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
224140563|NCT05424991|BEHAVIORAL|comedy movie group|The patients watched the collage videos of Turkish cinema Yeşilçam comedy films created by the researchers for 25 minutes. The videos were created by making collages from videos on youtube.
224140564|NCT00003157|DRUG|cisplatin|
223432765|NCT02063178|BEHAVIORAL|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
223432766|NCT02718183|OTHER|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
223432767|NCT02718183|OTHER|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
223740512|NCT02589782|DRUG|Pretomanid|
224042742|NCT02749032|DRUG|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
224042743|NCT02749032|DRUG|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
224042744|NCT02749032|OTHER|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
224042745|NCT04530461|DIAGNOSTIC_TEST|Serological test|Positive serological test of SARS Cov2
224042746|NCT00698464|DRUG|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
224140565|NCT00003157|DRUG|gemcitabine hydrochloride|
224140566|NCT00003157|RADIATION|radiation therapy|
224140567|NCT03688945|PROCEDURE|Art Therapy|Attend art viewing sessions
224140568|NCT03688945|OTHER|Best Practice|Receive standard of care
224140569|NCT03688945|OTHER|Questionnaire Administration|Ancillary studies
224140570|NCT04069741|OTHER|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
223432768|NCT02657577|OTHER|There is no intervention|There is no intervention
223432769|NCT06463483|DEVICE|Medtronic 780G System|Automated insulin delivery using Medtronic 780G system
223432770|NCT06463483|DEVICE|Continuous Glucose Monitoring|Usual care with continuous glucose monitoring
223432771|NCT05314140|DIAGNOSTIC_TEST|Coronary artery calcium score evaluation|The evaluation of the coronary artery calcium score will be performed with chest CT scan
223432772|NCT03265548|DEVICE|Video Laryngoscope|The use of video laryngoscopy
223432773|NCT03149120|BIOLOGICAL|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
223432774|NCT03149120|DRUG|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
223432775|NCT02553434|DEVICE|Pigtail catheter|Insertion of pigtail catheter
223432776|NCT06300476|GENETIC|JWK006|Subretinal administration of gene therapy vector JWK006 to one eye.
223432777|NCT01255462|BIOLOGICAL|LFG316|
224140571|NCT04069741|BEHAVIORAL|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
223432778|NCT01255462|BIOLOGICAL|LFG316|
224042747|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
224042748|NCT05373303|BIOLOGICAL|Recombinant Human Erythropoietin Alpha|This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
224140572|NCT02617017|DRUG|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
223432779|NCT01255462|BIOLOGICAL|LFG316|
224140573|NCT02617017|DRUG|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
223432780|NCT01255462|BIOLOGICAL|LFG316|
223432781|NCT03274557|PROCEDURE|RFM|
223432782|NCT03796819|PROCEDURE|lymphadenectomy|Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
223432783|NCT05906186|BEHAVIORAL|kiwifruit|eating two kiwifruits a day
224140574|NCT03506399|DRUG|Lanabecestat|Administered orally
224140575|NCT03506399|DRUG|Oral Contraceptive|Administered orally
223432784|NCT06622265|DEVICE|Electrocardiogram recording|ECG recording with investigational device
223432785|NCT02425722|DRUG|ASP0456|oral
223432786|NCT02425722|DRUG|Placebo|oral
224140576|NCT04717141|OTHER|Selective nerve block|"D0 :~* Information, collection of consent, inclusion,~* Clinical and instrumental evaluation,~* Realization of the selective nerve block,~* Post-selective nerve block clinical and instrumental re-evaluation,~* Performance of the botulinum toxin injection if indication selected.~D28 (+/-5 days) :~\- Clinical and instrumental post-botulinum toxin injection evaluation."
223432787|NCT05915676|DIAGNOSTIC_TEST|Leukocyte Immunoglobulin-like receptors A3|Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.
224140577|NCT00846261|DEVICE|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
223432788|NCT02335749|DEVICE|The ZELTIQ System|The CoolSculpting System with a Small Area Applicator will be used to deliver treatments.
223432789|NCT04420819|DEVICE|Ischemic Preconditioning|The IPC is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff
223432790|NCT05173285|DIAGNOSTIC_TEST|Baseline Assessment|At baseline (i.e. Pre-intervention) participants will complete several questionnaires online via Qualtrics.
223432791|NCT05173285|BEHAVIORAL|Brief Online ACT Intervention|Participants will complete the 4-week online intervention via Qualtrics
223432792|NCT05173285|DIAGNOSTIC_TEST|Post-Intervention Assessment (i.e. between 4-6 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
223432793|NCT05173285|DIAGNOSTIC_TEST|Follow-up Assessment (i.e. between 8-12 weeks after baseline assessment)|Participants will complete several questionnaires online via Qualtrics.
223432794|NCT01082393|DRUG|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
223432795|NCT01082393|DRUG|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
223432796|NCT01082393|DRUG|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
223432797|NCT01082393|DRUG|cold cream|4 applications (day 1, day 3, day 6 and day 10)
223432798|NCT00288808|DEVICE|Hemosense (PT/InR point of care device)|
223432799|NCT01044758|DRUG|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
223740513|NCT02589782|DRUG|Moxifloxacin|
224042749|NCT03067155|GENETIC|CMV-specific T cells|
224042750|NCT03067155|DRUG|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
224042751|NCT02634203|PROCEDURE|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP\< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
224042752|NCT02634203|DRUG|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
224042753|NCT01505010|PROCEDURE|Renal denervation|Renal denervation in the intervention group
224140578|NCT05950347|DEVICE|Active Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
224140579|NCT05950347|DEVICE|Sham Transcutaneous auricular vagus nerve stimulation|Two modiﬁed dot-like electrodes delivered the stimulation to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20/4 Hz; pulse width = 200 μs; 20 Hz lasting 7 seconds, alternated with 4 Hz lasting 3 seconds，repeat until 30 min. Every PD patient received stimulation twice daily , 30 minutes each time, for 14 consecutive days. The stimulation intensity was set as the maximum value the patient could tolerate without causing pain.
224140580|NCT00014664|BIOLOGICAL|apolizumab|
224140581|NCT03820037|DRUG|Ongentys|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
224140582|NCT03820037|DRUG|BIA 9-1067 (test)|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
224140583|NCT04991844|BEHAVIORAL|Intervention Group|Intervention group participants met once a week, for 2.5 hours, over a period of six weeks for the HES workshops. The HES workshops followed a scripted curriculum that incorporated information from the USDA's MyPlateTM, and the USDA 2015-2020 dietary guidelines. Participants were also taught goal-setting, problem-solving through brainstorming, group support, self-assessment and management of dietary and physical activity patterns.
224299659|NCT06264791|OTHER|Alcohol|Intoxication: Participants randomly assigned to the alcohol condition will be administered 100-proof Vodka mixed with orange juice (1:3 ratio) to induce a BAC of .06% (based on Widmark's formula). They will be breathalyzed every 5 minutes until they reach peak BAC, at which point they will continue with the experiment. Participants randomly assigned to the no alcohol condition will be administered water mixed with orange juice (1:3 ratio). Each participant in the no alcohol condition will be yoked to a participant in the alcohol condition and will complete the same number of breath tests. Once participants in the alcohol condition reach peak BAC and participants in the no alcohol condition performed the same number of breath tests as the participant they are yoked to, participants will continue to the stress induction.
223432800|NCT01044758|DRUG|Levetiracetam 125mg|125mg twice daily (2 weeks)
223432801|NCT01044758|DRUG|Levetiracetam 250mg|250mg twice daily (2 weeks)
223432802|NCT01044758|DRUG|Placebo|placebo capsule twice daily (2 weeks)
223432803|NCT01072981|BIOLOGICAL|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
223432804|NCT01072981|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
223432805|NCT01072981|RADIATION|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
223432806|NCT05887752|OTHER|Standard rehabilitation|"Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation."
223740514|NCT02589782|DRUG|Linezolid|
224042754|NCT06159192|DEVICE|Low intensity extracorporeal shock wave|Extracorporeal shock wave therapy generator: Wonjin beauty SW10 shock wave therapy system made in Korean.
224042755|NCT00328822|DRUG|Quetiapine|
224140584|NCT03611322|DRUG|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
224140585|NCT03611322|DRUG|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
224140586|NCT03611322|DRUG|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
224140587|NCT03611322|DEVICE|DV3372|DV3372 device will be used for administration of semaglutide
224140588|NCT03611322|DEVICE|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
224140589|NCT02154126|DEVICE|Continuous Glucose Monitoring Device (Senseonics)|
223740515|NCT02589782|DRUG|Clofazimine|
223740516|NCT02589782|DRUG|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
224042756|NCT00328822|DRUG|placebo|
224042757|NCT03837379|BEHAVIORAL|Treatment as Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
224042758|NCT03837379|COMBINATION_PRODUCT|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
224042759|NCT00270465|DRUG|VRC-HIVDNA016-00-VP|
224042760|NCT00270465|DRUG|VRC-HIVADV014-00-VP|
224042761|NCT03082950|DIAGNOSTIC_TEST|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
224042762|NCT02354781|BIOLOGICAL|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
224140590|NCT02775552|BEHAVIORAL|A&T community-based interventions|"1. Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~   \- Increase mothers' knowledge about adequate child feeding practices~2. Interpersonal communication delivered by agricultural extension workers to:~   \- Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~3. Community mobilization activities to:~   * Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~  * Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~  * Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~4. Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~   * Improve their ability to provide timely and appropriate information and support to mothers and families"
224042763|NCT03271346|BEHAVIORAL|intensive trauma-focused therapy|
223432807|NCT05887752|DEVICE|Hunova® rehabilitation|Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
223432808|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
224140591|NCT02775552|BEHAVIORAL|Mass media|Radio campaign - radio drama series, spots, and jingles
224042764|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10\^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
223432809|NCT00677859|BIOLOGICAL|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
223432810|NCT01768091|PROCEDURE|POEM|"1. Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~3. Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~4. Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~5. Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
224140592|NCT00073814|DRUG|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
223740517|NCT01860755|OTHER|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
223740518|NCT01860755|OTHER|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
224042765|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10\^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
224140593|NCT00073814|DRUG|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
224140594|NCT00073814|DRUG|Placebo|Placebo MDI QID
224140595|NCT05202093|DEVICE|Oclean electric toothbrush A|Use Oclean electric toothbrush to brush teeth twice a day for 8 weeks
224140596|NCT05202093|DEVICE|Oral B manual toothbrush|Use Oral B manual toothbrush to brush teeth twice a day for 8 weeks
224140597|NCT05202093|DEVICE|Oclean electric toothbrush B|Use Oclean electric toothbrush B to brush teeth twice a day for 8 weeks
224163424|NCT03161184|BEHAVIORAL|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
224163425|NCT05021731|DRUG|Rifampicin plus Isoniazid|Administration of rifampicin plus isoniazid for latent tuberculosis
224163426|NCT05021731|DRUG|Rifapentine plus Isoniazid|Administration of rifapentine plus isoniazid for latent tuberculosis
224163427|NCT05021731|DRUG|Rifampicin alone|Administration of rifampicin alone for latent tuberculosis
224163428|NCT00466986|DRUG|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
224042766|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10\^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
224042767|NCT02366013|BIOLOGICAL|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10\^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
224042768|NCT00626210|DRUG|modafinil|100-400 mg daily for 4 weeks
224042769|NCT01033435|OTHER|No intervention|
224042770|NCT00021450|DRUG|bicalutamide|
224042771|NCT00021450|DRUG|goserelin acetate|
224042772|NCT00021450|PROCEDURE|adjuvant therapy|
224042773|NCT00021450|RADIATION|radiation therapy|
224042774|NCT03617965|DIAGNOSTIC_TEST|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
224042775|NCT04553068|DRUG|EVO100|EVO100 vaginal gel
224042776|NCT04553068|DRUG|Placebo|Placebo vaginal gel
224042777|NCT01968070|DRUG|LY3127760|Administered orally
224042778|NCT01968070|DRUG|Celecoxib|Administered orally
224042779|NCT01968070|DRUG|Placebo|Administered orally
224042780|NCT01722149|GENETIC|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
224042781|NCT00497601|DRUG|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 \& 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 \& 5 mg/kg on day 1 \& 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 \& 2.5 mg/kg on day 1 \& 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
224042782|NCT00497601|DRUG|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
224042783|NCT00497601|DRUG|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
223432811|NCT01768091|PROCEDURE|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
223432812|NCT02085226|OTHER|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist~1. Meeting with Artist, discuss interests, stroke and explore initial creative goals.~2. Introduction to materials and mark making to create interpretations of established images.~3. From mark making and interpretations to developing personal project ideas.~4. Turning personal project ideas into creative finished pieces.~5. Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
223565582|NCT04917952|DEVICE|Sham Blood Flow Restriction (sham BFR)|"* Exercise: Bilateral knee extension at range 90ο-0ο~* Load: 30% 1RM~* BFR: Yes, Sham BFR, 10mm Hg at both legs~* Sets: 4~* Reps: 30-15-15-15~* Rest: 30'' between sets~* Tempo: 2-0-2-0~Participants of the control group will receive an exercise protocol with sham blood flow restriction once and will be measured for changes in PPT by the use of a digital dynamometer.~Exercise protocol will be four sets of bilateral knee extension 90ο-0ο, reps per set 30-15-15-15, tempo 2-0-2-0 and rest 30 sec between sets.~In order to determine the training load 30% of 1RM, participants will perform bilateral knee extension in range 90ο-0ο with pain-free maximum resistance. The derived 1RM will be used to determine the 30% 1RM load.~Sham technique for blood flow restriction will be applied by using pressure cuffs inflated at 10mm Hg. The cuffs will be applied to the proximal thigh. Cuff pressure will be applied for each individual at a seated and relaxed position."
223565583|NCT01979666|DRUG|nitrate patch|patients in the study group will get a nitrate patch
224042784|NCT02080455|DRUG|lomitapide|20 mg dose
224042785|NCT02080455|DRUG|Atorvastatin|80 mg
224042786|NCT04268043|DEVICE|flexible laryngeal airway mask|Ventilation with flexible laryngeal mask airway
224140598|NCT01498237|DEVICE|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
224140599|NCT01498237|PROCEDURE|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
224140600|NCT00712322|DRUG|Darifenacin|Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
223565584|NCT01979666|DRUG|placebo patch|control group patients will get a placebo patch
223565585|NCT01979666|DEVICE|MRI scan|MRI scan after 6 weeks of treatment
223565586|NCT03008668|OTHER|acupuncture|a stimulation of the body or auricular points
223565587|NCT02121106|BEHAVIORAL|Cognitive Remediation|
224042787|NCT04268043|DEVICE|proseal laryngeal mask airway|Ventilation with proseal laryngeal mask airway
224042788|NCT05344768|OTHER|aerobic exercise|Moderate intensity aerobic exercise training will be applied.
224042789|NCT05344768|OTHER|high-intensity interval exercise training|High-intensity interval exercise training will be applied.
224042790|NCT05344768|OTHER|resistance exercise training|resistance exercise training will be applied
224042791|NCT02883530|PROCEDURE|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
224042792|NCT02830997|DEVICE|Stereotactic guidance system|
224140601|NCT03760848|DRUG|Aramchol|Aramchol 600 mg
224140602|NCT03760848|DRUG|Midazolam|Midazolam 2 mg
224140603|NCT03760848|DRUG|Atorvastatin|atorvastatin 40 mg
224140604|NCT03054948|DRUG|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
224140605|NCT03054948|DRUG|Standard therapy|In most cases standard therapy will be IntraLipid.
224140606|NCT03608553|DEVICE|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
224299660|NCT01635062|DRUG|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
224299661|NCT01635062|DRUG|Placebo|Subjects will receive placebo for 3 weeks.
224299662|NCT02079168|DRUG|RXI-109|
223565588|NCT02121106|BEHAVIORAL|Sham Cognitive Remediation|
223565589|NCT02262026|DRUG|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
223565590|NCT02262026|DRUG|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
223565591|NCT02262026|DRUG|Placebo|Placebo
224299663|NCT02079168|DRUG|Placebo|
224299664|NCT02880020|BIOLOGICAL|Ipilimumab|Given IV
224042793|NCT01449318|DEVICE|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
224042794|NCT02150525|DIETARY_SUPPLEMENT|omega-3 fatty acid|Given PO (by mouth) daily
223432813|NCT02085226|OTHER|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
223432814|NCT01244217|DRUG|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
223432815|NCT03886389|DIETARY_SUPPLEMENT|PreOP|Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
223432816|NCT01025466|DRUG|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
224042795|NCT02150525|OTHER|placebo|Given PO(by mouth)daily
224042796|NCT02150525|BEHAVIORAL|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
224042797|NCT06493487|OTHER|integrated neuromuscular inhibition technique|integrated neuromuscular inhibition technique for gastrocniemus muscle
224042798|NCT06493487|OTHER|instrument assissted soft tissue mobilization|instrument assissted soft tissue mobilization for calf muscle
224042799|NCT06493487|OTHER|convential treatment|convential treatment (home education program, therapeutic ultrasound, plantar fascia stretching, intrinsic muscle strengthening of foot, Self stretching of calf muscle using a towel and Ice Massage using frozen bottle).
224042800|NCT00972426|DRUG|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
224042801|NCT03100201|OTHER|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
224042802|NCT03100201|OTHER|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
223432817|NCT01025466|DRUG|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
223432818|NCT06305260|DIAGNOSTIC_TEST|Lumbar Ultrasound|Investigators will utilize our ultrasound machine to complete a pre-procedural lumbar ultrasound prior to epidural placement.
223432819|NCT03502694|DRUG|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
223432820|NCT03502694|DRUG|Placebo|Participants will receive matching placebo tablets orally.
223432821|NCT05710692|DRUG|PRX-102 1 mg/kg every 2 weeks|PRX-102 1 mg/kg every 2 weeks
223432822|NCT05710692|DRUG|PRX-102 2 mg/kg every 4 weeks|PRX-102 2 mg/kg every 4 weeks
223432823|NCT02787057|DRUG|vancomycin|IP vancomycin 1g every 5 days
223432824|NCT02787057|DRUG|moxifloxacin|oral moxifloxacin 400mg QD
223432825|NCT02787057|DRUG|ceftazidime|IP ceftazidime 1g QD
223432826|NCT01260272|OTHER|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
224042803|NCT00108069|DRUG|Tamoxifen citrate|oral dose 120 mg twice a day, every day
224042804|NCT00108069|DRUG|Bortezomib|intravenous (IV) injection 1.3 mg/m\^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
224042805|NCT03051581|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
224042806|NCT05290688|GENETIC|50 ml blodd sampling|50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
224042807|NCT03943680|DEVICE|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
224042808|NCT03943680|DEVICE|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
224140607|NCT01294891|OTHER|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
224299665|NCT02880020|OTHER|Laboratory Biomarker Analysis|Correlative studies
223432827|NCT01260272|OTHER|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
223432828|NCT04774848|DEVICE|High Frequency Jet Ventilator|HFJV provides short bursts of gas into the respiratory circuit at a rate of 240 to 600/min (4 to 11 Hz) and expiration is passive. It is used in conjunction with a conventional ventilator which provides positive end expiratory pressure (PEEP) and can also provide occasional sigh breaths.
223432829|NCT04774848|DEVICE|High Frequency Oscillatory Ventilator|HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
223432830|NCT04951713|DRUG|XZP-3287 combined with clarithromycin|Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
223432831|NCT04951713|DRUG|XZP-3287 combined with rifampicin|Drug: XZP-3287, oral, 360 mg once daily for day 1 and day 14 Drug: rifampicin, oral, 600 mg once daily for day 8 to day 19
223432832|NCT02268682|OTHER|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
223565592|NCT03878381|COMBINATION_PRODUCT|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
223565593|NCT03878381|DRUG|Placebo|The placebo will be a formula with no active ingredients
223565594|NCT04955223|DRUG|Yinhu Qingwen Granules|For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
223565595|NCT02680041|DRUG|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
223565596|NCT04190381|OTHER|FR-Mask|"The investigational medical product of this study is a biomedical repair mask, FR-MASK, acting like moisturizing lotion applied on breasts.~The FR-Mask is applied to users' radiation-irritated breast skin for 15 to 20 minutes every 3 days."
224042809|NCT04696991|BEHAVIORAL|The postpartum discharge education with PechaKucha Method.|The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
224042810|NCT00995007|DRUG|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
224042811|NCT00995007|DRUG|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
224042812|NCT02670681|BEHAVIORAL|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
224042813|NCT03367715|DRUG|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
224042814|NCT03367715|DRUG|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
224042815|NCT03367715|RADIATION|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
224042816|NCT02370680|DRUG|Aspirin|steady-state run-in prior to Durlaza treatment
224042817|NCT02370680|DRUG|Durlaza™|comparison of different numbers of capsules
224042818|NCT03914404|DRUG|γ-linoleic acid and placebo(Thioctic Acid)|"* γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~* Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
224042819|NCT03914404|DRUG|Thioctic Acid and placebo(γ-linoleic acid)|"* Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~* γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
223565597|NCT05530395|DIAGNOSTIC_TEST|Testosterone levels|Blood sample to determine testosterone levels
223565598|NCT05455918|DRUG|TIP treatment (paclitaxel/ifosfamide/cisplatin)|Paclitaxel 240mg/m2/day D1 (total 240mg/m2) Ifosfamide 1.5g/m2/day D2\~5 (total 6g/m2) Cisplatin 25mg/m2/day D2\~5 (total 100mg/m2)
224042820|NCT03327441|OTHER|Almonds|Almonds will be provided as 15% energy
224042821|NCT03327441|OTHER|Omelette|Omelettes will be provided as 15% energy
224042822|NCT00882310|DRUG|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
224042823|NCT00882310|DRUG|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
224042824|NCT00882310|DRUG|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
224042825|NCT00080496|DRUG|Tigecycline|
224042826|NCT00080496|DRUG|Imipenem|
224042827|NCT00080496|DRUG|Cilastatin|
224042828|NCT05191069|OTHER|Moringa Oleifera Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
224042829|NCT05191069|OTHER|Placebo Mouthwash|15ml of the mouthwash to be used twice daily for 6 months
224042830|NCT00076557|GENETIC|Adeno-Associated Viral with Human Factor IX|
224042831|NCT00780819|DEVICE|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
224140608|NCT02687230|DRUG|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
224042832|NCT05106504|DRUG|Medical Cannabis|Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
224042833|NCT01770613|BIOLOGICAL|Stem cells|Allogeneic mesenchymal stem cells
224042834|NCT01186900|PROCEDURE|ultrasound-guided needle aspiration|one time drainage at time of randomization
224042835|NCT04119960|DEVICE|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
224042836|NCT02376608|DIETARY_SUPPLEMENT|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
224042837|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
224042838|NCT02376608|DIETARY_SUPPLEMENT|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
224042839|NCT02376608|DIETARY_SUPPLEMENT|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
224042840|NCT02756351|DEVICE|CytaCoat Nasal Prong|
224140609|NCT02687230|DRUG|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
224140610|NCT00205296|BEHAVIORAL|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
224140611|NCT01887587|DRUG|MLN9708|
224140612|NCT01887587|DRUG|Vincristine|
224140613|NCT01887587|DRUG|Doxorubicin|
224140614|NCT01887587|DRUG|Dexamethasone|
224140615|NCT05630170|DEVICE|AI-ECG|A novel AI-ECG model developed at the Cardiovascular Data Science (CarDS) lab will be used as Software as Medical Device (SaMD) on ECG images for detection of LVSD.
224140616|NCT05562024|BIOLOGICAL|T cell injection targeting B7-H3 chimeric antigen receptor|The subjects will be administered once.
224140617|NCT05225220|DEVICE|Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS)|Electrode clip will be placed on the left ear.
224140618|NCT02670330|DRUG|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
224140619|NCT03593863|BEHAVIORAL|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
224140620|NCT03359694|DRUG|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
224140621|NCT03359694|DRUG|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
224140622|NCT03359694|DRUG|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
224140623|NCT01766882|BEHAVIORAL|Lower sodium intervention|"1\. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately \>180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
224042841|NCT02756351|DEVICE|Inspiration Healthcare Inspire nCPAP Nasal Prong|
224042842|NCT00249210|DRUG|levofloxacin|
224042843|NCT05135221|BIOLOGICAL|dual biological therapy|Simultaneous use of two biologicals.
224042844|NCT05614973|PROCEDURE|Conventional method|The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.
224042845|NCT05614973|PROCEDURE|Coaxial method with needle-track plugging|The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
224042846|NCT05533879|OTHER|Tele-yoga|Women with chronic low back pain will be taken to group-based Tele-Yoga sessions of 60 minutes three times a week for 4 weeks, in an internet-based telerehabilitation environment.
224042847|NCT01643525|DEVICE|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
224042848|NCT01522482|DIETARY_SUPPLEMENT|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
224042849|NCT01522482|DIETARY_SUPPLEMENT|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
224042850|NCT01522482|DIETARY_SUPPLEMENT|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
224140624|NCT01766882|OTHER|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
224140625|NCT00032994|BEHAVIORAL|Behavior Therapy|
224140626|NCT04065087|BIOLOGICAL|GX-I7|Investigational drug
224140627|NCT04065087|OTHER|Placebo|Placebo drug
224299666|NCT02880020|BIOLOGICAL|Nivolumab|Given IV
224042851|NCT04445181|DRUG|The physician's prescription in routine clinical practice|This is an Observational study that will not involve prescription of the drugs.
224042852|NCT04134364|DRUG|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
224042853|NCT03351166|DRUG|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
224042854|NCT00223678|DRUG|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
224042855|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
224042856|NCT00521742|DRUG|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
224042857|NCT00521742|DRUG|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
224042858|NCT00521742|DRUG|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
224042859|NCT04423861|DRUG|Nitazoxanide|Patients will receive nitazoxanide 600 mg BID for 7 days.
224042860|NCT04423861|DRUG|Placebo|Patients will receive matching placebo BID for 7 days.
224042861|NCT02022345|PROCEDURE|Percutaneous Coronary Intervention|
224042862|NCT04525339|PROCEDURE|TAVI and Off pump CABG|Concomitant Transcatheter aortic valve implanatation and off pump coronary artery bypass grafting
224042863|NCT02435342|DRUG|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
224042864|NCT02435342|DRUG|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
224042865|NCT01395251|DRUG|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
224042866|NCT05732662|RADIATION|SBRT|24-50Gy/8-12.5Gy/3-4f
224042867|NCT05732662|DRUG|Cadonilimab|10 mg/kg,q3w
224042868|NCT04964570|BEHAVIORAL|Video _ behavioral change module|"A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support."
224042869|NCT04853329|DRUG|CPO107|CD20-CD47 Bispecific Fusion Protein
224042870|NCT06056674|BEHAVIORAL|U-PEACE Intervention|"This program will involve about 13 group sessions, with each group session lasting approximately 40-50 minutes. The program session will be held about 2 times a week during the school day (e.g., lunch time) if the group meets in person, or at a pre-scheduled time every week if the group meets online via Zoom.~Participants will learn how to better understand emotional experiences and use this understanding to embrace agency in challenging situations. Participants will develop skills to better deal with emotions by increasing awareness of what is happening in different settings and choose how to respond. Skill-building exercises may include mindfulness practices, flexible thinking, behavioral activation, problem-solving, and exposure activities."
224042871|NCT06056674|BEHAVIORAL|SAU|Participants in this group will continue to receive standard of care within their school clinic.
224042872|NCT06606444|DEVICE|Surfactant Administration Through Laryngeal or Supraglottic Airways|While the child is spontaneously breathing on nasal CPAP treatment, the neonatal intensive care (NICU) physician will place the LMA and assess for adequate airway by CO2-detection, chest movement, pulmonary auscultation of bilateral breath sounds, gastric insufflation, oxygen saturation and heart rate. A placement attempt should not last more than 30 seconds. Surfactant will be administered slowly in 1-2 ml aliquots (Curosurf 200 mg/kg) via an appropriate size laryngeal mask airway. The neonate should primarily be spontaneously breathing and if needed receives gentle supportive positive pressure ventilation (PPV). Gentle supportive PPV is given for 30 seconds after surfactant is administered, before LMA is removed.
224042873|NCT02733185|DRUG|disodium EDTA|IV Disodium Ethylene diamine tetra acetic acid in 500 cc
224042874|NCT02733185|DIETARY_SUPPLEMENT|Oral Multi Vitamins/Minerals (OMVM)|6 tablets of Multi-vitamin/Multimineral daily
224042875|NCT02733185|DRUG|Placebo disodium EDTA|IV Placebo comparator- 500 normal saline
224042876|NCT02733185|DIETARY_SUPPLEMENT|Placebo Oral Multi Vitamins/Minerals (OMVM)|6 tablets of a placebo Multi-vitamin/Multimineral daily
224042877|NCT05359549|DEVICE|Two endosseous dental implants (NobelReplace Groovy®) were placed 10 years ago|All patients were 10 years ago referred to the Department of Oral and Maxillofacial Surgery (University of Groningen, University Medical Hospital) because of having two failing teeth in the maxillary aesthetic region and were treated with dental implant placement and implant-supported restorations. Patients will have a regular routine control visit (as part of regular follow-up of these patients)
224042878|NCT02659579|BEHAVIORAL|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
224042879|NCT02659579|BEHAVIORAL|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
224042880|NCT01624259|DRUG|LY2189265|Administered SC
224042881|NCT01624259|DRUG|Liraglutide|Administered SC
224042882|NCT01624259|DRUG|Metformin|
224042883|NCT04768270|OTHER|no intervention|It is an observation trial.
224042884|NCT03029169|DRUG|Propafenone i.v.|Treatment
224042885|NCT03029169|DRUG|Amiodarone i.v.|Treatment
224042886|NCT04689997|BEHAVIORAL|cSBI|The standard CRAFFT SU screen has additional questions about reasons to use or not use, SU expectancies of effect and embedded education. The teens of enhanced care PCPs will also complete a Strengths and Goals tool. Data from both will be used by the PCP in counseling regarding continued abstention, reduction or cessation of SU or referral. Teens will also get monthly text messages about goals.
224042887|NCT01028456|OTHER|Light Therapy|10,000 lux / 30 minutes a day
224042888|NCT01028456|OTHER|100 lux|Placebo light
224140628|NCT01689376|DRUG|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
224140629|NCT05152277|DRUG|HRS9531|Administered SC once
224140630|NCT05152277|OTHER|placebo|Administered SC once
224140631|NCT05152277|DRUG|HRS9531|Administered SC for multiple dose
224140632|NCT05152277|OTHER|placebo|Administered SC for multiple dose
224042889|NCT02342756|DEVICE|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
224042890|NCT01116518|PROCEDURE|physiotherapy|
224042891|NCT01116518|PROCEDURE|acromioplasty|
224042892|NCT01116518|PROCEDURE|acromioplasty and rotator cuff reconstruction|
224042893|NCT06129123|BEHAVIORAL|Live Free From E-cigarettes|This is a 30-minute online educational program that focuses on providing information about e-cigarette and smoking social norms, harms of e-cigarettes and cigarettes, and ways to quit or reduce using e-cigarettes.
223432833|NCT02268682|OTHER|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
223432834|NCT06316388|PROCEDURE|vitrectomy|pars plana vitrectomy
223432835|NCT04396600|BEHAVIORAL|MinnRAP Peer Support Program|"The behavioral intervention consists of 1) pairing healthcare workers into Battle Buddies who maintain daily dialogue to detect stress and anxiety and 2) assigning a mental health consultant to each department to facilitate Battle Buddies and provide both small group sessions and individual psychological triage/referrals."
224042894|NCT04621929|DRUG|Phentermine / Topiramate Oral Product|All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)
224042895|NCT04621929|COMBINATION_PRODUCT|Citrate Salts, Allopurinol, Diet|Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
224042896|NCT06421545|BEHAVIORAL|Resilient Together for Dementia|A novel live video dyadic resiliency intervention
224042897|NCT07130721|DIAGNOSTIC_TEST|C-Reactive Protein (CRP) Test|Blood samples will be collected once from all participants to measure CRP levels
224042898|NCT07130721|DIAGNOSTIC_TEST|D-dimer Test|D-dimer levels will be assessed once to evaluate thrombotic risk.
224042899|NCT07130721|DIAGNOSTIC_TEST|Electrocardiogram (ECG)|A standard 12-lead ECG will be performed once per participant to assess cardiovascular status
224042900|NCT07128745|BEHAVIORAL|Shared Medical Appointment + Self-Management Strategy|Participants assigned to this arm will receive a self-management intervention delivered through shared medical appointments (SMAs). The SMA intervention will be conducted once every two months for a total of three sessions over six months. Each session includes structured medical consultation, health education, behavioral guidance based on the Behavior Change Wheel (BCW) framework, and facilitated peer discussion.
224042901|NCT07128745|BEHAVIORAL|Usual Care + Self-Management Handbook|Participants receive routine one-on-one GP care plus a printed COPD self-management education handbook.
224042902|NCT07130682|RADIATION|Pencil Beam Proton Therapy Treatment Machine|2 fractions will be delivered to treat low- or intermediate- risk prostate cancer
224042903|NCT07128628|DRUG|Lifitegrast/Perfluorohexyloctane Fixed Dose Combination|Topical ocular drop of lifitegrast and perfluorohexyloctane administered for 4 weeks
224042904|NCT07128628|DRUG|Lifitegrast|Topical ocular drop of lifitegrast administered for 4 weeks
224042905|NCT07128628|DRUG|Perfluorohexyloctane|Topical ocular drop of perfluorohexyloctane administered for 4 weeks
224042906|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
224042907|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
224042908|NCT07128628|DRUG|Vehicle|Topical ocular drop with no active ingredients administered for 4 weeks
224042909|NCT07128693|DRUG|Sacituzumab Tirumotecan in combination with tislelizumab|"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Tislelizumab，200 mg, iv, d1, Q3W, until disease progression or intolerable toxicity."
224042910|NCT07128693|DRUG|Sacituzumab Tirumotecan in combination with anlotinib|"Sacituzumab Tirumotecan 5mg/kg, iv, d1, Q2W ,until disease progression or intolerable toxicity.~Anlotinib 12mg QD po d1-14，Q3W,until disease progression or intolerable toxicity."
224042911|NCT07130149|PROCEDURE|Sonodynamic Therapy (SDT)|SDT: Hematoporphyrin 5 mg/kg.Sonodynamic therapy is administered 40 hours later, twice a day with an interval of 10-12 hours, for 5 consecutive days. One cycle lasts 28 days, and a total of 4-6 cycles are conducted.
224042912|NCT07130149|OTHER|Standard Treatment|Radiotherapy: The dose is 50-54 Gy, 1.8-2 Gy per day, 5 times a week, for a total of 25 sessions Chemotherapy: When temozolomide is administered concurrently with radiotherapy, the dose is 75 mg/m² per day, taken daily until the end of radiotherapy. For adjuvant chemotherapy with temozolomide, the dose is 150 mg/m² per day from day 1 to day 5, followed by a 23 - day rest period. Each cycle lasts 28 days. If well - tolerated, the dose should be adjusted to 200 mg/m² per day for the 2nd - 6th cycles Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses
224042913|NCT05775510|DEVICE|Commercially available neurostimulation systems|Spinal cord stimulation therapy delivered during trialing and following implant of commercially available neurostimulation systems
224140633|NCT04324918|DRUG|HCP1102|The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.
224140634|NCT04324918|DRUG|HGP1408|The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.
224140635|NCT05412537|OTHER|MI|How to motivate people
224140636|NCT05412537|OTHER|CAU|consult as usual
224140637|NCT03111017|OTHER|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
224140638|NCT03216083|DRUG|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
224140639|NCT03216083|OTHER|Placebo|67mL IV normal saline
224140640|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|patient with sponiloarthritis who comes to the clinic Hospital for clinical evaluation of disease. Assessment instrumental evaluation of the axial involvment t, with x-ray of the spine and pelvis every 5 years, and MRI of the spine and pelvis every 2 years.
223432836|NCT06329310|DEVICE|aXess-E conduit|The aXess-E conduit is a sterile, regenerative biodegradable polymer-based vascular conduit, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess-E conduit is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
223432837|NCT06370546|OTHER|Low intensity|Low intensity group: participants will be requested to perform the following exercises: 1)squat, 2) rowing, 3)deadlift and 4)bench press. All exercises will be performed with low intensity (40% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
223432838|NCT06370546|OTHER|high intensity|High intensity group: participants will be requested to perform the following exercises: 1)squat, 2)rowing, 3)deadlift and 4)bench press. All exercises will be performed with high intensity (80% of the maximum velocity used in one-repetition maximum) and will be supervised by a researcher.
223432839|NCT00435487|DRUG|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
223432840|NCT00435487|DRUG|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg \[units per kilogram\] and initial infusion of 12 U/kg/h \[units per kilogram per hour\]).
223432841|NCT06370728|DRUG|Orforglipron|Administered orally
223432842|NCT06370728|DRUG|Carbamazepine|Administered orally
223432843|NCT02627326|PROCEDURE|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
223432844|NCT06525025|OTHER|Observational study, non intervention|Observational study, non intervention
223432845|NCT03301844|COMBINATION_PRODUCT|Blephapad Combo|"Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.~The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes."
223432846|NCT03301844|OTHER|Standard treatment|Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
223432847|NCT01198561|DEVICE|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
223432848|NCT01935856|DRUG|KHK7580|Oral administration
223432849|NCT02730767|BEHAVIORAL|partially supervised exercise intervention|
223432850|NCT05087966|BEHAVIORAL|Safety Planning Intervention with Navigation Services|A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
223432851|NCT04695574|PROCEDURE|Some clinical evaluation performance tests together with procedure of Closed Kinetic Chain Lower Extremity Stability Test|Clinical evaluation methods
223432852|NCT04703374|DRUG|CKD-382(formulation I)|1 tablet administered under fasting condition for 7days
224042914|NCT00639210|OTHER|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
223432853|NCT04703374|DRUG|CKD-382(formulation II)|1 tablet administered under fasting condition for 7days
223432854|NCT04703374|DRUG|D026|1 tablet administered under fasting condition for 7days
223432855|NCT03934723|BEHAVIORAL|Exercise|The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
223432856|NCT02543372|BEHAVIORAL|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
223432857|NCT02543372|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
223432858|NCT03495739|DRUG|RDG-17012 Capsule|Dabigatran Etexilate tosylate 150mg
223432859|NCT03495739|DRUG|Dabigatran Etexilate Mesylate 150 MG Oral Capsule|Dabigatran Etexilate mesylate 150mg
223432860|NCT00993759|DRUG|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
223432861|NCT05839405|OTHER|None - Cross Sectional.|There is no intervention, this is cross-sectional only.
223432862|NCT05728853|RADIATION|Assessment of body composition|Assessment of body composition using BIA and DXA
223432863|NCT05402124|DRUG|acetylsalicylic acid delayed release tablets, 81mg|acetylsalicylic acid delayed release tablets, 81mg taken once per day for 90 days
223432864|NCT00707876|DRUG|ferumoxytol|Dose 1 versus non-contrast MRA
223432865|NCT00707876|DRUG|ferumoxytol|Dose 2 versus non-contrast MRA
223432866|NCT00707876|DRUG|ferumoxytol|Dose 3 versus non-contrast MRA
223432867|NCT01886586|BEHAVIORAL|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
224042915|NCT03331016|BEHAVIORAL|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
224042916|NCT06020807|DIAGNOSTIC_TEST|Bladder EpiCheck|Bladder EpiCheckTM (EpiCheck) is a urine test for monitoring of recurrence of NMIBC based on analysis of 15 informative DNA methylation biomarkers.
223432868|NCT01886586|BEHAVIORAL|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
224042917|NCT04822012|DIAGNOSTIC_TEST|Anti COVID19 IgG Antibodies|Detection of antibodies to SARS Cov 19 post infection or vaccination , measurements of female hormones in folicular fluid as compared to serum and Perlecan as a follicular quality marker
224042918|NCT02618954|OTHER|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
224042919|NCT01768650|BEHAVIORAL|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
224042920|NCT01768650|BEHAVIORAL|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
224042921|NCT02274168|PROCEDURE|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
224042922|NCT02274168|PROCEDURE|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
224299667|NCT05518266|PROCEDURE|US-guided Parasternal block|Bupivacaine 0.25 % will be injected into the fascial plane between the pectoralis major muscle and external intercostal muscle or costal cartilages on each side of sternum after skin closure under ultrasound guidance
224299668|NCT05518266|PROCEDURE|Surgeon-delivered parasternal block|Just before wiring of the sternum, the surgeon will inject bupivacaine 0.25 % in 4 mL aliquots into the anterior (2nd-6th) intercostal spaces on each side about 2 cm lateral to the sternal edge with a total volume of 40 mL under direct vision.
224042923|NCT06148857|DIAGNOSTIC_TEST|IOLMaster 700|"The IOLMaster 700, one of the most commonly used optical biometers for IOL power calculation, measures the anterior corneal surface radius using a telecentric keratometry. Additionally, it employs swept-source optical coherence tomography (SS-OCT) technology to simultaneously measures the posterior cornea surface radius and central corneal thickness (CCT).~The AK formula, described by Abulafia et al., is a regression formula that calculates an estimated TCA using K astigmatism.~The Barrett toric calculator uses an unpublished mathematical prediction method of TCA based on anterior corneal measurements."
224042924|NCT03828292|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered as an intravenous infusion.
224042925|NCT03828292|DRUG|Bortezomib|Bortezomib solution for injection will be administered subcutaneously.
224042926|NCT03828292|DRUG|Dexamethasone|Dexamethasone tablets will be administered orally.
224042927|NCT03828292|DRUG|Pomalidomide|Pomalidomide capsules will be administered orally.
224042928|NCT00359151|DRUG|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
224042929|NCT00359151|DRUG|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
224042930|NCT00291811|DRUG|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
224042931|NCT00285077|DRUG|SR57667B|
224042932|NCT03067012|OTHER|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
224042933|NCT05343026|DEVICE|Hearing aids|As for screening the hearing and tinnitus testing, the measure typically comprises PTA, SRS, DPOAE, and several widely accepted standardized tinnitus questionnaires, including the THI for tinnitus severity and VAS for tinnitus loudness.
224042934|NCT03325478|OTHER|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
224042935|NCT05060731|DRUG|Oral iron supplementation|Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
224042936|NCT05060731|DRUG|Intravenous iron supplementation|One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
224042937|NCT04227951|DEVICE|Avoid drain placement|In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.
223565599|NCT04611958|DRUG|ERCP with Bupivacaine infusion|"Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom."
224042938|NCT04227951|DEVICE|Drain placement|In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
224042939|NCT06153160|DEVICE|HemaShock device|The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
224042940|NCT06985056|BEHAVIORAL|Supervised 12-week Resistance and Endurance Exercise Program|60 Minute home-based and supervised endurance, resistance and coordination training 2x/week for 12 weeks, self-administered 20 minute home-based multimodal training 1x/week
224042941|NCT02247908|OTHER|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~1. SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~2. SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~3. SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~4. SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
224299669|NCT05199766|DRUG|Voxelotor 1500 mg oral per day (GBT440) for 48 weeks in patients with sickle-cell disease|This is an open-label, single-arm, single-stage phase II trial of voxelotor in patients with sickle-cell disease. Voxelotor 500mg tablets. Voxelotor will be administered as 500mg tablets orally once daily. The participant should always take all 3 tablets in a row at the same time each day, unless the study doctor has instructed them to adjust the dose.
224299670|NCT00040248|DRUG|Daclizumab|
224299671|NCT04698148|OTHER|Biological sample collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
224299672|NCT04698148|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
224299673|NCT04698148|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
224299674|NCT04757038|DEVICE|Intradiscal injection|The injection will be administered at V1 baseline (day 0). Any physical activity (e.g. jogging, tennis, weightlifting, prolonged upright position) in the 48 hours following the injection should be avoided.
224299675|NCT02307214|OTHER|BaroReflex Sensitivity, endothelial function measurement|no other
223565600|NCT04761679|BEHAVIORAL|Applying the Mepilex foam|Mepilex foam will be directly applied on the nasal bridge directly between the skin and the N95 mask.
224042942|NCT02247908|OTHER|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~1. Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~2. Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~3. Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~4. Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
224042943|NCT03896464|PROCEDURE|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
224042944|NCT03896464|PROCEDURE|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
224042945|NCT00478101|DRUG|oxycodone fentanyl|
223565601|NCT02183480|DRUG|Linagliptin, low dose|
224140641|NCT06261931|DIAGNOSTIC_TEST|Diagnostic assessment|peripheral involvement, with joint ultrasound at baseline, at 3 months from the start of a new therapy, and therefore in the event of reactivation of the disease
224140642|NCT00218790|PROCEDURE|Cool Dialysate|Decreased temperature of the dialysis bath
224140643|NCT04031053|OTHER|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
224140644|NCT00091936|DRUG|Didanosine|
224140645|NCT00091936|DRUG|Efavirenz|
224140646|NCT00091936|DRUG|Lamivudine|
224140647|NCT00091936|DRUG|Standard TB treatment|
224140648|NCT05688072|OTHER|trunk oriented exercise|trunk oriented exercises include: stretching exercises, stabilization exercises (active or active-assisted), arm exercises in fixed trunk position, trunk-oriented exercises (active or active-assisted), trunk mobilization (sitting and lying position), and functional reaching exercises with different ranges of motion in shoulder elevation
224140649|NCT05688072|OTHER|whole body vibration|WBV application technique. The children assume a full squatting position on a vibration platform. The apparatus will set at a frequency of 30 Hz, an amplitude of 2 mm, and a duration of 5 min. The children were instructed to remain in squatting position after the vibration started and to report any discomfort that arose. At the end of 5 min, the vibration turned off automatically. Thereafter, the children rested for 1 min. They were then asked to stand on the vibration platform while supported by the therapist for 5 min, with the same parameters as those used in the squatting position. The total time of application of WBV in each session was 10 min.
224140650|NCT01868776|DRUG|buffered lidocaine|
224140651|NCT01868776|DRUG|nonbuffered lidocaine|
224140652|NCT04799067|OTHER|observational study|no study drug involved, observational study.
224140653|NCT05399550|DRUG|Balovaptan|Intravenous Solution
224140654|NCT05399550|DRUG|Placebo|Matching Intravenous Solution
224042946|NCT06664411|DRUG|Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy|Patients were treated by Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Rituximab(375mg/m2 iv qd d1), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy
224042947|NCT06662032|DEVICE|LumbaCure®|LumbaCure® is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
224042948|NCT06662032|OTHER|Rehab program|Standard rehabilitation program
224042949|NCT04159337|OTHER|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
224042950|NCT06432946|OTHER|Video|A 7-minute video demonstrating the sensing-glove system, how it can be used to assess manual therapy biomechanics, and its relevance in research and clinical contexts. The video was created by the research team via a voiceover PowerPoint presentation.
224042951|NCT06432946|OTHER|Practice session|A 20-minute practice session during which participants received verbal information about the sensing-glove system. While wearing the sensing glove, participants performed palpation and manual therapy techniques (palpation, spinal mobilization/manipulation to the cervical and thoracic spine) on a human-sized manikin, guided by the researcher.
224042952|NCT06593470|BEHAVIORAL|MINDS-UP|MINDS-UP is a substance use prevention program for children/adolescents.It consists of 4 x 60-minute sessions, once weekly over 4 weeks. The four MINDS-UP classes will focus on the following: Mindfulness of Body; Mindfulness of Mind; Mindfulness of Environment/Community; Kindness, Compassion, Joy and Equanimity, respectively.
224042953|NCT06593470|BEHAVIORAL|Prevention Plus Wellness|PPW is a standardized, empirically-based intervention for substance use prevention in adolescents ages 10-14. It consists of 1 45-60 minute session between an adolescent and a trained PPW teacher.
224042954|NCT06593470|DIAGNOSTIC_TEST|fMRI|Functional MRI to investigate preliminary neural mechanisms of MINDS-UP
224140655|NCT02180217|DRUG|osilodrostat|Osilodrostat comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat was 30 mg bid.
224140656|NCT02180217|DRUG|LCI699 matching placebo|Osilodrostat placebo comes in the form of film-coated tablets for oral administration, in the following strengths: 1 mg, 5 mg, 10 mg, and 20 mg. The maximum dose of osilodrostat placebo was 30 mg bid.
224140657|NCT03685526|DEVICE|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
224140658|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
223432869|NCT01886586|OTHER|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
223565602|NCT02183480|DRUG|Linagliptin, medium dose|
223565603|NCT02183480|DRUG|Linagliptin, high dose|
224140659|NCT02738996|BEHAVIORAL|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
224140660|NCT02738996|BEHAVIORAL|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
224140661|NCT04832919|BEHAVIORAL|Nurse-Community-Family Partnership Intervention|Nurses conduct home visits on a monthly basis for the first five months post-baseline. During visits, nurses emphasize the importance of infection control measures and, jointly with household members, develop and follow-up on the implementation of an infection control plan tailored to the unique circumstances of the household. Nurses deliver training on infection control skills necessary for optimal implementation of the plan. Nurses offer at-home SARS-CoV-2 testing to all members of the household. Nurses conduct triage, medical case management, monitoring, and follow-up of individuals identified to have COVID-19 or any other acute health emergencies. CHWs conduct visits on a bi-weekly basis for the first five months post-baseline. CHWs deliver healthcare information and medical mistrust counseling in a culturally relevant and linguistically appropriate fashion; and provide social support, navigate household members to social welfare/vocational/economic/psychosocial services.
224140662|NCT04359355|DEVICE|Artificial Intelligence System for Detection of colorectal polyps|In this group, an artificial Intelligence System will be used for computer-aided diagnosis of colorectal polyps. Diagnostic Performance of the artificial intelligence System for detection of polyps will be compared against Operator-based detection in the same group
224140663|NCT05939596|BIOLOGICAL|SARS-CoV-2 Bivalent mRNA Vaccine|100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.
224140664|NCT05939596|OTHER|Saline|100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.
224163429|NCT01144091|DRUG|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
224163430|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
223565604|NCT02186652|DRUG|Pantoprazole|
224042955|NCT04084964|OTHER|Home-hospitalisation platform for heart failure|The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
224042956|NCT07129083|OTHER|Structured assessment interview|Participants completed a structured, in-person assessment conducted during one to three dialysis sessions. The assessment included validated instruments to measure overall quality of life (ACSA), health-related quality of life (EQ-5D-3L, EORTC QLQ-C30, QLQ-MY20), and various clinical, psychological, functional, and sociodemographic factors.
224042957|NCT07130916|DRUG|Aumolertinib|In Part A, participants will receive aumolertinib 110 mg (2 × 55 mg tablet) once daily, orally administrated under fasted condition (fasting from 2 hours before to 1 hour after dosing) in 21-day treatment cycles. In Part B, participants may continue study intervention (aumolertinib 110 mg once daily) until PD, death, intolerable toxicity, Investigator's decision, lost of follow-up, receiving another anti-cancer therapy, or any other pre-defined discontinuation criteria.
224042958|NCT04422756|DIAGNOSTIC_TEST|Seated intravenous saline infusion test|"The test will be conducted by infusing two litres of normal saline intravenously over 4 hours with the patient seated.Blood collection (for aldosterone, cortisol, renin, and electrolytes) will be performed at baseline and after completion of the infusion. Following infusion, plasma aldosterone levels \<140 pmol/L will be considered as negative, levels \>280 pmol/L as positive, and levels in between classified as indeterminate."
224042959|NCT04422756|DIAGNOSTIC_TEST|Ultra low-dose ACTH stimulation test|"The test will be performed by injecting 0.03 mcg of ACTH intravenously. Blood collection (for aldosterone, cortisol, and renin) will be performed at baseline and after 15 minutes. We expect a positive response to correspond with a plasma aldosterone \>2200 pmol/L and ARR \>220 pmol/L/mIU/L following stimulation."
224042960|NCT07007520|DRUG|DA-5223(Fasting)|once a day
224042961|NCT07007520|DRUG|DA-5223(Fed)|once a day
224042962|NCT06283394|BEHAVIORAL|Storefront Choice Architecture|An Instacart storefront with choice architecture manipulation (healthy items for diabetics appear first and less healthy items are less visible)
224042963|NCT06283394|BEHAVIORAL|Fresh Funds|The treatment groups will each receive a $160 subsidy per month for 3 months to be used on produce through Instacart.
224042964|NCT06283394|BEHAVIORAL|Loss Framing|They will receive text messages detailing how much of their $160 subsidy is left (beginning of weeks 1, 2, 3, and 4 and following end of the month).
224042965|NCT05488782|BEHAVIORAL|TEAM-Red|Five 60-minute group sessions with 6-10 patients. These sessions will be held weekly and delivered remotely via videoconference
224299676|NCT01631513|DRUG|Nucynta ER|100 to 250 mg every 12 hours
223432870|NCT03126565|OTHER|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
224042966|NCT05488782|OTHER|Waitlist|After the week 12 follow up visits subjects in the Waitlist group will receive the TEAM Red intervention
224140665|NCT01175278|PROCEDURE|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
224140666|NCT01175278|OTHER|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
224140667|NCT00195689|BIOLOGICAL|Human anti-TNF monoclonal antibody/adalimumab|
224140668|NCT04338516|DEVICE|Ossix™ Bone|a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
224140669|NCT04338516|DEVICE|Bio-Oss® Collagen|90% bovine derived xenograft granules and 10% porcine collagen
224140670|NCT04000555|DRUG|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
224140671|NCT04000555|OTHER|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
224140672|NCT02745236|OTHER|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
224140673|NCT02745236|OTHER|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
223432871|NCT02105714|PROCEDURE|Stool culturing for pathogenic bacteria|
223432872|NCT02105714|PROCEDURE|Kato-Katz technique|
224140674|NCT00396149|BIOLOGICAL|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
224140675|NCT00396149|BIOLOGICAL|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
224140676|NCT01984879|OTHER|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
224140677|NCT02730936|DEVICE|Antimicrobial Hernia Repair Device|hernia repair
224140678|NCT00878215|DEVICE|Explorer Liver Image Guided System|
224140679|NCT00878215|DEVICE|Explorer Liver Passive Tracking|
224140680|NCT00878215|PROCEDURE|Liver surgery|-Standard of care
224299677|NCT04734119|OTHER|Pre operative evaluation and anesthesia administration by the same anesthesiologist|Pre operative evaluation and anesthesia administration by the same anesthesiologist (instead of two different anesthesiologists, as routinely performed in our medical center)
223432873|NCT02105714|PROCEDURE|Baermann technique|
223432874|NCT02105714|DEVICE|Mini-FLOTAC|
223432875|NCT02105714|DEVICE|Crypto/Giardia Duo Strip|
223432876|NCT02105714|PROCEDURE|Formalin-ether concentration technique|
223432877|NCT02105714|DEVICE|CCA RDT|
224042967|NCT06902012|DRUG|Infusion of Axicabtagene Ciloleucel|"Drug: Axicabtagene Ciloleucel (CD19 CAR-T cells), 2×106 cells/kg, IV infusion at Day 0 and 30-90 days post-first infusion.~Drug: Cyclophosphamide (500 mg/m²) + Fludarabine (30 mg/m²), IV on Days -5, -4, -3.~Procedure: ctDNA monitoring via liquid biopsy at pre-lymphodepletion and Months 1, 2, 3, 6, 9, 12 post-infusion."
224042968|NCT01744353|DRUG|Dose level 1|Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
224140681|NCT00878215|PROCEDURE|Liver abalation|-Standard of care
224140682|NCT04575272|PROCEDURE|Ultrasound-guided continuous serratus anterior plane block|Local anesthetic infusion though a peripheral nerve catheter placed related to the serratus anterior muscle at the level of the 5th rib
224299678|NCT04048941|PROCEDURE|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
224042969|NCT01744353|DRUG|Dose level 2/MTD|Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
223432878|NCT02105714|PROCEDURE|Koga agar plate culture|
223432879|NCT02105714|PROCEDURE|Kinyoun staining|
223432880|NCT02105714|DEVICE|Multiplex PCR|
224042970|NCT01744353|DRUG|Dose level 3|Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
224042971|NCT01608867|BIOLOGICAL|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
224042972|NCT07024940|OTHER|Ethiopian Coffee|Ethiopian Coffee is used as a real-world example of one of the most common drinks in the world.
224042973|NCT07024940|DIETARY_SUPPLEMENT|Supplement|A pre-workout supplement that contains anthocyanins and caffeine as ergogenic aids
224042974|NCT07024940|OTHER|Water (Placebo)|Bottled water acting as the placebo
224042975|NCT07029438|DRUG|Mouthwash|Antiplaque/Antigingivitis Mouthwash
224042976|NCT07029438|DEVICE|Floss|Dental Floss
224042977|NCT07029438|DEVICE|Toothbrush|Soft bristled, manual toothbrush
224042978|NCT07029438|DRUG|Toothpaste|Sodium Monofluorophosphate 0.76 % (0.15% w/v fluoride ion) toothpaste
224042979|NCT07024641|DRUG|GIGA-2339|Administered by intravenous infusion
224042980|NCT07024641|DRUG|Placebo|Administered by intravenous infusion
224042981|NCT06376643|DEVICE|Augmented reality supportive tool|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario.~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
224042982|NCT06376643|OTHER|Conventional method (AHA pocket reference card)|"Participants will view a standardized orientation video describing the clinical environment, equipment, manikin functionality, and participant roles, followed by a 15-minute table-top practice simulation where participants have opportunity to use the assigned intervention by running through a cardiac arrest scenario~Then, participants will undertake a 20-minute tightly standardized cardiac arrest simulation scenario using a high-fidelity pediatric manikin. The scenarios will be videotaped from a bird's-eye view angle at the foot of the bed, along with three action video cameras worn by the participants, and positioned within the room.~Following completion of the scenario, participants will fill out five surveys (see secondary outcomes), which together take about 15 minutes to fill."
223432881|NCT02105714|PROCEDURE|Metagenomics analysis|
223432882|NCT04561024|DIAGNOSTIC_TEST|AI model|Deep Learning CNN model
223432883|NCT03193658|PROCEDURE|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
223432884|NCT03193658|DRUG|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
223432885|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
224042983|NCT06703879|DRUG|Anesthesia induction with propofol|Establishment of a database of clinical characteristics of propofol-induced loss of consciousness in patients with complete clinical information Acquisition of basic perioperative monitoring data and extended monitoring data: 1,000 patients aged ≥18 years who needed to undergo surgical treatment were included (according to the machine learning diagnosis results, if the poor model fit was due to the small sample size, the necessary number of samples could be continued to be collected), and perioperative monitoring and management of the patients was performed, and a video recorder was used to videotape the whole anesthesia induction process in real time, so as to facilitate the postoperative integration of various data. The basic characteristics of the patients and the perioperative monitoring characteristics were extracted from the surgical anesthesia recording system, including gender, age, height, weight, blood pressure, ASA classification, electroencephalographic parameters, the a
224042984|NCT07130084|OTHER|Virtual Reality Educational Film|The Virtual Reality Educational Film will be viewed during the antenatal appointment, post randomisation. The women will have access to the film at home should they want to watch it more than once.
224140683|NCT03370991|DIETARY_SUPPLEMENT|Blueberry Powder|22 g/day freeze-dried blueberry powder for 12 weeks
224140684|NCT03370991|DIETARY_SUPPLEMENT|Placebo Powder|22 g/day placebo powder for 12 weeks
224140685|NCT00738374|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
224140686|NCT00738374|DRUG|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
224140687|NCT00645294|DRUG|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
224140688|NCT00645294|DRUG|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
224299679|NCT04048941|PROCEDURE|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
224299680|NCT04048941|PROCEDURE|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
223432886|NCT01267201|DRUG|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
223432887|NCT01267201|DRUG|methylprednisolone|tablet 32 mg single dose
224140689|NCT00645294|DRUG|Adefovir Dipivoxil|ADV 10 mg on Day 1
223432888|NCT05060146|OTHER|Structured medico-pharmaceutical collaboration|Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.
223432889|NCT01338961|PROCEDURE|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
223432890|NCT04985175|BEHAVIORAL|Question prompt list|The specific QPS was a one page leaflet for chronic kidney disease which developed by applied literature and public QPL from the National Health Agency. It contains 3 domains 25 questions related to treatment, dialysis, and Kidney transplant. The QPL group participants were asked to read and mark those questions they concerned or write down additional problems.
223432891|NCT00501059|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
223432892|NCT00501059|DRUG|Placebo|Placebo, taken daily
223432893|NCT05661630|OTHER|EDUCATION AND COUNSELING WITH EX-PLISSIT MODEL|"In addition to the routine procedure, the women in the experimental group of the research will be given sexual education and counseling with the EX-PLISSIT model. The steps to be followed in accordance with this model are as follows; Session 1 Permission Limited Information The Specific Suggestions The IT-Intensive Therapy Session 2 At the beginning of the interview, the data forms will be reapplied, and then the homework given in the first session will be discussed. The information that the patient needs in line with his questions will be given within the steps of the Ex-PLISSIT model, within the steps of allowing, limited information, special recommendations and, if necessary, intensive therapy.~Session 3 At the beginning of the interview, the data forms will be applied for the last time and the patient's questions, if any, will be answered and the session will be ended."
223432894|NCT00517894|DRUG|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
223432895|NCT06142175|BIOLOGICAL|Relmacabtagene Autoleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
223432896|NCT02811588|DEVICE|Non-invasive ventilation|
223432897|NCT02978859|DRUG|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
224042985|NCT07130279|BEHAVIORAL|Postural Exercises + Post-Isometric Relaxation (PIR) Technique|Participants will perform a standardized postural exercise program (strengthening, stretching, and mobility exercises for the cervical and thoracic regions) three times per week for six weeks. In addition, the Post-Isometric Relaxation (PIR) technique will be applied to jaw muscles during each session to reduce muscle tension and improve mandibular mobility.
224042986|NCT07130279|BEHAVIORAL|Postural Exercises|Participants will perform a standardized postural exercise program designed to improve cervical and thoracic mobility and postural alignment. The program will include strengthening, stretching, and mobility exercises targeting the cervical spine, thoracic spine, and related musculature. Each session will last approximately 30-40 minutes and will be conducted three times per week for six weeks under the supervision of a trained therapist.
224042987|NCT07031973|DIETARY_SUPPLEMENT|Active Effervescent Powder|Participants receive a daily sachet of effervescent powder that is Orange flavored, containing multiple vitamins and minerals
224042988|NCT07031973|DIETARY_SUPPLEMENT|Placebo Effervescent powder|Participants receive a daily sachet of effervescent powder that is Orange flavored containing no active ingredients
224042989|NCT07031973|OTHER|Nutrition training and healthy lifestyle coaching|Participants receive Nutrition training and healthy lifestyle coaching
224042990|NCT07042152|OTHER|Smartwatch App for Movement Variability|This app measures movement variability in the upper extremity as described in our previous study (doi:10.3390/s24165266).
224042991|NCT07042152|OTHER|Smartwatch App for Active Time|The other software we are using measures total active time of the upper extremity.
224140690|NCT01665248|OTHER|18-F Sodium Fluoride Uptake in Positron emission tomography|
224140691|NCT06509724|RADIATION|Conventional Fractionated IMRT|"* Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions"
224140692|NCT06509724|RADIATION|Hypofractionated IMRT|"* Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions"
224042992|NCT07042152|BEHAVIORAL|Motivational Interviewing (Within Subjects)|Motivational Interviewing is an established therapeutic technique designed to increase patient adherence to therapy by addressing ambivalence. The motivational Interviewing sessions will include a variety of techniques such as: Open ended questions, Active Listening, Affirmation, Summarization, Questions focused on change talk, and Providing Information.
224163431|NCT01144091|DRUG|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
224163432|NCT01144091|DRUG|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
224163433|NCT02973997|OTHER|Laboratory Biomarker Analysis|Correlative studies
224163434|NCT02973997|DRUG|Lenvatinib|Given PO
224163435|NCT02973997|DRUG|Lenvatinib Mesylate|Given PO
224163436|NCT02973997|BIOLOGICAL|Pembrolizumab|Given IV
224163437|NCT03638518|OTHER|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
224163438|NCT03638518|OTHER|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
224163439|NCT02620124|DRUG|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
224163440|NCT02620124|DRUG|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
224042993|NCT06727682|BEHAVIORAL|Stress management|Ten-hour, three-course stress management programme with a psychologist via video conferencing over a 2 month period. The classes will be delivered in small groups of maximum seven care workers. Carers can be brought together in the same room, but the speaker will necessarily be at a distance, via videoconferencing. The formation will adress the following issues: i) Understanding the mechanisms of stress, ii) Identifying sources of stress and triggers, iii) Anticipate stressful situations and use their resources to prevent them, and iv) Use the most appropriate stress-reduction techniques, depending on their sensitivity.
224042994|NCT07128641|BIOLOGICAL|Odronextamab|A CD20xCD3 bispecific monoclonal antibody, glass vials, via intravenous (into the vein) infusion per protocol.
224140693|NCT02428452|BEHAVIORAL|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
223432898|NCT02237209|BIOLOGICAL|RSV LID ΔM2-2 Vaccine|10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
224140694|NCT00022971|BIOLOGICAL|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
224140695|NCT00022971|BIOLOGICAL|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
223432899|NCT02237209|BIOLOGICAL|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
223432900|NCT01046032|DRUG|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
223432901|NCT01046032|DRUG|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
223565605|NCT06424158|OTHER|Massage Therapy|Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
223565606|NCT00744978|DRUG|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
223565607|NCT00744978|DRUG|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
224042995|NCT07130032|COMBINATION_PRODUCT|reICB regimen (NSCLC)|"* ICI (one of the following): Atezolizumab 1200 mg every 3 weeks/Nivolumab 240 mg every 2 weeks/Pembrolizumab 200 mg every 3 weeks~* Cyclophosphamide 50 mg PO daily~* Bevacizumab 7.5 mg/kg every 3 weeks"
224042996|NCT07130032|COMBINATION_PRODUCT|reICB regimen (melanoma)|"* ICI (one of the following): Nivolumab 240 mg every 2 weeks/Pembrolizumab 200 mg every 3 weeks~* Cyclophosphamide 50 mg PO daily~* Bevacizumab 7.5 mg/kg every 3 weeks"
224042997|NCT07129421|DEVICE|"EMBLOK™ Embolic Protection System (EMBLOK EPS)"|The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
224042998|NCT07129902|BEHAVIORAL|Contingency Management|Participants in the active arm will receive payment (monetary incentive) contingent on outpatient MOUD treatment attendance.
224042999|NCT07129902|BEHAVIORAL|Usual care as prescribed by the ED physicians|All participants will receive standard outpatient care at their clinic.
224043000|NCT07129642|BIOLOGICAL|Allogeneic CAR-T|The participants will receive one dose of allogeneic CAR-T
224140696|NCT04949178|OTHER|No intervention|This is an observational study.
224140697|NCT06399731|DEVICE|High-frequency (10Hz) rTMS|High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
224140698|NCT06399731|DEVICE|Anodal tDCS|Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
224140699|NCT03334396|DRUG|Baricitinib|Administered orally.
224140700|NCT03334396|DRUG|Placebo|Administered orally.
224140701|NCT01070524|DRUG|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
224140702|NCT01070524|DRUG|Budesonide extrafine pMDI|Budesonide extrafine pMDI
224140703|NCT01070524|DRUG|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
224140704|NCT05824455|COMBINATION_PRODUCT|JS109 combine with irinotecan|JS109 PO,QD, q3w combine with irinotecan(65mg/m2,IV,D1,8,Q3w)
224140705|NCT04224818|DRUG|Dual trigger|Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
224140706|NCT04224818|DRUG|hCG (standard)|human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
224299681|NCT00390702|DEVICE|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
223432902|NCT02719938|BEHAVIORAL|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
223565608|NCT03311139|DRUG|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
224043001|NCT07076810|PROCEDURE|Lumbar facet joints medial branch nerve radiofrequency ablation|Patients will be positioned prone on the operation table. Intravenous access is opened. Monitorization for vital signs is performed. Light sedation with midazolam is performed. Under fluoroscopic guidance, medial branch nerve of each lumbar facet joint is found by searching the specific response to the stimulations of the radiofrequency needle. When the tip of the radiofrequency needle is close enough to the corresponding medial branch nerve, ablation with 80 degrees Celsius for 90 seconds is performed. Average 6-10 nerves are ablated in each procedure and the average duration of the procedure is 20-60 minutes.
224043002|NCT07076810|PROCEDURE|Lumbar facet joints medial branch nerve radiofrequency ablation|Patients are positioned prone on the operation table. Intravenous access is opened and monitorization of vital signs is applied. Skin is cleaned by povidone iodine solution. Light sedation is applied by midazolam. Lumbar vertebral region is seen under C-arm fluoroscopic view. Medial branch nerve of the lumbar facet joints is searched by 22 G width, 10-cm length radiofrequency needles. When the needle tip is close enough to the nerve, an 80 Celsius, 90-second radiofrequency ablation is applied. In each procedure, average 5-10 nerves is ablated and the duration of the procedure is 20-60 minutes.
224043003|NCT05784688|DRUG|TU2218 + KEYTRUDA® (Pembrolizumab)|TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered
224043004|NCT06901973|PROCEDURE|Intrafocal pinning|Intrafocal pinning involves the percutaneous insertion of Kirschner wires to stabilize the distal radius fracture, often followed by plaster immobilization.
224140707|NCT01255306|OTHER|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day"
224140708|NCT01255306|DRUG|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
224140709|NCT04613102|DRUG|AVCN583601 (3% Cannabidiol cream)|Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
224140710|NCT00039468|DRUG|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
224140711|NCT00039468|DRUG|thalidomide|400mg/day oral
224140712|NCT04724304|DIAGNOSTIC_TEST|Real-Time Myocardial Echocardiography (RTMPE)|Uses sound waves (ultrasound) to produce an images of the heart. During RTMPE a microbubble contrast agent is administered through an intravenous line (IV) to make the images of your heart clearer.
224140713|NCT04724304|DIAGNOSTIC_TEST|Magnetic resonance image (MRI)|Imaging that focuses on the heart or blood vessels to assess size and function of the heart's chambers, thickness and movement of the walls of the heart, and blood flow in the blood vessels.
224299682|NCT01301508|DRUG|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
224299683|NCT01301508|DRUG|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
224299684|NCT01301508|DRUG|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
223565609|NCT01218958|DRUG|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
223565610|NCT01218958|DRUG|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
223565611|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
223565612|NCT01218958|DRUG|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
223565613|NCT03580642|DEVICE|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
223565614|NCT02140008|DEVICE|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
223565615|NCT02140008|DEVICE|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
223565616|NCT04000308|DRUG|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
223565617|NCT04000308|DRUG|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
224299685|NCT01301508|DRUG|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
223565618|NCT03634566|DRUG|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
223565619|NCT03634566|DRUG|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
223432903|NCT01885715|DRUG|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
224043005|NCT06901427|BEHAVIORAL|Mediterranean Diet and exercise|A structured dietary intervention promoting Mediterranean-style eating patterns and regular exercise for 12 weeks.
224043006|NCT06901830|DRUG|YZJ-4729|Loading dose + demand dose
224163441|NCT02165644|DRUG|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
223432904|NCT00955968|DRUG|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
223432905|NCT04529512|DRUG|DEXTENZA®|DEXTENZA® is a corticosteroid implant indicated for the treatment of ocular pain following ophthalmic surgery. DEXTENZA® is inserted into the lower lacrimal punctum into the canaliculus by the physician following ophthalmic surgery. A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion. DEXTENZA® is preservative free, resorbable and does not require removal. Saline irrigation or manual expression can be performed to remove the insert, if necessary.
223432906|NCT02041650|DRUG|Ticagrelor|
223432907|NCT01455181|DRUG|NPSP558|50, 75, 100 μg
223432908|NCT06712849|DEVICE|Sham Transcranial Random Noise Stimulation|Sham transcranial random noise stimulation will be applied over the primary visual cortex (area V1) with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2.0 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 40 minutes.
223432909|NCT06712849|DEVICE|High Frequency Transcranial Random Noise Stimulation|Non-invasive brain stimulation will involve the use of high-frequency transcranial random noise stimulation (100-640 Hz) to apply a 2.0 milliamp current over the primary visual cortex (area V1) for approximately 40 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
223432910|NCT00117624|DRUG|darbepoetin alfa|
223432911|NCT03456999|BIOLOGICAL|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
224043007|NCT06901830|DRUG|Placebo Comparator: Saline|Loading dose + demand dose
224299686|NCT05173038|BEHAVIORAL|second ejaculate|group patients received IUI for pregnancy assistance 1 hour after the first sperm extraction. The two semen were mixed and treated.
224299687|NCT02547402|DRUG|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
224299688|NCT02547402|DRUG|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
223432912|NCT03456999|BIOLOGICAL|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
223432913|NCT05949424|DRUG|Olaparib|Starting dose of 200mg 2dd.
223432914|NCT05949424|DRUG|Lenvatinib|Starting dose of 10mg 1dd.
224043008|NCT06901830|DRUG|Active Comparator: Morphine|Loading dose + demand dose
223565620|NCT03424954|BEHAVIORAL|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
224043009|NCT06902844|DRUG|Equecabtagene Autoleucel Injection|dosage form: injection, dosage: 1.0×10\^6 CAR-T/kg, frequency: single dose.
224043010|NCT06901622|DRUG|Camrelizumab, anlotinib, nab-paclitaxel, S-1|"Initial treatment (4 cycles) Carrelizumab: 200 mg, day 1, iv, q3w. Anlotinib: 10 mg, taken orally once a day, day 1\~14, q3w. For patients with intolerance, the dose can be reduced to 8 mg.~Nab-paclitaxel: 200 mg/m\^2, day 1, iv, q3w. (Patients with poor tolerance can be given on the 1st and 8th days, and the total dosage remains unchanged).~S-1: 60 mg/day for body surface area \<1.25 m\^2; 80 mg/day for body surface area = 1.25\~1.50 m\^2; 100 mg/day for body surface area \>1.50 m\^2; 2 times a day, administered on days 1 to 14, 3 weeks as a treatment cycle.~After 4 cycles of initial treatment, the feasibility of surgery was evaluated. Operable patients: radical surgical resection, followed by 4 cycles of S-1 combined with carrelizumab (up to 1 year). During postoperative treatment, the investigator determined whether local radiotherapy (CCRT) was required.~Inoperable patients: carrelizumab + anlotinib + S-1 were treated until intolerance or disease progression."
224043011|NCT06901622|DRUG|Camrelizumab, nab-paclitaxel, S-1|"Initial treatment (4 cycles) Carrelizumab: 200 mg, day 1, intravenous drip, 3 weeks as a treatment cycle. Nab-paclitaxel: 200 mg/m\^2, day 1, intravenous drip, 3 weeks as a treatment cycle. (Patients with poor tolerance can be given on the 1st and 8th days, and the total dosage remains unchanged).~S-1: 60 mg/day for body surface area \<1.25 m\^2; 80 mg/day for body surface area = 1.25\~1.50 m\^2; 100 mg/day for body surface area \>1.50 m\^2; 2 times a day, administered on days 1 to 14, 3 weeks as a treatment cycle.~After 4 cycles of initial treatment, the patient's surgical feasibility was evaluated.~Operable patients: radical surgical resection, followed by S-1 (4 cycles) combined with carrelizumab treatment (up to 1 year). During postoperative treatment, the investigator determined whether local radiotherapy (CCRT) was required.~Inoperable patients: carrelizumab + S-1 treatment until intolerance or disease progression."
224043012|NCT06902090|DRUG|Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)|IV, 30 mg
224043013|NCT06902090|DRUG|Meloxicam Nanocrystal Injection (ANJESO®)|IV, 30 mg
224163442|NCT02165644|DRUG|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
224163443|NCT00131534|BEHAVIORAL|Individual therapy|Stage-based individual therapy for trauma survivors
224163444|NCT00131534|BEHAVIORAL|Group therapy|Stage-based group therapy for trauma survivors
223432915|NCT05949424|DRUG|Sunitinib|Starting dose of 25mg 1dd 28/42 days.
223432916|NCT05949424|DRUG|Palbociclib|Starting dose of 75mg 1dd 21/28 days.
223432917|NCT05949424|DRUG|Pazopanib|Starting dose of 200mg 1dd.
223432918|NCT05949424|DRUG|Olaparib|Starting dose of 300mg 2dd.
223432919|NCT05949424|DRUG|Lenvatinib|Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.
224043014|NCT06901453|PROCEDURE|Low shrinkage Giomer restorative material (Beautifil II LS)|Enamel margins are etched with 37% phosphoric acid for 15 seconds, then the cavity is bonded using FL bond two-step self-etch adhesive. Giomer is applied in increments (maximum 2mm thickness) and light-cured for 20 seconds with a properly calibrated LED curing light.
224043015|NCT06901453|PROCEDURE|RMGI alone - Control|Cavities will be restored with light-cured resin modified glass ionomer (GC Fuji II LC) only. After applying conditioner for 20 seconds, rinsing, and gentle drying, the RMGI will fill the entire cavity and be light-cured
224043016|NCT03904134|OTHER|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
223432920|NCT05949424|DRUG|Sunitinib|Starting dose of 50mg 1dd 28/42 days.
223432921|NCT05949424|DRUG|Palbociclib|Starting dose of 125mg 1dd 21/28 days.
224043017|NCT05756127|OTHER|Observational - no intervention given|Observational - no intervention given
224140714|NCT00436319|PROCEDURE|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2\<80 pg/ml and progesterone \<1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
223432922|NCT05949424|DRUG|Pazopanib|Starting dose of 800mg 1dd.
223432923|NCT05084365|DRUG|Sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
224043018|NCT06902155|DIAGNOSTIC_TEST|International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)|Urinary incontinence was assessed using the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), a validated instrument with a Cronbach's alpha of 0.88. This tool consists of four items: three scored questions evaluating leakage frequency (0-5), volume (0-6), and impact on quality of life (0-10), summing to a total score of 0-21, and one unscored question identifying situations where incontinence occurs. Two separate analyses were performed: total ICIQ-SF score and responses to question, which identified UI-triggering situations
224043019|NCT06901752|PROCEDURE|Kinesiotaping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs (paediatric, geriatric, orthopaedic, neurological, oncology and others) and levels of care (acute care,inpatient rehabilitation,outpatient, home care and Day Rehab). The idea of using elastic tape to mimic the therapist's hands was first presented by Dr Kenzo Kase in the 1970s. Since then, it became the modality used in pain management, soft tissue injury, tissues and joints malalignment, oedema, and more. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions. Kinesio Taping Method has also effectively treated animals and two special tapes are used: Kinesio Equine and Kinesio Canine. Kinesio Tex Tape contains either 100% cotton and elastic fibres or a blend of polyester and cotton with elastic fibres. The latter is preferable for Kinesio Taping application on sensitive skin
223432924|NCT05084365|DRUG|Placebo|Placebo
223432925|NCT04482595|DRUG|BIO 300 Oral Suspension|Suspension of genistein nanoparticles
224043020|NCT06901752|BEHAVIORAL|Exercise|Cat Camel Exercise, Bridge Exercise, Lateral Flexion, Cross Walking, Ipsilateral and Contralateral Stretching Exercises
224043021|NCT06913231|DEVICE|Whole body vibration device|Whole-body vibration (WBV) training using the Power Plate Pro 7HC (Northbrook, USA). The vibration frequency was set between 30-40 Hz, with an amplitude of 2-4 mm.
224043022|NCT06913231|OTHER|Sham Whole body vibration|A sham Whole body vibration will be used . participants will stand on the device without actual vibrations.This control condition will be used to isolate the effects of WBV from other potential influences such as standing posture and time spent on the the platform.
224140715|NCT05360823|OTHER|Birth ball|Exercises for childbirth
224140716|NCT05360823|OTHER|Squatting|Exercises for childbirth
224140717|NCT01283997|OTHER|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
224140718|NCT01283997|DRUG|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
224140719|NCT04890106|DRUG|Test - Bimatoprost 0.01% Ophthalmic Solution|Subjects in one arm will receive one drop of the test drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
223432926|NCT04482595|DRUG|Placebo|Matched placebo for BIO 300 Oral Suspension
223432927|NCT00876226|DRUG|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
224299689|NCT02547402|DRUG|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
223432928|NCT03559868|DRUG|Digoxin|Participants will receive 3 mcg/Kg/day doses of oral digoxin
223432929|NCT03559868|OTHER|Placebo|Oral placebo
223432930|NCT03559868|DRUG|Digoxin|Participants will receive 0.15 mcg/Kg/day doses of oral digoxin
223432931|NCT02201095|DEVICE|Forced air warming|
223432932|NCT02201095|DEVICE|Conduction warming mattress|
223565621|NCT02647541|DIETARY_SUPPLEMENT|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
223565622|NCT02185430|DRUG|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
224043023|NCT06796660|DRUG|Nephropathy Formula No. 1|On the basis of integrated treatment for chronic kidney disease (the specific plan is the same as the control group), Nephropathy Formula No. 1 is given orally. The composition and decoction method of the formula are as follows: Bupleurum, Paeonia lactiflora Pall. , Scutellaria baicalensis Georgi , Pinellia ternata (Thunb.) Breit. , Smilax glabra Roxb. , Oldenlandia diffusa (Willd.) Roxb. , Tussilago farfara L. , Poria cocos (Schw.) Wolf , decocted into 300ml, one dose per day, taken warm in two divided doses for 12 weeks.
223432933|NCT04511949|DIAGNOSTIC_TEST|COVID-19 IgG / IgM rapid test (whole blood, serum, plasma)|"* The rapid test is performed using a drop of blood obtained at the fingertip (10 microliters) using a lancet.~* The dropper pipette, held vertically, collects the drop of whole blood up to the sample line~* Place 1 drop of whole blood (10 μL in the sample well (S) of the cassette.~* Immediately add 2 drops (80μL) of buffer to the well (B) of the cassette.~* Avoid air bubbles; if there is an air bubble, add a 3rd drop of buffer.~The reading is taken after 10 minutes at most by the healthcare professional under medical supervision.~In case of sepositivity of the rapid test, it may be offered to index cases and adult contacts, a blood sample of 5 ml of blood for a serothèque allowing a characterization of the antibodies and in particular of the neutralizing antibodies."
224043024|NCT06796660|DRUG|integrated basic treatment for chronic kidney disease|"The integrated basic treatment for CKD includes the following:~Dietary Nutrition: α-Keto acid tablets (2.6 g tid) may be used. Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected. β-blockers or α-blockers may be used in combination if necessary.~Blood Sugar Control: Medications such as repaglinide tablets (1.0 mg qd) or gliclazide modified-release tablets (30 mg qd) can be used.~Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.~Anemia Treatment: Recombinant human erythropoietin (10000 u qw) can be administered via subcutaneous injection.~Regulation of Water, Electrolyte, and Acid-Base Metabolic Balance."
224043025|NCT07105176|DRUG|Cyclophosphamide|Cyclophosphamide administered via intravenous infusion once daily for 3 consecutive days.
224043026|NCT07105176|DRUG|Fludarabine|Fludarabine is administered once daily via intravenous infusion for 4 consecutive days.
224043027|NCT07105176|DRUG|IL-2 (interleukin 2)|IL-2 administered subcutaneously once daily. Dosing may be adjusted based on subject tolerance, including modifications to dose quantity, administration frequency, or complete treatment discontinuation, with a maximum treatment duration of 3 days.
224043028|NCT07105176|DRUG|HS-IT101 monotherapy|TIL Injection administered by intravenous infusion over 30-60 minutes.
224043029|NCT07110389|BEHAVIORAL|A tele-CR program|"The tele-CR program is divided into three parts: motivational interviewing, app delivery, and self-management and tracking. Motivational interviewing was conducted during hospitalization and involved evaluating individual risk factors, setting behavioral goals, and providing training on the installation and operation of the tele-CR app (approximately 30-60 minutes per session).~After discharge, researchers monitored app usage and conducted seven follow-up sessions via LINE or telephone at 1 week, and at 1, 2, 3, 4, 5, and 6 months post-discharge. These follow-ups, each lasting approximately 5-15 minutes, aimed to assess patients' living conditions, address any issues promptly, and provide encouragement or praise based on their engagement with the app.~After the completion of the 6-month tele-CR intervention, participants could still actively contact the researchers via LINE or the app to seek health-related assistance according to their personal needs, up to 12 months post-discharge."
224140720|NCT04890106|DRUG|Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)|Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
224140721|NCT02017899|BIOLOGICAL|S. sonnei 1790GAHB|
224140722|NCT02017899|BIOLOGICAL|Placebo|
223432934|NCT04947995|DEVICE|ctDNA multi-omics test|The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
223432935|NCT02331849|DEVICE|High resolution manometry (HRM)|High resolution manometry of the esophagus
223432936|NCT06730516|DRUG|Latanoprost (Xalatan)|latanoprost 0.005
223432937|NCT06730516|DRUG|Brimonidine 0.2 %|Brimonidine0.2
224140723|NCT02269384|PROCEDURE|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
224140724|NCT02269384|BEHAVIORAL|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
223432938|NCT04326439|DRUG|Cytarabine|100 mg/m²/dose every 12 hours IV Days 1-10
223432939|NCT04326439|DRUG|Daunorubicin|50 mg/m²/dose IV Days 1, 3, 5
223432940|NCT04326439|DRUG|Erwinase|25,000 International Units/m²/dose IM Days 2, 9
223432941|NCT04326439|DRUG|Etoposide|150 mg/m²/dose IV Days 1-5
223432942|NCT04326439|DRUG|Gemtuzumab ozogamicin|Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.
223432943|NCT04326439|PROCEDURE|Stem cell transplantation (SCT)|Transplantation of multipotent hematopoietic stem cells from bone marrow
224140725|NCT02269384|BEHAVIORAL|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
223432944|NCT04326439|DRUG|Sorafenib|200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
223432945|NCT00565669|DRUG|Cyclosporin A Restasis®|
224140726|NCT02269384|PROCEDURE|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
224140727|NCT02311790|DIETARY_SUPPLEMENT|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
223432946|NCT00565669|DRUG|Blink tears|blink tears to be used twice a day
223432947|NCT00565669|DRUG|Systane|systane to be used twice a day
223432948|NCT02930525|OTHER|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
224140728|NCT02311790|DIETARY_SUPPLEMENT|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each \[9 weeks total\]
224043030|NCT07110389|OTHER|Attention-controlled|The researchers conducted face-to-face communication with participants in the control group prior to discharge, aiming to establish a professional relationship and advise them to follow routine health education and adopt an appropriate lifestyle. After discharge, follow-up care was provided regularly via LINE or telephone at 1 week, and at 1, 2, 3, 4, 5, and 6 months post-discharge-a total of seven sessions, each lasting approximately 3-5 minutes-to inquire about any symptoms of discomfort.
224043031|NCT07110623|DEVICE|LIP device|The LIP device uses polarized Raman spectroscopy to enhance the early detection and diagnosis of oral cancer by facilitating more accurate guiding of biopsies. This non-invasive technology utilizes polarized laser light to generate Raman scattering that can be used to analyze molecular vibrations, which in the future will provide clinicians with insights into tissue composition and structure for identifying cancerous abnormalities.
224043032|NCT07110714|OTHER|Cold water hydrotherapy|Cold water hydrotherapy (5-10 minutes each), four times daily during the 3-week program and once daily during the 6-month follow-up period. Hydrotherapy interventions are individually tailored to each subject based on their responses and include various washing and pouring techniques.
224043033|NCT07115927|DRUG|Dostarlimab|Arm 1: Patients in the initial cohort will be treated with two doses of dostarlimab prior to surgery, receiving dostarlimab 500mg IV on day 1 and day 22.
224043034|NCT03315975|BIOLOGICAL|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
224043035|NCT07113860|BEHAVIORAL|Views on Aging Intervention|This intervention was developed by Wolff, Warner (47) in 2013-2014; refined by Beyer, Wolff (59) in 2017-2018; and further refined for this project. It will be delivered through three in-person one-hour sessions by two psychologists. it will include homework between sessions two and three. The first session will consist of a quiz on aging with questions about healthy aging and aging in general to detect own negative personal views on aging and misconceptions regarding aging. The second session will provide information on the benefits of more positive views on aging on health, functional and cognitive abilities, and longevity. During the third session participants are thought a technique to modify negative automatic thoughts about aging and asked/invited to put in practice this technique. Finally, the intervention ends with a focus on positive views on aging and their importance for one's health and wellbeing.
224043036|NCT07113860|BEHAVIORAL|Projecte Moviment|The intervention lasts 12 weeks and is based on international guidelines of physical exercise. Participants will be instructed to walk briskly in one continuous bout (45 minutes for 5 days, 225 minutes per week). Intensity, duration, and times per week will be initiated in a stepwise manner to reduce the possibility of injury. During the first week participants will be asked to walk 30 minutes at 9-10 on the Borg Rating of Perceived Exertion Scale (i.e., light intensity). During the second week, participants will be asked to walk 45 minutes with the same intensity. During the remaining weeks, participants will be asked to maintain the duration of 45 minutes and increase the intensity of the activity to a moderate-high effort that corresponds with 12-14 in the Borg Rating of Perceived Exertion Scale.
224043037|NCT07117097|PROCEDURE|Minimally Invasive Non- Surgical Periodontal Therapy (MINST)|The procedure consists of thorough debridement of the root surface through a subpapillary access using exclusively piezoelectric devices with specific thin and delicate tips (EMS, Switzerland) and 4X magnification loupes, taking care to minimize the soft tissue trauma and to stimulate the formation of a stable blood clot
224043038|NCT07117097|PROCEDURE|conventional Non-Surgical Periodontal Treatment (cNSPT)|The intervention consists of thorough debridement of the root surface under local anaesthesia, using conventional piezoelectric devices and hand instruments
223432949|NCT02930525|OTHER|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
223432950|NCT02689310|OTHER|Leptospermum scoparium honey|No information available- PI left- study being withdrawn.
223432951|NCT02689310|OTHER|Standard of Care Treatment|No information available- PI left- study being withdrawn.
224043039|NCT07123246|OTHER|Rigid Tape|Inelastic rigid tape (Strappal) applied to discharge the Achilles tendon
224043040|NCT07123246|OTHER|Placebo Control|A pre-tape and a short piece of rigid tape applied without tension.
224043041|NCT07123194|BEHAVIORAL|An Arts-Based Nursing Intervention Program to Help Develop Healthy Digital Habits|Session Time: Arts-Based Nursing Intervention Program Sessions to Help Develop Healthy Digital Habits Week 1, Session 1 - Introductions and Group Agreement Formation (60 minutes) Week 2, Session 2 - Where Am I in the Digital World? (60 minutes) Week 3, Session 3 - Digital Addiction: Are You Connected or Addicted? (90 minutes) Week 4, Session 4 - Digital Addiction and Its Effects (90 minutes) Week 5, Session 5 - Digital Danger: Cyberbullying (90 minutes) Week 6, Session 6 - Discovering Strengths: The Relationship Between Digital Addiction and Self-Efficacy (90 minutes) Week 7, Session 7 - Digital Detox and Alternatives (90 minutes) Week 8, Session 8 - Evaluation and Closing (90 minutes)
224043042|NCT07122479|OTHER|Three-Pronged Approach to Reduce Hospital Acquired Deconditioning|The intervention includes 1) providing and demonstrating a set of daily physical exercises to patient according to their baseline performance status as assessed by physical therapist, 2) maintaining a patient-completed daily log of physical exercise adherence and 3) standardize the monitoring of physical exercise by the healthcare team by its inclusion in daily progress notes.
224043043|NCT07123259|DIETARY_SUPPLEMENT|WHOLE WHEAT MUFFIN|400g whole wheat flour was used for the development of muffins
224043044|NCT07123259|COMBINATION_PRODUCT|1.5g enriched pomegranate muffins|1.5 g of pomegranate peel powder (PPP), alongside conventional medical therapy
224043045|NCT07123259|COMBINATION_PRODUCT|3g enriched pomegranate muffins|3 g of pomegranate peel powder (PPP), alongside conventional medical therapy
224140729|NCT03345940|DRUG|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
223432952|NCT04291677|OTHER|intervention musical|Intervention group in which musical intervention will be applied the first or third day of mechanical ventilation.
223432953|NCT04291677|OTHER|Without intervention musical|Control group with standard treatment without musical intervention.
223565623|NCT02185430|DRUG|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
223565624|NCT04842630|DRUG|SHR-1916|All participants receive SHR-1906 alone
224043046|NCT07129304|COMBINATION_PRODUCT|Collaborative Virtual Reality with Routine Physical Therapy|patients will receive routine Physiotherapy treatment and additional treatment in a Collaborative Virtual Reality Environment for 30 minutes per session 3 times /week for minimum of 8 weeks. There will be a real time interaction in this group between patients and Physiotherapist in the virtual environment. The tasks in the CVE will focus on motor control, balance, coordination, and social engagement while routine Physical Therapy session will consist of performing exercises based on similar goals of improving motor skills, enhanced coordination, functional mobility, muscle strength and stretching exercises.
223432954|NCT06272045|BEHAVIORAL|ENRICH|In the ENRICH intervention, home visitors will incorporate heart health information and activities into routine home visits beginning in pregnancy and continuing until children turn 2 years old. The intervention includes 1) Information and resources on topics such as healthy eating, physical activity, weight management, tobacco use, healthy sleep and stress reduction, 2) tools like scales, Fitbits, and blood pressure monitors to facilitate self-monitoring, and 3) activities and information focused on infant nutrition, feeding, healthy growth, sleep, play and emotions and soothing.
223432955|NCT06272045|BEHAVIORAL|Usual Home Visiting|Usual home visiting without cardiovascular health promotion content
223432956|NCT03643913|PROCEDURE|Deep neuromuscular block|Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
223432957|NCT03643913|PROCEDURE|Moderate neuromuscular block|Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
224140730|NCT03345940|DRUG|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
224140731|NCT01232751|DIETARY_SUPPLEMENT|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
224043047|NCT07129304|COMBINATION_PRODUCT|Non-Immersive Virtual Reality with Routine Physical Therapy|Patients will receive routine physiotherapy treatment along with the engagement with computer-based virtual rehabilitation content displayed on a standard computer monitor/ LED screen. There will be no real time interaction in this group between patients and Physiotherapist in the virtual environment. Patients will be viewing pre-recorded videos of therapeutic exercises, demonstration, and / or on-screen instructions and cues for performing exercises. This group's patients will be treated with non- immersive virtual reality along with routine physical therapy for 30 minutes session 3 times /week for 8 weeks. Routine Physical Therapy session will consist of performing exercise based on the goal of improving motor skills, enhanced coordination, posture correction, gait efficiency, functional mobility, muscle strength and endurance training, stretching exercises where required.
224043048|NCT07129681|OTHER|dextrose 5%|Dextrose, is an osmotic proliferant which acts by dehydrating the cells at the injection site which utlimately leads to release of cellular fragments that act as chemo attractants and start the inflammatory cascade leading todeposition of collagen
224043049|NCT07129681|OTHER|Arthrocentesis/Saline|Arthrocentesis , a highly successful, simple and minimally invasive procedure is a safe and simple method for treatment of anterior disc displacement with reduction of TMJ both in short term and long term follow up period, where it is a procedure of removing damaged tissues \&inflammatory mediators.it can be the treatment modality for the for control group
224043050|NCT07128446|OTHER|Standard physical and occupational therapy|Participants admitted to the Pediatric Intensive Care Unit (PICU) will receive standard occupational therapy as part of routine clinical care. Interventions will be tailored to each patient's medical status and functional needs and may include activities of daily living (ADL) training, positioning, range of motion exercises, sensory stimulation, and caregiver education. No additional experimental treatment will be introduced for study purposes. The primary focus of the study is to evaluate patient-centered outcomes using the Canadian Occupational Performance Measure (COPM), without altering the standard therapeutic approach.
224043051|NCT07128927|BEHAVIORAL|Sleep Healthy Using the Internet (SHUTi)|Web-based, self-administered, and interactive cognitive behavioral therapy for insomnia
224043052|NCT07128927|BEHAVIORAL|Patient education|Website that describes insomnia, including factors that may increase or decrease insomnia symptoms, and provides information about addressing insomnia symptoms.
224043053|NCT07130292|BEHAVIORAL|Abdominal Muscle Strengthening Exercises with Stabilizer Pressure Biofeedback|A supervised exercise program designed to strengthen abdominal and lumbar muscles, incorporating the use of a stabilizer pressure biofeedback device to enhance activation of deep stabilizing muscles such as the transversus abdominis. The program is delivered three times per week for 6 weeks (excluding menstruation weeks) and includes mobility, stretching, and strengthening exercises.
224140732|NCT03312868|RADIATION|SBRT|Stereotactic Body Radiotherapy
224140733|NCT02858687|OTHER|Nasopharyngeal swab|
224140734|NCT05444010|BEHAVIORAL|mandala painting|nurse painted mandala for relaksing
223432958|NCT03643913|DRUG|Neuromuscular Blocking Agents and reversing agents|Deep neuromuscular block versus moderate neuromuscular block.
223432959|NCT05603156|DRUG|the usage of Olverembatinib combined with Inotuzumab Ozogamicin|patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
224140735|NCT00168324|DRUG|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
224140736|NCT00168324|DRUG|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
224140737|NCT00168324|OTHER|Sham Injection|Sham injection on Day 0.
224140738|NCT01141218|OTHER|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
224140739|NCT04781452|OTHER|standard treatment|there ist no Intervention but our standart Treatment in the center
224140740|NCT00142402|DRUG|Modafinil|
224140741|NCT01677624|DEVICE|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
224299690|NCT05260164|DEVICE|HIFEM+RF|Combination of High-Intensity Focused Electromagnetic Field (HIFEM) and a high radio frequency (RF) field.
223432960|NCT00095745|DRUG|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
223432961|NCT04840420|OTHER|social prescribing|as above
223432962|NCT04840420|OTHER|usual care|as above
223432963|NCT05999617|OTHER|Rehabilitation|Conventional rehabilitation (stretching, strengthening, balance) and dual task exercise training (simple math during active stretching, carrying the ball without dropping child while on the balance pad) will be applied 3 days a week for 12 weeks. Interventions will be implemented individually. Patients will be evaluated before and 12 weeks after the interventions.
223432964|NCT00204477|DIETARY_SUPPLEMENT|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
223432965|NCT00204477|DIETARY_SUPPLEMENT|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
223432966|NCT06618196|BIOLOGICAL|LR20062|DTaP-HepB-IPV-Hib vaccine
224043054|NCT07130227|OTHER|Session 1: Preparatory Session|\*Meeting the patients \*Introducing the content of mindfulness-based stress reduction training \*Emphasizing the importance of regular and timely attendance at training \*Determining training dates \*Sharing individuals' experiences and expectations
224140742|NCT00804843|DRUG|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
224140743|NCT00804843|DRUG|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
224140744|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
224140745|NCT00804843|DRUG|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
224140746|NCT00003129|DRUG|valrubicin|
224140747|NCT05979714|OTHER|Patient-centered injection site|CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
224299691|NCT00157859|DRUG|Chloroquine and sulphadoxine-pyrimethamine|
224299692|NCT01832675|DRUG|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
224299693|NCT01832675|DRUG|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
223432967|NCT06618196|BIOLOGICAL|DTaP-HepB-IPV-Hib vaccine|Control hexavalent vaccine
223432968|NCT00632684|BEHAVIORAL|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
223432969|NCT00632684|BEHAVIORAL|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
223432970|NCT04543318|PROCEDURE|Deep temporal nerves|"Surgical procedure:~Group A Exploration on the affected side a facelift-type incision will be performed, and an anterior subcutaneous flap is then will be lifted for several centimetres. In the inferior zygomatic region, the plane of elevation is deepened into the sub-SMAS plane and a composite flap elevated for several centimetres. Following elevation in this plane, the distal facial nerve branches will be identified. The distal portion of the zygomatic nerve is usually located midway between the oral commissure and the helical root. and was confirmed by nerve stimulator.~The deep temporal fascia and temporalis muscle will be incised along the temporal fusion line and will be reflected from the skull to expose the divisions of the deep temporal nerves and the longest branch was traced and prepared for anastomosis end to end with the zygomatic branch after confirming the eyelid supply."
223432971|NCT04543318|PROCEDURE|massteric nerve|group B The same procedure as group A except tracing the masseteric nerve related to masseter muscle and anastomosis will be the same
223432972|NCT00388336|DRUG|Epoetin Alfa|
223432973|NCT06007963|PROCEDURE|Treatment with impella device.|Impella percutaneous mechanical supported patients will be included after revision to support.
223432974|NCT01500408|DRUG|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
223432975|NCT01500408|DRUG|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
223432976|NCT00359736|DRUG|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
223432977|NCT04272606|DRUG|Tranexamic Acid|Antifibrinolytic Agent
224043055|NCT07130227|OTHER|Session 2: Mindfulness|\*What is mindfulness? \*Being aware of daily activities. \*Raisin meditation.
223432978|NCT04272606|DRUG|Saline Solution|Placebo
223565625|NCT05607082|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms.
224043056|NCT07130227|OTHER|Session 3: Our Perspectives on Ourselves and the World|\*Breathing meditation. \*Habit Breaker: Watching the Sky.
224043057|NCT07130227|OTHER|Session 4: Body Scan *Body scan meditation.|\*Ten-finger gratitude practice. \*Habit Breaker: Spending some time in nature.
223432979|NCT04272606|DIAGNOSTIC_TEST|Visual Acuity Exam|Supplemented into standard of care daily neurological exam on day of surgery and day after
223432980|NCT04272606|DIAGNOSTIC_TEST|3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)|3D-CAM is a brief verbal assessment tool that can be used to test patients and study patients for delirium.
223432981|NCT02432391|BEHAVIORAL|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
223432982|NCT06588400|DEVICE|AOSEPT Plus and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
224043058|NCT07130227|OTHER|Session 5: Recognizing Schizophrenia|\*What is schizophrenia? \*What are its symptoms? \*What does treatment involve?
224043059|NCT07130227|OTHER|Session 6: Mindful Movement|\*Mindfulness movement meditation practice \*
224043060|NCT07130227|OTHER|Session 7: Mindful Breathing|\*Breathing meditation \*
224043061|NCT07130227|OTHER|Session 8: Treatment Evaluation|\*The importance of medication \*Things to consider when using medication \*Side effects of medication \*What is a flare-up in schizophrenia? \*What are the precursor symptoms?
224043062|NCT07130227|OTHER|Session 9: Mindful Thinking|\*Sounds and thoughts meditation \*Cinema activity.
224043063|NCT07130227|OTHER|Session 10: Coping with Anger|\*What is anger? \*What are its symptoms? \*What are the coping methods?
223432983|NCT06588400|DEVICE|AOSEPT Plus with HydraGlyde and AOCup lens case|Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc. The solution and lens case must be used together.
223432984|NCT06588400|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
223432985|NCT06530706|DRUG|Esketamine|Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.
223432986|NCT06530706|DRUG|normal saline|Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
224043064|NCT07130227|OTHER|Session 11: Coping with Difficult Emotions|\*Facing Difficulties meditation \*
224043065|NCT07130227|OTHER|Session 12: Mindful Communication|\*Communication \& mindful communication \*The importance of communication skills \*Fundamentals of communication, self-language practice \*Ways to prevent communication accidents
223565626|NCT04755166|PROCEDURE|Lateral ridge augmentation|
223432987|NCT06594562|DIAGNOSTIC_TEST|Telementored eFAST|Ultrasound examination guided in real-time by a remote expert for detecting free fluid.
224043066|NCT07130227|OTHER|Session 13: Different Connections|\*Breathing meditation. \*Habit Breaker: Thought and Emotional Play.
224043067|NCT07130227|OTHER|Session 14: The Joy of Small Things|\*Treasure of Pleasure Meditation \*Habit Breaker: Letter to Self.
224043068|NCT07130227|OTHER|Session 15: Dwelling on the Past or Living in the Present?|\*Friendship-Building Meditation \*Habit Breaker: Random Acts of Kindness.
224043069|NCT07130227|OTHER|Session 16: Evaluation|\*Reinforcing What Has Been Learned. \*Evaluating the Program. \*Obtaining Feedback.
223432988|NCT05973019|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|6 times/per week for 2 weeks, total 12 times rTMS with 10 Hz.
223432989|NCT01277653|DEVICE|tumor maker interval shortly|tumor maker interval every 3 month
223432990|NCT01353690|BIOLOGICAL|AMDC|Cell Treatment
223432991|NCT06715683|DRUG|BMS-986278 Batched method, Dose A|Specified dose on specified days
224043070|NCT07130227|OTHER|Session 1: Group 2, Preparation Session|\*Meeting Patients \*Introducing the Content of Psychoeducation \*Emphasizing the Importance of Regular and Timely Attendance at Training \*Determining Training Dates \*Sharing Individuals' Experiences and Expectations
224043071|NCT07130227|OTHER|Session 2: Group 2, Recognizing the Illness|\*What is Schizophrenia? \*What are its Symptoms? \*What Does Treatment Include?
223432992|NCT06715683|DRUG|BMS-986278 Batched method, Dose B|Specified dose on specified days
223432993|NCT06715683|DRUG|BMS-986278 Continuous method|Specified dose on specified days
224043072|NCT07130227|OTHER|Session 3: Group 2, Treatment Evaluation|\*Things to Consider When Using Medication \*Side Effects of Medication \*Exacerbation of Schizophrenia \*Precursor Symptoms.
224043073|NCT07130227|OTHER|Session 4: Group 2, What is anger?|\*What are the symptoms of anger? \*What are the methods for coping with anger?
224043074|NCT07130227|OTHER|Session 5: Group 2, Communication|"\*What is communication? \*The importance of communication. \*Fundamentals of communication, working on I language. \*Ways to prevent communication difficulties."
223565627|NCT02512601|DRUG|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
223565628|NCT02512601|OTHER|Compression therapy|"Compression:~* With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~* With a bandage: 7-10 m long and 10 cm wide.~* Both strategies (orthosis vs bandage) are equally applicable."
223565629|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
223565630|NCT01748526|DRUG|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
223565631|NCT00515294|DRUG|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
223565632|NCT00515294|OTHER|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
223565633|NCT00515294|DRUG|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
224043075|NCT07130227|OTHER|Session 6: Group 2, What is relaxation?|What is progressive relaxation? Introducing a relaxation CD
224043076|NCT07130227|OTHER|Session 7: Group 2, Relaxation|Practicing the relaxation CD with patients
224043077|NCT07130227|OTHER|Session 8: Group 2, Evaluation|\*Reinforcing what has been learned. \*Evaluating the program. \*Obtaining feedback
223432994|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
223432995|NCT05585125|DRUG|Beta blocker|"The intervention is a two-arm crossover withdrawal/reversal design (On \[A\] vs Off \[B\]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), participants will be on their home beta-blocker (or highest tolerable) dose. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued (or the lowest tolerable dose).~Participants will be randomized into either ABAB or BABA sequences.~Other names:~acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol, penbutolol, pindolol, propranolol, sotalol"
223432996|NCT01789580|OTHER|Gambling moderator|
223432997|NCT06592755|PROCEDURE|single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection|The included patients chose to undergo single-incision, gasless endoscopic total thyroidectomy with central compartment neck dissection via the subclavian approach based on patients preference.
224043078|NCT07129291|COMBINATION_PRODUCT|Experimental: Dual-Language Dysarthria Self-Assessment and Management Software (D-SAMS)|D-SAMS is a bilingual (Urdu and English) digital tool designed for adult dysarthria patients. It enables users to assess their speech through interactive tasks (e.g., repetition, reading, and pronunciation exercises), receive feedback, and track progress over time. The software includes audio-visual prompts, self-rating scales, and progress charts, and is tailored to accommodate varying levels of dysarthria severity. It supports independent practice and helps speech-language pathologists monitor patients remotely
224299694|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
223432998|NCT06592755|PROCEDURE|conventional open surgery|These patients chose to undergo total thyroidectomy with central compartment neck dissection via conventional open surgery based on patients preference.
224043079|NCT07130994|DEVICE|Mitral Valve Replacement|Implant of SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation
224043080|NCT07129889|DRUG|gradual withdrawal of medication|The dose was reduced by one day each month, ultimately reducing atropine treatment from seven days per week to complete withdrawal within six months, with a six-month follow-up.
224043081|NCT07129889|PROCEDURE|Auricular acupressure|First, treat the ear acupoint on one side, then leave the tape in place for 5 days. On the 6th day, remove the tape, rest for 2 days, and on the 8th day, apply new tape to the other side of the ear. Changing the tape aims to minimize adverse event (AE) that may result from prolonged stimulation on one side. Additionally, participants will be instructed to self-administer vertical pressure on the Wangbuluxing seeds 15-20 times to achieve sensation, with a duration of 4-5 times daily. The treatment process will last for 18 months, with a follow-up at 6 months.
224043082|NCT07129889|PROCEDURE|Sham auricular acupressure|Acupuncturists will use a gradual reduction method with 0.01% atropine eye drops, as used in the control group, and apply skin-colored adhesive tape without Wang Bu Liu Xing seeds to the ear acupoints. During treatment, no massage or acupoint pressure will be applied. The SAA group will follow the same protocol as the AA group for compensatory AA treatment at the end of the study.
224043083|NCT07129629|DRUG|Bedaquiline (B)|Bedaquiline tablets administered orally. Dosing: 400 mg once daily for the first 2 weeks, then 200 mg three times per week for weeks 3-17. Used in both experimental arms (BZMD and BZMH groups) as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
224043084|NCT07129629|DRUG|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally once daily before or after meals throughout the entire treatment period (17 weeks). Used in both experimental arms (BZMD and BZMH groups) as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
224043085|NCT07129629|DRUG|Pyrazinamide (PZA)|Pyrazinamide tablets administered orally once daily in the morning during intensive phase (8 weeks). Dosing by weight: 1000 mg for 40.0-49.9 kg, 1500 mg for 50.0-70.9 kg, 2000 mg for ≥75.0 kg. Used in both experimental arms (BZMD and BZMH groups) and control group as part of tuberculosis treatment regimen.
224043086|NCT07129629|DRUG|Delamanid (D)|Delamanid tablets administered orally at 100 mg twice daily (total daily dose 200 mg) throughout the entire treatment period (17 weeks). Used only in the BZMD experimental arm as part of the 4-month short-course regimen for drug-susceptible tuberculosis treatment.
224043087|NCT07129629|DRUG|Isoniazid (H)|Isoniazid tablets administered orally at 300 mg once daily in the morning throughout the entire treatment period. Used in the BZMH experimental arm (17 weeks) and in the standard control group (26 weeks) as part of tuberculosis treatment regimens.
224043088|NCT07129629|DRUG|Rifampicin (R)|Rifampicin tablets administered orally once daily in the morning throughout the entire treatment period (26 weeks). Dosing by weight: 450 mg for 40.0-49.9 kg, 600 mg for 50.0-70.9 kg and ≥75.0 kg. Used only in the standard control group as part of the 6-month standard tuberculosis treatment regimen.
224043089|NCT07129629|DRUG|Ethambutol (E)|Ethambutol tablets administered orally during the intensive phase (8 weeks). Dosing by weight: 750 mg for 40.0-49.9 kg, 1000 mg for 50.0-70.9 kg and ≥75.0 kg. Used only in the standard control group as part of the 6-month standard tuberculosis treatment regimen.
224043090|NCT07128862|OTHER|Heavy-Load Resistance Training with Blood Flow Restriction|"Blood Flow Restriction (BFR) Training (also known as Kaatsu training is an innovative and increasingly popular exercise technique to improve muscle strength and hypertrophy with relatively low loads. Heavy Load Resistance Training (HL-RT) is one of the most effective exercise methodology that is widely used to increase muscular strength and hypertrophy."
224043091|NCT07128862|OTHER|Heavy-Load Resistance Training Only|Heavy Load Resistance Training (HL-RT) is one of the most effective exercise methodology that is widely used to increase muscular strength and hypertrophy.
223432999|NCT02611128|OTHER|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
223433000|NCT00362713|DRUG|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
224043092|NCT07130214|DRUG|Biodentine|Biodentine is used in the treatment of existing dentin damage thanks to active bio-silicate technology.
224043093|NCT07130123|PROCEDURE|Suctionning extubation|We will remove the intubation tube with endotracheal suctioning during the extubation procedure and maintain positive end expiratory pressure (PEEP) and pressure support. The PEEP level will be 10 cmH2O and the pressure support 7 cmH2O for 2 minutes prior to extubation. The vacuum level will be the maximum level (standard procedure in the unit), i.e. 450 mmHg. The closed-system suction probe is inserted up to the last mark corresponding to 40cm. The size of our closed system is identical for all patients, i.e. 14 french.
224043094|NCT07130123|PROCEDURE|No suctionning Extubation|In the control group, removal of the intubation tube during the extubation procedure is performed with PEEP maintained, without endotracheal suctioning. The PEEP level will be set at 10 cmH2O and the pressure at 7 cmH2O in the 2 minutes prior to extubation.
224043095|NCT07131046|PROCEDURE|Combination of superficial cervical plexus block and supraorbital block|The combined anaesthesia technique involves the use of general anaesthesia and regional block in the superficial cervical plexus and supraorbital areas, with 6 ml of 0.25% bupivacaine injected into the superficial cervical plexus area and 2 ml into the supraorbital area.
224043096|NCT07131046|PROCEDURE|Scalp block with bupivacaine alone|A combination anaesthesia technique is used that involves general anaesthesia and scalp block. Scalp block using 0.25% bupivacaine in the supraorbital area (2 ml), supratrochlear (2 ml), zygomaticotemporal (2 ml), auriculotemporal (2 ml), major occipital (2 ml) and minor occipital (2 ml).
223433001|NCT04064021|PROCEDURE|Acupunture|Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
224043097|NCT07129746|DEVICE|Metallic clip ligation of the appendicular stump|The group A patients will be having the appendicular stump ligated using the metallic clip, and assessed in terms of length of surgery and associated intra operative complications.
223433002|NCT05428202|DRUG|GN037|GN-037 cream containing urea, salicylic acid, retinoic acid and clobetasol 17-propionate and matching placebo
224043098|NCT07129746|DEVICE|Suture ligation of appendicular stump|The appendicular stump in the second arm will be ligated using appropriate suture material and assessed in terms of length of surgery and rate of intraoperative complications.
224043099|NCT07130188|DIAGNOSTIC_TEST|PCI|Coronary angiography then SYNTAX score calculation
223433003|NCT05428202|DRUG|Placebo|Placebo cream containing base without active ingredients
223433004|NCT03061656|DRUG|Cyclophosphamide|1st HDCT
223433005|NCT03061656|DRUG|Carboplatin|1st HDCT
223565634|NCT00515294|OTHER|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
223565635|NCT02609230|DRUG|ONC-201|
223565636|NCT01331382|DIETARY_SUPPLEMENT|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
223565637|NCT01331382|OTHER|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
223565638|NCT00776672|DRUG|Fosinopril 40mg Tablets|
224043100|NCT06053255|DEVICE|High-intensity focused ultrasound for Sacroiliitis using the Neurolyser XR|HIFU is delivered via a non-invasive ultrasonic transducer, through a gel pad for acoustic coupling, into the patients body in a precise manner focused on the lateral sacral branch nerves.
224043101|NCT02423551|OTHER|MRE|MRE consumption
223433006|NCT03061656|DRUG|Etoposide|1st HDCT
223433007|NCT03061656|RADIATION|131I-MIBG|2nd HDCT
223433008|NCT03061656|DRUG|Thiotepa|2nd HDCT
223565639|NCT03335072|DRUG|Azithromycin|Mass Drug Administration
223433009|NCT03061656|DRUG|Melphalan|2nd HDCT
224043102|NCT03292289|PROCEDURE|Pre- and post-operative consultation|Before and between the two interventions
224043103|NCT03292289|PROCEDURE|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
224043104|NCT03292289|PROCEDURE|Questionnaires|"* QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~* Stoma-QoL before and after the 2nd intervention~* LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
223433010|NCT02250482|BIOLOGICAL|Optivate® (Human Coagulation Factor VIII)|
223433011|NCT00057304|DRUG|RO 205-2349|
223433012|NCT00301496|DEVICE|Coban 2 Layer Compression System|
223433013|NCT02012790|OTHER|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
223433014|NCT04404920|OTHER|Questionnaire|"Novel questionnaire about oral symptoms (Oral symptom assessment scale / OSAS), and validated questionnaire about physical and psychological symptoms (Memorial Symptom Assessment Scale / MSAS)."
223433015|NCT02923362|PROCEDURE|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
223565640|NCT01858142|BEHAVIORAL|Parental presence decision tool|
223565641|NCT01858142|BEHAVIORAL|Standard preparation|
223565642|NCT01647243|OTHER|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
223565643|NCT02471560|DRUG|dimethyl fumarate|As per the prevailing local label.
223565644|NCT02471560|DRUG|injectable MS DMT|As described above.
223565645|NCT01829633|PROCEDURE|Physiotherapy|Shoulder physiotherapy with exercises
223565646|NCT06489184|DRUG|Zanubrutinib|patients with treatment naive or R/R CLL who treatment with Zanubrutinib
223433016|NCT02923362|DEVICE|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
223433017|NCT00097955|DRUG|aliskiren|
223433018|NCT03324516|PROCEDURE|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
223433019|NCT03324516|PROCEDURE|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
223433020|NCT00710684|DRUG|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
223433021|NCT00710684|DRUG|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
223433022|NCT00710684|DRUG|Placebo|Placebo added to existing donepezil
223433023|NCT00710684|DRUG|donepezil 5-10mg|existing donepezil treatment
223433024|NCT04778059|DRUG|USB002|USB002 is pharmaceutically formulated Angiotensin 1-7 \[A(1-7)\], a non-hypertensive derivative of Angiotensin-II (A-II), and is suspended in a vehicle as a sterile solution of USB002. Depending upon cohort assignment, subjects in the USB002 group will receive one of four doses of USB002 administered intravenously (IV).
223433025|NCT04778059|DRUG|Placebo|The placebo formulation will be the USB002 formulated solution without the addition of A(1-7). The placebo will be administered intravenously (IV).
223433026|NCT05659862|BEHAVIORAL|Digitally assisted behavioral physical activity intervention|"Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward"
223433027|NCT05659862|BEHAVIORAL|Education|"Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website."
223433028|NCT01553240|DEVICE|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
223433029|NCT01665846|DRUG|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
223433030|NCT06648343|OTHER|Intensive cognitive and physical training|The cognitive and physical training program consists of 25-35 minutes of cognitive training (memory, attention, visuospatial orientation) and 10-15 minutes of physical training (stretching, strength training, coordination, and aerobic exercise). Additionally, participants will be instructed to perform 30-40 minutes of aerobic exercise 3-4 times per week
223433031|NCT01623973|OTHER|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
224043105|NCT02047539|DRUG|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
224043106|NCT02047539|DRUG|Placebo|
223433032|NCT00656487|DRUG|rimonabant|double blind, placebo controlled, single 90 mg dose
223433033|NCT00656487|DRUG|placebo|matched placebo
224043107|NCT04313153|DRUG|Vadadustat|oral tablets
224043108|NCT04313153|DRUG|Darbepoetin alfa|intravenous or subcutaneous solution
223433034|NCT03439540|DIETARY_SUPPLEMENT|Plantago major|Individuals receive Plantago major daily, for 12 weeks
223433035|NCT03439540|DIETARY_SUPPLEMENT|Placebo|Individuals receive placebo daily, for 12 weeks
223433036|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
223433037|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
223433038|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
223433039|NCT00157248|DRUG|dabigatran etexilate|dosage used at study start
223433040|NCT01518231|PROCEDURE|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
223433041|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
223433042|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
223433043|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
223433044|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt.
223433045|NCT01518231|DRUG|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
223433046|NCT01518231|DRUG|Warfarin|warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
223433047|NCT01518231|DRUG|Atorvastatin|atorvastatin 20mg,qd,po
224043109|NCT06830525|COMBINATION_PRODUCT|ACDP® and growth hormone treatment|A cohort of 40 families of children undergoing growth hormone treatment using a connected injector devices that quantifies treatment adherence will be recruited via the ACDP®, to capture additional data that combine Patient Reported Outcomes and Adherence Data.
224043110|NCT06424470|BIOLOGICAL|Stapokibart|Stapokibart Injection
223433048|NCT01518231|DRUG|Edaravone|edaravone 30mg,bid,ivgtt
224043111|NCT06424470|OTHER|Placebo|Placebo
224043112|NCT06212635|DIAGNOSTIC_TEST|T-TAS|Blood test, laboratory assays
224043113|NCT06379425|DRUG|Acetaminophen|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
224043114|NCT06379425|DRUG|Celecoxib|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
224043115|NCT06379425|DRUG|Gabapentin|Will add additional medications celecoxib and gabapentin to acetaminophen preoperatively prior to patient surgery
224043116|NCT02944253|OTHER|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates
224043117|NCT02944253|OTHER|Low energy diet 100 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women
224043118|NCT02944253|OTHER|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates
224043119|NCT03404089|DEVICE|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
224043120|NCT03404089|DEVICE|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
223433049|NCT00731757|DRUG|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
224043121|NCT04139044|PROCEDURE|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
223433050|NCT03702114|DEVICE|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
223433051|NCT02209805|DRUG|BIRB 796 BS, low dose|
223433052|NCT02209805|DRUG|BIRB 796 BS, high dose|
223433053|NCT02209805|DRUG|Placebo|
224043122|NCT04139044|PROCEDURE|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
223433054|NCT05985473|OTHER|audiological measurements|audiological measurements
223433055|NCT05985473|OTHER|Objective and subjective audiological measurements|Objective and subjective audiological measurements
223433056|NCT05985473|OTHER|Evaluation of the denoising methods REFINED|Evaluation of the denoising methods REFINED
223433057|NCT07088666|DRUG|MicroRepair ABX mouthwash|"At baseline (T0), participants receive clinical assessments, oral hygiene instruction, and begin a 14-day home regimen with MicroRepair® ABX mouthwash, which contains zinc-hydroxyapatite microcrystals and antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). The mouthwash is used twice daily (10 mL for 30 seconds) after toothbrushing, without rinsing, and participants avoid food or drink for 1 hour. All participants use a sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.~At 1 month (T1), participants undergo professional supragingival prophylaxis following the Guided Biofilm Therapy (GBT) protocol, which includes plaque disclosure, ultrasonic debridement with an EMS Piezon piezoelectric device, and air-polishing with glycine powder.~At 3 months (T2) and 6 months (T3), additional GBT sessions and a repeated 14-day mouthwash cycle are performed only if the Full-Mouth Bleeding Score (FMBS) remains greater than 10%."
223433058|NCT07088666|DRUG|Chlorhexidine 0.2% mouthwash|"At baseline (T0), participants undergo clinical and photographic assessments, receive oral hygiene instruction, and begin a 14-day home regimen with 0.2% chlorhexidine digluconate mouthwash, used twice daily (10 mL for 30 seconds) after toothbrushing. The solution is not rinsed away, and participants avoid food or drink for 1 hour. All participants use a standardized sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®).~At 1 month (T1), participants receive professional supragingival prophylaxis following the Guided Biofilm Therapy (GBT) protocol, which includes plaque disclosure, piezoelectric ultrasonic scaling with an EMS Piezon device, and air-polishing with glycine powder.~At 3 months (T2) and 6 months (T3), additional GBT sessions and repetition of the 14-day home regimen are performed only if the Full-Mouth Bleeding Score (FMBS) remains greater than 10%."
223433059|NCT01243502|DRUG|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
223433060|NCT01243502|DRUG|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
223433061|NCT01254851|BEHAVIORAL|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
223565647|NCT01179217|DRUG|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
223565648|NCT01179217|DRUG|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
223565649|NCT05295784|DRUG|Caffeine citrate|A single dose of intravenous caffeine citrate will be administered to neonates with hypoxic ischemic encephalopathy to determine the pharmacokinetics and tolerability.
224043123|NCT00332839|DRUG|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
224043124|NCT00332839|DRUG|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
224043125|NCT00332839|DRUG|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
224043126|NCT00332839|DRUG|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
224043127|NCT00332839|DRUG|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
224043128|NCT03202823|PROCEDURE|blood samples|3 tubes (5 ml volume) collected during surgery
224043129|NCT03202823|PROCEDURE|recover samples of atheromatous plaque|a carotid sample collected during surgery
224043130|NCT05099094|GENETIC|BD311|Integration-deficient lentiviral vector (IDLV) expressing VEGFA antibody
223433062|NCT01306045|DRUG|AZD6244|Cycle = 21 days AZD6244 Hydrogen Sulfate 75 mg by mouth (PO) every (Q) 12 Hours
224043131|NCT04977102|PROCEDURE|Intraocular caliper-assisted capsulotomy|Intraocular caliper is a modified intraocular caliper with standard calibration on the rinse needle.
224140748|NCT05979714|BEHAVIORAL|Patient-centered adherence support|A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
224140749|NCT05979714|OTHER|Provider education|To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
223433063|NCT01306045|DRUG|MK-2206|Cycle = 28 days MK-2206 200 mg by mouth (PO) every (Q) Week
223433064|NCT01306045|DRUG|Lapatinib|Cycle = 21 days Lapatinib 1500 mg by mouth (PO) every day (QD)
224140750|NCT05979714|BEHAVIORAL|Improved clinic communication strategies|For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
224140751|NCT04291924|DIAGNOSTIC_TEST|Dynamometry|A test for maximal muscle strength and explosive power in the lower limbs
223433065|NCT01306045|DRUG|Erlotinib|Cycle = 21 days Erlotinib 150 mg by mouth (PO) every morning (QAM)
223433066|NCT01306045|DRUG|Sunitinib|Cycle = 42 days Sunitinib 50 mg by mouth (PO) on days 1-28
224140752|NCT02223429|DRUG|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
224140753|NCT02223429|DRUG|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
224140754|NCT02223429|DRUG|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
224140755|NCT03978104|DIETARY_SUPPLEMENT|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
224140756|NCT03978104|DIETARY_SUPPLEMENT|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
224140757|NCT03978104|DIETARY_SUPPLEMENT|Control biscuits|Consumption of control biscuits together with habitual diet.
223433067|NCT01306045|PROCEDURE|Molecular Profiling|Molecular profiling of tumor tissue. Not Otherwise Specified (NOS) arm. Participants who do not meet the eligibility criteria for enrollment or who meet eligibility criteria for a particular arm but can't be enrolled
223565650|NCT03585036|DRUG|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
224043132|NCT04977102|PROCEDURE|Verion navigation system-assisted capsulotomy|Verion Image Guided System (Alcon Laboratories, Inc.) is a digital image guidance system consisting of a diagnostic reference unit and a surgery pilot for intraoperative surgical assistance. The device can be used to align toric intraocular lens during surgery as well as support manual creation of a capsulorhexis with a predefined target diameter.
223433068|NCT03944733|DIETARY_SUPPLEMENT|Iron|65 mg of iron (ferrous sulfate)
223433069|NCT03944733|DIETARY_SUPPLEMENT|Gelatin|600 mg gelatin
223433070|NCT04948554|BIOLOGICAL|MK-2225|Administered Subcutaneously (SC)
223433071|NCT04948554|BIOLOGICAL|Placebo|Administered SC
223433072|NCT05930834|BEHAVIORAL|exercise|All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
223433073|NCT06043479|OTHER|Fever Management Education|The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.
223433074|NCT02381938|BEHAVIORAL|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
223433075|NCT02381938|OTHER|Healthy Finances|6-month intervention to educate and improve financial health
223433076|NCT05669898|BEHAVIORAL|Pain scores (numerical rating scale at rest and motion): will be assessed with numerical rating scale at both rest and motion on both knees.|Pain scores will be assessed with numerical rating scale at both rest and motion on both knees.
223433077|NCT05669898|OTHER|Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale|For the functional assessment both before and after TKA surgery.
224043133|NCT00176345|BEHAVIORAL|Exercise Training|
224043134|NCT01109329|BIOLOGICAL|HMPV challenge virus|Single dose of 10\^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
224140758|NCT00884221|DRUG|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
224140759|NCT00884221|DRUG|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
223433078|NCT05669898|BEHAVIORAL|Rehabilitation physiotherapy|Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of both knees.
223433079|NCT00416676|DRUG|carboplatin|
223433080|NCT00416676|DRUG|cisplatin|
223433081|NCT00416676|DRUG|cyclophosphamide|
223433082|NCT00416676|DRUG|etoposide|
223433083|NCT00416676|DRUG|vincristine sulfate|
223433084|NCT00416676|PROCEDURE|adjuvant therapy|
224140760|NCT02517853|DEVICE|Posterior tibial nerve stimulation|
224140761|NCT02517853|DEVICE|Sham posterior tibial nerve stimulation|
224140762|NCT00978679|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
223433085|NCT00416676|PROCEDURE|conventional surgery|
223433086|NCT00416676|PROCEDURE|neoadjuvant therapy|
223433087|NCT00416676|RADIATION|radiation therapy|
223433088|NCT03293082|DEVICE|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
223433089|NCT03293082|DEVICE|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
223433090|NCT03031574|DRUG|SUVN-D4010|Tablets
223433091|NCT05479591|DRUG|IDegLira|Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
223433092|NCT04919876|DIETARY_SUPPLEMENT|fruit/vegetable supplement (FVS)|The supplement contains polyphenols, carotenoids, and other phytochemicals present in plant foods.
223433093|NCT04919876|DIETARY_SUPPLEMENT|Placebo|The product does not contain nutrients present in the FVS.
223433094|NCT03424629|BIOLOGICAL|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
223433095|NCT03424629|BIOLOGICAL|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
223433096|NCT03424629|DRUG|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
223433097|NCT04231396|OTHER|Audiobooks for hearing loss App|Same as Arm 1
223433098|NCT00382395|DEVICE|SOLX Gold Shunt GMS-plus|Single use implant
223433099|NCT00382395|DEVICE|Ahmed FP7 Glaucoma Valve|Single use implant
223433100|NCT00787917|DRUG|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
223433101|NCT00787917|DRUG|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
223433102|NCT00787917|DRUG|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
223433103|NCT00077116|DRUG|busulfan|
223433104|NCT00077116|DRUG|cyclophosphamide|
223433105|NCT00077116|DRUG|cytarabine|
223433106|NCT00077116|DRUG|gemtuzumab ozogamicin|
223433107|NCT00077116|DRUG|idarubicin|
223433108|NCT00077116|PROCEDURE|allogeneic bone marrow transplantation|
223433109|NCT00077116|PROCEDURE|peripheral blood stem cell transplantation|
223433110|NCT00077116|RADIATION|radiation therapy|
223433111|NCT01113138|DIETARY_SUPPLEMENT|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
223433112|NCT01113138|DRUG|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
223433113|NCT01230684|PROCEDURE|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
223433114|NCT06907992|DRUG|Antifungal treatment|Short-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)
223433115|NCT02672358|DRUG|Dabrafenib|Oral Dabrafenib 150 mg BID
223433116|NCT02672358|DRUG|Trametinib|Oral Trametinib 2 mg QD
223433117|NCT05631106|BEHAVIORAL|High Intensity Interval Resistance Training|During each group exercise session, the participants will be guided through a 5-minute warm-up, supervised to perform two sets of machine-based leg press, chest press, seated row, and shoulder press exercises at 30% of 1-RM, and guided through a cool-down. Each exercise set will be 40 -seconds in length with instructions to perform as many repetitions as possible followed by a 20-second rest in between sets and a three-minute rest between exercises.
223433118|NCT05631106|BEHAVIORAL|Stretching, Balance, and Range of motion|The stretching, balance, and range of motion intervention will include a rotating and varied routine of stretching exercises for large and small muscle groups, and activities to improve balance and range of motion. Participants will attend this intervention twice a week with each session lasting 30 minutes.
224140763|NCT00978679|DEVICE|Spectacles|Daily use of single vision lenses to correct refractive errors
224140764|NCT04318379|BIOLOGICAL|HCVax|HCVax is a lentiviral vector encoding several HCV antigens
224140765|NCT02472015|PROCEDURE|telemedicine|psycho-behavioural care by telemedicine
223433119|NCT05421052|OTHER|Unmet health needs|The students who have unmet health needs during the last 6 months will respond to the questionnaire to assess the causes and other factors
223433120|NCT05329051|BIOLOGICAL|SCTV01E|intramuscular injection
223433121|NCT05329051|BIOLOGICAL|Comirnaty|intramuscular injection
224043135|NCT04450563|DRUG|14-day outpatient intervention|The patient will be on the closed-loop insulin system and the intervention drug (placebo, empagliflozin 2.5 mg, or empagliflozin 5 mg) for 14 days. Insulin reductions will be made to avoid hypoglycemia with the drug agent. Remote contact around Day 4 (+/- 2 days) will be made to optimize insulin settings. The last 10 days will be used to assess continuous glucose monitoring data during each intervention. A wash-out period of 7 - 21 days will separate each intervention.
223433122|NCT01485445|DRUG|Fluticasone Furoate (200mcg unit strength)|inhalation powder
223433123|NCT01485445|DRUG|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
223433124|NCT04588727|DRUG|AZD3366|In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
223433125|NCT04588727|DRUG|Placebo|In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
223433126|NCT04588727|DRUG|Ticagrelor|In Part B, subjects will receive oral ticagrelor tablets.
223433127|NCT04588727|DRUG|acetylsalicylic acid (ASA)|In Part B, subjects will receive oral ASA chewable tablets.
223433128|NCT00778102|DRUG|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
223433129|NCT00778102|DRUG|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
223433130|NCT00778102|DRUG|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
223433131|NCT00778102|DRUG|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
223433132|NCT00778102|DRUG|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
223433133|NCT00778102|DRUG|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
223433134|NCT00778102|DRUG|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
223433135|NCT00778102|DRUG|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
223433136|NCT06912386|DEVICE|taVNS|"Intervention Name: Transauricular Vagus Nerve Stimulation (taVNS)~Intervention Description:~Participants will receive transauricular vagus nerve stimulation on the tragus. Frequency: 2 sessions per day (one at 10 AM and one at 6 PM). Duration: Each session will last 15 minutes. Treatment Cycle: Stimulation will be applied for 5 days each month, starting 2 days before the expected beginning of the menstrual cycle, for a total of 2 months. The participants will adjust the level of maximum stimulation they considered painless."
223433137|NCT06912386|DEVICE|SHAM stimulation|"Intervention Name: SHAM stimulation of the earlobe. Participants will receive SHAM stimulation on the earlobe, which does not stimulate the vagus nerve.~Frequency: 2 sessions per day (one at 10 AM and one at 6 PM). Duration: Each session will last 15 minutes. Treatment Cycle: Placebo stimulation will be applied for 5 days each month, starting 2 days before the expected beginning of the menstrual cycle, for a total of 2 months. The participants will adjust the level of maximum stimulation they considered painless."
223433138|NCT06912321|OTHER|No Intervention: Observational Cohort|No intervention：all participants did not receive any intervention measures throughout the study
223433139|NCT06911645|OTHER|Immediate access to customized version of GPT-4|Group is given immediate access to a customized version of GPT-4 to support their diagnostic reasoning for each case.
223433140|NCT06911645|OTHER|Access to customized version of GPT-4 following use of conventional resources|Group is first encouraged to reason through diagnostic cases with the support of conventional resources. After they submit a case's answers they are then given access to a customized version of GPT-4 and have the opportunity to change their initial answers.
223433141|NCT06911151|DEVICE|innovative footwear|HDC shoe
223433142|NCT06905834|DRUG|Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC|Subconjunctival injection is a widely used technique in ophthalmology due to its effectiveness, minimal invasiveness, and ease of administration. In a subconjunctival injection the cells adult adipose tissue-derived mesenchimal cells are delivered into the subconjunctival space, the area between the conjunctiva and sclera.
223433143|NCT03244670|OTHER|Observation study only, no specific intervention|Observation study only, no specific intervention
223433144|NCT03185806|DEVICE|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
224043136|NCT01999569|DRUG|Letrozole|Letrozole administered daily through the time of ovulation.
224043137|NCT01851278|DRUG|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
224140766|NCT04172701|DRUG|Long-acting Muscarinic Antagonists (LAMA)|drug
223433145|NCT03946878|DRUG|Acalabrutinib|Given PO
223433146|NCT03946878|DRUG|Venetoclax|Given PO
223433147|NCT00992628|DEVICE|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
223433148|NCT00992628|DEVICE|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
223433149|NCT05778032|OTHER|Multidisciplinary metabolic rehabilitation program|Multidisciplinary metabolic rehabilitation program with a duration of 3 weeks
223433150|NCT05368415|DRUG|Norepinephrine|mothers will received NE bolus of 3,4 or 5 mcg for management of hypotension according to group allocation
223433151|NCT06912568|DEVICE|Miniscrew insertion|four or two miniscrews insertions using computer-guided minimally-invasive and flapless approach
223433152|NCT06912568|DEVICE|Expander|In the TB group, the tooth-borne hyrax appliance was designed with bands on the maxillary first molars; in the BB4 group, the bone-borne expander was supported by 4 miniscrews inserted both in paramedian and parapalatal position of the palatal vault; in the BB2 group, the bone-borne expander was supported by 2 miniscrews inserted in the paramedian region of the palate. The same type of expansion screw and expansion protocol were used in all groups. Specifically, a 10mm hyrax click screw (Dentaurum, Bologna, Italy) was activated by 4 quarter-turns on the first day and by 3 quarter-turns per day during the active phase of treatment (0.20mm per turn, 0.6mm daily) until an 8mm screw opening was achieved.
224043138|NCT01851278|DRUG|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
224043139|NCT04063241|OTHER|Health Literacy-Informed Discharge Instructions|Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
224043140|NCT04063241|OTHER|Provider Training|20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
224043141|NCT00105404|DRUG|Triamcinolone Acetonide|
224043142|NCT00774280|DRUG|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
224043143|NCT05327374|DIAGNOSTIC_TEST|calculation of the inferior vena cava collapsibility index|the ΔIVC was calculated by the emergency physician who was blinded from the patient's medical history using the formula ((IVCmax-IVCmin)/IVCmax) X100.A cutoff of 15% was used to define the presence(\<15%) or absence(\>15%) of heart failure
224043144|NCT04662398|DEVICE|JT Device|Shocker giving electrical shocks on testes
224043145|NCT00900354|GENETIC|molecular genetic technique|
224043146|NCT00900354|OTHER|mass spectrometry|
224043147|NCT00900354|OTHER|pharmacological study|
224043148|NCT04641299|DRUG|AZD8233|PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
224043149|NCT04641299|DRUG|Placebo|Placebo solution
224043150|NCT02154360|DRUG|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
224140767|NCT04172701|DRUG|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
224140768|NCT06048653|OTHER|A computer based cognitive rehabilitation program (Rehacom system)|"Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction~* Patients will receive training for four weeks, two sessions per week.~* Each patient will assume a comfortable sitting position on a chair in front of the screen.~* A report will be generated at the end of the session. It will be used for follow up.~* Session duration will range from 45 to 60 min. including rest period."
223433153|NCT06912568|RADIATION|CBCT|"All patients underwent CBCT examinations before the application of the RME device (T0) and post-treatment, after the 6-month retention period (T1). The exposure settings were as follows: 10 mA, 90 kV, total scanning time of 15.0 seconds, effective radiation time of 4.0 seconds, voxel size of 0.2 mm, scanning area of 14 x 16.5 cm, and an effective radiation dose of approximately 524 mGy/cm2.~The CBCT images analyzed in this study were not acquired specifically for this research but were part of an ongoing prospective randomized clinical trial aimed at evaluating the skeletal and dentoalveolar effects of three different orthodontic devices. The imaging protocol was established in accordance with ethical guidelines and was approved by the relevant institutional review board."
223433154|NCT06910410|BEHAVIORAL|BodyScreen App|The BodyScreen App uses behavioural interventions along with haptic interruptions in social media app usage. The app will engage participants by sending them notifications, reminders, and activities to complete throughout the day and the week.
224043151|NCT05963789|OTHER|Cervical proprioceptive training|Cervical proprioceptive training: The laser pointer will fixed on the highest point of the subject head with a band, patients sit upright on a chair and kept their head at the neutral position, while setting the laser light at the point on the wall in front of them. From this position, patients will be asked to flex, extend and rotate their head and then return to the neutral position. This training commenced with open eyes and then progress with closed eyes, tracing a pattern and standing position.
224140769|NCT06048653|DEVICE|Vagus nerve stimulation|stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.
224140770|NCT03437317|BEHAVIORAL|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
224140771|NCT03437317|BEHAVIORAL|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
224299695|NCT06241859|DEVICE|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)|Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
224299696|NCT03102593|DRUG|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
224299697|NCT03102593|OTHER|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
224043152|NCT05963789|OTHER|Traditional exercises|Stretching posterior shoulder capsule Strengthening scapular muscles Shoulder stabilization PNF
224043153|NCT04807699|OTHER|Data collection|Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
224043154|NCT04672564|DRUG|Carrimycin|Carrimycin (400 mg) will be given once-daily for 14 days (2 x 200 mg tablets) after a meal, if a patient experiences an eating problem, carrimycin will be taken without food.
224043155|NCT04672564|DRUG|Placebo|Placebo will be given once-daily for 14 days (2 tablets) after a meal, if a patient experiences an eating problem, placebo will be taken without food.
224043156|NCT04650282|COMBINATION_PRODUCT|Lidocaine in SphenoCath device|Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.
224043157|NCT04650282|COMBINATION_PRODUCT|Saline Solution in SphenoCath device|Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
224043158|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4|Testmeal with free FeSO4
224043159|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
224043160|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
224043161|NCT03332602|DIETARY_SUPPLEMENT|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
224043162|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
224043163|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
224043164|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
224043165|NCT03332602|DIETARY_SUPPLEMENT|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
224140772|NCT02079051|BEHAVIORAL|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
224043166|NCT03332602|DIETARY_SUPPLEMENT|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
224043167|NCT06472154|OTHER|Experimental|The experimental group intervened based on the midnight-noon ebb-flow theory, listening to music corresponding to the five organs at different time periods.
224043168|NCT06472154|OTHER|Control|The control group listened to Chinese five elements music pieces from 13:00 to 18:00 p.m., each music piece for within 30 minutes for, 5 days per week, 4 weeks for a cycle, 3 cycles in total.
224140773|NCT02079051|BEHAVIORAL|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
224140774|NCT00453856|DRUG|Sulfadoxine Pyrimethamine|
224140775|NCT00360048|DRUG|oxytocin|
224140776|NCT02627833|OTHER|observation|Record lung function, Lung clearance index, inflammatory status
223433155|NCT00800306|DRUG|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
224043169|NCT00494728|BEHAVIORAL|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
224043170|NCT00494728|DRUG|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
224043171|NCT00494728|BEHAVIORAL|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
224043172|NCT05142800|DEVICE|Perometer|The perometer uses light sensors to calculate the length and volume of your arms
224043173|NCT05142800|DEVICE|SOZO device|The machine measures the amount of fluid on the arm(s)
224043174|NCT03040440|DEVICE|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated
224140777|NCT04077229|BEHAVIORAL|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
224140778|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
224140779|NCT01975246|DRUG|hydrochlorothiazide|tablet
224140780|NCT01975246|DRUG|Telmisartan + amlodipine|FDC tablet
224140781|NCT01975246|DRUG|Placebo|placebo matching hydrochlorothiazide tablet
224140782|NCT01263093|DRUG|Clopidogrel|
224140783|NCT01263093|DRUG|LY2216684|
224140784|NCT02571608|DRUG|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
224299698|NCT01940497|DRUG|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
223433156|NCT00800306|DRUG|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
224043175|NCT03040440|DEVICE|TaperGaurd endotracheal tube|TaperGaurd endotracheal tube was intubated
224043176|NCT04701177|DIAGNOSTIC_TEST|AltoidaML|Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
224043177|NCT00126633|BIOLOGICAL|bevacizumab|
224043178|NCT00126633|DRUG|cisplatin|
224043179|NCT00126633|DRUG|gemcitabine hydrochloride|
224043180|NCT04198506|OTHER|Tailored tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.
224043181|NCT04198506|OTHER|Conventional tacrolimus dosing|Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).
224043182|NCT01016964|DEVICE|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
224043183|NCT01016964|DEVICE|Sham Device|Sham Device
224043184|NCT01920594|DRUG|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
224043185|NCT01920594|DRUG|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
224043186|NCT06281769|DIAGNOSTIC_TEST|3D multi-parametric ultrasound targeted biopsy pathway using PcaVision|The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.
224140785|NCT02571608|DRUG|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
224299699|NCT01940497|DRUG|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
224299700|NCT01940497|DRUG|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
224299701|NCT01940497|DRUG|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
224299702|NCT02707861|DRUG|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
224299703|NCT02707861|DRUG|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
224299704|NCT00166153|DRUG|Mycophenolate Mofetil|
224299705|NCT04622397|DRUG|Tranexamic acid injection|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
224140786|NCT00424346|DRUG|Canakinumab|
224043187|NCT06281769|DIAGNOSTIC_TEST|MRI targeted biopsy pathway|MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).
224043188|NCT00516620|BEHAVIORAL|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
224043189|NCT00516620|BEHAVIORAL|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
224140787|NCT00424346|DRUG|Placebo|
224140788|NCT03508544|PROCEDURE|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
224299706|NCT04622397|DRUG|Saline|Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision
224299707|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1\) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Low-pressure pneumoperitoneum (8-9 mmHg)~2. Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~3. PONV prophylaxis in patients of risk~Postoperative care~1. Early mobilization (2 h after surgery)~2. Early fluid intake (2 h after surgery)~3. Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
223433157|NCT05481229|OTHER|nutritional interventions|Nutritional intervention will be initiated in patients at risk of overweight and obesity. A targeted nutritional intervention will be carried out, which will include consultation on dietary habits and physical activity as determined by diet and physical activity records. Consultations will be aimed at improving lifestyle and maintaining an adequate body weight.
223433158|NCT00282906|DEVICE|hybrid PET-CT imaging system|15 mCi of FDG
223433159|NCT05191589|OTHER|Haptic|Trainees are randomized in this group to use the haptic device.
224043190|NCT00516620|BEHAVIORAL|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
223433160|NCT06909916|OTHER|Periprosthetic Fracture Knee Repaired CT Scans|The investigators will be assessing the use of weight-bearing CT and conventional CT, specifically its imaging, with RSA-like software, for analyzing fracture healing for a periprosthetic distal knee fracture.
223433161|NCT06912490|OTHER|Amniotic Fluid Proteomic Analysis Using Capillary Electrophoresis-Mass Spectrometry (CE-MS)|This intervention consists of analyzing the amniotic fluid proteome using capillary electrophoresis coupled with mass spectrometry (CE-MS). The goal is to evaluate a predefined 98-peptide signature that predicts postnatal kidney function in fetuses with bilateral congenital anomalies of the kidney and urinary tract. Unlike standard prenatal assessments based on ultrasound and fetal biochemistry, this method provides a molecular-based prognostic tool to improve decision-making regarding pregnancy management and neonatal care
223433162|NCT01328548|DRUG|Zostavax|
223433163|NCT06910345|OTHER|A skin patch (2.1 mg melatonin) was applied to the melatonin group. The melatonin patches will be placed at 8:00 PM (on the upper chest or forearm, as determined by the patient) before going to sleep|A skin patch (2.1 mg melatonin) was applied to the melatonin group.
223433164|NCT06910735|OTHER|Control|Participants will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center
223433165|NCT06910735|BEHAVIORAL|Threshold financial incentive|Participants will receive the standard care with an additional financial incentive of 300 € if they successfully achieve the weight loss target corresponding to their weight at 12 months after bariatric surgery. This financial incentive will be awarded 12 months after their inclusion in the study.
223433166|NCT06910735|BEHAVIORAL|Proportional financial incentive|Participants will receive the standard care with an additional financial incentive, which will be determined based on the proportion of their actual weight loss in relation to the predefined weight loss target corresponding to their weight at 12 months after bariatric surgery. The financial incentive can be up to 300 € if the weight loss target is achieved 12 months after their inclusion in the study.
224140789|NCT03508544|PROCEDURE|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
224043191|NCT00516620|BEHAVIORAL|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
224140790|NCT03508544|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
224140791|NCT04464577|DRUG|Fluconazole|Specified Dose on Specified Days
224140792|NCT04464577|DRUG|Bupropion|Specified Dose on Specified Days
224140793|NCT04464577|DRUG|Itraconazole|Specified Dose on Specified Days
224140794|NCT04464577|DRUG|BMS-986235|Specified Dose on Specified Days
223433167|NCT05963451|OTHER|No intervention|No intervention will be given in our study since, the investigators are recruiting people who will receive already a facet thermal ablation.
223433168|NCT06329882|DRUG|Sitagliptin 100mg|Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
223433169|NCT06329882|DRUG|Doxycyclin|Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
224043192|NCT00516620|BEHAVIORAL|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
224043193|NCT00516620|BEHAVIORAL|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
223433170|NCT05919992|DRUG|Metyrapone 250 mg Oral Tablets|During one phase of the study: Metyrapone (pills of 250mg) on empty stomach: Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
223433171|NCT05919992|DRUG|Hydrocortisone 19.9mg s.c., pulsatile with a flow rate of 10μl/s|Hydrocortisone will be delivered subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7 in a total daily dose of 19.9mg
223433172|NCT05919992|DRUG|Placebo 250 mg Tablets|During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-3-3 day 4 3-4-4 day 5 4-4-4 day 6 4-4-4 day 7 4-0-0
224043194|NCT00516620|BEHAVIORAL|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
223433173|NCT05919992|DRUG|Placebo (0,9% NaCl solution)|Placebo (0,9% NaCl solution) 19.9 mg/d subcutaneously via a pump in a pulsed fashion with a flow rate of 10μl/s from day 1 to day 7
223433174|NCT06910085|BEHAVIORAL|kettlebell-training|15 min of body weight or kettlebell loaded strength training
223433175|NCT06911593|DIAGNOSTIC_TEST|Doppler ultrasonography|The delay time was determined as the time difference between the onset of the Doppler waveform and the R-wave on the electrocardiogram(ECG) of the USG device. The distance between the carotid and femoral arteries, where imaging was performed, was then measured. This distance was divided by the delay time to calculate the carotid-femoral pulse wave velocity(PWV) in meters per second, which was considered a measure of arterial stiffness.
223433176|NCT05766618|PROCEDURE|Injectable platelet rich fibrin (i-PRF): in acceleration of orthodontic tooth movement|"Preparatory phase~* Space closure will be done on a 17x25 stainless steel wire~* Both molars will be indirectly anchored to the miniscrew~* Extend closing coil spring of suitable length from the canine hock to the first molar hock for retraction.~* Apply a force of 150gm for each side. The force is measured by a force gauge and activated each visit to keep it constant all over the retraction phase. PRF Injection protocol~* The First injection will be 3 weeks before extraction~* By the end of the fourth week the patients will be referred for pre-intervention records. Upper arch CBCT will be obtained to take preintervention measurements of the alveolar bone.~* At the time of canine retraction patient will receive another injection immediately and an alginate impression will be taken~* follow up every month and injection will be repeated month after month with an observational period of 5 months."
223433177|NCT05890690|DIAGNOSTIC_TEST|Urea|"Diagnostic test with a single weight-adapted dose of oral urea dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The investigators will make use of the lemon-lime flavor to soften the bitter taste of urea.~\- Dose calculation: 0.5 g urea/kg body weight (rounded to no decimal places), with a minimal dose of 30g and a maximal dose of 45g."
223433178|NCT05890690|DIAGNOSTIC_TEST|Placebo|"Diagnostic test with a single weight-adapted dose of placebo dissolved in 200 ml water together with 5 g of lemon-lime flavor powder (containing maltodextrin and citric acid).~The placebo will contain a mixture of bitter herbal substances to mimic the taste of urea.~\- Dose calculation: 22 ml of placebo containing 20 ml Ergytonyl®, 1 ml Carmol®, and 1 ml Bitter Liebe®."
223433179|NCT04852796|OTHER|Patients with hemopathy|optimal humoral response at 1 month after COVID-19 vaccination
223565651|NCT03585036|DRUG|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
223565652|NCT03585036|DRUG|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
223565653|NCT02112474|DEVICE|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
223565654|NCT02112474|DEVICE|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
223565655|NCT02112474|DEVICE|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
223565656|NCT01644006|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
223565657|NCT00520702|PROCEDURE|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
224043195|NCT00516620|BEHAVIORAL|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
224043196|NCT00235820|DRUG|adalimumab|40 mg every other week following an 80 mg dose
224043197|NCT00235820|DRUG|MTX|MTX 7.5 to 25 mg once weekly
224043198|NCT00235820|DRUG|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
223565658|NCT00520702|PROCEDURE|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
223565659|NCT01849575|BEHAVIORAL|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2-4 weeks a follow-up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
223565660|NCT00178919|DRUG|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
224043199|NCT00880035|DEVICE|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
224043200|NCT05571046|DRUG|Glucocorticoids|Intramuscular injection of single dose of 1 ml betamethasone, Paracetamol (500 mg, 2 times a day)
224043201|NCT05571046|OTHER|Placebo|Intramuscular injection of %0.9 isotonic sodium chloride, Paracetamol (500 mg, 2 times a day)
224043202|NCT00016263|BIOLOGICAL|oblimersen sodium|
224043203|NCT00016263|DRUG|dacarbazine|
224043204|NCT04570111|OTHER|MOD Diet|The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day
224043205|NCT04570111|OTHER|Standard Care Diet|The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
223565661|NCT00178919|DRUG|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
224043206|NCT03707509|DRUG|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
224043207|NCT03707509|DRUG|Placebos|Maximum 6 cycles for combined therapy.
224140795|NCT02653313|DRUG|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
224140796|NCT00571519|DRUG|Rivoglitazone HCl|0.5 mg tablets administered orally, once daily
224140797|NCT00571519|DRUG|rivoglitazone HCl|1.0 mg tablets administered orally, once daily
224140798|NCT00571519|DRUG|rivoglitazone HCl|1.5 mg tablets administered orally, once daily
224140799|NCT00571519|DRUG|placebo|placebo tablets matching rivoglitazone tablets administered orally, once daily
223565662|NCT05397041|DRUG|BMB-101|Participants will receive one of several different oral doses of BMB-101 once or twice daily
224043208|NCT03707509|DRUG|Gemcitabine|Maximum 6 cycles for combined therapy.
224043209|NCT03707509|DRUG|Cisplatin|Maximum 6 cycles for combined therapy.
224299708|NCT03754751|PROCEDURE|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1\) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~1. Standard CO2 pressure (12-14 mmHg)~2. No additional anesthesia~Postoperative care~1. Mobilization in 4-6 h after surgery~2. Fluid intake in 6 hours~3. Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
224299709|NCT00034983|DRUG|aprepitant|
224299710|NCT00034983|DRUG|Comparator: paroxetine HCL|
223565663|NCT05397041|DRUG|Placebo|Matched Placebo
223565664|NCT03943550|DRUG|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
223565665|NCT03943550|DRUG|Placebo|Matching placebo will be administered SC.
223565666|NCT03359785|DRUG|Luvadaxistat|TAK-831 Tablets.
223565667|NCT03359785|DRUG|Matching Placebo|Matching Placebo Tablets.
224140800|NCT00571519|DRUG|pioglitazone HCl|15 mg capsules administered orally, once daily
224140801|NCT00571519|DRUG|pioglitazone HCl|30 mg capsules administered orally, once daily
224140802|NCT00571519|DRUG|pioglitazone HCl 45 mg|45 mg capsules administered orally, once daily
224140803|NCT00571519|DRUG|placebo|placebo capsules for pioglitazone administered orally, once daily
224140804|NCT00571519|DRUG|metformin|Oral tablets. Rescue medication.
224140805|NCT01924962|DEVICE|revascularisation|revascularisation of chronic occluded coronary artery
224140806|NCT03771690|BEHAVIORAL|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
224140807|NCT01343355|DRUG|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
224299711|NCT03123861|DRUG|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
223565668|NCT01887613|DRUG|Regnite|oral
223565669|NCT01713673|DRUG|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
223565670|NCT01713673|DRUG|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
223565671|NCT04077996|DEVICE|Peritonitis treatment placed in APD|Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
224140808|NCT05959304|OTHER|brolucizumab|There is no treatment allocation. Treatment with brolucizumab 6 mg intravitreal injection will be based on the local label/clinical practice.
224140809|NCT06376929|OTHER|oral carbohydrate containing fluid|administration of oral carbohydrate fluid and assessment of intraoperative blood glucose level and postoperative nausea and vomiting
224140810|NCT04595357|PROCEDURE|Iris shelf technique|Removal of posterior segment intraocular foreign bodies through corneal incision combined with phaco-vitrectomy
224140811|NCT04740060|OTHER|Augmented Feedback without Virtual Reality(VR|"For Walking Speed:One-minute fast walking with visual augmented feedback without VR interface (we ask participants to look at a screen where their walking speed and distance are tracked and increase their speed).~For Step Length: Maximum step length with visual augmented feedback without VR interface in which we ask participants to look at a screen where their step length is displayed and attempt to increase their step length up."
224140812|NCT04740060|OTHER|Augmented Feedback with Non-Game based VR|"For Walking Speed:One-minute fast walking with basic VR interface (we ask participants to look at a screen where their avatar walker representative will be represented in a virtual walking environment and try to make the avatar walk faster).~For Step Length: Maximum step length with basic VR interface in which we ask participants to look at their avatar feet in a virtual stepping environment and step with the avatar foot as far as possible."
224299712|NCT03123861|DRUG|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
224299713|NCT04554797|OTHER|Regional Hypothermia|Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
224299714|NCT01586403|BIOLOGICAL|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
223433180|NCT05903053|BEHAVIORAL|Early Self-Regulation Intervention|"Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total)."
224043210|NCT03272568|DRUG|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
224043211|NCT03272568|DRUG|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
223433181|NCT03655223|DIAGNOSTIC_TEST|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
223433182|NCT04641260|DRUG|Fezolinetant|Oral
223433183|NCT01896947|DIAGNOSTIC_TEST|MRI|evaluating to see if 3T MRI is as effective as MR arthrogram to diagnose labral pathology
223565672|NCT04077996|DEVICE|Peritonitis treatment with one exchange in CAPD|Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
223565673|NCT01777217|DRUG|Solifenacin succinate|IGRT with VESIcare
224043212|NCT03272568|DEVICE|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
224043213|NCT04398511|DRUG|L brevis|Lactobacillus brevis CD2 lozenges (4 billion CFU) after breakfast, lunch and dinner for 21 days.
224043214|NCT04398511|DRUG|Placebo|Placebo lozenges after breakfast, lunch and dinner for 21 days.
224043215|NCT00442065|DEVICE|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
224043216|NCT00928564|DRUG|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
224043217|NCT00928564|DRUG|Placebo|5ml of saline at each block site.
224043218|NCT04946903|DRUG|RLD2007|Take it once per period.
224043219|NCT04946903|DRUG|RLD2008|Take it once per period.
224043220|NCT04946903|DRUG|HCP1902|Take it once per period.
224043221|NCT06225635|DRUG|Ezerosu(monolayer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
224043222|NCT06225635|DRUG|Ezerosu(double layer tablet)|Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
224043223|NCT03203421|BIOLOGICAL|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
224043224|NCT03203421|BIOLOGICAL|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
224043225|NCT02206165|DRUG|Candesartan 8mg|Once a day, 8 weeks
223565674|NCT01777217|DRUG|Placebo|IGRT with placebo
224043226|NCT02206165|DRUG|Candesartan 16mg|Once a day, 8 weeks
224043227|NCT02206165|DRUG|Amlodipine 5mg|Once a day, 8 weeks
224043228|NCT02206165|DRUG|Amlodipine 10mg|Once a day, 8 weeks
223565675|NCT05071872|DEVICE|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
223565676|NCT03824678|DRUG|CC-220|CC-220
224043229|NCT01569165|PROCEDURE|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
224043230|NCT04218955|COMBINATION_PRODUCT|Silver Diamine Flouride|Material used to arrest caries in children
224140813|NCT04740060|OTHER|Augmented Feedback with Game based VR|"For Walking Speed: One-minute fast walking with the VR Racing exergame (we ask participants to look at a screen where their avatar walker representative present in a virtual racing environment with other avatar racers and try to beat the avatar racers).~For Step Length: Maximum step length with the VR Stepping Exergame (we ask participants to look at their avatar legs and avatar animals in a virtual stepping environment and try to step over the avatar animals without touching the animal."
224140814|NCT01902537|DRUG|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
224043231|NCT01244243|DEVICE|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
224043232|NCT01332565|DRUG|GSK1349572|50mg tablet
224043233|NCT05370066|DEVICE|CS6BP watches will be used in the study.|CS6BP watches will be used with FDA approved Blood pressure monitors
224043234|NCT04094896|DRUG|TCHP|Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
224043235|NCT02039726|DRUG|Quizartinib|20 or 30 mg quizartinib tablets administered orally once daily
224043236|NCT02039726|DRUG|Salvage Chemotherapy|Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
224140815|NCT02401802|DIETARY_SUPPLEMENT|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
224140816|NCT02401802|DIETARY_SUPPLEMENT|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
224140817|NCT05193851|DRUG|ricolinostat|"This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period."
224140818|NCT01603979|BIOLOGICAL|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
224140819|NCT06398093|BEHAVIORAL|Self-Compassion Tool Kit|Participants will mediate, journal their reactions, exercise, and apply sleep hygiene measures over the course of four weeks.
224140820|NCT06136455|DRUG|Listerine Clinical Solutions Teeth Strength|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Clinical Solutions Teeth Strength mouthwash.
224140821|NCT06136455|DRUG|Listerine Total Care Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
224140822|NCT06136455|OTHER|Listerine Cool Mint Zero Alcohol Mouthwash|After brushing for 1 timed minute, participants will rinse full strength for 30 seconds with Listerine Cool Mint Zero mouthwash.
224140823|NCT06136455|DRUG|Colgate Cavity Protection Toothpaste|Participants will brush for 1 timed minute with Colgate Cavity Protection toothpaste.
224140824|NCT03672669|GENETIC|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
224140825|NCT03672669|GENETIC|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
224140826|NCT02499575|DRUG|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
223565677|NCT01532284|OTHER|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
224140827|NCT02499575|DRUG|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
223565678|NCT04031664|DRUG|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
223565679|NCT01945411|DEVICE|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
224140828|NCT06347965|BEHAVIORAL|Low load blood flow restriction training|Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.
224140829|NCT06347965|BEHAVIORAL|Progressive resistance training group|The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
224140830|NCT02658968|DRUG|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
224140831|NCT05118711|DIAGNOSTIC_TEST|Cardiorespiratory fitness|Cardiopulmonary exercise testing
224140832|NCT05118711|DIAGNOSTIC_TEST|Lung function|Body plethysmography
224140833|NCT05118711|DIAGNOSTIC_TEST|Muscular strength and balance tests|Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
224043237|NCT04100629|BEHAVIORAL|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
224043238|NCT00288977|PROCEDURE|Islet Infusion|
224043239|NCT03336255|BEHAVIORAL|South Asian Healthy Lifestyle Initiative (SAHELI)|Culturally tailored lifestyle intervention for South Asians.
224043240|NCT02460497|DRUG|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
224043241|NCT02598609|BEHAVIORAL|Education program for NICU caregivers|"* standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries"
224043242|NCT01504256|DRUG|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
224043243|NCT01504256|DRUG|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
224043244|NCT03679156|DEVICE|OCT|Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
224043245|NCT00643669|DRUG|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
224043246|NCT00003108|DRUG|bryostatin 1|
224043247|NCT00003108|DRUG|cisplatin|
224043248|NCT05047783|DRUG|Masitinib Mesylate|3CL-protease inhibitor
224043249|NCT05047783|DRUG|Placebo|Placebo
224043250|NCT01891097|PROCEDURE|Acupuncture plus auricular acupuncture|"Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours."
224043251|NCT01891097|PROCEDURE|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
224043252|NCT05905510|DRUG|Lumbar Erector spinae plane block (L-ESPB)|The fourth lumbar vertebral level will be determined using the conventional method (the imaginary line between two crista iliacas). The convex transducer will be placed at the mid-vertebral line in the sagittal plane. The transducer will be shifted from the midline, 3.5-4 cm laterally, to the side of the surgery to visualize the erector spinae muscle and transverse process. Using the out-of-plane technique, a 22G/80-mm block needle will be advanced until it reached the transverse process. 0.5-1 ml of the prepared local anesthesia solution (30 ml bupivacaine 0.25%) will be administered, leading to hydro dissection to confirm the correct location. The needle will be repositioned by pulling back a few millimeters if resistance occurred when administering local anesthesia. All local anesthesia will be administered to this location between the transverse process and the erector spinae muscle
224043253|NCT05905510|DRUG|Fascia iliaca compartment block (FICB)|The transducer will be placed laterally to the femoral nerve. It then rotated 90 degrees to the sagittal plane, under ultrasound guidance, a regional block needle (22 G, 80 mm) will be introduced in the cranial direction. Once good needle alignment with the ultrasound beam is achieved, the needle will be inserted deep into the tissues until an optimal position of the needle tip is obtained. Needle location will be additionally verified by injecting 0.5-1 ml of the prepared local anesthesia solution and observing the solution spread within the tissues. Once the correct position of the needle tip is confirmed, the local anesthetic will be deposited under the iliac fascia to force its flow towards the lumbar plexus. 30 ml of bupivacaine 0.25% solution will be used for the block. local anesthesia will be administered as 5 mL boluses with a 20 second interval.
224043254|NCT05905510|DRUG|spinal anesthesia plane block|Patients will receive spinal anesthesia alone
224043255|NCT04013516|BEHAVIORAL|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
224043256|NCT04013516|BEHAVIORAL|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
224043257|NCT03274609|COMBINATION_PRODUCT|Augmented fluoroscopy|Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
224043258|NCT01419353|DRUG|estradiol valerate|2 mg P.O / day for 1-6 days.
224043259|NCT02992886|RADIATION|Preoperative radiation|Radiation treatment before surgery
224043260|NCT02992886|DRUG|Raltitrexed|concurrent chemotherapy
224043261|NCT02992886|PROCEDURE|Pelvic surgery|
224043262|NCT03846739|DRUG|Oxytocin nasal spray|Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
224043263|NCT03846739|DRUG|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
224043264|NCT01556035|DRUG|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
224043265|NCT02393677|DRUG|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
224140834|NCT05118711|DIAGNOSTIC_TEST|Micro- and macrovascular endothelial function and cardiac function|Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
224043266|NCT02393677|DRUG|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
223565680|NCT01945411|DEVICE|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
224043267|NCT02607553|DRUG|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
224043268|NCT05196581|DRUG|Dispersible NaCl powder 10 sessions|Dispersible NaCl powder 10 sessions
224043269|NCT05196581|DRUG|Dispersible NaCl powder 5 sessions|Dispersible NaCl powder 5 sessions
224043270|NCT02838082|BEHAVIORAL|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
224043271|NCT02838082|BEHAVIORAL|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
224043272|NCT00813319|BEHAVIORAL|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
224043273|NCT00752531|BEHAVIORAL|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
224043274|NCT02012296|DRUG|enzalutamide|Given PO
224043275|NCT02012296|DRUG|mifepristone|Given PO
224043276|NCT02012296|OTHER|laboratory biomarker analysis|Correlative studies
224043277|NCT02012296|OTHER|pharmacological study|Correlative studies
224043278|NCT01448213|DRUG|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
224043279|NCT01448213|DRUG|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
224043280|NCT05146362|OTHER|Vermont RETAIN|RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and a control group that is not.
224140835|NCT05118711|DIAGNOSTIC_TEST|Blood sampling and analysis|Blood sampling by venepuncture
224140836|NCT05118711|DIAGNOSTIC_TEST|Physical activity|Physical activity surveillance using accelerometers
224043281|NCT01916863|DRUG|LX4211 400 mg|
224140837|NCT05118711|DIAGNOSTIC_TEST|Questionnaires|Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
224140838|NCT05118711|DIAGNOSTIC_TEST|Body composition|Dual-energy x-ray absorptiometry (DXA)
224140839|NCT00384826|DRUG|erlotinib|Erlotinib 150 mg/day (until progression)
223565681|NCT00518648|OTHER|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
223565682|NCT00518648|OTHER|Usual care|Usual care
224140840|NCT00384826|DRUG|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
224140841|NCT00574119|DRUG|spironolactone|spironolactone 50 mg daily for 6 months
224140842|NCT01546844|OTHER|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
224140843|NCT01621724|GENETIC|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
224140844|NCT02860754|OTHER|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
224140845|NCT04084132|PROCEDURE|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
224140846|NCT00972842|DRUG|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
224140847|NCT03292952|DRUG|KP415 oral capsule|Daily dose
224140848|NCT03292952|DRUG|Placebo oral capsule|Daily dose
223565683|NCT02559323|OTHER|Survey|
224043282|NCT01916863|DRUG|canagliflozin 300 mg|
224043283|NCT01916863|DRUG|LX4211 Placebo|
224043284|NCT00919087|DEVICE|Avivo System|Non invasive external monitoring deive
224043285|NCT02485990|DRUG|Tremelimumab|
224043286|NCT02485990|DRUG|Olaparib|
224043287|NCT06318351|PROCEDURE|transcutaneous acupoint electrical stimulation|This is a safe and non-invasive procedure, similar to an electrode sheet, which applies a weak current to a specific site to achieve the purpose of acupoint stimulation.
224043288|NCT05452096|BEHAVIORAL|Education program and ergonomic schedulling|"The duration: six months. The explicit choice for a multimodal intervention to be tested as a whole is in line with the assertion of other experts that workplace interventions using a single approach will not be effective.~Multimodal intervention~1. Implementing healthy scheduling. This will imply fast forward-rotating shift schedules, being adapted to chronotype, allowing for adequate resting times between shifts and series of shifts, allowing for napping at work, in particular during the first two days of an early shift.~2. Education program for drivers: psychoeducation on the sleep-wake cycle chronotypes, based on the cognitive-behavioral treatment of insomnia (CBT-i), information on the impact of light on wakefulness and sleep, information on napping and creating awareness on daytime sleepiness, tools for stress reduction, physical exercise, information on healthy eating in the context of shiftwork The education program will consist of a one-day, 8-hour session."
224043289|NCT04624880|DEVICE|Giant magnetoresistive sensor (GMR)|Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
224043290|NCT02249754|BEHAVIORAL|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
224043291|NCT02249754|BEHAVIORAL|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
224043292|NCT04147026|DEVICE|SinnoTest®|"The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy."
224043293|NCT04147026|OTHER|Biotherapy prescription without SinnoTest® software|The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
224043294|NCT03786978|BEHAVIORAL|Structured pharmaceutical care|Patients receive a structured pharmaceutical care from one year after basal hospital discharge
224043295|NCT03786978|BEHAVIORAL|Comparator|Patient received a single phone call 30 days after basal hospital discharge.
224043296|NCT05320562|PROCEDURE|Kinesio taping|"Additionally, they received kinesio taping application for 7 days. Blue color kinesio tape (manufactured by Theraband®, USA) was used. Kinesio taping was done by experienced physiotherapist with 5 years of experience. Two Y shape bands were applied for lymphatic taping and to improve anterior upper leg muscle function (lymphatic correction and muscle correction techniques were integrated together).~Then two I shape bands (75-100% tension) were applied above the patella tendon and medial/lateral collateral ligaments in order to improve mechanoreceptor stimulation, proprioception and knee stability."
224043297|NCT05320562|PROCEDURE|Sham taping|Additionally, they received sham (placebo) taping: usual white patch was applied to the painful knee for 7 days. The technique of taping used was the same as in kinesiotaping group, but without stretching.
224043298|NCT00141895|DRUG|Misoprostol|2 tablets 200 micrograms Vaginal route
224043299|NCT00141895|DRUG|Misoprostol|2 tablets of 200 micrograms Sublingual route
224043300|NCT04249323|DRUG|CORT113176 Lipid Capsule Formulation|CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
224043301|NCT04249323|DRUG|Placebo matching CORT113176 Lipid Capsule Formulation|Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
224043302|NCT04249323|DRUG|Prednisone|Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
224043303|NCT02917668|OTHER|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
224043304|NCT02917668|OTHER|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of \> or = 95 %
224043305|NCT00220558|DEVICE|Coronary placement of bare metal stent vs. drug eluting stent|
224043306|NCT01326078|DRUG|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
224043307|NCT02611661|DEVICE|PET/MRI|
224043308|NCT02611661|RADIATION|Percutaneous ablation|
224043309|NCT02611661|RADIATION|Stereotactic body radiotherapy|
224043310|NCT03332914|DEVICE|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
224140849|NCT01206452|DRUG|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
224140850|NCT01206452|OTHER|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
224140851|NCT01206452|PROCEDURE|Ablation Procedure|Atrial Fibrillation (AF) ablation
224299715|NCT01586403|BIOLOGICAL|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
223433184|NCT04047134|OTHER|Action Observation Treatrment|Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
223565684|NCT03802305|DEVICE|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
224043311|NCT00613444|DEVICE|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
224043312|NCT01009892|DRUG|Codeine Sulfate|Tablet
224140852|NCT05359406|COMBINATION_PRODUCT|a combination therapy including tislelizumab|"For liver/pulmonary metastasis, the treatment plan is to implement large fraction radiotherapy for 4-8 times. For primary rectum lesion, short-course radiotherapy regimen through intensity-modulated radiotherapy will be applied with dose of 25Gy/5Fx. Immunotherapy contains anti-PD-1 monoclonal antibody, Tislelizumab(200mg, d1, q3w, i.v). For patients with RAS or BRAF mutation, chemotherapy adopts FOLFOX+BEV plan. For patients without RAS or BRAF mutation, chemotherapy adopts FOLFIRI+CET plan.~Patients will be followed for safety during the study. The safety follow-up period is defined as 90 days after the last dose of tislelizumab. Safety related data will be collected from the time of signing the informed consent until the end of the safety follow-up period or the start of new therapy."
224140853|NCT03008733|OTHER|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
224140854|NCT03008733|OTHER|Electro myography surface nerves|Electro myography surface nerves
224140855|NCT01780909|DRUG|Paromomycin Sulfate Fasted State|
224140856|NCT01780909|DRUG|Paromomycin Sulfate Fed State|
224140857|NCT01780909|DRUG|Paromomycin Sulfate w/ domperidone|
224140858|NCT01780909|DRUG|Paromomycin Sulfate w/ loperamide HCl|
224140859|NCT03302897|BIOLOGICAL|LEP-F1 + GLA-SE|Investigational vaccine
224140860|NCT04603040|DRUG|Toripalimab|"Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol."
224140861|NCT03634904|DRUG|Drug bood sampling|"Total: 6 per patient~* after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~* after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~* after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~* after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
224140862|NCT01948895|DRUG|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
224299716|NCT01586403|BIOLOGICAL|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
224043313|NCT02334787|DRUG|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
224043314|NCT02334787|DRUG|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
224043315|NCT02334787|DRUG|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
224140863|NCT05386121|PROCEDURE|Ultrasound-guided Erector Spinae Plane Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane deep to erector spinae muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline and observing the ﬂuid lifting the erector spinae muscle off the transverse process (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the spinous process on a parasagittal plane, to visualize the erector spinae muscle and transverse process, directing the needle craniocaudally using the in-plane technique. The spread of the injectate will be observed to distribute within this plane.
224299717|NCT01586403|BIOLOGICAL|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
224299718|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
224043316|NCT02334787|DRUG|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
223433185|NCT04047134|OTHER|Observation of videos with Non Motor contents|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
223433186|NCT05930795|PROCEDURE|pectopexy|pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament
223433187|NCT05930795|PROCEDURE|lateral suspension|lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
223433188|NCT06667882|DRUG|Alteplase Injectable Product|The 2019 ESC guideline for the diagnosis and management of acute pulmonary embolism (PE) recommended thrombolytic therapy only in high-risk PE cases because of the bleeding risk. The most often used drug for thrombolysis is the rtPA and the recommended dose is 100 mg over two hours. According to the literature, the risk of major haemorrhage is 10-13% and fatal or intracranial bleeding is 1.7-3.6% among patients receiving thrombolysis.
223433189|NCT00774254|BEHAVIORAL|A|Intervention
223433190|NCT00774254|BEHAVIORAL|B|Intervention
223433191|NCT04684758|OTHER|Self-completion of a questionnaire|The questionnaire will be translated into 5 languages (English, Spanish, Portuguese, Arabic, and Russian) in order to allow almost all of the participants to answer the survey themselves, without assistance. In order to not exclude those who cannot read, or those who do not master any of the 6 languages offered, the questionnaire may be administered with the assistance of a member of the research team of the associated center, including through a telephone interpretation service, if necessary.
223433192|NCT04655092|BIOLOGICAL|P1101 (Ropeginterferon alfa-2b)|The subjects who have completed the 52-week treatment duration in Study A19-201 will be treated with P1101, starting at the dose at Week 50. The dose during this study may be increased or decreased up to 500 μg depending on the condition. This study will be continued as a post-marketing clinical study after acquisition of the marketing approval of P1101.
223433193|NCT06085560|BEHAVIORAL|Usual Care Message|Usual care is provided by the FQHC for the screening option chosen.
224043317|NCT03461172|PROCEDURE|Surgery of breast cancer|Surgery of breast cancer
224043318|NCT03461172|OTHER|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
224043319|NCT06337084|DRUG|MNPR-101-DFO*-89Zr|Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans
223433194|NCT06085560|BEHAVIORAL|Implementation Intention Intervention: Standard Message|Implementation Intention Intervention module includes standard messaging in addition to the usual care provided by the FQHC for the screening option chosen.
223433195|NCT06085560|BEHAVIORAL|Implementation Intention Intervention: Culturally-Targeted Message|Implementation Intention Intervention module includes culturally-targeted framing of health information messages in addition to the usual care provided by the FQHC for the screening option chosen.
223433196|NCT04936048|BEHAVIORAL|Music Therapy|Music therapy will use rhythmic cues, music instruments (piano, drums, djembe, xylophone, harmonica), songs, and stories accompanied by songs or musical instruments to target common goals.
223433197|NCT04936048|BEHAVIORAL|Play therapy|Play therapy is designed as a play-based active comparison condition to control for factors such as support, therapist attention, positive expectancies, and emotional engagement. It will use verbal interaction, toys (Lego, finger puppets, Play Doh, puzzles), and the same stories as in MT, but without a musical component, to target common goals.
223433200|NCT05468203|DRUG|Dapagliflozin 10mg Tab|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
223433201|NCT05468203|DRUG|Placebo|Patients will be randomly assigned to receive either dapagliflozin 10 mg or placebo daily while in ICU for up to 30 days
223433202|NCT04917120|DEVICE|Virtual Reality|The procedure will consist of a virtual reality program associated with suggestions of hypnoanalgesia, be added to usual care. Included patients will benefit from the Virtual Reality program combined with hypnoanalgesia suggestions for a period of 20 minutes. We will use a helmet with a built-in screen and an audio headset connected to a control room. Patients will watch an Virtual Reality sequence while listening to narratives designed for the hypnoanalgesia of the present pain.
223433203|NCT04343274|DRUG|Tozuleristide|
223433204|NCT04983862|DRUG|Illuminare-1|Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Dose levels of the agent will be administered starting at 0.25mg/kg, with increases in dose between cohorts of no more than 0.75 mg/kg until a maximum dose of 3.0mg/kg is reached, if needed. At the dose identified to have the acceptable NMR and no associated DLTs, Illuminare-1 will be studied in up to 20 additional patients at this dose to optimize the imaging protocol and provide additional safety data.
223433205|NCT04983862|DEVICE|Karl Storz D-Light C photodynamic diagnostic (PDD)|The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.
223433206|NCT03385109|DEVICE|Surgery|Patients are approached surgically with the Senhance Surgical System
224043320|NCT06337084|DIAGNOSTIC_TEST|PET/CT Diagnostic Imaging|PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.
224043321|NCT06305949|DEVICE|Optimized transcranial Direct Current Stimulation|transcranial Direct Current Stimulation 2mA for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
224299719|NCT01012557|BIOLOGICAL|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
224140864|NCT05386121|PROCEDURE|Ultrasound-guided Quadratus Lumborum Block|Using a 22-gauge 80 mm echogenic needle under ultrasound guidance, 0.5 mL/kg of bupivacaine 0.125% will be injected in the fascial plane between the quadratus lumborum and psoas major muscle after conﬁrming correct needle location by a negative aspiration test then by injecting 0.5-1 ml saline (hydrodissection). The ultrasound probe will be placed 2-3 cm lateral to the L2 spinous process on an axial plane, to visualize the transverse process with psoas major muscle anterior, quadratus lumborum muscle lateral and erector spinae muscle posterior to it. The needle is inserted from the medial side of the probe and advanced laterally using the in-plane technique. The spread of the injectate will be observed to distribute within the target plane.
224140865|NCT05386121|DEVICE|Ultrasound Machine|Sonosite S-Nerve (USA) with a linear multi-frequency 6-13 MHz (hockey stick) transducer
224140866|NCT05386121|DEVICE|Echogenic needle|A 22-gauge 80 mm needle the sonoplex needle manufactured by PAJUNK (USA)
224140867|NCT05386121|DRUG|Fentanyl|Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)
223433207|NCT03961854|DRUG|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
223433208|NCT03961854|DRUG|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
223433209|NCT05673460|DRUG|Nemtabrutinib|Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
223433210|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A1|Suspension for injection. Route of administration: IM injection
223433211|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A2|Suspension for injection. Route of administration: IM injection
223433212|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose A3|Suspension for injection. Route of administration: IM injection
223433213|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B1|Suspension for injection. Route of administration: IM injection
223565685|NCT03802305|DEVICE|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
224043322|NCT06305949|DEVICE|Sham transcranial Direct Current Stimulation|transcranial Direct Current sham Stimulation for 30 min; The anode electrode will be located over the contralesional representation of the motor cortex swallowing area, while the cathode electrode will be positioned on the ipsilesional side
224043323|NCT05560256|OTHER|Diary/Journal|Participants will be given a diary to record their blood glucose measurements, and other pertinent information (diet and activities).
224043324|NCT06248814|DRUG|BMS-986326|Specified dose on specified days
224043325|NCT06248814|OTHER|Placebo|Specified dose on specified days
224043326|NCT03631667|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
224043327|NCT03631667|DRUG|[14C]-benzo[a]pyrene plus phenanthrene|Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
224043328|NCT04674267|OTHER|Phase 2 Intervention - Geriatric Co-Management|"Participants will complete an electronic fitness assessment questionnaire - once completed, they will receive a score of Robust, Pre-Frail or Frail. Those who are Pre-frail or Frail will be randomized to meet with a study geriatrician for geriatric co-management in addition to usual oncology care. All participants will be followed for a duration of 1 year."
224043329|NCT05660369|DRUG|CARv3-TEAM-E T cells|Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
224043330|NCT03323476|OTHER|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
224140868|NCT05386121|DRUG|Pethidine|Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
224140869|NCT04256304|BEHAVIORAL|PHEinAction-Personalized Patient Engagement Plan|The intervention includes two face-to-face sessions, a telephone consultation, and written home-based exercises. The first session aims to promote an awareness of patients with diabetes management, define an action plan to encourage engagement, introduce the patient to follow their strategy for the next four weeks, and encourage them to adopt the instruments with home-based exercises to reach their specified health goals. Two weeks after the first interview session, the researcher will provide telephone consultation to check the patient for their progress and support them to maintain motivation. The second session will include collecting patient's experiences and discussing the home-based exercises, re-determining the patient health engagement phase through the PHE-s®, discussing the personalized care goals by providing feedback aiming to support improvements, and setting a new engagement goal with the current status and encouraging the patient to maintain the health engagement plan.
224140870|NCT00438789|DRUG|eculizumab|600mg IV every week and 900mg IV every 2 weeks
224140871|NCT01353144|DRUG|aspirin|aspirin, 100 mg, qd x 8 weeks
223433214|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B2|Suspension for injection. Route of administration: IM injection
223433215|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose B3|Suspension for injection. Route of administration: IM injection
223433216|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C1|Suspension for injection. Route of administration: IM injection
223433217|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C2|Suspension for injection. Route of administration: IM injection
223433218|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose C3|Suspension for injection. Route of administration: IM injection
223433219|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 1|Suspension for injection. Route of administration: IM injection
223433220|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 2|Suspension for injection. Route of administration: IM injection
223433221|NCT06583031|BIOLOGICAL|RSV/hMPV vaccine dose 3|Suspension for injection. Route of administration: IM injection
223565686|NCT04674111|DEVICE|Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)|The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
224043331|NCT03323476|DRUG|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
223433222|NCT06583031|BIOLOGICAL|Monovalent RSV Vaccine|Suspension for injection. Route of administration: IM injection
223433223|NCT05128773|DRUG|Amcenestrant|tablet, oral
223433224|NCT05128773|DRUG|Tamoxifen|tablet, oral
223433225|NCT05128773|DRUG|Amcenestrant-matching placebo|tablet, oral
223433226|NCT05128773|DRUG|Tamoxifen-matching placebo|tablet, oral
224043332|NCT03568448|OTHER|Response monitoring (no intervention)|Response monitoring (no intervention)
224043333|NCT00427232|DRUG|BQ-123 and BQ-788|
224043334|NCT04683978|OTHER|Position|Neck extension
224043335|NCT00884325|DRUG|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
224043336|NCT00884325|DRUG|placebo|One tablet taken orally at night for 28 days
224043337|NCT04236648|PROCEDURE|Minimally-invasive non-surgical therapy (MINST)|subgingival root debridement with a minimally-invasive approach using piezoelectric/ultrasonic instruments
224043338|NCT02398448|DRUG|Zyloprim® 300 mg|
224043339|NCT02398448|DRUG|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
224043340|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
224043341|NCT02398448|DRUG|Allopurinol 300 mg; alternative condition 3|
224043342|NCT04699175|DRUG|HR021618|Treatment group A:HR021618; high dose
224043343|NCT04699175|DRUG|HR021618|Treatment group B:HR021618; low dose
224043344|NCT04699175|DRUG|Placebo|Treatment group C: HR021618 blank preparation.
224043345|NCT05679466|BIOLOGICAL|randomized, double-blinded, placebo-controlled|Approximately 3300 participants will be enrolled, including an immunogenic subgroup of approximately 240. Approximately 10% to 15% of all subjects will be 60 years of age and older. Enrolled subjects will be stratified by age (18-59 years, 60 years and older), number of previous doses of COVID-19 vaccine (2 or 3 doses), and interval from the last previous dose (180-365 days, 366-540 days). Participants will be randomized in a 1:1 ratio to receive 1 dose of the ReCOV or placebo on Day 0.
224043346|NCT03173066|DRUG|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
223433227|NCT04023331|DRUG|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
223433228|NCT04023331|DRUG|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
223433229|NCT06961760|DRUG|zervimesine|Zervimesine (CT1812) was shown to be safe and well tolerated in a study of healthy volunteers and in Phases 1 and 2 studies of participants with mild to moderate AD and DLB. This is an open label expanded access program designed to provide access to CT1812 and to evaluate the long-term safety of CT1812 administered once daily for 12 months in adults aged 50 to 86 who have been diagnosed with mild to moderate DLB (the targeted clinical indication for CT1812). Participants will receive 100 mg of CT1812 once daily for 360 days.
223433230|NCT05941442|DRUG|Darigabat|Oral tablets
223433231|NCT05941442|DRUG|Placebo|Oral tablets
223433232|NCT04250714|DEVICE|Boston Scientific Cardiac Cryoablation System|cryoablation of atrial fibrillation consisting in electrical isolation of the pulmonary veins
223433233|NCT06115824|DRUG|Orelabrutinib|Combination of orelabrutinib on a methotrexate-based chemotherapy regimen with a starting dose of 150 mg/d
223433234|NCT05738798|DIETARY_SUPPLEMENT|oral immunotherapy|oral immunotherapy is performed by freely available, widely used food products, regularly part of a normal infant's diet such as peanut butter or boiled egg.
223433235|NCT06254326|BIOLOGICAL|TTRNA-DC vaccines with GM-CSF|Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment
223433236|NCT06254326|BIOLOGICAL|Autologous Hematopoietic Stem cells (HSCs)|Participants will receive a single infusion of autologous CD34+ HSCs
223433237|NCT06254326|BIOLOGICAL|TTRNA-xALT|Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells
224043347|NCT05046574|OTHER|Stroke rehabilitative therapy sessions with therapy dog present|Therapy dog will be present during stroke rehabilitative therapy sessions. This is expected to be at least three times a week per 7-day period.
224043348|NCT04613856|OTHER|Hydration protocol - 237 mL water bolus|Subjects consume 237 mL of water every 20 minutes during 2 hours of high intensity work in the heat.
224043349|NCT04613856|OTHER|Hydration protocol - 500 mL water bolus|Subjects consume 500 mL of water every 40 minutes during 2 hours of high intensity work in the heat.
224043350|NCT03890991|BEHAVIORAL|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
224043351|NCT03890991|BEHAVIORAL|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
224043352|NCT03890991|BEHAVIORAL|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
224043353|NCT04640844|BIOLOGICAL|blood sample|measuring the expression and function of lymphocyte A2A receptors.
224299720|NCT01012557|BIOLOGICAL|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
224299721|NCT01012557|BIOLOGICAL|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
224043354|NCT01580865|DRUG|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients \> 50 Kg and Estimated Glomerular Filtration rate (eGFR) \> 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
223433238|NCT06254326|DRUG|Td vaccine|All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
223433239|NCT05996003|DRUG|NS-089/NCNP-02|"Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1"
223433240|NCT04048655|DRUG|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
223433241|NCT04676412|BIOLOGICAL|Pembrolizumab|IV infusion
223433242|NCT04676412|DRUG|Lenvatinib|oral capsule
224043355|NCT04055181|DEVICE|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
223433243|NCT04676412|DRUG|Placebo for lenvatinib|oral capsule
223433244|NCT04697056|DRUG|Imsidolimab|Humanized Monoclonal Antibody
224043356|NCT04055181|DEVICE|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
223433245|NCT04697056|BIOLOGICAL|placebo|placebo
223433246|NCT06459180|BIOLOGICAL|Sacituzumab Tirumotecan|IV infusion
223433247|NCT06459180|DRUG|Pemetrexed|IV infusion
223433248|NCT06459180|BIOLOGICAL|Tisotumab Vedotin|IV infusion
223433249|NCT06459180|DRUG|Topotecan|IV infusion
224043357|NCT04055181|DEVICE|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
224043358|NCT04055181|DEVICE|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
224043359|NCT04127825|PROCEDURE|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
224043360|NCT00892177|BIOLOGICAL|bevacizumab|Given intravenously
224043361|NCT00892177|DRUG|dasatinib|Given orally
224043362|NCT00892177|OTHER|placebo|Given orally
224043363|NCT02321826|BEHAVIORAL|Music|Participants choice among 4 genres of music matched on music characteristics
224043364|NCT02321826|BEHAVIORAL|Audiobook|Participants choice among 4 types of audiobooks
224043365|NCT04290299|OTHER|Data collection|Cancer (response, relapse) and fertility (pregnancy, delivery) outcomes
224043366|NCT00050765|DRUG|MyoCell™ Autologous Myoblasts|
224299722|NCT04186598|DEVICE|CPAP mask system|Intervention group will receive 15cm of H2O of positive end expiratory pressure
224299723|NCT04186598|DRUG|Nifedipine 30 MG|All participants will receive this intervention
223433250|NCT06459180|DRUG|Vinorelbine|IV infusion
223433251|NCT06459180|DRUG|Gemcitabine|IV infusion
223433252|NCT06459180|DRUG|Irinotecan|IV infusion
223433253|NCT05686330|DEVICE|Apple Watch|Smartwatch for detecting atrial fibrillation using photoplethysmography (PPG)
223433254|NCT06802094|OTHER|Single-session balance intervention in virtual reality|Single-session balance intervention (30 minutes) in a virtual reality environment, the Gait Real-time analysis Interactive Lab (GRAIL) or the Computer Assisted Rehabilitation Environment (CAREN) in children with and without Developmental Coordination Disorder (Motek Medical, The Netherlands).
223433255|NCT00646945|DRUG|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
223433256|NCT00646945|DRUG|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
223433257|NCT06103864|DRUG|Dato-DXd|Provided in 100mg vials. IV infusion. Experimental drug.
223433258|NCT06103864|DRUG|Durvalumab|Provided in 500mg vials. IV infusion. Experimental drug.
223433259|NCT06103864|DRUG|Paclitaxel|IV infusion. Active comparator.
223433260|NCT06103864|DRUG|Nab-paclitaxel|IV infusion. Active comparator.
223433261|NCT06103864|DRUG|Gemcitabine|IV infusion. Active comparator.
223433262|NCT06103864|DRUG|Carboplatin|IV infusion. Active comparator.
223433263|NCT06103864|DRUG|Pembrolizumab|IV infusion. Active comparator.
223433264|NCT05234983|BEHAVIORAL|LifeFirst SWASTH brief advice intervention|This intervention will support tobacco cessation among patients of high-reach, low-resource community healthcare settings in Mumbai (TB clinics, dental practices, and NGO-run health centers). The intervention will also use technology to build the capacity of practitioners in these settings to use evidence-based practices in their work and allow them to network and exchange best practices with one another.
223433265|NCT04242147|DRUG|KD033 (SAR445710)|Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
223433266|NCT05745714|DRUG|Ruxolitinib|oral
223433267|NCT05745714|DRUG|Venetoclax|oral
223433268|NCT05745714|DRUG|Dexamethasone|oral/intravenous
223433269|NCT05745714|DRUG|Cyclophosphamide|intravenous
223433270|NCT05745714|DRUG|Cytarabine|intravenous
224043367|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
224043368|NCT03587701|DRUG|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
224043369|NCT03587701|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
224043370|NCT03587701|DRUG|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
224043371|NCT04114188|DRUG|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA \< 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
224140872|NCT01615796|DRUG|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
224140873|NCT01615796|DRUG|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
224140874|NCT02905942|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
224140875|NCT02905942|DRUG|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
224043372|NCT02734823|OTHER|Cytology Specimen Collection Procedure|Undergo collection of serum
224043373|NCT02734823|OTHER|Laboratory Biomarker Analysis|Correlative studies
224140876|NCT03114878|OTHER|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
224140877|NCT03114878|BEHAVIORAL|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
224299724|NCT04186598|DEVICE|CPAP mask system without PEEP|Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
224299725|NCT03504995|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
224299726|NCT02527928|OTHER|None intervention|
224043374|NCT02734823|OTHER|Questionnaire Administration|Ancillary studies
224043375|NCT02734823|PROCEDURE|Ultrasonography|Undergo transvaginal pelvic ultrasonography
224043376|NCT01758263|DRUG|Metoprolol|Metoprolol, oral administration
224043377|NCT01758263|DRUG|Nebivolol|Nebivolol, oral administration
224043378|NCT02645760|OTHER|Core stabilization exercise|7-weeks of core stabilization exercise
224043379|NCT02645760|OTHER|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
224043380|NCT00347334|BEHAVIORAL|infant home positioning|
224043381|NCT02163460|PROCEDURE|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde \[Health Ministry registry\]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
224043382|NCT02163460|PROCEDURE|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
224043383|NCT04549727|OTHER|Organoids creation|Organoids are created from discarded tissue
224043384|NCT02432313|DRUG|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
224043385|NCT06508112|DEVICE|Masimo Radical-7® Pulse CO-Oximeter|Masimo Radical-7® Pulse CO-Oximeter device was attached to the index finger of the patients in the supine position and photoplethysmographic perfusion index and plethysmographic variability index were measured noninvasively, rapidly and continuously.
224043386|NCT01905124|DRUG|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
224140878|NCT03786198|BEHAVIORAL|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
224140879|NCT03786198|BEHAVIORAL|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
224140880|NCT05795010|OTHER|MRD test|ctDNA detection based on tumor whole exon sequencing
224140881|NCT00604435|DRUG|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
224043387|NCT01905124|DRUG|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
224043388|NCT02267603|OTHER|Laboratory Biomarker Analysis|Ancillary studies
224043389|NCT02267603|BIOLOGICAL|Pembrolizumab|Given IV
224043390|NCT00227487|OTHER|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
224043391|NCT00227487|OTHER|Administration of carbohydrate solution during clinically indicated endoscopy|"* A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~* Clinically indicated pinch biopsies will then be obtained.~* The endoscopy procedures will take at least 1 - 1 ½ hours.~* Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~* Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
224140882|NCT00604435|DRUG|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
224043392|NCT00227487|OTHER|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
224043393|NCT01520311|DEVICE|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
223433271|NCT05745714|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
223433272|NCT03819296|OTHER|Best Practice|Receive standard of care
223433273|NCT03819296|OTHER|Biospecimen Collection|Undergo collection of stool, blood, and tissue samples
223433274|NCT03819296|PROCEDURE|Endoscopic Procedure|Undergo endoscopy
223433275|NCT03819296|PROCEDURE|Fecal Microbiota Transplantation|Undergo FMT
223433276|NCT03819296|BIOLOGICAL|Infliximab|Given intravenously (IV)
224043394|NCT00049452|DRUG|zoledronic acid|
224043395|NCT06637462|DIAGNOSTIC_TEST|Endoscopy|Standard of care endoscopy
224043396|NCT02336789|OTHER|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
224140883|NCT03582735|OTHER|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
224299727|NCT05600881|DRUG|Methylphenidate|Participants will take their regular medication or a placebo (vitamin C)
223433277|NCT03819296|OTHER|Laboratory Biomarker Analysis|Ancillary studies
223433278|NCT03819296|DRUG|Prednisone|Given orally
223433279|NCT03819296|BIOLOGICAL|Vedolizumab|Given IV
223433280|NCT06557785|BIOLOGICAL|CH505M5 N197D mRNA-gp160|To be administered intramuscularly as a split dose
224043397|NCT02336789|OTHER|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
224140884|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 1|Nirmatrelvir 150mg qd (another 75mg will be supplied after hemodialysis treatment) and ritonavir 100mg bid everyday for 5 days.
224299728|NCT04310488|OTHER|The Centre of excellence self-administered (CESAM) questionnaire items|Complete a self-administered questionnaire within two days of their museum visit.
223433281|NCT06557785|BIOLOGICAL|CH505 TF mRNA-gp160|To be administered intramuscularly as a split dose
223433282|NCT06022120|BEHAVIORAL|An integrated health literacy intervention|The intervention investigates the effect of the Australian WorkHealth Improvement Network (WIN) program and the Total Worker Health (TWH) concepts in a Danish contexts among students at risk of poorer health outcomes compared to their peers with stronger literacy skills.
223433283|NCT05558397|DEVICE|Interventional Group (Epidural morphine)|Implantation of an epidural catheter for administration of morphine and ropvacaine
223433284|NCT05558397|DRUG|Control Group (Oral morphine)|Oral administration of morphine, pregabalin or duloxetin
223433285|NCT05989997|DRUG|68Ga-NOTA-SNA002|68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
223433286|NCT04550832|DRUG|Delpazolid|Delpazolid is not licensed yet. Current experience in humans upto Phase IIA. Dose according to randomization to dosing arms 2-5.
223433287|NCT04550832|DRUG|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which delpazolid is added in arms 2-5.
223433288|NCT05455450|OTHER|Eye movement desensitisation and reprocessing therapy|Up to 16 EMDR sessions (minimum of 8 sessions), and 1-month follow-up session, as well as attending neuropsychiatric appointments (NPC). Participants will be given the choice of attending EMDR physically face-to-face or virtually via a video-consultation platform. Sessions will normally be attended weekly, with treatment completed within 6 months. Sessions will be 60-90 minutes long. EMDR will follow the standard 8-phase protocol, with additions so that it is tailored for FND presentations. The FND-specific EMDR therapy protocol has been developed for the trial by the chief investigator.
223433289|NCT05455450|OTHER|Neuropsychiatric care|Standard medical care consisting of 1-3 30 minute appointments with neuropsychiatrist over the course of the 9-month trial period.
223433290|NCT05794178|BEHAVIORAL|Education|Education about health benefits of physical activity, 2018 US Physical Activity Guidelines, assigned goals tailored to baseline step counts, and worksheet to develop action and coping plans (three of each)
223433291|NCT05794178|BEHAVIORAL|Activity tracker|Fitbit activity tracker and mobile app to provide ad libitum behavioral feedback and self-regulatory support
224043398|NCT04621734|DEVICE|AMT BridlePro Device|A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
224043399|NCT04621734|DEVICE|Adhesive Tape|Adhesive tape used to secure nasoenteric tube
223433292|NCT05794178|BEHAVIORAL|Text messaging (random timing and selection)|Four text messages/day at random times within a participant's availability window and drawn at random from one of three content libraries (move more \[40%\], sit less \[40%\], inspirational quotes \[20%\])
223433293|NCT05794178|BEHAVIORAL|Text messaging (precision dosing)|Up to four text messages/day within a participant's availability window, timed and selected from one of three content libraries (move more, sit less, inspirational quotes) based on a person-specific dynamic model and contextual data
223433294|NCT04823130|DRUG|Dupilumab (SAR231893)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223433295|NCT04609839|OTHER|Follow-up of patients with COVID-19|"The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.~The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients."
223433296|NCT05264389|DEVICE|Poly-Tape Devices|Poly-Tape Devices, 10mm Poly-Tape or 5mm Infinity-Lock Tape, for Medial Patellofemoral Ligament (MPFL) Reconstruction
223433297|NCT06800248|DRUG|emodepside (BAY 44-4400)|Treatment with single dose of oral 15 mg emodepside
223433298|NCT06800248|DRUG|Mebendazole 100 MG|Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
223433299|NCT06800248|DRUG|similar placebo to mebendazole|Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
224043400|NCT06494865|DEVICE|MRI device|"Standered breast coils with small field of veiw and thin sections will be used for the examinatio.~MRI breast including Axial T1WI, T2WI Stir contrast DWI and Stir sagittal T1WI with contrast traction and subtraction"
224043401|NCT04573751|DRUG|Standard therapy|Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
224043402|NCT04573751|DRUG|Epinephrine|Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
224043403|NCT04573751|DRUG|Verapamil|Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
224043404|NCT04573751|DRUG|Epinephrine + verapamil|Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
224043405|NCT02626481|DRUG|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
224043406|NCT02626481|DRUG|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
224043407|NCT05559021|OTHER|Myofascial Therapy Treatments|"• Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~* Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~* Suboccipital inhibition: Performing a myofascial induction as described by Pilat"
224043408|NCT05559021|OTHER|Passive Mobilizations Approach|"• Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Postero-anterior cervical sliding~* Postero-anterior lumbar slippage~* Postero anterior dorsal slippage"
224043409|NCT03207711|BEHAVIORAL|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
224043410|NCT03207711|BEHAVIORAL|Mindfulness|Mindful eating app-use and instruction
224043411|NCT06837181|OTHER|observational study|This is an observational study.
223433300|NCT06800248|DRUG|matching placebo of emodepside|Treatment with single dose of oral emodepside matching placebo
223433301|NCT06546618|BEHAVIORAL|pictorial warning and no flavor|LCC Package with pictorial warning and no flavor
223433302|NCT06546618|BEHAVIORAL|pictorial warning and 'sweet' flavor|LCC Package with pictorial warning and 'sweet' flavor
223433303|NCT06546618|BEHAVIORAL|text-only warning and no flavor|LCC Package with text-only warning and no flavor
224043412|NCT00335894|DRUG|hMG-IBSA|
224043413|NCT00217191|DRUG|Ibuprofen|
224043414|NCT05222204|DRUG|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel|intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
224043415|NCT04392453|DEVICE|Robotic therapy|The treatment with the robot Icone will include 30 sessions, each session lasting 45 minutes, with a frequency from three to five times a week. The treatment will be provided in the patient's room. Patients will execute upper limb movement involving elbow flexion-extension, shoulder protraction-retraction, internal-external rotation, flexion-extension, and abduction-adduction. Visual and auditory feedback will be provided during the tasks. The exercises will train both motor and cognitive functions.
224043416|NCT03096925|BEHAVIORAL|Guided self-help|Web-based guided self-help intervention
224043417|NCT04281589|OTHER|if the ventilation parameter caused desaturation or hypercapnia we will change the parameter|we will increased fi02
224043418|NCT01550913|BEHAVIORAL|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
224043419|NCT01550913|OTHER|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
224140885|NCT05366192|DRUG|Nirmatrelvir and ritonavir stage 2|Nirmatrelvir 300mg qd (another 150mg will be supplied after hemodialysis treatment) and ritonavir 100 bid everyday for 5 days.
224299729|NCT05134194|DRUG|Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine|Camrelizumab in combination with capecitabine or eribulin or gemcitabine or vinorelbine
224043420|NCT05564871|OTHER|occupation-based teleintervention|Intervention protocol will include 12 weekly based on the principles of the CO-OP approach. The intervention will focus on solving problems in the participant's daily life and implementing strategies in accordance with the goals set according to the COPM (Law et al., 2017). In the research group, the intervention will be carried out through videoconference sessions between an occupational therapist located at one of the child development units and the participant and their parents who are at home. The control group will receive a weekly session of CO-OP intervention in-person in one of the child development units.
224043421|NCT04054609|DIAGNOSTIC_TEST|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
224043422|NCT03366051|PROCEDURE|Sentinel Node Mapping|At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
224043423|NCT03366051|PROCEDURE|Lymphadenectomy|Systematic Pelvic and Para-Aortic Lymphadenectomy
224043424|NCT03971656|DIETARY_SUPPLEMENT|Nutritional Supplement|Oral nutritional supplementation
224043425|NCT03971656|BEHAVIORAL|Preoperative Dietitian Consult|Nutritional assessment
224043426|NCT03971656|BEHAVIORAL|Education|Informational materials about nutrition
224043427|NCT03574441|DEVICE|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
223433304|NCT06546618|BEHAVIORAL|text-only warning and 'sweet' flavor|LCC Package with text-only warning and 'sweet' flavor
224140886|NCT02592395|DRUG|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
223433305|NCT06802263|DIAGNOSTIC_TEST|at-home quantitative urine b-hCG test|"Cases will begin performing urine and serum hCG testing 24 hours after the initial hCG level. Urine hCG testing will be performed on the first morning urine at home and participants will limit water for at least 8 hours before testing. Serum hCG testing will occur at a UCHealth laboratory before 10 am and within 2 hours of the urine test to allow for the comparison of the values. Both urine and serum hCG testing will then occur daily x 7 days, or until a medical or surgical intervention is indicated. If serum testing is indicated on a weekend, patients will present to the UCH Infusion Center.~Non-pregnant controls will test the first morning urine at home and undergo serum hCG testing in a UCHealth lab on the 4th and 6th day of the menstrual cycle. All urine hCG values will be recorded in the Mira home kit and evaluated in comparison to serum hCG levels."
223433306|NCT04162353|BIOLOGICAL|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
223433307|NCT05599984|DRUG|ABBV-706|Intravenous (IV) Infusion
223433308|NCT05599984|DRUG|Cisplatin|Intravenous infusion
223433309|NCT05599984|DRUG|Budigalimab|IV Infusion
223433310|NCT05599984|DRUG|Carboplatin|Intravenous infusion
223433311|NCT05204147|DRUG|Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A|Given IV
223433312|NCT05204147|PROCEDURE|Biospecimen Collection|Correlative studies
224043428|NCT03574441|DEVICE|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
224043429|NCT03574441|DEVICE|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
223433313|NCT04210349|BIOLOGICAL|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
223433314|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 1 SP Shz TIV1|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
224043430|NCT00307528|BIOLOGICAL|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
224043431|NCT00307528|BIOLOGICAL|Pneumovax 23™|Single dose intramuscular injection.
223433315|NCT04210349|BIOLOGICAL|Trivalent Influenza Vaccine 2 SP Shz TIV2|Pharmaceutical form: Suspension for injection Route of administration: intramuscular
223433316|NCT06374290|DRUG|Naltrexone (Vivitrol)|At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study
224043432|NCT03471936|DIAGNOSTIC_TEST|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
224043433|NCT04259294|BEHAVIORAL|Caspar Telerehabilitation|"The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists."
224043434|NCT02556866|DRUG|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
224140887|NCT02592395|DEVICE|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
224140888|NCT04843826|PROCEDURE|papilla reconstruction|subepithelial connective tissue graft for interdental papillary reconstruction around delayed
224140889|NCT00004938|DRUG|fluconazole|
224299730|NCT05134194|DRUG|Capecitabine/eribulin/gemcitabine/vinorelbine|Capecitabine or eribulin or gemcitabine or vinorelbine
224043435|NCT02556866|DRUG|Prednisone|
224140890|NCT06429423|BEHAVIORAL|Acute exercise low intensity|"A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
224140891|NCT06429423|BEHAVIORAL|Acute exercise moderate intensity|"A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state."
224140892|NCT01595165|PROCEDURE|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
224140893|NCT01595165|PROCEDURE|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
223433317|NCT06374290|DRUG|Bupropion|Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
223433318|NCT06474923|BEHAVIORAL|Face image and voice audio|Take photographs of the front, left and right side of the patient's face. Recording the patient's voice during doctor-patient communication.
223433319|NCT06533462|DIETARY_SUPPLEMENT|Multiallergen powder|OIT multiallergen powder.
223433320|NCT04089189|DRUG|IMP4297|IMP4297 100mg PO QD
223433321|NCT03312595|DEVICE|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
223433322|NCT03315455|DRUG|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
223433323|NCT06507618|DRUG|Tamoxifen, Letrozole, Anastrozole, or Exemestane|Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.
223433324|NCT03657394|OTHER|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
223433325|NCT03711058|DRUG|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
223433326|NCT03711058|DRUG|Nivolumab|"Nivolumab 480 mg will be administered as a 30 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
223433327|NCT03991091|DRUG|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
223433328|NCT03991091|DRUG|continuation of oxytocin administration|continuation of oxytocin administration
223433329|NCT06522854|DRUG|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor
223433330|NCT06522854|DRUG|Placebo Oral Tablet|Placebo tablet given orally every eight hours up to three times while mother is in labor
223433331|NCT04439357|DRUG|Trametinib Dimethyl Sulfoxide|Given PO
223433332|NCT06521554|DRUG|NVL-330|Oral Tablet of NVL-330
223433333|NCT04765722|DRUG|Mepolizumab|Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
224140894|NCT05467462|DRUG|I.V carbetocin administration|Group I: carbetocin was intravenously administered immediately after birth of the baby.
224299731|NCT02575274|PROCEDURE|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
224299732|NCT02206620|DRUG|Donepezil|
224299733|NCT01551147|DRUG|ONO-6950|200 mg QD for 8 days
223433334|NCT04765722|DRUG|Normal Saline|Placebo subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
223433335|NCT06244771|DRUG|FMC-376|Oral Capsule
223433336|NCT05343481|BIOLOGICAL|ChAdOx1-HBV|Chimpanzee Adenovirus Oxford 1-vectored Hepatitis B virus immunotherapeutic
224043436|NCT02556866|DRUG|Placebo|
223433337|NCT05343481|BIOLOGICAL|MVA-HBV|Modified Vaccinia Ankara-vectored Hepatitis B virus immunotherapeutic
223433338|NCT05343481|BIOLOGICAL|Nivolumab|Human immunoglobulin G4 monoclonal antibody
223433339|NCT05441514|DRUG|Cobimetinib|Given PO
223433340|NCT05441514|DRUG|Enasidenib Mesylate|Given PO
224043437|NCT05835089|DIAGNOSTIC_TEST|serum kisspeptin levels|Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels
224043438|NCT03068000|BEHAVIORAL|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
224140895|NCT05467462|DRUG|I.V Oxytocin administration|Group II: Oxytocin the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord.
224043439|NCT03068000|BEHAVIORAL|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
224043440|NCT00146679|BEHAVIORAL|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
224043441|NCT00146679|BEHAVIORAL|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
224140896|NCT05467462|DRUG|I.V carbetocin and tranexamic acid administration|Group III: carbetocin and tranexamic acid 100-mg carbetocin was intravenously administered immediately after birth of the baby and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord.
224140897|NCT05467462|DRUG|I.V Oxytocin and tranexamic acid administration|Group IV: oxytocin and tranexamic acid the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered and tranexamic acid infusion consisting of 1gr dissolved in 100 mL of normal 0.9 % sodium chloride solution was administered immediately after clamping the umbilical cord
224140898|NCT00445250|DRUG|Calcipotriol|
224140899|NCT04781907|PROCEDURE|Tissue Expansion|Tissue expanders are used to increase the soft tissue envelope after mastectomy to provide adequate and healthy coverage of prosthetic breast implants.
224140900|NCT00303615|DRUG|Fluoxymesterone 10 mg|
224140901|NCT00303615|DRUG|Anastrozole 1 mg|
224140902|NCT03939611|OTHER|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
224140903|NCT03939611|OTHER|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
224140904|NCT03882398|OTHER|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
224140905|NCT03882398|OTHER|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part\* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(\*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
224140906|NCT05195268|PROCEDURE|Intracardiac Catheter Ablation|Both arms will receive intracardiac catheter ablation procedures as described.
224140907|NCT02667457|RADIATION|99mTc-rhAnnexin V-128|
224140908|NCT03701646|DEVICE|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
223565687|NCT03215992|DEVICE|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
224043442|NCT00146679|BEHAVIORAL|Usual Care|Usual Care provided by providers
224043443|NCT04891341|OTHER|Technology Supported Task-Oriented Circuit Training|"Ten workstations, which are frequently used in the literature and determined according to the clinical experience of the research team, have been created. Each workstation will be applied for a total of 1 hour, in the form of 5 minutes of training and 1 minute of rest.~1. Sit to stand~2. Standing and trunk training~3. Standing and lower limb training~4. Stepping~5. Walking~6. Walking with object manipulation~7. Climbing and descending stairs~8. Unilateral upper extremity activity training (VR)~9. Bilateral upper extremity activity training (VR)~10. Upper extremity reaction time training (VR) Virtual reality games will be played using the USE-IT intelligent physiotherapy game system. The system offers unilateral, bilateral and bimanual upper extremity training to individuals with a 55 inch touch screen and 7 computer games (balloon popping, car washing, plumbing, arithmetic, apartment, drum and matching)."
224043444|NCT04891341|OTHER|Home-based Telerehabilitation|Strengthening, balance and coordination exercises will be sent to the participants via a mobile application. Patients will do the exercises at home and send a notification to their physiotherapist. Intervention will be applied for 1 hour, 3 days a week for 8 weeks.
224140909|NCT02475850|OTHER|Evidence-based tailored fall prevention|
224140910|NCT02475850|OTHER|Usual care|
224140911|NCT01930929|PROCEDURE|Bariatric surgery|
224140912|NCT01653002|OTHER|No intervention|
224140913|NCT02766595|OTHER|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
224140914|NCT03058822|DRUG|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
224140915|NCT03917225|DRUG|MIN-102|Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.
224140916|NCT03917225|DRUG|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
224140917|NCT01746940|DRUG|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
224140918|NCT01746940|DRUG|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
223565688|NCT04587414|BEHAVIORAL|eHealth +counselling contacts|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
223565689|NCT04587414|BEHAVIORAL|eHealth|The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
223565690|NCT04587414|BEHAVIORAL|Usual care|Usual care and councelling given to type 2 diabetics within the primary health care setting.
223565691|NCT04614870|DIAGNOSTIC_TEST|DETEC® Esterase|DETEC® Esterase is a disposable diagnostic device that is used to indicate the presence or absence of infection based on the presence or absence of the evaluated level of leukocyte esterase by testing the freshly recovered wound dressing which are soaked with wound exudate.
224043445|NCT02613689|BEHAVIORAL|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
224043446|NCT02613689|BEHAVIORAL|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
224043447|NCT02514408|PROCEDURE|Catheter Management|Insertion of venous catheter under ultrasound guidance
224043448|NCT02514408|OTHER|Cytology Specimen Collection Procedure|Collection of blood samples
224043449|NCT02514408|OTHER|Laboratory Biomarker Analysis|Correlative studies
224043450|NCT00381563|DEVICE|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
224043451|NCT00381563|DEVICE|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
224043452|NCT01248702|OTHER|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
224043453|NCT05040893|BEHAVIORAL|Physiotherapy|"Interventions will include:~1. Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~2. Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~3. Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises)."
224043454|NCT05128721|BIOLOGICAL|Covi Vax|Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.
224043455|NCT01366261|DEVICE|semirigid thoracoscopy|thoracoscopy with semirigid instrument
224043456|NCT01366261|DEVICE|rigid thoracoscopy|thoracoscopy with rigid instrument
224043457|NCT00364871|DRUG|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
224043458|NCT04937244|DIAGNOSTIC_TEST|5ALA exoscopic fluorescence filter|Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.
224043459|NCT03326895|DEVICE|Left-sided colon resection|Left-sided colon resection with powered stapler
224043460|NCT03640468|DRUG|Ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg
224043461|NCT03640468|DRUG|Ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg
224043462|NCT03640468|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg
224043463|NCT03640468|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
224043464|NCT03640468|DRUG|Normal saline|This group will receive normal saline 10 mL
224043465|NCT02693782|DIETARY_SUPPLEMENT|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
224043466|NCT02693782|DIETARY_SUPPLEMENT|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
224043467|NCT00378833|DRUG|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
224043468|NCT00378833|DRUG|niacin|Duration of Treatment: 18 Weeks
224043469|NCT02690220|DEVICE|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
224140919|NCT01746940|DRUG|Placebo Topical Solution|Placebo Topical Solution
224140920|NCT02017821|BEHAVIORAL|high intensity aerobic training|
224140921|NCT03297216|DRUG|17P|Synthetic progestin
224140922|NCT03297216|OTHER|Placebo|Non-active placebo comparator
224043470|NCT03187171|OTHER|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
223433341|NCT03513770|OTHER|Wrist-to-elbow (W-E) occlusion|"An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated."
224140923|NCT01332604|DRUG|GDC-0980|Oral escalating dose
224140924|NCT01332604|DRUG|bevacizumab|Intravenous repeating dose
224043471|NCT03187171|DEVICE|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
223433342|NCT03513770|DRUG|ketorolac tromethamine|In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( \~40-60 ml) will be infused into the occluded forearm at a rate of \~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
223433343|NCT03513770|DRUG|saline control|In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
224043472|NCT03122496|DRUG|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
224140925|NCT01332604|DRUG|capecitabine|Oral repeating dose
224140926|NCT01332604|DRUG|mFOLFOX6|Intravenous repeating dose
224140927|NCT02700919|DRUG|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
223565692|NCT03479294|DRUG|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
223565693|NCT03619096|PROCEDURE|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
223565694|NCT03619096|PROCEDURE|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
223565695|NCT02099344|DEVICE|Artegraft|Surgical placement of graft for hemodialysis access
223565696|NCT02099344|DEVICE|Propaten|Surgical placement of graft for hemodialysis access
223565697|NCT01410175|DEVICE|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
223565698|NCT01493102|DRUG|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
223565699|NCT01493102|DRUG|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
224043473|NCT03122496|DRUG|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
224043474|NCT03122496|RADIATION|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
224043475|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
224043476|NCT01109173|DRUG|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
224043477|NCT01109173|OTHER|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
224043478|NCT01109173|OTHER|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
224140928|NCT02700919|DRUG|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
224140929|NCT00003635|DRUG|nelarabine|
224140930|NCT03973203|DIETARY_SUPPLEMENT|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
224140931|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
224140932|NCT00730626|DIETARY_SUPPLEMENT|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
224140933|NCT00730626|DIETARY_SUPPLEMENT|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
224140934|NCT04374266|DIAGNOSTIC_TEST|physical examination, and computerized tomography|physical examination, and computerized tomography was performed during routine follow-up
224140935|NCT04771143|DRUG|AFQ056|oral administration
224140936|NCT04771143|DRUG|Placebo|matching placebo for oral administration
224043479|NCT02225717|PROCEDURE|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
223433344|NCT06291415|DRUG|HMPL-523|Syk inhibitor
224043480|NCT00038584|DRUG|SCH66336|
223433345|NCT05507931|DIETARY_SUPPLEMENT|1 Serving of broccoli sprouts|Participants will take 1 serving of broccoli sprouts daily for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
224043481|NCT04095078|DEVICE|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
224043482|NCT02764164|DEVICE|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
224043483|NCT04263350|DRUG|Atazanavir/Cobicistat|Specified Dose on Specified Days
224043484|NCT04263350|DRUG|Reyataz Atazanavir|Specified Dose on Specified Days
224043485|NCT04263350|DRUG|Cobicistat|Specified Dose on Specified Days
224043486|NCT02340728|DEVICE|ERCP with SEMS plus radiofrequency ablation|
224043487|NCT02340728|DEVICE|ERCP with SEMS alone (standard of care)|
224043488|NCT05242757|OTHER|Mixed-activated Killer Immune Cells|Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
224140937|NCT02752724|DRUG|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
224043489|NCT00806676|DRUG|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
224043490|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
224043491|NCT00902187|DRUG|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
224043492|NCT05881967|DIAGNOSTIC_TEST|Diagnostic biomarker|Diagnostic gene for uterine sarcoma
224043493|NCT01573078|BEHAVIORAL|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
224043494|NCT06306287|BEHAVIORAL|ePACE Personalized Intervention|The ePACE intervention is based on culturally and developmentally relevant youth treatments organized around an integrative approach based on Motivational Enhancement Therapy (MET) and Cognitive Behavior Therapy (CBT) to enhance motivation for change, support awareness of thoughts, emotions, and behavior, and address specific behavior change goals. The web-based approach is personalized, with youth-driven choices in terms of intensity, content, and sequencing of content and provide tailored feedback to youth regarding each individual's behavior change efforts. Modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Interactive activities, exercises, and quizzes are designed to promote skill acquisition. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary.
224043495|NCT06306287|BEHAVIORAL|eFACE Fixed Intervention|The eFACE intervention includes content that is similar to ePACE, but modules are offered in a fixed order with no tailoring features. Like ePACE, modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary. However, no personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
224043496|NCT02822950|DRUG|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
223433346|NCT05507931|DIETARY_SUPPLEMENT|3 Servings of broccoli sprouts|Participants will take 3 servings of broccoli a day for 28 days. The sprouts will be provided by the study team along with instructions on how to prepare the steamed broccoli sprouts (i.e., steamed for 10 minutes). In addition to taking the sprouts, participants will be asked to complete food diaries and surveys, collect blood and stool samples, as well as having 2 in-person visits.
223433347|NCT05502237|DRUG|Zimberelimab|Administered intravenously
223433348|NCT05502237|DRUG|Domvanalimab|Administered intravenously
223433349|NCT05502237|DRUG|Pembrolizumab|Administered intravenously
223433350|NCT05502237|DRUG|Carboplatin|Administered intravenously
223433351|NCT05502237|DRUG|Cisplatin|Administered intravenously
223433352|NCT05502237|DRUG|Paclitaxel|Administered intravenously
223433353|NCT05502237|DRUG|Nab-paclitaxel|Administered intravenously
223433354|NCT05502237|DRUG|Pemetrexed|Administered intravenously
224043497|NCT03406143|PROCEDURE|CGF injection|CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.
224043498|NCT03406143|PROCEDURE|Control|Saline will be injected into expanded skin
224043499|NCT03702751|PROCEDURE|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
224043500|NCT03702751|PROCEDURE|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
224140938|NCT02752724|DRUG|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
224140939|NCT03434418|DRUG|osimertinib|80 mg oral administration daily
224140940|NCT06392750|BEHAVIORAL|Collection of tumor tissue specimens|Collection of tumor tissue specimens during surgery
224140941|NCT00067613|OTHER|Benchmarking Management Practices|"The Benchmarking intervention included:~1. Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~2. Training in Continuous Quality Improvement (CQI) Techniques~3. Review of best existing evidence~4. Site visits to the Centers with the Lowest Rates of BPD~5. Selection of Practices to change: Each site team selected practices for modification at their own center"
223433355|NCT06246357|DRUG|[68Ga]Ga-PentixaFor|\[68Ga\]Ga-PentixaFor will be injected intravenously approximately 60 minutes prior to scanning at a dose of 150 +/- 50 MBq (4 mCi +/- 1.4).
223433356|NCT03859063|BEHAVIORAL|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
223433357|NCT03859063|BEHAVIORAL|Control|Community based follow-up as usual
223433358|NCT05991323|DRUG|Dupilumab|Injection solution; subcutaneous
223433359|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (high-dose)|140ml of chicken extract supplement (high-dose) to be consumed daily for 2 weeks
223433360|NCT06021223|DIETARY_SUPPLEMENT|Chicken extract supplement (low-dose)|140ml of chicken extract supplement (low-dose) to be consumed daily for 2 weeks
223433361|NCT06021223|OTHER|Placebo|140ml of placebo to be consumed daily for 2 weeks
223433362|NCT06131749|OTHER|No intervention|No intervention, observational cohort study
223433363|NCT04537416|OTHER|No intervention|No intervention
223433364|NCT05906836|DRUG|Rosuvastatin|Administered orally.
223433365|NCT05906836|DRUG|Selpercatinib|Administered orally.
223433366|NCT06474767|BEHAVIORAL|P-CGS (Pediatric Collaborative Goal Setting)|Electronic questionnaire sent to participants ahead of a pediatric primary care well child visit, assessing goals for themselves and the child's health with prompt to share with providers during visit
223433367|NCT03233191|PROCEDURE|Digital Mammography|Undergo DM
223433368|NCT03233191|PROCEDURE|Digital Tomosynthesis Mammography|Undergo TM
223433369|NCT03233191|OTHER|Laboratory Biomarker Analysis|Correlative studies
223433370|NCT04087291|OTHER|Chiropractic Care|"Chiropractic interventions:~1. Patient education.~2. Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~3. Transitional interventions, such as therapeutic exercise.~4. Recommendations for active interventions, such as general exercise and mind-body therapies.~5. Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
223433371|NCT04775355|PROCEDURE|Biospecimen Collection|Undergo collection of stool and urine
223433372|NCT04775355|OTHER|Electronic Health Record Review|Medical records are reviewed
223433373|NCT04775355|OTHER|Quality-of-Life Assessment|Complete quality of life questionnaires
224299734|NCT01551147|DRUG|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
223433374|NCT04775355|OTHER|Questionnaire Administration|Complete questionnaires
223433375|NCT06511193|DRUG|Budenoside/Glycopyrronium/Formoterol|Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
223433376|NCT05685602|PROCEDURE|Biopsy Procedure|Undergo a tumor biopsy
223433377|NCT05685602|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223433378|NCT05685602|PROCEDURE|Computed Tomography|Undergo a CT scan
223433379|NCT05685602|BIOLOGICAL|Emavusertib|Given PO
223565700|NCT06172803|BEHAVIORAL|Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise|8 week exercise program. 20 minutes of home aerobic exercise most days, phone- based motivational exercise coaching and supervised exercise with our team exercise physiologist.
223565701|NCT06172803|BEHAVIORAL|Light Stretching/Breathing Exercises|The control group will receive 8-week, attention-matched, stretching and breathing exercises, supervised by a rehabilitation clinician (via 20-minute weekly video visits). Exercises performed 5 days a week will not increase HR significantly. Participants will record and track their HR with Apple watch and app; like RESToRE, fidelity of treatment will be objectively measured using HR data.
223565702|NCT06127381|DRUG|Glycolic acid tetrasubstituted piceatannol (TGKP)|A total of 25 volunteers will be randomized and receive the study drug, of which 5 - will receive ¼ therapeutic dose, 5 - will receive ½ therapeutic dose, 15 - will receive the full therapeutic dose.
223565703|NCT00002873|RADIATION|brachytherapy|
223433380|NCT05685602|DRUG|Gemcitabine Hydrochloride|Given IV
223433381|NCT05685602|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223433382|NCT05685602|DRUG|Nab-paclitaxel|Given IV
223433383|NCT05685602|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223433384|NCT05685602|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223433385|NCT03672318|DRUG|CAR138 T Cells|"The MTD is defined as the dose at which approximately 0.20 of subjects experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10\^6 cells/m\^2 Dose level 2: 1X10\^7 cells/m\^2 Dose level 3: 2.5X10\^7 cells/m\^2 Dose level 4: 5X10\^7 cells/m\^2 Dose level 5: 1x10\^8 cells/m\^2 Dose level 6: 2x10\^8 cells/m\^2~Six subjects will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m\^2 and fludarabine 30 mg/m\^2 given once daily for three days."
223433386|NCT06378268|DRUG|Dydrogesterone 10 mg|Dydrogesterone 10mg orally 2 times daily, starting on the day of gonadotropin injection to the oocyte maturation trigger night.
223433387|NCT06378268|DRUG|Cetrorelix 0.25 mg|Cetrorelix 0.25mg is injected subcutaneously once a day. It is given from day 5 or day 6 of stimulation by the oocyte maturation trigger day.
223433388|NCT04109131|OTHER|Samples collection: Plasma|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
224299735|NCT01551147|DRUG|Montelukast|10 mg Montelukast QD for 8 days
224299736|NCT06877611|DRUG|S-4321|S-4321 via subcutaneous or intravenous administration
224299737|NCT06877611|OTHER|Placebo|Placebo via subcutaneous or intravenous administration.
224043501|NCT02933632|OTHER|Physical Therapy-SAP|"* Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~* Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~* Day 4 and other days) Patients repeated the gait training until the discharge date."
223433389|NCT04109131|OTHER|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
224043502|NCT02933632|OTHER|Physical Therapy-ARP|"* Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~* Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~* Day 2) Patients repeated three times the day 1-3°approach;~* Day 3) Patients repeated three times the day 1-3°approach."
224043503|NCT00006392|DRUG|Vitamin E|400 IU daily by mouth for 7-12 years
224043504|NCT00006392|DRUG|Selenium|200 mcg daily for 7-12 years
223433390|NCT04109131|OTHER|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
223433391|NCT04109131|OTHER|Brain MRI|"Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
224043505|NCT00006392|OTHER|Vitamin E placebo|daily for 7-12 years
223433392|NCT04109131|OTHER|Samples collection: Serum|"At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5."
223433393|NCT04281199|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HCT
224043506|NCT00006392|OTHER|selenium placebo|daily for 7-12 years
224043507|NCT04758299|OTHER|decision science-based design|decision science-based design explaining actions to take for a negative or positive COVID-19 test
224043508|NCT00864890|DRUG|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
224043509|NCT00864890|DRUG|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
224043510|NCT01186796|DRUG|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
224043511|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
224043512|NCT00652730|DRUG|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
223433394|NCT04281199|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223433395|NCT04281199|RADIATION|Tomotherapy|Undergo IMRT with tomotherapy
223433396|NCT04281199|RADIATION|Total-Body Irradiation|Undergo TBI
223433397|NCT04281199|RADIATION|Volume Modulated Arc Therapy|Undergo IMRT with VMAT
223433398|NCT04847466|DRUG|N-803|N-803 will be given via subcutaneous injection at a dose of 15 mcg/kg every 4 weeks (1 week after starting treatment with the PDL-1 CAR-NK cells).
223433399|NCT04847466|DRUG|Pembrolizumab|Pembrolizumab 400 mg will be administered as a 30-minute IV infusion every 6 weeks. Pembrolizumab will be administered on the same day as the PD-L1 CAR-NK cells.
223433400|NCT04847466|BIOLOGICAL|PD-L1 t-haNK|PD-L1 CAR NK cells (2x109) will be administered by IV infusion over approximately 30 minutes every week. After the week 6 treatment, these cells will be given every 2 weeks.
223433401|NCT04728516|DRUG|Vonoprazan-based dual eradication therapy for two weeks|Patients with ACS after PCI, associated with positive Hp need a long-term DAPT treatment. We conducted a study on the prevention of gastrointestinal bleeding between vonoprazan-based dual eradication therapy for two weeks and pantoprazole for six months of a rountine therapy.
223433402|NCT04728516|DRUG|amoxicillin|amoxicillin
224043513|NCT00652730|DRUG|Buspar|Tablets, 30 mg, single-dose, fed conditions
224043514|NCT03623594|PROCEDURE|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
224043515|NCT03579082|DRUG|Decitabine|Given ivgtt
223433403|NCT04728516|DRUG|Pantoprazole|Pantoprazole
223433404|NCT04227028|BIOLOGICAL|Bevacizumab|Given IV
223433405|NCT04227028|DRUG|Brigatinib|Given PO
224043516|NCT00245310|PROCEDURE|Indocyangreen (ICG) clearance|
224043517|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
224043518|NCT03083704|DRUG|Apixaban 5 MG|factor Xa inhibitor
224043519|NCT03083704|DRUG|Rivaroxaban 20 MG|factor Xa inhibitor
224043520|NCT03083704|DRUG|Enoxaparin sodium|low molecular weight heparin
224043521|NCT03083704|DRUG|Edoxaban 60 MG|factor Xa inhibitor
224043522|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
224043523|NCT03083704|BIOLOGICAL|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
224043524|NCT03083704|DRUG|Apixaban 10 MG|factor Xa inhibitor
223433407|NCT04107038|PROCEDURE|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
224043525|NCT03083704|DRUG|Rivaroxaban 10 MG|factor Xa inhibitor
224043526|NCT05022394|BIOLOGICAL|Nivolumab|Given IV
224043527|NCT05022394|DRUG|Sapanisertib|Given PO
224043528|NCT01657474|OTHER|Weekly application of EpiFix plus standard of care|
224043529|NCT01657474|OTHER|Biweekly application of EpiFix plus standard of care|
224043530|NCT04103489|DRUG|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
224043531|NCT00314509|DRUG|Ciclesonide/Formoterol Combination|
224043532|NCT02807051|DRUG|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
224043533|NCT02807051|DRUG|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
224043534|NCT02807051|DRUG|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
224043535|NCT05067426|OTHER|Exercise|high-intensity interval training sessions
224043536|NCT01294488|BEHAVIORAL|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
224043537|NCT00904293|OTHER|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
224043538|NCT00904293|OTHER|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
224043539|NCT05869292|DEVICE|Immediate implant loading|"Implants will be received immediately prosthetic restoration following surgical procedure.~For the provisional restoration, an open tray impression technique will be used. Plaster models with scan bodies will be digitized by the laboratory scanner (3Shape E1, 3Shape, Kopenhagen, Denmark), and the virtual design of provisional restoration will be performed with 3D designing software (Exocad-Matera 2.3, Exocad, Darmstadt, Germany). Provisional restorations will be then created using polymethyl methacrylate (PMMA) (Telio®CAD, Ivoclar Vivadent, Schaan, Lichtenstein) and were drilled from PMMA blocks using the 5-axis milling machine (Zenotec Select, Wieland, Pforzheim, Germany). Screw-retained abutments for the prosthetic bridge will be chosen according to implant angulation and surrounding soft tissue height.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
224043540|NCT05869292|DEVICE|Early implant loading|"Implants won't receive immediately prosthetic restoration following surgical procedure and will be left only healing caps.~At the end of the six-week healing period, definitive prosthetic restorations will be manufactured and delivered to the patients."
224043541|NCT01049243|DRUG|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
224043542|NCT05829642|BEHAVIORAL|Enhanced Care Management|"ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed"
224043543|NCT03214133|OTHER|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
224043544|NCT03214133|OTHER|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
224043545|NCT06326892|PROCEDURE|Natural Orifice Specimen Extraction (NOSE)|Low rectal cancer resection with Total Mesorectal Excision (TME) and Natural Orifice Specimen Extraction (NOSE)
223433408|NCT04107038|PROCEDURE|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
223433409|NCT04801290|PROCEDURE|TIPS insertion|Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
223433410|NCT06394999|DRUG|Mifepristone 50 mg|Once-weekly oral mifepristone 50 mg
224043546|NCT06326892|PROCEDURE|Traditional specimen extraction|Low rectal cancer resection with Total Mesorectal Excision (TME) and specimen extraction through Pfannenstiel incision
224043547|NCT01958788|BEHAVIORAL|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
224043548|NCT00383357|DRUG|zolpidem|
224140942|NCT00067613|OTHER|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
223433411|NCT06122779|DRUG|BMS-986435|Specified dose on specified days
223433412|NCT06122779|OTHER|Placebo|Specified dose on specified days
223433413|NCT05691504|PROCEDURE|Biopsy Procedure|Undergo biopsy
223433414|NCT05691504|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223433415|NCT05691504|DRUG|Cobimetinib|Given PO
223433416|NCT05691504|PROCEDURE|Computed Tomography|Undergo CT
223433417|NCT05691504|PROCEDURE|Echocardiography Test|Undergo ECHO
223433418|NCT05691504|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223433419|NCT05691504|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223433420|NCT05691504|DRUG|Pelcitoclax|Given IV
223433421|NCT06512623|DEVICE|Hemoadsoprtion|The hemoadsorption treatment will be performed during the entire duration of the CPB. Blood flow within the cartridge is standardized at 250 ml/min.
223433422|NCT06196008|OTHER|Educational Intervention|Attend telephone-based coaching sessions
223433423|NCT06196008|OTHER|Educational Intervention|Receive written educational materials on physical activity and standard preoperative care
223433424|NCT06196008|OTHER|Exercise Intervention|Receive a personalized physical activity program, set fitness goals
223433425|NCT06196008|OTHER|Medical Device Usage and Evaluation|Wear activity monitor
223433426|NCT06196008|OTHER|Physical Performance Testing|Ancillary studies
224043549|NCT05019157|OTHER|Telerehabilitation group|Participants will undertake the first three training sessions in the outpatient clinic for familiarization with the training modalities, the wearable sensors and the data uploading. Afterwards, the participants will proceed with the telerehabilitation program at their homes. The participants will be lent the wearable sensors and will undergo an exercise - based program 3 times/week, comprising of 10' warm up exercises, 40' aerobic, resistance, balance exercises and 10' cool down.Training sessions will be monitored, in real time, by the study investigator. Participants should upload the recorded data to Polar Flow web platform after every training session and should visit the outpatient clinic every month to upload the accelerometry's recorded data to a secure personal computer) application. Educational and informational videoconferences will be held every week for upright training exercise sessions, physical activity counseling, diet/nutritional and smoking cessation counseling.
224043550|NCT05019157|OTHER|Centre - based rehabilitation group|Participants will attend an exercise - based cardiac rehabilitation program at the outpatient clinic's facilities under the supervision of cardiac rehabilitation specialized staff. The participants will receive an individually tailored training program on a treadmill or a cycle ergometer. Total training attendance rate will be documented by the cardiac rehabilitation centre staff. Patients will be instructed to wear a tri - axial accelerometer during the entire 12 weeks study period. Participants should upload recorded data to the local server every month. Educational videoconferences will be held every week for physical activity counseling, diet/nutritional and smoking cessation counseling.
224043551|NCT03670043|DRUG|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
224043552|NCT03670043|DRUG|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
224043553|NCT04646681|BEHAVIORAL|ConnectCare|increased monitoring between clinical mental health visits
224043554|NCT03808389|OTHER|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
224043555|NCT03808389|OTHER|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
223433427|NCT06196008|OTHER|Quality-of-Life Assessment|Ancillary studies
223433428|NCT06196008|OTHER|Questionnaire Administration|Ancillary studies
223433429|NCT03297606|DRUG|Olaparib|300mg taken twice daily
223433430|NCT03297606|DRUG|Dasatinib|100mg administered orally once daily
223433431|NCT03297606|DRUG|Nivolumab plus Ipilimumab|"* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
223433432|NCT03297606|DRUG|Axitinib|5mg orally twice daily
223433433|NCT03297606|DRUG|Bosutinib|500mg orally once daily
223433434|NCT03297606|DRUG|Crizotinib|250mg orally twice daily
223433435|NCT03297606|DRUG|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
223433436|NCT03297606|DRUG|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
223433437|NCT03297606|DRUG|Temsirolimus|25mg infused over a 30-60 minute period once a week
223433438|NCT03297606|DRUG|Erlotinib|150mg orally, once daily
223433439|NCT03297606|DRUG|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
223433440|NCT03297606|DRUG|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
223433441|NCT03297606|DRUG|Vismodegib|150mg taken orally, once daily
223433442|NCT03297606|DRUG|Tucatinib|300mg taken orally, twice daily
223433443|NCT04044534|DRUG|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
223433444|NCT04044534|DRUG|Placebo|Subjects in this arm will receive placebo.
223433445|NCT03030118|DRUG|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
223433446|NCT03030118|DRUG|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
224043556|NCT05589779|OTHER|Asthma and cardiovascular disease|To know the clinical and inflammatory characteristics of patients with asthma and associated cardiovascular disease, as well as their relationship with eosinophil subtypes, biomarkers of chronic inflammation and bronchial remodeling.
224140943|NCT04197518|DIAGNOSTIC_TEST|neuro trax system and a neurology test.|"the neurology will check the patience before and after tonsillectomy or adenotonsillectomy usung the neurotrax system, these parameters will be measured in this system : Non verbal memory, Go no go test, stroop interference, Visual spatial processing, Staged information processing speed, catch game, problem solving."
224140944|NCT05343585|DEVICE|PortionSize AI|For this pilot study, using a convenience sample, the investigators will recruit up to 25 adults to use the Nutrition AI technology in Openfit to identify and estimate portion size of foods provided in a laboratory setting at Pennington Biomedical Research Center (PBRC) and/or Louisiana State University (LSU). Laboratory members within the Ingestive Behavioral Laboratory will also test the ability of Nutrition AI to identify foods and to quantify foods provided in the laboratory. Meals will be simulated, and participants will not consume the foods provided.
224140945|NCT00833807|DRUG|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
224140946|NCT06447571|OTHER|Trunk Rehabilitation|Activating and strengthening the trunk muscles.
223433447|NCT04529850|DRUG|Drug: GC4419|GC4419 60 Minute Infusion
223433448|NCT04529850|RADIATION|Intensity-modulated radiation therapy (IMRT)|2.0 to 2.2 Gy daily over 7 weeks
223433449|NCT04529850|DRUG|Cisplatin|100mg/m2 once every 3 weeks or 40mg/m2 once weekly for 6-7 doses
223740519|NCT04999150|PROCEDURE|Micro-Osteoperforations|"MOPs were performed with a stainless-steel manual drill tip that had 1.6mm diameter with an adjustable depth set to 5mm (Excellerator® RT; Propel Orthodontics, Milpitas, CA).~Six perforations were made along 2 parallel vertical lines (each line with 3 holes spaced \~2mm apart) distal to the canine and perpendicular to the buccal cortical bone.~The mini-screws were placed. A NiTi closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge was used to measure the force (150g)"
224140947|NCT06447571|OTHER|Core Stability|Standard core stability fucus on lower trunk.
224140948|NCT00085488|BIOLOGICAL|autologous tumor cell vaccine|
224140949|NCT00085488|BIOLOGICAL|therapeutic autologous dendritic cells|
224140950|NCT02854007|DEVICE|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
224140951|NCT01383109|DRUG|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
224140952|NCT01875913|BEHAVIORAL|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
224140953|NCT01875913|BEHAVIORAL|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
224140954|NCT04089436|DIAGNOSTIC_TEST|CSF sampling|CSF sampling by lumbar puncture
224140955|NCT04089436|DIAGNOSTIC_TEST|Blood sampling|Blood sampling by blood test
224140956|NCT04089436|DIAGNOSTIC_TEST|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
224140957|NCT03320538|OTHER|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
224140958|NCT03320538|OTHER|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
224140959|NCT03320538|DRUG|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
224140960|NCT04048538|OTHER|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
224140961|NCT04048538|OTHER|usual standard of care|individuals will receive treatment as per the usual standard of care
223433450|NCT00928655|DRUG|acetazolamide|acetazolamide 250mg 1/0/2
223433451|NCT00928655|PROCEDURE|nocturnal continuous positive airway pressure|continuous positive airway pressure
223433452|NCT00928655|DRUG|placebo|placebo capsules
223433453|NCT06553729|DRUG|Vitamin D3|Vitamin D3 (cholecalciferol), 1600 IU per day.
223433454|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics|Prebiotics (inulin), 10g per day.
223433455|NCT06553729|DIETARY_SUPPLEMENT|Prebiotics placebo|Prebiotics placebo.
223433456|NCT06553729|DIETARY_SUPPLEMENT|Vitamin D3 placebo|Vitamin D3 placebo
223433457|NCT00001029|DRUG|Zidovudine|
223433458|NCT00001029|DRUG|Zalcitabine|
223433459|NCT00001029|DRUG|Didanosine|
223433460|NCT06202625|DRUG|avatrombopag|The avatrombopag 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase avatrombopag dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within avatrombopag dosage at 40 mg/d, decrease avatrombopag dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop avatrombopag; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping avatrombopag , reuse avatrombopag at 40 mg/d.
224140962|NCT02482012|OTHER|Survey|This was a survey
224140963|NCT00751179|DRUG|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
224140964|NCT00751179|DRUG|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
224140965|NCT00751179|DRUG|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
223433461|NCT06202625|DRUG|Placebo|The placebo 20mg/d will be orally taken from +D7 after haplo-HSCT until meeting the adjustment indication or to +D60 after haplo-HSCT; When PLT\<50×10\^9/L or PLT transfusion-dependent on the +D30 after haplo-HSCT, increase placebo dosage to 40 mg/d; When PLT≥80×10\^9/L and without PLT transfusion within placebo dosage at 40 mg/d, decrease placebo dosage to 20 mg/d; When PLT≥80×10\^9/L for 7 consecutive days or PLT≥300×10\^9/L and without PLT transfusion, stop placebo; When PLT\<50×10\^9/L or PLT transfusion-dependent after stopping placebo, reuse placebo at 40 mg/d.
223433462|NCT02170467|OTHER|assessment of the intestinal permeability|
224043557|NCT05506579|OTHER|Exercises for knees, lower back, hip/groin and pelvic floor muscles in an expanded warm up program|Rhythmic gymnastics clubs allocated to the intervention group will be visited by a physiotherapist (the PhD candidate), which will perform thorough teaching of coaches and gymnasts on how to perform the exercises in the expanded warm up program. During the same visit, before commencing PFMT, the gymnasts will have an individual session were a portable 2D ultrasound machine (GE Healthcare -Logiq e R7, GE\>12L-RS - 5-13 MHz Wideband Linear Probe) will be used to teach and assess ability to perform a correct PFM contraction. The probe is placed suprapubically and provides concurrent visible biofeedback of the PFM contraction. Adherence to the intervention will be registered weekly by the coach in a training diary and asked for as an additional question in the monthly OSTRC-H2 sent to the gymnasts. Reminders will be sent by phone to the coaches every week. To assure proper execution and motivation, the PhD candidate will perform one extra visit midterm.
224043558|NCT02914054|DRUG|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
224043559|NCT02914054|DRUG|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
224043560|NCT05543278|DRUG|Amiodarone|Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
224043561|NCT03889275|BIOLOGICAL|MEDI5395|Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
224043562|NCT03889275|BIOLOGICAL|Durvalumab|Participants will receive IV infusion of durvalumab as stated in arm description.
224043563|NCT04894123|DRUG|Trifluridine/Tipiracil|"Trifluridine/tipiracil : 35 mg/m² orally twice a day from day 1 to day 5 every 14 days.~If oxaliplatin is stopped or it is not indicated, trifluridine/tipiracil in monotherapy 35 mg/m² orally twice a day between days 1-5 and days 8-12; repeated every 28 days."
224140966|NCT04226287|DEVICE|Monterey Pneumatic Compression Device|The MontereyInvestigational System is a compact pneumatic compression device used for the treatment of either primary or secondary lymphedema. The primary intention in this study is to gather usability design feedback. This will be done by observing how a patient uses the device after a brief demonstration from the clinician. Errors and difficulties will be noted by the ResMed representative observing the trial. The qualitative interview with the patient at the end of the trial will yield additional understanding of the patient experience with the device.
224140967|NCT00104156|PROCEDURE|External Qigong therapy|
223433463|NCT04051099|PROCEDURE|Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)|bilateral superficial cervical plexus
223433464|NCT04051099|DRUG|Dexmedetomidine plus propofol infusion|Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
223433465|NCT04051099|PROCEDURE|Local infiltraion analgesia|local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
223433466|NCT04051099|PROCEDURE|General anesthesia with endotracheal tube|Induction with Propofol and intubation with cisatracurium
223433467|NCT05390463|OTHER|PERformance guided Fracture Rehablitation Method (PERFoRM) protocol.|A structured rehabilitation protocol for surgically treated peri-articular fractures of the upper extremity (proximal humerus and distal radius fractures).
223433468|NCT04604964|OTHER|Evaluation of anastomotic leakage occurrence|Anastomotic leakage was defined as the communication between the intra and extraluminal compartments due to a defect in the integrity of the intestinal wall originating from the staple line of the neo-rectal reservoir between the colon and rectum
223433469|NCT00383682|DRUG|morphine and mexiletine|
223433470|NCT05710094|DRUG|SoftOx Biofilm Eradicator (Groups 1 to 7)|SBE is a water-based formulation containing hypochlorous acid (HOCl) at concentrations of 500-1000 µg/mL and acetic acid (HAc) at concentrations of 1-3 %. Both active ingredients are naturally occurring molecules and have a long history of safe use in medicinal products and in solutions approved as medical devices. Both molecules, exhibit broad-spectrum antimicrobial activity at the concentrations present in SBE. The antimicrobial effect of HOCl is rapid and powerful by acting on and disrupting the function of key microbial molecules such as proteins, lipids, and nucleic acids, while remaining safe to mammalian cells and not promoting the emergence of new resistant microbes. Moreover, HOCl is active against biofilms, and some studies suggest that HOCl may also increase oxygenation of the wound site leading to improved healing.
224043564|NCT04894123|DRUG|Oxaliplatin|Oxaliplatin : 85 mg/m² intravenous at day 1 every 14 days.
224140968|NCT05399108|PROCEDURE|Ultrasound Guided Lateral Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. On the image are displayed the trapezius muscle and layers of skin. Just above the trapezius muscle using the in-plane technique is done puncture of the vein. By Seldinger's technique, catheterization is done. The whole procedure is done according to the newest international recommendations for central vein catheterization.
224140969|NCT05399108|PROCEDURE|Ultrasound Guided Conventional Approach Catheterization of Jugular Internal Vein|The jugular internal vein is displayed on its short axis. The cannulation is done by the conventional approach (middle approach - the most frequently used).
224140970|NCT03039738|DEVICE|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
224304946|NCT00671918|DRUG|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
223433471|NCT05710094|DEVICE|Sterile isotonic saline (Groups 1 to 4)|Sterile isotonic saline was used as placebo because it is part of standard of care, used as an irrigation solution at dressing change and has the same appearance as SBE
223433472|NCT01534806|DRUG|Ketorolac|Ketorolac(0.5mg/kg) IV push
223433473|NCT01534806|DRUG|Placebo|Sodium Chloride 0.9% - 10 mL IV push
223433474|NCT01911780|DRUG|placebo|placebo matching amlodipine capsule
224043565|NCT00928174|DRUG|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
223433475|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
223433476|NCT01911780|DRUG|telmisartan + HCTZ|FDC tablet
223433477|NCT01911780|DRUG|amlodipine|capsule
224043566|NCT05793177|BEHAVIORAL|Everyday Life is Rehabilitation|Behavior change intervention focuses on implementing more movement into everyday life using action planning, goal setting, and fatigue management.
223433478|NCT05303402|BIOLOGICAL|PHH-1V|COVID-19 Vaccine HIPRA, 40 mcg/dose
223433479|NCT03529344|DIETARY_SUPPLEMENT|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
223433480|NCT03529344|DIETARY_SUPPLEMENT|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
223433481|NCT05337917|PROCEDURE|Surgical of the digital nerve|All patients (cases and controls) were subject to surgical repair of digital nerve injury.
224043567|NCT02681250|PROCEDURE|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
224043568|NCT02681250|PROCEDURE|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
224043569|NCT02790957|DRUG|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
224043570|NCT02790957|DRUG|Placebo|Single injection of an equal volume of NaCl solution
224043571|NCT00067457|DRUG|alosetron|
223433482|NCT02673294|OTHER|balance virtual rehabilitation|
223433483|NCT01337323|DRUG|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
224043572|NCT05542485|DIAGNOSTIC_TEST|ctDNA liquid biopsy - Roche Avenio Assay|The intervention will involve plasma ctDNA testing for patients with a radiological suspicion for newly diagnosed advanced NSCLC
224043573|NCT02232620|DRUG|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
224043574|NCT04194853|DEVICE|Electromyographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength .Electromyographic (EMG) biofeedback is a specific form of biofeedback. The biofeedback device records muscle activity through the application of electrodes superficially or subcutaneously when targeting specific muscles
224043575|NCT04194853|OTHER|Quadriceps Isometric exercises|In supine lying or sitting, Patient is asked to press down knee while contracting Quadriceps muscles.
223433484|NCT05196113|BEHAVIORAL|sipIT|Participants receive education and digital tools to monitor their fluid intake and just-in-time text messages to remind them when they have lapsed in regular fluid intake.
223433485|NCT05399732|DRUG|Luspatercept|Patients in each group will be treated for at least 6 months and continue the treatment for an additional 6 months unless disease progress or have intolerable side effects.
223433486|NCT05399732|DRUG|Cyclosporine|Cyclosporine was administered at a 3-5 mg/(kd/d) and maintained at a 100-200 ng/ml trough plasma concentration.
223433487|NCT05692635|DIAGNOSTIC_TEST|MRI of the Brain|An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
223433488|NCT05692635|OTHER|Blood draws|Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
224043576|NCT01481623|OTHER|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
224043577|NCT01481623|OTHER|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
224043578|NCT02414568|DRUG|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
224043579|NCT02414568|DRUG|Prednisone|Prednisone 40 mg/m² PO
224043580|NCT02414568|DRUG|Vinblastine|Vinblastine 6 mg/m² IV
224043581|NCT02414568|DRUG|Doxorubicin|Doxorubicin 40 mg/m² IV
224043582|NCT04199234|DIETARY_SUPPLEMENT|Experimental product consumption|Consumption of an encapsulated iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
224043583|NCT04199234|DIETARY_SUPPLEMENT|Comparator product consumption (Iron sulphate)|Consumption of iron supplement, 60 mg iron per day over 14 days, 2 hours before lunch
224043584|NCT03933397|OTHER|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
223433489|NCT05692635|OTHER|Quality of Life Questionnaires|Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
223433490|NCT05692635|DRUG|Gadolinium|Given intravenously
223433491|NCT04198766|DRUG|INBRX-106 - Hexavalent OX40 agonist antibody|The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).
223433492|NCT04198766|DRUG|pembrolizumab 200 mg|pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
224043585|NCT03933397|OTHER|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
224043586|NCT03933397|DRUG|Morphine|4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
224043587|NCT03933397|DRUG|Hydromorphone|1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
224140971|NCT03039738|DEVICE|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
224140972|NCT00397878|DRUG|saracatinib|Given orally
224140973|NCT00397878|OTHER|laboratory biomarker analysis|Correlative studies
224140974|NCT00912340|DRUG|Everolimus|
224140975|NCT00912340|BIOLOGICAL|Trastuzumab|
223433493|NCT04198766|DRUG|pembrolizumab 400 mg|pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
223433494|NCT04198766|DRUG|Carboplatin AUC-5|carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
223433495|NCT04198766|DRUG|Carboplatin AUC-6|carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
223433496|NCT04198766|DRUG|Pemetrexed 500 mg/m2|pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles
223433497|NCT04198766|DRUG|Cisplatin 75mg/m2|cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
223433498|NCT04198766|DRUG|Paclitaxel 200mg/m2|paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4
224140976|NCT04241146|DEVICE|Enteric Tube|A post pyloric feeding tube used in patients requiring enteral nutrition
224140977|NCT04241146|DEVICE|CORTRAK enteral access system|Electromagnetic guidance system for enteric feeding tube placement
224304947|NCT03422939|OTHER|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
224304948|NCT02845141|PROCEDURE|Actifuse|bone tunnel filled with Actifuse
223433499|NCT04198766|DRUG|Nab paclitaxel 100mg/m2|Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4
223433500|NCT04527003|DRUG|Cannabidiol (CBD) Extract|Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
223433501|NCT04527003|DRUG|Norethindrone Acetate|Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
223433502|NCT04527003|OTHER|Placebo|a substance or treatment which is designed to have no therapeutic value
223433503|NCT06271837|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
223433504|NCT06271837|DRUG|Bevacizumab|Bevacizumab by intravenous infusion
223433505|NCT04795193|PROCEDURE|Minimal invasive coronary surgery|Off-pump multi-vessel coronary artery bypass grafting via left thoracotomy under minimally invasive conditions.
223433506|NCT04795193|PROCEDURE|Off-pump coronary artery bypass surgery|Off-pump multi-vessel coronary artery bypass grafting with conventional thoracotomy.
223433507|NCT03140956|DRUG|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
223433508|NCT02496104|BEHAVIORAL|Package n°1 of the APIB|
223433509|NCT05667649|BIOLOGICAL|RB-ADSC|Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
223433510|NCT06365047|DEVICE|8% Arginine toothpaste|Investigative
223433511|NCT06365047|DRUG|1000 ppm F toothpaste|Control
223433512|NCT05336396|OTHER|BMI|Longitudinal data will be collected to determine the effectiveness of BMI compared to traditional OHI to maintain and improve periodontal health.
223433513|NCT02996552|PROCEDURE|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
223433514|NCT02996552|PROCEDURE|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
223433515|NCT00181350|DEVICE|Relocatable fixation system|
224140978|NCT03649516|DEVICE|iCKD APP|Use iCKD APP to upload home bio-information data
224140979|NCT02755025|OTHER|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
224140980|NCT02938546|RADIATION|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
224304949|NCT02845141|PROCEDURE|bone graft|bone graft to fill bone tunnel
224043588|NCT04641780|DRUG|Brexpiprazole|"For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment."
224043589|NCT01612143|DRUG|setrobuvir|200 mg capsule formulation, single oral dose
224043590|NCT01612143|DRUG|setrobuvir|200 mg tablet formulation, single oral dose
224043591|NCT03856307|DIAGNOSTIC_TEST|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
224043592|NCT02515578|OTHER|Enhanced practice transformation support|
224043593|NCT02515578|OTHER|Standard practice transformation support|
224043594|NCT04939662|DRUG|Olaparib+Bevacizumab to SCLC patients|"Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW."
224043595|NCT03732079|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
224043596|NCT04408014|DIAGNOSTIC_TEST|Serological test|IgM and IgG for SARS-CoV-2
224043597|NCT04408014|DIAGNOSTIC_TEST|Nasopharyngeal Swab|PCR for SARS-CoV-2
224043598|NCT04408014|DIAGNOSTIC_TEST|Oropharyngeal Swab|PCR for SARS-CoV-2
224043599|NCT06068660|BEHAVIORAL|The Goal-Oriented Care program|The Goal-Oriented Care Interventions The GOC intervention included the following steps: respecting the participant's values in setting goals, considering direct and indirect factors influencing the goals, communicating and setting goals, implementing goal-oriented strategies, and evaluating goals while adjusting the content of the strategies.
224043600|NCT06068660|BEHAVIORAL|The routine health education|The control group received routine education, which consisted of oral education and provision of educational pamphlets by nurses during hospitalization.
224299738|NCT06855030|OTHER|Scoliosis Specific Exercise|In the first session, the individual and their family will learn about AIS, the specific curvature, and the treatment process. They will also be taught correct posture and active self-correction, which means finding the best alignment in three planes. Once the individual becomes confident in their self-correction, they will start exercises. In the SEAS method, exercises begin in a sitting position, and as the individual improves, the exercises will be made more challenging and suited to their level. The rehabilitation protocol includes exercises in standing, squatting, single-leg stance, and on the floor. In each session, previous exercises will be reviewed, and new ones will be added. Individuals will be reminded to practice active self-correction during exercises and daily activities. In literature, there is no fixed protocol for exercise duration and frequency, but it is recommended to do exercises 2-3 times a week for 45 minutes or 20 minutes daily.
224043601|NCT04652713|OTHER|Protein-rich breakfast|"High protein yoghurt containing approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) yoghurt with 40 g oats for breakfast.~1 glas of water (150 ml)"
224043602|NCT04652713|OTHER|Carbohydrate-rich breakfast|"Low protein breakfast containing approx. 2 g protein per 100 g. Participants will be asked to consume \~60 g bread, 20 g jam and 250 ml juice for breakfast.~1 glas of water (150 ml)"
224043603|NCT04652713|OTHER|No breakfast|1 glas of water (150 ml)
224043604|NCT01910116|DRUG|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
224043605|NCT01910116|DRUG|Placebo|The study medication and placebo were identical in appearance.
223433516|NCT02899559|BEHAVIORAL|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
223433517|NCT06307691|PROCEDURE|Conventional drilling|Atraumatic extraction, followed by sequential drilling using conventional drills
223433518|NCT06307691|PROCEDURE|Osseodensification drilling|Atraumatic extraction, followed by osteotomy prepared using densah bur (sequential drilling)
224043606|NCT03956368|DRUG|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
224043607|NCT03956368|DRUG|Placebos|20mg (every evening orally) for 8 weeks.
224043608|NCT06363279|OTHER|Conducting questionnaires|The questionnaires will be administered online or in person.
224043609|NCT05330403|PROCEDURE|Moxibustion|"In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian."
224043610|NCT00813332|DRUG|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
224043611|NCT00813332|DRUG|Placebo plus Docetaxel|Placebo plus Docetaxel
224043612|NCT01037907|DRUG|Pleneva TM BGC20-0134|Placebo or 5 g dose
224043613|NCT01037907|DRUG|Placebo|Placebo or 5 g dose
224043614|NCT02742467|DRUG|Perindopril plus Amlodipine|Group 1
224043615|NCT02742467|DRUG|Perindopril plus Hydrochlorothiazide|Group 2
224043616|NCT02742467|DRUG|Amlodipine plus Hydrochlorothiazide|Group 3
224043617|NCT01686360|BEHAVIORAL|Decision Aid|
224043618|NCT00619905|DRUG|ACZ885|
224043619|NCT00619905|DRUG|ACZ885|
224043620|NCT00839709|PROCEDURE|blood sampling|peripheral blood draw
223433519|NCT04154462|OTHER|Scribes|Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
223433520|NCT05161455|BIOLOGICAL|platelet rich fibrin|we would like to measure the effect of PRF on soft and hard tissue healing
223433521|NCT03731559|DRUG|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
224043621|NCT02024451|DEVICE|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
224043622|NCT02024451|DEVICE|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
224043623|NCT02863627|OTHER|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
224140981|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK I & II® Anatomic Shoulder System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus. The range of cases in which it can be used is wider than a simple reconstructive anatomical prosthesis. In fact, thanks to its anchoring plate, and if cephalic perfusion criteria are met, the modular nature of HUMELOCK II® means it is possible to retain the patient's native humeral head, even in cases of severe osteopenia.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus, a common occurrence in severely injured shoulders. The HUMELOCK II® shoulder system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed. The HUMELOCK II® shoulder prosthesis is a hemi shoulder and a total shoulder prosthesis."
224140982|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK II® Reversible System|"HUMELOCK II® is a new-generation of modular implant designed for the effective treatment of 3 or 4 part fractures of proximal humerus.~The HUMELOCK II® shoulder prosthesis allows the reconstruction of the shoulder joint as a result of a trauma (complex fracture of the proximal humerus). It is designed for use in complex shoulder reconstruction procedures in patients with stage 3 or 4 fragments in the proximal humerus - a common occurrence in severely injured shoulders. The HUMELOCK II® reversible system may also be suitable for treating cases of failure of an existing shoulder prosthesis where a stem or other locking mechanism may be needed.~The HUMELOCK II reversible system is used when the rotator cuff is injured."
224140983|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMELOCK Reversed® Shoulder System|Humelock Reversed® is a new generation of reversed prosthesis, designed for numerous shoulder pathologies: ranging from offset arthritis to a complex cephalotuberosity fracture. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post and the position of which is guided by an intuitive adaptive instrumentation. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible. Options of locking or cementing will allow the surgeon to position the prosthetic stem at the required height, according to the patient's indication and anatomy. The surgery is called total shoulder arthroplasty. It is also indicated in a failed hemi-arthroplasty or a failed total arthroplasty. It is indicated for significant rupture of rotator cuff-tear (first surgery or revision surgery)
224299739|NCT06855030|OTHER|Basic Body Awareness Therapy|"Body awareness movements will be performed in lying, sitting, and standing positions. Then, they will be varied by incorporating walking, running, and voice use. The patient will be asked to perform these movements with a specific rhythm and coordination. BBAT aims to enhance body awareness and create a more realistic body image by normalizing posture, balance, and muscle tension. The training process will involve gradually increasing awareness of the relationship with the floor, the vertical axis, centering, breathing, and flow. During this therapy process, the goal is to improve the individual's awareness of themselves and their surroundings, helping them adopt the here and now experience and later apply it in daily life. At the end of each session, time will be given for the patient to respond to their experience and express their thoughts. There is variability in the application duration in the literature."
223433522|NCT03731559|DRUG|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
223565704|NCT00904098|DRUG|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
223565705|NCT00904098|DRUG|Usual Care|Current treatment used to treat all migraine headaches
224043624|NCT05384379|DRUG|Inhaled BZ371B|Intubated patients suffering from ARDS will receive BZ371B in a dose of 12 mg. This will be divided into 2 nebulizations, each with 10 ml. The first nebulization is at a dose of 3 mg and the second at a dose of 9 mg.
224043625|NCT04869254|OTHER|Lower lymphocyte/ATG ratio|
224043626|NCT04869254|OTHER|Higher lymphocyte/ATG ratio|
224043627|NCT00566917|PROCEDURE|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
224043628|NCT00566917|PROCEDURE|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
224140984|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Anatomic Shoulder System|"EASYTECH Anatomical Shoulder System is indicated for use in total shoulder replacement to treat a severely painful and/or disabled joint resulting from osteoarthritis or rheumatoid arthritis.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. The surgery is called total shoulder arthroplasty. EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability"
224140985|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversed System (Primary intention)|"EASYTECH Reversed Shoulder System is indicated for primary total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation"
224140986|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with EASYTECH® Reversible System (for revision only)|"EASYTECH Reversible Shoulder System is indicated for revision total shoulder arthroplasty for the relief of pain and to improve function in patients with a massive and non-repairable rotator cuff tear.~EASYTECH system is a new generation of modular implant designed for the reconstruction of the shoulder joint for treating cases of degenerative pathology. . EASYTECH prosthesis is a stemless system of shoulder components. It is a bone-preserving implant. The anchor base provides primary stability to pulling-out thanks to peripheral pegs in the shape of fir trees and their asymmetric orientations ensure its rotational stability. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post (compatible with positioning techniques), and the position of which is guided by an intuitive adaptive instrumentation."
224043629|NCT05206591|BIOLOGICAL|Secukinumab|Secukinumab 300 s.c.
224043630|NCT05206591|OTHER|Placebo|Placebo
224043631|NCT02677376|OTHER|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a second NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
224043632|NCT05362383|DEVICE|transcutaneous electrical nerve stimulation (TENS):Enraf Nonius® S82 model|Will be used TENS device with a maximum frequency of 120 Hz and an intensity range of 0 to 99.5 milliampere. TENS electrodes (diameter 35-52 mm) will be placed bilaterally on mandibular elevator muscles, on the superficial masseter muscle above the gonial angle, and bilaterally on the anterior temporal muscle. The device will be applied in an identical manner to all patients in both groups and kept in position for the same time period (30 min) and for the control group the the device will be not switched on
224043633|NCT01375257|DRUG|Oral treatment with antibiotics for endocarditis|
224043634|NCT01375257|DRUG|Guideline treatment with parenteral antibiotics|
224043635|NCT05750797|DRUG|Oral corticosteroids|The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
224043636|NCT00836251|DIETARY_SUPPLEMENT|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
224043637|NCT04495855|DRUG|Dienogest (Visanne,BAY86_5258)|2 mg (once a day), oral, tablet.
224043638|NCT03841695|DEVICE|RMTC finger-hand robot (Mirror Hand)|The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.
224043639|NCT03841695|OTHER|Conventional OT|The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association \[AOTA\], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
224043640|NCT02710617|DEVICE|Blood glucose monitoring systems for point-of-care-testing|
224043641|NCT00120861|DRUG|valopicitabine|
224043642|NCT00120861|DRUG|pegylated interferon|
224304950|NCT05122936|COMBINATION_PRODUCT|XRXPY-based Obesity Wellness Intervention(SOWI)|It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.
223565706|NCT01882426|OTHER|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
223565707|NCT01882426|OTHER|Usual Care|usual step care practice
224043643|NCT00120861|DRUG|ribavirin|
224043644|NCT01701076|DRUG|Bendamustine|"Induction treatment phase (cycle 1-6):~* Bendamustine 75 mg/m2 i.v day 1 and 2~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~* Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~* Lenalidomide 25 mg p.o. day 1-21~* Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
224043645|NCT05788003|DIAGNOSTIC_TEST|self-collected and operator-collected swab followed by molecular analysis|A single midday urine sample and two cervical-vaginal swabs (both self-collected and speculum-aided collected by a female healthcare worker) will be obtained from participating women and processed using urine filtration and polymerase chain reaction (PCR) for cervico-vaginal samples.
224043646|NCT03742635|OTHER|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
224043647|NCT03819036|OTHER|Questionnaires|Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
224140987|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Anatomic Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals. A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability. The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible.
224163445|NCT06433024|DIAGNOSTIC_TEST|PPG Diagnostic|The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
224043648|NCT05522049|DEVICE|hyperangulated videolaryngoscope|Intubation using a hyperangulated videolaryngoscope
224043649|NCT05522049|DEVICE|Macintosh videolaryngoscope|Intubation using a Macintosh videolaryngoscope
224043650|NCT04029116|DRUG|Fluconazole Tablet|150 mg every 72 hours for 3 doses
224043651|NCT04029116|DRUG|IBREXAFUNGERP|300 mg BID (one day) every 4 weeks for a total of 6 dosing days
224043652|NCT04029116|DRUG|Placebo oral tablet|BID (one day) every 4 weeks for a total of 6 dosing days
224043653|NCT06072560|DRUG|Adezunap (AP707)|Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
224043654|NCT06072560|DRUG|Placebo|Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
224043655|NCT03606980|DRUG|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
223565708|NCT02132923|BIOLOGICAL|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
223565709|NCT01174537|BIOLOGICAL|New Castle Disease Virus|Patients will receive IV 1\*10\^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
223565710|NCT02839720|OTHER|Laboratory Biomarker Analysis|Correlative studies
224043656|NCT03606980|PROCEDURE|Iontophoresis|Iontophoresis on affected knee
224043657|NCT03606980|PROCEDURE|Physical Therapy|Physical therapy of affected knee
224043660|NCT00797836|PROCEDURE|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/\*epidemiology/\*statistics \& numerical data Occupational Exposure/\*statistics \& numerical data~Tuberculosis/\*diagnosis/\*epidemiology/prevention \& control Immunologic Tests/methods/\*standards Disease Transmission, Horizontal/\*statistics \& numerical data Patient Isolation~Tuberculin Test/standards/\*methods Immunoassay/methods/\*standards T-Lymphocytes/immunology Interferon Type II/\*blood/\*analysis~\*Reagent Kits, Diagnostic~Mass Screening/\*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/\*methods"
224043661|NCT04048980|BEHAVIORAL|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
224043662|NCT02843763|OTHER|Blood sample|Blood sample (28 ml)
224043663|NCT05134090|DEVICE|Ovaian tissue explant|Ovarian tissue explant for cryopreservation of ovarian tissue
224043664|NCT01609751|DIETARY_SUPPLEMENT|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
224043665|NCT00194844|BEHAVIORAL|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
223433523|NCT05477485|BEHAVIORAL|Experimental: AIMS program - patient|Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by \>30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) \>30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for \>60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.
223433524|NCT05477485|OTHER|No Intervention/Usual care|Participants in the usual care arm will receive standard state-level care for late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.
223433525|NCT05983120|OTHER|Education|Educate the patients who suffer from Type 2 Diabetes Mellitus
223433526|NCT02720744|DRUG|FT218|
223433527|NCT02720744|DRUG|Placebo|
223433528|NCT06328881|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223433529|NCT06328881|DEVICE|Intermittent Oro-esophageal Tube|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223433530|NCT06328881|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223433531|NCT05525442|PROCEDURE|percutaneous cholecystostomy|Transhepatic gallbladder drainage was performed under ultrasound guidance after local anesthesia was administered by interventional radiology to patients with acute cholecystitis. Subsequently, an 8-10 Fr pigtail catheter was inserted into the gallbladder using a guide wire under fluoroscopy.
223433532|NCT04612881|DRUG|fitostimoline vaginal pessaries|vaginal pessaries
223433533|NCT04612881|OTHER|standard of care|standard of care
223433534|NCT01021475|PROCEDURE|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
224043666|NCT00194844|BEHAVIORAL|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
223433535|NCT01021475|DRUG|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
223433536|NCT01942499|OTHER|Community-based exercise program|
223433537|NCT03494972|DRUG|Tetracyclin ointment|During 3rd molar surgery
223433538|NCT00403650|DRUG|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
223433539|NCT04938219|OTHER|Gloves filled with warm tap water|The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
223433540|NCT05168332|BEHAVIORAL|patellar taping combined with isometric strength training|patellar taping combined with isometric strength training
224043667|NCT00194844|BEHAVIORAL|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
224043668|NCT02218190|DRUG|Alvimopan|
224043669|NCT02218190|DRUG|Placebo|
224043670|NCT06290063|DRUG|fsCBD Cannabidiol|Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
224043671|NCT06290063|DRUG|bsCBD Cannabidiol|Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
224043672|NCT06290063|DRUG|Placebo|Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
224043673|NCT02469896|DRUG|Tocilizumab|IV Infusion
224043674|NCT02469896|OTHER|Placebo|IV Infusion
224043675|NCT05972382|DIAGNOSTIC_TEST|Quantitative Sensory and Neurophysiological Testing|"Participants will undergo the following quantitative sensory and neurophysiological diagnostic tests:~Surface electromyography (EMG) of the neck flexor muscles during the craniocervical flexion test to assess neck flexor muscle fatigue. EMG sensors will be placed over the sternocleidomastoid and longus colli muscles. Cervical joint position error testing to evaluate proprioceptive awareness and cervicocephalic kinesthetic sensibility. Participants will be seated upright and blindfolded."
224043676|NCT05709236|DEVICE|Maxillary screw-retained prosthesis|Maxillary screw-retained prosthesis with conventional full-arch impression with conventional or digital impression
224043677|NCT05549778|DRUG|Polaprezinc group|Abiraterone plus Polaprezinc for 6 months
224043678|NCT05549778|DRUG|Control group|Abiraterone, radio- or chemotherapy
224140988|NCT05284357|DEVICE|Shoulder Arthroplasty Surgery with HUMERIS® Reversible Shoulder System|The HUMERIS Shoulder system is intended to be used in adult patients with glenohumeral joint degenerative pathologies associated or not with rotator cuff arthropathy or tears when all other non-invasive treatments have failed to reduce the pain or improve the quality of life. The HUMERIS shoulder is a system of short stem.The technical characteristics of this implant have been designed based on computer simulations, correlated to results previously published in medical journals, in order to avoid the disadvantages of traditional reverse prostheses. A centric or eccentric glenosphere, tilted at 10°, centered on a variable length baseplate post, the position of which is guided by an intuitive adaptive instrumentation.A 145° prosthetic epiphysis allows the pillar of the scapula to be protected while maintaining optimum stability.The humeral implant is positioned naturally in the center of the epiphysis, preserving the remaining bone as much as possible
223433541|NCT05168332|BEHAVIORAL|sham patellar taping combined with isometric strength training|sham patellar taping combined with isometric strength training
223433542|NCT06621069|DRUG|Bisphosphonates|Alendronate Sodium or Zoledronic acid
223433543|NCT06621069|OTHER|Control|control without BP
223433544|NCT05974644|OTHER|Registry|The purpose of this registry is to collect and store health information from people who are carriers of the gene known to cause hereditary amyloidosis and those with a confirmed diagnosis of the disease.
223433545|NCT02380495|OTHER|Data Collection|
223433546|NCT01942031|BEHAVIORAL|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
223433547|NCT06197412|DRUG|Yunnan Baiyao|On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
223433548|NCT01890616|DEVICE|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
223433549|NCT02026336|OTHER|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
223433550|NCT01696149|DEVICE|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
223433551|NCT05680831|BIOLOGICAL|0.070 ppm ozone concentration|The concentration of ozone a subject will randomly receive on a visit for 6.6 hours in a controlled atmospheric chamber while performing moderate intermittent exercise.
223433552|NCT05680831|BIOLOGICAL|Clean air (0.0 ppm ozone)|Same subject will randomly receive clean air on another visit separated by at least one week for 6.6 hours in the same controlled atmospheric chamber while performing moderate intermittent exercise.
223433553|NCT01681316|DRUG|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
223433554|NCT01681316|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
224043679|NCT05102578|BEHAVIORAL|Digital Decision Aid Tool|The digital DAT will ask people about their current pain levels, medications and physical activity. Following this, it will include a Discrete Choice Experiment (DCE)-like component with a series of questions that ask users to choose between different pain management packages. Similar to a standard DCE, packages (or plans) are described by attributes and levels, which include broad categories of guideline-based pain management strategies routinely available in clinical practice. The descriptors used for the attributes and levels were informed by a previous qualitative research study and based on therapeutic options that are helpful and important to people with persistent pain .
224043680|NCT04404322|OTHER|IPT A Suicide Crisis Intervention|The intervention is comprised of five weekly sessions followed by monthly emails to the patients and their parents over a period of three months. The first session is aimed at introducing the intervention, assessing depression and suicidal risk and building a safety plan. The safety plan consists of a prioritized list of coping strategies that the patient can use when suicidal risk is increased. The second session is focused on reviewing the patient's interpersonal relationships (using the closeness circle and interpersonal inventory) and conceptualizing the interpersonal problem area. Sessions 3-4 focus on developing and practicing interpersonal, emotional and behavioral coping strategies relevant for suicidal risk. Lastly, in session 5, patient and therapist go over the process and main issues which were worked on, emphasizing relapse prevention by going back to the safety plan. First and fifth sessions always involve the parents.
224043681|NCT04404322|OTHER|Treatment As Usual|patients receive an integrative combination of psychodynamic, supportive and cognitive behavioral therapy, usually lasting between 10-30 weeks
224043682|NCT03937284|OTHER|Patients not treated|
223433555|NCT01681316|DRUG|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
223433556|NCT03258008|DRUG|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
223433557|NCT03258008|BIOLOGICAL|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
223433558|NCT01199822|BIOLOGICAL|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
223433559|NCT01451242|OTHER|no intervention is made|no intervention is made
223433560|NCT02553707|DRUG|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
224043683|NCT03429439|OTHER|intestinal microbiota transplant|Participants in experimental group take 6 times IMT with 2-week intervals.
224043684|NCT03429439|DRUG|Antiviral Agents|All participants continue present antiviral therapy over 12 months.
224043685|NCT04341168|OTHER|this study is non- interventional|this study is non- interventional
224043686|NCT02839057|PROCEDURE|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
223433561|NCT02013856|DIETARY_SUPPLEMENT|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
224043687|NCT02839057|PROCEDURE|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
223433562|NCT02013856|DIETARY_SUPPLEMENT|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
223433563|NCT02013856|DIETARY_SUPPLEMENT|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
223433564|NCT02013856|DIETARY_SUPPLEMENT|Placebo|Placebo control once daily for 28 days
223433565|NCT00480493|BEHAVIORAL|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
223433566|NCT05958745|BEHAVIORAL|Aerobic Exercise|Aerobic exercise training Program
223433567|NCT05958745|BEHAVIORAL|Aerobic + resistance exercise|Aerobic + resistance exercise training Program
223433568|NCT03284645|DRUG|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
223565711|NCT02839720|DRUG|Selumetinib Sulfate|Given PO
224043688|NCT04862624|BEHAVIORAL|Catalina Story-Based Web-App|"Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety."
224043689|NCT04862624|BEHAVIORAL|Attention Control Web-App|Latinas in the attention control group will view non-story based media that is informational.
224043690|NCT01791023|OTHER|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
224043691|NCT01294150|DEVICE|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
224140989|NCT01517412|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
223433569|NCT03284645|DRUG|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
223433570|NCT03284645|DRUG|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
224043692|NCT01294150|OTHER|Cystoscopy|The Control Group will undergo cystoscopy.
224043693|NCT01294150|DEVICE|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
224043694|NCT03708120|OTHER|Citrepel (Insect Repellent) EPA Reg. No. 84878-2|Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
224140990|NCT01517412|DEVICE|Self-injector pen device (OptiClik®)|
224140991|NCT01517412|DRUG|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
223433571|NCT00568360|DEVICE|Oximeter|
223433572|NCT05362240|PROCEDURE|Four corner fusion|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denuded the articulating surfaces between lunate , capitate , hamate and triquetrum . Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones
223433573|NCT05362240|PROCEDURE|three corner fusion without triquetrum excision|First , we inspected the radiocarpal joint for any arthritis before starting the technique , if there was no arthritis , we go on for the procedure . After scaphoid excision , we denude the articulating surfaces between lunate , capitate , hamate and don not include triquetrum. Then ,any lunate extension deformity was corrected . Then we use k.wires as a fixation method between the above mentioned carpal bones.
223433574|NCT05123469|DEVICE|Electroencephalography|Simultaneous recording of electroencephalogram by conventional EEG device and the Zeto EEG device
223433575|NCT04375501|OTHER|Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail|If fit for anaesthesia patients may undergo relevant procedure for fractured neck of femur as per NICE guidelines within limitations of resources as defined by BOAST
224140992|NCT02851368|DEVICE|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
224140993|NCT02851368|DRUG|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
223565712|NCT00659100|DRUG|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
223565713|NCT01812200|DRUG|Dabigatran, Ticagrelor, ASA|
223565714|NCT01812200|DRUG|Rivaroxaban, Ticagrelor, ASA|
224163446|NCT05385913|OTHER|Multivitamin-no intervention|No intervention. All participants will be given a multi-vitamin to take for the duration of the study
223565715|NCT01812200|DRUG|Phenprocoumon, Ticagrelor, ASA|
223740520|NCT04999150|PROCEDURE|Corticotomy|"A full-thickness labial mucoperiosteal flap was reflected. Two vertical corticotomies (1 mesial and 1 distal to the canine) were performed. The cortical bone was cut 2 to 3 mm below the alveolar crest towards the apex, until bone marrow was exposed.~Cortical-cancellous bone grafts (0.5cc; PuraGraft, Kingwood, TX) were placed at the corticotomy sites.~The mini-screws were placed. A nickel-titanium (NiTi) closed-coil spring was placed and secured with a 0.014SS ligature wire at the canine and mini-screw. A Dontrix gauge (Orthopli Corp., Philadelphia, PA) was used to measure the force (150g)"
223433576|NCT03769675|DEVICE|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
223433577|NCT05914675|DRUG|Letermovir|For enrolled patients, Letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). The regimen would start between +7\~+14d after transplantation. The total duration of dosing was approximately 100 days or 14 weeks.
223433578|NCT01032070|DRUG|erlotinib|oral
224043695|NCT04236895|DRUG|Gan & Lee Insulin Glargine Injection|All IMPs will be administered as a 0.5 U/kg single subcutaneous dose by a pre-filled pen.
224043696|NCT05511493|DEVICE|fractional Erbium-YAG laser|Platelet-rich plasma with fractional Erbium-YAG laser in localized stable vitiligo
223433579|NCT01032070|DRUG|etoposide|oral
223433580|NCT04027075|BEHAVIORAL|Qlarity app users|Use of the Qlarity app involves completing 12 modules and 12 practice sessions over 30 days.
223433581|NCT05411094|PROCEDURE|Biopsy Procedure|Undergo biopsy
223433582|NCT05411094|PROCEDURE|Biospecimen Collection|Undergo collection of blood and buccal samples
223433583|NCT05411094|PROCEDURE|Computed Tomography|Undergo CT scan
223433584|NCT05411094|BIOLOGICAL|Durvalumab|Given IV
224043697|NCT05511493|DEVICE|microneedling|Platelet-rich plasma with microneedling in localized stable vitiligo
224043698|NCT06116227|DEVICE|Whole Body Vibration Training Plus Conventional Physical Therapy Exercise Program.|Patients in the study group will receive the traditional physical therapy program first, followed immediately by whole-body vibration training on the vibration platform (Power Plate International, Irvine, California, USA) at the same visit. The vibration frequency will be 30 Hz and the amplitude will be from 4 to 7 mm, with an increase of 1mm every two weeks. The WBV program was three sessions a week for eight weeks. WBV duration starts with 10 min in the 1st week and up to 25 min in the 8th week, with a regular increase of five minutes after every two successive weeks.
224043699|NCT06116227|OTHER|Conventional Physical Therapy Exercise Program.|The program will include 60 minutes of a supervised and individualized exercise program, including stretching exercises for the Calf and hamstring muscles, followed by strengthening exercises for hip, knee, ankle, and foot muscles, and scar management techniques to avoid scar or contracture formation.
223433585|NCT05411094|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223433586|NCT05411094|DRUG|Olaparib|Given PO
223433587|NCT00586287|OTHER|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
224043700|NCT05483205|DRUG|Normaderm Phytosolution Double-Correction Daily Care Moisturizer|Normaderm Phytosolution (NP) was to be applied for up to 90 days once or twice daily, according to the investigator's prescription.
224043701|NCT02755168|PROCEDURE|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
224043702|NCT02755168|PROCEDURE|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
224043703|NCT00127920|DRUG|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
224043704|NCT06124898|DEVICE|Alcohol-related mobile health technologies|Participants will be asked to use the three mobile technologies as they choose while drinking for a two-week period.
224043705|NCT06124898|BEHAVIORAL|Motivational interview and psychoeducation on blood/breath alcohol concentration|Brief 25/30-minute motivational interview and psychoeducation on blood/breath alcohol concentration that includes both personalized and standardized information.
224043706|NCT06124898|BEHAVIORAL|Lower tech facilitation|Study staff will review instructions for technology use closely with participants and guide them in use of existing phone technologies as reminders for use of the three moderate drinking technologies during drinking situations.
224043707|NCT06124898|DEVICE|Higher tech facilitation|Participants will use an app developed during the study that will provide protective behavioral strategies and reminders for use of the three moderate drinking technologies during drinking situations.
224043708|NCT06124898|BEHAVIORAL|Attention control psychoeducation|Brief 25/30-minute psychoeducation on a topic not related to alcohol use that will be developed in the course of the study.
223433588|NCT00586287|OTHER|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
223433589|NCT00586287|DRUG|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
223433590|NCT04306887|DRUG|TQ-B3101 capsule|Escalating doses starting at 200 mg bid.
223433591|NCT02888353|DEVICE|Device: MRI|Perform MRI in patients with cardiac devices
223433592|NCT00738062|DRUG|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
224043709|NCT06124898|DEVICE|Attention control technology|App or other form of technology that will be developed in the course of the study to deliver information not related to alcohol use
224043710|NCT02282566|OTHER|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
223433593|NCT00738062|DRUG|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
223740521|NCT05673044|PROCEDURE|modified Studer ileal neobladder|orthotopic ileal neobladders
224043711|NCT02368067|PROCEDURE|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
224043712|NCT02368067|PROCEDURE|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
224043713|NCT03675776|DRUG|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
223433594|NCT00426660|DRUG|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
223433595|NCT02772276|DRUG|MB-102-- single dose of 4 µmol/kg|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
224043714|NCT03675776|DRUG|Placebo|Placebo (prefilled syringe, weekly IV administration).
224140994|NCT00169910|DRUG|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
224140995|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
224140996|NCT01253187|DRUG|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
224299740|NCT06319079|DIETARY_SUPPLEMENT|Fortified powder milk|Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.
224299741|NCT06319079|OTHER|Powder milk|Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.
223433596|NCT02772276|DRUG|MB-102-- single dose of 130 mg|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
223433597|NCT02772276|DRUG|MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apart|130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.
223565716|NCT04816656|OTHER|ePROMs assessment|"At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations."
223565717|NCT02649218|BIOLOGICAL|Ligelizumab|QGE031 240 mg s.c. q4w
223740522|NCT01001507|PROCEDURE|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
224043715|NCT00058474|DRUG|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
224043716|NCT00058474|DRUG|fluorouracil|225 mg/m2 IV daily continuous infusion
224043717|NCT00058474|DRUG|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
224043718|NCT00058474|RADIATION|radiation therapy|Given 5 days a week for 5-6 weeks
224043719|NCT02401412|DEVICE|Test Ostomy Barrier|
224043720|NCT02401412|DEVICE|Control Ostomy Barrier|
224140997|NCT01253187|DRUG|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
224140998|NCT04018703|DRUG|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
224140999|NCT04018703|DRUG|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
224141000|NCT04445350|OTHER|External Focus Of Attention|Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.
224141001|NCT04445350|OTHER|Internal Focus Of Attention|In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
224141002|NCT05158179|DEVICE|Sensation testing|Sensation testing tactile aesthesiometer.
224141003|NCT00278941|DRUG|Quetiapine Fumarate Sustained Release|
224141004|NCT05143567|OTHER|standard of care anticoagulation in absence of thrombotic complications|Subgroup IA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IB - patients receive LMWH (enoxaparin) for the prevention or treatment of VTE Subgroup IC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
224299742|NCT01893645|DEVICE|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
224299743|NCT06922383|DRUG|arfolitixorin (ARFOX + bevacizumab)|Every 14 days during treatment phase, Bevacizumab will be administered as an i.v. infusion of 5 mg/kg, Oxaliplatin will be administered as an 85 mg/m2 i.v. infusion, 5-FU will be administered as a 400 mg/m2 i.v. bolus + a 2,400 mg/m2 i.v. infusion and Arfolitixorin will be administred as an i.v. infusion.
224043721|NCT01585220|DEVICE|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
224141005|NCT05143567|OTHER|standard of care anticoagulation in presence of thrombotic complications|Subgroup IIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) for the prevention or treatment of VTE Subgroup IIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) for the prevention or treatment of VTE Subgroup IIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) for the prevention or treatment of VTE
224043722|NCT00526396|DRUG|cisplatin|80 mg/m2 on day 1 for 6 cycles
224043723|NCT00526396|DRUG|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
224043724|NCT00526396|DRUG|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
224043725|NCT00526396|DRUG|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
224043726|NCT01519076|DEVICE|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
224043727|NCT03244748|PROCEDURE|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
224043728|NCT05558306|PROCEDURE|Surgery of distal radius fracture|Surgery of distal radius fracture for displaced fractures
224043729|NCT05558306|PROCEDURE|Reduction and cast treatment of distal radius fracture|Reduction and cast treatment of distal radius fracture for minimally displaced fractures
224043730|NCT04275141|OTHER|oral glucose load|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
224043731|NCT04275141|OTHER|exercise test|oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
224043732|NCT04246801|DRUG|Clobetasol propionate|Clobetasol propionate ophthalmic nanoemulsion 0.05%, is an oil-in-water (o/w), clear or slightly yellowish nanoemulsion containing the active ingredient clobetasol propionate at a concentration of 0.05% weight per weight (w/w)
224043733|NCT04246801|DRUG|Vehicle|Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
224043734|NCT03684642|DRUG|Efpeglenatide|Pharmaceutical form: solution for injection; Route of administration: SC
224043735|NCT03684642|DRUG|Dulaglutide|Pharmaceutical form: solution for injection; Route of administration: SC
224043736|NCT03684642|DRUG|Background therapy Metformin|Pharmaceutical form: tablet; Route of administration: oral; Dose to be kept stable throughout the study.
224043737|NCT06495385|DIAGNOSTIC_TEST|Evolution of renal function|Plasma creatinine levels and glomerular filtration rate estimated using the CKD-Epi formula adjusted for 1.73 m2 body surface area will be measured.
224043738|NCT06495385|DIAGNOSTIC_TEST|Measurement of haemoglobin levels|Haemoglobin levels will be measured.
224043739|NCT06495385|DIAGNOSTIC_TEST|Measurement of biological parameters|Plasma levels of urea, calcium, phosphorus and parathyroid hormone, as well as alkaline reserve, will be measured.
224043740|NCT06495385|DIAGNOSTIC_TEST|Measure sodium and protein consumption|24-hour urine volume, proteinuria, urea and sodium, will be measured.
224043741|NCT06495385|BEHAVIORAL|Quality of life questionnaire EUROQOL 5 dimensions (EQ-5D-5L)|"The descriptive system comprises five dimensions: mobility, personal care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The figures for the five dimensions can be combined into a 5-digit number describing the patient's state of health. Scores close to 1 indicate the best health you can imagine and those close to 0 the worst health you can imagine."
224043742|NCT06010771|OTHER|Listening to fairy tales|Fairy tales by children will be chosen by child psychologists. Tales will be read to the children by the researcher. The researcher has a fairy tale therapy certificate. The tale reading will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Tales will be read to children every other day. This process will continue for 3 weeks.
224043743|NCT06010771|OTHER|Watching Cartoon Film|The cartoons that children will watch will be preferred by child psychologists. Children will be watched cartoons with the help of tablets. Watching cartoons will start 5 minutes before the aspiration process and will continue throughout the aspiration process. Children will be shown cartoons every other day. This process will continue for 3 weeks.
224043744|NCT00717054|DRUG|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
224043745|NCT00717054|DRUG|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
224043746|NCT02743351|BIOLOGICAL|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
224043747|NCT02743351|BIOLOGICAL|Control Arm|Untreated mobilized peripheral blood (mPB) cells
224043748|NCT00161486|DRUG|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
224043749|NCT00161486|DRUG|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
224043750|NCT00161486|DRUG|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
224163447|NCT01326390|DEVICE|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
224163448|NCT01326390|PROCEDURE|DSA arteriogram- hepatic arteries|Standard of care
224163449|NCT01326390|PROCEDURE|CO2 aortogram|Standard of care
224163450|NCT01481766|DIETARY_SUPPLEMENT|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
224163451|NCT01481766|DIETARY_SUPPLEMENT|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
224163452|NCT01481766|BEHAVIORAL|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
224163453|NCT03737396|PROCEDURE|Self-administered electronic health screening|Health assessment using an electronic device
224163454|NCT00684463|DRUG|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
224163455|NCT00325949|DRUG|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
224163456|NCT00325949|DRUG|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
223433598|NCT02772276|DRUG|MB-102-- two doses of 130 mg 24 hours apart|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.
223433599|NCT02772276|DRUG|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
223433600|NCT02772276|DEVICE|QuantumLeap|Optical Renal Function Monitor (ORFM)
223433601|NCT02772276|DEVICE|Radiance|Optical Renal Function Monitor (ORFM)
223433602|NCT02772276|DEVICE|Brilliance (1 or 2 sensors)|Optical Renal Function Monitor (ORFM)
223433603|NCT02772276|DEVICE|Brilliance (2-part sensor)|Optical Renal Function Monitor (ORFM)
223433604|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with a 30 degree straight to cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
224043751|NCT00161486|DRUG|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
223433605|NCT06525662|PROCEDURE|Endotracheal intubation using an endotracheal tube with an arcuate cuff shape|Placement of an endotracheal tube into a simulated trachea in a mannequin using the abovementioned shape
223433606|NCT00980174|DRUG|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
223433607|NCT00980174|OTHER|Placebo|Placebo for denosumab (SC injection every 6 months)
223433608|NCT00455520|DRUG|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
224043752|NCT04556396|DIAGNOSTIC_TEST|Cone beam CT|On-table CT scan in the operating room to determine residual kidney stone burden at end of procedure
224043753|NCT01763151|DEVICE|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
224043754|NCT01763151|PROCEDURE|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
224043755|NCT01326728|BIOLOGICAL|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
224043756|NCT02966223|RADIATION|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
224043757|NCT00674193|OTHER|pharmacological study|Correlative studies
224043758|NCT00674193|OTHER|laboratory biomarker analysis|Correlative studies
223433609|NCT00455520|DRUG|placebo|matching placebo twice daily for 12 weeks
223433610|NCT02064465|DRUG|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
223433611|NCT02064465|DRUG|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
224043759|NCT00688012|DRUG|SPC3649|
224043760|NCT02939989|DRUG|Sofosbuvir|Tablet for oral administration
224043761|NCT02939989|DRUG|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
224043762|NCT02939989|DRUG|Ribavirin|Tablet for oral administration
224043763|NCT01615653|PROCEDURE|EUS|EUS Guided Therapy
224043764|NCT05767866|DRUG|YK-029A|Daily dose of YK-029A
223433612|NCT00109876|PROCEDURE|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
223433613|NCT00791830|DRUG|Irbesartan|Tablets, 300 mg \* 1 daily, 1 year
223433614|NCT00791830|DRUG|Placebo matching irbesartan 150 mg|Tablets, 300 mg \* 1 daily, 1 year
224043765|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =\>90 mL/min)
224043766|NCT01419041|DRUG|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr \<30 mL/min)
224043767|NCT06441526|DRUG|anti-tumour necrosis factor α antibodies|Biological drug
223433615|NCT06731569|DEVICE|Advanced intelligence drill|"The AI drill is an innovative surgical tool designed specifically for Maxillary Sinus Floor Augmentation (MSFA) procedures. It incorporates advanced technology to enhance safety, precision, and efficiency during lateral window preparation.~It has an Automated Pressure-Sensing Mechanism which makes the drill automatically stops rotating when it detects contact with the Schneiderian membrane, minimizing the risk of perforation.~The OLA kit consists of Hydraulic Lift which is compatibility with the drill connected to a saline-filled syringe to gently elevate the Schneiderian membrane from the sinus floor.~It involves a Multi-Step Drilling Process using different drill tips designed each for a specific task including the pilot drill for initial window creation and the non-cutting ball-end drill for lateral wall thinning and smoothing.~It works at a controlled high-Speed Performance of 6000 RPM with irrigation system included."
224043768|NCT06441526|PROCEDURE|Advancement plasty|Surgical closure of the internal opening
224043769|NCT04379648|OTHER|self-assessment and hetero-assessment|Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
224043770|NCT00528892|DRUG|Raltegravir|switching PI to raltegravir
224043771|NCT00528892|DRUG|boosted PI|continue on boosted-PI
224043772|NCT00628173|PROCEDURE|AGV implantation|
224043773|NCT02849158|OTHER|Biopsy|Rectoscopy with biopsy
224043774|NCT02169180|DRUG|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response \[CR\]), unacceptable toxicity, or end of treatment, whichever occurs first.
224043775|NCT03358511|DIETARY_SUPPLEMENT|Probiotic|Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
224163457|NCT00325949|DRUG|placebo|2 tablets BID
224163458|NCT04295668|BEHAVIORAL|Usual care|The preoperative standard measures consist of physical activity recommendation and advice on both smoking cessation and alcohol intake reduction. Moreover, in patients presenting with anemia, the anesthesiologists will assess its etiology and treat it accordingly, and nutritional intervention will be performed by a registered dietitian in to those patients at risk of malnutrition (Malnutrition Universal Screening Tool ≥2).
223433616|NCT06731569|DEVICE|Traditional rotary instrument|"Traditional Rotary Drill~The traditional rotary drill is a commonly used surgical tool in Maxillary Sinus Floor Augmentation (MSFA) procedures, employing conventional drilling techniques for lateral window preparation. It is a widely recognized method due to its accessibility and effectiveness in skilled hands.~It Uses a rose-head bur attached to a surgical straight handpiece that operates at speeds of 800-1200 RPM with irrigation to prevent overheating and ensure efficient bone cutting.~It is a manual operator control that requires the surgeon's skill and experience to control the depth and force of drilling. And relies on visual and tactile feedback to identify when the Schneiderian membrane is close to exposure.~It is versatile and can be adapted to varying bone densities and anatomical complexities. It is effective for creating the window for sinus access.~It comes with an irrigation system to avoid necrosis of the bone."
223433617|NCT03862768|PROCEDURE|surgery|Surgery requires at least removal of all drug-resistant lesions.
223433618|NCT03862768|DRUG|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
223433619|NCT03862768|DRUG|Imatinib escalation|Imatinib 600 MG/d
223433620|NCT03862768|DRUG|Sunitinib|Sunitinib 37.5 MG/d
223433621|NCT05763368|DIAGNOSTIC_TEST|Clinical tests and proprioception evaluation|Each patient will be evaluated using clinical scales (BBS, HHS, HOOS, SF12) and ''Delos Proprioceptive System'' to assess postural stability and proprioception.
223740523|NCT01077947|PROCEDURE|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
224043776|NCT04728126|OTHER|Survey|"The questionnaire will include socio-demographic information (i.e., gender, age, job seniority) and sub-scales for measuring study variables (i.e., menopausal symptoms, social and personal resources, burnout, and work ability).~Menopausal symptoms will be assessed using the Menopause-Specific Quality of Life questionnaire.~Job burnout will be measured through OBI inventory, which consists of 16 items describing the states of emotional exhaustion and detachment - two core dimension of burnout, and were developed to meet different occupational groups.~The menopause and the quality of working environment will be assessed using the Questionnaire developed by National Health Service in England and Wales."
224043777|NCT05973097|DRUG|total glucosides of paeony treatment|Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.
224043778|NCT05973097|OTHER|photodynamic therapy treatment|Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.
224043779|NCT05973097|OTHER|glucosides of paeony and photodynamic therapy combined treatment|Glucosides of paeony and photodynamic therapy are combined for the treatment
224043780|NCT01883986|BEHAVIORAL|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
224043781|NCT03624205|DEVICE|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
224043782|NCT01636791|BEHAVIORAL|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
224043783|NCT01636791|BEHAVIORAL|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
224043784|NCT03792386|PROCEDURE|Ultrasound guidance with fluoroscopic confirmation|the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
224141006|NCT05143567|OTHER|standard of care anticoagulation in combination with elastic compression|Subgroup IIIA - patients receive UFH (heparin, 7500 Units 2-3 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIB - patients receive LMWH (enoxaparin, 0.4ml 2 times daily) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE Subgroup IIIC - patients receive oral anticoagulants (rivaroxaban 10mg QD) in combination with class II elastic compression (compression stockings above the level of the knee) for the prevention or treatment of VTE
224141007|NCT01598207|DRUG|Marinol|5mg BID, orally for 1 month
224141008|NCT01598207|DRUG|Placebo|5mg BID, orally for 1 month
224141009|NCT01991405|DEVICE|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
224141010|NCT05399849|BEHAVIORAL|Mindfulness Exercises and Meditations|Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
224141011|NCT01566058|DEVICE|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
223433622|NCT01811836|DIETARY_SUPPLEMENT|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
223433623|NCT05839184|DEVICE|therapeutic toy|Neonates in the therapeutic toy group will be given an octopus-shaped therapeutic toy that they can hold in their hands throughout the procedure and IV catheter will be inserted and their comfort levels and vital signs will be monitored.
223433624|NCT06214702|DIAGNOSTIC_TEST|ELISA|ELISA estimation of PLGF, sFlt-1 and Serpin C
223433625|NCT06036784|DRUG|MBX 1416 (Part A)|Single Ascending subcutaneous (SC) dose of MBX 1416: 10mg, 30mg,100mg, 200mg
224043785|NCT03792386|PROCEDURE|Fluoroscopic guidance with ultrasonographic confirmation.|After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced \~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
224141012|NCT01566058|OTHER|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
224141013|NCT03434704|DRUG|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age \> 65 years.
224141014|NCT03434704|PROCEDURE|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
224141015|NCT03434704|DRUG|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: \>80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
224141016|NCT03434704|DRUG|Primary antifungal prophylaxis|Posaconazole delayed-release tablet \[available in 100 mg tablets\]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
224141017|NCT03484351|OTHER|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
224141018|NCT01509872|BEHAVIORAL|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
223433626|NCT06036784|DRUG|MBX 1416 (Part B)|Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
223433627|NCT06036784|DRUG|Placebo|Single dose or repeated subcutaneous (SC) dose of placebo.
223433628|NCT06036784|DRUG|MBX 1416 (Part C)|Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
223433629|NCT04056000|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine, 60 minutes before exercise
223433630|NCT04056000|DIETARY_SUPPLEMENT|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
223433631|NCT04056000|BEHAVIORAL|60-minutes of steady state exercise|See intervention name
223433632|NCT01477294|DRUG|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
223565718|NCT03745443|PROCEDURE|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
223433633|NCT01477294|DRUG|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
223433634|NCT01752894|DEVICE|Angio-guided PCI with EES or BES|Angio-guided intervention
223433635|NCT01752894|DEVICE|OCT-guided PCI with EES or BES|OCT-guided intervention
223740524|NCT01077947|PROCEDURE|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
223740525|NCT02631850|BEHAVIORAL|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
223433636|NCT01752894|DEVICE|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
223433637|NCT01752894|DEVICE|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
223565719|NCT01183052|OTHER|Training|20 sessions of training
223565720|NCT04161443|OTHER|physiotherapy|"* Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
223565721|NCT05986968|DRUG|Ticagrelor|Ticagrelor monotherapy for 12 months
223740526|NCT02631850|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
223740527|NCT02631850|BEHAVIORAL|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
223433638|NCT01752894|DRUG|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (\>6%) at 3months OCT follow up after stent implantation.
223433639|NCT01752894|DRUG|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
223433640|NCT02848989|OTHER|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
223433641|NCT03337594|DRUG|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
223433642|NCT03337594|DRUG|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
223565722|NCT05986968|DRUG|Aspirin|Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
223740528|NCT02631850|BEHAVIORAL|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
223740529|NCT06135233|OTHER|No intervention|all patients undergoing minimally invasive pancreatic surgery, no intervention, no randomization
223740530|NCT01415063|PROCEDURE|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
224043786|NCT02067182|DRUG|Dabigatran|"* Antral pulmonary vein ablation for patients with AF~* left atrial fibrosis/electrical scar assessment by electroanatomical mapping~* followed by 6 months OAC (3 months blanking period + 3 months observation period)~* in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~* followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~* Experimental arm (group A): OAC with dabigatran for 12 months~* Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
224043787|NCT01927185|DEVICE|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
224043788|NCT01927185|DEVICE|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
224043789|NCT00002313|DRUG|Nystatin|
224043790|NCT00002313|DRUG|Didanosine|
224141019|NCT01509872|BEHAVIORAL|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
224141020|NCT02388841|RADIATION|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
223433643|NCT03337594|PROCEDURE|Surgery|Cardiac surgery
223433644|NCT04858594|OTHER|Planned Chemotherapy|standard oncologic supportive care including antibiotic prophylaxis
223433645|NCT03138694|OTHER|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
223433646|NCT00199329|DRUG|ondansetron adding in PCA|
223433647|NCT03808025|BEHAVIORAL|opioid education|see arm/group descriptions
223433648|NCT05548491|DRUG|AZR-MD-001 ointment/semi-solid drug|ointment/semi-solid drug
223740531|NCT01415063|PROCEDURE|TACE-RFA|TACE first, then RFA within 2 weeks
223740532|NCT03013439|DRUG|Iron Isomaltoside|The trial is a dose escalating trial.
224043791|NCT04872881|PROCEDURE|Endotracheal Tube Insertion|ETT will be repositioned with direct laryngoscopy (ETT cuff will be inflated just above the vocal cords)
224141021|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 1|
224141022|NCT02317536|DIETARY_SUPPLEMENT|Carnipure Product 2|
224141023|NCT02317536|OTHER|Placebo|Placebo
223433649|NCT02887222|DRUG|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
223433650|NCT05859022|OTHER|Roux-en-Y gastric By-pass (RYGB) surgery|RYGB procedure requires 1-2 hours of operating time and two to three days length of hospital stay. Use the Kit-RYGB by J\& company.
223433651|NCT05859022|OTHER|Bariatric Arterial Embolization (BAE) procedure|use of Embosphere Microspheres (EM) that are designed to offer controlled, target embolization.
223433652|NCT00156039|BEHAVIORAL|Follow-up Strategy for Breast Cancer|
223433653|NCT00943176|DRUG|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
223433654|NCT00112255|BEHAVIORAL|Practice nurse-led partner notification|
223433655|NCT00112255|BEHAVIORAL|Referral to specialist genitourinary clinic|
223433656|NCT03511716|DEVICE|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
223565723|NCT04728152|OTHER|Blood and salivar test|"Saliva samples will be taken (concomitant with a visit carried out as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks).~Blood samples will be taken at two stages (concomitant with a blood test performed as part of routine care):~* At the pre-therapy visit (t3),~* At the post-treatment visit (at 3-6 weeks)."
223565724|NCT02082457|DRUG|YKP10811 5mg|
223565725|NCT02082457|DRUG|YKP10811 20mg|
223565726|NCT02082457|DRUG|YKP10811 placebo|
224141024|NCT06482580|OTHER|PNF exercise|Ankle and foot exercises practiced for 6 weeks.
224141025|NCT06482580|OTHER|Clam exercise|Hip exercise practiced for 6 weeks.
224141026|NCT06482580|OTHER|Short-foot exercise|Foot exercise practiced together for 6 weeks.
224141027|NCT05720442|DRUG|Tangweian Recipe|The Tangweian recipe is a combination of several Chinese herbs
224141028|NCT05720442|DRUG|Mosapride Citrate|The mosapride citrate tablets will be administrated.
223433657|NCT04405622|DRUG|Toripalimab plus gemcitabine|Subjects receive gemcitabine 1000mg/m2 (Day 1 and Day 8) and Toripalimab , 240mg, (Day 1) of each 21 days for at most 6 cycles, followed by Toripalimab 240mg every three weeks (Q3W) maintenance. Treatment was continued until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or investigator decision.
223433658|NCT01541839|DEVICE|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
223433659|NCT00248144|DRUG|Famciclovir|
223433660|NCT01053130|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
223740533|NCT03022344|RADIATION|Cardiac CT|
224043792|NCT04872881|PROCEDURE|Laryngeal Mask Insertion|After selecting the appropriate LMA size for the patient, the ET Tube will be removed and the LMA will be inserted.
224043793|NCT04872881|PROCEDURE|Fiberoptic Bronchoscopy|"After the patients' airway is established, the trachea and the process area will be displayed by the physician.~The success rate will be increased by performing the procedure with fiberoptic bronchoscopy."
224043794|NCT04872881|PROCEDURE|Radial Artery Monitoring|The radial artery will be cannulated. Hemodynamic monitoring and blood gas analysis will be done in this way.
224141029|NCT04276129|PROCEDURE|periodontal surgery + 24 hr buccal attached gingiva (G) biopsy|Periodontal surgery will be performed and 24 hr after the surgical procedure a 2mm punch biopsy will be harvested at the level of the buccal attache gingiva (G).
224043795|NCT04872881|DIAGNOSTIC_TEST|Anteroposterior chest x-ray|When the tracheostomy cannula is placed and the patient is ventilated, the procedure will be terminated and confirmed with anteroposterior chest x-ray.
224141030|NCT04276129|OTHER|post-surgical CHX mouth-rinses indication|CHX mouth-rinses (0.12%) will be indicated 2 times/day after the surgical procedure
224141031|NCT02540096|OTHER|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
223433661|NCT01053130|BEHAVIORAL|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
223433662|NCT02303990|DRUG|Pembrolizumab|
223433663|NCT02303990|RADIATION|Radiotherapy|
223433664|NCT06433934|DEVICE|Oxy2mask|Open design oxygen mask
223433665|NCT04352218|DEVICE|"PTA + Stenting using Petalo stent"|PTA and Petalo's Stenting are a minimally invasive endovascular procedures, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
223433666|NCT04352218|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA is a minimally invasive endovascular procedure, performed by a percutaneous access to the common femoral vein under local anesthesia and Duplex Ultrasound Guidance.
223433667|NCT03102307|OTHER|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
223433668|NCT03102307|PROCEDURE|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
223433669|NCT02271711|OTHER|Laboratory Biomarker Analysis|Correlative studies
223433670|NCT02271711|BIOLOGICAL|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
223433671|NCT05209711|PROCEDURE|Femoral nerve block under ultrasound control with a electrostimulator peripheral nerves 7.5 ml 1% lidocaine|"Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (7.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
223565727|NCT06412705|PROCEDURE|Tooth extraction, guided bone regeneration and dental implant|The arm received tooth extraction and contextual guided bone regeneration. After 4 months, a dental implant was inserted.
223565728|NCT01726400|DRUG|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
224043796|NCT04872881|DIAGNOSTIC_TEST|Arterial Blood Gas Analyses|Hypoxia, acidosis and carbon dioxide increase will be followed
224043797|NCT04872881|DRUG|Propofol Fresenius|2mg/kg of propofol 2% injectable solution was given and propofol infusion at the dose of 6 mg/kg/hour will be started.
224043798|NCT04872881|DRUG|Rocuronium|0.6 mg/kg of rocuronium 50mg/5ml injectable solution was given.
224043799|NCT04872881|DRUG|Fentanyl|1mcg/kg fentanyl of 0.5 mg/10ml injectable solution was given.
223565729|NCT01726400|DRUG|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
223565730|NCT00503581|PROCEDURE|Biopsy|Undergo biopsy
223565731|NCT00503581|OTHER|Laboratory Biomarker Analysis|Correlative studies
223565732|NCT00503581|DRUG|Megestrol Acetate|given orally
223565733|NCT00503581|OTHER|Pharmacological Study|Correlative studies
224299744|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
224141032|NCT02540096|OTHER|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
224141033|NCT06243822|DRUG|Ketamine|ketamine is initiated at 0.5 mg/kg/h and titrated by 0.25 mg/kg/h every 15 minutes to a maximum dosage of 4 mg/kg/h to achieve appropriate sedation.
224141034|NCT06243822|DRUG|Propofol|Propofol is initiated at 0.3 to 0.6 mg /kg/hr. and titrated by 0.3 to 0.6 mg/kg/h every 5 to 10 minutes up to a maximum dosage of 4.5 to 4.8 mg/kg/hr. to achieve appropriate sedation.
224141035|NCT01956240|PROCEDURE|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
224299745|NCT01030354|DIETARY_SUPPLEMENT|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
224299746|NCT05925777|DEVICE|THEAL (Mectronic, Bergamo)|laser therapy high intensity
223433672|NCT05209711|PROCEDURE|Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine|"Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed."
223433673|NCT02933905|DRUG|Intravitreal Ranibizumab injection|
223433674|NCT00648505|DRUG|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
223433675|NCT00648505|DRUG|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
223565734|NCT00503581|OTHER|Quality-of-Life Assessment|Ancillary studies
223565735|NCT00503581|PROCEDURE|Therapeutic Conventional Surgery|undergo hysterectomy
223565736|NCT03494530|DRUG|Edoxaban 60 MG|Anticoagulant used to treat atrial fibrillation
223565737|NCT03494530|DRUG|Edoxaban 30 mg|Anticoagulant used to treat atrial fibrillation
223565738|NCT05339750|DEVICE|AI-based smartphone application|AI-based smartphone application to record and interpret the patch test results
223740534|NCT06133192|DRUG|Uvadex|Uvadex use for ECP
223740535|NCT06133192|DRUG|Steroids|steroids 2 mg/kg/d
223740536|NCT00159250|DRUG|AVI-4658 (PMO)|morpholino antisense oligonucleotide
224043800|NCT03979560|OTHER|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
224043801|NCT00051480|GENETIC|TNFerade|
224043802|NCT00555555|BIOLOGICAL|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
224043803|NCT00611195|DRUG|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
224043804|NCT05079412|OTHER|Chest ultrasound|Chest ultrasound will be performed to eligiable (consented) patient after being on the respiratory support (NIV-NAVA vs NIPPV) for at least 24 hours. Both diaphragmatic function and lung ultrasound score will performed. Investigator interpreting the scans will be blind to patients type of respiratory support or clinical status.
224043805|NCT00000712|DRUG|Zidovudine|
223565739|NCT05339750|DIAGNOSTIC_TEST|Allergen patch|Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
224043806|NCT00000712|DRUG|Acyclovir|
224043807|NCT05109676|OTHER|Questionnaire|A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.
223565740|NCT03484507|DRUG|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
223565741|NCT03484507|DRUG|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
223565742|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
223740537|NCT03642210|COMBINATION_PRODUCT|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
223740538|NCT03331146|DRUG|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
224305024|NCT04522115|OTHER|exercises|"Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated."
224043808|NCT00020501|DRUG|FOLFIRI regimen|
224043809|NCT00020501|DRUG|floxuridine|
224043810|NCT00020501|DRUG|fluorouracil|
224043811|NCT00020501|DRUG|irinotecan hydrochloride|
224043812|NCT00020501|DRUG|leucovorin calcium|
224043813|NCT00020501|DRUG|melphalan|
224043814|NCT00020501|PROCEDURE|hyperthermia treatment|
224043815|NCT02798822|PROCEDURE|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
224043816|NCT04032730|DEVICE|Wisepill device|"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."
224043817|NCT00805025|DRUG|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
224043818|NCT00375219|DRUG|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m\^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m\^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
224043819|NCT05408104|DRUG|tolvaptan|LVAD recipients with post-operative hyponatremia (Na \< 135 mEq/L). Subjects took tolvaptan 15 mg daily as part of their standard care.
224043820|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
224043821|NCT00393952|DRUG|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
224043822|NCT00393952|DRUG|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
224043823|NCT00393952|DRUG|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
224043824|NCT00393952|DRUG|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
224043825|NCT01667107|DRUG|Posaconazole|
224043826|NCT01667107|DRUG|Calogen®|
224043827|NCT05235399|OTHER|Echo scans|Echo heart scan will be performed on the participating preterm infants on the 5th and 9th day of postnatal life.
224141036|NCT01956240|PROCEDURE|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
224141037|NCT01836211|OTHER|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
223433676|NCT06188104|DRUG|Trichloroacetic acid|Applying Trichloroacetic acid 95 % topical solution plus acetic acid at the transformation zone or lesion (if have) of the cervix during colposcopic examination (95% topical trichloroacetic acid is used just before finishing examination, while acetic acid is used normally when perform colposcopy)
223433677|NCT05526222|DRUG|Jaktinib Hydrochloride Tablet|Orally administered, twice a day
224043828|NCT03359525|DRUG|Tranexamic Acid|intravenous versus Intraarticular versus intravenous
224043829|NCT02448693|DEVICE|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
224141038|NCT01836211|OTHER|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
224141039|NCT04195659|PROCEDURE|Mastectomy and chest masculinization|A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
223433678|NCT02745912|DRUG|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
223433679|NCT02745912|DRUG|Metformin|Metformin immediate-release tablet.
223433680|NCT05220748|COMBINATION_PRODUCT|RM-1995|RM-1995 will be administered by intravenous (IV) infusion followed approximately 24 hours later by tumor illumination with 690 nm non thermal red light using the PIT690 Laser System. The starting dose of RM-1995 will be 0.25 mg/kg and escalated up to 2.0 mg/kg over 6 dosing cohorts
223433681|NCT05220748|BIOLOGICAL|Pembrolizumab|Pembrolizumab (200 mg) will be administered by intravenous (IV) infusion one week before the first RM-1995 PIT treatment and the second dose three weeks later for patients in the combination arm. Once the DLT window is complete, pembrolizumab dosage will be maintained at either 200 mg Q3w, or shift to 400 mg Q6w, per investigator discretion.
224141040|NCT02168894|PROCEDURE|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
223433682|NCT05289024|BEHAVIORAL|Mindful Awareness in Body-Oriented Therapy|Up to 8 individually delivered clinical sessions
224043830|NCT02448693|DEVICE|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
224043831|NCT01162239|DRUG|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
224043832|NCT01162239|BEHAVIORAL|Initial Individual counseling|Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
224043833|NCT01162239|BEHAVIORAL|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
224141041|NCT02168894|PROCEDURE|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
224141042|NCT02168894|BEHAVIORAL|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
224141043|NCT03252314|DEVICE|Second-generation hydrogel coils|Hydrogel coils 90% by length
224141044|NCT02092441|OTHER|Alcohol prep pad group|Subjects inhale scent of alcohol pad
224141045|NCT02092441|OTHER|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
224141046|NCT02705118|DEVICE|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
224141047|NCT02705118|DEVICE|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
223433683|NCT04629924|DEVICE|sleeper one|anesthesic injection with sleeper one device
223433684|NCT04629924|DEVICE|conventional technis|anesthesic injection with the conventional technic
223433685|NCT00958607|BEHAVIORAL|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care \& by telephone during inpatient rehabilitation and community discharge. SSP provides support, information \& guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
223433686|NCT00958607|BEHAVIORAL|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
223433687|NCT00627809|DRUG|Streptokinase|intracoronary infusion, 250.000 Units
223433688|NCT00627809|PROCEDURE|primary percutaneous coronary intervention|balloon catheter, stent
223433689|NCT06730308|RADIATION|Radiotherapy|Hypofractionated radiotherapy
223433690|NCT06730308|DRUG|Concurrent chemotherapy|weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
223433691|NCT06730308|DRUG|Methylprednisolone|Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
223433692|NCT02259634|BEHAVIORAL|Patient Navigation|Motivational Interviewing
223433693|NCT05245734|DRUG|Human Anti-D (rh) immunoglobulin|prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
223433694|NCT00783224|DRUG|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
223433695|NCT00783224|DRUG|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
223433696|NCT00783224|DRUG|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
223433697|NCT00783224|DRUG|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
223433698|NCT02073318|OTHER|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
223433699|NCT02073318|OTHER|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
223433700|NCT01197170|DRUG|Anastrozole|1 mg by mouth daily of a 28 day cycle.
224043834|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Health Model|Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
224043835|NCT01162239|BEHAVIORAL|Extended Individual Counseling - Relapse Prevention Model|Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
224043836|NCT03410459|DIAGNOSTIC_TEST|DEXA (= Dual-energy x-ray absorptiometry)|measurement of vertebral bone and hip bone mineral density
224043837|NCT00228566|DRUG|Armodafinil|
224043838|NCT05797233|BIOLOGICAL|Anti-CD19 and anti-CD20 bicistronic CAR T- cells|0.66x10\^6 CAR+ T - 10x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0
224043839|NCT05797233|DRUG|Cyclophosphamide|500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
224043840|NCT05797233|DRUG|Fludarabine|30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
224043841|NCT06012383|DRUG|Bortezomib|Alvocade® was given with a dose of 1.3 mg/m2.
224141048|NCT02982486|DRUG|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
224141049|NCT02982486|DRUG|Nivolumab|Ninolumab 240 mg IV every 2 weeks
224141050|NCT03329417|OTHER|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
223433701|NCT01197170|DRUG|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
223433702|NCT01197170|DRUG|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
223433703|NCT01197170|DRUG|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
223433704|NCT01197170|DRUG|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
223433705|NCT02635542|DRUG|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
224043842|NCT06221553|BIOLOGICAL|B7H3 specific CAR T cell with IL-7Ra signaling domain|Autologous T cells lentivirally transduced to express a B7H3 specific chimeric antigen receptor (CAR) with additional of IL-7 receptor alpha signalingdomain given via indwelling central nervous system (CNS) catheter
224043843|NCT05251623|OTHER|walking program|Subjects in PG walked to target steps daily with pedometer for 6 weeks
223433706|NCT02635542|DRUG|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
224043844|NCT05960929|COMBINATION_PRODUCT|Infasurf Aero™|A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
224043845|NCT06541262|DRUG|Silmitasertib|Capsules
224043846|NCT06541262|DRUG|Irinotecan|IV
224043847|NCT06541262|DRUG|Temozolomide|Oral
223433707|NCT04631107|DRUG|AD109 dose1- A|Oral administration at bedtime
223433708|NCT04631107|DRUG|AD109 dose2- B|Oral administration at bedtime
223433709|NCT04631107|DRUG|Placebo- C|Oral administration at bedtime
223433710|NCT01277809|BEHAVIORAL|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
223433711|NCT01277809|BEHAVIORAL|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
223433712|NCT04016246|DRUG|Propofol-Lipuro|sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
223433713|NCT04016246|DRUG|Placebos|injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
223433714|NCT02669914|DRUG|MEDI4736|
223433715|NCT04728555|PROCEDURE|Game about radiotherapy|A digital pedagogical game about radiotherapy
224043848|NCT06541262|DRUG|Vincristine|IV
224141051|NCT02321618|BEHAVIORAL|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
224141052|NCT02321618|BEHAVIORAL|BP educational materials|Exposure to hypertension educational materials
223565743|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
223565744|NCT03484507|DRUG|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
223565745|NCT03484507|DRUG|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
223565746|NCT06056336|DRUG|Tislelizumab|Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
223565747|NCT00883545|OTHER|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
223565748|NCT00883545|OTHER|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
223565749|NCT05705778|PROCEDURE|standard amblyopia treatment|amblyopia treatment following international guidelines and genetic tests.
223565750|NCT05231577|PROCEDURE|7.5fr ultra-fine ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 1 patients used 7.5fr ultra-fine ureteroscopy
223565751|NCT05231577|PROCEDURE|9.2fr Ureteroscopy|The patient placed the lithotomy position, placed the ureteroscope to explore the affected ureter, retrogradely placed the guide wire, and placed the 12 / 14fr ureteral sheath under X-ray monitoring until the affected ureter was close to the outlet of the renal pelvis. Group 2 patients used 9.2fr Ureteroscopy
223565752|NCT04561245|DRUG|ALT-801|Injected subcutaneously (SC)
223565753|NCT04561245|OTHER|Placebo|Injected subcutaneously (SC)
223565754|NCT01065194|DRUG|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
223565755|NCT01065194|DRUG|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
223565757|NCT00150228|DRUG|CP-526,555 (varenicline)|
223565758|NCT04000607|DEVICE|APTURE transcatheter shunt|Transcatheter treatment of symptomatic left heart failure patients
223565759|NCT05695898|DRUG|XmAb22841|Given intravenously (IV)
223565760|NCT05695898|DRUG|XmAb23104|Given intravenously (IV)
223565761|NCT05368285|BIOLOGICAL|barzolvolimab|Subcutaneous Administration
223565762|NCT05368285|DRUG|Matching Placebo|Subcutaneous Administration
223565763|NCT06107985|OTHER|Structured exercise program|This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.
224141053|NCT03609736|DIAGNOSTIC_TEST|18F-DCFPyL PET/CT|"* A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push.~* After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v).~* Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL.~* At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base."
223433716|NCT01192035|DRUG|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count \>250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
223433717|NCT01192035|DRUG|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is \< 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
223433718|NCT02621658|OTHER|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
223433719|NCT02621658|OTHER|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
223433720|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.
223433721|NCT04878458|PROCEDURE|phacoemulsification with intraocular lens implantation combined with trabeculectomy|The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.
224043849|NCT05705193|OTHER|NeuroFlex (computerized gamified tasks)|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant."
224043850|NCT03585556|DRUG|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
224043851|NCT03585556|BIOLOGICAL|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
224043852|NCT03585556|DRUG|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
224043853|NCT04448756|DRUG|M5049|Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
224043854|NCT04448756|DRUG|M5049|Participants received M5049 100 mg orally twice daily for 14 days.
224043855|NCT04448756|DRUG|Placebo|Participants received placebo tablets matched to M5049 daily for 14 days.
224141054|NCT00600028|DRUG|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
223433722|NCT02766452|BEHAVIORAL|"You and your child in the recovery room DVD"|
223433723|NCT02766452|BEHAVIORAL|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
223433724|NCT01857700|OTHER|Compensation for transport cost|
223433725|NCT01857700|OTHER|Compensation for lost wages|
224043856|NCT06068465|DRUG|pimavanserin tartrate|pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
224043857|NCT06068465|DRUG|placebo|placebo, capsule, once daily by mouth for 6 weeks
224043858|NCT04454437|DRUG|Sacituzumab Govitecan-hziy|Administered intravenously
224043859|NCT03902847|BEHAVIORAL|motor imagery|All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
224043860|NCT03902847|BEHAVIORAL|Action observation|A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
224141055|NCT00600028|DRUG|Placebo|Placebo 50-100 mg by mouth per day
223433726|NCT01857700|OTHER|Compensation for transport cost and lost wages|
223565764|NCT06107985|OTHER|Conventional Exercise Program|Conventional exercise program for shoulder impingement syndrome patients
224141056|NCT05990036|OTHER|Sports vision enhancement training curriculum|A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
224141057|NCT04658420|DRUG|Ketamine Hydrochloride|Individuals in the ketamine group will receive ketamine 0.5 mg/kg infused over 40 minutes
224141058|NCT04658420|OTHER|Music|"A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:~https://open.spotify.com/playlist/37i9dQZF1DWVbGPBkXJYHF"
224141059|NCT03555240|OTHER|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
223433727|NCT01857700|OTHER|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
223433728|NCT05366218|BIOLOGICAL|Tafasitamab|Antibody vaccination
223433729|NCT03650296|DEVICE|ePER vs PS vs PaedER|see detailed description of methods
223433730|NCT02035397|DRUG|Botulinum Toxin Type A|
223433731|NCT02035397|DRUG|Saline solution|
223433732|NCT06071572|OTHER|Biological samples collected specifically for the IBD Biobank|Biological samples will include: material intestinal biological waste (surgical leftover), 30 ml of peripheral blood, one sample stool standards and a saliva sample.
223433733|NCT03745040|DRUG|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
223433734|NCT04510389|DIETARY_SUPPLEMENT|Maltodextrin|Bariatric patients with or without sarcopenia receiving maltodextrin
223433735|NCT04510389|DIETARY_SUPPLEMENT|Whey|Bariatric patients with or without sarcopenia receiving whey protein
223433736|NCT06245967|DEVICE|Frequency specific microcurrent therapy|Concussion protocol
223433737|NCT06245967|DEVICE|Sham Frequency specific microcurrent therapy|Shan concussion protocol
223433738|NCT04592289|PROCEDURE|Full bowel preparation|MBP+OA
223433739|NCT04592289|PROCEDURE|Mechanical bowel preparation only|MBP
223433740|NCT04414189|DIAGNOSTIC_TEST|HostDx Sepsis|Blood collection for mRNA analysis
223433741|NCT01217125|DRUG|Sirolimus|plasma levels between 4 and 8
223433742|NCT04392830|DRUG|ALZ002 DS|Administered orally
223433743|NCT04392830|DRUG|Placebo|Administered orally
223433744|NCT00990067|DRUG|3,4-Methylenedioxymethamphetamine|125 mg, single dose
223433745|NCT00990067|DRUG|Duloxetine|120 mg two doses 12h and 2h before MDMA
223433746|NCT00990067|DRUG|Placebo|capsules identical to MDMA or duloxetine
223433747|NCT05385224|DIAGNOSTIC_TEST|PillSense|The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
223433748|NCT00551161|DRUG|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
223433749|NCT05547061|DRUG|Lu-177-DGUL|Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
224043861|NCT03902847|BEHAVIORAL|Motor Control Exercises|The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
223433750|NCT05547061|DRUG|Ga-68-NGUL|Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
223433751|NCT04620694|DEVICE|Choice of arterial cannulation site at the beginning of the surgery|Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
223433752|NCT04632056|DRUG|Beovu|There is no treatment allocation. Patients administered Beovu by prescription that have started before inclusion of the patient into the study were enrolled.
223433753|NCT02897388|OTHER|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling \& promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
223433754|NCT00803309|DRUG|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
224043862|NCT02338349|DRUG|Elacestrant|
224141060|NCT06375252|OTHER|Central Jugular Vein Catheter Lumen Holder Apparatus|Participants will experience the central jugular vein catheter lumen holder apparatus, perform walking, sitting, supine, right and left side lying activities and fill out the evaluation forms prepared by the researcher. They will then experience the same activities without the apparatus.
224141061|NCT03172481|DRUG|PRC-063 oral capsules|Daily dose
224141062|NCT03172481|DRUG|Placebo oral capsules|Daily dose
223433755|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
223433756|NCT00803309|DRUG|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
223433757|NCT00803309|DRUG|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
223433758|NCT03623971|DEVICE|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
223433759|NCT02253732|BEHAVIORAL|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength \& aerobic exercises
223433760|NCT00477997|DEVICE|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
223433761|NCT02100137|OTHER|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
223433762|NCT04012307|DRUG|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
223433763|NCT04012307|DRUG|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
223433764|NCT01935700|DRUG|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
223433765|NCT06510920|BEHAVIORAL|Aerobic exercise|The mixed design scheme of football and volleyball sports technology and competition will be adopted.aerobic exercise intensity will be moderate-intensity aerobic exercise load , and the intervention time was 12 weeks, 60 minutes each time, twice a week. The main preparation activities were jogging and special preparation activities (10 minutes), and the main part was technical teaching combined with competition (60 minutes).The end part is mostly jogging and stretching (10 minutes). Two subjects in each group were selected to wear Decathlon Bluetooth heart rate band, and the exercise intensity was controlled by detecting the heart rate of the subjects.
223433766|NCT01395173|PROCEDURE|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
223433767|NCT01395173|PROCEDURE|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
224043863|NCT06006338|OTHER|3D Printed Model for preoperative planning|Besides conventional preoperative planning based on contrast-enhanced CT/MRI, the investigator refers to a 3D printed model to determine the optimal surgical approach via a trial-and-error method. Specifically, a personalized 3D printed model is fabricated. By referring to the printed model and CT/MRI images, a preliminary surgical trace is determined. Then, a simulation surgery is performed on the model, and surgical margin and the potential injury of vital vascular structures are evaluated. This assessment leads to the adjustment of the surgical path as necessary. The refined surgical route is then validated through a second simulation surgery performed on the healed 3D model. This iterative process is repeated multiple times, allowing for a comprehensive exploration of various approaches until the optimal surgical strategy crystallizes. Next, the investigator proceeds to execute the real surgery on the participant, meticulously adhering to the determined optimal surgical approach.
224043864|NCT04571281|DIAGNOSTIC_TEST|capillary lactate measurements|In this study capillary lactate will be measured every 10 minute during CPR.
223433768|NCT00096993|DRUG|Placebo|Placebo was provided as a single-use formulation for infusion.
224043865|NCT02023255|DRUG|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
224043866|NCT02023255|OTHER|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
223433769|NCT00096993|DRUG|Gemcitabine|Gemcitabine was provided as a solution for infusion.
223740539|NCT03331146|DRUG|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
224043867|NCT00199433|DRUG|Istradefylline (KW-6002)|
224043868|NCT06292000|BEHAVIORAL|AM Exercise|Morning (0-3 hours from habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
224043869|NCT06292000|BEHAVIORAL|PM Exercise|Evening (9-12 hours after habitual wake time) aerobic exercise at 70% age predicted HR max for 45 minutes
224043870|NCT05467475|DRUG|BI 1819479|BI 1819479
224043871|NCT05467475|DRUG|Esomeprazole|Esomeprazole
224043872|NCT01117584|DRUG|ipragliflozin|oral tablet
224043873|NCT01117584|DRUG|Placebo|oral tablet
223433770|NCT00096993|DRUG|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
224043874|NCT01117584|DRUG|Metformin|oral tablet
224043875|NCT00232141|DRUG|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
223433771|NCT01935128|DRUG|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
223433772|NCT02658383|OTHER|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
223433773|NCT02658383|OTHER|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
223433774|NCT00772005|DRUG|armodafinil|150 mg/day armodafinil
224043876|NCT00232141|DRUG|Placebo|Placebo
224043877|NCT06031896|OTHER|No interventions|No interventions
224043878|NCT00339170|BEHAVIORAL|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
224043879|NCT00339170|BEHAVIORAL|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
224043880|NCT01088256|DRUG|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
224043881|NCT01088256|DRUG|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
224043882|NCT03474471|BEHAVIORAL|Pulmonary rehabilitation|Following a PR program
224043883|NCT03474471|DEVICE|EBV treatment|Bronchoscopic lung volume reduction using endobronchial valves (EBV)
224043884|NCT02307760|OTHER|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
224043885|NCT02307760|OTHER|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
224043886|NCT05511896|OTHER|Repeated trunk flexion|A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
223433775|NCT00772005|DRUG|placebo|placebo
224043887|NCT05057286|PROCEDURE|Clinical crown lengthening surgery|"* Clinical dental crown lengthening surgery protocol: a clinical crown lengthening surgery was performed.~* Post-operation protocol Patients were all prescribed antibiotics , anti-inflammation, analgesic, and an antiseptic mouthwash. Patients were instructed for oral hygiene and recalls.~* Botulinum Toxin A injection One hundred units (U) of botulinum toxin A (BTX-A) were diluted with 2.5ml of sterile saline solution without shaking. 1 mm syringe with a 30-gauge needle was used to get 0.25ml BTX-A for four-point injection, or 0.6ml in case injection of 6 points. Cold compress was applied extraoral 5 mins at injection site before injection.~After local anesthesia, the doctor administered slowly 2,5 U of diluted BTX-A at each point until white cellulite appeared.~Patients were recalled two weeks (T2), and two months (T3) after injection."
223433776|NCT00772005|DRUG|armodafinil|200 mg/day armodafinil
224299747|NCT06267547|OTHER|HAIL Online Platform|The HAIL online platform was developed based on feedback from our focus groups with older adults affiliated with BMA churches (conducted per IRB Protocol 2020P003100). Specifically, the HAIL online platform has a landing page where participants can access the links to the F\&S! exercise sessions, complete the exercise log, obtain tips from an exercise instructor, as well as view study announcements. The landing page has a navigation bar on the left to access 1) the study assessments; 2) the F\&S! exercise program participant manual; and 3) information on how to contact study staff. The goal of this adjunctive HAIL online platform is to support the continuation of exercise in the follow-up period once the 8-week F\&S! exercise program is over. We conducted an open trial (per IRB protocol 2022P001782) to assess the feasibility and acceptability of the HAIL online platform adjunct to the F\&S! program, which yielded positive results.
224305025|NCT05353387|OTHER|Motivational Interviewing|Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
223433777|NCT00772005|DRUG|armodafinil|250 mg/day armodafinil
223433778|NCT00287677|BIOLOGICAL|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
223433779|NCT00287677|BIOLOGICAL|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
223433780|NCT00287677|DRUG|HAART|HAART all over the trial
223433781|NCT03280225|OTHER|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
223433782|NCT04172922|DRUG|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
223433783|NCT01828216|DEVICE|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
223433784|NCT01828216|DEVICE|conventional polysomnography|conventional type I sleep study according to international guidelines
223433785|NCT06261541|DEVICE|ABLE Exoskeleton|Participants with MS will undergo a training program with the ABLE Exoskeleton device: a total of 10 sessions, distributed 1-2 sessions/week for up to 11 weeks.
224043888|NCT00150332|DRUG|linezolid|
223433786|NCT01159288|BIOLOGICAL|Dex2|"* Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~* Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~* Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
224043889|NCT04692454|OTHER|Modern acupuncture|use the scalp and ear acupuncture methods to identify diseases and checkpoints and apply them to regulate the immune function of patients with gastroenterological cancers.
224043890|NCT01479829|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI)
224043891|NCT01479829|DRUG|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug
223433787|NCT03330366|DIETARY_SUPPLEMENT|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
223433788|NCT03330366|DIETARY_SUPPLEMENT|Placebo|take two capsules per day
223433789|NCT02338466|DRUG|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
223433790|NCT02338466|DRUG|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
223433791|NCT01440569|DRUG|COBI|150 mg tablet administered orally with food once daily
223433792|NCT01440569|DRUG|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
223565765|NCT02244840|DEVICE|Electronic bidet|commercial electronic bidet
223565766|NCT02244840|DEVICE|Sitz bath|Conventional sitz bath
224043892|NCT01479829|DRUG|Placebo|Placebo is a manufactured capsule with no active ingredient
224043893|NCT04203862|DRUG|NPC-22|Single administration of low dose NPC-22
224043894|NCT04203862|DRUG|NPC-22|Single administration of low/middle dose NPC-22
224043895|NCT04203862|DRUG|NPC-22|Single administration of middle dose NPC-22
224043896|NCT04203862|DRUG|NPC-22|Single administration of middle/high dose NPC-22
224043897|NCT04203862|DRUG|NPC-22|Single administration of high dose NPC-22
223565767|NCT01039545|DRUG|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
224043898|NCT04203862|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
224043899|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
224043900|NCT00601250|DRUG|linagliptin|Patients receive linagliptin 5 mg tablets once daily
223433793|NCT01440569|DRUG|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
223433794|NCT03933722|DEVICE|Caretaker|Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
223433795|NCT04928469|OTHER|No intervention performed|Collection of clinical and laboratory data
223433796|NCT05821465|DEVICE|HeartWatch|The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
223433797|NCT02254122|DRUG|BEA 2180 BR|
224043901|NCT05638022|DIAGNOSTIC_TEST|Total cholesterol (TC) level test and direct Low density lipoprotein cholesterol (LDL-C) level test|Total cholesterol (TC) level testing and direct Low density lipoprotein cholesterol (LDL-C) level testing will be performed in all 10,000 newborns enrolled in the project.
223433798|NCT02254122|DRUG|Placebo|
223433799|NCT02254122|DEVICE|Respimat®|
223433800|NCT05389826|DEVICE|mHealth App|We will compare the degree of improvement in phosphate control with respect to baseline values and report any adverse event. Nephrologist will use a web management system to provide results of phosphorus levels and medical recommendations to the patient, mediated by a cloud IT environment. In addition, patients will receive alerts, suggestions, and general information. They will also be able to communicate with nephrologists and interact with their corresponding group of fellow patients.
223433801|NCT00596726|DEVICE|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
223433802|NCT00382902|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
223433803|NCT04092088|DEVICE|tDCS-r|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
223433804|NCT04092088|DEVICE|TENS-r|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
223433805|NCT04092088|DEVICE|tDCS-s|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
223433806|NCT04092088|DEVICE|TENS-s|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
224043902|NCT05638022|DIAGNOSTIC_TEST|DNA testing|DNA testing (NGS analysis of DNA mutations in 9 genes: LDLR, APOB, APOE, PCSK9, LDLRAP1, STAP1, ABCG5, ABCG8, LIPA and polygenic markers) will be performed in the subcohort of 1,500 newborns with highest level of Low density lipoprotein cholesterol (LDL-C).
224141063|NCT01028833|OTHER|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
224305026|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
223433807|NCT03471234|DEVICE|Angioplasty|Inspiron Drug Eluting stent implantation
223433808|NCT05477628|OTHER|Childcare Navigator|"Participants will be contacted by the CN to assist with access to centre-based childcare after enrolment. The CN will: a) educate the family on the benefits of centre based childcare; b) facilitate placement of the child on waiting lists for funding and centre based childcare placement in their neighbourhood with the aim of having full-time centre based childcare start at 1 year of age; and c) work with the family to overcome barriers to childcare placement prior to and during childcare. It is expected that the child will be in full-time centre-based childcare for a minimum of 12 months.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare according to the Rourke Baby Record."
223565768|NCT01039545|DRUG|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
223565769|NCT03365258|DIETARY_SUPPLEMENT|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
223565770|NCT03365258|DIETARY_SUPPLEMENT|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
224043903|NCT02482766|DRUG|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
224043904|NCT02482766|DEVICE|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
224043905|NCT02482766|DEVICE|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
224141064|NCT00003194|BIOLOGICAL|filgrastim|
224141065|NCT00003194|DRUG|carboplatin|
224141066|NCT00003194|DRUG|cyclophosphamide|
224141067|NCT00003194|DRUG|etoposide|
224141068|NCT00003194|DRUG|thiotepa|
224141069|NCT00003194|DRUG|topotecan hydrochloride|
224141070|NCT00003194|PROCEDURE|peripheral blood stem cell transplantation|
224141071|NCT02716194|BIOLOGICAL|BAX 826|
224141072|NCT02716194|BIOLOGICAL|Octocog alfa|
224141073|NCT02679196|DRUG|KA2237|PI3 Kinase p110β/δ inhibitor
223433809|NCT05477628|OTHER|Lactation Consultant|"Participants will be contacted by the LC on the same day as their first primary healthcare visit. They will also receive age-appropriate nutrition recommendations according to the Rourke Baby Record. The LC will be an International Board Certified Lactation Consultant (IBCLC) who will provide scheduled and on-call visits, along with phone calls, video conferencing, and text messaging as needed to support exclusive breastfeeding (using virtual care modalities as appropriate during COVID-19). The LC will contact the family once per week for the first 4 weeks to support breastfeeding technique and help with breastfeeding problems such as latching difficulties, painful nursing, and low milk production, monthly thereafter and provide on-call support as required to support exclusive breastfeeding through 6 months of age.~Control: All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare."
223433810|NCT05477628|OTHER|Lactation Consultant Support and Childcare Navigator Support|This intervention is a combination of the two interventions described above.
223433811|NCT05477628|OTHER|Control Group|All children randomized to the control condition will receive age-appropriate nutritional recommendations as part of routine healthcare.
223433812|NCT05801419|DEVICE|RETI-port/scan 21|Pattern visual event-related potential and pattern electroretinogram on right eye (non-dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
223433813|NCT05801419|DEVICE|Zilia Ocular|Eye fundus tissue oximetry measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
223433814|NCT05801419|DEVICE|OCT-A|Optical coherence tomography angiography measure on left eye (dilated pupil) at baseline, post e-cigarette vaping without nicotine and post e-cigarette vaping with nicotine.
224043906|NCT01174511|DRUG|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
224043907|NCT04326647|OTHER|Kinesiotaping|We used kinesiotaping in gastrocnemius and lumbar back
224043908|NCT04326647|OTHER|Exercise|Exercises about balance and gait
224141074|NCT02325687|PROCEDURE|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
224141075|NCT04101448|OTHER|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
224141076|NCT04084249|DIAGNOSTIC_TEST|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
224141077|NCT04084249|OTHER|Intensified Follow-up Schedule|PET/CT-scans every 3. month
223433815|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette without nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial without nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
223433816|NCT05801419|COMBINATION_PRODUCT|Electronic cigarette with nicotine|Vaping using an e-cigarette paired with an e-cigarette liquid vial with nicotine. Inhaling through the mouth and exhaling through the nose ten times. Inhalations must last 5 seconds and the participant has 5 minutes to do the 10 inhalations.
224141078|NCT05066633|DRUG|Metoprolol Succinate|Metoprolol Succinate will be in the form of tablets and will be administered orally once daily. The dose will depend on the patient's weight category. Subject should take their treatment at a consistent time each day to promote compliance. IMP will be up titrated. Every two weeks the patients will be given the higher dose of metoprolol succinate or placebo accordingly to scheme.
223433817|NCT01782560|DRUG|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
223433818|NCT01782560|DRUG|Placebo|
223433819|NCT00282386|DRUG|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
223433820|NCT00282386|DRUG|Placebo/ Duration of Treatment: 156 weeks|
223433821|NCT01009255|DRUG|GSK239512|Histamine H3 Antagonist
224141079|NCT05066633|DRUG|Placebo|Placebo will be in the form of identical tablets and will be administered orally once daily.
224043909|NCT01791803|BEHAVIORAL|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
224043910|NCT01791803|DRUG|Nicotine|free one month supply after hospital discharge
224043911|NCT05056324|DEVICE|Online vestibular rehabilitation tool|For those randomized to the intervention group, a 6 weeks duration vestibular rehabilitation will be delivered using an online tool (YrselTräning)
223433822|NCT01009255|DRUG|Placebo|Placebo to match GSK239512
224043912|NCT05056324|OTHER|Standard care (written instructions leaflet)|For those randomized to the control group, a 6 weeks duration standard vestibular rehabilitation will be delivered using a written instructions leaflet
224043913|NCT07128875|OTHER|Exercise + TENS + Hot Pack|"Therapeutic Exercises with Hot Pack and TENS This intervention focuses on improving physical function and reducing pain through structured therapeutic exercises for knee OA patients. The program includes Warm-Up (10 min): Light walking or stationary cycling. 2. Range of Motion (ROM) Exercises: Heel slides, seated knee flexion/extension. 3. Strengthening Exercises:~Quadriceps sets Straight leg raises Mini squats (pain-free range)~Seated knee extensions with resistance band 4. Stretching Exercises:~Hamstring stretch Calf stretch Quadriceps stretch 5. Cool Down (5-10 min): Breathing and relaxation. 6. Hot Pack (15 min) + TENS (10 min): Applied pre and post exercises for pain relief and muscle relaxation."
224043914|NCT07128875|OTHER|Exercise|"Warm-Up (10 min): Light walking or stationary cycling. 2. Range of Motion (ROM) Exercises: Heel slides, seated knee flexion/extension. 3. Strengthening Exercises:~Quadriceps sets Straight leg raises Mini squats (pain-free range)~Seated knee extensions with resistance band 4. Stretching Exercises:~Hamstring stretch Calf stretch Quadriceps stretch 5."
223433823|NCT00870610|PROCEDURE|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
223433824|NCT00714584|DRUG|Naltrexone HCl.|
223433825|NCT03737279|BEHAVIORAL|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
223433826|NCT03737279|BEHAVIORAL|Routine Care|"Routine care including ACOG educational pamphlets:~* Day 1: Nutrition in Pregnancy~* Day 2: Heart Health for Women~* Day 3: Exercise after Pregnancy"
223433827|NCT05667207|DIAGNOSTIC_TEST|Point-of-care microscopy and dipstick guided management|"GPs will be encouraged to apply the following diagnosis and treatment algorithm (figure 1) to consenting women, taking their preferences into account:~1. If POCTs are positive for bacteria by microscopy and/or for erythrocytes by dipsticks the GP issues, at his/her own clinical judgement, a delayed or immediate prescription for an antibiotic.10 In the MicUTI intervention, delayed prescription is defined as issuing an antibiotic prescription with the advice to take the medication only when symptoms do not improve or worsen in 48 hours.~2. If POCTs are negative for bacteria and erythrocytes, the GP advises for self-help remedies according to guidelines and to do without antibiotics Study specific training in point-of-care microscopy will be provided to intervention practices."
223433828|NCT04150705|DEVICE|FDG PET/MRI|-All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
224043915|NCT07123987|DEVICE|transcutaneous auricular vagus nerve stimulation (taVNS)|Use of the EV-906 device with TENS ear clips for transcutaneous auricular vagus nerve stimulation (taVNS), applied according to the study protocol, in addition to standard medical treatment for post-herpetic neuralgia. This device meets ISO 13485, FDA QSR, and CE standards
224043916|NCT07123987|OTHER|traditional medical treatment for PHN|Standard medical treatment for post-herpetic neuralgia as per current clinical guidelines, without the application of taVNS device.
224043917|NCT04572854|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
224043918|NCT06809790|BEHAVIORAL|Therapeutic Exercise Program|Participants in this group will receive a therapeutic exercise program (including cervical range of motion and trapezius stretching) during the study period.
224043919|NCT06809790|PROCEDURE|Dry Needling|Participants in this group will receive dry needling treatment for active trigger points in addition to the therapeutic exercise program. Dry needling treatment will be applied in a total of 3 sessions at 0, 1, and 2. weeks, one week apart.
224043920|NCT00846547|DRUG|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
224043921|NCT03248674|DIAGNOSTIC_TEST|CT FFR|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
224043922|NCT02750150|DRUG|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
224043923|NCT02750150|DRUG|Fresh-frozen plasma|
224043924|NCT04260009|DRUG|Brigatinib|Brigatinib tablets
224043925|NCT04260009|DRUG|Brigatinib AAF|Brigatinib age-appropriate formulation (AAF)
223433829|NCT00041210|BIOLOGICAL|bleomycin sulfate|
223433830|NCT00041210|DRUG|ABVD regimen|
223433831|NCT00041210|DRUG|Stanford V regimen|
223433832|NCT00041210|DRUG|dacarbazine|
224043926|NCT06812858|DRUG|Nivolumab, Pembrolizumab|"The choice of drug and its dose for maintenance therapy is at the discretion of the study centre (e.g. nivolumab, pembrolizumab). Maintenance therapy should be initiated no later than 60 days after D0, exceptions may be made due to reasonable justification in consultation with the Study PI and will not be considered a protocol deviation.~Nivolumab maintenance therapy regimens:~* Nivolumab (40 mg, fixed dose) IV D1 of each 14-days cycle up to 12 cycles~* Nivolumab (3 mg/kg) IV D1 of each 14-days cycle up to 12 cycles~Pembrolizumab maintenance therapy regimen:~-Pembrolizumab (200 mg, fixed dose) IV D1 of each 21-days cycle up to 8 cycles"
224043927|NCT06820034|OTHER|Empowering Cessation for the ACS South|All participants (N=400) will receive remotely-delivered smoking cessation support comprised of the National Cancer Institute's (NCI) free smoking cessation app and 12 weeks of mailed over-the-counter NRT (nicotine patches, gum or lozenges).. While receiving smoking cessation support, participants in the intervention group (n=200) will also engage in SGM-serving online volunteer activities (≥4 weekly sessions lasting \~1.5 hours each), the protocols for which will be developed in Phase 1 to address the needs of OK, AR, and TX communities. Volunteer sessions will be facilitated by an SGM culturally-competent facilitator employed by the research team (i.e., community partner organizations will not run volunteer sessions). The intervention group will also be added to a digital hub (i.e., a private Reddit group) for 12 weeks to foster social support and exchange of ideas between participants/community partners across the three states.
224043928|NCT03565731|BEHAVIORAL|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
224043929|NCT06987240|PROCEDURE|Ultrasonography-guided combined spinal epidural anesthesia application|patients with BMI\>30
224043930|NCT06987240|PROCEDURE|Combined spinal epidural anesthesia with Landmark|Patients with BMI\>30
223433833|NCT00041210|DRUG|doxorubicin hydrochloride|
223433834|NCT00041210|DRUG|etoposide|
223433835|NCT00041210|DRUG|mechlorethamine hydrochloride|
224043931|NCT03337698|DRUG|Atezolizumab|Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
224043932|NCT03337698|DRUG|Cobimetinib|Cobimetinib is administered orally on Days 1-21 of a 28 day cycle.
224141080|NCT02294422|DEVICE|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
223433836|NCT00041210|DRUG|prednisone|
223433837|NCT00041210|DRUG|vinblastine sulfate|
223433838|NCT00041210|DRUG|vincristine sulfate|
223433839|NCT00041210|RADIATION|radiation therapy|
224141081|NCT02294422|DEVICE|LOR|
224141082|NCT02294422|DEVICE|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
223433840|NCT01065714|DRUG|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
223433841|NCT01065714|DRUG|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
223433842|NCT06435546|DIAGNOSTIC_TEST|Blood samples|Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin
223433843|NCT06435546|OTHER|Adherence to anti-cancer therapies questionnaires|GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
223433844|NCT04923685|OTHER|Trier Social Stress Test|The TSST is a standardized test to induce acute psychological stress in humans. Participants will abstain from caffeine for 12 hours and nicotine for 2 hours prior to the test. An IV butterfly catheter will be placed in an arm vein and flushed with saline. Participants will rest for 15 minutes. A 10ml baseline blood sample will be drawn. They will perform the TSST task and then have 10ml of blood drawn at 0, 15, 30, 60, and 90 minutes post-TSST.
223433845|NCT05241847|BEHAVIORAL|PeLTQL delivery via electronic means|Delivery of PeLTQL scoring information to clinicians via electronic means.
223433846|NCT06683053|DRUG|empagliflozin|Comparing the benefits of both doses of empagliflozin (10 mg versus 25 mg) in terms of heart ejection fraction and quality of life.
223433847|NCT05548868|DEVICE|E4W mobile app|Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.
223433848|NCT05548868|BEHAVIORAL|Standard Care|Patients will receive standard dietary counselling as part of the weight management program.
223433849|NCT02431806|DRUG|Placebo|Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
224043933|NCT03337698|DRUG|RO6958688|"Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle."
224043934|NCT03337698|DRUG|Docetaxel|Docetaxel is administered by IV on Day 1 of each 21 day cycle.
224043935|NCT03337698|DRUG|CPI-444|CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.
224043936|NCT03337698|DRUG|Pemetrexed|Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
224043937|NCT03337698|DRUG|Carboplatin|Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
224043938|NCT03337698|DRUG|Gemcitabine|Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.
224141083|NCT00627770|DEVICE|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
223433850|NCT02431806|DRUG|Levomilnacipran|Over-encapsulated levomilnacipran ER capsules administered orally on Day 1 to Week 8.
223433851|NCT02431806|DRUG|Fluoxetine|Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
223433852|NCT01185223|DRUG|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
223433853|NCT01185223|DRUG|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
223433854|NCT03627416|DEVICE|rTMS|high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
223433855|NCT06098963|DEVICE|sacral neuromodulation|sacra neuromodulator implantation outcomes
224043939|NCT03337698|DRUG|Linagliptin|Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.
224043940|NCT03337698|DRUG|Tocilizumab|Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
224043941|NCT03337698|DRUG|Ipatasertib|Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
224141084|NCT01957709|OTHER|Laboratory Biomarker Analysis|Correlative studies
224141085|NCT01957709|BIOLOGICAL|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
224141086|NCT05094895|PROCEDURE|Stretta|Radiofrequency energy delivered to the gastro-esophageal junction
224299748|NCT06267547|BEHAVIORAL|Fit and Strong! Program|The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
223433856|NCT01342250|BIOLOGICAL|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
223433857|NCT01342250|BIOLOGICAL|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
223433858|NCT01342250|BIOLOGICAL|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
223433859|NCT01916603|BEHAVIORAL|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
223433860|NCT05619536|COMBINATION_PRODUCT|CD388 Injection|CD388 liquid for injection
223433861|NCT05619536|DRUG|Saline placebo|Sterile normal saline for injection
223433862|NCT02691728|DRUG|LDV/SOF FDC|
224043942|NCT03337698|DRUG|Bevacizumab|Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
224043943|NCT03337698|DRUG|Sacituzumab Govitecan|Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.
224043944|NCT03337698|OTHER|Radiation|Radiotherapy up to 21 days
224043945|NCT03337698|DRUG|Evolocumab|Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.
224043946|NCT03337698|DRUG|Tiragolumab|Tiragolumab is administered on Day 1 of each 21 day cycle.
224043947|NCT03337698|DRUG|XL092|XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
224141087|NCT05094895|PROCEDURE|Sham|Patients that have the sham condition will have a procedure using a 24Fr Savary bougie dilator over the guidewire, with the same sedation.
223433863|NCT06597188|DEVICE|VitaFlow Liberty|All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty
223433864|NCT06597188|DEVICE|Commercially available surgical bioprosthetic valve|All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.
223740540|NCT05972499|OTHER|task-oriented training with pretend play|"Pretend play: Children engage in pretend play by acting out themes, taking on roles, assigning attributes to inanimate objects, and using objects as if they were something else Props will be added to hold the child interest. Role play costumes, or occupation props (police officer's suit), stimulate pretending elements.~Task-oriented training: It is involving the active, repetitive practice of functional activities to learn or relearn a motor skill. Training implies that the behavioral experiences are not just repetition of the same sensorimotor skill but involves progressive challenges to a participant's capabilities and involves tasks that are meaningful to the participant. It is based on the following principles: functional goal-directed training focus on practicing specific activities of importance to the child during daily activities; planning activity-focused interventions by adapting knowledge of motor learning ; and allowing for the interest and participation of the children."
224043948|NCT03337698|DRUG|Camonsertib|Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
224043949|NCT05547165|DEVICE|Percutaneous Patent Ductus Arteriosus Closure (PPC)|Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.
224043950|NCT05547165|COMBINATION_PRODUCT|Responsive Management Intervention|"Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.~Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP)."
224043951|NCT05547165|DIAGNOSTIC_TEST|Echocardiogram, cardiac|"An echocardiogram, also known as ECHO, is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions."
224043952|NCT07123077|OTHER|Functional Exercises|"Warm-Up Exercises (10 min): Diaphragmatic breathing exercise, neck rotation (right \& left), rotational shoulder movements, trunk rotation, triceps stretching exercise, hamstring stretching exercise Each exercise was performed for 8 repetitions.~Strengthening Exercises (40 min):~In a seated position:~Ankle plantar flexion and dorsiflexion exercises, ankle circumduction, knee extension, hip flexion, shoulder joint range of motion exercises in all directions, elbow and hand flexion-extension exercises~In a standing position:~Hip extension, toe raises, mini squats, standing on one leg, 360-degree turning, tandem walking exercises Each exercise was performed for 8 repetitions.~Cool-Down Exercises (10 min): Diaphragmatic breathing exercise, neck rotation (right \& left), rotational shoulder movements, trunk rotation, triceps stretching exercise, hamstring stretching exercise Each exercise was performed for 8 repetitions."
224141088|NCT05766293|DEVICE|extracorporeal shockwave device|Fibroblast cell lines (n=10) were subjected to Shockwaves from extracorporeal shockwave device
224141089|NCT05766293|OTHER|Fibroblast cell lines not subjected to shockwaves from extracorporeal shockwave device|Fibroblast cell lines (n=10) without shockwave exposure
224141090|NCT00474825|DRUG|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
224141091|NCT00474825|DRUG|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
224141092|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
224141093|NCT00474825|DRUG|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
224141094|NCT05032417|OTHER|implementation of evidence-based nutrition practice guidelines|The comprehensive training includes the knowledge-focused training, plus access to the EBNPG virtual implementation toolkit. Due to the depth and breadth of the CKD EBNPG, which includes over 70 recommendations, consensus building discussions were conducted with key stakeholders, such as leadership from national dialysis companies and the Evidence Analysis Center guideline developers, to select five recommendations for patients on dialysis as the primary implementation focus for this project.
224141095|NCT01532713|PROCEDURE|oxygen administration|nasal O2 5L/min via nasal cannula
224299749|NCT06964750|BEHAVIORAL|Exercise|Groups will practice the exercises by different method for 6 week
224299750|NCT06964750|BEHAVIORAL|home based exercise|Participant were practice for 6 weeks home based exercises.
224299751|NCT03673332|DRUG|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
224299752|NCT04011215|OTHER|wool clothing|superfine merino wool ensembles for baby/child wear
224299753|NCT04011215|OTHER|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
223740541|NCT04727229|DRUG|Bupivacaine Hydrochloride|Injection of Bupivacaine near the stellate ganglion
223740542|NCT04727229|DRUG|Normal Saline|Injection of Normal Saline near the stellate ganglion
223740543|NCT02982850|DRUG|Dabigatran|
223740544|NCT02982850|DRUG|Acetylsalicylic acid|
224141096|NCT03388996|DIAGNOSTIC_TEST|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
223433868|NCT06664671|OTHER|Experimental|Patients will inhale thyme oil via inhaler sticks with instructions on proper usage, supervised by the researcher. Each patient will complete the Patient Introduction Form, Asthma Control Test, and pre-test sections of the Asthma Symptom and Respiratory Parameters Form. Measurements of FEV1 and FEV1/FVC will be recorded. On the fourth day of hospitalization, post-test data will be collected.
223433869|NCT06664671|OTHER|Placebo|Patients will receive an empty inhaler stick with usage instructions, completing the same pre- and post-test procedures as the intervention group.
224043953|NCT07123077|OTHER|Music Intervention|Slow-paced pieces in the Rast mode were selected for the warm-up and cool-down exercises, while more upbeat pieces in the Mahur mode were chosen for strength and balance exercises and played to the participants throughout the sessions alongside the exercises. To enhance participants' concentration, instrumental compositions in these selected Turkish classical music modes were used. Traditional Turkish instruments such as qanun, ney, kudüm, and oud were preferred in the performance of the compositions.
224043954|NCT07129356|BEHAVIORAL|Combined Exercise|"Participants engaged in a hybrid exercise program that included:~In-field sessions held twice weekly at a local sports facility (45-60 minutes per session, including rest).~Remote sessions delivered via pre-recorded videos through WhatsApp, with ongoing monitoring and feedback.~Exercises included walking, jogging, full-body stretching, and strength training targeting the trunk, limbs, and weak muscle groups (shoulders, back, knees).~The program aimed to reduce joint and muscle pain, improve strength and flexibility, and support daily functional activities.~Pre- and post-intervention assessments included muscle strength (via hand dynamometer), flexibility tests, BMI, and self-reported pain using the NRS-11 scale."
223433870|NCT06664671|OTHER|Control (Standard treatment)|Patients will complete pre- and post-test forms without any intervention.
223433871|NCT04482075|OTHER|segmental stability training|SEGMENTAL STABILISATION TRAINING (SST): This part of the therapy shall involve Isometric co-contraction of Lumbar Transversus abdominis and Lumbar Multifidus. The patient shall perform 10 repetitions of abdominal drawing-in manoeuvre with 30-40% Maximal Voluntary Contraction (MVC) with a 10-second hold in specific prescribed positions.
224043955|NCT06207864|PROCEDURE|Biospecimen Collection|Undergo collection of tissue, blood, saliva, and stool samples
224043956|NCT06207864|PROCEDURE|Return of Results|Receive results
224043957|NCT06207864|OTHER|Survey Administration|Surveys and Interviews
224043958|NCT02108860|DRUG|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
224299754|NCT04209686|DRUG|Paclitaxel|"1. Patients will receive treatment on Day 1 and 8 starting with cycle 2.~2. Paclitaxel (80 mg) will be administered IV on days 1 and 8 starting with cycle 2 (every 21 days).~3. Drug - Paclitaxel - 80mg IV"
224299755|NCT04209686|DRUG|Olaparib|"1. Olaparib will be taken by mouth daily for 3 weeks (every 21 days).~2. Drug - 100 mg or 300mg"
224299756|NCT04209686|DRUG|Pembrolizumab|"1. Patients will receive treatment every 21 days.~2. Pembrolizumab (200 mg) will be administered IV on day 1 (every 21 days).~3. Drug - 200mg IV"
224043959|NCT02108860|DRUG|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
224043960|NCT05091086|DRUG|Continuous Denosumab|Active comparator: persistent treatment of denosumab.
224043961|NCT05091086|DRUG|Administer zoledronate and denosumab on an alternating schedule|In the experimental group, zoledronic acid was administered for one year, followed by two years of denosumab. This cycle was repeated, with the regimen concluding with one year of zoledronic acid.
224043962|NCT01171352|PROCEDURE|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
224043963|NCT04184960|DIAGNOSTIC_TEST|Gastroscopy and gastric biopsies|Gastroscopy would be performed to assess the degree of atrophic gastritis and intestinal metaplasia. In addition, four random biopsies would be taken in the stomach for histological assessment of AG and IM
224043964|NCT00523718|DRUG|riluzole|50 mg PO bid, 12 weeks
224043965|NCT00523718|DRUG|placebo|placebo, 1 capsule PO bid, 12 weeks
224141097|NCT01610076|OTHER|Code Status Video|"10 minute video about Code Status"
224141098|NCT04899960|DRUG|Clinical Pharmacist Intervention|Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.
224141099|NCT05023850|PROCEDURE|TLIPB|Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
224299757|NCT05759806|DEVICE|Nephronyx system (Perfuser)|Temporary deployment of the Nephronyx system (Perfuser)
223433872|NCT04450134|OTHER|Lactose|Placebo: Lactose capsules
223433873|NCT04450134|DRUG|Fexofenadine Hydrochloride|H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
223433874|NCT04450134|DRUG|Famotidine|H2 receptor antagonist: 40 mg Famotidine
223433875|NCT04450134|OTHER|High-intensity interval training (HIIT)|6 weeks HIIT
223740545|NCT02982850|DRUG|Warfarin|
224141100|NCT05023850|PROCEDURE|ESPB|Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
224141101|NCT01759498|DIETARY_SUPPLEMENT|HYDRO|
224141102|NCT01759498|DIETARY_SUPPLEMENT|ACTIVE|
224141103|NCT01759498|DIETARY_SUPPLEMENT|HYDRO 2|
224141104|NCT00284739|DRUG|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
224141105|NCT00284739|OTHER|saline|saline injection twice daily for three days
224141106|NCT02069236|OTHER|G6PD Test|All subjects are tested by multiple G6PD tests
224299758|NCT03649685|DEVICE|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
223433876|NCT05665140|DRUG|Isatuximab|i.v. Induction Phase (Arm A and B): Induction Cycle 1 10 mg/kg D 1, 8, 15, 22, 29. Induction Cycle 2-3 10 mg/kg D 1, 15, 29 Consolidation Phase (Arm B): Consolidation Cycle 1-3 10 mg/kg D 1, 15, 29 Maintenance Phase (Arm A and B): Maintenance Cycle 1 and subsequent cycles 10 mg/kg D 1, 15, 29
223433877|NCT05665140|DRUG|Lenalidomide|hard capsule for oral use. Induction Phase (Arm A and B): Induction Cycle 1-3 25 mg D1-14, 20-35. Consolidation Phase (Arm B): Consolidation Cycle 1-3 25 mg D1-14, 20-35. Maintenance Phase (Arm A and B): Maintenance Cycle 1-2 10 mg D1-28. Maintenance Cycle 3 and subsequent cycles 15 mg D1-28 if tolerable
223433878|NCT05665140|DRUG|Bortezomib|s.c. injection. Induction Phase (Arm A and B): Induction Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32. Consolidation Phase (Arm B): Consolidation Cycle 1-3 1,3 mg/m² D1, 4, 8, 11, 22, 25, 29, 32
223433879|NCT05665140|DRUG|Dexamethasone|orally and i.v. Induction Phase (Arm A and B): Induction Cycle 1 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 8, 15, 22 and 29. Induction Cycles 2 and 3 20 mg p.o. D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. D1, 15 and 29. Consolidation Phase (Arm B): Consolidation Cycle 1-3 20 mg p.o. on D 1-2, 4-5, 8-9, 11-12, 15; 22-23, 25-26, 29-30, 32-33; 20 mg i.v. on D1, 15 and 29
223433880|NCT05665140|OTHER|autologous stem cell transplant|autologous stem cell transplant
223433881|NCT06509971|DRUG|QL1706|"The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab."
223433882|NCT06729541|OTHER|Multigenetic Pharmacogenomics-Guided Treatment (MPGT)|In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
223433883|NCT06995677|DRUG|TYRA-300 60mg|Self-administered 60mg dose Oral tablet(s) given daily
223433884|NCT06995677|DRUG|TYRA-300 50mg|Self-administered 50mg dose Oral tablet(s) given daily
223433885|NCT06995677|DRUG|TYRA-300 Dose TBD|To Be Determined Dose: Self-administered Oral tablet(s) given daily
223433886|NCT04626024|OTHER|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal|Stop taking TKI medication
223433887|NCT04626024|DRUG|Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation|Re-start TKI medication
223433888|NCT06033196|DRUG|Tocilizumab|"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
223433889|NCT06033196|DRUG|Placebo for Tocilizumab|"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
223433890|NCT01876537|DEVICE|Hardware wound healing|
223433891|NCT01876537|DEVICE|Usual Surgery|
224043966|NCT04308824|OTHER|clipping|a single clip will be placed in every case of polypectomy for large colorectal polyps
224043967|NCT04308824|OTHER|nebulization of glue|After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
224043968|NCT04712825|BEHAVIORAL|Cognitive-behavioural therapy|Cognitive-behavioural therapy sessions during 6 weeks of treatment
224141107|NCT02128984|DIETARY_SUPPLEMENT|Symbiotic Formula with DHA and antioxidants|6 months intervention.
224141108|NCT02128984|DIETARY_SUPPLEMENT|Standard Formula|6 months intervention.
224141109|NCT06517862|DRUG|Zinc sulfate|Neonates will receive oral Zn sulfate solution in either low doses (10 mg/day) or high doses (20 mg/day) given twice daily.
224141110|NCT06517862|DRUG|Ursodeoxycholic acid|Neonates will receive oral UDCA solution at 10 mg/day given as 5 mg twice daily.
223433892|NCT00398437|BIOLOGICAL|trastuzumab|
223433893|NCT00398437|DRUG|chemotherapy|
223433894|NCT00398437|PROCEDURE|magnetic resonance imaging|
223433895|NCT05614180|PROCEDURE|Percutaneous coronary intervention|Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.
223433896|NCT06948981|BIOLOGICAL|GT719 Injection|GT719 Injection
223433897|NCT01444729|DRUG|Xiapex|Xiapex administration will follow SMPC
223433898|NCT01444729|PROCEDURE|surgery|Non-pharmacological treatment
223433899|NCT02144480|BEHAVIORAL|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
223433900|NCT02144480|BEHAVIORAL|traditional training|usual care: conventional rehabilitation
224043969|NCT04712825|DEVICE|HypnoVR® device|HypnoVR® sessions during 6 weeks of treatment
224043970|NCT00049556|DRUG|gefitinib|
224043971|NCT00049556|OTHER|immunohistochemistry staining method|
224043972|NCT00049556|OTHER|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
224043973|NCT00049556|PROCEDURE|biopsy|
224043974|NCT00049556|PROCEDURE|sentinel lymph node biopsy|
224141111|NCT04182789|DRUG|KN035|KN035150mg，once a week, subcutaneously. Every 28 days is a treatment cycle.KN035 can be used for up to 2 years.
224141112|NCT03629691|OTHER|lung cavitation|apatinib treated patients developed lung cavitation
224141113|NCT06114394|PROCEDURE|UPV/EHU technique (Aguirre-Zorzano et al 2017)|"The UPV/EHU technique (Aguirre-Zorzano et al., 2017) begins with the elevation of the full thickness flap (FTF) in the palate and an intrasulcular incision performed with a number 12 blade, preserving the papillae in the interproximal spaces. Then, the FTF is dissected with a 15c blade, holding the flap with tissue forceps, leaving the epithelium and a thin layer of the connective tissue in the flap, so that the underlying connective tissue can be harvested. After that the flap is sutured."
224043975|NCT04156503|OTHER|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
224043976|NCT00067392|PROCEDURE|Dental Implant|Dental Implant 4 month time frame
224043977|NCT06177028|DRUG|Lenalidomide 10 mg|Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.
224043978|NCT06274008|DRUG|Exparel|Admixture bupivacaine 0.5 % 10 cc with Bupivacaine Liposome Injectable Suspension 10cc total 20
224043979|NCT04056481|DRUG|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
224043980|NCT03311321|DIETARY_SUPPLEMENT|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
224043981|NCT03311321|DIETARY_SUPPLEMENT|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
224043982|NCT00143065|DRUG|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
224043983|NCT00143065|DRUG|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
224043984|NCT00143065|DRUG|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
224043985|NCT03452293|DEVICE|Stent Peripheral System|Peripheral PTA with Supera Stent implantation
224043986|NCT03465631|DEVICE|SMART Glove system with tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
224043987|NCT03465631|DEVICE|SMART Glove system with sham-tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
224043988|NCT03187951|BEHAVIORAL|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
224043989|NCT03187951|BEHAVIORAL|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
224043990|NCT03187951|OTHER|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
224043991|NCT03187951|BEHAVIORAL|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
224043992|NCT03187951|BEHAVIORAL|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
224043993|NCT03187951|BEHAVIORAL|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
224043994|NCT03441334|DEVICE|High Frequency rTMS|Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
224043995|NCT03441334|DEVICE|Sham rTMS|Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
224043996|NCT04885088|DEVICE|Wisdom bracelet|Wisdom bracelet
224043997|NCT00575627|DRUG|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
224043998|NCT02137512|DEVICE|Closed-Loop Control System|"This investigational device system included the following components:~* DiAs - a smart-phone medical platform;~* Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~* Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~* Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~* Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
223433901|NCT06994364|OTHER|Trigger point release|"Ischemic compression technique is based on the application of manual pressure to treat trigger points.~The patient was asked to lie in the supine position on the examination table. The osteopath identified the muscle through deep palpation and movement-based muscle differentiation, then applied 90 seconds of tolerable pressure to the trigger point on both sides."
223433902|NCT06994364|OTHER|Simulation of the intestinal listening technique.|The patient will be asked to lie in a supine position on the treatment table to simulate the listening technique for assessing the mobility and motility of the small intestine without influencing the final results, with the sensory hand placed below the umbilicus.
224043999|NCT02137512|DEVICE|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~* Dexcom G4 Platinum CGM system;~* Roche Accu-Chek insulin pump"
224141114|NCT06114394|PROCEDURE|Single incision technique (Huerzeler & Weng 1999)|The CTG is harvested with the single incsion technique described by Huerzeler \& Weng in 1999.
224141115|NCT03461432|BEHAVIORAL|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
223433903|NCT03776643|DRUG|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
224044000|NCT05259371|DRUG|Transcutaneous Pulsed Electrical Stimulation (Device: Nu Eyne M02)|Pulse Electrical Stimulation Patients wear our clinical trial device 30mins once a day for 16weeks.
224044001|NCT05516589|DRUG|Nab-paclitaxel|260mg/m\^2 IV Q3W
224044002|NCT05516589|DRUG|Cisplatin|75mg/m\^2 IV Q3W
224044003|NCT05516589|BIOLOGICAL|Tislelizumab|200mg IV Q3W
224044004|NCT05516589|DRUG|Afatinib|30mg PO QD
224141116|NCT04759677|OTHER|Exercise with active video games|45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
224141117|NCT02899377|RADIATION|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
224141118|NCT02899377|RADIATION|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
224141119|NCT02899377|PROCEDURE|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
224141120|NCT02899377|PROCEDURE|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
224141121|NCT05145712|DIAGNOSTIC_TEST|Bowel readiness|"During the examination, the endoscopic physician required to stay in place while rinsing, and the lens could only be withdrawn after rinsing.~During the examination, the recorder should record the time points of the right colon, transverse colon, and left colon, as well as the time of irrigation.~If both are considered to be properly, then second colonoscopy was performed immediately.~If both results agree or either side agrees that the gut is not well prepared, the review will be carried out within a year"
223433904|NCT07001657|PROCEDURE|SPSIP Block|Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.
224044005|NCT04085341|DRUG|GB-102|Intravitreal injection of GB-102
224044006|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
224141122|NCT02424006|DEVICE|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
223433905|NCT07001657|PROCEDURE|PECS II Block|Patients in this group will receive an ultrasound-guided PECS II block with 30 mL of 0.25% bupivacaine hydrochloride (20 mL between the pectoralis minor and serratus anterior muscles, and 10 mL between the pectoralis major and minor muscles), 30 minutes before breast cancer surgery.
223433906|NCT06864806|OTHER|Genetic profile|Filiation analysis between the fetus and his father
223433907|NCT03713008|DIAGNOSTIC_TEST|Fluid bolus|All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
223433908|NCT06671925|BEHAVIORAL|Strengthening COnnections to Overcome Pain (SCOOP)|Each week for 7 weeks, SCOOP intervention group participants will watch a brief video on the study website teaching a pain management or social connectedness skill and have a session with a community health worker, where they will receive support with behavioral goal-setting related to pain management and/or social connections. Participants will be screened for unmet social needs and connected to appropriate resources.
223433909|NCT06308302|OTHER|Group A (Inspiratory Muscles Training + Aerobic Interval Training)|"Performed Inspiratory muscle training on a breather device (20), (10 inhales with maximum 3-sec hold), 3 sets with a 1-minute interval between each set, for 6 days a week along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40 minutes in 3rd week, 45-60 minutes in 4th week each session). (120)~Baseline treatment given is Aerobic interval training and COPD medications."
224044007|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
224044008|NCT02677012|PROCEDURE|Autologous Fat Graft|Undergo AFG using the Coleman technique
224044009|NCT02677012|PROCEDURE|Reconstructive Surgery|Undergo reconstructive surgery
224044010|NCT00319332|DRUG|Ibritumomab Tiuxetan|
224044011|NCT00319332|DRUG|Iodine I 131 Tositumomab|
224044012|NCT01131949|DRUG|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
224044013|NCT04309279|BEHAVIORAL|Zentangle|Zentangle is a mindful doodling process in which participants draw repetitive, structured patterns on small pieces of paper. The patterns consist of combinations of dots, lines, and curves.
224044014|NCT03053258|DEVICE|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
223433910|NCT06308302|OTHER|Group B (Expiratory Muscles Training +Aerobic Interval Training)|"Performed Expiratory muscle training along with aerobic interval training on alternate days (3 days a week for 20-25 minutes in 1st week, 30-35 minutes in 2nd week, 40-45 minutes in 3rd week, 45-60 minutes in 4th week per session). (120)~Baseline treatment given is Aerobic interval training and COPD medications."
224044015|NCT03700151|BEHAVIORAL|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
224044016|NCT02833480|DRUG|Fluticasone group|
224044017|NCT02833480|DRUG|Budesonide group|
224044018|NCT02833480|DRUG|Formoterol group|
224044019|NCT01096212|DRUG|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
224044020|NCT01096212|DRUG|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
224044021|NCT02615470|BEHAVIORAL|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
224044022|NCT02615470|OTHER|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
224044023|NCT02596243|BIOLOGICAL|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
224044024|NCT02596243|BIOLOGICAL|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
224044025|NCT04121611|DRUG|Unfractionated heparin|"1. Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~2. Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
224044026|NCT04121611|DRUG|Acetylsalicylic Acid (ASA)|"1. Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose \< 2 hours of EVT completion~2. ASA 81mg PO OD maintenance dose"
224044027|NCT02433171|PROCEDURE|Standard of Care FDG-PET Imaging|\[11C\]Methionine \[11\]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. \[11C\]PBR28 \[12\]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
224044028|NCT02460705|DRUG|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
224044029|NCT02488187|DEVICE|ABUS|Automated breast ultrasound
224044030|NCT06793033|PROCEDURE|Advanced Cardiac Life Support (ACLS)|Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.
224044031|NCT06793033|DEVICE|Aortic balloon occlusion (ABO)|"Aortic balloon occlusion (ABO) is a technique that diverts blood ﬂow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest.~In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest."
224044032|NCT01817907|DRUG|Placebo pill|Subjects will receive a sugar pill during the placebo arm
224044033|NCT01817907|DRUG|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
224044034|NCT05125094|DEVICE|TACE,Ablation|Transcatheter arterial chemoembolization
224044035|NCT04433806|BEHAVIORAL|Referral to weight loss program|16 weeks Diabetes Prevention Program based weight loss program at a local community partner
224299759|NCT03649685|DEVICE|shame rTMS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
223433911|NCT04339777|DRUG|Busulfan test dose|0.8 mg/kg IV infusion over 2 hours
223433912|NCT04339777|DRUG|Fludarabine|40 mg/m2 IV infusion over 30 min once daily for 4 days
224044036|NCT05597709|PROCEDURE|Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination|Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination
224044037|NCT04603365|DRUG|Pamiparib|Given PO
224044038|NCT04603365|DRUG|Temozolomide|Given PO
224044039|NCT03420079|DRUG|FCN-411 Dose-escalation|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
224299760|NCT05608837|DRUG|OCS-01|One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.
223433913|NCT04339777|DRUG|Busulfan|"AUC Targeted Dose based on busulfan test dose PKs, IV infusion over 3 hours once daily (3.2 mg/kg IV per day will be the default dose) per the below time frame: For 10/10 Matched Related and Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 4 days (-6, -5, -4, and -3).~For Intermediate Intensity Arm, the busulfan dose will be given for 3 days (-6,-5, and -4).~For Low Intensity Arm, the busulfan dose will be given for 2 days on days (-6 and -5). 9/10 HLA Matched Related or Unrelated Donor Recipients For the High Intensity Arm, the busulfan dose will be given for 3 days (-6,~-5, and -4). For the the Intermediate Intensity Arm, the busulfan dose will be given for 2 days (-6 and -5).~For the Low Intensity Arm, the busulfan dose will be given for 1 day on day (-6)."
223433914|NCT04339777|DRUG|Alemtuzumab|Alemtuzumab will be given if there is evidence of immune dysregulation 10 mg/m2 SC divided over three days (-14, -13, and -12)
223433915|NCT04339777|RADIATION|Total body Irradiation|200 cGy Transplant Day -1 (Only for 9/10 HLA Matched Related or Unrelated Donor Recipients )
223433916|NCT04339777|PROCEDURE|Allogeneic HSCT|Stem cell transplant
223433917|NCT04339777|DRUG|Tacrolimus (Tacro)|Tacrolimus 0.02 mg/kg IV continuous infusion over 24 hours starting on day +5
224044040|NCT03420079|DRUG|FCN-411 Dose-expansion|"* FCN-411 is a pan EGFR inhibitor, which has strong activity against wild type (WT), HER2, HER4 and EGFR sensitive mutations (including but not limited to T790M and L858R mutation).~* FCN-411 shows significant antitumor activity in a dose-dependent manner in in vivo models of lung cancer, esophageal cancer and pharyngeal squamous cell carcinoma mediated by EGFR."
224044041|NCT02597803|DRUG|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
224044042|NCT02597803|DRUG|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
224044043|NCT06165822|DRUG|TQB3909 tablets|TQB3909 100mg/tablet.
224044044|NCT06165822|DRUG|Itraconazole capsule|Itraconazole capsule is a strong inhibitor of CYP3A4.
224044045|NCT06165822|DRUG|Rifampicin capsule|Rifampicin capsule is a strong inducer of CYP3A4.
224044046|NCT02761824|OTHER|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
224044047|NCT03987724|OTHER|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
224044048|NCT04962217|OTHER|Semi-structured interviews|Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
224044049|NCT00221650|DRUG|Peginterferon alfa2a|
224044050|NCT00221650|DRUG|Ribavirin|
224044051|NCT03343392|DRUG|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
224044052|NCT03343392|DRUG|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
224044053|NCT00760396|DRUG|VGX-1027|Subjects will
224044054|NCT01650285|DRUG|Cabazitaxel|"Dose Level Day 1, 22, 43~1. 5.0 mg/m2~2. 10.0 mg/m2~3. 15.0 mg/m2~4. 20.0 mg/m2"
224044055|NCT02809742|DRUG|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
224044056|NCT02608060|DRUG|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
224044057|NCT00900523|GENETIC|protein expression analysis|protein expression analysis
224044058|NCT00900523|OTHER|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
224044059|NCT03915808|DIETARY_SUPPLEMENT|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
224044060|NCT03915808|DIETARY_SUPPLEMENT|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
224044061|NCT00659529|DRUG|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
224044062|NCT03719638|DEVICE|D-blade of videolaryngoscope|intubation will be done using d-blade of videolaryngoscope
224044063|NCT03719638|OTHER|simulated difficult airway|extension of head will be limited by using collar.
224044064|NCT03719638|DEVICE|Macintosh videolaryngoscope|intubation will be done using macintosh videolaryngoscope
224044065|NCT03222739|DEVICE|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
223433918|NCT04339777|DRUG|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 15 mg/kg IV over 2 hours three times a day starting on day +5 will continue until Approximately+35 (+/- two days)
223433919|NCT04339777|DRUG|Cyclophosphamide (Cytoxan)|Cyclophosphamide: 50 mg/kg IV once daily over 2 hours on days +3 and +4, dosed according to ideal body weight
223433920|NCT03405389|PROCEDURE|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
223433921|NCT02131818|DRUG|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
223433922|NCT02131818|DRUG|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
224044066|NCT00916539|DEVICE|Cast that immobilizes the thumb|Cast that immobilizes the thumb
224044067|NCT00916539|DEVICE|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
224044068|NCT04047160|DRUG|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
224044069|NCT05623397|OTHER|Acquisition of a digitized ECG by four modalities within 20 minutes|"Patients will have three visits during the cycle for a given dose (600mg/day, 400mg/day or 200mg/day): Baseline , Day 14, Day 28~At each visit, the patient will have the acquisition of a digitized ECG by four modalities within 20 minutes (A 10 second triplicate ECG with WELCH-ALYN ELI-280® with the three 10 sec ECGs collected at approximatively 2-minute intervals, 3 min holter acquisition with a CGM HI-patch ®, a 3 minutes acquisition with AliveCore 6L® device and 10 seconds triplicate acquisition with QT-medical ® device collected at approximatively 2-minute intervals ).~Concomitantly with the ECG acquisition, patients will have blood sampling for measurements of variables clinically important for assessment of QTc including potassium, fasting blood glucose, calcemia, magnesium, estradiol, progesterone, FSH, LH, D4-androstenedione, total and free testosterone, SHBG and TSH. Blood concentration of ribociclib will be also assessed."
224044070|NCT01826851|DRUG|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
224044071|NCT01826851|DRUG|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
223433923|NCT01910987|DRUG|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
223433924|NCT01910987|DRUG|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
223565771|NCT03430024|OTHER|Association of Myosin VI with oestrogen receptor|"1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
223565772|NCT01661777|DRUG|Nasal steroid|
223565773|NCT01661777|PROCEDURE|Myringotomy tube placement|
224044072|NCT03161288|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
224044073|NCT03161288|DRUG|Placebo|Matched placebo
224044074|NCT02053909|DRUG|Aspirin|
224044075|NCT02053909|DRUG|Ticagrelor|
224044076|NCT01817283|DRUG|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
224044077|NCT01817283|DRUG|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
224044078|NCT01817283|DRUG|placebo|Placebo pills produced the same as Triptolide wilfordii.
224044079|NCT03627767|DRUG|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
224044080|NCT03627767|DRUG|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
224044081|NCT03627767|DRUG|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
224044082|NCT04115579|OTHER|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
224044083|NCT04115579|OTHER|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
224044084|NCT02925572|OTHER|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
224044085|NCT04472143|DRUG|Granisetron Transdermal Delivery System|A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
224044086|NCT04163900|DRUG|NUC-1031|IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes
224044087|NCT04163900|DRUG|Gemcitabine|IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert
224044088|NCT04163900|DRUG|Cisplatin|IV in accordance with local institutional practice for biliary tract cancer, including the use of an appropriate hydration protocol
224044089|NCT05531487|OTHER|Questionnaire Survey|All students received a 'QR code' link to the survey.
224044090|NCT05491252|BEHAVIORAL|PAtient CEntered Self-Management Intervention (PACE-SMI)|"Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook.~Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy.~Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time."
224044091|NCT02228187|DEVICE|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
224044092|NCT06833255|OTHER|Interview|Ancillary studies
224044093|NCT06833255|OTHER|Questionnaire Administration|Ancillary studies
224044094|NCT06833255|OTHER|Support|Attend 1:1 peer mentoring sessions
224044095|NCT06833255|PROCEDURE|Support Group Therapy|Attend survivorship group support sessions
223565774|NCT01661777|DRUG|Diuretic|
224044096|NCT01873417|DRUG|BG00012 (DMF)|
224044097|NCT00785044|DRUG|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
224044098|NCT04157816|OTHER|Face-to-Face Training|This intervention is a traditional classroom-based (face-to-face) training program for non-specialist health workers offering instruction for the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The classroom instruction follows the HAP manuals and is facilitated by an experienced counselor with certification as a Master Trainer, meaning that they have significant experience delivering HAP to patients with depression in clinical settings and also training other health workers in the delivery HAP. The total duration of classroom instruction is 6 days.
224299761|NCT03516253|DIETARY_SUPPLEMENT|Fish oil + EPO|Supplementation with both fish oil and EPO
224044099|NCT04157816|OTHER|Digital Training|This 4-week digital training program for non-specialist health workers is accessed through a smart phone app and offers instruction in the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The digital training covers the same content as the Face-to-Face training. The course includes 16 modules with video lectures, role-play videos, graphics, slide presentations, quizzes, and assessment questions. Participants also receive low-intensity support to enhance their learning experience and sustain engagement, including: 1) access to an automated 'Help Line' that participants can call any time with questions about the program; 2) weekly automated messages sent through the mobile app to encourage participants; and 3) automated messages and phone calls to participants who show prolonged periods of inactivity in the mobile app to offer technical support and help them complete the training program.
224044100|NCT04157816|OTHER|Coaching Support|Individualized remote coaching is a form of high-intensity support that will be used to help sustain participant engagement in the digital training program and promote success in progressing through the course. Each week, a Coach will phone participants and offer encouragement and support related to the course. The phone call will last no more than 60 minutes. The Coach will be someone who has successfully completed the course, and therefore can offer first hand knowledge of the content. During the coaching session, the coach will review the participants' progress through the course, offer praise and encouragement, discuss any challenges or questions related to the course content, and review the participants' goals and plans for the upcoming week. Each participant will receive a maximum of 4 remote coaching sessions (1 per week over the 4-week training program).
224044101|NCT00960908|DEVICE|Endeavor Resolute stents|2nd generation ZES
224141123|NCT02424006|DEVICE|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
224141124|NCT01371448|DRUG|Paroxetine|
223433925|NCT01910987|DRUG|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
223433926|NCT01910987|DRUG|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
223433927|NCT06662864|OTHER|Patients reported outcomes|Patients reported outcomes were collected via telephone
223433928|NCT06662864|OTHER|questionnaire global Pittsburgh Sleep Quality Index (PSQI)|Patients reported outcomes were collected via telephone
223433929|NCT04446650|DRUG|Fedratinib|Oral
223565775|NCT01661777|DRUG|Antihistamine|
224141125|NCT05572788|PROCEDURE|EUS-guided fine needle aspiration of pancreatic cysts|Patients with pancreatic cysts requiring fine needle aspiration will be enrolled in this randomized trial
223565776|NCT01661777|BEHAVIORAL|Low salt diet|
224141126|NCT03600493|DRUG|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
224141127|NCT03600493|DRUG|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
224141128|NCT05380674|BEHAVIORAL|The short questionnaire of healthy habits|collects sociodemographic data, weight, height, and physical activity, self-reported.
224141129|NCT04702217|OTHER|Training program|A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
224141130|NCT01023438|OTHER|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
224141131|NCT01023438|OTHER|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
224141132|NCT00469209|DRUG|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
223433930|NCT05260385|DRUG|KC1036|KC1036 are administered orally QD or BID in 21-day cycles.
223433931|NCT04251728|DEVICE|Automated mechanical peripheral stimulation|Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
223433932|NCT04251728|OTHER|Physical Exercise|The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
223565777|NCT02403934|DEVICE|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
223565778|NCT05301257|BEHAVIORAL|Intervention group SOSteniamoci|Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
223565779|NCT02370485|DRUG|LY2801653|Administered orally
223565780|NCT05007496|BIOLOGICAL|AV-COVID-19|DCL previously loaded with varying quantity of S-protein
223565781|NCT06107803|DRUG|Roluperidone 64 mg|64 mg/day oral
223565782|NCT06107803|DRUG|Olanzapine 10 MG|10 mg/day oral
223565783|NCT05764759|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
223565784|NCT05764759|BEHAVIORAL|Treatment as usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking.
223565785|NCT05392114|DRUG|Donidalorsen|Donidalorsen will be administered by SC injection.
224044102|NCT00960908|DEVICE|Endeavor Sprint stent|1st generation ZES
224141133|NCT00469209|DRUG|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
224141134|NCT00469209|DRUG|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
224141135|NCT00469209|DRUG|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
224141136|NCT00041353|OTHER|cytology specimen collection procedure|
224141137|NCT00041353|PROCEDURE|comparison of screening methods|
223433933|NCT04251728|DEVICE|SHAM|Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
223433934|NCT05996640|OTHER|This is study does not use an intervention|This is study does not use an intervention. A survey will be used to collected data on patients' experiences and preferences about waiting list for heart surgery.
223433935|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention without Mutual Gaze|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
224044103|NCT03746899|BIOLOGICAL|PLX-PAD|PLX-PAD cell therapy to be administered via 30 IM injections (0.5 mL each) to the index leg leg per treatment, in each of two treatments, 8 weeks apart
224044104|NCT04841980|DRUG|Rifaximin|Administration route: PO Rifaximin 400mg TDS for 2 weeks
224141138|NCT00041353|PROCEDURE|study of high risk factors|
224141139|NCT00348413|DRUG|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
224141140|NCT00002434|DRUG|Trimetrexate glucuronate|
224299762|NCT03188666|DRUG|REGN2477|Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
224141141|NCT00002434|DRUG|Leucovorin calcium|
224141142|NCT04902898|DEVICE|Circumcision in adults using sterile single-use circular stapling device|Circumcision in adults using sterile single-use circular stapling device CIRCCURER II (Jiangxi Langhe Medical Instrument Co., Ltd., Guangzhou, China)
224141143|NCT04902898|PROCEDURE|Circumcision in adults|Circumcision in adults
224141144|NCT04693923|PROCEDURE|Fluid challenge|Fluid challenge according to the assigned group
224141145|NCT04668794|PROCEDURE|Osteosynthesis|Reduction and fixation of the carpometacarpal fracture dislocation of the hand with osteosynthesis (Kirschners wires, plate and screws)
224141146|NCT02014727|BIOLOGICAL|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
224141147|NCT02014727|BIOLOGICAL|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
224141148|NCT02014727|BIOLOGICAL|Group B2 : Placebo|
224141149|NCT03526315|OTHER|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
224299763|NCT03188666|DRUG|Matching placebo|Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
223565786|NCT05129072|DEVICE|kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D|kalifilcon A Daily Disposable Toric LD213001 lens
224044105|NCT04841980|OTHER|Low FODMAP diet|Low FODMAP diet under dietitian guidance for 4 weeks
224044106|NCT01628107|BIOLOGICAL|Epoetin Hospira|Intravenous (IV) injection
224044107|NCT01825642|PROCEDURE|nerve-sparing radical prostatectomy|
224044108|NCT01825642|PROCEDURE|seminal vesicle-sparing radical prostatectomy|
224044109|NCT02507622|OTHER|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
224044110|NCT02507622|OTHER|Parabolic flight|
224044111|NCT01971502|DRUG|Placebo to BI 1060469|single rising doses
224044112|NCT01971502|DRUG|BI 1060469|food effect
224141150|NCT03526315|OTHER|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
224141151|NCT03526315|OTHER|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
224141152|NCT05816694|DRUG|NAB-Paclitaxel plus Cisplatin|NAB-Paclitaxel will be administered as 125 mg/m2 IV infusion on Day 1 、Day8 of each 3-week cycle. Cisplatin will be administered as 75 mg/m2 IV infusion on Day 1 of each 3-week cycle. Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
224141153|NCT05816694|DRUG|Cisplatin plus Epirubicin plus Cyclophosphamide|Cisplatin was administered as 50 mg/m2 IV infusion on Day 1; Epirubicin was administered as 75 mg/m2 IV infusion on Day 1; Cyclophosphamide was administered as 500 mg/m2IV infusion on Day 1 of each 3-week cycle.Patients will receive maximum of 4 cycles if they do not meet the criteria for removal from the study.
224141154|NCT01608282|BEHAVIORAL|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
224141155|NCT02422082|DIETARY_SUPPLEMENT|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
224141156|NCT02422082|DIETARY_SUPPLEMENT|Placebo|Dietary supplementation with placebo twice daily for 12 months
224141157|NCT01889888|OTHER|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
224299764|NCT03696953|BIOLOGICAL|Florajen3|Probiotic combination product One capsule daily by mouth.
224299765|NCT01400802|BIOLOGICAL|Insulin Lispro|Dosage form- Subcutaneous Injection
224299766|NCT03502707|BIOLOGICAL|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
224299767|NCT03502707|BIOLOGICAL|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
223433936|NCT06733584|BEHAVIORAL|Culturally and Linguistically Responsive Pathways Parent-Mediated Intervention|Pathways-trained bilingual research clinicians will conduct 90-minute weekly coaching sessions with caregivers in the family's home or other convenient location. Caregivers will receive a written and audio version of the program manual which has been adapted to be culturally and linguistically responsive to the Hispanic community. Sessions will review information about social communication, infusing mutual gaze in social sensory routines, and using naturalistic developmental behavioral strategies. Interventionists will demonstrate intervention strategies and provide caregivers with feedback and self-reflection.
223433937|NCT06720974|OTHER|AquaReBal|"The interventions will be delivered one-on-one, in person at the KITE Research Institute by a trained and licensed physiotherapist. We will follow an RBT program previously developed by co-investigators. The interventions will be matched as closely as possible for frequency, intensity and time. The exercise interventions will be based on internal and external perturbations. Therapist-applied perturbations and multiple perturbation types and directions are of most benefit in terms of reactive balance control, so our study will focus on manual perturbations; the perturbations will be strong enough to cause stepping reactions. Interventions will be tailored to the individual participants' abilities.~Each session will include a 10 min warm-up, at least 40 min of perturbations and a 10 min cool-down. Internal perturbations will be achieved by asking the participant to complete tasks that challenge balance control, such that they lose balance when attempting to perform the task."
223433938|NCT04451616|DIAGNOSTIC_TEST|Blood sample collection|Fasting blood sample will be collected from forearm vein. In the sample the concentration of: progranulin and serum FAM19A5 protein, leptin, VEGF, insulin, neopterin, adropin and selected cytokines, adipokines, myokines and chemokines, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides and glucose will be determined. Whole blood sample will be secured to isolate genetic material, detect and examine progranulin and FAM19A5 genes, and genes associated with the development of metabolic syndrome and with the body's mineral management. Serum mineral analysis will be performed.
223433939|NCT04451616|DIAGNOSTIC_TEST|Hair sample collection|Hair sample collection will be performed. Hair mineral analysis will be performed.
223433940|NCT04451616|DIAGNOSTIC_TEST|Urine sample collection|Urine sample collection will be performed. Urine mineral analysis will be performed.
223433941|NCT04451616|DIAGNOSTIC_TEST|Body composition analysis|Body composition analysis with the use of electric bioimpedance will be performed.
223433942|NCT04451616|DIAGNOSTIC_TEST|Questionnaires|Dietary and lifestyle interview with the use of dietary and lifestyle questionnaires and dietary diaries will be performed.
223433943|NCT04451616|DIAGNOSTIC_TEST|Blood pressure, pulse and blood oxygen saturation measurement|Blood pressure, pulse and blood oxygen saturation measurements with the use of non-invasive methods will be performed.
223433944|NCT03065764|DRUG|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
223433945|NCT04836481|OTHER|Serum Sample Collection|Each patient will have 5 serum samples collected for analysis after a minimum six consecutive doses. Patients receiving LEV8 will have sampled collected at hours 0.5, 1, 4, 6, and 8. Patients receiving LEV12 will have sampled collected at hours 0.5, 1, 4, 8, and 12.
223433946|NCT05565144|OTHER|None, pure observational study|None, pure observational study
224044113|NCT01971502|DRUG|BI 1060469|single rising doses
224044114|NCT02953639|DRUG|Basmisanil|Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
224044115|NCT02953639|DRUG|Placebo|Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
224044116|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
224044117|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
224044118|NCT01830855|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
224044119|NCT01830855|BIOLOGICAL|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
224044120|NCT01830855|BIOLOGICAL|Saline|0.5 mL dose of sterile normal saline for injection.
224044121|NCT00515255|DRUG|Minocycline|Capsules
224299768|NCT03502707|BIOLOGICAL|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
223433947|NCT07041008|BEHAVIORAL|Digital intervention|Individual cognitive stimulation sessions will be delivered using RehaCom software, which provides adaptive, computerised exercises targeting specific cognitive domains.
223565787|NCT06585293|DEVICE|Mitra Microsampling Device|Microsampling tool for finger-prick blood collection
224044122|NCT02509104|DRUG|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
224044123|NCT02509104|DRUG|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
224044124|NCT06372951|DEVICE|Ultrasound|A device that use ultrasonic waves as a way to image the internal organs and tissues of the body in order to diagnose the different diseases.
224044125|NCT01840891|BEHAVIORAL|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
224044126|NCT00565591|DRUG|Albuterol sulfate|Single dose dry powder by inhalation
224299769|NCT03502707|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1\*10\^11 vp.
224044127|NCT01187069|BEHAVIORAL|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
224044128|NCT05260853|OTHER|Weaning Board|structured care concept
224044129|NCT02963038|BIOLOGICAL|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
223433948|NCT07041008|BEHAVIORAL|Physical/Analogue Intervention|Individual cognitive stimulation sessions will employ structured physical materials, specifically the 'Memories from North to South©' and 'Cognitive Domains' resources, applied on an alternating basis.
224044130|NCT03253757|OTHER|This study is non-interventional.|This study is non-interventional.
224044131|NCT03523728|DRUG|Venglustat|Pharmaceutical form: capsule; Route of administration: oral
224044132|NCT03523728|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
224044133|NCT04863079|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.
224044134|NCT02728661|BEHAVIORAL|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
224044135|NCT02728661|BEHAVIORAL|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
224141158|NCT05057741|BEHAVIORAL|Multimodal prehabilitation|"Patients who will receive a multimodal prehabilitation program consisting of guided self-care activities at home that include exercise, nutrition and relaxation. Information Will be share by e health. Monitored by telephone daily during the first week and three times a week between the second and fourth week.~The final evaluation of the program will be performed one working day after the control appointment with surgery, which will be scheduled ten days after hospital discharge; and the satisfaction survey will be applied. At 30 days after surgery, a telephone follow-up will be made to inquire about complications and mortality. On that day, self-care recommendations will be given."
224141159|NCT00000384|BEHAVIORAL|Cognitive Behavior Therapy|
224299770|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
223433949|NCT05701956|DRUG|Tenecteplase|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
224044136|NCT00621751|DRUG|Carbamazepine|800 mg daily
224044137|NCT00621751|DRUG|Placebo|Placebo
224044138|NCT05136365|DRUG|Xiongdan Wan|Xiongdan Wan is used as 450mg three times a day after meals with water for 8 weeks. The daily dose (e.g. 450mg/bag, 3 times/day) should be strictly controlled according to the experimental design. Patients should take medicine regularly every day under the guidance of doctors.
223433950|NCT05701956|PROCEDURE|Endovascular thrombectomy|The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.
223433951|NCT05538767|DRUG|Emodepside|Treatment with Emodepside 30 mg
223433952|NCT05538767|DRUG|Albendazole 400mg|Treatment with Albendazole 400 mg
223433953|NCT05094089|DEVICE|Hernia repair with mesh|Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
224044139|NCT05926154|PROCEDURE|Surgical tourniquet pressure selection|Limb occlusion pressure is calculated using the formulation by Graham: LOP = \[(Systolic Pressure - Diastolic Pressure)× (Limb Diameter) / 3 Cuff Width)\] + Diastolic Pressure. One group is LOP + 50 mm Hg and other one is LOP + 100 mmHg
224044140|NCT01782573|DRUG|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
224044141|NCT01782573|DRUG|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
224044142|NCT00250653|DRUG|Saredutant succinate (SR48968C)|
224044143|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
224044144|NCT00295633|DRUG|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
224044145|NCT00295633|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
224044146|NCT00295633|DRUG|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
224044147|NCT00295633|DRUG|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
224044148|NCT00295633|DRUG|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
224044149|NCT04918199|DEVICE|Computer based assessment (iBox)|Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.
224044150|NCT04918199|OTHER|Physician assessement|Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
224044151|NCT03262454|DRUG|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
224141160|NCT00000384|BEHAVIORAL|Educational Support|
224141161|NCT00000384|DRUG|Sertraline|
224141162|NCT00032617|PROCEDURE|Prolonged Exposure|trauma-focused exposure therapy
224141163|NCT00032617|PROCEDURE|Present Centered Therapy|therapy that focuses on current problems
224141164|NCT02750579|PROCEDURE|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
224141165|NCT00430963|DRUG|IncobotulinumtoxinA (Xeomin) (20 Units)|
224141166|NCT00430963|DRUG|Placebo|
224141167|NCT04291976|PROCEDURE|Back-to-back high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
224141168|NCT04291976|PROCEDURE|single-pass high-definition white light endoscopy|Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.
224141169|NCT04291976|PROCEDURE|chromoendoscopy|After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
224141170|NCT00783172|DRUG|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
223433954|NCT03619902|BIOLOGICAL|Imsidolimab|Humanized monoclonal antibody
223433955|NCT02923245|OTHER|point-of-care ultrasound|
223433956|NCT06747845|DRUG|Niraparib|Niraparib 200mg PO daily on days 1-21 of each 21-day cycle.
223433957|NCT06747845|DRUG|FOLFIRI|Standard chemotherapy FOLFIRI (5-fluorouracil, folinic acid, and irinotecan) will be administered intravenously every 14 days of a 28-day cycle.
223433958|NCT06747845|DRUG|Ipilimumab|Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.
223433959|NCT06828601|DRUG|IV Lidocaine|Participant receives IV Lidocaine during surgery. Infusion continues for 48 hours. An initial bolus dose of 1.5 mg/kg ideal body weight (IBW) of IV study infusion will be given at the start of surgery, followed by infusion rate of 2.0 mg/kg/hr IBW intraoperatively.This will be reduced to 1.5 mg/kg/hr IBW postoperatively for 48 hours - once the patient has reached recovery.
223433960|NCT06828601|DRUG|IV Saline|Participant receives IV Saline (placebo) during surgery. Infusion continues for 48 hours. An initial bolus dose of 1.5 mg/kg ideal body weight (IBW) of IV study infusion will be given at the start of surgery, followed by infusion rate of 2.0 mg/kg/hr IBW intraoperatively.This will be reduced to 1.5 mg/kg/hr IBW postoperatively for 48 hours - once the patient has reached recovery.
223433961|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
224044152|NCT01048749|OTHER|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
224044153|NCT01048749|OTHER|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
224141171|NCT00783172|BIOLOGICAL|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
224141172|NCT02080156|DEVICE|CPAP|
224044154|NCT00095082|DRUG|insulin detemir|
224044155|NCT00095082|DRUG|insulin glargine|
224044156|NCT00095082|DRUG|insulin aspart|
224044157|NCT01667536|DRUG|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
224044158|NCT00419120|BIOLOGICAL|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
224044159|NCT03088475|BEHAVIORAL|nurse-led smartphone-based self-management programme|The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
224141173|NCT00289744|BIOLOGICAL|TWINRIX™ ADULT|2 doses IM injection in primary study
224141174|NCT00289744|BIOLOGICAL|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
223433962|NCT02976675|BIOLOGICAL|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
224044160|NCT03088475|BEHAVIORAL|exiting nurse-led diabetes service|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
224044161|NCT00164047|DRUG|Nitrous Oxide|
224044162|NCT01950247|DRUG|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
224044163|NCT01950247|DRUG|SOC|
224044164|NCT00234936|DRUG|Adalimumab|
224044165|NCT00234936|DRUG|Methotrexate|
224044166|NCT05149898|DRUG|ZYN002|"CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD."
224044167|NCT00763971|DRUG|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
223433963|NCT06898177|BEHAVIORAL|mCBT-AR|mCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application
223565788|NCT02380664|DEVICE|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
223565789|NCT02380664|BEHAVIORAL|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
224044168|NCT00763971|DRUG|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
224044169|NCT00763971|DRUG|Placebo|Placebo capsule once per day (Overencapsulated)
224044170|NCT03887845|PROCEDURE|Surgery|The respective surgical approach for any gastric and colorectal surgery
224141175|NCT00865189|DRUG|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
223740546|NCT04860791|OTHER|questionnaires|Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
223433965|NCT07071558|BIOLOGICAL|RSV vaccine formulation 1 dose|Suspension for injection. Route of administration: IM injection
224141176|NCT00865189|DRUG|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m\^2) as a 2-hour IV infusion.
224044171|NCT04021199|GENETIC|Mody test|"Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test."
224044172|NCT01956149|DRUG|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
224044173|NCT05761054|RADIATION|RT|"The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy~/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed."
224044174|NCT00710879|DEVICE|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
224044175|NCT01043679|DRUG|Utapine|Efficacy and Safety of Utapine
224044176|NCT01043679|DRUG|Seroquel|Efficacy and Safety of Seroquel
224044177|NCT01923142|BIOLOGICAL|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
224141177|NCT00865189|DRUG|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m\^2 as a 2-hour infusion.
224141178|NCT00865189|DRUG|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
224044178|NCT01923142|BIOLOGICAL|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
224044179|NCT01519804|DRUG|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
224141179|NCT00865189|RADIATION|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
224141180|NCT00865189|PROCEDURE|Surgery|Radical rectal excision based on the TME technique.
223565790|NCT04730635|DRUG|Donepezil|Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
224044180|NCT01519804|DRUG|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
224044181|NCT01519804|DRUG|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
224141181|NCT02995213|BEHAVIORAL|Accelerometer based feedback about paretic arm use|
224141182|NCT01708616|DRUG|RO5285119|multiple doses
224141183|NCT01708616|DRUG|RO5285119 placebo|multiple doses
224141184|NCT01708616|DRUG|risperidone|single dose
224141185|NCT01708616|DRUG|risperidone placebo|single dose
224141186|NCT04913441|OTHER|Routine physical therapy|Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks
223433966|NCT07071558|BIOLOGICAL|RSV vaccine formulation 2 dose|Suspension for injection. Route of administration: IM injection
224044182|NCT01519804|DRUG|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
224044183|NCT06426251|DEVICE|Photobiomodulation|Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
224141187|NCT04913441|OTHER|Manual physical therapy with routine physical therapy|Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
224141188|NCT04913441|OTHER|Stretching physical therapy with routine physical therapy|Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
223433967|NCT07071558|BIOLOGICAL|RSV vaccine formulation 3 dose|Suspension for injection. Route of administration: IM injection
223565791|NCT04730635|DRUG|Placebo|Dose matched placebo capsule QD, orally for Days 1-56.
223565792|NCT01096368|RADIATION|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
223565793|NCT01096368|DRUG|Carboplatin|Given IV
223565794|NCT01096368|DRUG|Cisplatin|Given IV
223565795|NCT01096368|OTHER|Clinical Observation|Patients undergo observation
223565796|NCT01096368|DRUG|Cyclophosphamide|Given IV
223565797|NCT01096368|DRUG|Etoposide|Given IV
223565798|NCT01096368|BIOLOGICAL|Filgrastim|Given SC or IV
223565799|NCT01096368|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223740547|NCT00751647|OTHER|Physical Therapy|Treatment
224141189|NCT01978509|DRUG|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
224141190|NCT01978509|DRUG|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
223433968|NCT07071558|BIOLOGICAL|RSV vaccine formulation 4 dose|Suspension for injection. Route of administration: IM injection
224044184|NCT01809132|DRUG|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
224044185|NCT01809132|DRUG|Pentoxifylline|Pentoxifylline, generic
224044186|NCT01809132|DRUG|Zinc Sulfate|Zinc Sulfate, nutritional supplement
223433969|NCT07071558|BIOLOGICAL|RSV vaccine formulation 5 dose|Suspension for injection. Route of administration: IM injection
224141191|NCT01978509|DRUG|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
224141192|NCT02359695|DRUG|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
224141193|NCT03031548|DEVICE|Point-of-care ultrasound exam|No intervention
224141194|NCT03031548|RADIATION|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
224141195|NCT02293356|DRUG|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
224141196|NCT04324138|DRUG|Jianpi Qinghua granules|3 times a day and 1 hour after a meal, for 4 weeks
224141197|NCT04324138|DRUG|Jianpi Qinghua placebo granules|3 times a day and 1 hour after a meal, for 4 weeks
224141198|NCT05508685|OTHER|HIIT and Cognitive Reassessment|Participants will receive 40 minutes of high-intensity interval training focusing on the upper and lower limbs associated with a cognitive reassessment strategy during the exercises.
224141199|NCT05508685|OTHER|HIIT group|Participants will receive high-intensity interval training, lasting 40 minutes, focusing on upper and lower limbs.
224141200|NCT05508685|OTHER|Emotional regulation strategy group|Participants will be instructed to cognitively reassess the negative emotions they feel or do not feel during the practice of the exercises. Participants will receive instructions on how to reassess.
223433970|NCT07071558|BIOLOGICAL|RSV vaccine formulation 6 dose|Suspension for injection. Route of administration: IM injection
223433971|NCT07071558|BIOLOGICAL|RSV vaccine formulation 7 dose|Suspension for injection. Route of administration: IM injection
223433972|NCT07071558|BIOLOGICAL|RSV vaccine formulation 8 dose|Suspension for injection. Route of administration: IM injection
224044187|NCT01809132|DRUG|Methylprednisolone|Methylprednisolone, corticosteroid
224044188|NCT00259779|DRUG|budesonide/formoterol|
224044189|NCT00259779|DRUG|Prednisolone|
224141201|NCT05508685|OTHER|placebo group|Participants in this group will not receive any intervention. Only pre and post experiment will be evaluated.
224141202|NCT03141268|DIAGNOSTIC_TEST|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
224141203|NCT06391944|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days
224299771|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5\*10\^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
223433973|NCT06766851|OTHER|Procedure: TMJ Arthrocentesis|Temporomandibular joint arthrocentesis
223433974|NCT05138276|OTHER|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC
223433975|NCT05138276|DRUG|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
224044190|NCT05526742|DRUG|CKD-510 capsule (reference)|Single-dose of CKD-510 will be administered as oral capsule in a fasted state.
224044191|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fasted state.
224044192|NCT05526742|DRUG|CKD-510 tablet (test)|Single-dose of CKD-510 will be administered as oral tablet in a fed state.
224044193|NCT03349775|DRUG|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
224044194|NCT03349775|DRUG|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
224044195|NCT01516970|DRUG|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
224044196|NCT01516970|DRUG|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
224044197|NCT01516970|DRUG|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
224044198|NCT01516970|DRUG|NRTIs|The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
224044199|NCT01516970|DRUG|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
224141204|NCT06391944|DRUG|Osimertinib tablet|Osimertinib 80 or 160mg po everyday
224305027|NCT00699283|DRUG|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
223433976|NCT06561464|DEVICE|EzPAP®|EzPAP® is a portable, single-use respiratory exercise device that provides positive expiratory pressure during expiration while supporting respiration during inspiration. Its use has been increasing in recent years as an oxygenation device. It is portable, single-use, easy to use, well-tolerated, and cost-effective. EzPAP® helps increase functional capacity in the lungs and reduces atelectasis. With EzPAP®, an oxygen flow of 5-8 L/min reaches the patient as 35-42% fractionated oxygen, thus quadrupling the oxygen flow.
223433977|NCT06561464|DEVICE|Non-invasive mechanical ventilation (NIMV)|NIMV provides respiratory support during both expiration and inspiration through continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BiPAP). Treatment success can be monitored within the first 2 hours by the improvement in oxygenation and reduction in pCO2 levels
223433978|NCT02893982|RADIATION|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
224044200|NCT00612950|DRUG|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
224044201|NCT00612950|DRUG|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
224044202|NCT00612950|DRUG|Saline|continuous infusion of Saline for 120 min
224044203|NCT03066908|DEVICE|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
224044204|NCT06344819|PROCEDURE|Acupuncture|Acupuncture involves insertion of thin filiform needles (gauze 30-40) at certain points on the body.
224044205|NCT06344819|OTHER|Sham Acupuncture|During sham acupuncture, the point on the participant's thigh 6 inches proximal to the ST36 acupuncture point is gently tapped with an acupuncture needle guide tube and an acupuncture needle is taped flat to the skin. This point is not on any acupuncture meridian or point.
224044206|NCT01786200|DRUG|Aspirin|
224044207|NCT01786200|DRUG|Ibuprofen|
224044208|NCT05486520|DEVICE|Magnetic Resonance Imaging (MRI)|MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
224044209|NCT00434421|DRUG|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters \[mL\], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose \[0.42 mL, 1:10 wt/vol\] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
223433979|NCT06519344|BIOLOGICAL|anti-CD20/CD30-CAR-T Cells|Before cell infusion,researchers may decide, based on necessity, whether to administer prophylactic medication,which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after anti-CD20/CD30-CAR-T cell infusion,including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesice,etc.
223433980|NCT02715505|DRUG|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
223433981|NCT01963377|DEVICE|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
223433982|NCT01963377|DEVICE|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
223433983|NCT02520427|DRUG|AMG 330|0.5 µg/day - 1.6 mg/day cIV infusion administered in cycles from 14 to 28 days.
224044210|NCT00434421|DRUG|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
224044211|NCT02080442|OTHER|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
224044212|NCT05691231|DEVICE|NuVasive Simplify Cervical Artificial Disc|Simplify Disc is a weight-bearing cervical artificial disc implant consisting of PEEK (polyetheretherketone) endplates and one semi-constrained, fully articulating, mobile Zirconia Toughened Alumina ceramic (ZTA) core.
223433984|NCT00655473|DRUG|Dalcetrapib (RO4607381)|600mg po daily for 24 months
223433985|NCT00655473|DRUG|Placebo|po daily for 24 months
223433986|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
223433987|NCT02048917|DRUG|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
223433988|NCT02048917|DRUG|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
223433989|NCT02048917|DRUG|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
223565800|NCT01096368|DRUG|Mesna|Given IV
223565801|NCT01096368|DRUG|Vincristine|Given IV
223740548|NCT04699409|OTHER|stroke educational campaign: FAST|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
224044213|NCT05492734|DRUG|EDG-5506|single oral dose
224044214|NCT01756040|DRUG|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
224044215|NCT01582542|DRUG|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
224044216|NCT03642756|DEVICE|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
224044217|NCT01205438|DRUG|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
223433990|NCT02048917|DRUG|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
223433991|NCT02048917|DRUG|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
223433992|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
223740549|NCT04699409|OTHER|stroke educational campaign: STROKE 112|After randomization, study staff provided 15-minute education on the selected campaign to each individual participant using educational pictures.
224044218|NCT01205438|DRUG|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
224044219|NCT01205438|DRUG|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
224044220|NCT03133806|DEVICE|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
224044221|NCT05370716|DRUG|Polmacoxib|Polmacoxib
224044222|NCT05370716|DRUG|Pregabalin|Pregabalin
224044223|NCT06161662|OTHER|transcutaneous electrical acupoint stimulation|Electrodes will be attached on the surface of acupoints and electrical stimulation will be given
224044224|NCT06161662|OTHER|Control|Electrodes will be attached on the surface of acupoints but no stimulation will be given
224044225|NCT03653104|BEHAVIORAL|Melodica Intervention|The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.
224044226|NCT03653104|BEHAVIORAL|Pulmonary Health Education|A single session including education about COPD and related health topics.
224044227|NCT06460129|OTHER|Brugger's Exercises|"1. The participant will sit upright and wrap an elastic resistance band around each hand, leaving the palms open. They will perform thumb and finger abduction and extension, wrist extension, and forearm supination. This will be followed by scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension, holding this position for 10 seconds.~2. In both sitting and standing positions, the participant will sit at the edge of a seat, naturally lifting the sternum, with legs spread at a 45-degree angle and feet slightly turned out. Shoulders should be relaxed, chin tucked, and elbows fully extended. The participant will keep their shoulders down, imagining the scapulae pressing together and downward into a V shape, with thumbs turned out, palms up, and fingers spread. This position is held for 10 seconds."
224044228|NCT06460129|OTHER|Kendal Exercise|"1. In a supine position, the participant will place a towel around their neck. With their head on the floor, they will tuck their chin and use the towel to apply gentle resistance, holding for 10 seconds to strengthen the deep flexor muscles of the cervical spine.~2. In a prone position, the participant will point their thumbs toward the ceiling and extend their arms fully while leaning forward, then return to the starting position. They will then extend their arms horizontally and hold for 10 seconds.~3. The participant will place both hands on the back of their head, lift their elbows upward, pull them back, and simultaneously spread their arms out to the side. This position will be held for 10 seconds before returning to the starting position."
224044229|NCT00757536|PROCEDURE|Encircling Band|ppVE and encircling band
224044230|NCT00757536|PROCEDURE|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
224044231|NCT01958723|OTHER|Hospitalists|Introduction of Problem Specific Templates
224044232|NCT01997762|DIETARY_SUPPLEMENT|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
224044233|NCT01997762|DIETARY_SUPPLEMENT|Placebo|
224044234|NCT04483440|BIOLOGICAL|4D-110|4D-110 drug product developed for gene therapy which comprises an AAV capsid variant (4D-R100) carrying a transgene encoding a codon-optimized human CHM gene.
224044235|NCT05020444|DRUG|TriPRIL CAR T Cells|Intravenous infusion
224044236|NCT05020444|DRUG|Cyclophosphamide|Intravenous infusion
224044237|NCT05020444|DRUG|Fludarabine|Intravenous infusion
224044238|NCT04302584|DRUG|norepinephrine / Vasopressin|• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.
224044239|NCT03145545|DEVICE|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
224044240|NCT00378469|BEHAVIORAL|45 minute exercise on ergocycle|
224044241|NCT03891342|DRUG|Fluid bolus administration|"Fluid bolus administration either fast in 5 minutes or slow in 30minutes."
224044242|NCT06549556|DRUG|Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)|Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
224141205|NCT02471911|DRUG|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
223433993|NCT02048917|DRUG|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
223433994|NCT02048917|DRUG|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
224044243|NCT06549556|OTHER|Placebo|Placebo Capsule / Capsules per oral / once daily / 60 days duration
224044244|NCT05168891|PROCEDURE|Surgical therapy|Peri-implantitis surgical therapy by means of open flap debridement, detoxification/decontamination of the implant surface and xenograft regeneration.
224044245|NCT05168891|PROCEDURE|Non-surgical therapy of peri-implantitis|Peri-implant non-surgical therapy combined with antibiotic regimen consisting on metronidazole 500 mg every 8 hours for 7 days will be performed
224141206|NCT02471911|DRUG|Rituximab|IV Rituximab 375 mg/m2 on D1
224141207|NCT02471911|DRUG|Etoposide|IV Etoposide 100 mg/m2 on D1-3
224141208|NCT02471911|DRUG|Carboplatin|IV Carboplatin AUC 5 on D2
224141209|NCT02471911|DRUG|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
224141210|NCT02471911|DRUG|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
224141211|NCT05217953|DEVICE|LovedBy App|The LovedBy solution aims to leverage modern technologies such as smartphones, continuous glucose monitors (CGM), and other smart wearables to assist young sufferers managing their condition. The LovedBy platform offers a mobile application which connects to the user's smart wearables and CGM to monitor data streams that have been linked to long term risk. The mobile application is then able to deliver personally relevant educational content to the user through numerous channels including private social media message
223433995|NCT02048917|DRUG|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
223433996|NCT02048917|DRUG|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
223433997|NCT02048917|DRUG|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
223433998|NCT02683044|PROCEDURE|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
223433999|NCT00688233|DEVICE|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
223434000|NCT05843058|BEHAVIORAL|laughter yoga|The effect of laughter yoga on psychologıcal wellness ın women wıth gynecologıcal cancer has been evaluated.
223434001|NCT00247169|DRUG|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
223434002|NCT04909749|GENETIC|Oneome RightMEd Pharmacogenomic testing Kit|The RightMed test is an end-to-end solution which includes sample collection, pharmacogenomic (PGx) testing services, data analysis, and clinical interpretation that helps physicians select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on Food and Drug Administration (FDA) medication labels. The OneOme RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1.) Green - use as directed; 2.) Yellow - use with caution; and 3.) Red - adjust dose or choose alternative mediation and can be used proactively or reactively
223434003|NCT01828333|OTHER|No intervention|No intervention
224044246|NCT04830033|OTHER|ENO Breathe group|Six weekly group online workshop sessions, led by an ENO vocal specialist. Workshops will encourage participants to take part in exercises and activities especially designed to support breathing control, providing tools for self-management of breath and anxiety. They will also have access to bespoke online digital resources, designed to support participants between sessions. These will include exercises, song sheets and audio and video materials, especially recorded by the ENO for participants on the programme.
223434004|NCT01506154|DRUG|MRX-7EAT|Once daily application of a patch for 14 days
223434005|NCT04216446|BEHAVIORAL|Mobile Health Intervention|A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.
223434006|NCT06623578|PROCEDURE|robotic-assisted surgery|robotic-assisted surgery via single-incision transaxillary approach
223434007|NCT06623578|PROCEDURE|Open Surgery|conventional open surgery
223434008|NCT00264160|DRUG|AMN107|
223434009|NCT02319720|BIOLOGICAL|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
223434010|NCT02319720|BIOLOGICAL|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
223434011|NCT02319720|PROCEDURE|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
223434012|NCT05960227|DRUG|Iron dextran|Administration of 1.2g of iron dextran in infusion bolus as a loading strategy.
223434013|NCT05960227|DRUG|Placebo|250ml of saline 0,9% for 4 hours insusion.
223740550|NCT03104114|BEHAVIORAL|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
224044247|NCT00005081|DRUG|O6-benzylguanine|
224044248|NCT00005081|DRUG|carmustine|
224044249|NCT00143091|DRUG|CP-316,311|
224044250|NCT00143091|DRUG|Placebo|
224044251|NCT00143091|DRUG|Sertraline|
223740551|NCT03104114|BEHAVIORAL|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
224044252|NCT01446016|DRUG|Paclitaxel|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
223434014|NCT06351098|BEHAVIORAL|nap|Children are nap promoted
223434015|NCT06906523|OTHER|Blood flow restriction training|The intensity of the work will be set at around 40% of the maximum intensity that can be executed in a single repetition (1RM). To reach the established intensity, weights, weighted ankle supports and rubber bands of different resistances will be used. Three sets of 8-10 repetitions will be performed with breaks of 1-2 seconds between repetitions and 2-3 minutes between sets. The intensity of the work will be established by applying the rate of perceived exertion. A blood flow restriction device will be used (Akrafit, Valencia, Spain model).
223434016|NCT04101929|DRUG|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
224044253|NCT01446016|DRUG|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
224044254|NCT01446016|DRUG|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
224044255|NCT01446016|DRUG|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
224044256|NCT02525055|OTHER|Infectious titre 1 (H3N2)|Infectious titre 1: 2.8 x 10\*3 TCID50/mL
224044257|NCT02525055|OTHER|Infectious titre 2 (H3N2)|Infectious titre 2: 2.5 x 10\*4 TCID50/mL
224044258|NCT02525055|OTHER|Infectious titre 3 (H3N2)|Infectious titre 3: 3.6 x 10\*5 TCID50/mL
224044259|NCT02525055|OTHER|Infectious titre 4 (H3N2)|Infectious titre 4: 4.7 x 10\*6 TCID50/mL
224044260|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
223434017|NCT04101929|DRUG|S-1 capsule|Patients receive S-1 capsule According to the body surface area \<1.25m2 60mg/d, 1.25 \~ 1.5 m2 80 mg/d, \> 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
224044261|NCT02525055|OTHER|Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)|Infectious titre 5: 3.5 x 10\*5 TCID50/mL
224044262|NCT00955851|OTHER|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
224044263|NCT03517189|PROCEDURE|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
224044264|NCT05436769|DRUG|Klaribact 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
224044265|NCT05436769|DRUG|Klaricid 500 mg Clarithromycin Tablet|A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
224044266|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence ABFCED|Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D
224044267|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence BCADFE|Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E
224044268|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence CDBEAF|Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F
223434018|NCT04101929|DRUG|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
223434019|NCT04395092|BIOLOGICAL|K-NK002|"K-NK002 will be administered intravenous (IV) on Day -2, Day +7 and Day +28.~Part One (Safety run-in):~An initial safety run-in to confirm the starting dose, and safety and tolerability of K-NK002;~* Dose cohort 1 will include 3 patients who will receive a dose of K-NK002 at 1 x 10E7 NK cells per kg.~* Dose cohort 2 will include 3 patients who will receive K-NK002 at 1 x 10E8 NK cells per kg.~Part Two (Open Enrollment):~Enrollment into the second part of the study (Open Enrollment) can begin following Part One, confirmation of dose and safety."
224044269|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence DECFBA|Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A
224044270|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence EFDACB|Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C
224044271|NCT04735822|DRUG|Part 1: Belumosudil 40 mg/mL Sequence FAEBDC|Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
224044272|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GHI|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
224044273|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HIG|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
224044274|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IGH|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
224044275|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence IHG|1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
224044276|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence GIH|1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
223434020|NCT04395092|PROCEDURE|Conditioning Regimen|"From Day -7 to Day -3:~* Melphalan: 140 mg/m2 (100mg/m2 in patients ≥ 60) on Day -7.~* Fludarabine: 40 mg/m2 daily for 4 doses starting on days -7.~* TBI: 2 Gy on Day -3."
224044277|NCT04735822|DRUG|Part 2: Belumosudil 200 mg Sequence HGI|1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
224044278|NCT05488210|DIETARY_SUPPLEMENT|FontActiv DiaBest HP/HC|Daily intake of two FontActiv DiaBest HP/HC during 2 months
224044279|NCT00298467|DRUG|MDX-060|
224044280|NCT00943709|BIOLOGICAL|insulin glargine recombinant|Given subcutaneously
223434021|NCT04395092|PROCEDURE|HaploBMT|Bone marrow is the only allowed graft source for patients enrolled in this clinical trial
223434022|NCT03258970|OTHER|Observational cohort study|taking vitamin supplements
223434023|NCT00108511|DRUG|Gemfibrozil|
223434024|NCT06249854|DRUG|Bojungikki-tang(BJIKT)|"Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects"
224044281|NCT00943709|DRUG|therapeutic insulin|Given subcutaneously
224044282|NCT02091154|BEHAVIORAL|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~1. Fruit or vegetable on every tray~2. Meet requirements for vegetable varieties~3. 50% of all grains must be whole grain~4. Milk must be 1% or skim; flavored milk must be skim"
224044283|NCT02091154|BEHAVIORAL|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~1. 56''x72'' vinyl sign with the words \[school mascot\] Cafe~2. 8.5''x11'' signs describing the foods offered on a specific day~3. 2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~4. Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
224141212|NCT00002392|DRUG|Thalidomide|
223434025|NCT06249854|DRUG|Pembrolizumab|It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
223434026|NCT06237244|DIAGNOSTIC_TEST|triglyceride to glucose ratio|Ratio of triglyceride level to glucose
223434027|NCT06237244|DIAGNOSTIC_TEST|triglycerdie to HDL ratio|Ratio of triglyceride to HDL cholesterol
223434028|NCT05428163|OTHER|Biological sampling|3ml of blood
223434029|NCT05801510|BEHAVIORAL|Cognitive Muscular Therapy for knee pain|Psychologically informed physiotherapy which uses biofeedback training to reduce muscle overactivity and improve postural control and also encourages people to change the way they react to pain.
223434030|NCT02863510|DEVICE|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
223434031|NCT01903785|DRUG|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
223434032|NCT01903785|DRUG|Placebo|
223434033|NCT05724628|PROCEDURE|Laparoscopic appendectomy|Subjects will receive surgery (using 3 port Laparoscopic appendectomy) to remove appendix
223434034|NCT05724628|DRUG|Antibiotics (IV transitioned to oral)|"Subjects will be admitted to the hospital for antibiotic treatment, initially with IV antibiotics and then transitioned to by mouth (PO) antibiotics for the rest of the course.~Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin"
223434035|NCT02222597|DEVICE|infrascanner|
223434036|NCT06459505|OTHER|Routine or standard Physical Therapy|Participants will undergo physical therapy to stop abnormal movement patterns and restore control over output in the developmental sequence. Therapists will provide cues to elicit basic posture and movement patterns, inhibiting aberrant patterns. The therapy aims to promote normal posture and movement patterns, incorporating the hemiplegic side for symmetry and functional use. Active usage and targeted strengthening activities will be emphasized, with motor performance practice included.
223434037|NCT06459505|OTHER|Adapted Physical Activity|For Upper extremities, Manual Ability Classification Scale (MACS) is a tool designed to support individuals with hemiplegic cerebral palsy by providing structured support through activities focusing on strength, flexibility, balance, and coordination. Participants at different MACS levels receive tailored treatments, including adaptive tools, task-specific training, assistive gadgets, and functional training. For lower extremities, the therapy will begin on stable support surfaces before progressing to more challenging surfaces such as inflatable cushions, foam pads, or balance discs, focusing on slow and controlled motions for improved body alignment and coordination.
223434038|NCT04103827|OTHER|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
223434039|NCT00026429|BIOLOGICAL|denileukin diftitox|
223434040|NCT00153127|DRUG|polyethyleneglycol3350|
223434041|NCT04907331|BIOLOGICAL|Vaxzevria|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria followed by Comirnaty
224044284|NCT02091154|BEHAVIORAL|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~1. Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~2. Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~3. Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
224044285|NCT01582022|DRUG|Bupivacaine|local application for 5 minutes
224044286|NCT01582022|DRUG|normal saline|local application for 5 minutes
224044287|NCT01087957|DEVICE|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
224044288|NCT01087957|OTHER|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
224141213|NCT01504048|PROCEDURE|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
223434042|NCT04907331|BIOLOGICAL|Comirnaty|The participants either receive homologous vaccination with Comirnaty or Vaxzevria as approved or the new heterologous vaccination with Vaxzevria
223434043|NCT02432859|PROCEDURE|Electrical Stimulation|Direct current with sensory intensity for one hour
223434044|NCT02432859|PROCEDURE|Placebo|Direct current with zero intensity for one hour
224044289|NCT01291199|DRUG|vardenafil|10 mg p.o. bid for 6 weeks
224044290|NCT01291199|DRUG|Placebo|Placebo p.o. 6 weeks bid
224044291|NCT00408330|DRUG|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
224044292|NCT00408330|DRUG|Inactive 15% gel base|placebo, topically applied daily for six weeks
224044293|NCT03743883|DRUG|Acetylsalicylic Acid(BAYE4465, Aspirin )|Administration according to clinical practice
224044294|NCT01186939|DRUG|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
224044295|NCT02851420|OTHER|spectroscopy|
224044296|NCT02313298|RADIATION|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
224044297|NCT03171844|OTHER|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
224141214|NCT02097433|DRUG|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
223565802|NCT05591066|BEHAVIORAL|PFC I-PASS Intervention|Patient and Family-Centered I-PASS is a bundle of communication interventions to improve the quality of information exchange between physicians, nurses, and families, and to better integrate families into all aspects of daily decision making in hospitals. The intervention included a health literacy-informed, structured communication framework for family-centered rounds; written rounds summaries for families; a training and learning program; and strategies to support teamwork and implementation.
224141215|NCT03181074|OTHER|Non-Interventional|Non-Interventional
223434045|NCT03750747|DEVICE|Pulse Oximeter|SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing \<10 kg, the sensor will be placed on the big toe. For patients weighing \>10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
223434046|NCT07094412|OTHER|Educational content on statin side effects|Participants will view educational content that will include written material, graphics and video. The content will explain side effects and benefits of statin medications. The content will also explain placebo and nocebo effects and how they may impact people taking statins.
223434047|NCT03863327|OTHER|No intervention|There will be no intervention as a part of this protocol.
223434048|NCT02987972|BIOLOGICAL|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
223434049|NCT02987972|BIOLOGICAL|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
223434050|NCT02987972|BIOLOGICAL|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
223434051|NCT06906458|OTHER|Paresthesia|Patients experiencing paresthesia during the interscalene nerve block
223434052|NCT06906458|OTHER|No paresthesia|Patients not experiencing paresthesia during the interscalene nerve block
223434053|NCT05679817|OTHER|Dose-graded aerobic exercises|The D-GAE group received a 12-week aerobic training, three times in addition to the traditional physical rehabilitation. The D-GAE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The D-GAE program included a warm-up for 5 minutes and a cool-down for 5 minutes
223434054|NCT05679817|OTHER|Traditional physical rehabilitation|The control group received the traditional physical rehabilitation only, 45 minutes per session, three times a week for 12 consecutive weeks. The program consisted of flexibility exercises, strengthening exercises, balance training, and general conditioning exercises.
223434055|NCT06910488|OTHER|Daily Living Activities Mobile Application|mobile application was used for three months
223434056|NCT06910488|OTHER|Individual interviews|"The individual's daily living activities are assessed using forms and scales that evaluate disability, functional level, and the ability to perform skill-based activities.~Factors affecting daily living activities, such as strengths and weaknesses, barriers, accessible healthcare services, and social support networks, are examined.~The client's independent, semi-dependent, and dependent daily living activities are evaluated together.~Implementation steps are created to achieve the identified goals. Barriers to achieving the goals and supporting factors are identified."
223434057|NCT06910488|OTHER|Group education|"Information is provided about the symptoms of schizophrenia and bipolar disorder, their causes, and treatment.~The early warning signs are explained, along with the importance of recognizing that they can lead to an emergency situation.~The importance of prior planning for what to do in case of an emergency is discussed. As homework, the family is asked to make this plan together.~Information is provided about the importance of daily living activities and what they entail.~Information is provided about self-care skills, healthy nutrition, movement planning, good sleep hygiene, the importance of body temperature regulation, and elimination issues.~Information is provided about communication skills. Information is given about what to pay attention to in order to establish effective communication."
223434058|NCT06910488|OTHER|Routine rehabilitation program|It includes psychiatric rehabilitation services that are part of the clinic's program.
223434059|NCT07099365|DEVICE|Orbi|Orbi is adapted from COMPASS, a web-based cognitive behavioural therapy (CBT) intervention based on the Transdiagnostic Model of Adjustment in Long-Term (physical) Conditions Model. Orbi is made up of 13 topics, each exploring a different challenge faced by individuals with a LTC(s). Orbi is a self-guided CBT programme with no therapist involvement.
223434060|NCT04862897|OTHER|Patient-controlled admissions|Patients are allowed to admit themselves to inpatient care when needed (standard procedure, four days of inpatient care at a time, up to three times a month)
224044298|NCT02692664|DEVICE|Endovascular aorto-iliac repair|
224044299|NCT04420754|BIOLOGICAL|AIC100 CAR T Cells|Autologous CAR T cells directed against ICAM-1
224044300|NCT04179747|BEHAVIORAL|Cognitive Behavioral Psychotherapy|The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
224044301|NCT04179747|DRUG|Sildenafil Citrate 50Mg Tab|The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
224044302|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
224044303|NCT05366920|PROCEDURE|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with 5mm suction irrigation blunt dissection starting from fundus
224044304|NCT00987688|OTHER|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
224299772|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
224044305|NCT01817855|DRUG|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
224044306|NCT01817855|DRUG|Placebo to match|Multiple doses inhaled placebo via a nebulizer
224044307|NCT04695496|DEVICE|Theta bust stimulating|Theta burst stimulation with Magstim super rapid 2, over SMA. 3 section per day, for 5 days, total 15 sections.
224044308|NCT00616434|DRUG|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
224141216|NCT02368080|DEVICE|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
224141217|NCT01078714|DRUG|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
224141218|NCT04083001|DEVICE|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
224141219|NCT00148421|DRUG|Darbepoetin alfa and Epoetin alfa|
224141220|NCT02943512|OTHER|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
224141221|NCT01475864|PROCEDURE|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
223565803|NCT05591066|BEHAVIORAL|PFC I-PASS+ Intervention|PFC I-PASS+ builds on PFC I-PASS to make it better and focus on the special needs of patients who speak languages other than English. PFC I-PASS+ includes all parts of PFC I-PASS plus having interpreters during and after rounds, cultural humility training, and provider communication skills training.
224044309|NCT00616434|DRUG|Placebo|Placebo IM injection, self-administered per protocol.
224044310|NCT02455934|DIETARY_SUPPLEMENT|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
224044311|NCT00296179|DRUG|zolpidem tartrate|
224044312|NCT03302000|OTHER|Early Visual Stimulation|Early visual stimulation
224044313|NCT03302000|OTHER|standard care|standard care
224044314|NCT00251381|DRUG|Cetuximab|
224044315|NCT02686021|DRUG|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
224044316|NCT02686021|DRUG|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
224044317|NCT02686021|DRUG|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
224044318|NCT00929604|OTHER|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
224044319|NCT04997187|DIETARY_SUPPLEMENT|Bacillus coagulans group|Bacillus coagulans 400 mg/day for 12 weeks
224141222|NCT05398419|OTHER|Music listening intervention|Participants will listen to the music at bedtime and overnight for 7 consecutive nights. The music will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
224141223|NCT05398419|OTHER|Non-musical sounds listening intervention|Participants will listen to the non-musical sounds at bedtime and overnight for 7 consecutive nights. The non-musical sounds will be administered via headphones (sleep headbands without a cord) that are connected via Bluetooth to an MP3 player.
224141224|NCT02513784|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
224044320|NCT04997187|DIETARY_SUPPLEMENT|Control group|Placebo 400 mg/day for 12 weeks
224044321|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
224044322|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
224141225|NCT05923450|PROCEDURE|Colorectal Resection|Radical resection of colorectal cancer
224141226|NCT00843843|DEVICE|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
224141227|NCT00680290|PROCEDURE|Exercise|Exercise x 8 weeks
224141228|NCT01847898|PROCEDURE|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
224141229|NCT01847898|PROCEDURE|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
224141230|NCT00418379|DRUG|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
224141231|NCT00418379|DRUG|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
224141232|NCT00418379|DRUG|Placebo|Placebo tablet
224141233|NCT01035008|PROCEDURE|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
224141234|NCT04545398|OTHER|Food. Beef, Pasture-raised|Pasture-raised beef
224141235|NCT04545398|OTHER|Food. Beef, Grain-fed|Grain-fed beef
224141236|NCT04545398|OTHER|Food. Meat alternative|Meat alternative
224141237|NCT04545398|OTHER|Food, Lamb|Lamb
223434061|NCT06620653|OTHER|Telemonitoring|Patients assigned to the intervention group will receive a tablet (if the patients do not have a tablet, computer or smartphone), a weight scale and a blood pressure monitor. The patients will provide daily biometric data (weight, heart rate and blood pressure) and report symptoms through four questions to capture worsening symptoms of the cardiac condition.
224044323|NCT03979651|DRUG|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
224044324|NCT01690897|BEHAVIORAL|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
224044325|NCT01690897|BEHAVIORAL|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
224044326|NCT05988541|DIAGNOSTIC_TEST|Ultrasonography imaging|Ultrasonography: rotator cuff tendons (supraspinatus, infraspinatus, subscapularis) integrity, long head of the biceps tendon integrity and location, SASD (subacromial-subdeltoid) bursitis, synovitis and muscle atrophy.
224044327|NCT05988541|DIAGNOSTIC_TEST|American Shoulder and Elbow Surgeons (ASES) Score|"The patient self-assessment (pASES) includes 6 pain items and 10 functional items that are shoulder specific (Angst, 2008).~The pASES form has 3 sections: pain, instability, ADLs (Goldhahn, 2008).~1. Pain section: 4 questions with yes/no responses, 1 question covering number of pain tablets per day, and a VAS (visual analogue scale) from 0 (no pain) to 10 (worst pain).~2. Instability section: 2 questions (1. Response yes/no about feelings of instability, 2. Quantify instability from 0 (stable) to 10 (very unstable)).~3. Activities of daily living (ADLs): Each shoulder is included (affected/non affected), 10 items, with a 4 point ordinal scale, range: 0 (unable to perform activity) to 3 (no difficulty in doing activity) (Goldhahn 2008)."
224044328|NCT05988541|DIAGNOSTIC_TEST|The Constant-Murley score (CMS)|The test is divided into four subscales: pain (15 points), activities of daily living (ADL) (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points).
224044329|NCT05988541|DIAGNOSTIC_TEST|The Disabilities of the Arm, Shoulder and Hand (DASH)|"30-item self-report questionnaire designed to assess symptoms and function of the entire upper extremity.~Total scores range from 0 (minimum) to (100) maximum."
224044330|NCT06495502|OTHER|semi-structured interview|Semi-structured interviews by qualitative health researchers
224044331|NCT06249204|BEHAVIORAL|Coaching Group|Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
224044332|NCT06435676|DRUG|HRS9531|Single dose escalation of HRS9531 tablets in healthy subjects
224044333|NCT06435676|DRUG|Placebo|Single dose of placebo in healthy adults
224044334|NCT06435676|DRUG|HRS9531|Multiple dose escalation of HRS9531 tablets in healthy subjects
224044335|NCT06435676|DRUG|Placebo|Multiple dose of placebo in healthy adults
224044336|NCT04607954|BIOLOGICAL|Durvalumab|Given IV
224044337|NCT04607954|DRUG|Lurbinectedin|Given IV
224044338|NCT05003895|DRUG|Cyclophosphamide|Daily x 3 doses on Day -3, -2, -1 300 mg/m2 IV infusion (200 mg/m2 in Dose Level -1)
224044339|NCT05003895|BIOLOGICAL|CAR-T cell|Single infusion on Day 0
224044340|NCT05003895|DRUG|Fludarabine|Daily x 2 doses on Day -2 and -1 30 mg/m2 IV infusion administered following cyclophosphamide
224044341|NCT01118325|DRUG|ticagrelor|Drug oral treatment
224044342|NCT01118325|DRUG|clopidogrel|Drug oral treatment
223434062|NCT06620653|OTHER|Standard Care|patients with a recent admission for heart failureare seen in a first face-to-face appointment within two weeks of discharge as per current 2021 ESC Heart Failure Guidelines with face-to-face follow up at 6 and 12 weeks.
223434063|NCT00673751|DRUG|GLP-2|450 nmol subcutaneous
224044343|NCT05694520|OTHER|pistachios consumption of 1.5 oz thrice per week|According to the Chinese nutritional guidelines for GDM women, the energy intake of 1500-1800 kcal/d will be recommended for all the included participants with pregestational BMI≥24 kg/m2. Standard care and a balanced diet will be recommended to the women in CG incorporating the total nuts intake of less than 2.5 oz per week). While the women in the IG will be offered the otherwise same diet as their counterparts in the CG, except for the extra intake of pistachios of 1.5 oz thrice per week.
223434064|NCT00673751|DRUG|Placebo|
223565804|NCT05661981|DEVICE|GLYCAR Pericardial Patch|The Glycar patches are intended to be used by surgeons specialized in the field of cardiovascular surgery. The patch is intended to be used for pericardial closure, or repair and/or reconstruction of cardiovascular structures by replacing missing tissue, reinforcing weakened tissue and providing extra strength to repair tissue during healing.
223565805|NCT04934800|DRUG|Cladribine|No intervention will be administered as a part of this study. Participants who had switched from first-line DMD treatments to treatment with cladribine tablets in routine clinical practice will be assessed for 2 years in this study.
224044344|NCT03589690|DIETARY_SUPPLEMENT|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
224044345|NCT03589690|DIETARY_SUPPLEMENT|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
224044346|NCT03532646|PROCEDURE|upper endoscopy|endoscopy of the gastrointestinal tract
223434065|NCT06909851|PROCEDURE|Adductor Canal Block (ACB)|Evaluation of postoperative analgesic effectiveness of ACB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.
223434066|NCT06909851|PROCEDURE|Genicular Nerve Block (GNB)|Evaluation of postoperative analgesic effectiveness of GNB block in participants undergoing arthroscopic knee surgery under spinal anesthesia.
223434067|NCT06912256|BEHAVIORAL|Sleep restriction|During the intervention period (i.e., 9 consecutive days), the intervention group started the sleep protocol, sleeping only the quantity of hours defined for their individual chronic partial sleep restriction (15% of the usual sleep time). The amount and quality of sleep obtained were daily monitored through actigraphy devices, and all the players filled in a sleep diary when they woke up. During this period, players performed the SSGs in two different moments (moment 1 and moment 2), interspersed by 4 days.
223434068|NCT06910215|OTHER|Elastic therapeutic taping|Elastic therapeutic taping is a non-invasive method that uses a specially designed elastic cotton tape applied directly to the skin. In this study, it is used to support pain management after open-heart surgery (CABG via sternotomy). The tape is applied near the surgical site to gently lift the skin, which may help reduce pain, improve circulation, and support healing. The application is done by a trained physiotherapist following a standardized taping protocol. The tape remains on the skin for up to 48 hours.
223434069|NCT06910215|OTHER|Placebo Elastic Therapeutic Taping|In this group, the same type of elastic tape used in the therapeutic group is applied to the skin near the surgical area, but without any stretch or therapeutic technique. The tape does not provide physical support or intended therapeutic effects. It is used to help researchers understand whether any improvements are due to the taping itself or simply from receiving an intervention. The tape remains in place for up to 48 hours and is applied by trained personnel using a standardized, non-therapeutic method.
223434070|NCT06910215|OTHER|Therapeutic Taping on Non-Surgical Areas|In this group, elastic therapeutic tape is applied to body areas not directly related to the surgery, such as the shoulder, back, or rib area. The purpose is not to treat pain at the surgical site, but to simulate the experience of receiving a physical intervention. This approach helps researchers understand the potential impact of attention, expectation, or psychological support related to being part of a study. The tape is applied gently without therapeutic intent and stays on for up to 48 hours
224044347|NCT03258125|GENETIC|real time PCR (rPCR)|A villus tissue (2.5 cm \* 2.5 cm \* 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
224044348|NCT03334409|DRUG|Ascorbic Acid|Given IV
224044349|NCT03334409|DRUG|Pazopanib Hydrochloride|Given PO
224044350|NCT00975715|DRUG|TRI476|TRI476 oral suspension doses, based on body weight twice daily
224044351|NCT00975715|DRUG|Placebo to TRI476|Placebo oral suspension, taken twice daily
223434071|NCT07112391|OTHER|Observational Invasive Hemodynamic Assessment|Collection and analysis of invasive hemodynamic data obtained through routine cardiac catheterization performed as part of standard care. No intervention is mandated by the study protocol.
223434072|NCT04149574|DRUG|nivolumab|Specified Dose on Specified Days
223434073|NCT04149574|OTHER|Placebo|Specified Dose on Specified Days
223434074|NCT04149574|BIOLOGICAL|Bacillus Calmette-Guérin (BCG)|Specified Dose on Specified Days
223565806|NCT00516906|DRUG|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
223565807|NCT00516906|DRUG|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
224044352|NCT00975715|DRUG|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
223434075|NCT05305547|DRUG|S-217622|Administered as a round tablet.
223434076|NCT05305547|DRUG|Placebo|Administered as a round tablet.
223434077|NCT00073983|BIOLOGICAL|filgrastim|filgrastim
223434078|NCT00073983|BIOLOGICAL|pegfilgrastim|pegfilgrastim
224044353|NCT04116424|OTHER|nurse training of the patient|visit + telephone follow-up
224044354|NCT04116424|OTHER|neurologist accompaniement|presentation during consultation by neurologist
224044355|NCT03270566|DEVICE|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
224044356|NCT01245634|DRUG|Placebo|iv infusion every 4 weeks, 32 weeks
223434079|NCT00073983|DRUG|docetaxel|docetaxel
224044357|NCT01245634|DRUG|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
224044358|NCT05592067|OTHER|I tape technique|I tape technique described by Dr Kenzo Kase will be applied once a week, a total of 3 times, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
224044359|NCT05592067|OTHER|Button hole technique|Button hole technique defined by Dr Kenzo Kase will be applied once a week, 3 times in total, and the exercises will be taught to the patient and a total of 21 sessions will be applied once a day.
224044360|NCT05592067|OTHER|exercises|exercises will be taught to the patient and a total of 21 sessions will be applied once a day
224044361|NCT06048692|DRUG|Cefepime 1000 MG|Cefepime is a fourth-generation cephalosporin antibiotic
224044362|NCT06048692|DRUG|Ampicillin-sulbactam|Broad-Spectrum Antibiotic
224044363|NCT05683587|OTHER|ballet course, strength course|Include of two phase,first phase is strength course for three months and second phase is ballet course for three months.
224044364|NCT00418951|DRUG|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
224141238|NCT02612389|OTHER|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
224141239|NCT04240288|OTHER|Procalcitonin-guided antibiotic treatment|Antibiotics will be administered based on the procalcitonin lab results.
224299773|NCT03502707|BIOLOGICAL|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1\*10\^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
224044365|NCT00418951|DRUG|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
224044366|NCT00418951|DRUG|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
224044367|NCT02717663|BEHAVIORAL|Adaptive Goals|Prescribed goals change daily based on participant's performance
224044368|NCT02717663|BEHAVIORAL|Static Goals|Prescribed goals remain the same throughout study
224044369|NCT02717663|BEHAVIORAL|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
224044370|NCT02717663|BEHAVIORAL|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
224044371|NCT00872664|DIETARY_SUPPLEMENT|carotenoids|beta-carotene, lycopene, lutein
224044372|NCT04214301|DRUG|BLI800|BLI800 Bowel Preparation
224044373|NCT00727233|DRUG|Nexavar (BAY 43-9006) (Sorafenib)|
224044374|NCT00727233|DRUG|Toxicity, Pharmacokinetics|
224044375|NCT00727233|DRUG|Pharmacodynamics|
224044376|NCT00727233|DRUG|Radiographic Evaluation|
224044377|NCT00727233|DRUG|QOL assessment, Neuropsychological|
224044378|NCT00727233|DRUG|Bony Toxicity|
224044379|NCT05940610|BIOLOGICAL|MSC-EVs|10 E10 MSC-EV particles per 100ml for a single dose. Once a week for 4 weeks.
224141240|NCT04240288|OTHER|Standard of Care Antibiotic Treatment|Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
224141241|NCT01790711|PROCEDURE|FMT through mid-gut|
224141242|NCT05768425|DIAGNOSTIC_TEST|Real-time quaking-induced conversion (RT-QuIC)|RT-QuIC measures the ability of alpha-synuclein (aSyn) to misfold other aSyn proteins and is an amplification technique.
224299774|NCT03502707|BIOLOGICAL|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
224299775|NCT05892289|PROCEDURE|Robotic assisted proximal gastrectomy with double-flap technique|Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
224044380|NCT00467389|DRUG|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
223434080|NCT00073983|DRUG|gemcitabine hydrochloride|gemcitabine hydrochloride
223434081|NCT00073983|GENETIC|microarray analysis|microarray analysis
223434082|NCT00073983|OTHER|laboratory biomarker analysis|laboratory biomarker analysis
223434083|NCT00073983|OTHER|pharmacokinetic study|pharmacokinetic study
223434084|NCT05519488|BEHAVIORAL|Rubato Life Music|Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study
223434085|NCT05519488|BEHAVIORAL|Music of their desire|patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
224044381|NCT00467389|OTHER|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
224044382|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
224044383|NCT01674712|DRUG|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
224044384|NCT01674712|DRUG|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
224044385|NCT01674712|DRUG|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
224044386|NCT01674712|DRUG|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
224044387|NCT02279823|DRUG|CB-03-01 solution|Investigational drug solution
224044388|NCT02279823|DRUG|Minoxidil Solution 5%|FDA approved marketed product
224044389|NCT02279823|DRUG|Placebo solution|Vehicle solution
224044390|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
224044391|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
224044392|NCT00874770|DRUG|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
224044393|NCT00874770|DRUG|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
224044394|NCT00874770|DRUG|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
224044395|NCT00874770|DRUG|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
224044396|NCT03686956|OTHER|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
224044397|NCT01200108|DRUG|Budesonide|
224044398|NCT01200108|DRUG|Budesonide|
224044399|NCT01200108|DRUG|Budesonide|
224044400|NCT03877107|DIAGNOSTIC_TEST|Urinary symptoms profile questionnaire|Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized
224044401|NCT03877107|DIAGNOSTIC_TEST|Micturition calendar|Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
224141243|NCT05768425|DIAGNOSTIC_TEST|Cognitive test|Minimal Mental State examination (MMSE), Montreal Cognitive Assessment (MoCA)
224141244|NCT05768425|DIAGNOSTIC_TEST|Motor examination|Unified Parkinsons Rating Scale (UPDRS)
223434086|NCT06945640|DEVICE|RUS NE|RUS NE is a surgical navigation system designed for use in robot-assisted partial nephrectomy. It reconstructs CT images into 3D models, providing visualization of tumor and vascular structures to enhance surgical precision and optimize resection planning. This system aids in reducing resection volume and improving operative outcomes by integrating anatomical insights into the surgical workflow.
223434087|NCT07146230|DRUG|Durvalumab|Durvalumab is a human mAb of the immunoglobulin G 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD 1 on T cells and CD80 (B7.1) on immune cells.
223434088|NCT07146230|DRUG|Monalizumab|Monalizumab is a humanized mAb of the IgG4 subtype that specifically binds and inhibits Cluster of Differentiation 94 (CD94)/NK cell protein group 2 A(NKG2A).
223434089|NCT07146230|DRUG|Oleclumab|Oleclumab is a human IgG1λ mAb that selectively binds to and inhibits the ectonucleotidase activity of CD73.
223434090|NCT07146230|RADIATION|Radiotherapy|PET based dose painted radiotherapy. If these treatment techniques are not available for some reason treatment may be delivered using a sequential boost technique (2.75 Gy x 17 to the low-risk PTV followed by 2.75 Gy x 3 to the high-risk planning target volume).
223434091|NCT07176845|OTHER|Observational|This study is observational of nature: multidimensional data is collected and no interventional is imposed
224044402|NCT05573321|OTHER|BFR-RE|In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
224044403|NCT05573321|OTHER|HL-RE|In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.
224044404|NCT00490633|BEHAVIORAL|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
224044405|NCT00490633|BEHAVIORAL|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
224044406|NCT00325962|DRUG|6R-BH4 (sapropterin dihydrochloride)|
224044407|NCT01047696|DEVICE|Plancha|locally developed chimney stove
223434092|NCT07176312|DRUG|Zanidatamab|Zanidatamab 1,200 mg (patients \<70 kg at baseline) or 1,600 mg (patients ≥70 kg at baseline), administered i.v. on day 1 of each 2-week cycle (Q2W)
224044408|NCT06394596|OTHER|Prognostic factors affecting graft survival|The primary outcome measured was a 5-year graft survival, defined as the absence of any need for dialysis or re-transplantation five years following the initial transplantation
223434093|NCT07176312|DRUG|Pembrolizumab|Pembrolizumab 400 mg, administered i.v. on day 1 of every third cycle (Q6W)
223434094|NCT07176312|DRUG|mFOLFOX|modified FOLFOX with Oxaliplatin 85 mg/m2 i.v. on day 1; Folinic Acid 400 mg/m2 i.v. on day 1; 5-FU 2,400 mg/m2 i.v. continuous infusion over 48 hours (no bolus!) on days 1 and 2 of each 2-week cycle (Q2W)
223434095|NCT07174791|DEVICE|cone beam computed tomography|-Implant marginal bone height changes will be measured by cone beam radiograph after one and two years of loading
223434096|NCT07174791|DEVICE|photogrammetric scan using elite scanner (shining 3d)|implant placement accuracy will be evaluated using photogrammetric scan after implant insertion
223434097|NCT07176858|OTHER|brain gym exercise|specially designed physical therapy program in addition to brain gym exercises for 60 min (30 min designed P.T program and other 30 min for brain gym exercises), 3 sessions/ week for 3 successive months. eight Brain Gym exercises will be selected: Cross Crawl, Lazy 8s, Hook-ups, Brain Buttons, The Elephant, The Owl, Neck Rolls, Double Doodle
224044409|NCT00445562|OTHER|biologic sample preservation procedure|
224044410|NCT00445562|OTHER|informational intervention|
224044411|NCT03255057|DEVICE|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
224044412|NCT03255057|DEVICE|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
224044413|NCT00173745|DRUG|botulinum toxin A injection|
224044414|NCT04225468|BEHAVIORAL|ACL Opioid Exposure Reduction Program|Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
224044415|NCT02294084|DRUG|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
224044416|NCT02294084|DRUG|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
224044417|NCT03623451|DRUG|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
223434098|NCT07176858|OTHER|specially designed pt program|conventional physical therapy program including reinforcement of the normal motor development, reflex inhibiting patterns, postural reaction, stretching, strengthening exercises, and gait training was applied to children in the control group
223434099|NCT07177053|DRUG|non fluoridated hydroxyapatite tooth paste (KAREX KINDER tooth paste)|"arm 1 : hydroxyapatite tooth paste \[ HAP\] (study group): assessment will involve Quantitative Light-Induced Fluorescence- QLF at baseline, 3, 6, 9, and 12 months. The images were analyzed using a commercial software program (Inspektor QLF 1.97, Inspektor Research Systems, Amsterdam, The Netherlands) to determine the change in fluorescence~(ΔF, %) and extension of the lesion (area; mm2)."
224044418|NCT05395104|DRUG|Midazolam|Syrup for oral administration
224044419|NCT05395104|DRUG|Cefiderocol|Liquid for intravenous infusion
224044420|NCT05125068|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
224044421|NCT01313715|BIOLOGICAL|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
224044422|NCT01313715|BIOLOGICAL|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
224044423|NCT01313715|BIOLOGICAL|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
224044424|NCT01313715|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
224044425|NCT01617850|OTHER|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
224044426|NCT01617850|OTHER|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
224044427|NCT01805960|BIOLOGICAL|Canakinumab|
224141245|NCT04162535|DRUG|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~* Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~* Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~* Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
224141246|NCT04162535|BIOLOGICAL|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
224141247|NCT04162535|DRUG|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
224141248|NCT04162535|DRUG|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
224141249|NCT00565058|BIOLOGICAL|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
224141250|NCT02098694|OTHER|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
224141251|NCT06103448|DEVICE|Ankle-brachial index - system 100|Measurement of ankle brachial index on all four limbs, drawing three blood drops for point of care (POC) cholesterol meter and one drop of blood for POC glucometer
224141252|NCT03155633|OTHER|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
224044428|NCT01805960|BIOLOGICAL|Placebo|
224141253|NCT03155633|OTHER|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
223434100|NCT07177053|DRUG|fluoridated toothpaste (Colgate Total PROTECTION ACTIVE)|"Arm 2 :Fluoride-containing tooth paste \[1450ppm fluoride\] (control group):~assessment will involve Quantitative Light-Induced Fluorescence- QLF at baseline, 3, 6, 9, and 12 months. The images were analyzed using a commercial software program (Inspektor QLF 1.97, Inspektor Research Systems, Amsterdam, The Netherlands) to determine the change in fluorescence (ΔF, %) and extension of the lesion (area; mm2)."
224044429|NCT05146804|OTHER|BroccoCress|BroccoCress® is a brand name for an edible plant, broccoli sprouts. BroccoCress® is a product within the group of vegetable sprouts.
224044430|NCT05146804|OTHER|Affilla Cress|Pea sprouts commercially available as Affilla Cress® will be used as placebo in this study since these sprouts do not contain Glucoraphanin/Sulforaphane.
224044431|NCT03974334|BEHAVIORAL|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
224141254|NCT00869388|BIOLOGICAL|rBBX-01|
224141255|NCT03360045|DRUG|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
224141256|NCT03360045|DRUG|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
224141257|NCT03360045|DEVICE|Merocel|Merocel packing is applied.
224141258|NCT06445894|DEVICE|Active Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The first dorsal interossesous (FDI) muscle of the left motor cortex will be targeted using neuronavigation software.
223434101|NCT07177300|DRUG|PK-optimized oral hydroxyurea at MTD until 15 years of age.|Because people are different, we will measure how each participant's body absorbs and eliminates the medicine, hydroxyurea, using blood tests. This information will be used to determine the best dose for each participant (rather than using the same weight-based dose for everyone).
223434102|NCT07176221|PROCEDURE|endoscopic cardia constriction ligation|The experimental group used disposable endoscopes to perform ECCL, while the control group used traditional endoscopes to perform ECCL. ECCL involves ligating and fixing the mucosa and partial muscle layer above the dentate line under direct endoscopic visualization to create folds. Post-procedure, the ligated mucosa undergoes ischemic necrosis and heals to form scar tissue, thereby reducing the cardia diameter, increasing LES pressure, and alleviating reflux symptoms.
224044432|NCT06006325|DEVICE|electroacupuncture treatment|"Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min."
224044433|NCT06006325|DEVICE|sham electroacupuncture treatment|"The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized."
224044434|NCT05135026|DIAGNOSTIC_TEST|Ultrasonograpgy|2 USG in 3rd and 5th ANC visits and even more USG if needed + 4 ANC + Health education
224044435|NCT00141804|DRUG|Sirolimus|
224044436|NCT03447938|PROCEDURE|MICS CABG|Coronary artery bypass grafting performed through small incisions between the ribs.
224044437|NCT03447938|PROCEDURE|Conventional CABG|Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
224044438|NCT05874713|BIOLOGICAL|aH5N8c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
224044439|NCT05874713|BIOLOGICAL|aH5N6c on Day 1|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
224044440|NCT05874713|BIOLOGICAL|aH5N8c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
224044441|NCT05874713|BIOLOGICAL|aH5N6c on Day 22|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N6 vaccine (aH5N6c) for intramuscular administration, containing intermediate dose H5N6 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
224044442|NCT05874713|BIOLOGICAL|aH5N8c on Day 202|MF59-adjuvanted cell-culture derived subunit inactivated monovalent A/H5N8 vaccine (aH5N8c) for intramuscular administration, containing intermediate dose H5N8 hemagglutinin + standard dose MF59 (approximately 0.5 mL total volume)
224044443|NCT00024167|DRUG|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
224044444|NCT00024167|DRUG|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
224141259|NCT06445894|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|A sham coil will be utilized for the sham rTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham rTMS will be identical to Active rTMS.
224141260|NCT01992848|OTHER|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
224141261|NCT01992848|OTHER|4-day food diary|
224141262|NCT01992848|OTHER|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
224141263|NCT01992848|RADIATION|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
224141264|NCT04496648|PROCEDURE|Percutaneous Coronary Intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
224141265|NCT04496648|PROCEDURE|Sham-percutaneous coronary intervention|Sham-PCI procedure for at least 15 minutes that includes shifting the C-arm, reinserting the FFR-wire in the catheter and inflating the device.
223740552|NCT05757661|OTHER|Focal Vibration|"A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%."
224044445|NCT00024167|DRUG|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
223434105|NCT07175727|DEVICE|Pulmonary vein isolation|Pulmonary vein isolation for paroxysmal atrial fibrillation
223434106|NCT07175727|RADIATION|cerebral magnetic resonance tomography|A subset of consecutive patients of each group (n=25 of each group) receives cMRI on the day after the procedure to asses silent cerebral lesions. A control cMRI is scheduled in case of positive findings.
223434107|NCT07175727|DIAGNOSTIC_TEST|Biomarker assessment (C-reacitve Protein, troponine)|A subset of patients of each group (n=25 of each group) received blood tests to asses inflammation and troponine release.
224044446|NCT00024167|DRUG|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
224044447|NCT00024167|DRUG|Prednisone|5 mg orally 2 x daily, weeks 1-14
224044448|NCT00024167|DRUG|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
224044449|NCT00024167|RADIATION|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
224044450|NCT00024167|DRUG|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
224044451|NCT03457350|PROCEDURE|cervical negotiation|trial to bypass severe cervical stenosis
224141266|NCT05308615|DIETARY_SUPPLEMENT|Rhea® Health Tone|Rhea® Health Tone
224141267|NCT05379894|PROCEDURE|Percutaneous nephrolithotripsy|Extraction of kidney stones through skin using nephroscope
224141268|NCT02776501|DRUG|Coppertone (BAY987521)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: Y49-103)
224141269|NCT04861948|DRUG|IBI188|intravenous
223434108|NCT05569928|OTHER|Administration of deuterated compounds for kinetic study|Participants will be submitted to a standardized oral-fat load and kinetic study will be performed
223434109|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
223434110|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
223434111|NCT05009329|DRUG|JAB-21822|JAB-21822 will be administered orally
223434112|NCT03376971|PROCEDURE|Biopsy|Undergo lung biopsy
223434113|NCT03376971|OTHER|Laboratory Biomarker Analysis|Correlative studies
223434114|NCT03800836|DRUG|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle for all arms except for arms F1/F2 where it will be administered at a dose of 300 milligrams (mg) orally daily for the first two cycles and 400 mg for the remaining three cycles.
223434115|NCT03800836|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle for all arms, with the exceptions of Arms F1, F2, G1 and G2, where it will be also administered on Day 22 as well, of each 28 day cycle.
223434116|NCT03800836|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle for all arms, although in Arms C1/C2, it will be administered on Day 15 of Cycle 1 followed by Days 1 and 15 in subsequent cycles.
223434117|NCT03800836|DRUG|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m\^2 on Days 1, 8, and 15 of each 28 day cycle.
223434118|NCT03800836|DRUG|AC|AC (Doxorubicin and Cyclophosphamide) will be administered by IV infusion at 60 mg/m\^2 and 600 mg/m\^2 respectively on Days 1 and 15 of Cycles 1 and 2 for Arms F1, F2, G1 and G2.
223565808|NCT03926572|OTHER|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
223565809|NCT05732935|BEHAVIORAL|Time Restricted Eating intervention|"In the TRE intervention, participants will be asked to fast for a target of 16 hours per day for a period of 24 weeks. The first few weeks will involve of a ramp up to a full 16-hour fasting period (Week 1 - fast for 12-14 hours per day, Week 2 - fast for 14-16 hours per day, Week 3 - 16 - fast for 16 hours per day). Participants will be allowed to consume calorie-free beverages, tea, black coffee, sugar-free gum, and they will be encouraged to drink plenty of water throughout the entire intervention period. Participants will be asked to record the time of first and final food/drink consumption each day.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
224044452|NCT03858452|PROCEDURE|Muscles exercises program|
224141270|NCT04861948|DRUG|GM-CSF|subcutaneous injection
224141271|NCT04861948|DRUG|Cisplatin/Carboplatin|intravenous
224141272|NCT04861948|DRUG|Bevacizumab|intravenous
223434119|NCT06787924|DIETARY_SUPPLEMENT|Collagen hydrolyzed peptides|bovine collagen peptides
223434120|NCT06787924|DIETARY_SUPPLEMENT|Starch|Starch placebo
223434121|NCT02295059|DIETARY_SUPPLEMENT|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
223434122|NCT03254667|BIOLOGICAL|Brodalumab|Brodalumab
223434123|NCT03254667|DRUG|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
223434124|NCT05174286|BEHAVIORAL|SBIRT|"SBIRT is an evidence-based approach originally designed for people at risk of developing mental disorders. SBIRT is composed of three components: Screening with a validated instrument, Brief Intervention, Referral to Treatment. Motivational Interviewing (MI) is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. It decreases ambivalence and increases motivation for treatment.~The investigators will utilize the Culturally-adapted Alive! Program - a cost-effective, lifestyle coaching web-based automated platform that includes step-by-step individualized tailoring, feedback, and weekly guidance through interactive emails focused on increasing physical activity, improving eating habits, and weight control."
223434125|NCT05174286|BEHAVIORAL|Referral as Usual (RAU)|Referral as Usual will involve distributing CRC health educational materials (e.g. NCI or CDC brochures that include new guidelines) and contact information for screening service providers in our target community.
223434126|NCT02345265|PROCEDURE|Biopsy Procedure|Undergo biopsy of tumor
223434127|NCT02345265|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223434128|NCT02345265|DRUG|Cediranib Maleate|Given PO
223740553|NCT05757661|OTHER|Sham Group|The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
224044453|NCT03691090|DRUG|SHR-1210|SHR-1210 200mg
224044454|NCT03691090|DRUG|Placebo|Placebo
224044455|NCT03691090|DRUG|paclitaxel|paclitaxel 175mg/m2
224044456|NCT03691090|DRUG|cisplatin|cisplatin 75mg/m2
224141273|NCT04861948|DRUG|Sintilimab|intravenous
224141274|NCT04861948|DRUG|Pemetrexed|intravenous
224141275|NCT00863980|DRUG|Micardis (Telmisartan)|40-80 mg/day oral administration
224141276|NCT00863980|DRUG|Blopress (Candesartan)|8-12 mg/day oral administration
224141277|NCT03948126|OTHER|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
223434129|NCT02345265|PROCEDURE|Computed Tomography|Undergo CT scan
224044457|NCT00002016|DRUG|Sevirumab|
224044458|NCT03210103|RADIATION|Radiation|Standard of Care: Radiation +/- Chemotherapy
224044459|NCT03210103|PROCEDURE|Transoral Surgery (TOS) + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
224044460|NCT03610399|DRUG|Primaquine|Different total dose and supervision.
224141278|NCT02072512|DRUG|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
224141279|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
223434130|NCT02345265|PROCEDURE|Echocardiography Test|Undergo echocardiogram
223434131|NCT02345265|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI scan
223434132|NCT02345265|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223434133|NCT02345265|DRUG|Olaparib|Given PO
223434134|NCT02345265|OTHER|Questionnaire Administration|Ancillary studies
223434135|NCT03900832|OTHER|Without Heating|Subject will complete walking protocol without any heating procedure
223434136|NCT03900832|OTHER|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP \>20 mmHg), the subject will be removed from the bath even if the time is \<30 min."
223565810|NCT05732935|BEHAVIORAL|Successful Aging Comparison Group (LEARN)|"In the Successful Aging Comparison Group (LEARN), participants will attend lectures on topic relevant to healthy aging at the same frequency as the group meetings in the TRE intervention.~Both the TRE and Successful Aging comparison group will be group-mediated, with equal number of contact visits from study staff consisting of 10 group sessions over 24 weeks."
223565811|NCT05897619|BEHAVIORAL|Experimental: Maya Perinatal Cognitive Behavioral Skills App|The intervention includes the completion of a mobile skills app teaching evidence-based strategies tailored for perinatal mood and anxiety. Modules include psychoeducation, skill information, practice exercises, and homework.
223565812|NCT05242224|OTHER|Evolutionary Nutrition Package|The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
223565813|NCT06209593|DIETARY_SUPPLEMENT|Compleat plant protein tube feed|Patients on a tube feed will act as their own control and switch to new tube feed.
223565814|NCT05942053|DRUG|Placebo|Placebo match vitamin K2 capsules once per day.
223565815|NCT05942053|DRUG|Vitamin K 2|Patients will be treated with vitamin K2 (menaquinone-7) 90 mcg/day.
224044461|NCT04635566|DRUG|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.|mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
224044462|NCT04635566|DRUG|Placebo|Placebo one time/day at the evening.
224044463|NCT05001282|DRUG|ELU001|Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
224044464|NCT01892306|BEHAVIORAL|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
224044465|NCT01892306|DRUG|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
224044466|NCT01507467|RADIATION|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
224044467|NCT01507467|RADIATION|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
224044468|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.
224044469|NCT05490836|BIOLOGICAL|PEG IFN α-2b; TAF|TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
224044470|NCT00120640|DRUG|17 hydroxyprogesterone caproate intramuscular injections|
224044471|NCT02257996|BEHAVIORAL|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
224044472|NCT04123990|DIAGNOSTIC_TEST|Iron status testing|Iron status testing
224044473|NCT03049787|OTHER|Home Exercise Protocol|Home exercise therapy protocol given to patient to be completed at home.
223434137|NCT03900832|OTHER|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
223434138|NCT03900832|OTHER|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (\~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches \~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
223565816|NCT04603495|DRUG|Pelabresib|"Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).~Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF."
223565817|NCT04603495|DRUG|Ruxolitinib|Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.
223565818|NCT04603495|DRUG|Placebo|Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
224044474|NCT03049787|OTHER|Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
224044475|NCT02131441|PROCEDURE|laparoscopic hepatectomy|
224044476|NCT02131441|PROCEDURE|open liver resection|
224044477|NCT05506826|OTHER|fine motor activities|patient will perform fine motor exercises like therapy ball exercises, therapy putty exercises, table top exercises, moving beans, stacking pennies and rubber band resistances exercises etc. for 30 minutes along with conventional therapy
224141280|NCT02072512|DRUG|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
224141281|NCT02072512|DRUG|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
223434139|NCT03900832|OTHER|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at \~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
223434140|NCT03900832|OTHER|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
223434141|NCT03240809|BIOLOGICAL|Brodalumab|140 mg SC dose
223434142|NCT03240809|BIOLOGICAL|Brodalumab|70 mg SC dose
223434143|NCT05935735|BEHAVIORAL|Brief Behavioral Therapy for Insomnia (BBTI)|4 in-person sessions; 1 individual and 3 group sessions
223434144|NCT04726839|OTHER|Standard of care for stroke management and evaluation of functionnal outcome at 3 months|Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months
223434145|NCT05072106|DRUG|Lurbinectedin|3.2 mg/m² as a 1-hour i.v. infusion on Day 1.
223434146|NCT05072106|DRUG|Bosentan|Bosentan: 125 mg (one film-coated tablet of 125 mg) orally (p.o.) twice daily in the morning and in the evening during the prior five consecutive days before the day of lurbinectedin infusion (Day 1), and once daily on Day 1 (before lurbinectedin infusion).
223434147|NCT03839459|DRUG|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
223434148|NCT03713983|OTHER|Observational study|Observational study
223434149|NCT05400512|BEHAVIORAL|Cognitive Training|Computerized cognitive training targeting the underlying cerebral networks associated with depression.
223434150|NCT05400512|DEVICE|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system).
224044478|NCT05506826|OTHER|conventional therapy and mirror therapy|Patients in this group will receive conventional therapy for four weeks sixty minutes per day, five days per week. In addition, receive thirty minutes of mirror therapy, which included periodic wrist flexion-extension, flexion and extension exercises of fingers on non paralyzed limb
224044479|NCT01033552|DRUG|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
224044480|NCT01033552|DRUG|Fludarabine|40 mg/m\^2/day intravenously on Days -6, -5, -4, -3 and -2.
223434151|NCT05400512|DEVICE|tDCS (sham stimulation)|Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
224044481|NCT01033552|DRUG|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
224044482|NCT01033552|DRUG|Myeloablative Busulfan|Targeting AUC 1000 umol/min
224044483|NCT01033552|PROCEDURE|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
224044484|NCT01033552|RADIATION|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
224044485|NCT01033552|PROCEDURE|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
223434152|NCT06100809|BEHAVIORAL|Personalized coaching|Personalized fatigue mitigation coaching.
223434153|NCT06100809|BEHAVIORAL|Nutrition handout|Nutrition handout
223434154|NCT06161025|DRUG|R-DXd|R-DXd will be administered as an intravenously (IV) infusion
223434155|NCT06161025|DRUG|Gemcitabine|Gemcitabine will be administered as an IV infusion
223434156|NCT06161025|DRUG|Paclitaxel|Paclitaxel will be administered as an IV infusion
223434157|NCT06161025|DRUG|Topotecan|Topotecan will be administered as an IV infusion
223434158|NCT06161025|DRUG|PLD|PLD will be administered as an IV infusion
223434159|NCT05077384|DRUG|Surufatinib|Surufatinib 300 mg oral once daily
223434160|NCT04569240|DEVICE|Dexcom G6 continuous glucose monitor|Dexcom G6 continuous glucose monitor will be applied to the upper outer arm before cardiovascular surgery. Data will be collected for 10 days or upon discharge from the ICU.
224044486|NCT03341572|OTHER|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
223434161|NCT02785848|OTHER|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
223434162|NCT06638632|BEHAVIORAL|Decision aid|Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
223434163|NCT06645366|DEVICE|Treatment with BTL-785F|Three (3) treatment sessions will be applied to the subjects' face and neck using the BTL-785F system equipped with the BTL-785-4-4 tip on BTL-785-4 applicator, lasting from 20 to 60 minutes depending on the size of the treated area. Each treatment will be spaced 2 - 6 weeks apart, after the complete healing of scabs.
223434164|NCT03760835|DRUG|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
223434165|NCT03760835|DRUG|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
224044487|NCT00789750|DRUG|Colesevelam|Colesevelam 625 mg tablets
224044488|NCT00789750|DRUG|Placebo|Placebo tablets appearing to be colesevelam
224044489|NCT00789750|DRUG|Pioglitazone|30 mg or 45 mg pioglitazone therapy
224044490|NCT01138579|DRUG|FBTA05|
224044491|NCT04811404|DRUG|Ethyl Eicosapentaenoic Acid|Treatment will be for six weeks
224044492|NCT00278850|BEHAVIORAL|Educational|three 1 hour long educational seminars
224141282|NCT02666508|OTHER|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
223434166|NCT05751044|DRUG|Dasatinib|Oral
223434167|NCT05751044|DRUG|Venetoclax|oral
223434168|NCT05751044|DRUG|Dexamethasone|oral/intervenous
223434169|NCT05751044|DRUG|Cyclophosphamide|intravenous
223565819|NCT01974206|BIOLOGICAL|ASP0113|intramuscular injection
223565820|NCT01974206|DRUG|Placebo|intramuscular injection
224044493|NCT04582942|DRUG|PEG|Patients began to drink 1 L of PEG at 8:00 PM on the day before colonoscopy at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took the remaining 2 L of PEG 4-6 hours before colonoscopy.
224044494|NCT04582942|DRUG|PEG+lactulose|On the day before colonoscopy , Patients took 45 mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM at a rate of 250 mL every 10- 15 minutes. On the day of the procedure, patients took 45 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
224044495|NCT02794142|PROCEDURE|renal transplantation|
224044496|NCT02794142|OTHER|No intervention|
224044497|NCT05057260|OTHER|No drug invervention|No clinical trial
224044498|NCT04969445|BIOLOGICAL|Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)|The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant
224044499|NCT00018850|DRUG|ondansetron|
224044500|NCT00018850|BEHAVIORAL|neuropsychological testing|
224044501|NCT00018850|DRUG|nicotine|
224044502|NCT00018850|DRUG|haloperidol|
224141283|NCT02666508|OTHER|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
223565821|NCT06078202|DRUG|ABBV-903|Tablet; oral
223565822|NCT05235971|BEHAVIORAL|Episodic Future thinking|"During a visit with the study team, participants will identify personally-relevant reminders, or cues, that they will receive up to 3 messages a day via text-message over a two-week period.~The messages will describe positive, non-alcohol related events at future time points to facilitate extension of temporal consideration toward future-focused perspectives.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected"
223565823|NCT05235971|BEHAVIORAL|Volitional choice|"Volitional choice creates structured if-then plans to dismantle context-linked alcohol use The messages sent over a two-week period facilitate alternative, healthier choices by identifying and linking risky cues with alternative actions. Participants will receive up to 3 messages a day for 14 days that include assessment and intervention messages.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
223565824|NCT05235971|BEHAVIORAL|Monitoring only|"Participants will receive general psychoeducation about alcohol use, mental health, resources, and a description of the assessments to be completed over a two-week field testing period.~In addition, participants will have phone meetings (video or not) where health behaviors as well as survey information is noted and collected."
223565825|NCT05093335|DRUG|[68Ga]-Pentixafor|An intravenous bolus of 3 -5 mCi of \[68Ga\]-Pentixafor will be injected in all participants.
224044503|NCT02488499|BEHAVIORAL|Coping Power|15 sessions of concurrent parent and child group treatment
224044504|NCT02488499|BEHAVIORAL|Individualized Treatment|15 sessions of individualized child and parent treatment
224044505|NCT05896371|DRUG|177Lu-PSMA-I&T - escalating renal absorbed dose|Personalized 177Lu-PSMA-I\&T injected activity
224044506|NCT05896371|DRUG|177Lu-PSMA-I&T - recommended phase 2 regime|Personalized 177Lu-PSMA-I\&T injected activity
224044507|NCT05378997|DRUG|TCP-25 gel 0.86 mg/ml or placebo gel|TCP-25 gel (0.86 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
224044508|NCT05378997|DRUG|TCP-25 gel 2.9 mg/ml or placebo gel|TCP-25 gel (2.9 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
224044509|NCT05378997|DRUG|TCP-25 gel 8.6 mg/ml or placebo gel|TCP-25 gel (8.6 mg/mL) applied to two wounds per patient and placebo gel applied to two wounds per patient
224141284|NCT04712357|DRUG|Vitamin C 500 MG Oral Tablet|Vitamin C 500 MG per day for 10 days
223434170|NCT05751044|DRUG|Cytarabine|intravenous
223434171|NCT05751044|DRUG|intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
223434172|NCT03945162|COMBINATION_PRODUCT|Ruvidar® (TLD-1433) Bladder infusion and PDT|Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
223434173|NCT05904119|DRUG|Lomustine|Oral administration of Lomustine
223434174|NCT05904119|RADIATION|Reirradiation|Given at least 6 months after the end of prior radiotherapy
223434175|NCT06193954|DEVICE|VasoStar guidewire system|The VasoStar Vibrational Guidewire System vibrates longitudinally at the distal segment of a wire with an electromagnetic source.
223434176|NCT04064359|DRUG|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
223434177|NCT06630234|DRUG|DCC-3009|Administered orally
223434178|NCT03260491|DRUG|HER3-DXd (FL-DP)|HER3-DXd (frozen liquid drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a).
224044510|NCT04409899|DIAGNOSTIC_TEST|Blood tests|RT-PCR, D-dimer, CRP, procalcitonin, ferritin, complete haemogram
224044511|NCT04374643|OTHER|Slef questionnaires fulfilment|Questionnaires to assess the psychological impact of confinement and its evolution over 6 months
224044512|NCT04184492|DRUG|GP-40081|biphasic insulin aspart 30 in doses 0.4 IU/kg
224044513|NCT04184492|DRUG|NovoMix® 30 Penfill®|biphasic insulin aspart 30 in doses 0.4 IU/kg
224044514|NCT00006448|BEHAVIORAL|cognitive therapy|
224044515|NCT00006448|PROCEDURE|Physical Therapy|
224044516|NCT00006448|DRUG|Methadone|
224044517|NCT02179879|OTHER|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
224044518|NCT05668039|PROCEDURE|Enhanced external counterpulsation|15 one-hour sessions during 15 weeks of enhanced external counterpulsation.
224044519|NCT04338373|COMBINATION_PRODUCT|"0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)"|"nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months"
224044520|NCT00510081|DEVICE|Calcium Hydroxylapatite injection|filler injection
224044521|NCT02194036|BEHAVIORAL|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
224044522|NCT02194036|BEHAVIORAL|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
224044523|NCT00324051|DRUG|olanzapine therapy|
224044524|NCT00888420|OTHER|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
224044525|NCT03725579|DRUG|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
224044526|NCT03725579|DRUG|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
224044527|NCT02307487|DRUG|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
224044528|NCT02307487|DRUG|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
224044529|NCT02307487|DRUG|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
224044530|NCT02307487|DRUG|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
224044531|NCT02307487|DRUG|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
224044532|NCT02307487|DRUG|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
224044533|NCT01657097|DRUG|INCS|
224044534|NCT01657097|DRUG|Placebo|
224044535|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
224044536|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Mini PCNL will be performed.
224044537|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
224044538|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Micro PCNL will be performed.
224044539|NCT02522676|PROCEDURE|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
224044540|NCT02522676|PROCEDURE|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
224044541|NCT04373954|OTHER|Forgiveness Therapy|The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.
224044542|NCT04373954|OTHER|Carey Guides|The Carey Guides is a primary educational program deliberately chosen and approved by the Department of Corrections in Wisconsin, in which all inmates are encouraged (not required) to complete as they work toward custody reduction. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. It is the basis for the control group therapy as a way to ensure that the treatment has a uniform process as it is taught in the Department of Corrections (DOC) prison system.
224044543|NCT00334386|DRUG|Torasemide Prolonged Release (loop diuretic)|
224044544|NCT00334386|DRUG|Torasemide Immediate Release (loop diuretic)|
224044545|NCT03568045|DEVICE|standard light|usual care
224044546|NCT03568045|DEVICE|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
224044547|NCT03568045|DEVICE|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
224044548|NCT00770770|DRUG|Fluocinolone Acetonide|0.2 µg/day
224044549|NCT00770770|DRUG|Fluocinolone Acetonide|0.5 µg/day
224044550|NCT01961375|DRUG|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
224044551|NCT01761279|PROCEDURE|High definition white light endoscopy|
224044552|NCT02483559|OTHER|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (\~470 nm) to be worn prior to desired sleep onset time.
224044553|NCT02483559|OTHER|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
224044554|NCT05407233|DEVICE|Does not reuse the syringe for insulin application|Does not reuse needles for insulin application Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, bruises, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), who will review the records with the patient and guide them for subsequent completion.
224044555|NCT05407233|DEVICE|Uses the syringe for insulin delivery five times|Uses the needles for insulin application five times. Patients will be given quantity of needles for use during the study period according to the allocated group and a collector for sharps descarpack to collect the used syringes and needles. Initially, all patients will be instructed on the indication and importance of insulin use, aspects of conservation, preparation and administration, reviewing the dose aspirated in the syringe. They will also be instructed in relation to the use of the collector for sharps. Patients will also receive the booklet specially designed for this registry where they must indicate the number of hematomas, lipodystrophies, or inflammation that they identify whenever they occur. This booklet will be given to the team of researchers at each visit (monthly), and they will review the records with the patient and guide them for subsequent completion.
224044556|NCT00572026|DRUG|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
224044557|NCT00797875|PROCEDURE|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
224044558|NCT00797875|PROCEDURE|passive stretching|passive stretching x 5 repetitions continue 3 days
223434179|NCT03260491|DRUG|HER3-DXd (CTM-1 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the clinical manufacturing sites.
223434180|NCT03260491|DRUG|HER3-DXd (CTM-3 Lyo-DP)|HER3-DXd (lyophilized drug product) consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a) that was manufactured by the commercial manufacturing sites.
223434181|NCT03729544|BEHAVIORAL|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
223434182|NCT04590872|BIOLOGICAL|Tolerogenic Dendritic Cell Vaccine|PIpepTolDCs
223434183|NCT06797531|DRUG|ribociclib|This is an observational study. There is no treatment allocation. The decision to initiate ribociclib will be based solely on clinical judgement.
223434184|NCT05175131|DRUG|Mebeverine+Simethicone|fixed-dose combination, film-coated tablets, 135 mg + 80 mg
223434185|NCT05175131|DRUG|Mebeverine|Duspatalin®, coated tablets 135 mg
223434186|NCT05175131|DRUG|Simethicone|Espumisan® capsules 40 mg
223434187|NCT02542293|BIOLOGICAL|Durvalumab +Tremelimumab|
223434188|NCT02542293|DRUG|Paclitaxel + carboplatin|Chemotherapy Agents
223434189|NCT02542293|DRUG|Gemcitabine + cisplatin|Chemotherapy Agents
223434190|NCT02542293|DRUG|Gemcitabine + carboplatin|Chemotherapy Agents
223434191|NCT02542293|DRUG|Pemetrexed + cisplatin|Chemotherapy Agent
223434192|NCT02542293|DRUG|Pemetrexed + carboplatin|Chemotherapy Agent
223434193|NCT06432764|DRUG|AZD7798|Each participating patient will receive the study drug as specified in the study protocol.
223434194|NCT06432764|DRUG|[11C]AZ14132516|A single microdose (≤ 10 μg) of radiopharmaceutical \[11C\]AZ14132516 will be extemporaneously prepared and administered to each participant prior to each PET examination
223434195|NCT04822688|PROCEDURE|Biospecimen Collection|Undergo collection of tissue and blood samples
223434196|NCT06057142|BEHAVIORAL|Fun activities for reciting Tang poems|The students will participate in three weekly sessions of Tang poem classes and one session of performance show. Each session lasts for 1.5 hours. Parents can sit in the class. A total of six poems will be taught by two experienced Chinese teachers.
223434197|NCT06307496|OTHER|Smoking cessation intervention|Receive links to smoking cessation videos
223434198|NCT06307496|OTHER|Informational intervention|"Receive NCI's Clearing the Air booklet"
223434199|NCT06192992|OTHER|Peripheral heating of 2 feet|Heating of both feet
223434200|NCT06192992|OTHER|Sham|No heating
223434201|NCT03919500|DRUG|EPO|Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
223434202|NCT03919500|DRUG|Normal saline|Infants in control group are administered normal saline with the same volume and period as EPO.
223434203|NCT00310466|BIOLOGICAL|Sublingual immunotherapy|once daily intake of sublingual drops
223434204|NCT00310466|BIOLOGICAL|Placebo|once daily intake of sublingual drops
223434205|NCT02269254|DEVICE|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
223434206|NCT02269254|DEVICE|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
224141285|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG per day for 10 days
223434207|NCT03787199|DEVICE|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
223434208|NCT03787199|OTHER|Treadmill|Bodyweight supported treadmill walking
223434209|NCT01458951|DRUG|tofacitinib|10 mg oral BID
223434210|NCT01458951|DRUG|Placebo|Placebo oral BID
224141286|NCT04712357|DRUG|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet|Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
223434211|NCT06007794|OTHER|JUMP group|patients will have a femoral ultrasound and blood tubes in addition to the blood sample taken as part of the treatment
223434212|NCT00585013|DRUG|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
223434213|NCT03664830|DRUG|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
223434214|NCT06459570|BEHAVIORAL|Virtual reality based exercises|one experimental group with Virtual reality-based exercises. Subjects in the VR-based exercises will receive 12 sessions of the VR-based exercises treatment, administered four times a week over 3 weeks, with each session lasting approximately 60 minutes.
223434215|NCT06459570|OTHER|standard physical therapy|"Second control group with standard physical therapy and occupational therapy treatment.Subjects in the control group will receive 12 sessions of physical therapy treatment involving passive and active range of motion exercises, muscle strengthening, and therapeutic stretching, administered four times a week over a span of 3 weeks, with each session lasting approximately 60 minutes."
223434216|NCT00293371|DRUG|docetaxel|
223434217|NCT00293371|DRUG|prednisone|
223434218|NCT00293371|DRUG|vatalanib|
223434219|NCT02882880|DEVICE|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
223434220|NCT02963558|DEVICE|cycle ergometry|The cycler will provide 3 different possible modes of cycling-passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
223434221|NCT06531772|DRUG|Antitubercular Agents|Full regimen of antitubercular drugs for 6 month period or longer as justified by patient condition
223434222|NCT01194934|DRUG|NOX-A12|4 mg/kg daily IV for 5 days
223434223|NCT01194934|DRUG|NOX-A12|2 mg/kg daily IV for 5 days
223434224|NCT01194934|DRUG|Filgrastim|5 µg/kg SC daily for 5 days
223434225|NCT01194934|DRUG|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
223434226|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
224141287|NCT00391781|PROCEDURE|Temperature of contrast medium|
224141288|NCT06207695|BEHAVIORAL|Brief Group Intervention|This brief intervention consisted of four sessions. The contents of sessions were psychoeducation, emotion processing, practicing emotion regulation strategies, cognitive processing, reframing thoughts, practicing mindful exercises, strength social support networks, and problem management skills.
223434227|NCT01087580|DRUG|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
224044559|NCT02484976|BEHAVIORAL|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
224044560|NCT02775084|DIETARY_SUPPLEMENT|Fish Oil|4 capsules twice daily with food for 6 weeks
224044561|NCT02775084|DIETARY_SUPPLEMENT|Olive Oil|4 capsules twice daily with food for 6 weeks
224044562|NCT02131675|DIETARY_SUPPLEMENT|Boost shake|Blood draw after mixed-meal consumption
224044563|NCT04124484|DRUG|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
224044564|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
224141289|NCT00830804|DRUG|Raltegravir|400 mg tablet taken orally twice daily
224141290|NCT00830804|DRUG|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
223434228|NCT01087580|DRUG|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index \< 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
223434229|NCT06004492|BEHAVIORAL|blended learning program|blended learning program: 8 hours of workshops and four months of practical learning on technology platforms.
223434230|NCT02495194|BEHAVIORAL|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
223434231|NCT05320107|DRUG|Ketamine|0.5mg/kg bodyweight (or 0.25mg/kg bodyweight) ketamine, will be determined in pilot study
223434232|NCT05320107|DRUG|Placebo|0.9% NaCl
223565826|NCT05893160|DRUG|JAN101 SR|The dosage form of JAN101 to be used in clinical investigations is a sustained release (SR) tablet containing Sodium Nitrite drug substance.
223565827|NCT05893160|OTHER|Placebo|Inert placebo formulation
223740554|NCT05126342|DRUG|Niraparib|Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.
223740555|NCT05126342|DRUG|Dostarlimab|Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.
224044565|NCT04124484|DRUG|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
224044566|NCT04124484|DRUG|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
224044567|NCT05090553|PROCEDURE|Lumbar Spinal Fusion Surgery|During surgery will be collected five disc fragments and five fragments of muscle-ligament tissue adjacent to the collected disc.
224141291|NCT06182540|DIETARY_SUPPLEMENT|Mango puree|Mango puree 300g
224141292|NCT03248050|BEHAVIORAL|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
224141293|NCT00002707|DRUG|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
224141294|NCT00002707|DRUG|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
224141295|NCT00002707|DRUG|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
224141296|NCT00002707|DRUG|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
224141297|NCT00018018|DRUG|CD34+ cells transduced with ADA retrovir|
224141298|NCT02792049|DEVICE|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
224141299|NCT02792049|DEVICE|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
224141300|NCT00779311|DRUG|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
224141301|NCT00779311|DRUG|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
224305028|NCT03906552|OTHER|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
223434233|NCT01432821|OTHER|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~* Sequence A during visit 2 followed by sequence B during visit 3~* or sequence B during visit 2"
223434234|NCT01573767|DRUG|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
224044568|NCT05090553|BIOLOGICAL|Bacterial culture|Samples will be seeded on blood agar and anaerobic blood agar plates. After sowing in solid media, the swab will be inoculated in thioglycolate medium, where it will remain for 14 days
224044569|NCT05090553|GENETIC|Phenotypic and genotypic characterization|"The phenotypic identification of the species will be carried out through mass spectrometry, with the MALDI-TOF equipment.~PCR analyzes performed in two phases, the first to confirm the presence of bacteria (target and non-target) using primers capable of amplifying eubacteria ribosomal deoxyribonucleic acid (rDNA) 16s and the second directed to confirm C. acnes through specific rDNA 16s primers."
224044570|NCT05090553|GENETIC|Multiomics analysis|Whole Genome Sequencing, proteomics and metabolomics analysis
223740556|NCT03495830|PROCEDURE|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
223740557|NCT00706979|OTHER|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
224044571|NCT00046085|BEHAVIORAL|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
224044572|NCT00046085|BEHAVIORAL|Customary care|Participants received care as usual.
224044573|NCT03991819|DRUG|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
224044574|NCT03991819|DRUG|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
224044575|NCT02271997|DRUG|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
224044576|NCT02271997|DRUG|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
224044577|NCT02271997|DRUG|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
224044578|NCT04565886|DEVICE|Diode laser application|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Adjunctive diode laser (settings: 810 nm, 2.5 W, 50 Hz, 10 ms) will be applied 3x for 30 s (i.e., 90 s per appointment) using a 400-lm thick fiber (WhiteStar, Orcos Medical AG, Küsnacht, Switzerland) in the test group. In the control group, non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way. The laser tip will be checked after 4-5 s for coagulation to prevent hotspots in the soft tissues.
223740558|NCT00706979|BEHAVIORAL|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
224044579|NCT04565886|DEVICE|Sham Diode laser|After mechanical debridement, the pockets around the implant will be rinsed with sterile saline solution. Non-activated (= placebo) adjunctive diode laser will be applied. The entire treatment procedure, including mechanical debridement, will be performed at Day 0 (= baseline), 7 and 14. The laser decontamination procedure will occur by systematically moving the laser tip along the subgingival implant surface in a vertical and horizontal scanning way.
224044580|NCT04808622|DRUG|Trans-Sodium Crocetinate|TSC given as a one-time IV bolus injection
224044581|NCT04808622|DRUG|Placebo|Placebo normal saline given as a one-time 7 mL one-time IV bolus injection
224044582|NCT03267160|DIAGNOSTIC_TEST|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
224044583|NCT02173041|OTHER|Prevention Awareness Groups (PAG)|
224044584|NCT02173041|OTHER|Standard Care|
224044585|NCT02861443|BEHAVIORAL|practice of colonic irrigation|
224044586|NCT00920920|RADIATION|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
223434235|NCT01573767|DRUG|Placebo|Placebo inhalation powder during treatment period
223434236|NCT01573767|DRUG|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
224044587|NCT01748409|OTHER|Biopsies of peripheral autonomic nervous system|
224044588|NCT01748409|OTHER|Autonomic dysfunction questionnaires|
224044589|NCT01748409|OTHER|Electrophysiological tests|
224044590|NCT01230554|DEVICE|Daily disposable cosmetic tint lens|Bausch \& Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
224044591|NCT03750383|DRUG|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
224044592|NCT03750383|DRUG|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
224044593|NCT03750383|DRUG|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
224044594|NCT03750383|DRUG|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
223434237|NCT00476892|PROCEDURE|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
223565828|NCT03784911|DEVICE|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
223434238|NCT05473741|DRUG|Second Generation Long-Acting Injectable Antipsychotic Medications|Patients who have been stabilized on long-acting injectable formulations of paliperidone palmitate, risperidone and aripiprazole will be followed for 48 weeks to determine the rate of relapse when adherence is established. Blood samples to measure plasma antipsychotic levels and prolactin levels, and urine samples for drug screen will be collected at baseline and at the 24-week and 48-week time points.
224044595|NCT01480921|BEHAVIORAL|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~* 5-10 min warm-up~* 30 min aerobic interval training (walking or stationary bicycle)~* 10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
224044596|NCT01480921|BEHAVIORAL|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~* 5-10 min of warm-up~* 30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~* 10 min of cool down~Exercise will be tracked by the participant in exercise log books."
224044597|NCT03558256|BEHAVIORAL|Mindfulness-based Cognitive Therapy|Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
224044598|NCT03558256|DRUG|Medication|Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
224044599|NCT01524341|DRUG|KAE609|KAE609 was supplied as capsules for oral use.
224044600|NCT04088383|OTHER|Amnios™ RT|Acellular human allograft
224044601|NCT04088383|OTHER|Saline|Sterile saline
224044602|NCT03753009|PROCEDURE|corneal cross-linking|"Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes."
224044603|NCT02936934|DRUG|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
224141302|NCT00779311|DRUG|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
224141303|NCT03963934|OTHER|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
224141304|NCT01867866|DRUG|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
224141305|NCT01867866|DRUG|Trifluridine|35 mg/m2, orally, single dose
224141306|NCT04103398|COMBINATION_PRODUCT|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
224141307|NCT04103398|PROCEDURE|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
224141308|NCT00947843|DRUG|aspirin + pregrel (Clopidogrel resinate)|
224141309|NCT00947843|DRUG|aspirin + placebo|
224141310|NCT00947843|DRUG|aspirin + plavix (Clopidogrel bisulfate)|
224141311|NCT05605483|OTHER|Salad bar|Schools where the school district has installed salad bars
224044604|NCT02936934|DRUG|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
224044605|NCT02468596|OTHER|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
224044606|NCT02468596|OTHER|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
224141312|NCT05605483|OTHER|Waitlisted control|Schools where the school district has not yet installed salad bars
224141313|NCT05605483|OTHER|Salad bar post-COVID|Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
223434239|NCT00013000|BEHAVIORAL|Test strategy for implementation guideline|
224141314|NCT01794481|PROCEDURE|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
223434240|NCT00112021|DRUG|pramlintide acetate|
223434241|NCT00769535|GENETIC|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR\_RFLP
223434242|NCT04989972|DRUG|PSIL428|1 mg of psilocybin
223434243|NCT04989972|DIETARY_SUPPLEMENT|Oyster mushroom|1 mg of oyster mushroom
223434244|NCT04989972|DRUG|PSIL428|1 mg psilocybin
224044607|NCT00814567|RADIATION|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
224044608|NCT03755791|DRUG|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
224044609|NCT03755791|DRUG|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
224141315|NCT01160341|DRUG|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
224141316|NCT03428997|DEVICE|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
224141317|NCT03428997|OTHER|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
224305029|NCT02929524|DRUG|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
223434245|NCT06484335|BIOLOGICAL|VRC07-523LS|VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site
224044610|NCT03755791|DRUG|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
224044611|NCT03755791|DRUG|Atezolizumab|Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an IV infusion once every 3 weeks (q3w).
224044612|NCT06494007|DRUG|Sodium chloride|The Diltiazem monotherapy group received 6.66 mL of IV sodium chloride 0.9% (NaCl) prior to receiving IV weight-adjusted diltiazem.
223434246|NCT06484335|BIOLOGICAL|PGDM1400LS|PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.
223434247|NCT06484335|BIOLOGICAL|ChAdOx1.tHIVconsv1|ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.
223434248|NCT06484335|BIOLOGICAL|ChAdOx1.HIVconsv62|ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.
224044613|NCT06494007|DRUG|90 mg of calcium|The Diltiazem with 90 mg calcium group received 3.33 mL of IV calcium chloride (CaCl2, 90 mg) and 3.33 mL of IV NaCl 0.9% as pretreatment over 5-10 min prior to receiving IV diltiazem.
224044614|NCT06494007|DRUG|180 mg Calcium|The Diltiazem with 180 mg calcium group received 6.66 mL of IV CaCl2 (180 mg) as pretreatment prior to receiving IV diltiazem.
224044615|NCT00685685|DRUG|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
224044616|NCT00685685|DRUG|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
224044617|NCT02140333|DRUG|Erlotinib|100mg vs. 150mg
223434249|NCT06484335|BIOLOGICAL|MVA.tHIVconsv4|MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.
223434250|NCT06484335|BIOLOGICAL|A244d11 gp120|A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF\_01AE A244 derived from the CM244 CRF\_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.
223434251|NCT06484335|BIOLOGICAL|ALFQ|ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic
223434252|NCT06484335|OTHER|Placebo|Normal saline (0.9% sodium chloride for injection) will be used as a placebo.
224044618|NCT01558427|PROCEDURE|Surveillance|Active clinical surveillance
224044619|NCT01558427|PROCEDURE|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
224044620|NCT04029181|OTHER|Anti-CD8 PET imaging agent|An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
223434253|NCT05111392|BIOLOGICAL|Placebo|Ingestion of one (1) liter of beverage with observation for 2 h
223434254|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 1|Ingestion of one (1) liter of beverage with observation for 2 h
223434255|NCT05111392|BIOLOGICAL|Oral Rehydration Solution 2|Ingestion of one (1) liter of beverage with observation for 2 h
223434256|NCT02849392|OTHER|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
223434257|NCT04529304|DEVICE|Bilateral Bispectral Index and EEG|"raw-EEG and spectrographic EEG-visualization based on the Medtronic Device Bilateral BiSpectral Index"
223434258|NCT01920256|OTHER|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
223434259|NCT01920256|OTHER|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
223565829|NCT03784911|DEVICE|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
223565830|NCT06404515|OTHER|Telehealth Group Counseling|Group counseling for women via telehealth to provide educational materials about atherosclerotic heart disease and provide information about risk factors and modification of risk factors. Women then have an opportunity to discuss / ask questions.
223565831|NCT05808179|DEVICE|Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur every 20 s
223565832|NCT05808179|BEHAVIORAL|CBT|Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing
223565833|NCT05808179|DEVICE|Sham Light|Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur once
224044621|NCT00108914|DRUG|GW685698X|
224044622|NCT06138964|DRUG|siSPARC + siLR4A microneedle patches|siSPARC + siLR4A microneedle patch
224163459|NCT04295668|BEHAVIORAL|Prehabilitation|"i) Exercise training: Ambulatory exercise training sessions with two main components, namely: high-intensity endurance exercise training and strength muscular training.~ii) Promotion of physical activity: Pedometer-based program using a physical activity tracker linked to a mobile app.~iv) Nutritional optimization: Recommendations of a healthy balanced diet or adapted to their digestive symptoms. Daily amount of protein intake will be close to 2 g•Kg-1•day-1.~iv) Smoking cessation: Use of both cognitive behavioral intervention and pharmacological therapy by varenicline or nicotine replacement therapies.~v) Cognitive behavioral therapy: Weekly group sessions conducted by a clinical health psychologist, including psychoeducation, motivational and behavioral change, self-efficacy and adherence enhancement, coping strategies acquisition and patient empowerment."
223434260|NCT04298255|OTHER|Round Spermatid Injection (ROSI)|In Vitro Fertilization using Round Spermatid Injection (ROSI)
223434261|NCT04298255|OTHER|Half ROSI-half Sperm Donor Fertilization|Half ROSI-half Sperm Donor Fertilization
223434262|NCT01733485|DRUG|Aspirin|500 mg/8 h for 5 days
223434263|NCT01733485|DRUG|Indomethacin|25 mg/8 h for 5 days
223565834|NCT05871476|BEHAVIORAL|Hospital Cohort Care Intervention at the hospital|There will be 3 different cohort groups for the patients: 1) Unknown CRE colonisation status with increased barrier precautions (all patients until screening results arrive will belong to this group unless there are available screening results from referral hospital), 2) CREpos, and 3) CREneg. CREpos patients (2) will be treated in one area of the ICUs by specially assigned nurses/personnel.
224044623|NCT06138964|DRUG|siSPARC microneedle patch|siSPARC microneedle patch
224044624|NCT00951301|DRUG|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
224044625|NCT00951301|DRUG|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
223434264|NCT00850096|OTHER|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
224044626|NCT03967782|BEHAVIORAL|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224044627|NCT03967782|BEHAVIORAL|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224044628|NCT03967782|BEHAVIORAL|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
224044629|NCT01442116|PROCEDURE|stress echocardiography|safety and efficacy of stress echocardiography
224044630|NCT03533413|PROCEDURE|combined CT-fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
223434265|NCT00850096|DRUG|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
223434266|NCT01323036|DIETARY_SUPPLEMENT|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
223434267|NCT01323036|DIETARY_SUPPLEMENT|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
223434268|NCT05161078|DEVICE|CARPEDIEM|CARPEDIEM treatment as per local standard of care
223434269|NCT03721588|OTHER|Clinical interviews, psychometric scales were applied.|
223434270|NCT01371877|DRUG|High Dose Vitamin D3|Vitamin D 4000 IU per day for 3 months
223434271|NCT01371877|DRUG|Low Dose Vitamin D3|Vitamin D 600 IU per day
223434272|NCT04482166|OTHER|Training|20-times training of fiberoptic-guided tracheal intubation through supraglottic airway device to pediatric airway manikin
223434273|NCT04482166|DEVICE|supraglottic airway device|supraglottic airway device
224044631|NCT03533413|PROCEDURE|standard fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
224044632|NCT05692856|DRUG|Clenbuterol|Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
224044633|NCT05692856|DRUG|Placebo|Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
224044634|NCT02486809|DRUG|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
224044635|NCT00445523|BIOLOGICAL|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
224044636|NCT00445523|DRUG|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
224044637|NCT02650336|DRUG|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
224044638|NCT05125289|OTHER|Graston technique group|Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes
224044639|NCT05125289|OTHER|Active release technique group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~ART steps:~* Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~* Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~* Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release."
224044640|NCT05125289|OTHER|Proprioceptive Neuromuscular Facilitation stretching group|"* Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~PNF technique steps:~* The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~* The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~* Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~* This sequence is repeated 5 times at a 20 second interval."
224044641|NCT00252304|DRUG|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
224044642|NCT00252304|DRUG|Placebo|Placebo
224044643|NCT04349878|DIAGNOSTIC_TEST|gingival crevicular fluid evaluation|anaysis of interleukins in gingival crevicular fluid
224044644|NCT02818166|PROCEDURE|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
224044645|NCT04711148|OTHER|placebo|placebo
223434274|NCT00553982|PROCEDURE|Patellar component|Resurfacing with onlay technique
223434275|NCT00553982|PROCEDURE|No patellar component|Trimming of osteophytes when appropriate
223434276|NCT00869557|DRUG|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
223434277|NCT00869557|DRUG|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
223434278|NCT04498416|DIAGNOSTIC_TEST|Quantitative and qualitative assessments of mental health|Emergency semi-directed interview; Diagnosis Infant and Preschool Assessment (DIPA); Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS); Conners Scale - short version;Weiss functional impairment rating scale - parent (WFIRS); Parenting stress index-short form (PSI-SF); Anxiety Scale
224044646|NCT04711148|DRUG|orelabrutinib|Orelabrutinib is a white, round, uncoated tablet
223434279|NCT03246841|OTHER|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
223434280|NCT03013608|PROCEDURE|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
223434281|NCT02666638|OTHER|Control Volunteers|MRI on up to a 7T scanner without contrast.
223434282|NCT02666638|OTHER|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
223434283|NCT04842799|OTHER|Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform|"Participants will receive a link to the digital pre-test information. This will consist of text covering: Genetics and cancer risk; Genetics testing; What will happen if your test is positive; What will happen if your test is negative; Implications for insurance.~Where relevant, parts of the text will be linked through to additional information, such as insurance advice from the Association of British Insurers. Participants will be able to call a genetic counsellor on the hotline during weekday office hours, should they have any questions or require further information."
223434284|NCT04842799|OTHER|Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform|Participants will receive a digital message that their results are available. When they click this, they will receive digital notification of their negative (normal) result in short form. Full details will be provided in an individualised letter.
223434285|NCT06059729|DEVICE|Al-Lisaan|Al-Lisaan is a digital application for the self assessment and management of adult stutters.
224044647|NCT05597865|BEHAVIORAL|Economic Empowerment Intervention|Economic Empowerment Intervention comprising Financial Literacy Sessions and Youth Development Accounts
224044648|NCT05597865|BEHAVIORAL|Alcohol and Drug Use Risk Reduction Sessions|All participants in the control and treatment arm will receive Alcohol and Drug Use Risk Reduction sessions tailored for Adolescents and Youths Living with HIV.
223434286|NCT00097305|BEHAVIORAL|Body-Oriented Therapy|
223434287|NCT00097305|BEHAVIORAL|Standardized Massage Therapy|
223434288|NCT05974956|OTHER|Mastitis care teaching protocol|It was developed by the authors based on previous similar studies, articles and library resources. It was introduced to the study group in the form of face to face sessions plus a hand out copy. It consisted of three parts; (1): Theoretical part about mastitis (definition, types, clinical manifestation, possible causes, diagnosis and management). (2):Self-care practices, and (3):Recommendations regarding dietary measures, rest, medication and follow up.
224141318|NCT03304327|BEHAVIORAL|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
223434289|NCT05105516|PROCEDURE|Ablation|Ablation of ectopic foci causing PVCs
223434290|NCT00181649|DRUG|Recombinant human prolactin|
223434291|NCT06009809|DIAGNOSTIC_TEST|transesophageal echocardiogram|To measure mean blood velocity at the level of the right renal and superior mesenteric artery
223434292|NCT02507843|DRUG|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
223434293|NCT02507843|DRUG|Placebo|Placebo will be administered in placebo group monthly for 6 months.
223434294|NCT03065036|DRUG|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
224044649|NCT03056950|DEVICE|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
224044650|NCT02739750|OTHER|No intervention|There is no intervention for this study. It is a MRS.
224044651|NCT03661125|DRUG|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
224044652|NCT03661125|DRUG|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
224044653|NCT01552655|RADIATION|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
224044654|NCT02031939|DRUG|Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
224044655|NCT02031939|RADIATION|standard chemoradiotherapy|All rectal patients in this group will receive standard radiotherapy and surgical resection.
224141319|NCT05506969|BIOLOGICAL|rF1V-1018|rF1V vaccine and CpG 1018® adjuvant
223434295|NCT01967095|DRUG|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 \& D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 \& D2, \& will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 \& 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 \& 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
223434296|NCT02102100|DRUG|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
223434297|NCT02102100|DRUG|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
224141320|NCT05506969|BIOLOGICAL|rF1V vaccine|rF1V vaccine
224141321|NCT01630759|DEVICE|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
223740559|NCT05710809|OTHER|Targeted specialized physical group-based exercise and Comprehensive Geriatric Assessement|Vestibular rehabilitation, balance- and progressive resistance training for three months' three times/week and Comprehensive Geriatric Assessement including corresponding interventions
223740560|NCT02661542|DRUG|FF-10502-01|
224044656|NCT06113484|OTHER|DIET + EXERCISE|At first, a two-hour group session titled 'Discovering New Flavors' is conducted. This session aims to promote the consumption of healthy foods that should be included in the participants' daily diet. In order to create a different dynamic and enhance interaction, some recipe suggestions are prepared in a group setting. The intervention group is advised to have three (breakfast, lunch, and dinner) to four (breakfast, lunch, afternoon snack, and dinner) daily meals. Participants are encouraged not to count calories, thus emphasizing the importance of moderation. Regarding the main meals, legumes are recommended as a protein source for dinner. On the other hand, for lunch, the protein component can include white meats, fish, or eggs. Red and/or processed meats are excluded in this intervention. Moreover, all participants in this group are encouraged to practice a nightly fasting period of at least 12 hours.
223434298|NCT04424771|BEHAVIORAL|Maslach Burnout Inventory (MBI)|The Maslach Burnout Inventory is an introspective psychological inventory consisting of 22 items pertaining to occupational burnout.
223434299|NCT04478500|DRUG|Minocycline|"Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase."
223565835|NCT05871476|BEHAVIORAL|, Household Education Communication Hygiene Intervention, Livestock Antibiotic Intervention|The intervention will focus on two main measurable outcomes: 1) Decrease feco-oral-animal transmission route to prevent in-HH and community spread of CRE +/- CoRE. 2) Decrease unindicated community use of ABs for humans and animals. This WP focuses on a one health intervention in collaboration with local health authorities, developing and implementing an HH Education Communication Hygiene Intervention (HECHI) to improve HH hygiene and health management and reduce the risk of transmission between humans and animals, a Provider Engagement Intervention (PEI) to improve case management of common infection and decrease unindicated AB, and and a Livestock AB Intervention (LAI) to reduce the use of AB in livestock through improved biosecurity conditions and animal husbandry.
224044657|NCT06113484|OTHER|WITHOUT DIET + EXERCISE|"An educational session titled Healthy Eating: Nutritional Recommendations for Individuals at Risk of Cardiovascular Disease will be conducted in a group setting.~The objective of this session is to raise awareness among participants about the importance of a healthy diet and lifestyle in the prevention of cardiovascular diseases."
224044658|NCT06032338|OTHER|CRC screening invitation not including the screening test.|The invitation to CRC-PBOSP will only contain informations on how to get the screening test.
224044659|NCT06032338|OTHER|Mailing of FIT with invitation|The invitation to CRC-PBOSP will contain the CRC screening test.
224044660|NCT06032338|OTHER|Information letter before invitation|An information letter will be sent to future invitees a few weeks before the invitation, to announce the mailing of the CRC screening kit.
224044661|NCT03686098|DIETARY_SUPPLEMENT|Dietary soy|Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
224044662|NCT03686098|DIETARY_SUPPLEMENT|Soy Supplement|Soy isoflavones delivered in extracted form
224044663|NCT04766476|DRUG|BMS-963272|Specified dose on specified days
224044664|NCT04766476|OTHER|Placebo matching BMS-963272|Specified dose on specified days
224044665|NCT00549627|DEVICE|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
224044666|NCT03948360|DEVICE|Low-Irradiance Monochromatic Biostimulation (LIMB) Device|The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.
224044667|NCT03948360|OTHER|Standard of Care|Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
224044668|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp CBD|Participants will consume 1 Vantage Hemp capsule, daily for 4 weeks.
224044669|NCT05850754|DIETARY_SUPPLEMENT|Vantage Hemp Placebo Capsule|Vantage Hemp Placebo Capsule Intervention
224044670|NCT04513665|DRUG|ZW25|ZW25 at 20mg/kg intravenously (IV) every two weeks.
224044671|NCT03579420|BEHAVIORAL|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
224044672|NCT03579420|BEHAVIORAL|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
224044673|NCT05071495|DEVICE|Smartphone application|"Smartphone application named Signal, which connects patients and health providers"
224044674|NCT01653964|DIAGNOSTIC_TEST|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
224044675|NCT06470789|BEHAVIORAL|Shoulder blood restriction training|Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
224044676|NCT02608879|PROCEDURE|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
224044677|NCT02608879|PROCEDURE|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
224044678|NCT02608879|PROCEDURE|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
223565836|NCT03192020|PROCEDURE|Percutaneous needle fasciotomy (PNF)|The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure. If patient seeks for a treatment and the recurrence of the disease can not be treated by the PNF or patient is not willing to new PNF patient will be treated with LF.
224044679|NCT02608879|OTHER|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
224044680|NCT05035576|DRUG|OPN-019|400 mg OPN-019, 2 sprays per nostril (one dose)
223434300|NCT00840593|PROCEDURE|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
223434301|NCT00840593|PROCEDURE|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
223434302|NCT04577222|PROCEDURE|Technical modification during radical prostatectomy|Covering the NVB with fat
223434303|NCT02510300|DRUG|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
223434304|NCT02510300|DRUG|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
223434305|NCT02510300|DRUG|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
223434306|NCT02510300|DRUG|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
223434307|NCT06398392|DRUG|[18F]PBR111|\[18F\]PBR111 is a radiotracer produced at University Hospital of Geneva in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 10 mL (max) of formulated product, the maximal applicable dose being 200 MBq.
223434308|NCT06398392|PROCEDURE|PBR111 injection|\[18F\]PBR111 will be administered once, intravenously in the antecubital fossa at a dose of 200 MBq
223434309|NCT06398392|DEVICE|PET scan|Upon administration of the radiotracer, a 120-minute PET/CT scan will be initiated.
224044681|NCT01882842|PROCEDURE|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
223434310|NCT06398392|RADIATION|PBR111 dosimetry|to establish the exposure of the organs/tissues to a standard radioactive dose (200 MBq) of \[18F\]PBR111
224044682|NCT01882842|DEVICE|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
224044683|NCT00000604|PROCEDURE|cardiopulmonary bypass|
224044684|NCT00000604|PROCEDURE|heart arrest, induced|
224044685|NCT06216184|DIAGNOSTIC_TEST|Vortexing|use combined of vortexing and Maki techniques
224044686|NCT00209365|PROCEDURE|exposure to grass pollen/starch granules|
224044687|NCT03702803|DIETARY_SUPPLEMENT|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
224044688|NCT03702803|DRUG|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
223434311|NCT06558136|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
223434312|NCT03758976|DIAGNOSTIC_TEST|Biopsies, blood|We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
224044689|NCT04867889|DEVICE|iTBS (intermittent theta-burst stimulation)|"The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head"
224044690|NCT04867889|DEVICE|Sham iTBS|"The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead"
224044691|NCT05511623|DRUG|tislelizumab|standard radiotherapy with concomitant cisplatin 40mg/m2 once every week for 5 weeks, combined with tislelizumab (200 mg, day 1) once every 3 weeks until disease progression or intolerable toxicity occurs or one year.
223434313|NCT06006546|BIOLOGICAL|426c.Mod.Core-C4b|100 mcg and 300 mcg
223434314|NCT06006546|OTHER|Adjuvant 3M-052-AF+Alum|5 mcg
223434315|NCT04751409|PROCEDURE|Chest Radiography|Undergo CXR
223434316|NCT04751409|PROCEDURE|Computed Tomography|Undergo CT-chest
223434317|NCT04751409|PROCEDURE|Follow-Up|Undergo intense follow-up
223434318|NCT04751409|PROCEDURE|Follow-Up|Undergo limited follow-up
224044692|NCT05511623|OTHER|concurrent chemoradiotherapy|standard radiotherapy with concomitant cisplatin 40mg/m2 on day 1 once every week for 5 weeks.
223434319|NCT04751409|PROCEDURE|Imaging Technique|Undergo imaging
223434320|NCT04751409|OTHER|Questionnaire Administration|Ancillary studies
223434321|NCT06242691|BIOLOGICAL|MK-1200|IV Infusion
224141322|NCT01630759|OTHER|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
224141323|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)|The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
223434322|NCT06242691|DRUG|Antiemetic|One or more prophylactic antiemetic(s) (e.g. 5-HT3 receptor antagonists, dexamethasone, neurokinin-1 receptor antagonists, etc.) may be selected based on previous response of participants to antiemetic medications and individual factors, and will be administered per approved product label prior to MK-1200 infusion
224044693|NCT03785678|BIOLOGICAL|Tenecteplase|The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
224141324|NCT04655209|BEHAVIORAL|apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)|The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
224141325|NCT04655209|BEHAVIORAL|MT only with sham tDCS (MT)|For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.
224044694|NCT03785678|OTHER|Placebo|Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
224044695|NCT00094796|PROCEDURE|Exercise cardiopulmonary metabolic testing|
224044696|NCT00094796|PROCEDURE|Skeletal muscle biopsy|
224141326|NCT06517641|DRUG|Haploidentical donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1\. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1\. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant."
224141327|NCT06517641|DRUG|Unrelated donor bone marrow transplant|"Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1\. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1\. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant."
224141328|NCT03302208|DRUG|Pregabalin|Pregabalin capsule 150 mg oral
224141329|NCT03302208|DRUG|Placebo|Placebo
224141330|NCT00794014|PROCEDURE|Conservative strategy|"* Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) \>75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS \>50% or dissection in the Side branch after ballooning in LM subgroup."
224141331|NCT00794014|PROCEDURE|Aggressive strategy|"* Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS \>75% in the side branch after main vessel stenting in non-LM subgroup, and DS \>50% in LM subgroup.~* Side branch stenting was performed if DS \>50% in the side branch after ballooning in non-LM subgroup, and DS \>30% or dissection in the side branch after ballooning in LM subgroup."
224141332|NCT01259635|DEVICE|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
224141333|NCT01181440|DEVICE|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
224141334|NCT01181440|OTHER|Conventional care|Weekly application of conventional care
224141335|NCT01319916|DRUG|ATX-101|ATX-101 2mg/cm2
224141336|NCT00510068|DRUG|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
224141337|NCT00510068|DRUG|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
224141338|NCT01896739|BIOLOGICAL|Eutravac|
224141339|NCT05433636|BEHAVIORAL|Body Scan|Patients will listen to a 5-minute, audio-recorded body scan practice.
224141340|NCT05433636|BEHAVIORAL|Mindful Breathing|Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
224141341|NCT05433636|BEHAVIORAL|Mindfulness of Discomfort|Patients will listen to a 5-minute, audio-recorded mindfulness of discomfort practice.
223434323|NCT02497261|PROCEDURE|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
223565837|NCT03192020|DRUG|Collagenase Clostridium Histolyticum (CCH) 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord at least three different places in the outpatient clinic and the cord can be ruptured by gently force after one to three days. If patient seeks for a treatment and the recurrence of the disease can not be treated by the CCH or patient is not willing to new CCH patient will be treated with LF.
223434324|NCT04852770|BEHAVIORAL|Trial-Based Cognitive Therapy|TBCT is an approach that includes psychoeducation and cognitive restructuring techniques concerning automatic thoughts, underlying assumptions and core beliefs related to the traumatic events. It is conducted in a therapeutic setting that makes use of experiential techniques, allowing the patient to refer to him/herself in the third person and thus taking distance from him or herself. One of TBCT techniques for dealing with guilt and shame, emotions that provoke great limitation to patients with PTSD, is the participation grid (PG). Another important technique is the consensual role-play (CRP), designed to help patients resolve ambivalence and make decisions. In addition, the most important TBCT technique, the Trial, was developed to help patients change dysfunctional negative core beliefs. Therapists who will conduct this approach have a specialization level in CBT. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
223434325|NCT04852770|BEHAVIORAL|Mindfulness-Based Health Promotion|"The MBHP protocol is a structured program developed over 8 sessions, in group, where participants (8-15 people) meet every week for 2 hours (standard duration of one session), to experience the concepts and techniques of mindfulness. Participants are also given suggestions of daily activities to be implemented at home or in the workplace, that last in average 15-20 minutes, but may last up to 45 minutes in the case of more motivated and compliant participants. They are also encouraged to incorporate the idea of Mindfulness in their daily lives (the so-called informal practice), so that all daily activities somehow become opportunities to practice Mindfulness. In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line."
223434326|NCT04852770|BEHAVIORAL|Positive psychotherapy|PPT is the clinical and therapeutic work derived from PP. PPT consists of 15 specific practices that have been empirically validated, either separately, or in conjunction with two or three practices. After empirical validation, these practices were organized in a cohesive protocol of 15 sessions called PPT. Many of these practices have been studied through online interventions. In the present study, the protocol will be reduced to 14 sessions, with sessions called positive relationships, positive communication, and practical wisdom removed. It was understood that the other 12 would be more easily adapted to the moment of the study. (DUCKWORTH; STEEN; SELIGMAN, 2005; MONGRAIN; ANSELMO-MATTHEWS, 2012; RASHID; SELIGMAN, 2019). In this study, this treatment will be delivered in 14 sessions, weekly, individualy, one session by week and on line.
223434327|NCT06541158|OTHER|Best Practice|Receive usual care
223434328|NCT06541158|OTHER|Discussion|Participate in a CAB
223434329|NCT06541158|OTHER|Educational Intervention|Receive PAF pamphlet
223434330|NCT06541158|BEHAVIORAL|Health Promotion and Care|Receive the TRACT program
223434331|NCT06541158|OTHER|Media Intervention|Receive transportation awareness brief video
224044697|NCT00094796|PROCEDURE|Brachial artery reactivity testing|
223434332|NCT06541158|OTHER|Questionnaire Administration|Ancillary studies
224044698|NCT05861154|DEVICE|Photobiomodulation|"A diode laser (Sirolaser blue laser system, Sirona Dental Systems GmbH, Fabrikstraße 31, 64625 Bensheim, Germany) of Wavelength 660 nm will be used and the laser parameters will be set as follows: Power 0.1 W, energy 6 J, Continuous wave, Irradiation time 60 Seconds; energy Tip area 0.5 cm2, fluence 12 J/cm2 will be applied at the site of needle penetration.~It should be noted that before each application, the output of the laser device will be checked using the aiming beam on flat surface; both the patient and the operator will wear safety goggles during the irradiation."
224044699|NCT05861154|DRUG|Benzocaine Gel|a 20% Benzocaine topical anaesthetic gel will be applied. To increase the absorption of the topical anaesthetic gel, soft tissues will be dried with (2 x 2 cm) gauze. Topical anaesthetic gel will be applied at the site of needle penetration and left in contact with the soft tissues for one minute in order to to maximize its effect.
224044700|NCT01013766|DRUG|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
224044701|NCT01013766|DRUG|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
224044702|NCT02231788|DRUG|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
224044703|NCT02231788|DRUG|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2\~4weeks run-in period with Telmitrend®Tab. 40mg
224141342|NCT05433636|BEHAVIORAL|Mindful Savoring|Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
224141343|NCT05433636|BEHAVIORAL|Integrative Health Recording|Patients will listen to a 5-minute, audio-recorded description of integrative health.
224141344|NCT03771404|OTHER|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
224141345|NCT03886701|DRUG|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
224141346|NCT03886701|DRUG|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
224141347|NCT03886701|DRUG|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
224141348|NCT01397448|DRUG|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
224141349|NCT01397448|DRUG|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
224141350|NCT01397448|DRUG|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
224141351|NCT01619605|PROCEDURE|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
224141352|NCT03741296|PROCEDURE|Single stage revision|One-stage exchange hip joint replacement surgery
223434333|NCT01143064|DRUG|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
224044704|NCT05042037|DIETARY_SUPPLEMENT|(Microbial cell preparation) probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
224044705|NCT05042037|OTHER|Placebo|Placebo sachet with no microbial cell preparation
224044706|NCT03620019|DRUG|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
224044707|NCT03620019|DRUG|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
224044708|NCT03620019|DRUG|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
224044709|NCT02374021|DRUG|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
224044710|NCT02374021|DRUG|Sulfasalazine|1 gm bid
224044711|NCT02374021|DRUG|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
224044712|NCT02374021|DRUG|Etanercept|50 mg SC weekly
224044713|NCT02374021|DRUG|Adalimumab|40 mg SQ every other week
224044714|NCT03142971|PROCEDURE|focused shock wave therapy|
224044715|NCT03142971|PROCEDURE|ultrasound therapy|
224044716|NCT06010069|DIAGNOSTIC_TEST|body temperature measurament|body temperature of every patient was measured with tympanic thermometer during surgical procedure
224044717|NCT03350776|BEHAVIORAL|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
224044718|NCT03019757|RADIATION|DaTscan|A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
224044719|NCT03019757|RADIATION|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
224044720|NCT03019757|RADIATION|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
224044721|NCT03019757|GENETIC|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
224044722|NCT03019757|PROCEDURE|Polysomnogram|Overnight sleep study
224044723|NCT03019757|BEHAVIORAL|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
224044724|NCT03253939|PROCEDURE|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
224044725|NCT03253939|PROCEDURE|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
223434334|NCT01143064|DRUG|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
223434335|NCT00006033|BIOLOGICAL|gene therapy|
224044726|NCT04692038|DEVICE|Forceps biopsy combined with puncture biopsy under the guidance of Augmented Reality Navigation and Radial EBUS|During the operation, under the guidance of Augmented Reality Navigation, the bronchoscope will reach the location of the target pulmonary nodules, and the EBUS probe will be inserted through the bronchoscope working channel, and gradually approach the target nodules to obtain EBUS images. After typical EBUS images are observed and the location is confirmed, the EBUS probe will be withdrawn and biopsy forceps and puncture biopsy needle will be used to obtain samples at the target locations respectively.
224044727|NCT04603586|RADIATION|SBRT|SBRT: in 5-6 fractions with CyberKnife
223434336|NCT00006033|BIOLOGICAL|interleukin-2 gene|
223434337|NCT00006033|DRUG|methotrexate|
223434338|NCT05122533|DIAGNOSTIC_TEST|EOS|EOS Micro Dose imaging will be done. SterEOS lower limb alignment reconstruction will be performed measuring the lim length.
224044728|NCT04603586|DRUG|Chemotherapy|1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course
224044729|NCT00824824|DRUG|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
224044730|NCT00824824|DRUG|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
224044731|NCT00025441|BIOLOGICAL|dactinomycin|
224044732|NCT00025441|BIOLOGICAL|filgrastim|
224044733|NCT00025441|DRUG|carboplatin|
224044734|NCT00025441|DRUG|cyclophosphamide|
224044735|NCT00025441|DRUG|doxorubicin hydrochloride|
224044736|NCT00025441|DRUG|epirubicin hydrochloride|
224044737|NCT00025441|DRUG|etoposide|
224044738|NCT00025441|DRUG|ifosfamide|
224044739|NCT00025441|DRUG|vincristine sulfate|
224044740|NCT00025441|PROCEDURE|peripheral blood stem cell transplantation|
224044741|NCT00025441|RADIATION|radiation therapy|
224044742|NCT05144568|OTHER|Nutrition education|Nutrition education will be given to improve PMS
224044743|NCT04357821|DRUG|Combination Intervention|"1. IL-12 adjuvanted p24CE DNA prime (p24CE/IL-12) at Weeks 0 and 4~2. IL-12 adjuvanted DNA boost (p24CE plus p55gag) at Week 12~3. MVA/HIV62B (MVA62B) boost at Week 20~4. single dose of two bNAbs (VRC07-523LS and 10-1074, which target CD4 binding site and V3 loop, respectively) at week 24 with a TLR9 agonist (lefitolimod) administered weekly between Weeks 24 and 33 (10 doses)~5. ATI with single dose of VRC07 and 10-1074 at Week 34"
224044744|NCT01813851|DEVICE|Exercise training in addition to nutritional support|
224044745|NCT03219450|DRUG|NeoVax|It stimulates the immune system to attack cancer cells.
224044746|NCT03219450|DRUG|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
224044747|NCT03219450|DRUG|Pembrolizumab|Is a monoclonal antibody that helps the immune cells to be better at attacking cancer cells.
223434339|NCT05122533|DIAGNOSTIC_TEST|Clinical limb length measurements|"Clinical measurement of both lower limbs' length, 3 times in 3 different days by 3 observers.~* bony markers position (heel contour, patella and medial malleolus) in resupinate and side position also~* tape measuring:~  * Spina iliaca anterior superior - medial malleolus~ * umbilicus - medial malleolus~ * greater trochanter - lateral malleolus~ * in standing, sitting, resupinate and side position"
224044748|NCT05314712|BEHAVIORAL|Sleep intervention|Participants will receive a 9-week sleep intervention through text and Facebook that include traditional Blackfoot cultural components combined with scientifically validated strategies for sleep.
223434340|NCT00323037|DRUG|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
223434341|NCT00323037|DRUG|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
224044749|NCT06235931|DRUG|Darcilide +AI (letrozole/anastrozole/Exemestane) + pyrrotinib|"Darcilie: 125mg orally once a day, taken for 21 days and stopped for 7 days, 28 days as a cycle.~AI: Letrozole: 2.5mg orally once daily, or anastrozole 1mg orally once daily, or exemestane 25mg orally once daily.~Pyrrotinib: Initial dose of 240mg in the first week, if diarrhea and other side effects can be tolerated, 320 mg can be added in the second week, once a day, oral administration within 30 minutes after breakfast, 21 days for 1 cycle~All investigational drugs should be used for disease progression or when patients have an intolerable adverse reaction or are withdrawn from the study for other reasons.~Oral pyrrotinib is recommended along with prophylactic antidiarrheal medication. Antidiarrheal regimen 1: Oral imodium (2 tablets/times, 2 times a day) from the first week, 1 tablet, 2 times a day from the second week. Antidiarrheal regimen 2: montmorillonite powder (3 times a day, 1 pack/time)+ whole intestine sheng (3 pills/time 2 times a day)."
224044750|NCT01208688|DEVICE|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
224044751|NCT01208688|DEVICE|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
224044752|NCT01208688|OTHER|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
224044753|NCT01012154|DEVICE|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
224044754|NCT06382519|DRUG|Thalidomide|thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
224044755|NCT00660270|PROCEDURE|Pancreatic Surgery|
224044756|NCT00660270|RADIATION|Radiation therapy|
224044757|NCT00660270|DRUG|Cisplatin|
224044758|NCT00660270|DRUG|5-FU|
224044759|NCT00660270|DRUG|Alpha-interferon|
224044760|NCT00660270|DRUG|Gemcitabine|
224044761|NCT00074854|DRUG|CP-547,632|
223434342|NCT04933396|DIAGNOSTIC_TEST|ultrasound diagnostic criteria|evaluate using the recent consensus based definition for FGR using biometric and Doppler parameters to identify fetuses at risk of adverse perinatal outcomes compared to using solely biometric based parameter (EFW \<10th percentile according to the Hadlock growth standard).
223434343|NCT05943184|BEHAVIORAL|Cognitive Behavioral Nursing Model|(1)Psychological intervention was accessible to those who felt resistant to their treatment plans or developed inferior feelings due to visual impairment to establish a good relationship with patients and help them better cope with unhealthy emotions. (2) Health education was provided through self-developed booklets and question-and-answer sessions to publicize the fundamental knowledge and make sure all patients have a full understanding of the disease and related treatments. (3) Dietary guidelines were set out to encourage a light, healthy diet with fruits and vegetables, free of irritating food, and containing a limited amount of oily food. (4) Behavioral guidelines were developed to address the importance of quitting tobacco use and prevent eye strain due to excessive eye use with tailored eye care plans.
223434344|NCT03192618|PROCEDURE|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
223565838|NCT03192020|PROCEDURE|Limited fasciectomy (LF)|LF is performed in general or regional anesthesia in operating room. Constricting cords will be excised under direct vision. LF has been the dominant technique of surgical treatment. If patient seeks for a treatment the recurrence of the disease will be treated with LF as long as needed.
224044762|NCT04739072|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
224044763|NCT04739072|OTHER|Electronic Health Record Review|Review of medical records
224044764|NCT05483491|BIOLOGICAL|KK-LC-1 TCR-T cells|Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. KK-LC-1 TCR-T cells will be administered as a single intravenous infusion.
224044765|NCT05483491|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
224044766|NCT02270866|DEVICE|TNM Device|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
223565839|NCT04776187|DRUG|Gadodiamide|Gadodiamide Injection(OMNISCAN™)
223565840|NCT04776187|DRUG|Gadoteric Acid Meglumine Salt|Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
223565841|NCT02118766|DRUG|AN2728 Topical Ointment, 2%|
223565842|NCT02118766|DRUG|Matching vehicle control|
223434345|NCT03192618|DRUG|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
224044767|NCT06975644|DRUG|nab-paclitaxel, carboplatin, and bemotuzumab|nab-paclitaxel：260 mg/m2 Q3W；carboplatin：AUC 6；bemotuzumab：1200 mg Q3W
224044768|NCT06975644|DRUG|epirubicin, cyclophosphamide, and bemotuzumab|epirubicin：90 mg/m2 Q3W；cyclophosphamide：600 mg/m2 Q3W；bemotuzumab：1200 mg Q3W
224044769|NCT04777747|OTHER|viral infection|a child is infected by virus only
224044770|NCT04777747|OTHER|viral and bacterial infection|a child is infected by virus and progress to bacterial infection
224044771|NCT05114746|RADIATION|177Lu-PSMA-617|administered intravenously at a dose of 7.4 GBq (+/- 10%). 7.4 GBq dose is equivalent to 200 mCi or 7400 MBq.
224044772|NCT05114746|RADIATION|68Ga-PSMA-11|68Ga-PSMA-11 is manufactured by radiolabeling of PSMA-11 precursor with 68Ga directly at clinical trial sites immediately prior to administration into participants. The 68Ga used for radiolabeling will be eluted from the 68Ge/68Ga generator. 68Ga-PSMA-11 will be prepared as a sterile solution and administered intravenously at a dose of 111 - 259 MBq (3 - 7 mCi).
224044773|NCT05114746|OTHER|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator (Post taxane population only)
224044774|NCT04887454|BEHAVIORAL|Once-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT once weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Participants will repeat the 25-minute HIIT bout three times with 30-60 minutes break in between each 25-minute HIIT bout. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
224141353|NCT03741296|PROCEDURE|Two-stage revision|Two-stage exchange hip joint replacement surgery
224141354|NCT00931476|DRUG|somatropin|
224141355|NCT00931476|DRUG|placebo|
224299776|NCT03502525|BEHAVIORAL|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
223434346|NCT02255552|DRUG|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
223434347|NCT05265091|DRUG|KL590586 Capsule|Product Name: KL590586 Capsules Formulation：Capsule Specification: 10mg; 50mg Ingredients: KL590586, microcrystalline cellulose, mannitol, cross-linked sodium carboxymethylcellulose, colloidal silicon dioxide, magnesium stearate, hydroxypropylmethylcellulose hollow capsule
223565843|NCT01924273|DRUG|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
224044775|NCT04887454|BEHAVIORAL|Thrice-Weekly HIIT|Participants in this group will receive a 16-week intervention of HIIT thrice weekly supervised by certified athletic coaches. Participants will perform four 4-minute intervals at 85%-95% peak heart rate with a 3-minute active recovery between each 4-minute interval. Health information provided to the usual care control group will be made available to the participants in the HIIT groups.
224141356|NCT03809832|DIAGNOSTIC_TEST|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
224141357|NCT05125107|DEVICE|Quantitative Flow Ratio derived PPG and dQFR/ds|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2~Physiologic local severity of coronary atherosclerosis was assessed by instantaneous QFR gradient per unit length (dQFR/ds)"
224141358|NCT04156828|DRUG|Copanlisib|Given IV
224141359|NCT04156828|DRUG|Gemcitabine|Given IV
224141360|NCT04156828|DRUG|Carboplatin|Given IV
224305030|NCT02929524|DRUG|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
223434348|NCT03603951|DRUG|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
223434349|NCT00230022|BEHAVIORAL|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
223434350|NCT05044949|OTHER|Probiotic|The study product is a probiotic strain
223434351|NCT05044949|OTHER|Placebo|The study product is a placebo to the probiotic strain
224044776|NCT04887454|OTHER|Usual Care|Participants in the usual care control group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to obesity including causes, prevalence, epidemiology, associated diseases, healthy diet, caloric restriction advice, physical activity, stress management, adequate sleep, as well as lifestyle counseling/consultation and goal-setting/record-keeping strategies for behavioral changes.
224044777|NCT03819738|DIAGNOSTIC_TEST|fMRI|Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
224044778|NCT02509897|OTHER|Hypoxic training|Hypoxic training 3 times per week four four weeks
224044779|NCT02509897|OTHER|Normoxic training|Normoxic training 3 times per week four four weeks
224044780|NCT00782288|DRUG|digitoxin|0.05mg tabs, once daily for 28 days
224044781|NCT00782288|DRUG|digitoxin|0.1mg pills, once daily for 28 days.
224044782|NCT00782288|OTHER|placebo|pill taken once daily for 28 days
224044783|NCT00771563|DRUG|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
224141361|NCT04156828|DRUG|Dexamethasone|Given PO
224141362|NCT04156828|BIOLOGICAL|Rituximab|Given IV
224141363|NCT04156828|BIOLOGICAL|Pegfilgrastim|Given SC
223434352|NCT06622967|DIAGNOSTIC_TEST|CadAI-B|"The ultrasound is performed following the usual process. If there are any lesions or areas of concern identified by the patient, a more detailed analysis is conducted on the affected area.~When a lesion is confirmed, the examiner verifies the results through the frozen image, while also securing the results displayed on CadAI-B.~The examiner uses the analysis from CadAI-B as a reference to make the final BI-RADS classification.~Static images and cine clips are captured from the most suspicious areas."
224044784|NCT00771563|DRUG|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
224044785|NCT04775225|DRUG|Lidocaine|denervation of the obturator and femoral genicular branches by Lidocaine 2 %
224044786|NCT04775225|DRUG|Placebo|an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
224044787|NCT04775225|DRUG|Steroid|Intra-articular injection of 80mg of triamcinolone
224044788|NCT00591825|DRUG|D-cycloserine|D-cycloserine
224141364|NCT04172909|OTHER|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
224044789|NCT00591825|DRUG|Placebo|Placebo
224141365|NCT04172909|OTHER|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
224141366|NCT03624218|BEHAVIORAL|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
224305031|NCT03929991|OTHER|Observational|To record social and clinical characteristics
223434353|NCT05866367|DRUG|Low dose Regular Insulin|Regular insulin administered intranasally at either 40 IU
223434354|NCT05866367|DRUG|High dose Regular insulin|Regular insulin administered intranasally at either 80 IU
224044790|NCT03298672|DRUG|NDX-1017|Solution of NDX-1017 for subcutaneous injection
224044791|NCT03298672|DRUG|Placebo|Placebo solution for subcutaneous injection
224044792|NCT03759977|OTHER|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
224044793|NCT04513262|PROCEDURE|mechanical ventilation during video-assisted surgery|observed variation of ventilatory parameters during video-assisted surgery
224044794|NCT03882710|DRUG|Metoprolol XR|Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
224044795|NCT01306188|BIOLOGICAL|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
224044796|NCT01306188|BIOLOGICAL|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~* The analysis of TCR and BCR repertoire diversity,~* The phenotypic analysis of immune subpopulations,~* The analysis of the global lymphopenia or subpopulations T,~* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
224044797|NCT04221932|DEVICE|CRRT KPI Reports|This will involve the regular report of CRRT KPI reports across the CRRT programs across the province. It will also include standardization of CRRT practices across Alberta. Reports will include those for the program (i.e., structure), device (i.e., process) and patient outcomes (i.e., outcomes).
224044798|NCT05774431|OTHER|There was no intervention necessary.|There was no intervention necessary.
224044799|NCT07130799|OTHER|Immunomonitoring|To analyse monocyte HLA-DR expression (mHLA-DR) and CD4+ T lymphocyte count (CD4) in both group
224044800|NCT04279054|DRUG|Morphine Sulfate 150 mcg|Use of 150mcg of morphine sulfate for neuraxial block (dosing difference)
224044801|NCT04279054|DRUG|Morphine Sulfate 50mcg|Use of 50mcg of morphine sulfate for neuraxial block (dosing difference)
224044802|NCT07128940|OTHER|Meat vs fish|Metabolite differences: Meat vs fish
224044803|NCT07128940|OTHER|Meat vs Vegetarian|Metabolite differences: Meat vs Vegetarian
224044804|NCT07128940|OTHER|Fish vs Vegetarian|Metabolite differences: Fish vs Vegetarian
224044805|NCT07130110|DIAGNOSTIC_TEST|Transbronchial cryobiopsy|The c-TBB procedure was performed under general anesthesia with rigid bronchoscopy guidance. The biopsy site was selected based on the area of highest involvement seen on thoracic CT. After evaluating the trachea and main bronchi with a rigid bronchoscope, a flexible bronchoscope was advanced into the target segment. Using a 1.9 mm, 90 cm cryoprobe, tissue was frozen and rapidly retracted with the bronchoscope to obtain the biopsy. The specimen was placed in formalin without damage. Hemorrhage control was achieved with a Fogarty balloon. A chest X-ray was taken two hours later to check for pneumothorax risk.
224044806|NCT07130110|DIAGNOSTIC_TEST|Bronchoalveolar Lavage|The BAL protocol, including pre-procedural preparations and the procedure itself, was performed in accordance with the American Thoracic Society (ATS) guidelines. In cases of diffuse involvement, BAL was performed from the middle lobe or lingula, while in localized involvement, it was done from the affected area. The target segment was occluded with the bronchoscope, and room-temperature 0.9% NaCl solution was instilled in 20 cc portions and gently aspirated to prevent airway collapse. A minimum of 100 mL (maximum 300 mL) saline was used, with at least 30% recovery required. Cellular analysis of BAL fluid was conducted per ATS guidelines. Normal cell distribution: alveolar macrophages \>85%, lymphocytes 10-15%, neutrophils ≤3%, eosinophils ≤1%, squamous/ciliated columnar epithelial cells ≤1%.
224044807|NCT07128719|DRUG|Modafinil|dose of modafinil preoperatively for for active comparator
224044808|NCT05910372|OTHER|Color Comparison Task|Participants are presented with a series of colored squares and are instructed to compare the colors of two sequentially presented stimuli.
224044809|NCT05910372|OTHER|N-back Task|Participants are presented with a sequence of letters and they must indicate whether the current stimulus matches the one presented 2 steps back in the sequence.
224044810|NCT03872232|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
224044811|NCT03872232|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
224044812|NCT00972777|DRUG|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
223434355|NCT01573416|OTHER|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
223434356|NCT01573416|OTHER|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
223434357|NCT03801824|OTHER|Standard Nutrition Therapy|Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
224044813|NCT00972777|DRUG|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
224044814|NCT01093326|DRUG|Ponesimod 10 mg|Ponesimod 10 mg oral use
224044815|NCT01093326|DRUG|Ponesimod 20 mg|Ponesimod 20 mg oral use
224044816|NCT01093326|DRUG|Ponesimod 40 mg|Ponesimod 40 mg oral use
224044817|NCT04628884|DRUG|Conventional dose|Conventional dose used to calculated the protamine dose
224044818|NCT04628884|DRUG|Dosing according residual heparin|In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
224044819|NCT04263896|DRUG|Polyethylene Glycol 3350|Participants will take 1 17g pack per day for 10 days preceding surgery.
224044820|NCT06609213|OTHER|Medical Food|Enteral nutrition formula will be used both by mouth and via feeding tube. This product is considered a medical food.
224044821|NCT07001280|OTHER|No intervention|No intervention will be administered as part of this study.
224044822|NCT07061470|DIETARY_SUPPLEMENT|Ferrous Sulfate|Dosing of the iron supplement will be based on weight.
224044823|NCT07061470|OTHER|Placebo|Placebo pills will be provided to participants in the placebo arm
224141367|NCT00570531|DRUG|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
224141368|NCT00570531|DRUG|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
224044824|NCT07128381|DRUG|Axatilimab (SNDX-6352)|Taken orally
224044825|NCT07128381|DRUG|Ruxolitinib|Taken orally
224044826|NCT07130695|DRUG|Olutasidenib Investigational Agent Administration|Twice daily olutasidenib maintenance therapy
224044827|NCT07129876|OTHER|Simulator Motion|Motion fidelity of the simulator.
224044828|NCT07130162|DIAGNOSTIC_TEST|Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)|Measurement of serum PIGU protein concentrations of patients and controls by Enzyme-Linked Immunosorbent Assay (ELISA)
224044829|NCT02765087|OTHER|Medical History|Oriented Survey and complete physical exam.
224044830|NCT02765087|DEVICE|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
224044831|NCT02765087|OTHER|Chest CT|
224044832|NCT02765087|OTHER|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
224044833|NCT04661722|OTHER|No intervention|No intervention
224044834|NCT04286087|PROCEDURE|neck incisions closed at bedside at the time of drain removal under local anesthesia|Participants allocated to the investigational group will have neck incisions closed at bedside at the time of drain removal under local anesthesia
224141369|NCT00570531|DRUG|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
224305032|NCT02657265|DEVICE|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
224305033|NCT02657265|DEVICE|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
223434358|NCT03801824|OTHER|Low Glycemic Index|Subjects will be advised to eat low glycemic index foods
224044835|NCT04286087|PROCEDURE|standard treatment|Participants in the control group will have standard treatment performed as per current practice,their incision will be left to close by secondary intention
224044836|NCT01606267|OTHER|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
224044837|NCT04389021|DEVICE|Virtual Reality|"The VR goggles have a 2560×1440 5.5 (538ppi) fast-switching LCD screen with standard 60Hz refresh, overclocked 72Hz refresh, running Android 7.1.2 Nougat with a Quad-core Qualcomm Snapdragon 821 (two 2.3GHz Kryo HP cores and two 2.15GHz Kryo cores). Adreno 530 as GPU. It is 190 x 105 x 115 mm en weighs 470 g (1.04 lbs). The goggles have built-in speakers, a controller, proximity sensor, 3DOF sensors (both headset and controller).~Any pre-procedural self-administration of pain medication will be recorded. Trained staff-members or senior residents will do all IUD insertions, according to the local protocol."
224044838|NCT05586269|BEHAVIORAL|Meal Kit Delivery|Dyads (caregiver + child) receive one meal kit delivery per week. One meal kit is designed to include two recipes and ingredients to prepare 10 servings (\~2 meals for a household 5 people). Meal kits come with printed picture-based recipes in English or Spanish and access to online cooking demonstrations.
224044839|NCT05586269|BEHAVIORAL|Newsletter + Food Pantry Referral|Dyads (caregiver + child) receive a printed newsletter in English and Spanish that lists additional local food assistance resources. Dyads receive a referral to the clinic's associated food pantry.
224044840|NCT02899078|DRUG|Ibrutinib|Given PO
224044841|NCT02899078|DRUG|Nivolumab|Given IV
223434359|NCT06473025|BEHAVIORAL|Information on Relative Nutritional Status|The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards
224044842|NCT04491383|DRUG|Tocovid Suprabio (HOV-12020)|Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol
224044843|NCT04491383|OTHER|Placebo|Dietary supplement: Placebo. Placebo.
224044844|NCT03507673|DIAGNOSTIC_TEST|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
224044845|NCT00410293|PROCEDURE|NT-proBNP testing|
224044846|NCT06964555|DRUG|Intravenous Ketamine Infusions|Ketamine group received ketamine at 0.2mg/kg bolus intravenously followed by ketamine infusion at rate of 0.2mg/kg/hr throughout the surgery.
224044847|NCT06964555|DRUG|Intravenous lignocaine|IV Lignocaine was given at the rate of 1 mg/kg/hr.
224044848|NCT01125943|DRUG|Acetylcholine|Intra-arterial infusion
223434360|NCT06473025|BEHAVIORAL|Information on Returns to Child Nutrition|The intervention involves providing information on the effects of child undernutrition on long-term health, education, and labor market outcomes.
223434361|NCT05248334|DRUG|Ranibizumab Injection|"The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed."
224044849|NCT01125943|DRUG|Nitroprusside|Intra arterial infusion
224044850|NCT01125943|DRUG|Bevacizumab|Intra arterial infusion
223565844|NCT05413512|OTHER|Acute psychological stress|Experimental: Acute psychological stress Two, acute-psychological stress tasks known to reliably elicit a cardiovascular responses (Multi-source interference task; Stroop).
223565845|NCT06570512|DEVICE|transcutaneous posterior tibial nerve stimulation|Over three weeks, the TPTNS group underwent ten sessions of electrical stimulation along the course of the posterior tibial nerve behind the medial malleoli using cup electrodes, with a width pulse of 250 microseconds, and a frequency of 20 Hz. The TENS group used a sham device with the same parameters, but the electrodes were placed behind the lateral malleoli with underpowered amplitudes.
224044851|NCT05726539|BEHAVIORAL|Group-based peer support|Receipt of semi-structured curriculum based group peer support that addresses common concerns of military spouses
224044852|NCT01641211|BEHAVIORAL|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
224044853|NCT01641211|OTHER|Nutrition video|Children in this group will watch a 2-minute nutrition video.
224044854|NCT00088907|DRUG|docetaxel|Given IV
224044855|NCT00088907|OTHER|placebo|Given orally
224044856|NCT00088907|DRUG|gefitinib|Given orally
224044857|NCT05377190|OTHER|Continuum HFC-IN|Combination of a mobile application (with remote monitoring) and digital therapeutics
224044858|NCT05377190|OTHER|Standard of care for the follow-up|No mobile application or digital therapeutics are used
224044859|NCT05377190|OTHER|Continuum HFC-OUT|Combination of a mobile application (without remote monitoring) and digital therapeutics
224044860|NCT04946825|DRUG|Nicotine replacement therapy patch|The nicotine patch is attached to the participant's skin and provides a slight constant stream of nicotine. The smaller dose is meant to reduce nicotine dependence.
224044861|NCT04946825|DRUG|Nicotine replacement therapy lozenge|The nicotine lozenge contains small amounts of nicotine, which a participant slowly dissolves in their mouth. Like the patch, the smaller dose is meant to reduce nicotine dependence.
224044862|NCT04946825|BEHAVIORAL|Quit electronic cigarettes|Participants will receive instruction and text message support to quit electronic cigarettes when they quit combustible cigarettes.
224044863|NCT04946825|BEHAVIORAL|Continue electronic cigarettes|Participants will receive instruction and text message support to continue using electronic cigarettes after they quit combustible cigarettes.
224044864|NCT03426787|BEHAVIORAL|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
224044865|NCT00005666|PROCEDURE|PET scan use in radiotherapy planning|
224044866|NCT03137186|DRUG|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
224044867|NCT02476825|DRUG|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
224044868|NCT02476825|DEVICE|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
224044869|NCT03791242|DEVICE|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
224044870|NCT04072055|DEVICE|MOTO Medial|MOTO medial unicompartmental knee system
224141370|NCT00570531|DRUG|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
224163460|NCT00912639|DRUG|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
224044871|NCT02347475|OTHER|Observational Study|Ultrasound and NIRS
224044872|NCT05510154|BEHAVIORAL|Brief advice|A single, brief advice session on switching to electronic cigarettes.
224044873|NCT05510154|BEHAVIORAL|Single Training|A single, in-depth training session on switching to electronic cigarettes.
224044874|NCT05510154|BEHAVIORAL|Training to Competency|Multiple, in-depth training sessions on switching to electronic cigarettes.
224044875|NCT05335499|DRUG|TAS5315 Dose 1|Treatment period: oral administration for 12 weeks, QD
224044876|NCT05335499|DRUG|TAS5315 Dose 2|Treatment period: oral administration for 12 weeks, QD
223434362|NCT05248334|PROCEDURE|PPV|Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
223434363|NCT05936216|BIOLOGICAL|TVI-Brain 1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
223434364|NCT02697565|BEHAVIORAL|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
223434365|NCT02697565|BEHAVIORAL|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
223434366|NCT00081796|DRUG|larotaxel (RPR109881, XRP9881)|
223434367|NCT00081796|DRUG|capecitabine|
224044877|NCT05335499|DRUG|TAS5315 Dose 3|Treatment period: oral administration for 12 weeks, QD
224044878|NCT05335499|DRUG|TAS5315 Dose 4|Treatment period: oral administration for 12 weeks, QD
224044879|NCT05335499|DRUG|TAS5315 Dose 5|Treatment period: oral administration for 12 weeks, QD
224044880|NCT05335499|DRUG|Placebo|"* Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD"
224044881|NCT02020863|DEVICE|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
224044882|NCT01491048|PROCEDURE|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
224044883|NCT01491048|PROCEDURE|No physiotherapy after THA|No physiotherapy after THA
224044884|NCT01226823|DRUG|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
224044885|NCT01226823|DRUG|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
224044886|NCT02713035|BEHAVIORAL|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
224044887|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
224044888|NCT01437696|DIETARY_SUPPLEMENT|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
224044889|NCT01437696|OTHER|placebo|No liquid cholecalciferol will be added to the food.
224044890|NCT00274404|DRUG|valacyclovir|
224044891|NCT01033656|DRUG|anakinra|100 mg subcutaneous injection daily
224044892|NCT01033656|DRUG|comparators|po drugs, comparators
224044893|NCT05241509|DRUG|Cymbopogon citratus (lemongrass) oil gel|Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
224044894|NCT00004022|BIOLOGICAL|aldesleukin|
223434368|NCT02707471|BEHAVIORAL|SM-AET|self-management for improving adherence and reducing symptom interference (SM-AET)
223434369|NCT02707471|BEHAVIORAL|general health education|general health education intervention that focuses on improving overall health.
224044895|NCT00004022|BIOLOGICAL|autologous tumor cell vaccine|
223434370|NCT06500923|OTHER|Oral rehabilitation by means of implant-supported single unit crowns|Surgery: Implant placement; Prothetic rehabilitation: single unit crown
223434371|NCT01763138|BEHAVIORAL|oral health education|oral health education in the form of a pictorial pamphlet.
223434372|NCT01763138|BEHAVIORAL|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
224044896|NCT00004022|BIOLOGICAL|muromonab-CD3|
224044897|NCT00004022|BIOLOGICAL|therapeutic autologous lymphocytes|
224044898|NCT00004022|PROCEDURE|surgical procedure|
224044899|NCT05170425|DEVICE|Prospera|"Prospera™ detects allograft rejection noninvasively and with high accuracy by measuring the fraction of donor derived cell-free DNA (dd-cfDNA) in the patient's blood, without the need for prior donor or recipient genotyping.~Prospera is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
224044900|NCT04764851|DRUG|ecopipam HCl ~2mg/kg/day|oral tablet
224044901|NCT04764851|COMBINATION_PRODUCT|Cohort 1 Probe Cocktail|dextromethorphan, caffeine, omeprazole, and midazolam
224044902|NCT04764851|COMBINATION_PRODUCT|Cohort 2 Probe Cocktail|dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam
224044903|NCT04764851|COMBINATION_PRODUCT|Cohort 3 Probe Cocktail|bupropion
224044904|NCT01526044|DEVICE|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
224044905|NCT03247036|DRUG|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
224044906|NCT01968395|DRUG|Caspofungin 70 mg|Intravenous use
224044907|NCT04110964|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
224044908|NCT03956316|DEVICE|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
224044909|NCT01145716|PROCEDURE|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
224141371|NCT00570531|RADIATION|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
224141372|NCT00570531|PROCEDURE|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
224141373|NCT05085431|BIOLOGICAL|Assigned Interventions CD19/BCMA CAR T-cells|Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
224141374|NCT01797991|DRUG|Dexamethasone per os|
224044910|NCT05024305|DRUG|TWP-102 injection|IV infusion
224044911|NCT02742597|BEHAVIORAL|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
224141375|NCT01797991|DRUG|Matching placebo for dexamethasone IV|
223434373|NCT05673096|BEHAVIORAL|PACT|Paediatric Autism Communication Therapy
223434374|NCT05673096|BEHAVIORAL|MAU|Management as usual
224044912|NCT01794533|DRUG|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
224044913|NCT01794533|DRUG|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
224044914|NCT01671020|DRUG|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
224044915|NCT01671020|DRUG|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
224141376|NCT01797991|DRUG|Dexamethasone IV|
224044916|NCT05803408|OTHER|gluten-free oats|Early vs late introduction of gluten free oats
224044917|NCT00558155|DRUG|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
224044918|NCT00558155|DRUG|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
224141377|NCT01797991|DRUG|Matching placebo for dexamethasone per os|
224141378|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|DDD+/-R pacing
224141379|NCT01481168|DEVICE|Pacemaker implantation (Medtronic)|ODO pacing
224141380|NCT01481168|DEVICE|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
224141381|NCT00960258|DRUG|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
224141382|NCT04894812|OTHER|Neurodevelopmental technique|"1. st month: postural maintenance; exercises with weight on forearms and hands, in sitting, crawling, semi-kneeling and standing positions with support from therapist.~2. nd month: balance and corrective reactions; using CP ball and tilt board.~3. rd month: ambulation training; appropriate to motor development level (crawling, creeping, walking in a semi-kneeling position and walking between parallel bars)."
224141383|NCT05220761|DIAGNOSTIC_TEST|Cornell Assessment of Pediatric Delirium|Cornell Assessment of Pediatric Delirium is a diagnostic test for PICU delirium State Behavioral Scale and Richmond Agitation and Sedation Scale are diagnostic tests for sedation and agitation in children
223434375|NCT00919997|GENETIC|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
224141384|NCT02292992|DEVICE|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
224141385|NCT01747785|OTHER|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
224141386|NCT01747785|OTHER|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
223434376|NCT00919997|GENETIC|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
223434377|NCT00919997|OTHER|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
223434378|NCT00919997|OTHER|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
223434379|NCT00919997|OTHER|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
224044919|NCT00558155|DRUG|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
224044920|NCT00558155|DRUG|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
224044921|NCT00907257|DRUG|benzoyl peroxide wash|5% benzoyl peroxide wash
224044922|NCT00907257|DRUG|Tretinoin gel|0.04% tretinoin gel
224044923|NCT02616757|DEVICE|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
224044924|NCT05340725|DRUG|DEX-IV|patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.
224141387|NCT01747785|OTHER|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
224141388|NCT01158729|DRUG|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
224044925|NCT05340725|DRUG|DEX-Rectal|Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
224044926|NCT05340725|DRUG|DEX-Nano-Rectal|Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia
224044927|NCT04414371|OTHER|Yoga|Yoga Namaskar and Nadi Shuddhi
224044928|NCT01338623|DRUG|Tansulosine|capsule 0,4 mg
224044929|NCT03712436|COMBINATION_PRODUCT|Palliative care|The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
224141389|NCT01158729|OTHER|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
224044930|NCT03712436|COMBINATION_PRODUCT|Standard oncological care|Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
224141390|NCT00216177|DRUG|Infliximab|Remicade
224141391|NCT00216177|DRUG|Adalimumab|Humira
224141392|NCT01769703|DRUG|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
224141393|NCT03271788|OTHER|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
224141394|NCT03201887|BEHAVIORAL|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
223434380|NCT00919997|PROCEDURE|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
223434381|NCT03374670|DRUG|Zimura|Zimura in combination with Eylea
223434382|NCT03374670|DRUG|Eylea|Zimura in combination with Eylea
223434383|NCT03644056|DRUG|IMC-001|Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
223434384|NCT04996511|DEVICE|PulseOn|Postoperative HRV measurement
223565846|NCT06341881|BEHAVIORAL|Transitional Care Training Program|A nursing based transitional care training intervention would be carried out to prepare the family caregivers to take care of their elderly stroke survivors at home. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the family caregivers at their homes after hospitalization. The study participants would be evaluated after 8 weeks of the intervention. A structured, validated and literature based assessment checklist will be devised to assess the usefulness and feasibility of the intervention. Assistance of senior nurses and health professionals, specialized in stroke care will be taken during the training part of the program.
224044931|NCT05102851|DIAGNOSTIC_TEST|Troponin, Lipid profile, HBA1C, Fasting blood glucose level, Creatinine, Body Mass Index|Full history: age, sex, smoking, known diabetes, positive family history high serum creatinine, history of prior percutaneous coronary intervention (PCI) or coronary arteries bypass grafting (CABG), or acute coronary syndrome (ACS). hypertension, diet.
224044932|NCT00283049|DRUG|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
224044933|NCT00283049|DRUG|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c \>6.5%)
224044934|NCT00194181|DRUG|TPA Infusion|
224141395|NCT03201887|BEHAVIORAL|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
224141396|NCT05830188|BEHAVIORAL|Coping and Resilience Intervention for Adolescents|It is a school-based resilience enhancement program to help adolescents build skills of positive coping and social support to minimize negative coping and distress by sharing, identifying, and discussing their feelings, thoughts, and actions regarding problems and stressful events.
224141397|NCT05830188|OTHER|Printing materials of Coping and Resilience Intervention for Adolescents|Printing materials for the CERIA sessions will be given to school counselors who provide school counseling programs in the control group.
224141398|NCT04305886|OTHER|Discussion Guide|Written list of prompts to facilitate discussion
224141399|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
224141400|NCT03691610|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
224141401|NCT03691610|BIOLOGICAL|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
224141402|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
224141403|NCT03691610|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
224141404|NCT03691610|BIOLOGICAL|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
223434385|NCT03803228|DRUG|DUOSTIM|2 consecutive stimulations by Fertistartkit® on the same cycle
223434386|NCT03803228|DRUG|Conventional stimuli|2 stimulations by Fertistartkit® performed on 2 different cycles
223434387|NCT00204282|BEHAVIORAL|Educational presentation, group discussion, questionnaires|
223434388|NCT04160572|BEHAVIORAL|Morning sleep schedule|sleep right after night shifts
223434389|NCT04160572|BEHAVIORAL|Evening sleep schedule|sleep before night shifts
223434390|NCT05795920|DRUG|Utidelone injection in combination with gemcitabine|Utidelone injection: 30mg/m2, for days 1-5, once a day, 21 days for a treatment week Period; Gemcitabine: 1000mg/m2, Q3W on day 1 and day 8, 21 days for a treatment cycle
224044935|NCT01068197|BEHAVIORAL|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
223434391|NCT03747302|OTHER|Social Media Message about HPV and HPV vaccine|Messages educate parents with facts about HPV vaccination.
223434392|NCT03747302|OTHER|Social media message about risk of electronic cigarettes.|Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
223434393|NCT00583375|DEVICE|Augment® Bone Graft|Augment® Bone Graft
224044936|NCT03269851|RADIATION|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
224141405|NCT03691610|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
224141406|NCT03691610|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
224141407|NCT03691610|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
224141408|NCT03691610|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
224141409|NCT03691610|BIOLOGICAL|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
224141410|NCT01680588|DRUG|[18F]NAV4694|
224141411|NCT01662297|DRUG|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
224141412|NCT01662297|DRUG|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
224141413|NCT00122356|DRUG|Alendronate sodium|70mg tablets, once weekly
224141414|NCT02055430|PROCEDURE|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
223434394|NCT00583375|PROCEDURE|Standard of Care|Autologous Bone Graft
223565847|NCT03848130|OTHER|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
224044937|NCT05594316|DRUG|Trichloroacetic acid|5\. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
224141415|NCT02055430|PROCEDURE|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
224141416|NCT02055430|PROCEDURE|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
224044938|NCT05008536|BIOLOGICAL|Anti-BCMA CAR-NK Cells|1-3×10\^6 /KG, 3-6×10\^6 /KG, 0.6-1.2×10\^7/KG Treatment follows a lymphodepletion
224141417|NCT02938052|BEHAVIORAL|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
223434395|NCT06032520|BEHAVIORAL|FAST|FAST includes around 3 hours of face-to-face direct treatment time weekly and consists of a maximum of 10% online direct treatment time (i.e., treatment via phone, video-calling or texting). The treatment stage of FAST lasts five to nine months depending on the individual goals of the juvenile and the caregiver(s) and is followed by a period of aftercare.
223434396|NCT02645552|DRUG|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
223434397|NCT02645552|OTHER|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
223434398|NCT03059199|BEHAVIORAL|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
224141418|NCT02681952|DRUG|Renamezin capsule|
224141419|NCT02681952|DRUG|Kremezin granule|
224141420|NCT00202111|PROCEDURE|Laparoscopic-assisted colectomy|
224141421|NCT00202111|PROCEDURE|Conventional open colectomy|
224141422|NCT00679731|DRUG|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
224141423|NCT00679731|DRUG|Methotrexate|5.0 to 25 mg weekly
224141424|NCT02022696|GENETIC|Lentiviral Gene Transfer|
224141425|NCT00208312|DRUG|Regadenoson|0.4 mg, bolus intravenous injection
224141426|NCT00208312|DRUG|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
224141427|NCT02438995|DRUG|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
224141428|NCT05338957|DRUG|MRG002+HX008|Administrated intravenously
224141429|NCT04121312|BEHAVIORAL|Facilitation Intervention|"See arm description"
223434399|NCT00919906|DEVICE|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
223434400|NCT06498089|DRUG|Prednisone|This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.
223434401|NCT06498089|DRUG|Methotrexate|This drug will be used in the traditional arm. A dose of 15mg per week will be used.
223434402|NCT06498089|DRUG|Tocilizumab|This drug will be used in the precise treatment arm. For patients in constitutional type a dose (8mg/kg weight) will be used every 2 weeks (iv drip) for 12 weeks, then a dose (8mg/kg weight) will be used every 4 weeks (iv drip). For patients in vascular inflammation type, a dose (8mg/kg weight) will be used every 4 weeks (iv drip).
223434403|NCT06498089|DRUG|Tofacitinib|This drug will be used in the precise treatment arm. A sustained release tablet will be used (11mg per day).
224044939|NCT05008536|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
224044940|NCT05008536|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
224299777|NCT03502525|BEHAVIORAL|Bacterial Infection Prevention|Bacterial Infection Prevention is an attention control intervention. The content of Bacterial Infection Prevention is representative of the infection prevention information injection drug users ought to receive, and sometimes do, when they engage with service providers, such as syringe exchange programs. Bacterial Infection Prevention does not use Motivational Interviewing principles, but is more informational/educational in nature. This intervention focuses on bacterial infection risks that accompany injection drug use, with a special focus on risk reduction, identification, and treatment of abscesses and endocarditis.
223434404|NCT06498089|DRUG|Adalimumab|This drug will be used in the precise treatment arm. A dose of 40mg (ih) will used every 2 weeks.
223434405|NCT03448939|DRUG|S5G4T-1|Once a day topical cream
223434406|NCT03448939|DRUG|S5G4T-2|Once a day topical cream
223434407|NCT05055934|DRUG|SHR-1314 injection|SHR-1314 injection
223434408|NCT05055934|DRUG|placebo|placebo
223434409|NCT03461016|BEHAVIORAL|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure \[is\] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
223434410|NCT00040235|PROCEDURE|magnesium|
223434411|NCT05525234|DRUG|Thalidomide|Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
223434412|NCT05525234|DRUG|Placebo|Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
224044941|NCT01086410|DRUG|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
224044942|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
224044943|NCT01086410|DRUG|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
224044944|NCT01086410|DRUG|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
224044945|NCT01086410|DRUG|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
224044946|NCT06319313|DRUG|JMT101|JMT101, 6 mg/kg, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). or 9 mg/kg, IV infusion once every 3 weeks.
224044947|NCT06319313|DRUG|docetaxel|50 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 75 mg/m2, IV infusion once every 3 weeks.
224044948|NCT06319313|DRUG|HB1801|75 mg/m2, IV infusion once every 2 weeks (one treatment cycle is 4 weeks). Or 100 mg/m2, IV infusion once every 3 weeks.
224044949|NCT02047682|BEHAVIORAL|Biopsychosocial|
224044950|NCT02047682|BEHAVIORAL|Reference|
223434413|NCT03619824|DRUG|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
223434414|NCT03619824|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
223434415|NCT03619824|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
224044951|NCT00171444|BEHAVIORAL|Medical education|
224044952|NCT03569046|DRUG|local anaesthetic injection|ear block by 0.25% bupivacaine
224044953|NCT03569046|DRUG|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
224044954|NCT03569046|DRUG|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
224044955|NCT03569046|DRUG|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
224044956|NCT01386918|DEVICE|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
224044957|NCT03921320|PROCEDURE|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
224044958|NCT03921320|PROCEDURE|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
224044959|NCT03921320|PROCEDURE|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
224044960|NCT01145014|DRUG|BI 660848|2 mg oral drinking solution
224044961|NCT01145014|DRUG|BI 660848|10 mg oral drinking solution
224044962|NCT01145014|DRUG|BI 660848|20 mg oral drinking solution
224044963|NCT01145014|DRUG|BI 660848|50 mg oral drinking solution
224044964|NCT01145014|DRUG|BI 660848|100 mg oral drinking solution
224044965|NCT01145014|DRUG|BI 660848|150 mg oral drinking solution
224044966|NCT01145014|DRUG|BI 660848|200 mg oral drinking solution
224044967|NCT01145014|DRUG|BI 660848|400 mg oral drinking solution
224163461|NCT03380169|OTHER|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
224163462|NCT03380169|OTHER|Prophylactic conventional wound dressing|Conventional gauze dressing
224163463|NCT00673218|DRUG|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
224163464|NCT00673218|DRUG|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
224299778|NCT06158048|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
224299779|NCT06158048|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (0.5 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.1 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
224299780|NCT04737421|DEVICE|NobelActive TiUltra implant|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
224299781|NCT04737421|DEVICE|NobelParallel CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
223434416|NCT03619824|RADIATION|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
223434417|NCT06380803|OTHER|A educational program|A educational program using cadaver or porcine models for robotic brest surgery
223434418|NCT01744002|OTHER|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
223434419|NCT01744002|OTHER|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
223434420|NCT00894790|DRUG|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
223434421|NCT00894790|DRUG|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
223434422|NCT02482064|OTHER|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
223434423|NCT03013764|BEHAVIORAL|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
223434424|NCT03013764|BEHAVIORAL|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
223434425|NCT06730802|DRUG|PCSK9 inhibitor|the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
224163465|NCT02230787|DEVICE|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
224163466|NCT02230787|DEVICE|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
224163467|NCT03723811|DRUG|SJP002 BID|1 drop b.i.d for 12 weeks
224163468|NCT03723811|DRUG|SJP002 QID|1 drop q.i.d for 12 weeks
224163469|NCT03723811|DRUG|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
224163470|NCT03723811|DRUG|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
224163471|NCT04527536|DIAGNOSTIC_TEST|Neonatal hyperbilirubinemia|Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
224163472|NCT05126654|DIETARY_SUPPLEMENT|Partially Hydrolyzed Guar Gum (PHGG)|Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
224163473|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
224163474|NCT00444951|BIOLOGICAL|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
224163475|NCT00444951|BIOLOGICAL|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
224163476|NCT06139445|OTHER|Manual Lymphatic Drainage|Manual lymphatic drainage (MLD), one of the components of complex decongestive physiotherapy, is a gentle massage technique with proven positive effects on lymphatic circulation. MLD can be applied to different parts of the body (e.g., arms, legs, neck, abdomen, and trunk), with a different technique for each region (stationary circle, scoop, pump, and rotary)
224163477|NCT06139445|OTHER|Plasebo Group|random superficial touches not involved in any manual technique
224163478|NCT01998906|DRUG|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
224163479|NCT01998906|DRUG|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
224163480|NCT01998906|DRUG|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
224163481|NCT01998906|DRUG|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
224163482|NCT05148559|BEHAVIORAL|Reminder Sent Via Preferred Method of Communication|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a vaccine reminder notice every other month via their preferred method of communication (text message, email, mailed letter) until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
224163483|NCT05148559|BEHAVIORAL|Reminder Sent Via Mailed Letter|Parents of 12 year-old patients due for ≥1 adolescent vaccine will receive a mailed vaccine reminder letter every other month until the adolescent receives all recommended vaccines, opts out of reminders, or turns 13.
224163484|NCT00230373|DRUG|imiquimod 5% cream (Aldara)|
224163485|NCT03508245|OTHER|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
224163486|NCT04115891|OTHER|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
224163487|NCT04115891|OTHER|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
224044968|NCT01145014|DRUG|BI 660848|600 mg oral drinking solution
224044969|NCT01145014|DRUG|BI 660848|10,0 mg immediate release tablet
224044970|NCT01145014|DRUG|BI 660848|50,0 mg immediate release tablet
224044971|NCT01145014|DRUG|Placebo|matching placebo (oral drinking solution and IR tablets)
224141430|NCT06048237|DIAGNOSTIC_TEST|Diagnostic Ultrasound Imaging of the diaphragm|"In this reliability study, ultrasound imaging will be utilized by trained physiotherapists to assess diaphragm thickness and excursion. Participants will be positioned in a semi-recumbent position, while the scanning area will be marked with a surgical skin marker according to specific anatomical landmarks recommended, to ensure reproducibility of the procedure. Ultrasound probe will be placed at the zone of apposition to visualize the diaphragm through the liver window.~Diaphragm thickness will be assessed during both full inhalation and exhalation, capturing images in B-mode to measure distance between the diaphragmatic pleura and peritoneal fascia. Diaphragm excursion will be assessed during tidal volume diaphragmatic breathing, using M-mode to track the craniocaudal displacement of the diaphragm during respiratory cycle. Data obtained will contribute to the evaluation of the reliability of diaphragm thickness and excursion measurements for potential future clinical applications."
224141431|NCT05349058|DRUG|Immune Checkpoint Inhibitors|Patients receive Immune Checkpoint Inhibitor as per oncology protocol
224141432|NCT00669916|BIOLOGICAL|AIN457|single infusion of 3 mg/kg
224141433|NCT00669916|DRUG|Placebo|single infusion of placebo
224141434|NCT04296526|BEHAVIORAL|Exercise Prescription|To prescribe exercise programs that can be easily applied at home/dormitory/living place for students.
224141435|NCT04296526|BEHAVIORAL|Exercise Education|To organize sessions for how to proper exercise.
224141436|NCT04296526|BEHAVIORAL|Social Support|Supports such as peer influence or reminder phone messages
224141437|NCT00535015|DRUG|Betamarc|2 tabs BID
224141438|NCT02289482|DRUG|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
224141439|NCT02289482|DRUG|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
224299782|NCT04737421|DEVICE|NobelReplace CC TiUltra implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
224299783|NCT04737421|DEVICE|Nobel Biocare N1 TiUltra TCC implants|Subjects will be enrolled and treated with one of the above groups as per the their clinical requirement and standard of care of the clinic.
224299784|NCT06274164|DIAGNOSTIC_TEST|Electroencephalography/Polysomnography (EEG/PSG)|Instigators will determine if subjects are candidate for the procedure. A sleep study records the brain electrical waves, the oxygen level in the blood, heart rate breathing, as well as eye and leg movements. Subjects will need to be admitted overnight for the sleep study.
224299785|NCT06274164|PROCEDURE|Skin Biopsy|A special 3-4 mm (0.12 inches) wide circular tool will be used to remove a small section of skin including deeper layers. A numbing cream or injectable anesthetic (i.e. lidocaine) will be applied to the area before the procedure. Sample will be used to create a cell line. This means that investigators would treat the cells from the sample in a way that allows to grow them in the laboratory. Investigators will then use these cells in research.
224299786|NCT06274164|DIAGNOSTIC_TEST|Blood draw|A single blood sample of 15 cc (not exceeding 3 cc per kg) (\~3 teaspoons) will be collected for metabolomics (biomarker) study. From available family members, same amount of blood will be obtained to use as a control sample.
224299787|NCT06491511|PROCEDURE|Transcutaneous, repetitive phrenic nerve electrical stimulation|Phrenic nerve electrical stimulation with different stimulation intensity and frequency
224299788|NCT04155034|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224299789|NCT04155034|RADIATION|Prophylactic Cranial Irradiation|Undergo PCI
224299790|NCT05447923|OTHER|Educational Intervention|Undergo education for colorectal cancer screening
224299791|NCT05447923|OTHER|Fecal Immunochemical Test|Undergo FIT testing
224299792|NCT05447923|BEHAVIORAL|Patient Navigation|Undergo patient navigation for positive FIT results
224299793|NCT05447923|OTHER|Questionnaire Administration|Complete questionnaire about colorectal cancer screening and healthcare
224299794|NCT06432660|OTHER|Data collection|Information about radiation therapy via eye plaque brachytherapy and follow up
224299795|NCT05557357|PROCEDURE|Electroacupuncture (EA)|"Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11."
224044972|NCT04196803|DIETARY_SUPPLEMENT|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
224044973|NCT04196803|DIETARY_SUPPLEMENT|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
224141440|NCT02289482|DRUG|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
224141441|NCT02289482|DRUG|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
223434426|NCT06730802|DRUG|Statin|the control group will receive standard statin therapy.
223434427|NCT04575259|DRUG|ANAVEX2-73|Oral capsules
224044974|NCT01033526|DRUG|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
223434428|NCT01733459|DRUG|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
223434429|NCT01733459|DRUG|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
223434430|NCT01733459|DRUG|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
223434431|NCT01733459|DRUG|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
224044975|NCT01033526|DRUG|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
224044976|NCT06348550|DIETARY_SUPPLEMENT|Berberol® K|Nutraceutical containing an association of Berberine Fitosoma® and Monacolin K MonaKoPure®
224044977|NCT06348550|DIETARY_SUPPLEMENT|Placebo|Placebo
224044978|NCT04742881|PROCEDURE|Low pressure + microsurgical instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of microsurgical instruments (3mm and 5mm instruments)
224044979|NCT04742881|PROCEDURE|Low pressure + standard instruments|Low pressure pneumoperitoneum ((≤ 8 mmHg) and use of standard instruments (5mm and 10mm instruments)
224044980|NCT01022996|DRUG|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
224044981|NCT02675842|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
224141442|NCT05692648|BEHAVIORAL|Supine position group|These neonates were placed in supine position, fed every 2 hours in accordance with routine clinical practice, and then returned to supine position.
224141443|NCT05692648|BEHAVIORAL|Hourly position change group|"Infants in this group were repositioned every hour based on the time of phototherapy initiation. Neonates were initially placed in supine position and then changed to the prone position. Infants were alternated between supine and prone positions every hour for 24 hours."
224141444|NCT05692648|BEHAVIORAL|Control Group (2-hour position change)|Neonates in this group were repositioned every 2 hours as routine practice based on the time of phototherapy initiation. Phototherapy was started with neonates in supine position. In the second period, the neonate was placed in the prone position after routine feeding was performed.
224141445|NCT01981278|DRUG|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
224044982|NCT02675842|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
224141446|NCT01981278|DRUG|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
224141447|NCT01969799|DRUG|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
224141448|NCT01969799|DRUG|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
224141449|NCT06687122|DIETARY_SUPPLEMENT|3 whole eggs|Participants will be free-living and will not be supplied with any other food except for the eggs during the intervention period with no restrictions of energy intake.
224141450|NCT00289562|DRUG|forodesine hydrochloride (BCX-1777)|
224141451|NCT03828149|COMBINATION_PRODUCT|Drug:OP0201|Drug: OP0201
223434432|NCT03039491|BIOLOGICAL|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
223434433|NCT03039491|BIOLOGICAL|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
223434434|NCT02317770|DRUG|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
223434435|NCT02317770|DRUG|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
223434436|NCT00140530|DEVICE|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
224044983|NCT03832803|BEHAVIORAL|Empty bladder|No drinking protocol.
224044984|NCT03832803|BEHAVIORAL|Full bladder|Followed drinking protocol
224044985|NCT03059095|BEHAVIORAL|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
224044986|NCT00453648|OTHER|White-fleshed sweet potatoes|
224044987|NCT00453648|OTHER|Orange-fleshed sweet potatoes (boiled)|
224044988|NCT00453648|OTHER|Orange-fleshed sweet potatoes (fried)|
224044989|NCT00453648|OTHER|WFSP and capsule of retinyl palmitate|
224044990|NCT03251027|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
224044991|NCT03251027|OTHER|Quality-of-Life|Ancillary studies
224044992|NCT00930722|DRUG|quinapril|per label as non interventional study
224044993|NCT02146742|DRUG|ASP1707|oral
223434437|NCT00140530|DEVICE|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
224044994|NCT02146742|DRUG|Placebo|oral
224044995|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
224044996|NCT01292382|DEVICE|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
224141452|NCT03828149|COMBINATION_PRODUCT|Drug: Placebo|Drug: Placebo
223434438|NCT04812340|OTHER|High intensity circuit training|6 series with 3 minutes rest between the series. each series will consist of 30 seconds each of burpees, skipping, lunges, 1- legged squat, leg levers, and push-ups with 30 seconds rest in between. the volume of exercise will be increased progressively over a period of 8 weeks.
223434439|NCT04812340|OTHER|Low intensity interval training|4 series with 3 minutes rest in between. each series will consist of 10 minutes of jogging and 5 minutes walking with 30 seconds recovery in between. the volume of exercise will be increased progressively over a period of 8 weeks.
224141453|NCT04568941|BEHAVIORAL|Vacuum-Assisted Biopsy|Vacuum-Assisted Biopsy
224141454|NCT04568941|BEHAVIORAL|Core Needle Biopsy|Core Needle Biopsy
223565848|NCT03848130|OTHER|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
223434440|NCT05480865|DRUG|BBP-398|BBP-398 administered orally
223434441|NCT05480865|DRUG|sotorasib|sotorasib administered orally
223434442|NCT00002644|DRUG|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
224044997|NCT01377025|DRUG|Placebo|two tablets in the morning and two in the evening.
223434443|NCT00002644|OTHER|Placebo|Placebo 20Mg Tab
223434444|NCT01472965|DRUG|ethanol|70% ethanol catheter lock therapy
223434445|NCT01472965|DRUG|heparin-saline placebo|heparin-saline placebo catheter lock therapy
223434446|NCT05995457|OTHER|"Intramuscular injection of Haloperidol decanoate using the Z-track and Airlock techniques"|"Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the Z-track and Airlock techniques"
223434447|NCT05995457|OTHER|Intramuscular injection of Haloperidol decanoate using standard techniques|Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.
224044998|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
224141455|NCT04568941|BEHAVIORAL|Intraoperative Excisional Biopsy|Intraoperative Excisional Biopsy
224163488|NCT04115891|OTHER|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
223434448|NCT03005457|BEHAVIORAL|Hemiparesis Therapy with VR|An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
223434449|NCT00628095|DRUG|CE-224,535|500 mg po BID
223434450|NCT00628095|DRUG|Placebo|no active ingredient
223434451|NCT02555124|DRUG|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
223434452|NCT02555124|DRUG|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
223434453|NCT02555124|DRUG|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
223434454|NCT02555124|DRUG|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
223434455|NCT05234034|OTHER|online survey|participantion consists of filling in an online survey that will take approximately 53 minutes. An adapted battery of questionnaires is provided for each subgroup.
223434456|NCT01576003|DRUG|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
223434457|NCT01576003|DIETARY_SUPPLEMENT|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
223434458|NCT00189319|DRUG|Flecainide controlled release|
223478465|NCT05041686|COMBINATION_PRODUCT|CADISS® System|"The CADISS® device was procured from AuXin Surgery. It consists in three elements:~1. A single use disposable Remote Kit, containing a sterile cartridge, which prepares the Drug Product immediately before use, and the sterile tubing for fluid connexion. The Drug Product is a 30 ml sterile 5% mesna solution of pH 7.3+/-0.5 2.~2. Reusable stainless steel noncutting mechanical instruments similar to those used in the normal practice, except for the provision of an internal irrigation channel bringing the Drug Product at the working edge.~3. A pedal controlled electric motor driving the peristaltic cassette included in the disposable tubing in order to control the dispensing of the Drug Product during the procedure."
223478466|NCT04933565|DRUG|ORG-129|ORG-129 oral capsules
223478467|NCT04933565|DRUG|Placebo|Placebo oral capsules
224044999|NCT01377025|DRUG|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
224045000|NCT05242055|OTHER|Integrated diagnosis and treatment for CKD|This is an observational study. Investor will not intervene the clinical practice of doctors. In the real world, there would be many factors affect the proceeding of the guidelines contents. There will be integrated diagnosis and treatment during follow-up.
224045001|NCT05353049|BEHAVIORAL|Bathing technique based on Basale Stimulation|"The relaxing somatic modelling technique will be applied, framed within the concept of Basal Stimulation®. To do this, the user remains seated and the parts of the body that are not being washed at that moment are covered with a towel, favouring the preservation of the user's privacy. The user is lathered up with soft mittens previously moistened with lukewarm water and lathered up. This process shall be carried out starting from the shoulder in a proximal to distal direction on the upper limbs, lower limbs and trunk (taking into account the sagittal anatomical plane) and in a cephalic to caudal direction (taking into account the transverse anatomical plane).~Subsequently, rinsing is carried out following the same guidelines as described above, using moistened soft mittens. Finally, intimate hygiene is performed with a disposable soapy sponge and the soap is rinsed off again with moistened soft terrycloth mittens. Throughout the whole process, the activity is explained to the user."
224045002|NCT02075242|DRUG|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
224045003|NCT02075242|DRUG|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
224045004|NCT03040791|DRUG|Nivolumab|Nivolumab
224045005|NCT02649049|OTHER|there is no intervention|
223434459|NCT06721221|DEVICE|Point-by-point PVI with the QDot Micro catheter in QMODE+ setting with the Svtag software|PVI will be performed via femoral access after transseptal puncture, guided by fluoroscopy pressure monitoring, intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE). A fast anatomical left atrial map will be created; then, point-by-point PVI will be performed with QDot Micro catheter in QMODE plus with the Svtag software. Inter-tag distance should be ≤ 6 mm on the posterior wall and ≤ 4 mm on the anterior wall. All applications' duration should be 4 seconds. After creating the isolation circle, the presence or absence of first-pass isolation will be assessed on each side by the presence of entrance block. If PVI is complete, this is defined as first-pass isolation. If PVI is not complete at this point, touch-up lesions will be delivered to reach the isolation of all pulmonary veins. After that, acute PV reconnections will be evaluated during a 20 minutes waiting period.
224045006|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with midurethral tension free tape.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
224045007|NCT04101279|PROCEDURE|surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
224045008|NCT01724840|PROCEDURE|GraftJacket|Interposition with GraftJacket
224045009|NCT01724840|PROCEDURE|Tendon Interposition|Tendon Interposition with the FCR tendon
224045010|NCT01069120|DRUG|Proellex|2, 25 mg capsules once per day
224141456|NCT03337139|BEHAVIORAL|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
223434460|NCT03235115|DEVICE|Methafilcon A IV|Contact Lens
223434461|NCT03235115|DEVICE|Ocufilcon B|Contact Lens
223434462|NCT03235115|DEVICE|Omafilcon A|Contact Lens
223434463|NCT05654506|DRUG|Daratumumab|1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
224045011|NCT01069120|DRUG|Proellex|1, 25 mg capsule once per day
224045012|NCT00299052|DEVICE|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
224045013|NCT00299052|BIOLOGICAL|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
224045014|NCT04254588|OTHER|Abdominal examination|Examination by in-person physician vs. remote physician.
224045015|NCT05588466|OTHER|CDS Alone|The practices in the 'CDS alone' arm will receive an updated CDS for HTN management.
224045016|NCT05588466|OTHER|CDS plus practice facilitation|The practices in the 'CDS plus practice facilitation' arm will receive an updated CDS for HTN management plus practice facilitation to support the adoption of the CDS.
224045017|NCT05097716|DRUG|Ritlecitinib|Ritlecitinib 200 mg provided as four 50 mg oral capsules
224141457|NCT03337139|BEHAVIORAL|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
223434464|NCT00848978|BEHAVIORAL|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity \~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
223434465|NCT00771511|DRUG|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
223434466|NCT00771511|DRUG|Placebo|Only lidocaine gel will be appled to the cervix
224045018|NCT05097716|DRUG|Tolbutamide|Tolbutamide 500 mg provided as one 500 mg oral tablet
224045019|NCT02420132|OTHER|Ranibizumab|Ranibizumab administered as part of standard-of-care
224045020|NCT01875536|DEVICE|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
224045021|NCT01875536|BEHAVIORAL|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
224045022|NCT04229511|DIAGNOSTIC_TEST|Detection of CRKp colonization|Detection of CRKp colonization will be performed in all participants by sceening with rectal swab
224045023|NCT02560064|PROCEDURE|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
224045024|NCT04288830|BEHAVIORAL|Tai Chi Moving Mindfulness Meditation and Resilience Training|Low-impact mind-body exercise adapted from traditional tai chi.
224045025|NCT04288830|BEHAVIORAL|Aerobic Exercise|Low-impact aerobic exercise, led by instructor
223478468|NCT04596293|DRUG|BBT-401-1S or Placebo|Administered by 200mg capsules of BBT-401-1S or placebo
224045026|NCT05286983|BEHAVIORAL|Family Centred Care (FCC) interventions as potentially better practices (PBPs)|"After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness"
224045027|NCT04872348|DEVICE|OMNI® Surgical System|The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
224045028|NCT01754857|DRUG|Bendamustine|Given IV
224045029|NCT01754857|DRUG|Rituximab|Given IV
224045030|NCT01754857|DRUG|Lenalidomide|Given PO
224045031|NCT01509079|DRUG|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
224045032|NCT01509079|DRUG|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
224045033|NCT03664154|BEHAVIORAL|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
224045034|NCT01925352|DRUG|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
224045035|NCT03910712|DRUG|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
224045036|NCT03910712|DRUG|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
224045037|NCT03910712|DRUG|Aromatase inhibitor|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
224141458|NCT03337139|BEHAVIORAL|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
224141459|NCT06885125|DIETARY_SUPPLEMENT|anti-inflammatory diet|The anti-inflammatory diet consists of a 12-week plant-based diet, followed by guidance and monitoring from a nutritionist.
224141460|NCT00077376|BIOLOGICAL|trastuzumab|Given IV
224141461|NCT00077376|DRUG|ixabepilone|Given IV
224141462|NCT00077376|DRUG|carboplatin|Given IV
224141463|NCT00077376|OTHER|laboratory biomarker analysis|Correlative studies
224141464|NCT03288493|BIOLOGICAL|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
224045038|NCT05788822|DIETARY_SUPPLEMENT|Mevalproic acid|Methovalerate pathway is a metabolism of cholesterol and isoprenoid synthesized from acetyl coenzyme A Pathway, which plays a key role in human health and disease, is also necessary for human cells to maintain normal functions. There are a series of important metabolic intermediates in the mevalproate pathway, such as farnesyl diphosphate and incense Folyl vanillin diphosphates, which modify proteins through isoprene, play an important role in regulating cell function. In addition, the latest research shows that valproic acid, the key metabolic intermediate of valproic acid pathway, being the synthetic precursor of cholesterol and isoprene, it can activate insulin growth factor (IGF)1-R and mTOR signals and maintain cell function by mediating histone function
224045039|NCT00328991|DEVICE|duct tape occlusion therapy|
224045040|NCT04216186|DRUG|Atomoxetine|Atomoxetine once daily
224045041|NCT04216186|DRUG|Coenzyme Q|Coenzyme Q once daily
224045042|NCT03938038|DIAGNOSTIC_TEST|Serial ultrasound assessments for GDT|routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
224045043|NCT03938038|DIAGNOSTIC_TEST|Usual care|Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
224045044|NCT01464125|DRUG|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
224141465|NCT03288493|DRUG|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
223434467|NCT00006305|PROCEDURE|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
223434468|NCT00006305|PROCEDURE|Coronary Artery Bypass|Coronary Artery Bypass
223434469|NCT00006305|DRUG|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
224141466|NCT04419324|DEVICE|transoral flexible endoscope with magnifying narrow band imaging|To use an esophago-gastroscopy endoscope (OGD) with Narrow Band Imaging (NBI) passed transorally and retroflexed into the nasopharynx to view the nasopharynx with increased magnification and clarity for the diagnosis of nasopharyngeal carcinoma.
224141467|NCT04260828|DRUG|Aspirin 100mg|Daily active drug administered orally for 3 months.
224141468|NCT04260828|OTHER|Placebo|Sugar pill administered orally for 3 months.
223434470|NCT00006305|DRUG|Insulin, sulfonylurea|Insulin, sulfonylurea
224045045|NCT01464125|DRUG|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
224141469|NCT01238133|DRUG|Carboplatin|Given IV
224141470|NCT01238133|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223434471|NCT00006305|DRUG|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
223434472|NCT01928797|DEVICE|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
224141471|NCT01238133|OTHER|Laboratory Biomarker Analysis|Correlative studies
224141472|NCT01238133|DRUG|Paclitaxel|Given IV
224141473|NCT01238133|OTHER|Pharmacological Study|Ancillary studies
224045046|NCT05263063|OTHER|Comparison of Face-to-face, Synchronous and Asynchronous Use of Methods Used for Balance Assessment in Individuals With Chronic Stroke|On the first day, information about the patient and the disease, filling in the patient data form and face-to-face evaluation will be made face to face with the patients. The next day, one of the synchronous and asynchronous tele-evaluation methods will be applied. Face-to-face interview and face-to-face evaluation will be made by the first physiotherapist in a clinical setting. The synchronous tele-assessment will be evaluated online in real time by the second physiotherapist. For asynchronous tele-assessment, a reference evaluation video will be sent to the patients. Relatives of the patients will be asked to watch this video, make the evaluation and take a video recording at the same time. Then, these video recordings will be evaluated separately by the first and second physiotherapists and the results will be compared. Each assessment will take approximately 30 minutes.
224045047|NCT02213432|BIOLOGICAL|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
224045048|NCT00525889|DRUG|IL-2|Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.
224045049|NCT00525889|DRUG|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
224045050|NCT01399190|BIOLOGICAL|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
224141474|NCT01238133|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224141475|NCT03529123|DRUG|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
224141476|NCT03529123|DRUG|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
224141477|NCT03529123|DRUG|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
224141478|NCT03529123|DRUG|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
224141479|NCT03190226|PROCEDURE|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
224141480|NCT03190226|PROCEDURE|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
224141481|NCT05847491|DIAGNOSTIC_TEST|IGRA/Tuberculin skin test|"All patients will receive:~* Clinical evaluation;~* Chest x-ray.~* IGRA (or tuberculin skin test if immunocompromised)~* Therapeutic proposal if eligible"
224141482|NCT04480697|DRUG|HPG1860|6 subjects randomized to active compound and 2 subjects randomized to placebo
224141483|NCT04295200|OTHER|Dry needling with electrical stimulation|Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
224141484|NCT01144078|BEHAVIORAL|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
224141485|NCT01144078|BEHAVIORAL|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
224141486|NCT06011291|DRUG|SYH2051 tablets|Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.
223434473|NCT05207904|DRUG|Tislelizumab, paclitaxel, Carboplatin|Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
223434474|NCT04130048|DIAGNOSTIC_TEST|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
223434475|NCT01350440|BIOLOGICAL|IVIG|Intravenous Immune Globulin
223478469|NCT00681200|BEHAVIORAL|Enhanced health education|health education and social support
224045051|NCT01399190|BIOLOGICAL|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
224045052|NCT01399190|DRUG|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
224045053|NCT06141044|PROCEDURE|Avoid surgical drainage|Patients who undergo distal pancreatectomy, avoid placing a drain.
224045054|NCT00437385|DRUG|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
224141487|NCT06011291|RADIATION|Intensity-Modulated Radiation Therapy (IMRT)|Radical or adjuvant radiotherapy
224141488|NCT04061252|DRUG|KHK4827|brodalumab 210mg Q2W, SC
224141489|NCT04061252|DRUG|Placebo|Q2W, SC
224141490|NCT06890741|OTHER|exercise test|Participant perforemed 6000m ergometer test.
224141491|NCT06758518|OTHER|No Interventions|there will be no intervention
224141492|NCT06898671|BEHAVIORAL|Eye-Tracking in Visual World Paradigm|Participants complete six eye tracking tasks. They see images on a computer screen are tasked with finding a specific picture or saying a specific word (target). We track their eye movements to the visual representations of the target compared with their eye movements to visual representations of items that are similar to the target.
224141493|NCT02652507|DRUG|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
224141494|NCT02652507|DRUG|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
224141495|NCT00941616|BIOLOGICAL|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
224141496|NCT00941616|BIOLOGICAL|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
224141497|NCT00016393|DRUG|ixabepilone|
224045055|NCT00437385|PROCEDURE|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
224045056|NCT00437385|BEHAVIORAL|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
224045057|NCT03355313|RADIATION|Low level Light therapy|Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
224045058|NCT03099239|BIOLOGICAL|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
224045059|NCT05682079|OTHER|TCMS, PEDİ, respiration, GMFCS,PBS,functional capacity|"The Trunk Control Measurement Scale evaluates the two main components of trunk control, static sitting balance and dynamic sitting balance. The scale includes a total of 15 items. The Pediatric Disability Assessment Inventory evaluates ADLs in individuals between the ages of 6 months and 7.5 years. It is a detailed clinical assessment scale that evaluates the functional skills and performance of individuals. Items in this section are scored as 0=cannot and 1=can. The Pediatric Berg Balance Scale is an adapted version of the Berg Balance test for adults, which consists of 14 questions. It is a scale that consists of 14 questions and evaluates balance functionally. For the 2-minute walking test; They were asked to walk at their own pace without running for 2 minutes on a quiet, concrete walkway 15 m long. It was repeated 2 times with a 10-minute rest between each trial. Respiratory muscle strength was measured using a portable, electronic mouth pressure measuring device."
224045060|NCT00264225|DRUG|Lamaline® , 3 different doses, Dafalgan codeine|
224045061|NCT01981239|DEVICE|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
224045062|NCT06325618|OTHER|No intervention other than obtaining biopsies|Skin, fat, and muscle biopsies will be obtained
224045063|NCT06325618|DRUG|Indocyanine green (ICG)|Indocyanine green will be injected to evaluate the lymphatic system.
224045064|NCT03341741|DRUG|Tobramycin Powder|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
224141498|NCT00818285|DEVICE|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
224141499|NCT04486924|DEVICE|Globe Mapping and Ablation System|Prospective, non-randomized, open-label clinical study.
223434476|NCT01569750|DRUG|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
223434477|NCT01569750|DRUG|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
223434478|NCT01569750|DRUG|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
223434479|NCT01569750|DRUG|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
223434480|NCT01569750|DRUG|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
223434481|NCT00662558|DRUG|celecoxib|200 mg capsules BID for 6 weeks
223434482|NCT00662558|DRUG|tramadol HCL|50 mg capsules QID for 6 weeks
223434483|NCT04814316|DIAGNOSTIC_TEST|Blood and urine specimens|Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
223434484|NCT00047216|DRUG|tipifarnib|
224045065|NCT03341741|DRUG|Colistin|Colistin solution 2 x daily 1 Mega continuously
224141500|NCT03784027|DEVICE|CamAPS FX|"CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data"
224141501|NCT03784027|OTHER|Sensor augmented therapy|Study insulin pump and study CGM.
224163489|NCT04115891|BEHAVIORAL|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
224163490|NCT00017173|BIOLOGICAL|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
223478470|NCT00681200|BEHAVIORAL|Transcendental Meditation program|The TM program plus didactic-based health education classes
223434485|NCT04940416|DEVICE|Neurofit (oculometric testing)|The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
223434486|NCT05136534|PROCEDURE|spinal anesthesia|subarachnoid anesthesia with 2% hyperbaric pilicaine
224045066|NCT04353453|DEVICE|Study Procedure for Participants That Were Not in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Sitting down for 10 minutes,outdoor walking for one minute and repeat this sequence four times At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
223434487|NCT05136534|PROCEDURE|local anesthesia|(Mepivacaine 2%) performed by the surgeon before skin incision
224045067|NCT04353453|DEVICE|Study Procedure for Participants That Were Included in the Driving Group|"Subjects were fitted with One lead Holter monitor and the CardiacSense1 watch simultaneously and were tested in the following condition:~1. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 28 ±3 degree Celsius.~2. Sitting down for 10 minutes, walking for one minute and repeat this sequence twice at Indoor 22 ±3 degree Celsius.~3. Going from the indoor facility to the car and driving for 30 minutes at least. Subject drove the car in city streets under light traffic conditions. At the end the devices were removed from the subject by the medical staff.The recorded data was downloaded for analysis by the Sponsor"
224045068|NCT03706404|DIAGNOSTIC_TEST|Point-of-Care ultrasound and testing|Point-of-Care ultrasound + Point-of-Care blood gas testing
223434488|NCT03035435|OTHER|fast-track rehabilitation|
223434489|NCT03035435|OTHER|standard care rehabilitation|
223434490|NCT05646758|DRUG|TQB2934 injection|TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.
224045069|NCT02412020|DRUG|PA101|
224045070|NCT02412020|DRUG|Placebo|
224045071|NCT04157504|OTHER|Physical function assessment|Physical function assessment is a tool to evaluate mobility levels of patients
224045072|NCT06466811|OTHER|Patients of intensive care unit|Patients of intensive care unit having an EVD
224045073|NCT06466811|OTHER|Patients of surgical intensive care unit|Patients of surgical intensive care unit having an EVD.
224045074|NCT00611962|DRUG|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
224045075|NCT03957395|DEVICE|Device: Precision Novi™ system Neurostimulation procedures|SCS with Device: Precision Novi™ system
224045076|NCT01636414|PROCEDURE|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
224045077|NCT01636414|PROCEDURE|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
224045078|NCT01636414|PROCEDURE|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
224045079|NCT05248451|OTHER|Not an Interventional Study|Not an Interventional Study
224045080|NCT00518414|OTHER|Marketed infant formula with DHA and ARA|
224141502|NCT06898229|BEHAVIORAL|Education|The intervention program aimed to increase participation in breast cancer screenings and reduce fear among illiterate women. The three-month training was structured in three phases. In the first month, awareness was raised through visual-audio materials about breast cancer, risk factors, and the importance of early diagnosis. In the second month, practical training was provided on breast self-examination (BSE), and clinical breast examination (CBE) and mammography procedures were introduced. In the final month, group discussions and success stories supported behavioral change, reinforcing knowledge. The program's effectiveness was evaluated through pre-test and post-test comparisons.
224141503|NCT02632695|DEVICE|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
224141504|NCT06416059|BEHAVIORAL|Mobile Application|The mobile application is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety,
224141505|NCT06898710|PROCEDURE|z mini plate with lingual extension|patient with class III mandible fracture will be treated with patient specific z mini plate with lingual extension
224141506|NCT06898710|PROCEDURE|conventional 2 mini plates|patient with class III mandible fracture will be treated with conventional 2 mini plates
224141507|NCT06899295|DIAGNOSTIC_TEST|Continuous measurement of esophageal pressure Peso (cmH2O)|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia.
224141508|NCT06899295|DIAGNOSTIC_TEST|Measurement of impedance variation with each respiratory cycle (EIT), Z in ohm|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
223434491|NCT00975858|PROCEDURE|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
223434492|NCT06285734|DIAGNOSTIC_TEST|Breath test|The concentration of methane and hydrogen in the exhaled gas of patients with Abdominal distention is measured by a breath test to determine the presence of SIBO and abnormal OCTT.
223434493|NCT05771818|OTHER|Falls Prevention Program|The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
224141509|NCT06899295|DIAGNOSTIC_TEST|Measurement of regional respiratory compliance (EIT), Ohm/cmH2O|This parameter will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
224141510|NCT06899295|DIAGNOSTIC_TEST|Measurement of lung volumes (EELV or CRF) mL, (ml/kg)|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
224045081|NCT00518414|OTHER|Milk-based infant formula with DHA and ARA|
224045082|NCT00518414|OTHER|Milk-based formula with DHA, ARA, prebiotics|
224045083|NCT04474457|DRUG|Favipiravir|"Turkish patient cohort diagnosed with COVID-19 and previously initiated treatment with Favipiravir."
224141511|NCT06899295|DIAGNOSTIC_TEST|Continuous measurement of multiparametric monitoring data in place (hemodynamics, depth of sedation, respiratory data, temperature).|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
224141512|NCT06899295|DIAGNOSTIC_TEST|Quantification of delivered doses of hypnotics, morphine and paralytics|These parameters will be recorded during the alveolar recruitment maneuvers routinely performed during general anesthesia
224141513|NCT06899295|DIAGNOSTIC_TEST|Demographic criteria: age, sex, height, weight, BMI, theoretical ideal weight, ASA. - Procedure-related criteria: type of surgery, technique (laparoscopic, endoscopic, laparoscopic), position, duratio|These parameters will be recorded during the perioperative hospitalization
224141514|NCT06897592|BEHAVIORAL|Enneagram|The training will be offered to students as 10 modules, 2 hours per week, for 8 weeks. The training content will consist of the Enneagram basic level and relationships.
224141515|NCT06899035|OTHER|Intervention Group (water-based and conventional exercise)|Patients in the study group will undergo individualized water-based exercises (including standing, balance, weight shifting, breathing exercises, range of motion, stretching, and strengthening exercises) under the supervision of an experienced physiotherapist, 2-3 times per week for six weeks. Additionally, routine conventional exercises will be continued daily for six weeks.
224141516|NCT06899035|OTHER|control group (conventional exercise)|Patients in the control group will continue passive, active, active-assisted, or resistance-based upper and lower extremity conventional exercises appropriate to their functional level and muscle strength. They will be instructed to perform these exercises 2-3 times per week, with each session lasting no more than 45 minutes, for six weeks.
224141517|NCT06898112|DRUG|PrEP|oral PrEP
224141518|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
224141519|NCT05967403|DRUG|Propofol|Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
224141520|NCT02541006|DRUG|Tiotropium 18 mcg|tiotropium 18 mcg once a day
223434494|NCT01934075|BEHAVIORAL|Mental health treatment|6 sessions of individual mental health counseling.
223434495|NCT04394793|RADIATION|Low dose radiation therapy|Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
224045084|NCT03150316|DRUG|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
224045085|NCT05097729|DEVICE|Transcranial Magnetic Stimulation|The brain stimulation can be delivery using different devices; in this project a MagPro X100 stimulator connected to a MagPro Cool-B65 liquid-cooled butterfly coil (MagVenture A/S, Farum, Denmark) will be used. Resting motor threshold (M1-rTMS) will be determined during the visit 1 or visit 2 and used along all visits. The rTMS pulse sequences and intensities used are all within the published safety guidelines
224045086|NCT03109548|OTHER|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
224045087|NCT00005920|DRUG|L-743,872|
224045088|NCT00436618|DRUG|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
224045089|NCT05489692|PROCEDURE|hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)|"FOLFOX-HAIC as the following dosage: 130 mg/m2 oxaliplatin infusion for 2 hours; 400 mg/m2 of leucovorin infusion for 2 hours; and 400 mg/ m2 of 5-FU bolus and 1200 of mg/m2 continuous infusion of 5-FU for 23 hours.~Patients received targeted therapy, three different targeted therapy were applied including: 1. lenvatinib 2. sorafenib; 3. apatinib. A portion of patients received PD-1 inhibitor administered intravenously every three weeks."
224141521|NCT00825383|OTHER|High Fiber and Moderate Fiber Diets|Dietary
224141522|NCT01917110|DEVICE|omafilcon A|
224141523|NCT01917110|DEVICE|Spectacle|
224163491|NCT00017173|DRUG|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
224163492|NCT00017173|PROCEDURE|conventional surgery|conventional surgery
224163493|NCT00017173|RADIATION|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
224163494|NCT00813774|BIOLOGICAL|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
223434496|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
223434497|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
224045090|NCT06343012|OTHER|Caring leadership Intervention program|Caring leadership intervention program
224045091|NCT03146767|DEVICE|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
224045092|NCT00698204|DRUG|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
224045093|NCT00698204|DRUG|placebo|Subject was asked to take placebo each day that radiation therapy was given.
224141524|NCT04253041|BEHAVIORAL|Effects of Instagram Exposure on Lifestyle Satisfaction|Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
224141525|NCT01806376|DRUG|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
224141526|NCT04890574|DEVICE|CellMist™ System|Open Label, Safety and Feasibility
224141527|NCT02494739|OTHER|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
224141528|NCT02494739|OTHER|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
224141529|NCT03630978|PROCEDURE|Liver resection|Major or minor, open or laparoscopic liver resection
224141530|NCT03629392|BEHAVIORAL|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
224141531|NCT03629392|BEHAVIORAL|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
224141532|NCT03629392|BEHAVIORAL|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
224141533|NCT00937794|BEHAVIORAL|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
224141534|NCT00937794|OTHER|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
224141535|NCT02199301|PROCEDURE|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7\~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6\~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5\~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
224141536|NCT05524740|DEVICE|BTL-785-7|Treatment with the BTL-785F device with the BTL-785-7 applicator for improvement of the structure of facial muscles.
224141537|NCT04777214|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active TMS will be at 90% motor threshold
224141538|NCT04777214|DEVICE|Sham TMS|Sham TMS will be administered
224141539|NCT02102984|DEVICE|covered biliary stents|endoscopic placement of covered biliary stents
224141540|NCT02102984|DEVICE|uncovered biliary stents|endoscopic placement of uncovered biliary stents
223434498|NCT00558051|BIOLOGICAL|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
224141541|NCT01064076|DEVICE|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
223434499|NCT05704777|BEHAVIORAL|Exercise|A 24-weeks concurrent exercise training program
224045094|NCT04757441|OTHER|Group A: Conventional Treatment + Elongation Longitudinaux Decoaption of Osteo-Articulaire|"ELDOA position for L5, S1 level Patient will ask to lie on his back, wedge buttocks in the corner of wall and raise his legs. Then Stretch the legs and push the heels toward ceiling. Extend the spine and stretch the arms above head .~• Patient will hold this position for one minute and repeat it for 4 -5 times.~Conventional treatment will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
224045095|NCT04757441|OTHER|Group B: Conventional treatment|"Participants will receive only conventional treatment which will include:~* Hot pack for 15 minutes .~* TENS for 10 minutes .~* self stretching of hamstrings"
224045096|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFU IM, 1.0 mL
224045097|NCT00376090|BIOLOGICAL|Placebo|1.0 mL IM
224141542|NCT03522831|DRUG|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
224045098|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^6 PFU ID, 0.1 mL
224141543|NCT03522831|DRUG|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
224141544|NCT01738737|DEVICE|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
224141545|NCT01738737|OTHER|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
224141546|NCT01738737|DEVICE|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
224045099|NCT00376090|BIOLOGICAL|Placebo|0.1 mL ID
224045100|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^8 PFU IM, 1.0 mL
224163495|NCT00813774|BIOLOGICAL|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
223434500|NCT05704777|OTHER|Control|Usual care
223434501|NCT03219086|PROCEDURE|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
223434502|NCT03219086|DRUG|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
223434503|NCT03219086|DRUG|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
223434504|NCT00160134|DRUG|SLV320|
223434505|NCT00169624|DRUG|Metformin|
223434506|NCT00169624|DRUG|Gliclazide|
224045101|NCT00376090|BIOLOGICAL|MVA-CMDR|10\^7 PFD ID, 0.1 mL
224045102|NCT02941653|DEVICE|Potassium nitrate 2% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water;~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
224045103|NCT02941653|DEVICE|Potassium oxalate 5% gel|"* Teeth will be cleaned using rubber cups associated to pumice and water~* Relative isolation with roller cotton will be done;~* Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~* Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~* A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
224045104|NCT03714321|DEVICE|Mechanical insufflation-exsufflation (MIE)|Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
224045105|NCT03083847|DRUG|Chloroquine Phosphate|Chloroquine has been widely used for treatment and prophylaxis of malaria since 1946 (Most, London et al. 1984). It was the treatment of choice for uncomplicated malaria for decades because it was safe, well tolerated, affordable and highly effective for the treatment of malaria. However, increasing spread of chloroquine- resistant Pf over the last two decades has severely limited its use (Wellems 2002). Chloroquine phosphate is U.S Food and Drug Administration (FDA) approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf.
224045106|NCT03083847|DRUG|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January2014)
224045107|NCT03083847|BIOLOGICAL|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
224045108|NCT02290860|PROCEDURE|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
224045109|NCT03001973|OTHER|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
224045110|NCT04216251|DRUG|AMR101|AMR101-oral predetermined protocol dosage, daily for a minimum of 8 weeks and maximum of 12 weeks
224045111|NCT01949155|DRUG|OTO-201|Single, intratympanic injection
224045112|NCT01949155|DRUG|Sham|Simulated single, intratympanic injection
224045113|NCT00314249|DRUG|Placebo|Placebo, oral administration, twice daily for 12 weeks
224045114|NCT00314249|DRUG|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID \[twice a day\])
224141547|NCT03724617|DRUG|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
224045115|NCT06121453|BEHAVIORAL|Multicomponent Adherence Intervention|multi-part intervention to reduce barriers to medication use
224045116|NCT04292028|OTHER|Pilates|The Pilates group participated in an 8-week clinical Pilates training program
224045117|NCT04292028|OTHER|Home exercises|Control group were given a home-based exercise program.
224045118|NCT01887951|DRUG|Penthrox Inhaler|
224045119|NCT01887951|DRUG|Tramadol Injection|
224045120|NCT03120806|PROCEDURE|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
224045121|NCT03120806|PROCEDURE|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
224141548|NCT04697602|DRUG|Stepwise dose titration of febuxostat and low-dose colchicine|Febuxostat 10 mg, orally, once daily, in week 1-4 Febuxostat 20 mg, orally, once daily, in week 5-8 Febuxostat 40 mg, orally, once daily, in week 9-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
224141549|NCT04697602|DRUG|Fixed dose febuxostat and low-dose colchicine|Febuxostat 40 mg, orally, once daily, in week 1-12 Concomitant colchicine 0.5 mg, orally, once daily in week 1-12
224141550|NCT05355935|DRUG|Brensocatib|Oral tablet.
224141551|NCT05355935|DRUG|Moxifloxacin|Oral tablet.
224045122|NCT00184626|DRUG|biphasic insulin aspart|
224045123|NCT00184626|DRUG|insulin glargine|
224045124|NCT00184626|DRUG|metformin|
224141552|NCT05355935|DRUG|Placebo|Oral tablet.
224141553|NCT01670175|DRUG|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
224141554|NCT05220241|BIOLOGICAL|Nasopharyngeal swab for RT-PCR SARS-CoV-2|2 nasal swabs (one per nostril) of olfactory mucosa cells under local anesthesia for SARS-CoV-2 RT-PCR and pathological analysis
224141555|NCT04744610|DIAGNOSTIC_TEST|Add 4-hour delayed radiographs|Normal patients only need to take delayed radiographs 24h after HSG operation. In this study, 4-hour delayed radiographs were added to the 24-hour delayed radiographs, so that the patients had to take one more delayed radiographs .
224141556|NCT05281848|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment includes periodontal prophylaxis and root planning. No other methods or any of drugs will be used.
224141557|NCT04457570|OTHER|mortality|To measure the excess risk of mortality of patients with a history of cancer among patients hospitalized for a SARS-CoV-2 infection
224141558|NCT05340101|BEHAVIORAL|ROGRESSIVE MUSCLE RELAXATION EXERCISE|"In the application, Relaxation Exercises CD Audio Recordings prepared by the Turkish Psychological Association were used. In the the second part of 30 minutes were explained with the sound of the PKGE stream and verbal instructions. Audio recordings in the second part were used in this study. In line with the PCGE sound recordings, each muscle group starting from the hands to the feet, and then the facial and whole body muscles were stretched for about 10 seconds. The exercise was applied by taking deep breaths while tensing each muscle group, and releasing this breath slowly during relaxation. The relaxation lasted 10-20 seconds before the next muscle group was stretched. In this way, the muscles groups in the hands, arms, neck, shoulders, chest, abdomen, hips, feet and fingers, face and whole body were voluntarily stretched and relaxed, respectively, and the students were relaxed."
224141559|NCT01374672|OTHER|laboratory biomarker analysis|Correlative studies
224141560|NCT04938271|DEVICE|HEAL-122 microcurrent electroceutical with e-textile sports knee sleeve|Using a bluetooth connected iPhone, subject activates the HEAL-122 electroceutical device that is docked onto an e-textile sports knee sleeve worn on the osteoarthritic knee
223565849|NCT03848130|OTHER|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
223565850|NCT04717024|DEVICE|Observational Study - no intervention|Observational Study - no intervention
223565851|NCT00053677|DRUG|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
223740561|NCT05792631|DEVICE|Near infra red imaging|"The iTero Element 5D is an intra-oral scanner that incorporates near-infrared illumination capabilities used to provide a near-infrared image of the teeth enabling the detection of both occlusal and proximal caries, at the various stages, ranging from initial enamel caries to established caries reaching the DEJ.~Near-infrared Imaging (NIRI) is a nonionizing imaging technology that leverages differences in scattering and absorption of near-infrared light depending on the degree of tooth mineralization."
223740562|NCT02556268|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
223740563|NCT02556268|DRUG|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
223740564|NCT02556268|DRUG|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
223740565|NCT02556268|DRUG|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
223740566|NCT02556268|DRUG|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
223740567|NCT02556268|DRUG|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
223740568|NCT03949205|OTHER|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
223740569|NCT02109120|PROCEDURE|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
223740570|NCT02248350|BEHAVIORAL|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
223740571|NCT02248350|BEHAVIORAL|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
223740572|NCT05799807|PROCEDURE|Conservative treatment|Patients with negativ weight-bearing CT will be treated conservative
223740573|NCT05799807|PROCEDURE|Minimally invasive stabilization|Patients with positive weight-bearing CT will be operated by minimally invasive stabilization (eg, isolated homerun screw)
223740574|NCT00729027|DRUG|25 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
224163496|NCT00813774|BIOLOGICAL|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
223740575|NCT00729027|DRUG|50 mg/day AVE5530|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
223740576|NCT00729027|DRUG|placebo|"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
223740577|NCT06214429|DIAGNOSTIC_TEST|Vascular Ultrasound|Complete vascular ultrasound routine in B mode, color mode and Doppler.
223740578|NCT06214429|DIAGNOSTIC_TEST|Shear Wave Elastography|Vascular ultrasound assisted shear wave elastography of the atherosclerotic plaque.
223740579|NCT06214429|DIAGNOSTIC_TEST|Greyscale Median|Vascular ultrasound assisted assessment of the plaque in B mode. The plaque image will be post-processed for the histogram median value for the plaque area.
223740580|NCT06214429|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Assessment of the plaque and carotid residual lumen by magnetic resonance.
223565852|NCT00053677|DRUG|Placebo|For subjects who were randomly assigned to placebo.
223740581|NCT06214429|DIAGNOSTIC_TEST|Histopathology|Histopathology findings for patients that undergo carotid endarterectomy.
224141561|NCT04087408|DRUG|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"1. Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-450 IU~2. doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~3. Trigger will be done using HCG followed by OPU 36 h later.~4. Retrieved oocytes will be fertilized by ICSI.~5. LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~6. GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~7. Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~8. Quantative BHCG will be performed 14 days after OPU."
224141562|NCT03019705|OTHER|Observation|
224141563|NCT01141127|DRUG|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
224141564|NCT06330974|OTHER|No intervention|No intervention
224141565|NCT05709314|DRUG|AMDX-2011P|AMDX-2011P single bolus injection intravenous for diagnostic review
224141566|NCT00562640|BIOLOGICAL|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
224141567|NCT00562640|BIOLOGICAL|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
224141568|NCT00562640|DRUG|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
224141569|NCT00562640|OTHER|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
224141570|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir under fasted conditions
224141571|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with water under fasted conditions
224141572|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with applesauce under fasted conditions
224141573|NCT05263921|DRUG|PF-07321332/ritonavir|Single oral dose of PF-07321332/ritonavir mixed with vanilla pudding under fasted conditions
224141574|NCT02787603|OTHER|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels \< 0,25ng/mL OR PCT \> 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
224141575|NCT01952704|BEHAVIORAL|Aerobic exercise|
224141576|NCT01952704|BEHAVIORAL|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
224141577|NCT05431049|PROCEDURE|Percutaneous nephrolithotomy surgery (PNL)|Percutaneous nephrolithotomy (PNL) surgery was performed in all arms of the study to remove the renal stones. This surgery was performed with 2 anesthesia methods, CSEA and GA. These formed the groups of the study.
224141578|NCT04717076|BEHAVIORAL|App-based nutritional concept and fitness tracking|The App-based nutritional concept based on menu plan, which are personalized according to participants age, gender, physical activity. The App is coupled with a Smartwatch to encourage and track physical activity over the study period.
224141579|NCT04717076|BEHAVIORAL|Nutritional concept with individual nutritional counselling|Nutritional concept based on personalized menu plans and individual nutritional counselling every four weeks (4 times during the study)
223565853|NCT03645941|BEHAVIORAL|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
224141580|NCT04717076|BEHAVIORAL|Nutritional concept without individual nutritional counselling|Nutritional concept based on personalized menu plans
224141581|NCT00700531|DEVICE|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
224141582|NCT00700531|PROCEDURE|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
224141583|NCT05244499|OTHER|Evidence-based leadership training|7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.
224141584|NCT05244499|OTHER|Conventional training|7-modules online training over six months. Independent reading only.
223565854|NCT02723552|BEHAVIORAL|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
223565855|NCT01581528|GENETIC|gene expression analysis|
224141585|NCT03355794|DRUG|ribociclib|Oral capsule or liquid formula
224141586|NCT03355794|DRUG|Everolimus|Oral tablets or dispersible tablets
223565856|NCT01581528|OTHER|cell culture procedure|
223565857|NCT01581528|OTHER|flow cytometry|
223565858|NCT01581528|OTHER|laboratory biomarker analysis|
223565859|NCT01581528|OTHER|metabolic assessment|
223565860|NCT00726791|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
223434507|NCT03660124|DEVICE|Deep Brain Stimulation|DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
223434508|NCT04946019|COMBINATION_PRODUCT|Unity-based MR-Linac guided FSRT|The FSRT was delivered using the Unity-based MR-Linac treatment machine, with a total dose of 30Gy in 5 fractions.
223434509|NCT01711619|DEVICE|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
223434510|NCT01711619|OTHER|Optimized Medical Management|Optimized medical management
223434511|NCT06238713|PROCEDURE|Single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive single-port extraperitoneal robotic-assisted radical prostatectomy with Vattikuti Institute Prostatectomy（VIP） techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
223434512|NCT06238713|PROCEDURE|Multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques|Patients with localized prostate cancer are randomized into this group in a 1:1 ratio and receive multi-port transperitoneal robotic-assisted radical prostatectomy with bilateral intrafascial nerve-sparing techniques. The investigators will monitor patients for perioperative data recording, treatment and 1-year follow-up.
223434513|NCT03827902|DEVICE|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
223434514|NCT01601002|DRUG|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
224045125|NCT06231420|OTHER|Encourage using pedometer|Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator
224045126|NCT06231420|DEVICE|pedometer|pedometer
224045127|NCT03821818|BEHAVIORAL|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise \> 75% max heart rate, 5/day)
224045128|NCT02595021|PROCEDURE|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
224045129|NCT02595021|PROCEDURE|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
224045130|NCT03347981|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
224045131|NCT03347981|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
224141587|NCT06279663|PROCEDURE|Revascularization|revascularization
224163497|NCT05914480|OTHER|PCR for legionella ,blood ,urine cultures and from catheters or source of infection|Investigations to detect cause of sepsis as blood cultures ,urine cultures and from catheters .also PCR for legionella will be done
224163498|NCT00443794|DRUG|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
223434515|NCT02240303|PROCEDURE|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
223434516|NCT02240303|PROCEDURE|Physical Performance|Participants in both groups will have a Physical Performance test.
223565861|NCT02144688|DRUG|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
223565862|NCT01394692|PROCEDURE|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
223565863|NCT01394692|PROCEDURE|standard microsurgery|microsurgical tumor resection
223565864|NCT00210457|DRUG|Lanreotide (Autogel formulation)|
223565865|NCT06235593|BEHAVIORAL|Self-care Intervention|"The intervention will focus on self-care behavior of people with chronic diseases according to two distinct periods (through a longitudinal study - follow-up nursing interventions):~(i) baseline; and (ii) 4 months;"
223565866|NCT06812026|OTHER|no melatonin and massage|receiving no melatonin and massage
223740582|NCT06238635|DRUG|Dostarlimab|Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
224163499|NCT00443794|DRUG|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
223740583|NCT06238635|DRUG|Cobolimab|Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
224045132|NCT04825171|DRUG|Bryophyllum 50 % Chewing Tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g.
224163500|NCT00443794|DRUG|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
224163501|NCT00443794|DRUG|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
224045133|NCT05165355|DRUG|Furmonertinib|Furmonertinib (80 mg orally, once daily) for 3 years.
224045134|NCT00210184|DRUG|Irinotecan associated to fluorouracil and leucovorin|
224045135|NCT04146428|BEHAVIORAL|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
224045136|NCT04146428|BEHAVIORAL|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
224045137|NCT06237543|OTHER|hypotension|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
224045138|NCT00401739|DRUG|CSL360|Weekly IV Infusion. Dose escalation study.
224163502|NCT00443794|DRUG|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
224045139|NCT00956657|BEHAVIORAL|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
223565867|NCT06812026|DIETARY_SUPPLEMENT|receive melatonin|receiving only melatıonin pills
223565868|NCT06812026|OTHER|receiving lymphatic drainage|receiving lymphatic drainage massage
224045140|NCT04060563|DEVICE|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
224141588|NCT06000436|OTHER|Cardiovascular disease risk assessment|"Cardiovascular disease risk assessment~Training and Consultancy Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. By using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the working hours of the participants.~Mobile Application To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Monitoring Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application."
224045141|NCT00851682|DEVICE|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
224045142|NCT04858906|DEVICE|McGrath laryngoscope|The patients in this group will be evaluated and intubated with McGrath laryngoscope (angulated videolaryngoscope).
224141589|NCT06000436|OTHER|Training and Consultancy|Based on the literature, the researcher prepared a Training Guide for the Prevention of Cardiovascular Diseases, including the subjects of Cardiovascular Diseases and Risk Factors, Physical Activity, Smoking and Heart Health, BMI and Heart Health, Nutrition, and Stress. Using the training guide, training time for individual training intervention will be planned for one day of the week with the participants. Individual training will last 30 minutes at the stops with waiting areas during the participants' working hours.
224141590|NCT06000436|OTHER|Mobile Application|"To the participants in the intervention group 2, 4. In the 6th and 6th weeks, text messages will be shared once a week to increase motivation and prevent cardiovascular diseases.~Text Messages Week 2 Tobacco use causes 6 million deaths in the world. The risk of death is reduced by 90% in those who stop using tobacco. Alcohol use causes damage to the heart muscle, arrhythmia, and stroke. For a healthy life, you should stay away from smoking and alcohol. ' Week 4 '' Inadequate physical activity increases the risk of death from all causes. Physical activity reduces the risk of hypertension, stroke, and depression. 30 minutes of moderate-intensity physical activity daily is recommended.~Week 6 Adequate consumption of vegetables and fruits reduces the risk of cardiovascular disease. Saturated and trans fats increase the risk of cardiovascular disease. It is recommended to consume \<5 g less per day to prevent cardiovascular diseases."
224141591|NCT06000436|OTHER|Monitoring|Daily data from the previous week (cardio score, number of steps) will be taken from the Google Fit application.
224141592|NCT00556335|PROCEDURE|manual aspiration|air aspiration
224141593|NCT00556335|PROCEDURE|conventional drainage|drainage, pneumocath
224141594|NCT01666145|DEVICE|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
224141595|NCT02406053|GENETIC|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
223740584|NCT05637112|OTHER|None (Observational study)|Not Applicable since Observational Study
224141596|NCT01798017|DRUG|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
224141597|NCT00915538|DRUG|pMDI budesonide/formotrol 160/4.5 is in group 1|The asthmatic subjects will receive budesonide/formoterol pMDI 160/4.5 pMDI 2 inhalations used in conventional fashion, and have pulmonary function measured over 12 hours who are expected to show bronchodilation.
224141598|NCT00915538|DEVICE|Symbicort 160/4.5 plus Aerochamber Plus included in group 2|Symbicort 160/4.5 2 inhalations will be administered through a valved holding chamber, Aerochamber Plus, Pulmonary functions will be measured over 12 hours in asthmatic subjects who are expected to show bronchodilation.
224141599|NCT02527187|BIOLOGICAL|10 HEP/mL Betula verrucosa allergen extract|The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
224141600|NCT02527187|BIOLOGICAL|25 HEP/mL Betula verrucosa allergen extract|The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
224141601|NCT02527187|BIOLOGICAL|50 HEP/mL Betula verrucosa allergen extract|The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
224045143|NCT04858906|DEVICE|C-MAC D-blade laryngoscope|The patients in this group will be evaluated and intubated with C-MAC D-blade laryngoscope (hyperangulated videolaryngoscope).
224163503|NCT00443794|DRUG|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
223565869|NCT04778631|DEVICE|Heat therapy|Application of warm compresses, soaked in hot tap water (between 38° and 44 °C), to the perineum, at each contraction or pushing effort from the start of perineum distension until birth.
223565870|NCT04778631|DEVICE|Cryotherapy|Application of a perineal instant col pack to the perineum, after placental delivery or perineum suturing, for at least 20 minutes.
223565871|NCT04319380|BIOLOGICAL|Tetanus/diphtheria toxoids|One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.
224045144|NCT02676388|PROCEDURE|Freeze-dried, Capsulized FMT|
224045145|NCT02676388|PROCEDURE|Fresh FMT|
223434517|NCT02240303|PROCEDURE|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
223434518|NCT02240303|PROCEDURE|Blood Sample|Participants in both groups will have blood samples taken.
224045146|NCT06281067|DIAGNOSTIC_TEST|"full-physiology approach arm"|"* All MB patients belonging to the full-physiology arm will undergo functional assessment of the intramural artery with basal Pd/Pa, FFR (after intravenous adenosine), RFR, CFR and IMR.~* In the presence of a negative functional assessment (Pd/Pa\> 0.92, FFR\> 0.80, RFR\> 0.89, CFR≥ 2.0 and IMR\< 25), FFR, CFR and IMR will be measured after inotropic stimulation with dobutamine (respectively FFR-d, CFR-d and IMR-d) to exalt the epicardial hemodynamic significance of MB or its impact on structural microvascular remodelling (impaired endothelium-independent vasodilatation).~* In the absence of epicardial hemodynamic significance (FFR-d\> 0.75) and structural microvascular dysfunction (CFR≥ 2.0 and IMR\< 25), ACH provocative test will be performed to evaluate the presence of epicardial or microvascular spasm (impaired endothelium-dependent vasodilatation)."
224045147|NCT06281067|DIAGNOSTIC_TEST|"standard approach arm"|"In the standard approach arm patients will undergo an angiographic evaluation of the tunnelled artery"
224045148|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
224045149|NCT00072358|BIOLOGICAL|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
224045150|NCT06417463|PROCEDURE|thyroidectomy opeartion|correlation between TIRADS and Bethesda scoring system (preoperative) and final histopathology (postoperative) in cases of thyroidectomy
224045151|NCT01534013|DEVICE|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
224141602|NCT02527187|BIOLOGICAL|100 HEP/mL Betula verrucosa allergen extract|The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
224141603|NCT06506838|DRUG|Anlotinib|For patients with the soft tissue sarcoma, the standard doxorubicin monotherapy regimen involves administering 37.5 mg/m² intravenously on days 1-2 of every 3 week . The treatment includes 3 cycles of neoadjuvant chemotherapy before surgery and 3 cycles of adjuvant chemotherapy after surgery, totaling 6 cycles. Anlotinib is administered at 12mg/d QD，day1\~14, 21d/cycle. Neoadjuvant radiotherapy is conducted before surgery, starting after the second chemotherapy cycle, using stereotactic body radiation therapy (SBRT) with a dose of 4\*10 Gy. Radical resection surgery is performed after the third chemotherapy cycle.
224141604|NCT02335203|DRUG|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
224141605|NCT02335203|OTHER|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
224141606|NCT04059471|BIOLOGICAL|Yellow fever vaccine, Institut Pasteur|Full dose and 500IU/dose
224141607|NCT03081598|DRUG|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
223434519|NCT01325259|OTHER|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
223434520|NCT01325259|RADIATION|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of \[18F\]AV-45
223434521|NCT01325259|RADIATION|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
223434522|NCT01325259|OTHER|MRI|Magnetic Resonance Imaging
223434523|NCT04136275|BIOLOGICAL|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
223434524|NCT04127175|DEVICE|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
223434525|NCT01971632|DRUG|Oxycodone & naloxone combination, prolonged release|
223434526|NCT01971632|DRUG|placebo oxycodone / naloxone|
223434527|NCT04018807|OTHER|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
223434528|NCT04018807|BEHAVIORAL|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
223434529|NCT04365478|PROCEDURE|Radial Extracorporeal Shock Wave Therapy|rSWT group: One radial shock wave therapy session a week for 8 weeks (parameters: 1.5 bar, 10 Hz, 2000 shots for each muscle group treated) administered daily during the morning for 40 minutes of conventional rehabilitation treatment.
224045152|NCT01534013|DEVICE|Open loop|glucose sensor and pump
224045153|NCT01379573|DRUG|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
224045154|NCT00962390|DRUG|S-equol|10mg S-equol 50mg S-equol, \& 150mg S-equol
224045155|NCT00962390|DRUG|Placebo|Placebo
224045156|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
224045157|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
224045158|NCT00152282|DRUG|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
224045159|NCT00152282|DRUG|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
224045160|NCT04347070|OTHER|Phsyiotherapy|To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time
224045161|NCT02613884|DRUG|Treatment|
224045162|NCT06317675|OTHER|Osteopathic manipulative treatment (OMT)|Manual therapy on different area of the body.
224045163|NCT05131984|DRUG|Ocrelizumab|At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
224045164|NCT02428543|DRUG|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
224045165|NCT05836636|OTHER|Torque teno virus DNA measurement|Torque teno virus DNA level will be obtained from all study subjects upon recruitment, when subjects are admitted and when subjects undergo kidney allograft biopsies.
224045166|NCT00441415|DRUG|Adapalene BPO|
224045167|NCT00143663|DRUG|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
224045168|NCT00143663|DRUG|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
224141608|NCT03081598|OTHER|Placebo|Placebo soft gelatine capsule
224141609|NCT05739357|DEVICE|NIRS, EEG|During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
224141610|NCT02057367|DRUG|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
224141611|NCT02057367|DRUG|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
224141612|NCT03392441|OTHER|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
224141613|NCT04807101|DRUG|midazolam alone|elimination of fentanyl from conscious sedation
224163504|NCT00443794|DRUG|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
224045169|NCT04272658|DIAGNOSTIC_TEST|value of 4D body-to-whole dynamic acquisition in FDG|"differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI"
224045170|NCT04350385|OTHER|Agility training|In experimental group, 30 meter sprint test will be used as intervention with complexity in different stages. Test 1 was a straight sprint and tests 2-7 involved multiple changes of direction. Tests 2-7 were designed to involve progressively greater change-of-direction complexity by increasing either the angle of directional change and/or the number of changes of direction. In experimental group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week.
224045171|NCT04350385|OTHER|Conventional|In group B, Conventional intervention was given to the players under the supervision of Physical Therapist that includes warm-up, strength training, agility training and cool down. In control group, 6 weeks of intervention will be done on alternate days and assessment will be done on 1st, 3rd \& 6th week
224045172|NCT05183113|OTHER|Acute Intermittent Hypoxia|Participants will wear a non-rebreathing face mask and alternate between breathing 9% O2 gas mixture for up to 1 minute, or until the target SpO2 of 85 percent is reached, and normal room air (21 percent O2) until 2 minutes are complete. This cycle will be repeated 15 times, resulting in a 30-minute protocol.
224163505|NCT00443794|DRUG|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
224163506|NCT00443794|DRUG|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
224163507|NCT06058351|BEHAVIORAL|ABI-motion program|The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
224163508|NCT05724069|DRUG|Velusetrag 15 mg once daily for 4 weeks.|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
224163509|NCT05724069|DRUG|Placebo once daily for 4 weeks.|Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
224045173|NCT01091688|BEHAVIORAL|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
224163510|NCT03552289|DEVICE|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
224163511|NCT03552289|DEVICE|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
224163512|NCT02749786|OTHER|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
224163513|NCT03425851|OTHER|Diapers|Receive 600 diapers.
224045174|NCT02897232|OTHER|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
224045175|NCT00771004|DRUG|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
224045176|NCT00771004|DRUG|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
224045177|NCT01514136|DEVICE|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
224141614|NCT02254551|DRUG|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
224045178|NCT02019225|OTHER|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
224045179|NCT01827579|BIOLOGICAL|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10\^5 /kg at day 30 post-SCT, 3 x 10\^5 /kg at day 60 and 10\^6 /kg at day 90 post transplant
224045180|NCT05902078|DRUG|Eldecalcitol capsules|Oral eldecalcitol 0.75μg daily
224045181|NCT05902078|DRUG|Calcitriol capsules|Oral calcitriol 0.5μg daily
224045182|NCT03126526|BEHAVIORAL|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
224045183|NCT03126526|BEHAVIORAL|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
224045184|NCT03126526|BEHAVIORAL|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
224045185|NCT02729740|DEVICE|Penumbra Smart Coil|
224045186|NCT02729740|DEVICE|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
224045187|NCT00531882|DRUG|Pioglitazone|30 mg once a day
224045188|NCT00531882|DRUG|Simvastatin|40 mg once a day
224045189|NCT00531882|DRUG|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
224045190|NCT02319291|DEVICE|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
224045191|NCT01318720|OTHER|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
224045192|NCT04609332|DIAGNOSTIC_TEST|Endothelial damage and angiogenic biomarkers|Blood samples for biomarkers study
224045193|NCT06469099|OTHER|excercises|exercises for strength and balance
224045194|NCT05646212|OTHER|Project ECHO|Project Extension for Community Healthcare Outcomes® (ECHO): This EBP, tested originally to facilitate HCV care into non-specialty settings, is based on established educational theories of social learning \& behavior change in where non-specialists collaborate with specialists, resulting in an innovative healthcare delivery model that results in equivalent quality care for patients in non-specialty settings.
224141615|NCT02254551|DRUG|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
224141616|NCT02539719|DRUG|SC-003|
224141617|NCT02539719|DRUG|SC-003 in combination with ABBV-181|
224141618|NCT05451472|DIAGNOSTIC_TEST|thyroid function tests|Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
224141619|NCT05451472|DIAGNOSTIC_TEST|complete blood count|complete blood count
224141620|NCT05451472|DIAGNOSTIC_TEST|serum creatinine|serum creatinine
224141621|NCT05451472|DIAGNOSTIC_TEST|blood urea|blood urea
224141622|NCT05451472|DIAGNOSTIC_TEST|serum electrolyte|serum electrolyte
224141623|NCT05451472|DIAGNOSTIC_TEST|serum calcium|serum calcium
224141624|NCT05451472|DIAGNOSTIC_TEST|serum phosphorus|serum phosphorus
224141625|NCT05451472|DIAGNOSTIC_TEST|parathyroid hormone level|parathyroid hormone level
224141626|NCT05451472|DIAGNOSTIC_TEST|liver function test|ALT\_AST\_Total biliruin\_total protein \_serum albumin
224141627|NCT05451472|DIAGNOSTIC_TEST|arterial blood gases|PH\_PCO2\_PO2\_HCO3\_base deficit
224141628|NCT05451472|DIAGNOSTIC_TEST|complete urine analysis|complete urine analysis
224141629|NCT02591004|DRUG|Magesium sulphate|\*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
224141630|NCT02591004|DRUG|Nifedipine|\*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
224163514|NCT03425851|OTHER|Resources of diaper banks|Caregivers will receive resources of diaper banks.
224045195|NCT05646212|OTHER|Payment for Performance|"P4P in healthcare, endorsed by 3 IOM reports, gives financial incentives to clinicians for adhering to clinical guidelines and achieving better health outcomes. One 2007 IOM report recommended physician incentives so that profitability and improved healthcare delivery is aligned with patient safety goals and strengthen the business case for healthcare quality and safety."
224045196|NCT00601705|DRUG|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
224141631|NCT02591004|RADIATION|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
224141632|NCT04573205|DRUG|FSME-IMMUN Vaccine|0.5 ml intramuscular injection scheduled in the two different arms
224141633|NCT04190212|BEHAVIORAL|High-intensity interval training + standard care|HIIT sessions will include: (1) warm-up for 2 minutes at 50% of peak power output (PPO); (2) 2 x 8-minute interval training blocks (total: 16 minutes) of 30-seconds at 80-100% of PPO interspersed with 30-seconds active recovery, 4 minutes of recovery will be permitted between the blocks; and, (3) 2 minute cool-down at 25% of PPO after the last 30-second exercise bout.
224141634|NCT04865185|DIAGNOSTIC_TEST|Xylocaine spray 100mg/ml|Topical application
224141635|NCT04865185|DIAGNOSTIC_TEST|Ethanol|Topical application
224141636|NCT01053702|DRUG|R475|IV
224299796|NCT05557357|PROCEDURE|Electroacupuncture Combined With Warm Needling (EAWN)|"Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17."
224299797|NCT05557357|OTHER|Waitlist Control|No treatment will be provided during the 10-week waiting period after baseline assessment.
223434530|NCT04365478|PROCEDURE|Conventional physiotherapy|Control group: 40-minutes of conventional rehabilitation treatment 5 days per week in the morning (strength exercise, trunk control exercise, stretching exercise, occupational therapy, and neurodevelopmental facilitation techniques) for 8 weeks
223434531|NCT00001569|DRUG|Cisplatin|
223434532|NCT00001569|DRUG|Paclitaxel|
223434533|NCT00001569|DRUG|5-FU|
223434534|NCT00503997|DRUG|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
223740585|NCT06411691|DRUG|KRAS Vaccine with Poly-ICLC adjuvant|"SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC"
224299798|NCT05753306|DRUG|Cisplatin|Given via HIPEC
223434535|NCT00503997|DRUG|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
223434536|NCT06361615|OTHER|Single-Task|Single-task (ST) training group developed an exercise program based on Functional Exercise Circuit (FEC) protocol. This exercise program has been published previously12, which considered 15 different exercises in a functional exercise circuit.
223434537|NCT06361615|OTHER|Dual-Task|DT training (multicomponent physical exercise + cognitive tasks)
223740586|NCT06411691|DRUG|Balstilimab|"240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 240 mg IV"
224141637|NCT01053702|DRUG|Placebo|Placebo
224141638|NCT04469803|BEHAVIORAL|Intra-Shift Napping|The Brief Nap opportunity will allow for a 30-minute nap between the hours of 0200 and 0400 during the 12-hour simulated night shift. The Longer Nap opportunity will allow for a 2-hour nap between the hours of 0200 and 0400 during the 12-hour simulated night shift.
224299799|NCT05753306|PROCEDURE|Computed Tomography|Undergo CT scan or PET/CT
224299800|NCT05753306|PROCEDURE|Gastrectomy|Undergo robotic gastrectomy
224299801|NCT05753306|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224299802|NCT05753306|PROCEDURE|Positron Emission Tomography|Undergo PE/CT
224045197|NCT00601705|DRUG|epirubicin hydrochloride|50 mg/m2 IV bolus
224045198|NCT00601705|DRUG|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
224045199|NCT00601705|DRUG|oxaliplatin|130 mg/m2 IV infusion over 2 hours
224045200|NCT00601705|PROCEDURE|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
224045201|NCT00601705|PROCEDURE|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
224045202|NCT02277977|OTHER|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
224045203|NCT04643080|OTHER|Yogurt|6 oz. of a commercially available yogurt were provided daily for 12 weeks
224045204|NCT00630851|DRUG|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
224045205|NCT00630851|DRUG|Placebo|Matching placebo tablets orally once daily for 6 months
224141639|NCT00425568|DRUG|AndroGel (Transdermal Testosterone Gel)|
224299803|NCT05753306|OTHER|Questionnaire Administration|Complete questionnaire
224299804|NCT05753306|DRUG|Paclitaxel|Given via HIPEC
223565872|NCT04319380|DRUG|SMC with SP+AQ|Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
224299805|NCT05753306|DRUG|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
223434538|NCT01195844|BIOLOGICAL|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children \< 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
223434539|NCT00851773|DRUG|semaglutide|0.1 mg once weekly, s.c. injection
223434540|NCT00851773|DRUG|semaglutide|0.2 mg once weekly, s.c. injection
223434541|NCT00851773|DRUG|semaglutide|0.4 mg once weekly, s.c. injection
223565873|NCT04319380|BIOLOGICAL|RTS,S/AS01|One booster dose of RTSS/AS01 (June) in year 1 and 2.
223565874|NCT04319380|DRUG|SMC placebo|Year 1 and 2 (2020/21) Four cycles of SMC placebo (July, August, September, October)
223565875|NCT06650748|DRUG|Dalpiciclib|Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
223565876|NCT06650748|DRUG|Letrozole|2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
223565877|NCT03709745|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
223565878|NCT03709745|DRUG|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
223565879|NCT00081549|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
224045206|NCT00978835|BEHAVIORAL|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
224045207|NCT00978835|BEHAVIORAL|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
224045208|NCT04588194|DRUG|Romiplostim|Romiplostim 2mcg/Kg subcutaneously weekly days 1, 7, 14, 21
224045209|NCT04588194|DRUG|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
224045210|NCT04588194|DRUG|Dexamethasone|40 mg IV/PO days 1-4
224045211|NCT03254654|DRUG|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
224045212|NCT03254654|DRUG|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
224045213|NCT03391206|DIAGNOSTIC_TEST|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
224045214|NCT00002920|DRUG|medroxyprogesterone|
224045215|NCT00002920|DRUG|tamoxifen citrate|
223565880|NCT03871010|DEVICE|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
223565881|NCT04654221|DIAGNOSTIC_TEST|mGFR by iohexol clearance|Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
223565882|NCT02302092|DRUG|Flomoxef|Flomoxef intravenous infusion
224045216|NCT00002920|PROCEDURE|adjuvant therapy|
224045217|NCT00002970|DRUG|nelarabine|Given IV
224045218|NCT00002970|DRUG|methotrexate|Given IT
224045219|NCT00002970|DRUG|cytarabine|Given IT
224045220|NCT00002970|DRUG|therapeutic hydrocortisone|Given IT
223565883|NCT02302092|DRUG|Cefepime|Cefepime intravenous infusion
223565884|NCT06981065|PROCEDURE|Simple Sling and Physiotherapy|Non-surgical treatment with a simple sling and physiotherapy according to standardized program.
223565885|NCT06981065|PROCEDURE|Surgical treatment|Surgical treatment with plate and screws (lateral clavicle plate, clavicle plate or hook plate with/without coracoclavicular fixation).
224045221|NCT00440479|DRUG|Bortezomib|dose as determined (observational study) by treating physician
224045222|NCT01758458|BIOLOGICAL|Aldesleukin|Given SC
224045223|NCT01758458|OTHER|Laboratory Biomarker Analysis|Correlative studies
224045224|NCT01758458|BIOLOGICAL|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
224045225|NCT01758458|RADIATION|Radiation Therapy|Undergo radiation therapy
223434542|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
223434543|NCT00851773|DRUG|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
223434544|NCT00851773|DRUG|placebo|0.1 mg once weekly, s.c. injection
223434545|NCT00851773|DRUG|placebo|0.2 mg once weekly, s.c. injection
223434546|NCT00851773|DRUG|placebo|0.4 mg once weekly, s.c. injection
223434547|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
223565886|NCT06984926|DRUG|BI 3810477|BI 3810477
223565887|NCT06984926|DRUG|Placebo|Placebo for BI 3810477
224045226|NCT01758458|BIOLOGICAL|Recombinant Interferon Beta|Given intralesionally
224141640|NCT05197140|OTHER|food: cooked 85% lean ground beef|see arm description
224141641|NCT05197140|OTHER|food: Impossible Burger (R)|see arm description
224141642|NCT02297737|BEHAVIORAL|Tai Chi|
224141643|NCT02297737|OTHER|Health Education|
224141644|NCT00407173|DRUG|HCV-796|HCV-796 1000mg single dose
224141645|NCT06064903|BIOLOGICAL|CD7-CART01|A single IV infusion of CD7-CART01 on Day 0
224141646|NCT04255017|DRUG|Abidol hydrochloride|Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
224141647|NCT04255017|DRUG|Oseltamivir|Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
224045227|NCT02431897|DRUG|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
224045228|NCT02431897|DRUG|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for \>5 weeks before surgery, then 2x/week for 1 year after surgery.
224045229|NCT00546299|DRUG|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
224045230|NCT03527082|OTHER|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
224045231|NCT06273670|OTHER|screening and data collection|"Structured questionnaire prepared in English and translated to local language (Arabic). The questionnaire is then linguistically validated by two forwards translations and one backward translation. Data was collected by the investigators who were not participating in the study.~Personal or telephone interview will be conducted with clients and service providers conducted to collect the data."
224045232|NCT06110260|DIETARY_SUPPLEMENT|AstraGin (Ginseng and Astragalus Saponin Extract)|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + AstraGin. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
224045233|NCT06110260|DIETARY_SUPPLEMENT|Placebo|In this study, we are investigating the effects of AstraGin on healthy adults. The testing sample is orally administrated to subjects with 35g whey protein + Placebo. After intervention, a 180-min kinetics study of plasma amino acids was conducted.
224045234|NCT01811784|BEHAVIORAL|Ask people not to drink raw sap|
224141648|NCT04255017|DRUG|Lopinavir/ritonavir|Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
223434548|NCT00851773|DRUG|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
223434549|NCT05170230|DRUG|Terlipressin|intracapsular injection of Terlipressin versus Carbetocin for decreasing blood loss in women undergoing laparoscopic myomectomy
223434550|NCT00240825|DRUG|Ibuprofen|
223434551|NCT00240825|DRUG|Placebo|
223434552|NCT00240825|DRUG|Acetaminophen|
223434553|NCT05833828|PROCEDURE|on-pump surgery|"the surgery will be performed on-pump"
223434554|NCT05833828|PROCEDURE|off-pump surgery|"the surgery will be performed off-pump"
223565888|NCT04432064|DEVICE|Active TI-NDBS|In the active TI-NDBS condition, subjects will receive stimulation for 60 minutes applied to the brain through scalp electrodes. There will be a maximum of 2 mA per electrode pair and no single region will receive more than 2 mA because the currents will be administered to distinct regions. At the beginning of each stimulation period, the current will increase slowly at a constant rate for 30 seconds until it reaches the appropriate intensity. At the end of the stimulation, the current will decrease slowly for 30 seconds until it reaches zero.
223565889|NCT04432064|OTHER|Sham TI-NDBS|This is the control condition in which participants will receive sham stimulation for 60 minutes.
224045235|NCT01811784|BEHAVIORAL|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
224045236|NCT01811784|OTHER|No Intervention|
224045237|NCT01811784|OTHER|No Intervention|
224045238|NCT05380011|OTHER|Constraint Induced Movement Therapy and Bimanual Task Training|Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
224141649|NCT02030587|PROCEDURE|Radiofrequency Ablation|
223434555|NCT05433480|DRUG|BPI-16350|BPI-16350 400 mg, orally once daily
223434556|NCT05433480|DRUG|placebo|Placebo 400 mg, orally once daily
223565890|NCT04432064|DEVICE|tDCS|This is a well established method of brain stimulation and will be used to compare against the efficacy of TI-NDBS in the reduction of nicotine craving and inhalation. Participants will receive stimulation for 60 minutes.
224141650|NCT02030587|PROCEDURE|Laparoscopic Adrenalectomy|
224141651|NCT04944381|BIOLOGICAL|SARS-Cov-2 mRNA vaccine immunization|The 98 participants will be inoculated with one dose SARS-Cov-2 mRNA vaccine from Stemirna Therapeutics Co., Ltd and .
224141652|NCT04944381|BIOLOGICAL|Inactivated SARS-Cov-2 vaccine immunization|The 14 participants will be inoculated with one dose inactivated SARS-Cov-2 vaccine from institute of medical biology, Chinese academy of medical sciences(IMBCAMS).
224141653|NCT02045251|DRUG|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
224141654|NCT01322451|DRUG|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
224141655|NCT01322451|DRUG|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
224141656|NCT00502632|DRUG|Urokinase and Dornase alfa|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
223434557|NCT05433480|DRUG|Fulvestrant|Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
223434558|NCT03632226|DRUG|18F-OGA-1|
223434559|NCT05037539|DRUG|Fentanyl Citrate 50Mcg/Ml Inj_#1|Injectable Fentanyl in Sublingual Route 50 mcg
223434560|NCT05037539|DRUG|Morphine|Oral Morphine Syrup 2.5 ml ( 5 mg)
223434561|NCT02799173|BIOLOGICAL|RANKL/OPG ratio|
223434562|NCT02799173|DEVICE|bone densitometry|
223434563|NCT02799173|DEVICE|fan beam CT scan|
223434564|NCT02799173|DEVICE|Doppler ultrasound|
223434565|NCT00104468|DRUG|Troxatyl™ (Cytotoxic Chemotherapeutic)|
223434566|NCT00081926|DRUG|Gleevec|
223434567|NCT02991014|BEHAVIORAL|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
224045239|NCT05380011|OTHER|Bimanual Task Training|Bimanual Task Training will be performed. Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.
224045240|NCT06373471|OTHER|Comprehensive geriatric assessment (CGA) and treatment|"CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include:~* Assessment of comorbidity and treatments~* Review of medications including potential adjustment~* Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue~* Objective examination including blood tests and electrocardiogram~* Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires~* Assessment of domestic conditions, including need for assistance~* Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required"
224045241|NCT03453658|PROCEDURE|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
224045242|NCT03453658|PROCEDURE|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
224045243|NCT02101021|DRUG|Momelotinib|Tablet (s) administered orally once or twice daily
224045244|NCT02101021|DRUG|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
224045245|NCT02101021|DRUG|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
224045246|NCT02101021|DRUG|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
224045247|NCT00398671|DEVICE|Application of cool cap after primary successful CPR|
224045248|NCT01621542|BIOLOGICAL|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
224045249|NCT04533087|OTHER|No intervention|No intervention
224045250|NCT00760669|DRUG|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
223434568|NCT02991014|BEHAVIORAL|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
224045251|NCT00760669|DRUG|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
224045252|NCT00279019|DRUG|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
224045253|NCT00279019|DRUG|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
224045254|NCT00279019|DRUG|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
224045255|NCT02241369|BIOLOGICAL|INO-3106, INO-9012|
224141657|NCT00502632|DRUG|Urokinase|"Intrapleural administration of:~* Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~* 25ml normal saline, twice daily for 4 days"
224141658|NCT03587584|DRUG|liposomal bupivacaine|Experimental
224141659|NCT03587584|DRUG|Bupivacaine|Active Comparator
224141660|NCT03336762|DIAGNOSTIC_TEST|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
224141661|NCT03336762|DIAGNOSTIC_TEST|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
224141662|NCT04142749|DRUG|Oltipraz|Total 90mg, By mouth, TID
224141663|NCT04142749|DRUG|Placebos|Total 90mg, By mouth, TID
224141664|NCT02152358|DRUG|Aciclovir|Intravenous 15 mg/kg/d during 14 days
224141665|NCT02152358|DRUG|Ganciclovir|intravenous 10 mg/kg/d for 14 days
224141666|NCT02152358|DRUG|Placebo|
224141667|NCT01001858|OTHER|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
224141668|NCT00387348|DRUG|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
224141669|NCT00387348|DRUG|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
224141670|NCT03010722|DRUG|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
224141671|NCT04579796|OTHER|ultrasound exam|An abdominal ultrasound exam to assess the placenta implantation site.
224141672|NCT04579796|PROCEDURE|hysteroscopy diagnostic|Diagnostic hysteroscopy to asses the placenta implantation site.
223434569|NCT02991014|BEHAVIORAL|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
224141673|NCT05905757|PROCEDURE|Dexmedetomidin + bupivacaine|dexmedetomidine was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
223434570|NCT03217019|PROCEDURE|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
223434571|NCT03217019|PROCEDURE|Direct|catheter insertion without guidewire assist(catheter over needle)
223434572|NCT00776802|DRUG|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
223434573|NCT00776802|DRUG|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
223434574|NCT02851979|OTHER|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
223434575|NCT03361436|DRUG|Eribulin Mesylate|Given IV
223434576|NCT03361436|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223434577|NCT03361436|OTHER|Laboratory Biomarker Analysis|Correlative studies
223434578|NCT03361436|OTHER|Quality-of-Life Assessment|Ancillary studies
223434579|NCT03361436|OTHER|Questionnaire Administration|Ancillary studies
223434580|NCT03361436|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223434581|NCT02733575|OTHER|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
223434582|NCT01676506|DRUG|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
223434583|NCT01676506|PROCEDURE|Ranibizumab Injection|
224045256|NCT03078712|OTHER|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
224141674|NCT05905757|DRUG|Tramadol + Bupivacaine|tramadol was added as adjuvant to bupivacaine in transversus abdominis plane block (TAP)
224141675|NCT02501837|DRUG|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
224141676|NCT04234763|BEHAVIORAL|Strategies to lower postprandial hyperglycemia in T2D patients|T2D patients will undergo a 14-day chronic feeding trial intervention where the strategies to lower postprandial hyperglycemia will be educated. For example, to control portion of carbohydrate, incorporate low GI food and diabetes-specific formula, promote physical activity and practice consistent meal timing. After that, patients will undergo MCT again to evaluate the difference before and after the intervention.
224141677|NCT04234763|BEHAVIORAL|Control group|Assess nutritional status and no active intervention is conducted.
224141678|NCT01755741|COMBINATION_PRODUCT|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
224141679|NCT01755741|DEVICE|Condom|Male condom
223434584|NCT01118988|BEHAVIORAL|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
223434585|NCT01846468|DRUG|LHW090|1 mg, 12.5 mg, 100 mg capsules
223434586|NCT01846468|DRUG|Placebo|Matching placebo capsules
224045257|NCT03078712|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
224045258|NCT05016206|DRUG|Danicopan|Danicopan tablets administered as a single oral dose.
224141680|NCT05969912|OTHER|Graston Technique (Instrumented assisted soft tissue mobilization)|"They would received Graston technique (Instrumented assisted soft tissue mobilization) as follow:~Using lubricant (Vaseline) on the skin then a stainless steel instrument to relax the fascia and muscles. Frequency: 60 reps per min for 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Graston technique (Instrument assisted soft tissue mobilization)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
223434587|NCT03453996|OTHER|Intervention|"Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~1. Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~2. Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation."
223565891|NCT06657651|PROCEDURE|immediate implant placement with dentin-derived membrane|immediate implant placement with dentin-derived membrane and allograft in mandibular molar area
224045259|NCT05016206|DRUG|Moxifloxacin-matching Placebo|Moxifloxacin-matching placebo was administered as a single oral dose.
224045260|NCT05016206|DRUG|Danicopan-matching placebo|Danicopan-matching placebo was administered as a single oral dose.
224045261|NCT05016206|DRUG|Moxifloxacin|Moxifloxacin 400 mg was administered as a single tablet oral dose.
224045262|NCT04352192|OTHER|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of biceps brachii muscle.
224141681|NCT05969912|OTHER|Bowen's Technique(Soft tissue technique)|"They would received Bowen's technique (Soft tissue technique) as follow:~Bowen moves (15 - 20 times) with 2 mins gap between each set. Frequency: 3 times/week for 3 consecutive weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: Bowen's technique (Soft tissue technique)~Additionally, the would receive Conventional PT :~Ultrasound for 5 min Stretching exercises at lumbar : Frequency: 10 reps with 5 sec hold for 3 times/week for 3 weeks"
224141682|NCT03421509|OTHER|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
223434588|NCT03453996|OTHER|Control|Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
223434589|NCT03516006|DRUG|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
223434590|NCT03516006|DRUG|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
224141683|NCT00505752|DRUG|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
224141684|NCT00505752|DRUG|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
224141685|NCT00505752|DRUG|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
224141686|NCT00505752|DRUG|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
224141687|NCT00505752|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[\>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of \>= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
224141688|NCT02349737|OTHER|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
224141689|NCT05525312|PROCEDURE|"Open-lung protective ventilation strategy"|"In the open-lung group, the positive end-tidal pressure (PEEP) is titrated to match the best lung compliance. During a PEEP decrement trial, PEEP is decreased from 20 cmH2O to 4 cmH2O by steps of 2 cmH2O/minute, and the driving the transpulmonary pressure (PTP) is calculated at each level of PEEP. In the open-lung group, the targeted PEEP corresponds to the lowest driving PTP during the PEEP decrement trial, meaning the best lung compliance. Thereafter, the PEEP is set at this level and maintained until extubation."
223434591|NCT02479971|DRUG|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
223434592|NCT02479971|DRUG|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
223434593|NCT03566875|PROCEDURE|Total knee arthroplasty with the Stryker's MAKO™ system|The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
223434594|NCT03566875|PROCEDURE|Total knee arthroplasty with mechanical ancillary|The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
223434595|NCT01432275|DEVICE|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
224141690|NCT05525312|PROCEDURE|"Standard protective ventilation strategy"|"In the standard group, the positive end-tidal pressure (PEEP) is arbitrarily set at 5 cmH2O, since this is the currently recommended level of PEEP, commonly used in control groups of previous clinical trials."
224141691|NCT03046017|DEVICE|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
224141692|NCT03046017|OTHER|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
224141693|NCT03046017|OTHER|Control cream|A neutral cream will be applied as a control.
223434596|NCT01432275|DEVICE|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
223434597|NCT01432275|DEVICE|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
223434598|NCT01048970|OTHER|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
223434599|NCT01048970|DIETARY_SUPPLEMENT|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
223434600|NCT02565706|BEHAVIORAL|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
223434601|NCT02565706|BEHAVIORAL|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
223434602|NCT02623842|DEVICE|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
223434603|NCT03315611|DRUG|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
223434604|NCT03315611|OTHER|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
223434605|NCT06294873|DIAGNOSTIC_TEST|A screening device for the detection of colorectal and other aerodigestive tract cancers|DNA test to screen to detect colon cancer and precancerous lesions
223565892|NCT06657651|PROCEDURE|immediate implant with extended platelet rich fibrin membrane|immediate implant with extended platelet rich fibrin membrane and allograft in mandibular molar area
223565893|NCT00453609|DRUG|long-lasting injectable naltrexone|
224045263|NCT06417112|DIAGNOSTIC_TEST|Transthoracic Echocardiogram|All participants have been referred for a transthoracic echocardiogram by a clinician.
223434606|NCT03985189|DRUG|ME-401|"\[Phase 1 study (DLT evaluation)\] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~\[Roll over study\] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met."
223434607|NCT03646149|BEHAVIORAL|Housing Skills Training Group|12-session social skills training group for persons with homeless experiences and serious mental illness delivered once a week for 12 weeks
223740587|NCT06411691|DRUG|Botensilimab|"75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 15 in the Boost Phase.~Drug: 75 mg IV"
224045264|NCT05950295|OTHER|Intranasal lavage with hypochlorous acid solution|intranasal lavage for ten days
224045265|NCT02663271|DRUG|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
224045266|NCT02663271|DEVICE|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
224045267|NCT02663271|OTHER|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
224141694|NCT04163107|DRUG|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
224141695|NCT04163107|DRUG|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
223434608|NCT01551706|DIETARY_SUPPLEMENT|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
223434609|NCT01551706|OTHER|Placebo|Placebo
223434610|NCT00475878|DRUG|escitalopram|10mg escitalopram/day for 3 months
223434611|NCT00475878|DRUG|placebo|placebo capsule/day for 3 months
223434612|NCT03040505|OTHER|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
223434613|NCT04678401|RADIATION|Radiation|Total Myeloid and Lymphoid Irradiation (TMLI) delivered through Radiation Oncology institutional standards
223434614|NCT04678401|DRUG|Fludarabine|Given intravenously -10 to -6 days prior to hematopoietic stem cell transplant (HSCT)
223434615|NCT04678401|DRUG|Thiotepa|Given intravenously on day -10 and day- 9 prior to hematopoietic stem cell transplant (HSCT)
223434616|NCT04678401|DRUG|Cyclophosphamide|Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
223434617|NCT04678401|DRUG|Mesna|Given intravenously with Cyclophosphamide on day -8 and day -7 prior to hematopoietic stem cell transplant (HSCT)
223565894|NCT03520751|DRUG|scAAV1.tMCK.NTF3|gene vector
223740588|NCT02881242|OTHER|Laboratory Biomarker Analysis|Correlative studies
223740589|NCT02881242|OTHER|Quality-of-Life Assessment|Ancillary studies
223740590|NCT02881242|DRUG|Trametinib|Given PO
224045268|NCT02663271|OTHER|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
224045269|NCT01572675|DRUG|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
224045270|NCT01572675|DRUG|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
224141696|NCT04163107|DRUG|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
224045271|NCT05788744|DIAGNOSTIC_TEST|ctDNA|ctDNA guided surveillance
224045272|NCT03618784|BIOLOGICAL|FURESTEM-RA Inj|"The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~* Dose level 1: 5.0 x 10\^7 cells /body 3 repeated intravenous injection at 4 week intervals~* Dose level 2: 1.0 x 10\^8 cells /body 3 repeated intravenous injection at 4 week intervals"
224045273|NCT03618784|OTHER|sterile saline|"sterile saline 3 repeated intravenous injection at 4 week intervals~Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump."
224045274|NCT05798130|OTHER|No intervention group.|No intervention group.
224045275|NCT00053703|DRUG|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
224045276|NCT00053703|DRUG|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
224141697|NCT00022958|DRUG|Iodine-131 Anti-B1 Antibody|
224141698|NCT01149343|BIOLOGICAL|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
223434618|NCT04678401|BIOLOGICAL|Treg-enriched donor cell|Given intravenously -4 day prior to hematopoietic stem cell transplant (HSCT)
223434619|NCT04678401|BIOLOGICAL|Unmodified donor T Cell|Given intravenously -1 day prior to hematopoietic stem cell transplant (HSCT)
223434620|NCT04678401|PROCEDURE|CD34+ Haplo Peripheral Blood Stem Cell|CD34+ Haplo Peripheral Blood Stem Cell Transplantation
223434621|NCT00567697|DRUG|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
223434622|NCT00567697|DRUG|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
223434623|NCT05016297|DRUG|Baricitinib|baricitinib 4mg per day
223434624|NCT05016297|DRUG|Hydroxychloroquine|Hydroxychloroquine 200mg twice a day
223434625|NCT00231283|DEVICE|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
223434626|NCT00019422|DRUG|carboplatin|
223434627|NCT00019422|DRUG|lobradimil|
223434628|NCT05956405|BEHAVIORAL|AIR + Mindfulness|AIR + Mindfulness program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
223740591|NCT06067542|PROCEDURE|Surgery of impacted mandibular wisdom teeth|All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
224045277|NCT00053703|DRUG|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
224045278|NCT01931787|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
224045279|NCT03476564|DRUG|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
224045280|NCT03476564|DRUG|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
224045281|NCT03277326|PROCEDURE|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
224045282|NCT03277326|PROCEDURE|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
224045283|NCT03277326|PROCEDURE|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
224045284|NCT01910805|BEHAVIORAL|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
224045285|NCT02832700|DIETARY_SUPPLEMENT|Casein glycomacropeptide|
224045286|NCT02832700|DIETARY_SUPPLEMENT|Placebo|
224045287|NCT03940547|OTHER|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
224045288|NCT03940547|OTHER|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
224045289|NCT03200964|OTHER|anesthesia given as required for surgical procedure|
224045290|NCT04997928|OTHER|Serum PAI-1 alpha analysis.|After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.
224045291|NCT04836663|DRUG|TQ-B3525 tablet|TQ-B3525 tablet administered orally once a day. Each cycle is 28 days.
224045292|NCT04001907|BEHAVIORAL|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
224045293|NCT04001907|DIETARY_SUPPLEMENT|β-hydroxy-β-methylbutyrate|
224045294|NCT04001907|DIETARY_SUPPLEMENT|placebo|
224045295|NCT00576433|DRUG|Methotrexate|As prescribed
224045296|NCT00576433|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
224045297|NCT06323122|DEVICE|2.0 miniplates|2.0 miniplates
224141699|NCT06308146|DIETARY_SUPPLEMENT|Bacillus subtilis ATCC 122264|One capsule (5 billion CFU) per day for 8 weeks.
223434629|NCT05956405|BEHAVIORAL|Relaxation condition|Relaxation program consists of 8 sessions of 120 minutes/session (10-12 people) Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
223434630|NCT02379507|OTHER|DEC033 Study Product|Apply twice daily
223434631|NCT03030885|DRUG|131I-MIP-1095|"First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
223434632|NCT00316407|DRUG|lapatinib (GW572016)|1000 mg po qd
223434633|NCT00316407|DRUG|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
223740592|NCT05665530|DRUG|PRT2527|PRT2527 will be administered by intravenous infusion once weekly.
224045298|NCT06323122|DEVICE|2.3 high profile miniplates|2.3 high profile miniplates
224045299|NCT06323122|DEVICE|3D miniplates|3D miniplates
224045300|NCT03626584|OTHER|18F-NaF PET|Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
224045301|NCT03725163|BEHAVIORAL|Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)|This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
224045302|NCT05009186|OTHER|PSA value|We measure PSA value during and after covid-19 infection
224045303|NCT05689723|PROCEDURE|Lumbar manipulation|Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
223434634|NCT00316407|DRUG|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
224045304|NCT05689723|PROCEDURE|Sham Manipulation|The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
224045305|NCT02921269|DRUG|Atezolizumab|Given IV
224045306|NCT02921269|BIOLOGICAL|Bevacizumab|Given IV
224045307|NCT02921269|OTHER|Laboratory Biomarker Analysis|Correlative studies
224045308|NCT05927922|DRUG|Oral Ibuprofen (Abbott, Egypt)|ibuprofen is analegisic drug used to relieve pain
224045309|NCT04702282|DIAGNOSTIC_TEST|ropivacain concentration measurements|Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
224045310|NCT06249724|DEVICE|Active stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused low-intensity ultrasound stimulation
224141700|NCT06308146|DIETARY_SUPPLEMENT|Placebo|One capsule per day for 8 weeks.
224141701|NCT01925612|DRUG|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
223434635|NCT04471571|OTHER|Resin infiltration and microabrasion for MIH-affected incisors|MIH-affected incisors will be treated with microabrasion followed by resin infiltration as a combined treatment
223434636|NCT04471571|OTHER|Resin infiltration for MIH-affected incisors|MIH-affected incisors will be treated with resin infiltration alone
223434637|NCT06441695|DIETARY_SUPPLEMENT|xumXR extended release caffeine|proprietary capsule for extended release of caffeine
223434638|NCT06441695|DIETARY_SUPPLEMENT|immediate release caffeine|immediate release caffeine capsule
223434639|NCT05463757|DRUG|Vismodegib|Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)
223434640|NCT05463757|DRUG|Sonidegib|Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)
223434641|NCT06094894|OTHER|sucralose|Food additive used to replace sugar providing a sweet taste without calories.
223434642|NCT06094894|OTHER|placebo|Cornstarch without significant physiological effects
223434643|NCT05840406|DRUG|Postoperative pain management with acetaminophen|During the 24 hours postoperatively, participants will receive 1 g acetaminophen intravenously (i.v.) three times a day. On the second and third postoperative days, participants will receive 1g acetaminophen per os three times a day.
223434644|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine will be administered to the participant on each side.
223434645|NCT05840406|PROCEDURE|Bilateral TAP Block with levobupivacaine and dexmedetomidine|Ultrasound-guided bilateral TAP block will be performed, and 20 ml of 0,25 % levobupivacaine with the addition of 0,5 μg/kg dexmedetomidine will be administered to the participant on each side.
223434646|NCT05840406|DRUG|Postoperative pain management with tramadol|During the 24 hours postoperatively, participants will receive 500 mg tramadol + 500 ml 0,9% NaCl i.v. continuously 30ml/h.
223434647|NCT05840406|DRUG|Postoperative pain management with ketoprofen|During the 24 hours postoperatively, participants will receive 100 mg ketoprofen + 100 ml of 0,9% NaCl i.v. twice a day. The first dose will be administered in the theatre at the end of the surgical procedure.
223565895|NCT06659666|DEVICE|COPD Optimiser|Patients will receive enhanced usual medical care as determined by their physician. The study visit is a standard consultation supported by the COPD Optimiser webtool. The extra elements added to the COPD consultation are the use of the COPD Optimiser and a short questionnaire directly following the consultation on the patient's experience with the COPD Optimiser. Patients can additionally consent to two optional elements: 1) a determination of blood eosinophil count using a point of care test and 2) a brief interview on their experience with the COPD Optimiser. this tool creates an overview of fac- tors and characteristics that may be associated with suboptimal COPD and provides GOLD guideline-based management suggestions. Implementation of the COPD Optimiser will sup- port healthcare professionals in providing optimal care for their COPD patients by providing individualized GOLD-guided management suggestions.
223740593|NCT05665530|DRUG|Zanubrutinib|Zanubrutinib will be provided in capsules for oral administration once or twice daily.
223740594|NCT05665530|DRUG|Venetoclax|Venetoclax will be provided in tablet for oral administration once daily
224045311|NCT06249724|DEVICE|Sham stimulation using low-frequency ultrasonic transducer|The ultrasonic transducer delivers focused zero-intensity ultrasound stimulation
224045312|NCT00703053|BIOLOGICAL|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
224045313|NCT00703053|BIOLOGICAL|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
224141702|NCT01925612|DRUG|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
224141703|NCT01925612|DRUG|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
224141704|NCT01925612|DRUG|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
223434648|NCT05840406|DRUG|Postoperative pain management with ibuprofen|On the second and third postoperative days, participants will receive 600 mg ibuprofen per os three times a day.
223434649|NCT05844735|DRUG|SAR441566|Tablet
223434650|NCT05844735|DRUG|Placebo|Tablet
223434651|NCT05844735|DRUG|Ciprofloxacin|Tablet
224045314|NCT06026683|DEVICE|Pacemaker implant|Implantation of pacemaker with conduction system pacing or right ventricular apical pacing
224141705|NCT01925612|DRUG|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
224141706|NCT01925612|DRUG|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
224141707|NCT01925612|DRUG|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
224141708|NCT05987345|DEVICE|PEF|PEF device treated in the trial.
224141709|NCT05987345|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
224141710|NCT02591888|DRUG|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
223434652|NCT05732701|OTHER|Algorithm-guided DAPT duration|"PRECISE-DAPT score ≥25~* Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~* Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score \<25:~* Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~* Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~* Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)"
223434653|NCT05732701|OTHER|Standard-of-care DAPT duration|DAPT strategy at the operators´ discretion in accordance with applicable guidelines
223434654|NCT03910452|DRUG|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
223434655|NCT03910452|DRUG|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
223434656|NCT03910452|DRUG|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
223565896|NCT06661707|PROCEDURE|Sonar guided Quadratus Lumborum block|The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
223565897|NCT06661707|PROCEDURE|Sonar guided Ilioinguinal/Iliohypogastric block|"The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg"
224045315|NCT02052063|DEVICE|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
224045316|NCT02052063|DEVICE|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
224045317|NCT05745454|BIOLOGICAL|HER2-E-CART cells|E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
224045318|NCT03697434|BEHAVIORAL|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
224045319|NCT04561596|DEVICE|OnComfort autohypnosis|"Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual except for the virtual reality mask and autohypnosis software that will run during the whole intervention.~Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
224045320|NCT04561596|OTHER|Treatment as usual, without the OnComfort autohypnosis system|"The Participant arrive in our day care clinic and is prepared as any other patient in interventional radiology. The investigator will collect the signed informed consent form and proceed to randomization.~The participant will then fill the pre and post-operative anxiety and pain questionnaire.~The percutaneous vascular procedure will be performed as usual. Pain and anxiolytic medication are provided if needed during the intervention. Immediately after the intervention, the participant will fill the post-operative anxiety and pain questionnaire. The participant will be instructed to report anxiety and pain felt during the intervention.~A clinical visit at 3 month is conducted as part of the standard clinical protocol. The participant will fill a 3rd questionnaire about the remembered anxiety and pain during the intervention."
224141711|NCT02591888|DRUG|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
224141712|NCT01009918|DRUG|Coreg CR®|Given orally
224141713|NCT01009918|DRUG|lisinopril|Given orally
223434657|NCT03910452|DRUG|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
223434658|NCT03910452|RADIATION|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
223434659|NCT03910452|BIOLOGICAL|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
223434660|NCT06484452|DEVICE|No Intervention|No Intervention
223434661|NCT02171013|DRUG|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
223434662|NCT02171013|DRUG|Dabigatran polymorph I|
223434663|NCT04912388|OTHER|Lumbal stabilization excercises|The stabilization group will perform lumbal stabilization exercises in lying, sitting, standing and on a swisball 3 times a week during 6 weeks.
223434664|NCT04912388|OTHER|Conventional exercises|The general exercise group will perform conventional exercises 3 times a week during 6 weeks.
223434665|NCT01734915|DEVICE|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
223434666|NCT02464761|DRUG|Visudyne|
224045321|NCT03247426|OTHER|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
224045322|NCT05356468|OTHER|Structured pain neuroscience education|"Structured pain neuroscience~* Neurophysiology of pain~* The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~* Metaphor Alarm system: Your nerves working like an alarm system to protect you.~* BOOKLET Consist of education about pain neurophysiology.(31)~* Steps of booklet :~  1. Extract content~ 2. English to Urdu translation~ 3. Content Validity~ 4. Expert Panel review by Physiotherapists~ 5. Content validity Analysis review(Focus Group)~ 6. Pilot study 4 to 5 patients~ 7. Content improved (PNE) and Finalized~ 8. After Analysis RCT"
224045323|NCT05356468|OTHER|Conventional Treatment|"ELECTROTHERAPY MODALTIES-15 min~* IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~* Hot pack(27)~Therapeutic exercises~* Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~* Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~* Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~* Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~* good posture when sitting standing and while driving~* Avoid weight lifting~* Avoid too much bed rest~* Sit in firm places. (30)"
224045324|NCT06427291|BIOLOGICAL|Herpes virus T3011 injection|T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water
224045325|NCT00724295|DRUG|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
224045326|NCT00724295|DRUG|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
224045327|NCT05138913|DRUG|TXA|After the arthroscopic operation was completed, a local TXA injection was performed
224045328|NCT05138913|DRUG|Saline|After the arthroscopic operation was completed, a local saline injection was performed
224045329|NCT00716053|DRUG|BLVR|BLVR 20 mL
224045330|NCT00504153|DRUG|dasatinib|
224045331|NCT00504153|OTHER|laboratory biomarker analysis|Correlative studies
224045332|NCT00108992|DRUG|Diclofenac, topical|
224045333|NCT06374914|DRUG|Intravesical Solution|Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
224045334|NCT00348062|DRUG|Bimatoprost|
224045335|NCT02322229|DRUG|Ocriplasmin 0.125 mg in a 0.1 mL volume|
224045336|NCT02838095|BEHAVIORAL|Nap|A 1-hour daytime nap opportunity
224045337|NCT01859468|DIETARY_SUPPLEMENT|Amorphous calcium carbonate|
224045338|NCT01859468|OTHER|Placebo|
223434667|NCT02292186|DRUG|Revusiran (ALN-TTRSC)|
223434668|NCT05406505|DRUG|Dapagliflozin 10mg Tab|patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
223434669|NCT05406505|OTHER|Placebo|patients will receive placebo and standard care.
223740595|NCT01849627|BEHAVIORAL|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
224045339|NCT05355779|OTHER|Not Application as this is a qualitative study|Not Application as this is a qualitative study
224045340|NCT00961753|DRUG|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
224045341|NCT00961753|DRUG|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
224045342|NCT00705432|BIOLOGICAL|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
224045343|NCT00705432|DRUG|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
224045344|NCT00705432|DRUG|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
224045345|NCT00705432|DRUG|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
224141714|NCT01009918|OTHER|placebo|Given orally
224299806|NCT03994055|OTHER|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
223434670|NCT00370981|DRUG|pagoclone|
223434671|NCT01637766|DRUG|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
223434672|NCT00835679|BIOLOGICAL|cetuximab|Given IV
223434673|NCT00835679|DRUG|dasatinib|Given orally
223434674|NCT00835679|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223434675|NCT00835679|OTHER|laboratory biomarker analysis|Correlative studies
223740596|NCT01849627|BEHAVIORAL|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
223740597|NCT03222596|BEHAVIORAL|Exercise training|Exercise programme includes breathing and upper limbs exercises.
224045346|NCT02827240|OTHER|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
224045347|NCT00598260|PROCEDURE|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
224045348|NCT06328998|BEHAVIORAL|Routine rehabilitation treatment|"Routine rehabilitation treatment Includes oral rehabilitation, rehabilitation training for temporomandibular disorders, orthodontic treatment, and other physical therapy methods.which can alleviate symptoms by adjusting the bite, relaxing muscles, and increasing the range of motion of the temporomandibular joint.~Besides, it also Includes temporomandibular joint exercise training, relaxation training for facial muscles, and functional chewing training aimed at improving temporomandibular joint function and muscle balance."
224045349|NCT06328998|PROCEDURE|Intra-articular Injection|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
224045350|NCT06328998|DRUG|Lidocaine Hydrochloride|The patient is positioned to maximize mouth opening, and a needle is inserted approximately 10-12 mm in front of the tragus after touching the ankle prominence. An 8# injection needle is chosen and inserted upward and slightly forward into the joint cavity. A total of 2 mL of lidocaine hydrochloride injection solution is injected, repeated once every 5 days for a total of 15 days.
224045351|NCT00521053|DRUG|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
224141715|NCT05848180|OTHER|Ankle proprioceptive training (APT)|"APT comprise of exercises including towel curls, uni-leg stance on foam with activity, writing alphabets on gym ball with toes, picking marbles with toes.~BT includes tendem walk, side leg raises, sit to stand, side walk, back leg raise"
224141716|NCT05848180|OTHER|Balance training (BT)|Balance training exercises comprising of side walk, tandem walk, standing on one leg, walking with alternating arm raise up to 90 degrees
224141717|NCT01093755|DRUG|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
224141718|NCT01093755|DRUG|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
224141719|NCT03056976|DEVICE|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
224141720|NCT03056976|DEVICE|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
223740598|NCT00531024|DRUG|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
223740599|NCT00531024|DRUG|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
223740600|NCT03964155|BIOLOGICAL|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
223740601|NCT02201186|OTHER|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
224045352|NCT04243603|BEHAVIORAL|Internet-based Emotion Regulation Individual Therapy for Adolescents (ERITA-DK)|Please see description of experimental arm (arm one)
224045353|NCT03511404|OTHER|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
224045354|NCT03663881|DRUG|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
224045355|NCT01353079|BIOLOGICAL|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
224045356|NCT01353079|BIOLOGICAL|Placebo|Placebo: Glycero-COCAs sublingual
224045357|NCT00726934|OTHER|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
224045358|NCT00726934|OTHER|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~1. Avoid raw vegetables and fruit (Oranges and bananas are okay.)~2. Avoid take-out foods and fast foods and fountain drinks.~3. Avoid aged cheese (blue, Roquefort, Brie).~4. Cook all produce to well done. Eggs must be hard-boiled.~5. Avoid deli meats.~6. No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~7. No well water~8. No yogurt"
224045359|NCT00143481|DRUG|Tolterodine ER 4mg QD|
224045360|NCT05419401|DRUG|Capivasertib film-coated tablet, 200 mg|400mg dose, oral, fasted
224045361|NCT05419401|DRUG|[14C]AZD5363 (Capivasertib)|"Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted"
224141721|NCT03056976|DEVICE|Fixed mandibular denture|A fixed mandibular denture retained by four implants
224141722|NCT02542436|OTHER|No intervention|No intervention administered in this study
224141723|NCT05167461|OTHER|Collection of imaging by ultrasonography|The investigators will collect burn image data to be processed through the software combined with the deep machine learning to find automated diagnostic burn assessment with accuracy of \>95% compared to human assessment
224141724|NCT02580994|DRUG|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
224141725|NCT02580994|DRUG|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
224141726|NCT00868166|DRUG|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
224141727|NCT00868166|DRUG|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
223434676|NCT06011304|DRUG|[18F]Florastamin Injection|"The subjects who participate in phase 3 study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 110 min after the injection.~Subjects who participate in pilot study will be intravenously injected with \[18F\]Florastamin Injection and undergo PET/CT scan at 5 min, 30 min, 60 min, 110 min, 160 min after the injection."
223434677|NCT02560324|DRUG|Ramelteon|
223434678|NCT02560324|DRUG|Placebo|
223434679|NCT06052540|DIETARY_SUPPLEMENT|Probiotic supplement|"* Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~* Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin."
223434680|NCT06052540|DIETARY_SUPPLEMENT|Placebo|"* Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~* Stick: Maltodextrin."
223434681|NCT04417140|BIOLOGICAL|dHACM (AmnioWrap)|Dehydrated human amnion-chorion membrane (dHACM) is a healing adjunct that has been applied in a broad range of disease, and is FDA registered for wound healing.
223434682|NCT04658524|DIAGNOSTIC_TEST|Thyroid function|laboratorial thyroid tests
223434683|NCT04683354|DRUG|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
223434684|NCT00126269|DRUG|cisplatin|
224045362|NCT03665389|DEVICE|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
224045363|NCT02347488|DEVICE|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
224045364|NCT02347488|PROCEDURE|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
224045365|NCT02082899|DRUG|Active Comparator EBI-005 5 mg/mL|
224045366|NCT02082899|DRUG|Placebo Comparator|
224045367|NCT05723354|PROCEDURE|axillary block guided by ultrasound|axillary block using local anesthetics
224045368|NCT03082131|DIETARY_SUPPLEMENT|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
224141728|NCT00868166|DRUG|Riluzole|Riluzole given as add-on therapy 50mg bid
224045369|NCT02281357|BIOLOGICAL|Tralokinumab|Tralokinumab dose
224045370|NCT02281357|OTHER|Placebo|Placebo dose
224045371|NCT06493877|OTHER|Retraining program after thoracic surgery|"An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2)."
224045372|NCT04417101|DRUG|Chinese Herb|The participants will be instructed to take their JBT and take it as a dose of 3 g (per bag) each time, trice daily for 4 weeks.
224045373|NCT00636467|OTHER|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
224141729|NCT04191603|DEVICE|MONOPOLAR HOOC|COLPOTOMY WITH MONOPOLAR HOOC
223434685|NCT00126269|DRUG|gemcitabine|
223434686|NCT05152654|DEVICE|Tacker|metallic staples used to fix the mesh
224141730|NCT04191603|DEVICE|PLASMAKINETIC BIPOLAR SPATULA|COLPOTOMY WITH BIPOLAR SPATULA
223434687|NCT06618365|DRUG|Vitamin D Deficiency|"The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each."
223434688|NCT03477994|DRUG|Dexmedetomidine|an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
223434689|NCT03477994|DRUG|Clonidine|an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
223478471|NCT01118676|DRUG|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
223434690|NCT05481268|OTHER|Kinesiotaping Group|In the Kinesiotaping Group patients had muscle technique-inhibition method. An 'I' shaped tape was used for both SCM and upper trapezius. The tension of the tape was adjusted between 20 and 25% and the application was performed in the longest position of the muscle. The inhibition technique was applied from the insertion to the origin of the muscle. The tape was applied to cover the trigger points where pain was felt. For upper trapezius, the muscle was taped in the opposite direction on the cervical region in lateral flexion, slight flexion, shoulder depression and using the muscle technique with the I tape. For SCM muscle, the tape was applied on the muscle in the opposite direction on the cervical region with positioning in lateral flexion, extension and ipsilateral rotation using the muscle technique with I tape Taping was applied every 3 days and totally in 4 cycles.
223434691|NCT05481268|OTHER|Stretching Group|In our application, 3 cycles of 20 seconds of stretches were applied to upper trapezius and SCM muscle. The patient was stretched in a relaxed and supported position and physiotherapist positioned the patient passively for stretching. For the SCM muscle, stretching was achieved in the positions of contralateral lateral flexion, ipsilateral rotation and extension. For upper trapezius, stretching was performed in flexion and lateral flexion. Stretching was performed every 3 days in 4 cycles in total.
223434692|NCT05481268|OTHER|Control Group|Control Group patients, after the assessment by the dentist, the treatment method approved by the dentist was performed. The assessment was performed before treatment, at the end of week 1 and at the end of week 2.
223434693|NCT01312714|DRUG|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
223434694|NCT01312714|DRUG|Placebo|3 tablets of 1000 IU daily for 26 weeks
223434695|NCT00951834|DRUG|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
224045374|NCT04800588|DIAGNOSTIC_TEST|California Cognitive Assessment Battery|The California Cognitive Assessment Battery (CCAB) is a collection of computerized cognitive tests that will be telemedically administered to participants in their homes using a tablet computer and accessories provided by the research team. Testing may also occur in research laboratories. Previous versions of CCAB tests have been described in 16 manuscripts which describe (a) the psychometric characteristics of normative data collected in large participant populations (300 to 2,300 subjects for different tests) and (b) the sensitivity of CCAB tests for detecting performance abnormalities in patients with traumatic brain injury (TBI) and in control participants simulating the cognitive deficits that follow mild TBI.
224045375|NCT03007979|DRUG|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
224045376|NCT03007979|DRUG|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
224045377|NCT03007979|DRUG|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
224045378|NCT03007979|PROCEDURE|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
224141731|NCT06014294|BEHAVIORAL|HIIT|Participants will receive a 16-week HIIT program, with 2 sessions per week. Each session will comprise three sections, including warm-up, main exercise and cool down. The time will be between 34 to 40 minutes with progression of training. Each HIIT section will include ten combined exercises with self-weight. For Weeks 1-2, the HIIT section will include 10 intervals of 30 seconds HIIT workout at corresponding intensity, separated by 9 intervals of 60 seconds of active recovery.
224141732|NCT06014294|BEHAVIORAL|Baduanjin|As a typical MICT, Baduanjin Qigong will be performed. The instructor will provide group teaching with individual instructions on specific movements. The same training principles of individuality and progression used in the HIIT group will also be applied to Baduanjin Qigong group.
224141733|NCT06014294|BEHAVIORAL|Workshop|Participants in the non-exercise control group will receive a series of workshops related to daily recreation.
223434696|NCT00951834|DRUG|Placebo|Placebo
223434697|NCT01860742|DRUG|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
223434698|NCT01860742|DRUG|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
223434699|NCT00911209|BEHAVIORAL|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
224045379|NCT03007979|DRUG|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
223434700|NCT04020081|OTHER|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
223478472|NCT01182025|OTHER|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
223478473|NCT01182025|DRUG|Xiyanping Injection|"Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
224045380|NCT03007979|PROCEDURE|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression"
224141734|NCT01274455|GENETIC|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
224045381|NCT03007979|PROCEDURE|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
224045382|NCT03007979|PROCEDURE|Tumor biopsy (optional)|-Baseline and progression
224045383|NCT00482703|DRUG|Dasatinib|tablets, Oral, 100 mg, once daily
224045384|NCT00482703|DRUG|dasatinib|tablets, Oral, 50 mg, twice daily
224045385|NCT04447807|BEHAVIORAL|Metacognitive Training|MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. This study will conducted this intervention using group format, on a weekly basis, with duration of 9 weeks total.
223478474|NCT01182025|DRUG|Xiyanping Injection with western medicine|"1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
224045386|NCT04447807|OTHER|Treatment as Usual|Patients will continue to receive medical attention in the Bipolar Disorder Program -PROMAN- part of the University of São Paulo Medical School.
224045387|NCT01152762|PROCEDURE|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
224045388|NCT01608542|DRUG|Fostamatinib 100mg|oral tablet
224045389|NCT01608542|DRUG|Fostamatinib 200mg|oral tablet
224045390|NCT02885805|DRUG|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
224045391|NCT02885805|DRUG|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
224045392|NCT01559194|BEHAVIORAL|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
224045393|NCT01559194|BEHAVIORAL|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
224045394|NCT04817384|OTHER|Graston technique|For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
224045395|NCT04817384|OTHER|Classical Massage|In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
224045396|NCT04765241|BEHAVIORAL|Physical Activity|The intervention includes a physical activity prescription, a Polar activity tracker watch, access to a private AYA cancer survivor community through the Polar Flow community platform, mHealth nudges and surveys via text messaging, and regular phone or email contact from study staff.
224045397|NCT04726007|DRUG|Antithrombotic Agents|Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
224045398|NCT04319302|PROCEDURE|Isolated Vascularized Gastric Tube (IVGT) graft|A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
223478475|NCT06472921|BEHAVIORAL|Butylphthalide treatment initiation time|Eligible participants with acute ischemic stroke will be randomly assigned in a 1:1 ratio to two groups: an early initiation group (\&lt;3 hours) and a late initiation group (3-6 hours).
223740602|NCT01068119|PROCEDURE|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
224045399|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-TELEMEDICINE|Routine follow up care conducted remotely with video-conferencing tools
224045400|NCT04936243|BEHAVIORAL|FOLLOW UP VISIT-FACE TO FACE|Routine follow up care conducted in person
224045401|NCT05005455|DRUG|bevacizumab with new manufacturing process.|3mg/kg,I.V.,single dose
224045402|NCT05005455|DRUG|bevacizumab with old manufacturing process.|3mg/kg,I.V.,single dose
224045403|NCT04202523|RADIATION|Radiofrequency ablation|Liver cancer radiofrequency ablation is a clinical treatment method that uses electrode needles to penetrate the skin and liver into the tumor and completely destroy the tumor through the principle of heat production to achieve the purpose of treating tumors.
224045404|NCT04202523|DEVICE|IMRT & SBRT|Tumor radiation therapy is a local treatment method using radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioactive isotopes and x-rays, electron beams, proton beams, and other particle beams produced by various types of x-ray therapy machines or accelerators. Current mainstream radiotherapy technologies include stereotactic radiation therapy (SRT). Stereotactic radiation therapy (SRT) includes three-dimensional conformal radiation therapy (3DCRT) and three-dimensional conformal intensity modulated radiation therapy (IMRT).
224045405|NCT06197334|DEVICE|Gastro-intestinal biopotentials recording|Participants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, they will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.
224045406|NCT00186264|DRUG|venlafaxine XR|
224045407|NCT00186264|DRUG|hydrocortisone|
224045408|NCT01553877|DIETARY_SUPPLEMENT|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
224045409|NCT01553877|DIETARY_SUPPLEMENT|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
224141735|NCT06134791|OTHER|No intervention|No intervention
224141736|NCT00240539|PROCEDURE|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
223434701|NCT06443801|OTHER|THE GROUP THAT WILL TAKE WEB-BASED BREASTFEEDING EDUCATION IN PREGNANCY|"The data of the study will be applied to both groups at the same time. No training will be given to the control group, and web-based breastfeeding training consisting of 4 modules will be given to the experimental group during their pregnancy. As data collection tools; Pregnant data collection form, Postpartum information form, IOWA infant feeding attitude scale, IMDAT scale, Edinburgh depression scale, Breastfeeding motivation scale, Insufficient milk perception scale, Breastfeeding self-efficacy scale and System usability scale will be used. Data collection tools will be applied to women at pregnancy, postpartum 7th day, PP 3rd month and PP 6th month.~Appropriate methods will be used in the evaluation of the data. The significance level will be determined as α=0.05.~The sample of the study consisted of 90 primiparous pregnant women, 45 of whom were in the control and 45 in the experimental group, who met the inclusion criteria."
223434702|NCT05745467|DRUG|Povidone Iodine 5% Soln,Top,Kit|5% povidone iodine will be swabbed in patients nares of the experimental group.
223434703|NCT01572467|GENETIC|RNA analysis|
223434704|NCT01572467|GENETIC|gene expression analysis|
224045410|NCT01553877|DIETARY_SUPPLEMENT|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
224045411|NCT01387165|DRUG|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
224045412|NCT00630461|BIOLOGICAL|Clinical Center Reference Endotoxin|single inhalation challenge
224045413|NCT05622825|BIOLOGICAL|DC-CIK|To explore the therapeutic effect and safety of cryoablation combined with autologous DC-CIK (through hepatic artery infusion, HIA) for patients with advanced liver cancers
224045414|NCT05251818|OTHER|acupressure|A suitable environment will be prepared for postpartum women where privacy can be protected. Application points will be determined by choosing the most comfortable position of the mother. LI4 and TH were selected as the most preferred points among the points reported to be effective on intestinal functions by scanning the literature on the determined points. Acupressure will be applied to the LI4 and TH6 points for a total of 12 minutes in the first hour after the surgery. Light pressure will be applied with the thumb of the practitioner's hand. After applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is done without interruption
224045415|NCT05251818|OTHER|Control|No application will be made to puerperant women in this group. Only hourly follow-up will be done until the first bowel sound is heard. In addition, defecation and gas extraction will be questioned every 12 hours.
224045416|NCT00126074|DRUG|Tedisamil sesquifumarate|
224045417|NCT05149664|DEVICE|Therapeutic ultrasound (TUS)|As described elsewhere, a sleeve is wrapped around the subject's targeted calf such that the inner lining with attached transducers are positioned around the calf muscle, with a gel-skin interface. The ultrasound energy is transmitted from these transducers to the deeper layers of the muscle.
224045418|NCT04248309|DRUG|intramuscular progesterone 20-40mg from D3 until pregnancy test|serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
224045419|NCT00506545|DRUG|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
224045420|NCT00506545|DRUG|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
224141737|NCT02147496|OTHER|Dietary Intervention|
224141738|NCT00031499|DRUG|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
224141739|NCT00031499|DRUG|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
224141740|NCT00031499|DRUG|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
224141741|NCT05519618|PROCEDURE|Epidural veins pressure and flow measurement|"The purpose of this study is to measure to pressure and flow of epidural venous plexus.~The procedure will be performed alongside during pre-operative embolization at the angiography suite.~It will be performed under general anesthesia. A the start of the procedure, a venous access will be established at the inguinal region. Co-axial catheters will be navigated to epidural venous plexus under the guidance of fluoroscopy. After the placement of catheter, the pressure and flow of epidural venous plexus will be measured at three time points: 1. Right after catheter reach the targeted location 2. Right before embolization. 3. After embolization. The participant will be instructed to control their breathe during measurement.~After measurement, the catheter will be removed alongside with embolization devices, and achieved hemostasis as routine."
224045421|NCT03197688|OTHER|Notapplicable|Not applicable as non-interventional study
224045422|NCT05903911|OTHER|Trans Care Web App|an educational and interactive website designed to improve coping strategies of TNB individuals
224045423|NCT03491709|DRUG|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
224045424|NCT03491709|DRUG|Cetuximab injection|Cetuximab injection
224045425|NCT04803110|PROCEDURE|Dental implant placement after tooth extraction|Immediate implant placement after partial or complete tooth extraction.
224045426|NCT06179771|DEVICE|HA 380|HA380 hemoperfusion cartridge is filled with neutral macroporous resin, mainly adsorbing molecules from 10 to 60 kDa. Because of the accurate 3D macroporous structure and over 54000 m2 adsorption surface area of the resin. The cartridge is attached to the extracorporeal circuit in series with the oxygenator/ filter of the extracorporeal circuit.
224141742|NCT03108209|OTHER|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
224141743|NCT03108209|OTHER|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
223434705|NCT01572467|GENETIC|mutation analysis|
223434706|NCT01572467|GENETIC|reverse transcriptase-polymerase chain reaction|
223434707|NCT01572467|OTHER|laboratory biomarker analysis|
223434708|NCT01572467|OTHER|medical chart review|
223434709|NCT06620367|PROCEDURE|conventional guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) covered with bilayer collagen membrane stabilized by tacks
223434710|NCT06620367|PROCEDURE|digital guided bone regeneration|10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) placed by digital designed guide covered with bilayer collagen membrane stabilized by tacks
223434711|NCT01740869|BIOLOGICAL|Autologous Intrathecal Hematopoietic Stem Cells|Patients will be stimulated with granulocyte colony-stimulating factor (G-CSF) for 3 consecutive days. Bone marrow will be harvested, processed to isolate CD34+ hematopoietic stem cells and reduce red blood cells. An inoculum of 5-10 mL will then be infused intrathecally into the cerebrospinal fluid.
223434712|NCT01740869|OTHER|Observation with IDEA and CARS Scales|Participants will be observed for 6 months without active intervention. They will be evaluated using the Childhood Autism Rating Scale (CARS) and the IDEA scale at baseline, 30 days, and 180 days. After 6 months, participants may crossover to the experimental arm.
224045427|NCT06976567|DEVICE|Telemedicine for urology consultations|The patients that are assigned to the intervention group will receive a virtual urology consultation with urologists from Ahmadu Bello University in Zaria, Nigeria as opposed to physically presenting for the consultation.
224045428|NCT06843174|DRUG|Rectal Methadone administer during spinal surgery|Rectal Methadone administered during spinal surgery for post-operative pain management
224045429|NCT06843174|OTHER|Placebo: Rectal saline solution|Placebo: Rectal saline solution single dose received during surgery
224045430|NCT03850782|DRUG|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the PRN treatment period.~Fellow Eye: Standard of care or Bimatoprost SR."
224045431|NCT05334537|OTHER|Aromatherapy|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
224045432|NCT05334537|OTHER|Placebo oil (odorless baby oil- jojoba and almond oil)|Ninety-six patients aged between 18 and 45 years, with a height of ≥156 centimeters (cm), and a gestational age of \>37 weeks, in the ASA II risk group, who were scheduled for elective CS under spinal anesthesia, were included in the study. Patients who were to undergo lavender aromatherapy with an oxygen mask after the birth of the baby were randomly divided into two groups: aromatherapy (A) (n=48) and control (C) (n=48), who inhaled odorless essential oil. Participants were admitted to the preoperative preparation room 20 min before the operation, and their age, height, weight, and ASA risk scores were recorded after their informed consent was obtained. They were monitored and sent to the operating room after their baseline anxiety levels were measured and recorded using the Visual Analog Scale (VAS) for pain and State-Trait Anxiety Inventory (STAI-I).
224045433|NCT05619978|OTHER|3L Therapy|Treatments received in 3L were dasatinib, nilotinib, imatinib, ponatinib, bosutinib, and allo-SCT
223434713|NCT06331195|OTHER|Placebo phytosterol|Placebo of phytosterol, in the same quantity of the active phytosterol.
224045434|NCT05619978|OTHER|T315I|Patients with chronic myeloid leukemia with T315I mutation
224045435|NCT06984159|DRUG|Leuprolide Injectable Emulsion (CAMCEVI®)|Leuprolide Injectable Emulsion (CAMCEVI®)，Subcutaneous injection，Once every 24 weeks for a total of 2 doses
224045436|NCT03612284|DEVICE|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
224045437|NCT05568602|DIAGNOSTIC_TEST|Dexamethasone suppression test|1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
224141744|NCT03089970|DIAGNOSTIC_TEST|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
224141745|NCT04173052|DEVICE|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
224141746|NCT05833685|OTHER|no intervention|no intervention
224141747|NCT01216449|DRUG|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
224141748|NCT01216449|DRUG|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
223434714|NCT06331195|OTHER|Placebo krill oil|Placebo of krill oil, in the same quantity of the active krill oil.
223740603|NCT00914355|RADIATION|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
223740604|NCT00746642|DEVICE|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
223740605|NCT01518777|OTHER|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
223740606|NCT04679792|DIAGNOSTIC_TEST|Dynamic posturography|Balance evaluation
223434715|NCT06331195|DIETARY_SUPPLEMENT|Phytosterol|2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
223434716|NCT06331195|DIETARY_SUPPLEMENT|Krill oil|2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.
223740607|NCT05153031|OTHER|lithiasic|Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.
223740608|NCT05153031|PROCEDURE|Emergency surgery|Emergency cholecystectomy
223740609|NCT05153031|PROCEDURE|cholecystectomy|cholecystectomy
224045438|NCT01540383|BEHAVIORAL|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, \>=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
223434717|NCT01528657|OTHER|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
223434718|NCT01528657|OTHER|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
223434719|NCT06348121|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study had last 56 days, and each patient will make 3 visits (d0, d28, d56).
224045439|NCT01540383|BEHAVIORAL|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
224045440|NCT02752750|OTHER|MRI|MR imaging (MRI) at 3 Tesla
224045441|NCT04631796|DEVICE|Lehfilcon A contact lenses|Silicone hydrogel contact lenses with investigational coating
224045442|NCT04631796|DEVICE|Multipurpose disinfection solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
224045443|NCT00563667|PROCEDURE|pterygium excision|
224045444|NCT06863155|DEVICE|Supraflex Cruz Sirolimus-eluting Stent|PCI with SupraFlex Cruz® stent in de novo coronary stenosis of patients under chronic oral anticoagulation.
224045445|NCT06607172|DEVICE|oral irrigator|water flosser device
224045446|NCT06607172|DEVICE|oral irrigator|water flosser and 0.075% CPC
224141749|NCT04856956|OTHER|Diagnostic decision support software|Comparing use of decision support group (intervention group) to use only of common literature (control group) among pediatric trainees diagnosing patients with possible rheumatologic disorder
224141750|NCT02203669|OTHER|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
224141751|NCT02203669|OTHER|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
224141752|NCT03121118|OTHER|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
223434720|NCT03802565|DRUG|Tolperisone|TID
223434721|NCT03802565|DRUG|Placebo|Placebo
224045447|NCT06607172|DRUG|Cetylpyridinium Chloride (CPC)|Cetylpyridinium 0.075%
224045448|NCT05835713|DRUG|Remimazolam besylate|Remimazolam group is induced general anesthesia using remimazolam besylate injection (0.2mg/kg bolus). General anesthesia is maintained using remimazolam infusion at a rate of 1mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min. After recovering spontaneous respiration during emergence, remimazolam group receive flumazenil injection (0.5 mg)
224045449|NCT05835713|DRUG|Propofol|Propofol group is induced general anesthesia using propofol injection (2 mg/kg bolus). General anesthesia is maintained using propofol infusion at a rate of 4-8 mg/kg/h and remifentanil infusion at a rate of 0.05-0.15 mcg/kg/min.
224141753|NCT05273658|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
224141754|NCT05273658|DRUG|Alcohol|Participants will ingest alcohol to achieve the target breath alcohol level
224141755|NCT02625675|OTHER|Ultrasound scan|
223434722|NCT07119229|DEVICE|Implantable Artificial Bronchus|The Implantable Artificial Bronchus (IAB) is a tapered, flexible and fenestrated polymer-based airway stent that is implanted bronchoscopically using a proprietary delivery system into diseased lungs of patients with emphysema.
223740610|NCT04991155|DRUG|BIA 5-1058|BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
224045450|NCT07130019|PROCEDURE|Fluorescence guided thermal ablation of epidermal tissue|Thermal ablation of epidermal tissue under fluorescence control.
224045451|NCT07130019|PROCEDURE|Thermal ablation of epidermal tissue|Thermal ablation of skin tissue a vue
224045452|NCT07032818|OTHER|Additional post discharge phone call|24-72 hours after hospital discharge, a nurse will call participants to review the written After Visit Summary (AVS) given at discharge, including primary diagnosis, self-care instructions, emergency plan, medication changes, how and why to take medication, and scheduled follow up. These phone calls will take on average 10-15 minutes.
224045453|NCT06725225|BEHAVIORAL|Symptom cluster-based care intervention|The patient symptoms were surveyed to develop a symptom cluster care intervention plan. The specific steps were as follows: a research team was established, relevant literature was reviewed, and qualitative interviews were conducted. Guided by symptom management theory and the Knowledge-Attitude-Practice (KAP) behavior model, a draft of the care intervention was created. This draft was then refined through expert consultation to finalize the intervention plan.
224141756|NCT02322268|DIETARY_SUPPLEMENT|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
224141757|NCT04219969|DRUG|Fludeoxyglucose F-18|Given IV
224141758|NCT04219969|DEVICE|Magnetic Resonance Imaging|Undergo PET-MRI
224141759|NCT04219969|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
223434723|NCT00055861|BIOLOGICAL|bevacizumab|Given IV
223434724|NCT00055861|DRUG|docetaxel|Given IV
223434725|NCT00055861|OTHER|laboratory biomarker analysis|Correlative studies
223740611|NCT03164928|DRUG|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
223740612|NCT03164928|OTHER|Placebo|SC Q6M placebo
223740613|NCT02278263|DRUG|Tranexamic Acid|Given intravenously or topically
223740614|NCT02278263|DRUG|Normal saline (0.9% NaCl)|Administered in all 3 groups
224141760|NCT02819505|DIETARY_SUPPLEMENT|beta-alanine|
224141761|NCT02819505|DIETARY_SUPPLEMENT|Placebo|
224141762|NCT05605977|BEHAVIORAL|Traditional visual-motor training program|Traditional visual-motor program includes play and paper-and-pencil activities
224141763|NCT05605977|BEHAVIORAL|Computerized visual-motor training program|Computerized visual-motor training program includes tablet visual-motor games
224141764|NCT00074802|DRUG|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
224045454|NCT06725225|BEHAVIORAL|Conventional care intervention|Standard nursing intervention. This refers to routine clinical care without a specific care plan tailored to the patient's symptoms. For example, if a patient has symptoms, the nurse assists the patient in notifying the doctor but does not provide any special treatment themselves
224141765|NCT00074802|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
224141766|NCT01902862|DRUG|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
224141767|NCT01902862|DRUG|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
224141768|NCT00225680|DEVICE|drug eluting coronary stent|
224141769|NCT01030380|DEVICE|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
224141770|NCT04164329|DRUG|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
224141771|NCT06257329|OTHER|register|Multicentre prospective observational register
224141772|NCT04801394|PROCEDURE|hernioplastic and insertion of FLaPp® composite mesh|"After the reduction of the large incisional hernia, the polypropylene transparent film of this mesh (lower flap) was sutured to the margins of the residual peritoneum and posterior rectus sheath as a neo-peritoneum; the macroporous light polypropylene layer (upper flap) was then sutured circumferentially with full-thickness transabdominal stitches in the retromuscular space."
223434726|NCT05020899|BEHAVIORAL|Sessions with a trained counselor|4 sessions will be provided with a trained counselor who will discuss the participant's' smoking habits with them and strategies to help them quit. The first session is in-person, lasts for 20 minutes, and typically happens when the participant comes to the HIV clinic to pick up their medication. Sessions 2 through 4 are over the telephone and last for 15 minutes each. These occur 1 week, 4 weeks, and 8 weeks after the first session.
224141773|NCT01108562|DRUG|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
224141774|NCT01108562|OTHER|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
224141775|NCT00221429|DRUG|Lithium|lithium
223434727|NCT05020899|OTHER|Cell phone messages|Brief messages that give tips to help quit smoking will be sent to participants' cell phones using WeChat. 3 messages per day will be sent for the first week, 2 messages per day for the next 3 weeks, 1 message per day for the next 1 week, and 1-2 messages per week for the rest of the time
223434728|NCT05020899|OTHER|Offered nicotine replacement therapy|Participants will be offered nicotine replacement therapy (gum or patch, depending on which one is available).
223740615|NCT06149507|DRUG|Acetaminophen|Prescribe the drug to the child
223740616|NCT06149507|DRUG|Ibuprofen|Prescribe the drug to the child
224045455|NCT06708611|DRUG|torsemide|Extended release formulation of torsemide
224141776|NCT00221429|DRUG|sodium divalproex|Depakote
224141777|NCT00221429|OTHER|Placebo|Placebo
224141778|NCT02999880|PROCEDURE|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
224141779|NCT00110578|PROCEDURE|Adoptive transfer of HIV-specific CD8+ T cells|
224141780|NCT00110578|DRUG|Aldesleukin|
224141781|NCT00654953|DRUG|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
224141782|NCT00654953|DRUG|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
224141783|NCT00654953|DRUG|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
224141784|NCT00489372|DRUG|Se-methyl-seleno-L-cysteine|Given orally
224045456|NCT02247154|BIOLOGICAL|Vigam® (Human Normal Immunoglobulin)|
224045457|NCT06736613|DIAGNOSTIC_TEST|Cerebral Spinal Fluid ctDNA|MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019
224045458|NCT06741761|OTHER|12-hour time-restricted feeding (TRF12)|The 12 hour feeding group will receive tube feeding only over a 12 hour period (6:00 AM to 6:00 PM feeding schedule).
224045459|NCT06741761|OTHER|Continuous 24 hour feeding (CONT24).|Patients in this control group will receive the standard of care which is tube feeding continuously over 24 hours.
224141785|NCT00489372|OTHER|placebo|Given orally
224141786|NCT00489372|OTHER|pharmacological study|Correlative studies
224141787|NCT00489372|OTHER|laboratory biomarker analysis|Correlative studies
224141788|NCT01231607|DRUG|1mg Finasteride active|1mg finasteride active, by mouth once daily
224141789|NCT01231607|DRUG|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
224141790|NCT01231607|DRUG|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
224141791|NCT01231607|DRUG|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
224141792|NCT01231607|DRUG|Finasteride placebo|finasteride placebo, by mouth once daily
224141793|NCT01231607|DRUG|Dutasteride placebo|dutasteride placebo, by mouth once daily
224163515|NCT03793270|DIAGNOSTIC_TEST|for patients and healthy donors|"1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry~2. Determine the serum level of IL 10 using ELISA plate"
224299807|NCT03994055|OTHER|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
223434729|NCT05020899|OTHER|Self-help guide for quitting smoking|Participants will be offered a self-help guide with information about quitting smoking.
223434730|NCT03433313|DRUG|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
223434731|NCT03433313|DRUG|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
223434732|NCT05619406|DEVICE|Riskometer Application|The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.
223434733|NCT05619406|BEHAVIORAL|Routine Clinic Therapy|After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.
224045460|NCT06885294|BEHAVIORAL|Physiotherapy|Stroke patients will be randomly assigned to join one of the three groups. The first group will undergo a pre-treatment evaluation, receive 6 sessions of physiotherapy (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. After another month without any treatment, they will undergo a third and final assessment. All evaluations will last approximately 1 hour.
224045461|NCT06885294|BEHAVIORAL|Physiotherapy and Hypnosis|Stroke patients will be randomly assigned to join one of the three groups. The second group will undergo a pre-treatment evaluation, receive 6 sessions of physiotherapy combined with hypnosis (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. Patients will continue their standard physiotherapy care during these 4 weeks. After another month without any treatment, they will undergo a third and final assessment. All evaluations will last approximately 1 hour.
224045462|NCT06885294|BEHAVIORAL|Control group Physiotherapy and Hypnosis|The control group will be assessed initially and then after 4 weeks. After the second assessment, they will receive 6 sessions of physiotherapy combined with hypnosis (2 sessions per week, approximately 20-30 minutes each), and undergo a post-treatment evaluation after 1 month. All evaluation sessions will last approximately 1 hour.
224045463|NCT06894784|DRUG|Intervention Period 1: Semaglutide + Empagliflozin|"Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.~Empagliflozin Tablet: Oral tablet (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
224045464|NCT06894784|DRUG|Intervention Period 2: Semaglutide + Empagliflozin Placebo|"Semaglutide Injection: Subcutaneous injection, titrated over 12 weeks to a stable dose (1 mg), administered weekly.~Empagliflozin Placebo Tablet: Oral placebo tablet, matched in appearance to empagliflozin (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
224045465|NCT06894784|DRUG|Intervention Period 3: Semaglutide Placebo + Empagliflozin|"Semaglutide Placebo Injection: Subcutaneous placebo injection (titrated over 12 weeks to a stable 1 mg dose), matched in appearance to semaglutide, administered weekly.~Empagliflozin Tablet: Oral tablet (2.5 mg), administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
224141794|NCT05841108|DEVICE|force feedback rehabilitation robot (SEM™ Glove)|In the experimental group, the therapists were asked to illustrate and demonstrate the motor points of the cylindrical grasping and spherical grasping movements, and the patients were instructed to imitate them with nonparalytic hand, while the latter patients wore SEM™ Glove were used for task-oriented training, such as inserting pegs, grasping a ball into a barrel, and drinking water exercises. The difficulty of task-oriented training can be adjusted according to the patient's actual condition, such as changing the shape, weight, size of the target or changing the distance, duration, and so on during training
224141795|NCT05841108|OTHER|assisted by a therapist|The control group received task-oriented training assisted by a therapist to complete the same task as the experimental group. Therapists need to instruct patients to try to grasp items and give appropriate assistance to guarantee their completion of the grasping task. If finger extension is weak, the therapist assists the patient in extension of the digits before grasping the items, and if the finger flexion angle does not meet the grasp function needs, it should assist in flexion finger movements
223434734|NCT04314375|DRUG|Low Dose Budesonide|3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
223434735|NCT04314375|DRUG|High Dose Budesonide|6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
223434736|NCT04314375|DRUG|Placebo|Matching placebo once daily.
223565898|NCT06661551|PROCEDURE|Miniscrew insertion in dynamic-computer guided surgery|"The intervention more executed in the literature is by using static computer-guided systems (s-CAS) . However, the s-CAS has limitations, including the time and cost associated with guide production, furthermore, the guide's bulk prevents its use in patients with limited mouth opening, and reduced irrigation potentially leads to overheating and bone burns during implant placement. Additionally, the inability to adjust the surgical plan intraoperatively, the lack of real-time visualization during implant site preparation and implant insertion, and the requirement for specific surgical kits for each implant system present further challenges.~Dynamic navigation systems offer several benefits as highlighted in the literature, including: real-time feedback of the position of surgical drill or implant, allowing intraoperative changes adjusting the implant position during the surgery, reduction of risk of injury to adjacent anatomical structures, promotion of accuracy in novices"
224141796|NCT01768312|DRUG|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
223434737|NCT00693342|BIOLOGICAL|immunological adjuvant OPT-821|Given subcutaneously
223434738|NCT00693342|BIOLOGICAL|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
223434739|NCT02124759|DRUG|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
223434740|NCT02124759|DRUG|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
223434741|NCT02124759|DRUG|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
223434742|NCT02124759|OTHER|High Fat diet|The High Fat diet consists of 60% energy from fat (50% saturated), 15% of energy as carbohydrate and 25% from protein consumed while study intervention is being administered.
223434743|NCT02124759|OTHER|Low Fat diet|The isocaloric low fat diet will provide 55% energy from carbohydrates, 20% from fat and 25% from protein.
223434744|NCT03938649|RADIATION|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
223434745|NCT03938649|DRUG|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
223434746|NCT05014269|PROCEDURE|Phacoemulsification in eyes with corneal opacities|senile cataract extraction using lens emulsification under the slit illuimnation of the surgical microscope
223434747|NCT00006486|DRUG|carboxyamidotriazole|Given orally
223434748|NCT00006486|OTHER|placebo|Given orally
223434749|NCT05262868|DEVICE|rTMS|The stimulus intensity will be 80% of the motor threshold and the frequency will be 20 Hz for all patients. The total number of pulses will be 1200 for a single treatment session. We plan a total of 15 sessions distributed over 5 days a week for 3 consecutive weeks.
223434750|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|10 daily sessions (50 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
224045466|NCT06894784|DRUG|Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo|"Semaglutide Placebo Injection: Subcutaneous placebo injection (titrated over 12 weeks to a stable 1 mg dose), matched in appearance to semaglutide, administered weekly.~Empagliflozin Placebo Tablet: Oral placebo tablet (2.5 mg), matched in appearance to empagliflozin, administered daily.~Automated Insulin Delivery (AID) System: Continuous use of the participant's personal commercial AID system."
224045467|NCT06749444|OTHER|CBT-I|Cognitive therapy tailored for insomnia symptoms.
224045468|NCT06749444|OTHER|CBT|Cognitive behavioral therapy for general psychopathology
223434751|NCT06523439|DEVICE|MagPro X100 edition (MagVenture, Skovlunde, Denmark)|5 daily sessions (25 total over 5-days) of SAINT® (3-pulse 50-Hz bursts at 5-Hz for 2-second trains, with trains every 10 seconds) guided by MNS, delivered with 50-minute inter-session intervals (10-minute sessions, 50-minutes in between sessions). Stimulation will be delivered at 90% of the resting motor threshold (with depth correction to account for the distance between the scalp and cortex).
224045469|NCT06896175|DIETARY_SUPPLEMENT|Yerba mate consumption (Ilex paraguayensis) A|Yerba mate of the begining of the harvest time
224045470|NCT06896175|DIETARY_SUPPLEMENT|Yerba mate comsuption (ilex paraguayencis) B|Yerba mate of the final time of the harvest
224045471|NCT05228067|DEVICE|anodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
224045472|NCT05228067|DEVICE|cathodal transcranial direct current stimulation|anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
224045473|NCT05228067|DEVICE|sham transcranial direct current stimulation|Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
224045474|NCT04223791|DRUG|DOR/ISL|100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily
224045475|NCT04223791|DRUG|BIC/FTC/TAF|50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
224045476|NCT04223791|DRUG|Placebo to BIC/FTC/TAF|Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
224045477|NCT04223791|DRUG|Placebo to FDC DOR/ISL|Placebo to FDC DOR/ISL in a tablet taken orally, once daily
224045478|NCT06773364|DRUG|Levetiracetam|Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH
223434752|NCT04907500|DEVICE|Intraocular lens|Cataract surgery
224045479|NCT06773364|OTHER|Guide-recommended management|To receive stroke management according to standard local guidelines, but to avoid prophylactic use of an anti-seizure drug.
224045480|NCT06773364|OTHER|The lying flat (0°) head position|Lie flat (0°) - in the ambulance as soon as possible until arrival at hospital.
224045481|NCT06773364|OTHER|The sitting-up (≥30°) head position|Sit up(30-60°) - in the ambulance as soon as possible until arrival at hospital.
224045482|NCT07066345|DEVICE|My Pelvic Plan|My Pelvic Plan is comprised of a self-guided program that combines education on several individual conditions that often contribute to CPP, and will include instruction on cognitive and behavioral restructuring techniques that can help to manage chronic pelvic pain symptoms.
224045483|NCT07066345|BEHAVIORAL|Bend|Bend is a highly rated physical activity application that helps guide users through gentle stretching and yoga poses.
224141797|NCT05955157|BIOLOGICAL|Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy|DC+CIK immunotherapy will be administrated with S-1 chemo drug as maintenance treatment for patients with advanced PDAC
224141798|NCT05955157|DRUG|Tegafur Only Product|Tegafur (TS-1) will be administrated alone as maintenance treatment to control group as standard of care
224141799|NCT04152148|BIOLOGICAL|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
224141800|NCT04152148|BIOLOGICAL|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
224141801|NCT04152148|BIOLOGICAL|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
224045484|NCT02529007|DEVICE|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
224045485|NCT02529007|OTHER|Standard colonoscopy|Standard colonoscopy without end-cuff
223434753|NCT03860116|BEHAVIORAL|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
223434754|NCT03860116|BEHAVIORAL|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
223434755|NCT03648554|DRUG|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
223434756|NCT03648554|OTHER|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
223434757|NCT00822575|DEVICE|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
223434758|NCT01068626|DRUG|Rosuvastatin|10 mg once daily
223434759|NCT01068626|DRUG|Placebo for rosuvastatin|once daily
223565899|NCT06659497|BEHAVIORAL|web-based patient education|"The web-based training, which will provide the following information about the IUI treatment process, will last a total of 60 minutes.~MODULE 1: General Information About Fertility MODULE 2: Diagnostic and Therapeutic Methods in Infertility / Insemination Treatment MODULE 3: Drugs Used in Insemination Treatment and Their Application MODULE 4: Things to Consider After Insemination"
223565900|NCT06658587|DIAGNOSTIC_TEST|No interventions|No interventions
223565901|NCT06600763|OTHER|Ice pack|The temperature of the area where the ice pack is applied will be measured at one minute intervals, and when the relevant area reaches a temperature of 13.6 0C, the physician will be informed and the drain removal procedure will be initiated.
223565902|NCT06600763|OTHER|warm gel pad|Gel pads kept at room temperature will be applied to the drain area of the pediatric patient whose surgical drain indication is decided to end, in a sheath designed to wrap around the drain. After waiting for 10 minutes in the application area, the drainage system will be removed by the physician.
224045486|NCT05610735|DRUG|DOXIL|DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes first to a maximum of 10 cycles.
224045487|NCT05610735|DRUG|Withaferin A|Ashwagandha in the form of tablets will be administered orally on daily basis.
224045488|NCT05610735|DRUG|Ashwagandha|Administered orally on daily basis twice a day
224045489|NCT05610735|DRUG|Combination of ASWD and DOXIL|DOXIL administered IV once every four weeks. ASWD administered orally on daily basis, twice a day.
224045490|NCT06900348|DIAGNOSTIC_TEST|PSA-Activated PSA-PAH1|Intravenous blood sample
224045491|NCT06895291|DIAGNOSTIC_TEST|Whole Body-Magnetic Resonance Imaging (WB-MRI)|"This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed:~* at staging~* at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients."
224045492|NCT06895707|OTHER|BioFlx crown|NuSmile® BioFlx crown (Group A) will be placed on primary lower second molar.
224045493|NCT06895707|OTHER|Zirconia crown|Zirconia crown (Group B) will be placed on the contralateral primary lower second molar.
224045494|NCT07129720|BEHAVIORAL|Educational Program on MIH|"A 30-minute interactive educational session that includes a PowerPoint presentation, clinical images, and case-based discussions on Molar-Incisor Hypomineralization (MIH).~The session covers the definition, eatiology , clinical features, diagnosis and evidence-based treatment options of MIH.~The goal is to improve the participants' knowledge ,attitude and awareness . Evaluation will be conducted through pre- and post-intervention questionnaire."
224045495|NCT06927609|OTHER|kendall exercises|Stretching of Cervical Extensors Strengthening Deep Cervical Flexors Strengthening Shoulder Retraction Stretching Pectoralis Muscle
224141802|NCT04152148|BIOLOGICAL|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
224045496|NCT06927609|OTHER|Conventional therapy group|Cervical Traction Neck Isometric Exercises (Cervical flexors), Static Stretching (Cervical extensors) General Cervical Extension and Flexion Exercises Shoulder Shrugs
224045497|NCT07131020|BEHAVIORAL|Yifei moxibustion|The conventional Western medicine treatment is based on the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the 2021 Chinese Thoracic Society guidelines for the diagnosis and management of chronic obstructive pulmonary disease. Bronchodilators, inhaled corticosteroids, or a combination therapy are administered.The Yifei moxibustion is applied from the Dazhui to Yaoshu acupoints along the Governor Vessel. Ginger juice is spread over the treatment area, followed by sprinkling moxa powder and covering with mulberry bark paper. A 2.5 cm thick layer of ginger paste and a 3 cm thick layer of moxa wool are then placed on the mulberry bark paper. The moxa wool is ignited and allowed to burn out naturally, being replaced every 30 minutes. After 90 minutes, the ginger paste is removed. The treatment is performed once every 15 days, with 6 sessions constituting one course of treatment, totaling 3 months.
224045498|NCT07131020|DRUG|Conventional Western medicine treatment|The conventional Western medicine treatment is based on the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the 2021 Chinese Thoracic Society guidelines for the diagnosis and management of chronic obstructive pulmonary disease. Bronchodilators, inhaled corticosteroids, or a combination therapy are administered.
224045499|NCT07131020|DRUG|TCM syndrome differentiation treatment|The conventional Western medicine treatment followes the same protocol as described above. The diagnosis of TCM pattern-based therapy is made in accordance with the TCM Syndrome Diagnostic Criteria for Chronic Obstructive Pulmonary Disease issued by the Pulmonary Disease Committee of the Internal Medicine Branch, China Association of Chinese Medicine and the treatment is based on the 2019 Guidelines for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease issued by the China Association of Chinese Medicine.
224045500|NCT07128420|DEVICE|Application of 3 sessions of microneedle therapy|"Enrolled study participants will receive 3-4 treatments of microneedling to the affected area.~Study participants will microneedling (Fusion Tip Potenza Fractional Radiofrequency Microneedle Electrosurgical Unit, Jeisys Medical Inc, Seoul, KR) at a depth of 2.0 to 2.75mm."
224045501|NCT06771817|BEHAVIORAL|Written Exposure Therapy|WET may be an optimal treatment for pregnant or postpartum adolescents and youth with PTSD in a low resource setting. WET addresses many of the barriers above. It is delivered in just 5 sessions, with no homework, and may promote a sense of self-efficacy in adolescents and youth due to the nature of writing assignments and brief therapist involvement. It is attractive in resource-poor settings because just 10-15 min of direct therapist time per follow-up session is needed.
224299808|NCT03994055|OTHER|Soluble fiber|Diet will include foods rich in soluble fiber.
224299809|NCT03994055|OTHER|Probiotics|Diet will include foods rich in probiotics.
224045502|NCT07083479|DRUG|ELI-002 7P|ELI-002 Amph-CpG-7909 (10.0 mg) admixed with ELI-002 Amph-Peptides 7P (4.9 mg) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization Period; additional SC injections weekly for 4 weeks during the Booster Period (the two periods are separated by 2 months of no dosing).
224045503|NCT06902974|DRUG|Psilocybin 25 mg|Single dose, 25mg psilocybin, encapsulated, oral administration
224045504|NCT06902025|DRUG|JY231 Injection|Patients were enrolled and given a single dose of JY231 injection intravenously, hospitalized for observation over the following month, and followed up for observation over the following 15 years.
224045505|NCT06902649|BEHAVIORAL|Internet-based parenting support|An internet-based parent training program with 5 active modules and a final summarizing module, based on social learning theory/cognitive behavior therapy. All parents participate in this intervention (Step 1) before being randomized to the other three arms of the stepped care model in the randomized controlled trial (Step 2).
224045506|NCT06902649|BEHAVIORAL|"YourSkills for children/youth"|Cognitive behavioral therapy for children/youth with role-plays in virtual reality. A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
224045507|NCT06902649|BEHAVIORAL|Step-by-step parent support|A parent training program based on social learning theory and cognitive behavioral therapy (CBT), including some sessions where virtual reality may be used for training in brief role plays. The program includes similar strategies as other common CBT-parent training programs for parents of children with behavior problems, with the difference that virtual reality can be used as an additional way to practice skills.
224045508|NCT06902649|BEHAVIORAL|Intervention/support as usual and prolonged use of internet-based parenting support|Based on other available support, interventions, courses at the units. Parents have access to the internet-based parenting support provided in Step 1 (the first intervention of the study). After 10 weeks with intervention/support as usual, the parents are asked if they want to participate in the CBT-VR-intervention for children (YourSkills) or for parents (Step-by-Step parent support).
224045509|NCT06901804|DIAGNOSTIC_TEST|Experimental Group (training and stabilization)|"Plyometric Shoulder Training \[28\] and Pilates Core Stabilization \[27\]~Exercise 1-2 weeks (rep × kg) 3-4 weeks (rep × kg) 5-6 weeks (rep × kg) Throwing Movements Medicine ball chest pass 8 × 1 kg 10 × 2 kg 12 × 3 kg Medicine ball step and pass 8 × 1 kg 10 × 2 kg 12 × 3 kg Medicine ball side throw 8 × 1 kg 10 × 2 kg 12 × 3 kg Tubing Plyos IR/ER 8 × 10 10 × 10 12 × 12 Tubing Plyos Diagonal 8 × 10 10 × 10 12 × 12 Tubing Plyos Biceps 8 × 10 10 × 10 12 × 12 Plyo Push-ups (boxes) 8 × 10 10 × 10 12 × 12 Push-ups (clappers) 8 × 10 10 × 10 12 × 12"
223434760|NCT03342131|OTHER|Circulating wnt 2 and wnt 4 concentration|"Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission."
224141803|NCT02267278|DRUG|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
224141804|NCT02267278|DRUG|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
224141805|NCT02267278|BEHAVIORAL|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
224141806|NCT04374279|DRUG|Bicalutamide 150 Mg Oral Tablet|Bicalutamide 150 mg by mouth daily for 7 days
224141807|NCT05008068|DRUG|Simvastatin|Simvastatin with PRF at site of osteotome
224141808|NCT04950205|DRUG|Sevoflurane inhalant product|propofol plus 1% sevoflurane after open Carotid artery until the end of surgery
224141809|NCT01712217|DRUG|AT13387|HSP90 inhibitor
224141810|NCT01712217|DRUG|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
224141811|NCT02505815|PROCEDURE|Surgery|
224141812|NCT02505815|PROCEDURE|Cortisol Level Measurement|
224141813|NCT02505815|PROCEDURE|Neurocognitive Testing|
224141814|NCT03886441|DRUG|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
224141815|NCT04172311|OTHER|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
224141816|NCT04172311|DRUG|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
223434761|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
223434762|NCT03653091|DEVICE|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
224045510|NCT06901804|COMBINATION_PRODUCT|Control Group (physiotherapy and exercise)|Physiotherapy Care for Low Back Pain \[30\] Exercise Week 1-2 (Sets x Reps/Duration) Week 3-4 (Sets x Reps/Duration) Week 5-6 (Sets x Reps/Duration) Plank 3 x 20 sec 3 x 30 sec 4 x 45 sec Bicycle Crunches 3 x 12 3 x 15 4 x 20-25 Leg Raises 3 x 12 3 x 15 4 x 20-25 Russian Twists 3 x 20 3 x 25 4 x 30-35 Slump Exercise 3 x 10 3 x 12 4 x 15-18 Bridge Exercise with Swiss Ball 3 x 12 3 x 15 4 x 18
224045511|NCT06903325|OTHER|As an observational study, we did not intervene|Interventions
224045512|NCT06901479|OTHER|Blood was drawn for proteomics testing and Magnetic Resonance Imaging.|The function of the glymphatic system was assessed by MRI before the surgery. Blood was drawn before the surgery. Delirium was assessed on postoperative days 1 to 5. Blood was drawn on the second day after surgery. The function of the glymphatic system was assessed again by MRI on the fifth day after surgery.
224045513|NCT06902623|RADIATION|Radiation|Radiation only to 66Gy
224045514|NCT06895109|OTHER|improvement of cognitive functions and psychological aspects|To analyze the neuropsychological, motor and functional profile of a sample of patients with severe acquired brain injury, who underwent craniotomy and subsequent opercular reapposition surgery
224045515|NCT06901609|DRUG|SGLT2 inhibitor (Dapagliflozin 10mg)|Renal response after 6 months of Dapagliflozin therapy among patients with heart failure reduced ejection fraction.
224045516|NCT06893237|OTHER|virtual reality goggles and inhalation treatment|Video recording will be started after the consent is obtained. One minute before the procedure, the child's physical parameters (peak heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, the child will be fitted with virtual reality goggles and inhalation treatment will be started by watching the aquarium and sea creatures video. Inhalation treatment will last for 10 minutes with the most appropriate air flow rate of 6-8 L/min. Then, the virtual reality goggles will be removed and the child's physiological parameters and anxiety will be measured and recorded again after 1 minute. For participants who want to participate in the study but do not approve the video recording, the evaluations will be made by a nurse independent of the study.
224045517|NCT06893237|OTHER|distraction cards and inhalation therapy|After the consent is obtained, the video recording will be started. 1 minute before the procedure, the child's physical parameters (heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, the child will be shown distraction cards and inhalation therapy will be started simultaneously. Playing with the distraction cards will continue for 10 minutes until the end of the inhalation therapy. Then, the use of the toys will be stopped and the child's physiological parameters and anxiety will be recorded after 1 minute. The video recording will be ended. For participants who want to participate in the study but do not consent to being video recorded, the evaluations will be made by a nurse independent of the study.
224045518|NCT06893237|OTHER|inhalation therapy|After the consent is received, the video recording will be started. 1 minute before the procedure, the child's physical parameters (heart rate, respiratory rate, oxygen saturation) and anxiety will be measured and recorded. Then, inhalation therapy will be started with routine service application. The child will receive inhalation therapy for 10 minutes. 1 minute after the procedure, physiological parameters and anxiety will be measured and recorded again. The video recording will be ended. For participants who want to participate in the study but do not approve of being video recorded, evaluations will be made by a nurse independent of the study.
224045519|NCT06902870|OTHER|Scenario-Based Online Simulation Training Program|"Classroom-Based Teaching and Online Simulation-Assisted Instruction~Classroom-Based Instruction:~Participants were provided with a QR code to access the Moodle platform and download the electronic course materials.~The classroom instruction covered the following topics:~Mechanisms of trauma and prehospital assessment. Principles of major trauma activation and evaluation. Types of chest trauma and associated clinical signs. Principles of chest trauma care and recognition of changes in patient conditions.~Care I Decide! Online Simulation-Assisted Teaching:~A detailed explanation of the operational process for the Care I Decide! online simulation-assisted teaching materials was provided.~The session integrated classroom knowledge with the Care I Decide! online simulation. It presented clinical scenarios involving changes in vital signs and symptoms of chest trauma patients, guiding participants through clinical decision-making processes."
224141817|NCT04655703|DEVICE|DJO X4 brace with Motion Intelligence Platform|The X4 Knee brace with the Motion Intelligence platform uses both a bio-measurement equipment with an interactive application thereby providing the patient with immediate feedback on their exercise regime. The X4 Knee brace is a postoperative brace worn by a patient to monitor compliance to prescribed protocol based on the movement and function of the knee joint. The device also connects wirelessly to a companion mobile application, Motion Intelligence, and streams both real-time and collected data for review and record collection. Prescribed exercises are uploaded into the patient application, with a number of the exercises actively tracked by the Mi360 sensor housed in the X4 brace. Compliance can be tracked by the physician in real-time between postoperative visits and any medical staff on a separate dashboard.
224141818|NCT03999541|OTHER|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
223434763|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group|Intramuscular injection of deltoid muscle of upper armof 25μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223434764|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group|Intramuscular injection of deltoid muscle of upper armof 50μg/0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223434765|NCT04550351|BIOLOGICAL|Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group|Intramuscular injection of deltoid muscle of upper armof 0.5ml/person doseRecombinant new coronavirus vaccine (CHO cells).
223740617|NCT05545566|PROCEDURE|Thoracic ultrasound versus chest X-ray|"Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain."
224045520|NCT06902870|OTHER|Classroom-Based Teaching|"Classroom-Based Teaching~Delivery of Course Materials:~Participants were provided with a QR code to access the Moodle platform, where they could download the electronic course handouts.~Classroom Instruction Content:~The classroom teaching session included the following topics:~Mechanisms of trauma and prehospital assessment. Principles of major trauma activation and evaluation. Types of chest trauma and associated clinical signs. Principles of chest trauma care and recognition of changes in patient conditions.~Chest Trauma Case Sharing~Case Presentation and Reflection:~Clinical cases involving chest trauma were presented to participants. They were guided to describe the case details, reflect on the management process, and receive constructive feedback.~Discussion and Problem Solving:~During the discussion, questions and uncertainties raised by participants were addressed to enhance understanding and clarify key concepts."
224045521|NCT06808932|DRUG|VK4-116|D3R antagonist
224045522|NCT06808932|DRUG|Placebo|Each of the four dose groups of n=8 participants will be assigned to active drug or placebo in the ration 6:2.
224045523|NCT06902103|DRUG|Nabufine Hydrochloride Injection|PartA: Nabufine Hydrochloride Injection are administered Intravenous injection single dose
224045524|NCT06902103|DRUG|Nabufine Hydrochloride Injection|PartB: Nabufine Hydrochloride Injection are administered Intravenous injection multi dose
224045525|NCT06902987|DRUG|Upadacitinib|Enrolled patients received oral upatinib treatment with a conventional induction dose of 45mg/d for 12 weeks, followed by a maintenance dose of 15m/d or 30mg/d
224045526|NCT06902259|OTHER|randomised controlled trial|"Breathing exercise group: Sixty patients, including 20 patients in each group, who met the inclusion criteria were identified. The details of the study were explained to the patients and their consent was obtained. In order to minimise selection bias, a simple random sampling method, the random numbers table, was used and patients were assigned to groups as 20 reiki group, 20 breathing exercise group and 20 control group.~Reiki group: Sixty patients, including 20 patients in each group, who met the inclusion criteria were identified. The details of the study were explained to the patients and their consent was obtained. In order to minimise selection bias, a simple random sampling method, the random numbers table, was used and patients were assigned to groups as 20 reiki group, 20 breathing exercise group and 20 control group."
224045527|NCT06902675|OTHER|Artificial Intelligence|Artificial Intelligence as a decision making tool
224045528|NCT06902675|OTHER|Retrospective Data Extraction of 10,000 Neurology ER Cases|This intervention involves collecting and de-identifying clinical data from 10,000 patients previously evaluated by neurologists in the Emergency Department. The data are then used retrospectively to refine and fine-tune a large language model (LLM). No real-time clinical decisions or recommendations are made for these patients, as the purpose is to improve the model's accuracy and relevance for future use.
224045529|NCT06903247|OTHER|Neurosonographic Findings of Vitamin D Deficiency in Single Healthy Pregnancies Presenting for Routine Antenatal Care Between 20-30 Weeks of Gestation.|Comparison of Neurosonographic Findings in Patients with and without Vitamin D Deficiency.
224045530|NCT06903377|BIOLOGICAL|ZG005 for Injection|intravenous infusion
224045531|NCT06903377|DRUG|Gecacitinib Hydrochloride Tablets|Oral
224045532|NCT06660342|DRUG|Vonoprazan|Oral tablet.
224045533|NCT06901934|OTHER|junctional adhesion molecule3 expression by immunhistochemistry|"* Data record of patient will be reviewed for the following:~* Clinical features:~* Age~* Performance status~* Risk factors(smoking,stones or bilharziasis)~* Comorbidities~* Family history~* Pathological features:~* Histological subtype~* Grade~* Muscle invasion~* Carcinoma in situ~* Immunohistochemistry(IHC):~JAM3 expression by IHC~* TNM staging~* Number of chemotherapy cycles received~* Radical surgery or~* CCRT and type of concurrent~* Post treatment histological response~* . Follow-Up and Survival Analysis:~* During treatment: Monitoring for adverse events of chemotherapy and clinical response.~* After treatment: Imaging and clinical examination every 3 months for 2 years.~* Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS).."
224045534|NCT06618807|DEVICE|Active tPBM device|The Neuro RX Gamma (version 2) delivers a synchronized pulse frequency of 40 Hz from all LED clusters. The gamma pulse frequency of 40 Hz has been demonstrated to attenuate amyloid beta proteins production in the hippocampus and modulate microglial activity resulting in increased scavenging of amyloid beta which may lead to improving cognition in MCI. Finally, the Vielight Neuro RX Gamma (version 2) has been designed to target the delivery of NIR energy to particular brain regions; specifically the default mode network (DMN). The active intervention device proceeds to deliver light to each LED at 40 Hz with a 50% duty cycle for 20 minutes and stops automatically. During the 20 minute treatment the power indicator LED on the controller flashes green at 40 Hz. The operator is notified that the treatment is finished when the power indicator LED on the controller stops flashing and the device beeps 2 times.
224045535|NCT06618807|DEVICE|Sham device|The sham device delivers infrared light for only a few seconds before stopping. The controller will still show a green light to maintain the study\&#39;s blinding. If the headset is removed, the device will emit a beep and cease functioning.
224045536|NCT06927206|OTHER|Experimental Group A: Segmental vibrator only on dorsiflexor|"Segmental vibrator only on dorsiflexor:~After standard physiotherapy session this group received the intervention of segmental vibration. Tibialis anterior muscle targeted for dorsiflexor. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator."
223434766|NCT01785849|DRUG|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
223740618|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
223434767|NCT01785849|DRUG|Placebo|Administered intravenously (IV) three times per week.
224045537|NCT06927206|OTHER|Experimental Group B: Segmental vibrator + Electrical stimulation on dorsiflexors|"Segmental vibrator + Electrical stimulation on dorsiflexors:~After standard physiotherapy session this group received the intervention of neuromuscular electrical stimulations by means of EMS. Two electrodes were used for this procedure. Tibialis anterior muscle targeted for dorsiflexor. One pad of electrode was placed on anterior of lower leg just below tibial tuberisty and other was 5cm below to it .With a 250-microsecond pulse duration, the EMS device was set up to provide a biphasic current with a symmetrical waveform at 50 Hz for 15 seconds. It was also tuned for a 3-second ramp up time and a 30-second rest period. Each respondent set the intensity to the highest level they could tolerate. Secondly, segmental vibrator was applied for focal vibrations on tibialis anterior. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator."
223434768|NCT01110213|BEHAVIORAL|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
223434769|NCT01110213|BEHAVIORAL|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
223434770|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
223434771|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
223434772|NCT00881907|DRUG|Triple Antibiotic Paste|ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
223434773|NCT05461937|BEHAVIORAL|Getting things done after stroke|A two-session, online rehabilitation intervention focussing on cognitive executive functions supplemented with weekly homework tasks.
223434774|NCT05461937|BEHAVIORAL|Stroke psychoeducation|A two-session, online stroke psycho-education intervention supplemented with weekly homework tasks.
223434775|NCT06124586|PROCEDURE|Percutaneous transluminal angioplasty|Percutaneous transluminal angioplasty of the leg
223434776|NCT06354205|DIAGNOSTIC_TEST|Sliva Procalcitonin|Sliva Procalcitonin vs Blood procalcitonin
224141819|NCT03086538|DRUG|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
224141820|NCT03086538|DRUG|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
224141821|NCT04062370|DRUG|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
223434777|NCT04118556|BIOLOGICAL|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
224141822|NCT04062370|DEVICE|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
223434778|NCT04118556|DRUG|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
223434779|NCT05118061|DIAGNOSTIC_TEST|Ketone|compare diagnostic tests to reference methods
223434780|NCT05929248|DRUG|Telitacicept|160mg once a week for 48 weeks
223565903|NCT06660537|PROCEDURE|Balloon-blowing exercises in 90/90 bridge position with a ball.|In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.
223565904|NCT06660537|PROCEDURE|Buteyko breathing exercises management|In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
223434781|NCT05929248|DRUG|conventional therapy|Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
223434782|NCT05929248|DRUG|Placebo|Used once a week in combination with standard treatment
223434783|NCT06288204|DIETARY_SUPPLEMENT|Propolis associated with Royal Jelly|The participants will consume 4 capsules a day, providing daily royal jelly in an amount of 100 mg/day plus 500 mg/day of propolis together, for 2 months.
223434784|NCT06288204|DIETARY_SUPPLEMENT|Royal Jelly|The participants will consume 1 capsules a day, providing daily royal jelly in an amount of 100 mg/day, for 2 months.
223434785|NCT06288204|DIETARY_SUPPLEMENT|Placebo|The participant will consume 4 capsules a day of placebo, for 2 months.
223434786|NCT03759145|OTHER|Exergame|Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
223434787|NCT03759145|OTHER|usual care|participants continued their planned rehabilitation sessions
223740619|NCT04260542|BEHAVIORAL|Fasting/refeeding|2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
224045538|NCT06902363|DEVICE|Macroduct Advanced|Sweat stimulation and collection using the Macroduct Advanced system on two anatomical sites (forearm and thigh) in infants under 6 months of age.
224045539|NCT07103733|PROCEDURE|Cardiac Magnetic Resonance Imaging|Non-invasive imaging test that uses powerful magnets and radio waves to create detailed pictures of the heart without using radiation.
224045540|NCT07103733|DEVICE|ZioPatch Monitoring|ZioPatch is a small, wearable heart monitor that sticks to the chest and records the heart's electrical activity continuously for up to 14 days. It helps doctors detect irregular heart rhythms (arrhythmias) without the need for bulky wires or equipment.
224045541|NCT07103733|PROCEDURE|Myocardial Tissue Biopsy|During the MVr procedure, surgeons will biopsy approximately 50 μg of tissue from the endocardial and subendocardial myocardium in the inferobasilar and control areas using a surgical rongeur.
224045542|NCT07104539|BEHAVIORAL|Strength Training|Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.
224045543|NCT07104539|OTHER|Wait first, then strength training|Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
224045544|NCT07102264|DEVICE|CPMX1|Compressibility of thyroid nodules using CPMX1 during pre surgery planning visit
224045545|NCT07111013|DRUG|Lifitegrast/perfluorohexyloctane (PFHO)|fixed-dose combination (FDC) (5%/95%)
224045546|NCT07104123|OTHER|Social drivers of health screening|Patients will undergo a structured and protocoled screening for social drivers of health and be linked to support services
224045547|NCT07104123|BEHAVIORAL|Patients will undergo a program of contingency management|Patients will enter into a 12 week program of contingency management
224045548|NCT06325293|DRUG|Azithromycin Pfizer®|Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm: 1 daily dose for 5 days, 10mg/kg/day on day 1 and 5mg/kg/day on days 2-5
224045549|NCT06325293|DRUG|Placebo|Control comparator arm: 5 days of placebo
224045550|NCT07121166|BEHAVIORAL|tgCBFI programme|a six-week online group intervention programme for dyads of service users and caregivers
224045551|NCT07121166|BEHAVIORAL|Treatment as Usual (TAU)|Integrated community psychiatric care with psychiatric outpatient follow-up
224045552|NCT07119983|BEHAVIORAL|Stress ball|The effects of stress balls on pain, distress and physiological parameters during surgical debridement in patients with diabetic foot ulcers will be investigated.
224045553|NCT07123064|BEHAVIORAL|Individual Level|A 8-weekly, 1hour telephone-delivered sessions using mindfulness and SOLUS-D program. Key contents include: introduction to mindfulness - Body awareness and present moment experiences, emotional awareness and mind-body labeling, relaxation techniques and sensory discrimination, deepening awareness and accepting feelings, personal values, interconnection between thought patterns and emotions, identifying and analyzing of thought traps, and challenging thoughts and future planning. Booster sessions which focus on embedding mindfulness practices and SOLUS-D program among older adults as a persistent habit will be conducted.
224045554|NCT07123064|BEHAVIORAL|Interpersonal Level|A 8 weekly, 1hr sessions through telephone or Zoom using the Group 4 Health and community navigator prgram. Key contents include: understanding the benefits of social connections, exploring self and community, community and action, support and breakthrough, summary and moving forward. Booster sessions which focus on continuous practice of support and community will be conducted.
224045555|NCT07123064|BEHAVIORAL|Community Level|A 4 weekly, 2hour in-person sessions through (1) strengthening collective efficacy via neighbor identification with the community. Key contents include: building neighbourhood connections, getting to know each other, health aging, neighbourhood care, vibrant exploration, thriving community, connecting the dots.
224045556|NCT07123064|BEHAVIORAL|Usual Care Control|Monthly SMS over a period of 6 months will be sent out. Key content includes: healthy diet tips, recognizing warning signs of health, understanding dementia, fall prevention tips, health message, and anti-fraud tips.
224045557|NCT07130604|DRUG|D-2570|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.
224045558|NCT07130604|DRUG|Placebo|Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-2570 group1, group 2 or placebo group.
224045559|NCT07128472|DRUG|Humira|Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.
224141823|NCT04372342|DRUG|nalbuphine|Nalbuphine hydrochloride has strong analgesic effect, quick effect and long time by stimulating receptor, and has partial antagonistic effect on the receptor, so the incidence of respiratory depression is low in theory.
223434788|NCT02702141|DRUG|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
223434789|NCT04958759|OTHER|Functional Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 4 weeks of foundation inspiratory muscle training and 6 weeks of functional inspiratory muscle training
224141824|NCT04372342|DRUG|remifentanil|remifentanil
223434790|NCT04958759|OTHER|Inspiratory Muscle Training|The inspiratory muscle training program will be consist of 10 weeks of foundation inspiratory muscle training
223434791|NCT04958759|OTHER|Breathing exercises|The program will be consist of 10 weeks of breathing exercises
223434792|NCT05452616|OTHER|ART first- Therapeutic use trial|ART initiation on the day of enrolment independent of TB investigations in PLHIV with presumptive TB but no signs of CNS disease. The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
223434793|NCT05452616|OTHER|TB results first- Therapeutic use trial|Deferral of ART initiation until active TB has been refuted or confirmed. PLHIV presenting with symptoms (cough, fever, night sweat, weight loss) are defined as presumptive TB, and should have microbiological TB investigations. Routine TB investigations in Malawi and Lesotho usually consist of two sputum bottles for analysis using nucleic acid amplification tests (Xpert MTB/RIF (Ultra)).The trial uses treatments and drug-doses as per international and national guidelines. All treatment components will be applied at standard dosage and no new substances or alternative indications will be tested.
223434794|NCT05546658|DRUG|Psilocybin|Psilocybin administration under supportive conditions
224045560|NCT07130838|BEHAVIORAL|MB-EAT program|Phase 2 will include 12 modules, delivered across 12 weeks. The program will contain seated and guided mindfulness practices designed to cultivate better awareness of hunger cues, sensory-specific satiety, as well as external and emotional food-related triggers through body scans, taste satiety and mindful eating practices, self-compassion meditations, and diaphragmatic breathing. The intervention will also include mindful movements. Each session will be focused on a specific theme related to promoting healthy eating behaviours and emotional regulation. Each module will be unlocked as the participant progresses through the program. AmDTx-Epiq also incorporates goal setting, daily feedback, prompts for change, and positive reinforcement in the form of an encouraging text messages from the study coach.
224045561|NCT07130838|BEHAVIORAL|Feasibility study|"Phase 1 will include 4 modules, delivered across 4 weeks. All participants will receive a modified, shortened version of the MB-EAT program through AmDTx-Epiq within the AmDTx app. Participants will also complete the Keep in Balance questionnaire every week on the app, a questionnaire which assesses weekly physically activity and eating habits, as well as associated thoughts and feelings to these. Participants will receive regular check-ins twice per week from a coach (unblinded study coordinator) via text designed to promote engagement and answer questions participants may have during the 4-week intervention period."
224045562|NCT07130838|BEHAVIORAL|Psychoeducation|Patients in the control group will receive audio-recorded psychoeducation in the form of standard diet/exercise information. The comparator is publicly available psychoeducational information available on nutrition, physical activity, and weight management through best practice guidelines, clinical guidelines, and public health guidelines. These comparators were chosen as they are easily accessible standard of care practices and interventions available in the community (i.e., the general public have access to it in the community), such as through consultation with a dietician, community care provider, or family physician.
224045563|NCT07129473|DRUG|Metformin Extended Release Oral Tablet|"Participants in the Treatment Arm will receive oral extended-release metformin (metformin-XR) once daily with the evening meal starting prior to conception. The dosing will begin at 500 mg daily and increase gradually over an eight week period (+500mg every 2 weeks, as tolerated) to a maximum tolerated dose of up to 2,000 mg daily. Treatment at highest tolerated dose will continue (maintenance phase) until either two weeks after a positive pregnancy test or 12 months from treatment initiation, whichever comes first. Participants will attend three clinic visits and provide blood samples at baseline, after dose escalation, and during early pregnancy to assess GDF15 levels. Daily dosing, adherence, and any side effects are recorded via MyCap; clinical visits at baseline, post-escalation (week 8), and after pregnancy confirmation include vital signs, PUQE-24/HELP scores, and blood draws for CBC, creatinine, and GDF15 levels."
224045564|NCT07128394|DRUG|Recombinant Luteinizing Hormone (rLH)|Recombinant LH administered subcutaneously in combination with recombinant FSH (rFSH) at a ratio of 2:1 starting on stimulation day, continued throughout controlled ovarian hyperstimulation. Dosage adjusted according to follicular growth and serum hormone levels.
224045565|NCT07128394|DRUG|Recombinant Follicle-Stimulating Hormone (rFSH)|Recombinant FSH administered subcutaneously for controlled ovarian hyperstimulation after pituitary downregulation with a long-acting GnRH agonist. Dosage adjusted based on follicular development and hormone monitoring.
224045566|NCT07128394|DRUG|Gonadotropin-Releasing Hormone Agonist (GnRH-a)|Long-acting GnRH agonist (3.75 mg) administered subcutaneously on menstrual cycle day 2-4 for pituitary downregulation before controlled ovarian hyperstimulation.
224045567|NCT07128823|OTHER|(High-frequency segmental vibration and ASAP with Routine Physical Therapy)|"A Segmental vibration device was used to provide vibratory stimulation with a frequency of 100 Hz and an amplitude of 1.0 mm. This stimulation was used because vibratory stimulation with a high frequency (80-120 Hz) and low amplitude can elicit strong activity in Ia afferents from the muscle spindles. 100 Hz frequency vibration was applied perpendicularly along the muscle fibers of the forearm extensor muscle (extensor carpi ulnaris (ECU), extensor carpi radialis (ECR), triceps).~The Accelerated Skill Acquisition Programme (ASAP), a structured, taskoriented motor training program for the upper extremities, is a best-practice synthesis implementing neuroscientific evidence regarding motor training approaches and schedules. The Accelerated Skill Acquisition Program (ASAP) for subacute stroke patients focuses on integrating motor training with motivational enhancement and impairment mitigation."
224045568|NCT07128823|OTHER|(Accelerated Skill Acquisition Programme with Routine Physical Therapy)|"Exercises within the ASAP typically include:~Task-Specific Training: Patients engage in activities that mimic daily tasks, such as reaching, grasping, and manipulating objects, to improve their functional abilities Repetitive Practice: Patients perform repetitive movements to strengthen neural pathways and improve motor skills. This can involve tasks like buttoning a shirt, picking up small objects, or pouring water Bilateral Arm Training: This approach involves using both arms simultaneously to perform coordinated tasks, enhancing bimanual skills and improving upper extremity functions Motivational Strategies: The program incorporates motivational techniques to enhance patient engagement and adherence to the exercises, ensuring sustained practice and better outcomes."
224141825|NCT05505396|OTHER|Sampling of blood and cerebrospinal fluid|Blood HbA1c, insulin, C-peptide and IL-6 measured at admission. Glucose and lactate measured every 4 hours during intensive care stay. Daily sampling of CSV analysed for glucose and lactate in patients with EVD.
224163516|NCT01609491|DRUG|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
223434795|NCT01110785|BIOLOGICAL|panitumumab|
223434796|NCT01110785|DRUG|simvastatin|
223434797|NCT01110785|OTHER|laboratory biomarker analysis|
223434798|NCT06853886|OTHER|blood sample HBV patient|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 2 dry tube per patient"
223434799|NCT06853886|OTHER|blood sample healthy volunteers|"* 3 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 2 dry tube"
223434800|NCT05551273|DRUG|Selgantolimod|1.5 mg tablet
223434801|NCT05551273|DRUG|Placebo|Matching placebo tablet
223434802|NCT04340843|DRUG|Belinostat|Given IV
223434803|NCT04340843|PROCEDURE|Biopsy Procedure|Undergo biopsy
224045569|NCT07129369|BEHAVIORAL|PASIM program|The program consists of 5 modules for ROP patients (translated, refined and validated by research team) and 4 group sessions (1.5 hours per session; 8-10 members/group; in-between completion of the 5 modules) facilitated by a peer-support worker over 5 months. The 5 modules include: Module 1-Patient's well-being; Module 2-Getting the best out of support services; Module 3-Acceptance and insight toward psychosis and long-term self-care; Module 4-Dealing with psychosocial effects of the illness- I; and Module 5-Dealing with physical/mental health effects of the illness- II. The 4 group sessions will be conducted at the orientation and after reading the 1st, 3rd and 5th module to introduce the program, encourage to complete the module per month, performing value clarifying and acceptance (psychological flexibility) exercises, and clarify and discuss self-care learning and and challenges.
224045570|NCT07129369|BEHAVIORAL|Psychoeducation|The psychoeducation group (5 subgroups with 12-14 patients per group) will be led by one trained psychiatric nurse experienced in psychiatric rehabilitation and psychoeducation group. The program consists of 12 two-hour sessions held weekly or biweekly (similar to the PASIM) over 5 months with four key components, including introduction and goal setting; an education workshop on psychosis care and community service; learning effective coping and self-care skills with rehearsals/reviews; and skills practices and preparing for future life.
224045571|NCT07129369|BEHAVIORAL|Usual-Care-only|Participants receive usual community mental healthcare services provided by POPCs and ICCMWs.
224045572|NCT07130331|DRUG|Secikinumab|secukinumab 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg s.c. every 4 weeks
224045573|NCT07129044|BEHAVIORAL|Flipped Classroom Training on Pediatric Pain Management|Participants in this group received pediatric pain management training designed to increase nursing students' knowledge and motivation. The training was delivered using a flipped classroom model over 4 weeks. Students were provided with pre-class educational materials, including video lectures, readings, and lecture notes. In-class sessions included interactive activities, discussions, case-based learning, and problem-solving exercises. Content was based on current pediatric pain management guidelines and adapted to nursing education standards.
224045574|NCT07129044|BEHAVIORAL|Self-Directed Learning on Pediatric Pain Management|Participants in this group received pediatric pain management training designed to increase nursing students' knowledge and motivation. Students were provided with the same pre-class educational materials as the intervention group, including video lectures, readings, and lecture notes, for self-study without any interactive activities or instructor-led sessions. Content was based on current pediatric pain management guidelines and adapted to nursing education standards.
224299810|NCT03994055|OTHER|Lactose restriction|Diet will be restricted to 5g lactose/day
224299811|NCT03994055|OTHER|Fiber restriction|Diet will be restricted to 20g fiber/day
223434804|NCT04340843|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223434805|NCT04340843|PROCEDURE|Computed Tomography|Undergo CT
223434806|NCT04340843|DRUG|Decitabine and Cedazuridine|Given PO
223434807|NCT04340843|DRUG|Guadecitabine|Given SC
223434808|NCT04340843|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223434809|NCT04249622|OTHER|Best Practice|Given standard of care pertuzumab-based chemotherapy
223434810|NCT04249622|OTHER|Questionnaire Administration|Ancillary studies
223434811|NCT04249622|DRUG|Rifaximin|Given PO
223434812|NCT06654466|DEVICE|Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.|The Nest software platform includes the Nest Care Studio, Nest Patient Navigator and the Analytics Dashboard. Nest Care Studio is a clinician facing portal that can be used standalone or electronic medical record (EMR) integrated. Care Studio enables clinicians to effectively manage patients' genetic information over time. Clinicians can see a list of patients that meet criteria for testing, run risk assessment calculations, order genetic tests, manage patients based on results and view education modules.The Nest Patient Navigator is a secure mobile device accessible platform that provides a centralized location for patients to store, manage, and follow-up with their genetic results. The Analytics Dashboard is an interactive dashboard that can track outcomes of genomic programs and trigger interventions to optimize them.
223565905|NCT04522102|DRUG|Start antiplatelet monotherapy|Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
223565906|NCT06608264|OTHER|stress ball intervention|Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
223565907|NCT06608264|OTHER|hand holding intervention|Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
223565908|NCT06608524|BEHAVIORAL|Self-regulated learning strategy|The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.
223565909|NCT06608524|BEHAVIORAL|Standard learming method|The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
223434813|NCT06620549|DIAGNOSTIC_TEST|gastric ultrasonograppy|Patients will be scanned in both supine and right lateral decubitus position (RLD)s. If the antrum is visible, it will be judged if the antrum is empty in both positions or the antrum is empty in supine position and fluid apparent in RLD position suggesting a low fluid volume (\<1,5 ml/Kg). The third option is fluid apparent in both supine and RLD position, suggesting a higher fluid volume (\>1,5ml/Kg) and the last option is solid food in one or both positions.
223434814|NCT03075202|DEVICE|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
224045575|NCT07128589|DEVICE|3MTM FiltekTM Supreme Flowable Composite|"3M ™ Supreme Flowable Restorative contains BisGMA,TEGDMA and Procrylat resins. The fillers are a combination of ytterbium trifluoride filler with a range of particles sizes from 0.1 to 5.0 microns, a non-agglomerated/non-aggregated surface modified 20nm silica filler, a non-agglomerated/non/aggregated surface modified 75nm silica filler, and a surface modified aggregated zirconia/silica cluster filler (comprised of 20 nm silica and 4 to 11nm zirconia particles). The aggregate has an average cluster particle size of 0.6 to 10 microns. The inorganic filler loading is approximately 65% by weight (46% by volume).~3M (TM) Filtek(TM) Supreme Flowable Restorative is a modification of predicate device 3M(TM) Filtek(TM) XT Flowable Restorative (which was a modification of 3M(TM) Filtek(TM) Flow. 3M Filtek Supreme Flowable Composites are used per indication and its approved labeling in this study."
224045576|NCT07130760|PROCEDURE|Intraligamentary Injection|Intraligamentary local anesthesia will be administered using a standard dental syringe with 2% lidocaine and 1:100,000 epinephrine.
224141826|NCT06701188|BEHAVIORAL|Virtual Coaching and social support|The investigators propose a randomized clinical trial (RCT) of a virtual coaching and social support intervention that integrates evidence- and theory-based approaches to build self-efficacy, self-regulation, and perceived social support after cardiac rehabilitation (CR) to improve physical activity, psychosocial, social cognitive, and clinical outcomes, delivered via a social networking platform (Trainerize). Our intervention will also include goal setting for exercise and tailored feedback by our qualified intervention team.
224141827|NCT06263699|PROCEDURE|ROM measurement of the MCP and PIP joints in digits 4 and 5|standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
224141828|NCT04041908|OTHER|Experimental Product|2 sachets per day
223434815|NCT00779688|DEVICE|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
223434816|NCT06977568|DRUG|Zilretta|triamcinolone acetonide, extended release injectable suspension
223434817|NCT06977568|DRUG|Triamcinolone Acetonide|Triamcinolone Acetonide, Immediate Release (TCA-IR)
223434818|NCT04250298|DIETARY_SUPPLEMENT|sucrosomial iron|oral intake of iron as sachets or capsules
224045577|NCT07130760|PROCEDURE|Inferior Alveolar Nerve Block|Inferior alveolar nerve block will be performed with 2% lidocaine and 1:100,000 epinephrine using the conventional technique.
224141829|NCT02330913|PROCEDURE|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
223434821|NCT06806995|DRUG|Zidebactam-Cefepime|(1) ZID-FEP 3g IV (ZID 1 g plus FEP 2 g) administered over 1 hour (h)
223565910|NCT06662006|DRUG|nal-IRI,5-fu,LV, benmelstobart, anlotinib|liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) combined with benmelstobart and anlotinib ± SBRT
224141830|NCT01927393|OTHER|palliative care|Receive PCPI
224141831|NCT01927393|BEHAVIORAL|educational intervention|Receive education sessions
224141832|NCT01927393|PROCEDURE|quality-of-life assessment|Ancillary studies
224141833|NCT01927393|OTHER|questionnaire administration|Ancillary studies
224141834|NCT01927393|BEHAVIORAL|telephone-based intervention|Receive telephone contacts
224141835|NCT02816879|PROCEDURE|Cytology Specimen Collection Procedure|Undergo anal cytology collection
224141836|NCT02816879|OTHER|Laboratory Biomarker Analysis|Correlative studies
224141837|NCT00797069|OTHER|standard nutritional product (medical food)|once during crossover
224141838|NCT00797069|OTHER|nutritional product for diabetes (medical food)|once during crossover
224141839|NCT00797069|OTHER|diabetes specific experimental nutritional product (medical food)|once during crossover
224141840|NCT06071637|PROCEDURE|Double low-power laser therapy simultaneous applicated|Double low-power laser therapy, with simultaneous application of two wavelengths, red and infrared in in the mouth and neck
224141841|NCT02307838|OTHER|Assessments arm|Protocol required assessments not provided in standard of care
224141842|NCT05545904|BEHAVIORAL|Substance use brief intervention (BI)|The BI will be delivered in a single session (20-30 minutes) using motivational interviewing techniques and the FRAMES model i.e.(i) providing feedback on screening results (ii) ensuring responsibility on the part of the adolescents (iii) giving clear advice to stop/cut down (iv) giving menu of options (alternative healthy behaviors to engage in) (v) expressing empathy, and (vi) encouraging self-efficacy (15). The BI will be delivered for the highest scoring substance or the one the adolescent identifies as the most problematic.
224141843|NCT05545904|BEHAVIORAL|substance use education intervention|This intervention will entail review of material in the NACADA substance use education manual for adolescents, and will be followed by a question and answer session. The manual contains summarized and simple information on the harms and myths related to alcohol, tobacco, cannabis, prescription medication and khat use, substances. This education intervention will be delivered over a single 20-30 minute session by a counselor stationed at Rafiki clinic.
224141844|NCT01098825|OTHER|web-based survey|Anonymous web-based survey
224141845|NCT03605199|DRUG|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
224141846|NCT05200156|DIETARY_SUPPLEMENT|Phosphatidyl Choline|conventional management + phosphatidyl choline tablets
223434822|NCT06806995|DRUG|Metronidazole|(2) metronidazole 0.5 g IV alone administered over 1 h
223434823|NCT06806995|DRUG|FEP-ZID|(3) metronidazole 0.5 g IV over 1 h, followed by ZID-FEP 3g IV over 1 h over 3 treatment periods separated by a 48 h washout period.
223434824|NCT05296798|DRUG|Phesgo|Phesgo will be administered subcutaneously (SC) at a fixed non-weight-based dose. In the induction therapy phase, a loading dose (1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase \[rHuPH20\]) will be administered in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses (600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20) will be administered once every 3 weeks (Q3W).
223565911|NCT06660303|BEHAVIORAL|Comprehensive Preoperative Education for Enhanced Recovery in Colorectal Surgery|The intervention in this study involves preoperative patient education aimed at improving outcomes for individuals undergoing colorectal surgery. Patients in the study group will receive targeted educational sessions that focus on setting expectations, managing anxiety, understanding pain control, and preparing for the surgical process as part of the Enhanced Recovery After Surgery (ERAS) protocol. This educational approach is designed to empower patients, reduce anxiety, enhance satisfaction, and potentially improve post-surgical recovery compared to those receiving routine hospital care.
223565912|NCT06660303|OTHER|Routine hospital care|The control group, designated as Group II, will receive standard hospital care, encompassing the usual preoperative and postoperative procedures provided by the hospital. This includes typical preparation and recovery guidelines without any added specialized preoperative education or targeted nursing instructions. This routine hospital care serves as a baseline, allowing for a direct comparison of outcomes against the intervention group, which will receive comprehensive preoperative education aimed at enhancing recovery and improving surgical outcomes.
224045578|NCT06203418|BEHAVIORAL|Multi-Family Therapy|Multi family therapy for anorexia nervosa (MFT-AN) draws on the same principles as FBT but is delivered in a more intensive format to help families to overcome a sense of isolation and stigmatization and to maximize their own resources. In the case of eating disorders, this program utilizes FBT principles (both approaches are guided by the family-based treatment philosophy, which stresses the impact of ED on family functioning and attempts to mobilize families as the primary agents of change in achieving recovery), and also utilizes learning from structural, systemic, strategic, narrative, and psychodrama-based family therapy practices,(Knatz et al., 2015). Generally between 5-7 families take part in MFT, sharing their experiences, learning by example, and providing support for one another. Study will utilize virtual adaptation of manualized treatment published by Simic et al 2021
223434825|NCT05296798|DRUG|Giredestrant|A 30 milligram (mg) capsule of giredestrant will be taken orally once a day on Days 1 to 21 of each 21-day cycle.
223565913|NCT06606509|DEVICE|Continuous Glucose Monitoring System (GX-01S)|Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
224045579|NCT05294354|BEHAVIORAL|aerobic exercise group (AE)|The participants will ride the cycle ergometer for 35 minutes. The training consisted of a 5-minute warm-up period followed by 25 minutes of moderate exercise and a 5-minute recovery.
224045580|NCT05294354|BEHAVIORAL|aerobic exercise with virtual reality group (AE-VR)|The participants will receive the 3D VR training program and ride the cycle ergometer at the same time. The training protocol is similar to the aerobic exercise group.
224045581|NCT05294354|BEHAVIORAL|combined exercise group (CE)|The intervention consists of 5-minutes aerobic warm-up, 25-minutes bodyweight exercise, and 5-minutes mindfulness meditation for recovery. The participants will follow the video to do the program.
224045582|NCT05294354|BEHAVIORAL|Control group|Participants will watch a 35-min video about exercise science.
224045583|NCT02705209|OTHER|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
224045584|NCT02705209|OTHER|Placebo Cataplasm|Poultice of Kaolin and Water
223565914|NCT06606795|OTHER|Spinal Manipulation|For the treatment to be applied in the SMT group, segmental dysfunctions will be determined using static and dynamic palpation techniques and the applications will be applied with a chiropractic method, high-speed, low-amplitude spinal manipulation method, at the level of the dysfunctional spine.
223565915|NCT06607666|DRUG|Lanreotide autogel|Identification of clinical, biochemical, molecular markers of response to low and high dose of fg-SRLs
224045585|NCT06954142|OTHER|Fluid restriction|Fluid restriction strategy (fluid target 135 ±5 mL/kg/d)
224045586|NCT06954142|OTHER|Liberal fluid intake|Liberal fluid intake strategy (fluid target 165 ± 5 mL/kg/d)
223565916|NCT06607419|DRUG|Blinatumomab|Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.
223565917|NCT05097677|OTHER|Not applicable (observational study)|Not applicable (observational study)
224045587|NCT07130253|DRUG|Vonoprazan based ET|Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or quadruple therapy
224045588|NCT07130253|DRUG|Vonoprazan based SGT|Susceptibility testing guided therapy Based onsusceptibility test:Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin quadruple therapy
224045589|NCT06291831|DRUG|nirmatrelvir, ritonavir|Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
224045590|NCT06291831|OTHER|Controls|Patients who do not receive Nirmatrevir/ritonavir (Paxlovid)
224045591|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg intravenously (IV) every 2-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
224045592|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 15mg/kg intravenously (IV) every 3-week cycle plus anlotinib on Day 1-14 of every 3-week cycle (Q3W) until progression.
224045593|NCT04646330|DRUG|AK104+anlotinib|Subjects receive AK104 10mg/kg Q3W plus anlotinib 1-14days of every 3-week cycle until progression.
224141847|NCT06199622|OTHER|music|20 minutes of classical Turkish musicor classical western music
224141848|NCT06379438|COMBINATION_PRODUCT|Photodynamic therapy (indocyanine green+laser)|Photodynamic therapy with indocyanine green
224141849|NCT01015729|DRUG|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
224141850|NCT01015729|DRUG|Esomeprazole|oral, single dose
224141851|NCT01015729|DRUG|ASA|Tablet, oral, single dose
224299812|NCT03994055|OTHER|Fat restriction|Diet will be restricted to 20% total energy intake
223434826|NCT05296798|DRUG|Docetaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Docetaxel will be administered at 75 milligrams per metre squared of body surface area (mg/m2) intravenously over 60 (±10) minutes on Day 1 of each cycle for 4 to 8 cycles (a cycle is 21 days); this dose may be escalated to 100 mg/m2 if the initial dose was well tolerated.
224141852|NCT01882777|BEHAVIORAL|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
223434827|NCT05296798|DRUG|Paclitaxel|During the induction therapy phase, the investigator's choice of taxane-based chemotherapy (i.e., docetaxel or paclitaxel) will be administered after Phesgo. Paclitaxel will be administered at 80 milligrams per metre squared of body surface area (mg/m2) intravenously over a minimum of 1 hour on Days 1, 8, and 15 of each cycle for 4 to 8 cycles (a cycle is 21 days); this weekly regimen is considered as one complete cycle whenever 3 weekly doses are given.
223434828|NCT05296798|DRUG|LHRH Agonist|A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
223434829|NCT05296798|DRUG|Optional Endocrine Therapy of Investigator's Choice|For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.
223434830|NCT06981936|DRUG|Balance Tablet|Each Balance tablet contains a broad range of vitamins and trace minerals at doses designed to prevent deficiencies (including but not limited to vitamins A, B-complex, C, D, E, K, calcium, iron, zinc, magnesium, selenium, and others, per standard multivitamin composition).
223434831|NCT06981936|DRUG|Control (placebo)|The placebo is an inert pill formulated to be indistinguishable from the Balance tablet in appearance, weight, and taste.
223434832|NCT06983353|DEVICE|transphyseal screw|transphyseal screw in proximal femoral physis
223478476|NCT05729321|COMBINATION_PRODUCT|neutrox|Each ECC, after discontinuing the Parental Nutrition (NP) infusion, will be flushed with 0.3 ml saline. Subsequently, Saline will be infused at a rate of 2 ml/h for 10 minutes. The ECC will then be closed for 1 hour. At the end of the hour the ECC will be once again flushed with 0.3 ml Saline and infused with SF at the rate of 2 cc/h for 10 minutes. The difference in pressure of the two infusions, before and after catheter closure, will be evaluated.
223740620|NCT04260542|BEHAVIORAL|Ketogenic diet/ fasting|1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
223740621|NCT03043625|OTHER|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
223740622|NCT03043625|OTHER|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
223740623|NCT00002490|BIOLOGICAL|BCG vaccine|
223740624|NCT00002490|DRUG|mitomycin C|
223740625|NCT00002490|RADIATION|radiation therapy|
223740626|NCT01829555|BEHAVIORAL|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
223740627|NCT00598247|DRUG|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
223740628|NCT05328128|BEHAVIORAL|Toilet training|As the training model, Brazelton's child-oriented toilet training method was taken as the basis in study group. In addition, literature studies on toilet training in Turkey were scanned and the final form of training to be given to mothers was created. In the control group, families manage training process themselves.
223478477|NCT01309334|PROCEDURE|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
223740629|NCT00777647|OTHER|Sugar-sweetened soft drink|One litre a day for six months.
223740630|NCT00777647|OTHER|Aspartame-sweetened soft drink|One litre a day for six months.
223740631|NCT00777647|OTHER|Semi-skimmed milk|One litre a day for six months
223740632|NCT00777647|OTHER|Water|One litre a day for six months.
223740633|NCT04780763|OTHER|Milk product fermented by lactic bacteria or not fermented|2 bottles of 100g consumed daily during 28 days
223740634|NCT03997383|DRUG|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
223740635|NCT03997383|DRUG|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
223740636|NCT04327232|DRUG|Spironolactone 25mg|Mineralocorticoid Receptor Antagonists
224045594|NCT06148987|OTHER|Questionnaire|The translation and cultural adaptation of the survey will be conducted according to the guidelines of Beaton et al. Following the Beaton guidelines, the translation and cultural adaptation steps are as follows: 1) The original version of the survey will be translated into Turkish separately by two individuals whose native language is Turkish and who are proficient in English. One translator will be an English linguistics scholar unfamiliar with the concepts and terms, while the other will be a physiotherapist familiar with the concepts and terms; 2) Subsequently, the translations will be merged into a single text by these two translators; 3) The final Turkish version of the survey will be translated back into English by two translators who are unaware of the study; 4) The translations will then be combined by these two translators to create a harmonized and single text; 5) The back-translation and cultural adaptation
224045595|NCT00001181|DRUG|Testolactone|
224045596|NCT01330134|DRUG|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
224045597|NCT01330134|DRUG|lidocaine|1% lidocaine subcutaneous injection alone
224045598|NCT06474416|GENETIC|BD111 Injection (Investigative New Drug)|BD111 Injection (Investigative New Drug) is a type of lentiviral-like particle, which can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP).
224045599|NCT06474416|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
224045600|NCT01514487|DRUG|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
224045601|NCT00395863|DRUG|Multihance|0.5 M at a single injection
224045602|NCT00395863|DRUG|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
224045603|NCT04564963|OTHER|Cryotherapy|Application of cryotherapy (e.g. ice in resealable zipper storage bags, gel packs, ice packs) over largest closed incision in the post-operative period every 4 hours, at minimum, for up to 72 hours (while participant is awake and admitted to hospital). The cryotherapy should not be placed in direct contact with skin.
224045604|NCT04673227|DIAGNOSTIC_TEST|Blood draw|Blood draw and the analysis of blood in laboratory
224045605|NCT00024050|DRUG|busulfan|
224045606|NCT00024050|DRUG|cyclophosphamide|
224045607|NCT00024050|DRUG|cyclosporine|
224045608|NCT00024050|DRUG|methotrexate|
224045609|NCT00024050|PROCEDURE|allogeneic bone marrow transplantation|
224045610|NCT00024050|PROCEDURE|peripheral blood stem cell transplantation|
224045611|NCT00316355|BEHAVIORAL|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
224045612|NCT00316355|BEHAVIORAL|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
224045613|NCT01406288|OTHER|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
224045614|NCT02791113|OTHER|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
224045615|NCT04485273|DEVICE|Laryngeal Mask Airway|Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.
224045616|NCT04485273|DRUG|Sevoflurane|Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.
224045617|NCT04485273|PROCEDURE|Subtenon's Block|Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.
224045618|NCT04485273|DRUG|Local Anesthetic Solution and Dexmedetomedine|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
224045619|NCT04485273|DRUG|Local Anesthetic Solution|The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
224045620|NCT02873650|DRUG|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
223434833|NCT06811480|OTHER|Conventional Physiotherapy|"Participants in the first group underwent conventional physiotherapy interventions for 6 weeks, 5 days per week. These interventions included Ultrasound (US), Transcutaneous Electrical Nerve Stimulation (TENS), wrist joint range of motion exercises, stretching exercises, and strengthening exercises using Digiflex, Powerweb, and dumbbells. The number of repetitions and sets of the exercises was adjusted based on the patients' conditions, following a progressive approach.~US was applied to the affected wrist for a total of 30 sessions, 5 days a week, once daily, for 6 minutes at an intensity of 1.5 W/cm², using an underwater application method. TENS was administered at a frequency of 100 Hertz for 20 minutes. All participants received manual stretching exercises for wrist flexion, extension, ulnar and radial deviation, supination, and pronation. These stretches were performed by a physiotherapist, with 5 repetitions in each direction, holding the end position for 20 seconds."
223478478|NCT01309334|PROCEDURE|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
223478479|NCT02397746|DEVICE|total hip arthroplasty implant|
224045621|NCT05867082|OTHER|Neural Mobilization|Radial Nerve Mobilization, Medial Mobilization, Ulnar Mobilization
224045622|NCT06098625|DRUG|Empagliflozin 25 MG|Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
224045623|NCT06098625|DRUG|Linagliptin 5 mg Oral Tablet|linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
224045624|NCT02020057|PROCEDURE|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
224045625|NCT02830672|PROCEDURE|Surgical release A1 pulley for Trigger finger of the hand|
224045626|NCT04703036|DIETARY_SUPPLEMENT|Glycine|Glycine is an amino-acid (protein)
223434834|NCT06811480|OTHER|Closed Kinetic Chain Exercise|Participants in the second group received a treatment protocol that included closed kinetic chain exercises (CKCE) in addition to conventional physiotherapy. CKCE exercises were performed with 15 repetitions each and involved stabilizing a ball between the hand and the wall in different arm positions, rolling it in multiple directions. Participants also performed weight-shifting exercises against a wall and on a table, holding positions for 6 seconds. Additionally, in a crawling position, they moved their unaffected arm diagonally on both a firm surface and a cushion.
223434835|NCT03604705|DRUG|APX001|APX001
224045627|NCT04703036|DIETARY_SUPPLEMENT|N-acetylcysteine|This is a donor of the amino-acid cysteine (protein)
224045628|NCT04703036|DIETARY_SUPPLEMENT|Alanine|Alanine is an amino-acid (protein)
224045629|NCT00880659|BEHAVIORAL|Soap|Promotion of handwashing with soap
224045630|NCT00182832|BEHAVIORAL|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
224045631|NCT00182832|BEHAVIORAL|Standard Care|Standard care for hospitalized older patients with cognitive impairment
224045632|NCT04670497|PROCEDURE|bupivacaine 0.5% with 1:200000 adrenaline|regional anesthesia to block lumbar plexus for analgesia of lower limb
224045633|NCT02768337|DRUG|Afatinib|
224045634|NCT02768337|RADIATION|2 Gy targeted radiotherapy|
224045635|NCT02768337|RADIATION|4 Gy targeted radiotherapy|
224299813|NCT06958926|PROCEDURE|Radical surgery for colon and rectum cancer|Radical surgery for colon and rectum cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
223478480|NCT00336544|DRUG|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
223478481|NCT00336544|DRUG|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
223478482|NCT03711721|DIETARY_SUPPLEMENT|Food basket|
223478483|NCT03711721|DIETARY_SUPPLEMENT|Ready-to-Use Therapeutic Food|
223478484|NCT00459017|DEVICE|Portable blood pressure wrist manometer|
223478485|NCT03174639|PROCEDURE|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
224045636|NCT00000225|DRUG|Buprenorphine|
224045637|NCT05952245|BEHAVIORAL|iCBTI-based EMI|Including brief iCBT-I for sleep support, stroke care education, and nurse-led real-time chat-based support messages, which were delivered according to participants' preferences (e.g., time and frequency).
224045638|NCT05952245|BEHAVIORAL|Education-based EMI|Stroke and brief sleep hygiene education with chat-based support on the topics.
224045639|NCT02642770|DEVICE|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
224045640|NCT05052073|DIAGNOSTIC_TEST|oral glucose load at rest|oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.
224045641|NCT05052073|DIAGNOSTIC_TEST|oral glucose load and exercise|oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
224045642|NCT04677673|DRUG|Chemotherapy|Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day
224045643|NCT04677673|PROCEDURE|Curative gastrectomy|Radical gastrectomy with D2 lymph node dissection
224045644|NCT02245438|DRUG|Tipranavir low dose|
224045645|NCT02245438|DRUG|Tipranavir high dose|
224045646|NCT02245438|DRUG|Ritonavir low dose|
224045647|NCT02245438|DRUG|Ritonavir high dose|
224045648|NCT02245438|DRUG|Norethindrone-Ethinyl Estradiol|
224045649|NCT01085552|DRUG|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
224045650|NCT02592551|DRUG|MEDI4736|MEDI4736 is formulated at 50 mg/mL in 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0.
224045651|NCT02592551|DRUG|Tremelimumab|Tremelimumab Drug Product is formulated at a nominal concentration of 20 mg/mL in 20 mM histidine/histidine hydrochloride, 222 mM trehalose dihydrate, 0.02% (weight/volume \[w/v\]) polysorbate 80, 0.27 mM disodium edetate dihydrate (EDTA), pH 5.5.
224045652|NCT02592551|OTHER|no other name|Neither MEDI4736 nor Tremelimumab will be used.
224045653|NCT02839408|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
224045654|NCT02839408|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn
224045655|NCT02839408|OTHER|Talc powder|Sachet containing talc powder and tablet containing talc powder
224045656|NCT02839408|PROCEDURE|Periodontal treatment Scaling and root planning|
224045657|NCT05151081|OTHER|basicly|Do not repeat information already included in arm/group descriptions.
224045658|NCT01876251|DRUG|PF-03084014|Tablet, 10 mg, twice a day
224045659|NCT01876251|DRUG|PF-03084014|Tablet, 50 mg, twice a day
224045660|NCT01876251|DRUG|PF-03084014|Tablet, 100 mg, twice a day
224045661|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 75 mg/m\^2, every 3 weeks
224045662|NCT01876251|DRUG|Docetaxel|Solution for IV infusion 100 mg/m\^2, every 3 weeks
224045663|NCT00268437|DRUG|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
224045664|NCT00268437|DRUG|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
224045665|NCT00268437|PROCEDURE|conventional surgery|
224045666|NCT00268437|PROCEDURE|neoadjuvant therapy|
224045667|NCT00268437|RADIATION|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
224045668|NCT01454245|DRUG|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
224045669|NCT01454245|DRUG|JNJ-39439335|"Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods."
223434836|NCT06453473|OTHER|TSBR|"The intervention consists of 20 training sessions on the PerStBiRo system (\~ twice a week within 3 months period). Each session lasts for 20 minutes and includes three parts: stage 1) warm up, stage 2) main exercise and stage 3) cool down.~Stage 1 contains 3 minutes of self-paced pedalling with the same bicycle resistance. At Stage 2, the main exercise, all participants will perform a 15-minute hands-free cycling training on the PerStBiRo system with a pulse watch to maintain moderate-intensity training, corresponding to 64-76% of the predicted maximal heart rate (Borg scale 12-14), including cognitive tasks projected at a screen in front of the participant. Stage 3 includes the cool down with 2 minutes of self-paced pedalling without bicycle resistance and cognitive tasks. During the training sessions, all participants will wear a loose safety harness that can arrest falling using the PerStBiRo system, but still allow comfortable pedalling."
223434837|NCT06453473|OTHER|PerTSBR|Participants of the intervention group will receive a combination of lateral and medial tilting unannounced perturbations during stage 2 of the TSBR training. This will be provided by roll and pitch angles (tilt) balance perturbations that aim to evoke trunk and arm balance recovery responses.
223434838|NCT06657222|DRUG|TUB-030|A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
223434839|NCT06878807|BEHAVIORAL|eye movement|Participants underwent EM tasks during the first 30 seconds of the extinction phase. All participants in this group experienced identical EM conditions in terms of speed and duration.
223434840|NCT06878807|BEHAVIORAL|TMT-B|Participants performed the Trail Making Test B (TMT-B).
223434841|NCT06652633|GENETIC|GLPG CAR T-cell therapy|No investigational products will be administered to participants in this study.
223434842|NCT06592521|DEVICE|OPTI-FREE EXPRESS MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
224045670|NCT05161091|DEVICE|Topical application of Orosol®|Orosol® is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Orosol® every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
224045671|NCT05161091|DEVICE|Topical application of Placebo comparator|Placebo comparator is a 20 ml aluminum bottle equipped with a spray without propellant gas for local application. Simply shake the bottle gently, apply the product to the injured surface by pressing your finger on the spray to deliver the product (4 to 5 times so as to form a thin film on the surface of the mouth) . It is recommended to use Placebo comparator every 2 hours at the start of treatment and then 3 to 4 times a day. The maximum duration of treatment will be 28 days. Eating or drinking should be avoided for the first 15 to 30 minutes after applying the product.
223434843|NCT06592521|DEVICE|OPTI-FREE PureMoist MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
223434844|NCT06592521|DEVICE|OPTI-FREE REPLENISH MPDS and Alcon contact lens case|Multi-purpose disinfecting solution (MPDS) used for cleaning, disinfecting, and storage of soft contact lenses; commercially available in country of conduct.
223565918|NCT06163703|BEHAVIORAL|Family Life Skills Triple P|The intervention is a 12-session program that combines parenting support with trauma-informed life skills coaching. It includes content related to positive parenting strategies, self-regulation, coping with emotions, effective communication, dealing with the past, and developing healthy habits.
224045672|NCT01355484|DRUG|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
224045673|NCT01355484|DRUG|placebo|subject will receive placebo for the duration of the trial
224045674|NCT03335163|DRUG|Topiramate|"Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily"
224045675|NCT03715842|OTHER|Tub shaped design|The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
224045676|NCT03715842|OTHER|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
224045677|NCT04339907|OTHER|Sampling of tears|Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -150 degrees.
224299814|NCT06958926|PROCEDURE|Radical surgery for colorectal cancer|Radical surgery for colorectal cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.
223565919|NCT05403437|OTHER|Evaluation of pain|Painful areas will be marked on the body chart. The presence and severity of pelvic girdle pain will be determined by the Visual Analog Scale (VAS).
223565920|NCT05403437|DIAGNOSTIC_TEST|Evaluation of pelvic girdle pain diagnostic tests|Pelvic girdle pain diagnostic tests will be applied. The severity of the pain that occurs in positive tests will be evaluated with VAS.
223565921|NCT05403437|OTHER|Evaluation of activity limitation|The Pelvic Girdle Questionnaire will be filled.
223565922|NCT03537248|DEVICE|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
223434845|NCT06592521|DEVICE|Habitual contact lenses|Daily wear, reusable, soft (including hydrogel and silicone hydrogel) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
223434846|NCT06158074|PROCEDURE|electrical pudendal nerve stimulation|The patient was positioned prone post-micturition. Long needles (0.40 Х 100 mm) were inserted perpendicularly, 1 cm bilateral to the sacrococcygeal joint, to a depth of 80-90 mm, eliciting sensations referred to the urethra or anus. The lower points, 1 cm bilateral to the coccyx tip, received oblique insertion of longer needles (0.40 Х 125 mm) toward the ischiorectal fossa (90-110 mm depth), inducing sensations precisely to the urethra. Connected to a G6805-2 Multi-Purpose Health Device, the ipsilateral needles created an electric loop, with the upper as anode and lower as cathode. Direct electrical stimulation (2.5 Hz, 25\~35 mA) for 60 minutes targeted the pudendal nerve, thrice weekly for a total of 4 weeks.
223434847|NCT06158074|PROCEDURE|sacral neuromodulation|In the prone position, patients undergo sacral nerve root localization through MRI and CT fusion analysis. A 3D-printed sacral foramen puncture template is crafted for precision. Using local anesthesia, a 20G needle at a 60° angle enters the S3 sacral foramen along the template. A temporary stimulator, delivering square waves (14-35 Hz, 210-360 μs), tests motor and sensory responses to confirm accuracy. Self-fixating electrodes are then implanted, validated, and tunneled subcutaneously. External connection to a temporary stimulator provides a 4-week therapeutic experiential stimulation.Patients are administrated by antibiotics peri-operatively to prevent lead site infection.
223434848|NCT06819592|DRUG|Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride|2 grams of Ceftriaxone diluted in \>200ml of 0.9%sodium chloride are administered intravenously once following randomisation
223434849|NCT06819592|DRUG|Placebo comparator - no ceftriaxone|placebo: \>200ml 0.9% sodium chloride given as an intravenous infusion once after randomisation
223434850|NCT06816446|DEVICE|Myopia control spectacle lens|The intervention group will wear specially designed lenses that aim to slow the progression of myopia. Follow-up visits will take place at regular intervals.
223434851|NCT06816446|DEVICE|Single-vision lens|The control group will wear single vision lenses for one year. They will then switch to the myopia control lens for a further year. Follow-up visits will take place at regular intervals.
224045678|NCT04339907|OTHER|Sampling of aqueous humor|Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.
224045679|NCT04271007|DRUG|Mometasone Furoate|mometasone furoate
223434852|NCT05741853|BEHAVIORAL|Video-Implemented Script Training for Aphasia (VISTA)|Participants with nonfluent/agrammatic variant primary progressive aphasia (PPA) or a predominantly nonfluent profile work on producing personally relevant scripts of 4-6 sentences in length. Length and complexity of scripts are individually tailored. The participant completes two (one hour each) teletherapy sessions per week with a clinician targeting clear and accurate script production, script memorization, and conversational usage of scripts. The participant completes 30 minutes of independent, computer-based practice 5-7 times per week, during which they speak in unison with a video/audio model of a healthy speaker clearly articulating the scripts.
223434853|NCT05741853|BEHAVIORAL|Lexical Retrieval Training (LRT)|Participants with logopenic variant PPA, participants with semantic variant PPA, and participants with a predominantly anomic profile will work on producing spoken and written names of personally relevant target items using a self-cueing hierarchy. Treatment focuses on the use of strategies that capitalize on spared cognitive-linguistic abilities to support word retrieval. The participant completes two (one hour each) teletherapy sessions per week with a clinician plus 30 minutes of additional independent, computer-based practice exercises 5-7 times per week.
223434854|NCT00323401|OTHER|Antenatal classes|3 sessions of 3 hours each
223434855|NCT02913014|OTHER|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
223434856|NCT01229033|PROCEDURE|Ablation|Ablation of atrial tachycardia
223434857|NCT01229033|PROCEDURE|Cardioversion|Cardioversion of atrial tachycardia
223434858|NCT02233920|DRUG|Ventilat® - metered dose inhaler|
223434859|NCT02966119|DRUG|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
223434860|NCT06097689|DEVICE|Lab Demo 1.0|"Lowering of the participants blood glucose with the application of insulin to induce hypoglycaemia, followed by the application of glucose to induce hyperglycaemia and finally insulin to restore euglycemia.~During the different glycaemia states, transcutaneous spectral data are collected continuously with the device and paired with reference measurements (venous blood and interstitial fluid)."
223434861|NCT02252471|BEHAVIORAL|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
224045680|NCT03667534|DIAGNOSTIC_TEST|Dry blood spot screening|Dry blood spot measurement of biomarker for screening of cholestasis patients
224045681|NCT00418990|DRUG|Multivitamin/Mineral supplements|
224045682|NCT03013283|OTHER|self questionnaire|"* Interface side effects and degree of satisfaction of the patients~* Technician evaluation and device measures."
224045683|NCT01361243|BEHAVIORAL|NOURISH+|6 week face-to-face parent intervention.
224045684|NCT01361243|BEHAVIORAL|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
224045685|NCT05316402|OTHER|training on the risks associated with sun exposure|15-minute power point and presentation on the risks of sun exposure
224045686|NCT05316402|OTHER|dosimetry|dosimetry
224045687|NCT01295528|DEVICE|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
224045688|NCT01863940|DEVICE|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
223434862|NCT05036057|OTHER|Questionnaire|"Patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD), the COPD Assesment Test (CAT), the Saint George Respiratory Disease Questionnaire (SGRQ), the Charlson Comorbidity Index, and will rate the disease and general knowledge level on a numerical scale.~Proxies of patients will do the Individual Knowledge Statement Questionnaire of Chronic Obstructive Pulmonary Disease (COPD) and will rate the disease and general knowledge level on a numerical scale."
223434863|NCT01634659|DEVICE|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
223740637|NCT04327232|DRUG|Placebo oral tablet|Placebo
224045689|NCT01182402|DEVICE|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
224045690|NCT05725070|DRUG|212Pb-NG001|"212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.~Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001."
224045691|NCT03015675|DRUG|ascorbic acid|20g/day, D1-3, every 2 weeks
224045692|NCT03015675|DRUG|mFOLFOX6|"mFOLFOX6~* Oxaliplatin 85 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
224045693|NCT01121523|BEHAVIORAL|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
224045694|NCT05574595|OTHER|Music theraphy|In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
224045695|NCT06788938|DRUG|Tarlatamab treatment|"* 1 mg step dose on cycle 1 day 1 (C1D1)~* 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle.~* 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle"
224045696|NCT04900558|PROCEDURE|Radical Cystectomy|All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc...
224045697|NCT04628299|OTHER|Sham Laser|Sham Laser in plantar fascia
224045698|NCT04628299|OTHER|Myofascial Induction|Myofascial Induction in plantar fascia
224045699|NCT02422888|DRUG|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
224045700|NCT02422888|DRUG|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
224045701|NCT01025492|DRUG|Trilipix|135 mg po daily
224045702|NCT01025492|DRUG|placebo|one tablet po daily
223434864|NCT01634659|DEVICE|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
223434865|NCT05189067|DRUG|Paclitaxel|i.v. 80mg/m\^2
223434866|NCT05189067|DRUG|Trastuzumab|i.v. loading dose of 8 mg/kg, followed by 6mg/kg
223434867|NCT05189067|DRUG|Docetaxel|i.v. 100mg/m2
223434868|NCT06624033|OTHER|amino acids kinetics|"After a fasting blood sample (T0), the subjects will consume one of the test meals. Nine samples will be then collected at several times after meal ingestion.~On these samples, plasma concentrations of amino acids, insulin, blood sugar, lipid balance and inflammatory markers will be measured."
223434869|NCT06234696|OTHER|entrepreneurial intervention|The experimental group will be given psychoeducation for 4 weeks.
223434870|NCT00006013|DRUG|semaxanib|
223740638|NCT05539391|OTHER|Data patient|Medical History and characteristic of patient
223740639|NCT05539391|OTHER|Physical examination|Arterial pressure, arterial oxygen saturation, heart rate
223740640|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Rocuronium /Bag-mask ventilation /GEB|Rapid sequence intubation (RSI) will be performed with use of rocuronium as paralytic agent (1.2 mg/ kg). Bag-mask ventilation between induction and laryngoscopy will be performed. The GEB will be systematically used at the first attempt to facilitate intubation.
223740641|NCT05539391|PROCEDURE|Rapid sequence intubation (RSI) : Recommendations for emergency intubation|Rapid sequence intubation (RSI) using succinylcholine as a paralytic agent (1 mg/kg), no systematic bag-mask ventilation between induction and laryngoscopy, use of GEB to facilitate intubation in case of intubation failure under direct laryngoscopy.
224045703|NCT03971994|BEHAVIORAL|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
224045704|NCT03305939|BEHAVIORAL|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~1. simple healthy eating and moderate physical activity messages;~2. behavioral skills such as problem solving/goal setting/self-monitoring; and~3. enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
224045705|NCT03945591|DRUG|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
224045706|NCT03945591|DRUG|Cyclophosphamide|50 mg/kg IV over 2 hours on Day +3 and +4
224045707|NCT05378646|DRUG|Interferon gamma human recombinant (IFN-G)|received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
224045708|NCT05798234|DEVICE|high flow oxygen device|no intervention
224045709|NCT00621231|DIETARY_SUPPLEMENT|Placebo|Placebo
223434871|NCT05593536|BEHAVIORAL|Breastfeeding Education|Biological feeding and classical breastfeeding trainings will be given to pregnant women by a trained nurse.
223434872|NCT00689559|DRUG|AZD3480|AZD3480 capsules qd, oral, 22 days
223434873|NCT00689559|DRUG|Placebo|Placebo qd, 12 days
223434874|NCT00689559|DRUG|Aripiprazole|single dose on day 5
223434875|NCT00875433|DRUG|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
224045710|NCT00621231|DIETARY_SUPPLEMENT|Protein|30 E% from protein
224045711|NCT04170712|OTHER|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
224045712|NCT02805049|DRUG|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
224045713|NCT00741325|DRUG|granulocyte colony-stimulating factor (G-CSF)|
224045714|NCT00741325|DRUG|plerixafor|
224045715|NCT00741325|DRUG|Placebo|
224045716|NCT04122404|DIAGNOSTIC_TEST|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
224045717|NCT00287274|DEVICE|computerized physician order entry|
224045718|NCT04290520|OTHER|bioassay|Serum progesterone level (ng/ml)
224045719|NCT04188795|PROCEDURE|Delirium Preventive Care Protocol|"Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day."
224045720|NCT03260634|DRUG|Voriconazole|
224045721|NCT06247436|DIETARY_SUPPLEMENT|Branch Chained Amino Acids|postoperative BCAA consumption
224045722|NCT00461344|DRUG|Docetaxel|
224045723|NCT00461344|DRUG|Doxorubicin|
224045724|NCT02783443|OTHER|General anesthesia|General anesthesia
223434876|NCT01167049|DRUG|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
223434877|NCT04781829|DIAGNOSTIC_TEST|BioFire Pneumonia Panel|Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
223434878|NCT02433067|OTHER|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
223434879|NCT02433067|OTHER|Control Group|standard oncologic care
223434880|NCT02079142|BEHAVIORAL|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
223434881|NCT02079142|BEHAVIORAL|Low Intensity Strategy: Expert Consultation|Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
223434882|NCT00556205|DRUG|Sunitinib|Sunitinib orally once daily
223434883|NCT00556205|DRUG|Bevacizumab|Intravenously every 14 days
223434884|NCT06621498|PROCEDURE|Ridge preservation technique|Tooth extraction, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
223434885|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, socket filling with PRP, deperiostation of the buccal and oral marginal gingiva, placement of d-PTFE membranes and suturing.
223434886|NCT06621498|PROCEDURE|ridge preservation|Tooth extraction, full-thickness graft harversting and socket sealing with it.
224045725|NCT02783443|OTHER|Regional anesthesia|Regional anesthesia
224045726|NCT01213875|BEHAVIORAL|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
224045727|NCT01794572|DRUG|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
224045728|NCT01794572|BIOLOGICAL|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10\^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
224045729|NCT00859599|DEVICE|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
224045730|NCT00859599|DEVICE|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
224299815|NCT06837233|DRUG|Pumecitinib Nasal Spray 0.3%|2 sprays in each nostril, twice daily for 14-day treatment period.
223434887|NCT06594016|DRUG|Fosigotifator|Oral
223565923|NCT03537248|DEVICE|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
223565924|NCT06051318|OTHER|Standardized breakfast A|Participants will initiate the interventional period by eating the low-carb muffin first following the established muffin order for the next days.
224141853|NCT03636568|OTHER|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients \>100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh \> 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
224141854|NCT00085917|DRUG|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
224141855|NCT00085917|DRUG|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
224141856|NCT05424185|BEHAVIORAL|different type of scapular dyskinesis|rapid arm elevation to see the different of EMG rise and force development
224141857|NCT00397709|DRUG|I ( isoniazid), II (isoniazid + rifampin )|
224141858|NCT02234557|BEHAVIORAL|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
224141859|NCT01641965|DEVICE|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 \< 45 mmHg and improve symptoms.
224141860|NCT01022151|DRUG|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
224141861|NCT01022151|DRUG|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL \[group A2\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
224141862|NCT01022151|DRUG|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL \[group A3\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
224141863|NCT01022151|DRUG|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
224045731|NCT06170138|OTHER|Test product 1 - Test product 2 - Comparator product|"Each subject will be randomised to 1 of 6 IP use sequences The IPs will be administered as single pouches in a pre-determined randomised order.~Test product 1 - Ampli-01 3 mg, nicotine pouch Test product 2 - Ampli-01 6 mg, nicotine pouch Comparator product - ZYN Cool Mint Mini Dry 6 mg nicotine /pouch Single 30-minutes IP use on 3 occasions (Visits 2 to 4)."
224141864|NCT01022151|DRUG|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
224141865|NCT01022151|DRUG|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
224299816|NCT06837233|DRUG|Pumecitinib Nasal Spray 0.6%|2 sprays in each nostril, once daily for 14-day treatment period.
223434888|NCT06122233|BEHAVIORAL|Pulmonary Fibrosis self-management package and smartphone application|"The pulmonary fibrosis package includes modules on understanding treatment options for pulmonary fibrosis, managing medication and side effects, understanding and accessing clinical trials, managing shortness of breath, managing fatigue and mood, managing co-existing conditions, the role and importance of pulmonary rehabilitation and regular physical activity, role of oxygen therapy, smoking cessation advice and support, accessing community support, and communicating with others when living with pulmonary fibrosis.~The RE-BUILD app is used as a tool for data collection and to help participants self-monitor their disease over time. Participants enter their health data, including baseline conditions, medications and diagnosis, pulmonary function results and supplementary oxygen use. It also tracks air quality data close to the participant as well as physical activity level (step count). The app also has links to ILD-related educational resources."
223740642|NCT05064878|DRUG|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.
223740643|NCT05064878|DRUG|Matching ZX008 Placebo|Matching ZX008 placebo is supplied as an oral solution.
224045732|NCT00319280|PROCEDURE|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
224045733|NCT00703001|BEHAVIORAL|Educational Intervention|students in this arm will receive several oral health educational modules in class
224045734|NCT00703001|BEHAVIORAL|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
223740644|NCT06960902|OTHER|Coronary CT scan with CAC score measurement|Coronary CT scan with CAC score measurement (on the same day or within 6 months after the inclusion visit).
224045735|NCT01986920|DRUG|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
224045736|NCT01986920|DRUG|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
224045737|NCT01986920|DRUG|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
224045738|NCT01986920|DRUG|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
224141866|NCT03825263|DEVICE|Intermittent Pressure Compression|The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
224141867|NCT02071264|BEHAVIORAL|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
224141868|NCT00280241|DRUG|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
224141869|NCT00280241|DRUG|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
224141870|NCT00280241|DRUG|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
224141871|NCT01894464|BEHAVIORAL|Teacher led intervention|
224045739|NCT02238704|DIETARY_SUPPLEMENT|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
224045740|NCT02238704|DIETARY_SUPPLEMENT|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
224045741|NCT06847269|DRUG|Fludarabine|Given IV
224141872|NCT01119157|BIOLOGICAL|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
224141873|NCT02645279|OTHER|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
224141874|NCT02645279|DRUG|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
223434889|NCT06991166|BEHAVIORAL|Cognitive behavioral therapy (CBT) psychotherapy group/telehealth|Type of psychotherapy. CBT focuses on identifying and changing unhelpful beliefs and behavioral patterns that lead to negative emotions (e.g., depression, anxiety, grief, shame) in order to break the emotion-thought-behavior cycle
224045742|NCT06847269|DRUG|Cyclophosphamide|Given IV
224045743|NCT06847269|DRUG|Mesna|Given IV
224045744|NCT06847269|BIOLOGICAL|CD19-CAR T cell Infusion|Patients will receive the CD19-CAR T cells by vein, through either an IV or a central line.
224045745|NCT05511428|DRUG|Daratumumab and Hyaluronidase-fihj|Given SC
224045746|NCT05511428|OTHER|Questionnaire Administration|Ancillary studies
224045747|NCT05511428|OTHER|Quality-of-Life Assessment|Ancillary studies
224045748|NCT05511428|OTHER|Interview|Ancillary studies
224045749|NCT02091661|PROCEDURE|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
224045750|NCT02091661|RADIATION|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
224045751|NCT06218901|DRUG|immunotherapy|
224141875|NCT03372603|DRUG|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
224141876|NCT03372603|DRUG|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
224163517|NCT01609491|DRUG|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
224163518|NCT02462122|DRUG|IDP-118 Lotion|Lotion
224163519|NCT02462122|DRUG|IDP-118 Vehicle Lotion|Lotion
224163520|NCT04594889|PROCEDURE|angioplasty|Balloon releasing a drug inflated in the target vessel
224163521|NCT01253967|PROCEDURE|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
224163522|NCT01253967|OTHER|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
224163523|NCT04489602|OTHER|ObsQoR-10F Questionnaire|The ObsQoR-10F questionnaire consists of 10 items assessing different aspects of postpartum recovery: physical comfort and pain, physical independence and emotional status. It takes two minutes to complete all the items. If the patient is not able to read the questionnaire herself, a third person can ask the questions orally to the patient. If the patient has returned home with her child, she can be contacted by phone to complete the questionnaire. Each item is scored from 0 to 10 and the total score is the sum of the score for each item, which is a score from 0 to 110.
223434890|NCT06991166|BEHAVIORAL|Interpersonal therapy (IPT) psychotherapy group/telehealth|Type of psychotherapy. IPT focuses on improving interpersonal communication and deficits, processing grief, and role transitions
224163524|NCT06115512|DRUG|AGA111|AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
224299817|NCT06837233|DRUG|Placebo (twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
224299818|NCT06837233|DRUG|Pumecitinib nasal spray 0.6%(twice daily)|2 sprays in each nostril, twice daily for 14-day treatment period.
224045752|NCT06218901|DRUG|Targeted Therapy Agent|
224045753|NCT04788264|OTHER|Medical Device Usage and Evaluation|Receive Fitbit
224045754|NCT04788264|OTHER|Consultation|Receive consultation from a physical therapist
224045755|NCT04788264|OTHER|Exercise Intervention|Attend exercise training sessions
224045756|NCT04788264|BEHAVIORAL|Behavioral Intervention|Attend sessions with a behavioral therapist
224045757|NCT04788264|OTHER|Questionnaire Administration|Ancillary studies
224045758|NCT04788264|OTHER|Quality of Life Assessment|Ancillary studies
224045759|NCT06298721|BEHAVIORAL|Personalized outcome prediction tool + targeted interventions|"* TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation"
224045760|NCT06298721|BEHAVIORAL|Standard of Care TKA|\- Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
224045761|NCT04872452|PROCEDURE|Skin biopsy|Any combination of the following six 3-6mm skin biopsies may be taken: palm, dorsum of hand, calf, other non-genital and non-face (this last one includes areas for use as negative controls which are not on the distal limbs). No more than 6 biopsies will be taken at one time.The biopsy size 3-6mm and method (punch, shave or wedge) will be done depending on the biologic assay destined for the biopsy. While 3mm will be sufficient for microarray analysis, 6mm will be required for any cell sorting preceding microarray analysis.
224045762|NCT01338415|DRUG|Bosentan|Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
224045763|NCT03001128|DRUG|Antiretroviral treatment pause|Antiretroviral treatment pause
224045764|NCT02887690|DEVICE|Modular Prosthetic Limb|
224045765|NCT04235023|OTHER|myeloid PTP1B expression analysis|peripheral blood macrophage PTP1B expression
224045766|NCT02150499|DRUG|levalbuterol tartrate HFA inhalation aerosol|
224045767|NCT02150499|DRUG|placebo|
224045768|NCT04092972|OTHER|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
224045769|NCT04092972|OTHER|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
224045770|NCT03990857|OTHER|Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care|This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
224045771|NCT06388304|BEHAVIORAL|THRIVE Online PAT Program|Online program: behavioral intervention based on Positive Affect Training (PAT)
224045772|NCT05215262|BEHAVIORAL|Treat Act Know Engage (T.A.K.E.) Steps|Intervention sessions will consist of psychoeducation, HIV/STI goal identification, referral to HIV testing and PrEP, and communication skill building.
224045773|NCT05215262|BEHAVIORAL|Standard or Care|S.O.C. arm will receive treatment as usual. After the baseline interview, participants will be referred to their PCP for management of any clinical issues that arise. Their clinic visit schedule will follow their clinical needs and recommendations of their clinic provider
224045774|NCT03708172|DEVICE|Repetitive Transcranial Magnetic Stimulation|Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
224045775|NCT03708172|OTHER|Cognitive Training|Computer-based cognitive training designed to enhance executive function
224045776|NCT03708172|OTHER|sham Cognitive Training|Computer-based inactive sham training
224045777|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
224045778|NCT03422289|DIETARY_SUPPLEMENT|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
224299819|NCT06837233|DRUG|Placebo|2 sprays in each nostril, once daily for 14-day treatment period.
224299820|NCT05791682|DRUG|Sealant, Fissure|FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
224299821|NCT05935436|DEVICE|Cardiac Shock Wave Therapy|When operating CSWT, it is necessary to determine the target myocardium for treatment, adjust the height of the water bladder, set the energy that the patient can tolerate, and then start the treatment. During the treatment, the vital signs of the subjects should be detected.
223434891|NCT04555655|DIETARY_SUPPLEMENT|Chicken extract supplement|70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
223434892|NCT04555655|DIETARY_SUPPLEMENT|Peptide Supplement|70ml of Peptide Supplement (670mg) to be consumed daily in the morning before meals for 2 years.
224045779|NCT00866749|DRUG|Daunorubicin|Starting Dose 25 mg/m\^2 by vein weekly
224299822|NCT04055818|DRUG|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
224299823|NCT04908683|BIOLOGICAL|Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Participants will receive a single IM injection of an RSV vaccine.
223434893|NCT04555655|OTHER|Placebo|70ml of placebo (caesinate) to be consumed daily in the morning before meals for 2 years.
223434894|NCT06865495|OTHER|Handwashing Hardware and Supply Provision|Households will be given a locally available handwashing facility called the Kalingalinga bucket. Intervention delivery workers will set-up the handwashing facility, and demonstrate how it works, including where to place soap on the stand. Households will also be given supplies and materials to make their own liquid soap from locally available soap products (soapy water). Discussions will also be held on HWF maintenance. This component of the intervention should take no longer than 30 minutes. Intervention delivery workers will return to households after three months (one visit) to ensure there are no issues with the handwashing station (e.g., broken stand or tap), to bring more liquid soap and to remind households how to make soapy water.
223434895|NCT06865495|BEHAVIORAL|Hand Hygiene Behavioural Promotion|"The hand hygiene behavioural promotion intervention employs interactive storytelling and visual aids to promote handwashing with soap. Intervention delivery workers will act as storytellers, narrating stories about three characters with different handwashing habits.~The intervention progresses through five bi-weekly visits, with a final sixth visit 4 weeks after the fifth visit. The 30-minute visits progress through different stages: (1) identifying behaviours, (2) understanding disease risks, (3) encouraging practical solutions and (4) promoting practice. The penultimate stage of the intervention focuses on reflection and commitment, encouraging participants to assess their behaviours and pledge to adopt improved hygiene practices. The final visit allows participants to reflect on the whole intervention and covers information participants would like to revisit."
223434896|NCT05617079|OTHER|Survey|an electronic survey will be conducted
223434897|NCT06992362|DRUG|Perioperative treatment|RC48+SOX+Sindilizumab
223434898|NCT06255379|DRUG|Fuquinitinib+Tegafur Gimeracil Oteracil|Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） \>1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
223434899|NCT06998524|DRUG|Emicizumab|"Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W).~During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators."
223434900|NCT06998524|DRUG|von Willebrand Factor (VWF) Concentrates|Used according to local labeling or local treatment guidelines.
223434901|NCT06998524|DRUG|Factor VIII (FVIII) Concentrates|Used according to local labeling or local treatment guidelines.
223434902|NCT06998524|DRUG|von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates|Used according to local labeling or local treatment guidelines.
223434903|NCT06998524|DRUG|Bypassing Agents|Used according to local labeling or local treatment guidelines.
223434904|NCT07003386|DRUG|Galantamine|Start within 24 hours of hospitalization, administer 5.0 mg of galantamine via intramuscular injection once daily, and continue the treatment for 10 days.
223434905|NCT07003386|DRUG|Standard treatment for acute ischemic stroke|Standard treatment for acute ischemic stroke
223434906|NCT01758198|BIOLOGICAL|Abatacept|
223565925|NCT06051318|OTHER|Standardized breakfast B|Participants will initiate the interventional period by eating the vegan muffin first following the established muffin order for the next days.
224045780|NCT00866749|DRUG|Vincristine|Starting Dose 2 mg by vein weekly
224045781|NCT00866749|DRUG|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
224045782|NCT00866749|DRUG|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
224045783|NCT00866749|DRUG|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
223434907|NCT01758198|DRUG|Placebo matching with Abatacept|
223434908|NCT01758198|DRUG|Methotrexate|
223434909|NCT06542432|GENETIC|Disclosure of integrate risk score for coronary artery disease|Participants will receive their integrated risk score for coronary disease along with an optional genetic counseling visit to discuss the results.
223434910|NCT07006948|DIAGNOSTIC_TEST|Autism Diagnostic Observation Schedule, the 2nd edition(ADOS-2)|The toddlers diagnosed with ASD will receive the ADOS-2 evaluation to confirm the diagnosis.
223434911|NCT07006948|DIAGNOSTIC_TEST|Griffiths Developmental Scales, Chinese edition(GDS-C)|The toddlers diagnosed with ASD, GDD, LD, and typically developing will receive the GDS-C evaluation to confirm the diagnosis.
223565926|NCT06753669|BEHAVIORAL|health education and social network building|The investigators will use techniques from the social network literature to build each treatment group as a cohesive social network and will diffuse educational messages through these groups.
223565927|NCT06753669|BEHAVIORAL|dental referral and educational materials|Control arm will receive a referral to vetted dentist and educational materials on child health
223565928|NCT04669262|DRUG|BGB-DXP604|Administered as intravenous (IV) infusion over 30 to 60 minutes
223565929|NCT04669262|DRUG|BGB-DXP593|Administered as intravenous (IV) infusion over 30 to 60 minutes
223565930|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP593
223565931|NCT04669262|DRUG|Placebo|Placebo to match BGB-DXP604
223565932|NCT04505553|PROCEDURE|Acupuncture Therapy|Undergo acupuncture
223565933|NCT04505553|PROCEDURE|Acupressure Therapy|Undergo acupressure
224045784|NCT00866749|DRUG|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
224045785|NCT00866749|DRUG|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
224045786|NCT00866749|DRUG|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
224045787|NCT00866749|DRUG|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
224045788|NCT00866749|DRUG|Thioguanine|60 mg/m2 by mouth daily for two weeks
224045789|NCT03109158|DRUG|NC-6004|NC-6004 provided by NanoCarrier
224045790|NCT03109158|DRUG|Cetuximab|Commercially Available
224045791|NCT03109158|DRUG|5-FU|Commercially Available
224163525|NCT06115512|DRUG|Placebo|Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.
223434912|NCT07003789|BEHAVIORAL|Women-Centered HIV Prevention Program|This behavioral intervention consists of a participatory, youth-designed HIV prevention program that uses Human-Centered Design (HCD) principles and WhatsApp-based engagement. It includes information and support for HIV self-testing and PrEP, with the goal of increasing awareness, improving uptake, and reducing stigma among young women in Ghana.
224045792|NCT04880447|BIOLOGICAL|BNT162b2|COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
223434913|NCT05186974|DRUG|Sacituzumab Govitecan-hziy (SG)|Administered intravenously
223434914|NCT05186974|DRUG|Pembrolizumab|Administered intravenously
223434915|NCT05186974|DRUG|Carboplatin|Administered intravenously
223434916|NCT05186974|DRUG|Cisplatin|Administered intravenously
223434917|NCT06686251|DEVICE|App LuAna|Inclusion of chest x-ray images in the LuAna app to receive feedback on lung findings.
224141877|NCT04673487|DIAGNOSTIC_TEST|1. SD Bioline Salmonella Typhi IgG/IgM Fast test, 2. Typhidot Rapid IgG/IgM combo test, 3. TUBEX TF test, 4.Typhoid IgG/IgM Combo Rapid Test CE, 5. Enterocheck WB test, 6. Test-itTM Typhoid IgM test|Evaluation of 11 different Typhoid Rapid Diagnostic Tests that are commercially available internationally and use Blood culture as standard for comparison
223434918|NCT07058623|PROCEDURE|Nurse-Led Telehealth Consultation|Participants receive scheduled postoperative nursing consultations delivered remotely via the HA Go mobile application, a secure, hospital-approved telehealth platform. Consultations occur approximately two weeks after total knee replacement surgery, with additional sessions arranged as clinically needed within the first month post-surgery. Each telehealth session lasts about 20 to 30 minutes and includes assessment of recovery progress, monitoring for complications, patient education, and guidance on rehabilitation exercises. Patients receive technical support to facilitate effective use of the telehealth platform. This intervention leverages virtual care technology to provide convenient, accessible nursing follow-up without requiring in-person clinic visits.
224045793|NCT03934255|OTHER|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
224141878|NCT05825196|DIAGNOSTIC_TEST|tumor tissue and blood tests|In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination.
224141879|NCT02674165|BEHAVIORAL|HART|Skills based sexual education intervention plus PTSD awareness
224141880|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
224045794|NCT03659279|BEHAVIORAL|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
224141881|NCT02518100|DEVICE|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
224141882|NCT05399030|DRUG|ICP-332|ICP-332 will be administered as tablet
224141883|NCT05399030|OTHER|Placebo|Matching placebo will be administered as tablet
224141884|NCT05363670|DRUG|ARS-1|ARS-1
224141885|NCT05363670|DRUG|Albuterol MDI|180 mcg
223434919|NCT07058623|PROCEDURE|Traditional In-Person Nursing Consultation|Participants receive scheduled postoperative nursing consultations in person at the Specialist Outpatient Department. Each consultation lasts approximately 20 to 30 minutes and includes physical assessment, monitoring for complications, patient education, and rehabilitation guidance. Follow-up visits are typically scheduled two weeks after total knee replacement surgery, with additional visits as clinically indicated. This intervention represents standard postoperative nursing care delivered face-to-face.
224045795|NCT00761852|DRUG|Ruboxistaurin|32 mg daily for 2 weeks
223565934|NCT04505553|PROCEDURE|Oral Cryotherapy|Undergo oral cryotherapy
223565935|NCT04505553|OTHER|Questionnaire Administration|Ancillary studies
223565936|NCT04505553|OTHER|Quality-of-Life Assessment|Ancillary studies
224045796|NCT00761852|DRUG|Placebo|1 tab po QD for 2 weeks
224045797|NCT04227886|RADIATION|Radiation|Neoadjuvant radiotherapy consisted of 50 Gy in 25 fractions using intensity-modulated radiotherapy to the primary tumor and to mesorectal, presacral, and internal iliac lymph nodes.
224045798|NCT04227886|DRUG|Capecitabine-Irinotecan Combination|The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.
224045799|NCT03184324|DRUG|DWP14012|tablet
224045800|NCT03184324|DRUG|Esomeprazole|tablet
224141886|NCT05363670|DRUG|Placebo|Placebo
224141887|NCT03345433|BEHAVIORAL|interactive group drumming sessions|interactive group drumming sessions
224141888|NCT04374812|OTHER|Exposure to registered nurses|Change in outcomes associated with a one hour per patient day increase in exposure to registered nurses
224141889|NCT04374812|OTHER|Exposure to nursing assistants|Change in outcomes associated with a one hour per patient day increase in exposure to nursing assistants
224141890|NCT02992834|BIOLOGICAL|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
224141891|NCT02992834|BIOLOGICAL|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
224141892|NCT01153841|BIOLOGICAL|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
224141893|NCT01153841|BIOLOGICAL|Infanrix hexa™|Intramuscular, 3 doses
224163526|NCT04722289|BEHAVIORAL|Together on Diabetes|Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
224045801|NCT03184324|DRUG|DWP14012 placebo|tablet
224045802|NCT03184324|DRUG|Esomeprazole placebo|tablet
224045803|NCT02443649|BEHAVIORAL|Sleep hygiene program|Sleep hygiene program
224045804|NCT02443649|BEHAVIORAL|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
224045805|NCT03505385|BEHAVIORAL|Co-created intervention - Get Ready (GR)|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~1. The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~2. The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~3. The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
224045806|NCT01092975|DRUG|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
224045807|NCT06379308|OTHER|questionaries|"Questionaries will be administered :~* Anterior Cruciate Ligament Return to Sport and Injury (ACL-RSI)~* Tegner Activity Scale (TAS)~* Simple Knee Value (SKV)~* International Knee Documentation Commitee (IKDC)"
224045808|NCT06379308|OTHER|datas of medical record|datas of medical record will be collected : epidemiological data, morphological data, operative data, clinical and functional outcomes, and surgical complication.
224045809|NCT00718549|DRUG|Cladribine|Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
224045810|NCT00718549|DRUG|Cyclophosphamide|Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
224045811|NCT00718549|DRUG|Rituximab|Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
224045812|NCT02746666|BEHAVIORAL|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
224045813|NCT01353508|DRUG|LCZ696|200 mg and 400 mg tablets
224045814|NCT01353508|DRUG|Valsartan|160 mg tablets
224045815|NCT05745051|DIAGNOSTIC_TEST|CVAid Flow|CVA-FLOW is a Telestroke mobile software solution that enables the neurologist to remotely assess, on his smartphone, patients suspected with stroke. Real-time, objective, patient-specific data such as images, videos and vocal records of the patient, are acquired by a first responder (CVA-COLLECTOR) at the patient's location. This allows the neurologist to complete the NIH Stroke Scale and independently reach a diagnostic conclusion and treatment plan (CVA-MED).
224045816|NCT00004152|DRUG|iodinated contrast dye|
224045817|NCT00004152|PROCEDURE|computed tomography|
224045818|NCT00004152|PROCEDURE|positron emission tomography|
224045819|NCT00004152|RADIATION|fludeoxyglucose F 18|
224045820|NCT02606461|DRUG|Selinexor|Selinexor 60mg
224045821|NCT02606461|DRUG|Placebo|
224045822|NCT00432536|OTHER|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
224141894|NCT06140277|PROCEDURE|extraction with chitosan particles as a replacement for bone graft with collagen membrane|to replace the bone at the extraction site we will put either chitosan or allograft particles
223434921|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
223434922|NCT00793624|DRUG|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
223434923|NCT00793624|DRUG|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
223434924|NCT00793624|DRUG|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
223434925|NCT00793624|DRUG|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
224045823|NCT04924504|OTHER|No interventions|No interventions
223740645|NCT05778578|BEHAVIORAL|Universal Basic Income|Universal basic income (UBI) is a system that gives everyone a minimum amount of money regularly, regardless of their income or work status.
224045824|NCT03654014|DEVICE|SofPulse|SofPulse PEMF device treatment of the brain after traumatic injury
224045825|NCT02172287|DRUG|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
224045826|NCT02172287|DRUG|Salmeterol|Inhalation aerosol twice daily
224045827|NCT02172287|DRUG|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
224045828|NCT02172287|DRUG|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
224045829|NCT02952040|DRUG|ASP1517|Oral dose
224045830|NCT02952040|DRUG|Lanthanum carbonate hydrate|Oral dose
224045831|NCT00446524|DRUG|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
224045832|NCT01131026|DRUG|Levofloxacin|tablet, 500 mg, once a day for ten days
224045833|NCT01131026|DRUG|Amoxicillin|tablet, 1000 mg, once a day for ten days
224141895|NCT06140277|PROCEDURE|extraction with placing of allograft particles with collagen membrane|to replace the bone at the extraction site we will put allograft particles
224045834|NCT01131026|DRUG|Lansoprazole|capsule, 30 mg, twice a day for ten days
224141896|NCT06140277|PROCEDURE|tooth extraction only|hopeless tooth will be extracted without any intervention
224141897|NCT03823807|DRUG|SH-1028|Oral,100mg or 200mg ,QD, fasted
224141898|NCT06089954|OTHER|private web-portal eHealth disclosure of genetic results|The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
224163527|NCT01446549|OTHER|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
223434926|NCT07088653|DRUG|MicroRepair ABX mouthwash|Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using MicroRepair® ABX mouthwash. The formulation contains zinc-hydroxyapatite with antibacterial agents (cetylpyridinium chloride, magnolol, honokiol). Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same sodium lauryl sulfate (SLS)-free toothpaste (Biorepair®) throughout the study.
223434927|NCT07088653|DRUG|Chlorhexidine 0.12% mouthwash|Participants begin at T0 (baseline) with clinical assessments, oral hygiene instruction, and the start of a 14-day home regimen using 0.12% chlorhexidine (CHX) mouthwash. Mouthwash is used twice daily (10 mL for 30 seconds) without rinsing, and participants avoid food or drink for 1 hour afterward. All participants use the same SLS-free toothpaste (Biorepair®) throughout the study.
223434928|NCT04724577|RADIATION|carbon ion radiotherapy|dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
224045835|NCT06473883|OTHER|Training recommendation|The players in the intervention group are also given specific training recommendations for the prevention of head injuries, which are compiled by experts (sports scientists, physiotherapists and neuroscientists). The exercise selection covers several areas that can be affected after a head injury. Each section contains 8 different exercises with increasing levels of difficulty (3x Basic-3x Intermediate-2x Advanced). The recommendations should be used as a warm-up program throughout the season before each training session. The coach or athletic coach will lead the warm-up program and ensure that each player follows the sequence and completes each phase according to the scheduled weeks. The warm-up program should be conducted as an 8-week cycle.
224045836|NCT03130179|DRUG|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
224045837|NCT03130179|DRUG|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
224045838|NCT02297360|DIETARY_SUPPLEMENT|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
224045839|NCT02297360|OTHER|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
224045840|NCT00780013|DRUG|metformin hydrochloride liquid 500 mg per 5 mL|
224045841|NCT03496324|DRUG|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
224141899|NCT06089954|OTHER|eHealth education intervention (web or chatbot)|The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
224141900|NCT01996891|OTHER|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
224141901|NCT00258388|DRUG|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
224141902|NCT00258388|DRUG|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
224141903|NCT00258388|DRUG|prednisone|5mg PO BID
223434929|NCT02568228|DIETARY_SUPPLEMENT|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
223434930|NCT02568228|OTHER|Lean and fatty fish|The fish group will be open labeled.
223434931|NCT02568228|DIETARY_SUPPLEMENT|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
223434932|NCT04494763|DRUG|Propanolol|Non-selective Beta-blocker
224045842|NCT03496324|DRUG|Algifor® Junior|Algifor® Junior 400 mg/20 ml
224045843|NCT06209008|DRUG|Intravesical injection of Platlet Rich Plasma (PRP)|Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
224141904|NCT00425477|BIOLOGICAL|sargramostim|
224141905|NCT00425477|DRUG|bexarotene|
224141906|NCT00425477|GENETIC|cytogenetic analysis|
224141907|NCT00425477|GENETIC|fluorescence in situ hybridization|
224141908|NCT00425477|OTHER|flow cytometry|
224141909|NCT00425477|OTHER|laboratory biomarker analysis|
223434933|NCT04494763|OTHER|Placebo|Inactive drug
224141910|NCT00425477|PROCEDURE|biopsy|
224141911|NCT04207268|BEHAVIORAL|Gardening and Nutrition Advice|Participate in gardening activities, gardening instructions and nutrition advice
224141912|NCT04207268|BEHAVIORAL|Nutrition Advice|Participate in only nutrition advice
224141913|NCT05928676|DIETARY_SUPPLEMENT|Vascanox® HP|Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
224141914|NCT00672360|DIETARY_SUPPLEMENT|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
224141915|NCT00672360|DIETARY_SUPPLEMENT|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
224141916|NCT00044486|DRUG|Posaconazole oral suspension|
224163528|NCT01446549|PROCEDURE|Deep Brain Stimulation|Deep Brain Stimulation implantation
224045844|NCT05045326|BEHAVIORAL|Smoking cessation program|"Participants will receive intensive treatment for smoking cessation during day hospital admission.~The intervention is carried out individually and in an open-ended group. The treatment, provided by trained and multidisciplinary professionals (nursing, psychiatry, psychologist, occupational therapist, social work), includes psychological, psycho-educational support, and pharmacological treatment advice.~The group intervention takes place once a week and is divided into six structured sessions that are repeated. Sessions include nicotine addiction and withdrawal, health consequences, benefits of quitting, motivation for change, triggers, coping responses, social support, decision making, pharmacological treatment advice and healthy lifestyle habits."
224141917|NCT04511442|OTHER|Evaluation of food preferences during a standardized and validated buffet.|"The dietary preferences of people will be collected by a direct measurement of eating behavior in front of a dedicated and standardized ad-libitum buffet.~As part of this buffet, 3 dichotomous categories of food will be studied:~* high / low in fat (HF / LF)~* high / low in carbohydrates (HC / LC)~* high / low in protein (HP / LP). During the buffet, participants will be filmed to study their food choices and the microstructure of their meal. We will define food preferences as the relative consumption choices of the food categories studied. We will also collect the time spent at the buffet, the duration of ingestion, the total duration of the meal, the number of bites per minute, the total number of bites and the number of bites by type of food.~Weighing's will be carried out before and after consumption in order to determine the total energy intake and the macronutrient intake (proteins, lipids, carbohydrates) of the participants."
224141918|NCT04700852|DEVICE|Puressentiel protective nasal spray|provocative nasal test with grass pollen and nasal lavage
223434934|NCT06912438|OTHER|Fill out questionnaire|"After signed consent all patients will be asked to fill a series of questionnaires in print. The questionnaires administered are standardized and validated in Hebrew.~Patients will be asked to fill out:~Diagnostic Criteria for Temporomandibular Disorders (DC-TMD) questionnaire.~Patient Health Questionnaire 9 PHQ-9-HEB~Emotion Regulation Questionnaire (ERQ)~Toronto Alexithymia Scale (TAS - 20)~At each injection session, all patients will be asked to fill out the Profile of Mood States Hebrew translation (POMS-H) before and after trigger point injections."
223434935|NCT07091864|OTHER|Best Practice|Receive SOC treatment
223434936|NCT07091864|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223434937|NCT07091864|OTHER|Dietary Intervention|Attend dietary counseling sessions
223434938|NCT07091864|OTHER|Glucose Measurement|Undergo intermittent glucose monitoring
223434939|NCT07091864|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223434940|NCT07091864|OTHER|Monitoring|Undergo CGM
223434941|NCT07091864|OTHER|Questionnaire Administration|Ancillary studies
223434942|NCT07091864|OTHER|Supportive Care|Receive endocrinology-guided interventions
223434943|NCT07133646|OTHER|Rib Mobilization Technique and Diaphragm Release Technique|The RMT, adapted from Henderson et al10 and Abdelaal et al,15 was carried out in 2 different participant positions: supine and seated. In the supine position, the therapist was placed next to the participant and positioned the last 4 fingertips of both hands at the rib angles. The therapist mobilized the costal angles in the postero anterior direction accompanying the participant's normal inspiration The movement was performed in 2 series of 10 respiratory cycles in each hemi thorax, with a 1-minute interval between sets.
223434944|NCT07133646|OTHER|Diaphragm Release Technique|The DRT was performed according to the protocol described by Rocha et al.13 In this protocol, the participant remains in the supine position so that the therapist is able to maintain manual contact with the bottom edge of the rib cage. During inspiration, the therapist exerts traction after the natural rib-cage movement, then deepens the manual contact and maintains the resistance exerted in the previous phase throughout exhalation. The technique was applied in 2 series of 10 deep respiratory cycles, with a 1-minute interval between the series, under the therapist's verbal command.
223434945|NCT07095270|DEVICE|Circadian OS software|Circadian OS is a software program that runs on existing iPads. It utilizes the iPad capabilities to control and deliver circadian-effective light.
223434946|NCT06908109|DEVICE|Yankauer Suction Device|The Yankauer suction device is a hollow, curved and flexible tube that has a suction tip surrounded by a bulbous head to allow effective suctioning without damaging the surrounding tissue. It has been frequently used in multiple settings that range from minor dental procedures to large surgeries. It is also frequently used in the intensive care units to suction oropharyngeal secretions and prevent aspiration. Throughout this study, and regardless of the study group (control or intervention group), the Yankauer suction device is attached to a distinct suction port and placed, at the other end, inside the oral cavity of the patient.
224141919|NCT00364325|OTHER|Acute Decompensated Heart Failure|Standard of Care
224141920|NCT04095754|PROCEDURE|Head-Up Position|Anti-Trendelenburg Position
223434947|NCT06908109|PROCEDURE|Bronchoscopy|Flexible bronchoscopy done for the following indications: presence of a lung mass or collapse, persistent pulmonary infiltrates, pulmonary infection in the setting of immunosuppression, hemoptysis, or other rare causes like chronic cough. Flexible bronchoscopy (FB) is a medical procedure that has been used for more than five decades for the diagnostic evaluation and/or therapeutic intervention in a multitude of pulmonary and bronchial diseases
223434948|NCT06696443|DRUG|Suzetrigine|Tablets for oral administration.
223434949|NCT04084730|RADIATION|Accelerated Partial Breast Irradiation|Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
223434950|NCT06395103|BIOLOGICAL|Zilovertamab vedotin|Administered via IV infusion
223478486|NCT02177994|DRUG|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
223478487|NCT01649765|DRUG|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
224045845|NCT05045326|BEHAVIORAL|Placebo Comparator: Brief Counselling|Participants will receive brief counseling on smoking cessation during their hospital stay. This brief intervention is based on motivational techniques to increase motivation to reduce tobacco use or to initiate treatment.
224045846|NCT01970488|BIOLOGICAL|Adalimumab|Administered by subcutaneous injection
224045847|NCT01970488|BIOLOGICAL|ABP 501|Administered by subcutaneous injection
223478488|NCT01649765|OTHER|placebo|Normal Saline 250 ml
223434951|NCT07109609|DRUG|Topical application of 20% menthol solution in MCT oil.|To facilitate reproducible and correct application of the solution, the subject wears glasses while the product is applied. The solution is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers about 12 mg solution, i.e. 2.4 mg menthol to one cheek. Or this method delviers 12 mg of placebo oil. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
223434952|NCT07109609|DRUG|Topical Placebo Oil rolled onto the cheek.|To facilitate reproducible and correct application of the Placebo oil, the subject wears glasses while the product is applied. The Placebo oil is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers zero active agent. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
223434953|NCT06940713|DEVICE|Imaging Time|"fUS:~transfontanellar functional ultrasound imaging, performed using the CONEXUS system.~fUS-EEG:~transfontanellar functional ultrasound imaging, performed using the CONEXUS system, performed simultaneously with an EEG examination.~The fUS examinations consist of recording brain activity for a few minutes in one of the imaging planes (Posterior Coronal, Median Coronal, Frontal Coronal, Right Para-sagittal, Right/Left Para-sagittal, 3-plane Antero-posterior Coronal) including structures involved in brain functional connectivity networks (somatosensory, auditory, visual, salience).~These fUS examinations are conducted to perform longitudinal follow-up of patients in the 5 different groups."
223434954|NCT07071051|OTHER|Non-Interventional Study|Non-interventional study
223434955|NCT07175675|PROCEDURE|Operative treatment of surgeons choice|treatment of single finger amputation with revision amputation, local or micro-vascular flap as best befits each specific injury
224045848|NCT01795300|RADIATION|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
224141921|NCT04095754|DRUG|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
223434956|NCT07175675|PROCEDURE|Semi-occlusive film|The film is placed on a cleansed wound surface. bone is shortened to the level of injury. Visible nerves, arteries and tendons are cut and allowed to retract. The film is to be changed once weekly until the wound has closed.
223565937|NCT06687668|OTHER|Short Leg Walking Plaster Cast|A short leg walking plaster cast that extends from the head of the metatarsal to the mid-calf. This cast provides stability to the fracture site while allowing limited weight-bearing, and is designed to restrict inversion and eversion movements, thereby reducing the risk of fracture displacement. Applied for six weeks.
223565938|NCT06687668|OTHER|Walking Foot Plaster Cast|A walking foot plaster cast that covers the foot from the metatarsal heads but leaves the toes exposed. This cast allows weight-bearing while restricting side-to-side movement, providing support to the fracture area without immobilizing the ankle. It will be used for six weeks.
223565939|NCT06628284|DEVICE|Dexcom G7|The study will be conducted as a single-arm trial consisting of participants enrolled in the test group. Each participant will receive a G7 CGM and their blood glucose levels will be continuously transmitted to the Dexcom Clarity system for monitoring and data collection. As a observational study, the test group glucose levels will be monitored after receiving a steroid for pain management. The CGM profile of steroid-induced hyperglycemia in patients will be studied for the following corticosteroids: dexamethasone (10 mg), methylprednisolone (40 mg or 80 mg), triamcinolone (40 mg or 80 mg).
223565940|NCT01191645|DRUG|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
224141922|NCT04095754|DRUG|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
224141923|NCT03130712|DRUG|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
224141924|NCT04183699|DIAGNOSTIC_TEST|Prostate biopsy|MRI-targeted + systematic random prostate biopsy
224141925|NCT03146052|DRUG|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
223565941|NCT01191645|DRUG|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
223565942|NCT01191645|DRUG|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
224141926|NCT00454155|DRUG|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
224163529|NCT00611416|DIETARY_SUPPLEMENT|green tea|different catechin combinations
224163530|NCT00611416|DIETARY_SUPPLEMENT|Mix of catechins and caffeine|3 tablet a day
224163531|NCT00611416|DIETARY_SUPPLEMENT|EGCG|3 tablets a day
224163532|NCT00611416|DIETARY_SUPPLEMENT|EGC|3 tablets a day
224163533|NCT00611416|DIETARY_SUPPLEMENT|Caffeine|3 tablets a day
224163534|NCT00611416|DIETARY_SUPPLEMENT|Placebo|3 tablets a day
224163535|NCT00062972|DRUG|donepezil|
224163536|NCT00062972|DRUG|glucose|
224163537|NCT00004256|BIOLOGICAL|sargramostim|
224163538|NCT00004256|PROCEDURE|quality-of-life assessment|
223565943|NCT01191645|DRUG|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
223434957|NCT07175571|PROCEDURE|Intracytoplasmic Sperm Injection (ICSI)|Mature oocytes are injected with a single frozen-thawed donor sperm cell using micromanipulation under a microscope. This fertilization method is performed shortly after oocyte retrieval. Sperm used are pre-screened and standardized for post-thaw motility and morphology. ICSI is conducted in accordance with standard embryology lab protocols. The oocyte allocation to ICSI is randomized within each participant's cycle.
223434958|NCT07175571|PROCEDURE|Conventional Insemination (IVF)|Oocytes are inseminated by co-incubation with frozen-thawed donor sperm in a culture dish for 16-18 hours. Sperm are washed and prepared according to lab protocol to ensure motility and concentration suitability. This method does not involve direct sperm injection. Oocytes are randomly assigned to this method within each participant's retrieved cohort.
223434959|NCT07174700|OTHER|Questionnaire|An online questionnaire will be used to assess the prevalence of internet addiction, gaming addiction, and porn addiction, and their relation with stress, anxiety and depression
223434960|NCT07175493|BIOLOGICAL|CM336 Injection|subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol
223434961|NCT07175168|OTHER|No medical or experimental intervention will be administered|Laboratory procedures (blood sampling for karyotyping, basic investigations such as echocardiography, thyroid function tests, abdominal ultrasound) are part of standard diagnostic assessment, not rese
223434962|NCT07174817|BEHAVIORAL|weight loss|The weight loss intervention group underwent dietary and exercise programs for three months prior to initiating IVF treatment. These interventions included consuming foods with a low glycemic index (GI), achieving a daily net energy expenditure of 500-750 kcal, and engaging in moderate-intensity exercise 3-5 times per week. After the three-month period, weight maintenance was managed according to each patient's preferences.
223434963|NCT07176624|PROCEDURE|Enteral nutrition is reduced before the prone position|Before the prone position, the gastric contents are aspirated with a syringe, and the dose of enteral nutrition reduction is determined based on the different amounts of gastric residue. If the residual volume in the stomach is less than 200ml, the enteral nutrition intake will be reduced by one third. Gastric residual volume 200-500ml: Reduce enteral nutrition by half. If the residual gastric volume is greater than 500ml: Stop enteral nutrition and consider post-pyloric feeding
223434964|NCT07175974|BEHAVIORAL|Feldenkrais Method - Awareness Through Movement (ATM)|Participants attended eight consecutive sessions of the Feldenkrais Method, each lasting 90 minutes, over 8 days (total 12 hours). Sessions focused on enhancing upper limb functionality, trunk integration, posture, coordination, body awareness, and somatic regulation through slow, mindful, guided movements.
224045849|NCT01795300|RADIATION|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
224045850|NCT01795300|RADIATION|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
224045851|NCT01795300|RADIATION|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations \>3mm are corrected prior to radiotherapy.
224045852|NCT04323826|OTHER|olive oil-water mixture|50% olive oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
224045853|NCT04323826|OTHER|olive oil-water emulsion|50% olive oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
223434965|NCT07175077|DEVICE|7t MRI|7t brain MRI followed by up to 12 months of standard of care 1.5t/3t MRI scans
223434966|NCT07175883|PROCEDURE|Redon drain|Patients in group A will have a Redon drain placed at the end of the procedure following the usual technique
223434967|NCT07176390|DRUG|Tulisokibart|Subcutaneous (SC) administration
224045854|NCT04323826|OTHER|coconut oil-water mixture|50% coconut oil in water, processed with high shear mixer at 8000 rpm power without adding emulsifier, well shaked before consumption.
224045855|NCT04323826|OTHER|coconut oil-water emulsion|50% coconut oil in water (4% whey protein isolate), stirred for 5 mins using a high shear mixer at 8000 rpm power and was further processed with high pressure homogenizer at 100 MPa.
224045856|NCT04532736|DRUG|Emthexate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
224163539|NCT00004256|RADIATION|radiation therapy|
224163540|NCT02996110|BIOLOGICAL|Nivolumab|Specified Dose on Specified Days
224163541|NCT02996110|BIOLOGICAL|Ipilimumab|Specified Dose on Specified Days
223740646|NCT06245681|DRUG|gender affirming hormone therapy|both groups are receiving gender-affirming hormone therapy; we do not compare the groups, but look at whether hormone therapy with testosterone or estrogen might have an effect on myocardial function, organ lipid content and subcutaneous to visceral fat ratio
223740647|NCT06637072|BIOLOGICAL|Efgartigimod PH20 SC|Subcutaneous injection of efgartigimod PH20 SC
224045857|NCT04532736|DRUG|Prednol|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
223740648|NCT05498038|BEHAVIORAL|Aerobic Exercise|Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
223740649|NCT06043102|DEVICE|TheraClearX|TheraClear®X combines vacuum pressure with a broadband light source (500 nm to 1,200 nm) to treat facial acne.
223740650|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
224045858|NCT04532736|DRUG|Mometasone Furoate|After randomization, the patients were divided into three groups including 14 volunteers in each study groups and 11 in the control group. One of the study groups was take methotrexate (n=14, eight weeks) and the other was take methylprednisolone (n=14, eight week)
224045859|NCT04727320|DRUG|Tauroursodeoxycholic acid|Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
224045860|NCT04727320|DRUG|Placebo|Oral placebo, once a day, one tablet at a time for 6 months
224045861|NCT03382015|OTHER|BKR-013 or Placebo|Encapsulated L-glutamine
224045862|NCT04323085|BEHAVIORAL|Speech-in-Noise Treatment Program|Speech therapy program for hypophonia.
224045863|NCT04323085|BEHAVIORAL|Speech-to-Noise Feedback Device Program|Speech Feedback device program for hypophonia.
224045864|NCT06175546|DEVICE|Compression socks|Wearing of compression sock in prescribed regimen
224045865|NCT00892320|DRUG|ER OROS paliperidone|
224045866|NCT02092350|DRUG|Grazoprevir|Grazoprevir 100 mg tablet
224045867|NCT02092350|DRUG|Elbasvir|Elbasvir 50 mg tablet
224045868|NCT02092350|DRUG|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
224045869|NCT02092350|DRUG|Placebo to Elbasvir|Placebo tablet matched to elbasvir
224045870|NCT00002326|DRUG|Adefovir|
223434968|NCT07176390|DRUG|Placebo|SC Injection
223434969|NCT07176390|DRUG|Methotrexate|Background Therapy - SC injection or oral administration. Per protocol, parenteral administration is allowed.
223740651|NCT06179511|DRUG|AZD9829|AZD9829 will be administered by IV infusion
223740652|NCT03495323|DRUG|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
223740653|NCT03495323|DRUG|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
223740654|NCT00961844|BIOLOGICAL|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
223740655|NCT00961844|DRUG|Temozolomide|
224045871|NCT00002326|DRUG|Zidovudine|
224141927|NCT05463042|BEHAVIORAL|Intermittent Hypoxia|During the intermittent hypoxia session, participants will be sitting during the entire breathing protocol. Hypoxic air will be inhaled through a mask connected to a two-way non-rebreathing valve, which will itself be connected to a 5-liter non-diffusing gas bag (Hans Rudolph, Inc, USA). The rebreathing bag will be connected to a certified medical grade gas tank containing 11% oxygen and a balance of nitrogen. The intermittent hypoxia protocol will consist of eight 4-min cycles of breathing hypoxic air interspersed with normoxic cycles breathing room air. After four min of hypoxia, participants will be switched back to breathing room air until resaturation, which takes approximately one minute. Once arterial oxygen saturation reaches baseline levels, participants will be switched back to breathing hypoxic air, beginning the next hypoxic cycle.
224163542|NCT02996110|BIOLOGICAL|Relatlimab|Specified Dose on Specified Days
223740656|NCT04754737|OTHER|No antibiotic|No antibiotics will be given prior to intravesical injection of onabotulinumtoxinA
223740657|NCT04754737|OTHER|Prophylactic antibiotic|This is the current standard of care, this group of patients will be given a single dose of prophylactic antibiotic prior to the injection of onabotulinumtoxinA via cystoscopy
224045872|NCT05361109|DRUG|Baricitinib|The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
224045873|NCT06411587|DIAGNOSTIC_TEST|Ultrasound imaging and functional assessment|Participants in this study will undergo two types of assessments: capturing muscle images using ultrasound and evaluating their function through clinical scales.
224045874|NCT00239226|PROCEDURE|IAS pacing - study group|site of implant and permanent pacing
223434970|NCT07174713|BIOLOGICAL|Biologic Therapy|Participants with severe asthma (GINA 5) who are eligible to begin biologic therapy. Participants will undergo serial assessment with pulmonary imaging (CT, MRI), lung function testing, sputum collection, and symptom questionnaires. A subset of participants (\~15%) will be randomized to undergo MRI-guided bronchoscopy with airway sampling at baseline and 2 years.
224045875|NCT00239226|PROCEDURE|IAS pacing control group|site of implant and permanent pacing
224045876|NCT00239226|PROCEDURE|Pacing RAA study group|site of implant and permanent pacing
224045877|NCT00239226|PROCEDURE|Pacing RAA control group|site of implant and permanent pacing
224045878|NCT01614821|DRUG|PCI-32765|Taken orally, once daily in the morning
224045879|NCT04107883|BIOLOGICAL|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
224045880|NCT04107883|DIAGNOSTIC_TEST|blood sample|get blood samples at several specific points in time during perioperation
224045881|NCT00041301|OTHER|QoL assessment|qol questionnaires
224045882|NCT00000138|DRUG|Prednisolone Phosphate|
224045883|NCT00000138|DRUG|Acyclovir|
224045884|NCT04559945|DEVICE|Aveir VR Leadless Pacemaker System|Patients will undergo an attempted leadless pacemaker implant
224045885|NCT05335148|DRUG|oral colchicine(0.6 mg) once a day|The standard of care arm will receive a placebo colchicine pill once a day
223434971|NCT07176702|DRUG|HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy|"Drugs: HLX22 (15 mg/kg IV) + trastuzumab (8 mg/kg loading dose → 6 mg/kg maintenance) + nab-paclitaxel (125 mg/m² IV) + gemcitabine (1000 mg/m² IV).~Administration: Administered every 3 weeks until disease progression, unacceptable toxicity, or withdrawal."
223434972|NCT07175350|OTHER|PROFFIT|The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire is a 30-item questionnaire that measures health-related quality of life (HRQOL) in cancer patients ; PRO-CTCAE is a short list of 43 symptoms relevant for ovarian cancer
223740658|NCT04754737|PROCEDURE|cystoscopic injection of onabotulinumtoxinA|cystoscopic injection of onabotulinumtoxinA
223434974|NCT07174960|BEHAVIORAL|Life-Skills Training Program|This study aims to assess the impact of a life-skills training program on self-efficacy in patients with substance use disorders. The program is designed to prevent relapse by equipping individuals with crucial skills for managing triggers and challenges. It focuses on developing constructive coping strategies, effective stress and craving management techniques, social competencies like assertiveness, and emotional regulation abilities including anger control. By enhancing these domains, the intervention seeks to strengthen patients' confidence in their capacity to resist substance use and make adaptive decisions, thereby reducing relapse risk.
223434975|NCT07176169|PROCEDURE|Muscle Energy Technique for Sacral torsion|"Conventional management including Electrotherapy by application of Thermotherapy or Cryotherapy, Transcutaneous Electrical Nerve Stimulation (TENS) for 20 minutes, Core-stabilization Exercises,~* Clamshells~* Four Point Kneeling~* Bridging/Side Bridges~* Bird-Dog Pose~* Dead Bugs~* Dynamic Core Stability (Unstable Surfaces) For Sacral Torsions, Six MET protocols address Forward and Backward torsions on Left and Right Oblique axis using patient generated force in Prone or Side-lying positions. Left-on-Left (LOL) Forward Torsion, Right -on-Right (ROR) Forward Torsion, Right-On-Left (ROL) Backward Torsion, Left-on-Right (LOR) Backward Torsion, Bilateral Sacral Nutation, Bilateral Sacral Counternutation"
223434976|NCT07176169|PROCEDURE|Muscle Energy Technique for Innominate rotation|Conventional management including Electrotherapy by application of Thermotherapy or Cryotherapy, Transcutaneous Electrical Nerve Stimulation (TENS) for 20 minutes, Core-stabilization Exercises, • Clamshells • Four Point Kneeling • Bridging/Side Bridges • Bird-Dog Pose • Dead Bugs • Dynamic Core Stability (Unstable Surfaces). Anterior Innominate Rotation and Posterior Innominate Rotation.
223434977|NCT07174921|PROCEDURE|Laparoscopic Lateral Suspension|Participants in this arm will undergo laparoscopic lateral suspension for post-hysterectomy vaginal cuff prolapse. The procedure involves attaching a synthetic mesh from the vaginal cuff to the lateral abdominal wall to provide support and restore normal vaginal anatomy. Standard perioperative care, including anesthesia and postoperative pain management, will be provided.
223434978|NCT07174921|PROCEDURE|Laparoscopic Sacrocolpopexy|Participants in this arm will undergo laparoscopic sacrohysteropexy for post-hysterectomy vaginal cuff prolapse. The procedure involves suspending the vaginal cuff to the sacral promontory using a synthetic mesh, restoring vaginal support. Standard perioperative care, including anesthesia and postoperative pain management, will be provided.
223434979|NCT07175948|OTHER|Standard Medical Therapy|All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (e.g., dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and/or diuretics as indicated. Treatment is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status. The goal is to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.
224045886|NCT00005007|DRUG|Etanercept|
224045887|NCT03042078|DEVICE|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
224045888|NCT03042078|DEVICE|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
224045889|NCT04706611|PROCEDURE|Fecal Microbiota Transplantation|Procedure: Fecal Microbiota Transplantation
223740659|NCT04322747|DIAGNOSTIC_TEST|Distortion product otoacoustic emissions (DPOAE)|Audiometry for extended high frequencies, DPOAE, and, ECochG measurements will be collected before and after skull-based surgeries.
223740660|NCT03130842|DRUG|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
224045890|NCT00646906|DRUG|Aspirin First|Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
224045891|NCT00646906|DRUG|Aspirin Last|Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
224045892|NCT00646906|DRUG|Acetaminophen 1000 mg/d|Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
224045893|NCT00646906|DRUG|Acetaminophen 4000 mg/d|Crossover period Acetaminophen 4000 mg/d: Acetaminophen (1000 mg p.o.) orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
224045894|NCT00646906|DRUG|Ibuprofen 800 mg/d|Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
224045895|NCT00161876|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
224141928|NCT05463042|BEHAVIORAL|Normoxia (sham)|During the sham condition, compressed air (21% oxygen) from a gas tank will be delivered throughout the protocol instead of 11% oxygen. Participants will not receive information about which condition (Intermittent hypoxia or sham) they are experiencing during the trials.
224141929|NCT00622869|DRUG|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
224141930|NCT00622869|DRUG|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
223434980|NCT07175948|DRUG|Standard Medical Therapy|"All enrolled children will receive standard medical therapy tailored to clinical status. This includes inotropes (dopamine, dobutamine, milrinone), ACE inhibitors, beta-blockers, and/or diuretics as indicated. Therapy is supportive and adjusted according to severity of cardiac dysfunction and hemodynamic status to stabilize heart failure, improve cardiac output, and prevent progression to dilated cardiomyopathy.~2️⃣ Intervention 2"
223434981|NCT07176754|DRUG|Infliximab|"The TNF-α antagonist (infliximab) used by the experimenter was manufactured by Hisun Biopharmaceuticals Ltd. under the trade name anbaite.The dosage was administered at 5 mg/kg, dissolved in 250 mL of 0.9% sodium chloride injection, and delivered via intravenous infusion over 2 hours."
223434982|NCT07176754|DRUG|Sodium chloride injection USP, 0.9% (placebo)|Patients in the control group received 250 mL of 0.9% sodium chloride injection as a placebo, administered via intravenous infusion over 2 hours.
223434983|NCT07176494|PROCEDURE|Patients who underwent surgery under general anesthesia|Patients undergoing surgery under general anesthesia will undergo general anesthesia induction. During the skin closure, patients received 50 mg of dexketoprofen. Additionally, a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered intravenously for multimodal analgesia.
223434984|NCT07176494|PROCEDURE|Patients who underwent surgery under regional anesthesia|"25 cc (15 cc 0.5% bupivacaine + 5 cc 2% lidocaine + 5 cc isotonic) local anesthetic solution is prepared. 10 cc of the medication is administered into the interpectoral plane, and 15 cc into the pectoserratus plane.~During the skin closure, patients received 50 mg of dexketoprofen. Additionally, a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered intravenously for multimodal analgesia."
223434985|NCT07175337|BEHAVIORAL|Surah Maryam group|Pregnant women who came for birth were taught Surah Maryam. They were monitored throughout the labor process, and in addition to routine midwifery care, Surah Maryam was played twice during labor to provide spiritual support.
223434986|NCT07175337|BEHAVIORAL|Virgin Mary's Hand Plant Group|he pregnant woman was monitored throughout labor; in addition to routine midwifery care, she was given spiritual support by placing the Virgin Mary's Hand plant in water and watching the plant unfold, encouraging her to believe that the birth canal also opens in the same way.
223434987|NCT07174830|DRUG|Allisartan Isoproxil Tablets 240mg or placebo|Allisartan Isoproxil Tablets 240mg or placebo, QD
224045896|NCT01106495|DEVICE|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
224045897|NCT01106495|DRUG|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
224045898|NCT00486772|DRUG|Sevelamer (Renagel), calcium acetate (Phos-ex)|
224045899|NCT02584322|OTHER|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
224045900|NCT00910195|DEVICE|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
224045901|NCT00910195|DEVICE|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
224045902|NCT02882542|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
224045903|NCT00050648|DRUG|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
224045904|NCT00050648|DRUG|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
224045905|NCT00050648|DRUG|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
224045906|NCT00510991|DEVICE|nippv|
224045907|NCT00917527|DRUG|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
224045908|NCT02265861|DRUG|HCG|
224045909|NCT00809211|DRUG|nilotinib|
224045910|NCT00809211|GENETIC|cytogenetic analysis|
224045911|NCT00809211|GENETIC|mutation analysis|
224045912|NCT00809211|GENETIC|polymerase chain reaction|
224045913|NCT00809211|OTHER|pharmacological study|
224045914|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
224045915|NCT02448225|PROCEDURE|Computed Tomography|Undergo 18F-FSPG PET/CT
224163543|NCT02996110|DRUG|BMS-986205|Specified Dose on Specified Days
224163544|NCT02996110|DRUG|BMS-813160|Specified Dose on Specified Days
223434988|NCT07174830|DRUG|Allisartan Isoproxil Tablets 480mg or placebo|Allisartan Isoproxil Tablets 480mg or placebo, QD
223434989|NCT07174830|DRUG|Allisartan Isoproxil Tablets 720mg or placebo|Allisartan Isoproxil Tablets 720mg or placebo, QD
223478489|NCT02188550|DRUG|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
223478490|NCT01648764|DRUG|LY2334737|Administered orally
223478491|NCT00715208|DRUG|rituximab|
223478492|NCT00715208|DRUG|cyclophosphamide|
223478493|NCT00715208|DRUG|doxorubicin|
223478494|NCT00715208|DRUG|VELCADE|
223478495|NCT00715208|DRUG|prednisone|
223478496|NCT05197439|DRUG|Dexmedetomidine|The 4.8ug/kg dexmedetomidine will be diluted into 100ml and pump 2ml/h at the beginning of the second of DBS and last for 48 hours.
223478497|NCT05197439|DRUG|0.9% saline|The 0.9% saline is administered with the same volume at the same speed as the other group.
223478498|NCT00052338|DRUG|gemcitabine hydrochloride|Given IV
223478499|NCT00052338|DRUG|carboplatin|Given IV
223478500|NCT00052338|DRUG|bortezomib|Given IV
223478501|NCT00052338|OTHER|laboratory biomarker analysis|Correlative studies
223478502|NCT05662969|DEVICE|MACHINE PERFUSION|Different outcomes of MP use in low/mid-volume and high-volume LT centres
223434990|NCT07175545|DEVICE|Independent use of the Mobili® Device by patients, overseen by pharmacists|"After recruitment each participant will be subject to a type I medication review.~After allocation to the intervention group, pharmacists will provide initial training to participants, and during the course of the intervention whenever necessary (e.g. when delivering the eDosette with the therapeutic regime). Pharmacists will prepare the eDosette in the pharmacy and deliver it directly to participants with no further intervention.~Participants will receive the number of eDosettes their therapeutic regime allows, to minimize visits to the pharmacy. For the control group, pharmacists will also provide the number of DAAs the therapeutic regime allows. Upon finishing the intervention, a new type II medication review will be performed for all participants (intervention and control) and information related to their personal therapeutic regime will be provided, ensuring a safe exit of the study."
224045916|NCT02448225|RADIATION|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
224045917|NCT02448225|DRUG|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
224045918|NCT02448225|OTHER|Laboratory Biomarker Analysis|Correlative studies
223434991|NCT07176351|DRUG|Buprenorphine|Weekly or monthly extended-release subcutaneous injection
223434992|NCT07175688|DEVICE|Abdominal Ultrasound|Standard abdominal ultrasonography performed to evaluate pancreatic steatosis by comparing pancreatic echogenicity to liver and kidney tissue.
223434993|NCT07175688|DEVICE|Transient elastography|Non-invasive transient elastography used to assess hepatic steatosis and liver stiffness in patients with chronic hepatitis B.
223434994|NCT07175688|DIAGNOSTIC_TEST|Waist Circumference|The midpoint between the superior aspect of the iliac crests and the lower lateral margins of the ribs using an inelastic tape (TBW Import Ltd) that was 0.5 cm in width and 200 cm in length, according to World Health Organization (WHO) recommendations. Abdominal obesity, determined as a waist circumference of ≥94 cm in males or ≥80 cm in females according to the recommendations of the International Diabetes Federation group
223434995|NCT07175688|DIAGNOSTIC_TEST|Body mass index|"It was calculated by the equation dividing the weight in kilograms by height in meters squared.~BMI=〖mass〗\_kg/(〖height〗\_m\^2 )"
223434996|NCT07177144|OTHER|anti müllerian hormone|participants were checked for amh levels preoperatively
223434997|NCT07177144|DIAGNOSTIC_TEST|anti müllerian hormon|participants were checked for amh levels at 3 months postoperatively.
223434998|NCT07174908|DRUG|IN10018 in combination with D-1553|IN10018 100mg QD PO and D-1553 600mg BID PO, 21days per cycle
223434999|NCT07174908|DRUG|anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed|Tislelizumab 200mg Q3W IV + Carboplatin AUC 5 mg/mL/min or Cisplatin 75mg/m² Q3W IV+ Pemetrexed 500mg/m² Q3W IV
223435000|NCT07172386|DRUG|Toripalimab and axitinib|Patients will undergo super-selective embolization of the feeding arteries to the renal tumour one week prior to drug therapy, followed by toripalimab administered every three weeks for four consecutive cycles combined with axitinib administered for four consecutive cycles before surgery, and followed by 17 cycles' toripalimab for adjuvant therapy.
223435001|NCT07177066|DRUG|EDG-15400|EDG-15400 is administered orally
223435002|NCT07177066|DRUG|Placebo|Placebo is administered orally
223435003|NCT07176429|DEVICE|Measurement of refractive error and amplitude of pseudoaccommodation|We will be using an assessor, masked as to which participant received what particular lens implant to determine the range of pseudoaccommodation in each eye. This will be done for each eligible eye and the 3 cohorts will be studied and compared.
223435004|NCT07174427|BIOLOGICAL|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.
224045919|NCT02448225|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
224045920|NCT02448225|PROCEDURE|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
224045921|NCT06186713|OTHER|This was an observational study, and no Intervention was given to the patients.|This was an observational study, and no Intervention was given to the patients.
224045922|NCT04454697|DEVICE|tissue retractors|Patients receive a tissue retractor to spare healthy tissue during the course of radiation
223435005|NCT07174427|DRUG|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
223435006|NCT07174427|DRUG|Fludarabine|Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
223435007|NCT07176208|DRUG|Dronabinol (Marinol®)|Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.
223435008|NCT07176208|DRUG|Dronabinol (Marinol®)|Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with a placebo beverage in one of the assigned treatment days.
223740661|NCT03130842|DRUG|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
223740662|NCT02118012|DRUG|Chlorcyclizine HCl|Chlorcyclizine HCl (75 mg twice daily)
223740663|NCT02118012|DRUG|Ribavirin|RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
224045923|NCT02137122|DEVICE|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
224045924|NCT02137122|DEVICE|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
224045925|NCT03514030|DIAGNOSTIC_TEST|serum AQP4-antibody testing method|there are different methods of testing serum AQP4-antibody
224045926|NCT05872490|OTHER|Semi-structured interviews|An interview guide was developed for each population. Depending on the population interviewed, this interview guide focuses on the current state of driving, the obstacles and levers to driving, the representations related to driving by the elderly, their opinion concerning the implementation of a potential aptitude test and more generally their opinion on policies related to road safety.
223435009|NCT07176208|DRUG|Dronabinol (Marinol®) + Alcohol|Subjects in this arm will receive one dose of 5 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
223740664|NCT03899376|RADIATION|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
223740665|NCT03899376|RADIATION|conventional radiotherapy|Radiotherapy focus on pelvis area
224163545|NCT00305266|DRUG|intravenous gammaglobulin|individual dose
223435010|NCT07176208|DRUG|Dronabinol (Marinol®) + Alcohol|Subjects in this arm will receive one dose of 10 mg THC (Dronabinol) with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
223435011|NCT07176208|DRUG|Alcohol beverage|Subjects in this arm will receive placebo capsule with an alcoholic beverage (to achieve a target BAC of 0.08%) in one of the assigned treatment days.
224045927|NCT05872490|OTHER|Questionnaire|The questionnaire asks people aged 80 and over included in the PROOF cohort about their relationship to driving, their driving status, their societal and personal environment, the circumstances in which they stopped driving, recent accidents and, more generally, their driving habits.
224045928|NCT04354545|DRUG|Xiidra (Lifitegrast ophthalmic solution) 5%|FDA approved lifitegrast opthalmic solution eye drop
224045929|NCT02004951|DEVICE|Misago RX|
224045930|NCT02004951|DEVICE|Zilver PTX|
224045931|NCT01131416|BEHAVIORAL|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
224045932|NCT02551614|PROCEDURE|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
224045933|NCT02551614|PROCEDURE|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
224045934|NCT02551614|PROCEDURE|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
224045935|NCT02112136|OTHER|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
224045936|NCT01105676|PROCEDURE|skin biopsy|Two skin biopsies will be taken one time
224045937|NCT06282276|BEHAVIORAL|cross sectional survey|filling out the electronic survey form
224045938|NCT00943891|PROCEDURE|Tumor biopsies|
224045939|NCT04602169|PROCEDURE|PVI|PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise \>38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
224045940|NCT04602169|PROCEDURE|PVI + SVC|Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
224045941|NCT05744622|OTHER|KetacTM Universal AplicapTM|chemically cured conventional GICs
224045942|NCT05744622|OTHER|KetacTM Universal AplicapTM with light cure|chemically cured conventional GICs with light curing enhancement
223435012|NCT07176208|DRUG|Placebo|Subjects in this arm will receive a placebo capsule with a placebo beverage in one of the assigned treatment days.
223435013|NCT07176676|OTHER|Lavanda Angustifolia essential oil|Administration of Lavender Angustifolia essential oil by inhalation in reducing nausea after abdominal, vascular, neurosurgical and gynaecological surgery under general anaesthesia during the 24-hour postoperative period.
224045943|NCT05836142|PROCEDURE|progressive pressure release|Bilateral progressive pressure release in latent trigger points of the Flexor digitorum Brevis Muscle
224045944|NCT02486653|DRUG|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: tamsulosin 0.4mg in the evening~* Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
224045945|NCT02486653|DRUG|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~* Day 1-7: placebo in the evening~* Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~* Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual \<200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
224163546|NCT01149044|PROCEDURE|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
223478503|NCT02939352|DEVICE|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
223740666|NCT00649623|DRUG|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
223740667|NCT00649623|DRUG|Benicar® Tablets 40 mg|40mg, single dose fasting
223740668|NCT05958407|DRUG|Tralokinumab|After a loading dose of 600 mg under the skin (s.c.) at baseline, trial participants are administered a dose of 300 mg every two weeks for 32 weeks
224163547|NCT04825106|OTHER|Diagnostic context|A life-threatening situation occurs in 3 different contexts
224163548|NCT04409340|DEVICE|Magnetic Resonance Viscoelastography|Magnetic Resonance Viscoelastography
224163549|NCT04409340|DEVICE|QUS|QUS
224163550|NCT03507270|DIAGNOSTIC_TEST|FABP|Assessment of changes in FABP concentrations
224163551|NCT01008436|DRUG|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
224163552|NCT01008436|DRUG|Control|Traditional surgical Hemostasis
223435014|NCT07176676|OTHER|Usual Care|Patients in the Usual Care group will follow the standard procedure, which consists of administering antiemetics if provided in therapy or reporting to the doctor with a subsequent treatment decision
223435015|NCT05769868|DRUG|Esmolol Injection [Brevibloc]|"Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min)."
224045946|NCT02324959|DEVICE|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
223435016|NCT03647163|BIOLOGICAL|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
223435017|NCT03647163|BIOLOGICAL|Pembrolizumab|Pembrolizumab
223435018|NCT03647163|BIOLOGICAL|ipilimumab + nivolumab|Intravenous ipilimumab 1mg/kg in combination with nivolumab 360mg, or Intravenous ipilimumab 1mg/kg in combination with nivolumab 3mg/ kg for 4 cycles, followed by fixed dose nivolumab 480mg
224045947|NCT02324959|DEVICE|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20\|DU20) and Shenting (GV24\|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
224045948|NCT06002308|OTHER|Age|The retrospective study included 540 patients with primary ACL tears (71 pediatric patients and 469 adults) whose MRI examination and pivot-shift test were conducted within 14 days after injury. To detect concomitant KF and ALL injury in knees with ACL injury using MRI in both adult and pediatric patients and compare the effect of KF injury and multiple risk factors on anterolateral rotatory laxity as measured by the pivot-shift test in a clinical setting.
224045949|NCT02518997|OTHER|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
224045950|NCT01050686|PROCEDURE|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
223435019|NCT06227715|OTHER|universal adhesive|
223435020|NCT05622279|PROCEDURE|Percutaneous tenotomy + PRP|The patients will receive a percutaneous ultrasound-guided treatment including a needle tenotomy followed by a PRP injection in the plantar fasciitis.
223435021|NCT05503719|PROCEDURE|Surgical wound closed with an absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with an absorbable suture according to their respective study group.
223435022|NCT05503719|PROCEDURE|Surgical wound closed with a non-absorbable suture|Patients undergoing median nerve release surgery will get their surgical wound closed with a non-absorbable suture according to their respective study group.
223435023|NCT04802447|DRUG|SurVaxM|Each participant will receive 4 doses of SVN53-67/M57-KLH (SurVaxM) spaced two weeks apart. This phase of treatment is known as the prime-boost phase and will take 6 weeks to complete. After completion of the prime-boost phase of treatment, the participant will receive a dose ofSVN53-67/M57-KLH (SurVaxM) every 3 months for up to two years
223435024|NCT04313725|DEVICE|Tangible Boost|Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.
223435025|NCT04313725|OTHER|Placebo|Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.
223435026|NCT06191887|BIOLOGICAL|Autologous BAFFR-targeting CAR T Cells|Given IV
223435027|NCT06191887|DRUG|Bendamustine|Given IV
223435028|NCT06191887|PROCEDURE|Biopsy|Undergo biopsy
223435029|NCT06191887|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223435030|NCT06191887|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy/aspirate
223435031|NCT06191887|PROCEDURE|Computed Tomography|Undergo CT scan
223435032|NCT06191887|DRUG|Cyclophosphamide|Given IV
224045951|NCT01050686|PROCEDURE|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
224045952|NCT05351047|DRUG|AZD2373 subcutaneous injection|Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
224141931|NCT00622869|DRUG|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
224141932|NCT00622869|DRUG|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
223435033|NCT06191887|PROCEDURE|Echocardiography|Undergo echocardiography
224163553|NCT05191381|BIOLOGICAL|Application of exosomes in a whole blood assay|Co-incubation of patient-derived whole blood samples with mesenchymal stem cell derived exosomes and read-out of biomarkers, RNA and immune phenotypes after 24h.
223435034|NCT06191887|DRUG|Fludarabine|Given IV
223435035|NCT06191887|PROCEDURE|Leukapheresis|Undergo leukapheresis
223435036|NCT06191887|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223435037|NCT06191887|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223435038|NCT02921750|DEVICE|Exufiber Gelling Fibre Dressing|Gelling fibre dressing
223435039|NCT02921750|DEVICE|Aquacel Extra Hydrofiber® Dressing with Strengthening Fibre|Hydrofiber® Dressing with Strengthening Fibre
223435040|NCT04104932|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation
223435041|NCT05014841|BEHAVIORAL|Speech Tasks|Listen to 20-minutes of speech sounds in English, Spanish, and/or Mandarin.
223435042|NCT00669643|DRUG|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
223435043|NCT00669643|DRUG|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
224045953|NCT05351047|DRUG|Placebo|Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
223435044|NCT00669643|DRUG|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
223435045|NCT00669643|DRUG|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
223435046|NCT03309696|DEVICE|sham tDCS and sham rTMS|Both combinations of tDCS and rTMS in this intervention are sham.
223435047|NCT03309696|DEVICE|sham tDCS and active rTMS|tDCS in this intervention is sham and rTMS is active
223435048|NCT03309696|DEVICE|active tDCS and active rTMS|Both combinations of tDCS and rTMS in this intervention are active
223435049|NCT03176615|DIETARY_SUPPLEMENT|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
223435050|NCT06665971|DRUG|Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]|Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks
223435051|NCT06294665|DRUG|Pericapsular Nerve Group (PENG) Block|The PENG block will be performed ,the patient is placed in the supine position , the procedural leg is slightly abducted, the curvilinear low-frequency ultrasound probe will be placed over the line parallel to the inguinal ligament. It will subsequently rotated 45◦ to identify the anterior inferior iliac spine, the iliopubic eminence, and the psoas tendon. A 22-gauge, 80 mm echogenic needle will inserted in an in-plane approach to place the tip in the musculofascial plane between the pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration, by one of the two syringes each one has a serial number corresponding to each group.
223435052|NCT05024526|DRUG|edaravone dexborneol or edaravone|Edaravone dexborneol or edaravone is going to be used in two different groups to compare the efficacy.
223435053|NCT01625208|PROCEDURE|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
223435054|NCT01625208|PROCEDURE|Supraclavicular block|Standard supraclavicular brachial plexus block
224045954|NCT01504490|DRUG|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
224045955|NCT03244410|DIAGNOSTIC_TEST|complete blood picture|complete blood picture
224045956|NCT00497783|DRUG|Lactoserum|
224045957|NCT02365753|DEVICE|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
224045958|NCT01177384|DRUG|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
224141933|NCT00622869|DRUG|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
224141934|NCT00622869|DRUG|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
224299824|NCT04908683|BIOLOGICAL|Placebo|Participants will receive a single IM injection of matching placebo.
224299825|NCT05748483|DRUG|Atogepant|Oral Tablet
224045959|NCT01177384|DRUG|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
224045960|NCT01177384|DRUG|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
224045961|NCT01177384|DRUG|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
224045962|NCT01672034|PROCEDURE|Laparoscopic gastric bypass surgery|
224045963|NCT03641495|OTHER|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
224045964|NCT03641495|OTHER|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
224045965|NCT04869163|OTHER|Non-red meat|Red meat analogues and alternatives
224045966|NCT04435379|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
224141935|NCT02472925|BEHAVIORAL|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
224141936|NCT03487640|PROCEDURE|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
224141937|NCT03487640|PROCEDURE|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
224141938|NCT04534569|OTHER|Experts consensus|Consensus opinion using Delphi Methodology
224141939|NCT03230344|PROCEDURE|open flap debridement|open flap debridement simultaneously with root canal treatment
223435055|NCT03219905|DEVICE|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
223435056|NCT03219905|DEVICE|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
223435057|NCT06091592|OTHER|Serum autotaxın levels|Autotaxin molecule is a nucleotide pyrophosphatase/phosphodiesterase enzyme.
223435058|NCT00461110|DRUG|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
223435059|NCT05940077|BEHAVIORAL|Exercise|Community-based exercise involving non-contact boxing and individualized balance training
223435060|NCT02683148|DRUG|DHEA|
223435061|NCT02683148|OTHER|FACT-67 validated survey|"* Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much."
224045967|NCT04435379|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
224045968|NCT03525535|OTHER|data collection|data from patient included will be collected during the study
224045969|NCT00579683|OTHER|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
224045970|NCT01845454|DEVICE|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
224141940|NCT03230344|PROCEDURE|open flap debridement|open flap debridement and delayed root canal treatment
224141941|NCT02695706|DEVICE|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
224299826|NCT05748483|DRUG|Placebo for Atogepant|Oral Tablet
224045971|NCT04654520|OTHER|Drug therapy concurrent radiotherapy for primary tumor omitted CTV|Thoracic intensity modulated radiotherapy for primary tumor omitted CTV+Chemotherapy or Targeted drug therapy
224045972|NCT01849497|BIOLOGICAL|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
224141942|NCT00645567|DEVICE|Unassisted Manual Transfer|No device assistance
223435062|NCT03218605|OTHER|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
223435063|NCT01580345|DIETARY_SUPPLEMENT|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
223435064|NCT01580345|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
224045973|NCT01849497|BIOLOGICAL|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
224045974|NCT02560363|DRUG|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
224141943|NCT00645567|DEVICE|Standard Transfer Board|Flat surface board
223435065|NCT05450185|PROCEDURE|Critically ill patients with continuous renal replacement therapy|Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.
223435066|NCT02532114|DRUG|Enzalutamide|Given PO
223435067|NCT02532114|OTHER|Laboratory Biomarker Analysis|Correlative studies
223435068|NCT02532114|DRUG|Niclosamide|Given PO
223435069|NCT02532114|OTHER|Pharmacological Study|Correlative studies
224045975|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
224045976|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
224045977|NCT02560363|DRUG|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
224045978|NCT04841512|BIOLOGICAL|XT-150|non-viral Plasmid DNA encoding an IL-10 variant transgene
224045979|NCT01398865|PROCEDURE|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
224045980|NCT02830763|DIETARY_SUPPLEMENT|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
224141944|NCT00645567|DEVICE|Glide n' Go|Flip down power lift chair
224141945|NCT00645567|DEVICE|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
224141946|NCT00645567|DEVICE|Ryno lift|Lift for the wheelchair
224141947|NCT05602610|OTHER|No intervention|No intervention
224141948|NCT00422708|PROCEDURE|Local anesthesia|
223435070|NCT05717803|PROCEDURE|Segmentectomy|The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.
223435071|NCT01172964|DRUG|flucytosine|Given orally
224141949|NCT00353964|DRUG|rEV131|
224141950|NCT00353964|DRUG|Prenisolone sodium phosphate 1.0%|
224141951|NCT00353964|DRUG|rEV131 vehicle|
224141952|NCT06429878|DIAGNOSTIC_TEST|Biparametric prostatic MRI|
224299827|NCT05748483|DRUG|Topiramate|Oral Capsule
223435072|NCT01172964|OTHER|polymerase chain reaction|Correlative studies
223435073|NCT01172964|OTHER|immunohistochemistry staining method|Correlative studies
223435074|NCT01172964|BIOLOGICAL|gene therapy|Injected at the time of the surgery to resect the tumor
223435075|NCT01172964|OTHER|pharmacological study|Correlative studies
223435076|NCT01172964|OTHER|3-Tesla magnetic resonance imaging|Correlative studies
223435077|NCT01172964|OTHER|laboratory biomarker analysis|Correlative studies
223565944|NCT06875518|PROCEDURE|BTLH with bilateral uterine artery ligation from its origin|The round ligament close to the pelvic side wall is first coagulated and separated before the procedure is applied. Further incision is then made in the peritoneum. The bladder fold is pulled downward by opening the anterior leaf of the wide ligament. It shows the ureters lateralized and the posterior leaf of the wide ligament. After that, the ureters' path is shown, the retroperitoneal area is revealed, and the location where the uterine artery leaves the iliac artery is seen.
223565945|NCT06875518|PROCEDURE|Conventional TLH|The conventional TLH technique involved division of the corneal pedicles and securing the uterine pedicles. Preoperative Preparation of bowel wasn't routinely done to improve enhanced recovery of patients. Antibiotic prophylaxis with 3rd generation cephalosporin and metronidazole was given one hour preoperatively. Obese patients received subcutaneous low molecular weight heparin and compression devices after surgery. Under general anesthesia, patients were placed in a Lloyd Davis position.
223565946|NCT06874517|OTHER|no intervention|no intervention
224045981|NCT00502489|PROCEDURE|Closed-loop sytem for5 weaning from mechanical ventilation|
224045982|NCT05261035|BEHAVIORAL|stretching exercises|For the stretching exercises group; the researchers explained to the women how to perform the stretching exercises through different visual materials like videos \& pictures, provided a demonstration of each step, and emphasized that they could perform this exercise at any comfortable position, standing, sitting, or dorsal.
224045983|NCT05261035|OTHER|thermotherapy|women were instructed to warm the water to 43-47 C° using a water thermometer or test it with the inner aspect of their wrists. They are also advised to avoid using too hot or too cold water. Then immerse their legs for 20 minutes in the warm water at a h
224045984|NCT03139708|DRUG|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
224045985|NCT03139708|DRUG|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
224045986|NCT03139708|DRUG|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
224045987|NCT02770443|DRUG|withdrawal|withdrawal of beta blocker and ACE inhibitors
224045988|NCT02770443|DRUG|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
224045989|NCT02451579|DRUG|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
224045990|NCT02451579|OTHER|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
223565947|NCT01638013|DRUG|Peficitinib|Oral Tablet
223565948|NCT07022392|OTHER|Technology-enhanced gender support platform|Technology-based platform to support parents
223565949|NCT07028645|DRUG|desmopressin melt form 120 μg|Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.
224045991|NCT00809419|DEVICE|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
224045992|NCT01852604|DRUG|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
223435078|NCT01172964|PROCEDURE|therapeutic conventional surgery|Surgery to resect the tumor
223435079|NCT01172964|BIOLOGICAL|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
223435080|NCT00053508|BIOLOGICAL|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
224045993|NCT01852604|DRUG|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
224141953|NCT05109819|RADIATION|Esophagus sparring radiotherapy treatment|A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.
224141954|NCT04811469|DRUG|CBP-174|CBP-174 oral solution, given once
223435081|NCT00053508|BIOLOGICAL|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
223435082|NCT04128891|DRUG|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
223435083|NCT00962936|DRUG|CT-011|CT-011
223435084|NCT03006263|PROCEDURE|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
223565950|NCT07028645|DRUG|Desmopressin lyophilisate (Melt)|Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.
223565951|NCT07028645|DRUG|Propiverine tablet|Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg
223565952|NCT04919889|OTHER|Exercise prescription|All individuals referred to the community-based Exercise on Prescription program
223740669|NCT05958407|DRUG|Placebo|After a loading dose under the skin (s.c.) at baseline, trial participants are administered a placebo dose every two weeks for 16 weeks
224141955|NCT04811469|DRUG|Placebo|Placebo oral solution, given once
224163554|NCT03188133|OTHER|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
224299828|NCT05748483|DRUG|Placebo for Topiramate|Oral Capsule
223435085|NCT03006263|PROCEDURE|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
223435086|NCT02003989|OTHER|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
223435087|NCT03241433|OTHER|High intensity interval training|exercise by use of stationary cycles
223435088|NCT03241433|OTHER|Moderate intensity continuous training|exercise by use of stationary cycles
223435089|NCT03241433|OTHER|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
224045994|NCT01852604|DRUG|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
224045995|NCT01852604|DRUG|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
223435090|NCT01483989|OTHER|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
224045996|NCT01852604|DRUG|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
224045997|NCT01852604|BIOLOGICAL|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
224045998|NCT01852604|OTHER|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
224045999|NCT02941926|DRUG|Ribociclib|Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
224046000|NCT02941926|DRUG|Letrozole|Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
224046001|NCT02941926|DRUG|Goserelin|Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
224046002|NCT02941926|DRUG|Leuprolide|Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
224046003|NCT02910765|DRUG|methylene blue|
224046004|NCT02910765|DRUG|ozone|
224046005|NCT02910765|OTHER|saline infusion|
224046006|NCT02910765|OTHER|oxygen|
224046007|NCT03217942|DRUG|NGF|Intramuscular injection
224141956|NCT03775772|PROCEDURE|Oral Health|"* test group will receive an dental hygiene program for one year~* control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
224141957|NCT03775772|PROCEDURE|Bite Force|"* test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~* control group will remain without such training"
224141958|NCT01632735|BEHAVIORAL|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
224299829|NCT06639854|PROCEDURE|Hematopoietic Cell Transplant|"Participants choices may include to receive standard post-transplant virus prevention with letermovir or other standard drugs without being part of this study. Participants may choose to receive other investigational therapy, if available.~These alternative treatments have risks and benefits that may be the same or different than those in this research study."
224299830|NCT06639854|DRUG|Letermovir|Given by PO
223435091|NCT00328094|DRUG|continuous intravenous insulin infusion|Tight glucose control versus standard of care
223435092|NCT06397989|DIETARY_SUPPLEMENT|Ready-to-use school food|80 grams of peanut paste-based food containing skim milk powder, cowpea, peanuts, vegetable oil, and multiple micronutrients
224141959|NCT00001906|BIOLOGICAL|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
223435093|NCT06397989|DIETARY_SUPPLEMENT|Standard meal|300ml of porridge made with rice/millet flour
223478504|NCT02939352|DEVICE|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
223478505|NCT02106507|DRUG|apalutamide|apalutamide, 240 mg/day, oral
223478506|NCT02106507|DRUG|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
223478507|NCT04069858|DRUG|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
223478508|NCT04227912|OTHER|Transversus abdominis plane block|Before surgery, Ultrasound-guided TAP block was performed preemptively to Group TAP patients.
223478509|NCT04227912|OTHER|Local anesthetic infiltration|Before surgery, Ultrasound-guided Local anesthetic infiltration to the surgical incision line was performed preemptively to Group Local patients.
223478510|NCT04227912|OTHER|Intravenous dexketoprofen|Before surgery, 50 mg intravenous dexketoprofen was performed preemptively to Group dexketoprofen patients.
223478511|NCT05522478|DEVICE|Fall risk|Fall risk, static postural balance and sensorimotor integration were assessed using the Biodex Balance System.
223478512|NCT05500937|DRUG|UDCA|UDCA vs. placebo together with statin in ASCVD patients
223478513|NCT02295137|PROCEDURE|Using pre-procedural CTA to guide advanced EVAR procedure|
223478514|NCT04796974|DEVICE|Cention|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques
223478515|NCT00312442|DRUG|Treatment with WST09 Vascular Photodynamic therapy|
223478516|NCT03371550|DRUG|Docetaxel|Induction chemotherapy
224141960|NCT04108013|DRUG|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
223435094|NCT05470855|BIOLOGICAL|Live attenuated varicella vaccine|The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm.
223435095|NCT02368210|DRUG|122-0551 Foam|Topical Foam
223435096|NCT02368210|DRUG|Vehicle Foam|Topical Foam
223435097|NCT00078949|BIOLOGICAL|rituximab|Given IV
223435098|NCT00078949|DRUG|cisplatin|Given IV
224046008|NCT00307333|DEVICE|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
224046009|NCT02537938|DRUG|NGP 555|
223435099|NCT00078949|DRUG|cytarabine|Given IV
224046010|NCT02768233|BEHAVIORAL|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
224046011|NCT04195035|DEVICE|Air-Q intubating laryngeal airway|Air-Q intubating laryngeal airway will be used for ventilation \& intubation through fiberoptic bronchoscope.
224046012|NCT04195035|DEVICE|Ambu-Aura intubating laryngeal mask|Ambu-Aura intubating laryngeal mask will be used for ventilation \& intubation through fiberoptic bronchscope.
224046013|NCT00698932|DRUG|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
224046014|NCT00698932|DRUG|Placebo|oral tablet, once daily for 24 weeks
224046015|NCT02445118|OTHER|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
224046016|NCT06131333|PROCEDURE|Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation|PCI was performed according to the general and local recommendations. The choice of DES among the new generation DES and the decision on procedure optimization belonged to the operator.
224046017|NCT02390479|OTHER|non surgical periodontal treatment|"1. SRP under local anaesthesia, in a total of four clinical visits~2. Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
224046018|NCT02232282|DEVICE|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
224046019|NCT02232282|DEVICE|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
224046020|NCT03812484|BEHAVIORAL|SCF Supervision|SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.
224046021|NCT03812484|BEHAVIORAL|Parole-as-Usual|Parolees are supervised under standard parole supervision practice in New Jersey
224046022|NCT05017220|OTHER|Nature-based sensory stimuli|A program based on stimulation using nature-based sensory stimuli will be implemented
223435100|NCT00078949|DRUG|dexamethasone|Given IV
223435101|NCT00078949|DRUG|gemcitabine hydrochloride|Given IV
223435102|NCT01142765|BIOLOGICAL|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
223435103|NCT01142765|BIOLOGICAL|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
223435104|NCT01142765|BIOLOGICAL|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
223478517|NCT03371550|RADIATION|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
223478518|NCT03371550|DRUG|Cisplatin|Induction chemotherapy
223478519|NCT02934685|RADIATION|hypofraction|70 Gy in 28 fractions over 5.6 weeks
223478520|NCT02934685|RADIATION|convention|80Gy in 40 fractions over 8 weeks
224046023|NCT05017220|OTHER|Control group intervention|An activity based on a placebo intervention will be implemented
224046024|NCT02426528|OTHER|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
223478521|NCT01715831|DRUG|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
224046025|NCT02201121|OTHER|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
223435105|NCT01142765|BIOLOGICAL|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
223435106|NCT01142765|BIOLOGICAL|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
224046026|NCT00905684|DRUG|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
224046027|NCT00905684|DRUG|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
224046028|NCT05948475|DRUG|Tinengotinib 8 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.
224141961|NCT04108013|DRUG|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
223435107|NCT04214405|PROCEDURE|fixation of tripodal zygomatic fractures|One point versus two point fixation of tripodal zygomatic fractures
223435108|NCT02441751|PROCEDURE|intra-operative blood loss|surgery in the urology and orthopedics
223435109|NCT06083545|BEHAVIORAL|App|The low-protein diet app introduces the perceived significant efficacy of low-protein diets for patients with chronic kidney disease.
223435110|NCT01290497|DRUG|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
223435111|NCT01290497|DRUG|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
223435112|NCT01290497|DRUG|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
223740670|NCT04506853|DEVICE|MED-EL Cochlear Implant System|Cochlear implant and audio processor
224046029|NCT05948475|DRUG|Tinengotinib 10 mg|Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.
224046030|NCT05948475|DRUG|Physician's Choice|For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.
224046031|NCT00000808|DRUG|Nevirapine|
224046032|NCT00908024|DRUG|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
224046033|NCT00908024|DRUG|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
224141962|NCT05228106|DIAGNOSTIC_TEST|[68Ga]-PSMA-617|The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
224141963|NCT02300428|DIETARY_SUPPLEMENT|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
224141964|NCT04742426|OTHER|WHO recommended PPE|Uses polycarbonate safety spectacles, fluid-resistant (Type IIR) surgical mask and disposable surgical gown. No head or foot cover.
224141965|NCT04742426|OTHER|Super-safe setup|Uses surgical cap, FFP3 respirator covered by surgical mask, face shield, whole-body suit (Tyvec), 3 pairs of gloves typed to suit sleeves and disposable foot cover.
224046034|NCT01766271|BEHAVIORAL|Health Coaching|biweekly health coaching for 5 months
224046035|NCT01766271|GENETIC|9p21|Genetic testing results of 9p21
224046036|NCT01766271|OTHER|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
224141966|NCT01199250|OTHER|Laboratory Biomarker Analysis|Correlative studies
224141967|NCT05685667|DEVICE|needless laser injector (Mirajet)|Mirajet injection was performed 2-3 passes until a total of 2cc of diluted PLA/HA solution was completely injected to the one half of the face.
224141968|NCT05685667|DEVICE|needle injection|For traditional method of needle injection, intradermal injection using multi-puncture/micro-papule technique was used. A series of injections at 0.5-1 cm apart was performed on one half of the face so that a total of 2cc of diluted PLA/HA solution was injected.
224141969|NCT03097796|DRUG|PUL-042|PUL-042 Inhalation Solution
224141970|NCT00601796|BIOLOGICAL|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
224141971|NCT00601796|DRUG|Cyclophosphamide|Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
223435113|NCT04647994|DIAGNOSTIC_TEST|SARS-CoV-2 serology|Serology test of SARS-CoV-2 for pregnant women
223478522|NCT01715831|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
223478523|NCT03052777|BEHAVIORAL|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
223478524|NCT03799861|OTHER|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
223435114|NCT03994757|BEHAVIORAL|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
223435115|NCT03994757|BEHAVIORAL|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
223435116|NCT01046357|DRUG|AZD7687|Single oral dose
223435117|NCT01046357|DRUG|Placebo|Single oral dose
223435118|NCT01153789|PROCEDURE|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
223435119|NCT01153789|OTHER|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
223435120|NCT00362531|DRUG|tacrolimus combined with prednisone|
223435121|NCT05477992|PROCEDURE|Endovascular embolization|Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
223435122|NCT06035939|BEHAVIORAL|Voice Crisis Alert V2|The mHealth self-management intervention consists of the following components: 1) condition-specific electronic educational materials; 2) pain/symptom monitoring and tracking; 3) health history information documentation; 4) medication tracking; 5) secure messaging with a provider; 6) functioning monitoring and tracking; and 7) transmission of health information (graphs with recorded pain and functioning histories) to a provider.
223435123|NCT06035939|BEHAVIORAL|Electronic educational materials|The control arm will receive enhanced usual care, which will consist of usual educational materials distributed at the clinic plus a version of the intervention (Voice Crisis Alert V2) that only includes the electronic educational materials.
223435124|NCT05279768|BIOLOGICAL|UC-MSCs|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
223740671|NCT05911399|DRUG|Tiratricol|Tiratricol (3,3',5-triiodothyroacetic acid) is available as 350 µg tablets for oral administration (suspended in water and, if needed, mixed with food) or by percutaneous endoscopic gastrostomy (PEG), nasogastric or jejunal tube.
224046037|NCT04919252|DRUG|Vedolizumab|"* Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks."
224046038|NCT06490341|DRUG|GP Regimen, Nimotuzumab, Sintilimab|gemcitabine,ciplatin, nimotuzumab, sintilimab
224046039|NCT02730052|DEVICE|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
224046040|NCT02730052|DEVICE|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
224046041|NCT01687140|DRUG|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
224046042|NCT01687140|DRUG|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
224046043|NCT04345770|PROCEDURE|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
224046044|NCT04345770|DRUG|SOX neoadjuvant or postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
224046045|NCT04345770|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
224046046|NCT00995475|DRUG|Fluticasone propionate|
224046047|NCT00995475|DRUG|Placebo|
224046048|NCT01655420|PROCEDURE|LASIK|Laser eye surgery
224046049|NCT06057584|BEHAVIORAL|somatosensory-motor integration training|Participants will use both hands to perform functional tasks requiring somatosensory discrimination to provide different somatosensory stimuli to facilitate motor control. The experimental group will receive somatosensory-motor integration training, 3-5 sessions a week, for a total of 15 sessions.
223435125|NCT05279768|BIOLOGICAL|Secretomes|Treatment with tablet (placebo) once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
223435126|NCT05279768|BIOLOGICAL|UC-MSCs and Secretomes|Treatment with tablet (placebo) once for 30 days, IV 0.3 million kg/bb UC-MSCs once, and nasal drop 0.5 ml/day (Secretomes) for 30 days.
223435127|NCT05279768|BIOLOGICAL|Control|Treatment with Metformin once for 30 days, IV placebo (NaCl 0.9%) once, and nasal drop 0.5 ml/day (growth medium) for 30 days.
223435128|NCT04787861|OTHER|motorized movement therapy|The study group received an aerobic exercise regimen using a motorized movement therapy device 3 times /week in addition to the same traditional program used with the control group.
223435129|NCT02309723|DEVICE|Beta amyloid imaging|
224141972|NCT00601796|DRUG|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
224046050|NCT06057584|BEHAVIORAL|pure somatosensory training|Participants will use the affected hand to perform somatosensory discrimination tasks, including limb position discrimination and object discrimination.The experimental group will receive pure somatosensory integration training, 3-5 sessions a week, for a total of 15 sessions.
224046051|NCT06057584|BEHAVIORAL|pure motor training|Participants will conduct bilateral task-oriented training, but the training task does not require somatosensory discrimination. Each round only uses the same target and target position to repeatedly practice the functional task movements, but the target or target position is different in different rounds. The experimental group will receive pure motor integration training, 3-5 sessions a week, for a total of 15 sessions.
224046052|NCT00243698|DRUG|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
224046053|NCT05755295|OTHER|horse therapy|equitherapy and hippotherapy once a week during 16 weeks
224046054|NCT00077051|DRUG|cisplatin|
224046055|NCT00077051|DRUG|cytochlor|
224046056|NCT00077051|DRUG|tetrahydrouridine|
224046057|NCT00077051|RADIATION|radiation therapy|
224046058|NCT03854929|DRUG|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
224046059|NCT03854929|DRUG|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
224046060|NCT05812040|DIAGNOSTIC_TEST|Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)|all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
224046061|NCT04173884|OTHER|Coaching|Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
224046062|NCT04173884|OTHER|Constructive Feedback|Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
224046063|NCT00474734|DEVICE|Intravascular ultrasound of the liver|
224046064|NCT02800070|BIOLOGICAL|Lentivirus Alpha-gal A transduced stem cells|
224046065|NCT03908320|OTHER|Menstrual Cycle Timing|Quit date is set to menstrual phase.
224046066|NCT03908320|OTHER|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
224046067|NCT03908320|DRUG|NRT Patch|NRT patch is provided
224141973|NCT01013896|BEHAVIORAL|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
224141974|NCT01013896|OTHER|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
224046068|NCT03908320|BEHAVIORAL|Cessation Counseling|Cessation counseling is provided
224046069|NCT06491082|DRUG|Cisplatin, Carboplatin, Paclitaxel, Docetaxel|Solid cancer Patients receiving any one drug or in combination
224046070|NCT03197857|BEHAVIORAL|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
224046071|NCT03197857|BEHAVIORAL|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
224046072|NCT03197857|BEHAVIORAL|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
224046073|NCT03197857|BEHAVIORAL|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
224046074|NCT02018198|DIAGNOSTIC_TEST|FebriDx|Point of Care Host Immune Response Test
224046075|NCT01665547|DRUG|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
224141975|NCT01414712|OTHER|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
224141976|NCT06518200|BEHAVIORAL|Individualised health recommentations|Individualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.
224141977|NCT06518200|BEHAVIORAL|General health recommendations|Recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.
224141978|NCT06518200|BEHAVIORAL|Individualised physical exercise program|Follow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.
224046076|NCT05449626|DIAGNOSTIC_TEST|Assessment|The Standardized Mini-Mental Test and Clinical Dementia Rating Scale will be administered by the physician to the healthy individuals with dementia to be included in the study.
223435130|NCT02534519|OTHER|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
223435131|NCT06342453|PROCEDURE|Art Therapy|Participate in CrA
223435132|NCT06342453|PROCEDURE|Discussion|Participate in art focus group, art-making
223435133|NCT06342453|OTHER|Media Intervention|Watch videos
223435134|NCT06342453|OTHER|Survey Administration|Ancillary studies
223435135|NCT04088708|OTHER|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
223435136|NCT04088708|OTHER|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
223435137|NCT02929251|DRUG|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
223435138|NCT02929251|DRUG|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
223565953|NCT07034014|DEVICE|Dressing|The dressing will be applied to intact skin on healthy volunteers participants to assess the self-adhesive properties of two investigational devices compared to a test specimen reference. The dressing will be worn for up to 14 days on a designated area on the health volunteers participants back.
223740672|NCT02249533|OTHER|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
224046077|NCT00560742|PROCEDURE|Control|Coronary artery bypass grafting without bone marrow cells injection
224046078|NCT00560742|PROCEDURE|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
224046079|NCT00560742|PROCEDURE|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
224046080|NCT02846350|BEHAVIORAL|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
224046081|NCT03044249|DRUG|MP-101|Capsules
224046082|NCT03044249|DRUG|Placebo|Capsules
224046083|NCT00515736|DRUG|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
224046084|NCT00515736|DRUG|Placebo|vehicle
224046085|NCT02369107|OTHER|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
224141979|NCT02449954|DRUG|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
224141980|NCT02449954|DRUG|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
224299831|NCT06080841|DIETARY_SUPPLEMENT|Curcumin|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin. They will be instructed to consume orally 1 capsule with breakfast for group 1, 1 capsule with each meal for group 3, and 2 capsules with each food for group 5.
223435139|NCT02929251|DRUG|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
223435140|NCT06346574|BEHAVIORAL|Experimental|Participants will receive access to health and wellness app and guide
223435141|NCT04511988|OTHER|Diagnostic Test|blood sample (20 ml) and biopsy
223435142|NCT05412095|OTHER|Ultrasound of the abdominal wall muscles|the measurements will be performed during inspiration and expiration to take into account variability during the respiratory cycle. The examination is performed bilaterally and comparatively and lasts between 3 and 5 minutes.
223435143|NCT05412095|OTHER|Ultrasound quadricipital|The examination is performed bilaterally and comparatively and takes between 3 and 5 minutes.
223435144|NCT05412095|OTHER|Ultrasound of the diaphragm|The examination is performed bilaterally and comparatively and takes between 5 and 10 minutes.
223740673|NCT02548520|OTHER|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
224141981|NCT02449954|DRUG|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
224141982|NCT01464463|BEHAVIORAL|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
224141983|NCT01464463|BEHAVIORAL|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
224046086|NCT02369107|OTHER|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
224046087|NCT03111485|DRUG|Sinemet CR|Capsule 250 mg / 50 mg taken at bedtime
224046088|NCT03111485|DRUG|Placebo oral capsule|Capsule taken at bedtime
224046089|NCT00955279|DRUG|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
224046090|NCT00955279|DRUG|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
224046091|NCT00955279|DRUG|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
224046092|NCT06474975|DEVICE|AURA 10 PET/CT|The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
224046093|NCT04057534|BEHAVIORAL|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
224046094|NCT04057534|BEHAVIORAL|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine.
224046095|NCT04057534|BEHAVIORAL|Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smoking cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities, metacognition and also inhibition."
224046096|NCT04057534|BEHAVIORAL|Standard therapy for TUD|"Behavioral: standard smoking cessation therapy for TUD in group therapy setting.~Patients who voluntarily submit to enter a qualified smokind cessation program will be examined in an out-patient setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy (one 1,5 hours group therapy per week). Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week."
224046097|NCT00110981|DEVICE|NB-UVB|Three times a week (TIW) for 12 weeks
224046098|NCT00110981|DRUG|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
224046099|NCT00110981|DRUG|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
224046100|NCT01166100|DRUG|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
224046101|NCT02383095|BEHAVIORAL|Art therapy|
224046102|NCT02383095|BEHAVIORAL|metacognitive therapy|
224046103|NCT03201913|DRUG|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
224141984|NCT01464463|BEHAVIORAL|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
224141985|NCT00699101|DEVICE|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
224141986|NCT02499341|DRUG|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
224141987|NCT02499341|DRUG|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
223435145|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|measurements performed bilaterally on a patient in a half-sitting position at 45° and in spontaneous ventilation
223435146|NCT05412095|OTHER|Ultrasound of the inter-costal muscles|In spontaneous ventilation, lying down, arms by the side of the body, palms up, head down
223435147|NCT06102044|DIETARY_SUPPLEMENT|Zinc Supplements|Dispersible zinc citrate tablets
223435148|NCT06102044|DIETARY_SUPPLEMENT|Placebo Supplements|Dispersible placebo tablets
224141988|NCT02475395|DEVICE|TRAK device|Use of TRAK to attain sperm concentration measurement
224141989|NCT01461512|DRUG|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
224141990|NCT01461512|DRUG|Placebo administration|NaCl isotonic
224141991|NCT02387619|DRUG|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
224141992|NCT02387619|DRUG|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
223435149|NCT03811210|BEHAVIORAL|portion size|"Smaller than normal portion size - the intervention is the main meal component size perceived as 'smaller than normal' that participants are provided with during lunch and dinner in the laboratory.~Small-normal portion size - the intervention is the main meal component size perceived as 'small-normal' that participants are provided with during lunch and dinner in the laboratory.~Large-normal portion size - the intervention is the main meal component size perceived as 'large-normal' that participants are provided with during lunch and dinner in the laboratory."
223435150|NCT06394830|DRUG|VNX001|Intravesical administration of VNX001
223435151|NCT05853289|OTHER|Maternal Opioid use Disorder Management and Care Resources (MOM CARE) in Custody|MOM CARE is a web-based implementation resource designed for jail staff to help the staff provide evidence-based, trauma-informed and patient-centered care and support to pregnant people with opioid use disorder in and leaving custody. MOM CARE's content will include medical guidance and best-practices from intake to discharge, reentry steps and recommendations, and implementation 'how to' content. There will be specific content for jail administrators, medical and custody staff. Content will be curated from existing resources regarding this topic with new original tools specific to pregnant people with OUD in jail.
223565954|NCT07032896|BEHAVIORAL|Nurse-led Patient Education|The training program will be implemented in line with patient needs determined by the researcher. In order to overcome this lack of information, existing research findings and evidence-based treatment guidelines were extensively reviewed. The training program will be based on the following guidelines. The program will start with a 30-minute individual training session on patients' self-efficacy level, self-care behaviors, medication and diet compliance processes. This training will be carried out in the hospital in accordance with the patient's plan. Discharged intervention group patients will then be interviewed by telephone six times over a period of three months, and two interviews will be scheduled for each of these monthly periods. In order to measure the impact of the intervention, data will be collected twice, before and after the training for the intervention group
223435152|NCT00128804|BEHAVIORAL|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
224046104|NCT03694613|OTHER|Placental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
224046105|NCT02632721|DRUG|Decitabine|
224046106|NCT02632721|DRUG|BI 836858|
223435153|NCT06277271|OTHER|E-cigarette|Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
223435154|NCT01565668|DRUG|AC220|oral
223435155|NCT00160225|DRUG|Daglutril|
223435156|NCT02895724|DRUG|Medical Oxygen|Hyperbaric oxygen therapy
223435157|NCT03613558|DRUG|Dexmedetomidine|Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia
223435158|NCT03613558|DRUG|Placebo|saline solution
223435159|NCT02918903|PROCEDURE|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
223435160|NCT02918903|PROCEDURE|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
223435161|NCT01947426|DIETARY_SUPPLEMENT|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
223565955|NCT07032701|OTHER|Best Practice|Undergo SOC non-adherent dressing wound care
223565956|NCT07032701|OTHER|Educational Intervention|Receive SNaP education
223565957|NCT07032701|OTHER|Educational Intervention|Receive SOC wound care education
224046107|NCT02221349|DEVICE|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
224046108|NCT02221349|DRUG|Sodium fluoride paste|Toothpaste used by subject
224046109|NCT02221349|DRUG|Stannous fluoride paste|Toothpaste used by subject
223435162|NCT01947426|DIETARY_SUPPLEMENT|Control (milk without DHA)|mothers consuming placebo product and their neonates
223435163|NCT06618430|OTHER|None (Observational Study)|None (Observational Study)
223565958|NCT07032701|OTHER|Electronic Health Record Review|Ancillary studies
223565959|NCT07032701|OTHER|Follow-Up Care|Attend SNaP device follow-up visits
223565960|NCT07032701|OTHER|Follow-Up Care|Attend SOC wound care follow-up visits
223740674|NCT00171223|DRUG|STI571|STI571 oral capsules or tablets.
224046110|NCT05380258|OTHER|stress ball|Pregnant women with 4-5 cm cervical dilatation were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes when their contractions came, and when the cervical opening was 6-8 cm, they were asked to tighten the ball for 5 seconds and relax for 2 seconds within 20 minutes.
224046111|NCT05380258|OTHER|chewing gum|Pregnant women with 4-5 cm cervical dilatation were asked to squeeze the ball for 5 seconds and loosen it for 2 seconds as soon as their contractions came and within 20 minutes, and when the cervical opening was 6-8 cm, they chewed gum again for 20 minutes.
224046112|NCT05997433|PROCEDURE|7days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*7days
224046113|NCT05997433|PROCEDURE|14 days bismuth quadruple|Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*14days
224141993|NCT02387619|DRUG|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
224141994|NCT02075749|DRUG|Triamcinolone Acetonide|
224141995|NCT02075749|DRUG|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
224141996|NCT01098838|DRUG|LCL161|
224141997|NCT04507620|DEVICE|cervical neck collar|devices used for cervical immobilization
223435164|NCT01276522|DRUG|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
223435165|NCT05900817|OTHER|antivet|A material used for micro abrasion of teeth
223435166|NCT05900817|OTHER|Oplsture|A material used for micro abrasion of teeth
223435167|NCT03570554|DRUG|Naproxen Sodium (Aleve, BAY117031)|660 mg daily for 3 days, 440 mg on the fourth day, over-encapsulated tablet, oral (Treatment A)
223435168|NCT03570554|DRUG|Acetaminophen ER|3900 mg daily for 3 days, 1300 mg on the fourth day, over-encapsulated extended release (ER) tablet, oral (Treatment B)
223435169|NCT03570554|DRUG|Celecoxib|200 mg daily for 3 days, 100 mg on the fourth day, over-encapsulated capsule, oral (Treatment C)
223435170|NCT03570554|DRUG|Placebo|Over-encapsulation capsule, 4 days, oral (Treatment D)
223435171|NCT03147300|BEHAVIORAL|Current routine practice|Current routine practice for the primary care management of LBP
224046114|NCT02113384|OTHER|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
224046115|NCT00544648|DRUG|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
224046116|NCT00544648|DRUG|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
224046117|NCT00544648|RADIATION|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
224046118|NCT00003784|DRUG|CHOP regimen|
224046119|NCT00003784|DRUG|cyclophosphamide|
223435172|NCT03147300|BEHAVIORAL|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:~1. Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~2. Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~3. Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~4. Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
224046120|NCT00003784|DRUG|doxorubicin hydrochloride|
224046121|NCT00003784|DRUG|prednisone|
223435173|NCT00801437|DRUG|Xalacom|Xalacom 1 drop into the affected eye daily
223435174|NCT04960852|OTHER|a single shade structurally colored universal resin composite|Omnichroma is a single shade composite that is claimed to have blending effect with the tooth color, thus eliminate shade matching procedures during restorative treatment
223435175|NCT00842998|DRUG|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
223435176|NCT02307084|PROCEDURE|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
223435177|NCT02107287|RADIATION|IMRT Technique|
223565961|NCT07032701|OTHER|Medical Device Usage and Evaluation|Undergo dNPWT with SNaP device
223565962|NCT07032701|PROCEDURE|Negative Pressure Wound Therapy|Undergo dNPWT with SNaP device
224046122|NCT00003784|DRUG|vincristine sulfate|
224046123|NCT00003784|RADIATION|tositumomab and iodine I 131 tositumomab|
224046124|NCT02694770|BIOLOGICAL|Neihulizumab Treatment|Monoclonal antibody
224046125|NCT02694770|BIOLOGICAL|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
224046126|NCT05529849|DRUG|TCMCB07|Subcutaneous injection of TCMCB07
224046127|NCT05529849|DRUG|Placebo|Matching subcutaneous placebo
224046128|NCT04204187|BEHAVIORAL|service learning|service learning for university students
224046129|NCT05744570|PROCEDURE|Epidural anesthesia|Regional anesthesia for labor pain
224046130|NCT01947452|BEHAVIORAL|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
224046131|NCT01947452|BEHAVIORAL|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
224046132|NCT04437160|DRUG|Epirubicin or Pirarubicin|Epirubicin 80-90mg/m2 IV or Pirarubicin 50mg/m2 IV, q21d\*4cycls
223435178|NCT05265156|OTHER|Plant based formula for children aged between 12 and 36 months|Daily intake of plant based formula for 3 weeks (400ml-600ml per day).
223435179|NCT03466125|PROCEDURE|Cardiac surgery|Retrospective cohort study
223435180|NCT01764724|BEHAVIORAL|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
223435181|NCT02523235|DRUG|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
223435182|NCT06607835|BEHAVIORAL|Mindful- compassion|Online mindful-compassion weekly for four weeks
223435183|NCT06607835|BEHAVIORAL|Mindful-compassion and cannabis suppositories|Cannabis suppositories and online mindful-compassion for vaginal pain
223565963|NCT07032701|OTHER|Photography|Ancillary studies
223565964|NCT07032701|OTHER|Questionnaire Administration|Ancillary studies
223435184|NCT05259384|PROCEDURE|Robotic pancreaticoduodenectomy|The Intervention of MIPD-ROB group
223435185|NCT05259384|PROCEDURE|Laparoscopic pancreaticoduodenectomy|The Intervention of MIPD-LAP group
223435186|NCT05259384|PROCEDURE|Robotic Distal Pancreatectomy|The Intervention of MIDP-ROB group
223435187|NCT05259384|PROCEDURE|Laparoscopic Distal Pancreatectomy|The Intervention of MIDP-LAP group
224046133|NCT04437160|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 IV, q21d\*4cycls
224046134|NCT01172405|DRUG|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
224046135|NCT01172405|DRUG|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
224046136|NCT04154423|OTHER|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
224046137|NCT04154423|OTHER|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
224046138|NCT05133401|DEVICE|Ultrasound-guided tracheal width measurement|Ultrasound measurements will be made with a 5-10 MegaHertz linear probe positioned in the horizontal plane at the midline of the anterior neck. After identifying the vocal cords as paired hyperechoic linear structures, the probe was moved caudally to visualize the cricoid arch. The transverse air column diameter was measured at the lower border of the cricoid cartilage.
224046139|NCT03689647|DEVICE|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
224046140|NCT04622189|DEVICE|Action observation training|"Integration of four main tools:~* PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~* MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~* EEG data will be collected during video observation using an Enobio wireless system integrated with the platform."
224046141|NCT00800423|DRUG|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
224046142|NCT00800423|DRUG|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
224046143|NCT03718663|OTHER|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
224046144|NCT03718663|OTHER|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
224046145|NCT03602274|DIAGNOSTIC_TEST|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
224046146|NCT03602274|DIAGNOSTIC_TEST|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
224046147|NCT03602274|OTHER|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
224046148|NCT01692691|DRUG|Dacarbazine|Dacarbazine IV - Day 1
224046149|NCT01692691|DRUG|Carmustine|Carmustine IV- Day 2
224046150|NCT01692691|DRUG|Neulasta|Neulasta SC - Day 3
224046151|NCT06013462|PROCEDURE|Descemet Membrane Endothelial Keratoplasty|DMEK (Descemet Membrane Endothelial Keratoplasty) is a surgical technique used to treat primary or secondary corneal endothelial decompensation.
224046152|NCT04993833|DEVICE|NPi-200 and NPi-300 pupillometers|Device which measures PLR.
224046153|NCT02907138|OTHER|Medical Yoga|
224046154|NCT02907138|OTHER|Treatment as Usual (physical therapy)|
224046155|NCT03698890|DEVICE|Network-based home blood pressure monitor|A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
224046156|NCT00267709|DRUG|Visilizumab|
223435188|NCT06514703|PROCEDURE|CT-Guided Genicular Nerve Ablation|This procedure involves using computed tomography (CT) imaging to guide the precise placement of a needle for the ablation of genicular nerves in the knee. The goal is to disrupt the pain signals caused by osteoarthritis, providing long-term pain relief. The intervention is performed under local anesthesia and is aimed at patients who have not responded adequately to conservative pain management strategies.
223435189|NCT06514703|PROCEDURE|Fluoroscopic-Guided Genicular Nerve Ablation|This procedure utilizes fluoroscopy to accurately guide the needle placement for the ablation of genicular nerves associated with osteoarthritis knee pain. The technique focuses on minimizing pain and improving functional mobility by disrupting nerve pathways that transmit pain signals. Like the CT-guided approach, it is intended for use in patients whose symptoms have not been sufficiently managed with non-invasive treatments.
223435190|NCT03415659|DRUG|HWH340 tablet|"1. single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~2. multiple-dose study conducted on oral HWH340 tablet BID. The DLTs evaluating period is 4 weeks and the safety evaluation period lasts till 4 weeks after drug withdrawal.~3. dose-expansion study conducted on oral HWH340 tablet BID in 2 to 4 dose groups. Patients with BRCA mutation OR HRD will be assigned to 2 cohort in each dose group."
223435191|NCT03479593|DIAGNOSTIC_TEST|CMR and OCT in NSTEMI patients with MVD|Lesions \>50% stenosis i patients with NSTEMI are examined by OCT. All patients will have CMR performed prior to angiography
224046157|NCT04787250|BIOLOGICAL|Phage Therapy|Phage will be administered based on patient's matching results.
224046158|NCT04787250|PROCEDURE|Two-Stage Exchange Arthroplasty|Performed per the study center's standard of care. No investigational products are used.
224046159|NCT02209337|DEVICE|SRS|
224046160|NCT04166383|BIOLOGICAL|Vascular Biogenics (VB)-111|1E13 or 0.7E13 VP via intravenous (IV) infusion on Day 1 of cycle 1 and continue every 6 weeks
224046161|NCT04166383|DRUG|Nivolumab|240 mg of nivolumab via intravenous (IV) infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
224046162|NCT05192538|DEVICE|Endoscopic endoloop pre-test treatment|A novel endoloop was inserted into the gastric cardia by forceps through the single-channel endoscopy. After adjustment of the endoloop's location and angle, it was anchored onto the edge of the gastric cardia with clip and another 1 or 2 clips were inserted to hold the opposite side of endoloop at about 1/2 circumference. Then the hook was connected with the endoloop, which was tighted by slight pulling together of all the clips.
224046163|NCT03346057|DRUG|Sugammadex 2 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Sugammadex 2 mg/kg for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
224046164|NCT03346057|DRUG|Sugammadex 4 mg/kg|Following administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 4 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
224046165|NCT03346057|DRUG|Sugammadex 16 mg/kg|Following administration of NMBA (Rocuronium) to achieve deep NMB, participants received a single i.v. bolus of Sugammadex 16 mg/kg for reversal of deep NMB. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
224046166|NCT03346057|DRUG|Neostigmine + Glycopyrrolate|Following administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants received a single i.v. bolus of Neostigmine (50 μg/kg; 5 mg maximum) and Glycopyrrolate (10 μg/kg; 1 mg maximum) for reversal of moderate NMB. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
224046167|NCT03346057|DRUG|Rocuronium|To achieve NMB, participants received steroidal NMBA Rocuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
224046168|NCT03346057|DRUG|Vecuronium|To achieve NMB, participants received steroidal NMBA Vecuronium Bromide administered via IV infusion and dosed according to participant body weight. NMBAs were concomitant medications used per label and at Investigator's discretion as an adjunct to general anesthesia.
224046169|NCT00680563|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
224046170|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
224046171|NCT00185250|DRUG|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
224046172|NCT00185250|DRUG|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
224046173|NCT00185250|DRUG|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
224046174|NCT01543386|DRUG|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
224046175|NCT03044886|DIETARY_SUPPLEMENT|vitamin D|Subjects took vitamin D or placebo
224299832|NCT06080841|DIETARY_SUPPLEMENT|Curcumin + Piperine|Patients will receive capsules with curcumin C3 (Sabinsa Corp, NJ, USA) containing 1g of curcumin additioned with 5 mg of piperine. They will be instructed to consume orally 1 capsule with breakfast for group 2, 1 capsule with each meal for group 4, and 2 capsules with each meal for group 6.
223435192|NCT02745691|OTHER|Surgery|Thoracic surgery for lung cancer
223740675|NCT03987893|DRUG|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
224046176|NCT00935545|BIOLOGICAL|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
224046177|NCT05373524|BIOLOGICAL|Biological analysis|Rheopheresis using plasma separation and plasma filtration, coupled to hemodialysis
224046178|NCT00984035|OTHER|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
224046179|NCT00984035|OTHER|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
224299833|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the general population
223435193|NCT02745691|OTHER|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
223435194|NCT02745691|OTHER|Targeted therapy|New targeted therapies for lung cancer
223435195|NCT02745691|OTHER|Immunotherapy|New immunotherapies for lung cancer
223435196|NCT02604550|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
223435197|NCT02604550|DRUG|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
223435198|NCT02604550|DRUG|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
223435199|NCT04742166|PROCEDURE|Reconstruction|Lateral gastrojejunal Terminolateral gastrojejunal
223435200|NCT03014713|DRUG|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
223435201|NCT03014713|DRUG|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
223435202|NCT03014713|DRUG|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
223435203|NCT04134065|DRUG|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration \<75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
223435204|NCT04134065|DRUG|Placebo oral capsule|the capsule contain nothing
223435205|NCT03906721|DRUG|Placebo|Sugar pill used to condition patients.
223435206|NCT03906721|DRUG|Oxycodone|An opioid used for analgesia.
223435207|NCT03906721|OTHER|Essential Oil|An aromatic oil used for conditioning.
223435208|NCT03165474|OTHER|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
223435209|NCT03165474|OTHER|Didactic health information|Didactic health information and resources by email and/or text
224046180|NCT00984035|OTHER|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
224046181|NCT03692572|DIETARY_SUPPLEMENT|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
224046182|NCT03692572|DIETARY_SUPPLEMENT|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
224046183|NCT01375335|DRUG|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
224046184|NCT05001451|BIOLOGICAL|GDX012 Suspension for IV Infusion|"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"
224046185|NCT02003014|DRUG|Pioglitazone|Pioglitazone Tablets
224046186|NCT01660451|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
224046187|NCT04645771|PROCEDURE|Questionnaires|Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
224046188|NCT03805009|DEVICE|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
223435210|NCT03844594|DRUG|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
223740676|NCT03987893|DRUG|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
224046189|NCT04697121|DIETARY_SUPPLEMENT|Combined Bergamot phytosome and Artichoke leaf dry extract|600 mg of Bergamot Phytosome and 100 mg of Artichoke leaf standardized dry extract. Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
223435211|NCT01004601|DRUG|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
223435212|NCT01004601|DRUG|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
223435213|NCT01488669|PROCEDURE|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
223435214|NCT01488669|PROCEDURE|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
224046190|NCT04697121|COMBINATION_PRODUCT|Placebo|Supplementation regimen was 2 daily tablets, one before lunch and one before dinner, for 8 continuous weeks.
224046191|NCT05216757|DRUG|Iguratimod|iguratimod, 25mg bid po.
224046192|NCT05216757|DRUG|placebo|placebo 1 tablet bid po.
224046193|NCT02690805|DEVICE|MR-compatible scinti-mammography (MRI-SMM) system|
224046194|NCT00499954|PROCEDURE|Microdialysis|
224046195|NCT00499954|DEVICE|Guardian RT|
224046196|NCT00499954|DEVICE|Glucoday S|
224046197|NCT06188169|PROCEDURE|Increasing the inspiratory pressure if atelectasis detected by US|The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
224046198|NCT05245019|BIOLOGICAL|cardamom|cardamom is used as a flavoring agent in foods as well as for treating various cardiovascular, gastrointestinal, and neural problems
224046199|NCT05245019|BIOLOGICAL|fennel|fennel is Known for its anti-inflammatory, anti-spasmodic, and analgesic properties, it is also widely used for treating gastroenteritis and indigestion.
224046200|NCT00916630|DRUG|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
224299834|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_cirrhosis|A neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population with liver cirrhosis
224299835|NCT06140823|OTHER|Liver Risk Computation Model (LIRIC)_no_cirrhosis|neural network model (LIRIC-NN) and a logistic regression model (LIRIC-LR) that use routinely collected EHR data to stratify individuals into HCC risk groups for the population without liver cirrhosis
224299836|NCT04848038|BEHAVIORAL|Exercise|Standard public health exercise recommendations
223435215|NCT00303212|OTHER|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
223435216|NCT00112281|DRUG|Tilarginine Acetate Injection intravenous infusion|
224046201|NCT04515069|PROCEDURE|traditional technique of tooth preparation|"Depth cutter wheels of predetermined depths (Komet, Germany) were used to perform the preparation directly on the tooth structure.~Depth cuts were performed on the labial surface using depth cutter wheels (Komet, Germany) with radius of 0.3 mm and 0.5 mm which is directly related to the thickness of the laminate veneers in the cervical and incisal one thirds respectively. Then islands of tooth structure between depth orientation grooves were removed.~Proximal reduction:~The interproximal reduction was completed just labial to the contact areas using a round end tapered diamond stone (Mani, Japan), and polishing was performed using polishing strips (Sof-Lex, 3M ESPE, Seefeld, Germany).~Incisal reduction:~Vertical depth grooves were created. Then, the round end tapered diamond stone (Mani, Japan)was used to create 1.5 mm incisal butt joint preparation.~Then, finishing and polishing of tooth preparation was performed."
224046202|NCT04515069|PROCEDURE|aesthetic preevaluative temporary technique for tooth preparation|"The data obtained from digital smile design was used for construction of the diagnostic wax-up. The wax-up was then be transferred to the mouth using a silicone index, creating the aesthetic pre-evaluative temporary (APT). The APT was tested esthetically and functionally. Once approved by the operator and the patient, tooth preparation was performed through the APT. Depth cuts were performed similar to those performed in the traditional preparation with the difference of being prepared on the aesthetic pre-evaluative temporary instead of directly on the dental structure. Using tapered stone with round end (Mani, Japan), islands of tooth structure between depth orientation grooves were removed.~Proximal reduction, Incisal reduction Finishing and polishing of tooth preparation were carried out using the same technique as in the Group T with the difference of being performed through the APT, resulting in minimal tooth preparation"
224046203|NCT01387919|BEHAVIORAL|Prolonged fasting|48 hours of fasting
224046204|NCT04998487|DRUG|LY3471851|Administered SC.
224046205|NCT03920722|DRUG|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
224046206|NCT03920722|DRUG|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
224046207|NCT02210377|OTHER|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
224046208|NCT02210377|OTHER|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
224046209|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
224046210|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
224046211|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
224046212|NCT02061098|DIETARY_SUPPLEMENT|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
224046213|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
224046214|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
224046215|NCT02061098|DIETARY_SUPPLEMENT|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
224046216|NCT02061098|DIETARY_SUPPLEMENT|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
223435217|NCT04053010|BIOLOGICAL|Sabin-IPV and DTaP|Sabin-IPV +DTaP at the age of 3/4/5 months old respectively
223435218|NCT04053010|BIOLOGICAL|Sabin-IPV|Sabin-IPV only at the age of 3/4/5 months old respectively
223435219|NCT04053010|BIOLOGICAL|DTaP|DTaP only at the age of 3/4/5 months old respectively
223435220|NCT00000710|DRUG|Didanosine|
223435221|NCT02962323|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
223435222|NCT02962323|DRUG|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
224141998|NCT05675891|OTHER|Supplemental Feeding System Group|The body weight is measured in the morning fasting on the day when oral feeding is decided, 3 feeding between 08-16:00 are carried out with the supplemental feeding system, The amount of food prepared is recorded, Heart rate, oxygen saturation, respiratory rate and early feeding skill score are recorded before, during and after feeding, When the feeding is finished, the total amount of food taken by the baby and the feeding time are recorded, The rate of food intake (%) and the amount of food received per minute are calculated and recorded, Infants who can take 80% of the amount of food given at each meal by being fed orally for 8 meals two days in a row are considered to have switched to full oral feeding.
223435223|NCT00240955|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
223740677|NCT03786757|DRUG|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
223740678|NCT03199300|DRUG|Anthracyclines|Chemotherapy regimen containing anthracyclines.
224299837|NCT05287347|DIAGNOSTIC_TEST|Blood Specimen|"Blood samples will be collected from study participants at one time-point in the study, for the following:~1. tumor markers CEA and CA 19-9: 2 ml blood will be collected.~2. glycomics: 0.5 cc blood will be collected~3. ctDNA: 20 cc blood will be collected"
224046217|NCT00248846|BEHAVIORAL|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
224141999|NCT02178176|BEHAVIORAL|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
224142000|NCT02178176|BEHAVIORAL|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
224142001|NCT05237180|OTHER|spatial localisation training|8 spatial localization training sessions MBAA and SSQ tests before and after training sessions.
224142002|NCT03730194|DIETARY_SUPPLEMENT|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
224142003|NCT03730194|BEHAVIORAL|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
224299838|NCT06235307|OTHER|motivational interviewing|Upon entry into the program, all patients will be seen for an assessment of their physical condition at the premises of Amiens Métropole by a teacher in adapted physical activity (APA) in order to be assessed and directed to a club or a approved associations. The EM group will also benefit from a motivational interview at 0 and 3 months by a doctor trained in the technique. The entire cohort will complete the SF12 (perception of quality of life) and IPAQ (current level of physical activity) questionnaires at 0 and 6 months during the usual appointments with the APA teacher.
224299839|NCT05422703|DEVICE|Kinesio tape|Skin-colored Kinesiology Tape (ARES tape,5 cm×5 m) is waterproof tape is made of 100% cotton,applied in the shape of a fan strip, waterproof. The width is 5 cm and thickness of 0.5 mm (5 cm×5 m ).This tape is sticking with a small stretch (about 15%).
224299840|NCT05422703|OTHER|Gauze pack|Place gauze pack over surgical site for one hour after surgery.
224046218|NCT05426759|DEVICE|Pulsed Field Ablation of epicardial Ganglionated Plexi.|Using Pulsed Field Ablation (PFA), delivered via an epicardial catheter, to selectively ablate the ganglionated plexi (GP) on the epicardial surface of the heart.
224046219|NCT05073887|PROCEDURE|Current Targets|blockade and radio frequency stimulation of genicular nerves
224046220|NCT02456662|DRUG|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
224046221|NCT02456662|DRUG|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
224046222|NCT04574479|PROCEDURE|Supra-inguinal fascia iliaca compartment block|"Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.~Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump"
223435224|NCT03240224|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
224299841|NCT05422703|DEVICE|ice pack|Ice packs will be applied for 6 hours after surgery in all patients
223435225|NCT03240224|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
223435226|NCT00634595|DRUG|E10A|E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
223435227|NCT00634595|DRUG|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
223435228|NCT00634595|DRUG|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
223435229|NCT02769039|OTHER|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit \& sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
223435230|NCT02456038|DRUG|Asfotase Alfa (ALXN1215)|
223435231|NCT02570139|DEVICE|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
223435232|NCT02570139|DEVICE|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
223435233|NCT00693602|DRUG|Erwinase|Chemotherapy
223435234|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
223435235|NCT02156375|DRUG|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
223435236|NCT00002756|BIOLOGICAL|filgrastim|
223435237|NCT00002756|DRUG|asparaginase|
223435238|NCT00002756|DRUG|cyclophosphamide|
223435239|NCT00002756|DRUG|cytarabine|
223435240|NCT00002756|DRUG|daunorubicin hydrochloride|
224046223|NCT04574479|DRUG|Multimodal analgesia and PCA morphine pump|Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
224046224|NCT05141123|PROCEDURE|Complex Endovascular Aortic Procedures treated by Preloaded Fenestrated Stent-graft Designs for|Evaluate the outcomes of the preloaded stent-graft design (PLD) in the routine treatment of para-renal and thoraco-abdominal aneurysms
224046225|NCT02407522|DIETARY_SUPPLEMENT|Black rice|They asked to keep their normal life style during intervention
223435241|NCT00002756|DRUG|etoposide|
223435242|NCT00002756|DRUG|leucovorin calcium|
223435243|NCT00002756|DRUG|mercaptopurine|
223435244|NCT00002756|DRUG|methotrexate|
223435245|NCT00002756|DRUG|prednisone|
223435246|NCT00002756|DRUG|therapeutic hydrocortisone|
223435247|NCT00002756|DRUG|vincristine sulfate|
224046226|NCT02407522|OTHER|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
223435248|NCT02689882|DIETARY_SUPPLEMENT|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
223565965|NCT07034144|OTHER|Drop Table Technique|"The Drop Table Technique is a chiropractic intervention that utilizes a segmented treatment table with adjustable sections that can be elevated slightly and then dropped.~During the procedure, a high-velocity, low-amplitude (HVLA) thrust is applied while the specific segment of the table drops slightly in coordination with the thrust.~This technique aims to reduce the resistance experienced during the adjustment and to enhance the mechanical effect on targeted spinal joints.~In this study, the Drop Table Technique will be specifically applied to the cervical spine to address mechanical neck pain.~All applications will be performed by a licensed chiropractor using standardized positioning and adjustment protocols to ensure consistency across sessions."
223565966|NCT07034144|OTHER|Cervical Spine Manipulation|"Cervical spinal manipulation (SM) will be applied with the participant supine to restrictions found on motion palpation, following the technique described by Bergmann and Peterson. The participant's head and neck will be simultaneously rotated and laterally flexed over the contact point-specifically, the posterior supramastoid groove or zygomatic arch (C0-C1), the posterior aspect of the transverse process (C1-C2), or the posterior articular pillar of superior vertebrae (C2-C7)-to the end of passive range of motion (ROM).~Subsequently, a high-velocity, low-amplitude thrust will be delivered in the direction of restricted movement. Participants with greater ROM restriction in the lateral plane will receive more laterally-to-medially directed thrusts. Participants with more restriction in rotation will be given thrusts in the direction of restricted axial rotation, and those with more restriction in extension will receive more anteriorly directed thrusts."
223565967|NCT06718426|DRUG|Fertitonex capsule|Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.
223565968|NCT06718426|DRUG|Placebo Oral Capsule|placebo oral capsule. the dose is twice daily for 3 months
224046227|NCT04923048|BIOLOGICAL|GB261|Drug:GB261 IV, participants with B-cell NHL or CLL will receive GB261 via IV infusion weekly for the first two cycles(1cycle=21days), followed by Q3W from C3 and afterwards in given doses until progression disease or other situations specified in the protocol, whichever comes earlier.
224046228|NCT06102603|OTHER|the biobased polyester cast|long arm casting
224046229|NCT06102603|OTHER|the synthetic fiberglass cast|long arm casting
224046230|NCT03426423|OTHER|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB\_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
224046231|NCT03426423|OTHER|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
223435249|NCT06073275|DIETARY_SUPPLEMENT|Beetroot juice ingestion|Beetroot juice ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
223435250|NCT06073275|DIETARY_SUPPLEMENT|Placebo ingestion|Placebo ingestion was randomly administered 3 h before the start of the test to the participants in two assessment sessions with a one-week washout between both sessions.
223435251|NCT05676476|DRUG|Antihypertensive treatment|Antihypertensive treatment to goal of less than 140/90 mmHg
223435252|NCT00956631|PROCEDURE|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
223435253|NCT05939791|OTHER|Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518|The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.
223435254|NCT05939791|OTHER|Physical exercise|The individual online (MS Teams) training program for PALL in the length of 8 weeks included 25-45 minutes of moderate-to-vigorous physical exercise, twice a week, under the supervision. The structure of the exercise program was developed to improve endurance and gradually rebuild muscular strength. The exercise program's structure was created to increase endurance and gradually rebuild muscular strength. Large muscle groups were the focus of training sessions, which also placed a strong emphasis on proper technique. A strength exercise squat was given consideration as a movement required to meet necessities. (e.g., sitting or standing). Each exercise consisted of between 10 and 15 repetitions in each series and 2 to 3 series overall.
223435255|NCT00033657|DRUG|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
223435256|NCT00033657|DRUG|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
223435257|NCT00033657|DRUG|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
223435258|NCT00033657|PROCEDURE|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
223435259|NCT00033657|RADIATION|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
223565969|NCT07034534|BEHAVIORAL|Three typical yoga poses|duration for both group includes 10 mins 5 sec, rest period will be included
223565970|NCT07034534|BEHAVIORAL|Deep breathing technique|duration for both group includes 10 mins 5 sec, rest period will be included
224046232|NCT04563000|DRUG|Vitamin C|Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days
223565971|NCT06896812|DEVICE|The app-based treatment consists of a combination of physical exercise, graded activity, and pain journaling.|"The app-based treatment consists of a combination of physical exercise, graded activity, and pain journaling. The app will be installed on the participant's mobile device. The app will be used anonymously, and patients use their unique study code to activate the app.~The content and user-interface of the app-based treatment were developed in collaboration with healthcare professionals for relevant medical specialties, including orthopedic surgery, neurosurgery, neurology, physiotherapy, and rehabilitation. The content is based on expert opinion from these fields. Additionally, there is scientific evidence indicating that the treatments used within the app are safe and effective. The app has been tested for usability and functionality by both professionals and laypersons, including individuals with back pain."
223565972|NCT06897319|DEVICE|High-Flow Tracheal Therapy|Device: Airvo 2 (Fisher \& Paykel Healthcare) Settings: Flow rate start at 40L/min and will be adapted according to tolerance; temperature aimed at 37°C or 34°C according to tolerance, FiO₂ set (if needed) according to SpO2 target values.
223435260|NCT03994744|DRUG|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
223565973|NCT06897423|OTHER|Education|"Midwifery students in the intervention group of the study will receive 8 weeks of disaster midwifery training. The training content will be covered in 8 main categories: safe prenatal, delivery and postnatal period, women's reproductive health services, family planning, immunization, violence and sexually transmitted infections and newborn and infant care, reproductive health in disadvantaged groups, emergency obstetric situations."
223565974|NCT06896370|OTHER|observational study|By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
223565975|NCT06896552|DIETARY_SUPPLEMENT|Ketogenic diet|Ketogenic Diet as an Adjunct to Immunotherapy: Unlike many trials focused on chemotherapy or targeted therapies, this study specifically investigates the synergistic effects of the ketogenic diet with immune checkpoint inhibitors (ICIs), a promising approach for enhancing immunotherapy efficacy. The diet's high-fat, low-carbohydrate regimen is designed to shift metabolism towards ketone bodies and fatty acid utilization, potentially modulating immune responses and tumor immunogenicity in a way that standard diets do not.
223565976|NCT06897384|DRUG|Saline (NaCl 0,9 %)|The control group involves only adding 50ml of normal saline to a 50ml syringe, without any labels to ensure identical appearance, and the method of administration and dosage are the same with vitamin C group.
223565977|NCT06897384|DRUG|Vitamin C (Ascorbic Acid)|Vitamin C at dose of 500mg/kg/24h, 2g/h
223565978|NCT06897345|PROCEDURE|transversus abdominis plane block|The transversus abdominis plane (TAP) block is a regional anesthesia technique used primarily to provide pain relief for patients undergoing surgery in the abdominal region. The TAP block targets the nerves that supply sensations to the skin and muscles of the abdominal wall.
224046233|NCT04563000|DRUG|Placebo|0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
224046234|NCT03445260|OTHER|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
224046235|NCT03445260|OTHER|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
224046236|NCT00407654|DRUG|aflibercept|Given intravenously
224046237|NCT00074581|DRUG|Atazanavir|300 mg taken orally once daily
224046238|NCT00074581|DRUG|Didanosine|400 mg taken orally once daily
224046239|NCT00074581|DRUG|Efavirenz|600 mg taken orally once daily
224046240|NCT00074581|DRUG|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
224046241|NCT00074581|DRUG|Lamivudine|300 mg taken orally once daily
224046242|NCT00074581|DRUG|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
224046243|NCT00074581|DRUG|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
224046244|NCT00074581|DRUG|Stavudine|Dosage depends on weight
224046245|NCT00074581|DRUG|Tenofovir disoproxil fumarate|300 mg taken orally once daily
224046246|NCT00074581|DRUG|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
224046247|NCT02926469|DEVICE|Virtual Reality|Using Virtual Reality during labor
224046248|NCT00002355|DRUG|Fomivirsen sodium|
224046249|NCT04733781|DRUG|Tumescent Lidocaine and Epinephrine|Subcutaneous injection of a relatively large volume (125ml to 250ml) of a relatively dilute solution of lidocaine (1gm/L) and epinephrine (1mg/L or 2mg/L).
224046250|NCT04411953|DRUG|Haloperidol Tablets, Mylan Pharmaceuticals Inc.|single dose, 2 mg Haloperidol tablet
224046251|NCT04411953|DRUG|Haloperidol Tablets, Cycle Pharmaceuticals Ltd|single dose, 2 mg Haloperidol tablet
224046252|NCT04087954|BEHAVIORAL|Stigma reduction program|"Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community."
223435261|NCT03994744|DRUG|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
223435262|NCT03595358|DIAGNOSTIC_TEST|Ellume Home Flu Test|The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.
223435263|NCT03595358|DIAGNOSTIC_TEST|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.
223565979|NCT06897345|PROCEDURE|rectus sheat block|The rectus sheath block is a type of regional anesthesia used primarily for pain management in the abdominal area. It involves injecting local anesthetic into the rectus sheath, which is the fibrous sheath that envelops the rectus abdominis muscle. This block targets the lower intercostal nerves as they traverse through the sheath, thereby providing analgesia to the anterior abdominal wall.
223565980|NCT06817512|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 (MK-7) 300µg/d for 2 year
224046253|NCT02794077|DRUG|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
224046254|NCT03613662|DRUG|SP-102|Injection
224046255|NCT04733339|BEHAVIORAL|Secondary Prevention|behavioral changes in dieting and exercising up to one year after clinical discharge
224046256|NCT03142438|DEVICE|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
224046257|NCT06306079|DEVICE|Lateral Wedge insole|Insoles with lateral wedges are placed in patients' shoes to control biomechanical knee loading on the medial side of the knee. Insoles with lateral wedges are designed to be thinner on the inside (medially of the foot) and thicker on the outside (laterally of the foot) to relieve knee biomechanical loading parameters.
224046258|NCT05955404|OTHER|Kangaroo mother care|This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.
224046259|NCT01512563|DEVICE|Biliary stent|palliative treatment for malignant patients
224046260|NCT04411628|DRUG|LY3819253|Administered IV.
224046261|NCT04411628|DRUG|Placebo|Administered IV.
224046262|NCT01372722|DEVICE|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
224046263|NCT01372722|DEVICE|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
224046264|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with GABA before ileostomy closure surgery|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of a solution with 3000 mg of GABA diluted in 100 ml of 0.9% physiological saline.
224046265|NCT05905393|DIETARY_SUPPLEMENT|preoperative stimulation of the efferent loop with only physiological saline|Foley catheter No.14 Ch connected to an infusion set was introduced through the defunctioned bowel to allow the slow infusion, for 10-20 minutes, of 100 ml of 0.9% physiological saline.
224046266|NCT00732251|DRUG|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
223435264|NCT03595358|DIAGNOSTIC_TEST|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT\_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
223435265|NCT03595358|DIAGNOSTIC_TEST|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
223565981|NCT06817512|DIETARY_SUPPLEMENT|Zinc|Zinc, 15mg/d for 2 year
223565982|NCT06817512|DIETARY_SUPPLEMENT|Placebo|Placebo for 2 year
224046267|NCT01034540|DRUG|POM3|4 g/day
224046268|NCT01034540|DRUG|Placebo|matching placebo capsule, 4 g/day
224046269|NCT00351416|DRUG|Letrozole|Letrozole 20 mg orally one time
223435266|NCT04093492|OTHER|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
223435267|NCT04093492|OTHER|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
223565983|NCT05539963|DRUG|STIMULAN VG|Participants will receive STIMULAN VG via implantation during debridement surgery on Day 1.
223565984|NCT05539963|DRUG|Systemic Antibiotics|Participants will receive Antibiotics per site-specific requirements.
223565985|NCT06896591|PROCEDURE|Deep posterior post gluteal nerve block|One injection with ultrasound guidance injection of 5, 10 or 15 mL of naropeine 0.35 % Procedure : injection below the piriformis muscle in front of the head of the femur.
223565986|NCT06896955|OTHER|PMR+VR Education|PMR and VR education
223565987|NCT06896955|OTHER|PMR Education|PMR education
223740679|NCT03199300|DRUG|Trastuzumab|Systemic treatment including trastuzumab.
224046270|NCT00351416|DRUG|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
224046271|NCT00526981|OTHER|Prone position|Prone position during spontaneous breathing.
223435268|NCT02698644|DRUG|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
223435269|NCT06412458|BIOLOGICAL|IM83 CAR-T Cells|IM83 CAR-T Cells, 5×10\^8 cells, 1×10\^9 cells, and 2×10\^9 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D- 3), determined by tumor burden at baseline. Drug: Fludarabine Recommendation: 30 mg/m\^2 (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 300 mg/ m\^2 (D-5\~D-3), determined by tumor burden at baseline.
223435270|NCT04970017|RADIATION|Cardiac MRI, Echocardiography|Magnetic resonance imaging, Echocardiography
223435271|NCT00329641|DRUG|carboplatin|Given IV
223435272|NCT00329641|DRUG|paclitaxel|Given IV
223435273|NCT00329641|DRUG|sorafenib tosylate|Given orally
223435274|NCT05765253|DEVICE|Scorpion Portal Vein Access Kit|Portal Vein Access with Scorpion or Scorpion X set
224046272|NCT03859713|BEHAVIORAL|Physical Therapy|Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.
224046273|NCT03859713|BEHAVIORAL|Cognitive Behavioral Therapy|Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction
224046274|NCT03859713|BEHAVIORAL|Mindfulness|Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
224046275|NCT03772470|OTHER|1X airtime incentive|An incentive given in the form of airtime
224046276|NCT03772470|OTHER|2X airtime incentive|An incentive given in the form of airtime
224046277|NCT03772470|OTHER|Lottery airtime incentive|An incentive given in the form of airtime
223435275|NCT05765253|DEVICE|Cook Transjugular Liver Access Set|Portal Vein Access with Ring or Rosch-Uchida set
223565988|NCT06888869|OTHER|Other: Clinical rehabilitation group|Rehabilitation training for twice a week, total 12 weeks in hospitals.
223565989|NCT06888869|OTHER|Other: Home-based rehabilitation group|Rehabilitation training for twice a week, total 12 weeks at home.
224046278|NCT02803853|BEHAVIORAL|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
224046279|NCT05922020|OTHER|Oxygen gas|Administration of Oxygen by inhalation
224142004|NCT00845494|BEHAVIORAL|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
224142005|NCT00115765|DRUG|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
223435276|NCT05765253|PROCEDURE|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Transjugular Intrahepatic Portosystemic Shunt (TIPS)
224299842|NCT05422703|PROCEDURE|Manual therapy|passive and active range of motion, stretching exercises, resistive mouth exercises, mobilization exercises and coordination exercices.
224299843|NCT05422703|DRUG|Analgesic|NSAIDs like ibuprofen (600-800 mg) or declophenac sodium (50-150 mg) 3 times a day
223435277|NCT03375515|DRUG|Hydromorphone|"1. For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~2. For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydromorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."
223435278|NCT03375515|DEVICE|PCA pump|"1. For opioid-intolerant patients: initial dose 0.5 mg intravenous hydromorphone.~2. For opioid-tolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."
223435279|NCT02945254|DEVICE|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
223435280|NCT03161886|DEVICE|Pan-enteric Capsule Endoscopy (PCE)|Second generation of colon capsule endoscopy (Medtronic)
223435281|NCT02709681|OTHER|Physician standard-of-care in SCD patients|
223435282|NCT05988710|DRUG|Buccal Buprenorphine 300 mcg|buprenorphine for 300mcg buccal administration
223435283|NCT05988710|DRUG|Buccal Buprenorphine 600 mcg|buprenorphine for 600mcg buccal administration
223435284|NCT05988710|DRUG|Buccal Buprenorphine 900 mcg|buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
223435285|NCT05988710|DRUG|Buccal Placebo|Placebo for buccal administration
223435286|NCT05988710|DRUG|Oral Placebo|Placebo for oral administration
223435287|NCT05988710|DRUG|Oral immediate-release oxycodone 10mg|Immediate-release oxycodone for 10 mg oral administration
223565990|NCT00318279|DEVICE|Surgical simulator to practice vascular anastomosis|
223565991|NCT06889428|DIAGNOSTIC_TEST|CMR|No CMR
223565992|NCT01585779|DEVICE|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
223565993|NCT01585779|DEVICE|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
223565994|NCT01846299|OTHER|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
223565995|NCT01846299|DRUG|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
223565996|NCT03559517|BIOLOGICAL|Ontamalimab|Subcutaneous injection of ontamalimab will be administered using a prefilled syringe.
223740680|NCT03199300|DRUG|Cisplatin|Chemotherapy including cisplatin.
223435288|NCT05988710|DRUG|Buccal Buprenorphine 450mcg|buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
224046280|NCT03519867|DRUG|MK-8616|MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
223435289|NCT02424864|OTHER|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
223435290|NCT00150306|DRUG|Zoloft (Sertraline)|
223435291|NCT03422159|DRUG|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
224046281|NCT03519867|DRUG|Zemuron®|Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
224046282|NCT03653221|OTHER|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
223435292|NCT03422159|DRUG|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
223435293|NCT03422159|DRUG|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
223435294|NCT03422159|DRUG|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
223435295|NCT03186859|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB) surgery|RYGB operation using surgeons' standard technique
223565997|NCT03559517|OTHER|Placebo|Subcutaneous injection of placebo matched with ontamalimab will be administered using a prefilled syringe.
223565998|NCT06422221|DRUG|Clindamycin|Receiving 600 mg oral Clindamycin 1 hour before general anesthesia and before any dental manipulation
223565999|NCT06422221|DRUG|Doxycycline|Receiving 100 mg oral Doxycycline 1 hour before general anesthesia and before any dental manipulation
223435296|NCT03186859|PROCEDURE|Sleeve Gastrectomy (SG) surgery|SG surgery using surgeons' standard technique
223435297|NCT02348359|DRUG|X-82|
223435298|NCT02348359|DRUG|Anti-VEGF|
223435299|NCT02348359|DRUG|Placebo|
223435300|NCT04060459|DRUG|Paclitaxel-binding albumin|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
223566000|NCT04974827|DRUG|Camrelizumab|200mg/3weeks
223566001|NCT04974827|DRUG|Cisplatin or Carboplatin|Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
224046283|NCT03653221|OTHER|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
224142006|NCT00115765|DRUG|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
224142007|NCT00115765|DRUG|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
224142008|NCT00115765|DRUG|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
224142009|NCT00781248|DEVICE|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
224142010|NCT06179030|DIAGNOSTIC_TEST|serum samples|The serum samples were taken from the patients at the 3rd month (switch point)
224142011|NCT06179030|DRUG|dexamethasone implant versus ranibizumab|dexamethasone implant versus ranibizumab will be studied as a secondary outcome
224142012|NCT03014440|DRUG|Cannabidiol|
224142013|NCT05751057|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance|All NSTEMI patients will undergo to CMR before invasive coronary intervention.
223435301|NCT02155075|DEVICE|MIRA device imaging|MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
223435302|NCT02631070|DRUG|Luspatercept|
223435303|NCT02631070|OTHER|Placebo|
223435304|NCT02732236|OTHER|Rituximab|Cohort observation study
223435305|NCT06731153|DRUG|Ivarmacitinib|a selective Janus kinase 1 inhibitor
223435306|NCT06731153|DRUG|Camrelizumab (SHR-1210)|a humanised anti-programmed death-1 (anti PD-1) antibody
223435307|NCT06731153|DRUG|Eribulin|Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.
223566002|NCT01730326|DRUG|Paracetamol|1000 mg
223566003|NCT01730326|DRUG|Dexketoprofen|50 mg
223566004|NCT02251561|DEVICE|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
223566005|NCT02251561|DEVICE|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
223566006|NCT02251561|DEVICE|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
223566007|NCT00725192|BEHAVIORAL|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
223566008|NCT00725192|BEHAVIORAL|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
223566009|NCT02614170|OTHER|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
223566010|NCT04208386|DRUG|JNJ-73763989|JNJ-73763989 will be administered SC under fasted condition.
223566011|NCT01027234|DRUG|AZD8418|Single oral dose
223566012|NCT01027234|DRUG|Placebo|single oral dose
223566013|NCT01961856|DRUG|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
223566014|NCT01961856|DRUG|Ticagrelor|Ticagrelor 180mg loading dose
223740681|NCT03199300|DRUG|Bleomycin|Chemotherapy including bleomycin.
223435308|NCT00588081|BEHAVIORAL|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
223435309|NCT02077413|PROCEDURE|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
224046284|NCT06083831|OTHER|feeding type|In our department, the ICU patients received continuous feeding or sequential feeding. Patients received continuous feeding with a constant velocity by an enteral feeding pump over one day. In sequential feeding type, after achieving ≥80% of the nutrition target calories (25-30 kcal/kg/d), the patients received intermittent feeding. The total daily dosage of enteral nutrition was equally distributed during three periods at 7-9:00, 11-13:00 and 17-19:00. The enteral nutritional suspension administered during each period was given at a uniform rate within two hours by an enteral feeding pump. The other times of the day were fasting times.
223435310|NCT02077413|PROCEDURE|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of \~5 minutes."
223435311|NCT02077413|PROCEDURE|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
223435312|NCT02077413|PROCEDURE|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
223435313|NCT02525536|DRUG|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
223435314|NCT02525536|DRUG|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
223435315|NCT02525536|DRUG|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
223435316|NCT01759836|DRUG|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
223435317|NCT05148845|BIOLOGICAL|Booster vaccine|"To evaluate the effectiveness and safety of the single dose Ad26.COV2.S (Jansen) COVID-19 vaccine plus a homologous boost with Ad26.COV2.S (Janssen) COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonke participants~In addition we will continue to evaluate VE of the Sisonke Boost compared to:~i) Vaccinated populations pre boosts ii) Unvaccinated populations in South Africa."
223435318|NCT03848806|DRUG|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
223435319|NCT03848806|DRUG|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
223435320|NCT05940896|DRUG|Disitamab vedotin|Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
223435321|NCT05871671|BEHAVIORAL|Pulmonary Rehabilitation|A 16-week PR programme shall be delivered twice weekly to the active group. This shall be followed by a 36-week maintenance home exercise programme which shall be monitored every 4 weeks via a phone call from the researcher herself for 36 weeks. The subjects shall self-document their adherence to the home exercise programme on a diary which shall be returned to the researcher at week 52.
223435322|NCT05871671|OTHER|Control|The control group shall not receive the 16-week PR programme and the following 36-week maintenance home exercise programme until completion of the study.
223435323|NCT03539185|DEVICE|Videolaryngoscope Airtraq|Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation
223435324|NCT03539185|DEVICE|Fiberoptic bronchoscope|Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
224046285|NCT05844371|DRUG|tirelizumab|Tirelizumab (200 mg, q3w) was added and maintained until one year, starting with adjuvant chemotherapy after surgery.
224046286|NCT05844371|DRUG|chemotherapy with oxaliplatin + heroda|chemotherapy with oxaliplatin + heroda
224046287|NCT02205411|DEVICE|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
224046288|NCT02205411|DEVICE|Control VAD|The HeartMate II® VAD or HVAD®
224046289|NCT01252810|DRUG|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
224046290|NCT05551767|DRUG|Pembrolizumab|3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
224046291|NCT02447692|OTHER|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
224046292|NCT02447692|OTHER|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
224046293|NCT02493894|DRUG|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
224046294|NCT02493894|DRUG|placebo|placebo each 8 hours for 24 hours
224046295|NCT02493894|DRUG|Cefazolin|cefazolin 1gram, every 6hours for 2 days
223435325|NCT01752868|DIETARY_SUPPLEMENT|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
223435326|NCT05029804|OTHER|Education|This intervention will be applied to the patients in the experimental group. The education will be provided by the researcher and based on the transtheoritical model. Printed materials and PowerPoint presentations will be used for the education and the education will be conducted in a face-to-face session with each participant (10 weeks).
224046296|NCT02693522|DRUG|somatropin|Subcutaneous injection
224046297|NCT02693522|DRUG|Eutropin|Subcutaneous injection
224299844|NCT05422703|DRUG|Proteolytic enzymes|1-2 ampoules daily IM box of 3 ampoules of 5 mg crystallized and lyophilized chymotrypsin (450 E. A. Units) + 3 ampoules of 3 ml apyrogenic saline for one week.
223435327|NCT04982172|DRUG|Infliximab|Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
223435328|NCT04982172|DRUG|Infliximab|Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
224046298|NCT06013657|PROCEDURE|Liver Resection|Resection of a part of the liver afflicted by hepatocellular carcinoma
224046299|NCT04796922|DRUG|parsaclisib|parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.
224046300|NCT04796922|DRUG|rituximab|rituximab will be administered intravenously on select days as per protocol.
224046301|NCT04796922|DRUG|obinutuzumab|obinutuzumab will be administered intravenously on select days as per protocol.
224046302|NCT04468620|BEHAVIORAL|Assistive Soft Skills & Employment Training (ASSET)|The ASSET curriculum covers six key social skill areas: (a) Communication; (b) Networking; (c) Attitude \& Enthusiasm; (d) Teamwork; (e) Problem Solving \& Critical Thinking; and (f) Professionalism, as well as new content added based on our pilot findings (Mental Health; Stress Management and Self-Advocacy; and Awareness of Self \& Others). The schedule includes two sessions for Communication and Professionalism, and a graduation session; thus, bringing the total number of sessions to 13. The structural elements of the training format include didactic lecture, experiential activities, group discussions, role-plays, performance feedback,and weekly take-home assignments. A key element is a social hour following each 90-minute session, in which participants practice learned skills while sharing a meal.
224070504|NCT04017260|PROCEDURE|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
224142014|NCT04427917|DRUG|PF-06835919|PF-06835919 300 mg repeated doses
224142015|NCT04427917|DRUG|Placebo|Placebo repeated doses
224142016|NCT05985434|PROCEDURE|Surgical treatment|decompression with or without stabilization; stabilization only; debulking; en bloc resection
224142017|NCT05606224|BEHAVIORAL|internet-based mindfulness intervention for emotional distress|The internet-based self-help version of the Mindfulness Intervention for Emotional Distress (iMIED) program integrates rationales and practices from the UP and MBIs. Formal mindfulness exercises (e.g., body scan, mindful breathing, and mindful stretching) and informal mindfulness practices (e.g., mindful tooth-brushing) were retrieved from MBIs. In addition, iMIED selected several important tasks from the UP, like practicing tolerating uncomfortable feelings by interoceptive exposure practices (e.g., rapid breathing), identifying avoidant behaviors and emotion-driven behaviors and reducing them step by step, identifying common maladaptive automatic thoughts (e.g., overestimating probability and catastrophizing), and using the above strategies in daily life by completing challenging tasks.
224142018|NCT01240655|DRUG|LCL161|
224142019|NCT01240655|DRUG|Paclitaxel|
224142020|NCT00243100|DRUG|vorinostat|Given orally
224142021|NCT00243100|DRUG|gemcitabine hydrochloride|Given IV
224142022|NCT00004799|BIOLOGICAL|whole-cell pertussis vaccine|
224142023|NCT00004799|BIOLOGICAL|diphtheria-tetanus vaccine|
224142024|NCT04764409|PROCEDURE|Chemoembolization|Transarterial Chemoembolization (TACE)
224142025|NCT04764409|PROCEDURE|Chemoinfusion|Transarterial Infusion (TAI)
224142026|NCT04259385|BEHAVIORAL|Exposure to sugar-sweetened beverage warning labels|Graphic images of the amount of sugar (randomly assigned teaspoons, packets, or cubes) and text warning labels
224142027|NCT04259385|BEHAVIORAL|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
224142028|NCT01464242|DRUG|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
223435329|NCT04499105|DRUG|Mesenchymal Stem Cell + NaCl 0,9% 2ml|Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
223478525|NCT03799861|OTHER|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
224142029|NCT01464242|DRUG|Placebo|Placebo 400mg orally 3 times a day for 20 days
224142030|NCT01464242|DRUG|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
224142031|NCT04287101|OTHER|Post-operative PT and OT|Strengthening exercise, range-of-motion exercise, functional training, balance training, adjustment for assistive devices, adaptation and modiﬁcation of the home environment, and patient/caregiver education
224299845|NCT05422703|DRUG|Mouth wash|use 0.12% chlorhexidine or povidone iodine mouthwash daily
224299846|NCT05422703|DIETARY_SUPPLEMENT|Soft cold diet|For the day of surgery
224299847|NCT05034120|DRUG|XZP-3621|Administer a single dose of XZP-3621 tablet after a low-fat meal.
223435330|NCT05899647|DIAGNOSTIC_TEST|Ultraviolet Microscopic Analysis|"Data to be collected from subjects at the time of their clinical visit; or upon chart review by the research team; will include demographic information, whether the subject is presenting for a routine screen or for a follow-up, and the subject's most recent cervical cytology result. Data to be collected from the standard-of-care cytology will include the cytologic diagnosis and the presence or absence of human papilloma virus (HPV), if applicable based on the subject's age. The Pap results of each subject will be reviewed and classified as screen negative (NIL), screen positive (LSIL, HSIL), or indeterminate (ASCUS, ASC-H). Subjects with a positive screen, or an indeterminate result, who undergo colposcopy will have their colposcopy results recorded as well. The UV microscopy imaging features will be coded and collected."
223435331|NCT01962545|DRUG|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
223435332|NCT01153620|DRUG|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
223435333|NCT01153620|OTHER|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
223435334|NCT01413074|OTHER|Peritoneal Dialysis treatment|PD treatment
223435335|NCT01413074|OTHER|Hemodialysis treatment|HD treatment
223566015|NCT02617394|OTHER|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
223566016|NCT02617394|OTHER|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
223566017|NCT07081880|OTHER|biological sampling|DNA and Cells will be sampled
224046303|NCT01841463|DRUG|P1446A-05|\- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) \& vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 \& vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, \& 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples \& undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
224046304|NCT01841463|DRUG|Vemurafenib (Zelboraf®)|"* In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~* In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~* Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
224046305|NCT03344419|DRUG|CI-581a|Medication infusion intravenously over 1 hour.
224046306|NCT03344419|DRUG|CI-581b|Medication infusion intravenously over 1 hour.
224046307|NCT03344419|BEHAVIORAL|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
224046308|NCT03344419|BEHAVIORAL|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
224046309|NCT06325748|BIOLOGICAL|SENTI-202|"SENTI-202 is an investigational off-the-shelf CAR NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematological malignancies while sparing healthy cells using a NOT logic gate.~SENTI-202 is administered in either a 3 dose regimen (Schedule 1: Days 0, 7, 14) or a 5 dose regimen (Schedule 2: Days 0, 3, 7, 10, 14) of a 28-day treatment cycle following a lymphodepletion conditioning regimen of fludarabine and cytarabine (flu/Ara-C). Subjects will receive a minimum of 1 and maximum of 3 treatment cycles to achieve optimal response with the optionality of an additional consolidation cycle thereafter. Additional dosing schedules may be explored depending on study data."
224046310|NCT06295068|DEVICE|Transcatheter Aortic Valve Replacement (TAVR)|Replacement of the aortic valve with use of the OpSens SavvyWire
224046311|NCT06295068|DEVICE|Balloon Aortic Valvuloplasty (BAV)|Dilation of the narrowed aortic valve by balloon inflation with use of the OpSens SavvyWire
224046312|NCT01367353|PROCEDURE|surgery or debulking surgery|surgery or debulking surgery
224046313|NCT05666037|BEHAVIORAL|Mobile health intervention(mHealth)|The intervention group will receive mobile health messaging intervention on behavior change to uptake early postpartum modern contraceptive method.
224046314|NCT06455150|OTHER|Assessment of pelvic floor dysfunctions' symptoms and sings, pelvic floor muscle strength and quality of life|"It will be assessed the presence of urinary incontinence, anal incontinence, pelvic organ prolapse and female sexual dysfunction' symptoms by using the questionaries validated to Spanish population International Consultation on Incontinence Questionnaire-Short Form, Pelvic Floor Distress Inventory Short Form and Female Sexual Function Index; in addition, the sign of stress urinary incontinence and pelvic organ prolapse will be assessed by using the cough stress test and Pelvic Organ Prolapse Quantification System, the pelvic floor muscle strength by using manometry, and quality of life by using SF-12 questionnaire."
224046315|NCT04582981|DRUG|Fruquintinib and raltitrexed|Fruquintinib 5mg qd plus raltitrexed 2mg/m2, q2w
224046316|NCT04582981|DRUG|Fruquintinib|Fruquintinib 5mg qd monotherapy
223435336|NCT06304740|DRUG|IMG-007|Subcutaneous injection of IMG-007
223435337|NCT06304740|DRUG|Placebo|Subcutaneous Injection of Placebo
223435338|NCT05489640|OTHER|No Intervention|No Intervention will be administered in this study.
223435339|NCT06404840|DRUG|nimotuzumab|nimotuzumab (400 mg, iv, d1, qw)
223435340|NCT06404840|DRUG|AG chemotherapy|(gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
223435341|NCT01201174|OTHER|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
223566018|NCT02693054|DEVICE|HALO|Laser Treatment
223566019|NCT01330628|DEVICE|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
223566020|NCT01330628|PROCEDURE|Balloon angioplasty|standard balloon catheters for PTA
223566021|NCT01357161|DRUG|adavosertib|Adavosertib capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
224046317|NCT02785679|DIETARY_SUPPLEMENT|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
224046318|NCT01499953|DRUG|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
224046319|NCT01499953|DRUG|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
224046320|NCT04759261|OTHER|SMAD4 expression and methylation|Effect of SMAD4 methylations on smad4 expression
224046321|NCT06969989|OTHER|10 % water extract of Boswellia Sacra|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant( 10 % water extract of Boswellia sacra) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
224046322|NCT06969989|OTHER|1 % Sodium Hypochlorite|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant ( 1 % NaOCl ) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
224046323|NCT06969989|OTHER|0.9 % Normal Saline|Canal shaping will be done using and rotary files with aid of 10 mL of the tested irrigant (0.9 % saline) for lubrication, flushing of debris and canal disinfection via a plastic disposable syringe with a 30-gauge side vented needle will be used 2mm short from the working length
224046324|NCT04685915|DRUG|Ibrutinib|Capsule, taken by mouth once daily
224046325|NCT04685915|DRUG|Copanlisib|Intravenous Infusion
224046326|NCT04685915|DRUG|Acalabrutinib|Capsule, taken by mouth twice daily
224046327|NCT05565846|COMBINATION_PRODUCT|NTX-001|One-time use surgical product of three solutions and a device
224046328|NCT06447207|BEHAVIORAL|Occupational Therapy Led Social Prescription|The intervention includes encouragement to participate in the co-designed social prescription with 6 monthly sessions with an occupational therapist or occupational therapy doctoral student.
224046329|NCT02575404|DRUG|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
224046330|NCT02575404|DRUG|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
224046331|NCT00823303|DRUG|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
224046332|NCT00823303|DRUG|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
224046333|NCT02403843|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
224046334|NCT02710773|OTHER|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
224046335|NCT02710773|OTHER|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
224046336|NCT05503563|PROCEDURE|terta modal bladder preservation|neoadjuvant chemotherapy, partial cystectomy, radiotherapy
224046337|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
224046338|NCT04412538|BIOLOGICAL|Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
224046339|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
224046340|NCT04412538|BIOLOGICAL|Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
224046341|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
224142032|NCT05225051|OTHER|skin biopsy|skin biopsy
224142033|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
224142034|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
224142035|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
224142036|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
223435342|NCT04167930|OTHER|electronic medical record(EMR) Data and patient survey|"1. Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~2. Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
223435343|NCT00980018|DRUG|Nilotinib|Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
223435344|NCT01621971|DRUG|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
223435345|NCT01621971|DRUG|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
223435346|NCT01474031|OTHER|Biomechanics|"* Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)"
223435347|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
224046342|NCT04412538|BIOLOGICAL|High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
224046343|NCT04412538|BIOLOGICAL|Placebo on a 0- and 28-day schedule|Two doses of placebo at the vaccination schedule of day 0,28
224046344|NCT04412538|BIOLOGICAL|Placebo on a 0- and 14-day schedule|Two doses of placebo at the vaccination schedule of day 0,14
224046345|NCT05805566|OTHER|Blood collection|Blood samples will be collected from the patient at baseline. This blood will be collected during the standard of care blood drawing in extra.
224046346|NCT04806139|BEHAVIORAL|Remote Enhance Fitness|The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
224046347|NCT02834416|BEHAVIORAL|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
224046348|NCT02834416|BEHAVIORAL|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
224046349|NCT02927418|BEHAVIORAL|Strength & Conditioning|
224046350|NCT02927418|BEHAVIORAL|Control|
224142037|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
224142038|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
223566022|NCT01357161|DRUG|Placebo|placebo to adavosertib, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
223566023|NCT01357161|DRUG|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
223566024|NCT01357161|DRUG|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
223566025|NCT03407053|DIETARY_SUPPLEMENT|Ultra-processed diet|Consuming ultra-processed diet over a 2-week period
224142039|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
224142040|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
224142041|NCT03814590|BIOLOGICAL|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
224142042|NCT03814590|DRUG|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
223435348|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
223435349|NCT01053520|DRUG|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
223435350|NCT05769920|DRUG|TTHX1114(NM141) Ophthalmic Solution|Eye drop twice daily
223435351|NCT02758873|GENETIC|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
223566026|NCT03407053|DIETARY_SUPPLEMENT|Unprocessed diet|Consuming unprocessed diet over a 2-week period
223566027|NCT01151605|DRUG|insulin infusion|insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
223566028|NCT01151605|DRUG|Dextrose infusion|Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
224142043|NCT03011450|DRUG|K-877|
224142044|NCT03011450|DRUG|Fenofibrate|
223566029|NCT01151605|DRUG|Saline Infusion|Saline will be infused at 100ml/hr
223566030|NCT03453255|DRUG|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
223566031|NCT01399632|BEHAVIORAL|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
224142045|NCT03011450|DRUG|Placebo (for K-877)|
224142046|NCT04385615|OTHER|Fasting Mimicking Diet|Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
224142047|NCT03623282|DRUG|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
224046351|NCT07128849|OTHER|upper limb exercise with arm ergometer|upper limb exercise on arm ergometer lasting 5 min at 30 rpm (Rotation per minute) 3 times a day for 7 days and standard treatment which includes breathing exercises (3 sets of 10 repetitions daily for 7 days); active upper and lower exercises (3 sets of 10 repetitions daily for 7 days) with bed inclined at 45°; ambulation within the inpatient wards for 6 min, transfer to chair (allocated at the side of bed sitting for 30min), that will be progressed as patient condition till 7th day
224046352|NCT07128849|OTHER|upper limb exercise with out arm ergometer|standard treatment which includes breathing exercises (3 sets of 10 repetitions daily for 7 days); active upper and lower exercises (3 sets of 10 repetitions daily for 7 days) with bed inclined at 45°; ambulation within the inpatient wards for 6 min, transfer to chair (allocated at the side of bed sitting for 30min), that will be progressed as patient condition till 7th day
224046353|NCT06985628|DEVICE|Transcutaneous vagal nerve stimulation (tVNS)|tVNS will be applied at the cervical level of the vagal nerve.
224046354|NCT06985628|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|TENS will be applied facially on the trigeminal nerve.
224046355|NCT05336253|BEHAVIORAL|EVERYbody Project-Connect|3-week dissonance-based, group, online body image program (4.5 hours total)
224046356|NCT05336253|BEHAVIORAL|Self-Help Workbook|Time-matched 3-week passive, individual workbook condition (4.5 hours total)
224142048|NCT03714282|DEVICE|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
223435352|NCT02758873|GENETIC|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
224142049|NCT03714282|DEVICE|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
223435353|NCT02758873|OTHER|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
223435354|NCT01821950|BEHAVIORAL|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
223435355|NCT04694768|BEHAVIORAL|Rehabilitation|Rehabilitation program
223435356|NCT01858623|DRUG|Losartan/hydrochlorothiazide|
223435357|NCT01858623|DRUG|Losartan|
223435358|NCT01858623|DRUG|Hydrochlorothiazide|
223435359|NCT00087126|DRUG|topotecan hydrochloride|
223435360|NCT00699712|DRUG|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
223435361|NCT05096572|DEVICE|VIM Stimulation|Subjects will receive stimulation at VIM site only based on best settings ascertained during monopolar review.
224046357|NCT07129538|OTHER|inspiratory muscle retraining|Familial mediterranean fever (FMF adolescents ) will be inspiratory muscle retraining group (IMR group) that will contain 20 FMF adolescents. IMR group will receive two IMR sessions daily, five times weekly, for eight weeks (every IMR session will contain 3 sets of IMR and the set will contain 10 breath cycles).. this group will receive their prescribed colchicine medications daily
224046358|NCT07129538|OTHER|colchicine only|Familial mediterranean fever (FMF adolescents ) will be collected in this group OF FMF that will contain 20 FMF adolescents. this group will receive their prescribed colchicine medications daily for eight weeks
223435362|NCT05096572|DEVICE|PSA Stimulation|Subjects will receive stimulation at PSA site only based on best settings ascertained during monopolar review.
223435363|NCT05096572|DEVICE|VIM+PSA Stimulation|Subjects will receive stimulation at VIM+PSA based on best settings ascertained during monopolar review.
223435364|NCT01832818|DEVICE|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
223435365|NCT01399970|OTHER|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
223566032|NCT01399632|BEHAVIORAL|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
223435366|NCT01399970|OTHER|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
223435367|NCT04220099|PROCEDURE|Electroconvulsive therapy(ECT)|Patients recieve 8-sessions ECT treatments and those kinds of drugs they take since they were recruited remain unchanged during this study.
223435368|NCT01839799|DRUG|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
223435369|NCT01839799|DRUG|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
223566033|NCT02096666|DRUG|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
223566034|NCT01341717|DRUG|Sitagliptin|100 mg once daily for 6 months
224046359|NCT07130643|DRUG|CDK4/6 inhibitors+Endocrine Therapy|CDK4/6 inhibitors：dalpiciclib,palbociclib,abemaciclib,ribociclib
224046360|NCT06733935|DRUG|NKX019|NKX019 is an investigational allogeneic CD19-Directed CAR NK
224046361|NCT06733935|DRUG|Fludarabine|Lymphodepletion
224046362|NCT06733935|DRUG|Cyclophosphamide|Lymphodepletion
224142050|NCT03714282|OTHER|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
223566035|NCT01341717|DRUG|Glimepiride|1 mg/2 mg/3 mg once daily
223435370|NCT01839799|DRUG|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
223435371|NCT01839799|RADIATION|Chemoradiation|
223435372|NCT00934856|DRUG|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics \[SmPC\]).
223435373|NCT00934856|DRUG|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
223435374|NCT00934856|DRUG|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
224046363|NCT06023537|BEHAVIORAL|Behavioral weight loss program|All participants will participate in the same remote, behavioral weight loss program. As part of the baseline assessment, participants will be asked to watch a series of custom-made videos on the study's dietary and physical activity prescriptions, dietary self-monitoring, self-weighing, and cognitive-behavioral skills to facilitate engagement in study prescriptions. Participants will be prescribed a reduced-calorie diet that will be individualized based on the individual's starting weight and weight loss goal (recommended goal of 5-10% weight loss over 12 weeks). Participants also will be prescribed a goal of 150 minutes of moderate-to-vigorous physical activity per week. They are also given, free of cost, a Fitbit Charge 5 health tracker, the Fitbit Aria Air digital scale, and a MyFitnessPal Premium subscription for the duration of the study.
224046364|NCT03273296|DRUG|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
223435375|NCT01742715|OTHER|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
223435376|NCT01742715|OTHER|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
223435377|NCT01742715|OTHER|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
224046365|NCT03273296|DRUG|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
224046366|NCT03273296|DRUG|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
224046367|NCT06895135|OTHER|Amoxicillin|Participants in this group will receive oral amoxicillin at a dosage of 30mg/kg/day. The treatment will be administered in divided doses for the duration of the study, with the aim of resolving symptoms of acute otitis media in children.
224046368|NCT06895135|OTHER|Clavulanic Acid|Participants in this group will receive a combination of oral amoxicillin and clavulanic acid at a dosage of 30mg/kg/day. The medication will be given in divided doses, and participants will be monitored for symptom resolution and any potential side effects.
224142051|NCT03107676|OTHER|trunk extensors endurance training|endurance training
223435378|NCT05112757|OTHER|Smartphone application use|Use of a smartphone application
223435379|NCT02184910|DRUG|pepsinogen and gastrin|
223435380|NCT03765112|DEVICE|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
223435381|NCT06731634|DEVICE|Hand grip strength dynamometer, pinch strength dynamometer|Both devices will be used to assign the strength of grip and pinch for both dominant and non dominant hands by using jamar hydraulic hand grip strength dynamometer and Jamar hydraulic pinch strength dynamometer
223566036|NCT01341717|DRUG|Metformin|\>=1000 mg twice daily
224046369|NCT05845658|DEVICE|Active VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
224046370|NCT05845658|DEVICE|Sham VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
224046371|NCT03910621|DRUG|Miglustat|capsule, oral use
224046372|NCT07130136|DEVICE|Cochlear™ Osia® System|The Osia System consists of the OSI300 Implant, Osia 2 Sound Processor, Osia 2 Sound Processor Magnets, Osia 2 Sound Processor Magnet Tool, Osia Fitting Software 2 (OFS 2), and Osia Smart App.
224142052|NCT04039191|BEHAVIORAL|SMS education|Patients will receive additional educational SMS messages post-operatively
224142053|NCT04039191|BEHAVIORAL|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
224142054|NCT04209894|DIAGNOSTIC_TEST|Ultrasound|Evaluation consisted of the detection of grey scale (GS) enthesitis and Power Doppler signal in enthesis areas of participants. The Madrid Sonography Enthesitis Index (MASEI) scoring system was used to quantify the extent of sonographic entheseal abnormalities
223566037|NCT01341717|DRUG|Insulin|TDD \> 10 IU once/twice daily
223566038|NCT02509572|BEHAVIORAL|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
224142055|NCT02089620|DRUG|Yasmin|will be used every 21 days for three months by the patient
223435382|NCT06731634|DIAGNOSTIC_TEST|Finkelstein test|Finkelstein test which is used to diagnose the de quervain tenosynovitis and it will be used to assist the people with smartphone addiction
223435383|NCT04423575|OTHER|Outpatient health care pathway|A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
223435384|NCT04297475|DIAGNOSTIC_TEST|Multi-modal photoacoustic/ultrasonic (PA/US) imaging system|The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
223435385|NCT06511115|OTHER|Experimental Group|"Each session will be divided into three clearly differentiated parts:~i) A 5-minute warm-up consisting of a series of gentle, low-intensity exercises designed to gradually prepare the muscles and joints of older adults for the main exercise. This portion will include flexibility and stretching movements, as well as joint mobility exercises; ii) 35 minutes dedicated to the main section of the intervention using the Nintendo Wii to promote physical, mental, and cognitive activity; iii) 5 minutes for relaxation techniques that incorporate flexibility exercises and stretches.~Each session will be led by a qualified and experienced professional. No incidents of injuries or negative effects were reported during the intervention period. Throughout the 12-week intervention, participants will be periodically followed up by phone to inquire about their physical activity habits."
224046373|NCT07130136|DEVICE|Cochlear™ Baha® System|The Baha Connect System consists of the BIA300 (BI300 Implant and BA300 Abutment), Baha 7 Sound Processor, and Baha Fitting Software 7 (BFS 7).
224046374|NCT07128732|OTHER|Peer mentoring training|As part of the intervention, a 15-hour peer mentoring training program was implemented, covering topics such as self-management and self-awareness, stress management, coaching and mentoring, critical thinking, problem-solving and decision-making, effective communication and relationship management.
223435386|NCT04255407|DEVICE|I-ONE® therapy|I-ONE® therapy will be used in patients with bone bruise on the knee after anterior cruciate ligament (ACL) injury 15 days before and 60 days after ACL reconstruction surgery for 4 hours a day compared to a control group (no-treatment).
223435387|NCT04255407|DRUG|Anti-inflammatory drug|Pain before and after ACL reconstruction will be managed with common anti-inflammatory drugs (Paracetamol)
223435388|NCT04952207|DRUG|Direct-acting antiviral agents|The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
223435389|NCT04015778|BIOLOGICAL|Nivolumab|240mg Q2W or 360mg Q3W
223435390|NCT04015778|DRUG|carboplatin|AUC 5, d1 every three weeks
223435391|NCT04015778|DRUG|nab-paclitaxel|135 mg/m2, d1, 8
223435392|NCT01256385|BIOLOGICAL|Cetuximab|Given IV
223435393|NCT01256385|OTHER|Laboratory Biomarker Analysis|Correlative studies
223566039|NCT03891004|PROCEDURE|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
224046375|NCT07130318|BEHAVIORAL|exercise plus diet restriction|Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months. also, this group, Group I, will also perform elliptical aerobic exercise (this exercise will be applied for 40 minutes three times weekly and this exercise will be maintained for 6 months)
224046376|NCT07130318|BEHAVIORAL|diet restriction|Familial Mediterranean fever (FMF women ) will be collected in this group. the group OF FMF will contain 20 FMF women. the group will follow their colchicine (traditional daily drug therapy for FMF) in addition to Mediterranean diet for six months.
224046377|NCT05540574|DRUG|Zolpidem|5mg (and up to10mg) Diphenhydramine given orally
224046378|NCT05540574|DRUG|Placebo|Matching Placebo given orally
224046379|NCT07075016|DRUG|Venetoclax 400|day 1-28 per cycle
224046380|NCT07075016|DRUG|Placebo|day 1-28 per cycle
224046381|NCT05515861|PROCEDURE|Endoscopic ultrasound|Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
224046382|NCT06903156|DRUG|Mexidol|Neuroretinoprotector
224046383|NCT06903156|OTHER|Placebo|Placebo therapy
224046384|NCT05124080|DRUG|Deucravacitinib|All participants will receive 6 mg of Deucravacitinib daily.
224046385|NCT06903013|OTHER|Non vitalPulp therapy|Pulp therapy deals about management of inflamed vital dental pulp With complete pulp removal and obturation with resorbable materi
224046386|NCT06903013|OTHER|Vital pulp therapy|Pulp therapy through partial root removal and using of regenerative capping material
224142056|NCT02089620|DIETARY_SUPPLEMENT|Calver|Calver will be given daily for 3 months
224142057|NCT02089620|DRUG|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
224142058|NCT02089620|DRUG|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
224142059|NCT03126331|DRUG|Nivolumab|"Nivolumab monotherapy will be administered dosed at 480mg IV over 30 minutes for all patients every 4 weeks, regardless of weight (when given in combination with ipilimumab, the dose of nivolumab is 3mg/kg every 3 weeks).~Tumor assessed after 12 weeks If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more."
224142060|NCT03126331|DRUG|Ipilimumab|Ipilimumab is dosed at 1mg/kg over 30 minutes every 3 weeks
224299848|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
223435394|NCT01256385|DRUG|Temsirolimus|Given IV
223435395|NCT04246645|OTHER|CORE STABILITY EXERCISES|SELECTED CORE EXERCISES
223435396|NCT01741571|DEVICE|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
223435397|NCT00017680|DRUG|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
224046387|NCT06827171|COMBINATION_PRODUCT|aerobic exercise + low-level laser therapy|low- level laser parameters: The wavelength: 808 +/- 5nm The power: output is 450 Mw Type of beam: red laser beam. Beam Divergent \>,025 rad+/- ,005rad Nominal Distance of Sight hazard \>8m The duration: is 20 min for each artery. Treatment period: 3 times/week for 3 months.
224046388|NCT06827171|OTHER|Aerobic exercise|Aerobic exercise Frequency = 3sessions/week duration: 10 min warm up and 10 min cool down/ 30 min stance phase Intensity: moderate intensity initiating with 50% HR max to end 75% HR max
224046389|NCT07129512|PROCEDURE|Intracorporeal anastomosis|In this group, the vessel ligation and dissection is performed using an ultrasonic scalpel with advanced hemostasis mode.
224046390|NCT07129512|PROCEDURE|Extracorporeal anastomosis|In this group, the vessel ligation and dissection is performed using a monopolar energy device and surgical clips.
224046391|NCT07128901|DEVICE|Ekso Indego Therapy|User-balancing lower Limb exoskeleton
224046392|NCT07128901|DEVICE|Wandercraft Atalante X|Self-balancing lower limb exoskeleton
224046393|NCT07130669|BEHAVIORAL|Cognitive Remediation|computerized cognitive training with a closed-loop human machine interface that monitor facial expression as engagement status of the person
224046394|NCT07130669|BEHAVIORAL|Cognitive Remediation II|traditional computerized cognitive training
224046395|NCT07130942|PROCEDURE|Inhalation using a molecular hydrogen generator|"Hydrogen inhalation will be performed by using a hydrogen gas generator similar in terms of capabilities to the generator Hycellvator ET100 (Helix Japan, Co., Ltd., Tokyo, Japan). The apparatus will be generating 30.0 mL/s gas mixture, consisting of 68.0% hydrogen (hydrogen purity, 99.99%) and 32.0% of oxygen. All gases will be supplied through a nasal cannula connected to the gas generators. Although we could not measure directly the hydrogen and oxygen An average inspiratory flow rate will be adjusted to 500 mL/s at rest, the hydrogen concentration in the inspired gas must have been around 4.08% at most.~Control population will have inhalation with the use of gas generator that has the same outer shape as the used generator to produce Placebo (30.0 mL/s, ambient air 400 m above sea level) consisting of 0.00005% of hydrogen and 20.9% of oxygen."
224046396|NCT07129434|BEHAVIORAL|ECoFam|Mother-infant dyads randomized into the intervention group receive four personal coaching sessions to facilitate emotional connection via multisensory channels including comfort touch and communication of face-to-face affect during holding time.
224046397|NCT07128459|PROCEDURE|The Five-Step lip reduction surgery|The Five-Step lip reduction surgery: (1) measurement and design; (2) incision and reduction of lip volume; (3) fixation and shape of the dry lip; (4) fixation and shape of the skin (the SMISS approach); (5) shaping of the wet lip mucosa (the SMISS approach).
224046398|NCT07130500|BEHAVIORAL|Financial incentives for adherence to long-acting injectable medication|This intervention is a randomized controlled trial where patients in the treatment group are offered financial incentives for taking long-acting injectable (LAI) versions of the antipsychotic and substance use disorder medications they need and the control group receives the status quo standard of care.
224046399|NCT07130500|BEHAVIORAL|Standard of care with monthly surveys|Receives standard outpatient care and incentives for completing monthly surveys.
224046400|NCT07129759|DRUG|LUM-201|1.6 mg/kg/day, administered orally once daily
224046401|NCT07129525|RADIATION|Radiation therapy|Patients treated with radiotherapy will be evaluated within a period of five to seven weeks, during which time radiation-induced skin toxicities will be assessed.
224299849|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after on an empty stomach in a single dose on Day19.
224299850|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
224299851|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9) : Administer the XZP-3621 tablet on an empty stomach in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a standard meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day19.
224299852|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet after a standard meal in a single dose on Day19.
224299853|NCT05034120|DRUG|XZP-3621|Cycle1(D1-D9): Administer the XZP-3621 tablet after a standard meal in a single dose on Day1; Cycle2(D10-D18): Administer the XZP-3621 tablet after a high-fat meal in a single dose on Day10; Cycle3(D19-D27): Administer the XZP-3621 tablet on an empty stomach in a single dose on Day19.
223435398|NCT00017680|PROCEDURE|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
223435399|NCT04494594|BEHAVIORAL|Drinks:Ration app|Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
223435400|NCT01836991|PROCEDURE|surgery|
223435401|NCT05679180|DEVICE|micropulse laser|treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
223435402|NCT02428894|DEVICE|LVAD|
223435403|NCT00022880|DRUG|Iodine-131 Anti-B1 Antibody|
223566040|NCT03891004|DEVICE|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
224046402|NCT07129330|PROCEDURE|RSPO3/SDC-1 pathway profiling assay|"Peripheral Blood: 5 mL collected into EDTA tubes; PBMCs isolated within 2 h for RT-qPCR analysis of RSPO3/SDC-1 mRNA and sandwich ELISA quantification of protein levels.~Saliva: 2-3 mL unstimulated saliva naturally expectorated into sterile tubes, kept at 4 °C and processed within 2 h (centrifuged, aliquoted) before -80 °C storage Subcutaneous Fat: 100-200 mg obtained during elective procedures, preserved in RNAlater at 4 °C for 24 h, then frozen at -80 °C 3D Alveolar Organoid Assay: Lung tissue-derived organoids are cultured in Matrigel and treated ex vivo with recombinant RSPO3 or SDC-1 neutralizing antibody; epithelial repair is assessed over 7 days by Ki-67 immunostaining and wound-closure measurement"
224046403|NCT07129330|PROCEDURE|Blood and Saliva|"Peripheral Blood: 5 mL collected into EDTA tubes; PBMCs isolated within 2 h for RT-qPCR analysis of RSPO3/SDC-1 mRNA and sandwich ELISA quantification of protein levels.~Saliva: 2-3 mL unstimulated saliva naturally expectorated into sterile tubes, kept at 4 °C and processed within 2 h (centrifuged, aliquoted) before -80 °C storage"
224046404|NCT07129278|BEHAVIORAL|Breathwork|Participants will complete their single-session, 2-hour training in a small group with the Breathwork instructor.
224046405|NCT04665570|DRUG|BAY81-9783 (Acarbose/Metformin)|Tablet (FDC of 25/50mg acarbose + 500mg metformin), three times daily
224046406|NCT06925451|OTHER|sourdough bread 24|fermentation time=24 hours
224046407|NCT06925451|OTHER|sourdough bread 48|fermentation time=48 hours
224046408|NCT06925451|OTHER|sourdough bread 72|fermentation time=72 hours
224046409|NCT06925451|OTHER|yeast bread|no fermentation
224046410|NCT07129343|BIOLOGICAL|VONVENDI|VONVENDI is administered by intravenous injection.
224046411|NCT07129343|BIOLOGICAL|ADVATE|ADVATE is administered by intravenous injection.
224046412|NCT00269165|PROCEDURE|Balloon Aortic Valvuloplasty|
224046413|NCT00269165|PROCEDURE|External Beam Radiation|
224046414|NCT06936202|OTHER|Spirulina capsules|active intervention
224046415|NCT06936202|OTHER|Placebo|no active ingredient
224046416|NCT06936384|BEHAVIORAL|In this group, patients will be provided with a white noise sleep mask in accordance with the protocol determined for the postoperative period. Patients will sign an informed voluntary consent form be|White Noise Sleep Mask Group In this group, patients will be provided with a white noise sleep mask in accordance with the protocol determined for the postoperative period. Patients will sign an informed voluntary consent form before the surgery and fill out a patient information form.
223435404|NCT01225289|DIETARY_SUPPLEMENT|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
223435405|NCT01225289|DRUG|Placebo|1 capsule per day for six months
223435406|NCT00401960|DRUG|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
223435407|NCT04670380|OTHER|Posture and movement analysis during a simulated forceps vaginal operative delivery|It will be request from each volunteer to perform a vaginal operative delivery using a Suzor's forceps on a mannequin. The condition will be standardized (anterior occiput low fetal presentation). Each participant will be equipped with 34 reflecting markers allowing to record their movement using infra red cameras (VICON system).
223566041|NCT06454448|DRUG|Adebrelimab;decitabine;|Adebrelimab:1200 mg Decitabine:10mg/m2 or 15mg/m2
223566042|NCT02549625|BIOLOGICAL|Autologous Bone Marrow-derived Mononuclear Cells|
223566043|NCT00762567|DRUG|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
224046417|NCT06938386|DIETARY_SUPPLEMENT|Haskap|A whole, frozen Haskap berry puree blended with water in a 2:1 ratio of berry to water.
224046418|NCT04376827|DRUG|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 via IV administration.
223740682|NCT04999462|OTHER|Full-fat fermented dairy|Subjects assigned to the full-fat fermented dairy condition will consume 1 serving/d each of full-fat yogurt (plain or reduced sugar varieties) and full-fat fermented cheese.
223740683|NCT04999462|OTHER|Low-fat fermented dairy|Subjects assigned to the low-fat fermented dairy condition will consume 1 serving/d each of low-fat yogurt (plain or reduced sugar varieties) and lower-fat fermented cheese (e.g., reduced-fat or low-fat fermented cheese).
224046419|NCT04376827|DRUG|Placebo|Participants will receive placebo IV at Weeks 0, 4 and 8 (that is, 3 IV doses) and placebo SC q4w from Week 12 through Week 48.
224046420|NCT04376827|DRUG|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 via SC route.
224046421|NCT04376827|DRUG|Standard-of-care treatment|Participants will receive standard of care treatment including MMF/MPA and glucocorticoids from Week 12 through Week 48.
224046422|NCT06040281|BEHAVIORAL|intensive individual support in nutrition and exercise|"Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)"
224046423|NCT06040281|BEHAVIORAL|Usual Care|Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
224046424|NCT02296450|BEHAVIORAL|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
224046425|NCT04266756|DRUG|Selexipag matrix tablet|Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.
223435408|NCT02649426|DEVICE|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
223435409|NCT02649426|DEVICE|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
223435410|NCT03173365|DRUG|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
223435411|NCT06308757|DIETARY_SUPPLEMENT|Very-low-calorie ketogenic diet (VLCKD) with meal replacements|The VLCKD study arm will receive an experimental diet therapy with very-low-calorie ketogenic meal replacements (VLCKD) consisting of 5 successive phases (600 - 1500 kcal/day).
223435412|NCT06308757|DIETARY_SUPPLEMENT|Mediterranean low-calorie diet (LCD)|The Control arm LCD will receive standard Mediterranean type low-calorie diet (LCD) therapy by the most recent guidelines on MAFLD/NAFLD (1200-1500 kcal/day).
223435413|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
223435414|NCT01652066|DIETARY_SUPPLEMENT|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
223435415|NCT02612350|GENETIC|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
223435416|NCT00135902|DRUG|17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
223435417|NCT00135902|DRUG|17 alpha-hydroxy progesterone caproate and Placebo supplement|Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
223435418|NCT01606202|DRUG|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
223435419|NCT01606202|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
223435420|NCT02859688|GENETIC|pyrosequencing|
223435421|NCT02859688|GENETIC|Methylome|
223435422|NCT02190409|DEVICE|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
223435423|NCT05658640|DRUG|Trametinib|Oral
223435424|NCT05658640|DRUG|Dexamethasone|Oral/ Intravenous
223435425|NCT05658640|DRUG|Cyclophosphamide|Intravenous
223435426|NCT05658640|DRUG|Cytarabine|Intravenous
223435427|NCT05658640|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
223435428|NCT01634451|OTHER|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
223435429|NCT01634451|OTHER|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
223435430|NCT01634451|DEVICE|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
223435431|NCT06730451|OTHER|Washed Microbiota Transplantation|Washed microbiota suspension delivered through mild-gut and lower-gut
223435432|NCT00444860|BIOLOGICAL|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
223478526|NCT03257579|OTHER|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
223478527|NCT03257579|BEHAVIORAL|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
223478528|NCT00146068|DRUG|Avonex/Zocor|
223478529|NCT03626896|DEVICE|NaviFUS System|BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
223478530|NCT02663700|DRUG|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
223478531|NCT02663700|BIOLOGICAL|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
223478532|NCT02663700|OTHER|Placebo|Placebo
223478533|NCT06140134|PROCEDURE|Liver Transplant|Whole liver allotransplantation will be performed for patients on the liver transplant waiting list
223478534|NCT02253342|DRUG|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
223478535|NCT00144313|BIOLOGICAL|hepatitis B vaccine|
223478536|NCT01897116|DRUG|Hydroxychloroquine (HCQ)|
224046426|NCT04266756|DRUG|Selexipag encapsulated pellets|Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
224046427|NCT04266756|DRUG|Selexipag Immediate-release (IR) tablet|Participants will receive Selexipag immediate-release tablet orally under fasted condition.
224046428|NCT05296642|OTHER|Moderate Cycling|Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).
224046429|NCT05296642|OTHER|Personalized Tourniquet System|An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
224046430|NCT05351775|DEVICE|Smartphone application|Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.
224046431|NCT05351775|DEVICE|Bed sensor|The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.
224046432|NCT05351775|DEVICE|Wrist-worn photoplethysmography (PPG) and accelerometer data logger.|Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.
224046433|NCT05351775|DEVICE|Patch-holter ECG|The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
224046434|NCT06433947|DRUG|OPN-6602|orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
224046435|NCT06433947|DRUG|Dexamethasone|Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
224046436|NCT04344340|DIAGNOSTIC_TEST|clinical examination|clinical examination
224046437|NCT01792804|DRUG|Trimethoprim-Sulfamethoxazole|study drug 1
224046438|NCT01792804|DRUG|Clindamycin|study drug 2
224046439|NCT01792804|DRUG|Linezolid|study drug 3
224046440|NCT01792804|DRUG|Flucloxacillin|study drug 4
224046441|NCT01792804|DRUG|Cloxacillin|study drug 5
224046442|NCT01792804|DRUG|Vancomycin|study drug 6
224046443|NCT01792804|DRUG|Daptomycin|study drug 7
223478537|NCT01897116|DRUG|Vemurafenib (VEM)|
223478538|NCT01339169|DRUG|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
223478539|NCT00316004|DRUG|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
223740684|NCT04999462|OTHER|Non-dairy, non-fermented foods|Subjects assigned to the control condition will consume 2 servings/d of nondairy, nonfermented foods with a macronutrient composition that is similar to that of the low-fat fermented dairy condition.
224046444|NCT01792804|DRUG|Cefazolin|study drug 8
224046445|NCT05691998|OTHER|Prosthetic foot questionnaire|Prosthetic foot related questions will be asked to the patients
224046446|NCT01978821|PROCEDURE|Autologous bone marrow mononuclear cell transplantation|
224299854|NCT04637126|OTHER|Cardiac output measurement by transpulmonary thermodilution and transthoracic echocardiography|Cardiac output is measured for all patients with transpulmonary thermodilution TPTD and transthoracic echocardiography TTE according to the recommendations
223478540|NCT00316004|DRUG|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
224046447|NCT00729378|OTHER|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
224046448|NCT02670824|DRUG|CN-105|Single and multiple intravenous (IV) doses of CN-105
224046449|NCT02670824|DRUG|Placebo|Normal Saline
224046450|NCT03683940|DIAGNOSTIC_TEST|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
224046451|NCT06200844|BIOLOGICAL|ROTAVAC 5D|Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.
224046452|NCT06200844|OTHER|Placebo|Placebo is administered as three doses 4 weeks apart
224046453|NCT04310241|BEHAVIORAL|Patching therapy, Glasses|Patching, glasses and strabismus surgery are commonly employed measures in treatment of amblyopia and strabismus.
224046454|NCT04790136|DRUG|GLA-015|administration followed by PK blood sampling
224046455|NCT04790136|DRUG|"DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml"|administration followed by PK blood sampling
224046456|NCT02246582|DEVICE|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen \& arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
224046457|NCT02246582|DEVICE|Guardian Mobile App|
224046458|NCT02246582|DEVICE|640G Insulin Pump|
224046459|NCT01360541|PROCEDURE|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
223435433|NCT05756361|BEHAVIORAL|Family-Based Treatment for T1D|"Our FBT curriculum, which has been delivered successfully in the specialty and primary care settings, has 3 components: 1. Meal planning including quality of carbohydrates and glycemic index for both parents and children while ensuring that youth have a balanced meal plan with adequate amounts of carbohydrates for optimal growth. Our FBT has a focus on Food Literacy including healthy food selection and sourcing of affordable healthy food, food preparation and preplanning, social engagement tailoring the meal plan to the needs to the family in socio cultural appropriate way and also feasibility based on logistics and economic aspects; 2. Physical activity (PA) component with shaping strategy to allow for a progressive shaping of easy PA starting, if needed, with as little as with 10 minutes of walking/day and strategies to incorporate PA in daily routines, family, and social activities; 3. Extensive behavioral component which has been shown to be very powerful in obesity treatment"
223435434|NCT05133414|OTHER|Selective left subclavian ansae stimulation|Percutaneous, transarterial approach for target stimulation
223435435|NCT06419010|PROCEDURE|Surgery with the use of L-PRF|The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes
223435436|NCT06419010|PROCEDURE|Standard surgery|The standard surgical treatment, taking place in the operating room under general anesthesia
223435437|NCT04116541|DRUG|HDM201|HDM201 120mg, Every 3 weeks, Per os
223435438|NCT04116541|DRUG|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
224046460|NCT01360541|OTHER|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
224046461|NCT05473910|DRUG|SOC + TSC-100|HA-1 positive
224046462|NCT05473910|DRUG|SOC + TSC-101|HA-2 positive or HA-1 negative
224046463|NCT05473910|OTHER|Control|SOC alone
224046464|NCT00522054|OTHER|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
224046465|NCT02060383|DRUG|Pasireotide s.c.|Administered to Cushing's disease participants.
224046466|NCT02060383|DRUG|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
224046467|NCT02060383|DRUG|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
224142061|NCT02204826|DRUG|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
224142062|NCT02204826|PROCEDURE|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
224142063|NCT04065373|DEVICE|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
224142064|NCT03975374|DRUG|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
224142065|NCT03975374|DRUG|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
224142066|NCT04084340|PROCEDURE|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
224142067|NCT04084340|PROCEDURE|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
224142068|NCT01240148|DRUG|AZD3161|Single dose, intradermal injection
224142069|NCT01240148|DRUG|Lidocaine|Single dose, intradermal injection
223435439|NCT04116541|DRUG|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
223435440|NCT04116541|DRUG|Alectinib|Alectinib, 600mg twice daily, Per os
223435441|NCT04116541|DRUG|Regorafenib|Regorafenib 160mg, once daily, 3 weeks on/1 week off, Per os
223435442|NCT04116541|DRUG|Trametinib|Trametinib 2 mg/day, continuous, Per os
223435443|NCT04116541|DRUG|Dabrafenib|Dabrafenib 150 mg twice daily, Per os
224046468|NCT02060383|DRUG|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
224046469|NCT02060383|DRUG|Pasireotide LAR|Administered to Acromegaly participants.
224046470|NCT02060383|DRUG|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
224046471|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
224046472|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon GV Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
224142070|NCT01240148|DRUG|AZD3161 Placebo|
223435444|NCT04116541|DRUG|Avapritinib|300 mg/day,continuous, Per os
223435445|NCT00840736|PROCEDURE|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
223435446|NCT00840736|PROCEDURE|vertical banded gastroplasty|vertical banded gastroplasty
223435447|NCT02030496|PROCEDURE|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
223435448|NCT02030496|OTHER|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
223435449|NCT00164502|BEHAVIORAL|Community-based eight session group self-management program|
223435450|NCT00865579|DRUG|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
224046473|NCT04769453|DEVICE|Canaloplasty using the iTrack microcatheter with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
224046474|NCT04769453|DEVICE|Canaloplasty using the Omni surgical system with Healon Pro|360 degree microcatheterization and viscodilation of Schlemm's canal
224046475|NCT03907631|OTHER|Standard of care|care decisions driven by local physicians; this is an observational cohort
224046476|NCT05452330|OTHER|Connective tissue massage|Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.
224046477|NCT05452330|OTHER|Classical massage|Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
224046478|NCT01762176|PROCEDURE|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
224046479|NCT01762176|PROCEDURE|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
224046480|NCT00464347|DRUG|Avastin|
224046481|NCT00464347|PROCEDURE|Photodynamic Therapy (PDT)|
224046482|NCT00464347|DRUG|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
224046483|NCT03307434|OTHER|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
224046484|NCT03307434|OTHER|regular training|The regular training will be performed by control group according to the standard practice.
224046485|NCT02008279|BIOLOGICAL|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
224046486|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
224046487|NCT02008279|BIOLOGICAL|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
224046488|NCT02008279|BIOLOGICAL|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
224046489|NCT02008279|DRUG|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
224046490|NCT03409848|DRUG|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
224142071|NCT01951248|DEVICE|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
224046491|NCT03409848|DRUG|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
224046492|NCT03409848|DRUG|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
224046493|NCT01932242|BIOLOGICAL|ETI-204|Monoclonal Antibody
224046494|NCT01932242|OTHER|Placebo|Placebo for ETI-204
224046495|NCT05831826|BIOLOGICAL|the inactivated COVID-19 vaccines|receive the doses of inactivated COVID-19 vaccines
224046496|NCT00866450|DIETARY_SUPPLEMENT|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
224046497|NCT00866450|DIETARY_SUPPLEMENT|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
224046498|NCT03725514|PROCEDURE|Conventional|Conventional Blood Clot Technique
224046499|NCT03725514|PROCEDURE|PRF|Platelet Rich Fibrin Technique
224142072|NCT02649530|DRUG|WNT974|
224142073|NCT02260648|DRUG|Evacetrapib|Administered orally
224142074|NCT02260648|DRUG|Ezetimibe|Administered orally
224142075|NCT02260648|DRUG|Atorvastatin|Administered orally
224142076|NCT02260648|DRUG|Placebo|Administered orally
224142077|NCT05331430|OTHER|Dry needling on cervical trigger point|One experimental group will receive dry needling treatment on the upper trapezius fibres using the Hong technique and the other experimental group will receive passive muscle stretching treatment on the upper trapezius fibres.
224142078|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
223435451|NCT05559684|PROCEDURE|Erector spinae plane block|Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.
223435452|NCT05559684|PROCEDURE|Transversus thoracis plane block|Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
223435453|NCT01678703|DEVICE|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
223435454|NCT01678703|DRUG|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
223435455|NCT00771979|DRUG|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
224046500|NCT02349399|DRUG|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
224046501|NCT01095406|DEVICE|S1 ventilation|Ventilation with a O2 and CO2 controller
224046502|NCT03377842|DRUG|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
224046503|NCT03377842|DRUG|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
224046504|NCT01819649|DIETARY_SUPPLEMENT|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
224046505|NCT03419039|DIETARY_SUPPLEMENT|Anthocyanins|Medox tablet containing 80 mg anthocyanins.
224046506|NCT03419039|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules.
224046507|NCT04778982|DRUG|KN026 combined with Palbociclib and Fulvestrant|HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
224046508|NCT02549430|DRUG|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
224046509|NCT02549430|DRUG|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
224046510|NCT02549430|DRUG|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
224046511|NCT02549430|DRUG|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
224046512|NCT02549430|DRUG|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
224046513|NCT00372242|BEHAVIORAL|Prospective Longitudinal Interventional Stury|
224046514|NCT02198339|DRUG|BIBN 4096 BS|
224046515|NCT02198339|DRUG|Placebo|
224046516|NCT05988450|DEVICE|SQ-Kyrin Transcatheter Mitral Valve Repair System|Transcatheter mitral valve clip placement to repair the valve and correct regurgitation.
224046517|NCT05732090|OTHER|therapeutic exercise program|therapeutic exercise program (3 sessions/week/two months).
224046518|NCT05732090|OTHER|diaphragmatic myofascial release|therapeutic exercise program in addition to diaphragmatic myofascial release (3 sessions/week/two months).
224046519|NCT03173131|BEHAVIORAL|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
224046520|NCT01715220|DRUG|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
224046521|NCT03317470|OTHER|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
224046522|NCT03317470|BEHAVIORAL|Life Navigator|"* The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~* The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
224046523|NCT03317470|OTHER|Follow-up survey|-5 questions about the acceptability of the basic needs survey
224046524|NCT03317470|OTHER|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
224046525|NCT00399789|DRUG|Perifosine|Perifosine will be tested in 3 dose forms
224046526|NCT00761306|DRUG|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
223435456|NCT00771979|DRUG|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
223435457|NCT06509490|DRUG|KD-025 cell injection|This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumor. In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be undergo screening, pre-treatment (cell product preparation;lymphodepleting chemotherapy), treatment and follow up
224046527|NCT00933179|DRUG|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
224046528|NCT00933179|DRUG|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
224046529|NCT05162027|DRUG|Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
224046530|NCT05162027|DRUG|Placebo|Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
224046531|NCT01687075|DEVICE|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
224046532|NCT06054191|DRUG|Dabrafenib + Trametinib|Dabrafenib 150mg BID + Trametinib 2mg QD/（2 cycles）
224046533|NCT06054191|DRUG|Capmatinib|Capmatinib 400mg BID/（2 cycles）
224142079|NCT03060330|PROCEDURE|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
224142080|NCT03956225|DEVICE|Systane iLux® Dry Eye System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
224142081|NCT03956225|DEVICE|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
224142082|NCT04237740|DRUG|relenvatinib|The enrolled patients are treated with lenvatinib (dose: body weight \< 60 kg: 8 mg/day, body weight ≥ 60 kg 12 mg/day).
224142083|NCT04093258|DEVICE|Dailies Total 1® Multifocal Contact Lenses|TEST
224142084|NCT04093258|DEVICE|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
224142085|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
223435458|NCT04015752|DIAGNOSTIC_TEST|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
223435459|NCT02584959|DRUG|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor \[Human\] Liquid administered Subcutaneously as specified on specified days
223435460|NCT02584959|DRUG|Placebo|Placebo
223435461|NCT01440387|BIOLOGICAL|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
223435462|NCT04849585|OTHER|semi-directed entretien|semi-directed entretien
223435463|NCT02690597|OTHER|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
223435464|NCT02364154|OTHER|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
223435465|NCT02364154|OTHER|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
223435466|NCT04909814|BIOLOGICAL|The performance of colposcopy in vaccinated women|Evaluating the performance of colpscopy in HPV vaccinated women by comparing vaccinated and unvaccinated women taking their first test within the organized screening program
223478541|NCT00316004|DRUG|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
224046534|NCT00222170|DRUG|Rabeprazole|
224046535|NCT04284202|DRUG|PD-1 plus Dasatinib|Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.
224046536|NCT02036632|DEVICE|Eye Patching|
224046537|NCT04729673|DEVICE|Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
224046538|NCT05406388|PROCEDURE|Erector Spinae Plane Block|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
224046539|NCT05406388|PROCEDURE|Intravenous fentanyl patient control device|Intravenous fentanyl patient control device 48-hour fentanyl consumption will be recorded.
224046540|NCT03764163|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
224046541|NCT03764163|DIAGNOSTIC_TEST|CT Scans|volume scans, perfusion scan, ventilation scan
224046542|NCT03764163|BEHAVIORAL|Questionnaires|Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
224046543|NCT03764163|DIAGNOSTIC_TEST|MRI|proton scans, hyperpolarized 3-Helium scan
224142086|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
224142087|NCT04268472|DRUG|GP30101|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
224142088|NCT04268472|DRUG|Prezista®|Single oral dose 800 mg, administered in a fed condition, co-administered with low dose ritonavir as a pharmacokinetic enhancer
224142089|NCT05298644|BIOLOGICAL|VLA2001|whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
224142090|NCT05298644|DRUG|Active Comparator|Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
224142091|NCT04755465|DEVICE|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) is based on the principle of creating a contraction by stimulating the nerve fibers innervating the related muscle in the healthy muscle and the muscle fibers in the denervated muscle with electrical current. The electric currents used in stimulation of muscles and nerves perform this function by changing the electrical potential of cell membranes.~It is contraindicated in pregnancy, presence of pacemaker, severe heart disease, epilepsy, fracture, dementia and impaired consciousness. We prevent contraindicated situations by excluding volunteer participants with these characteristics."
224142092|NCT04755465|OTHER|Structured Exercise|Warm-up exercise, main training program and cool down exercise. Main training consists of resistance exercises to be applied with resistance bands of different resistance or with the patient's own body weight. Our prescribed training protocol includes 4-6 different exercises for each limb (bench press with resistance band, upper extremity proprioceptive neuromuscular facilitation exercises, biceps/triceps curl, leg press, knee extension, 4-way hip motion, mini squat). Intensity, sets, and number of repetitions will be adapted to a target score between 12 and 14 using the Borg scale. It will be applied as low intensity, long-term passive stretching exercises to the pectoral, hamstring, and gastrosoleus muscle groups. Patients will perform 1 set of 10 repetitions of each resistance exercise determined by their level of fatigue. Resistance will be increased every three visits. If the patient complains of excessive fatigue, the resistance will be reduced to the previous level.
224142093|NCT05454722|DEVICE|ADEX Gel|Emollient Gel with added anti-inflammatory
224142094|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
224142095|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
224142096|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
224142097|NCT01093001|OTHER|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
224142098|NCT00594204|DRUG|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
224142099|NCT00594204|DRUG|Placebo|matching placebo 1 tablet twice a day for 12 weeks
224142100|NCT05091892|OTHER|Hydrotherapy programm|Treatment
224142101|NCT01477372|BEHAVIORAL|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
224142102|NCT01825655|DRUG|Cetirizine|
224142103|NCT01825655|DRUG|Placebo or sugar pill|
224142104|NCT00567541|DEVICE|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
224142105|NCT00176241|DRUG|gemcitabine|2000-3000mg/m2 IV on days 1 \& 15
224142106|NCT00176241|DRUG|paclitaxel|150 mg/m2 IV on days 1 \& 15
224142107|NCT00176241|RADIATION|radiation|50-80 cGy on days 1,2,15,16
224142108|NCT02335112|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
224142109|NCT02335112|DEVICE|NanoKnife|
224046544|NCT03764163|BIOLOGICAL|Xenon gas|ventilation CT scans
224046545|NCT00838214|DRUG|budesonide|3mg capsule, 3x per day for 6 months
224046546|NCT00838214|DRUG|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
224046547|NCT02978534|DRUG|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
224046548|NCT06013592|DIETARY_SUPPLEMENT|0 kcal liquid meal|Flavoured water, given as one meal at one study visit only
224046549|NCT06013592|DIETARY_SUPPLEMENT|600 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
224046550|NCT06013592|DIETARY_SUPPLEMENT|900 kcal liquid meal (only for group without obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
224046551|NCT06013592|DIETARY_SUPPLEMENT|1200 kcal liquid meal|Fortisip Compact Vanilla, given as one meal at one study visit only
224046552|NCT06013592|DIETARY_SUPPLEMENT|1800 kcal liquid meal (only for group with obesity)|Fortisip Compact Vanilla, given as one meal at one study visit only
224046553|NCT03713034|OTHER|PlayTest!|Participants in the PlayTest! intervention arm played the game on their assigned iPads once per week for an hour over the course of 4-5 weeks.
224046554|NCT03713034|OTHER|Control games|Participants in the control arm played the games on their assigned iPads once per week for an hour over the course of 4-5 weeks.
224046555|NCT02500667|DRUG|N91115|200 mg BID
224046556|NCT02500667|DRUG|Rifampin|600 mg QD
224046557|NCT00713817|DRUG|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
224046558|NCT00713817|DRUG|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
224046559|NCT02293850|BIOLOGICAL|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
224046560|NCT00707850|DRUG|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
224142110|NCT02757781|BEHAVIORAL|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
224142111|NCT01213095|DRUG|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
224142112|NCT01147081|BIOLOGICAL|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
224142113|NCT01529385|DEVICE|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
224142114|NCT01529385|DEVICE|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
224142115|NCT01975233|DEVICE|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
223435467|NCT05297110|DRUG|atherolive|In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
223435468|NCT05571423|BEHAVIORAL|Medical Play|Study subject will be engage in the medical play.
223435469|NCT05571423|BEHAVIORAL|Routine Play|Study subject will be engage in the routine play (coloring exercise).
223435470|NCT05855408|BIOLOGICAL|Intramuscularly administered Ad5-nCoV vaccine|This vaccine is produced by CanSino Biologics Inc.
224142116|NCT03691753|DEVICE|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
224142117|NCT03691753|DEVICE|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
224142118|NCT05369026|OTHER|Single leg immobilization|2 weeks of single-leg immobilization
224142119|NCT01773096|DRUG|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
224142120|NCT01773096|DRUG|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
224142121|NCT00450047|DEVICE|Speed-feedback therapy system with a bicycle ergometer|
224142122|NCT00450047|DEVICE|Ergometer at conventional settings|
224142123|NCT05496894|DRUG|Mitoxantrone Hydrochloride Liposome Injection|IV, once every 3 months (Q3M)
224142124|NCT06319001|OTHER|Low-volume high intensity exercise|This intervention will consist of 10 x 10-second interval sprints on a stationary bicycle interspersed with 50-second breaks between repetitions. The cycle resistance will be adjusted to the level equaling the highest power output, which will be determined during warm-up sprints.
224142125|NCT06319001|OTHER|Combined intermittent sauna and cold water bath (sauna+cold bath).|This intervention will consist of 3x10 min bouts in the dry sauna interspersed with 2x 60 seconds of cold water immersion up to the neck.
224142126|NCT01213069|OTHER|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
224142127|NCT00321269|BEHAVIORAL|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
224142128|NCT00321269|BEHAVIORAL|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
224142129|NCT01830296|DRUG|Remifentanil+morphine|Morphine, Remifentanil+Morphine
224142130|NCT00964158|BIOLOGICAL|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
224142131|NCT02961517|OTHER|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
224142132|NCT03785795|DEVICE|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
224142133|NCT02137759|RADIATION|Standard Radiation Therapy|Radiation therapy to 60 Gy
224142134|NCT02137759|DRUG|Standard Temozolomide|Temozolomide given orally
224142135|NCT02137759|DRUG|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
224142136|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
224142137|NCT01666678|DRUG|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
224142138|NCT01666678|DRUG|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
224142139|NCT01666678|DRUG|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
224142140|NCT03658993|DRUG|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
224142141|NCT01077388|BEHAVIORAL|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
224142142|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6
223435471|NCT05855408|BIOLOGICAL|Aerosolized Ad5-nCoV|This vaccine is produced by CanSino Biologics Inc.
223435472|NCT05855408|BIOLOGICAL|DelNS1-2019-nCoV-RBD-OPT1|This vaccine is produced by Wantai Biopharmaceutical Company.
224142143|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6
224142144|NCT03895944|BIOLOGICAL|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
224142145|NCT03011580|DIETARY_SUPPLEMENT|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
224142146|NCT03011580|DIETARY_SUPPLEMENT|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
224142147|NCT00986427|DRUG|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
223435473|NCT05855408|BIOLOGICAL|SYS6006|This vaccine is produced by CSPC Pharmaceutical Group Co., Ltd.
223435474|NCT03526055|DEVICE|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
223435475|NCT04328610|PROCEDURE|LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique|Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
224142148|NCT00986427|DRUG|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
224142149|NCT01401465|DRUG|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
224142150|NCT01401465|DRUG|mometasone|200 mcg mometasone aqueous nasal spray once daily
224142151|NCT03497260|DIETARY_SUPPLEMENT|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
224142152|NCT03497260|OTHER|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
224142153|NCT06006312|DIAGNOSTIC_TEST|fecal elastase-1 test|Personal information of the enrolled subjects will be collected and a fecal collection device will be distributed. Fecal elastase-1 levels will be measured after the fecal sample is collected.
224142154|NCT06006312|DIAGNOSTIC_TEST|72-hour fecal fat quantification|Enrolled subjects will eat a standard meal (100g of fat) daily for five consecutive days and collect stool samples for the last 72h. The fat content in the sample will be quantitatively detected and the fat absorption coefficient will be calculated.
223435476|NCT04298034|DRUG|Labetalol, Nifedipine|Antihypertensive treatment that is safe and well studied in peripartum women.
223435477|NCT00542100|DEVICE|PCMRI|
223435478|NCT05849506|DEVICE|Touch® Prosthesis|The Touch® prosthesis is a medical device approved in Switzerland, which is an effective surgical treatment for advanced CMC I osteoarthritis.
223435479|NCT03107975|BIOLOGICAL|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
223435480|NCT03637530|OTHER|inverse ratio ventilation|during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
223435481|NCT01807468|PROCEDURE|haploidentical stem cell transplantation and NK cell therapy|
223435482|NCT00570180|DRUG|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
223435483|NCT00195494|DRUG|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
223435484|NCT00195494|DRUG|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
223435485|NCT00195494|DRUG|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
223435486|NCT04283526|DRUG|MBG453|Intravenous. 600mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
223435487|NCT04283526|DRUG|NIS793|Intravenous. 2100mg. Every first day of a 21-day cycle, or on days 8 and 29 of a 42-day cycle (when in combination with Decitabine).
224142155|NCT06006312|DIAGNOSTIC_TEST|blood sample test|The enrolled subjects will undergo oral glucose tolerance test and will be collected blood samples for measurement of plasma glucose, insulin level, C-peptide level, glycosylated hemoglobin and vitamin.
224142156|NCT02389140|OTHER|Trigger point release|Trigger point therapy
224142157|NCT02389140|OTHER|Ultrasound|sham ultrasound
224142158|NCT04910763|BEHAVIORAL|Resistance Exercise|Increasing strength and fitness and thereby influencing hormones and perceptions involved in appetite regulation.
224142159|NCT03385382|DRUG|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
224142160|NCT03385382|DRUG|Ranibizumab Injection|Injection of ranibizumab
224142161|NCT04564326|PROCEDURE|Pericapsular nerve Group block|Under ultrasound guidance a needle is inserted between the iliopectineal eminence and the iliopsoas muscle and tendon to block articular branches supplying the capsule of hip joint.
224142162|NCT04564326|PROCEDURE|Facia Iliaca block|Under ultrasound guidance a needle is inserted between the fascia iliaca and Psoas muscle to block the femoral, obturator and lateral cutaneous nerves.
224142163|NCT04564326|DRUG|Fentanyl|Intravenous fentanyl in a dose of 1mic/kg divided into two boluses with 5 minutes interval in between.
224142164|NCT05155657|BIOLOGICAL|Conventional therapy plus low dose UCMSCs treatment|Patients will receive the conventional therapy plus low dose UCMSCs treatment (0.5×10\^6 UCMSCs/kg body)
224142165|NCT05155657|BIOLOGICAL|Conventional therapy plus medium dose UCMSCs treatment|Patients will receive conventional therapy plus medium dose UCMSCs treatment (1×10\^6 UCMSCs/kg body)
224142166|NCT05155657|BIOLOGICAL|Conventional therapy plus high dose UCMSCs treatment|Patients will receive conventional therapy plus high dose UCMSCs treatment (2×10\^6 UCMSCs/kg body)
224142167|NCT00261326|DRUG|simvastatin|80 mg once daily
224142168|NCT00261326|DRUG|placebo|calcium tablets once daily
223435488|NCT04283526|DRUG|Spartalizumab|Intravenous. 300mg. Every first day of a 21-day cycle
223435489|NCT04283526|DRUG|Decitabine|Intravenous. Starting dose: 5mg/m2 (dose cap at 20mg/m2). On days 1, 2 and 3 of a 42-day cycle
223435490|NCT05775926|OTHER|Education|Nursing Care and Challenges Training for Nurses Caring for Dying Cancer Patients and Their Families was given in 4 modules and 2 days.
223435491|NCT03252366|DEVICE|GELFOAM|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
223435492|NCT03252366|DEVICE|xenograft|"* Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
223435493|NCT06730269|BEHAVIORAL|Face-to-Face Rehabilitation Program|The Face-to-Face Rehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group engaged in the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction. The exercises were performed three times per week over six weeks, under the direct supervision of a trained therapist. This setup ensured real-time feedback, personalized adjustments, and guidance during each session, optimizing the effectiveness of the rehabilitation process.
223435494|NCT06730269|BEHAVIORAL|Telerehabilitation Program|The Telerehabilitation Program is a structured rehabilitation regimen designed to improve posture, reduce pain, and strengthen back extensor muscles in children with thoracic hyperkyphosis. Participants in this group followed the Thoracic Corrective Exercise Program, which included four specific exercises targeting thoracic spine correction, performed three times per week over six weeks. The program was delivered remotely through the Fiziu platform, allowing therapists to provide virtual guidance, feedback, and monitoring during the sessions. This approach offered flexibility for families and ensured accessibility to rehabilitation services from the comfort of their homes.
223435495|NCT02020512|DRUG|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
224046561|NCT05244707|BEHAVIORAL|Mediterranean style diet|The intervention will consist of an intensive food and nutrition intervention program to improve adherence to the Mediterranean dietary pattern. In addition to individual and face-to-face nutrition consultations, other strategies will be used, such as telephone contacts, short text messages, consultation support tools, podcasts, short open access videos, nutrition workshops and nutrition sessions for caregivers of participants in the study.
224046562|NCT05244707|BEHAVIORAL|Standard of care|The usual care group will only have access to face-to-face and individual nutrition consultations in order to improve adherence to the Mediterranean dietary pattern.
224046563|NCT03846349|DEVICE|IOPI|IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
224046564|NCT03846349|DEVICE|EMT threshold|EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
224046565|NCT05443230|DIAGNOSTIC_TEST|gait speed; ct scan; grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
224046566|NCT02982239|BEHAVIORAL|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
224046567|NCT02982239|DEVICE|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
224046568|NCT02982239|DEVICE|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
224046569|NCT02982239|DEVICE|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
224046570|NCT02982239|OTHER|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q\&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
224142169|NCT02247674|PROCEDURE|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
224142170|NCT01115738|DRUG|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
224142171|NCT01115738|DRUG|Clopidogrel|Loading dose administered once orally.
224142172|NCT01115738|DRUG|Placebo|Loading dose administered once orally
224142173|NCT03633565|DRUG|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
223435496|NCT05023551|DRUG|DSP-0390|DSP-0390 administered orally
224142174|NCT03633565|DRUG|Prednisolone (Steroids)|tablet 20 mg
224142175|NCT03633565|PROCEDURE|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
223435497|NCT02624622|PROCEDURE|Chlorhexidine application to cord by mother|
223744830|NCT06162442|DRUG|Preservative-free sterile ophthalmic solution, with 0.3% propylene glycol and 0.4% polyethylene glycol (400)|"The procedures during the study consist of ophthalmological activities and attention to the participating subject with a diagnosis of DED and who starts using a specified ocular lubricant, free of preservatives. The ophthalmologist will notify the subject of the wash out, which will consist of suspending the usual treatment medication for 7 days, to then start with the lubricant Glicolub Ultra®, with a dosage of 1 drop every 6 hours in both eyes. Self-assessment questionnaires will be delivered for their respective completion. An assessment will be made by the comprehensive ophthalmologist in all clinical tests for dry eye with a mild to moderate diagnosis, under compliance with the TOSF DEWS II criteria and study inclusion criteria."
224046571|NCT02982239|BEHAVIORAL|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
224046572|NCT06495528|DEVICE|Pain management with BLISS DTx|Bliss DTx is a Digital Therapeutics (DTx) which uses virtual reality augmented with sound and visual stimuli to reduce pain during Port-A-Cath setting
224046573|NCT06495528|OTHER|Pain Management with site standard of care sedation protocol|Sedation (morphine and/or hypnotics and/or anxiolytics and/or conversational hypnosis) reduces pain during Port-A-Cath setting
224046574|NCT04415658|DRUG|Thyroxine|Infusion prepared by mixing 500 μg of drug in 500-ml of normal saline (i.e. concentration of 1 μg/ml) and enclosing the bag in an opaque sleeve. Infusion started at 30 μg/hour (30 ml/hour) for twelve hours.
224046575|NCT04415658|DRUG|Saline|The placebo will be a 500-ml bag of normal saline (without active drug) also enclosed in an opaque sleeve. This infusion will also be started at 30 ml/hour for twelve hours.
224046576|NCT05049980|DRUG|Medical treatment with Mifégyne® and MisoOne®|When participants arrive for their uterine emptiness check-up, 12 days after treatment, patients will be asked to drop off the study questionnaire the same day in a box provided for this purpose in the department.
224046577|NCT05049980|PROCEDURE|Endo-uterine aspiration|When patients arrive in hospital on the day of the surgery, participants will be asked to complete a questionnaire at home 1 week after surgery and return it to investigators.
224046578|NCT05837520|DEVICE|i-BiSSkApp (tablet application) with swallowing therapy|"The device, International Biofeedback Strength and Skill App (i-BiSSkApp) is an at-home swallowing biofeedback tool (hardware and software) to target rehabilitation of both skill and strength of swallowing function. The program utilizes submental surface electromyography coupled with a user-friendly interface to display visual feedback of swallowing strength and timing."
224046579|NCT05837520|BEHAVIORAL|Traditional behavioral swallowing therapy|Participants will receive standard behavioral swallowing exercises based on the results of a swallowing evaluation. Participants will complete daily at-home exercises with written and verbal instructions and return weekly to clinic for 12 weeks of therapy.
224046580|NCT01938131|DEVICE|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
224046581|NCT03561792|OTHER|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
224046582|NCT02475226|OTHER|type of the brain injury|epidural hematoma
224046583|NCT02475226|OTHER|type of the brain injury|subdural hematoma
224046584|NCT02475226|OTHER|type of the brain injury|subarachnoid hematoma
224046585|NCT02475226|OTHER|type of the brain injury|intraparenchymal hematoma
224046586|NCT02475226|OTHER|type of the brain injury|scull fracture
224046587|NCT02475226|OTHER|type of the brain injury|brain contusion
224046588|NCT06227364|DIAGNOSTIC_TEST|MCI patients|patients with mild cognitive impairment submitted to Magnetic Resonance, neuropsychological evaluation, neurological assessment
224046589|NCT06227364|DIAGNOSTIC_TEST|metabolic patients|patients with obesity and metabolic dysfunction submitted to haematological tests, psychological and neuropsychological evaluation and endocrinologu assessment
224046590|NCT06070077|PROCEDURE|Chest compressions|2 minutes of chest compressions
224046591|NCT05894174|BEHAVIORAL|Board Game|Food Hunter board game intervention, which includes various nutrient cards and question cards and is played with pawns and dice, will be played with children for approximately 4 weeks, one day a week and one session (40 minutes) with the researcher dietitian. By talking about the nutrients in the game on the game cards, children will be able to recognize the nutrients and important points will be emphasized for the participants with the answers to the cards containing various questions about healthy nutrition.
224046592|NCT00452049|PROCEDURE|parathyroidectomy|parathyroidectomy
224142176|NCT01363557|OTHER|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
224142177|NCT01363557|DRUG|Gefitinib (IRESSA)|250 mg/day
224142178|NCT04597892|DIAGNOSTIC_TEST|serum creatinine assay|point-of-care and standard laboratory assay of serum creatinine
223435498|NCT02624622|PROCEDURE|Chlorhexidine application by CHW|
223435499|NCT04949763|OTHER|rehabilitation|Patients underwent ususal rehabilitation treatment
223435500|NCT01758718|PROCEDURE|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
223435501|NCT01635309|OTHER|Coronary CT Angiogram|pre-operative coronary CTA
223435502|NCT00878605|DRUG|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
223435503|NCT00878605|DRUG|Placebo|Placebo control
224142179|NCT04395963|DEVICE|Tobii Pro Glasses 50 Hz wearable wireless eye tracker|This system can measure eye movements using cameras integrated into the eyeglasses which record the corneal reflection of infrared lighting to track pupil position, mapping the subject's focus of attention on video recordings of the subject's field of vision (gaze).
224142180|NCT03077763|DRUG|Sodium Nitrite|
224142181|NCT01606735|DRUG|IBI-10090|dexamethasone
224142182|NCT02160886|BEHAVIORAL|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
224142183|NCT02160886|BEHAVIORAL|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
224142184|NCT00295217|DEVICE|ExAblate 2000|
224142185|NCT04758858|OTHER|Insulin treatment optimization with participant's usual diet|Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
224142186|NCT04758858|DEVICE|Abbott's FreeStyle Libre|During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
224142187|NCT04758858|OTHER|Three-day food journal|Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
224142188|NCT04758858|OTHER|Medical visit|During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
224142189|NCT04758858|OTHER|Blood pressure measurements|Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
223435504|NCT04854083|DRUG|Semaglutide, 1.34 mg/mL|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
223744831|NCT05434806|DIETARY_SUPPLEMENT|Jarlsberg cheese|Daly oral intake
224142190|NCT04758858|OTHER|Anthropometric parameters measurements|Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
224142191|NCT04758858|OTHER|Indirect calorimetry test|Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
224142192|NCT04758858|OTHER|Well-being questionnaire|Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
224142193|NCT04758858|OTHER|Diet appreciation questionnaire|Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
224299855|NCT02221037|DRUG|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
224299856|NCT02221037|DRUG|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
224299857|NCT03947736|DIAGNOSTIC_TEST|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
224299858|NCT00229736|GENETIC|AAV-hAADC-2|9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
224299859|NCT00229736|GENETIC|AAV-hAADC-2|3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
224299860|NCT05000970|DEVICE|blood pressure cuff PLUS tablet|all arms
224299861|NCT05000970|OTHER|Telehealth Consult|Telehealth consult with an RN
224299862|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04+PreforPro|One 15mg capsule taken orally each day
224299863|NCT04511221|DIETARY_SUPPLEMENT|Bifidobacterium animals subsp. lactis BL04|One 15mg capsule taken orally each day
224299864|NCT04511221|OTHER|Placebo|One 15mg capsule taken orally each day
224299865|NCT00031122|OTHER|No Intervention|There is no intervention in this study
223478542|NCT02202252|PROCEDURE|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
223478543|NCT02202252|PROCEDURE|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
223744832|NCT01787227|DEVICE|xTAG RPP|
223435505|NCT04854083|DRUG|Placebo|The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
223435506|NCT03353948|DRUG|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
223435507|NCT03353948|DRUG|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
223478544|NCT02202252|PROCEDURE|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
224046593|NCT06289322|OTHER|Digital toolkit for assessment|The pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
224046594|NCT04296877|DEVICE|Daily Disposable Contact Lens|Soft, daily disposable spherical contact lens used to correct distance vision.
224046595|NCT05331040|DIAGNOSTIC_TEST|MRI|Radiomic analysis of newly diagnosed rectal cancers
224046596|NCT03361150|PROCEDURE|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
224046597|NCT03361150|PROCEDURE|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
224046598|NCT03443505|DIAGNOSTIC_TEST|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
224046599|NCT00237575|DRUG|gemcitabine|
224046600|NCT00237575|DRUG|cisplatin|
224046601|NCT00237575|DRUG|sargramostim|
224046602|NCT00237575|DRUG|filgrastim|
224046603|NCT06302647|OTHER|Questionnaires|Three questionnaires have been developed to be used by subjects, pharmaceutical industry or doctors in regards to the willingness to use a platform for clinical trial recruitment
224046604|NCT03868852|DRUG|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
224046605|NCT03868852|RADIATION|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
224046606|NCT00886704|DIETARY_SUPPLEMENT|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
224046607|NCT00886704|DIETARY_SUPPLEMENT|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
224046608|NCT02256605|DIETARY_SUPPLEMENT|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D \[259OH)D\] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
224046609|NCT01956825|DIETARY_SUPPLEMENT|"slim water"|
224046610|NCT04968041|BEHAVIORAL|Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program|The intervention using strategies from motivational interviewing and cognitive behavioral therapy to promote motivation and adherence to ketogenic nutrition in older adults at high risk for Alzheimer's disease. The program is a 6-week, group program led by a psychologist and nutrition expert.
224046611|NCT01129050|DIETARY_SUPPLEMENT|Fish Oil|Fish oil capsule
224046612|NCT01129050|DIETARY_SUPPLEMENT|Flaxseed Oil|Flaxseed oil capsule
224142194|NCT04758858|DEVICE|Pedometer (PiezoRxD)|Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
224299866|NCT00306943|BIOLOGICAL|Influsplit SSW®|
223478545|NCT00779337|BIOLOGICAL|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
223478546|NCT01118299|DEVICE|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
223478547|NCT01503047|DIETARY_SUPPLEMENT|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
223478548|NCT01503047|DIETARY_SUPPLEMENT|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
224046613|NCT01129050|DIETARY_SUPPLEMENT|Placebo|Soybean oil capsule
224046614|NCT04183816|OTHER|Total cold-water immersion|TCWI group completed a session of 15-minutes in cold water with a temperature of 12°C.
223435508|NCT04573166|PROCEDURE|Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation|After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
223435509|NCT06234371|BEHAVIORAL|Financial Incentive|The intervention is offering a $500 gift card as an incentive for completing 6 counseling sessions to eligible individuals randomized into the treatment group. Another $500 gift card will be given after completing 12 counseling sessions, and another $500 gift card will be given after completing 18 counseling sessions.
223435510|NCT03023540|DRUG|PXT3003|Liquid oral solution, twice 5 mL (Dose 1) bid
223435511|NCT05691621|DRUG|Standard Reagents, Whole Blood|All patients receive standard treatment, only their blood and urine samples are needed
223566044|NCT05173610|RADIATION|Radiation: Stereotactic body radiotherapy (SBRT)|"Patients will be treated with stereotactic body radiotherapy (SBRT) for oligometastasis from hepatocellular carcinoma.~1. Target delineation The GTV is set using diagnostic CT, MRI, PET-CT, etc. CTV is delineated including the microscopic range in GTV and internal margin using 4D-CT. The PTV is expanded by considering the uncertainty of the daily patient posture setting and placement.~2. Radiotherapy All patients are treated using 3D-CRT, IMRT, or VMAT. Total dose and fractionations will be determined depending on the location and character of the metastasized tumor. Detailed radiation prescriptions is summarized in the following paragraph.~   i. Liver: 48-60 Gy in 4 fractions ii. Lung: 45-60 Gy in 3-4 fractions iii. Brain: 27-30 Gy in 3-5 fractions iv. bone: 24-40 Gy in 3-5 fractions v. adrenal gland: 30-60 Gy in 3-8 fractions vi. other organ: depending on the clinicians' decision"
224046615|NCT04183816|OTHER|Ice massage|Ice cubes massage in a clockwise circular motion on the thigh area (quadriceps) for 15 minutes.
224046616|NCT02676999|PROCEDURE|Implantation of a Scheker total distal radioulnar joint prosthesis|
224046617|NCT05990751|BIOLOGICAL|GD2 CAR T cells|The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.
224046618|NCT00087347|DRUG|ferumoxytol|
224046619|NCT00087347|PROCEDURE|magnetic resonance imaging|
224046620|NCT03712748|BEHAVIORAL|Imaginal Exposure therapy|All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
224046621|NCT03975270|DRUG|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
224046622|NCT03846570|DRUG|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
224046623|NCT03846570|DRUG|Placebo|Matching placebo (identically package) administered BID
224142195|NCT04758858|OTHER|Hepatic imaging (MRI)|Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
224142196|NCT04758858|OTHER|Glucagon efficiency test|The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
224142197|NCT04758858|OTHER|Body composition : Dual Energy X-ray absorptiometry (DEXA)|Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
223566045|NCT03369041|DRUG|Irinotecan-Eluting Beads|
224299867|NCT05441995|OTHER|Cryotherapy|Ice packs were applied in the buccal mucosa related to the tooth for 5 minutes after IANB administration
224046624|NCT04860375|PROCEDURE|Multidisciplinary patient care|A holistic, multidisciplinary, patient-centered care.
224046625|NCT04860375|OTHER|Standard care|Standard care in Sweden
224046626|NCT02107495|DEVICE|Samsung LABGEO IVD-A20 CHF Test|
224046627|NCT02767323|DEVICE|rTMS|excitatory 5Hz rTMS will be used
224046628|NCT02767323|DEVICE|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
224046629|NCT01865526|DIETARY_SUPPLEMENT|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~1. Do not add salt at table and for cooking;~2. Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~3. Replace noodle or bread with special no-protein food;~4. The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~5. 4-5 servings/day of fruits or vegetables are suggested;~6. Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
224046630|NCT01865526|DIETARY_SUPPLEMENT|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
224070505|NCT04017260|PROCEDURE|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
223435512|NCT05323747|OTHER|Observation|Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
223435513|NCT02453659|BEHAVIORAL|Distress Tolerance Treatment for Weight Concern (DT-W)|
223435514|NCT02453659|BEHAVIORAL|Health Education (HE)|
223435515|NCT02453659|BEHAVIORAL|Smoking Cessation counseling|
223435516|NCT02453659|DRUG|Transdermal Nicotine Patch|
223435517|NCT05326126|DEVICE|coronary physiology|To evaluate the association between microvascular disfunction and myocardial fibrosis identified per computed tomography among subjects undergoing TAVI for severe, symptomatic aortic stenosis.
223435518|NCT03019003|DRUG|Oral Decitabine|DNA methyltransferase inhibitor
223435519|NCT03019003|DRUG|Durvalumab|anti-PD-L1
224046631|NCT05558826|DEVICE|HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software|After induction of anesthesia, intra-arterial catheterization will be done for invasive blood pressure monitoring and blood sampling as routine clinical practice for major laparoscopic surgery. Arterial line will be connected to HemoSphere advanced monitoring platform with Acumen Hypotension Prediction Index Software for arterial pressure waveform analysis. Dynamic indices including pulse pressure variation (PPV), stroke volume variation (SVV), Hypotension Prediction Index (HPI), Dynamic arterial elastance (Eadyn) and dP/dt will be continuously recorded. Changes in levels of intra-abdominal pressure and angles of Trendelenburg position will be recorded. Data analysis and statistics will be particularly performed to explore the effects of levels of intra-abdominal pressure and angles of Trendelenburg position on dynamic indices of arterial pressure waveform.
224046632|NCT05500820|DRUG|CIN-107|A repeat oral dose of CIN-107 once daily for 10 days.
224046633|NCT05500820|DRUG|Matching Placebo|A repeat oral dose of matching placebo once daily for 10 days.
224046634|NCT05341648|OTHER|Aerobic Exercise Training|Warm-up: 5 minutes Aerobic Training Treadmill/cycle ergometer Frequency:3 days a week Intensity:40-70% of HR max(Start from 40% than increment to as per patient tolerance) Total Duration:6 weeks. Duration of each session:15-30 mins. Cool-down: 5 minutes
224046635|NCT05341648|OTHER|Home Plan|"* Positions to ease breathlessness~* Controlled breathing/Deep breathing\*10 Reps\* TD,s~* Progressive Muscle Relaxation Exercises.~* ROM \& Flexibility Exercises. 3 days a week for 6 weeks."
223435520|NCT03019003|DRUG|5' Azacitidine|DNA methyltransferase inhibitor
224046636|NCT00906893|PROCEDURE|18F]-FMISO PET-CT|pretherapy(\[18F\]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe \[18F\]-FMISO uptake will be used.
224046637|NCT00827684|DRUG|Irinotecan|
224046638|NCT00827684|DRUG|Temsirolimus|
224046639|NCT05957250|DIAGNOSTIC_TEST|[68Ga]Ga-FAPI-46 PET/CT|one or two \[68Ga\]Ga-FAPI-46 PET/CT scan(s)
224046640|NCT00745199|DRUG|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
224046641|NCT00745199|DRUG|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
224046642|NCT00349167|DRUG|PR-104|
224046643|NCT00349167|OTHER|laboratory biomarker analysis|
224046644|NCT00349167|OTHER|pharmacological study|
224046645|NCT04485143|DEVICE|Wisdom bracelet|routine medical
224046646|NCT02408705|DRUG|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
223435521|NCT03019003|DRUG|Tremelimumab|anti-CTLA4
223435522|NCT00912106|OTHER|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
223435523|NCT04786171|DIAGNOSTIC_TEST|4D X-ray Velocimetry|X-ray velocimetry uses fluoroscopy to quantify local ventilation in the lung.
223435524|NCT01133496|DRUG|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
223435525|NCT03029845|DRUG|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
223435526|NCT03029845|DRUG|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
223435527|NCT03029845|DRUG|Placebo|Participants will take placebo twice a day for 2 weeks
224046647|NCT02408705|DRUG|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
224046648|NCT02408705|DRUG|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
223435528|NCT02300961|BEHAVIORAL|Cognitive rehabilitation program|
223435529|NCT05599347|DRUG|Azithromycin Pill|Tablet - 500 mg azithromycin (as dihydrate)
223435530|NCT05599347|OTHER|Placebo|Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm
223435531|NCT06153173|DRUG|Mirdametinib|Mirdametinib is administered by mouth twice daily on a continuous schedule, with each cycle being 4 weeks. Patients are instructed to take consecutive doses separated by a minimum of 6 hours and a maximum of 14 hours.
223478549|NCT01700803|DRUG|Povidone Iodine 10% vand cesarean section wound infections|
223478550|NCT01700803|DRUG|Povidone Iodine 7.5% vand cesarean section wound infections|
224046649|NCT00699803|DRUG|T-PRED|T-PRED sterile ophthalmic solution
224046650|NCT00699803|DRUG|Pred Forte|Pred Forte sterile ophthalmic solution
224046651|NCT03505047|DEVICE|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
224046652|NCT04688151|DRUG|Rituximab|Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
224046653|NCT06387654|BIOLOGICAL|Blood sampling|Blood will be taken in larger quantity
224046654|NCT06387654|BIOLOGICAL|Remainders of samples taken as part of the treatment|blood, CSF, saliva, stools, urine, other biological fluids and tissue biopsies, hair follicles
224046655|NCT01161602|DRUG|Pumosetrag|
224046656|NCT01161602|DRUG|Pumosetrag|
224046657|NCT01161602|OTHER|Placebo|
224046658|NCT01161602|DRUG|Pumosetrag|
223435532|NCT06350643|OTHER|Quit and Screen Project training|This online course will be developed for healthcare providers and will fill gaps in knowledge and attitudes toward lung cancer screening and smoking not covered by the G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training.
224142198|NCT04758858|OTHER|Blood tests|Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
224142199|NCT04758858|OTHER|Stool sample collections (optional)|Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
223435533|NCT06350643|OTHER|G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training|The G02 (Global Knowledge Center for Lung Cancer) Lung Cancer Screening training is an online course that covers disparities in lung cancer and smoking, patient barriers to lung cancer screening, and provider resources for addressing common barriers.
223435534|NCT05808764|DRUG|Risdiplam|Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
224046659|NCT02895620|BIOLOGICAL|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
224046660|NCT00415506|DRUG|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
224142200|NCT04758858|OTHER|Hypoglycemia journal|During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
224142201|NCT04758858|OTHER|Ketone journal|During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
224046661|NCT00151970|DRUG|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
224046662|NCT00151970|DRUG|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
224046663|NCT00151970|DRUG|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
224142202|NCT04758858|OTHER|Adherence to the diet (Keenoa)|During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
224142203|NCT01623141|PROCEDURE|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
224142204|NCT04908917|DEVICE|Portable Air Cleaner with a HEPA Filter|A novel intervention using a portable air cleaner with HEPA filter to treat mildly high BP to potentially reduce the cardiovascular effects of PM2.5. Leave the PAC running with the HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
223435535|NCT05754255|DEVICE|Nasal Cannula|"A nasal cannula is a medical device to provide supplemental oxygen therapy to people who have lower oxygen levels. There are two types of nasal cannulas: low flow and high flow.~The device has two prongs and sits below the nose. The two prongs deliver oxygen directly into your nostrils."
223435536|NCT05754255|DEVICE|Nasal Positive Airway Pressure System|Positive airway pressure (PAP) treatment uses a machine to pump air under pressure into the airway of the lungs. This helps keep the windpipe open during sleep. The forced air delivered by CPAP (continuous positive airway pressure) prevents episodes of airway collapse that block the breathing in people with obstructive sleep apnea and other breathing problems.
223435537|NCT05211895|DRUG|Durvalumab|Durvalumab IV (Intravenous infusion)
223566046|NCT02772796|DRUG|SENS-218|Oral Administration
224142205|NCT04908917|DEVICE|Portable Air Cleaner without a HEPA Filter|Leave the PAC running without a HEPA filter installed on the highest setting during sleeping periods in the room in which the participant sleeps.
223435538|NCT05211895|DRUG|Domvanalimab|Domvanalimab IV (Intravenous infusion)
223435539|NCT05211895|OTHER|Placebo|Placebo IV (Intravenous infusion)
223566047|NCT05536622|DIAGNOSTIC_TEST|High resolution infrared imaging|High resolution infrared imaging of limb of concern and unaffected limb (control).
223566048|NCT00536016|DRUG|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
224046664|NCT04666467|DEVICE|Transcatheter mitral valve repair|Transvenous approach with a transeptal puncture to place the study device
224046665|NCT06208384|DRUG|Statin eye drop|Use of topical atorvastatin eye 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
224046666|NCT06208384|DRUG|Placebo|Use of topical eye drops as a placebo same as intervention group but without active ingredient of atorvastatin 8 times a day; in addition to eyelid hygiene and artificial tear drops (8 weeks)
224046667|NCT00492830|DRUG|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
224046668|NCT01847430|BIOLOGICAL|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
224046669|NCT01686776|OTHER|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
224046670|NCT01104038|BEHAVIORAL|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
224046671|NCT01104038|BEHAVIORAL|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
223435540|NCT05245331|DEVICE|Peristeen® Transanal irrigation system with the conic catheter|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
223435541|NCT05245331|DEVICE|Standard reusable enema|"The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference."
223435542|NCT06234956|BIOLOGICAL|BIMERVAX|BIMERVAX
223435543|NCT01060878|DRUG|PYM50028|IMP
223435544|NCT01060878|DRUG|Placebo|Matching placebo comprising identical vehicle to active doses
223744833|NCT04398069|PROCEDURE|hemodynamic optimisation aiming to achieve normal cerebral perfusion|hemodynamic optimisation aiming to achieve normal cerebral perfusion: titration of catecholamin infusion.
224046672|NCT01104038|BEHAVIORAL|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
224046673|NCT05166915|DEVICE|UVA Light Emitting Catheter|Experimental Device intended to eliminate microorganisms using UV-A light, thereby reducing the viral burden of SARS-CoV-2
224142206|NCT02290886|OTHER|Intravenous administration of placebo|
224142207|NCT02290886|DRUG|Intravenous administration of 1 million of MSC|
224142208|NCT02290886|DRUG|Intravenous administration of 2 million of MSC|
224046674|NCT05166915|DEVICE|Sham Control Catheter|Sham Control Device
224070506|NCT00106171|DRUG|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
223435545|NCT04788225|OTHER|Balance assessment|"Static balances will be measured with the Biodex-BioSway 950-462 static balance device according to 3 different standard test procedures (Postural Stability Test, Stability Limit Test and Modified Sensori Organization Test) in single foot stance and double foot stance.~Dynamic balances will be evaluated with the Y balance test."
223435546|NCT04788225|OTHER|Functionality assessment|Functionality will be evaluated with the Lower Extremity Functional Scale and AOFAS (American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale)
223435547|NCT04788225|OTHER|Performance assessment|Performance evaluation will be made with a single leg jump test and time up and go test.
223435548|NCT04788225|OTHER|ROM assessment|Range of motion (ROM) of the ankle will be measured with an electrogonyometer in dorsi-plantar flexion.
223435549|NCT01443494|OTHER|NE|norepinephine
223744834|NCT03163888|PROCEDURE|Navigation TKR|Traditional over Conventional TKR
224070507|NCT01785134|PROCEDURE|Omentectomy|
224070508|NCT01785134|PROCEDURE|Gastric bypass operation|
224070509|NCT03074474|DEVICE|OviTex 1S Permanent|OviTex 1S Permanent is a reinforced tissue matrix consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
224070510|NCT02987621|DEVICE|tDCS|Less than 10V of Transcranial Direct Current Stimulation. Sham 0V of Transcranial Direct Current Stimulation.
224070511|NCT03612986|DIETARY_SUPPLEMENT|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
224070512|NCT03612986|DIETARY_SUPPLEMENT|Placebo|Placebo comparator. No chemical effect expected
224070513|NCT02963532|OTHER|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
224070514|NCT01035905|DEVICE|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224070515|NCT01035905|DEVICE|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
224070516|NCT02751840|DIETARY_SUPPLEMENT|Caffeine|200 mg of caffeine capsule before RMR measurement
224070517|NCT02751840|DIETARY_SUPPLEMENT|Placebo|Placebo capsule (starch) before RMR measurement
224070518|NCT02751840|OTHER|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
224070519|NCT02751840|OTHER|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
224070520|NCT02179229|DIETARY_SUPPLEMENT|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
224070521|NCT02179229|DIETARY_SUPPLEMENT|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
224070522|NCT04947670|PROCEDURE|Renal arteriography followed by renal denervation|Renal arteriography followed by renal denervation
224070523|NCT04947670|PROCEDURE|Sham Renal arteriography|Renal arteriography only
224070524|NCT01088581|DRUG|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
224070525|NCT04817111|DRUG|MIB-626|Two (2) 500 mg Tablets, By Mouth, Daily
224070526|NCT04385654|DRUG|Toripalimab|Toripalimab (240 mg,ivgtt,q3w) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
224070527|NCT04385654|DRUG|Axitinib|Axitinib (5 mg,po,qd) was administered to patients for 6 weeks and underwent surgery within 2-4 weeks
224070528|NCT00710073|DEVICE|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
224070529|NCT02615444|DIETARY_SUPPLEMENT|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
224070530|NCT02615444|DIETARY_SUPPLEMENT|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
224070531|NCT05307029|PROCEDURE|rehabilitation with fixed full-arch prosthesis|
224046675|NCT02019576|RADIATION|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
224046676|NCT01389167|DRUG|Vivitrol|An extended release naltrexone formulation for intramuscular injection
223435550|NCT04441684|DIAGNOSTIC_TEST|Blood sample for serological test|"Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."
223435551|NCT05998434|BEHAVIORAL|Improving Low Back Pain Through Motor Control Training|In the digital healthcare group, participants utilized app-based online motor control training. In contrast, participants in the traditional treatment group underwent motor control training under the guidance of healthcare professionals at the hospital.
224046677|NCT01389167|DRUG|Naltrexone (oral)|Naltrexone 50 mg pills, daily
224046678|NCT01389167|BEHAVIORAL|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
224046679|NCT01389167|BEHAVIORAL|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
224046680|NCT03228303|DRUG|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
224046681|NCT03228303|DRUG|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
224046682|NCT00575536|PROCEDURE|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
224046683|NCT04327765|COMBINATION_PRODUCT|0.5mg AZ-010|Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo
224046684|NCT04327765|COMBINATION_PRODUCT|1mg AZ-010|Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo
224046685|NCT04327765|COMBINATION_PRODUCT|3mg AZ-010|Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo
224046686|NCT05362422|DEVICE|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
223435552|NCT06402591|DRUG|Cefazolin|cefazolin extended prophylaxis 5 days (15 doses)
223435553|NCT03812562|BIOLOGICAL|Nivolumab|Given IV
223435554|NCT03812562|RADIATION|Yttrium Y 90 Glass Microspheres|Given IV
224046687|NCT05362422|DEVICE|sham long-term paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
224046688|NCT02991742|OTHER|contrast media|Compare 2 contrast media
224142209|NCT02290886|DRUG|Intravenous administration of 4 million of MSC|
224142210|NCT04752124|OTHER|Exercise Therapy|High intensity speed based interval treadmill training
223435555|NCT02994758|OTHER|Personalised treatment|Treatment based on NGS or DSRT
223435556|NCT03056365|PROCEDURE|Advanced Nurse (AN)|Protocoled AN-based management of detox
223744835|NCT01179477|DEVICE|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
224142211|NCT04752124|OTHER|conventional therapy|conventional physical therapy
223435557|NCT03056365|PROCEDURE|General Practitioner (GP)|'As usual' medical management of detox
223435558|NCT02622841|PROCEDURE|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
223744836|NCT00189228|DRUG|Xolair|Patients are administered Xolair
223744837|NCT03031808|DRUG|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
223744838|NCT03031808|DRUG|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
223744839|NCT03031808|OTHER|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
223744840|NCT05601323|DEVICE|Suizenji|HIFU treatment
224046689|NCT03582930|COMBINATION_PRODUCT|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
224046690|NCT00653042|DRUG|Nesiritide|
224142212|NCT02063919|OTHER|the mucosal microbiome in the biopsy specimen was analysed|
224142213|NCT00413335|DRUG|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
224142214|NCT00413335|DRUG|Placebo|Subject receives placebo.
224142215|NCT02491502|DEVICE|Echopulse|HIFU Under ultrasound guidance
224299868|NCT05050890|OTHER|ctDNA level during neoadjuvant chemotherapy|ctDNA samples will be collected from patients at baseline, during neoadjuvant therapy (every 15 days) and before the surgical procedure
224046691|NCT04553848|BEHAVIORAL|Augmented Reality|Augmented Reality (AR) systems are computer-based applications that allow an individual to view a simulated environment and dynamically interact within this environment in real-time. Augmented reality activities will be chosen by the therapist based on the primary deficits assessed during baseline testing.
224046692|NCT04553848|BEHAVIORAL|Treadmill training|The goal of each session will be to increase balance and mobility challenge by increasing speed and minimizing BWS. Appropriate BWS will be chosen at the beginning of each training session. Participants will walk for 1 minute on the treadmill at 30%, 20% and 10% BWS. Maximum walking speed will be determined at each level of BWS and the participant will spend the remainder of the session ambulating with BWS at which they were able to achieve maximum walking speed. Additional BWS will be provided up to 30% of the participant's total body weight if the treating therapist identifies safety concerns or unfavorable gait kinematics. If a safe and kinematically appropriate gait pattern is unable to be achieved at up to 30% BWS, the previously determined walking speed will be reduced to achieve a safe and appropriate walking pattern. Participants will be encouraged not to use upper extremity support while ambulating with BWS.
224046693|NCT04553848|BEHAVIORAL|Over ground training/standard of care|"Standard of care interventions to address balance and mobility deficits will be chosen from a list of commonly used interventions in outpatient therapy. The goal of each session will be to increase balance and mobility challenge in an over ground condition focusing treatment in the following areas:~* Biomechanical Constraints~* Stability Limits~* Anticipatory Postural Adjustments~* Reactive Postural Response~* Sensory Orientation~* Stability in Gait"
224046694|NCT02791022|DEVICE|SPYDER ECG sensor|
224046695|NCT06396585|DRUG|Tislelizumab|Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
224046696|NCT06396585|DRUG|Anlotinib|Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
224046697|NCT06396585|DRUG|Oxaliplatin|Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
224046698|NCT06396585|DRUG|Tegafur|Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
223435559|NCT04197895|PROCEDURE|Socket preservation with APRF|Socket preservation with APRF , A-PRF membranes were implanted into the extraction socket following tooth extraction. One entire A-PRF membrane would be placed at the base of the extraction socket and another A-PRF membrane will cover the extraction site then suturing will be done .Venous blood will be collected via venipuncture of the forearm with a butterfly needle into at least 10 mL sterile glass vacuum tube. The blood sample will be immediately centrifuged at 1,300 rpm (200 x g) for 8 minutes
223435560|NCT04197895|PROCEDURE|natural healing|after atraumatic extraction , the socket will be left for natural healing after suturing
223435561|NCT03994614|OTHER|TEAS|Patients in the experimental group will be given TEAS treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint Baihui(DU20), abdominal acupoint Zhongji (RN3), Guanyuan (RN4), Zigong(EX-CA1), leg acupoint Sanyinjiao(SP6), waist acupoint Shenyu (BL23) and Guanyuanyu(BL26).
223435562|NCT00270283|DRUG|epoetin alfa|
223435563|NCT00274443|DRUG|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
223435564|NCT06080906|BIOLOGICAL|IRV on a 0- and 28-day schedule|Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28
223435565|NCT06080906|BIOLOGICAL|IRV on a 0-, 28- and 56-day schedule|Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56
223435566|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28|Two doses of placebo at the vaccination schedule of Day 0, 28
223435567|NCT06080906|BIOLOGICAL|Placebo on Day 0, 28, 56|Three doses of placebo at the vaccination schedule of Day 0, 28, 56
224046699|NCT01831921|BEHAVIORAL|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
224046700|NCT01831921|BEHAVIORAL|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
224046701|NCT03932656|BEHAVIORAL|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
224142216|NCT02496481|BEHAVIORAL|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
224142217|NCT02496481|BEHAVIORAL|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
223435568|NCT06521580|PROCEDURE|Open reduction and internal fixation|Open reduction and internal fixation of those with osteopetrosis and weight bearing fractures
223435569|NCT05436678|DRUG|PrimeC 748 mg|PrimeC is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
223435570|NCT05436678|DRUG|Ciprofloxacin 750 MG|Ciprofloxacin
223435571|NCT05436678|DRUG|Celecoxib 200mg|Celecoxib
223435572|NCT01839305|OTHER|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
223744841|NCT05601323|DRUG|Nal-IRI/FL|Nanoliposomal irinotecan, Fluorouracil, Levofolinate
223744842|NCT05601323|DRUG|mFOLFIRINOX|Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
223744843|NCT05601323|DRUG|Gem/nab-PTX|Gemcitabine, nab-Paclitaxel
223744844|NCT00152581|DRUG|Pegylated interferon-alfa2a (Pegasys); ribavirin|
223435573|NCT04174937|DRUG|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
223435574|NCT04174937|OTHER|Placebo PA|Intervention is administered to patients in this Arm
224046702|NCT03932656|DRUG|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
224046703|NCT00139347|BIOLOGICAL|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
224046704|NCT05349851|OTHER|Follow-up with blood and urine analysis|The patients will receive the preparation standards according to the usual clinical practice of each center. On the day of the colonoscopy, patient will be informed about this study and the informed consent will be requested to record the study information. Then, an analysis will be carried out. A second visit will be carried out, follow-up at 3-7 days, which will include a clinical interview and an analysis, being the unique intervention that patients receive.
224046705|NCT02995486|OTHER|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
224046706|NCT00633711|DEVICE|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
224046707|NCT00633711|DEVICE|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
224046708|NCT00773721|DEVICE|CPAP mask|"Current CPAP masks are mainly silicone elastomers, which though well understood and accepted, are often uncomfortable.~Test Units: The test unit is a foam seal component which directly replaces the patients existing silicone mask cushion, and is fitted to the patients existing mask frame.~Subjects will wear the test unit mask, instead of their current CPAP mask, each night whilst sleeping."
224046709|NCT02847455|DRUG|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
224046710|NCT02847455|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
224046711|NCT02847455|DRUG|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
224046712|NCT04891094|DIAGNOSTIC_TEST|Ultrasound|daily ultrasound of the lung and the diaphragm
224046713|NCT02596477|DRUG|Vepoloxamer|
224046714|NCT02596477|OTHER|5% dextrose in water|
224142218|NCT00545987|DEVICE|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
224142219|NCT00545987|DEVICE|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
224142220|NCT03716518|DRUG|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
224142221|NCT03716518|DRUG|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
224142222|NCT00966303|OTHER|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
224142223|NCT04009213|DEVICE|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
224142224|NCT04009213|DEVICE|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
224142225|NCT05529290|DRUG|Dexketoprofen Trometamol + Thiocolchicoside|Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
224142226|NCT05529290|DRUG|Dexketoprofen Trometamol + Paracetamol|Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
224142227|NCT05529290|DRUG|Dexketoprofen Trometamol (25mg)|Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
224142228|NCT05529290|DRUG|Paracetamol|Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
224046715|NCT03108547|OTHER|Determination of scalp hair steroids|
224046716|NCT04026347|DEVICE|Vesair Balloon|Indwelling, intravesical balloon
224046717|NCT04026347|OTHER|Sham balloon placement|Sham balloon placement procedure
224142229|NCT00922350|OTHER|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
224142230|NCT00922350|OTHER|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
224299869|NCT02872792|DEVICE|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
224299870|NCT02872792|OTHER|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
223435575|NCT04810559|DEVICE|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test|OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in oral fluid and fingerstick blood conducted by untrained healthcare providers compared to laboratory 4th generation Ag/Ab EIA results performed on venous blood.
223435576|NCT04769739|OTHER|CO2|using CO2 insufflation to help insertion
223435577|NCT04769739|OTHER|Water|using water instead of traditional gas to help insertion
223435578|NCT04769739|OTHER|50% saline|using 50% saline solution instead of traditional gas to help insertion
224046718|NCT01375842|DRUG|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure \</= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
224046719|NCT03988348|PROCEDURE|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
224046720|NCT03988348|PROCEDURE|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
224046721|NCT00542464|BIOLOGICAL|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
224046722|NCT03339388|DEVICE|Enhanced Lithotripsy System|Stone treatment with the Enhanced Lithotripsy System
224142231|NCT00922350|OTHER|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
224142232|NCT00922350|OTHER|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
224142233|NCT02545842|DRUG|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224142234|NCT05414370|DRUG|Liquid oxygen|Liquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
224299871|NCT03416803|RADIATION|Radiotherapy|Radiotherapy
224299872|NCT03805503|DRUG|Chloroprocaine 1% Injectable Solution|"standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed."
224299873|NCT05692050|DRUG|Epcoritamab|Subcutaneous Injection
224299874|NCT02637375|DRUG|Ganetespib|
224046723|NCT03449498|OTHER|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
224046724|NCT03449498|OTHER|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
224142235|NCT05414370|DRUG|medical air|Synthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.
224142236|NCT01252342|DRUG|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
224142237|NCT01252342|DRUG|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
224299875|NCT02637375|DRUG|Paclitaxel|
224299876|NCT02637375|DRUG|Doxorubicin|
224142238|NCT00997178|PROCEDURE|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
224142239|NCT00997178|OTHER|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
224299877|NCT02637375|DRUG|Cyclophosphamide|
224299878|NCT05717504|DEVICE|Implantable Loop Recorder|Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
224142240|NCT01991938|DRUG|VS-5584|
224299879|NCT05717504|OTHER|Quality of life survey|A quality of life survey will be performed at the end of the follow-up period. The survey will be done over the phone or in person if the follow-up visit is in person.
223435579|NCT04769739|OTHER|25% saline|using 25% saline solution instead of traditional gas to help insertion
224299880|NCT00423995|DRUG|Loratadine/montelukast combination|
224299881|NCT03098914|OTHER|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
224299882|NCT01864850|RADIATION|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
224299883|NCT01864850|RADIATION|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
224046725|NCT05831748|OTHER|Classic Exercise|Classic exercise group consists of straight leg raising, back extensor strengthening, and abdominal strengthening exercises.
224046726|NCT05831748|OTHER|Clinical Pilates|In the Clinical pilates group, pilates exercises will be given. Clinical pilates exercises improve back extensors, trunk flexors, and pelvis stabilization. These exercises will be applied along with breathing exercises.
224299884|NCT03867461|PROCEDURE|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
224299885|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
224299886|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
224299887|NCT03867461|OTHER|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
224299888|NCT03867461|OTHER|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
224299889|NCT04864405|OTHER|Morning administration of endocrine therapy|Endocrine therapy administered within one hour of patient wake up time
224299890|NCT04864405|OTHER|Evening administration of endocrine therapy|Endocrine therapy administered within one hour of the patient bed time
224299891|NCT04299906|DEVICE|Solaris Vascular Stent Graft|Solaris Vascular Stent Graft for treatment of Iliac Lesions
224299892|NCT00006438|DEVICE|Shoes with Rocker Soles|
224299893|NCT02766374|BEHAVIORAL|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
224299894|NCT02766374|BEHAVIORAL|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
224299895|NCT01338948|PROCEDURE|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
224299896|NCT03758404|BIOLOGICAL|adeno-associated virus vector AAV- CNGA3|Adeno-associated virus (AAV) gene therapy for defects in CNGA3 gene
224299897|NCT02875158|PROCEDURE|Cyclophotocoagulation protocol|"* Intravenous route is installed~* Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~* Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~* Pars plana measurement using transillumination (if needed)~* Laser treatment applied approximately 1mm post to limbus~* Dexamethasone 0,5 mg subconjunctival injection~* Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
224299898|NCT02875158|PROCEDURE|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
224299899|NCT02875158|PROCEDURE|Modified cyclophotocoagulation|2000 mW for 2 seconds.
224299900|NCT00006239|DRUG|sodium phenylbutyrate|
224299901|NCT00006239|DRUG|tretinoin|
224299902|NCT02064114|PROCEDURE|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
224046727|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in PD|Colored Progressive Matrices (BDM), Stroop Test (Caffarra et al., 2000), Stroop Test (Caffarra et al., 2000), Attentional Matrices (part I - Della Sala et al., 1992), Attentional Matrices (part The - Della Sala et al., 1992), Trail Making Test (Giovagnoli et al., 1996 - part A), Trail Making Test (Giovagnoli et al., 1996 - part B), Trail Making Test (Giovagnoli et al., 1996 - B-A), MMSE (Grigoletto et al., 1999), Clock Drawing - PD (Caffarra et al., 2011), Digit Span Forward (Orsini et al., 1987), Digit Span Backward (Monaco et al. , 2012), 15 Rey Words - Immediate Recall (BDM), 15 Rey Words - Deferred Recall (BDM), Phonemic Fluency (Costa et al., 2014), Semantic Fluency (Costa et al., 2014), Frontal Assessment Battery ( FAB - Apollonio et al.,2005).
224046728|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in PD|STAI Y2 (trait anxiety), TEIque (153 items), STAI Y1 (state anxiety), ERQ (10 items), EISR (33 items), BDI (21 items), WLEIS (16 ITEMS), CFI (20 ITEMS ), CCFQ (18 ITEM).
224046729|NCT06323564|DEVICE|International Affective Picture System (IAPS)|Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. The images will be chosen based on the arousal-valence parameters, eliminating those with stimuli that are too salient with respect to the disorders examined. The order of administration will be organized and randomized between subjects as follows: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).
224046730|NCT06323564|DIAGNOSTIC_TEST|Neuropsychological tests in AN|Verbal Fluencies, Tower of London, TMT-A \& B
224046731|NCT06323564|DIAGNOSTIC_TEST|Self-report questionnaires in AN|STAI Y2 (20 items trait anxiety), TEIque (153 items), STAI Y1 (20 items state anxiety), DFlex (24 items), ERQ (10 items), EISR (33 items), BDI (21 items), TAS-20 (20 items), WLEIS (16 ITEMS), CFI (20 ITEMS), CCFQ (18 items).
224046732|NCT06323564|DIAGNOSTIC_TEST|Analysis of bio-humoral parameters|the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1
223435580|NCT01825239|OTHER|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
223435581|NCT01669200|OTHER|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
223435582|NCT01669200|OTHER|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
224046733|NCT02982369|OTHER|Spinal Manipulation|High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
224046734|NCT02982369|OTHER|Pain Education|Subjects will receive pain education based in biopsychosocial approach
224046735|NCT02982369|OTHER|Sham|A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
224046736|NCT01187966|DRUG|Safinamide|
224046737|NCT01187966|DRUG|Safinamide|
224046738|NCT01187966|DRUG|Placebo|
224142241|NCT04105569|PROCEDURE|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
224142242|NCT01552824|PROCEDURE|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
224046739|NCT04449770|DEVICE|double lumen tube|prospective cohort study
224046740|NCT00625989|DRUG|Aeroallergen|
224046741|NCT02361450|DEVICE|Retrograde Colonic Irrigation|
224046742|NCT02361450|OTHER|Usual Care|
224046743|NCT04479436|DRUG|Patritumab Deruxtecan|U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
224046744|NCT02176473|BEHAVIORAL|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
224142243|NCT01552824|PROCEDURE|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
224142244|NCT00011479|DRUG|Abacavir sulfate|
224142245|NCT01022346|DRUG|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
224142246|NCT01022346|DRUG|RO5217790|RO5217790 will be administered at a dose of 5\*10\^7 pfu subcutaneously on Days 1, 8, and 15.
224142247|NCT04545788|DRUG|Total oral short-term therapy that includes linezolid, bedaquiline and/or cycloserine.|AM is the traditional anti-TB drugs. Linezolid, bedaquiline and/or cycloserine, that might have potential efficacy of replacing injectable anti-TB drugs, are included into the total oral short-term therapy, and replace AM.
224142248|NCT01259973|DRUG|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
224142249|NCT01259973|DRUG|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
224046745|NCT02921191|DRUG|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
224046746|NCT00376116|DEVICE|Cardiac resynchronisation therapy|
224046747|NCT00376116|DEVICE|Implantable cardioverter-defibrillator|
224046748|NCT03228472|DEVICE|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
224046749|NCT03228472|DEVICE|sham stimulation|Placebo treatment
224046750|NCT02675816|DEVICE|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
224046751|NCT04311697|DRUG|Aviptadil by intravenous infusion + standard of care|Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
224046752|NCT04311697|DRUG|Normal Saline Infusion + standard of care|Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.
224046753|NCT04782284|OTHER|Comprehensive swallowing rehabilitation|The treatment time per session is 30 minutes. Total 12 sessions are provided for 6 weeks.
224142250|NCT01259973|DRUG|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
223435583|NCT01922154|DRUG|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
223435584|NCT01922154|PROCEDURE|Trabeculectomy with mitomycinC|All participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
224046754|NCT04782284|OTHER|Swallowing education|The education is 30 minutes. Total 1 session is provided immediately after baseline evaluation.
224046755|NCT00012220|DRUG|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle
224046756|NCT00012220|DRUG|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle
224046757|NCT00012220|DRUG|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle"
224046758|NCT00012220|DRUG|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
224046759|NCT06473675|PROCEDURE|Hysterectomy with adnexal surgery|Robotic-assisted and laparoscopic hysterectomy with adnexal surgery for benign disease.
224046760|NCT06256315|PROCEDURE|Hyper-ERAS Program|Patients who met the inclusion criteria were treated with Hype-ERAS protocol, including preoperative education, intraoperative quality control, postoperative preventive analgesia, early ambulation, early recovery of diet, early removal of the drainage tube, urinary catheter, and gastric tube, and discharge within 48 hours or more than 48 hours safter surgery, and closely and standardized follow-up outside the hospital.
224046761|NCT01102348|OTHER|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
224046762|NCT00064220|DRUG|soblidotin|
224046763|NCT04465448|OTHER|MRI|Those included will perform an MRI without injection to obtain the QSM then they will exit the machine and reinstall themselves there to perform the second measurement. They will then change the MRI machine to perform a third measurement
224046764|NCT06438848|OTHER|Physical therapy program|group will be prescribed a usual physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises, and manual therapy. The program will start with 10-minute warm-up and 10-minute cool-down periods of physical therapy sessions
224046765|NCT06438848|OTHER|Physical therapy program with lymphedema drainage|physical therapy program three times a week for four weeks, which will be conducted in the clinic. The program consists of eight sessions comprising warm-up and cool-down, stretching activities, and strengthening exercises,And manual lymphatic drainage prescribed 20 minutes of MLD daily. The program will be prescribed five times a week, for four weeks
224046766|NCT04739267|DEVICE|CardioFlux|Not an intervention
224046767|NCT04195048|OTHER|Risk factors|Risk factors: modifiable and unmodifiable risk factors
224046768|NCT05401799|DEVICE|BURT|Use of Barrett Upper extremity Robot (BURT) to improve strength and mobility of hemiplegic upper extremity.
224046769|NCT05401799|PROCEDURE|Other Occupational Therapy|Standard occupational therapy sessions will be 60-90 minutes a day and are UE neuroeducation sessions are typically focused on improving strength and mobility of the hemipelagic arm.
224142251|NCT06069011|OTHER|Interdisciplinary management|assessment and treatment in an interdisciplinary model
224142252|NCT06069011|OTHER|usual care|assessment and treatment in usual care model
224046770|NCT04466644|DIAGNOSTIC_TEST|ELISA|Antibody test (serology) in the blood samples to determine if the subject was previously infected.
224046771|NCT04466644|DIAGNOSTIC_TEST|RT-PCR|For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
224046772|NCT05982093|DRUG|Elacestrant|Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
224142253|NCT01011452|DRUG|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
224142254|NCT01011452|DRUG|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
224142255|NCT03450915|BIOLOGICAL|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
223435585|NCT02657070|BEHAVIORAL|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
223435586|NCT02657070|BEHAVIORAL|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
223435587|NCT02081664|BEHAVIORAL|lifestyle intervention|
223435588|NCT06977724|DRUG|ABBV-319|Intravenous (IV) Infusion
223435589|NCT06679257|DIAGNOSTIC_TEST|cell-free dNA|Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
223435590|NCT06678893|DEVICE|Acupuncture Needle on an adhesive|This study utilizes acupuncture needs on small adhesives which will be placed according to the 5NP NADA Auricular Acupuncture Protocol.
223435591|NCT06678893|DEVICE|Adhesives|For those randomized to the placebo arm, adhesives without needles will be placed according to the 5NP NADA Auricular Acupuncture Protocol placement
223435592|NCT06347068|BIOLOGICAL|iC9-CAR.B7-H3 T Cell Therapy|iC9-CAR.B7-H3 T cells will then be administered intravenously
223435593|NCT06347068|DRUG|cyclophosphamide|cyclophosphamide 300 mg/m2 IV will be given.
223435594|NCT06347068|DRUG|fludarabine|fludarabine 30 mg/m2 IV will be given.
223435595|NCT03689543|DRUG|Estradiol|Estradiol patch 0.1 mg transdermal every three days for three weeks
223435596|NCT03689543|DRUG|ER Beta Agonist|Lilly Compound LY500307, a selective estrogen receptor (ER) beta agonist
224046773|NCT05982093|DRUG|Triptorelin|Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
224142256|NCT03450915|BIOLOGICAL|Saline|0.9% sodium chloride (NaCl)
224142257|NCT04944888|DRUG|Eliglustat|Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).
224142258|NCT04944888|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor (physician decided).
224299903|NCT02064114|PROCEDURE|control group|Followed for a period of 3,6 and 12 months after the procedure.
224142259|NCT04782193|BIOLOGICAL|CD19 and CD22 targeted prime CAR- T cells|A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously
224142260|NCT04973215|OTHER|no intervention|this is not an intervention study
224142261|NCT00684125|DEVICE|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
224142262|NCT00684125|DEVICE|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
224142263|NCT02812446|OTHER|IAI infection|
224142264|NCT02812446|OTHER|Staphylococcus aureus nasal carriage infection|
224142265|NCT03565848|PROCEDURE|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
224142266|NCT02793323|OTHER|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
224142267|NCT02793323|OTHER|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
224142268|NCT02793323|OTHER|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
224142269|NCT02793323|OTHER|IV placebo|100 ml IV saline
224142270|NCT02793323|OTHER|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
224142271|NCT02766790|DIETARY_SUPPLEMENT|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
224142272|NCT02766790|OTHER|Placebo|Placebo, an inactive formulation
224142273|NCT01709981|DRUG|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
224142274|NCT01709981|DRUG|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
224142275|NCT03299855|OTHER|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
224142276|NCT03558451|OTHER|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
224142277|NCT03558451|OTHER|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
224142278|NCT04090047|DRUG|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
224142279|NCT04090047|DRUG|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
224299904|NCT00060138|BIOLOGICAL|monoclonal antibody CAL|
224299905|NCT00060138|DRUG|zoledronic acid|
224142280|NCT04901533|PROCEDURE|O-A-A|patient is supine, and the therapist stands on the side to be manipulated. The cranial hand of the therapist globally grasps the patient's skull and turns the patient's neck on that same side. The caudal hand is placed on the patient's face. The technique is performed by an impulse in pure rotation on the side that the cervical region is rotated, with a helical movement.
224142281|NCT04901533|PROCEDURE|cranial listening|The patient is in the supine position, and the therapist sitting at the head of the patient. The therapist places his hands on the head of the patient, the thumbs touch each other, without touching the vault cranial. A perception of the cranial rhythm is carried out passively.
224142282|NCT04249505|DEVICE|"2WIN Photoscreener"|"non-cycloplegia refraction by Adaptica 2WIN"
224142283|NCT04249505|DEVICE|"Plusoptix A12"|"non-cycloplegic refraction by Plusoptix A12 photoscreener"
224142284|NCT04249505|DEVICE|"Retinomax"|"non-cycloplegic refraction by Retinomax K+ auto refractor"
224142285|NCT01054976|DRUG|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
224142286|NCT04870827|DRUG|13N Amonia|Administered during PET/CT scans
224142287|NCT00744016|DRUG|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
224142288|NCT00744016|DRUG|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
224142289|NCT02661841|OTHER|LI-Guided Therapy|Preemptive treatment according to LI monitoring
224142290|NCT02661841|OTHER|Heart Failure Guidelines|Treatment according to clinical signs
224142291|NCT01763866|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
224142292|NCT01763866|DRUG|Ezetimibe|Administered orally once a day
224142293|NCT01763866|DRUG|Placebo to Evolocumab|Administered by subcutaneous injection
224142294|NCT01763866|DRUG|Placebo to Ezetimibe|Administered orally once a day
224142295|NCT01763866|DRUG|Atorvastatin|Administered orally once a day
224142296|NCT01763866|DRUG|Rosuvastatin|Administered orally once a day
224142297|NCT01763866|DRUG|Simvastatin|Administered orally once a day
224142298|NCT00514436|BEHAVIORAL|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
224142299|NCT01106742|DIETARY_SUPPLEMENT|AndoSan|AndoSan, 20mlx3, 12 days
224142300|NCT02058485|DRUG|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
224142301|NCT02058485|DRUG|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
224142302|NCT05055570|OTHER|No intervention|No intervention
224299906|NCT06486961|DEVICE|BeatMove Application|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
224046774|NCT03385720|PROCEDURE|modified neck dissection|Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
224046775|NCT03385720|PROCEDURE|traditional neck dissection|traditional neck dissection without preservation of submandibular gland
224046776|NCT04457076|DRUG|LevoCept|Levonorgestrel-Releasing Intrauterine System
224046777|NCT05444842|OTHER|insulin iontophoresis|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor\_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
224142303|NCT05157399|DEVICE|Otoband|Participants with Dizziness and Vertigo will wear the Otoband set at normal power (effective) during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
223435597|NCT03689543|OTHER|Placebo|Placebo orally once daily
223435598|NCT03689543|DRUG|Provera|Provera 5 mg orally once a day for one week after completion of randomization
224046778|NCT05444842|OTHER|topical insulin|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
224046779|NCT05444842|OTHER|conventional treatment|All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
224142304|NCT05157399|DEVICE|Placebo Device|Participants with Dizziness and Vertigo will wear the placebo device set at low power during vestibular test battery and outcome measurements will be recorded by the investigator during site visit.
224142305|NCT02825433|OTHER|No intervention, only ventilation monitoring|
224142306|NCT00847756|OTHER|questionnaire|Identification of risk factors
224142307|NCT00847756|PROCEDURE|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
224142308|NCT00847756|PROCEDURE|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
224142309|NCT00847756|PROCEDURE|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
224142310|NCT00750165|DEVICE|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
224142311|NCT04275050|DRUG|TQB3303|TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
224142312|NCT00187629|BEHAVIORAL|dietary phosphorus|varying amts dietary phosphorus
224142313|NCT03556748|OTHER|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
224142314|NCT03308565|BIOLOGICAL|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
224142315|NCT01559064|DEVICE|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
223435599|NCT05921578|DIAGNOSTIC_TEST|Pre-operative planning based on CBCT|Pre-operative planning based on CBCT
223435600|NCT01736605|PROCEDURE|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
224046780|NCT06041399|DRUG|hypoglycemic Agents(metformin)|patients treated with hypoglycemic Agents(metformin)
224046781|NCT06041399|DRUG|lipid-lowering drug(Statin)|patients treated with lipid-lowering drug(Statin)
224046782|NCT04625842|OTHER|Focus group interview|Group interview with patients who received radiation treatment
224046783|NCT05002569|BIOLOGICAL|Nivolumab|Specified dose on specified days
224046784|NCT05002569|BIOLOGICAL|Nivolumab + Relatlimab Fixed Dose Combination|Specified dose on specified days
224046785|NCT02424942|DRUG|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
224046786|NCT02424942|DRUG|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
224142316|NCT03850327|DEVICE|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
224142317|NCT03320291|DEVICE|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
223435601|NCT01736605|PROCEDURE|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
223435602|NCT00932451|DRUG|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
224046787|NCT01903642|OTHER|proteomic analysis|
224046788|NCT06459596|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
224046789|NCT05224908|DEVICE|EOS|pelvimetry by EOS in standing and sitting position
224142318|NCT02603185|DRUG|Hemay007|
224142319|NCT02603185|DRUG|placebo|
224142320|NCT02833116|DRUG|Betamethasone|
224142321|NCT02833116|DRUG|Dexamethasone|
224142322|NCT03128216|PROCEDURE|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
224142323|NCT03128216|PROCEDURE|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
224142324|NCT03128216|PROCEDURE|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
224142325|NCT03128216|DRUG|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
224142326|NCT03128216|DRUG|Bupivacaine|Local anesthetic used for Spinal Anesthesia
224142327|NCT01146041|DRUG|Rivastigmine|Rivastigmine 1.5 mg Capsules
223435603|NCT01451632|DRUG|MM-121|escalating doses MM-121 IV QW
224046790|NCT05321914|BEHAVIORAL|Exercise training|Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
224046791|NCT05053477|DRUG|mehylprednisolone injection|(40 mg)
224046792|NCT05053477|DEVICE|pulsed radiofrequency (PRF)|. PRF lesion will be carried out for 120 seconds at a 2 Hz frequency and pulse width of 20 ms at 42°C
224142328|NCT05978687|DRUG|OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G|"In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
224142329|NCT05978687|DRUG|Xylocaine with Epinephrine|"In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon."
224142330|NCT03826355|PROCEDURE|CO2 (carbon dioxide) laser vaporisation|CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma
224046793|NCT05053477|BIOLOGICAL|platelet-rich plasma|2 ml of PRP
224046794|NCT00003440|DRUG|paclitaxel|Given IV over 1 hour or 3 hours
224046795|NCT00003440|BIOLOGICAL|trastuzumab|Given IV
224046796|NCT00003440|PROCEDURE|quality-of-life assessment|Ancillary studies
224046797|NCT00003440|OTHER|laboratory biomarker analysis|Correlative studies
224046798|NCT03754140|DRUG|Polidocanol Injection|Sclerotic agent
224142331|NCT03826355|PROCEDURE|Stripping technique|Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
224142332|NCT06127706|DEVICE|twin vaginal delivery simulation|skill test after formal lecture and simulation in group 1 and after digital learning only
224299907|NCT06486961|DEVICE|BeatMove Application without synchronized music|"The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
223435604|NCT01451632|DRUG|Irinotecan|180 mg/m2 IV Q2W
224046799|NCT01681134|DRUG|Advagraf®|oral
224046800|NCT01681134|DRUG|Prograf®|oral
224046801|NCT05368961|BEHAVIORAL|Distraction|Distraction (interactive tablet)
224046802|NCT05368961|OTHER|Usual care|Anxiolytic ordered by anesthesiologist is usual care
224046803|NCT01612468|DRUG|Liraglutide|1.8 mg/day subcutaneous
224046804|NCT01612468|DRUG|Placebo|1.8 mg/day subcutaneous
224046805|NCT04130633|DRUG|Placebo|Placebo vapor (distilled water)
224046806|NCT04130633|DRUG|THC|Pure THC vapor
224046807|NCT04130633|DRUG|Alpha-Pinene|Pure alpha-pinene vapor
224046808|NCT04748653|BEHAVIORAL|Multi-component reintegration intervention|The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
224046809|NCT01322503|BIOLOGICAL|Norovirus|Norovirus challenge pool administered to each subject
224046810|NCT02575248|DRUG|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
224046811|NCT02575248|DRUG|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
224046812|NCT03770949|DEVICE|3-D Printed Orthotic (Ankle Foot Orthosis)|Participants will receive a custom individual 3-D printed ankle foot orthosis (AFO).
224046813|NCT00004754|DRUG|epoprostenol|
224046814|NCT00791258|DRUG|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
224046815|NCT00791258|DRUG|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
223435605|NCT01451632|DRUG|Cetuximab|escalating doses cetuximab IV QW
223435606|NCT05538975|OTHER|Physiotherapy Treatment|Pulmonary Rehabilitation Techniques
223435607|NCT05764746|DRUG|Artemether-lumefantrine and Amodiaquine Drug Combination|AL and AQ will be given together for three days then followed by placebo for three days
223435608|NCT05764746|DRUG|Artemether-lumefantrine then Artesunate amodiaquine|AL will be given twice a day for three days then followed by artesunate amodiaquine once a day for three days
224046816|NCT02599454|DRUG|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
224046817|NCT02599454|RADIATION|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
224046818|NCT02637115|DIETARY_SUPPLEMENT|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
223435609|NCT05764746|DRUG|Artemether-lumefantrine|This will be the comparator arm as standard treatment, where only AL will be given twice a day for three days then placebo for three days
223435610|NCT00585715|DEVICE|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
223435611|NCT00425893|BEHAVIORAL|hand hygiene|alcohol-based hand wash
223435612|NCT00425893|OTHER|health education|Proper nutrition, etc.
223435613|NCT00425893|DEVICE|face masks|face masks
223435614|NCT03050047|BIOLOGICAL|BCD-100|Anti-PD1 monoclonal antibody
223566049|NCT04362475|BEHAVIORAL|Community Health through Engagement and Environmental Renewal (CHEER)|FYI and ESPI intervention activities will be implemented in the overall study, CHEER. It will also allow us to examine possible synergistic effects of both interventions when implemented in the same neighborhoods. Separate sets of participants will be selected for the FYI comparisons and for the ESPI comparisons. Because the FYI intervention focuses on mothers and their children, participants for the FYI comparisons will be selected by Respondent Driven Sampling of eligible families from the neighborhoods in all four cells. The ESPI intervention targets the whole neighborhood, and thus a random sample of neighborhood residents will be enrolled in each of the four cells. Because the primary outcomes for FYI and ESPI are connected but differ from each other, the FYI samples will be assessed for the FYI outcomes in all four cells and the ESPI samples will be assessed for the ESPI outcomes in all four cells.
224046819|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
224046820|NCT02637115|DIETARY_SUPPLEMENT|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
224046821|NCT02637115|DIETARY_SUPPLEMENT|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
224046822|NCT00156234|BEHAVIORAL|One-knee extension ergometer|
224046823|NCT00805662|DRUG|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
224046824|NCT01698866|BIOLOGICAL|Vaccin GenHevac B Pasteur|
224142333|NCT04981574|OTHER|Massage and stretching on neck area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the neck area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the neck area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching will be made on the trapezius superior, musculus levator scapulae and sternocleidomastoideus holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
223435615|NCT05843201|DEVICE|The AquaPass System|The system is a non-invasive, multiple use device intended for use at the hospital, at the outpatient clinic settings or at home. The system administers warm, dry air around the patients' body in order to create environmental conditions that increase the patients' sweat rate. Throughout the treatment, fluids from the interstitial compartment are removed from the body by the eccrine sweat glands.
223435616|NCT01933178|DEVICE|Cirrus AS-OCT|
223566050|NCT04525859|BIOLOGICAL|Safety|See previous Safety group description
223566051|NCT04525859|BIOLOGICAL|Expansion Cohort|See previous Expansion Cohort
224046825|NCT01262937|DEVICE|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
224046826|NCT03819062|DEVICE|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
224046827|NCT02934997|OTHER|Observational study|
224046828|NCT03540082|OTHER|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
224046829|NCT03540082|OTHER|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
223435617|NCT01718145|DRUG|Daclatasvir|
223435618|NCT01718145|DRUG|Asunaprevir|
223435619|NCT01718145|DRUG|Ribavirin|
223435620|NCT01718145|BIOLOGICAL|pegIFNα-2b|
223435621|NCT01718145|DRUG|Telaprevir|
223435622|NCT00005604|BIOLOGICAL|recombinant interleukin-12|Given IV
223435623|NCT00005604|BIOLOGICAL|aldesleukin|Given SC
223435624|NCT00005604|OTHER|laboratory biomarker analysis|Correlative studies
223435625|NCT04891406|OTHER|A|Use of product A (ZoneX #2, white tobacco-free nicotine pouch, 5.8 mg nicotine/pouch) for 20 minutes
223435626|NCT04891406|OTHER|B|Use of product B (ZoneX #3, white tobacco-free nicotine pouch, 10.1 mg nicotine/pouch) for 20 minutes
223435627|NCT04891406|OTHER|C|Use of product C (Skruf snus fresh slim white, 10.9 mg nicotine/pouch) for 20 minutes
223435628|NCT04891406|OTHER|D|Use of product D (Nicotine pouch, 10.6 mg/pouch) for 20 minutes
223435629|NCT04891406|OTHER|E|Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
223435630|NCT05717764|DRUG|Mitoxantrone hydrochloride liposome injection|Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
224046830|NCT05264818|PROCEDURE|Glycocheck|Assessment of the sublingual microvascularization
224046831|NCT05264818|PROCEDURE|Ophthalmological examinations|"Description :~Measurement of best corrected distance visual acuity with ETDRS (Early Treatment Diabetic Retinopathy Study) Measurement of intraocular pressure by aplanation and forced air tonometer Central corneal thickness measurement with OCT (Optical Coherence Tomography) Non-mydriatic retinophotography Humphrey 24-2 visual field OCT-RNFL (Optical Coherence Tomography - retinal nerve fiber layer)"
224046832|NCT01053299|OTHER|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
224046833|NCT06047847|DIETARY_SUPPLEMENT|TOTUM-448|The study is divided in two phases. The first clinical phase of the project is aimed at determining TOTUM-448's metabolites absorption peak (two galenic forms will be tested: capsules and powder). Then, human circulating metabolites from polyphenols will be quantified and characterized by ultra-high performance liquid chromatography hyphenated with tandem mass spectrometry (UPLC-MS/MS). Once the absorption profile is characterized, volunteers will visit once again the clinical center for the collection of serum fractions either naïve (before ingestion) or enriched (containing circulating metabolites following TOTUM-448 ingestion). The enriched fraction (circulating bioactive collection) will be collected at t-max as characterized in the first phase (absorption profil's peak). Finally, biological activity of TOTUM-448 on human hepatocytes will be studied by comparing naïve serum and serum containing circulating metabolites according to an in vitro protocol.
224046834|NCT02603367|OTHER|Communication Intervention|Undergo communication coaching
223435631|NCT05717764|DRUG|Capecitabine|Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
223435632|NCT03794505|DRUG|Methylprednisolone Acetate|depo-medrol 40 mg
223435633|NCT03794505|DRUG|Lidocaine 2% Injectable Solution|2ml of 2% lidocaine
223435634|NCT03794505|DRUG|Ropivacaine HCl Inj 7.5 MG/ML|25 mg
224046835|NCT02603367|OTHER|Educational Intervention|Receive COMFORT communication curriculum
223435635|NCT04080518|DRUG|Dapagliflozin 10 MG [Forxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
223566052|NCT03074292|PROCEDURE|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
223566053|NCT02013206|DRUG|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
224046836|NCT02603367|OTHER|Psychosocial Support for Caregiver|Undergo communication coaching
224046837|NCT02603367|OTHER|Questionnaire Administration|Complete questionnaires
224046838|NCT01599910|OTHER|Scribes|Scribe
224046839|NCT05119621|DEVICE|TENS application|Assigned Interventions: In addition to the standard pain management applied in the clinic, TENS will be applied to children who have had surgery.
224046840|NCT04511832|DRUG|Diclofenac|Patients who were diagnosed as breast cancer and met the inclusion criteria will be recruited and randomly assigned to acupuncture group or drug (NSAIDs) group. After each subgroup completing the 4 weeks intervention, all the participants were enter washout period lasting 2 weeks to eliminate the effect of the previous treatment. Crossover was held after washout period and made the patients to have the other treatment in the following 4 weeks. After receiving the case, the third group recorded the pain indicators for the first month, followed by a one-month trial- combination of acupuncture and NSAID treatment, and then followed up for another month after stopping.
224046841|NCT04587011|DRUG|Tegoprazan dose A or placebo|Tegoprazan A mg or placebo taken orally twice daily for 3 days.
224046842|NCT04587011|DRUG|Tegoprazan dose B or placebo|Tegoprazan B mg or placebo taken orally twice daily for 3 days.
224046843|NCT04587011|DRUG|Tegoprazan dose C or placebo|Tegoprazan C mg or placebo taken orally twice daily for 3 days.
224046844|NCT04587011|DRUG|Tegoprazan dose D or placebo|Tegoprazan D mg or placebo taken orally twice daily for 3 days.
223566054|NCT02513290|DRUG|Bilastine|
223566055|NCT02513290|DRUG|Loratadine|
224142334|NCT04981574|OTHER|Massage and stretching on low back area and thoracic thrust manipulation|"1. Twenty (20) minutes massage in the low back area. The volunteer will be in prone position during the massage.~2. Technical thrust manipulation in thoracic area. For this technique the volunteer will be in supine position with their arms folded on the chest (making a V). The therapist will locate one hand on the spinous processes to be treated, and the other one on the arms of the patient to make easier the manipulation.~3. Ten (10) minutes specific stretching for the low back area. These stretching exercises shall be repeated twice a week by each volunteer. Stretching activities will be: cat-cow pose, lower back stretches and knee twist holding the position thirty (30) seconds. Each muscle stretch shall be repeated three times."
223435636|NCT06258317|PROCEDURE|fixation of conventional polypropylene mesh|"By fixation of the polyprolene mesh,patients will be divided into two groups:~Group 1 includes patients with fixation of conventional polypropylene mesh. Group 2 includes patients without fixation of the mesh."
223435637|NCT04079257|OTHER|Blood collection for measurement of eculizumab peak concentrations|collection of blood
223435638|NCT01920659|BEHAVIORAL|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
223435639|NCT01920659|BEHAVIORAL|REHIT|6 weeks 3 x week (20sec intervals)
223435640|NCT03969303|DEVICE|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
223435641|NCT01246037|DRUG|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
223435642|NCT03108872|DEVICE|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
223435643|NCT03108872|DRUG|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
223435644|NCT03363451|DRUG|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment
223435645|NCT06080880|DRUG|Ondansetron every 3 weeks|Ondansetron, Po, 24mg/d, 3 days' application every 3 weeks
223435646|NCT06080880|DRUG|Aprepitant|aprepitant, Po, 125mg/d, 1day' application every 3 weeks
223566056|NCT02791191|DRUG|LY3202626|Administered orally
223435647|NCT06080880|DRUG|Dexamethasone|dexamethasone, iv, 10mg/d, 1day' application every 3 weeks
223435648|NCT06080880|DRUG|Ondansetron weekly|Ondansetron, Po, 24mg/d, 3 days' application weekly
223435649|NCT03414996|OTHER|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
223566057|NCT02791191|DRUG|Placebo|Administered orally
224046845|NCT00058552|DRUG|Pertuzumab (rhuMAb 2C4)|
224046846|NCT00105716|BEHAVIORAL|Telephone behavioral education|
224046847|NCT00105716|BEHAVIORAL|Computer behavioral education|
224142335|NCT01669811|DRUG|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
224142336|NCT01669811|DRUG|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
224142337|NCT00101803|DRUG|vildagliptin|
224142338|NCT02571751|DEVICE|UNIGEL Silicone Gel-Filled Breast Implant|
224142339|NCT02730442|DRUG|F901318|Administration of F901318 intravenously
223435650|NCT01795092|OTHER|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
223435651|NCT03227172|PROCEDURE|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
223435652|NCT04760288|DRUG|Pralsetinib|Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.
224046848|NCT04532216|PROCEDURE|Arthroscopic-Assisted Acromioclavicular Joint Reconstruction Using the TightRope Device|Arthroscopic-assisted AC joint reconstruction with the TightRope device with allograft augmentation and with the patient in the lateral decubitus position is a method of restoring joint stability
224142340|NCT02730442|DRUG|Fluconazole|Oral administration
224142341|NCT00844064|DRUG|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
223566058|NCT03474900|DEVICE|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
224142342|NCT04627142|DRUG|BI 1701963|Tablet
224142343|NCT04627142|DRUG|Camptosar®|Solution for infusion
224142344|NCT02723110|OTHER|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
224142345|NCT02723110|OTHER|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
224142346|NCT04794556|DEVICE|tight-fitting of KF94 mask with clip|The general-fitting method involved wearing a mask with ear loops, and the tight-fitting method involved wearing a clip that connected ear loops on the occiput after wearing a mask according to the general method
224142347|NCT02663479|DIETARY_SUPPLEMENT|Cardiopressin|
224142348|NCT02663479|DIETARY_SUPPLEMENT|Placebo|
224299908|NCT06486961|DEVICE|BeatMove Application without music|The participant walks for 15 to 30 minutes a day, 5 day a week for 3 months. During the walking session, BeatMove Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
223566059|NCT03474900|DEVICE|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
224142349|NCT04390568|DRUG|Spesolimap|Spesolimap
224142350|NCT06366828|OTHER|retrospective|follow up
224142351|NCT05864183|DIAGNOSTIC_TEST|HbA1c|HbA1c will be measured for all patients to minimize the risk of developing diabetes or its complications .
223435653|NCT04760288|DRUG|Cabozantinib|Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.
223435654|NCT04760288|DRUG|Vandetanib|Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
223435655|NCT02968433|DRUG|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
223435656|NCT00043667|DRUG|Daclizumab|
223435657|NCT01293513|OTHER|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
224142352|NCT05864183|DIAGNOSTIC_TEST|lipid profile|lipid profile will be measured for all patients to minimize the risk of developing diabetes or its complications .
224046849|NCT04532216|PROCEDURE|Traditional surgery|Tendon transfer
224046850|NCT02319668|DRUG|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
224046851|NCT02319668|DRUG|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
224142353|NCT05864183|DIAGNOSTIC_TEST|CBC|CBC will be measured for all patients to minimize the risk of developing diabetes or its complications
224142354|NCT05864183|DIAGNOSTIC_TEST|Alb/cr ratio|Alb/cr will be measured for all patients to minimize the risk of developing diabetes or its complications
224142355|NCT05864183|DIAGNOSTIC_TEST|serum creatinine .|serum creatinine will be measured for all patients to minimize the risk of developing diabetes or its complications
224142356|NCT05864183|DIAGNOSTIC_TEST|CRP|CRP will be measured for all patients to minimize the risk of developing diabetes or its complications
224142357|NCT05864183|DIAGNOSTIC_TEST|urine analysis|urine analysis will be measured for all patients to minimize the risk of developing diabetes or its complications
224142358|NCT05864183|DIAGNOSTIC_TEST|ECG|ECG will be done for all patients to minimize the risk of developing diabetes or its complications
223435658|NCT04275726|DEVICE|Myval THV Series|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
223435659|NCT04275726|DEVICE|Contemporary Valves (Sapien THV Series and Evolut THV Series)|The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy. Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
223435660|NCT04291664|DRUG|Abiraterone Acetate|Abiraterone Acetate 1000mg will be administered orally once daily
223435661|NCT04291664|DRUG|Prednisone 5Mg Tab|"Prednisone 5mg will be administered orally twice daily with Abiraterone Acetate 1000mg~Prednisone 5mg will be administered orally twice daily with DST-2970 for 28 days after dosing of Abiraterone Acetate is stopped"
224046852|NCT06240000|PROCEDURE|Radiofrequency ablation|Firstly, the posterior superior iliac spine was showed in the transverse plane, and it was gradually moved proximally until gluteus maximus muscle disappears and gluteus medius arises. Medial branch of the SCN is seen between iliac crest and thoracolumbar fascia as an ovoid structure. Radiofrequency device was utilized with 22-gauge 10-cm, 5 mm RF cannulas for all procedures. Cannula was placed thorough the SCN area and Sensory fiber stimulation was started between 0.3 and 0.5 V. The patient was asked for feedback on symptoms such as numbness, paresthesia or pain. If the patient did not report any sensory symptoms within the specified sensory stimulation range, the cannula was repositioned. Motor stimulation was given up to 1.5 V and it was checked whether there was any contraction or not. If there is no contraction detected, the SCN was ablated at 42° degrees centigrade for 240 seconds.
223435662|NCT04291664|DRUG|DST-2970 (Abiraterone)|DST-2970 will be administered orally twice daily for 28 days (for every cycle) after dosing of Abiraterone Acetate is stopped
223435663|NCT06647901|DRUG|ICG (Indocyanine Green)|Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.
223435664|NCT06184113|PROCEDURE|Aortic valve replacement surgery|Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.
224046853|NCT05641870|PROCEDURE|Sample collection|Tumor samples will be collected as standard diagnostic procedure at diagnosis. Plasma samples from whole blood extractions will also be collected at diagnosis, after chemoradiotherapy, and every 3 months from there until completing one year of follow-up.
224046854|NCT05641870|DIAGNOSTIC_TEST|Characterization of the tumoral tissue genomic alterations|Genomic alterations of tumor tissue samples will be analyzed locally by next-generation sequencing when material is adequate, as standard diagnostic procedure.
224070532|NCT01031914|DEVICE|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
224070533|NCT01632566|DRUG|Placebo|Capsules administered orally
224070534|NCT01632566|DRUG|LY3031207|Administered orally
224070535|NCT01632566|DRUG|Celecoxib|Administered orally
223435665|NCT06184113|DIAGNOSTIC_TEST|Computed tomography|All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.
224070536|NCT01632566|DRUG|Simvastatin|Administered orally
223435666|NCT06184113|DIAGNOSTIC_TEST|Echocardiography|All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.
223435667|NCT00877149|DRUG|telbivudine/LDT600|
223435668|NCT06623877|DIAGNOSTIC_TEST|renal shear wave elastography|"Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups"
224070537|NCT05594043|DRUG|MK-6598|Oral tablet
224070538|NCT05594043|BIOLOGICAL|Pembrolizumab|Intravenous (IV) infusion
224070539|NCT02126085|PROCEDURE|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
224070540|NCT02677155|RADIATION|Radiotherapy|Radiotherapy 8 Gy single dose
224070541|NCT02677155|BIOLOGICAL|Rituximab|Intranodal injection 5 mg
224070542|NCT02677155|BIOLOGICAL|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
224070543|NCT02677155|BIOLOGICAL|GM-CSF|Subcutaneous injection of 50 ug
224070544|NCT02677155|BIOLOGICAL|Pembrolizumab|Intravenous infusion of 200 mg
224070545|NCT01227551|BIOLOGICAL|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
224070546|NCT02158091|DRUG|IPI-145|oral PI3K delta/gamma inhibitor
224070547|NCT02158091|DRUG|Fludarabine|intravenous chemotherapy
224070548|NCT02158091|DRUG|Cyclophosphamide|intravenous chemotherapy
224070549|NCT02158091|DRUG|Rituximab|intravenous immunotherapy
224070550|NCT04404062|DIAGNOSTIC_TEST|Membrane-based immunoassay kit|The kit is a qualitative membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 in whole blood, serum or plasma specimens. IgG and IgM detection components are separate allowing for differential detection of each antibody.
224070551|NCT04404062|DIAGNOSTIC_TEST|Quantitative antibody Tests|Antibody titres will be measured from whole blood samples taken from volunteers.
223435669|NCT00637806|DRUG|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
223435670|NCT00637806|DRUG|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
223435671|NCT00637806|DRUG|Placebo|Placebo oral suspension, 5 mL once daily
223435672|NCT01923844|DRUG|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
223435673|NCT03196037|BEHAVIORAL|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
223435674|NCT01890213|BIOLOGICAL|AVX701|
223435675|NCT00622336|DRUG|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
223435676|NCT00622336|DRUG|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
224046855|NCT05641870|DRUG|Chemoradiation treatment regimen and maintenance (if amenable)|Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
224046856|NCT05641870|DIAGNOSTIC_TEST|Genomic and methylation analysis in liquid biopsy|"Blood samples for ctDNA genomic and methylation analysis (4 mL of plasma for each sample) will be sent to the Guardant Health Laboratories in the US and analyzed after Contractual Agreement signature, using the Guardant Reveal test.~This liquid biopsy test uses ctDNA to detect presence of MRD and monitor for recurrence after definitive surgical/systemic therapy for patients with cancer. It has been validated in early-stage colorectal cancer and integrates assessment of somatic alterations with an epigenomic cancer signature to identify the presence of methylation signatures associated with cancer versus normal DNA."
224046857|NCT01372150|DRUG|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
224046858|NCT01372150|DRUG|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
223435677|NCT04520516|DEVICE|Active VAGUSTIM device|Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session
223435678|NCT04520516|DEVICE|Sham VAGUSTIM device|The sham device : no electrical signal for VNS will be delivered.
224046859|NCT01372150|DRUG|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
224046860|NCT00277420|BEHAVIORAL|Comprehensive weight management|
224046861|NCT00006254|BIOLOGICAL|salmonella VNP20009|
224046862|NCT03427567|PROCEDURE|Sublobar dissection|Sublobar dissection plus lymphadenectomy
224046863|NCT04823572|PROCEDURE|A-PRF/OFD|Comparing healing effect of an autologous and open flap debridement
224046864|NCT02640833|DRUG|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
224046865|NCT02640833|DRUG|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
224046866|NCT03017638|OTHER|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
224046867|NCT02316340|DRUG|Vorinostat|400mg by mouth daily
224046868|NCT02316340|DRUG|Hydroxychloroquine|600mg by mouth daily
224046869|NCT02316340|DRUG|Regorafenib|160 mg by mouth daily
224070552|NCT04404062|DIAGNOSTIC_TEST|PCR Test|PCR tests will be conducted on throat swabs taken from volunteers.
224070553|NCT03977467|DRUG|Atezolizumab|Atezolizumab at a flat dose of 1200 mg IV every 3 weeks
224070554|NCT03977467|DRUG|Standard of Care Chemotherapy|Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
224070555|NCT03977467|DRUG|Tiragolumab|Tiragolumab at a flat dose of 600 mg IV every 3 weeks
224070556|NCT05913232|DRUG|H-1337 0.6%|ophthalmic solution
224070557|NCT05913232|DRUG|H-1337 1.0%|ophthalmic solution
224070558|NCT05913232|DRUG|H-1337 Placebo|ophthalmic solution
224070559|NCT05913232|DRUG|Timolol 0.5%|ophthalmic solution
224070560|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
224070561|NCT01318109|DRUG|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
224070562|NCT01318109|DRUG|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
224070563|NCT01328951|DRUG|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
224046870|NCT04611165|DRUG|Nivolumab|"* Nivolumab 3mg/kg IV is administered as 30-minute IV infusion every 2 weeks.~* EBRT begins 2-7 days after the first dose of nivolumab.~* The follow-up phase begins when the decision to discontinue study is made. The follow-up phase is defined as the day after the end of study treatment until the day the subject dies."
223435679|NCT07004790|DIAGNOSTIC_TEST|Transcranial Doppler Ultrasound|A non-invasive bedside diagnostic procedure used to measure cerebral blood flow velocities and pulsatility index in intracranial arteries, primarily the middle cerebral artery (MCA). The test is performed within the first 24 hours of symptom onset using standard ultrasound equipment with a 2-MHz probe. The data collected is used solely for prognostic evaluation and does not influence treatment decisions.
224046871|NCT05218785|DRUG|Botox|75 U in medial gastrocbemius head. x 3
224046872|NCT06169241|DIETARY_SUPPLEMENT|Beetroot extract|Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
224046873|NCT06169241|DIETARY_SUPPLEMENT|Placebo|The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
224142359|NCT05864183|DIAGNOSTIC_TEST|fundus examination|fundus examination will be done for all patients to minimize the risk of developing diabetes or its complications
223435680|NCT04858880|RADIATION|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.|Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
224046874|NCT05541263|BEHAVIORAL|Mindfulness Based Stress Reduction|The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
224046875|NCT06962397|DEVICE|Active Touch-Based Sensory Training|This intervention combines functional electrical stimulation with active tactile exploration of virtual textures. Using a touch-sensitive screen and a programmable functional electrical stimulator (MotionStim 8), participants explore two invisible virtual textures by moving their index finger across the screen. Each time the finger crosses a virtual texture line, an electrical pulse is delivered to the finger, simulating tactile sensation. Participants are asked to compare the density of two virtual textures and select the denser one. The stimulation is synchronized with finger movement to ensure real-time sensory feedback. The training consists of 50 trials divided into 5 blocks, and is designed to enhance tactile discrimination and proprioception through sensorimotor integration. The paradigm is interactive, personalized based on individual sensory thresholds, and aims to promote neural plasticity in stroke survivors.
224046876|NCT06319066|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
224046877|NCT06319066|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
224046878|NCT03575078|DRUG|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
224046879|NCT03781323|DRUG|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
224046880|NCT05720455|DRUG|Fexofenadine HCL and pseudoephedrine HCL|Extended-Release Tablets
224046881|NCT03508570|BIOLOGICAL|Ipilimumab|Given i.p.
224142360|NCT02214316|OTHER|Hypertonic Saline|
224142361|NCT06372054|OTHER|Biological sample collection|Collection of biological samples (blood, urine, saliva) and clinical data
224142362|NCT00338468|DRUG|epoetin alfa|
224142363|NCT03758430|OTHER|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
224142364|NCT03758430|DEVICE|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
224046882|NCT03508570|OTHER|Laboratory Biomarker Analysis|Correlative studies
224046883|NCT03508570|BIOLOGICAL|Nivolumab|Given i.p.
224142365|NCT03201172|DEVICE|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
224142366|NCT03245723|PROCEDURE|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethysmography
224142367|NCT03245723|PROCEDURE|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
224142368|NCT03245723|PROCEDURE|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
224142369|NCT03245723|PROCEDURE|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
224142370|NCT00519493|PROCEDURE|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
224142371|NCT00519493|DEVICE|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
224142372|NCT02612961|OTHER|3mL of normal saline from the pink sodium chloride bullet|
224142373|NCT02612961|OTHER|Sham Comparator of 3mL normal saline|
224046884|NCT03508570|OTHER|Pharmacokinetic Study|Correlative studies
224046885|NCT05109208|DIAGNOSTIC_TEST|Ulrasound Vibroelastography (UVE)|Ultrasound technique to quantitatively assess tissue stiffness (elasticity and viscosity) by applying vibration through a specialized probe (indenter).
223435684|NCT04739813|BIOLOGICAL|obinutuzumab|administered intravenously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223566060|NCT06389734|BEHAVIORAL|Manual soft tissue release|"The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
224299909|NCT03047798|DRUG|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
224299910|NCT00022542|DRUG|ixabepilone|Given IV
224299911|NCT00147953|DRUG|Rituximab|
224046886|NCT04679753|DEVICE|Brainsway DTMS with intermittent Theta Burst Stimulation (iTBS)|Brainsway DTMS with iTBS
224299912|NCT00147953|PROCEDURE|Total nodal irradiation|
224046887|NCT04679753|DEVICE|Brainsway DTMS with High Frequency (HF) Stimulation|Brainsway DTMS with HF
224046888|NCT05755074|PROCEDURE|Ablation through left arm|Ablation through left arm
224046889|NCT05755074|PROCEDURE|Ablation through femoral vein|Ablation through femoral vein
224046890|NCT01526551|OTHER|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
224299913|NCT02933268|DIETARY_SUPPLEMENT|High water intake|High water intake aimed at achieving an urine osmolality \< 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
224299914|NCT02933268|OTHER|Ad libitum water intake|Water intake guided by thirst
224299915|NCT04706286|DRUG|CKD-501, D759, D150|CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
224299916|NCT04706286|DRUG|CKD-393 0.5/100/1000 mg|CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
223435685|NCT04739813|DRUG|prednisone|administered orally, days 1-7, at a dose of 100 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223435686|NCT04739813|DRUG|Revlimid|administered orally, days 1 and 14, at a dose of 15 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223435687|NCT04739813|BIOLOGICAL|Polatuzumab|administered intravenously, on day 2, at varying doses of 1.4-1.8 mg/kg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223435688|NCT04739813|DRUG|ibrutinib|administered orally, days 1-14, at a dose of 560 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223435689|NCT04739813|DRUG|venetoclax|administered orally, days 2-14, at a dose of 800 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
223435690|NCT06870591|DEVICE|Cardiac Performance System (CPS)|CPS is a non-invasive platform for hemodynamic assessment that uses acoustic sensors and electrocardiogram electrodes.
223435691|NCT07009210|BEHAVIORAL|AI Assisted Personalized Legacy Program|AI Assisted Personalized Legacy Program will be facilitated by a clinician trained in legacy work.
223566061|NCT06389734|BEHAVIORAL|Myofascial release|"The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time."
224046891|NCT01526551|OTHER|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
224046892|NCT02087072|OTHER|Collaborative visit with provider and pharmacist|
224046893|NCT01129726|DEVICE|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
224070564|NCT01328951|DRUG|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
224070565|NCT01328951|DRUG|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
224070566|NCT00912249|BEHAVIORAL|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
224070567|NCT05504733|DEVICE|Layperson Audiovisual Assist Tourniquet (LAVA TQ)|The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.
224070568|NCT05504733|DEVICE|Combat Application Tourniquet|The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
224070569|NCT05346705|BEHAVIORAL|New individualized upper airway muscle functional training|The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
224070570|NCT03268928|BEHAVIORAL|Story Starters Intervention|Shared reading intervention
224070571|NCT03268928|BEHAVIORAL|Wait-list Control|Wait-list control
224070572|NCT00970853|BEHAVIORAL|MOM Program home visiting|Mixed professional home visiting program.
223435692|NCT04794322|DIAGNOSTIC_TEST|Uterine lavage, or a wash of the womb|Uterine lavage is performed during surgery using a flexible, 3-way balloon tipped catheter. The catheter is inserted through the cervix, the balloon expanded and the uterine cavity lavaged using 10 cc of sterile saline which is collected, processed and stored for later analysis.
224299917|NCT01293539|DRUG|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
223435693|NCT04794322|DIAGNOSTIC_TEST|Blood sample|Participants undergo two blood draws (one required, one optional) up to 31 days before surgery
223435694|NCT04794322|DIAGNOSTIC_TEST|Pap smear|Participants undergo a standard Papanicolaou smear to collect cells and fluid from the cervix.
223435695|NCT07011342|DRUG|18F-rhPSMA-7.3|Utility of 18F-rhPSMA-7.3 in the diagnosis of prostate cancer after Focal Gland Treatment (SCOUT)
223435696|NCT06394557|PROCEDURE|In-office Dental Bleaching Conventional|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 7 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
223435697|NCT06394557|PROCEDURE|In-office Dental Bleaching Alternative|Participants will undergo 2 sessions of in-office dental bleaching, using a 35% Hydrogen Peroxide bleaching gel, with 2 days of interval between sessions. Bleaching gel will be used in 3 15-minutes applications as indicated by the manufacturer. A 2% Potassium Nitrate and Sodium Fluoride desensitizing gel will be applied 15 minutes before the dental bleaching procedure, in both sessions.
223435698|NCT07008456|DRUG|APHD-012|12 g dextrose beads
223435699|NCT07008456|DRUG|APHD-002|2 g dextrose beads
223435700|NCT07008456|DRUG|APHP-012|12 g placebo beads
223566062|NCT06389734|BEHAVIORAL|Exercise training|The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
223566063|NCT03756363|PROCEDURE|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
223566064|NCT03756363|PROCEDURE|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
223566065|NCT01851486|DRUG|Clonidine|Clonidine 0.15 mg
224046894|NCT00164619|BEHAVIORAL|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). \[see Brief Summary above\]
224046895|NCT00164619|BIOLOGICAL|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
224046896|NCT00139646|DRUG|Parecoxib|
224046897|NCT00139646|DRUG|Diclofenac|
223435701|NCT07008456|DRUG|APHP-002|2 g placebo beads
223435702|NCT07005362|BEHAVIORAL|Fitbit and AI Chatbot|Participants will wear their Fitbit devices daily for 12-weeks and will receive personalized messages from the AI Chatbot every week with a new exercise recommendation based on their previous week's activity level. Additionally, they can engage with the AI Chatbot through text message for further support and education.
224046898|NCT01672567|DIETARY_SUPPLEMENT|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
224046899|NCT01672567|DIETARY_SUPPLEMENT|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
224046900|NCT01672567|DIETARY_SUPPLEMENT|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
224070573|NCT00970853|OTHER|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
224070574|NCT06849440|BEHAVIORAL|Training|Participants will be divided into groups of ten and the training is planned in 4 sessions. Session contents are prepared as sharing general information on preparation for birth, explanation of frequently applied interventions in labor, explanation of non-drug pain relieving methods, teaching and practicing active birth positions that help the labor progress. The duration of the sessions is planned as 2 hours on average.
223435703|NCT07005362|OTHER|Routine Care|The control group will consist of patients with type 2 diabetes who meet the study's inclusion criteria but have not participated in the intervention.
223435704|NCT05477212|DIETARY_SUPPLEMENT|Ketogenic Diet|all patients will receive a very low calorie ketogenic diet
223435705|NCT07138118|BEHAVIORAL|Blood Flow Restriction + Dual Task Training|Participants will undergo lower limb resistance and gait training while wearing blood flow restriction cuffs at 40% of their individualized arterial occlusion pressure. Tasks include walking, sit-to-stand, and obstacle crossing combined with verbal fluency or serial subtraction. Training is performed 3 times per week for 5 weeks.
224070575|NCT06127251|BEHAVIORAL|PATH Intervention|"The PATH intervention guides participants in making changes in their lifestyle and PA habits to support gradual improvement of PA. The health coach provides participants with access to the PATH website and instructions on how to use the resources included in PATH. The health coach meets remotely with each participant twice per month to develop a tailored plan geared towards increasing MVPA. After assigning the PATH level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days per week.~Participants will use a combination of walking, dance, and abdominal core workouts to add at least 10 minutes of MVPA to their baseline PA every two weeks. The remote coach will encourage each participant to engage in at least 2 days of aerobic training (walking or dance sessions), and one day of abdominal core workouts."
223435706|NCT07138118|BEHAVIORAL|Dual Task Training Only|Participants will perform the same cognitive-motor dual task training without blood flow restriction. Tasks include forward walking, obstacle crossing, and sit-to-stand exercises with concurrent cognitive tasks such as verbal fluency or serial subtraction. Training is performed 3 times per week for 5 weeks.
223435707|NCT06879418|OTHER|Low dose shock wave therapy plus strengthening and stretching exercise for upper trapezius|Patients will receive 2000 shocks, 1 bar (energy flux density 0.045 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching exercises for upper trapezius.
223435708|NCT06879418|OTHER|Medium dose shock wave therapy plus strengthening and stretching exercise for upper trapezius|patients will receive 2000 shock with 4 bars (Energy flux density 0.18 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching for upper trapezius
223435709|NCT06879418|OTHER|sham shock wave therapy plus strengthening and stretching exercise for upper trapezius|patients will receive 2000 shock with energy flus density 0.00 on upper trapezius trigger points plus strengthening and stretching exercise for upper trapezius.
224142374|NCT02240537|DRUG|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
224142375|NCT02240537|DRUG|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
223435710|NCT07039461|DEVICE|OptiLIGHT|three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment
224046901|NCT03480412|PROCEDURE|Follicular Phase|The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
224046902|NCT03480412|PROCEDURE|Luteal Phase|Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
224046903|NCT02126449|OTHER|Fasting mimicking diet|
224142376|NCT02240537|DRUG|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
224142377|NCT00154141|DRUG|Fibrin sealant (FS2)|
224142378|NCT00835419|DRUG|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
224142379|NCT04782804|DRUG|Capecitabine|Capecitabine+PD-1 Antibody（Tislelizumab）as Adjuvant Therapy Oral capecitabine (1250 mg/m²) was given post operatively twice a day on days 1 to 14 of a 3-weekly cycle for 24 weeks (eight cycles), and observation commenced within 16 weeks of surgery.
223435711|NCT07044687|DRUG|Venetoclax|Oral Tablet
224142380|NCT04782804|DRUG|PD-1 Antibody（Tislelizumab）|PD-1 Antibody（Tislelizumab, 200mg） was given q3w iv.
224142381|NCT00597935|PROCEDURE|SSLF|sacrospinous ligament fixation (SSLF)
224142382|NCT00597935|PROCEDURE|ULS|uterosacral vaginal vault ligament suspension (ULS)
224142383|NCT00597935|BEHAVIORAL|PMT|Pelvic muscle training and exercises (PMT)
224142384|NCT00676936|DRUG|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
223435712|NCT07044687|DRUG|Azacitidine|Subcutaneous (SC) Injection
223435713|NCT07044687|DRUG|Azacitidine|Intravenous (IV) Injection
224046904|NCT00156351|BEHAVIORAL|Physical activity promotion|
224046905|NCT01364623|DRUG|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
224046906|NCT01364623|DRUG|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
224046907|NCT01364623|DRUG|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
223435714|NCT06735664|PROCEDURE|Biopsy|Undergo ultrasound guided biopsy
223435715|NCT06735664|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223435716|NCT06735664|PROCEDURE|Bone Marrow Biopsy|Undergo optional bone marrow biopsy
223435717|NCT06735664|PROCEDURE|Computed Tomography|Undergo CT
223435718|NCT06735664|PROCEDURE|Echocardiography|Undergo ECHO
223435719|NCT06735664|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224046908|NCT01364623|DRUG|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
224142385|NCT00676936|DRUG|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
224142386|NCT05901285|DRUG|VAX014|Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
224142387|NCT05901285|COMBINATION_PRODUCT|Nivolumab or pembrolizumab|VAX014 will be given in combination with Investigator's choice of nivolumab or pembrolizumab.
224299918|NCT03370016|PROCEDURE|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
224046909|NCT02251925|BIOLOGICAL|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
224046910|NCT02251925|DRUG|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
224142388|NCT05894070|OTHER|Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire|"The following speech samples will be recorded from the study participants:~* Standardized, phonetically balanced text~* Sustained, modulated production of five vowels~* Picture description~* Diadochokinetic exercise.~Before starting speech recording, the participant fills in a questionnaire consisting of:~* Health barometer~* Self-rating in terms of stress/fatigue/emotional status.~An Ear, Nose and Throat examination incl. transnasal fiberendoscopy is performed at each visit. The investigators will assess the vocal folds/aryepiglottic folds for the presence of paralysis or reduced mobility, as well as the presence of scar/synechia, edema, erythro-/leukoplakia, or a cancer-suspicious lesion/mass in the larynx/hypopharynx or a chondroradionecrosis in the larynx.~Additionally, it will be assessed, if a tracheotomy canula or a nasogastric tube is in place or was used since the last visit.~Furthermore, the investigators will ask the patients to fill out the VHI-30."
223435720|NCT06735664|BIOLOGICAL|Odronextamab|Given IV
223435721|NCT06735664|PROCEDURE|Positron Emission Tomography|Undergo PET
223435722|NCT06735664|PROCEDURE|Ultrasound Imaging|Undergo ultrasound guided biopsy
223435723|NCT06735664|DRUG|Zanubrutinib|Given PO
224046911|NCT02251925|DRUG|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
224046912|NCT02251925|DRUG|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
224046913|NCT00534820|PROCEDURE|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
224046914|NCT05349526|OTHER|None, pure observational study|None, pure observational study
224046915|NCT05242731|DEVICE|MSmonitor, a self-management/education program with e-health interventions|A self-management/education program with e-health interventions
224046916|NCT05242731|DEVICE|"Video calling program Better-close"|Video calling program.
223435724|NCT06745804|DRUG|68Ga-R10602 injection|68Ga-R10602 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions in hormone receptor positive breast cancer
224046917|NCT05242731|DEVICE|Researchmanager program|Case Report Form, Datamanagement program
224046918|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal|Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
224046919|NCT05522179|DIETARY_SUPPLEMENT|NutraHeal Plus|Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
224046920|NCT00659620|BIOLOGICAL|mesenchymal stem cell|transplantation of mesenchymal stem cell
224046921|NCT06374472|PROCEDURE|Osteosynthesis|Some patients had osteosynthesis using a long construct, others had osteosynthesis using a short construct. Short constructs designated constructs only taking one level above and one level below the injury level (the fractured vertebra was not always included in the construct). The montages taking more than one level above or below the lesion were considered to be a long montage. Osteosynthesis is carried out using Cotrel Dubousset type rods and screws.
224046922|NCT00619970|PROCEDURE|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
224046923|NCT00619970|DRUG|xifaxan|xifaxan 550mg TID x10days
224046924|NCT00619970|DRUG|placebo|placebo TID x 10days
224046925|NCT00619970|PROCEDURE|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
224046926|NCT04422990|DEVICE|Lehfilcon A contact lenses|Investigational silicone hydrogel contact lenses
224046927|NCT04422990|DEVICE|Comfilcon A contact lenses|Commercially available silicone hydrogel contact lenses
224046928|NCT04422990|DEVICE|CLEAR CARE|Hydrogen peroxide-based contact lens cleaning and disinfecting solution
224046929|NCT00005641|BIOLOGICAL|anti-thymocyte globulin|
223435725|NCT06894394|BEHAVIORAL|UP-A|The UP-A (Ehrenreich-May et al., 2018, 2020, 2022) is a transdiagnostic intervention with eight modules targeting neuroticism. It improves emotion regulation and reduces avoidance, with summaries after each module and a Parent Module (P). The intervention is a group adaptation of the Spanish version of UP-A that consists of 16 weekly sessions, each lasting 60 to 90 minutes, held in person at a Day Hospital within the Spanish public healthcare system. Due to the complexity of the setting, parent sessions are not viable. However, parents receive summaries of the modules covered with the adolescents, as well as the Parent Module (Parenting the Emotional Adolescent), to support their understanding of the treatment content.
223435726|NCT02742883|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
223435727|NCT04835428|DEVICE|Treatment Group: AGN1 LOEP SV Kit|The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation. Following saline lavage to create space, the AGN1 implant material is injected and hardens in situ to augment the fractured vertebral body. The AGN1 implant material is then resorbed and replaced with new bone.
223566066|NCT01851486|DRUG|Naloxone|naloxone 0.15 mg/kg
224046930|NCT00005641|DRUG|busulfan|
224046931|NCT00005641|DRUG|cyclophosphamide|
223435728|NCT04835428|DEVICE|Control Group: PMMA bone cement|High viscosity PMMA bone cement will be used for vertebral augmentation.
224046932|NCT00005641|DRUG|cyclosporine|
224046933|NCT00005641|DRUG|leucovorin calcium|
224046934|NCT00005641|DRUG|methotrexate|
224046935|NCT00005641|DRUG|methylprednisolone|
224046936|NCT00005641|PROCEDURE|allogeneic bone marrow transplantation|
224046937|NCT00005641|PROCEDURE|in vitro-treated bone marrow transplantation|
224046938|NCT00005641|RADIATION|radiation therapy|
224046939|NCT03831867|OTHER|Pilates|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
224046940|NCT01436136|OTHER|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
224046941|NCT01436136|OTHER|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
224046942|NCT03627897|DRUG|Bupivacain|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
224046943|NCT03627897|DRUG|saline|No drugs or interventions were administered to the control group.
224046944|NCT00097942|DRUG|memantine HCl|
224046945|NCT02355249|PROCEDURE|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
224046946|NCT02355249|PROCEDURE|OE|Patients will be treated with traditional three incisions esophagectomy.
224046947|NCT04429854|BIOLOGICAL|Convalescent Plasma|"4 units of convalescent plasma:~* 2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible~* 2 units of plasma should be administered between 24h and 36h after the first infusion~Other investigational products may be added as part of the adaptive study design."
224046948|NCT04429854|DRUG|Standard of care|Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.
224046949|NCT00433914|BIOLOGICAL|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
224046950|NCT00433914|BIOLOGICAL|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
223435729|NCT05803382|DRUG|BET Bromodomain Inhibitor ZEN-3694|Given PO
223435730|NCT05803382|PROCEDURE|Biopsy Procedure|Undergo biopsy
223435731|NCT05803382|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224046951|NCT00713479|DRUG|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
224046952|NCT00713479|DRUG|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
224046953|NCT01750320|DEVICE|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
224046954|NCT02942914|DRUG|LY3209590|Administered SC
223435732|NCT05803382|DRUG|Capecitabine|Given PO
223435733|NCT05803382|PROCEDURE|Computed Tomography|Undergo CT and PET/CT
223435734|NCT05803382|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224046955|NCT02942914|DRUG|Placebo|Administered SC
224046956|NCT02942914|DRUG|Insulin Glargine|Administered SC
224046957|NCT02648516|COMBINATION_PRODUCT|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
224046958|NCT03789461|PROCEDURE|Fecal Microbiota Transplantation|FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
223435735|NCT05803382|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223478551|NCT03161054|DRUG|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
223566067|NCT01851486|DRUG|placebo|
223566068|NCT01851486|OTHER|saline|
224046959|NCT04973579|PROCEDURE|Simutaneous (single anaesthesia) carotid artery stenting with MicroNet covered stent (CGuard) and cardiac surgery (CABG or surgical valve replacement / repair procedure)|"The registry enrolls patients qualified for treatment with the methods evaluated in the registry, using routinely applicable procedures and devices.~In cardiac surgery - surgical treatment systems for advanced ischemic heart disease and/or valvular disease (including - mechanical/biologic heart valves - regulatory approved for routine use and typically used at the Facility.~In the simultaneous treatment of stroke-threatening carotid artery atherosclerosis - temporary neuroprotection systems (proximal, distal, according to medical indications and local experience) - regulatory approved for routine use and typically used at the center (for over 20 years).~CGuard anti-embolic mesh stent system - a self-expanding nitinol carotid stent wrapped in MicroNet, which prevents fragments of atherosclerotic plaque from entering the lumen of the carotid artery - approved for routine use and typically used at the Center (over 5 years)."
224046960|NCT00004047|DRUG|exatecan mesylate|
224046961|NCT02844920|DEVICE|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
223435736|NCT07059078|BEHAVIORAL|Brief Motivational Interviewing-based Alcohol Intervention|"Participants in both arms (BMAI and BMAI + MT) will receive a brief motivational interviewing-based alcohol intervention (BMAI) delivered by a pediatric clinician in the primary care setting.~BMAI is adapted from the Provider Guide: Adolescent SBIRT Using the S2BI-CRAFFT Screening Tool, grounded in the stages of change model and motivational interviewing (MI). It consists of one or more brief sessions involving structured feedback, advice, and goal setting to help adolescents recognize links between substance use and health outcomes and develop personalized change plans. The intervention is face-to-face, delivered during routine or follow-up visits, and modeled after the brief negotiated interview. The first session lasts 10-30 minutes and includes six MI-based steps. This is followed by one or more additional brief MI sessions lasting 5-15 minutes where the patient's goals are reviewed, gains or barriers are addressed, and ongoing support is provided."
223435737|NCT07059078|BEHAVIORAL|Smartphone App-delivered Mindfulness Training|"In addition to BMAI, participants in the BMAI + MT arm will receive 8 weeks of smartphone-delivered mindfulness training using the Healthy Minds Program (HMP) app.~The HMP app provides self-guided, self-paced mindfulness and meditation training designed to improve psychological well-being, reduce stress/anxiety, and enhance self-regulation. It includes podcast-style teachings and guided meditations. The app features four modules-Awareness, Insight, Connection, and Purpose-based on neuroscience research. Each module offers 27 practices (5-30 minutes each). This study focuses on the Awareness and Insight modules, which teach breath and body awareness and emotion noting to support mindfulness in daily life. Participants will be asked to use the app 5-30 minutes per day, following 4 weeks of Awareness content, then 4 weeks of Insight. After 8 weeks, they will have open access to all modules and be encouraged to explore additional practices as they find helpful during follow-up."
223435738|NCT05201066|DRUG|decitabine|Solution for intravenous infusion
223435739|NCT05201066|DRUG|spartalizumab|Solution for intravenous infusion
223435740|NCT05201066|DRUG|sabatolimab|Solution for intravenous infusion
223435741|NCT05201066|DRUG|azacitidine|Solution for subcutaneous injection or intravenous infusion
223435742|NCT05201066|DRUG|venetoclax|Tablet for oral administration
223435743|NCT05201066|DRUG|INQOVI (oral decitabine)|Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
223435744|NCT06917456|DEVICE|Virtual Reality Headset|Participants will use either a Meta Quest VR device, or a Pico headset. Both of these devices are standard non-medical hardware items.
223435745|NCT06901245|DRUG|Tirzepatide|Subjects will take Tirzepatide for 48 weeks
223435746|NCT04874116|BEHAVIORAL|Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging|Office-GAP incorporates shared decision-making and a decision/support checklist to be completed during office visits, to foster patients' investment in their own care. Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
224046962|NCT01966614|DRUG|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
224142389|NCT05130632|BEHAVIORAL|The community working group|"The intervention consists of educational working group (WG) sessions over 12 weeks. Eight core modules discussing essential elements (such as main problems of solid waste management, health effects of exposure to burning plastic, sustainable alternatives to plastic litter) and four periphery modules to help identify community-driven interventions to reduce plastic burning in household fires, consume less plastic, recycle, and repurpose plastic, will be held.~Participants will prioritize one task that can be attained in the next 9 months, with the guidance of community workers (promotoras), such as:~* engaging in a community clean-up~* starting an organic compost pile free of plastic waste~* training on community recycling, focusing on plastics recycling~* making organic soaps, to use for personal grooming or washing clothes, eliminating plastic packaging~* creating materials out of plastic, like bottle planters"
224142390|NCT05456256|DRUG|LP-300|LP-300: 18.4 g/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
223435747|NCT04874116|BEHAVIORAL|Mobile text messaging|Way to Health is a cell phone messaging service that informs and encourages patients to adhere to goals and improve communication.
223435748|NCT05031416|COMBINATION_PRODUCT|LTQ|The investigators will test the LTQ-Connect application and a standard 10-week course of nicotine replacement therapy (NRT) nicotine patches, and Facebook groups, which will run for a total of 3 months with research study participants
224046963|NCT01966614|OTHER|Placebo|Single intraprostatic bilateral injection of vehicle only
223435749|NCT02280616|DRUG|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
223435750|NCT02280616|DRUG|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
223435751|NCT02280616|DRUG|high dose budesonide suspension|placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily
223435752|NCT02280616|DRUG|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
223435753|NCT06483815|DIAGNOSTIC_TEST|Culture, İsolation|Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
223566069|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
224046964|NCT02429726|DRUG|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
224046965|NCT02429726|DRUG|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
224046966|NCT02429726|DRUG|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
224046967|NCT02224313|DRUG|oral estradiol 1.0 mg|one tablet of oral estradiol 1.0 mg once a day for 28 days
224046968|NCT02224313|DRUG|oral progesterone 100 mg|one tablet of oral progesterone 100 mg once a day for 14 days
224046969|NCT00224094|DRUG|Premarin® (oral) vs. Alora® (transdermal)|
224046970|NCT04862533|DRUG|Beta-Alanine|Participants will receive 1150mg of beta-alanine three times a day
224046971|NCT04862533|DRUG|Placebo|Participants will receive matching placebo three times a day
224142391|NCT05456256|DRUG|Pemetrexed|Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
224142392|NCT05456256|DRUG|Carboplatin|Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
224142393|NCT04860752|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Subjects will undergo TAVI
224142394|NCT06025396|DRUG|Cohort 1 - TMP-301|50 mg BID Fasted
224142395|NCT06025396|DRUG|Placebo|Multiple ascending dose comparator
224142396|NCT06025396|DRUG|Cohort 2 - TMP-301|50 mg QD Fasted
224142397|NCT06025396|DRUG|Cohort 3 - TMP-301|50 mg QD Fed
224142398|NCT06025396|DRUG|Cohort 4 - TMP-301|25 mg QD Fed
224142399|NCT02801422|OTHER|fMRI|
224142400|NCT00889811|PROCEDURE|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
224142401|NCT01773798|DRUG|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
224142402|NCT01773798|DRUG|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
224142403|NCT01773798|DRUG|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
224142404|NCT01773798|DRUG|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
223435754|NCT06461715|OTHER|Machine learning with artificial intelligence software program|This is a retrospective observational study using cardiac MRI, cardiac CT and x-ray fluoroscopy images to develop a 3D hybrid guidance system with the use of deep learning methods.
223435755|NCT00059605|GENETIC|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
223435756|NCT04417972|DRUG|SHR7280|treatment
223435757|NCT04417972|DRUG|Placebo oral tablet|blank control
223435758|NCT00867828|DIETARY_SUPPLEMENT|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
223435759|NCT00867828|DIETARY_SUPPLEMENT|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
223435760|NCT00867828|DIETARY_SUPPLEMENT|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
223435761|NCT04655040|DRUG|Caffeine|100milligram (mg) tablet taken orally in period 1 and period 2
223566070|NCT01543672|RADIATION|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
224142405|NCT01773798|DRUG|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
224142406|NCT00646113|DEVICE|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
223566071|NCT00286195|DEVICE|Multi-Link Frontier Coronary Stent System|Bare metal stent
224142407|NCT02109744|DRUG|Decitabine|
224142408|NCT04638868|DEVICE|Microsieve device|Both portal venous and peripheral blood will be processed through a label-free size-based silicon microsieve microfiltration device, which will isolate both epithelial-type and mesenchymal-type pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
224142409|NCT04638868|DEVICE|Cell surface marker-based platform|Both portal venous and peripheral blood will be processed through a cell surface marker-based platform, which contains antibodies for epithelial cell markers on pancreatic cancer circulating tumor cells. Downstream mutational analyses will be performed to confirm identity of the cells.
223435762|NCT04655040|OTHER|Ritlecitinib|200 milligrams (mg) taken orally once a day(QD) for 8 days
223435763|NCT02681757|DEVICE|triple antibiotic ointment dressing|used for control group under soft cast
223435764|NCT02681757|DEVICE|Mepitel Ag|used for variable/experimental group under soft cast
223435765|NCT06730477|OTHER|observational study|Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
223566072|NCT00713921|DRUG|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
223566073|NCT01448824|DRUG|LY2484595|Administered orally
223566074|NCT01448824|DRUG|Placebo|Administered orally
223566075|NCT01448824|DRUG|Ketoconazole|Administered orally
223566076|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets|Investigational Medicinal Product
224046972|NCT04862533|PROCEDURE|Pelvic floor muscle training (PFMT)|Participants in both groups will undergo PFMT training program
224046973|NCT05281107|DIETARY_SUPPLEMENT|Placebo, 500 mg calcium|Berry flavoured sachet powder (500 mg calcium)
224046974|NCT05281107|DIETARY_SUPPLEMENT|600 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
224046975|NCT05281107|DIETARY_SUPPLEMENT|1200 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
223435766|NCT02359799|DEVICE|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
223435767|NCT06907654|DEVICE|well-being app|The HMP app is a meditation-based smartphone app designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of guided practices. HMP has guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.
223435768|NCT06907654|BEHAVIORAL|List of well-being resources|Participants will be given a list of resources that promote well-being.
223566077|NCT04713904|DRUG|Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets|Evafem 20 (Trademark)
223566078|NCT00932620|DRUG|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
223566079|NCT00932620|DRUG|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
223566080|NCT00771732|DEVICE|light therapy|6 minute light therapy
224046976|NCT05281107|DIETARY_SUPPLEMENT|4000 IU vitamin D + 500 mg calcium|Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
224046977|NCT01520233|GENETIC|RNA analysis|
224046978|NCT01520233|GENETIC|gene expression analysis|
224046979|NCT01520233|OTHER|laboratory biomarker analysis|
224142410|NCT02572011|OTHER|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
224142411|NCT04095442|DEVICE|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
224142412|NCT04095442|DEVICE|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
224142413|NCT05725330|OTHER|Gamification and education with mobile game application|This study aimed to provide self-care management by playing mobile games to patients with type 2 diabetes.
224142414|NCT00083343|DRUG|MK0991, caspofungin acetate/Duration of Treatment: variable|
223435769|NCT04064541|OTHER|Virtual Visit|Virtual Visit
223478552|NCT03161054|DRUG|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
223478553|NCT03161054|DRUG|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
223478554|NCT03161054|DRUG|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
223478555|NCT03161054|DRUG|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
223478556|NCT00255385|DRUG|Micronutrient (Zinc and Iron) fortification|
224046980|NCT04092348|OTHER|complete blood count|"1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
224046981|NCT02193321|BIOLOGICAL|Amniotic Membrane Patch|
224142415|NCT00536848|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
224142416|NCT00536848|DIETARY_SUPPLEMENT|Placebo|
224142417|NCT00536848|DRUG|Metronidazole|
224142418|NCT01926470|PROCEDURE|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
224142419|NCT01926470|PROCEDURE|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
224142420|NCT05986825|OTHER|Verneuil questionnaire Validation|Request patient to Complete the questionnaire for validation of the French version
224142421|NCT00567060|DRUG|Piracetam|
223478557|NCT00255385|DRUG|Pre and Probiotic fortification|
223478558|NCT04287179|DRUG|Semaglutide|Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
224142422|NCT04489537|BIOLOGICAL|MarzAA|A cross over design to assess the efficacy of a dosing regimen of 60 µg/kg of MarzAA compared with standard of care for the treatment of bleeding episodes.
224142423|NCT04625985|DRUG|Metformin Glycinate|Participants randomized to metformin glycinate will take 620 mg bid (PO) for 14 days plus standard treatment
224142424|NCT04625985|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
223478559|NCT04176913|DRUG|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
223478560|NCT00784875|DRUG|LY2624803|1 mg, oral capsule, once nightly before bedtime
223478561|NCT00784875|DRUG|LY2624803|3 mg, oral capsule, once nightly before bedtime
223478562|NCT00784875|DRUG|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
223478563|NCT00784875|DRUG|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
224142425|NCT03159013|OTHER|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
224142426|NCT01304472|DRUG|Prasugrel|Prasugrel 10mg per day
224142427|NCT01304472|DRUG|Clopidogrel|Clopidogrel 150mg per day
223435770|NCT06731452|BEHAVIORAL|Strategic Memory Advanced Reasoning Training teaches meta-cognitive strategies for individuals to apply to their daily lives for improved performance|"Online SMART is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~Stress Solutions extends the SMART principles to relevant domains of stress and resilience."
223435771|NCT06910553|OTHER|Non-exposed group|Pregnant individuals with IBD who are not exposed to an IBD pharmacotherapy during pregnancy
224046982|NCT05952674|DEVICE|Vagus Nerve Stimulation (VNS)|The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
224046983|NCT05952674|OTHER|Best Medical Treatment|Best Medical Treatment for resistant depression.
224046984|NCT05005806|DRUG|Omega 3 fatty acid|omega 3 fatty acid soft gel
224046985|NCT05005806|DRUG|Placebo|placebo soft gel
224046986|NCT05963958|COMBINATION_PRODUCT|Active HD-tDCS|Brain stimulation using active high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
224046987|NCT05963958|COMBINATION_PRODUCT|Sham HD-tDCS|Sham high definition transcranial direct current stimulation is applied simultaneously with the use of dexmedetomidine as a pharmacological treatment for delirium in critical illness patients with covid-19
224046988|NCT05339581|RADIATION|intensity-modulated radiotherapy|Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.
224046989|NCT05339581|COMBINATION_PRODUCT|Pembrolizumab|Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.
224046990|NCT05339581|DRUG|Sintilimab|Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.
224142428|NCT04919746|OTHER|Systemic acupuncture|Systemic acupuncture will be performed on the lower limb, bilaterally, at points E36 (Zusanli) and BP6 (Sanyinjiao). Point location specificity will be determined using the anatomical and directional F-cun reference method. Stimulation of pre-defined points will be performed using needles with a threadlike, sterile, disposable character and size 0.25 x 30.0 mm, within a period of 20 minutes. The insertion of the needle will be at a depth of 0.5 inches, aiming to obtain the De Qi, sensation of energy at the point and in the corresponding meridian, referring to the effectiveness of systemic acupuncture.
223435772|NCT06910553|DRUG|Exposed to IBD pharmacotherapy during pregnancy|Pregnant individuals with IBD who are exposed to an IBD pharmacotherapy during pregnancy
223435773|NCT03982446|GENETIC|Mutations|
223435774|NCT07111078|BIOLOGICAL|VRC-FLUMOS0122-00-VP (SteMos1) with and without Army Liposome Formulation containing saponin QS-21 (ALFQ) Adjuvant|"FLUMOS0122-00-VP (SteMos1) is a sterile, aqueous buffered solution supplied in 3 mL single-dose glass vials containing 0.7 +/- 0.1 mL with a vaccine concentration of 1080 mcg/mL.~The ALFQ drug product is a sterile suspension that contains 240 mcg of monophosphoryl 3-deacyl Lipid A (3D-PHAD) and 120 mcg QS-21 that is vialed at 0.6 mL/vial in 3.0 mL glass vials. 0.5 mL of ALFQ adjuvant will be mixed with the 60 or 180 mcg dose of SteMos1 during preparation in the pharmacy prior to"
223566081|NCT00771732|DEVICE|light therapy|combination of wavelengths
223566082|NCT03293433|OTHER|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
223566083|NCT02036164|RADIATION|Pelvic radiation|"Radiation:~* Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~* Brachytherapy 30-35 Gy for 4-5 times"
223566084|NCT02036164|DRUG|Cisplatin|Cisplatin 40 mg/m2 i.v.
223566085|NCT02036164|DRUG|Paclitaxel|Paclitaxel 175 mg m2 i.v.
224046991|NCT05339581|DRUG|Camrelizumab|Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.
224142429|NCT02407314|PROCEDURE|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
223566086|NCT02036164|DRUG|Carboplatin|Carboplatin AUC 5 i.v.
224046992|NCT05339581|DRUG|Tislelizumab|Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.
224046993|NCT05339581|DRUG|Lenvatinib Mesylate Capsule|Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
224046994|NCT00053950|DRUG|pyrazoloacridine|Given IV
224046995|NCT00053950|BIOLOGICAL|filgrastim|Given IV or SC
224046996|NCT00053950|PROCEDURE|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
224046997|NCT00053950|PROCEDURE|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
223566087|NCT04338724|DRUG|CS1002|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
223566088|NCT03128268|DEVICE|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
224046998|NCT00053950|OTHER|laboratory biomarker analysis|Correlative studies
223435775|NCT04506905|DRUG|MK-8189|MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization
224046999|NCT00053950|OTHER|pharmacological study|Correlative studies
224047000|NCT01127659|DRUG|testosterone|intramuscular every 2 weeks
224047001|NCT01127659|DRUG|placebo|saline intramuscular every 2 weeks
224047002|NCT05750875|DRUG|Loratadine|Participants were given loratadine 10mg, oral, daily, for 4 weeks
224047003|NCT05750875|DRUG|Gabapentin|Participants were given gabapentin 100mg, oral, daily, for 4 weeks
224047004|NCT01948336|DRUG|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
224047005|NCT01948336|DRUG|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
223435776|NCT04506905|DRUG|Placebo|Oral tablets of dose-matched placebo to MK-8189 according to randomization
223435777|NCT06225271|BEHAVIORAL|the combined intervention of exercise, fruit, and vitamin supplementation|"Group intervention~After each intervention, investigators will hold a 15-minute communication and discussion session for the participants. Besides, community health workers will organize at least one health education activity per week during the intervention for no less than 45 minutes.~Individual intervention~Physical activity~The participants will be gathered at the community activity center or day care center. The participants will be allowed to exercise in a way that interests them. The duration of exercise should be longer than 30 minutes.~Fruit supplementation~Consideration of seasonal supply situation and the participants' diabetic status, various types of fruit will be prepared. The fruit will be divided into 50g/100g servings. Participants will be required to eat on site.~Vitamin supplementation~During the intervention, the participants will be required to take 1 tablet of vitamin B complex plus 1 tablet of vitamin C every day."
223435778|NCT05319743|OTHER|Medicaid Expansion|Expansion of Medicaid, 01/01/2014
223566089|NCT02378194|DRUG|Placebo|24 weeks, once daily oral administration
223566090|NCT02378194|DRUG|HD-003 (800mg/day)|24 weeks, once daily oral administration
224047006|NCT01948336|DRUG|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
224047007|NCT05801328|DEVICE|Ending of the wires on Erich arch bar in the occlusal direction|The wires of the Erich arch bar will be placed on the occlusal direction
224047008|NCT04344470|DEVICE|EMG|EMG will be recorded from two electrodes placed on both extensor carpi radialis (ECR) muscles
224047009|NCT04344470|DEVICE|EEG|EEG electrodes will be positioned according to 10-20 International System, with every impedance kept under 5 kOhm. EEG data will be amplified, filtered (DC-100 Hz), digitized at 1000 Hz, and stored on a computer for offline analysis.
224047010|NCT00721370|DEVICE|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
224047011|NCT04472520|DEVICE|AliveCor Heart Monitor|Records single-channel ECG rhythms
224047012|NCT00047671|DRUG|Citalopram|PDA Approved antidepressant
224047013|NCT05244291|OTHER|Therapeutic Touch|Therapeutic Touch will be applied to infants for 3 consecutive days, once a day, 10 minutes at any time during the day. There will be a four-day break. The Therapeutic Touch will be done a total of 3 times a week or 6 times in 2 weeks.
224047014|NCT05284279|OTHER|Exploring health professionals' perceptions of patients with ECC using semi-structured interviews|"Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences."
224047015|NCT00240981|DRUG|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
224047016|NCT00240981|DRUG|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
223566091|NCT02378194|DRUG|HD-003 (1600mg/day)|24 weeks, once daily oral administration
223566092|NCT03092986|DRUG|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
223566093|NCT03092986|DRUG|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
223566094|NCT03092986|DRUG|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
223566095|NCT03092986|DRUG|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
223566096|NCT03092986|RADIATION|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
223566097|NCT03447210|BEHAVIORAL|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
223566098|NCT03167112|DRUG|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
223566099|NCT03167112|DRUG|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
224047017|NCT00699465|DRUG|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
223435779|NCT06937762|DEVICE|Intra capsular coblation tonsillotomy|Tonsils were dissected from the surface inward with the wand set at Coblate 7 setting. The wand skims the tonsil surface with continuous saline irrigation. Ablation was performed without penetrating the tonsillar capsule. Retraction of the tonsillar pillars is done to define the margins for near complete ablation. When the capsule is approached, the wand is turned down to Coblate 3 setting. Thin layer of tonsillar tissue is left to protect the capsule. Bleeding does not occur in most cases, but when it occurs, the wand was used in the Coagulate 5 setting for homeostasis
223435780|NCT06937762|DEVICE|Extracapsular cold knife dissection tonsillectomy|Begin by retracting the anterior tonsillar pillar to expose the tonsil, use a cold knife (scalpel or tonsil dissector) to make an incision along the anterior pillar near the mucosal margin of the tonsil, identify the plane between the tonsillar capsule and the underlying pharyngeal muscle, then carefully dissect the tonsil away from the surrounding tissues, following the plane to avoid trauma to the underlying structures, proceed from the superior pole of the tonsil to the inferior pole, ensuring that the entire tonsil is removed, use gauze or sponges to control minor bleeding during the procedure, for more significant bleeding, apply direct pressure or use ligatures and cold packs, achieve final hemostasis using absorbable sutures or electrocautery if needed
223435781|NCT06937762|DEVICE|Extra capsular Radiofrequency tonsillectomy|Radiofrequency bipolar forceps, connected to a radiofrequency apparatus model Ellman Surgitron 4 MHz (Ellman International, New York, USA) by which cutting and dissection with coagulation were done in the same time with minimal diffuse heating to the surrounding tissue. The power was adjusted to a power grade 40 in a bipolar mode.
223566100|NCT03167112|DRUG|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
223566101|NCT03167112|DRUG|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
223566102|NCT05311943|DRUG|olverembatinib|olverembatinib, 40mg, taken orally once every other day of a 28-day cycle
224047018|NCT00699465|DRUG|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
223566103|NCT03789136|OTHER|Not applicable, observational study|Not applicable, observational study
223566104|NCT06006507|OTHER|control|no exercise will be given
223566105|NCT06006507|OTHER|exercise|In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
224047019|NCT00800436|DRUG|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
224047020|NCT00766090|DRUG|GW685698X|Inhaled Corticosteroid
224142430|NCT02407314|DEVICE|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
224142431|NCT02407314|OTHER|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
224142432|NCT02407314|OTHER|Six minute walk distance|Assessment of the walking distance in 6 minutes.
223435782|NCT07143487|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224142433|NCT02407314|DRUG|Aspirin|Aspirin, also known as acetylsalicylic acid \[ASA\], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
224142434|NCT02407314|DRUG|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
224142435|NCT01674816|DEVICE|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
224142436|NCT01674816|DEVICE|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
224142437|NCT02953613|DEVICE|NIRS/IVUS|Cardiac catheterization using infraredx
224142438|NCT02774044|DRUG|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
224142439|NCT02774044|DRUG|Survanta|
223435783|NCT07143487|OTHER|Genetic Testing|Undergo genetic testing
223435784|NCT07143487|OTHER|Communication Intervention|Receive proband-mediated communication
223435785|NCT07143487|OTHER|Survey Administration|Ancillary studies
223435786|NCT07158541|PROCEDURE|tunneled coronally advanced flap with connective tissue graft|The gum at the recession site is undermined, only partially detached and reattached higher (combined withh a connective tissue graft).
223435787|NCT07158541|PROCEDURE|modified tunnel with connective tissue graft|At the recession site, the gingiva is undermined to create a tunnel, and a connective tissue graft is inserted through the sulcus into this space before advancing the flap coronally.
224047021|NCT00021320|DRUG|cisplatin|
224047022|NCT00021320|DRUG|fluorouracil|
224047023|NCT00021320|DRUG|paclitaxel|
224047024|NCT00021320|PROCEDURE|conventional surgery|
223435788|NCT07161102|OTHER|Reflexology|A complementary technique that involves applying pressure to reflexology points on the feet. In this study, foot reflexology will be applied in 10 sessions, twice a week, for 30 minutes, aiming to reduce anxiety symptoms.
223435789|NCT07161102|OTHER|Sham Reflexology|A simulated procedure consisting of superficial and random maneuvers on the feet, without stimulation of specific reflexology points. Ten sessions will be conducted twice a week, each lasting 30 minutes, for placebo control purposes.
224047025|NCT00021320|PROCEDURE|neoadjuvant therapy|
224047026|NCT00021320|RADIATION|radiation therapy|
224047027|NCT03331770|DRUG|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
224047028|NCT05172414|OTHER|No intervention|The single group had no intervention. All followed the same procedures of different collection methods.
224047029|NCT03331861|DRUG|Metformin hydrochloride|Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
224047030|NCT03331861|DRUG|Placebo|Similar dosing regime as active comparator
224047031|NCT06052163|DRUG|Bumetanide|Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
224047032|NCT06052163|DRUG|Placebo|A placebo has no active properties and is taken orally.
224047033|NCT04858763|OTHER|No Intervention|There will be no intervention during this study.
224047034|NCT03250260|OTHER|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
224047035|NCT03250260|OTHER|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
224047036|NCT01578408|PROCEDURE|Total Hip Arthroplasty|
224047037|NCT01578408|DEVICE|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
224047038|NCT01578408|DEVICE|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
224047039|NCT04195854|DEVICE|P4HB product|Retrospective use of P4HB in various anatomies
224047040|NCT01750931|DRUG|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \&amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
223435790|NCT07167030|BEHAVIORAL|Virtual Reality Digital Storytelling|Participants in the intervention group will receive digital storytelling modules using virtual reality (VR) headsets once a week for four weeks, starting at 28 weeks of gestation. Each module will include three topics (2-10 minutes). After each topic, there will be a rest period followed by an interactive session. The final two modules will be administered during the NST recording, and mother and baby status will be monitored. Each module, including the interactive session, will last 45-50 minutes. Participants will receive an educational brochure after the module and will be reminded via WhatsApp.
223566106|NCT04122183|OTHER|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
224047041|NCT01750931|DRUG|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH \& Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
224047042|NCT00528580|DRUG|Simvastatin|80 mg once daily PO/NG x 4 days
224047043|NCT00528580|DRUG|Identical-appearing placebo|once daily x 4 days
224047044|NCT06170112|OTHER|Spinal Orthosis Application|Spinal orthosis treatment is to prevent secondary curvature and provide correction. Corrective pressure forces in spinal orthosis are basically; There are pressure points on the material of the spinal orthosis, pressure pads, and velcros used to adjust the tightness and ensure the stability of the orthosis. The duration of use of spinal orthoses varies from patient to patient; It is known that using it for an average of 23 hours a day gives the best results. Orthosis use is required for 12 weeks during the study.
224047045|NCT02855671|DEVICE|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
224142440|NCT02919735|DRUG|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
224142441|NCT02919735|DRUG|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
223566107|NCT04576039|DIAGNOSTIC_TEST|saline infusion sonography|Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.
224142442|NCT00272545|BEHAVIORAL|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
224142443|NCT00272545|BEHAVIORAL|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
224142444|NCT01852630|DRUG|cefepime + Albumin|cefepime + Albumin will be given for 2 days
224142445|NCT01852630|DRUG|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
224047046|NCT00587392|DEVICE|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
224047047|NCT02198092|OTHER|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
223435791|NCT07165340|COMBINATION_PRODUCT|Indocyanine Green near infrared fluorescence imaging|A total of 10 intradermal injections of 25 ug indocyanine green (ICG) in 0.1 mL saline are administered in the feet, medial ankles, lateral calves, and thigh. The total dose of ICG will not exceed 250 ug. After injection, the legs will be illuminated by the dim output of a 780 nm laser diode, and the resultant fluorescent signal emanating from ICG-laden lymph will be collected by a custom built near-infrared fluorescent lymphatic imager.
223435792|NCT07165340|DEVICE|advanced pneumatic compression|The advanced pneumatic compression device (APCD) mimics manual lymphatic drainage, a light massage that stimulates lymphatic uptake and function and frequently prescribed for lymphedema therapy. Daily treatment will be prescribed for approximately 30 days.
223435793|NCT07165340|DIAGNOSTIC_TEST|Duplex ultrasound|Duplex ultrasound to measure venous reflux will be done at each visit.
223435794|NCT07165340|DEVICE|compression wrap|A compression wrap, to provide 20-40 mm Hg of pressure, will be provided for daily use between visits (approximately 30 days).
223435795|NCT07176468|OTHER|Neuronavigation-guided individualized iTBS|"Participants will receive individualized iTBS for 14 consecutive days in addition to their usual medication regimen.~iTBS parameters: 50 Hz bursts every 200 ms (5 Hz), 2s on/8s off, total 600 pulses per session;6 sessions/day (3 in morning, 3 in afternoon, 3600 pulses/day); 100% RMT intensity; Neuronavigation: Brainsight system (Rogue Research, Canada)"
223435796|NCT07175714|OTHER|Methodologies to induce gait perturbations|Method 1: Obstacles deployed at the frond end side of the treadmill Method 2: Obstacles deployed on the side of the treadmill Method 3: Spit-bell treadmill to induce slip perturbations Method 4: String method
223435797|NCT07176689|DRUG|Nirogacestat|Nirogacestat oral tablet
223435798|NCT07175207|BIOLOGICAL|UCB-MNCs|UCB-MNCs will be administered via intravenous infusion three times, once per week, with a dose of 3×10⁸ cells per infusion.
223435799|NCT07174947|DRUG|Fluoxetine (drug)|Fluoxetine: Maintain at 20mg per day, orally, until disease progression or intolerance
223435800|NCT07174947|DRUG|Placebo|Placebo: 1 placebo tablet per day for maintenance, orally.
224047048|NCT01106027|DRUG|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
224142446|NCT03203590|DRUG|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
224142447|NCT03203590|DRUG|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
224142448|NCT06362395|RADIATION|Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)|Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
224142449|NCT06440265|OTHER|AM-PAC inpatient short form (low function)|"The Activity Measure for Post-Acute Care(AM-PAC) 6-clicks instruments have advantages in that they are simple and quick to complete, easy to use within usual care and has been validated in the entire hospital population. It has gained broad adoption in acute care hospital and, although it includes items for people at lower levels of function, there is a concern of a floor effect in ICU measurement. So, new AM-PAC items are developed to measure physical function at the lowest level and added 2 new items to AM-PAC inpatient mobility short form. It lowered the floor effect and increased statistical power, measurement breath, and sensitivity.~2 new items~* Turning head~* Following simple instructions"
224142450|NCT04644965|DIAGNOSTIC_TEST|CombynTM Function & Spaces ECG|Multi-frequency impedance measurement to assess the muscle and fat mass
224142451|NCT04644965|DIAGNOSTIC_TEST|Blood Taking|Sampling of blood of the finger pad to assess liver function
224142452|NCT04644965|DIAGNOSTIC_TEST|Spiroergometry|Spiroergometry to assess cardiopulmonary capacity. The intensity will be raised in steps until total exhaustion. In between each step we will take blood of the ear lobe to determine the lactate level
224142453|NCT04644965|DIAGNOSTIC_TEST|Dordel Koch Test (DKT)|Dordel Koch Test (DKT) to evaluate the motor activity. The DKT is a heterogeneous test battery for children and adolescents and consists of seven parts: lateral jumping, sit and reach, situps, long stand jump, one-legged stand, push-ups and 6-min-run
224142454|NCT04644965|DIAGNOSTIC_TEST|Ultrasound|Ultrasound for abdominal wall muscles
224142455|NCT04644965|DIAGNOSTIC_TEST|Stance and gait analyses|Stance and gait analyses for measuring the core stability
223435801|NCT07174401|DRUG|Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.|The eye not selected as the study eye will be used for comparison so both eyes will be imaged with the study devices to assess blood flow changes.
223435802|NCT07174401|DEVICE|Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.|One OCT device is FDA-cleared while the other is still experimental. Both devices assess blood flow in different ways.
223435803|NCT07177248|BEHAVIORAL|Family-Based 12-Week Multicomponent Program|Weekly digital materials to parents (email/WhatsApp) + three on-site sessions (\~90 min each: functional training; modified games; outdoor trekking); 12 weeks total; delivered by a Physical Education teacher; attendance and delivery logs for fidelity.
223435804|NCT07175311|DIAGNOSTIC_TEST|Multimodal imaging findings|Fundus photography, Optical Coherence Tomography, and Fluorescein Angiography will be performed 7 days after meeting the criteria for inactivation of endophthalmitis, as outlined in the MEX-ESG guidelines. These imaging tests will be repeated one month after meeting the inactivation criteria.
224142456|NCT02025803|DRUG|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
223435805|NCT07175012|DEVICE|ELECTROVEST|A wearable vest device that delivers airway clearance therapy through high-frequency chest wall oscillation (HFCWO) combined with surface neuromuscular electrostimulation (EEM). The session includes a 2-minute warm-up phase at 4 Hz, 16 minutes of active stimulation at 8 Hz, and a 2-minute recovery phase at 4 Hz (total duration: 20 minutes). The intervention is administered during supervised physiotherapy sessions to promote mucociliary clearance and respiratory muscle activation in patients with chronic respiratory diseases.
223435806|NCT07175012|DEVICE|The Vest® Model 105|A conventional airway clearance therapy using a commercial high-frequency chest wall oscillation (HFCWO) device (The Vest® Model 105 or AffloVest®). The session includes a 2-minute warm-up phase at 13 Hz, 16 minutes of treatment at 20 Hz, and a 2-minute cool-down at 13 Hz (total duration: 20 minutes). This intervention serves as the active comparator in the crossover trial.
223435807|NCT07176000|BEHAVIORAL|Patient Navigation|Receive tailored PN activities
223435808|NCT07176000|OTHER|Educational Intervention|Receive LCS educational handout
223435809|NCT07176000|OTHER|Best Practice|Receive enhanced usual care
223435810|NCT07176000|OTHER|Interview|Ancillary studies
223435811|NCT07176000|OTHER|Survey Administration|Ancillary studies
223435812|NCT07176000|OTHER|Electronic Health Record Review|Ancillary studies
223435813|NCT07175649|DRUG|Methylprednisolone sodium succinate|"Intravenous methylprednisolone sodium succinate will be administered at a dose of 2 mg/kg/day for 3 days, with a maximum daily dose of 160 mg (4 vials, 40 mg/vial).~It is recommended that the initial dose be administered as soon as possible after randomization."
223435814|NCT07175649|DRUG|Placebo|Matched intravenous placebo will be administered for 3 days, with a maximum daily dose of 4 vials.
223435815|NCT07175753|OTHER|chiropractic applied clinical neuroscience care|Standard chiropractic care with physiotherapy and phototherapy over two sessions
223435816|NCT07175909|DEVICE|The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology|The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.
223435817|NCT07177222|PROCEDURE|laparoscopic esophagocardiomyotomy|Heller myotomy, is a minimally invasive surgical procedure that involves cutting the muscle at the lower end of the esophagus to treat achalasia, a condition where this muscle (esophageal sphincter) fails to relax and hinders food passage into the stomach.
223435818|NCT07177222|PROCEDURE|open surgery|Open surgery, or traditional surgery, involves a surgeon making one large incision to directly access and view the internal organ or body part being operated on.
224047049|NCT02115425|OTHER|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
224047050|NCT02115425|OTHER|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
224047051|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
224047052|NCT02115425|OTHER|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
224047053|NCT02115425|OTHER|add name here|
223435819|NCT07177170|OTHER|Differentiated screening delivery|More flexibility in the screening delivery will be offered. A decision aid process will be implemented to help the participants deciding between the two options.
223435820|NCT07177170|OTHER|Single visit|All the steps of the screening (using HPV test) and of the treatment will be performed in a single visit (when possible).
223435821|NCT07175051|DRUG|Empagliflozin (oral)|10 mg
224047054|NCT03875989|PROCEDURE|Anterior colporraphy|It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
224047055|NCT03875989|PROCEDURE|vaginal patch plastron|It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
224047056|NCT02871778|DRUG|VX-371|
224047057|NCT02871778|DRUG|Hypertonic Saline|
224142457|NCT01635010|PROCEDURE|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
224142458|NCT02134067|DRUG|TAS-119|
223435822|NCT07174414|DRUG|Cilostazol 100 mg|Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability.
223435823|NCT07174414|DRUG|Placebo|Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability.
223435824|NCT07176780|DEVICE|Semiconductor embedded body sleeve|The active device contains semiconductors embedded into the body sleeve fabric
223435825|NCT07176780|DEVICE|Placebo Non-Compressive Body Sleeve|Identical body sleeve absent of semiconductors
223435826|NCT07174557|OTHER|MoodTriggers Application|"The Mood Triggers application, developed by Dr. Jacobson, will be used for collecting smartphone sensor data. This HIPAA-compliant app has been incorporated into various projects at Dartmouth, Stanford, and MGH/Harvard, with development supported by NIDA, NIMHD, NCI, and the Department of Veterans Affairs. The Mood Triggers app will capture a wide range of metrics, including psychomotor agitation, sleep disturbances, low behavioral activation, social contact, exposure to natural light, heart rate, heart rate variability, and screen time. The app also tracks the patient's screen time and app usage data. The Mood Triggers App will be installed on the smartphones at time of informed consent for all 120 patients enrolled in Phase 1 and for 100 clinical trial participants randomized to the early warning system (intervention arm) in Phase 2. Data will be collected from the Mood Triggers App starting on day of discharge from care and for 6 months post-discharge date."
223435827|NCT07174635|BEHAVIORAL|Intervention-telenursing|The first researcher sent an educational booklet prepared on the educational topics or the topics the patient needed to the patients in the experimental group as a message. The patient was then called by phone and informed about the educational booklet. After the main interview, the patients were called 2 more times for follow-up. The intervention group was given education on topics such as reducing pain complaints, increasing activity level, exercise, and coping with stress. The education of the intervention group lasted approximately 4 weeks.
223435828|NCT07175844|OTHER|Vocal exercises|"Participants performed six weekly sessions of 30 minutes, guided by videos focusing on diaphragmatic breathing and contemporary singing techniques. Initial exercises (weeks 1-2) included sustained s sounds, lip trills, humming, melodic vowel sequences, and Ja exercises. Weeks 3-6 included advanced solo exercises such as short and long S, humming variations, mum vocalizations, rhythmic patterns (cha-cha-cha), melodic sequences (Niemak 1-3), and counting exercises. Exercises were performed standing, preferably in front of a mirror."
223435829|NCT07175844|OTHER|Breathing exercises|"Participants in the breathing exercises group were given access to a 30-minute instructional video, in which a licensed physiotherapist demonstrated how to perform the exercises. Participants were instructed to complete the exercises twice per week at a time convenient for them. They could reflect on the exercises and submit questions to the physiotherapist within a closed social media group. Two weeks after the start of the intervention, participants were advised to increase the intensity of the exercises: lengthening inhalation, exhalation, and breath-holding during square breathing, and increasing the number of exhalations during Kapalabhati breathing from 20 to 60 per series, while respecting individual comfort and tolerance."
223435830|NCT07175090|COMBINATION_PRODUCT|Coconut oil|The rinse is used three times a day during three weeks
223435831|NCT07175090|OTHER|Placebo|Inactive ingredients with same taste and colour
223435832|NCT07175597|DIETARY_SUPPLEMENT|Hibiscus sabdariffa drink|A daily dose of Hibiscus sabdariffa drink that provides 9.6 mg of anthocyanins
223435833|NCT07172074|DIAGNOSTIC_TEST|General Psych Trait Measure|Respondents were randomized to answer whether psychological trait questions were general or about vaccines
223435834|NCT07172074|OTHER|Vaccine-Specific Psych Trait Measures|Respondents were randomized to answer whether psychological trait questions were general or about vaccines
223435835|NCT07177183|DIETARY_SUPPLEMENT|Dietary supplement creatine|Dietary supplement creatine. The dosage of creatine will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.
223435836|NCT07177183|DIETARY_SUPPLEMENT|Dietary supplement - placebo|Dietary supplement polydextrose as a placebo. The dosage of placebo will be as follows: for the first 7 days after enrolment, the daily dose will be 2x5g. From days 8 to 21, the daily dose will be 1x5g. The substance will be administered orally or through a nasogastric tube.
223435837|NCT07177183|OTHER|No intervention|Patients in Group 1 will serve as controls and will receive no intervention, only standard care.
223435838|NCT07176013|BEHAVIORAL|Voice therapy|All patients will receive a course of voice therapy as normal.
223435839|NCT07176013|BEHAVIORAL|Meditation|Meditation at the start of each session. (each session is 30 minutes)
223435840|NCT07176013|DEVICE|Virtual Reality|TRIPP application in the Meta Quest 2 Virtual Reality Headset.
223435841|NCT07176039|RADIATION|High-Intensity Laser Therapy (HILT)|will be administered to active myofascial trigger points in the neck and shoulder region. The laser device used is an 808 nm gallium-aluminum-arsenide (GaAlAs) diode laser in continuous mode. Parameters: power output of 8-10 W, frequency of 2000 Hz, and application time of 60 seconds per trigger point, targeting 5-6 trigger points per session. Treatment will be delivered twice weekly for 4 consecutive weeks, totaling 8 sessions.
223435842|NCT07176039|OTHER|Extracorporeal Shockwave Therapy (ESWT)|ESWT will be applied to active myofascial trigger points using a radial shockwave device. Parameters: Energy flux density 0.1-0.2 mJ/mm², 2000 shocks per session, frequency of 2 sessions per week for 4 weeks (8 sessions).
223566108|NCT05470543|BEHAVIORAL|Nurse-led supportive care|Nurse-led supportive care was given to primary caregivers of women with breast cancer. Nurse-led supportive care was applied to primary caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 30 minutes to interview with primary caregivers at the clinic.
223566109|NCT02997553|DRUG|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
224047058|NCT02871778|DRUG|Placebo (0.17% saline)|
224047059|NCT02871778|DRUG|VX-371 + HS|
224047060|NCT02871778|DRUG|Ivacaftor|
224047061|NCT02945150|DRUG|elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
224047062|NCT03149614|OTHER|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
224047063|NCT03149614|OTHER|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
224047064|NCT02078635|BEHAVIORAL|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
223435843|NCT07177001|BEHAVIORAL|Clinical Control Group (Group A)|The participants who reported the presence of neck or low back pain and were assigned to the clinical control group (Group A) after randomisation will receive a non-specific spine exercise program provided in a handout. The interventional group (Group B) will be asked to keep the standardised spine-specific exercise program confidential and not share with the control group (Group A). After eight (8) weeks, Group A participants will receive: the Cornell Musculoskeletal Discomfort Questionnaires (CMDQ) to assess for changes in the frequency, discomfort and interference with work due to musculoskeletal pain; a Questionnaire B, to ascertain any changes in their pain level using the Numeric Rating Scale (NRS); as well as their knowledge, attitude and practice towards musculoskeletal problems of the neck and low back pain.
223435844|NCT07177001|BEHAVIORAL|Spine Exercise Program (Group B)|The standardised spine-specific exercise program will be provided in a handout and given only to the intervention group (Group B), and will include specific spine basic neck or low back exercises to be done three (3) times per week, as well as brief stretching exercises, to be done during periods of sitting for greater than sixty (60) minutes. The selected participants will be asked to comply with instructions on the handout. Participants who experience worsening of their symptoms, or who develop new symptoms will be assessed as having an adverse outcome and will be withdrawn from the study and referred for evaluation and treatment if necessary.
223435845|NCT07177079|DRUG|Azacitidine|A chemotherapy drug known as a hypomethylating agent
223435846|NCT07177079|DRUG|Venetoclax|Targeted cancer therapy used to treat certain blood cancers. It specifically targets a protein called BCL-2 to trigger the self-destruction of cancer cells.
223435847|NCT07177079|DRUG|High-dose ascorbate|Administering vitamin C intravenously to achieve very high concentrations in the bloodstream. In contrast to low doses, which act as antioxidants, these pharmacological doses can function as a pro-oxidant, killing cancer cells while leaving healthy cells unharmed.
223435848|NCT07177079|DRUG|Decitabine|Azacitidine may be substituted with decitabine 20 mg/m2 daily, on days 1-5, at PI discretion in the event of toxicity/drug supply shortage.
223435849|NCT06410248|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223435850|NCT06410248|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223435851|NCT06410248|OTHER|Questionnaire Administration|Ancillary studies
223435852|NCT06410248|PROCEDURE|Resection|Undergo surgical resection
223435853|NCT06410248|DRUG|Temozolomide|Given PO
223435854|NCT06410248|DRUG|Triapine|Given PO
223435855|NCT07174843|BIOLOGICAL|CD19/CD22/BCMA CAR-T cells(BZE2204)|"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of BZE2204 CAR T cells.~On day0 subjects will receive a single dose BZE2204 CAR T cells by intravenous (IV) injection."
223435856|NCT07176910|OTHER|conduct angiopuncture on perforator points|conducted angiopuncutre on patients of intervention group, and compare those patients pain scores before and after angiopuncture therapy.
223435857|NCT07176403|OTHER|intradialytic exercise|"50 patients will undergo Exercise training program for twelve weeks during hemodialysis session.~1. Type of exercise: aerobic exercise training sessions using a lower limb ergometer.~2. Frequency: three times per week.~3. Duration: thirty minutes per session."
223435858|NCT07176403|OTHER|control group|50 patients will not perform exercise during hemodialysis session
223435859|NCT07176923|BIOLOGICAL|CS-121|CS-121 is a in vivo base editing therapy formulated in lipid nanoparticles for targeted editing of the APOC3 gene in hepatocytes. In this study, participants receive a single intravenous infusion of CS-121 at escalating dose levels. The investigational product is designed to reduce ApoC3 protein expression and serum triglyceride levels in adults with familial chylomicronemia syndrome (FCS).
223435860|NCT07174609|DEVICE|Scrambler Therapy|"Adults with chronic pancreatitis and refractory abdominal pain will receive Scrambler Therapy, a non-invasive neuromodulation device. Electrodes are placed near the painful area to deliver non-pain signals aimed at reducing pain perception. Participants will complete 5-10 daily treatment sessions, each lasting 30-40 minutes, with pain ratings collected before and after sessions and follow-up assessments over 3 months."
224047065|NCT02078635|BEHAVIORAL|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
224047066|NCT01134835|OTHER|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
224047067|NCT01134835|DRUG|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
224047068|NCT02653300|BIOLOGICAL|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
224070576|NCT06127251|BEHAVIORAL|Control Group|Study staff will have a Zoom meeting with each control group participant where they will be advised to use the Be Active Your Way handout and to self-monitor PA using ScanWatch. Additionally, the group will be introduced to www.health.com, a jargon-free website that focuses on general health topics (e.g., dry eye) and the latest medical news (e.g., vaccines). Every 2 weeks control participants will meet on Zoom with study staff to review their progress in the study so as to keep the contact between the groups as similar as possible.
223435861|NCT07177235|DRUG|Ketamine|Timing of ketamine initiation will differ between groups (early versus late ketamine)
223435862|NCT07177235|DRUG|Midazolam|Midazolam infusion will be initiated at the same time in both groups
223435863|NCT07175298|PROCEDURE|conventional opioid-based technique|Control Group: Participants will receive general anaesthesia with a conventional opioid-based technique
223435864|NCT07175298|PROCEDURE|SPSIPB Group|SPSIPB Group: Participants will receive an ultrasound-guided Serratus posterior superior intercostal plane block with 30 ml 0.25% bupivacaine per side pre-incision and general anaesthesia with opioid based fentanyl
223435865|NCT07176078|OTHER|Osteopathic care|"Participants allocated to the osteopathic care group will receive 4 weekly consultations of person-centered osteopathic care. Each consultation will last approximately 45 minutes and consist of a careful medical history, a clinical examination, treatment, and advice (e.g. exercise, dietary, lifestyle).~The osteopathic treatment protocol could be labeled as 'custom tailored': the determination of the treatment was left to the clinical judgment of the osteopath, meaning that no predefined, standardized osteopathic protocol would be implemented. Standard osteopathic techniques (Glossary of Osteopathic Terminology) can be applied, including diagnostic techniques (e.g. observation, neurological tests, palpation, and motion testing) and therapeutic direct (e.g. high-velocity low-amplitude, muscle energy), indirect techniques (e.g. strain counter strain, balanced ligamentous tension, balanced membranous tension), or combined techniques."
223435866|NCT07176078|OTHER|Sham Osteopathic care|"For this trial, sham intervention will mimic the osteopathic care according to the touch equality assumption. Therefore, it mimics a clinical examination and treatment. The sham clinical evaluation involves a full evaluation of the position and mobility of the spine.This screening of the patient will be performed using conventional osteopathic manual tests, without any intention to make a diagnosis. Sham treatment will involve light manual contact, with the subject lying supine on the treatment table."
223435867|NCT07176078|BEHAVIORAL|Flexi-FODMAP Diet|"In addition to the real or sham osteopathic care, all participants will follow a 4-week flexi-FODMAP diet delivered online. Participants will receive structured dietary instructions via a customized online platform, based on the NHS Gentle-FODMAP diet guidelines and informed by expert input from dieticians. This modified FODMAP-gentle approach involves a targeted, less restrictive elimination of selected high-FODMAP foods."
223435868|NCT07175779|OTHER|Face-to-Face Preanesthesia Consultation|Participants receive a standard preoperative anesthesia consultation in person at the hospital
223435869|NCT07175779|OTHER|Telemedicine Preanestehsia Consultation|Participants receive a preoperative anesthesia consultation remotely via video conferencing using a secure telemedicine platform.
223435870|NCT07175818|PROCEDURE|Silk suture only|After third molar extraction, the surgical wound will be closed using silk sutures without plasma application.
223435871|NCT07175818|PROCEDURE|PTFE suture only|After third molar extraction, the surgical wound will be closed using PTFE sutures without plasma application.
223435872|NCT07175818|PROCEDURE|Silk Suture + Cold athmospheric Plasma|After third molar extraction, silk sutures will be exposed to cold atmospheric plasma before being used for wound closure.
223435873|NCT07175818|PROCEDURE|PTFE Suture + Cold athmospheric Plasma|After third molar extraction, the surgical wound will be closed using PTFE sutures without plasma application.
223435874|NCT07175818|PROCEDURE|Silk Suture + Cold athmospheric argon Plasma|After third molar extraction, silk sutures will be exposed to cold atmospheric argon plasma before being used for wound closure.
224142459|NCT02134067|DRUG|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
224070577|NCT06127251|DEVICE|Physical activity tracker|Participants will be asked to wear a ScanWatch tracker on their non-dominant hand for the entire duration of the study using a 24-hour wear protocol.
224142460|NCT03794752|DEVICE|Head-Mounted Visual Enhancement Device|Evergaze has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It is powered by a battery pack connected to the device. The electronic display will be affixed over only one of the participant's eye. The vision through the unobstructed eye will aid with the participant's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black \& white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
224142461|NCT01362946|BEHAVIORAL|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
224142462|NCT01362946|BEHAVIORAL|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
224142463|NCT00709358|OTHER|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
223435875|NCT07175818|PROCEDURE|PTFE Suture + Cold athmospheric argon Plasma|After third molar extraction, PTFE sutures will be exposed to cold atmospheric argon plasma before being used for wound closure.
223435876|NCT06508515|BEHAVIORAL|Unadapted Research Units in Behavioral Intervention (RUBI) implementation strategy|"The unadapted RUBI IS involves weekly, one hour educational meetings where sessions involve discussion of homework from the week prior (5 minutes), didactic instruction on targeted behavioral strategies (40 minutes), coaching and consultation around the newly learned strategy (10 minutes), and fidelity review, where RUBI implementation is observed (5 minutes). Finally, Attend\| Behavior® is a HIPAA-compliant mobile application support that is designed to support RUBI delivery and implementation."
224142464|NCT00709358|OTHER|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
224142465|NCT00671216|DRUG|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
224142466|NCT00671216|DRUG|GW642444|Subjects will receive 50 mcg once daily as a single dose
224142467|NCT00671216|DRUG|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
224070578|NCT06127251|BEHAVIORAL|Dietary education|The research team will examine diet quality and provide all study participants with educational content curated to promote diet quality. To minimize participants' burden, both the intervention and control arms will receive an email with a brief PDF addressing new diet components every 4 weeks
224070579|NCT05502575|BEHAVIORAL|Self-monitoring and personalized stress management|Self-monitoring and personalized stress management education and materials.
223435877|NCT06508515|BEHAVIORAL|RUBI in Educational Settings (RUBIES)-Team|RUBIES is an 8-module intervention that provides educators a range of skills to support the building of a behavioral management toolbox to be used, as needed, with autistic children and disruptive behavior. The program emphasizes: 1) tailoring the intervention to the specific child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice; 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g., use of visual supports), reinforcement, and functional communication strategies to modify behaviors. All educators will receive RUBIES training across 24 weeks via Zoom.
223435878|NCT05670314|DIETARY_SUPPLEMENT|Inulin Fibre supplement|20g/ day. Inulin is easily dissolvable in liquid and can be incorporated into the usual diet - by adding to water, juice, smoothies, cereal, yogurt etc.
223435879|NCT05670314|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|10g/ day which can be consumed by adding to breakfast cereal/ smoothie/ yogurt or drink of choice
223435880|NCT05670314|BEHAVIORAL|Exercise|Joint Academy An app-based exercises platform (Joint Academy®) will be used as an intervention given to the treatment arm. The programme consists of a mixture of open and close chain exercises, a combination of concentric, eccentric and focusing on the global strength of legs including the muscles around the hips and knee joints as well as balance enhancement exercises.
223435881|NCT03073356|BIOLOGICAL|Infusion of 3-OHB|Increase in 3-OHB levels
223435882|NCT03073356|BIOLOGICAL|Infusion of placebo|NaCl
223435883|NCT01618461|BEHAVIORAL|Drug indication icons|Icons illustrate the purpose of each medication
223435884|NCT01618461|BEHAVIORAL|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
223435885|NCT04964583|DRUG|Hydroxychloroquine with Azithromycin|Fixed combination of Hydroxychloroquine with Azithromycin 200 mg / 250 mg one tablet every 12 hours for five days and continue with Hydroxychloroquine 200 mg one tablet every 12 hours for 5 more days.
223435886|NCT04009161|PROCEDURE|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
223435887|NCT06558214|DRUG|Pembrolizumab|Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
223435888|NCT06558214|DEVICE|Optune GIO®|".~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2."
223435889|NCT06558214|DEVICE|NeuroBlate®|Treatment with NeuroBlate will occur one time at the beginning of the study.
223435890|NCT06529029|DEVICE|Sigma-Stim|Right Ultra-Brief Low Amplitude Seizure Therapy at 600mA or 700mA vs Right Unilateral Ultra-Brief Standard ECT at 800mA.
223435891|NCT03436212|DEVICE|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
223435892|NCT06352827|BEHAVIORAL|Survey|All participants will complete a baseline survey and have medical information collected.
223435893|NCT06095479|DEVICE|2D ultrasound scan and MRI examination|All subjects will undergo a 2D ultrasound scan and MRI examination.
223435894|NCT05337410|BEHAVIORAL|YES IDEAS|YES IDEAS is an adapted version of the evidence based YES (Youth Empowerment Solutions) program. Through the YES program, youth design and implement their own projects to help improve their own communities. The adapted YES IDEAS curriculum empowers youth from various backgrounds to address bullying and promote positive behaviors as a way to reduce violent behavior. Over the course of the program, youth carry out a community change project aimed at promoting non-violence in their community.
223435895|NCT03876769|BIOLOGICAL|CTL019|"Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects \> 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
223435896|NCT05414396|BEHAVIORAL|Behavioral Intervention|Attend EML program sessions
224047069|NCT05217563|BEHAVIORAL|Memory-reframing intervention (Reframe the Pain)|Parents will be taught to reminisce with their children about the vaccination experience by emphasizing positive aspects of the child's pain memory, using less utterances about pain and fear, correcting negative exaggerations in memory, and enhancing children's self-efficacy regarding their ability to cope with pain (e.g., when children used coping methods such as deep breathing, highlighting that they were brave). Parents will be instructed to reminisce with their children about the vaccine experience using the intervention strategies. Parents in the intervention groups will receive text/email reminders to use needle pain management strategies before each second vaccination appointment. Additionally, parents randomized to the intervention groups will receive text/email reminders approximately once every two weeks to use the memory-reframing principles until the second vaccination appointment.
223435897|NCT05414396|OTHER|Questionnaire Administration|Ancillary studies
223566110|NCT02997553|DRUG|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
224047070|NCT01568398|DRUG|TAK-438|
224070580|NCT05502575|BEHAVIORAL|Self-monitoring and general stress management|Self-monitoring and general stress management education and materials.
223435898|NCT02502266|DRUG|Cediranib|Given PO
223435899|NCT02502266|DRUG|Cediranib Maleate|Given PO
223435900|NCT02502266|PROCEDURE|Computed Tomography|Undergo CT
223435901|NCT02502266|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223435902|NCT02502266|DRUG|Olaparib|Given PO
223435903|NCT02502266|DRUG|Paclitaxel|Given IV
223435904|NCT02502266|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
223435905|NCT02502266|OTHER|Questionnaire Administration|Ancillary studies
223435906|NCT02502266|DRUG|Topotecan|Given IV
223435907|NCT02502266|DRUG|Topotecan Hydrochloride|Given IV
223566111|NCT02997553|DEVICE|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
223566112|NCT02997553|DEVICE|Quest Camera|The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
223566113|NCT06497777|GENETIC|MicroRNA (mir-642b-3p)|A circulating microRNA in the blood of pancreatic cancer patients.
223566114|NCT05319483|OTHER|No intervention|No intervention.
224070581|NCT01631136|DRUG|Cisplatin|75 mg/m²
224070582|NCT01631136|DRUG|Pemetrexed|500 mg/m²
224070583|NCT01631136|DRUG|Cisplatin|80 mg/m²
224142468|NCT00671216|DRUG|Placebo|Placebo matching study medication will be inhaled by subjects
223566115|NCT03121677|BIOLOGICAL|Personalized tumor vaccine|"* Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
223566116|NCT03121677|DRUG|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
223566117|NCT03121677|BIOLOGICAL|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
224047071|NCT04900922|DEVICE|isokinetic dynamometer|We will use an isokinetic dynamometer to conduct the concentric isokinetic fatigue protocol. The start position is shoulder abduction 90°, elbow flexion 90°and range of motion is set from 0 ° (internal rotation) to 90 ° (external rotation) under 120°/s. To calculate maximum torque of shoulder external and internal rotation, the subject will perform maximum isokinetic test 5 times before fatigue. Fatigue protocol include 10 sets, and each set include 32 repetitions with 30 seconds of rest between sets. The fatigue protocol will be stopped under three conditions: 1. the torque decreases 50% of maximum torque three times in one set or 2.rating of perceived exertion (RPE) abrove 15 and players can not perform the fatigue protocol or 3. finish the whole test.
224047072|NCT02927587|DRUG|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
223566118|NCT03121677|PROCEDURE|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
223566119|NCT03121677|PROCEDURE|Leukapheresis|"* Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
223566120|NCT03121677|BIOLOGICAL|Rituximab|-Other anti-CD20 mAb treatment can be used
224047073|NCT04646070|PROCEDURE|Reduction mammaplasty|Breast reduction surgery
224047074|NCT02761486|DRUG|Aspirin|325mg aspirin per day
224047075|NCT02761486|DRUG|Placebo|placebo in matching capsules
224047076|NCT03248830|DEVICE|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
224142469|NCT02131012|DRUG|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
224142470|NCT00898404|OTHER|laboratory biomarker analysis|Correlative studies
224142471|NCT00627835|DRUG|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
224142472|NCT00627835|DRUG|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
224142473|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
224047077|NCT04554238|DEVICE|Armeo spring|Armeo spring is an exoskeleton that allows intensive therapy aimed at upper extremity tasks, which can be regulated according to the anthropometric measurements of the child and the objective of the session. The software contains an extensive library of game-like exercises that are run in a motivating and informative virtual reality training environment, clearly showing the functional task to be performed through immediate feedback in a 3D work space.
224047078|NCT04554238|OTHER|Occupational Therapy|This treatment includes passive stretching exercises, weight bearing, stimulation of protective reactions, muscle strengthening exercises and different types of motivating bimanual games, favoring reaching, grasping, exploration and manipulation.
224142474|NCT00627835|DRUG|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
224142475|NCT00627835|DRUG|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
224142476|NCT04768699|DRUG|TQG203|TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
224142477|NCT04768699|DRUG|TQG203/NovoSeven®|In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
224142478|NCT04768699|DRUG|TQG203|TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
224142479|NCT03185104|DRUG|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
224142480|NCT03185104|DRUG|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
223566121|NCT03121677|PROCEDURE|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
224047079|NCT04450511|DEVICE|Magnetic stimulation -Armchair type (MS)|MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks.
224047080|NCT04450511|OTHER|Bladder Training (BT)|Bladder Training (BT)
224047081|NCT00427089|DRUG|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
224142481|NCT02282176|DRUG|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
224142482|NCT02282176|DRUG|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
224142483|NCT00673686|DRUG|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
224142484|NCT00673686|DRUG|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
224142485|NCT04656418|BIOLOGICAL|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody
224142486|NCT04656418|DRUG|Placebo|Buffer without active ingredient
224142487|NCT02770313|BEHAVIORAL|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
224142488|NCT02267226|DRUG|Octafibrin|
223435908|NCT06298864|BEHAVIORAL|Internet-CBT|"* Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle."
223435909|NCT06298864|BEHAVIORAL|Internet-CL|"* Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle."
223435910|NCT01604317|PROCEDURE|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
223435911|NCT01604317|PROCEDURE|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
223435912|NCT06370832|OTHER|IMT and exercise training group|Participants will perform supervised exercise training per usual care and will be provided with a personalized prescription for an IMT program during the pre-transplant phase. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session) 5 days per week in their home environment or in-person visits. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
224047082|NCT00427089|DRUG|Sodium Phosphate solution (NaP)|45 ml solution; BID
224047083|NCT00842738|BEHAVIORAL|Mindfulness meditation|Mindfulness meditation
223435913|NCT02707406|OTHER|NEOX®CORD 1K|use of human tissue product wound covering
223435914|NCT02707406|OTHER|standard of care|standard wound coverings
223435915|NCT03298659|DIAGNOSTIC_TEST|iFR|Treatment guided by instantaneous wave-free ratio
223435916|NCT03298659|DIAGNOSTIC_TEST|CMR|Treatment guided by stress perfusion CMR
224047084|NCT00842738|OTHER|No meditation|Health care services as usual
224047085|NCT00842738|OTHER|Controls|No intervention
224047086|NCT03530917|DRUG|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
224047087|NCT03530917|DRUG|Placebo|Placebo hard capsules will be administered orally as per the dosing schedules described above.
224047088|NCT04795726|DRUG|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
224142489|NCT04693520|DRUG|ALZ-801|ALZ-801 265 mg twice daily (BID)
224142490|NCT01883869|DRUG|ticagrelor|
224142491|NCT01883869|DRUG|placebo|placebo
223435917|NCT04295213|OTHER|oligosaccharides|1 dose a day of oligosaccharides or placebo
223435918|NCT02481180|DRUG|T0001|injection (SC) T0001 15mg weekly for 12 weeks
224047089|NCT04795726|DRUG|Placebo|Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.
224047090|NCT01581944|DRUG|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
224047091|NCT01581944|DRUG|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
224047092|NCT03920553|BIOLOGICAL|Hyaluronic acid|Topical application of hyaluronic acid following Laser assisted frenectomy
224047093|NCT03407404|COMBINATION_PRODUCT|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
224047094|NCT03407404|COMBINATION_PRODUCT|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
224047095|NCT04039854|DRUG|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
224047096|NCT04039854|DRUG|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
224047097|NCT03312088|DEVICE|Freedom Knee PCK Components|Total Knee Revision
224047098|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
224047099|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
224047100|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
224047101|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
224047102|NCT01286454|DRUG|fesoterodine|single dose of tablet
224142492|NCT04811001|DRUG|Osimertinib|TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
224142493|NCT04811001|DRUG|Dacomitinib|Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
224142494|NCT03330041|DEVICE|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
224142495|NCT05382988|DRUG|Sodium zirconium cyclosilicate|The experimental group was required to take SZC 10g at 6 am on the day of surgery.
223435919|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg weekly for 12 weeks
223435920|NCT02481180|DRUG|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
223435921|NCT02481180|DRUG|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
223435922|NCT02481180|DRUG|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
223435923|NCT05284929|GENETIC|A single blood sample for HLA typing|Extracting of DNA from the blood sample using PCR-reaction
223435924|NCT05201040|DEVICE|JETKNEE Synovial Fluid Supplement|2mL of JETKNEE Synovial Fluid Supplement
223435925|NCT05201040|DEVICE|Normal saline|2mL of normal saline
223435926|NCT03824821|OTHER|No intervention|No intervention
223435927|NCT00405743|DRUG|CP-4055|CP-4055 Continuous IV infusion
223566122|NCT04202146|BEHAVIORAL|Contingency Management + Motivational Interviewing|Seven-day combined CM with two sessions of brief Motivation Interviewing (MI) followed by standardized individual drug counseling on cannabis use and relapse.
224047103|NCT01286454|DRUG|fesoterodine|single dose of beads in capsule
224047104|NCT00800683|DRUG|BI 1356|BI 1356 dosed once daily
224047105|NCT00800683|DRUG|placebo|placebo matching BI 1356 taken once daily
224047106|NCT00172653|PROCEDURE|functional tasks|
224047107|NCT00004639|PROCEDURE|Furlow double z-plasty palatoplasty palate repair|
224047108|NCT00004639|PROCEDURE|Von Langenbeck palatoplasty palate repair|
224047109|NCT01478360|DRUG|AIN457 (secukinumab)|Secukinumab intravenous injection
224142496|NCT03097614|DEVICE|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
224142497|NCT00989612|BIOLOGICAL|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
224142498|NCT00388323|OTHER|blood and biopsies|blood and biopsies
223435928|NCT00405743|DRUG|CP-4055|CP4055 2 and 4 hour IV infusion
223435929|NCT03298256|RADIATION|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
223435930|NCT06156137|OTHER|Glucose variability|A retrospective cohort study was conducted in hospitalized T2DM patients with NCP who were discharged or died. Clinical data and blood glucose variability parameters were collected by computer blood glucose monitoring technology (CGM). Time in range (TIR), time above target range (TAR), time below target range (TBR), mean amplitude of glycemic excursions (MAGE), absolute mean daily difference (MODD) and other indicators were used.
223435931|NCT00810017|DRUG|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
223435932|NCT00810017|DRUG|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
223435933|NCT03729414|PROCEDURE|mucopexy with Doppler artery ligation|Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
223435934|NCT03729414|PROCEDURE|mucopexy without Doppler artery ligation|Hemorrhoids will be treated by mucopexy alone performed in all quadrants
223435935|NCT03310294|DIETARY_SUPPLEMENT|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
223435936|NCT03310294|DIETARY_SUPPLEMENT|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
223435937|NCT04653623|PROCEDURE|High tibial osteotomy|Treatment option for medial compartment osteoarthritis of knee
224047110|NCT01478360|DRUG|Placebo|Placebo intravenous injection
224047111|NCT02289352|DRUG|Brimonidine|
224047112|NCT02289352|DRUG|placebo|
223566123|NCT00004446|DRUG|fluoxetine|
223566124|NCT04463199|OTHER|Craniocervical flexion training|"PBU airbag was clipped together and folded in, fastened, and placed suboccipital. Uninflated pressure sensor was kept below the neck, so that it touched the occiput then inflated to a stable baseline pressure of 20 mmHg to just fill the space below the neck but not to push it into lordosis. Subjects were demonstrated the correct action of the deep cervical flexors that is gentle nodding of head as if saying yes."
224047113|NCT06310954|DIETARY_SUPPLEMENT|Early ketogenic diet combined with conventional pharmacotherapy.|This arm of the trial explores the efficacy of an early initiation of the ketogenic diet in conjunction with conventional antiepileptic drugs (AEDs) for children with refractory epilepsy. The intervention aims to evaluate the impact on seizure frequency, and inflammatory markers, and identify patient characteristics predicting a better response to the ketogenic diet, to improve overall therapeutic response rates in refractory epilepsy.
224070584|NCT01631136|DRUG|Gemcitabine|1250 mg/m²
224070585|NCT06412497|DRUG|Rituximab|For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.
224070586|NCT06412497|DRUG|Rabbit ATG|Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.
224142499|NCT05248555|DIAGNOSTIC_TEST|Point-of-Care Testing|Participants will be offered finger-stick point-of-care testing for HCV
224142500|NCT02839824|PROCEDURE|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
223435938|NCT04653623|DRUG|Tranexamic acid|Medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation
224047114|NCT06310954|DRUG|Common diet combined with conventional pharmacotherapy|Participants in this arm will receive a standard diet without any ketogenic restrictions, alongside conventional antiepileptic drugs. This comparator aims to assess the standard care's efficacy against the experimental intervention, focusing on seizure control, and inflammatory markers, and identifying patient characteristics associated with treatment responsiveness.We know that drug information for registering clinical information is necessary, but our research design is to add ketogenic diets as a supplementary treatment plan when traditional drug treatment is ineffective. Therefore, in terms of specific drug selection, this is not absolutely the same. Depending on individual differences, the choice of drugs will also vary. Control the number of episodes, time, etc., and everyone uses different drugs. Therefore, we cannot decide on a single drug for comparison like traditional content.
223435939|NCT00554541|OTHER|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
223435940|NCT00664794|PROCEDURE|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
223435941|NCT00664794|PROCEDURE|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
223435942|NCT03734900|OTHER|Saline injection|5ml Placebo infusion of 0.9% Sodium Chloride
223435943|NCT03734900|BIOLOGICAL|PRP injection|"Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection"
223435944|NCT03734900|BIOLOGICAL|PL injection|"Device: Aeon Acti-PRP~5ml autologous platelet lysate injection"
223435945|NCT01535586|DEVICE|CPAP versus MAD|Cross over design
223435946|NCT05422768|BEHAVIORAL|Warrior Renew|Warrior Renew is a program for military sexual trauma (MST).
223435947|NCT05422768|BEHAVIORAL|Warrior Renew + EAL|Warrior Renew and EAL are combined into one program for military sexual trauma (MST).
223435948|NCT05370404|OTHER|Prescription by surgical team|The surgical team prescribes medications to the patient
223435949|NCT05370404|OTHER|Recommendation by surgical team|The surgical team recommends the patient to take over-the-counter medications
223435950|NCT04140916|DEVICE|Midline catheter|Peripherally inserted short intravenous catheter
223435951|NCT04140916|DEVICE|PICC-line catheter|Peripherally inserted long intravenous catheter
223435952|NCT03535532|PROCEDURE|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
223435953|NCT03535532|DRUG|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
223435954|NCT06002256|PROCEDURE|Mostafa Maged maneuver|While the patient is on the lithotomy position , The first step in the Mostafa Maged maneuveur step is placing the right hand to the posterior fornix of vaginal canal trying to put pressure on the cervix and the lower part of uterus compressing the anterior and posterior walls of the lower uterine segment. The second point is placing the left hand over the fundus of the uterus and the posterior wall of the uterus from the abdominal part of the pregnant mother (the side of the abdominal skin). The third step is trying to grasp the whole uterus by the two hands abdominally and vaginally against the symphysis pubis as if the uterus is containing or surrounding the symphysis pubis bone, and in this way, getting the anterior and posterior walls of the uterus against each other (compression achieved)
223435955|NCT06002256|PROCEDURE|Bimanual uterine compression|the clinician places one hand on the abdomen and the other hand inside the vagina then compresses the uterus between the two hands.
223435956|NCT02398513|DRUG|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
223435957|NCT03605849|DRUG|Centanafadine SR|200mg, BID, oral tablets
224047115|NCT04557319|BIOLOGICAL|GNR-038, 25 МЕ/kg|25 МЕ/kg once per study
224047116|NCT04557319|BIOLOGICAL|GNR-038, 50 МЕ/kg|50 МЕ/kg once per study
224047117|NCT04557319|BIOLOGICAL|GNR-038, 100 МЕ/kg|100 МЕ/kg once per study
223435958|NCT02488590|DRUG|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
223435959|NCT02488590|DRUG|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
224047118|NCT02649296|OTHER|Skanlab bodywave|The intervention will be done twice a week
224047119|NCT00911625|DRUG|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
224142501|NCT00525239|DRUG|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
224142502|NCT03261063|DEVICE|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
224142503|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
224142504|NCT00603733|DRUG|5-ASA (5-Aminosalicylate)|500 mg tablet
224142505|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Hybrid Technique|The rotation flap of the Millard II technique was expanded by extending the incision into the columella - similar to the well-known Mohler technique. The caudal part of the advancement flap of the Millard II technique was lengthened by a wave cut as known from the Pfeiffer procedure. For the vermillion a Noordhoff plasty is applied.
224142506|NCT05102513|PROCEDURE|Unilateral Cleft Lip Repair: Millard 2 Technique|A curved incision is marked skirting the philtral ridge. If more length is required a back-cut incision can be performed. The C-flap is outlined by the incision just marked and the incision along red-white border up to the base of the columella. On the cleft side an advancement flap is designed. For the vermillion a Noordhoff plasty is applied.
223435960|NCT02488590|DRUG|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
223435961|NCT02488590|DRUG|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
223435962|NCT02488590|DRUG|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
223435963|NCT02278692|DIETARY_SUPPLEMENT|Vitamin K|Oral vitamin K
223435964|NCT02278692|OTHER|Placebo|Oral placebo tablet
224142507|NCT00444470|DRUG|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
224047120|NCT00911625|DRUG|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
224047121|NCT01289821|DRUG|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
223435965|NCT04480333|DRUG|Drug: NA-831 - 0.10 mg/kg|NA-831 in nanoparticle inhalation formulation
224142508|NCT00444470|DRUG|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
224142509|NCT00605696|DRUG|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
224142510|NCT02623387|PROCEDURE|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
223435966|NCT04480333|DRUG|Placebo- 0.10 mg/kg|Placebo in nanoparticle inhalation formulation
223435967|NCT04480333|DRUG|Drug: NA-831 - 0.20 mg/kg|NA-831 in nanoparticle inhalation formulation
223435968|NCT04480333|DRUG|Placebo- 0.20 mg/kg|Placebo in nanoparticle inhalation formulation
223435969|NCT04480333|DRUG|Drug: GS-5734 - 1.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
223435970|NCT04480333|DRUG|Placebo- 1.00 mg/kg|Placebo in nanoparticle inhalation formulation
223435971|NCT04480333|DRUG|Drug: GS-5734 - 2.00 mg/kg|GS-5734 in nanoparticle inhaled formulation
223435972|NCT04480333|DRUG|Placebo- 2.00 mg/kg|Placebo in nanoparticle inhaled formulation
223435973|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
223435974|NCT04480333|COMBINATION_PRODUCT|Placebo 0.10 mg + 1.00 mg/kg|The combined placebo are in nanoparticle inhaled formulation
223435975|NCT04480333|COMBINATION_PRODUCT|Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)|The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
224142511|NCT02035579|BEHAVIORAL|Aerobic Training Intervention|
224142512|NCT02035579|BEHAVIORAL|Stretching Intervention|
224142513|NCT01842646|DRUG|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
224142514|NCT04197024|DEVICE|Exercise capacity test|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm). Heart rate (HR) will be continuously recorded using a monitor Polar H10.
224142515|NCT04197024|DEVICE|Exercise capacity test in virtual reality|Patients will be assessed by symptom-limited maximal cardiopulmonary exercise testing (CPET) following a 25W, tree-minute stage, beginning at 25W (healthy volunteers will start the test with a load of 50W). For both sexes and arms, participants will be instructed during the test to remain at the frequency between 60 to 80 rotations per minute (rpm).Heart rate (HR) will be continuously recorded using a monitor Polar H10. VR HTC Vive Pro goggles along with VR health care (aerobic exercise) VR Cycling software will be used for stimulation throughout the duration of the test. The HTC Vive Tracker device will be also use to link images in virtual reality with the pedal speed.
223435976|NCT04480333|COMBINATION_PRODUCT|Placebo 0.20 mg + 2.00 mg/kg|Placebo 0.10 mg + 1.00 mg/kg
223435977|NCT04688398|DIETARY_SUPPLEMENT|Seal oil|Consumption of seal oil once per day (at breakfast)
223435978|NCT04688398|DIETARY_SUPPLEMENT|Control|Consumption of vegetable oil once per day (at breakfast)
223435979|NCT00577005|DRUG|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
223435980|NCT00577005|DRUG|Placebo|
224047122|NCT01289821|DRUG|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m\^2 oxaliplatin as a 2 hour i.v. infusion.
223435981|NCT02022475|DRUG|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
223435982|NCT02022475|OTHER|placebo|2 placebo capsules will be applied as a single dose
223435983|NCT01004432|DRUG|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
223435984|NCT01004432|DRUG|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
223435985|NCT01004432|DRUG|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
223435986|NCT01004432|DRUG|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
223435987|NCT01004432|DRUG|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
223435988|NCT06731842|OTHER|18F-RO948|Tau PET imaging using the tau PET tracer 18F-RO948 in famial and sporadic Alzheimer´s disease
224047123|NCT01289821|DRUG|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m\^2 D/L-folinic acid or 200 mg/m\^2 L-folinic acid) as a 2 hour i.v. infusion.
223435989|NCT02667626|OTHER|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
223435990|NCT02667626|OTHER|Control|Web-based resource lists and text-based study adherence reminders
223435991|NCT05167331|DRUG|Nitrous Oxide inhalation|use of Nitrous Oxide inhalation on children's anxiety during a dental treatment
223435992|NCT05167331|DEVICE|Dispositif de RV - HYPNO VR|use of Virtual Reality on children's anxiety during a dental treatment
223435993|NCT04909372|BEHAVIORAL|Labelling|"Food products in the virtual supermarket will display an environmental label on their packaging, from A (lowest impact) to E (highest impact). The label categories are based on the Product Environmental Footprint, a score recommended by the European Commission that evaluates the environmental impact of a food product based on 16 indicators calculated throughout the life cycle of the products (e.g., climate change in kg carbon dioxide eq, marine eutrophication in kg N eq, land and water use or acidification in mol H+ eq).~Instructions will introduce and explain the environmental label to the participants as In the virtual supermarket, each product will have an environmental label. This label describes whether a product had a negative impact on the environment (green house gaz emissions, water resources depletion, etc.) from A, lowest impact, to E, highest impact."
223435994|NCT00568568|DRUG|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
223566125|NCT03668938|OTHER|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
223566126|NCT03668938|OTHER|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
223566127|NCT01995669|OTHER|Laboratory Biomarker Analysis|Correlative studies
223566128|NCT01995669|DRUG|Lenalidomide|Given PO
223566129|NCT01995669|BIOLOGICAL|Obinutuzumab|Given IV
223566130|NCT05425732|BIOLOGICAL|V116|0.5 mL injection solution in prefilled syringe containing 4 μg of each PnPs antigen (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) given by intramuscular (IM) injection.
223566131|NCT05425732|BIOLOGICAL|PCV20|0.5 mL injection suspension in prefilled syringe containing 2.2 μg of each PnPs antigen (1, 3, 4, 5, 6A, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F) and 4.4 μg of PnPs antigen 6B.
224047124|NCT01289821|DRUG|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m\^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m\^2 5 FU 46 hour i.v. infusion.
224047125|NCT02884154|DEVICE|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
224047126|NCT03591354|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology \& Dexcom G6 CGM for 3 months.
224142516|NCT01057134|DEVICE|Cutera Ultrasound Device|Pulse duration 10-100 ms, fluence greater or equal to 50 J/cm2, contact tip temperature 5-30 celsus, frequency 5-20 MHz.
224142517|NCT02474823|OTHER|polysomnogram|all participants will undergo PSG for assessment of OSA
224142518|NCT02474823|OTHER|home sleep test|all participants will undergo HST for assessment of OSA
223566132|NCT02944864|DRUG|TQ-B3395|TQ-B3395 p.o. qd
223566133|NCT02871713|OTHER|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
223566134|NCT02871713|OTHER|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
224047127|NCT03591354|DEVICE|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
224047128|NCT02379767|DEVICE|Electroconvulsive therapy|
224047129|NCT02379767|OTHER|Positron emission tomography of the brain using [11C]harmine|
224047130|NCT02379767|OTHER|Structural magnetic resonance imaging|
224047131|NCT04006340|COMBINATION_PRODUCT|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
224047132|NCT04006340|COMBINATION_PRODUCT|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
224047133|NCT04006340|DIAGNOSTIC_TEST|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
224047134|NCT02844621|DRUG|Omeprazole|20mg orally once daily
224047135|NCT03364582|OTHER|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
224142519|NCT02474823|OTHER|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
224142520|NCT03029949|BEHAVIORAL|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
224047136|NCT01930149|BEHAVIORAL|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
223435995|NCT04715217|BIOLOGICAL|CD19-CD22 CAR-T cells|A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
224047137|NCT06143150|OTHER|transthoracic ultrasound|"The following parameters will be assessed by TUS:~Diaphragmatic copulae position and mobility (inspiratory time, excursion, diaphragmatic thickening fraction TF , excursion time E-T index )"
224047138|NCT01891708|OTHER|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
224047139|NCT04695067|BEHAVIORAL|Central fatigue group|a fatigue protocol that pitchers need to pitch 80 trials in a simulated game
224142521|NCT03029949|BEHAVIORAL|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
224142522|NCT03029949|OTHER|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
224047140|NCT06061679|DEVICE|Omron C28P nebuliser|switch from portable inhalers to the Omron C28P nebuliser
224047141|NCT01245387|DRUG|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
224047142|NCT00757003|DEVICE|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
224047143|NCT05440838|DIAGNOSTIC_TEST|Next-generation sequencing|Next-generation sequencing and cytokine profile will be established in all patients before the start of treatment.
224047144|NCT06178250|OTHER|3D sonography|Fetal liver, placenta, and ductus venosus were defined in 3 orthogonal multi-plane images in the voluson 4D view vocal program.
224142523|NCT00352313|DRUG|ATN-161|Given IV
224142524|NCT00352313|DRUG|carboplatin|Given IV
224047145|NCT00627783|OTHER|a bicycle exercise test|
224142525|NCT04521309|BIOLOGICAL|SARS-CoV-2 antibody based IVIG therapy|"Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics"
224142526|NCT05359809|BEHAVIORAL|Graspin Palmar Reflex Stimulation|The grasping reflex is an involuntary response involving the hands and fingers. flexion-adduction movement. The reflex resembles the grasping movement of the hand. The reflex can be achieved by moving an object distally across the palm.
223435996|NCT00590538|DRUG|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
223435997|NCT00590538|DRUG|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
223435998|NCT00590538|DRUG|Placebo|The placebo is given to match the active comparator for four days.
223435999|NCT00381329|BEHAVIORAL|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
223436000|NCT00381329|BEHAVIORAL|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
223436001|NCT02411981|OTHER|Autogenic drainage|
223436002|NCT03718195|OTHER|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
223436003|NCT03990779|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
223436004|NCT06127654|DEVICE|Healthy lung sparing treatment plan|CT Ventilation imaging will be used to create a healthy lung sparing treatment plan for patients who will receive radiation therapy treatment for their lung cancer.
223436005|NCT06289998|DRUG|Tamibarotene|Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.
223436006|NCT06289998|DRUG|Placebo|Subjects are administrated to placebo in daily for 52 weeks.
223436007|NCT02539134|DRUG|TAK-935|TAK-935 oral solution
223436008|NCT02539134|DRUG|Placebo|TAK-935 placebo-matching oral solution
223436009|NCT00985426|BIOLOGICAL|HEPLISAV-B|Intramuscular (IM) injections of HEPLISAV-B at Weeks 0, 4, and 24
224047146|NCT01892514|PROCEDURE|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
224047147|NCT00471900|DRUG|dehydroepiandrosterone (DHEA)|
224047148|NCT03723317|PROCEDURE|Liver transplantation|First deceased-donor liver transplantation
224142527|NCT00833677|BEHAVIORAL|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
224142528|NCT02670018|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg \* 2 tablets, for 1 day
224142529|NCT02670018|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg \* 2 tablets, for 1day
224142530|NCT00606853|BEHAVIORAL|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
224142531|NCT01297309|DRUG|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
224142532|NCT00324688|DRUG|Viread|
223436010|NCT00985426|BIOLOGICAL|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
224047149|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
223436011|NCT00985426|OTHER|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
223436012|NCT02436902|PROCEDURE|TACE|TACE is performed one month after resection.
223436013|NCT02436902|DRUG|Sorafenib|Sorafenib is submitted one month after resection.
223436014|NCT02436902|DRUG|TACE plus sorafenib|TACE plus sorafenib will be submitted one month after resection.
223436015|NCT02436902|OTHER|empty control|This group will not receive adjuvant therapy.
223436016|NCT03193749|DRUG|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
223436017|NCT03193749|DRUG|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
223436018|NCT02971800|DRUG|sodium fluorescein injection 10%|
223436019|NCT05969496|DRUG|Axitinib|Axitinib is a potent oral, vascular endothelial growth factor, c-kit and platelet derived growth factor inhibitor.
223436020|NCT05969496|DRUG|Pembrolizumab|Pembrolizumab is a type of immunotherapy. It stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
223436021|NCT06435351|PROCEDURE|Leukapheresis|"Removal of white blood cells (leukocytes) from the blood. The dendritic cells are harvested from the white blood cells that are collected and trained to recognize the specific abnormal proteins found in the tumor sample.~One needle is inserted in each arm. An apheresis machine removes blood from the vein in one arm, separates and retains the leukocytes from the blood, and then returns the rest of the blood to the other arm."
224047150|NCT01610895|OTHER|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
224047151|NCT04349982|DIAGNOSTIC_TEST|Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)|Factorial
224047152|NCT00396994|DEVICE|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
224047153|NCT00396994|DEVICE|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
223436022|NCT06435351|BIOLOGICAL|Dendritic Cell (DC) Vaccine|"The vaccine will be given intranodally (inguinal or axillary) under ultrasound guidance using a dose of 40-50 million cells three times spaced 2 weeks apart for the initial priming sequence.~3 doses of the priming vaccines are given once every 2 weeks. 2 booster shots (if available) will be given 6 months and 12 months following completion of initial priming vaccines."
223436023|NCT06029933|BIOLOGICAL|Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)|Fluad Quadrivalent vaccine is an inactivated influenza vaccine formulated to contain 60 mcg of hemagglutinin (HA) total, with 15 mcg from each of the four recommended influenza strains and the MF59 adjuvant in single-dose prefilled 0.5 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluad as part of routine clinical care during the influenza season.
223566135|NCT04516538|BEHAVIORAL|Mini Mental State Examination|test for evaluating a person's cognitive functions and memory capacity
223566136|NCT04516538|DIAGNOSTIC_TEST|6 Minutes Walk Test|a standardized test of an individual's functional ability that involves walking the greatest distance a person can walk in six minutes. This walking may be limited by shortness of breath or fatigability.
224047154|NCT05144113|BEHAVIORAL|Survey subjects to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.|"The following questionnaires will be answered by subjects:~Questionnaires:~Barriers to Physical Activity Questionnaire for People with Mobility Impairments (BPAQ-MI): measures barriers to physical activity across the intrapersonal and interpersonal domains.~Physical Activity and Disability Survey (PADS): measures physical activity for people with chronic neurological conditions.~Demographic and Mobility Questionnaire: Important information to inform on user and design needs and potential market for at home FES-row system.~Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)-(FES-row participants only): measures satisfaction with current FES-row system used in the ExPD Program."
224047155|NCT03422679|DRUG|CB-103|Hard gelatine capsules taken orally during treatment period. Treatment cycle is 28 days.
224047156|NCT02146599|OTHER|Administration of patient self-assessment|
224047157|NCT00005950|DRUG|nelarabine|Given IV
223436024|NCT06029933|BIOLOGICAL|High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)|Fluzone High-Dose Quadrivalent vaccine is an inactivated split virion influenza vaccine formulated to contain 240 mcg of HA total, with 60 mcg from each of the four recommended influenza strains in single-dose prefilled 0.7 mL syringes. Kaiser Permanente Northern California members ≥65 years may receive Fluzone High-Dose as part of routine clinical care during the influenza season.
223566137|NCT04516538|DIAGNOSTIC_TEST|Timed up and go|A simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time it takes for a person to get up from a chair, walk three metres, turn around, walk to the chair and sit down.
224047158|NCT06490393|OTHER|Questionnaires|EORTC QLQ-C30 (General Health), EORTC QLQ-SH22(sexual Health), Financial questionnaire as routinely used by the Social Department
224047159|NCT06461182|DRUG|Ga-68-CXCR4|Ga-68-CXCR4 for PET/CT procedure in Indolent B-cell Lymphoma
224047160|NCT05214170|DEVICE|Electroanatomic mapping with the NeuTrace System|Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.
223436025|NCT05000203|BEHAVIORAL|Online prenatal specific education|"The sessions will start around 30 weeks of gestation with the intention that around 35-37 weeks all pregnant women have had the opportunity to attend all the sessions.~Five specific online group sessions have been established for the fear of childbirth, each divided into three parts, and lasting approximately 60 minutes. In the first part, the aspects that are most relevant according to the reported experience of women with fear of childbirth will be discuss. In a second part, videos will be displayed starring midwives who will collaborate in specific intrapartum support with the aim of presenting the personnel involved in the care of women during delivery and immediate postpartum, and where the procedures and options available in the obstetric service of HUMIC. The session will end with brief therapy tasks. After each session, written documentation on the topics discussed will be made available to the participants."
224047161|NCT05708950|DRUG|KVA12123 - Dose Escalation|Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.
224047162|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Escalation|Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
224047163|NCT05708950|DRUG|KVA12123 - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.
224047164|NCT05708950|DRUG|KVA12123 Plus Pembrolizumab - Dose Expansion|KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.
224047165|NCT01799187|PROCEDURE|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
224047166|NCT01799187|PROCEDURE|apexification|apexification uses calcium hydroxide as root medication
224047167|NCT04267770|DRUG|Insulin (circadian)|Participant's own insulin adjusted to circadian infusion rates
224047168|NCT04267770|DRUG|Insulin (flat rate)|Participant's own insulin set to flat basal rates
224047169|NCT02821923|DIETARY_SUPPLEMENT|E967-Xylitol|24g xylitol/d
224047170|NCT02821923|DIETARY_SUPPLEMENT|E968-Erythritol|36g erythritol/d
224047171|NCT01770470|DIETARY_SUPPLEMENT|Chitosan|The product chitosan is contained in a chewing gum formulation
224047172|NCT02705807|DRUG|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen \[pH\] 10.2 - 10.8 diluent) for Injection.
224047173|NCT02705807|DRUG|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
224047174|NCT03061175|OTHER|Internet-Based Intervention|Receive web-based CPM-DA
224047175|NCT03061175|OTHER|Survey Administration|Ancillary studies
224047176|NCT02613845|OTHER|no intervention|
224047177|NCT01713270|PROCEDURE|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
224047178|NCT01713270|DRUG|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
224047179|NCT01713270|PROCEDURE|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
224047180|NCT05151120|BIOLOGICAL|blood sample|In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up
224047181|NCT02116257|DRUG|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
224047182|NCT02116257|DRUG|PCA regimen|
224047183|NCT02243865|DEVICE|Chordate System S200 + CT100 (active treatment)|Chordate S200 + CT100 (active treatment) gives Kinetic Oscillation Stimulation for 15 minutes to each nostril and by that giving an effect on the autonomic nervous system (ANS).
223744845|NCT05980520|DIETARY_SUPPLEMENT|Taurine+corn starch+white sugar|Taurine granules mixed with corn starch and white sugar, 0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day. The use of taurine is strictly in accordance with the specifications of Chinese Pharmacopoeia.
224047184|NCT02243865|DEVICE|Chordate System S200 + CT100 (placebo treatment)|Chordate S200 + CT100 (placebo) is used in the same way as Active treatment, but no Kinetic Oscillation Stimulation is given. Catheter is not inflated and no vibration is given.
224047185|NCT04207801|DRUG|AUR101|Inhibitor of RORγ
224047186|NCT04207801|DRUG|Matching Placebo|Drug-Placebo of AUR101 tablet
224047187|NCT01235793|DRUG|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
224047188|NCT00175214|BEHAVIORAL|Multifaceted intervention (patient education, physician guidelines, reminders)|
224047189|NCT03308409|OTHER|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
223436026|NCT05000203|BEHAVIORAL|Intrapartum specific support|"At first, a group of expert midwives will be formed in support of pregnant women with fear of childbirth. The objective is that three midwives from each work group shift will include the women from the experimental group in the intrapartum support team. The working group will receive a seminar given by the researcher where the study protocol and an update on fear of childbirth will be explained, which will include information on: concept and prevalence, risk factors, consequences, diagnosis and treatment.~For the follow-up of the participants, an instant messaging group will be formed where the collaborating midwives and the main researcher will be able to find out the existence of a participant within the emergency area or in the maternity ward, facilitating continued care in the changes of guard"
223436027|NCT05000203|BEHAVIORAL|Prenatal usual education|The participants in this group will follow the development of the usual interventions by midwives and obstetricians according to the established protocol for monitoring the pregnancy and / or by the private care system, as well as additional consultations for complications in pregnancy or consultations on demand that are considered necessary Group maternal education is offered in primary care center starting at week 28 of gestation. Although its content is supported by the Affective-Sexual and Reproductive Health Care Program, midwives are responsible for preparing the sessions according to their criteria to adapt them to the population. In addition to group interventions, pregnant women in the intervention environment also receive individualized educational attention in follow-up and control visits. After delivery, an inquiry will be made about the maternal education received by pregnant women during their current pregnancy.
223436028|NCT05000203|BEHAVIORAL|Intrapartum usual support|A routine detection of fear of childbirth or a protocolized practice for this problem is currently not contemplated in the trial setting. The different professionals who pay their attention to the pregnant woman can detect the fear of childbirth thanks to their experience or different indicators such as the expression of fears by the pregnant woman, being able to offer individualized attention and resources for the approach, according to their awareness of the problem .
223566138|NCT04516538|DIAGNOSTIC_TEST|Isokinetic Body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isokinetic BW-QIF test blocks consist in 100 contractions at 120° deg.s-1 and 60° of range of motion (0.5-s contraction /0.5-s rest)."
223566139|NCT04516538|DIAGNOSTIC_TEST|Cycloergometer body weight-based quadriceps intermittent fatigue test (BW-QIF Test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The BW-QIF test blocks on the cycloergometer consist in 100 s of cycling at 60 Revolution Per Minute (RPM)."
224047190|NCT00106522|DRUG|Methotrexate|10-25mg weekly
224047191|NCT00106522|DRUG|Placebo|iv every 4 weeks
224047192|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
224047193|NCT00106522|DRUG|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
224047194|NCT00460551|BIOLOGICAL|Zalutumumab|8 mg/kg
224047195|NCT00460551|DRUG|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
224047196|NCT00460551|RADIATION|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
224047197|NCT02870413|BEHAVIORAL|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
224047198|NCT00253188|DRUG|galantamine hydrobromide|
224047199|NCT06207357|PROCEDURE|optical trocar to create the pneumoperitoneum for bariatric surgery|The technique involves the use of 4 12 mm trocars. Pneumoperitoneum is induced by a 0° optical trocar and maintained at 15 mmHg. The first trocar is usually inserted along the left mid-clavicular line approximately 2 fingers from the costal arch, another trocar along the left axillary line, a third trocar 1 cm to the right of the midline, and the fourth trocar along the right mid-clavicular line. A 10 mm, 30 ° laparoscope is used.
224047200|NCT00004912|DRUG|megestrol acetate|
224047201|NCT00004912|PROCEDURE|physical therapy|
224142533|NCT06418568|DEVICE|Ultra-pulsed Shockwave Therapy Device by Shenzhen Lifotronic Technology Co., Ltd.|The intervention involves treating melasma using tranexamic acid (aminomethylbenzoic acid) delivered through ultra-pulsed shockwave therapy on one side of the face, while the other side receives topical application of tranexamic acid at the same concentration. The shockwave therapy parameters are tailored based on patient tolerance. Each patient undergoes 3 treatment sessions spaced 3 weeks apart, followed by a 4-week follow-up period. Facial skin is assessed using the VISIA system before each treatment and at the 4-week follow-up, evaluating the Melasma Area Severity Index (MASI). Patient and researcher satisfaction levels are rated on a scale of 1 to 5. Adverse reactions, including short-term effects like pain and swelling, and potential long-term effects such as allergic reactions and hyperpigmentation, are monitored after each treatment session.
224047202|NCT01039025|DRUG|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m\^2 intravenously given over 30 minutes on Days 1 - 5.
223436029|NCT02113995|OTHER|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
223436030|NCT02056106|DRUG|antidepressant therapy|
223436031|NCT01778738|PROCEDURE|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
223436032|NCT01778738|PROCEDURE|Sleeve gastrecomy|Vertical sleeve gastrectomy
223436033|NCT01778738|PROCEDURE|Bastric bypass|Gastric bypass surgery
223436034|NCT00034619|DRUG|ALIMTA|
223436035|NCT00034619|DRUG|Oxaliplatin|
223436036|NCT05350332|DEVICE|Negative Pressure Ventilator|The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
223436037|NCT05350332|DEVICE|Pulmonary Function Testing (PFT)|PFT is a routine standardized clinical test evaluating lung function, consisting of two parts: spirometry and body plethysmography. In spirometry, participants breathe through a mouthpiece that measures airflow and volume to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants enter in an enclosed chamber where they breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing are used to calculate the volume of air that remains in the lung after expiration. A MiniBox+ device may be used. The MiniBox+ device derives total lung capacity (TLC) during tidal breathing by the analysis of gas pressures and airflows immediately preceding and immediately following airway occlusions to calculate the same measures as conventional PFT analysis.
223436038|NCT05350332|DEVICE|Transcutaneous Phrenic Nerve Stimulation|Phrenic nerve stimulation (PNS) will be performed transcutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS8R Bipolar Constant Current Stimulator). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
223436039|NCT06292858|DRUG|IMB071703 injection|Intratumoral injection
223436040|NCT03722745|BEHAVIORAL|TARGET|TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
223436041|NCT03722745|BEHAVIORAL|TAU|It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
223436042|NCT03613883|PROCEDURE|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
223436043|NCT04605380|OTHER|Virtual reality online world|Virtual patient with open fracture inside a virtual world
223436044|NCT03444051|PROCEDURE|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
223436045|NCT03444051|PROCEDURE|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
223566140|NCT04516538|DIAGNOSTIC_TEST|Isometric BW-QIF Test (Body weight-based quadriceps intermittent fatigue test)|"The BW-QIF test is an interval incremental contraction test including blocks of discontinuous 100-s effort. Neuromuscular evaluation of the knee extensors between blocks (duration 25 s) includes one maximal voluntary contraction, one contraction at the 60% of the actual maximal force and at the 80% of the actual maximal force. During each contraction, transcranial magnetic stimulation over the motor cortex will be delivered to assess corticospinal voluntary activation (central fatigue). Single-twitch electrical stimulations will be delivered on the femoral nerve during the maximal voluntary contraction and at rest to evaluate peripheral fatigue.~The isometric BW-QIF test blocks consist in 10 contractions (5-s contraction / 5-s rest)."
223566141|NCT06145204|OTHER|questionnaire|anamnesis, OMSPQ, Brief Pain Inventory-short form, lymph-ICF-LL
223744846|NCT05980520|DIETARY_SUPPLEMENT|Corn starch+white sugar|0.4g in 1 bag, taken orally. One time dosage: 1 bag each time for 1-2 years old, 3 times a day, 1.5 bags each time for 3-5 years old, 3 times a day, 2 bags each time for 6-8 years old, 3 times a day, 2.5-3 bags each time for 9-13 years old, 3 to 4 bags each time for children and adults over 14 years old, 3 times a day.
224047203|NCT01039025|DRUG|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m\^2/day intravenously given over 2 hours on Days 1 - 3.
224047204|NCT01039025|DRUG|Melphalan|After stem cells are collected, Melphalan 70 mg/m\^2/day intravenously given on Days 4 and 5.
224047205|NCT01039025|OTHER|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
224047206|NCT01557933|OTHER|No interventions will be used|No interventions will be used
224047207|NCT01159912|DRUG|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
224299919|NCT04059458|DEVICE|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
224047208|NCT01159912|DRUG|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
224047209|NCT01159912|DRUG|Placebo|Placebo inhalation powder
224047210|NCT00378235|DRUG|IL13-PE38QQR|
224047211|NCT03575286|DIAGNOSTIC_TEST|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
223436046|NCT00361920|DRUG|prednisone|
223436047|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
223436048|NCT02864927|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
224047212|NCT05099653|OTHER|physical activity|physical activity
224047213|NCT04535180|DIAGNOSTIC_TEST|Dual-energy X-ray absorptiometry (DXA)|"Body composition will be measured using whole-body DXA (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.). Extremity skeletal muscle mass will be calculated using the values measured via the DXA; ASM will be calculated as the sum of skeletal muscle mass in the arms and legs, assuming that the mass of lean soft tissue is a skeletal muscle. Appendicular skeletal mass index (ASM/Ht2 ) will be determined as the sum of the arm and leg lean mass (kg)/height2 (m2~). BMD will be measured in lumbar spine and bilateral hip by the same DXA device (GE Lunar iDXA, GE Healthcare Lunar, Madison, Wisconsin, U.S.A.)"
224047214|NCT06174051|BEHAVIORAL|Flashforward EMDR|The Flashforward procedure in EMDR-treatment aims to reduce fear evoked by images of imagined future adverse events.
224047215|NCT06174051|BEHAVIORAL|Flashback EMDR|The Flashback procedure in EMDR-treatment aims to successfuly process the memories of traumatic events that happened in the past.
224047216|NCT03020238|PROCEDURE|BiClamp group|electric energy
224047217|NCT03020238|PROCEDURE|water jet group|water jet energy
224047218|NCT00822354|DRUG|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
224047219|NCT00594321|DEVICE|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
224047220|NCT00594321|DEVICE|standard vertebroplasty|standard vertebroplasty
224047221|NCT02499081|DRUG|Ixazomib|
224047222|NCT02629471|BEHAVIORAL|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
224142534|NCT04641819|DRUG|Yangzheng Compound Mixture|"At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions."
223436049|NCT03221140|DRUG|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
223436050|NCT06100692|DRUG|Vitamin D|the patients will receive a 30 pts a combination of oral vit D and zinc
223436051|NCT04336462|DEVICE|oxyhydrogen|Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
223436052|NCT04336462|DEVICE|Oxygen|oxygen inhaled,3 L/min . 6 hour a day.
223436053|NCT03041103|OTHER|Food Product 1|50 grams of fortified nutritious product from legumes
223566142|NCT06277700|OTHER|Chiropractic Manipulation (HVLA - high velocity low amplitude)|Participants in the groups receiving DNS will be asked to hold the lower leg in the side lying position with the lower leg in the extended position and to clamp the upper leg to the lower leg with hip and knee flexion. During the application, the HLVA technique will be applied once by positioning the hypothenar part of the physiotherapist's hand on the transverse process of the lumbar vertebra where tenderness is felt by palpation and vertebral subluxation is thought to be present.
223566143|NCT06277700|OTHER|Dynamic Neuromuscular Stabilization|Participants in the groups receiving DNS exercise therapy will be given individualized exercises under the supervision of a physiotherapist. First, the participants were taught posterior diaphragm activation in the supine position and the ability to direct the intraabdominal pressure caudally, while preventing the cranial movement of the thorax, so that the chest and pelvis are in a neutral position and the thoracic diaphragm and pelvis are aligned in parallel. Participants will then be taught the ability to perform a chin tuck without disturbing the alignment of the rib cage. In this way, the cervical diaphragm, thoracic diaphragm and pelvic diaphragm will be aligned in parallel. Our aim in this alignment will be to activate the deep stabilizers as a reflex response to intra-abdominal pressure change with the correct diaphragm movement pattern. Participants will be asked to focus on and maintain this alignment throughout the entire DNS exercise pattern.
224047223|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
223566144|NCT02998203|DIETARY_SUPPLEMENT|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
224047224|NCT00982007|DRUG|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
224142535|NCT04641819|OTHER|Conventional Treatment|Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
224142536|NCT02759562|DRUG|Andecaliximab|Administered via subcutaneous injection
223436054|NCT04363918|DEVICE|bioelectric stimulation|bioelectric stimulation
224047225|NCT00982007|DRUG|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
224047226|NCT00982007|DRUG|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
224047227|NCT05459285|BIOLOGICAL|14028 injection|14028 injection, single dose, s.c. injection
224047228|NCT05459285|BIOLOGICAL|dulaglutide injection|dulaglutide injection(TRULICITY®), single dose, s.c. injection
224047229|NCT02176187|DRUG|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
224047230|NCT02176187|DRUG|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
224047231|NCT00154336|DRUG|Imatinib|
224047232|NCT00154336|DRUG|Methotrexate|
224047233|NCT00154336|DRUG|Imatinib Placebo|
223436055|NCT03289325|DRUG|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
223436056|NCT03289325|DRUG|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation."
223436057|NCT01149421|DRUG|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
224047234|NCT04286425|OTHER|seminal plasma|Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine
223436058|NCT01149421|DRUG|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
223436059|NCT03160001|DRUG|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
223436060|NCT03160001|DRUG|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
223436061|NCT03160001|DRUG|Etanercept|Etanercept 50mg weekly
223436062|NCT03964467|DEVICE|transcranial direct current stimulation|see arm/group descriptions
223436063|NCT01067625|DEVICE|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
223436064|NCT02222675|PROCEDURE|Sonography assisted breast surgery|
223436065|NCT02222675|PROCEDURE|Conventional breast surgery|
223436066|NCT00176436|BEHAVIORAL|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
223566145|NCT04666103|PROCEDURE|Intraoperative thermal ablation|"After the thyroid lobectomy, the contralateral benign thyroid nodule was treated with intraoperative thermal ablation. The hydrodissection technique'' was used during the ablation process to prevent recurrent laryngeal nerve, esophageal and other important structures from being destroyed by heat energy."
223566146|NCT04037631|DIAGNOSTIC_TEST|Diagnostic device|Diagnostic test
223566147|NCT04187144|DRUG|Gepotidacin|Gepotidacin will be available as tablets at a unit dose strength of 750mg. Participants will administer two 750 mg tablets, BID. Each dose will be taken with water after consumption of food.
224047235|NCT04286425|OTHER|saline solution|saline solution
224047236|NCT05096351|OTHER|Blood test|Collection of blood samples at 1 and 6 months for HLA typing for donor and recipient antibodies
224047237|NCT02885194|OTHER|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
224047238|NCT01347775|DEVICE|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
224047239|NCT01347775|DEVICE|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
224047240|NCT04379921|DEVICE|Apple Watch and App|Participants in the Apple Watch and App arm will receive an Apple Watch and download an App (NeuroCoach). The Apple Watch and App are used for this study to record patient's mobility information (e.g., step counts, heart rate, stairs climbed, distance traveled) as well as provide an additional platform for patients to complete questionnaires.
224142537|NCT02759562|DRUG|Placebo|Administered via subcutaneous injection
224142538|NCT03487328|PROCEDURE|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
224142539|NCT04230798|OTHER|Injury prevention program|The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
224142540|NCT05066867|OTHER|Smart sharps bin - collects data on compliance|collects compliance data
223436067|NCT00176436|BEHAVIORAL|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
223436068|NCT06623279|GENETIC|HG202|Method of Administration: Once unilateral subretinal injection; The duration of the study includes a 4-week screening period, enrollment visit, treatment visit and 52 weeks follow-up period, 4 more years long term follow up as an extension study.
223436069|NCT00355706|PROCEDURE|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
223436070|NCT04428242|DEVICE|RHMS-RTM|Assessment of retinal thickness.
223436071|NCT04428242|DIAGNOSTIC_TEST|SD-OCT|Assessment of retinal structure.
223436072|NCT03738800|DRUG|CD5789 Cream 200 µg/g|A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
223436073|NCT03738800|DRUG|CD5789 Cream 100 µg/g|A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
223436074|NCT03738800|DRUG|CD5789 Cream Vehicle|A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
223436075|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
223436076|NCT06547242|DRUG|Levothyroxin|Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence
224142541|NCT00232505|BIOLOGICAL|cetuximab|Given IV
224142542|NCT00232505|DRUG|carboplatin|Given IV
224047241|NCT05714956|BEHAVIORAL|Mothers and Babies Online (eMB)|"This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention."
224047242|NCT04272970|DIAGNOSTIC_TEST|Validation of a new gene / protein variant implicated in familial CT|Realize a blood sample to perform functional studies of circulating blood platelets and hematopoietic progenitor cells, in order to prove the pathogenicity of variants of new genes potentially involved in constitutional thrombocytopenia.
223436077|NCT03008993|BEHAVIORAL|HQIS implementation|
223436078|NCT00766467|DRUG|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
223436079|NCT00766467|OTHER|Placebo|Placebo taken once a day in the morning
223436080|NCT00676572|OTHER|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
223436081|NCT00566956|PROCEDURE|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
223436082|NCT01313494|DRUG|Roflumilast|Roflumilast tablets
223436083|NCT01313494|DRUG|Placebo|Placebo tablets
223436084|NCT01313494|DRUG|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
224142543|NCT06020573|DEVICE|Clip-on electrode with fiber optics|The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
223436085|NCT00111371|DRUG|Levodopa|
223436086|NCT04288336|OTHER|Food Diary|Ancillary studies
223436087|NCT04288336|OTHER|Preventative Dietary Intervention|Follow intermittent fasting
223436088|NCT04288336|OTHER|Questionnaire Administration|Ancillary studies
223436089|NCT01021488|DRUG|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
223436090|NCT01021488|DRUG|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
223566148|NCT04187144|DRUG|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Participants will administer 1 capsule BID. Each dose should be taken with water after consumption of food.
224047243|NCT01428661|DRUG|tasimelteon|20 mg once daily
224047244|NCT01428661|DRUG|placebo|once daily
224142544|NCT04229069|DIETARY_SUPPLEMENT|alkaline salt mixture|blood and tissue alkalinisation
223436091|NCT00000865|DRUG|Abacavir sulfate|
223436092|NCT00000865|DRUG|Lamivudine|
223436093|NCT00000865|DRUG|Stavudine|
223436094|NCT00000865|DRUG|Zidovudine|
223436095|NCT00000865|DRUG|Didanosine|
223436096|NCT04824755|PROCEDURE|Yune Zhao|Yune Zhao did congenital cataract surgeries
223436097|NCT01404208|DRUG|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
223436098|NCT01404208|DRUG|Placebo|Sugar pill
223436099|NCT03847415|DIAGNOSTIC_TEST|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
223436100|NCT02970019|DRUG|K0706|Once a day administration after fast
223436101|NCT02970019|DRUG|Placebo|Once a day administration after fast
223436102|NCT03146871|DRUG|Azacitidine|Given IV or SC
223436103|NCT03146871|DRUG|Decitabine|Given IV
223436104|NCT03146871|OTHER|Laboratory Biomarker Analysis|Correlative studies
223436105|NCT03146871|OTHER|Pharmacological Study|Correlative studies
223436106|NCT03146871|BIOLOGICAL|Recombinant EphB4-HSA Fusion Protein|Given IV
223436107|NCT05180955|OTHER|Digital drainage system|In the intervention group; chest tube removal will be determined by air flow criteria as indicated by the digital drainage system data, the tube will not be clamped.
223436108|NCT05180955|OTHER|Digital drainage system + clamping trial|In the control group removal will be determined by the same criteria of the digital drainage system but before removal, a chest tube clamping test will be performed.
223436109|NCT00231309|DRUG|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
223436110|NCT00432315|DRUG|Docetaxel + CDDP|"* 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel"
223436111|NCT00432315|DRUG|docetaxel + CDDP|"* 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel"
223436112|NCT05320068|DRUG|Oral Vancomycin|A blinded capsule that contains 125mg of vancomycin every 6 hours during 10 days.
223436113|NCT05320068|DRUG|Placebo|A blinded capsule that contains no vancomycin every 6 hours during 10 days.
223436114|NCT05416645|PROCEDURE|patients with GERD after LSG|patients with GERD after LSG
223436115|NCT01819948|DIETARY_SUPPLEMENT|PhytoMed™|
224142545|NCT04229069|DIETARY_SUPPLEMENT|placebo|no blood and tissue alkalinisation
224047245|NCT06752031|BEHAVIORAL|OSCAR-S Care Transition Model|Patients and families in the intervention arm will receive touch points from the surgery nurse coach to support their care transition from hospital to home after surgery.
223436116|NCT01522235|DRUG|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
223436117|NCT01522235|OTHER|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
223436118|NCT01522235|OTHER|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
223436119|NCT04853108|OTHER|Remote Monitoring of COVID-19|Remote monitoring of acute COVID-19 illness included use of a Medtronic pulse oximeter, photoplethysmography (PPG), patient-reported symptoms data, static vital signs captured during the course of the clinical evaluation and various physiomarkers.
223436120|NCT05886998|DRUG|Heparin|Heparin sodium (Generic, 5000 IU/ml ampoules)
223436121|NCT05886998|OTHER|Normal Saline|0.9% sodium chloride solution (normal saline)
223436122|NCT02802644|DRUG|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
223566149|NCT04187144|DRUG|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated 100 mg capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Participants will administer one 100 mg capsule, BID. Each dose should be taken with water after consumption of food.
224142546|NCT00634465|DEVICE|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
224142547|NCT02932150|DRUG|TAF|Administered orally once daily
224142548|NCT02932150|DRUG|Placebo|Administered orally once daily
224142549|NCT03064568|DRUG|Misoprostol 200Mcg Tab|4 tablets will be inserted rectally
224142550|NCT03064568|DRUG|Placebo|
224142551|NCT05810844|DIAGNOSTIC_TEST|Motor Relearning Program (MRP)|MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke
224142552|NCT05810844|DIAGNOSTIC_TEST|Neuro Development Treatment (NDT)|Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
224142553|NCT01596530|DRUG|Drug-AZD8931|Active drug for biological activity
223436123|NCT02802644|DRUG|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
223566150|NCT04187144|DRUG|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Participants will administer two tablets, BID. Each dose should be taken with water after consumption of food.
223566151|NCT02650804|DRUG|BPM31510 Nanosuspension Injection|
223566152|NCT02650804|DRUG|Gemcitabine|
224142554|NCT01596530|DRUG|Drug-Placebo|Placebo comparator for biological activity comparison
224142555|NCT06042530|DIAGNOSTIC_TEST|Neuropsychological investigation|Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification
224142556|NCT06042530|DIAGNOSTIC_TEST|Optometric investigation|Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.
223436124|NCT05039320|DIETARY_SUPPLEMENT|Bactoblis|dissolve the tablets in the mouth once a day for 4 weeks
223436125|NCT05039320|DIETARY_SUPPLEMENT|Placebo|dissolve the tablets in the mouth once a day for 4 weeks
223566153|NCT05927675|BEHAVIORAL|Physical activity|"The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements."
223566154|NCT00004248|BIOLOGICAL|aldesleukin|
223566155|NCT00004248|DRUG|doxorubicin hydrochloride|
223566156|NCT04984265|RADIATION|Stereotactic Body Radiation Therapy|SBRT targeting the area of the circuit of Ventricular Tachycardia
224070587|NCT06412497|DRUG|Cyclophosphamide|"Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses.~Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines."
224299920|NCT04059458|DRUG|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
223436126|NCT02791646|BEHAVIORAL|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
223436127|NCT02791646|BEHAVIORAL|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
223436128|NCT00622596|OTHER|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
223436129|NCT02433899|PROCEDURE|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
223436130|NCT02433899|PROCEDURE|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
224047246|NCT06773169|OTHER|IAMABLE web-based app|The Intervention Group will use the IAMABLE app for 4 months. IAMABLE users identify activities that they are having difficulty with because of their health problem and set goals they want to work toward. Self-management (SM) modules help them reach their goals, providing information and rehabilitation strategies about exercise, fall prevention, fatigue management, pain management, physical activity, and stress management. Users complete a self-assessment associated with each module, and receive tailored recommendations that guide them to access relevant module topics. Users create 7-day action plans using the strategies in the module to address their activity goals. Users receive automated notifications when it is time to evaluate action plans and activity goals, as well as weekly messages to remind them to engage with the app. Users have access to therapist support using the Ask a Therapist feature and receive individual consultations in response to queries about SM.
224047247|NCT06773169|OTHER|General health information|The Control Group will receive a monthly email with general health information (not specific to rehabilitation or chronic diseases) for 4 months. Topics will include Nutrition, Vision Care, Foot Care, Hearing, Skin Care and Oral Care. Each email will include an introduction to the topic and links for additional information.
224047248|NCT01148706|DEVICE|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
224047249|NCT00137228|PROCEDURE|figure-of-eight hand measurements|
224047250|NCT00137228|PROCEDURE|water volumetry hand measurements|
224047251|NCT04968977|PROCEDURE|PCI vs. CABG|PCI vs. CABG
224047252|NCT00992940|PROCEDURE|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
223436131|NCT02433899|DRUG|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
223436132|NCT02433899|DRUG|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
223436133|NCT02433899|DRUG|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
223436134|NCT05555316|DRUG|TACE combined with Lenvatinib|Three days after the first TACE treatment, when the liver function was evaluated as grade A / B, Lenvatinib was taken orally, 8mg / day (body weight less than 60kg) or 12mg / day (body weight equal to or more than 60kg). Lenvatinib reduction standard: 8mg / day; 4mg / day; 4mg, the next day.
223436135|NCT02810171|BEHAVIORAL|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
223436136|NCT02810171|BEHAVIORAL|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
223436137|NCT06302023|DIETARY_SUPPLEMENT|Docosahexaenoic acid (DHA) 1000 mg|Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
223436138|NCT02548923|DRUG|Dexmedetomidine|comparison to propofol
223436139|NCT01488396|DRUG|0.05%cyclosporin eye drop|use twice daily for 6 months
223436140|NCT01666210|DRUG|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
223436141|NCT01666210|DRUG|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
223436142|NCT06731712|OTHER|Physical Function Exercises|Physical function interventions included strength, balance, and mobility exercises. More specifically, the exercises include progressively increasing intensity strengthening exercises with a resistance band for the following muscle groups: hip abductor and extensor muscles, knee flexor and extensor muscles, and shoulder abductor and external rotator muscles. Other exercises consist of standing calf raises, squats, bridges, and push-ups. Additionally, functional exercises include heel-to-toe standing or walking, single-leg standing, stepping over obstacles, bending down, and lifting an object with feet together.
224047253|NCT00992940|PROCEDURE|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
224047254|NCT04492462|OTHER|Formal Physical Therapy|Patients will undergo standard physical therapy following their surgery with a physical therapist in an office
224047255|NCT04492462|OTHER|Self-directed Physical Therapy|Patients will undergo self-directed physical therapy in the comfort of their own home by completing a list of exercises and stretches without the direct supervision of a physical therapist in a physical therapist office
224047256|NCT01969487|OTHER|Preoperative warm-up on simulator|
224047257|NCT01925924|OTHER|Resin-modified glass ionomer cement|This material contains fluoride
224047258|NCT01925924|OTHER|Composite resin|This material does not include fluoride
224047259|NCT06206564|DRUG|Artesunate ointment|Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
224047260|NCT06206564|DRUG|Placebo|Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
224047261|NCT05323188|OTHER|Tryptase dosage|Collection of biological waste from a blood test for complete blood count (CBC) of care. Centrifugation to recover the plasma, then dosage of the tryptase.
224047262|NCT04133818|BEHAVIORAL|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~* Lectures and explanations about low back pain~* Physical activity~* Relaxation"
224070588|NCT06412497|DRUG|Fludarabine|For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.
224299921|NCT04156958|DRUG|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
223436143|NCT01715519|DRUG|Treatment (Viibryd)|
223436144|NCT05307718|DRUG|Oral Anticoagulant, Direct-Acting|Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
223436145|NCT02234336|PROCEDURE|Noncontrast echocardiography|
223436146|NCT02234336|PROCEDURE|Contrast Echocardiography|
223436147|NCT02234336|PROCEDURE|Cardiac magnetic resonance imaging|
223436148|NCT06224036|DRUG|JDB0131|"JDB0131 benzenesulfonate is a new anti tuberculosis compound based on delamanid. According to the existing results of pre clinical in vitro activity, in vivo efficacy, pharmacokinetics and safety in human body, JDB0131 benzenesulfonate has the same in vivo efficacy, better lung tissue distribution and better safety as delamanid.~In December 2016, JDB0131 obtained the drug clinical approval issued by the CFDA, and were approved the clinical stage research that development of drug-resistant tuberculosis adaptation."
223436149|NCT06224036|DRUG|Delamanid|Delamanid is a new drug developed by Otsuka Pharmaceutical Co., Ltd. in Japan to treat multidrug resistant tuberculosis. In 2014, Delamanid was conditionally approved for marketing by the European Medicines Agency and recommended for use in adult MDR-TB patients who cannot form an effective regimen due to drug resistance or tolerance reasons. In the same year, WHO recommended that Delamanid be conditionally used for long-term treatment of adult MDR-TB. In 2016, the WHO recommended widening the age range for Delamanid to 6-17 years old. In March 2018, Delamanid was listed in China.
223436150|NCT06224036|DRUG|Ethylpyrazine rifampicide (II)|Ethylpyrazine rifampicide (II) is suitable for the first two months of intensive treatment of pulmonary tuberculosis with short-term therapy. This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol hydrochloride (C10H24N2O2 · 2HCl) per tablet.
224047263|NCT02395757|DEVICE|MAIA™ (Centervue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|"An automatic microperimetry exam of the 10° central macular coverage expert test (customized grid) will be performed with the MAIA™ device at each semi-annual follow-up visit."
224047264|NCT03706417|DIAGNOSTIC_TEST|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
223436151|NCT02495818|PROCEDURE|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
223436152|NCT02495818|PROCEDURE|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
224047265|NCT04590950|OTHER|Non interventional study|Non interventional study
224047266|NCT03200327|PROCEDURE|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
224047267|NCT03200327|PROCEDURE|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
224047268|NCT05938998|BEHAVIORAL|Yoga; Support Group|BEHAVIORAL: Group Exercise Sessions- Yoga. BEHAVIORAL: Social Support Sessions
224047269|NCT06159621|DRUG|PD-1inhibitor - LVGN 3616|Administration of one dose of LVGN 3616 - 300mg. Commercially available PD-1 inhibitor may be substituted.
224047270|NCT06159621|DRUG|CD 40 Agonist - LVGN 7409|Administration of one dose of LVGN 7409 - 1mg/kg
224047271|NCT05263739|DRUG|ESG206|Administered via intravenous (IV) infusion
224047272|NCT06833983|DRUG|GS1191-0445 injection|A single intravenous administration of GS1191-0445 injection at a dose of 3E12 vg/kg
224047273|NCT04045795|DRUG|isatuximab SAR650984 IV|"Pharmaceutical form: solution~Route of administration: intravenous"
224047274|NCT04045795|DRUG|pomalidomide|"Pharmaceutical form: tablet~Route of administration: oral"
224047275|NCT04045795|DRUG|dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
224047276|NCT04045795|DRUG|isatuximab SAR650984 SC|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224047277|NCT04045795|DEVICE|Investigational injector device|Subcutaneous administration
224047278|NCT03022318|DRUG|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
224047279|NCT04675931|DRUG|KAE609|"Two doses of Intravenous Cipargamin will be evaluated in the initial phase of the study (Cohorts 1-2).~These doses will cover a wider exposure range and facilitate the selection of an appropriate dose for later Cohorts 3-5."
224047280|NCT04675931|DRUG|IV Artesunate|Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.
224047281|NCT04675931|DRUG|Coartem|Oral Standard of Care
224047282|NCT02229539|DRUG|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
224299922|NCT00887055|DEVICE|CRT device|
224047283|NCT02229539|DRUG|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
224047284|NCT02229539|OTHER|Placebo|2.5 mL placebo and 2.5 mL water administered orally
224047285|NCT04244916|BIOLOGICAL|AUC of MPA measure|"Plasmatic AUC determination of MPA requires 3 blood punctures at H0, H30 and H2.~These punctures will be made at inclusion after 6 weeks, 12 weeks, 6 months and one year."
224047286|NCT05748171|DRUG|Inotuzumab ozogamicin|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.
224047287|NCT05748171|DRUG|ALLR3|The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
224299923|NCT04808310|DEVICE|Quantitative flow ratio|Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)
224299924|NCT04808310|DIAGNOSTIC_TEST|Assessment of angiographic severity of the stenosis|The indication to coronary stent intervention will be based on angiography
223436153|NCT02495818|OTHER|Homemade exercises|Codman and Hughston exercises.
223436154|NCT01935713|DRUG|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
223436155|NCT01935713|DRUG|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
223436156|NCT01935713|DRUG|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, \>2 packs per day).
223436157|NCT03322436|DIAGNOSTIC_TEST|HeartLinc kit|Samples are collected and analyzed afterwards
223436158|NCT05846113|DIAGNOSTIC_TEST|Renasight|"The Renasight™ test is a next generation sequencing (NGS) gene mutation assay for patients with chronic kidney disease (CKD) which utilizes genomic DNA from patient blood or buccal swab samples to analyze over 380 genes that are associated with autosomal dominant, autosomal recessive and X-linked disorders.~Patients undergoing Renasight™ testing are offered optional genetic information sessions in addition to their test results.~RenasightTM is a commercially available Laboratory Developed Test (LDT) certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA)."
223436159|NCT00609713|BEHAVIORAL|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
223436160|NCT00609713|OTHER|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
223436161|NCT01957943|DIETARY_SUPPLEMENT|SMOFLipid|
223566157|NCT06229431|OTHER|The Carer Support Needs Assessment Tool Intervention (CSNAT-I)|"The CSNAT tool The tool includes 16 questions about the need for more support.~The five-stage person-centered approach~In the present study, the CSNAT-I consist of at least two meetings between the older spousal caregiver and the district nurse,1-4 weeks apart, following 5 stages:~1. Introduction of the CSNAT tool as a conversation starter.~2. Time for the spousal caregiver to consider the questions in which more support is needed.~3. An assessment conversation takes place.~4. A shared action plan is formed based on the assessment conversation.~5. Continuous shared review of the action plan."
224047288|NCT00246909|DRUG|Pantoprazole|
224047289|NCT01688284|DEVICE|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14\_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
224047290|NCT03862144|DRUG|Netupitant/Palonosetron|
224047291|NCT00077532|BIOLOGICAL|gp100 antigen|
224142557|NCT06042530|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.
224142558|NCT06042530|DIAGNOSTIC_TEST|Immunological biomarkers|Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.
224142559|NCT00004696|DRUG|morphine|
223436162|NCT01957943|DIETARY_SUPPLEMENT|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
223566158|NCT02396771|PROCEDURE|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
223566159|NCT02396771|PROCEDURE|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
223566160|NCT00473967|BIOLOGICAL|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
224047292|NCT00077532|BIOLOGICAL|incomplete Freund's adjuvant|
224047293|NCT00077532|BIOLOGICAL|ipilimumab|
224047294|NCT00521924|BIOLOGICAL|infliximab|infliximab 3 mg/kg and basic treatment
224142560|NCT00225147|DRUG|Recombinant Human C1 Inhibitor|IV
224142561|NCT00225147|DRUG|placebo|saline solution
224142562|NCT01121003|BEHAVIORAL|weight maintenance, low sugar diet|
224142563|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet|
224142564|NCT01121003|BEHAVIORAL|weight maintenance, high fructose diet+ exercise|
224142565|NCT03713216|DRUG|Naldebain|150 mg Nalbuphine sebacate
224142566|NCT03713216|DRUG|Morphine|Morphine
224047295|NCT00521924|DRUG|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
224047296|NCT04050670|DRUG|Tirzepatide|Tirzepatide administered SC
224047297|NCT05564975|OTHER||
223436163|NCT04309903|OTHER|Manual therapy|Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
224047298|NCT00982865|DRUG|MSC1936369B|
224047299|NCT00982865|DRUG|MSC1936369B|
224047300|NCT00982865|DRUG|MSC1936369B|
224047301|NCT00982865|DRUG|MSC1936369B|
224047302|NCT05560542|DRUG|Atropine and Dexamethasone|Intrathecal dexamethasone, atropine or their combination.
224047303|NCT01745250|DEVICE|Emervel Lips|Lip treatment of both upper and lower lip
224047304|NCT01745250|DEVICE|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
224047305|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
224047306|NCT01458912|DRUG|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
224142567|NCT04169113|OTHER|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
224142568|NCT04169113|OTHER|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
224142569|NCT05558241|DEVICE|High-resolution micro-ultrasound|In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
224142570|NCT03937193|DIAGNOSTIC_TEST|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
224142571|NCT00193219|DRUG|Bevacizumab|5 mg/kg IV
224142572|NCT00193219|DRUG|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
224142573|NCT00193219|DRUG|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
224142574|NCT00193219|DRUG|Leucovorin|350 mg IV
224142575|NCT00193219|DRUG|Oxaliplatin|85 mg/m2 IV
224142576|NCT03151252|DIAGNOSTIC_TEST|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
224142577|NCT01900678|DEVICE|VytronUS Ablation System|Pulmonary vein isolation.
224299925|NCT04441710|OTHER|Questionnaire|Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
224299926|NCT02767895|BEHAVIORAL|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
224047307|NCT01458912|DRUG|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
224047308|NCT01458912|DRUG|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
224047309|NCT01810185|DRUG|Low dose naltrexone|4.5 mg daily for 12 weeeks
224047310|NCT01810185|DRUG|Placebo|
224047311|NCT01653288|BEHAVIORAL|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
224047312|NCT03868969|DRUG|Fosfomycin Oral Suspension|Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
224047313|NCT06426485|DRUG|Toludesvenlafaxine Hydrochloride Sustained-release Tablets|orally once a day
224047314|NCT06426485|DRUG|placebo|orally once a day
224047315|NCT03380351|BEHAVIORAL|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
224047316|NCT00668070|DRUG|ASP9831|Oral
224047317|NCT00668070|DRUG|Placebo|Oral
224047318|NCT03042780|DRUG|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
224047319|NCT03042780|DRUG|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
224047320|NCT02581293|PROCEDURE|Group 1: Only visceral peritoneum will be closed|
224047321|NCT02581293|PROCEDURE|Group 2 : Only parietal peritoneum will be closed|
224299927|NCT02777814|DRUG|Entecavir|anti hepatitis B virus
224047322|NCT02581293|PROCEDURE|Group 3 : Both of them will be closed|
223436164|NCT04116606|DRUG|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
223436165|NCT04116606|DRUG|Placebo|Matching placebo containing the same excipients
223436166|NCT01711775|DRUG|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
223436167|NCT03593187|DRUG|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
223436168|NCT01870297|DRUG|LY3025876|Administered SQ
223436169|NCT01870297|DRUG|Placebo|Administered SQ
223436170|NCT01870297|DRUG|Liraglutide|Administered SQ
223436171|NCT00956605|BEHAVIORAL|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
223436172|NCT04128124|OTHER|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
223436173|NCT03268512|OTHER|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
223436174|NCT03268512|OTHER|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
223436175|NCT04760223|BEHAVIORAL|Video intervention|a 100-second video, presenting a personal story of a boy/girl dealing with depression
223436176|NCT00441155|DRUG|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
224047323|NCT02581293|PROCEDURE|Group 4: None of them will be closed|
224047324|NCT02465983|BIOLOGICAL|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
224299928|NCT02031458|DRUG|Atezolizumab|1200 mg IV every 3 weeks
224299929|NCT06632561|DRUG|Empagliflozin 10 mg|Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
223436177|NCT04341558|OTHER|Family supplemented patient monitoring|Intervention training sessions will last 30 minutes and will be held twice a day over a period of six months. Carers will be welcome to attend as often as they wish. Carers will be given practical training to assess the following vital signs: heart rate, respiratory rate, conscious level (AVPU scale) and arterial oxygen saturation (SpO2) in accordance with trial standard operating procedures. An important component of the training package will be ensuring carers know how to wash their hands before and after contact with their patients. The study team will ensure that handwashing facilities are available on the ward for use by carers. Carers will record vital signs on a basic observation chart every 4 hours after surgery. They will compare results with colour posters displayed throughout each ward, providing guidance on how and when to notify nursing staff of abnormal vital signs.
223436178|NCT02926417|PROCEDURE|High Density-Electroencephalogram|
223436179|NCT05133258|OTHER|Aspiration of middle ear fluid following standard-of-care delivery of ciprofloxacin and dexamethasone suspension|Micro-aspirate of middle ear fluid will be taken from participants with a Juhn Tym-Tap specimen trap following standard-of-care delivery of ciprofloxacin 0.3% and dexamethasone 0.1% suspension. Samples will be analyzed to measure antibiotic concentration in the middle ear fluid.
224047325|NCT02465983|DRUG|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
224047326|NCT04741386|BIOLOGICAL|SARS-CoV-2 vaccination|All participants will receive two vaccinations against COVID-19 according to the manufacturer's instructions.
224142578|NCT03803592|BEHAVIORAL|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
224142579|NCT04121520|OTHER|Questionnaire|"1. Comprehensive perioperative assessment~2. Questionnaire administration"
224142580|NCT00456794|DRUG|Istradefylline (KW-6002)|
224142581|NCT05812937|PROCEDURE|Intraabdominal ultrasound|To assess the diagnostic value of the intraoperative intrabaabdominal ultrasound (IIUS) for endometriosis patients as well as the predictive potential of changing the therapeutic strategy during the surgery based on the ultrasound findings.
224299930|NCT06632561|DRUG|Placebo|Sugar pills one tablet daily for 6 months
223436180|NCT00464555|PROCEDURE|Islet transplant|Transplantation of pancreatic islet cells
223436181|NCT00464555|DRUG|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
223436182|NCT00464555|DRUG|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
223566161|NCT01223885|DIETARY_SUPPLEMENT|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
223566162|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
224047327|NCT06074991|OTHER|musıc therapy|Music therapy was applied to the patients in the experimental group with the help of mp3 and headphones for 30 minutes in a position where they felt comfortable. Hüseyni makam was used for music therapy.
224047328|NCT03528278|BEHAVIORAL|Motivational interviewing and environmental interventions|"* Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~* Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~* Training equipment~* Motivational Interviewing (MI) techniques applied by staff~* Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
224047329|NCT02114775|DRUG|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
224047330|NCT02114775|DRUG|Sildenafil|50 mg by mouth daily
224047331|NCT02114775|DRUG|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
224142582|NCT02174783|OTHER|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
224142583|NCT02174783|OTHER|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
224142584|NCT02174783|OTHER|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
224142585|NCT03213483|PROCEDURE|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
224142586|NCT03213483|PROCEDURE|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
224142587|NCT05082298|BEHAVIORAL|Dental FearLess app|Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
223436183|NCT00464555|DRUG|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
223436184|NCT00464555|DRUG|Sirolimus|Maintenance immunosuppressive therapy
223436185|NCT00464555|DRUG|Tacrolimus|Maintenance immunosuppressive therapy
223436186|NCT01004458|BEHAVIORAL|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
223566163|NCT00644904|DIETARY_SUPPLEMENT|Vitamin D3|
223566164|NCT02645643|OTHER|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
223566165|NCT03658200|OTHER|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
224047332|NCT03767036|DRUG|Tramadol hydrochloride 25 mg capsule|Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
223436187|NCT01004458|OTHER|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
223436188|NCT04408508|DRUG|Amoxicillin 250 MG|Low dose oral amoxicillin will be administered to patients enrolled in the study meeting the inclusion and exclusion criteria.
223436189|NCT00337779|DRUG|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
224047333|NCT03767036|DRUG|Ketorolac Tromethamine 10 mg tablet|Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
224047334|NCT02000596|DRUG|Trastuzumab plus Pertuzumab|
224047335|NCT02000596|DRUG|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
224047336|NCT02000596|DRUG|Chemotherapy with Eribulin|
224047337|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via auto-injector (AI)
224047338|NCT05617183|BIOLOGICAL|CT-P47|CT-P47, 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
224047339|NCT02960178|BEHAVIORAL|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
224047340|NCT02960178|BEHAVIORAL|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
224047341|NCT01764971|OTHER|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
223436190|NCT00337779|DRUG|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
223436191|NCT01512459|DRUG|Venlafaxine|Venlafaxine MR Capsules 150 mg
223436192|NCT01544192|DRUG|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
224047342|NCT01764971|OTHER|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
223436193|NCT01544192|DRUG|α-tocopherol|2x300 mg α-tocopherol
223436194|NCT01544192|DRUG|Placebo|control group did not receive oral neuroprotective agent
223436195|NCT01544192|DRUG|Antioxidant formula|2x1 tablet AOF
223436196|NCT03932929|DEVICE|Scotchbond Universal Adhesive (3M ESPE)|Adhesive system
223436197|NCT03008278|DRUG|Olaparib|Give PO
223436198|NCT03008278|BIOLOGICAL|Ramucirumab|Given IV
223436199|NCT01126866|DRUG|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
223436200|NCT00819572|BIOLOGICAL|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
223436201|NCT00819572|DRUG|Placebo|
224047343|NCT03662672|PROCEDURE|Rib raising and lumbar release|Rib raising per protocol described in arm description.
224047344|NCT03662672|PROCEDURE|Sham procedure|Sham procedure per protocol described in arm description
224047345|NCT04634981|PROCEDURE|anesthesia of emergency cesarean section|compare General versus spinal anesthesia
224047346|NCT02419326|BEHAVIORAL|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
224047347|NCT02530372|DEVICE|UriCap-F|non-invasive urine collection device for women
224047348|NCT01971983|OTHER|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
224047349|NCT01971983|OTHER|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
223436202|NCT00513357|DRUG|Melatonin|20 mg by mouth daily for 4 Weeks
224047350|NCT01971983|OTHER|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
223436203|NCT00513357|DRUG|Placebo|Capsule by mouth daily for 4 Weeks
223436204|NCT02897167|GENETIC|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
223436205|NCT02897167|GENETIC|Prospective study of fresh samples|Samples of serum and cells will be drawn.
223436206|NCT01162122|BIOLOGICAL|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
223436207|NCT01162122|BIOLOGICAL|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
223436208|NCT00088816|DRUG|cisplatin|
223436209|NCT00088816|DRUG|tegafur-gimeracil-oteracil potassium|
223436210|NCT00088816|PROCEDURE|adjuvant therapy|
223436211|NCT00088816|PROCEDURE|conventional surgery|
223436212|NCT00088816|PROCEDURE|neoadjuvant therapy|
223436213|NCT02262416|DRUG|leuprolide|normal saline
223436214|NCT01001806|DRUG|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
223436215|NCT01001806|DRUG|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
223436216|NCT01001806|DRUG|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
223436217|NCT04460131|DIAGNOSTIC_TEST|soluble ST2|Serum sST2 was measured on a monoclonal electrochemiluminescence immunoassay. Samples were exposed to two freeze cycles before analysed. Samples were exposed to two thawfreeze cycles before analysed.
223436218|NCT00753844|BIOLOGICAL|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
223566166|NCT03658200|OTHER|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
224047351|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
224047352|NCT01565044|OTHER|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
224047353|NCT03405805|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
224047354|NCT02276664|BEHAVIORAL|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
224047355|NCT02276664|BEHAVIORAL|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
224047356|NCT03294226|DEVICE|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
224047357|NCT03294226|DEVICE|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
224047358|NCT01587378|DRUG|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
224047359|NCT01587378|DRUG|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
223436219|NCT05282589|OTHER|lumbopelvic manipulation and conventional therapy|"Lumbopelvic manipulation was given along with conventional physical therapy~Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
223436220|NCT05282589|OTHER|conventional therapy|"Transcutaneous Electrical Nerve Stimulation was applies for 15 minutes. 3 alternate days per week.~Static stretching exercises for targeted muscles Erector spinae, hamstrings and calfs) - 4 repetations X 2 sets with 30 seconds hold and 1 minute of resting interval. On 03 alternate days per week.~Strengthening exercises for traverses abdomminis and lumber multipedus muscles - 15 repetitions X 3 sets. On 03 alternate days per week.~Total 12 session were given, each consisting of 45 minutes."
224047360|NCT03029741|DRUG|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
224047361|NCT03029741|DRUG|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg \[14C\]AZD0284 solution
224047362|NCT05948007|DEVICE|Neurofeedback training|12 training sessions within 6 weeks will be provided. In each training session, participants will have neurofeedback training for five 3-minute training periods.
224047363|NCT05948007|DEVICE|Sham-neurofeedback training|The Sham group has the same training dosage as the neurofeedback group.
224047364|NCT05948007|BEHAVIORAL|Pain management protocol|The treatment components include sleep psychoeducation, sleep hygiene education, exercise consultation, and cognitive-behavioral pain management, i.e., practice in changing dysfunctional thoughts, setting and working toward behavioral goals, relaxation skills
224142588|NCT05082298|BEHAVIORAL|In-Chair Treatment Protocol|This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
224142589|NCT02501902|DRUG|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
224142590|NCT02501902|DRUG|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
224142591|NCT05852730|DRUG|DPI-386 Nasal Gel|Subjects will self-administer DPI-386 Nasal Gel
224142592|NCT05852730|DRUG|Other (e.g., promethazine, meclizine)|Subjects will self-administer other medications as available.
223436221|NCT00546494|DRUG|Effexor® (Venlafaxine)|
223436222|NCT00422422|DRUG|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5"
223436223|NCT02928601|DRUG|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
223436224|NCT02928601|DRUG|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
223436225|NCT06073756|RADIATION|Echocardiogram|Evaluate PLR and NLR and their assiotation to vascular complications and glycemic control in type 2 DM
223436226|NCT05721183|BEHAVIORAL|NOST|"The intervention is to implement NOST, which includes:~observation and recording of compliance with hand hygiene recommendations identification of areas for improvement training or other actions taken to improve IPC in general or compliance with hand hygiene.~Thus, the intervention includes both observation of compliance and any additional improvement measures initiated as a result of the introduced NOST.~When the intervention group has implemented and followed NOST for a year, the investigators will measure compliance with hand hygiene recommendations and reported HAIs, in wards that have had NOST and in wards that have not introduced NOST.~The intervention arm will be followed over time with repeated measurements of both compliance with hand hygiene and other outcome measures, to see if the effect increases in line with implemented observations and quality improvement measures, or if the effect decreases during the study period."
223436227|NCT00019630|DRUG|doxorubicin HCl liposome|
223436228|NCT01529294|DRUG|Iloperidone|
224047365|NCT01651104|BIOLOGICAL|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
224047366|NCT02794818|BEHAVIORAL|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
224299931|NCT05368311|OTHER|Dietary recommendations including protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations and 2 protein enriched bars per day to be eaten 45 minutes before lunch and dinner.
224299932|NCT05368311|OTHER|Dietary recommendations without protein enriched bars|Volunteers allocated in the experimental group will receive dietary recommendations.
224299933|NCT02390687|DRUG|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
224299934|NCT02390687|DRUG|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
224047367|NCT03453073|BEHAVIORAL|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
224047368|NCT03453073|OTHER|physician diagnosis of first occurrence of serious chronic disease|
224142593|NCT04771026|DRUG|Dexamethasone|Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
224299935|NCT02885597|DRUG|Juanbi pill|4g, twice a day, 3month, oral
224299936|NCT02885597|DRUG|Juanbi pill placebo|4g, twice a day, 3month, oral
224299937|NCT02885597|DRUG|Methotrexate|5mg, once a week, 3 month, oral
224299938|NCT01250197|DRUG|AR-12286|Ophthalmic Solution
224299939|NCT04106167|GENETIC|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
223436229|NCT06311526|OTHER|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy administered to the belly of spastic muscles of the upper limb.
223436230|NCT04535128|OTHER|No intervention|No intervention
223436231|NCT02454868|DRUG|Remifentanil|Remifentanil for intubation without neuromuscular blockade
223436232|NCT01527708|PROCEDURE|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
223436233|NCT03313310|BEHAVIORAL|Employment Intervention|Participants will complete 4 workshop sessions in groups of 6-12. The workshop curriculum was based on the pre-existing iFOUR program, and tailored based on feedback from a Community Advisory Board (CAB), Focus Groups, and In Depth Interviews.
223436234|NCT05187559|OTHER|Standard physiotherapy|Neuromuscular exercise program with standard physiotherapy with no visual feedback
223436235|NCT05187559|DEVICE|Biodex Balance SD and Biodex Gait Trainer|Neuromuscular exercise program with physiotherapy with visual feedback using Biodex platform
223436236|NCT01756508|DRUG|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
223436237|NCT00898495|GENETIC|loss of heterozygosity analysis|
223436238|NCT00898495|GENETIC|polymerase chain reaction|
223436239|NCT00898495|GENETIC|polymorphism analysis|
223436240|NCT01217385|PROCEDURE|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
223436241|NCT00090987|DRUG|imatinib mesylate|400 mg orally once a day for up to 6 months.
223436242|NCT04053985|COMBINATION_PRODUCT|TAI combine lenvatinib|TAI combine lenvatinib
223436243|NCT04053985|DRUG|Lenvatinib|lenvatinib only
223436244|NCT05213026|PROCEDURE|Regenerative endodontics|Regenerative endodontic procedure with 3 Mix-MP
223436245|NCT03825185|PROCEDURE|Transcervical Thymectomy|Transcervical Thymectomy. All transcervical thymectomies were performed with an 8 cm transversal cervicotomy was performed approximately 2 cm above the sternal notch. Musculocutaneous flaps were developed up to the thyroid cartilage and the suprasternal notch. Strap muscles were split in the middle and retracted laterally. The upper horns of the thymus were exposed and were freed up to the level of the innominate vein. All tributary veins were suture ligated. A sternal retractor was then placed to retract the sternum upward until the patient was nearly lifted off the table. The rest of the Thymus was dissected, from the pericardium and the pleura. Care was specially taken to remove as much fatty tissue adjacent to the thymus as possible preserving the phrenic nerves.
223436246|NCT03825185|PROCEDURE|Transsternal Thymectomy|Transsternal Thymectomy. A standard formal median sternotomy was carried out. The sternum was retracted laterally using an automatic retractor. All thymic tissue with the adjacent adipose tissue was removed starting with the inferior horns of the thymus. Thymic vessels were ligated and dissection was continued until the upper horns could be separated from the thyroid. A mediastinal tube was placed before closing the sternum and was kept in close suction for 2 to 3 days.
223436247|NCT00757185|DRUG|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
223436248|NCT00757185|DRUG|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
223436249|NCT03370523|OTHER|No intervention is planned in our study|No intervention is planned in our study
223436250|NCT03290547|DEVICE|Cutera enLighten laser|Subjects will receive laser treatments.
223436251|NCT03463707|DRUG|BP101|Investigational product BP101, nasal spray
223436252|NCT03463707|DRUG|Placebo|Placebo to Investigational product BP101, nasal spray
223566167|NCT06032104|DIETARY_SUPPLEMENT|Dry beans|0.5 cup of Bush's Best Cannellini Beans, three times per day before meals blended into a smoothie. If interested and depending on tolerance, participants will also have the opportunity to gradually increase the bean smoothie to a maximum of 1 cup three times per day before meals during the last week of the two-week bean smoothie intervention. If patient cannot not tolerate 1.5 cup of canned cannellini bean, we will reduce per tolerance or offer the option of choosing a bean-based flour (100 gram/day, 23% fiber from Archer Daniels Midland)
224299940|NCT06104995|OTHER|Interventional video|The educational video comprises of health care professionals explaining the durability of the back against the popular belief that the back is fragile and the multifactorial nature of back pain.
224299941|NCT06104995|OTHER|Control video|The control video is a neutral video with no content addressing back beliefs (fragility and need for protection).
223436253|NCT03545646|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
223436254|NCT02079636|DRUG|Abemaciclib|Administered orally
223436255|NCT02079636|DRUG|Pemetrexed|Administered IV
223436256|NCT02079636|DRUG|Gemcitabine|Administered IV
223436257|NCT02079636|DRUG|Ramucirumab|Administered IV
223436258|NCT02079636|DRUG|LY3023414|Administered orally
223436259|NCT02079636|DRUG|Pembrolizumab|Administered IV
224299942|NCT05910476|DRUG|a high dose of statin/ezetimib|"In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation."
223436260|NCT02437032|DRUG|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
223436261|NCT02437032|DRUG|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
223436262|NCT02437032|DRUG|hMG|Controlled ovarian stimulation with 150-300 UI hMG
223566168|NCT06032104|DIETARY_SUPPLEMENT|Usual diet|Usual diet without adding the bean smoothie
223436263|NCT05309473|DEVICE|Philips SmartSleep Acoustic Stimulation Device|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.
223436264|NCT05309473|DEVICE|Sham (no Acoustic Stimulation)|Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
223436265|NCT01058759|DRUG|Enoxaparin|
223436266|NCT01058759|OTHER|No Enoxaparin|
223436267|NCT05715047|BEHAVIORAL|CBT for Fatigue|10, individualized counseling sessions with a behavioral health counselor via Zoom platform.
223436268|NCT05715047|BEHAVIORAL|Usual Care|Standard transplant care.
223436269|NCT00725101|DRUG|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
223436270|NCT05583500|OTHER|Experimental: Single group: excentric exercise protocol|Excentric exercise protocol will be performed for all subjets, consisted of 10 sets of 20 repetitions of squats, jumping from a height of 50 cm
223436271|NCT05582369|BEHAVIORAL|Affective Rewards Messages|Messages about the affective rewards of exercise
223436272|NCT04939753|DRUG|Sevoflurane|Sevoflurane administration to sedate the patient
223566169|NCT00453037|BEHAVIORAL|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
224047369|NCT01421927|DRUG|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~\- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia \< 75000/mm3 or neutropenia \< 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~\- Duration~* until persistent stringent complete response for 3 months~* or progression defined by IMWG criteria12~* or unacceptable toxicity~* or one year after transplant"
224047370|NCT02718599|DRUG|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
224299943|NCT01510548|BIOLOGICAL|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
223566170|NCT00453037|BEHAVIORAL|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
224047371|NCT02718599|DRUG|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
224047372|NCT02614391|OTHER|Active distraction using a tablet|Playing a videogame using a computer tablet
224047373|NCT02614391|OTHER|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
224047374|NCT06171620|DEVICE|Virtual reality headset|Distraction therapy using a virtual reality headset. Participants will access a digitally created environment such as a forest or sub sea exploration with relaxing auditory cues.
223436273|NCT01686698|DIETARY_SUPPLEMENT|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
223436274|NCT01686698|OTHER|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
223436275|NCT05572177|DEVICE|Asthma SMART|The intervention is a smartphone application to improve self-management of asthma designed to appeal to adolescents. The app integrates four components to facilitate asthma self-management: 1) self-monitoring of peak-flow and symptoms; 2) graphical health user interfaces with avatars, infographics, and rewards; 3) interactive educational materials; and 4) patient-provider interactions.
223436276|NCT04403659|DEVICE|Telemedicine/telemonitoring (TM) suite|"The couples patient/caregiver will receive and trained to use a suite of TM instruments including: sphygmomanometer, pulse oximeter, weight scale, thermometer, glucometer, electrocardiograph. During the intervention phase (i.e. from allocation to exit from the study), the caregiver/patient will be asked to measure twice daily, at prespecified times, the following parameters using TM devices: arterial blood pressure, peripheral arterial haemoglobin saturation, tympanic temperature. Body weight will be evaluated once daily.~The TM glucometer and TM electrocardiograph will be used exclusively by healthcare staff in case of patients in need of capillary blood glucose testing and according to clinical needs, respectively. All data will be automatically sent to a central interface and made readily available to physicians and nurses, to enable a prompt clinical response. In case of malfunctioning, a technical support will be ensured."
223436277|NCT03866733|OTHER|continous erector spinea block|Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
223566171|NCT05749510|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
223566172|NCT02743949|DRUG|Vonoprazan|Vonoprazan over-encapsulated capsules
223566173|NCT02743949|DRUG|Esomeprazole|Esomeprazole over-encapsulated tablets
223566174|NCT02743949|DRUG|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
223566175|NCT01404793|DRUG|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
223566176|NCT03549208|BIOLOGICAL|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
224047375|NCT06171620|OTHER|Standard of care|Elective procedure performed as planned according to current standard of care in the hospital.
223436278|NCT03866733|DRUG|intravenous narcotics|intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
223436279|NCT04134520|DEVICE|ProLung System|Non-invasive bioconductance measurements
223436280|NCT03564080|OTHER|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
223436281|NCT01592292|DRUG|Rituximab|Rituximab as per physician's discretion.
223436282|NCT01592292|DRUG|Adalimumab|Adalimumab as per physician's discretion.
223436283|NCT01592292|DRUG|Etanercept|Etanercept as per physician's discretion.
223436284|NCT01592292|DRUG|Infliximab|Infliximab as per physician's discretion.
223436285|NCT02598011|BIOLOGICAL|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
223436286|NCT02598011|DRUG|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
223436287|NCT00670605|OTHER|medical chart review|
223436288|NCT00670605|OTHER|study of socioeconomic and demographic variables|
223436289|NCT03528564|DRUG|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
223436290|NCT03528564|DRUG|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
223566177|NCT03549208|BIOLOGICAL|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
224047376|NCT06417320|DRUG|ACEI, SGLT-2i|"Group 1 (ACEI group) will receive a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg) /kg/ day)~❖ Group 2 (combined ACEI and SGLT-2inhibitrs group) patients on a single dose of oral ACE inhibitors tablets per day (0.2-0.6mg /kg/ day) presenting with persistent nephrotic range proteinuria will add a single dose of oral SGLT-2 inhibitors tablets 5mg per day (weight≤30kg) or 10mg per day (weight \>30kg)"
224047377|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
224047378|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
224047379|NCT02005991|DRUG|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
224142594|NCT04016688|PROCEDURE|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
224142595|NCT00103571|DRUG|Olanzapine|
224142596|NCT00103571|DRUG|Aripiprazole|
224142597|NCT02513771|DRUG|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
223436291|NCT03528564|DRUG|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
223436292|NCT02501083|OTHER|no intervention|The study will not include any intervention.
223436293|NCT06604767|BIOLOGICAL|parainfluenza virus type 3 vaccine (PIV3)|Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
223436294|NCT06604767|BIOLOGICAL|RSV/hMPV/PIV3 vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
223566178|NCT03549208|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
224047380|NCT02982590|DRUG|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
224047381|NCT02982590|DRUG|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
224142598|NCT02513771|DRUG|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
224142599|NCT02770118|BEHAVIORAL|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
223436295|NCT06604767|BIOLOGICAL|RSV/hMPV vaccine|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
223436296|NCT06604767|BIOLOGICAL|RSV vaccine 1|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
223436297|NCT06604767|BIOLOGICAL|RSV vaccine 2|Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
223436298|NCT06592768|DRUG|Briquilimab|Subcutaneous Administration
223436299|NCT06592768|OTHER|Placebo Comparator|Subcutaneous Administration
223436300|NCT06668922|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
223436301|NCT00877955|DRUG|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
223436302|NCT00877955|DRUG|alprazolam sublingual tablet test|0.5 mg tablet, single dose
223436303|NCT01521156|OTHER|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
223566179|NCT01611363|DRUG|ASP1941|Oral
223566180|NCT01611363|DRUG|Placebo|Oral
223436304|NCT01521156|OTHER|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
223436305|NCT04173728|OTHER|Standard mixed macronutrients tolerance test|Consumption a standard mixture containing 75g glucose, 60g fat and 20 protein.
223436306|NCT00189852|DEVICE|Chronic heart failure monitoring system|
223436307|NCT00189852|DEVICE|Lifestyle monitoring system|
223436308|NCT04582500|DRUG|Iohexol|Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.
223436309|NCT03751800|DRUG|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
223436310|NCT03964506|DRUG|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
223436311|NCT02106416|PROCEDURE|PET/MRI|Simultaneous PET/MRI (3T system)
223740685|NCT04245423|BEHAVIORAL|Collaborative Care for Opioid Use Disorders and Mental Health Conditions|CC is delivered using the investigators' Foundations for Integrated Care model. The first line pharmacotherapy is buprenorphine-naloxone. The second line pharmacotherapy included is extended-release injectable naltrexone. Pharmacotherapy is accompanied by brief problem-solving therapy, cognitive-behavioral therapy, and/or motivational interviewing. The primary care physician, in consultation with the addictions psychiatrist and care manager, also will provide psychotropic medications for psychiatric disorders. In-person and telephone visits consist of the care manager carrying out intervention activities over 6 months. Visits are at baseline (90-minute intake appointment), home or office induction when in moderate opiate withdrawal if buprenorphine is prescribed, twice a week for two weeks with telephone calls in between visits, then weekly, and when stable once a month. There will be a final visit at 6 months. The intervention includes routine collection of urine drug screens.
224047382|NCT04533282|DIAGNOSTIC_TEST|Blood samples.|Peripheral blood samples (TEMPUS(TM) whole blood samples, EDTA plasma and heparin plasma, total volume 40ml) taken during (1) initial hospitalisation and (2) three month follow-up visit after hospital stay (follow-up samples are not taken from coronary CT healthy control patients).
224047383|NCT04533282|DIAGNOSTIC_TEST|Collection of right atrial appendage tissue sample.|Collection of the clinically insignificant small piece of heart's right atrial appendage tissue during either standard cannulation of the right atrium for the installation of the heart-lung machine in the beginning of the operation or additionally for routine surgical protocol.
224142600|NCT02770118|BEHAVIORAL|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
223436316|NCT01018381|PROCEDURE|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
223436317|NCT01018381|PROCEDURE|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
223436318|NCT01018381|PROCEDURE|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
223436319|NCT01018381|PROCEDURE|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
223436320|NCT01018381|DIETARY_SUPPLEMENT|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
223436321|NCT01018381|DRUG|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
223436322|NCT07012291|DEVICE|Whole Blood Clotting Time|"Fresh whole blood samples from patients on rivaroxaban or apixaban taken at various times during the day to obtain samples from DOAC patients that represent the entire analytical range to the extent possible, as opposed to a strict trough/peak testing schedule."
223436323|NCT07012291|DEVICE|Whole Blood Clotting Time|Fresh whole blood samples, non-citrated, are drawn and loaded onto a cuvette free of any biological reagents, to obtain a whole blood clotting time value.
223436324|NCT07021248|DIETARY_SUPPLEMENT|Elan Believe|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Believe for SG addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
223436325|NCT07021248|DIETARY_SUPPLEMENT|Elan Compass|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Compass for RYGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
224142601|NCT02770118|BEHAVIORAL|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
223436326|NCT07021248|DIETARY_SUPPLEMENT|Elan Supreme|Participants will receive a specialized Elan bariatric supplement matched to the type of MBS they undergo. Elan Supreme for OAGB addresses the distinct micronutrient absorption profiles and physiological alterations associated with this surgical procedure. Importantly, all formulations contain a standardized dose of vitamin B6 of 400 micrograms, facilitating valid comparisons of postoperative B6 levels across procedures.
224142602|NCT01797445|DRUG|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
223436327|NCT05497960|BEHAVIORAL|Vivo workout|2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
223436328|NCT07021170|DIETARY_SUPPLEMENT|Elan Believe|Elan Believe is formulated specifically for patients undergoing SG and contains 18 mg of elemental zinc.
223436329|NCT07021170|DIETARY_SUPPLEMENT|Elan Compass|Elan Compass is tailored for RYGB and contains 24 mg of zinc.
223436330|NCT07021170|DIETARY_SUPPLEMENT|Elan Supreme|Designed for OAGB, provides 36 mg of zinc.
223436331|NCT07021170|DIETARY_SUPPLEMENT|Standard Multivitamins|Over-the-counter multivitamin containing 100% of the recommended daily allowance (RDA) for essential vitamins and minerals. Unlike the specialized formulations, the standard multivitamin is not designed to accommodate the altered gastrointestinal absorption characteristics of post-MBS patients.
223436332|NCT04148287|DRUG|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
223436333|NCT05439616|DRUG|Cariprazine|Oral Capsules or Oral Solution
223436334|NCT05439616|DRUG|Placebo|Oral capsules or Oral Solution
223436335|NCT06596577|BEHAVIORAL|Palliative care needs information|clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs
223436336|NCT06596577|BEHAVIORAL|Default consult order|clinician-directed EHR alert providing information about serious illness diagnosis(-es) and unmet palliative care needs + a choice to cancel the default palliative care consult order
223740686|NCT04245423|BEHAVIORAL|Augmented Usual Care|If not already waivered, PCPs will be trained and waivered to treat OUD with medications. All practices will have mental health clinicians to treat mild psychiatric disorders. Other than that, the research team will provide no support to the PCP or practice staff. However, an addiction psychiatrist is available for consultation for OUD.
224142603|NCT01797445|DRUG|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
223436345|NCT06694688|DIAGNOSTIC_TEST|the supine/standing postural change test|The prevalence of orthostatic hypotension will be characterized by the percentage of patients with a decrease of ≥ 20mmHg in systolic blood pressure or ≥ 10mmHg in diastolic blood pressure following the supine/standing postural change position.
224142604|NCT01797445|DRUG|E/C/F/TDF Placebo|Tablet administered orally once daily
224142605|NCT01797445|DRUG|E/C/F/TAF Placebo|Tablet administered orally once daily
224142606|NCT03908905|DIAGNOSTIC_TEST|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
224142607|NCT06306326|DIAGNOSTIC_TEST|3dMD technology|By taking photos using 3dMD, we obtained preoperative, immediate postoperative, and long-term postoperative three-dimensional data of patients. The software automatically fused the data to obtain the volume difference of facial volume at different time points, and then divided it to obtain the objective data of facial volume improvement rate. To improve the reliability of the measurements, two researchers measured independently and took the average value.
224142608|NCT02397590|DRUG|Fimasartan|
224142609|NCT02397590|DRUG|Atorvastatin|
223436346|NCT06631768|OTHER|Casual labor subsidy|Eligible participants will be offered a voucher that can be redeemed for a set number of days of agricultural labor from casual laborers hired by local One Acre Fund offices. Casual laborers receive standard training in line with the trainings currently offered by the organization to participating farmers.
223436347|NCT06685965|DRUG|RE03|Buccal Dexmedetomidine
223436348|NCT06685965|DRUG|Placebo|Matching Placebo
223436349|NCT06492486|RADIATION|Adaptive radiotherapy|Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.
223436350|NCT03164265|BIOLOGICAL|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
223436351|NCT06874335|DRUG|BHV-1530|BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle
224142610|NCT06200285|OTHER|Registry of patients with accidental hypothermia|
223436352|NCT07027735|OTHER|Rotator Cuff Repair with Allograft Patch|Rotator cuff repairs will be augmented with use of a decellularized human placental allograft patch
223436353|NCT07027735|OTHER|Rotator Cuff Repair with No Augmentation|Standard rotator cuff repair with no augmentation
223436354|NCT06702332|DRUG|MSD-001|MSD-001 is being developed as part of future two-agent combination treatment approaches for the management of mental health indications
223436355|NCT06702332|DRUG|Placebo Comparator|Matching Placebo
223436356|NCT06702592|BEHAVIORAL|Virtual support|Subjects will use a virtual support platform that was built for their needs.
223436357|NCT06702592|BEHAVIORAL|Patient educational material|Participants will have access to patient educational material.
223436358|NCT02144207|DEVICE|Glidescope|
223436359|NCT06704295|BEHAVIORAL|Control ad with dark gray product with tobacco flavor name|The e-cigarette ad with a dark gray product with a tobacco flavor name
223436360|NCT06704295|BEHAVIORAL|Dark gray product with strawberry flavor name|The e-cigarette ad with a dark gray product with a strawberry flavor name
223436361|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor name|The e-cigarette ad with a colorful (strawberry color) product with strawberry flavor name
223436362|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor name and image|The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name and strawberry image
223436363|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor features|The e-cigarette advertisement with colorful (strawberry color) product with strawberry flavor name, strawberry image, and strawberry flavor sensation descriptor
223436364|NCT06704295|BEHAVIORAL|Colorful (strawberry color) product with strawberry flavor features and choice claim|The e-cigarette ad with colorful (strawberry color) product with strawberry flavor name, strawberry image, strawberry flavor sensation descriptor, and flavor choice claim
223566181|NCT03854526|OTHER|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis are registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
223566182|NCT03389555|DRUG|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
223566183|NCT03389555|DRUG|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
223566184|NCT00920218|BIOLOGICAL|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
224047384|NCT04533282|DIAGNOSTIC_TEST|Health Survey, Clinical symptom scaling|Patients in the study CABG and AVR cohorts are invited to both pre- and postoperative (3-month time-point), and in the case of PCI cohort only to postoperative, appointments led by experienced clinical cardiologists. The appointments will include clinical anamnesis, status and assessment of morbidity level with combined use of Canadian Cardiovascular Society grading of Angina Pectoris (CCS), New York Heart Association Classification for Heart Failure (NYHA) classification systems and Short Form 36 (SF36) Health Survey. The CT imaging control cohort is not invited to these appointments.
224047385|NCT04533282|DIAGNOSTIC_TEST|Transthoracic echocardiography (TTE)|In order to acquire comprehensive insight into the patients' functional heart status, all appointments are supplemented with echocardiographic evaluation for both functional as well as structural parameters. Detailed echocardiographic analysis criteria for the IHD-EPITRAN study are prespecified in the research plan.
224047386|NCT03340649|OTHER|taking peripheral blood|taking peripheral blood of no more than 3ml
224047387|NCT02744300|BEHAVIORAL|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
224047388|NCT00350584|BEHAVIORAL|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
224142611|NCT01022385|DIETARY_SUPPLEMENT|24-hour low-residual diet|
224047389|NCT00350584|BEHAVIORAL|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
224047390|NCT01168973|BIOLOGICAL|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
224047391|NCT01168973|DRUG|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
224142612|NCT04745312|DEVICE|Visible light|Ambient room lighting will be supplemented with additional light from a task lamp.
224142613|NCT01595438|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
224142614|NCT01595438|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
224142615|NCT01595438|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
224299944|NCT04478630|OTHER|Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract|Inhaled Aromatherapy via a pocket sized diffuser which contains one of the following:Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract (placebo-control).
224299945|NCT03547700|DRUG|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
224299946|NCT03547700|DRUG|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
224047392|NCT01168973|DRUG|Docetaxel|75 milligrams per square meter (mg/m\^2) (60 mg/m\^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
224142616|NCT01595438|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
224142617|NCT00650091|DRUG|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
224142618|NCT00650091|DRUG|Placebo|Participants will receive placebo each day.
224299947|NCT03487952|OTHER|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
224299948|NCT04540354|DRUG|Optimal Medical Therapy (OMT)|Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
223566185|NCT00920218|BIOLOGICAL|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
223566186|NCT01007435|DRUG|Tocilizumab|Tocilizumab was supplied in vials.
223566187|NCT01007435|DRUG|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
223436365|NCT06709391|PROCEDURE|Fusion surgery|"After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to fusion (active treatment):~Pedicle screws are placed. Interbody cages may be used. Fluoroscopy or intraoperative computed tomography with or without intraoperative navigation is performed for correct implant positioning. Decortication is performed in the surgical area, and the cartilage in the facet joints is partially removed to allow fusion. Local bone graft is used and placed in the surgical area. Rods are placed in the screws and the fixation system is locked. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue, and skin is sutured."
223436366|NCT06709391|PROCEDURE|Non-fusion surgery|"After anaesthesia, the surgical area is identified through intraoperative fluoroscopy. After sterile draping, incision is made through skin and subcutaneous fat. Dissection is performed bilaterally down to the facet joints and transverse processes. Intraoperative fluoroscopy or computed tomography is performed to verify the surgical level. When the dissection is complete, randomization takes place.~Randomization to non-fusion surgery (control):~No implants are placed. No decortication is performed. The facet joints are left intact. Local anaesthesia is given in the surgical area. Fascia, subcutaneous tissue and skin is sutured."
224047393|NCT06021899|OTHER|modified constraint induced movement therapy|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
224047394|NCT05902377|DIAGNOSTIC_TEST|68Ga-NY104 PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-NY104 The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-NY104 administration."
224047395|NCT02230254|DEVICE|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
224047396|NCT05291442|OTHER|To integrate Family System Care and Theme Care Action Module|"First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance."
224047397|NCT02023242|DEVICE|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
224047398|NCT02023242|DEVICE|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
224047399|NCT04512053|DRUG|TAS-303 18 mg/day|Oral administration for 12 weeks, once daily
224047400|NCT04512053|DRUG|Placebo|Oral administration for 12 weeks, once daily
224047401|NCT03805997|DEVICE|Dietary advice|participants will benefit of dietary device 30-minute dietary advice carried out by a doctor at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
224047402|NCT03805997|OTHER|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
224047403|NCT03805997|OTHER|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
224299949|NCT04540354|DEVICE|Implantable cardioverter-defibrillator (ICD)|"An ICD consists of an electronic medical device and electrode leads. The surgery can be performed in local anaesthesia, but a short general anaesthesia is required if the ICD has to be tested giving the patient an electric shock. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing).~The subcutaneous defibrillator is an established and valid alternative to the conventional ICD for the preven-tion of SCD. According to current guidelines, the subcutaneous defibrillator should be considered as an alternative to transvenous defibrillators in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronisation or antitachycardia pacing is not needed."
224299950|NCT01546935|DRUG|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
224047404|NCT03805997|BIOLOGICAL|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
224047405|NCT03805997|OTHER|Contact|Participants of the group A will be contacted by phone,sms, mail by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
224047406|NCT03805997|OTHER|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
224047407|NCT03805997|OTHER|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
224047408|NCT03805997|OTHER|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
224070589|NCT06412497|RADIATION|Total Body Irradiation|"For patients age \>/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1.~Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus."
224070590|NCT06412497|BIOLOGICAL|Cell Infusion|On day 0 the cells will be infused per cell source specific institutional guidelines.
224070591|NCT06412497|DRUG|Post-Transplant G-CSF|Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.
224299951|NCT06055530|DIAGNOSTIC_TEST|Artificial Intelligence Digital Pathology|School aged children will be asked to leave a stool sample. The samples will be prepared with the Kato-Katz method and scanned and processed by an artificial intelligence digital pathology system to determine the infection level of soil transmitted helminths and schistosomiasis. The samples will also be analyzed by a human microscopist for comparison.
224299952|NCT02382055|BEHAVIORAL|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
224299953|NCT02382055|BEHAVIORAL|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
224299954|NCT02382055|BEHAVIORAL|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
223436367|NCT07136272|DEVICE|SSAM|Embedded software featuring neural-network classifiers designed to detect and classify sleep stages (N1/N2, N3, REM, Wake), autonomic arousals, and an Arousal Index based on data (specifically instantaneous pulse rate and full-resolution flow waveforms) collected during PAP therapy.
224047409|NCT02528370|DEVICE|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
224047410|NCT05689970|DIAGNOSTIC_TEST|AI platform to detect ST elevation in ECG|A clinical decision support software as a medical device that detects whether a patient has ST elevation due to acute myocardial ischemia or due to another etiology based upon the input of one or more ECGs and other clinical data obtained at the point-of-care.
224047411|NCT00979706|DRUG|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
224047412|NCT00979706|DRUG|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (\>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
224047413|NCT01434420|GENETIC|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
224047414|NCT01796587|DEVICE|LoFric Origo|
224047415|NCT04540146|DIAGNOSTIC_TEST|Flow-Cytometric analysis|IL-2, 4, 5, 6, 9, 10, 13, 17A, 17F, 22, IFN-γ and TNF-α levels in the intraabdominal ascites
224047416|NCT00069927|DRUG|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
224047417|NCT00069927|DRUG|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
224047418|NCT06354582|DRUG|Vitamin C Injection|Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.
224047419|NCT06354582|OTHER|Normal saline|The placebo comparator will receive normal saline with the same volume and be administered after the induction of epidural labor anesthesia.
224047420|NCT05326945|OTHER|Presence or Absence of a Blood Pressure Cuff Sheath|Monitoring of microorganism transfer from the sphygmomanometer to the patient, from the patient to the sphygmomanometer in case the sheath designed in the research is put on or not before the blood pressure measurement process
224047421|NCT05507775|DRUG|Digoxin tablet|"Participants will be treated with digoxin tablets for 3 weeks. On the first they, participants will start with a starting dosage of 3x0.25mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.25mg. Participants aged \>70 years or with body weight \<55kg will initiate a starting dosage of 3x0.125mg with 6 hours between each administration. Thereafter they will continue with a dosage of 1x0.125mg.~After one week the blood concentration of digoxin will be measured. According to this blood concentration, the dose of digoxin will be adjusted."
224047422|NCT02679014|DRUG|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
224047423|NCT02679014|DRUG|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
224047424|NCT03010124|PROCEDURE|Blood sample|
224047425|NCT02326454|DRUG|talaporfin sodium|1 mg/kg
224047426|NCT02326454|DRUG|Saline|
224047427|NCT02326454|DEVICE|Drug Activator 100 J/cm|Light Dose: 100 J/cm
224047428|NCT02326454|DEVICE|Drug Activator 200 J/cm|Light Dose: 200 J/cm
224047429|NCT03886753|OTHER|Registry|Collect data on subjects
224299955|NCT04120038|DEVICE|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 6-week tablet-based education program for individuals with LLA that will provide them with self-management education.
224299956|NCT03126357|OTHER|Product A|Usual Brand Cigarette
224299957|NCT03126357|OTHER|Product B|FT21039 an electronic tobacco vapor product
223436368|NCT07136272|DIAGNOSTIC_TEST|Polysomnography|Polysomnography (PSG) is an overnight, in-laboratory diagnostic procedure that records multiple physiological parameters during sleep. It typically includes monitoring of brain activity (EEG), eye movements (EOG), muscle activity (EMG), heart rhythm (ECG), respiratory effort, airflow, oxygen saturation, and body position. PSG is used to evaluate sleep architecture, identify sleep stages, detect arousals, and diagnose sleep disorders such as sleep apnea. The collected data are analyzed manually by trained sleep technologists following standardized scoring criteria.
224047430|NCT03886753|OTHER|PK microsampling of blood|Obtain 5 microsamples of blood from subjects via a fingerstick.
224047431|NCT02650999|DRUG|Pembrolizumab|200mg intravenously (IV)
224047432|NCT00388505|DRUG|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
224047433|NCT00388505|DRUG|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
224047434|NCT01414699|BEHAVIORAL|Variety|These conditions will have snack served with an increase of fruit variety.
224142619|NCT01003353|BEHAVIORAL|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
224142620|NCT02252575|DEVICE|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
224142621|NCT03128385|OTHER|Intensive CIT Model Program|"Day Camp Model:~1. The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
224142622|NCT03128385|OTHER|Distributed CIT Model Program|"Home-Based Model:~1. The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~2. constraint of the unaffected hand to encourage the use of the affected hand~3. massed and repetitive practice of the affected hand during the period of constraint~4. use of behavioral techniques termed shaping to train the affected hand"
224142623|NCT04072172|DEVICE|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
224299958|NCT03126357|OTHER|Product C|FT21092 an electronic tobacco vapor product
224299959|NCT03126357|OTHER|Product D|FT21018 an electronic tobacco vapor product
224299960|NCT03126357|OTHER|Product E|4mg nicotine gum
224299961|NCT02494934|BEHAVIORAL|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
224299962|NCT02494934|BEHAVIORAL|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
224299963|NCT04214717|COMBINATION_PRODUCT|DC-CIK combined with Chemotherapy|Patients will receive 4 cycles of DC-CIK treatments combined with Chemotherapy within 8 months.
224299964|NCT04214717|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
224299965|NCT03324321|OTHER|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
224299966|NCT05222542|OTHER|Sampling of plasma and cerebrospinal fluid at specified time points|Samples (plasma, and in patients with in-dwelling cerebrospinal fluid drainages also cerebrospinal fluid) will be taken within 72 hours of subarachnoid hemorrhage and 7, 14 and 21 days following initial bleeding. Another plasma sample will be obtained if an antihypertensive therapy with a RAS modifying drug has been started.
224299967|NCT02276079|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
224299968|NCT02276079|BEHAVIORAL|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
224299969|NCT05052242|DIAGNOSTIC_TEST|primary angle closure disease|2 swept source OCT biometers, IOL Master700 and Anterion
224299970|NCT00059787|DRUG|paclitaxel|Given IV
224299971|NCT00059787|DRUG|carboplatin|Given IV
224299972|NCT00059787|DRUG|erlotinib|Given PO
224299973|NCT00292188|DRUG|pregabalin|pregabalin
224299974|NCT00292188|DRUG|Placebo|placebo
224047435|NCT01414699|BEHAVIORAL|Non-Variety|These conditions will receive a snack without a variety of fruit.
224047436|NCT03195751|DEVICE|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
224142624|NCT01817647|PROCEDURE|Colorectal surgery|
224142625|NCT04689841|OTHER|Vojta Therapy|"Reflex locomotion is activated by the reflexogenic pathway. In context with reflex locomotion, the term reflex does not represent the mode of neuronal control, but rather refers to defined, automatic and always equal motor responses produced by external stimuli, applied therapeutically."
224299975|NCT02253836|DRUG|Tipranavir|TPV
224299976|NCT02253836|DRUG|Ritonavir|RTV
224299977|NCT02253836|DRUG|Atazanavir|TAZ
224047437|NCT03195751|DEVICE|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
224047438|NCT00094692|DEVICE|Eye patch|
224047439|NCT00094692|DEVICE|spectacles|
224047440|NCT00094692|DRUG|atropine|
224047441|NCT02251379|DRUG|Flovent Diskus|Inhaled corticosteroids
224047442|NCT02251379|OTHER|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
224047443|NCT02251379|DRUG|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
224047444|NCT05287971|BEHAVIORAL|Lifestyle advice|Patients will receive lifestyle advice regarding nutricion and exercise and will be monitored with regard to exercise and vital signs.
224047445|NCT01471314|BEHAVIORAL|Headache day versus non-headache day|
224142626|NCT04689841|OTHER|placebo|In the control group, a placebo intervention is administered, similar to an experimental intervention
224299978|NCT00010608|BEHAVIORAL|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
224299979|NCT00010608|BEHAVIORAL|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
224299980|NCT00824616|DRUG|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
224299981|NCT00824616|DRUG|Placebo|Placebo tablets, taken 3 times daily.
224299982|NCT00824616|DRUG|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
224299983|NCT00665938|OTHER|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
224299984|NCT04449757|DRUG|Bicarbonated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
224299985|NCT04449757|DRUG|Lactated Ringer's solution|Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
224299986|NCT00206492|DRUG|Iressa|Iressa
224299987|NCT00206492|DRUG|Tamoxifen|Tamoxifen
224299988|NCT01714375|DEVICE|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
224299989|NCT03762499|DIAGNOSTIC_TEST|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
224299990|NCT05476653|OTHER|MRI procedure|Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
224299991|NCT04322149|DRUG|AT-1501|AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
224299992|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment A)|Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.
224299993|NCT06645938|DRUG|single dose of vepdegestrant as tablet formulation (Treatment B)|Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
224299994|NCT03342599|DIETARY_SUPPLEMENT|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
224299995|NCT03342599|DIETARY_SUPPLEMENT|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
224299996|NCT02135653|RADIATION|Radiotherapy|
224047446|NCT05503784|OTHER|BITE Deodorant|BITE natural Deodorant
224047447|NCT00370227|BIOLOGICAL|10 valent pneumococcal conjugate (vaccine)|
224047448|NCT04854434|DRUG|Selinexor|Participants will receive selinexor oral tablets.
224047449|NCT04854434|DRUG|Pembrolizumab|Participants will receive pembrolizumab intravenously.
224047450|NCT04854434|DRUG|Trifluridine|Participants will receive trifluridine oral tablets as SOC.
224047451|NCT04854434|DRUG|Tipiracil|Participants will receive tipiracil oral tablets as SOC.
224047452|NCT01974492|PROCEDURE|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
224047453|NCT01974492|PROCEDURE|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
224142627|NCT04105413|DIAGNOSTIC_TEST|Blood culturs|CBC, Blood culture and CRP
224142628|NCT01147406|DRUG|N6022|This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
224142629|NCT01147406|DRUG|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
224142630|NCT00797485|BIOLOGICAL|bevacizumab|Given IV
224142631|NCT00797485|DRUG|capecitabine|Given orally
224142632|NCT00797485|DRUG|fluorouracil|Given IV
224299997|NCT02135653|OTHER|Eischens Yoga|
224299998|NCT06221267|DRUG|Rimegepant|No intervention. The study will record the usage, timing, frequency, and dosage of rimegepant in a real-world clinical setting.
224299999|NCT03040557|DEVICE|Flexible footwear|\- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
224300000|NCT03040557|DEVICE|Orthopedic insole|\- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
224300001|NCT02340845|BIOLOGICAL|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
224300002|NCT06190535|DRUG|Etamsylate|Enteral administration of Etamsylate as solution galenic form
224300003|NCT01796912|OTHER|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
224142633|NCT00797485|DRUG|irinotecan hydrochloride|Given IV
224142634|NCT00797485|DRUG|leucovorin calcium|Given IV
224142635|NCT00408759|BEHAVIORAL|hypnosis|
224142636|NCT00329134|DRUG|Administration of quinine sulphate taste-masked pellets|
224142637|NCT04319419|DIETARY_SUPPLEMENT|Supplement with micronutrients|Obese children were divided in 2 groups. A group received the supplement plus nutrition education and other group was a control, only received nutrition education.
224142638|NCT04319419|OTHER|Nutrition education|Group received nutrition education program during 6 months
223436369|NCT07136272|DEVICE|EnsoSleep|EnsoSleep is software-only medical device intended for use by physicians to assess sleep quality and aid in the diagnosis of sleep disorders. The software analyzes physiological signals and automatically scores sleep study results, including respiratory, sleep staging, arousal and movement events. Automatically scored events and physiological signals are analyzed, displayed, and summarized for review by clinicians.
223436370|NCT06718803|BEHAVIORAL|Hypnosis|"The Evia program includes three mayor components, 1. A hypnotherapy program for the reduction of hot flashes, 2. Educational readings on hot flashes and menopausal-related topics, 3. Daily hot flash tracker.~The hypnotherapy is delivered in short, daily 10-20 minute audio recordings that involve numerous suggestions for coolness and relaxation (i.e., cool breeze, snowy mountain, deep lake) for a period of five weeks. The hypnotherapy program is based on previous randomized controlled trials for the reduction of hot flashes (Elkins et al., 2008; Elkins et al., 2013)."
223436371|NCT06718803|OTHER|Structured Attention|Data collection of hot flash severity and frequency will mirror the hot flashes daily tracker offered by the intervention group (Evia app), and account for time and structured attention control while removing any potential therapeutic effects.
223436372|NCT03080766|DRUG|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
223436373|NCT06702436|OTHER|Observational Study|This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians
223436374|NCT07031739|BEHAVIORAL|Resource information|Participants randomized to this arm will receive a tailored list of information about community resources.
223436375|NCT07031739|BEHAVIORAL|Community Health Worker (CHW) assistance|The CHW will meet with the participant at the baseline visit and will follow up with participants at least every other week. The CHW will also work directly with the patient's care team.
223436376|NCT07031739|BEHAVIORAL|Medically-tailored Meals (MTM)|MTM will consist of weekly home meal delivery. During the 3 months, participants will receive 10 medically tailored refrigerated or frozen meals (5 lunches and 5 dinners) delivered to their home weekly.
223566188|NCT01007435|DRUG|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
223566189|NCT01007435|DRUG|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
223566190|NCT04503135|DIAGNOSTIC_TEST|ultrasound|ultrasound of the central veins of the neck and chest and a (compression ultra-sound) CUS of the femoral veins will be performed bilaterally
224142639|NCT05931133|OTHER|NO INTERVENTION|NO INTERVENTION WILL BE GIVEN
223566191|NCT02503670|BEHAVIORAL|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
224142640|NCT01784588|DEVICE|Solyx Single Incision Sling System|Solyx Single Incision Sling System
224142641|NCT01784588|DEVICE|Obtryx II Sling System|Standard outside-in transobturator sling
224142642|NCT04499846|OTHER|Therapeutic education|Patients will follow a therapeutic education in order to inform them about the mechanism of action of statins. After this intervention a questionnaire will use to measure compliance.
223436377|NCT05876767|DRUG|SAR444336|Single or repeated dose subcutaneous injection
223436378|NCT05876767|DRUG|Placebo|Single or repeated dose subcutaneous injection
223566192|NCT02503670|OTHER|Control Group|Continue with standard care.
223566193|NCT00521690|DRUG|insulin detemir|
223566194|NCT04545190|DIETARY_SUPPLEMENT|Glucose|To investigate the effects of glucose intake during resistance training on muscle biological adaptations
223566195|NCT04131387|DEVICE|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
223566196|NCT04131387|DEVICE|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
223566197|NCT02613117|DEVICE|Potassium Oxalate Gel|Self applied
224142643|NCT04116073|DRUG|INCMGA00012 (PD-1 antibody)|INCMGA00012 (PD-1 antibody): 500 mg, 30 min IV infusion on Day 1 of each cycle (every 28 days)
224142644|NCT06281574|PROCEDURE|Questionnaires|"To assess the shoulder function, the following questionnaires will be used:~The validated Dutch translation of the Oxford Shoulder Score (OSS) The validated Dutch translation of the Simple Shoulder Test (SST) The Subjective Shoulder Value (SVV) To assess the work ability patients will use the validated Dutch work-related questionnaire for upper extremity disorders (WORQ-UP)"
224142645|NCT04871139|PROCEDURE|Biopsy|Undergo biopsy
224142646|NCT04871139|PROCEDURE|Contrast-Enhanced Mammography|Undergo CEM
224142647|NCT04871139|OTHER|Questionnaire Administration|Ancillary studies
223566198|NCT02613117|DEVICE|Potassium Oxalate Liquid|Professionally Applied
223566199|NCT02613117|DRUG|Stannous fluoride paste|SnF2 Paste
224142648|NCT04871139|OTHER|Radioactive Iodine|Given IV
224142649|NCT00695214|DRUG|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
224142650|NCT05799079|DRUG|Venetoclax|Given by mouth
224142651|NCT05799079|DRUG|Decitabine|Given by mouth
224142652|NCT05799079|DRUG|Cedazuridine|Given by mouth
224142653|NCT05799079|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow biopsy
223566200|NCT01606683|OTHER|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
223566201|NCT01606683|OTHER|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
223566202|NCT01606683|OTHER|No intervention|
224047454|NCT04424160|BIOLOGICAL|PRP injection in the endometrium|Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
224047455|NCT02106286|DRUG|Bisoprolol|
224047456|NCT00215995|DRUG|Cisplatin|As outlined in Detailed Description
224047457|NCT00215995|DRUG|Irinotecan|As outlined in Detailed Description
224047458|NCT00215995|DRUG|ZD 1839|As outlined in Detailed Description
224047459|NCT02218281|BEHAVIORAL|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
224047460|NCT02218281|BEHAVIORAL|NCI's QuitSTART app|NCI's smoking cessation app
224047461|NCT02218281|BEHAVIORAL|Written smoking cessation materials only|Receipt of written smoking cessation materials
224047462|NCT03832491|OTHER|Home based therapy|Airway clearence techniques
224047463|NCT03832491|OTHER|Game and home based therapy|Game based approach programme and airway clearence techniques
224047464|NCT00932204|DEVICE|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
224047465|NCT01487642|DEVICE|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
224142654|NCT05799079|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224142655|NCT06256029|PROCEDURE|Recruitment maneuver|The recruitment maneuver will be performed by increasing the current peak pressure (Ppeak) by 5 cm H2O, changing the inspiratory/expiratory ratio from 1:2 to 1:1, with PEEP values of 5 and 7 cm H2O. The respiratory rate during the recruitment maneuver will be 10 breaths per minute, and the recruitment maneuver will last 30 seconds (5 breaths). The recruitment maneuver will be performed 3 times: the first time immediately after the formation of the pneumoperitoneum and the positioning of the patient in the reverse Trendelenburg position with a PEEP of 5 cm H2O, the second time with a PEEP of 7 cm H2O, during the duration of the operation. The third recruitment maneuver will be performed with a PEEP of 7 cm H2O at the end of the operative procedure, and immediately before the patient wakes up. After each increase, PEEP will be maintained at higher pressure values with a peak value of 7 cm H2O.
224142656|NCT05814471|DEVICE|Cable fastening system and 3d printed straps(14 days)|The participants will wear a Odra knee brace held in place with by a cable fastening system and 3d printed straps for 2 weeks.
224142657|NCT05814471|DEVICE|Velcro straps system(14 days)|The participants will wear a Odra knee brace held in place with by a velcro straps system for 2 weeks.
223566203|NCT02356419|DRUG|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
223566204|NCT01345591|PROCEDURE|Fat Grafting|
223566205|NCT03100916|DRUG|BI 690517|once daily
223566206|NCT03100916|DRUG|Placebo|once daily
223566207|NCT03100916|DRUG|BI 690517 (Reference)|Fasting
223566208|NCT03100916|DRUG|BI 690517|Non- fasting
224142658|NCT05814471|DEVICE|Adjustment period(Velcro-14 days)|The participants will wear a new Odra knee brace held in place with by a velcro straps system for 2 weeks.
224142659|NCT04904614|DRUG|Letermovir|Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
224142660|NCT03182465|DIAGNOSTIC_TEST|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
224142661|NCT03770195|DEVICE|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
224142662|NCT03905395|BEHAVIORAL|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
224142663|NCT04965129|DRUG|Placebo|Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo
224142664|NCT04965129|DRUG|Fish oil|All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.
223436379|NCT06729060|OTHER|Combination of Motor Imagery and Physical Performance|"For 15 minutes you will physically eliminate targets by clicking on them in the Aim Lab Trainer (Physical Performance Part).~Then, on a screen divided into 60 squares, the target will appear and disappear in a random square for 5 seconds. At the same time, the metronome will give a warning sound at each new target. The stimulus will come every five seconds and each time the stimulus comes, the target will imagine that it has disappeared. In the next 5 seconds, the stimulus will come again in a different place and he will imagine that he has destroyed it again. In the first two weeks, this will happen for 60 stimuli with 5 second intervals.~(60target\*5sec=300sec \*3=900sec/60 =15 min). In the next 2 weeks, the interval will be reduced by 1 second and in the last two weeks it will not be reduced. But the duration will always be 15 minutes (Motor Imagery Part)."
223436380|NCT06729060|OTHER|Physical Performance|For 30 minutes, they will eliminate the Aim Lab Trainer test by clicking quickly and accurately with their dominant hands. The physical performance practice to be applied both in this group and in the Motor Imagery and Physical Performance Combination Group is the same and will be applied in the same way for 8 weeks
224047466|NCT01487642|DEVICE|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
224047467|NCT01487642|DEVICE|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
224047468|NCT01487642|DEVICE|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
224047469|NCT06388850|BEHAVIORAL|Healthy Relationships Project|The Healthy Relationships Project (HRP), created by the community-based organization Prevent Child Abuse Vermont (PCAVT), will be the focus of this rigorous evaluation study. The program is fully manualized with a widely accepted curriculum designed for Pre-K to 2nd graders (Care for Kids) and 3rd to 6th graders (We Care Elementary, though implementation will stop at 5th grade for this study). The HRP uses an upstream universal public health approach for the primary prevention of child and youth perpetration of child sexual abuse with developmentally appropriate intervention elements for children, faculty and staff at their schools, and for their caregivers.
224142665|NCT05270850|PROCEDURE|Control group|Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
224142666|NCT05270850|PROCEDURE|SVF group|SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
224142667|NCT06483165|OTHER|BE FAST Educational video|A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
224142668|NCT06483165|OTHER|F.A.S.T. Educational Video|A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
224142669|NCT00151749|DRUG|Colesevelam hydrochloride|
224142670|NCT05142540|PROCEDURE|blood and saliva samples will be taken|"For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2."
224142671|NCT01429077|DRUG|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
224300004|NCT01796912|OTHER|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
224142672|NCT01429077|DRUG|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
224142673|NCT03838445|DEVICE|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
224142674|NCT00178048|DRUG|paroxetine|
224142675|NCT02495740|BEHAVIORAL|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
224142676|NCT04335604|DRUG|JPI-547|The dose levels will be escalated following a 3+3 dose escalation scheme.
224142677|NCT05911464|DRUG|HS-10386|Starting dose 10 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of HS-10386, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined
224300005|NCT02726893|OTHER|no intervention|
224300006|NCT00725530|DEVICE|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
224300007|NCT00725530|DEVICE|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
224300008|NCT03814525|RADIATION|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
224047470|NCT05681000|DRUG|Utidelone Capsule|"At least 4 dose cohorts are planned, and 16-28 cases are expected.~1. Cohort 1 and 2: 2 cases are planned for each. In cohort 1, the subjects will receive Utidelone Capsule at a dose of 25 mg/m2/d for 5 days, in a 21-day cycle. In cohort 2, the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days, in a 21-day cycle.~2. Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days in a 21-day cycle respectively."
224047471|NCT05700305|OTHER|12-week, low threshold physical rehabilitation intervention with protein supplementation|12 week, low threshold, rolling exercise intervention with protein supplementation
224047472|NCT02318862|PROCEDURE|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
224142678|NCT04945213|DRUG|Biperiden|5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
224142679|NCT04945213|OTHER|Placebo|1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
224142680|NCT03260972|DRUG|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
224142681|NCT03260972|DRUG|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
224142682|NCT04980313|DEVICE|Xenogenic collagen matrix|Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
224142683|NCT04980313|DEVICE|Autogenous connective tissue graft|Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
224142684|NCT05688319|BEHAVIORAL|Problem-Solving Training|Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
224142685|NCT03067129|DRUG|Glecaprevir/Pibrentasvir Adult Formulation|Co-formulated film-coated tablet (100 mg/40 mg)
224142686|NCT03067129|DRUG|Glecaprevir + Pibrentasvir Pediatric Formulation|Film-coated pellets/granules (15.67%/8.25%) administered by mixing with a small amount (1-2 teaspoons) of a soft food vehicle, such as hazelnut spread, Greek yogurt, or peanut butter.
224142687|NCT03562754|PROCEDURE|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
224142688|NCT03562754|PROCEDURE|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
224142689|NCT00943085|BEHAVIORAL|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
224300009|NCT03814525|RADIATION|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
224300010|NCT02882685|PROCEDURE|Roux-en-y gastric bypass|
224300011|NCT02882685|PROCEDURE|Single anastomosis gastric bypass|
224300012|NCT05018520|DRUG|Six Courses of R-CHOP Plus Two Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 2 courses)
224300013|NCT05018520|DRUG|Four Courses of R-CHOP Plus Four Courses of Rituximab|The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 4 courses) followed by Rituximab (375mg/m2 d1, every 21 days for total 4 courses)
224300014|NCT02050425|DEVICE|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
224300015|NCT02050425|DEVICE|CPAP|Patients continue therapeutic CPAP therapy
224300016|NCT06406517|DRUG|Gadopiclenol|Gadopiclenol is an FDA-approved gadolinium-based contrast agent (GBCA) for neurological and abdominal contrast-enhanced MRI. Participants will receive this contrast agent at one of three different doses prior to undergoing a congenital heart cardiac MRI/MRA. This contrast agent will be compared to gadobenate dimeglumine, the standard-of-care.
224300017|NCT06406517|DRUG|Gadobenate dimeglumine|Gadobenate dimeglumine is an FDA-approved GBCA that is used in standard clinical practice at UCSD for contrast-enhanced MRI/MRA studies, including cardiac MRI/MRA. This contrast agent is the standard of care to which gadopiclenol will be compared.
224300018|NCT01660464|BEHAVIORAL|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
224300019|NCT01646047|DIETARY_SUPPLEMENT|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
224300020|NCT01646047|DIETARY_SUPPLEMENT|multi-component dietary supplement|placebo capsules
224300021|NCT06063759|DEVICE|VitalDetect|measurement of microcirculating blood flow, SpO2 (mmHg or %), heart rate (beats/min)
224300022|NCT03535675|DRUG|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
224300023|NCT03535675|DRUG|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
224047473|NCT01274715|BEHAVIORAL|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
224142690|NCT00943085|BEHAVIORAL|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
223436385|NCT04888845|BEHAVIORAL|Safety Plan|The safety plan is a written, prioritized list of coping strategies and resources for reducing suicide risk.
223436386|NCT04888845|BEHAVIORAL|Crisis Response Plan|Crisis response planning intervention teaches a range of coping strategies and provides support that can reduce suicide attempts and ideation.
223436387|NCT04888845|BEHAVIORAL|Structured interview|In the structured interview approach, clinicians ask a series of predetermined questions and/or assess a specified set of risk and protective factors, typically using a checklist-based approach.
223436388|NCT04888845|BEHAVIORAL|Narrative Assessment|"In the narrative assessment approach, clinicians ask patients to tell the story of their suicidal crisis."
223436389|NCT06633861|DEVICE|spot-check measurement|Spot-check measurement: different Philips SpO2 sensors and Philips FAST pulse oximeter system, capnography
223436390|NCT06740071|BEHAVIORAL|somatosensory interactive pelvic floor muscle training|synchronized PFMT guidance through a combination of audio and video
223436391|NCT06740071|PROCEDURE|pelvic floor magnetic stimulation therapy|stimulation frequency was set at 10 Hz, with stimulation administered in cycles of 5 seconds on followed by 5 seconds off. Each treatment session lasted 20 minutes, conducted twice a week, for a total of 10-12 sessions
223436392|NCT06740071|BEHAVIORAL|standard pelvic floor muscle training|"traditional verbal instructions and paper-based educational materials of PFMT are given to participants.~All patients would receive PFMT under the guidance of digital rectal examination by nurses, and their pelvic floor muscle function was graded according to the Oxford Grading System (grades 0-5), ensuring the correctness of subsequent PFMT."
223436393|NCT06738641|BEHAVIORAL|Pro2col Health|The Pro2col Health application is a smartphone application that provides users with health behavior guidance, personalized feedback, and assessments designed to estimate their current healthspan and biological age.
223436394|NCT06738641|BEHAVIORAL|Control|The control group will receive subject-facing materials depicting current general activity recommendations as published by the American Heart Association (AHA) and current dietary guidelines provided by the United States Department of Agriculture (USDA).
223436395|NCT06828445|BEHAVIORAL|Veggie Vouchers|"Caregivers will receive brief education about a SNAP fruit and vegetable incentive program in South Carolina during their child's pediatrician visit. Following the visit, caregivers will receive a free trial of this SNAP program to encourage first-time use. After the free trial, caregivers can continue purchasing the same fruit and vegetable boxes at a steeply discounted price using their SNAP card. Free home delivery during the free trial and for all subsequent boxes purchased at a discounted rate will be offered during the full study duration."
223436396|NCT07054489|OTHER|Beta blocker|Participants randomized to intervention will be dosed and titrated on beta blocker according to study protocol.
223436397|NCT06497582|OTHER|zhan-zhuang|zhan-zhuang as a fundamental type of qigong
223436398|NCT06497582|OTHER|self-acupressure|Self-acupressure as a common type of traditional Chinese medicine therapies
223566209|NCT05475210|DRUG|177Lu-DOTA-EB-TATE|Peptide Receptor Radionucleotide Therapy ( PRRT) using 177Lu-DOTA-EB-TATE with a defined number of cycles will be administered.
223566210|NCT05475210|OTHER|Amino Acid Solution|The Amino acid solution to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
224142691|NCT01313481|BEHAVIORAL|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
224142692|NCT01313481|BEHAVIORAL|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
224142693|NCT06528899|BEHAVIORAL|Physical Therapy|Assessment and/or treatment by physitoherapist during the visit
224142694|NCT03330600|BEHAVIORAL|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
224300024|NCT00103311|DRUG|ispinesib|Given IV
223566211|NCT05960331|BEHAVIORAL|Autonomy supported learning|The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
223566212|NCT05960331|BEHAVIORAL|Practice with predetermined feedback|Learners practice the motor task, while the feedback is provided according to their counterpartner
224047474|NCT04816929|OTHER|Bobath Method|Neurodevelopmental Treatment
224047475|NCT04816929|OTHER|Task-Oriented Approach|Task-Oriented Treatment
224047476|NCT00338039|DRUG|Cetuximab|500 mg/m\^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
224047477|NCT00338039|DRUG|Gemcitabine|"Induction Therapy: 1 gm/m\^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m\^2/week over 100 minutes weekly for 3 weeks then 1 week off."
224047478|NCT00338039|DRUG|Oxaliplatin|Induction Chemotherapy: 100 mg/m\^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
224300025|NCT00103311|OTHER|laboratory biomarker analysis|Correlative studies
224300026|NCT05986331|DRUG|BCD-201|up to 8 treatment cycles
224300027|NCT05986331|DRUG|Keytruda|up to 8 treatment cycles
224300028|NCT00349557|DRUG|bevacizumab, bicalutamide and goserelin|
224300029|NCT00349557|PROCEDURE|intensity modulated radiation therapy (IMRT)|
224047479|NCT00338039|DRUG|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
224047480|NCT00338039|RADIATION|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
224047481|NCT04248101|PROCEDURE|Double Ligation|
224047482|NCT04248101|DRUG|Topical Silver Nitrate|
224047483|NCT05578859|DRUG|AMG 510|Single oral dose of AMG510.
224047484|NCT00363324|PROCEDURE|intracoronary injection of bone marrow cells|
224047485|NCT03075813|OTHER|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
224070592|NCT06412497|DRUG|Tacrolimus|Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.
224142695|NCT03330600|BEHAVIORAL|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
224142696|NCT00049218|BIOLOGICAL|Autologous dendritic cell-adenovirus p53 vaccine|
224300030|NCT03928314|DRUG|ORIC-101|ORIC-101 once daily, 5 or 7 days/week, for 21 days of each 28-day cycle
224300031|NCT03928314|DRUG|Nab-paclitaxel|75 or 100 mg/m2 Days 1, 8, and 15 of each 28-day cycle
224300032|NCT02681224|OTHER|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
224300033|NCT02681224|OTHER|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
224300034|NCT02681224|OTHER|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
224300035|NCT02681224|OTHER|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
224300036|NCT03063879|DRUG|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
223436399|NCT06482437|DRUG|NMD670|Tablets taken twice daily for 21 days
223436400|NCT06482437|DRUG|Placebo|Tablets taken twice daily for 21 days
224142697|NCT00049218|DRUG|Carboplatin|
224142698|NCT00049218|DRUG|Etoposide|
224142699|NCT04828356|OTHER|Reflexology|Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applied to the reflex points, the energy blockages are broken and this energy flow is distributed in a balanced way to the relevant organs.
224142700|NCT03109756|DRUG|OV101|Single-dose 5 mg OV101
224142701|NCT02806947|DRUG|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
224142702|NCT02806947|DRUG|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
224142703|NCT04635761|BEHAVIORAL|Educational Intervention|Complete AIR Program and receive the High-Risk Lung Cancer Tip Sheet
224142704|NCT04635761|BEHAVIORAL|Questionnaire Administration|Ancillary studies
224142705|NCT01500928|DEVICE|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
224142706|NCT01326117|DRUG|tadalafil|7 days of Cialis for Daily Use (5mg)
224142707|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
224142708|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
224142709|NCT01327872|DRUG|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
224142710|NCT01327872|DRUG|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
224142711|NCT00082329|DRUG|AMD 3100 (Mozobil plerixafor)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
224142712|NCT00082329|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
224142713|NCT04914078|DRUG|Mepolizumab 100 MG|The patients will treated with subcutaneous Mepolizumab at 100 mg every 30 days. Patients will be recruited among those eligible to Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco) guidelines who will accept to participate to the study. In particular inclusion criteria will be: severe (Step 4 and 5 GINA) asthma with at least blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation. In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
224142714|NCT02085057|PROCEDURE|Functional Magnetic Resonance Imaging|
223436401|NCT07059234|BEHAVIORAL|Non-exercise activity|The 5-week intervention to assess the effects of non-exercise activity on the activity-subjective energy association incorporates two high-intensity Ambulatory Assessment (AA) weeks at the beginning and end, with a tapered 3-week Ecological Momentary Intervention (EMI) phase in between. Momentary targeted micro interventions (JITAIs) with a Within-Person-Encouragement Design (WPED) are used to tailor the activity to the individual situation and phenotype of each participant.
223436402|NCT06752850|DRUG|Efanesoctocog alfa|50 IU/kg once weekly, Intravenous injection
223436403|NCT03449381|DRUG|BI 907828|Film-coated tablet
223436404|NCT07058909|DEVICE|ELISIO™-HX Dialyzer|Following consent, participants will undergo a baseline hemodialysis treatment with their currently used dialyzer, the ELISIO-H™, and following the baseline visit will receive hemodialysis with the investigational device, ELISIO™-HX, three times a week for 12 weeks.
223436405|NCT00139100|DRUG|antimicrobial agent in soap|
223436406|NCT05171634|DEVICE|DiscoveryTM|Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).
223566213|NCT04723641|OTHER|functional training exercises|progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
223566214|NCT02163967|DEVICE|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
223566215|NCT00569244|DRUG|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
224047486|NCT04169750|BEHAVIORAL|Exergames|"The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading."
224142715|NCT03335787|OTHER|Intervention|Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.
224142716|NCT03335787|OTHER|Control|Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
224142717|NCT04268095|OTHER|Dressing protocol|Patients are assigned with different postoperative dressing protocols.
223436407|NCT05171634|DEVICE|iSCAN|Virtual colonoscopy assisted by iSCAN
223436408|NCT01786824|DRUG|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
223436409|NCT01786824|DRUG|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
223436410|NCT01786824|DRUG|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
223436411|NCT01786824|PROCEDURE|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
223436412|NCT03660475|DRUG|Naltrexone|naltrexone formulated as ophthalmic solution
223566216|NCT00569244|DRUG|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
223566217|NCT03645525|DRUG|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10\^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
223566218|NCT03645525|DRUG|placebo|saline
223566219|NCT00067847|BEHAVIORAL|State-directed nutrition policy change|
223566220|NCT03926000|DRUG|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
223566221|NCT03926000|DRUG|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
223566222|NCT00960037|DIETARY_SUPPLEMENT|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
223566223|NCT00960037|DIETARY_SUPPLEMENT|Placebo equivalent|One capsule daily for 8 weeks
223566224|NCT04657380|BEHAVIORAL|PLAN-e-PSY mobile application|"The full version of the application to be evaluated will result from the process of co-design phase of the intervention based on the iterative user-centered design approach, involving representatives of carers, patients and caregivers, to define the content and form of the smartphone application during co-building workshops"
223566225|NCT04657380|BEHAVIORAL|Control Group|The first-episode psychosis services participating in the study offer case-management, which will correspond to the treatment as usual in the control group. All the centers are part of the National Transition Network (https://idpsy.org/reseau-transition/centres/). Involvement in this network ensures homogeneity of the usual practices which correspond to the internationally standards. Care delivery is based on intensive treatment during the critical period of psychosis, relying on a wide network
224047487|NCT04169750|BEHAVIORAL|Adaptive COGNI-TRAcK|"The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row."
224047488|NCT04169750|BEHAVIORAL|Sham COGNI-TRAcK|The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
223436413|NCT03660475|DRUG|Placebos|Placebo ophthalmic solution
223436414|NCT04445506|DRUG|Dexamethasone|4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
223436415|NCT06897839|OTHER|Air-sham|Room air for intratracheal administration
223436416|NCT06897839|DRUG|Zelpultide alfa|Reconstituted Zelpultide alfa for intratracheal administration
223436417|NCT06795581|DRUG|18F-PF-06445974|Injected IV followed by PET scanning
223436418|NCT03911557|DRUG|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
223436419|NCT03912428|DRUG|11C-MC1|PET radioligand for Cyclooxygenase-2 (COX-2)
223436420|NCT03912428|DRUG|Celecoxib|Cyclooxygenase-2 (COX-2) inhibitor
223436421|NCT03912428|DRUG|[11C]ER176|Radioligand for 18-kDa Translocator Protein
223566226|NCT03661424|DRUG|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
223566227|NCT04621214|DEVICE|Audio-Visual Triage System (AVT)|Audio System was added to visual triage that resulted in an AVT. Protocols of AVT included, a medical personal sits on TRIAGE DESK (with glass barrier sheet on it) wearing personal protective equipment (PPE) at a distance of more than 6 feet from the PATIENT DESK. Both desks are connected with Non-touchable MIC SYSTEM for communication
223566228|NCT06466941|PROCEDURE|regional anesthesia|Patients who underwent surgery and received an epidural or peripheral nerve block
223566229|NCT06466941|PROCEDURE|no regional anesthesia|Patients who underwent surgery and did not received an epidural or peripheral nerve block
223566230|NCT06466941|OTHER|acute pain consultation|Patients who underwent surgery and had a perioperative (preop, intraop, or postop) acute pain consultation
223566231|NCT06466941|OTHER|no acute pain consultation|Patients who underwent surgery and did not have a perioperative (preop, intraop, or postop) acute pain consultation
223436422|NCT03912428|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)/computed tomography (CT) Scan|Whole body or brain PET/CT scans
223436423|NCT06427798|DRUG|68Ga-DOTATATE|68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.
223436424|NCT06427798|DRUG|[203Pb]VMT-alpha-NET|\[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.
223436425|NCT06427798|DRUG|[212Pb]VMT-alpha-NET|\[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.
224047489|NCT05694351|BEHAVIORAL|Healthy meals and physical activity in families with type 2 diabetes|Families will participate in telehealth family education on diabetes management and prevention through lifestyle modifications in their everyday occupations regarding current recommendations for physical activity, grocery shopping, meal preparation, and family meal routines. Each family will be assisted in setting tailored goals for the family as a whole and individually regarding physical activity and dieting habits. The goals will be incorporated into family daily routines, to secure manageability and sustainability of the new lifestyle habits. Local facilities and communy networks will be engaged in this process to empower and motivate the participants. Working with the goals will be monitored and facilitated throughout the intervention period of 3 months. Before discharge, each family will co-produce a maintenance plan for physical activity and healthy dieting.
224047490|NCT05893979|DEVICE|Spectacle Lenses|Standard Spectacle Lenses
224047491|NCT03199820|DEVICE|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
224047492|NCT03199820|DRUG|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
224047493|NCT04405154|BIOLOGICAL|Camrelizumab|Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.
224047494|NCT04405154|DRUG|Cisplatin|75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.
224047495|NCT04405154|RADIATION|IMRT or VMAT|66-70 Gy given in 33-35 fractions over 6-7 weeks.
223566232|NCT05596617|DRUG|Oral bedtime melatonin|Different doses of oral bedtime melatonin
223566233|NCT04023357|OTHER|PEEK|New polyetheretherketones material
224047496|NCT03129087|BEHAVIORAL|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
224047497|NCT02285920|DRUG|Spironolactone|The trial will be conducted in 2 phases - a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
224142718|NCT02029638|BIOLOGICAL|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
224142719|NCT02029638|DRUG|Fludarabine|Fludarabine at dose 30 mg/m\^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
223566234|NCT04023357|OTHER|Emax|standard etchable glass ceramic used for Endocrowns
223566235|NCT00847665|OTHER|repositioning|Turning every 4 or 2 hours
223566236|NCT05877040|DRUG|Rituximab|Open label proof-of-concept study with intravenous Rituximab, given at the dose of 1g in one day, followed by the same dose after two weeks
224047498|NCT04942717|BEHAVIORAL|CONVO intervention|The CONVO intervention consists of oncology nurse-led discussions exploring patients' health-related values as part of routine oncology care for all patients, from the beginning of oncologic care. Nurses will use the Nurse's Values Discussion Guide. At these sites, chemotherapy nurses will deliver the CONVO discussion, as patients at these sites do not have primary nurses assigned and because oncology doctors, BPs and PAs do not work one-on-one as a pair with a unique nurse.
224047499|NCT06016465|DRUG|Dexamethasone Oral|Two 4mg pills
224047500|NCT06016465|DRUG|Placebo|2 placebo pills
224047501|NCT03055754|PROCEDURE|Argon randomized arm|Endoscopic argon plasma coagulation
224047502|NCT03055754|PROCEDURE|Control arm|No Endoscopic procedure
224142720|NCT02029638|DRUG|Cyclophosphamide|"1. Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~2. High dose cyclophosphamide \[50mg/kg (Ideal Body Weight)\] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
224142721|NCT02029638|RADIATION|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
224142722|NCT02029638|DRUG|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
224142723|NCT02029638|DRUG|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
224142724|NCT02029638|DRUG|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
224142725|NCT02029638|BIOLOGICAL|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
224142726|NCT02029638|DRUG|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
224300037|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
224300038|NCT04029987|PROCEDURE|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
224300039|NCT04029987|PROCEDURE|Control|Conventional analgesia
224300040|NCT01264042|DIETARY_SUPPLEMENT|Ferrous Sulfate|60 mg with 200 mL water, single administration
224300041|NCT00225537|DRUG|4-Methylumbelliferone (Heparvit®)|
224300042|NCT03195153|DRUG|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
224300043|NCT03195153|DRUG|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
224300044|NCT03195153|DRUG|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
224300045|NCT04973553|OTHER|upper limb rehabilitation|the intervention consisting of two components: a) Upper limb training protocol; b) Technology-assist training.
224300046|NCT04324593|DEVICE|Peripheral intravenous analysis (PIVA) algorithm|An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
224300047|NCT00635115|DEVICE|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
224300048|NCT00635115|DEVICE|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
224300049|NCT05892146|DRUG|Prevention therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
224300050|NCT05892146|DRUG|Rescue therapy|Sacubitril/Valsartan (25/80) mg twice a day for 1 year
224300051|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5\*10\^10 vp/0.5 milliliter (mL).
224300052|NCT02926430|BIOLOGICAL|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1\*10\^11 vp/0.5 milliliter (mL).
224300053|NCT02926430|DRUG|Placebo|Participants will receive placebo as formulation buffer.
224300054|NCT02400424|RADIATION|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
224300055|NCT00003436|DRUG|amsacrine|
224300056|NCT00003436|DRUG|asparaginase|
224300057|NCT00003436|DRUG|cytarabine|
224300058|NCT00003436|DRUG|daunorubicin hydrochloride|
224300059|NCT00003436|DRUG|etoposide|
224300060|NCT00003436|DRUG|methotrexate|
224300061|NCT00003436|DRUG|mitoxantrone hydrochloride|
224300062|NCT00003436|DRUG|therapeutic hydrocortisone|
224300063|NCT00003436|PROCEDURE|allogeneic bone marrow transplantation|
224300064|NCT04270136|PROCEDURE|total mastectomy|breast cancer non conserving surgery
223566237|NCT01820403|OTHER|portion size kcal of box lunch|
223566238|NCT05362591|PROCEDURE|resin bonded bridge with no preparation|resin bonded bridge without enamel preparation
224047503|NCT06046222|DRUG|NS-229|Experimental
224047504|NCT06046222|DRUG|Placebo|Placebo comparator
223436426|NCT06192758|DEVICE|TheraSphere PCa|Single session treatment of TheraSphere PCa - Yttrium-90 Glass Microspheres for the treatment of prostate cancer. Dose vials will be available in activity ranging from 0.1 GBq (2.7 mCi) to 3 GBq (81 mCi).
224047505|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
223436427|NCT06844669|DRUG|Carvedilol|6.25 mg with food
223436428|NCT06844669|DRUG|Empagliflozin|10 mg in the morning with or without food
224047506|NCT04903106|DEVICE|FAST-FIX FLEX Meniscal Repair System|Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
224047507|NCT00003765|DRUG|O6-benzylguanine|
223436430|NCT06864169|BIOLOGICAL|Raludotatug Deruxtecan (R-DXd)|Administered via intravenous (IV) infusion.
223436431|NCT04008940|DEVICE|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
223436432|NCT06778876|OTHER|lavender sachet group|The normal procedure applied in the sleep clinic (keeping a sleep diary, sleep hygiene education) will be followed and participants will be asked to sleep with lavender sachets inside their pillows for two weeks.
223436433|NCT06778876|OTHER|control group|Participants will follow the normal procedure applied (keeping a sleep diary, sleep hygiene training) in the sleep clinic and no additional intervention will be performed.
223436434|NCT04847453|PROCEDURE|Biospecimen Collection|Undergo blood and urine specimen collection
223436435|NCT04847453|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
223436436|NCT04847453|PROCEDURE|Computed Tomography|Undergo CT scan
223436437|NCT04847453|DRUG|Dexamethasone|Given PO
223436438|NCT04847453|PROCEDURE|Echocardiography Test|Undergo ECHO
223436439|NCT04847453|DRUG|Ixazomib Citrate|Given PO
223436440|NCT04847453|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223436441|NCT04847453|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223436442|NCT04847453|PROCEDURE|Transabdominal Ultrasound|Undergo transabdominal ultrasound
224047508|NCT00003765|DRUG|carmustine|
224047509|NCT05546164|OTHER|Assessment of hand grip strength|Assessment of hand grip strength
224142727|NCT02029638|DRUG|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
223436443|NCT04847453|DRUG|Venetoclax|Given PO
223436444|NCT04847453|PROCEDURE|X-Ray Imaging|Undergo x-ray
223436445|NCT07076433|OTHER|Core Stability Exercises|Participants will engage in core stability exercises targeting the muscles of the trunk and pelvis, such as pelvic tilting, abdominal crunches, back extension, side bridges, and bird dog. These exercises will be performed twice a week for 6 weeks, with each session lasting 30 minutes. The intensity will be progressively increased based on individual tolerance.
223436446|NCT07076433|OTHER|Pilates:|Participants will undergo Pilates sessions that emphasize flexibility, posture, and core engagement. Pilates exercises will be performed twice a week for 6 weeks, with each session lasting 30 minutes. The focus will be on breathing, spinal alignment, and strengthening exercises that challenge flexibility and balance.
223436447|NCT03233204|DRUG|Olaparib|Given PO
223436448|NCT06891911|BEHAVIORAL|Dietitian-Assisted DASH groceries|"The DASH (Dietary Approaches to Stop Hypertension), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.~Intervention Phase:~This intervention is a weekly, 4-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size."
224047510|NCT05546164|OTHER|Assessment of pinch strength|Assessment of pinch strength
224047511|NCT05546164|OTHER|Assessment of upper limb dexterity|Assessment of upper limb dexterity
224047512|NCT06196645|BEHAVIORAL|Physical Activity Intervention Based on Theory of Planned Behavior|The content of the intervention plan to be implemented consists of the following components: (I) transferring knowledge about health-related physical fitness and physical activity, (II) taking individual responsibility for physical activity monitoring and simple individual planning, (III) including in the program the types of activities that female adolescents choose and declare that they would enjoy participating in.
224142728|NCT02029638|DRUG|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
224300065|NCT00233506|DRUG|CpG 7909|
223436449|NCT06891911|BEHAVIORAL|Self-directed shopping|"Intervention Phase:~Participants will receive some basic information on healthy eating and a stipend during the 4-week intervention period. They are permitted to use the stipend however they choose and will not be asked about how they spent these funds."
223436450|NCT06842173|BIOLOGICAL|Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg|Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg + IB160 adjuvant (0.5mL total)
223436451|NCT06842173|BIOLOGICAL|Monovalent influenza vaccine type A (H5N8) 15 mcg|Monovalent influenza vaccine type A (H5N8) 15 mcg + IB160 adjuvant (0.5mL total)
223436452|NCT06842173|OTHER|Placebo|Phosphate buffered saline (PBS) (0.5 mL/dose).
223436453|NCT04961398|DEVICE|OCT imaging|OCT imaging on Normal Eyes without any filter and with various ND filters as per protocol
224047513|NCT01480284|DRUG|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
224047514|NCT01480284|DRUG|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
224047515|NCT02730273|DEVICE|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
224047516|NCT03305289|PROCEDURE|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
224300066|NCT02740829|DRUG|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
223436454|NCT07081178|DRUG|Semaglutide|Semaglutide injection will be self-administered once weekly subcutaneously at any time of the day with or without meals.
223436455|NCT07083765|DRUG|Dehydrated Alcohol Injection, USP|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
223436456|NCT07083765|PROCEDURE|Sham procedure|Endovascular, renal angiography
223436457|NCT06930976|DRUG|13C6-Glucose|Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion
223436458|NCT06929338|DIAGNOSTIC_TEST|Functional precision medicine|The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices. Treatment will not be given as part of the study.
223436459|NCT04522973|OTHER|Beverage with ethanol and E-cigarette liquid with ethanol|Beverage with ethanol and E-cigarette liquid with ethanol
223436460|NCT04522973|OTHER|Beverage with ethanol and E-cigarette liquid without ethanol|Beverage with ethanol and E-cigarette liquid without ethanol
223436461|NCT04522973|OTHER|Beverage without ethanol and E-cigarette liquid with ethanol|Beverage without ethanol and E-cigarette liquid with ethanol
223436462|NCT04522973|OTHER|Beverage without ethanol and E-cigarette liquid without ethanol|Beverage without ethanol and E-cigarette liquid without ethanol
223436463|NCT00545389|DRUG|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
223436464|NCT05126667|PROCEDURE|Breast-conserving surgery|Breast conserving surgery plus whole breast irradiation
223436465|NCT05126667|PROCEDURE|Mastectomy|Breast mastectomy
223436466|NCT06243783|BEHAVIORAL|Montreal Imaging Stress Test|In the Montreal Imaging Stress Test, participants are required to solve basic mathematical tasks, but the allowed reaction time is set lower than their average.
223436467|NCT06881277|BEHAVIORAL|Mobile phone based intervention|The PRIMI intervention is a 6-month smartphone-based digital health program designed to promote a healthy diet and physical activity among migrant women after pregnancy.
223566239|NCT05362591|PROCEDURE|resin bonded bridge with minimal preparation|resin bonded bridge with minimal preparation of tooth enamel
224047517|NCT03305289|PROCEDURE|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
224047518|NCT04678596|DEVICE|EonAligner|EonAligner system is one stage system.
223436468|NCT06620965|PROCEDURE|Mulligan Mobilization Technique|NAGs (Natural Apophyseal Glides) involve passive oscillatory movements of a spinal facet joint in an anterocranial direction, performed with the patient seated. SNAGs (Sustained Natural Apophyseal Glides) maintain facet glides during active movements, aiming to reach the joint\&#39;s end range. In SNAGs, the patient actively participates, and overpressure is applied at the end of movements to enhance the range of motion. Techniques include increasing rotation, lateral flexion, flexion, and extension. These were applied by a certified physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain.
223436469|NCT06620965|PROCEDURE|Proprioceptive Neuromuscular Facilitation (PNF) Technique|"Proprioceptive Neuromuscular Facilitation (PNF) Technique: PNF consists of four movement patterns in two diagonals:~Flexion-left rotation and extension-right rotation Flexion-right rotation and extension-left rotation 3 PNF techniques were applied.~Combined Isotonic Contractions: This technique involves concentric, eccentric, and stabilizing contractions of a muscle group (agonist). The goal is to increase active range of motion (ROM), strength, and improve control and coordination.~Dynamic Stabilization (Stabilizing Reversal): This involves applying resistance in various directions to prevent movement, aiming to enhance dynamic stability, strength, and agonist-antagonist coordination.~Hold-Relax Technique: This relaxation method involves isometric contractions against maximum resistance without movement to increase passive ROM and reduce pain. These were applied by physiotherapist three times a week for four weeks, aiming to improve joint mobility without causing pain."
223436470|NCT02680834|DEVICE|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
223436471|NCT02680834|DEVICE|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
223436472|NCT01639547|DRUG|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000\~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
223436473|NCT03885180|DRUG|Warfarin Sodium|Extending warfarin anticoagulation
223436474|NCT02888392|OTHER|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
223436475|NCT02888392|DIETARY_SUPPLEMENT|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
223566240|NCT03582553|DIETARY_SUPPLEMENT|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
223566241|NCT03582553|OTHER|Placebo|Cellulose
223566242|NCT06629896|DIAGNOSTIC_TEST|Contrast Enhancement Mammography|In the experimental arm women will receive two rounds of CEM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk non mutated women at each participating center.
224047519|NCT04678596|DEVICE|Clearfix|Clearfix system is three-stage system.
224047520|NCT01546974|DEVICE|HME filter Twin Star 55, Drager Medical, Germany|
224047521|NCT01546974|DEVICE|Heated humidification|
224047522|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
224047523|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
224142729|NCT02029638|DRUG|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
224300067|NCT02740829|DRUG|Intranasal placebo|Placebo
224047524|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
224047525|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
223436476|NCT05210114|DEVICE|Skin Hydration Sensor|The device is a skin hydration sensor. The sensor is placed on the skin at the inner arm. It is non-invasive and measures in seconds the percent water content of the dermis by quantifying its dielectric constant.
223436477|NCT04056273|OTHER|Guide sheath group|After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
223436478|NCT04056273|OTHER|Conventional group|After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
223436479|NCT02180802|BEHAVIORAL|motivational interviewing|
223436480|NCT02180802|BEHAVIORAL|motivational interviewing with parental involvement|
224047526|NCT01540825|DRUG|Placebo|Powder for oral solution
224047527|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
224047528|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
224047529|NCT01540825|DRUG|BI 113608|High dose powder for oral solution
224047530|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
224047531|NCT01540825|DRUG|BI 113608|Medium dose powder for oral solution
224047532|NCT01540825|DRUG|BI 113608|Low dose powder for oral solution
224047533|NCT02247765|DEVICE|Arterial line|Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
224047534|NCT02247765|DEVICE|Motion|The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
224047535|NCT01641237|DRUG|sodium fluoride|fluoride as sodium fluoride
224142730|NCT03427450|DIAGNOSTIC_TEST|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
224142731|NCT02570646|BEHAVIORAL|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
223436481|NCT02180802|BEHAVIORAL|Control group|
223436482|NCT03647774|DRUG|Extended release naltrexone|380mg injectable extended release naltrexone every four weeks
224142732|NCT04134741|OTHER|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
224142733|NCT00781872|BIOLOGICAL|Injection of autologous bone marrow derived mesenchymal stem cells|60 million cells intrathecally (approximately 1 million cells per Kg of body weight) and 20 million cells intravenously
224142734|NCT01127295|DRUG|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
224142735|NCT02431130|OTHER|low-fidelity instructor driven simulation training|
223436483|NCT02889835|DEVICE|Supreme Universal Restorative|
223436484|NCT02889835|DEVICE|Supreme Flowable Restorative|
223436485|NCT02889835|DEVICE|Bulk Fill Flowable Restorative|
223436486|NCT06912451|DEVICE|Sport custom mouthguard|This mouthguard will be made using two 3mm vinyl acetate ethylene sheets in a vacuum machine, following the recommendations for an appropriate mouthguard regarding trauma prevention and patient comfort. The patients will be monitored after 1, 3, and 6 months of using the mouthguard.
223436487|NCT06403046|DRUG|intraarticular injection|all patients will be subjected to routine (TMJ) arthrocentesis followed by Tenoxicam injection into the superior joint space in the (Tx group) and Meloxicam injection among the patients of (Mx group).
223436488|NCT07109739|DEVICE|POWERbreathe K5|The POWERbreathe K5 is portable, battery-powered, and commercially available. No modifications to the FDA-approved design are being made. Its use in this study is consistent with prior published human research and does not constitute a significant deviation from labeled use in terms of safety or function.
224047536|NCT01641237|DRUG|no added fluoride in a silica base|no added fluoride
224047537|NCT02716675|BIOLOGICAL|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
224047538|NCT02716675|BIOLOGICAL|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
224047539|NCT06188819|PROCEDURE|Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium|In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
224047540|NCT00709111|DRUG|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
224047541|NCT05075837|BIOLOGICAL|Virus -specific T cells|The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
224047542|NCT00623974|DRUG|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
224047543|NCT00623974|DRUG|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
224047544|NCT00623974|DRUG|Calcitriol|0.25 micrograms PO Every 12 Hours
223436489|NCT07110441|DRUG|Single Dose G1090N|Subjects will receive single ascending doses of G1090N up to 1200mg.
223436490|NCT07110441|DRUG|Multiple dosing of G1090N|Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.
223436491|NCT07110597|OTHER|Statement communicating 1 source of uncertainty|It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
224047545|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
224047546|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
224047547|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
224047548|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
224047549|NCT01301456|BIOLOGICAL|Placebo|Single subcutaneous injection of placebo
223436492|NCT07110597|OTHER|Statements communicating 2 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her."
223436493|NCT07110597|OTHER|Statements communicating 3 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.~Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live."
223436494|NCT07110597|OTHER|Statements communicating 4 sources of uncertainties|"It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.~Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.~Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.~Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown."
223436495|NCT07110597|OTHER|Control group|No information about uncertainty
223436496|NCT06911437|OTHER|treatment group|"Xiaoyu Zhitong Formula: 10g of long pepper, 10g of cloves, 10g of borneol, 10g of papaya, 10g of white peony, 10g of licorice, 15g of chicken blood vine, 10g psoralen, 10g of cistanche, powdered petroleum jelly, wrapped in gauze and heated and applied to the affected area.~Freehand lymphatic drainage technique: the patient is in the supine position, first use the thumb to press the deep lymph nodes of the trunk for 3-5 min, which are lymph nodes in the groin, neck, lumbosacral spine and supraclavicular fossa, and then perform freehand lymphatic drainage at the lymphatic vessels or superficial lymph nodes, according to the clockwise circle method, all the way to the outside of the thigh, and then to the lateral malleolus of the calf, and then press the medial malleolus of the inner calf to the inner thigh. 20min each time, 1 time every other day. 3 times a week for a total of 9 treatments for 3 weeks."
223436497|NCT06911437|OTHER|control group|External application of Diclofenac Diethylamine Emulgel（Manufacturer: Switzerland,Haleon CH SARL） combined with lymphatic drainage technique for treatment，Freehand lymphatic drainage technique: the patient is in the supine position, first use the thumb to press the deep lymph nodes of the trunk for 3-5 min, which are lymph nodes in the groin, neck, lumbosacral spine and supraclavicular fossa, and then perform freehand lymphatic drainage at the lymphatic vessels or superficial lymph nodes, according to the clockwise circle method, all the way to the outside of the thigh, and then to the lateral malleolus of the calf, and then press the medial malleolus of the inner calf to the inner thigh. 20min each time, 1 time every other day. 3 times a week for a total of 9 treatments for 3 weeks.
223436498|NCT07111182|DEVICE|HIVEN Medical Device|A medical device (HIVEN®) detects 5-ALA-induced fluorescence from the surgical suction and gives sound feedback to the operating surgeon indicating tumor tissue and overcoming the challenges is the contemporary FGS methods. The device is used for detecting fluorescence of flowing tissues within a transparent tube and providing auditory feedback of tissue fluorescence for neurosurgeons. There is no patient contact intended with this device.
223436499|NCT04440891|DEVICE|TMS stimulation with X-Torp task|TMS-Stimulation with X-Torp task
223436500|NCT04440891|DEVICE|TMS-Stimulation with MindMotion Go|TMS-Stimulation with MindMotion Go
223566243|NCT06629896|DIAGNOSTIC_TEST|magnetic resonance imaging (MRI) and digital mammography (DM)|women will receive two rounds of MRI+DM surveillance. After 2 years, all women who were randomly assigned to receive either MRI or CEM will undergo the same exit test. This exit test is the standard test used for the surveillance of high-risk nonmutated women at each participating center.
223566244|NCT00868088|PROCEDURE|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
223566245|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with symptomatic knee osteoarthritis|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
223566246|NCT05848544|DIETARY_SUPPLEMENT|Very low-calorie ketogenic diet for patients with fibromyalgia|A personalized very low-calorie ketogenic diet will be prepared for each patient by specialized dietitians using a combination of commercially-available ketogenic preparations and patient's handmade prepared meals
224047550|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
224047551|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
224047552|NCT01301456|BIOLOGICAL|PF-04856883|Single subcutaneous injection of PF-04856883
224047553|NCT01301456|BIOLOGICAL|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
224047554|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
224047555|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
224047556|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
224047557|NCT01301456|BIOLOGICAL|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
224047558|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Low-Dose: (1mg) level
224047559|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|Mid-Dose: (2mg) level
224047560|NCT05171946|DRUG|S.opt.FL COVID-19 pDNA vaccine|High-Dose: (4mg) level
224047561|NCT05704686|DEVICE|Isopure 1.2.3 intraocular EDOF lens implantation|Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.
224142736|NCT00443235|DRUG|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
223436501|NCT04440891|DEVICE|TMS-Sham with X-Torp task|TMS-Sham with X-Torp task
223436502|NCT04440891|DEVICE|TMS-Sham with MindMotion Go|TMS-Sham with MindMotion Go
223436503|NCT06910371|BEHAVIORAL|smartphone screen time reduction|Smartphone screen time has to be reduced to less-equal 2 hours per day for 3 consecutive weeks.
223436504|NCT02826668|OTHER|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
223436505|NCT06677151|DEVICE|nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device|The NPA-OSA is a flexible, medical-grade silicone, tube-like device that is self-inserted into the user's nasopharyngeal airway through one nostril prior to sleep and worn throughout the night to reduce or alleviate snoring and obstructive sleep apnea.
223436506|NCT07113054|DRUG|Edoxaban 60 MG [Lixiana]|Single administration of edoxaban
223436507|NCT07113054|OTHER|Edoxaban 60 MG [Lixiana] + Grapefruit Juice|Coadministration of edoxaban and grapefruit juice
223436508|NCT07116200|OTHER|Early Literacy Intervention in Kindergarten|In the kindergarten intervention, children will receive early literacy instruction through the Early Literacy Program, adapted for those using augmentative and alternative communication. Based on Accessible Literacy Learning by Light and McNaughton, the program enables nonverbal responses such as signs, symbol pointing, or eye-gaze, removing the need for speech. Instruction follows evidence-based practices including direct and explicit teaching, scaffolding, immediate feedback, cumulative review, practice, and subvocal rehearsal. The program targets five foundational literacy skills: phonological awareness, letter-sound correspondence, sound blending, shared reading, and understanding concepts about print. Supplementary materials such as flashcards and lotto games will also be used to reinforce learning.
223436509|NCT07116200|OTHER|Literacy Intervention in First Grade|In the first-grade intervention, students will receive literacy instruction using the Reading for All program, which is adapted for children who use augmentative and alternative communication. Based on Accessible Literacy Learning by Light and McNaughton, the program allows responses through nonverbal methods like signs, symbol pointing, or eye-gaze, eliminating the need for oral replies. Instruction is grounded in evidence-based practices such as direct and explicit instruction, scaffolding, immediate corrective feedback, cumulative review, practice, and subvocal rehearsal. Reading for All addresses six key literacy skills: sound blending, letter-sound correspondence, phoneme segmentation, sight word recognition, shared reading, and decoding. Additional activities (flashcards and lotto games) will be a supplement to the material.
223436510|NCT05105828|DIAGNOSTIC_TEST|Share wave fibro scan|Shear wave elastography (SWE) measures LS by quantifying the velocity of shear waves produced in the liver tissue and uses a normal B-mode ultrasound probe for measuring LS in real time. In addition, SWE imaging using the Aixplorer system provides a high frame-rate and may be able to provide more accurate scoring of fibrosis
223436511|NCT03816319|PROCEDURE|Biospecimen Collection|Undergo urine and blood sample collection
223436512|NCT03816319|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223436513|NCT03816319|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223436514|NCT03816319|PROCEDURE|Echocardiography Test|Undergo ECHO
223436515|NCT03816319|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223436516|NCT03816319|DRUG|UAE Inhibitor TAK-243|Given IV
223436517|NCT07119437|PROCEDURE|low pneumoperitoneum laparoscopy with microsurgery|Use of low pressure for pneumoperitoneum (8-10 mmHg) and mini surgical access for bariatric procedure (sleeve gastrectomy).
223436518|NCT07119437|PROCEDURE|standard laparoscopy|Standard laparoscopy (12-14 mmHg) and normal surgical access for bariatric procedures (sleeve gastrectomy).
223740687|NCT04245423|BEHAVIORAL|Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists|This intervention includes the Collaborative Care Intervention plus Certified Recovery Specialist to assist with treatment engagement and retention.
223740688|NCT05544565|DRUG|IV Antibacterial Agents|Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .
224142737|NCT00443235|DRUG|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity \< grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
224142738|NCT02424812|BEHAVIORAL|Lifebuoy School of Five Handwashing Intervention|
223436519|NCT06917872|DRUG|BI 1291583|BI 1291583
223436520|NCT06917872|DRUG|erythromycin|erythromycin
223436521|NCT00602290|DRUG|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were \> 2 until treatment completion.
224142739|NCT04915326|PROCEDURE|rectal resection|every patients will undergo to the appropriate rectal resection
224142740|NCT00255879|DRUG|Quetiapine|
224142741|NCT00255879|DRUG|Risperidone|
224142742|NCT00255879|DRUG|Olanzapine|
224142743|NCT04935970|DIAGNOSTIC_TEST|diagnostic blood test|vitamin D deficiency/insufficiency reveal, hyperhomocysteinaemia reveal
224142744|NCT04935970|DIAGNOSTIC_TEST|neuropsychological test|neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
224300068|NCT04530240|PROCEDURE|Liver Transplantation|Use prospectively collected databases from each participate centre, register MELD score recorded at the time of drop-out, liver transplantation and end of the follow-up.
223436522|NCT00602290|DRUG|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
223436523|NCT00602290|DRUG|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
223436524|NCT07095894|DRUG|Atropine|Daily 0.05% atropine eyedrops
223436525|NCT07095894|DEVICE|Spectacles with HAL|Spectacle lenses with highly aspherical lenslets (HAL)
223436526|NCT07095894|DRUG|Placebo Eyedrops|Daily placebo eyedrops
223740689|NCT05544565|DRUG|Orally antibacterial agents|Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days
223436528|NCT03175692|DIAGNOSTIC_TEST|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
223436529|NCT04824794|BIOLOGICAL|GEN3014|GEN3014 is administered by IV infusion.
223436530|NCT04824794|DRUG|Daratumumab|Daratumumab is administered by SC injections.
223436531|NCT06940037|OTHER|Progressive Resistance Training|3 times a week
223436532|NCT06940037|OTHER|Health Education|once a week
223436533|NCT07145918|DRUG|Emraclidine|Oral Tablets
223436534|NCT07145918|DRUG|Placebo|Oral Tablets
223436535|NCT06945952|DEVICE|diaphragmatic ultrasonography|using diaphragmatic ultrasonography to measure diaphragmatic thickening fraction and then calculate the ratio RR/DTF
223740690|NCT05544565|PROCEDURE|Fecal/Rectal Swab|Collected by the nurse or the physician (D0,D3,D10 or 17 and D31 or D38), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.
224047562|NCT03138187|BEHAVIORAL|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
223436536|NCT05194072|DRUG|Felmetatug Vedotin|Given into the vein (IV; intravenously)
223436537|NCT05194072|DRUG|Pembrolizumab|400 mg every 6 weeks, given by IV
223436538|NCT06948656|OTHER|fitting a blood glucose sensor|automatic, continuous collection by the blood glucose sensor for 14 days
223436539|NCT06948656|OTHER|food collection|14-day dietary record in a notebook for the patient
223436540|NCT06948656|OTHER|tests and questionnaires|measurement of muscle strength using a hand-held dynamometer, animal enumeration test, self-questionnaire on the frequency of consumption of the main food groups
224047563|NCT03138187|BEHAVIORAL|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
224047564|NCT04442191|BIOLOGICAL|Convalescent plasma|This study will use convalescent plasma collected from those who have previously had COVID-19 and have been shown to have cleared the infection and made antibodies against the virus.
223436541|NCT07144527|DIETARY_SUPPLEMENT|NMN, betaine, low-dose hydrogen peroxide (EGA)|Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.
223436542|NCT07144527|DIETARY_SUPPLEMENT|Nicotinamide Mononucleotide (NMN)|Conventional NMN supplement.
223436543|NCT07144527|DIETARY_SUPPLEMENT|Placebo|Organoleptically matched inert control.
223436544|NCT07152548|OTHER|Task-oriented exercises and mirror therapy|Patients in this group will receive task-oriented exercises 3 sessions per week for 6 weeks.Therapy will include the following functional tasks: reaching, grasping or holding, lifting, placing objects, and counting fingers.Mirror therapy group: 3 sessions per week for 6 weeks.A mirror will be placed on the learning table, and exercises will be carried out by the patient looking into the mirror, where an unaffected limb would be placed in front of the mirror. Through looking into the mirror, the patient will assume the reflection of the unaffected limb is the affected limb. Exercises will be performed by hand opening and closing, wrist extension and flexion, squeezing, opposition, calculation, and finger flexion and extension.
223436545|NCT07152548|OTHER|Task-oriented exercises|Patients in this group received task-oriented exercises 3 sessions per week for 6 weeks.Therapy included the following functional tasks: reaching, grasping or holding, lifting, placing objects, and counting fingers.
223436546|NCT07152548|OTHER|Mirror Therapy|Mirror therapy group 3sessions per week for 6 weeks. Mirror will be placed on the learning table and exercises will be carried out by the patient looking into the mirror where an unaffected limb would be placed in front of the mirror, through looking into the mirror patient will assume the reflection of the unaffected limb as the affected limb. Exercises will be performed hand opening and closing, wrist extension and flexion, squeezing, opposition, the calculation, finger flexion and extension.
223436547|NCT07153263|PROCEDURE|Ultrasound-guided retro-SCTLB|Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the retro-SCTLB was performed under ultrasound guidance.
223436548|NCT07153263|PROCEDURE|Ultrasound-guided TPVB|Patients undergoing CT-guided lung nodule localization were selected for the study. Before the surgery, the TPVB was performed under ultrasound guidance.
223436549|NCT07153016|OTHER|Legal Services|Legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota.
223436550|NCT07150702|OTHER|Conventional physical therapy program|Conventional physical therapy program that includes hot packs, transcutaneous electrical nerve stimulation, ultrasound, and core stabilization exercises
223436551|NCT07150702|BEHAVIORAL|Close follow-up by a physician|Daily physician-patient meetings during the sessions
223436552|NCT07153497|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223740691|NCT05544565|PROCEDURE|PCT assay|Dosage of procalcitonin (if not performed in standard care) at D0
224047565|NCT04442191|BIOLOGICAL|Placebo|The placebo arm of this study will use fresh frozen plasma that presumably does not contain antibodies against COVID-19.
224300069|NCT05320848|BEHAVIORAL|cardiac rehabilitation|Cardiac rehabilitation is a valuable treatment for patients with a broad spectrum of cardiac disease.
223436553|NCT07153497|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223436554|NCT07153497|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223436555|NCT07153497|DRUG|Decitabine and Cedazuridine|Given PO
223436556|NCT07153497|DRUG|Olutasidenib|Given PO
223436557|NCT07153497|DRUG|Venetoclax|Given PO
223436558|NCT05652205|DRUG|Linaclotide|Capsule; oral
223436559|NCT05652205|DRUG|Placebo for Linaclotide|Capsule; oral
223436560|NCT07157540|BEHAVIORAL|Personalized Feedback on Cannabis Protective Behavioral Strategies, Cannabis Use, Cannabis Expenditures, and Cannabis-Related Consequences (PF)|"PF comprises the following content:~* Self-reported PBS questionnaire, personalized feedback on PBS, possibility to select strategies to start using or use more often, possibility to set a reminder to use PBS strategies.~* Short questionnaire on cannabis use (frequency/number of hours under the influence) and normative feedback on participant's cannabis use as compared to people of same age and gender in the general population and among Cann-L participants.~* Question on money spent for cannabis purchase, personalized feedback (total amount spent and corresponding number of grams of cannabis over one year), gamified gauge to picture potential yearly savings, reflection on how to use the saved money, and possibility to set a reminder for money saving objectives.~* Questionnaire on cannabis-related consequences, feedback on the level of consequences met, question about which consequence(s) participant might want to think about, and possibility to set a reminder to think about consequences."
223436561|NCT07157540|BEHAVIORAL|Imagining the Future Using Counterfactual Thinking and Episodic Future Thinking (IMAGIN)|"Two-task intervention including:~1. Counterfactual thinking:~   * Description of a recent negative situation related to cannabis use encountered by the participant~  * Identification of a preventive strategy that would have addressed this situation~  * Writing a sentence formatted as If only +preventive strategy, then + description on how the specific past problem would have improved~  * Assessment of participant's intention and confidence in using the preventive strategy~  * Imagining a future situation using this preventive strategy~  * Possibility to set a reminder of the preventive strategy.~2. Episodic future thinking:~   * Description of a significant positive event that might occur in the short-term (3 months) and that does not involve cannabis use~  * Assessment of the importance and enjoyment of this positive event~  * Encouragement to imagine it as vividly as possible~  * Suggestion to describe the positive event in detail and to write it down~  * Possibility to set a reminder of the positive event."
223436562|NCT07157540|BEHAVIORAL|Behavioral Economics-Informed Exercises to Increase Motivation to Engage in Substance-Free Activities (SFAS)|"SFAS includes:~* A questionnaire on how participant value different aspects of their life, and feedback on valued domains.~* Two open-ended questions on short- and long-term life goals.~* A questionnaire assessing time allocation (hours per week allocated to different activities, e.g. socializing, working, etc.), and personalized feedback including the time spent using substances and recovering from their effects.~* Gamified exercise to imagine allocating time in a different way.~* List of substance-free recreational activities in the region of Lausanne, with possibility to select activities on a wish-list including internet hyperlinks.~* Possibility to set a reminder of the selected activities.~* Single-item questionnaire on stress and mood, and feedback on stress and mood level.~* Open-ended question on coping strategies currently used for stress and mood.~* List of coping strategies that can be selected.~* Possibility to set a reminder of stress/mood coping strategies."
223436563|NCT07157540|BEHAVIORAL|Information|Minimal intervention (Control Intervention), consisting of simple, text-only web pages containing information on cannabis effects and health-related risks, cannabis consumption modes, cannabis harm reduction and protective behavioral strategies, as well as hyperlinks to additional resources and online help.
223436564|NCT07161141|DEVICE|Immersive Virtual Reality Platform to Support Birth Preparedness and Mental Wellbeing|"The VR-based intervention will be grounded in a childbirth education framework designed to enhance women's awareness of their attitudes toward childbirth, their readiness for the birthing process, and their expectations related to labor, delivery, and the postpartum period. The program aims to strengthen emotional insight and coping capacities by guiding participants to reflect on their feelings and thoughts throughout the childbirth journey. The intervention will integrate key components such as breath awareness exercises, coping techniques, and motivational messages. While participants receive structured childbirth education, they will simultaneously be supported in developing psychological preparedness through immersive and reflective experiences tailored to foster emotional resilience and self-efficacy.~The digital labyrinth will be designed both visually and functionally to facilitate immersive navigation. It will be set in an expansive virtual landscape enriched with natural elem"
223436565|NCT07163481|DRUG|Sacituzumab Govitecan + Fulvestrant|Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with Fulvestrant 500 mg intramuscularly into the buttock on Day 1 of 28-day cycles and Cycle 1 Day 15
223436566|NCT07163481|DRUG|Sacituzumab Govitecan + Anastrozole / Exemestane|Sacituzumab Govitecan 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles Combined with One of the Two Investigator's choice of aromatase inhibitors (ICAI), orally, once daily: Anastrozole 1 mg Exemestane 25 mg
223478564|NCT04345224|OTHER|Dynamic tape|A kinesiology tape will be applied to the lateral hip of the affected side to facilitate the gluteus medius muscle activation while the participant is lying down. The first third of one I-strip will begin at the posterior iliac crest without tension to provide an anchor that will not cross the target tissue. The participant will actively flex the adducted hip to allow for the application of the middle third of the tape with approximately 50 percent tension (able to visualize the wave pattern in the tape). Subsequently, with the leg in the original position, the remainder of the tape will be applied without tension, ending approximately at the greater trochanter. Afterward, the second I-strip will be applied in the same manner starting at the anterior iliac crest.
224142745|NCT04763590|BEHAVIORAL|Cognitive Behavioral Therapy|"This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful."
224142746|NCT02563925|RADIATION|Brain radiotherapy or Stereotactic Radiosurgery|
224142747|NCT02563925|DRUG|Tremelimumab|
223436567|NCT07164664|PROCEDURE|External Oblique Intercostal Block|Bilateral ultrasound-guided External Oblique Intercostal Block (30 mL, 0.25% bupivacaine, bilaterally) will be performed. All patients will receive multimodal analgesia, including a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated using a PCA device programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum of 0.1-0.15 mg/kg (IBW). Upon arrival in the PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the surgical ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW) in 50-100 mg slow doses, not exceeding 400 mg/day.All patients will receive 8 mg dexamethasone and 0.15 mg/kg ondansetron (IBW) for PONV prophylaxis.
223436568|NCT07164664|PROCEDURE|Port-Site Infiltration|Before port placement, 0.25% bupivacaine solution will be injected into the laparoscopic port insertion sites (5 mL at each port site).
223436569|NCT07164664|DRUG|ıv morphine PCA|A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/ kg (IBW). No basal infusion will be used.
223436570|NCT07169214|DRUG|BT-114143 Injection at low dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at low dose. BT-114143 will be administered twice daily for three consecutive days.
223436571|NCT07169214|DRUG|BT-114143 Injection at Medium-dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at Medium-dose. BT-114143 will be administered twice daily for three consecutive days.
223436572|NCT07169214|DRUG|BT-114143 Injection at High-dose|A total of 10 subjects were enrolled. All of them received BT-114143 Injection at High-dose. BT-114143 will be administered twice daily for three consecutive days.
223436573|NCT07169214|DRUG|control group|The ratio of subjects in the experimental group to those in the control group is 10:3, with 3 placebo - treated control subjects corresponding to each dose group. The subjects will receive placebo treatment twice a day for 3 consecutive days.
223436574|NCT07169890|OTHER|Dextrose Phonophoresis|To apply Dextrose Phonophoresis on a patient with acne vulgaris, begin by cleansing the affected skin area thoroughly with a gentle, non-comedogenic cleanser to remove any dirt or oils. Pat the skin dry with a clean towel. Prepare a dextrose gel, a 10% dextrose gel, which is then coupled with low-frequency ultrasound to facilitate deeper penetration of the dextrose
223436575|NCT07169890|OTHER|Ultrasound|the ultrasound probe is moved in a circular motion over the skin for a duration of 5 to 10 minutes per session
223436576|NCT07169890|OTHER|Dextrose Topical application|Apply a thin layer of the dextrose gel evenly across the acne-affected areas using a sterile applicator or cotton pad
223436577|NCT05934903|DEVICE|Transcranial Direct Current Stimulation|Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
223436578|NCT07170267|OTHER|Transversalis fascia plane block|Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) with bilateral transversalis fascia plane (TFP) block (using 20 mL of bupivacaine 0.25%) at the end of surgery.
223740692|NCT05700825|BEHAVIORAL|Expiratory Muscle Strength Training + Cough Skill Training|"Expiratory Muscle Strength Training (EMST). EMST is a widely used and efficacious treatment approach that uses a calibrated device with a one-way, spring-loaded pressure relief valve to mechanically overload the expiratory and submental muscles.~Cough Skill Training (CST) involves a digital peak flow meter device which measures PEFR (peak expiratory flow rate) in liters/second and allows patients to receive immediate biofeedback."
224047566|NCT05337579|OTHER|Supplemental Micro Breaks|Supplemental Micro Breaks, of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours
224047567|NCT05337579|PROCEDURE|Exercise Breaks|Exercise Breaks, of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.
224047568|NCT00267683|DRUG|insulin aspart|
224047569|NCT00267683|DRUG|glibenclamide|
224047570|NCT00220168|DRUG|Irinotecan, Capecitabine|
223436579|NCT07170267|DRUG|Intrathecal dexmedetomidine|Patients will receive spinal anesthesia (using 2.5 mL of hyperbaric bupivacaine 0.5%) + (5 µg intrathecal dexmedetomidine diluted in 0.5ml saline) with a sham block at the end of surgery.
223436580|NCT07169136|DRUG|GLP-1 Receptor Agonists|Weekly subcutaneous Semaglutide.
223436581|NCT07175896|BEHAVIORAL|Immediate delivery of low-sodium DASH diet group coaching plus hand-on cooking program|Low-sodium DASH diet group coaching enhanced by cooking classes
223436582|NCT07175896|BEHAVIORAL|Delayed delivery of low-sodium DASH diet group coaching plus hand-on cooking program|Low-sodium DASH diet group coaching enhanced by cooking classes
223436583|NCT07177196|DRUG|nL-PRPH2-001|Personalized antisense oligonucleotide
223436584|NCT07177092|PROCEDURE|Surgery|① Preoperative evaluation must confirm resectability. Thoracoscopic minimally invasive surgery will be performed, with the surgical approach selected according to disease conditions, such as lobectomy, segmentectomy, wedge resection, or sleeve resection; ② Systematic mediastinal lymph node dissection or lymph node sampling (based on preoperative imaging and intraoperative evaluation) must be performed; ③ Postoperative recovery must be adequate (postoperative complications ≤ Clavien-Dindo grade II).
223436585|NCT07177092|DRUG|Osimertinib|Dose: 80 mg orally, once daily, until disease progression or the occurrence of unacceptable toxicity. The dose should be administered at approximately the same time each day, at 24-hour intervals.
223740693|NCT05414331|OTHER|Discontinuing all beta-blocker|All beta-blockers will be stopped 2 months after CABG
224047571|NCT04256460|BEHAVIORAL|Healthy diet, regular exercises and peer support|After assessing the exercise and nutritional status of the participants, health staff in community health centers implemented personalized healthy diet and regular exercises intervention, including coaching on healthy exercises and developing personalized dietary prescriptions for participants. Besides, peer support is implemented as a self management strategy in community health service centers or community self management groups to enhance the behavioral change support for these participants.
224047572|NCT00918853|PROCEDURE|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
224047573|NCT00915772|DRUG|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
224047574|NCT00915772|DRUG|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
224047575|NCT00915772|DRUG|Metformin|Metformin 1000 mg tablet bid
223436586|NCT07175389|DRUG|JDB153|JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
223436587|NCT07175389|DRUG|Serplulimab|Serplulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).
223436588|NCT07176637|BEHAVIORAL|A-B-C Program|"The purpose of this study is to assess the effectiveness of the 4-week A-B-C program in implementing and maintaining daily PA. We will explore outcomes for the effectiveness of the program, on (1) increasing the weekly duration of PA, and (2) reducing baseline depressive symptoms and other mental health outcomes among sedentary older adults with depressive symptoms at baseline. Specifically, we will evaluate the change in depressive symptoms, stress, and self-esteem from baseline, at the end of the 4-week intervention, and after additional 4 weeks from the end of the intervention (at follow-up). The intervention will be 4 weeks overall, with total of 8 sessions: the duration of each session will be 60 minutes each, and the frequency will be twice weekly for 4 weeks."
223478565|NCT04345224|OTHER|Rigid tape|The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.
224142748|NCT02563925|DRUG|HER2 directed therapy|
224047576|NCT00393796|DRUG|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
224142749|NCT02563925|DRUG|Durvalumab|
224142750|NCT06423872|DRUG|ZT002|Participants will receive a single subcutaneous (SC) ZT002 injection.
224142751|NCT06423872|OTHER|Placebo|Participants will receive same volume as of the study drug.
224142752|NCT04395534|PROCEDURE|Complete mesocolic excision|
224142753|NCT05511025|DRUG|AZD6234|Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
224142754|NCT05511025|DRUG|Placebo|Participants will receive matching volumes of the placebo as a solution via SC or IV injection
224142755|NCT05511025|COMBINATION_PRODUCT|Acetaminophen|Participants will receive a single dose of acetaminophen as part of a meal
224142756|NCT05006339|DEVICE|Dental Monitoring|Patients in this arm are not required to attend in-office retention appointments except if they have any problems with their retainers and when data collection is necessary. Instead they are required to submit scans of their teeth through the DM mobile application at the designated intervals.
224142757|NCT05006339|OTHER|Clinic Review|Patients in this arm are required to attend in clinic appointments for their retention review
224142758|NCT03220711|DEVICE|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
224142759|NCT03220711|DRUG|Fluorescein|Fluorescent dye used for imaging contrast only.
224047577|NCT00393796|OTHER|Placebo|
224142760|NCT02257164|PROCEDURE|Femoral nerve block|2 mg/ml
224142761|NCT02257164|PROCEDURE|obturator nerve block|
224142762|NCT02257164|PROCEDURE|intraarticular injection|
224047578|NCT03504514|DEVICE|speech trials during different ventilation conditions|ventilator parameters are modified
224047579|NCT03504514|OTHER|speech trial|reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
224047580|NCT00564005|OTHER|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
224047581|NCT00564005|OTHER|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
224047582|NCT00564005|OTHER|Combined therapy (CT)|combined different treatment approaches
224142763|NCT00400712|BEHAVIORAL|physical rehabilitation|two weeks intensive physical rehabilitation
224142764|NCT00001735|PROCEDURE|Gene therapy|
224142765|NCT04729062|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
224142766|NCT02335580|DRUG|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
224142767|NCT02335580|PROCEDURE|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
224142768|NCT04857749|OTHER|Standard care|As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.
224142769|NCT04857749|OTHER|Navigation Nursing|With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
224142770|NCT04387526|DRUG|(SOF and DCV)|
224142771|NCT04387526|DRUG|(SOF, DCV, and RBV)|
224142772|NCT03176173|RADIATION|Image-guided Radiation Therapy|"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."
224142773|NCT03176173|DRUG|Immunotherapy (physician's choice for standard of care immunotherapy)|Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.
224142774|NCT00237445|DRUG|telithromycin|
224142775|NCT00237445|DRUG|azithromycin|
224142776|NCT02466412|OTHER|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
224142777|NCT02466412|OTHER|mCC|Single use of subject's own menthol conventional cigarette (mCC)
224047583|NCT00564005|BEHAVIORAL|Control intervention|Conventional treatment program
224047584|NCT01383096|DRUG|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
224047585|NCT01383096|DRUG|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
224047586|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
224047587|NCT01383096|DRUG|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
224047588|NCT04679779|OTHER|designed occupational therapy program|Exercises facilitating hand skill patterns will include basic reach, grasp, carry and release and the more complex skills of in-hand manipulation and bilateral hand use.
224047589|NCT04679779|OTHER|Wii virtual reality games|"1. Bowling~2. Frisbee~3. Basketball~4. Boxing"
224047590|NCT01211535|DEVICE|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
224047591|NCT01211535|DEVICE|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
224047592|NCT01211535|DEVICE|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
224047593|NCT03288870|DRUG|BCD-100|monoclonal antibody to PD-1 receptor
224047594|NCT03288870|DRUG|Docetaxel|Chemotherapy drug (taxane)
224047595|NCT04747834|DEVICE|MICOR-304|The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.
224047596|NCT02342366|DRUG|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
224047597|NCT02342366|DRUG|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
224047598|NCT04187300|DRUG|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
224047599|NCT03974087|DEVICE|Transcranial Direct Current Stimulation (tDCS)|2mA stimulation for 20 minutes
224142778|NCT04198233|DRUG|Diazepam|Diazepam 10 mg compounded suppository
224142779|NCT04198233|DRUG|Placebos|Placebo suppository
224300070|NCT04460196|OTHER|survey|Each admitted patient will complete a questionnaire
224300071|NCT03847103|OTHER|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
224300072|NCT03847103|OTHER|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
224047600|NCT00670501|DRUG|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
224047601|NCT00670501|DRUG|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
224047602|NCT00670501|DRUG|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
224047603|NCT00670501|DRUG|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
224047604|NCT00670501|DRUG|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
224047605|NCT02781142|OTHER|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
224047606|NCT03485248|DIETARY_SUPPLEMENT|Beetroot Juice|140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
224047607|NCT03485248|DIETARY_SUPPLEMENT|Placebo|140ml of Beetroot Juice (nitrate free)
224047608|NCT01411020|PROCEDURE|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
224047609|NCT00164073|PROCEDURE|Liver biopsy|
224047610|NCT03289936|DEVICE|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
224047611|NCT03289936|DEVICE|SNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
224047612|NCT02508051|BEHAVIORAL|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
224047613|NCT02508051|BEHAVIORAL|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
224142780|NCT05058898|OTHER|blood samples|5 mL
224142781|NCT05058898|OTHER|Scabs and pus samples|if available
224142782|NCT02709772|BEHAVIORAL|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
224142783|NCT03509987|DEVICE|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
224142784|NCT03620812|DIETARY_SUPPLEMENT|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
224142785|NCT00553137|DRUG|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
224142786|NCT00553137|DRUG|fluconazole|150 mg fluconazole tablets once daily for 14 days
224142787|NCT04776421|PROCEDURE|Diverting ileostomy|Diverting ileostomy
224142788|NCT02711904|DRUG|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~* 20 years old - 6.0 mcg/Kg/h~* 30 years old - 5.7 mcg/Kg/h~* 40 years old - 5.3 mcg/kg/h~* 50 years old - 5.0 mcg/kg/h~* 60 years old - 4.6 mcg/kg/h~* 70 years old - 4.3 mcg/kg/h~* 80 years old - 4.0 mcg kg/h."
224142789|NCT02711904|DRUG|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~* 20 years old - 9.0 mcg/Kg/h~* 30 years old - 8.5 mcg/Kg/h~* 40 years old - 8.0 mcg/kg/h~* 50 years old - 7.5 mcg/kg/h~* 60 years old - 7.0 mcg/kg/h~* 70 years old - 6.5 mcg/kg/h~* 80 years old - 6.0 mcg kg/h."
224142790|NCT02330107|OTHER|MAT & LAT|"For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
224142791|NCT06016140|OTHER|Medication plan|Involved participants will jointly agreed on continued medication treatment (treatment aim, planned monitring and evaluation and responsibility, and the physician will document the plan in the electronic health record
224142792|NCT02553317|BIOLOGICAL|Caplacizumab|"* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
223436589|NCT07176637|OTHER|Physical Activity Educational Program|"The control group will serve as an sham active comparator, designed to control for group format, scheduled sessions, and social interaction. The agenda for the control group was designed to specifically function as a control to compare the A-B-C program. These participants will also attend twice-weekly 60-minute sessions over four weeks, focusing on educational content about the health benefits of physical activity and current physical activity guidelines.~The difference between the two interventions is that the control program is strictly educational, whereas the A-B-C program focuses on challenging cognitive biases that change decision making related to physical activity. To reiterate, the control program simply provides education on the effects of physical activity with physiological evidence."
223436590|NCT07175805|PROCEDURE|Bariatric Surgery|Patients in this arm plan to undergo gastric sleeve or gastric bypass surgery.
223436591|NCT07175805|DRUG|GLP1 receptor agonist|Patients in this arm plan to start a GLP-1 receptor agonist.
223436592|NCT07175480|DRUG|Intermittent PD-1/PD-L1 ICI + VEGFR-TKI|Any PD-1/PD-L1 inhibitor or VEGFR-TKI that is commercially marketed, regulatory-approved and reimbursed under public health plans.Dose as recommended by the manufacturer.
223436593|NCT07175428|DRUG|REGN7508|Administered per the protocol
223436594|NCT07175428|DRUG|REGN9933|Administered per the protocol
224047614|NCT02782936|OTHER|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
224300073|NCT03847103|OTHER|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
223436595|NCT07175428|DRUG|Apixaban|Administered per the protocol
223436596|NCT07177261|BEHAVIORAL|Fast Friends|"Participants will interact with another person while both have their EEG recorded. They will ask and answer 12 questions with the other person that become increasingly personal in nature, e.g., When did you last cry in front of another person? By yourself?"
223436597|NCT07177261|BEHAVIORAL|Small Talk|"Participants will interact with another person while both have their EEG recorded. They will ask and answer 12 impersonal questions with the other person , e.g., Do you prefer digital watches and clocks or the kind with hands? Why?"
223436598|NCT07176325|OTHER|Creatine Monohydrate|Creatine Monohydrate was dosed based on industry recommendations, with and without a loading dose
223436599|NCT07174765|OTHER|Person-level linkage of the database looking for relationship with septic shock survival and comorbidities, previous intake of medication, and previous dependence on health services.|"A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted with septic shock to hospitals in the region will be carried out.~The overall data of patients admitted to hospitals will be analysed. The survival data of patients will be compared with their previous individual drug consumption and inhospital survival to septic shock. In addition, drug dependence and dependence on health services of survivors will be studied in comparison with their situation prior to sepsis.~The objective is to establish the Registry of Administrative Data Automatically Recorded for Septic Shock (RADAR-Septic Shock), leveraging administrative data to characterize septic shock incidence, describe patient profiles, identify population-specific healthcare needs, and provide benchmark values for performance assessment in Catalonia's public health system."
223478566|NCT04345224|OTHER|Sham tape|The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
224142793|NCT02553317|BIOLOGICAL|Placebo|"* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
224142794|NCT01965912|DRUG|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
224142795|NCT03092349|DEVICE|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
224142796|NCT05521100|PROCEDURE|Vascular closure device|Suture of lower extremity veins using the Proglide Vascular Closure Device
223436600|NCT07175116|DEVICE|3M™ Tegaderm™ Antimicrobial Transparent Dressing (chlorhexidine gluconate-impregnated)|Individually applied transparent dressing containing chlorhexidine gluconate (0.5-1 mg/cm²) for antimicrobial protection at the central venous catheter insertion site. The dressing maintains site visibility, reduces catheter manipulation frequency, and provides sustained release of chlorhexidine to lower colonisation and bloodstream infection risk.
223436601|NCT07175116|DEVICE|Conventional transparent polyurethane dressing|Transparent polyurethane dressing without antimicrobial impregnation, applied at the central venous catheter insertion site. This dressing allows site inspection and is widely used in standard paediatric intensive care protocols but provides no antimicrobial activity.
224047615|NCT02782936|DEVICE|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
224047616|NCT03593850|BEHAVIORAL|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
224047617|NCT03593850|BEHAVIORAL|Silence Group|Audio file that contained no sounds.
224047618|NCT02539420|DEVICE|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
224047619|NCT05582395|DRUG|Mavacamten|Specified dose on specified days
224142797|NCT05521100|PROCEDURE|figure eight stitch|Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures
224142798|NCT00406991|DRUG|aspirin|
224142799|NCT00406991|DRUG|clopidogrel|
224047620|NCT05582395|OTHER|Placebo|Specified dose on specified days
224142800|NCT05341635|DIAGNOSTIC_TEST|Swab sampling|Collection of three nose-pharyngeal and oral swabs
224142801|NCT00188266|DRUG|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
224142802|NCT01492699|DRUG|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
224047621|NCT02946242|DEVICE|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
223436602|NCT07177157|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|2000 IU of Vitamin D daily (1 pill)
223436603|NCT07175064|BEHAVIORAL|Nursing-Led Livelihood Programs|A set of community-based livelihood initiatives introduced in 2016 and facilitated by nursing faculty in partnership with local leaders. Activities included bracelet making, rag making, and liquid dishwashing. The programs aimed to provide sustainable income, build women's confidence and skills, and indirectly improve health outcomes by addressing poverty-related social determinants of health.
224047622|NCT03357315|BIOLOGICAL|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
224047623|NCT01735279|DRUG|Omega 3|Each fish oil capsule contained 210.99 mg of EPA and 129.84 mg of DHA.
224047624|NCT01735279|DRUG|Placebo|mineral oil + food dye #2 (simulating the colour of essential fatty acids); 1000 mg of mineral oil per capsule
224047625|NCT01106820|OTHER|Supervised progressive resistance training|Supervised progressive resistance training
224047626|NCT01106820|OTHER|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
224047627|NCT00189189|BEHAVIORAL|parent management training|
224047628|NCT02170779|BEHAVIORAL|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
224142803|NCT02830035|PROCEDURE|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
224142804|NCT02830035|PROCEDURE|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
224142805|NCT04206527|BEHAVIORAL|Training of AHSAs on PCC for FP|ASHAs provided with training on FP methods and counseling plus PCC for FP
224047629|NCT02170779|OTHER|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
224047630|NCT00409929|DRUG|AEB071|
224142806|NCT04206527|BEHAVIORAL|Enhanced FP training|Participation in an enhanced FP training including PCC
224142807|NCT03000387|DRUG|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
224142808|NCT03000387|DRUG|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
224047631|NCT00369785|DRUG|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
224047632|NCT00369785|DRUG|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
224047633|NCT02946632|DRUG|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
224047634|NCT02946632|DRUG|Stepwise add-on therapy|metformin -\> glimepirde -\> sitagliptin
224047635|NCT02977754|OTHER|This is an observational study|Imaging
224047636|NCT02615704|DEVICE|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
224047637|NCT02615704|DEVICE|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
224047638|NCT02615704|DEVICE|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
224047639|NCT02615704|DEVICE|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
224047640|NCT00048620|DRUG|N-acetylgalactosamine 4-sulfatase|
224047641|NCT05182996|BEHAVIORAL|smoking education|Educate on the relationship between inflammatory bowel disease and smoking and the necessity and importance of quitting smoking.
224047642|NCT01584076|DRUG|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
224047643|NCT01584076|OTHER|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
224047644|NCT03100669|PROCEDURE|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
224047645|NCT03623581|BIOLOGICAL|GB226|3mg/kg treat every 2 weeks
224047646|NCT01968850|DRUG|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
224047647|NCT02819076|OTHER|pain scale|
224047648|NCT01883479|BEHAVIORAL|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
224047649|NCT01883479|BEHAVIORAL|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
224047650|NCT04822610|PROCEDURE|interscalene block|peripheral nerve block
224300074|NCT04866849|OTHER|examination|"The presence of bruxism was based on self-reported bruxism and examination. Self reported bruxism was recorded as yes or no . Participants were examined for the existence of four clinical signs of bruxism: (I) abnormal tooth wear, (II) impressions of teeth in the buccal area, (III) impressions of teeth on the tongue, and (IV) hypertrophy of the masseter muscle. In this study, clinical signs of bruxism were considered present if one of the four items was answered yes."
224300075|NCT02592109|BEHAVIORAL|Enhanced Counseling using CFR based on Linear Programming|
224047651|NCT04822610|PROCEDURE|suprascapular block + axillary block|peripheral nerve block
224047652|NCT01636479|DRUG|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
224047653|NCT02827669|BEHAVIORAL|One Drop Experts Program|
224047654|NCT02827669|BEHAVIORAL|One Drop Experts Program + Apple Watch|
224047655|NCT02367066|DRUG|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
223478567|NCT00574639|DRUG|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
223478568|NCT00574639|DRUG|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
223478569|NCT04943393|OTHER|nointervention|Nointervention
223478570|NCT05316870|BEHAVIORAL|Standardized anticoagulation management plan and process of atrial fibrillation in primary medical institutions|Compared with the current anticoagulation management service, we pay more attention to early initiation of anticoagulant therapy and long-term follow-up management.
223478571|NCT05316870|BEHAVIORAL|Conventional general practitioner management model|The current general practitioner anticoagulation management model was continued in the control group.
223478572|NCT02215902|DEVICE|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
224047656|NCT02367066|OTHER|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
224047657|NCT04616391|DEVICE|insulin pump Medtronic 780G|"Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits."
224047658|NCT02231021|DRUG|alogliptin|alogliptin 25 mg add-on background medication metformin
224047659|NCT02231021|DRUG|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
224047660|NCT02231021|DRUG|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
224047661|NCT01898689|DRUG|Ropivacaine 0.1%|A sciatic catheter was inserted and ropivacaine 0.1% was administered as a basal infusion for 6 hours.
224047662|NCT01898689|DRUG|Ropivacaine 0.4%|A sciatic catheter was inserted and ropivacaine 0.4% was administered as a basal infusion for 6 hours.
223436604|NCT07176741|DIAGNOSTIC_TEST|TREM-1 expression (via immunohistochemistry) between SAH patients and controls|"this is the first study to focus on hepatocyte-specific TREM-1 expression in human liver tissue~What Distinguishes This Study Tissue-Level Focus: Unlike most studies that assess blood biomarkers or systemic inflammation, this research directly measures TREM-1 expression in liver tissue (hepatocytes), offering localized insights into disease severity and immune response.~Retrospective Biobank Utilization: Leverages a rich biobank of archival biopsies spanning 10 years, ensuring real-world data and long-term clinical follow-up-rarely combined at this scale in similar research.~Dual Purpose (Diagnostic \& Prognostic): Most biomarkers are evaluated for either diagnostic or prognostic value-this study uniquely addresses both in a single, comprehensive framework.~Therapeutic Translation Potential: TREM-1 is already a target for pharmacological inhibition (e.g., with peptide inhibitors tested safely in humans for other conditions). This positions the study for rapid clinical translation,"
223436605|NCT07177014|BEHAVIORAL|Stress First Aid for Harm Reduction Workers|Stress First Aid for Harm Reduction Workers is a 2-hour training and up to six virtual 30-minute monthly learning collaborative meetings.
223436606|NCT07176650|DRUG|HLX13|Patients will receive HLX13 (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
224047663|NCT03628937|DIETARY_SUPPLEMENT|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
223436607|NCT07176650|DRUG|Yervoy|Patients will receive US-sourced YERVOY® (3 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles.
223436608|NCT07176650|DRUG|OPDIVO|Patients will receive EU-sourced OPDIVO® (EU-sourced nivolumab) (1 mg/kg) treatment on the first day of each 3-week cycle, up to 4 cycles. Subjects who may continue to benefit from OPDIVO® treatment as assessed by investigators will be subsequently treated with local-sourced OPDIVO® monotherapy every 4 weeks, up to 2 year after randomization.
223436609|NCT07174778|BEHAVIORAL|Episodic future thinking|Participants will engage in episodic future thinking prompted via text-based cues and picture-based cues to help them adhere to oral anticoagulants. Participants will also receive health education on atrial fibrillation-related stroke prevention.
224047664|NCT03628937|OTHER|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
224047665|NCT00627302|DRUG|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
224047666|NCT00627302|DRUG|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
224047667|NCT00570817|OTHER|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
224047668|NCT00814671|DRUG|Rifapentine 450|rifapentine 450 mg
224047669|NCT00814671|DRUG|Rifapentine 600|rifapentine 600 mg
224047670|NCT00814671|DRUG|Rifampin|rifampin 600 mg
224047671|NCT05594758|DRUG|Olverembatinib|Oral Olverembatinib
224047672|NCT03788395|DEVICE|Symbicort Turbohaler plus Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
224047673|NCT03788395|DRUG|Symbicort Turbohaler without Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
224047674|NCT00786123|DIETARY_SUPPLEMENT|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
224047675|NCT00786123|DIETARY_SUPPLEMENT|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
224047676|NCT04556136|DEVICE|Standing Phototherapy Kiosk|Benesol is a freestanding booth designed to deliver a small amount of targeted UVB with an interactive user interface and cloud-based software that enables patient self-care. The treatment delivery mechanism uses a metal halide lamp with a series of filters and a lens to optimize full-body exposure to the narrow spectrum (293 - 303nm) of UVB light most efficient at producing vitamin D3. The device uses software to identify patients, establish individual skin types and determine dosage. The system has been designed to manage exposure time and frequency and deliver 60% of a skin-type-adjusted Minimal Erythemal Dose (MED). The expected result for users is a rise in blood levels of 25(OH)D via the endogenous pathway.
224047677|NCT04556136|DIETARY_SUPPLEMENT|D3 Oral supplement|Each subject assigned to the comparison group was instructed to take one vitamin D3 pill, dispensed by the research pharmacist, each day with a meal for 70 days. Subjects were instructed not to take any additional vitamin D supplementation during the study period. This dosing frequency is consistent with the RDA recommendation. Subjects were instructed to bring their pill bottle with them when returning for their follow up appointment.
224047678|NCT02678416|DRUG|IV Acetaminophen (Treatment A)|Acetaminophen administered by intravenous (IV) infusion
224047679|NCT02678416|DRUG|Oral Acetaminophen (Treatment B)|Acetaminophen administered by oral tablets
224142809|NCT03671382|BEHAVIORAL|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
224142810|NCT06076200|DRUG|Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
223436610|NCT07174778|BEHAVIORAL|attention control|The control group will receive standard care, including routine health education from ward nurses and one post-discharge telephone follow-up. In additon, participants will receive a message from the researcher at the same time point each day, but the message will only involve daily greetings.
223436611|NCT07175519|DEVICE|Endovascular treatment of aneurysms|Aneurysm can be treated by endovascular devices using catheters, Treatment modalities can include coils, stents, flow diverters as well as intrasaccular devices
223436612|NCT07175272|DRUG|Holy basil extract|"Holy basil extract (Ocimum sanctum) will be provided as an oral capsule formulation. Each capsule contains 300 mg of standardized holy basil extract with defined amounts of active compounds including ursolic acid (≥0.10 mg) and rosmarinic acid (≥0.50 mg). Participants will be instructed to take one capsule once daily for 28 consecutive days.~The capsules will be dispensed in blister packs, with labeling according to clinical trial regulatory requirements. Participants will be asked to record daily intake in a study diary, and compliance."
223436613|NCT07177209|DRUG|Non-Interventional Study|As provided in real world practice
223436614|NCT07174973|OTHER|Balance training with FES|"Participants assigned to this group complete a standardized balance training program while receiving FES to the lower limb muscles. Training sessions involve standing in a safety harness and performing interactive, game-based balance tasks on a force plate that provides real-time visual feedback of body sway.~FES will be applied bilaterally to specific leg muscles (e.g., tibialis anterior, quadriceps, gastrocnemius) using surface electrodes. Stimulation parameters (pulse width, frequency, and amplitude) are individually adjusted to produce visible yet comfortable muscle contractions that support functional standing and balance activities. Stimulation is delivered in synchrony with balance exercises to augment muscle activation during postural adjustments."
223436615|NCT07174973|OTHER|Balance training wiith combined neuromodulation (TSCS+FES)|Participants in this group complete the standardized balance training program while receiving both FES and TSCS. Training sessions take place in a safety harness and involve interactive, game-based balance exercises performed on a force plate with real-time visual feedback of body sway.FES is delivered bilaterally to lower limb muscles (e.g., tibialis anterior, quadriceps, gastrocnemius) through surface electrodes. Stimulation parameters (pulse width, frequency, amplitude) are individualized to produce visible, comfortable contractions that facilitate muscle activation during postural tasks.TSCS is applied simultaneously via electrodes placed over the thoracolumbar spinal region to modulate spinal excitability and enhance neuromuscular control. Standardized stimulation parameters are used across participants, with adjustments made to ensure tolerance and safety.
223436616|NCT07174973|OTHER|Balance training only|Participants in this group complete the standardized balance training program without electrical stimulation. Sessions are conducted in a safety harness and consist of interactive, game-based balance exercises performed on a force plate, which provides real-time visual feedback of body sway. Tasks are designed to challenge postural control by requiring weight shifting in multiple directions, maintaining stability during perturbations, and progressively increasing task difficulty.
223436617|NCT07175662|BIOLOGICAL|NWRD08 administered by electroporation|NWRD08 delivered via IM injection + electroporation using TERESA device
223436618|NCT07175662|BIOLOGICAL|Placebo administered by electroporation|Placebo delivered via IM injection + electroporation using TERESA device
223436619|NCT07175636|DRUG|Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)|"QL1706 is an investigational bifunctional MabPair antibody that simultaneously targets PD-1 (IgG4) and CTLA-4 (IgG1). It is administered intravenously according to the study protocol during the neoadjuvant chemotherapy cycles. The use of QL1706 aims to enhance antitumor immunity in the pMMR/MSS rectal cancer setting, a population typically unresponsive to immune checkpoint blockade alone.~mFOLFOX6 is a standard oxaliplatin-based chemotherapy regimen composed of oxaliplatin, leucovorin, and 5-fluorouracil. It is administered in combination with QL1706 during the neoadjuvant phase as part of total neoadjuvant therapy (TNT). The regimen is modified to optimize tolerability while maintaining efficacy in locally advanced rectal cancer.~Short-course radiotherapy consists of a total dose of 25 Gy delivered in 5 fractions over one week to the pelvis. This approach is designed to rapidly downstage tumors, release tumor antigens, and prime the immune microenvironment for subsequent immunotherapy"
223478573|NCT04496232|DEVICE|PICSI|Semen processing by density gradient centrifugation followed by sperm selection by PICSI dishes of the first ejaculate
223478574|NCT04496232|OTHER|Second ejaculate|Semen processing by density gradient centrifugation for the second ejaculate
223478575|NCT02669875|DRUG|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
223478576|NCT02669875|DRUG|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
223478577|NCT01653691|PROCEDURE|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
223478578|NCT01653691|PROCEDURE|Sham|No treatment to one side of subject's scar.
223478579|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract LD and white bread|109g of white bread with 0.5g of seaweed extract
224047680|NCT02678416|DRUG|Placebo (Treatment C)|Placebo administered by IV infusion or oral tablets
224047681|NCT02678416|OTHER|Morphine (Treatment D)|Morphine administered by IV infusion
224047682|NCT00409097|DRUG|Rosiglitazone|
224047683|NCT04645043|OTHER|US_Eso|After applying ultrasound guided esophageal pressure, the peak inspiratory pressure increased from 10cmH2O to 24cmH2O (increased by 2 cmH2O) during mask ventilation.
224047684|NCT04749966|OTHER|This is an observational study, there are no interventions|This is an observational study, there are no interventions
224047685|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
223478580|NCT05460884|DIETARY_SUPPLEMENT|Seaweed extract HD and white bread|109g of white bread with 1g of seaweed extract
223478581|NCT05460884|DIETARY_SUPPLEMENT|White bread|109g of white bread
223478582|NCT04182893|DIAGNOSTIC_TEST|ctDNA and Exosome Combined Detection|Through the detection and analysis of blood and alveolar lavage fluid of 300 patients with pulmonary nodules and 100 healthy population, the diagnostic efficacy of ctDNA and exosomes combined detceion will be studied.
223436620|NCT07177105|PROCEDURE|Cytoreductive surgery|* Preoperative evaluation must confirm resectability. Thoracoscopic minimally invasive surgery will be performed, with the surgical approach selected according to disease conditions, such as lobectomy, segmentectomy, wedge resection, or sleeve resection; ② Systematic mediastinal lymph node dissection or lymph node sampling (based on preoperative imaging and intraoperative evaluation) must be performed; ③ Postoperative recovery must be adequate (postoperative complications ≤ Clavien-Dindo grade II).
224047686|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
223436621|NCT07177105|DRUG|Immunochemotherapy|"1. Treatment phase:~   ① Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less;~   ② Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less;~   ③ Carboplatin Dose: administered according to the area under the curve (AUC) of 5 mg/mL/min, with infusion time controlled within 15-60 minutes.~   The above regimen will be administered every 3 weeks after surgery for a total of 4 cycles.~2. Maintenance phase:~   * Sintilimab Dose: 200 mg, administered intravenously over 30 minutes or less; ② Pemetrexed Dose: 500 mg/m², administered intravenously over 10 minutes or less; The above regimen will be administered every 3 weeks. Maintenance with sintilimab will continue for up to 31 cycles, or the total duration of systemic therapy from randomization will not exceed 2 years, or until disease progression or the occurrence of unacceptable toxicity"
223436622|NCT07176117|PROCEDURE|Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)|A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.
223436623|NCT07176117|PROCEDURE|Continuous Positive Airway Pressure (CPAP)|Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).
223436624|NCT07174531|PROCEDURE|Transcatheter valve in Valve implantation|Transcatheter valve-in-valve implantation for patients with degenerated aortic/mitral/tricuspid bioprosthetic valves who are at high-risk to redo surgical valve replacement.
223436625|NCT07175740|DIETARY_SUPPLEMENT|Fasting|No meal
223436626|NCT07175740|DIETARY_SUPPLEMENT|Sucrose enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 22g sucrose
223436627|NCT07175740|DIETARY_SUPPLEMENT|Fructose enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 22g fructose
224142811|NCT04260061|DEVICE|training systems|Participants will receive 18 intervention sessions for about 6-9 consecutive weeks in a clinical setting (75 minutes per session, 2-3 sessions per week). For each intervention session, participants will first receive 10 minutes of warm-up followed by 50 minutes robotic-assisted training (robotic-assisted training includes 10 minutes passive training mode, 20 minutes active training mode, and 20 minutes robot-participant interactive training mode) and then 15 minutes of functional activity without robotic-assisted (content will be related to robotic-assisted training and will be based on the action function and preferences of the participants).
223436628|NCT07175740|DIETARY_SUPPLEMENT|Fat enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, 15g fat
223436629|NCT07175740|DIETARY_SUPPLEMENT|Aspartame enriched meal|175 ml of oatmeal cereal, one slice of bread, 30g of cheese, aspartame (matched for taste)
224047687|NCT00872976|DRUG|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
224047688|NCT00872976|DRUG|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
223436630|NCT07175740|OTHER|Exercise session|A 60-minutes exercise session on a cycle ergometer (Corival 400, Quinton Instruments, Seattle, WA, USA) at 60% of the VO2peak (determined at a baseline visit)
224047689|NCT01318252|DRUG|AL-54478 0.005%|
223566247|NCT05302167|BEHAVIORAL|Molehill Mountain app|"The Molehill Mountain app (currently Version 2) was developed jointly by King's College London (Lead: Prof Emily Simonoff; Advisors: Dr Ann Ozsivadjian and Dr Rachel Kent) and UK autism charity Autistica (Product Owner: Andy Clarke; Product Designer: Joanna Alpe) for use by autistic people aged ≥12-years (https://www.autistica.org.uk/molehill-mountain).~The app was designed based on a self-guided paper-and-pencil CBT toolkit adapted for autism by Professor Emily Simonoff. Since the first version of Molehill Mountain (a two-week long programme) was launched in 2016, and based on surveys of autistic people and five rounds of prototype testing, the Molehill Mountain V2 app was relaunched in April 2021 as a three-month long app-based programme with enhanced interactive features. This 3-month V2 Molehill Mountain app, with enhanced interactive features supporting short daily logins, that will be implemented in the current study."
224142812|NCT03125876|DRUG|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
223566248|NCT05302167|DEVICE|Molehill Mountain app|As above.
223740694|NCT03033511|DRUG|Placebo for dexamethasone|Placebo for dexamethasone PO twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
224047690|NCT01318252|DRUG|Latanoprost 0.005%|
224047691|NCT01318252|DRUG|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
224047692|NCT01848353|BEHAVIORAL|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
224047693|NCT01983397|OTHER|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
224047694|NCT01983397|OTHER|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
223436631|NCT07177027|BEHAVIORAL|Music intervention|Participants listened to 12 relaxing music tracks introduced during prenatal childbirth classes at 36 weeks of gestation. The tracks were shared via WhatsApp to encourage regular listening during pregnancy. During labor, participants were encouraged to listen to music whenever they wished. At cervical dilations of 4 cm, 6 cm, and 8 cm, participants listened to their preferred tracks from the playlist for 20 minutes. Pain intensity was measured before and after each session using the Visual Analog Scale (VAS).
223436632|NCT07177027|BEHAVIORAL|Breathing Exercise|Participants were trained in Lamaze breathing techniques during prenatal childbirth classes. They practiced guided breathing exercises during labor at cervical dilation points of 4 cm, 6 cm, and 8 cm. Pain intensity was assessed before and after each session using the Visual Analog Scale (VAS).
223436633|NCT07177274|RADIATION|Low Level Laser Therapy|Collecting wound stiffness data using the OCT-air-jet and Myoton Pro before and after the LLLT treatment using the device's indentation system. Then the intervention is applying LLLT to the wound for 3 min. The LLLT utilized the Red Dot Laser Diode Module Class IIIA.
223436634|NCT07176897|DIAGNOSTIC_TEST|Normal Toric IOL implantation with digital marking|Digital marking was compared to bedside marking, but there was no change in clinical practice. The difference in the marks was measured.
223436635|NCT07175324|DEVICE|optical coherence tomography angiography|correlation between OctA and Visual field changes in Multiple Sclerosis
223436636|NCT07175324|DEVICE|Visual Field Perimetry|Correlation between OctA and Visual field changes in Multiple sclerosis
223436637|NCT07175857|DEVICE|Lyv Endo app|Lyv Endo is a CE-marked Class I therapeutic digital medical device offering a patient-centered, integrative approach. Its innovation lies in its ability to deliver personalized content based on symptoms, surpassing the limits of traditional care.
223566249|NCT03229772|DEVICE|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
224047695|NCT05807880|DRUG|The combination treatment of anlotinib, penpulimab and capecitabine.|Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
224047696|NCT00935272|DEVICE|Restylane®|Restylane® injections in the lips
224047697|NCT00935272|DEVICE|Non-Treatment|Non- Treatment
224047698|NCT00611338|BEHAVIORAL|HIV Skills-based Prevention|
224047699|NCT00953719|DEVICE|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
224047700|NCT00953719|DEVICE|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
224047701|NCT04085796|OTHER|ICCI|Intentional Compassionate Communication Intervention
224142813|NCT05816967|PROCEDURE|Medication review and discharge counseling|Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.
224142814|NCT03070561|BIOLOGICAL|sublingual film with peanut extract|
224142815|NCT01478399|DRUG|PB1023 Injection|90 mg Dose
224142816|NCT02308176|BEHAVIORAL|APP + health advice|health advice and reinforcement to it
224300076|NCT02439671|BEHAVIORAL|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~* Social communication (e.g. listening, perspective taking)~* Self-determination (e.g. problem-solving, self-advocacy)~* Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
224300077|NCT06111274|DRUG|Pimicotinib (ABSK021)|The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
224300078|NCT05887895|DRUG|INS062 injection、INS068 injection、HR20014 injection|"INS062 injection：A single dose of 0.4 DU/kg is administered to healthy subjects.~INS068 injection：A single dose of 0.4 U/kg is administered to healthy subjects.~HR20014 injection：A single dose of 0.4 U/kg is administered to healthy subjects."
224142817|NCT02308176|BEHAVIORAL|health advice|health advice
224300079|NCT00971841|DRUG|Paclitaxel|
223566250|NCT06368505|OTHER|ultrasound guided PRP injection|whole blood is initially collected in tubes that contain anticoagulants, such as citrate dextrose A to prevent platelet activation prior to its use. Then PRP is prepared by a differential centrifugation. Then 3ml of PRP will be delivered via the in-plane ulnar approach
224047702|NCT00017121|BIOLOGICAL|sargramostim|
224142818|NCT03223493|OTHER|No treatment given|Completion of a questionnaire
224142819|NCT03483116|BIOLOGICAL|RV3-BB|Oral administration
224142820|NCT03483116|BIOLOGICAL|Placebo|Oral administration
224142821|NCT02204514|PROCEDURE|Surgery for external snapping hip|
224142822|NCT01181102|DRUG|edoxaban|
224142823|NCT01181102|DRUG|enoxaparin sodium|
224300080|NCT02920918|DRUG|Canagliflozin|
224300081|NCT02920918|DRUG|Sitagliptin|
223436638|NCT07175363|DRUG|An postoperative analgesic pump was used|The drugs in the analgesic pump include butorphanol, hydromorphone, tramadol, and other medications.
223436639|NCT07174570|DRUG|Celecoxib|Receive by mouth (PO).
224047703|NCT03483467|OTHER|Omnigen|For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
224047704|NCT03483467|OTHER|Dummy Packaging|For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
224047705|NCT01170546|OTHER|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
224142824|NCT03120728|DRUG|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
224142825|NCT02439944|DRUG|Nicotine patch|
223436640|NCT07174570|BIOLOGICAL|Durvalumab|Receive intravenously (IV).
223436641|NCT07174570|BIOLOGICAL|Tremelimumab|Given intravenously (IV).
223436642|NCT07174570|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224047706|NCT01170546|OTHER|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
223436643|NCT07174570|PROCEDURE|Computed Tomography|Undergo Computed Tomography (CT).
223566251|NCT06368505|OTHER|ultrasound guided hydrodissection|5ml will be injected to detach the median nerve from the TCL (2ml saline, 2ml dexamethasone and 1ml lidocaine), the injectate will be delivered via the in-plane ulnar approach, and the median nerve will be hydrodissected from its undersurface while advancing the needle among the superficial surface of the median nerve and the TCL
224047707|NCT01170546|OTHER|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
224142826|NCT02439944|DRUG|Nicotine mouthspray|
224142827|NCT01315002|DRUG|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
224142828|NCT01315002|DRUG|Placebo patch|Placebo patch
224142829|NCT02360553|BEHAVIORAL|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
224142830|NCT02360553|BEHAVIORAL|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
224142831|NCT06086756|BEHAVIORAL|Exposure intervention plus positive mood induction|Positive mood induction followed by a brief VR exposure session for public speaking anxiety.
224142832|NCT06086756|BEHAVIORAL|Exposure intervention plus negative mood induction|Negative mood induction followed by a brief VR exposure session for public speaking anxiety.
223436644|NCT07174570|PROCEDURE|Magnetic Resonance Imaging|Undergo Magnetic Resonance Imaging (MRI).
223436645|NCT07174570|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy.
223436646|NCT07174895|DRUG|Intra-articular Tranexamic Acid + Suction Drainage|Patients received intra-articular injection of 3 g tranexamic acid in 100 mL normal saline after wound closure, along with a closed suction drain inserted intra-articularly and subcutaneously, activated two hours postoperatively.
223436647|NCT07174895|DRUG|Intra-articular Tranexamic Acid|Patients received intra-articular injection of 3 g tranexamic acid in 100 mL normal saline after wound closure. No suction drain was used.
223436648|NCT07174895|DEVICE|Suction Drainage Only|Patients had a closed suction drain inserted intra-articularly and subcutaneously, activated two hours postoperatively. No tranexamic acid was administered.
223478583|NCT04587804|DEVICE|rPMS+RF|The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of the device will be applied over umbilicus and visible muscle contractions along with heating of the subcutaneous fat will be induced by the device.
223478584|NCT00129337|DRUG|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
223478585|NCT03414632|DRUG|99mTc-PYP|Radioisotope used in the SPECT/CT imaging
223566252|NCT01612650|DEVICE|tomosynthesis|2 incidences 3D numeric mammography
223566253|NCT01612650|DEVICE|2D mammography|2 incidences 2D analogic mammography
223566254|NCT02545881|OTHER|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
223566255|NCT01357954|OTHER|Regular physiotherapy|The child's regular physiotherapy
224047708|NCT04046796|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
224047709|NCT05617651|DRUG|IY-NT-T|Ilaprazole 20mg
224047710|NCT05617651|DRUG|IY-NT-R|Ilaprazole 10mg
224047711|NCT06473376|PROCEDURE|arthrocentesis|TMJ arthrocentesis and arthroscopy
224047712|NCT02017379|DRUG|Erythromycin|
224047713|NCT02017379|DRUG|Metoclopromide|
224142833|NCT03119818|DEVICE|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
224300082|NCT03814616|DRUG|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
223436649|NCT07175246|DIAGNOSTIC_TEST|Polysomnography (PSG)|Polysomnography (PSG) is the gold standard, multi-parametric diagnostic test used to comprehensively assess sleep architecture and diagnose sleep disorders. This objective, overnight recording captures simultaneous physiological data channels, including electroencephalography (EEG) to stage sleep, electrooculography (EOG) to detect eye movements, electromyography (EMG) to measure muscle tone, electrocardiography (ECG) for heart rhythm, respiratory effort (via thoracic and abdominal belts), nasal airflow, and pulse oximetry for blood oxygen saturation. As the primary/secondary outcome measure, PSG will be administered to quantitatively evaluate the intervention's effect on key sleep parameters such as total sleep time (TST), sleep efficiency (SE), wake after sleep onset (WASO), latency to sleep onset, and the frequency of sleep-disordered breathing events (e.g., Apnea-Hypopnea Index, AHI) or periodic limb movements.
223436650|NCT07175870|PROCEDURE|Non-cardiac surgery followed by postoperative PCI|Patients undergo the planned time-sensitive non-cardiac surgery first in a hybrid operating room, with PCI standby available in case of an intraoperative acute coronary event. If such an event occurs, immediate PCI will be performed. Additional PCI will be performed postoperatively if clinically indicated.
223436651|NCT07175870|PROCEDURE|Preoperative PCI followed by delayed non-cardiac surgery ~3 months later|Patients undergo PCI first. The planned non-cardiac surgery will then be performed approximately 3 months after PCI, in accordance with current guideline recommendations for the timing of non-cardiac surgery following PCI.
223436652|NCT07176182|DRUG|mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group|"The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy.~Treatment Protocol~Preoperative (4-6 cycles) and Postoperative (6-8 cycles):~Each 14-day cycle includes:~Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.~Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.~5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours.~Citrus flavonoid tablets (Alvenor) : 500 mg orally three times daily (Days 1-14), administered with or without the chemotherapy regimen (depending on group assignment)."
223436653|NCT07176182|DRUG|mFOLFOX regimen neoadjuvant therapy group|"The trial evaluates a regimen combining mFOLFOX chemotherapy with citrus flavonoid tablets (Alvenor) for neoadjuvant therapy (pre-surgery) and postoperative adjuvant therapy.~Treatment Protocol~Preoperative (4-6 cycles) and Postoperative (6-8 cycles):~Each 14-day cycle includes:~Oxaliplatin: 85 mg/m² via 180-minute intravenous infusion on Day 1.~Leucovorin: 400 mg/m² via 120-minute intravenous infusion on Day 1.~5-Fluorouracil: 2400 mg/m² via continuous intravenous infusion over 46 hours."
223436654|NCT07175701|BEHAVIORAL|Behavioral: Nutritional education and diet counselling|"All participants will be asked to visit the study site after the 10-day baseline monitoring period. They will receive a 30-minute nutrition education focusing on reducing UPF intake; and personalized counselling session based on their dietary intake observed during the baseline monitoring period.~Participants allocated to the intervention group will receive nutrition education and personalized counselling aimed at reducing ultra-processed food (UPF) intake by encouraging the substitution of UPFs with unprocessed/minimally processed foods, thereby improving overall diet quality. Participants will be educated on the definition of UPFs, how to identify them, practical strategies for reducing UPF intake, UPF-reducing recipes, and the associations between UPF intake and health outcomes. The content related to UPFs was developed based on previous studies exploring the health effects of UPF intake, while the content on diet quality was based on the 2020 Korean Dietary Reference Intakes."
223436655|NCT07175701|BEHAVIORAL|Conventional nutrition education and diet counseling|All participants will be asked to visit the study site after the 10-day baseline monitoring period. Participants in the control group will receive a conventional nutrient-based education and personalized diet counseling developed based on the 2020 Korean Dietary Reference Intakes.
223436656|NCT07175259|RADIATION|Echocardiography|Simple, bedsides, non invasive
223436657|NCT07176533|PROCEDURE|Suprazygomatic maxillary nerve block (SZMN) with ropivacaine|Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of 0.25% ropivacaine (local anesthetic), up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
223478586|NCT01944423|DRUG|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
223478587|NCT01944423|DRUG|Pill Placebo|
223566256|NCT01357954|OTHER|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
224047714|NCT02612740|BIOLOGICAL|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
224047715|NCT02612740|DEVICE|granules of deproteinized bovine bone (Bio-Oss)|
224047716|NCT00163462|DRUG|Ciclesonide|
224047717|NCT04575142|DEVICE|CO2 laser|"the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues."
224047718|NCT04465097|DRUG|Tucidinostat|Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
224047719|NCT04465097|DRUG|Exemestane|Exemestane: 25 mg QD from week 1 to week 26.
224047720|NCT04465097|DRUG|Ovarian function suppression|If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
224047721|NCT05967117|DRUG|Iohexol (320mgI/mL) with 120kVp|Patient undergoing CT scan with 120kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
224142834|NCT03119818|OTHER|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
224142835|NCT04334915|DRUG|Cenicriviroc Mesylate (CVC)|Administered orally
223436658|NCT07176533|PROCEDURE|Suprazygomatic maxillary nerve block (SZMN) with placebo|Participants will receive 15 mg/kg of Tylenol and 4 mg/kg of celecoxib (a nonsteroidal anti-inflammatory (NSAID drug) up to a maximum dose of 200 mg prior to the start of general anesthesia. which will consist of gas or intravenous induction (2 mcg/kg fentanyl, 0.5 mg/kg dexamethasone). The SZMN block will be performed using 0.2 ml/kg of saline (placebo) up to a maximum dose of 5 mL. The surgery (tonsillectomy or adenotonsillectomy) will then proceed according to standard of care practices.
223436659|NCT07176884|PROCEDURE|nurse-performed coronary catheterization|nurse-performed coronary catheterization
223436660|NCT07176884|PROCEDURE|interventional cardiologist-performed coronary catheterization|interventional cardiologist-performed coronary catheterization.
223436661|NCT07176611|OTHER|Guided imagery|Participants in this group will receive the guided imagery intervention. The guided imagery audio recording will be applied in a quiet room once during the initial session, and participants will be instructed to continue the practice at home before sleep for eight weeks.
223436662|NCT07174505|DEVICE|Mechanical Thrombectomy using the CONDA Stent Retriever|Intravenous sedation, local or general anesthesia, and anticoagulation management will be administered following the institution's standard of care to ensure subject safety and comfort. These procedures should be applied to the target population at the discretion of the investigator and in accordance with clinical guidelines. The use of CONDA is no different than that established for other CE marked stent retrievers. The use of supportive devices including, long sheaths, guide catheters with our without balloons, distal access catheters, ANA funnel catheter, microcatheters and microwires, along with the CONDA device, will be guided by operator preference and/or center established practices. Operators are required to use these devices according to their labeling and instructions for use.
224047722|NCT05967117|DRUG|Iohexol (320mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 320 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
223436663|NCT07176260|OTHER|Patients with pre-Capillary pulmonary hypertension|Patients will be followed for 3 years with routine clinical, hemodynamic, and laboratory assessments. Blood samples for oxidative stress and mitochondrial function analyses will be collected during scheduled follow-up visits or catheterization procedures. No intervention beyond standard care will be performed.
223436664|NCT07175415|DRUG|Capivasertib|Oral
223436665|NCT07175415|DRUG|Venetoclax|Oral
223436666|NCT07175415|DEVICE|Dexamethasone|oral/intravenous
223436667|NCT07175415|DRUG|Intrathecal chemotherapy|IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
223436668|NCT07176715|OTHER|Same-Day Colectomy|"study, they will undergo extensive education during their preoperative visit. Perioperative education includes management of perioperative medications, bowel prep and perioperative antibiotics. Perioperative education will include that of the patient and their designated caregiver.~Perioperative nursing staff will go over postoperative discharge instructions again. A custom discharge instruction sheet will be made and given to all patients upon discharge. On days 1 and 3 postoperatively, patients will receive a phone call or virtual visit from a member of the research team. Questions will be asked of patients based on a script made. Patients will then be seen in the clinic between postoperative day 5-7.~Patients' medical record will be followed for six months postoperatively to track emergency department visits, readmissions, and postoperative complications. Postoperative complications will include surgical site infection, deep surgical infection, bleeding requiring transfusion, ana"
223566257|NCT01407835|BIOLOGICAL|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
223566258|NCT02660593|DIETARY_SUPPLEMENT|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
223566259|NCT03385915|PROCEDURE|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
223566260|NCT03378609|OTHER|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
224047723|NCT05967117|DRUG|Iohexol (270mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 270 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
223566261|NCT01150058|GENETIC|western blotting|
223566262|NCT01150058|OTHER|flow cytometry|
224047724|NCT05967117|DRUG|Iohexol (240mgI/mL) with 100kVp|Patient undergoing CT scan with 100kVp protocol and using Iobrix inj. 240 (Taejoon pharm, Seoul, South Korea). CT images were obtained 55sec after Contrast media injection(100mL, 2mL/sec) with 20mL saline flushing.
224047725|NCT03248934|OTHER|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
224047726|NCT03248934|OTHER|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
224047727|NCT01182766|DRUG|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
224047728|NCT01182766|DRUG|Placebo with brief behavioral enhancement therapy|placebo
224047729|NCT00037869|DRUG|I-131 Metaiodobenzylguanidine|
224047730|NCT01639768|DRUG|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
224047731|NCT03492554|OTHER|1-Lead ECG|All participants will record three single-lead ECGs
224142836|NCT04334915|DRUG|Placebo|Administered orally
224142837|NCT00057395|DRUG|Aroplatin (Liposomal NDDP, L-NDDP)|
224142838|NCT04846894|DIAGNOSTIC_TEST|Ga-68 PSMA-11 PET/CT imaging|Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
224142839|NCT00769808|DEVICE|Bausch & Lomb 217z Excimer Laser|LASIK correction of myopia and myopic astigmatism
224142840|NCT00497354|DRUG|Variation in volume of local anesthetic|
224142841|NCT00497354|PROCEDURE|Ultrasound-guided interscalene brachial plexus block|
224142842|NCT02238288|DRUG|Aminocaproic acid|Crushed tablet in the dental socket
223436669|NCT07176819|BEHAVIORAL|Gait retraining|The intervention is a wearable device-assisted gait retraining program designed specifically for female runners with patellofemoral pain (PFP). Unlike conventional physiotherapy or exercise-based interventions, this program integrates real-time biofeedback through a commercially available smartwatch and its mobile application. Participants are instructed to increase their step rate by 10% above their preferred cadence. The smartwatch provides auditory metronome cues and real-time cadence feedback to ensure accurate step-rate modification.
223436670|NCT07176819|BEHAVIORAL|Education|PFP education, load management strategies, symptom-based training modifications, and strengthening exercises.
223436671|NCT07174752|PROCEDURE|Non-Submerged De-Epithelialized Free Gingival Graft|The Free gingival graft will be de-epithelialized and fixed at the recipient site in a non-submerged manner to increase the keratinized mucosa
223436672|NCT07174752|PROCEDURE|Conventional FGG|The Free gingival graft will be fixed at the recipient site to increase the keratinized mucosa
224047732|NCT03492554|DEVICE|12-Lead ECG|All participants will simultaneously record three 12-lead ECGs
223436673|NCT07176975|DRUG|BI 1831169|BI 1831169
223436674|NCT07176975|DRUG|nivolumab|nivolumab
223436675|NCT07174661|BEHAVIORAL|Advance Care Planning|Attend ACP appointment
223436676|NCT07174661|OTHER|Educational Intervention|Watch on-demand early ACP educational video
223436677|NCT07174661|OTHER|Electronic Health Record Review|Ancillary studies
223436678|NCT07174661|OTHER|Survey Administration|Ancillary studies
223436679|NCT07175558|OTHER|Reiki|"The patient will be explained about reiki (life energy recovery) and the application environment will be kept quiet.~Metal objects on the patient and the researcher will be removed. The researcher will wash and warm their hands. The patient's privacy will be ensured. The patient will be given a flat lying position with their arms and legs on both sides and comfortable. The patient will be asked to close their eyes. The researcher's fingers will be straight, side by side and closed, and energy will be provided to the application areas; crown chakra (top of the head), forehead chakra (top of the forehead), throat chakra (top of the throat), heart chakra (middle of the chest), solar plexus (under the chest, above the navel), sacral chakra (below the navel) and root chakra (upper back). Reiki application will be applied to the points on the 7 chakra regions for 4 minutes each, for a total of 28 minutes. The patient will be asked to open their eyes at the end of the application."
224047733|NCT00662350|DEVICE|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
224047734|NCT04384393|BIOLOGICAL|ThisCART19 cells|0.2-60 x 10\^6 CAR T cells per kg body weight.
224047735|NCT05895162|DRUG|JUVIA zinc containing vaginal gel treatment|Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per week thereafter).
224047736|NCT05895162|DRUG|Fluconazole 150Mg Tab|Women receive oral fluconazole treatment with a single dose of oral fluconazole (150 mg).
224047737|NCT01727765|OTHER|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H\&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
224047738|NCT06079944|PROCEDURE|Progressive resistance training|"* 6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~* 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~* Speed of movement will be 2 seconds for both the eccentric and concentric phases.~* To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system."
224047739|NCT06079944|PROCEDURE|Traditional physical therapy|"* TENS+ Hot pack~* Pendulum exercises and stretching exercises"
224142843|NCT02238288|OTHER|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
223436680|NCT07176091|DEVICE|Combined treatment of tDCS and rTMS|Bilateral pre-treatment with tDCS is carried out for 10 minutes. The current is 2 mA, and the electrodes are spaced 5 cm apart. The current gradually rises and falls in the first and last 30 seconds. Subsequently, the bilateral primary motor cortex (M1 area) of the patient is stimulated with iTBS at a frequency of 5 Hz. The magnetic field intensity is set at 80% of the resting motor threshold. Each train contains 10 pulses, and each pulse consists of 3 bidirectional pulses at 50 Hz. The interval between each train is 8 seconds. There are 60 trains per session (1800 pulses per session), and the treatment lasts for 5 days in total.
224142844|NCT02238288|DRUG|lidocaine and epinephrine|2%
224142845|NCT02238288|DRUG|Paracetamol|750 mg
224142846|NCT06139536|DRUG|BAT4706 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
223566263|NCT01150058|OTHER|laboratory biomarker analysis|
224047740|NCT05803434|DRUG|Cannabidiol oral solution|"Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks."
224047741|NCT02556125|DEVICE|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
224047742|NCT00480688|BIOLOGICAL|BCG|
224047743|NCT00331123|DRUG|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
224047744|NCT00331123|DRUG|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
224047745|NCT00268307|DRUG|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
224047746|NCT02900183|DRUG|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
224047747|NCT01052896|DRUG|Gabapentin|300mg po TID
224047748|NCT01052896|DRUG|Placebo|Look-alike of gabapentin 300mg given po tid
224047749|NCT04340557|DRUG|Losartan|Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days. Upon the treating clinician's discretion, losartan may be continued beyond 10 days for non-COVID-19 indications.
223436681|NCT07176091|DEVICE|sham-tDCS combined with real TMS|Participants received sham transcranial direct current stimulation combined with intermittent theta burst stimulation for a total of 5 days
223436682|NCT07174479|DEVICE|Augmented reality|Augmented reality markers show the surgical trainee the expert's gaze location during the kidney exploration phase of surgery.
223436683|NCT07176338|DIAGNOSTIC_TEST|Blood and lens capsule samples for PK testing|Blood samples and lens capsule tissue will be collected from patients for PK testing
223436684|NCT07175129|PROCEDURE|Transverse Tibial Bone Transport|Tibial tibial bone transport is a novel surgical procedure that involves the gradual movement of a bone segment in order to improve perfusion and tissue healing.
223436685|NCT07175129|DEVICE|TrueLok Elevate|This device is used to move the bone segment as a part of the tibial bone transport surgery.
223436686|NCT07174687|DRUG|Dapagliflozin|Dapagliflozin is an SGLT2 inhibitor used in diabetes, heart failure, and chronic kidney disease patients.
223436687|NCT07174687|OTHER|Matching Placebo|Matching oral placebo to dapagliflozin
223740695|NCT03033511|DRUG|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
224047750|NCT02671045|GENETIC|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
224047751|NCT02671045|GENETIC|Genomic profile by other methods|Genomic profiling by other testing methods.
223436688|NCT07175285|DRUG|Current standard of care treatment options|According to the product label
223436689|NCT07176130|OTHER|No Intervention: Observational Cohort|Not applicable, No intervention. Observational study.
223436690|NCT07174466|OTHER|Standard Referral to 211|Participants receive a standard referral to United Way 211 for assistance with social needs. 211 specialists contact referred patients, provide available service referrals, and follow up in an ad-hoc manner as per standard 211 protocols.
223436691|NCT07174466|BEHAVIORAL|e-SINCERE (Phone Support)|Participants receive a study-provided cellphone to ensure stable phone access. Using this device, participants are connected to United Way 211 specialists, who provide referral services for identified social needs. This intervention focuses on overcoming communication barriers that might otherwise prevent successful service connection.
223436692|NCT07174466|BEHAVIORAL|e-SINCERE (Digital Navigation)|Participants receive a study-provided TracFone and direct support from a trained Digital Navigator. The Digital Navigator assists participants with accessing United Way 211 services, troubleshooting barriers to phone or internet use, and reinforcing follow-through on referrals. This arm is designed to provide enhanced, structured navigation support to address digital access barriers and increase successful service connections.
223436693|NCT07176481|BEHAVIORAL|Diné Parents Taking Action Program|A culturally adapted parent training program delivered by trained Navajo Family Advisors, focused on teaching parents/guardians evidence-based strategies to support their child's development and family well-being.
223436694|NCT07176663|DRUG|Tirzepatide|2.5 mg weekly first month and 5 mg weekly for two month
223436695|NCT07176988|OTHER|Hierarchical method|"Participants in the hierarchical version of Conversation Training Therapy (CTTH) will receive four weekly sessions of voice therapy. This approach gradually increases the difficulty of speaking tasks-from simple sounds to full conversations-based on the participant's progress. The therapy begins with basic awareness and speech sounds (e.g., consonant-vowel pairs), then progresses through words, phrases, and sentences, culminating in natural conversation. Each level must be completed with at least 80% accuracy before proceeding to the next one.~The structure is modeled after traditional voice therapies like resonant voice and aims to help participants succeed early and reduce mental fatigue. Daily homework includes seven short (2.5-minute) practice sessions, aligned with prior research showing this is a realistic and effective amount of practice."
223436696|NCT07176988|OTHER|Non Hierarchical method|"The therapy includes four weekly sessions and several key techniques:~Clear Speech: Speaking clearly, like leaving an important voicemail.~Awareness Training: Paying attention to how the voice sounds and feels in the mouth and face.~Negative Practice: Switching between their bad voice and good therapy voice to recognize and improve differences.~Embedded Gestures: Briefly holding certain speech sounds to reduce vocal strain and boost clarity.~Prosody and Projection: Working on pitch, rhythm, and speaking louder through better technique.~Participants practice these skills throughout the day using a mobile app to track their progress and record a weekly sample. Unlike hierarchical models, components in CTT can be introduced in any order based on individual needs, making it flexible and personalized"
223566264|NCT03927235|PROCEDURE|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
223740696|NCT03033511|DRUG|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
224047752|NCT01678482|DEVICE|light based device for treatment of acne|
224047753|NCT02794467|DRUG|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
224047754|NCT02794467|DRUG|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
224142847|NCT06139536|DRUG|BAT1308 Injection|Intravenous infusion, 3 weeks one cycle(Q3W), Administer on the first day of each cycle. In the first four cycles, administration starting with BAT1308, and then administering BAT4706 on the same day. Maintain administration of BAT1308 monotherapy after four cycles.
223436697|NCT07174934|BIOLOGICAL|application of injectable platelet-rich fibrin on the wound area .|Injectable platelet-rich fibrin will be prepared using low speed centrifugation technique, after centrifugation, the I-PRF in the upper part of the tube will be collected via an injector and will be transferred to a metal godet. It will be left for 15-20 min for polymerization of the I-PRF ,Then the polymerized I-PRF will be applied to the secondary wound of test area.
223436698|NCT07176936|DEVICE|Cymba Conchae stimulation|Electrical stimulation applied to the cymba conchae region of the outer ear
223436699|NCT07176936|DEVICE|Earlobe stimulation|Electrical stimulation applied to the earlobe region of the outer ear
223436700|NCT07175103|BEHAVIORAL|Nurses' Stress Self-Care Educational Program (NSSCEP)|A control intervention consisting of four 1-hour sessions over one month, focusing on general technical skills relevant to pediatric oncology nursing (e.g., procedural updates, equipment use). The program does not include stress management content. Participants complete weekly checklists and pre- and post-intervention surveys to measure burnout and stress levels.
223436701|NCT07175103|OTHER|General Technical Skills Program|A control program with four 1-hour sessions over one month, focusing on technical skills (e.g., procedural updates, equipment use) without stress management content. Includes weekly checklists and pre/post surveys to measure burnout and stress.
223436702|NCT07171801|DEVICE|Three-Dimensional Endoscopic Visualization|Use of a stereoscopic 3D high-definition endoscopic system with dual optical channels, projecting to a stereoscopic monitor viewed with polarized glasses, to perform standardized spinal simulation tasks.
223436703|NCT07171801|DEVICE|Two-Dimensional Endoscopic Visualization|Use of the same high-definition endoscopic system with stereoscopic function deactivated, providing conventional monoscopic two-dimensional visualization, to perform standardized spinal simulation tasks.
223436704|NCT07176520|DEVICE|AI-assisted rehabilitation|Receives AI-assisted rehabilitation post-discharge at home in addition to usual care
223436705|NCT07176520|OTHER|usual care only|Verbal and written discharge summary, advice, and referral to outpatient physiotherapy (if applicable)
223436706|NCT07174804|OTHER|Yoga (IAYT) Intervention|Yoga practice for a period of three months
223436707|NCT07174453|DRUG|Nivolumab|Immunotherapy
223436708|NCT07174453|DRUG|Pembrolizumab|Immunotherapy
223436709|NCT07175038|DRUG|ROC-101|Oral, daily administered Rho kinase inhibitor
223436710|NCT07174544|BEHAVIORAL|Mobile Self-Management Program integrated with Positive Psychology and Behavioral Activation)|The mobile self-management program consisted of a 4-week guided intervention phase followed by a 4-week self-directed period to encourage continued use. The guided phase was organized around weekly objectives: (1) experiencing positive affect, (2) identifying personal strengths, (3) applying strengths in daily life, and (4) planning a positive future. Program activities included emotional check-ins, gratitude journaling, mindfulness practice, positive behavioral tasks, and goal setting. During the self-directed phase (Weeks 5-8), participants selected from 10 recommended activities tailored to their strengths, promoting sustained engagement and self-management. The program integrated Positive Psychology and Behavioral Activation strategies to reduce stress, enhance resilience, and foster positive behavioral change.
223436711|NCT07175766|DIETARY_SUPPLEMENT|Dachundou No Sugar Added Soymilk|Participants will consume two bottles of Dachundou No Sugar Added Soymilk daily (375 mL each; total 750 mL per day) for 8 consecutive weeks. The product is packaged in 375 mL cartons and made from non-GMO soybeans, containing approximately 4.2 g of soy protein per 100 mL. The soymilk is unsweetened and stored at 0-7°C.
223436712|NCT07177118|DRUG|Ustekinumab|Ustekinumab group (induction phase with intravenous equivalent doses at weeks 0 and 8, maintenance phase with 90 mg subcutaneously every 8 weeks)
223436713|NCT07177118|DRUG|Risankizumab|Risankizumab group (induction phase with intravenous 600 mg at weeks 0, 4, and 8, maintenance phase with 360 mg subcutaneously every 8 weeks)
223436714|NCT07176832|DRUG|Stiripentol capsule (Diacomit®)|Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.
224047755|NCT06125379|BEHAVIORAL|brief mindfulness|The mindfulness intervention protocol in this study is an adaptation of the Mindfulness Based Stress Reduction (MBSR) protocol with the cultural adaptation suits Indonesia population with addition of Islamic elements (i.e., a series of spiritual approaches) to improve emotional regulation, make sense of their life, be grateful and feel closer to God.
224047756|NCT06582316|OTHER|Brain Health Training Programme|"Train Your Brain (TYB) - group-based cognitive intervention programme for mild cognitive impairments. This programme equips participants with knowledge on cognition and brain health, provide cognitive coping strategies and boost their confidence and maintain independence in daily activities."
224142848|NCT03548974|BEHAVIORAL|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
224142849|NCT03548974|BEHAVIORAL|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
223436715|NCT07176832|DRUG|Stiripentol oral suspension (Diacomit®)|Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.
223436716|NCT07176052|PROCEDURE|cancer surgery|All surgery will be performed at Copenhagen University Hospital, Rigshospitalet, Denmark
223566265|NCT03077438|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 milliliter (mL), Intramuscular
223566266|NCT03077438|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
223566267|NCT00094159|DRUG|SNS-595|
223566268|NCT01338350|DRUG|AZD5423|Inhalation, suspension
224300083|NCT04572126|BEHAVIORAL|Mindfulness Intervention|The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
223566269|NCT01338350|DRUG|Placebo|Inhalation, solution
224047757|NCT04710953|DEVICE|Continuous positive airway pressure machine|CPAP device set at 6-8cmH2O for several hours
223436717|NCT07176871|PROCEDURE|Archwires|All patients were treated with 0.022-inch MBT brackets and sequential NiTi/HANT archwires. A 0.014 NiTi wire was placed initially, followed by monthly archwire changes if no deflection remained. Digital scans were taken from baseline (T0) to 6 months (T6) to measure alignment using Little's irregularity index. Pain was recorded at 24 hours, 3 days, and 1 week with a visual analog scale. CBCT scans before and after alignment assessed root length and alveolar bone changes, with standardized 3D superimpositions ensuring accurate comparisons.
223436718|NCT07176065|DRUG|Ropivacaine + saline solution|0.5% ropivacaine (19 mL) + 1 mL normal saline administered intraoperatively via periarticular injection.
223436719|NCT07176065|DRUG|Ropivacaine + Dexmedetomidine|0.5% ropivacaine (19 mL) + dexmedetomidine 100 µg in 1 mL administered intraoperatively via periarticular injection.
223436720|NCT07176156|OTHER|No intervention|Observational one-time questionnaire study without intervention
223436721|NCT07176143|PROCEDURE|Delivering human bone marrow mesenchymal stem cells via the uterine artery|"Interventional Uterine Artery Infusion of Human Bone Marrow Mesenchymal Stem Cells (hBMSCs):~Subjects in the experimental group will undergo iodine allergy testing and groin area shaving/disinfection preoperatively. The procedure is performed on Day 10 of the endometrial proliferation phase.~Step-by-Step Procedure:~1. Positioning \& Anesthesia: (Patient placed in supine position; Local infiltration anesthesia administered)~2. Arterial Access: (Femoral artery punctured using Seldinger technique; Vascular sheath and catheter inserted)~3. Catheterization: (Catheter/microcatheter advanced into one uterine artery; Position confirmed by angiography)~4. Stem Cell Infusion: (Under fluoroscopic guidance, slowly inject 15mL solution containing 1×10⁶ cells/kg hBMSCs via microcatheter)~5. Postoperative Care: (Hospital observation for 48 hours)~6. Concurrent Treatment: (Hormone replacement therapy cycle maintained during the procedure month)~Treatment Frequency: Single intervention"
223436722|NCT07176949|DRUG|0.01% atropine eye drops|Participants will use 0.01% atropine eyedrops nightly for myopia control.
223436723|NCT07176949|DRUG|0.05% atropine eye drops|Participants will use 0.05% atropine eyedrops nightly for myopia control.
223436724|NCT07176949|DEVICE|Spectacle lenses with highly aspherical lenslets|"These are a special type of eyeglass lenses designed primarily to slow down the progression of myopia (nearsightedness) in children. The center of the lens provides a clear correction for distance vision, just like regular glasses. The surrounding area contains hundreds of tiny, invisible, and highly aspherical (complex curved) microlenses. These microlenses create a special optical effect. While the child looks straight ahead clearly, peripheral light rays are focused in front of the retina. This is called myopic defocus. Research suggests that this myopic defocus signal helps to control the excessive elongation of the eyeball, which is the main cause of myopia getting worse."
223436725|NCT05179759|BEHAVIORAL|Tealeaf|Tealeaf-Mansik Swasta (Tealeaf) Tealeaf is a task-shifting intervention in which teachers deliver transdiagnostic mental health care. Mental health challenges are understood through basic functional behavior assessments, providing a framework for the analysis of observable behaviors. Teachers deliver care primarily through the incorporation of basic therapeutic interactions into classroom instruction time, supplemented by one-on-one interactions with the child and family.
223436726|NCT05179759|BEHAVIORAL|Enhanced Usual Care|Enhanced Usual Care (EUC) is a less intensive version of the Tealeaf intervention. The EUC service package has been designed to be the most intensive form of care that could be envisioned as viable in the study setting in the foreseeable future without a significant increase in resource investment
223436727|NCT02839382|OTHER|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
223436728|NCT02839382|OTHER|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
223436729|NCT02839382|OTHER|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
223436730|NCT01063894|OTHER|breakfast cereal|breakfast cereal and milk
223436731|NCT01063894|OTHER|water|water
223436732|NCT00946062|OTHER|orientation and mobility training|orientation and mobility training
223436733|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
223436734|NCT01733992|DRUG|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
223436735|NCT01733992|DRUG|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
223436736|NCT01733992|DRUG|Placebo|Placebo, single and multiple ascending dose
223740697|NCT03033511|DRUG|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
223740698|NCT04232670|PROCEDURE|EUS + SHAM|Endoscopic Ultrasound
223740699|NCT04232670|PROCEDURE|EUS + Pancreatic Endotherapy|Pancreatic endotherapy may include any or all of the following maneuvers: pancreatic endoscopic sphincterotomy, stricture dilation using a bougie or hydrostatic balloon catheter, pancreatic stone extraction with or without mechanical or electrohydraulic lithotripsy, extracorporeal shock wave lithotripsy, and stent placement.
224047758|NCT02627352|PROCEDURE|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
224047759|NCT02663284|DRUG|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
224047760|NCT06232928|DEVICE|Early Class II elastics|Participants were treated by a fixed orthodontic appliance with intermaxillary class II elastics to correct the class II malocclusion. patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.
224047761|NCT06232928|DEVICE|Conventional Class II elastics|patients were treated by a fixed orthodontic appliance with intermaxillary Class II elastics. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours after reaching to rigid stainless steel arch wires.
224047762|NCT01221727|DRUG|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
224047763|NCT01221727|DRUG|Midazolam|All subjects will receive two oral dose administrations of midazolam.
224047764|NCT01196533|DEVICE|Non invasive peripheral blood monitoring|non invasive monitoring
224047765|NCT01984944|OTHER|Autistic functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
224047766|NCT01984944|OTHER|Control functional exploration|"* 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer"
224047767|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
224047768|NCT02538003|DRUG|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
224047769|NCT04458103|DEVICE|Percutaneous RVAD|ProtekDuo or Impella RP
224047770|NCT00219050|DRUG|aliskiren|
224047771|NCT03595319|DRUG|Sevoflurane|Inhaled sevoflurane until allocated dose (see adaptive protocol)
224047772|NCT03948633|OTHER|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
224047773|NCT06214871|DEVICE|rTMS|Transcranial Magnetic Stimulation
224047774|NCT01772004|DRUG|Avelumab|Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
224047775|NCT01458704|OTHER|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
224047776|NCT01549626|DIETARY_SUPPLEMENT|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
224047777|NCT01549626|DIETARY_SUPPLEMENT|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
224047778|NCT01549626|DIETARY_SUPPLEMENT|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
224047779|NCT00529451|DRUG|Aliskiren|Aliskiren
224047780|NCT00529451|DRUG|Ramipril|comparator
224047781|NCT01217151|DEVICE|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
224047782|NCT01217151|OTHER|Usual treatment|Hemodynamic monitoring based on common practice
224047783|NCT05342181|OTHER|Static exercises|"Participants will be treated with static core muscle exercises that are traditional group of exercises :~1. supine bridge~2. plank~3. oblique crunch~4. side lying with Abduction~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
224047784|NCT05342181|OTHER|Dynamic exercises|"Participants will be treated with dynamic core muscle exercises that were swiss ball exercises~1. bridging~2. straight leg raise in prone lying~3. straight leg raise with hand raise in prone lying~4. pelvic tilts~This program includes static exercises performed thrice a week for 4 weeks.This exercise comprises 5 minutes warm up and slight stretching.Rest time of 2-3 minutes with proper stretching in between sets of activity. Subjects will be requested to undertake cool down exercises, which include aerobic workouts followed by stretching exercises, at the end of each day's exercise programme. Before beginning the next session's training, the subjects will be asked if they had any discomfort."
224047785|NCT00738413|DRUG|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
224047786|NCT00738413|DRUG|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
224047787|NCT05729295|PROCEDURE|Endovascular embolization or surgery|Endovascular embolization with embolizing agents (including glue, non-adhesive agents) or neurosurgical excision of the lesion.
224047788|NCT04665336|BEHAVIORAL|Circadian Timing Program|"Sleep hygiene training will be provided to the participants. They will be asked to make lifestyle changes according to the Circadian Timing Program created by the researcher."
224047789|NCT04665336|BEHAVIORAL|Sleep Hygiene Training|Sleep hygiene training will be given by the researcher. There will also be sleep hygiene training sections on the website.
224047790|NCT02101515|OTHER|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
223436737|NCT03457844|DRUG|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
224047791|NCT02183155|DRUG|Meloxicam - low|
224047792|NCT02183155|DRUG|Meloxicam - medium|
224047793|NCT02183155|DRUG|Meloxicam - high|
224047794|NCT02183155|DRUG|Placebo|
224047795|NCT02183155|DRUG|Extended-release indomethacin|
224047796|NCT00481897|BEHAVIORAL|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
224047797|NCT01095367|PROCEDURE|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
224047798|NCT00184080|DRUG|Elsamitrusin|
224047799|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
223436738|NCT06468163|DEVICE|Drug infusion into joint through catheter.|With or without using catheter after DAIR operation for drug infusion.
223436739|NCT00481013|DRUG|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
223436740|NCT00481013|DRUG|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
223436741|NCT00516490|DRUG|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
223436742|NCT00516490|DRUG|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
224047800|NCT01309139|DRUG|Tiotropium|Medium dose of oral inhalation
224047801|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
224047802|NCT01309139|DRUG|BI 54903|Medium dose of oral inhalation
224047803|NCT02024568|DRUG|Pregabalin|See arm description
223436743|NCT03947775|DRUG|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
223436744|NCT06288542|OTHER|group d|this group will receive 1 mL/kg/h 5% Dextrose infusion, applied preoperatively during fasting until induction of anesthesia
223436745|NCT06288542|OTHER|group R|this group will receive 1 mL/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia
223436746|NCT04624542|DEVICE|Electromyographic device|the EMG machine will be used to measure NCV of femoral nerve within individuals with PFPS
223436747|NCT00224406|DRUG|Repertaxin|An initial 'loading dose' of repertaxin was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The study medication was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
223436748|NCT00224406|OTHER|Placebo|An initial 'loading dose' of placebo was administered over 30 minutes by intravenous infusion followed by a maintenance dose lasting 47.5 hours.The infusion was to start approximately 2 hours prior to the anticipated time of reperfusion and was to continue during the ICU/hospital stay. The placebo was administered as a continuous intravenous infusion into a (high flow) central vein, by an infusion pump adequate to provide reliable infusion rates , as per treatment schedule. Total infusion volume was not to exceed 500 mL/24 hours.
223436749|NCT00934232|DRUG|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
223436750|NCT04368832|OTHER|Remote consultation|One or more consultation is conducted by phone or teleconsultation during prenatal monitoring
223436751|NCT05033483|DIETARY_SUPPLEMENT|Ferrous Fumarate|Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
223436752|NCT05033483|DIETARY_SUPPLEMENT|Placebo|Gelatin capsule containing microcrystalline cellulose
223436753|NCT01556997|DRUG|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
223436754|NCT01556997|DRUG|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
223436755|NCT01556997|DRUG|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
223436756|NCT02535377|OTHER|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
223436757|NCT03315598|PROCEDURE|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
223436758|NCT03529799|DEVICE|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
223436759|NCT00428012|BEHAVIORAL|Quality of Life Therapy|8 weekly individual counseling sessions
223436760|NCT00428012|BEHAVIORAL|Supportive Therapy|8 weekly individual counseling sessions
223436761|NCT03315962|BEHAVIORAL|SPIRIT Intervention|The intervention will include implementing a teaching collaborative among group of DHOs and TB Supervisors, enabling text messaging between DHOs and front line providers, and establishing a report collaborative where DHOs will receive feedback on the performance of their district in administering IPT compared to other districts.
223436762|NCT04063995|DEVICE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
223436763|NCT00450853|DRUG|granisetron|Granisetron SC followed by granisetron IV
223436764|NCT00719394|DRUG|GSI 136|
223436765|NCT00719394|DRUG|placebo|
223740700|NCT03467841|DEVICE|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
224047804|NCT02024568|DRUG|Placebo|See arm description
224047805|NCT00302510|PROCEDURE|immunoadsorption|immunoadsorption
224047806|NCT05440396|DIAGNOSTIC_TEST|Photographs collection phase|"Three medical experts have been selected to review the photo collected. Each expert medical assesses the presence of local signs of infection on the photographs by annotating them directly via a dedicated software. They will annotate local signs: redness, perfusion extravasation, necrosis, hematoma, edema, non-purulent discharge, and purulent discharge.~A convolutional neural network model will determine the probability of local sign presence. Each picture will be annotated to determine the main characteristics of the catheter. A dataset preparation with photo cropping will be performed for modelling."
224047807|NCT03923751|OTHER|Invitation to regional anesthesia survey|An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
224047808|NCT00313040|BEHAVIORAL|Brief Consultation with Health Counselor, workbook|
224047809|NCT00313040|BEHAVIORAL|Usual Care wait list|
224047810|NCT02955420|DRUG|BC 007|
224047811|NCT02955420|DRUG|NaCl 0.9 %|
224047812|NCT05240183|DIAGNOSTIC_TEST|Daily SARS-CoV-2 PCR Testing for 10 days|Each participant will undergo daily SARS-CoV-2 PCR testing to assess viral dynamics
224047813|NCT02231463|OTHER|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
224047814|NCT02231463|OTHER|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
224047815|NCT02231463|OTHER|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
224047816|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
224047817|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
224047818|NCT02231463|OTHER|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
224047819|NCT01329887|DRUG|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
224047820|NCT00590044|DRUG|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
223436766|NCT01010009|DIETARY_SUPPLEMENT|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
223436767|NCT01010009|OTHER|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
223436768|NCT00401401|DRUG|zalutumumab|Eight weekly infusions
223436769|NCT00401401|DRUG|cisplatin|Infusions
224047821|NCT00590044|DRUG|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
224047822|NCT02478905|OTHER|Influenza|
224142850|NCT03438578|DEVICE|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
224142851|NCT04990661|BEHAVIORAL|intradialytic massage|intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
224142852|NCT00000361|DRUG|Corticosteroids|
224142853|NCT00000361|DRUG|Methotrexate|
224142854|NCT02745132|OTHER|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
223436770|NCT00401401|PROCEDURE|Radiotherapy|Daily in the treatment period
223436771|NCT05563935|DEVICE|Repetitive transcranial magnetic stimulation|The OCD group will receive rTMS treatment for 6 weeks. There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total. Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil. Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
223436772|NCT05459558|DRUG|Experimental Dentifrice 1|5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP).
223436773|NCT05459558|DRUG|Experimental Dentifrice 2|5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica.
223436774|NCT05459558|DRUG|Reference Dentifrice|Regular Fluoride Dentifrice.
224142855|NCT05831527|DRUG|ARMRA™ Bovine Colostrum|"Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks."
224142856|NCT01459770|OTHER|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
223436775|NCT01777139|DRUG|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
223436776|NCT05313802|DRUG|LY3502970|Administered orally.
223436777|NCT03758235|DRUG|IncobotulinumtoxinA 100 UNT Injection [Xeomin]|Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
223436778|NCT03758235|DRUG|OnabotulinumtoxinA 100 UNT [Botox]|Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
223436779|NCT05625477|BIOLOGICAL|TNM002 (low dose)|Single dose of TNM002 administered by intramuscular injection
223436780|NCT05625477|BIOLOGICAL|TNM002 (medium dose)|Single dose of TNM002 administered by intramuscular injection
223740701|NCT01457066|BEHAVIORAL|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
223740702|NCT02409459|DRUG|Injectafer|
223740703|NCT02409459|DRUG|Placebo|Normal saline solution
224047823|NCT05132270|DRUG|hydroxyurea and thalidomide|Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
224047824|NCT00273936|DRUG|AVN-944 capsules for oral administration|
224047825|NCT00572962|PROCEDURE|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
223740704|NCT04147455|BEHAVIORAL|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men
224047826|NCT01054950|BEHAVIORAL|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
224047827|NCT01054950|BEHAVIORAL|Placebo phone call|Phone call w/ no behavioral counseling
224047828|NCT02218957|PROCEDURE|Extended Pouch RYGB|
224047829|NCT02218957|PROCEDURE|Standard RYGB|
224142857|NCT01459770|OTHER|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
224142858|NCT03945903|DRUG|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
224047830|NCT04475900|DIAGNOSTIC_TEST|Corneal biomechanics (Corvis ST, Oculus, Wetzlar, Germany)|To measure corneal biomechanics with Scheimpflug based tonometry
224047831|NCT04475900|DIAGNOSTIC_TEST|Corneal topography and tomography (Pentacam, Oculus, Wetzlar, Germany)|To measure corneal topography and tomography with Scheimpflug tomograph
224047832|NCT04475900|DIAGNOSTIC_TEST|Optic nerve head measurement|To measure optic nerve excavation
224047833|NCT02437617|PROCEDURE|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
224047834|NCT00518427|DRUG|Insulin Glargine|"Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
224047835|NCT02013453|DRUG|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
223436781|NCT05625477|BIOLOGICAL|TNM002 (high dose)|Single dose of TNM002 administered by intramuscular injection
224047836|NCT02013453|DRUG|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
223436782|NCT05625477|BIOLOGICAL|HTIG|Single dose of HTIG administered by intramuscular injection
223436783|NCT05625477|BIOLOGICAL|Placebo|Single dose of placebo administered by intramuscular injection
223436784|NCT04088721|BIOLOGICAL|AD17002|LTh(αK) as immunomodulator
223436785|NCT04088721|OTHER|Formulation Buffer|Formulation buffer
223436786|NCT00689624|DRUG|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
223436787|NCT00689624|DRUG|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
223436788|NCT00689624|DRUG|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
223436789|NCT00689624|DRUG|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
223436790|NCT00689624|DRUG|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
223436791|NCT00311103|PROCEDURE|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
223436792|NCT03321461|DRUG|TMTP1|Fluorescent sites will be removed
223436793|NCT03321461|DRUG|ICG|Fluorescent sites will be removed
224047837|NCT02013453|DRUG|5FU|Administered by infusion.
224047838|NCT02013453|DRUG|Paclitaxel|Administered by infusion.
224047839|NCT02013453|DRUG|Pemetrexed|Administered by infusion.
223436794|NCT03458923|DRUG|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
224047840|NCT03566433|PROCEDURE|Tep surgery for inguinal hernia|TEP surgery
224047841|NCT03566433|PROCEDURE|Lichtenstein|Lichtenstein surgery for inguinal hernia
223436795|NCT03458923|DRUG|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
223436796|NCT01765608|DRUG|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
224142859|NCT03743207|OTHER|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
223436797|NCT01765608|DRUG|Placebo|
223436798|NCT01765608|DEVICE|nCPAP|
223436799|NCT03030274|DEVICE|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
223436800|NCT01301885|PROCEDURE|Laparoscopy/laparotomy|Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.
223436801|NCT03292458|DRUG|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
223436802|NCT01326000|DRUG|FOLFIRI|standard iv chemotherapy
223436803|NCT01326000|DRUG|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
223566270|NCT03736057|OTHER|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at \<1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
223566271|NCT01190475|DRUG|Active treatment with a high dose of BGS649|
224142860|NCT03743207|OTHER|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
224142861|NCT00225056|DRUG|docetaxel and capecitabine|
223436804|NCT01326000|DRUG|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
223436805|NCT01197014|DRUG|Amlodipine plus Losartan|Amlodipine/Losartan high dose
223436806|NCT01197014|DRUG|Amlodipine, Losartan|Amlodipine, Losartan
223436807|NCT00593606|DRUG|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
223436808|NCT01420562|PROCEDURE|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
223436809|NCT05940129|BEHAVIORAL|Women and Child, Safety, Health and Empowerment (WC-SHE)|The WC-SHE component includes a risk assessment and tailored safety planning for women in domestic violence relationships. In addition, the component involves one-on-one education with husbands and in-laws. The economic empowerment component is designed to support women and their husbands in economic empowerment activities. The advocacy arm involves community education of husbands and in-laws, advocacy support by a support committee comprised of multidisciplinary professionals and phone support by women community resource persons
223436810|NCT02278367|DRUG|Flortaucipir F18|IV injection, 370 MBq (10 mCi), up to two doses
223436811|NCT02278367|PROCEDURE|Brain PET scan|positron emission tomography (PET) scan of the brain
223436812|NCT01493700|PROCEDURE|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
224142862|NCT05459766|BEHAVIORAL|Action observation and motor imagery|Observation and imagination of functional tasks that will be performed during the postoperative rehabilitation program.
223436813|NCT01493700|PROCEDURE|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
223436814|NCT00933582|DRUG|JNJ-39439335; Placebo; Naproxen|
223436815|NCT02397291|DRUG|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
224047842|NCT00515957|GENETIC|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level \<100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10\^7 cells/m2~1x 10\^8 cells/m2 3 x 10\^8 cells/m2~1 x 10\^9 cells/m2"
224047843|NCT03281967|DEVICE|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
223436816|NCT02397291|DRUG|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
223436817|NCT02397291|DRUG|Placebo|placebo
223436818|NCT02323737|DRUG|Irinotecan and cisplatin|
223436819|NCT02323737|DRUG|Etoposide and cisplatin|
223436820|NCT02211092|BEHAVIORAL|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
223436821|NCT02211092|OTHER|Usual care|Access to usual community resources but no active lifestyle coaching.
223436822|NCT00729040|BEHAVIORAL|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
223436823|NCT00004892|DRUG|O6-benzylguanine|
223566272|NCT01190475|DRUG|Active treatment with a low dose of BGS649|
223566273|NCT01190475|DRUG|Placebo treatment to blind study|
224047844|NCT02907710|DRUG|Endostar|intravenous infusion
224047845|NCT02907710|DRUG|DDP|
224047846|NCT00773136|DRUG|Bimatoprost Suspension|see prior
224047847|NCT01688856|DEVICE|Electrical Stimulator|"The 12-week treatment period consists of two components:~1. Therapist-guided task practice performed 70 minutes twice a week in the research laboratory. If Arm+Hand CCFES or Hand CCFES, the stimulator is used during task practice.~2. Self-administered muscle stimulation exercise performed 10 sessions per week at home using the device. If Arm+Hand CCFES or Hand CCFES, each session is 46 minutes. If Arm+Hand Cyclic NMES, each session is 60 minutes."
224047848|NCT01475929|DIETARY_SUPPLEMENT|Probiotic supplement|A single strain probiotic supplement given at two doses
224047849|NCT02607449|DRUG|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
224047850|NCT02607449|DRUG|Placebo|Placebo without any active pharmaceutical ingredients
224047851|NCT06301672|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224047852|NCT06301672|DEVICE|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224070593|NCT06412497|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.
224070594|NCT02051543|BEHAVIORAL|Brief Behavioral Treatment of Insomnia -Military Version|
224142863|NCT05459766|BEHAVIORAL|Usual care|Participants will be educated about the postoperative rehabilitation program
224142864|NCT04819581|DRUG|SP-103|lidocaine topical system 5.4%
223436824|NCT00004892|DRUG|polifeprosan 20 with carmustine implant|
224047853|NCT06301672|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224047854|NCT03945357|DRUG|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
224047855|NCT03945357|DRUG|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
224047856|NCT01010633|DRUG|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
224047857|NCT01010633|DRUG|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
224142865|NCT04819581|DRUG|ZTlido|lidocaine topical system 1.8%
224142866|NCT04226963|DRUG|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.
224142867|NCT05840341|DRUG|QingyiHuaji optimized formula|Qingyihuaji Optimization Formula each bag contains: (1)Scutellaria barbata D. Don (Banzhilian); (2) Hedyotis diffusa Willd. (Sheshecao); (3) Amorphophallus rivieri Durieu (Sheliugu); (4) Amomi Fructus Rotundus (Doukou); (5) Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan); (6) Semen Coicis (Yiyiren); (7) Ganoderma lucidum (Curtis) P. Karst. (Lingzhi). One bag at a time, twice a day, rinsing with boiling water, continuous administration, oral administration in the morning and evening, every 3 weeks as a cycle.
223436825|NCT00004892|PROCEDURE|conventional surgery|
223436826|NCT05070468|DRUG|Dexamethasone 0.5mg|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
223436827|NCT05070468|DRUG|Placebo|Pregnant women with a gestational age of 38 weeks and older admitted to Labor Of Kamali Hospital, for termination of pregnancy, by accident and based on the coding done by a statistician to identify groups of users of pill A or pill B, 14 pills are used vaginally . The client and the researcher are blinded and the pharmacist delivers the dexamethasone and placebo tablets with codes A and B to the researcher.
223436828|NCT00763516|RADIATION|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
223436829|NCT03220568|OTHER|Fatty acids present in adipose tissue samples|
223436830|NCT00308750|DRUG|enzastaurin|1125-1200 milligrams (mg) loading dose then 500 mg, oral, daily, until disease progression
223436831|NCT00308750|DRUG|pemetrexed|500 milligrams per square meter (mg/m\^2), intravenous (IV), once every (q) 21 days, six 21 day cycles or progressive disease
223436832|NCT00308750|DRUG|docetaxel|75 mg/m\^2, IV, q 21 days, six 21 day cycles or progressive disease
223566274|NCT00624585|DRUG|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~* Dose Level and Dose of dasatinib:~  1. Starting dose (1-8 weeks)= 100 mg orally (po) daily~ 2. +1 (\<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~* Dose Level and Dose of dasatinib:~  1. Starting dose = 100 mg po daily~ 2. -1 = 70 mg po daily~ 3. -2 = 50 mg po daily~OR~* Dose Level and Dose of dasatinib:~  1. Starting dose = 150 mg po daily~ 2. -1 = 120 mg po daily~ 3. -2 = 90 mg po daily~ 4. -3 = 50 mg po daily"
223566275|NCT05774054|DRUG|Crystalloid|received (30ml /kg) ringer's lactate solution after first presentation then norepinephrine was added when persistent mean arterial pressure (MAP)\> 65 mmHg despite adequate fluid resuscitation
223566276|NCT05774054|DRUG|noradrenaline|received ( 30ml /kg) ringer's lactate solution after first presentation combined with norepinephrine infusion (0.05 mic/kg/min)
224142868|NCT01153308|OTHER|Observational Study|This is an Observational study
223740705|NCT04147455|BEHAVIORAL|Health Education Control Condition|Participants will view six 30-minute web-based serial drama modules designed to promote health.
224142869|NCT04685499|DRUG|OBP-301|Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
224142870|NCT04685499|DRUG|Pembrolizumab|Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
224142871|NCT03176277|DRUG|ONO-7475 3mg once daily|Part A initial dose level
223436833|NCT00308750|DRUG|carboplatin|Area under the curve (AUC) 6, IV, q 21 days, six 21 day cycles or progressive disease
224142872|NCT03176277|DRUG|ONO-7475 6mg once daily|Part A 2nd dose level
224142873|NCT03176277|DRUG|ONO-7475 10mg once daily|Part A 3rd dose level
224142874|NCT03176277|DRUG|ONO-7475 6mg + Venetoclax (70-400mg)|Part D ONO-7475 + Venetoclax Combination
223436834|NCT01358578|DRUG|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
223436835|NCT01358578|DRUG|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
223436836|NCT01358578|DRUG|etanercept|etanercept 50mg subcutaneous
223436837|NCT06731829|DRUG|HRS-9231|HRS-9231
223436838|NCT06731829|DRUG|Gadobutrol|Gadobutrol
223436839|NCT04959214|BEHAVIORAL|progressive relaxation egzersize|Performing exercises in a quiet environment for 45 minutes with the Turkish Psychologists Association CD. Filling the PSQI and FSS before and 1 month after the application
223436840|NCT04283474|DRUG|XG005-03|3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation
223436841|NCT04283474|DRUG|Placebo|Placebo topical formulation
223436842|NCT06096298|OTHER|Vitamin B12 bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour containing vitamin B12 produced by P. freudenreichii bacteria.
224047858|NCT03966781|PROCEDURE|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
224047859|NCT03966781|PROCEDURE|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
224047860|NCT03966781|PROCEDURE|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
223436843|NCT06096298|OTHER|Control bread|Wheat bread with 30 % of wheat flour replaced with fermented faba bean flour.
223436844|NCT01185262|DRUG|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
223436845|NCT03745105|DRUG|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
223436846|NCT03745105|DRUG|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
223436847|NCT03745105|DRUG|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
223436848|NCT04616846|DIAGNOSTIC_TEST|Peripheral venous ultrasound|Screening for VTE from D7 to 42
223436849|NCT04023305|DRUG|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
223436850|NCT01125813|BIOLOGICAL|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
223436851|NCT06433817|RADIATION|Spectral computed tomography scan|Spectral CT scans acquisition performed during the arterial phase and venous phase for cervical cancer
223436852|NCT02327013|DRUG|vortioxetine 10 mg tablet|Oral tablets, once daily
223436853|NCT02327013|DRUG|vortioxetine 20 mg tablet|Oral tablets, once daily
224047861|NCT03966781|PROCEDURE|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
224047862|NCT01648894|PROCEDURE|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
224300084|NCT04572126|BEHAVIORAL|Control Intervention|The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
223436854|NCT02327013|OTHER|Placebo tablet|Oral tablets, once daily
223436855|NCT02911259|DEVICE|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
223436856|NCT02911259|DEVICE|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
223436857|NCT04258254|BEHAVIORAL|Multimodal|Multimodal intervention will involve hello songs, warm up mainly involve sensory and stretching games, music time involves playing instruments, moving game involves use of music or songs to move the whole body, yoga involves themes/songs to perform yoga poses, and good bye involves a goodbye song and reflections about the session. In all movement conditions, trainers emphasize complex and multilimb coordination (asymmetrical and ipsi/contralateral movements) and balance.
223436858|NCT04258254|BEHAVIORAL|General|The general exercise group will begin with hello games/set up and end with reflections and cleanup. Children will engage in limb and body warmup routines, specific strengthening exercises (single-joint/single-limb/symmetrical), moderate intensity endurance exercises involving various obstacle courses, and a cool down routine.
223436859|NCT04258254|BEHAVIORAL|Standard of Care|The seated play group will also begin with hello/icebreaker games and end with goodbye and cleanup. In between, they will read books and review the story line and overall message and engage in fine-motor activities involving building supplies and art-craft.
223436860|NCT05913206|BEHAVIORAL|Ambiguity|The intervention is a novel communication approach to communicate ambiguity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
223436861|NCT05913206|BEHAVIORAL|Complexity|The intervention is a novel communication approach to communicate complexity related to the potential risks and benefits associated with clinical decision making for parents and caregivers of children with medical complexity.
224300085|NCT03537274|BIOLOGICAL|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
224300086|NCT03537274|BIOLOGICAL|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
224300087|NCT03952234|DRUG|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
223436862|NCT05913206|BEHAVIORAL|Normalizing language|The intervention is a novel communication approach to normalize and explain the inherent uncertainty faced by parents of children with medical complexity during clinical decision making.
224047863|NCT01648894|PROCEDURE|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
224047864|NCT03241199|DRUG|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
224300088|NCT00033124|BEHAVIORAL|Behavior Therapy|
223436863|NCT05913206|BEHAVIORAL|Narrative|Parent and caregiver narratives about their decision making experiences for the care of their child with medical complexity.
223436864|NCT03570606|DEVICE|bone graft substitute|orthopaedic or spine bony defects
223436865|NCT03593421|DRUG|synthetic PreImplantation Factor|peptide
223436866|NCT04443621|BEHAVIORAL|questionnaire|Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.
223436867|NCT04443621|BEHAVIORAL|in-depth interview|Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
224047865|NCT01040065|PROCEDURE|distal clavicle resection|Presence of tenderness at 2 years after surgery
224047866|NCT00356616|DRUG|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
224142875|NCT05015738|OTHER|Traditional education|Diabetes education will be given by the trainer for 10 weeks, 2 hours of presentation.
224142876|NCT05015738|DEVICE|Diabetes Education supported by digital tools|Diabetes education will be given for 10 weeks with 2-minute animations. At the end of the course, learners' knowledge was measured with a knowledge test using the Kahoot app.
224142877|NCT04508062|PROCEDURE|pectopexy operation|Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.
224142878|NCT04508062|PROCEDURE|uterosacral ligaments plication operation.|At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
224142879|NCT03700632|OTHER|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
224142880|NCT04565600|DRUG|Etoricoxib|Etoricoxib 60 Mg Oral Tablet
223436868|NCT04829331|DEVICE|Restrata|Restrata is a sterile, single use device intended for use in local management of wounds
223436869|NCT01253668|DRUG|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
223566277|NCT03995056|BEHAVIORAL|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
224047867|NCT00356616|DRUG|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
224047868|NCT01561495|RADIATION|Proton Therapy|
223566278|NCT04392141|DRUG|Standard Treatment|Standard Treatment for COVID-19 based on National Recommendations
224047869|NCT05110339|DRUG|Ropivacaine plus dexmedetomidine|Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.
224047870|NCT05110339|DRUG|Ropivacaine|Erector spinae block with ropivacaine at a dose of 0.5%.
224142881|NCT00634114|DRUG|Esomeprazole|10mg once daily oral administration
224300089|NCT02409602|OTHER|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
223436870|NCT01253668|GENETIC|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
223436871|NCT01253668|OTHER|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
223436872|NCT01253668|PROCEDURE|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
223436873|NCT01253668|GENETIC|Protein expression analysis|Correlative studies
223436874|NCT01253668|OTHER|Immunohistochemistry|correlative studies
223436875|NCT05528913|DRUG|Fasenra Prefilled Syringe|Fasenra 60mg s.c. administration at weeks 0,4 and 8
223436876|NCT05528913|OTHER|Matching Placebo Solution|Placebo s.c. administration at weeks 0,4 and 8
223436877|NCT03425357|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
223436878|NCT06623565|PROCEDURE|Multimodal image-guided resection|Supramarginal resection using combination of ADC MRI and FET PET
223436879|NCT02823834|DEVICE|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
223436880|NCT02193139|DRUG|WL8713, 6 mg|
223436881|NCT02193139|DRUG|WL8713, 12 mg|
223436882|NCT02193139|DRUG|WL8713, 18 mg|
223436883|NCT02193139|DRUG|WL8713, 24 mg|
223436884|NCT02193139|DRUG|Placebo|
223436885|NCT06643767|DEVICE|Bexa and focus ultrasound|The Bexa exam uses pressure elastography to produce a map of the breast tissue's elasticity to identify any masses. Focused ultrasound is then used to further classify the mass into a BIRADS category.
223436886|NCT00707902|DRUG|chlorhexidine/lidocaine|
223436887|NCT00707902|DRUG|echinacea/sage|
224047871|NCT04711798|OTHER|passive leg raising maneuver (PLR)|Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
224142882|NCT00634114|DRUG|Esomeprazole|20mg once daily oral administration
224142883|NCT00634114|DRUG|Omeprazole|10mg once daily oral administration
224142884|NCT02598505|DRUG|Indacaterol|
224142885|NCT02598505|DRUG|Placebo|
224142886|NCT01442532|DRUG|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
224142887|NCT01442532|DRUG|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
224142888|NCT01442532|DRUG|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
224142889|NCT01442532|DRUG|Placebo|Form=tablet, route=oral use, for 14 days
224142890|NCT01442532|DRUG|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
223436888|NCT00616603|DRUG|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
223436889|NCT00616603|DRUG|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
223436890|NCT00616603|DRUG|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
223436891|NCT00616603|DRUG|Normal Saline|2ml of normal saline given once intravenously.
223436892|NCT06514378|BIOLOGICAL|Mesenchymal stem cells|Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.
223436893|NCT03588078|DRUG|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
223436894|NCT03588078|DRUG|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
223436895|NCT04108988|BEHAVIORAL|InvestiDate|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
223436896|NCT04108988|OTHER|Non-Health Related Video Game|Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
223436897|NCT04980651|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
223436898|NCT04980651|PROCEDURE|Sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
223436899|NCT04566133|DRUG|Trametinib|orally 2 mg once a day
223436900|NCT04566133|DRUG|Hydroxychloroquine|orally 600 mg twice a day-1,200 mg total dose
223436901|NCT05286359|DIAGNOSTIC_TEST|NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device|"NxTekTM Malaria Pf/Pv Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and Plasmodium lactate dehydrogenase (pLDH) of Plasmodium falciparum(P.f.) on one test line and of pLDH of Plasmodium vivax (P.v.) malaria on a second test line in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms.~NxTekTM Malaria Pf Plus: A sensitive rapid chromatographic immunoassay for the qualitative detection of histidine-rich protein 2 (HRP2) and pLDH on a single test line of Plasmodium falciparum(P.f.) malaria in human whole blood. This test is a lateral flow test for in vitro professional diagnostic use and intended as an aid to early diagnosis of Malaria infection in-patients with clinical symptoms."
223436902|NCT00317200|DRUG|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
223436903|NCT00317200|DRUG|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
223436904|NCT00328159|DRUG|Oil special 107 and MYGLIOL 810|
223436905|NCT03180515|DEVICE|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
223566279|NCT04392141|DRUG|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions|Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
223566280|NCT03549572|BEHAVIORAL|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
223566281|NCT03017716|OTHER|Gluten free diet|The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
223566282|NCT06397027|DRUG|Ziftomenib|Given by IV
223436906|NCT00390442|DEVICE|continuous positive airway pressure|
223436907|NCT01642485|DRUG|Moxifloxacin 400 mg fasted|"Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.~This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies."
223566283|NCT06397027|DRUG|Venetoclax|Given by PO
223436908|NCT01642485|OTHER|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
223566284|NCT06397027|DRUG|Azacitidine|Given by PO
223566285|NCT05970133|PROCEDURE|Colectomy with NOSE procedure|The specimen will be extract from the anus.
223566286|NCT06571591|DRUG|CT-L03 Group 1|tablets, QD, oral administration
223566287|NCT06571591|DRUG|CT-L03 Group 2|tablets, QD, oral administration
223566288|NCT06571591|DRUG|Placebo|tablets, QD, oral administration
223566289|NCT06571591|DRUG|Empagliflozin|tablet, QD, oral administration
223566290|NCT06571591|DRUG|Metformin|tablets, oral administration
223436909|NCT01642485|OTHER|Continental breakfast|High carbohydrate breakfast (\>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
223436910|NCT01642485|DRUG|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
223436911|NCT01642485|PROCEDURE|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
223436912|NCT01642485|DRUG|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
223436913|NCT06154642|DIAGNOSTIC_TEST|Determination of arterial compliance using blood pressure waveform analysis|Measurement of arterial stiffness using a non-invasive pressure transducer placed on the skin of the wrist, which records the pulse wave at the level of the radial artery in order to analyze the characteristics of the arterial wall. The parameters of interest are the arterial stiffness of large- and small-caliber arteries (ml/mmHg).
224047872|NCT04711798|OTHER|lung recruitment maneuver (LRM)|lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
224047873|NCT04711798|OTHER|echographic evaluation of the right cardiac function|echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
224047874|NCT01929239|DRUG|Anti-PSMA Designer T Cells|
224047875|NCT02463071|DRUG|AZD0585|1g soft capsule
224047876|NCT02463071|DRUG|AZD0585 placebo|1g soft capsule
224047877|NCT00003865|DRUG|toremifene|
224047878|NCT04650724|DRUG|T cell infusion agent targeting BCMA chimeric antigen receptor|Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.
224047879|NCT01613495|DRUG|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
224047880|NCT01613495|DRUG|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
224047881|NCT00447486|DRUG|GW842166|
224047882|NCT01925898|DRUG|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
224047883|NCT01925898|DRUG|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
224142891|NCT04895098|DRUG|statin and ezetimibe combination therapy|Receiving statins (atorvastatin/rosuvastatin or others) in combination with ezetimibe 10mg/day in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
224142892|NCT04895098|DRUG|statin monotherapy|Receiving statins (atorvastatin/rosuvastatin or others) as monotherapy in a stable dosing regimen (without changing the dose of the therapy and/or replacing the statin) for 3 or more months at the time of enrolment in the study.
224142893|NCT04742049|OTHER|Telerehabilitation-based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
224142894|NCT04742049|OTHER|Follow-up based|15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
224142895|NCT05445011|DRUG|Fludarabine + Cyclophosphamide + TAA05 Cell Injection|Fludarabine + Cyclophosphamide + TAA05 Cell Injection Fludarabine 25 mg/kg \* 3d on day-7\~-2; Cyclophosphamide 250 mg/kg \*3d on day-7\~-2; TAA05 Cell Injection on day 0.
224142896|NCT06999993|DRUG|Sodium hyaluronate jell|sodium hyaluronate gel was used to decrease or prevent tissue lyres adhesion after surgery
224142897|NCT06999993|DRUG|Sodium Bicarbonate|sodium bicarbonate decreases tissue acidosis and so it decreases fibrosis
224142898|NCT06999993|DRUG|Saline|saline 0.9% is a placebo
223436914|NCT06154642|DIAGNOSTIC_TEST|Measurement of plasma Vascular Endothelium Growth Factor|Measurement of plasma Vascular Endothelium Growth Factor levels by ELISA
223436915|NCT06154642|DIAGNOSTIC_TEST|Skin temperature gradient|Measurement of skin surface temperature gradient, defined as the difference in temperature between the skin surface of the forearm and that of the fingertip (forearm-to-fingertip)
224142899|NCT00344149|DRUG|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
224142900|NCT03661827|DIAGNOSTIC_TEST|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
224142901|NCT04597255|DEVICE|Holographic optical coherence tomography|Descriptive wavefront analysis with holographic optical coherence tomography
224142902|NCT01996904|PROCEDURE|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
224300090|NCT03743740|OTHER|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
224047884|NCT04666350|OTHER|Direct Skin Feeding Assay (DSFA)|In the direct feeding assay a cup with 60 unfed, sterile insectary-reared Anopheles gambiae mosquitoes will be allowed to feed on a participant's calf or arm for 15 minutes.
223436916|NCT06154642|DIAGNOSTIC_TEST|Vaso-occlusion test|Measurement of endothelial function by a vaso-occlusion test performed by inflating a cuff on the arm to occlude arterial flow for 3 min. Reactive hyperemia on deflation of the cuff is measured by photoplethysmography placed on the index finger, and tissue oxygen saturation (StO2) by near-infrared spectroscopy (NIRS). The amplitude of the reperfusion flow corresponding to the peak of the perfusion index (ΔPI Peak) and the time to reach this peak (time to peak) are the parameters recorded by photoplethysmography. Tissue resaturation rate (rStO2) is the parameter recorded by NIRS.
223436917|NCT06154642|DIAGNOSTIC_TEST|Transthoracic echocardiography|The diameter of the left ventricular outflow tract is measured in the tele systolic parasternal long-axis view. The pulsed Doppler flow profile is acquired at the level of the left ventricular chamber in the apical five-chamber view. The time-velocity integral of the aortic flow is then calculated. Left ventricular end-diastolic and end-systolic volumes are also measured using Simpson's method in the 4-cavity monoplane view. Measurements of vena cava diameter and respiratory variability of vena cava diameter provide an estimate of right atrial pressure. These measurements estimate cardiac output and systemic vascular resistance.
223436918|NCT06154642|DIAGNOSTIC_TEST|Photoplethysmography|The perfusion index (PI) is derived from the signal and represents the ratio between the absorbance or reflectance of pulsatile and non-pulsatile light of the photoplethysmography signal. PI is measured non-invasively using a photoplethysmographic sensor placed on the earlobe or finger.
223436919|NCT06154642|PROCEDURE|Transcatheter aortic valve insertion (TAVI)|TAVI is a treatment for aortic valve stenosis. A new valve is inserted with minimally invasive procedure without removing the old, damaged valve.
223436920|NCT06292793|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
223436921|NCT06292793|BEHAVIORAL|Cyclical Sighing|A 4-minute audio recording consisting of a 1-minute introduction to cyclical sighing followed by a 3-minute cyclical sighing practice.
223436922|NCT05100953|BEHAVIORAL|Physical Activity Counseling|Physical activity counseling will be provided under supervision by the researcher physiotherapist via video conference and an individual physical activity program will be organized weekly for two months.
223436923|NCT00130429|DRUG|PYM50028|
223436924|NCT02893904|DEVICE|EEG monitoring|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
224047885|NCT04666350|DRUG|Primaquine|Participants will receive one dose of primaquine 26.3 mg tablet on Day 2 after completion of the direct feeding assay.
224047886|NCT04666350|DRUG|Artemether/Lumefantrine|Participants will receive artemether (80 mg) and lumefantrine (480 mg) combination tablets twice a day for 3 days, starting after completion of the direct feeding assay on Day 2.
223436925|NCT02893904|DEVICE|Target Controlled Infusion|Steady state effect site concentrations of remifentanil administrated to all patients.
223436926|NCT02718248|DEVICE|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
223436927|NCT02718248|BEHAVIORAL|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
223566291|NCT05552261|DRUG|Cenegemin in the DEFENDO Study|"Cenegemin as administered in the DEFENDO Study. Long-term safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered in Stage 1 Neurotrophic Keratitis (NK) patients enrolled in the DEFENDO Study (NCT number NCT04485546).~No intervention was performed in this follow-up / extension trial."
223566292|NCT05466292|OTHER|Survey1|Closed-ended survey on the level of knowledge, use, and dissemination of the CEC.
223566293|NCT05466292|OTHER|semi-structured interview_1|the semi-structured interview concerns participants'motivations/expectations for implementing CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered
224047887|NCT01881945|OTHER|Non-invasive physiological signal recording on healthy volunteer|
224047888|NCT02765620|OTHER|drug&radiation|"1. Early treatment response assessment: using baseline data and early follow-up data~2. Evaluate treatment response: using baseline data, early follow-up data and final data~3. Compare PERCIST to RECIST criteria: correlation analysis~4. Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
224047889|NCT03039166|DEVICE|MRI 7T|
224142903|NCT01996904|PROCEDURE|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
224142904|NCT00764400|BEHAVIORAL|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
224047890|NCT03039166|DEVICE|MRI 3 T|
224047891|NCT03039166|BIOLOGICAL|blood sample|
223436928|NCT02863081|OTHER|Survey|Administered to healthcare providers
223436929|NCT02863081|OTHER|interview|Administered to patients and LAR (i.e., interviews)
223436930|NCT02223819|DRUG|Crizotinib|"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
223436931|NCT02849067|OTHER|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
223436932|NCT02849067|OTHER|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
223436933|NCT02956057|DRUG|Polyethylene Glycols|
224047892|NCT01116141|DRUG|CH-4051|Different doses CH-4051 to be compared
224047893|NCT01116141|DRUG|Methotrexate (MTX)|20 mg MTX weekly
223436934|NCT02956057|DRUG|Natrium picosulfate / Magnesium citrate|
224047894|NCT01116141|DRUG|Folic Acid|1 mg folic acid daily
224047895|NCT02629796|OTHER|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
224047896|NCT04353479|DRUG|Camrelizumab(SHR-1210)|A humanized monoclonal immunoglobulin
224047897|NCT04353479|DRUG|Decitabine|A DNA methyltransferase inhibitor
224047898|NCT05060705|DRUG|Efesovir|Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
224047899|NCT01759004|OTHER|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
224047900|NCT03428022|DRUG|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
224047901|NCT00211848|DRUG|Polyenylphosphatidylcholine (PPC)|
224047902|NCT00211848|DRUG|Pegylated Interferon|
224047903|NCT00211848|DRUG|Ribavirin|
224047904|NCT03965936|PROCEDURE|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
224047905|NCT03965936|PROCEDURE|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
224047906|NCT02937194|BEHAVIORAL|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
224047907|NCT02937194|BEHAVIORAL|Pamphlets distribution|Oral health pamphlets distribution
224047908|NCT00910572|DEVICE|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
224047909|NCT03975101|BIOLOGICAL|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
224047910|NCT04387955|DIAGNOSTIC_TEST|Biological Sample Collection|"* Diagnostic test : biological sample collection at Day 0~* Two skin biopsies on chilblain at Day 0 (one biopsy for histological analysis, one biopsy for basic research)~* Anal swabbing at Day 0~* Blood test at Day 0~* Blood test at Month 1~* Blood test at Month 2"
224047911|NCT00888381|BIOLOGICAL|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
224047912|NCT04635410|OTHER|ULTRASOUND IMAGING|SCAN LABOURING WOMEN BY ULTRASOUND
223436935|NCT02956057|DRUG|Polyethylene glycol / Ascorbic acid|
223436936|NCT01492725|DEVICE|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
223436937|NCT01492725|GENETIC|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
223436938|NCT00985517|BIOLOGICAL|CERE-120: Adeno-Associated Virus Delivery of Neurturin|
223436939|NCT00985517|PROCEDURE|Sham Surgery|
223436940|NCT00565916|DRUG|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
223436941|NCT00565916|DRUG|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
223436942|NCT00565916|DRUG|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
223436943|NCT00972634|OTHER|computer-assisted intervention|symptom assessment
223436944|NCT00972634|OTHER|questionnaire administration|Symptom assessment
223436945|NCT00972634|PROCEDURE|assessment of therapy complications|Symptom assessment
223436946|NCT00972634|PROCEDURE|quality-of-life assessment|Symptom assessment
223436947|NCT00104819|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
223436948|NCT00104819|BIOLOGICAL|sargramostim|
223436949|NCT00367484|BIOLOGICAL|Rebif® (clone 484-39)|s.c. administered Rebif®
224047913|NCT05662696|OTHER|Raabta Telemonitoring Program (Mobile Application)|Raabta is a smartphone application that will allow pregnant women at high-risk for preeclampsia to measure and record daily blood pressure readings and self-reported symptoms. An algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated alert self-care message based on their measurements and reported symptoms.
224047914|NCT00298025|DRUG|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
223436950|NCT02253550|DRUG|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
223436951|NCT02253550|DRUG|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
223436952|NCT02149316|PROCEDURE|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
223436953|NCT02149316|PROCEDURE|control|a deflated cuff placed on the right upper arm
223436954|NCT00801697|BIOLOGICAL|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
223436955|NCT00801697|BIOLOGICAL|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
223436956|NCT00801697|BIOLOGICAL|rAd35|VRC-HIVADV027-00-VP 1 x 10\^10 PU administered as 1 mL
223436957|NCT00801697|BIOLOGICAL|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
223436958|NCT00801697|BIOLOGICAL|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
223566294|NCT05466292|OTHER|semi-structured interview_2|semi-structured interview concerns participants motivations and expectations to be a member of the CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered.
224047915|NCT00298025|DRUG|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.
224047916|NCT00298025|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
224142905|NCT05833321|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|"measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire"
224142906|NCT02840890|PROCEDURE|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
223436959|NCT00801697|BIOLOGICAL|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
223436960|NCT01273740|PROCEDURE|External support|Bypass surgery with externally supported graft
223566295|NCT05466292|OTHER|semi-structured interview_3|semi-structured interview concerns participants' experiences with the ethics consultation service provide by the Clinical Ethics Committee
223566296|NCT05466292|OTHER|survey_2|survey of 20 multiple-choice questions and supplemented by free-text questions.
223566297|NCT05584111|DRUG|STC-15|STC-15 oral capsules various dosing regimen in 3-week cycles
223566298|NCT04253106|GENETIC|Liquid biopsies (blood, gastric fluid).|Next generation sequencing of a panel of diffuse gastric cancer genes, methylation analysis. Samples collected during routine screening endoscopy.
224047917|NCT00298025|DRUG|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
224047918|NCT00298025|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of \>=18 mm and two additional follicles of \>=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
224142907|NCT02840890|PROCEDURE|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
224142908|NCT00923819|PROCEDURE|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
224142909|NCT00923819|BEHAVIORAL|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
224300091|NCT00974974|DRUG|IPX066|extended-release carbidopa-levodopa capsules
223436961|NCT01398189|DRUG|clozapine|C-11 clozapine
223436962|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled in the study during the first trimester of gestation or later, if the diagnosis of APS is made during pregnancy followed by clinical practice. During the quarterly visits scheduled by clinical practice, the following will be collected relevant clinical information and the additional biological samples for analysis of serum levels of sFlt-1 and PlGF. A follow-up postpartum visit is scheduled by clinical practice at 6 weeks after completion of delivery.
223436963|NCT05786235|OTHER|Collection of epidemiological and anamnestic data and collection of biological material (peripheral blood)|Patients will be enrolled during the performance of prenatal diagnosis, routinely chosen by the patient, at which the relevant clinical information and the additional biological sample . Collection of biological material in the 2nd and 3rd TM of gestation will take place at occasion of the routinely scheduled ultrasound scans . A postpartum follow-up visit is scheduled by clinical practice at 6 weeks after the completion of delivery.
223436964|NCT02651519|DRUG|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
223436965|NCT02651519|DRUG|saline|stellate-ganglion block with saline
223436966|NCT06478602|BIOLOGICAL|Fecal microbiota transplantation|Performing a colonoscopy with fecal microbiota transplantation at the level of the cecum.
223436967|NCT06027502|BEHAVIORAL|Passive Heating|20 minutes of baseline data collection, up to 45 minutes of immersion in the hot tub to achieve a core temperature of 38.5 degrees celsius, followed by up to 90 minutes of recovery.
223436968|NCT04794413|DRUG|Pimavanserin|Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
223436969|NCT02308813|OTHER|Braking and functionality|
223436970|NCT02322502|DRUG|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
223436971|NCT02322502|DRUG|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
223436972|NCT02322502|DRUG|propofol|intravenous injection to maintain anaesthesia
223436973|NCT00339196|DRUG|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
223436974|NCT01685853|DRUG|Bisacodyl plus PEG-CS|"* the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
223436975|NCT01685853|DRUG|PEG 4 litres split|"* the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
223436976|NCT03499405|BEHAVIORAL|Family Navigator Intervention|Caregivers will be paired with a culturally matched family navigator.
223436977|NCT06385197|DEVICE|App randomizing dosing regimen|patients will receive their dimethyl fumarate treatment and the dose and time of administration will be determined using a designated app.
223436978|NCT03684551|OTHER|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
223436979|NCT03684551|OTHER|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
223436980|NCT03684551|OTHER|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
223566299|NCT02405247|OTHER|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
223566300|NCT01117298|DRUG|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
224047919|NCT00097773|DRUG|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
224047920|NCT00097773|DRUG|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
224047921|NCT00097773|DRUG|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
224047922|NCT01961401|BEHAVIORAL|exercise|
224047923|NCT04637893|OTHER|Colonoscopy|Pt. underwent colonoscopy
224047924|NCT00003702|BIOLOGICAL|Dactinomycin|Given IV
224047925|NCT00003702|DRUG|Methotrexate|Given intramuscularly
224047926|NCT00362349|DRUG|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
224047927|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
224047928|NCT02427230|BEHAVIORAL|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
224047929|NCT02427230|DRUG|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
224070595|NCT05491226|DRUG|Pembrolizumab|Pembrolizumab 200 mg is administered intravenously at Week 1, then every 3 weeks during the treatment period (6 weeks). Therapy will continue for until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
224300092|NCT00974974|DRUG|IR CD-LD|immediate-release carbidopa-levodopa tablets
224070596|NCT05491226|RADIATION|Radiation Therapy|Radiation therapy (RT) consists of 8 Gy for 3 fractions over 3 consecutive days at Week 2.
224070597|NCT05491226|DRUG|Axatilimab|Axatilimab 1 mg/kg is administered intravenously weekly starting 1 week post- RT (Week 3). Therapy will continue until initiation of SOC curative-intent treatment (neoadjuvant chemo therapy or surgery) at Week 7.
224070598|NCT03627403|DRUG|Selinexor|"Selinexor will be administered orally at a dose of 80 mg once weekly until IWG-MR disease progression, intolerable toxicity, or no clinical benefit per treating physician's discretion whichever occurs first.~For patients enrolled after Protocol v7, Selinexor will be administered by oral route beginning at 40mg once weekly. Prior to protocol version 7, the starting dose of sSelinexor was 60 mg and 80 mg once weekly."
224047930|NCT04943003|DEVICE|Transcranial Direct Current Stimulation (tDCS)|"Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered."
223436981|NCT00564044|PROCEDURE|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm\*5mm\*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
223436982|NCT00908076|DRUG|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
223436983|NCT02382796|DRUG|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
223436984|NCT03768700|OTHER|Data gathering|Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
223436985|NCT00782600|DRUG|suspension IR|50 mg IR suspension once daily for one day
223436986|NCT00782600|DRUG|CR 1|50 mg shorter release CR once daily for one day
223436987|NCT00782600|DRUG|CR 2|50 mg medium release CR once daily for one day
223436988|NCT00782600|DRUG|CR 3|longer release SR formulation once daily for one day
223436989|NCT03125187|BIOLOGICAL|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
223436990|NCT03125187|BIOLOGICAL|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
223436991|NCT03356899|DRUG|Low dose bupivacaine 0.5% (8mg)|8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
223436992|NCT03356899|DRUG|High dose bupivacaine 0.5% (10mg)|10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
223566301|NCT01117298|DRUG|Placebo|Tab Placebo every alternate day for 8 weeks
223566302|NCT05431387|DRUG|cytisinicline|film-coated oral tablets containing 3 mg cytisinicline
223566303|NCT05431387|DRUG|Placebo|film-coated oral tablets containing matched placebo
223566304|NCT05431387|BEHAVIORAL|Behavioral support|Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
223566305|NCT05072223|PROCEDURE|Pericapsular nerve group block|A new nerve block guided by ultrasound that aims to block articular branches of the shoulder.
223740706|NCT06363656|DEVICE|Wears the smartwatch during the sleep time to capture sleep characteristics and answer questionaires|"* Synchronization of smartwatch with smartphone (internet connection) to send sleep characteristics captured by the application~* Weight~* Height~* Body measurements (circumferences)~* Questionnaires about overall health status~* Pittsburgh Sleep Quality Index questionnaire~* Insomnia Severity Index~* Sleep Hygiene Index~* Epworth Sleepiness Scale~* NoSAS score (Neck, Obesity, Snoring, Age, Sex)"
224047931|NCT01009034|OTHER|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
224047932|NCT03707613|PROCEDURE|DWT learning curve|trainees learn to perform DWT after unsuccessful initial cannulation
224047933|NCT03763669|DIETARY_SUPPLEMENT|Myoinositol|myo-inositol (2 g. twice a day)
224047934|NCT03763669|DIETARY_SUPPLEMENT|Placebo (for myoinositol)|(twice a day)
224047935|NCT04160169|OTHER|Counseling messages on injectable use and HIV acquisition risk|Counseling messages based on 2017 World Health Organization guidance, a review of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-related Risks, and the Family Planning Global Handbook were provided to clients expressing interest in injectables during regular family planning appointments.
223566306|NCT05072223|PROCEDURE|Interscalene block|A common and rapid-onset nerve block method guided by ultrasound for pain control of patients undergoing shoulder surgery.
223566307|NCT01803191|DRUG|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
223566308|NCT01803191|DRUG|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
223566309|NCT04282265|DIETARY_SUPPLEMENT|Placebo|Oral placebo capsules will be taken consisting of maltodrextrin daily for 11 weeks
223566310|NCT04282265|DIETARY_SUPPLEMENT|Red Spinach Extract (RSE)|Oral capsules containing 2g of Red Spinach Extract will be consumed daily for 11 weeks
223566311|NCT06179277|DEVICE|PrefGel® + Emdogain®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®) and application of 0.3 mL Emdogain® to root surface with 27-gauge needle
223740707|NCT01132131|OTHER|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
223436993|NCT02570321|PROCEDURE|Corneal Cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
223436994|NCT02570321|DRUG|Anti Fungal Drug|Topical Amphotericin B vs Topical Natamycin
223436995|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.
223436996|NCT05422209|PROCEDURE|Mesh-augmented sacrospinal fixation with posterior colporrhaphy.|Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy.
223436997|NCT04007107|DRUG|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
223436998|NCT04007107|DRUG|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
223436999|NCT06250907|PROCEDURE|The guidance of dynamic navigation|Osteotomy and implant placement with the guidance of dynamic navigation
223437000|NCT06250907|PROCEDURE|The guidance of static template|Osteotomy and implant placement with the guidance of static template
223437001|NCT03412188|DRUG|Eltrombopag|Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
223437002|NCT03412188|DRUG|conventional|Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
223437003|NCT04022356|DEVICE|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~* By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~* By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
223437004|NCT05100498|DEVICE|Web-based oncofertility support tool|The website structure was developed to satisfy the needs of reproductive-age women was investigated based on four domains of social support, as developed by Cohen and Syme (1985). The important needs of patients can be classified as emotional, informational, appraisal, and instrumental support.
223437005|NCT05910060|DIAGNOSTIC_TEST|OTTAWA ANKLE RULES|count the ottawa score and do an x-ray if the score is greater than or equal to 1
223437006|NCT04448600|OTHER|MRI|"The patients included in the study will all have a cerebral MRI as part of the cholesteatoma follow-up or for the assessment of cerebral or inner ear pathology.~\- ENT evaluation"
223437007|NCT05729542|DEVICE|Arthrex Tightrope|High-tensile strength suture syndesmosis repair
223437008|NCT05729542|DEVICE|Synthes Fibulink|High-tensile strength suture syndesmosis repair
223437009|NCT05356975|BEHAVIORAL|Superset|"A strength circuit training will be performed in a supersets fashion. Three strength circuit training in three blocks.~1. One leg squat, side plank, and push up.~2. Deadlift, lumbar extension stretch, and row.~3. Glute bridge, crunches, and front raise."
224047936|NCT02670941|DRUG|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
223437010|NCT05356975|BEHAVIORAL|Concurrent|Six resistance exercises in a traditional fashion: three exercises for the lower body (one leg squat, deadlift, and glute bridge). Three exercises for the upper body (push up, row, and front raise). And three aerobic exercises (floor tap squat, jumping jacks, and skaters).
223566312|NCT06179277|DEVICE|PrefGel®|Surgical crown lengthening procedure with root conditioning with 24% EDTA (PrefGel®)
224047937|NCT02670941|DRUG|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
224047938|NCT02670941|DRUG|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
224047939|NCT02670941|DRUG|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
224047940|NCT00000626|DRUG|Vinblastine sulfate|
224047941|NCT00000626|DRUG|Dacarbazine|
224047942|NCT00000626|DRUG|Filgrastim|
224047943|NCT00000626|DRUG|Bleomycin sulfate|
224047944|NCT00000626|DRUG|Doxorubicin hydrochloride|
223566313|NCT00676520|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
223566314|NCT05483257|DEVICE|Multigene panel for next-generation sequencing|HLA-I genotyping based on next-generation sequencing for prognosis evaluation
223566315|NCT01425359|DRUG|Ranolazine|
224047945|NCT00535275|DRUG|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
224047946|NCT00535275|DRUG|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
224047947|NCT02180620|OTHER|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
223437011|NCT05648175|BEHAVIORAL|e-CBT|The participant will submit their weekly homework and receive personalized feedback from their assigned therapist on OPTT. The feedback adds customization by acknowledging the participant's experiences in the past week and ensures the participant has understood the CBT concepts.
223566316|NCT01425359|DRUG|Ranolazine placebo|
223566317|NCT03179254|DRUG|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
223566318|NCT03179254|DRUG|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
223566319|NCT04137588|DRUG|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
224047948|NCT02180620|OTHER|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
223437012|NCT05648175|BEHAVIORAL|e-CBT + Phone Call|In addition to the e-CBT program (see 1 above), the participant will receive a weekly phone/video call from their assigned therapist. The goal is to build on the therapeutic relationship and to add personalization with direct verbal encouragement. This phone/video call is limited to a one-time, 15-20 minutes call each intervention week.44 The purpose is to check with the patient on their treatment progress. The secure call will either be a phone or video (via Microsoft Teams) call, depending on the preference of the patient.
223437013|NCT05648175|BEHAVIORAL|e-CBT + Phone Call + Pharmacotherapy|In addition to the e-CBT program (see 1 above), the participant will receive standard pharmacotherapy following DSM-5 guidelines. A pharmacotherapy allocation system has been developed (Figure 1; Figure 2) that follows clinical guidelines. All medications will be prescribed by a psychiatrist on the research team. All medications are a part of the clinical standard of care. The medications will be provided to the participant through the normal process of receiving medication (i.e., pharmacy). Participants allocated to the e-CBT + Phone Call + Pharmacotherapy arm will begin the pharmacotherapy optimization process at the same time as they begin the e-CBT program. Oversight of medication in the e-CBT + Pharmacotherapy arm will be conducted by a psychiatrist on the team who will make a judgement regarding whether to alter the medications. This will not require any additional study visits/time commitment for the participants in this arm.
223437014|NCT01678885|BEHAVIORAL|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
223437015|NCT01678885|OTHER|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
223437016|NCT01678885|DEVICE|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
224142910|NCT02051894|DRUG|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
224142911|NCT02416362|OTHER|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
223437017|NCT01678885|BEHAVIORAL|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
223566320|NCT04137588|DRUG|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
223566321|NCT03800446|DIAGNOSTIC_TEST|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
223566322|NCT02376725|PROCEDURE|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
223566323|NCT02376725|PROCEDURE|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
223740708|NCT03031977|OTHER|visceral mobilization|
223740709|NCT05691296|BEHAVIORAL|Home training|Letter Chart Accomodative Rock Training for 2 minutes each time
224047949|NCT02180620|OTHER|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
224047950|NCT05656625|OTHER|descriptive|The block performed (distal peripheral nerve block and/or brachial nerve block) and the volume applied, block performance time, first analgesia times, surgery times, surgery types, discharge times, presence of additional complaints will be recorded. The data obtained by grouping the patients according to the type of anesthesia applied (brachial plexus block and distal nerve blocks) will be subjected to statistical analysis.
224047951|NCT01761825|DRUG|ivabradine|
224047952|NCT04521829|OTHER|Walking with different optic flow speeds with 2 different VR devices|Participants will perform 2 sessions of VR-enhanced treadmill walking. One session with the GRAIL system (semi-immersive) and the other session with a fully immersive head-mounted display (Oculus Rift S). In both sessions, the speed of the optic flow will be manipulated: equal to, 2 times faster and 2 times slower than the participant's comfortable walking speed.
224047953|NCT04577729|PROCEDURE|Allogenic Fecal Microbiota Transplantation|Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
224047954|NCT04577729|PROCEDURE|Autologous Fecal Microbiota Transplantation|Patients receiving their own stool in terms of sham FMT.
224047955|NCT04119141|DIAGNOSTIC_TEST|X ray imaging|"Acquisition:~* 140 kVp,~* 1/2 mAs/kg,~* Pitch: 1.35,~* Rotation time: 0.5 sec.~Reconstruction:~* I70f filter, 3 iteration loops,~* Cutting thickness 1 mm/0.7 mm~* Fenestration: C -600/W 1600~* Field of view (Size, x \& y coordinates) identical on both acquisitions."
224047956|NCT04077541|BEHAVIORAL|internet platform|The trauma care bundles combined with the internet platform.
224047957|NCT04016831|BEHAVIORAL|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
224047958|NCT04016831|OTHER|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
224142912|NCT02416362|OTHER|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
223437018|NCT01678885|DEVICE|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
223437019|NCT01678885|DEVICE|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
223437020|NCT06450639|DRUG|Satralizumab|Satralizumab will be administered SC in the abdominal or femoral region on Day 1, Weeks 2 and 4 (loading doses) and then Q4W from Weeks 8 to 104 (maintenance doses) until the study completion visit.
224142913|NCT02678663|PROCEDURE|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
224047959|NCT01923350|BEHAVIORAL|Weight Reduction Intervention|"The weight trial intervention components were:~* Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~* Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~* Print mailings/emailings~* 3 Get Ready e-messages in the four weeks before the weight intervention began~* Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~* Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
223437021|NCT06472999|PROCEDURE|Nephroprotective measures|Due to the observational design of the study, no study specific interventions are performed. The treatment of the patients is completely guided by the responsible physicians.
223437022|NCT06391593|DRUG|ALTO-203 25 μg|Active, ALTO-203 25 μg
224047960|NCT01923350|BEHAVIORAL|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
224142914|NCT02678663|PROCEDURE|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
224047961|NCT01923350|BEHAVIORAL|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
224047962|NCT01923350|BEHAVIORAL|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
224047963|NCT02654249|DEVICE|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
224047964|NCT02654249|PROCEDURE|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
224047965|NCT02654249|DEVICE|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
224142915|NCT03378154|PROCEDURE|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
224142916|NCT03378154|PROCEDURE|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
224142917|NCT02541474|OTHER|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
224142918|NCT00972829|DRUG|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
224142919|NCT00972829|DRUG|Ezetimibe|Ezetimibe 5 or 10 milligrams
224142920|NCT03800862|DEVICE|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
224142921|NCT02399592|DRUG|Bevacizumab|10 mg/kg q3w
224142922|NCT02399592|DRUG|Tocotrinol|300 mg tid
224142923|NCT00041769|PROCEDURE|Therapeutic Drug Monitoring (TDM)|
224142924|NCT04664855|OTHER|Trauma-Informed Yoga|8 weeks of twice weekly trauma-informed yoga for 45 minutes per session
224142925|NCT05127421|DRUG|Ruxolitinib cream|"Ruxolitinib cream 1.5% applied twice a day (BID)"
224142926|NCT05127421|DRUG|Vehicle|Vehicle cream applied twice a day (BID) to affected areas
223437023|NCT06391593|DRUG|ALTO-203 75 μg|Active, ALTO-203 75 μg
223437024|NCT06391593|DRUG|Placebo|Comparator, Placebo-to-match
223437025|NCT04068688|BEHAVIORAL|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
223566324|NCT00338208|BEHAVIORAL|Training in the Use of Low Vision Devices|
223740710|NCT05691296|BEHAVIORAL|School training|Letter Chart Accomodative Rock Training for 2 minutes each time
224142927|NCT02219087|DRUG|Liposomal bupivacaine|
224142928|NCT02219087|DRUG|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
224142929|NCT00103467|BIOLOGICAL|rPA102 Vaccine|
224142930|NCT00156299|DRUG|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
224142931|NCT00156299|DRUG|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
224142932|NCT00153894|BEHAVIORAL|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
224142933|NCT00153894|BEHAVIORAL|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
224142934|NCT03093961|DEVICE|IASD implant|Single arm for implant
224142935|NCT00282789|DEVICE|bilevel positive airway pressure|
224047966|NCT02654249|DEVICE|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
224047967|NCT03621527|OTHER|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
224142936|NCT00282789|DEVICE|bilevel positive airway pressure (Device)|
224142937|NCT02389673|DEVICE|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
224142938|NCT02760017|DRUG|B. forficata|
224142939|NCT02760017|DRUG|Placebo|
223566325|NCT03525184|OTHER|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (\~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of \~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C \& D, zinc and omega-3 fatty acids (DHA and EPA).
223566326|NCT03525184|OTHER|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
223566327|NCT04419051|OTHER|Owlet Band|The Owlet Band is a wearable fabric band pregnancy tracker made up of small sensors that are able to detect natural low-level electrical signals normally produced by the mother's heart and baby's (fetal) heart.
223566328|NCT00218816|BEHAVIORAL|Nebulizer Education Intervention|Asthma Education
224047968|NCT03621527|OTHER|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
224142940|NCT00900913|DRUG|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
223566329|NCT00218816|BEHAVIORAL|Standard Asthma Education Groups|Asthma Education
224047969|NCT02654366|BEHAVIORAL|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
224142941|NCT03829865|DIAGNOSTIC_TEST|High resolution esophageal manometry|High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
224142942|NCT04840706|DEVICE|HFNC Airvo|HFNC device (Airvo) long-term use in in stabile hypercapnic COPD patients, who are non-compliant to NIV after an acute exacerbation of COPD
224142943|NCT04840706|OTHER|Standard care|No HFNC treatment
223566330|NCT05460052|OTHER|Physical activity training program|"The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference."
223566331|NCT05460052|OTHER|Weekly phone call.|Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
224142944|NCT02352805|DEVICE|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
224142945|NCT00574496|DRUG|cyclophosphamide|
224142946|NCT00574496|DRUG|cyclosporine|
224142947|NCT00574496|DRUG|fludarabine phosphate|
224142948|NCT00574496|DRUG|gemcitabine hydrochloride|
224142949|NCT00574496|DRUG|ifosfamide|
224142950|NCT00574496|DRUG|mechlorethamine hydrochloride|
224142951|NCT00574496|DRUG|melphalan|
224142952|NCT00574496|DRUG|methotrexate|
224142953|NCT00574496|DRUG|mycophenolate mofetil|
224142954|NCT00574496|DRUG|prednisone|
224142955|NCT00574496|DRUG|procarbazine hydrochloride|
224142956|NCT00574496|DRUG|vincristine sulfate|
224142957|NCT00574496|DRUG|vinorelbine tartrate|
224142958|NCT00574496|PROCEDURE|allogeneic bone marrow transplantation|
224142959|NCT00574496|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
224142960|NCT00574496|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
224142961|NCT00574496|PROCEDURE|peripheral blood stem cell transplantation|
224142962|NCT00574496|PROCEDURE|umbilical cord blood transplantation|
224142963|NCT00574496|RADIATION|total-body irradiation|
224142964|NCT04387994|OTHER|Blood samples collection|Collection of blood samples from consenting subjects to evaluate circulating biomarkers concentrations.
224142965|NCT01714752|PROCEDURE|measure of left ventricular and diastolic pressure at exercise|
224300093|NCT04648566|PROCEDURE|Intrauterine administration of hCG-activated peripheral blood mononuclear cells|Administration of hCG-activated peripheral blood mononuclear cells in the uterine cavity of the patient
224300094|NCT04648566|PROCEDURE|Intrauterine administration of sperm washing medium|Administration of sperm washing medium instead of PBMC in the uterine cavity of the patient
224300095|NCT00422981|DRUG|AL-108|5 mg QD
224300096|NCT00422981|DRUG|AL-108|15 mg BID
223437026|NCT04068688|BEHAVIORAL|Telehealth coaching|The telehealth coaching intervention was informed by the Community-Early Start Denver Model (C-ESDM) materials. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) were developed by the research team. Over 12, 1-hour asynchronous caregiver coaching sessions that are delivered by non-specialists, caregivers were coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors. The session itself being delivered via phone. Prior to the coaching session staff shared session materials with the family via WhatsApp. Prior to the session the caregiver shared a 6-min video of an interaction with their child. During the session, the caregiver and coach reviewed the video, and the caregiver completed a self-reflection checklist.
223437027|NCT01901861|DRUG|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
223437028|NCT01901861|DRUG|Placebo|Placebo is given before meal ingestion
223437029|NCT05225571|OTHER|no intervention|there is no any intervention in this study. it is an observational and cross-sectional study.
223437030|NCT05217511|BEHAVIORAL|Neuromuscular Electrical Stimulation|NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
223437031|NCT04679051|BEHAVIORAL|Sleep duration|Participants will be asked to alter time in bed to achieve specified sleep durations.
223437032|NCT05956353|BEHAVIORAL|Digital Storytelling Intervention|Culturally tailored narrative-based videos created by individuals to promote colorectal, breast and cervical cancer screening among eligible participants in a primary care practice.
223437033|NCT05123976|DRUG|Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
223437034|NCT05123976|DRUG|Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)|After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
223437035|NCT02618694|PROCEDURE|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
223437036|NCT02618694|PROCEDURE|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, \& Ihara, 2012; Linos, 2005; George \& Kavoussi, 2010).
223437037|NCT01286194|DRUG|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
223437038|NCT06622291|DRUG|Nitric Oxide|Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
223437039|NCT06622291|OTHER|Placebo|This is the placebo group. The standard CPB protocol involves delivering an air-gas mixture to the cardiopulmonary bypass circuit during cardiac surgery and avoiding the use of nitric oxide within 12 hours after surgery.
223437040|NCT00156000|DEVICE|Fetal Fibronectin|fFN test done during pregnancy
223437041|NCT00156000|DEVICE|Salivary Estriol|Salivary Estriol done during pregnancy
223437042|NCT04837599|DEVICE|Discovery TM of Pentax medical on/off in colonoscopy|on the monitor artificial integlligence Discovery can be switched on or off.
223437043|NCT02554318|DRUG|Rifampicin|
223437044|NCT02554318|DRUG|Isoniazid|
223740711|NCT04940650|DIAGNOSTIC_TEST|exercise testing|To define the strenuous physical exercise in this study, each participant will be asked to perform two hours of high intensity (HIT)-effort during the endurance exercise of at least 6 to 7 hours. Therefore all participants will have exercise testing approximately 1 week before the physical exercise to set aerobic and anaerobic gas exchange thresholds, as well as VO2max.
224047970|NCT01494350|DRUG|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
224047971|NCT02753660|PROCEDURE|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
224047972|NCT02753660|PROCEDURE|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
224300097|NCT00422981|DRUG|Placebo|Placebo
224300098|NCT01959035|DRUG|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
224300099|NCT01898325|DEVICE|Fibroscan|Fibroscan
224047973|NCT05421962|DRUG|Ketamine|Ninety patients were included and randomized to either fentanyl-propofol (Group FP, n: 30), ketamine-propofol (Group KP, n: 30) or propofol-control group (Group C, n: 30). Group FP patients received fentanyl and propofol, Group KP received ketamine and propofol and Group C, propofol.
224047974|NCT00714467|BEHAVIORAL|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
224047975|NCT00714467|BEHAVIORAL|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
224047976|NCT06395233|DEVICE|BetterPoints App|The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.
224047977|NCT05638451|DRUG|Sintilimab plus Bevacizumab and Temozolomide|200mg Sintilimab plus 10mg/kg Bevacizumab very 3 weeks 200 mg/m2/day Temozolomide on days 1-5 out of a 28 days schedule
224047978|NCT01408433|OTHER|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
224047979|NCT01408433|OTHER|Double embryo transfer|two (2) embryo transfer of untested embryos
224047980|NCT05010954|DRUG|LXI-15028 50mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
224047981|NCT05010954|DRUG|Lansoprazole 30mg group|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Lansoprazole 30mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks.
224047982|NCT02806154|OTHER|DEXA|The appendicular muscle mass measured by DEXA
224047983|NCT05274802|DRUG|ALS-4|Single dose of ALS-4 before Breakfast
224047984|NCT05274802|DRUG|Placebo|Single dose of placebo before Breakfast
224047985|NCT05274802|DRUG|ALS-4|Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
223437045|NCT02554318|DRUG|Pyrazinamide|
223566332|NCT05460052|OTHER|Personalized training plan.|After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
224047986|NCT05274802|DRUG|ALS-4|Multiple dose of ALS-4 up to two times daily
224047987|NCT05274802|DRUG|Placebo|Multiple dose of placebo up to two times daily
224047988|NCT04771585|OTHER|Community Mask|Fabric mask, no medical device
224047989|NCT04771585|OTHER|Surgical Mask|Medical face mask (personal protective equipment), CE-certified
224047990|NCT04771585|OTHER|FFP2 respirator|Filtering Face Piece with no less than 94% filtering capacity, CE-certified
224047991|NCT04771585|OTHER|FFP3 respirator|Filtering Face Piece with no less than 99% filtering capacity, CE-certified
224047992|NCT05169216|BEHAVIORAL|Cognitive-Behavioral Therapy|"Each week, a sheet of tasks to be executed and a diary were provided to verify compliance with the guidelines:~1. Week 0. Familiarization: Information gathering~2. 1st week. Self-knowledge and concentration: To know sports psychology and mental training. Information on beliefs and expectations in sport.~3. 2nd week: To integrate daily mental training.~4. 3rd week. Trust: To consolidate concentration activation. To integrate and build confidence (in oneself and in the team).~5. 4th week. Application to sports tactics: To apply concentration strategies to your sports practice. To know those strategies that provide the best results for each athlete.~6. 5th and 6th weeks: To integrate the content already provided.~7. 7th week. Link with the team: To strengthen the bond between team members.~8. 8th week. Daily routines: To improve the daily routine prior to the competition.~9. 9th and 10th weeks: To integrate the content already provided."
224142966|NCT04803968|OTHER|bicycle ergometer and arm ergometer exercise|"After the bicycle ergometer training is completed, there will be a 15-minute break for blood pressure measurement of the patients.~Then the combined upper and lower extremity training group will participate in the arm ergometer exercise separately from the lower extremity training group.~For this, the patient will sit upright in front of the height-adjustable arm ergometer stand (Lode Angio Arm Ergometer with Automat) with the fulcrum of the handle at shoulder height.~The arm endurance training group will work for a total of 20 minutes, at 60% of the peak workload and at 50 rpm."
224300100|NCT03750435|PROCEDURE|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
224300101|NCT00531141|OTHER|examination only|OCT performed twice
224300102|NCT02317718|OTHER|monitor reproductive outcome|
223437046|NCT02554318|DRUG|Ethambutol|
223437047|NCT02554318|DIETARY_SUPPLEMENT|Fermented soybean|
223437048|NCT05143216|OTHER|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Canula)|Low concentration oxygen group: Room air (0-2Litre Oxygen via Nasal Cannula)
223437049|NCT05143216|OTHER|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)|High concentration oxygen group: Room air (12-15Litre Oxygen via Non-rebreather Mask)
223437050|NCT03707366|BEHAVIORAL|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
223437051|NCT05344690|GENETIC|SLMAP and EPO genetic polymorphism|Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
223566333|NCT02959541|DRUG|Leucovorin|
224047993|NCT00683566|PROCEDURE|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
224047994|NCT02494466|DRUG|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
224047995|NCT01995578|DRUG|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
224047996|NCT02054325|DRUG|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
224047997|NCT02054325|DRUG|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
224047998|NCT00617604|DRUG|Alefacept|IV and subcutaneous injection
224142967|NCT04803968|OTHER|bicycle ergometer exercise|All patients in the control and study groups will participate in the routine lower extremity bicycle ergometer training (Lode Corival Cpet Ergoline type: 960900 serial number: 20160094, Netherlands). The exercise protocol for the lower extremities will consist of a total of 40 minutes, including an 8-minute warm-up phase and an 8-minute cool-down phase. Exercise intensity, on the other hand, will be arranged as recommended in the European Society of Cardiology (ESC) 2020 guideline for chronic heart failure patients, at a workload corresponding to 70-80% of peak oxygen consumption (VO2peak), with a turnover rate of 60 cycles / min.
224142968|NCT03064958|OTHER|Herbs and spices|Mix of commonly used herbs and spices
224142969|NCT03064958|OTHER|High fat meal|Meal containing 1000kcal and 45g fat
224142970|NCT00574431|OTHER|Data Collection|Collection of patient data before implementation of a nutritional management protocol
224142971|NCT00574431|OTHER|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
224142972|NCT03543358|DRUG|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
224142973|NCT03543358|DRUG|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
224142974|NCT00955292|DRUG|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
224142975|NCT00695240|DEVICE|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
224142976|NCT04521335|DRUG|Disulfiram|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
224142977|NCT04521335|DRUG|Copper Gluconate|Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
224142978|NCT03204435|PROCEDURE|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
224047999|NCT00617604|DRUG|placebo|IV and subcutaneous injection
224048000|NCT00617604|DRUG|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
224048001|NCT00617604|DRUG|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
224048002|NCT00617604|DRUG|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
223566334|NCT06367686|DEVICE|IscAlert sensor|Insertion of an IscAlert sensor at the nasal mucosa
223740712|NCT04940650|DIAGNOSTIC_TEST|Echocardiography|Measurements of mass, volumes and function will be obtained of both the left and right ventricles at rest enabling comparisons with cardiac MRI and traditional echo measures.
224048003|NCT03250832|DRUG|TSR-033|TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
224048004|NCT03250832|DRUG|Dostarlimab|Dostarlimab (previously referred to as TSR-042) is an IgG4 antibody.
224048005|NCT03250832|DRUG|mFOLFOX6|mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
224048006|NCT03250832|DRUG|FOLFIRI|FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
224048007|NCT03250832|DRUG|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF)-A to inhibit angiogenesis.
224048008|NCT00115791|DRUG|RSD1235|IV
224048009|NCT00115791|DRUG|placebo|IV
224048010|NCT02862405|OTHER|vision tests|
224048011|NCT02303704|PROCEDURE|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
224048012|NCT02303704|PROCEDURE|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
224142979|NCT03204435|PROCEDURE|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
224048013|NCT03410836|DRUG|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
224142980|NCT03204435|PROCEDURE|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
223437052|NCT04826133|DRUG|Calcitriol|Subjects will receive an oral administration of calcitriol (1,25-dihydroxyvitamin D3) 1.5 μg (three capsules of 0.5 μg each) at 9 pm, night before each cocaine session, and at 8 am, morning of each cocaine session. This dose of calcitriol is lower than doses safely administered in other human studies and for a duration of time shorter than doses safely administered in other trials. In addition, this dose has been already tested by our group, subject of a different grant application, and should be effective at enhancing stimulant's induced dopamine release, in comparison to placebo.
223437053|NCT04826133|OTHER|Placebo|Subjects will receive an oral administration of three capsules of placebo at 9 pm the night before each cocaine session, and at 8 am, morning of each cocaine session.
223437054|NCT06731387|OTHER|Pharmaceutical technical assistants supported medication dispensation on the hospital ward|Pharmaceutical technical assistants (PTAs) visit the hospital ward for two hours in the morning or afternoon to dispense medications for admitted patients for the following day. Night nurses then complete any final additions or adjustments as needed.
223437055|NCT04788875|PROCEDURE|Small bite suturing Technique|Small bite suturing technique with PDS 2.0
224048014|NCT03410836|OTHER|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
224142981|NCT03204435|PROCEDURE|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
224142982|NCT06101524|PROCEDURE|Free gingival unit, free gingival greft|The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
224142983|NCT05202769|OTHER|Video filming|Video clips taken using RGB and thermal imaging cameras under varying conditions of lighting, movement and procedures taking place.
224142984|NCT00004095|DRUG|gemcitabine hydrochloride|
223437056|NCT04788875|PROCEDURE|Standardised Large Bites Technique|Standardised large bite suturing technique with PDS 2.0
223437057|NCT01417585|BEHAVIORAL|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
223437058|NCT01417585|BEHAVIORAL|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
223437059|NCT03027206|OTHER|Vibration technique|Comparison of different technique
223437060|NCT03027206|OTHER|Acceleration of expiratory flow|Comparison of different technique
223437061|NCT03514706|DIAGNOSTIC_TEST|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
224048015|NCT05880017|PROCEDURE|Modified ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; modified ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify longissimus (LG) and intercostalis muscles. After identifying the muscles and decontamination of the skin, the modified TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 15ºangle from the skin in-plane in a medial to lateral direction injecting the anesthetic locally between the longissimus and intercostalis muscles, which are easy to define using ultrasonography. After negative aspiration, injection will be in each side bilaterally in the interface between the LG and intercostalis muscles.
224142985|NCT00004095|DRUG|irinotecan hydrochloride|
223437062|NCT03514706|DIAGNOSTIC_TEST|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
224142986|NCT04413643|DEVICE|Noninvasive Ventilation|The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 \>45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
224300103|NCT02613013|DEVICE|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
223437063|NCT05499078|DEVICE|SULFEX 13081.22|Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
223437064|NCT01329588|DRUG|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
223437065|NCT01329588|DRUG|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
223437066|NCT03725501|DRUG|ALS-L1023|ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.
223437067|NCT03725501|DRUG|Ranibizumab|LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
223437068|NCT03725501|OTHER|Placebo|Control group for comparison with oral administration of ALS-L1023
223437069|NCT01303640|DEVICE|Biolimus-eluting stent|Biolimus-eluting stent
223437070|NCT01303640|DEVICE|Everolimus-eluting stent|Everolimus-eluting stent
223437071|NCT05005689|DRUG|Fluoride mouthwash (0.05%; 225ppm).|Mouthwash
223437072|NCT05005689|DRUG|Tooth Mousse Plus|Tooth Mousse
223566335|NCT04500080|BEHAVIORAL|PE Intervention|"Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities"
223566336|NCT01854216|DRUG|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
223740713|NCT03946904|DEVICE|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
224048016|NCT05880017|PROCEDURE|Conventional ultrasound guided thoracolumbar interfascial plane (TLIP) block.|Patients will be placed in a prone position; conventional ultrasound guided TLIP block will be performed using a SonoSite 2-5 MHZ Curved array (C60X) transducer. The transducer will be positioned in a transverse midline position at the level of the L3 vertebra. After the identification of the spinous process and interspinous muscles, the probe will be moved laterally to identify the multifidus (MF) and longissimus (LG) muscles. After identifying the muscles and decontamination of the skin, the TLIP block will be performed under real-time ultrasound guidance using an insulated 90-mm 22G echogenic needle which will be inserted at a 30ºangle from the skin in-plane lateral to the medial direction through the belly of the LG toward the MF muscle. After negative aspiration, injection will be done in each side bilaterally in the interface between the MF and LG muscles.
224048017|NCT05880017|DRUG|Morphine for peritoperative analgesia (control group).|Morphine based analgesia, after emergence they will receive 5mg morphine IV as a start and the rest of the first 24 hours they will receive incremental dose of intravenous morphine according to pain score.
224048018|NCT05880017|DRUG|Bupivacain|As a local anesthetic will be injected in modified and conventional groups 20ml in each side.
224142987|NCT06446206|DRUG|Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib|Adebrelimab plus paclitaxel, carboplatin and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib and bevacizumab.
224142988|NCT00674518|BEHAVIORAL|One on one counseling|Motivational Interviewing
224142989|NCT00674518|BEHAVIORAL|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
224142990|NCT00674518|BEHAVIORAL|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
224142991|NCT01236313|PROCEDURE|TEE report|Information will be collected during cardiac surgery.
224142992|NCT00870818|DIAGNOSTIC_TEST|Blood samples for safety|serum chemistry, hematology, infection screen, thyroid function, Insulin, hemoglobin A1c,and autoantibodies
224142993|NCT00870818|BEHAVIORAL|Patient reported outcome questionnaires|EQ-5D, Peds QL, Low blood sugar survey, and hospitalization information.
223437073|NCT04324866|DIAGNOSTIC_TEST|Nasopharyngeal swab|Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection
223437074|NCT00688922|DRUG|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
223437075|NCT05495217|DEVICE|Conventional Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY using Induced pneumoperitoneum.
223437076|NCT05495217|DEVICE|Gasless Laparoscopy|A procedure in which a laparoscope (LAPAROSCOPES) is inserted through a small incision near the navel to examine the abdominal and pelvic organs in the PERITONEAL CAVITY without Induced pneumoperitoneum.It mechanically elevates the abdominal wall and allows laparoscopic visualization through a single incision, providing diagnostic and therapeutic procedures.
223437077|NCT04982016|OTHER|crystal therapy|Infusion of 250ml crystal solution before anesthesia induction
223437078|NCT04982016|OTHER|colloid therapy|Infusion of 250ml colloid solution before anesthesia induction
223566337|NCT01854216|DRUG|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
223566338|NCT01854216|DRUG|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
223566339|NCT01940250|DRUG|Magnesium Sulphate|MgSO4 IV infusion
223566340|NCT01940250|DRUG|Sterile water|H2O IV infusion
223566341|NCT05249933|DRUG|Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8|Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
223566342|NCT02453945|DEVICE|Adjustable Support Bra|A ClearPoint Medical support bra
223740714|NCT00140569|PROCEDURE|CHVP + interferon|
223740715|NCT00140569|DRUG|fludarabine|
223740716|NCT00140569|PROCEDURE|CHOP + TBI and autotransplant|
224048019|NCT05629429|DRUG|Olaparib|Olaparib 300mg BID PO
224048020|NCT05629429|DRUG|Chemotherapy drug|Continue platinum based chemotherapy
224048021|NCT01518283|DRUG|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
224048022|NCT03407651|BIOLOGICAL|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
224048023|NCT04181944|OTHER|Exercise Treatment Group|be specific
224048024|NCT00355979|DEVICE|intragastric balloon|
224048025|NCT04682704|DEVICE|Parasym|Tragus stimulation
224048026|NCT02774616|DEVICE|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
224048027|NCT02774616|DEVICE|Plexa ICD lead|predefined follow-up schedule
224048028|NCT02149212|DRUG|Phlebotonic|Aminaftone -- 75 mg BID
224048029|NCT02149212|DEVICE|Stent|Iliac Vein Stenting
224048030|NCT02149212|PROCEDURE|Limb elastic compression support|CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages
224048031|NCT02149212|PROCEDURE|Unna boot dressing|CEAP 6 \> Unna boot dressing
224300104|NCT02613013|DEVICE|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
224048032|NCT00137163|DEVICE|Dermafill Dressing|
224048033|NCT05614687|BEHAVIORAL|Community-informed art-based programme|The Community-informed art-based programme is an intervention incorporating art in the form of for example poetry and drawings in addressing trauma and encouraging community attitudes towards the positive reintegration of ex-offenders.
224300105|NCT02613013|DRUG|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
224300106|NCT02613013|PROCEDURE|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
224300107|NCT02613013|DRUG|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
224300108|NCT02613013|PROCEDURE|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.
223437079|NCT03105921|DEVICE|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
223437080|NCT05260216|COMBINATION_PRODUCT|Comprehensive prevention and treatment|Children with low risk of caries will receive routine prevention including fluoride foam application twice a year and oral hygiene guidance. Children with middle or high risk of caries will receive fluoride varnish application twice a year and caries restorative treatment in addition to routine prevention. The risk-graded intervention is one kind of comprehensive prevention and treatment.
223437081|NCT05260216|COMBINATION_PRODUCT|Routine prevention|Routine prevention includes fluoride foam application twice a year and oral hygiene guidance.
223437082|NCT01836809|DRUG|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
223437083|NCT01836809|DRUG|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
223566343|NCT03172325|DRUG|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
223566344|NCT03172325|DRUG|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
224048034|NCT05614687|OTHER|Government Media Intervention|Government Media Intervention involving media content from the National Orientation Agency and other media sources
224300109|NCT01130636|DRUG|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
224300110|NCT05129436|DRUG|Vaxigrip Tetra 2020/2021|vaccine against seasonal influenza
224048035|NCT03050996|PROCEDURE|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
224048036|NCT05173142|DRUG|HMPL-453|HMPL-453 administered orally.
224048037|NCT05173142|DRUG|gemcitabine and cisplatin|Gemcitabine and Cisplatin administered intravenously.
224048038|NCT05173142|DRUG|toripalimab|Toripalimab administered intravenously.
224048039|NCT05173142|DRUG|Docetaxel|Docetaxel administered intravenously.
224048040|NCT00397033|DRUG|Paliperidone ER|6mg/day paliperidone er for 6 weeks
224048041|NCT00397033|DRUG|Paliperidone ER|12mg/day paliperidone er for 6 weeks
224048042|NCT00397033|DRUG|Placebo|Placebo for 6 weeks
224048043|NCT00502346|DRUG|PM10|
224048044|NCT02630446|OTHER|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
224048045|NCT03533595|DEVICE|Barbed|Barbed Suture
224048046|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
224048047|NCT00895141|DIETARY_SUPPLEMENT|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
224300111|NCT05778136|OTHER|Resistance training|Supervised resistance training. 2 sessions/week for 12 weeks. The exercises are one-legged leg-press and one-leg knee extension. Resistance training start-up phase comprises 3 sets of 10 repetitions in each of the two exercises with 50% of 1RM. Resistance training progressive phase comprises 3 sets (leg-press) of 5-8 repetitions (70-90% 1 RM) and 6 sets (knee extension) of 8 repetition (75% 1RM). Rest between sets: 3 minutes
224142994|NCT00870818|DIAGNOSTIC_TEST|Analysis of T-cell subsets|CD3, CD4, CD8, CD19, CD3+ CD16+ CD56+ subsets; CD3-CD16+ CD56+ subsets; CD4+CD25+, CD8+CD25+, CD4+CD69+, CD8+CD69+, CD4+CD40+ subsets CD4+ and CD8+CD25+FoxP3+Treg Subsets
224142995|NCT02723136|DEVICE|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
224048048|NCT00067860|DRUG|recombinant human growth hormone|
224048049|NCT00067860|BEHAVIORAL|diet modification|
224048050|NCT01984164|DRUG|Candesartan|blinded
224300112|NCT01527136|DRUG|entolimod|Given IM or SC
224300113|NCT01527136|OTHER|pharmacological study|Correlative studies
224300114|NCT01527136|OTHER|laboratory biomarker analysis|Correlative studies
224300115|NCT02034058|DEVICE|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
224300116|NCT05367479|DRUG|Antibiotic|Peri-operative, intravenous antibiotic for surgical site infection
224300117|NCT05937984|DEVICE|Active Controlled Transcranial Magnetic Stimulation (cTMS)|cTMS is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 1500 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of cTMS requires 9 minutes in total.
224300118|NCT05937984|DEVICE|Sham Controlled Transcranial Magnetic Stimulation (cTMS)|A sham coil will be utilized for the sham cTMS condition. It is important to note that from the participant perspective, the sham stimulation will feel and sound identical to active. The location and all other parameters of Sham cTMS will be identical to Active cTMS.
224300119|NCT03254602|DEVICE|Intense Therapeutic Ultrasound Treatment|
224300120|NCT02369900|DRUG|Esmolol|
224048051|NCT01984164|DRUG|Lisinopril|Blinded
224142996|NCT02902913|OTHER|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
224142997|NCT02902913|OTHER|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
224142998|NCT02902913|OTHER|D2i0|No oleocanthal and no oleacein
224300121|NCT02369900|OTHER|Saline|
224300122|NCT03309007|DRUG|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
224300123|NCT03309007|DRUG|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
224300124|NCT02963311|DRUG|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
224300125|NCT02963311|DRUG|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
223566345|NCT03172325|DRUG|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
223566346|NCT03172325|DRUG|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
223566347|NCT03848208|DRUG|cytisine|cytisine film-coated oral tablet
224048052|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with novel Dynamic Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Dynamic Bar.
224048053|NCT05293743|DEVICE|Foot abduction bracing for clubfoot with Standard Bar|After Ponseti treatment of serial casting and tenotomy for clubfoot, patients are braced full time x 3 months then night time until age 5. This study compares standard bars in a foot abduction brace to our novel Dynamic Bar. This group uses the Standard Bar.
224048054|NCT03031379|OTHER|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
224048055|NCT00584883|DRUG|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
224048056|NCT05187624|DRUG|RO7428731|Participants will receive RO7428731 as described.
224048057|NCT00215800|DRUG|Ampligen|
224142999|NCT02902913|DRUG|Ibuprofen|400 mg of Ibuprofen
224143000|NCT00178464|DRUG|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
224143001|NCT01766817|DRUG|BMS-986020|
224143002|NCT01766817|DRUG|Placebo matching with BMS-986020|
224143003|NCT04900038|DRUG|GSK3640254|GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
224143004|NCT04900038|DRUG|Dolutegravir|DTG was available as 50 mg tablets administered orally.
224143005|NCT04900038|DRUG|Lamivudine capsules|3TC was available as 300 mg capsules administered orally as a blinded treatment.
224048058|NCT06315738|BIOLOGICAL|ST266|Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.
224143006|NCT04900038|DRUG|Lamivudine tablets|3TC was available as 300 mg tablets administered orally as an unblinded treatment.
224143007|NCT02227108|DRUG|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
224143008|NCT04060264|BIOLOGICAL|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
224143009|NCT04060264|BIOLOGICAL|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
224143010|NCT05166759|DEVICE|Doppler ultrasound|Pulmonary artery pressure and right heart function will be assessed using Doppler ultrasound
224143011|NCT00094887|DRUG|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
224143012|NCT00094887|DRUG|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
224143013|NCT02281903|DEVICE|The TrueCPR feedback device|feedback devices
224143014|NCT02281903|DEVICE|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
224143015|NCT02486952|DRUG|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
224143016|NCT02486952|DRUG|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
224143017|NCT02486952|DRUG|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
224143018|NCT02486952|DRUG|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
224143019|NCT02486952|DRUG|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
224143020|NCT01333852|DRUG|metformin up to 2500mg/d|metformin up to 2500mg/d
224143021|NCT01333852|DRUG|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
224143022|NCT01333852|DRUG|placebo|placebo
224143023|NCT02099942|DEVICE|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~* as stand-alone intervention~* as a bridge to transcatheter aortic valve replacement (TAVR)~* as a bridge to surgical aortic valve replacement (SAVR)~* as an intraprocedural predilatation prior to TAVR"
224143024|NCT02878733|DRUG|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
224143025|NCT00258206|BIOLOGICAL|rituximab|
224143026|NCT00258206|DRUG|cyclophosphamide|
224143027|NCT01843400|DRUG|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
224143028|NCT04675359|PROCEDURE|Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint|Injections of the two adipose tissue derived products containing MSCs into the knee joints with osteoarthritis
224143029|NCT04810299|OTHER|Aromatherapy|Aromatherapy; It is one of the complementary therapy methods defined as the therapeutic use of essential oils obtained from parts of plants such as root, seed, leaf, flower, shell with appropriate methods.
223566348|NCT03848208|DRUG|placebo|matching placebo oral tablet
224048059|NCT06598241|DEVICE|Borate-base Bioactive Glass Fiber Matrix (BBGFM)|Bioactive glass materials are biocompatible water-soluble inorganic ceramic materials that release their constituent ions when immersed in body fluids.
224143030|NCT04810299|OTHER|Classical foot massage|Classical foot massage; It is defined as a massage technique based on the principle of systematic relaxation
224143031|NCT00530556|DRUG|zolpidem|
224143032|NCT02679209|BIOLOGICAL|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
223566349|NCT03962257|OTHER|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
224048060|NCT05744908|OTHER|Pentosan Polysulphate|300mg 3 times a day
224048061|NCT06043674|DRUG|Glofitamab|"2:1 T-cell bispecific humanized monoclonal antibody, administered via intravenous infusion per protocol."
224143033|NCT02679209|BIOLOGICAL|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
224143034|NCT01928485|OTHER|active surveillance|Undergo active surveillance
224143035|NCT01928485|DRUG|Sunphenon|Given PO
224048062|NCT06043674|DRUG|Obinutuzumab|Humanized glycoengineered type II anti-CD20 monoclonal antibody, administered via intravenous infusion per protocol.
224048063|NCT06043674|DRUG|Polatuzumab Vedotin|Antibody-drug conjugate, administered via intravenous infusion per protocol.
224048064|NCT06043674|DRUG|Atezolizumab|Humanized immunoglobulin monoclonal antibody, administered via intravenous infusion per protocol.
224143036|NCT01928485|OTHER|laboratory biomarker analysis|Correlative studies
224143037|NCT01928485|OTHER|Questionnaire Administration|Ancillary studies
224143038|NCT04450056|OTHER|No intervention|No intervention
224143039|NCT05907993|DRUG|Ibuprofen 800 mg|Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
223437084|NCT06536088|OTHER|Walking assesment|Spatiotemporal walking assessments are performed using the Gait Analyzer app (version 0.9.95.0) on a smartphone. Participants who can walk independently without assistance walk a 25-meter path at their normal speed, with the smartphone securely attached to their body above the third lumbar vertebra using a belt. The app records gait velocity, cadence, step time, step length, and vertical center of mass for all participants.
224048065|NCT06043674|DRUG|Tocilizumab|For the treatment of Cytokine Release Syndrome. Recombinant, humanized, anti-human monoclonal antibody, administered via intravenous infusion per protocol.
224048066|NCT06043674|DRUG|Pirtobrutinib|Selective inhibitor of BTK, 50 mg or 100 mg tablet, via oral administration per protocol.
224048067|NCT05425914|DRUG|Vitamin D|New treatment option for dry eye patients with low serum vitamin D Level
224048068|NCT05425914|DRUG|Artificial tear|Conventional dry eye treatment
224048069|NCT05566613|RADIATION|Blood sample|Blood sample before and after radiotherapy and photography before radiotherapy
224048070|NCT06537778|DRUG|Atosiban|Women in the atosiban group received i.v. atosiban (Manufacturer: Pfizer, Germany) 30 min before the surgery with a bolus dose of 6.75 mg, and the infusion was continued with an infusion rate of 18 mg/h for 3 h. The dose of atosiban was then reduced to 6 mg/h for another 45 h.
224048071|NCT06537778|DRUG|Normal saline|Participants in the placebo group received only normal saline infusion for the same duration as atosiban group.
224048072|NCT05296837|DRUG|Doxycycline 40 MG ( 20mg twice daily)|Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
224048073|NCT05296837|DRUG|Doxycycline 200 MG ( 100 mg twice daily)|200 mg dose doxycycline to be administered as 100mg twice daily
224048074|NCT05296837|DRUG|Placebo|Placebo to be administered in tablet form twice daily
224048075|NCT06970496|DRUG|B019|B019： Intravenous infusion, 2.0×10\^6 cell/kg-8.0×10\^6 cell/kg
224143040|NCT01393756|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
224143041|NCT03179007|BIOLOGICAL|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10\^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
224143042|NCT04111107|DRUG|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
224143043|NCT04111107|OTHER|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
224143044|NCT04111107|DIAGNOSTIC_TEST|Next Gen Sequencing Report|1\) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
224143045|NCT06472388|DRUG|Everolimus 5 MG|oral everolimus 5 mg/daily
224143046|NCT00002903|DRUG|docetaxel|
224143047|NCT03905629|OTHER|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay \>15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~* Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~* Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~* Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
224143048|NCT03512977|PROCEDURE|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
224143049|NCT03512977|DRUG|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
224143050|NCT03132168|BEHAVIORAL|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
224143051|NCT03132168|PROCEDURE|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
223566350|NCT03520348|DRUG|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
224143052|NCT03132168|OTHER|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
224143053|NCT03215524|BIOLOGICAL|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
224143054|NCT03215524|BIOLOGICAL|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
224143055|NCT06252857|DRUG|Imiquimod Topical|Topical application of imiquimod (once daily, 5 days a week, during 6 weeks) versus surgical excision.
224143056|NCT02329002|DEVICE|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
224143057|NCT04005950|DEVICE|Scalpel Bougie technique|ScalpelCric Set
224143058|NCT04005950|DEVICE|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
224143059|NCT03637907|OTHER|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
223437085|NCT01273155|DRUG|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
223437086|NCT00360802|BEHAVIORAL|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
223437087|NCT00360802|BEHAVIORAL|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
223437088|NCT01438814|DRUG|metformin placebo|metformin placebo tablets 500mg
223437089|NCT01438814|DRUG|linagliptin placebo|linagliptin placebo tablets 5mg
223437090|NCT01438814|DRUG|metformin|metformin tablets 500mg
223437091|NCT01438814|DRUG|metformin|metformin tablets 500 mg
224048076|NCT00667823|DRUG|Macitentan|Tablet, oral administration, 10 mg dose once daily
224048077|NCT05634252|BEHAVIORAL|Education|All conditions will receive education on skin cancer and strategies to prevention skin cancer, including sun protection strategies and avoidance of intentional and unintentional tanning.
224143060|NCT00946569|DRUG|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
224143061|NCT00946569|DRUG|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
224143062|NCT02834091|PROCEDURE|Hypnoanalgesia|
224143063|NCT03180827|PROCEDURE|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
224143064|NCT01417065|DRUG|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
224143065|NCT00679068|DRUG|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
224048078|NCT05634252|BEHAVIORAL|Action Plan|Participants will be guided through a worksheet for creating a personalized action plan for creating individualized sun protection and tanning plans for situations in which they receive UVR exposure. For the tanning worksheet, participants who report any tanning identify the locations at or activities during which they tan, select a tanning behavior to plan for, and then are guided through the steps of making a specific plan for an alternate activity that meets their goals while minimizing tanning and using sun protection.
224143066|NCT05760820|BEHAVIORAL|SES Children (SES Mini & SES Nxt)|"SES Children (SES Mini \& SES Nxt) is a digital intervention aiming to develop children's self-efficacy and ability to overcome the challenges that come with a divorce and major life crises, thereby reducing the negative impacts of these on children's overall mental health and wellbeing. The intervention formatted to specific age groups between the ages of 3 and 17, and is relevant to all children whose parents have split up, regardless of whether they experience a higher or lower degree of conflict between the parents, a or higher or lower degree of strain from the judicial divorce.~The intervention covers a variety of topics, including when my parents fight, a bonus family, packing the overnight bag, to live in two places, and children's rights."
224143067|NCT00599261|PROCEDURE|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
224143068|NCT02721251|BEHAVIORAL|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
224300126|NCT06418685|DEVICE|Treatment with Vibrating Capsule|"Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation."
224143069|NCT02721251|BEHAVIORAL|Weight Loss|16 week. the goal is 10% weight loss.
224143070|NCT02721251|BEHAVIORAL|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
224143071|NCT03001583|BEHAVIORAL|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
224143072|NCT03001583|BEHAVIORAL|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
224300127|NCT01211080|DRUG|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
223437092|NCT01438814|DRUG|linagliptin|linagliptin tablets 5mg
223437093|NCT00336323|PROCEDURE|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
223437094|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
223437095|NCT00336323|DRUG|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
223437096|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
223437097|NCT00336323|DRUG|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
223437098|NCT03017521|DRUG|TAS-117|TAS-117 16mg, daily
223437099|NCT01448863|OTHER|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
224048079|NCT05634252|BEHAVIORAL|UV Photo|Participants will receive a printout of a photo of their face in visible light and UV light from the VISIA Complexion Analysis system. Participants will receive a handout of their photos accompanied by an explanation of UV light, its harmful effects on skin, and that using sun safe behaviors early in life will have the greatest impact and help to decrease risk for skin cancer.
223437100|NCT01385956|DRUG|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
223437101|NCT01385956|DRUG|Gemcitabine|Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off
223437102|NCT05330585|DEVICE|Hearing aids|Participants will listen to stimuli in the environment while wearing hearing aids which should make the stimuli more audible. Speech in noise performance is expected to improve and PFC oxygenation is expected to be reduced in this condition.
223437103|NCT05330585|OTHER|Unaided|Participants will listen to stimuli in the environment with their hearing loss. Speech in noise performance is expected to decline and PFC oxygenation is expected to be increased in this condition.
223437104|NCT00990665|DEVICE|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
223437105|NCT02460523|PROCEDURE|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
223437106|NCT02460523|PROCEDURE|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
223437107|NCT02656134|PROCEDURE|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
223437108|NCT02656134|GENETIC|Molecular analysis.|DNA analysis
224048080|NCT05634252|BEHAVIORAL|MC1R Test|Participants will provide a saliva sample using an Oragene® clinical-grade saliva kit. Once sequenced, participants will receive their MC1R testing results via web as well as a standardized booklet that addresses personal risk level and population risk level, strategies to reduce skin cancer risk, and number to call or email for further information.
223437109|NCT02660879|OTHER|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
223437110|NCT02660879|OTHER|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
223437111|NCT02143167|DRUG|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
223437112|NCT02143167|DRUG|Placebo|
223437113|NCT02877719|OTHER|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
223437114|NCT04204928|DRUG|pralsetinib (BLU-667)|Pralsetinib will be administered orally (PO) at a dose of 400 mg once daily (QD) in continuous 28 day cycles
223437115|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (330mg)|High dose capsules
223437116|NCT03058367|DIETARY_SUPPLEMENT|IQP-AE-103 (165mg)|Low dose capsules
223437117|NCT03058367|DIETARY_SUPPLEMENT|Placebo|Placebo identical to verum capsules
223437118|NCT00672841|DRUG|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
223437119|NCT00672841|DRUG|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
224048081|NCT06985420|OTHER|Resistance exercise|Resistance Exercise Protocols: Participants will perform exercises, including belt squats, hex bar deadlifts, and plyometric drop jumps. The load and intensity will be standardized based on each participant's 1-repetition maximum (1RM) to ensure uniformity across trials.
224048082|NCT06985420|OTHER|Menstrual Cycle Phases|Menstrual Cycle Phases: The key exposure variable is the phase of the menstrual cycle, with participants being assessed during the early follicular, late follicular, and mid-luteal phases.
224048083|NCT04711668|DRUG|Ketamine|intraoperative ketamine bolus and infusion
224048084|NCT04711668|DRUG|Lidocain|intraoperative lidocain bolus and infusion
224048085|NCT04711668|DRUG|Saline|intraoperative saline bolus and infusion
224048086|NCT03732651|PROCEDURE|alteration of PaCO2 level|step changes between 30, 40 and 50 mmHg
224048087|NCT00583024|BIOLOGICAL|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
224048088|NCT05953272|OTHER|EMG Biofeedback therapy and Bobath therapy|"EMG Biofeedback therapy will be used to up-train the ankle dorsiflexors in stroke patients. It will be given for 15 minutes. Patient will practice 2 blocks of Tibialis Anterior muscle contraction trials (holding for 10 seconds per trial with 10 seconds of rest, 20 trials per block with 1 minute 40 seconds of rest in between the blocks) with the heel contacts the floor for a total of 40 trials.~In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
224048089|NCT05953272|OTHER|Bobath therapy|"In Bobath therapy, we will use exercises as per Bobath guidelines for management of stroke patients to improve the lower extremity function, balance and gait ability. All of the exercises will be performed for 10 repetitions in each session.~Patient will also perform a set of Home Exercise Program given to them for once daily in their home during the treatment period."
224048090|NCT00271778|PROCEDURE|mastoidotympanoplasty and tympanoplasty|
224048091|NCT02348775|DIETARY_SUPPLEMENT|GlyNAC (combination of glycine and n-acetylcysteine)|HIV patients will be studied before and after receiving GlyNAC
224048092|NCT02553265|DRUG|Carbidopa Low-Dose|300 mg/day
224048093|NCT02553265|OTHER|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
224048094|NCT02553265|DRUG|Carbidopa High-Dose|600 mg/day
224048095|NCT03556553|DEVICE|Vertise Flow|Composite resin
224048096|NCT03556553|DEVICE|LuxaFlow|Composite resin
223740717|NCT01114165|OTHER|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
223740718|NCT01114165|OTHER|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
224300128|NCT01234792|DRUG|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
224300129|NCT01234792|DRUG|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
224300130|NCT01234792|DRUG|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
224300131|NCT01295294|DRUG|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
224300132|NCT01295294|DRUG|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
224300133|NCT01295294|DRUG|Placebo|3 times daily per oral during bleeding/spotting episodes
224300134|NCT01295294|DRUG|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
224300135|NCT06255301|DIAGNOSTIC_TEST|EYEPRIM|Collection of conjunctival impressions using the EC(European Conformity )-marked EYEPRIM device . This device enables cells to be collected the superficial ocular surface cells by applying a membrane for few seconds to the ocular surface.
224300136|NCT02897986|DRUG|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
224300137|NCT03239886|OTHER|imatinib discontinuation|imatinib discontinuation
224300138|NCT02788786|DRUG|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
224300139|NCT02788786|DRUG|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
224300140|NCT02788786|DRUG|Salt and Water|salt and water mix oral rinse
224300141|NCT02375139|DRUG|DA-1229_01|complex single administration
223740719|NCT04955522|DIAGNOSTIC_TEST|radiomics|Differential diagnosis of spinal myeloma and metastases by radiomics
223740720|NCT00050843|DRUG|thalidomide|
223740721|NCT00494988|DRUG|insulin aspart|
223740722|NCT00494988|DRUG|insulin NPH|
223740723|NCT00999557|DRUG|bimatoprost ophthalmic solution|Applied topically
223740724|NCT00999557|DRUG|placebo|Applied topically
223740725|NCT00222196|PROCEDURE|lifestyle, PTA|
224300142|NCT02375139|DRUG|E+M|co-administration of 2 drugs
224300143|NCT02195466|DRUG|Tipranavir (TPV)|500 mg bid on days 7-14
224300144|NCT02195466|DRUG|Ritonavir (RTV)|200 mg bid on days 7-14
224300145|NCT02195466|DRUG|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
224300146|NCT05162365|BIOLOGICAL|IBI314|Low/medium/high dose, intravenously, once, on Day 1
224300147|NCT05162365|OTHER|Placebo|Placebo, intravenously, once, on Day 1
224300148|NCT06625918|DEVICE|Ultraviolet B exposure to produce vitamin D synthesis|Exposure using a UV skin care device on vitamin D production and immune response in healthy adults
224300149|NCT00212121|RADIATION|high dose boost|high dose boost
224300150|NCT00212121|PROCEDURE|boost|low dose versus high dose
224300151|NCT03728218|DEVICE|Contact lenses (Orthokeratology)|Contact lenses
224300152|NCT03728218|DEVICE|Contact lenses (Soft Multifocal)|Contact lenses
224300153|NCT04398264|OTHER|COVID-19 positive via testing|Pregnant women admitted to Obstetric Units undergo RT-PCR testing for the detection of SARS-Cov2 (COVID-19 infection)
224300154|NCT00874003|DRUG|mirtazapine|oral tablet, 30 mg daily
224300155|NCT00874003|DRUG|placebo|oral tablet, 1 daily
224300156|NCT05334264|PROCEDURE|Cervical cerclage|McDonald cervical cerclage will be applied using Mersaline braided tape with double needle. Single stitch (4 bites) will be applied as close as possible to the level of internal os. The Knot will be put either anterior or posterior according to the surgeon desire.
224300157|NCT00845806|OTHER|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
223740726|NCT02045576|DEVICE|sleep position trainer|
223740727|NCT02045576|DEVICE|Oral Appliance Therapy|
223740728|NCT00004489|DRUG|alendronate sodium|
223740729|NCT00004489|DRUG|calcium carbonate|
223740730|NCT00004489|DRUG|cholecalciferol|
224048097|NCT03556553|DEVICE|Teco Adhesive|Adhesive system
224048098|NCT02018406|DRUG|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
224048099|NCT02018406|DRUG|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
224048100|NCT00693914|BEHAVIORAL|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
224048101|NCT02667275|DRUG|A-101 Solution|
224048102|NCT02667275|OTHER|Vehicle Solution|Placebo
224048103|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow oxygen
224048104|NCT02357134|PROCEDURE|Oxygen Therapy|Receive high-flow air
224048105|NCT02357134|OTHER|Quality-of-Life Assessment|Ancillary studies
224048106|NCT02357134|OTHER|Questionnaire Administration|Ancillary studies
224048107|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow oxygen
224048108|NCT02357134|PROCEDURE|Respiratory Therapy|Receive low-flow air
224048109|NCT04745013|BEHAVIORAL|PRIORITY|PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
224048110|NCT04745013|BEHAVIORAL|Usual care|Only a written personalized exercise prescription will be provided.
224048111|NCT04012034|DEVICE|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
224048112|NCT04012034|DEVICE|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
223437120|NCT03578146|COMBINATION_PRODUCT|PRT064445/Rivaroxaban|
223437121|NCT03578146|COMBINATION_PRODUCT|Placebo/Rivaroxaban|
223437122|NCT03578146|DRUG|Placebo|
223437123|NCT06143254|BEHAVIORAL|Infant sign training|Training session 1: Information is given about what infant signs are, how they originated, how speech and (gestural) language develop in young children with CP ± L, the possible advantages of using infant signs and tips for success. Twelve signs are chosen to start with: six narrative signs (mostly object concepts) and six steering signs (mostly non-object concepts). Training session 2: Experiences with using infant signs at home are shared, repetition of the 12 infant signs and tips for success are discussed. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Another 12 signs are chosen to add to the repertoire the caregivers can use, based on caregiver input. Reading aloud while using infant signs is shown and practiced.
223437124|NCT06143254|BEHAVIORAL|Verbal training|Training session 1: Information is given about how speech and language develop in young children with CP ± L and how caregivers can support their child during this development Tips for success and suggestions on how to use these supportive verbal techniques at home are discussed. Training session 2: Experiences with using supportive verbal techniques at home are shared and supportive verbal techniques repeated. Information is provided about how children learn new words and tips for success are expanded. Training session 3: The same as training session 2. The content is based on the input the caregivers experience. Additionally, advances of reading aloud are discussed and reading aloud is practiced.
223437125|NCT04294251|DRUG|DWP450|Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
223437126|NCT04294251|DRUG|Placebo|Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
223437127|NCT01717391|DRUG|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
223437128|NCT01731769|PROCEDURE|vacuum assisted closure in experimental arm|
223437129|NCT01731769|PROCEDURE|Axillary dissection|
223437130|NCT04172857|PROCEDURE|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch \& Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
223437131|NCT04338243|DRUG|Glumetinib|Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D
223437132|NCT04201678|PROCEDURE|CLIA Group (conventional local anesthesia infiltration)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the CLIA group, the needle (50 mm 22 Gauge) was directed towards the laminar periosteum at the pedicular projection point at the 10-15 ° angle with the sagittal plane. A mixture of 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be applied bilaterally."
223437133|NCT04201678|PROCEDURE|EPIAA Group (Extrapedicular infiltration anesthesia)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~The anesthesia process of the CLIA + EPIA group also includes the third step called EPIA. For this stage, the anesthetic needle (50 mm 22 Gauge) is first drawn into the subcutaneous tissue, then through the lateral superior articular process to the lateral half of the pedicle and the upper border of the transverse process (5-10 degrees with sagittal plane and 5-10 with coronal plane), and after negative aspiration 3 mL 2% Lidocaine Hydrochloride and 7 mL 0.5% bupivacaine mixture will be applied bilaterally"
223437134|NCT04201678|PROCEDURE|ESP Group (Erector Spina Block)|"The first step was to determine the pedicle to be vertebroplasty, and 5 mL of 1% Lidocaine Hydrochloride bilaterally to infiltrate the skin, subcutaneous tissue and a portion of the lumbodorsal muscles from a point of 1 cm to the pedicle projection point.~In the ESP group, a high-frequency-50 15-6 MHz linear ultrasound probe will be placed vertically approximately 3 cm laterally at the point of application. Once the erector spinae muscle and transverse process have been identified, the peripheral nerve blockage needle (50 mm 22 Gauge) will be advanced from caudal to cranial between the fascia of the erector spina muscle and the transverse process. After 1 ml normal saline injection, this plane was opened. Bilateral 3 mL of 2% Lidocaine Hydrochloride and 7 mL of 0.5% bupivacaine will be administered."
223437135|NCT03677934|DRUG|PDS Implant filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
223437136|NCT03677934|DRUG|Intravitreal Injections of 10 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
223437137|NCT00003734|DRUG|flutamide|
223437138|NCT00003734|DRUG|triptorelin|
223437139|NCT00003734|RADIATION|radiation therapy|
223566351|NCT03520348|DRUG|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
223566352|NCT00201357|DRUG|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
224143073|NCT04005196|DIAGNOSTIC_TEST|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
224143074|NCT06314529|OTHER|Assessments|Safety and efficacy assessments
224143075|NCT01714817|BIOLOGICAL|BMS-188667|
224143076|NCT01714817|DRUG|Mycophenolate mofetil|
224143077|NCT01714817|DRUG|Prednisone|
224143078|NCT01714817|BIOLOGICAL|Placebo matching with BMS-188667|
223437140|NCT02285543|DRUG|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m\^2), cisplatin(75 mg/m\^2), 5-Fu(750 mg/m\^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
224048113|NCT05023863|DRUG|Alpha Lipoic Acid 600 MG Oral Tablets|Alpha Lipoic Acid (ALA) is a drug which has been used in treatment of diabetic neuropathy . It act through enhancing nitric oxide-mediated endothelium-dependent vasodilation, thus improving microcirculation in patients with diabetic polyneuropathy. It is considered a safe drug, generally with a daily dose of 200 to 2400 mg/day is considered tolerable without significant side effects. Only gastrointestinal tracts side effects like nausea, vomiting, dyspepsia and abdominal pain have been described in some clinical trials. Also FDA experts confirm its safety and efficacy in humans
224048114|NCT05023863|OTHER|Placebo tablets|placebo tablets of the same generic of active drug which contain all the same ingredients as active tablets except alpha lipoic acid
224048115|NCT05023863|RADIATION|radiation or concurrent chemoradiation|radiation or concurrent radiotherapy plus platinum-based chemotherapy
223437141|NCT02285543|PROCEDURE|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
224048116|NCT01194713|BEHAVIORAL|Sleep deprivation|subjects will undergo one night of full sleep deprivation
224300158|NCT01031459|DRUG|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
223437142|NCT02285543|RADIATION|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
224143079|NCT00131820|BIOLOGICAL|Typhoid Vi vaccine|
224143080|NCT00131820|BIOLOGICAL|Hepatitis A (control)|
224143081|NCT02916095|DRUG|Kanitinib|Oral administration of Kanitinib tablets.
224143082|NCT02921763|DRUG|Dydrogesterone|
224143083|NCT02527655|BEHAVIORAL|Choice-Based Physical Activity and Active Transportation|
224143084|NCT06051851|DRUG|Penpulimab|"Penpulimab 200mg IV D1~1 cycle every 21 days"
224143085|NCT06051851|DRUG|Anlotinib|"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"
224143086|NCT06051851|DRUG|Nab paclitaxel|"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"
224143087|NCT06051851|DRUG|Gemcitabine|"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"
224143088|NCT05454930|OTHER|Filtered Air|The vehicle is fitted with a (High-Efficiency Particulate Absorbing, HEPA) filter device incorporating a charcoal filter, as well as an augmented cabin filter
224143089|NCT01737658|OTHER|Exercise Program|Exercise Program for Obese Adolescents
224143090|NCT01582971|OTHER|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
224143091|NCT01338883|DRUG|Cenicriviroc 100 mg|100 mg CVC plus Truvada
224143092|NCT01338883|DRUG|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
224143093|NCT01338883|DRUG|Sustiva + Truvada|Sustiva plus Truvada
224143094|NCT03307954|DEVICE|Ekso Therapy (Exoskeleton Suit)|
224143095|NCT03307954|OTHER|Usual Physiotherapy|
224143096|NCT02746354|OTHER|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
223437143|NCT06649123|DIAGNOSTIC_TEST|Oricol Test|Assessment of diagnostic accuracy of Oricol Sampling device for triage in patients with suspected lower gastrointestinal cancer
223566353|NCT03121235|DIAGNOSTIC_TEST|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
223566354|NCT02292758|BIOLOGICAL|Bevacizumab|Given IV
224143097|NCT03095053|PROCEDURE|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
224143098|NCT06101082|BIOLOGICAL|Intravenous infusion anti-HER2-CAR-T cell|Anti-HER2-CAR-T cell is administered as a single intravenous infusion. Follow-up infusions are based on the investigator's decision.The dose group to be infusion was 1×10\^6 CAR-T cells/kg, 3×10\^6 CAR-T cells/kg, and 1×10\^7 CAR-T cells/kg based on the 3+3 dose escalation principle. The infusion dose refers to the number of CAR-positive cells.
224143099|NCT04965376|PROCEDURE|Glenohumeral joint steroid injection|Ultrasound guided steroid injection into the glenohumeral joint (10mls of 1% lidocaine with 40mg depo-medrone)
224300159|NCT01631175|BEHAVIORAL|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
224300160|NCT02721693|DEVICE|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
224300161|NCT00263991|DEVICE|EEC-techniques|
224143100|NCT04965376|PROCEDURE|Suprascapular nerve block steroid injection|Ultrasound guided steroid injection as a suprascapular nerve block at the spinoglenoid notch adjacent to the nerve as it traverses under the spinoglenoid ligament (10mls of 1% lidocaine with 40mg depo-medrone)
224143101|NCT00218920|BEHAVIORAL|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
224143102|NCT00218920|BEHAVIORAL|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
224300162|NCT01101204|DRUG|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
224300163|NCT02163486|DEVICE|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
223437144|NCT04096443|BIOLOGICAL|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
223437145|NCT03067675|DEVICE|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
223437146|NCT01605032|DRUG|Busulfan|Given IV
223437147|NCT01605032|DRUG|Melphalan|Given IV
223437148|NCT01605032|DRUG|Bortezomib|Given IV
223437149|NCT01605032|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
223437150|NCT01605032|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
223437151|NCT06400706|PROCEDURE|EEG guided general anesthesia|EEG guided general anesthesia: General anesthesia is guided by SedLine (EEG-guided care). The goal of EEG-guided care is to maintain spectral edge frequency (SEF) between 10 and 15 and patient state index (PSI) between 25 and 50.
223437152|NCT01100892|DRUG|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
223437153|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
223437154|NCT02222441|DRUG|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
223437155|NCT02222441|DRUG|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
224048117|NCT02202291|GENETIC|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
224048118|NCT03583450|DEVICE|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
224143103|NCT00218920|BEHAVIORAL|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
223437156|NCT02222441|DRUG|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
224143104|NCT06079866|DEVICE|Mask A (Oran Park Mask) then Mask B (Evora Mask)|Mask A (Oran Park Mask) for 7 days followed by Mask B (Evora Mask) for 7 days
223437157|NCT01731470|BIOLOGICAL|Liposomes|Intravesical instillation of liposomes.
223437158|NCT04486469|OTHER|Physical Therapy Group|"1. Performing direct physical treatment on the diaphragm, using stretching, followed by teaching exercises for re-education of the abdomen and diaphragm.~2. Transcutaneous retrograde electrostimulation: L1-L4 (2hz-10hz) rectangular asymmetric biphasic at the level of the dermatome. From the anterior inferior iliac spine to a pubic symphysis. Second canal from the greater trochanter to the saphenous veins. (30 min). Parameters of this program: 2 Hz and 180ms.~3. Connective Tissue Massage or Dicke~4. Massage with direct maneuvers on the abdomen: The direction of the maneuvers will be clockwise. We will perform 6 very slow strokes adding small pressures on the ascending, transverse and descending colon respectively and repeating this maneuver 3 times. (10 minutes)"
223437159|NCT01205074|DEVICE|13C Methacetin Breath Test|
223437160|NCT01205074|DIETARY_SUPPLEMENT|Grape fruit juice|
223437161|NCT01205074|DRUG|Non selective beta blocker - Propranolol|
223437162|NCT01205074|DIETARY_SUPPLEMENT|Ethanol|
223437163|NCT01541670|DRUG|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
223437164|NCT05842005|DEVICE|Mesh-reduced Sling|In this proposed study, the investigators aim to evaluate the role of using a ¾ x ⅜ inch cm polypropylene mesh suspended by sutures as a mesh-reduced solution for SUI.
223437165|NCT01546597|DRUG|Metformin|"* Metformin 500 mg bid on Days 1-5~* Metformin 850 mg bid on Days 6-10~* Metformin 500 mg bid on Days 11-15~* Metformin 850 mg bid on Days 16-20"
223437166|NCT01546597|DRUG|Ranolazine|"* Ranolazine 1000 mg bid on Days 11-15~* Ranolazine 1000 mg bid on Days 16-20"
223437167|NCT06619886|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R248Q|TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements
223437168|NCT05365269|BEHAVIORAL|Proactive Automatized Lifestyle intervention|Multi-behavioral; including individually-tailored, theory-based, repetitive, ipsative and normative feedback.
223437169|NCT05103839|BEHAVIORAL|Gentle Yoga|Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
223437170|NCT03438526|DRUG|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
223437171|NCT03438526|DRUG|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
224048119|NCT03374995|OTHER|Best Practice|Receive standard of care
224048120|NCT03374995|OTHER|Quality-of-Life Assessment|Ancillary studies
224143105|NCT06079866|DEVICE|Mask B (Evora Mask) then Mask A (Oran Park Mask)|Mask B (Evora Mask) for 7 days followed by Mask A (Oran Park Mask) for 7 days.
224143106|NCT03665012|OTHER|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
224143107|NCT00000341|DRUG|Buprenorphine|
224143108|NCT04928495|DRUG|Vitamin C|Vitamin C 500 mg / day for ten days
223437172|NCT04738136|DRUG|S-1226|S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) delivered in vapour form within a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8%, or 12% CO2
223437173|NCT00335959|DRUG|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
223437174|NCT00335959|DRUG|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
223437175|NCT00335959|PROCEDURE|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
224048121|NCT03374995|DEVICE|Topical Keratin|Given topically
223437176|NCT00335959|RADIATION|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
223437177|NCT06413745|DRUG|SHR-A1811|SHR-A1811
223437178|NCT05727306|OTHER|No intervention|Observational analysis of usual care only.
223437179|NCT04430023|OTHER|epidemiological and demographic characteristics|Patients' age, gender, BMI, medical history, symptoms at admission (e.g., cough, fever, myalgia, gastrointestinal symptoms, headache), concomitant diseases (e.g., diabetes mellitus, hypertension, chronic lung disease, cerebrovascular disease, kidney disease, heart disease, cancer, smoking
223437180|NCT02624245|OTHER|Conventional Physical Therapy|
223437181|NCT02450552|DRUG|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
223437182|NCT02450552|DRUG|Placebo|Matched placebo
223437183|NCT04300452|DRUG|Carbetocin|Administration of Carbetocin after placental detachment
223437184|NCT04300452|DRUG|Ergometrine Maleate|Administration of ergometrin after placental detachment
224048122|NCT02783716|PROCEDURE|Subcutaneous adipose tissue collection|During standard of care device implantation procedure, a small piece of fat tissue will be removed from the device pocket inside the chest
224143109|NCT04928495|DRUG|N-acetylcysteine (NAC)|N-acetylcysteine 1800 mg / day for ten days.
223437185|NCT02903524|DRUG|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
223437186|NCT02903524|DRUG|pirarubicin and cyclophosphamide|
223437187|NCT02722837|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
223437188|NCT04877535|DEVICE|ML-based report card|PACU and ward providers caring for participants will be notified by Anesthesia Control Tower clinicians before arrival if the patient's report card. The notification will contain a report card of the patient's forecast risk of major adverse events, explanatory machine-learning outputs, most influential pre- and intraoperative data, and predicted treatments.The ML risk profile generated for each patient will include risk of 30 day mortality, risk of respiratory failure, risk of acute kidney injury, and risk of postoperative delirium
223437189|NCT03431662|PROCEDURE|Ellipse IM HTO Nail|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
224048123|NCT02783716|DIAGNOSTIC_TEST|Peripheral arterial tonometry (PAT)|Non-invasive testing for blood vessel function. Specially designed finger probes placed on the middle finger of each hand. Pulsatile volume changes of the distal digit inducing pressure alterations in the finger cuff will be sensed by pressure transducers and recorded. Endothelial function will be measured via a reactive hyperemia (RH)-PAT index (RHI)
224048124|NCT03229564|BIOLOGICAL|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
224048125|NCT03229564|BIOLOGICAL|STSG|Transplantation of autologous split-thickness skin graft to the control area
223437190|NCT03431662|PROCEDURE|TomoFix|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
223437191|NCT06183203|PROCEDURE|Pulpotomy|Pulpotomy is a conservative pulp treatment option where only the coronal pulp is removed and a bioactive medicament (MTA) is placed over the remnant radicular pulp after haemostasis is achieved.
223437192|NCT06183203|PROCEDURE|Pulpectomy|Pulpectomy is treatment procedure in primary teeth where the entire coronal and radicular pulp is extirpated and the root canal system filled with a resorbable material (Endoflas)
224048126|NCT04559191|DEVICE|continuous glucose monitoring (CGM)|CGM (FreeStyle Libre Pro®, Abbott, Chicago, Illinoi, the United States)
224048127|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
224048128|NCT00929877|DRUG|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
224048129|NCT00929877|DRUG|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
224048130|NCT01172197|DRUG|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
224048131|NCT01172197|DRUG|Ropivacaine|Bolus and infusion
224143110|NCT04928495|DRUG|NAC + Bromhexine (BMX)|NAC + Bromhexine (BMX) 32 mg / day for ten days.
224143111|NCT01178736|PROCEDURE|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
223437193|NCT02167815|DEVICE|Mepilex XT|Experimental arm
223437194|NCT02167815|OTHER|standard care|
223437195|NCT06647680|DRUG|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles|Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
223437196|NCT04321317|OTHER|Measure of body composition by Air Displacement Plethysmography (ADP)|Each patient included will have one measure of body composition by Air Displacement Plethysmography (ADP) during the initial consultation in the referent center for food disorders of Lyon and one year later.
223437197|NCT06649565|OTHER|no intervention|no intervention
224048132|NCT01518881|DRUG|TKM-100201|IV Infusion
224048133|NCT01518881|DRUG|Placebo|IV infusion
224143112|NCT01178736|PROCEDURE|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
223437198|NCT05069311|DRUG|Multimodal analgesia|"Multimodal analgesia includes the combination of:~1. morphine given by PCA (patient-controlled analgesia) at 1 mg/dose~2. bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively~3. bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively~4. bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour~5. etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery~6. paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery"
223437199|NCT05069311|DRUG|Conventional intravenous analgesia|Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose
223437200|NCT02490462|OTHER|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
223437201|NCT02490462|OTHER|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
223437202|NCT00825656|DRUG|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
223437203|NCT02595281|OTHER|Experimental arm|"Serum samples are collected:~* at each neoadjuvant chemotherapy cycle~* before surgery~* at each adjuvant chemotherapy cycle~* at each injection of bevacizumab as maintenance therapy~* stop at the progression or after 24 months post chemotherapy"
223437204|NCT06696157|BEHAVIORAL|PRSS intervention for MOUD initiation|All participants of this expanded scope pilot study will be in a single-arm of an uncontrolled trial of PRSS intervention for MOUD initiation for a total of 8 weeks, starting in inpatient substance abuse treatment. This is distinguished from the R34 parent grant which targets MOUD retention and adherence rather than MOUD initiation.
223437205|NCT07027176|BEHAVIORAL|walking exercise|Divided into low-intensity and moderate-intensity exercise intervention groups, participants exercised either during the day or at night. The intervention lasted for 12 weeks.
223437206|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：1mL AI, injection two needles. Second period: 2mL AI, injection one needle).
223437207|NCT06182384|DRUG|SHR-1314|Receive a single dose of 240mg SHR-1314 at every period (First period：2mL AI, injection one needle. Second period: 1mL AI, injection two needles).
223437208|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
223437209|NCT00507650|DIETARY_SUPPLEMENT|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
223437210|NCT01451944|BEHAVIORAL|education|home asthma case management and education
223437211|NCT06631326|PROCEDURE|hepatic artery infusion chemotherapy|Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
223437212|NCT06631326|DRUG|Lenvatinib + PD-1 monoclonal antibody|PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab
223437213|NCT03715231|OTHER|NIDEK Gonioscope GS-1|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
223437214|NCT03715231|OTHER|Standard Digital Gonioscopic Images|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
223437215|NCT01876979|DEVICE|IMF Screws|stainless steel screws placed in bone
223437216|NCT01876979|DEVICE|Erich Arch Bars|Surgical braces wired around teeth
223437217|NCT06890637|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
223437218|NCT06890637|OTHER|Crohns Disease Exclusion Diet|The modified diet plan will be given to each study participant
223437219|NCT06890637|OTHER|Sham transplantation|Sham transplantation will involve saline infusion via colonoscopy
224048134|NCT01380730|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223437220|NCT06890637|OTHER|Sham Diet|Dietary counselling alone
223437221|NCT06890637|OTHER|Advanced therapy|Advanced therapy as standard dose and schedule
223437222|NCT06375616|DRUG|Nafamostat Mesylate|During RRT, a priming dose of 20 mg of nafamostat mesylate (NM) is administered before initiation of the procedure. Upon starting the machine, there is no loading dose, but a maintenance infusion rate of 25 mg/h of NM is maintained. NM is discontinued in the last half hour before the end of the RRT session.
223566355|NCT02292758|BIOLOGICAL|Cetuximab|Given IV
223566356|NCT02292758|DRUG|Irinotecan|Given IV
223566357|NCT02292758|OTHER|Laboratory Biomarker Analysis|Correlative studies
223566358|NCT02292758|OTHER|Placebo|Given IV
223566359|NCT00067964|BEHAVIORAL|small changes in physical activity and diet|
223566360|NCT00415337|PROCEDURE|endobronchial ultrasound|EBUS
224048135|NCT01380730|OTHER|Placebo to Evolocumab|Administered by subcutaneous injection
224143113|NCT01178736|PROCEDURE|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
223437223|NCT06375616|DRUG|Unfractionated Heparin|During RRT, a priming dose of 50 mg of unfractionated heparin (UFH) is administered before initiation of the procedure. Upon starting the machine, a loading dose of 0.2 mg/kg of UFH is given, followed by a maintenance infusion rate of 0.1 mg/kg/h of UFH. The anticoagulant is discontinued in the last half hour before the end of the RRT session.
223437224|NCT05308602|BIOLOGICAL|SCTV01C|Day 0; intramuscular injection
224048136|NCT01111942|OTHER|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta\* 6 mg SC Day 5 (\*Neupogen may be substituted at the investigator's discretion)"
224048137|NCT01111942|PROCEDURE|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
224048138|NCT00068211|DRUG|ILX651|
224048139|NCT03268434|BEHAVIORAL|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
224048140|NCT03268434|BEHAVIORAL|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
224048141|NCT05340361|DEVICE|Optical coherence tomography-guided percutaneous coronary intervention|OCT examination is performed using a frequency-domain OCT system (C7 Dragonfly OPTIS Imaging Catheter, Abbott Vascular, Santa Clara, CA, USA) with a 5.4 or 7.5 cm total pullback length according to a non-occlusive technique. The procedure is performed via radial or femoral access with a ≥6 Fr guiding catheter. The OCT catheter is advanced over the 0.014-inch PCI wire and the implanted stent was crossed after administration of intracoronary nitrates of 200 µg. For blood clearing, contrast media was injected through the guiding catheter with an automated power injector. The standard infusion rate was 4 mL/s for 4 seconds with 250 PSI. Follow-up OCT image acquisition was achieved with the same method. After post-PCI OCT, we evaluate the factor regarding post-PCI optimization target by European Expert Consensus.
224300164|NCT02163486|DEVICE|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
224048142|NCT05340361|DEVICE|Optical coherence tomography-guided Onyx family stent expansion|"1. Expansion of 2.25, 3.0, and 4.0 mm Onyx family stent@ nominal pressure~2. OCT pullback~3. Expansion with over 0.5mm sized non-compliant balloon of each stent~4. OCT pullback~5. Expansion with over 1.0mm sized non-compliant balloon of each stent~6. OCT pullback~7. Expansion with over 1.25\~1.5mm sized non-compliant balloon of each stent~8. OCT pullback~9. Evaluation of polymer status with overexpansion assessed by an electric microscope"
224048143|NCT04103905|DRUG|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
224048144|NCT05460611|DEVICE|Sciton HALO 1470nm Non-ablative laser|Patients will be treated with the 1470nm non-ablative laser.
224300165|NCT06132217|DRUG|Simmitinib|Patients will oral administration according to study protocol until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
224300166|NCT06132217|DRUG|SG001|Patients will receive intravenous infusion of SG001 according to study protocol until disease progression, unacceptable toxicity, meeting the suspension or termination criteria, or up to 24 months in patients without disease progression.
224305034|NCT00394524|DEVICE|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG- 60).
223437225|NCT05308602|BIOLOGICAL|SCTV01C|Day 28; intramuscular injection
223437226|NCT05308602|BIOLOGICAL|SCTV01C|Day 180; intramuscular injection
223437227|NCT05308602|BIOLOGICAL|SCTV01E|Day 0; intramuscular injection
223437228|NCT05308602|BIOLOGICAL|SCTV01E|Day 28; intramuscular injection
223437229|NCT05308602|BIOLOGICAL|SCTV01E|Day 180; intramuscular injection
223437230|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 0; intramuscular injection
223437231|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 28; intramuscular injection
223437232|NCT05308602|BIOLOGICAL|mRNA vaccine manufactured by Pfizer or Moderna|Day 180; intramuscular injection
223437233|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 0; intramuscular injection
223437234|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 28; intramuscular injection
223437235|NCT05308602|BIOLOGICAL|Sinopharm inactivated COVID-19 vaccine|Day 180; intramuscular injection
223437236|NCT03366324|GENETIC|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
223437237|NCT03366324|PROCEDURE|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
223437238|NCT00948506|DRUG|1% topical cidofovir|1% topical cidofovir
223437239|NCT00948506|DRUG|3% topical cidofovir|3% topical cidofovir
223437240|NCT00948506|DRUG|Placebo|topical placebo
223437241|NCT06392854|DRUG|Insulin|2 dose insulin infusion 4 hours
223437242|NCT06766656|PROCEDURE|Incision|"The pocket for the vascular port is made through a small incision in the skin in the subclavicular area. The skin incision can be made transversely or longitudinally"
223437243|NCT05156554|DRUG|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
223437244|NCT05156554|DRUG|rhG-CSF|rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil\>0.5×10\^9 /L.
224048145|NCT06330961|OTHER|Isometric exercise|Biering-Sorensen maneuver.Participants will be in a prone position with the anterosuperior iliac spines on the edge of a stretcher. Their lower body will be strapped by the ankles and hips, with the upper body suspended. Participants will keep their trunk extended and parallel to the ground for 60 seconds.
223437245|NCT01224652|DRUG|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
223437246|NCT01224652|DRUG|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
223437247|NCT06861062|DRUG|Vitamin D3|Vitamin D3(cholecalciferol),1600 IU per day.
223437248|NCT06861062|DIETARY_SUPPLEMENT|yeast β-glucan|yeast β-glucan, 600mg per day.
223437249|NCT06861062|DIETARY_SUPPLEMENT|Vitamin D placebo|Vitamin D placebo
223437250|NCT06861062|DIETARY_SUPPLEMENT|yeast β-glucan placebo|yeast β-glucan placebo
223437251|NCT03846115|BEHAVIORAL|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
223437252|NCT03846115|BEHAVIORAL|Control app|This app offers the Seeking Safety content but without the enhanced features
223437253|NCT04026334|DEVICE|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
223437254|NCT06860932|BEHAVIORAL|Palliative care video comprises the conversation and advance directives.|The palliative care video was done in a way that facilitates discussion and minimizes anxiety or any psychological risk/burden. The video is narrated by a young adult who opens with an empathic statement regarding the situation the young adult/adult patient finds themselves in. Then, there is a transition to contemplating what the future might hold and decisions about medical care and introducing the concept of ACP. There is acknowledgment that decision making is difficult, and that the presence of caregivers often helps. There is an explicit statement regarding values and spiritual beliefs and how that might impact decision making. The video then attempts to translate the preceding conversation into actionable medical orders using the most common three-goal framework that is based on the Physician Orders for Life Sustaining Treatment (POLST) paradigm: life-prolonging care, limited/blended care and comfort care.
223437255|NCT06860932|BEHAVIORAL|Palliative care written material|Written materials about palliative care conversation and advance directives.
223566361|NCT05816642|DRUG|sunitinib or pazopanib|Single targeted therapy
223566362|NCT05816642|DRUG|PD-1 inhibitor combined with axitinib|targeted therapy combined with immunotherapy
223566363|NCT02357082|RADIATION|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
223566364|NCT03075488|DEVICE|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
224048146|NCT06330961|OTHER|Aerobic exercise|After adjusting height, pedals and backrest in a cycloergometer, there will be 20 minutes of cycling, of which 5 minutes will be a warm-up at 50-60% of maximum heart rate and 15 minutes at 60-70% of maximum heart rate. There will be a constant monitoring of heart rate and oxygen saturation.
224048147|NCT06330961|OTHER|Placebo intervention|A maneuver equivalent to Biering-Sorensen test, but with upper limb support on a level step and electromyographic monitoring to ensure minimal activation of the erector spinae. It will be explained to the participant that the aim of such an intervention is to cause electromyographic silence of the erector spinae and keep it for 1 minute.
223566365|NCT03075488|PROCEDURE|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
223740731|NCT00954902|DIETARY_SUPPLEMENT|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
224048148|NCT05925556|BEHAVIORAL|Communal Coping Intervention|The components of the intervention were described in the experimental arm.
224143114|NCT01178736|PROCEDURE|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
224143115|NCT03700970|DRUG|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
224143116|NCT03700970|DRUG|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
224143117|NCT02396342|GENETIC|AAV5-hFIX|AAV5hFIX gene therapy
224143118|NCT00434499|DRUG|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
224143119|NCT02545491|BEHAVIORAL|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
224143120|NCT02545491|BEHAVIORAL|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
224143121|NCT04362904|OTHER|acupressure|
224143122|NCT02246023|DEVICE|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
224143123|NCT02246023|DEVICE|Oxygen saturation|Continuous measurement of oxygen saturation;
224048149|NCT06033885|DEVICE|PONDUS®|"PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported."
224048150|NCT00119041|BEHAVIORAL|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
224048151|NCT00119041|BEHAVIORAL|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
224048152|NCT00119041|BEHAVIORAL|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
224048153|NCT02429297|OTHER|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
224048154|NCT02429297|OTHER|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
224048155|NCT03157141|PROCEDURE|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
224048156|NCT03157141|PROCEDURE|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
224048157|NCT05686928|DRUG|Cetaphil Healing Ointment|Topical ointment application twice daily
224048158|NCT00697450|DRUG|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
224048159|NCT00610545|DRUG|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
224048160|NCT00610545|DRUG|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
224048161|NCT00314626|DRUG|efavirenz|Efavirenz
224048162|NCT00314626|DRUG|Abacavir+lamivudine|Abacavir+lamivudine
223740732|NCT00954902|BEHAVIORAL|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
223740733|NCT00954902|OTHER|Placebo antioxidant concentrate|Placebo capsules
224048163|NCT02383290|OTHER|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
224048164|NCT00467779|DRUG|cobimetinib|Repeating oral dose
224048165|NCT00467779|DRUG|dextromethorphan|In Stage III only: single dose of dextromethorphan
224048166|NCT00467779|DRUG|midazolam|In Stage III only: single dose of midazolam
224048167|NCT03883191|OTHER|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
224048168|NCT03883191|OTHER|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
224048169|NCT00625352|DRUG|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
224048170|NCT02790255|OTHER|Cold air|
224048171|NCT02790255|OTHER|Cold water|
224048172|NCT03413852|DEVICE|SQUID non-adhesive liquid embolic agent|AVM embolization using SQUID non-adhesive liquid embolic agent
224048173|NCT04170790|DRUG|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
224048174|NCT04170790|DRUG|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
224048175|NCT01701999|BIOLOGICAL|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
224048176|NCT04232696|DEVICE|Neuspera Implantable Sacral Nerve Stimulation System|Stimulation of the Sacral Nerve.
224048177|NCT01195090|DRUG|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
224048178|NCT01195090|DRUG|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
224143124|NCT02246023|DEVICE|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
224143125|NCT02246023|DEVICE|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
224143126|NCT02246023|DEVICE|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
224143127|NCT02993913|DRUG|Simmiparib|Simmiparib Tablets, oral administration
224143128|NCT00854555|OTHER|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
224143129|NCT00854555|OTHER|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
224143130|NCT06287944|BIOLOGICAL|Actinium Ac 225-DOTA-Daratumumab|Given IV
224143131|NCT06287944|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224143132|NCT06287944|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224143133|NCT06287944|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224143134|NCT06287944|PROCEDURE|Computed Tomography|Undergo CT
223437256|NCT06894368|BEHAVIORAL|UP-A|The intervention is a group adaptation of the Spanish version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018, 2020, 2022). It consists of 16 weekly 90-minute sessions held in person at a public Mental Health Center. The intervention also includes three in-person group sessions for parents, each lasting one hour, held at the beginning, middle, and end of the program. These sessions cover content from the therapist's guide, including the Parent Module (Parenting the Emotional Adolescent), and provide a space for questions and emotional support.
223437257|NCT06894914|BEHAVIORAL|24-hour Activity Counselling|"Physiotherapists will participate in the self-paced brief action planning (BAP) online training (2-4 hours long), followed by 2-3 hours of practice and feedback over the phone with an experienced BAP instructor. In addition, they will attend a 2-hour session with the research team on training around on prescribing physical activity while balancing with rest and sleep.~Once training is complete the PT can start implementing the counselling approach with the older adult patients."
223437258|NCT06741644|DRUG|CS2009|CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).
223437259|NCT06741644|DRUG|CS2009|CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).
224048179|NCT05111041|BEHAVIORAL|#EnufSnuff.TXT- First Responder|Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.
224048180|NCT05111041|BEHAVIORAL|Enough Snuff Intervention|Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
224048181|NCT00051675|DRUG|ING-1(heMAb)|
224048182|NCT01205230|DRUG|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
224048183|NCT02520375|OTHER|Prebiotic|
224048184|NCT02520375|OTHER|Control|
224048185|NCT02712151|PROCEDURE|Abdominal Wall Block|bilateral TAP and RS blocks.
224048186|NCT02712151|PROCEDURE|Surgical infiltration|distributed between the 4 laparoscopic port sites.
224048187|NCT02712151|DRUG|Sterile saline|Placebo injection
224048188|NCT02712151|DRUG|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
224048189|NCT02712151|DEVICE|Ultrasound|For nerve localization
224143135|NCT06287944|BIOLOGICAL|Daratumumab|Given IV
224143136|NCT06287944|PROCEDURE|Echocardiography|Undergo echocardiography
224143137|NCT06287944|DRUG|Fludarabine|Given IV
224143138|NCT06287944|PROCEDURE|Hematopoietic Cell Transplantation|Undergo SCT
224143139|NCT06287944|BIOLOGICAL|Indium In 111-DOTA-Daratumumab|Given IV
224143140|NCT06287944|DRUG|Melphalan|Given IV
224143141|NCT06287944|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223437260|NCT06741644|DRUG|Pemetrexed|IV infusion
223437261|NCT06741644|DRUG|Carboplatin|IV infusion
223437262|NCT06741644|DRUG|Paclitaxel|IV infusion
223437263|NCT06741644|DRUG|Etoposide|IV infusion
223437264|NCT06741644|DRUG|Nab-paclitaxel|IV infusion
223437265|NCT06741644|DRUG|Oxaliplatin|IV infusion
223437266|NCT06741644|DRUG|Capecitabine|oral tablets
223437267|NCT07074977|DRUG|nemolizumab|Participants will receive either 30 mg or 60 mg dose of nemolizumab as SC injection.
223437268|NCT07074977|DRUG|Placebo|Participants will receive matching placebo as SC injection.
223437269|NCT06927804|PROCEDURE|Virtual reality intervention|A virtual reality device will be used in one study arm during the implantation of the subcutaneous port.
224048190|NCT02712151|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
224048191|NCT04217304|DRUG|Definity® with High Mechanical Index Ultrasound|Sonothrombolysis; Echocardiographic imaging with intermittent diagnostic high mechanical index during an intravenous 5% Definity® infusion
224048192|NCT05851742|DEVICE|TENS|TENS 50-280 HZ frequency and a pulse duration of 50 us for 10 minutes along with 10 minutes myofascial release.
224048193|NCT05851742|OTHER|Myofascial trigger point release|Release of trigger points
224048194|NCT04972981|DRUG|ADCT-901|Intravenous infusion
224048195|NCT01480453|DEVICE|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
224143142|NCT06287944|PROCEDURE|Radionuclide Imaging|Undergo nuclear scan
224143143|NCT06287944|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT scan
224143144|NCT06287944|DRUG|Sirolimus|Given sirolimus
224143145|NCT06287944|DRUG|Tacrolimus|Given tacrolimus
224143146|NCT06287944|RADIATION|Total Marrow and Lymphoid Irradiation|Undergo TMLI
224143147|NCT00729313|DRUG|Lanreotide microparticles|
224143148|NCT00729313|DRUG|Placebo|
224143149|NCT00313534|DRUG|masoprocol|
224143150|NCT01524367|DRUG|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
224143151|NCT01524367|DRUG|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
224143152|NCT02556593|RADIATION|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
224143153|NCT02556593|RADIATION|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
224143154|NCT02556593|DRUG|erlotinib|erlotinib 150mg daily
224143155|NCT05580861|DRUG|Sulfasalazine|Sulfazalazine 500mg-tablets ; 7 dose levels explored in the phase I part of the trial.
224143156|NCT02554253|DRUG|Ketamine|Ketamine used for induction
224143157|NCT02554253|DRUG|Propofol|Propofol for induction
224143158|NCT01754077|BEHAVIORAL|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
224300167|NCT05737316|BEHAVIORAL|Combat PD|CombatPD is an aerobic exercise programme hosted on a mobile application that pairs with motion sensors and heart rate monitor, which connects to a web-based portal for remote monitoring. The wearable sensors consist of (i) 2 motion sensors worn across one thigh and attached to an exercise ring which is held by the participant during the exergame and (ii) 1 heart rate sensor worn across the participant's chest. They will receive once weekly physiotherapy sessions at the study site for the first 4 weeks where they will be guided through the use of the CombatPD. Participants will be instructed to perform 2 sessions of 30-minute exergames in addition to a session of 30-minute brisk walking every week for 12 weeks at home. They will be instructed to exercise at a target heart rate zone at moderate intensity (i.e., 40% - 60% Heart Rate Reserve), which will be gradually increased.
224048196|NCT04713423|DIAGNOSTIC_TEST|Diagnosis and treatment of the case|The infant was transferred to a hospital for better management of her infection. She was immediately started on intravenous acyclovir (20 mg/kg/6 h/5 d) while acetaminophen suppositories (80 mg/8 h/5 d) were given to lower her body temperature. In addition, other palliative drugs, such as diphenhydramine syrup (12.5 mg/5 mL, 2.5 mL orally) once-a-night for five days, were given to ease the effort of drinking and to aid in achieving good sleep. Upon completion of five days of therapy, the patient showed complete recovery and was subsequently discharged from the hospital free from symptoms.
224300168|NCT05737316|BEHAVIORAL|Usual Care|Participants in the control group (usual care) will receive once weekly physiotherapy sessions for first 2 weeks and another session at week 6 where they will be taught home exercises based on a standard PD exercise booklet, consisting mainly of range of motion and stretching exercises , as well as brisk walking techniques. Participants in the control group will be instructed to perform these home exercises twice a week, in addition to a 30-minute brisk walk for 12 weeks.
224300169|NCT02836496|DRUG|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
224300170|NCT02836496|DRUG|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
224048197|NCT06219070|OTHER|Core straining|The experimental group received 12 weeks of core training, and the control group received 12 weeks of conventional training, 3 times/times Of the week. Each session lasts 60 minutes and includes warm-up, exercise, and relaxation.
224048198|NCT05285709|DIAGNOSTIC_TEST|Biomarker|blood and urine sampling before and after surgery (1-admission to operating ward, 2-leaving operation ward, 1st day postop, 2nd day postop, 5th day postop, or the day patient leaves hospital, whichever is first)
224048199|NCT05285709|DIAGNOSTIC_TEST|RRI measurement|patients able to cooperate will have renal resistive index measured before and after surgery (admission to operating ward, leaving operating ward)
224048200|NCT00774813|DEVICE|Nexalin 1.3mA Device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of placebo antidepressant"
224048201|NCT00774813|DEVICE|Nexalin 15mA device|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a placebo antidepressant"
224048202|NCT00774813|DRUG|placebo device and Citalopram|"* 3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~* Daily receipt of a a SSRI (Citalopram or similar)"
224048203|NCT02678338|DRUG|Hu5F9-G4|
224048204|NCT03979222|DEVICE|Extracorporeal Membrane Oxygenation|ECMO provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into either the venous or arterial circulation dependent on configuration.
224048205|NCT05439668|OTHER|Classic abdominal strengthening exercises|Classic abdominal strengthening exercises (Curl-up, sit-ups and leg-rise), balance exercises, general mobility and upper limb strengthening exercises.
224143159|NCT01754077|BEHAVIORAL|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
224143160|NCT01754077|BEHAVIORAL|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
224143161|NCT05507060|DEVICE|Vibrating MESH nebulizer (Aerogen Ultra)|Medication will be applied with Vibrating MESH nebulizer
224300171|NCT02836496|DRUG|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
224143162|NCT05507060|DEVICE|Jet nebulizers (Philips Respironics)|Medication will be applied with Jet nebulizers
224048206|NCT05439668|OTHER|Hypopressive abdominal exercises program|Hypopressive abdominal exercises, balance exercises, general mobility and upper limb strengthening exercises
224048207|NCT00041080|DRUG|tamoxifen citrate|Given orally
224048208|NCT00041080|DRUG|thalidomide|Given orally
224048209|NCT00041080|OTHER|laboratory biomarker analysis|Correlative studies
224048210|NCT00163267|DRUG|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
224048211|NCT00922480|DRUG|Fimasartan|Fimasartan 60 \~ 120mg/po take one tablets once a day
224048212|NCT00922480|DRUG|Losartan (Control)|Losartan 50 mg \~ 100 mg/po, take one tablets once a day
223437270|NCT06927804|PROCEDURE|Standard Care (in control arm)|Patients in this study arm will receive standard care, without the use of VR.
223566366|NCT02924194|DEVICE|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
223740734|NCT05381467|PROCEDURE|immediate implant placement with The Dual-Zone Therapeutic Concept|After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.
223744847|NCT05980520|BEHAVIORAL|Behavioral rehabilitation therapy|Structured training courses which included: visual arrangement, routine, environmental arrangement, program schedule, personal work system consists of five parts. The course is designed and implemented by qualified behavioral rehabilitators who have worked for more than 5 years, with the participation of parents. The daily training time is about 6-8 hours, and the total intervention time is not less than 40 hours per week.
224048213|NCT03269643|DEVICE|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
224048214|NCT03269643|DEVICE|Reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
224048215|NCT03877978|BIOLOGICAL|Nephrocheck test|Nephrocheck® measurement on urine sample at different timepoints.
224048216|NCT02811055|BIOLOGICAL|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
224048217|NCT02811055|PROCEDURE|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
224048218|NCT02811055|DEVICE|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
224048219|NCT02811055|PROCEDURE|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
224048220|NCT02811055|DRUG|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
224048221|NCT02811055|DRUG|Administration of placebo|Administration of placebo once per day during 14 days
224048222|NCT05140122|DRUG|Multiple|We will collect information on all medications taken by the caregiver and the person they care for.
224048223|NCT05140122|OTHER|Multiple|We will collect information on all forms of therapy or medical intervention taken by the caregiver and the person they care for.
224048224|NCT02877862|BEHAVIORAL|mAGIC app|7-day app to encourage uptake of genetic counseling
224048225|NCT02745366|PROCEDURE|BFPSC+FDBA+PRF|
224048226|NCT02745366|PROCEDURE|FDBA+PRF|
224048227|NCT01017367|DRUG|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
224048228|NCT01017367|DRUG|Placebo|Placebo
224048229|NCT04784897|DRUG|Brilacidin|Brilacidin IV infusion
224048230|NCT04784897|DRUG|Placebo|Placebo IV infusion
224048231|NCT04784897|DRUG|Standard of Care (SoC)|SoC therapies for COVID-19
224048232|NCT00233688|DEVICE|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
224048233|NCT00233688|PROCEDURE|Open surgical repair|Open surgical repair
224048234|NCT01893229|DRUG|Lithium|Lithium is used as a mood stabiliser
224048235|NCT01893229|DRUG|Valproate|Valproate is used as a mood stabiliser
224048236|NCT01893229|DRUG|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
224048237|NCT01893229|DRUG|Quetiapine|Quetiapine is used as a mood stabiliser
224048238|NCT01893229|DRUG|Olanzapine|Olanzapine is used as a mood stabiliser.
224048239|NCT01893229|DRUG|Ziprasidone|Ziprasidone is used as a mood stabiliser
224048240|NCT04918745|DEVICE|Cochlear Vestibular Implant (CVI)|"The Cochlear Vestibular Implant (CVI) is a modified cochlear implant (CI) which also incorporates a vestibular component (VI) in order to restore both hearing and vestibular function. Three vestibular stimulation algorithms will be compared in a randomized order (3 treatments x 3 periods, = 6 arms). These stimulation algorithms are:~* A - Baseline stimulation, no modulation stimulation~* B - Baseline stimulation, modulated stimulation~* C - Reduced baseline stimulation, modulated stimulation"
224048241|NCT00502073|DRUG|cyclosporine|
224048242|NCT01994382|DRUG|Cerdulatinib|Oral capsule
224048243|NCT01994382|BIOLOGICAL|Rituximab|IV infusion
224048244|NCT02879227|DRUG|Cisplatin|Arm cisplatin : 75mg/m2, day n\*1 and day n\*22, And radiotherapy 50 Gy, 2Gy/f
224048245|NCT02879227|DRUG|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
224048246|NCT04841824|OTHER|Observational study|Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
223478588|NCT01944423|DRUG|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
224048247|NCT01200004|DRUG|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
223437271|NCT07078877|OTHER|home based exercise|The conventional home based exercise program includes: hip and knee range of motion (ROM) exercises; stretching exercises for the hamstring, calf, and quadriceps muscles; isometric, concentric, and eccentric strengthening exercises for the quadriceps, hamstrings, and hip adductors/abductors; relaxation exercises; and walking as aerobic exercises. The program will begin with ROM, stretching, relaxation, aerobic, and isometric strengthening exercises. After one week, concentric and eccentric strengthening exercises will be added using elastic bands. The home exercise program will be performed 3 days a week, each exercise in 3 sets of 10 repetitions and 2 minutes of rest between sets. Aerobic walking at a moderate pace (as determined by the talk test: the patient can talk but not sing during exercise) for 30 minutes will be recommended. Program will continue for 12 weeks.
223437272|NCT07078877|DEVICE|Low Level Laser Therapy|Patients will receive LLLT treatment, they will be treated in a supine position with the knee flexed to 30 degrees, 5 sessions per week for 2 weeks. A total of 6 points will be treated each for 60 seconds. The treatment will be applied using the BTL SMART 4000 laser device at a wavelength of 835 nm and a dose of 10 J/point.
223437273|NCT06510777|DEVICE|PICO Treatment|"PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped."
223437274|NCT06510777|DEVICE|Standard of Care (SOC) Treatment|"Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value."
223437275|NCT04173104|DIAGNOSTIC_TEST|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with \[18F\]PARPi
223566367|NCT02924194|DEVICE|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
223566368|NCT00668382|BIOLOGICAL|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
223566369|NCT02072460|OTHER|electromyography|
223566370|NCT02072460|OTHER|electroencephalography|
223744848|NCT04188652|OTHER|Detailed symptomregistration|Information on symptoms, specialized ultrasound in accordance to IOTA, and HE4 is registered in women with ovarian cysts. Participation in the study including symptom registration, description of the cyst using IOTA terminology, and HE4 determination will not affect further diagnostics or treatment. HE4 will not be informed to the patient or clinician.
224048248|NCT01200004|DRUG|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
224048249|NCT01200004|DRUG|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
224048250|NCT03878173|OTHER|No intervention|No intervention
224048251|NCT04667377|DRUG|BI 456906|BI 456906
224048252|NCT04667377|DRUG|Placebo|Placebo
224048253|NCT04722120|RADIATION|Low radiation dose CT|Underwent liver CT with 30% lower radiation dose
224048254|NCT04722120|RADIATION|Conventional CT (radiation)|Underwent liver CT without change of radiation.
224048255|NCT04722120|DRUG|Low contrast dose CT|Underwent liver CT 20% lower dose contrast media.
224048256|NCT04722120|DRUG|Conventional CT (contrast agent)|Underwent liver CT without change of contrast media doses.
224048257|NCT04722120|OTHER|Deep-learning based contrast boosting algorithms|Applied deep-learning based contrast boosting algorithms on acquired CT images
224048258|NCT00006345|BIOLOGICAL|denileukin diftitox|
224048259|NCT00006345|DRUG|dexamethasone|
224048260|NCT01312454|DRUG|AL-59412C injectable solution|Concentration 1 and Concentration 2
224048261|NCT01312454|DRUG|Travoprost injectable solution|
224048262|NCT01312454|DRUG|AL-59412C Vehicle|Inactive ingredients used as placebo
224048263|NCT01011439|DRUG|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
224048264|NCT03558165|DIAGNOSTIC_TEST|Oncomine Comprehensive Assay|Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
224048265|NCT03687645|DIAGNOSTIC_TEST|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
224048266|NCT03660709|BEHAVIORAL|Intervention|"1. Standard-of-care HIV testing and counseling~2. Watch a video clip while waiting for the HIV testing result on a tablet.~3. Receive a pamphlet and post-test counselling promoting HIV retesting.~4. Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~5. Receive brief e-health reminder for retesting at Month 3 and 5."
223437276|NCT04173104|DRUG|[18F]PARPi|Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
224048267|NCT03660709|BEHAVIORAL|Control|Standard-of-care HIV testing and counseling
224048268|NCT03528759|DIAGNOSTIC_TEST||phenotypic and genotypic Method
224143163|NCT03558191|DRUG|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
223566371|NCT02072460|OTHER|approaches from psychophysics|
224048269|NCT05931796|OTHER|NON-ERAS pathway|All patients received best of care practice, with standardization of preoperative and postoperative care
224300172|NCT02836496|DRUG|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
224300173|NCT05549908|BIOLOGICAL|rabies vaccine|The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared
224300174|NCT03438214|DRUG|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
224300175|NCT03438214|DRUG|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
224048270|NCT05931796|OTHER|ERAS pathway|ERAS pathway ERAS consist of approximately 15 elements (or components) that include preoperative, intraoperative, and postoperative interventions .
224048271|NCT02302352|OTHER|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
224048272|NCT02302352|OTHER|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
224048273|NCT05781230|BEHAVIORAL|High Intensity Exercises Program|HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
224048274|NCT05781230|BEHAVIORAL|Low Intensity Exercises Program|LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE\>14 indicates high intensity
224048275|NCT01887067|PROCEDURE|Renal denervation therapy|
224300176|NCT04483635|DIETARY_SUPPLEMENT|Placebo|Weekly oral dose of placebo
224300177|NCT04483635|DIETARY_SUPPLEMENT|Vitamin D|Weekly oral dose of Vitamin D
223566372|NCT01896076|OTHER|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
223566373|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Test product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Mankind Pharma Limited, India
223744849|NCT01755884|DIETARY_SUPPLEMENT|Wheat oral immunotherapy|Cooked spaghetti
223744850|NCT01819454|DEVICE|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
224048276|NCT02428855|DRUG|Dasatinib|
224048277|NCT02057796|DEVICE|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
224048278|NCT02057796|DRUG|ART (Atripla, Truvada, Efavirenz, Combivir)|"* ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~* ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
224048279|NCT02057796|DRUG|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
224048280|NCT02066311|DRUG|Nelfinavir|
224048281|NCT00006151|BEHAVIORAL|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
224048282|NCT05623930|DEVICE|laser acupuncture|In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
224048283|NCT05623930|OTHER|wet cupping|in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
224048284|NCT00702364|DRUG|atomoxetine|
224048285|NCT00702364|DRUG|placebo|
224300178|NCT04236570|DEVICE|Thermode(hot plate) and cold water bath|Standardized protocol will consisted of stimulus test (TS) generated by thermode and conditioning stimulus (CS) using cold water bath.
224048286|NCT06462300|BEHAVIORAL|A meaning-centered intervention for young women with weight and shape concerns|"* adapted version of the manualized meaning-centered psychotherapy for cancer patients developed by van der Spek et al. (2017)~* six weekly individual online sessions, each lasting one hour~* sessions led by a certified trainer~* four sources of meaning will be explored: personal life story, dealing with life's limitations, creating one's own life, and meaningful experiences~* homework assignments designed to deepen participants' experience and reflection on meaning in their daily lives"
223437277|NCT06785051|BEHAVIORAL|AI-based physiotherapy|jaw, neck, shoulder ROM exercises, and scapular-focused exercises guided by AI technology, 30 minutes of intervention, once a week, and a total of 12 weeks
223437278|NCT06785051|BEHAVIORAL|Conventional physiotherapy|jaw, neck, shoulder ROM exercises, and scapular-focused exercises, 30 minutes of intervention, once a week, and a total of 12 weeks
224048287|NCT04781231|DEVICE|MusicCare® device|The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.
224048288|NCT04781231|DEVICE|Device with quiet recorded music|An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist
224143164|NCT05657704|DRUG|The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype|Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
224143165|NCT00042250|DRUG|Chemotherapy for hematologic malignancy|
224143166|NCT04748406|DEVICE|Extracorporeal Shock Wave Therapy(ESWT)|Group 2 (n = 35) will be applied 1 session per week for 3 weeks, 3 sessions of ESWT (1.8 bar, 10.0 Hz, 2000 beats) + cold application + home exercise program will be applied.
224143167|NCT04748406|OTHER|Peloid therapy|Group 1 (n = 35) will be given 15 sessions of peloid therapy + cold application + home exercise program for 3 weeks, 5 days a week
223437279|NCT06785051|BEHAVIORAL|Scar management|scar massage and jaw-mobilizing exercises combined with devices or depressors
223740735|NCT05381467|PROCEDURE|Immediate implant placement with the bone shielding concept|After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
223740736|NCT03258190|DRUG|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
223437282|NCT05983198|DRUG|225Ac-PSMA-R2|PSMA-R2 is a ligand coupled with 225Ac an alpha emitting radionuclide
223437283|NCT05983198|RADIATION|68Ga-PSMA-R2|Kit for radiopharmaceutical preparation
223437284|NCT05983198|RADIATION|68Ga-PSMA-11|Kit for radiopharmaceutical preparation
224048289|NCT04781231|OTHER|Usual management of anxiety|No specific intervention
224048290|NCT01312038|DRUG|Simethicone|single 125 mg chewable tablet
223437285|NCT06665620|BEHAVIORAL|ViraBrite nudges|Each day, participants will receive prompts via smartphone notifications that encourage them to access the ViraBrite app and utilize suicide safety planning skills.
223437286|NCT04149782|OTHER|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
223437287|NCT07082738|DRUG|AZD6793|Oral dosage
223437288|NCT07082738|OTHER|Placebo|Oral dosage
223437289|NCT07086339|DEVICE|Implantable pulmonary stent|Implantable polymer based pulmonary stent for severe COPD/emphysema
224048291|NCT01312038|DRUG|Placebo|chewable calcium tablet
224143168|NCT04748406|OTHER|Home Workout Program|Patients will be given a home exercise program consisting of eccentric strengthening exercises and stretching exercises, which are planned to increase resistance every week. The patients will be taught strengthening exercises for forearm pronation-supination with wrist extensors and a home exercise program will be started 3 sets of 10 repetitions per day.
224143169|NCT04748406|OTHER|Cold application|At the beginning of each treatment, gel ice packs are wrapped with a moist towel and placed around the elbow joint for 15 minutes. will be applied.
223437290|NCT04132453|DEVICE|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
223437291|NCT04132453|DEVICE|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
223437292|NCT04132453|DEVICE|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
223437293|NCT05401448|BIOLOGICAL|Influenza|Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
223437294|NCT05401448|BIOLOGICAL|MMR vaccines|MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
223437295|NCT05401448|OTHER|Placebo|Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
223566374|NCT06233201|DRUG|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Reference product|Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Manufactured by: Patheon Puerto Rico, Puerto Rico 00674
223740737|NCT03106220|BEHAVIORAL|exercise|home exercise program
223740738|NCT03106220|OTHER|placebo|encourage walking and physical therapy per standard care.
223740739|NCT00455429|DRUG|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
223740740|NCT00455429|DRUG|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
224048292|NCT02116504|PROCEDURE|Sampling of blood|Sampling of blood for dosage of antibodies
223437296|NCT06430580|DRUG|Hydrocortisone Oral|20mg hydrocortisone, single oral dose
223437297|NCT06430580|DRUG|Yohimbine Hydrochloride|54mg yohimbine hcl, single oral dose
223437298|NCT06430580|DRUG|Cornstarch Placebo 20mg|20mg cornstarch placebo, single oral dose
223437299|NCT06430580|DRUG|Cornstarch Placebo 54mg|54mg cornstarch placebo, single oral dose
223437300|NCT00824382|DRUG|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
223437301|NCT00824382|DRUG|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
224048293|NCT00655954|PROCEDURE|Induced sputum|Used Ultrasonic nebuliser
224048294|NCT04624464|OTHER|Rectal swabs - microbiological analysis|Microbial analyses will be performed from the rectal swabs obtained.
224048295|NCT04624464|OTHER|Examination of patient room|Only performed for cohort 2
224048296|NCT03487809|DRUG|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
224048297|NCT03099642|RADIATION|ultrasound-assisted lumbar puncture|The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
224048298|NCT02607592|DRUG|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
224048299|NCT02607592|DRUG|nedaplatin+pemetrexed|nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
224143170|NCT03838770|DEVICE|Active tDCS|Active target 2.0mA tDCS (n=60)
224143171|NCT03838770|DEVICE|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
224143172|NCT05049447|DRUG|Pascoflair|1 x 2 tablets (single-dose)
224143173|NCT05049447|OTHER|Placebo|1 x 2 tablets (single-dose)
224143174|NCT04699214|DRUG|Endostar (recombinant human endostatin injection)|The experimental group is Endostar combined with AI
224143175|NCT04699214|DRUG|Chemotherapy AI|AI: Doxorubicin (ADM) 60mg/m2 iv D1+ Ifosfamide (IFO) 2g/m2/d D1-5+ Mesna 400mg/m 2 (ifosfamide start infusion, time after infusion 4 hours, 8 hours injection) D1-5, Q3W
224143176|NCT05556551|OTHER|Full Ceramic restoration|Two different dental restoration inserted in patient mouth ( split mouth)
223437302|NCT00824382|DRUG|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
223437303|NCT00824382|DRUG|Placebo|2 puffs delivered by the RespimatÂ® inhaler
223437304|NCT01482143|DRUG|AFQ056|
223437305|NCT00721279|DRUG|Sifrol® (pramipexole dihydrochloride)|
223437306|NCT00311064|BEHAVIORAL|physical activity|
223437307|NCT03977753|DRUG|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
223437308|NCT03977753|DRUG|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
223740741|NCT00455429|DRUG|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
223437310|NCT01958216|OTHER|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
223437311|NCT00862342|DRUG|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
223437312|NCT05744037|BIOLOGICAL|regimen with BTK inhibitor +Anti-CD19 CAR T cells|After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
223437313|NCT02573831|DRUG|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
223437314|NCT02573831|DRUG|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
224048300|NCT05784779|DRUG|GH509|Orally, once daily before bedtime (qhs)
224048301|NCT05784779|DRUG|Placebo|Orally, once daily before bedtime (qhs)
224048302|NCT03198520|DEVICE|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
224048303|NCT06340048|DRUG|HiCM-188 therapy|Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
224048304|NCT05223634|OTHER|Collection of oral and/or nasal samples|Collection of oral and/or nasal samples after SOC test performed
224143177|NCT05556551|OTHER|Hybrid resin Ceramic restoration|Hybrid resin Ceramic restoration
224143178|NCT01671722|DRUG|Montelukast sodium|Montelukast sodium tablets 10mg
224143179|NCT01736254|DRUG|Evacetrapib|
224143180|NCT01736254|DRUG|Gemfibrozil|
224143181|NCT00165581|DEVICE|High Dose Intracavitary Brachytherapy|
224048305|NCT01670539|DEVICE|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
224048306|NCT01444482|BIOLOGICAL|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
224048307|NCT01444482|BIOLOGICAL|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
223437315|NCT05047731|DRUG|Antihypertensive medication|Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
223437316|NCT02535130|DEVICE|Positive expiratory pressure|
223437317|NCT02535130|DRUG|amikacine nebulization|
223437318|NCT05330702|DEVICE|Xenogeneic Volume-Stable Collagen Matrix (VCMX) graft No Intervention: No Soft Tissue Augmentation|Fibro-gide is the VCMX
223437319|NCT05330702|PROCEDURE|Tuberosity Connective Tissue Graft (CTG)|CTG will be taken from the patient's own mouth
223437320|NCT05222022|DEVICE|Retitrack|Retitrack device measures and analyzes eye movement
223437321|NCT03535454|OTHER|working hours|weekly working hours
223437322|NCT03471728|DRUG|linaclotide|Oral
223437323|NCT02974920|DRUG|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
223437324|NCT02974920|DRUG|Aspirin|Aspirin 100 mg once daily for 180 days
223437325|NCT06619678|DRUG|MK-8507|Oral administration
223437326|NCT06619678|DRUG|Islatravir|Oral administration
223437327|NCT05519137|DEVICE|Active lighting intervention|Lighting intervention designed to impact the circadian system
223566375|NCT04802512|PROCEDURE|validity and reability study|validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
224048308|NCT01684072|BIOLOGICAL|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
223566376|NCT05818917|DRUG|FHND5071|"The proposed starting dose is 40 mg FHND5071 once daily (QD) orally (PO). For the purposes of this study treatment cycles will be 28 days or 4 weeks.~FHND5071 will be administered orally in the morning following a fast of approximately 10 hours before dosing on PK collection days. Subjects will continue to fast for approximately 4 hours after the administration of FHND5071. On non-PK days the subjects will fast approximately 2 hours before FHND5071 and continue to fast for approximately 2 hours afterwards.~Other dosing regimens may be considered based on the analysis of emerging PK, progressive disease, and/or safety data."
224048309|NCT01684072|BIOLOGICAL|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
224048310|NCT06075342|BEHAVIORAL|exercise|Exercise intervention according to the training program
224048311|NCT04353596|DRUG|ACE inhibitor, angiotensin receptor blocker|In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.
223566377|NCT00273520|DRUG|Telithromycin|
223740742|NCT00455429|DRUG|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
223437328|NCT05519137|DEVICE|Control lighting intervention|Lighting intervention designed to have no impact on the circadian system
223437329|NCT04491747|DIAGNOSTIC_TEST|functional capacity|Six minute walk test used assessment of functional capacity.
223437330|NCT03809377|PROCEDURE|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
223437331|NCT00475345|BEHAVIORAL|Bedtime snacks|
223437332|NCT06128291|PROCEDURE|posterior colporrhaphy|posterior colporrhaphy for rectocele.
223437333|NCT00718380|DRUG|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
223740743|NCT00455429|DRUG|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
223740744|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
223740745|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
223740746|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
223437334|NCT04514744|PROCEDURE|Knee bracing|Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.
223437335|NCT04514744|OTHER|Unilateral Resistance Exercise Training|Participants will perform resistance training on 4 occasions throughout an 8 day time period.
223437336|NCT02222831|PROCEDURE|Day 0 denudation and time lapse culture on IVF-oocytes.|
223437337|NCT03467763|DRUG|Metformin Extended Release Oral Tablet|Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
223437338|NCT03467763|DRUG|Placebo oral capsule|Placebo capsule
223437339|NCT04106050|DRUG|BIIB095|Administered as specified in the treatment arm.
223437340|NCT04106050|DRUG|BIIB074|Administered as specified in the treatment arm.
223437341|NCT04106050|DRUG|Placebo|Administered as specified in the treatment arm.
224048312|NCT01599520|BEHAVIORAL|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
224048313|NCT01599520|BEHAVIORAL|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
224048314|NCT01688128|DEVICE|Phase I U-SMART (4 wks)|Intervention\_Control Group, 4-weeks U-SMART(2 session/week); Control\_Intervention Group, no intervention
224048315|NCT01688128|OTHER|Washout (2 wks)|2-weeks wash out period in both arms
224048316|NCT01688128|DEVICE|Phase II U-SMART (4 wks)|Intervention\_Control Group, no intervention; Control\_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
224048317|NCT05418673|DRUG|BIIB122|Administered as specified in the treatment arm.
224048318|NCT05418673|DRUG|BIIB122-Matching Placebo|Administered as specified in the treatment arm.
224048319|NCT05088642|DRUG|Hetrombopag Olamine Tablet|Hetrombopag Olamine Tablet
224048320|NCT01141114|OTHER|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
224048321|NCT01141114|OTHER|Usual care|Usual care
224048322|NCT02603770|DRUG|XueZhiKang|
224048323|NCT02603770|DRUG|Lovastatin|
224048324|NCT02463721|OTHER|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
224143182|NCT06460636|OTHER|progressive muscle relaxation therapy|Participants will undergo progressive relaxation exercises, including muscle tension and release with deep breathing, held for 5 seconds each. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall
224143183|NCT06460636|OTHER|aquatic therapy|participants will receive aquatic therapy. Sessions will be conducted twice a week for 8 weeks and duration will be 30 minutes. 16 sessions overall.
224143184|NCT02559206|DRUG|Linaclotide|Oral, once daily
224143185|NCT02559206|DRUG|Matching Placebo|Oral, once daily
224143186|NCT01647659|DRUG|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
224143187|NCT01647659|DRUG|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
224143188|NCT01478152|OTHER|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
224143189|NCT00754728|DEVICE|JACTAX DES|Drug Eluting Stent
224143190|NCT00093678|DRUG|celecoxib|
223437342|NCT04106050|DRUG|Lidocaine|Administered as specified in the treatment arm.
223740747|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
223740748|NCT03439670|DRUG|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
224048325|NCT05224063|DEVICE|Individualized CEN-targeted rTMS|Delivers patterned magnetic stimulation based on individualized CEN targeting
224048326|NCT05224063|DEVICE|Neuronavigated rTMS|Delivers patterned magnetic stimulation based on MRI images
224048327|NCT05224063|DEVICE|Scalp-targeted rTMS|Delivers patterned magnetic stimulation based on BEAM F3 targeting
224048328|NCT05224063|DEVICE|Sham rTMS|Delivers placebo magnetic stimulation
224048329|NCT05488600|BEHAVIORAL|Executive Function Assessment|Digit Span (Forward and Backward) Test, Stroop Test, Trail Making Test A and B forms, Tower of London Test were used to evaluate executive functions.
224048330|NCT00490178|DRUG|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
224143191|NCT00093678|PROCEDURE|anticachectic therapy|
224143192|NCT00093678|PROCEDURE|nutritional support|
224143193|NCT00093678|PROCEDURE|pain therapy|
224143194|NCT00093678|PROCEDURE|supportive care/therapy|
224143195|NCT01561560|DEVICE|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
224143196|NCT01561560|DEVICE|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
224143197|NCT06754189|DEVICE|Time Limited stimulation|The participant self-administer 30 min. of electrical stimulation using Time Limited stimulation to the dorsal genital nerve (DGN) for 6 weeks using UCon with the UCon-Patch electrode.
224143198|NCT06754189|DEVICE|Sham stimulation|The participant self-administer 30 min. of sham stimulation to the dorsal genital nerve (DGN) for 6 weeks using a sham device with the UCon-Patch electrode.
224143199|NCT00004986|DRUG|Nitazoxanide|
224143200|NCT04767919|PROCEDURE|Standard Percutaneous Nephrolithotomy (sPCNL)|Endoscopic stone procedure using a laser placed in the kidney through an 30 Fr access sheath following balloon dilation.
224143201|NCT04767919|PROCEDURE|Minimally Invasive Percutaneous Nephrolithotomy (MIP)|Endoscopic stone procedure using a laser placed in the kidney through an 18 Fr access sheath following either balloon dilation or dilation using a single step metal dilator.
224143202|NCT06812520|BEHAVIORAL|Educational intervention in adherence|An educational intervention of 4 face-to-face sessions will be carried out as a complement to the care provided by professionals to users with venous ulcers, which consists of the advanced healing procedure that includes compressive bandaging of the venous ulcer.
224143203|NCT02024204|DRUG|Fluticasone propionate 230mcg for 3 Months|
224048331|NCT04492098|DIAGNOSTIC_TEST|MAIT cells|1- Decidual tissues will be washed in phosphate buffer saline (PBS), and then preserved in Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin and 5% fetal bovine serum (GIBCO BRL, Thermo Fisher Scientific, USA) until transfer to the laboratory. At the flow cytometry laboratory, the tissue samples will be minced finely and enzymatically digested by adding 3 ml collagenase enzyme type Ia and 2 ml PBS for 40 minutes at 37°C in shaking water path at 100 r.p.m. Cell suspensions obtained will be filtered, then the pellet after centrifugation will be treated with red blood cells lysing solution and washed with PBS.
224048332|NCT04717518|OTHER|Measurement of Pain|Patients will fill out a brief survey concerning the current visit to the ED.
224048333|NCT00659568|DRUG|metformin hydrochloride|
223437343|NCT06451796|DEVICE|Obtinu|Treatment of Female Stress Incontinence with a hydrophilic coated valved intraurethral catheter
223740749|NCT03439670|OTHER|Placebo|Oral administration of placebo daily for 24 weeks.
224048334|NCT00659568|DRUG|temsirolimus|
224048335|NCT02475070|DRUG|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
224048336|NCT02475070|DRUG|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
224048337|NCT03568474|DRUG|Silver Diamine Fluoride|Indirect pulp capping material
224048338|NCT03568474|DRUG|Glass Ionomer|Indirect pulp capping material
224048339|NCT02558114|DRUG|Ribavirin|
224048340|NCT02665052|DEVICE|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
224048341|NCT02665052|DEVICE|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
224048342|NCT02665052|BEHAVIORAL|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
224143204|NCT02024204|DRUG|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
224143205|NCT02024204|DRUG|Salmeterol 21mcg for 3 Months|
224143206|NCT07091162|OTHER|CTCA results|Participants who are assigned to CTCA group will receive their CTCA results
224143207|NCT07091162|OTHER|PRS results|Participants who are assigned to PRS group will receive their PRS results
224143208|NCT05506553|DEVICE|Intervention arm - Eyhance Toric II Intraocular Lens|Bilateral cataract extraction and insertion of Eyhance Toric II Intraocular Lens
224143209|NCT05506553|DEVICE|Control Arm - Alcon IQ Toric Intraocular lens|Bilateral cataract extraction and insertion of Alcon IQ Toric Intraocular Lens
223437344|NCT00989456|BEHAVIORAL|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
223437345|NCT00989456|BEHAVIORAL|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
223740750|NCT03439670|DRUG|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
223740751|NCT03439670|DRUG|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
224048343|NCT05415475|BIOLOGICAL|CEA CAR-T cells|Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
224048344|NCT00823823|OTHER|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
224048345|NCT00823823|OTHER|Circumferential cast|Circumferential cast will be applied following closed reduction
224048346|NCT00082524|DRUG|caspofungin acetate|Duration of Treatment - 7-90 days
224048347|NCT00066768|DRUG|suramin|Given IV
224048348|NCT00066768|DRUG|docetaxel|Given IV
224048349|NCT00066768|DRUG|gemcitabine hydrochloride|Given IV
224048350|NCT00066768|OTHER|laboratory biomarker analysis|Correlative studies
224048351|NCT00066768|OTHER|pharmacological study|Correlative studies
224048352|NCT02793440|OTHER|cortivazol treatment|
224048353|NCT02793440|OTHER|lumbar traction|
224048354|NCT02234284|BEHAVIORAL|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
223437346|NCT04109937|RADIATION|External beam radiation therapy|The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
223437347|NCT02231593|OTHER|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
223437348|NCT06128785|DEVICE|Electroacupuncture group|Acupoint: bilateral Hegu (LI4), Zhigou (SJ6), Zusanli (ST36), Shangjuxu (ST37). All acupoints will be taken by tonifying method after obtaining qi, and unilaterally connected to an electroacupuncture instrument for electrical stimulation with a continuous wave frequency of 5 Hz and a stimulation intensity as tolerated by the patient for 30 min each time. Acupuncture stimulation was given every 12 h. The duration of treatment was from postoperative to the fourth postoperative day (d0-d4) or until the patient's first postoperative anal exhaust or until the fourth day.
223437349|NCT06128785|OTHER|Sham EA group|Sham acupuncture needle will have the same appearance as the traditional needle, with a blunt tip (Suzhou Medical Supplies Factory, specification 0.25×40mm), lifting and inserting and twisting, but not piercing the adhesive pad. The output wire of the special sham electroacupuncture apparatus is cut in the middle, and the appearance is as usual; that is, the electroacupuncture apparatus shows an on state, but is not actually energized; the electroacupuncture points, acupuncture time points, frequency, retention time, and duration of treatment are the same as the intervention group, and the patients are informed that it is an effective light current input and may not feel stimulation, but the current is output.
223437350|NCT01615211|DRUG|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
223437351|NCT01615211|DRUG|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
223437352|NCT01366859|DIETARY_SUPPLEMENT|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
223437353|NCT01366859|DIETARY_SUPPLEMENT|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
223437354|NCT02407054|DRUG|LY3023414|Administered orally
223437355|NCT02407054|DRUG|Enzalutamide|Administered orally
223437356|NCT02407054|DRUG|Placebo|Administered orally
223740752|NCT06069960|PROCEDURE|sequential adult left lateral lobe liver transplantation (SALT)|Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
224048355|NCT01659242|DRUG|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
223437357|NCT03195647|DRUG|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
223437358|NCT03376347|DEVICE|FlotracIQ with HPI algorithm|FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
223437359|NCT05097547|BEHAVIORAL|Contingency Management|Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
223437360|NCT01091545|RADIATION|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
223437361|NCT04656197|OTHER|Ocular microbiome|Taxonomical and functional characterization of the ocular microbiome
223437362|NCT02039973|BEHAVIORAL|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
223437363|NCT02039973|BEHAVIORAL|Enhanced standard of care|
223437364|NCT02826265|DEVICE|multiple breath washout test (MBW)|
223437365|NCT02826265|DEVICE|impulse oscillometry (IOS)|
223437366|NCT02826265|DEVICE|body plethysmography (BP)|
223437367|NCT02826265|DEVICE|quantitative computed tomography (qCT)|ultra-low-dose qCT
223437368|NCT00131365|DEVICE|ExAblate 2000|
223740753|NCT00431210|BIOLOGICAL|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
224048356|NCT01659242|DRUG|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
224048357|NCT05240911|DRUG|Levothyroxine Sodium Tablets|For patients in experimental group, initial levothyroxine dose is calculated through the Poisson regression model; and for patients in comparator group, initial levothyroxine dose is calculated through 1.6 ug/kg/d.
224048358|NCT01835015|DRUG|CLG561|Administered by intravitreal injection, Day 1
224048359|NCT02330887|OTHER|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
224143210|NCT04643223|OTHER|kinesio tape with tension|The application of kinesio tape follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following the application of kinesio tape, with tension between seventy to ninety percent on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
224143211|NCT04643223|OTHER|kinesio tape without tension|The application of kinesio tape without tension follows a protocol, which involves the sanitization of the selected scar with liquid soap, drying and application of alcohol to remove sebum. Measurement of the scar and marking of the therapeutic zone and anchors. Following application of the kinesio tape, no tension on the treated hypertrophic scar. This process follows the routine of patient care established by the service and will continue for a period corresponding to three months. In which, the evaluations of Vancouver, the collections of cicatricial material will be carried out, in the time spaces corresponding to forty-five and ninety days, having as reference the initial evaluation made after being elected.
224143212|NCT03170557|OTHER|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
223740754|NCT01165554|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
224143213|NCT03170557|OTHER|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
224143214|NCT04829955|OTHER|Eccentric manual resistance training|Eccentric bodyweight resistance training
224143215|NCT04829955|OTHER|Concentric manual resistance resistance training|Concentric bodyweight resistance training
224143216|NCT01871896|DEVICE|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
224048360|NCT02330887|OTHER|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
224048361|NCT02242084|DRUG|Intravenuse Alteplase|
224048362|NCT01667770|PROCEDURE|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
224048363|NCT03044938|DRUG|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
224048364|NCT03044938|DRUG|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
224143217|NCT03203889|BEHAVIORAL|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
224143218|NCT03203889|BEHAVIORAL|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
224143219|NCT01017822|BIOLOGICAL|conatumumab|
224300179|NCT04236570|DEVICE|TENS(transcutaneous electrical nerve stimulation)|TENS protocol will consisted of test stimulus (TS) and conditioning stimulus (CS) both generated by TENS
223740755|NCT06072950|OTHER|Usual care|Patients received usual care
223740756|NCT02951156|BIOLOGICAL|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
224143220|NCT01017822|DRUG|capecitabine|
224143221|NCT01017822|DRUG|gemcitabine hydrochloride|
224143222|NCT01017822|RADIATION|3-dimensional conformal radiation therapy|
224143223|NCT02415439|DRUG|VBP15|
224143224|NCT02415439|DRUG|Placebo|
224143225|NCT05466266|DEVICE|ICE|All patients received ICE examination.
224300180|NCT00073242|DRUG|Leptin|leptin administration
224300181|NCT00073242|BEHAVIORAL|Dietary modification|Subjects lose 10% of body weight via dietary restriction
223740757|NCT02951156|BIOLOGICAL|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
223740758|NCT02951156|BIOLOGICAL|Rituximab|CD20-directed cytolytic antibody
223740759|NCT02951156|OTHER|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
224048365|NCT06290349|DRUG|DA5221-T1|DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks
224048366|NCT06290349|DRUG|DA5221-T2|DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks
224048367|NCT06290349|DRUG|Placebo|DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks
224048368|NCT06290349|DRUG|DA5221-B1|DA5221-B1, orally, daily for background therapy
224048369|NCT06290349|DRUG|DA5221-B2|DA5221-B2, orally, daily for background therapy
224048370|NCT04973982|DRUG|Envarsus|3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
224048371|NCT04973982|DRUG|Adoport|3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
224048372|NCT03923556|DRUG|Sugammadex|Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
224143226|NCT05466266|DEVICE|TEE|All patients received TEE examination.
224143227|NCT04557254|DEVICE|graft|evaluate the early and long-term clinical results, up to 5 years (through follow-up outpatient visits), of a silver and triclosan knitted collagen coated polyester vascular graft (InterGard Synergy), in patients submitted to aortic surgical repair, and compare them with concurrent results of standard Dacron grafts.
224143228|NCT05912920|PROCEDURE|gastric band|gastric band
224300182|NCT00073242|DRUG|T3 repletion|administer T3
224300183|NCT03822832|DRUG|BI 655130|Solution for infusion
224300184|NCT03822832|DRUG|Placebo|Solution for infusion
224300185|NCT06174870|OTHER|Inspiratory muscle training|Inhale against 60% of Maximal inspiratory pressure 30breaths/day 5days/week for 6 weeks
224048373|NCT03923556|DRUG|Neostigmine|Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
224048374|NCT02887664|PROCEDURE|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
224048375|NCT06261073|DIAGNOSTIC_TEST|blood sample and tissue biopsy|Serum level of Cathepsin L: 3 cm of blood will be taken on EDTA tubes from patients and control subjects and will be analyzed by double antibody sandwich enzyme-linked immune-sorbent assay (ELISA) to assess the level of CTSL in blood samples. Tissue expression of Cathepsin L: 5 mm punch biopsies will be taken under local anesthesia from lesions and from the adjacent normal skin of patients (from the lesional and peri-lesional sites). Also, skin biopsy of normal skin will be taken from healthy volunteers. The specimen of skin will be immediately placed in a formalin saline, and then immune-histochemical evaluation will be done to evaluate the CTSL expression in tissue.
224048376|NCT05840926|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12|Oral 1 billion CFU of Probiotic Streptococcus salivarius K12
224048377|NCT05840926|OTHER|No probiotic supplementation|Children who did not receive any probiotic supplementation
224143229|NCT02497872|PROCEDURE|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
224143230|NCT06088407|DRUG|with Tranexamic acid|Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
224143231|NCT01248494|DRUG|BEZ235|"* Dose level 1: 400mg PO BID~* Dose level -1: 400mg PO in AM and 200mg PO in PM~* Dose level -2: 200mg PO BID"
224143232|NCT01248494|DRUG|BKM 120|"* Dose Level 1: BKM120, 100 mg PO daily~* Dose level -1: BKM120, 80 mg PO daily~* Dose Level -2: BKM120, 60 mg PO daily"
224143233|NCT01248494|DRUG|Letrozole|All levels: 2.5mg/day PO
224300186|NCT05070871|DIETARY_SUPPLEMENT|Hydrolyzed Collagen|Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.
223437369|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-normal version|Mindfulness Intervention for Emotional Distress (MIED) program provides standard audio instructions for mindfulness exercises, introduces the nature and law of anxiety, depression, and other emotions, the source of anxiety, depression, and other emotional distress, and the strategies and methods to alleviate emotional distress. These exercises, knowledge and strategies are based on the latest progress in the field of psychological counseling and treatment, and their application in daily life can help alleviate anxiety, depression and other emotional problems.
224143234|NCT01248494|DRUG|BKM120|"* Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~* Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~* Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
224143235|NCT01046383|DIETARY_SUPPLEMENT|IMN1207|20 grams of IMN1207 per day for 40 weeks.
224143236|NCT01046383|DIETARY_SUPPLEMENT|Casein|20 grams of Casein per day for 40 weeks
224143237|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
224143238|NCT00800865|OTHER|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
224143239|NCT05958615|BEHAVIORAL|Reimagining Us in the Context of Bariatric Surgery (ReConnect)|ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
224143240|NCT06076148|DEVICE|Virtual reality games|three individual games (physical, cognitive and relaxation) and two multiplayer games will be tested.
224143241|NCT05844865|OTHER|Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)|Subjects with a known diagnosis of GI primary tumor with or without PC, with a planned standard of care surgery.
224300187|NCT05070871|OTHER|Placebo|Pure maltodextrin.
224300188|NCT05070871|DIETARY_SUPPLEMENT|CalGo|CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
224300189|NCT05219461|DRUG|Single dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
224300190|NCT05219461|DRUG|Single dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
224300191|NCT05219461|DRUG|Single dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
223740760|NCT02951156|DRUG|Bendamustine|Alkylating drug
224048378|NCT00097747|DRUG|Placebo|
224048379|NCT00097747|DRUG|peginesatide|
224048380|NCT06005337|BEHAVIORAL|Blogshots 1-3|"1. Don't routinely do a throat swab when children present with a sore throat if they have a cough, rhinitis, or hoarseness~2. Don't recommend the use of cough and cold remedies in children under six years of age~3. Don't use antibiotics for acute asthma exacerbations without clear signs of bacterial infection"
224048381|NCT06005337|BEHAVIORAL|Blogshots 4-6|"1. Don't routinely use antibiotics in children with uncomplicated sore throats~2. Don't prescribe antibiotics in adults with bronchitis/asthma and children with bronchiolitis~3. Don't use antibiotics in adults and children with uncomplicated acute otitis media"
224048382|NCT00352287|DRUG|Recombinant human growth hormone; pioglitazone|
223437370|NCT06622122|BEHAVIORAL|Mindfulness Intervention for Emotional Distress(MIED)-increase cognitive flexibility|Increase the intervention dose of cognitive flexibility in Mindfulness Intervention for Emotional Distress (MIED). For example, including more cognitive reappraisal practice, psychoeducational content and practice about regarding thoughts just as thoughts.
223437371|NCT04608344|DRUG|Atorvastatin|Administered as single dose tablet orally.
223437372|NCT04608344|DRUG|Pravastatin|Administered as single dose tablet orally.
223437373|NCT04608344|DRUG|Rosuvastatin|Administered as single dose tablet orally.
223437374|NCT04608344|DRUG|Filgotinib|Administered as tablet orally once daily for 11 days.
223437375|NCT02781181|DEVICE|CAS with CPD|using a neuroprotection device
223437376|NCT02781181|OTHER|CAS without CPD|No Neuroprotection
223437377|NCT00645281|DRUG|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
224048383|NCT06396091|DRUG|zolbetuximab|Zolbetuximab will be administered intravenously on day 1 then every two weeks.
224048384|NCT06396091|DRUG|mFOLFIRINOX|Modified oxaliplatin, leucovorin, irinotecan and fluorouracil (mFOLFIRINOX) will be administered intravenously within 2 days after administration of zolbetuximab.
224048385|NCT01202851|OTHER|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
224048386|NCT01202851|BEHAVIORAL|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
224048387|NCT01202851|OTHER|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
224048388|NCT00550654|OTHER|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
224048389|NCT00550654|RADIATION|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
224048390|NCT00550654|RADIATION|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
224048391|NCT00550654|RADIATION|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
224048392|NCT00550654|RADIATION|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
224048393|NCT06016179|DRUG|Tocilizumab|Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
224048394|NCT03406299|DRUG|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
224048395|NCT03406299|DRUG|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
223437378|NCT04888403|DRUG|Toripalimab+Nedaplatin+Albumin Paclitaxel|"Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel"
223437379|NCT00058084|DRUG|ixabepilone|Given IV
223437380|NCT00058084|DRUG|mitoxantrone hydrochloride|Given IV
224300192|NCT05219461|DRUG|Multiple dose of rhEGF 10mcg/ml or placebo|6 subjects will be assigned to rhEGF 10mcg/ml eye drop and 2 subjects will be assigned to placebo
223437381|NCT00058084|DRUG|prednisone|Given orally
223437382|NCT00846703|DRUG|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd~Methotrexate p.o. qw"
223437383|NCT00846703|DRUG|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)"
223437384|NCT05545020|DRUG|Trivalent chromium versus synthetic and/ or biological DMARDs|Supplement and immunesuppressants
223437385|NCT04533191|PROCEDURE|LAL IOL lens|Standard of care Cataract surgery with IOL placement
223437386|NCT02549976|PROCEDURE|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
223437387|NCT02549976|PROCEDURE|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
223437388|NCT02549976|PROCEDURE|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
223437389|NCT02549976|PROCEDURE|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
223437390|NCT02044874|DRUG|APD356-lorcaserin hydrochloride|
223437391|NCT02044874|DRUG|Placebo|
223437392|NCT05531305|DEVICE|Muscle ultrasound|Standardized ultrasonographic measurement of quadriceps muscle layer thickness.
223437393|NCT05531305|DEVICE|Indirect calorimetry|Non-invasive measurement of resting energy expenditure using the Q-NRG metabolic monitor with hood and canopy.
223437394|NCT05531305|DIAGNOSTIC_TEST|Hand dynamometry|Assessment of handgrip strength using hand dynamometry.
223740761|NCT02951156|DRUG|Gemcitabine|Nucleoside analogue
224048396|NCT03406299|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
224048397|NCT03406299|DRUG|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
224048398|NCT03406299|DRUG|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
224048399|NCT01125449|DRUG|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
224048400|NCT04762316|DRUG|SB-UF|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
223437395|NCT05531305|DIAGNOSTIC_TEST|MRC Sum Score|Assessment of muscle function/limb strength using the Medical Research Council sum score (12-60 points).
223437396|NCT00415597|DRUG|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
223437397|NCT00389298|DRUG|VCH-759 (BCH-27759)|
223437398|NCT04506398|PROCEDURE|liver transplant|Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
223437399|NCT04506398|DIAGNOSTIC_TEST|ctDNA|Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
223437400|NCT04506398|DIAGNOSTIC_TEST|whole exome sequencing|xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
223437401|NCT06512454|OTHER|No Intervention|This is a non-interventional study.
224048401|NCT04762316|DEVICE|SB-UF Placebo|"Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy."
224143242|NCT02306174|BEHAVIORAL|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|"The group sessions consists of 20 classes, each lasting approximately 90 minutes and may consist of some or all of the following:~* A group agreement and a confidentiality contract~* Homework assignments~* Viewing informational videos about hoarding~* Behavioral experiments including sorting and discarding exercises~* Non-acquisition exposures~This course is based on the Manual Cognitive Rehabilitation and Exposure/Sorting Therapy for Compulsive Hoarding (Ayers et al., 2014)."
224143243|NCT06234059|DEVICE|TMS|This paradigm uses theta-burst transcranial magnetic stimulation (tbTMS) to modulate the excitability of sensory cortices to examine the effect on sensory acuity and sensorimotor adaptation. Participants will complete three total sessions targeting primary somatosensory cortex (S1): one using intermittent theta-burst stimulation (iTBS), one using continuous theta-burst stimulation (cTBS), and one with sham stimulation.
224143244|NCT06234059|BEHAVIORAL|Speaking Tasks|Participants will produce four training words under a vowel centralization feedback paradigm in which auditory feedback is altered. The investigators will measure changes in produced vowels as a result of the altered feedback in concert with the different stimulation regimes described in the TMS intervention.
224143245|NCT04020055|DRUG|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
224143246|NCT05220410|DRUG|Psilocybin|Open-Label
224143247|NCT06074068|BEHAVIORAL|Fathers for Change|18 week individual therapy focused on fathers' emotion regulation, reflective functioning and family communication.
224143248|NCT06074068|BEHAVIORAL|Duluth BIP|18 week individually delivered psychoeducation and CBT focused program focused on intimate partner violence
224143249|NCT01512108|DRUG|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
224048402|NCT06574880|DRUG|Lu-PSMA-617|"Lu-PSMA will be administered at a fixed dose of 7.4GBq per cycle, on a dose escalation schedule:~* Level 0: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT.~* Level 1 (Starting Dose Level): Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2.~* Level 2: Lu-PSMA-617 for 1 cycle, followed 6 weeks later by SBRT, followed 6 weeks later by cycle 2, followed 6 weeks later by cycle 3."
224048403|NCT06574880|RADIATION|5-fraction Stereotactic Body Radiation Therapy (SBRT)|Prostate and nodal SBRT will begin at the completion of cycle 1 (6 weeks after the first Lu-PSMA-617 infusion, ± 4 weeks).
224143250|NCT01512108|DRUG|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
224143251|NCT03488628|OTHER|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours
224143252|NCT03488628|OTHER|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher \& Paykel Healthcare,New Zealand) through nasal canula.
224143253|NCT05984199|BIOLOGICAL|VCAR33|Allogeneic Anti-CD33 Chimeric Antigen Receptor (CAR) T Cell therapy
224143254|NCT02373371|DRUG|Metvix®|
224143255|NCT02373371|PROCEDURE|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
224143256|NCT02373371|PROCEDURE|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
224143257|NCT05446298|DRUG|ONC-392|ONC-392 will be given by IV infusion, q3w.
224143258|NCT05446298|DRUG|Pembrolizumab|Pembrolizumab in fixed dose of 200 mg will be given by IV infusion, q3w.
224143259|NCT01539811|PROCEDURE|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
224143260|NCT01539811|DRUG|Short course antibiotics|Short course (\<2 weeks) of antibiotics will be prescribed
224143261|NCT01539811|DRUG|Long course antibiotics|Long course (\>2 weeks) of antibiotics will be prescribed
224143262|NCT00219518|PROCEDURE|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
224143263|NCT06147713|DEVICE|Vibrotactile foot device (Smart shoe)|A foot device deliver vibrotactile stimulation triggered by a foot pressure sensor.
223437402|NCT01447927|DRUG|metformin hydrochloride|Given PO QD and BID
223437403|NCT01447927|OTHER|placebo|Given PO QD and BID
223437404|NCT06730776|OTHER|Topical medication|It will be given to all participants in both groups (A\&B). The most commonly prescribed topical medication is lidocaine ointment 5% (Xylocaine jelly 2% or ointment 5%; AstraZeneca Pharmaceuticals LP, Wilmington, DE), applied as required for symptoms and for 30 minutes before sexual activity.
223740762|NCT02951156|DRUG|Oxaliplatin|Platinum-based drug
223740763|NCT01427894|OTHER|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
224048404|NCT03128567|DEVICE|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
223437405|NCT06730776|OTHER|Transcutaneous electrical acupoint stimulation|This procedure will be applied for group B only. Before starting the first treatment session, each patient will be instructed briefly about the nature of the treatment to gain the patient's confidence and cooperation. This procedure will be performed by using TENS device on acupoints as the following: The participating woman will be placed in a relaxed comfortable supine position with her back well supported. The surface of the treated skin and the electrodes will be cleaned with alcohol wipe. The TENS protocol consists of a 30-minute weekly. session for 10 weeks of biphasic pulses with modulation 0/10-50 Hz of frequency and 300/100/3000 microseconds of pulse duration (s). The intensity parameter will be adapted individually according to each woman's perception, and modulated so that it is applied without discomfort, ranging between 10 and 100 mA (pulsing sensation) (Dionisi and Senatori ,2011)
223437406|NCT04005144|DRUG|Binimetinib|Given PO
223437407|NCT04005144|DRUG|Brigatinib|Given PO
223437408|NCT00222482|DRUG|Depakote ER|
223437409|NCT01043562|DIAGNOSTIC_TEST|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
223437410|NCT01043562|OTHER|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole \>4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a \>10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
223437411|NCT04102865|DEVICE|Negative-Pressure Wound Therapy (NPWT)|Investigational single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 7 days.
223437412|NCT06648291|DEVICE|QOCA EKG Device|The investigators scheduled telephone interviews every three days to encourage and monitor the development of good self-health care behaviors by: (1) asking about daily blood pressure, weight, and lower extremity edema; (2) providing medication counseling, as well as exercise and dietary hygiene recommendations; (3) offering wound care guidance; (4) advising on the proper use of wounds; (5) advising on avoiding cardiac risk factors such as smoking and secondhand smoke; and (6) following up on physical status at outpatient clinics and assisting with referrals to relevant clinics, such as nutrition or rehabilitation, based on the patient's condition. A QOCA portable electrocardiogram (ECG) measurement device will be provided for patients to use at home. In the event of abnormal physiological values, the investigator will contact the patient to assess his or her medical status and provide 24-hour online counseling.
223437413|NCT06648291|OTHER|Usual Care|Provide post-operative education on the day of discharge and follow up with a phone call one week after discharge to check on the patient.
223437414|NCT02063048|BEHAVIORAL|Text Message Based Weight Loss Support|
223744851|NCT06238232|DIAGNOSTIC_TEST|68Ga-Pentixafor PET/CT|The patients had a normal diet with no special preparation before 68Ga-Pentixafor PET/CT imaging. The dosage of intravenously injected 68Ga-Pentixafor was calculated based on the patient's weight (1.85 MBq \[0.05mCi\]/kg). Local PET/CT scanning of the upper abdomen was performed on a hybrid PET/CT scanner at 10 minutes after the injection of the intravenous tracer, respectively.
224048405|NCT05955391|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
224048406|NCT05133440|DRUG|Radium dichloride|Two cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks followed 2-3 weeks later by SBRT at a dose of 9 Gy per fraction for 3 fractions (total dose of 27 Gy) to all sites of radiographically apparent metastatic disease. SBRT fractions can be administered every day or every other day per institutional practice. An additional 4 cycles of Radium (Ra-223) dichloride at 55 kBq/kg or 0.00149 mCi/kg or 1.49 uCi/kg every 4 weeks will then be administered, resuming 2-3 weeks after completion of the final fraction of SBRT.
224048407|NCT05133440|DIAGNOSTIC_TEST|PET Scan|For both arms, the NaF PET will be used to identify discrete osseous lesions which will become index lesions for the study. The simulation scan (either baseline or after 2 cycles of Ra-223) will be used to generate a suitable SBRT radiation plan, per standard practice. If the index lesions are no longer visible after two cycles of Ra-223, we still intend to consolidate the area with radiation. If the lesions are initially radio-occult on the CT and only visible on the NaF PET, we will fuse the pre-treatment NaF PET/CT to the simulation CT after 2 cycles of Ra-223 to delineate the SBRT treatment volumes.
224048408|NCT05512247|BEHAVIORAL|Meal Delivery|10 home-delivered meals per week provided by a local meal delivery company + brief weekly behavioral support with study staff
224048409|NCT00215124|DRUG|Filgrastim|
224048410|NCT04329351|PROCEDURE|Guided Bone regeneration|Guided bone regeneration to ridge preservation
224048411|NCT03469583|DRUG|EYP001|EYP001 self administered capsules, morning, with non carbonated water
224143264|NCT00860418|BEHAVIORAL|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
224143265|NCT00860418|BEHAVIORAL|Standard asthma education|Standard asthma education during 2 home visits.
224143266|NCT00653913|DRUG|SCH 58235|SCH 58235 10 mg (once daily)
224143267|NCT00653913|DRUG|pitavastatin|Pitavastatin 2 mg (once daily)
224300193|NCT05219461|DRUG|Multiple dose of rhEGF 50mcg/ml or placebo|6 subjects will be assigned to rhEGF 50mcg/ml eye drop and 2 subjects will be assigned to placebo
224300194|NCT05219461|DRUG|Multiple dose of rhEGF 100mcg/ml or placebo|6 subjects will be assigned to rhEGF 100mcg/ml eye drop and 2 subjects will be assigned to placebo
223437415|NCT05531448|OTHER|two way texting|"Automated 2WT-based adherence support messages combined with scheduled visit reminders focus on preventing visit default will be implemented. One-way blast motivational support messages will be sent to all new ART patients who opt-into 2WT. ART visit reminders 3- and 1- day before visits will ask clients to respond with 1=attend and 0=no, triggering 2wT responses to clients to reschedule visits, record transfers, etc. 2WT clerks proactively communicate with clients before a visit to prevent default or ascertain true outcomes for those who don't return. Those who miss visits receive additional 2wT reminders. On day 14 post visit, 2wT patients who missed visits, did not respond to text or did not have outcomes updated (transfer, stop, etc.), are identified by the 2WT system and referred to B2C for tracing, days or months earlier than routine B2C. The 2wT-generated tracing list is more timely and accurate, reducing workload and increasing B2C effectiveness"
223437416|NCT03218319|BIOLOGICAL|Renin measurement|patients will have a blood sample for measuring renin activity
223437417|NCT00147784|DRUG|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
223437418|NCT00147784|DRUG|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
223437419|NCT00615979|DEVICE|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
223437420|NCT00223964|DRUG|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
223437421|NCT02910570|DRUG|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
224048412|NCT03469583|DRUG|Entecavir 1 MG|Entecavir self administered tablets, morning, with non carbonated water
224048413|NCT06155110|DRUG|cardiomyopeptidin|cardiomyopeptidin intervention group will accept cardiomyopeptidin (Dalian Zhenao Pharmaceutical Co., Ltd., approval number: National Drug Approval No. H20052173, specification: 20 mg/tube) 3 mg/(kg·d)；
224143268|NCT04752449|BEHAVIORAL|Virtual Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
224300195|NCT00334061|DEVICE|Penumbra System|
224300196|NCT00776165|BIOLOGICAL|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
223437422|NCT02910570|DRUG|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
223437423|NCT00493233|DRUG|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
223566378|NCT06362655|BEHAVIORAL|Intervention|Intervention study. In this intervention study for teachers, a 5-month continuous training program will be included that will improve teaching style and promote teaching training. It will also strengthen teaching competencies to create teaching improvement strategies affecting PEaH and interpersonal and personal factors. This is expected to improve schoolchildren's AB, even when they are not directly influenced. The program will be designed according to the results of the cross-sectional study. The greatest associations found between the three proposed factors (school, interpersonal and personal factors) and schoolchildren AB will be sought. In addition, the characteristics of the schools and the possibilities of time and physical spaces available will be taken into account. This information will be recorded through validated questionnaires and interviews in the pre-test, post-test 1 and after follow-up post-test 2.
223566379|NCT00535704|BEHAVIORAL|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
223566380|NCT00535704|BEHAVIORAL|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
223566381|NCT00599391|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
223566382|NCT00453115|DRUG|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
224300197|NCT00776165|BIOLOGICAL|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
223566383|NCT00453115|DRUG|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
223566384|NCT01480518|GENETIC|DNA analysis|
224048414|NCT04328948|RADIATION|Chemoradiotherapy|Chemoradiotherapy
223437424|NCT00493233|DRUG|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
223437425|NCT05745207|DRUG|E2086|E2086 tablets.
223437426|NCT05745207|DRUG|Placebo|E2086 matched placebo tablets.
224048415|NCT06330350|OTHER|Qualitative interview|Gaining insight into the perspectives of patients with genodermatoses and their partners, and health care professionals concerning reproductive decision-making and counselling.
224048416|NCT03884712|DEVICE|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
224048417|NCT05451563|DEVICE|Double-S|Wearable device for intercourse
224048418|NCT05362929|DEVICE|Sciton Halo|Laser treatment
223437427|NCT03966937|OTHER|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
223437428|NCT03966937|OTHER|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
224300198|NCT00153608|BIOLOGICAL|WT1 126-134 peptide|
223437429|NCT01764997|DRUG|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
223437430|NCT01764997|DRUG|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
223437431|NCT01764997|DRUG|Methotrexate|Dispensed according to local practice.
223437432|NCT01764997|DRUG|Placebo (for sarilumab)|
223437433|NCT01764997|DRUG|Placebo (for etanercept)|
223437434|NCT01764997|DRUG|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
223437435|NCT02895646|OTHER|Collection of blood sample|
223437436|NCT06909292|DEVICE|Sacroiliac Joint transfixing and fusion system (Nevro1)|The Nevro1 is a titanium cage the is implanted in the sacroiliac join from a posterior direction, and then anchors are deployed that stabilize the joint. It has multiple openings to allow surgeons to fill them with autogenous bone graft to encourage bone bridging through the implant for SIJ fusion.
223437437|NCT04237129|DRUG|Gan & Lee Insulin Aspart|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
223437438|NCT00621465|BEHAVIORAL|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
223437439|NCT00621465|BEHAVIORAL|Usual care|Usual care will include the standard aftercare and community care services.
223437440|NCT02386930|BEHAVIORAL|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
223437441|NCT03013296|OTHER|GIP-A|GIP-A
223437442|NCT03013296|OTHER|Placebo|Placebo
223566385|NCT01480518|GENETIC|comparative genomic hybridization|
223566386|NCT01480518|GENETIC|gene expression analysis|
223437443|NCT03013296|OTHER|GLP-1 receptor antagonist Exendin[9-39]|Exendin\[9-39\]
223437444|NCT03013296|OTHER|GIP-A + Exendin[9-39]|GIP-A + Exendin\[9-39\]
223437445|NCT01893580|BEHAVIORAL|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
223437446|NCT01893580|BEHAVIORAL|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~1. Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~2. Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
223437447|NCT01893580|BEHAVIORAL|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
223566387|NCT01480518|GENETIC|mutation analysis|
223566388|NCT01480518|GENETIC|polymerase chain reaction|
223566389|NCT01480518|GENETIC|polymorphic microsatellite marker analysis|
223566390|NCT01480518|OTHER|laboratory biomarker analysis|
223566391|NCT04841161|BEHAVIORAL|Balance function, gait ability, weight- distribution and weight-shifting|Healthy adults and stroke patients accepted two measurements within a week. Balance function, gait ability, weight- distribution and weight-shifting during sit-to-stand, quite standing, and weight-shifting toward the forward foot.
223566392|NCT04841161|BEHAVIORAL|Weight- distribution and weight-shifting training program|The stroke patients received a weight-shifting training program , 30 minutes/time, 2-5 days a week for 2-3 weeks(8 sessions). After training, they accepted a post-test within a week.
224300199|NCT00257218|BEHAVIORAL|Life style modification|
224300200|NCT04650152|DRUG|Tricor (fenofibrate), 145 mg, film-coated tablet|Observational study without intervention. Fenofibrate is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
224048419|NCT05827653|DRUG|NX210c|3 times a week, for 28 days
224048420|NCT05827653|DRUG|Placebo|3 times a week, for 28 days
224048421|NCT00536809|DRUG|lapatinib|onced daily Days 1-21
224048422|NCT00536809|DRUG|oxaliplatin|Day one of each cycle
224048423|NCT00536809|DRUG|capecitabine|given BID days 1-14
224048424|NCT00190827|DRUG|duloxetine|
224143269|NCT03135886|OTHER|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
224143270|NCT03135886|OTHER|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
224143271|NCT03135886|OTHER|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
224143272|NCT04669782|DIETARY_SUPPLEMENT|Vitamin K (MK7)|MK-7 will be administered at a dose of 375 microg / day
224143273|NCT04669782|DRUG|Teriparatide|Teriparatide will be administered as standard of care
224143274|NCT06422377|DRUG|Soticlestat|Soticlestat tablets or mini-tablets
224143275|NCT06794125|RADIATION|Hypofractionated Radiation Therapy|Hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy
224143276|NCT06794125|RADIATION|Radiation Therapy|standard of care palliative thoracic radiotherapy using volumetric modulated arc therapy/intensity-modulating radiotherapy
224143277|NCT06030362|DIETARY_SUPPLEMENT|Probiotic|Dietary Supplement taken once daily for 3 months (90 days).
224143278|NCT06030362|DIETARY_SUPPLEMENT|Placebo|Dietary Supplement taken once daily for 3 months (90days).
224300201|NCT04213352|OTHER|Wrist Splint|Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
223437448|NCT01893580|BEHAVIORAL|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at \~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at \~70-90% of individually determined HRmax. The intensity of the strength exercise program is at \~60-80% of 1 RM."
223437449|NCT00979524|BEHAVIORAL|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
223566393|NCT02019446|DEVICE|Laser Treatment YAG laser|YAG Laser / FOX Laser
224048425|NCT00190827|DRUG|placebo|
224048426|NCT05119218|OTHER|No Intervention|No Intervention
224048427|NCT04992962|DRUG|CBD/CBN|A water-soluble sublingual tablet containing 10 mg of CBD and 10 mg of CBN.
224048428|NCT04992962|DRUG|CBD/THC|A water-soluble sublingual tablet containing 10 mg of CBD and 5 mg of THC.
224048429|NCT04992962|DRUG|Placebo|An inactive compound.
224048430|NCT02441673|DRUG|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
224048431|NCT02441673|DRUG|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
224048432|NCT02441673|DRUG|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
224048433|NCT02441673|DRUG|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
224048434|NCT02441673|DRUG|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
224048435|NCT02441673|DRUG|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
224048436|NCT02441673|DRUG|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
224048437|NCT06399848|OTHER|Skip one day of peritoneal dialysis treatment|Skip one day of peritoneal dialysis treatment
224048438|NCT04956042|DRUG|Fosciclopirox|Fosciclopirox, 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle
224048439|NCT04956042|DRUG|Fosciclopirox + Cytarabine|"Fosciclopirox - 900 mg/m2 administered as a 20-minute IV infusion once daily on D1-D5 of each 21-day treatment cycle~Cytarabine - 1g/m2 once daily on D1-D5 of each 21-day treatment cycle"
224048440|NCT05857540|PROCEDURE|Plyometric and strengthening exercises|Each session includes 2 upper-extremity plyometric exercises in bodyweight or with weight ball for 15-20 minutes and 4-5 strengthening exercises with band, dumbbell or barbell for 30-35 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
224048441|NCT05857540|PROCEDURE|Strengthening exercise|Each session includes 5 upper-extremity strengthening exercises with band, dumbbell or barbell for 50 minutes. The difficulty of the movement protocol will increase weekly. They will be trained 2 times per week for 6 weeks with an average duration of 50 min per session.
224048442|NCT02912299|PROCEDURE|Skin biopsies|2 3mm skin biopsies will be taken
224048443|NCT02912299|OTHER|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
223437450|NCT06908941|DIETARY_SUPPLEMENT|dark chocolate|Participants consumed 85% dark chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.
224048444|NCT02912299|OTHER|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
224048445|NCT00217529|BIOLOGICAL|pegfilgrastim|
224048446|NCT00217529|DRUG|carboplatin|
224048447|NCT00217529|DRUG|docetaxel|
224048448|NCT00217529|DRUG|erlotinib hydrochloride|
224143279|NCT05536713|DEVICE|Guardant SHIELD blood-based colorectal cancer screening test|The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
224143280|NCT01726283|DEVICE|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
224143281|NCT01726283|DRUG|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
224143282|NCT03086681|DRUG|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
223437451|NCT06908941|DIETARY_SUPPLEMENT|milk chocolate|Participants consumed milk chocolate (1g/kg body weight) before high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles. Finger-toe pulse wave velocity (ftPWV), arterial stiffness, blood pressure, and plasma NO levels were measured at rest, 2 hours after chocolate consumption (baseline), immediately post-exercise (T0), and at 60 (T60) and 120 (T120) minutes post-exercise.
223437452|NCT06908941|BEHAVIORAL|high-intensity resistance exercise|Participants performed high-intensity resistance exercise during the early follicular (days 2-5) and mid-luteal (days 18-24) phases of two menstrual cycles.
223437453|NCT02921633|OTHER|Intervention letter|
223437454|NCT06182046|PROCEDURE|Complete decongestive treatment program|It consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
223437455|NCT06182046|PROCEDURE|Balance exercises|These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
224048449|NCT01219647|BEHAVIORAL|exercise|subjects will participate in one of two forms of exercise
224048450|NCT01219647|BEHAVIORAL|stretching|subjects will particiopate in supervised stretching as described in arm description.
224048451|NCT04638582|DRUG|Pembrolizumab|Neoadjuvant pembrolizumab 200 mg IV every 3 weeks, given on cycle day 1. Adjuvant pembrolizumab 400 mg IV every 6 weeks, given on cycle day 1.
223744852|NCT05615649|DEVICE|MED-EL BONEBRIDGE Bone Conduction Implant|Subjects will be implanted with the MED-EL BONEBRIDGE Bone Conduction Implant System. Subjects will be fit with the appropriate external audio sound processor.
223566394|NCT02019446|DRUG|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
224048452|NCT04638582|DRUG|Carboplatin|Carboplatin AUC 6 IV (maximum dose: 900 mg) for squamous cell carcinoma, and AUC 5 IV (maximum dose: 750 mg) for non-squamous cell carcinoma, every 3 weeks, given on cycle day 1.
224048453|NCT04638582|DRUG|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks, given on cycle day 1. Only given to participants with squamous cell carcinoma.
224048454|NCT04638582|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 every 3 weeks, given on cycle day 1. Only given to participants with non-squamous cell carcinoma.
224048455|NCT04005651|DEVICE|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
224048456|NCT04005651|DEVICE|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
224048457|NCT04005651|DEVICE|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
224048458|NCT03166163|DRUG|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
224048459|NCT03166163|DRUG|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
224048460|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 1|2 doses of study intervention are administered to participants intramuscularly.
224048461|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 2|2 doses of study intervention are administered to participants intramuscularly.
224048462|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 3.|2 doses of study intervention are administered to participants intramuscularly.
223566395|NCT01418131|DRUG|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
223566396|NCT01418131|DRUG|Placebo|Placebo
223437456|NCT03383900|DEVICE|Inspiratory muscle training|"The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 6 days a week for 8 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value."
223437457|NCT02505451|DRUG|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
223437458|NCT01650545|DRUG|Liposomal aerosol cyclosporine|inhaled form of immune suppression
223437459|NCT01650545|OTHER|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
223437460|NCT01264354|DRUG|Clevudine 30mg|Clevudine 30mg
223437461|NCT01264354|DRUG|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
223437462|NCT01264354|DRUG|Clevudine 20mg|Clevudine 20mg
223437463|NCT06649227|DRUG|CAR-T cell therapy|cyclophosphamide and fludarabin conditioning , followed by a target dose of 1 x 10exp6 of autologous, genetically modified, anti-CD19 CAR-T cells per kg of body weight.
223437464|NCT00001076|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
223437465|NCT00001076|BIOLOGICAL|ALVAC-RG Rabies Glycoprotein (vCP65)|
223437466|NCT00001076|BIOLOGICAL|rgp120/HIV-1 SF-2|
223437467|NCT00834730|DRUG|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
223437468|NCT01463267|DEVICE|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
223437469|NCT01463267|BEHAVIORAL|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
223437470|NCT06618625|PROCEDURE|nasotracheal intubation|"For nasotracheal intubation, the nasal RAE tube will be inserted with it rotated by 90 degrees in counter-clockwise direction for patients in the 'Rotation' arm.~For nasotracheal intubation, the nasal RAE tube will be inserted without tube rotation for patients in the 'Neutral' arm."
223437471|NCT01013623|PROCEDURE|Surgery|surgical resection to remove all known disease
223437472|NCT01013623|PROCEDURE|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
223566397|NCT04793230|DIAGNOSTIC_TEST|biopsying|The procedure was carried out under general or local anesthesia. An otolaryngologist conducts the endoscopic intranasal operation, while an eye surgeon removes tissue from the sac and lacrimal tubes using lacrimal probes passed through the canaliculi.
223566398|NCT04801433|OTHER|Boleda Supramolecular Active Zinc Conditioner|Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
224048463|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_ Dose level 4|2 doses of study intervention are administered to participants intramuscularly.
224048464|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 5|2 doses of study intervention are administered to participants intramuscularly.
224143283|NCT03086681|DRUG|DDP|DDP: 40mg /m2，per week, for 5 cycles
223566399|NCT04801433|DRUG|Capotetriol scalp solution|Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
223566400|NCT04801433|OTHER|Supramolecular Hydrogel|Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
223566401|NCT03305419|DRUG|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
224048465|NCT06382311|BIOLOGICAL|Flu Pandemic mRNA_Dose level 6|2 dose of study intervention is administered to participants intramuscularly.
224048466|NCT06382311|BIOLOGICAL|Influenza virus vaccine|2 doses of Influenza virus vaccine are administered to participants intramuscularly.
223437473|NCT01013623|OTHER|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
223437474|NCT05297084|PROCEDURE|non surgical periodontal therapy|Scaling and root planing
224048467|NCT06382311|DRUG|Placebo|2 doses of Placebo are administered intramuscularly to participants in Phase 1 and Phase 2 Part A and 2 dose is administered to participants in Phase 2 Part B.
224048468|NCT02868177|DIETARY_SUPPLEMENT|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
224048469|NCT02868177|DIETARY_SUPPLEMENT|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
224048470|NCT03607123|OTHER|programing of pacemaker|Different programing parameters will be set in different group/stage
224048471|NCT03607123|PROCEDURE|AF ablation|AF ablation can only be performed in Step 3
224048472|NCT03607123|DRUG|Anti arryhthmic drugs|Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
224048473|NCT01495858|DRUG|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
224048474|NCT01495858|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
224048475|NCT01495858|DRUG|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
224143284|NCT00412906|DRUG|Escherichia Coli Endotoxin|
223437475|NCT00737334|DEVICE|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
223437476|NCT03211429|BEHAVIORAL|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
223437477|NCT03211429|OTHER|Tai chi|Tai Chi training in the Yang style of 24 movement
223437478|NCT03211429|OTHER|Postural control exercise|Individually adjusted progressive and specific postural control training,
223437479|NCT04659629|DRUG|NL-201|NL-201 is a de novo protein therapeutic.
223437480|NCT04659629|DRUG|Pembrolizumab Injection [Keytruda]|A programmed death receptor-1 (PD-1)-blocking antibody
223437481|NCT06911125|DEVICE|TENS|"TENS will be applied paravertebrally using four electrodes in the neck and back areas. Self-adhesive electrodes specific to each participant will be used for the application. TENS will run on symmetrical biphasic current at 100 Hz and 120 microseconds. The current intensity is determined by the level at which the person perceives the current. The participants are informed that they will get a current, which may induce a pins-and-needles sensation. It is essential for them to perceive the current distinctly; the intensity should be sufficient to be sensed without causing discomfort. The duration of the treatment is 20 minutes. Participants will receive exercises to strengthen the muscles around the neck.~All participants will receive treatment once a day, five days a week. A total of 15 sessions will be conducted over a duration of 3 weeks."
223437482|NCT06911125|DEVICE|Diadinamic Current|Diadynamic current will be performed paravertebrally using two electrodes on the neck and back areas. Participant-specific self-adhesive electrodes will be utilized for the application. In diadynamic current, two distinct current modules, namely diphase-fixed (2 minutes) and short period (8 minutes), will be utilized. The cumulative duration of the treatment is 10 minutes. The program will provide the current intensity at the threshold perceived by the individual. The participants will be informed about the application as follows: 'You will receive a current; you may have a pins-and-needles sensation; it is crucial to perceive the current distinctly and thoroughly; the intensity should neither be insufficient to be felt nor excessive to cause discomfort.' Participants will receive exercises to strengthen the muscles around the neck.All participants will receive treatment once a day, five days a week. A total of 15 sessions will be conducted over a duration of 3 weeks.
223566402|NCT03305419|DRUG|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
223566403|NCT02443194|DRUG|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
223566404|NCT02443194|DRUG|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
223566405|NCT06584331|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
223566406|NCT06584331|DIETARY_SUPPLEMENT|2 doses of Beetroot juice intake|This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
223566407|NCT06584331|DIETARY_SUPPLEMENT|Placebo|In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.
224048476|NCT00233363|DRUG|Rebamipide|
224048477|NCT00000180|DRUG|AIT-082|
224048478|NCT01561625|OTHER|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
224048479|NCT04092517|OTHER|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
224048480|NCT04092517|OTHER|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
224048481|NCT06155747|OTHER|Epidemiologic investigation|"Identification of:~1. overlaps in source(s) of care between participants with NTM isolates in a healthcare center.~2. environmental NTM isolates that are highly related to respiratory isolates.~3. common water source exposure among subjects with clustered NTM infections via shared home of residence watershed."
224048482|NCT00284323|DRUG|Adenosine|
224048483|NCT00164827|DEVICE|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
224048484|NCT01659372|RADIATION|low level laser therapy|
224048485|NCT01659372|DRUG|Naproxen|
224143285|NCT04923698|OTHER|yoga training|All women in group B were treated by the same antidepressant drugs as in group A and yoga program, 50 minutes daily, 7 days per week for 12 weeks (Total 84 sessions).
224143286|NCT04796025|DRUG|Sintilimab; Bevacizumab Biosimilar|1-4 cycles, intra-arterial infusion: sindilimab 200mg + bevacizumab 7.5mg/kg, q3w; 5-18 cycles: Sintilimab (200mg ivdrip D1 Q3W)+Bevacizumab Biosimilar (15mg/kg ivdrip D1 Q3W）
224300202|NCT04213352|OTHER|Rigid Taping|Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
224048486|NCT01541579|OTHER|Cx601|120 million cells administered by intralesional injection.
224048487|NCT01541579|OTHER|Saline solution|24 mL saline solution by intralesional injection
224048488|NCT04817241|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224048489|NCT04817241|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
224048490|NCT04817241|DRUG|Cytarabine|Given IV
224048491|NCT04817241|DRUG|Daunorubicin|Given IV
224048492|NCT04817241|DRUG|Decitabine and Cedazuridine|Given PO
224048493|NCT04817241|DRUG|Venetoclax|Given PO
223437483|NCT06909786|PROCEDURE|HPI guided hemodynamic management|"BP, ECG and SpO2 were monitored after entering the operating room, peripheral venous access was established, radial artery puncture catheterization under local anesthesia and connected to the HPI (Edwards Lifesciences).~The treating anesthetist is trained to understand Acumen IQ parameters and the meaning of HPI, MAP, CI, SVI, SVR, SVV, Eadyn, dP/dtmax. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and how to treat hypotension. The hemodynamic management is performed according to the HPI guided algorithm."
223437484|NCT06909786|OTHER|standard arterial line|BP, ECG and SpO2 were monitored after entering the operating room, peripheral venous access was established, radial artery puncture catheterization under local anesthesia and connected to TruWave DPT and run data via HemoSphere machine (Edwards Lifesciences). The target of intraoperative blood pressure was to maintain MAP \> 65mmHg. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
223437485|NCT06912139|DRUG|Nitroglycerin transdermal|Nitroglycerin cream is applied \~ 15 minutes before radial artery puncture for emergency or planned invasive cardiology procedure (example: coronary angiography), and radial artery spasm and diameter are determined by angiography, injecting contrast into the radial artery through the placed radial sheath.
223437486|NCT06912139|OTHER|Placebo|Placebo cream with no active compounds is applied by the designated nurse to the radial puncture site, similar to NTG cream, with both patient and invasive cardiologist blinded wo which arm the patient is included in.
223437487|NCT06911489|DIAGNOSTIC_TEST|68Ga-NRT6020 Injection|Participants will receive a single intravenous injection of 68Ga-NRT6020 Injection (3 mCi or 5 mCi) and PET/CT scans at multiple time points.
223437488|NCT06911489|DRUG|177Lu-NRT6020 Injection (stage 2)|It is planned to evaluate 4 dose levels of 177Lu-NRT6020 Injection: 50mCi, 100mCi, 150mCi and one/more adaptive dose groups (ranged from 150 to 250 mCi, the specific doses and/or doses with other frequencies within the range of 150\~250mCi, need to be determined after the completion of the dose-limiting toxicity (DLT) assessment for the previous three dose groups, in combination with the safety, pharmacokinetics and radiation dosimetry results of the participants, following confirmation by the SRC) which will be administered every 6 weeks (Q6W), and/or other dosing intervals determined by the SRC, for up to 6 cycles.
223437489|NCT06911489|DRUG|177Lu-NRT6020 Injection (stage 3)|Participants will receive intravenous injection of 177Lu-NRT6020 Injection, administered Q6W and/or other dosing intervals determined by the SRC, for up to 6 cycles.
224048494|NCT02334124|OTHER|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
224048495|NCT02334124|OTHER|Ward|Admission to a hospital based ward
224048496|NCT02334124|DRUG|ceftriaxone|50mg/kg once daily
224048497|NCT02334124|DRUG|flucloxacillin|50mg/kg 6 hourly
224048498|NCT04743479|DIAGNOSTIC_TEST|high-resolution MRI/CT examinations|Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).
224048499|NCT02792179|DRUG|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
224048500|NCT02493504|DRUG|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
224048501|NCT02905253|DRUG|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
224143287|NCT03429322|BEHAVIORAL|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
224143288|NCT03429322|OTHER|Usual Care|Participants will receive and provide usual and customary care in their communities.
224143289|NCT01645865|BEHAVIORAL|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
223740764|NCT04291391|OTHER|North American-type diet|All groups will receive an isocaloric diet for 4 weeks composed of 48% of energy as carbohydrate, 17% as protein, and 35% as lipid (12.5% of saturated fat, 13% of monounsaturated fat, and 6% of polyunsaturated fat), designed to reflect as closely as possible current macronutrient intake averages in North America/Canada.America/Canada (35% of energy as fat, 12.5% as saturated fat, 13% as monounsaturated fat, 6% as polyunsaturated fat, 48% as carbohydrate, 17% as protein)
224048502|NCT02905253|DRUG|Placebo|Placebo capsules matching AC-084 capsules
224048503|NCT05986513|BEHAVIORAL|Cold Pressor Gel Test|This test will allow the research team to induce a painful sensation in participants in a safe, non-invasive, standardized, and short-lasting manner. The protocol for the cold pressor gel test is simple: participants will place their non-dominant hand in the container of cold water for as long as they can up to a maximum of two minutes. If it becomes too painful or uncomfortable during those two minutes, participants can remove their hand from the container. It should be noted again that this is not a treatment for knee OA or chronic pain and will be used to investigate the effects of acute pain in the brain of individuals with a chronic pain condition.
224048504|NCT05933486|DRUG|Tongluo-Kaibi tablet plus placebo of pregabalin|Tongluo-Kaibi Tablet 0.93g qd； Placebo of pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
224048505|NCT05933486|DRUG|placebo of Tongluo-Kaibi tablet plus pregabalin|placebo of Tongluo-Kaibi Tablet 0.93g qd； Pregabalin 150mg qd. If the patient can tolerate it, it will be increased to 150mg bid one week later. If the patient cannot tolerate it, it will be maintained at 150mg qd until the 8th week.
224048506|NCT03520478|DRUG|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
224300203|NCT00593632|DIETARY_SUPPLEMENT|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
224300204|NCT00017537|BIOLOGICAL|MVF-HER-2(628-647)-CRL 1005 vaccine|
223437490|NCT06910189|DEVICE|Fish Skin Graft (FSG)|FSG will be applied to the wound bed, followed by a wound VAC at the time of surgical debridement
224048507|NCT03520478|DRUG|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
224048508|NCT03226405|OTHER|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
224048509|NCT03226405|OTHER|Usual Care|the standard of care provided by the institution
224048510|NCT04668053|OTHER|Traditional training protocol|Mobility and core strengthening and the steps and lunges As per athletes requirement Body weight squat with 12 reps, Body weight split squat with 8 each side, Bilateral hip raise with 12 reps, Push-up with15 reps and Cricket related skills as per coach advised
224048511|NCT04668053|OTHER|Hip flexor resistance protocol|"Warm up prior to training The loop bands (Resistance-band©) that were used are in several colors-Red, black, yellow, blue and green extended from strongest type to weakest.~Athletes executed 3 training sessions of 3 sets per week for 6 weeks.~The relative load was:~Week 1----15 RM Week 2-4----10 RM Week 5-6----8 RM The Therapist has ensured a concentric contraction of 3-s, an isometric contraction of 2-s, eccentric contraction of 3-s, rest for 2-s prior to the next repetition and rest for 2-min prior the next set.~It took 10 min to complete each session, with rest between sets."
224048512|NCT02320136|BEHAVIORAL|cognitive testing|patients perform simple tasks like watching a video or memorizing items
224048513|NCT01536236|DEVICE|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
224048514|NCT01536236|DEVICE|Placebo|Placebo
224143290|NCT01645865|BEHAVIORAL|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
224143291|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
224143292|NCT00852319|BEHAVIORAL|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
224143293|NCT04675736|PROCEDURE|brushing force|Using duplication method, vertical force was applied from 1-5.5 N in linear mesial-distal brushing motion at 4 strokes per second for 5 seconds Force was increase 0.5 N in every testing until plaque was completely removed from enamel surface
224143294|NCT06109519|PROCEDURE|implant supported overdenture|patients would be delivered mandibular implant overdenture using conventional locator and Locator RTX attachments
224143295|NCT05157711|DRUG|Anusol|Daily at night and in the morning and after each bowel movement for two weeks
224143296|NCT05157711|DRUG|Relief [Name]|Daily at night and in the morning and after each bowel movement for two weeks
224143297|NCT05157711|DRUG|Placebo|Daily at night and in the morning and after each bowel movement for two weeks
224048515|NCT00752687|DRUG|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
224048516|NCT00752687|DRUG|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
224143298|NCT05294341|DRUG|Norethindrone Acetate 5 MG|As specified in arm design
223437491|NCT06910189|DEVICE|Wound Vacuum-Assisted Closure (VAC)|Participants will have a wound VAC applied to their wound bed at the time of surgical debridement.
223437492|NCT06911463|OTHER|suprainguinal fascia iliaca block group (SIFIB)|The anterior superior iliac spine is identified by a high-frequency linear probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) the inguinal ligament in the parasagittal plane, following appropriate disinfection and draping of the patient in the supine position. Then, the probe is moved medially, and the internal oblique muscle in the cranial direction, the sartorius muscle in the caudal direction, the bow-tie shape formed by these muscles, the underlying iliacus muscle, and the fascia iliaca surrounding it is visualized. (21) An 80-mm peripheral nerve block needle is inserted from the caudal side, and the iliac fascia is passed. After identification of the correct area following 2 to 3 mL of hydro-dissection, 40 mL of 0.25% bupivacaine is injected.
223566408|NCT03440567|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
223566409|NCT03440567|DRUG|Avelumab|Given IV
224048517|NCT04047550|DIAGNOSTIC_TEST|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
224048518|NCT01576172|DRUG|Abiraterone Acetate|Given PO
224048519|NCT01576172|OTHER|Laboratory Biomarker Analysis|Correlative studies
223566410|NCT03440567|DRUG|Carboplatin|Given IV
223566411|NCT03440567|DRUG|Etoposide Phosphate|Given IV
224048520|NCT01576172|DRUG|Prednisone|Given PO
224143299|NCT05294341|DRUG|Norethindrone 0.35 MG|As specified in arm design
223566412|NCT03440567|DRUG|Ibrutinib|Given PO
224048521|NCT01576172|DRUG|Veliparib|Given PO
224048522|NCT03747978|DRUG|Perindopril and Amlodipine|Fixed combination of Perindopril 5mg and Amlodipine 5mg
224048523|NCT03747978|DRUG|Perindopril-indapamide|Perindopril 5mg and Indapamide 1.25mg
224143300|NCT04104061|OTHER|iron profile|blood test
224143301|NCT02843178|BEHAVIORAL|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
224143302|NCT01002898|DRUG|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
224048524|NCT02061605|DEVICE|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
224048525|NCT04374409|DIETARY_SUPPLEMENT|High-flavanol cocoa powder|Non-alkalized fat-reduced cocoa powder (Natural Acticoa)
224048526|NCT04374409|DIETARY_SUPPLEMENT|Low-flavanol cocoa powder|Alkalized fat-reduced cocoa powder (10/12 DDP Royal Dutch)
224048527|NCT00057356|DRUG|conivaptan|IV
224048528|NCT00057356|DRUG|placebo|IV
224048529|NCT04714528|OTHER|Physical Exercise|Physical exercise as described before.
224048530|NCT04714528|OTHER|Relaxation Therapy|Relaxation therapy as described before.
224048531|NCT02032602|OTHER|Deep Dry Needling|
224048532|NCT01731314|BEHAVIORAL|Learning and Memory of Pain|
223437493|NCT06911463|OTHER|iliohypogastric and ilioinguinal group (IL-IH)|Group II (I): iliohypogastric and ilioinguinal group (IL-IH) After preparation of the inguinal region sterile linear high frequency probe (SonoSite HFL50x, 15-6 MHz, 55-mm broadband linear array, USA) is placed between the iliac crest and costal margin (more cephalad than the usual location for ilioinguinal block). In this location, the ilioinguinal and iliohypogastric nerves in between the transverses abdominus and internal oblique are well defined (22) After visualization, a 22G 1.5-inch needle is used in out of-plane approach to reach the nerves. After identification of the correct area following 2 to 3 mL of hydro-dissection, 40 mL of 0.25% bupivacaine is injected (kayak sign).
223437494|NCT06911463|OTHER|Local infiltration|patients receive infiltration of 0.5% 10ml bupivacaine and 1% 10 ml lidocaine in the groin at the site of puncture.
223437495|NCT06909981|RADIATION|Low-Dose Computed Tomography Scan|Imaging of chest to screen for lung cancer.
224048533|NCT00300287|DRUG|Vildagliptin|
224048534|NCT03706495|BEHAVIORAL|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
224048535|NCT03706495|BEHAVIORAL|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
224048536|NCT00344565|DRUG|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
224048537|NCT00344565|BEHAVIORAL|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
224143303|NCT03271060|PROCEDURE|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
224143304|NCT03271060|PROCEDURE|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
224143305|NCT01985971|RADIATION|PET/CT Imaging|
224143306|NCT05718661|BEHAVIORAL|Watching video with virtual glasses|Using Mobile Virtual Glasses; In the preoperative period, after the patient is taken to the surgical service, a virtual reality video will be watched with mobile virtual glasses at the specified time (before going to the operating room on the day of surgery). Measurements will be made before and after the application. Necessary hygiene will be provided before the use of glasses, and the researcher will ensure hand cleaning before entering the patient's room.
224143307|NCT05718661|BEHAVIORAL|watching video without virtual glasses|The plain version of the video, which was shown to the intervention group by the researcher (SŞ) to the placebo group, will be watched over the phone with the naked eye and the stress level on the smart bracelet will be recorded.
224143308|NCT00539318|PROCEDURE|Blood drawing|Once when enroll in study
224300205|NCT01246011|DRUG|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
224300206|NCT01988961|BIOLOGICAL|Golimumab|SC injections
223437496|NCT06911814|OTHER|kinesio taping|KT is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin.We are going to apply to patients in three times.
223437497|NCT06911814|OTHER|THE EXERCİSE|KT is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin.We are going to apply to patients in three times.
223566413|NCT03440567|DRUG|Ifosfamide|Given IV
223566414|NCT03440567|OTHER|Laboratory Biomarker Analysis|Correlative studies
223566415|NCT03440567|BIOLOGICAL|Rituximab|Given IV
223566416|NCT03440567|BIOLOGICAL|Utomilumab|Given IV
223566417|NCT06232980|PROCEDURE|urological surgical intervention|Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
223566418|NCT03639623|DRUG|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
223437498|NCT06910995|BEHAVIORAL|AR location-based game|This study aims to utilize the AR location-based game Pikmin Bloom to gradually encourage middle-aged and older adults in the community to develop a habit of walking outdoors. A step goal will be set every two weeks to progressively increase daily walking activity. By integrating the AR game with a LINE chatbot for feedback and engagement, this approach aims to motivate older adults, enhance their willingness to go outside, and increase their daily step count.
223437499|NCT06911138|BEHAVIORAL|Behavorial|Behavioral intervention that focuses on improving syntactic knowledge.
223437500|NCT06912399|DEVICE|Transauricular Vagus Nerve Stimulation|Participants enrolled will have a commercial transcutaneous electrical nerve stimulation unit (tVNS501,RISHENA,Changzhou,China) attached to their left outer ear after VATS. The stimulation pulses will target at the cymba concha which is 100% dominated by the auricular branch of the vagus nerve. Stimulation pulses will be 25Hz in frequency according to current clinical research, 500µs in pulse width which has been suggested to be most biologically active, with its amplitude increasing to the maximum amount that the patients can tolerate without pain.
223437501|NCT06912399|DEVICE|Sham Transauricular Vagus Nerve stimulation|The only thing differs with the taVNS group is that the device will automatically shut down after running for 15 seconds.
223437502|NCT06911047|BEHAVIORAL|Education Intervention|Participants in the intervention group will be provided e-learning about dementia prevention and promoting brain health, consisting of following components: 1. One multimedia e-learning lesson on promoting brain health and preventing dementia; 2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson. 3. Curated resources related to dementia risk factors
223437503|NCT06911047|BEHAVIORAL|Education Control|Participants in the control group will be provided e-learning about mild cognitive impairment, consisting of following components: 1. One multimedia e-learning lesson on mild cognitive impairment; 2. A series of 12 'micro-learning' emails (3 emails/week) with small segments of content to reinforce the material from the lesson. 3. Curated resources related to mild cognitive impairment
223437504|NCT06911307|OTHER|standard care group|The standard care (SC) group will also include 80 participants. Wounds will be cleansed with sterile normal saline and managed using conventional wound care techniques. Participants will undergo regular postoperative follow-ups to assess wound healing progression and secondary outcome measures.
223437505|NCT06911307|OTHER|NPWT|The NPWT group will also include 80 participants. Wounds will be cleansed with sterile normal saline and coverd the SIMO NPWT dressing. Participants will undergo regular postoperative follow-ups to assess wound healing progression and secondary outcome measures.
223437506|NCT06911554|BIOLOGICAL|Recombinant Human Albumin Injection|Recombinant Human Albumin injection, strength: 10 g/vial (20%, 50 mL); storage conditions: 2-8°C, protected from light; manufactured and supplied by Tonghua Anrate Biopharmaceutical Co., Ltd.
223437507|NCT06911554|BIOLOGICAL|Human Albumin|Human Albumin (An Pu Lai Shi®), strength: 10 g/vial (protein concentration 20%, 50 mL/vial), storage conditions: 2-8°C, protected from light; manufactured by Shanghai RAAS Blood Products Co., Ltd.
223437508|NCT01715402|PROCEDURE|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
223437509|NCT02972333|DRUG|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
223437510|NCT02972333|RADIATION|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
223437511|NCT02920814|OTHER|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
223437512|NCT00094549|DRUG|olanzapine|
223437513|NCT00094549|DRUG|divalproex sodium|
223437514|NCT00094549|DRUG|placebo|
223437515|NCT02713854|PROCEDURE|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
223437516|NCT06460337|OTHER|Modified Otago exercises|Participants will engage in modified Otago exercise sessions, either individually or in groups, for 45 minutes, thrice weekly over an 8-week period. The program entails moderate-intensity strengthening exercises targeting various muscle groups such as hip extensors, abductors, knee flexors and extensors, inner range quadriceps, ankle plantar flexors, and dorsiflexors, performed at 10 repetitions maximum (RM) with ankle cuff weights ranging from 0.5 to 1 kg. Additionally, balance exercises will be conducted, initially with support and gradually progressing to without support, including knee bends, backwards walking, sideways walking, tandem stance and walk, one leg stance, heel and toe walking, sit-to-stand, stair climbing, stepping over objects, and bending to pick up objects from the floor. Participants are also encouraged to walk outdoors at their usual pace for 30 minutes at least three times weekly.
223437517|NCT06460337|OTHER|Frenkel's exercises|Frenkel's exercise regimen comprises a series of movements performed in lying, sitting, stride standing, and standing positions aimed at improving coordination and motor control. In the lying position, exercises include alternating hip and knee flexion/extensions, hip abduction/adduction, pedaling the lower limbs, and simultaneous movements of hips and knees. These are executed slowly to enhance coordination. In sitting, exercises involve leg stretching, hip flexion with knees flexed or straightened, and transitions from sitting to standing and back. Stride standing exercises focus on weight transfer and sideways walking, while standing exercises encompass walking on marked paths, trunk rotations, 360-degree turns, smaller arcs of hip abduction/adduction and flexion/extension, straight-line walking, and directional changes to simulate real-life obstacles. 3 sets comprising 10 repetitions are performed for each exercise, aiming for motor skill improvement and balance enhancement
223437518|NCT06020209|DIAGNOSTIC_TEST|Cardiac Computed Tomography|A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.
223566419|NCT00889603|DRUG|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
224300207|NCT04492020|DRUG|Ubrogepant 100 mg|For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
224048538|NCT04597957|DIETARY_SUPPLEMENT|Fresh Rx Intervention group|"Fresh Rx Intervention participants will be able to fill their prescription at the FQHC based Farmers Market for fresh produce up to eight times during the 15-week Fresh Rx program. The provided debit cards will be loaded with the $10 stipend at each visit. At each market session, cooking demonstrations will take place that reinforce healthy food options and how to prepare foods that were available at the Mercado.~All control group participants will be given flyers describing all the health and wellness programs at the FQHC including the Mercado. Control group participants will receive a $10 gift card to a national brand pharmacy (no fresh produce available). The enrollment time for the control group will overlap with the Fresh Rx group. After a 3-month time period, the control group will follow up and be given a $20 gift card to the same national brand pharmacy."
224143309|NCT05912036|BEHAVIORAL|CRT|CA-CRT treatment will entail exercises aimed to improve cognitive strategies, encourage subjects' reflection on their way of thinking, and explore the possibility of implementing new schemas in everyday life. The CA-CRT program will employ a range of cognitive exercises and tasks to address cognitive inflexibility and weak central coherence. The treatment will consist of 10 individual CA-CRT sessions, 2 times per week for 5 weeks, for a duration of 40 minutes per session with 15 individual CA-CRT sessions, 3 times a week for 5 weeks, with a duration of 30 minutes per session
223437519|NCT06020209|DIAGNOSTIC_TEST|Cardiac Magnetic Resonance|A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.
223437520|NCT04066777|PROCEDURE|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
223437521|NCT05315154|PROCEDURE|No axillary surgery|In the study arm will be omitted surgery in axilla
223437522|NCT05315154|PROCEDURE|SLNB|in the control arm will be realized SLNB
223437523|NCT00715845|PROCEDURE|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
223437524|NCT02539654|DRUG|EXE844 Sterile Otic Suspension, 0.3%|
223437525|NCT02539654|PROCEDURE|Tympanostomy Tube Insertion|
223437526|NCT06210373|DEVICE|Myrialen Gel|Myrialen Gel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment.
223437527|NCT06210373|DEVICE|Recugel|"Recugel will be instilled as 1 drop per eye 3 times a day and one drop per eye before going to bed in the conjunctival sac for 30 days.~In case of bilateral dry eye syndrome, both eyes will be treated. In case of monolateral dry eye syndrome, the decision to treat both eyes will be taken according to the Investigator's judgment."
223437528|NCT04247568|OTHER|Listening to an audiotape|The participants listen to a audiofile that consists of hypnosis
223437529|NCT05331781|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block|patient in the supine position, ultrasound will be used to identify the plane between the internal oblique and transversus abdominis muscle to inject 20 ml of local anesthetic for each side
223437530|NCT05331781|DRUG|Morphine|intrathecal 150 microgram morphine in a 0.5 ml volume will be added to bupivacaine as an adjuvant to spinal anesthesia
223437531|NCT01709773|PROCEDURE|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
224048539|NCT04731038|DRUG|Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin|This is a single-arm study with all patients receiving these four drugs.
224048540|NCT01274936|DRUG|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
224048541|NCT01274936|DRUG|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
224048542|NCT03262792|DIETARY_SUPPLEMENT|Placebo|Microcrystalline cellulose
224048543|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 150 mg
224048544|NCT03262792|DIETARY_SUPPLEMENT|Andrographis Paniculata|Andrographis Paniculata 300 mg
224048545|NCT03635814|DRUG|YD312 50mg|YD312 50mg \* 1 + placebo 6 tablets
224143310|NCT00554255|DRUG|SB751689|
224143311|NCT00289861|DRUG|Risperidone|
224143312|NCT00289861|DRUG|placebo|
223437532|NCT03318081|BEHAVIORAL|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
223437533|NCT04825496|GENETIC|ssCART-19 Cells|"Split-Dose of ssCART-19 cells will be infused, and classic 3+3 dose escalation will be applied."
223437534|NCT04825496|DRUG|Fludarabine|Fludarabine is used for lymphodepletion.
223437535|NCT04825496|DRUG|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
223437536|NCT01892800|PROCEDURE|Lung resection|
223437537|NCT06910852|PROCEDURE|Vascular stapler|the utilization of vascular staplers for the division of the right portal and hepatic veins in patients undergoing right lobe liver donation for living donor liver transplantation
223437538|NCT05835427|OTHER|Cervical Extensor Stretch|Fibromyalgia individual: Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
223437539|NCT05835427|OTHER|Cervical Extensor Stretch|Healthy volunteers : Within the scope of the study, relaxation and stretching exercises will be applied to both groups for eight weeks.
223437540|NCT04582565|COMBINATION_PRODUCT|Decongestive lymphatic therapy (DLT)|Manual lymphatic drainage
223437541|NCT04582565|OTHER|Standard Care|
224143313|NCT00873145|PROCEDURE|HMRS|Modular prosthetic replacement of the humerus and elbow.
224143314|NCT03453970|BEHAVIORAL|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
223437542|NCT00059878|BIOLOGICAL|recombinant interferon gamma|
223437543|NCT00059878|DRUG|voriconazole|
224143315|NCT03099980|BIOLOGICAL|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
224143316|NCT05041153|DRUG|Lenvatinib|Given by PO
224300208|NCT04492020|DRUG|Placebo|For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
223437544|NCT03618563|OTHER|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
223437545|NCT00005941|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223437546|NCT00005941|DRUG|cyclosporine|
223437547|NCT00005941|DRUG|fludarabine phosphate|
223437548|NCT00005941|DRUG|mycophenolate mofetil|
223437549|NCT00005941|PROCEDURE|peripheral blood stem cell transplantation|
223437550|NCT00005941|RADIATION|radiation therapy|
223437551|NCT04318171|DEVICE|3D Imaging.|"When the normal Doppler assessment is done following nationally approved protocol for scanning Carotid arteries, lower and upper limb arteries, AVF and Vein mapping. PIUR tUS infinity system 3D Bluetooth motion sensor which is linked to video transmission box will be used to scan the patient's common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) in transverse view to obtain the following measurements:~* Plaque volume where detectable.~* Max area stenosis.~* Volumetric stenosis.~* Measured length.~* 3D GSM. The entire assessment should not take more than 45 minutes."
223437552|NCT04438499|DEVICE|eSense 7fr Single Sensor Bladder Catheter|Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
223437553|NCT06910150|PROCEDURE|Non-invasive analgesic electrostimulation|Application of a single session of non-invasive analgesic electrostimulation to motor points of the vastus medialis and vastus lateralis of the quadriceps femoris muscle in patients who have undergone an anterior cruciate ligament reconstruction. A biphasic, symmetrical, square-wave current was applied at a frequency of 100 Hz, a pulse width of 200 μs, and an intensity adjusted to the patient's pain threshold for 30 minutes.
223437554|NCT06910150|PROCEDURE|Invasive analgesic electrostimulation|Application of a single session of invasive analgesic electrostimulation to a motor point of the vastus medialis of the quadriceps femoris muscle in patients who have undergone an anterior cruciate ligament reconstruction. A biphasic, symmetrical, square-wave current was applied at a frequency of 100 Hz, a pulse width of 250 μs, and an intensity defined as perceptible to the patient but never painful (200 μA above the detection threshold for each subject).
223437555|NCT06251024|BIOLOGICAL|RSV vaccine candidate|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
224048546|NCT03635814|DRUG|YD312 150mg|YD312 50mg \* 3 + placebo 6 tablets
224048547|NCT03635814|DRUG|YD312 350mg|YD312 50mg \* 7 tablets
224048548|NCT03635814|DRUG|Placebo|YD312 0mg \* 7 tabets
224048549|NCT06493682|BEHAVIORAL|Experimental (Motivational Interviews)|Monitoring 'behaviour of healthcare demand procrastination, health beliefs regarding cervical cancer screenings, and screening participation' with motivational interviewing
224048550|NCT01068392|DRUG|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
224048551|NCT00646594|DRUG|budesonide/formoterol (Symbicort)|
224048552|NCT00646594|DRUG|fluticasone/salmeterol (Advair)|
224048553|NCT01756469|BEHAVIORAL|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
224048554|NCT05885867|BEHAVIORAL|Seniors with mild cognitive impairment over 65 years of age|"A total of 30 subjects will perform four tasks per person for a single task (motor task) and a double task (motor task + cognitive task), and the test order will be randomly assigned. The subject's prefrontal cortex activity will be measured using fNIRS (NIRSIT, OBELAB).~The single task will be to perform a 10-meter walk test and an 8-way walk test as exercise tasks. as not affected by acceleration and deceleration. The dual task will be carried out together with the exercise task and the cognitive task. The cognitive task will be a simple calculation problem so that it can be performed without much difficulty when walking.Subjects will perform a total of three iterations and have a break of 20 seconds before each task begins."
224048555|NCT05553483|OTHER|pranayama plus acupoint stimulation by laser|"This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama )."
224048556|NCT05553483|OTHER|acupoint stimulation by laser|This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
224300209|NCT03858192|PROCEDURE|Colorectal surgery procedure|Elective admission for colorectal surgery
224300210|NCT03858192|PROCEDURE|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
224300211|NCT03858192|DRUG|Antibiotics|Treatment for infection and reason for admission
223437556|NCT06251024|BIOLOGICAL|Placebo|Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
223437557|NCT06912178|OTHER|Acupuncture|Whether or not a patient has been treated with acupuncture will be one of the exposure factors of interest in the study
223437558|NCT07102810|BEHAVIORAL|Standardized Hypnotic Susceptibility Testing|Participants will be guided through the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A), a validated group hypnosis protocol that includes standardized hypnotic inductions and suggestibility tasks.
224048557|NCT06048315|DRUG|Anlotinib|Every 3 weeks is a treatment cycle, starting from the first day of each treatment cycle with oral administration of 12mg of arotinib once a day, stopping for one week after taking it for two weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
224143317|NCT05041153|BIOLOGICAL|Pembrolizumab|Given by IV
224143318|NCT03604068|DEVICE|RecoveryRx|A pulsed shortwave therapy medical device
223437559|NCT07128199|DRUG|Cisplatin|IV infusion.
224048558|NCT06048315|DRUG|Penpulimab|On the first day, Pianzumab (200mg intravenous infusion) was administered every 3 weeks until disease progression (PD), unacceptable toxic reactions, withdrawal of informed consent, end of study, loss of follow-up or death, whichever occurs first.
224048559|NCT02439996|DRUG|IVIG (1g/kg,once)|"Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
224048560|NCT02439996|DRUG|IVIG (1g/kg,twice)|"Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
224048561|NCT02439996|DRUG|IVIG (2g/kg.once)|"Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
224143319|NCT03604068|DEVICE|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
224143320|NCT06580184|BEHAVIORAL|LEARN 2 Platform|The LEARN 2 Platform will provide tailored prevention education of HIV-comorbidities with shared risk factors. Participants will navigate LEARN 2 and access targeted health content.
224300212|NCT02982031|PROCEDURE|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
224300213|NCT02982031|PROCEDURE|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
224300214|NCT02929446|PROCEDURE|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
224300215|NCT02929446|PROCEDURE|Mobilisation and breathing exercises|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
223437560|NCT07128199|DRUG|Carboplatin|IV infusion.
223437561|NCT07128199|DRUG|Pemetrexed|IV infusion.
223437562|NCT07128199|DRUG|TAS6417|Oral tablets.
224300216|NCT03199430|DIETARY_SUPPLEMENT|Epigallocatechin gallate|
224300217|NCT03199430|DIETARY_SUPPLEMENT|Placebo|1450mg Corn Flour
223437563|NCT07128199|DRUG|Zipalertinib Matching-placebo|Oral tablets.
223437564|NCT04918355|OTHER|Clinical Decision Support (CDS) alerts|CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
223437565|NCT07137624|BEHAVIORAL|Action Observation + Motor Imagery|Participants will watch videos showing walking actions and will be instructed to mentally simulate the movement.
223437566|NCT07137624|BEHAVIORAL|Nature Video|Participants will watch a video of nature scenes.
223437567|NCT07143734|DEVICE|transcranial pulse stimulation (TPS)|The TPS/Sham-TPS therapy is administered for the first two weeks, followed by additional sessions at some week intervals.
223437568|NCT07143734|DEVICE|transcranial pulse stimulation (TPS-Sham)|Participants will undergo an identical procedure using a device that mimics the sound and sensation of active TPS but delivers no therapeutic energy pulses to the brain.
223437569|NCT07140146|DEVICE|Trehalose Powder Air-Polishing|Air-polishing procedure using trehalose-based powder (particle size \<65 µm, low abrasiveness) applied supra- and subgingivally with a professional air-polishing device in patients diagnosed with peri-implant mucositis. The intervention is combined with non-surgical debridement using manual curettes and ultrasonic scalers. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). Clinical outcomes assessed include Plaque Index (PI), Bleeding on Probing (BoP), Probing Pocket Depth (PPD), and Bleeding Score (BS). Implant surfaces are also evaluated in vitro using scanning electron microscopy (SEM) to assess any surface alterations after powder application.
224048562|NCT04048590|OTHER|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
224048563|NCT00463268|DRUG|alendronate|alendronate 70 mg every 2 weeks
224048564|NCT00463268|DIETARY_SUPPLEMENT|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
224048565|NCT00463268|DRUG|placebo|identical placebo every 2 weeks
224143321|NCT06580730|PROCEDURE|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
224143322|NCT06580730|OTHER|Standard medical treatment|Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician.
224143323|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
224143324|NCT06394401|DIETARY_SUPPLEMENT|BAL:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
224143325|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU|80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
224143326|NCT06394401|DIETARY_SUPPLEMENT|DEF:GLU+FRU|53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
224143327|NCT03827668|DRUG|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
224143328|NCT03827668|DRUG|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
224143329|NCT03827668|DRUG|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
224143330|NCT01128335|DRUG|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
224143331|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
224143332|NCT01128335|DRUG|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
223566420|NCT03481166|OTHER|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
223566421|NCT04497103|OTHER|control|The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
224143333|NCT01128335|DRUG|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
224143334|NCT03287245|DRUG|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
224048566|NCT00473551|DRUG|Rituximab|375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8.
224048567|NCT00473551|DRUG|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
224048568|NCT00473551|DRUG|Fludarabine|40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
224048569|NCT00473551|DRUG|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
224143335|NCT02701192|OTHER|Coccygectomy|Patient receiving coccygectomy surgery.
224143336|NCT01094951|BEHAVIORAL|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
224300218|NCT03317886|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
224300219|NCT03474250|DIAGNOSTIC_TEST|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
224300220|NCT04790838|DRUG|Test|2 inhalations of Test and Reference product in each study period
223566422|NCT04497103|OTHER|Xbox kinect|The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
224048570|NCT00473551|RADIATION|Radiation Treatment|2Gy Total body radiation day before transplantation
224048571|NCT00473551|PROCEDURE|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
224048572|NCT00473551|DRUG|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
224048573|NCT00473551|PROCEDURE|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
224048574|NCT00729482|DRUG|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
224048575|NCT01303965|DRUG|Sirolimus|Start on Day -3 and continue for 1 year
224048576|NCT01303965|DRUG|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
224048577|NCT01303965|DRUG|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
224048578|NCT02177890|DEVICE|Transcutaneous vagal nerve stimulation|
224048579|NCT02177890|DEVICE|Sham vagal nerve stimulation|
224048580|NCT02931136|DRUG|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
223437570|NCT07140146|DEVICE|Glycine Powder Air-Polishing|Air-polishing procedure using glycine-based powder (particle size \~25 µm, amino acid composition) applied supra- and subgingivally with a professional air-polishing device in patients with peri-implant mucositis. This treatment is combined with standard non-surgical supportive peri-implant therapy involving manual and ultrasonic debridement. The procedure is performed at baseline (T0), and repeated at 1 month (T1), 3 months (T2), and 6 months (T3). The intervention aims to reduce plaque accumulation and inflammation. Clinical parameters recorded include PI, BoP, PPD, and BS. Implant surfaces are also assessed in vitro via SEM to compare the effects of glycine versus trehalose on implant surface integrity.
224048581|NCT02931136|DRUG|Placebo|The participants will treatment by the placebo in 52 weeks.
224048582|NCT02111460|RADIATION|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
224048583|NCT03042182|BIOLOGICAL|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
224048584|NCT02941874|OTHER|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
224048585|NCT01433757|DRUG|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
224048586|NCT01433757|DRUG|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
224048587|NCT00029913|OTHER|Observation|Observation of participants who received HIV preventive vaccine and became infected.
224048588|NCT03178708|DRUG|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
224143337|NCT02779673|OTHER|Yoghurt drink containing plant stanol as esters|
224048589|NCT03178708|OTHER|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
224048590|NCT05971862|DRUG|SKI-G-801|Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
224143338|NCT02779673|OTHER|Yoghurt drink without plant stanol as esters|
223437571|NCT07141732|BIOLOGICAL|Resection of newly diagnosed glioblastoma combined with intraoperative balloon electronic brachytherapy using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System|The Elekta Xoft® Axxent® Electronic Brachytherapy (eBx®) System is a device that delivers high-dose-rate radiation. It is designed for use with Axxent applicators to treat neoplastic tumors inside or on the body surface where radiation therapy is indicated. The Axxent System and its applicators were cleared by the FDA under 510(k) submissions K050843, K072683, K090914, and K122951. The Russian Federation medical device registration certificate (No. RZN 2015/2593) was obtained on April 17, 2015.
223566423|NCT04497103|OTHER|task oriented training|The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
223566424|NCT04947345|DRUG|Remimazolam Besylate|Remimazolam Besylate are used as sedatives for subjects in this arm.
223566425|NCT04947345|DRUG|Propofol|Propofol are used as sedatives for subjects in this arm.
224048591|NCT04351763|DRUG|Amiodarone|Ion channel blocker
224048592|NCT04351763|DRUG|Verapamil|Ion channel blocker
224048593|NCT01460953|BEHAVIORAL|health literacy training video|participants will watch a training video
224048594|NCT01797497|BEHAVIORAL|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
224048595|NCT02902081|DRUG|Cannabidiol|
224048596|NCT02902081|DRUG|Placebo|
224048597|NCT03390543|DEVICE|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
224048598|NCT03390543|DEVICE|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
224143339|NCT04765748|DEVICE|Cytosorb|Cytokine filter, which can be used intraoperatively while using a heart lung machine
224143340|NCT00949910|DRUG|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
224143341|NCT01611766|PROCEDURE|Secondary Cytoreductive Surgery|Complete Cytoreduction
224143342|NCT01611766|DRUG|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
224143343|NCT01641757|PROCEDURE|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
224143344|NCT05482035|DEVICE|wrist blood pressure monitor|Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .
224143345|NCT02150213|PROCEDURE|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
224143346|NCT02150213|PROCEDURE|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
224048599|NCT03916887|BEHAVIORAL|Golf instruction|Non-golfers instructed to golf over 10 weeks
224048600|NCT02742064|OTHER|Cogito Companion Mobile Phone Application|
224048601|NCT03512639|DRUG|Homeopathic Medication|Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
224048602|NCT03512639|DRUG|Placebo|placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
224048603|NCT04307160|PROCEDURE|Bilateral lateral rectus recession|All patients will undergo bilateral lateral rectus recession according to standard tables. In the younger age group, the amount of lateral rectus recession will be reduced by 0.5 mm. in those with inferior oblique overaction, inferior oblique recession will be performed
224143347|NCT02150213|PROCEDURE|Sonogram|Sonogram of the uterus (females only)
223437572|NCT06946680|BIOLOGICAL|Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells|Single dose of 8R-70CAR T cells administered IV
223437573|NCT03200847|DRUG|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
223437574|NCT03632538|DIAGNOSTIC_TEST|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
224048604|NCT00073151|DRUG|ABT-751|
224048605|NCT01937533|PROCEDURE|Magnetic Resonance Imaging using an endovaginal receiver coil|
224143348|NCT02150213|PROCEDURE|Biopsy|Uterine endometrial biopsy (females only)
224143349|NCT02150213|DRUG|BGG492|No study-drug was administered in this study
224143350|NCT03667508|PROCEDURE|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
224143351|NCT03667508|PROCEDURE|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
223437575|NCT06953817|BEHAVIORAL|Kangaroo Care Intervention Group|The mother should wear a comfortable outfit that can be easily opened at the front, and attention should be given to the mother's privacy. The infant should be covered with a light blanket. While applying kangaroo care, the baby may be completely naked, or the baby may wear items such as a hat, diaper, and socks. The kangaroo care position involves placing the baby upright between the mother's breasts. The newborn's abdomen should be positioned at the level of the mother's epigastric region. While performing kangaroo care, the mother should ensure that the baby's face is visible and that the baby's head is not in extreme extension or excessive flexion. During the procedure, care should be taken to ensure that the baby can breathe comfortably while on the mother's chest. The pregnant women will be instructed to practice kangaroo care intermittently for 30 minutes.
223437576|NCT07157800|OTHER|ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors."
223437577|NCT07157800|OTHER|exercise + ergonomics training|"Each of the control group participants will receive separate ergonomics training. The content of this training will include the topics of what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk factors.~Other: exercise program stretching exercises strengthening exercises waist exercises core exercises relaxation exercises"
223566426|NCT05140304|DEVICE|OCT angiography|OCT angiography of foveal avascular zone in diabetic retinopathy
223566427|NCT03370380|DRUG|Aflibercept|Patients are treated according to authorization of Aflibercept
224048606|NCT04702776|DRUG|Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%|Application of one drop of Humylub Ofteno® PF (Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%) QID in both eyes (OU) during 30 days.
224048607|NCT04702776|DRUG|Sodium hyaluronate 0.15%|Application of one drop of Hyabak® PF (Sodium hyaluronate 0.15%) QID in OU during 30 days.
224048608|NCT04702776|DRUG|Sodium hyaluronate 0.4%|Application of one drop of Lagricel Ofteno® PF (Sodium Hyaluronate 0.4%) QID in OU during 30 days.
224048609|NCT01723215|BEHAVIORAL|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
224048610|NCT01723215|BEHAVIORAL|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
224048611|NCT01723215|BEHAVIORAL|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
224048612|NCT05662475|DIAGNOSTIC_TEST|GCF (gingival crevicular fluid) collection|Prior to GCF (gingival crevicular fluid) sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Gingival fluid collection strips were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed GCF volume was estimated by a calibrated instrument. Then, the strips were sealed into sterile tubes before freezing at -80 °C. The readings were converted to an actual volume (μl) by reference to the standard curve.
224143352|NCT01345370|DRUG|Temozolomide|According to sites procedures
224143353|NCT01345370|RADIATION|Radiation Therapy|According to sites procedures
224143354|NCT00122421|BEHAVIORAL|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
224143355|NCT00122421|OTHER|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
224143356|NCT01993056|BEHAVIORAL|"FIFA 11+"|
224143357|NCT01993056|BEHAVIORAL|"no FIFA 11+"|
224143358|NCT03025893|DRUG|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
224143359|NCT03025893|DRUG|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
224143360|NCT00024193|BIOLOGICAL|filgrastim|
224143361|NCT00024193|DRUG|busulfan|
224143362|NCT00024193|DRUG|cisplatin|
224143363|NCT00024193|DRUG|cyclophosphamide|
224143364|NCT00024193|DRUG|doxorubicin hydrochloride|
224143365|NCT00024193|DRUG|etoposide|
224143366|NCT00024193|DRUG|melphalan|
224143367|NCT00024193|DRUG|vincristine sulfate|
223437578|NCT07157566|BEHAVIORAL|Mindfulness|Structured over 8 weeks (twice weekly) with dual modules (dietary + movement), this group employs Mindfulness-Based Eating Awareness Training (MB-EAT) to improve mind-body awareness. Week 1 establishes foundational practices through mindful eating concepts and introductory yoga; Weeks 2-4 systematically train awareness of hunger/satiety cues using partner breathing techniques, postural alignment, and group-assisted stretching; Week 5 analyzes emotional eating triggers while integrating therapeutic yoga for emotional regulation; Weeks 6-7 foster body acceptance and autonomous food choices; the program concludes with closing rituals. Rooted in Mindfulness-Based Stress Reduction (MBSR), it strengthens interoceptive awareness, non-judgmental self-acceptance, and emotional management to transform dysfunctional eating patterns.
223437579|NCT07157566|BEHAVIORAL|e-Health Literacy|This 8-week program (twice weekly) aims to enhance participants' ability to access, evaluate, and apply digital health information. It progresses through sequential modules: Week 1 introduces e-Health literacy fundamentals and physical activity principles; Weeks 2-3 focus on nutritional assessment and personalized planning; Week 4 addresses sleep health; Weeks 5-7 train health information retrieval skills, including database navigation and source reliability verification; the final week hones critical appraisal capabilities. The intervention is based on the e-Health Literacy 3.0 model and cultivates three core competencies: digital navigation, information discernment, and evidence-based decision-making, enabling participants to independently navigate the digital health ecosystem.
223437580|NCT07154225|BEHAVIORAL|Social Prescribing|SP is a person-centred approach to wellbeing involving the co-development of a non-clinical prescription, between an individual (i.e. young person) and Link Workers (LWs), based on the perceived difficulties for the referral and the YPs values, needs and preferences. LWs have a good knowledge of their local areas, via community asset mapping and networking, allowing them to connect individuals with different types of available support and activities. Typically, SP ranges from 6-12 sessions (average 8 sessions: unpublished data from sites) with a LW over an 8-week period. Sessions may take place online, via phone call, or in person. As part of this process, LWs draw on psychological skills such as motivational interviewing and behavioural activation as well as employ problem solving and goal setting. Following the identification of issues and preferences, the LW will discuss with the YP what the available local activities and support structures are that best match their preferences.
223437581|NCT07154225|BEHAVIORAL|Signposting|Those in the control group will receive signposting to activities and local sources of support in their communities. This will consist of school pastoral staff meeting with YP identified as lonely and providing them with a leaflet detailing the same local sources of support identified by the LW from asset mapping.
223566428|NCT05403372|DEVICE|PAS-C System|The InterShunt PAS-C System is a transcatheter system that creates a shunt by excising tissue from the interatrial septum resulting in a left to right atrial shunt that off-loads elevated left atrial pressure, potentially reducing symptoms and improving quality of life. The PAS-C System does not require a permanent implant to maintain patency of the interatrial shunt.
223566429|NCT02350413|OTHER|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
223566430|NCT00980512|BEHAVIORAL|Parent Training|16 weeks of parent training led by trained group facilitator
224048613|NCT05662475|PROCEDURE|Non-surgical periodontal treatment completed in 24 hours|After clinical periodontal parameters were recorded and GCF samples were obtained, non-surgical periodontal treatment was started under local anesthesia. All periodontal treatments were performed by a single investigator. Local infiltrative anesthesia was applied to the buccal and palatal/lingual areas of the maxilla and mandible of the patients. After anesthesia was achieved, scaler and ultrasonic tips of various thicknesses were used together to remove supragingival and subgingival hard attachments. Root surface smoothing was performed with region-specific periodontal curettes. The roughness of the surfaces was controlled using a periodontal probe. Polishing was performed. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning is explained. The patient was told not to use any chemical agent for plaque removal.
224048614|NCT05662475|DIAGNOSTIC_TEST|HbA1c level determination in blood serum|Blood samples were taken from the patients and HbA1c concentration was measured in serum.
224048615|NCT06156436|DEVICE|ResAppDx v.20|Software application used to aid diagnosis of respiratory disorders
224048616|NCT00196638|DRUG|Antiretroviral combination (drugs)|
224048617|NCT00196638|DRUG|Pegylated Interferon alpha (drug)|
224048618|NCT05275348|BEHAVIORAL|Tele-Enhance Fitness|"Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode."
224048619|NCT05275348|BEHAVIORAL|In-person Enhance Fitness|Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
224048620|NCT01490814|PROCEDURE|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
224048621|NCT01490814|PROCEDURE|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
224048622|NCT03092206|DRUG|F/TAF|antiretroviral therapy
223437582|NCT07161427|PROCEDURE|Fu's Subcutaneous Needling therapy|Participants first assume the supine position. After routine disinfection, the Fu's subcutaneous needle is inserted parallelly into the subcutaneous loose connective tissue around the pathologically taut muscles (such as the tibialis anterior, peroneus longus, gastrocnemius, soleus, peroneus brevis, and extensor digitorum longus, etc.). After the needle is fully inserted, fix the protruding part of the hose holder onto the card slot.To minimize the participants' perception of pain, the doctor uses the index finger and ring finger to perform a smooth, gentle, and fan-shaped swinging motion in an alternating front-to-back manner.The sector angle is approximately 60°. It makes a total of round - trips 45 times within 30 seconds. The rocking motion is accompanied by Reperfusion Approach: A set of procedures consists of 20 times of rocking followed by 10 seconds of reperfusion method. Each target lesioned tense muscle requires 2 - 3 sets of the above - mentioned procedures.
223437583|NCT07161427|BEHAVIORAL|Ankle joint aids combined with exercise therapy|Participants in the combination therapy group wore ankle orthoses during their daily activities from 9:00 to 20:00 every day for a total of 2 weeks. To ensure standardization, a unified specification is selected for the ankle joint orthosis: Product number: 100159548, the 195R Super Sports Ankle Brace for Inversion/Eversion Sprains and Ligament Fixation by McDavid from the United States. During the treatment with ankle joint orthosis, complete the resistance training every day.
223437584|NCT07163026|PROCEDURE|Erector Spine Plane Block|Bilateral erector spinae plane block was performed under aseptic conditions at the T7 vertebral level using ultrasound guidance with a convex probe. An 80-mm peripheral nerve block needle was inserted 3-4 cm lateral to the midline with an in-plane approach to the fascial plane deep to the erector spinae muscle. After negative aspiration and hydrodissection with 1-3 ml of saline, 30 ml of 0.25% bupivacaine was injected on each side, with craniocaudal spread confirmed by ultrasound. Patients were then positioned for surgery.
223437585|NCT07163026|PROCEDURE|External Oblique - Intercostal Plane Block|Bilateral external oblique-intercostal plane block was performed under aseptic conditions by identifying the 6th and 7th ribs along the midclavicular line. Using ultrasound guidance with the probe placed parallel to the midclavicular line, the ribs, intercostal muscles, external oblique muscle, and pleura were visualized. A 50-mm block needle was advanced craniocaudally into the plane between the external oblique and intercostal muscles. After negative aspiration and hydrodissection with 1-3 ml saline, 30 ml of 0.25% bupivacaine was injected on each side, with craniocaudal spread confirmed by ultrasound. Patients were then positioned for surgery.
223437586|NCT07158528|PROCEDURE|coronally advanced flap with connective tissue graft|The gum at the recession site is elevated and repositioned higher, combined with a connective tissue graft.
223437587|NCT07158528|PROCEDURE|tunneled coronally advanced flap with a connective tissue graft|The gum at the recession site is undermined, only partially detached, and repositioned higher, combined with a connective tissue graft.
223437588|NCT07160361|DRUG|Lenvatinib + losartan|"Patients will receive a combination of lenvatinib and losartan at the same time after surgery for treatment cycles once daily (lenvatinib and losartan).~Adjuvant therapy will be started within 2-6 weeks after surgery for a period of time to evaluate the effect of different treatment regimens on reducing tumor recurrence and improving survival.~lenvatinib: orally once daily according to standard dosing guidelines, starting postoperatively.~losartan: 50mg losartan potassium tablets orally once daily starting postoperatively."
224048623|NCT03092206|DRUG|E/C/F/TAF|antiretroviral therapy
224048624|NCT03092206|DRUG|R/F/TAF|antiretroviral therapy
224048625|NCT02386748|DIETARY_SUPPLEMENT|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
224048626|NCT02386748|DIETARY_SUPPLEMENT|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
224143368|NCT00024193|PROCEDURE|conventional surgery|
224143369|NCT00024193|PROCEDURE|peripheral blood stem cell transplantation|
224048627|NCT02386748|OTHER|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
224048628|NCT05417607|BEHAVIORAL|P-ESDM informed caregiver coaching|Caregiver coaching informed by P-ESDM done remotely (via telehealth)
224048629|NCT05929560|OTHER|Conventional impression|Palatal impressions obtained using an irreversible hydrocolloid impression material
224048630|NCT05929560|OTHER|Digital impression|after obtaining stone models from conventional impression material, stone models were scanned using the I700 (Medit) scanner and Patients were directly scanned intraorally using an intraoral 3D scanner Subsequently, the printed 3D model scan data of the seven patients were then used for standard triangulated language (STL)
224048631|NCT03024970|DEVICE|stenfilcon A lens with solution additive (test)|silicone hydrogel lens
224143370|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
224143371|NCT02678312|DRUG|Enalapril|Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
224048632|NCT03024970|DEVICE|stenfilcon A lens (control)|contact lens
224143372|NCT02678312|DRUG|Placebo of LCZ696|
224143373|NCT02678312|DRUG|Placebo of Enalapril|
224143374|NCT02678312|DRUG|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
224048633|NCT04457466|DRUG|Nerve Growth Factor|Induction of experimental muscle soreness using intramuscular injections of Nerve Growth Factor.
224048634|NCT00277251|DRUG|Alendronate|
224048635|NCT02119754|DRUG|Plurogel PN|
224143375|NCT01646801|DEVICE|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
224143376|NCT00683813|BEHAVIORAL|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
223437589|NCT07166913|BEHAVIORAL|Toolkit|The toolkit contains information regarding enhanced stakeholder engagement strategies. The toolkit includes guidance materials, checklists, and templates/ sample materials, to increase stakeholder engagement in the research. This includes guidance on setting up a stakeholder advisory board (SAB) and ensuring literacy- and language- sensitivity of participant-/stakeholder-facing materials.
223437590|NCT07166211|BIOLOGICAL|CM512 injection|subcutaneous injection
223437591|NCT07166211|DRUG|placebo|subcutaneous injection
224048636|NCT03299634|OTHER|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
224048637|NCT05221723|BEHAVIORAL|High Intensity Interval Exercise Training Group|Participants will participate in a maximum of twice weekly exercise classes (90 minutes each class) for a total of 6 months. While participants will be encouraged to attend as many classes as able, there is no minimum requirement for class attendance. During the exercise classes, participants will participate in a 10-minute warm up, followed by 30-60 minutes of aerobic, resistance and/or balance training up to a maximum intensity of 8/10 on the rating of perceived exertion scale. Participants will finish each class with a 10-minute cool-down consisting of lower intensity exercise.
224048638|NCT03244514|OTHER|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
224048639|NCT00457873|DRUG|0.9% saline in 5% dextrose (intravenous)|
224048640|NCT00457873|DRUG|0.45% saline in 5% dextrose (intravenous)|
223437592|NCT07161882|OTHER|Observational Data Collection|Collection of clinical, pathological, molecular, and treatment-related data during routine care, with no additional procedures or interventions required by the study.
224048641|NCT00909233|DRUG|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
224048642|NCT06035991|PROCEDURE|Heart transplantation|Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
224048643|NCT00053924|DRUG|perifosine|
223437593|NCT07175220|DRUG|SHR2554; SHR-A2102|SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days
223437594|NCT07175220|DRUG|SHR2554; Adabelimumab|SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days
223437595|NCT07175220|DRUG|SHR2554; SHR-1701|SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days
223437596|NCT07176247|DRUG|Aztreonam-Avibactam|Antibiotic therapy with Aztreonam-Avibactam
223437597|NCT04683939|DRUG|BNT141|Intravenous (IV)
223437598|NCT04683939|DRUG|Nab-paclitaxel|IV
223437599|NCT04683939|DRUG|Gemcitabine|IV
223437600|NCT05875493|DRUG|JAB-21822|2 discrete single doses
223437601|NCT05875493|DRUG|JAB-21822|2 discrete single doses
223437602|NCT04455776|DRUG|Propofol|Sedation by propofol
224048644|NCT03750578|BEHAVIORAL|Virtual Reality goggle (Oculus Rift ® Helmet)|as described
224048645|NCT05586750|DRUG|Atorvastatin 40 Mg Oral Tablet|40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
224048646|NCT05586750|DRUG|Placebo|2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
223437603|NCT02000882|DRUG|BKM120|
223437604|NCT02000882|DRUG|capecitabine|
223437605|NCT02000882|DRUG|Trastuzumab|
223437606|NCT03964701|OTHER|no intervention|no interventional study
223437607|NCT00549601|DRUG|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
223437608|NCT00549601|DRUG|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
223437609|NCT00549601|DRUG|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
223437610|NCT03690362|DRUG|VNRX-5133 and VNRX-5022|intravenous infusion
223437611|NCT05816460|OTHER|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I)|Digital Cognitive Behavioural Therapy for Insomnia (dCBT-I) will be delivered through an online platform called Sleepio (BigHealth Ltd)
223437612|NCT05816460|OTHER|Sleep Hygiene Education (SHE)|Sleep Hygiene Education (SHE) will be provided electronically
223437613|NCT00004176|DRUG|amifostine trihydrate|
223437614|NCT00004176|DRUG|cisplatin|
223437615|NCT00004176|DRUG|etoposide|
223437616|NCT00004176|RADIATION|radiation therapy|
223437617|NCT02102594|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
223437618|NCT01145794|BEHAVIORAL|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
223437619|NCT04719429|DIETARY_SUPPLEMENT|Cricket-derived Protein|Beverage containing 25 g cricket-derived protein
223437620|NCT04719429|DIETARY_SUPPLEMENT|Beef-derived Protein|Beverage containing 25 g beef-derived protein
224048647|NCT03015519|DRUG|Albiglutide|30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
224048648|NCT03015519|DRUG|Placebo|Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
224048649|NCT01974388|PROCEDURE|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
224048650|NCT01974388|PROCEDURE|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
224048651|NCT01937572|OTHER|Visionaire system (Knee MRI)|
224048652|NCT01937572|OTHER|No Knee MRI|
224048653|NCT02901574|DEVICE|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
224048654|NCT02901574|DEVICE|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
223437621|NCT03081091|DEVICE|Acupuncture|"The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms."
223437622|NCT03081091|DEVICE|Sham Acupuncture|"It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120."
223437623|NCT02215746|DRUG|BI 44370 powder for oral solution|
223437624|NCT02215746|DRUG|BI 44370 tablet|
223437625|NCT02215746|OTHER|high fat breakfast|
223437626|NCT00915265|OTHER|Multilobed catheter (group CPA)|\- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
223566431|NCT02047773|OTHER|Duration|If bacterial load checked on day 7 is less than 10\^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10\^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
223566432|NCT02047773|DRUG|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
223566433|NCT02047773|DRUG|Meropenem|
223566434|NCT05227560|OTHER|Complementary Therapies|The emotional freedom technique was applied to the experimental group.
223566435|NCT01747408|DRUG|Human Albumin|"25% human albumin given in four escalating doses:~1. Group 1: .625g/kg infused over 3hrs daily X 7day~2. Group 2: 1.25g/kg infused over 3hrs daily X 7day~3. Group 3: 1.875g/kg infused over 3hrs daily X 7day~4. Group 4: 2.5g/kg infused over 3hrs daily X 7day"
224048655|NCT02901574|BEHAVIORAL|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
224048656|NCT04980950|DIETARY_SUPPLEMENT|Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science|Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients.
224143377|NCT01207284|OTHER|Physical Therapy|strengthening passive and active stretching balance training gait training
224143378|NCT00271271|DRUG|oxaliplatine / gemcitabine / Vinorelbine|
224143379|NCT06339606|OTHER|Biospecimen collection|Biospecimens, including maternal blood and cervical mucus will be collected serially during pregnancy. After delivery tissue samples from the placenta and umbilical cord blood will be collected.
224143380|NCT01189799|BEHAVIORAL|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
224143381|NCT01189799|BEHAVIORAL|Dual Recovery Anonymous/Tx as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
224143382|NCT01250652|DRUG|Levocetirizine|20 mg levocetirizine for 5 days
224143383|NCT01250652|DRUG|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
224143384|NCT06380764|PROCEDURE|Greater Occipital Nerve Block|"The occipital artery was localized, while the patient was setting with flexed neck, at the point of meeting of the medial third and the lateral two-thirds of a line drawn extending from the ipsilateral mastoid process to the external occipital protuberance and the GON was located on the medial side of the artery where it exits out of the trapezius fascia into the nuchal line about 5-cm lateral to midline.~For assurance of GON localization, pressure was applied and the resultant tenderness indicated the site of the nerve. Injection procedure was performed as distal injection at the site of nerve localization and proximal injection was performed at 1.5 cm lateral to the sagittal plane and 3 cm below to the level of the external occipital protuberance."
224300221|NCT04790838|DRUG|Reference|2 inhalations of Test and Reference product in each study period
224300222|NCT04690517|PROCEDURE|tracheal ultrasound|When checking tracheal ultrasound, several signs are used in judgements. Direct signs include reverberation artifact and double ring sign. Indirect sign means checking the bilateral lung sliding.
224300223|NCT01691924|DRUG|PBF-509|
224300224|NCT01691924|DRUG|Placebo|
224300225|NCT00063635|DRUG|Metformin|500 mg, twice daily
224300226|NCT00063635|DIETARY_SUPPLEMENT|Vitamin E|400 IU, twice daily
224048657|NCT03084406|OTHER|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
224048658|NCT00225979|DRUG|Octreotide LAR|
224048659|NCT02616744|DRUG|Ibandronic acid|150 mg per month oral ibandronate
224143385|NCT06380764|PROCEDURE|Bilateral suboccipital intramuscular injection|Sub-occipital intramuscular injection of the prepared solution was carried out on both sides while the patient was setting with maximally flexing the neck to expose these muscles.
224300227|NCT00063635|DRUG|Matching placebo|Twice daily
224300228|NCT03795896|DIAGNOSTIC_TEST|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
224300229|NCT02263235|BIOLOGICAL|administration of stable isotope-labelled leucine-|\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
224300230|NCT02263235|OTHER|collection of CSF, blood, urine, saliva|\- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
224300231|NCT01663935|DRUG|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
224300232|NCT02792959|DEVICE|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
223437627|NCT00915265|OTHER|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
223437628|NCT05063526|DEVICE|ultrasound|ultrasound on diaphragm
223437629|NCT04525326|DRUG|Cetuximab|mFOLFOX+Cetuximab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
223437630|NCT04525326|DRUG|Bevacizumab|mFOLFOX+Bevacizumab for Ras / BRAF Wild Type Unresectable Right Colon Cancer Patients With Liver Metastasis
223437631|NCT04525326|DRUG|mFOLFOX/FOLFIRI ( Standard Chemotherapy)|Standard Chemotherapy
223437632|NCT02389374|DRUG|chloroquine|standard dose
223437633|NCT02389374|DRUG|Artemether-lumefantrine combination|standard dose
223437634|NCT02389374|DRUG|Primaquine|single dose
223437635|NCT02389374|DRUG|Primaquine|14 days
223437636|NCT00937092|DRUG|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
223566436|NCT05386862|BEHAVIORAL|Reduce THC Use|Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
224048660|NCT02616744|DRUG|Placebo|1 oral capsule of placebo per month
224048661|NCT00189618|DRUG|Aspirin|100mg p.o. OD
224048662|NCT00189618|DRUG|Clopidogrel|75mg p.o. OD
224048663|NCT05864742|DRUG|Ibrutinib|560 mg daily continuously
224048664|NCT05864742|DRUG|Venetoclax|Oral daily. Dose escalation every 7 days (if no TLS) 20mg, 50mg, 100mg, 200mg and 400mg
224143386|NCT06380764|PROCEDURE|Epidural Blood Patch|Patients showed manifestations of block failure within 24-h after block, received lumbar Epidural blood patch under non-invasive monitoring in the theater. Patient was positioned in the lateral decubitus position, lumbar area was sterilized and the epidural space previously used for receiving the previous neuraxial anesthesia was identified. Fifteen ml of venous blood was obtained aseptically and slowly injected while patient was monitored for the extent of pain severity until complete pain relief.
224300233|NCT02792959|DEVICE|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
224300234|NCT00562575|DRUG|SLx-4090|
224300235|NCT00562575|DRUG|Placebo|
224300236|NCT05050006|BIOLOGICAL|ITIL-168|ITIL-168 is a cell therapy product derived from a patient's own TILs. A tumor sample is removed from each patient to make a personalized ITIL-168 product. Once ITIL-168 has been made, the patient is treated with 5 days of lymphodepleting chemotherapy including cyclophosphamide and fludarabine, followed by a single infusion of ITIL-168, and up to 8 doses of IL-2.
224300237|NCT02075671|DRUG|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
224300238|NCT02075671|DEVICE|Blu-U Light Therapy|Intervention used in experimental and sham arms
224300239|NCT02075671|OTHER|Placebo vehicle only|Intervention only includes the placebo vehicle solution
224300240|NCT05912907|OTHER|potassium nitrate in polycarboxilate cement|5% potassium nitrate in polycarboxylate; pre-weighed 95 mg zinc oxide powder and 5mg of KNO3 will be placed on a glass slab followed by mixing by polyacrylic acid (liquid) in a 1:1 P/L ratio
224300241|NCT06360315|OTHER|Incentive letter for pneumococcal vaccination to the patient and to the GP|Incentive letter for pneumococcal vaccination to the patient and to the GP
223437637|NCT00937092|DRUG|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
223437638|NCT04081857|DRUG|HGP1810|HGP1810: Vildagliptin/Metformin
223437639|NCT04081857|DRUG|HCP1704|HCP1704: Vildagliptin/Metformin
223437640|NCT05264103|DEVICE|Exoskeleton for gait rehabilitation (Atalante)|Subjects will walk with different levels of assistance given by the robot.
224048665|NCT05864742|DRUG|Navitoclax|Oral daily. Dose-escalation every 14 days (if plt \>75x10\^9/L) 50mg, 100mg, 150mg, and 200mg (target dose)
224048666|NCT05864742|DRUG|Rituximab|375mg/m2, intravenous. To be given on day 1 of weeks 1, 2, 3, 4 of C1 and day 1 of C2-C8
224048667|NCT02790138|DRUG|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
224048668|NCT02790138|DRUG|Ciprofloxacin|Ciprofloxacin tablets
224048669|NCT02790138|DRUG|Vedolizumab|Vedolizumab IV infusion
224048670|NCT04360499|OTHER|Low- weight-high-repetitions training|LWHR refers to a specific form of resistance exercise which utilizes low weights and very high repetitions
224048671|NCT04360499|OTHER|Pilates training|Pilates style exercise training
224048672|NCT02903251|DRUG|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
224048673|NCT02903251|OTHER|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
224048674|NCT06343935|DRUG|Linperlisib|Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-δ (PI3K-δ)
224300242|NCT00554307|DEVICE|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
224300243|NCT00038987|BIOLOGICAL|Wetvax (APSV)|
224300244|NCT05941689|DEVICE|AI-assisted colonoscopy|AI can not only detect suspicious lesions timely, and label them in the field of view of the colonoscopy, but also monitor withdrawal speed and calculate the clean withdrawal time automatically.
224300245|NCT03914950|DIAGNOSTIC_TEST|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen with parenteral contrast medium (Visipaque=Iodixanol) if creatinine, GFR, and TSH levels are within the normal range and oral (water) contrast medium within TOF-18F-FDG PET/CT. In the case of elevated creatine or decreased GFR or TSH levels a diagnostic CT of the abdomen or upper abdomen without contrast medium is performed.~Biopsy or FNA or operation of the pancreas."
224300246|NCT04101500|DRUG|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
224300247|NCT04101500|DRUG|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
224300248|NCT04101500|DRUG|Placebo Tablets|Applied only to the control group.
224300249|NCT03674086|DEVICE|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
224300250|NCT04199013|DRUG|Ropivacaine 0.75% Injectable Solution|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
224300251|NCT04199013|DRUG|Fentanyl Citrate|Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
224300252|NCT02517437|DRUG|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
224300253|NCT02517437|DRUG|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
224300254|NCT01330771|DRUG|hMG-HP/r-FSH|
224300255|NCT02575911|DEVICE|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
224300256|NCT02575911|PROCEDURE|LASIK surgery|
224300257|NCT02589483|PROCEDURE|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
224300258|NCT02589483|DEVICE|Hemopatch|The rectal anastomosis reinforced with Hemopatch
224300259|NCT05418166|DRUG|Evolocumab|evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
224300260|NCT01249365|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
224300261|NCT03069950|DRUG|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
224300262|NCT03069950|DRUG|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
224300263|NCT03069950|DRUG|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
224300264|NCT03069950|DRUG|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
223437641|NCT05328388|DIETARY_SUPPLEMENT|Lycomato|Lycomato sof gels
223437642|NCT02175381|DRUG|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
224048675|NCT05300321|DEVICE|frame lens|The subjects were randomized to allocate in Single Vision (SV) lens or Defocus Incorporated Multiple Segments (DIMS) Lens group.
224048676|NCT02408107|BEHAVIORAL|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
224048677|NCT02985099|DRUG|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
224048678|NCT02985099|DRUG|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
224048679|NCT01786603|DRUG|Rasagiline|Rasagiline 2mg once a day for 12 months.
224048680|NCT01786603|DRUG|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
223437643|NCT02175381|DRUG|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
224048681|NCT03848754|DRUG|Gemtuzumab Ozogamicin 3 mg/m^2|"GO 3 mg/m\^2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
224048682|NCT03848754|DRUG|Gemtuzumab Ozogamicin 2 mg/m^2|GO 2 mg/m\^2 on Day 1 of a 28-day cycle.
223437644|NCT02245113|OTHER|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
224143387|NCT06380764|DRUG|Normal Saline 10 mL Injection|Placebo drug
223437645|NCT03468452|OTHER|extubation|Time of extubation
223437646|NCT01361113|DRUG|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
224048683|NCT03848754|DRUG|Pracinostat - 45 mg|Induction: 45mg administered orally 3 days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.
224143388|NCT06380764|DRUG|Lidocaine 2% Injectable Solution|Lidocaine is the main drug used in the interventions as it was injected to achieve bilateral block or intramuscular infiltration
224143389|NCT04154657|PROCEDURE|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
224143390|NCT02281968|DRUG|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
223437647|NCT01631838|DIETARY_SUPPLEMENT|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
224143391|NCT02281968|DRUG|Placebo|
224143392|NCT04678297|BEHAVIORAL|Physical activity + emotion regulation intervention|The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
224143393|NCT04678297|BEHAVIORAL|Physical activity control intervention|The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
224163678|NCT03409575|OTHER|5 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
223437648|NCT01631838|DIETARY_SUPPLEMENT|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
223437649|NCT04395313|OTHER|no intervention carried out|no intervention was done
223437650|NCT01807728|OTHER|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
224048684|NCT03848754|DRUG|Pracinostat - 60 mg|Escalation: 60 mg administered orally three days a week with 48 hours between dosing (e.g., Monday, Wednesday, and Friday) for three consecutive weeks, followed by one week of rest, in 28-day cycles.
224048685|NCT01226459|DRUG|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
224048686|NCT01226459|DRUG|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
224048687|NCT01059110|DRUG|Salicylate ointment|cream, one application every night, for 90 days
224048688|NCT01059110|DRUG|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
224048689|NCT01059110|DRUG|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
224048690|NCT01059110|DRUG|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
224048691|NCT01112176|PROCEDURE|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
224048692|NCT00474708|DRUG|Effexor|
223437651|NCT01807728|OTHER|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
223566437|NCT03118427|PROCEDURE|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
223566438|NCT03118427|PROCEDURE|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
224048693|NCT00474708|DRUG|SSRI|
224048694|NCT01030159|OTHER|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
224048695|NCT03770091|DRUG|Theraworx|Theraworx foam applied to skin and/or compression wrap
224048696|NCT03770091|DRUG|Placebo|Placebo foam
224048697|NCT00136526|DRUG|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
224048698|NCT00625495|DRUG|Esomeprazole|40mg Intravenous infusion over 3 minutes
224143394|NCT02771652|BEHAVIORAL|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
224143395|NCT02771652|OTHER|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
224143396|NCT04157868|DRUG|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
224143397|NCT04157868|DRUG|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
224048699|NCT00625495|DRUG|Esomeprazole|40mg Oral
224048700|NCT03700320|DRUG|Standard of Care (SOC) Migraine Preventive Medication|Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.
224048701|NCT03700320|DRUG|Atogepant|Atogepant tablets taken orally, once daily for 52 weeks.
224048702|NCT00187213|DEVICE|Cardiac Resynchronization Therapy|
224048703|NCT00480181|DRUG|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
224048704|NCT00480181|OTHER|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
224048705|NCT03193762|OTHER|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
224048706|NCT03951051|DRUG|Olmesartan Medoxomil 40 mg|Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
224048707|NCT03951051|DRUG|Olmetec®|Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
224048708|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
224048709|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
224048710|NCT01504165|DRUG|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
224048711|NCT01504165|DRUG|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
224048712|NCT01504165|DRUG|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide \> 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
224048713|NCT03039231|DEVICE|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
224048714|NCT02841202|DRUG|oral contraceptive pills|
224048715|NCT01391403|DRUG|Artemisinin|400 mg/day
224143398|NCT05414149|PROCEDURE|preoperative intravitreal injections of ranibizumab or conbercept|IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
224048716|NCT01391403|OTHER|Placebo|400mg/day
224048717|NCT01083524|DRUG|Dichloroacetate Sodium|3 mg po bid for 28 weeks
224048718|NCT01083524|DRUG|Dichloroacetate Sodium|6.25 mg po bid
224048719|NCT01083524|DRUG|Dichloroacetate Sodium|12.5 mg po bid
224048720|NCT04970550|OTHER|Non intervention|Non intervention
224048721|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Consult
224048722|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Control - Standard of Care
224048723|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Newsletter
224048724|NCT01427465|BEHAVIORAL|Brief Prevention Program Using Positive Image|Parent Letter
224048725|NCT00838292|DIETARY_SUPPLEMENT|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
224048726|NCT00838292|OTHER|nutrition counseling|
224048727|NCT00175877|BIOLOGICAL|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
224143399|NCT06068179|DRUG|Mycophenolate Mofetil, Oral, 250 Mg|Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
224300265|NCT03069950|DRUG|DEXAMETHASONE|flat dose of 25 mg on Day 1
224300266|NCT03069950|DRUG|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
224048728|NCT03306355|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
224048729|NCT03306355|DEVICE|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
224048730|NCT01978535|DRUG|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
224048731|NCT01978535|DRUG|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
224048732|NCT05311670|BEHAVIORAL|Patient-reported outcomes monitoring|o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
224300267|NCT00003851|BIOLOGICAL|proteolytic enzymes|
223437652|NCT02810015|DRUG|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
223437653|NCT02513602|PROCEDURE|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
223437654|NCT00919542|DRUG|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
224048733|NCT05520437|DIETARY_SUPPLEMENT|Omega-3 fatty acids|Participants received Omega-3 supplements (NAMEDSPORT) in the form of softgels over a period of 12 weeks. The supplement is certified by the International Fish Oil Standards™ (IFOS™) Program. Daily dose contained a total of 3276 mg of Omega 3 (4000 mg of fish oil of which: EPA 2234mg; DHA 916mg).
224048734|NCT05520437|DIETARY_SUPPLEMENT|Placebo|Participants will receive a placebo in the form of MCT oil capsules with no effect on the hypothesized outcome.
224048735|NCT04961268|DRUG|TraMADol 50 Mg Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
224048736|NCT04961268|DRUG|Tramadol 100 MG Oral Tablet|The patients were randomly given the medication by mouth 60 min before administering IANB.
224048737|NCT04961268|DRUG|Ibuprofen 600Mg Tab|The patients were randomly given the medication by mouth 60 min before administering IANB.
224048738|NCT04961268|DRUG|ibuprofen 600 mg/acetaminophen 1000 mg|The patients were randomly given the medication by mouth 60 min before administering IANB.
224048739|NCT04961268|DRUG|Placebo|The patients were randomly given the medication by mouth 60 min before administering IANB.
224143400|NCT06068179|DRUG|methimazole, oral, 10mg|Methimazole 15-30mg daily initially then titrate to maintenance dose.
224048740|NCT03456648|DRUG|apixaban|non-vitamin K oral anticoagulant (NOAC)
224048741|NCT04278300|BIOLOGICAL|blood sampling|dosage of omega 3 polyunsaturated fatty acids, search for age-related macular degeneration susceptibility genese
224143401|NCT00971425|BIOLOGICAL|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
224143402|NCT00971425|BIOLOGICAL|Fluarix™|1 dose intramuscular injection
224143403|NCT00971425|BIOLOGICAL|Placebo|1 dose intramuscular injection
224143404|NCT00171106|DRUG|valsartan|
224143405|NCT00966810|PROCEDURE|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
224143406|NCT06418126|BIOLOGICAL|blood sampling before radiotherapy|A blood sample (20 ml) will be taken prior to radiotherapy
223437655|NCT00919542|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
223437656|NCT06355856|DRUG|DNN.22.17.036|Apply twice daily to the affected area and around it.
223437657|NCT06355856|DRUG|10573048700|Apply twice daily to the affected area and around it.
223437658|NCT05509764|DIAGNOSTIC_TEST|lung ultrasound score|determination of atelectasis by lung ultrasound score
224048742|NCT04278300|BIOLOGICAL|faecal sampling (optional)|analysis of the microbiota by DNA sequencing
224048743|NCT02042651|DEVICE|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
224048744|NCT02042651|DEVICE|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
223437659|NCT04167163|DRUG|Abaloparatide|18 month ABL treatment
223437660|NCT01378715|DRUG|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
224048745|NCT05680571|DEVICE|BulbiCam|BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation
224048746|NCT05511974|DIAGNOSTIC_TEST|BASET score|The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
224048747|NCT03171766|DIAGNOSTIC_TEST|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
224048748|NCT03171766|DIAGNOSTIC_TEST|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
224048749|NCT03171766|DIAGNOSTIC_TEST|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
224143407|NCT06418126|BIOLOGICAL|blood sampling after the fourth radiotherapy session|A blood sample (20 ml) will be taken immediately after the 4th radiotherapy session.
224143408|NCT06418126|OTHER|collection of acute toxicity (radiodermatitis)|for the entire duration of radiotherapy
224143409|NCT06418126|OTHER|collection of late toxicity|every year for 5 years
224143410|NCT06418126|OTHER|collection of disease status|throughout the study
223437661|NCT02461680|PROCEDURE|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
223437662|NCT02461680|PROCEDURE|suture|
223437663|NCT06455397|BEHAVIORAL|The Building Emotional Awareness and Mental Health (BEAM) Program|"The BEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving maternal mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy, and the Unified Protocol.~Program delivery will be facilitated through a mobile application. The BEAM program uses a stepped care model to address the pressing need for accessible and effective mental health interventions. Stepped care is a framework that provides mental health services in a tiered manner, ensuring that participants receive appropriate levels of support based on the severity of needs. At the heart of this model are BEAM peer coaches, who will have the most direct contact with participants. Peer coaches are trained to escalate concerns to the program clinical team as required."
223437664|NCT03564132|DRUG|Yigansan|Yigansan granules
223437665|NCT03564132|DRUG|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
223437666|NCT05030207|DIAGNOSTIC_TEST|Real-time Gated 4DCT|Real-time gated four-dimensional cone beam computed tomography (4DCT) will be conducted at the simulation session. The Real-Time Gated 4DCT will be conducted while the patient moves through the rotating X-ray imager. This method detects and then pauses the CT beam during irregular breathing events.
223437667|NCT05030207|DIAGNOSTIC_TEST|Conventional 4DCT|Four-dimensional computed tomography (4DCT), the standard of care for modern high-precision stereotactic ablative body radiotherapy (SABR), will be conducted at the simulation session. It will run continuously while the patient moves through the rotating X-ray imager.
223437668|NCT05026580|BEHAVIORAL|Joint Academy exercise and education smart phone application|The Joint Academy® (www.jointacademy.com) program for people with hip or knee OA consists of video instructed and progressively adaptable daily exercises, patient education through text lessons and a continuous asynchronous chat function with a personal reg. physiotherapist who supervises the patient during the full participation period.
223566439|NCT04552639|BEHAVIORAL|Newbridge Eating disorders Activity Treatment group|A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.
223566440|NCT04552639|BEHAVIORAL|Newbridge House treatment as usual|Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
223566441|NCT01895543|DRUG|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
223566442|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (≥5 times per week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
224048750|NCT04961151|OTHER|Multimodal therapeutic warming w/ esophageal d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
224048751|NCT04961151|OTHER|Multimodal therapeutic warming w/ conductive d/c|In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
224048752|NCT04514120|OTHER|AJESS scoring process|We will collecto endoscopic pictures from stable and non stable participants. Pictures will be taken for each sinus, olfactory cleft, and middle meatus in private clinical exam rooms. For each anatomic site \[left middle meatus (LMM), left ethmoid sinus (LES), left frontal sinus (LFS), left maxillary sinus (LMS), left olfactory cleft (LOC), left sphenoid sinus (LSS), right middle meatus (RMM), right ethmoid sinus (RES), right frontal sinus (RFS), right maxillary sinus (RMS), right olfactory cleft (ROC), right sphenoid sinus (RSS)\], numerical scores describe edema or polyposis while alphabetical scores, in lower case or upper case corresponding to severity, describe CRS features: crusting, synechiae, purulence, mucus, recirculation, and ostial narrowness.
224048753|NCT01092143|DRUG|BI 671800|BI 671800
224048754|NCT01092143|DRUG|Fluticasone propionate placebo|Placebo matching Fluticasone propionate
224048755|NCT01092143|DRUG|Fluticasone propionate|Fluticasone propionate
224048756|NCT01092143|DRUG|BI 671800 Placebo|Placebo matching BI 671800
224048757|NCT02407470|DRUG|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
224048758|NCT02407470|PROCEDURE|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
224048759|NCT02407470|PROCEDURE|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
224143411|NCT06418126|RADIATION|Radiotherapy - Breast +/- lymph node areas|40.05 Gy in 15 fractions of 2.67 Gy, one fraction per week, 5 days per week Or 50 Gy in 25 fractions of 2 Gy, one fraction per week, 5 days per week
224143412|NCT06418126|RADIATION|Radiotherapy - Boost operating bed|10 Gy in 4 fractions of 2.5 Gy, one fraction per week, 5 days per week Or 16 Gy in 8 fractions of 2 Gy, one fraction per week, 5 days per week
224143413|NCT01811381|DRUG|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
224300268|NCT00003851|DRUG|gemcitabine hydrochloride|
224300269|NCT00003851|PROCEDURE|Gonzalez regimen|
224300270|NCT04402775|OTHER|Tourniquet|A tourniquet will be used during surgery
223437669|NCT06404684|BEHAVIORAL|Cognitive behavioral therapy (CBT)|se above
223437670|NCT06285136|PROCEDURE|DEC3-VEN|Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
223437671|NCT05850104|OTHER|the effects of classical Chopart prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of classical Chopart prosthesis and silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
223437672|NCT05850104|OTHER|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.|the effects of silicone prosthesis on socket comfort, satisfaction level and quality of life in patients with unilateral Chopart amputation.
224048760|NCT05117255|BEHAVIORAL|Negative Emotions and Addiction Tools Program (NEAT)- Cognitive Behavioral Therapy|The program provides simplified clinical, learning and neuroscience-based education about the vicious cycle in which negative affect serves to motivate drinking, which, in turn, worsens negative affect. Participants also learn how each of three skills (breathing control, cognitive restructuring, problem solving) was designed to disrupt a specific element of the vicious cycle that includes physiological, psychological and behavioral processes.
224048761|NCT05117255|BEHAVIORAL|Progressive Muscle Relaxation Training (PMRT)|PMRT is a standard stress management coping skill that entails tensing and releasing specified muscle groups to obtain deep muscle relaxation.
224048762|NCT05538520|OTHER|Traditional Pilates|This group will perform a traditional Pilates session, which consists of stretching exercises, followed by exercises to strengthen the core (trunk flexors and extensors), lower limbs and upper limbs. The total duration of the intervention in this group should be approximately 50 minutes.
224048763|NCT05538520|OTHER|Pilates without stretching|This group will conduct a non-traditional Pilates session. This is because stretching exercises will be excluded. The muscle strengthening exercises will be the same as in the TP group, so that it is possible to discuss the influence of the inclusion/exclusion of stretching for the considered outcomes. The total duration of the intervention in this group should be approximately 35 minutes.
224048764|NCT05189613|BIOLOGICAL|Mepolizumab|Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
224048765|NCT05406843|OTHER|Preoperative cognitive functions of participants undergoing open heart surgery|Surgery times and cross-clamping times of the participants who will undergo open heart surgery were recorded.
224048766|NCT05406843|OTHER|Postoperative cognitive functions of particiants undergoing open heart surgery|Changes in mini mental test scores were recorded in the postoperative period.
224048767|NCT00932984|DRUG|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
224048768|NCT04326699|PROCEDURE|Bilateral SIJ injection|under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ
224048769|NCT06306885|BEHAVIORAL|Action observation plus motor imagery followed by sleep|Participants will be asked to observe video-clips showing motor contents immediately before sleeping
224048770|NCT06306885|BEHAVIORAL|Action observation plus motor imagery|Participants will be asked to observe video-clips showing motor contents at least 12 hours before sleeping
224048771|NCT06306885|BEHAVIORAL|Control|Participants will be asked to observe video-clips showing landscapes before sleeping
224048772|NCT03536975|OTHER|Platform|"The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it"
224048773|NCT03986866|OTHER|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
224048774|NCT05738811|OTHER|TENS treatment protocol|The 2 sets of electrodes of TENS were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot.
224048775|NCT05738811|OTHER|EMS treatment protocol|The electrodes were placed over the common peroneal nerve as it passes over the head of fibula and the motor point of tibialis anterior to elicit dorsiflexion and eversion of foot. A portable comfy EMS channel was used to apply EMS protocol to set at threshold of muscle contraction level.
224048776|NCT05738811|OTHER|Exercises|Patient were given 30 minutes treatment session, 10 minutes of supported walking 10 minutes of BWS treadmill training 10 minutes of Task-specific over ground locomotor training (LT) There was rest of 2 minutes The frequency of the sessions was five times a week for 12 weeks.
224048777|NCT04820374|PROCEDURE|pupil's light and pupil diameter|It is necessary to meet the requirement that the pupil's light reflection is slightly restored to the state of entering the room, and then the tube is extubated and the pupil diameter and the light reflection are restored to the state of entering the room, leaving the recovery room
224048778|NCT04295096|DEVICE|Peripheral blood mononuclear cell apheresis|Peripheral blood mono-nuclear cell donation for tumor immunotherapy study of Universal CAR-T cells
224048779|NCT00024414|DRUG|DHA-paclitaxel|
224143414|NCT01811381|BEHAVIORAL|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
223437673|NCT02897726|DRUG|NVP-1402|Oral
223437674|NCT02897726|DRUG|NVP-1402R|Oral
223437675|NCT01601457|DRUG|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
223437676|NCT01601457|DRUG|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
223437677|NCT05948124|DRUG|L-carnitine|L-carnitine supplementation
223437678|NCT05948124|OTHER|isotonic saline|Intravenous 5 ml of isotonic saline
224048780|NCT01560923|BIOLOGICAL|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
223437679|NCT06622525|DRUG|Sodium bicarbonate|This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.
223437680|NCT06622525|OTHER|No intervention|The usual management for heat stroke will be given to this group
223437681|NCT06730503|DRUG|Immune checkpoint inhibitor|Observe a situation before and after immunotherapy
223437682|NCT03145662|DEVICE|high pressure balloon|high pressure balloon will be used to treat stenosis
223437683|NCT03145662|DEVICE|cutting balloon|cutting balloon will be used to treat stenosis
223437684|NCT01897662|DIETARY_SUPPLEMENT|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
223437685|NCT01897662|DIETARY_SUPPLEMENT|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
223437686|NCT05523141|DRUG|ASC10|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner"
223437687|NCT05523141|DRUG|Placebo|"Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner"
223437688|NCT03416634|BEHAVIORAL|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
223566443|NCT05383443|BEHAVIORAL|Physical exercise|"This component will be based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher:~i. In-person group training (monthly); ii. In-person group training or remote synchronous training (group) or provision of education booklets with photos and exercise instructions to be performed individually (twice weekly), depending on the evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic."
223566444|NCT05383443|BEHAVIORAL|Nutrition education|"This component will be based on the following activities:~i. In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants; ii. In-person individual appointment with a nutritionist (monthly)."
223566445|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|This component will be based on in-person 60-minute group sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
223566446|NCT05383443|OTHER|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
224048781|NCT01560923|BIOLOGICAL|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
224048782|NCT01560923|OTHER|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
224048783|NCT00201669|DRUG|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
224048784|NCT04158921|OTHER|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. \> 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
224048785|NCT05093322|DRUG|Surufatinib in combination with Gemcitabine|Surufatinib in combination with Gemcitabine
223437689|NCT03416634|BEHAVIORAL|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
223437690|NCT03416634|BEHAVIORAL|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
223437691|NCT03416634|BEHAVIORAL|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
223437692|NCT03035734|DRUG|BMS-986141 Form A Tablet|tablet
223437693|NCT03035734|DRUG|BMS-986141 Form B tablet (low dose)|tablet
223437694|NCT03035734|DRUG|BMS-986141 Form B tablet (high dose)|tablet
223437695|NCT04936698|DRUG|PTU 50 MG Oral Tablet|to treat if the patient has hyperthyroidism
223437696|NCT04936698|DRUG|Levothyroxin|to treat if the patient has hypothyroidism
223437697|NCT00018291|DRUG|Risperidone|
223437698|NCT00018291|DRUG|Gabapentin|
223437699|NCT03605940|COMBINATION_PRODUCT|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
223437700|NCT03605940|DRUG|Corticosteroids|2 mg/kg/day
223437701|NCT02839564|PROCEDURE|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
223437702|NCT02839564|PROCEDURE|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
224048786|NCT05710926|BEHAVIORAL|Evolutionary Systems Therapy for Schizotypy|A novel therapy for schizotypal traits integrating evolutionary psychopathology, compassion focused therapy, and metacognitively oriented psychotherapy.
223437703|NCT05792995|DRUG|Sindillimab|Any treatment regimen that includes immunotherapy.
223437704|NCT04977492|PROCEDURE|extracapsular release of lateral retinaculum|A new kind of surgery which releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
223437705|NCT04713436|DRUG|Differentiation Markers|Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
223437706|NCT04480567|DRUG|BMN 307|AAV Gene Therapy Infusion
223437707|NCT01022775|PROCEDURE|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
223437708|NCT01022775|PROCEDURE|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
223437709|NCT04739332|BEHAVIORAL|The Newborn behavioral observations system|The NBO system is a relationship building tool to enhance parental sensitivity in the newborn period. Mothers at risk for post-partum depression are supported by a clinician to respond with confidence to their newborn's individual needs.
223566447|NCT05383443|BEHAVIORAL|Cognitive training|"This component will comprise the following activities:~i. In-person group training (monthly): 60-minute sessions, supervised by a psychologist; ii. Home individual training (once a week): unsupervised 30-minutes remote sessions, using the COGWEB® online platform or paper/pencil exercises (for those participants without computer/internet or who do not use one autonomously)."
223566448|NCT05383443|BEHAVIORAL|Physical exercise|In-person group training (monthly): 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, supervised by a physical education teacher.
223566449|NCT05383443|BEHAVIORAL|Nutrition education|In-person group 120-minute sessions (monthly), guided by a nutritionist, comprising: presentation and discussion of healthy and easy to cook recipes by the nutritionist and preparation of healthy meals by the participants. The participants will have the opportunity to consume the prepared meals at home.
224048787|NCT05710926|BEHAVIORAL|Cognitive Behavioral Therapy|An adaptation of Cognitive Behavioral Therapy for those diagnosed with personaloty disorders.
224143415|NCT01811381|BEHAVIORAL|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
224143416|NCT01811381|DIETARY_SUPPLEMENT|Placebo|Subjects will take 4 capsules x BID of placebo
223566450|NCT05383443|BEHAVIORAL|Capacitation to deal with cognitive decline|In-person group 60-minute sessions (monthly), guided by a psychologist, allowing participants to share experiences and learn strategies to cope with cognitive decline in their daily life.
224143417|NCT03573440|OTHER|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
223566451|NCT05383443|BEHAVIORAL|Diagnosis and correction of hearing impairment|This component will be based on an evaluation session conducted by otolaryngologists and audiologists, who will evaluate previous hearing problems and use of hearing aids, and will include an otoscopy and an audiogram.
223566452|NCT04597216|DEVICE|sample of blood and saliva|sample of 3ml of blood by veinous puncture, of 1 drop of blood by needlestick, and of saliva by spitting
223566453|NCT04907773|OTHER|Capillary blood sampling|Each subject will have one to two capillary blood collections.
224143418|NCT01705964|DRUG|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
224048788|NCT02452281|DRUG|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
224048789|NCT02452281|DRUG|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
224048790|NCT01079897|DEVICE|Atopiclair|topical applied cream, twice daily
224048791|NCT01079897|DEVICE|EHK02-01|topical applied cream containing 7% ectoine
224048792|NCT01033253|BEHAVIORAL|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
224143419|NCT01705964|OTHER|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
224143420|NCT02293993|DRUG|SGI-110|
224143421|NCT01697852|OTHER|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
223437710|NCT02340312|PROCEDURE|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
223437711|NCT02340312|OTHER|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
223437712|NCT06237816|OTHER|Patient Education Intervention|Multimedia Educational Videos
223437713|NCT06237816|OTHER|Provider Education Intervention|Provider workshops via zoom
223437714|NCT04643964|BEHAVIORAL|Entrée: Cognitive skills|In this condition, participants view a video-based intervention covering cognitive emotion regulation skills. This intervention asks participants to respond to questions and practice identifying and evaluating their own thoughts using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
223566454|NCT04907773|OTHER|Venous blood sampling|Each healthy subject will also have a reference venous blood collection.
224048793|NCT04643314|OTHER|Guided video-based self-evaluation|"In addition to their usual residency training, participants randomized to this group will undergo the following interventions:~The participants will be asked to review their own operating room recordings (of each of the 5 consecutive submitted laparoscopic cholecystectomy cases that the participant acted as the primary operator) and to assess themselves (within 72 hours (3 days) of the procedure) using validated intra-operative assessment tools. The completion of the self-evaluations is to guide and document video-based self-reflection. The duration of self-assessment/reflection session will be up do the participant. Residents in this group will have unlimited access to their recordings through the web-based platform. On the other hand, they will not be able to access the battery of assessment forms after the third day following the procedure."
223566455|NCT04907773|OTHER|Arterio-venous blood sampling|Each hemodialysed subject will also have a reference arterio-venous blood collection.
224048794|NCT00786812|DRUG|Nilotinib|
224048795|NCT02743416|OTHER|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
224048796|NCT00919555|DRUG|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
224048797|NCT00919555|DRUG|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
224048798|NCT00919555|DRUG|Placebo|Placebo
224048799|NCT01380639|OTHER|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
224048800|NCT01491295|DRUG|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
224048801|NCT01491295|DRUG|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
224048802|NCT05831553|DIAGNOSTIC_TEST|Tissue Immune Profile|Tissue samples of the patients will be analized for the presence of TILs, CD73 and PDL1 (\>=1%)
224048803|NCT01528813|DEVICE|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
224048804|NCT01528813|DRUG|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
224048805|NCT00103428|BIOLOGICAL|CG7870|
224048806|NCT03920150|DRUG|Vitamin D3|Patient will be treated with 3 doses of alcoholic solution for 3 months.
224048807|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with 3 capsules for 3 months.
224048808|NCT03920150|DRUG|Vitamin D oily capsules|Patient will be treated with weekly capsules for an individually calculated number of weeks.
224048809|NCT02495350|OTHER|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
224048810|NCT04115826|PROCEDURE|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
224048811|NCT04115826|PROCEDURE|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
224048812|NCT04295616|DEVICE|Intrapulmonary percussive ventilation (IPV)|"IPV is a well-tolerated method to pump air jets into the lungs via a mouth mask at frequencies of 100-400 pulses per minute.~Each IPV session lasts 15 minutes, whereby the person with MS is firstly administered with a mask for 3 minutes at a high frequency (250 to 400 cycles per minute) and then 12 minutes with a low frequency (75 to 150 cycles per minute). The pressure (1.1 - 1.4 bar) is adjusted so that it is comfortable for every participant, yet there is the maximum possible expansion of the thorax. The sessions are given by speech therapists who are familiar with IPV. The IPV treatment will be provided 5 days a week, during 3 or 4 weeks."
224143422|NCT01697852|OTHER|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
224143423|NCT04698109|OTHER|Biological sample collection|Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
224143424|NCT04698109|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
224143425|NCT04698109|OTHER|Medical examination|Blood pressure measurement, abdominal and thoracic physical examination
224143426|NCT02401087|PROCEDURE|Anaesthesiological procedure|
224143427|NCT03015025|GENETIC|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
223566456|NCT04324996|BIOLOGICAL|NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells|The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
223566457|NCT03539211|OTHER|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
223566458|NCT03539211|OTHER|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
224048813|NCT04295616|BEHAVIORAL|Active breathing training|The active breathing exercises are based on the flow-based incentive spirometer (Inspirix). The Inspirix is a device consisting of a tube with a ball. A plastic tube is connected to the device with a mouthpiece in which the person with MS will has to breathe in and out. The device is equipped with a control button to build up the resistance (number of cc / sec). The aim is to train the inspiratory and expiratory volume as well as the inspiratory and expiratory exhalation force. These exercises are offered 5 times a week in groups under the supervision of an experienced speech therapist, during 3 or 4 weeks.
224048814|NCT01400581|BEHAVIORAL|Collaborative Care Intervention|See description of Intervention arm
223566459|NCT01024972|DRUG|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
224048815|NCT00620568|DRUG|SLV-313 SR|sustained release tablets taken once daily for 14 days
224048816|NCT01542268|DRUG|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
224048817|NCT01542268|DRUG|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
224048818|NCT05147064|PROCEDURE|minimally invasive surgery|using (tubular dilators, surgical microscope, and/ or endoscope). the other group will be operated by conventional inter laminar decompression.
224048819|NCT05147064|PROCEDURE|conventional open surgery|open interlaminar lumbar decompression
224048820|NCT04420650|DEVICE|transcranial direct current stimulation|anodal or cathodal transcranial direct current stimulation
224048821|NCT00545402|DRUG|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
224048822|NCT00545402|DRUG|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
224048823|NCT00545402|DRUG|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
224048824|NCT00545402|DRUG|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
224048825|NCT00545402|DRUG|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
224048826|NCT01486797|DRUG|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~* 3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~* Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
224048827|NCT00555477|DRUG|anastrozole|1 mg tablet by mouth once a day
224048828|NCT00514163|DRUG|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
224048829|NCT00514163|DRUG|gemcitabine|gemcitabine DIV on day one , 8th and 15th
224048830|NCT01721876|DRUG|Placebo|Placebo matching Volasertib
224048831|NCT01721876|DRUG|Volasertib|Volasertib
224048832|NCT01721876|DRUG|Cytarabine|Cytarabine
224048833|NCT01773642|BEHAVIORAL|Cognitive behavioral intervention to support pediatric HIV disclosure|
224048834|NCT01714778|OTHER|e-Cigarette|
224048835|NCT05354076|DRUG|doxorubicin hydrochloride liposome injection|According to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)
224048836|NCT06280222|DEVICE|The VR instrument - Oculus Quest 2|Patients in the interventional group will watch 20-minute scenery movies in the VR instrument before entering the oocyte retrieval procedure.
224048837|NCT03862365|GENETIC|Nerve conduction Studies|Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
224048838|NCT05757336|DRUG|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab|Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab
224048839|NCT03086265|DEVICE|THRIVE|active nasal oxygen delivery system
224300271|NCT03074773|DRUG|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
224300272|NCT03074773|DEVICE|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
224048840|NCT03086265|DEVICE|Endotracheal tube|Plastic tube for supporting ventilation during surgery
224048841|NCT01001468|DRUG|VB-201|Single daily dose of oral VB-201 20 mg
224048842|NCT01001468|DRUG|VB-201|Single daily dose or oral VB-201 80 mg
224048843|NCT01001468|OTHER|Placebo|Single daily dose of oral placebo
224048844|NCT01848886|PROCEDURE|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
224048845|NCT01848886|PROCEDURE|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
224048846|NCT01848886|PROCEDURE|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
224048847|NCT01848886|PROCEDURE|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
224048848|NCT01721057|DRUG|Placebo|Administered orally
224048849|NCT01721057|DRUG|Baricitinib|Administered orally
224048850|NCT01721057|DRUG|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
224143428|NCT06180668|PROCEDURE|Trauma Laparotomy|Emergency abdominal surgery through midline incision to access abdominal and / or pelvic organs, to access identified injuries or exploratory diagnostic reasons
223437715|NCT04643964|BEHAVIORAL|Entrée: Behavioral skills|In this condition, participants view a video-based intervention covering behavioral emotion regulation skills. This intervention asks participants to respond to questions and practice scheduling activities that might give them a sense of pleasure or accomplishment using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to schedule and engage in behaviors in line with the intervention skills.
224143429|NCT03515018|DRUG|hydroxyurea|pulse therapy
223437716|NCT04643964|BEHAVIORAL|Entrée: Interpersonal skills|In this condition, participants view a video-based intervention covering interpersonal emotion regulation skills. This intervention asks participants to respond to questions and practice communicating effectively using an intervention worksheet. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
223437717|NCT04643964|BEHAVIORAL|Sampler skills|In this condition, participants view a video-based intervention covering three emotion regulation skills: cognitive, behavioral, and interpersonal skills. This intervention asks participants to respond to questions and practice using skills using intervention worksheets. One week after the intervention, participants are asked to upload a worksheet showing their efforts to use the intervention skills.
223437718|NCT05932225|OTHER|Propylene glycol solution/drops|Commercially available eye drops
223437719|NCT02633566|DEVICE|Plantar orthoses|
223437720|NCT02777281|BEHAVIORAL|Shoulder pain and SCI|Shoulder pain and SCI
223437721|NCT02777281|BEHAVIORAL|Shoulder pain and able bodies|
223437722|NCT00334191|DRUG|Sodium Bicarbonate|
223437723|NCT00334191|DRUG|Placebo|
223437724|NCT02638129|DRUG|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
223437725|NCT02638129|DRUG|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
223437726|NCT06201455|PROCEDURE|PEI+GT|After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).
223437727|NCT06201455|PROCEDURE|PEI+MED|Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
223437728|NCT02949908|DRUG|Rebif|Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
223566460|NCT01024972|DRUG|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
224048851|NCT05407597|DRUG|Icatibant|"Solution for injection, 30mg (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
224048852|NCT05407597|DRUG|0.9% Sodium Chloride Injection|"Solution for injection (3mls) administered as a single subcutaneous injection~SARS CoV-2 patients will receive all supportive treatment and medications that are used as standard of care including but not limited to Dexamethasone, Remdesivir, Tocilizumab and antibiotics."
224143430|NCT03515018|DRUG|Imatinib|400mg qd PO per day
224143431|NCT00944788|OTHER|qi-gong|Physical activity similar to tai-chi
223437729|NCT04236336|DEVICE|TSV dental implant|Qualified patient will be those patients who have been newly diagnosed with needing a dental implant (or more than one) in one or more edentulous areas in the maxilla and/or mandible.
224143432|NCT05304572|DIAGNOSTIC_TEST|Multi-Detector CT angiography|Multiphasic CT within 4 weeks interval prior to TACE will be done including non-enhanced, arterial, portal and venous phases using IV bolus injection of a 75-100-mLiodinated contrast material iopamidol at a rate of 3.0 mL/s. The images of arterial phase will be transferred to workstation to produce 3D angiographic reconstruction images .
224048853|NCT05487898|DEVICE|Cycling wheelchair|Apply the mechanical principle of pedaling on a bicycle to a conventional wheelchair
224048854|NCT01202279|DRUG|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
224048855|NCT01202279|DEVICE|Placebo|Placebo bid for 7 days
224048856|NCT05877222|DRUG|Daridorexant 10 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 10 mg.
224048857|NCT05877222|DRUG|Daridorexant 25 mg|Daridorexant will be available as film-coated tablets for oral administration formulated at strengths of 25 mg.
224143433|NCT05304572|PROCEDURE|Trans-arterial chemoembolization and DSA|Percutaneous arterial access is achieved through the common femoral artery (19 G needle) under local anesthesia with placement of a 5-Fr sheath. A 5-Fr Cobra (C2) or sidewinder (SIM1) catheter was used for catheterizing the coeliac trunk and SMA. Then celiac and superior mesenteric angiography was done by injecting 24 mL of iopamidol using forced manual injection method or using a pump at a rate of 6 mL/s according to the operator preferences.Then a microcatheter was used for selective and super-selective access of the hepatic arteries. The micro-catheter was placed in the feeding artery as close as possible to the tumor.The chemotherapeutic drugs (Doxorubicin 50 mg) solved within 5 ml of iodinated non-ionic contrast media and then mixed with 10 ml of iodized oil (lipiodol) will be delivered through the feeding hepatic artery and then embolized using Poly-vinyl Alcohol (PVA) particles.
224143434|NCT00734812|PROCEDURE|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
223437730|NCT03442166|RADIATION|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
223437731|NCT03442166|RADIATION|Sham group|Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
223437732|NCT00000774|BIOLOGICAL|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
224048858|NCT05881889|DEVICE|low-frequency repetitive transcranial magnetic stimulation|For patients in the rTMS group, we will first determine the intensity of the rTMS protocol by assessing the individual resting motor threshold (rMT). After determination of each individual's rMT, we will set rTMS intensity at 100% of the rMT and apply a single train of low-frequency rTMS over the DLPFS at 1 Hz for a total duration of 30 min (2000 pulses).
223437733|NCT00000774|BIOLOGICAL|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
223437734|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
223437735|NCT00000774|BIOLOGICAL|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
223437736|NCT01679912|OTHER|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
223437737|NCT01472939|DRUG|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
223437738|NCT01472939|DRUG|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
223437739|NCT01472939|DRUG|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
223437740|NCT01472939|DRUG|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
223437741|NCT01131039|DRUG|Gemcitabine/Bevacizumab|"Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression"
223437742|NCT00402610|DRUG|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
223437743|NCT01991899|BIOLOGICAL|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
223437744|NCT01991899|BIOLOGICAL|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
223437745|NCT06146699|DEVICE|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross-sectional view of the retina.
224048859|NCT05881889|DEVICE|sham low-frequency repetitive transcranial magnetic stimulation|sham low-frequency repetitive transcranial magnetic stimulation
223437746|NCT06146699|DEVICE|Fundus fluorescein angiography (FFA)|Fundus fluorescein angiography (FFA) is an invasive diagnostic procedure. It helps to assess the anatomy, physiology, and pathology of retinal and choroidal circulation. It aids in the diagnosis of various ocular pathologies.
223437747|NCT00114738|DRUG|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
223437748|NCT00114738|BIOLOGICAL|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
223437749|NCT00114738|DRUG|Bortezomib (B)|Bortezomib is given alone for one cycle.
223437750|NCT00114738|DRUG|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
223437751|NCT00114738|DRUG|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
223437752|NCT06212713|OTHER|Questionnaire administration|Questionnaire administration - version older adults and informal caregivers
223437753|NCT01137461|PROCEDURE|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
223437754|NCT04946552|DIAGNOSTIC_TEST|PET Scan|Participants will come to the PET Center to undergo the whole body \[11C\]MRB PET scan. An intravenous bolus dose of MRB (\~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
224048860|NCT04054089|DRUG|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
224048861|NCT04054089|DRUG|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
224048862|NCT03970850|DIAGNOSTIC_TEST|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
224048863|NCT03970850|DIAGNOSTIC_TEST|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
224143435|NCT00734812|PROCEDURE|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
224143436|NCT05138341|DEVICE|Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation|"Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood."
224143437|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 20 µg in 2 ml of saline injected into csf
224143438|NCT04645823|DRUG|Lidocaine 1% Injectable Solution|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
224143439|NCT04645823|DRUG|Fentanyl Citrate|Fentanyl citrate 100µg and lidocaine hydrochloride 80 mg in 10 ml volume
224048864|NCT00514774|DRUG|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28"
224048865|NCT00514774|DRUG|placebo|placebo 600mg twice daily for study days 0 through 28
224048866|NCT02041754|DEVICE|IQP-AK-102|
224048867|NCT02041754|DEVICE|Placebo|
224048868|NCT05802394|DRUG|Later-line therapy|Another chemotherapy regimen, targeted therapy, or immunotherapy
224048869|NCT00686296|OTHER|Taliderm™|taliderm™ dressing application once
223437755|NCT04946552|DIETARY_SUPPLEMENT|Mixed Meal Test|High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in \~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
223437756|NCT04946552|DIAGNOSTIC_TEST|Muscle sympathetic nerve activity (MSNA)|Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
223437757|NCT04946552|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
223437758|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)|will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
224048870|NCT00686296|OTHER|Taliderm™|Taliderm™ dressing application up to three applications
224048871|NCT00686296|OTHER|standard wet to dry dressing with gauze|wet to dry dressing standard of care
224048872|NCT05923749|DEVICE|Biatain Ag|Biatain with silver
224048873|NCT05923749|DEVICE|Cutimed Siltec Sorbact|comparator device
224048874|NCT01177683|DRUG|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
223437759|NCT04946552|DIAGNOSTIC_TEST|CT Scan|A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV \< 1.25 for WAT.
223437760|NCT04946552|OTHER|Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)|For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
223437761|NCT02890849|OTHER|Liquid biopsy|
223437762|NCT03453112|DRUG|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
224048875|NCT01177683|DRUG|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
223437763|NCT03453112|DRUG|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA\_134a propellant
224048876|NCT01177683|DRUG|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
224048877|NCT01177683|DRUG|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
224048878|NCT01177683|DRUG|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC \>1000"
224048879|NCT03516890|PROCEDURE|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
224048880|NCT02859376|DIETARY_SUPPLEMENT|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if \> 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
224048881|NCT03745833|DEVICE|Virtual Reality Mindfulness|Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
224048882|NCT05492695|DRUG|Galcanezumab|Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
224048883|NCT05492695|OTHER|Placebo|Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
224048884|NCT02684513|DIETARY_SUPPLEMENT|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
224048885|NCT02684513|DIETARY_SUPPLEMENT|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
224048886|NCT05733273|OTHER|Nordic hamstring exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
223437764|NCT04484155|DEVICE|Minimally Invasive Micro Sclerostomy (MIMS)|The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.
223437765|NCT06449508|DRUG|Probiotic Formula|drops of probiotic supplement containing bacillus clausil spores (Enterogermania Amp 2 Billion/5Ml )
223437766|NCT00841308|OTHER|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
224048887|NCT05733273|OTHER|Single leg bridge exercise program|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
224048888|NCT05733273|OTHER|Hamstring razor curl|Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise. Set 1 with 12 reps, set 2 with 10 reps and set 3 with 8 reps
224048889|NCT02564107|DRUG|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
224048890|NCT06487832|OTHER|Subcutaneous GLP1-RA|Subcutaneous administration of semaglutide
224048891|NCT06487832|OTHER|Subcutaneous placebo|Subcutaneous administration of NaCl
224048892|NCT07129590|OTHER|Expired carbon monoxide (CO)|Expired CO will be measured using a non-investigational device
224048893|NCT07129590|OTHER|Interviews|Participants will be interviewed via video conference or in person
224048894|NCT07129590|OTHER|Questionnaires|Participants will receive questionnaires to complete through the course of the study
224048895|NCT07130864|PROCEDURE|Early cholecystectomy|Early cholecystectomy is performed within 72 hours of ERCP.
224048896|NCT07130864|PROCEDURE|Late cholecystectomy|Late cholecystectomy is performed after 72 hours of ERCP
224048897|NCT03045783|DRUG|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
224048898|NCT06902467|DRUG|Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstron|Following 3 or 4 cycles of systemic neoadjuvant chemotherapy and complete interval CC-0 surgery, patients in the study will receive 4 cycles of 21 days every 3 weeks of the regimen studied by Armstrong 8 and modified by GEICO 18: IV paclitaxel 175 mg /m2 (day 1) + IP cisplatin 100 mg/m2 (day 2) + IP paclitaxel 60 mg/m2 (day 8).
224048899|NCT06901921|DIAGNOSTIC_TEST|PT-intervention|60 participants undergoing PT-intervention for about 3 months will be taken and questionnaire (KOOS-12) will be filled by them at regular intervals of baseline, 4, 8 and 12 weeks respectively while global rating of change questionnaire will be filled by them at start and end of intervention and these values will be compared to see if patients' condition has improved or not.
224048900|NCT06902116|PROCEDURE|No Mechanical Bowel Preparation|In this group patients will not receive any mechanical bowel preparation prior to undergoing colostomy reversal.
224048901|NCT06902116|PROCEDURE|Mechanical Bowel Preparation|In this group patients will receive 3 days mechanical bowel preparation prior to undergoing colostomy reversal.
223437767|NCT00337324|DEVICE|Frequency-modulated electromagnetic neural stimulation|
223437768|NCT00092339|DRUG|MK0966, rofecoxib|
224048902|NCT06902038|DRUG|PD-1 inhibitor|100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2
224048903|NCT06902038|DRUG|Sidarbenamide|Sidarbenamide 10mg biw orally for 2 weeks
224048904|NCT06902038|DRUG|Saline (NaCl 0,9 %) (placebo)|Saline 50ml Q3W ×2
224048905|NCT05469269|BEHAVIORAL|Passive Education|Education: QR codes will be posted at each barber's station within a barber shop, as well as on other study materials located within the shop. The QR code recruitment mechanism will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire (ie. Screener) which acts as a screener for study eligibility. The screener can be completed by scanning the QR code with a cell phone while in the barbershop. Barbers will encourage their clients to complete the Screener.
224048906|NCT05469269|BEHAVIORAL|Education by Community Navigator|A community navigator will be onsite to assist in information delivery, navigation to resources, and encourage the completion of the Screener through the QR code. Participants can opt to connect with the community navigator if they have questions, need assistance in scheduling a PSA screening, or if they have other resource needs. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
224143440|NCT00278863|DRUG|S-1|
224143441|NCT00278863|DRUG|Capecitabine|
224143442|NCT01351311|OTHER|Exercise|Resistance Training exercise with swiss ball
223437769|NCT00092339|DRUG|Comparator: valdecoxib, placebo|
223437770|NCT02065063|DRUG|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
223437771|NCT02065063|DRUG|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
223437772|NCT03528057|DEVICE|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
223437773|NCT03102697|DEVICE|Air-filled Intragastric balloon|Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
223437774|NCT04129840|OTHER|dual combination|Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
223437775|NCT04129840|OTHER|triple combination|Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
223437776|NCT04129840|OTHER|Standard of care|Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP \</=130/80mmHg in patients \<65years and \</=140/90mmHg in patients \>65years)
223437777|NCT04260386|OTHER|Non-Interventional|"During the cardiac arrest scenario, the delegates observing will be asked to refer to the maternal cardiac arrest proforma and record those details of events that they are able to see/hear from the video link. In addition, the proforma will be provided to the team taking part in the simulation. One or more team members would routinely be given the role of 'scribe', recording events as they occur. The proforma is accompanied by explanatory notes on how to use it.~Delegates (observers plus scribes) will then be asked to complete a questionnaire, seeking their opinions on the usefulness of the proforma. Questionnaires will be linked to the written consent forms by a participant ID number."
223437778|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|All drugs on awakening
223437779|NCT00741585|DRUG|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
223437780|NCT00741585|DEVICE|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
223566461|NCT04659174|DRUG|Xanomeline and Trospium Chloride Capsules|Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
223566462|NCT04945850|PROCEDURE|routine care intraocular sx|Fluid was collected during routine intraocular surgery
223566463|NCT03822455|DRUG|OligoG DPI|OligoG Dry Powder for Inhalation
223566464|NCT05129449|DEVICE|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Endoscopic Retrograde Cholangio-Pancreatography (ERCP) conducted with motorized PowerSpiral in subjects presenting with surgically altered GI anatomy indicated for ERCP with biliary indication.
223566465|NCT02745067|BEHAVIORAL|enhanced cognitive behavioral therapy|
224048907|NCT05469269|BEHAVIORAL|Education at Community Outreach Screening Event|The Community Navigator will set up PSA screening events at specific barber shops for participants who wish to move forward with screenings.
224048908|NCT03543098|PROCEDURE|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
224048909|NCT03543098|PROCEDURE|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
224048910|NCT03543098|PROCEDURE|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
224143443|NCT01351311|OTHER|Drug treatment|Drug treatment
224143444|NCT04145869|PROCEDURE|Cholangiography|All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
224143445|NCT04662411|DIETARY_SUPPLEMENT|Placebo|acute intake of 0 mg butyrate and hexanoate
224143446|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 1|acute intake of 650 mg butyrate and hexanoate
223566466|NCT01083979|DRUG|Liposomes|Intravesical instillation
223566467|NCT03650803|DEVICE|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
223566468|NCT01217879|DRUG|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
223566469|NCT02901054|DRUG|Ondansetron|A single 15-min intravenous infusion of ondansetron
224048911|NCT03543098|PROCEDURE|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
224143447|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 2|acute intake of 1325 mg butyrate and hexanoate
224143448|NCT04662411|DIETARY_SUPPLEMENT|butyrate and hexanoate amount 3|acute intake of 2000 mg butyrate and hexanoate
224143449|NCT03288740|DRUG|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
224143450|NCT03288740|DRUG|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
224143451|NCT03288740|DRUG|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
224143452|NCT03288740|DRUG|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
224143453|NCT03989856|DEVICE|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
224048912|NCT06903390|BEHAVIORAL|QPL-based Communication Intervention|"This QPL-based communication intervention stands out with the following key features:~Patient-Centered \& Cancer-Specific QPL: The intervention uses a QPL tailored for cancer patients, culturally adapted to enhance empowerment and manage anxiety.~Structured Training \& Support: Patients receive training before consultations, with additional guidance for effective QPL use at subsequent visits.~Multiple Assessment Points: The QPL's impact is measured after the first, second, and third consultations, allowing for longitudinal evaluation.~RCT Design: This study is a randomized controlled trial (RCT), comparing the intervention group (QPL) to a control group receiving standard care.~Focus on Empowerment \& Anxiety: Unlike prior studies, this intervention focuses on empowering patients and reducing anxiety, with outcomes measured through validated scales (Patient Empowerment Scale and HADS).~These features differentiate this intervention by offering a structured, culturally relevant approach."
224048913|NCT06901791|DIETARY_SUPPLEMENT|Conventional treatment and Probiotic|Participants will continuously take Lactobacillus rhamnosus LRa05 from the time of enrollment until delivery.
224048914|NCT06902935|DIAGNOSTIC_TEST|Diagnosis of Breast Cancer by Traditional Chinese Medicine Four Examinations|The Daosheng TCM Four-Diagnostic Instrument (DS01-A) comprehensively collects patients' TCM four-diagnostic information, covering tongue (e.g., overall color, coating color/thickness/greasiness, tooth marks, etc.), pulse (e.g., position, force, rhythm, etc.), face (e.g., overall color, luster, lip color/dryness, etc.) and constitution scores (quantifying 9 constitutions via the TCM Constitution Classification Table).
224048915|NCT06902935|DIAGNOSTIC_TEST|Ultrasound diagnosis of breast cancer|Professional ultrasound physicians use B - ultrasound equipment of the same model to accurately collect detailed parameters of breast masses according to a standardized process. These parameters include shape (oval, round, irregular), orientation (parallel, non - parallel), margin (smooth, non - smooth, with non - smooth including blurred, angular, microlobulated, spiculated, etc.), echo pattern (anechoic, hyperechoic, complex cystic - solid echo, hypoechoic, isoechoic, heterogeneous echo), posterior echo characteristics (no change, enhancement, shadowing, mixed), calcification (microcalcification and coarse calcification within the mass, calcification outside the mass, intraductal), and vascular supply (no blood supply, internal blood supply, marginal blood supply), etc.
224048916|NCT06902792|DRUG|treated group|This study marks the first application of Adebrelimab in pediatric patients with Langerhans Cell Histiocytosis (LCH). The initial dose is 20 mg/kg, delivered via a 60-minute intravenous infusion. If no Dose-Limiting Toxicity (DLT) occurs, the second dose of 20 mg/kg will be administered in the second cycle. Treatment cycles consist of dosing every 4 weeks, up to a maximum of 6 cycles.
224048917|NCT06901661|BEHAVIORAL|Telerehabilitation|Exercise program include Warm-up, Targeted muscle Strengthening, Joint mobilization, and Proprioception
224048918|NCT06901661|BEHAVIORAL|Standard care|Education session on their pain, disability, and functional activities
224048919|NCT06901999|DRUG|Orelabrutinib|150 mg qd po. D1-21, 6 cycles, 21 days per cycle For patients continue transplant, maitaining for 1 year follow-up; otherwise maintaining during 2 years of follow-up，unless disease progression or intolerable toxicity occurs.
224048920|NCT06901999|DRUG|RCHOP+MTX or Thiotepa|rituximab: 375 mg/m2, D0; cyclophosphamide: 750 mg/m2, D1; doxorubicin: 50 mg/m2, D1; vincristine: 1.4 mg/m2, D1; prednisone: 100 mg, D1-5; MTX: 3.5 g/m2, D0; Thiotepa: 40 mg/m2, D3; Induction therapy, 6 cycles, 21 days a cycle
224048921|NCT06902298|DEVICE|LTFUS to SCC|Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex
224048922|NCT06902298|DEVICE|LTFUS to ALIC|Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule
224048923|NCT06108648|DRUG|Lavender essential oil 10%, diluted in 90% olive oil|"Lavender chest wrap:~Before the first application pour 10-15 ml of lavender essential oil 10% evenly on the cotton cloth.~Put the soaked cotton in the plastic bag, close it and put it to heat in two heating pads (2-5 minutes) so that the oil is distributed on all the fabric. Place the cotton cloth around the patient's chest.~Cover the cotton cloth with a woolen fabric that is 2 cm larger than the cotton cloth."
223437781|NCT02164032|DRUG|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
223437782|NCT02164032|DRUG|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
224048924|NCT06108648|OTHER|Control|Standard care according to national standards.
224048925|NCT02706561|BEHAVIORAL|questionnaires|
224048926|NCT02706561|BEHAVIORAL|three in-person sessions|
224048927|NCT02706561|BEHAVIORAL|monthly phone calls|
224048928|NCT02706561|BEHAVIORAL|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
224048929|NCT02706561|BEHAVIORAL|Enhanced Monitoring and Education (EME)|
224048930|NCT00537498|DRUG|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is \> 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is \< 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is \< 1,6g/l treatment must be stopped and continued after rising up to \>2g/l"
224048931|NCT01839253|DRUG|b-blocker(Atenolol)|
224048932|NCT01839253|DRUG|ACE inhibitor(Enapril)|
224048933|NCT01839253|OTHER|control|
224048934|NCT03700450|DRUG|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
224048935|NCT04890314|OTHER|Patient-reported questionnaire|Validated questionnaires administered at baseline, 8 months following treatment, and 12 months following treatment.
224048936|NCT05450367|OTHER|Data collection|Data collection
224048937|NCT01864187|DRUG|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
223437783|NCT02164032|OTHER|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
223437784|NCT00388297|DRUG|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
223437785|NCT00388297|DRUG|Placebo for Levothyroxine|
223437786|NCT02363985|DIETARY_SUPPLEMENT|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
224048938|NCT02823795|BEHAVIORAL|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
224048939|NCT05767554|BEHAVIORAL|Brief modified behavioral activation|The clinician will deliver psychoeducation about the nature of depression and the rationale behind the behavioral activation model (i.e. increasing level of activation can begin a positive feedback cycle of reward and improvements in mood state). Participants will be encouraged to add new, enjoyable activities to their daily schedules. Clinicians will emphasize the importance of novelty and increased engagement with the surrounding environment in the psychoeducational portion and in activity scheduling.
223437787|NCT05514743|PROCEDURE|6 minute walk test , Blood pressure monitoring|"Heart rate monitors can assess a person's heart rate and reveal whether it is high or low. Heart rate Trusted Source is a clinical indicator of overall cardiac health, and it can also help a person determine their performance during a workout.~Six minute walk test:~It will be carried out before and after interventions to determine the patients functional capacity (in the 7th.day \&in the 21st.day.) It will be used as a training tool as well as an assessment tool. They will receive conventional physical therapy program which includes deep breathing exercise in form of (diaphragmatic, apical and costal breathing), Training about right way of cough and early ambulation from bed for 3 sessions / week, twice daily for 21 days."
223437788|NCT04087616|BEHAVIORAL|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
223437789|NCT04087616|BEHAVIORAL|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
224048940|NCT04516317|OTHER|None (Observational study Group intravenous artesunate)|Retrospective descriptive study of Group intravenous artesunate
224048941|NCT04516317|OTHER|None (Observational study Group intravenous quinine)|Retrospective descriptive study of Group intravenous quinine
224048942|NCT02777697|OTHER|chronic pain|
224048943|NCT02525393|DEVICE|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
224048944|NCT02525393|DEVICE|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
224048945|NCT02525393|DEVICE|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
224048946|NCT00682448|DRUG|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
224048947|NCT00682448|DRUG|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
224048948|NCT04714242|DRUG|Ranibizumab Injection|Three monthly intravitreal injections of Ranibizumab
224048949|NCT00311376|BIOLOGICAL|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
224048950|NCT00311376|BIOLOGICAL|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at \> 12 weeks interval
223437790|NCT03623659|PROCEDURE|Laser assisted hatching|After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
224143454|NCT03989856|DEVICE|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
223437791|NCT02607280|DRUG|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
223437792|NCT06401343|DRUG|Empagliflozin 10 MG|Participants randomized to the study group will received Empagliflozin 10mg q.d. for 12 months.
223437793|NCT04148898|DRUG|Osimertinib|Treatment of LM With osimertinb
223437794|NCT04148898|DRUG|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
223437795|NCT06428994|RADIATION|Radiotherapy|Post-operative radiotherapy for head and neck cancer
223437796|NCT02862132|DRUG|Vedolizumab|
224048951|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval
224048952|NCT00311376|OTHER|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at \> 12 weeks interval
224048953|NCT00257166|DRUG|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
224048954|NCT00257166|DRUG|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
224048955|NCT00829049|DRUG|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
224048956|NCT00829049|DRUG|Adapalene|1 pea-size amount, QD x 16 weeks
224048957|NCT02737852|DEVICE|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
224048958|NCT00364520|OTHER|Shanghai workers|
224048959|NCT04223895|DRUG|CKD-386 Formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
224048960|NCT04223895|DRUG|CKD-386 Formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
224300273|NCT03074773|PROCEDURE|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
224300274|NCT03074773|DRUG|Bupivacaine|it is an amino amide local anesthetic drug
224300275|NCT03074773|OTHER|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
224300276|NCT03900065|PROCEDURE|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
223437797|NCT02532452|BIOLOGICAL|Viral Specific VST Infusion|"VSTs will be infused into immunocompromised patients with evidence of viral infection or reactivation defined as any of the following:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR \>1,000~* Plasma JC Virus PCR \> 1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy~* Evidence of PML or other CNS infection due to JC virus"
223437798|NCT00507065|DRUG|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
223437799|NCT00507065|DRUG|Placebo|
223437800|NCT03933020|DEVICE|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
223437801|NCT03933020|BEHAVIORAL|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
223437802|NCT03933020|BEHAVIORAL|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
223437803|NCT00201812|DRUG|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
224048961|NCT04223895|DRUG|D012, D326 and D337|A single oral dose of 3 tablets(D012, D326 and D337) under fasting conditions for each period
224048962|NCT03193645|DRUG|Degarelix|Injection
224048963|NCT05865444|BEHAVIORAL|Values alignment wise intervention|"The intervention includes: (1) reading materials, such as recent journalistic works that expose the deceptive and manipulative marketing practices of food companies and the harmful effects of these practices on society, with particular emphasis on harm to young children and the economically disadvantaged. Stories from other young people will also be included in order to contribute to the perception of widespread outrage and to suggest how that outrage can be channeled into taking a stand against the injustice perpetrated by food companies by eating less unhealthy or healthier food; (2) writing exercises, such as a story with a brief statement of what the participants would tell a younger child about the ads; and (3) an interactive activity, called Make It Real in which they are shown pictures of food ads and allowed to write and draw about them, making whatever changes (e.g., crossing out and substituting words) they feel necessary to make the ad real (i.e., no longer misleading)."
224048964|NCT05865444|BEHAVIORAL|Educational traditional intervention|The educational intervention includes information on nutrition and physical exercise. It includes reading and writing exercises.
224048965|NCT04146194|OTHER|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
224048966|NCT03882138|PROCEDURE|open flap debridement|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
224048967|NCT02225470|DRUG|E7389 (Eribulin Mesylate)|
224048968|NCT02225470|DRUG|Vinorelbine injection|
224048969|NCT00714675|DIETARY_SUPPLEMENT|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
224048970|NCT00714675|DIETARY_SUPPLEMENT|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
224048971|NCT01689675|BEHAVIORAL|Computer based pain management|
224048972|NCT03251742|DEVICE|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
224048973|NCT00525044|DRUG|Ambroxol|
224048974|NCT00525044|DRUG|Placebo|
224048975|NCT05497596|OTHER|Vitamin D|Vitamin D (2000IU/day) for 6 months
224048976|NCT05497596|OTHER|Placebo|Placebo
224048977|NCT05596682|DEVICE|supplementary intraocular lenses|Implantation of supplementary intraocular lenses into the ciliary sulcus in previously pseudophakic eyes.
224048978|NCT01131533|PROCEDURE|Vitrectomy|vitrectomy following intravitreal erythropoietin
224048979|NCT04125550|DRUG|Propofol|2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
224048980|NCT04125550|DRUG|Sevoflurane|sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
224048981|NCT03652038|DRUG|TD-8236|Study drug to be administered via inhaler device
224048982|NCT03652038|DRUG|Placebo|Placebo to be administered via inhaler device
224048983|NCT02125227|DRUG|Rosuvastatin, Metformin, YH14755|single dose
224048984|NCT02125227|DRUG|YH14755|single dose
224048985|NCT03286062|COMBINATION_PRODUCT|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
224048986|NCT05251740|DEVICE|Altimate Medical EasyStand Bantam|The child will stand in the device for 60 min per day, 5 days per week for 2 months.
223437804|NCT00201812|DRUG|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
223437805|NCT00201812|DRUG|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
223437806|NCT02944435|DRUG|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
224048987|NCT03333720|DIETARY_SUPPLEMENT|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
224048988|NCT06466629|BIOLOGICAL|Triaxis, Sanofi Pasteur|tetanus, diphtheria, acellular pertussis (aP) (Tdap) vaccine
224048989|NCT06331442|OTHER|Photodynamic therapy|Patients allocated to the first group (n=10) will receive photodynamic therapy. Buccal/labial surface around the bracket of each tooth in the upper dental arch (from right to left second premolar) will be treated with toluidine blue based dye (155 mg/mL; LaserHF Paro-PDT, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany). This photosensitive solution will be applied on teeth with the sterile syringe and left for 60 s. Then, the excess of the photosensitive solution will be rinsed with the sterile syringe containing a saline solution. Then, a 660 nm diode laser (Laser HF, Hager \& Werken, GmbH \& Co. Kg, Duisburg, Germany) will be used for photoactivation (power output 100 mW, power density 124.34 W/cm2 and continuous working mode). Buccal/labial surface of each tooth will be radiated for 60 s at approximately 5 mm away from the enamel surface. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
224048990|NCT06331442|OTHER|Tricalcium phosphate (TCP) varnish with 5% NaF|Tricalcium phosphate varnish with 5% NaF (Clinpro™ White Varnish, 3M ESPE 3M Deutschland GmbH, Germany) will be applied to the patients allocated to the second group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
224048991|NCT06331442|OTHER|Chlorhexidine varnish|Chlorhexidine varnish (1% CHX, 1% thymol; Cervitec® Plus, Ivoclar Vivadent AG, Schaan, Liechtenstein) will be applied to the patients allocated to the third group (n=10). The varnish will be applied to the buccal/labial surfaces of 10 teeth in the upper dental arch (from right to left second premolar) according to the manufacturer's recommendations. This intervention will be performed right after the placement of a fixed orthodontic appliance (T0), 6 weeks (T1) and 12 weeks (T2) later.
224048992|NCT04758442|OTHER|Additional blood sample|Included subjects will provided three blood samples to follow vancomycin concentration
224048993|NCT03426371|DRUG|KL-140|"KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
224048994|NCT03426371|DRUG|Placebo|"Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m\^2/day intravenously followed by 2400 mg/m\^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
224048995|NCT00483561|DRUG|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
224048996|NCT02220842|DRUG|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
224048997|NCT02220842|DRUG|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
224048998|NCT02220842|DRUG|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
224048999|NCT01164774|DRUG|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
224049000|NCT01164774|DRUG|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
223437807|NCT02944435|DRUG|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
223437808|NCT06366620|BEHAVIORAL|FAST-B PEERS|FAST-B PEERS consists of trained Peer Support providing weekly check-in calls with families going through FAST-B behavioral parent training program. Peer Support are parents who have previously participated in a behavioral parent training program who have undergone 6-8 hours of additional dedicated training.
223437809|NCT06366620|BEHAVIORAL|FAST-B (First Approach Skills Training - Behavior)|5-week parent behavioral management training program
223437810|NCT01116713|DRUG|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
223437811|NCT01116713|DRUG|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
224049001|NCT04750759|DRUG|Niclosamide + Camostat|Niclosamide will be applied in combination with camostat.
224049002|NCT04750759|OTHER|Placebo|Placebo to interventional drug
224049003|NCT02623127|DRUG|Sunitinib|
224049004|NCT00443807|DEVICE|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
224049005|NCT00443807|DEVICE|EEGo vs BIS|comparison of two processed EEG monitors.
224049006|NCT00000761|DRUG|Interferon gamma-1b|
224049007|NCT01908985|PROCEDURE|high intensity focused ultrasound for cyclodestruction in the eye|
224049008|NCT04265846|DEVICE|bifocal IOL|The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.
224049009|NCT04265846|DEVICE|mix bifocal IOL|The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.
224049010|NCT04265846|DEVICE|trifocal IOL|The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.
223437812|NCT01810705|DRUG|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
223437813|NCT02552498|PROCEDURE|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
223437814|NCT04929860|BEHAVIORAL|social marketing campaign|social marketing campaign delivered over 4 weeks in 4 separate sessions
223566470|NCT01534260|DRUG|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
224049011|NCT04265846|DEVICE|EDOF IOL|The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.
224049012|NCT04265846|DEVICE|different IOLs|The patients will undergo phacoemulsification and different IOLs implantation bilaterally.
224049013|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
224049014|NCT04265846|DEVICE|monofocal IOL|The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
224049015|NCT02688491|DRUG|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
224049016|NCT06336720|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The active PoNS device delivers amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes.
224049017|NCT00635037|DRUG|bupivacaine and acupuncture|"* trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~* acupuncture twice a week"
224049018|NCT03471039|DRUG|PACAP27|Infusion of PACAP27 over 20 minutes.
223566471|NCT00642434|DRUG|carvedilol|variable
224049019|NCT03471039|DRUG|Saline|Infusion of Saline over 20 minutes.
224049020|NCT00836628|DRUG|Busulfan|
224049021|NCT04042740|DRUG|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
224049022|NCT03580239|DRUG|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
224049023|NCT03580239|DRUG|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
224049024|NCT02975193|BEHAVIORAL|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
224049025|NCT02975193|BEHAVIORAL|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
224049026|NCT02975193|PROCEDURE|Deep Brain Stimulation Surgery|DBS surgery for the implantation of electrodes for the treatment of motor disorders.
224049027|NCT06414928|OTHER|Acute Heart Failure|Consecutive patients presented at Emergency Departement with Acute Heart Failure
224049028|NCT06236295|DRUG|SHR6508|SHR6508 will be administered to all the eligible subjects
223566472|NCT00642434|DRUG|metoprolol|variable
223566473|NCT01792713|DRUG|Sertaconazole 2% cream|
223566474|NCT01792713|DRUG|Placebo|
223566475|NCT03252886|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
223566476|NCT01407471|DRUG|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
223566477|NCT01407471|DRUG|Clobetasol + Placebo|One application 6 days a week during 4 weeks
223566478|NCT01407471|DRUG|Placebo + Spironolactone|One application 6 days a week during 7 weeks
223566479|NCT01407471|DRUG|Placebo + Placebo|One application 6 days a week during 7 weeks
224049029|NCT00647153|OTHER|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
224049030|NCT00647153|PROCEDURE|single photon emission computed tomography|One day post infusion
224049031|NCT00647153|RADIATION|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
224049032|NCT03995732|DRUG|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
224049033|NCT03995732|DRUG|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
224049034|NCT03358199|PROCEDURE|LOD|Women underwent LOD in the preceding 3 months prior to IVF/ICSI
224049035|NCT02375152|PROCEDURE|Anterior Capsulotomy|
224143455|NCT03206112|OTHER|PAS25|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
224143456|NCT03206112|OTHER|PAS10|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles. TBS is a special form of
224049036|NCT03999723|DIETARY_SUPPLEMENT|Vitamin C|Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
223437817|NCT01811862|PROCEDURE|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
223437818|NCT01811862|PROCEDURE|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
223437819|NCT04355429|DRUG|captopril 25mg|Drug administration
223437820|NCT01984489|DRUG|Placebo|
223437821|NCT01984489|DRUG|SHR117887|
223437822|NCT00002369|DRUG|Indinavir sulfate|
223437823|NCT00002369|DRUG|Lamivudine|
223437824|NCT00002369|DRUG|Stavudine|
223437825|NCT00002369|DRUG|Zidovudine|
223437826|NCT00067769|BEHAVIORAL|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
223566480|NCT00441428|DRUG|solifenacin|
224049037|NCT03999723|DIETARY_SUPPLEMENT|Placebo|Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
224049038|NCT06466785|DRUG|Efepoetin Alfa|Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
223437827|NCT00067769|BEHAVIORAL|treatment as usual|Routine clinical care.
223566481|NCT02725814|OTHER|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
224049039|NCT06466785|DRUG|Darbepoetin Alfa|Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
224049040|NCT05327413|OTHER|CT and MRI|CT and MRI were conducted to measure the femoral external rotation
224049041|NCT00003370|DRUG|irofulven|
224049042|NCT05140655|DRUG|Fulvestrant|Medicine for Advanced breast cancer
224143457|NCT03206112|OTHER|PAS25-cTBS150|We will record surface electromyography from the target abductor pollicis brevis muscle and adjacent first dorsal interosseous and abductor digiti minimi muscles.
224143458|NCT00933192|DEVICE|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
223437828|NCT03160222|OTHER|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
223437829|NCT01397539|DRUG|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
223437830|NCT01397539|OTHER|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
223437831|NCT04701918|DRUG|Pembrolizumab|Intravenous injection through a vein (IV) every 3 weeks
223437832|NCT04701918|PROCEDURE|Cryoablation|Needle inserted through the skin and into the tumor using CT guidance
223566482|NCT04703816|OTHER|Interpersonal Skills Multifaceted Training Program for the physician-patient relationship|The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
223566483|NCT05638269|OTHER|no intervention|Observational studies, no intervention
223566484|NCT01551576|DEVICE|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe|Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
223566485|NCT03092830|GENETIC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
224049043|NCT04671277|OTHER|Chewing of breads|"During the video recording session, participants were asked to place the whole sample (5-6 g) in the mouth (e.g. single bite) and chew naturally until the bolus is ready for swallowing.~During the second section, participants were asked to place the whole sample in the mouth and chew naturally. After 5 chewing cycles, participants checked all the attributes that describe the texture sensations perceived at the beginning of mastication. A list of attributes and their definitions were provided to guide the participants. Participants proceeded with chewing until the swallowing point when they again checked all the attributes that characterize the texture sensations perceived at the end of mastication. The food bolus was then spat in a container."
224049044|NCT02389023|OTHER|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
224049045|NCT02389023|OTHER|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
224049046|NCT01440842|OTHER|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
224049047|NCT01440842|OTHER|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
223437833|NCT04701918|DRUG|Avelumab|Intravenous injection through a vein (IV) every 2 weeks
223437834|NCT00034346|DRUG|ABX-EGF|
223437835|NCT00034346|DRUG|paclitaxel|
224049048|NCT00737256|DRUG|Aripiprazole|15-30 mg
224049049|NCT00737256|DRUG|Perphenazine|8-16 mg
224049050|NCT00161187|BIOLOGICAL|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
224049051|NCT01931748|DRUG|MELSMON|
224049052|NCT01931748|DRUG|UNCNT|
224049053|NCT00618436|DRUG|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
224049054|NCT00618436|DRUG|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
224049055|NCT02258789|OTHER|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
224049056|NCT05066321|BEHAVIORAL|Mindfulness Oriented Recovery Enhancement Sessions|The MORE intervention will involve 8 weekly sessions (approximately 1 hour each), during which participants will be taught how to use mindfulness skills to regulate addiction severity, pain, and stress.
224049057|NCT04935892|BEHAVIORAL|Slippers|Patients in the intervention group wear slippers when out of bed
224049058|NCT05548348|DRUG|Furmonertinib 160 mg, Q.D.|Furmonertinib will be administered orally at a dose of 160 mg per time, Q.D.
224049059|NCT02071212|DRUG|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
224049060|NCT03529721|OTHER|zumba dance fitness|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
224049061|NCT03529721|OTHER|non zumba dance|participants in this group will be doing their normal daily activities throughout the 8-week period.
224049062|NCT00844155|DRUG|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
223437836|NCT00034346|DRUG|carboplatin|
223437837|NCT05190822|OTHER|College student|Our research will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students studying in departments other than Physiotherapy and Rehabilitation at Acibadem Mehmet Ali Aydinlar University.
223437838|NCT06648525|DRUG|Adebrelimab|Adebrelimab, IV
223437839|NCT06648525|DRUG|Irinotecan liposomes|Irinotecan liposomes, IV
223437840|NCT06648525|DRUG|Lenvatinib|Lenvatinib, po
223437841|NCT06648525|DRUG|5-Fluorouracil (5-FU)|5-Fluorouracil (5-FU), IV
223437842|NCT06648525|DRUG|Calcium Folinate|Calcium folinate, IV
223437843|NCT04750733|OTHER|Assessment|Assessment of core strength and endurance, muscle strength, postural sway in different condition, physical capacity and fatigue
223437844|NCT05865275|DEVICE|Low-level laser treatment|a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity
223437845|NCT05865275|OTHER|tooth bleaching procedure|The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
223437846|NCT04486170|OTHER|Education provided via a video format|The intervention group will be shown a 5 minute educational video on hypertension in the postpartum period. The patients will be shown the video on the ipad while they are in the comfort of their room and the investigator will step outside. At the conclusion of the video, the investigator will return into the patient room and provide a pamphlet with similar information that was discussed in the video for them to take home.
223437847|NCT05520970|BIOLOGICAL|AdCLD-CoV19-1|All 200 participants will receive 2 doses of investigational product by 2 months interval via intramuscular injection in the deltoid region
223437848|NCT03042871|DRUG|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
223437849|NCT03194711|DEVICE|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
223437850|NCT00148577|DEVICE|Transcutaneous Electrical Nerve Stimulation|
224049063|NCT03897907|OTHER|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
223437851|NCT00901784|DRUG|Topiramate|25mg Tablets
223437852|NCT02613429|BEHAVIORAL|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
223437853|NCT02613429|BEHAVIORAL|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
223437854|NCT04395391|DIAGNOSTIC_TEST|SARS-CoV-2|Determine usability of study materials and kit
224049064|NCT03897907|OTHER|Anatomy Education Video|Participants in the control group will watch three videos equal in length to the psychologically-informed videos. The control videos will discuss anatomy of the lower extremity, basic instruction in proper lower extremity biomechanics, and simple lower extremity exercises. The control videos will provide no psychologically-informed education or positive reinforcement about the condition.
224049065|NCT00299962|BIOLOGICAL|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
224049066|NCT00299962|BIOLOGICAL|SCH 721015|Comparison of different doses and frequency of investigational agent
224049067|NCT03621865|DIETARY_SUPPLEMENT|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
224049068|NCT03621865|DIETARY_SUPPLEMENT|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
223437855|NCT02110940|OTHER|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
223437856|NCT02110940|OTHER|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
223437857|NCT04766255|PROCEDURE|Soft Tissue graft augmentation|"Donor site:~SCTG group: The SCTG will be harvested in the palat,In order to extract the same thickness in each grafts a double-bladed knife (separated by 1,5mm) will be used. The donor area will be sutured.~Recipient site:~SCTG group: the connective tissue graft will be trimmed to the correct dimensions (10mm height, 12mm length and 1,5mm thick) and placed and secured at the recipient site with a resorbable 5-0 suture CM group: The CM graft (Geistlich Fibro-gide) will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture PADM Group: the ADM (NovoMatrix, Biohorizons, Birmingham AL) graft will be trimmed to the indicated dimensions (10mm height, 12mm length) and placed and secured at the recipient site with resorbable 5-0 suture"
223437858|NCT04766255|PROCEDURE|Implant Placement|A crestal incision will be made in the implant reception area, extending from the distal of the most mesial tooth to the mesial of the most distal tooth. A mucoperiosteal flap will be elevated in the most crestal part of the ridge. The receptor bed will be prepared following the established drilling protocol for the placement of a BioHorizons Tapered Pro Implant (Biohorizons, Birmingham AL). The diameter and length of the implant will be previously established during the implant study. Later a healing abutment will be placed.
223437859|NCT00800956|DRUG|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi \[14C\]-esreboxetine
223437860|NCT00259285|DRUG|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
223437861|NCT00259285|DRUG|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
224049069|NCT03621865|DIETARY_SUPPLEMENT|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
224049070|NCT03621865|DIETARY_SUPPLEMENT|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
224049071|NCT03621865|DIETARY_SUPPLEMENT|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
223437862|NCT01284387|BIOLOGICAL|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
223437863|NCT06618378|BEHAVIORAL|Biofeedback exercise combined with breathing exercise|Urotherapy training will be given at the beginning of the treatment process. Contraction and relaxation will be applied around the external sphincter in combination with diaphragmatic breathing by visual imagery with EMG biofeedback application. The second channel EMG will be placed on the transversus abdominus muscle and its activation will be checked. The treatment will be completed with 30-minute sessions twice a week for 12 weeks. Each session will consist of 40 cycles of 10 minutes of diaphragmatic breathing exercise followed by 20 minutes of 10 seconds of contraction followed by 20 seconds of relaxation.
223566486|NCT01818258|DRUG|ZDV+3TC+LPV/r|
224049072|NCT04680728|OTHER|collection of biological parameters|haemoglobin, haematocrit, sodium, chloraemia, total protein, albumin, L-lactate, pro-BNP, creatinine, uremia, AST, ALT, GGT, ALP, bilirubin, prothrombin time, urinary test if available.
223566487|NCT00159328|PROCEDURE|Magnetic Resonance Guided Focused Ultrasound|
223437864|NCT06618378|BEHAVIORAL|urotherapy educational group|"1. An important part of urotherapy is to provide parents and children with detailed explanations of etiology, prevalence and pathophysiology. This will reassure parents and help them understand the causes of the child's bedwetting accidents and the rationale for treatment. This will increase compliance with treatment.~2. Recommendations are given regarding appropriate fluid intake and regular voiding throughout the day. The child is encouraged to go to the toilet seven times a day and drink seven glasses of water.~3. The correct sitting position for the toilet is explained. If the feet do not touch the floor easily, it is recommended to use a step stool for foot support. Additionally, children are taught to relax their abdomen when peeing.~4. In addition to monitoring and motivation, a bladder diary should be kept to give the child and parents an idea about the progress of treatment, compliance with treatment and continuity."
224049073|NCT04680728|OTHER|collection of echographic parameters|echocardiography (FEVG, subaortic ITV before and after LJP, cardiac index, MAPSE, mitral flow doppler, RVFAC, FEVD, STDVD, VD/VG ratio, TAPSE, tricuspid S wave, IT with PAPs, tricuspid flow doppler), Doppler of suprahepatic veins (S wave, D wave, S/D ratio), renal doppler (VII, RRI, aspect of venous flow in cortical and hilar), femoral venous doppler, doppler of the portal trunk, diameter of the VCI.
223437865|NCT03652948|BEHAVIORAL|Meru Health Ascend Program|Cognitive-behavioral skills, mindfulness
224049074|NCT04680728|OTHER|collection of clinical parameters|eason for hospitalisation, co-morbidities, IGS2 score, SOFA, haemodynamic signs (BP, HR, CVP), sinus rhythm or not, temperature, diuresis, weight, input-output assessment, use of dialysis, ventilatory parameters (intubation, mode, FiO2(%), Vt, FR, PEEP, plateau pressure, driving pressure), state of shock (sepsis, postoperative, haemorrhagic, cardiogenic), transfusion (type, number), catecholamines (type, dose, duration), diuretics and dose, clinical criteria of venous congestion (jugular turgidity, hepato-jugular reflux, hepatosplenomegaly, pitting oedemas of the lower limbs, hepatalgia), neurological evaluation (Glasgow Coma Scale, CAM-ICU), time to resume enteral feeding and bowel movements, weight.
224049075|NCT05092178|BEHAVIORAL|calorie restricted diet and exercise|The CR diet and exercise group received a balanced diet with an energy consists carbohydrates 45-65%; fat 20-35%; and protein 10- 35% and a deficit of 600 kcal/day from their daily energy requirement.The exercise intervention consists of aerobic exercises and resistance exercise, flexibility exercises about 150 minutes for≥2 d•wk for six months. The aerobic exercises included walking on a treadmill, stationary cycling for at least 30 minutes for≥2 d•wk, while, resistance exercises included nine upper-extremity and lower-extremity exercise with weighting lift machines for ≥2 d•wk, while, flexibility exercise including the major muscle-tendon groups (a total of 60 s per exercise) for ≥2 d•wk. Participants performed 1 or 2 sets with 8-12 repetitions of each exercise. The exercise sessions were monitored by telephone video.
223437866|NCT01667939|BEHAVIORAL|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
224049076|NCT05092178|BEHAVIORAL|exercise alone|In exercise alone group, participants then underwent their usual habitual dietary diet and the above exercise intervention during the program.
224049077|NCT00654914|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
224049078|NCT03094351|PROCEDURE|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
224049079|NCT03094351|PROCEDURE|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
224049080|NCT03439436|DRUG|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
224049081|NCT03439436|DRUG|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
224049082|NCT05435170|DRUG|linerixibat|linerixibat will be administered per the treatment sequence
224049083|NCT02709694|OTHER|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
224049084|NCT01586884|PROCEDURE|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
224049085|NCT04458662|PROCEDURE|Interval running protocol / eccentric-based resistance exercise protocol|
224070599|NCT05024864|DIAGNOSTIC_TEST|Urea breath test (UBT)|"After fasting for six hours prior to testing, the patient swallows a C13 Urea tablet or solution and waits. After 10 minutes, the patient exhales and breath is collected (breath bag). The production of 13CO2 is measured by a desktop analyzer (infrared mass spectrometry) and active H. pylori infection diagnosis is made based on previously established cut-off levels for H. pylori infection.~In patients tested positive, eradication therapy according to the national society of gastroenterology guidelines will be prescribed at the caring physician's discretion.~Control of successful H. pylori eradication 6 weeks after completed eradication therapy is recommended to the treating physician.~During the period without H. pylori screening, the study´s UBT equipment will not be available."
223437867|NCT04492917|OTHER|CV4|The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.
224143459|NCT01646463|BEHAVIORAL|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
223437868|NCT04492917|OTHER|ST|The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point
223437869|NCT04492917|OTHER|Sham CV4|the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
223437870|NCT04492917|OTHER|Sham ST|The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
223437871|NCT03435224|DEVICE|INVSENSOR00012|Noninvasive pulse oximeter sensor
223437872|NCT00002063|DRUG|Zidovudine|
223437873|NCT03678896|BEHAVIORAL|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
224143460|NCT01646463|BEHAVIORAL|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
224143461|NCT02051738|DRUG|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
224143462|NCT02051738|DRUG|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
224143463|NCT04618926|DEVICE|Device intubating Laryngeal Tube Suction Disposable|Resuscitation in covid 19 patients
224143464|NCT03457480|OTHER|Computer-Assisted Intervention|Read computer messages
224143465|NCT03457480|BEHAVIORAL|Focus Group|Attend focus group
224143466|NCT03457480|OTHER|Informational Intervention|Receive text messages
224300277|NCT04905030|BEHAVIORAL|Information T1|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in non-scientific, non-statistical terms and is emotionally charged: the consequences of cervical cancers are portrayed by testimonies of cancer survivors from Sweden.
224300278|NCT04905030|BEHAVIORAL|Information T2|A4 information sheet on HPV vaccine containing a reminder of the upcoming HPV vaccination, and information on: (i) its safety and efficacy in preventing a number of cancerous diseases, affecting both women and men; (ii) what is HPV and how contagion happens; (iii) the consequences of cervical cancer for women, in terms of invasive medical treatments and temporary or permanent loss of fertility. The information is framed in scientific terms and incidence and mortality statistics are reported. The information is not emotionally charged but rather aseptic.
223437874|NCT03678896|BEHAVIORAL|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
223437875|NCT03757637|OTHER|NLSCP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
224143467|NCT03457480|OTHER|Survey Administration|Complete surveys about experience
224143468|NCT05129761|DRUG|Syrup Hydryllin|( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
224143469|NCT02778945|DRUG|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
224300279|NCT04905030|BEHAVIORAL|Information C|A4 information sheet containing a reminder of the upcoming HPV vaccination, and information on the history and characteristics of the Swedish national vaccination program.
224300280|NCT04974866|DRUG|EGFR-TK Inhibitor|epidermal growth factor receptor tyrosine kinase inhibitors
224300281|NCT00517179|DRUG|Vardenafil 10mg|
224300282|NCT05291039|DRUG|Infliximab|group 1 (n=20): patients will receive IFX
224070600|NCT06296342|BEHAVIORAL|Exposure to information framing message|The information framing message presents the objective of the front-of-package labeling policy as providing nutritional information.
223566488|NCT05559840|DEVICE|S-Condom Uterine Tamponade|The condom catheter will be inflated with air
223566489|NCT05559840|DEVICE|Traditional condom catheter|The condom catheter will be inflated with saline following national protocol
224070601|NCT06296342|BEHAVIORAL|Exposure to healthier choices framing message|The healthier choices framing message presents the objective of the front-of-package labeling policy as encouraging consumers to make healthier choices.
224070602|NCT06296342|BEHAVIORAL|Exposure to industry framing message|The industry framing message presents the objective of the front-of-package labeling policy as encouraging the food industry to make healthier products.
224070603|NCT04500782|OTHER|Observation at home.|An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, \& Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
224070604|NCT04042103|DRUG|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
224070605|NCT06108895|OTHER|ilio-inguinal/ilio-hypogastric nerve block (IINB)|Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
224070606|NCT06108895|OTHER|intrathecal morphine|200 mcg morphine intrathecally with bupivacaine
224070607|NCT06122480|PROCEDURE|Surgery|All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible
224070608|NCT04263337|DRUG|[11C] PiB|Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
224070609|NCT04263337|DRUG|[18F] PBR111|Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
224070610|NCT04263337|DRUG|[18F] Flortaucipir|Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
224070611|NCT04539210|DEVICE|Electric Welded Metal Framework|Screw-retained Maxillary Complete Denture With Electric Welded Metal Framework
224070612|NCT04186494|DRUG|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|GLP-1 analogue treatment in combination with advice on diet and physical exercise
224070613|NCT04186494|DEVICE|Continuous positive airway pressure treatment|Gold standard treatment for obstructive sleep apnea
224070614|NCT04186494|COMBINATION_PRODUCT|Liraglutide and CPAP|Combination of both treatments
224070615|NCT01762852|DRUG|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
224070616|NCT01762852|DRUG|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
224070617|NCT03787498|DRUG|PLX2853|Tablets
224070618|NCT01483781|DRUG|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
224070619|NCT01483781|DRUG|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
224070620|NCT00325026|DRUG|Misoprostol|
224070621|NCT00325026|DEVICE|Foley bulb|
224070622|NCT04553120|BEHAVIORAL|Alternating single stimulus and multiple stimuli|"P-ARET for cockroach phobia alternating between two interventions: exposure to a single stimulus (always using the same projected cockroach) and exposure to multiple stimuli (different cockroaches in terms of number, shape, colour and movement). It will be counterbalanced to start the same number of participants in each of the two modalities. The two conditions will be randomly applied for each participant, with the restriction of that each condition will be applied 3 times.~There will be 6 weekly sessions of approximately 1 hour. The purpose of this exposure treatment is to confront patients to the phobic stimuli in a controlled manner, which favors the habituation process and allows them to accept that the negative consequences they fear do not actually occur. All exposure sessions should be recorded (patients will sign informed consent for recording prior to treatment initiation)."
224070623|NCT03476499|DEVICE|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
224049086|NCT06289244|DIAGNOSTIC_TEST|Ultrasound|"The thickness of the diaphragm and quadriceps will be assessed using bedside ultrasound, utilizing a 13-6 MHz cm linear probe. The measurement of the right hemidiaphragm's end-expiratory thickness will be conducted via diaphragm ultrasound. For accurate positioning, the ultrasound probe will be placed along the right anterior axillary line, specifically between the ninth and tenth intercostal spaces, in a sagittal oblique orientation. To enhance measurement consistency, the probe's position on the skin will be marked.~To ascertain accuracy, the operator will conduct each measurement three times, and the mean of these three values will be used for analysis. Similarly, for diaphragmatic assessment and peripheral assessments (Qthick and CSA) of the lower limbs, the examination areas will be demarcated on the skin with a dermatographic pen, ensuring measurement reproducibility over different timepoints."
224049087|NCT06289244|DIAGNOSTIC_TEST|Muscle strength measurement|"The assessment of limb muscle strength in this study will be conducted using the Medical Research Council (MRC) Score. For a more precise evaluation of quadriceps strength, a dynamometer will be employed.~Furthermore, the study will incorporate an invasive method for gauging inspiratory muscle strength, utilizing the negative inspiratory force (NIF) metric. Post-extubation, the maximum inspiratory pressure (MIP) will be determined using an electronic manometer. Three separate MIP measurements will be executed, and the highest reading among these will be recorded as the definitive measurement."
224049088|NCT01975740|OTHER|Sham manual diaphragm release technique|
224049089|NCT01975740|OTHER|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
224143470|NCT02778945|DRUG|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
224143471|NCT03331224|DEVICE|OTSC|OTSC placement
224143472|NCT03331224|DEVICE|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
224143473|NCT01537094|DIETARY_SUPPLEMENT|Placebo|
224143474|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 250 mg once daily|
223437876|NCT03757637|OTHER|ICT supported HAP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
223437877|NCT06718270|DRUG|CAR-T cells Infusion|chimeric antigen receptor T cells
223437878|NCT05400031|BIOLOGICAL|propolis|"After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification."
223437879|NCT05400031|BIOLOGICAL|Placebo|Placebo
223437880|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
223437881|NCT02616315|DRUG|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
223437882|NCT04472026|BEHAVIORAL|Counseling using the electronic conversation aid|This conversation aid will help you and your doctor discuss ways to care for your thyroid nodule. We will evaluate the acceptability of the conversation aid and barriers to implementation in clinical practice. Post visit semi structured interviews and recordings of the clinical visits will be qualitatively analyzed. We hypothesize that the conversation aid will be accepted and facilitate the decision making process.
223437883|NCT03156907|DRUG|Buprenorphine|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
223437884|NCT00829088|DRUG|AZD2066|1 dose oral solution
223437885|NCT01720329|DIETARY_SUPPLEMENT|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
223437886|NCT01720329|OTHER|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
224143475|NCT01537094|DIETARY_SUPPLEMENT|Vitamin C 1,000 mg once daily|
224143476|NCT02547519|DRUG|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
223437887|NCT04374682|OTHER|exercises|stretching exercises - physiotherapy modalities - self care instructions
224143477|NCT02547519|DRUG|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
223437888|NCT05483894|DRUG|Atorvastatin 10mg|Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
223437889|NCT05483894|DRUG|Placebo|Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
223437890|NCT00079872|DRUG|Pemetrexed|
223437891|NCT01777295|BIOLOGICAL|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223437892|NCT01777295|BIOLOGICAL|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
224049090|NCT05347186|OTHER|Systematic corrective exercises and non-biomechanical functional exercises|"1. Restraint exercise or self-release: will involve the gastrocnemius muscle, soleus muscle, fibula, knee compressor muscles, adductors of the thighs, the short head of the biceps femoris, and iliotibial band for 30 seconds, using a foam roller.~2. Static stretching drills: involving the soleus and gastrocnemius muscles on an inclined plane, tensor fasciae latae muscle, short head of the biceps femoris, and ilio- psoas muscle;~3. Resistance exercises: will consist of strengthening the eccentric muscles of the feet including dorsiflexion and knee inversion, adduction, and extension, external rotation of the hip joint with TheraBand exercise band, and strengthening the intrinsic muscles of the foot.~4. Integrative exercises: including the star balance test on all planes and resistive exercises."
223437893|NCT01777295|BIOLOGICAL|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
223437894|NCT04122664|DEVICE|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
223437895|NCT04122664|DEVICE|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
223437896|NCT05578105|OTHER|no intervention|No intervention, only observation
223437897|NCT05094544|RADIATION|Non-ablative SBRT|Non-ablative SBRT (800 cGy X 3 fractions) given 5-7 days preoperatively in selected patients with stage I-II NSCLC
223437898|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Sucrosomial® B12
223437899|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|B-SUB® B12
223437900|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Mecogen SL® B12
223437901|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Evermin® B12
223437902|NCT06376591|DIETARY_SUPPLEMENT|Vit B12|Neuromax® B12
223437903|NCT05260424|OTHER|non-invasive ventilation|Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
223566490|NCT02708849|DRUG|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
223566491|NCT02708849|DRUG|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
224049091|NCT05347186|OTHER|Non biomechanical functional exercises|Conventional treatment involved Non biomechanical Functional exercises (NBF), these exercises indicated for the control group consists of dorsal and plantar flexion of the metatarsophalangeal joints in unloading of the subject in a long sitting position on a chair or couch with the knee at 90◦ for a period of eight weeks. Feet will be in hanging position to allow plantar flexion smoothly. The exercises will carry out daily without any kind of resistance for a period of 30s. A total of five series will be completed for each foot. These exercises will be considered as non-therapeutic which might have affected the foot's posture.
224049092|NCT04857801|DRUG|Teduglutide|effect of teduglutide on intestinal rehabilitation
224070624|NCT06354114|DRUG|SYHX2011|IV infusion, 260 mg/m\^2
224070625|NCT02244502|DEVICE|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
224300283|NCT05291039|DRUG|Adalimumab|group 2 (n=20): patients will receive ADA
223566492|NCT02708849|DRUG|Placebo|oral dose placebo
223566493|NCT06362473|DRUG|Lipid-lowering treatments|
223437904|NCT05307796|BEHAVIORAL|Strategy training|The strategy training of focus in this study is metacognitive strategy training intended to build awareness of naming and methods to overcome instances of difficult naming. Strategy training involves (a) teaching the participant to identify instances in which they are unable to name objects, (b) learn a 6-feature framework (e.g. group, use, action) that has been identified to support semantic feature activation in aphasia, (c) learn and practice strategies to utilize the framework in instances of word finding difficulty
223437905|NCT04526574|BIOLOGICAL|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)|Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
223437906|NCT04526574|OTHER|Saline|Normal saline for injection
223437907|NCT04526574|BIOLOGICAL|Influenza vaccine|Seasonal inactivated influenza vaccine (SIIV)
223437908|NCT06016985|DIETARY_SUPPLEMENT|caffeine gum|This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
223437909|NCT04717388|OTHER|acoustics tests, Questionaries,|"acoustics tests at V1 Questionaries at V1~* cognitive~* emotional~* auditory"
223437910|NCT04717388|RADIATION|MRI|Anatomical and functional MRI at V2
223437911|NCT02340611|DRUG|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
223437912|NCT02340611|DRUG|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
223437913|NCT05673161|OTHER|iron|iron treatment
223566494|NCT04296175|DRUG|Epirubicin|90mg/m2, d1 every 2 or 3 weeks
223566495|NCT04296175|DRUG|CTX|600mg, d1 every 2 or 3 weeks
223566496|NCT04296175|DRUG|Paclitaxel|80mg/m2,d1,d8,d15, every 3 weeks
223566497|NCT04296175|DRUG|ddEpirubicin|90mg/m2, d1 every 2 weeks
223566498|NCT04296175|DRUG|ddCTX|600mg, d1 every 2 weeks
223566499|NCT04296175|DRUG|Paclitaxel(with carbo)|80mg/m2,d1,d8,d15, every 4 weeks
223566500|NCT04296175|DRUG|Carboplatin|AUC=2,d1,d8,d15, every 4 weeks
224070626|NCT02244502|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
224070627|NCT00376870|DRUG|Pioglitazone|pioglitazone 30 mg/d
224070628|NCT00376870|DRUG|Placebo|Placebo 30 mg/d
224070629|NCT01003210|DRUG|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
224070630|NCT03861754|BEHAVIORAL|Lifestyle modification|
224070631|NCT00089362|DRUG|alvespimycin hydrochloride|Given IV
224070632|NCT00089362|OTHER|laboratory biomarker analysis|Correlative studies
224070633|NCT00089362|OTHER|pharmacological study|Correlative studies
224070634|NCT00601536|DRUG|Lithium|
224070635|NCT02256514|BIOLOGICAL|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
223437914|NCT03616561|DRUG|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
223437915|NCT02889705|OTHER|Ultrasonographic examination|
224049093|NCT02999542|OTHER|Music|Children will be randomised to receive either music via headphones or silence via headphones
224049094|NCT02999542|OTHER|No music|Children will be randomised to receive either music via headphones or silence via headphones
223437916|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient undergoing pulmonary function tests.
223437917|NCT05863091|DEVICE|HiCardi+|A patch-type electrocardiogram device is attached to a patient on a ventilator in an intensive care unit.
223437918|NCT02939482|DRUG|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
224049095|NCT02925702|DRUG|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
224049096|NCT04308070|DEVICE|AQUABEAM System followed by catheter without hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.
224049097|NCT04308070|DEVICE|AQUABEAM System followed by catheter with hemostatic agent|The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
224049098|NCT06069336|DRUG|Hypertonic saline|Nebulised 3% hypertonic saline (NEBU-dose hypertonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
224049099|NCT06069336|DRUG|Normal saline|0,9% normal saline (NEBU-dose isotonic). Nebulisation will be performed by trained study nurses or by parents under the supervision of a nurse
223437919|NCT01099774|DRUG|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
224049100|NCT02834169|OTHER|Non interventional|Data collection
224049101|NCT02302508|DRUG|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
224049102|NCT03242265|DIAGNOSTIC_TEST|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
224049103|NCT00130702|DRUG|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
224049104|NCT02713542|DEVICE|ACP|Autologous Conditioned Plasma
223437920|NCT01099774|DRUG|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
223437921|NCT02167048|DRUG|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
223437922|NCT06649448|DRUG|Efbemalenograstim alfa Injection|This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.
223437923|NCT06649448|DRUG|carboplatin/cisplatin-etoposide|one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.
224049105|NCT02713542|OTHER|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
224049106|NCT06489639|BEHAVIORAL|DOCT-SAD|Developmentally Oriented Cognitive Therapy for Social Anxiety Disorder is a 10-session, combined individual/group clinical intervention for treating social anxiety in adolescents. It consists of four individual and six group sessions during ten weeks. DOCT-SAD groups are formed for 4-6 adolescnts. One parent or both parents attend two of the individual sessions.
223437924|NCT06649448|DRUG|Carboplatin plus Paclitaxel|"For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W)."
223437925|NCT06649448|DRUG|Cisplatin/pemetrexed or Carboplatin/pemetrexed|"For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W)."
224049107|NCT06489639|BEHAVIORAL|SC|Standard Counseling (SC) is a intervention consisting of counseling sessions delivered by a school health and welfare (SHWS) professional (i.e., school nurse, school social worker, or school psychologist) to support a student with social anxiety. The defined length of intervention is ten weeks, and number of sessions will be according to what is routinely agreed between the professional and the adolescent. In SC, routine professional working methods and procedures available to the SHWS professional delivering the intervention are used.
224049108|NCT00066742|DRUG|tirapazamine|Given IV
224049109|NCT00066742|DRUG|cisplatin|Given IV
224049110|NCT00066742|DRUG|etoposide|Given IV
224049111|NCT00066742|RADIATION|radiation therapy|Undergo radiation therapy
224143478|NCT04121572|DEVICE|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
224143479|NCT04624672|DRUG|Semaglutide (1 Mg Dose)|Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
224143480|NCT04624672|DRUG|Placebo|Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
224143481|NCT02791867|DRUG|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
224143482|NCT01216904|DRUG|nicotine patch|7 mg patches to be worn for 16 hours per day
223437926|NCT06649448|DRUG|TP regimen|"The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W)."
223437927|NCT03025568|OTHER|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
223437928|NCT03025568|OTHER|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
223437929|NCT04602572|BEHAVIORAL|Lifestyle course.|Pharmacotherapy
224143483|NCT01216904|DRUG|placebo|placebo patch to be worn 16 hours per day
224143484|NCT03373318|DRUG|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
223437930|NCT04602572|PROCEDURE|Bariatric surgery.|Sleeve gastrectomy or gastric bypass.
223437931|NCT06126094|DIETARY_SUPPLEMENT|Myrkl|The subject of the test will be supplementation with precise probiotic for hangovers (Myrkl, De Fair) in the form of one pill of 800 mg
223437932|NCT06126094|DIETARY_SUPPLEMENT|dextrin|The subject of the test will be supplementation with placebo (maltodextrin) in the form of two pills (each 400 mg)
223437933|NCT02248974|OTHER|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
224049112|NCT00066742|OTHER|laboratory biomarker analysis|Correlative studies
224049113|NCT04860986|DEVICE|EarliPoint|EarliPoint is a non-invasive diagnostic device for ASD
224300284|NCT04569396|DIAGNOSTIC_TEST|Biochemistry analysis|Biochemistry analysis of liver parameters were analyzed among the study subjects before and after the surgery.
224049114|NCT03761381|DEVICE|Optical Coherence Tomography Angiography (OCTA) Imaging|Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The Solix device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers.
224049115|NCT03761381|DEVICE|Noninvasive Retinal Amyloid Imaging (NRAI)|The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.
223437934|NCT01122940|DRUG|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
223437935|NCT01122940|DRUG|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
224049116|NCT01369420|DEVICE|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
224049117|NCT01150175|PROCEDURE|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
224049118|NCT01150175|PROCEDURE|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
224049119|NCT00359021|DRUG|TMC125|200 mg twice daily until commercially available
224049120|NCT04530903|DRUG|Clonidine|75 µg (0.5mL) per injection site
224049121|NCT04530903|DRUG|Levobupivacaine|0.25% (10 ml) per injection site
224049122|NCT04530903|DRUG|NaCl 0.9%|Nacl 0.9% (0.5ml) per injection site
224049123|NCT01442194|DRUG|other disease-modifying therapy|
224049124|NCT01442194|DRUG|Fingolimod|
224049125|NCT04654442|DIAGNOSTIC_TEST|TestNPass|Patients will undergo saliva sampling. Grenoble University Hospital lab will perform diagnosis using TestNPass IVDMD. Results won't be used for patient care (only recorded for RESEARCH purpose).
223437936|NCT05189522|DEVICE|Innova Breeze®-based roadmap|An Innova Breeze® bolus chase acquisition is realized to assess the final result of the Revascularization of the target limb. Both Innova Breeze® bolus chases are required at field of view 30-cm
224049126|NCT03280654|OTHER|overactive bladder|Association between groups and over active bladder symptoms
224049127|NCT02161575|DRUG|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
224049128|NCT03735927|OTHER|Spot monitoring device, excl. Sham|During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
223437937|NCT05189522|OTHER|Control Group|"2D roadmap guidance is used based on DSA. The treatment of the target lesion is let at the physician discretion. Treatment result of each lesion is checked by a DSA with 1 incidence.~After treatment overall limb assessment will be done through multiple staged DSA.~Finally, the sheath is retrieved and the hemostasis at the puncture site is realized via a manual compression or using a vascular closure device.~DSAs are performed with the injector set at 7mL/s and the volume at 7mL (pressure limit 1000psi) for femoropopliteal assessment. An injector with iodinated contrast (50% of dilution) will be used.~For hospitalized patients, three to five days after the procedure, a blood test is performed to assess the eGFR, as part of the usual care of patients. If the patient is no longer hospitalized, at the time of this examination, the investigating physician has given him an order before his discharge to perform this examination in an analysis laboratory."
223437938|NCT02332239|BEHAVIORAL|iDOVE Intervention (ED+text)|"1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored text-message program"
223437939|NCT02332239|BEHAVIORAL|Control (EUC)|"1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program"
223437940|NCT00374218|DRUG|High Fructose Corn Syrup|
223437941|NCT00374218|DRUG|Sucromalt|
223437942|NCT02271724|PROCEDURE|Lumbar puncture|Lumbar puncture for spinal fluid
223437943|NCT02271724|PROCEDURE|Blood sample|Blood sample
223437944|NCT05691764|DRUG|Cyclosporin|Cyclosporin was administered intravenously with the dose of 3 mg/ kg body weight
224049129|NCT02909075|DEVICE|PET/CT scans|
224049130|NCT02909075|DEVICE|MRI|
224049131|NCT02150148|BEHAVIORAL|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
224143485|NCT03373318|DRUG|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
224143486|NCT01489761|DEVICE|percutaneous coronary intervention|drug eluting stent implantation
224143487|NCT03472040|DRUG|BCX7353|BCX7353 mg oral capsules administered once daily
224143488|NCT02072694|OTHER|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
224143489|NCT02072694|OTHER|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~* 300 mL final volume of the solution.~* Time of oral ingestion inferior than 2 minutes.~* 30 minutes before the radiopharmaceutical injection.~* 12 hours fasting minimum."
224143490|NCT04669145|DRUG|Ropivacaine|Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
223437945|NCT05691764|PROCEDURE|remote ischemic preconditioning|Performed by inflating pressure cuff on the extremity 30 mmHg higher than systolic blood pressure of the patient for 5x5 minutes with 5 minutes reperfusion interval
223437946|NCT05691764|DRUG|Placebo|Intravenous placebo
223437947|NCT00504959|DRUG|ranibizumab|
223437948|NCT04734275|DRUG|AZD5718|Subjects will receive single doses of AZD5718 on 3 occasions, separated by at least 7 days washout, under fasted and fed conditions.
223437949|NCT00673426|BIOLOGICAL|Enoxaparin sodic|
223437950|NCT03212066|BEHAVIORAL|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
223437951|NCT01897610|DRUG|Immuncell-LC|intravenous dripping of 200ml(10\^9\~2x10\^10 lymphocytes/60kg adult) for 1 hour
223437952|NCT02879708|OTHER|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
223566501|NCT05137171|DRUG|AK105 and anlotinib|AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
223566502|NCT01382303|DRUG|Pentoxifylline|Pentoxifylline 400mg three times a day
223566503|NCT01382303|DRUG|Placebo|placebo tablet three times a day
223437953|NCT02879708|OTHER|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
223437954|NCT05502991|DRUG|Tislelizumab plus Bevacizumab|200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
223437955|NCT00115037|DRUG|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
224049132|NCT05281133|OTHER|The group using virtual reality glasses|The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
224049133|NCT01257815|DRUG|Ranibizumab|
224049134|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler|
224049135|NCT03060044|DRUG|Salmeterol/fluticasone Easyhaler with charcoal|
224049136|NCT03060044|DRUG|Seretide Diskus|
224049137|NCT03060044|DRUG|Seretide Diskus with charcoal|
223437956|NCT00115037|DRUG|placebo|placebo comparer for 16 weeks in phase 2.
223566504|NCT03213782|OTHER|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
224049138|NCT05599542|OTHER|Solution-oriented approach|A preliminary assessment of the pregnant woman's thoughts on breastfeeding was made and the EARS (Eliciting, Amplifying, Reinforcing and Start Over) process was applied. Eliciting, Amplifying, Reinforcing and Start Over process guides the second and subsequent sessions in a sequential order. The Eliciting, Amplifying, Reinforcing and Start Over technique reminds the counselor of the basic concepts of solution-oriented approach and its explanation is as follows;
224049139|NCT05599542|OTHER|Hypno-breastfeeding|A preliminary assessment was made about the pregnant woman's thoughts on breastfeeding. In the hypno-nursing philosophy, affirmation, relaxation, imagination and visualization techniques were used in order to positively affect the subconscious mind during the breastfeeding process.
224049140|NCT04107415|OTHER|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
224049141|NCT03753646|OTHER|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
224049142|NCT01879995|PROCEDURE||
224049143|NCT02036242|DRUG|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
224049144|NCT02036242|DRUG|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
224049145|NCT02036242|DRUG|Ropivacaine|
224049146|NCT06189846|DEVICE|International Cohort|"Assessing tumour response following neoadjuvant treatment in rectal cancer include :~* Digital rectal examination~* Rectal MRI~* Rectoscopy ( Lumeneye device)~The monitoring of tumour response intervals up to 6 months following completion of the neoadjuvant treatment at 8 weeks, at 16 weeks, at 24 weeks after the end of neoadjuvant treatment."
224049147|NCT03000088|DEVICE|intubate with 60° angled stylet|
224049148|NCT03000088|DEVICE|intubate with 60° angled stylet|
224049149|NCT00105144|DRUG|Micafungin|IV
224049150|NCT00105144|DRUG|Caspofungin|IV
224049151|NCT04234672|DRUG|TAK-831 Oral Tablet|TAK-831 tablet.
224049152|NCT04234672|DRUG|[14C]TAK-831 IV Infusion|\[14C\]TAK-831 IV infusion.
224049153|NCT04234672|DRUG|[14C]TAK-831 Oral Suspension|\[14C\]TAK-831 oral suspension.
224049154|NCT00779792|DRUG|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
224049155|NCT00779792|DRUG|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
223437957|NCT00115037|BEHAVIORAL|Medication Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
224049156|NCT00779792|DRUG|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
224049157|NCT00779792|DRUG|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
224049158|NCT00779792|DRUG|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
224049159|NCT04935398|OTHER|Physiotherapy|The aim is to test two treatment techniques against each other to see how effective they are.
224049160|NCT03366675|DRUG|AZD2811|AZD2811 100mg/vial
224049161|NCT04091490|DRUG|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
224143491|NCT06526247|BEHAVIORAL|Strength at Home (SAH)|SAH is a group intervention that incorporates elements from interventions for violence and trauma. It is administered during 12 two-hour weekly sessions. The program uses a social information processing model based on the premise that trauma negatively impacts one's ability to interpret and respond to social situations effectively. It underscores the importance of cognitive behavioral strategies to monitor one's thoughts and responses to interpersonal situations.
224143492|NCT06526247|BEHAVIORAL|Treatment as usual for IPV|Treatment as usual for IPV includes court-mandated interventions delivered over the 26 two-hour weekly sessions in Washington state.
224143493|NCT02769832|DRUG|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1 and day 8 of a 21-day cycle
224143494|NCT02769832|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2, day 1 and day 8 of a 21-day cycle
224143495|NCT04473781|PROCEDURE|Interstitial Radiation Therapy|Undergo interstitial brachytherapy
223437958|NCT00115037|BEHAVIORAL|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
223437959|NCT00115037|BEHAVIORAL|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
223437960|NCT03241537|RADIATION|Intensity modulated radiotherapy|
223437961|NCT00396877|DRUG|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
223437962|NCT00396877|DRUG|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
223437963|NCT03168490|DIETARY_SUPPLEMENT|Gluten Friendly bread|parallel study
223437964|NCT00073502|DRUG|OSI-7904L|
223566505|NCT02052336|DRUG|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
223566506|NCT02052336|DRUG|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
223566507|NCT02052336|DRUG|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
224049162|NCT00016380|DRUG|dexamethasone|
224049163|NCT00016380|DRUG|ondansetron|
224049164|NCT00016380|PROCEDURE|quality-of-life assessment|
224049165|NCT02520323|OTHER|Blood draw|
224049166|NCT02520323|PROCEDURE|Bronchoscopy|
224049167|NCT02520323|BEHAVIORAL|Questionnaires|
224049168|NCT02651051|DIETARY_SUPPLEMENT|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
223437965|NCT00334802|DRUG|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
223437966|NCT00334802|DRUG|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
223437967|NCT02274064|BEHAVIORAL|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
223437968|NCT04289090|DRUG|Sevoflurane Inhalant Product|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
223437969|NCT04289090|DRUG|Propofol 10 MG/ML|This study will perform intra-operative sonographic ONSD measurements in order to compare the change in ONSD during transition from inhalational maintenance anesthesia (using sevoflurane) to total intravenous anesthesia (TIVA) using propofol.
223437970|NCT02009059|DEVICE|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
223566508|NCT04812119|DIAGNOSTIC_TEST|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)|The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F; Robins, Fein, \& Barton, 2009) is a 2-stage parent-report screening tool to assess risk for Autism Spectrum Disorder (ASD). It is valid for children 16-30 months old.
224049169|NCT02651051|OTHER|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
224049170|NCT06072989|BIOLOGICAL|B4T2-001 autologous CAR-T|Each subject will receive multiple intravenous infusions of B4T2-001 autologous CAR-T without preparative chemotherapy (lymphodepletion)
224049171|NCT00702325|DRUG|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
224049172|NCT00702325|DRUG|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
224049173|NCT04756037|DRUG|Relugolix Combination Therapy|Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
224049174|NCT03368950|OTHER|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
224049175|NCT01118416|BEHAVIORAL|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
224049176|NCT05889455|DRUG|Sildenafil|Oral administration of 100mg
224049177|NCT05889455|OTHER|Placebo|Placebo
224049178|NCT06493539|PROCEDURE|Standard of Care group|The control group will receive standard of care wound treatment
224300285|NCT04569396|DIAGNOSTIC_TEST|NAFLD fibrosis score|NAFLD fibrosis score was determined among the study subjects before and after the surgery.
223437971|NCT00001300|DRUG|doxorubicin|
223437972|NCT00001300|DRUG|ifosfamide|
223437973|NCT00001300|DRUG|mesna|
223437974|NCT00672399|DRUG|exenatide|Subcutaneously injected, 10 mcg, single doses
223437975|NCT00672399|DRUG|Moxifloxacin|oral, 400 mg tablet, single doses
223437976|NCT00672399|DRUG|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
223437977|NCT03436199|DRUG|ADS-5102, 137 mg|Oral capsules
223437978|NCT03436199|DRUG|ADS-5102, 274 mg|Oral capsules
223437979|NCT03436199|OTHER|Placebo|Oral capsules
223437980|NCT06731309|PROCEDURE|Punch Debridement|A punch biopsy tool is positioned over the inflamed follicular unit, and a small circle of skin (4 to 8 mm in diameter) is excised. A firm twisting motion is necessary to ensure adequately deep excision.
223437981|NCT06731309|PROCEDURE|Incision and Drainage|Incision and Drainage is a minimally invasive surgical procedure often employed for the treatment of intensely painful, tense, and fluctuant abscesses that are too deep to drain spontaneously. After administration of a broad circumferential local anesthetic, a small linear incision is made using a standard scalpel blade. Digital pressure is applied to expel the fluid collection. Saline rinses can be used to flush out the remaining contents. This method offers instant pain relief, commonly performed in acute settings by dermatologists, emergency department physicians and general practitioners
223437982|NCT01792323|DRUG|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
224049179|NCT06493539|DEVICE|CINPWT|Subject will receive CINPWT until discharged
224049180|NCT01591317|DRUG|Prasugrel|Tablets orally
224049181|NCT01022502|DRUG|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
224049182|NCT01022502|DRUG|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
224049183|NCT05479279|OTHER|Neck Stabilization Training Program|3 times a week stretching exercises approximately 10 mins dumb bell exercises - 2 sets of 15 reps with weights varying from 1 to 2 kg cranio-cervical isometrics for 10 sec with 15 sec breaks between holds with 10-15 reps Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
224049184|NCT05479279|OTHER|Conventional physical therapy|Tens 5-10 mins Hotpack 5-10 mins neck stretches home plan - 5 reps/set, 3 sets/ day
224049185|NCT01073241|PROCEDURE|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
224049186|NCT01073241|PROCEDURE|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
224049187|NCT03716050|DRUG|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
224300286|NCT04569396|OTHER|BMI measurement|BMI was measured among the study subjects before and after the surgery.
224300287|NCT04569396|DIAGNOSTIC_TEST|Fibrosis 4 Index|Fibrosis 4 Index was determined among the study subjects before and after the surgery.
224049188|NCT03716050|DEVICE|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
224049189|NCT03716050|OTHER|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
224143496|NCT06226103|OTHER|Aerobic Exercise and Computerized Cognitive Training|"Aerobic Exercise (AE) included walk briskly, increasing intensity and duration progressively. The first week they had to walk 30 min per day, 3 days per week, up to 9-10 on the Borg Rating of Perceived Exertion Scale (BRPES; Borg, 1982) perceived as light intensity; during the second week, the duration was increased to 45 min and the intensity 9-10 and frequency (3 days per week) were maintained; the following 10 weeks they maintained the duration (45 min) and frequency (3 days per week) and increased the intensity up to 12-14 on BRPES perceived as moderate-high effort.~Computerized Cognitive Training (CCT) included a multidomain computer-based cognitive training using the brainHQ software in sessions of 45 min, 3 days per week for 12 weeks. Cognitive tasks targeted attention, recognition, colour and shape, identification, calculation, visual perception, visual spatial processing, memory, and executive function."
223437983|NCT05490134|DRUG|Naloxone|A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
223566509|NCT04812119|DIAGNOSTIC_TEST|The Autism Spectrum Quotient-Children's Version (AQ-Child)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 4-11 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
224049190|NCT03716050|OTHER|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
224049191|NCT00003172|BIOLOGICAL|filgrastim|
224049192|NCT00003172|BIOLOGICAL|recombinant interferon alfa|
224049193|NCT00003172|DRUG|docetaxel|
224143497|NCT06226103|OTHER|Conventional Exercises and Brain health lectures|Participants were exposed to balancing, coordination, stretching, and core exercises. Additionally, they attended brain health lectures to provide a comparative non-interactive cognitive engagement. Both the exercises and lectures were scheduled similar to the intervention group over 12 weeks
224143498|NCT04874480|DRUG|Decitabine|Given IV
224049194|NCT00003172|DRUG|doxorubicin hydrochloride|
224049195|NCT00003172|DRUG|fluorouracil|
224049196|NCT00003172|DRUG|hydroxyurea|
224049197|NCT01812889|DRUG|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
224143499|NCT04874480|DRUG|Tegavivint|Given IV
224143500|NCT01309490|DRUG|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
224143501|NCT04658199|DRUG|UCB0107 (bepranemab)|UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
224300288|NCT04569396|DIAGNOSTIC_TEST|Fatty Liver Index|Fatty Liver Index was determined among the study subjects before and after the surgery.
223437984|NCT05490134|DRUG|Saline|0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
223437985|NCT02898558|BEHAVIORAL|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
223437986|NCT02898558|DEVICE|magnifying lenses|
223437987|NCT02484638|DRUG|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
223566510|NCT04812119|DIAGNOSTIC_TEST|The Autism-Spectrum Quotient (AQ)-Adolescent Version (AQ-Adolescent)|"The Autism Spectrum Quotient-Children's Version (AQ-Child; Auyeung, Baron-Cohen, Wheelwright \& Allison, 2008) is a parent-report questionnaire that aims to quantify autistic traits in children 12-15 years old. It contains 50 likert-type items with responses ranging from definitely agree to definitely disagree."
224049198|NCT01812889|DRUG|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
224049199|NCT01587339|DRUG|retigabine/ezogabine|oral - all doses
223437988|NCT02484638|DRUG|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
223437989|NCT04559035|OTHER|Nasal lavage|Twice daily nasal lavage.
223437990|NCT04189133|DRUG|Lutropin alfa|daily increasing dosages of lutropin alfa
223437991|NCT04189133|DRUG|Human chorionic gonadotropin|human chorionic gonadotropin increasing administration
224049200|NCT01587339|DRUG|lacosamide|oral - all doses
224049201|NCT01587339|DRUG|zonisamide|oral - all doses
224049202|NCT01587339|DRUG|pregabalin|oral - all doses
224049203|NCT01587339|DRUG|eslicarbazepine|oral - all doses
224049204|NCT03229421|OTHER|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
224049205|NCT03123250|DEVICE|Aquablation|The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.
224049206|NCT04135339|OTHER|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
224049207|NCT04135339|OTHER|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
224049208|NCT04135339|OTHER|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
223437992|NCT04507893|OTHER|Clinical, laboratory and imaging characteristics of pneumonia|"Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients."
223437993|NCT06125340|DRUG|Placebo|5 days of placebo to be given after 3-5 days of antibiotics
223437994|NCT06125340|DRUG|Amoxicillin|Standard-dose amoxicillin (approved by Health Canada) to be given x 5 days.
223437995|NCT00085098|BIOLOGICAL|filgrastim|Given by infusion or injection
223437996|NCT00085098|DRUG|carboplatin|Given IV over 1 hour
223437997|NCT00085098|DRUG|cisplatin|Given IV over 6 hours
224049209|NCT06200649|OTHER|massage|Massage application; It will be done on the back, which is the five basic massage areas. Massage application will be started with eflorage. The massage will be continued with petrissage by grasping the subcutaneous tissue and muscle layer with the help of thumb and other fingers, starting from the waist circumference. Petrissage will be applied for 5 minutes. After petrissage, the massage was continued with friction movements, which is the other stage. Friction will be applied for 5 minutes. Tapotment will be done after friction. Tapotman will take 5 minutes. After taping, the entire back area will be finished by efflorescence for 2 minutes, just like at the beginning.
224049210|NCT03963414|COMBINATION_PRODUCT|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
224049211|NCT03963414|COMBINATION_PRODUCT|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
224143502|NCT04568317|BEHAVIORAL|Space from Depression|This is a 7-module internet-based CBT program. The structure and content of the modules follow evidence-based CBT principles; they are structured to incorporate quizzes, videos, psychoeducational content and interactive tools, personalised homework suggestions and summaries. One of the interactive tools is the mood monitor, where users are encouraged to monitor their mood and reflect on several factors that might had influenced it. Clients are allocated to a psychological wellbeing practitioner (PWP). The PWP is responsible for monitoring and guiding the client's progress throughout the intervention. Over the course of the 8 week supported intervention period, on 6 separate occasions the PWP will review participants progress, leaving feedback for them and responding to the work they have completed. The basic share level allows PWP is to view users' goals for the week, key messages and progress points. Each PWP will provide post-session feedback of between 10 and 15 minutes per session.
223437998|NCT00085098|DRUG|cyclophosphamide|Given IV over 1 hour
223566511|NCT04812119|DIAGNOSTIC_TEST|The Viking's Speech Scale|The Viking Speech Scale (Pennington, Virella, Mjøen, da Graça Andrada, Murray, Colver, … \& Andersen, 2013) is used to classify children's speech production, specifically the ease at which children can make themselves understood using different methods of communication. The scale has four levels and is ordinal. The four levels include: (1) speech is not affected by motor disorder (2) speech is imprecise but usually understandable to unfamiliar listeners (3) speech is unclear and not usually understandable to unfamiliar listeners out of context (3) no understandable speech. It is intended for children above the age of 4 years.
223566512|NCT04812119|DIAGNOSTIC_TEST|The Functional Communication Classification System (FCCS)|The Functional Communication Classification System (Barty, Caynes \& Johnston, 2016) was designed to classify how children with cerebral palsy communicate on a daily basis. The tool focuses on how children typically communicate with familiar and unfamiliar communication partners. There are five classifications a child can be categorized in: (1) effective communicator in most situations (2) effective communicator in most situations, but does need some help (3) an effective communicator in most situations and can communicate small ranges of messages and topics to most familiar people (4) assistance is required in most situations, especially with unfamiliar people and environments. Communicates daily needs and wants to familiar people (5) communicates using undirected movement, vocalisation and/or behaviour, for interpretation by familiar people. The FCCS is valid for use in children up to 13 years.
224049212|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
224049213|NCT01390272|BEHAVIORAL|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
224049214|NCT01390272|BEHAVIORAL|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
224049215|NCT01390272|BEHAVIORAL|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
224049216|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
223437999|NCT00085098|DRUG|etoposide|Given IV over 2 hours
223438000|NCT00085098|RADIATION|radiation therapy|Patients undergo radiotherapy 5 days a week
223438001|NCT04698421|BIOLOGICAL|Blood collection on admission and longitudinally|Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
223438002|NCT04222140|COMBINATION_PRODUCT|ERIPTO Protocol|combination biologic treatment
223438003|NCT04222140|BIOLOGICAL|BMAC Only|BMAC treatment only
223438004|NCT04902729|DRUG|Carbetocin|Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
223438005|NCT04902729|DRUG|Oxytocin|Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
223438006|NCT03515629|DRUG|REGN2810/ipi|REGN2810 plus ipilimumab
223438007|NCT03515629|DRUG|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
223438008|NCT03515629|DRUG|Pembrolizumab|Reference drug administered IV infusion
223438009|NCT05993026|BEHAVIORAL|Mental health course|The student course involves classroom-based teaching of eight lessons over eight weeks. The aim is to strengthen students' faith in their own abilities (self-efficacy) and ability to understand themselves and others (mentalization). In this way, students become better at entering into positive relationships and communities as well as better at handling everyday challenges both academically and socially. The student course includes teaching, exercises and training in simple tools for mastery and mentalization. The student courses in the classes are handled by staff close to the students and are based on both physical and digital material as well as an app for the students. The employees initially participate in a competency development course.
223438010|NCT03595865|DRUG|tafluprostin|Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6months. Each eye will be preformed tafluprostin 0.0015% at 9 PM.
224049217|NCT03564951|PROCEDURE|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
224049218|NCT01958190|DRUG|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
224049219|NCT01958190|DRUG|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
224049220|NCT05893602|OTHER|Blood sample analysis|Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
224143503|NCT04568317|DEVICE|Mood Monitor watch app|"The Mood Monitor watch app will allow in-the-moment self-report of patients' mood and automated monitoring of their sleep and activity level. This data will be integrated into the existing Mood Monitor tool within the participant's Space from Depression program. During the intervention, prompts to record mood data will appear on the watch app; participants will be encourage to choose the frequency and time ranges to receive prompts. The watch app main screen will provide a daily and weekly visualisation of participant's mood, bedtime, hours slept and steps count, and visual cues on their progress. Participants will receive encouragement prompts to reward frequent and consistent self-report of mood over time and a good sleep hygiene. Finally, the app Tips to Stay Well feature will allow participants to go through a list of lifestyle-related tips extracted from the Space from Depression program."
224143504|NCT04308473|OTHER|Ultra-processed Food Meal|An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
224143505|NCT04308473|OTHER|Whole Food Meal|A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
224143506|NCT00834886|DIETARY_SUPPLEMENT|Melatonin|Capsules, 3 mg, once every night
224143507|NCT00834886|OTHER|Bright light|Bright light therapy 10.000 lux by Miljølys AS
224143508|NCT00834886|OTHER|Placebo red light|Red light 400 lux as placebo light
224143509|NCT00834886|OTHER|Placebo capsule|Capsules containing 3 mng rice flour, once every night
224143510|NCT04568187|DEVICE|zeltiq|Zeltiq prototype device (Zeltiq Aesthetics, Pleasanton, CA) approved by FDA 2010
224143511|NCT04568187|DEVICE|placebo|radiofrequency with 3000 Hz
224143512|NCT02204813|DRUG|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
224143513|NCT02204813|DRUG|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
224143514|NCT02204813|DRUG|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
224143515|NCT02204813|DRUG|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
223438011|NCT00000448|DRUG|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
223566513|NCT04812119|DIAGNOSTIC_TEST|Brief Infant Sleeping Questionnaire (BISQ)|The Brief Infant Sleep Questionnaire (BISQ; Sadeh, 2004) is used to assess sleep patterns, parent perception, and sleep-related behaviors in young children (0-36 months). The BISQ has been validated against actigraphy, daily logs, and has high sensitivity in documenting expected developmental trends in sleep.
224143516|NCT02765503|RADIATION|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
224143517|NCT05521464|OTHER|cast|Application of a short arm cast from just below the elbow to the finger's knuckles. The cast was from a Plaster of Paris bandage over a cotton pad. The participants who received this treatment modality were considered group 1 (control group)
224049221|NCT05973552|OTHER|CO-rebreathing|In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume
223438012|NCT00000448|DRUG|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
224143518|NCT05521464|OTHER|Robert Jones Bandage|Modified RJ bandage (firmly applied two layers of bulky cotton layers alternating with two layers of elastic bandage in the following order: bandage - cotton - bandage - cotton - bandage). It was applied from below the elbow to the finger's knuckles. The participants who received this treatment modality were considered group 2 (trial group).
224143519|NCT03874351|DEVICE|non-invasive transcranial direct current stimulation (tDCS)|"Active tDCS: transcranial direct current stimulation at intensity 1.5mA for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.~Sham tDCS: transcranial direct current stimulation at intensity 1.5mA for 30seconds followed by 0 mA current for remaining time of the 20-minute intervention per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right."
224300289|NCT04514536|DEVICE|Health monitors|"* The connected scale (iHealth HS2) measures weight from 5 to 180kg and BMI.~* The connected actimeter (iHealth AM4) monitors activity (number of steps, distance, calories), sleep (automatic sleep recognition, effective sleep time, number of awakenings) and swimming (automatic activity recognition, session duration, swim type recognition and number of laps).~* The connected blood pressure monitor (iHealth Track KN-550BT)is a medical device that measures blood pressure and pulse rate.~* The activity monitor (manufactured by RF Track) consists of a housing that can be positioned as a pendant or at the hip. It includes an accelerometer, gyroscope, magnetometer, barometer, radio transceiver, and led. The sensor records the raw signals.~* The touchpad allows the subject to connect to the Calliope app. This app allows the data recovery, storage, analysis, visualization, and all the required settings for the platform to work together."
223438013|NCT00002048|DRUG|Zidovudine|
223438014|NCT05155722|DRUG|BAT1308|A 21 day treatment cycle was administered every 3 weeks (Q3W) on day 1 of each cycle. Six consecutive dosing cycles are recommended for the dose escalation phase. In the extended study phase, after the end of the 6th treatment cycle, after the risk and benefit are evaluated by the investigator in combination with the clinical practice, if the subjects are still in a state of clinical benefit (including CR, PR and SD), the investigator can decide to appropriately extend the treatment of BAT1308. Until disease progression, unacceptable toxicity, withdrawal of informed consent, loss of follow-up, death, acceptance of new antitumor therapy, termination of treatment by investigator evaluation, or 12 months after initial administration, whichever is the earliest.
223566514|NCT04812119|DIAGNOSTIC_TEST|Pediatric Sleep Questionnaire (PSQ)|Pediatric Sleep Questionnaire (PSQ; Chervin, Hedger, Dillon, Pituch, 2000) has been designed to screen for sleep problems in children. The scale consists of 22 parent-reported items examining snoring and breathing problems, daytime sleepiness, inattention, hyperactivity, and other signs and symptoms of apnea including obesity and nocturnal enuresis. Those questions specifically relate to sleep-disordered breathing (SDB) in children. PSQ has been validated for children 2-18 years old.
224049222|NCT05973552|OTHER|Oral iron isotope administration (54Fe)|Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption
224049223|NCT05973552|OTHER|Intravenous iron isotope administration (58Fe)|Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
224049224|NCT05053516|OTHER|A standardized training program for social workers|A standardized training program for social workers who work with drug addicts / drug users based on industry needs
224049225|NCT02910960|DEVICE|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
224049226|NCT02910960|DEVICE|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
224049227|NCT00087750|DRUG|Quetiapine|
223438015|NCT03493581|PROCEDURE|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
224049228|NCT03931967|DIAGNOSTIC_TEST|MR-proADM|to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
224049229|NCT01466530|DRUG|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
223438016|NCT03493581|DIAGNOSTIC_TEST|blood-sampled|"* after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~* after 6 weeks (V2),~* after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~* \- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).~* after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),~* after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses)."
224049230|NCT01466530|DRUG|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
224049231|NCT00041925|DRUG|CGT003 (E2F Duplex Decoy)|
224049232|NCT06038240|BEHAVIORAL|Savoring Meditation|Participants will learn about pain neuroscience and will learn/practice a positive emotion generative practice (Savoring Meditation).
224049233|NCT06038240|BEHAVIORAL|Pain Self-Management and Education|Participants will learn about the biopsychosocial drivers of chronic pain.
224143520|NCT01510223|DIETARY_SUPPLEMENT|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
224143521|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
224143522|NCT01510223|DIETARY_SUPPLEMENT|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
224143523|NCT01510223|DIETARY_SUPPLEMENT|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
224143524|NCT00453843|DEVICE|rehabilitation robotics|sequence of intervention
223438017|NCT03493581|OTHER|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
223438018|NCT06731595|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
223566515|NCT04812119|DIAGNOSTIC_TEST|The Eating and Drinking Ability Classification System (EDACS)|The Eating and Drinking Ability Classification System (EDACS; Sellers, Mandy, Pennington, Hankins, Morris, 2013) has been developed for people with cerebral palsy to describe five distinct levels of ability using the key features of safety and efficiency. The patient can be categorized in: (1) eats and drinks safely and efficiently, (2) eats and drinks safely but with some limitations to efficiency, (3) eats and drinks with some limitations to safety; maybe limitations to efficiency, (4) eats and drinks with significant limitations to safety or (5) unable to eat or drink safely - tube feeding may be considered to provide nutrition. The EDACS is valid for use in children above the age of 36 months.
224049234|NCT03199040|DRUG|Durvalumab|-Human monoclonal antibody
224049235|NCT03199040|BIOLOGICAL|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
224049236|NCT03199040|DEVICE|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
224049237|NCT03199040|PROCEDURE|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
224049238|NCT03882203|DRUG|CLAGE-FluBu|Cladribine combined with cytarabine and VP16 sequential with Fludarabine combined with busulifan
224049239|NCT02580942|DEVICE|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
224049240|NCT02580942|DEVICE|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
224143525|NCT00453843|PROCEDURE|Movement therapy|sequence of intervention
224143526|NCT02739256|PROCEDURE|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
224143527|NCT03465176|OTHER|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
224143528|NCT03465176|OTHER|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
223438019|NCT01886781|DRUG|Lactobacillus plantarum 299v|two capsules of 5 X 10 \^9 c.f.u each
224049241|NCT02580942|DRUG|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
224049242|NCT03778567|DRUG|Telbivudine|CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
224049243|NCT04290338|OTHER|PIOMI|Intraoral and extraoral stimulation.
223438020|NCT01886781|DRUG|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
223438021|NCT01886781|OTHER|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
223438022|NCT01886781|OTHER|Wash - out period|Wash - out period following treatment phase of eight weeks
223438023|NCT03974841|PROCEDURE|laparoscopic cornual resection|patients undergoing laparoscopic cornual resection due to cornual ectopic pregnancy
224143529|NCT02467023|DEVICE|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
223438024|NCT04570163|DEVICE|Interventional therapy mainly of tricuspid regurgitation (TriClip, Cardioband)|Catheter-based therapy of valve diseases of the right heart with various devices (e. g. TriClip, Cardioband).
223438025|NCT05725213|DRUG|Metvix® 160 mg/g Creme|Patients are treated with Metvix creme and exposed to artificial daylight
223438026|NCT00424021|DRUG|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
223438027|NCT00123461|DRUG|Hectorol (doxercalciferol capsules), 0.5mcg|
223438028|NCT06730282|DRUG|Danggui Shaoyao San (DSS)|Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
223438029|NCT06730282|DRUG|Cuscuta Chinensis (Tu Si Zi)|Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
223438030|NCT06730282|DRUG|Combination Therapy (DSS + Tu Si Zi)|This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
223438031|NCT06730282|DRUG|Placebo|Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
223438032|NCT03442374|OTHER|Exercise|The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
223438033|NCT03769194|BIOLOGICAL|VLA15|a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate
224049244|NCT06059924|OTHER|Anastomotic leakage|Anastomotic leakage was defined as a defect of the intestinal wall at the anastomotic site leading to a communication between the intra- and extraluminal compartments. It was diagnosed by clinical, laboratory, radiological (ultrasound, endosonography, computed tomography), endoscopic, and/or surgical findings.
224049245|NCT05838079|OTHER|Clinical examination|Echocardiography Electrocardiography Analysis of umbilical and/or venous blood. Peripheral measurement of oxygen saturation
224300290|NCT05041621|DEVICE|Sensor augmented MDI therapy plus mobile application|"Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention."
224300291|NCT00336245|DEVICE|Copper T Intrauterine Contraceptive Device|
223438034|NCT03769194|BIOLOGICAL|Placebo|Placebo: PBS (Phosphate Buffered Saline)
223438035|NCT01944826|OTHER|Registry of patients with Tako-Tsubo cardiomyopathy|
223438036|NCT05123391|RADIATION|External beam image guided radiotherapy|Volumetric modulated arc therapy (VMAT)-Image-guided radiation therapy (IGRT)
223438037|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
223438038|NCT01523704|DEVICE|BIOTRONIK Home Monitoring System with In-office Follow-up|
223438039|NCT06083701|DRUG|Linperlisib in combined with Chidamide|"* Phase 1: dose escalation phase. Drug Linperlisib: 3 dose level of 40mg, 60mg, 80mg qd; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;~* Phase 2: dose expansion phase. Drug Linperlisib: RP2D established in the phase I study; Drug Chidamide: fixed dose of 20mg twice weekly in a 4-week cycle;"
224049246|NCT05168748|DRUG|IMJ995 single agent|Single intravenous administration of IMJ995
223438040|NCT06655467|BEHAVIORAL|Routine Care|This study involves no change in clinical care and no study specific interventions for participants.
223438041|NCT04262804|DRUG|Margetuximab|Margetuximab IV
223438042|NCT04262804|DRUG|Trastuzumab|Trastuzumab IV
223438043|NCT04262804|DRUG|Chosen Chemotherapy (Capecitabine)|Capecitabine tablet
223438044|NCT04262804|DRUG|Chosen Chemotherapy (Vinorelbine )|Vinorelbine IV
223438045|NCT04262804|DRUG|Chosen Chemotherapy (Gemcitabine )|Gemcitabine IV
224049247|NCT00588510|OTHER|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
224049248|NCT01652742|DRUG|BI 135585 XX|one single dose
224300292|NCT00336245|DRUG|Hormonal Contraception|
224300293|NCT01022944|PROCEDURE|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
224300294|NCT01022944|PROCEDURE|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
224300295|NCT03141866|OTHER|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
224300296|NCT03141866|OTHER|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
224049249|NCT01089998|DRUG|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
224049250|NCT01089998|DRUG|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
224143530|NCT02467023|DEVICE|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
224049251|NCT01089998|DRUG|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
224049252|NCT01089998|DRUG|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
224049253|NCT02566291|DEVICE|Success|Success rate and time for insertion
224049254|NCT04541979|DRUG|aerosolized DNase|DNase
224049255|NCT04541979|DRUG|NaCl|NaCl 0.9%, isotonic saline
224049256|NCT02951286|DEVICE|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
224049257|NCT02951286|DEVICE|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
224143531|NCT02467023|PROCEDURE|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
224143532|NCT02467023|DRUG|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
224143533|NCT02467023|DRUG|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
224143534|NCT02467023|DRUG|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
224143535|NCT02467023|OTHER|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
224143536|NCT02467023|DEVICE|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
224143537|NCT03522883|DIETARY_SUPPLEMENT|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
224049258|NCT02984579|DEVICE|YD REBA MTB-MDR|Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
224049259|NCT02984579|DEVICE|Hain Genotype MTBDRplus V1|Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
224049260|NCT02984579|DEVICE|Hain Genotype MTBDRplus V2|Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
224049261|NCT00199836|BIOLOGICAL|NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51|
224049262|NCT02301663|OTHER|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
224049263|NCT02301663|OTHER|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
224049264|NCT02301663|OTHER|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
224049265|NCT00449384|BEHAVIORAL|Diagnostic Screening|
224049266|NCT00940381|DRUG|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
224049267|NCT00940381|DRUG|Cetuximab|Beginning dose 100 mg/m\^2 by vein over two hours on Day 1, and 65 mg/m\^2 on Days 8, 15 and 22 for a 28 day cycle.
224049268|NCT02582320|DRUG|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
224049269|NCT02967705|BEHAVIORAL|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
224049270|NCT01114282|DRUG|velcade|
224049271|NCT01114282|DRUG|Pralatrexate|
224049272|NCT05353400|OTHER|Early urinary catheter removal|Early catheter removal
224049273|NCT05353400|OTHER|Urinary catheter removal on POD 3|Catheter removal on POD 3
223438046|NCT03138746|PROCEDURE|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
223438047|NCT03138746|PROCEDURE|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
223438048|NCT03597022|DRUG|Befovacimab (BAY1093884)|Once weekly doses until premature termination of the study, subcutaneous injection
224049274|NCT04267718|OTHER|Application of Padua and IMPROVE Bleeding scores|Eligible patients hospitalized in centres randomized to the Experimental group will be evaluated, within 48 hours from admission to hospital, by means of the Padua predictive score and the IMPROVE Bleeding score.
224049275|NCT02237404|DEVICE|Telemedicine System|Telemedicine System is used in remote monitoring group
224049276|NCT02400034|OTHER|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
224049277|NCT03392272|DEVICE|Using of Tisseel fibrin glue|Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
224049278|NCT03392272|OTHER|Using sutures|Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
224049279|NCT04301362|DIAGNOSTIC_TEST|Thrombosis biomarkers|Blood samples shall be prepared according to the manufacturer's instructions and stored at -80°C until analysis. Thrombin generation will be measured using the commercial kit STG®-Tromboscreen kit (Stago). The D-dimers will be quantified using STA LIATEST® D-DI PLUS (Stago).
224049280|NCT04575103|DRUG|Antipsychotic|Antipsychotic treatment \>0.5 DDD
224049281|NCT00503243|DRUG|Delayed and extended release mesalazine|
224049282|NCT03228069|PROCEDURE|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
224049283|NCT06375434|OTHER|No intervention|No intervention
224143538|NCT01778400|PROCEDURE|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
224143539|NCT01778400|PROCEDURE|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
224300297|NCT00283023|PROCEDURE|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
224300298|NCT03638778|DRUG|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
224300299|NCT03638778|DRUG|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
223438049|NCT06247072|DEVICE|Tonometer|measures IOP
223438050|NCT02716766|DRUG|Sorafenib|PO
224049284|NCT04254744|DRUG|Sevoflurane|Sevoflurane inhalation for anesthesia
224049285|NCT03870516|PROCEDURE|Mitral valve replacement|Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.
224049286|NCT03870516|DEVICE|Speckle tracking echocardiography|We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
224300300|NCT03638778|DRUG|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
224300301|NCT03638778|DRUG|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
223438051|NCT02716766|DRUG|Capecitabine|PO
224049287|NCT04215614|DRUG|Lidocaine and Bupivacaine solution|1:1 ratio 2% lidocaine, and 0.5% bupivacaine
224049288|NCT04215614|DEVICE|Costoclavicular block|Ultrasound-guided costoclavicular brachial plexus block
224049289|NCT04215614|DEVICE|Lateral Sagittal block|Ultrasound-guided lateral sagittal brachial plexus block
224049290|NCT02232126|OTHER|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
224300302|NCT03638778|DRUG|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
224300303|NCT03638778|DRUG|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
224300304|NCT03638778|DRUG|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
224300305|NCT03638778|DRUG|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
224300306|NCT05068089|PROCEDURE|Nissen fundoplication|Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
224300307|NCT05068089|BIOLOGICAL|Enteral nutrition|Type and switch of enteral nutrition formula (tube, PEG, PEJ)
223438052|NCT02716766|DRUG|Oxaliplatin|IV
223438053|NCT06255717|BEHAVIORAL|Comprehensive rehabilitation training|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
224300308|NCT05702671|DIAGNOSTIC_TEST|Total Immunoglobulin E, Obtained From Fingerstick Sample|The Kenota 1 System is intended to be a specialized tool in a professional allergist setting. It will help streamline the patient testing process by bringing quantitative, minimally invasive fingerstick IgE blood testing to the allergy clinic.
223438054|NCT06255717|BEHAVIORAL|Rise-bed Training|"gradually elevating the bed (head-up tilt) is one of the common methods to treat orthostatic hypotension. This treatment adjusts the patient's bed angle to gradually raise their body, promoting balanced blood distribution throughout the body and reducing orthostatic hypotension symptoms.~In head-up tilt treatment, the bed angle is usually gradually increased from a horizontal position, and the specific angle can be determined based on the patient's condition and tolerance. This treatment process is generally monitored and controlled by medical personnel to ensure safety and effectiveness.~The mechanism of head-up tilt treatment is to increase venous return by changing the body position and increasing the effect of gravity, thereby increasing cardiac preload, output, and blood pressure. This helps to reduce orthostatic hypotension symptoms such as dizziness, lightheadedness, and fatigue."
223438055|NCT01985958|DEVICE|Radiation therapy|
224300309|NCT01328665|OTHER|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
223438056|NCT05786638|DRUG|Allergen Immunotherapy Extract|Sublingual subcutaneous allergen immunotherapy
223438057|NCT05462275|DEVICE|Intubation using 3-cuffed double lumen endotracheal tube|After patient's position, 3-cuffed double lumen endotracheal tube is intubated without fiberoptic bronchoscopy guidance
223438058|NCT04126642|BEHAVIORAL|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
223438059|NCT04126642|BEHAVIORAL|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
223438060|NCT06240988|DEVICE|Modified Constraint Induced Movement Therapy|Modified Constraint Induced Movement Therapy
223438061|NCT06240988|OTHER|Motor Imagery Technique|Motor Imagery Technique
223438062|NCT05937607|BEHAVIORAL|Hand massage|It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
223438063|NCT01672294|OTHER|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
223438064|NCT01672294|OTHER|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
223438065|NCT03881891|BEHAVIORAL|Follow-app intervention arm|The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
223438066|NCT01550107|DRUG|Allopurinol|300mg b.d for 24 weeks
223438067|NCT01550107|DRUG|Lactose tablets|matched placebo tablets b.d
223438068|NCT05370508|COMBINATION_PRODUCT|SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)|SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS
224300310|NCT03595085|PROCEDURE|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
223438069|NCT06731543|OTHER|No interventions will be made|
223438070|NCT00203463|DRUG|topiramate|
223438071|NCT03887117|OTHER|IQOS + Exercise Training Program|Switch to IQOS use + participation in a training program
223438072|NCT03887117|OTHER|IQOS without Exercise Training Program|Switch to IQOS use only, without participation in a training program
223438073|NCT03887117|OTHER|Cigarette Smoking + Exercise Training Program|Continue to smoke cigarettes + participation in a training program
223438074|NCT03887117|OTHER|Smoking Abstinence + Exercise Training Program|Switch to smoking abstinence + participation in a training program
223438075|NCT04879836|DEVICE|Teething Gel|Dosage: application of an even coat of 1mm thickness Frequency: 5 times/day (after main meals and before sleeping) Duration: 4 weeks
223438076|NCT04879836|DEVICE|Teething Ring|The teething ring was filled with a coolant Usage: 5/10 min per time Frequency: 5 times/day Duration: 4 weeks
223438077|NCT05626218|OTHER|stress ball|The woman is usually laid in the last side position during the procedure. A stress ball will be given to the right hand of the participants during the NST procedure (average 15-20 minutes). This stress ball will be squeezed for 2-3 seconds, and then the hand and arm will be told to relax. This process will be repeated throughout the NST. Hospital protocol will also be applied to these participants.
223566516|NCT04812119|DIAGNOSTIC_TEST|Mini Manual Ability Classification System (Mini-MACS)|The Mini Manual Ability Classification System (Mini-MACS; Eliasson, Krumlinde-Sundholm, 2013) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 1-4 years of age.
223566517|NCT04812119|DIAGNOSTIC_TEST|Manual Ability Classification System (MACS)|The Manual Ability Classification System (MACS; Eliasson, Krumlinde Sundholm, Rösblad, Beckung, Arner, Öhrvall, Rosenbaum, 2006) describes how children with cerebral palsy use their hands to handle objects in daily activities. MACS describes five levels. The levels are based on the children's self-initiated ability to handle objects and their need for assistance or adaptation to perform manual activities in everyday life. It has been validated for children 4-18 years.
224049291|NCT02336763|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
224049292|NCT02336763|OTHER|Laboratory Biomarker Analysis|Correlative studies
223438078|NCT01739764|DRUG|Vemurafenib|Vemurafenib was given based on the last dose of the antecedent study (minimum 480 mg orally BID).
224049293|NCT01515293|PROCEDURE|Single Incision Laparoscopic Appendectomy|
224049294|NCT01515293|PROCEDURE|Conventional appendectomy|
224049295|NCT00286351|DRUG|Combined treatment with Arimidex and Zoladex before IVF|
224049296|NCT00041054|DRUG|carboplatin|
224300311|NCT03595085|DRUG|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
224300312|NCT02594085|OTHER|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
224300313|NCT02594085|OTHER|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
224300314|NCT02594085|OTHER|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
224300315|NCT02594085|OTHER|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
224300316|NCT02594085|OTHER|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
224049297|NCT00041054|DRUG|etoposide|
224049298|NCT00041054|DRUG|exisulind|
224049299|NCT04257565|DEVICE|Wheeled Knee Walker|The Wheeled Knee Walker allows total offloading of a healing limb and may diminish excessive force on the contralateral limb.
224049300|NCT04257565|OTHER|Usual and Customary Care|This group will receive usual and customary care for treatment of their diabetic foot ulcer
224049301|NCT02465385|DRUG|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
224049302|NCT00000551|BEHAVIORAL|health education|
224049303|NCT05425069|DRUG|Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P|We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
224049304|NCT02980120|OTHER|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig \& Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
224049305|NCT02980120|OTHER|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner \& Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
224049306|NCT02980120|OTHER|EDI-2|The Eating Disorder Inventory 2 (Paul \& Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
224049307|NCT02980120|OTHER|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig \& Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
224049308|NCT02980120|OTHER|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke \& Krischer, 2011).
224049309|NCT02980120|OTHER|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann \& Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
224070636|NCT00542256|DEVICE|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
224300317|NCT02594085|OTHER|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
224300318|NCT02045082|PROCEDURE|Corneal sampling|Slit lamp corneal sampling with a Swab
223438079|NCT06204120|DRUG|LPM3480392 Injection|PCA administration
224049310|NCT02980120|DEVICE|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
224049311|NCT00518388|BEHAVIORAL|Focus Group|Focus groups each lasting about 2 hours.
223438080|NCT06204120|DRUG|Placebo|PCA administration
224049312|NCT00518388|BEHAVIORAL|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
224049313|NCT04297501|DRUG|Antiretroviral Therapy|All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
224049314|NCT01212978|BEHAVIORAL|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
224049315|NCT00024401|DRUG|DHA-paclitaxel|
224049316|NCT03982342|DEVICE|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
224143540|NCT05060796|BIOLOGICAL|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
224143541|NCT01867645|DRUG|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
224143542|NCT01867645|DRUG|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
224143543|NCT00222742|PROCEDURE|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
224143544|NCT06314997|DRUG|panitumumab (EGFR inhibitors)|Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
224143545|NCT03532776|DRUG|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
224300319|NCT01460901|BIOLOGICAL|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
223438081|NCT06204120|DRUG|morphine hydrochloride injection|PCA administration
224049317|NCT03982342|OTHER|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
224049318|NCT03171727|DRUG|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
224049319|NCT02627755|DEVICE|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
224300320|NCT01857765|BEHAVIORAL|Rehabilitation|Range of motion stretching exercises
224300321|NCT01857765|BEHAVIORAL|Follow-up|Follow-up with surgeon's clinic
223438082|NCT05639504|DIAGNOSTIC_TEST|IMX-BVN-4 and IMX-SEV-4|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
223438083|NCT04260269|DRUG|Fluoropyrimidine|"This is the assessment of a specific evaluation of cardiac safety for patients with solid tumors who have experienced cardiotoxicity grade 1-4 during treatment with a fluoropyrimidine based treatment and are re-challenged with a different fluoropyrimidine.~This multicentre, retrospective database is built to assess the impact on the cardiac and global safety of two different fluoropyrimidine based treatment regimens, of which the first has caused cardiotoxicity grade 1-4.~Cardiac data will be collected by medical record review from initiation of first fluoropyrimidine-based treatment and switch to second fluoropyrimidine-based treatment until death or last follow-up. Basic demographics, cancer and treatment information from the whole course of cancer until death or last follow-up."
223438084|NCT03717168|DRUG|Recombinant human growth hormone|All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
224049320|NCT02627755|DEVICE|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
224049321|NCT01854645|DRUG|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
224049322|NCT01854645|DRUG|GP MDI|GP MDI administered as two puffs BID
224049323|NCT01854645|DRUG|FF MDI|FF MDI administered as two puffs BID
224049324|NCT01854645|DRUG|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
224049325|NCT01854645|DRUG|Placebo MDI|Inhaled placebo administered as two puffs BID
224143546|NCT03532776|DRUG|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
224143547|NCT03532776|DRUG|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
224049326|NCT03517384|BEHAVIORAL|I-CBT for Body Dysmorphic Disorder|The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
223438085|NCT03717168|OTHER|Control|All patients will not receive growth hormone.
223438086|NCT03544125|BIOLOGICAL|Durvalumab|Given IV
223438087|NCT03544125|DRUG|Olaparib|Given PO
223438088|NCT06009289|BEHAVIORAL|Light therapy|One hour of exposure to bright light, either by being outdoors or with a phototherapy lamp if indoor
223438089|NCT01914965|DRUG|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
223438090|NCT01914965|DRUG|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
223438091|NCT01389258|DEVICE|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
224049327|NCT01903291|DRUG|dimethyl fumarate|As described in the treatment arm
224049328|NCT04553510|DRUG|Bevacizumab and steroid|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.
224049329|NCT04553510|DRUG|Bevacizumab and placebo|Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential placebo 2 pills per day orally, the total course of 12 weeks.
224049330|NCT02748850|BIOLOGICAL|blood sample|a blood sample 20 milliliter
224049331|NCT02748850|BIOLOGICAL|Stem cell donation|The volume of stem cells remained in the tube is recovered
224049332|NCT02975492|DRUG|Cholecalciferol sequential dose|sequential dose administration of the treatment
224049333|NCT02975492|DRUG|Cholecalciferol daily dose|daily dose administration of the treatment
224049334|NCT01223521|DEVICE|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
224049335|NCT04253535|OTHER|questionnaries|Study on questionnaries
224049336|NCT01898897|PROCEDURE|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
224049337|NCT01898897|PROCEDURE|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
224049338|NCT01910350|BEHAVIORAL|Kin KeeperSM Cancer Prevention Intervention|
223438092|NCT02772146|DEVICE|CLS UF|One single ultrafiltration session of 10 hours.
223438093|NCT01052623|DRUG|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
223438094|NCT01916421|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
223438095|NCT00926536|DEVICE|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
223438096|NCT00926536|DEVICE|DSA only|DSA imaging only
223438097|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
223438098|NCT02830932|OTHER|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
224049339|NCT01910350|OTHER|Standard of care|
224049340|NCT04915651|DEVICE|Gallbladder Cryoablation|Percutaneous cryoablation of the gallbladder.
224049341|NCT00430482|BEHAVIORAL|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
224049342|NCT00430482|BEHAVIORAL|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
224049343|NCT06387849|OTHER|Aromatherapy|women enrolled in the experimental group received aromatherapy with lavender essential oil (EO) through dry inhalation (inhalation via a cotton support soaked in a few drops of EO)
224049344|NCT06387849|OTHER|Placebo|women enrolled in the placebo group received ihaled a cotton support soaked in a few drops of distilled water
224049345|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
224049346|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
224049347|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
224049348|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
224049349|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
224049350|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
224049351|NCT01274663|DRUG|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
224049352|NCT04416347|OTHER|SARS-CoV2 Infection|Laboratory confirmed SARS-CoV2
224049353|NCT00946504|DRUG|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
224049354|NCT00946504|DRUG|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
223438099|NCT02830932|BIOLOGICAL|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
224049355|NCT06035796|DEVICE|tNGS|By means of super-multiple PCR amplification or probe hybridization capture, tNGS can enrich dozens to hundreds of known pathogenic microorganisms and their virulence and drug resistance genes in the samples to be tested, and then conduct high-throughput sequencing.
223438100|NCT03013985|DRUG|Glargine U300|Glargine U300 is a new generation long-acting insulin.
223438101|NCT03013985|DRUG|Glargine U100|Glargine U100 is a long-acting insulin.
223438102|NCT03013985|DRUG|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
223438103|NCT02612545|DRUG|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
223438104|NCT02612545|DRUG|Mefloquine (MQ)|ACT partner drug
223438105|NCT05610579|OTHER|Remedial exercise|Remedial exercise program will be taught by qualified physiotherapist. Patients will be practiced to the exercise 3 sets of 15 repetitions without compression. Patients will be monitored telephonically in the washout period for remain the routine activities.
223438106|NCT05610579|OTHER|Compression bandage|Multi-layered short stretch bandaging will be applied for 23 hour. Patients will be practiced to the exercise 3 sets of 15 repetitions with compression bandage. The bandage will be removed at the same time the next day. Patients will be monitored telephonically in the washout period for remain the routine activities.
223438107|NCT05635500|PROCEDURE|Different Approach to endotracheal intubation.|Different insertion way.
223438108|NCT00449228|PROCEDURE|-preoperative education and total hip replacement|-preoperative education and total hip replacement
223438109|NCT06618612|OTHER|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
223438110|NCT06618612|DEVICE|PuraPly AM|PuraPly Antimicrobial Wound Matrix is a 2-layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
223438111|NCT06618612|DEVICE|PuraPly XT|PuraPly Antimicrobial XT Wound Matrix is a 5- layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
224049356|NCT04353466|PROCEDURE|quantitative chemical shift imaging (QCSI)|"Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered bone at risk"
224143548|NCT03967756|DEVICE|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
223438112|NCT04568291|OTHER|model treatment|the treatment decisions were decided by Machine Learning （ML） model in model treatment group
223438113|NCT04568291|OTHER|routine treatment|the treatment decisions were decided by multi-disciplinary team （MDT）
223438114|NCT06648187|OTHER|Early motor-cognitive integrative training (e-MCIT)|Early motor-cognitive integrative training (e-MCIT) is an approach where motor and cognitive training are conducted simultaneously. The intervention consists of 30-minute sessions, conducted 4-5 times per week, until discharging from the hospital. Both motor and cognitive training have five stages each, and their progression is independent, meaning that during training, a participant might be in the fourth stage of motor training and the second stage of cognitive training. According to hospital's policy, occupational therapy and speech therapy will be provided in schedule if needed. Motor training is derived from a previous protocol of early mobilization intervention applied to a population with SAH, which based on the ICU Mobility Scale. The activities of cognitive training target areas such as attention, orientation, language ability, memory, calculation, judgment, working memory, executive function, and daily living functions.
224049357|NCT04353466|DRUG|Elelyso|intravenous (IV) infusions of Elelyso
224049358|NCT05546294|DEVICE|Aerobic and home exercise|"A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients.Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor will be used to follow subjects' heart rate during aerobic exercise.~Then the patients were showed a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
224143549|NCT01729572|OTHER|Tele-medicine monitoring of medication adherence|
224143550|NCT00207012|DRUG|BMS-599626|
223438115|NCT05007574|DEVICE|Microphone MI-305|Remote data collection
224049359|NCT05546294|OTHER|Home exercise|"The patients were showed only a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning."
224049360|NCT05546294|OTHER|Healthy control group|Serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken only once from healthy control group in the early morning. It will be checked whether there is a difference between the basal serum BDNF and irisin levels of rheumatoid arthritis patients and healthy control group.
223438116|NCT03838237|DIAGNOSTIC_TEST|Cardiological evaluation|"Baseline evaluation~* FAbry STabilization indEX (FASTEX)~* 12 leads ECG~* Blood samples for microRNA, TnT HS and NT-proBNP dosages~* 2D echocardiogram~* Cardio-pulmonary test~* Contrast-enhanced CMR including:~  * Cine images~ * T2 mapping sequences~ * T1 mapping sequences before and 15' after contrast medium administration~ * Late Gadolinium Enhancement (LGE) imaging~ * Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated"
224143551|NCT01285063|OTHER|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
223438117|NCT06516874|BEHAVIORAL|Trauma-Focused Cognitive Behavioral Therapy for complex presentation (TF-CBT-CP)|This TF-CBT-CP is a short-term intervention to treat outpatients. This will be carried out via videoconference.
223438118|NCT06516874|OTHER|TAU|waiting list, access to pharmacological treatment, and/or non-specialized PTSD psychotherapy sessions.
223438119|NCT05541900|BEHAVIORAL|TEC-Sacredness|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a self-related word paired with a life-related stimulus, a sacredness of life-related stimulus paired with a pleasant stimulus, and a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
223438120|NCT05541900|BEHAVIORAL|TEC-Control|The participant is asked to identify and select the correct match on each trial as quickly as possible. Match pairs (i.e., a neutral stimulus paired with a neutral stimulus) are first presented to the participant. A grid is then shown containing one of the match pairs along with distraction stimuli.
223438121|NCT01080391|DRUG|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
223438122|NCT01080391|DRUG|Lenalidomide|25 mg orally on days 1-21
223438123|NCT01080391|DRUG|Carfilzomib|20 mg/m², 27 mg/m² intravenously
223438124|NCT01534208|DRUG|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
223438125|NCT06505161|OTHER|Dry needling|It consists in application of dry needling on active and/or latent TPs in low back multifidus muscles
224049361|NCT00000420|DRUG|Ortho-Novum 777|
223438126|NCT06505161|OTHER|Percutaneous electrolysis|It consists in the application of intratissue percutaneous electrolysis with galvanic current as a cathodic flow electrode in the low back multifidus muscles. The intervention will be guided by ultrasound equipment medically certified.
223438127|NCT04501783|DRUG|Favipiravir|TL-FVP-t will be administered orally
223438128|NCT04501783|DRUG|Standard of care (SOC)|SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
223438129|NCT04501783|DRUG|standard concomitant therapy|Standard of care according to MoH of Russian Federation recomendation for COVID-19
223438130|NCT04377464|OTHER|SF12, EQ-5D-5L and work status standardized quantitative assessments|Quality of life assessments
223438131|NCT01904903|DRUG|Trastuzumab|HER2 therapy
224049362|NCT04687332|OTHER|Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)|One group was treated with IA and the single use tryptophan adsorber, the other group was treated with PE and the Plasmaflow (see above). In total, all patients receive 5 treatments.
224049363|NCT05852041|PROCEDURE|Biopsy of Prostate|Undergo MRI/PET prostate biopsy
224049364|NCT05852041|GENETIC|Decipher Prostate Cancer Test|Undergo decipher
224049365|NCT05852041|OTHER|Flotufolastat F-18 Gallium|Given IV
224049366|NCT05852041|PROCEDURE|Magnetic Resonance Imaging|Undergo PET-MRI
224049367|NCT05852041|PROCEDURE|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
224049368|NCT05852041|PROCEDURE|Positron Emission Tomography|Undergo PET-MRI
224049369|NCT05852041|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
224049370|NCT01908972|DRUG|Prednisolone|2mg/kg/day for 16weeks
224049371|NCT01908972|DRUG|Propranolol|2mg/kg/day for 16weeks
224049372|NCT00493090|BEHAVIORAL|modification of an interactive seminar|
224049373|NCT04747093|BIOLOGICAL|CAR-ITNK cells|CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
223438132|NCT01904903|DRUG|Pertuzumab|HER2 therapy
223438133|NCT01904903|DRUG|Ado Trastuzumab Emtansine|HER2 therapy
224049374|NCT03057613|DRUG|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
223438134|NCT01616849|DRUG|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
223438135|NCT04164823|DEVICE|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
224049375|NCT03057613|RADIATION|IMRT 60-66Gy|60-66Gy for 6 weeks
224049376|NCT02366975|DRUG|Testosterone gel 2%|testosterone gel 2% (50mg/die).
224049377|NCT02366975|OTHER|Placebo|placebo gel
224049378|NCT02546765|DRUG|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
224049379|NCT02546765|DRUG|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
224049380|NCT02546765|DRUG|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
224049381|NCT02546765|DRUG|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
224049382|NCT01640912|DRUG|RXI-109|Single intradermal injection of RXI-109 at incision sites
224049383|NCT01640912|DRUG|Placebo|Single intradermal injection of placebo at incision sites
224049384|NCT05197413|DIETARY_SUPPLEMENT|Arrae bloat supplement|The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.
223438136|NCT04164823|DRUG|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
223438137|NCT03138200|BIOLOGICAL|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
224143552|NCT05779800|DEVICE|Flowble resin composite stent|Flowble resin composite is a filling material used in operative dentistry and characterized by being flow and easily adapting the surfaces.
224143553|NCT05779800|DEVICE|periodontal pack|Non eugenol containing dressing supplied in two tubes
223438138|NCT02453854|BEHAVIORAL|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
223438139|NCT00004809|PROCEDURE|gene therapy|
223438140|NCT04477733|DRUG|Butorphanol Injection|Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy
223438141|NCT04477733|DRUG|Saline|Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
223438142|NCT06055998|DEVICE|MRI|MRI SPINE
223438143|NCT05032456|DEVICE|Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system|The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
223438144|NCT01909726|OTHER|ScreenPlay|Interactive technology
223438145|NCT04251962|DRUG|Bupivacaine|epidural solution containing bupivacaine 0.1% in normal saline
223438146|NCT04251962|DRUG|Fentanyl|Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
223438147|NCT04192656|DEVICE|non-invasive positive airway pressure|non-invasive positive airway pressure is the first-line treatment for obstructive sleep apnea
223438148|NCT04192656|DRUG|Methylprednisolone Hemisuccinate|Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
223438149|NCT04192656|DRUG|Ginaton|ginnaton is ginkgo biloba extract
223438150|NCT04604405|RADIATION|photobiomodulation|650nm low energy red light eye irradiation
223438151|NCT05509686|DEVICE|Intermittent theta burst stimulation (iTBS)|A single-session standard 600-pulse intermittent theta burst stimulation (iTBS) is applied to the ipsilesional primary motor cortex.
223438152|NCT05509686|DEVICE|Sham intermittent theta burst stimulation (iTBS)|The sham stimulation is the same as that of iTBS, but the coil is placed five centimeters away from the scalp. Electrical field simulation shows that the setups for sham stimulation would not induce any valid cortical activation.
223438153|NCT06516185|DEVICE|direct-printed aligner|Patients will be treated with direct-printed aligners until dental alignment is achieved.
224049385|NCT02026921|DRUG|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
224049386|NCT02026921|DRUG|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
224143554|NCT02685995|DEVICE|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
223438154|NCT06516185|DEVICE|thermoformed aligner|Patients will be treated with thermoformed aligners until dental alignment is achieved.
223438155|NCT00519792|DRUG|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
223438156|NCT06228833|DEVICE|monopolar radiofrequency|Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face
223438157|NCT06228833|OTHER|SkinCeuticals A.G.E and Skinceuticals CE FERULIC|Test Side receives SkinCeuticals A.G.E and Skinceuticals CE FERULIC
223438158|NCT06228833|OTHER|Standard Cream|Control Side applies Standard Cream
223438159|NCT02247232|DRUG|Z-100|
223438160|NCT02247232|DRUG|Placebo|
223438161|NCT01260584|DRUG|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
223438162|NCT01260584|DRUG|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
223438163|NCT05360914|OTHER|Hospital at Home (HaH) treatment|The intervention is a new pathway of providing acut treatment for elderly acute ill patients in their own home. If the patient is randomized to the intervention group, the municipalities acute teams start the treatment. The acute team can take venous blood tests, ECG and bladder scan at home. The acute team handles the treatment at home and follows the patient closely. During the treatment course, the acute team and the ED specialist discuss the treatment process either over the phone or virtually on an iPad, where the patient is also involved. If the specialist would like to see the patient for assessment or send the patient for an X-ray, the specialist informs the acute team that the patient must go to a short check-up in the ED. Here, the specialist examines the patient himself and assesses whether the patient can continue to be treated at home, or whether the patient must be admitted to the hospital due to deterioration of the condition.
223438164|NCT05360914|OTHER|Standard hospital admission|The active comparator is the standard hospital admission for elderly acute ill patients.
224049387|NCT01710995|DRUG|Zegerid|
224049388|NCT01710995|DRUG|Losec|
223438165|NCT05269589|OTHER|Thermoneutral water|Participants will immerse their feet in a foot bath that contains thermoneutral water
223438166|NCT05269589|OTHER|Hot water|Participants will immerse their feet in a foot bath that contains hot water
223438167|NCT05489042|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|5 Sessions of rTMS - brief single pulse TMS or short TMS pulse bursts consisting of 2-5 pulses delivered per second at a standard intensity. If a brief single pulse TMS is applied, a standard single pulse TMS procedure will be used - This procedure consists of 10 trains of 180 seconds duration and each train will be separated by at least 30 seconds. If short TMS pulse bursts are applied, a standard theta-burst TMS procedure will be used - This procedure consists of TMS triplets (i.e., 3 pulses) that repeat for 10 trains of a total duration of 40-190 seconds and these bursts will be separated by at least 6 seconds and each train will be separated by at least 30 seconds
224300322|NCT02766426|BEHAVIORAL|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
223438168|NCT05489042|DEVICE|sham rTMS|5 sessions of sham rTMS
223438169|NCT06977269|DEVICE|High-frequency repetitive transcranial magnetic stimulation|High-frequency repetitive transcranial magnetic stimulation targeting the primary motor cortex (M1) of the limbs, delivered at a frequency above 5 Hz and an intensity of 90-100% of the resting motor threshold, across 10 sessions with up to 2400 stimuli per session, is a standard intervention used in various neurological disorders. However, its effects have not been studied in patients with spinal muscular atrophy (SMA).
223438170|NCT06977269|DIAGNOSTIC_TEST|lumbar puncture|Cerebrospinal fluid sampling to measure SMN protein and neurofilament concentrations before and after the TMS intervention.
223438171|NCT06601296|DRUG|IMSA101|"All enrolled patients to undergo the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)"
223438172|NCT06660108|GENETIC|blood draw|Multiple blood draw for genomic and transcriptomic investigations
223438173|NCT05972941|BEHAVIORAL|Health communications|Participants will view eight culturally targeted or non-targeted health communications about the health risks of nicotine and tobacco use.
223438174|NCT05636787|DRUG|Treosulfan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
223438175|NCT05636787|DRUG|Melphalan|Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
223438176|NCT00787098|OTHER|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
223438177|NCT02784522|DEVICE|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
224049389|NCT02380950|BEHAVIORAL|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
223438178|NCT02784522|DEVICE|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
223438179|NCT06648005|PROCEDURE|the spinal manipulative therapy combined brace|Besides bracing, the SMTB group was treated with spinal manipulative therapy. If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination.
223438180|NCT06648005|OTHER|brace|Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
223438181|NCT03295552|DRUG|Decitabine|decitabine 7mg/m2, d1-d5, q3w
223438182|NCT03295552|DRUG|Carboplatin|carboplatin AUC = 6, d6, q3w
223438183|NCT02624388|DRUG|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
223438184|NCT02624388|DRUG|Placebo|Pill that contains no medicine
223438185|NCT00618241|DRUG|lamotrigine|100 mg
223438186|NCT00618241|DRUG|Raltegravir|400 mg BD
223438187|NCT04101032|BEHAVIORAL|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
223438188|NCT06475885|OTHER|Infant Massage Program|The experimental group received the International Association of Infant Massage (IAIM) Infant Massage Program starting from day 14 postpartum for a duration of 5 weeks.
224049390|NCT02763228|BEHAVIORAL|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
224049391|NCT02763228|BEHAVIORAL|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
224049392|NCT02763228|BEHAVIORAL|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
224049393|NCT02763228|BEHAVIORAL|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
224049394|NCT02763228|BEHAVIORAL|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
224049395|NCT02763228|BEHAVIORAL|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
224049396|NCT02763228|BEHAVIORAL|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
224143555|NCT02685995|DEVICE|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
223438189|NCT00586508|DRUG|enzastaurin|1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
223438190|NCT00586508|DRUG|bevacizumab|10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
223438191|NCT00586508|DRUG|Enzyme-inducing antiepileptic drugs (EIAED)|Administered orally
223438192|NCT00586508|DRUG|Non-enzyme inducing antiepileptic drugs (NEIAED)|Administered orally
223438193|NCT04977414|BEHAVIORAL|Making Data Count Training intervention|The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
224143556|NCT03823040|DRUG|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
223438194|NCT04679636|BEHAVIORAL|heart rate variability biofeedback|receive biofeedback training for heart rate variability for eight weeks
223438195|NCT05753891|DEVICE|Suture Tape Reconstruction|This intervention will utilize a suture tape to suspend the 1st and 2nd metacarpal post trapeziectomy compared to the standard procedure of a trapeziectomy followed by ligament reconstruction and tendon interposition.
223438196|NCT02928146|PROCEDURE|Hernia Repair|
223438197|NCT05700812|PROCEDURE|Sound sparing levonorgestrel 52 mg IUD placement|"In phase one, the IUD will be placed in a standard fashion with the use of a uterine sound to obtain baseline data.~In the experimental phases of the study (phase 2 and 3) the levonorgestrel 52 mg IUD will be placed without the use of a uterine sound. In phase 2 the IUD will be placed under abdominal ultrasound guidance. In phase 3 the IUD will be placed without abdominal ultrasound guidance."
223438198|NCT04316039|DRUG|Temozolomide|Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
223438199|NCT04316039|RADIATION|intensity modulated radiation therapy|The radiation dose is 50-54 Gy given in 25-30 fractions (1.8-2.0 Gy once daily, 5 days per week).
223740765|NCT04669392|DRUG|70% Ethanol Alcohol|"Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time."
224049397|NCT05327621|DRUG|Pamiparib|40 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
224049398|NCT02698748|DRUG|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
224049399|NCT02698748|DRUG|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
224049400|NCT00475722|BEHAVIORAL|1 Healthy Eating|6 months telephone counseling
224049401|NCT00475722|BEHAVIORAL|2 Mediterranean|6 months telephone counseling
224049402|NCT03182985|BEHAVIORAL|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
224049403|NCT03687073|DRUG|Indole-3-Carbinol|Cohorts 2, 3, \& 4: 400 mg PO BID
224049404|NCT03687073|DRUG|Silibinin|Cohorts 1 \& 4: 720mg
224049405|NCT03687073|DRUG|Silibin|Cohort 3: 360mg
224049406|NCT04291248|DRUG|AK105|AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
224049407|NCT04291248|DRUG|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
224049408|NCT03001960|DRUG|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
224049409|NCT03001960|DRUG|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
224049410|NCT06039462|BEHAVIORAL|Application of a virtual reality headset|Use of a headset to experience a different reality
223438200|NCT02387528|BEHAVIORAL|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
223438201|NCT02387528|BEHAVIORAL|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
224049411|NCT05201027|DEVICE|trifocal intraocular lens|cataract extraction and implantation of a posterior chamber trifocal intraocular lens
224143557|NCT03823040|DRUG|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
224143558|NCT03625141|DRUG|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1-21 of each 28-day cycle.
223438202|NCT02387528|OTHER|3- Wait List Control Group|No intervention
223438203|NCT03058224|DRUG|IGN-ES001|Only active product will be compared with placebo as described in Arms and Interventions.
223438204|NCT03058224|DRUG|Parol 500 mg Tablets (acetaminophen)|Analgesic Rescue Medication
223438205|NCT06252701|BEHAVIORAL|Reduction of Ultra-processed foods|Reduction of Ultra-processed foods for four weeks.
223438206|NCT02169206|RADIATION|Bilateral shoulder anteroposterior radiography|"1. Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~2. In the same position, the patient only elevates the arm up to 90 degrees of abduction."
223438207|NCT00945204|OTHER|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
223438208|NCT00561470|DRUG|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
223438209|NCT00561470|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
223438210|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
223438211|NCT00561470|DRUG|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours"
223740766|NCT04954612|OTHER|Questionnaire study (Cross-sectional analytical clinical research)|Questionnaire study (Cross-sectional analytical clinical research)
224300323|NCT01322126|DEVICE|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
224049412|NCT00086970|DRUG|ifosfamide|Given IV
224049413|NCT00086970|DRUG|O6-benzylguanine|Given IV
224049414|NCT03128970|OTHER|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
224049415|NCT02495220|DRUG|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
224049416|NCT02495220|DRUG|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
224049417|NCT01377064|BEHAVIORAL|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
224049418|NCT01377064|OTHER|Standard Care Group|No intervention, the group will be followed under their standard medical care.
224049419|NCT06346184|DRUG|HCP2303|Take 1 tablet once per period
224049420|NCT06346184|DRUG|RLD2302|Take 1 tablet once per period
224049421|NCT06346184|DRUG|RLD2102|Take 1 tablet once per period
224143559|NCT03625141|DRUG|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
224143560|NCT03625141|DRUG|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
224300324|NCT04775186|PROCEDURE|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)|Laparoscopic Burch colposuspension and Mid-urethral slings (TVT and TOT)
223438212|NCT04650906|BEHAVIORAL|Mindhelper - a national youth mental health promotion website|Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
223438213|NCT00426777|DRUG|risedronate|risedronate 35mg tablet, weekly for 12 months
223438214|NCT00426777|DRUG|risedronate|35mg weekly
223438215|NCT00426777|DRUG|Control|risedronate-matched placebo weekly
223438216|NCT04089345|DRUG|Ustekinumab|All patients will receive intravenously (IV) ustekinumab \~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
223438217|NCT01044953|OTHER|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
223438218|NCT06244498|DRUG|Tranexamic acid injection|Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.
223438219|NCT03434249|DIETARY_SUPPLEMENT|Bifidobacterium, BB-12® (Bifidolactis Infant)|
223438220|NCT03434249|DIETARY_SUPPLEMENT|Bifidolactis Infant Placebo|
223438221|NCT00825526|BEHAVIORAL|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
223438222|NCT02918552|DRUG|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
223438223|NCT02918552|DRUG|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
223438224|NCT03256292|DRUG|Testosterone replacement|Testosterone replacement therapy
223438225|NCT03256292|BEHAVIORAL|lifestyle|lifestyle intervention consisting of diet and increased physical activity
224049422|NCT04765475|BEHAVIORAL|Motivational Interviewing|A culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years).
224049423|NCT04765475|BEHAVIORAL|COVID-19 Symptom Monitoring System|A daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts.
224049424|NCT04765475|BEHAVIORAL|Motivational Interviewing and COVID-19 Symptom Monitoring System|A combination of: 1) a culturally-tailored brief motivational interviewing (MI) intervention to promote preventive behaviors and COVID-19 testing when experiencing symptoms, and isolation and care-seeking when positive among two important high-risk groups in American Indian and Alaska Native communities-ages 18-34 and elders (ages ≥65 years); 2) a daily COVID-19 symptoms (CS) monitoring system with alerts, ways for participants to request home testing after first symptoms, and Geographic Information System (GIS) routing for those responding to alerts
224049425|NCT04765475|OTHER|Supportive Services|Provision of supportive services such as referrals to needed medical, mental or behavioral health care and delivery of a hygiene kit containing basic hygiene supplies. Participants will also be provided information on COVID-19 and nearby testing locations and basic information about COVID-19, mask wearing, how to prevent the spread in the home and managing stress during COVID-19.
224049426|NCT02762279|OTHER|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
224049427|NCT05799599|BEHAVIORAL|Stay-Play-Talk Basic|Stay-Play-Talk (SPT) Basic and SGD with augmented peer input in which peers are taught to model verbal responses while simultaneously selecting screen icons with spoken peer input only (i.e., peers taught to model language)
224143561|NCT04429152|DRUG|Doravirine/Lamivudine/Tenofovir|DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination
224143562|NCT04560673|DRUG|Duloxetine|Given PO
224143563|NCT04560673|BEHAVIORAL|Neurofeedback|Receive neurofeedback training
224143564|NCT04560673|OTHER|Quality-of-Life Assessment|Ancillary studies
223438226|NCT03705000|DEVICE|Slit Stent II|The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.
223438227|NCT03705000|DEVICE|BIKA for DCR|The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
223438228|NCT04003545|RADIATION|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
224143565|NCT04560673|OTHER|Questionnaire Administration|Ancillary studies
224143566|NCT05069285|OTHER|self-help book|information and advice given in the self-help book
224143567|NCT05069285|OTHER|sleep hygiene advice|information and advice given on the sheet of paper with sleep hygiene
224143568|NCT05093998|DRUG|AV5080|oral hard gelatin capsules
223438229|NCT04003545|OTHER|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
223438230|NCT03652116|DRUG|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
223438231|NCT03652116|DRUG|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
223438232|NCT06448858|DIAGNOSTIC_TEST|serum Mn, Se, iron, Cu & Zn levels|Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.
223438233|NCT05359770|DEVICE|Active HD-tDCS|Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.
223438234|NCT05359770|DEVICE|Control group|Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
223438235|NCT03325894|DRUG|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
223438236|NCT02315872|DRUG|ACTH|ACTH injections twice weekly for 28 weeks.
223438237|NCT02315872|DRUG|Placebo|Placebo injections twice weekly for 28 weeks.
223438238|NCT01920867|PROCEDURE|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
223438239|NCT01920867|PROCEDURE|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
223438240|NCT01920867|PROCEDURE|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
223438241|NCT01920867|PROCEDURE|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
223438242|NCT01920867|PROCEDURE|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
223438243|NCT05961345|OTHER|late mobilization|Early mobilization of patients after surgery is supported. The relationship between early mobilization and pain level was examined. The experimental group is 80 people.
223438244|NCT02690519|DRUG|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
223438245|NCT02690519|DRUG|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
223438246|NCT02643797|BEHAVIORAL|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
223438247|NCT06260046|DRUG|Sufentanil|Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml
223438248|NCT06260046|DRUG|Remifentanil|Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml
223438249|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
223438250|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
223438251|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
223438252|NCT00814944|DRUG|Sirolimus|Subconjunctival injection of placebo in each eye.
223438253|NCT01001598|DRUG|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
223438254|NCT01319851|DRUG|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
223438255|NCT04836364|OTHER|No Intervention|There is no intervention; observation only.
223438256|NCT04746729|OTHER|No intervention|No intervention
223438257|NCT06350604|BEHAVIORAL|Project WHADE: A Partner-Based Physical Activity Program for Women|Combination of behavioral, cognitive, social, and acceptance-based skills training to increase physical activity
223438258|NCT00005876|DRUG|rubitecan|
223438259|NCT05496283|OTHER|denture adhesive|After 1 month of using the complete denture with no denture adhesives, patients fill up satisfaction and quality of life forms and given 1 of 3 types of denture adhesive to use for month to compare satisfaction and quality of life forms
223438260|NCT05706038|DRUG|Adalimumab|"Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.\[4\] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential."
223438261|NCT03796338|DEVICE|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
223438262|NCT06084390|OTHER|Interdisciplinary care + booster session (intervention)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden + one extra booster-session 3 months after the standard care rehabilitation. At the booster-session, the participant´s individual rehabilitation plan is followed-up and adjusted. This extra period also includes extended access to the team, meaning that the participants have the possibility to contact the team and, if needed, have digital or telephone contact.
223438263|NCT06084390|OTHER|Interdisciplinary care (control)|Standard care for interdisciplinary rehabilitation at any of the six interdisciplinary teams in primary health care in Region Västra Götaland, Sweden.
223438264|NCT05519046|DEVICE|Cardiac Contractility Modulation (CCM)|Cardiac Contractility Modulation (CCM) implantation
223438265|NCT05519046|DEVICE|CRT|Cardiac Resynchronization Therapy
224143569|NCT05093998|OTHER|Placebo|Hard gelatin capsules with a white body
224143570|NCT02375269|DEVICE|RIPC with a tourniquet|
224300325|NCT05263622|OTHER|Split-mouth administration for group B|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q1 and Q3) and with Mectron handpiece (quadrants Q2 and Q4)~* Calculus removal with EMS ultrasound handpiece (Q1 and Q3) and with Mectron handpiece (Q2 and Q4)"
223438266|NCT02519634|PROCEDURE|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
223438267|NCT02519634|PROCEDURE|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
223438268|NCT03720145|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
223438269|NCT01046851|DRUG|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
224049428|NCT05799599|BEHAVIORAL|Stay-Play-Talk Plus|SPT Plus with augmented SGD peer input (i.e., peers taught to use verbal language models concurrently while selecting SGD icons).
224049429|NCT05799599|BEHAVIORAL|Stay-Play-Talk Advanced|SPT Advanced adds direct instruction strategies for the children with ASD (i.e., adult prompts, reinforcers, and embedded teaching trials) to increase peer-directed communication.
224049430|NCT01298583|BEHAVIORAL|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
224049431|NCT04095728|DIETARY_SUPPLEMENT|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
224049432|NCT04095728|OTHER|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
224049433|NCT02580851|OTHER|diagnostic test - cardiac magnetic resonance imaging|
224049434|NCT02580851|OTHER|diagnostic test - coronary angiography|
224049435|NCT02453373|DEVICE|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
224049436|NCT02453373|DRUG|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
224049437|NCT02453373|DRUG|tPA|tPA will be administered intravenously if indicated
224049438|NCT02453373|DRUG|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
223438270|NCT01046851|DRUG|Placebo|Placebo in a manner similar to the active comparator
223438271|NCT01343667|DEVICE|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
223438272|NCT01343667|DEVICE|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
223438273|NCT02852668|OTHER|Power Training|This experimental groups underwent an intervention period of power training
223438274|NCT02852668|OTHER|Strength Training|This experimental groups underwent an intervention period of strength training
223438275|NCT01352247|PROCEDURE|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
223438276|NCT01352247|PROCEDURE|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
223438277|NCT04445844|BIOLOGICAL|Pelareorep|Given IV
223438278|NCT04445844|OTHER|Quality-of-Life Assessment|Ancillary studies
223438279|NCT04445844|OTHER|Questionnaire Administration|Ancillary studies
223438280|NCT04445844|BIOLOGICAL|Retifanlimab|Given IV
224049439|NCT02453373|DRUG|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
224049440|NCT02453373|PROCEDURE|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
224049441|NCT01021787|DRUG|Titanium dioxide|Topical cream
224049442|NCT00916279|DEVICE|Lutonix Paclitaxel-Coated Balloon|PTCA
224049443|NCT02064920|DRUG|Placebo|Placebo for donepezil hydrochloride capsule
223438281|NCT04817566|DEVICE|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (2 mA).
223438282|NCT04817566|DEVICE|Sham tDCS|Sham transcranial direct current stimulation (tDCS), 9 sessions with 30 sec stimulation each (2 mA) to ensure blinding of participants.
223438283|NCT04817566|BEHAVIORAL|Intensive cognitive training|Intensive cognitive training of a letter memory updating task, 9 sessions for approximately 20 min
223438284|NCT03899532|DEVICE|Remote Ischemic Conditioning|Standard manual blood pressure cuff
223438285|NCT03899532|OTHER|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
223438286|NCT05498792|DRUG|CBL0137|Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
223438287|NCT05498792|DRUG|Ipilimumab|Patient will be on Ipilimumab (1 mg/kg)
223438288|NCT05498792|DRUG|Nivolumab|Patient will be on Nivolumab (3 mg/kg)
223438289|NCT04492072|DRUG|Oxytocin|Intervention
223438290|NCT04492072|DRUG|Misoprostol|Control
223438291|NCT05621005|DRUG|Rifaximin 550 milligram Oral Tablet [XIFAXAN]|Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months
223438292|NCT04407416|PROCEDURE|Breath sampling|The breath of all subjects included will be sampled using a device able to capture the alveolar air and to fix it on carbon tubes, Then the tubes will be desorbed and analysed using gas chromatography
224049444|NCT02064920|DRUG|Donepezil|5 mg donepezil hydrochloride capsule.
224049445|NCT02064920|DRUG|Donepezil|10 mg donepezil hydrochloride capsule.
224049446|NCT00865397|DRUG|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
224049447|NCT02441465|DRUG|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
224049448|NCT02441465|DRUG|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters \[mL\], which corresponds to a dose of 20 micrograms \[mcg\] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
224049449|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
224049450|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
223438293|NCT02521558|BEHAVIORAL|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
223438294|NCT02521558|BEHAVIORAL|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
223438295|NCT04546321|OTHER|serum L carnitine level measuring|The serum level of total L carnitine was measured for both HIE and TTN cases
223438296|NCT05433909|DIAGNOSTIC_TEST|Blood, fecal, vaginal and endometrial liquid samples|"During the surgical pre-hospitalization, eligible patients who accept participation in the study will undergo a blood sample and collection of stool samples.~Before surgery, after anesthesia, they will undergo a vaginal swab and endometrial fluid sampling."
224049451|NCT00310804|BIOLOGICAL|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
223438297|NCT03451916|DRUG|PLX-PAD|PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
223438298|NCT03451916|DRUG|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
223438299|NCT03978013|OTHER|Pomegranate juice|Pomegranate juice
223438300|NCT03978013|OTHER|Apple juice|Apple juice
223438301|NCT03788980|PROCEDURE|Carotid endarterectomy|Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)
224049452|NCT00310804|BIOLOGICAL|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
224049453|NCT02109562|DRUG|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
224049454|NCT02109562|DRUG|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
224049455|NCT02109562|DRUG|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
224049456|NCT03877536|DRUG|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Participants will receive 1 tablet per day throughout study duration (96 weeks).
224049457|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
224049458|NCT02453490|DRUG|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
224049459|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
224049460|NCT02453490|DRUG|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d\*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
224049461|NCT04700384|BEHAVIORAL|Virtual Operative Assistant Training|Individuals receive the same basic information, have the same amount of time and perform the same scenarios as the control group. In the 5-minutes between attempts, participant receive the Virtual Operative Assistant assessment of their performance and audiovisual feedback.
224049462|NCT04700384|BEHAVIORAL|Remote-Based Expert Instructor Training|Individuals receive the same information, have the same amount of time and perform the same scenarios as the control group. Meanwhile, a trained instructor observes the participant's on-screen performance, that is live-streamed, remotely. Instructors are senior neurosurgery residents with extensive experience in performing and assessing this scenario. During the 5-minute feedback session, they chat with the student, discussing the performance and help in setting goals for the next trial.
224049463|NCT03598647|BEHAVIORAL|Affect and physical activity|The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.
223438302|NCT03788980|DIAGNOSTIC_TEST|Mini Mental Status Examination|Short questionnaire used to diagnose cognitive dysfunction
223438303|NCT00169728|BIOLOGICAL|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
223438304|NCT00169728|BIOLOGICAL|heptavalent pneumococcal conjugate vaccine, Prevenar|
223438305|NCT03817034|DRUG|Multimodal analgesia|Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
223438306|NCT05564026|OTHER|Questionnaire Administration|Questionnaire provide to participant's about their health and quality of life since treatment
224143571|NCT04331990|OTHER|Standard Physcial Therapy|Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle strengthening and stretching, and neuromuscular control exercises. Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
224143572|NCT04331990|OTHER|Intermittent Mechanical Traction|In addition to the standard treatment, patients in this group will receive intermittent knee joint decompression for 20 minutes. Patients will be lying supine with the knee semiflexed to 30° and supported by a wedge under the knee. A customized leg cuff will be placed around the lower leg and two ropes will be extending horizontally from the cuff to the vertical traction weight using a pulley system to transfer the traction force to the tibiofemoral articulation. The magnitude of the traction force will be between 10-15% of the patient's body weight. The traction force will be applied for 10 application cycles; each cycle comprised of 2 minutes traction followed by 30 seconds relief. This will sum up to 20 minutes of actual joint traction duration. The traction force application and relief time will be controlled manually by the treating therapist. Knee joint traction procedures will be applied at the end of the physical therapy session.
224143573|NCT04331990|OTHER|Continuous Mechanical Traction|Patients assigned to this group will receive the same treatment protocol as those in the Intermittent Mechanical Traction group. However, the knee traction force will be applied continuously for 20 minutes without intermittent force relief periods.
224143574|NCT03819218|DRUG|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
224143575|NCT00433446|BIOLOGICAL|CNTO 328|
224300326|NCT05263622|OTHER|Split-mouth administration for group A|"* Plaque disclosing agent application and instructions to patients for a correct oral hygiene;~* Airflow deplaquing with EMS handpiece (quadrants Q2 and Q4) and with Mectron handpiece (quadrants Q1 and Q3)~* Calculus removal with EMS ultrasound handpiece (Q2 and Q4) and with Mectron handpiece (Q1 and Q3)"
223438307|NCT05564026|OTHER|Tumor Specimen Collection|Tumor DNA requested from the Biopathology Center
224049464|NCT03598647|BEHAVIORAL|Physical activity information|Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
223438308|NCT05564026|OTHER|Germline DNA Samples|Germline DNA specimens requested from the Biopathology Center or newly collected saliva
224049465|NCT02198443|DRUG|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
223438309|NCT05564026|PROCEDURE|Blood Sample Collection|Collection and storing of serum/plasma
223438310|NCT01915654|PROCEDURE|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
223438311|NCT05420857|OTHER|Overground Visual Biofeeback|Subjects participate in biofeedback training for 3 6-minute bouts in a single session.
223438312|NCT03482570|DEVICE|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
223438313|NCT00100841|BIOLOGICAL|cetuximab|Given IV
224049466|NCT02198443|DRUG|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
224049467|NCT00688155|BEHAVIORAL|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
224049468|NCT00688155|BEHAVIORAL|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
224049469|NCT00688155|BEHAVIORAL|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
224143576|NCT05996380|DRUG|SHR-3167|SHR-3167, Single administration
224143577|NCT05996380|DRUG|SHR-3167 Placebo|SHR-3167 Placebo Single administration
224143578|NCT05100433|PROCEDURE|Ultrasonic irrigation|Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
224143579|NCT03396978|OTHER|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
224300327|NCT02566993|DRUG|Lurbinectedin (PM01183)|
223438314|NCT00100841|BIOLOGICAL|bevacizumab|Given IV
223438315|NCT00100841|DRUG|oxaliplatin|Given IV
223438316|NCT00100841|DRUG|leucovorin calcium|Given IV
224049470|NCT05744336|OTHER|Group 1 Immersive Virtual Reality (VR)|Participants in Group 1 Immersive Virtual Reality (VR) participants wear the device covering their eyes. The viewing experience will include calming nature sounds for between 15-20 minutes before their planned plain clinic procedure
224143580|NCT01823770|DRUG|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
224143581|NCT01823770|DRUG|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
224143582|NCT01188538|DRUG|Epiduo gel|Once daily application on the face in the evening for 12 weeks
224300328|NCT02566993|DRUG|Doxorubicin (DOX)|
224300329|NCT02566993|DRUG|Cyclophosphamide (CTX)|
224300330|NCT02566993|DRUG|Vincristine (VCR)|
224300331|NCT02566993|DRUG|Topotecan|
223438317|NCT00100841|DRUG|fluorouracil|Given IV
223438318|NCT02920177|DRUG|platelet-rich plasma injection|platelet-rich plasma injection
223438319|NCT02920177|DRUG|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
224049471|NCT05744336|OTHER|Group 2 Control Group|Group 2 control group participants have no preprocedural intervention. Standard clinic waiting conditions for 15-20 minutes before their planned pain clinic procedure.
224049472|NCT04310085|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h
224049473|NCT04310085|BIOLOGICAL|PfSPZ-DVI Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
224049474|NCT06456528|DRUG|QL0911|QL0911
224049475|NCT06456528|DRUG|QL0911 plus Placebo|QL0911 plus Placebo
224143583|NCT01188538|DRUG|BPO|Once daily application on the face in the evening for 12 weeks
224143584|NCT05460650|BEHAVIORAL|App Promoting Healthy Behaviours|Women on the study will receive two months access to the app.
223438320|NCT00936130|PROCEDURE|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
223438321|NCT00936130|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
223438322|NCT00936130|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
224049476|NCT06456528|DRUG|Placebo|Placebo
224049477|NCT03543111|BEHAVIORAL|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
224143585|NCT04320277|DRUG|Baricitinib|Baricitinib 4 mg/day/orally combined to antiviral therapy ritonavir for 2 weeks. Baricitinib tablets 4 mg were administered in the morning.
223438323|NCT00936130|BEHAVIORAL|Low Calorie Diet|Low Calorie Diet Program
223438324|NCT02054910|PROCEDURE|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
223438325|NCT02054910|PROCEDURE|Sham|Patients will not receive celiac plexus block during endoscopy.
223438326|NCT05470816|DRUG|Tranexamic Acid 100Mg/ml Inj Vial 10ml|Intervention is from the Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial. A multicentre, pragmatic, double-blind, randomised clinical trial will compare the incidence of surgical site infection and red cell transfusion requirements after IV tranexamic acid and placebo in patients undergoing gastrointestinal surgery
223438327|NCT05470816|DRUG|Placebo|Normal saline
223438328|NCT06912542|OTHER|Whole flaxseed bread|French bread with the addition of 30g of whole flaxseed.
223438329|NCT06912542|OTHER|Ground flaxseed bread|French bread with the addition of 30g of ground flaxseed.
223438330|NCT06912542|OTHER|French bread|Plain French bread (control).
223438331|NCT05638802|DRUG|DS-7011a|20 mg/kg intravenous dose to be administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
223438332|NCT05638802|DRUG|Placebo|Saline intravenous solution administered every 4 weeks at baseline (Day 1), Day 29, and Day 57
223438333|NCT07024888|DRUG|SSS17|Single oral administration of SSS17
223438334|NCT00181129|BEHAVIORAL|home based self paced walking program|
223438335|NCT01131065|DRUG|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
224049478|NCT02366559|DEVICE|Hyfrecator|
224049479|NCT02366559|DEVICE|532 nm Q-switched Nd:YAG laser|
224049480|NCT03044782|OTHER|53-Item Survey|
224049481|NCT03631030|DEVICE|Cooled radiofrequency ablation|Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
224143586|NCT00370877|DRUG|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
224143587|NCT00370877|PROCEDURE|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
224143588|NCT02846805|PROCEDURE|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
223438336|NCT04489875|BEHAVIORAL|Chewing Gum|The intervention would be chewing gum. The patients in the intervention arm would be asked to chew gum for 15 minutes before meals thrice a day.
224049482|NCT04334707|PROCEDURE|Kidney Biopsy|A kidney biopsy is a procedure that involves taking a small piece of kidney tissue for examination with a microscope. A licensed health care provider will perform a kidney biopsy.
224049483|NCT01248286|OTHER|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
224049484|NCT01248286|OTHER|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
224049485|NCT02484833|DRUG|Cetuximab|
224143589|NCT01917708|DRUG|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
224143590|NCT03553550|OTHER|biospecimen collection|Peripheral blood collection Archival tissue collection
224143591|NCT04943666|OTHER|Hemorrhoid Disease Questionnaire|a new patient specific questionnaire (HDQ) with appropriate sensitivity and specificity to use for screening of patients with haemorrhoids in Russia in clinical practice for wider screening of haemorrhoids in population and for increasing patients' awareness of the disease and prompting them to seek professional advice.
223438337|NCT03229629|BEHAVIORAL|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
223438338|NCT03229629|OTHER|Food Voucher (Monetary)|Monthly voucher worth 200 birr(\~$10) every month for the duration of 6 month
223438339|NCT05237804|OTHER|Patient component|Video, booklet, website
223438340|NCT05237804|OTHER|Organisational component|Coronarography, CT-scan, anesthesia...
223438341|NCT01587417|DRUG|Placebo to BI 187004 CL|1 single dose per subject as oral solution
223438342|NCT01587417|DRUG|BI 187004 CL|1 single dose per subject as oral solution
223438343|NCT01902212|OTHER|Oral Nutritional Supplement|
223438344|NCT03679169|PROCEDURE|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
224049486|NCT02484833|DRUG|FOLFIRI|
224049487|NCT04549870|DRUG|Roflumilast|Treatment according to national roflumilast guidelines
224049488|NCT05520099|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
224049489|NCT05149222|DEVICE|Digital ACT|This is a virtual, single-arm, non-significant risk study. Study participants will receive 9 months of Digital Acceptance and Commitment Therapy (ACT) in addition to their standard care for fibromyalgia.
224049490|NCT00068575|BIOLOGICAL|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
224300332|NCT04488835|OTHER|Electromagnetic field therapy and transcutaneous electrical nerve stimulation|Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
224300333|NCT01834430|DIETARY_SUPPLEMENT|enteral nutrition|
223438345|NCT06711146|DRUG|Metabolically Armed CD19 CAR-T cells|Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion
223438346|NCT02143830|DRUG|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
223438347|NCT02143830|DRUG|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
223438348|NCT02143830|DRUG|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
223438349|NCT02143830|DRUG|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
223438350|NCT02143830|DRUG|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
223438351|NCT02143830|BIOLOGICAL|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
223438352|NCT06886269|DRUG|14C-VX-993|Solution for Oral Administration.
223438353|NCT04963959|DEVICE|Peripheral blood mononuclear cell apheresis|mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
223438354|NCT02634372|BEHAVIORAL|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
223438355|NCT02634372|BEHAVIORAL|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
223438356|NCT00426140|DRUG|Patupilone|
223740767|NCT06192186|DRUG|Adebrelimab combined with SOX regimen|Adebrelimab combined with SOX regimen preoperatively used 3 cycles(stop adebrelimab and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
223740768|NCT06192186|DRUG|Placebo combined with SOX (S-1/oxaliplatin) regimen|Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles (stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging) → radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
224049491|NCT00068575|DRUG|Cisplatin|30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
224049492|NCT00068575|DRUG|Fluorouracil|175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
224049493|NCT00068575|RADIATION|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
224049494|NCT01043341|BEHAVIORAL|educative folder|folder about HPV infection and vaccines
224049495|NCT01241799|PROCEDURE|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
224049496|NCT01241799|PROCEDURE|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
224049497|NCT05132374|OTHER|I-T CHILD|This study will evaluate the I-T CHILD's application in early childhood mental health consultation services provided to family/group family child care programs
224049498|NCT01889238|DRUG|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
223740769|NCT01735643|DEVICE|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
223740770|NCT01735643|OTHER|waiting|waiting for 12 weeks
223438357|NCT06888778|OTHER|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a non-invasive brain stimulation technique that stimulates specific brain areas through repeated magnetic pulses to treat depression, anxiety and other mental illnesses, and to study brain function.
223438358|NCT06888778|OTHER|Non-stimulation|participants receive Non-stimulation:The side of the double cone coil is placed against the scalp, and the target of the coil is stimulated in the direction of air.
223438359|NCT01428687|BEHAVIORAL|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
223438360|NCT01428687|BEHAVIORAL|No change in sleep|This group is taught to maintain their current sleep habits.
223438361|NCT05496608|PROCEDURE|L-PRF|a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.
223438362|NCT05496608|PROCEDURE|OFD|Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
223438363|NCT05496608|PROCEDURE|CM|Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
223438364|NCT00671827|BEHAVIORAL|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
223438365|NCT06448195|DRUG|Polyethylene Glycol Somatropin (rDNA origin) Injection|Specification: 54IU/9.0mg/1.0ml/ bottle Dosage form: injection; Dose: 1mg/ week. Subcutaneous injection (upper arm, thigh or abdomen periumbilical) for a total course of 6 months, a total of 3 bottles per patient
223438366|NCT06738849|DEVICE|EkiYou V2|"Use of a Digital Therapy in the form of a mobile application that helps users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.~The device includes the following features to participants:~* Carbohydrate counting through an extensive food database with more than 200k items.~* Bolus calculation based on their meal, physical activity and blood glucose.~* Bolus correction advice.~* Long-acting insulin reminders and automatic periodic titration.~* Insulin-to-carb ratios and correction factor automatic adjustment."
223438367|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement|Ready-to-drink protein beverage consumed once daily for 28 days
223438368|NCT05814705|DIETARY_SUPPLEMENT|Protein supplement with Urolithin A|Ready-to-drink protein beverage with 1000 mg of Urolithin A consumed once daily for 28 days
223438369|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
223438370|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
223438371|NCT01096589|DEVICE|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
223438372|NCT01096589|DEVICE|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
223438373|NCT05850897|OTHER|Masaj|Appropriate position is given to the patients. Thumb and finger movements, patting, rubbing and squeezing techniques are used in foot massage. During training, the active hand applies pressure, while the passive hand uses both hands to support the foot. The intervention begins with rubbing and warming the feet. The duration of the foot warming process is approximately 5 minutes, and after the foot warming maneuvers, the methods of moving the thumbs of both hands towards the soles of the feet and spinning the laundry are used. The inner and outer parts of the foot are patted in a balanced way. This caressing movement on both feet is done with these movements in a light and rhythmic way and the massage is completed. Data will be obtained with Patient Descriptive Information Form, Vital Signs Follow-up Form, Surgical Anxiety Scale for Adult Patients, Perianesthesia Comfort Scale, Numerical Pain Scale.
223438374|NCT06781827|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).
223438375|NCT06781827|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
224049499|NCT00745693|DRUG|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
224049500|NCT00745693|DRUG|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
224049501|NCT04136184|DRUG|Inotersen|Inotersen by subcutaneous injection
223438376|NCT04513444|OTHER|Relaxation with music listening and medical hypnosis during radiotherapy treatment:|"* Music listening (According to the patient's wishes),~* Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session,~* Self-hypnosis during the 4th and 5th radiotherapy session,~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
223438377|NCT04513444|OTHER|Relaxation with music listening during radiotherapy treatment:|"* Music listening (According to the patient's wishes),~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations."
223438378|NCT03439215|DRUG|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
224049502|NCT04136184|DRUG|Eplontersen|Eplontersen by subcutaneous injection
224049503|NCT05112627|PROCEDURE|Biospecimen Collection|Undergo blood collection
224049504|NCT05432882|BIOLOGICAL|bi-4SCAR CD19/22 T cells|Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
224049505|NCT00052351|BIOLOGICAL|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
224049506|NCT00052351|BIOLOGICAL|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
224049507|NCT00052351|BIOLOGICAL|sargramostim|
224049508|NCT00052351|DRUG|cyclophosphamide|
224049509|NCT00052351|DRUG|doxorubicin hydrochloride|
224049510|NCT00052351|DRUG|paclitaxel|
224049511|NCT00052351|RADIATION|radiation therapy|
224049512|NCT06073990|BEHAVIORAL|Brief Behavioral Treatment for Insomnia (BBTi)|The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
224049513|NCT01316094|DRUG|ASP1941|oral
224049514|NCT01316094|DRUG|placebo|oral
224049515|NCT05017753|PROCEDURE|Thoracentesis|Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.
223438379|NCT04245215|DRUG|Ustekinumab|re-induction and dose escalation form every 8 weeks to every 4 weeks only in arm 2
224049516|NCT05017753|DRUG|Standard-of-care medical treatment|Standard-of-care medical treatment
224143592|NCT05506917|PROCEDURE|periodontal treatment|Patients will receive an intensive (non surgical) regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrational to treat will be extracted at the oral hygiene visit. After the 2 months re-assessment individuals if presenting with at least one periodontal pocket of 6 mm in depth will undergo additional corrective periodontal therapy consisting of periodontal surgery and re-instrumentation under local analgesia. If surgical periodontal therapy is not indicated, appropriate re-instrumentation of the sites will be performed.
224143593|NCT02685657|DRUG|Drug: Selumetinib|
223438380|NCT03326284|OTHER|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
223438381|NCT03326284|OTHER|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
223438382|NCT03326284|OTHER|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
223438383|NCT03326284|OTHER|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
223438384|NCT04561102|DIAGNOSTIC_TEST|Diagnostic test for detection of SARS-CoV-2|The COVIDSeq is designed to test RNA extracted from NP swab specimens from patients symptomatic for COVID-19
223438385|NCT06815263|BEHAVIORAL|Listener Training|Partner participants are presented with individual audio phrases that make up passage reading speech stimuli and orthographic transcriptions of what the patient is saying. Partners are asked to listen carefully to the audio files and use the written subtitles to help them understand what is being said.
223438386|NCT06863636|DRUG|Celecoxib + Acetaminohen|One tablet of 200 mg / 200 mg a day
223438387|NCT06863636|DRUG|Celecoxi + Acetaminophen|One tablet of 200 mg / 500 mg a day
223566518|NCT04812119|DIAGNOSTIC_TEST|The Gross Motor Function Classification System - Expanded and Revised (GMFCS - E&R)|The Gross Motor Function Classification System - Expanded \& Revised (GMFCS - E\&R; Palisano, Rosenbaum, Bartlett, Livingston, 2007) is a 5-level classification system that describes the gross motor function of children and youth with cerebral palsy on the basis of their self-initiated movement with particular emphasis on sitting, walking, and wheeled mobility. Distinctions between levels are based on functional abilities, the need for assistive technology, including hand-held mobility devices (walkers, crutches, or canes) or wheeled mobility, and to a much lesser extent, quality of movement. The questionnaire is available for four age groups of children and youth: 2 to \< 4 years, 4 to \< 6 years, 6 to \< 12 years, and 12 to 18 years.
224049517|NCT04887155|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Group-based transdiagnostic cognitive-behavioral treatment
224049518|NCT03318978|DRUG|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
223438388|NCT06863636|DRUG|Celecoxib|One capsule of 200 mg a day
223438389|NCT05179018|DIAGNOSTIC_TEST|Ribosomal p2 Autoantibodies as a Serum marker|Using serum marker
223438390|NCT02838836|PROCEDURE|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
223438391|NCT04998721|BEHAVIORAL|Promoting First Relationships-Brief|A brief version of the evidence based Promoting First Relationships (PFR) parenting intervention in which a parent is supported in appropriate interpretation of infant cues and in developing skills to effectively parent an infant. Sessions consist of reflective content (observing and reflecting back to the mother on patterns of dyadic interaction) and informational handouts. Reflective content will be delivered in person, and text messaging protocol will deliver informational content at developmentally appropriate times. PFR-B sessions are delivered in primary care settings beginning in the third trimester and continuing postpartum.
223438392|NCT04998721|BEHAVIORAL|Perinatal Collaborative Care|Collaborative Care (CC) is an integrated care model that is effective in the treatment of perinatal depression. CC provides team driven, population focused, measurement guided and evidence based care to improve access and outcomes, control costs, and increase patient satisfaction.
223438393|NCT05554913|DRUG|QL0911|This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer
223438394|NCT05554913|DRUG|Placebo|Placebo comparator
223438395|NCT02183259|DRUG|ESR 1150 CL, Capsule, oral|
224049519|NCT02844816|DRUG|Atezolizumab|Given IV
224049520|NCT04085315|DRUG|Osimertinib|Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
224143594|NCT02685657|DRUG|Doxorubicin|
224143595|NCT02685657|DRUG|Cyclophosphamide|
224143596|NCT02685657|DRUG|Docetaxel|
224143597|NCT01877785|DRUG|MHAA4549A|Single-ascending dose of MHAA4549A
223438396|NCT02183259|DRUG|ESR 1150 CL, solution, intravenous|
223740771|NCT03571074|OTHER|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
223740772|NCT05635240|OTHER|Interview / questionnaires|At each of the 4 visits, the participant will have to answer several questions regarding trauma-related data, employment and sport practice.
224143598|NCT01877785|DRUG|Placebo|Placebo to MHAA4549A
224143599|NCT01261598|PROCEDURE|Positron Emission Tomography|Positron Emission Tomography
224143600|NCT03202745|OTHER|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
224143601|NCT03202745|OTHER|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
224143602|NCT01972854|DRUG|riboflavin solution|0.12% riboflavin ophthalmic solution
224143603|NCT01972854|DRUG|placebo solution|0.0% riboflavin ophthalmic solution
224143604|NCT01972854|DEVICE|KXL System|30mW/cm2
224049521|NCT04085315|DRUG|Alisertib|Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
224049522|NCT01292798|DRUG|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
224143605|NCT00511849|DRUG|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
224143606|NCT00561613|OTHER|SILCS and lubricant|
224143607|NCT00561613|OTHER|SILCS and spermicide|
224300334|NCT05337774|DRUG|[18F]PI-2620|The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
223438397|NCT05836974|PROCEDURE|Ex-utero cord blood collection|SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.
223438398|NCT05836974|PROCEDURE|In-utero cord blood collection|The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
223566519|NCT04812119|DIAGNOSTIC_TEST|The Visual Function Classification System (VFCS)|The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
223566520|NCT04812119|DIAGNOSTIC_TEST|The Early Childhood Oral Health Impact Scale (ECOHIS)|The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.
224049523|NCT04629352|DEVICE|Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)|In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
223566521|NCT04812119|DIAGNOSTIC_TEST|The Family Impact Scale (FIS)|The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.
223566522|NCT04812119|DIAGNOSTIC_TEST|The Achenbach System of Empirically Based Assessment (ASEBA)|The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.
224049524|NCT04629352|DEVICE|Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)|In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
224049525|NCT03573609|DEVICE|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
224049526|NCT00997451|BEHAVIORAL|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
224049527|NCT00997451|BEHAVIORAL|Symptom monitoring|Daily symptom via web diary
224049528|NCT00000353|DRUG|Buprenorphine/naloxone|
224143608|NCT03007719|DRUG|Fluorine F 18 Ara-G|Given IV
224143609|NCT03007719|PROCEDURE|Positron Emission Tomography|Undergo PET/MR imaging
224143610|NCT03007719|PROCEDURE|Magnetic Resonance Imaging|Undergo PET/MR imaging
224143611|NCT03140683|DEVICE|non-stress test|antepartum fetal monitoring
224143612|NCT01254578|OTHER|Laboratory Biomarker Analysis|Correlative studies
224143613|NCT01254578|DRUG|Lenalidomide|Given orally
223438399|NCT05032274|OTHER|Home-based Exercise Program|The exercise program will include chink tuck and shoulder retraction exercises. The chin tuck exercise will be performed in standing position. The shoulder retraction exercise includes activation and strengthening components. The activation component will be performed in standing position and strengthening component will be performed in prone position.
223438400|NCT05296902|DEVICE|Mucosal Closure|mucosal closure in oral surgery (mucosal sutures)
223438401|NCT03673345|BIOLOGICAL|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
223438402|NCT01483482|PROCEDURE|Conservative Treatment|Simple Sling
223566523|NCT04812119|DIAGNOSTIC_TEST|Adaptive Behavior Assessment System Third Edition (ABAS-3)|The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
223566524|NCT01226641|DEVICE|Telemedicine|CPAP treatment with telemedicine system
224049529|NCT04453293|BIOLOGICAL|BCG (Tokyo 172) vaccine|Freeze-Dried Glutamate Bacillus Calmette-Guérin BCG Vaccine (Japan BCG Laboratory), 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
224049530|NCT04453293|DRUG|Placebo|Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
224049531|NCT04451850|OTHER|Noninvasive actigraphy monitor|Noninvasive chest-mounted actigraphic device to be worn for 2 hour intervals two times per week during the six month study participation.
223438403|NCT01483482|PROCEDURE|Surgical treatment|Superior Locking plate
224049532|NCT05054738|BEHAVIORAL|Combined Recovery Program|A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
224049533|NCT05054738|BEHAVIORAL|Stable & Able (S&A)|A 90-day Home Telehealth program designed to help maintain skills to stay sober.
223438404|NCT00033176|DRUG|Alpha Lipoic Acid|
223438405|NCT01362244|DRUG|Mepolizumab|750 mg of mepolizumab by IV infusion
223438406|NCT01362244|DRUG|Placebo|Placebo by IV infusion
224049534|NCT03613753|DRUG|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
224049535|NCT03613753|DRUG|irinotecan|irinotecan chemotherapy alone
223438407|NCT01362244|DRUG|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
223438408|NCT05714046|BEHAVIORAL|Control|An informative presentation
223438409|NCT05714046|BEHAVIORAL|Yoga training|Yoga exercise training
223438410|NCT06157112|OTHER|Lifestyle behaviour (exposure in a observational study)|Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
223566525|NCT01226641|DEVICE|Standard care|Standard care, including CPAP
223566526|NCT02174029|PROCEDURE|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
223566527|NCT02174029|PROCEDURE|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
224049536|NCT04749342|OTHER|Physiotherapy Treatment|Physical Therapy sessions for treatment of advanced Lymphedema Cases
224049537|NCT03447951|DRUG|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
224049538|NCT01200238|DRUG|STA-9090|
224049539|NCT02717754|DRUG|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
224049540|NCT02717754|DRUG|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
224049541|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
224049542|NCT02823249|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
224049543|NCT02823249|DIETARY_SUPPLEMENT|50 g Xylitol|
224049544|NCT02823249|DIETARY_SUPPLEMENT|75 g Erythritol|
224049545|NCT02823249|DIETARY_SUPPLEMENT|75 g Glucose|
224049546|NCT02823249|DIETARY_SUPPLEMENT|Tap water|
224049547|NCT02823249|DIETARY_SUPPLEMENT|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
224049548|NCT02823249|DEVICE|Nasogastric Tube|
224049549|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
224049550|NCT01063387|RADIATION|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
224049551|NCT03548285|RADIATION|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
223438411|NCT04954716|OTHER|Deep Neck Flexor Massage|Deep friction massage is a specific connective tissue massage that was given across the affected fibers.The therapist's fingers and patient's skin must move as one, otherwise moving subcutaneous fascia against muscle or ligament could lead to blister formation or subcutaneous bruising.The friction massage must have sufficient sweep and be deep enough.
224049552|NCT06970704|OTHER|Erector Spinae Plane Block using 0.25 % bupivacaine|After induction of anesthesia and prone positioning and before surgery, Erector Spinae Plane Block was performed bilaterally using a low-frequency curved ultrasound transducer placed in a longitudinal orientation 3 cm lateral to the spinous process one vertebral level above a predetermined marked surgical incision. An 8-cm 22-gauge block needle was inserted in a cephalad to caudad direction until the tip lay in the interfascial plane below the erector spinae muscle, the block was performed by injection of 20 ml of 0.25% bupivacaine. Fentanyl 1 µg/kg as a rescue analgesia was given based on hemodynamic parameters.
224049553|NCT06966596|DRUG|Ketamine only|Group A received ketamineat 0.2mg/kg bolus intravenously followed by ketamine infusion at rate of 0.2mg/kg/hr throughout the surgery. W
224049554|NCT06966596|OTHER|Placebo Normal Saline (NS)|Control group received normal saline to maintain double blinding
224049555|NCT06970886|BEHAVIORAL|Rhythm-Based Music Intervention|The rhythm-based music intervention is designed to reduce anxiety and improve emotional well-being in pregnant women with gestational diabetes. This intervention involves structured music sessions, utilizing rhythm as a therapeutic tool to engage participants in either active creation or passive listening. The intervention aims to promote relaxation, reduce stress, and support overall psychological health by leveraging the emotional and cognitive effects of rhythm and music.
224049556|NCT06646354|DRUG|Ezetimibe/Rosuvastatin/Candesartan/Amlodipine|PO, QD, 8 weeks
224049557|NCT06646354|DRUG|Candesartan/Amlodipine|PO, QD, 8 weeks
224049558|NCT06646354|DRUG|Candesartan/Rosuvastatin/Ezetimibe|PO, QD, 8 weeks
224049559|NCT05834348|DRUG|lorlatinib|As provided in real world practice
224049560|NCT05834348|DRUG|crizotinib|As provided in real world practice
224049561|NCT05834348|DRUG|brigatinib|As provided in real world practice
224049562|NCT05834348|DRUG|ceritinib|As provided in real world practice
224049563|NCT05834348|DRUG|alectinib|As provided in real world practice
224049564|NCT05834348|DRUG|atezolizumab|As provided in real world practice
224049565|NCT05834348|DRUG|bevacizumab|As provided in real world practice
224049566|NCT05834348|DRUG|paclitaxel|As provided in real world practice
224049567|NCT05834348|DRUG|carboplatin|As provided in real world practice
224049568|NCT05834348|DRUG|docetaxel|As provided in real world practice
224049569|NCT05834348|DRUG|erlotinib|As provided in real world practice
224049570|NCT05834348|DRUG|gefitinib|As provided in real world practice
224049571|NCT05834348|DRUG|afatinib|As provided in real world practice
224049572|NCT05834348|DRUG|dacomitinib|As provided in real world practice
224049573|NCT05834348|DRUG|osimertinib|As provided in real world practice
224049574|NCT05834348|DRUG|pembrolizumab|As provided in real world practice
224049575|NCT05834348|DRUG|nivolumab|As provided in real world practice
223438412|NCT04954716|OTHER|Post-Isometric Relaxation Technique|The PIR technique is performed as follows.The hypertonic muscle is taken to a length just short of pain, or to the point where resistance to movement is first noted.A submaximal (10-20%) contraction of the hypertonic muscle is performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction . The patient should inhale during this effort.After the isometric contraction the patient is asked to relax and exhale while doing so.Following this a gentle stretch is applied to take up the slack till the new barrier.Starting from this new barrier, the procedure is repeated two or three times.
223438413|NCT03328494|DRUG|BOS172722|Oral capsules
223438414|NCT03328494|DRUG|Paclitaxel|IV infusion
224049576|NCT05834348|DRUG|entrectinib|As provided in real world practice
224049577|NCT05992025|BEHAVIORAL|Physical activity|Intervention with physical activity more than 150 minutes of medium to high intensity per week.
224049578|NCT05992025|BEHAVIORAL|Sleep hygiene|Intervention with sleep hygiene to optimize sleep duration and quality.
224049579|NCT04154917|OTHER|HOME|HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
224049580|NCT05257941|DRUG|IT Injection|an intrathecal (IT) injection in the back in which a small dose duramorph and bupivacaine will be placed into the spinal fluid
224049581|NCT05257941|DRUG|ESP Block|an erector spinae plane (ESP) block in which bupivacaine and decadron are injected near the nerves under a muscle in the back
224049582|NCT06972888|DRUG|AC-201|AC-201 tablets will be administered orally
224049583|NCT06972888|DRUG|Placebo|Matching placebo tablets will be administered orally.
224049584|NCT03933670|DRUG|Hyperpolarized Carbon C 13 Pyruvate|Given IV
224049585|NCT03933670|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
224049586|NCT03933670|PROCEDURE|MRI Ultrasound Fusion Guided Biopsy|Undergo MR/US fusion-guided prostate biopsy
224049587|NCT05770102|DRUG|Atezolizumab|"Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.~Paediatric patients will receive atezolizumab at a dose of 15 mg/kg (maximum 1200 mg) every 21 days.~Patients may continue on treatment until disease progression without clinical benefit, unacceptable toxicity or withdrawal of consent."
224049588|NCT03734016|DRUG|Zanubrutinib|160 mg orally twice daily
224049589|NCT03734016|DRUG|Ibrutinib|Ibrutinib 420 mg orally once daily
224049590|NCT03188393|PROCEDURE|Biopsy of Breast|Undergo stereotactic biopsy
223438415|NCT06911411|OTHER|Prospective observational cohort study.|"No systematic approach exists for symptom assessment, management, and reporting in delivered basic palliative care within the Danish healthcare system, implying considerable variation in hospital-based palliative care. The PALMA study consists of two superior phases divided in a development and an implementation stage that anchors basic palliative assessment and management within existing geriatric workflows and cross-sectoral collaborative care.~The PALMA cohort will test the applicability of the EORTC-C15-PAL questionnaire along with measures of clinical frailty and sociodemographic risk factors.~The development phase will enable the development of a clinical algorithm for elderly patients' need for cross-sectoral palliation care planning."
224049591|NCT02620267|DEVICE|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
224049592|NCT06241807|DRUG|Camrelizumab Plus Chemotherapy|Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
224049593|NCT05051150|DRUG|Epinephrin 0.03|epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
224049594|NCT05051150|DRUG|Epinephrin 0.05|epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
224049595|NCT05051150|DRUG|Epinephrin 0.07|epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
224049596|NCT05234554|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
224049597|NCT05234554|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
224049598|NCT00794443|DRUG|YM529 / ONO-5920|Oral
224049599|NCT01979835|DEVICE|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
224049600|NCT03608982|OTHER|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
224049601|NCT03608982|OTHER|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
223438416|NCT06911411|OTHER|A prospective observational cohort study|Observational design
223438417|NCT06911762|BEHAVIORAL|Exercise|Participants will receive a 6-week structured hand exercise program. Participants will attend a face-to-face exercise session to learn all hand exercises. The exercise program will include: (1) Finger flexor stretching, (2) Tendon gliding exercise and (3) Isometric finger flexor exercise. A weekly tele follow-up will be done to participants in the experimental group
223438418|NCT05079776|OTHER|Physical length measurement|Physical length will be measured and images will be collected for AI to estimate the length
223438423|NCT04648527|PROCEDURE|arthroscopic synovectomy and thermocoagulation|An diagnostic arthroscopy and an arthroscopic synovectomy and thermocoagulation of the dorsal hypertrophic synovial will be performed
223438424|NCT02724566|DRUG|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
223438425|NCT02724566|DRUG|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
223438426|NCT04959292|DIAGNOSTIC_TEST|arthroscopy|arthroscopy
223438427|NCT06028386|DEVICE|AC5® Advanced Wound System|This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.
223438428|NCT06028386|DEVICE|Fibracol Plus Collagen Dressing|This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
223438429|NCT00908596|DRUG|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
223438430|NCT00932386|DRUG|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
223438431|NCT00932386|DRUG|normal saline|0.9% normal saline infusing
223438432|NCT05365334|BEHAVIORAL|Low intensity exercise session|subjects will exercise at 30% maximal oxygen consumption (VO2max) for 45-60 minutes
224049602|NCT01320787|DRUG|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
224049603|NCT04063254|RADIATION|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
224049604|NCT01777412|DRUG|Bevacizumab|
224049605|NCT04623372|PROCEDURE|suture|suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy
224049606|NCT04623372|PROCEDURE|directed wound healing|application of a dry dressing without any prior suture after the skin biopsy.
224049607|NCT01710592|DRUG|Epirubicin|
223438433|NCT05365334|BEHAVIORAL|Moderate intensity exercise session|subjects will exercise at 65% maximal oxygen consumption (VO2max) for 30-45 minutes
223438434|NCT05365334|BEHAVIORAL|High intensity exercise session|subjects will completed 10x1minute exercise intervals at maximal oxygen consumption (VO2max) with 1 minute active recovery between
223438435|NCT03812263|BIOLOGICAL|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
223438436|NCT05919524|RADIATION|Prostate SBRT (stereotactic body radiation therapy) with focal boost|"* Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~* mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~* Additional urethra and bladder trigone sparing constrains~* Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking"
223438437|NCT03010241|DRUG|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
224049608|NCT01710592|DRUG|Oxaliplatin|
223438438|NCT03010241|DRUG|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
223438439|NCT02232555|DRUG|Duloxetine|
223438440|NCT02232555|DRUG|Placebo|
223438441|NCT02148016|PROCEDURE|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
224049609|NCT01710592|DRUG|Capecitabine|
224143614|NCT01254578|OTHER|Pharmacological Study|Correlative studies
224143615|NCT04606368|DEVICE|Thermage FLX|Monopolar radiofrequency will be applied through the Thermage FLX machine to the subject's right lower jaw and submentum area.
224143616|NCT01157546|PROCEDURE|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
224143617|NCT01157546|PROCEDURE|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
223438442|NCT02148016|PROCEDURE|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
223438443|NCT02148016|PROCEDURE|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
223438444|NCT02148016|PROCEDURE|PRK only (Traditional Technique)|PRK alone will be performed.
223438445|NCT02148016|DRUG|Levofloxacin|
223438446|NCT02148016|DRUG|Betamethasone|
223438447|NCT02148016|DRUG|Limbal stem cells (LSCs)|
223438448|NCT05727150|PROCEDURE|Reconstruction of Soft tissue defects of head and neck by Supraclavicular artery flap|Supraclavicular artery flap will be used in the reconstruction of traumatic and non-traumatic defects of head and neck.Flap harvesting and reconstruction will be performed under general anesthesia. The defect dimensions are measured and the superficial landmarks for the supraclavicular artery are drawn .The flap will be used as island flap, transposed or interpolated flap depending on the arc of rotation needed to achieve flap inset without tension and flap elevation proceeds from lateral to medial.The flap is rotated and inset into the defect
223438449|NCT03627650|PROCEDURE|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
223566528|NCT02174029|PROCEDURE|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
223438450|NCT03627650|PROCEDURE|placebo injection|
224049610|NCT01710592|DRUG|Docetaxel|
223438451|NCT01943955|BEHAVIORAL|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
224049611|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
224049612|NCT02807649|DIETARY_SUPPLEMENT|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
224049613|NCT02807649|DIETARY_SUPPLEMENT|Placebo Comparator: Placebo|Two tablets consume daily with meal.
224049614|NCT00021151|BIOLOGICAL|alemtuzumab|
224143618|NCT03351010|BEHAVIORAL|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
224143619|NCT03351010|DEVICE|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
224143620|NCT04547998|DEVICE|Control Intervention (UVB)|Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.
224143621|NCT04547998|DEVICE|Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)|Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
224143622|NCT00189787|DRUG|tacrolimus|
224143623|NCT05306184|PROCEDURE|Electroconvulsive therapy (ECT)|ECT
224143624|NCT03669406|PROCEDURE|Autograft fat|autograft fat
223438452|NCT03691506|OTHER|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
223438453|NCT03691506|OTHER|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
223438454|NCT00678964|DRUG|Erlotinib|Erlotinib 150 mg, p.o., once daily
223438455|NCT00678964|DRUG|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
223438456|NCT03747913|DIETARY_SUPPLEMENT|Antioxidative supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
223438457|NCT05259618|OTHER|Tasso+ SST|alternative site blood sample collection.
224049615|NCT01879787|OTHER|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
224049616|NCT00376584|DRUG|MK-0524A|
224049617|NCT00376584|DRUG|ER Niacin|
224049618|NCT00376584|DRUG|Placebo|
224049619|NCT00567684|DEVICE|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
224049620|NCT00567684|OTHER|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
224143625|NCT01960426|OTHER|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
224143626|NCT01960426|OTHER|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
223438458|NCT02219386|OTHER|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
223438459|NCT02219386|OTHER|group 2. Passive analitical stretch (performed in both groups)|
223438460|NCT05037890|DIETARY_SUPPLEMENT|Margarine|Intake of margarine
223438461|NCT01075464|DRUG|MEGF0444A|Intravenous escalating dose
223438462|NCT01075464|DRUG|bevacizumab|Intravenous repeating dose
223438463|NCT01075464|DRUG|paclitaxel|Intravenous repeating dose
223438464|NCT01281943|DRUG|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
224049621|NCT00878852|BEHAVIORAL|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
223438465|NCT03793959|DIETARY_SUPPLEMENT|Synbiotic Supplement|
223438466|NCT03793959|DIETARY_SUPPLEMENT|Placebo|
223438467|NCT03259906|OTHER|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
223438468|NCT03259906|PROCEDURE|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
223438469|NCT03259906|PROCEDURE|posterior osteosynthesis|Osteosynthesis using a posterior plate
224049622|NCT00878852|BEHAVIORAL|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
224143627|NCT05621590|DRUG|MLC 901|MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components
224143628|NCT05621590|DRUG|Placebo|placebo capsules filled with stevia sweetened powder
223438470|NCT03259906|PROCEDURE|Anterior osteosynthesis|Osteosynthesis using an anterior plate
223438471|NCT03354052|DEVICE|Real-rTMS + Gloreha device|The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
224143629|NCT00930709|DRUG|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
224049623|NCT04633174|DEVICE|Sous Vide Device (SVD)|A basin will be filled to the marked line with water from jugs at room temperature, for each frozen extremity. The sous vide device (SVD) will be attached to the distal edge of the basin. The SVD will be turned on and set to maintain the bath at a constant 38 degrees celsius for 30 minutes duration. The thermometers will be powered on continuously and the researcher will record temperatures simultaneously from each thermometer every 2 minutes. At the end of the 30 minute treatment, the SVD will be powered off and the extremity assessed by the researcher for warmth and pliability. If the extremity still feels cold or frozen, an additional 30 minutes in the water bath will commence, with subsequent reassessment. Rewarming will be considered complete when the affected tissue becomes red or purple, soft, and pliable.
224049624|NCT02903069|DRUG|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
224049625|NCT02903069|DRUG|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
224143630|NCT00930709|BEHAVIORAL|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
224143631|NCT01525056|RADIATION|ct and mri scans|ct and mri scan preradiation and postradiation
223438472|NCT03354052|DEVICE|Sham-rTMS + Gloreha device|The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
223438473|NCT04202536|DRUG|Besifovir Dipivoxil Maleate|Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
223438474|NCT04202536|DRUG|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily Other Name: VIREAD®
223438475|NCT01842906|DEVICE|Theravent|nasal EPAP device
224049626|NCT02903069|RADIATION|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
224049627|NCT02903069|DEVICE|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
224049628|NCT00890253|DRUG|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
224049629|NCT00890253|DRUG|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
224143632|NCT01525056|RADIATION|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
224143633|NCT01525056|RADIATION|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
224143634|NCT01452724|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
224143635|NCT01452724|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
224300335|NCT02356003|DEVICE|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
223438476|NCT01842906|DEVICE|Control|Sham device without EPAP
224049630|NCT00890253|DRUG|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
224049631|NCT00890253|DRUG|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
223438477|NCT00095459|DRUG|Bevacizumab|
223438478|NCT00095459|DRUG|BAY 43-9006|
223438479|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
223438480|NCT01335854|BEHAVIORAL|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
223438481|NCT03695328|BEHAVIORAL|physical activity level|
223438482|NCT03695328|BEHAVIORAL|Dietary Intake|
223438483|NCT00003328|DRUG|porfiromycin|
223438484|NCT00003328|RADIATION|radiation therapy|
223438485|NCT00638261|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
223566529|NCT03702348|OTHER|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
223740773|NCT04351087|DEVICE|Platelet Rich Plasma|"Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance."
224143636|NCT01452724|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
224143637|NCT01452724|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
224143638|NCT04644055|DIAGNOSTIC_TEST|EUS- share wave of the liver|Evaluation of the right and left hepatic lobe with EUS-guided share wave
223438486|NCT04852211|PROCEDURE|Open or laparoscopic surgery|"Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~1. Laparoscopic group: LMH~2. Open group: OMH"
224049632|NCT05031988|OTHER|No intervention will be used.|Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
224143639|NCT06962631|BIOLOGICAL|5% (5g/100 ml) intravenous immunoglobin|"A 5% human normal immunoglobulin I.P. (5 g/100 mL) V-IMMUNE® will be administered at a dose of 1 g/kg, intravenously, once daily for 2 consecutive days (Day 1 and Day 2). The infusion rate starts at 0.01 mL/kg/min during the first 30 minutes and is gradually increased up to 0.06 mL/kg/min if no adverse events occur. This will constitute the first cycle of V-IMMUNE® treatment. The dose of 1 g/kg/day on 2 consecutive days is consistent with recommendations for the use of other IVIG products in Immune Thrombocytopenia.~If the platelet count is not maintained for the desired duration after the first V-IMMUNE® cycle, and at the discretion of the investigator and the patient/legal representative, participants may receive up to one additional cycle of V-IMMUNE®-at the same dosing regimen used in Cycle 1-between Day 15 and Day 30"
224143640|NCT04707378|DEVICE|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 10 treatment sessions per week for 2 weeks (a total of 10 sessions). In each rTMS session, 1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left DLPFC. Each session is 20 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
224143641|NCT03625297|OTHER|shelter cat|families will adopt a shelter cat
224143642|NCT02321683|DEVICE|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
223438487|NCT03510078|DRUG|Insulin|Insulin for glycemic control according to the allocation
223438488|NCT03287011|OTHER|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
223438489|NCT03287011|OTHER|Colgate toothpaste|fluoridated
223438490|NCT00413309|PROCEDURE|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
223438491|NCT03290183|DEVICE|Confocal laser endomicroscopy|Real-time microscopic imaging technique
223438492|NCT06174545|DRUG|Pigment Solution Program|adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
223438493|NCT02552953|DRUG|CYC065|
223438494|NCT00935454|PROCEDURE|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
223438495|NCT01709864|DRUG|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
223438496|NCT01709864|DRUG|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
223438497|NCT02517021|DRUG|Pro-netupitant/Palonosetron|
223438498|NCT02517021|DRUG|Netupitant/Palonosetron|
223438499|NCT02517021|DRUG|Dexamethasone|
223566530|NCT06420856|OTHER|Assessment of the musculoskeletal system and its functions|Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
224049633|NCT02747953|DRUG|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
224049634|NCT02592018|DRUG|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
224143643|NCT05167188|OTHER|no intervention|no intervention
224143644|NCT01620008|PROCEDURE|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
224143645|NCT05133206|OTHER|Advice on fasting before the procedure|Patients are allowed to eat and drink freely up to the point of transfer to the Catheter Laboratory.
224143646|NCT01444872|DRUG|TRV120027|IV infusion
223438500|NCT05365919|OTHER|Family Talk Intervention|FTI entails six meetings, with intervals of 1-2 weeks between meetings. Meetings 1-2 include only the parent(s) and focus on their experiences of the situation, as well as the consequences of the diagnosis for each family member. The parent(s) will formulate the goal of the intervention. Meeting 3: Interviews will be held with each child and includes the child's life situation. Meeting 4 includes the parent(s) and focuses on planning the family meeting. The children's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5 is a family meeting and consists of questions and issues raised earlier by the family members. Meeting 6 is a follow-up with all family members. The meeting is guided by the family members' needs, e.g., regarding communication and parenting. If the intervention is interrupted unexpectedly and cannot be finished as scheduled due to extraordinary circumstances, extra meetings are available (Meetings 7-11).
223438501|NCT00001646|DRUG|Voriconazole|
223438502|NCT00001646|DRUG|Amphotericin B|
224049635|NCT02638350|DEVICE|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
223438503|NCT01619098|OTHER|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
223566531|NCT01639339|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
224049636|NCT04230707|OTHER|Endogenous Melatonin Levels|High Endogenous Melatonin Levels is Group 1 Low Endogenous Melatonin Levels is group 2
224049637|NCT02422407|PROCEDURE|Biopsy|Salivary Gland
224049638|NCT03599895|PROCEDURE|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
224049639|NCT03599895|PROCEDURE|non 3D printing model|da Vinci robot assisted radical gastrectomy
224049640|NCT02964299|DEVICE|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
224049641|NCT04416061|DIAGNOSTIC_TEST|COVID 19 Diagnostic Test|COVID 19 Diagnostic Test
224049642|NCT06363669|DIETARY_SUPPLEMENT|multi-ingredient pre-workout dietary supplement (caffeine-based)|The participants performed the exercise twice, in random order: as a control test and after supplement administration. The acute effects of MIPS supplementation (beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin)) on aerobic and anaerobic performance were evaluated in untrained men
224049643|NCT00314353|DRUG|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles\*~\*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
224049644|NCT00314353|DRUG|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
224049645|NCT00314353|DRUG|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*#~\*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
224049646|NCT00314353|DRUG|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
224049647|NCT01255969|OTHER|Exercise|Personalized exercise program
224049648|NCT03800290|DRUG|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
224143647|NCT01444872|DRUG|Normal Saline|IV infusion
224143648|NCT04790539|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
224143649|NCT01000519|OTHER|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
224300336|NCT06206200|OTHER|Cognitive dual task training (intervention group)|Simultaneously performing cognitive tasks and motor rehabilitative exercises.
223566532|NCT01639339|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
223566533|NCT01639339|DRUG|Standard therapy|"The standard therapies allowed in this study are:~\- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~\- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
224049649|NCT03800290|DRUG|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
224143650|NCT01000519|OTHER|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
224143651|NCT03932019|DRUG|Jitongning tablet(High-dose )|Jitongning tablet,3tablets,bid,treat 12 weeks
224143652|NCT03932019|DRUG|Jitongning tablet(Low-dose )|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
224143653|NCT03932019|DRUG|Placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
223438504|NCT01619098|OTHER|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
223438505|NCT02661061|DRUG|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
223438506|NCT02661061|DRUG|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
223438507|NCT02331784|BEHAVIORAL|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
223438508|NCT02331784|BEHAVIORAL|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
224143654|NCT01113788|DEVICE|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
224143655|NCT04925518|DEVICE|Closed Loop Mechanical Ventilation|Closed loop ventilation mode (Intellivent-ASV+®). Intellivent-ASV+® was initiated by activating the controllers for minute volume, PEEP (range 5 to 18 cmH2O) and fraction of inspired oxygen (FiO2) (range 21 to 100 %). The target shift ranges for CO2-management were set between -2.5 and +2.5 kPa, and for O2-management between -2 and +2 %.
224143656|NCT04925518|DEVICE|Conventional Mechanical Ventilation|Mechanical ventilation with a conventional mode, usually either biphasic positive airway pressure ventilation (DuoPAP®) or adaptive support ventilation (ASV®)
224300337|NCT06206200|OTHER|Standard of care physiotherapy (control group)|The current best physical therapy treatment for patients with anterior cruciate ligament reconstruction based on existing scientific evidence.
224049650|NCT02710136|BIOLOGICAL|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
223438509|NCT02993965|OTHER|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
223566534|NCT06523218|DIETARY_SUPPLEMENT|MindMD Supplement|Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.
224049651|NCT02558478|GENETIC|blood sampling|
224049652|NCT00418665|BIOLOGICAL|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
224049653|NCT00418665|DRUG|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
224049654|NCT02483377|OTHER|Quality-of-Life Assessment|Ancillary studies
224049655|NCT02483377|OTHER|Questionnaire Administration|Complete questionnaires
224049656|NCT00891319|DEVICE|Electrical stimulator|"• 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
224049657|NCT00918047|DRUG|SPN-804O|Open Label study
224049658|NCT01871636|PROCEDURE|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
224049659|NCT01871636|PROCEDURE|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
224049660|NCT01871636|DEVICE|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
224049661|NCT00246597|DRUG|epoetin alfa|
224049662|NCT01177436|BIOLOGICAL|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
224143657|NCT03911778|OTHER|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
224143658|NCT04713579|OTHER|No intervention - observational study|There is no intervention in this study as it is purely observational.
224143659|NCT06527638|BEHAVIORAL|Experimental Group: eHealth intervention for UI symptoms improvement|"The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
224143660|NCT06527638|BEHAVIORAL|Control Group: Delivery of a Health Literacy single-leaflet|"A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention."
224143661|NCT04403529|DRUG|Traditional Chinese Medicine Formulation|"The prescription for breast cancer Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption."
223438510|NCT00183833|DRUG|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
224049663|NCT04084106|DRUG|Phenoxymethylpenicillin|Oral administration
224049664|NCT04084106|DRUG|Amoxicillin|Oral administration
224049665|NCT04084106|DRUG|Amoxicillin-clavulanic acid|Oral administration
224143662|NCT04403529|DRUG|Placebo Formulation|"Placebo granules contains 5% prescription for breast cancer Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption."
223438511|NCT03436069|OTHER|Conventional treatment protocols of breast cancer|
223438512|NCT01013389|PROCEDURE|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
223438513|NCT01013389|PROCEDURE|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
223438514|NCT02020837|PROCEDURE|Lymphaticovenous Micro-Anastomosis|
224049666|NCT03662217|OTHER|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
224049667|NCT03662217|OTHER|ADA- based diet|The American standard of care dietary guidelines for diabetes.
224049668|NCT04952740|PROCEDURE|IPC+PCI|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.) + immediate post-ischemic adaptation: 30 seconds balloon inflation and 30 seconds deflation for 3 cycles
223438515|NCT04421157|OTHER|Schroth Exercises|The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
223566535|NCT06523218|OTHER|Placebo|Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.
223566536|NCT00754949|DRUG|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
223566537|NCT00754949|DRUG|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
224049669|NCT04952740|PROCEDURE|No IPC|Routine PCI operations (including thrombus aspiration, stent injection, application of GPIIb/IIIa, etc.
224049670|NCT01557179|DEVICE|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
224049671|NCT01557179|DEVICE|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
224049672|NCT04180150|DRUG|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
223566538|NCT00754949|DRUG|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
224049673|NCT04180150|DRUG|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
224049674|NCT04180150|DRUG|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
224049675|NCT04363073|DEVICE|Annabella Breast Pump|Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
224049676|NCT04363073|DEVICE|Control Breast Pump|Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
224049677|NCT00407589|DRUG|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
224049678|NCT01133379|DEVICE|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
223566539|NCT03267043|BEHAVIORAL|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
223566540|NCT03267043|BEHAVIORAL|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
223566541|NCT02613468|OTHER|collection of periodontal records|"1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
223566542|NCT02613468|OTHER|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
224049679|NCT01133379|DEVICE|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
224049680|NCT01133379|DEVICE|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
224049681|NCT02795533|BEHAVIORAL|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~1. A medical examination~2. Quality of life questionnaires~3. Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
224049682|NCT03585218|BIOLOGICAL|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
224049683|NCT00130195|DRUG|imatinib|
224049684|NCT00130195|DRUG|cyclophosphamide|
224049685|NCT00130195|DRUG|daunorubicin|
224049686|NCT00130195|DRUG|vincristine|
224049687|NCT00130195|DRUG|prednisolone|
224049688|NCT00130195|DRUG|methotrexate|
224300338|NCT03086837|BEHAVIORAL|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
224300339|NCT02820649|OTHER|Sleep deprivation|40 hours of continuous wakefullness
223566543|NCT02613468|OTHER|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
223740774|NCT03386942|DRUG|Farletuzumab Ecteribulin|Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
224049689|NCT00130195|DRUG|cytarabine|
224049690|NCT00130195|DRUG|dexamethasone|
224049691|NCT00282178|DRUG|Hydrochlorothiazide|25-50 mg once daily
224049692|NCT00282178|DRUG|Placebo|Once daily
224049693|NCT00282178|DRUG|Candesartan|16-32 mg once daily 12 weeks
224049694|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) at baseline|Detailed imaging of coronary arteries
223566544|NCT01282307|BEHAVIORAL|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
223566545|NCT03420391|DEVICE|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
224049695|NCT06519292|DIAGNOSTIC_TEST|Coronary computed tomography angiography (CCTA) after 1 year|Detailed imaging of coronary arteries
224049696|NCT00049803|DRUG|sodium oxybate|
224049697|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
224049698|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
224049699|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
224049700|NCT01516151|DRUG|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
224049701|NCT01516151|DIETARY_SUPPLEMENT|CaPre™|4 capsules of 1 g total per day for 8 weeks.
224049702|NCT01166503|PROCEDURE|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
224049703|NCT01166503|PROCEDURE|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
224049704|NCT01166503|PROCEDURE|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
224049705|NCT01166503|PROCEDURE|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
224049706|NCT01166503|PROCEDURE|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
224049707|NCT03587714|DIAGNOSTIC_TEST|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
224049708|NCT02786134|RADIATION|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
224049709|NCT02786134|RADIATION|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
224049710|NCT05957952|PROCEDURE|Motor control exercise with dynamic taping|Subjects will learn how to control their scapula during motor control exercise with application of dynamic tape
224049711|NCT05957952|PROCEDURE|Motor control exercise|Subjects will learn how to control their scapula during motor control exercise without taping
224049712|NCT05470465|DRUG|Placebo and Oxycodone|Participants will receive placebo on days 1-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
224049713|NCT05470465|DRUG|Paroxetine and Oxycodone|Participants will receive 40 mg paroxetine (2 x 20 mg tablets) on days 1-6 and 60 mg paroxetine (3 x 20 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
224049714|NCT05470465|DRUG|Escitalopram and Oxycodone|Participants will receive 20 mg escitalopram (2 x 10 mg tablets) on days 1-6 and 30 mg escitalopram (3 x 10 mg tablets) on days 7-21 for this treatment period. Oxycodone 10 mg (2 x 5 mg tablets) will be administered on days 6, 12, and 21 of this treatment period.
223566546|NCT04452071|RADIATION|periapical xray|periapical xray on the middle phalanax of the middle finger
224143663|NCT06145152|PROCEDURE|Adaptive exercise training|The training recommendation for the day will be adjusted based on the readiness level. The adjustments can be both up or down (increased or decreased training)
224143664|NCT06145152|PROCEDURE|Static exercise training|The training recommendation for the day will not be adjusted based on the readiness level.
224143665|NCT01691287|BEHAVIORAL|Michael Method|
224143666|NCT01280266|DRUG|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
224143667|NCT03103880|DEVICE|BreatheSmart|BreatheSmart is a comprehensive asthma monitoring system that combines a medical device and mobile application that are designed for use with Apple and Android mobile devices. The medical device connects to the mobile application using Bluetooth to facilitate the collection of controlled medication adherence, rescue medication usage, and asthma control.
224049715|NCT05906576|DRUG|Infliximab|Infliximab in the treatment of Crohn's disease in children
224049716|NCT06650982|OTHER|Pecha Kucha presentation on MDPRI|Students in the experimental arm will be given training on MDRPI.
224049717|NCT06653426|DIETARY_SUPPLEMENT|Sodium Butyrate (NaBu)|Participants will self-administer Sodium Butyrate (NaBu) daily for 12 weeks. The study aims to evaluate the effect of NaBu on menstrual symptoms by comparing symptom severity before and during the intervention. Participants will maintain an electronic diary (eDiary) to record their daily symptom severity, which will be used to assess changes over time. Regular follow-ups will be conducted to monitor progress and address any side effects or concerns.
224143668|NCT00215241|DRUG|sertraline and risperidone|
224143669|NCT01422512|BIOLOGICAL|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
224143670|NCT05929352|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
224300340|NCT04002336|BEHAVIORAL|Traditional Voice therapy|Traditional method of voice therapy
224300341|NCT04002336|BEHAVIORAL|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
224049718|NCT06978855|DEVICE|Wrist band acupressure application to P6 point|"The intervention group received standardized instructions for applying the wristband to the P6 acupressure point on their wrist, with daily application scheduled from 8 pm to 8 am. Those who have night shifts will be asked to apply the wrist band for 12 hours after the end of their shift the intervention was applied for 30 days.~At the end of the first phase the participants will be asked to avoid applying the wrist band for 7 days, to allow a washout period before crossing over."
224070637|NCT00542256|DEVICE|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
224300342|NCT00298779|DRUG|omeprazole and bortezomib|
224300343|NCT06428318|DIAGNOSTIC_TEST|Conventional Sputum culture|Sputum culture was done to patients and they received Antibiotics According to its results
224300344|NCT06428318|DIAGNOSTIC_TEST|BioFire Pneumonia Panel (BFPP)|BioFire Pneumonia Panel (BFPP) was done to patients and they received Antibiotics According to its results
224300345|NCT06127368|DRUG|GB-5001A|Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.
224300346|NCT06127368|DRUG|GB-5001D|Depending on the cohort, volume will be varied to administer.
223438516|NCT04421157|OTHER|Core stabilization Exercises|Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
223438517|NCT03986229|OTHER|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~* Evaluation of the pain~* Berg test~* One test per condition starting with open eyes~* Standardized instructions:~* Break about 15 minutes (wash-out) between each test.~* Both conditions will be tested on the same day.~* Evaluation in an environment free from visual and audible interference."
223438518|NCT01048905|DRUG|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
223438519|NCT03790605|DRUG|1 % curcumin chip|CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
223438520|NCT03790605|OTHER|Placebo chip|PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
223438521|NCT03790605|PROCEDURE|Scaling and root planing|Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
223438522|NCT01822951|DRUG|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
223438523|NCT01822951|DRUG|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
223438524|NCT00669851|DRUG|AI-700|
223740775|NCT03849833|DIETARY_SUPPLEMENT|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
224070638|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
224070639|NCT00271817|DRUG|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.
224070640|NCT00271817|DRUG|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
224070641|NCT00271817|DRUG|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
224070642|NCT00271817|DRUG|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.
224070643|NCT00271817|DRUG|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
224070644|NCT00271817|DRUG|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
224070645|NCT00271817|DRUG|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
224070646|NCT03754075|PROCEDURE|Complete mesocolic excision|The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
224070647|NCT03754075|PROCEDURE|Conventional colon resections|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
224070648|NCT02037932|DEVICE|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
224070649|NCT05590286|DRUG|Vonoprazan Tablets|Vonoprazan 20 mg, tablets, orally，QD
224070650|NCT05590286|DRUG|Amoxicillin Capsules|Amoxicillin 750mg, Capsules ,orally，QID
224070651|NCT05590286|DRUG|Esomeprazole|Esomeprazole 20mg, Capsules ,orally，BID
223438525|NCT06356818|OTHER|Conventional physiotherapy program|Physiotherapy and rehabilitation treatment program will be applied to the patients. In this program, a 30-40-minute exercise protocol covering proprioceptive, balance and strengthening exercises will be implemented. For a total of 12 sessions, 3 days a week, over a 4-week period
223438526|NCT06356818|OTHER|Virtual reality (VR)|virtual reality (VR) program will be applied using balance and strengthening games by Nintendo Wii Fit Plus; warm-up exercise (5 minutes), workout (20 minutes) and cool-down exercise (5 minutes) for a total of 30 minutes. For a total of 12 sessions, 3 days a week, over a 4-week period
223438527|NCT06356818|OTHER|Motor imagery (MI)|Patients will be introduced to explicit Motor imagery program which the content of the imagery program will last 20 minutes in total, with 5 minutes of relaxation and 15 minutes of imagery training. For a total of 12 sessions, 3 days a week, over a 4-week period.
223438528|NCT02106702|BEHAVIORAL|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
223438529|NCT02106702|BEHAVIORAL|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
223438530|NCT01492101|DRUG|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
223438531|NCT01492101|DRUG|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel"
223438532|NCT01378832|PROCEDURE|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
223438533|NCT06386900|OTHER|Cyclist|Participating in the Grand Tour as cyclist
224049719|NCT06978855|DEVICE|Wrist band acupressure application to sham point|the control group will receive standardized instructions to apply the wristband to a sham point, with daily application from 8 pm to 8 am. Those who have night shifts will be asked to apply the wrist band for 12 hours after the end of their shift. This will occur for 30 days. At the end of the first phase the participants will be asked to avoid applying the wrist band for 7 days, to allow a washout period before crossing over.
224049720|NCT02672098|PROCEDURE|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
223438534|NCT05369689|OTHER|No interventions|As this is a prognosis evaluation study, there are no interventions.
223438535|NCT00770666|DRUG|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
223438536|NCT00770666|DRUG|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
223438537|NCT01055080|DIETARY_SUPPLEMENT|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
223438538|NCT02114294|OTHER|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
223438539|NCT02114294|OTHER|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
223438540|NCT02114294|OTHER|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
223438541|NCT01652625|DRUG|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
223438542|NCT01652625|DRUG|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
223566547|NCT05798936|DRUG|Polidocanol|Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
223566548|NCT05798936|DRUG|Alcohol|Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
223740776|NCT00130416|BEHAVIORAL|E-mail coaching to improve patient communication with doctor|
223740777|NCT01066247|DRUG|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
223740778|NCT01066247|DRUG|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
224300347|NCT06127368|DRUG|Oral cohort|Single dose of Aricept tablet.
224300348|NCT00649818|DRUG|Lorazepam Tablets 2 mg|2mg, single dose fasting
224300349|NCT00649818|DRUG|Ativan Tablets 2 mg|2mg, single dose fasting
224300350|NCT03024736|OTHER|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
224300351|NCT03748849|PROCEDURE|Physiotherapy|
224300352|NCT03776721|PROCEDURE|Liposuction|Liposuction is performed on the abdomen or thighs.
223438543|NCT04219839|BEHAVIORAL|SOC + Educational Videos Designed Especially for post-transplant patients|Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
223438544|NCT06304922|BEHAVIORAL|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer|Assess the response to platinum-based chemotherapy in correlation to BRCA status in neoadjuvant and recurrent ovarian cancer
223438545|NCT04888858|DRUG|Epidural analgesia (0.125% bupivacaine/2mcg fentanyl solution)|As part of standard protocol for all patients who receive a labor epidural, the epidural will then be tested using 3ml of 1.5% lidocaine and 1:200,000 epinephrine test solution, and the epidural catheter will then be loaded with 10ml of 0.125% bupivacaine solution. The epidural catheter will then be connected to a programmed intermittent epidural bolus pump which will administer 5ml of a 0.125% bupivacaine/2mcg fentanyl solution every 30minutes. The first dose will be given following 30minutes after the loading dose. 30 minutes after loading the loading dose and after the first pump dose has been given, we will assess the VAS pain scores and the level of the analgesic based on decreased sensation to ice.
223438546|NCT04501016|BEHAVIORAL|Tailored behavioral counseling|Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.
223438547|NCT04501016|DRUG|Tobacco cessation pharmacotherapy|Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.
223438548|NCT02696434|DRUG|Naltrexone|daily dosing
223438549|NCT02696434|DRUG|Placebo|daily dosing
223438550|NCT02696434|DRUG|Buprenorphine|daily dosing
223438551|NCT02411318|BEHAVIORAL|Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
223438552|NCT02411318|DRUG|ProLab 200mg caffeine capsule|Participants will swallow one ProLab caffeine 200mg tablet.
223438553|NCT02411318|OTHER|Ethanol ingestion|Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
223438554|NCT02411318|DRUG|Glucose Tolerance Drink|Participants will consume 100 grams of glucose
223438555|NCT00034918|DRUG|ZD6474|
223438556|NCT00235781|DRUG|Thymoglobulin|
223438557|NCT04895488|DRUG|Vortioxetine|"First treatment phase: vortioxetine will be initiated at 10 mg / day for 2 weeks, followed by 20 mg /day for 22 weeks. The dose of vortioxetine can be lowered to 5 mg or 10 mg for tolerability reasons at clinician criteria.~Wash-out period 2 weeks"
224049721|NCT02672098|DRUG|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
224143671|NCT06249022|BEHAVIORAL|Rehabilitation therapy|Including:Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation. Others: Regular turning, back patting, and position changes performed by caregivers.
223566549|NCT05783310|BEHAVIORAL|Psychoeducation Intervention|The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
223566550|NCT03387007|BEHAVIORAL|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
224143672|NCT06249022|DEVICE|Intermittent Oro-esophageal Tube Feeding|Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding. During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.
223438558|NCT04895488|DRUG|Usual Antipsychotic Treatment|Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
223438559|NCT02435056|OTHER|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~* Minimum Data Set for supporting the diagnosis~* Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~* Second opinion system for improving the management"
223438560|NCT04657575|PROCEDURE|Narcotrend|ECT stimulation within an anaesthesia depth range of 41-64
223438561|NCT06731751|OTHER|Management of spontaneous intracranial haemorrhage|Admission to hospital for spontaneous intracranial haemorrhage management. This includes admission for observation, conservative or interventional (surgical or endovascular) management to both ward-based and critical care settings.
223438562|NCT01200277|PROCEDURE|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
223438563|NCT01200277|PROCEDURE|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
224143673|NCT06249022|DEVICE|Nasogastric tube feeding|The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.
224143674|NCT02091245|DRUG|KPT-330|
224049722|NCT06854913|OTHER|Post-Operative monitoring using wearable biosensor|The protocol involves the use of the Medtronic Zephyr BioPatch™, a wearable biosensor, to monitor sleep quality and patterns in patients recovering from shoulder surgery. The device tracks physiological signals (ECG, HRV, respiratory rate) and postural changes, providing objective data on sleep profiles. Patients are assessed at three key time points: before surgery (baseline), two weeks after surgery (early recovery phase), and 30 days post-surgery (mid-recovery phase). The primary goal is to evaluate changes in sleep quality and patterns during the post-operative period, while also monitoring improvements in shoulder functionality and pain levels. This approach aims to provide insights into the relationship between sleep quality and recovery outcomes following shoulder surgery.
224049723|NCT06854913|OTHER|Usability Assessment and Patient Willingness to Use Technology Description|The usability of the Medtronic Zephyr BioPatch™ is evaluated through patient feedback and questionnaires, focusing on comfort, ease of use, and reliability. Additionally, patient willingness to continue using the wearable sensor for sleep monitoring is assessed. This evaluation helps determine the practicality and acceptance of the technology in real-world rehabilitation settings, providing insights into its potential for long-term use in clinical practice.
224049724|NCT06655909|OTHER|consumption of maize porridge containing stable iron isotope|consumption of maize porridge containing stable iron isotope
224049725|NCT06985810|OTHER|Accentuated Eccentric Loading training|18 particpants will train in AEL group for three days a week for eight weeks and each session will take about 60-75 minutes, focusing on eccentric exercises like back squats, leg press, and hip thrusts at 90% 1RM intensity. Sessions, supervised by coaches, include free weight and weight machine exercises. Performance tests (20m sprint, T-agility, broad jump, 1RM assessments) will evaluate progress at the study's start and end.
224143675|NCT05007015|PROCEDURE|Transanal Irrigation|Each participant will receive a mailed package of TAI materials, given access to the LARS website, and have two scheduled virtual visits with a trained research nurse to learn how to use TAI once assigned to the intervention arm. These sessions will include one on one session with the nurse for review of the material, discussion of the device and any questions. TAI involves introducing an applicator into the anus for irrigation. An initial volume of 1000 mL will be suggested but can be increased to 1500 mL or reduced to 500 mL as per patient preference and tolerance. Applicators are single-use instruments that can be disposed of into standard waster receptacle after each treatment. The irrigation system is multiple-use and can be used for the duration recommend by the manufacturer manual. Daily irrigation can take anywhere between 20 and 90 minutes depending on individual patient experience.
224143676|NCT05879250|PROCEDURE|Biospecimen Collection|Undergo collection of blood
224143677|NCT05879250|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224143678|NCT05879250|RADIATION|Radiation Therapy|Undergo routine radiation therapy
224143679|NCT05879250|DRUG|STAT3 Inhibitor WP1066|Given PO
224143680|NCT05879250|PROCEDURE|Surgical Procedure|Undergo removal or biopsy of tumor
223566551|NCT04171791|DRUG|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
224143681|NCT03814967|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
223566552|NCT01663324|DEVICE|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
223740779|NCT05202509|DRUG|Obicetrapib|10mg obicetrapib tablet
224300353|NCT03776721|PROCEDURE|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
223740780|NCT05202509|DRUG|Placebo|Placebo tablet to resemble obicetrapib
223740781|NCT02260479|PROCEDURE|Preheated|Skin disinfection solution is preheated in a warming cupboard
223438564|NCT00747253|DEVICE|AutoLITT system|laser treatment with the AutoLITT system
223438565|NCT05080361|DRUG|BRAF inhibitor|Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
223438566|NCT02455973|BEHAVIORAL|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
223438567|NCT02455973|BEHAVIORAL|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
223438568|NCT04277767|DIAGNOSTIC_TEST|observational|No intervention
223438569|NCT00805519|DRUG|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
223438570|NCT00805519|DRUG|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
223438571|NCT00805519|DRUG|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
223438572|NCT00805519|DRUG|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
223438573|NCT04347655|PROCEDURE|handgrip test|The patient will be supine for at least 5 minutes to collect baseline data before being handed a dynamometer device. The subject will then be asked to squeeze the dynamometer with maximum force for a minimum of 2 minutes while only engaging their forearm and remaining relaxed in the rest of their body. The subject will then release the dynamometer and remain supine, in recovery, for a minimum of 5 minutes.
223438574|NCT04655534|OTHER|Inspiratory Muscle Warm-up (IMW)|The IMW protocol applied before each inspiratory muscle training (IMT) session by using a threshold inspiratory muscle trainer. The IMW protocol consists of 2 sets of 30 breaths in 40% of the maximal inspiratory pressure (MIP), with 1 min rest between sets. The intensity of MIP adjusted by two weekly MIP measurements.
223438575|NCT04655534|OTHER|Inspiratory Muscle Training (IMT)|The IMT applied twice a day as 30 breath repetitions at 60% of the maximal inspiratory pressure (MIP). The intensity of MIP adjusted by two weekly MIP measurements.
223438576|NCT04655534|OTHER|Respiratory exercises and aerobic exercise program|Then the respiratory exercises and aerobic exercise program performed in both groups in each session. Aerobic exercise program; After 5 min of general body warming, applied 20 min with a load of 4-6 according to the modified Borg scale on the treadmill, finished with 5 min whole body cool-down. All program applied to 3 days a week for 8 weeks under the supervision of a physiotherapist and other days of the week without a supervisor.
223438577|NCT04103034|DRUG|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
223438578|NCT04103034|DRUG|Desmopressin|Sterile solution for injection
223438579|NCT04103034|DRUG|Placebo|Sterile saline for injection
223438580|NCT00316914|DRUG|calcium gluconate|Given IV
223438581|NCT00316914|DRUG|magnesium sulfate|Given IV
223566553|NCT01663324|DEVICE|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
224049726|NCT06985810|OTHER|Flywheel exercises|18 particpants will train in FW group for three days a week for eight weeks and each session will take about 60-75 minutes, incorporating compound movements, Flywheel exercises (squats, sprints, jumps), and relevant free weight and weight machine exercises. Supervised sessions maintain consistent parameters. Performance tests (20m speed, T-agility, broad jump, 1RM assessments) will measure improvements at study start and end for evaluation.
224300354|NCT03776721|PROCEDURE|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
223438582|NCT00316914|OTHER|placebo|Given IV
223438583|NCT05457114|DEVICE|Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA)|PAC was inserted and connected to a continuous cardiac output monitor (Vigilance I from 2006 to 2012; Vigilance II from 2012 to 2022, Edward Lifesciences, Irvine, USA)
223438584|NCT05457114|DEVICE|FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA)|Without PAC, monitoring with FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) was performed for continuous cardiac output monitoring.
223438585|NCT01589679|OTHER|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
223438586|NCT01589679|DEVICE|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
223438587|NCT02687295|DIETARY_SUPPLEMENT|Thylakoids|
223438588|NCT02687295|OTHER|Control|
223438589|NCT03038776|BIOLOGICAL|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
223566554|NCT03610945|DRUG|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
224300355|NCT03776721|BIOLOGICAL|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
224300356|NCT03776721|PROCEDURE|Saline injection|4mL saline injected at the affected axillary site.
224143682|NCT06605430|DRUG|Medical Cannabis|The Early Cannabis group will be provided with 8 weeks of medical cannabis at no charge. Following 8 weeks of cannabis, the Early Cannabis group will be observed as per standard of care for the remaining 8 weeks. The Delayed Cannabis group will receive usual care for the first 8 weeks, and then be provided up to 8 weeks of medical cannabis at no charge for the second 8 weeks. Prior to receiving cannabis, patients must first be certified by a provider for eligibility to receive medical cannabis before registering with the Minnesota Medical Cannabis Program. Collective experience with precise dosage CBMs supports a pharmacist-guided titration protocol with robust patient input and close patient follow up. The treating pharmacist in the Minnesota Medical Cannabis Program thoroughly instructs patients on dose titration at the initial visit.
224143683|NCT05256082|DIAGNOSTIC_TEST|six-minutes-walking test|Patients conducting a six-minutes-walking test
224143684|NCT00957255|DEVICE|OrthoADAPT|soft tissue augmentation device
224143685|NCT00957255|PROCEDURE|Standard of care|Standard of care rotator cuff repair
223438590|NCT04780633|BEHAVIORAL|Precede-Proceed based Training Program on Genital Hygiene Behaviors|A Training Program for Genital Hygiene Behaviors prepared in line with the Precede-Proceed model was presented to the women in the experimental group. The trainings started one week after the pre-test data were collected and were conducted in a total of 5 sessions, each lasting an average of 40 minutes, once a week. At the end of the five-week training, a post-test was applied. In order to determine the behavior changes of the women in the experimental group, a follow-up test was applied 4 weeks after the training ended. At the end of the training, women were given a training booklet prepared by the researcher.
223438591|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in NSCLC|Stage 3 NSCLC with radical curative intent at baseline (pre-treatment) and at 4-8 weeks into treatment.
223438592|NCT05889312|DIAGNOSTIC_TEST|18F-FSPG PET/CT in HNSCC|Stage 3 and 4 HNSCC with radical curative intent at baseline and at 2-4 weeks into treatment.
223566555|NCT03610945|DRUG|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
223566556|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
224049727|NCT06985602|COMBINATION_PRODUCT|Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery|"* Adebrelimab: Given concurrently with chemotherapy, 1200mg by intravenous infusion every three weeks for four cycles.~* Chemotherapy: Oxaliplatin 130mg/m² on day 1 + Capecitabine 1000mg/m² bid (XELOX regimen), from day 1 to day 14, repeated every three weeks for four cycles;~* Radiotherapy: Unresectable limited metastatic lesions with SBRT; Potentially resectable lesions with low-dose radiotherapy.~* Surgery: Performed 3-5 weeks after the completion of conversion therapy."
224049728|NCT06986252|OTHER|Consultation|Consultations at a specialist surgical nurse-led clinic
224143686|NCT03519672|OTHER|No intervention|This is a non-interventional study.
224143687|NCT01381718|DRUG|modafinil|Given PO
223566557|NCT03610945|DRUG|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
223566558|NCT04903873|DRUG|EU101|EU101 will be administered via intravenous infusion.
224049729|NCT06984237|DIAGNOSTIC_TEST|TNF-α Analysis in saliva|Unstimulated whole saliva samples will be collected in the morning, at least one day after periodontal examination. Participants will be instructed to refrain from eating, drinking, brushing, or chewing gum for at least one hour before collection. The samples will be centrifuged at 1500 rpm for 10 minutes, and the supernatants will be stored at -80°C until analysis. TNF-α levels will be measured using ELISA.
224049730|NCT06984237|DIAGNOSTIC_TEST|IL-17A analysis in saliva|Unstimulated whole saliva samples will be collected in the morning, at least one day after periodontal examination. Participants will be asked to avoid eating, drinking, brushing their teeth, or chewing gum for at least one hour prior to sampling. The samples will be centrifuged at 1500 rpm for 10 minutes, and the supernatants will be stored at -80°C until analysis. IL-17A levels will be determined using ELISA.
224143688|NCT01381718|OTHER|placebo|Given PO
224143689|NCT03795818|BEHAVIORAL|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
224143690|NCT02570282|DRUG|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
224143691|NCT02570282|DRUG|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
224143692|NCT01668030|DRUG|Enzymatic agent|Enzymatic agent
224143693|NCT01668030|DRUG|Bacitracin|
224143694|NCT03634917|DRUG|Acamprosate Calcium|1 capsule with 666 mg Acamprosate
224143695|NCT03634917|DRUG|Calcium Carbonate|1 capsule with 1500 mg Calcium Carbonate
224143696|NCT03634917|DRUG|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
224143697|NCT03634917|DRUG|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
224143698|NCT01701219|DRUG|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
223566559|NCT02493257|DRUG|Capsaicin|
223566560|NCT02493257|DRUG|Placebo|
223566561|NCT01456208|DRUG|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
223566562|NCT01456208|DRUG|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
223566563|NCT01456208|DRUG|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
223566564|NCT00809991|RADIATION|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
223566565|NCT04690907|BEHAVIORAL|Dietary intervention|Written material on healthy diet during pregnancy and 2 virtual dietary counseling sessions.
223566566|NCT03897725|OTHER|Telehealth Coaching|Telehealth coaching to promote adherence
223566567|NCT05460364|DRUG|BR1018-1|"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
223438593|NCT04035629|COMBINATION_PRODUCT|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
223438594|NCT04105010|DRUG|golidocitinib|golidocitinib will be administered orally as capsules. golidocitinib treatment will be continued until disease progression or intolerant adverse reactions
223438595|NCT06944860|DEVICE|Conventional TBA|Conventional TBA fabricated with polymethylmethacrylate
223438596|NCT06944860|DEVICE|3D TBA|3D TBA made out of a 3D printing resin (Graphy TR07)
223438597|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
223438598|NCT01072578|DRUG|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
224143699|NCT00870974|DRUG|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]F-PEB
224143700|NCT06365476|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the flexor carpi ulnaris, flexor carpi radialis, and flexor digitorum superficialis.
224049731|NCT06984237|DIAGNOSTIC_TEST|YKL-40 Analysis in saliva|Unstimulated whole saliva samples will be obtained from participants in the morning, at least one day after the periodontal clinical assessment. They will be instructed not to eat, drink, chew gum, or brush their teeth for at least one hour before collection. Samples will be centrifuged at 1500 rpm for 10 minutes, and the clear supernatants will be stored at -80°C until the time of analysis. YKL-40 levels will be measured using ELISA.
224143701|NCT05420194|OTHER|Postural stability measurement|Postural stability of the participants will be evaluated with the NeuroCom Balance Master Static Posturography device. Evaluations will be carried out in the presence of two physiotherapists to prevent the patient from falling. Posturography devices allow us to quantitatively evaluate posture and balance and obtain objective results by measuring postural sway.
223566568|NCT05460364|DRUG|BR1018-2|"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."
224143702|NCT05420194|OTHER|Timed Up and Go test|During the Timed Up and Go test, which is applied to evaluate dynamic balance and performance, the participant is asked to get up from the chair, walk 3 meters and sit back on the chair. The participant's time to complete the test is recorded. Completion of the test for more than 10 seconds indicates an increased risk of falling
224143703|NCT02538367|DRUG|YH12852 IR 0.05mg|
224143704|NCT02538367|DRUG|YH12852 IR 0.1mg|
224143705|NCT02538367|DRUG|YH12852 IR 0.3mg|
224143706|NCT02538367|DRUG|YH12852 IR 0.5mg|
223438599|NCT04735471|GENETIC|ADI-001|Anti-CD20 CAR-T
224143707|NCT02538367|DRUG|YH12852 IR 1mg|
224143708|NCT02538367|DRUG|YH12852 IR 2mg|
224143709|NCT02538367|DRUG|YH12852 IR 3mg|
224143710|NCT02538367|DRUG|YH12852 DR1 0.5mg|
224143711|NCT02538367|DRUG|YH12852 DR1 1mg|
224143712|NCT02538367|DRUG|YH12852 DR1 2mg|
224143713|NCT02538367|DRUG|YH12852 DR1 4mg|
224143714|NCT02538367|DRUG|YH12852 DR2 8mg|
224143715|NCT02538367|DRUG|Prucalopride 2mg|
224300357|NCT00952549|PROCEDURE|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
223438600|NCT04735471|DRUG|Fludarabine|Chemotherapy for Lymphodepletion
223438601|NCT04735471|DRUG|Cyclophosphamide|Chemotherapy for Lymphodepletion
223438602|NCT05480228|DRUG|NRD135SE.1|The double-blind treatment phase is up to 13 weeks.
223566569|NCT02980146|OTHER|Non interventional study|
223438603|NCT05480228|OTHER|Placebo|A matching placebo will be taken for up to 13 weeks.
223438604|NCT05279937|DRUG|Dextrose 50% Intravenous Solution|5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
223740782|NCT05992597|DRUG|ZR2 RDHAP|ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
224143716|NCT02538367|DRUG|Placebo|
224143717|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation.|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days"
224143718|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
224300358|NCT04050150|BEHAVIORAL|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
224300359|NCT01169532|DRUG|ridaforolimus|Given PO
224300360|NCT01169532|DRUG|vorinostat|Given PO
223438605|NCT05279937|DRUG|Lidocaine 1% Injectable Solution|10mL of 1% Lidocaine (Control)
223438606|NCT03701698|DRUG|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet （Jakafi）, 5\~10mg bid po for at least 28 days.
224049732|NCT06984237|DIAGNOSTIC_TEST|TNF-α analysis in serum|A total of 8 mL of venous blood will be collected from the antecubital fossa of seated participants. Samples will be transferred into BD Vacutainer® SST™ II Advance serum separator tubes containing acrylic gel and will be allowed to clot for 30 minutes at room temperature. The samples will then be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The resulting serum will be transferred into Eppendorf tubes using a Pasteur pipette and will be stored at -80°C until analysis. TNF-α levels will be measured using ELISA.
224300361|NCT01169532|PROCEDURE|biopsy|Optional correlative studies
223438607|NCT03701698|DRUG|Methylprednisolone|Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
223438608|NCT01675154|DRUG|SLx-4090 placebo|Given for 4 weeks
223438609|NCT01675154|DRUG|Orlistat Placebo|Given for 4 weeks
223438610|NCT01675154|DRUG|Orlistat|Given for 4 weeks
223438611|NCT01675154|DRUG|Slx-4090|Given for 4 weeks
223438612|NCT00541008|DRUG|sunitinib malate|
223438613|NCT06490172|DEVICE|Shock wave therapy|Radial Extracorporeal Shock Wave Therapy and feasibility as treatment for adhesive capsulitis
223438614|NCT04268654|PROCEDURE|Preoperative Arterial Embolization|"PAE will be performed by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. Embolization by coils of the left gastric artery, splenic artery and the right gastric artery is realized."
224049733|NCT06984237|DIAGNOSTIC_TEST|IL-17A analysis in serum|A total of 8 mL of venous blood will be obtained from the antecubital fossa of participants in a seated position. After collection, the blood will be placed into BD Vacutainer® SST™ II Advance tubes with acrylic gel and will rest for 30 minutes to allow clotting. The samples will be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The serum will be extracted using a Pasteur pipette and stored in Eppendorf tubes at -80°C until analysis. IL-17A levels will be analyzed using ELISA.
223438615|NCT02210169|DRUG|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
223438616|NCT04202289|DEVICE|Nile Tilapia Fish Skin|In the search of new therapies for burns, the skin of Brazil's most cultivated fish, the Nile tilapia, which was mostly a waste product (although sometimes used as a resistant material for artisanal handicraft), was suggested as a possibility for the development of a low-cost xenograft. Apart from non-infectious microbiota, Nile Tilapia Fish Skin presented histomorphological similarities with human skin in pre-clinical studies. It was shown to have a deep dermis formed by thick collagen fibers organized on parallel/horizontal and transversal/vertical arrangement and composed, in comparison, by larger amounts of type I collagen. Nile Tilapia Fish Skin did not present variations in its microscopic structure and tensile strength after glycerolization, irradiation and posterior rehydration, recovering its natural consistency after glycerol removal.
223438617|NCT04202289|DRUG|Silver Sulfadiazine Cream 1%|Topical antibiotic commonly used for the treatment of superficial and deep partial-thickness burns.
223438618|NCT00556738|PROCEDURE|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
223438619|NCT00556738|PROCEDURE|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
223438620|NCT00427999|DRUG|imatinib mesylate|
223438621|NCT00427999|DRUG|Treosulfane|
223438622|NCT00427999|DRUG|etoricoxib|
223438623|NCT00427999|DRUG|pioglitazone|
223438624|NCT00427999|DRUG|dexamethasone|
223438625|NCT03889938|DIAGNOSTIC_TEST|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
223438626|NCT02380859|BEHAVIORAL|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
223438627|NCT00098462|DRUG|gefitinib|
223438628|NCT00098462|DRUG|sirolimus|
223438629|NCT03767777|DEVICE|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
223438630|NCT06543719|OTHER|Simulated work in the heat|Participants perform a continuous heavy-intensity work bout (metabolic rate of \~260 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 1:1 work-rest allocation, starting with a 30 min rest break followed by a 30 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
223438631|NCT02284568|DRUG|Placebo|Placebo
224049734|NCT06984237|DIAGNOSTIC_TEST|YKL-40 analysis in serum|Venous blood (8 mL) will be drawn from the antecubital fossa of seated participants. The samples will be placed in BD Vacutainer® SST™ II Advance tubes containing acrylic gel and will be left to clot for 30 minutes at room temperature. Following this, the samples will be centrifuged at 1500 rpm for 10 minutes at 18-25°C. The supernatant serum will be separated with a Pasteur pipette and transferred into Eppendorf tubes. All samples will be stored at -80°C until analysis. YKL-40 levels will be measured using ELISA.
224300362|NCT01169532|OTHER|pharmacological study|Correlative studies
224300363|NCT01169532|OTHER|laboratory biomarker analysis|Correlative studies
224300364|NCT01622374|BEHAVIORAL|Music|Ten minutes of music or silence were applied prior to dental procedures
224300365|NCT01775865|DRUG|Salsalate|4 weeks of daily salsalate
224300366|NCT01775865|DRUG|Placebo (for salsalate)|4 week of daily placebo
224300367|NCT01716689|DRUG|oral cyclophosphamide|50mg daily
224049735|NCT06984237|DIAGNOSTIC_TEST|Clinical periodontal evaluation|Clinical periodontal parameters will be recorded from participants who meet the inclusion criteria. The following indices will be measured from all teeth present in the oral cavity: Plaque Index (PI; Silness \& Löe, 1964), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), and Bleeding on Probing (BOP). Radiographic evaluations will also be performed. All measurements will be conducted by the same calibrated clinician (HD) using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA).
224049736|NCT06985511|PROCEDURE|Immediate implant placement|Tooth extraction was performed atraumatically on one side, followed by immediate implant placement, right after extraction.
224049737|NCT06985511|PROCEDURE|Early implant placement|The tooth was extracted, and the implant was placed four weeks later (early placement).
223438632|NCT02284568|DRUG|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
223438633|NCT02284568|DRUG|Placebo|Placebo capsules
223438634|NCT05483101|OTHER|Alternative birth units|"Midwife-led alternative birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative birth units named Filière physiologique (FP) co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room."
223438635|NCT04487483|BEHAVIORAL|Sleep App|A sleep app offering 6 evidence based techniques to improve sleep (such as Cognitive Behavioural Therapy for Insomnia, Progressive Muscle Relaxation and Mindfulness Meditation), allowing for a personally tailored journey of sleep aids within the app.
223438636|NCT02953587|PROCEDURE|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
223438637|NCT02953587|DRUG|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
224049738|NCT06984445|DIAGNOSTIC_TEST|Cord blood S100B protein level prior to IUT|One milliliter of cord blood will be collected before each IUT procedure to measure S100B protein concentration. The sample will be labeled with the mother's name, date of birth, collection date, and IUT indication, then sent to the laboratory for centrifugation.
224143719|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased."
224143720|NCT04346693|PROCEDURE|Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection combined with Leitragin inhalation|"Hydroxychloroquine + azithromycin + / - tocilizumab. Hydroxychloroquine intake is conducted according to the following schedule: 400 mg twice per day for 1-2 days of the treatment and 200 mg twice per day during six days of the treatment course.~For the tocilizumab, 400 mg intravenously drip slowly (for at least 1 hour), with insufficient effect, administration is repeated the after 12 hours. Simultaneously no more than 800 mg of tocilizumab could be administered.~For the azithromycin admission 500mg on day 1 is prescribed followed by 250mg per day, the next four days.~Additional inhalation of the drug Leitragin, at a dose of 10 mg daily once per day until the symptoms of pulmonary complications will be ceased.~Additional intramuscular injection of the drug Dalargin (solution for intravenous and intramuscular doses) under dosage of 1 mg daily once per day for 10 days"
224143721|NCT01057914|DIETARY_SUPPLEMENT|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
224143722|NCT01057914|OTHER|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
224143723|NCT01057914|OTHER|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
224143724|NCT01522443|DRUG|cabozantinib|Tablets taken orally once daily.
224143725|NCT01522443|DRUG|mitoxantrone|Given by IV once every 3 weeks.
224143726|NCT01522443|DRUG|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
223438638|NCT02953587|DRUG|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
223438639|NCT04738422|DRUG|Alkaline glycine|Subjects will inhale alkaline glycine via nebulizer. Alkaline glycine is an alkaline medication designed for medication.
223438640|NCT06037525|DEVICE|PowerGlide™ Pro Midline Catheter|Clinical evaluation of the PowerGlide™ Pro Midline Catheter in patients with vascular disease
223438641|NCT06119243|DEVICE|Vivior|The Vivior is a wearable clip-on sensor that objectively quantifies near viewing distance and duration, and ambient illumination. The Vivior will be attached to the spectacles frame of children undergoing myopia control treatment.
223438642|NCT04643418|DRUG|MPB-1734|Administered once daily in a 21-day cycle
223438643|NCT02581228|DEVICE|ML-PrediCare|
224143727|NCT01256983|BEHAVIORAL|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
224143728|NCT01256983|BEHAVIORAL|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
224143729|NCT01444313|DEVICE|narafilcon A contact lens|Soft contact lenses with UV protection
223438644|NCT05167175|DRUG|Olaparib tablet|Lynparza (Olaparib tablets) 300 mg should be taken orally twice daily.
223566570|NCT06066021|OTHER|health educational sessions in diabetic patients type 2.|Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
223438645|NCT05167175|DRUG|Abiraterone acetate|Qingkeshu (Abiraterone acetate tablets) 1000 mg should be taken orally once daily.
223438646|NCT05167175|DRUG|Prednisone tablet|Prednisone Tablets should be taken 5 mg once daily.
223438647|NCT00641875|PROCEDURE|Nocturnal Hemodialysis|
223438648|NCT00385775|DRUG|AEG35156|weekly IV solution infused over 2 hrs
223438649|NCT02454075|DRUG|YF476|Gastrin receptor antagonist
223438650|NCT00237471|DRUG|Insulin (tight blood glucose control)|
223438651|NCT02631278|DEVICE|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
223438652|NCT00150397|DRUG|Tofimilast|
223438653|NCT03921970|OTHER|ESP block (Group ESP)|Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. The PCA device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 20 mcg bolus without infusion dose, 20 min lockout time and 4 hour limit.
224049739|NCT06984445|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis prior to IUT|Half a milliliter of cord blood will be collected before each IUT procedure for immediate umbilical cord blood gas analysis, including pH, base excess (BE), and lactate levels.
224049740|NCT06984445|DIAGNOSTIC_TEST|Fetal blood count evaluation prior to IUT|Fetal blood count data, including hemoglobin and hematocrit levels, will be collected before each IUT procedure.
224049741|NCT06984445|DIAGNOSTIC_TEST|Cord blood S100B protein concentration at birth|After delivery, one milliliter of blood will be collected from the severed umbilical cord to measure the concentration of S100B protein. The sample will be labeled with the mother's name, the child's birth date and sex, and the collection date, before being sent to the laboratory for centrifugation.
224049742|NCT06984445|DIAGNOSTIC_TEST|Umbilical cord blood gas analysis at birth|After birth, 0.5 mL of blood will be collected from the severed umbilical cord to assess pH, base excess (BE), and lactate levels in an umbilical cord blood gas analysis.
224049743|NCT06984445|DIAGNOSTIC_TEST|Complete blood count after birth|Complete blood count parameters, including hematocrit (Hct) and hemoglobin (Hgb) concentrations, will be measured within six hours after birth.
224049744|NCT06984445|DIAGNOSTIC_TEST|Ultrasound evaluation of fetal blood flow|Fetal cerebral blood flow will be routinely assessed via ultrasound, including measurements of MCA-PSV values.
223438654|NCT01685957|BEHAVIORAL|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
223438655|NCT01685957|BEHAVIORAL|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
224049745|NCT06984445|DIAGNOSTIC_TEST|Neonatal transfontanelle ultrasound assessment|A transfontanelle ultrasound examination will. be performed to assess for any abnormalities in the newborn.
224143730|NCT01444313|DEVICE|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
224143731|NCT04744636|DRUG|Other|"Healthy volunteers will be selected within 3 weeks before inclusion (Day 0). The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and Case Report Form (CFR) on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP) :~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
223438656|NCT01685957|BEHAVIORAL|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
223438657|NCT02777944|BEHAVIORAL|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
223438658|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT|Residual rotator cuff defect will be reconstructed using LHBBT.
224049746|NCT06984445|DIAGNOSTIC_TEST|Complete blood count analysis in cord blood at birth|Complete blood count parameters, including hematocrit (Hct) and hemoglobin (Hgb) concentrations, will be measured in cord blood samples collected at birth.
224049747|NCT06986005|OTHER|No intervention will be performed as part of this study. However, regardless of the study, all participants will receive neoadjuvant chemotherapy.|All participants will receive neoadjuvant chemotherapy appropriate to the characteristics of their breast cancer as part of their standard care.
224049748|NCT06984198|BEHAVIORAL|Sandplay Therapy|Sandplay Therapy - The objects involved in this form of therapy are: sandtray, sand, multiple figurines in all categories (people, animals, buildings, vehicles, vegetation, structures, natural objects and symbolic objects). The subject engaging in this therapy is instructed to build a sand picture with the minatures present. There is no time limit to these sessions; however, they tend to be 20-30 minutes long. Upon completion of their sand picture the child, if comfortable, may elaborate on their creation.
223438659|NCT06016439|PROCEDURE|Arthroscopic rotator cuff partial repair|Rotator cuff will be repaired with remaining residual defect.
223438660|NCT06016439|PROCEDURE|Arthroscopic complete rotator cuff repair|Arthroscopic complete repair as a standard procedure.
223438661|NCT06016439|DEVICE|Suture anchor(s)|Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
223566571|NCT04640493|DRUG|Dapagliflozin|If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.
224049749|NCT06984198|BEHAVIORAL|Art Therapy|"Art Therapy - The instruments used in this form of therapy are: a blank 8 x 11 paper and coloring utensils (markers, crayons, and color pencils). During each 30-minute session, the subject is informed to draw whatever they feel with the coloring utensils provided. Possible drawing topics may include: their family, a memory of their life back in their country of origin, or something from their imagination."
224049750|NCT06984978|COMBINATION_PRODUCT|AI-assisted, village doctors and express services-involved personalized fall prevention strategy|"The EXPRESS trial implements a pragmatic, community-based, AI-assisted fall prevention strategy tailored to the needs of older adults in rural China. The intervention is structured around five core components-SAFER:~1. Screening: multidimensional fall risk screening and assessment tailored to rural older adults;~2. AI-assisted recommendations: AI-assisted personalized fall prevention recommendations;~3. Fitness: Tailored balance and strength training via Health Intervention Cartoon Brochure and Action Demonstration Video;~4. Events-based engagement: culturally integrated seasonal intervention packages following the traditional Chinese calendar;~5. Reach-home delivery: home delivery of fall prevention services through local couriers."
224049751|NCT06984809|BEHAVIORAL|Intervention|The intervention group will receive Invest in Play (iiP), a 12 session group-based parent program, which is led by two trained group leaders.
224049752|NCT06986044|DIAGNOSTIC_TEST|Serum Total Oxidant Status|Serum total oxidant status
224049753|NCT06986044|DIAGNOSTIC_TEST|Salivary Total Oxidant Status|Salivary Total Oxidant Status
224049754|NCT06986044|DIAGNOSTIC_TEST|Serum Total Antioxidant Status|Serum Total Antioxidant Status
224049755|NCT06986044|DIAGNOSTIC_TEST|Salivary Total Antioxidant Status|Salivary Total Antioxidant Status
224049756|NCT06986044|DIAGNOSTIC_TEST|Serum Oxidative Stress Index|Serum Oxidative Stress Index
224049757|NCT06986044|DIAGNOSTIC_TEST|Salivary Oxidative Stress Index|Salivary Oxidative Stress Index
224049758|NCT06986044|DIAGNOSTIC_TEST|Serum Arylesterase|Serum Arylesterase
224049759|NCT06986044|DIAGNOSTIC_TEST|Salivary Arylesterase|Salivary Arylesterase
223438662|NCT03546010|BEHAVIORAL|Neuropsychological tests|WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
223566572|NCT04640493|DEVICE|WatchPat|HF patients undergo SDB testing with the WatchPat device. (non-experimental)
224049760|NCT06986044|DIAGNOSTIC_TEST|Serum Heme Oxygenase|Serum Heme Oxygenase
224049761|NCT06986044|DIAGNOSTIC_TEST|Salivary Heme Oxygenase|Salivary Heme Oxygenase
224049762|NCT06986044|DIAGNOSTIC_TEST|Serum Nuclear Factor Erythroid 2 Related Factor 2|Serum Nuclear Factor Erythroid 2 Related Factor 2
224049763|NCT06986044|DIAGNOSTIC_TEST|Salivary Nuclear Factor Erythroid 2 Related Factor 2|Salivary Nuclear Factor Erythroid 2 Related Factor 2
223438663|NCT03546010|BEHAVIORAL|Oculometric tests|When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
223438664|NCT03754855|BEHAVIORAL|Questionnaire|Questionnaire
223438665|NCT01966419|DRUG|ornithine phenylacetate|Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
223438666|NCT01966419|DRUG|placebo intravenous infusion|Placebo for continuous IV infusion that is visually identical to the experimental product
223566573|NCT05250076|DEVICE|Kinesio Tape|"The beige Kinesio Tape (Prim Tape®) will be applied, from distal to proximal, 5cm wide, cut in I and with tension below 50%. The Kinesio Tape will be placed along the entire path of the median nerve, from the wrist to the armpit. The participants will remain in the supine position on a treatment table (Posturarte® Olympic), without inclination."
223566574|NCT00895752|DRUG|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
223566575|NCT05564884|OTHER|no intervantion|no intervention
223740783|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
224049764|NCT06986044|DIAGNOSTIC_TEST|Gingival Index|Gingival Index
224049765|NCT06986044|DIAGNOSTIC_TEST|Plaque Index|Plaque Index
224049766|NCT06986044|DIAGNOSTIC_TEST|Bleeding on Probing Index|Bleeding on Probing Index
224049767|NCT06986044|DIAGNOSTIC_TEST|Clinical Attachment Loss|Clinical Attachment Loss
224049768|NCT06986044|DIAGNOSTIC_TEST|Pocket Deep|Pocket Deep
224049769|NCT06984146|DRUG|Nivolumab|40 mg day 1 and 15
224049770|NCT06984146|DRUG|Doxorubicin|25 mg/m2 day 1 and 15
224049771|NCT06984146|DRUG|Vinblastine|6 mg/m2 (not exceeding 10 mg) day 1 and 15
224049772|NCT06984146|DRUG|Dacarbazine|375 mg/m2 day 1 and 15
224049773|NCT06986057|DRUG|Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy|Iparomlimab and tuvonralimab (QL1706) combined with platinum-based chemotherapy
224049774|NCT06984640|DIETARY_SUPPLEMENT|Curcumin|Each capsule contained 400 mg of a patented lipophilic matrix, delivering 80 mg of curcumin. Longvida® is a trademark of Vendure Sciences, Noblesville, IN, USA.
224049775|NCT06984640|DIETARY_SUPPLEMENT|Placebo|Each capsule contained 400 mg of a patented lipophilic matrix, delivering 80 mg of curcumin.
224049776|NCT06985030|DEVICE|gyroscope embedded eye-sheild|Small pcb with gyroscope and lithium polymer battery embedded eyeshield will be distributed right after surgery
224049777|NCT06984016|OTHER|Work-related Musculoskeletal Disorders Risk Among Physical Therapists|217 Males and females Egyptian physical therapists at will be included in the study.
224049778|NCT06985290|DRUG|Dexmedetomidine Infusion|Dexmedetomidine infusion given for sedation during therapeutic hypothermia. Dexmedetomidine infusion at a starting dose of 0.2 μg/kg/h, with titration in 0.1 μg/kg/h increments with a maximum of 0.5 μg/kg/h based on objective assessment of sedation.
224049779|NCT06985290|DRUG|Morphine Infusion|Morphine infusion given for sedation during therapeutic hypothermia. Morphine infusion at a starting dose of 4 μg/kg/h, with titration in 2 μg/kg/h increments with a maximum of 10 μg/kg/h based on objective assessment of sedation.
223438667|NCT06840080|OTHER|Placebo|Single dose of 2 capsules. Capsules contain the same excipients as the active arms, except for the OEA with LipiSperse in capsules that appear identical to the OEA with LipiSperse capsules
223438668|NCT06840080|DIETARY_SUPPLEMENT|125mg OEA with LipiSperse|Single dose of 2 capsules. 1 capsule contains 125mg of OEA and 13.9mg of LipiSperse, the other capsule is a placebo.
223438669|NCT06840080|DIETARY_SUPPLEMENT|250mg OEA with LipiSperse|Single dose of 2 capsules. Each capsule contains 125mg of OEA and 13.9mg of LipiSperse.
223438670|NCT01484093|OTHER|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
223438671|NCT00266591|DRUG|topiramate|
223438672|NCT01152216|DRUG|Dimebon|20 mg orally three times daily
223438673|NCT02466217|OTHER|1: AID groups|Clinical and Biological investigations
223438674|NCT02466217|OTHER|2: Control groups|Clinical and Biological investigations
223438675|NCT00697034|DRUG|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
223438676|NCT04984317|DRUG|onabotulinumtoxin A|One-time injection of 100U BOTOX
223438677|NCT05146063|DIAGNOSTIC_TEST|Take the patient's subcutaneous fat tissue to detect the expression of LNK|Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.
223438678|NCT01420679|DRUG|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met."
223438679|NCT04605432|DRUG|PEG-FFI|"Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher."
223438680|NCT04605432|DRUG|PEG-nonFFI|"All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse."
223438681|NCT06519409|PROCEDURE|Open flap debridement and photodynamic therapy|
224049780|NCT06655454|DRUG|Supplemental Postoperative Bupivacaine|This is the intervention of interest. A supplemental injection of bupivacaine will be given postoperatively to patients who are assigned this intervention.
223438682|NCT00943670|BIOLOGICAL|pertuzumab|Intravenous repeating dose
223438683|NCT00943670|BIOLOGICAL|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
223438684|NCT03956615|OTHER|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
223438685|NCT05046431|DRUG|BAT2506|50mg/0.5mL
223438686|NCT05046431|DRUG|EU Simponi|50mg/0.5mL
223438687|NCT03713840|BEHAVIORAL|Healthy Beverages in Child Care|12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
223438688|NCT03484221|DRUG|FOLFOXIRI|IRINOTECAN 150 mg/m\^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m\^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m\^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m\^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
223438689|NCT03484221|RADIATION|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy\*5) after 4 cycles of FOLFOXIRI.
223438690|NCT03484221|DRUG|XELOX|OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
223438691|NCT00073892|DRUG|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
224049781|NCT06655454|DRUG|Placebo Injection|This intervention will appear to give patients an additional injection, but no additional drug will be given.
223438692|NCT01038414|BEHAVIORAL|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
223438693|NCT00624559|DRUG|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
223438694|NCT00624559|OTHER|Placebo|Placebo pill taken twice per day on each day of the diet
223438695|NCT04385875|BIOLOGICAL|Vaccine + extension of the ATI period|During the AELIX-002 trial participants received the following: DNA.HTI at weeks 0, 4, and 8 and MVA.HTI at weeks 12 and 20 (DDDMM) followed by ChAdOx1.HTI at weeks 0 and 12 and MVA.HTI at week 24 (CCM), starting at least 24 weeks after MVA.HTI week 20. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
223438696|NCT04385875|OTHER|Placebo + extension of the ATI period|During the AELIX-002 trial participants received the following: Normal saline solution at weeks 0, 4, 8, 12, and 20 (PPPPP) followed by normal saline solution at weeks 0, 12 and 24 (PPP), starting at least 24 weeks after week 20 administration. After that, on ATI\_extension trial, ATI will be extended for 48 weeks.
224049782|NCT06985524|DRUG|Weipi Formula（Wu SiSi Formula）|take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
224049783|NCT06985524|OTHER|Placebo|Take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
224049784|NCT06985017|BEHAVIORAL|Playing Playfully to Overcome Adversity|This training is provided via virtual group sessions (Telehealth) and consists of five 45-minute-long weekly sessions addressing ways to promote children's play and playfulness in the classroom and techniques to reduce teacher/caregiver burnout.
223438697|NCT05313282|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2\. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 8th day 30minutes after meals, once a day, for continuous medication.~3\. On the 22nd day of treatment, namely the second session of HAIC, intravenous infusion of Camrelizumab 200mg every 3 weeks.~4\. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
223438698|NCT05313282|COMBINATION_PRODUCT|Apatinib combined with Camrelizumab|Drug: Camrelizumab for injection and Apatinib-Mesylate Tablets Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication 2. Intravenous infusion of Camrelizumab 200mg every 2 weeks.
223566576|NCT05446792|OTHER|PFMT|The PFMT will consist of 10 maximum voluntary contractions that must be maintained for at least 6 seconds. Participants will be encouraged to sustain the maximum contraction for a longer time each week. The interval time between contractions will be the same seconds as the contraction. Participants will perform 4 sets of 10 contractions, and at the end of each set of 10 contractions, five fast contractions will be performed. Each series will be performed in one position: lying in lateral decubitus; seated; on all fours and standing.
223566577|NCT05446792|OTHER|PE|"The PE group will be instructed and reminded to voluntarily contract the PFMs during each repetition of the Pilates strengthening exercises. During the stretching exercises, the participant will be instructed not to perform the contraction.~The stretching and strengthening exercises will be performed in a single series of 10 repetitions, totaling 10 exercises aimed at the main muscle groups."
223566578|NCT06380439|PROCEDURE|wrist ankle acupuncture|wrist ankle acupuncture: wrist ankle acupuncture using 0.25 x 25mm filiform needle on lower 1, lower 4, lower 5 area ipsilateral to the surgical side, then covered with 5cm long micropore, retention for 4 hours
223566579|NCT02839577|DRUG|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
224143732|NCT04744636|DRUG|Other|"Type 2 diabetic patients will be selected within 3 weeks before inclusion (Day 0).~The investigations will be performed on 2 days (Day 1 (D1) and Day 2 (D2)): vascular endothelial function assessment and blood collection for biomarker investigation on Day 1 and CFR on Day 2.~Then, subjects will be discharged at the end of the last investigation day (Day 2).~All the participants have received two pharmacological agents (NIMP):~* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.~* Adenosine : administered intravenously during MRI for the measurement of CFR."
224143733|NCT05590767|PROCEDURE|Patients scheduled to undergo shoulder rotators repair surgery|Patients scheduled to undergo shoulder rotators repair surgery, and received combined general anesthesia and interscalene block
224143734|NCT00403819|DRUG|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
224143735|NCT00233818|DEVICE|Sirolimus-coated Bx VELOCITY Stent|
224143736|NCT00228930|DRUG|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
224143737|NCT01866345|PROCEDURE|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
223566580|NCT02839577|DRUG|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
224049785|NCT06985537|DRUG|Ultrasound guided intralesional Steroids injection (Triamicinolone)|Radiological guided steroid injection of IGM
224049786|NCT06984588|DRUG|Uliledlimab|30 mg/kg, administered on Days 1 and 8 of Cycle 1 (C1D1 and C1D8), then once every 3 weeks (Q3W) starting from C2D1,
224143738|NCT01866345|PROCEDURE|Conventional orthodontic treatment|Conventional orthodontic Procedure
224049787|NCT06984588|DRUG|Toripalimab|240 mg on Day 1, once every 3 weeks (Q3W)
224049788|NCT06984588|DRUG|Pembrolizumab|200 mg on Day 1, once every 3 weeks (Q3W)
224049789|NCT06985693|PROCEDURE|Medipixel XA-Assisted Percutaneous Coronary Intervention|"Medipixel XA-Assisted Percutaneous Coronary Intervention (MPXA-PCI) is an AI-assisted coronary intervention procedure utilizing Medipixel XA (MPXA), an artificial intelligence-based quantitative coronary analysis (AI-QCA) software. MPXA analyzes angiographic images in real-time to assist in lesion assessment, optimal balloon and stent selection, and procedural decision-making during percutaneous coronary intervention (PCI).~In this study, all participants will undergo MPXA-assisted PCI, where the software provides automated vessel segmentation, diameter measurement, and lesion quantification to optimize procedural outcomes. Operators will follow a predefined protocol incorporating MPXA measurements for balloon sizing, stent selection, and post-dilation strategies.~The study evaluates the safety, feasibility, and clinical impact of MPXA-assisted PCI in real-world coronary artery disease patients."
224143739|NCT06965907|OTHER|Kinesio Taping|The participant will be seated upright in a chair with the elbow flexed at 90 degrees. The forearm under examination will be placed in a pronated position, and the wrist will be maintained in a neutral position. I-shaped kinesio taping will be applied as described by Mohammadi et al. Prior to taping, the extensor surface will be cleaned using a cotton swab moistened with alcohol. The tape length will be measured from a point 2 cm distal to the lateral epicondyle to the radial styloid process. Each end of the tape will be 2 cm in length (totaling 4 cm for both ends). To achieve 35% tension, the following formula will be used: (L - 4) / 1.35 + 4. In this formula, L represents the total length of the tape, 4 is the combined length of the two tape ends, and 1.35 corresponds to the factor required to achieve the desired 35% tension.
224143740|NCT06965907|OTHER|Sham Taping|The participant will be seated in a chair with the forearm resting comfortably. The tape will be applied to the middle of the forearm without any tension. The taping will be performed from the medial to the lateral direction.
223566581|NCT00775112|DEVICE|pillow|use of pillow for lumbar punctures
223740784|NCT02240199|DRUG|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
223438699|NCT04958902|BEHAVIORAL|RESTORE: Recovering from Extreme Stressors Through Online Resources and E-health|RESTORE (www.restoreonline.ca) includes eight e-modules anticipated to be approximately 30-40 minutes each in length and intended to be completed over 4-8 weeks. The modules address cognitive and behavioural factors posited to cause and maintain psychological distress related to the COVID-19 pandemic. These include cognitions about the cause and meaning of stressors related to the pandemic, including self-blame, other blame and hindsight bias, as well as problematic beliefs related to safety, trust, and control. The modules also address the importance of: (1) expressing emotions that are natural to the events of the pandemic (e.g., sadness in the face of loss), (2) working through, rather than avoiding, thoughts, feelings and grief related to the pandemic, and (3) utilizing social supports. The modules consist of written materials, brief videos, and practice assignments delivered through the platform. RESTORE includes guidance via direct messaging and/or brief telephone calls.
224049790|NCT06984887|DIAGNOSTIC_TEST|Diagnostic procedures|This study will be evaluated by conducting a non-inferiority diagnostic trial within routine ACF settings by comparing the New Diagnostic tests (NAT) to the reference standard test (Xpert MTB/Rif Assay) to determine how well it can detect and diagnose TB. All samples will be tested for MTB using cultures.
223438700|NCT00970099|BEHAVIORAL|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
223438701|NCT00970099|BEHAVIORAL|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
223438702|NCT04076371|DRUG|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
223438703|NCT04076371|DRUG|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
223438704|NCT04076371|DRUG|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
223438705|NCT04076371|DRUG|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
223438706|NCT04076371|DRUG|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
223438707|NCT04076371|DRUG|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
223740785|NCT02240199|DRUG|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
224049791|NCT00232583|DRUG|Metformin|Metformin 1000mg/BID
224049792|NCT00232583|DRUG|Insulin|Insulin Novolg 70/30 per protocol titration
224049793|NCT00232583|DRUG|Metfomin|Metformin 1000mg/BID
224049794|NCT00232583|DRUG|Pioglitazone|Pioglitazone 45mg
224049795|NCT00232583|DRUG|glyburide|Glyburide per protocol titration
224049796|NCT06984757|DEVICE|Deep-brain Stimulation|a neurosurgical procedure that uses implanted electrodes and electrical stimulation to treat movement disorders and certain neuropsychiatric conditions when medications are ineffective or cause significant side effects.
224049797|NCT06984757|DEVICE|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive treatment that uses magnetic fields to stimulate specific areas of the brain.
224049798|NCT06984757|DEVICE|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation (tACS) is a non-invasive brain stimulation technique that uses weak, alternating electrical currents applied to the scalp to modulate brain activity and potentially influence cognitive processes by entraining brain oscillations.
224143741|NCT01764256|BIOLOGICAL|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
224143742|NCT01764256|OTHER|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
223438708|NCT04076371|DRUG|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
224049799|NCT05804643|PROCEDURE|Diffusion magnetic resonance imaging|Free water elimination diffusion MRI and diffusion kurtosis MRI techniques
224049800|NCT01255852|DRUG|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
224049801|NCT06729905|DIETARY_SUPPLEMENT|Yerba mate tea|Consumption of three cups per day of a beverage prepared with yerba mate
223438709|NCT04076371|DRUG|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
223438710|NCT01916161|OTHER|Questionnaire|
223438711|NCT03603977|DRUG|Lpv/r+3TC|It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
223438712|NCT03859791|OTHER|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
223438713|NCT00162175|DRUG|Muraglitazar|
223438714|NCT05873335|COMBINATION_PRODUCT|Mixtures of nitrogen, air, and carbon dioxide|Hypoxia was induced to different and stable levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician by adjusting gas flows with valves according to breath-by-breath estimates of oxygen saturation calculated from end-tidal PO2 and PCO2 displayed on a screen using LabVIEW 2015
224049802|NCT06729905|DIETARY_SUPPLEMENT|Control drink|Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
223438715|NCT00299559|DRUG|smart textiles containing menthol, camphor, cineol|application to skin
223566582|NCT05145322|DEVICE|Composite with 90 degree cavosurface angle|Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the preparation will be restored with a bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
224049803|NCT06906796|OTHER|Diaphragmatic breathing exercise and posture exercises|"Diaphragmatic breathing exercise: Before starting the exercise protocol, individuals in the exercise group will be given training on diaphragmatic breathing exercises. During the exercise sessions, individuals will be advised to place one hand on their abdomen and the other on their chest while lying on their back and to increase abdominal movement by breathing slowly through the nose, thus decreasing rib cage movement. The diaphragmatic breathing exercise will be performed for 5 minutes.~Posture exercises: Individuals will be given posture exercise training before starting the exercise protocol. The smoothness of the movements will be checked throughout the exercise. Chin tuck, shoulder rotation, neck extension with exercise rubber and right-left lateral flexion, pectoral stretching with hands behind, pectoral stretching in the corner and head rib cage extension exercises will be applied as posture exercises. Each exercise will be done with 10 repetitions."
224049804|NCT06903260|COMBINATION_PRODUCT|Mixed Reality|Virtual reality (VR) is defined as an artificial 3D visual environment and augmented reality (AR), as virtual objects superimposed on the real world; mixed reality is the association between VR and AR. The images were exported from CT image in DICOM (Digital Imaging and Communications in Medicine) and applied in Brainlab Elements software (Brainlab AG, Munich, Germany), where the images and 3D drawing were rendered in partnership with the collaborating bioengineer of this work to obtain the VR. AG was obtained during the intraoperative through the Magic Leap 1 goggle (Magic Leap Inc., Plantation, FL, USA)
224049805|NCT06749899|DRUG|QL1706|QL1706 5mg/kg will be given every 3 weeks for 3 cycles in induction chemotherapy and for 9 cycles in adjuvant chemotherapy, started on day 1 of induction chemotherapy and adjuvant chemotherapy, respectively.
224049806|NCT06749899|DRUG|Gemcitabine|Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
224049807|NCT06749899|DRUG|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
224049808|NCT06749899|RADIATION|Intensity-modulated radiotherapy|Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy will be given in 33 fractions.
224049809|NCT06901765|PROCEDURE|Kinesiotaping|Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs (paediatric, geriatric, orthopaedic, neurological, oncology and others) and levels of care (acute care, inpatient rehabilitation, outpatient, home care and Day Rehab). The idea of using elastic tape to mimic the therapist's hands was first presented by Dr Kenzo Kase in the 1970s. Since then, it became the modality used in pain management\[5\], soft tissue injury, tissues and joints malalignment, oedema, and more. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions. Kinesio Taping Method has also effectively treated animals and two special tapes are used: Kinesio Equine and Kinesio Canine. Kinesio Tex Tape contains either 100% cotton and elastic fibres or a blend of polyester and cotton with elastic fibres. The latter is preferable for Kinesio Taping application on sensitive
224049810|NCT06901765|BEHAVIORAL|Exercise|Range of Motion Exercise, Stretching Exercises
224049811|NCT06901674|PROCEDURE|Modified surgical approach|An electrode typically placed under the temporalis muscle will be placed into the cochlear helicotrema instead.
224049812|NCT06901674|DEVICE|Cochlear Nucleus CI632 cochlear implant|Cochlear implant (CI) system where stimulation from one of the intracochear electrodes is grounded via one of two (or both) extra cochlear electrodes in the device.
224049813|NCT01490853|DRUG|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
224049814|NCT02558920|OTHER|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
224049815|NCT03203499|DRUG|ANS-6637 Oral Tablet|Ascending single doses administered orally.
224049816|NCT03203499|DRUG|Placebo Oral Tablet|Placebo administered orally.
224049817|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 1|6Gy x 2 fractions to all sites in 2 weeks
224049818|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 2|6Gy x 3 fractions to all sites in 3 weeks
224049819|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 3|6Gy x 4 fractions to all sites in 4 weeks
224049820|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - Level 4|6Gy x 5 fractions to all sites in 5 weeks
224049821|NCT04530513|RADIATION|Stereotactic ablative radiotherapy - De-escalation Level|6Gy x 1 fraction to all sites in 1 week
224049822|NCT00188565|DRUG|Celecoxib|
224049823|NCT00791336|DRUG|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
224049824|NCT00127868|DRUG|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
223438716|NCT04603794|DRUG|0.5% Povidone Iodine|Commercially Available Mouth Rinses and Over the Counter Standard Formulations
223438717|NCT04603794|DRUG|0.12% Chlorhexidine Gluconate Mouth Rinse|Commercially Available Mouth Rinses
223438718|NCT04603794|DRUG|1% Hydrogen Peroxide|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
223438719|NCT04603794|DRUG|0.9% Normal Saline|Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
223438720|NCT02615392|BEHAVIORAL|Park Prescription|Please refer to the information included in the arm description.
223438721|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
223740786|NCT02240199|DRUG|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
223438722|NCT00947024|DRUG|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
224143743|NCT03102177|DRUG|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
223438723|NCT00947024|DRUG|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
224049825|NCT01488279|DRUG|Dexamethasone 2.5 mg and Sitagliptin 100 mg|Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
224049826|NCT01488279|DRUG|Dexamethasone 2.5 mg and placebo tablet|Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
224049827|NCT05342662|DEVICE|Blue light-blocking glasses|Participants will be randomly assigned to wear either blue light-blocking glasses or glasses with clear lenses during the second week of the study. During the third week, participants will be assigned to wear the opposite pair of glasses.
224049828|NCT05342662|DEVICE|Glasses with clear lenses|Non-blue light-blocking glasses
224049829|NCT06540976|BEHAVIORAL|Cognitive testing|Cognitive tasks testing executive and episodic based decisions, and the switching between these processes.
224049830|NCT04186975|DEVICE|Non-Invasive fetal ECG|Non-Invasive fetal ECG
224049831|NCT04186975|DEVICE|Fetal heart rate monitor|Fetal heart rate monitor
224049832|NCT04227314|DRUG|Apremilast|Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
224049833|NCT04227314|DRUG|Placebo oral tablet|Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
224049834|NCT02510092|DEVICE|Percutaneous coronary intervention with new generation fully resorbable scaffold|
224049835|NCT01472770|DRUG|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
224049836|NCT02910947|PROCEDURE|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
224049837|NCT06324006|DRUG|LIB-01|LIB-01 oral suspension
224049838|NCT06324006|OTHER|Placebo|Placebo oral suspension
224049839|NCT01134614|BIOLOGICAL|Ipilimumab|Given IV
224049840|NCT01134614|BIOLOGICAL|Sargramostim|Given SC
224049841|NCT02275585|OTHER|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
223438724|NCT03905356|BEHAVIORAL|Exercise Therapy|Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
223438725|NCT04840524|PROCEDURE|Laminate veneers preparation|facial laminate veneers teeth preparation
223438726|NCT01881087|DRUG|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
223438727|NCT05570370|OTHER|This is an observational study|This is an observational study
224049842|NCT06425484|OTHER|Bilateral US TAP block|epidural plus bilateral US guided TAP block
224049843|NCT00657865|DRUG|ramipril|oral intake
224049844|NCT00657865|DRUG|placebo|placebo
224049845|NCT06182150|BEHAVIORAL|Moderate-Intensity Indoor Cycling Exercise|The 45-minute indoor cycling moderate-intensity cardiovascular exercise will take place once a week over four weeks. The group fitness-based class consists a 5-minute warm-up, a 35-minute conditioning segment, and a 5-minute cooldown.
224049846|NCT00955812|DRUG|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
224049847|NCT03010969|PROCEDURE|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
224049848|NCT03802279|OTHER|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~* CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~* Muscle oxygenation is measured using a near-infrared spectroscopy device.~* VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
224143744|NCT02067741|DRUG|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
224143745|NCT01874249|OTHER|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
224143746|NCT01874249|OTHER|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
223438728|NCT01923337|DRUG|irinotecan hydrochloride|Given IV
223438729|NCT01923337|DRUG|alisertib|Given PO
223438730|NCT04205149|OTHER|ERAS post-operative pathway|ERAS Pathway
224049849|NCT03802279|OTHER|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
224143747|NCT01874249|OTHER|Transient elastography|Transient elastography values greater than 8 kPa
224143748|NCT04328922|OTHER|Fecal microbial transplantation|Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
224143749|NCT04328922|OTHER|Placebo capsuls|capsules of glycerol and saline (placebo).
224143750|NCT04717778|DIETARY_SUPPLEMENT|Comparison of salivary pH after consuming milk of origin vegetable vs cow's milk|They were given 5 types of milk, each one was measured on different days (Monday cow's milk, Tuesday coconut milk, Wednesday almond milk, Thursday soy milk, Friday rice milk).
223438731|NCT00711607|DRUG|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
223438732|NCT02193711|OTHER|Topical Arthritis Cream|
223438733|NCT03447652|OTHER|Resistance Band Ankle Rehabilitation|Resistance Band - uses a tension band to provide resistance during ankle motion
223438734|NCT03447652|OTHER|Biomechanical Ankle Platform System Rehabilitation|Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
223438735|NCT03447652|OTHER|Combination Rehabilitation|Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
223438736|NCT06291740|DEVICE|continuous nebulization|continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
223438737|NCT06291740|DEVICE|Intermittent nebulization|intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
223438738|NCT01433744|PROCEDURE|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
224049850|NCT05260905|BEHAVIORAL|REHIT|REHIt involves 10 minutes of unloaded cycling on a stationary bike, interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
224049851|NCT02436564|GENETIC|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
224143751|NCT02451202|PROCEDURE|Deep Neuromuscular Blockade|"* During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~* At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
224143752|NCT02451202|PROCEDURE|Moderate Neuromuscular Blockade|\- During maintenance phase, if recovery at the presence of \<10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
223438739|NCT03129789|OTHER|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
223438740|NCT05808790|PROCEDURE|Minimally invasive pulmonary metastasectomy|Surgical margin is equal to tumor size, if possible The goal is a parenchymal-sparing resection
223438741|NCT05808790|RADIATION|Stereotactic ablative radiotherapy|Depending on tumor location, 54 Gy in 3 fractions, 55 Gy in 5 fractions, 60 Gy in 8 fractions.
223438742|NCT00849134|DRUG|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
223438743|NCT03853902|BEHAVIORAL|Mindfulness Program|Mindfulness Program
223438744|NCT04621162|BEHAVIORAL|Positive Expectations (initial)|"A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia"
223438745|NCT04621162|BEHAVIORAL|Negative Expectations (initial)|"A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia"
223438746|NCT04621162|BEHAVIORAL|Neutral Expectations (initial)|This group will act as a control. No expectations will be given that will influence the participant.
224049852|NCT06245876|OTHER|Blood collection|Blood collection
223438747|NCT04621162|BEHAVIORAL|Positive Expectations (during intervention)|"A positive expectation will be given during the performance of the mental practice. This is working very well"
224143753|NCT02451202|DRUG|Sugammadex|
223438748|NCT04621162|BEHAVIORAL|Experimental: Negative Expectations (during intervention)|"A negative expectation will be given during the performance of the mental practice. This is working very bad"
223438749|NCT04621162|BEHAVIORAL|Neutral Expectations (during intervention)|This group will act as a control. No expectations will be given that will influence the participant.
223438750|NCT03000530|DRUG|SAGE-217|
223438751|NCT03000530|DRUG|Placebo|
223438752|NCT01996657|DRUG|Warfarin|
224049853|NCT01553175|GENETIC|DNA analysis|
224049854|NCT01553175|GENETIC|gene expression analysis|
224049855|NCT01553175|GENETIC|mutation analysis|
224143754|NCT02451202|DRUG|Rocuronium|
223438753|NCT04240860|BIOLOGICAL|platlet rich plasma|"Drug: PRP PRP subendometrial infusion~Device: ovum oickup needle PRP subendometrial infusion by hysteroscopic guided ovum pickup needle day 9 of the cycle"
223438754|NCT04240860|PROCEDURE|endometrial scratch|Three Snip Hysteroscopic Endometrial Scratching in luteal phase of preceeding cycle
223438755|NCT05414266|DRUG|Placebo|Placebo is acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
223740787|NCT01865539|DEVICE|Custom Foot Orthotic|Custom foot orthotic with custom design pads
223438756|NCT05414266|DRUG|SADBE 5%|SADBE 5% is a solution of 5% Squaric Acid Dibutyl Ester (SADBE) in acetone. At baseline, the investigator will record the area that will be treated in mm2 . Use of a 1 mm x 1 mm gridded transparency will be used to record the treatment area at baseline. At subsequent visits, the study intervention will be applied to the entire treatment area defined at baseline, regardless of any new hair growth. The assigned study intervention is applied monthly by the PI (or designee) to the treatment areas affected by AA on the scalp and/or eyebrows identified at Baseline. The topical solution is applied with a cotton tip applicator by the PI or their qualified designee. Solution is applied by gently pressing a cotton tip applicator that has been soaked in the study solution against the skin. Treatment is repeated monthly.
224143755|NCT04131985|PROCEDURE|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (20 cc).
224143756|NCT03373110|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy|see arm description
224143757|NCT03373110|BEHAVIORAL|Online Cognitive Behavioral Therapy|see arm description
223438757|NCT06725667|OTHER|Transversalis fascia plane block|Patients will receive transversalis fascia plane block after the induction of general anesthesia.
223438758|NCT06725667|OTHER|Caudal block|Patients will receive caudal block after the induction of general anesthesia.
223438759|NCT04662294|BIOLOGICAL|CD70 CAR T-cells|Each subject receive CD70 CAR T-cells by intravenous infusion
223438760|NCT01018160|DRUG|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
223438761|NCT02219776|DRUG|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
223438762|NCT02219776|OTHER|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
223438763|NCT00190372|BEHAVIORAL|Controlled diet|Controlled diet
223438764|NCT00190372|BEHAVIORAL|Self-hypnotic relaxation|Self-hypnotic relaxation
223438765|NCT05343104|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
223438766|NCT01281267|PROCEDURE|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
223438767|NCT00601822|BEHAVIORAL|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
223438768|NCT00601822|BEHAVIORAL|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
223438769|NCT02014922|DRUG|TheraTears® Lubricant Eye Drop|
223438770|NCT02014922|DRUG|TheraTears® preservative-free single-use containers|
223438771|NCT02014922|DIETARY_SUPPLEMENT|TheraTears® Nutrition|
223438772|NCT02014922|OTHER|TheraTears® TheraLid® Eyelid Cleanser|
223438773|NCT03195972|OTHER|Drug diary filling|patient will fill every day a drug diary
223438774|NCT00312572|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
223438775|NCT03012763|DRUG|Paracetamol|Oral administration of 250 mg paracetamol
223438776|NCT03012763|DRUG|Sulfasalazine|Oral administration of 50 mg sulfasalazine
223438777|NCT03012763|DRUG|Fexofenadine|Oral administration of 120 mg fexofenadine
223438778|NCT03012763|DRUG|Valsartan|Oral administration of 40 mg valsartan
223438779|NCT03012763|DEVICE|non-caloric water|Oral administration of 240 ml non-caloric water
224143758|NCT03373110|BEHAVIORAL|Fitbit Alone|see arm description
224143759|NCT05096494|DRUG|SP-103|SP-103 topical system is worn daily for 12 hours per day for 28 days
223438780|NCT03012763|DEVICE|caloric drink|Oral administration of 240 ml caloric drink
223438781|NCT03012763|DEVICE|grapefruit juice|Oral administration of 240 ml grapefruit juice
223438782|NCT02561663|DIETARY_SUPPLEMENT|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
223438783|NCT02561663|OTHER|Placebo|
223438784|NCT03398863|PROCEDURE|Cleaning of uterine cavity|Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
223438785|NCT04825886|DEVICE|Zotarolimus-Eluting Stent|Percutaneous coronary intervention using zotarolimus-eluting stent
223566583|NCT05145322|DEVICE|Composite with wide bevel|Lesion-specific cavity design with wide bevel throughout the cavity margins will be prepared. The total etch method will be performed, i.e. with a 32% by weight phosphoric acid (3M Scotchbond™ Universal Etchant) on enamel and dentine for 15 seconds. The etchant will be rinsed away and an adhesive (3M Scotchbond™ Universal Adhesive) will be applied on dentine with a microbrush for 20 seconds. The adhesive will be light-cured for 10 sec with the Elipar S10 curing light (3M Oral Care). Subsequently the cavity will be restored in with a pre-warmed (using Bioclear Heatsync Kit) bulkfill resin composite (3M Filtek™ One Bulk Fill Restorative) and cured for 20 seconds.
223566584|NCT03022097|DRUG|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
223566585|NCT03022097|DRUG|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
223566586|NCT03022097|DRUG|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
224143760|NCT05096494|DRUG|Placebo|Placebo topical system is worn daily for 12 hours per day, for 28 days
224143761|NCT04871230|DIAGNOSTIC_TEST|3G DBS|Collection of capillary blood samples for the 3G q-PCR test
224143762|NCT04871230|DIAGNOSTIC_TEST|Sputum Test|Collection of sputum for test culture, microscopy, GeneXpert
224143763|NCT04871230|DIAGNOSTIC_TEST|3G Veinous Blood|Collection liquid veinous blood for the 3G q-PCR test
224143764|NCT03407508|DIETARY_SUPPLEMENT|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
224143765|NCT02452268|DRUG|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
223438786|NCT06206122|DEVICE|Nasogastric tube|Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
223478589|NCT01944423|BEHAVIORAL|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
223566587|NCT03022097|DRUG|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
223566588|NCT06102122|DIETARY_SUPPLEMENT|Compleat|Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
223566589|NCT05126797|OTHER|Questionnaire Administration|Ancillary studies
224049856|NCT01553175|GENETIC|protein expression analysis|
224049857|NCT01553175|OTHER|immunohistochemistry staining method|
224049858|NCT01553175|OTHER|laboratory biomarker analysis|
224049859|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device does not deliver stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
224049860|NCT06470009|DEVICE|Portable Neuromodulation Stimulator (PoNS)|The PoNS device delivers stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
224049861|NCT03861936|BIOLOGICAL|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A;BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
224049862|NCT03861936|DRUG|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
224049863|NCT05863975|DRUG|Human interferon alpha 2b vaginal Effervescent capsules|①Interferon group: human interferon alpha 2b vaginal effervescent capsule vaginal medication. ② Promestriene group: promestriene cream vaginal medication. ③Interferon + promestriene combination group: two drugs were given in combination.
224049864|NCT00698724|DRUG|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
224049865|NCT00698724|DRUG|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
224049866|NCT00587548|OTHER|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
224049867|NCT01247636|OTHER|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
224049868|NCT01247636|OTHER|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
224049869|NCT03941678|DIETARY_SUPPLEMENT|Creatine monohydrate|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
224049870|NCT03941678|DIETARY_SUPPLEMENT|Placebo|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
224049871|NCT01534104|PROCEDURE|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI \& DSI, neurological/physical testing \& brain MRI showing tumor \&/or edema located in or near (\<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), \&/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately \<48 hours before surgery\*) fMRI to localize gray matter DTI, DSI \& tractography to localize white matter, DSI \& updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray \&/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (\<48 hours after surgery)
224070652|NCT01319409|PROCEDURE|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
224143766|NCT02452268|DRUG|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
224143767|NCT00305812|DRUG|dexamethasone|
223566590|NCT05126797|DEVICE|Stent Device|Wear customized 3D printed oral stent
223740788|NCT01865539|DEVICE|Sham Orthotic|Leather insert without the custom design pads
224049872|NCT05322928|BEHAVIORAL|Engagement in daily occupations|"The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life."
224049873|NCT06153875|OTHER|Sensory Thresold, Burst High Frecuency|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 5 trains of 5 seconds, 55 seconds apart, at a frequency of 100Hz, making 5 minutes of total treatment. The intensity will be set 200 microamperes (μA) above the detection threshold for each patient, guaranteeing a sensitive but not painful perception.
224049874|NCT06153875|OTHER|Theta-Burst Stimulation|The ultrasound guided percutaneous peripheral nerve stimulation will be applied to the Spinal or Inferior Gluteal and Tibial Nerve. The parameters will be 40 trains separated by 7 seconds from each other, where each train contains 5 trains separated by 200ms, at a frequency of 5Hz, resulting in 6 minutes and 45 seconds of total treatment. The intensity will be set at the motor threshold of the patient, ensuring a non-painful stimulation.
224049875|NCT06153875|OTHER|Transcutaneous Electrical Nerve Stimulation|The transcutaneous electrical nerve stimulation will be applied on the trapezius or low back and internal calf muscles at a frequency of 80Hz and a pulse width of 250 microseconds, for 15 minutes. The intensity will be set at the detection threshold of each patient generating a sensitive but non-painful perception.
224049876|NCT01236573|DRUG|Fludarabine|Fludarabine 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
223438787|NCT06206122|DEVICE|Intermittent Oro-esophageal Tube|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223438788|NCT06206122|BEHAVIORAL|Comprehensive rehabilitation training|"1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223438789|NCT05476666|PROCEDURE|Peripherial and central venous access|Passing a peripherial and a central venous catheter/cannula
223438790|NCT00997022|DRUG|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
224049877|NCT01236573|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
224049878|NCT01236573|BIOLOGICAL|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
224049879|NCT00330876|DRUG|Pitavastatin|
224049880|NCT01232543|DRUG|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
224049881|NCT04578860|OTHER|Music therapy with Music Care app|Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
224143768|NCT00305812|DRUG|lenalidomide|
224143769|NCT00305812|DRUG|melphalan|
224143770|NCT05185648|BEHAVIORAL|standard trauma care taining|trauma care training
224143771|NCT03329599|DRUG|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
224143772|NCT03917082|DRUG|Tamoxifen Citrate|current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
224143773|NCT05976932|DRUG|pegylated liposomal doxorubicin|All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
224143774|NCT02755142|BIOLOGICAL|Gliolan|
224143775|NCT03876145|OTHER|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
224143776|NCT04161612|OTHER|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
223438791|NCT05104424|DRUG|Insulin aspart|intranasal rapid insulin 40 I.U as 0.1 ml as 2 puff at each nostril once weekly for 8 weeks zinc 50 mg orally daily Gabapentin 300 mg once daily for 1 month small ice cube at mouth before meals thrice daily
223438792|NCT00295516|PROCEDURE|Fetal Middle Cerebral Artery Doppler measurement|
223438793|NCT05200117|DEVICE|Pregnolia System|The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
224049882|NCT04578860|OTHER|Sound therapy with White Noise|Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
223438794|NCT05140616|DRUG|Chidamide|After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
223438795|NCT03385616|DEVICE|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
224143777|NCT03063853|OTHER|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
224143778|NCT03063853|PROCEDURE|Elective cesarean delivery|non emergent elective cesarean delivery
224049883|NCT04578860|OTHER|Treatment as usual for sleep disorders|No intervention
224049884|NCT05947994|PROCEDURE|Intracranial stenting with Credo® stent|Symptomatic ischemic stroke patients were treated with Credo® Stent
224049885|NCT03496220|DEVICE|Angulus|Feedback on patient recumbency
224049886|NCT01846728|DRUG|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
224049887|NCT02700152|DEVICE|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
224049888|NCT02614365|BEHAVIORAL|Aerobic exercise|Cardiovascular fitness
224049889|NCT02614365|BEHAVIORAL|Stretch exercise|Muscle stretch
224049890|NCT00374686|DRUG|Valganciclovir|
224049891|NCT05753072|OTHER|Carer Support Nurse|Specialist community nursing role to support unpaid family/carers with complex health-related support needs or unresolved health-related support needs that cannot be met by their usual health care team
224049892|NCT06387511|DIETARY_SUPPLEMENT|Small-quantity lipid-based nutrition supplements (SQ-LNS) NutriVax|"1. The SQ-LNS distribution program will be implemented for 12 consecutive months in the NutriVax arm.~2. Community mobilizers in the NutriVax arm will give information in the community about SQ-LNS and eligibility criteria for SQ-LNS distributions.~3. All SQ-LNS distributions will take place at the primary health care center (PHCC) of each ward.~4. Children aged 6-22m, residing in settlements of the catchment area of the NutriVax arm are eligible for a monthly ration of SQ-LNS (28 sachets per month) following a check and update of his or her vaccine status at PHCC; unless there are serious issues related to access to PHCC, in which cases ration sizes may be revised upwards to three months' worth.~5. All children will exit the SQ-LNS distribution program when they are 23 months of age OR after receiving a maximum of 12 consecutive monthly rations, whichever comes first.~6. The total amount of SQ-LNS a child receives will depend on when they enroll in the SQ-LNS distribution program."
223438796|NCT04916314|BEHAVIORAL|Low Carbohydrate diet|Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
223438797|NCT02984514|RADIATION|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
224049893|NCT06387511|BEHAVIORAL|Sensitization on vaccination and on Infant and Young Child Feeding (IYCF) practices|"1. Parents or guardian of children will be encouraged/sensitised to attend their scheduled preventive visits to receive other essential paediatric services;~2. Sensitization on vaccination and recommended Infant and Young Child Feeding (IYCF) practices including the need to consume a diverse nutritious diet and support for continued breastfeeding will be conducted according to the Ministry of Health's routine plans in the community and at primary health care centres;~3. Community mobilizers will promote the importance of vaccinations according to the Expanded Program on Immunization (EPI) as well as IYCF good practices messages."
223438798|NCT03493022|OTHER|Test Granola|50.5 Test Granola
224049894|NCT00938808|DIETARY_SUPPLEMENT|day formula diet|The Cambridge Programme. Formula diet
224049895|NCT02446314|DIETARY_SUPPLEMENT|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
224143779|NCT01827241|OTHER|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
224143780|NCT03419936|DIAGNOSTIC_TEST|Endoscopic biopsy|"1. Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~2. Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~3. Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~4. Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
223438799|NCT03493022|OTHER|Control Granola|54.3 Control Granola
223740789|NCT01593423|BEHAVIORAL|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
223740790|NCT01593423|BEHAVIORAL|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
223438800|NCT04929158|PROCEDURE|Intravascular Ultrasound (IVUS) -guided Primary Percutaneous Intervention (PCI)|Preoperative criminal vascular assessment； The criminal vascular assessment after surgery
223438801|NCT03872258|BEHAVIORAL|Control|Counseling on physical activity
223438802|NCT03872258|BEHAVIORAL|Intervention group|Program of combined exercise and a Smartband for 6 months.
224049896|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
224049897|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
224049898|NCT02446314|DIETARY_SUPPLEMENT|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
223438803|NCT01430624|BEHAVIORAL|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
223438804|NCT01430624|BEHAVIORAL|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
223438805|NCT05199896|BEHAVIORAL|Behavioral protocol|A touch sensitive computer screen either displaying a downscaled (45cm long) image of the rod (for the sighted), or supporting a same sized wooden rod (for the blind), will be placed on the table in front of the participant to record their localization performance. They will be instructed to use their left index fingertip to indicate on the image of the screen (for sighted) or on the wooden rod (for the blind) the position where they have felt the touch provided to the 90 cm long they held in their right dominant hand. Participants will wear a headset playing white noise to prevent any auditory localization cues when the long rod will be touched. The rod will be touched by a computer controlled solenoid. Thus, participants will respond with a hand gesture on the image or rod and will be asked to validate the position by pressing a foot-pedal with their left foot.
223438806|NCT05199896|DEVICE|EEG protocol|"The EEG protocol will be similar as the behavioral one described above, with the distinction of taking place in two separate sessions: one where the rod are touched, and one where their hand is touched. The participant will hold a rod in each hand and he will have to indicate on which rod he felt the touch.~Additionally electrophysiological responses will be continuously recorded using a 65 channel ActiCap system (Brain Products)."
223438807|NCT05199896|DEVICE|fMRI protocol|"The same behavioral task and procedures of the behavioral protocol described above will be applied, adapted to take into account the constraints posed by the magnetic environment of the MR scanner. The participant will be placed on the scanner bed and provided with earphones that will both protect against the noise of the machine (80dB) and ensure a continuous communication with the participant.~During the fMRI sessions, the participant will solve the same rod localization behavioral task while we will record brain activations by measuring the brain oxygen level dependent signal via Echo Planar Imaging sequences. We will use an MRI compatible tactile stimulator to touch the hand-held rod and participants location judgement will be recorded by using an MRI-compatible tablet, positioned on their abdomen, where the participant will have to indicate the judged position."
223438808|NCT05426824|DRUG|Pegaspargase（P-GOD）|stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
223438809|NCT05426824|DRUG|Pegaspargase（PEMD）|stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
223438810|NCT01789671|BEHAVIORAL|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
223438811|NCT06400407|DEVICE|Continuous Theta-burst Stimulation|Based on the map, an 8-shaped coil was used to stimulate the motor function-related targets. The stimulation intensity was RMT80%, 600 pulses, 50Hz, 40s per target, and the stimulation interval was more than 2 hours. The total course of treatment lasted 7 days.
223438812|NCT06400407|DEVICE|Sham stimulation|A Sham stimulation coil was used to stimulate based on the map. The sound and duration were the same as the cTBS group, ensuring no effective stimulation. The total course of treatment lasted 7 days.
223438813|NCT04578093|BEHAVIORAL|LARC peer-based curriculum|Peer-based educational videos and supplemental activities
223438814|NCT00853515|OTHER|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
223438815|NCT05608278|BEHAVIORAL|Bergen 4-Day Treatment (B4DT)|Novel CBT treatment
223438816|NCT05608278|BEHAVIORAL|Gold standard cognitive behavioral therapy (gold standard CBT)|Gold standard CBT treatment
223438817|NCT01069315|PROCEDURE|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
223438818|NCT01069315|PROCEDURE|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
223478590|NCT01590615|DRUG|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
224049899|NCT00182312|DRUG|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
224049900|NCT04670185|BEHAVIORAL|BIP SAMBA|Behavioral parent management training
224143781|NCT06318221|DIETARY_SUPPLEMENT|Experimental (Immunonutrition) Group|"Immunonutrition was given to the patients in the intervention group and ready-to-use liquid in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day as taken between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. The ready-to-use immunonutrition product was given to the patients in the intervention group."
224143782|NCT06318221|DIETARY_SUPPLEMENT|Active Comparator Group ( Standard enteral nutrition)|"Standard enteral nutrition was given to patients in the control group in addition to their normal nutrition 5 days before the operation. The patients were instructed to consume three enteral products per day between meals.~In the postoperative period, feeding was started in the first 24 hours with the NG tube placed during the operation. Liquid standard enteral nutrition was given to the patients in the control group."
223438819|NCT04753268|BEHAVIORAL|Noom Healthy Weight Program|"The intervention consists of a curriculum, provided through daily articles that users are encouraged to read; logging features for weight, meals, and physical activity; in-app groups; and a virtual coach, who will communicate with participants via in-app messaging. During the first week of the study, participants will be introduced to the program, the Noom app, and their coach.~Coaches will use a secure dashboard to monitor patient progress, which is used to increase engagement and motivation. Participants are encouraged to log their weight, physical activity, and meals daily."
223438820|NCT03197194|DRUG|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
223438821|NCT03197194|DRUG|acetylsalicylic acid|one tablet of aspirin 300 mg
223438822|NCT03197194|DRUG|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
223438823|NCT03197194|DRUG|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
224049901|NCT01610180|DRUG|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count \>60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count \>200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count \>400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
224049902|NCT06850077|BEHAVIORAL|Cognitive-Balance dual task|"The cognitive-balance dual task consists of three levels of difficulty and is performed simultaneously.~The cognitive tasks include the N-back test, while the balance tasks consist of static balance tasks."
223438824|NCT01577719|BEHAVIORAL|Multimedia Lifestyle Improvement|"* Online Goal setting to improve diet, physical activity or smoking behaviours~* regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~* Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
223438825|NCT01577719|BEHAVIORAL|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
223438826|NCT02764203|OTHER|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
223438827|NCT02764203|DEVICE|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
223438828|NCT02614131|DRUG|LY2599666|Administered SC
223438829|NCT02614131|DRUG|Solanezumab|Administered IV
223438830|NCT02614131|DRUG|Placebo SC|Administered SC
224049903|NCT04117776|OTHER|Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
224049904|NCT04117776|OTHER|Skin microbiological sampling (wash with mild soap)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
223438831|NCT02614131|DRUG|Placebo IV|Administered IV
223740791|NCT01593423|BEHAVIORAL|a comparison group|No intervention.
224049905|NCT04109222|BIOLOGICAL|Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224049906|NCT04109222|BIOLOGICAL|Fluzone High-Dose vaccine, 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224049907|NCT06435858|DRUG|Empagliflozin|Empagliflozin 10mg
224049908|NCT06435858|DRUG|Placebo|Placebo capsule
223740792|NCT03420469|DRUG|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
224143783|NCT01056419|PROCEDURE|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
224143784|NCT01056419|DRUG|Propylthiouracil|150-600 mg in two-three divided doses
224143785|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan, for PK testing. The first four time points are +/- 2 min and the last two time points are +/- 5 minutes.
223438832|NCT00655512|DRUG|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
223438833|NCT00655512|DRUG|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
223438834|NCT00655512|DRUG|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
223438835|NCT00655512|DRUG|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
223438836|NCT00655512|DRUG|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
223438837|NCT05901584|DRUG|Cadonilimab|Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+platinum-based chemotherapy or Cadonilimab (10mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit), Q3W, 4cycles), every 3 weeks (21 days) is a treatment cycle.
223438838|NCT01562249|OTHER|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
223438839|NCT01562249|OTHER|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
223438840|NCT01562249|OTHER|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
223438841|NCT00853879|DIETARY_SUPPLEMENT|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
223438842|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
223438843|NCT00853879|DIETARY_SUPPLEMENT|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
223438844|NCT03080584|OTHER|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
223438845|NCT00354042|DRUG|GW597901X|
223438846|NCT04665518|OTHER|Acupressure|Acupressure will be applied to the patients in the acupressure group for 10 min before the venipuncture procedure. Venipuncuture is applied to all patients by the same nurse in the same room. Venipuncture is performed from the left arm of all patients using a vacuum tube and a needle tip of 0.8 \* 38 mm (21G x 1½, green).
223438847|NCT04240275|DEVICE|Reliability of the G-Walk device in children with Cerebral Palsy|"The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position."
223740793|NCT06547008|BEHAVIORAL|Army-SPRING|Army-SPRING includes a package of implementation options to support implementation of ASIST.
223740794|NCT06547008|BEHAVIORAL|Risk Reduction Group (Control)|Risk Reduction Group is a mandated training from National Guard Service members
223740795|NCT01603459|DRUG|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
224070653|NCT01319409|PROCEDURE|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
223438848|NCT00798018|DRUG|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
223438849|NCT00798018|DRUG|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
223438850|NCT00798018|DRUG|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
223740796|NCT01946373|DRUG|Cyclophosphamide|
223740797|NCT01946373|DRUG|Fludarabine|
223740798|NCT01946373|BIOLOGICAL|T cells|
223740799|NCT01946373|BIOLOGICAL|Interleukin-2|
224070654|NCT00931359|DEVICE|DTS-G2 System|Treatment with microwave energy
224070655|NCT00931359|DEVICE|DTS System (Sham treatment)|Sham treatment - no energy is delivered
223438851|NCT00798018|DRUG|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
223438852|NCT05721638|DIAGNOSTIC_TEST|Neutrophil gelatinase-associated lipocalin|Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 KDa, neutrophil-derived molecule from the lipocalin family. It is also secreted in small amounts from kidney, prostate, and respiratory tract epithelial cells. After ischemic and nephrotoxic acute tubular necrosis, NGAL levels peak at the 3rd hour and remain elevated for approximately 24 hours. In patients who do not progress to AKI, NGAL levels begin to decrease as of the 1st hour after injury.
223438853|NCT00840242|DRUG|Nicotine gum|8-12 pieces per day, maximum 24 daily
223740800|NCT01946373|BIOLOGICAL|Dendritic cell vaccine|
223740801|NCT06430203|BEHAVIORAL|Peer mentoring|Indigenous young adult peer mentors who will develop and deliver the program based on needs and wants of our participants. The program will be built on their experience and ideas. They will be empowered to guide the program in the direction they see best for their communities.
223438854|NCT00840242|DRUG|Placebo gum|8-12 pieces per day, maximum 24 daily
223438855|NCT00840242|DRUG|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
223438856|NCT00840242|DRUG|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
223438857|NCT03888183|DRUG|salt solution without 0.15% HA|received AIM Artificial Tears (4 to 8 times per day) with 12 weeks
223438858|NCT03888183|DRUG|preservative-free 0.15% HA|received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
223438859|NCT04523870|DIETARY_SUPPLEMENT|Botanical extract|One capsule
223438860|NCT04523870|DIETARY_SUPPLEMENT|Main compound of the botanical extract|one capsule
223438861|NCT04523870|DIETARY_SUPPLEMENT|Placebo|Maltodextrin, one capsule
224049909|NCT05788042|DEVICE|MagPro TMS device (ARTG: 204659)|rTMS will be administered using a MagPro TMS device (ARTG: 204659) which is approved for its intended use in this trial. rTMS involves the application of transient magnetic pulses which induce small currents in the underlying cortex via the principal of electromagnetic induction. rTMS will be administered using a patterned frequency stimulus called intermittent theta-burst stimulation (iTBS).This form of rTMS was chosen because a recent large multicentre trial showed 3 minutes of iTBS attained the same therapeutic effect as 30 minutes of standard rTMS, leading to FDA approval for depression. Each treatment session will comprise an extended iTBS session, i.e., 6.6 mins, delivered at 100% resting motor threshold (RMT). It will be targeted to the left DLPFC (F3 using the 10-20 International EEG system), consistent with the prior RCT of rTMS for AN.
224049910|NCT05788042|DEVICE|tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637)|tDCS will be self-administered using the 1x1 tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) with two saline-soaked sponge electrodes held in place on the scalp using the Soterix Ole-2 headband. The device is intended to treat different neurological and psychiatric disorders. tDCS involves the passing of weak electrical current through the brain via electrodes placed upon the scalp. The current modulates the resting membrane potential of stimulated neurons which causes changes in neuronal excitability. The anode will be placed over the left F3 (10-20 System) and the cathode over F4 (electrode sizes 5 x 5cm, 25cm2). This montage was chosen to target the left DLPFC, consistent with prior pilot studies of tDCS in AN.
224049911|NCT02686125|DEVICE|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
224049912|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4）Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
224049913|NCT04785768|DRUG|Hydromorphone Hydrochloride Injection|Intravenous PCA with hydromorphone after successful titration of 24 hours.the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4)Evaluate every 24 hours and PCA parameters were adjusted according to the dose of the previous day.
224049914|NCT04785768|DRUG|Morphine Sulfate Sustained-release Tablets|"Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for day 1; 2）the total equianalgesic of the previous 24 hours/2 for day 2 ; 3）Evaluate every 24 hours and the dose for the next day is adjusted according to the dose of the previous day；4) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours;"
224143786|NCT05540340|OTHER|Pharmacokinetics|Six peripheral blood samples of 5 ml in lithium heparin tubes will be collected at 5, 15, 30, 40, 75, and 150 minutes after the melphalan to determine the actual AUC achieved using the population PK.
223438862|NCT01285492|DRUG|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
223438863|NCT01285492|DRUG|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
223438864|NCT06112678|DRUG|CKD-348(6)|QD, PO
223438865|NCT06112678|DRUG|CKD-828, D097, D337|QD, PO
223438866|NCT03365453|OTHER|frailty evaluation|frailty and comorbidity scores
223438867|NCT01797094|BIOLOGICAL|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
223438868|NCT01797094|BIOLOGICAL|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
223438869|NCT03798392|DEVICE|Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
223438870|NCT03798392|DEVICE|Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
223438871|NCT00899613|OTHER|laboratory biomarker analysis|
223438872|NCT00899613|PROCEDURE|study of high risk factors|
223438873|NCT04373564|PROCEDURE|Motor Tests|To assess motor function annually
223438874|NCT04373564|PROCEDURE|Cognitive Tests|To assess cognitive function annually
223438875|NCT04373564|PROCEDURE|Unenhanced-MRI of the brain|The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality
223438876|NCT04373564|PROCEDURE|Gadolinium Measurements|Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration
223438877|NCT04373564|DRUG|Gadoxetate disodium|Administered as defined by the treating physician as part of routine clinical practice
223438878|NCT04373564|DRUG|Gadobenate dimeglumine|Administered as defined by the treating physician as part of routine clinical practice
223438879|NCT04373564|DRUG|Gadodiamide|Administered as defined by the treating physician as part of routine clinical practice
223438880|NCT04373564|DRUG|Gadoterate meglumine|Administered as defined by the treating physician as part of routine clinical practice
223438881|NCT04373564|DRUG|Gadobutrol|Administered as defined by the treating physician as part of routine clinical practice
223438882|NCT04373564|DRUG|Gadoteridol|Administered as defined by the treating physician as part of routine clinical practice
223438883|NCT05640388|OTHER|RV3278A - ET0943 cosmetic product|RV3278A - ET0943 study product is applied twice a day on the face during the whole study.
223438884|NCT05640388|OTHER|RV4632A - RY1845 cosmetic product|RV4632A - RY1845 study product must be applied only in case of sensation of skin discomfort
224049915|NCT06067971|DEVICE|Laparoscopic surgery with augmented reality device|Gynecological laparoscopic surgery with augmented reality device.
224049916|NCT03738969|PROCEDURE|Laparotomic radical hysterectomy|Radical hysterectomy applied by laparotomy
224049917|NCT03738969|PROCEDURE|Laparoscopic radical hysterectomy|Radical hysterectomy applied by laparoscopic
224049918|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.
224049919|NCT02676856|PROCEDURE|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.
224049920|NCT02676856|DRUG|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
224049921|NCT02676856|DRUG|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
224049922|NCT01410435|DRUG|Monofer|Infusion according to current HB level
223438885|NCT06368882|DRUG|Peg-Interferon α|Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
223438886|NCT00310076|DRUG|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
223438887|NCT00310076|PROCEDURE|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
224049923|NCT04637698|BIOLOGICAL|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
224049924|NCT02442726|DEVICE|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
223478591|NCT00166400|DRUG|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
224049925|NCT01187849|DRUG|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
224049926|NCT01187849|DRUG|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
224049927|NCT00034190|DRUG|S-8184 Paclitaxel Injectable Emulsion|
224049928|NCT04569032|DRUG|brentuximab vedotin|1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
223478592|NCT01829347|BIOLOGICAL|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
223478593|NCT01829347|OTHER|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
223478594|NCT03468504|DEVICE|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
224049929|NCT04569032|DRUG|cyclophosphamide|750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
224049930|NCT04569032|DRUG|doxorubicin|50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
224049931|NCT04569032|DRUG|prednisone|100 mg daily administered orally on Days 1-5 of each cycle
224049932|NCT00588536|DRUG|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
224049933|NCT00588536|DRUG|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
224049934|NCT00588536|DRUG|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
224049935|NCT00701090|DRUG|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
224049936|NCT00701090|DRUG|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
224049937|NCT00701090|DRUG|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
224049938|NCT04615468|DRUG|TQ-B3525|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
224049939|NCT00873366|DRUG|dextromethorphan hydrobromide|
224049940|NCT00873366|DRUG|tamoxifen citrate|
224049941|NCT00873366|OTHER|high performance liquid chromatography|
224049942|NCT00873366|OTHER|laboratory biomarker analysis|
224049943|NCT00873366|OTHER|pharmacogenomic studies|
224049944|NCT00873366|OTHER|pharmacological study|
224049945|NCT00873366|PROCEDURE|fluorescence imaging|
224049946|NCT00473577|DRUG|CRA-24781|
224049947|NCT00648804|DRUG|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
224049948|NCT00648804|DRUG|Zofran ODT® Tablets 8 mg|8mg, single dose fed
224049949|NCT00343876|DRUG|aspirin|
224049950|NCT00343876|DRUG|clopidogrel|
224049951|NCT06321926|DEVICE|ActiveWaiting App|"The final prototype aims at increasing physical activity during the day by providing exercises for waiting periods and other idle time periods. The user can choose from a pool of exercises from five different categories (11 exercises for endurance, 65 exercises for strength, 67 exercises for flexibility, 11 exercises for relaxation, or 5 exercises for balance). Additionally, within each category, the user can choose only discrete exercises which are not noticeable to an observer. If the user has used the app before, the last or previously saved settings can be chosen. Every input field has an information icon showing a short description of the input field."
224049952|NCT00328744|BEHAVIORAL|Standard|18-month standard behavioral weight loss intervention
224143787|NCT06263231|DRUG|INT230-6|INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
224143788|NCT06263231|DRUG|Eribulin|Eribulin IV
224143789|NCT06263231|DRUG|Trabectedin|Trabectedin infusion
224143790|NCT06263231|DRUG|Pazopanib|Pazopanib pill
223438888|NCT02914431|DEVICE|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
223438889|NCT04591457|DRUG|Insulin Glargine Sansulin|Insulin Glargine (Sansulin Log-G) once daily at individually adjusted dose
223438890|NCT04591457|DRUG|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
223438891|NCT00630591|BEHAVIORAL|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
223438892|NCT00630591|BEHAVIORAL|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
224049953|NCT00328744|BEHAVIORAL|Limited Variety|Two chosen snack foods
224049954|NCT03899363|PROCEDURE|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
224049955|NCT01820936|DRUG|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
224049956|NCT01820936|DRUG|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
224049957|NCT01820936|DRUG|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
224049958|NCT01820936|DRUG|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
224070656|NCT01480336|DRUG|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
224070657|NCT01480336|DRUG|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
224070658|NCT02613962|PROCEDURE|biopsy or surgical resection of tumor and blood sampling|
224070659|NCT03711578|DRUG|Tenalisib,|BID, Orally
223438893|NCT00630591|BEHAVIORAL|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
223438894|NCT02203162|DEVICE|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
223438895|NCT03942926|DRUG|Sirolimus|Patients will receive sirolimus for 6 months.
223438896|NCT05262166|DRUG|INTRATHECAL dexmedetomidine INJECTION|intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
223438897|NCT05020704|DRUG|Empagliflozin 10 MG|SGLT2inhibitor
224070660|NCT03834428|BEHAVIORAL|Text Message Intervention|A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
224070661|NCT03834428|BEHAVIORAL|ICOUGH protocol|Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
224070662|NCT00185978|BEHAVIORAL|diet, physical activity, reduced sedentary behavior|
224070663|NCT05687461|OTHER|Build a national diagnosis and treatment quality control platform for major respiratory diseases|"1. Build a national diagnosis and treatment quality control platform for major respiratory diseases~2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases~3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases"
224070664|NCT04943991|DIAGNOSTIC_TEST|blood sampling (alpha-Galactosidase & LysoGb3)|"A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured.~Amendment: Offering of genetic testing for fabry specific GLA-gene"
224070665|NCT05138835|DRUG|Botox Cosmetic|"BOTOX® Cosmetic is approved and commercially available for use in Canada.~BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe frown lines between the eyebrows, crow's feet lines, and forehead lines in adults."
224143791|NCT01274312|PROCEDURE|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
224143792|NCT06642610|DEVICE|CGM Dynamic Index (CDI)|Participants will undergo one-time oral glucose tolerance test (OGTT) and a one-time use of a CGM device, which will be worn for up to 10 days.
224143793|NCT03745300|DRUG|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
224143794|NCT03745300|DRUG|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
224143795|NCT03745300|DRUG|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
224143796|NCT00335998|DRUG|triapine|Given IV
224143797|NCT00335998|OTHER|laboratory biomarker analysis|Correlative studies
224049959|NCT01820936|DRUG|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
223438898|NCT05020704|DRUG|Placebo|Matched placebo
223438899|NCT03217968|DEVICE|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
223438900|NCT00625404|DRUG|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
224143798|NCT00335998|RADIATION|external beam radiation therapy|Undergo external beam radiation therapy
224049960|NCT02237963|PROCEDURE|Posterolateral thoracotomy|
224143799|NCT00335998|RADIATION|brachytherapy|Undergo intracavitary or interstitial brachytherapy
224143800|NCT00335998|DRUG|cisplatin|Given IV
224143801|NCT00335998|OTHER|pharmacological study|Correlative studies
223740802|NCT05212714|DEVICE|taVNS|The non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) device that will be used in this study is a wearable TENS unit called the Vorso STIM100 System. The Vorso system consists of a wearable, external stimulator, a neural interface ear piece, and an arm band designed to be safe for human contact. The external stimulator generates electrical pulses that are transcutaneously delivered to the auricular branch of the vagus nerve through the ear canal. The ear piece contains 4 electrodes that carry current from the external stimulator to the auricular branch of vagus nerve. The external stimulator connects to a flexible arm band that attaches to the upper arm for ease of use during each stimulation session. The type of stimulation (including shape, frequency, pulse width, amplitude, total charge, and energy delivered) is comparable to the levels applied by commercially available TENS stimulators. The sham control group will not receive any stimulation.
224143802|NCT04875403|OTHER|Inspiratory muscle trainning|linear load device, associated with the resisted training. The initial training load for each participant will be adjusted to 25% of MIP. Each week, the researcher determines the new values for load (1 to week 25%, 2 to week 35%;. 3 to week 40%;. 4 to week 45%;. 5 to week 50%.).
224143803|NCT04875403|OTHER|Exercise|exercise bike for 30 minutes, which will be divided into 10 minutes for the foot heating and 20 minutes for the workout aerobic exercise that will have to maintain a target training heart rate
224143804|NCT03630484|OTHER|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
224143805|NCT03630484|OTHER|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
224143806|NCT01833325|RADIATION|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
224143807|NCT03962556|OTHER|bimanual palpation|bimanual palpation....i..
223438901|NCT00625404|OTHER|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
223438902|NCT00886925|DRUG|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
223438903|NCT00886925|DRUG|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
223438904|NCT05590117|DRUG|Pentoxifylline|Pentoxifylline is a potent anti inflammatory may prevent chemotherapy induced neuropathy and mucositis and will be administered 400mg twice daily
223740803|NCT02014844|DRUG|250 mg/m2 aldoxorubicin|
224049961|NCT02237963|PROCEDURE|Axillary thoracotomy|
224049962|NCT03076931|PROCEDURE|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
224049963|NCT03076931|PROCEDURE|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
224143808|NCT02199613|DRUG|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
224143809|NCT00164736|DRUG|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
223438905|NCT05590117|DRUG|Placebo|placebo tablets
223438906|NCT05590117|DRUG|FOLFOX-6 regimen|12 cycles of FOLFOX-6 regimen
224143810|NCT00164736|DRUG|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
224143811|NCT00164736|DIETARY_SUPPLEMENT|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
223438907|NCT01655134|OTHER|Blood simples|
223438908|NCT01655134|OTHER|Capillary punction|
223438909|NCT01655134|OTHER|Urine simples|
223438910|NCT06415396|OTHER|Complete Decongestive Therapy|conventional CDT program consisting of MLD, compression bandage, skin care and lymphedema exercises, for a total of 15 sessions, five days a week for three weeks.
223438911|NCT06415396|DEVICE|ESWT|ESWT was applied to the second group for a total of 5 sessions, 2 sessions in the first two weeks and 1 session in the last week. .
223438912|NCT06415396|DEVICE|LLLT|In the third group, LLLT was applied for a total of 9 sessions, 3 sessions per week, in addition to conventional CDT.
223438913|NCT06011096|OTHER|skin-to-skin contact and delayed cord clamping|Placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated with skin-to-skin contact and late cord clamping after delivery.
223438914|NCT06011096|OTHER|avoiding skin-to-skin contact and early cord clamping|After delivery, placental separation time, separation method, amount of postpartum bleeding and postpartum comfort were evaluated without skin-to-skin contact and late cord clamping.
224049964|NCT03076931|PROCEDURE|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
224049965|NCT03056560|BEHAVIORAL|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
223438915|NCT03326752|DRUG|DV281|\- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
223438916|NCT03326752|DEVICE|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
223438917|NCT03326752|DRUG|DV281 (RP2D)|\- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
223438918|NCT03326752|DRUG|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
223438919|NCT02447575|OTHER|Education on Use of MDI|After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
223438920|NCT04387799|DIAGNOSTIC_TEST|Serology for Covid-19|Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
223438921|NCT05045404|DRUG|Poziotinib Hydrochloride|"1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE~Given PO"
224049966|NCT05970497|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
223566591|NCT03306979|DRUG|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
223566592|NCT03306979|OTHER|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
223740804|NCT02014844|DRUG|350 mg/m2 aldoxorubicin|
223740805|NCT05585151|DRUG|Evolocumab 140 MG/ML|Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
224049967|NCT05970497|DRUG|Opdualag|Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
224049968|NCT05970497|DRUG|KEYTRUDA ®( Pembrolizumab)|Immunotherapy (PD-1 immune checkpoint inhibitor)
224049969|NCT03512691|BEHAVIORAL|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
224049970|NCT03512691|BEHAVIORAL|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
224049971|NCT00324753|BEHAVIORAL|Communication|Communication sheet
224049972|NCT00324753|BEHAVIORAL|Standard of care|Standard of care brochures
224049973|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
224049974|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
224049975|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
224049976|NCT01508195|DRUG|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
224049977|NCT01508195|DRUG|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
224049978|NCT01508195|DRUG|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
224049979|NCT02274181|DRUG|Androxal|
224143812|NCT01804036|DRUG|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
224143813|NCT01804036|BEHAVIORAL|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
223438922|NCT05045404|BIOLOGICAL|1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE|"Biological/Vaccine Ramucirumab 947687-13-0, anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, ramucirumab, RAMUCIRUMAB~Given IV"
224049980|NCT02180971|PROCEDURE|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (\>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
223438923|NCT04622072|DRUG|XZP-5809-TT1 Tablet|Single tartrate of XZP-5809
223438924|NCT02407587|DEVICE|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
223438925|NCT00895570|DRUG|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
223438926|NCT00895570|DRUG|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
223438927|NCT00580749|PROCEDURE|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
223438928|NCT00580749|PROCEDURE|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
223438929|NCT00220948|PROCEDURE|CERSR Myoelectric monitoring during standardized tasks|
223438930|NCT02488967|DRUG|Carboplatin|Given IV
223438931|NCT02488967|DRUG|Cyclophosphamide|Given IV
223438932|NCT02488967|DRUG|Doxorubicin Hydrochloride|Given IV
224049981|NCT02180971|PROCEDURE|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
223438933|NCT02488967|OTHER|Laboratory Biomarker Analysis|Correlative studies
224049982|NCT03090087|BIOLOGICAL|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
224049983|NCT03090087|DRUG|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
224049984|NCT05923021|OTHER|cheek acupuncture|Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
223438934|NCT02488967|DRUG|Paclitaxel|Given IV
223438935|NCT04183569|OTHER|Sequencing RNA.|RNA-seq, central pivot between genomics and proteomics allows to make the connection between the observed mutations and alteration of protein expression with the identification and quantification of RNA. Thus, we can attest to the expression of mutations identified on DNA, protein and understand whether deregulation is linked to dysregulation of transcription or post-translational modification
223438936|NCT01538394|DRUG|Varenicline|
223438937|NCT01538394|DRUG|Nicotine patches|
223438938|NCT01538394|DRUG|Placebo (nicotine patches)|
223438939|NCT04686812|BEHAVIORAL|Worksite health promotion program|Physical activity, nutrition, and stress management programs
223438940|NCT05664451|BEHAVIORAL|UI-Assist|"To support primary care in implementing guideline-based care, it is helpful to distill interventions to their key components, such as the five major intervention steps for tobacco use and dependence (the 5 A's). The 5 A's (Ask, Advise, Assess, Assist, Arrange) has been shown to help primary care providers implement clinical practice guidelines with minimal additional burden. The 5 A's can be similarly simplified for urinary incontinence (UI) screening and treatment to Ask (screen for UI); Advise (inform that effective nonsurgical treatments exist); and Assist (help patient get treatment with pharmacotherapy, referral to community classes, physiotherapy or urology / urogynecology)."
223438941|NCT05664451|OTHER|Partnership Building|In addition to the strategies described above, those practices allocated to streamlined practice facilitation and partnership building will have facilitation and configurable solutions that engage community resources and enable coalition building. In addition to a practice facilitator, a partnership facilitator from the Wisconsin Institute for Healthy Aging (WIHA) will identify existing local community resources with which the practice may choose to partner. After initiating academic detailing, these practices will have further access to Drs. Brown and Neuner for ongoing consultation. An online learning community will also be created where information can be shared and exchanged throughout the duration of the project and beyond the maintenance phase.
223438942|NCT02094950|PROCEDURE|Acupuncture|
223566593|NCT00741195|DRUG|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
223566594|NCT00741195|DRUG|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
223566595|NCT06508177|OTHER|İnterfascial plane block|Interfascial plane blocks will be added to the routine analgesia plan as part of multimodal analgesia.
223566596|NCT06508177|OTHER|Standart analgesia plan|This is the routine analgesia plan applied in our clinic.
223566597|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule|Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
223566598|NCT04170504|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
223566599|NCT04170504|DRUG|Qing Re Huo Xue (QRHX) granule placebo|Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
223740806|NCT05585151|DRUG|Intensive statin treatment|Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
224049985|NCT01086020|DRUG|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
224049986|NCT01086020|DRUG|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
223438943|NCT03486964|DRUG|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
223438944|NCT03489902|PROCEDURE|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
223438945|NCT03489902|PROCEDURE|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
223438946|NCT02366403|BEHAVIORAL|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
223438947|NCT02366403|BEHAVIORAL|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
223438948|NCT02702232|OTHER|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
223438949|NCT00511654|DRUG|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
223438950|NCT00511654|DRUG|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
223438951|NCT00511654|DRUG|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
223566600|NCT01349322|RADIATION|Standard fractionation whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 25 fractions of 2.0 Gy for a total dose of 50.0 Gy or 16 fractions of 2.67 Gy for a total dose of 42.7 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
223566601|NCT01349322|RADIATION|Hypofractionated whole breast irradiation|Target-based radiation using three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) to deliver 15 fractions of 2.67 Gy for a total dose of 40.0 Gy. Must begin within 9 weeks of last surgery or chemotherapy delivery.
223566602|NCT01349322|RADIATION|Concurrent boost|15 fractions of 3.2 Gy for a total dose of 48 Gy to the lumpectomy cavity. Given concurrently with treatment to the entire breast. May be given by either electron beam or photon beams using either 3D-CRT or IMRT.
223566603|NCT01349322|RADIATION|Sequential boost|6 fractions of 2.0 Gy per fraction for a total dose of 12 Gy or 7 fractions of 2.0 Gy for a total dose of 14 Gy to the lumpectomy cavity. May be given by either electron beam or photon beams using either 3D-CRT or IMRT. Begins without a treatment break after completion of the treatment to the entire breast.
224049987|NCT00050141|DRUG|ZARNESTRA, tipifarnib, R115777|
224049988|NCT02489643|PROCEDURE|Individualized practical training|
224049989|NCT04450667|DIETARY_SUPPLEMENT|Nutricia PreOp|Oral rehydration 2 hours before the scheduled cesarean section under spinal anesthesia
224163679|NCT03409575|OTHER|10 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
223566604|NCT06053112|OTHER|New infant formula with 6 HMOs blend|Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
223566605|NCT06053112|OTHER|Standard infant formula without 6 HMOs blend|Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
223438952|NCT01714856|DRUG|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
223438953|NCT06526325|DEVICE|Enhanced golgi tendon organ stimulation|Enhanced Golgi Tendon Organ Stimulation is a method that can be used by physiotherapists and doctors. The Golgi tendon organ is the proprioceptors located in the tendon adjacent to the myotendinous junction. It is applied using two separate heads, the stimulator and the algometer. The sternocleidomastoideus, platysma, colli longus, capitis longus, scalene, rhomboid major and minor, levator scapulae and trapezius muscles and their tendons will be vibrated with a stimulator for 30 seconds, then 0.5 kilograms of pressure will be applied with an algometer from the origin to the insertion of the muscle in the region at 0.5 centimetre intervals at an angle of 90 degrees.
223566606|NCT05295121|DRUG|XC221 100 mg tablets|XC221, 3 discrete doses separated by 7-day wash-out periods
223566607|NCT04301128|OTHER|Experimental|Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
223566608|NCT04301128|OTHER|control|Patients in the control group were informed same informations verbally and given an education book.
224049990|NCT03633526|DRUG|VX-659/TEZ/IVA|VX-659/TEZ/IVA FDC tablet.
224049991|NCT03633526|DRUG|IVA|IVA mono tablet.
224049992|NCT00656240|DRUG|DE-104 ophthalmic solution|
224049993|NCT00656240|DRUG|DE-104 vehicle|
224049994|NCT01085786|DRUG|14-day sequential treatment|"* 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
223438954|NCT04509817|DEVICE|Acupuncture+Usual care|"Acupuncture intervention Disposable, sterilized needles (0.25×40 mm and 0.30×50 mm) will be used and selected acupoints will include GV20, CV4, and bilateral BL32, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9. Subject will be prone position first and BL32 will be inserted with an angle of 30-45° in an inferomedial direction and a depth of 30-50 mm. Once the subject has a needle sensation ('De-qi'), the needle will be removed immediately. Then the subject will be supine position, and GV20, CV4, ST25, ST29, EX-CA1, LI4, LR3, SP6, SP9 will be needled with a depth of 10-40mm. After subject feel 'De-qi', the needles will be placed for 20 min to maintain the stimulation.~Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise.~Behavioral: Usual care Usual care intervention The subjects will receive the health advice including diet with regular meal, enough sleep, and appropriate exercise."
223438955|NCT04509817|BEHAVIORAL|Usual care|Usual care intervention The subjects will receive the health advice
224049995|NCT01085786|DRUG|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
224049996|NCT00006469|DRUG|carboplatin|
223438956|NCT01304303|DRUG|SPARC1023 I|IV administration
223438957|NCT01304303|DRUG|SPARC1023 II|IV administration
223438958|NCT01041677|DRUG|R256918|10 mg capsule twice daily
223438959|NCT01041677|DRUG|placebo|placebo capsule twice daily
223438960|NCT01041677|DRUG|R256918|15 mg capsule twice daily
223438961|NCT03556397|PROCEDURE|Sentinel lymph node biopsy (SLNB)|Sentinel lymph node biopsy will be performed in the patients
223438962|NCT03556397|PROCEDURE|Axillary dissection|Axillary dissection procedure will be performed in the patients
223438963|NCT01044589|DEVICE|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
223438964|NCT01044589|OTHER|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
223438965|NCT01017757|PROCEDURE|High-resolution CT scanning|High-resolution CT scanning
223438966|NCT02322333|DRUG|MLD10|
223438967|NCT02322333|DRUG|Placebo|
223438968|NCT06620419|DEVICE|Perineal-applied electrical stimulation|Small controller that outputs stimulation for stress incontinence and OAB, attached to a male-anatomy thin GelPad placed in the perineal area.
223438969|NCT06618677|OTHER|LOW FODMAPs Diet|patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).
223438970|NCT00739505|BIOLOGICAL|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
223438971|NCT00739505|BIOLOGICAL|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
223566609|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)|"HABIT-ILE (Hand-Arm Bimanual Intensive Therapy including Lower Extremities) is an intensive therapy that continuously incorporates postural control and LE function. This motor learning-based approach include specificity of the practice, motivation, shaping of the task, intensive blocks of training and Hands-Off. Moreover, the therapy is goal-oriented to increase functional independence during daily living. This therapy has shown impressive improvements in children with PC."
223740807|NCT04602182|PROCEDURE|music therapy intervention|Patients will receive a daily music therapy intervention from the beginning until the end of the weaning from mechical ventilation.
223740808|NCT02078609|DRUG|LGH447|LGH447 in patients with AML or MDS
223740809|NCT02078609|DRUG|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
224049997|NCT00006469|DRUG|paclitaxel|
224049998|NCT00006469|PROCEDURE|conventional surgery|
223438972|NCT03457805|DEVICE|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
223478595|NCT03468504|DEVICE|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
223478596|NCT03468504|DEVICE|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
223478597|NCT01750437|DRUG|YH1885L(Revaprazan)|
223478598|NCT01750437|DRUG|Esomeprazole 20mg|
224049999|NCT00006469|PROCEDURE|neoadjuvant therapy|
224050000|NCT00006469|RADIATION|radiation therapy|
224050001|NCT01792349|BEHAVIORAL|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
224050002|NCT05175573|DEVICE|SuperNO2VA Et Nasal Positive Pressure Mask|Nasal mask with capnography providing continuous positive airway pressure at 10LPM
224050003|NCT05175573|DEVICE|Supplemental Oxygen Face Mask|Face mask with capnography providing oxygenation at 10 LPM
224050004|NCT04420611|OTHER|Session 1 (day 1)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
224163680|NCT04692896|DRUG|lidocaine|different concentrations of lidocaine with same concentration of adrenaline
224050005|NCT04420611|OTHER|Session 2 (day 3)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
223438973|NCT00526565|BEHAVIORAL|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
223438974|NCT00526565|BEHAVIORAL|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
223438975|NCT06619431|DEVICE|Mobile Application|"Rumbo is an easily shared bi-lingual application that helps Hispanic individuals with unhealthy substance use find and access treatment services and related resources. The application stands out from other eHealth tools by leveraging the collective efficacy of the Hispanic community to overcome barriers and support individuals' self-efficacy for engaging the treatment system. Rumbo's simple, user-centered design provides less-acculturated Hispanic individuals with a culturally appropriate tool to understand their needs within the complex US treatment system. Rumbo is comprised of four innovations: (1) a sharing function that facilitates its own implementation among the target population; (2) culturally responsive content and design; (3) problem identification and treatment navigation enhanced to include related resources; (4) an API that is designed for interoperability across extant technologies."
223438976|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
223438977|NCT00463294|PROCEDURE|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
223438978|NCT01953835|DRUG|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
223438979|NCT01953835|DRUG|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
223478599|NCT01750437|DRUG|placebo|
223478600|NCT05890079|OTHER|Subcostal transversus abdominis plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure.
224050006|NCT04420611|OTHER|Session 3 (day 15)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to drink or eat caffeinated food/drinks 24 hours prior to night-time urine collection (at least one cup of coffee or a can of Coca-Cola®).~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
224143814|NCT05708937|BEHAVIORAL|Mindfulness based phone app|"Creating mindfulness-based suggestions for infertile women:~Mindfulness-based content was created by taking the opinions of experts in the fields of women's health nursing, psychology and linguistics. It consists of 6 different parts. The content of meditation that the patient will apply according to the treatment stage is different. Infertility mindfulness departments; Breath Awareness, Body \& Uterus Awareness, Needle Therapy and Ovarian Awareness, Pre-Egg Collection (OPU) Diaphragm Breathing, Pre-embryo Transfer Uterine Awareness, Embryo and Uterine Awareness (Post transfer).~Audio recordings of mindfulness-themed meditation content:~After the meditation contents are planned; the sound recording was taken with a professional recorder (Sony ICD-PX470). The audio recordings taken were professionally edited by the expert. Mp3 recordings were created by adding background music to sound recordings in computer environment. Audio recordings of mindfulness-themed meditation content"
224143815|NCT03297437|OTHER|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
224143816|NCT05161182|OTHER|High fat, low carbohydrate diet|Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
224143817|NCT05161182|OTHER|Low fat, high carbohydrate diet|Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
224143818|NCT05265130|DRUG|YiQiFuMai|YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
224143819|NCT05265130|DRUG|0.9% Normal Saline 250ml|0.9% Normal Saline 250ml IV, about 40 drops per min.
224050007|NCT04420611|OTHER|Session 4 (day 30)|"12 hours overnight urine (9 pm - 9 am) will be collected. First morning voids will be collected separately in order to be also analysed independently from the 12 hours collection. 24 hours before the 12 hours overnight urine collection, volunteers will be asked to refrain from alcohol consumption and methylxanthine-containing beverages and foods.~After the 12-hour urine collection (around 9:00 a.m.), subjects will be given a cup of coffee or a can of Coca-Cola®. Capillary blood samples (10 μL) will be taken from the fingertips 2 hours after the coffee or Coca-Cola®."
224050008|NCT02147366|BEHAVIORAL|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
224050009|NCT02147366|BEHAVIORAL|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
224050010|NCT02153554|BEHAVIORAL|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
224050011|NCT04563780|DEVICE|99mTC pertechnetate thyroid scan|Thyroid scintigraphy was performed just before RIT. 20 min after intravenous injection 99mTc-pertechnetate, anterior images of the neck were acquired using a scintillation camera equipped with low-energy high resolution collimator. Energy discrimination was provided with a 20% window that was centered on the 140 keV peak of 99mTc .
224050012|NCT04366050|DRUG|Ramipril 2.5 MG Oral Capsule|Include description or ramipril from protocol
224050013|NCT04366050|DRUG|Placebo oral capsule|Placebo
224050014|NCT04792567|DRUG|BAF312|taken orally once per day (dose depends on CYP2C9 genotype)
224050015|NCT04792567|DRUG|Baseline disease modifying therapies (DMTs)|DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC
224050016|NCT04792567|BIOLOGICAL|BNT162|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.
224143820|NCT03452891|OTHER|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
224143821|NCT03452891|DRUG|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
224143822|NCT00776555|DRUG|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
224143823|NCT00776555|DRUG|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
224143824|NCT00002212|DRUG|Bexarotene|
224050017|NCT04792567|BIOLOGICAL|mRNA-1273|Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
224050018|NCT03533972|DRUG|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
224050019|NCT03533972|OTHER|Placebo|placebo capsules given twice daily after meals for 1 month
224050020|NCT03320928|OTHER|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
224050021|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
224050022|NCT01516840|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
224050023|NCT01516840|DRUG|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
224050024|NCT01516840|DRUG|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
224050025|NCT00239811|DRUG|FTY720|
224050026|NCT02201420|DRUG|Tc 99m tilmanocept|
224050027|NCT03856853|DRUG|Pirfenidone|pirfenidone for SSc-ILD treatment
224050028|NCT03856853|OTHER|placebo|as control
224050029|NCT00001096|BIOLOGICAL|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
224050030|NCT00001096|BIOLOGICAL|QS-21|
224050031|NCT00001096|BIOLOGICAL|rgp120/HIV-1MN|
224050032|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray|"In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray."
224050033|NCT04200235|DRUG|Dexmedetomidine hydrochloride nasal spray blank preparation.|"In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation."
224050034|NCT00227292|DRUG|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
224050035|NCT00227292|DRUG|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
224050036|NCT00005798|DRUG|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
224050037|NCT00005798|DRUG|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
224143825|NCT04744701|DIAGNOSTIC_TEST|Hemochron Signature Elite Whole Blood Microcoagulation System|Bedside test of Activated Partial Thromboplastin Time
224143826|NCT00002247|DRUG|Ganciclovir|
224143827|NCT05836363|PROCEDURE|Ascending aorta replacement|The aneurysmatic ascending aorta tract is replaced with a tubular dacron prosthesis
223438980|NCT01953835|DRUG|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
223438981|NCT01953835|DRUG|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
223438982|NCT02983435|OTHER|G1 - Thrust manipulation|Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
223438983|NCT02983435|OTHER|G2 - Muscle Energy|Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
223438984|NCT05220566|BEHAVIORAL|Reserved Therapeutic Space|The main objective of the 'Reserved Therapeutic Space' intervention is to enhance the therapeutic bond of trust, to enable the agreement of objectives and interventions in a shared manner in relation to their recovery process in the unit. The intervention is carried out through individual meetings between the nurse and the patient in a comfortable and intimate space, where there are no interruptions and which is also chosen by the person who is hospitalized. The content of the spaces must be constructed individually according to the patients' concerns at each moment of the process.
223438985|NCT03161626|DRUG|Coagadex|Plasma-driven blood coagulation factor X concentration
223438986|NCT01361269|DRUG|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
223438987|NCT04182568|DRUG|nab-paclitaxel followed by anthracycline and cyclophosphamide|nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
223438988|NCT04182568|DRUG|Docetaxel followed by anthracycline and cyclophosphamide|Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
223438989|NCT02987569|BEHAVIORAL|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
223438990|NCT02987569|BEHAVIORAL|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
223438991|NCT00775554|OTHER|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
224050038|NCT00005798|DRUG|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
224050039|NCT05728931|BIOLOGICAL|Test of biological samples|Different tests can be use on biological sample : western bloc, dot blot, immune-fluorescence, immunoprecipitation, CBA, functional test, epitope research, IgG title
224050040|NCT06091085|DRUG|Acetazolamide|Administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2x250mg pills) for 2 nights
224050041|NCT06091085|DRUG|Placebo|Placebo sugar pills administered for 3 nights, half-dose (1 pill) on the first night followed by full dose (2 pills) for 2 nights
224050042|NCT03163251|BEHAVIORAL|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
224050043|NCT01214694|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
224050044|NCT01214694|BEHAVIORAL|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
224050045|NCT01214694|BEHAVIORAL|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
223438992|NCT00775554|OTHER|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
223478601|NCT05890079|OTHER|External oblique intercostal plane block|External oblique intercostal plane block will be administered at the end of the surgery and after skin closure. .
224050046|NCT02831192|BIOLOGICAL|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
224163681|NCT04712643|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
224163682|NCT04712643|DRUG|Becavizumab|Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
224163683|NCT04712643|DEVICE|Transarterial chemoembolization (TACE)|TACE will be performed by clinical demand.
224143828|NCT02086721|DRUG|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
224143829|NCT02878512|PROCEDURE|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
224143830|NCT02878512|PROCEDURE|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
224143831|NCT05405907|OTHER|PuraBond haemostatic agent|Application of Purabond to surgical field
224143832|NCT06275243|DIAGNOSTIC_TEST|Kit Buccal swab collection & stabilization de Canvax®|Assessment of ApoE variant in saliva samples as a potential biomarker for Alzheimer's disease.
224143833|NCT06275243|OTHER|Cholesterol levels according to ApoE Genotype|Enhancing the quality of life of study participants by investigating cholesterol levels based on their ApoE genotype.
224143834|NCT06275243|OTHER|Assessing cardiovascular risk factors in all participants|Through individual interviews, record cardiovascular factors and assess their correlation with Alzheimer's disease.
224143835|NCT04776564|OTHER|Participation in the couple enhancement program|Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
224050047|NCT04049955|PROCEDURE|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
224050048|NCT04497896|OTHER|Repair of open globe injury|repair of corneal, corneoscleral, or scleral wounds
224143836|NCT00866515|DRUG|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
224050049|NCT01231659|DRUG|Everolimus|Everolimus 10 mg (2 tablets of 5 mg) once daily
224143837|NCT00866515|DRUG|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
224143838|NCT03379480|BEHAVIORAL|Yoga arm|Yoga module developed for patients with Schizophrenia
224143839|NCT03292679|PROCEDURE|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
224143840|NCT01364350|OTHER|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
224143841|NCT02940626|DRUG|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
224143842|NCT02940626|DRUG|Placebo|Placebo
224143843|NCT05737173|DRUG|Leukocyte-rich platelet-rich plasma|Intra-articular knee injection
224143844|NCT05737173|DRUG|Leukocyte-poor platelet-rich plasma|Intra-articular knee injection
223478602|NCT06399042|DEVICE|SP5M002 inj|pre-filled syringe
223478603|NCT06399042|DEVICE|Synovian inj|pre-filled syringe
224050050|NCT01231659|DRUG|Letrozole|Letrozole 2.5 mg once daily
224050051|NCT04534491|DRUG|Oxybutynin (Oxytrol, BAY839380)|Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
224050052|NCT05501938|PROCEDURE|Physical Exam Indicated Cerclage|Transvaginal cervical cerclage
224050053|NCT03526770|OTHER|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
224143845|NCT05737173|DRUG|Corticosteroid|Intra-articular knee injection
224143846|NCT02430662|PROCEDURE|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
224143847|NCT02430662|DEVICE|NanoKnife|
224143848|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
224143849|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
224143850|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
224143851|NCT00871949|DRUG|PNU-100480|300 mg oral suspension given once
224143852|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
224143853|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
224143854|NCT00871949|DRUG|PNU-100480|100 mg oral suspension given once
224143855|NCT00871949|DRUG|PNU-100480|35 mg oral suspension given once
224143856|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
224143857|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
224143858|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
224143859|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
224143860|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
224143861|NCT00871949|DRUG|PNU-100480|1500 mg oral suspension given once
224143862|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
224143863|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
224143864|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
224143865|NCT00871949|DRUG|PNU-100480|1000 mg oral suspension given once
224143866|NCT00871949|DRUG|PNU-100480|600 mg oral suspension given once
224143867|NCT00871949|DRUG|PNU-100480|Fed conditions, 600 mg oral suspension given once
224143868|NCT00871949|DRUG|Placebo|placebo to match oral suspension given once
224050054|NCT03526770|OTHER|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
224050055|NCT03526770|DRUG|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
223438993|NCT03806023|DEVICE|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
223438994|NCT05294159|OTHER|The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)|The Feasibility and Acceptability of Intervention Measure (FIM and AIM) are used to evaluate the feasibilit and acceptability of our implementation strategies. The FIM and AIM is a validated implementation outcome measure where higher scores indicate greater feasibility and acceptability
223438995|NCT03490396|DEVICE|Gelclair|Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
224050056|NCT03526770|OTHER|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
224050057|NCT03526770|OTHER|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
223438996|NCT03490396|COMBINATION_PRODUCT|First® Mouthwash BLM|Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
223438997|NCT01323816|OTHER|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
223438998|NCT06451328|DRUG|Lignosus rhinoceros TM02®|Lignosus rhinoceros TM02®
224050058|NCT03526770|OTHER|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
224050059|NCT03708549|DRUG|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
224050060|NCT03708549|DRUG|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
224050061|NCT02355899|DRUG|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
224050062|NCT01010698|DRUG|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
224050063|NCT03936283|BEHAVIORAL|Intervention|The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
224050064|NCT05040802|OTHER|Not applicable / dataset analysis|Not applicable / dataset analysis
224050065|NCT05837442|OTHER|Osteopathic Manual Therapy|Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
224143869|NCT00648193|DRUG|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
224143870|NCT00648193|DRUG|Paxil® 40 mg Table|40mg, single dose fasting
224143871|NCT01047761|OTHER|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
224143872|NCT00198445|DRUG|Bromfenac|One drop in study eye every 12 hours for 14 days
224143873|NCT00198445|DRUG|Placebo|One drop in study eye every 12 hours for 14 days
224143874|NCT00756496|DEVICE|Mammography screening and diagnosis|Mammography screening and diagnosis
224143875|NCT02205606|DRUG|HGP0816 5mg|P.O.
224143876|NCT02205606|DRUG|HGP0816 10mg|P.O.
224143877|NCT02205606|DRUG|HGP0816 20mg|P.O.
224143878|NCT02205606|DRUG|HCP1306 5/10mg|P.O.
224143879|NCT02205606|DRUG|HCP1306 10/10mg|P.O.
224143880|NCT02205606|DRUG|HCP1306 20/10mg|P.O.
224143881|NCT00585923|DEVICE|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
224143882|NCT00585923|DEVICE|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
223438999|NCT01479192|DRUG|Fenretinide|100mg (2cps/day) for 5 years
223439000|NCT01479192|OTHER|Placebo|2 cpr/day of matched placebo for 5 years
223439001|NCT02027857|DEVICE|EIT monitoring|
223439002|NCT02027857|DEVICE|non-invasive ICP monitoring|
223439003|NCT01097070|DRUG|Bevirimat|
224143883|NCT05322057|DRUG|Darvadstrocel|Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract
224143884|NCT04345406|DRUG|ACEIs|Captopril or enalapril
224143885|NCT04345406|DRUG|Conventional treatment|alexoquine
224143886|NCT03447613|PROCEDURE|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
224143887|NCT01869062|DEVICE|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
223439004|NCT04248504|OTHER|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
223439005|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
223439006|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
223439007|NCT00971035|DRUG|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
223439008|NCT00971035|DRUG|placebo|Subcutaneous repeating dose
223439009|NCT04191941|BIOLOGICAL|Novel CAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of Novel CAR-T cells
223439010|NCT03533881|DIETARY_SUPPLEMENT|Arom Digest Slim|"Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day"
224050066|NCT06432829|BEHAVIORAL|Unified Protocol for the transdiagnostic treatment of emotional disorders|This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
224050067|NCT05063721|BIOLOGICAL|autologous mesoangioblasts|intra-arterial administration of autologous mesoangioblasts in lower leg (50x10E6/kg)
224050068|NCT04785170|DRUG|Amino Acid|"A novel non-protein amino acid secreted by skeletal muscles which aids the cross-talk between skeletal muscles, liver, and adipose tissue at molecular levels. amino acid is generated by catabolism of the branched-chain amino acid valine. Existing literature states, amino acid induces body fat loss by increasing energy expenditure, stimulating free fatty acid (FFA) oxidation in the liver and skeletal muscle cell, and by enhancing oxygen consumption by adipose tissue and hepatocytes. It was observed that amino acid stimulated differentiation of energy storing white adipose tissue preadipocytes to an energy burning beige (brown to white) phenotype."
224050069|NCT02197338|OTHER|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
224050070|NCT02851381|DRUG|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~* Dose: 35 mg/kg~* Route: IV over one hour following completion of gemcitabine infusion~* Schedule:~  * Days 1, 8, and 15~ * Please note that Day 8 infusion will on be completed during the first treatment cycle"
224050071|NCT01984372|DRUG|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
224050072|NCT04637607|OTHER|Auricular acupoints stimulation|Noninvasive auricular acupoints stimulation with seeds
224050073|NCT04216745|DIAGNOSTIC_TEST|bile culture|Bile samples will be collected for microbial cultures and antimicrobial susceptibility testing using COMPACT-15 automated system (Bio Merieux, Marcy I'Etoile, France) for bacteria and saboroud's agar for fungal culture.
224050074|NCT04383873|DEVICE|Training by means of Armeo Spring device|This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.
224050075|NCT04383873|OTHER|Current treatment based on conventional therapy|All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.
224050076|NCT04383873|OTHER|Additional treatment based on conventional therapy|This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.
224050077|NCT01314963|DEVICE|Prototype intraoperative handheld gamma camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium \[NaI(Tl)\] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.
224143888|NCT01869062|DEVICE|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
224143889|NCT00000944|DRUG|Indinavir sulfate|
224143890|NCT00000944|DRUG|Lamivudine|
224143891|NCT00000944|DRUG|Zidovudine|
224163684|NCT05554055|BIOLOGICAL|Anti Xa activity measurement.|Arterial blood samples of 3cc will be taken during the procedure at each ACT. Blood samples will be sent to the lab for anti Xa activity measurement.
223439011|NCT03533881|BEHAVIORAL|Nutritional changes|Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
223439012|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
223439013|NCT00719914|DRUG|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
223439014|NCT00719914|DRUG|normal saline|Intra-coronary injection, weight based, of normal saline.
223439015|NCT01367600|DRUG|SC Methylnaltrexone (MNTX)|
223439016|NCT01162148|BEHAVIORAL|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
223439017|NCT01162148|DEVICE|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
224163685|NCT03208075|OTHER|normal diet|Diet containing 1500mg of phosphorus
224163686|NCT03208075|OTHER|low-phosphorus diet|Diet containing 500mg of phosphorus
224163687|NCT03208075|OTHER|high-phosphorus diet|Diet containing 2300mg of phosphorus
223439018|NCT01162148|DEVICE|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
223439019|NCT01162148|DEVICE|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
223439020|NCT03600012|OTHER|Cycling Functional Electrical Stimulation|
224050078|NCT01314963|DEVICE|Lymphoscintigraphy with intraoperative gamma probes (GP)|Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)
224050079|NCT01314963|RADIATION|radioactive Tc99M|Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
223439021|NCT03600012|OTHER|Physiotherapy|
224050080|NCT03863600|BEHAVIORAL|Midwife-led continuity of care|Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
224143892|NCT04958616|DIAGNOSTIC_TEST|Skin prick test.|Skin prick test: for (Dermatophagoides pteronyssinus and Dermatophagoides Farina). Through the use of specific allergen extracts, positive and negative controls, then interpretation after 15-20 minutes of maneuver, a wheal ≥3 mm diameter is considered positive \[9\]. Before the test, we checked that the patient has not taken medications that might interfere with the test and antihistamines had stopped using before the skin prick test (2 days for the first generation and 7 days for the second generation)
224050081|NCT04898920|DRUG|Normal saline|The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.
224050082|NCT04898920|DRUG|Dexamethasone|Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.
224143893|NCT01791114|OTHER|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
224143894|NCT01791114|OTHER|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
223439022|NCT05656703|DEVICE|BIS guidance of anesthesia|Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
224050083|NCT03556436|DRUG|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
224050084|NCT01147328|OTHER|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
224050085|NCT05377268|PROCEDURE|LH Protocol|Patients will be randomized and data interpreters will be blinded to two, randomized, alternating 14-day protocols where the patients will be advised by the nurse educator verbally to inject insulin in sites of subclinical lipohypertrophy
224050086|NCT02504359|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
224050087|NCT02504359|DRUG|Carmustine|Given BEAM chemotherapy
224050088|NCT02504359|DRUG|Cytarabine|Given BEAM chemotherapy
224050089|NCT02504359|DRUG|Etoposide|Given BEAM chemotherapy
224050090|NCT02504359|DRUG|Ixazomib Citrate|Given PO
224050091|NCT02504359|DRUG|Melphalan|Given BEAM chemotherapy
224050092|NCT02504359|DRUG|Methotrexate|Given IV
223439023|NCT05656703|OTHER|Standard of Care|Anesthesia is administered as usual
223439024|NCT00634049|DRUG|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
223478604|NCT04662333|PROCEDURE|Transcrestal approach for sinus lift|After surgical exposure of maxillary alveolar crest, implant site preparation and transcrestal detachment of Schneiderian's membrane will be performed. Thereafter implant will be placed, protruding in the maxillary sinus with its apical part.
223478605|NCT04662333|PROCEDURE|Xenograft application|Before implant placement, xenogenic collagen membrane and bone granules will be pushed under the Schneiderian's membrane through the surgical site.
224050093|NCT02504359|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
223478606|NCT05720637|DRUG|SSRI|SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
224050094|NCT02504359|OTHER|Quality-of-Life Assessment|Ancillary studies
224050095|NCT02504359|DRUG|Tacrolimus|Given IV or PO
224050096|NCT04646785|BEHAVIORAL|Mindfulness-based cognitive therapy + TAU|The proposed intervention is mindfulness-based cognitive therapy (MBCT), based on the protocol published by Segal, Williams and Teasdale. MBCT consists of eight weekly 2.5h group sessions, a six-hour silent day and daily home practice assignments guided by audio files. The program includes both formal and informal meditation exercises. Cognitive techniques include monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan. Psycho-education and interactive dialogue typically focus on stress management, balancing activities, and (lifestyle) strategies to stay well in the future (relapse prevention).
224050097|NCT04646785|OTHER|Treatment as usual (TAU)|Treatment as usual (TAU) according Dutch and European IBD treatment guidelines. TAU focuses on pharmacological and surgical disease control, and prevention of complications.
224050098|NCT03875209|BIOLOGICAL|10E8.4/iMab|bispecific monoclonal antibody
224050099|NCT03295877|DRUG|RO7171009|Patients will receive RO7171009 via ITV injection.
224050100|NCT03764891|PROCEDURE|Uphold|Uphold system in treating women with cystocele
224050101|NCT03764891|PROCEDURE|Perigee|Perigee system in treating women with cystocele
224050102|NCT05541822|DRUG|Vabametkib|"Tablets~Route of Administration: Oral"
224050103|NCT05541822|DRUG|Lazertinib|"Tablets~Route of Administration: Oral"
223439025|NCT02018354|PROCEDURE|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
223439026|NCT02018354|PROCEDURE|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
223439027|NCT04148859|PROCEDURE|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
223439028|NCT02561741|DRUG|COV155|COV155 tablets
223439029|NCT05559424|DIAGNOSTIC_TEST|OCT|OCT will be used to assess results after intervention
223439030|NCT01564641|DEVICE|iDuo G2|single comparator
223439031|NCT06081959|DRUG|SKB264|IV infusion on day 1 and Day 15 of each 28 day cycle
224050104|NCT05348148|DRUG|Oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
224050105|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
224050106|NCT05348148|DRUG|Combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline|"Patients will be randomly assigned into three groups. Patients in oral Levocetirizine group will use oral antihistamine only (Levocetirizine), another in combined Intranasal Mometasone Furoate with oral Levocetirizine group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine), and the other in combined Intranasal Mometasone Furoate with oral Levocetirizine plus intranasal Oxymetazoline group will use combined intranasal corticosteroids (intranasal Mometasone Furoate) with oral antihistamine (Levocetirizine) plus one-week intranasal decongestant (intranasal Oxymetazoline).~Digital images and the questionnaires, including PRQLQ, AdolRQLQ, and mini-RQLQ, of every participant will be taken at the beginning of the study. Further assessments will be taken at least 3 times, on the seventh day, fourteenth day, and twenty-eighth day after treatment."
224050107|NCT00131469|DRUG|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
224050108|NCT00131469|DRUG|Placebos|
224050109|NCT02094963|DRUG|Ticagrelor|180mg loading and 90mg bid
224050110|NCT02094963|DRUG|Clopidogrel|600mg loading and 75mg qd
224050111|NCT02577614|DRUG|FEIBA|Administration of FEIBA after cardiopulmonary bypass
224050112|NCT02577614|DRUG|Normal Saline|Administration of placebo after cardiopulmonary bypass
224050113|NCT02923089|OTHER|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
224050114|NCT02923089|OTHER|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
224050115|NCT02923089|OTHER|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
224050116|NCT02923089|OTHER|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
223439032|NCT06081959|DRUG|Eribulin|1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
223439033|NCT06081959|DRUG|Capecitabine|1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
223439034|NCT06081959|DRUG|Gemcitabine|1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
223439035|NCT06081959|DRUG|Vinorelbine|25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
224050117|NCT02923089|OTHER|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
223439036|NCT00314132|BIOLOGICAL|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
223439037|NCT00314132|BIOLOGICAL|0.9% Saline|0.5 mL, Subcutaneous
223439038|NCT03583905|DRUG|CKD-330|CKD-330 Tab.
223439039|NCT03583905|DRUG|Placebo of CKD-330|Placebo of CKD-330 Tab.
223439040|NCT03583905|DRUG|D086|D086 Tab.
223439041|NCT03583905|DRUG|Placebo of D086|Placebo of D086 Tab.
223439042|NCT03583905|DRUG|D723|D723 Tab.
223439043|NCT03583905|DRUG|Placebo of D723|Placebo of D723 Tab.
223439044|NCT02461797|OTHER|healthy controls|biopsy of nasal mucosa for healthy controls
223439045|NCT02461797|OTHER|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
223439046|NCT02461797|OTHER|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
224050118|NCT02923089|OTHER|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
224050119|NCT02923089|OTHER|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
224050120|NCT02923089|OTHER|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
223439047|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
223439048|NCT03131934|BIOLOGICAL|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
223439049|NCT03131934|PROCEDURE|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
223439050|NCT05475626|PROCEDURE|Arthroereisis-|Surgical options include soft tissue procedures, realignment osteotomies and non-fusion motion-limiting techniques.
223439051|NCT03930784|OTHER|Nil intervention|
223439052|NCT00815334|PROCEDURE|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
223439053|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
224050121|NCT02923089|OTHER|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
224050122|NCT04087278|DIETARY_SUPPLEMENT|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
224050123|NCT04087278|DIETARY_SUPPLEMENT|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
224050124|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
224050125|NCT01448239|DRUG|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
224050126|NCT05489835|BEHAVIORAL|Nutritional counseling|Nutritional counseling
224050127|NCT00204971|DIETARY_SUPPLEMENT|Enteral glutamine powder|nutritional supplement
224050128|NCT00204971|OTHER|placebo|placebo control
224050129|NCT02575768|OTHER|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
224050130|NCT02695433|DIETARY_SUPPLEMENT|Active|Active Treatment Diet Plan
224050131|NCT02695433|DIETARY_SUPPLEMENT|Control|Control Diet Plan
224050132|NCT00530283|OTHER|PET-CT|
224050133|NCT00152555|BEHAVIORAL|Physical Therapy or Relaxation Therapy|
224050134|NCT06097117|DIAGNOSTIC_TEST|MultiplexPCR|PCR is a simple, yet elegant, enzymatic assay, which allows for the amplification of a specific DNA fragment from a complex pool of DNA.. Only trace amounts of DNA are needed for PCR to generate enough copies to be analyzed using conventional laboratory methods. For this reason, PCR is a sensitive assay.
224050135|NCT03926754|DRUG|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
224050136|NCT04494139|BEHAVIORAL|Behavioral and Canteen intervention|Behavioral intervention: 16 weeks
224050137|NCT04494139|OTHER|Canteen|Canteen changes to introduce health foods
224050138|NCT06227273|DIETARY_SUPPLEMENT|Hydrogen water|Daily consumption of hydrogen water for 16 weeks.
224050139|NCT02261779|DRUG|Tranylcypromine|
224050140|NCT02261779|DRUG|Tretinoin|
224050141|NCT00990054|DRUG|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
224050142|NCT01025596|DRUG|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
224050143|NCT02700568|DRUG|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
224050144|NCT01419782|OTHER|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
224050145|NCT06006663|DRUG|Ibuprofen 400 mg.|synthetic intracanal medicament
224050146|NCT06006663|DRUG|modified triple antibiotic paste|synthetic intracanal medicament
224050147|NCT06006663|DIETARY_SUPPLEMENT|curcumin|herbal intracanal medicament
224050148|NCT06006663|DIETARY_SUPPLEMENT|olive leaves extract|herbal intracanal medicament
224050149|NCT02247960|DRUG|Ciprofloxacin|
224050150|NCT02131909|PROCEDURE|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
224050151|NCT02131909|PROCEDURE|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
224050152|NCT00356889|DRUG|erlotinib hydrochloride|Given orally, 150 mg, once daily.
224050153|NCT00356889|BIOLOGICAL|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
224050154|NCT00750971|PROCEDURE|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
224050155|NCT01990092|OTHER|Metanx|Metanx is a prescription medical food.
224050156|NCT01990092|OTHER|Placebo|
224050157|NCT05141162|BEHAVIORAL|case and control group|randomized controlled experimental study
224050158|NCT03910426|OTHER|Blood sampling|Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.
224050159|NCT03910426|OTHER|Nails collection|At the occasion of the blood sampling, finger nails are cut and collected.
223439054|NCT01048684|DRUG|Mannitol|Variation of mannitol dose
223439055|NCT00045734|DRUG|imatinib mesylate|Given orally
223439056|NCT00045734|OTHER|laboratory biomarker analysis|Correlative studies
223439057|NCT00045734|OTHER|pharmacological study|Correlative studies
223439058|NCT02811575|OTHER|Biopsy|Ileon and colon biopsy
223439059|NCT00571025|BEHAVIORAL|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
223439060|NCT01060605|DRUG|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
224050160|NCT03910426|OTHER|Stool collection|At the occasion of the blood sampling, patients are asked to bring a stool sample.
224050161|NCT03910426|OTHER|Physical Functioning|A subgroup of patients are asked to perform some physical tests.
224050162|NCT03910426|OTHER|Sleep|A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.
224050163|NCT05744765|OTHER|breathing exercises|After the initial 5 minutes of relaxed breathing, the participants will perform diaphragmatic and costal breathing for 10 minutes. .5 diaphragmatic breathing will be done in 1 minute.
224050164|NCT03038750|OTHER|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
224050165|NCT03038750|OTHER|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
224050166|NCT03038750|OTHER|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
224050167|NCT03038750|OTHER|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
224050168|NCT03038750|OTHER|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
224050169|NCT03038750|OTHER|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
224050170|NCT03038750|OTHER|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
224143895|NCT01791114|OTHER|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
223566610|NCT05740605|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities at home|The HABIT-ILE therapy at home will follow the same principles as the classic HABIT-ILE. The therapy will take place in the patient's home and a close person (caregiver) will accompany the patient during the therapy. A device will be used to facilitate the implementation of home therapy. Supervision of the therapeutic process will be done remotely by a team of trained supervisors. One hour of remote supervision per day will be scheduled within 6.5 hours of therapy.
223566611|NCT05740605|BEHAVIORAL|Follow-up Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|HABIT-ILE follow-up at home follow the same principles as classic HABIT-ILE but is delivered at the patient home with 4 hours per week in autonomy and 1 hour per week under supervision.
223566612|NCT05740605|BEHAVIORAL|Usual Care|Usual care is all the weekly physiotherapy and occupational therapy sessions that the patient usually receives.
223439061|NCT02991417|BIOLOGICAL|CDVAX|
223439062|NCT00690300|DRUG|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
223439063|NCT00690300|DRUG|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
223439064|NCT06465914|BIOLOGICAL|9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
223439065|NCT06465914|BIOLOGICAL|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule (0.5 mL intramuscular injection in the deltoid muscle).
223439066|NCT04311281|BIOLOGICAL|[F-18]FDDNP-PET|\[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
223439067|NCT00367419|DRUG|Erythromycin|
224050171|NCT03038750|OTHER|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
224050172|NCT03038750|OTHER|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
224050173|NCT03038750|OTHER|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
224050174|NCT03038750|OTHER|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
224050175|NCT03038750|OTHER|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
224050176|NCT03038750|OTHER|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
224050177|NCT03038750|OTHER|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
224050178|NCT03038750|OTHER|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
224050179|NCT03038750|OTHER|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
224050180|NCT03038750|OTHER|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
224050181|NCT03038750|OTHER|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
224050182|NCT03038750|OTHER|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
224050183|NCT03038750|OTHER|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
224143896|NCT01791114|OTHER|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
223439068|NCT00758147|DEVICE|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
223439069|NCT04108221|PROCEDURE|laparoscopy or laparotomy withTransversusAbdominis Plane Block|"The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance."
223439070|NCT06731361|COMBINATION_PRODUCT|Systematic multidisciplinary medication review + ACP (SMMR+)|"The intervention is a training in medication assessment. The goal is to align prescription with the treatment goals of nursing home patients which are set in advance care planning conversations. The training consists of 2 components:~1. Medication assessment with the use of the ReNeWAL criteria (adjusted STOPP/START criteria, tailored to nursing home patients with a limited life expectancy)~2. Advance care planning component. Discussing medication in line with the treatment goals set in advance care planning conversations.~Healthcare professionals receive the training in combination with supporting tools (pocket card) and educational material (the ReNeWAL criteria and PowerPoint slides of the training if requested). Also, intervision moments are planned."
224143897|NCT01791114|OTHER|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
223439071|NCT05490602|PROCEDURE|Running subcutaneous sutures technique|The Running subcutaneous sutures consist of running sutures in the profound and superficial dermis without knotting the thread (suture).
223439072|NCT05490602|PROCEDURE|Classical closures|Classical closures
224050184|NCT06023316|DEVICE|mGain system|passive, noninvasive surface electromyography measurement device and gaming mobile application
223439073|NCT06358729|BEHAVIORAL|Typical Nipple|Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.
223439074|NCT06358729|BEHAVIORAL|Challenging Nipple|Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
224050185|NCT02417155|BEHAVIORAL|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
224050186|NCT02417155|BEHAVIORAL|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
223439075|NCT03482167|DRUG|Niagen®|250 mg capsules (4 capsules daily)
223439076|NCT03482167|OTHER|Placebo|placebo
223439077|NCT00885742|BIOLOGICAL|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023\_2002 \[NCT00883090\]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
224050187|NCT00395889|PROCEDURE|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
224050188|NCT00395889|PROCEDURE|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
224050189|NCT00936403|DRUG|NNC126-0083|One single dose administered in four dose levels in an escalating order
224050190|NCT00936403|DRUG|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
224050191|NCT01624987|BEHAVIORAL|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
224050192|NCT01624987|OTHER|Control group|The control group receives no intervention.
224143898|NCT01791114|OTHER|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
223439078|NCT02200237|BIOLOGICAL|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
223439079|NCT02200237|BIOLOGICAL|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
223439080|NCT05958771|DRUG|ROTAVAC 5D|monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU
223439081|NCT05958771|DRUG|Placebo|Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
223439082|NCT00002615|DRUG|cisplatin|
223439083|NCT00002615|DRUG|epirubicin hydrochloride|
223439084|NCT00002615|DRUG|fluorouracil|
224050193|NCT05924737|OTHER|Sleep deprivatin|40 hours of continuous awakening
224143899|NCT01791114|OTHER|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
224143900|NCT03016299|PROCEDURE|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
224143901|NCT05625854|BEHAVIORAL|Blow a fan to the face combine aromatherapy|Blow a fan with aromatherapy to the face
224143902|NCT05625854|BEHAVIORAL|Blow a fan to the face|Blow a fan to the face
223439085|NCT00002615|PROCEDURE|conventional surgery|
223439086|NCT00737893|DRUG|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
223439087|NCT00737893|DRUG|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
223439088|NCT05640297|BEHAVIORAL|KMC with Massage therapy|investigator will provide tactile and kinesthetic massage
223566613|NCT02666495|OTHER|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement \& stabilisation; phase 2 - developing trust \& understanding; phase 3 - developing awareness \& acceptance; phase 4 - testing change \& strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
224050194|NCT05924737|OTHER|Sleep recovery|sleep recovery after 40 hours of continuous awakening
224050195|NCT01456689|DRUG|LGH447|
224050196|NCT01456689|DRUG|midazolam|
224050197|NCT02049268|DRUG|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
224050198|NCT02049268|DRUG|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
224050199|NCT02049268|DRUG|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
224050200|NCT00143195|DRUG|Amlodipine|
224050201|NCT00143195|DRUG|iso- 5 - mononitrate|
224050202|NCT00143195|PROCEDURE|Blood tests|
224050203|NCT00143195|PROCEDURE|Exercise Stress Test|
224050204|NCT00736034|DIETARY_SUPPLEMENT|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
224050205|NCT05232006|DRUG|Niraparib|Niraparib, once daily
224050206|NCT00300768|DRUG|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
224050207|NCT00300768|DRUG|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
224050208|NCT00300768|DRUG|4 mg moxidectin|Single dose, tablets encapsulated for blinding
224050209|NCT00300768|DRUG|8 mg moxidectin|single dose, tablets encapsulated for blinding
224050210|NCT01982721|DEVICE|Locking mechanism for prosthetic knee|
224050211|NCT04190433|DRUG|Carvedilol|Given PO
224050212|NCT04190433|DRUG|Lisinopril|Given PO
224050213|NCT04190433|DRUG|Pravastatin|Given PO
224050214|NCT04190433|DRUG|Spironolactone|Given PO
224050215|NCT04143360|DEVICE|New Closed Drainage Device|For the first group, a new closed drainage device was adopted.
224050216|NCT04143360|DEVICE|Traditional closed drainage device|For group 2, conventional closed drainage device was used.
223439089|NCT04668170|BIOLOGICAL|Blood collection on admission and longitudinally|Samples already collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)
223439090|NCT04668170|BIOLOGICAL|Blood collection on their first consultation and 10 to 14 days later|Samples already collected on consultation (D0) and 14 days later
223439091|NCT04568967|DIAGNOSTIC_TEST|Concentrated urine with Xpert Ultra|Molecular TB diagnostic test on urine
223439092|NCT04568967|DIAGNOSTIC_TEST|Stool with Xpert Ultra|Molecular TB diagnostic test on stool
224050217|NCT03300167|DEVICE|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
224050218|NCT00861913|OTHER|Laboratory Biomarker Analysis|Correlative studies
224050219|NCT00861913|DRUG|Pazopanib Hydrochloride|Given orally
224050220|NCT00861913|OTHER|Pharmacological Study|Correlative studies
224050221|NCT02566577|BIOLOGICAL|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (\<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
224050222|NCT02566577|BIOLOGICAL|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (\>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
224050223|NCT02566577|DEVICE|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
224050224|NCT06154655|OTHER|E-zine|Health education will be delivered through an electronic magazine
224050225|NCT00350168|DRUG|valsartan + amlodipine|
224050226|NCT01210170|DRUG|placebo|placebo inhalation before albuterol.
224050227|NCT01210170|DRUG|mometasone 400 mcg|mometasone inhalation before albuterol.
224050228|NCT01210170|DRUG|mometasone 200 mcg|200ug mometasone before albuterol.
224050229|NCT03612011|OTHER|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
224050230|NCT04239105|DEVICE|Microfluidic and Raman spectrum|Detection of Circulating Tumor Cells
224050231|NCT03052504|OTHER|Registration of complications|Prospective registration
224050232|NCT01751399|DRUG|LY2605541|
224050233|NCT00606450|DRUG|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
224050234|NCT00606450|DRUG|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
224050235|NCT00606450|DRUG|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
224143903|NCT05625854|BEHAVIORAL|Blow a fan to the feet|Blow a fan to the feet
224050236|NCT05301920|DEVICE|Elexir (trigeminal nerve electrical stimulator)|Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
224050237|NCT02558387|DRUG|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
224050238|NCT01866397|OTHER|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
224050239|NCT02284620|PROCEDURE|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
224143904|NCT01592669|PROCEDURE|passive leg raising|bilateral PLR was achieved by raising the legs of patient
224143905|NCT00057590|BEHAVIORAL|Care manager outreach and monitoring|
224050240|NCT02284620|PROCEDURE|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
224050241|NCT05891184|DEVICE|color doppler ultrasound, transient elastography, upper endoscopy|"Abdominal US: for detecting the portal hypertension, splenomegaly and portosystemic abdominal collaterals .~Doppler US: detecting the diameter and mean blood flow velocity, blood flow volume, perfusion pressure gradient, congestion index, resistive index, pulsatility index of hepatic artery and platelet count-to-spleen diameter ratio will be performed using logic 10 with a 3.5-MHz duplex convex transducer, in supine position after overnight fasting, with holding their breath in maximal expiration in order to minimize the effect of respiration, body position and postprandial changes on the portal flow Endoscopy : Using Sarin classification ( The presence of esophageal varices, their number, exact location, shape, size and cherry-red spots ) Fibroscan: using the standard-probe, and on a fasting (4 h) patient lying flat on his/her back, with the right arm tucked behind the head to facilitate access to the right upper quadrant."
223439093|NCT04827537|DRUG|20-hydroxyecdysone Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
224050242|NCT03086057|BEHAVIORAL|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
224050243|NCT03086057|BEHAVIORAL|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
224050244|NCT02207998|DRUG|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
224143906|NCT00424333|DRUG|Inhaled human insulin|
224143907|NCT00618449|DRUG|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 \& Day 30 for a total of 2 doses.
223439094|NCT04827537|DRUG|Metronidazole Oral|500 mg (one pill) x two times a day orally, 10 consecutive days
223439095|NCT04827537|DRUG|Placebo Oral|100 mg (one pill) x two times a day orally, 10 consecutive days
223439096|NCT00925652|DRUG|Bevacizumab|
223740810|NCT03519347|OTHER|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
223740811|NCT03519347|OTHER|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
224050245|NCT02207998|DRUG|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
224050246|NCT00195312|BIOLOGICAL|HIV-1 gag DNA (formulated with bupivacaine)|
224050247|NCT00195312|BIOLOGICAL|IL-15 DNA (formulated with bupivacaine)|
224050248|NCT00195312|BIOLOGICAL|IL-12 DNA (formulated with bupivacaine)|
224050249|NCT00195312|BIOLOGICAL|Sodium chloride injection USP (0.9%)|
224143908|NCT00618449|DRUG|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
224143909|NCT01441115|PROCEDURE|Radiation Therapy|
224143910|NCT01441115|DRUG|ECI301|
224163688|NCT04819867|DRUG|Propolis|propolis is an extract derived from bee hives
224163689|NCT04819867|DRUG|Gluma Desensitizer|Gluma is a desensitizer agent
223439097|NCT00925652|DRUG|Cyclophosphamide|
223439098|NCT00925652|DRUG|Methotrexate|
223439099|NCT00925652|BEHAVIORAL|Lifestyle: Diet|
223439100|NCT00925652|BEHAVIORAL|Lifestyle: Diet+Exercise|
223439101|NCT04797156|DRUG|High Dose Tranexamic acid|50mg/kg IV TXA
223439102|NCT04797156|DRUG|Low Dose Tranexamic acid|20mg/kg IV TXA
223439103|NCT04797156|DRUG|Tranexamic acid Topical|2g topical TXA
223439104|NCT04797156|DRUG|Normal saline|Normal saline poured on wound
223478607|NCT05720637|DEVICE|SIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.
224050250|NCT03924336|PROCEDURE|Advanced- platelets rich fibrin (A-PRF+) + Open flap debridement (OFD)|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded , A-PRF+ of the required size will be filled into the intraosseous defect. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
224050251|NCT03924336|PROCEDURE|Open flap debridement (OFD) alone|Elevation of flap.Thorough debridement of the defects using curettes and ultrasonic scalers. Clinical measurements will be then recorded. After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
223439105|NCT05650346|OTHER|Deep Cervical Training|The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.
224050252|NCT01485341|DIETARY_SUPPLEMENT|gluten|gluten is administered once a day at 10g/day for 15 days
224143911|NCT02709473|DRUG|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
224050253|NCT01485341|DIETARY_SUPPLEMENT|rice starch|rice starch is administered once a day at 10 g/day for 15 days
224050254|NCT00775736|DRUG|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
224050255|NCT00775736|DRUG|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
224143912|NCT02709473|DRUG|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
224143913|NCT02709473|DRUG|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
223439106|NCT05650346|OTHER|Deep cervical training + Upper cervical mobilization group|"1. the patient in supine crook lying with the neck in a neutral position.The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg~2. The therapist will cover the rear of the cervical part of the participant with his right hand for stabilization, and will place his thumb and index fingers on the atlas of the participant. To conduct the atlanto-occipital mobilization, the therapist will place his left hand at the right side of the participant and at the same time will place his fifth finger under the occipital area and will pull the participant's head toward his trunk."
224050256|NCT00775736|DRUG|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
224143914|NCT00234416|DRUG|Gefitinib|
224143915|NCT00234416|DRUG|Gemcitabine|
224143916|NCT01589055|DRUG|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
224143917|NCT02787642|DRUG|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
223740812|NCT03519347|OTHER|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
223740813|NCT03519347|OTHER|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
223740814|NCT03519347|DIAGNOSTIC_TEST|Point of Care Testing|POC testing will use the Abbott BLUE I-STAT CHEM8+ , a portable, handheld device that provides lab quality analysis within 2-3 minutes using a few drops of whole blood (≤100uL).
223740815|NCT03519347|DEVICE|Cardiac Monitor|Device is one-third of the size of a triple-A battery and is placed subcutaneously in the left chest during a brief procedure that can be done in-office under local anesthesia.
223740816|NCT04890366|DRUG|Dimethyl Fumarate|Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
223740817|NCT05517382|OTHER|supportED|suicide prevention videogame
223740818|NCT05517382|OTHER|Control|non-health related videogame
224050257|NCT01406236|PROCEDURE|Transradial PCI|Transradial PCI
224050258|NCT01406236|PROCEDURE|Transfemoral PCI|Transfemoral PCI
224050259|NCT03180164|OTHER|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
224050260|NCT04088825|OTHER|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
223439107|NCT05650346|OTHER|Deep cervical training + Upper thoracic mobilization group|"1. The Cranio cervical flexion exercise will be performed with the patient in supine crook lying with the neck in a neutral position (no pillow) such that the line of the face is horizontal and a line bisecting the neck longitudinally is horizontal to the testing surface. The uninflated pressure sensor will be placed behind the neck so that it abutted the occiput and is inflated to a stable baseline pressure of 20 mm Hg, a standard pressure sufficient to fill the space between the testing surface and the neck but not push the neck into a lordosis. the patient attempted to sequentially target five, 2-mm Hg progressive pressure increases from the baseline of 20 mm Hg to a maximum of 30 mm Hg as well as to maintain a isometric contraction at the progressive pressures as an endurance task.~2. The participants will be placed in the prone position and the therapist will stand facing the joint where the mobilization will be applied to improve the extension of the upper thoracic spine (T1-2)."
223439108|NCT01534780|PROCEDURE|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
224050261|NCT03196986|DRUG|mil60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
224050262|NCT03196986|DRUG|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
224050263|NCT00247936|PROCEDURE|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
224143918|NCT02787642|RADIATION|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
223566614|NCT05137457|OTHER|"Delivering Online ZZZ's with Empirical support (DOZE) app"|"The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal."
224050264|NCT06027736|OTHER|pharmacist-led education|A patient education protocol and an algorithm of pharmaceutical care in managing allergic rhinitis.
224050265|NCT01244295|BEHAVIORAL|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
224050266|NCT01244295|BEHAVIORAL|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
224050267|NCT03126396|DEVICE|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
224050268|NCT00000580|DRUG|immunoglobulins, intravenous|
224050269|NCT05496179|DRUG|Prucalopride|Prokinetic
224050270|NCT05496179|DRUG|Metoclopramide|Prokinetic
223439109|NCT01534780|DEVICE|Protack|fixation of mesh with protack
223439110|NCT01534780|DEVICE|Securestrap|fixation of mesh with Securestrap
223439111|NCT01534780|DEVICE|Glubran|fixation of mesh with Glubran
223566615|NCT05137457|OTHER|Sleep diary|The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
223566616|NCT01956747|PROCEDURE|venapunction|
223566617|NCT01956747|PROCEDURE|bone marrow punction|
223566618|NCT02572505|DRUG|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
224050271|NCT04874519|BEHAVIORAL|Questionnaire|The questionnaire will be completed at the time of enrollment, every month, and at the end of study. Regardless of current interventions or lack of, assessments will be completed at enrollment and then monthly for a total of 18 months. In order to provide reasonable flexibility to participants, physicians, and study teams, the assessments can be completed within 30 days of the last assessment. The next month will be recalculated based on last reporting date.
224050272|NCT03459118|BEHAVIORAL|Function Focused Care|The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
224143919|NCT06019910|OTHER|Snus with or without tobacco|At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
224143920|NCT03488914|BEHAVIORAL|YMHP Intervention|
224143921|NCT03488914|BEHAVIORAL|Enhanced Treatment as Usual|
224163690|NCT04044313|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
224163691|NCT04044313|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224050273|NCT01622192|DEVICE|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
224050274|NCT03838055|PROCEDURE|Injection of tracer ( ICG) and detection of sentinel lymph nodes|Pelvic SLN's defined by ICG injected cervically
223439112|NCT04612777|BEHAVIORAL|Opening Doors to Recovery|Opening Doors to Recovery (ODR) was created by a large, collaborative group in southeast Georgia as a recovery-oriented approach that navigates clients into services that may in some cases be fragmented and seemingly inaccessible. The team of three Community Navigation Specialists (CNSs) strives to help clients reduce institutional (e.g., hospital, jail) recidivism and embrace recovery. Their process of community navigation is a broader function than traditional case management as it includes mapping out and connecting clients to all available local resources, which requires being embedded in the community. The work of the CNSs benefits from commitments of diverse collaborative ODR partners, including local treatment providers, law enforcement, employers, and housing programs. Each CNS was expected to meet with the client at home or in community settings at least monthly, with the client having contact with at least one CNS weekly.
223439113|NCT04612777|BEHAVIORAL|Case Management|Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
223566619|NCT05463718|DEVICE|Virtual Reality|children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
223566620|NCT04700657|DIAGNOSTIC_TEST|corneal sensation test|Thorough ocular surface study including corneal sensation test in the GVHD group, comparing to the normal control group
223740819|NCT01871116|BEHAVIORAL|POWER-remote|Web-based weight loss program.
223740820|NCT01871116|BEHAVIORAL|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
223740821|NCT01641692|DRUG|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
223740822|NCT01641692|PROCEDURE|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
224050275|NCT05712135|OTHER|supine position|The patient group whose cuff pressure was measured in the supine position
224050276|NCT05712135|OTHER|prone position|The patient group whose cuff pressure was measured in the prone position
224050277|NCT05712135|OTHER|semi-fowler position|The patient group whose cuff pressure was measured in the semi-fowler position
224050278|NCT04843046|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|All participants will receive evidence-based individual Cognitive Behavioral Therapy (CBT) shown to be an effective intervention for maintaining abstinence following detoxification. Trained masters-level licensed professional counselors will deliver CBT.
224050279|NCT04843046|DRUG|Pioglitazone|Pioglitazone capsules will start at 30 mg (Detox days 3 and 4) and increase to fixed dose of 45 mg for study weeks 1-12 and will also contain riboflavin.
224050280|NCT04843046|DRUG|Placebo|Placebo capsules will be filled with corn starch and riboflavin.
224050281|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II hemispherical cup
224050282|NCT04350255|DEVICE|Total hip arthroplasty|Total hip arthroplasty with a Trident II Tritanium cup
224050283|NCT01129830|DIETARY_SUPPLEMENT|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
224050284|NCT04305275|DRUG|SAGE-324|SAGE-324 oral tablet
224050285|NCT04305275|DRUG|SAGE-324 Placebo|SAGE-324 matched placebo oral tablet
224050286|NCT01728415|OTHER|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
224050287|NCT02867124|DRUG|XR-NTX|Vivitrol
223566621|NCT00426400|DRUG|The cessation of anti-aggregative treatment for 10 days|
223566622|NCT06179134|BEHAVIORAL|Goal Management Training|"The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017)."
224050288|NCT02867124|OTHER|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
224050289|NCT02867124|OTHER|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
224050290|NCT00348920|PROCEDURE|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
224050291|NCT05360173|BEHAVIORAL|acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating on the patient's arm and leg.
224050292|NCT05360173|BEHAVIORAL|sham acupressure|The researcher use thumb and put about 3 kilogram on four acupoints where locating at about 3 cm next to the acupoint on the patient's arm and leg.
224070666|NCT00716755|DRUG|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, \[11C\]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
224163692|NCT04044313|DRUG|Toripalimab|240mg intravenously every 3 weeks
223439114|NCT04612777|BEHAVIORAL|Intensive Case Management|Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
224050293|NCT02433197|DEVICE|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
223439115|NCT00154050|DRUG|candesartan (drug) or quinapril (drug)|
224050294|NCT02801136|BEHAVIORAL|ReACT|
223439116|NCT00810446|DRUG|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
224050295|NCT02801136|BEHAVIORAL|Supportive Therapy|
224050296|NCT05881174|PROCEDURE|acupuncture|acupuncture
224050297|NCT03978221|OTHER|Post-extubation TDI|A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
224050298|NCT02525250|PROCEDURE|Realization of 3 Blood samples during study during treatment with lenalidomide|
224050299|NCT03959124|DEVICE|Deep brain stimulation|Brain stimulation electrodes at parameters 2.0\~4.5 V；60 μs；20 Hz
224050300|NCT03959124|DRUG|Best medical treatment for Alzheimer's disease|Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
224050301|NCT02524548|OTHER|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
224050302|NCT05604820|BEHAVIORAL|Progressive Muscle Relaxation Exercise|Training on progressive muscle relaxation exercises will be given to the experimental group in the chemotherapy unit. Before going to sleep in the evening and during the day, they will be asked to do progressive muscle relaxation exercises in line with the instruction of the video. They will be asked to do the application every day for 8 weeks. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. Only routine care will be applied to the control group and no intervention will be made. At the end of the 2nd week, 4th week, 6th week and 8th week, they will be asked to fill the PUKI again. After the evaluations, information about progressive muscle relaxation exercises will be given.
224050303|NCT03163784|BIOLOGICAL|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
224050304|NCT03163784|BIOLOGICAL|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
224050305|NCT03163784|DRUG|Antibiotic|Antibiotic pre-treatment
224050306|NCT03163784|DRUG|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
224050307|NCT01236664|BEHAVIORAL|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
224050308|NCT01236664|BEHAVIORAL|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
224050309|NCT01067755|DEVICE|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
224050310|NCT00458796|DRUG|zoledronic acid|
224050311|NCT00458796|PROCEDURE|quality-of-life assessment|
224050312|NCT00749476|BIOLOGICAL|Factor IX recovery|
224050313|NCT01937598|DRUG|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
224050314|NCT01937598|OTHER|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
224050315|NCT01937598|DRUG|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
224050316|NCT01937598|DRUG|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
224050317|NCT01700270|DRUG|dovitinib (TKI258)|
224163693|NCT00002852|DRUG|paclitaxel|Given IV
224163694|NCT00002852|DRUG|carboplatin|Given IV
224163695|NCT00002852|PROCEDURE|therapeutic conventional surgery|Undergo surgery
223439117|NCT02455609|PROCEDURE|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
223439118|NCT02455609|DRUG|Dexmedetomidine|
223439119|NCT02455609|DRUG|ketamine|
223439120|NCT02455609|DRUG|Bupivacaine|
223439121|NCT05079230|DRUG|Magrolimab|Administered intravenously (IV)
223439122|NCT05079230|DRUG|Venetoclax|Tablets administered orally
223439123|NCT05079230|DRUG|Azacitidine|Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)
223439124|NCT05079230|DRUG|Placebo|Administered intravenously (IV)
223439125|NCT01524783|DRUG|Everolimus|Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
223439126|NCT01524783|DRUG|Placebo|Participants were treated with two tablets of matching placebo once daily orally taken.
223439127|NCT01524783|OTHER|Best suportive care (BSC)|Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
223439128|NCT04181437|DRUG|NVP-1203-R1|1 tablet, Single oral dosing
223439129|NCT04181437|DRUG|NVP-1203-R2|1 tablet, Single oral dosing
223439130|NCT04181437|DRUG|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
223439131|NCT06465134|OTHER|No intervention|There is no intervention
223439132|NCT00733083|DRUG|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
223439133|NCT00733083|DRUG|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
224050318|NCT01700270|DRUG|fluvoxamine|perpetrator drug; 7 days of dosing
224050319|NCT03566355|RADIATION|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
224050320|NCT01022242|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
223439134|NCT00733083|DRUG|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
223439135|NCT00733083|DRUG|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
223439136|NCT01370824|PROCEDURE|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
223439137|NCT01370824|PROCEDURE|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
223439138|NCT05255250|BEHAVIORAL|PLAYshop|The intervention includes: 1. Educational Training - the 60 min virtual workshop will be delivered by a trained facilitator. Parents will be introduced to physical literacy via education, group discussion, and active participation in fundamental movement skills (FMS) based activities with their child. 2. Distribution of Education Resources- Parents will be sent physical literacy and physical activity printed resources. 3. Material resources -parents will also be provided a bag of inexpensive active play equipment (e.g., ball, bean bag, balloons). 4. Provide Follow-up Support- After the workshop, participants will gain access to an app with an online toolkit including new active play ideas, tips, and equipment they can make at home for active play. Additionally, participants will receive four bi-weekly booster lessons that include key workshop messages, support and encouragement for parents, reflection and check-in questions, and new activities to try with their child.
223439139|NCT00835627|DRUG|sertraline|flexible dose sertraline
223439140|NCT00835627|BEHAVIORAL|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
223439141|NCT00835627|OTHER|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
223439142|NCT00835627|OTHER|Standard Care|community care, treatment as usual: routine follow up with existing providers
223439143|NCT04045899|DEVICE|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
223439144|NCT04045899|DEVICE|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
223439145|NCT04045899|DEVICE|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
224050321|NCT01022242|DRUG|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
224050322|NCT00069732|BEHAVIORAL|qigong|
224050323|NCT00069732|BEHAVIORAL|acupressure-TAT|
224070667|NCT00861744|BIOLOGICAL|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
224050324|NCT03648008|DRUG|Hydromorphone|0.002 mg\*kg-1 bolus with 0.002 mg\*kg-1 background infusion for group BH 0.002 mg\*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
223566623|NCT02063867|DRUG|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
224050325|NCT03648008|DRUG|Morphine|0.015 mg\*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
224050326|NCT01037491|DRUG|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
224050327|NCT05520151|DIETARY_SUPPLEMENT|ORAL IMPACT treatment|the group of patients will be received a 7-days course of ORAL IMPACT
224050328|NCT05520151|OTHER|control|no intervention
224050329|NCT03502291|BIOLOGICAL|Study one: LAIV + Inoculation|Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
224050330|NCT03502291|BIOLOGICAL|Study one: Placebo + Inoculation|Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
224050331|NCT03502291|BIOLOGICAL|Study two: Inoculation + LAIV|Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
224050332|NCT03502291|BIOLOGICAL|Study two: Inoculation + placebo|Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
224050333|NCT00545727|BEHAVIORAL|Diet|Whole-foods, low glycemic index diet
224050334|NCT00545727|OTHER|Standard diet|Standard diet meeting American Diabetes Association guidelines
224050335|NCT01390766|DRUG|Azathioprine|
224050336|NCT05340894|PROCEDURE|MCKENZIE exercises|McKenzie method is popular amongst physiotherapists as a management approach for spinal pain and McKenzie exercises for LBP are beneficial treatment for increasing flexibility of spine and improving the pain with better results in pain relief
224050337|NCT05340894|PROCEDURE|WILLIAM'S exercises|William flexion exercise is to reduce pain or soreness and provide lower trunk stability by actively developing the abdominal muscles,gluteus maximus and hamstring, passively stretching the hip flexors and lower back muscles(sacro spinalis) and to restore or improve the work balance between the postural flexor and extensor muscle groups
224050338|NCT00745407|DRUG|fenofibrate|
224050339|NCT02674698|OTHER|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
224050340|NCT02674698|OTHER|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
224050341|NCT02674698|OTHER|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
224050342|NCT02674698|OTHER|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
224050343|NCT05344794|DIAGNOSTIC_TEST|Enzyme-linked immunosorbent assay|Serum N/OFQ , IL-6 and NE levels were detected.
224050344|NCT05839275|DRUG|Surufatinib|In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
224050345|NCT05839275|DRUG|Sintilimab|200mg, d1, q3w
224050346|NCT05839275|RADIATION|Radiotherapy|"BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy)."
224070668|NCT00861744|BIOLOGICAL|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
223566624|NCT00156988|DRUG|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
223566625|NCT01335724|DRUG|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
224070669|NCT00861744|BIOLOGICAL|Varivax®|Subcutaneous injection, one dose
223566626|NCT01335724|DRUG|Placebo gel|Placebo gel
224070670|NCT00861744|BIOLOGICAL|Havrix®|Intramuscular injection, one dose
224070671|NCT00861744|BIOLOGICAL|Prevnar®|Intramuscular injection, one dose
224070672|NCT00862264|DRUG|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
224070673|NCT03042208|OTHER|Self guided handout|Written handout with basic weight management strategies
224070674|NCT03042208|BEHAVIORAL|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
224070675|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery lower than 50%
224070676|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent covers the deep femoral artery in 50-90%
224070677|NCT04713865|PROCEDURE|endovascular treatment|The bare metal stent totally covers the deep femoral artery
224070678|NCT05259982|PROCEDURE|Vital root resection|Vital resection of root with attachment loss exceeding 2/3 of the root with the use of calcium silicate cement in the pulpal wound
224070679|NCT06129266|OTHER|oral care with breastmilk|No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.
224070680|NCT01490619|BEHAVIORAL|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
224070681|NCT01490619|OTHER|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
224070682|NCT05107765|DRUG|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by end of week 1, which is within standard titration parameters as per the investigator's brochure.
224070683|NCT05107765|DRUG|Placebo|Pill capsules will look same as that of active drug.
224070684|NCT02542709|DEVICE|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
224070685|NCT02542709|DEVICE|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
224070686|NCT06092073|PROCEDURE|recto-intercostal fascial plane block|Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.
224050347|NCT01762215|BEHAVIORAL|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
224050348|NCT02782520|DRUG|Ringer Lactate (10ml/kg) fluid expansion|
224050349|NCT02782520|DRUG|Hypertonic saline (3ml/kg) fluid expansion|
224050350|NCT01638078|DRUG|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
223566627|NCT01498393|DEVICE|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
223566628|NCT02918461|BEHAVIORAL|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
224050351|NCT01638078|DRUG|Placebo|Placebo, pill, once p.d., 6 weeks
224050352|NCT00956397|DRUG|Rifaximin|rifaximin 550 mg TID PO x 10 days
224050353|NCT00956397|PROCEDURE|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
224050354|NCT00956397|DRUG|Placebo|placebo TID x 10 days
224050355|NCT00002400|DRUG|Indinavir sulfate|
224050356|NCT00002400|DRUG|Delavirdine mesylate|
224050357|NCT00002400|DRUG|Lamivudine|
224050358|NCT00002400|DRUG|Zidovudine|
223566629|NCT00665054|DRUG|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
224050359|NCT01640652|BIOLOGICAL|MenPF-1.|A new vaccine against meningococcal disease.
224050360|NCT02032563|DRUG|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
224050361|NCT05069506|OTHER|Glucose as reference food|Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224050362|NCT05069506|OTHER|Goat milk as test food|Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224050363|NCT05069506|OTHER|Goat milk and currants as test food|Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224050364|NCT05069506|OTHER|Currants as test food|Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224050365|NCT05069506|OTHER|Sultanina raisins as test food|Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
224050366|NCT05069506|OTHER|Goat milk yogurt as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
224050367|NCT05069506|OTHER|Milk with lactic acid as preload|Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
224050368|NCT05992103|PROCEDURE|Fundic Ablation in Combination with Endoscopic Sleeve Gastroplasty|Fundic mucosal ablation followed by endoscopic sleeve gastroplasty in the treatment of adults with obesity
224050369|NCT05992103|DEVICE|Fundic Mucosal Ablation with ERBE HybridAPC|Fundic mucosal ablation utilizing approved ERBE HybridAPC
224163696|NCT03209986|PROCEDURE|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
223566630|NCT00665054|DRUG|Placebo|Matching placebo tablets orally prior to sexual activity
223566631|NCT03922347|DIAGNOSTIC_TEST|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
223566632|NCT03922347|DIAGNOSTIC_TEST|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
223566633|NCT03126058|PROCEDURE|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
223566634|NCT04470908|DRUG|Zanubrutinib|Single oral dose of 320 mg
223566635|NCT04470908|DRUG|Rifabutin|Oral dose of 300 mg once daily
223566636|NCT06435364|OTHER|Vagus nerve stimilation|This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
224050370|NCT05992103|DEVICE|Apollo ESG|Using only Apollo ESG as approved per label
224050371|NCT04040075|DRUG|Biktarvy Tab|Antiretroviral drug
224163697|NCT03209986|OTHER|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
224163698|NCT03846089|PROCEDURE|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
224163699|NCT05848336|BEHAVIORAL|Gluten Free Casein Free Diet|Thirty children with autism were evaluated before the diet (Pre-Test) and after 8 weeks of dietary intervention (Post-Test).
224050372|NCT00788281|PROCEDURE|laparoscopic surgery|surgery would be performed by laparoscope
223566637|NCT06435364|OTHER|Manual therapy|Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
223566638|NCT04376684|BIOLOGICAL|Otilimab|Otilimab will be administered once via IV route.
223566639|NCT04376684|BIOLOGICAL|Placebo 1|Placebo 1 will consist of sterile 0.9 percent (%) sodium chloride solution administered once via IV route.
224050373|NCT00788281|PROCEDURE|open surgery|surgery would be performed by traditional surgery.
224050374|NCT01702714|DRUG|RO5083945|multiple ascending doses
224050375|NCT01702714|DRUG|carboplatin|up to 6 cycles
224050376|NCT01702714|DRUG|cisplatin|up to 6 cycles
224050377|NCT01702714|DRUG|gemcitabine|up to 6 cycles
224050378|NCT01702714|DRUG|paclitaxel|up to 6 cycles
224050379|NCT03470038|DRUG|NGF|Intramuscular injection
224050380|NCT03470038|DRUG|Isotonic saline|Intramuscular injection
224050381|NCT00839670|OTHER|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
224050382|NCT00839670|OTHER|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
224050383|NCT00449683|DRUG|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
224050384|NCT04173689|DEVICE|Threshold IMT|7 days a week, 2 times a day 15 min each
224050385|NCT04173689|OTHER|breathing exercises combined with upper extremity and trunk|upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
223439146|NCT01294007|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
223439147|NCT01294007|PROCEDURE|Autograft bone|Iliac Crest and Local Autograft Bone
223439148|NCT02713438|BEHAVIORAL|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
223439149|NCT02713438|BEHAVIORAL|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
224050391|NCT04144374|DRUG|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
224070687|NCT06092073|DRUG|bupivacaine|bupivacaine 0.25%
224070688|NCT04391699|DEVICE|heated humidification|heated humidification system
224070689|NCT01295216|BEHAVIORAL|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
224070690|NCT04726878|PROCEDURE|Erector spinae plane block|Ultrasound-guided the erector spinae plane block with 0.375% ropivacaine, 0.4 mL per KG, up to 40 mL (maximum dose).
224070691|NCT04726878|PROCEDURE|Sham block|Ultrasound-guided the erector spinae plane block with 0.9% saline, 0.4 mL per KG, up to 40 mL (maximum dose).
224070692|NCT04726878|PROCEDURE|General anesthesia|"Standard general anesthesia. The induction with fentanyl, 1-3 mcg per KG; propofol, 1.5-2 mg per kg. Then, the laryngeal mask airway will be inserted. Patients with the risk of aspiration will be intubated using rocuronium or suxamethonium.~The maintenance with oxygen/air mixture, sevoflurane, and fentanyl."
224070693|NCT04726878|PROCEDURE|Patient-controlled analgesia|All patients will receive a PCA pump with oxycodone (1 mg/mL, 5-minute interval) after transfer to PACU (post-anesthesia care unit)
224070694|NCT04726878|DRUG|Oxycodone|Intravenous oxycodone will be administered about 30 minutes before the end of the surgery at a dose of 0.1 mg/KG. Additional 2 doses can be given if pain on the visual analog scale will be higher than 40.
224070695|NCT04726878|DRUG|paracetamol|intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
224070696|NCT05416853|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin or the radial, and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open.
224070697|NCT02135887|DRUG|MB-6|6# TID with meal
224070698|NCT02135887|DRUG|Placebo|6# TID with meal
224070699|NCT00128544|DRUG|telbivudine|
224070700|NCT00128544|DRUG|valtorcitabine|
224070701|NCT04794712|DEVICE|Venous reflux tools (Ultrasound and Photo plethysmography (PPG))|Venous reflux tools Pain assessment tools
224050392|NCT04144374|PROCEDURE|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
224163700|NCT02985489|DIETARY_SUPPLEMENT|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
223439150|NCT02713438|BEHAVIORAL|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
223439151|NCT02713438|BEHAVIORAL|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
223439152|NCT02252900|OTHER|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
224050393|NCT03295370|PROCEDURE|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
224163701|NCT02078089|DRUG|Morphine|Morphine will be given to patients as part of their standard care
223439153|NCT01870804|DRUG|Rosuvastatin|
223439154|NCT01870804|DRUG|Atorvastatin|
223439155|NCT00992134|DRUG|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
223439156|NCT06745674|BEHAVIORAL|a mobile app-delivered Acceptance Commitment Therapy (ACT)|The study utilized a specially tailored internet-based self-help ACT program for cancer patients. It consisted of an introductory module and six core intervention modules: (1) Refusing Avoidance; (2) Accepting Distress; (3) Living in the Present Moment; (4) Observing Yourself Psychologically; (5) Exploring Meaningful Values; and (6) Committing to Action. Each module, designed to take 30-60 minutes, was delivered over a two-week period.
223439157|NCT02589327|OTHER|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
223566640|NCT04376684|BIOLOGICAL|Placebo 2|Placebo 2 will consist of sterile 5% dextrose or 5% glucose solution administered once via IV route.
223566641|NCT04376684|DRUG|Standard of care|All participants will receive standard of care as per institutional protocol.
223566642|NCT03197987|DEVICE|Endocuff|Endocuff-assisted colonoscopy
224050394|NCT00525993|DRUG|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
224050395|NCT00525993|DRUG|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
224050396|NCT02179671|DRUG|Gefitinib|Gefitinib once daily followed by MEDI4736
224050397|NCT02179671|DRUG|AZD9291|AZD9291 once daily followed by MEDI4736
224050398|NCT02179671|DRUG|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
224050399|NCT02179671|DRUG|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
224050400|NCT04820400|OTHER|Immersive VR Video|"The VR-360 video will be custom-made for the burn patient population. Through a review of current evidence for video scenarios/patients surveys, the study team will define and implement the key components appropriate for acute procedural pain such as type, duration and severity in this patient population. Next, patients will be asked about preferred pain relief elements (e.g. individual colours, geographical locations, sounds, etc.) that would help to design a video scenario. Finally, using a Likert pain scale, patients will be asked to rate each individual descriptor that exacerbates or alleviates pain. For instance, the colour red may be associated with 'flames', 'heat' and 'burns', and thus elevated pain, the colour blue may have the opposite effect, representing 'cooling' or 'cold'.~Combined, this information will be used to create a VR-360 video geared towards alleviating acute procedural pain in patients with burn injuries undergoing dressing changes after skin graft."
224050401|NCT05421312|DRUG|sampling blood|During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
224050402|NCT05421312|DRUG|Sampling synovial fluid|During the reimplantation 1 synovial fluid sample will be taken prior to incision.
224050403|NCT05421312|DRUG|Sampling bone tissue|During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
224050404|NCT02247895|DEVICE|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
224050405|NCT02247895|DEVICE|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
224050406|NCT05573659|OTHER|time of cutaneous recoloration|In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.
223439158|NCT06277869|DEVICE|Thermal Jacket|In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention Thermal Jacket as well as Kangaroo Mother Care.
223439159|NCT06277869|PROCEDURE|Kangaroo Mother Care|Skin-to-Skin care, provided by primary caregiver.
224050407|NCT05573659|OTHER|video assisted cutaneous recoloration|"Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second."
223439160|NCT03033316|DRUG|Dexamethasone|
223439161|NCT02202044|DEVICE|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
223439162|NCT03073694|DRUG|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
223566643|NCT03197987|DEVICE|cap|Cap-assisted colonoscopy
224050408|NCT01909427|DRUG|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
224050409|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
224050410|NCT01909427|DRUG|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
224050411|NCT01909427|DRUG|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
224050412|NCT01909427|DRUG|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
224050413|NCT01909427|DRUG|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
224050414|NCT01909427|DRUG|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
224050415|NCT05355025|BEHAVIORAL|WiserAD|"See Arms"
224050416|NCT05355025|BEHAVIORAL|Attention control|"See Arms"
224050417|NCT01431326|DRUG|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
224050418|NCT05298982|BEHAVIORAL|Early activity and Mobilisation Intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
224050419|NCT01708291|BEHAVIORAL|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
224050420|NCT01708291|BEHAVIORAL|only pre and post evaluation measures|
224050421|NCT02543827|BIOLOGICAL|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
224050422|NCT02543827|BIOLOGICAL|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
223439163|NCT03073694|DRUG|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
223439164|NCT06647706|DEVICE|Transthoracic echocardiography|MPNs patients who have echocardiographic probability of PH
223566644|NCT03326921|BIOLOGICAL|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
223566645|NCT03326921|OTHER|Laboratory Biomarker Analysis|Correlative studies
223740823|NCT01641692|DRUG|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
223740824|NCT03164096|DRUG|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
224050423|NCT00096668|DRUG|TOCOSOL(R) Paclitaxel|
224050424|NCT02290626|DRUG|Elmental diet|elemental diet is administered using PEG.
224050425|NCT02290626|DRUG|Semi-solid diet|Semi-solid diet is administered using PEG.
224050426|NCT02357823|OTHER|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
224050427|NCT02357823|OTHER|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
224050428|NCT06211465|PROCEDURE|Total joint arthroplasty|Hip or knee total joint arthroplasty
224050429|NCT04382196|OTHER|Online survey|An online survey will be administered
224050430|NCT05613166|DRUG|Everolimus|Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA \>=2.2 m\^2, the dosage was 7.5 mg/time.
224050431|NCT05613166|DRUG|Placebo|Vitamin C
224050432|NCT05033665|BEHAVIORAL|Increase water consumption|The underhydrated individuals will be instructed to increase their water intake for one week in order to meet the following two criteria: a) urinate at least 7 times per day and b) have straw-like color urine. A 2-mile run will be completed before and after the 7-day intervention.
224050433|NCT05033665|BEHAVIORAL|Maintain adequate water consumption|The subjects that are classified as euhydrated will be asked to maintain high water intake for one week to ensure proper hydration. A 2-mile run will be completed before and after the 7-day intervention.
224050434|NCT04169490|OTHER|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
224050435|NCT04169490|OTHER|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
224050436|NCT04169490|OTHER|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
224050437|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
224050438|NCT04169490|OTHER|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
224050439|NCT01536951|DRUG|LY3009104|administered orally
224050440|NCT01536951|DRUG|Placebo|Administered orally
224050441|NCT01536951|DRUG|moxifloxacin|Administered orally
224050442|NCT02345304|DRUG|Omeprazole|
224050443|NCT02345304|DRUG|Warfarin|
224050444|NCT02345304|DRUG|BI 1181181|
223439165|NCT05718427|BEHAVIORAL|Ayres Sensory Integration Therapy|Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
224050445|NCT02345304|DRUG|Midazolam|
224050446|NCT02345304|DRUG|Omeprazole|
224050447|NCT02345304|DRUG|BI 1181181|
224050448|NCT02345304|DRUG|Midazolam|
224050449|NCT02345304|DRUG|Midazolam|
224050450|NCT02345304|DRUG|Warfarin|
224050451|NCT02345304|DRUG|BI 1181181|
224050452|NCT02345304|DRUG|Digoxin|
224050453|NCT02345304|DRUG|Digoxin|
224050454|NCT03093779|OTHER|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
224050455|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 6
224050456|NCT01843972|DRUG|BI 691751|oral solution
224050457|NCT01843972|DRUG|Placebo|placebo solution
224050458|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 2
224050459|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 5
224050460|NCT01843972|DRUG|BI 691751|1 tablet
224050461|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 3
224143922|NCT06310096|OTHER|TLF fascial stretching exercise|"Relaxed lumbo-pelvic upright sitting with arms in neutral anatomical position (O'Sullivan et al., 2006). The subjects had to bend both knee flexed 90. The feet of the Participant lied flat on the ground. Trunk was in aligned position and the angle between upper body and lower body was 90. Seated position led to caudal tensioning of the pTLF via stretching of the gluteus maximus (GM)~Seated position with passive arms elevation Seated position with passive caudal stretching of TLF through thigh elevation. The subjects had to bend both hips while keeping their feet onto a stool (30 cm high) so to pull the GM and the TLF"
223439166|NCT06648876|DRUG|YG1699|10mg qd for 8 days
223439167|NCT06648876|DRUG|Placebo|10mg qd for 8 days
224050462|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 4
224050463|NCT01843972|DRUG|BI 691751|oral solution BI 691751, dose 7
224050464|NCT01843972|DRUG|BI 691751|oral solution BI 69175, dose 1
224143923|NCT06310096|OTHER|conventional physiotherapy program.|hotpack, ultrasound ,Tens
223439168|NCT02763982|OTHER|Physical evaluation|
223439169|NCT05918419|DRUG|Serplulimab|PD-1 antibody
224050465|NCT05584254|DIETARY_SUPPLEMENT|yeast-beta glucan|
224050466|NCT00189072|DRUG|gabapentin|
224050467|NCT01961206|OTHER|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
224050468|NCT03817866|DIAGNOSTIC_TEST|BRAHMS CgA II KRYPTOR|"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."
224050469|NCT06178237|DEVICE|Purabond|Application of Purabond to surgical field
224050470|NCT00393809|DRUG|DTA-H19|
224050471|NCT05116150|DIETARY_SUPPLEMENT|Grape seed extract|Effects of 7 days of combined GSE with L-citrulline supplementation on hemodynamic responses at rest and during cycling exercise.
224050472|NCT05116150|DIETARY_SUPPLEMENT|Placebo|Effects of 7 days of placebo supplementation on hemodynamic responses at rest and during cycling exercise.
224050473|NCT05378854|OTHER|LifeChamps Platform|Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
224050474|NCT00932425|DEVICE|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
224050475|NCT02154542|DEVICE|Neurovent Monitor XIII|
224050476|NCT03410017|OTHER|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
224050477|NCT05218681|OTHER|"Unit-based Person First Anti-stigma Awareness Rounds"|Educational rounds on stigma
224050478|NCT05218681|OTHER|Individual Text-based Messaging|Weekly evidence based messages to reduce SUD stigma
224050479|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
224050480|NCT01028326|BIOLOGICAL|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
224050481|NCT01028326|BIOLOGICAL|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
224050482|NCT05916781|DRUG|Mycophenolate Mofetil|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
224143924|NCT02503631|DEVICE|Stool Sample Collection Kit|Stool sample collection kit
224143925|NCT05619562|DIAGNOSTIC_TEST|Device for CTC/DTC detection|The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
224050483|NCT05916781|DRUG|Tacrolimus|"Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC."
224050484|NCT05916781|DRUG|Glucocorticoid|"Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare."
223439170|NCT01426464|DRUG|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
223439171|NCT04000698|DRUG|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
224050485|NCT03759483|DIAGNOSTIC_TEST|AI diagnostic algorithm|The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
224050486|NCT04403750|PROCEDURE|Combined laser-surgical technology of RRD treatment|"1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)"
224050487|NCT00334126|DRUG|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
224050488|NCT03061461|DEVICE|rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith \& Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
224050489|NCT03061461|DEVICE|Sham rESWT|"All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with sham rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
224050490|NCT02422342|DEVICE|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
224050491|NCT02896829|BEHAVIORAL|Interruption of the treatment by Imatinib|
224050492|NCT04607928|DRUG|Pirfenidone|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
224050493|NCT04607928|DRUG|Placebo|Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
224050494|NCT01669967|DRUG|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
224050495|NCT01669967|DRUG|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
223439172|NCT05137847|DRUG|Remitoro|Intravenous infusion.
223439173|NCT05153148|DRUG|NDI-034858|NDI-034858 oral capsule
223439174|NCT05153148|OTHER|Placebo|NDI-034858-matching oral placebo capsule
223439175|NCT03357133|DRUG|Tirofiban|Tirofiban Injection after the alteplase intravenous thrombolysis
223439176|NCT03357133|DRUG|Alteplase|Only alteplase intravenous thrombolysis
223439177|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
223740825|NCT01685996|DRUG|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
223439178|NCT01712334|DRUG|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
223439179|NCT03668717|DEVICE|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
223439180|NCT01732471|DRUG|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
224050496|NCT04164576|GENETIC|Transplant patients|Study the specific immunity against Polyomavirus
224143926|NCT00208741|DRUG|Gabitril|
224143927|NCT03811717|OTHER|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
224143928|NCT03811717|OTHER|FAST|Participants will complete an 8-hour fast.
224143929|NCT02843581|DEVICE|Cryosurgery|Argon-helium cryosurgical system
224143930|NCT02843581|BIOLOGICAL|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
224143931|NCT01498081|DRUG|AZD2115|AZD2115 administered via inhalation
224143932|NCT01498081|DRUG|Placebo|Placebo administered via inhalation
224143933|NCT01498081|DRUG|Indacaterol|Indacaterol administered via inhalation
224143934|NCT01498081|DRUG|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
224143935|NCT01492283|OTHER|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
224143936|NCT01492283|OTHER|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
224143937|NCT02477228|PROCEDURE|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
224163702|NCT02078089|DRUG|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
223439181|NCT01253174|DRUG|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
223439182|NCT01253174|DRUG|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
223439183|NCT01253174|DRUG|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
223439184|NCT02244346|DRUG|Secotex®|
224050497|NCT03827772|OTHER|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
224050498|NCT03827772|OTHER|Standard of care treatment|Nutritional supplementation, supportive management.
223439185|NCT02106663|PROCEDURE|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
223439186|NCT02106663|PROCEDURE|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
223439187|NCT02267135|BIOLOGICAL|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
223439188|NCT02267135|BIOLOGICAL|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
223478608|NCT05720637|DEVICE|AIA|This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
223740826|NCT01685996|DRUG|placebo|
223740827|NCT00841087|DRUG|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
223740828|NCT00841087|DRUG|insulin detemir|Injection subcutaneously at bedtime
223740829|NCT00841087|DRUG|insulin aspart|Injection subcutaneously immediately before each meal.
223740830|NCT03249311|DRUG|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
224050499|NCT01765842|BIOLOGICAL|Rituximab|Only one cycle of rituximab will be administered in this arm.
224050500|NCT01881893|BEHAVIORAL|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
224050501|NCT00010920|DRUG|Ginkgo Biloba Extract|
224050502|NCT03178968|OTHER|Orange juice|3 immersion times in orange juice were investigated
224050503|NCT05443893|DEVICE|Application Research of key points detection technology|"Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis"
224050504|NCT00382018|DRUG|chemotherapy|No administration details available
224050505|NCT02611804|DRUG|Diclofenac sodium|
224050506|NCT02611804|DRUG|Diclofenac sodium|
224050507|NCT02611804|DRUG|Placebo|
224050508|NCT01537536|DRUG|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
224143938|NCT02477228|PROCEDURE|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
224050509|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
224050510|NCT01251263|DRUG|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
224143939|NCT03901261|PROCEDURE|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
224143940|NCT04311177|DRUG|Losartan|Losartan; 25 mg daily; oral administration
223439189|NCT02123836|BIOLOGICAL|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter."
223439190|NCT02892513|DEVICE|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics \[Jeffersonville, IN, USA\] and distributed by Innovative Health Solutions \[Versailles, IN, USA\]) provides continual neurostimulation for five days with alternating current.
223439191|NCT02892513|DEVICE|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
223439192|NCT03273400|OTHER|Lumbar Mobilisations|Please see arm (intervention) description
223439193|NCT06107907|DEVICE|Non-invasive ventilation (NIV) or high-flow oxygen therapy (HFOT) using electrical impedance tomography (EIT)|Participants will be randomly assigned to Groups A and B using a computerized randomization process. Each group will undergo specific protocols for 5-10 minutes per phase. NIV will be administered in continuous positive airway pressure (CPAP) mode. The participants will be positioned in a semi-recumbent position at 45 degrees, and the EIT belt will be placed around the fifth (or sixth) intercostal space for monitoring. The EIT signals will be filtered with a cut-off frequency set at 10 beats below the current heart rate. The entire procedure is estimated to take approximately 1-1.5 hours, and recalibration will only be performed in case of significant signal abnormalities.
223439194|NCT06003907|OTHER|conventional|hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
223439195|NCT06003907|OTHER|traditional and complementary medicine methods|"The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing."
224050511|NCT03805750|DRUG|CBD/THC|Oral formulation of combined Cannabidiol (CBD) and Tetrahydrocannabinol (THC).
224050512|NCT03805750|DRUG|Placebo oral capsule|Matched Placebo
224050513|NCT06270342|OTHER|dual task assessment|The Minnesota Manual Dexterity Test was used to evaluate the upper extremity function of the participants in single and dual task conditions, and the Dual Task Questionnaire was used to evaluate the difficulties experienced during dual tasks. In the dual-task turning test, in addition to the single-task turning test, they were given a cognitive task, the task of counting the months of the year backwards from December to January. The dual-task turning test was continued by changing hands at the end of each turn until the last disk was turned. Meanwhile, verbal fluency and hand errors made while spinning the disc were recorded.
223439196|NCT04367493|DIETARY_SUPPLEMENT|Chocolate|25 g of chocolate by day for 4 weeks
223439197|NCT06624254|OTHER|lung mechanics, respiratory drive and effort|Patient lung mechanics and respiratory drive and effort will be measured
223439198|NCT00841347|BEHAVIORAL|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
223439199|NCT00841347|BEHAVIORAL|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
223740831|NCT03249311|DRUG|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
223740832|NCT03249311|DRUG|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
224050514|NCT00789880|DRUG|Vitamin D3|Administration of oral vitamin D3 at 4000IU
224050515|NCT00789880|DRUG|Placebo|Administration of oral Vitamin D3 placebo
224050516|NCT00217243|OTHER|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
224050517|NCT00236769|DRUG|norelgestromin + ethinyl estradiol|
224050518|NCT00003111|DRUG|carboplatin|
224050519|NCT00003111|DRUG|cisplatin|
224050520|NCT00003111|DRUG|irinotecan hydrochloride|
224050521|NCT00003111|DRUG|paclitaxel|
224050522|NCT00003111|PROCEDURE|neoadjuvant therapy|
224143941|NCT04311177|OTHER|Placebo|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
224163703|NCT04130880|DIAGNOSTIC_TEST|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
223740833|NCT02254928|DRUG|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
223740834|NCT01761838|OTHER|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
224050523|NCT00003111|PROCEDURE|surgical procedure|
224050524|NCT00003111|RADIATION|radiation therapy|
224050525|NCT01112020|DEVICE|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
224050526|NCT01112020|DEVICE|Biopatch|Biopatch applied to 7 sites
224050527|NCT01112020|DEVICE|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
224050528|NCT02685579|OTHER|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
224050529|NCT05484479|BEHAVIORAL|Baduanjin training/exercise|For 6 months, MeTS elderly (25 elderly) with chronic periodontal disease will be trained using sixty-minute Baduanjin training/exercise (5 times weekly)
223439200|NCT03129282|OTHER|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
223439201|NCT05968027|OTHER|"Nouveal numeric application Onco'nect"|A remote monitoring application, Onco'nect® (smartphone /tablet /PC), in partnership with the company Nouveal facilitates communication between patients undergoing Intra Vascular (IV) chemotherapy and the care team. A questionnaire before and after each session can be used to alert the oncology department and adapt patient management.
223439202|NCT03104426|DRUG|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
223439203|NCT02261662|DRUG|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
223439204|NCT02261662|DRUG|Betamethasone|Topical Steroids alone will be used; Betamethasone
223439205|NCT00900731|DRUG|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
224143942|NCT06271447|OTHER|Traditional therapy|"All participants will receive a 60-minute individual treatment program consisting of 16 sessions of routine physiotherapy aimed at reducing pain and improving function over four weeks. These treatments are already the patient's routine physiotherapy modalities. No changes will be made to the study.~Since the questionnaires to be used in the study are related to fear of movement and pain, neuroscience education will be included in the treatment program of the patients. Patients will be informed about proper posture and movement regarding fear of movement and pain avoidance behaviors."
223439206|NCT00900731|DRUG|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
223439207|NCT00900731|DRUG|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
223439208|NCT00900731|DRUG|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
223439209|NCT03806231|DRUG|Outpatient Dinoprostone 10mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
223439210|NCT03806231|DRUG|Inpatient Dinoprostone 10 mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
223439211|NCT02919267|DEVICE|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
223439212|NCT02919267|DEVICE|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
223439213|NCT04546516|DEVICE|HYAcorp Lips and HYAcorp Face|Dermal filler injection to different facial areas
223439214|NCT05454046|OTHER|Food intake among women and men in fertility treatment|Filling in an FFQ
224050530|NCT05995015|BIOLOGICAL|Universal CD19-specific CAR gene-engineered T cells|Infusion of 4SCAR19U cells
224050531|NCT02219321|DRUG|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
224143943|NCT01802554|BEHAVIORAL|Pleasant Events Program (PEP)|Behavioral Activation Therapy
224143944|NCT01802554|BEHAVIORAL|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
223439215|NCT05546723|BIOLOGICAL|Autologous CAR-T cell therapy expressing the BAFF-ligand.|LMY-920
223439216|NCT02652598|DRUG|Tolcapone|
224143945|NCT02517151|DRUG|Ferric carboxymaltose|
223439217|NCT05075044|BIOLOGICAL|Inactivated COVID-19 vaccine|three doses of inactivated COVID-19 vaccine
223439218|NCT01524068|DRUG|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
223439219|NCT01524068|DRUG|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
223439220|NCT06250634|DRUG|esomeprazole + amoxicillin|esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily
223478609|NCT05808985|DRUG|sodium butyrate|Take butyric acid (sodium butylate 600mg 2 tablets, BodyBio⒭, per day)
224143946|NCT02517151|DRUG|Placebo|
224143947|NCT01911234|BIOLOGICAL|TNF-Kinoid|IM administration
224143948|NCT01911234|OTHER|Placebo|IM administration
224050532|NCT02219321|DRUG|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
224050533|NCT04538872|BEHAVIORAL|StraDiMS implicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
223439221|NCT06250634|DRUG|esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent|20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)
223439222|NCT06250634|DRUG|Vonoprazan + amoxicillin|20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)
223439223|NCT06250634|DRUG|Vonoprazan + amoxicillin + clarithromycin|20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
223439224|NCT03510221|DIETARY_SUPPLEMENT|Antioxidants capsules|1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
223439225|NCT05345769|BIOLOGICAL|AM712(ASKG712)|AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.
223439226|NCT06911606|DRUG|4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin|After 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin then MDT determines surgery or radical radiotherapy
223439227|NCT06912191|OTHER|Left cerebellar TMS stimulation combined with the RECT task|The first group will receive left cerebellar single-pulse TMS stimulation combined with the RECT task. RECT refers to rostral anterior cingulate cortexr (rACC)-engaging cognitive task. The theoretical basis of this task is that when subjects are in a state of focused attention, the power of theta neural oscillations in the midline of their frontal lobe will increase. By considering the features of post-stroke depression, this study combines the emotional recognition task with the RECT task. During each trial, individuals will view 4 faces consecutively, each displaying a different expression, and they will be required to memorize the sequence of expressions. Emoticons consist of joy, sorrow, and rage. After displaying four facial expressions, a brief text flowchart will appear. Participants need to check if the sequence reflected in the flowchart matches the order in which the four facial expressions appeared. If they match, click the left mouse button; if they do not match, click the
223439228|NCT06912191|OTHER|Right cerebellar TMS stimulation combined with the RECT task|Right cerebellar single-pulse TMS stimulation combined with the RECT task
223439229|NCT06912191|OTHER|Midline cerebellar TMS stimulation combined with the RECT task|Midline cerebellar single-pulse TMS stimulation combined with the RECT task
223439230|NCT06912191|OTHER|Sham cerebellar TMS stimulation combined with the RECT task|Sham cerebellar single-pulse TMS stimulation combined with the RECT task, The TMS coil was placed at the cerebellar site but tilted 90° to prevent effective magnetic field penetration.
223439231|NCT06912191|OTHER|The best stimulation protocol combined with left dorsolateral prefrontal cortex iTBS|The optimal stimulation protocol determined in Experiment 1 combined with stimulation of the left dorsolateral prefrontal cortex.
223439232|NCT06912191|OTHER|Left dorsolateral prefrontal cortex iTBS stimulation, as well as sham TMS stimulation and sham RECT task.|Subjects in the group underwent left dorsolateral prefrontal cortex iTBS stimulation, in addition to receiving sham TMS stimulation and participating in a sham RECT task. The sham RECT task involves having participants watch a continuous scroll of faces without needing to react.
223439233|NCT06912191|OTHER|Sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.|The participants in this group received sham left dorsolateral prefrontal cortex iTBS stimulation, sham cerebellar TMS stimulation, and sham RECT task.
223439234|NCT05417308|DRUG|Minoxidil|Applied topically
223439235|NCT05417308|DRUG|Minoxidil|Given PO
223439236|NCT05417308|OTHER|Quality-of-Life Assessment|Ancillary studies
223439237|NCT05417308|OTHER|Questionnaire Administration|Ancillary studies
223439238|NCT01879033|OTHER|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
224050534|NCT04538872|BEHAVIORAL|StraDiMs explicit|participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up. Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task. The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task. The latter group will get more knowledge on the task than the former.
224050535|NCT00617539|DRUG|irinotecan hydrochloride|
224050536|NCT00617539|DRUG|temozolomide|
224050537|NCT02741869|DEVICE|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
224050538|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-4 schedule)|Subjects receive the booster vaccine 3 months after the second dose.
224143949|NCT04813939|DEVICE|IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany)|Point of care assessment of bio-adrenomedullin concentration will be performed using the IB10 sphingotest® bio-ADM® apparatus (Sphingotec GmbH, Hennigsdorf, Germany) on the 1,3,5-day ICU stay in COVID-19 patients. The method used is a double monoclonal sandwich immunoassay to measure the concentration of C-terminal amidated, biologically active adrenomedullin (bio-ADM) in whole blood. Additional measurement of bio-ADM will be performed as standard monitoring in patients suspected of septic complications of the course of COVID-19.
224050539|NCT05104333|BIOLOGICAL|Covid-19 vaccine (0-1-6 schedule)|Subjects receive the booster vaccine 5 months after the second dose.
224143950|NCT01912716|DRUG|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
224143951|NCT01912716|DRUG|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
224143952|NCT00118508|DRUG|risedronate (including placebo)|risedronate 35mg weekly
223439239|NCT01879033|OTHER|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
223439240|NCT02093390|DRUG|TAK-385|TAK-385 tablets
223439241|NCT02093390|DRUG|Fluconazole|Fluconazole tablets
223439242|NCT02093390|DRUG|Atorvastatin|Atorvastatin tablets
223439243|NCT04381507|DEVICE|endovascular repair|Endovascular repair of descending thoracic aneurysms or PAU using a stent graft.
223439244|NCT06382441|BEHAVIORAL|tele-exercise|It is a prospective and pilot study of RCT. It will be a pilot to test acceptability and feasibility of a two-armed tele-exercise RCT to mitigate symptoms and improve health for breast cancer survivors. In this study, outcome assessors and data analysts will be masked from the allocation results. The pilot will recruit 24 patients and randomly assign them to an intervention group (Group A) and an active control group (Group B). All participants in both groups will continue receiving usual care from the study hospital during the study period. Additionally, those in Group A (intervention) will receive the tele-exercise (12 home-based online training sessions + 4 psychological counselling sessions), while those in Group B (active control) will receive 4 essays on exercise and health. Outcome measurements will be repeatedly performed before and after the intervention.
223439245|NCT04723953|DIAGNOSTIC_TEST|68Ga-FAPI PET/MRI|PET and MRI in patients with acute myocardiac infarction are simultaneously analyzed using hybrid PET/MRI device for monitoring myocardial fibrosis and function.
224050540|NCT04743921|DEVICE|Reparel Knee Sleeve|Patients who are recommended for non-operative management of knee osteoarthritis and have been consented in clinic to participate in the study will be given a Reparel™ knee sleeve to wear for knee osteoarthritis management. Each device will be numbered and recorded in the patient's REDCap entry for future reference if needed. Following administration of the Reparel™ knee sleeve, patients will be given instructions on how to use/wear the sleeve while performing activities of daily living or sports that had previously resulted in knee pain and also be asked to do the follows: wear the sleeve as much as they possibly can; not change their usual activities and diet during the time they are on this study; record in a diary the number of hours sleeve was worn per day; record any adverse eﬀects or discomfort due to sleeve use; refrain from altering treatment for knee osteoarthritis.
224050541|NCT02098642|OTHER|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
224050542|NCT02098642|OTHER|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
223439246|NCT05176548|DIAGNOSTIC_TEST|Bone-cardiac scintigraphy|Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
224050543|NCT00924105|DRUG|CYT013-IL1bQb|s.c. injection
224050544|NCT00924105|DRUG|Placebo|s.c. injection
224050545|NCT02081404|DRUG|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
224050546|NCT02081404|DRUG|Placebo|placebo
224050547|NCT01977820|DRUG|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
224050548|NCT01977820|DRUG|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
224050549|NCT00123292|DRUG|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
224050550|NCT00123292|DRUG|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
224050551|NCT00123292|DRUG|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
224050552|NCT03043521|DRUG|Dexlansoprazole 60 MG|
224050553|NCT03043521|DRUG|CJ-12420 50mg|
224050554|NCT03043521|DRUG|CJ-12420 100mg|
224050555|NCT03043521|DRUG|CJ-12420 200mg|
224143953|NCT02391350|BEHAVIORAL|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
224143954|NCT02391350|PROCEDURE|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
224143955|NCT05310513|OTHER|Whether the patient needs to be admitted to the ICU|According to ICU admission or not, patients were grouped into ICU group and NOT-ICU group.
224143956|NCT00999219|DRUG|FK199B|oral
224143957|NCT00999219|DRUG|Zolpidem|oral
224143958|NCT04045717|RADIATION|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
224143959|NCT05696262|BEHAVIORAL|6-walking program|Perform 6 minutes of walking exercise 3 times a day, 3 days a week, in a comfortable manner
224050556|NCT04468789|OTHER|Six-month ARV dispensing|Patients in the intervention group who meet eligibility criteria will receive a six-month supply of antiretroviral medications, rather than the standard of care supply which is typically 2-3 months.
223439247|NCT02121353|DRUG|Lucentis|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
223439248|NCT02121353|DRUG|PF582|Single-use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha-trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra-vitreal
223439249|NCT03331705|DEVICE|Uro-C (Use of new cystoscope)|Diagnostic cystoscopic procedure of the urethra and bladder
223439250|NCT03545620|DEVICE|rescue technique|which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
223439251|NCT03571776|PROCEDURE|Surgery|Laparoscopic ovarian cystectomy
223439252|NCT03571776|PROCEDURE|Sclerotherapy|US-aspiration and alcohol sclerosis
223439253|NCT06032026|DRUG|11C-HY-2-15 PET|2 hour Positron Emission Tomography (PET) scan using new radiotracer 11C-HY-2-15
224143960|NCT03435263|OTHER|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
224143961|NCT04284020|BEHAVIORAL|Therapeutic educational program|See arm/group descriptions
224143962|NCT04284020|OTHER|PFMT|See arm/group descriptions
223439254|NCT06032026|DIAGNOSTIC_TEST|brain MRI|brain MRI scan
223439255|NCT06032026|DIAGNOSTIC_TEST|Amyloid PET scan|PET scan with Florbetaben F18 or 11C-PiB
224143963|NCT04284020|OTHER|TTNS|See arm/group descriptions
224143964|NCT05412472|DRUG|GC4419|45 mg IV infusion of GC4419 over 60 minutes.
224143965|NCT01833104|BEHAVIORAL|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills \& interoceptive body awareness. 2 exercises: Breathing Meditation \& Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, \& other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation \& Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
224143966|NCT01833104|BEHAVIORAL|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
224143967|NCT01833104|BEHAVIORAL|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation \& Affect Dyad."
224143968|NCT05679973|DEVICE|Polybutester suture|After third molar surgery this suture used for primary closure.
224143969|NCT05679973|DEVICE|Polypropylene suture|After third molar surgery this suture used for primary closure.
224143970|NCT01018719|DEVICE|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
224143971|NCT01230736|DRUG|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
224163704|NCT03521401|BEHAVIORAL|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
224163705|NCT01351857|OTHER|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
224163706|NCT01744041|BEHAVIORAL|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
223439256|NCT06032026|BEHAVIORAL|Neurological assessments|Neurological assessments, including video interview
223439257|NCT02437188|BEHAVIORAL|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
223439258|NCT01172808|DRUG|Placebo|Placebo that represents comparator
223439259|NCT01172808|DRUG|tiotropium Respimat® low dose|IMP
223439260|NCT01172808|DRUG|Placebo|Placebo that represents comparator
223439261|NCT01172808|DRUG|Placebo|Placebo that represents comparator
223439262|NCT01172808|DRUG|tiotropium Respimat® high dose|IMP
223439263|NCT01172808|DRUG|50 mcg salmeterol HFA MDI|Active comparator
223439264|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
223439265|NCT01172808|DRUG|Placebo|Placebo that represents BI drug
223439266|NCT00507858|DRUG|Pemetrexed|Starting dose of 500 mg/m\^2 IV Once Over 10 Minutes Every 3 Weeks
223439267|NCT00507858|DRUG|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
223439268|NCT06291285|DRUG|Decitabine-THU|Orally administered immediate release tablets.
223439269|NCT06291285|DRUG|Decitabine-THU|Orally administered delayed release capsules.
223439270|NCT03917043|DRUG|APG-2449|Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
224050557|NCT02568475|BEHAVIORAL|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
223439271|NCT05942781|DEVICE|Vestibular training using VR followed by Control|A cross-over design will be used with group one receiving the training intervention for 7 days, a 6-day washout period, and a 7-day no-training period.
223439272|NCT05942781|DEVICE|Control followed by Vestibular training using VR|Group two will follow the reverse sequence.
223439273|NCT02376205|DRUG|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
223439274|NCT02376205|DRUG|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
223439275|NCT06219018|DRUG|Medical grade honey formulation (MGH) (L-Mesitran®)|Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.
223439276|NCT03246061|DEVICE|Intracept System|BVN ablation using radiofrequency energy
223439277|NCT03246061|OTHER|Standard Care|Non-surgical standard care
223439278|NCT01937715|DRUG|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
223439279|NCT01937715|DRUG|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
223439280|NCT01937715|BIOLOGICAL|Bevacizumab|5 mg/m\^2 every 2 weeks or 7.5 mg/m\^2 every 3 weeks
223439281|NCT01937715|DRUG|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
223439282|NCT04843358|BEHAVIORAL|Emotional Disclosure|"The trial member will deliver instructions For the next three days, I want you to write about your experience with cancer. In your writing, I want you to really let go and explore your very deepest emotions and thoughts. It is critical that you delve deeply. Ideally, I would like you to write about those parts of the experience you found hard to share with others. Perhaps this will provide an opportunity to really examine those thoughts and emotions. You might tie your personal experiences to other parts of your life. How is it related to your family life, relationship with your spouse, your children, your sexuality, daily activities, hobbies, your past, your childhood, your work? These are just some examples."
223439283|NCT04843358|BEHAVIORAL|Non-Emotional Writing|"The trial member will deliver instructions were as follows. For the next three days, I want you to write about how you use your time. We are interested in everything you do during the course of a day. In your writing I want you to be completely objective. We are not interested in your emotions or opinions. Feel free to be as detailed as possible"
223439284|NCT01922856|BIOLOGICAL|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
223740835|NCT01761838|OTHER|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
224050558|NCT00493220|DRUG|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
224050559|NCT00493220|DRUG|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
224050560|NCT00493220|DRUG|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
224050561|NCT03860675|DIAGNOSTIC_TEST|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
224050562|NCT05659784|OTHER|Telerehabilitation|Education based telerehab with rehabilitation therapists providing education on home exercises and stroke specific information
224050563|NCT02743884|DEVICE|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
224050564|NCT02743884|DEVICE|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
224050565|NCT05453903|DRUG|Bleximenib|Participants will receive bleximenib.
224050566|NCT05453903|DRUG|Venetoclax (VEN)|Participants will receive VEN.
224050567|NCT05453903|DRUG|Azacitidine (AZA)|Participants will receive AZA.
224050568|NCT05453903|DRUG|Cytarabine|Participants will receive cytarabine.
223439285|NCT01922856|OTHER|No Intervention|Controls only receive challenge
223439286|NCT02864316|DRUG|Nivolumab|
223439287|NCT03331731|DRUG|pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
223439288|NCT04793373|DEVICE|Syringe|A syringe will be used to detect the loss of resistance and needle's entry of epidural space.
223439289|NCT04721366|OTHER|Standard of Care|Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.
223439290|NCT01793350|DRUG|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
223740836|NCT01761838|OTHER|Low back pain participants without SMT|No treatment
223439291|NCT05300659|OTHER|Action for Rehabilitation for Neurological Injury (ARNI)|If randomised to upper limb training, a patient will undertake 10 therapy sessions with an instructor from the Action for Rehabilitation for Neurological Injury (ARNI) program during their hospital stay. The last two ARNI-led sessions will be filmed by a nurse/carer on either their own tablet/phone or an i-pad. Participants in the ARNI group will be encouraged to continue doing their personalized exercises while in hospital and continued at home. They will also be given a task-training board to take home
223439292|NCT05885776|DRUG|Pyrrolidine、trastuzumab、AI|Subjects who met the inclusion criteria underwent surgery after 6 cycles of treatment with pirotinib+trastuzumab+AI, and their postoperative pathological remission was evaluated.
223439293|NCT03286660|DIAGNOSTIC_TEST|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~* dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~* Saturation at rest, and at the end of the exercise~* the number of total a chair rise"
223439294|NCT04638556|DIAGNOSTIC_TEST|lncRNA detection|The lncRNAs in the plasma of three groups of patients will be tested.
223439295|NCT06180083|DRUG|Azelastine Hydrochloride/ Fluticasone propionate nasal spray|A single dose \[four sprays (two sprays in each nostril)\] of Azelastine HCL/ Fluticasone Propionate 137 mcg/50 mcg Nasal Spray
223439296|NCT06180083|DRUG|'DYMISTA' NASAL SPRAY|A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
224050569|NCT05453903|DRUG|Daunorubicin or Idarubicin|Participants will receive daunorubicin or idarubicin.
224050570|NCT02324855|OTHER|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
224050571|NCT05911659|DRUG|Ticagrelor|Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI
224050572|NCT02625233|DEVICE|senofilcon C|
224143972|NCT05127070|DEVICE|Neotree|The Neotree is a digital app, data collection and quality improvement system. collecting and collating routine health data at the bedside for babies on admission and discharge and for laboratory results. it provides point of care education and clinical decision support to optimise the clinical care of sick and vulnerable newborns according to approved and best available clinical guidelines.
224143973|NCT02292316|BEHAVIORAL|gait and cognitive assessments|several tests are given in each domain
224143974|NCT02292316|BIOLOGICAL|blood sample|routine analyses in rheumatology such blood count and 25OH-D
224143975|NCT02292316|OTHER|osteodensitometry|Looking for osteoporosis
224143976|NCT00005060|DRUG|Taxotere-Cisplatin-5FU|Preoperatively
224143977|NCT00005060|DRUG|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
223583993|NCT06082830|BEHAVIORAL|Intervention|"The intervention arm includes five components:~1. Personalized goal: Participants will complete an interview with a registered dietitian to review their baseline diet quality data and establish their personalized dietary goals.~2. Meal timing: Participants will receive information on why eating later at night is detrimental and specific strategies on how to limit eating past 8pm in the evening.~3. Nutrition skills: Participants will receive nutrition education and cooking skills text messages, using adolescent specific guidance from the Dietary Guidelines for Americans.~4. Home food environment: Participants will receive text messages on how to better select and prepare foods in the home environment (e.g., fruit and vegetable availability).~5. Engagement strategies: Researchers will design and implement text messages that recognize participant time and effort (e.g., text badges in recognition of completing the first study week)."
223740837|NCT06144346|RADIATION|Stereotactic Ablative Radiation Therapy|SABR to all metastatic lesions
223740838|NCT06144346|PROCEDURE|Locoregional treatment|mastectomy or BCS for the primary tumor
223740839|NCT06144346|OTHER|Standard of Care|Systemic treatment and palliative treatment
224050573|NCT02625233|DEVICE|comfilcon A|
224050574|NCT04190979|DEVICE|Medyria TrackCath System|The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
224143978|NCT05062941|OTHER|Conventional physiotherapy|Conventional therapy (CT) included application of 15 minutes of hot-pack, 20 minutes of transcutaneous electrical nerve stimulation, 5 minutes of ultrasound, 20 minutes of interference current with vacuum electrodes, and exercises.
224143979|NCT05062941|DEVICE|High-intensity laser therapy (HILT)|"HILT stimulates oxidation of mitochondria and ATP creation by delivering high energy output inside the tissues and with this photochemistry effect, metabolism and blood circulation is increased resulting HILT to cause quick absorption of edema and removal of exudates.~HILT (BTL 6000, BTL Industries, Inc., USA) application was to the shoulder area in the analgesic mode of the device at a frequency of 25 Hz with a power of 10 W and a dosage of 12 j/cm2 for 2 minutes: 5 sessions a week for 3 weeks and 15 sessions in total."
224143980|NCT00935519|DEVICE|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
223439297|NCT01885663|PROCEDURE|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
223439298|NCT05274087|DRUG|Risankizumab|Subcutaneous autoinjector
223439299|NCT03341494|DRUG|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
223439300|NCT01760213|OTHER|CBT delivered via Internet|
223439301|NCT01493115|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223439302|NCT01493115|DRUG|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224050575|NCT02426476|BEHAVIORAL|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
223439303|NCT03126123|PROCEDURE|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
223439304|NCT03748368|OTHER|Cataract presentation|Presentation about cataract surgery
223439305|NCT03748368|OTHER|Placebo presentation|Presentation about the history of the hospital
223439306|NCT03165084|BEHAVIORAL|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
223439307|NCT03165084|OTHER|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
223439308|NCT03165084|OTHER|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
223439309|NCT00452153|PROCEDURE|Characterization Legionnella|"* Characterisation Legionnella by polymerase chain reaction (PCR)~* Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
223740840|NCT02913079|BEHAVIORAL|Sit-stand desk|
223439310|NCT04844983|DRUG|STP705|The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
223439311|NCT04844983|OTHER|Placebo Saline|Normal Saline
223439312|NCT01408082|DRUG|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
223439313|NCT01408082|DRUG|Azasite|Azasite twice daily for 2 weeks
223439314|NCT01408082|DRUG|Dexamethasone|Dexamethasone twice daily for 2 weeks
223740841|NCT02913079|BEHAVIORAL|Sitting desk|
223740842|NCT03051321|DEVICE|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
223740843|NCT00000609|DRUG|amiodarone|
224050576|NCT02426476|BEHAVIORAL|sham HRVB training|passive relaxation
224050577|NCT06491108|DRUG|Vardenafil 5 Mg Oral Tablet|Comparing safety and efficacy of Vardenafil 5 mg twice oral daily versus established drugs e.g.Tadalafil 5mg and Tamsulosin 0.4 mg once oral daily in terms of (voiding function, sexual function and quality of life) in the management of moderate BPH related LUTS (benign prostatic hyperplasia related lower urinary tract syptoms )
224050578|NCT05184673|OTHER|Behavioral and environmental|These are all active comparator yoga sequences
224050579|NCT02866799|OTHER|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
224050580|NCT02866799|OTHER|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
224050581|NCT02691208|OTHER|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
224050582|NCT02691208|OTHER|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
224050583|NCT05273879|PROCEDURE|decompression|laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.
224050584|NCT05273879|PROCEDURE|fusion|First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
224050585|NCT02254577|DRUG|Endometrin® plus Progesterone in Oil (PIO)|
224050586|NCT02254577|DRUG|Progesterone in Oil (PIO) Only|
224050587|NCT03023930|OTHER|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
224143981|NCT03454412|PROCEDURE|Intensive Neurophysiological Rehabilitation|Intensive Neurophysiological Rehabilitation System (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
224143982|NCT05316090|PROCEDURE|Core stability exercises program|Strengthening to the trunk muscles
224143983|NCT05316090|PROCEDURE|Traditional physical therapy program|Neurodevelopmental training excercises
224143984|NCT03360136|BEHAVIORAL|Multi-professional CBT-rehabilitation|"See Detailed description"
224143985|NCT04793854|OTHER|Measure of the Life habits (MHAVIE)|"Life habits include daily activities and social in 6 groups. Environmental factors include social (9 different subgroups) and physical factors (7 different subgroups).~Personal factors are person related parameters (gender, age, sociocultural ethnic, skills, deficiencies factors,…)."
223439315|NCT01408082|OTHER|Vehicle|Vehicle twice daily for 2 weeks
223439316|NCT01887288|DRUG|Capecitabine|650 mg/m\^2 PO b.i.d.
223439317|NCT01887288|DRUG|Digoxin|0.25 mg once daily
223439318|NCT05212779|DIAGNOSTIC_TEST|Signatera testing|26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.
223439319|NCT05212779|DIAGNOSTIC_TEST|Altera Testing|6ml blood and tissue sample.
223439320|NCT02883621|PROCEDURE|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
223439321|NCT02883621|PROCEDURE|standard upper endoscopy|standard examination without using a cap
223439322|NCT05870670|DRUG|NNC0519-0130|Administered subcutaneously.
223740844|NCT00000609|DEVICE|defibrillators, implantable|
223740845|NCT03945487|BIOLOGICAL|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0\*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
224050588|NCT03023930|OTHER|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
223439323|NCT05870670|DRUG|Placebo|Administered subcutaneously.
223439324|NCT04002778|DIAGNOSTIC_TEST|Fine needle aspiration|
223439325|NCT04002778|DIAGNOSTIC_TEST|Rapid on-site evaluation|
223439326|NCT00799799|BIOLOGICAL|NK cells|NK cells infusion after immunosuppressive chemotherapy
223439327|NCT00597064|DRUG|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
224050589|NCT03778853|DRUG|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
224143986|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
224143987|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
224143988|NCT03888859|BIOLOGICAL|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
224143989|NCT00901147|DRUG|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
224143990|NCT00490659|DRUG|gemcitabine|
224143991|NCT00490659|DRUG|cisplatin|
224143992|NCT00490659|PROCEDURE|radical surgery|
224143993|NCT00490659|PROCEDURE|chemoradiotherapy|
224143994|NCT05762874|DRUG|Ruxolitinib|JAK inhibitor
224050590|NCT02703415|DRUG|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
224050591|NCT02703415|DRUG|Tramadol|caudal block with tramadol 1 mg/kg
224050592|NCT05517928|DRUG|Omeprazole|40 MG oral capsules daily
224050593|NCT05517928|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Given as Culturelle Digestive Probiotic in the form of oral capsules daily
224050594|NCT05517928|DRUG|Placebo|Oral capsules daily that look exactly like the study drug, but contains to active ingredient
224143995|NCT02231294|DRUG|Sifrol®|
224143996|NCT02303873|DRUG|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp \& Dohme．LTD.).
224143997|NCT02836860|OTHER|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
224143998|NCT03267992|BEHAVIORAL|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
224143999|NCT03441568|DEVICE|Modified Diprobase formulation (BAY987534)|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
224144000|NCT00004992|BEHAVIORAL|Intensive lifestyle|
224144001|NCT00004992|DRUG|Metformin|
224144002|NCT00004992|DRUG|Placebo|
223439328|NCT02657824|OTHER|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
223439329|NCT03872141|DIAGNOSTIC_TEST|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
223478610|NCT01482832|BEHAVIORAL|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
223478611|NCT04018066|DIETARY_SUPPLEMENT|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
224050595|NCT00253396|DRUG|Unfractionated heparin|
224050596|NCT00253396|DRUG|Enoxaparin|
224144003|NCT00736580|OTHER|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
224144004|NCT00736580|OTHER|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
224144005|NCT04493294|RADIATION|Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis|Low dose whole lung radiotherapy may decrease the cytokines storm related to the viral infection and may improve survival by decreasing the need for artificial ventilation
224144006|NCT00693680|DIETARY_SUPPLEMENT|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
224144007|NCT00693680|DIETARY_SUPPLEMENT|Placebo|placebo + imipramine (100-200mg/day)
224144008|NCT02557360|DIETARY_SUPPLEMENT|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
224144009|NCT01681576|DRUG|Valsartan|Valsartan 320mg tablet once daily
224144010|NCT01681576|DRUG|LCZ696|LCZ696 400mg tablet once daily
224144011|NCT01431729|OTHER|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
223439330|NCT03637309|BEHAVIORAL|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
223439331|NCT00565227|DRUG|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
223439332|NCT00565227|DRUG|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
223439333|NCT04616040|DRUG|Camrelizumab|The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
223439334|NCT00493987|DRUG|Testosterone Enanthate|testosterone ester
223439335|NCT00493987|DRUG|Dutasteride|5 alpha-reductase inhibitor
223439336|NCT01134289|PROCEDURE|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
223439337|NCT03706001|OTHER|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
223439338|NCT01308632|DRUG|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
223439339|NCT01955317|BEHAVIORAL|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
223439340|NCT01955317|BEHAVIORAL|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
223439341|NCT05900089|DRUG|SHR0302|SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
224163707|NCT01744041|OTHER|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
223439342|NCT02060266|DRUG|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
223439343|NCT03616444|DRUG|Shenbai Granules|In the first year, the trial granules will be started after enrollment for 3 months; In the second year, the trial granules will be started in the first 3 months; Each participant should have completed 6 months of trial granules.
223439344|NCT04658706|OTHER|A supervised exercise program|is a 12-week exercise program supervised by specially trained instructors combining moderate to high intensity aerobic and strength exercises (three 1 hour sessions a week).
223439345|NCT04658706|OTHER|exercise prescription|they will receive a prescription concerning healthy lifestyles and a personalized exercise plan
223439346|NCT05620992|DEVICE|Echocardiography|Echocardiography 3 and 6 months post operative
223439347|NCT06621667|OTHER|diaphragmatic myofascial release with traditional physical therapy exercises for hyperkyphosis|diaphragmatic myofascial release
223439348|NCT06621667|OTHER|traditional physical therapy exercises for hyperkyphosis|traditional physical therapy exercises for hyperkyphosis
223583994|NCT06277245|DRUG|LNK01001|Capsule; Oral
223583995|NCT06277245|DRUG|Placebo|Capsule; Oral
224050597|NCT00445224|OTHER|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
224050598|NCT00445224|OTHER|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
224050599|NCT01157754|DRUG|levonorgestrel and ethynilestradiol|
224050600|NCT04280965|DRUG|Quetiapine Fumarate|Atypical antipsychotic
224050601|NCT04280965|OTHER|Standard of care meducations|SSRI's/SNRI's/Trazodone/Prazosin/Hydroxyzine
224050602|NCT00841204|DRUG|sulindac|Given orally
224050603|NCT00841204|OTHER|placebo|Inactive agent
224050604|NCT00841204|OTHER|laboratory biomarker analysis|Correlative studies
224050605|NCT00591214|DRUG|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
224050606|NCT00161460|BEHAVIORAL|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
224050607|NCT03926845|OTHER|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
224050608|NCT03926845|OTHER|Vehicle|Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
224050609|NCT01129921|DEVICE|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
224050610|NCT01129921|DEVICE|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
223439349|NCT04600063|PROCEDURE|Isolation procedure (RAMPS procedure)|In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
224300368|NCT02664233|BEHAVIORAL|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
223439350|NCT04600063|PROCEDURE|Conventional procedure|In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
224144012|NCT02225574|DRUG|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
223439351|NCT04291495|DIAGNOSTIC_TEST|ANDROSITOL®TEST|Sperm incubation with ANDROSITOL®DGN and evaluation of sperm motility and mithocondrial membrane potential
223439352|NCT03541109|DRUG|Polypill|fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)
224050611|NCT06505239|DIETARY_SUPPLEMENT|FSD-F2R6-A-CP|FSD-F2R6-A-CP is a unique dietary supplement with natural ingredients, vitamins and minerals that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism and may accelerate alcohol metabolism in the body.
224050612|NCT06505239|DIETARY_SUPPLEMENT|Placebo|Placebo drink designed to match FSD-F2R6-A-CP in color and taste.
223583996|NCT06980727|DRUG|Salbutamol 2,5 mg|In this study group, patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml IV normal saline as placebo, and 5mg salbutamol in 5ml nebulisation during 10min.
224050613|NCT02000076|BEHAVIORAL|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
224050614|NCT02000076|BEHAVIORAL|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
224144013|NCT02225574|DRUG|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
224300369|NCT01708590|DRUG|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
223583997|NCT06980727|DRUG|Dexamethasone|Patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml intravenous dexamethasone (8mg), and 5ml nebulisation of of normal saline during 10min as placebo.
224050615|NCT03800888|OTHER|Daily SMS reminders for TB patients|Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
224050616|NCT03800888|OTHER|SMS Notifications for social supporters|SMS Notifications will be sent to social supporters to assit TB patients take their medication
224144014|NCT02225574|BEHAVIORAL|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
224144015|NCT05368129|PROCEDURE|Balloon dilation|Balloon dilation was performed after DES implantation.
224144016|NCT05072665|DEVICE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE|HIGH ECHOENDOSCOPY WITH THE FAST PROCEDURE
224144017|NCT02172092|DRUG|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
224144018|NCT03386331|BEHAVIORAL|diet and exercise|Diet and lifestyle intervention
224300370|NCT01708590|DRUG|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
224300371|NCT01708590|DRUG|placebo|Placebo administered subcutaneous (SC)
224300372|NCT03731871|DIAGNOSTIC_TEST|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
224300373|NCT00297856|BIOLOGICAL|Boostrix®|Single dose
224300374|NCT00297856|BIOLOGICAL|Td (Tetanus diphtheria) vaccine|Single dose
223583998|NCT06980727|DRUG|Placebo|Patients will receive 1000mg intravenous injection of paracetamol in combination with 4ml intravenous dexamethasone (8mg), and 5ml nebulisation of of normal saline during 10min as placebo.
224144019|NCT01518244|DRUG|Brinzolamide/timolol maleate fixed combination|
224144020|NCT02289404|DRUG|NVP-1203|Oral
224144021|NCT02289404|DRUG|NVP-1203|Oral
224144022|NCT01839201|OTHER|control|No psychological intervention
223439353|NCT02783456|PROCEDURE|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
223439354|NCT02783456|PROCEDURE|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
223439355|NCT04505605|OTHER|Blood samples|A blood sample will be collected on a dry tube with 5mL separating gel on each enrolled patients. Those will be made depending on the patients hospitalization.
223439356|NCT03526198|DEVICE|Force plate|Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
223439357|NCT03011983|DEVICE|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
223439358|NCT03011983|DEVICE|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
224144023|NCT01839201|OTHER|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
223439359|NCT03011983|BEHAVIORAL|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
223439360|NCT03114657|DRUG|Crenezumab|Crenezumab was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
224050617|NCT03800888|OTHER|Weekly SMS remiders|Weekly SMS reminders sent to TB patients to remind them take medication
224050618|NCT05785390|DRUG|NP-101|NP-101 is an organically derived, GMP manufactured product covered under IND #152687.
224144024|NCT01839201|OTHER|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
223439361|NCT03114657|DRUG|Placebo|Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
223566646|NCT06303440|OTHER|Routine Physical Therapy+ Balance Training|Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.
223566647|NCT06303440|OTHER|Virtual Reality+ Routine Physical Therapy|The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.
223740846|NCT03945487|OTHER|Comprehensive treatment|"1. All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~2. Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
224050619|NCT05785390|OTHER|Placebo|Identical placebo
224144025|NCT01144234|BEHAVIORAL|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
224144026|NCT01144234|BEHAVIORAL|Information letter|In this arm the pregnant women got an information letter
223439362|NCT06620250|COMBINATION_PRODUCT|Digital Prevention and control of myopia|The Digital Intervention Programme for parents/primary caregivers is primarily a digital intervention to address the attitudes, knowledge and actions of parents or primary caregivers of pre-school children regarding the prevention and control of myopia.
224070702|NCT03343496|PROCEDURE|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I\~II, aged 18\~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
224070703|NCT01411085|DRUG|Risperidone + Desipramine|
224144027|NCT00546039|DRUG|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
224144028|NCT00546039|DRUG|Placebo|Capsule
224144029|NCT01257919|DRUG|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
224144030|NCT01257919|DRUG|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
223439363|NCT01236950|DRUG|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
223439364|NCT01236950|DRUG|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
223439365|NCT03042416|DRUG|18F-DOPA|18F-DOPA intravenous injection single dose
223439366|NCT06304558|DEVICE|Non-Invasive Neuromodulation (NESA)|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus,. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs are covered through the sympathetic paravertebral ganglia and the sacral plexus.
223439367|NCT03631719|BIOLOGICAL|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
224050620|NCT06973252|BEHAVIORAL|Eye masks|The intervention group patients were fitted with an eye mask designed by the researcher by placing a black fabric in the size of the mask between two three-layer surgical masks with Asfor brand soft elastic earphones and stapling the edges. The designed eye mask was cut with scissors according to the shape of the nose so that the mask would fit the eye exactly and prevent the light from entering the eye. A separate mask was used for each patient in the intervention group. Patients who were admitted to the NICU after surgery were evaluated for agitation-pain-delirium at 23:00 on postoperative days 0, 1, and 2, were told to wear their eye masks after the scale application, and the patients were allowed to sleep at 23:00 at the latest. Patients were allowed to remove the eye patch for short periods of time (10 minutes or less at a time) and then put it back on when uncomfortable and when necessary.
224050621|NCT04194281|OTHER|Action Observation Training [AOT]|Parents are instructed to show their child repetitive arm, hand and finger movements in a playful and age-appropriate way for about 20 minutes a day, divided into several short sequences. AOT is to be carried out for four weeks at home by the parents and, if necessary, other caregivers. The parents receive instructions which contain background information on the possible importance of AOT for improving the functions of the upper limb, information about positions, promoting motivation, attention and interest as well as tips for promoting movement observation in everyday life.
224050622|NCT06980519|BIOLOGICAL|MNPR-101-PCTA-177Lu|MNPR-101-PCTA-177Lu is a monoclonal antibody-radionuclide conjugate intended to target and deliver radioactivity to solid tumors expressing uPAR.
224050623|NCT06593249|OTHER|No Intervention: Observational Cohort|no intervention, observational study
224050624|NCT01978353|BEHAVIORAL|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
224050625|NCT01978353|BEHAVIORAL|Psychoeducation|Participants receive information about memory functioning and aging
224050626|NCT01794364|DRUG|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
224050627|NCT01794364|OTHER|placebo|Correspondingly, placebo doses will be administered as suspension.
224050628|NCT06656455|DRUG|sevoflurane via LMA|In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
224050629|NCT06656455|DRUG|Propofol with oxygen via simple mask|"In group P, the sevoflurane will be discontinued, and propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV. Propofol pump is maintained initially at a rate of 200mic/kg/min. with oxygen at 3 liters/min via facemask.~If movement requires interruption of the exam, a bolus of propofol 1mglkg is given and the infusion rate is increased by 20mic/kg/min up to a maximal rate of 350mic/kg/min. The total number of boluses needed will be recorded as the need for additional sedation. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, the infusion pump will be stopped until the proper airway intervention is taken to achieve saturation above 95% with spontaneous breathing. Afterwards, the propofol pump will be resumed at a rate decreased by 20mic/kg/min."
224050630|NCT05470322|DEVICE|Er: YAG laser|Patients will be treated with laser for their HS scarring.
224050631|NCT06984393|OTHER|home tele-rehabilitation|Patients will receive a personalised home tele-rehabilitation exercise program consisting of 3 sessions per week for a duration of 12 weeks. The sessions will be organised as follows: one session will be conducted via tele-rehabilitation with the support of a physiotherapist in small groups of up to 5 patients; in the remaining two sessions, the patient will perform the exercises independently at home. BTS TELEREHAB is the platform that will allow the delivery of remote rehabilitation services. The patient is given the system to take home, where they will connect the small Brain PC, that is the computer unit of the BTS TELEREHAB solution, to their television. Before starting the rehabilitation program, the patient will receive training with the technology in the hospital, in the presence of the physiotherapist. During motor rehabilitation sessions, the patient wears a special inertial sensor, the G-Sensor device.
224070704|NCT03258658|BIOLOGICAL|Autologous Engineered Urethral Construct|urethral construct
223439368|NCT01135875|OTHER|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
223439369|NCT01135875|OTHER|Normal Controls|2 teaspoons of blood will be collected once.
223478612|NCT06157424|OTHER|Thread Embedding Acupuncture|Thread Embedding Acupuncture is applied at acupoints including CV-12, CV-13, ST-36, PC-6, BL-17, BL-18, BL-21 on both sides of the body every 2 weeks, totaling 2 sessions over 4 weeks of intervention.
223478613|NCT06157424|OTHER|Auricular acupuncture|Auricular acupuncture is administered using adhesive patches with small needles (0.25 x 1.3 mm) placed at acupoints TF4, AH6, CO12, CO4, CO2 once a week, totaling 4 sessions over the 4-week intervention period.
223478614|NCT06157424|OTHER|Standard treatment|Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of proton pump inhibitors, additional antacids as needed, and lifestyle modifications.
223439370|NCT01075399|DRUG|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
223439371|NCT01179737|DRUG|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
223439372|NCT01179737|DRUG|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
223439373|NCT01326507|BIOLOGICAL|Dosage de l'h-FABP|Dosage de l'h-FABP
223439374|NCT03349905|PROCEDURE|fresh transfer|"Women randomized in the non experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~* All of their embryo kept in prolonged culture~* A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~* Supernumerary blastocysts cryopreserved"
223439375|NCT03349905|PROCEDURE|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~* Antagonist stimulation protocol~* Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~* All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~* A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
223439376|NCT00971061|DEVICE|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
223439377|NCT00971061|DEVICE|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
223439378|NCT04769505|BEHAVIORAL|digital mindfulness-based intervention (MBI)|The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.
223439379|NCT06507631|BEHAVIORAL|Blended care pirate group|During the blended care pirate group, children will receive training while their less affected arm is in a sling. They will perform play-like activities with their affected arm both on-site and at home.
223439380|NCT05467670|DRUG|Pembrolizumab|A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
223566648|NCT06303440|OTHER|Motor Imagery+ Routine Physical Therapy|"The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video."
223740847|NCT04023448|PROCEDURE|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
223740848|NCT01897012|DRUG|Alisertib|Given PO
224050632|NCT06984393|OTHER|Usual care|Participants will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises.
224050633|NCT06986018|DRUG|RD06-04 Cell Injection Infusion|CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
224050634|NCT06984471|OTHER|Palliative care consult|A palliative care (PC) consult involves a specialized palliative care team to provide symptom management, psychosocial support, and assistance with goals-of-care discussions for patients with serious or life-limiting illnesses.
224050635|NCT06985823|OTHER|Rotational exercises|14 participants will be in experimental group A, giving them rotational exercises (Rotational Crunch exercise, Single leg romanian deadlift with rotation, rotational medicine ball throws for six weeks. Measure all values before giving them protocol and after protocol.
224050636|NCT06985823|OTHER|Anti-Rotational exercises|14 participants will be in experimental group B, giving them anti-rotational exercises (Quadruped exercise 3 sets of 15 repetition, planks 3 sets of 60 second hold, pallof press 3 sets of 15 repetition) for six weeks. Measure all values before giving them protocol and after protocol.
224050637|NCT06985225|COMBINATION_PRODUCT|Hyperpolarized 129 Xenon|Xenon gas contrast agent for MRI
224050638|NCT06984458|BEHAVIORAL|Robot Dementia Prevention Course|"It is expected that through the eight-week course design activities, the cognitive functions, social activities, emotional management (such as alleviating depression), well-being, reduce loneliness and can be achieved, thereby preventing or delaying cognitive decline.~The experimental group conducted a two-month Robot Dementia Prevention Course intervention. The research subjects were 40 people. Each group of 5 people was assigned a Kebbi robot. The course intervention was divided into 8 groups. The Kebbi robot mainly taught and communicated with the elderly interactively. There is a well-trained teaching assistant in the class to enhance the learning effect of the elderly. The two classes per week are about 2 hours long, with 50 minutes of course knowledge introduction, 10 minutes of rest, 50 minutes of interaction with Kebbi Artificial Intelligence-based board games, and 10 minutes of prize-based quizzes after class."
224050639|NCT06985316|DRUG|Tunlametinib combined with Fruquintinib|Tunlametinib combined with Fruquintinib
224050640|NCT01467453|DEVICE|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
224050641|NCT03122717|DRUG|Gefitinib|gefitinib is a EGFR inhibitor
223439381|NCT05467670|DRUG|ALX148|A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
223439382|NCT05467670|DRUG|Doxorubicin|An anthracycline that slows/stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, used as second line non-platinum chemotherapy in patients with platinum-resistant ovarian cancer.
224144031|NCT03085355|PROCEDURE|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
223439383|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
224050642|NCT03122717|DRUG|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
224050643|NCT06985160|OTHER|Specific single nucleotide polymorphisms|Next-generation sequencing was performed to analyze the TLR4, LTA, and RFP175 genes, with a focus on specific single nucleotide polymorphisms
224050644|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
223566649|NCT06274996|DRUG|Upadacitinib|Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
223566650|NCT04117490|OTHER|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
223566651|NCT04117490|OTHER|Placebo|Two capsules twice daily 30 mins before meals (breakfast \& dinner).
223566652|NCT06433505|DRUG|BMS-986365|Specified dose on specified days
224050645|NCT00640484|DRUG|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
224050646|NCT00640484|DRUG|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
224050647|NCT00640484|DRUG|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
224050648|NCT06984770|BEHAVIORAL|Virtual peer support group intervention|The virtual peer support group aims to improve emotional well-being, reduce isolation, and help caregivers cope by offering a safe space to share experiences and receive support from others facing similar caregiving demands.
224050649|NCT06984770|BEHAVIORAL|Caregiver Support intervention|The caregiver support intervention is a personalized program designed to improve quality of life, reduce fatigue and caregiver burden, and build resilience.
224050650|NCT06984770|OTHER|Resources|Participants will be given a list of resources to contact in case of emotional or psychological distress.
224050651|NCT06599476|DEVICE|BioProtect Balloon Implant™ System|The BioProtect Balloon Implant System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, and by creating this space, to reduce the radiation dose delivered to the anterior rectum. The balloon is inserted into the perirectal space and inflated to its pre-defined size. The Balloon is made of biodegradable materials that maintain the space for the entire course of prostate radiation treatment and are absorbed by the patient's body over time
224050652|NCT06984081|PROCEDURE|CAPA IVM|In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.
224070705|NCT01547325|DRUG|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
223439384|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
223439385|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
223439386|NCT01546038|DRUG|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
223566653|NCT06433505|DRUG|[14C] BMS-986365|Specified dose on specified days.
223566654|NCT06433505|DRUG|[14C] BMS-986409 + BMS-986410|Specified dose on specified days
223566655|NCT06433505|DRUG|[14C] BMS-986410 + BMS-986409|Specified dose on specified days
223740849|NCT01897012|OTHER|Laboratory Biomarker Analysis|Correlative studies
224070706|NCT01547325|DRUG|placebo hydrogel|placebo hydrogel
224070707|NCT00147524|DRUG|quinapril|
224070708|NCT00147524|PROCEDURE|Laser Doppler imaging|
224070709|NCT07132840|PROCEDURE|Kinesio tape application followed by single session of balance training on various unstable surfaces.|Participants with functional ankle instability received balance training on various unstable surfaces after kinesio tape application.
224144032|NCT03085355|PROCEDURE|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
223439387|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
223439388|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
223439389|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
223439390|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days
223439391|NCT01546038|DRUG|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
223439392|NCT01546038|DRUG|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
223439393|NCT01546038|DRUG|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
223740850|NCT01897012|DRUG|Romidepsin|Given IV
224163708|NCT01614041|DRUG|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
224163709|NCT01614041|DRUG|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
224163710|NCT05221593|DRUG|Lithium Carbonate|400 mg tablet in controlled released formula
224163711|NCT01936272|DEVICE|Chhabra Shunt Placement|
224163712|NCT01936272|PROCEDURE|ETV/CPC|
223439394|NCT01546038|DRUG|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
223439395|NCT01980810|DRUG|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
224050653|NCT06605248|BEHAVIORAL|App-based self-management tool plus usual care|The app-based self-management tool will be delivered after patients receive usual care from their general practitioners. The 8-week mobile app intervention will involve daily sessions on pain education and clinical hypnosis for back pain management (5 minutes, 15 minutes of listening to hypnotherapy audio and engaging in physical/social activities for 5 minutes.
224144033|NCT06441110|DRUG|Tislelizumab in Combination with Bacillus Calmette-Guérin|Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
224144034|NCT04119817|DIETARY_SUPPLEMENT|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
224144035|NCT04119817|DIETARY_SUPPLEMENT|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
224050654|NCT06605248|BEHAVIORAL|Patient information digital fact-sheet plus usual care|The face-sheet will be delivered after patients receive usual care from their general practitioners.This digital intervention will contain educational material for chronic back pain that includes details about diagnosis, prognosis and treatment options.
224050655|NCT05694819|DRUG|Darolutamide|Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.
224050656|NCT05694819|DRUG|Goserelin|Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.
224050657|NCT04437537|DEVICE|Bioresorbable 3D electrospun synthetic matrix|All participants in this study will receive PHOENIX Wound Matrix® in addition to the SOC treatment for their chronic DFU.
224050658|NCT06681467|OTHER|Respiratory monitoring band|The only intervention in this study is the application of two CE marked study approved chest bands- the Go direct respiratory sensor and a biosignal respiration belt
224050659|NCT06249711|DEVICE|Active stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused low-intensity ultrasound stimulation
224050660|NCT06249711|DEVICE|Sham stimulation with Diadem ultrasonic transducer array|Diadem ultrasonic transducer array delivers focused zero-intensity ultrasound stimulation
224050661|NCT06099210|DIAGNOSTIC_TEST|Glasgow coma scale|Closed tach brain injury due to external force was included according to the GCS score
224050662|NCT03779919|DEVICE|extracorporeal shock wave|Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
224144036|NCT03503214|DIAGNOSTIC_TEST|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
224144037|NCT03503214|DIAGNOSTIC_TEST|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
224144038|NCT04426370|OTHER|Observational|Physical examination and questionnaires
224300375|NCT04787393|DEVICE|Heartfelt device|The Heartfelt device uses a system of scanner in a compact device to generate depth images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit, For the measurements to take place, the participant walks in the field of view of the device, measurments are only taken when the patients has bare feet and no slippers/shoes, so the location of the device in the home is choosen to match this requirement. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.
223439396|NCT01980810|DRUG|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
223439397|NCT04339010|OTHER|Hypopressive exercise|The hypopressive exercise is performed mainly via transversus abdominis (Tra) activation. The exercise relaxes the diaphragm, decreases intra-abdominal pressure and may activate the abdominal and PFM simultaneously.
223439398|NCT04339010|OTHER|Pelvic floor muscle contraction|Pelvic floor muscle contraction (PFMC) is performed through a sequence of contraction and relax the PFM. It will improve PFM strength and is effective for treating urinary incontinence.
223439399|NCT03410810|DIAGNOSTIC_TEST|MRI|MRI analysis
223439400|NCT03410810|DIAGNOSTIC_TEST|Neurodevelopmental/Neuropsychological Assessment|Standardized Cognitive and Developmental Tests
223439401|NCT02570334|OTHER|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
223478615|NCT05517590|DRUG|Tranexamic acid|1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
223478616|NCT05517590|DRUG|Saline|100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
223478617|NCT06275399|DIAGNOSTIC_TEST|OCT examination|OCT examination for precise evaluation of plaque morphology within the coronary stenosis.
223478618|NCT06275399|DIAGNOSTIC_TEST|Blood sampling|Blood sampling directly from coronary artery (proximal and distal segment) arteries
224144039|NCT01756066|BEHAVIORAL|Different levels of cost sharing|
223439402|NCT02235441|OTHER|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
223439403|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
223439404|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
223439405|NCT01276119|BIOLOGICAL|CDP6038|100 mg/mL solution for injection Single sc injection
223439406|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
224144040|NCT03110419|OTHER|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
224144041|NCT03765255|OTHER|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
224144042|NCT01583452|OTHER|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
224050663|NCT06902220|DEVICE|continuous high-frequency oscillation therapy|Once patients' CPOT score reaches 0, intubated patients will receive continuous high-frequency oscillation (CHFO) therapy three times daily, with 8-hour intervals and 10-minute sessions. Extubated patients will receive CHFO and continuous positive expiratory pressure (CPEP) therapy twice daily, with 12-hour intervals and 10-minute sessions.
224050664|NCT06850883|OTHER|A person-centered dementia home care scenario-based training program|"The training program primarily consists of three major themes in dementia care scenario-based training: Empathy, Challenging Behavior Management, and Interactive Activity Design."
224144043|NCT00033033|DRUG|Reserpine|
224144044|NCT03314714|PROCEDURE|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
224144045|NCT02266758|OTHER|GDM Screening Methods|
224144046|NCT06483490|OTHER|This is a cross-sectional, non pharmacological study|Measurement of immune checkpoint levels, mitochondrial dysfunction, pollutant concentrations and G-quadruplex levels and their correlation in all enrolled subjects.
224050665|NCT06850883|OTHER|Routine Treatment|Routine Treatment
224144047|NCT00325338|BIOLOGICAL|Ragweed MATAMPL|
224144048|NCT01644942|OTHER|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
223439407|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
223439408|NCT01276119|OTHER|Placebo|0.9% sodium chloride for injection Single sc injection
223439409|NCT04240964|OTHER||
223439410|NCT04245202|DEVICE|HFNCOT|The patient will receive a high flow nasal of humidified oxygen, set between 2 to 25 l/min. The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
223439411|NCT04245202|OTHER|St-FMOT|The inspired fraction of oxygen (FiO2) will be adjusted to obtain the oxygen saturation \>92%.
223439412|NCT02253121|DRUG|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
223439413|NCT02253121|DRUG|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
223439414|NCT02818621|DRUG|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
223439415|NCT06013202|OTHER|Nigella Sativa Oil Mouth Rinse|Nigella Sativa Oil Mouth Rinse
223439416|NCT06013202|OTHER|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)|isotonic (normal saline) with concentration 0.90% of sodium chloride (NaCl)
223439417|NCT00696202|DRUG|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
224144049|NCT02000453|DRUG|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
224144050|NCT00874679|DRUG|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
224144051|NCT01422590|DRUG|Sitagliptin|Single oral administration of sitagliptin 100 mg
224144052|NCT01422590|DRUG|Mitiglinide|Single oral administration of mitiglinide 10 mg
224144053|NCT01422590|DRUG|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
224144054|NCT06050967|COMBINATION_PRODUCT|Enzyme replacement therapy for Gaucher disease in combination with altus care application|In coordination with the patient's treating physician and the home treating nurse, an individualized treatment plan was prepared for each patient within a pre-defined range of minimal and maximal once in two weeks enzyme replacement therapy dosages and timing frames for its administration. Per protocol, the patient's monthly dose was not changed, but each dose and the timing of administration was changed randomly using the app.
224144055|NCT00005848|DRUG|chemotherapy|
224144056|NCT00005848|DRUG|tipifarnib|
224144057|NCT04142216|DIETARY_SUPPLEMENT|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
223439418|NCT04295343|DIAGNOSTIC_TEST|Three-dimensional (3D) rectal water contrast transvaginal ultrasonography|Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.
223439419|NCT04295343|DIAGNOSTIC_TEST|Computed colonography|Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.
223439420|NCT02470403|DRUG|LIK066|LIK066 25 mg tablets
223439421|NCT02470403|DRUG|Placebo|Matching placebo tablets
223439422|NCT03146975|PROCEDURE|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
223439423|NCT00717275|DRUG|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
223439424|NCT04241393|DRUG|Tavapadon tablet|Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)
224144058|NCT00778986|DEVICE|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
224144059|NCT01589510|DRUG|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
224144060|NCT01718626|DRUG|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
224144061|NCT01718626|DRUG|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
224144062|NCT02013089|DRUG|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
223439425|NCT04241393|DRUG|Tavapadon [14C] suspension|Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16
223439426|NCT06535633|OTHER|Intervention arm: Exercise class|The exercise trainers, who are educated in chronic pain, will lead a set of classes, adapted to the needs of people with chronic pain. The investigators have conducted PPI activities with the members of Chronic Pain Ireland, to understand the barriers and facilitators for community-based exercise and their needs in relation to same. A forthcoming publication reports the results of a survey of a survey of (n=130) members of CPI highlightinged that key barriers to community-based exercise included fear of pain exacerbation, and not having skilled exercise instruction. The exercise modalities of choice have been informed by the survey results as well as alignment with the LSP class offerings and trainer competency. Classes on offer are focused on aquatic exercise, Activator pole walking, yoga or Pilates, and circuit-style fitness, for participants to choose their own preferred option. Classes will run weekly for 8 weeks, duration 1 hour.
224050666|NCT06902207|DRUG|Faricimab Injection [Vabysmo]|The procedures followed local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of an eye speculum, topical 5% povidone-iodine disinfection, 33G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in the supertemporal or the inferotemporal quadrant, sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.
224144063|NCT02013089|DRUG|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
224144064|NCT02013089|DRUG|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
224163713|NCT04364906|OTHER|Regional anesthesia|The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
223439427|NCT04146623|BIOLOGICAL|CodaVax-H1N1 influenza vaccine|CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10\^5 plaque forming units (PFU).
223439428|NCT04146623|BIOLOGICAL|Normal Saline Placebo|Saline (0.9%) administered intranasally via sprayer
223583999|NCT06979479|BEHAVIORAL|school-based intervention|AFL is a four-day program aimed at combating the stigma associated with mental health conditions and reducing suicidal ideation among youth. The program focuses on improving knowledge about depression and mental illness, enhancing self-efficacy skills for coping and seeking help, and increasing receptiveness to receiving assistance. Facilitated by mental health experts, the educational curriculum equips youth with the necessary tools to address feelings of hopelessness.
223584000|NCT06980545|DRUG|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin) will be given in complete six cycles
224050667|NCT06903273|DRUG|Tislelizumab|"Tislelizumab plus chemotherapy (14 days as one cycle) 3 cycles every 2 weeks as neoadjuvant therapy and followed by a curative surgery.~Tislelizumab 200 mg fixed-dose IVD on day 1. Gemcitabine 800 mg/m2 on day 1 with a fixed-infusion rate of 80 mins. Cisplatin 25 mg/m2 on day 1. S-1 70 mg/m2 daily as a BID dosing per oral on day 1 to 7. (daily total dose determined by body surface area (BSA): \<1.25 m2, 80 mg; 1.25-1.50 m2, 100 mg; ≥1.50 m2, 120 mg)"
224050668|NCT06902597|PROCEDURE|Dual energy X-ray absorptiometry|Very low radiation dose technique to show fat mass (FM) and lean mass (LM)
224050669|NCT01384630|DRUG|RA-18C3|200 mg subcutaneous injection
224050670|NCT02522507|BEHAVIORAL|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
224050671|NCT05429645|PROCEDURE|setting up of the pace maker|Setting up of a pace maker using a 3-dimensional (3D) guidance technique
224050672|NCT06044714|PROCEDURE|Manual Standardized Stress Acupuncture (MSSA)|Participants in the experimental group will receive 4 weekly sessions of MSSA, which consists of 8 acupuncture points: bilateral auricular (ear) shen men, GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. Needles are left in situ for 30 minutes per session.
223439429|NCT00263055|DRUG|oxaliplatin|
223584001|NCT06980818|OTHER|No intervention|No intervention will take place.
223439430|NCT03794934|BEHAVIORAL|Structured Education for new glucose management devices|Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
223439431|NCT03662113|DRUG|Domperidone|5ml Domperidone prior to VCE
223439432|NCT03662113|DIETARY_SUPPLEMENT|water|5ml water prior to VCE
223439433|NCT02564406|DEVICE|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
223439434|NCT02636556|RADIATION|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w\*4.
223439435|NCT04742309|DRUG|Pecs-2 block (single injection)|For Pecs-2 blocks, the needle will be advanced to the tissue plane between the pectoralis major and minor muscles at the vicinity of the pectoral branch of the acromiothoracic artery where 10 mL of local anesthetic will be deposited. In a similar manner, 20 mL will be deposited at the level of the third rib above the serratus anterior muscle with the intent of spreading injectate to the axilla. The study fluid will be ropivacaine 0.3% with epinephrine.
223439436|NCT04742309|DRUG|Paravertebral block (single injection)|For paravertebral blocks, ropivacaine 0.5% (with epinephrine) 9 mL will be administered at each of two levels per side: the T3 and T5 levels for sides without axillary involvement; and at the T2 and T4 level for sides with axillary involvement.
223439437|NCT02634905|OTHER|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
223584002|NCT06980571|DEVICE|radiofrequency ablation|FDA approved intervention being compared with gold standard (most common intervention)
224050673|NCT06044714|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants will receive four sessions of MBSR group psychotherapy (no more than 10 participants per group session) via Microsoft Teams. The first session will be 90 minutes followed by three 60-minute weekly sessions.
224050674|NCT06290193|BIOLOGICAL|Acute Normovolemic Hemodilution/ANH|For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.
224050675|NCT06934720|BEHAVIORAL|aPAVRCT|"* We offered a system integrated with an indoor bike (for physical activity) and a multisensory VR environment (for cognitive training, such as reminiscence).~* Participants will actively navigate the virtual environment by pedaling and steering the handlebar.~* Care professionals will deliver the intervention using this system."
224050676|NCT00645957|PROCEDURE|penrose drain|incision and drainage of the infection with placement of a penrose drain
224050677|NCT00645957|PROCEDURE|red rubber drain|incision and drainage of infection and placement of a red rubber drain
224050678|NCT03464994|DIAGNOSTIC_TEST|ophthalmological examination|"* Refraction~* Best corrected visual acuity~* Intraocular pressure~* Slit lamp examination with vital dye (Oxford grading)~* Tear break-up time (TBUT)~* Schirmer I testing~* Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies~* Pachymetry~* Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~* questionnaire about ichthyosis severity~* questionnaire about life quality specifically for patient presenting ichthyosis"
224050679|NCT05048368|DRUG|Larotinib|Capsules, Oral, 350 mg, single dose, one day
224050680|NCT04969770|OTHER|Ultrasound elastography (USE)|"Visualization of the vertebral disc and the para-vertebral muscles.~Intra and inter observer reproducibility analysis carried out for each of the measurements made, by two operators.~Patients with instrumented neuromuscular scoliosis: 5 elastographies : preoperatively, then during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Patients with neuromuscular pathologies without instrumented scoliosis: 4 elastographies during the usual follow-up consultations with the surgeon every 6 months for 2 years.~Healthy control patients without neuromuscular pathology or scoliosis :~1 elastography during an usual consultation."
224050681|NCT04396002|DIAGNOSTIC_TEST|Life Space Questionnaire|This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.
224144065|NCT02013089|DRUG|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
224144066|NCT02013089|DRUG|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
223439438|NCT02634905|OTHER|Phone Call|
223439439|NCT06221098|PROCEDURE|bilateral medial rectus recession|release muuscle from its original insertion and backword inserted in sclera
224050682|NCT04396002|DIAGNOSTIC_TEST|Low Luminance Questionnaire|This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.
224050683|NCT04396002|DIAGNOSTIC_TEST|Contrast sensitivity under dim illumination|Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.
224050684|NCT04396002|DIAGNOSTIC_TEST|Visual field under dim illumination (MAIA)|Sensitivity in the central visual area will be assessed under dim illumination
224050685|NCT04396002|DIAGNOSTIC_TEST|Macular Pigment Optical Density (MPOD)|Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.
224144067|NCT00377429|DRUG|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
224144068|NCT04644016|DRUG|Clofarabine|Clofarabine
223439440|NCT05693545|DRUG|phenoxymethyl penicillin|Prophylaxis
223439441|NCT05693545|DRUG|intramuscular benzathine penicillin G (BPG) prophylaxis|Prophylaxis
223439442|NCT00047229|BIOLOGICAL|oblimersen sodium|
223439443|NCT00047229|DRUG|doxorubicin hydrochloride|
223439444|NCT03329248|BIOLOGICAL|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
223439445|NCT03329248|BIOLOGICAL|ETBX-011|Ad5 \[E1-, E2b-\]-CEA
223439446|NCT03329248|BIOLOGICAL|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
223439447|NCT03329248|BIOLOGICAL|haNK for infusion|NK-92 \[CD16.158V, ER IL-2\]
223439448|NCT03329248|BIOLOGICAL|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
223439449|NCT03329248|BIOLOGICAL|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
223439450|NCT03329248|DRUG|Capecitabine|5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
223439451|NCT03329248|DRUG|Cyclophosphamide|2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
223439452|NCT03329248|DRUG|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
223439453|NCT03329248|DRUG|Leucovorin|L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
223439454|NCT03329248|DRUG|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
223439455|NCT03329248|DRUG|lovaza|Omega-3-acid ethyl esters
223439456|NCT03329248|DRUG|Oxaliplatin|cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
223439457|NCT03329248|PROCEDURE|SBRT|Stereotactic Body Radiation Therapy
223439458|NCT04812795|OTHER|Culturally tailored anti-smoking messages|Anti-smoking messages that are culturally tailored for sexual minority women.
223439459|NCT04812795|OTHER|Non-culturally tailored interventions|Anti-smoking messages that are not culturally tailored for sexual minority women.
223439460|NCT00421317|DRUG|Imatinib|800 mg/day until disease progression or toxicity
223439461|NCT01510535|DRUG|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
223439462|NCT01510535|DRUG|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
223439463|NCT01510535|DRUG|LBSA0103|at third week LBSA0103(60mg) once in experimental group
223439464|NCT02827643|DRUG|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
223439465|NCT02827643|OTHER|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
223439466|NCT03181243|PROCEDURE|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
223439467|NCT03181243|PROCEDURE|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
223439468|NCT01254721|DRUG|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
224050686|NCT04396002|DIAGNOSTIC_TEST|Dark Adaptation|After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
224050687|NCT04230278|BEHAVIORAL|START-Play Physical Therapy|Physical Therapy focused on movement and cognitive skills at the same time
224050688|NCT04230278|BEHAVIORAL|Usual Care Physical Therapy|Physical Therapy focused on movement and reducing impairments
223439469|NCT01254721|DRUG|lithium|300mg tablet, oral
223439470|NCT04633902|DRUG|Olaparib|Olaparib 300 mg BID daily
223439471|NCT04633902|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV eveyr 3 weeks (for up to 2 years)
224050689|NCT05050318|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
224050690|NCT05050318|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation|Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
223439472|NCT00987402|OTHER|Plain soap and water (PSW)|Presence or absence of infection
223439473|NCT00987402|OTHER|Alcohol-based hand rub (ABHR)|Presence or absence of infection
223439474|NCT05640661|DEVICE|Oculus Quest II|"active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.~During the realization of the exposure with VRi they will be recorded through an Ipad Tablet, and after performing the entire intervention a terminal visual feedback therapy will be performed by observation of actions in holocentric vision."
223439475|NCT05640661|DEVICE|Oculus Quest II|active treatment using Virtual Reality software based on pain education and gamified exercise for gradual exposure to shoulder movement. The game involves visual stimuli and shoulder movement exercises in the shoulder flexion and abduction ranges in real time using immersive glasses located on the head and two controls on both hands. Patients will inhabit an avatar from an egocentric perspective.
223439476|NCT00948415|BEHAVIORAL|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
223439477|NCT04685278|BIOLOGICAL|Blood samples|Blood samples were collected in dry tubes on days 1, 3, 5, 8 and 10 of hospitalization
224050691|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 1|Loading Dose: 0.05 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
224050692|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 2|Loading Dose: 0.08 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
224050693|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 3|Loading Dose: 0.12 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
223439478|NCT01805973|BEHAVIORAL|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
223439479|NCT02736591|DRUG|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
223439480|NCT02736591|DRUG|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
223439481|NCT02736591|DRUG|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
223439482|NCT02736591|DRUG|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
223439483|NCT01772680|DIETARY_SUPPLEMENT|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
223439484|NCT02538692|DRUG|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
223439485|NCT02538692|DRUG|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
223439486|NCT00757029|GENETIC|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
224050694|NCT05907213|DRUG|Ketamine (Ketalar) Dose Level 4|Loading Dose: 0.18 mg/kg/hr X 1 hour; Maintenance Dose 0.05 mg/kg/hr x 12 hours
224050695|NCT01198860|DRUG|CTH Chronic Hepatitis B|"Drug:~* Tenofovir/ 300mg daily~* Phyllanthus Urinaria/300mg daily~* Adenosma Glutinosum/150mg daily~* Eclipta Prostrata/150mg daily~* Ascorbic Acid / 500mg daily"
224050696|NCT06097962|DRUG|NK510|Intravenous infusion
224050697|NCT06097962|DRUG|Tislelizumab，atezolizumab or sugemalimab|Administer according to the instructions
224050698|NCT06293430|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing AF ablation and/or LAAC procedures.
224050699|NCT05045066|DIETARY_SUPPLEMENT|Cholecalciferol|Given PO
224050700|NCT05045066|OTHER|Quality-of-Life Assessment|Ancillary studies
224050701|NCT05045066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224050702|NCT06131840|DRUG|PF-08046050|Given into the vein (IV; intravenous)
224144069|NCT04644016|DRUG|Fludarabine|Fludarabine
224144070|NCT04644016|DRUG|Busulfan|Busulfan per PK
224144071|NCT04644016|DRUG|Cyclosporine-A|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
224144072|NCT04644016|DRUG|Mycophenolate Mofetil|GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.
223439487|NCT02647255|PROCEDURE|Plasma Exchange (PE)|PE treatment\>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
223439488|NCT02647255|DRUG|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
223439489|NCT04012424|DRUG|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
224050703|NCT06131840|DRUG|bevacizumab|Given into the vein (IV; intravenous)
224050704|NCT06521437|DEVICE|TMS targeting the hippocampus indirectly via its network|Subjects will receive high-frequency repetitive TMS to a parieto-occipital location defined in each subject based on high resting-state fMRI connectivity with the hippocampus at baseline
224050705|NCT05740735|OTHER|"Use of expressive sounds"|"Use of expressive sounds, that is to say the own first name pronounced by the voice of the relative to generate the P300 and a sound with an approaching character of the subject to generate the MMN.~The investigators will thus be able to compare:~* MMN: present/absent for each modality (neutral vs approaching sounds)~* Wave P3a: latencies and amplitudes for each modality (own first name voice of the near vs unfamiliar)."
224050706|NCT05740735|OTHER|Having benefited from a prognostic evaluation by event related potentials (without sound research methods, only neutral sounds)|"Retrospective inclusion Have already had an assessment with event related potentials without emotional modalities (VF and similar sounds) as part of their care between April 2022 and December 2022 in intensive care at Cochin hospital."
224050707|NCT03730636|PROCEDURE|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
224050708|NCT05532904|BEHAVIORAL|Personalized multidisciplinary day-hospital intervention|"This 6-week program of care will include:~* group education sessions including a psycho-education component (1 session / week)~* a personalized exercise training protocol (from 1 session of supervision to 3 sessions of guided exercise per week) adapted to the results of the VO2max exercise test.~* if dysfunctional health beliefs are identified (SSD-12 score ≥ 26): a group protocol of cognitive and behavior therapy (2 sessions per week, including at least 1 in person).~* if cognitive complaints and/or neuropsychological impairment: a cognitive remediation protocol (1 group session plus 2 home sessions per week)"
224050709|NCT05917496|OTHER|LENA tool: Language ENvironment Analysis|"Recording of the language environment of the child at home, in daily environment, with the LENA.~The parameters recorded relate to four domains: adult words, conversation turns, child vocalizations and exposure to electronic media.~The LENA box is worn for 10-16 hours, with a minimum of 10 consecutive hours. the families make 2 separate recordings of 6 months at T1 and T2."
224144073|NCT04644016|BIOLOGICAL|Cord Blood Graft|The CB graft will be infused on day 0 per standard practice
224144074|NCT06375967|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
224144075|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm, 8x8mm. Consider 10x10mm or 10x15mm if abundant pathological material in gallblader.~* DPPS size: 7Fr x 3-5-7cm."
223439490|NCT04012424|DIETARY_SUPPLEMENT|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
223439491|NCT02778386|DRUG|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
224050710|NCT05917496|BEHAVIORAL|Return of the analysis of the data of LENA|The analysis of the LENA data is carried out by the speech therapist using the LENA Pro Version Software v3.4, during the times T1 and T2. The return of the analysis of the data collected via the LENA will be made to the family of the patient after T1 and after T2 and personalized advice will then be given to parents with the aim of improving their child's language skills.
223439492|NCT02778386|OTHER|Placebo Capsule|Two patients in Cohort 3 \& 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
223439493|NCT02358772|OTHER|thrombolysis in a pre-hospital setting (STEMO concept)|
223439494|NCT06323317|BEHAVIORAL|Multi-component exercise programme|Each exercise session will start with a warm-up, followed by core exercise training and ending with a cool-down period. A series of flexibility training and stretching exercises will be performed during the warm-up and cool-down phases (10 minutes in total). The core exercise session will comprise aerobic (10 minutes), resistance (20 minutes), and balance (20 minutes) training, where resistance and balance exercises constitute the major components, as they are particularly effective in strengthening functional capacity, muscle strength, and balance function for mobility in frail patients.
224050711|NCT06316102|BEHAVIORAL|Gender Affirming Abriendo Puertas (Opening Doors) (GAP)|Multilevel intervention with 4 components
224050712|NCT05961085|PROCEDURE|Adductor Canal Catheter|Ultrasound guided Adductor Canal Catheter for total knee arthroplasty analgesia
224050713|NCT05338515|DRUG|Selpercatinib|Administered orally.
224144076|NCT06375967|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm."
223439495|NCT06323317|OTHER|Attention Placebo|The control group will receive routine preoperative care provided by the clinical team, which includes unstructured patient education on the surgeries/procedures, and a brief session on the use of an incentive spirometer, breathing, and coughing exercise. Other perioperative care procedures will be implemented according to the existing clinical protocols.
223439496|NCT06323317|BEHAVIORAL|Structured preoperative education|The prehabilitation programme will begin with a 60-minute (group- or individual-based) structured education session at the centre. The content will cover frailty, its impacts on postoperative recovery, cardiovascular and overall health, and functional well-being. The importance of nutrition and exercise on their recovery potential and postoperative functional capacity will be elaborated. Their commitment to intervention engagement will be highlighted as the key to success. This session will also cover the principles of exercise, its progression, and exercise safety.
223439497|NCT06323317|BEHAVIORAL|Nutritional optimization|The Malnutrition Universal Screening Tool (MUST) will be used for a nutritional screening to determine the risk of malnutrition (low, medium, or high). The nurse will evaluate the dietary patterns of each participant, and provide tailored nutritional advice on daily protein intake according to a protein supplementation protocol. The participants and their caregivers will be provided with plenty of suggestions for high-quality protein foods according to patients' preferences. The nurse will follow-up with the participants to identify any barriers they encountered in real-world settings when they attend the exercise sessions. She will reinforce the advice and provide suggestions to overcome barriers according to the preference and lifestyle of the participants.
224050714|NCT05714969|BIOLOGICAL|TAK-755|TAK-755 IV infusion
224050715|NCT05036603|OTHER|chest physiotherapy|diffferent chest physiotherapy methods
224050716|NCT06963125|DIETARY_SUPPLEMENT|Low-Dose Prune Juice|Intervention Name: Prune Juice 100 mL/day Description: 100 mL prune juice daily (1.07 g dietary fiber), administered once each morning for 4 weeks.
224050717|NCT06963125|DIETARY_SUPPLEMENT|Medium-Dose Prune Juice|Intervention Name: Prune Juice 150 mL/day Description: 150 mL prune juice daily (1.61 g dietary fiber), administered once each morning for 4 weeks.
224144077|NCT05876208|OTHER|BAND Connect's VirtuaCare™ platform|Band Connect provides a medical-grade and condition-specific platform that augments the clinician workflow by extending the in-clinic MSK rehabilitation experience into the patient's home - leading to higher quality personalized treatment and increased adherence with enhanced economics and reimbursement for the clinic.
224144078|NCT05876208|OTHER|Standard of Care Physical Therapy|Standard of care physical therapy without the use of the BAND CVCP
223478619|NCT06275399|DIAGNOSTIC_TEST|Assessment of vFFR and shear stress parameters|The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
223584003|NCT01114360|DRUG|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
224050718|NCT06963125|DIETARY_SUPPLEMENT|High-Dose Prune Juice|Intervention Name: Prune Juice 200 mL/day Description: 200 mL prune juice daily (3.22 g dietary fiber), administered once each morning for 4 weeks.
224050719|NCT01315639|BIOLOGICAL|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
224163714|NCT00285649|OTHER|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
224163715|NCT00285649|OTHER|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
224163716|NCT00285649|OTHER|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
224163717|NCT02447068|DEVICE|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
224163718|NCT02447068|DEVICE|Luma Light|NBUVB light
224163719|NCT02447068|DEVICE|Occlusive Dressing|Off-the-shelf occlusive dressing
224163720|NCT01105949|DEVICE|Marketed nasal strip|Marketed nasal strip
223439498|NCT06323317|BEHAVIORAL|Stress management|Relaxation techniques to reduce tense arousal, including guide imagery and breathing techniques, will be taught. Guided imagery makes use of attention-focus to target mental arousal, whereas deep and diaphragmatic breathing is a fundamental relaxation method for various stress relieving techniques. Both techniques are designed to reduce sympathetic arousal, which is particularly beneficial to cardiac patients. Participants will be encouraged to self-practice on a daily basis, and a sound track will be provided to guide their practice.
223439499|NCT00201617|DEVICE|Bone-anchored hearing aid|
223439500|NCT01362517|BIOLOGICAL|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (\>= 30 IU), tetanus antitoxin (\>= 60 IU), whole-cell inactive pertussis bacteria (\>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
223439501|NCT06083688|DRUG|Dihydroartemisinin-Piperaquine|Treatment will be with DP (females less than 13 years old and all males) or chloroquine alone (females 13 years old or older).
223439502|NCT06083688|DRUG|Chloroquine|Treatment will be with CQ alone if female and 13 years old or older in both intervention arms.
223439503|NCT06083688|DRUG|Sulfadoxine-pyrimethamine-amodiaquine|Treatment in Arm 2 (females less than 13 years old and all males).
223439504|NCT06400004|DRUG|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]|Bolus administration of 2 mL undiluted Lumason®, to be administered in 20 seconds
223439505|NCT06400004|DRUG|Lumason|Continuous infusion of 8 mL of diluted Lumason® (4 mL of Lumason® diluted in 4 mL of saline) at a rate of 1.0 mL/min
223439506|NCT04176081|DRUG|Darolutamide|Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
224050720|NCT05405803|BEHAVIORAL|Web-App based Lifestyle Physical Activity Promotion Program|"WPAPP-K includes group and individual coaching/support by health care providers, peer coaching/support, and information to change the women's attitudes, self-efficacy, perceived barriers, and social influences.~The program includes 3 components in 2 languages (English and Korean):~1. Social media sites: allow participants to share their experiences and to receive individual and group coaching/ support from culturally matched peers and healthcare providers.~2. Interactive online educational sessions: information on 15 topics related to depressive symptoms and lifestyle physical activity.~3. Online Resources: include 20 links in English or Korean (only from scientific authorities including NIH, CDC,etc.).~Weekly group coaching and support will start after the first 10 participants are enrolled, but individual coaching/support will start as soon as a participant enrolls."
224050721|NCT05405803|BEHAVIORAL|The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines|A link to the CDC website will be provided through the project website, and participants will be asked to use it during the study period (12 months). Their use of the CDC website will be automatically measured through the project website.
224050722|NCT05977959|BEHAVIORAL|Mentoring Program|Schools in this group will participate in meetings and discussion boards and receive newsletters to help with program implementation.
224050723|NCT05977959|BEHAVIORAL|Enhanced Resources|Schools in this group will receive extra resources such as program incentives to aid in program implementation.
224050724|NCT05977959|BEHAVIORAL|Enhanced Engagement|Schools in this group will participate in program contests to aid program implementation.
224050725|NCT05546450|BEHAVIORAL|Diet|"Patient in Diet Group and Cornus mas L. and Diet Group will be given a personalized diet and be followed up by a dietician."
224050726|NCT05546450|DIETARY_SUPPLEMENT|Cornus mas L.(Cornelian Cherry)|"Patients in Cornus mas L. Group and Cornus mas L. and Diet Group will receive 30 g/day freeze-dried Cornus mas L. fruit powder supplement."
223439507|NCT04176081|DRUG|Degarelix|Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
223439508|NCT04176081|RADIATION|Radiation Therapy|The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
223439509|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method A
223439510|NCT01507402|DRUG|REGN1033(SAR391786)|Administration method B
223439511|NCT01507402|DRUG|Placebo|(inactive substance)
224050727|NCT05848089|BEHAVIORAL|Brief skills sessions plus EMI skills practice prompts|(1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
224050728|NCT05848089|BEHAVIORAL|Ecological momentary assessment (EMA)|4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs
224050729|NCT05848089|BEHAVIORAL|Treatment as usual (TAU)|TAU (or usual care) during hospitalization and the 28-day post-discharge period
224050730|NCT01907542|PROCEDURE|stapled skin closure|as above
224050731|NCT01907542|PROCEDURE|monocryl skin suture|as above
224050732|NCT00574145|PROCEDURE|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
224050733|NCT00574145|PROCEDURE|fatigue assessment and management|duration
224050734|NCT00574145|PROCEDURE|psychosocial assessment and care|duration
224050735|NCT00574145|PROCEDURE|quality-of-life assessment|duration
224050736|NCT00574145|PROCEDURE|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
224050737|NCT01944293|DRUG|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
223439512|NCT00390624|DRUG|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
223439513|NCT00390624|DRUG|MANNITOL|
223439514|NCT00780624|DEVICE|NIPPV|Ventilator is Bird VIP.
223439515|NCT00780624|DEVICE|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
224050738|NCT01944293|DRUG|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
224163721|NCT01105949|DEVICE|NexGen AB 2R11|Nasal strip prototype
224163722|NCT01105949|DEVICE|NexGen JB Organic PET/PE|Nasal strip
223439516|NCT00780624|DEVICE|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
223439517|NCT01469975|DRUG|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
223439518|NCT01469975|DRUG|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
223439519|NCT01469975|DRUG|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
223439520|NCT00416793|DRUG|bortezomib|Given IV
223439521|NCT00416793|DRUG|carboplatin|Given IV
224144079|NCT05821556|DRUG|Valproic acid|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
223439522|NCT00416793|OTHER|laboratory biomarker analysis|Correlative studies
224050739|NCT06083441|DIAGNOSTIC_TEST|SeeMe|"A video-recorded SeeMe command following assessment by a trained professional once a day Each session involves three command sets that are played from an audio recording 10 times over the course of 8 minutes. These commands are Stick out your tongue, Open your eyes, and Show me a smile Each command set is recorded separately for a total of 3 videos per session. These videos are then analyzed by SeeMe to detect if subjects are responding to commands."
224050740|NCT06083441|DIAGNOSTIC_TEST|Coma Recovery Scale-Revised (CRS-R)|A video-recorded CRS-R score assessment by a trained professional once a day. A score of 10 or greater, an auditory score \>2, or an arousal score \> 0 means that a subject is responding to commands
223439523|NCT06307509|OTHER|Diagnosis of sepsis|Patients will be recruited on the basis of a diagnosis of sepsis, as this is the exposure of interest
223439524|NCT06504888|DRUG|Penicillin|Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
223439525|NCT03696485|BIOLOGICAL|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
223439526|NCT05977465|DRUG|Empagliflozin 25 MG|treatment
224050741|NCT00121836|DRUG|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
223439527|NCT03317457|BIOLOGICAL|Durvalumab and Tremelimumab|immun checkpoint inhibitor
223439528|NCT03317457|DRUG|Doxorubicin|Anthracycline
223439529|NCT05035849|DRUG|sitagliptin and acarbose|One group used first sitagliptin and metformin, then used acarbose and metformin. Another group used first acarbose and metformin, then used sitagliptin andmetformin.
223439530|NCT01121536|DRUG|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
223439531|NCT06184906|DIETARY_SUPPLEMENT|Weaning by Mediterranean Diet|Introduce solid foods typical of the Mediterranean Diet at weaning of infants
223439532|NCT00387049|BEHAVIORAL|Anxiety Sensitivity Program for Smoking Cessation|
224050742|NCT00121836|DRUG|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
224050743|NCT03227471|DRUG|IVA|IVA tablet for oral administration
224050744|NCT03227471|DRUG|TEZ/IVA|TEZ/IVA fixed-dose combination for oral administration.
224050745|NCT03227471|DRUG|VX-445|VX-445 tablet for oral administration.
224050746|NCT03227471|DRUG|Matched Placebo|Matched placebo.
224050747|NCT03227471|DRUG|TEZ|Tablet for oral administration.
224050748|NCT03227471|DRUG|VX-561|Tablet for oral administration.
224050749|NCT03227471|DRUG|VX-445|VX-445 IV injection
224163723|NCT02541500|DRUG|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
224163724|NCT02382965|DEVICE|transcranial focused ultrasound|
224163725|NCT02454452|PROCEDURE|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
224163726|NCT02454452|PROCEDURE|Saphenous vein stripping|Saphenous vein stripping
223439533|NCT05763056|PROCEDURE|McGrath videolaryngoscopy|The McGrath video laryngoscope has a thin, disposable, clear, regularly shaped blade similar to a Macintosh blade and a large LCD display attached to the arm. It is lighter in weight and the Mc VL has a small camera at the tip, with a more compact screen and handle that can make tracheal intubation easier and faster in normal or difficult airway. The smaller volume, thinner and portrait screen helps reduce blind spots
223439534|NCT05763056|PROCEDURE|C-MAC videolaryngoscopy|The Macintosh blade is attached to the handle and the light beam is passed through the blade tip into a small metal guide tube indented 40 mm. The camera cable is connected to the control unit and the optical cable is connected to the light source. The video macintosh system is installed in a small trolley for easy portability of the device. The trolley supports an 8-inch monitor mounted on a rotating arm on the patient's left side. C-MAC VL devices can create continuous video recordings or static images on a secure removable digital card. The electronic module includes 2 buttons for photo and video shooting. In addition, the image of the C-MAC VL device can be viewed on other devices or recorded via a standard video output port. 3 C-MAC VL reusable metal macintosh blades (sizes 2 to 4) can be used for adult patients. These non-disposable knives have a closed design without gaps in terms of hygiene and have beveled edges to prevent tissue damage.
223478620|NCT04284254|DRUG|Autologous Plasmablasts|"Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~\- Maximum Tolerated Dose (MTD) established in Phase I"
223478621|NCT04568655|DEVICE|noninvasive ventilation|noninvasive ventilation to support the COVID-19 patients with respiratory failure
223478622|NCT00244309|DRUG|tamsulosin and/or dutasteride|
224050750|NCT00345189|DRUG|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
224050751|NCT04494230|BEHAVIORAL|Motor Proficiency in School Age ADHD: Contribution of Different Comorbidities|to investigate whether motor skills, manual dexterity and visual perception differ in the presence of ADHD and comorbid psychiatric conditions in school-age boys by comparing them typical development children.
224050752|NCT02536768|BEHAVIORAL|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
224050753|NCT05571748|DIETARY_SUPPLEMENT|Alpha-lipoic acid|A trial of acute exercise before and after 4 weeks of alpha-lipoic acid supplementation.
223439535|NCT05763056|DEVICE|Direct laryngoscopy|During intubation with a direct laryngoscope (DL), the laryngoscope is inserted into the oral cavity from the right side of the mouth, the tongue is pushed to the left, and after advancing up to the vallecula, it hangs up and forward. In this way, the floor of the mouth and the epiglottis structure are removed from the field of view. If a straight blade laryngoscope is to be used, it is advanced so that the epiglottis remains under the blade after viewing the epiglottis (1). In DL, manipulations such as head extension, sniffing position, and compression of the cricoid cartilage may be required to facilitate visualization of the vocal folds. In 10-15% of the complications experienced during intubation with DL, there are problems related to the angle of view.
223439536|NCT05135793|DRUG|Topoprazan|1 tablet contains 20 mg vonoprazan
223439537|NCT05135793|DRUG|Takecab|1 tablet contains 20 mg vonoprazan
223439538|NCT05580328|DRUG|Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy|Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
223439539|NCT03146728|OTHER|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
224050754|NCT05571748|OTHER|Placebo|A trial of acute exercise before and after 4 weeks of placebo supplementation.
224050755|NCT01855763|DRUG|Metformin|
224144080|NCT05821556|DRUG|Simvastatin 20mg|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
224163727|NCT02454452|PROCEDURE|CHIVA|conservative hemodynamic treatment venous insufficiency
224163728|NCT04837781|PROCEDURE|Micro-osteoperforation|Micro-osteoperforation Mini-implant facilitated micro-osteoperforation (MOPs) were placed in the experimental side before canine retraction. Three MOPs were placed distal to canine on experimental sides in all group.
224163729|NCT04501172|BEHAVIORAL|Questionnaire completion|"Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire."
224050756|NCT01855763|DRUG|Insulin|
224050757|NCT00382720|DRUG|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
224050758|NCT00382720|DRUG|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
224050759|NCT00382720|DRUG|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
224050760|NCT01740960|DRUG|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
224050761|NCT01740960|DRUG|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
223439540|NCT02977728|OTHER|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
223584004|NCT01114360|DRUG|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
223439541|NCT04436705|OTHER|Progressive Muscle Relaxation (PMR) technique|The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
223439542|NCT05197205|PROCEDURE|nasopharyngeal swabbing|A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
223439543|NCT03205098|BIOLOGICAL|Blood analysis|Blood test of biological markers of mesenteric ischemia
223439544|NCT02925377|BEHAVIORAL|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
223439545|NCT02925377|BEHAVIORAL|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
223439546|NCT05000853|DRUG|Iron Carboxymaltose|Iron supplementation when is needed according to usual care
223439547|NCT03213925|RADIATION|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
223439548|NCT02560857|OTHER|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
223439549|NCT00568334|BIOLOGICAL|Varilrix (inactivated varicella vaccine)|subcutaneously injection
223439550|NCT05721690|DEVICE|UED-A Videolaryngoscopy|Tracheal Intubation with UED-A videolaryngoscope
223439551|NCT05721690|DEVICE|Glidescope Videolaryngoscopy|Tracheal Intubation with Glidescope Titanium videolaryngoscope
223439552|NCT00004770|DRUG|thioctic acid|
223439553|NCT03777111|OTHER|Exercise|Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
224050762|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
224050763|NCT00437502|BIOLOGICAL|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
224050764|NCT02414399|DRUG|Azithromycin|oral administration of Azithromycin
224050765|NCT02414399|DRUG|Placebo|5 days of taste/appearance/bottle-matched inactive substance
224050766|NCT03755128|OTHER|No intervention|No investigational drugs will be administered as part of the study
224050767|NCT06361290|OTHER|Data collection from hospital medical records|Data collection from hospital medical records of patients concerning the 5 years following the resection of the tumor.
224050768|NCT02088112|DRUG|Gefitinib|Gefitinib QD
224050769|NCT02088112|DRUG|MEDI4736|MEDI4736 IV Q2W
223439554|NCT00211315|DRUG|anecortave acetate|
223439555|NCT02357615|DRUG|nifedipine CR tablets (Xin Ran)|
223439556|NCT02357615|DRUG|Adalat|
223439557|NCT03299894|PROCEDURE|systematic calculation of qSOFA|calculation of qSOFA for each patient
223439558|NCT05172791|BEHAVIORAL|Antibiotic stewardship messaging|Counseling regarding antibiotics for patients prescribed antibiotics for possible pneumonia despite respiratory rates and oxygenation levels within normal ranges
223439559|NCT00178269|DRUG|docetaxel|
223439560|NCT00178269|PROCEDURE|Radiation Therapy|
223439561|NCT01329666|DIETARY_SUPPLEMENT|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
223439562|NCT01329666|DIETARY_SUPPLEMENT|Vitamin D3|"Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
223439563|NCT04720950|OTHER|Exercise|1 hour of exercise on a motorised treadmill at 70% maximal heart rate
223439564|NCT02168452|PROCEDURE|sentinel lymph node biopsy(SLNB)|"* incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.~* double check after removal of the sentinel lymph node~* sending frozen biopsy"
223439565|NCT01600599|DRUG|Tranexamic Acid|intravenous 1g and topical 1g
223584005|NCT06979999|PROCEDURE|Positive End-Expiratory Pressure (PEEP)|Application of 10 cmH₂O PEEP during mechanical ventilation after pneumoperitoneum creation in patients undergoing laparoscopic cholecystectomy.
223740851|NCT06526637|OTHER|Paper Package|Paper based (as per current practice at Central and North West London (CNWL) NHS Foundation Trust) version of Palliate.
224050770|NCT02171845|OTHER|surgical biopsies|
224050771|NCT05570942|DIETARY_SUPPLEMENT|Oral Lactobacillus rhamnosus TCELL-1|A kind of probiotics which was isolated from the intestinal mucosa of health Taiwanese people
224050772|NCT00993642|DRUG|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
224163730|NCT05861557|DRUG|Toripalimab|240mg, Q3W，I.V., D1, 2 cycles (1cycle of toripalimab before and after the SBRT radiotherapy, respectively), followed by the maintenance of toripalimab for 6 months after the surgery.
224163731|NCT05861557|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|Subjects were treated with SBRT radiotherapy (8Gy\*5Fx), after 1 cycle of immunotherapy
224144081|NCT05821556|DRUG|Gemcitabine 1000 mg|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
224144082|NCT05821556|DRUG|Nab paclitaxel|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
223439566|NCT01600599|DRUG|saline|100mls of topical saline
224050773|NCT04788251|OTHER|Exercise-based fall prevention intervention (Modified Otago Exercise Programme and Modified Stepping On Programme)|"The modified OEP is a group exercise programme that consists of progressive strength and balance exercises led by trained exercise leaders (fitness instructors or health coaches). The supervised sessions will be conducted twice a week (1 hour each) for 7 weeks. Participants will be given an exercise booklet and encouraged to exercise at home.~The modified SOP is a group fall prevention programme that consists of exercise sessions and discussions on various falls prevention aspects facilitated by a trained programme leader and supported by programme facilitators and peer facilitators. The supervised sessions will be conducted once a week (2 hours each) for 7 weeks. Participants will be given homework and encouraged to exercise at home. In addition, there will be an optional home visit (Week 11), a 1-hour booster session (Week 19) and a telephone call (Week 31)."
223439567|NCT00306787|DRUG|Famciclovir|Famciclovir 500 mg tablet
224050774|NCT04788251|OTHER|Wait-list control|To receive fall prevention resources while waiting for their programme to start
224163732|NCT00141401|DRUG|Pregabalin|
224163733|NCT03342404|DRUG|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
224163734|NCT03342404|OTHER|Placebo|Placebo, Subcutaneous, every 21 days
223439568|NCT00306787|DRUG|Valacyclovir|Valacyclovir 500 mg capsule
223439569|NCT00306787|DRUG|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
223439570|NCT00306787|DRUG|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
223439571|NCT02089087|BIOLOGICAL|CFZ533|Single dose at varying dosage levels depending on treatment assignment
223439572|NCT02089087|DRUG|Placebo|
223439573|NCT05922813|BIOLOGICAL|BMI2004|hyaluronidase, recombinant
224163735|NCT03342404|OTHER|Best Supportive Care (BSC)|Best Supportive Care (BSC)
224163736|NCT03986567|BEHAVIORAL|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
224163737|NCT03889990|DEVICE|IQOS|"Smoke IQOS"
223439574|NCT05922813|OTHER|0.9% NaCl|Normal Saline
223439575|NCT05106920|OTHER|NMP|Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
224050775|NCT04193020|OTHER|Surveillance card|Surveillance card and additional examination to find novel markers and better assess the existing ones
224050776|NCT04175106|OTHER|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
223439576|NCT01436864|BIOLOGICAL|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
223439577|NCT04924023|BEHAVIORAL|kaleidoscope application|The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished.
223439578|NCT01064635|DRUG|Letrozole|letrozole for 2-3 years after Tam
223439579|NCT01064635|DRUG|Letrozole|Letrozole for 5 years after Tam
223439580|NCT00469495|DRUG|Anti-helminthic|
223439581|NCT00469495|DRUG|meglumine antimony|
223439582|NCT02273908|OTHER|No intervention|The study is observational
223439583|NCT04352738|DIAGNOSTIC_TEST|Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)|Magnetic resonance scanning for 150 minutes involving ingestion of 60g of 6,6, 2H2-glucose diluted in 200ml of tap water. Frequent blood samples will be drawn for measurements of plasma glucose, insulin, C-peptide and glucagon
223439584|NCT03472313|DRUG|[18F]MNI-958|Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.
223439585|NCT03371056|BIOLOGICAL|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
223439586|NCT02106143|DEVICE|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
223740852|NCT06526637|OTHER|V1 + Preparation Sheet|Paper based version of Palliate plus a preparation sheet, that provides visual cues as to what equipment is required for the preparation and administration of the medications.
224050777|NCT04175106|OTHER|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
224050778|NCT04175106|OTHER|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
224144083|NCT05821556|DRUG|Cisplatin|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
224163738|NCT00927329|BIOLOGICAL|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
224163739|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
223439587|NCT01691703|DEVICE|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
223439588|NCT05917808|OTHER|Ready-to-eat wholegrain porridge|A ready-to-eat wholegrain porridget will be consumed shortly after a diagnostic OGTT on two consecutive evenings, the OGTT will then be repeated
223439589|NCT04908475|DRUG|Risankizumab|Subcutaneous injection
223439590|NCT04908475|DRUG|Apremilast|Oral Tablets
223439591|NCT02962206|DEVICE|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
223439592|NCT02962206|PROCEDURE|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
223439593|NCT05555602|DEVICE|Cold-air cooling|Cryo 6 works with a compressor system like those in refrigerators and uses ambient air to generate a permanent stream of cold air with a maximum flow to 1000 L/min and a temperature as low as -30°C, depending on the cooling delivery system and the desired cooling level (range 1-9).
223439594|NCT01980498|DRUG|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
223439595|NCT01980498|DRUG|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
223584006|NCT06983769|DEVICE|MAD|"Mandibular Advancement Device. It is a custom-fitted oral appliance used primarily to treat obstructive sleep apnea (OSA) and snoring. The device works by gently advancing the lower jaw (mandible) forward, which helps keep the airway open during sleep by preventing the tongue and soft tissues from collapsing and blocking the airway.~MADs are a non-invasive alternative to CPAP therapy and are especially suitable for patients with mild to moderate OSA or those who are intolerant to CPAP"
223740853|NCT06526637|OTHER|V2 + Video Training|Hybrid - paper based materials, preparation sheet, and video instructions available via an interactive portable document format (PDF) version of the training materials.
223740854|NCT04615663|BEHAVIORAL|Score SMI|the investigator will complete the SMI score
224050779|NCT04175106|OTHER|a control beverage of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
224050780|NCT01490099|DRUG|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
224050781|NCT01454375|BEHAVIORAL|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
224050782|NCT05026281|DEVICE|Quantra analyzer|one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
224050783|NCT01987206|DEVICE|MPC control algorithm|
224050784|NCT01987206|DEVICE|PID control algorithm|
224050785|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
223439596|NCT01644760|PROCEDURE|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
224050786|NCT00649883|BIOLOGICAL|Influenza Trivalent Inactivated vaccines|Children 6 to \<36 months of age will receive two 0.25 mL doses, and children 36 to \<60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
224050787|NCT06302348|DRUG|Sepiapterin|Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.
224050788|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
224050789|NCT04856787|DRUG|SHR-1701、 BP102 、XELOX|"Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
224050790|NCT04856787|DRUG|placebo、 BP102、 XELOX|"Phase 3：Randomized~Drug:Placebo 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days"
223439597|NCT05175820|OTHER|No intervention|Survey questions were sent through the mailing list of the Turkish Dental Association, where all dentists in Turkey are registered
223439598|NCT03303391|OTHER|Intradialytic Blood Pressure Slope Based Ultrafiltration|Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
223439599|NCT02103257|DRUG|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
224050791|NCT02142738|DRUG|Pembrolizumab|Pembrolizumab IV solution
224050792|NCT02142738|DRUG|Paclitaxel|Paclitaxel IV solution
224144084|NCT05821556|DRUG|Capecitabine|"The treatment should be started within 3 days from randomization. One cycle consisted of 28 days of treatment for both arms. Patients will continue to receive study treatment up to 6 cycles until disease progression, unacceptable toxicity, physician's decision, patient's refusal, or any other discontinuation criteria. Continuation of treatment, over the six cycles, will be allowed only in case of clinical benefit, defined as continuous decrease of CA19-9 concentration or radiological response, without unacceptable toxicity.~All subjects who finish treatment, whichever the reason, will enter in the follow-up. We expect that for the primary endpoint, PFS, follow-up will last up to 10 months after enrollment.~Anyhow, all subjects will be followed until death and data on subsequent treatment will be collected."
224144085|NCT06588660|BIOLOGICAL|Vevoctadekin|Given SC
224144086|NCT06588660|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
223439600|NCT02103257|DRUG|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
223439601|NCT03913104|DRUG|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
223439602|NCT06150469|COMBINATION_PRODUCT|"Blend of ginger and lemon essential oils, Neutral oil"|Patients will be given aromasticks to inhale the blend of essential oils.
223439603|NCT01074255|DRUG|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
223740855|NCT05943145|OTHER|Group Dance and Movement Training|Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
223740856|NCT05666258|DIAGNOSTIC_TEST|GEP|GEP before surgery to determine need for neoadjuvant chemotherapy
224050793|NCT02142738|DRUG|Carboplatin|Carboplatin IV solution
224050794|NCT02142738|DRUG|Pemetrexed|Pemetrexed Lyophilized Powder for Infusion
224050795|NCT02142738|DRUG|Cisplatin|Cisplatin IV solution
224050796|NCT02142738|DRUG|Gemcitabine|Gemcitabine Lyophilized Powder for Infusion
224050797|NCT00985803|OTHER|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
224050798|NCT00985803|OTHER|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
224144087|NCT06588660|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224144088|NCT06588660|OTHER|Medical Chart Review|Ancillary studies
224144089|NCT06588660|DRUG|Teclistamab|Given SC
224144090|NCT06588660|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224144091|NCT05867212|DRUG|Cabotegravir Injection [Apretude]|People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
224144092|NCT06028750|PROCEDURE|Dynamic Computer Assisted Surgery|Surgical navigation system (X-Guide guided surgery system) Navigation system X-Guide
224144093|NCT06028750|PROCEDURE|Freehand|Freehand implant placement
223439604|NCT05239117|DEVICE|Plenhyage|"Plenhyage® is an elastic, sterile, injectable, non-pyrogenic, re-absorbable gel made with polymerised polynucleotides (PDRN) of animal origin (fish). Due to its hydrophilic and polyanionic nature, PDRN binds water molecules, thereby filling intradermal spaces and making tissues firmer and more hydrated.~The polynucleotide chain binds water molecules, has an anti-free radical action, and serves as a scavenger of hydroxyl radicals (OH), which accumulate under stress or due to foreign agents, such as UV radiation. Its hydration and anti-free radical activity help create the optimal environment for fibroblast growth, thereby restoring tissue elasticity.~Plenhyage® is a colourless gel contained in a pre-filled, graduated, disposable, and sterile syringe with a Luer Lok adapter."
224050799|NCT03688880|DEVICE|MAR-CUTIS|MAR-CUTIS was applied in 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue was applied over the length of the wound on each side. The amount of the glue applied was calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds \>8 cm, 2 syringes were required.
224050800|NCT03688880|DEVICE|Dermabond Advanced|Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges.
224050801|NCT02110368|DRUG|Testosterone Topical Gel, 1.62% Metered Pump|
224144094|NCT06392724|GENETIC|GEN6050X intravenous injection|GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.
224144095|NCT05524597|BEHAVIORAL|Writing Intervention|Participants will be asked to write about different kinds of experiences.
224144096|NCT06362005|DRUG|Triamcinolone Acetonide 0.1% Oint|RCT
224144097|NCT06362005|DRUG|Tacrollimus Topical|RCT
224144098|NCT06362005|DRUG|Selenium|RCT
224144099|NCT06362005|DRUG|Selenium & Triamcinolone Acetonide 0.1% Oint|RCT
224144100|NCT06362005|DRUG|Selenium& Tacrollimus topical|RCT
224144101|NCT04469764|DRUG|Abemaciclib|Given PO
224144102|NCT04469764|DRUG|Anastrozole|Given PO
224144103|NCT04469764|DRUG|Letrozole|Given PO
224144104|NCT06382064|DEVICE|Biweekly replacement contact lenses|Biweekly replacement reusable contact lenses.
224050802|NCT02110368|DRUG|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
224050803|NCT00732511|DRUG|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
224050804|NCT00732511|DRUG|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
224050805|NCT06100887|DRUG|Sevasemten Dose 1|Sevasemten is administered orally once per day
224050806|NCT06100887|DRUG|Sevasemten Dose 2|Sevasemten is administered orally once per day
224050807|NCT06100887|DRUG|Sevasemten Dose 3|Sevasemten is administered orally once per day
224050808|NCT06100887|DRUG|Placebo|Placebo is administered orally once per day
224050809|NCT00177775|DRUG|MucoMilk product|
224050810|NCT05745675|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter SW version: 01-15)
224050811|NCT01529177|DRUG|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
224050812|NCT01529177|DRUG|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
224050813|NCT03110926|DRUG|mFOLFOX6|Induction Chemotherapy
224050814|NCT03110926|COMBINATION_PRODUCT|Chemoradiation|Chemoradiation
224050815|NCT06138522|BEHAVIORAL|Semi-structured interviews|Semi-structured interviews
224050816|NCT06138522|BEHAVIORAL|Child Post-Traumatic Stress Response Index (CPTS-RI) scale|Child Post-Traumatic Stress Response Index (CPTS-RI) scale
224050817|NCT06138522|BEHAVIORAL|- Therapeutic Alliance Questionnaire (HAQ-CP)|\- Therapeutic Alliance Questionnaire (HAQ-CP)
224050818|NCT01704287|BIOLOGICAL|Pembrolizumab|IV infusion
224144105|NCT06382064|DEVICE|One week replacement contact lenses|One week replacement reusable contact lenses.
224144106|NCT06065202|DIETARY_SUPPLEMENT|Nutrition Supplement|Total parenteral nutrition (TPN) will be administered within 72 hours of abdominal surgery. Nutritional shakes will be started with a liquid diet and given 3 times a day. This will continue for 4 weeks after discharge.
224144107|NCT04368559|DRUG|Rezafungin for Injection|Intravenous antifungal therapy
224144108|NCT04368559|DRUG|Posaconazole|Oral antifungal therapy
224144109|NCT04368559|DRUG|Fluconazole|Oral antifungal therapy
224144110|NCT04368559|DRUG|Trimethoprim-sulfamethoxazole (TMP/SMX)|Oral antibacterial therapy
224144111|NCT04368559|DRUG|Intravenous Placebo|Normal saline
224144112|NCT04368559|DRUG|Oral Placebo|Microcrystalline cellulose
224144113|NCT05455190|BEHAVIORAL|Fit Together|Fit Together intervention follows a clinic and community partnership model for childhood obesity treatment. Children with obesity will receive standard of care obesity treatment from their usual provider and will also receive a referral to an activity program run out of the local community center. Each session delivers a combination of high-intensity individual exercises, sports and games, and unstructured playtime to help children reach the US Physical Activity guidelines of 60min moderate-to-vigorous physical activity daily. There will also be a nutrition activity session offered regularly.
224144114|NCT05455190|BEHAVIORAL|Educational materials|Participants will receive a child-friendly cooking magazine mailed quarterly and a local Parks and Recreation program guide.
224144115|NCT05726305|PROCEDURE|Live donor uterus transplantation|Transplantation of uterus from a living donor.
224144116|NCT05726305|PROCEDURE|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
224144117|NCT04690205|OTHER|End of Life (EOL) Care at at Home|Remote monitoring and home-based care designed for patients with advanced hematologic malignancies
224144118|NCT06474364|DRUG|Long-acting Cabotegravir injection|Cabotegravir is a potent integrase inhibitor that has been approved for use as PrEP.
224144119|NCT06474364|OTHER|SEARCH-YOUTH|It is a life stage informed HIV care model that dynamically supports adolescents and young adults living with HIV to achieve viral suppression and reduce depression through life event tailored solutions.
223439605|NCT06215794|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
223439606|NCT06215794|PROCEDURE|Glossopharyngeal Nerve Block|The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
223439607|NCT03233789|BEHAVIORAL|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
223439608|NCT00179894|BEHAVIORAL|Physician training|Physicians are trained in guidelines for medication management.
223439609|NCT06154174|DIETARY_SUPPLEMENT|C-RUTF (Ready-to-Use Therapeutic Food with added choline)|Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
223439610|NCT06154174|DIETARY_SUPPLEMENT|S-RUTF (Ready-to-Use Therapeutic Food without added choline)|Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications
223439611|NCT06154174|DRUG|Amoxicillin|Oral amoxicillin tablets twice per day for 7 days dosed based on weight
223439612|NCT03953625|OTHER|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
223740857|NCT02775734|DRUG|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
223740858|NCT02775734|DRUG|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
223740859|NCT03021239|PROCEDURE|Echo Guided Testing|
223740860|NCT03021239|PROCEDURE|Hemodynamic-Echo Ramp Testing -|
223740861|NCT05855668|BEHAVIORAL|CBT|12 weeks of group CBT for AUD or CUD
223740862|NCT01801644|DRUG|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
223740863|NCT02563795|DRUG|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
223740864|NCT02563795|DRUG|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
223740865|NCT00656409|DRUG|Conjugated pneumococcal vaccine (Prevenar)|
223740866|NCT01326767|DRUG|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
223740867|NCT01326767|DRUG|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
223740868|NCT03563417|PROCEDURE|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
223740869|NCT03563417|OTHER|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
223740870|NCT00206414|DRUG|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
223740871|NCT00206414|DRUG|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
223740872|NCT00199927|DRUG|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
223740873|NCT00199927|DRUG|standard therapy|standard therapy
223740874|NCT05482009|OTHER|Traditional Chinese Medicine Treatment Combined with Western Medicine Basic Treatment|The cumulative observation and treatment (including Chinese patent medicine, Chinese medicine decoction, Chinese medicine granule, Chinese medicine injection, and western medicine) were more than 5 months, and the follow-up was 1.5 years.
223740875|NCT04321148|PROCEDURE|standard of care PCI|optimal medical care PCI
223740876|NCT04321148|PROCEDURE|Impella-protected PCI|Impella-protected PCI
223740877|NCT04368286|BEHAVIORAL|pulmonary rehabilitation|Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
223740878|NCT04432051|BEHAVIORAL|mechanical ventilator settings and position|Mechanical ventilation settings and patient position will be re-evaluated
223740879|NCT06447727|DRUG|SIRT with Yttrium-90 Microspheres|Selective Internal Radiation Therapy (SIRT) with Yttrium-90 \[90Y\] Microspheres Injection
223740880|NCT06447727|DRUG|FOLFIRI and Bevacizumab|FOLFIRI and Bevacizumab
223740881|NCT00897247|GENETIC|microarray analysis|
223740882|NCT00897247|GENETIC|protein expression analysis|
223740883|NCT00897247|GENETIC|proteomic profiling|
223740884|NCT00897247|OTHER|laboratory biomarker analysis|
223740885|NCT03099876|PROCEDURE|treatment period|7 days treatment or 10 days treatment
223439613|NCT02734225|OTHER|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
223439614|NCT02734225|OTHER|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
223439615|NCT02734225|OTHER|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
223439616|NCT05338866|RADIATION|Magnetic resonance guided radiotherapy|Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.
223439617|NCT05338866|DRUG|Chemotherapy|"For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses."
223439618|NCT01239524|PROCEDURE|denervation of thoracodorsal nerve or saving the nerve|
223439619|NCT02585687|DEVICE|liver Perfusion MRI|
223439620|NCT01870167|DRUG|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
223439621|NCT01870167|DIETARY_SUPPLEMENT|Placebo|Placebo
223439622|NCT02026869|DRUG|Metformin|Metformin is taken either orally or vaginally every 12 hours
223439623|NCT05619770|DRUG|101-PGC-005|Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
223439624|NCT06000553|OTHER|blood sampling at inclusion, 6 months, 1 year and 2 years. Tumor and intracystic fluid samples are taken only if a biopsy is planned following MRI results.|If the patient agrees to take part in the study, he or she will have a blood sample taken from 8 x 4 ml EDTA tubes at the time of inclusion in the trial.Then, at 6 months (+/- 1 month), 1 year and 2 years, the patient will have the same blood sample as at inclusion.If a biopsy is performed as part of routine care, a tumor sample will be taken and sent to the IPC pathology department for FFPE block. If a biopsy is performed and the patient consents, a cystic fluid sample will be taken.
223439625|NCT06500650|BEHAVIORAL|Person-centred Occupational Therapy Intervention|Person-centred Occupational Therapy Intervention
223439626|NCT01593254|DRUG|Imatinib|
223439627|NCT01593254|DRUG|Dasatinib|
223439628|NCT00191802|DRUG|teriparatide|
223439629|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
223439630|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
223740886|NCT00358566|BIOLOGICAL|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
223740887|NCT00358566|DRUG|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
223740888|NCT04948450|BEHAVIORAL|Physical activity intervention|"Progressive resistance training (PRT) for the physical intervention will be provided at the nursing home for 45 minutes twice a week. The sessions will be organized in groups (6-10 patients/ group) and supervised by 2 physiotherapists. Within each small group (maximum 10), participants will follow the program tailored to their individual functioning level, with constant oversight by trainers.~People with dementia and care staff will be instructed to follow the prescribed PRT exercises for the rest of the week. Subjects will be encouraged to exercise daily."
224050819|NCT01704287|DRUG|Carboplatin|Carboplatin per institutional standard
224050820|NCT01704287|DRUG|Paclitaxel|Paclitaxel per institutional standard
224050821|NCT01704287|DRUG|Dacarbazine|Dacarbazine per institutional standard
224050822|NCT01704287|DRUG|Temozolomide|Temozolomide per institutional standard
223439631|NCT01202552|BIOLOGICAL|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
223439632|NCT01438385|PROCEDURE|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
223439633|NCT02408952|BEHAVIORAL|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
223439634|NCT02408952|BEHAVIORAL|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
223439635|NCT00520052|DRUG|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
223439636|NCT01887678|DRUG|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
223439637|NCT01887678|DRUG|Placebo|Placebo is an injection of Saline
223439638|NCT02456961|PROCEDURE|iontophoresis of riboflavin|
223439639|NCT02456961|PROCEDURE|epithelium-off|
223439640|NCT02456961|PROCEDURE|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
223439641|NCT02456961|DEVICE|galvanizator, Potok-1|Device for providing iontophoresis procedure
223439642|NCT02456961|DRUG|Dextralink|Riboflavin 0,1% + Dextran T-500
223439643|NCT02456961|DRUG|Riboflavin 0,1%|
223439644|NCT02456961|DEVICE|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
223439645|NCT00099177|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
224050823|NCT04356664|DRUG|GnRH agonist|One or two intramuscular injections of Decapeptyl 3 mg
224144120|NCT04756388|OTHER|Strategy Development|Participants engage in cognitive strategy discussions to develop new executive function strategies that can be used in daily life, and track their strategies between sessions. No computerized cognitive training.
224050824|NCT06790641|BEHAVIORAL|Program in Support of Moms (PRISM)|Program in Support of Moms (PRISM): a practice-level intervention with implementation support that helps obstetric practices integrate mental health care for perinatal individuals. To help obstetric practices implement pathways for screening, assessment, and a stepped intervention response for mental health problems and social determinants of health. PRISM offers training in trauma informed and equitable care, technical assistance, and implementation and change management support.
223439646|NCT00099177|DRUG|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
223439647|NCT05288933|DEVICE|Instrument assisted soft tissue mobilization ( IASTM ) and Ultrasound|"Instrument-assisted soft tissue mobilization (IASTM) is a popular treatment for the myofascial limitation that is based on James Cyriax's rationale.~High-power pain threshold ultrasound is a noninvasive approach used in myofascial pain syndrome ( MPS) treatment, and it has no serious adverse effects."
223439648|NCT05501067|OTHER|tai chi exercise|specific tai chi exercise
223439649|NCT05501067|OTHER|no intervention|no intervention
223439650|NCT00076869|DRUG|MK0991, caspofungin acetate|
224050825|NCT06790641|BEHAVIORAL|PSI Peer Support|Postpartum Support International (PSI) Peer Support: a service administered by PSI that pairs perinatal individuals with a volunteer peer mentor who provides support, psychoeducation, behavioral activation, and navigation services, which includes planning, goal setting, and practical tools to manage parenting and mental health symptoms.
224144121|NCT04756388|OTHER|Computerized Cognitive Training|Participants practice computerized training exercises targeting executive functioning skills, and complete computerized exercises between sessions.
224050826|NCT06157957|DIAGNOSTIC_TEST|Lung cancer screening with low dose CT scan|Low dose CT scan in active smokers or ex-smokers with an age between 50 and 75 years old
224050827|NCT03776474|BIOLOGICAL|Blood collection|Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
224050828|NCT00645814|DRUG|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
224050829|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
224050830|NCT00645814|DRUG|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
224050831|NCT00532181|BEHAVIORAL|Savings Behavior and Consumer's Approach to Risk|
224050832|NCT04175665|DRUG|Semaglutide|Prescription for semaglutide as part of usual clinical practice
224050833|NCT02214602|DRUG|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
224050834|NCT06051513|DRUG|treatment with or without colistin|For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
223439651|NCT00076869|DRUG|Comparator: amphotericin B|
223439652|NCT00076869|DRUG|Comparator: lipid formulation of amphotericin B and/or azole|
224050835|NCT01094587|PROCEDURE|Gastroschisis closure with suture|
224050836|NCT01094587|PROCEDURE|Gastroschisis closure without suture|
224050837|NCT02524522|DEVICE|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
224050838|NCT02524522|DEVICE|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
224144122|NCT04421963|DRUG|Olaparib|300 mg olaparib (2×150 mg tablets) twice daily
224144123|NCT04112732|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
224144124|NCT04112732|OTHER|Placebo|Placebo
223439653|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|"* individualized α frequency~* left DLPFC 110% motor threshold (MT)~* 13-15 sessions for 3 weeks"
223439654|NCT01941251|DEVICE|navigated Transcranial Magnetic Stimulation|\- placebo treatment: sham coil
223439655|NCT04166058|DRUG|Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
223439656|NCT04166058|DRUG|Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)|Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
224050839|NCT00297635|DEVICE|GlucoDYNAMIX™ intervention system|
224144125|NCT03452202|DEVICE|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
224144126|NCT03452202|DEVICE|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
224144127|NCT02762799|BIOLOGICAL|Leucostim®|Leucostim® is filgrastim biosimilar.
224144128|NCT02762799|BIOLOGICAL|Neupogen®|
224144129|NCT00453180|DRUG|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
224144130|NCT00453180|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
224144131|NCT06067893|DRUG|Dexmedetomidine|Patient receives dexmedetomidine for 48 hours post-operatively
224144132|NCT06067893|DRUG|Normal Saline|Patient receives normal saline for 48 hours post-operatively
223439657|NCT00103298|DRUG|FOLFOX regimen|
223439658|NCT00103298|DRUG|fluorouracil|
223439659|NCT00103298|DRUG|isolated perfusion|
223439660|NCT00103298|DRUG|leucovorin calcium|
223439661|NCT00103298|DRUG|melphalan|
224050840|NCT00297635|DEVICE|GlucoMON™ telemetry device|
224050841|NCT04024228|BIOLOGICAL|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
224050842|NCT04024228|BIOLOGICAL|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
224050843|NCT01570764|DRUG|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
224050844|NCT01570764|DRUG|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
224050845|NCT04490395|BEHAVIORAL|Engage PA|Engage PA will consist of a 2-session intervention delivered to participants at the medical center or virtual visit by their study therapist, and includes a wearable personal fitness monitor for tracking their daily activity levels throughout.
224050846|NCT04490395|OTHER|Treatment as Usual plus (TAU+)|The comparison condition will receive treatment as usual throughout the study, and are given a wearable personal fitness monitor for tracking their daily activity levels throughout the study.
224050847|NCT02875249|OTHER|patients stool collection|patients stool collection
224050848|NCT03053700|DRUG|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
224050849|NCT03053700|DEVICE|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
224050850|NCT02456597|DRUG|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
224050851|NCT02456597|DRUG|Isotonic Saline|Isotonic saline injected through the novel Catheter
224050852|NCT02809014|OTHER|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
224050853|NCT02809014|OTHER|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
224050854|NCT02809014|OTHER|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
224050855|NCT02809014|OTHER|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
224050856|NCT05014360|DRUG|JNJ-64251330|JNJ-64251330 tablets will be administered orally.
224050857|NCT03553914|DRUG|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
224050858|NCT06386211|DRUG|MAGNE-B6 Oral Solution|Oral solution.
224050859|NCT06386211|DRUG|MAGNE-B6 New Formulation Tablet|New formulation tablet.
224050860|NCT00938717|DRUG|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
224050861|NCT02800434|PROCEDURE|hand allograft|
224050862|NCT03128398|DRUG|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
224050863|NCT04383379|BEHAVIORAL|Experimental: Intervention group|The intervention NICUs (n = 6) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes toimprove the rate of breastfeeding . Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
224050864|NCT00998049|DRUG|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
224050865|NCT00998049|DRUG|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
224144133|NCT05817955|DRUG|Azacitidine (AZA) with Ruxolitinib|"1. Antibiotics: Antibiotic treatment is positively given when symptoms related to infection, and other support treatment is strengthened.~2. Blood products: Infuse the blood products according to the patient's blood routine test. Drugs that need to be used by other diseases must be recorded in detail in the case report form, including the general name of the drug, the dosage of the medication, and the frequency of administration. Drugs are not allowed to be combined: Avoiding the use of granulocyte colony-stimulating factor (G-CSF), there may be risk of spleen rupture."
223439662|NCT00103298|DRUG|oxaliplatin|
223439663|NCT00791492|DRUG|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
223439664|NCT05559372|DIETARY_SUPPLEMENT|Acute energy drink or placebo consumption|Participants consumed either 16 oz of Nutrabolt C4 Energy Carbonated, Monster Energy Original, or Placebo in randomized order in three separate visits separated by 7±3 days.
223439665|NCT00927225|DRUG|ropivacaine 0.2%, 50 mL|
223439666|NCT00927225|DRUG|normal saline|
223439667|NCT05624736|DIAGNOSTIC_TEST|multi-parametric magnetic resonance imaging scan|Pre-operative multi-parametric magnetic resonance imaging scans including T1WI, T2WI, T1CE, FLAIR and DWI were taken for clinical needs.
223439668|NCT05624736|DIAGNOSTIC_TEST|Pathology examination|The tumor specimen obtained from the surgery were sent to the pathology department for histopathologic examination, immunohistochemistry and gene sequencing test
223439669|NCT04716036|OTHER|Alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
223439670|NCT04716036|OTHER|Placebo beverage|placebo beverage condition.
223439671|NCT01465256|DRUG|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
223439672|NCT03699813|OTHER|Comparison of two approaches to bleeding management|
223439673|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
223439674|NCT00076999|DRUG|TPV oral solution|Tipranavir oral solution
223439675|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
223439676|NCT00076999|DRUG|RTV oral solution|Ritonavir oral solution
223439677|NCT04964986|DRUG|Apraglutide|Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
223439678|NCT06538285|DRUG|Ketamine|Ketamine 0.50 mg/kg IM will be administered during the first dosing visit, and either 0.50 mg/kg IM or 0.75 mg/kg IM will be administered at the two subsequent dosing visits, depending on the participant's toleration of prior ketamine dose(s). All ketamine dosing visits will be facilitated by a licensed study therapist and clinician (i.e., NP or MD).
223439679|NCT06538285|BEHAVIORAL|Psychotherapy|Psychotherapy will consist of three 1-hour preparatory talk therapy sessions over the 14 days preceding the first ketamine dosing visit, a 1-hour integration talk therapy session within 1-3 days following each ketamine dosing visit, and a final 1-hour integration talk therapy session about 1 week following the last ketamine visit. All talk therapy visits will be conducted by a licensed study therapist.
223439680|NCT04296851|DRUG|Niclosamide|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
223439681|NCT04296851|DRUG|placebo|The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
223566656|NCT05563805|DEVICE|Virtual Reality-based physical activity intervention|The V-RATE intervention will be delivered through a 360-degree non-mobilized treadmill in a university clinical laboratory for 6-8-weeks (1-2 days/week, 30 minutes/session) totaling 6 sessions. The V-RATE program will be focused on creating a safe and immersive environment supportive of physical activity. The treadmill enables an individual can walk and run at self-paced speed, moving in 360-degrees (i.e., forwards, sideways, and backwards) without risk of falling. The core feature of the self-paced treadmill is a concave walking platform with an adjustable waist hardness that enables a safe, smooth, natural gait while adults with elevated BMI engage in an immersive walking and running motion. During the V-RATE intervention, participants will self-pace their locomotor action (walking/running/bending/ jumping) while they wear the VR headset and experience immersive VR adventure games using the Omniverse VR system.
223740889|NCT04948450|BEHAVIORAL|Cognitive stimulation intervention|"The study subjects will receive cognitive intervention based on Cognitive Stimulation Therapy with rehabilitation experts. The intervention involves 14 sessions of themed activities, which typically run twice weekly. The sessions will be organized in groups (6-10 patients/ group).~People with dementia and their care staff will be instructed on how to practice the various activities at their nursing home for the rest of the week."
223740890|NCT04948450|BEHAVIORAL|Social intervention|Social intervention will be combined with physical and cognitive interventions through doing these in a group, playing games during exercises (dancing, throwing ball to each other) or doing cognitive stimulation therapy in a group.
223740891|NCT04948450|OTHER|Management of metabolic and vascular risk factors|"Study physicians will assess the risk of developing new chronic diseases, change in blood pressure, weight and BMI, and hip and waist circumference, blood test (glucose, lipid parameters, fasting glucose, and HbA1C if the person with dementia has diabetes) at 3 and 6 months.~Participants in the intervention group will be provided with information on the importance of reducing risk factors, guidance on lifestyle changes and prescribing treatment if necessary by cardiologists and endocrinologists. The target for blood pressure is less than 120/90 mmHg and the target for HbA1c is less than 8 %."
223740892|NCT01352988|DRUG|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
223740893|NCT00623064|DRUG|cisplatin|
223740894|NCT00623064|DRUG|gemcitabine hydrochloride|
223740895|NCT00623064|DRUG|lapatinib ditosylate|
223740896|NCT00623064|OTHER|pharmacological study|
223740897|NCT04528745|DIAGNOSTIC_TEST|Bio Impedance Spectroscopy (BIS)|Determination of fat free mass by BIS
223740898|NCT02478554|OTHER|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
223740899|NCT00657241|DRUG|Carvedilol CR|
223740900|NCT00657241|DRUG|Valsartan|
223740901|NCT03906903|DEVICE|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
223740902|NCT03906903|BEHAVIORAL|Cognitive Stimulation|Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
223740903|NCT04078061|BEHAVIORAL|MABA|Adaptive, modular, behavioral intervention.
224050866|NCT06074406|DEVICE|Hyperfine|Enrolled subjects will undergo a Hyperfine MRI exam, which is a portable, low-field MRI, at various timepoints during their clinical course on ECMO
223439682|NCT05821296|DEVICE|Crystal Peel|3 applications performed by a dermatologist.
223439683|NCT04844905|DRUG|Ivermectin|Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.
223740904|NCT04078061|BEHAVIORAL|EIBI|Early Intensive Behavioral Intervention
223740905|NCT05198843|DRUG|Dasatinib|Given PO
223740906|NCT05198843|DIETARY_SUPPLEMENT|Icosapent Ethyl|Given PO
223740907|NCT06972953|DEVICE|SmartGUIDE (deflectable guidewire)|SmartGUIDE is a deflectable guidewire for use in interventional procedures in the neurovasculature and the peripheral vasculature. It can be used to selectively introduce and position catheters and other interventional devices within the peripheral and neurovasculature. The device is a steerable guidewire with a deflectable tip. This allows adjusting the shape of the tip, dynamically, while the physician navigates the device in the patient's arterial and venous circulatory system.
223740908|NCT06972953|DEVICE|Any standard of care guidewire|The control device is any standard of care guidewire as per hospital routine indicated for neuro-interventional procedures.
223740909|NCT05982392|DRUG|Tramadol|Tramadol 100mg will be given 60 minutes before start of procedure.
223740910|NCT05982392|DRUG|Naproxen Sodium|Naproxen sodium 550mg will be given 60 minutes before start of procedure.
223740911|NCT05982392|DRUG|Placebo|Placebo will be given 60 minutes before start of procedure.
223740912|NCT07132983|DRUG|Ensifentrine 3 mg|Single dose, administered by oral inhalation using a standard jet nebulizer
224144134|NCT05363709|DRUG|Balstilimab|Given by Vein (IV)
224050867|NCT02897492|OTHER|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
223439684|NCT04844905|DRUG|Placebo|Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
223439685|NCT04844905|DRUG|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
223439686|NCT01115556|DRUG|Ranibizumab|2.0 mg
223439687|NCT01115556|DRUG|Ranibizumab|0.5 mg
223439688|NCT02137109|DRUG|natalizumab|Administered as specified in the treatment arm.
223439689|NCT02648477|DRUG|Anastrozole|Given PO
223439690|NCT02648477|DRUG|Doxorubicin Hydrochloride|Given IV
223439691|NCT02648477|DRUG|Exemestane|Given PO
223439692|NCT02648477|OTHER|Laboratory Biomarker Analysis|Correlative studies
223439693|NCT02648477|DRUG|Letrozole|Given PO
223439694|NCT02648477|BIOLOGICAL|Pembrolizumab|Given IV
223439695|NCT00713661|DRUG|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
224050868|NCT04144270|OTHER|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
224050869|NCT04660513|PROCEDURE|Bariatric surgery|Subjects with morbid obesity underwent bariatric surgery
224050870|NCT00022867|DRUG|Nondigestible oligosaccharide (NDO)|
224050871|NCT03215550|PROCEDURE|CEA|Carotid Endarterectomy
224050872|NCT03215550|RADIATION|18F PET-MRI|18F-fluoride Hybrid PET-MRI
224050873|NCT03215550|DIAGNOSTIC_TEST|Transcranial Doppler|Microembolic Signals detection
224050874|NCT06226909|PROCEDURE|different types of ultrasound technique|Shear-wave elastography-guided or B-mode ultrasound-guided
223439696|NCT02119221|DRUG|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of \[14C\]
223439697|NCT03772977|BEHAVIORAL|Brain Health Champion|A health coach embedded within an existing clinical care team
223439698|NCT06079762|BEHAVIORAL|AGE SELF CARE group visit program|"AGE SELF CARE: Adaptation, Growth, and Engagement; Socialization, Empowerment, Learning, and Function; and Community Activation for Resilience in Elderhood, is a virtual group visit program. It includes education and behavioral change elements in the broad areas of self/health, home environment, and community. There are 8 weekly 90-minute virtual sessions facilitated by an aging expert (e.g., geriatrician). Examples of topics include Aging Well: The Power of Movement, People Can Change, Homes Can Too, and Social World."
223439699|NCT04536961|DRUG|Reference Treatment- BMS-986165-01|Specified dose on specified days
223439700|NCT04536961|DRUG|Prototype BMS-986165|Specified dose on specified days
223439701|NCT04536961|DRUG|Famotidine|Specified dose on specified days
223439702|NCT04536961|OTHER|Alcohol|Specified quantity on specified days
223439703|NCT01939626|DEVICE|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
223439704|NCT01939626|DEVICE|Standard culture medium|This culture system needs media change on day 3 of culture.
223740913|NCT07132983|DRUG|Glycopyrrolate 42.5 mcg|Single dose, administered by oral inhalation using a standard jet nebulizer
224050875|NCT00170612|BIOLOGICAL|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
224050876|NCT00170612|BIOLOGICAL|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
224050877|NCT00330395|DRUG|caspofungin acetate|Duration of Treatment 28 Days
223439705|NCT04291482|BEHAVIORAL|Choosing Health Intervention|The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
223740914|NCT07132983|DRUG|Ensifentrine 1.5 mg|Single dose, administered by oral inhalation using a standard jet nebulizer
223740915|NCT07132983|DRUG|Ensifentrine 3 mg (marketed formulation)|Single dose, administered by oral inhalation using a standard jet nebulizer
224050878|NCT03853811|DEVICE|Ankle Foot Orthosis (AFO)|The intervention group will receive the custom AFO to use in their standard Mitchell shoe.
224050879|NCT03156348|OTHER|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
224050880|NCT03277742|BEHAVIORAL|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
223439706|NCT04291482|BEHAVIORAL|Choosing Health Control|The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
223439707|NCT01022164|PROCEDURE|fibrin glue|
224050881|NCT03277742|DRUG|Standard of care|DOTS plus standard DM2 care
224050882|NCT05926388|OTHER|Video-assisted training|Patients will be given training on insulin therapy and management using lecture, question-answer, video and demonstration methods.
224050883|NCT00268632|DRUG|risedronate|
224050884|NCT06433609|DRUG|SHR-A1811|Via intravenous infusion
224050885|NCT06433609|DRUG|SHR-A1921|Via intravenous infusion
224050886|NCT06433609|DRUG|Adebrelimab|Via intravenous infusion
224050887|NCT01462435|DRUG|Diclofenac Test (lower dose)|Capsules
224050888|NCT01462435|DRUG|Diclofenac Test (upper dose)|Capsules
224050889|NCT01462435|DRUG|Celecoxib|200 mg Capsules
224144135|NCT05411328|DEVICE|virtual reality|All children in the two groups received physical therapy protocol for 30 minutes in addition to virtual reality game traditional physical therapy group traditional physical therapy group
223740916|NCT05039281|BIOLOGICAL|Atezolizumab|Given IV
223740917|NCT05039281|DRUG|Cabozantinib|Given PO
223740918|NCT06142357|OTHER|Secukinumab|There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled
224050890|NCT01462435|DRUG|Placebo|Capsules
224050891|NCT05860075|DRUG|IMM01|IMM01 will be administered once a week for 4 weeks.
224050892|NCT03239366|OTHER|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
224050893|NCT03239366|OTHER|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
224050894|NCT05092919|OTHER|Flavor|Sweet flavored vs. non-flavored cigarillos.
224050895|NCT05899244|OTHER|muscle streching exercice|"For this exercice the participant will have to place the foot of the stretched leg on a step while maintaining his knee in extension.~From this starting position the patient will have to do a pelvic anterior tilt while keeping is back straight and his gaze horizontal until the movement induce a feeling of stretching in the posterior part of the thigh."
224144136|NCT04183387|DRUG|Simvastatin 40mg|
224144137|NCT03722472|BIOLOGICAL|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
224144138|NCT00665678|DRUG|paroxetine|treatment for three months with paroxetine
224144139|NCT00665678|DRUG|placebo|treatment for three months with placebo
223439708|NCT03799406|DRUG|Cholecalciferol|Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
223439709|NCT03799406|OTHER|Placebo|Placebo supplementation during acute episode of bronchiolitis
223584007|NCT06983769|DEVICE|CPAP|"CPAP stands for Continuous Positive Airway Pressure. It is the standard treatment for obstructive sleep apnea (OSA). A CPAP machine delivers a constant stream of air through a mask worn over the nose or nose and mouth during sleep. This air pressure keeps the airway open, preventing pauses in breathing caused by airway collapse.~CPAP is highly effective, especially for moderate to severe OSA, but some patients may find it uncomfortable or difficult to tolerate."
223584008|NCT06855641|PROCEDURE|Opioid based Anesthesia|in this group, patient will receive standard of care at UCLA including fentanyl administration during surgery
223740919|NCT07115329|DRUG|Zelquistinel|Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
223740920|NCT07119944|OTHER|Not Related|This observational study does not involve any therapeutic intervention. Instead, all participants undergo gait analysis using two different measurement methods-2D pose estimation algorithms and an inertial measurement unit (G-Walk system)-to compare their outputs. Both assessments are performed on the same individuals under standardized conditions without altering their routine care.
223740921|NCT06978582|BEHAVIORAL|Mindful and conscious movement-based exercise|The program will last for 12 weeks and will consist of one weekly 45-minute session, with an additional 5 minutes of exercise added each month: • 15 minutes of health education. Educational content will focus on self-management, pacing, planning of activity and rest, basic theoretical framework about the conditions, and familiarization with mindful and awareness practices and their purported benefits. • 30 minutes of conscious movement-based exercise practice, increasing by 5 minutes each month and guided by pacing recommendations. Additionally, participants will be encouraged to engage in at least 15 minutes of daily practice with the support of recorded material.
224050896|NCT05899244|OTHER|Slider|"In order to define the starting position for a slider, the participant will be positioned in lateral decubitus with the knee extended and will perform a hip flexion until a sensation of pain or stretching feeling appears on the posterior part of the thigh or of the knee. If the hip flexion does not induce a stretching sensation or pain, a dorsal ankle flexion is added. Once this position is defined the patient slightly reduces the amount of hip flexion until the stretching/pain sensation disappears.~From this starting position, to perform the slider: the subject performs a hip flexion movement and simultaneously a cervical extension movement, this corresponds to the outward movement. For the return movement the patient performs a hip extension and at the same time a cervical flexion. The slider technique must be pain free."
224144140|NCT00547898|DRUG|Crofelemer 125 mg|Crofelemer 125 mg
224144141|NCT00547898|DRUG|Crofelemer 250 mg|Crofelemer 250 mg
224144142|NCT00547898|DRUG|Crofelemer 500 mg|Crofelemer 500 mg
224144143|NCT00547898|DRUG|Placebo|Placebo
224163740|NCT00635440|DEVICE|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
223566657|NCT05441163|OTHER|APA and nutrition intervention|"\- APA intervention: weekly supervised sessions at home with the APA professional combined with unsupervised sessions, alone or with the APA partner, for 8 weeks.~The supervised session will be broken down as follows: warm-up block (approximately 10'), aerobic block (15'), muscle strengthening/resistance block (15') and stretching/relaxation block (10'). The remaining 10' will be used to review the session and the individual sessions. This program can be adapted to the needs and abilities of the patient if necessary.~\- Nutritional intervention: dietitian weekly visits at home during 8 weeks with dietetic counseling; decision of oral, enteral and/or parenteral feeding validated by the clinical steering committee according to the Société Francophone de Nutrition Clinique et Métabolisme (SFNCM) guidelines."
223566658|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
223566659|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
223566660|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
223566661|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
223566662|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
223566663|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
224050897|NCT05899244|OTHER|Tensioner|"The participant will be positioned in lateral decubitus with the knee extended and the hip, the cervical, thoracic and lumbar spine placed in neutral position.~For the outward movement, the participant will perform a hip flexion associated with a simultaneous movement of cervical extension until a sensation of pain or a stretching feeling appears on the posterior part of the thigh or of the knee.If this combined movements do not induce a stretching sensation or pain, a dorsal flexion of the ankle is added.~For the return movement, the participant will realize a hip extension simultaneously associated to a movement of extension of the cervical spine. If the dorsal flexion of the ankle was used during the outward movement, a movement plantar flexion of the ankle must be used in association to the movement of hip extension."
224050898|NCT00011908|DRUG|hLL2 (Epratuzumab)|
224050899|NCT00063141|DRUG|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
224050900|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
224050901|NCT00063141|DRUG|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
224050902|NCT02821611|BEHAVIORAL|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
224050903|NCT01942148|DRUG|Aripiprazole|
224050904|NCT03371979|DRUG|Pegzilarginase|Administered IV
224050905|NCT03371979|DRUG|Pembrolizumab|Administered IV
224050906|NCT03143010|DRUG|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
224050907|NCT03143010|DRUG|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
224050908|NCT03143010|DRUG|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
224050909|NCT03143010|DRUG|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
224050910|NCT04162496|DEVICE|Restylane Refyne|Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
224050911|NCT04452045|DEVICE|SweetDreams|SweetDreams is a mHealth adaptation of existing evidence-based sleep interventions. It is a user friendly and developmentally appropriate modularized 4-week web-based intervention available on computer, tablet or mobile phones.
224163741|NCT01855425|RADIATION|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
224163742|NCT06242093|DEVICE|whole body vibrator|• WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform
224163743|NCT06242093|OTHER|GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.|"Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks"
224163744|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib|TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
224163745|NCT05013697|DRUG|Paclitaxel + Cisplatin + TQB2450 injection|TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.
223566664|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
223566665|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
223566666|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
223566667|NCT00964912|DRUG|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
223566668|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
223566669|NCT00964912|DRUG|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
223566670|NCT05186701|OTHER|Kinesio Tape|"Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis."
224144144|NCT03406364|DRUG|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy."
224144145|NCT01082978|DEVICE|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
224163746|NCT01961102|PROCEDURE|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
223439710|NCT06034379|DEVICE|eSpectacle Clinical prototype (CP1) device|The CP1 device consists of a clear 15° central aperture and projects +9.00D defocused micro-LED lights of approximately 4800 nits illumination to the peripheral retina.
223439711|NCT06034379|DRUG|0.01% atropine|Atropine is a and anticholinergic medication which can be used for dilation and cycloplegia.
223439712|NCT02762552|DEVICE|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
223740922|NCT06978582|BEHAVIORAL|Conventional exercise|"The program will last for 12 weeks and will consist of one weekly 45-minute session, with an additional 5 minutes of exercise added each month:~* 15 minutes of health education. Educational content will now focus on self-management, pacing, planning of activity and rest, basic theoretical framework about the conditions, and the rationale for the impact of exercise in symptom management.~* 30 minutes of low intensity strength and aerobic exercise practice, with session duration progressively increased by increasing by 5 minutes each month and guided by pacing recommendations.~Additionally, participants will be encouraged to engage in at least 15 minutes of daily practice with the support of recorded material."
223740923|NCT06979050|BEHAVIORAL|The Ronnie Gardiner Method|The intervention involves participants performing coordinated movements while saying specific cue words, synchronized to rhythmic music. The exercises are guided by a visual notation system consisting of 19 colored symbols that represent different body parts and movements. Red symbols indicate movements on the left side of the body, while blue symbols represent the right side. Each symbol corresponds to a specific movement and verbal cue. Exercises are typically performed standing to maximize balance effects and are accompanied by rhythmic, often popular, music to enhance engagement and motivation. Complexity can be increased by adjusting the tempo of the music or combining multiple symbols. Training sessions are conducted in groups, led by certified instructors, twice per week for 12 weeks (60 minutes per session), with an additional home-based practice session each week.
223740924|NCT06437184|DIAGNOSTIC_TEST|ODP|se previously
223740925|NCT06255886|DRUG|Protein pump inhibitor.|1 mg/kg /day
223740926|NCT06255886|BEHAVIORAL|Mother or infant diet|Mother on cow milk protein diet or infant on hypoallergenic formula in case of bottle fed
224050912|NCT02644564|OTHER|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
224050913|NCT02470468|BIOLOGICAL|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
224050914|NCT02470468|BIOLOGICAL|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
224050915|NCT02470468|OTHER|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
224050916|NCT05328726|DRUG|GZR-18|As previously described in Arms
224050917|NCT05328726|OTHER|Placebo|Placebo will be dosed in an identical manner to active study drug.
224050918|NCT00739011|DEVICE|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
224050919|NCT06098365|OTHER|segmental cervical stabilization exercises|Segmental spine stabilization exercises were composed of axial extension, cervical extension exercises, cervico-scapulothoracic strengthening and cranio-cervical flexion exercises.
224050920|NCT06098365|OTHER|cervical isometric exercises|Cervical isometric exercises consist of 6 sets in a sitting position, each movement lasting 10 seconds, each repeated 5 times, with a 5-second rest in between.
224050921|NCT02163187|DEVICE|Implantation of the InterStimTM|
224050922|NCT02163187|BEHAVIORAL|MSK BFI questionnaires|
224050923|NCT02163187|BEHAVIORAL|The Low Anterior Resection Score (LARS) questionnaires|
224050924|NCT02163187|BEHAVIORAL|The EuroQOL5D questionnaires|
224050925|NCT02163187|BEHAVIORAL|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
224050926|NCT01329250|DRUG|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
224050927|NCT06353828|DRUG|CBD, synthetic form|Cannabidiol enema
223439713|NCT06060106|PROCEDURE|Endoscopic submucosal dissection|The patient was positioned in the left lateral decubitus position.Marking dots were made with a dual knife/hybrid knife around the lesion, and a solution of glycerin fructose with indigo carmine was injected into the submucosal layer to lift the lesion. Finally, after pre-cutting of the mucosal and submucosal layers around the lesion and dissection of the submucosa, the lesion was removed en bloc.
223439714|NCT06060106|PROCEDURE|Esophagectomy|The main surgical methods of esophagectomy include the McKeown operation, Lvor-lewis, Sweet and minimally invasive radical resection of esophageal cancer (MIE)
223740927|NCT06255886|DRUG|Placebo|Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
224050928|NCT06353828|DRUG|Placebo|placebo enema
224050929|NCT04591730|OTHER|First time father questionnaire self-administration|The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
224050930|NCT06433830|DRUG|Hetrombopag Olamine|The administration of hetrombopag as a monotherapy and at an initial dose of 7.5 mg QD.The dose adjusted based on platelet count.
224050931|NCT02556502|DEVICE|18F-Florbetaben PET|
224144146|NCT01082978|DEVICE|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
224144147|NCT02420795|DRUG|Akt/ERK Inhibitor ONC201|Given PO
223439715|NCT02603562|BIOLOGICAL|ATYR1940|Concentrate for solution for infusion
223439716|NCT04805359|BEHAVIORAL|Normoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
223439717|NCT04805359|BEHAVIORAL|Hypoxic exercise|Trained on a bicycle ergometer at 60% of maximal work-rate (60%Wmax)for 30 minutes per day, 5 days per week for 6 weeks
223439718|NCT02608255|OTHER|blood samples|
223439719|NCT06098417|DIAGNOSTIC_TEST|Plasma Test|IGF-2 (insulin-like growth factor 2)
223439720|NCT06098417|DIAGNOSTIC_TEST|Plasma test|SPARC (secreted protein acidic and rich in cysteine)
223439721|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EPICAN (heparan sulfate proteoglycan)
223439722|NCT06098417|DIAGNOSTIC_TEST|Plasma test|EGFR (epidermal growth factor receptor)
223439723|NCT06098417|DIAGNOSTIC_TEST|Liver biopsy|Fibrosis and steatosis grade according to Brunt-Kleiner classification
224144148|NCT02420795|OTHER|Laboratory Biomarker Analysis|Correlative studies
223439724|NCT06098417|DIAGNOSTIC_TEST|Visceral adipose tissue biopsy|Presence of inflammation
223439725|NCT06098417|DIAGNOSTIC_TEST|Liver elastography|Grade of fibrosis according to Hamaguchi score
223566671|NCT05186701|OTHER|Conventional Physical Therapy|Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
224050932|NCT00258336|BIOLOGICAL|autologous immunoglobulin idiotype-KLH conjugate vaccine|
224144149|NCT02420795|OTHER|Pharmacological Study|Correlative studies
224144150|NCT04833868|OTHER|hippotherapy and schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week hippotherapy intervention combined with Schroth exercise
224144151|NCT04833868|OTHER|schroth exercise|pulmonary function and aerobic capacity were measured in patients with mild idiopathic scoliosis before and after 10-week of Schroth exercise
224144152|NCT01874119|DRUG|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
224144153|NCT02671955|DRUG|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
224144154|NCT02318069|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 5 arms
223439726|NCT06098417|DIAGNOSTIC_TEST|Blood test|Determination of surrogate based diagnostic tests/scores for liver fibrosis
223439727|NCT06622096|DIAGNOSTIC_TEST|Evaluation of laboratory exams prescription|Evaluation of laboratory exams prescription
223439728|NCT04108663|BEHAVIORAL|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
223439729|NCT04491305|PROCEDURE|Surgically treated women with endometriosis and confirmed diagnosis|Women with indication for surgery or diagnostic laparoscopy will be enrolled in study.
223439730|NCT06290804|OTHER|education|Training program on Health Impacts of Sustainable Behaviors and Climate Change
223439731|NCT05604872|PROCEDURE|Small Incision Lenticule Extraction|A 500 kHzVisumax (Carl Zeiss Meditec AG) femtosecond laser was used with cap thickness ranging from 100 to 130μm, cap diameter from 7.3 to 7.9 mm. The lenticule was dissected with a blunt spatula through a 30 to 60-degree incision at the 10 o'clock position and removed using forceps afterward. Treatment targets of both eyes were set to emmetropia, the refraction corrections were based on manifest refractions
223439732|NCT04986943|DEVICE|Using ABTHERA Advance without a Wittmann Patch|In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
223439733|NCT00438802|DRUG|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
223439734|NCT01481272|DRUG|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
223439735|NCT01481272|DRUG|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
224050933|NCT00258336|BIOLOGICAL|rituximab|
224050934|NCT00258336|BIOLOGICAL|sargramostim|
224050935|NCT00366964|DEVICE|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
224050936|NCT00366964|DEVICE|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
224050937|NCT05439486|DEVICE|hyperbaric oxygen therapy within hyperbaric oxygen therapy chamber.|ED patients in this group exposed to hyperbaric oxygen 100 % concentration at 2.2 ATM for 90 minutes for 30 consecutive sessions.
224050938|NCT05972200|DEVICE|Active HD-tDCS over V5/MT|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V5/MT, whereas the other 4 electrodes return electrical currents that flow away from that area. V5/MT will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
223439736|NCT01481272|DRUG|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients \>/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
223439737|NCT01481272|DRUG|Mesna|300mg/m2 or 200mg/m2 (patients \>/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients \>/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
223439738|NCT01481272|DRUG|Cytarabine|2g/m2 or 0,5-1g/m2 (patients \>/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
223439739|NCT01481272|DRUG|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
223439740|NCT01481272|DRUG|Leukovorin|15mg, po 24 hours after methotrexate it
223439741|NCT01481272|DRUG|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC\>1.0x109/l
223439742|NCT02550704|PROCEDURE|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
223439743|NCT02403349|DRUG|Fimasartan|
223439744|NCT02403349|DRUG|Valsartan|
223439745|NCT02403349|DRUG|Atenolol|
223439746|NCT01724801|RADIATION|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
224144155|NCT06203483|DRUG|Adductor canal block|A linear ultrasound probe will be placed medial to the patella, the probe will be advanced to cephalad, and the superficial femoral artery will be visualized. The block site will be confirmed by injecting 5 ml of saline around the saphenous nerve in the subsartorial region under ultrasound guidance. Then, 30 ml of local anesthetic solution containing 0.25% bupivacaine (Marcain 0.5% AstraZeneca, England) will be administered.
223439747|NCT01724801|DRUG|Icotinib|administered orally at a dose of 125 mg 3 times daily
223439748|NCT00497770|DRUG|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
223439749|NCT02472626|DRUG|6,8-Bis(benzylthio)octanoic Acid|Given IV
223439750|NCT02472626|DRUG|Cytarabine|Given IV
223439751|NCT02472626|DRUG|Daunorubicin Hydrochloride|Given IV
223439752|NCT03750409|DEVICE|Helmet|The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
223566672|NCT05102097|BEHAVIORAL|Warm-up|Participants will walk on treadmill at a speed of 1.7 mile per hour (MPH) and 0 inclination each session for 6weeks 3 times in a week
223439753|NCT05180370|OTHER|Questionnaies|Data entry staff who will be assigned to the centers for 2 weeks will apply a questionnaire consisting of different questions to the patients referred to them by clinicians with the diagnosis of HF (presented in the appendix to this protocol). In addition, Pittsburg Sleep Quality Index will be applied to all cases.
223439754|NCT06333405|DRUG|Fecal Microbiota Transplantation|"Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI"
223439755|NCT04339309|PROCEDURE|Non-surgical periodontal treatment with interdental hygiene devices|
223439756|NCT04339309|PROCEDURE|Non-surgical periodontal treatment without interdental hygiene devices|
223439757|NCT00833118|PROCEDURE|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
223439758|NCT06135025|OTHER|Telemonitoring|the patients included receive a weekly phone call from the participating physician to to support self-management improvement, use of inhalation devices, rehabilitation, monitoring of signs/symptoms by treatment management, counseling, motivation, and prevention of exacerbations, early recognition of exacerbation signs and planify access to health care facility. at 1 month a Face to Face visit is planned to collect data.
223439759|NCT00796744|DRUG|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
223439760|NCT03698968|DEVICE|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
223439761|NCT02046772|DRUG|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
223566673|NCT05102097|BEHAVIORAL|Main exercise|Participants will walk on a treadmill with a starting speed of 1.7 mile per hour with inclination of 1 to 4% starting with 1% and increased by 1% each week until 4 weeks and at week 5 and 6 speed will be increased to 5mile per hour starting from 1.7mile per hour and increased by 0.5 mile per hour each 1minute while inclination will be increased to 5% in week 5 and 6% in week 6. Main exercise will be perform 3 times in a week for 6 weeks
223566674|NCT05102097|BEHAVIORAL|Cool down|Participants will walk on treadmill at the speed of 1.7 mile per hour 0 inclination each session for 6 weeks 3 times in a week
223439762|NCT02046772|DRUG|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
223439763|NCT02046772|DRUG|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
223439764|NCT06045442|BEHAVIORAL|Intradialytic exercise training|The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
223439765|NCT06045442|BEHAVIORAL|Control|Usual care
223439766|NCT03333408|DRUG|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
224050939|NCT05972200|DEVICE|Active HD-tDCS over V1|For HD-tDCS a 4 × 1 montage (Kessler et al., 2013), small circular electrodes (diameter 1 cm) will be used with the anode placed centrally with a current intensity of 1 mA for a total of 20 minutes (30 s ramp up/down). Hereby, the anodal electrode modulates the excitability of the targeted area left V1, whereas the other 4 electrodes return electrical currents that flow away from that area. V1 will be localised via published procedures and electrode's placement will be done according to the 10-20 International EEG 10-20 System for electrode placement.
224050940|NCT05972200|DEVICE|Sham HD-tDCS over V5/MT or V1|Sham HD-tDCS will be delivered over left V5/MT or left V1. The same electrodes placement as well as the stimulation set-up will be used as in the active stimulation conditions, but the current will be applied for 30 s and will be ramped down (0 mA) during the rest of the session without the participants awareness. .
223740928|NCT06922149|OTHER|Group A Funtional massage therapy and eccentric exercise in lower limb|Functional Massage (FM) on lower limb. FM is a therapeutic technique that incorporates joint motion with massage to treat musculotendinous pain and impairments. Eccentric exercises training for lower limb. It can be useful in strengthening the muscles of the lower limbs, and promoting gait performance.
223740929|NCT06922149|OTHER|Group B. Eccentric exercises training|Eccentric exercises training and therapeutic exercise is a type of physical activity used to treat or prevent injuries and improve functional outcomes. Eccentric exercises focuses on movements, or phases of a movement, that lengthen the muscles. Some examples of eccentric exercise include lowering into a squat or lowering into a press-up. In contrast, when a person pushes out of a squat or press-up, this shortens the muscles. This is known as concentric movement
224050941|NCT00792194|OTHER|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
224050942|NCT04956003|BEHAVIORAL|45-minute daily physical activity|45-minute daily physical activity session as an integral part of learning (during regular school sessions)
224050943|NCT02965521|BEHAVIORAL|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
223740930|NCT07126483|PROCEDURE|Thoracic paravertebral block|Ultrasound-guided single-injection thoracic paravertebral block using 0.4 mL/kg of 0.25% bupivacaine with epinephrine (1:400,000) before induction of standardized general anesthesia. Postoperative analgesia will be provided with intravenous patient-controlled analgesia morphine, along with scheduled paracetamol and NSAIDs.
223740931|NCT07126483|DRUG|Morphine|Single intrathecal injection of morphine (5 mcg/kg diluted in 3 mL 0.9% saline) at the L3-L4 or L4-L5 interspace before induction of standardized general anesthesia. Postoperative analgesia will be provided with intravenous patient-controlled analgesia morphine, along with scheduled paracetamol and NSAIDs.
224050944|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
224050945|NCT05926583|GENETIC|AAV5-hRKp.RPGR|AAV5-hRKp.RPGR will be administered by subretinal injection using a standardized surgical procedure.
224050946|NCT00319150|DRUG|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
224050947|NCT01309542|DRUG|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
224050948|NCT01231256|BEHAVIORAL|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
224050949|NCT04425603|DEVICE|Anthology Hip Replacement System|
224050950|NCT05371977|PROCEDURE|Trabeculectomy|trabeculectomy glaucoma surgery
224050951|NCT05371977|PROCEDURE|Deep Sclerectomy|deep sclerectomy glaucoma surgery
224050952|NCT04501068|DEVICE|Ambu® AuraGainTM|Evaluate the time of insertion, performance, security and insertion success rate of the Ambu® AuraGainTM in patients undergoing ambulatory surgery and general anaesthesia
224050953|NCT01775332|OTHER|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
224050954|NCT01262768|BEHAVIORAL|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
224050955|NCT04106882|DRUG|Ketones|Supplement administered mid-scan.
224050956|NCT04106882|DRUG|Glucose|Supplement administered mid-scan.
224050957|NCT02418780|OTHER|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
224050958|NCT00029874|DRUG|Minocycline|
224050959|NCT00857532|DRUG|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
223439767|NCT01889121|BEHAVIORAL|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
224050960|NCT00284206|DRUG|long-acting injectable risperidone|
224050961|NCT03134742|OTHER|Control Group|No interventions this is the control group-no additional scans
224050962|NCT03134742|DIAGNOSTIC_TEST|CT Scan|CT Scan of affected and contralateral limb
224050963|NCT03134742|DIAGNOSTIC_TEST|DEXA Scans|DEXA Scan of affected and contralateral limb
224050964|NCT03134742|DIAGNOSTIC_TEST|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
224050965|NCT04368572|BEHAVIORAL|Hypnosis|"An interview assesses the patient's level of anxiety, interests and dissociative abilities. Hypnosis is done by following the steps:~First step: reception and installation of the patient Second step: induction phase Third step: hypnotic trance phase Fourth step: reorientation phase"
224050966|NCT03119961|DEVICE|SONOCLOUD®|BBB opening by ultrasound
224050967|NCT00257725|DRUG|B-MPH|Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
224050968|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
224050969|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
224050970|NCT05002270|DRUG|JAB-21822 (KRAS G12C inhibitor)|Administered orally
223439768|NCT02150070|DRUG|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
223439769|NCT02150070|DRUG|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
223439770|NCT04962828|OTHER|Vocabulary based intervention- Non Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks Only with SLP
223439771|NCT04962828|OTHER|Vocabulary based intervention - Collaborative|List of 10 words functional words Therapy 3 times a week for 20 minutes Duration = 9 weeks With SLP and to be reinforced by teachers in class over the week
223439772|NCT01180556|DIETARY_SUPPLEMENT|Probiotics|Daily oral supplementation for four weeks
224050971|NCT05002270|DRUG|Cetuximab (EGFR inhibitor)|Administered IV
224050972|NCT01858532|DRUG|Atrasentan|Film-coated tablet
224050973|NCT01858532|DRUG|Placebo|Film-coated tablet
224050974|NCT00514514|DRUG|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
224050975|NCT00514514|DRUG|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
224050976|NCT00514514|DRUG|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
224050977|NCT00514514|DRUG|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
224050978|NCT03271814|BIOLOGICAL|LPS|0.6 by/kg LPS single dose iv
224050979|NCT03271814|OTHER|Placebo|Sterile Water
224144156|NCT06203483|DRUG|PENG block|The probe will be placed at the anterior superior level of spina iliaca, parallel to the inguinal ligament. The probe will be scanned gradually towards the caudal. After the anterior inferior of the spina iliaca is visible, the probe will be slightly turned medially until the hyperechoic shadow of the superior pubic ramus is visible. The psoas muscle tendon will be visualized above the superior pubic ramus, then 5 ml of saline will be injected under the psoas tendon and the block location will be confirmed. After that 30 ml of 0.25% bupivacaine will be administered.
224144157|NCT04401397|PROCEDURE|Intensive early mobilization techniques|"Pulmonary techniques: lung mechanics and breathing pattern restoration, mucus clearance techniques, breathing control and cough techniques.~Musculoskeletal techniques: strengthening and functional exercises, active assistive moving techniques."
223439773|NCT01180556|DIETARY_SUPPLEMENT|Placebo|Placebo administration
223439774|NCT02733198|OTHER|Prognosis-guided therapy|
223439775|NCT00206089|DRUG|EXANTA|
223439776|NCT00678470|DRUG|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
223439777|NCT03383952|BIOLOGICAL|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
223439778|NCT03108937|DRUG|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
223439779|NCT03108937|DRUG|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
224050980|NCT00366275|PROCEDURE|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 2 and cyclophosphamide 400 mg/m\^2 on days 2-6. Courses were started if granulocytes \>1.5 · 10\^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m\^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m\^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM \[carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan\] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m\^2 on days +14 and +21 after autotransplant.
224050981|NCT02753322|OTHER|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
224050982|NCT02753322|OTHER|Single-task training|Balance and walking exercises and and attention demanding task performed separately
224050983|NCT02753322|OTHER|Limbs exercise|Stretching and strengthening exercises
224144158|NCT05750238|OTHER|no intervention|no intervention, survey was applied to the participants
224144159|NCT01646567|DRUG|SHP-141C|Topical Cream
223439780|NCT00968097|DRUG|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
223439781|NCT00428922|DRUG|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
223439782|NCT00428922|DRUG|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
224050984|NCT00333671|DRUG|Glycerol|
224050985|NCT03785925|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
224050986|NCT03785925|BIOLOGICAL|Nivolumab|Specified dose on specified days
224050987|NCT00954720|OTHER|No Intervention|There is no intervention on this trial
224050988|NCT03370536|DEVICE|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
224050989|NCT03370536|PROCEDURE|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
224050990|NCT03370536|DRUG|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
223439783|NCT00428922|DRUG|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
223439784|NCT01380691|DRUG|LY2216684|Administered orally
223439785|NCT01380691|DRUG|Placebo-matching LY2216684|Administered orally
223439786|NCT01380691|DRUG|Placebo-matching alcoholic beverage|Administered orally
223439787|NCT01380691|DRUG|Alcoholic beverage|Administered orally
223439788|NCT03996226|DRUG|E7386|E7386 oral tablets.
223439789|NCT03151213|DRUG|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
223439790|NCT03151213|OTHER|Placebo|Placebo before RFA of liver cancer
223439791|NCT06204406|OTHER|Observational|This is a prospective observational study with observation only and no intervention
224050991|NCT03164057|DRUG|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
224050992|NCT03164057|DRUG|Decitabine|Administered intravenously (IV) over approximately one hour.
224144160|NCT01646567|DRUG|Placebo to SHP-141C|Placebo Topical Cream
224144161|NCT01646567|DRUG|Betamethasone Valerate|Topical cream, 0.02%
224144162|NCT01646567|DRUG|Calcipotriol|Topical cream, 0.005%
224144163|NCT01238913|PROCEDURE|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
224144164|NCT04568811|BIOLOGICAL|Adenovirus Type-5 Vectored COVID-19 Vaccine|Low dose adenovirus type-5 vectored COVID-19 vaccine (5E10 vp)
223439792|NCT01987232|DRUG|Carfilzomib|Administered by intravenous infusion.
223439793|NCT01987232|DRUG|Carboplatin|Administered by intravenous infusion.
223439794|NCT01987232|DRUG|Etoposide|Administered by intravenous infusion.
223439795|NCT00051181|DRUG|Travoprost (0.004%)|
223439796|NCT00051181|DRUG|Latanoprost (0.005%)|
223439797|NCT04904783|RADIATION|Low dose radiotherapy|Patients in study group will receive LDRT to both lungs by two parallel opposed fields, antero-posterior (AP) and postero-anterior (PA) to deliver a midplane dose of 0.5 Gy in a single fraction. As this dose is very less, doses to the critical structures including heart and lungs would be very low. All the patients will be treated on Telecobalt unit (Theratronics Phoenix, Canada) and not on the linear accelerator to avoid risks to cancer patients on treatment with linear accelerator. CT based plan will not be undertaken for logistic issues and is also not felt to be mandatory for this LDRT. Dose computation would be carried out by manual dose calculation for the Telecobalt unit.
223439798|NCT00235066|DEVICE|PCI|PCI with Cypher Sirolimus-Eluting Stent
223439799|NCT06731660|OTHER|Education with personalized performance feedback|Education about proper otitis media diagnosis following criteria from the American Academy of Pediatrics with personalized performance feedback on otitis media diagnosis and treatment rates delivered via email
223439800|NCT06731660|DEVICE|Use of digital otoscope|Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope
224050993|NCT03164057|DRUG|Cytarabine|Given IV or intrathecally (IT).
224144165|NCT06229483|DRUG|TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION|Tranexamic acid 20 mg/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 mg/kg/hr infusion of TXA, for the duration of surgery. Treatment is blinded.
224144166|NCT06229483|OTHER|Placebo|0.9% normal saline 20ml/kg IV bolus within 30 minutes prior to the skin incision followed by a 1 ml/kg/hr infusion of 0.9 % sodium chloride for the duration of surgery. Treatment is blinded.
224144167|NCT01002742|DRUG|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
224144168|NCT01002742|DRUG|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight \> 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours."
224144169|NCT00154219|DRUG|Lumiracoxib (drug)|
224144170|NCT00786097|DRUG|Dermacyd PH_DETINLYN (Lactic Acid)|
224144171|NCT02438046|PROCEDURE|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
223439801|NCT01067261|DEVICE|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
223439802|NCT01067261|OTHER|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
223439803|NCT02014220|OTHER|dietary treatment|
223566675|NCT05102097|BEHAVIORAL|Standard of care|Participants will perform Abdominal hollowing, isometric back extension exercise, bridging exercise, graded active flexion, graded active extension by holding for 5seconds and repeated 10times
224050994|NCT03164057|DRUG|Daunorubicin|Given IV.
224050995|NCT03164057|DRUG|Etoposide|Given IV.
224050996|NCT03164057|COMBINATION_PRODUCT|ITMHA|Given IT.
224050997|NCT03164057|DRUG|Idarubicin|Given IV.
224050998|NCT03164057|DRUG|Fludarabine|Given IV over approximately 30 minutes.
224050999|NCT03164057|DRUG|Mitoxantrone|Given IV.
224051000|NCT03164057|DRUG|Erwinia asparaginase|Given IV or intramuscularly (IM).
224051001|NCT03164057|DRUG|Sorafenib|Given PO.
224051002|NCT03164057|DRUG|G-CSF|Given IV.
224051003|NCT03164057|DRUG|Dexrazoxane|Given IV immediately before idarubicin administration.
223439804|NCT05721300|DRUG|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments"|"NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）"
224051004|NCT03164057|BIOLOGICAL|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
224051005|NCT03164057|DRUG|Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn|May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).
223439805|NCT05721300|DRUG|"NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments"|"patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks"
223439806|NCT01782352|DRUG|Omega-3 fatty acids (fish oil)|
224144172|NCT01001728|RADIATION|Imaging investigations (with radiation)|
224144173|NCT02818413|OTHER|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
224144174|NCT03780413|BEHAVIORAL|PR-ESSENCE treatment|
224144175|NCT03780413|BEHAVIORAL|Control (TAU)|
224144176|NCT03532724|DEVICE|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
224144177|NCT04863313|DIETARY_SUPPLEMENT|Probiotic|Experimental group will consume one probiotic capsule every day during 12 weeks at breakfast.
224144178|NCT04863313|DIETARY_SUPPLEMENT|Placebo|Placebo group will consume one placebo capsule every day during 12 weeks at breakfast.
224144179|NCT01158066|PROCEDURE|CT Cardiac|the patient will undergo cardiac CT
223439807|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3|
223439808|NCT01782352|DIETARY_SUPPLEMENT|Vitamin D3 placebo|
223439809|NCT01782352|DIETARY_SUPPLEMENT|Fish oil placebo|
223439810|NCT05299372|OTHER|Telemonitoring via Careportal®|The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
223439811|NCT01589107|BEHAVIORAL|video decision aid|video decision aid
223439812|NCT04263636|PROCEDURE|Phacoemulsification with bilateral trifocal diffractive IOLs|Uneventful bilateral pseudophakic presbyopic correction with trifocal diffractive IOLs
223439813|NCT06901323|DRUG|L-carnitine|44 patients diagnosed as a case of phenylketonuria will receive l-carnitine at a dose of 100 mg/kg/day for 1 year and then blood sample will examined for level of brain-derived neurotrophic factor levels before and after therapy and another group composed of 44 patients diagnosed as a case of phenylketonuria will not receive l-carnitine and their blood sample will examined for level of brain-derived neurotrophic factor levels treated and untreated patients will compared with healthy children and infants has same age and sex .
224051006|NCT06389864|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
224144180|NCT04904380|OTHER|Active peer learning|HMS, HBS and peer learning in combination with AIR and PRISMS
224144181|NCT00702260|DRUG|Ramipril|10 mg capsule
224144182|NCT06441747|DRUG|Durvalumab|Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.
224144183|NCT06441747|DRUG|Olaparib|Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
224144184|NCT05241938|PROCEDURE|PSLT|PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
224144185|NCT05241938|DRUG|Prostaglandin analogue eye drops|Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
224144186|NCT00271791|DRUG|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
224144187|NCT00271791|DRUG|Prednisone|PO, Placebo, 17 days
224144188|NCT03064165|DRUG|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
224144189|NCT03064165|PROCEDURE|Sham block|Injection as for obturator nerve block, but with placebo
224144190|NCT03064165|PROCEDURE|Obturator nerve block|Postoperative obturator nerve block
224144191|NCT03064165|DRUG|Sodium Chloride 9mg/mL|Placebo
224144192|NCT00300612|BIOLOGICAL|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
224144193|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and mFOLFOX6|Dose and schedule per protocol
224144194|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab and docetaxel|Dose and schedule per protocol
224144195|NCT04306900|COMBINATION_PRODUCT|TTX-030 and mFOLFOX6|Dose and schedule per protocol
224144196|NCT04306900|COMBINATION_PRODUCT|TTX-030 and budigalimab|Dose and schedule per protocol
224144197|NCT04306900|COMBINATION_PRODUCT|TTX-030, budigalimab, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
224051007|NCT02205203|DEVICE|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
224051008|NCT02205203|OTHER|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
223439816|NCT02086084|DEVICE|NIV|Standard care
223439817|NCT02086084|DEVICE|ECCO2R|Application of ECCO2R in addition to NIV
224051009|NCT06449066|OTHER|Non applicable|Non applicable (data collection)
223439818|NCT01765244|DRUG|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
223439819|NCT01765244|OTHER|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
223439820|NCT05893004|DIAGNOSTIC_TEST|Headache Screening Questionnaire|The Dutch Headache Screening Questionnaire (HSQ) is the only screening questionnaire based on ICHD-3 which has at least moderate confidence in its criterion validity according to GRADE. The HSQ has already been translated into Portuguese and validated5. The HSQ has only 8 items and requires little time to complete. Due to its good sensitivity, the HSQ screening questionnaire is particularly well suited to exclude migraine.
223439821|NCT05616117|OTHER|Intrauterine 90µg D-vitamin|Children of mothers who received 90 µg vitamin D3 daily during pregnancy:10 µg from a standard prenatal multivitamin + an additional supplement containing 80µg of vitamin D3
223439822|NCT05616117|OTHER|Intrauterine 10µg D-vitamin|Children of mothers who received 10 µg vitamin D3 daily during pregnancy, which is the dose in a standard prenatal multivitamin and the dose currently recommended by the Danish Health Authorities to all pregnant women. They will receive a prenatal vitamin containing 10µg of vitamin D + a placebo supplement.
223439823|NCT01953432|DRUG|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
224051010|NCT03422562|DIETARY_SUPPLEMENT|Florababy|Probiotic supplement
224051011|NCT03506711|DIAGNOSTIC_TEST|Isometric Handgrip Exercise during magnetic resonance imaging|Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
224051012|NCT05005026|OTHER|VR Game 1|"Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
224051013|NCT05005026|OTHER|VR Game 2|"Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
224051014|NCT03537144|DRUG|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
224051015|NCT03537144|DRUG|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
224051016|NCT05506956|DRUG|Flotetuzumab|Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
224144198|NCT04306900|COMBINATION_PRODUCT|TTX-030 and pembrolizumab|Dose and schedule per protocol
223439824|NCT01953432|DRUG|Placebo|Matched placebo daily dosing
223566676|NCT03760016|BEHAVIORAL|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
224144199|NCT04306900|COMBINATION_PRODUCT|TTX-030, nab-paclitaxel and gemcitabine|Dose and schedule per protocol
224144200|NCT04306900|COMBINATION_PRODUCT|Budigalimab and mFOLFOX6|Dose and schedule per protocol
224144201|NCT03513289|OTHER|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
224051017|NCT05410613|COMBINATION_PRODUCT|electromagnetic field and a plantar resistance exercise|"Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening)."
223439825|NCT00232596|DRUG|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
223439826|NCT00232596|DRUG|Placebo|Oral tablet.
223439827|NCT06439589|DRUG|HRS2398|HRS2398: Tablets, 40mg/tablet, oral
223439828|NCT06439589|DRUG|Adebrelimab|Adebrelimab (SHR-1316): injection, 600mg(12mL), intravenous infusion
223439829|NCT04535050|DEVICE|Renal denervation|Renal Denervation: DENEX system
223439830|NCT04535050|PROCEDURE|Renal angiography|Renal angiography
223439831|NCT03426436|DIAGNOSTIC_TEST|Two consecutive 15-lead ECGs|The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
223439832|NCT02522013|DRUG|Aminophylline|
223439833|NCT02522013|DRUG|isotonic saline|
223439834|NCT01873300|PROCEDURE|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
223439835|NCT06486649|DIAGNOSTIC_TEST|Multimodal Large Language Model Diagnosis|Diagnosis for heart failure with preserved ejection fraction (HFpEF) using the multimodal large language model MedGuide-72B.
223439836|NCT06486649|DIAGNOSTIC_TEST|Routine diagnostic and therapeutic procedure|Routine diagnostic and therapeutic procedure
224051018|NCT05410613|DEVICE|Pulsed electromagnetic field|Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz
224051019|NCT05410613|OTHER|usual care|standard general advice according to hospital protocol
224051020|NCT02097524|DRUG|Sarilumab|
224051021|NCT02097524|DRUG|Tocilizumab|
224051022|NCT01305642|DIETARY_SUPPLEMENT|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
224051023|NCT04092712|DRUG|[14C]-CTP-543|Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
224051024|NCT05429970|BEHAVIORAL|Mind-body resilience training|MBRT is a meditation technique used to achieve relaxation)
224051025|NCT05429970|BEHAVIORAL|Music therapy|Music listening was found, in multiple trials, to significantly reduce self-reported anxiety, physiologic indicators of anxiety, and/or sedation requirements
224051026|NCT05429970|DRUG|Propranolol|Propranolol 20 mg PO BID (for 21 consecutive days), Propranolol 10mg PO BID (for 3 consecutive days POD 14-16)
223439837|NCT06618209|DIAGNOSTIC_TEST|physical and chemical methods|Salivary flow rate, pH
223566677|NCT03760016|BEHAVIORAL|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
224051027|NCT05429970|DRUG|Etodolac|Etodolac 400 mg PO BID (for 21 consecutive days)
224051028|NCT01848288|DEVICE|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
224051029|NCT01848288|DEVICE|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
223439838|NCT06618209|DIAGNOSTIC_TEST|biochemical methods|Total oxidant and antioxidant capacities, Lactoperoxidase, Oxidative Stress Index, Glutathione, Superoxide Dismutase
224051030|NCT02091778|DEVICE|Fast gelling dressing|
224051031|NCT04110457|PROCEDURE|spinal decompression|spinal surgery by decompression or fixation
224051032|NCT06210698|DIAGNOSTIC_TEST|Venipuncture|venipuncture
224051033|NCT06239337|DIAGNOSTIC_TEST|Xpert MTB/RIF Ultra in stools and urine|All children with presumptive TB had at least 1 sample collected of respiratory or extrapulmonary specimen (considered as gold standard) and 1 sample of stools and 1 sample of urine. All of them were analyzed with Xpert MTB/RIF Ultra.
223439839|NCT06618209|DIAGNOSTIC_TEST|Oral Findings|DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index.GI (Gingival Index): Assesses the severity of gingivitis based on inflammation.PI (Plaque Index): Assesses the severity of plaque based on inflammation. basic erosive wear examination: measures dental erosion
223439840|NCT06618209|DIAGNOSTIC_TEST|Pediatric Oral Health Quality of Life|The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.
224051034|NCT06398899|DRUG|Group S: sugammadex injection|Reversal agent: sugammadex
224051035|NCT06398899|DRUG|Group N: neostigmine/glycopyrrolate|Reversal agent: glycopyrrolate and neostigmine
224051036|NCT02809131|DRUG|polymixin/bacitracin|Antibacterial irrigation
224051037|NCT02809131|DRUG|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
224051038|NCT02809131|DRUG|Saline|Saline irrigation
224051039|NCT02438891|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
224051040|NCT02244320|DRUG|Tamsulosin|
224051041|NCT01456650|DRUG|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
224051042|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
224051043|NCT00380770|DRUG|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d \> 60 kg , 30mg bd \<60kg Lamivudine 150mg b.d \> 50 kg 2mg/kg \< 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
224051044|NCT03585985|PROCEDURE|Standard patient monitor|Measurement of reference data: heart rate, heart rate variability and respiratory rate
224051045|NCT03585985|PROCEDURE|Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)|Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
223566678|NCT02844244|BEHAVIORAL|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
224051046|NCT00774865|PROCEDURE|MIBI and CTA|Rest and Stress MIBI and CT Angiography
224144202|NCT03654079|OTHER|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
224144203|NCT05038852|DEVICE|smartphone applications|app is designed to help you learn relaxation skills.
224144204|NCT05038852|DEVICE|smartphone applications|app is designed to help you increase your positive feelings, behaviors, and thoughts.
224144205|NCT04300790|DRUG|Alpelisib|Alpelisib (BYL719): starting dose at 300 mg/QD.; 2 tablets once a day, oral administration, continuously during 28-day cycles until disease progression or unacceptable toxicity.
223566679|NCT04199975|DEVICE|Orthoses|Power-Driven or Mechanical Orthoses
223566680|NCT04094259|BEHAVIORAL|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
223566681|NCT05026840|PROCEDURE|GDM screening criteria|difference in risk factors and clinical outcomes between groups
224051047|NCT02088814|BEHAVIORAL|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
223566682|NCT00050531|DRUG|Gleevec|400 mg orally twice daily.
223566683|NCT00050531|DRUG|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
224051048|NCT05841030|OTHER|No Intervention|There is no interventional treatment administered to the participants as a part of this study.
224051049|NCT06455592|BEHAVIORAL|practice adapted physical activity|practice daily adapted physical activity during 4 days
224051050|NCT06455592|OTHER|control arm|practice once adapted physical activity during 4 days
224051051|NCT00689702|DRUG|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
224051052|NCT00192387|BIOLOGICAL|CAIV-T, Liquid|
224051053|NCT03319407|DEVICE|EPAD monitoring system|EPAD system will be used as part of routine care
224051054|NCT04092296|OTHER|resin infiltration|using infiltrant resin intervene proximal caries
224051055|NCT04092296|OTHER|remineralization|using fluoride to remineralize proximal caries
224051056|NCT04092296|OTHER|sham|replace resin with water
224051057|NCT03073668|PROCEDURE|Anterior pericardiotomy|The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
224051058|NCT03073668|DRUG|Saline|During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
224144206|NCT04300790|DRUG|Metformin|500 mg BID with breakfast and dinner. After 3 days, if no (GI) intolerance, increase to 1000 mg BID with breakfast and dinner. If not tolerated, reduce to prior tolerated dose. Titrate to 1000mg BID over a period of at least 4 additional days
224144207|NCT04300790|DRUG|Fulvestrant|"fulvestrant (500 mg IM injections; loading dose 500mg every two weeks for the first month; then every 4 weeks as per standard of care \[SoC\].~Patients should be started on metformin and fulvestrant within 7 to 14 days prior to start on alpelisib (D1C1)"
224144208|NCT04300790|DRUG|Letrozole|Letrozole 2.5 mg tablets, once daily, orally
224144209|NCT04300790|DRUG|Exemestane|Exemestane 25 mg tablets, once daily, orally
224144210|NCT04300790|DRUG|Vildagliptin|Vildagliptin 50 mg tablets, twice daily, orally with breakfast and dinner
224144211|NCT04300790|DRUG|Tamoxifen|Tamoxifen 20 mg tablets, once daily, orally
224144212|NCT03776162|PROCEDURE|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
224144213|NCT03776162|DEVICE|Bridge Enhanced ACL Restoration (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR implant) between the torn ends of the ACL, providing a sponge for the ligament ends to group into.
224144214|NCT02269150|BIOLOGICAL|fecal microbiota transplantation (FMT)|
224144215|NCT02269150|OTHER|No fecal microbiota transplantation (FMT), routine management|
223439841|NCT03627377|BEHAVIORAL|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
223439842|NCT04398654|DEVICE|CardioMEMSTM HF sensor - pulmonary artery pressure measurement|CardioMEMSTM HF sensor implantation to meassure pulmonary artery pressure. Evaluation of the pressure curves by telemetric transmission and coordination of necessary adjustments of the therapy.
223439843|NCT04590677|OTHER|Samples required from group 1 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs~* Daily Heart rate monitoring (only applicable to a subset of women in group 1)"
223439844|NCT04590677|OTHER|Samples required from group 2 (procedure within observational study)|"* Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs"
223439845|NCT02631460|DRUG|S1 80-120 mg/d|d1, every 3 weeks
223439846|NCT02631460|DRUG|pemetrexed 500 mg/m2|d1, every 3 weeks
224051059|NCT04601623|OTHER|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
224051060|NCT04244526|OTHER|Talking a urine sample|Just taking a urine sample
224051061|NCT02342496|DIETARY_SUPPLEMENT|Placebo|Powder
224051062|NCT02342496|DIETARY_SUPPLEMENT|Active, only probiotics|Powder
223439847|NCT02631460|DRUG|carboplatin AUC=5|d1, every 3 weeks
223439848|NCT05418894|DEVICE|Device: Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
223439849|NCT04323267|DEVICE|Limber Digital Application|A mobile application was recently developed to address these needs. The application provides evidence-based, symptom specific home-exercise video programs for MSK conditions, as well as clinically-validated outcome measures for tracking progress.
223439850|NCT04323267|BEHAVIORAL|Physical therapy Therapy|Therapy prescription 2 x a week for 8 weeks (specified by physician)
223439851|NCT03379844|DEVICE|Holmium-166 radioembolization|An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
223439852|NCT01759316|OTHER|heliox|heliox or oxygen is used in the two groups respectively
223439853|NCT01228110|DRUG|Hydrocortison|
223439854|NCT01228110|DRUG|Saline Solution|
223439855|NCT00256321|DRUG|Oxaliplatin|Oxaliplatin 70mg/m2 IV on Days 1 and 8
223439856|NCT00256321|DRUG|Capecitabine|Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
224051063|NCT02342496|DIETARY_SUPPLEMENT|Active, blend of berries and probiotics|Powder
224051064|NCT02617186|PROCEDURE|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
224051065|NCT02617186|PROCEDURE|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
224051066|NCT02177396|DRUG|Telmisartan|
224051067|NCT02177396|DRUG|Valsartan|
224051068|NCT02177396|DRUG|Placebo|
223439857|NCT00256321|DRUG|Celecoxib|Celecoxib 400mg PO BID from Days 1 through 21.
223439858|NCT00574210|DRUG|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
223439859|NCT00574210|DRUG|Placebo|Placebo Tablets administered twice per day
223439860|NCT04505384|PROCEDURE|left bundle branch pacing|left bundle branch pacing
223439861|NCT04505384|PROCEDURE|biventricular pacing|biventricular pacing
223439862|NCT02521532|DIETARY_SUPPLEMENT|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
223439863|NCT02521532|DIETARY_SUPPLEMENT|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
223439864|NCT00526903|BEHAVIORAL|Elimination Diet|Daily diet change for 8 days.
223439865|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
223439866|NCT00692107|RADIATION|Gray|68 Gy vs. 78 Gy
223439867|NCT06394856|PROCEDURE|Rotator Cuff Repair With a Modified Versus Classic Double-Row Suture -Bridge Techniques|rotator cuff tears with modified versus classic double row suture bridge
223439868|NCT04613193|OTHER|Blood presssure reduction|Patients will be uptitrated in antihypertensive treatment until the treatment target is achieved.
223439869|NCT05541978|OTHER|Multiple myeloma|We will explore the multiple myeloma associated thrombosis risk.
223439870|NCT02599597|BEHAVIORAL|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
223566684|NCT00050531|DRUG|Sargramostim (GM-CSF)|125 mcg/m\^2 three times per week subcutaneously.
224051069|NCT05921734|PROCEDURE|AF-termination Group|Each center completes the ablation according to the above ablation procedure. The choice of ablation strategy is not restricted, but efforts should be made to achieve termination of AF during the ablation procedure. If cannot terminate AF for safety or other reasons involving difficulties to remap AFEGM or creating a complete conduction block despite the operator's best efforts, then direct current conversion (DCCV) was performed.
224051070|NCT05921734|PROCEDURE|Prespecified-ablation Group|Each center completes the prespecified ablation according to the above ablation procedure. Although there is no restriction on the choice of ablation strategy, Ablation must be performed following the PVI plus strategy, which can be combined with one or more additional ablation procedures, but each ablation must achieve its own endpoints, such as bidirectional block of linear damage, posterior wall isolation, etc. After completing the preset ablation steps, DCCV will be performed. If AF is terminated after or during ablation, it is also considered the endpoint of ablation in this group, but the preset ablation steps must be completed.
224051071|NCT06584942|DRUG|Suvorexant|Subjects will titrate up to 20 mg of suvorexant daily. Subjects will follow a titration schedule with 10 mg once daily on days 1-3, 15 mg once daily on days 4-6, then 20 mg on day seven and for the remainder of the study. If participants report AEs (worsening depression/suicidal ideation, complex sleep behaviors, sleep paralysis, etc.) dose may be decreased to the previous dose taken. Participants will be treated for 14 days in total; however, due to scanner availability, the second scan may occur more than 14 days after the first scan. In this case, participants will be allowed to continue taking this dose for up to 14 additional days until the final scan occurs (28 days total).
224051072|NCT05257083|DRUG|Daratumumab|Daratumumab will be administered SC.
224051073|NCT05257083|DRUG|Bortezomib|Bortezomib will be administered SC.
224051074|NCT05257083|DRUG|Lenalidomide|Lenalidomide will be administered orally.
224051075|NCT05257083|DRUG|Dexamethasone|Dexamethasone will be administered orally.
224051076|NCT05257083|DRUG|Cilta-cel|Cilta-cel will be administered intravenously
224051077|NCT05257083|DRUG|Cyclophosphamide|Cyclophosphamide will be administered intravenously.
224051078|NCT05257083|DRUG|Fludarabine|Fludarabine will be administered intravenously.
224051079|NCT03794583|DRUG|Inhaled treprostinil solution|Inhaled treprostinil solution per dose and schedule specified in the arm
224051080|NCT00036439|DRUG|Infliximab|
224051081|NCT03685383|DEVICE|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
224051082|NCT03685383|DEVICE|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
224051083|NCT01345136|DRUG|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
224051084|NCT06108713|OTHER|Addition of juggling|Participants will not change ther daily activities, and participate in juggling intervention lasted 4 weeks and consisted of 12 meetings (3 trainings per week), each lasting 45 minutes.
224051085|NCT04457180|DRUG|Apatinib Mesylate|Apatinib will be administered daily from on D5 through D16
224051086|NCT04457180|DRUG|Repaglinide|Repaglinide will be administered daily on D1 and D12
224051087|NCT04457180|DRUG|Bupropion|Bupropion will be administered daily on D2 and D13
224051088|NCT01440868|PROCEDURE|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher \& Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm ).
224051089|NCT00768326|DRUG|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
224144216|NCT04920136|PROCEDURE|Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)|A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
224144217|NCT04920136|PROCEDURE|Free Gingival graft|Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
224144218|NCT04175301|DRUG|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
224144219|NCT04175301|DRUG|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
224144220|NCT06356155|DRUG|Enfortumab vedotin|1.25 mg/kg IV
224051090|NCT00768326|DRUG|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
224051091|NCT00768326|DRUG|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
224051092|NCT00768326|DRUG|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
224051093|NCT00768326|DRUG|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
224051094|NCT00768326|DRUG|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
224051095|NCT05568108|PROCEDURE|masseteric nerve to central branch facial nerve|masseteric nerve to central branch facial nerve. (Early fibrillation on EMG)
224051096|NCT05568108|PROCEDURE|Masseteric nerve to free functioning muscle transfer|Masseteric nerve to free functioning muscle transfer. (Late no fibrillation on EMG)
224051097|NCT03936621|DRUG|Omega 3 fatty acid|To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
224144221|NCT06356155|DRUG|Pembrolizumab|200 mg IV
223439871|NCT02599597|BEHAVIORAL|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
223439872|NCT00932698|DRUG|Ixazomib|Ixazomib capsules
223439873|NCT00655681|DRUG|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children \< 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
223439874|NCT00655681|OTHER|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
223439875|NCT05822362|DRUG|Cannabidiol|The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
223439876|NCT05822362|OTHER|Placebo|Placebo arm.
223439877|NCT02594774|OTHER|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
223439878|NCT03604770|OTHER|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
223439879|NCT01519297|DRUG|Irbesartan|150mg orally for one dose
223439880|NCT04805697|DIETARY_SUPPLEMENT|placebo group|subjects drank 50 ml , 1 bottle a day for 8 week
223439881|NCT04805697|DIETARY_SUPPLEMENT|fermented grape drinks|subjects drank 50 ml , 1 bottle a day for 8 week
224051098|NCT03052556|PROCEDURE|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~* In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~* In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
224051099|NCT00003895|BIOLOGICAL|HPV 16 E7:12-20|Given SC
224051100|NCT00003895|BIOLOGICAL|gp100:209-217(210M)|Given SC
223439882|NCT06619665|DRUG|MK-6552|MK-6552 gelatin coated capsules taken orally two times 8 hours apart
223439883|NCT06619665|DRUG|MK-6552 placebo|MK-6552 placebo gelatin coated capsules taken orally two times 8 hours apart
223439884|NCT06619665|DRUG|Modafinil|Modafinil tablet taken once orally
223439885|NCT06619665|DRUG|Modafinil placebo|Modafinil placebo tablet taken once orally
223439886|NCT03034473|OTHER|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor \& mucosa) are taken pretherapeutically. Blood samples (serum \& plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma \& serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen \[(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75\]."
223439887|NCT06620874|BIOLOGICAL|STABHA Injection|Participants will receive two ultrasound-guided STABHA injections into the medial collateral ligament of the knee at a 2-week interval
223439888|NCT06620874|OTHER|High-Concentration Glucose Water Injection|Participants will receive two ultrasound-guided high-concentration glucose water injections into the medial collateral ligament of the knee at a 2-week interval
223439889|NCT06620874|OTHER|Saline Injection|Participants will receive two ultrasound-guided saline injections into the medial collateral ligament of the knee at a 2-week interval
223439890|NCT06648330|PROCEDURE|Paraaortic retroperitoneal lymph node dissection|The relationship between lactate level and mesenteric ischaemia in gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection will be evaluated.
223439891|NCT00560586|DRUG|Budesonide|1 puff each nostril (32 micrograms) at bedtime
223439892|NCT00560586|DRUG|placebo|1 puff each nostril at bedtime
223439893|NCT03486002|DEVICE|Cleansweep|The Cleansweep closed suction system
223439894|NCT03486002|DEVICE|Halyard|Halyard Closed Suction System
224051101|NCT00003895|OTHER|laboratory biomarker analysis|Correlative studies
224051102|NCT00415857|BIOLOGICAL|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
224051103|NCT00415857|DRUG|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
224051104|NCT00415857|DRUG|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
224051105|NCT00415857|DRUG|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
224051106|NCT03182647|PROCEDURE|Surgically treatment of the ACL|Surgical initial ACL treatment
224051107|NCT03182647|OTHER|Non surgical initial ACL treatment|Non surgical initial ACL treatment
223439895|NCT02429310|DEVICE|Revitive IX|This is a neuromuscular electrical stimulation device
223439896|NCT05561946|DEVICE|Owlet OSS 3.0|The Owlet OSS 3.0 is worn continuously for a minimum of 48 hours and the skin where the device is worn is monitored for any skin injury/irritation
223439897|NCT03240523|DRUG|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
223439898|NCT00394433|DRUG|Bevacizumab|
223439899|NCT00394433|DRUG|Docetaxel|
223439900|NCT00394433|DRUG|Cisplatin|
223439901|NCT00394433|DRUG|Irinotecan|
224144222|NCT03421574|DEVICE|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
224144223|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol will be taken sublingually, 1 mg BID for 8 weeks
224144224|NCT05387577|DRUG|Transdermal patch|Estradiol patch therapy for 8 weeks
224144225|NCT05387577|DRUG|Estradiol Tablets|Oral estradiol 1 mg BID for 8 weeks
224144226|NCT01705548|RADIATION|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
224300376|NCT04787393|DEVICE|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records if they wish to do so.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link.~The data from the scales will be reviewed retrospectively, as the comparison in this study is with standard care, not with enhanced provision of care, which would be the case if we were using automatic reporting of weights."
224051108|NCT06132165|DRUG|Deoxycholic Acid|Injection into the cutaneous Neurofibromas lesion.
224051109|NCT06132165|DRUG|Polidocanol|Injection into the cutaneous Neurofibromas lesion.
224051110|NCT06132165|DEVICE|1064nm Nd:YAG laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion.
224051111|NCT06132165|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion
224051112|NCT04897022|DRUG|Pembrolizumab|Fixed dose of pembrolizumab 200mg IV q3 weeks
224051113|NCT04897022|RADIATION|IMPRINT|The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
224051114|NCT00806195|BIOLOGICAL|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
224051115|NCT00806195|BIOLOGICAL|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
224051116|NCT00806195|BIOLOGICAL|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
224051117|NCT00806195|BIOLOGICAL|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
224051118|NCT00806195|BIOLOGICAL|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
224051119|NCT00806195|BIOLOGICAL|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
224051120|NCT00806195|BIOLOGICAL|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
224051121|NCT00806195|BIOLOGICAL|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
224051122|NCT04192851|PROCEDURE|Tent Pole Technique|"* All patients were operated under local or general anaesthesia according to the case and patient tolerability.~* The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution\* for thirty seconds.~* Full thickness incision down to the bone with blade no.15.~* A periosteal elevator was used to perform mucoperiosteal flap.~* Gentle elevation of the flap~* Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~* Bone graft was mixed with the patient blood and placed to cover the screws completely.~* PRF membrane was be placed over the grafted sites.~* Repositioning of the flap and suturing with 3/0 black silk suture material"
224051123|NCT02490475|DRUG|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
224051124|NCT02490475|DRUG|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
224051125|NCT02075489|OTHER|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for \~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for \~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
224144227|NCT02862548|DRUG|TAF|Tablet administered orally
224144228|NCT02862548|DRUG|TDF|Tablet administered orally
224144229|NCT02862548|DRUG|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
224144230|NCT00880763|DRUG|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
224144231|NCT00880763|DRUG|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
224144232|NCT00880763|DRUG|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
224144233|NCT00880763|DRUG|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
223439902|NCT01554176|DRUG|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
223439903|NCT01554176|DRUG|Placebo|Placebo, one tablet, orally, once daily at bedtime
224051126|NCT02075489|OTHER|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
224051127|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
224144234|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
224144235|NCT05716815|DIAGNOSTIC_TEST|CT scans 2D plus 3D Reconstruction|Before performing the surgery, patient performs a chest CT scan with contrast medium and standard two-dimensional (2D) reconstructions plus a 3D reconstruction are performed to study the lesion, the anatomy of the bronchi and the pulmonary venous and arterial vessels.
224144236|NCT03865511|DRUG|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
223439904|NCT04777669|OTHER|Noise Reduction|In within subject design, listeners will have background noise removed by a noise reduction algorithm
223439905|NCT00503451|DRUG|LBH589|
223439906|NCT01090154|DRUG|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
223439907|NCT03094676|OTHER|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
223439908|NCT03094676|OTHER|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
223439909|NCT00386425|DRUG|Drotrecogin alfa (activated)|intravenous
223439910|NCT03330067|DEVICE|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
223439911|NCT03330067|DEVICE|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
224051128|NCT00139776|DRUG|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
224051129|NCT05316532|DEVICE|Prismalung + treatment|Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy
224144237|NCT03865511|GENETIC|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~1. Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~   * C797S testing (digital PCR)~  * MET amplification (dPCR/FISH)~  * Histological examination of the tissue sample (to identify small cell transformation)~  * Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~2. At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
223439912|NCT06354790|OTHER|Motor evaluations|Evaluation of patients motor function using motor scales (MFM32, RULM), Timed functioned tests (6MWT, Rise from floor, 4SCT, 10mWT), dynamometric strength evaluation (grip, pinch, flexion/extension)
223439913|NCT06354790|OTHER|Cognitive assessment|Patients cognitive evaluation (WPPSI-IV, WISC-V)
223439914|NCT06354790|OTHER|Pulmonary function test|Evaluation of patients' respiratory function (FVC, PCF, MIP, MEP, SNIP)
223439915|NCT06354790|OTHER|Cardiac evaluation|Evaluation of patients' cardiac function (ECG, Echo-cardiography)
223439916|NCT06354790|OTHER|Quality of life|Evaluation of patients quality of life with questionnaires and PROM
223439917|NCT06354790|OTHER|Spine X Ray|Evaluation of spinal deformities by X-ray
223439918|NCT06354790|OTHER|Muscular MRI|Evaluation of a qualitative whole-body muscle part and a quantitative lower limb muscle part by MRI
223566685|NCT02521233|DRUG|Candesartan + Chlorthalidone (8mg+12,5mg)|
223566686|NCT02521233|DRUG|Candesartan + Chlorthalidone (8 mg + 25 mg)|
223566687|NCT02521233|DRUG|losartan+hydrochlorothiazide|
223566688|NCT02684877|OTHER|Questionnaire|
223566689|NCT03447899|BEHAVIORAL|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
223566690|NCT06651385|OTHER|Remote digital therapeutic exercise program|Participants will be introduced to the digital therapeutic exercise program during Screening and Consent (Visit 0, V0). Participants will be provided with an orientation to the Vitala platform and assistance will be offered in the download and access to the application, as needed. The study team will ensure access has been obtained via the health care professionals' dashboard on the Vitala app. Information obtained in the assessments outlined above will inform the tailored exercise prescription to meet the participant's needs. Participants will be encouraged to complete a total of 150 minutes of remote exercise sessions each week for 12 weeks via the Vitala platform. Participants will receive daily notifications to remind them to complete their assigned daily exercises.
223566691|NCT06658379|DIAGNOSTIC_TEST|CD8+TEMRA|
223566692|NCT06658990|PROCEDURE|buccal acupuncture|ultrasound positioning assisted buccal acupuncture
223439919|NCT06354790|OTHER|Biomarkers collection and analysis|Collection of blood and urinary sample for biomarkers research.
223439920|NCT00657306|DRUG|hydrocortisone|50 mg/6 h per day
224051130|NCT02953353|DEVICE|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
224051131|NCT02953353|OTHER|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
224051132|NCT02953353|OTHER|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
224051133|NCT02994277|DEVICE|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
224051134|NCT06228820|DRUG|Aspirin 81Mg Ec Tab|Healthy patients will then undergo at least a 2-week course of 81mg of Bayer Aspirin per oral daily, followed by platelet function testing. The patients will then undergo a washout period of 2 weeks, followed by another 2-week course of 81mg Vazalore Aspirin per oral daily, followed by a second round of platelet function testing.
224051135|NCT06650462|BEHAVIORAL|Community-led discussion|Participants engage in weekly community-led small group discussions about health related topics
224051136|NCT02825004|BEHAVIORAL|Psychological Intervention|
224051137|NCT04024150|BIOLOGICAL|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
224051138|NCT01288222|OTHER|KIR genotype|KIR genotype data from unrelated donor are collected
224051139|NCT03399981|BIOLOGICAL|Tysabri|Administered as specified in the treatment arm.
224051140|NCT04697810|DRUG|Namodenoson|25 mg q12hours x 36 weeks
224051141|NCT04697810|DRUG|Placebo|Matching capsules q12hours x 36 weeks
224051142|NCT04375579|OTHER|Comprehensive geriatric assessment (CGA)|Questionnaires on nutritional status, autonomy and quality of life
224051143|NCT00674583|BIOLOGICAL|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
224051144|NCT00674583|BIOLOGICAL|Menjugate|Intramuscular administration, 1 dose
224051145|NCT05563519|PROCEDURE|I-PRF with collagen|The products will be applied to the sockets after tooth extractions
224051146|NCT05563519|PROCEDURE|L-PRF|The products will be applied to the sockets after tooth extractions
224051147|NCT06145399|DIAGNOSTIC_TEST|18F-FDG PET/CT|Standard-of-care 18F-FDG PET/CT will be performed using one of the commercially available GE PET/CT scanners
224051148|NCT06145399|DIAGNOSTIC_TEST|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
224144238|NCT03865511|GENETIC|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~* Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~* Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~* Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~* Kinetics studies of the alterations"
224144239|NCT02849249|BIOLOGICAL|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
224051149|NCT06145399|DRUG|18F-FDHT|18F- FDHT PET/MRI examinations will be performed to evaluate the association between 18F-FDHT uptake and AR expression levels as determined by immunohistochemistry (IHC) in selected lesions.
224051150|NCT05784636|DEVICE|Non-invasive BiPAP ventilation|Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2\>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
224144240|NCT03678584|OTHER|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
224144241|NCT05307445|DEVICE|Photobiomodulation with Bioptron Hyperlight Therapy|The Bioptron® Device provides polarized visible polychromatic noncoherent light with 90 W; light wavelength = 480-3400 nm; degree of polarization = 95%; specific power = 40 mW/cm2; energy density = 2.4 J/cm2. The duration of each treatment session was 10 min. Bioptron light was positioned 10 cm from the oral mucosa and a mouth opener was positioned for the entire duration of the session. Two weekly sessions during the first 4 weeks of treatment were applied.
223439921|NCT00657306|DRUG|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
223439922|NCT03305900|OTHER|No Intervention|Cross-sectional study requiring a single serum sample
223439923|NCT01582659|OTHER|Telephone counseling|2 planned telephone counseling sessions are conducted.
223439924|NCT01582659|OTHER|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
223439925|NCT04412837|DRUG|Topical CBD Patch|35 mg CBD patch
224051151|NCT05784636|DEVICE|HFNC|On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
224051152|NCT04912245|BEHAVIORAL|Telehealth visit|Patients with either MCI or unrecognized dementia and their care partners (if available) will be approached to participate in a telehealth Advance Care Planning (ACP) visit with a member of the patient's primary care team via either telephone or video. Patients without willing or available care partners are still eligible to participate in the study.
224051153|NCT02751593|DRUG|Dexamethasone|dexamethasone 40mg/d for 4 days
224051154|NCT04675164|DEVICE|Laser Assisted Immotile Sperm Selection|LAISS will be performed using diode laser system at the lowest working power with a single laser shot at the lower one third of the sperm tail. If sperm tail curling occurred, the sperm is then viable and will be utilized for ICSI after immobilization in PVP.
224051155|NCT04675164|PROCEDURE|Hypo-osmotic Swelling Test|HOST will be performed by transferring immotile sperms from incubation droplet into HOST droplet, with any sperm showing tail swelling will be identified as viable and will be utilized for ICSI after immediate transfer and immobilization.
224051156|NCT06506812|BIOLOGICAL|High-Dose Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
224051157|NCT06506812|BIOLOGICAL|Standard-Dose Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the governmental influenza vaccine programs may be used.
224051158|NCT05198726|DEVICE|alpha tACS|2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)
224051159|NCT05198726|BEHAVIORAL|Speed of Processing Training|SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)
224051160|NCT03520543|DRUG|[11C]Yohimbine|Each subject will receive an intravenous (IV) bolus injection of \[11C\]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of \[11C\]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of \[11C\]Yohimbine.
224051161|NCT03520543|DRUG|[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)|"Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following \[11C\]Yohimbine PET scan (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after \[11C\]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of \[11C\]Yohimbine (IV bolus injection of \[11C\]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of \[11C\]Yohimbine obtained at baseline (part A)."
224144242|NCT05203627|OTHER|Best Practice|Receive standard nutritional support
224144243|NCT05203627|OTHER|Questionnaire Administration|Ancillary studies
224144244|NCT05203627|OTHER|Telemedicine Visit|Receive telehealth sessions
224144245|NCT01223326|DRUG|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
224144246|NCT01223326|DRUG|Saline|Na Cl 0.9% infusion
224144247|NCT00966069|OTHER|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
224144248|NCT00966069|OTHER|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
224144249|NCT06315244|PROCEDURE|US Guided Perineural Injection and Neuroprolotherapy|Participants will receive an ultrasound-guided injection of a solution into the sacrotuberous ligament and the sensory innervation area of the perforating cutaneous nerve.
224144250|NCT03620435|DRUG|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
224144251|NCT04868136|BEHAVIORAL|Exercise|30 minutes of exercise at 80% of maximum predicted heart rate performed on an indoor stationary bicycle. Exercise was preceded by 10 min of gradually increasing cycling intensity in one of two exercise trials
224144252|NCT05561712|OTHER|Laboratory method validation|Test several sampling conditions
224144253|NCT03524911|BEHAVIORAL|CHFFF nutrition education|
224300377|NCT06110728|BEHAVIORAL|Habit Change|Participants assigned to the Habit Change arm will be asked to track behaviors related to their specific goals on a daily basis through the app and will be allowed to engage with the app freely. Goals can include things like reaching a step goal, sleeping for a certain number of hours, or making healthy food choices.
224300378|NCT00760565|DRUG|RO4905417|3mg/kg iv every 28 days for 3 infusions
224300379|NCT00760565|DRUG|RO4905417|20mg/kg iv every 28 days for 3 infusions
224300380|NCT00760565|DRUG|RO4905417|7mg/kg iv every 28 days for 3 infusions
223439926|NCT04412837|OTHER|Placebo Patch|Identical patch without active ingredient.
223439927|NCT04303754|OTHER|Diabetes-Specific Formula|Other: Diabetes Specific Formula
223439928|NCT04303754|OTHER|Bread with Spread|Other: White Bread with Spread
223439929|NCT04303754|OTHER|Rice Porridge|Other: Rice Porridge
223439930|NCT04447677|OTHER||
223439931|NCT02535351|DRUG|sunitinib or pazopanib|First-line treatment
223439932|NCT02535351|PROCEDURE|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
223439933|NCT03897933|PROCEDURE|Erector Spinae Plane block ( Group I)|ESP Block was performed preoperative to all patients in ESP block group. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
223566693|NCT06658990|DRUG|control|Sufentanil is used after surgery
223439934|NCT03897933|PROCEDURE|non- blocked Group (GROUP II)|This group was received no intervetion. Patients in all groups were provided with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
224051162|NCT01512836|BEHAVIORAL|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~* Formulation and implementation of care plans together with the patient~* Monitoring of individual status and care plan effectuation~* Overall coordination between health care providers~* Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~* Regular telephone consultations and home visits~* Promote disease-self management through coaching"
224051163|NCT02240979|DEVICE|cardiac MRI|cardiac MRI
223439935|NCT02268747|DRUG|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade \<2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade \>2, then the patient will interrupt the treatment following the criteria for dose reduction."
223439936|NCT03053427|DRUG|Placebo|Oral administration
223439937|NCT03053427|DRUG|Gabapentin enacarbil|Oral administration
223439938|NCT00407927|DRUG|Epinastine Nasal Spray|
223439939|NCT03984227|GENETIC|Taking peripheral blood samples|quantitative real-time polymerase chain reaction
223439940|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
223439941|NCT02334176|PROCEDURE|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
223439942|NCT02334176|DRUG|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
223439943|NCT02604173|DRUG|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
223439944|NCT02604173|DRUG|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
223439945|NCT02604173|DRUG|Placebo|Placebo pill and sham inhaler
223439946|NCT01803776|BEHAVIORAL|lifestyle counseling|The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
223439947|NCT04205344|DRUG|Bupivacaine 5 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
223439948|NCT04205344|DRUG|Bupivacaine 10 mg|Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
223439949|NCT06061172|OTHER|gp-multitool.de|"The intervention is based on a digital tool, which implements recommendations of the S3 guideline multimorbidity of the German College of General Practitioners and Family Physicians. The tool includes nine questionnaires addressing four dimensions of care:~1. preferences (including a. treatment goals, and b. involvement of other persons in decision making);~2. activities (including a. activities and participation, and b. social support);~3. treatment (including a. problems with medication, and b. treatment burden);~4. complaints (including a. pain, b. psychiatric disorders, and c. other complaints).~The GPs can send the questionnaires by email to the patients and the patients can fill out the questionnaires at their home or in the waiting room of the GP's practice using their own smartphones, tablets or computers. The digital tool also includes instructions for conducting a medication review. Results from talks between GPs and patients can be documented in the tool."
223566694|NCT06658444|OTHER|Phonophoresis|Pulsed ultrasound will be used at a frequency of 1 MHz with an intensity of 0.5 W/ cm2 for 5 minutes.
223439950|NCT00365001|DRUG|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
223439951|NCT00365001|DRUG|Methotrexate|10-25mg po/week
223566695|NCT06658444|OTHER|sham ultrasound|sham ultrasound
223566696|NCT06660251|OTHER|Egg intervention|Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
223566697|NCT06660251|OTHER|Meatball intervention|Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
223566698|NCT06660017|DRUG|Placebo|Patients in this arm will receive unmedicated syrup solution dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
223566699|NCT06660017|DRUG|Ketamine Topical|Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
223566700|NCT06659406|DIETARY_SUPPLEMENT|Coenzyme Q10|Coenzyme Q10 will be given once daily, 200mg for the period of 3 months
224051164|NCT05150600|PROCEDURE|Inverse Ratio Ventilation|The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
224051165|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
224051166|NCT01119742|DRUG|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
224051167|NCT01119742|DRUG|Butenafine Hydrochloride 1%|Twice daily application for 7 days
224051168|NCT01119742|DRUG|Vehicle A|Twice daily application for 7 days
224051169|NCT01119742|DRUG|Vehicle B|Twice daily application for 7 days
224300381|NCT00760565|DRUG|placebo|3mg/kg iv every 28 days for 3 infusions
223439952|NCT00365001|DRUG|Simvastatin|40mg po on days 1, 15 and 43
223439953|NCT02172040|DRUG|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
223439954|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
223439955|NCT02172040|DRUG|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
223439956|NCT02172040|DRUG|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
223439957|NCT03816644|OTHER|5-Cog|The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
223439958|NCT03816644|OTHER|Health Literacy & Grip Assessment|The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
223439959|NCT03112668|BEHAVIORAL|Cognitive Behavior Therapy|Undergo ACT
223439960|NCT03112668|OTHER|Quality-of-Life Assessment|Ancillary studies
223439961|NCT03112668|OTHER|Questionnaire Administration|Ancillary studies
223439962|NCT03112668|OTHER|Survey Administration|Ancillary studies
223439963|NCT01801241|DEVICE|Anatomic TSA using IRI Instrumentation|Anatomic Total Shoulder Arthroplasty (TSA) will be performed using the SmartBone and Intelligent Reusable Instrument (IRI) to transfer the pre-operative plan for glenoid implant positioning to the patient's anatomy.
224051170|NCT06537440|OTHER|Electroacupuncture|Electroacupuncture TE6 Zhigou (double), ST36 Zusanli (double), ST25 Tianshu (double), CV12 Zhongwan
224051171|NCT00428909|DRUG|Imatinib/Acetaminophen|
224051172|NCT02752035|DRUG|gilteritinib|Tablet, oral
224051173|NCT02752035|DRUG|azacitidine|Subcutaneous injection or intravenous infusion
223439964|NCT01801241|PROCEDURE|Anatomic Total Shoulder Arthroplasty|Anatomic Total Shoulder Arthroplasty will be performed by the two surgeons of the study as their Standard of Care. All procedures associated with the surgery will be the same in the two arms, with the exception of the tools used to place the guide pin for placement of the glenoid implant.
223439965|NCT03903003|DEVICE|high flow nasal oxygen device (POİNT)|With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.
223439966|NCT03903003|DEVICE|Face mask|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
223439967|NCT05215379|DRUG|xintilimab injection|neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle
223439968|NCT05215379|OTHER|Control|neoadjuvant chemoradiation therapy
223439969|NCT00756600|DRUG|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
224051174|NCT02849470|PROCEDURE|Intradermal Injection in hair loss|Comparative Injection of Control (PRP \& Acel) in hair loss; 2) Intradermal Injection in hair loss
223439970|NCT00756600|DRUG|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
223439971|NCT01324570|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
223439972|NCT03240406|OTHER|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
223439973|NCT03240406|OTHER|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
223439974|NCT02607306|DRUG|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
223439975|NCT02607306|DRUG|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
223439976|NCT02607306|DRUG|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
223439977|NCT02061449|DRUG|Romidepsin|
223439978|NCT02061449|DRUG|Poly ICLC|
223439979|NCT02061449|RADIATION|Focal lesional radiation|
223439980|NCT00792506|DRUG|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to anticipated end of treatment (week 18). The patients had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
223439981|NCT03026933|DRUG|KI1107 4 Capsules, QD|KI1107 4 Capsules
223439982|NCT03026933|DRUG|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
224051175|NCT02849470|PROCEDURE|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
224051176|NCT02849470|PROCEDURE|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
224051177|NCT02849470|PROCEDURE|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
224051178|NCT02849470|PROCEDURE|MatriStem Matrix (ACell) - Current Standard of Care|
224051179|NCT02849470|PROCEDURE|HD-PRP (High Density Platelet Rich Plasma)|
224051180|NCT02849470|PROCEDURE|Emulsified AD-tSVF|
224051181|NCT02849470|PROCEDURE|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
224051182|NCT05160584|OTHER|No intervention|There is no interventional treatment component for participants with RRMM in this study.
224051183|NCT03869281|PROCEDURE|Pancreas transplantation alone|Pancreas transplantation
224051184|NCT04769050|DRUG|Docetaxel combined with Trastuzumab±Pertuzumab|Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
224300382|NCT00760565|DRUG|placebo|7mg/kg iv every 28 days for 3 infusions
224300383|NCT00760565|DRUG|placebo|20mg/kg iv every 28 days for 3 infusions
224051185|NCT04769050|DRUG|T-DM1 or Capecitabine combined with Pyrotinib regimen.|T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
224051186|NCT00357214|DIETARY_SUPPLEMENT|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
224051187|NCT00357214|DIETARY_SUPPLEMENT|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
224051188|NCT00357214|DIETARY_SUPPLEMENT|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
224051189|NCT00357214|DIETARY_SUPPLEMENT|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
224051190|NCT06461767|DEVICE|transcranial magnetic stimulation device|"Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30"
224051191|NCT06820853|DEVICE|Diaphragmatic excursion evaluation|They will receive 10 ml of 0.5% bupivacaine over 10 minutes
224051192|NCT00544050|DRUG|Levetiracetam|
224051193|NCT01009827|OTHER|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
224051194|NCT04062019|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
224051195|NCT05648058|DRUG|Nefopam ampule|nefopam ampule 50 mg
224051196|NCT05648058|DRUG|diphenhydramine ampule|diphenhydramine ampule 10 mg
224051197|NCT06465251|DEVICE|Home-based CIMT|Participants and their families will be required to attend clinic to practice 3 times (Monday, Wednesday and Friday) during the first week, 2 times (Monday and Friday) during the second week and once (Monday) during the 3rd week under the supervision of a trained research assistant. They will be allowed to practice exclusively at home during the 4th week under the supervision of their family members.
224051198|NCT06465251|DEVICE|Clinic-based CIMT|Participants in both groups will perform 5 tasks with the affected upper limb, each 100 times, making it 500 repetitions in total within a duration of 2 hours every day, five days a week for 4 weeks at home and in the clinic respectively. Details of the tasks to be performed are presented in table 1. We chose 2 hours because, patients with stroke can perform about 300 repetitions of tasks practice within one hour. Similarly, we chose 500 repetitions because the number of repetitions of tasks practice required for motor recovery ranges between 300 and 600 repetitions per day
224051199|NCT06465251|DEVICE|Control|Participants will attend 45 minutes health talk provided by a research assistant twice in a week (Mondays and Fridays) in the clinic for 4 weeks. They will receive each talk in either a group of 3 or 5 patients. Similar control intervention was used in previous study
224051200|NCT02509182|DRUG|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
224051201|NCT02509182|DRUG|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
224051202|NCT00897806|GENETIC|Microarray analysis|
224051203|NCT00897806|OTHER|Laboratory biomarker analysis|
224051204|NCT05606250|OTHER|Ultrasound-Guided Percutaneous Neuromodulation|Ultrasound guided percutaneous neuromodulation in femoral nerve. Patients were placed in supine lying with the anterior aspect of the hip uncovered. The intervention consisted of the application of a biphasic square wave electric current, with a frequency of 2 Hz, a phase duration of 250μs, and a maximum tolerable intensity to cause an exacerbated muscle contraction for 15minutes in total
224051205|NCT05919654|DEVICE|MyoCare|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
224051206|NCT05919654|DEVICE|ClearView|Children assigned to the study group will wear ZEISS MyoCare lenses, while those assigned to the control group will wear conventional ZEISS ClearView single-vision lenses in their spectacles. Both lenses will be made of the same material (MR8) and hard as well as anti-reflection coating (ZEISS DuraVision Platinum) and will have the same surface treatments.
224051207|NCT05788887|OTHER|Authentic Ladotyri Mytilinis PDO cheese|Branding PDO cheese from Mytilini, purchasing by E.Thimelis Dairy S.A.
224051208|NCT05788887|OTHER|Control|Branding Parmesan PDO cheese from Italy, supplied by LIDL Hellas
223566701|NCT06388148|DRUG|Medical management|Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.
224051209|NCT03175354|DRUG|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
224051210|NCT03175354|DRUG|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
224051211|NCT03801954|BEHAVIORAL|Educational Videos|15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
224051212|NCT01186120|DEVICE|Biolimus A9-eluting stent|drug-eluting stent
224051213|NCT01186120|DEVICE|Everolimus-eluting stent|drug-eluting stent
224051214|NCT02472041|DEVICE|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
224051215|NCT02472041|DEVICE|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
223584009|NCT06855641|PROCEDURE|opioid free anesthesia|In this group, patients will not receive any opioids intraoperatively
223439983|NCT06336278|DIAGNOSTIC_TEST|Pressure Algometer|Pressure algometer is used to detect pain pressure treshold.
223439984|NCT02811497|DRUG|Azacitidine|
223439985|NCT02811497|DRUG|Durvalumab|
223439986|NCT06622954|OTHER|Protein- and Calorie restriction|The intervention consists of 30% calorie and 70% protein restriction, based on their daily nutritional intake. The protein and calorie restriction will be given in the form of Scandishake from Nutricia. These are ready available and easy to tailor to the caloric and protein need of each individual study subject.
223439987|NCT02484300|DIETARY_SUPPLEMENT|Melatonin|
223439988|NCT02484300|OTHER|Placebo|
223439989|NCT03204487|DRUG|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp \& Dohme, Wien)
223439990|NCT04268940|DIAGNOSTIC_TEST|Thromboelastography|Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time \[PT\], anti-Xa, activated clotting time\[ACT\], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.
223439991|NCT02983916|PROCEDURE|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
223439992|NCT05362695|DRUG|IW-3300|A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
223439993|NCT05362695|DRUG|Placebo|A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
223439994|NCT00435019|DRUG|insulin detemir|s.c. injection, once or twice daily.
224051216|NCT04701385|DIAGNOSTIC_TEST|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) can undertake detailed characterisation of plaque morphology in patients with myocardial infarction at the time of percutaneous treatment. This allows plaque rupture, erosion and other mechanisms of myocardial infarction to be differentiated
223439995|NCT00435019|DRUG|insulin NPH|s.c. injection, once or twice daily.
224051217|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 200 mg"|"This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily."
223439996|NCT00435019|DRUG|insulin aspart|s.c. injection, at main meals.
223439997|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet|The preliminary data demonstrated that the Jing Si Herbal Tea Liquid Packet may improve gastrointestinal symptoms and anxiety in patients with Coronavirus disease 2019(COVID-19). Therefore,this study aims to investigate the impact of the Jing Si Herbal Tea Liquid Packet on psychophysical burden and metabolites of microbiota in patients with FD through a double-blind randomized manner.
223439998|NCT05668104|DIETARY_SUPPLEMENT|Jing Si Herbal Tea Liquid Packet Placebo|Compared with the improvement effect of Jing Si Herbal Tea Liquid Packet, to avoid participants thinking that the improvement is due to psychological effects.
223439999|NCT03660150|OTHER|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
223440000|NCT04470284|OTHER|Mobile Application|SMBP with mobile App based feed-back algorithm. The App based feed-back algorithm will remind the patients of taking drug to improve BP control and drug compliance.
223440001|NCT04470284|OTHER|Standard SMBP|Standard treatment (SMBP-alone)
224051218|NCT01687179|DRUG|"Sirolimus and Hydroxychloroquine 400 mg"|Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
224051219|NCT02677948|DRUG|Pacritinib|
224051220|NCT02677948|DRUG|Ibrutinib|
224051221|NCT00587002|PROCEDURE|IVUS|Intravascular ultrasound with virtual histology
224051222|NCT01429818|DRUG|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
224051223|NCT01429818|DRUG|Metformin|1000 mg tablets once daily for eight weeks
224051224|NCT03804736|BIOLOGICAL|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
224051225|NCT03804736|BIOLOGICAL|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
224051226|NCT06372938|DIAGNOSTIC_TEST|Ultrasound measurement|The diagnosis of FGR was made according to the following Delphi criteria . EFW \<3rd percentile or EFW \<10th percentile with Doppler evidence of placental dysfunction (Umbilical artery Doppler (UA) pulsatility index (PI) \>95th percentile, absence of umbilical artery end-diastolic flow (UAEDF), or reverse-UAEDF and/or cerebroplacental ratio (CPR) \<5th percentile).
224300384|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
224300385|NCT03127644|DRUG|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
224300386|NCT03127644|DRUG|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
224300387|NCT01182558|OTHER|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
223440002|NCT04104113|OTHER|Modified Xiang Bei Yang Rong Tang|Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
223440003|NCT04104113|OTHER|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
223440004|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
223440005|NCT02696954|DRUG|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
223566702|NCT06388148|PROCEDURE|Endovascular thrombectomy|Endovascular thrombectomy with stent-retriever, local aspiration, angioplasty, and/or stenting.
223440006|NCT02696954|DRUG|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
223440007|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
223440008|NCT02696954|DRUG|Primaquine|Primaquine on Day 0 Washout period: more than 1 week
224051227|NCT06372938|DIAGNOSTIC_TEST|Laboratory Tests and Inflammatory Markers|"The laboratory values were measured at the time of FGR diagnosis (between 32 and 37 weeks of pregnancy). After evaluation of hemoglobin (g/dl), leukocytes (103/μL), monocytes (103/μL), lymphocytes (103/μL), neutrophils (103/μL), platelets (103/μL) and albumin (g/dl), the inflammation values were calculated as follows: ;~* SII = Absolute platelet count (APC)\* Absolute neutrophil count (ANC) / Absolute lymphocyte count (ALC);~* SIRI = Absolute monocyte count (AMC) \* ANC/ ALC;~* NPAR = Proportion of neutrophils (in total leukocytes) (%) × 100/albumin (g/dL)."
224051228|NCT00659399|DRUG|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
224051229|NCT05242042|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
224051230|NCT05242042|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
224051231|NCT02200354|DRUG|pemetrexed with bevacizumab|
224051232|NCT06127927|DEVICE|Interventional Left Ventricular Assist System|Interventional left ventricular assist system for cardiogenic shock patients
224051233|NCT02902354|OTHER|Nifedipine for tocolysis|observational
224051234|NCT05794386|PROCEDURE|LVA-guided LA substrate modification|The LVA-guided additional LA ablation is included linear ablation or LVA zone border modification/isolation/ homogenization. The additional ablation strategies are finally selected at the physicians' discretion, considering LVA location and distribution.
224051235|NCT06482736|DEVICE|Extracorporeal Shockwave Therapy|Extracorporeal Shockwave Therapy could reduce the pain of myofascial pain syndrome by pain signal alteration, promoting angiogenesis and increasing perfusion in ischemic tissues induced by sensitization of nociceptors and muscle ischemia.
224051236|NCT01418807|PROCEDURE|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
224051237|NCT01418807|PROCEDURE|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
224051238|NCT04212455|OTHER|Non-interventional study|This is an observational, non-interventional study
224051239|NCT06849843|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa 3mg/0.5ml
224051240|NCT06849843|DRUG|Efsubaglutide Alfa Injection|Efsubaglutide Alfa 1mg/0.5ml
224051241|NCT01540253|DRUG|PI3K inhibitor BKM120|Given PO
224051242|NCT01540253|DRUG|docetaxel|Given IV
223440009|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
224051243|NCT01540253|OTHER|pharmacological study|Correlative studies
224051244|NCT01540253|OTHER|questionnaire administration|Ancillary studies
224051245|NCT01540253|OTHER|laboratory biomarker analysis|Correlative studies
223440010|NCT02696954|DRUG|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
223440011|NCT02696954|DRUG|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0
223440012|NCT00107354|BIOLOGICAL|aldesleukin|
223440013|NCT00107354|BIOLOGICAL|therapeutic allogeneic lymphocytes|
224051246|NCT04183829|PROCEDURE|induced termination of pregnancy|Medically, induced termination of pregnancy (I-TOP) is defined as an intervention to voluntarily terminate a pregnancy (ie, induced abortion) by either surgical or medical means so it does not result in a live birth.
224300388|NCT01182558|OTHER|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
223440014|NCT00107354|BIOLOGICAL|therapeutic autologous lymphocytes|
223440015|NCT00107354|DRUG|cytarabine|
223440016|NCT00107354|DRUG|etoposide|
223440017|NCT00107354|DRUG|mitoxantrone hydrochloride|
223440018|NCT00107354|PROCEDURE|allogeneic bone marrow transplantation|
223440019|NCT00107354|PROCEDURE|peripheral blood stem cell transplantation|
224051247|NCT05644652|OTHER|designed physical therapy program|"it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training."
224051248|NCT05644652|OTHER|Nordic walking|it will be conducted according to the guidelines of the International Nordic Walking Federation
224051249|NCT03023059|DRUG|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
224051250|NCT06055257|DRUG|modified PENTOCLO (mPENTOCLO)|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) treatment phase consisting of 800 mg pentoxifylline (400 mg morning and night) and 800 IU tocopherol (400 IU morning and night) taken orally 5 days per week (Monday to Friday with no medications on Saturday and Sunday). If the patient deteriorates (i.e., worsening of ORN T 6 or 9-month follow-up) then clodronate 1600 mg once daily (Monday to Friday) for the rest of the study period will be added."
224051251|NCT06055257|DRUG|sham mPENTOCLO|"4-week pre-treatment phase consisting of 2 g daily of Amoxicillin+Clavulanic acid 875/125 mg (1 g morning and night), 1 g ciprofloxacin (500 mg morning and night) and 50 mg Fluconazole daily (morning), taken orally by the patient.~This is followed by an additional 11 months (12 months total) of sham treatment phase (placebo)."
224051252|NCT06961968|DRUG|iloperidone|iloperidone LAI
224051253|NCT06961968|DRUG|placebo|matching placebo
224051254|NCT06091488|OTHER|Orthopure|Reconstruction of the anterior cruciate ligament of the knee in the patient.
224051255|NCT06129591|DRUG|Vantage Hemp CBD Isolate + Silicone patch|"The study intervention is prospective in nature. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
224051256|NCT06129591|DRUG|Silicone patch|"Standard of care silicone patch will be used as the control part of the split scar study. This split scar study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale."
224051257|NCT06650111|OTHER|Rereading of biopsies|Rereading of biopsies, blinded to the final diagnosis, by a pathologist specializing in nephropathology. This review includes: an optical microscopy study on a fragment fixed with routine staining, an optical microscopy study on a frozen fragment, an immunohistochemical study on a frozen fragment if available.
224051258|NCT06650111|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The clinical data of the care of patients at whom the biopsies belong will be analyzed until the date of the patient's last follow-up (before 12/31/2021).
224144254|NCT05671315|DRUG|Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue|"1.Peginterferon alfa-2b injection: 180μg, subcutaneously inject, once a week, from week 1 to Week 48.~2, NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
224144255|NCT05671315|DRUG|Nucleos(t)ide analogue|"NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse."
224144256|NCT00334646|DRUG|Oral GW679769|150mg oral, once daily on days 1-3
224144257|NCT00334646|DRUG|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
224144258|NCT05610657|DRUG|Mitapivat|Mitapivat tablets
224144259|NCT02660866|DRUG|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
224144260|NCT02660866|DRUG|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
224144261|NCT02889757|DRUG|Acteylcysteine|randomized into three arms
224144262|NCT04394143|DRUG|AD128|Oral administration of two capsules before sleep for 7 days.
224051259|NCT04400084|OTHER|Placenta perfusion|Placenta perfusion in double closed circuit, during 3 hours
224051260|NCT04057976|DIAGNOSTIC_TEST|Probabilistic diffusion tensor tractography|Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
224144263|NCT04394143|DRUG|Mannitol|Oral administration of two capsules before sleep for 7 days.
224051261|NCT04162015|DRUG|Nivolumab|nivolumab 360 mg
224051262|NCT04162015|DRUG|Pemetrexed|500 mg/m\^2
224144264|NCT00656084|DRUG|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar--\>Novantrone--\>Rituxan.
224144265|NCT00656084|DRUG|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
224144266|NCT00656084|DRUG|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar--\>Novantrone--\>Rituxan."
224144267|NCT01268033|DRUG|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
224144268|NCT01268033|DRUG|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
224144269|NCT04721938|BEHAVIORAL|Systematic weight loss intervention|"Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month"
224144270|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Bolus|20 mL of ropivacaine 0.2% will be injected via parasternal multi-orifice catheters on each side
224144271|NCT05054179|OTHER|Normal Saline Infusion|3 mL/hour infusion of normal saline for 48 hours via parasternal multi-orifice catheters on each side of the sternum
224144272|NCT05054179|DRUG|Ropivacaine 0.2% Injectable Solution Infusion|3 mL/h infusion of Ropivacaine 0.2% for 48 hours via parasternal multi-orifice catheters on each side of the sternum
224144273|NCT01293006|DRUG|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants \<65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
224144274|NCT01293006|DRUG|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
224144275|NCT04549415|DRUG|Metformin Hydrochloride|"patients were divided into 2 groups: 1st group was on lifestyle modification (LSM), 2nd group on regimen LSM+ metformin (1000 g b.i.d) during 12 months"
223440020|NCT02178527|OTHER|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
223440021|NCT02178527|OTHER|Usual Care|Usual general podiatry care provded by UK National Health Service
224144276|NCT04549415|OTHER|lifestyle modification|Lifestyle modification Standard Principles
224144277|NCT06360471|OTHER|fertility preservation|If a patient have a desire to fertility preservation, oocyte freezing or embryo freezing will be offered.
224144278|NCT04329000|DRUG|Esomeprazole 40mg|On-demand Esomeprazole 40 mg QD
224144279|NCT04329000|DRUG|Esomeprazole|Continuous Esomeprazole 40 mg QD
223440022|NCT03903367|DRUG|Fentanyl Citrate|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
224051263|NCT04162015|DRUG|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
223440023|NCT01669785|DEVICE|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
223440024|NCT01669785|DEVICE|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
223440025|NCT01669785|DEVICE|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
223440026|NCT02978885|RADIATION|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
224051264|NCT05368038|DIAGNOSTIC_TEST|Confirmatory Testing|All positive screens will be referred using standard notification procedures, where the New York State NBS reporting team contacts the ScreenPlus site medical geneticist, who will contact the newborn's pediatrician and family. The initial evaluation will include a clinical examination and confirmatory molecular studies, enzymatic and biomarker studies, when available. All aspects of the confirmatory testing will be at no cost to the participants. If confirmed to have a ScreenPlus disorder, the investigators will counsel the family and help connect them with treatment, clinical trials and disease specialists. The investigators will also provide emotional and social support resources to help in this journey.
224051265|NCT05074810|DRUG|avutometinib and sotorasib|The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
224051266|NCT05074810|DRUG|avutometinib and sotorasib and defactinib|The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
224051267|NCT05380141|BEHAVIORAL|Individual patient interviews|"Two individual interviews, of one hour duration, will take place for each patient before the beginning of participating to the workshops and in the month following the end of the workshops.~They will be led by a psychologist and a nurse from the functional pain and palliative medicine unit of Necker Hospital and 3 questionnaires will be completed during each interview."
224051268|NCT04754802|DRUG|PH94B Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
224051269|NCT04754802|DRUG|Placebo Nasal Spray|Nasal spray delivered 20 minutes before the public speaking stressor
224051270|NCT03653247|BIOLOGICAL|Plerixafor|Plerixafor subcutaneous injection will be administered prior to apheresis.
224051271|NCT03653247|DRUG|Busulfan|Busulfan IV infusion will be administered as myeloablative conditioning therapy.
224051272|NCT03653247|GENETIC|BIVV003|BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
223440027|NCT02978885|DRUG|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
223440028|NCT02978885|PROCEDURE|Whipple procedure|"A Whipple procedure - also known as a pancreaticoduodenectomy - is a complex operation to remove the head of the pancreas, the first part of the small intestine (duodenum), the gallbladder and the bile duct.~The Whipple procedure is used to treat tumors and other disorders of the pancreas, intestine and bile duct. It is the most often used surgery to treat pancreatic cancer that's confined to the head of the pancreas. After performing the Whipple procedure, your surgeon reconnects the remaining organs to allow you to digest food normally after surgery. Standard of care."
224051273|NCT04451161|BEHAVIORAL|Beliefs and Attitudes for Successful Implementation in Schools (BASIS)|BASIS blended (i.e., multifaceted and protocolized) implementation strategy, which occurs at the beginning of active implementation. BASIS is designed to facilitate observable implementation outcomes, including EBP adoption and intervention fidelity, via strategic education, motivational Interviewing, and social influence strategies.
224051274|NCT04451161|BEHAVIORAL|Trauma-Focused Cognitive-Behavioral Therapy|TF-CBT is an evidence-based treatment that helps children from elementary to high school to address the negative effects of trauma and promote greater emotion and behavior regulation, including processing their traumatic memories, overcoming problematic thoughts and behaviors, and developing effective coping and interpersonal skills. It also includes a treatment component for parents or other caregivers. Parents can learn skills related to stress management, positive parenting, behavior management, and effective communication.
224051275|NCT04451161|BEHAVIORAL|Treatment as Usual|Scaffolded intervention as usual. Includes: initial assessment of trauma symptoms, psychoeducation, follow-up planning and support.
224144280|NCT02490943|OTHER|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
224144281|NCT02490943|OTHER|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
224144282|NCT04099706|PROCEDURE|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
224144283|NCT01494987|DRUG|Ranolazine|Ranolazine tablet(s) administered orally
224144284|NCT01494987|DRUG|Placebo|Placebo to match ranolazine for the duration of the study
224144285|NCT01494987|DRUG|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
224144286|NCT01494987|BEHAVIORAL|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
224144287|NCT01494987|BEHAVIORAL|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
224144288|NCT04639843|DRUG|CC-486 (5-azacitidine)|CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.
224144289|NCT04639843|DRUG|Duvelisib|Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).
224144290|NCT04639843|DRUG|Romidepsin|Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.
223440029|NCT02978885|PROCEDURE|Major surgery|Additional surgical procedure(s) that is clinically indicated. Standard of care.
223566703|NCT06821009|OTHER|mPATH-CRC|Individuals will receive an automated text message inviting them to use the mPATH-CRC WebApp. The WebApp takes approximately 5 to 8 minutes to complete. The WebApp verifies patients are due for routine CRC screening, educates them about their options, and lets them request a screening test via the program.
224144291|NCT04639843|DRUG|Doxorubicin|Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
224051276|NCT04451161|BEHAVIORAL|Attention Control|Didactic presentation of implementation-related content (e.g., information about the importance of implementing, definitions of key terms, etc.) to control for facilitator, dose, information provided, and delivery platform
223440030|NCT01381991|DEVICE|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
223440031|NCT05807438|OTHER|Self myofascial Release|Myofascial release participants on their own will roll the foam roller in each area for two minutes.
223440032|NCT05807438|OTHER|myofascial release|Myofascial release will be applied to the participants by the physiotherapist.
223440033|NCT06474650|DRUG|LPM3770164 sustained release tablet|Single-dose of 30 mg of LPM3770164 sustained release tablet
223440034|NCT05286164|DRUG|Eltrombopag|Eltrombopag 150 mg QD for 8 weeks
223440035|NCT05247021|PROCEDURE|erector spinae block for group E|. The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
223440036|NCT00465543|OTHER|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
223440037|NCT00465543|OTHER|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
223440038|NCT04239443|DRUG|PD-1 inhibitor|Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)
223440039|NCT04239443|DRUG|Apatinib|NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).
223440040|NCT01764659|OTHER|Contrast-enhanced 4D computed tomography|All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
223440041|NCT06906835|OTHER|RET-He-Guided Iron Supplementation|"Participants in this arm will receive intravenous (IV) iron therapy guided by reticulocyte hemoglobin equivalent (RET-He) levels.~Iron dosing will follow a protocol based on RET-He values:~* RET-He \< 26 pg: IV iron 100 mg weekly~* RET-He ≥ 26 pg and \< 30 pg: IV iron 100 mg every 2 weeks~* RET-He ≥ 30 pg and ≤ 36 pg: IV iron 100 mg every 4 weeks~* RET-He \> 36 pg or ferritin ≥ 800 ng/mL: Discontinue iron supplementation to prevent iron overload"
223440042|NCT06906835|OTHER|TSAT-Guided Iron Supplementation|"Participants in this arm will receive IV iron therapy guided by transferrin saturation (TSAT) and serum ferritin, as per the Thai Clinical Practice Guidelines for Anemia in CKD (2021).~Iron dosing will follow this TSAT-based protocol:~* TSAT \< 30% and ferritin \< 200 ng/mL: IV iron 100 mg weekly~* TSAT \< 30% and ferritin 200-500 ng/mL: IV iron 100 mg every 2 weeks~* TSAT \< 30% and ferritin 500-800 ng/mL or TSAT 30-40%: IV iron 100 mg every 4 weeks~* TSAT ≥ 40% or ferritin ≥ 800 ng/mL: Discontinue iron supplementation"
223440043|NCT06906835|OTHER|Common|"All participants will receive erythropoiesis-stimulating agents (ESAs) according to a standardized dose adjustment protocol based on hemoglobin levels.~Oral iron supplements will be discontinued."
223440044|NCT06911671|DEVICE|Virtual Reality Interface + Cerebellar iTBS (c-iTBS)|Subjects will sit in a chair with their forearm inserted in a splint attached to a force transducer. The subjects' view of their hand will be occluded by a mirror displaying the virtual scene. EMGs from arm and shoulder muscles will be recorded by surface EMG electrodes. Subjects will displace a virtual handle according to either the forces recorded by the force transducer or forces estimated from the recorded EMGs (EMG control).
223440045|NCT06911671|DEVICE|Vitual Reality + Sham Cerebellar iTBS (sham c-iTBS)|c-iTBS will be carried out using Magstim Rapid magnetic biphasic stimulator. Twenty 2-s trains of three-pulse bursts at 50 Hz repeated every 200 ms with an inter-train interval of 10 s, for a total of 190 s will be applied over the contralesional lateral cerebellum. The coil will be positioned tangentially to the scalp for real and 90° angled for sham c-iTBS.
223440046|NCT06911671|OTHER|Physical Therapy|Passive mobilization and motor recruitment of impaired upper limb will be performed with the support of a physical therapist specialized in neurological rehabilitation.
223440047|NCT01298141|BIOLOGICAL|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
223440048|NCT02187575|DRUG|UHAC 62 XX tablet|
223440049|NCT02187575|DRUG|UHAC 62 XX capsule|
223440050|NCT03795025|OTHER|Strength training 3x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
223440051|NCT03795025|OTHER|Strength training 6x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
223440052|NCT03795025|OTHER|3x10RM + 6x10RM|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
223440053|NCT03919591|OTHER|Challenge virus RSV-A Memphis 37b|Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
224051277|NCT06029660|DEVICE|IMPEDE-FX RapidFill Implants|Filling of the available flow lumen within the AAA sac with IMPEDE-FX RapidFill Implants
224051278|NCT06029660|PROCEDURE|EndoVascular Aneurysm Repair|Standard EVAR repair of abdominal aortic aneurysms using a commercially available stent.
224051279|NCT06351020|DRUG|LM-302|LM-302 intravenous-injection every 2 weeks on Day 1 of each 14-day cycle
223440054|NCT03958942|OTHER|Ultrasound quadratus lumborum block with bupivacaine 25%|echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
223440055|NCT03958942|OTHER|lumbar epideural block with bupivacaine 25%|lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
223440056|NCT06912334|DEVICE|tVNS|tVNS L is a battery-driven electrical stimulator connected to an ear electrode which is positioned over the skin of the cymba conchae. Thus, auricular vagal stimulation will be applied using the typical ear electrodes of the tVNS® L device. tVNS will be applied over the left branch for safety reasons. For sham auricular tVNS, the anodal electrode will be placed over the center of the left ear lobe. The cathode will be placed over the antitragus. This method and these stimulation parameters have been previously used for reliable blinding in other clinical studies. Series of electrical pulses with 250 μs pulse width, 25 Hz frequency, and 28 s inter-burst interval (32 sec on/28 sec off duty cycle) will be applied in each intervention session. Auricular tVNS will be applied at 1mA - 5mA intensity for 30 min per session (1 session per day, 7 consecutive days a week, 14 sessions in total)
223440057|NCT06912412|OTHER|Community-based supervised remote cardiac rehabilitation|"Community-based supervised remote cardiac rehabilitation begins with a weekly session led by exercise specialists, who use remote-based materials to match each participant's target heart rate and rate of perceived exertion (RPE). During these sessions, participants perform aerobic, strength, and respiratory exercises using progressive overload principles, with devices such as the POWERbreathe Plus supporting individualized respiratory training.~Depending on the risk classification for each participant, they will be provided with different intensity of exercises (depending on their measured HR max, HRR, and/or RPE)."
223440058|NCT06912412|OTHER|Home-based cardiac rehabilitation program|"Beyond the single supervised session, participants undertake four weekly home-based sessions.~* Low-Risk Group: Aerobic and respiratory exercises are performed four times per week, plus strength training once or twice weekly. Each 60-minute session includes a 10-minute warm-up, 40-minute main exercise, and 10-minute cool-down. Indoor sessions use remote exercise content and respiratory training devices, while outdoor activities may involve walking, jogging, cycling, or swimming. Exercises progress in duration, intensity, and resistance.~* Moderate-Risk Group: Aerobic and respiratory exercises are done four times per week with an RPE of 8-13. Intensity and duration increase gradually, contingent on symptom stability and improved endurance.~* High-Risk Group: Aerobic and respiratory sessions occur four times a week at an RPE of 8-10, each lasting around 30 minutes (5-minute warm-up, 20-30-minute main exercise, 5-minute cool-down)."
223566704|NCT06821009|OTHER|Usual Care (Control)|"Patients randomized to the control arm will receive usual care, which includes the organizations' standard procedures for addressing CRC screening. In the participating Fee-for-Service and Value-Based settings, the EHR flags patients who are overdue for CRC screening as a care gap that is visible to all primary care providers."
223566705|NCT01916252|DRUG|bortezomib (Velcade ®)|
223566706|NCT01916252|DRUG|lenalidomide (Revlimid®)|
223566707|NCT01916252|DRUG|busulfan (Busilvex ®)|
223566708|NCT01916252|DRUG|Dexamethasone acetate|
223566709|NCT01916252|DRUG|Melphalan|
224051280|NCT06351020|DRUG|Apatinib|The subjects will receive Apatinib orally,qd
224051281|NCT06351020|DRUG|Irinotecan|The subjects will receive Irinotecan intravenous-injection,every 2 weeks on Day 1 of each 14-day cycle
224051282|NCT02246725|OTHER|Contact with palliative care unit.|
224051283|NCT04105907|DEVICE|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
224051284|NCT05911750|DIAGNOSTIC_TEST|Anal pap smear and oral swab for cytology and HPV testing|Anal and oral swab sampling for HPV detection (polymerase chain reaction) and cytology
224051285|NCT03372109|DIETARY_SUPPLEMENT|Meal replacement shake|Meal replacement shake taken two days per week during the modified fasting periods
224051286|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral capsules|Multivitamin/mineral supplement
224051287|NCT03372109|DIETARY_SUPPLEMENT|Fish oil with sesame lignans and olive extract softgel|Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels
224051288|NCT03372109|DIETARY_SUPPLEMENT|Prebiotic Chewable tablet|Prebiotic Fiber 1,400 mg/tablet
224051289|NCT03372109|DIETARY_SUPPLEMENT|Clove Extract and Maqui Berry extract capsule|Clove extract 250mg and maqui berry extract 200mg/capsule
224051290|NCT03372109|DIETARY_SUPPLEMENT|.Whole Food Blend capsule|Whole food blend 1000mg/3 capsules
224144292|NCT03350971|OTHER|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
224051291|NCT03372109|DIETARY_SUPPLEMENT|Turmeric extract capsule|Turmeric 25:1 extract 400mg/capsule
224051292|NCT03372109|DIETARY_SUPPLEMENT|European White Kidney Bean capsule|White kidney bean extract 100mg/capsule
224051293|NCT03372109|DIETARY_SUPPLEMENT|Saffron extract capsule|Saffron extract 88.25mg/capsule
224051294|NCT03372109|DIETARY_SUPPLEMENT|Ubiquinol with Fulvic acid complex softgel|Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel
224051295|NCT03372109|DIETARY_SUPPLEMENT|Calcium with Hesperidin and gynostemma extract tablet|Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet
224144293|NCT03350971|OTHER|Control|chest physical therapy exercises
224144294|NCT04712487|DIAGNOSTIC_TEST|Microbiological culture, viral PCR, histopathological analysis|"Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue"
224144295|NCT00105209|DRUG|Aspirin|
224144296|NCT00105209|DRUG|clopidogrel|
224144297|NCT04297293|DRUG|Ramosetron|Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2)
224051296|NCT03372109|DIETARY_SUPPLEMENT|Multivitamin and mineral supplement|Multivitamin and multimineral supplement
224051297|NCT01951079|DRUG|Intra-amniotic injection of DIGOXIN|
224051298|NCT03373981|DEVICE|rTMS|repetitive transcranial magnetic stimulation
224051299|NCT04431336|BEHAVIORAL|movement|movement
224051300|NCT04537546|DEVICE|OBESINOV elasto-compressive belt|It is a customised medical device, using a technique for calculating the compression ratio adapted to each patient according to his morphology
224051301|NCT05573776|OTHER|Exercise Therapy, High Protein supplement|patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
224051302|NCT04476901|BIOLOGICAL|allogeneic human mesenchymal stem cells (hMSCs)|allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).
224051303|NCT04476901|OTHER|Placebo|Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)
224051304|NCT00702754|BIOLOGICAL|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
224051305|NCT03172832|PROCEDURE|PTBD|Percutaneous access and tube placement into the bile duct
224051306|NCT03172832|PROCEDURE|ERC|Endoscopic access and stent placement in the bile duct
224051307|NCT04994197|OTHER|Observational study only - no intervention|Observational study only - no intervention
224051308|NCT02432222|BEHAVIORAL|Visual Arts Training|Visual arts training
224051309|NCT02432222|BEHAVIORAL|Music Training|Music training
224051310|NCT03725124|OTHER|Interview|Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
224051311|NCT04032470|DEVICE|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
224144298|NCT06195098|OTHER|Nutritional educational intervention|The interventional activities were targeted to the local population, according to their educational level and culture and it was composed by a theoretical part and a more practical part. The objective was to improve nutritional knowledge and their awareness about the role of food in connection to the human health. According to the theoretical part: to make the activities more appealing, three informative graphic posters were drafted. According to the practical part: a cooking class activities were conducted, involving women of the Ampanithosa and Bevoko villages. The researchers teaching them how to use a bamboo steamer and how to process vegetables, grew up in the organic gardens built by the Kukula team. The activities were carried out in each village thanks to a local enumerators involvement.
224144299|NCT04600687|OTHER|Placebo tablets|Participants will take placebo tablets identical to the commercial versions of the two combination antiretroviral single tablet regimens of bictegravir/emtricitabine/tenofovir alanfenamide and dolutegravir/abacavir/lamivudine.
224144300|NCT00425074|DRUG|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
224144301|NCT00425074|DRUG|ASA|normal release acetylsalicylic acid
224051312|NCT05312424|DIETARY_SUPPLEMENT|Placebo|300 mg olive oil
224051313|NCT05312424|DIETARY_SUPPLEMENT|Low GG|150 mg GG
224051314|NCT05312424|DIETARY_SUPPLEMENT|High GG|300 mg GG
224144302|NCT00425074|DRUG|SR-ASA|slow release acetylsalicylic acid 150 mg
224051315|NCT04094753|DIAGNOSTIC_TEST|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
224051316|NCT04094753|DIAGNOSTIC_TEST|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
224051317|NCT04094753|DIAGNOSTIC_TEST|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
223478623|NCT00235807|PROCEDURE|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
224051318|NCT04094753|DIAGNOSTIC_TEST|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
224144303|NCT04310865|DRUG|Yinhu Qingwen Granula|"Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days."
224144304|NCT04310865|DRUG|Yin Hu Qing Wen Granula(low does)|This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
223478624|NCT00235807|PROCEDURE|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
224051319|NCT04094753|DIAGNOSTIC_TEST|Questionaires|"Patients have to fulfill the following questionaires~* ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~* TILBURG FRAILTY INDICATOR~* SF-36 Quality of Life score~* N- QOL"
224051320|NCT04094753|DIAGNOSTIC_TEST|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
224051321|NCT04094753|DIAGNOSTIC_TEST|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
223440059|NCT06911710|DRUG|CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）|"Phase I study: dose-escalation component.This part follows the 3+3 dose-escalation model, with 5 dose groups: 1×10\^6, 1.5×10\^6, 2×10\^6, 2.5×10\^6, 3×10\^6 CAR+ cells/kg (different target CAR-T can be adjusted by the investigator according to the dose used in the previous clinical trial). Each dose group enrolled 3\~6 patients with relapsed/refractory hematological diseases respectively, totaling 15\~30 subjects, in order to evaluate the safety of CAR-T cells for the treatment of relapsed/refractory malignant hematological neoplasms and to determine the MTD. Phase II study: dose-expansion portion. After the MTD was confirmed, in the dose-expansion portion of the study (Phase II), it was expected that 65\~60 subjects would receive the CAR-T cell injection infusion under RP2D to further evaluate the efficacy of CAR-T cell injection."
223440060|NCT06909812|DRUG|pirfenidone 8% gel|topic aplication
223440061|NCT06909812|DRUG|silicon gel|topic aplication
223440062|NCT06912516|PROCEDURE|Controlled desaturation|"A subject rests comfortably on a hospital bed, so that they do not have to move during the desaturation process.~The subject wears the altitude simulator head bivy and breathes freely without any oxygen regulation. During the measurement, the time in low O2 saturation plateaus is limited to ten minutes in each desaturation plateau.~They are monitored with ECG, clinical pulse oximeter, EtCO2 from non-invasive capnography with nasal cannulas and periodically non-invasive blood pressure. The monitoring is supervised by two medical doctors, present during the entire duration of the study."
223440063|NCT06910982|BEHAVIORAL|Sphinx Pose Yoga Therapy|A structured yoga-based intervention focusing on the Sphinx Pose, aimed at improving spinal flexibility and reducing pain. Participants will perform three sessions per week for 12 weeks.
223440064|NCT06910683|BEHAVIORAL|TREE-Connect|TREE-Connect is a mental health app that aims to increase engagement in rewarding activities
223440065|NCT06910683|BEHAVIORAL|Clinician-delivered psychotherapy|Clinician-delivered psychotherapy is delivered remotely and aimed to increase engagement in rewarding activities
223440066|NCT02622490|OTHER|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
223440067|NCT04284930|DRUG|Depobupivacaine|surgeons receive schematic for injection of Depobupivacaine. Subjects receive an injection of 166mg depobupivacaine. Injection on either side of the suture line, injected directly into the fascia.
223440068|NCT04284930|DRUG|OnQ pump|group 2: Surgeons receive instruction sheet with specific placement of catheter. All patients have two OnQ soaker catheters installed into abdominal donor site before donor closure.
223440069|NCT04284930|DRUG|0.25% Bupivacaine|group 3: given 0.25% bupivacaine without epinephrine between internal oblique and transverse abdominal muscle.
223440070|NCT06910111|DEVICE|Polyglucosamine|The treatment will continue for 12 months administering a customized Polyglucosamine (formoline AtheroGuard) (twice/day) before the two main meals for a total of 4 tabs/day (each tab consists of 750 mg). Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months
223440071|NCT06910111|DEVICE|Placebo|2x 2 Placebo tablets The treatment will continue for 12 months administering Placebo (twice/day) before the two main meals for a total of 4 tabs/day. Controls will be conducted at screening/baseline, and after 3/6/9 and 12 months
224051322|NCT06267170|DRUG|Adebrelimab|Treatment with adbelizumab
224051323|NCT02403362|DRUG|EPO-018B|
224051324|NCT02427451|DRUG|Bcl-2 Inhibitor GDC-0199|Given PO
224051325|NCT02427451|BIOLOGICAL|Obinutuzumab|Given IV
223440072|NCT03744845|OTHER|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
224051326|NCT02427451|DRUG|Ibrutinib|Given PO
224051327|NCT02427451|OTHER|Pharmacological Study|Correlative studies
224051328|NCT02427451|OTHER|Laboratory Biomarker Analysis|Correlative studies
224051329|NCT02427451|OTHER|Quality-of-Life Assessment|Ancillary studies
224051330|NCT01219049|DRUG|Tyrosine|1000 mg / day
224051331|NCT01219049|DRUG|Tyrosine|2000 mg / day
223440073|NCT01854879|DEVICE|Nucleus 6 sound processor|
224051332|NCT01219049|DRUG|Placebo|Placebo daily
224051333|NCT02884063|PROCEDURE|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
224144305|NCT04310865|OTHER|standard medical treatment|Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
223440074|NCT02301039|DRUG|Pembrolizumab|
224144306|NCT02771457|DRUG|Infliximab at weeks 0,2, and 6|
224144307|NCT02771457|DRUG|Infliximab at weeks 0,4, and 8|
224144308|NCT02771457|DRUG|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
224144309|NCT00436982|DEVICE|Cemented Triathlon total knee system|Orthopaedic implant
224144310|NCT00436982|DEVICE|Duracon total knee system|Orthopaedic implant
223440075|NCT03811288|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
223440076|NCT01210677|DRUG|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
223440077|NCT02249689|OTHER|Definitive 65|
224051334|NCT02938130|OTHER|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
224051335|NCT06526195|DEVICE|CardioMEMS HF System|The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.
224051336|NCT06526195|DEVICE|HeartMate 3 Left Ventricular Assist System|The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.
224051337|NCT06526195|OTHER|Guideline Medical Directed Therapy|Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
223440078|NCT02249689|OTHER|Definitive 74|
224051338|NCT03705637|DRUG|Exparel|"* Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~* The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~  o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~* Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
224051339|NCT06042777|BEHAVIORAL|Acupuncture and TCM-based lifestyle management|Non-pharmacological treatment based on traditional Chinese medicine.
224051340|NCT06044064|PROCEDURE|A blood sample for CA 19-9 (cancer detection test)|"* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline.~* Contrast CT abdomen - Pancreas protocol will be done at baseline.~* EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you.~* If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done."
224144311|NCT02181036|OTHER|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
223440079|NCT01504191|BEHAVIORAL|Internet-based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text-messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
223440080|NCT01958398|BEHAVIORAL|Promillekoll|Smartphone app monitoring alcohol use with feedback.
223440081|NCT01958398|BEHAVIORAL|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
224144312|NCT00953225|DRUG|vitamin D3|4,000 IU daily for one year
224144313|NCT00953225|DRUG|Placebo daily for one year|Placebo
224144314|NCT05004519|DRUG|Dexmedetomidine Injection [Precedex]|dexmedetomidine or remifentanil during laparoscopic gastric bypass
224300389|NCT01182558|OTHER|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds \[two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs\])."
224300390|NCT01182558|OTHER|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
223440082|NCT02306421|PROCEDURE|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
223440083|NCT02306421|PROCEDURE|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
223440084|NCT02306421|PROCEDURE|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
223478625|NCT00235807|PROCEDURE|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
223478626|NCT00388921|DRUG|Vitamin A|
223478627|NCT03620448|DEVICE|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
223478628|NCT03620448|OTHER|Oxygen Arm|Oxygen therapy from oxygen cylinders
224051341|NCT01737385|PROCEDURE|Measurement with O2C|Measurement of microcirculation using O2C light probes.
224051342|NCT04782271|DRUG|SYL18001 sodium Low dose q.d|1 drop in the randomized eye once daily
224051343|NCT04782271|DRUG|SYL18001 sodium Middle dose q.d|1 drop in the randomized eye once daily
224144315|NCT05004519|DRUG|Remifentanil|dexmedetomidine or remifentanil during laparoscopic gastric bypass
224144316|NCT04225390|DRUG|Dacarbazine (DTIC)|Dacarbazine powder for IV solution
224144317|NCT03864536|BEHAVIORAL|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
224300391|NCT01795274|RADIATION|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
224300392|NCT02536326|DEVICE|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
223440085|NCT02306421|PROCEDURE|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
223440086|NCT02306421|PROCEDURE|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
223440087|NCT03309345|OTHER|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
223440088|NCT01967979|DRUG|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
223440089|NCT01967979|DRUG|fluoxetine|Multiple doses
223440090|NCT01967979|DRUG|itraconazole|Multiple doses
223440091|NCT01698268|PROCEDURE|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
223440092|NCT01698268|PROCEDURE|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
223440093|NCT05989971|OTHER|continuous renal replacement therapy|continuous veno-venous hemofiltration or continuous veno-venous hemodialysis set-up: predilution 30 ml/kg/h, dialysate dose 30 ml/kg/h, ultrafiltration rate was equal to the total rate of substitution fluid infusion
223440094|NCT00298363|DRUG|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
223440095|NCT00298363|DRUG|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
224051344|NCT04782271|DRUG|SYL18001 sodium High dose q.d|1 drop in the randomized eye once daily
224051345|NCT04782271|DRUG|SYL18001 sodium High dose b.i.d|1 drop in the randomized eye twice daily
224051346|NCT03255707|DEVICE|eye patch|Occluding the better seeing eye for a given number of hours daily
224051347|NCT03255707|DEVICE|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
223440096|NCT00298363|DRUG|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
223440097|NCT00298363|DRUG|TDF placebo|Placebo to match TDF QD
223440098|NCT00298363|DRUG|FTC/TDF placebo|Placebo to match FTC/TDF QD
223440099|NCT00298363|DRUG|ETV placebo|Placebo to match ETV QD
223440100|NCT03105856|BIOLOGICAL|CERVARIX|\- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
223440101|NCT03105856|BIOLOGICAL|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
224051348|NCT06288945|OTHER|Educational Program|The educational program included information about definition and causes of Dry eye syndrome (DES), symptoms of DES, diagnostic measures of DES, differentiation between DES and eye allergy, complications of DES, the effect of DES on vision, management of DES, health education about proper eyelid hygiene, proper nutrition to improve the quality of tear film, measures, and precautions to prevent DES such as avoiding exposure to smoke and environmental changes, avoiding prolonged periods in air-conditioned environments; limiting contact lens use to shorter periods, avoiding staring at the computer screen or smartphone for long periods, and taking frequent breaks. In addition, health education about the importance of compliance with the treatment of DES, and instructions to maintain normal eye and vision in patients with DES.
224051349|NCT06115941|DEVICE|Pre-Op Incentive Spirometer|"incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file."
224051350|NCT01365585|DRUG|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
224051351|NCT03342313|OTHER|Food - Sandwich|Sandwich as a breakfast for testing chewing activities.
224051352|NCT00051285|DRUG|Enoximone|Participants receive oral enoximone
224051353|NCT00051285|DRUG|Enoximone placebo|Participants receive placebo to match enoximone
224051354|NCT01600976|DRUG|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
224051355|NCT00496236|DRUG|TNFerade biologic|
224051356|NCT00524849|BIOLOGICAL|Zoledronic acid|Zometa 1 mg weekly (intravenous)
224051357|NCT00524849|DRUG|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
224051358|NCT01214863|DEVICE|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
224051359|NCT01214863|DEVICE|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
224051360|NCT01214863|DEVICE|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
223440102|NCT04710368|DRUG|Evolocumab Injections|Administered on day 1 (the day of the first treatment) and through week 26 with a personal injector or prefilled auto injector/pens.
223440103|NCT04393376|DIAGNOSTIC_TEST|PSA Glycomics Assay|PSA Glycomics Assay will be performed on urine and blood samples
224051361|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
224051362|NCT00354081|DRUG|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
224051363|NCT00354081|DRUG|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
224051364|NCT00354081|DRUG|placebo|placebo, in a capsule, taken orally once a day
224051365|NCT03851003|PROCEDURE|Endometrial suturing|Suturing will include endometrium during cesarean incision repair
223440104|NCT00914082|BEHAVIORAL|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
223440105|NCT00135356|DRUG|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
223440106|NCT00135356|DRUG|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor \[PI\] combination + 2 NRTIs
223440107|NCT00153816|DRUG|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
223440108|NCT00153816|DRUG|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
223440109|NCT00153816|DRUG|placebo|placebo; two tablets per day
223440110|NCT05327088|DRUG|Dexmedetomidine|Dexmedetomidine, a highly selective α₂ receptor agonist, has a sympatholytic, sedative and opioid sparing effect.
223440111|NCT05327088|DRUG|Nalbuphine|Nalbuphine, a derivative of 14-hydroxymorphine is a strong analgesic with mixed k agonist and µ antagonist properties. The analgesic potency of nalbuphine has been found to be equal to morphine
223440112|NCT04024566|DEVICE|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
223566710|NCT02136680|OTHER|CASA Education|Basic palliative care competencies for outpatient use.
223566711|NCT06607497|OTHER|Intervention using an AI enabled risk communication tool (PERDICT.AI)|Risk communication using PERDICT.AI dynamically communicates an individual's glycemic control, offering a comparative ranking among peers to enhance motivation and awareness. Furthermore, it assesses the risk of potential complications comparing with peer data with exemplary cases to underscore the consequences of suboptimal management. In addition, it will generate personalized recommendations including medication adjustment and personalized health plans.
224051366|NCT03851003|PROCEDURE|Non- endometrial suturing|Suturing will not include endometrium during cesarean incision repair
224144318|NCT00672295|DRUG|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m\^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
224051367|NCT03851003|DEVICE|Vaginal ultrasonography|All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar
224144319|NCT01855113|DEVICE|Invisalign|
224144320|NCT04991064|OTHER|Complete denture base modified by Titanium dioxide nanoparticles.|Titanium dioxide nanoparticles will be mixed with resin powder of the denture base before mixing the powder and liquid of the heat cure denture base material.
224144321|NCT01261260|DRUG|Uridine|1 gram tablets BID for 7 days
224144322|NCT01410162|DRUG|Tacrolimus|tacrolimus extended release capsules vs Prograf
224144323|NCT03609489|DRUG|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
223440113|NCT06323395|DRUG|Vizol S LIPID BALANCE eye drops|1 drop 4 times a day
223440114|NCT06323395|DRUG|ophthalmic saline eye drops|1 drop 4 times a day
223440115|NCT02799888|DRUG|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
223440116|NCT02799888|DRUG|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
223440117|NCT02799888|DRUG|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
223440118|NCT02799888|DRUG|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
223440119|NCT01913522|PROCEDURE|Pulmonary Vein Isolation|
223584010|NCT06981221|DEVICE|Masimo Radical-7 Pulse Oximeter|"PVI is continuously monitored using the Masimo Radical-7 pulse oximetry device to evaluate respiratory variation in the plethysmographic waveform amplitude during laparoscopic-assisted vaginal hysterectomy (LAVH). No fluid intervention is applied; device use is for observational measurement of fluid responsiveness."
224144324|NCT03609489|DRUG|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
224144325|NCT01727557|PROCEDURE|regional anesthesia|Regional anesthesia will be compared to local anesthesia
224144326|NCT01727557|PROCEDURE|local anesthesia|Regional anesthesia will be compared to local anesthesia
223440120|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +200mg ALA|200mg green coffee extract + 200mg alpha-lipoic acid
223440121|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE +400mg ALA|200mg green coffee extract + 400mg alpha-lipoic acid
223440122|NCT06137066|DIETARY_SUPPLEMENT|200mg GCE + 200mg DHB|200mg green coffee extract + 200mg dihydroberberine
223440123|NCT06137066|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose with 5 mg magnesium stearate and 5 mg silicon dioxide
223440124|NCT02253381|PROCEDURE|Right|Right lateral decubitus position during spinal anesthesia
223440125|NCT02253381|PROCEDURE|Left|Left lateral decubitus position during spinal anesthesia
223440126|NCT01327092|OTHER|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
223440127|NCT02527317|DRUG|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
223440128|NCT00000589|PROCEDURE|platelet transfusion|
223440129|NCT01692002|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate capsule or tablet
223440130|NCT01692002|DIETARY_SUPPLEMENT|Sodium Chloride|Placebo capsule or tablet
223440131|NCT01692002|PROCEDURE|Oral glucose tolerance test|
223440132|NCT01692002|PROCEDURE|Intravenous glucose tolerance test.|
223440133|NCT05567406|DRUG|Belumosudil|Pharmaceutical form: Tablet; Route of administration: Oral
223440137|NCT05210803|OTHER|No intervention.|All subjects that previously received RGX-314 in a parent study
223740932|NCT07128888|DRUG|GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets|GZR18 injection: 3 mg-36 mg，16 weeks; Warfarin Sodium Tablets:2.5mg，twice; Rosuvastatin Calcium Tablets：10mg，twice; Digoxin Tablets:0.25mg，twice
223740933|NCT07119645|DIETARY_SUPPLEMENT|NT-II™ (240 mg)|A once-daily capsule containing 240 mg of NT-II™, a marine-derived undenatured type II collagen supplement obtained from enzymatically processed salmon cartilage and bone. Taken orally for 12 weeks.
224144327|NCT01092026|OTHER|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
224144328|NCT04600843|OTHER|Physical therapy with Patient education|patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home
224144329|NCT04600843|OTHER|Physical Therapy without patient Education|Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
224144330|NCT02821091|OTHER|Interactive Dynamic Balance Training|
224144331|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via AI on Day 1 followed by 10 weeks
223440138|NCT05481918|PROCEDURE|Home-based therapy after ACL reconstruction|Five physiotherapeutic supervisions (individual) take place within the first 12-13 weeks after ACL reconstruction with focus on home exercises
223440139|NCT05481918|PROCEDURE|Standardized ambulant therapy after ACL reconstruction|16 physiotherapeutic supervisions (groups+ individual) take place within the first 12-13 weeks after ACL reconstruction.
223440140|NCT01166854|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
223440141|NCT02272153|OTHER|Egg refined grain|
223440142|NCT02272153|OTHER|Egg Whole Grain|
223440143|NCT02272153|OTHER|Cereal Refined grain|
223440144|NCT02299505|DRUG|ceritinib|The investigational drug ceritinib was supplied to the Investigators as 150 mg capsules, for oral administration.
223440145|NCT02503644|DRUG|IVA337|Capsules of 200mg IVA337
223440146|NCT02503644|DRUG|Placebo|Identical capsules without active substance
223440147|NCT05128045|BEHAVIORAL|NEW-R|Eight session class on nutrition, physical activity, diet, and weight management
223440148|NCT05601297|OTHER|questationair|acceptability of women to partner violance
223440149|NCT05758272|BEHAVIORAL|mobile phone-based simple physical exercise reminder to help quit smoking|Regular messages supporting participants in practicing simple physical exercises and assist in managing cravings will be sent to participants via IM apps and scheduled in a tapering manner for 3 months (twice per week in the first month to once per week in the third month). Images and videos explaining and demonstrating the simple physical exercises will be sent to the participants via IM apps, which serves as a reminder and supporting materials for participants. The benefits of exercise in SC will be explained. The investigator will also encourage the practice of moderate/ vigorous exercises to further improve the physical activity and well-being of the participants. Various delivery formats of messages will be considered to attract participants' interest such as text, emojis, voice, image, animation, and video. The simple exercises consist of a) Zero-time exercises (ZTEx), b) handgrip exercises and c) resistance exercises.
223440150|NCT05758272|BEHAVIORAL|regular text-based intervention|The control group will receive 6 regular messages via IM at twice per month within 3 months. These messages cover simple cessation advice and reminders for telephone follow-ups.
223440151|NCT05921422|OTHER|Cognitive assessment|"All participants will receive cognitive assessment with a core battery (CPCog) and a supplemental battery.~The core battery includes standardized tests of general cognitive functioning (intelligence) and visual-spatial abilities, as well as a questionnaire on executive functioning in daily life. The supplemental battery assesses attention, executive functioning, memory, fatigue, and symptoms of mental health issues (including symptoms of anxiety, depression, and attention deficit hyperactivity disorder/ADHD)."
223740934|NCT07119645|DIETARY_SUPPLEMENT|NT-II™ 480 mg|Two capsules of NT-II™ (each 240 mg), taken orally once daily for a total of 480 mg/day over 12 weeks. Sourced from salmon bone and cartilage to support joint health via oral tolerance.
224144332|NCT04295356|BIOLOGICAL|CT-P17|subjects will receive a single dose (40 mg) of CT-P17 via PFS on Day 1 followed by 10 weeks
223440152|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
223440153|NCT01463358|DEVICE|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
223440154|NCT00941824|DRUG|mycophénolate acid|"* Day 0 to Day 7, 720 mg twice daily~* Day 8 to Day 30, 540 mg twice daily~* Day 30 to Day 90, 360 mg twice daily"
223440155|NCT06537050|DRUG|JX2105|Oral capsule
223440156|NCT06537050|DRUG|Placebo|Oral capsule
223440157|NCT01906281|OTHER|Blood analyse, arthrocentesis, ultrasound examination|
223440158|NCT04656678|DEVICE|Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance|Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
223440159|NCT04111861|OTHER|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
223440160|NCT05775861|DRUG|single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group|"For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block."
223740935|NCT07119645|DIETARY_SUPPLEMENT|Glucosamine/Chondroitin|A combined dietary supplement containing 1500 mg glucosamine and 1300 mg chondroitin, taken orally once daily for 12 weeks. This supplement serves as the active comparator and is widely used to support joint structure and function.
224144333|NCT01734707|DIETARY_SUPPLEMENT|Allicor|
224144334|NCT01734707|DRUG|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
224144335|NCT01913860|BEHAVIORAL|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
224144336|NCT04818528|OTHER|Constraint Induced Movement Therapy and Routine Physical Therapy|"Intensive, graded practice of the paretic upper limb to enhance task-specific use of the affected limb. Constraint or forced use therapy, with the non-paretic upper limb contained in a mitt to promote the use of the impaired limb during 90% of the total hours awake. Adherence enhancing behavioral methods designed to transfer the gains obtained in the clinical setting or the laboratory to patients' real-world environment (ie, a transfer package).~As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization."
224300393|NCT04738682|OTHER|Digital dietary registration|"The purpose of the intervention is to test whether digital dietary registration can yield more precise and consistent data, than conventional pen and paper based registration.~Furthermore a subjective evaluation of the use of digital registration will be conducted by the staff upon completion of the intervention. The format will be individual interviews held by the investigators."
224300394|NCT04738682|OTHER|Conventional dietary registration|The conventional way of doing dietary registration. This is done by a paper form, with the dietary options listed. The form is then filled in and logged by staff working in the afternoon.
224300395|NCT04587063|BEHAVIORAL|Fear Appeals|Email
224300396|NCT04587063|BEHAVIORAL|Message about Future Healthcare Costs|Email
223740936|NCT06930391|DRUG|Oxytocin|Oxytocin 10-5M will be added to 3 groups of myometrial strips for 2 hours to induce desensitization.
223740937|NCT06930391|DRUG|Carbetocin|Increasing concentrations of carbetocin in a pattern of 1 log molar increase every 10 min, from 10-10 M to 10-5 M
223740938|NCT06930391|DRUG|Calcium|Calcium chloride in the following concentrations:1.25mM, 2.5mM and 5.0mM.
223478629|NCT03287544|OTHER|Combined rehabilitation|Linguistic training as well as communication training.
223478630|NCT03287544|OTHER|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
223478631|NCT05021653|OTHER|no intervention|No intervention involved
223478632|NCT00937534|DRUG|Fimasartan|Fimasartan 240mg/day
223478633|NCT01027949|DRUG|Oral Treprostinil|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
224144337|NCT04818528|OTHER|Routine Physical Therapy|As part of routine physical therapy patients received intervention that worked on aerobic capacity, muscle strengthening exercise, walking ability, postural and balance disorders and improving hand arm function. Three stages were used in each session: (i) warm-up phase: passive mobilization of major joints and lower limb muscle strengthening; (ii) active phase (both standing and sitting): motor control exercises for upper and lower limbs, and (iii) cool down phase (in seating position): respiratory exercises and mobilization.
224144338|NCT00175162|DEVICE|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
224144339|NCT01274117|PROCEDURE|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
224300397|NCT04587063|BEHAVIORAL|Endorsement from a Doctor|Email
224300398|NCT04587063|BEHAVIORAL|Comparison Table|Email
224051368|NCT03851003|OTHER|Questionnaire|All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
224051369|NCT04812067|DRUG|TTHX1114|engineered FGF-1
224051370|NCT03200054|OTHER|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last \~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
224051371|NCT04651543|OTHER|X-Ray|X-ray obtained at one-week of the fracture
224051372|NCT04046081|DRUG|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
224051373|NCT04760951|DIETARY_SUPPLEMENT|TOTUM-070|5-g dose of TOTUM-070 diet supplement, a mix of 5 plant extracts. Eight capsules per day to consume orally in two intakes
224051374|NCT04760951|DIETARY_SUPPLEMENT|Placebo|Placebo. Eight capsules per day to consume orally in two intakes
224051375|NCT00596661|DEVICE|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
224051376|NCT02032550|OTHER|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
224051377|NCT02630342|BEHAVIORAL|Mock MRI scanner|Using a mock scanner for preparation for MRI
224051378|NCT02630342|BEHAVIORAL|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
223740939|NCT06934057|DRUG|Nivolumab|Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion.
224051379|NCT02630342|BEHAVIORAL|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
224051380|NCT02630342|BEHAVIORAL|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
224144340|NCT05244538|DEVICE|Virtual reality distraction|Patients will be exposed to a virtual reality representing a forest walk. A reduction of at least 50 percent in the remifentanil and propofol doses required for oocyte retrieval is expected.
224300399|NCT04587063|BEHAVIORAL|Highlighting Cost Savings and Convenience|Email
223740940|NCT06934057|DRUG|Cabozantinib|Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.
224051381|NCT03960073|DIETARY_SUPPLEMENT|MitoQ|4 week 20mg oral daily dose of Mito Q
223740941|NCT06934915|DRUG|Prednisone|Starting dose: 5 mg daily. Maximum dose: 60 mg daily. Dosage forms: 5 mg, 10 mg, and 20 mg capsules.
224051382|NCT03960073|DIETARY_SUPPLEMENT|Placebo|4 week oral daily dose of TTP placebo
224051383|NCT00073528|DRUG|Lapatinib|1500 mg orally once a day
223740942|NCT06934915|DRUG|Placebo|Capsules identical in size and appearance to those containing prednisone. Placebo capsules contain inactive ingredients.
224051384|NCT00073528|DRUG|Letrozole|2.5 mg orally once a day
224051385|NCT00073528|DRUG|Placebo|Placebo (which matched with lapatinib tablet)
224051386|NCT05855057|PROCEDURE|Flank suspended supine position percutaneous nephrolithotomy|The patients will be placed in the supine position with the shoulder and the buttock will be raised by a 3-l bag of water suspending the flank of the affected side. The body contour will be aligned to the edge of the table. The operating table will be adjusted to the jack knife position, with the tip of the lower part of the table will be slightly lowered. The leg of the affected side of the patent will be straightened dorsally flexed and slightly inner rotated, with the knee of the other side will be flexed. The patients will be then immobilized at the chest and the pelvis with two adherent tapes which crossed each other at the abdomen to form a 'V' shape.
224051387|NCT05855057|PROCEDURE|Supine percutaneous nephrolithotomy group|The patient will remain in the supine position, with the side of interest at the edge of the table, with a small cushion placed under the flank to elevate it 15-20°.
224051388|NCT05855057|PROCEDURE|Prone percutaneous nephrolithotomy group|Prone percutaneous nephrolithotomy. The prone position (PRON) technique followed these classic steps: patients will be placed in a lithotomy position and a ureteral catheter will be inserted through a rigid cystoscope to perform a retrograde pyelogram. The ureteral catheter will be fixed to a Foley catheter, and then the patient will be repositioned to the prone position with pads under their shoulders.
224051389|NCT02769663|BEHAVIORAL|questionnaires and neuropsychological assessments|
224144341|NCT05244538|DRUG|Propofol-remifentanil sedation|"Target controlled infusion (TCI) of remifentanil will be started at an effect concentration (Ce) of 1.5 ng/mL and TCI propofol at Ce 1.5 ug/mL.~The concentration of remifentanil will be adjusted in 0.5 ng/ml increments based on hand sign from the patient with a maximum effect concentration of remifentanil at 2.5 ng/ml."
224144342|NCT05843812|DRUG|Magnesium Sulfate 10 MG/ML|Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management
224144343|NCT04263779|BEHAVIORAL|Order of Options|Relevant providers who are part of the Geisinger preferred provider network will be presented at the top of the otherwise ranked list of SNFs.
224144344|NCT04263779|BEHAVIORAL|Default Option|Both the list and the map will present only the P-SNFs, with a button allowing patients to view all results only if they opt to do so. The optional P-SNF advantage video will be included and the link to it highlighted.
224144345|NCT00778726|DRUG|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
224144346|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.
224051390|NCT02467283|GENETIC|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
224051391|NCT06011564|DEVICE|Reminder function on Android computer tablet|Computer tablet with reminder function
224051392|NCT03979690|DEVICE|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
224051393|NCT00943020|DIETARY_SUPPLEMENT|Nutricia PreOp nutritional supplement|nutritional supplement
224051394|NCT00943020|DIETARY_SUPPLEMENT|Lipid|Drink
224051395|NCT00943020|DIETARY_SUPPLEMENT|Glutamine|Drink
224051396|NCT02341703|DRUG|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
224051397|NCT02341703|DRUG|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
224051398|NCT02341703|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
224051399|NCT02341703|OTHER|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
224051400|NCT01033617|PROCEDURE|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
224051401|NCT02887404|OTHER|Spine surgery analgesic pathway|Enhanced pain management care
224051402|NCT02887404|OTHER|Usual Care|Standard of pain management care
224051403|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
224051404|NCT00117598|DRUG|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
224051405|NCT00117598|DRUG|Investigator's choice|"Any of the following single agent treatments:~1. Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~2. Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~3. Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~4. Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~5. Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~6. Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~7. Prednisone 40 (20-60) mg/m2 PO daily or every other day~8. Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
224051406|NCT03956914|OTHER|Placebo|Placeob water 440 ml/day for 8 weeks
224051407|NCT03956914|OTHER|Deep sea water|Deep sea water 440 ml/day for 8 weeks
224051408|NCT00901771|DEVICE|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
224051409|NCT01616420|OTHER|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
224051410|NCT02198703|DIETARY_SUPPLEMENT|Probiotics bacterial strains|
223566712|NCT06607497|OTHER|Telemonitoring with Primary Tech Enhanced Care (PTEC-DM)|The Primary Tech-Enhanced Care (PTEC) programme focuses on encouraging patients to manage chronic conditions at home through user-friendly kits. The Home Diabetes Monitoring programme (PTEC-DM) enables home-based glucose and blood pressure monitoring once a week using a Bluetooth enabled device. These reading will be securely transmitted to the study team via the app and managed appropriately through teleconsultation. Additionally, participants will receive health nudges, encouragements, and reminders through in-app messages to support their well-being.
223566713|NCT06604793|DIETARY_SUPPLEMENT|Creatine|Creatine monohydrate
223566714|NCT06604793|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
224051411|NCT02198703|DIETARY_SUPPLEMENT|Placebo|
224051412|NCT00595322|OTHER|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains \< 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
224051413|NCT03853681|DIAGNOSTIC_TEST|additional blood sampling|additional blood sampling
224051414|NCT00236925|DRUG|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
224051415|NCT00236925|DRUG|Placebo|Placebo
224051416|NCT02887287|DRUG|EEN|
224051417|NCT01775735|DEVICE|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
224051418|NCT00617500|OTHER|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
224051419|NCT00617500|OTHER|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
224051420|NCT00617500|OTHER|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
224051421|NCT00617500|DRUG|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
224051422|NCT04118296|DRUG|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
224051423|NCT04227262|OTHER|MIRROR THERAPY|The children were instructed to sitting on chair and a mirror is placed in midsagittal plane of the child, with the normal limb in front of mirror and the affected limb is blocked so the patient see only the reflected movement of the sound limb (non affected).
224051424|NCT01586351|DEVICE|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
224051425|NCT04970225|OTHER|1 blood sample|4 tubes of 7 ml per sample (a single sample)
224051426|NCT04970225|OTHER|2 blood samples|4 tubes of 7 ml per sample / 2 samples : before / after antibiotic treatment
223440161|NCT05775861|DRUG|continuous interscalene brachial plexus block|The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
223440162|NCT00935064|DRUG|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
223440163|NCT00935064|OTHER|Placebo|Placebo orally one tablet once a day for 6 weeks.
223740943|NCT07137208|PROCEDURE|ESP block|In the ESP group, patients will be positioned in the right lateral position. The ultrasound probe will be placed vertically about 3 cm lateral to the spinous process of T9 to visualize the transverse process, trapezius, and erector spinae muscles. A 22-gauge spinal needle will be inserted in-plane in the cranial-to-caudal direction until the needle tip reaches the fascial plane between the erector spinae muscle and transverse process. Following hydrodissection with 2 mL of sterile saline to confirm needle placement, and negative aspiration to rule out intravascular placement, the local anesthetic will be injected. Likewise, the same block procedure will be performed at the T11 level and on both levels on the other side, 10 mL will be injected at each of the four injection sites.
224051427|NCT06284265|DRUG|Raphamin|Tablet for oral use.
224051428|NCT06284265|DRUG|Placebo|Tablet for oral use.
224051429|NCT03208751|BEHAVIORAL|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
224051430|NCT04688775|DRUG|Eptinezumab|Eptinezumab - concentrate for solution for infusion, intravenously
224051431|NCT04688775|DRUG|Placebo|Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously
224051432|NCT00898443|OTHER|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
224051433|NCT00898443|OTHER|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
224051434|NCT05198479|RADIATION|77 Lu-DOTA0-Tyr3-Octreotate|Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
224051435|NCT01028950|DRUG|YM150|oral
224051436|NCT02017639|DRUG|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
224051437|NCT02017639|DRUG|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
224051438|NCT00656773|DRUG|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
224051439|NCT00656773|DRUG|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
224051440|NCT00002860|PROCEDURE|Surgery|Complete surgical resection of metastatic melanoma
224051441|NCT05330247|OTHER|Carbohydrate-reduced high-protein (CRHP) Diet|Macronutrient intake of 30 percentage of energy from carbohydrate, 30 percentage of energy from protein and 40 percentage of energy from fat.
224051442|NCT05330247|OTHER|Conventional diabetes (CD) Diet|Macronutrient intake of 50 percentage of energy from carbohydrate, 17 percentage of energy from protein and 33 percentage of energy from fat.
224051443|NCT03591848|BEHAVIORAL|Online support decision tool|Online support decision tool, in addition of the standard oral information
224051444|NCT03591848|BEHAVIORAL|standard oral information|standard oral information
224051445|NCT06235840|BEHAVIORAL|working memory adaptive training|The computerized n-back training lasted 4 weeks and consisted of 12 training sessions, 3 per week, about 45 minutes for each
223440164|NCT06201468|OTHER|Group A SCAPULAR MOBILIZATION|"Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks."
223440165|NCT01723020|DRUG|AMG 232|Given an an oral tablet in escalating doses.
223440166|NCT06253000|PROCEDURE|Cryoablation|Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
223440167|NCT06253000|PROCEDURE|Radiofrequency ablation|"Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system."
224051446|NCT06235840|BEHAVIORAL|multi-domain non-adaptive control training|The cognitive training in active control groups included cognitive tasks involving: visual-spatial functions, visual and verbal memory, reasoning on visual and verbal material, and calculia. The training schedule in active control groups was the same as in the experimental groups.
224051447|NCT03644654|PROCEDURE|Standard care group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
223440168|NCT01211483|DRUG|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
224051448|NCT03644654|PROCEDURE|Noninvasive monitoring group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
224051449|NCT04695392|OTHER|R2 Bundle|"During the intervention phase subjects will receive R2.~1. Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~2. Cycled day-night lighting and modulation of sound to match the child's routine,~3. Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~4. Night fasting with bolus enteral daytime feedings,~5. Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~6. Continuity in nursing care, and~7. Parent diaries."
224051450|NCT00422526|DRUG|Micronised progesterone (Utrogestan)|
224051451|NCT00391664|BEHAVIORAL|Psychosocial|
224051452|NCT01918423|BEHAVIORAL|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
224051453|NCT00691990|PROCEDURE|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
224051454|NCT00615472|DRUG|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
224051455|NCT00615472|DRUG|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
224051456|NCT00615472|DRUG|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
224051457|NCT03929081|BEHAVIORAL|Inference Based Approach (IBA)|The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.
224051458|NCT03929081|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
224051459|NCT02019823|BEHAVIORAL|Informational SMS-text|
224051460|NCT02019823|BEHAVIORAL|Interactive SMS-text|
224051461|NCT02019823|BEHAVIORAL|Enhanced usual care|
224051462|NCT04045704|PROCEDURE|Cataract Surgery|Patients with bilateral Advanced Age-related macular degeneration and concurrent cataracts will be receiving bilateral cataract surgery
224051463|NCT06292572|PROCEDURE|Retinal Detachment Surgery|Retinal Detachment Surgery that consists in either Pars Plana Vitrectomy or Scleral Buckling or a combination of both techniques, and with or without use of intraocular tamponade
224051464|NCT05138666|BIOLOGICAL|respiratory sample|tracheal aspirate or sputum if the patient is not intubated
224051465|NCT05138666|BIOLOGICAL|blood sample|Blood sampling drawn from an existing arterial line twice a week
223440169|NCT01211483|DRUG|Erlotinib|Tablet 150 mg for oral administration
223440170|NCT01211483|DRUG|Placebo|Placebo liquid matching U3-1287 for IV infusion
223440171|NCT01700543|PROCEDURE|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
223740944|NCT07137208|PROCEDURE|TAP Block|In the TAP group, patients will be positioned in the supine position. A posterior approach will be employed, with the ultrasound probe placed transversely on the anterolateral abdominal wall, midway between the costal margin and iliac crest, posterior to the midaxillary line. This will allow visualization of the external oblique, internal oblique, and transversus abdominis muscles. The probe will then be moved posteriorly to identify the tapering of the transversus abdominis muscle toward the quadratus lumborum. A 22-gauge spinal needle will be inserted in-plane from anterior to posterior. Following hydrodissection with 2 mL of sterile saline to confirm needle placement, and negative aspiration to rule out intravascular placement, the local anesthetic will be injected into the plane between the internal oblique and transversus abdominis muscles. Likewise, the same block procedure will be performed on the other side.
224051466|NCT05218590|DEVICE|Video rigid stylet|Nasal intubation was performed using the video rigid stylet.
224051467|NCT06098898|DRUG|NK510|NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles.
224051468|NCT06098898|DRUG|Tislelizumab，atezolizumab or Trastuzumab|Administer according to the instructions.
224144347|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients that are heterozygous carriers of c.1236G\>A or c.2846A\>T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.
224144348|NCT04194957|DRUG|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.
224144349|NCT02084069|DRUG|Atorvastatin|
223478634|NCT03398096|DEVICE|Cardiac shock wave therapy|Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
224051469|NCT02492477|PROCEDURE|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
223440172|NCT05748158|BEHAVIORAL|Weight loss|"A behavioral lifestyle program, up to 20 weeks in duration, based on interventions shown to be successful for weight loss such as the Diabetes Prevention Program (DPP), Action for Health in Diabetes (Look AHEAD), and Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy Study (CALERIE). Weekly sessions, led by experienced interventionists, will provide education and behavioral strategies for weight loss focused an energy-reduced diet and physical activity.~Participants must meet the following milestones to continue in the study:~* ≥ 2% weight loss anytime between 28 and 34 days after the start of the intervention~* ≥ 5% weight loss anytime between 140 and 146 days after the start of the intervention~* ≥ 7% weight loss by the end of 35 weeks~After achieving ≥7% weight loss followed by weight stability, participants are observed, without further intervention, for 52 weeks."
223440173|NCT03420807|DEVICE|MHRC|Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
223440174|NCT05288296|DEVICE|dynamic taping|"1. The intervention of dynamic tape can improve the LESS, which also means that we may reduce the probability of ACL injury through the intervention of dynamic tape.~2. By establish a native model of single-leg and double-leg LESS can predict the occurrence of ACL injury early and further prevent it."
223440175|NCT02090621|PROCEDURE|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
223440176|NCT00041665|DRUG|Recombinant Human Keratinocyte Growth Factor|
223440177|NCT00460265|DRUG|ARM 2|Subjects will receive Cisplatin plus 5FU
223440178|NCT00460265|DRUG|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
223440179|NCT02289846|DRUG|IW-9179|
223440180|NCT02289846|DRUG|Matching Placebo|
223440181|NCT04692766|BIOLOGICAL|RPH-104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
223440182|NCT04692766|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
223440183|NCT05878821|DEVICE|Shockwave|Shockwave therapy session once a week for month 1000shock per session
223440184|NCT00880386|DRUG|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
223440185|NCT02416050|PROCEDURE|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
223440186|NCT01534364|OTHER|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
223440187|NCT02680613|BEHAVIORAL|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
223440188|NCT02680613|BEHAVIORAL|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
223440189|NCT05596500|DIETARY_SUPPLEMENT|Blueberry-protein gel|Sport gel with blueberry extract and plant protein.
223440190|NCT05596500|DIETARY_SUPPLEMENT|Blueberry gel|Sport gel with blueberry extract only.
223440191|NCT05596500|DIETARY_SUPPLEMENT|Placebo|Sport gel without the blueberry extract polyphenols and without protein.
223440192|NCT03203759|OTHER|Home hospitalization|See above
223440193|NCT03203759|OTHER|Traditional inpatient hospitalization|See above
223440194|NCT02440542|OTHER|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
223440195|NCT01741506|DRUG|Dalteparin (Fragmin®)|
223440196|NCT01992315|DEVICE|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
223440197|NCT05939115|DEVICE|Transcranial Magnetic Stimulation MagPro R30 with the MCF-B70 figure-of-eight coil (MagVenture, Denmark)|TMS Therapy System with Theta Burst Stimulation
223440198|NCT06437275|OTHER|Questionnaire for the degree of knowledge and attitude|Questionnaire for the degree of knowledge and attitude of Egyptian physicians regarding emergency treatment of traumatic dental injuries.
223440199|NCT06649071|OTHER|Naturalistic observation|Naturalistic observation
224051470|NCT02492477|DRUG|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
224051471|NCT02492477|DRUG|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
224051472|NCT05392504|OTHER|Core stability exercise|The core stability training consist of three phases
224051473|NCT05392504|OTHER|Scroth's Program|The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
224051474|NCT03617250|OTHER|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
224051475|NCT02849197|PROCEDURE|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
224144350|NCT00861588|DRUG|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
224144351|NCT00861588|DRUG|placebo|starch placebo
224051476|NCT06272786|PROCEDURE|conventional physiotherapy program.|It will be applied to a rehabilitation program including joint range of motion exercises and physical therapy modalities by a physiotherapist at the Physical Therapy Hospital.
224051477|NCT06272786|PROCEDURE|Suprascapular nerve block|Bupivacaine hydrochloride will be used in this injection. 5 ml of bupivacaine hydrochloride 5% and 5 ml of saline will be drawn into a 10 ml syringe and ejection will be performed from the superior of the suprascapular noch under USG guidance.
224051478|NCT00121784|DRUG|mycophenolate mofetil [CellCept]|1
224051479|NCT02811549|DEVICE|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults with eligible hearing profile.
224051480|NCT00241995|DRUG|Anticonvulsants|
224051481|NCT03911973|DRUG|Gedatolisib|Gedatolisib, 150-180MG IV
224051482|NCT03911973|DRUG|Talazoparib|.75-1.00mg
224051483|NCT04123236|OTHER|Age 0-18|Patients under 18 years of age
224051484|NCT04123236|OTHER|Age 18-26|Patients over18 years of age
224051485|NCT04123236|OTHER|Girls|Girls
224051486|NCT04123236|OTHER|Boys|Boys
224051487|NCT00278759|PROCEDURE|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
224051488|NCT00649259|DRUG|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
224144352|NCT03273231|DRUG|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
223440200|NCT03776071|DRUG|Enzastaurin Hydrochloride|mg
223440201|NCT03776071|OTHER|Placebo|mg
223440202|NCT03776071|DRUG|Temozolomide|mg/m\^2
224051489|NCT00649259|DRUG|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
224051490|NCT02478970|DEVICE|Konan SP4000|current standard of care at Kellogg Eye Center
224051491|NCT02478970|DEVICE|NIDEK CEM-350|newly marketed device
224051492|NCT04784728|DRUG|Lidocaine topical system 1.8%|lidocaine patch
224051493|NCT04712877|DIAGNOSTIC_TEST|ctDNA, tumor NGS|Testing for actionable oncogenic drivers
224051494|NCT01379469|DRUG|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated..
224051495|NCT01379469|DRUG|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
224051496|NCT01431196|BIOLOGICAL|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
224051497|NCT05500001|BEHAVIORAL|Supporting Patients by Family Education in Psychotic Illness Group|Psychoeducation for families supporting young adults with psychosis.
224051498|NCT01771055|PROCEDURE|Galactose|Galactose dripped into the abdomen after surgery
224051499|NCT01771055|PROCEDURE|Standard surgical methods|
224051500|NCT04391036|DEVICE|High Eudragit® Content Vaginal Film|High (12.8%) Eudragit® Content Vaginal Film
224051501|NCT04391036|DEVICE|Low Eudragit® Content Vaginal Film|Low (6.4%) Eudragit® Content Vaginal Film
224051502|NCT04801875|OTHER|Selected Exercise|The violin and ney groups performed a structured exercise training program 3 times a week for a total of 8 weeks. Adherence to the exercise training program was checked using a follow-up schedule to ensure regular participation of the musicians. The 8-week exercise training program was given with same physiotherapist under the same conditions. The every exercise session consisted of warm-up (3-5 min), main exercise (30-35 min) and cooling periods (3-5 min). The main exercise period was included ROM (10 min), stretching (5-7 min), isometric (5-10 min) and stabilization exercises (5 min).
224144353|NCT03273231|DRUG|Saline|0.9% saline solution
224144354|NCT02452112|DRUG|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
224144355|NCT02452112|DRUG|Placebo|Placebo patch to be placed on the site of pain
223440203|NCT03776071|RADIATION|Radiotherapy|Gy
223440204|NCT04792671|BEHAVIORAL|Sociodemographic variables|age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.
223440205|NCT04792671|BEHAVIORAL|Family affluence scale (FAS)|a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.
223440206|NCT04792671|BEHAVIORAL|Edinburgh postnatal depression scale (EPDS)|s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed
223440207|NCT04792671|BEHAVIORAL|"Symptom Checklist 90 SCL 90:"|is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed
223440208|NCT02719353|DEVICE|comfilcon A Extended Range test lens|contact lens
223440209|NCT02719353|DEVICE|comfilcon A control lens|contact lens
223440210|NCT05730153|BIOLOGICAL|advanced PRF|advanced PRF+ surgery
223440211|NCT02737228|DRUG|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
223440212|NCT02737228|DRUG|Gemcitabine|1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)
223440213|NCT02737228|DRUG|Erlotinib|100 mg per oral daily per cycle (4 weeks)
224051503|NCT01856244|BEHAVIORAL|treadmill walking|
224051504|NCT01856244|DEVICE|Treadmill|
224051505|NCT00971763|BIOLOGICAL|rituximab|
224051506|NCT00971763|DRUG|cyclophosphamide|
224144356|NCT00515580|PROCEDURE|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
223440214|NCT03386617|DRUG|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
223440215|NCT06025253|DEVICE|Negative Pressure Wound Therapy|Application of negative-pressure wound therapy (NPWT) post major lower extremity amputation
223440216|NCT06025253|DEVICE|Standard Wound Dressing|Application of standard wound dressing post major lower extremity amputation
223440217|NCT02651415|DRUG|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is \<30% fat, \~300-550 calories."
223440218|NCT02651415|DRUG|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
224051507|NCT00971763|DRUG|gemcitabine hydrochloride|
224051508|NCT00971763|DRUG|prednisolone|
224051509|NCT00971763|DRUG|vincristine sulfate|
224051510|NCT02072928|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
224051511|NCT05466812|DRUG|Sr-89|"1. strontium-89 chloride treatment~2. periodical evaluation and follow-up"
224051512|NCT05741281|BEHAVIORAL|Physical exercises program|\- Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
224051513|NCT05529056|DRUG|Atropine Sulfate 01|Atropine sulfate 01 ophthalmic solution
224051514|NCT05529056|DRUG|Atropine Sulfate 02|Atropine sulfate 02 ophthalmic solution
224051515|NCT05529056|DRUG|Atropine Sulfate 03|Atropine sulfate 03 ophthalmic solution
224051516|NCT05529056|DRUG|Placebo|Placebo ophthalmic solution
224051517|NCT02937012|DRUG|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
224051518|NCT02937012|DRUG|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
224051519|NCT02937012|DRUG|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
224051520|NCT00331695|DRUG|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
224051521|NCT02724384|DEVICE|MOE Plasma Delivery System A|Plasma treatment
224051522|NCT02724384|DEVICE|MOE Plasma Delivery System B|Plasma treatment
224051523|NCT04972240|OTHER|customization of abutment|we will customize abutment for every patient not ready made
224051524|NCT05667948|DRUG|Chemotherapy|different treatments based on the molecular analysis
224051525|NCT01708070|BEHAVIORAL|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
224051526|NCT05179226|DRUG|Ferric Derisomaltose|All subjects will be treated with Ferric derisomaltose 20 mg/kg at baseline visit except for 12 subjects included in the PK-group, who will be treated with 10 mg/kg
224051527|NCT00291798|PROCEDURE|rate of remission|
224051528|NCT02905370|BEHAVIORAL|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
224051529|NCT02905370|BEHAVIORAL|Enhanced Usual Care (EUC)|"Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group."
224144357|NCT05099536|DRUG|3D011-08|participants will receive 15mg (starting dose)intravenous drop of 3D011-08,All subjects in each cohort will receive a single dose of 3D011-08 first, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive doses on 1,3,5day of each week (28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first.Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RPTD).
223440219|NCT06355167|DIETARY_SUPPLEMENT|Bacopa monnieri|Daily oral intake of Bacopa monnieri during 6 weeks
224144358|NCT01933321|BIOLOGICAL|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
224144359|NCT02178072|DRUG|5-Azacitadine|
224144360|NCT04373018|PROCEDURE|Sodium hypochlorite|Sodium hypochlorite irrigant will be used during biomechanical preparation.
223478635|NCT03315949|DRUG|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
223440220|NCT03284372|BEHAVIORAL|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
223440221|NCT03284372|BEHAVIORAL|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
223440222|NCT04234269|OTHER|Assessment|Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
223440223|NCT04258969|BEHAVIORAL|Pedaling|Participants will pedaling at a low-moderate intensity using a stationary pedal ergometer concurrent to their chemotherapy (FOLFOX or FOLFIRI) infusion. Participants will cycle for 30 min within the first 2 hours of their infusion.
223440224|NCT00103922|DRUG|cilomilast|
223440225|NCT01917344|OTHER|MRI|
223440226|NCT01497886|BEHAVIORAL|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
223440227|NCT01497886|BEHAVIORAL|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
223440228|NCT01626625|DRUG|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
223440229|NCT01626625|OTHER|autograft taken from iliac crest|patient will be transplanted with autograft
223440230|NCT03594019|PROCEDURE|Connective tissue graft|Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
223440231|NCT03594019|PROCEDURE|socket shield technique|The procedure is used to split the teeth and preserve the buccal part
224051530|NCT01719315|OTHER|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
223440232|NCT03594019|PROCEDURE|Immediate implant placement|The implant will be placed in the frest socket immediately after tooth extraction
223440233|NCT05388695|BIOLOGICAL|Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells|Single or sequential injection of CD19, CD20 and CD22 CAR T cells.
223440234|NCT06071182|DEVICE|Task-oriented Fruit ninja game|The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks
223440235|NCT06071182|OTHER|sham-controlled therapy|The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
224051531|NCT02573870|DRUG|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
224051532|NCT02573870|DRUG|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
224051533|NCT02573870|DRUG|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
224051534|NCT00760019|DRUG|salsalate|1.5 grams orally 3 times daily
224051535|NCT00760019|DRUG|placebo|matching placebo
224051536|NCT06427408|OTHER|Non applicable|Placental transcriptomic analysis
224051537|NCT01575106|DEVICE|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
224051538|NCT02541279|PROCEDURE|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
224051539|NCT01414881|DRUG|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
224051540|NCT01414881|DRUG|Placebo|Placebo administered subcutaneously (SC) once weekly
224051541|NCT03785158|OTHER|Liquid Melatonin|Melatonin is a natural supplement.
224051542|NCT03785158|OTHER|Placebo|Similar looking/tasting placebo syrup
224144361|NCT04373018|PROCEDURE|Chlorhexidine|Chlorhexidine irrigant will be used during biomechanical preparation.
224144362|NCT04373018|PROCEDURE|Chlorhexidine + Hydrogen peroxide|Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
224144363|NCT00438919|DEVICE|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
224144364|NCT01661309|DIETARY_SUPPLEMENT|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
224144365|NCT01661309|DIETARY_SUPPLEMENT|Methylcobalamin|Aimed at reducing plasma tHcy.
224144366|NCT00280605|DRUG|Alfuzosin|
224144367|NCT06279637|BEHAVIORAL|Joint Home-DM-BAT Intervention|8 weekly sessions of telephone-delivered, manualized education on diabetes management, problem solving of social needs, and behavioral activation.
224144368|NCT06279637|BEHAVIORAL|Usual Care|Diabetes education materials will be mailed weekly and monthly according to the booster schedule
224144369|NCT02268136|DRUG|BIII 890 CL|
224144370|NCT02268136|DRUG|Placebo|
224144371|NCT02701179|DRUG|Lignocaine 1% concentration solution|
224144372|NCT02701179|DRUG|Lignocaine 2% concentration solution|
224144373|NCT01106391|DEVICE|"Cordis AAA stent graft system INCRAFT TM"|
224144374|NCT03200795|OTHER|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula (\[Heart rate reserve x training percentage\] + resting heart rate)(Nuhu \& Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu \& Maharaj, 2017)."
224144375|NCT03200795|OTHER|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
224144376|NCT05041491|BEHAVIORAL|BREAK|The BREAK intervention is a physical activity regimen.
224144377|NCT05041491|BEHAVIORAL|ONE|The ONE intervention is a physical activity regimen.
223440236|NCT00412217|DRUG|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
223440237|NCT00412217|DRUG|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
223440238|NCT00412217|OTHER|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
224144378|NCT06643390|DRUG|MK-2225|Subcutaneous administration
224144379|NCT06643390|OTHER|Placebo|Subcutaneous administration
223440239|NCT06731114|PROCEDURE|Suboccipital muscle release|"Suboccipital muscle release.6 consecutive sessions for 2 weeks~• Frequency:( 3mins 3 reps) 9 mins .12 sessions in total"
223440240|NCT06731114|PROCEDURE|Conventional physical therapy|TENS and hot pack for 10 mins 6 days a week for consecutive 2 weeks
223440241|NCT06731114|PROCEDURE|Sternocleidomastoid release|Frequency: 5 mins of SCM release and 9 mins (3 mins 3 reps )of suboccipital release. 12 sessions in total.
224144380|NCT02103036|PROCEDURE|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
224144381|NCT02103036|PROCEDURE|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
224144382|NCT02103036|DEVICE|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
224144383|NCT02103036|DEVICE|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
224144384|NCT01110772|DEVICE|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
224144385|NCT01110772|DEVICE|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
223440242|NCT04453800|DRUG|sofadil【Neu2000KW】|500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
224051543|NCT01206062|DRUG|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP \<120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
224051544|NCT01206062|DRUG|Standard control of SBP|Participants in the Standard BP arm have a goal of SBP \<140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
224051545|NCT04229433|DRUG|SHR2285 tablet|Pharmaceutical form: SHR2285 tablet Route of administration: single dose and multiple doses.
224051546|NCT04229433|DRUG|Placebo|Pharmaceutical form: Placebo tablet Route of administration: single dose and multiple doses.
224051547|NCT04347707|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel structured form of therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. The program involves 20, once per week, scheduled group therapy sessions that last for 2 hours. There are two components of the program, the first is the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and will target maternal mental health symptomology. The second section is the parent skill training materials, which have been designed to correspond to the 4 core DBT modules (Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
224051548|NCT06090214|DIAGNOSTIC_TEST|Liquid biopsy|For cases: 60 mL blood sample (40 ml for CellSave analysis and 20ml for collection) at visit1 then 20 ml for CellSave analysis at visit2 and visit3 For controls: 40 ml (20ml for CellSave analysis and 20ml for collection) at visit1
224051549|NCT03717909|DRUG|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
224051550|NCT03717909|DRUG|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
224051551|NCT05270837|DRUG|Pegvaliase|Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
224051552|NCT05270837|OTHER|Diet Only|Diet Control
224051553|NCT00762892|DRUG|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
224051554|NCT00762892|DRUG|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
224051555|NCT02407262|DIETARY_SUPPLEMENT|Black seed oil|
224144386|NCT02919137|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
224300400|NCT01617694|DRUG|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
224300401|NCT01617694|DRUG|Normal Saline|
224144387|NCT04426890|BIOLOGICAL|CT-P39|Prefilled syringe (PFS) of 1 mL solution
224300402|NCT01599065|OTHER|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
224300403|NCT03267875|PROCEDURE|Blood Test|draw out 2 blood tubes from a patient
223440243|NCT04453800|DRUG|Sofadil|750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
223440244|NCT04453800|DRUG|Sofadil|1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
223440245|NCT04453800|OTHER|placebo|Saline was administered intravenously
223440246|NCT04676685|DRUG|E2730|E2730 capsules.
224051556|NCT02407262|OTHER|Placebo|vegetable oil
224144388|NCT04426890|BIOLOGICAL|EU-approved Xolair|Prefilled syringe (PFS) of 1 mL solution
224144389|NCT06799234|BIOLOGICAL|ChAdOx1 RVF|One 0.36mL dose contains 5x10\^10vp ChAdOx1 RVF.
224144390|NCT06799234|BIOLOGICAL|Rabies Vaccine|1mL per dose
224144391|NCT06789432|DRUG|Atorvastatin 10 mg and ezetimibe 10 mg|Atorvastatin/Ezetimibe 10/10mg once daily
224144392|NCT06789432|DRUG|Atorvastatin 20 mg|Atorvastatin (20 mg) Monotherapy once daily
224300404|NCT00390130|DRUG|Pentacel (DPTaP+Hib)|
224300405|NCT00390130|DRUG|Prevnar (conjugated pneumococcal vaccine)|
224144393|NCT06665256|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel
224144394|NCT06665256|OTHER|Active Comparator Option|Investigator choice of treatment as per protocol
224144395|NCT03894098|PROCEDURE|Nerve block|High ankle nerve block
224144396|NCT01772836|DRUG|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
224144397|NCT01772836|DRUG|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
223440247|NCT04676685|DRUG|E2730-matched placebo|E2730-matched placebo capsules.
223440248|NCT01007760|OTHER|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
223440249|NCT04072991|OTHER|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
224051557|NCT01378507|BEHAVIORAL|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
224051558|NCT03514537|PROCEDURE|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
224051559|NCT03514537|DEVICE|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
224051560|NCT03514537|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
224051561|NCT03514537|DRUG|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
224144398|NCT01772836|DRUG|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
224144399|NCT04365894|OTHER|Transformative learning theory|According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
224144400|NCT01241123|PROCEDURE|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
224051562|NCT03514537|DRUG|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
224051563|NCT03947983|BEHAVIORAL|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
224144401|NCT01241123|DRUG|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
224144402|NCT01241123|RADIATION|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
223440250|NCT01103947|DEVICE|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
223440251|NCT01103947|DEVICE|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
223440252|NCT01103947|DEVICE|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
223440253|NCT01103947|DEVICE|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
224051564|NCT03947983|BEHAVIORAL|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
224051565|NCT00245544|DRUG|MK0759|
224051566|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
224051567|NCT04074967|DRUG|Phase Ib ARRY-614 + nivolumab+ipilimumab|ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
224051568|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
224051569|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
224051570|NCT04074967|DRUG|Phase II ARRY-614 + nivolumab+ipilimumab (RCC)|"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
224051571|NCT02466711|DRUG|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
224051572|NCT02466711|DRUG|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
224144403|NCT01241123|DEVICE|pedometers|to record the amount of ambulation
224144404|NCT01673269|OTHER|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
224144405|NCT00954057|DRUG|LIPO-102|intraorbital injection
224144406|NCT00954057|DRUG|Placebo|intraorbital injection
223440254|NCT00805077|PROCEDURE|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
223440255|NCT00805077|OTHER|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
223440256|NCT00237250|DRUG|vildagliptin|
223440257|NCT06637436|BEHAVIORAL|Motivational Interviewing (MI)|This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting pre-exposure prophylaxis (PrEP) in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
224144407|NCT00972972|DIETARY_SUPPLEMENT|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
224144408|NCT00972972|DIETARY_SUPPLEMENT|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
224144409|NCT04227327|DRUG|Abemaciclib|Abemaciclib will be administered orally at 150 mg twice daily
223566715|NCT06606756|OTHER|Patient Registry without intervention|This is a patient registry that collects real world data without intervening with therapeutic decision
224144410|NCT04227327|DRUG|Aromatase Inhibitors|Letrozole 2,5 mg daily or Anastrozole 1 mg daily
223440258|NCT06637436|BEHAVIORAL|Contingency Management (CM)|Provides incentives for initiating PrEP care ($50) and filling a PrEP prescription ($50) in the three months following randomization.
223440259|NCT04351126|DRUG|Fludrocortisone 0.1 Milligrams (mg)|0.2-0.6 mg/day of fludrocortisone is prescribed
223440260|NCT04351126|DRUG|Bromocriptine|2.5 mg prescribed Vaginally twice daily
223440261|NCT02332564|OTHER|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
223440262|NCT00365209|OTHER|laboratory biomarker analysis|Correlative studies
223440263|NCT00365209|OTHER|pharmacological study|Correlative studies
223440264|NCT00365209|DRUG|curcumin|Given orally
224051573|NCT05237232|OTHER|Magnetic Resonance Angiography (MRA) additional acquisition time|Additional acquisition time, time of flight, during brain MRA of the care allowing to obtain the same quality of vascular anatomical visualization as the brain MRA with gadolinium contrast medium injection performed for the care of the patients treated with jugulocarotid ECMO.
223440265|NCT01618110|DEVICE|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
224051574|NCT05237232|OTHER|Modeling cerebral vascularization|"The modeling of cerebral vascularization from CRIMSON software (CaRdiovascular Integrated Modeling \& Simulation) requires several inputs:~* The MRA images~* The cardiac function curve~* The cerebral blood flow~* Measurement of systolic, diastolic and mean arterial blood pressure"
224051575|NCT06151912|OTHER|Postoperative Nausea and Vomiting scala|The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.
224051576|NCT06151912|OTHER|Quality of life|The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.
224051577|NCT05895006|DEVICE|Alternating Current Stimulation (tACS)|A weak electrical current will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 milliamp (mA) sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup. Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
224051578|NCT05895006|DEVICE|Sham for Transcranial Alternating Current Stimulation (tACS)|Stimulation electrodes will be placed on the scalp, but no current will be passed. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
224144411|NCT06549218|DIAGNOSTIC_TEST|newborn genetic screening and whole genome sequencing|newborn genetic screening (panel of treatable diseases); whole genome sequencing (if newborn develops symptoms suggestive of a genetic disease)
224144412|NCT05551793|DRUG|Dupilumab|Dupilumab: 300mg SC injections
224144413|NCT05551793|DRUG|Placebo|Placebo: SC injections of equivalent volume
224144414|NCT01631292|DIETARY_SUPPLEMENT|600 IU Vitamin D3|Once daily
224144415|NCT01631292|DIETARY_SUPPLEMENT|2000 IU Vitamin D3|Once daily
224144416|NCT01631292|DIETARY_SUPPLEMENT|4000 IU Vitamin D3|Once daily
223440266|NCT01618110|OTHER|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
223440267|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
223440268|NCT01398410|DRUG|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
223440269|NCT03628248|PROCEDURE|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
223440270|NCT03628248|PROCEDURE|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
223440271|NCT06234111|COMBINATION_PRODUCT|Semaglutide 2.4 mg, total diet replacement, behavioural intervention|Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.
224144417|NCT01353755|DRUG|Grass pollen specific immunotherapy|"* Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
223440272|NCT03724240|BIOLOGICAL|Placebo solution|4 x 2 injection over 21 days the dosage is100 µg/ml
223440273|NCT03724240|BIOLOGICAL|gpASIT+TM|4 x 2 injection over 21 days the dosage is100 µg/ml
223440274|NCT02176460|DRUG|Colchicine|0.5mg twice daily for 16 weeks
223440275|NCT02176460|DRUG|Placebo|1 tablet twice daily
223440276|NCT04587401|PROCEDURE|normotensive patients|patients who do not have high blood pressure diagnosis and actual blood pressure is within the normal range
223440277|NCT04587401|PROCEDURE|patients with hypertension diagnosis|Patients who have high blood pressure diagnosis
223440278|NCT04587401|PROCEDURE|patients who do not know they are hypertensive but actual blood pressure is high|patients with preoperative high blood pressure, who do not know they are hypertensive
223478636|NCT02426697|DRUG|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
224051579|NCT05895006|DEVICE|Transcranial Random Noise stimulation (tRNS)|A weak electrical currents will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 mA sinusoidal current oscillating at random frequency (1-200 Hz). Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
224051580|NCT01007032|BIOLOGICAL|Cixutumumab|Cixutumumab intravenously
224144418|NCT01353755|DRUG|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
224144419|NCT03241732|OTHER|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
224144420|NCT03241732|DIETARY_SUPPLEMENT|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
224144421|NCT03241732|BEHAVIORAL|Neuro Emotive Technique|Neuro Emotive Technique sessions
224144422|NCT04906135|OTHER|Experimental manipulation of stimulation parameters|This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
224144423|NCT04702165|DEVICE|lung resection with Lung Resection Marker Locator Kit|Nodules eligible for surgical resection using the Lung Resection Marker Locator Kit
224144424|NCT06172127|DRUG|Trastuzumab deruxtecan|10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.
224144425|NCT06172127|DRUG|Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection|20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.
224144426|NCT06172127|DRUG|Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection|15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
224144427|NCT05380453|BIOLOGICAL|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
224300406|NCT03808662|RADIATION|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x \[1 + d/(α/β)\] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
224300407|NCT03808662|DRUG|Standard of care|Standard of care per physician discretion
224300408|NCT05520320|DEVICE|Hypothermic oxygenated machine perfusion (any device)|After static cold storage, all grafts included in this study are subjected to \>1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
224051581|NCT01025960|PROCEDURE|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
224051582|NCT01025960|PROCEDURE|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
224300409|NCT01550744|DRUG|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
224300410|NCT01550744|DRUG|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
224300411|NCT01550744|DRUG|Placebo|Form = Injection, route = subcutaneous
223566716|NCT06606756|OTHER|Digital Registry and Feedback on clinical data|The data is entered via a validated online platform and is provided back to the center in aggregated form
224051583|NCT04292808|DRUG|Methoxyflurane|Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.
224051584|NCT05843721|DEVICE|KOS (Intranasal kinetic oscillation stimulation)|Treatment is 10 minutes in each nasal cavity. Totally 2 x 10 minutes per treatment.
224051585|NCT01737918|PROCEDURE|TOT|
224051586|NCT01737918|DRUG|solifenacin|
224144428|NCT05380453|DRUG|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter.
224144429|NCT05840614|BEHAVIORAL|The remote family support program|"Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT."
224144430|NCT06295107|DIAGNOSTIC_TEST|Ankle Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
224144431|NCT06295107|DIAGNOSTIC_TEST|Knee Passive Range of Movement (pROM)|Ankel and knee pROM measurements.
224144432|NCT04459052|DIETARY_SUPPLEMENT|N acetyl cysteine|Intervention: IV NAC infusion: Dose: 50mg in 200ml of Dextrose 5% in Water (D5W), frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 500 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
224300412|NCT01534923|BEHAVIORAL|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
224300413|NCT05376852|COMBINATION_PRODUCT|based decitabine and olverembatinib（HQP1351)chemotherapy|"AP-CML treated with decitabine 10mg/m2 d1-5 intravenously (IV) over 60 minutes on days 1-5 and HQP1351 40mg qod every 28 days.After completion of HQP1351 lead-in, patients will receive HQP1351 PO qod on days 1-28 of subsequent cycles.~BC-CML:treated with decitabine 20mg/m2 d1-5 IV on days 1-5 and HQP1351 40mg qod every 28 days,with or without other chemotherapy Drugs"
224144433|NCT04459052|DRUG|[F-18] Fluorodopa Positron Emission Tomography|FDOPA PET diagnostic imaging to to measure dopamine function, serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 months.
223440279|NCT03845101|BEHAVIORAL|CBT with virtual reality exposure therapy|The patients receiving the in virtuo exposure will be immersed using an Oculus Go head-mounted display, enabling viewing of 360° spherically camera recorded VR environments. The VR scenarios will thus be high-resolution 360° stereoscopic films, that are played around the viewer. For ease of use, the individual videos will be administered from an app that has been designed to be as intuitive to operate as possible. The patient will only have to put on the headset, adjust the focus and choose the desired environment by looking at it in the app. 360° video was chosen because it gives the most photorealistic visuals, while also being the cheapest to produce. The downside is that it does not allow direct user-interaction (e.g. the viewer cannot affect the environment in any way). To circumvent this, there are multiple junctions throughout the films where the actors will talk directly and unsolicited to the viewer while also allowing time for the viewer to respond.
224051587|NCT01841749|PROCEDURE|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
224144434|NCT05625828|BEHAVIORAL|Cognitive-motor Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of cognitive-motor exercises where participants have to perform two tasks consequently (for example, walking while answering math questions or throwing a ball while reverse walking) and 5 minutes of stretching exercises.
224144435|NCT05625828|BEHAVIORAL|Multifactorial Physical Activity|Physical activity program that consist of 1 sessions per week during 10 weeks (from Week 2 to Week 11). Each session includes a 10 minutes warm up with light walking, 45 minutes of multifactorial exercises that consists of high speed walking, resistance training and balance training in single task condition and 5 minutes of stretching exercises.
224144436|NCT04268004|BEHAVIORAL|FP Decision Tool and Discussion|The intervention will be administered by a trained interventionist. The interventionist will administer the digital FP Decision Tool to families in the intervention arm. The tool asks questions examining each AYA's thoughts or feelings regarding parenthood and fertility preservation. The parent version asks the same questions, plus additional questions asking the parent to rate their son's feelings on certain topics (i.e., whether their son wants to have a child, whether their son would be as happy with an adopted child versus a biological child). Items are coded based on the domains of the Health Belief Model (perceived benefits, perceived barriers, perceived threats, self-efficacy, and cues to action). Items are scored and the trained interventionist will facilitate a guided discussion based on the family's responses and discrepancies.
224144437|NCT05558696|DRUG|Bomedemstat|Oral tablet
224144438|NCT01383642|OTHER|No intervention, observational study|
224300414|NCT00344851|DRUG|metformin, exenatide or combined (metformin & exenatide )|
224051588|NCT00677820|BIOLOGICAL|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
224144439|NCT03995108|DRUG|Mavorixafor|Mavorixafor provided as 100 mg capsules.
224144440|NCT03995108|DRUG|Placebo|Placebo matching to mavorixafor capsules
224144441|NCT06135415|DRUG|Tirbanibulin|Participants will apply tirbanibulin ointment topically on the face or balding scalp with AK.
224144442|NCT06135415|OTHER|Vehicle ointment|Participants will apply vehicle ointment topically on the face or balding scalp with AK.
224144443|NCT04946084|PROCEDURE|Tympanocentesis|When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.
224144444|NCT04946084|OTHER|Nasal Phalangeal Swab and Wash|Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.
224300415|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
223740945|NCT07137208|DRUG|Bupivacaine injection|A total of 20 mL of 0.25 bupivacaine will be administered at each side.
224051589|NCT00677820|BIOLOGICAL|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
224051590|NCT05252429|DRUG|Docetaxel|Docetaxel 75mg/m2; q21
224051591|NCT05252429|DRUG|Pembrolizumab|Pembrolizumab 200mg, q21
224051592|NCT04253184|DEVICE|Micra AV Transcatheter Pacing System|The Micra AV Transcatheter Pacing System (TPS) is a miniaturized single chamber pacemaker that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart to provide bipolar sensing and pacing. The Micra AV system provides a form of VDD pacing that is based on mechanical atrial sensing utilizing a 3-axis accelerometer.
224051593|NCT05322018|DIAGNOSTIC_TEST|Faces Thermometer Scale (FTS)|The Faces Thermometer Scale (FTS) is a one-item measure with 11 numeric rating scale steps (0, no pain to 10, much pain). Each step is associated with different faces and colors. The app presents all information in text, sound, and picture. FTS is part of PicPecc, an application for mobile devices. The child/adolescent assesses their pain on a tablet by moving the finger on the scale and points to the color and face that represent their appraised level of pain.
224144445|NCT04946084|OTHER|Blood Draw|Venipuncture
224144446|NCT01743170|OTHER|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
224051594|NCT04653636|OTHER|Arthrographic distension|"The treatment consists in one to three shoulder joint capsule arthrographic distension. It consists after local anesthesia, in an injection under pressure of xylocaine 1% and physiological serum in the glenohumeral joint associated with an ampoule of corticosteroids (Betamethasone or Triamcinolone hexacetonide ) at the end of the operation.~* first arthrographic distension is performed under scopic guidance~* second and/or third arthrographic distension are performed under ultrasound guidance"
224051595|NCT04653636|OTHER|Immediate joint mobilization|"This procedure was associated with intensive (immediate mobilization, recovery of maximum amplitudes by the physiotherapist and on arthro-motor).~Physical treatment aimed at rapid amplitude gain and is started immediately after the arthrographic distension, under the effect of local anesthesia. It is at best continued daily at a rate of 2 to 8 hours per day for one to 2 weeks. Depending on the effect obtained on pain and the daily progression of rehabilitation, arthrographic distension may be repeated once or twice during the mobilization period."
224051596|NCT01554644|DEVICE|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
224051597|NCT01554644|DEVICE|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
224051598|NCT04774250|DRUG|Zonisamide 100Mg Cap|ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
224144447|NCT02730416|DRUG|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
224051599|NCT04774250|DRUG|Placebo|The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
224051600|NCT01673919|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
224051601|NCT06211517|OTHER|Semi-structured interviews with visual mediations|Semi-structured interviews with visual mediations / An hour-long interview
224051602|NCT06211517|OTHER|Semi-structured interviews|Semi-structured interviews
224144448|NCT03783442|DRUG|Cisplatin|Cisplatin 60-80 mg/m² administered by intravenous infusion every 3 weeks. Cisplatin was used as the platinum agent in China, Taiwan, and Japan.
224144449|NCT03783442|DRUG|Oxaliplatin|Oxaliplatin 130 mg/m² administered by intravenous infusion every 3 weeks.
224144450|NCT03783442|DRUG|Fluorouracil (5-FU)|Fluorouracil 750-800 mg/m² administered by intravenous infusion on Days 1-5 of each treatment cycle.
224144451|NCT03783442|DRUG|Capecitabine|Capecitabine 1000 mg/m² administered orally twice daily on Days 1-14 of each treatment cycle
224144452|NCT03783442|DRUG|Paclitaxel|Paclitaxel 175 mg/m² administered by intravenous infusion every 3 weeks.
224144453|NCT03783442|BIOLOGICAL|Tislelizumab|Tislelizumab 200 mg administered by intravenous infusion every 3 weeks.
224144454|NCT03783442|DRUG|Placebo|Placebo to match tislelizumab administered by intravenous infusion every 3 weeks.
224144455|NCT06394804|DRUG|Avutometinib|Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks
224144456|NCT06394804|DRUG|Defactinib|Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks
224144457|NCT06394804|DRUG|Letrozole|2.5 mg PO daily
224144458|NCT05818865|DEVICE|CLG|"The development of an innovative device (CLG) consisting of an aqueous gel based on hyaluronic acid and commercially available (Belotero) able to be loaded and to release chemokine CXCL12 recreating a kind of fake niche able to attract immune cells- and CTCs-CXCR4+. The added value is the ability to attract and trap cells capable of leaking out and potentially with a higher metastatic capacity."
224144459|NCT00881361|DRUG|systemic chemotherapy|
223478637|NCT02426697|DRUG|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
224051603|NCT05534347|BIOLOGICAL|Blood sample|Addtional tube of blood needed for follow up of patients
224051604|NCT05534347|BIOLOGICAL|Joint puncture|Joint puncture if needed according to routine care of the patients
224051605|NCT03776487|DRUG|Fluorouracil|Given IV
224051606|NCT03776487|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224051607|NCT03776487|BIOLOGICAL|Ipilimumab|Given IV
224051608|NCT03776487|BIOLOGICAL|Nivolumab|Given IV
224051609|NCT03776487|DRUG|Oxaliplatin|Given IV
224051610|NCT03776487|PROCEDURE|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
224144460|NCT00881361|PROCEDURE|axillary lymph node dissection|
224144461|NCT00881361|PROCEDURE|neoadjuvant therapy|
224144462|NCT00881361|PROCEDURE|sentinel lymph node biopsy|
224144463|NCT00881361|PROCEDURE|therapeutic conventional surgery|
224051611|NCT01101438|DRUG|metformin hydrochloride|Given orally
224051612|NCT01101438|OTHER|placebo|Given orally
224051613|NCT02722538|DRUG|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
224051614|NCT00001520|DRUG|neostigmine|
224144464|NCT00881361|PROCEDURE|ultrasound imaging|
224144465|NCT02079558|DRUG|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
224144466|NCT02079558|DRUG|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
224144467|NCT02445599|DRUG|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
224144468|NCT02445599|DRUG|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
224144469|NCT02445599|DRUG|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
224051615|NCT06361693|OTHER|Auto-preoxygenation|"Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1).~Monitoring of : inspired fraction of oxygen, expired fraction of oxygen and end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient.~The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making :~* objectives achieved : end of this sequence.~* objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%."
224051616|NCT06361693|OTHER|APAIS scale|APAIS scale
224051617|NCT06361693|OTHER|Visual analog anxiety scale (VAS-A)|Visual analog anxiety scale (VAS-A)
224051618|NCT06361693|OTHER|Visual analog comfort scale (VAS-C)|Visual analog comfort scale (VAS-C)
224051619|NCT04237649|DRUG|KAZ954|KAZ954 will be administered in every arm.
224051620|NCT04237649|DRUG|PDR001|KAZ954 + PDR001
224051621|NCT04237649|DRUG|NIR178|KAZ954 + NIR178
223478638|NCT03258255|PROCEDURE|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
224051622|NCT04237649|DRUG|NZV930|KAZ954 + NZV930
224051623|NCT05865327|PROCEDURE|Cryoneurolysis|Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
224051624|NCT05865327|PROCEDURE|Sham Cryoneurolysis|Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
224051625|NCT00986544|PROCEDURE|no drain|drain positioned on the skin
224144470|NCT02445599|DRUG|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
224144471|NCT02445599|DRUG|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
224144472|NCT02445599|DRUG|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
224144473|NCT02445599|DRUG|Metamizole-sodium|Additional rescue analgetic 2g intravenously
224144474|NCT02445599|DRUG|Tramadol|Additional rescue analgetic 100mg intravenously
224144475|NCT03101046|DRUG|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.
224144476|NCT03101046|DRUG|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
224144477|NCT00012883|BEHAVIORAL|Homewalking exercise program|
224144478|NCT05119088|OTHER|Return to Sport testbattery|At baseline, approximately 3 weeks before surgery and 6 months after surgery: patients conduct a testbattery consisting of 2 PROMs: the NPI-No and BPII2.0-No together with three physical tests: isokinetic strength tests, hop tests and Y-balance test. For the cross-cultural validation of NPI and BPII2.0 patients also conduct KOOS, IKDC 2000 and Tampa Scale.
224144479|NCT02585726|DEVICE|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
224144480|NCT04765618|PROCEDURE|bariatric surgery|laparoscopic sleeve gastrectomy,or gastric bypass
224144481|NCT01027572|DEVICE|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
224144482|NCT01906957|OTHER|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
224144483|NCT01906957|OTHER|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
224144484|NCT01668381|PROCEDURE|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
224144485|NCT00703170|DRUG|Temsirolimus|
224144486|NCT00703170|DRUG|Pegylated liposomal doxorubicin|
224144487|NCT04503850|DRUG|Mirabegron 50 MG|Mirabegron 50 mg daily dose and follow Up of erectile function using international index of erectile function 5 scoring system
224144488|NCT04503850|DRUG|Alpha Blockers|Alpha blocker daily and evaluation of erectile function using international index of erectile function 5 scoring system
224144489|NCT00365768|DRUG|Glutamine|Administered orally twice daily for 21 days
224144490|NCT00365768|OTHER|Placebo|Administered orally twice daily for 21 days
223440280|NCT03845101|BEHAVIORAL|CBT in vivo|The therapeutic intervention is manual-based cognitive-behavioral CBT group therapy adapted from the approach of Turk, Heimberg \& Magee and Graske \& Barlow with worksheets from Arendt \& Rosenberg and inspiration from Bouchard et al. The treatment will consist of 14 weekly two-hour group sessions following the manual to ensure equal and uniform treatment for every patient throughout the study. Concurrent psychopharmacological treatment is allowed in both intervention arms.
223440281|NCT02258269|OTHER|SQ|
223440282|NCT02258269|OTHER|Control|
223440283|NCT06084624|DRUG|Rebamipide mouthwash|Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinone-4-yl\]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
223440284|NCT06084624|DRUG|Betamethasone mouthwash|Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
223440285|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
223440286|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
223440287|NCT01122784|BIOLOGICAL|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
224051626|NCT00986544|PROCEDURE|drain positioned|drain positioned in the subhepatic space
224051627|NCT00986544|PROCEDURE|drain not positioned|Drain positioned in the abdominal wall
224051628|NCT06536023|DRUG|IBI362|IBI362 SA.QW
223440288|NCT01122784|BIOLOGICAL|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
223440289|NCT03878875|DIAGNOSTIC_TEST|Session One Test Battery|"Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test (Around 35 minutes with breaks if required)~* Extended Frequency Audiometry (\~ 8 min), 0.25-16 kHz: Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~* DPOAE (\~ 5 min), 0.5-10 kHz: A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~* MEMR (\~ 8 min), 4 kHz: A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~* Speech-in-Noise Test (\~ 5 min): Participants asked to repeat back a list of words as best as they can.~* Tinnitus: Participants were also asked if they experience any tinnitus i.e. bilateral, lasting \> 5 minutes. This was reported as Y/N."
223440290|NCT03878875|DIAGNOSTIC_TEST|Session Two Test Battery|"Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital or sound level meter applications to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over."
224051629|NCT06536023|DRUG|IBI362 placebo|IBI362 placebo SA.QW
224051630|NCT05990439|BEHAVIORAL|Baby-Feed|The Baby-Feed web application was developed by the researchers of this application at Florida International University. It was designed based on a validated infant food frequency questionnaire (FFQ) developed by our group. The Social Cognitive Theory (SCT) and the Health Self-Empowerment Theory (HSET) were used in the development of the different components. The main intervention component is showing automatic results on how well parents are feeding their infants, upon completion of the infant FFQ, showing results on which food groups are consumed at the recommended level, which are consumed above and which are consumed below. It also shows a growth chart showing how the baby is progressing when they add their baby's weight and length. The website also includes a tracking system with short questions asking about their weekly progress and the recommendations to review frequently, if needed.
224051631|NCT05990439|BEHAVIORAL|Limited access to the Baby-Feed web application|Limited access to the Baby-Feed web application, with only the options of completing the FFQ and inputing their baby's weight and length.
224051632|NCT01407640|PROCEDURE|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
224051633|NCT06477341|DIETARY_SUPPLEMENT|various available nutrition as those contain high protein content as ensure milk|note effect with usually prescribed suitable oral and parenteral nutrition for head and neck cancers receiving radiotherapy
224051634|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, on day 1.
224051635|NCT04630353|DRUG|HB-201 IV|HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
224051636|NCT03194282|OTHER|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
224144491|NCT02467829|DEVICE|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
224144492|NCT04015440|BEHAVIORAL|HBMT|Individual is presented with words with some letters missing and told to complete the word.
224144493|NCT04015440|BEHAVIORAL|Other Training|Alternative to HBMT training
224144494|NCT04309669|DRUG|TOT'HEMA|three ampoules per day during 12 weeks
224144495|NCT01930526|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
224144496|NCT01413542|DRUG|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
223440291|NCT03878875|DIAGNOSTIC_TEST|Session Three Test Battery|1 week later (recovery): Repeat test battery.
223440292|NCT00296127|DRUG|Celecoxib|
223440293|NCT00718796|OTHER|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
224051637|NCT04594382|DIAGNOSTIC_TEST|Pupillometry-Opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~Opioid administration will be given by a single dose of piritramid (0.1 mg kg -1) in case of measured PDR values of ≥12 (high analgesic sensitivity as specified by the producer) after T30 and T60 stimulation. The pupillometry measurement will be repeated once on both eyes."
224051638|NCT04594382|DIAGNOSTIC_TEST|Pupillometry -standardized opioid treatment|"At the end of anesthesia, before extubation, pupillometry measurements will be performed on both eyes, using the tetanus mode T30 (30mA tetanic stimulation) and T60 (60mA tetanic stimulation) and the standardized pupillary pain index (PPI) mode at the pupillometer.~A standardized single dose of piritramid (0,1 mg kg -1) will be given intravenously, regardless of the measured values. The pupillometry measurement will be repeated once on both eyes."
224144497|NCT01413542|DRUG|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
224144498|NCT01413542|DRUG|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
224300416|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
223440294|NCT00718796|OTHER|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
224144499|NCT01413542|DRUG|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
224144500|NCT01413542|DRUG|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
224144501|NCT01413542|DRUG|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
224144502|NCT05326217|OTHER|Aerobic exercise|The aerobic exercise :In this study, the exercise intensity is set based on the subject's maximum heart rate, and the target heart rate is adjusted according to the literature to reach 60-90% of the maximum heart rate. A gradual increase of intermittent exercise will be designed for current exercise prescription. In terms of exercise frequency and time, there will be two times interventions per week for at least 60 minutes per time (including warm-up and cool down exercises).
224300417|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
223440295|NCT03209518|DRUG|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
223440296|NCT06182618|OTHER|dietary, semaglutide or/and metformin|patients were prescribed dietary and pharmaceuticals for weight loss
223440297|NCT05687838|OTHER|Music|Music medicine
223440298|NCT00236899|DRUG|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
224051639|NCT05217199|OTHER|Measurements|Demographic information of infants and parents, prenatal, postnatal and natal risk factors, Magnetic Resonance Images (MRI), General Movements (GMs) evaluations of babies with Prechtl method from NICU will be recorded. Video recordings for General Movements (GMs) analyzes with the Prechtl method will be taken at postterm 12th to 20th weeks. The infants' sensory processing (general, auditory, visual, tactile, movement, oral) will be evaluated with the adjusted Infant Sensory Profile-2 (ISP-2) family scale, which will be filled in by their mothers at the 3rd month. For motor assessments, the postterm corrected 3 month Hammersmith Infant Neurological Examination (HINE) will be used. A pediatric neurologist who was blinded to all testing made the diagnosis of CP in a 2-year-old child based on neuroimaging and clinical tests.
224144503|NCT05326217|OTHER|Resistant exercise|The resistant exercise : muscular endurance (15-20RM) and muscular hypertrophy (8-12RM) are applied to main exercise intensity. The intensity is gradually adjusted according to the state of each subject, and the intervention is performed twice a week (50 minutes per time).The target muscles of resistance training include quadriceps femoris, biceps femoris, calf muscles, core muscles (including pelvic floor muscles), back muscles, pectoralis major, biceps/triceps and other muscle groups.
224144504|NCT00993395|BEHAVIORAL|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
224144505|NCT03281447|OTHER|Nurse navigation|
224144506|NCT03281447|OTHER|Current care coordination|
224144507|NCT04922697|OTHER|Educational Intervention|Watch educational videos and use wearable air pollution sensor
224300418|NCT00311311|DRUG|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
223440299|NCT00236899|DRUG|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
223440300|NCT00236899|DRUG|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
224051640|NCT05069064|OTHER|music|In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphone in order to maintain a good communication and interaction between the participant and the doctor.
223440301|NCT06301009|DIAGNOSTIC_TEST|AI-CAC score|Deep-learning based prediction of the coronary artery calcium score with a plain chest x-ray
223440302|NCT06018506|DRUG|BR108 injection|Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle
224144508|NCT04922697|OTHER|Questionnaire Administration|Complete questionnaires
224144509|NCT03685487|PROCEDURE|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
223440303|NCT02388711|OTHER|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
223440304|NCT04413383|OTHER|Traditional Curved Iris Scissors|Aesculap Curved Iris Scissors
223440305|NCT04413383|OTHER|Wuennenberg Modified Curved Iris Scissors|Modified Silent Curved Iris Scissors
223440306|NCT04413383|OTHER|Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors|Patients experience both types of scissors
223740946|NCT07141901|BEHAVIORAL|Decision Tool|"For patients with life expectancy \<10 years: Active (i.e. interruptive) BPA that will fire when the clinician orders colorectal cancer screening. The BPA will advise that screening is not recommended due to \<10 year life expectancy. An active alert is required to prevent the clinician from ordering a potentially inappropriate test. The BPA will contain a box with suggested language with which to express this to the patient.~For patients with life expectancy ≥10 years: Passive alert on the Storyboard indicating that patient could benefit from screening as their predicted life expectancy is ≥10 years. A passive alert does not interfere with workflow and is available whenever it is convenient for the clinician to address it."
223740947|NCT07153276|DEVICE|Fractional CO2 laser (vaginal)|Vaginal fractional CO2 laser applications will be performed once a month for three consecutive months.
224051641|NCT05069064|OTHER|no music|Participants in the non-music group will undergo hysterosalpingography in the same setting and standard procedure without listening to any music.
224051642|NCT05988658|DEVICE|ESTOP - AKI 2.0|Medical software as a Noninvasive medical device, which at the time of the project will not implement directly into subject/clinical care.
224051643|NCT03515798|DRUG|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
224144510|NCT03685487|OTHER|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
223440307|NCT03009383|DEVICE|A bedside portable endoscopy|
223440308|NCT00423397|BIOLOGICAL|PEG-interferon alfa-2a|
223440309|NCT00423397|DRUG|gefitinib|
223440310|NCT00237276|PROCEDURE|colonoscopy|
223440311|NCT05619380|PROCEDURE|physiotherapy treatment|Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
223440312|NCT01429974|OTHER|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
223440313|NCT00070213|DRUG|FOLFOX regimen|
223440314|NCT00070213|DRUG|capecitabine|
223440315|NCT00070213|DRUG|fluorouracil|
223440316|NCT00070213|DRUG|leucovorin calcium|
223440317|NCT00070213|DRUG|oxaliplatin|
223440318|NCT00070213|PROCEDURE|quality-of-life assessment|
223440319|NCT02703818|DEVICE|Senza|Spinal Cord Stimulation
224051644|NCT03515798|DRUG|neoadjuvant EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
224051645|NCT06580340|OTHER|AFA (Adapted Physical Activity)|An exercise program to improve joint mobility, muscle strength, static and dynamic balance, motor coordination will be performed 2 times/week for 6 months.
224051646|NCT03333642|PROCEDURE|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
224051647|NCT06527625|BEHAVIORAL|Cultural Arts Program|9-session group art program using Chinese calligraphy as the channel for gaining emotional awareness and facilitating expression
224051648|NCT06527625|BEHAVIORAL|Treatment as usual|Treatment as usual provided in local community aged care centres
224051649|NCT05772572|OTHER|Questionnaires|"Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life"
224051650|NCT06543290|DRUG|Azithromycin Pill|Azithromycin 2 grams to be administered prior to start of induction for those randomized to intervention group
224051651|NCT06543290|DRUG|Placebo|4 magnesium oxide tablets prior to the start of induction for those randomized to placebo
224051652|NCT00616915|DRUG|Wellbutrin XL|Wellbutrin XL 300mg daily
224051653|NCT04827719|DRUG|BST-236|Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)
224144511|NCT03516409|DIETARY_SUPPLEMENT|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~* Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~* DHA + EPA: \>1mg per sachet~* Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
224051654|NCT01888120|DRUG|Ziconotide|
224144512|NCT03516409|DIETARY_SUPPLEMENT|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
224300419|NCT00311311|DRUG|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
224300420|NCT00311311|DRUG|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
224051655|NCT03778528|PROCEDURE|cataract surgery|tissue collection.
224051656|NCT03420014|DRUG|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
224051657|NCT03420014|COMBINATION_PRODUCT|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
224051658|NCT04814342|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
224051659|NCT01864499|PROCEDURE|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
224051660|NCT01871220|DEVICE|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
224051661|NCT01871220|DEVICE|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
224144513|NCT03748277|PROCEDURE|Decompression|Bilateral decompression
224051662|NCT02508142|DRUG|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
224051663|NCT03576599|DRUG|Zoledronic Acid Injectable Product|One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
224051664|NCT03576599|DRUG|Placebo|Placebo
224144514|NCT03748277|PROCEDURE|PLIF|Traditional open surgery
223440320|NCT05674318|DIETARY_SUPPLEMENT|Alpha-lactalbumin|Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
224051665|NCT03896542|DEVICE|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
224051666|NCT03896542|DEVICE|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
224144515|NCT03748277|PROCEDURE|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
224144516|NCT03748277|PROCEDURE|Screw Fixation|Transpedicular Screw Fixation
224144517|NCT02806466|PROCEDURE|Fiberoptic bronchoscopy|
224144518|NCT02505542|BIOLOGICAL|Certolizumab Pegol|"* Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"
224144519|NCT02505542|OTHER|Placebo|"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"
224144520|NCT02764983|BEHAVIORAL|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
224144521|NCT02764983|BEHAVIORAL|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
224051667|NCT05542407|DRUG|Atezolizumab|10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
224051668|NCT05542407|DRUG|ONC201|375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
224051669|NCT05102344|BEHAVIORAL|Behavioral Social Skills Training|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.
224051670|NCT05102344|BEHAVIORAL|Animal Assisted Intervention|Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
224051671|NCT06268171|OTHER|ultrasound measurement of the cross-sectional area of the rectus femoris|ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
224051672|NCT01825057|BEHAVIORAL|See One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.
224051673|NCT01825057|BEHAVIORAL|Do One|A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.
224300421|NCT00311311|DRUG|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
224300422|NCT01610453|PROCEDURE|ultrasound examination|transabdominal and transperineal ultrasound examinations
224300423|NCT01957228|PROCEDURE|bone biopsies|
224300424|NCT04184661|OTHER|blood sample|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
224300425|NCT04872972|OTHER|Simulation based learning|Faculty development courses on simulation based learning
223440321|NCT01487213|OTHER|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
223440322|NCT05805007|DRUG|ZVS203e|ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
223440323|NCT01589809|DRUG|nicotinamide|dose-escalation, 2-8 grams, oral
224051674|NCT01825057|BEHAVIORAL|Order One|"A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians."
224051675|NCT01688596|DRUG|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
224051676|NCT06552338|OTHER|Observational|No intervention. Study is observational
224051677|NCT00794599|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
224051678|NCT00794599|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
224051679|NCT03023020|DRUG|Aspirin|Dosing per current guidelines and local practice
224051680|NCT03023020|DRUG|P2Y12 inhibitor|Dosing per current guidelines and local practice
224051681|NCT03831061|OTHER|Cognitive stimulation|
224051682|NCT00975299|DRUG|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
224051683|NCT00975299|DRUG|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
224051684|NCT05865379|DEVICE|BUFY01 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
224144522|NCT02764983|OTHER|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
224144523|NCT02764983|BEHAVIORAL|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
224051685|NCT05865379|DEVICE|SVS20 eye drops in single-dose containers|1 to 2 drops in each eye, as often as needed
224051686|NCT02075372|OTHER|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
224144524|NCT02764983|BEHAVIORAL|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
224144525|NCT02764983|BEHAVIORAL|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
224144526|NCT02764983|PROCEDURE|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
224300426|NCT00264368|DRUG|intravenous (IV) ganciclovir|
224300427|NCT00080405|DRUG|Bortezomib|
224300428|NCT02660528|DRUG|Tocilizumab|Subcutaneous tocilizumab
224300429|NCT01521182|OTHER|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
224300430|NCT01521182|OTHER|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
224300431|NCT02996760|DRUG|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
224300432|NCT03979820|DRUG|BI 1467335|Film-coated tablet
224300433|NCT03979820|DRUG|Placebo|Film-coated tablet
224300434|NCT03979820|DRUG|Phenelzine sulfate|Film-coated tablet
224300435|NCT03979820|DRUG|Tyramine|Capsules
223440324|NCT03896178|OTHER|None, observational study|None, observational study
223440325|NCT02696928|DRUG|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
223440326|NCT02696928|DRUG|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
223440327|NCT02696928|DRUG|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
223440328|NCT00257205|DRUG|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
223440329|NCT00257205|DRUG|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
224300436|NCT03214874|DRUG|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
224300437|NCT03214874|DRUG|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
224051687|NCT00547872|PROCEDURE|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
224051688|NCT04746833|BEHAVIORAL|SUMMIT|multicomponent web-based application focused on pain self-management skills
224051689|NCT04746833|BEHAVIORAL|control|My Pain Diary app
224051690|NCT03380455|DRUG|Lucerastat|Single oral dose of 500 mg lucerastat under fasted conditions
224051691|NCT03380455|DRUG|Cimetidine|Twice daily oral dose of 800 mg cimetidine under fasted conditions
224051692|NCT03968614|OTHER|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
224051693|NCT03968614|OTHER|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
223440330|NCT00257205|DRUG|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
223440331|NCT02860871|OTHER|infrared spectroscopy|
223440332|NCT03345628|DRUG|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
224051694|NCT00541320|DRUG|GW813893|
224051695|NCT04925167|DRUG|Argatroban|Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
224051696|NCT04925167|DRUG|unfractionated heparin|unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
224051697|NCT05570812|DRUG|Placebo|(4-week ramp, 4-week steady dosing)
224051698|NCT05570812|DRUG|Pregnenolone|(4-week ramp, 4-week steady dosing)
224051699|NCT06490549|OTHER|RSV infection observation cohort|No intervention; Epidemiological Study. Participants will receive standard care based on local clinical practice
224051700|NCT05075525|OTHER|High Intensity Laser Therapy Group|High Intensity Laser Therapy (HILT) and exercises will be used.
224051701|NCT05075525|OTHER|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Transcutaneous electrical nerve stimulation(TENS), ultrasound (US) will be applied.
224051702|NCT05075525|OTHER|Ultrasound and Interferential Current Stimulation Group|Ultrasound (US) ,interferential current stimulation and exercise will be used.
224051703|NCT04906356|GENETIC|Genetic sub-study|One time saliva sample collection
224051704|NCT03450291|OTHER|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
224051705|NCT04942652|DRUG|Itraconazole 200 mg|Itraconazole 100 mg capsule x 2
224051706|NCT04942652|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg tablet x 1
224051707|NCT05250973|DRUG|Daratumumab|Daratumumab will be administered subcutaneously.
224051708|NCT05250973|DRUG|Cyclophosphamide|Cyclophosphamide will be administered either orally or IV.
224051709|NCT05250973|DRUG|Bortezomib|Bortezomib will be administered by SC injection or IV.
224051710|NCT05250973|DRUG|Dexamethasone|Dexamethasone will be administered orally or IV.
224144527|NCT02764983|OTHER|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
224144528|NCT02651792|DRUG|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
224144529|NCT02651792|DRUG|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
224144530|NCT02783144|PROCEDURE|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
224144531|NCT02783144|OTHER|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
224144532|NCT02783144|DRUG|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
224144533|NCT00895648|DRUG|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
224144534|NCT00895648|DRUG|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
224144535|NCT02759861|DRUG|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
224144536|NCT00526461|DRUG|HPPH|IV
224144537|NCT03645889|OTHER|PLTG|A combination of 13 herbal granules
224144538|NCT03645889|OTHER|Placebo|90% starch filler and 10% PLTG
224144539|NCT01503580|DRUG|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
224144540|NCT00367029|BEHAVIORAL|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
224144541|NCT05825599|DEVICE|Hydroxypropyl methylcellulose eye drops|Hydroxypropyl methylcellulose (HPMC)-based eyedrops
224144542|NCT01428999|DIETARY_SUPPLEMENT|probiotics|probiotics 1 pack (2g) bid for three weeks
224144543|NCT03673696|DRUG|HEC74647PA Capsule|Capsule administered orally once daily
224144544|NCT03673696|DRUG|placebo|Matching Placebo Capsule
224144545|NCT02814695|DIETARY_SUPPLEMENT|Vit E|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (2 mg/ml) Vitamin E and incubated at 37o C for 30 minutes.
224144546|NCT02814695|DIETARY_SUPPLEMENT|Yeast|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (20 mg/ml) yeast extraction and incubated at 37o C for 30 minutes.
224144547|NCT02814695|DIETARY_SUPPLEMENT|Vit C 1|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.02 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
224051711|NCT01163812|PROCEDURE|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
224144548|NCT02814695|DIETARY_SUPPLEMENT|Vit C 2|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.04 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
223440333|NCT05708183|DIETARY_SUPPLEMENT|Multiple micronutrient supplementation (MMS)|Ethiopia will distribute the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation that includes 30mg iron. The supplement contains 15 essential vitamins and minerals including: Retinol (Vitamin A-acetate) 800 μg; Vitamin E (as vitamin E-acetate) 10 mg; Vitamin D (as Cholecalciferol) 200 IU; Vitamin B1 (Thiamine mononitrate) 1.4 mg; Vitamin B2 (As Riboflavin) 1.4 mg; Vitamin B3 (As Nicotinamide) 18 mg; Vitamin B6 (as Pyridoxine 1.9 mg; Vitamin B12 (as Cyanocobalamin) 2.6 mg; Folic Acid 400 μg; Vitamin C (As Ascorbic Acid) 70 mg; Iron (As ferrous sulphate) 30 mg; Zinc (As zinc sulphate) 15 mg; Copper (as Copper Sulphate) 2 mg; Selenium (as Sodium selenite) 65 μg; Iodine (as Potassium Iodate) 150 μg.
223440334|NCT05708183|DIETARY_SUPPLEMENT|Iron folate supplementation (IFA)|IFA delivered as part of routine antenatal care, according to current policy
223740948|NCT07153276|DRUG|Promestriene Vaginal|Patients in the group treated with promestriene will apply a 10 mg vaginal capsule at night for fifteen consecutive days and, after this period, one application every three days, until completing six months of treatment.
223740949|NCT00296374|DRUG|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
224051712|NCT05867433|BEHAVIORAL|STHS Intervention|"STHS program~The intervention group (10 schools) will participate in the STHS program. During the fall semester (September to December), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that provide education on civic engagement, healthy eating, and physical activity. During the spring semester (February to May), the intervention group will receive 24 thirty-minute modules (or twelve 1-hour modules) that focus on implementing the school health environmental change project and receive support for maintaining individual-level healthy eating and physical activity behaviors."
224051713|NCT05867433|BEHAVIORAL|Usual Care|"No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study."
224051714|NCT02015442|DIETARY_SUPPLEMENT|Sucrose|
224051715|NCT00290290|DRUG|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
224051716|NCT00290290|DRUG|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
224051717|NCT06491056|DEVICE|Focal Therapy for Prostate Cancer|Ablation of \<75% of the prostate gland for limited volume prostate cancer
224051718|NCT04067479|DIETARY_SUPPLEMENT|Amino Acids|Oral bolus of essential amino acids
224051719|NCT06473311|DEVICE|whole bady vibration and virtual reality|study group I received a whole body vibration program in addition to a conventional physical therapy program, and study group II received a Wii-fit therapy program (a virtual reality treatment program) in addition to the same. A two-month treatment program was implemented for both groups. Every child in both groups had the same evaluation processes, which included using the Physical Self Maintenance Scale (PSMS) for daily living activities and a dynamometer to measure quadriceps muscular strength. Evaluation was done prior to the start of treatment and was done again after one month (post I) and two months (post II).
224051720|NCT01062633|DIETARY_SUPPLEMENT|A, erythritol|2,5 g 3 times a day
224051721|NCT01062633|DIETARY_SUPPLEMENT|xylitol|2,5 g 3 times a day
224051722|NCT01062633|DIETARY_SUPPLEMENT|C, sorbitol|2,5 g 3 times aday
224051723|NCT04603885|BEHAVIORAL|Aerobic exercise program|A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
224051724|NCT04603885|BEHAVIORAL|Stretching exercise|stretching exercise
224051725|NCT05317507|DRUG|CBD oil|50 mg
224051726|NCT05317507|DRUG|CBD oil|100 mg CBD
224051727|NCT05317507|DRUG|Placebo|Placebo
224051728|NCT05149027|DRUG|HBM4003 and Triprilimab|Subjects will be treated with HBM4003 and Toripalimap on Day 1 during each 21-day cycles.
224051729|NCT04013789|DEVICE|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
224051730|NCT04013789|DEVICE|DACP contact lenses|Nelfilcon A soft contact lenses
224051731|NCT01482585|OTHER|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
224051732|NCT06538584|DRUG|Caffeine citrate 15mg/kg|Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 15mg/kg Caffeine citrate 15 minutes post surgery.
224051733|NCT06538584|DRUG|0.9% Sodium Citrate|Subjects will be randomized prior to surgery into one of the two study arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
224144549|NCT02814695|DIETARY_SUPPLEMENT|Vit C 3|0.1ml liquefied semen was mixed with 0.1ml Ham's F10 medium supplemented with (0.06 mg/ml) Vitamin C and incubated at 37o C for 30 minutes.
224144550|NCT03931395|DIETARY_SUPPLEMENT|Honey|Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child
224144551|NCT03931395|OTHER|Standard of Care|Patients will receive standard post operative medications per surgeon
224144552|NCT00879983|DRUG|azithromycin (Zithromax)|"1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg"
224051734|NCT01247987|PROCEDURE|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
224051735|NCT01247987|PROCEDURE|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
223440335|NCT05022628|DRUG|Donafenib|"Donafenib treatment regimen.~1. Donafenib started on the day of the first radiation treatment.~2. starting dose 0.2 g bid twice daily orally on an empty stomach (1 hour before or 2 hours after a meal).~3. Surgery after at least 1 week off Donafinil; resume Donafinil dosing as soon as possible after postoperative wound healing until any of the following occurs, whichever occurs first: (i) the subject develops an intolerable toxic reaction that does not resolve after dose adjustment (see 5.3 for details); (ii) 12 months of postoperative dosing; (iii) the subject has the first imaging-confirmed recurrence of disease or withdraws from the study (whichever occurs first).~4. Dose adjustment/withdrawal: Subjects are allowed up to 2 dose adjustments if they experience an adverse event related to the trial drug during treatment."
223440336|NCT03924505|OTHER|Organize and Mobilize for Implementation Effectiveness|Our trial is trying to understand how a multi-faceted, facilitation-based implementation strategy advances effective implementation of naloxone within syringe services programs
223440337|NCT03924505|OTHER|Dissemination|Our comparison group receives dissemination of best practice recommendations for naloxone implementation.
223440338|NCT01290198|DRUG|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
223440339|NCT00213577|DRUG|type A botulinum toxin|
223440340|NCT02854605|DRUG|GS-9674|Tablet administered orally once daily
224051736|NCT05714982|OTHER|Label with text health warning|Labels with e-cigarette health warning that include text about health harms of vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
224051737|NCT05714982|OTHER|Label with pictorial health warning|Labels with e-cigarette health warning that include the same text about health harms of vaping and corresponding pictorial images will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 warnings based on their assigned trial arm; at Visit 3, they will get 2 additional warnings based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
224051738|NCT05714982|OTHER|Label with neutral statements about vaping|Labels with neutral statements about vaping will be applied to participants' vaping devices and refills. At Visit 1, devices and refills will be labeled with 2 statements based on their assigned trial arm; at Visit 3, they will get 2 additional statements based on their assigned trial arm. The order of the 4 labels within this trial arm will be randomized using a Latin square design. Study investigators developed the text and design of these labels.
224051739|NCT00549939|DRUG|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
224051740|NCT00549939|DRUG|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
224051741|NCT03677596|DRUG|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
224051742|NCT03677596|DRUG|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
224144553|NCT00879983|DRUG|azithromycin (Zithromax)|"1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g"
223440341|NCT02854605|DRUG|Placebo to match GS-9674|Tablet(s) administered orally once daily
223440342|NCT04191122|OTHER|COPESS|The intervention includes brief psychotherapy to be delivered within primary care settings
224144554|NCT00225212|DRUG|Rituximab 375 mg/m2|
224144555|NCT02718391|BIOLOGICAL|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
224144556|NCT03052439|OTHER|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
224144557|NCT01519063|DRUG|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
224144558|NCT01519063|DRUG|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
224144559|NCT01309841|DRUG|NKTR-118|12.5 mg oral tablet once daily
224144560|NCT01309841|DRUG|NKTR-118|25 mg oral tablet once daily
224144561|NCT01309841|DRUG|Placebo|Oral tablet once daily
224144562|NCT01330641|PROCEDURE|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
223440343|NCT02644330|PROCEDURE|transthoracic device closure|minimally invasive transthoracic device closure
223440344|NCT02644330|PROCEDURE|surgical repair|surgical repair with cardiopulmonary bypass
223440345|NCT03014622|BIOLOGICAL|Botulinum Toxins, Type A|Intramuscular injection
223440346|NCT03014622|BIOLOGICAL|Placebos|Intramuscular injection
223440347|NCT00153010|DRUG|NS 2330 (Tesofensine)|
223440348|NCT05869110|OTHER|Effects of odours on calorie intake, food choice and metabolic parameters|"Evaluation of the effects of olfactory stimulation compared to placebo on calorie intake and preference of food during a test-buffet.~Odours will be assigned in a randomized order. Each participant will receive both odours, in between there will be a wash-out period of 1 week."
223740950|NCT00296374|DRUG|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
223440349|NCT05415241|DRUG|FB2001|"Stage 1 (Exploring the dose): Twenty participants will be enrolled for aerosol inhalation of FB2001 once daily for 5 consecutive days. If the drug is well tolerated but efficacy is inadequate, another twenty participants will be enrolled for aerosol inhalation of FB2001 BID for 5 consecutive days.~Stage 2 (Sample size expansion): Another twenty participants will be enrolled for aerosol inhalation of FB2001 once daily or twice daily for 5 consecutive days depending on the result of stage 1."
223440350|NCT06137534|OTHER|Proprioceptive Neuromuscular Facilitation Upper Extremity Pattern|"Proprioceptive neuromuscular facilitation upper extremity pattern exercises will be actively applied to 20 individuals in groups of 5 in a standing position for 30 minutes in each session 3 days a week for 4 weeks.~PNF upper extremity patterns to be applied to the participants:~1. Bilateral symmetrical flexion-adduction-external rotation.~2. Bilateral symmetrical flexion-abduction-external rotation.~3. Bilateral asymmetric right: flexion-abduction-external rotation, left: flexion-adduction-external rotation.~4. Bilateral reciprocal (same diagonal) right: extension-adduction-internal rotation, left: flexion-abduction-external rotation.~5. Bilateral reciprocal (same diagonal) right: flexion-adduction-external rotation, left: extension-abduction-internal rotation.~6. Bilateral reciprocal (opposite diagonal) right: extension-adduction-internal rotation, left: flexion, adduction, external rotation."
223440351|NCT01421745|OTHER|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
223440352|NCT01897571|DRUG|Tazemetostat|Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
223440353|NCT01897571|DRUG|Prednisolone|Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
223440354|NCT01897571|DRUG|Tazemetostat|Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.
223440355|NCT00939471|DEVICE|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
223440356|NCT01528137|BIOLOGICAL|talactoferrin|Given PO
223440357|NCT01528137|OTHER|laboratory biomarker analysis|Correlative studies
223740951|NCT00296374|DRUG|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
223740952|NCT01721330|DRUG|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
223740953|NCT01721330|DRUG|Placebo|Placebo twice a day for 6 weeks
223740954|NCT07153796|DRUG|Blinatumomab|Given by IV
223740955|NCT07153796|DRUG|Mini-CVD|Given by IV
223740956|NCT07153796|DRUG|MTX/ARA-C|Given by IV
224051743|NCT04726384|DEVICE|Assessment of physical activity level|Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (\>3MET) and moderate ( \>6MET) exercise.
224051744|NCT00305968|BEHAVIORAL|patient education|Patient education group
224051745|NCT04932850|BIOLOGICAL|MAD0004J08|Human mAb 100 mg / 2.5 mL solution for injection
224051746|NCT04932850|OTHER|Placebo|Placebo matching to MAD0004J08 2.5 mL solution for injection
224051747|NCT05201781|DRUG|Cilta-cel|Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
224051748|NCT06216379|DIAGNOSTIC_TEST|Assessment|Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.
223740957|NCT07166042|BEHAVIORAL|10-15 minute, Audio-Recorded Guided Mediation Practices|"The 5 mindfulness practices, all of which have been validated in prior research.~Body Scan practice will consist of how to direct non-judgmental attention to different regions of the body~The Mindful Breathing practice will consist of focused attention on the breath and metacognitive monitoring and acceptance of discursive thoughts, negative emotions, and body sensations.~The Mindfulness of Discomfort practice will consist of instruction in how to zoom in to deconstruct discomfort and precisely map each feelings' spatial location, use mindful breathing to zoom out and broaden the field of awareness to include neglected sensory elements, and shift attention from unpleasant feelings to neutral/pleasant sensations or experiences.~The Savoring practice will consist of instruction in identifying and amplifying pleasant memories.~The Loving-Kindness practice will consist of instruction in cultivating feeling of warmth and compassion toward the self and others."
223740958|NCT07169162|DRUG|ADZENYS XR-ODT|ADZENYS XR-ODT™ (amphetamine) is an extended-release orally disintegrating tablet approved for once-daily oral administration for the treatment of ADHD in patients 6 years and older.
223740959|NCT07169162|DRUG|Placebo Oral Tablet|Participants in this arm will be given placebo as matching ODT once daily during the double-blind treatment period.
224051749|NCT04520048|OTHER|Determination of the UEMP levels|Quantification of UEMP by flow cytometry in urine (10 ml) collected at 26 ± 2 week and 34th ± 2 week of amenorrhea.
224051750|NCT04520048|PROCEDURE|Aortic central pressure and the carotid-femoral pulse wave velocity|Measurement of the aortic central arterial pressure (systolic and diastolic arterial pressure) by applanation tonometry, and the index of aortic increase by applanation tonometry, the carotid-femoral pulse wave velocity using the SphygmoCor® system (PWV Medical) and/or Popmetre.
224051751|NCT04520048|OTHER|Vascular biomarker assay|Plasma angiogenic biomarker levels determination using an immunoassay, including circulating sFlt-1, circulating PIGF, sFlt-1 / PIGF ratio, circulating VEGF, circulating soluble endoglin (sEng), other biomarkers assessment, including anti-angiotensin II receptor (AT1), circulating copeptin, circulating interleukin 17 (IL-17), Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL), as well as CEMP and CEC quantification using flow cytometry.
224144563|NCT03530618|DEVICE|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
224144564|NCT03530618|DEVICE|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
223440358|NCT04422314|DIAGNOSTIC_TEST|T-Detect Lyme|T-Detect Lyme is an investigational use test that uses multiplex PCR and NGS to assess rearranged T-cell receptor beta (TRB) gene sequences from genomic DNA isolated from human peripheral blood.
223440359|NCT01126008|DRUG|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
223440360|NCT03370458|DIETARY_SUPPLEMENT|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
223440361|NCT03370458|DIETARY_SUPPLEMENT|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
224051752|NCT04520048|PROCEDURE|Measurement of the uterine artery diameter|This measurement is added to the routine examination of the uterine artery. Bi-dimensional ultrasound imaging with angio-Doppler allows the study of the artery as the blood flow velocity and vessel diameter. Uterine artery Doppler pulsatility index (UtA-PI), mean flow velocity and diameter measurement could be calculated with Doppler instrument with software could determine instantaneous true mean blood flow velocity. Measurement is made by placing the cursor from outer edge to outer edge of the artery adventitia, on a cross-section and taking the largest diameter
224051753|NCT05140512|DRUG|LY01005|LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
223440362|NCT02084914|PROCEDURE|Endometrial scratching|Group A: pipelle Group B: sound
223440363|NCT03246919|DRUG|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
223440364|NCT03246919|DRUG|Placebo|Placebo will be administered after delivery of the placenta
223440365|NCT02797418|BEHAVIORAL|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
223440366|NCT00513266|BIOLOGICAL|bevacizumab|
223440367|NCT00513266|BIOLOGICAL|cetuximab|
224051754|NCT05140512|DRUG|ZOLADEX® 3.6 mg|ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, Casodex® (50 mg/day) was orally administered during the whole study period.
224051755|NCT04632303|OTHER|Early Palliative Care|Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
224051756|NCT06581471|DEVICE|Transcatheter Tricuspid Valve Replacement|Replacement of the tricuspid valve through a transcatheter approach
223440368|NCT00513266|DRUG|fluorouracil|
224051757|NCT01279577|DRUG|Low dose TSO|Low dose TSO suspension
224051758|NCT01279577|DRUG|Medium dose TSO|Medium dose TSO suspension
224051759|NCT01279577|DRUG|High dose TSO|High dose TSO suspension
224051760|NCT01279577|DRUG|Placebo|Placebo solution
224051761|NCT03127267|DRUG|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
223440369|NCT00513266|DRUG|irinotecan hydrochloride|
223440370|NCT00513266|DRUG|leucovorin calcium|
223440371|NCT00513266|DRUG|oxaliplatin|
223440372|NCT00513266|OTHER|laboratory biomarker analysis|
223440373|NCT00513266|PROCEDURE|adjuvant therapy|
223440374|NCT00513266|PROCEDURE|biopsy|
223440375|NCT00513266|PROCEDURE|conventional surgery|
223440376|NCT00513266|PROCEDURE|neoadjuvant therapy|
223440377|NCT02620358|OTHER|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
223440378|NCT02620358|OTHER|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
223440379|NCT00827658|PROCEDURE|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
223440380|NCT00827658|PROCEDURE|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
223440381|NCT00089635|DRUG|Panitumumab|Administered by intravenous infusion
223440382|NCT00166049|BEHAVIORAL|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
223440383|NCT00166049|BEHAVIORAL|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
223440384|NCT00166049|BEHAVIORAL|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
223440385|NCT02477709|DRUG|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
224051762|NCT03127267|DRUG|Riluzole|Riluzole 50 mg tablet, treatment per os
224051763|NCT03127267|DRUG|Placebo|treatment per os
224051764|NCT03127267|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
224051765|NCT03634397|BEHAVIORAL|Less-Impaired Arm Training|Participants receive virtual reality and manipulation training in their less impaired arm.
224051766|NCT03634397|BEHAVIORAL|Contralesional Arm Comparison|Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
223440386|NCT02943785|DRUG|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
224051767|NCT05843435|BEHAVIORAL|Go-Nogo-task during functional magnetic resonance imaging|Go-Nogo-task (GNG) implemented as a mixed block- and event-related design paradigm for task-related functional resonance imaging. It is composed of six blocks, each containing an event-related inhibitory control GNG. There are two blocks with an alcohol-related GNG, two blocks with a neutral GNG, and two blocks with a mixed GNG paradigm. The blocks are presented in a counterbalanced fashion between the participants. Each block contains 125 Go-trials and 25 NoGo-trials (ratio 5:1), resulting in 150 trials per block with a block time of 5 minutes. Participants are instructed to press a button whenever a stimulus appears on the screen (Go-trial). The only exception to this rule is when the same stimulus appears twice (NoGo-trial). Stimulus material consists of 60 alcohol-related and 60 neutral pictures, presented in a pseudo-randomized order.
223440387|NCT02943785|DRUG|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
223440388|NCT01353573|RADIATION|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
223440389|NCT01353573|RADIATION|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
223440390|NCT05243667|OTHER|Wearable wrist Smart Device of Huami|"All enrolled patients underwent continuous monitoring by wearing huami blood oxygen testing equipment, and signed the informed consent for the clinical trial.Smart wrist wristbands will be issued, and patient information will be bound to the Migang Health platform, and clinical trial doctors will improve relevant personal information and clinical data.After binding to the APP Migu Health, you can start collecting and recording dynamic data such as peripheral blood oxygen saturation, heart rate, exercise steps, sleep data, etc., and upload the data once a day."
223440391|NCT02254057|DRUG|BIBT 986 BS - single rising dose|
223440392|NCT02254057|DRUG|Placebo|
223440393|NCT00825981|OTHER|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
223440394|NCT02751164|OTHER|Day/time of admission to the critical care unit|
223440395|NCT00033306|DRUG|ixabepilone|
223440396|NCT00033306|DRUG|Fluoropyrimidine|
223440397|NCT00033306|DRUG|Irinotecan|
223740960|NCT07168564|DEVICE|AVA lenses|Participants are prescribed to receive AVA lenses through the AVA protocol and wear these lenses during 2 weeks.
224051768|NCT05843435|OTHER|Resting-state functional magnetic resonance imaging|An fMRI (multiband-echo-planar imaging) blood oxygenated level dependent (BOLD) protocol is run during 6 minutes of rest. This protocol allows the assessment of connectivity measures at rest, which can be compared to connectivity changes during the GNG task.
224051769|NCT00861250|DRUG|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
224051770|NCT06429280|DEVICE|N/A this is an observational study of Standard of Care|Medical Device which treats unilateral amblyopia through therapeutic software which stimulate vision
224051771|NCT06380660|DRUG|ACE-86225106 tablet|ACE-86225106 will be administered orally daily as a continuous regimen. Subjects will continue to receive study treatment until PD as judged by local investigator review, development of unacceptable toxicity, or withdrawal of consent.
224144565|NCT03315728|OTHER|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
223440398|NCT04103515|DEVICE|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
223440399|NCT04103515|DEVICE|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
223440400|NCT00821015|DEVICE|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
223440401|NCT03170609|BIOLOGICAL|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
223440402|NCT03170609|BIOLOGICAL|Placebo|Saline Control
223440403|NCT02679456|DRUG|SCY-078|
223440404|NCT02679456|DRUG|Fluconazole|
223440405|NCT01281956|DRUG|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
223440406|NCT01281956|DRUG|Placebo|Placebo
223740961|NCT07168564|DEVICE|Standard lenses|Participants are prescribed to receive Standard lenses through the Gold standard protocol and wear these lenses during 2 weeks.
223740962|NCT07167225|OTHER|Effectiveness of different recruitment approaches|Subjects will asked which type of recruitment material they've seen when completing the screening survey
223440407|NCT00359177|DRUG|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
223440408|NCT02929615|OTHER|Hematopoietic stem cell transplantation|
223440409|NCT01361867|DEVICE|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
223440410|NCT01897792|DIETARY_SUPPLEMENT|Vitamin C|
223440411|NCT01897792|DIETARY_SUPPLEMENT|Vitamin E|
223740963|NCT07167225|OTHER|Choice of study completion locations|subjects will choose location when coordinator calls to schedule appointment
223440412|NCT01897792|DIETARY_SUPPLEMENT|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
223440413|NCT01897792|DRUG|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
224144566|NCT02448004|DRUG|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
223440414|NCT02550080|DRUG|Dapsone|For the HLA-B\*1301 positive subjects, dapsone will not be administrated.
223440415|NCT02550080|GENETIC|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
223440416|NCT00265408|DRUG|aspirin|
223440417|NCT00265408|DRUG|warfarin|
224051772|NCT06445153|OTHER|Intervention with clinical decision support system|To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
223440418|NCT00939237|DRUG|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
223440419|NCT00939237|DRUG|Placebo|
223440420|NCT05698537|DIAGNOSTIC_TEST|EEG|EEG registration performed in PwE to confirm epilepsy diagnosis
223740964|NCT07167225|OTHER|Cannabis Engagement Assessment|Self reported measure of current cannabis use that contains 30 questions assessing quantity, frequency of use and method of consumption in the past 30 days.
223740965|NCT07167225|OTHER|E-cigarette dependence Scale|A 22-item questionnaire measuring e-cigarette dependence. Higher scores indicate greater dependence.
223740966|NCT07167238|BEHAVIORAL|Virtual reality exercises|"Program Duration: 8 weeks Implementation: The conventional program plus supervised video game-based training sessions.~Additional Protocol: Video Game-Based Exercises~1. Breathing Labs - Breathing Games (Slovenia) Frequency: 3 days per week, on non-walking days, supervised at the hospital. Structure: 5 mini-games per session, performed sequentially.~   Exercises:~   Balloon: Weeks 1-4: Level 1; Weeks 5-8: Level 2. Focus on sustained controlled exhalation.~   Plane: Weeks 1-4: \~6 sec breath cycle; Weeks 5-8: \~8 sec breath cycle. Wolf: Weeks 1-4: Easy; Weeks 5-8: Medium. Flowers: Weeks 1-4: Sunflower module; Weeks 5-8: Rose module. Pluto: Weeks 1-4: Easy; Weeks 5-8: Medium. Intensity: Target MBS 4-6/10 for dyspnea and fatigue.~2. Nintendo Wii / Wii Fit - Functional Training Duration: \~5 minutes per game, 30-40 minutes total per session.~Games and targets:~Lower limb/aerobic: Basic Run, Basic Step, Obstacle Course, Island Cycling. Upper limb: Boxing, Canoe. Balance: Rhythm Parade."
224051773|NCT05822843|DRUG|ESG206|Administered via intravenous (IV) infusion
224144567|NCT03699631|DRUG|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
224144568|NCT03699631|DRUG|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
224144569|NCT03699631|DRUG|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
224144570|NCT06440369|OTHER|Training group|"The patient will perform an intermittent exercise which consists of nine 5-minute cycles with a succession of work (top: 1 minute; bottom: 4 minutes). The high-intensity work phase will be adjusted so as to achieve a target Heart Rate (HR) corresponding to resting HR + 80% reserve HR (reserve HR = (200 - age) - resting HR). The low-intensity work phase will be adjusted to achieve a target maximum HR corresponding to resting HR + 60% reserve HR. In total duration, the exercise presents a submaximal intensity, commonly used in exercise rehabilitation studies carried out with various pathologies. It is an intensity capable of promoting benefits on the cardiovascular aspect without representing a severe intensity for the patient.~In order to adapt the training and guarantee patient safety, the first exercise session will be carried out with an alternation between a high-intensity work phase of resting HR + 70% reserve HR and a work phase. at low intensity of resting HR + 50% reserve HR."
224144571|NCT06440369|OTHER|Physical activity orientation group|Every week, for around ten minutes, patients in the AP orientation group will be contacted by telephone. The main objective of this exchange is to provide targeted advice on physical activity, its role, its objectives as well as its different ways of carrying it out. The second objective is to provide each week a personalized objective for each patient which can evolve over the weeks to increase levels of physical activity as far as possible. During each call, the evaluator will practice reflective listening, ask open-ended questions to facilitate the exchange, value and summarize the patient.
224051774|NCT03364153|DRUG|avacincaptad pegol|Intravitreal Injection
224051775|NCT03364153|DRUG|Sham|Intravitreal Injection
224051776|NCT00015054|DRUG|Methylphenidate|
223440421|NCT05698537|DIAGNOSTIC_TEST|Neuroimaging|Neuroimaging performed in PwE to diagnose epilepsy etiology
223440422|NCT05698537|DIAGNOSTIC_TEST|Blood sample|Blood samples from both PwE and controls will be collected to measure full blood count, IgM and IgG antibodies to parasitic antigens including Taenia solium, Toxoplasma gondii and Plasmodium falciparum, to perform ELISA for HIV1 and HIV2, to measure HIV viral load and to conduct an emmel test.
223440423|NCT05698537|OTHER|Risk factor questionnaire|Both PwE and control subjects will complete a structured questionnaire on a wide range of potential risk factors present before the onset of the epilepsy.
223440424|NCT05656885|DEVICE|Lens A|Soft spherical hydrogel contact lens for 15 minutes
223440425|NCT05656885|DEVICE|Lens B|Soft spherical silicone hydrogel contact lens for 15 minutes
223440426|NCT02242370|DRUG|Low dose of telmisartan|
223440427|NCT02242370|DRUG|High dose of telmisartan|
223440428|NCT01033708|BEHAVIORAL|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
223440429|NCT02452255|DRUG|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
223440430|NCT02452255|DRUG|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
223440431|NCT02452255|DRUG|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
223440432|NCT06229899|DIAGNOSTIC_TEST|Serum follistatin levels|blood samples are taken
223440433|NCT02572856|DEVICE|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
223440434|NCT01134861|DRUG|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 \& 29
223440435|NCT01134861|DRUG|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area \< 1.7 m2
223440436|NCT01134861|DRUG|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
223440437|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
224051777|NCT06169475|DRUG|Dexmedetomidine Hydrochloride|The continuous intravenous infusion of dexmedetomidine (0.1mg/ml) will start at 0.1ug/kg/h, increasing every 20 minutes by a step change of 0.05-0.2ug/kg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stopped if the heart rate fall below 80b.p.m..
224051778|NCT06169475|DRUG|Esmolol Hydrochloride|The continuous intravenous infusion of esmolol (10mg/ml) will start at 20mg/h, increasing every 20 minutes by a step change of 20mg/h to reach the target heart rate with the expectation that this should be within 12 hours. The infusion will be reduced by step change, and if necessary, ultimately stop if the heart rate fall below 80b.p.m..
224051779|NCT06959511|DRUG|Zanzalintinib|Given by po
224051780|NCT03654677|BIOLOGICAL|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
224051781|NCT03654677|BIOLOGICAL|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
224051782|NCT06385795|DRUG|NOE-115|NOE-115 is an investigational monoamine modulator which has potential anti-inflammatory activity.
224051783|NCT06407648|OTHER|Personalized Assessments|Personalized CBT will use individualized OCD symptom networks to guide CBT strategies to target central symptom nodes in contemporaneous networks.
224051784|NCT06407648|OTHER|Standard of Care|The standard CBT condition will use standard-of-care approaches to guide CBT strategies to target OCD symptoms.
224051785|NCT00533143|OTHER|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
224051786|NCT04858984|DEVICE|Virtual Reality|A portable, standalone VR headset called Oculus Go (Facebook Technologies, LLC. 1601 Willow Road, Menlo Park, CA 940250) with a head-mounted display with built in audio drivers was used. Disposable hygiene masks and a surgical cap were used as an underlay below the headset an
224051787|NCT06075576|DIAGNOSTIC_TEST|Intervention|No test articles will be used in the study. However, while taking measurements, the subject's eye will be exposed to light or light flashes that are about the same or lesser intensity than those in a routine eye exam in an eye care provider's office.
224051788|NCT05197049|DRUG|Guselkumab Dose 1|Guselkumab (Dose 1) will be administered by subcutaneous (SC) injection.
224051789|NCT05197049|DRUG|Guselkumab Dose 2|Guselkumab (Dose 2) will be administered by SC injection.
224051790|NCT05197049|DRUG|Guselkumab Dose 3|Guselkumab (Dose 3) will be administered by SC injection.
224051791|NCT05197049|DRUG|Placebo|Placebo will be administered by SC injection.
223440438|NCT01134861|DRUG|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
223440439|NCT01134861|RADIATION|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
223440440|NCT01134861|RADIATION|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
224051792|NCT05097521|OTHER|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings|Practitioner-delivered CIH therapies (acupuncture, therapeutic massage, chiropractic care) as received in VHA and community practice settings
224051793|NCT05097521|OTHER|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings|Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
224144572|NCT00382980|BIOLOGICAL|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
224144573|NCT00382980|BIOLOGICAL|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
224144574|NCT00382980|DRUG|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
223440441|NCT02748733|OTHER|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
223440442|NCT02748733|OTHER|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
224144575|NCT06391957|DIETARY_SUPPLEMENT|Spirulina supplement|Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.
223440443|NCT05345756|DEVICE|Intraoral protraction device|Use of modified lingual arch with indirect anchorage from screws between lower lateral incisor and lower canine to protract maxilla after ALT-RAMEC protocol
223440444|NCT05345756|DEVICE|Extraoral protraction device|Facemask which is an extraoral appliance used for maxillary protraction
223440445|NCT06165913|PROCEDURE|Early implant placement(type II)|in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed
223440446|NCT06165913|PROCEDURE|Early implant placement (type III)|in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
223440447|NCT04965428|BEHAVIORAL|Fear-focused Self-Compassion Therapy|The Fear-focused Self-Compassion Therapy will be delivered as a group format. The intervention consists of eight group face-to-face sessions (60-90 minute for each session) and will be delivered by three trained therapists for eight weeks (sessions are weekly). Each intervention group involves 10 patients.
223440448|NCT06137911|DRUG|JYP0061|JYP0061 orally administered
224051794|NCT05097521|OTHER|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings|Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
224051795|NCT01368536|DRUG|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
224051796|NCT01368536|DRUG|Amlodipine|Amlodipine 5 mg and 10 mg capsule
224051797|NCT01368536|DRUG|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
224051798|NCT01368536|DRUG|Placebo of Valturna Tablet|Matching placebo of valturna tablet
224051799|NCT01368536|DRUG|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
224051800|NCT00139282|DRUG|Squalamine Lactate|
224051801|NCT00786747|BEHAVIORAL|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
224051802|NCT00786747|BEHAVIORAL|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
224051803|NCT04344795|DRUG|TPST-1495 twice daily|TPST-1495 administered orally twice daily
224051804|NCT04344795|DRUG|TPST-1495 once daily or on intermittent schedule|TPST-1495 administered orally once daily or on intermittent schedule
224051805|NCT04344795|DRUG|Pembrolizumab|Pembrolizumab dosed per label recommendations
224051806|NCT05636189|PROCEDURE|warming during induction of anesthesia|Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.
224051807|NCT05636189|PROCEDURE|Prewarmed intravenous fluid administration|Prewarmed intravenous fluid is connected.
224051808|NCT04263064|DRUG|High Volume-Low Concentration without Clonidine|The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block
224051809|NCT04263064|DRUG|High Volume-Low Concentration with clonidine|The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
224051810|NCT04886648|BEHAVIORAL|Music Therapy|
224051811|NCT03442036|DEVICE|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
224051812|NCT03442036|DEVICE|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
224051813|NCT01161043|DEVICE|Sensor wear|All subjects to wear sensors
224051814|NCT01612182|OTHER|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
224051815|NCT00309465|DRUG|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
223440449|NCT06137911|DRUG|placebo|Placebo orally administered
224051816|NCT00309465|OTHER|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
224051817|NCT00309465|DRUG|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
224051818|NCT02999867|DIETARY_SUPPLEMENT|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
224144576|NCT06391957|PROCEDURE|Eccentric exercise|On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.
224051819|NCT02999867|DIETARY_SUPPLEMENT|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
224051820|NCT06402175|OTHER|follow up|follow up
224051821|NCT05279144|OTHER|Ventroguleal|Vastus Lateralis
224051822|NCT02164929|PROCEDURE|TAP block|
224051823|NCT02164929|PROCEDURE|Epidural|
224051824|NCT02164929|PROCEDURE|Paravertebral block|
224051825|NCT02164929|DRUG|Acetaminophen 1g IV|
224051826|NCT02164929|DRUG|Dexamethasone 4mg|
224051827|NCT02164929|DRUG|Midazolam up to 2mg|
224051828|NCT02164929|DRUG|Propofol 1-2.5 mg/kg|
224051829|NCT02164929|DRUG|Sevoflurane to keep a bispectral index of between 40-60|
224051830|NCT02164929|DRUG|Local infiltration with 10 mL of plain ropivacaine 0.25%|
224051831|NCT02164929|DRUG|Lidocaine|1.5% lidocaine
224051832|NCT02164929|DRUG|Epinephrine|1:200,000 epinephrine
224051833|NCT02164929|DRUG|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
224051834|NCT00971178|DRUG|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
224051835|NCT00971178|DRUG|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
224051836|NCT00971178|DRUG|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
224144577|NCT06391957|DIETARY_SUPPLEMENT|Placebo supplement|Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
224144578|NCT00054249|DRUG|T900607|
224144579|NCT04566822|BEHAVIORAL|High Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
224051837|NCT03364244|DRUG|Sildenafil|"\[REVATIO® Tablets / REVATIO® OD Film\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~\[REVATIO® Dry Syrup for Suspension\] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily."
224051838|NCT03101228|BEHAVIORAL|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
224051839|NCT01925573|DEVICE|Optune(NOVOTTF-100A)|
224051840|NCT00665899|BEHAVIORAL|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
224051841|NCT00665899|BEHAVIORAL|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
224300438|NCT06303973|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224300439|NCT06303973|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224300440|NCT00988065|DRUG|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
224300441|NCT00988065|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
224300442|NCT00988065|DRUG|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
224300443|NCT00988065|DRUG|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
224300444|NCT04890951|PROCEDURE|Hysteropexy|Uterine preservation through suspension
224300445|NCT04890951|PROCEDURE|Hysterectomy and vaginal vault suspension|Uterine removal and sewing the vagina upwards
224300446|NCT05438498|DRUG|Evusheld (tixagevimab+cilgavimab) IM or IV|Evusheld (tixagevimab 300 mg +cilgavimab 300 mg) IM or IV
224300447|NCT05286723|OTHER|Multicomponent Training|Warm up, aerobic training, stenght training, balance and coordination training and return to calm
224300448|NCT02685202|DEVICE|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
224300449|NCT01229735|DRUG|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
224300450|NCT01229735|DRUG|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
224300451|NCT03241381|DIAGNOSTIC_TEST|vitamin D serum assay study and control groups|Serum- vitamin D assay
224300452|NCT03241381|DIAGNOSTIC_TEST|Photometry|Serum- Hemoglobin assay
224300453|NCT03241381|OTHER|Russels periodontal index|Clinical examination for periodontitis
224300454|NCT02747862|OTHER|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP \[i.e. identifiable APC mutation\], and/or a compatible family history or personal adenoma burden of \> 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
224300455|NCT03956836|DIAGNOSTIC_TEST|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
224051842|NCT04404387|DRUG|Administration of vitamin C|"The intervention is intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).~The other name of the drug: Ascorbic acid."
224051843|NCT04404387|DRUG|Administration of placebo|Administration of placebo. Patients (in the control arm) will receive dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C. Placebo will be infused over 30 to 60 minutes or more for participants over 120 kg not to exceed 100 mg/minute as per the infusion instructions of vitamin C.
224051844|NCT00424749|DRUG|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m\^2.
224300456|NCT00968292|DEVICE|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
223740967|NCT07167238|BEHAVIORAL|Home exercises|"Program Duration: 8 weeks Implementation: Home-based, instructed face-to-face at baseline by a physiotherapist, supported with video materials, and monitored with regular feedback.~A) Posture + Breathing Exercises Frequency: 3 sessions per day (morning, noon, evening)~Content:~Shoulder girdle mobilization: Scapular elevation-depression, abduction-adduction (3 sets × 3 repetitions).~Stretching exercises: Shoulder, cervical, and trunk muscles; 5-second hold at end range.~Combined with breathing: Inspiration during concentric phase, expiration during eccentric phase.~B) Breathing Exercises Frequency: 3 sessions per day; 10 repetitions of each exercise per session~Content:~Pursed-Lip Breathing, Thoracic Expansion Exercises, Diaphragmatic Breathing, Breathing Control C) Walking Program Frequency: 2 days per week Duration: 30 minutes (5 min warm-up, 20 min walking, 5 min cool-down) Intensity: Self-selected pace targeting Modified Borg Scale (MBS) 4-6/10 for dyspnea."
224051845|NCT00424749|DRUG|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
224051846|NCT00530114|DRUG|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
224051847|NCT00530114|DRUG|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
224051848|NCT05138809|BEHAVIORAL|Exercise|Use online exercise platform
224051849|NCT01990638|OTHER|exercise capacity test|
224051850|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and warm and humidified CO2 Insufflation|low pressure pneumoperitoneum (5-8mmHg) and use warm (35°C), humidified (95% relative humidity) CO2 insufflation.
224051851|NCT05934981|PROCEDURE|Laparoscopic surgery under low pressure and conventional Insufflation|low pressure pneumoperitoneum (5-8mmHg), and use standard room temperature with dry insufflation.
224051852|NCT02577406|DRUG|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
224051853|NCT02577406|OTHER|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
224051854|NCT02577406|DRUG|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
224051855|NCT02577406|DRUG|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
224051856|NCT02577406|DRUG|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
224051857|NCT03742349|BIOLOGICAL|spartalizumab|LIVI (Liquid in vial) Concentrate for Solution for infusion
224051858|NCT03742349|BIOLOGICAL|LAG525|LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
223740968|NCT07174492|DRUG|Masitinib 4.5 mg/kg/day|Masitinib (titration to 4.5 mg/kg/day)
223740969|NCT07174492|DRUG|Placebo|treatment per os
223740970|NCT07174492|DRUG|Riluzole (100 mg)|Riluzole 50 mg tablet, treatment per os
224051859|NCT03742349|DRUG|NIR178|Capsule
224051860|NCT03742349|DRUG|capmatinib|Tablet
224051861|NCT03742349|BIOLOGICAL|MCS110|LIVI (Liquid in vial) Concentrate for Solution for infusion
224051862|NCT03742349|BIOLOGICAL|canakinumab|LIVI (Liquid in vial) Solution for injection
224051863|NCT02138617|DRUG|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
224051864|NCT02138617|DRUG|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
224051865|NCT02138617|DRUG|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
224051866|NCT02138617|DRUG|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
224051867|NCT05660083|DRUG|L-NMMA|Patients with HER2 negative metastatic or locally advanced MpBC, will receive a combination of an iNOS inhibitor, nab-paclitaxel and alpelisib . As prophylaxis against deep venous thrombosis and hypertension, patients will receive aspirin (81 mg po daily) and amlodipine (10 mg po Days 0-5 each cycle). Metformin will be initiated at 500 mg once daily starting one week prior to treatment to reduce risk of severe hyperglycemia. Based on tolerability and serial blood sugar assessments, metformin dose will be increased to 500 mg twice daily, followed by 500 mg with breakfast and 1000 mg with dinner, followed by further increase to 1000 mg twice daily if needed. Insulin sensitizers and/or SGLT2i will be used as second anti-diabetic agents, if necessary. For prophylaxis of alpelisib rash, patients will be treated with an anti-histamine (cetirizine 10 mg daily) along with alpelisib.
224051868|NCT05628727|OTHER|Time Restricted Feeding|This group will use the 16:8 method every day, eating only during an 8-hour period that will commence at wake-up time.
224051869|NCT05628727|OTHER|5:2 Fasting|This group will use the 5:2 method and fast for two non-consecutive days of the week.
224051870|NCT06106945|DRUG|AZD0305|AZD0305
224051871|NCT06150417|DRUG|Androgen deprivation therapy (ADT)|Standard androgen deprivation therapy (ADT) will be administered at the discretion of treating physician.
224144580|NCT04566822|BEHAVIORAL|Medium Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
224144581|NCT04566822|BEHAVIORAL|Low Touch intervention|The Calm app is downloadable by participants onto their smartphone to access the Calm app and Calm Sleep Coaching. The Calm app is used to deliver the intervention to experimental group participants.
224051872|NCT06150417|DRUG|Androgen receptor signaling inhibitor (ARSI)|Standard androgen receptor signaling inhibitors (ARSI) will be administered at the discretion of the treating physician.
224051873|NCT06150417|OTHER|Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)|"Local therapy will either be radiotherapy (RT) or radical prostatectomy (RP).~* Prostate +/- pelvic nodal radiation~* Radical prostatectomy + pelvic lymph node dissection"
224144582|NCT04566822|BEHAVIORAL|Sleep Education Control|Participants in the sleep education control will not have access to a coach. Weekly sleep education will be accessible to the participant on a weekly basis. The sleep education content will be the same that is provided to the intervention participants.
224144583|NCT01324622|DEVICE|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
224144584|NCT01324622|PROCEDURE|laminectomy|standard procedure
224300457|NCT03880916|DRUG|Duloxetine|"1. Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~2. Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
224051874|NCT06150417|RADIATION|Metastasis directed radiotherapy (MDRT)|In participants randomized to the MDRT arm, MDRT to all lesions will be performed by the end of Week 24. Selection of a particular regimen (the dose and fractionation) will based on the size and location of the participant's metastatic site and the surrounding normal tissue constraints.
224051875|NCT04153344|OTHER|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
224051876|NCT04153344|OTHER|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
224051877|NCT05884398|DRUG|Apalutamide|Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of Cycle 7 up to at least 18 months.
224051878|NCT05884398|DRUG|Androgen-deprivation Therapy (ADT)|The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
224051879|NCT06323980|DEVICE|Reverse Total Shoulder|Uncemented Reverse Total Shoulder
224051880|NCT06428058|BEHAVIORAL|Comprehensive sexual health curriculum|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing the effects on sexual health knowledge, attitudes, and sexual history and counseling skills at medium (6-) and long-term (12 and 24 months) follow-up. At the end of the intervention as compared with waitlist controls.~The intervention was a 4-day, Afrocentric, comprehensive sexual health curriculum. Tanzanian faculty wrote the curriculum in English and Kiswahili to address the most common sexual health challenges clinicians experience in Tanzania. The 4-day curriculum covers sexual health across the lifespan, lesbian, gay, bisexual, and transgender (LGBT) and sexual violence, clinical skills training, ethics, and community resources and cultural considerations."
224051881|NCT04397276|DRUG|JNJ-70218902|JNJ-70218902 will be administered.
224051882|NCT03006172|DRUG|Inavolisib|Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
224300458|NCT03880916|DRUG|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
224300459|NCT05711836|GENETIC|HLA-genotyping|HLA genotyping in DNA samples from peripheral blood of patients and controls
224300460|NCT03203486|OTHER|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
224300461|NCT00128414|DRUG|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
224300462|NCT00128414|DRUG|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
224300463|NCT03080415|DRUG|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
224300464|NCT00005595|DRUG|arsenic trioxide|
224300465|NCT02041910|BIOLOGICAL|Stem Cells|MSCs injection intratesticular
224300466|NCT02041910|BIOLOGICAL|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
224300467|NCT02400242|DRUG|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
224300468|NCT02400242|DRUG|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
224300469|NCT02400242|DRUG|Dexamethasone|40 mg qd on days 1, 8, 15, 22
224300470|NCT02748811|OTHER|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
224300471|NCT02787408|DEVICE|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
224300472|NCT00985712|DRUG|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
224300473|NCT00985712|DRUG|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
224300474|NCT00985712|DEVICE|HumaPen Memoir|subcutaneously, daily for 24 weeks
224300475|NCT00985712|DEVICE|HumaPen Luxura|subcutaneously, daily for 24 weeks
224300476|NCT04056975|BIOLOGICAL|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
224300477|NCT02743143|BEHAVIORAL|Exercise therapy|
224300478|NCT02743143|OTHER|Follow-up care as usual|
224300479|NCT04376528|DRUG|Cyclosporin A|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
224300480|NCT04376528|DRUG|Mycophenolate Mofetil|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )
224300481|NCT04338217|DEVICE|Bionator|This is a functional appliance that is used to overcome the functional problems and to correct the open bite deformity
224300482|NCT04338217|DEVICE|Removable Appliance with Posterior Bite Planes|This is a one-jaw appliance that is used in conjunction with a tongue crib to control the faulty positions of the tongue and to help in closing the open bite through the use of posterior bite planes.
224300483|NCT03816813|OTHER|blood and saliva sampling|blood and saliva sampling
224051883|NCT03006172|DRUG|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
224051884|NCT03006172|DRUG|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
224051885|NCT03006172|DRUG|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
224051886|NCT03006172|DRUG|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
224300484|NCT05897918|DRUG|Tranexamic Acid 500 MG|Each patient received treatment on both sides of the face, one side treated by micro needling with 10% topical tranexamic acid, and othert side treated by 10% topical tranexamic acid alone every 2 weeks for 3 sessions
223440450|NCT05911672|DEVICE|PRICE|Working closely with 51 cancer patients, medical and paramedical personnel, we co-designed an intelligent personalized mobile application to first collect ecologically momentary assessment data on symptoms like pain and fatigue and Health-Related Quality of Life and subsequently enhance symptom management of cancer patients at home. The full description is available here: https://dl.acm.org/doi/abs/10.1145/3491101.3503562?casa\_token=tC5fSN8-k5EAAAAA:56\_TMf6HitVQXZypY2j9FCCcroIFZW9kxxzCEt0yJNFJmNrv79m9W7htznSzMWqGLwE4eimBU0vkLA
223440451|NCT00072748|DRUG|EKB-569|
223440452|NCT01903759|OTHER|Blood samples|
223440453|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
223440454|NCT00802958|DRUG|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
223440455|NCT04283110|DRUG|intrthecl midazolam|midazolm as as adjuvant in spinal anesthesia
223440456|NCT04482036|OTHER|Mobile Phone Application Assessments|"The BrainCare Notes app was designed to be installed on the caregiver's phone. It has the capacity to send Neuropsychiatric Inventory Questionnaire (NPI-Q) assessments to the caregiver. If the answers to the behavioral and psychological symptoms rise above the threshold, the clinicians will be notified, and a care plan will be enacted, in order to keep the patient and caregiver safe.~The application also has the ability to send and receive private messages between caregiver and the patient's clinical care team."
224051887|NCT03006172|DRUG|Trastuzumab|Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
224051888|NCT03006172|DRUG|Pertuzumab|Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
223440457|NCT04482036|OTHER|Standard Assessments|The caregiver and patient will receive the same questionnaires and surveys that the intervention group will receive. However, they will not receive the mobile phone application questionnaires.
223740971|NCT07178444|BEHAVIORAL|"New care pathway"|"Initially, the patient will have an interdisciplinary consultation aimed at identifying personalized goals for the patient and providing educational/preventive care using tools that will be provided to all centers. This consultation will bring together a cardiologist, an advanced practice nurse (APN), a dietitian and a pharmacist. This consultation will take place approximately 4 weeks after the hospitalization for acute coronary syndrome (ACS).~Secondly, the patient will have 3 follow-up consultations with the APN (at 3, 6 and 12 months after discharge from hospitalization for an ACS). During these consultations, the APN will perform a clinical assessment, a personalized educational support, a coaching based on the patient's personalized goals, an adjustment of therapies and, depending on needs, referral to other health professionals."
224051889|NCT06452238|OTHER|External Oblique Intercostal Plane Block|Patients will receive external oblique intercostal plane block .
223440458|NCT02463006|DRUG|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
223440459|NCT02463006|DRUG|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
223440460|NCT00149370|PROCEDURE|Breast reduction surgery|
223440461|NCT05634642|DEVICE|Ultrasound|Using ultrasound to measure the diameter of distal radial artery
224051890|NCT06452238|OTHER|Transversus Abdominis Plane Block|Patients will receive ultrasound-guided transversus abdominis plane block.
224051891|NCT04611568|OTHER|Educational Intervention|Receive educational and training material
224051892|NCT04611568|OTHER|Educational Intervention|Receive educational lecture
224051893|NCT04611568|BEHAVIORAL|Health Education|Receive melanoma curriculum
224051894|NCT04611568|BEHAVIORAL|Media Campaign|View digital media strategies
224051895|NCT04611568|OTHER|Survey Administration|Complete survey
224051896|NCT04033445|DRUG|Placebo|Participants will receive matching placebo IV or SC.
224051897|NCT04033445|DRUG|Guselkumab|Participants will receive guselkumab IV or SC.
224051898|NCT04461691|PROCEDURE|Cryoballoon Pulmonary Vein Isolation|Cryoballoon pulmonary vein isolation is a common method for catheter ablation of atrial fibrillation. Cryoenergy is applied through a balloon in a single-step approach resulting in necrosis by tissue freezing.
224051899|NCT06639659|PROCEDURE|Sphenopalatine Ganglion Block|patients will receive ultrasound guided bilateral supra-zygomatic sphenopalatine ganglion block.
224051900|NCT06639659|DRUG|Dexmedetomidine|patients will receive 1 µg/kg dexmedetomidine within 10 minutes, followed by maintenance dose throughout the surgery.
224051901|NCT06639659|OTHER|General Anesthesia (control group)|patients will be operated under general anesthesia including routine protocol for these cases
224051902|NCT05703854|DRUG|CAR.70/IL15-transduced CB-derived NK cells|Given by IV (vein)
224051903|NCT05703854|DRUG|Fludarabine phosphate|Given by IV (vein)
224051904|NCT05703854|DRUG|Cyclophosphamide|Given by IV (vein)
224300485|NCT04158336|DRUG|ZN-c3|ZN-c3 is a study drug
224300486|NCT04277871|BEHAVIORAL|Pelvic floor muscles training (PFMT) combined with yoga|All study participants were instructed to perform PFMT combined with yoga with an expectation of performing a 70-minute practice section 3 days in a week. All study participants received a booklet with menopause-related information, a booklet plus an instructional Digital Video Disc for PFMT and yoga practice.
224300487|NCT01000493|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
224300488|NCT01000493|OTHER|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
223440462|NCT00240656|DRUG|spironolactone captopril carvedilol|
223440463|NCT02410213|DRUG|Ferric Carboxymaltose (FCM)|
223440464|NCT00264030|DEVICE|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
223440465|NCT00264030|OTHER|PTCA|PTCA
223440466|NCT01857102|DEVICE|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
223440467|NCT01857102|DEVICE|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
223440468|NCT03485937|BEHAVIORAL|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
223440469|NCT03485937|BEHAVIORAL|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
224144585|NCT04223700|PROCEDURE|Ultrasound imaging & fluoroscopic confirmation|The researchers use ultrasound to scan the left and right sides of the paravertebral sagittal imaging to identify trapezius, semispinalis, erector spinae muscle, transverse process and rhomboid muscle. The radiopaque marker is attached respectively to the skin of the inferior margin of the rhomboid muscle on the left and right thoracic spinal spines. Then, as the first step for the scheduled nerve block to the patient, thoracic vertebra level verification using C-arm is performed. At this time, left and right level of the transverse process of thoracic spine marked with the radiopaque marker are confirmed and recorded.
224144586|NCT02530957|DEVICE|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
224144587|NCT02530957|DEVICE|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
223440470|NCT03485937|BEHAVIORAL|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
223440471|NCT06230029|OTHER|Music listening|Music will be played through individual headphones (BOSE AE2®). The headphones give the impression of personalized music that only the patient can hear. Patients will have a mask over their eyes to limit visual aggression. The songs will be pre-recorded on a digital tablet (Samsung Galaxy®) allowing the broadcasting of music programs. Patients will have the choice to listen to a song according to their musical preferences among 16 different musical styles. The volume will be adapted to the level that suits the patient.
223566717|NCT06608004|OTHER|test taking|Measurement of VAS for sensation of hunger, LFQP-France test, 24-hour semi-quantitative dietary recall, Assessment of energy expenditure linked to physical activity using the IPAQ (International Physical Activity Questionnaire) (only at inclusion), Screening for undernutrition risk factors using the SSQ (Social Support Questionnaire) (only at inclusion), Measurement of body composition by impedancemetry, Measurement of isometric grip strength by handgrip test, Measurement of quality of life (SF36), Study of olfacto-gustatory sensoriality (olfaction via the Sniffin\&#39; Sticks test, gustation via lingual application of impregnated strips and AHSP self-questionnaire) (carried out every other visit) and Measurement of gustatory evoked potentials in response to sugar.
223566718|NCT06606938|PROCEDURE|Faecal Microbiota Transplantation|FMT at baseline, week 2, week 4
223566719|NCT06606938|PROCEDURE|Normal Saline (Placebo)|Placebo at baseline, week 2, week 4
224144588|NCT01798940|DRUG|Torrent's Pioglitazone|
224144589|NCT00000524|DRUG|cyclosporine|
224144590|NCT00000524|DRUG|prednisone|
224144591|NCT00138424|DRUG|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
224144592|NCT00138424|DRUG|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
224144593|NCT01743014|DRUG|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
224144594|NCT01743014|DRUG|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
224144595|NCT00258102|DRUG|Levofloxacin|
224144596|NCT02521961|OTHER|Informational Intervention|Watch a Chair-robics DVD
224144597|NCT02521961|OTHER|Informational Intervention|Receive community resource booklet
224144598|NCT02521961|OTHER|Quality-of-Life Assessment|Ancillary studies
223440472|NCT01490697|DRUG|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
223440473|NCT01490697|DRUG|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
223440474|NCT01490697|DRUG|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
223440475|NCT01490697|DRUG|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
223566720|NCT03426462|DRUG|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
223740972|NCT07178444|OTHER|"Standard care pathway"|The French National Health Authority recommends two medical visits (at 6 and 12 month) and, if necessary, a third one (between the first and third month post-ACS) for the monitoring of the left ventricular. - The European Society of Cardiology recommends a reassessment of the lipid profile within 4-6 weeks post-ACS.
224144599|NCT02521961|OTHER|Questionnaire Administration|Ancillary studies
224144600|NCT02521961|PROCEDURE|Support Group Therapy|Attend support group sessions
224144601|NCT01172834|BEHAVIORAL|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
223440476|NCT01585610|BEHAVIORAL|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (\< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
223440477|NCT01585610|BEHAVIORAL|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (\< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
224051905|NCT01648478|OTHER|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~* A basal period (from T-30 to T0)~* The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~* The infusion of glucose at variable rate (so as to maintain euglycemia)"
223440478|NCT04093791|BEHAVIORAL|"Collective Intervention G"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~2. Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
223440479|NCT04093791|BEHAVIORAL|"Individual Intervention I"|"The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~2. Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
223440480|NCT04935008|DIAGNOSTIC_TEST|The recruitment maneuver|In patients with ARDS, 30 cm H2O positive pressure support and 30 seconds recruitment maneuver will be applied. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver. Optic nerve diameter will be evaluated with a linear probe on the eyeball before and after the collection maneuver, taking a value of 3 mm from the eyeball.
223440481|NCT00090584|DRUG|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
223440482|NCT00090584|BEHAVIORAL|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
223740973|NCT07178405|OTHER|Meal low in energy density, low in ultra-processed food|Meal low in energy density, low in ultra-processed food
223740974|NCT07178405|OTHER|Meal low in energy density, high in ultra-processed food|Meal low in energy density, high in ultra-processed food
223740975|NCT07178405|OTHER|Meal high in energy density, low in ultra-processed food|Meal high in energy density, low in ultra-processed food
223740976|NCT07178405|OTHER|Meal high in energy density, high in ultra-processed food|Meal high in energy density, high in ultra-processed food
224051906|NCT05195437|OTHER|QoLiSSY and PedsQL 4.0 questionnaires|"Patients have been reaching adult size complete the two questionnaires of the study :~Quality of Life of Short Stature Youth questionnaire (QoLiSSY), assessing health-related quality of life in short stature youth.~Pediatric Quality of Life Inventory (PedsQL) 4.0 : general health-related quality of life.~The patients have previously completed the PedsQL 4.0 and QoLiSSY questionnaires when starting their growth hormone therapy and after one year of growth hormone therapy."
224051907|NCT05851066|DRUG|VSA003|sequential dosing, SC, single dose: 50 mg, 100 mg, 200 mg
224051908|NCT05851066|DRUG|0.9% NaCl|placebo
224144602|NCT04370717|OTHER|telehealth consultation|"A telehealth consultation will be scheduled and conducted without modifications from the routine clinic protocol. The case report will include ICD-10 code and plan of care.~After one week, patients will receive an electronic satisfaction survey. An in-person follow-up and/or procedural visit will be subsequently scheduled. During this visit, the same physician will complete physical examination, document the diagnosis and proceed with either the same or modified plan of care. The research coordinator will enter diagnostic and procedural codes in the case report form."
224144603|NCT05378516|OTHER|no intervention|no intervention
224144604|NCT00062699|DRUG|Zemplar (paricalcitol injection)|
224051909|NCT06521762|DRUG|Etrasimod|2 mg/day oral tablet
224051910|NCT06521762|DRUG|Placebo|matching placebo oral tablet
224051911|NCT06521762|DRUG|Corticosteroids|Corticosteroids will be given in conjunction with study drug or placebo
224051912|NCT04630171|DEVICE|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #1: VerTouch utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
224144605|NCT00062699|DRUG|Calcijex|
224144606|NCT00912899|DRUG|Noscapine HCl|Escalating doses given twice per day
224144607|NCT04156932|PROCEDURE|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
224144608|NCT02893527|BEHAVIORAL|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
224144609|NCT00413062|DRUG|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
224051913|NCT04630171|DEVICE|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure|Group #2: Ultrasound (US) utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
224051914|NCT04630171|OTHER|Group #3: Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure|Control group, palpation utilized for identification of site for labor epidural or spinal anesthesia procedure for women requesting labor analgesia
223440483|NCT01436331|OTHER|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
223440484|NCT01436331|BEHAVIORAL|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
223440485|NCT05248724|COMBINATION_PRODUCT|periarticular infiltration (50ml) with Ropivacaine Hydrochloride 10 MG/ML (200 mg) + ketorolac tromethamine 30 mg/ml (30 mg) + adrenaline 1mg/ml (300 microgram) + morphine hydrochloride 10mg/ml (5 mg)|Patients allocated to the intervention group received a periarticular infiltration with a solution containing 200 mg of ropivacaine hydrochloride ,150 mg if the patient weight was below 65kg, 5 mg of morphine hydrochloride , 30 mg of ketorolac tromethamine, 300 micrograms of adrenaline and saline 0.9% till reaching 50 ml of volume. Half of the solution was injected into the proximal hamstring stump. The surgical team closed the wounds and injected the other half of the intervention into the subcutaneous tissue in the distal wound and portals. There was not any medication introduced inside the articulation. Patients of the placebo group were treated in the same way, but the solution injected was 50 ml of saline 0.9%.
223440486|NCT05248724|DRUG|placebo|50 ml of 0.9 saline
223566721|NCT05151445|BEHAVIORAL|mHealth dietary app + health coaching intervention|"The Lose-It app will be set up with Gmail accounts with unique unidentifiable codes developed by the research team. Participants be trained to enter their dietary intake and physical activity daily for 12-weeks. Participants will monitor their vegetable intake, fat intake, carbohydrate intake, weight, and blood pressure. Wi-Fi connected weight scales and blood pressure cuff will be supplied for weight and blood pressure monitoring. Participants will be taught how to sync the data from the scales and blood pressure cuff to the app for the research team to access. Participants will perform a return demonstration to confirm that they can record their dietary intake daily, physical activity, weight, and blood pressure using the Lose-It app. We also review with the participant the My Plate method for proper nutrition and the steps to distance conversion chart."
223566722|NCT04193085|OTHER|Observational|Observational
224051915|NCT00647166|DRUG|corticosteroid and azathioprine|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
224051916|NCT00647166|DRUG|corticosteroid and placebo|"* Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
224051917|NCT04550715|BEHAVIORAL|Brief intervention (BI)|A remote brief intervention delivered by health coaches that uses Motivational Interviewing to address opioid misuse and risk factors. Remote health coaches use a web-based clinician support guide to maintain fidelity, while tailoring the session to unique participant factors.
224051918|NCT04550715|BEHAVIORAL|Portal|Remote health coaches will push tailored messages to participants over a 4-week period. The messages will use Motivational Interviewing strategies. The messages are designed to elicit a response from the participant. Health coaches will also respond to participant replies consistent with Motivational Interviewing over a course of 4 weeks.
224051919|NCT04550715|BEHAVIORAL|Enhanced Usual Care (EUC)|The brochure covers educational topics like opioid storage and disposal and overdose prevention, as well as resources such as naloxone, suicide hotlines, mental health, and substance use treatment. It will be available online and in print.
224051920|NCT05007483|DIETARY_SUPPLEMENT|BodyBio Balance Oil|nutraceutical supplement
224051921|NCT05007483|DIETARY_SUPPLEMENT|Kirunal Fish Oil|nutraceutical supplement
224051922|NCT05007483|DIETARY_SUPPLEMENT|BodyBio PC|nutraceutical supplement
224051923|NCT05007483|BEHAVIORAL|Modified Paleolithic Elimination diet|"1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast."
224144610|NCT00413062|DRUG|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
224144611|NCT04621669|DRUG|SHR3680|240 mg
224144612|NCT04621669|DRUG|digoxin|0.25 mg
224144613|NCT04621669|DRUG|Rosuvastatin calcium|10 mg
224144614|NCT04621669|DRUG|metformin hydrochloride|500 mg
224144615|NCT04935125|PROCEDURE|Standard Program + Endurance and Strength training|Sessions of strength training added to a standard inpatient multidisciplinary programme
224144616|NCT04935125|PROCEDURE|Standard Program|Standard inpatient multidisciplinary programme (including endurance training)
224051924|NCT05007483|BEHAVIORAL|Time Restricted Olive Oil Based (TROO) Ketogenic Diet|"1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables."
224051925|NCT05007483|BEHAVIORAL|Usual diet with Dietary Guidelines for Americans Diet information|"1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods."
224051926|NCT05678010|DRUG|AZD1390|Dose level 1: 20 Dose level 2: 40 Dose level 3: 60 Dose level 4: 80
224144617|NCT02946541|DRUG|evogliptin 5mg|evogliptin 5mg, QD
224144618|NCT02946541|DRUG|Placebo|Placebo, QD
224144619|NCT04658381|GENETIC|Genetic analysis|Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
224144620|NCT04658381|PROCEDURE|Ophthalmologic exam|Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
224144621|NCT01669941|DRUG|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
224144622|NCT01669941|DRUG|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
224144623|NCT01669941|DRUG|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
224144624|NCT04237324|PROCEDURE|Treatment one side BLE by NAFL|One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
224144625|NCT04237324|PROCEDURE|Treatment another side BLE by FMR|One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
223440487|NCT01572311|BEHAVIORAL|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
223440488|NCT01572311|BEHAVIORAL|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
223440489|NCT02013661|PROCEDURE|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
223566723|NCT04199091|PROCEDURE|Craniosacral Therapy (CST) self-help techniques|Manual self-help techniques based on Craniosacral Therapy (group setting).
224144626|NCT01005511|DEVICE|Grindcare|Active treatment
224144627|NCT01005511|DEVICE|Grindcare - inactive|Placebo treatment
224144628|NCT01881971|DRUG|Placebo|suger pill manufactured to mimic crestor pills
223566724|NCT04199091|PROCEDURE|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation according to Jacobsen (group setting).
223566725|NCT05300568|OTHER|No Intervention|This is a non-product related survey.
223566726|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
223566727|NCT06690242|DRUG|MT1013|MT1013 is a novel calcimimetic agent
223566728|NCT06690242|DRUG|Etelcalcetide Hydrochloride|the already-marketed therapeutic agents
223566729|NCT06690242|DRUG|Placebo|The measure does not contain the active ingredients
224051927|NCT05678010|RADIATION|Stereotactic Body Radiotherapy|Participants will receive Stereotactic Body Radiotherapy/SBRT to 2 sites of metastatic tumors consecutively. The two treatment sites will be randomized to SBRT to one site and SBRT + AZD1390 to the other site. Both sites will receive 30Gy in 5 fractions.
224051928|NCT05734391|DIAGNOSTIC_TEST|Routine Infection control|routine part of hospital IPC activities
224144629|NCT01881971|DRUG|Rouvastatin calcium|
224144630|NCT00740883|DRUG|warfarin|18 months of warfarin therapy, once daily
224144631|NCT00740883|DRUG|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
224144632|NCT04473144|DRUG|Ulinastatin|In the Ulistine administration group, 300,000 KIU was mixed with 100 mL physiological saline and administered over 15 minutes after induction of anesthesia.
224144633|NCT01318772|DEVICE|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
224144634|NCT02713763|DRUG|Sunitinib|Sunitinib 37.5 mg/day
224051929|NCT05467150|DIETARY_SUPPLEMENT|Probiotic Supplement|The probiotic that will be used is Culturelle® Digestive Daily Probiotic Capsules. Each capsule contains 10 billion CFU of Lactobacillus rhamnosus GG (LGG).
224051930|NCT06008093|DRUG|Durvalumab|Participants will receive intravenous (IV) Durvalumab q3w for four 21-day cycles as induction treatment. Durvalumab will also be given during the maintenance treatment period q4w until disease progression or unacceptable toxicity.
224051931|NCT06008093|DRUG|Tremelimumab|Participants will receive IV Tremelimumab q3w for four 21-days cycles as induction treatment. Tremelimumab will also be given during the maintenance therapy phase at week 16 and week 104 (at the investigators discretion).
223440490|NCT04456166|DIETARY_SUPPLEMENT|noNPO|"Patients with diabetes mellitus type 2 who are planned to receive a carbohydrate beverage (400 ml (12.8% carbohydrates, 50 kcal/100 ml; Nucare NONPO Ⓡ , Daesang Wellife, Korea) before the operation and up to 2 hours before the induction of anesthesia outside this clinical study setting will be asked to be enrolled into the study.~Before induction of general anesthesia, all patients were evaluated the gastric volume under ultrasonography."
223440491|NCT01461252|PROCEDURE|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
223440492|NCT01461252|PROCEDURE|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
223440493|NCT04937907|DRUG|Hydroxychloroquine Sulfate 100 milligram (mg) Tab|Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.
223440494|NCT04937907|DRUG|Benazepril hydrochloride 10 milligram (mg) Tab|Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.
223440495|NCT03409120|DEVICE|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
223440496|NCT05614778|OTHER|Zoledronic Acid injection, 5mg/100mL|Zoledronic Acid injection, 5mg/100mL
223440497|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
223440498|NCT01147003|DRUG|Placebo|
223440499|NCT01147003|DRUG|Investigational new drug, company code: BGG492|
223440500|NCT04442438|OTHER|Monthly moral case deliberation|Once per month, ICU professionals will take part in moral case deliberation. As part of the intervention, two or three ICU professionals (physicians and nurses) are tasked with selecting a case for moral discussion. Moral case deliberation is attended by around thirty individuals per month per unit. A feedback system will be developed used to spread the knowledge/insights from the case deliberation to all professionals in the unit.
223440501|NCT01451138|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
224051932|NCT06008093|DRUG|Pemetrexed|Participants in Arm A and Arm B will receive IV pemetrexed q3w for four 21-day cycles as induction treatment. In the maintenance therapy phase, Treatment Arm A will receive Pemetrexed q4w, Treatment Arm B will receive Pemetrexed q3w until disease progression or unacceptable toxicity.
224051933|NCT06008093|DRUG|Pembrolizumab|Participants will receive IV pembrolizumab q3w for four 21-days cycles as induction treatment. Pembrolizumab will also be given in the maintenance treatment phase q3w until disease progression or unacceptable toxicity or up to 24 months.
224051934|NCT06008093|DRUG|Carboplatin|Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
224051935|NCT06008093|DRUG|Cisplatin|Participants will receive IV Carboplatin or IV Cisplatin on Day 1 of each 21-day cycle for 4 cycles as induction treatment.
224051936|NCT05836987|DEVICE|AFSW Guided DOAC|The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.
224051937|NCT05836987|DRUG|Continuous DOAC therapy|DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
224144635|NCT00360919|BEHAVIORAL|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
224144636|NCT06552806|DIETARY_SUPPLEMENT|SLAB51|One dose of SLAB51 is administered after arrival to high altitude, then three times a day approximately every 5 hours upon waking during Days 2 and 3, and a final dose the morning of Day 4 of acclimatization.
224144637|NCT01848899|DRUG|Iodixanol|contrast media used during coronary angiography
224144638|NCT01848899|DRUG|Ioxaglate|contrast media used during coronary angiography
224144639|NCT01848899|DRUG|Bivalirudin|A direct thrombin inhibitor
224144640|NCT02699242|DEVICE|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
223440502|NCT00703287|OTHER|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
223440503|NCT00703287|OTHER|Physiotherapy|Generic physiotherapy
223440504|NCT04787328|DRUG|HA121-28 tablets|HA121-28 450 mg, po, QD×21 days, every 4 weeks (28 days)
224051938|NCT04252859|DRUG|[18F]Fluoroestradiol (FES) PET/CT|\[18F\]Fluoroestradiol (FES) PET/CT for invasive lobular carcinoma (ILC)
224051939|NCT05807464|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
224144641|NCT05947747|DRUG|EXO-CD24|Twice a day for 5 days, dose 10\^10
224144642|NCT05947747|OTHER|Placebo|Twice a day for 5 days
224051940|NCT06799819|BEHAVIORAL|Mobility group|Free mobility between FDG injection and scanning (without exiting the Nuclear Medicine Department)
224051941|NCT02113930|BIOLOGICAL|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
224051942|NCT02113930|GENETIC|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
224051943|NCT05064579|OTHER|Questionnaires|Questionnaire in two parts: one part on the objectives related to taking the treatment and the objectives related to the treatment modality and a second part on the general characteristics of each participant and the characteristics of the child's asthma.
224051944|NCT05400941|BEHAVIORAL|Practice Led Intervention|This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.
224051945|NCT02344433|BEHAVIORAL|VICKY|Relational agent/virtual counselor
224051946|NCT02344433|BEHAVIORAL|MFHP|US Surgeon General's family history tool
224051947|NCT00125762|DEVICE|FibroScan|
224051948|NCT05343897|BEHAVIORAL|Low intensity exercise - Ping-Shuai Gong (PSG)|Participants were asked to conduct and record 30 minutes of PSG in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
223440505|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat drug screen|Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen
223440506|NCT06618183|DIAGNOSTIC_TEST|Fingerprint sweat laboratory analysis|Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
223440507|NCT04208321|OTHER|Placebo|Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
223440508|NCT04208321|DRUG|VT-1598|VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
223440509|NCT01058902|DRUG|Aspirin 75 mg|Aspirin 75 mg
223440510|NCT01058902|OTHER|no aspirin|nothing
223440511|NCT03925584|OTHER|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
223440512|NCT00129181|DRUG|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
223740977|NCT07183800|OTHER|Water|Participants will undergo a standardized 10-minute high-intensity trampoline jumping protocol designed to elicit mechanical loading on the pelvic floor. Prior to the jumping session, bladder volume will be assessed via transabdominal ultrasound. If a participant's bladder contains less than 100 mL of urine, they will be asked to drink water and wait until a target range of 100-200 mL is reached to ensure consistent pre-jump bladder filling across participants. This approach minimizes variability in bladder volume, which could influence pelvic floor measurements.
223740978|NCT07184047|OTHER|Adjuvant Chemotherapy (Standard of Care)|"Patients aged 65 years and older with non-metastatic or locally advanced gastrointestinal cancers will receive standard adjuvant chemotherapy regimens as part of routine clinical practice. Regimens may include FOLFOX, CAPEOX, FOLFIRI, FOLFOXIRI, FOLFIRINOX, capecitabine, gemcitabine, 5-FU/leucovorin, or oxaliplatin-based combinations, depending on tumor type and physician decision.~No investigational drugs or experimental interventions are administered. The study is observational, and all treatments follow standard of care."
223440513|NCT00129181|DRUG|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
223440514|NCT00129181|PROCEDURE|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
224051949|NCT05343897|BEHAVIORAL|Low intensity exercise - Arm-Swing Exercise (ASE)|Participants were asked to conduct and record 30 minutes of ASE in one day lasting for 2-month, and at least 3 days a week. A record sheet were sent to the participants in the first time, and the contact information of examiner were given as well. The examiner will check the completion of exercise execution via phone every two to three days and visit participants to confirm the correctness of movement at least one time during the 2-month intervention period.
224051950|NCT06366074|DEVICE|Watch-TEA group|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
224051951|NCT06366074|DEVICE|Tethered TEA device|"Subjects will wear the device for 3 days. The subjects will self-apply the TEA for 60 min once daily with the current amplitude set at a maximal tolerable level.~To increase the subject compliance, two measures will be implemented: timely alerts by the app (and phone calls, if needed) for performing the TEA sessions, and recording full history of therapy sessions on the device for monitoring the compliance."
224051952|NCT06166979|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e8 cfu/ dose (Active)
224144643|NCT02815293|DRUG|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
223440515|NCT06645912|DIETARY_SUPPLEMENT|oral nutritional supplement|The ONS group received a high-protein ONS providing 18.8 g of protein, 7 g of fat, 28 g of carbohydrates, and 250 calories of energy per 200 mL and medical nutrition therapy. The product is gluten-free and contains lactose, minerals, trace elements, and vitamins . The Control group received only standard nutrition therapy without ONS supplementation.
223440516|NCT01800019|DRUG|Nicotine Replacement Therapy (NRT)|
223440517|NCT01800019|DRUG|Varenicline|
223440518|NCT01800019|BEHAVIORAL|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
223440519|NCT02117713|DRUG|LUM001 (Maralixibat)|Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
224051953|NCT06166979|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e6 cfu/ dose (Active)
224051954|NCT05486026|DRUG|Duloxetine 30 MG|patient in first group (case) will receive duloxetine tablet 30mg for two weeks then titrated up to duloxetine 30mg BID. Patients will be instructed to take the medication with meals. The for 13 weeks
224051955|NCT05486026|DRUG|Nonsteroidal Antiinflammatory Drug|patient in this second group will receive NSAID for 3 weeks
224051956|NCT05888324|OTHER|Questionnaires|Questionnaires by phone at 1 and 6 months after inclusion
224051957|NCT04689659|BIOLOGICAL|chimeric antigen receptor T cell treatment|CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
224051958|NCT03648359|PROCEDURE|multiparametric MRI Diagnostics|Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
224051959|NCT06406855|OTHER|BCI-TSCS|BCI-TSCS therapy, completed 3-4 times per week, that will include activity-based training, with TSCS activated by BCI system detecting movement attempt.
224051960|NCT00144612|DRUG|MRA(Tocilizumab)|8mg/kg/2weeks
224051961|NCT04434196|DRUG|CC-99282|CC-99282
224051962|NCT04434196|DRUG|Obinutuzumab|Obinutuzumab
223440520|NCT03466749|DEVICE|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
224051963|NCT01017588|DEVICE|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
223440521|NCT05641662|OTHER|Heart Farming|Heart Farming is a mobile game. which can be played indoors and outdoors and stimulates players to be physically active. The game is built around a theme (farming) and users are challenged to collect products by being active. The phone will register movements and convert them into points and fruits and vegetables. For the basic playing only 10 minutes walking a day with the game is possible and is rewarded. For players who want more challenge and level of trading products and collecting products in groups is added. The game is adaptable to different levels of mobility and players can invite others to play with them. Players can see their own game results, progression, and active time.
223566730|NCT07017647|OTHER|Conservative treatment|Conventional physiotherapy treatments will be administered to patients in both groups three days a week for six weeks. This programme will include the following treatments: electrotherapy modalities for pain relief (TENS current application), moist heat application, flexibility and strengthening exercises to stretch and strengthen the back and spinal muscles, and massage and manual therapy applications to relax the back muscles and reduce pain. First, TENS current will be applied for 15 minutes using an electrical stimulation device due to its pain-relieving properties. Then, moist heat application will be performed for 15 minutes. Following this, flexibility and strengthening exercises aimed at stretching and strengthening the lower back and back muscles will be performed under the supervision of a physical therapist for approximately 20 minutes.
223566731|NCT07017647|OTHER|Patient Education|Patient education will be provided immediately after conventional physiotherapy applications in each session. Patients will be asked to pay attention to and comply with the recommendations/issues covered in this education. Comprehensive patient education includes the following: the cause of chronic back pain, negative factors that may cause discomfort and exacerbate symptoms, how to cope with back pain, ways to prevent pain, exercises and proper postures to reduce pain, and harmful movements and positions to avoid in daily life.
223566732|NCT04428190|DIETARY_SUPPLEMENT|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
223566733|NCT04428190|OTHER|Placebo|Sachet manufactured to mimic 10g of HMO
223566734|NCT06352892|DRUG|Maridebart Cafraglutide|Solution for SC injection.
223566735|NCT07021157|DRUG|SK-08|Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given SK-08 once.
224051964|NCT05891795|DRUG|Clascoterone 1% Top Cream|Apply a thin layer to the affected area twice daily.
224051965|NCT05891795|DRUG|Vehicle|Apply a thin layer to the affected area twice daily.
224051966|NCT03021148|OTHER|Questionnaire|Administration of questionnaire.
224051967|NCT02015325|BEHAVIORAL|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health \& Hygiene education program.
224051968|NCT03019250|DIETARY_SUPPLEMENT|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
224051969|NCT03019250|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
223440522|NCT02942043|DRUG|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
223440523|NCT04736732|OTHER|Medical follow-up|Patients will be followed for medical evaluation and for biobanking of data and biological samples.
223440524|NCT05913596|DRUG|Daratumumab|After successful enrollment, the patient will receive daratumumab of 16mg/kg once every two weeks (0-22 weeks) for a total of 12 times. Peripheral blood samples were collected from 0 to 24 weeks (weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24) for routine blood tests, liver and kidney function electrolytes, tacrolimus or cyclosporine trough concentrations, HLA antibody quantification (weeks 0, 4, 8, 12, 16, 20, and 24), infection indicators (weeks 0, 8, and 24), immune status assessments (weeks 0, 4, 8, 12, 16, 20, and 24), and biopsy of transplanted kidneys was performed at 24 weeks to assess pathological changes.
223440525|NCT06266520|PROCEDURE|MNK therapy to release the superficial fascia|The patient, positioned supine and wearing shorts for full lower limb exposure, undergoes layered palpation by the practitioner at the procedure points, identifying tender nodules and swelling in superficial fascia and muscles, followed by disinfection with an iodophor cotton swab. The practitioner, donning sterile latex gloves, holds the micro-needle-knife between the thumb and index finger of the right hand, inserting it parallel to the body's longitudinal axis, while the left thumb presses and holds the cord-like nodules for parallel incisions, with a maximum insertion depth of 5mm, performing lifting and cutting motions. Depending on the nodule size, 1-3 incisions are made. Post-procedure, any bruising or tissue fluid is expelled by massaging from distal to proximal around the incision. The area is then compressed with dry sterile gauze until bleeding ceases. Treatments are administered every other day, totaling six sessions.
223440526|NCT06266520|PROCEDURE|acupuncture|Acupuncture treatment employing needles produced by Suzhou Medical Supplies Factory Co., Ltd., with specifications of 0.30mm\*40mm and conforming to standard GB2024-1994. Patients, positioned prone or laterally with exposed lower limbs below the knee, are disinfected with an iodophor cotton swab. Acupuncture points selected include GB34, GB39, BL60, BL40, ST41, KI9, and KI6. The practitioner applies pressure to the points with the left hand and swiftly inserts the needle with the right, using a 0.30mm\*40mm disposable sterile acupuncture needle, penetrating the skin about 0.5-0.8 inches. After achieving deqi, the needle is twisted and thrust several times, left in place for 30 minutes. Upon removal, the needle site is compressed with a dry cotton swab until bleeding stops. Treatments occur every other day, totaling six sessions
223440527|NCT06977230|PROCEDURE|Remote Ischemic Preconditioning|Remote ischemic preconditioning (RIPC) will be performed after anesthesia induction and before surgical incision. A standard blood pressure cuff will be placed on the upper limb (without arterial cannulation), inflated to 200 mmHg for 5 minutes, and then deflated for 5 minutes. This cycle will be repeated five times prior to sternotomy. The procedure will be carried out under general anesthesia, ensuring patient blinding. No pharmacological agents are involved in this intervention
223440528|NCT03905746|OTHER|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
223440529|NCT03905746|OTHER|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
223440530|NCT03905746|OTHER|stool sample at Day 0|stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
223440531|NCT03123029|DRUG|Venetoclax|Venetoclax will be administered orally.
223440532|NCT04764786|OTHER|EVOO+POLY|a test meal seasoned with extra virgin olive oil rich in polyphenols
223440533|NCT04764786|OTHER|OO-POLY|a test meal seasoned with olive oil poor in polyphenols
223566736|NCT07021157|DRUG|Placebo|Dose groups of 5 mg, 7.5mg,12.5 mg, 30 mg, 45 mg, and 60 mg were given placebo once.
223566737|NCT07024901|BEHAVIORAL|Dance-walk|Dance-Walk is a 4-week somatic intervention combining movement, dance, and walking elements designed to enhance body awareness and emotional regulation. The program consists of 4 weekly group sessions, each lasting approximately 90-120 minutes. Sessions focus on helping participants connect with their body sensations through guided movement exercises that integrate dance movements with mindful walking practices. The intervention targets autonomic nervous system regulation and aims to improve interoceptive awareness, emotional expression, and stress management through embodied practices. Sessions are facilitated by trained practitioners and emphasize non-verbal emotional expression and somatic experiencing to promote mental health and vitality.
224051970|NCT05629234|DRUG|Osimertinib|Osimertinib (dose range of 40 mg to 240 mg orally, once daily)
224051971|NCT04301232|OTHER|Modified Aldrete Scoring System (mASS)|Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg \> preanesthetic level, 20 - 50 mm Hg \> preanesthetic level, 50 mm Hg \> preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 \> 92% on room air, Supplemental O2 required to maintain SpO2 \> 90%,SpO2 \< 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
224144644|NCT02815293|DRUG|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
224144645|NCT00628953|DRUG|Esomeprazole|40mg twice a day
224144646|NCT00628953|DRUG|Placebo|40mg twice a day
224144647|NCT01129180|DRUG|azacitidine|Given SC
224144648|NCT01129180|DRUG|bortezomib|Given IV
224144649|NCT01129180|PROCEDURE|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
224144650|NCT00118729|DRUG|GW685698X Aqueous Nasal Spray|
224144651|NCT00006604|DRUG|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
224051972|NCT04301232|OTHER|White's Fast-Track Scoring System (WFTSS)|Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)\<15%, Blood pressure 15-30%, Blood pressure\>30%, Level of consciousness,(Awake\&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value\>90% on room air, Requires supplemental oxygen, Saturation\<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea\&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score\<1 in any individual category)would be required for a patient after general anesthesia
224051973|NCT04301232|OTHER|SPEEDS criteria|"Extremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP \> 90 and \< 180, HR \> 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation \>90% in room air Y/N, Pain Control (VAS \< 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery"
224144652|NCT00006604|DRUG|Ritonavir|Administered as 100 mg capsules or oral solution.
224144653|NCT03414762|DEVICE|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
224144654|NCT03414762|DEVICE|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
224144655|NCT02752568|PROCEDURE|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
223740979|NCT07180875|BEHAVIORAL|hypoventilation group|"Traditional Aerobic Training Participants will perform supervised aerobic exercise (e.g., cycling or treadmill walking) under controlled intermittent hypoxic conditions.~Hypoxia protocol: alternating cycles of low-oxygen exposure (FiO₂ 12-16%) for 3-5 minutes followed by normoxic recovery for 2-3 minutes, repeated 6-8 times per session.~Frequency: 3 sessions per week for 12 weeks.~Exercise intensity: Moderate (50-70% of heart rate reserve), adjusted individually based on baseline exercise testing"
224144656|NCT02752568|PROCEDURE|assisted hatching|using Octax laser 20120644-laser 5452
224144657|NCT02752568|PROCEDURE|controlled ovarian hyperstimulation|using merional\&/ or fostimon doses individualized as judged by patient age \& ovarian reserve \& monitored by follicular size \& serum estradiol
224300489|NCT00530686|DRUG|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
224300490|NCT00653484|BEHAVIORAL|Physical Activity|
223440534|NCT05284734|PROCEDURE|Regional anesthesia intervention|Ultrasound-guided caudal and erector spinae blocks were administered
223440535|NCT04748172|BIOLOGICAL|SARS-CoV-2 virus vaccines|mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
223440536|NCT04748172|DIAGNOSTIC_TEST|AMH sampling|Blood sample for AMH on recruitment and after three months
223440537|NCT04748172|DIAGNOSTIC_TEST|anti Covid-19 antibody levels (Serology)|Blood sample for IgG against S1 protein after three months
223440538|NCT01889355|DEVICE|AgaMatrix Blood Glucose Monitor|
223440539|NCT06671587|DRUG|iGlarLixi (insulin glargine/lixisenatide)|"iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~\- iGlarLixi must not be mixed with other insulins nor diluted."
223440540|NCT06671587|DRUG|Gla-100 (insulin glargine)|Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
223440541|NCT02959515|PROCEDURE|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
224144658|NCT03180489|DRUG|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
223440542|NCT02959515|PROCEDURE|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
223440543|NCT06603220|DRUG|Oral EVO756|Oral EVO756, once daily
223440544|NCT06353646|BIOLOGICAL|XH001|XH001 will be administered 12 weeks post-tumor resection (+/- 2 weeks)
224300491|NCT00653484|BEHAVIORAL|Energy Restriction|
224300492|NCT00653484|BEHAVIORAL|Physical Activity and Energy Restriction|
224300493|NCT04800341|OTHER|Questionnaire|Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
224051974|NCT04095780|OTHER|Advanced oral hygiene care programme|"1. Brush teeth with standardized power tooth brush twice a day.~2. Rinse mouth with chlorhexidine twice a day.~3. Oral hygiene education"
223440545|NCT06353646|DRUG|Ipilimumab Injection|Ipilimumab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
223440546|NCT06353646|DRUG|Sintilimab injection|Sintilimab will be administered 12 weeks post-tumor resection (+/- 2 weeks)
223440547|NCT06353646|DRUG|Chemotherapy|gemcitabine + capecitabine
224051975|NCT04095780|OTHER|Oral hygiene instruction|Oral hygiene education
224051976|NCT05525689|BEHAVIORAL|IntelliCare|Application with patient-facing tools for depression symptom monitoring, self-management, and care manager communication as well as care manager dashboards for workflow optimization
224051977|NCT05525689|OTHER|COMPASS-Care|Website with content specific to perinatal depression and standard EHR-based tools for patient communication
224051978|NCT05394220|DIAGNOSTIC_TEST|16S rRNA gene amplicon sequencing|molecular sequencing for the microbiome in parapneumonic effusion
224051979|NCT00779922|DRUG|lenalidomide|
224051980|NCT01039077|PROCEDURE|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
224051981|NCT05374382|BEHAVIORAL|Strengthening|3x/w, 9 wks supervised strengthening program, during prehabilitation to ACL surgery
224051982|NCT05374382|BEHAVIORAL|Conventional|Participants received a 9-weeks conventional prehabilitation program (targeting pain knee mobility) before ACL reconstruction, followed by a standardized post-operative rehabilitation program
224051983|NCT03165435|BIOLOGICAL|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
224051984|NCT03165435|BIOLOGICAL|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
224051985|NCT00122811|DRUG|Indapamide SR 1.5mg; Perindopril 2-4mg|
224051986|NCT05534906|OTHER|Blood & Urine Samples|Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time
224144659|NCT03180489|DRUG|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
224144660|NCT01881841|BEHAVIORAL|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
224144661|NCT01056341|DRUG|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
224144662|NCT01056341|DRUG|Placebo|Treatment with placebo for 6 months
224144663|NCT01476384|DIETARY_SUPPLEMENT|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
224144664|NCT01476384|DIETARY_SUPPLEMENT|Placebo|250 ml water
224144665|NCT00987012|DIETARY_SUPPLEMENT|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
224144666|NCT00987012|DIETARY_SUPPLEMENT|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
224144667|NCT03766802|BEHAVIORAL|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
224144668|NCT03766802|BEHAVIORAL|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
224144669|NCT03766802|BEHAVIORAL|Supervised exercise training group|3/week training supervised by a physical therapist
223440548|NCT05958069|DRUG|minocycline|Treatment with minocycline combined with antiepileptic drugs: After enrollment, 100mg/day (50mg specification) of minocycline hydrochloride was administered for 12 consecutive weeks;
223440549|NCT06991686|DIAGNOSTIC_TEST|Blood samples|blood sample for CBC and procalcitonin
223440550|NCT06991686|DIAGNOSTIC_TEST|blood sample|blood sample for procalcitonin and CBC
223440551|NCT06011460|DRUG|Clozapine|"Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old."
223440552|NCT06173739|PROCEDURE|Non-surgical mechanical treatment|"Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered."
223740980|NCT07175623|DRUG|Methyl Prednisolone (MP)|"Dose: 1 mg/kg IV~Timing: at the induction of anesthesia"
223740981|NCT07175623|DRUG|Dexamethasone (0.2 mg/kg)|"Dose: 0.2 mg/kg IV (glucocorticoid equivalent to 1 mg/kg methylprednisolone)~Timing: at the induction of anesthesia"
224051987|NCT05534906|OTHER|Imaging|MRI \& MRE Scans
224051988|NCT05098392|BEHAVIORAL|Sibling-mediated intervention|Typically developing siblings will be trained to use an explicit instruction strategy (model-lead-test) and a checklist to self-monitor their teaching when working with their siblings with ASD on reading and social skills.
224051989|NCT05696275|BEHAVIORAL|exercise|20-30 minutes of walking and elastic band exercise per day
224051990|NCT03042104|DEVICE|Edwards SAPIEN 3 / SAPIEN 3 Ultra THV|Patients will receive the SAPIEN 3 / SAPIEN 3 Ultra THV.
224051991|NCT02056197|OTHER|Placebo|Shortwave
224051992|NCT02056197|OTHER|Stable surface exercises|Stable surface exercises
224051993|NCT02056197|OTHER|Unstable surface exercises|
224144670|NCT00661349|DRUG|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
224144671|NCT00661349|DRUG|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
223440553|NCT04610502|BIOLOGICAL|Administration of Equine immunoglobulin anti SARS-CoV-2|The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.
224051994|NCT05554796|PROCEDURE|Endoscopic classic stapedotomy|Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.
223440554|NCT03176667|PROCEDURE|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
223740982|NCT07175623|DRUG|Saline (0.9% NaCl)|"Dose: 5 ml IV~Timing: at the induction of anesthesia"
223740983|NCT07177326|DRUG|Tadalafil 2.5 mg|patients recived Tadalafil 2.5 mg daily
223740984|NCT07177326|DRUG|Sildenafil 25 mg|patients recived Sildenafil 25 mg daily
223740985|NCT07177326|DRUG|Tadalafil 5 mg|patients recived Tadalafil 5 mg daily
223740986|NCT07184541|BEHAVIORAL|Wake and Weigh|The Wake and Weigh tool includes the patient's dry weight and instructions for daily weight monitoring. Participants in the intervention group will be instructed on the use of the tool. While in the hospital, weight is being managed by the healthcare team, so the goal during hospitalization is to educate the patient on what to do once discharged, and to recognize changes in weight.
224051995|NCT05554796|PROCEDURE|Endoscopic reversal stapedotomy|Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
224051996|NCT01671111|DRUG|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
224051997|NCT05774925|DIAGNOSTIC_TEST|saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224051998|NCT06079983|DRUG|JSKN003|Administered intravenously according to protocol.
224051999|NCT06079983|DRUG|Capecitabine tablets|Administered according to protocol, as one option for investigator's choice (determined before randomization).
224144672|NCT05819736|OTHER|Monitoring|Monitoring
224144673|NCT04790552|OTHER|Dinner|Study subjects will consume a standardized ready-to-eat meal as dinner.
223740987|NCT07184541|BEHAVIORAL|Usual care|The usual care group will receive the heart failure handbook that is routinely given to heart failure patients.
223740988|NCT07181473|DRUG|TJ101|TJ101 is a EGFR/B7H3 directed antibody conjugate with a cleavable linker and a noval topoisomerase I inhibitor.
223740989|NCT07182565|RADIATION|hypofractionated radiotherapy|In Phase Ib, hypofractionated radiotherapy (HFRT) will be administered at one of three dose levels: 3 Gy × 5 fractions, 4 Gy × 5 fractions, or 5 Gy × 5 fractions. The recommended dose determined in Phase Ib will be used in Phase II (delivered as 5 fractions).
224052000|NCT06079983|DRUG|Gemcitabine hydrochloride for injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
224052001|NCT06079983|DRUG|Vinorelbine tartrate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
224052002|NCT06079983|DRUG|Paclitaxel for injection (albumin-bound type)|Administered according to protocol, as one option for investigator's choice (determined before randomization).
224052003|NCT06079983|DRUG|Docetaxel injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
224052004|NCT06079983|DRUG|Eribulin mesylate injection|Administered according to protocol, as one option for investigator's choice (determined before randomization).
224052005|NCT06397417|OTHER|Data collection|The data from hospital treatment will be used for research as well as subsequently, that is to say after discharge from the intensive care units, medical reports and correspondence with the attending physician will be used for the study.
224052006|NCT00006090|DRUG|arsenic trioxide|
224052007|NCT00520728|BEHAVIORAL|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
224052008|NCT02295345|OTHER|Cognitive Behavioural Therapy for Insomnia|
224052009|NCT00894062|DEVICE|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
224052010|NCT00894062|DEVICE|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
224052011|NCT04269148|OTHER|Measurement of Quality of Life|Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
224144674|NCT04790552|OTHER|Fasting|Subjects will be asked to fast overnight for approximately 15 hours.
224144675|NCT04790552|OTHER|Fast Bar|Subjects will be asked to consume a Fast Bar.
224144676|NCT04790552|OTHER|Bar with Coffee|Subjects will be asked to consume a Fast Bar with coffee.
224144677|NCT04790552|OTHER|Bar with Tea|Subjects will be asked to consume a Fast Bar with tea.
224144678|NCT02247284|DEVICE|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
224052012|NCT05354583|DRUG|Appropriate treatment|Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
224052013|NCT00596947|DRUG|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
224052014|NCT00596947|DRUG|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
224052015|NCT00596947|DRUG|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
224052016|NCT00596947|DRUG|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
223440555|NCT03176667|PROCEDURE|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
223440556|NCT06624436|DRUG|Dexamethasone|Dexamethasone 6mg in 10mL NaCl 0.9% i.v. bolus + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
223740990|NCT07182565|DRUG|PD-1 inhibitor|Serplulimab will be administered concurrently with chemotherapy at a fixed dose of 300 mg via intravenous infusion on Day 1 of each 3-week cycle.
223740991|NCT07182565|DRUG|TS-1|The TS regimen includes paclitaxel at a dose of 175 mg/m² administered via intravenous infusion on Day 1, and oral administration of tegafur-gimeracil-oteracil (S-1) for 14 consecutive days followed by a 7-day rest period (21-day cycle). The S-1 dose is based on body surface area (BSA): 40 mg twice daily (bid) for BSA ≤ 1.5 m²; 50 mg bid for BSA 1.5-1.6 m²; and 60 mg bid for BSA ≥ 1.6 m².
224052017|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
224052018|NCT00596947|DRUG|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
224144679|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application with DEP algorithm|4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
224144680|NCT04602676|DIAGNOSTIC_TEST|Rehydration calculator application|4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
224144681|NCT04060576|PROCEDURE|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
224052019|NCT00496730|DRUG|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
224052020|NCT00496730|DRUG|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
224144682|NCT04060576|PROCEDURE|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
224144683|NCT04060576|PROCEDURE|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
224144684|NCT01167582|BIOLOGICAL|Red blood cell transfusion|Liberal versus restrictive transfusion
223740992|NCT07191158|DEVICE|Group 1 conventional|Conventional miniscrew-supported distal jet appliance
223740993|NCT07191158|DEVICE|Group 2 3D printed|New 3D printed miniscrew-supported molar distalizers
224144685|NCT02723292|BEHAVIORAL|TOP|
224144686|NCT02723292|BEHAVIORAL|Control intervention|
224144687|NCT02033772|PROCEDURE|Thoracoscopic surgery|
224144688|NCT03074994|DRUG|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
224144689|NCT03074994|DRUG|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
224144690|NCT03074994|PROCEDURE|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
224144691|NCT03074994|PROCEDURE|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
224052021|NCT02162524|BEHAVIORAL|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
223440557|NCT06624436|DRUG|Tocilizumab|Tocilizumab 600mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
223440558|NCT06624436|DRUG|Anakinra|Anakinra 200mg in 100mL NaCl 0.9% i.v. in 1 hour + a bolus of 10mL NaCl 0.9% placebo infusion on the first LPS challenge.
223440559|NCT06624436|DRUG|Placebo|Bolus of 10mL NaCl 0.9% placebo + 100mL NaCl 0.9% placebo infusion in 1 hour on the first LPS challenge.
223440560|NCT06624436|BIOLOGICAL|LPS|This is a non-investigational product. It is used as challenge agent to achieve a controlled inflammatory state.
223440561|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
224052022|NCT03920189|DIAGNOSTIC_TEST|echocariographic ultrasound|left ventricular diastolic function description
224052023|NCT00578110|DEVICE|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
223440562|NCT05215912|DRUG|TNB-738|TNB-738 is an investigation drug. Other: Matching placebo
223440563|NCT06207240|DEVICE|NeuroLife FES Sleeve / NeuroLife EMG-FES Sleeve|Electrical stimulation will be delivered via the NeuroLife FES Sleeve and NeuroLife EMG-FES Sleeve devices to assist with movement during functional task practice.
223440564|NCT04984759|DRUG|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).
224052024|NCT00113074|DRUG|Nicotine Replacement Therapy|Nicotine replacement therapy program
223440565|NCT04984759|DRUG|Tafenoquine|Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.
223440566|NCT02580474|DRUG|Daclatasvir plus Asunaprevir|
223440567|NCT06006273|DRUG|Eribulin|Given by vein (IV)
223440568|NCT06006273|DRUG|Irinotecan|Given by vein (IV)
223440569|NCT06006273|DRUG|Temozolomide|Given by PO
223740994|NCT07190599|BEHAVIORAL|Proprioceptive neuromuscular facilitation (PNF) with neuromuscular electrical stimulation (NMES)|The NMES was applied during the plantarflexor contraction phase of the PNF stretching (described as below). Two electrodes (4 × 8 cm) were used for stimulation, placed on the triceps surae of the affected side: one positioned 5 cm below the popliteal fossa, and the other placed 5 cm below the first electrode, directly over the triceps surae. The hold-relax technique of proprioceptive neuromuscular facilitation (PNF) will be applied to stretch the triceps surae muscle. It will be performed ten times on the affected limb during each treatment session, lasting approximately 10 minutes in total. Participants will receive interventions three times per week for four weeks, for a total of twelve sessions.
224052025|NCT00113074|BEHAVIORAL|Diet|Diet program
224052026|NCT03680911|DRUG|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
223440570|NCT04402281|DIAGNOSTIC_TEST|suPAR algoritm|All medical patients attending to the ED and who will have blood drawn for routine examination will be part of the study. In patients with low suPAR (green group, suPAR below 3 ng/ml) and in patients with high suPAR (red group, suPAR \> 6 ng/mL) the Intervention will be carried out
223440571|NCT07027189|DIAGNOSTIC_TEST|Artificial intelligence in diagnosis|AI-based diagnostic programs have proved to enhance diagnostic performance, however research on its effects on treatment decisions is scarce. In contrast to other studies focusing on AI's accuracy or the resulting increase in dentists' accuracy, this study aims to investigate the differences in dentists' treatment recommendations when supported by AI versus when they are not during caries detection.
223440572|NCT04441476|OTHER|Questionnaires|"An online questionnaire (Limesurvey platform) will be made available at 4 different times (M0, M1, M2 and M6).~* The first questionnaires (M0 and M1) will include a component for professional characterization. Generic and specific stress factors related to ICU and the current pandemic and collective and individual defensive strategies will also be collected in M0 and M1.~* At M2 and M6, the traumatic impact of the crisis, burnout, signs of depression and recourse to internal or external support in the department (occupational medicine, support unit) will be collected."
223440573|NCT04441476|OTHER|psychological and sociological interviews|"conducting semi-directive psychological interviews (40 interviews in M2, 40 interviews in M6).~sociological interviews: 40 (20 in M1-M2 then 20 in M6) in order to understand the consequences of the epidemic on daily life, both intra-family and micro-social."
223440574|NCT04907227|BIOLOGICAL|Pembrolizumab|IV infusion
223740995|NCT07190599|BEHAVIORAL|Proprioceptive neuromuscular facilitation (PNF) only|The hold-relax technique will be applied to stretch the triceps surae muscle. It will be performed ten times on the affected limb during each treatment session, lasting approximately 10 minutes in total. Participants will receive interventions three times per week for four weeks, for a total of twelve sessions.
223740996|NCT07189403|DRUG|DS9051b|Administered orally
224052027|NCT03680911|DRUG|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
224052028|NCT03799445|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224052029|NCT03799445|BIOLOGICAL|Ipilimumab|Given IV
224052030|NCT03799445|BIOLOGICAL|Nivolumab|Given IV
224052031|NCT03799445|OTHER|Quality-of-Life Assessment|Ancillary studies
224052032|NCT03799445|OTHER|Questionnaire Administration|Ancillary studies
224052033|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
224052034|NCT02114268|DRUG|Placebo|Participants received placebo on Day 1.
224052035|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
223440575|NCT04907227|DRUG|Docetaxel|IV infusion
223440576|NCT04907227|DRUG|Prednisone|Oral tablets
223440577|NCT04907227|DRUG|Placebo|IV infusion
223440578|NCT04907227|DRUG|Dexamethasone|Oral tablets
223440579|NCT00410462|DRUG|brostallicin|
223440580|NCT00410462|DRUG|doxorubicin hydrochloride|
223440581|NCT05073354|DEVICE|Full SWOT Model|Bundle of care that includes devices such as X Series monitor/defibrillator, AutoPusle automated compression device, Z Vent ventilator, and IPR therapies as well as bedside monitoring and diagnostics and training on a standardized care process.
223440582|NCT06655701|DIAGNOSTIC_TEST|No intervention|No intervention
223440583|NCT02773745|BEHAVIORAL|Aquatic Prehab|Pool therapy
223440584|NCT02208050|DRUG|Fampridine|
223440585|NCT02208050|DRUG|Placebo|
224052036|NCT02114268|DRUG|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
223440586|NCT00824434|DEVICE|PROMUS Element™|Drug eluting coronary stent system
223440587|NCT04496505|DEVICE|Device|is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .
223440588|NCT04496505|DEVICE|Sham Device|The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
223440589|NCT02829827|DRUG|Radiprodil|Radiprodil at individualized doses.
223440590|NCT00432276|DRUG|Alogliptin|Alogliptin tablets.
223440591|NCT00432276|DRUG|Pioglitazone|Pioglitazone tablets.
223440592|NCT00432276|DRUG|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
223440593|NCT00432276|DRUG|Placebo|Matching placebo tablets.
223440594|NCT02985073|DEVICE|Veritas®|Biologic mesh
224052037|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
224052038|NCT02114268|DRUG|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
223440595|NCT02985073|DEVICE|TIGR®|Non biologic mesh
223440596|NCT04299139|OTHER|chiropractic treatment|There is no intervention. Data that has been collected during the time a patient was attending a chiropractor. This data will be evaluated
223440597|NCT02330757|DRUG|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
223440598|NCT02330757|DRUG|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
223440599|NCT00086112|DRUG|risperidone oral tablets|
223440600|NCT03948035|DRUG|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
223440601|NCT03948035|DRUG|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
223440602|NCT03948035|DRUG|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
224052039|NCT02741804|DIETARY_SUPPLEMENT|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
224052040|NCT02741804|OTHER|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
224052041|NCT02741804|DIETARY_SUPPLEMENT|Brain Health Placebo|Treatment with placebo consisting of soybean oil
224052042|NCT04981314|DRUG|Equinacea Arkopharma|Echinacea hard caplets
224052043|NCT04981314|OTHER|Placebo|Placebo hard caplets
223440603|NCT03948035|DRUG|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
223440604|NCT03948035|OTHER|autologous stem cell transplant|autologous stem cell transplant
224052044|NCT00889226|DRUG|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
224052045|NCT00889226|DRUG|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
224052046|NCT03988231|DRUG|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
224052047|NCT03988231|DRUG|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
224052048|NCT04154410|OTHER|Analgesia Nociception Index|Non invasive finger tip monitoring before during and 5 minutes after cannulation
224052049|NCT04154410|OTHER|algiscan|Portable videopupillometer to measure pupillary light reflex (PLR), variation coefficient of pupillary diameter (VCPD), pupillary diameter (PD) fluctuations before, during and 5 minutes after cannulation
223440605|NCT05135884|BEHAVIORAL|Standard inpatient stroke rehabilitation|According to Swiss national guidelines and local protocols
223440606|NCT01454843|PROCEDURE|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
223440607|NCT01454843|PROCEDURE|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
223440608|NCT06618443|OTHER|Scapular mobilization with movement|The treatment consisted of scapular mobilization with arm movement in all directions for 15 min/session for 3 sessions/week for 4 weeks. Scapular mobilization included scapular upward glide and downward glid. Scapular upward glide was performed with shoulder adduction and extension, while scapular downward glide was performed with shoulder abduction and flexion.
223440609|NCT01101659|DRUG|JNJ-40411813|500 mg as 20 mL of oral suspension
224052050|NCT04991467|BEHAVIORAL|CARE Program and Valera Application with care manager functionality|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials as well as the ability to connect to their child's treatment team via care manager.
224052051|NCT04991467|BEHAVIORAL|Valera Application with care manager functionality|Participant will receive the Valera health application which will provide parent education materials and the ability to connect to their child's treatment team via care manger.
224052052|NCT04991467|BEHAVIORAL|CARE Program|Participant will take part in 12 week CARE program.
224052053|NCT04991467|BEHAVIORAL|Valera Application|Participant will receive the Valera health application which will provide parent education materials.
224052054|NCT04991467|BEHAVIORAL|CARE Program and Valera Application|Participant will take part in 12 week CARE program and receive the Valera health application which will provide parent education materials.
224052055|NCT01997736|DEVICE|Ablation|
224052056|NCT03434171|BEHAVIORAL|Aerobic excercise|practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
224052057|NCT03434171|DIETARY_SUPPLEMENT|soy products|diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
224052058|NCT03962738|DRUG|Lasmiditan|Administered orally
224052059|NCT03962738|DRUG|Placebo|Administered orally
224052060|NCT06493149|OTHER|Massage therapy|Participants receive a Swedish massage based on the tensegrity principle.
224052061|NCT01862068|OTHER|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
223440610|NCT01101659|DRUG|normal saline|single dose
223440611|NCT01101659|DRUG|ketamine|20 mL of oral suspension
223440612|NCT01101659|DRUG|Placebo|single dose
224052062|NCT01862068|OTHER|Blood sample|Blood sample will be performed at inclusion from all healthy patients
224052063|NCT05627557|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
224052064|NCT05627557|DRUG|MMF|MMF will be administered as per schedule specified in the respective arm.
224052065|NCT05627557|DRUG|Prednisone|Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
224052066|NCT05627557|DRUG|Methylprednisolone|Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
224052067|NCT05627557|DRUG|Acetaminophen/ Paracetamol|Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
224052068|NCT05627557|DRUG|Diphenhydramine Hydrochloride|Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
224052069|NCT03731104|DEVICE|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=\[SpO2-rScO2\]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
224052070|NCT03731104|DEVICE|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
223440613|NCT00467961|COMBINATION_PRODUCT|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
223440614|NCT02250261|BEHAVIORAL|KÄPY|
223440615|NCT00643461|DEVICE|Adhesive A|Applied per manufacturer's instructions.
223440616|NCT00643461|DEVICE|Adhesive B|Applied per manufacturer's instructions.
223440617|NCT00643461|DEVICE|Adhesive C|Applied per manufacturer's instructions.
223440618|NCT05249127|DRUG|64Cu-SAR-bisPSMA|64Cu-SAR-bisPSMA
223566738|NCT05980104|BEHAVIORAL|Empowered Relief|The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
223440619|NCT01619020|DIETARY_SUPPLEMENT|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
223440620|NCT03493750|OTHER|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
223440621|NCT02720900|DIETARY_SUPPLEMENT|B-GOS|1.8 g/day for 6 weeks
223440622|NCT02720900|DIETARY_SUPPLEMENT|Maltodextrin|1.8 g/day for 6 weeks
223440623|NCT01528943|DRUG|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
223440624|NCT01528943|DRUG|Isotonic saline|same volume as the group that are allocated to prostacycline
224144692|NCT01182337|DRUG|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
224144693|NCT01182337|DRUG|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
224052071|NCT03731104|DEVICE|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = \[π x d2 x VTI x HR\] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
224052072|NCT00509067|DRUG|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
224144694|NCT02819895|OTHER|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
224144695|NCT02679443|DIETARY_SUPPLEMENT|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
223440625|NCT00326170|DRUG|5-Azacytidine (5-aza)|Start at 75 mg/m\^2 subcutaneously daily for 7 days.
223440626|NCT00326170|DRUG|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
224144696|NCT03991559|DRUG|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
224144697|NCT03991559|DRUG|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
224144698|NCT03991559|COMBINATION_PRODUCT|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
224144699|NCT01654042|OTHER|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
224052073|NCT00509067|DRUG|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
224144700|NCT03103906|OTHER|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
224144701|NCT03103906|OTHER|Cleanser (Reference Product)|Moisturizing facial cleanser
224144702|NCT03103906|OTHER|Sunscreen (Reference Product)|SPF 50 sunscreen
224144703|NCT05685888|OTHER|Medication history|The study was retrospective and did not involve the application of interventions
223440627|NCT00326170|DRUG|All-Trans Retinoic Acid (ATRA)|45 mg/m\^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
223566739|NCT07026305|PROCEDURE|Pressure-guided laminectomy (PGL)|Osseous resection of the lamina and ligamentum flavum until the epidural pressure reaches a normal value at the stenotic segment.
223566740|NCT07026305|PROCEDURE|Laminectomy without pressure guidance (LWPG)|Complete resection of both the lamina and the ligamentum flavum at the stenotic segment.
223566741|NCT06877104|OTHER|Healing @ Home Program (H@H 2.0)|Healing @ Home 2.0 is a clinically used comprehensive technology-based postpartum support program, which provides 24/7 support to individuals through use of a text message based chatbot for six weeks postpartum. Content of H@H 2.0 includes anticipatory guidance regarding physical recovery, infant care and feeding, clinical algorithms to respond to urgent patient needs.
223566742|NCT07033403|DEVICE|Low Level Laser Therapy|low-level laser therapy (LLLT) at a wavelength of 660nm (SiroLaser Blue, Dentsply Sirona, USA) after extraction
224052074|NCT00509067|DRUG|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
223440628|NCT05210153|DRUG|Sertraline|"Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia."
223440629|NCT03359798|BEHAVIORAL|Narcotic counseling script|Script regarding post-cesarean section narcotic use
223440630|NCT03359798|BEHAVIORAL|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
223440631|NCT00322127|DRUG|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
223440632|NCT02073565|DEVICE|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
223440633|NCT02073565|DEVICE|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
223440634|NCT02250066|OTHER|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
223440635|NCT05400395|DRUG|GNX80|GNX80 oral intake(BID) for 24 weeks
224052075|NCT00509067|DRUG|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
224052076|NCT03463733|DRUG|Hydroxyurea|147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
224052077|NCT03463733|DRUG|Temozolomide|85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
224052078|NCT00574288|DRUG|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
224052079|NCT00574288|DRUG|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
224052080|NCT00574288|OTHER|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
224052081|NCT00574288|OTHER|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
224052082|NCT01479179|DRUG|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
224052083|NCT01479179|DRUG|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
224052084|NCT01135862|DRUG|platelets|6 packs of platelets will be administered
224052085|NCT05731570|BEHAVIORAL|Cognitive rehabilitation|Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.
224144704|NCT03477071|PROCEDURE|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
223440636|NCT05400395|DRUG|Placebo|Placebo oral intake(BID) for 24 weeks
223440637|NCT00698074|DEVICE|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
223440638|NCT05964114|DRUG|Vancomycin|Initial dosing based on (a combinations of) pharmacokinetic models tailored to the individual patient. Dose adjustment starting dose (within registered dosing range).
223440639|NCT06657170|PROCEDURE|Pulmunary veins reconnection plus hidden slow conduction ablation|"Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms)."
223440640|NCT06657170|PROCEDURE|Pulmunary veins (PV) reconnection ablation only|Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
223440641|NCT05493813|BEHAVIORAL|Cognitive function and delirium evaluation|Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
224052086|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
224052087|NCT00807326|DRUG|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
224052088|NCT00807326|DRUG|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
224052089|NCT03202784|DRUG|BCX7353|BCX7353
224052090|NCT01507779|BIOLOGICAL|IVACFLU|IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.
224052091|NCT01507779|OTHER|Placebo|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
224052092|NCT04621396|OTHER|Observational screening study|
224052093|NCT02361944|DRUG|Oxygen - normoxia|Titration of FIO2 to maintain normal hemoglobin oxygen saturation (95-97%)
224052094|NCT02361944|DRUG|Oxygen - hyperoxia|Administration of 1.0 FIO2 during ventilation and 0.8 or above during cardiopulmonary bypass
224052095|NCT01733966|DRUG|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
224052096|NCT01733966|DRUG|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
224052097|NCT05829356|BIOLOGICAL|H3 mRNA / LNP Vaccine|"Pharmaceutical Form: Suspension for injection~Route of Administration: Intra-Muscular"
224052098|NCT05829356|BIOLOGICAL|Quadrivalent recombinant influenza Vaccine (RIV4)|"Pharmaceutical Form: Solution for injection in a pre-filled syringe~Route of Administration: Intra-Muscular"
224052099|NCT06115187|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
224144705|NCT03571256|DRUG|TEV-50717|6-, 9-, 12-, 15-, and 18 mg oral tablets
224144706|NCT03571256|DRUG|Placebo|Placebo matched to TEV-50717 tablets will be taken BID.
224144707|NCT06410079|PROCEDURE|total hip replacement|Replacement of the hip joint with a total prosthesis, a femoral stem, an acetabular cup, a joint head, in metal, ceramic, dual mobility or polyethylene
224144708|NCT02899117|OTHER|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
224144709|NCT00575094|DRUG|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
223440642|NCT05493813|BEHAVIORAL|Neurological functional assessment|National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
223440643|NCT00898599|DIETARY_SUPPLEMENT|Prebiotic|Inulin type fructooligosaccharides
224052100|NCT06115187|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
223440644|NCT00898599|DIETARY_SUPPLEMENT|Placebo|Maltodextrin as placebo
223440645|NCT05455359|DRUG|Prucalopride|Prucalopride 0.04 mg/kg/day
224052101|NCT02132884|OTHER|cytology specimen collection procedure|Undergo collection of tissue and blood samples
224052102|NCT02132884|PROCEDURE|therapeutic procedure|Receive standard of care treatment
224052103|NCT02132884|DRUG|targeted therapy|Receive specific targeted therapy
224052104|NCT02132884|OTHER|laboratory biomarker analysis|Correlative studies
224052105|NCT00255762|DRUG|carboplatin|Given IV
223440646|NCT05455359|DRUG|Famotidine|Famotidine 0.4 mg/kg/day
224052106|NCT00255762|DRUG|paclitaxel|Given IV
224052107|NCT00255762|BIOLOGICAL|bevacizumab|Given IV
224052108|NCT00255762|OTHER|laboratory biomarker analysis|Correlative studies
224052109|NCT04810182|DRUG|Regorafenib 40 MG Oral Tablet [STIVARGA]|As per the treating physicians discretion
224052110|NCT04237727|DEVICE|Fluxmed GrH will be used to measure the ventilation parameters|The study will be a prospective descriptive multicenter study where measurement of ventilation data will be sampled during CPR by EMS treating patients with OHCA.
224052111|NCT04053647|OTHER|Non-interventional study|Non-interventional study
224052112|NCT05597475|DIAGNOSTIC_TEST|GLP-1R PET|Beta cell function (tests) and measure for beta cell mass (PET)
224052113|NCT03654976|BIOLOGICAL|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
224052114|NCT03654976|OTHER|Placebo|Placebo sublingual tablet, for daily administration (1 tablet per day)
224052115|NCT05404399|BEHAVIORAL|"Free From Pain Exercise Book"|"Participants in Group 1 will be provided with the Free From Pain Exercise Book."
224052116|NCT05404399|BEHAVIORAL|Physiotherapy|Participants in Group 2 would be referred to Physiotherapy (usual care)
224052117|NCT00771134|DRUG|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
224144710|NCT01788982|DRUG|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
224144711|NCT01788982|DRUG|Placebo|
224144712|NCT02290964|PROCEDURE|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
224144713|NCT00868452|DRUG|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
224144714|NCT00868452|DRUG|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
223440647|NCT02132975|DEVICE|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
223440648|NCT02132975|PROCEDURE|Biopsies using UroStation® (image fusion)|
223440649|NCT06617988|OTHER|Not applicable- observational study|Not applicable- observational study
223440650|NCT02494375|OTHER|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
223440651|NCT05992961|DIAGNOSTIC_TEST|Troponin I|"Troponin I were measured 6-12 hours postoperatively and on each of the succeeding four postoperative days for patients operated March 1, 2019, to February 28, 2021.~Patients with increased troponin I levels were assessed regarding symptoms of myocardial ischaemia including electrocardiography. Each patient was individually assessed, and relevant treatment and follow-up were planned in collaboration between surgeons, cardiologists, and anaesthesiologists."
223440652|NCT02707588|DRUG|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
223440653|NCT02707588|DRUG|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
224052118|NCT00771134|DRUG|Placebo|B.I.D. for 8 weeks
223440654|NCT02707588|RADIATION|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
223440655|NCT06620328|PROCEDURE|endoscopic ultrasonography-guided biliary drainage|"Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover"
223440656|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
223440657|NCT01502137|DRUG|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
223440658|NCT06293105|OTHER|Qualitative interview, participant observation|Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation
223440659|NCT05766345|BIOLOGICAL|BCG-Vaccine SSI [Statens Serum Institut]) Danish strain 1331|Nothing to add
223440660|NCT05766345|BIOLOGICAL|Placebo|Nothing to add
223440661|NCT02651805|DEVICE|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
223566743|NCT07033403|BEHAVIORAL|Placebo plus Treatment As Usual|placebo (Sham) with only the aiming beam of thelow-level laser therapy (LLLT)
223566744|NCT07033468|DEVICE|VR-WLC|First, conduct the Virtual Reality (VR) training activity. After the evaluation is completed, proceed to the Waitlist Control (WLC) session, approximately 5 to 10 weeks later.
223566745|NCT07033468|DEVICE|CTL-VR|First, conduct the Control (CTL) session for approximately 5 to 10 weeks. After the evaluation is completed, proceed to the Virtual Reality (VR) training activity.
223566746|NCT07033806|OTHER|Exercise Tabata Protocol|more effective
223566747|NCT07034456|DEVICE|Tape with mangetic particles|An elastic adhesive tape containing magnetic particles, designed to be applied directly to the skin. In this study, the tape is applied to the lumbar region. The tape remains in place during standardized sensory and vascular measurements
224052119|NCT00771134|DRUG|Quetiapine|300mg/day for 8 weeks
223566748|NCT07034456|DRUG|Topical Anesthetic Cream|EMLA®, a topical anesthetic cream containing lidocaine and prilocaine, will be applied under occlusion prior to tape application during 30 minutes with the aim of anesthetize the cutaneous sensory receptors
224052120|NCT04451577|OTHER|No intervention|No intervention, analysis of biological samples
224052121|NCT05095870|OTHER|No intervention|Pure observational study
224052122|NCT03648775|DEVICE|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
224052123|NCT04838665|DRUG|0.5% cyclopentolate and 2.5% phenylephrine|Multiple Alternate Instillation of 0.5% cyclopentolate and 2.5% phenylephrine (MAI) dropped every 5 minutes for two doses
224052124|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine|Single instillation of 0.5% tropicamide + 0.5% phenylephrine
224052125|NCT04838665|DRUG|0.5% tropicamide + 0.5% phenylephrine with a cotton wick|Single instillation of 0.5% tropicamide + 0.5% phenylephrine with a cotton wick weighing 0.02 milligrams placed in the inferior fornix for the entire 45 minutes
224052126|NCT03098836|DRUG|ARN-509|240 mg orally daily
224052127|NCT03098836|DRUG|Abiraterone Acetate|1000 mg orally daily
224052128|NCT03098836|DRUG|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
224052129|NCT04510688|DRUG|Cabozantinib|Observation of treatment with Cabozantinib
224052130|NCT03521375|PROCEDURE|Open Surgery|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
224144715|NCT01461408|BEHAVIORAL|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect-their hairdressers-will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
223440662|NCT02651805|OTHER|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
223440663|NCT05640284|DIAGNOSTIC_TEST|Nuclear Factor-Kappa B Ligand (RANKL) analysis|samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
223440664|NCT05640284|DIAGNOSTIC_TEST|Osteoprotegerin (OPG) analysis|samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
223440665|NCT05640284|DIAGNOSTIC_TEST|Tumor Necrosis Factor Alpha (TNF-α) analysis|samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
223440666|NCT05640284|DIAGNOSTIC_TEST|MicroRNA-223 analysis|samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
223440667|NCT05640284|DIAGNOSTIC_TEST|Microrna-27a analysis|samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
223440668|NCT05766904|BIOLOGICAL|4CMenB vaccine|Four-component MenB vaccine
223440669|NCT05766904|OTHER|Placebo|0.9% Sodium Chloride Inj. B.P.
223440670|NCT00411073|DRUG|Darapladib|
223440671|NCT02795520|DRUG|OTS167IV|
223440672|NCT06278727|DRUG|angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor|Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
223440673|NCT06278727|OTHER|The development of the prediction model|The prediction model of FMR regression would be developed to recognize patients whose FMR would regress due to GDMT, and consequently help determine the treatment.
223440674|NCT06903299|DRUG|Intra-articular Tranexamic acid application|Intra-articular Tranexamic acid application during THA and evaluation of postoperative blood losses, hemoglobin decline and associated blood transfusion, heterotopic ossification and other parameters.
223440675|NCT05330273|DRUG|Ganaplacide|Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
223440676|NCT05330273|COMBINATION_PRODUCT|Lumefantrine|Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
223566749|NCT07034456|DEVICE|Control KinesioTape|An elastic adhesive tape, designed to be applied directly to the skin. In this study, the tape is applied to the lumbar region. This tape does not content magnetic particles, thus is used as a comparator. The tape remains in place during standardized sensory and vascular measurements
224144716|NCT03390712|DRUG|Paliperidone Palmitate|Monthly injections
224144717|NCT03390712|DRUG|Risperidal Consta|Bi-weekly injection
223440677|NCT05330273|DRUG|Efavirenz|Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
223440678|NCT02436031|DRUG|Desipramine|200 mg administered 2 hours before normal sleep time
223440679|NCT02436031|DRUG|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
223440680|NCT06455124|RADIATION|Radiation|Shor-course radiotherapy: 25Gy/5Fx
223440681|NCT06455124|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
223440682|NCT06455124|DRUG|Capecitabine|Capecitabine: 1000mg/m2 d1-14 q3w
223440683|NCT06455124|DRUG|Oxaliplatin|Oxaliplatin: 130mg/m2 d1 q3w
223440684|NCT01382316|BEHAVIORAL|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
223440685|NCT01382316|BEHAVIORAL|Usual care|Group format, six weekly education sessions about alcohol and drugs
223440686|NCT03168919|RADIATION|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
223440687|NCT03168919|DRUG|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
223566750|NCT07034456|DEVICE|Moisturizing Cream (control)|A neutral moisturizing cream (control) will be applied under occlusion prior to tape application during 30 minutes. The application will be blind and use as a placebo vs the anesthetic cream.
223566751|NCT07033871|DIAGNOSTIC_TEST|comprehensive geriatric assessment|The comprehensive geriatric assessment (CGA) is a multi dimensional diagnostic process used to determine the medi cal, psychological, and functional capabilities of a frail elderly person to develop a coordinated and integrated plan for treat ment and long-term follow-up.
223566752|NCT07033533|DRUG|Allopurinol Tablet|allopurinol 300
223566753|NCT07033533|DRUG|Placebo|placebo tablet
223440688|NCT03168919|DEVICE|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
223440689|NCT06009016|DIAGNOSTIC_TEST|Inflammatory factors and coagulation factors level in cerebrospinal fluid after subarachnoid hemorrhage|Inflammatory factors and coagulation factors level in cerebrospinal fluid will be tested by ELISA kits.
223440690|NCT02103335|DRUG|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
223440691|NCT02103335|DRUG|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
223440692|NCT02103335|DRUG|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
224144718|NCT03390712|DRUG|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
224144719|NCT05128682|DIAGNOSTIC_TEST|Urodynamic testing with and without pudendal nerve stimulation|A urodynamic test (UDT) for eligible subjects with and without acute PNS will be conducted. Prior to introducing the acute PNS, the subject's original stimulation properties will be turned off. The implanted neurostimulator device will be programmed to deliver acute PNS per individual tolerance level with the objective of increasing external urethral sphincter pressure. The LPP during Valsalva maneuver or forceful coughing will be assessed with and without acute PNS. The LPP will be assessed at increasing bladder volumes until major detrusor instability, significant leakage (more than drops, stream) or subject discomfort (strong desire to void) is observed. Finally, a UPP with PNS set in an on/off cycling regimen will be conducted to observe the effect on pressures along the length of the urethra.
223440693|NCT06090617|PROCEDURE|Skin Biopsy|Skin biopsies were obtained in all recruited patients.
224052131|NCT03521375|PROCEDURE|Video Assisted Thoracoscopic Surgery (VATS)|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
224052132|NCT01053390|DRUG|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
224052133|NCT01053390|DRUG|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
224052134|NCT05834309|OTHER|Physical exercise|The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
224052135|NCT03843281|DRUG|Paracetamol|s. above
224052136|NCT03843281|DRUG|Placebo|s. above
224052137|NCT03843281|DRUG|Morphine|s. above
224144720|NCT00906867|OTHER|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
224144721|NCT00906867|PROCEDURE|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
223440694|NCT06090617|PROCEDURE|Video-laparoscopic adrenalectomy|Video-laparoscopic adrenalectomy in those with unilateral PA. (PA group 1)
223440695|NCT03641534|PROCEDURE|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
223440696|NCT03641534|PROCEDURE|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
223440697|NCT03641534|PROCEDURE|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
223440698|NCT03641534|PROCEDURE|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
223440699|NCT03641534|PROCEDURE|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
223440700|NCT03641534|PROCEDURE|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
223440701|NCT03641534|PROCEDURE|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
223440702|NCT03641534|PROCEDURE|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
223440703|NCT03641534|PROCEDURE|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
223440704|NCT03641534|PROCEDURE|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
223440705|NCT05520021|DRUG|Nifedipine|A total of 30 pregnancies with preterm labor threats will be treated with Nifedipine.
223440706|NCT05520021|DRUG|Magnesium sulfate|A total of 30 pregnancies with preterm labor threats will be treated with Magnesium sulfate.
223566754|NCT07033312|DRUG|oral hyaluronate and injection|The patient receives oral hyaluronate and hyaluronate injection
223566755|NCT07033312|DRUG|hyaluronate injection|The patient receives hyaluronate injection only
223440707|NCT06906315|DRUG|Dexamethasone 4 mg|Participants in this group received a single 4 mg oral dose of dexamethasone 1 hour before undergoing endodontic treatment. No additional preoperative analgesics were administered. Standard endodontic procedures, including local anesthesia, were performed. Post-treatment, no routine analgesic medication was provided unless additional pain relief was required. Pain intensity was assessed at 4, 6, 8, 12, and 24 hours using the Visual Analog Scale (VAS) to evaluate the efficacy of preoperative dexamethasone in controlling postoperative pain and inflammation.
223440708|NCT06906315|DRUG|Ibuprofen group|Participants in this group received no preoperative medication but were prescribed 400 mg of ibuprofen every 4 hours postoperatively for pain management. The same standard endodontic procedures were performed. Pain levels were recorded at 4, 6, 8, 12, and 24 hours using the VAS scale to compare the effectiveness of postoperative ibuprofen with preoperative dexamethasone.
223440709|NCT03589118|OTHER|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
223440710|NCT01072513|OTHER|Semen analysis|Semen analysis before and after proton radiation therapy.
223440711|NCT06619470|OTHER|binaural beats|binaural beats
223440712|NCT01085136|DRUG|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
223440713|NCT01085136|DRUG|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
223440714|NCT04605393|DRUG|Cannabidiol|CBD
224052138|NCT05088408|DIETARY_SUPPLEMENT|Resource® Energy Apricot|"Bowel preparation as usual plus two bottles of Resource® Energy Apricot (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), with ingestion of one bottle of 200 mL of the dietary supplement at 08:00 and the other at 12:00, and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
223440715|NCT04605393|DRUG|Placebo|Placebo
223440716|NCT04605393|DRUG|Delta-9-THC|THC
224052139|NCT05088408|OTHER|Bowel preparation as usual.|"Bowel preparation as usual (one day before the colonoscopy with no ingestion of solid foods, possibly with ingestion of clear liquids with or without sugar (such as tea or other transparent beverages without pulp, but not milk, yogurt, broth or gelatine), and with ingestion of 275,84 g (4 sachets) of polyethylene glycol 3350 (Klean-Prep®) in 4 litres of water in 3 to 4 hours (250 mL every 15 minutes), starting at 18:00; in the day of the exam the patients can drink the same clear liquids with or without sugar until 4 hours before the colonoscopy, which will be carried out in the morning).~Colonoscopy."
224163911|NCT05092763|BEHAVIORAL|FIT4SURGERY|The Fit4Surgery intervention consists of the FitBit Inspire HR device, the Fit4Surgery mobile app, and weekly coaching calls. Patients are asked to wear the Fitbit through the entire 9-12 weeks in which they are receiving neoadjuvant chemotherapy both when asleep and when awake. Patients are taught how to understand the Fitbit outputs on the application, for example, understanding how to monitor their steps and heart rate. Caregivers are also be encouraged to assist patients. Patients are provided with information about the benefits of physical activity and effective behavior change strategies for incorporating physical activity into their daily lives. These include things such as short bouts of activity by walking around the room during commercial breaks or planning to be dropped off a short walk from a destination.
223440717|NCT06505551|BIOLOGICAL|SCG142|Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy
223440718|NCT06505551|DRUG|Cyclophosphamide|for 3 consecutive days
223440719|NCT06505551|DRUG|Fludarabine|for 3 consecutive days
223440720|NCT05581433|OTHER|Topical Cooling Spray|The process of cooling the area to be injected with a cooling spray before the application in order to reduce the pain.
223440721|NCT05581433|OTHER|Saline spray as Placebo|Application of saline spray without cooling effect to the area to be injected for placebo purposes
223440722|NCT01079754|DRUG|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
223440723|NCT01079754|DRUG|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
223440724|NCT04469673|BIOLOGICAL|Biological：JS002|Administered by subcutaneous injection
223440725|NCT04469673|BIOLOGICAL|Placebo|Administered by subcutaneous injection
223440726|NCT00379431|DRUG|Administration of rituximab and methylprednisolone|"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
223440727|NCT00083720|BIOLOGICAL|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
223440728|NCT03650725|OTHER|Mandatory Split bowel preparation|Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
223440729|NCT06223321|DIAGNOSTIC_TEST|Computed Tomography in congenital heart diseases|"● CT examination will be done by~* 160 MDCT Toshiba Machine or 128 MDCT GE machine or 160 MDCT Philips Machine:~* We used the following parameters during cardiac CT scanning:~  * Pitch of 1.3, helical thickness of 0.5 mm and coverage of 32 cm.~ * The radiation dose set to 80-100 kvp.~ * Tube current from 10 to 40 mA/kg.~ * The gantry rotation speed at 0.35-.4 sec.~ * ECG gated Retrospective With MA modulation.~ * Wide FOV.~* A scout will be taken and dual-phase injection conducted using non ionized contrast material. The total contrast volume is 1.5-3 ml/kg.~* Scanning begins when contrast filled the LV by bolus tracking.~* All images were transferred to workstation multiplanar reformation (MPR), maximum (MIP) and minimum (MinIP) intensity projections and volume rendering images will be performed for reporting."
223440730|NCT03838406|GENETIC|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
223440731|NCT03838406|DRUG|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
223440732|NCT05497336|DRUG|IBI351|IBI351 is administered orally
224052140|NCT01965977|DRUG|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
224052141|NCT02803528|DRUG|Biodentine|Biodentine is going to be used as the direct pulp capping material
224052142|NCT02803528|DRUG|MTA|MTA is going to be used as the direct pulp capping material in the second group
224052143|NCT00631501|DRUG|Placebo|
223440733|NCT05497336|DRUG|Cetuximab|Cetuximab is administered intravenously
223440734|NCT00441532|DRUG|Lidocaine|
223440735|NCT02678000|DRUG|LHW090|LHW090 is orally administered
223440736|NCT02678000|DRUG|Placebo|Matching placebo of LHW090
223440737|NCT06245447|OTHER|Retrospective evaluation of specific brain MRI features|"* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"
223440738|NCT06440733|OTHER|Multicomponent exercise program focused in elderly.|"Each of these sessions will be carried out taking into account the main physiotherapy objectives, such as gaining strength in both upper and lower limbs, as well as proprioception, balance, and promoting a pleasant and safe social environment where these older people feel valid.~All sessions will begin with a 5-minutes. It will begin with a general warm-up based on general joint mobility of the head and neck, shoulders, trunk, elbows, hands, wrists, hips, knees and ankles to begin to accustom the body to the physical work environment. And at the end of the sessions, a stretching program will be carried out, and it will end with a return to calm with a respiratory training program, in which you will be instructed to take in air through the nose and release it through the mouth, while the room is silent, and thus promote self-awareness."
224052144|NCT00631501|DRUG|Doxycycline|
224052145|NCT05159154|DEVICE|Myocardial Work|Myocardial work (MW) is emerging as an alternative tool for studying LV myocardial systolic function, because it incorporates both deformation and load into its analysis. In this context, MW could be considered as an advancement of myocardial strain, allowing to investigate LV performance also in cases of changes in afterload that could lead to misleading conclusions if relying only on strain analysis. This parameter will be evaluated by using an echographer equipped with a specific software for the analysis (Ecog Vivid E95 Ultra GE®)
224052146|NCT03156127|DRUG|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
224052147|NCT00433342|DRUG|Flucloxacillin|500 mg QD oral
223440739|NCT01498705|OTHER|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
223440740|NCT04038177|BEHAVIORAL|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
223440741|NCT04038177|BEHAVIORAL|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
223440742|NCT01465633|DRUG|levothyroxine|
223440743|NCT01465633|DRUG|levothyroxine|
223440744|NCT04220333|BEHAVIORAL|Mandalas of Emotions|Application of mandalas during 15 minutes
224052148|NCT05998083|OTHER|exercise|"In addition to the individual support training program, the exercise group was given a balance and coordination exercise protocol including 40 minutes, 2 days a week.~These exercises are:~It consisted of warm-up (10 minutes), purposeful balance and coordination exercises (20 minutes), and cool-down (10 minutes) exercises.~Balance and coordination exercises with purpose were created with a series of exercises based on copying the shape of the blocks on the cards placed at the beginning of a track consisting of stations at the end of the track. The stations were composed of hopscotch station, tandem walking station in one line, bounce station, bucketing ping pong balls station and eight running stations."
223440745|NCT04220333|BEHAVIORAL|Control|"Participants were requested to lie down, relax and pay attention to your breath."
223440746|NCT00857597|PROCEDURE|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
223440747|NCT00857597|DRUG|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
223440748|NCT05037487|DRUG|Placebo Cannabis|Smoked placebo cannabis
223440749|NCT05037487|DRUG|20 mg CBD Cannabis|Smoked cannabis with CBD
223440750|NCT05037487|DRUG|20 mg CBD + 20 mg THC Cannabis|Smoked cannabis with CBD and THC
223440751|NCT05037487|DRUG|20 mg THC Cannabis|Smoked cannabis with THC
223566756|NCT06716619|BIOLOGICAL|Tumor Associated Lymph node T cell|At least one lymph sample is resected from each participant, then it is separated and cultured ex vivo to expand the population of Tumor Associated Lymph node T cells . After lymphodepletion, patients are infused with TAL-T.
224052149|NCT05998083|OTHER|control|The control group continued only the individual support education program.
224052150|NCT02483624|DRUG|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
224052151|NCT02483624|DRUG|Placebo|Placebo
224052152|NCT03216811|DRUG|nutraceutical|8-week administration of nutraceutical compound
224052153|NCT04824781|OTHER|Qualitative interview|Participants will be interviewed about their experiences of recovery from paranoia.
223440752|NCT05530980|BEHAVIORAL|GameDay Ready Program|GameDay Ready is a 12-week, group-based behavioral weight management program in which participants will meet in-person once per week at a publicly accessible walking track. Each weekly session will be led by a trained facilitator and will include a brief educational component, participant updates on progress, group discussions about overcoming barriers, supervised competitive physical activities, and goal setting for the upcoming week. Educational content will be reinforced and social support will be provided during warmup and cool down walks. Participants will be asked to set behavioral goals toward increasing physical activity and improving dietary habits and will be provided resources to self-monitor their activity, dietary intake, and weight.
223440753|NCT04407429|DIAGNOSTIC_TEST|Laboratory Analyses|Storage of serum for SARS-CoV-2-antibodies and biomarkers
223440754|NCT00759057|DEVICE|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
223440755|NCT02764567|OTHER|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
224052154|NCT03724734|DEVICE|Adaptive DBS|We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.
223440756|NCT03248414|DIETARY_SUPPLEMENT|Lactobacillus sakei|1 pack contained 5 x 109 cfu
223440757|NCT04733716|PROCEDURE|Using Tourniquet|The purpose of this prospective randomized double blinded study was to compare the effect of using a tourniquet on early-stage pain and 1-year postoperative functional outcomes when patients were divided into two groups according to the pain threshold.
223440758|NCT06287710|PROCEDURE|Non interventional study (study of diagnostic accuracy with an extra echocardiographic assessment).|"Study of diagnostic accuracy (non-interventional, prospective, monocentric). Fluid expansion will be delayed for a few minutes while our index test is performed. After fluid expansion, patient will undergo an echocardiographic assessment of response to fluid expansion (gold-standard test). This will allow to test the diagnostic performance of the index test for the prediction of fluid responsiveness.~The index test is the ΔSVi-AC: indexed percentage of stroke volume variation between baseline and during a standardized abdominal compression. Stroke volume will be assessed by transthoracic echocardiography.~Patient will undergo 3 echocardiographic assessment: At baseline (stroke volume, cardiac output, left ventricular ejection fraction), During a standardized abdominal compression (stroke volume),After the 10 to 20ml/kg fluid expansion prescribed by the physician in charge (cardiac output)."
223440759|NCT00001502|DRUG|RMP-7 and carboplatin|
223440760|NCT00142259|DEVICE|Deep brain stimulation of the internal globus pallidus|
223440761|NCT03909854|PROCEDURE|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
223440762|NCT06088251|BEHAVIORAL|Nutri Training|Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.
223440763|NCT06088251|BEHAVIORAL|Standard Nutrition Education|Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
223440764|NCT02904551|PROCEDURE|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
223440765|NCT02904551|PROCEDURE|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
223566757|NCT06716619|DRUG|Serplulimab Injection|Srulizumab injection was given intravenous infusion both before and after the TAL-T cells infusion.
224052155|NCT03724734|DEVICE|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
223566758|NCT07033975|OTHER|Flavonoid-enriched Mediterranean Diet|A set of dietary guidelines describing an adjusted Mediterranean diet focusing on the intake of flavonoid-rich products.
223566759|NCT06887920|DEVICE|Acuvue Oasys for Presbyopia|ACUVUE OASYS for PRESBYOPIA contact lenses will be prescribed to children with myopia to be worn in one eye for 10 hours a day for one year.
223566760|NCT06887920|DEVICE|MiSight 1 Day|MiSight 1 Day contact lenses will be prescribed to children with myopia to be worn in one eye for 10 hours a day for one year.
223740997|NCT07190170|BEHAVIORAL|TRE|Participants randomized to the TRE arm will be instructed to consume all food and beverages in a self-selected 10-hr eating window.
224052156|NCT04322435|OTHER|Continuous blood glucose measurement|Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.
224052157|NCT04322435|OTHER|Measurement of capillary blood glucose|"Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips."
224052158|NCT06001112|OTHER|cheek acupuncture|Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
223440766|NCT01918150|DEVICE|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
224052159|NCT06001112|DRUG|Etoricoxib|etoricoxib 120mg
224144722|NCT04186468|OTHER|ICU follow-up clinic|The intervention aims at improving health-related quality of life and will contain three components: information, consultation and networking. More information will be available for the participants from the intensive care stay onwards, e.g. an information brochure, and during the entire follow-up period, e.g. by contacting the outpatient clinic via telephone. Participants will be invited to visit the ICU follow-up clinic at least once during the first six months after discharge from ICU. During the visits, participants will be screened for symptoms of PICS and, if required, referred to specialists for further treatment. The aim of the networking part is to improve the exchange between the health sectors and disciplines, e.g. through a special referral letter from the ICU follow-up clinic, and thus to provide a network of outpatient care providers for the former ICU patients.
224144723|NCT01673191|DRUG|Dexamethasone intravitreal implant|
224144724|NCT01673191|DRUG|Steroid plus NSAID eye drop combination therapy|
224300494|NCT03325400|OTHER|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
224300495|NCT04887233|OTHER|Longan nasal spray|The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
224300496|NCT04887233|OTHER|Placebo|The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
224052160|NCT01770912|DRUG|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
224052161|NCT01770912|DRUG|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
224052162|NCT00581685|DRUG|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
224144725|NCT02833220|DEVICE|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
224300497|NCT01346774|DRUG|Cranberry powder capsules|2 cranberry powder capsules twice a day
223440767|NCT01918150|DEVICE|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
223440768|NCT06035861|DRUG|XBD173|Participants will be treated with XBD173 90mg twice daily for 6 weeks
223440769|NCT03101722|DRUG|BTHE and Huperzine A|huperzine A intervention
224052163|NCT01864772|DRUG|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
224052164|NCT04444960|PROCEDURE|percutaneous coronary intervention|Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
224144726|NCT04223401|OTHER|Prehabilitation|"Patients will undergo 6 Minutes Walking Test (6-MWT), spiroergometry (VO2 max; AT), a grip strength test, a timed Up \& Go (TUG) test, 10 m sprint test and sit to stand test before and after prehabilitation. The trimodal intervention will involve:~1. Nutritional intervention~2. Psychological intervention~3. Exercise intervention"
224300498|NCT01346774|DRUG|Placebo powder capsules|2 placebo capsules twice a day
224300499|NCT03580122|DRUG|Arginine Aspartate|Asparten
223440770|NCT03101722|OTHER|BETH|basic treatment and health education
223440771|NCT02528890|OTHER|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
223440772|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223440773|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223440774|NCT02360475|BIOLOGICAL|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223440775|NCT02360475|BIOLOGICAL|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
223440776|NCT00180427|DEVICE|ICD|
224300500|NCT05266820|DRUG|Thalidomide|For the experimental group, the intervention was thalidomide（100mg PO Bid)
224300501|NCT05266820|DRUG|TAS-102|TAS-102
224052165|NCT03378323|DRUG|Multiple injection local anesthetic|Multiple injection local anesthetic
223440777|NCT03017027|BEHAVIORAL|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
223440778|NCT03017027|BEHAVIORAL|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
224052166|NCT03378323|DRUG|Single injection local anesthetic|Single injection local anesthetic
224052167|NCT01193881|DRUG|Erlotinib Hydrochloride|Given PO
224052168|NCT01193881|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
224052169|NCT01193881|OTHER|Laboratory Biomarker Analysis|Correlative studies
223440779|NCT00316862|DRUG|cisplatin|Given IV
224052170|NCT01193881|OTHER|Pharmacological Study|Correlative studies
224052171|NCT05259579|PROCEDURE|Anti-reflux mucosal ablation|Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
224052172|NCT05370885|BIOLOGICAL|VE202|VE202 is a rationally defined, live biotherapeutic product for oral administration.
223440780|NCT00316862|DRUG|irinotecan hydrochloride|Given IV
223440781|NCT00316862|PROCEDURE|therapeutic conventional surgery|Undergo Surgery
223440782|NCT00316862|RADIATION|radiation therapy|Undergo radiation
223440783|NCT04554992|BIOLOGICAL|COVID 19 Convalescent Plasma|COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
223440784|NCT03759366|DRUG|Eculizumab|Eculizumab will be administered by IV infusion.
224052173|NCT05370885|DRUG|Vancomycin Oral Capsule|Vancomycin is an antibiotic used to treat or prevent infection
224144727|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%) under Sildenafil|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour. given by a facemask, first at rest and then during exercise under Sildenafil."
224144728|NCT04697862|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
224144729|NCT00772382|DRUG|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
224144730|NCT00643604|DRUG|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
224144731|NCT02763072|DEVICE|Enlighten Laser|
224144732|NCT02763072|DEVICE|Excel V Laser|
223440785|NCT00174226|DRUG|Atomoxetine|
223440786|NCT00174226|DRUG|Buspirone|
223440787|NCT00930631|DRUG|[3H] BMS747158|Single bolus intravenous injection of \[3H\] BMS747158
223440788|NCT04279782|OTHER|Comprehensive treatment|Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.
223440789|NCT00622804|PROCEDURE|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
223740998|NCT07190170|BEHAVIORAL|Weight-Loss Maintenance Advice|The CON arm participants will receive written baseline advice following randomization assignment that includes determinants associated with long-term weight-loss maintenance success (e.g., physical activity, and strategies to limit calorie intake).
223740999|NCT07189468|DEVICE|Smartwatch and mobile application|Wearing a smartwatch and using a mobile application for one year
223741000|NCT07189650|DEVICE|MRI|Proton Density Fat Fraction Magnetic Resonance Imaging (MRI-PDFF )
224052174|NCT05370885|OTHER|VE202 Placebo|VE202 Placebo
224052175|NCT05370885|OTHER|Vancomycin Placebo|Vancomycin Placebo
224052176|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines with nitrate|consumption of herbal pralines with nitrate
224052177|NCT06090851|DIETARY_SUPPLEMENT|herbal nitrate Pralines without nitrate|consumption of herbal pralines without nitrate
224052178|NCT02715336|DRUG|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
224052179|NCT03128476|DIETARY_SUPPLEMENT|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
224052180|NCT03128476|DIETARY_SUPPLEMENT|Placebo (Energy matched)|
224052181|NCT02871804|PROCEDURE|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
224052182|NCT02871804|PROCEDURE|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
223440790|NCT00622804|PROCEDURE|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
223440791|NCT00622804|PROCEDURE|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
223440792|NCT04226495|DRUG|Sufentanil Infusion|Intra-operative sufentanil infusion
223440793|NCT04226495|DRUG|Sufentanil Bolus|Intra-operative sufentanil bolus
223440794|NCT01466517|DRUG|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
223440795|NCT01466517|DRUG|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
223440796|NCT02596217|DRUG|ABBV-066|SC injection
223440797|NCT02596217|DRUG|ABBV-066|IV infusion
223440798|NCT02596217|DRUG|Placebo|SC injection (stage 1)
223440799|NCT02596217|DRUG|Placebo|IV infusion (stage 2)
223440800|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223440801|NCT00539032|BIOLOGICAL|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224052183|NCT06419959|DEVICE|NightWare|Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.
224052184|NCT06075160|DIAGNOSTIC_TEST|Resting full-cycle ratio (RFR)-guided revascularization|The decision of coronary intervention is based on an RFR cut-value of 0.89. If RFR ≤ 0.89, target lesion will be revascularized, and if RFR \> 0.89, PCI will be deferred. However, even if RFR ≤ 0.89, PCI can be deferred if the RFR gradient of the lesion ≤ 0.02, or if the diffused type of stenosis, because physiological gain is expected to be very low.
224052185|NCT06075160|DIAGNOSTIC_TEST|Fractional flow ratio (FFR)-guided revascularization|Study participants of FFR-guided PCI arm will be selected from a large-scaled, ongoing FFR registry. The decision of coronary intervention is based on an FFR cut-value of 0.80. If FFR ≤ 0.80, target lesion will be revascularized, and if RFR \> 0.80, PCI will be deferred.
224052186|NCT05965869|OTHER|diabetes program|CHWs will contact participants weekly via phone or text, send bimonthly diabetes education videos, and provide optional monthly seminars.
224144733|NCT05796804|PROCEDURE|ERECTOR SPINAE PLANE BLOCK|ULTRASOUND GUIDED - ROPIVACAINE 30 ml 0.5%
224144734|NCT05796804|PROCEDURE|Peng block + lateral femoral cutaneous nerve block|ULTRASOUND GUIDED - ROPIVACAINE 20 ml 0.5% + 10 ml 0.5%
224144735|NCT05796804|PROCEDURE|spinal anesthesia|bupivacaine 0.5% 2.2 ml
223440802|NCT06302088|OTHER|SAINTS program|A brief descriptive name used to refer to the intervention(s) studied in each arm of the clinical study. A non-proprietary name of the intervention must be used, if available. If a non-proprietary name is not available, a brief descriptive name or identifier must be used.
223440803|NCT06909929|DIETARY_SUPPLEMENT|Lipid IV 2 g|This group will get 2 g of lipid IV in the early 24 hours of life
223440804|NCT06909929|DIETARY_SUPPLEMENT|lipid IV 1 gram|This group will get 1 g of lipid IV in the early 24 hours of life
223440805|NCT06909994|OTHER|individual assessments|Participants in the CP group underwent individual assessments using seven standardized instruments to evaluate sensory and motor function, as well as independence in daily activities. Data collection was conducted in person at the participating institutions by trained professionals following a structured protocol. All procedures were performed after verifying cognitive eligibility (score ≥ 19) and obtaining informed consent. The same protocol was applied across both centers to ensure consistency. The control group followed the same assessment process. Each evaluation session lasted approximately two hours per participant.
223440806|NCT06910891|DIAGNOSTIC_TEST|measurement of the peripheral perfusion index and marbling assessment|in addition to the classic hemodynamic parameters measured in all patients, a measurement of the peripheral perfusion index (from 1 sec to 10 sec) and marbling assessment (scale from 0 to 5) will be performed
223440807|NCT00441818|DRUG|TNX-650|
224144736|NCT00760604|PROCEDURE|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
224144737|NCT03608904|OTHER|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
223440808|NCT05760742|DIETARY_SUPPLEMENT|MicAlgae|2 months of supplementation with an innovative microalgae based ingredient
223440809|NCT05760742|DIETARY_SUPPLEMENT|Placebo|2 months of supplementation with a placebo (Maltodextrin)
223741001|NCT07189598|PROCEDURE|Adaptive Stereostatic Body RadioTherapy (SBRT) including both Whole Pelvic RadioTherapy (WPRT) and dose-escalation on the Dominant Intraprostatic Lesion (DIL)|"The doses delivered will be:~* the prostate gland, at a dose of 36.25 Gray, in 5 fractions,~* the dominant intraprostatic lesion, up to 50 Gray, in 5 fractions,~* seminal vesicles, at a dose of 25 Gray in 5 fractions,~* pelvic lymph nodes, at 25 Gray in 5 fractions"
224144738|NCT03608904|OTHER|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
224144739|NCT05594108|DIAGNOSTIC_TEST|ultrasonography|transabdominal ultrasonography
224144740|NCT03843736|BEHAVIORAL|Lifestyle intervention|"1. Balance the diet;~2. Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~3. Monitor body weight, avoid sedentary, get more sun and regular activities;~4. Mental health regulation."
224300502|NCT03282149|BIOLOGICAL|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
224300503|NCT00116519|DRUG|PPAR alpha|
224300504|NCT00116519|DRUG|placebo|
223440810|NCT05510219|DRUG|intravenous rapid infusion of obinutuzumab|This study was a prospective, single-arm, open-label, phase IV clinical trial that included patients with B-cell non-Hodgkin's lymphoma who visited the Department of Hematology, Jiangsu Provincial People's Hospital. All patients were treated with the standard infusion regimen of obinutuzumab in cycle 1, and for patients who did not develop severe infusion-related reactions (IRRs) in cycle 1, a rapid 90-min obinutuzumab infusion regimen was used from cycle 2 onward while recording any occurrence of infusion reactions in different treatment cycles.
223440811|NCT06911918|OTHER|time restricted eating with caloric restriction|will be asked to reduce their energy intake by 550 each day. Total energy expenditure will be calculated using the Bioelectrical impedance (BIA); Inbody 120 and multiplied by the physical activity factor and reduced by 550 kilo calories for each participant. The acceptable macronutrient distribution range (AMDR) will be 45-60% carbohydrates, 15-25% protein, and 20-30% fat of the total caloric value and fasted from 18:00 to 8:00 daily (a 14-h fast) in the 12-weeks intervention
223440812|NCT06911918|OTHER|time restricted eating without caloric restriction|will be asked to maintain their normal diet to the acceptable normal distribution ranges and fast from 8:00 to 18:00. They do not need to restrict caloric intake during the feeding window
223440813|NCT06911918|OTHER|Caloric restriction without Time restricted eating|will be asked to reduce their energy intake by 550 each day. Total energy expenditure will be calculated using the Bioelectrical impedance (BIA); Inbody 120 and multiplied by the physical activity factor and reduced by 550 kilo calories for each participant. The acceptable macronutrient distribution range (AMDR) will be 45-60% carbohydrates, 15-25% protein, and 20-30% fat of the total caloric value
224052187|NCT02867176|DRUG|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
224052188|NCT02867176|DRUG|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
223440814|NCT06911918|OTHER|No time restricted eating - Normal diet|will be asked to maintain their normal diet as the second intervention arm without time restricted eating throughout the trial
223440815|NCT06912113|BEHAVIORAL|Motivational interviewing|What distinguishes this intervention from other clinical applications is that in this study, the clinical effectiveness of motivational interviewing was examined by using a smoking cessation intention scale before and after the intervention.
223440816|NCT06907056|DRUG|dual therapy|Intervention arm will be dual therapy oh DRV/C 800/150 mg + 3TC 300 mg, this will be compared to standar therapy of 3 drugs with: DRV/c 800/150 mg + TDF/FTC 300/200 mg
223440817|NCT06907056|DRUG|Standard Medical Therapy|DRV/c+TDF/FTC
223440818|NCT05602129|DRUG|HSK36273|HSK36273
223440819|NCT05602129|DRUG|Heparin sodium|Heparin sodium
223440820|NCT06648694|PROCEDURE|Abdominoplasty surgery|Correlation between IAP and Diaphragmatic Mobility
223566761|NCT06895018|DIETARY_SUPPLEMENT|Supplementation with Polyphenol Rich Drink|Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with control drink (Placebo) devoid of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the RGPD 60 minutes prior.
224052189|NCT06308432|OTHER|Low intensity|The subject will perform the 30-minute test at an intensity of 50% of the power at which he/she has reached his/her VO2max.
224052190|NCT06308432|OTHER|Low temperature|The performance test will be carried out in a room conditioned to a temperature of 22º.
224052191|NCT06308432|OTHER|Low Humidity|The performance test will be carried out in a room conditioned to 40% humidity.
224144741|NCT03843736|DRUG|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
224144742|NCT03843736|DRUG|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
224144743|NCT01644955|DRUG|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
224144744|NCT01644955|PROCEDURE|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
224144745|NCT01225471|BIOLOGICAL|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
224144746|NCT03591055|OTHER|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
224144747|NCT04426838|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBTi) via Videoconference|The CBTi protocol will include stimulus control, sleep compression, relaxation, sleep hygiene, and cognitive restructuring which will be done over 4 weeks with one session weekly delivered via videoconference.
224052192|NCT06308432|OTHER|High intensity|The subject will perform the 30-minute test at an intensity of 60% of the power at which he/she has reached his/her VO2max.
224052193|NCT06308432|OTHER|High temperature|The performance test will be carried out in a room conditioned to a temperature of 35º.
224052194|NCT06308432|OTHER|High humidity|The performance test will be carried out in a room conditioned to 65% humidity.
224052195|NCT03412279|BEHAVIORAL|Application of the initial evaluation|Initial evaluation involves the application of Hausa ODI, NPRS, RMDQ, SF-12, PCS, GROC, BBQ, VAS for pain and disability, and FFD.
224052196|NCT03412279|BEHAVIORAL|Final application of instruments|Application of the Hausa versions of ODI, NPRS, RMDQ, SF-12, PCS, GROC and BBQ one week after initial evaluation
224052197|NCT02510781|DRUG|Epirubicin|75mg/m2 d1 evry 21days
224052198|NCT02510781|DRUG|Docetaxel|75mg/m2 d1 evry 21days
224052199|NCT02510781|DRUG|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
224052200|NCT02510781|DRUG|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
223440821|NCT06648694|PROCEDURE|Abdominoplasty|For the practice of the surgical procedure, the region to be operated on was marked using a surgical marking pen (Textel®). With the patient in the orthostatic position, a median line was drawn from the xiphoid appendix to the pubic symphysis, reaching the anterior vulvar commissure. Then, with the patient in the dorsal position, a transverse line was drawn 6 cm above the vulvar commissure and elongated to the iliac spine on each side. From there, the lateral skin surplus was estimated by means of bidigital clamping. The excess tissue was marked in a triangular shape, with a slight arching up to the xiphoid appendix. To determine the horizontal skin surplus, marking was performed, similar to that performed in classic abdominoplasty described in the literature(AMORIM FILHO; AMORIM, 2012). In this study, an anchor incision was recommended for all volunteers. All patients underwent intravenous sedation followed by spinal anesthesia.
223440822|NCT06281626|OTHER|Data collection|Data collection
223440823|NCT06910163|DIAGNOSTIC_TEST|Diagnostic standard of care|Participants will receive the diagnostic standard of care: standard laboratory workup, non-contrast brain CT, brain CTA, brain CTP, or brain MRI.
223440824|NCT06910163|DIAGNOSTIC_TEST|LVOne Test|Participants will receive the LVOne test, which will measure D-dimer and Glial Fibrillary Acidic Protein (GFAP) levels to diagnose acute stroke.
223440825|NCT04364464|DRUG|Riociguat (Adempas, BAY 63-2521)|0.5 mg riociguat as an immediate-release (IR) tablet
223440826|NCT03601273|PROCEDURE|Left gastric artery embolization|"450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.~30-day post-embolization endoscopic biopsy"
223440827|NCT05865847|OTHER|Not applicable, this is an observational study|Not applicable, this is an observational study
223440828|NCT01725360|DRUG|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
223440829|NCT00004982|DRUG|Combination Iron Chelation Therapy|
223440830|NCT03858283|BEHAVIORAL|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
223440831|NCT00372047|DEVICE|multiphoton laser imaging|
223440832|NCT03121573|DRUG|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
223440833|NCT03286231|DIAGNOSTIC_TEST|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
224052201|NCT05643612|DIAGNOSTIC_TEST|Deep learning algorithm|A sequential two-stage 3D spleen injury detection framework to identify splenic injury in the CT scans
224052202|NCT04261504|BEHAVIORAL|IBMT|mindful presence in a non-judgmental way
224052203|NCT04261504|BEHAVIORAL|RT|progressive muscle relaxation
224052204|NCT05149703|OTHER|Mezieres Postural Treatment|Implementation of 12 weeks suitable postures of Mezieres method
224144748|NCT03550638|DEVICE|Coil system(Ton-bridgeMT)|1\. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
223440834|NCT01210352|DRUG|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
223440835|NCT06169956|DRUG|Neoadjuvant nivolumab in combination with platinum-based chemotherapy|Neoadjuvant treatment of resectable non-small cell lung cancer with nivolumab in combination with chemotherapy according to current summary of product characteristics
223440836|NCT03279354|BEHAVIORAL|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
223440837|NCT03279354|BEHAVIORAL|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics \& Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
223440838|NCT01635907|DRUG|Dovitinib|
223440839|NCT04886362|DRUG|Ivermectin|Treatment with Ivermectin in the first 7 days from symptoms onset.
223440840|NCT04886362|DRUG|Placebo|Treatment with Placebo in the first 7 days from symptoms onset.
224052205|NCT03765242|OTHER|Non-Interventional|Non-Interventional
224052206|NCT04426604|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|Each restoration margins will be assessed by Light induced fluorescence intraoral camera to assess its validity in diagnosing secondary caries around margins of resin composite restorations
224052207|NCT04426604|DIAGNOSTIC_TEST|Laser-induced fluorescence device|Each restoration margins will be assessed by Laser-induced fluorescence device to assess its validity in diagnosing secondary caries around margins of resin composite restorations
224052208|NCT04426604|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|Each restoration margins will be assessed by visual-tactile assessment method which includes the use of mirror, probe under good illumination condition to assess its validity in diagnosing secondary caries around margins of resin composite restorations
224052209|NCT04941066|BEHAVIORAL|Active neurofeedback|The session will be done on an individual basis. The active group will receive neurofeedback training from the rumination-related brain functional connectivity.
224052210|NCT04941066|BEHAVIORAL|Sham neurofeedback|The session will be done on an individual basis. The sham group will receive neurofeedback training from an artificially generated random feedback signal.
224052211|NCT00454285|DRUG|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
224052212|NCT01817751|DRUG|sorafenib tosylate|Given by mouth
224052213|NCT01817751|DRUG|valproic acid|Given by mouth
223440841|NCT05993091|OTHER|mirror therapy (MT)|Each participant will practice two different MT protocols: UMT and BMT. During UMT, the affected hand is static, whereas during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements (i.e., shoulder flexion, elbow flexion/extension, forearm pronation/supination, and wrist flexion/extension and circumduction), fine motor movements (i.e., opposition, grasp, and release), and object manipulation (i.e., reaching out to grasp a cup, flipping coins).
223440842|NCT05993091|OTHER|augmented reality (AR)|The training program with different levels of difficulty provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg, etc.), activities of daily living training (i.e., reaching to grasp functionally relevant objects), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
223440843|NCT05993091|OTHER|Control intervention|Participants will perform 90 minutes of therapist-mediated conventional therapy. The treatment protocols will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. Specifically, the affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques will be used to alleviate functional deficits. In addition, the therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
224052214|NCT01817751|DRUG|sildenafil citrate|Given by mouth
224052215|NCT03947840|BEHAVIORAL|Physical activity|Se their physical activity level
224052216|NCT02946593|BEHAVIORAL|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 \& 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
224052217|NCT02946593|BEHAVIORAL|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
224144749|NCT03550638|DEVICE|Axium Detachable Coil(Medtronic)|2\. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
223440844|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
223440845|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
223440846|NCT00422292|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
223440847|NCT00422292|BIOLOGICAL|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
224052218|NCT05222529|DRUG|Glycopyrronium bromide 25ug|25μg Glycopyrronium bromide capsules for oral inhalation via Breezhaler
224052219|NCT05222529|DRUG|Placebo|Placebo to Glycopyrronium bromide capsules for oral inhalation via Breezhaler
224052220|NCT05222529|DRUG|Glycopyrronium bromide 12.5ug|12.5ug Glycopyrronium bromide capsules for oral inhalation via Breezhaler
224052221|NCT01120548|OTHER|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
224052222|NCT02193048|OTHER|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
224052223|NCT02504554|DRUG|oral Vancomycin|an antibiotic
224052224|NCT02504554|DRUG|MoviPrep|a bowel cleanse
224052225|NCT02504554|DRUG|Prilosec|a stomach acid suppressan
224052226|NCT02504554|BIOLOGICAL|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
224052227|NCT02504554|BIOLOGICAL|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
224052228|NCT02187679|DRUG|Abobotulinum toxin A|
224144750|NCT05931055|DIAGNOSTIC_TEST|Fragmentomics|The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. Fragomics relies on WGS (Whole Genome Sequencing), and the target covers the whole Genomics level. Thus, the cfDNA Fragmentomics testing can help differentiation and early diagnosis.
224144751|NCT02165033|DRUG|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
224144752|NCT02702011|DRUG|empagliflozin medium dose|
224144753|NCT02702011|DRUG|empagliflozin low dose|
224052229|NCT03364361|PROCEDURE|Acupuncture|Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
223440848|NCT03988673|OTHER|Decision aid with implicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
223440849|NCT03988673|OTHER|Decision aid with explicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
223440850|NCT04616001|DRUG|IVIG|Patients will receive IVIG daily for four days.
223440851|NCT05105399|PROCEDURE|Serratus plane block (continuous or single-shot)|Patients assigned to the interventional arms will receive either continuous serratus plane block or single-shot serratus plane block
223440852|NCT00520754|DRUG|levocetirizine dihydrochloride|
223440853|NCT05517733|BIOLOGICAL|Platelet Rich Fibrin|"for the preparation of PRF, A well-trained professional nurse drew 10ml of patient blood from the antecubital vein and transferred it to a test tube without anticoagulant. The blood sample was immediately centrifuged for 10-12 minutes at 3000 rpm. L-PRF was ready to use after centrifugation.~PRF membrane was put over the implant and slightly tucked under the soft tissue periphery, then held in place with a figure-of-8 suture by 0.5 proline suture"
223440854|NCT05517733|DEVICE|Diode laser|"* A 980 nm diode laser device (BIOLASE) was applied in a circular motion to the blood formed at the socket orifice at a power of 1W for 1 minute with a continuous wave mode, the application was done without touching the pooling blood and with a non-activated tip of the fiber optic.~* The laser application cycle was repeated 3-5 times to yield a stable fixed blood clot covering the dental implant with no oozing blood from its periphery."
223440855|NCT05905133|DRUG|CBP-201|subcutaneous injection
224052230|NCT01852682|DRUG|PA21|
224052231|NCT03898492|OTHER|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
224144754|NCT02702011|DRUG|empagliflozin high dose|
224144755|NCT02702011|DRUG|placebo|
224144756|NCT03203954|BEHAVIORAL|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
224144757|NCT03203954|BEHAVIORAL|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
224144758|NCT03203954|BEHAVIORAL|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
224144759|NCT03017365|OTHER|Stable Resistance Training|traditional machine-based resistance training
224144760|NCT03017365|OTHER|Unstable Resistance Training|free weight resistance training using unstable devices
224144761|NCT03017365|OTHER|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
224144762|NCT06251219|DIAGNOSTIC_TEST|PCR|PCR test for EV71, CA16, CA10, or CA6
223440856|NCT02440854|DRUG|afatinib|Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib.
223440857|NCT00699231|BIOLOGICAL|HBV-MPL vaccine 208129|IM injection
223440858|NCT00699231|BIOLOGICAL|Engerix™-B|IM injection
224052232|NCT01846624|DRUG|Decitabine|Given IV
224052233|NCT01846624|DRUG|Midostaurin|Given PO
224052234|NCT02073071|OTHER|Preterm infant formula per standard of care|Commercially available preterm infant formula
224052235|NCT03752008|BEHAVIORAL|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
224052236|NCT03752008|BEHAVIORAL|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
224144763|NCT04208334|DIETARY_SUPPLEMENT|Curcumin|We give an Intervention arm to consume Curcumin 4000mg/day for 60 consecutive days.
224144764|NCT04208334|OTHER|Placebo|We give a control arm to consume placebo for 60 consecutive days.
224144765|NCT02930616|DEVICE|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
224144766|NCT02930616|DEVICE|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
224144767|NCT04143763|OTHER|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
223440859|NCT03329105|OTHER|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
224052237|NCT04754750|DRUG|Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]|
224144768|NCT03546790|DRUG|Marijuana|Marijuana smoked via blunts with different cigar wrappers
224144769|NCT02407041|DRUG|GR-MD-02|IV infusion
224144770|NCT01703611|OTHER|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
224144771|NCT01703611|OTHER|Usual Nutrition Care|Usual nutrition care in India
224144772|NCT05022745|OTHER|Multimodal, multidisciplinary approach|The patient management is adapted pre-operatively, per-operatively and post-operatively
224144773|NCT04944329|PROCEDURE|Hip fracture surgery|Hip fracture surgery
224144774|NCT02615795|DEVICE|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
224300505|NCT03736213|BEHAVIORAL|Visual-acoustic biofeedback|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
224300506|NCT03736213|BEHAVIORAL|Ultrasound biofeedback|In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
224300507|NCT02213913|DRUG|lenalidomide|Given PO
224300508|NCT02213913|DRUG|etoposide|Given IV
224300509|NCT02213913|DRUG|prednisone|Given PO
224300510|NCT02213913|DRUG|vincristine sulfate|Given IV
224300511|NCT02213913|DRUG|doxorubicin hydrochloride|Given IV
223440860|NCT03329105|OTHER|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
223440861|NCT02174705|DRUG|Sucrose|Sucrose 24% orally prior to vaccine injections
224052238|NCT04754750|DRUG|Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]|
224052239|NCT01020591|OTHER|Osteopathic evaluation|evaluation of movement and tissue mobility
224052240|NCT01020591|OTHER|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
224052241|NCT03517787|OTHER|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
224052242|NCT03517787|OTHER|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
224052243|NCT03517787|OTHER|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
224052244|NCT03517787|OTHER|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
224300512|NCT02213913|DRUG|cyclophosphamide|Given IV
224300513|NCT02213913|BIOLOGICAL|rituximab|Given IV
224300514|NCT02213913|OTHER|quality-of-life assessment|Ancillary studies
224300515|NCT02213913|OTHER|laboratory biomarker analysis|Correlative studies
224300516|NCT01955213|DRUG|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
223440862|NCT02174705|DRUG|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
224300517|NCT05077436|DRUG|Vamifeport Formulation 1|Vamifeport Formulation 1 is available as 60 mg oral capsules
224300518|NCT05077436|DRUG|Vamifeport Formulation 2|Vamifeport Formulation 2 is available as 60 mg oral capsules
223440863|NCT01758978|DRUG|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
223440864|NCT03338569|DRUG|Vitamin C|Continuous infusion of vitamin C
224052245|NCT00580372|DRUG|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
224052246|NCT00580372|DRUG|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
224052247|NCT00580372|PROCEDURE|Hemopoietic stem cell procurement|Collection target = 10 x 10\^6 cells/kg
224144775|NCT05536193|DRUG|Topical Metformin Emulgel and salicylic acid|"Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use).~Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.~Other Names:~• 2-hydroxybenzoic acid"
224144776|NCT05536193|DIAGNOSTIC_TEST|Insulin- Like growth factor (ILGF-1)|3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
223440865|NCT03338569|DRUG|Placebo|Placebo designed to mimic intervention
223440866|NCT02243046|DRUG|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
224144777|NCT02007954|DEVICE|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
224144778|NCT00460447|DRUG|Gemtuzumab Ozogamicin|
223440867|NCT02243046|DRUG|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
223440868|NCT02243046|DRUG|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
223440869|NCT02897180|BIOLOGICAL|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
223440870|NCT02897180|BIOLOGICAL|Placebo|Capsules containin Placebo
223440871|NCT04865991|PROCEDURE|TCI Propofol|Peripheral venous catheters were placed in all subjects. Subjects in the TCI propofol group had one specific intravenous catheter for propofol infusion apart from medication or intravenous fluid line. Subjects in the TCI Propofol group received TCI propofol (Schneider) with targeted Ce 4 -5 mcg/ml for anesthesia induction and maintenance. Subjects in the TCI propofol group received TCI propofol for anesthesia maintenance, Ce value was titrated until a targeted BIS score of 40-60 achieved.
224052248|NCT00580372|DRUG|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
224052249|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
224052250|NCT00580372|PROCEDURE|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
223440872|NCT04865991|PROCEDURE|Sevoflurane|subjects in the sevoflurane group were cannulated only with one venous catheter. Midazolam 0.05 mg/kg BW and fentanyl 1 mcg/kg BW were given as premedication. Subjects in the sevoflurane group received intravenous propofol 1 - 2 mg/kg BW.
223440873|NCT05415371|BEHAVIORAL|Standard Care + Financial Incentives|Financial incentive participants will receive standard care and receive incentives for completing counseling calls and for abstinence.
223440874|NCT05415371|OTHER|Standard Care|Participants randomized to Standard Care will be offered weekly counseling calls and pharmacotherapy.
223440875|NCT02669082|DRUG|Ramelteon|Ramelteon tablets
224052251|NCT00580372|DRUG|Maintenance|3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
224144779|NCT02659605|PROCEDURE|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
224144780|NCT02659605|PROCEDURE|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
224144781|NCT01195363|DRUG|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
224144782|NCT01195363|DRUG|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
224144783|NCT01156207|DRUG|Aliskiren|300mg Aliskiren qd for 6 month
224144784|NCT00475540|DEVICE|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
224144785|NCT06205394|OTHER|Non-Interventional Study|Non-interventional study
223440876|NCT06910007|PROCEDURE|dental implant will be inserted using surgical guide|dental implant will be inserted using blue sky plan computer software
223440877|NCT06910007|PROCEDURE|dental implant|surgical guide will be fabricated using exoplan computer software
223440878|NCT06910007|PROCEDURE|dental implant will be inserted using surgical guide|surgical guide will be fabricated using real guide computer software
223440879|NCT05883774|DEVICE|Repetitive Transcranial Magnetic Stimulation|rTMS is applied using a transcranial magnetic stimulator with a figure-of-8 coil once per day for 10 consecutive days. rTMS is delivered to the right dorsolateral prefrontal cortex (DLPFC) at a frequency of 1 Hz for 20 minutes (1200 total pulses).
224052252|NCT03472924|DEVICE|Kinesiotaping|The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
224052253|NCT06004648|PROCEDURE|Upper extremity surgery|Comparison of 2 different peripheral nerve blocks
224144786|NCT05589480|OTHER|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.|preoperative demographics, blood markers, surgical pathology information，and enhanced CT features.
224144787|NCT03114566|OTHER|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
224300519|NCT03083236|OTHER|Standard PBI|Standard Parent Based Intervention (PBI)
224300520|NCT03083236|OTHER|Enhanced|Enhanced Parent Based Intervention (EPBI)
224052254|NCT00427349|DRUG|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
224052255|NCT00427349|DRUG|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
224052256|NCT01660321|DRUG|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
224052257|NCT04860271|PROCEDURE|Manual Acupuncture|Manual acupuncture treatment using different types of needle
224052258|NCT00441181|DRUG|Travoprost|
224052259|NCT00698997|BEHAVIORAL|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching \& coaching parents to use the ESDM in all natural caretaking routines \& play periods with their child. Parents are taught \& coached on 1 aspect of the ESDM each week in the clinic session, \& then practice it at home daily in natural family routines \& play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines \& play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
223440880|NCT05883774|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|Sham-rTMS is performed in the same way as the treatment group except that the coil is rotated 90° away from the scalp.
223440881|NCT06209762|OTHER|Exercise|The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
223440882|NCT05682729|BEHAVIORAL|Book Reading Intervention|Children read books containing relevant stimuli.
224052260|NCT00698997|BEHAVIORAL|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
224052261|NCT00978549|DRUG|docetaxel|
224052262|NCT00978549|DRUG|steroid therapy|
224144788|NCT01692223|BEHAVIORAL|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety \& Depression Scale (HADS), revised Impact of Events Scale (IES-R), \& a questionnaire about their health behaviors, to establish baseline distress levels \& health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider \& discuss resultant therapeutic \& management recommendations for the participants \& their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
224144789|NCT05291416|DIAGNOSTIC_TEST|densitometry/ handgrip dynamometer|all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer
224144790|NCT04718324|OTHER|e-PROMS|Participants randomised to the e-PROMS arm will receive a safe link to the e-PROMS and a unique identification number in the electronic form, so as to preserve anonymity. This is a one-time intervention
224144791|NCT04718324|OTHER|p-PROMS|Participants randomised to the p-PROMS arm will receive the PROMS and PREMS questionnaires and a unique identification number in paper form.
223440883|NCT02824562|BEHAVIORAL|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
223440884|NCT02824562|BEHAVIORAL|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
223440885|NCT04562857|BEHAVIORAL|Moderate intensity interval training (MITT)|interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
224052263|NCT00978549|OTHER|questionnaire administration|
224052264|NCT00978549|PROCEDURE|nausea and vomiting therapy|
224052265|NCT00978549|PROCEDURE|pain therapy|
224052266|NCT00978549|PROCEDURE|quality-of-life assessment|
224052267|NCT00978549|PROCEDURE|standard follow-up care|
224052268|NCT00978549|RADIATION|radiation therapy|
224052269|NCT00002128|DRUG|Adefovir dipivoxil|
224052270|NCT02720770|DRUG|norditropine simplex|
224052271|NCT03041350|OTHER|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
223440886|NCT00161967|BIOLOGICAL|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
223440887|NCT02259686|DRUG|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
224052272|NCT03491007|DRUG|DHEA|Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period \[all participants\], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
224052273|NCT03130062|OTHER|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
224052274|NCT05082376|DRUG|CLM Original|Sunscreen lip balm.
224052275|NCT06198803|DRUG|L Carnitine|The study population will be randomly divided into 2 groups, 1 group will receive Carnitine supplementation in a dose of 100mg/kg/day
224052276|NCT00360906|DRUG|Triomar™ (omega-3 fatty acids)|
224052277|NCT00538330|DRUG|Tamoxifen|Tamoxifen
223440888|NCT02259686|DRUG|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
223440889|NCT02259686|DRUG|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
224052278|NCT01398020|DRUG|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
224052279|NCT01398020|DRUG|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
224052280|NCT00162760|DRUG|Thalidomide|
224052281|NCT01415128|DRUG|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
224052282|NCT01415128|DRUG|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
224052283|NCT01415128|DRUG|Desipramine|Single dose of Desipramine (50 mg) for 1 day
224052284|NCT05403320|DEVICE|Continuous cuff pressure regulation|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 control device. It includes an automatic high-sensitive subglottic capnograph which measures every few minutes the carbon dioxide level in the subglottic space. If the level of carbon dioxide is above the threshold (established by animal studies) the system will increase the cuff pressure by a formula, if the level is below the threshold, the system will decrease the cuff pressure by 1 mmHg. Variations of cuff pressure are allowed only between pressure limits set by the user (minimum and maximum)
224052285|NCT05403320|DEVICE|Intermittent cuff pressure regulation|ET cuff pressure will be manually measured three times per day using a portable manometer, and kept constant within 20-30 cmH2O
224052286|NCT05403320|DEVICE|Automatic subglottic secretion drainage|Within 24 hours, AnapnoGuard tube will be connected to AnapnoGuard 100 device control which provides continuous subglottic secretion drainage (two different suction lines) and venting/rinsing (a third dedicated line)
224144792|NCT00904995|DRUG|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
224144793|NCT00904995|DRUG|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
224144794|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
224144795|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
224144796|NCT00685841|DRUG|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
224144797|NCT00685841|DRUG|Salmeterol MDI|Salmeterol MDI 42 mcg BID
224144798|NCT00685841|DRUG|Placebo|Placebo BID MDI
224144799|NCT03870685|PROCEDURE|TAP Block|Transversus Plane block
224144800|NCT03870685|PROCEDURE|Surgical Site Infiltration|Surgical Site Infiltration
224144801|NCT03870685|DRUG|Exparel|liposomal bupivacaine
224144802|NCT05918588|DRUG|Belumosudil mesylate|Pharmaceutical form: capsule; Route of administration: oral
224144803|NCT05918588|DRUG|Placebo|Pharmaceutical form: capsule; Route of administration: oral
224144804|NCT04169854|DRUG|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
224144805|NCT04169854|DRUG|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
224144806|NCT04125173|OTHER|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
224144807|NCT04125173|OTHER|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
223440890|NCT02259686|DRUG|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
223440891|NCT02259686|DRUG|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
223440892|NCT05743647|DEVICE|Observation (OBS)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement."
224144808|NCT04125173|OTHER|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
224144809|NCT03036449|BEHAVIORAL|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~\- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~* Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~* Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
224144810|NCT02436733|PROCEDURE|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
224144811|NCT02436733|DRUG|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
223440893|NCT05743647|DEVICE|Observation and imagination (OBS-IM)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it."
223440894|NCT05743647|DEVICE|Observation and realization (OBS-REAL)|"Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it"
223440895|NCT02084433|PROCEDURE|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
224052287|NCT05403320|DEVICE|Manual subglottic secretion drainage|Subglottic secretions will be manually drained with a 10 mL syringe, using the only dedicated lumen
223440896|NCT02084433|PROCEDURE|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
224052288|NCT05403320|DIAGNOSTIC_TEST|Tracheobronchial colonization assessment|Tracheal aspirate will be performed after intubation and after 72 hours for microbiological colture
224052289|NCT05403320|DIAGNOSTIC_TEST|Microaspiration assessment|Tracheal aspirates will be performed 72 hours after intubation, and collected in a predefined study center to measure pepsin and salivary amylase
224052290|NCT05403320|DIAGNOSTIC_TEST|VAP assessment|Patients will be follow to detect clinical, radiological or microbiological signs of VAP. If suspected, a tracheal aspirate or a bronchoalveolar lavage is performed to confirm the diagnosis
224052291|NCT05442255|OTHER|Toxicological analysis|Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
224052292|NCT05561361|PROCEDURE|Super selective adrenal artery embolization|Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
224300521|NCT03077321|BEHAVIORAL|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
223440897|NCT06376305|DEVICE|EndoBarrier|"During screening visit, a brief history, examination, blood tests and 2 sleep studies within a gap of 1 week will be performed. Then, there will be an assessment by gastroenterologist for EndoBarrier insertion. EndoBarrier will be inserted endoscopically as a day case procedure after the midnight fast, under general anaesthesia. Following the EndoBarrier insertion, there will be 3 monthly trial visits until one year where the following assessments will be performed - brief interview, observations, blood tests, urine test, dietitian review, compliance check with CPAP and quality of life questionnaire.~At the end of one year, EndoBarrier will be removed endoscopically again as a day case procedure under general anaesthesia. Then, there will be follow up trial visits every 3 months up to one year where there will be clinical assessments, sleep studies, blood tests, urine test, dietitian, compliance check and quality of life questionnaires."
223440898|NCT06509347|OTHER|Preassure release|Preassure release in Flexor digitorum brevis trigger point muscle.
223440899|NCT06509347|OTHER|Non-emision laser|Bilateral non emission Laser in latent trigger points of the Flexor digitorum Brevis Muscle
223440900|NCT00550576|DRUG|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
224300522|NCT03077321|BEHAVIORAL|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
223440901|NCT02427243|DRUG|Crenezumab|
223440902|NCT02427243|DRUG|Crenezumab|
223440903|NCT02168777|DRUG|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
223566762|NCT06895018|DIETARY_SUPPLEMENT|Supplementation with Control Drink (Placebo)|Participants were instructed to consume, over a 6-week period, within the context of a Mediterranean diet, a control drink (Placebo) (150 mL) containing 0 g of polyphenols. After this treatment period, participants underwent a two-week washout period before switching to the alternative treatment with a polyphenol-rich drink RGPD (150 mL) containing 1.5 g of polyphenols. To evaluate metabolic responses during both fasting and postprandial states, participants participants consumed a standardized test meal at the end of the 6 weeks. This standard meal was preceded by the consumption of the Control drink (Placebo) 60 minutes prior.
224052293|NCT05561361|DRUG|Spironolactone|Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
224052294|NCT01906775|OTHER|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
224052295|NCT02043821|DRUG|Capecitabine|14days
224052296|NCT02043821|OTHER|placebo|14 days
224052297|NCT06243406|OTHER|Intravitreal injection of anti-VEGF|Intravitreal injection of anti- vascular endothelial growth factor (VEGF) treatment
224052298|NCT00199446|DRUG|Istradefylline (KW-6002)|
224052299|NCT04425720|DEVICE|LifeSignals Biosensor 1AX*|Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX\* and a pulse oximeter.
224052300|NCT04425720|OTHER|Standard of Care|This group will be treated based on standard of care at our institution.
224052301|NCT00947700|BEHAVIORAL|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
224052302|NCT01614938|DRUG|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
224052303|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
224052304|NCT01614938|DRUG|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
224052305|NCT01614938|RADIATION|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
224052306|NCT01614938|DRUG|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
224144812|NCT02726113|DRUG|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
224300523|NCT04226573|OTHER|Preoperative anxiety levels|"Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale."
223440904|NCT02168777|DRUG|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
223440905|NCT05243563|DEVICE|MonaLisa Touch|3 laser treatments at 6 week intervals for 6 months by a single trained operator
223440906|NCT05243563|DRUG|Topical steroid|self-applied topical steroid therapy using clobetasol propionate 0.05%
223440907|NCT06728709|DIAGNOSTIC_TEST|ultrasound detection of any abnormal ultrasonographical findings.|"ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress.~While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 8-region technique will be used. The areas are four on each side of the chest. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left . Each region will be scored using the LUS aeration score. as follows: 0, A-pattern with 0-2 B-lines; 1, more than 2 separated B-lines; 2, multiple coalescent B-lines; or 3, lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 24.~posterior region will be assessed if needed and if feasible. The venous status will be assessed through a subcostal view for inferior vena cava diameter."
223440908|NCT02510703|OTHER|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
223440909|NCT02329782|BEHAVIORAL|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
223440910|NCT05229627|DRUG|MPH|the drug would be prescribed to patients without any contraindication
224300524|NCT02033330|DIETARY_SUPPLEMENT|phenolics form orange peel|
223440911|NCT05229627|DRUG|ATX|the drug would be prescribed to patients without any contraindication
224052307|NCT00290186|DEVICE|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
224052308|NCT00290186|DEVICE|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
224052309|NCT04752176|DEVICE|ØREBLUE® Method|"The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence."
224052310|NCT02882490|BEHAVIORAL|Parent Training|
224052311|NCT02882490|OTHER|Supportive Therapy|
224300525|NCT00004734|DRUG|pyridoxine|
224052312|NCT02895503|BEHAVIORAL|Yoga|Participate in yoga
224052313|NCT02895503|BEHAVIORAL|Support Group Therapy|Participate in emotional support group therapy
224052314|NCT02895503|OTHER|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
224144813|NCT02726113|OTHER|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
224144814|NCT01305213|BIOLOGICAL|Bevacizumab|Given IV
224144815|NCT01305213|DRUG|Fosbretabulin Tromethamine|Given IV
224144816|NCT01305213|OTHER|Laboratory Biomarker Analysis|Correlative studies
224144817|NCT05588180|PROCEDURE|FVD/FAD ratio guided|Ultrasound-guided ratio
224144818|NCT05588180|PROCEDURE|PPV|PPV
224144819|NCT01511510|DRUG|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
224144820|NCT01511510|DRUG|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
224144821|NCT01511510|DRUG|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
224144822|NCT01511510|DRUG|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
224300526|NCT00004734|DRUG|cyanocobalamin|
224300527|NCT00004734|DRUG|folic acid multivitamin|
224300528|NCT01876550|DRUG|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
223440912|NCT05240703|DEVICE|Stabilization splint treatment|The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
223440913|NCT03153345|DEVICE|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
223440914|NCT03153345|BEHAVIORAL|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
224052315|NCT02895503|OTHER|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
224052316|NCT00075595|DRUG|FOLFIRI regimen|
224052317|NCT00075595|DRUG|fluorouracil|
224052318|NCT00075595|DRUG|irinotecan hydrochloride|
223440915|NCT03115593|PROCEDURE|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
224052319|NCT00075595|DRUG|leucovorin calcium|
224052320|NCT00833950|DEVICE|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
224052321|NCT04247958|PROCEDURE|Colorectal resection|Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
224052322|NCT05167682|OTHER|Prehabilitation program|Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
224052323|NCT00071942|BIOLOGICAL|recombinant vaccinia-MUC1 vaccine|Given intradermally
224052324|NCT00071942|BIOLOGICAL|recombinant vaccinia-TRICOM vaccine|Given intradermally
224052325|NCT00071942|OTHER|laboratory biomarker analysis|Correlative studies
224052326|NCT00071942|PROCEDURE|quality-of-life assessment|Ancillary studies
224052327|NCT02911506|OTHER|Polysomnography|
224052328|NCT04194359|DRUG|Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine|Humanized PD-1 antibody (Sintilimab, IBI308)+bevacizumab+oxaliplatin+capecitabine
224052329|NCT01590550|PROCEDURE|Use of citrate based dialysate|Use of heparin free citrate based dialysate
224052330|NCT06633367|OTHER|Increasing time in nature|This intervention includes requesting an increase in time spent outdoors, eligibility to receive a prize, and information on peer performance.
224052331|NCT06280482|DRUG|Nicotinamide riboside (NR)|Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
224052332|NCT03388632|DRUG|rhIL-15|IL-15 is a stimulatory cytokine that activates the immune system, inducing proliferation of T lymphocytes and NK cells. Administration of recombinant human IL-15 (rhIL-15) has been shown to result in a dramatic increase of circulating CD8+T cells and NK cells; these changes in immune cell populations suggest potential for anti-tumor activity.
224052333|NCT03388632|DRUG|Ipilimumab|Ipilimumab is a fully human monoclonal antibody against CTLA-4, a receptor present on the surface of activated T cells that functions as an immune checkpoint. Immune checkpoints pathways typically act to downregulate T cell activity and are co-opted by tumors to allow the malignant cells to evade the immune response. Blocking the engagement of CTLA-4 with ipilimumab allows infiltrating T cells to mount an anti-tumor response. Ipilimumab is approved by the FDA for the treatment of certain patients with melanoma and has shown clinical activity in other tumor types as well.
224052334|NCT03388632|DRUG|Nivolumab|Nivolumab is a humanized monoclonal antibody against programmed death 1 (PD-1), a receptor present on the surface of activated T cells that functions as an immune checkpoint. One of the ligands for PD-1, PD-L1, is commonly expressed by tumor cells. Similar to inhibition of the CTLA-4 pathway by ipilimumab, blocking of PD-1/PD-L1 signaling by nivolumab allows infiltrating T cells to mount an an immune response against the tumor. Nivolumab is approved as a single agent for several cancer types, as well as for the treatment of advanced melanoma in combination with ipilimumab.
224052335|NCT04192968|OTHER|Cortical auditory evoked potentials|Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.
224052336|NCT04192968|OTHER|Additional exams|"* Cortical auditory evoked potentials Recording of automated cortical auditory evoked potentials in response to a vocal stimulus.~* Recording of cortical auditory evoked potentials in response to a click~* Realization of electrical potentials via the implant Followed up once a year during a visit scheduled for usual care, for 3 years, that to say up to 6 years post-implant."
224144823|NCT01511510|DRUG|Placebo|Placebo oral solution Q24 hours for 14 days
224163912|NCT05092763|BEHAVIORAL|Healthy Lifestyle Control|Participants assigned to this study arm are instructed to go about their usual activities and receive education about physical activity and a healthy lifestyle for ovarian cancer patients. They are encouraged to download the free Cancer.Net mobile app and visit the cancer.net website for educational materials related to ovarian cancer and survivorship. At the end of the 9-12 week intervention, participants in the Healthy Lifestyle group receive a Fitbit for their optional, personal use after surgery.
224163913|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
224163914|NCT00742846|DRUG|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
224300529|NCT01876550|DRUG|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
224052337|NCT06218472|OTHER|Day Hospital Treatment|Scheduling of 12 half-day sessions per week, alternating between sessions with only the patients or involving the entire family. Close medical monitoring and multidisciplinary interventions during sessions (pediatrician, psychiatrist, dietitian, recovered former patients...).
224052338|NCT06218472|OTHER|"Multidisciplinary follow-up as usual within the service"|"Multidisciplinary follow-up as usual within the service"
224052339|NCT06218472|OTHER|Conduct semi-structured qualitative interviews|Conduct semi-structured qualitative interviews
224052340|NCT05741307|BEHAVIORAL|Self-hypnosis application|"The Hypnotidoo application offers screenless self-hypnosis sessions for 5-12 year olds. Each session lasts 6 to 8 minutes and focuses on one of the following themes: stress and anxiety, sleep, daily troubles and discomforts, hypersensitivity, hyperactivity and difficulty concentrating, self-confidence, difficult life events, anger. Each session begins with breathing and refocusing work, followed by self-hypnosis through stories and metaphors suitable for children.~The application will be used by patients in the context of research for 6 weeks, 5 days out of 7 in parallel with the usual treatment."
224052341|NCT05741307|OTHER|Questionnaires|"Before and after (at T0, T1, T2 and T3) the 6-week period of use of the application and a wash-out period of 2 weeks (= usual treatment only), self- and hetero-questionnaires which constitute the gold standard for evaluating the symptoms of inattention and anxiety are proposed: Conners III, Child Behavior Checklist (CBCL) and Revised-Children's Manifest Anxiety Scale (R-CMAS).~* T0: inclusion~* T1: 6 weeks after T0 (inclusion)~* T2: 2 weeks after T1~* T3: 6 weeks after T2"
224052342|NCT06083844|DRUG|Pembrolizumab|Given by IV (vein)
224052343|NCT06083844|DRUG|Bevacizumab|Given by IV (vein)
223440916|NCT03115593|PROCEDURE|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
223440917|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
223440918|NCT03992378|DEVICE|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
224052344|NCT06083844|DRUG|Cyclophosphamide|Given by mouth
224052345|NCT03706482|BIOLOGICAL|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
224052346|NCT05635669|DEVICE|Sacral acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached transversely to the needle handles at bilateral Huiyang(BL35) and Zhongliao(BL33) .
224052347|NCT05635669|DEVICE|Abdominal acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. In this group, paired electrodes from the electroacupuncture apparatus were attached to the needle handles respectively at Zhongji(RN3) and one side of Dahe(KI12), as well as Guanyuan(RN4) and another side of Dahe(KI12).
224144824|NCT04924010|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|The CBT intervention will be delivered by a Senior Psychologist with seventeen years of hospital psychology experience, six in the treatment of chronic pain patients. Sessions are delivered in one hour, individual therapy appointments to patients, and there is an emphasis on relaxation training, cognitive restructuring, exercise and pacing, behavioral activation, improving sleep, and anger management. Standardized worksheets and homework assignments are an important part of CBT-CP and these will be given (post or email) to patients who will be asked to read and complete in terms of complementing the consultations. This intervention has been developed with reference to two sources: A successful national implementation of CBT for chronic pain (CBT-CP) using video teleconferencing format \[Connolly KS et al\] AND an evidence-based CBT manual specifically designed to treat chronic pain \[Murphy JL et al\].
224163915|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
224163916|NCT00742846|DRUG|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
223440919|NCT00963846|DRUG|placebo|matching pill placebo
223440920|NCT00963846|DRUG|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
223440921|NCT00963846|DRUG|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
223440922|NCT00963846|DRUG|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
223440923|NCT06515964|OTHER|observational study|observational study, no intervention
224163917|NCT03489850|DRUG|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
224163918|NCT03489850|OTHER|Placebo|Placebo is matched to ibudilast active medication.
224163919|NCT01526005|DRUG|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
224163920|NCT01526005|DRUG|Transdermal Placebo Patch|1 patch per day; 8 weeks total
223566763|NCT06897059|OTHER|Vuka+ application|The Vuka+ smartphone app included PrEP daily reminders, tracking for pill taking, resources for sexual reproductive health including quizzes and articles, and chat access to other Vuka+ users and medical expert.
224163921|NCT00053222|DRUG|arsenic trioxide|
223566764|NCT06896084|DEVICE|da Vinci Xi System|A group of surgeons will make determinations as to the material within identical balloons while using the da Vinci Xi System
224052348|NCT05635669|DEVICE|Alternating acupoints acupuncture|Before treatment, the participants will be asked to go to the toilet. All treatments will be performed after skin disinfection. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate the sensation of de qi. The electroacupuncture stimulation lasted for 30 minutes with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive three treatments per week (every other day), each lasting 30 minutes, for a total of 18 sessions over the course of 6 weeks. The follow-up sessions are on week 18, 30, 42 and 54. The application of electroacupuncture is the same as Sacral group and Abdominal group.
224052349|NCT04085523|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
224052350|NCT04085523|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
224052351|NCT06284902|DRUG|Fexofenadine HCl Coated tablet|Film-coated tablet.
224052352|NCT06284902|DRUG|Fexofenadine HCl New Formulation Tablet|New formulation tablet.
224052353|NCT02848950|DRUG|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
224052354|NCT02524470|DEVICE|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
224052355|NCT02524470|DEVICE|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
224052356|NCT01766128|DRUG|Zonisamide|The first arm will be treated by zonisamide
224052357|NCT01766128|DRUG|Placebo|The second arm will receive placebo
224052358|NCT06985797|OTHER|Funfitness program with no music|Group A will undergo FunFitness program without music (Control Group)
224052359|NCT06985797|OTHER|funfitness program with slow music|Group B will undergo FunFitness program with slow music (Experimental Group)
224052360|NCT06985797|OTHER|Funfitness program with fast music|Group C will undergo FunFitness program with fast music (Experimental Group)
224052361|NCT06986239|BIOLOGICAL|PCV-LITE|Fractional dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)
224052362|NCT06986239|BIOLOGICAL|PCV-LITE+LVA|Fractional dose of pneumococcal polysaccharide conjugate vaccine with 1 mg of LiteVax Adjuvant (LVA)
224052363|NCT06986239|BIOLOGICAL|PCV20|Standard (full) dose of pneumococcal polysaccharide conjugate vaccine without LiteVax Adjuvant (LVA)
224144825|NCT04924010|BEHAVIORAL|Education and Mindfulness|To control for differences in attention between the two interventions, patients in the mindfulness group will also have two meetings before the surgery and two meetings afterward. As the same person will be providing the CBT-CP and educational interventions, this confounding factor will be controlled for. The control intervention consists of discussing pain education, as derived from the self-management section of the chronic pain Ireland website (https://www.chronicpain.ie/our-services/self-management) and the persistent pain section of the pain toolkit website (https://www.paintoolkit.org/persistent-pain). Four mindfulness-based stress reduction exercises will be completed including an introductory session on mindful breathing, a guided meditation, progressive muscle relaxation, and a body scan. These sessions will last about half an hour.
224144826|NCT02905916|DRUG|PEG-rhG-CSF|
224052364|NCT06986239|BIOLOGICAL|PCV20+LVA|Standard (full) dose of pneumococcal polysaccharide conjugate vaccine with LiteVax Adjuvant (LVA)
224052365|NCT06985615|DRUG|Single dose of HDM1002 on Day 1|Single dose of HDM1002 will be administered on Day 1
224052366|NCT06984575|OTHER|No interventions|No interventions
224052367|NCT06984185|DIAGNOSTIC_TEST|combined assay on capillary blotting paper|combined assay on capillary blotting paper
224144827|NCT01693718|DRUG|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
224144828|NCT01693718|DRUG|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
224144829|NCT01693718|DRUG|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output \> 100 cc/ hour.
224052368|NCT06985680|BEHAVIORAL|LINE@ Diabetes Health Education Chatbot|"Upon opening the LINE application, the research subjects need to enter Diabetes Smart Helper in the LINE@ Diabetes Health Education Chatbot. Once added to the program, the LINE interface will directly display six small windows for diabetes symptoms/complications, diet, medication, exercise, mental health, and others, facilitating self-selection by users."
224052369|NCT06606587|DEVICE|Comfort-in Jet Injection Method|Application of Comfort-in Jet Injection Method: Comfort-in jet injection method was used for palatal anesthesia of the permanent 1st molar.
224052370|NCT06606587|OTHER|Traditional Dental Injection|Application of Traditional Dental Injection Method: Traditional Dental Injection method was used for palatal anesthesia of the permanent 1st molar.
224144830|NCT06092632|OTHER|Pigmented rice|Cooked black rice
224052371|NCT06985407|DIETARY_SUPPLEMENT|Grape extract (VinteraTM Premium Red Grape)|Each condition will last 7 days for assessing both acute and chronic effects, and there will be a wash-out period of 7 days.
224052372|NCT06985407|DIETARY_SUPPLEMENT|Control (placebo) group|Each condition will last 7 days for assessing both acute and chronic effects, and there will be a wash-out period of 7 days.
224052373|NCT04870411|BIOLOGICAL|Blood sample|Humoral and cellular immune response. Sample before vaccination, 1 month, 3 months, 6 months and 12 months post-vaccination
224144831|NCT06092632|OTHER|White Rice|Cooked white rice
224144832|NCT05371470|DEVICE|Ellipsis Health Voice Application|Smartphone application that utilizes voice biomarkers to assess for potential presence and severity of depression and anxiety
224144833|NCT01431261|OTHER|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
224144834|NCT01431261|BEHAVIORAL|Pain management|Educational sessions in pain management 4 times
223440924|NCT03260114|OTHER|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
223440925|NCT01238341|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
223440926|NCT04047823|DEVICE|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
223440927|NCT00546312|DEVICE|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
223440928|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
224052374|NCT06590493|DRUG|doxecitine and doxribtimine|TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.
224052375|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule]|1st phase and 2nd phase : 1 capsule per day of OM-89 for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of OM-89 for 10 consecutive days each month for three months.
224052376|NCT06588010|DRUG|OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]|"1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months."
224052377|NCT06602921|DIETARY_SUPPLEMENT|TruBeet inorganic beetroot juice|400 mg nitrate-rich beetroot powder, mixed with 300 mL water.
224144835|NCT04982835|DEVICE|M6-C Artificial Cervical Disc|An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed so that the M6-C artificial cervical disc can be placed into the space where the damaged disc was removed. This procedure will be performed using x-ray technology (fluoroscopy) guide the surgeon in placement of the M6-C in between the cervical vertebrae. This process will be repeated to replace the second damaged disc.
224144836|NCT04982835|DEVICE|ACDF|One of four FDA-approved cervical plate systems will be used for the ACDF. An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed. Then, a piece of donor bone will be placed in the space where the damaged disc was removed and a metal plate will be screwed into the bones above and below the disc. This procedure will be performed using x-ray technology (fluoroscopy) to guide the surgeon in the placement of the cervical plate system. This process will be repeated to treat the other damaged disc.
223440929|NCT01229319|DRUG|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
223440930|NCT02117219|BIOLOGICAL|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
223440931|NCT02117219|DRUG|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
223440932|NCT02117219|BIOLOGICAL|tremelimumab|tremelimumab will be administered by IV infusion
223440933|NCT03300414|OTHER|One time blood draw|Same as part 1
223440934|NCT02889614|OTHER|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
223440935|NCT04826835|BEHAVIORAL|Prehabilitation intervention|"Participants will:~* Receive four supervised exercise classes (twice per week for two weeks) one-to-one by an exercise specialist;~* Practice six sessions of home-based exercise (three times per week for two weeks);~* Practice unsupervised respiratory muscle training at home (twice daily for two weeks);~* Receive usual care."
223566765|NCT06895421|BEHAVIORAL|Cognitive behavior therapy based guided self help manual for psychosis plus treatment as usual|The Cognitive Behavior Therapy-Based Guided Self-Help (CBTp-GSH) manual is a structured intervention designed specifically for individuals with psychosis, particularly those diagnosed with Schizophrenia Spectrum Disorders. This manual offers a culturally adapted approach, providing participants with tools and strategies rooted in Cognitive Behavioral Therapy (CBT) principles, tailored to be delivered through guided self-help.
223566766|NCT06895421|DRUG|Treatment as usual|anti psychotic drugs which they are already using
223741002|NCT07189598|PROCEDURE|conventional or a moderately hypofractionated|"* Conventional fractionation includes the prescription of a total dose of 78 Gray in 39 fractions to the prostate gland (and seminal vesicles, in case of T3b disease), and a dose de 50Gy in 25 fractions to pelvic nodal areas.~* Moderate hypofractionation includes the prescription of a total dose of 60 Gray to the prostate gland (and seminal vesicles, in case of T3b disease), and 44 Gray to pelvic nodal areas in 20 fractions using a simultaneous integrated boost (SIB)"
223741003|NCT07190820|PROCEDURE|digital impression|complete arch implant impression with intraoral photogrammetry
224052378|NCT06602921|DIETARY_SUPPLEMENT|Caffeine|6 mg/kg caffeine powder in capsule form.
224052379|NCT06602921|OTHER|Cold pressor test|3 min cold pressor test using the left foot in cold water (0-2 degree).
224052380|NCT06864858|DEVICE|etafilcon A with PVP with cosmetic pattern contact lens|Test Lens
224052381|NCT06864858|DEVICE|1-DAY ACUVUE® DEFINE® with LACREON®, FRESH Honey|Control Lens
224052382|NCT00733915|DEVICE|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
224052383|NCT06647615|DEVICE|VR headset|The VR portion of the study will last for 8 weeks. You will be asked to use your headset on a daily basis for at least 30 minutes, but you are free to use the headset as much as you would like.
224052384|NCT06675123|PROCEDURE|Biopsy|Undergo optional tissue biopsy
224052385|NCT06675123|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224052386|NCT06675123|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224052387|NCT06675123|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224300530|NCT01876550|DRUG|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
223440936|NCT04826835|BEHAVIORAL|Health education control|"Participants will:~* Receive four recorded health education talks (twice per week for two weeks)~* Receive a brief health education booklet on dietary education for chronic lung conditions, preoperative preparation, and postoperative recovery~* Receive usual care."
223440937|NCT00499343|DRUG|Etoposide|150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.
223440938|NCT00499343|DRUG|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
223440939|NCT00499343|DRUG|GM-CSF|250 mcg/m\^2 injection given every evening till the completion of apheresis.
223440940|NCT00499343|DRUG|Isophosphamide|10 g/m\^2 given intravenously continuous infusion over 72 hours.
223440941|NCT00499343|DRUG|Rituximab|Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.
223440942|NCT00499343|PROCEDURE|Apheresis|Peripheral blood stem cell collection.
224052388|NCT06675123|DRUG|BTK Inhibitor|Given BTK inhibitor
224052389|NCT06675123|PROCEDURE|Computed Tomography|Undergo PET/CT
224052390|NCT06675123|DRUG|Pacritinib|Given PO
223440943|NCT05992259|DEVICE|TENS|TENS will be performed from the moment of admission to the PCI, during the PCI and for the next 30 minutes after it.
223440944|NCT02153125|DRUG|Eplerenone|
223440945|NCT03584230|BEHAVIORAL|Assigned to positive group|See arm description
223440946|NCT03584230|BEHAVIORAL|Assigned to negative group|See arm description
224052391|NCT06675123|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224052392|NCT06687356|PROCEDURE|Surgery with Intraoperative Optical Coherence Tomography application|Surgery with the application of intraoperative optical coherence tomography technique. Intraoperative optical coherence tomography technique can provide intraocular images and show changes in intraocular structures, assisting in analyzing the correlation between preoperative, intraoperative anterior segment structural changes and postoperative surgical effects in patients with lens diseases.
224052393|NCT06687356|PROCEDURE|Conventional surgery|Conventional lens surgery, without the application of intraoperative optical coherence tomography technique.
223440947|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
223440948|NCT01540747|DIETARY_SUPPLEMENT|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
223440949|NCT06138717|OTHER|yoga based exercises|Aerobic exercises will be performed with a lower extremity ergometer for 30 minutes and 12 sessions.In group 2, in addition to aerobic exercises, spinal stretching, relaxation, respiration and meditation will be performed. A yoga-based exercise programme consisting of exercises will be applied for 40 minutes and 12 session
223741004|NCT07190820|PROCEDURE|conventional impression|conventional open tray splint impression
224052394|NCT05556096|COMBINATION_PRODUCT|ALXN1720|Combination product consisting of syringe prefilled with ALXN1720.
224052395|NCT05556096|COMBINATION_PRODUCT|Placebo|Combination product consisting of syringe prefilled with placebo.
224052396|NCT04000282|DRUG|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
224052397|NCT05047250|DRUG|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by investigators.
224052398|NCT06714123|DRUG|Senicapoc|administering 30 mg senicapoc a day, in addition to standard of care.
224052399|NCT06714123|DRUG|Placebo|Tablets similar in size and color
224052400|NCT06903416|OTHER|Transcutaneous Cervical Spinal Cord Stimulation|"Cervical transcutaneous spinal cord stimulation will be delivered following previously reported guidelines. Circular (1.25) electrodes will be placed over the cervical spinal cord between the C3 and C4 vertebral level, with rectangular return electrodes placed either over the clavicles or iliac crests. Biphasic stimulation will be delivered continuously at 30Hz, with a 1ms pulse width, and overlapping 10kHz carrier frequency (Gelenitis et al 2024; Moritz et al 2024). Stimulation will be delivered at a current intensity below motor threshold, that is below the intensity required to elicit a muscle twitch. Cervical tSCS will be delivered for at least 60 minutes during each training session, and FTP will occur during the active stimulation."
224300531|NCT00602277|OTHER|Laboratory Biomarker Analysis|Correlative studies
224300532|NCT00602277|BIOLOGICAL|Wild-type Reovirus|
224300533|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
223440950|NCT04542876|DRUG|Guduchi Ghan Vati|Guduchi Ghan Vati was orally administered 2 tablets (1000 mg) twice daily for 2 weeks.
223440951|NCT00851188|BEHAVIORAL|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
223440952|NCT00851188|BEHAVIORAL|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
223440953|NCT00851188|OTHER|Waiting list|Waiting list
223440954|NCT03870750|OTHER|Supportive Palliative Care|focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects
223440955|NCT03870750|OTHER|Clinical Management|physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education
224300534|NCT00472836|DRUG|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
224300535|NCT00697684|DRUG|Antithymocyte Globulin|
224144837|NCT07011901|BEHAVIORAL|Exposure and Response Prevention|Exposure and response prevention (EX/RP) is the gold-standard behavioral treatment for OCD. It involves confronting the content of obsessions (distressing thoughts, images, or impulses) and resisting the urge to engage in compulsions (observable behaviors or mental acts that are repeated to reduce the anxiety/distress associated with compulsions).
223440956|NCT03870750|OTHER|Best Practice|Given standard of care
223440957|NCT03870750|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
223440958|NCT03870750|OTHER|Questionnaire Administration|Ancillary studies
224052401|NCT06903416|OTHER|Paired Corticospinal Motoneuronal Stimulation|Paired transcranial magnetic stimulation and nerve stimulation will be implemented following a previously-published protocol for individuals with SCI (Jo et al 2023). Two figure-eight coils will be used to deliver bilateral magnetic stimulation of the motor cortex and will be combined with synchronous electrical stimulation of the brachial plexus and ulnar nerves, bilaterally. The timing of stimuli will be determined to ensure that electrical volleys arrive at the corticospinal motoneuronal synapse at an appropriate interval to induce long term potentiation. During each session, 360 paired stimuli will be delivered at a frequency of 0.2 Hz. The stimulation paradigm should take approximately 30 minutes. Following this, participants will then complete 60 minutes of FTP.
224052402|NCT06903416|OTHER|Functional Task Practice|A typical rehabilitation program will be defined and delivered in consultation with physical and occupational therapists. The program will consist of functional tasks including repetitive activities of gross upper extremity movement, isolated finger movements, simple and complex pinch, and grasping activities. For each category, 4-10 activities with various difficulty levels will be identified. Each participant will perform at least 1-2 exercises within each category during each treatment session. Activities in each category will be chosen according to the participants' ability and adjusted based on the evolution of the ability to perform the functional task over time (graded training).
224052403|NCT06929572|PROCEDURE|Autologous umbilical cord patch|Surgery will occur from birth to 24 hours of age. The autologous umbilical cord patch is harvested at time of delivery and immediately processed in a sterile setting in order to create a dural patch as a spinal cord cover to close the developmental defect within a few hours after birth.
224052404|NCT07117266|OTHER|radiologists reference AI reports|Radiologists generate reports with reference to AI reports
224052405|NCT07138937|PROCEDURE|Root canal treatment in primary molars with irreversible pulpitis|Root canal treatment in primary molars with irreversible pulpitis followed by coronal restoration with stainless-steel crowns in a single visit.
224144838|NCT00638924|OTHER|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
224144839|NCT01325324|DEVICE|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
224144840|NCT02547636|OTHER|Observational study|No intervention will be used in this study.
224300536|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
224144841|NCT02969447|DRUG|Administration of 10 units of intra venous oxytocin after fetal expulsion|
224144842|NCT05010525|DRUG|ATG-016|48 patients enrolled, orally, each 3 week (21-day) a cycle
224300537|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
223440959|NCT03870750|OTHER|Quality-of-Life Assessment|Ancillary studies
223440960|NCT03870750|OTHER|Survey Administration|Complete surveys
223440961|NCT05572892|OTHER|FAC scale|"Measurement of walking dependency according to the FAC scale :~* in the first week after stroke (in neurology by physiotherapists),~* then at 6 weeks, 12 weeks and 6 months (by telephone).~Trunk Control Test score (in the first week after stroke, by physiotherapists).~MRC score of hip extension and hip flexion, knee flexion/extension, ankle plantar and dorsal flexion (in the first week after stroke, by physiotherapists).~PHQ-9 depression scale (at 6 weeks by phone).~Denutrition (weight loss between neurology weight and 6-week weight, BMI +/- albumin).~Other intercurrent medical problems (at each telephone interview)."
223440962|NCT00259428|DRUG|Dronedarone (SR33589)|oral administration
223440963|NCT00259428|DRUG|placebo|oral administration
223440964|NCT00020202|DRUG|FR901228|
223440965|NCT00000613|BEHAVIORAL|dietary supplements|
223440966|NCT00000613|DRUG|genistein|
223741005|NCT07191054|DEVICE|LifeFlow Rapid infuser|Use of rapid infuser to fluid resuscitate
223440967|NCT00000613|BEHAVIORAL|diet, soy proteins|
223440968|NCT01482299|DRUG|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
223440969|NCT06033170|DEVICE|CELOX™ PPH|Celox™ PPH is intended to be a physical haemostatic treatment for control and treatment of uterine postpartum hemorrhage (PPH) when conservative management is warranted.
223741006|NCT07191054|DEVICE|Push Pull|Use of Push Pull syringe technique to fluid resuscitate
223741007|NCT07191119|DEVICE|Soterix tVNS device|"Active transcutaneous auricular vagus nerve stimulation (tVNS) using the Soterix device.~Stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold."
223741008|NCT07191119|DEVICE|Soterix tVNS device (sham programmed)|The sham stimulation used the Soterix device, but without active electrical stimulation. The procedure mimics the verum condition in duration and setup. Inactive stimulation is delivered nightly for 20 minutes at 80% of the participant's discomfort threshold.
223440970|NCT05492747|OTHER|Kangaroo Care an Effect|Researchers evaluated vital signs and oxygen saturation of preterm infants in the kangaroo care group 15 minutes before kangaroo care. After the baby's mother was admitted to the NICU, she was assisted by the researcher for hand hygiene and they went to the incubator together. The mother was seated in a comfortable chair next to the incubator. After the researcher covered the head and back of the preterm baby with a baby blanket, she took it from the incubator and placed it between the mother's breasts, with the head up and upright. The baby was supported not only by the neck and shoulders, but also by the whole body. Skin contact between mother and baby was ensured at the highest level. The baby was positioned so that its lips were touching the mother's nipple. The researcher waited until the baby opened its mouth.
223440971|NCT02249507|OTHER|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
223440972|NCT03872817|OTHER|Intervention ProLiSMentAl|"Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available."
223440973|NCT04557436|DRUG|PBLTT52CAR19|gene therapy
223440974|NCT02626650|OTHER|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
224052406|NCT07138937|DEVICE|EDDY system for sonic activation of irrigation|sonic activation of irrigation with EDDY system during root canal treatment in primary molars
224144843|NCT01575405|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
224144844|NCT01575405|DRUG|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
224144845|NCT01575405|DRUG|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
224144846|NCT07014267|DEVICE|Intervention Group (Virtual Reality intervention)|"Patients will experience the VR mindfulness intervention using the Tripp App or comparable applications.~Anxiety levels will be measured using the STAI before the VR experience, immediately after the VR experience, and after the procedure."
224144847|NCT07017933|DEVICE|Renal assist device|The JuxtaFlow RAD includes two endoscopically placed ureteral catheters connected to a bedside pump system. The catheters are designed to deliver a mild, controlled negative pressure (-15 mmHg ± 2mmHg) into the renal pelvis of each kidney for up to 72 hours. This pressure is designed to diffuse through each of the million nephrons lowering intratubular pressure thereby improving the filtration gradient at the glomerulus while supporting overall kidney function.
224144848|NCT06875765|OTHER|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
224052407|NCT07138937|DEVICE|side-vented needle|conventional irrigation with side-vented needle without activation during root canal treatment in primary molars
224052408|NCT06936657|OTHER|optimized carbohydrate diet|In this dietary pattern, 50-60% of total energy is derived from carbohydrates, 15-20% from protein, and 25-30% from fat. Among the carbohydrates, resistant starch (RS) constitutes 15-20% of daily starch intake (around 40 g/day), slowly digestible starch (SDS) 5%, rapidly digestible starch (RDS) 75-80%, with dietary fiber at 20-40g per 1000 kcal and free sugars contributing less than 5% of total energy.
224052409|NCT06936657|OTHER|conventional diabetes diet|In this dietary pattern, 50-60% of total energy is derived from carbohydrates, 15-20% from protein, and 25-30% from fat. Among the carbohydrates, resistant starch (RS) constitutes 5% of daily starch intake, slowly digestible starch (SDS) 5%, rapidly digestible starch (RDS) 90%, with dietary fiber at 14g per 1000 kcal and free sugars contributing less than 5% of total energy.
224052410|NCT06935656|OTHER|Tablet-based executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented in a gamified environment, and each executive function is stimulated for an equal amount of time through activities that children complete on a tablet.
224052411|NCT06935656|OTHER|Traditional executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented as a game, and each executive function is stimulated for an equal amount of time through activities that require motor skills, the manipulation of cards and the use of paper and pencil tasks.
224144849|NCT06875765|OTHER|18F-PE2I PET-CT|Positron Emission Tomography (PET) of dopamine transporter (DAT) using the radioligand 18F-FE-PE2I.
224144850|NCT06875765|DIAGNOSTIC_TEST|MRI brain|Magnetic resonance imaging of brain volume.
223440975|NCT06443515|DIAGNOSTIC_TEST|lung ultrasound|Lung ultrasound examinations will be performed within 6 hours before and after blood transfusion to assess interstitial-alveolar fluid retention and calculate a LUS score
223440976|NCT04524767|BEHAVIORAL|SBIRT|Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.
223440977|NCT04524767|BEHAVIORAL|Referral as Usual|We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
223440978|NCT04024878|DRUG|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
223440979|NCT04024878|BIOLOGICAL|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
223440980|NCT04024878|PROCEDURE|Core Needle Biopsy|Surgical procedure
223440981|NCT02474355|PROCEDURE|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
223440982|NCT02474355|PROCEDURE|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
223566767|NCT06897371|OTHER|Games-based education|"A 5-question trial test on Kahoot usage will be applied to the students in the intervention group (questions must be prepared in advance, students must have full internet connection, students must enter the Kahoot application with their phones, students must enter the code required to enter the platform, etc.). The questions that make up the trial test will be created independently of the subject covered in the theoretical training and students will be adapted to Kahoot. After the 2-hour theoretical training is completed, reinforcement will be provided using the 25-question game-based learning method on the Kahoot platform. Brief explanations will be made to reinforce the subject and the reinforcement session will last for 30 minutes. The Self-Confidence/Competence Scale in Patient Intervention, Postpartum Hemorrhage Management Information Form and Motivation Scale Regarding the Teaching Material will be applied to both groups as a post-test."
224052412|NCT06935656|OTHER|Mixed executive function intervention|This intervention contains activities that have been designed to stimulate the development of children's executive functioning (working memory, inhibitory control and cognitive flexibility). Each activity is presented as a game, and each executive function is stimulated for an equal amount of time. Half of the intervention sessions utilize activities that require motor skills, the manipulation of cards and the use of paper and pencil tasks, and the other half are activities that are completed on a tablet.
224052413|NCT07145827|DRUG|Metfomin|Metformin Tab. 500mg twice daily for 12 months (titrated to tolerance if needed).
224052414|NCT07145827|DRUG|tamoxifen|Standard prescribed oncological dose.
224052415|NCT07145827|DRUG|Placebo matching Metformin|"An inert, film-coated tablet identical in appearance and packaging to metformin 500 mg (same size, shape, color, coating, weight, and dosing schedule), manufactured without active ingredient using standard excipients (e.g., microcrystalline cellulose, starch/croscarmellose, povidone, magnesium stearate) and identical film coat (e.g., hypromellose, polyethylene glycol, titanium dioxide). Packaged in sealed blisters to minimize odor/taste cues. Dispensed by the investigational pharmacy per randomization; to be taken twice daily"
224144851|NCT00897325|OTHER|Cytology Specimen Collection Procedure|Correlative studies
224144852|NCT00897325|OTHER|Laboratory Biomarker Analysis|Correlative studies
224144853|NCT06627777|BEHAVIORAL|Laboratory tasks in early adolescence|Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
224144854|NCT02259127|DRUG|Dolutegravir|
224144855|NCT02259127|DRUG|Standard of Care|PI or non nucleoside transcriptase inhibitors
224144856|NCT06695026|DRUG|RZ-001 Dose 1|RZ-001 Dose 1 and VGCV, Atezolizumab/Bevacizumab
224144857|NCT06695026|DRUG|RZ-001 Dose 2|RZ-001 Dose 2 and VGCV, Atezolizumab/Bevacizumab
224144858|NCT06695026|DRUG|RZ-001 Dose 3|RZ-001 Dose 3 and VGCV, Atezolizumab/Bevacizumab
224144859|NCT04465123|DRUG|Spironolactone or hydrochlorothiazide|"Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours."
224144860|NCT04465123|DRUG|Placebo|"Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours."
224144861|NCT02550314|DRUG|fiblast,gelatin sponge,fibrin glue|
224144862|NCT03509571|OTHER|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
223440983|NCT02474355|PROCEDURE|Baseline ECG|ECG to ensure absence of any cardiac abnormality
223440984|NCT02474355|PROCEDURE|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
223440985|NCT02474355|DRUG|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
223440986|NCT05420493|BIOLOGICAL|CAR-T cells|Drug: CAR-T cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
223440987|NCT05753540|OTHER|Laser therapy|Multiwave locked system laser therapy
223440988|NCT05753540|OTHER|Sham laser therapy|Sham laser therapy
223440989|NCT05373030|BIOLOGICAL|Recombinant adenovirus type-5-vectored COVID-19 vaccine|One dose COVID-19 vaccine
223440990|NCT05545085|DEVICE|Laser Speckle Contrast Imaging using the PerfusiX-Imaging Device|Patient will undergo the standard of care lobectomy for pulmonary cancer. In addition, peroperative imaging using the Laser Speckle Contrast Imaging device will be performed.
224052416|NCT07171151|OTHER|cyst fluid examination|Participants will not undergo any procedures outside of the routine for the study. The cyst fluid obtained during the puncture will be collected in a tube and centrifuged at 3000 rpm for 20 minutes at 4 degrees Celsius. The Eppendorf tubes will be stored at -80 °C until the clear liquid remaining above is taken and examined, without removing the particles that have settled at the bottom of the tube. The biochemical parameters of the cyst fluid obtained from the study participants will be analyzed using the ELISA method. MMP-8, MMP-9, RANKL, and MIP1alpha will be analyzed using commercially available ELISA kits, following the manufacturer's instructions.
224052417|NCT07171112|DRUG|Standard Varenicline Dosing (1 mg BID)|Varenicline PO (oral) 1mg twice daily
224052418|NCT07171112|DRUG|Bupropion 150 mg twice daily|Bupropion 150 mg PO twice daily
223440991|NCT01082796|DRUG|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
223440992|NCT03484624|DEVICE|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
223440993|NCT03298308|DEVICE|Cranial Electric Stimulation|Micro amperage TCDS
223440994|NCT04586465|DRUG|pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin|"Patients will receive 3 cycles pembrolizumab 200mg, fix dose, 60 minute IV infusion combination with chemotherapy.~Chemotherapy regimen: ① Eligible patients with non-squamous cell lung cancer, Pemetrexed 500mg/m2, IV infusion on day 1 and cisplatin 75mg/m2 or carboplatin area under the curve (AUC=5), on day 1 of a 3-week schedule for 3 cycles. ② Eligible patients with squamous cell lung cancer. Patients will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC=5 on day 1 of a 3-week schedule for 3 cycles"
223440995|NCT04747665|OTHER|Patient and endoscopist reported experience|Exploration of patient and endoscopists experiences of colonoscopy.
224052419|NCT07171112|DRUG|Increased Varenicline Dosing (1mg TID)|Varenicline 1mg PO (oral) three times daily
224052420|NCT07170098|DEVICE|EDDY sonic irrigation system|Sonic activation of irrigating solutions during endodontic treatment.
224052421|NCT07170098|DEVICE|EndoActivator (EA) sonic irrigation system|Sonic activation of irrigating solutions during endodontic treatment.
224052422|NCT07170098|DEVICE|980-nm diode laser|Diode laser irradiation during endodontic treatment.
224052423|NCT00546767|BEHAVIORAL|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
224052424|NCT00546767|BEHAVIORAL|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
224052425|NCT00546767|BEHAVIORAL|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
224052426|NCT00546767|BEHAVIORAL|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
224052427|NCT01798368|DEVICE|PBASE system 2.0|
224052428|NCT02231151|BEHAVIORAL|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
224052429|NCT06039124|OTHER|bevacizumab treatment|Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
223440996|NCT04247451|DIAGNOSTIC_TEST|Metabolic profile and nutritional goals in diabetic foot surgery patients|"Nutritional intake: these data will be evaluated daily during preoperative hospitalization, at home, and during the actual hospitalization, from surgical intervention to discharge. Before the follow-up consultation, patients will keep a food diary. The dieticians will calculate intake and need.~Metabolic data: body composition using Bio electrical Impedance Analysis BIA (Nutrilab Akern) and Resting Energy Expenditure REE using indirect calorimetry (Cosmed Q NRG) will be analysed in three timepoints: preoperative, postoperative and at follow-up consultation. This measurements take maximum ten minutes and do not cause discomfort to the participants."
223440997|NCT04653155|BEHAVIORAL|Cognitive behavioural therapy for insomnia|Cognitive behavioural therapy for insomnia
224052430|NCT03690076|OTHER|Endocarditis|Comparison : Endocarditis vs. control
224052431|NCT03690076|OTHER|Obese vs. control|Comparisons : Obese vs. control
224052432|NCT01155362|BIOLOGICAL|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
224052433|NCT01155362|DRUG|Vehice Control|
224052434|NCT06272461|DRUG|Lidocaine IV|Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
224052435|NCT06272461|DRUG|Ketamine Injectable Solution|Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
224052436|NCT04086394|PROCEDURE|Pectoral Nerve Block|Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
224052437|NCT04086394|PROCEDURE|Surgery without Nerve Block|Patient's underwent indicated procedure without regional pectoralis nerve block
224052438|NCT01509495|DEVICE|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
224052439|NCT03697720|DRUG|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
224052440|NCT04031144|PROCEDURE|Ultrafiltration|At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.
223440998|NCT05118217|OTHER|This is a non-interventional study|This is a non-interventional study
223440999|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
223441000|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
223441001|NCT00943501|DRUG|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
223441002|NCT00943501|DRUG|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
223441003|NCT04605926|BIOLOGICAL|EQ001|itolizumab \[Bmab600\]
223566768|NCT06897111|BIOLOGICAL|Implantation of allogeneic cartilage mini-grafts (Allogeneic Cartibeads)|Implantation of allogeneic cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant).
223566769|NCT06896253|DRUG|Pulse bolus corticosteroids|Treatment administration
223566770|NCT06896253|DRUG|Pulse bolus corticosteroids and IVIG|Treatment administration
224052441|NCT05910502|BEHAVIORAL|Autism Family Empowerment Coaching and Training Program|Participants in the intervention group will be connected with Project AFECT Coaches who will provide: Coaching to (1) assure parents understand diagnosis, (2) assist parents in finding accurate, current information about autism, (3) guide parents to free online autism training resources, (4) empower parents to evaluate child's intervention plan holistically, and (5) provide emotional support to reduce stress; Navigation to (1) help family access autism treatments, and (2) connect to early intervention and educational services.
224052442|NCT00683163|DRUG|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
224052443|NCT00683163|DRUG|Ibandronate|150mg by mouth once monthly
224052444|NCT00683163|OTHER|Placebo injection|Daily injections as placebo for PTS 1-84
224052445|NCT00683163|OTHER|Placebo pills|Monthly pills as placebo for oral ibandronate
224052446|NCT00479128|DRUG|Bortezomib|Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
224144863|NCT03509571|OTHER|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
224144864|NCT07026162|DRUG|Oliceridine|For gynecological laparoscopic surgery, general anesthesia was induced with Oliceridine at a dose of 0.06 mg/kg (Yichang Renfu Pharmaceutical Co., Ltd., China). Intraoperative analgesia was administered with a total dose of Oliceridine ranging from 0.1 to 0.15 mg/kg. Postoperatively, Oliceridine was administered through a patient-controlled analgesia (PCA) system.
224144865|NCT07026162|DRUG|Sufentanil|For gynecological laparoscopic surgery, general anesthesia was induced with Sufentanil at a dose of 0.3 µg/kg (Yichang Renfu Pharmaceutical Co., Ltd., China). Intraoperative analgesia was provided with a total dose of Oliceridine ranging from 0.5 to 0.8 µg/kg. Postoperatively, Sufentanil was administered through a patient-controlled analgesia (PCA) system.
224144866|NCT06127966|PROCEDURE|Erector Spinae Plane Block|The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
224163922|NCT03708757|OTHER|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
223441004|NCT04605926|BIOLOGICAL|EQ001 Placebo|EQ001 Placebo
224052447|NCT00479128|DRUG|Gemcitabine|Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
224052448|NCT00479128|DRUG|Doxorubicin|Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
224052449|NCT03919279|DEVICE|active tVNS|tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
224052450|NCT05396079|OTHER|tahini and bread|Fifthy grams of tahini with 2 slices of white bread
224052451|NCT05396079|OTHER|margarine, cheese and bread|46 g of margarine and 38 g of cheese with 2 slices of white bread
224052452|NCT03045445|DIAGNOSTIC_TEST|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
224052453|NCT03045445|DIAGNOSTIC_TEST|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
223441005|NCT04209907|OTHER|retrolaminar block tecnique|By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
223441006|NCT05290077|DIAGNOSTIC_TEST|NGAL|Serum NGAL in blood for early detection of CVR
223441007|NCT04688606|DIAGNOSTIC_TEST|Circulating tumor cell capture technology|CTCBIOPSY® automatic testing platform
223441008|NCT04535557|DRUG|Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once daily in 28-day treatment cycles for up to approximately 4 months.
223441009|NCT00004464|DRUG|cyclophosphamide|
223441010|NCT00004464|DRUG|filgrastim|
223566771|NCT06896253|DRUG|Pulse bolus corticosteroids (G5%) and IVIG (G5 %)|Treatment administration
223566772|NCT06896539|OTHER|Telemedicine|"Contraceptive Counselling using the LOWE Method and through Tele Health, Video Call with Midwife."
223566773|NCT06896539|OTHER|Counselling in person visit|"Contraceptive Counselling using the LOWE Method. In-person visit with midwife at Maternal Health Clinic."
223566774|NCT06769425|DRUG|HS-10502 + NHA|HS-10502 + NHA
223566775|NCT06769425|DRUG|HS-10502 + HS-20093|HS-10502 + HS-20093
224052454|NCT03433014|PROCEDURE|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
223441011|NCT01859871|BEHAVIORAL|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
223441012|NCT05118048|DIAGNOSTIC_TEST|Lactate, Hemoglobin, Hematocrit|Compare diagnostic tests to reference methods
223441013|NCT01066793|DRUG|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
223441014|NCT01066793|DRUG|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
223441015|NCT03102671|OTHER|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
223441016|NCT03102671|OTHER|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
224052455|NCT03433014|OTHER|Control|No infiltration
224052456|NCT00003398|BIOLOGICAL|anti-thymocyte globulin|
224052457|NCT00003398|BIOLOGICAL|filgrastim|
223441017|NCT02171832|DRUG|BI 1744 CL, low dose|
223441018|NCT02171832|DRUG|BI 1744 CL, high dose|
223441019|NCT05033977|OTHER|Exercise (center-based)|Exercise therapy with a physical therapist in a clinic.
223441020|NCT05033977|OTHER|Exercise (home-based)|Patients did exercises at home every day and 3 times per day.
223441021|NCT00315484|DRUG|Epoetin alfa and Darbepoetin alfa|
223441022|NCT02844036|PROCEDURE|Percutaneous angioplasty|
223441023|NCT02844036|PROCEDURE|Balloon angioplasty|
223441024|NCT02844036|PROCEDURE|Right heart catheterization|
224052458|NCT00003398|DRUG|cyclophosphamide|
223566776|NCT06769425|DRUG|HS-10502+ Apatinib|HS-10502+ Apatinib
224052459|NCT00003398|DRUG|thiotepa|
224052460|NCT00003398|PROCEDURE|allogeneic bone marrow transplantation|
224052461|NCT00003398|PROCEDURE|bone marrow ablation with stem cell support|
224052462|NCT00003398|RADIATION|radiation therapy|
224052463|NCT03235648|PROCEDURE|cardiophrenic lymph nodes resection|surgical resection
224052464|NCT01027611|DRUG|proparacaine HCL 0.5%|
224052465|NCT01027611|DRUG|proparacaine HCL 0.5% + 4% lidocaine solution|
224052466|NCT01027611|DRUG|3.5% viscous lidocaine gel|
224163555|NCT05240781|DEVICE|Zotarolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used by CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and Chronic Coronary Syndrome (CCS). Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
224052467|NCT05488587|DIAGNOSTIC_TEST|magnesium and zinc levels|measuring magnesium and zinc levels
224052468|NCT02025868|BEHAVIORAL|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
224052469|NCT02025868|DRUG|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
224052470|NCT06781632|DRUG|ropivacaine|Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)
224052471|NCT04456764|BEHAVIORAL|SaFTiE|A multi-modal fatigue risk management program.
223441025|NCT02844036|PROCEDURE|Echocardiography|
223441026|NCT02844036|OTHER|A six-minute walking test|
223441027|NCT02844036|PROCEDURE|Functional respiratory investigations|
223441028|NCT02844036|PROCEDURE|Pulmonary tomography or pulmonary angiography|
223441029|NCT02844036|OTHER|Biological parameters|
223441030|NCT01520519|DRUG|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
223441031|NCT01520519|DRUG|PCI-32765|420 mg (3 \* 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
223441032|NCT01090297|DEVICE|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
223441033|NCT01090297|DEVICE|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
223566777|NCT06769425|DRUG|HS-10502 + HS-20089|HS-10502 + HS-20089
224052472|NCT04456764|BEHAVIORAL|Attention Placebo Control|A multi-modal teamwork assessment program.
224052473|NCT05696483|DRUG|OLX-07010 Active|25 and 75 mg capsules
224052474|NCT05696483|DRUG|OLX-07010 Placebo|25 and 75 mg capsules
223441034|NCT01090297|DEVICE|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
223441035|NCT05992688|OTHER|Sucrose sweetened beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
223441036|NCT05992688|OTHER|Stevia sweetened beverages|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
223441037|NCT05992688|OTHER|Calorie free flavored water beverage|Children who habitually consume sugar (sucrose) - sweetened beverages who are randomized to this arm, will consume the study product for 8 to 12 weeks.
223441038|NCT01911793|DEVICE|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
223441039|NCT03334422|DRUG|Baricitinib|Administered orally
223441040|NCT03334422|DRUG|Placebo|Administered orally
223441041|NCT03774394|DRUG|Clopidogrel|Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
223441042|NCT03774394|DRUG|Clopidogrel active metabolite|In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
223441043|NCT06956625|OTHER|Topical cosmetic cleanser|After applying the model pollutant, the test area will be topically cleaned with the active cosmetic cleanser with Mitopure.
223441044|NCT06956625|OTHER|Topical tap water|After applying the model pollutant, the test area will be topically cleaned with tap water (control).
224052475|NCT04635800|DRUG|MHU650|MHU650 powder for solution for injection
224052476|NCT02946658|PROCEDURE|lipoaspiration|Closed syringe harvesting subdermal fat
223441045|NCT02697916|DRUG|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
224144867|NCT06127966|PROCEDURE|0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).|The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.
223441046|NCT00293800|DRUG|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
223441047|NCT00293800|DRUG|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
223441048|NCT00293800|DRUG|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
223441049|NCT00293800|OTHER|Timolol Vehicle|Placebo
223441050|NCT05880667|RADIATION|Adaptive Stereotactic Body Radiation|"Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate."
223441051|NCT05574829|DEVICE|Esophageal manometry and monitoring of electrical activity of the diaphragm|Esophageal manometry and monitoring of electrical activity of the diaphragm
224052477|NCT02946658|PROCEDURE|ADcSVF|Isolation of AD-cSVF
224052478|NCT02946658|PROCEDURE|Normal Saline IV|Normal Saline IV containing AD-cSVF
224052479|NCT03788772|OTHER|Multiple blood sampling|ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
224052480|NCT03788772|OTHER|Simple blood sampling|Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
224052481|NCT03831659|OTHER|self-questionnaires|After collecting their non-opposition, a self-questionnaire will be given to them. This questionnaire is validated in the literature concerning the diagnosis of migraine. It includes questions about medical history and possible headaches
223441052|NCT06327360|OTHER|Psychological questionnaires|The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.
223441053|NCT05668572|BIOLOGICAL|Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)|0.5-mL suspension for injection, each 0.5-mL prefilled syringe dose contains L1 proteins of HPV types 6/11/16/18/31/33/45/52/58 in the amounts of 30mcg, 40mcg, 60mcg, 40mcg, 20mcg, 20mcg, 20mcg, 20mcg and 20mcg, respectively, totaling 270mcg of antigens. A 3-dose regimen administered at months 0, 2 and 6.
223441054|NCT05668572|BIOLOGICAL|Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®）|0.5-mL suspension for injection, each 0.5-mL single-dose syringe contains approximately 20 mcg of HPV Type 6 L1 protein, 40 mcg of HPV Type 11 L1 protein, 40 mcg of HPV Type 16 L1 protein, 20 mcg of HPV Type 18 L1 protein, totaling 120 mcg of antigens
223441055|NCT00824707|DRUG|Entecavir|Entecavir 0.5mg per day
223441056|NCT00824707|DRUG|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
223566778|NCT06769425|DRUG|HS-10502 + Platinum + Bevacizumab|HS-10502 + Platinum + Bevacizumab
223441057|NCT00525876|DRUG|Cyclophosphamide|"Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
223441058|NCT00525876|DRUG|Fludarabine|"30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
223441059|NCT00525876|DRUG|Rituximab|"Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
224052482|NCT05704387|PROCEDURE|individualized GDFT|In this group, from anesthesia induction until skin closure, fluid will be given to the patients based on the recommandation of the AFM software in order to optimize patient's SV
223441060|NCT00525876|DRUG|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
223441061|NCT00525876|PROCEDURE|Allogeneic Stem Cell Infusion|Infusion of stem cells.
224052483|NCT05704387|PROCEDURE|Restrictive fluid therapy strategy|from anesthesia induction until end of the liver resection, patient will have a restrictive fluid therapy strategy
224052484|NCT03140358|DRUG|Atropine sulfate 0.01%|Atropine 0.01%
224052485|NCT03140358|DRUG|Placebo|placebo
224052486|NCT03096041|DEVICE|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
224052487|NCT03096041|DEVICE|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
224052488|NCT05431595|DRUG|Haloperidol|Given by Vein (IV)
223441062|NCT01313221|BIOLOGICAL|etanercept|Administered by subcutaneous injection
224052489|NCT05431595|DRUG|Chlorpromazine|Given by Vein (IV)
224052490|NCT05431595|DRUG|Valproate|Given by Vein (IV)
224052491|NCT05431595|DRUG|Placebo|Given by Vein (IV)
224052492|NCT03116997|DRUG|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
224052493|NCT03116997|DRUG|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
224052494|NCT05854316|DIAGNOSTIC_TEST|Comprehensive Biomechanical assessment|Magnetic resonance images, electromyography and dynamometry data will be used, together with data from the gait assessment and clinical questionnaires/measures, to characterize the biomechanics of the participants, and to develop and inform personalised musculoskeletal models
224052495|NCT05876221|DRUG|Cablivi|Patients with immune Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®)
224052496|NCT05281666|DEVICE|Absorbable Surgical Gut Suture material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using absorbable surgical gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
224052497|NCT05281666|DEVICE|Non-absorbable Nylon Suture Material|Participants with lacerations below the level of the forearm that meet inclusion criteria and are consented and randomized to this group will undergo washout and laceration repair using non-absorbable nylon gut suture material. They will be sent home with antibiotics. They will be asked to return to the outpatient hand clinic at 2, 6, and 12 weeks follow-up. Their sutures will be removed at the 2-week follow-up visit. Their wound will be assessed by a single observer, utilizing the POSAS and VAS.
224052498|NCT03496012|GENETIC|BIIB111|Administered as specified in the treatment arm.
224052499|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (blinded)|Anifrolumab treatment delivered subcutaneously, once weekly for 52 weeks
224052500|NCT05925803|DRUG|Placebo (blinded)|matched placebo delivered subcutaneously, once weekly for 52 weeks
224052501|NCT05925803|COMBINATION_PRODUCT|Anifrolumab (unblinded, open label)|At Week 52, all patients will receive Anifrolumab subcutaneously once weekly for 52 weeks
223441063|NCT01313221|DRUG|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%"
224052502|NCT04753853|PROCEDURE|Stromal Vascular Fraction injection|intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
224052503|NCT04116086|DIAGNOSTIC_TEST|Prostate Biopsy Test|see earlier information
224052504|NCT02671357|PROCEDURE|ERAMIP|3D-LPD with stented umbrella-pancreaticogastrostomy \& Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
224052505|NCT02322125|DEVICE|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
224052506|NCT01199588|DRUG|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
224052507|NCT01199588|DRUG|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
224052508|NCT01199588|DRUG|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
224144868|NCT02369575|OTHER|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
224144869|NCT01413048|DRUG|Carvedilol 25mg|Tablet, q.d.
224144870|NCT01413048|DRUG|AGSCT101 12.5mg|Tablet, q.d.
224144871|NCT01809678|BEHAVIORAL|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
224144872|NCT01809678|BEHAVIORAL|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
224144873|NCT01809678|OTHER|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
223441064|NCT01516294|RADIATION|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
223441065|NCT01265004|PROCEDURE|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
223441066|NCT01265004|PROCEDURE|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
223441067|NCT01265004|PROCEDURE|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
223441068|NCT04468815|DRUG|BMS-986278 Tablet|Specified dose on specified days
223441069|NCT04468815|DRUG|Esomeprazole|Specified dose on specified days
223441070|NCT04468815|DRUG|BMS-986278 suspension|Specified dose on specified days
223441071|NCT06337747|DEVICE|Traditional technique|Subjects randomized to the traditional technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region.
224052509|NCT04429906|DEVICE|Huami smart wearable device|"Wear the pulse-oxygen monitoring finger set of the medical monitor while wearing the Huami Smart Wearable device on the ipsilateral wrist according to the instructions for use. The medical monitor displays a steady pulse oximetry level for at least 30 seconds, starts the first measurement, slides the main dial page of the wearable device to the Oxygen Saturation measurement interface, clicks the measurement button to start the single measurement of blood oxygen saturation. Record the pulse oximetry and pulse rate values measured at the same time by the medical monitor and the Huami Smart Wearable Pulse Oximetry Device, respectively. After an interval of 30 seconds, repeat the above steps to start the second measurement and record the measured value. After an interval of 30 seconds, repeat the above steps to start the third measurement and record the measured value. The average of three measurements was taken as data for the test group."
224052510|NCT06195982|DIETARY_SUPPLEMENT|ketone ester|500 mg/kg of ketone ester administered approximately 1 hour prior to the maximal exercise testing and 250 mg/kg administered approximately 30 minutes prior to submaximal exercise testing
224144874|NCT04896190|OTHER|Evaluation of Q angle and Quadriceps muscle activation on dynamic balance position|Evaluation of Q angle, Quadriceps muscle activation, static and dynamic balance and functionality of all individuals was done.
224144875|NCT03395756|DRUG|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
224144876|NCT00538824|DRUG|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
224144877|NCT00538824|DRUG|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
224144878|NCT00538824|DRUG|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*"
224144879|NCT02178501|DIETARY_SUPPLEMENT|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
224052511|NCT06195982|DIETARY_SUPPLEMENT|placebo|ketone-free placebo administered approximately 1 hour prior to the maximal exercise testing and ketone-free placebo administered approximately 30 minutes prior to submaximal exercise testing
224144880|NCT02336412|OTHER|SMS reminder|Daily SMS medication reminder
223441072|NCT06337747|DEVICE|Experimental technique|Subjects randomized to the extended technique will receive 3cc of PLLA (per side, per treatment) in the anterior temporal region, as well as 2cc (per side, per treatment) in the posterior (i.e., behind the hairline) temporal region.
223441073|NCT01537991|RADIATION|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
223441074|NCT00003781|DRUG|docetaxel|
223441075|NCT00003781|PROCEDURE|pain therapy|
223441076|NCT00003781|PROCEDURE|quality-of-life assessment|
223441077|NCT00333632|DRUG|Dexmedetomidine|
223441078|NCT00333632|DRUG|Propofol|
223441079|NCT00333632|DRUG|Midazolam|
223441080|NCT00333632|DRUG|Fentanyl|
223441081|NCT00333632|DRUG|Isoflurane|
223441082|NCT00533559|DRUG|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
223441083|NCT00533559|DRUG|Placebo|Placebo comparator
223441084|NCT05947435|DRUG|Tranexamic acid|Tranexamic acid was administered in intravenous or locally within irrigation fluid
223441085|NCT02708030|OTHER|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
223441086|NCT02708030|OTHER|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
224052512|NCT01815047|DIETARY_SUPPLEMENT|Vitamin D3 Supplementation|
224052513|NCT03085979|PROCEDURE|Burch Colposuspension|Anti-incontinent surgery
223441087|NCT02708030|OTHER|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
223441088|NCT00994214|DRUG|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
223441089|NCT01716611|DRUG|Tolvaptan|15 - 60 mg/day for 28 days
224052514|NCT03085979|PROCEDURE|trans obturator tape|Anti-incontinent surgery
224052515|NCT03085979|PROCEDURE|tension free vaginal tape|Anti-incontinent surgery
224052516|NCT04336670|DEVICE|Immersive Virtual Reality exercise program|Sessions with an exercise program focused in upper and low limbs movements in a virtual enviroment, all performed in standing position.
224052517|NCT04336670|OTHER|Usual care|Usual center therapies (Physical therapy, occupational therapy..)
224052518|NCT05996159|DEVICE|QDOT MicroTM catheter|Novel high power-short duration ablation catheter for atrial fibrillation
224052519|NCT05996159|DEVICE|AI-guided ablation only for PVI|Ablation is the removal or destruction of something from an object by vaporization, chipping, erosive processes, or by other means.
224052520|NCT01463670|DRUG|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
223441090|NCT01716611|DRUG|placebo|
224052521|NCT05502042|BEHAVIORAL|Case Manager and Peer Support Group|Assignment of a Village health team member to provide support to the family through SMS messages (weeks 1-3) and phone call (week 4), as well as home visits as needed if no contacts are reached. These contacts are intended to provide encouragement and education to participants and families to encourage SAP and peer group attendance. Peer groups will have simple play and support activities, led by the village health team member, to improve the experience of SAP for the participating children.
224052522|NCT02034942|OTHER|Non-sedation|
224300538|NCT00697684|DRUG|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
224300539|NCT01662349|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
223441091|NCT06532058|DRUG|QHRD107 capsule，Venclexta and Azacitidine|QHRD107（orally），Venclexta（orally），Azacitidine（subcutaneous injection）
223441092|NCT05639686|DRUG|Tranexamic acid injection|Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.
223441093|NCT05639686|DRUG|Total Intravenous Anesthesia|Within 10 minutes of induction, patients in the control (TIVA) group will be administered a 100mL bolus of normal saline as placebo.
224052523|NCT02034942|OTHER|Sedation, control|
224052524|NCT01395199|DRUG|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
224052525|NCT00565253|DRUG|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
224052526|NCT02055651|BEHAVIORAL|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
224052527|NCT05045898|OTHER|plantar massage|The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.
224052528|NCT05045898|OTHER|textured insoles|"Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks."
224052529|NCT02280395|DRUG|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
224052530|NCT02280395|DRUG|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
224052531|NCT01720342|PROCEDURE|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
224052532|NCT05261958|OTHER|SAQ training|interventions listed above were applied on the players which will improve running mechanics and impove speed power and agility in football players
224052533|NCT00665873|DEVICE|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
224144881|NCT04093687|OTHER|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
224144882|NCT01005446|DEVICE|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
224144883|NCT07047365|DRUG|TQB2930+ chemotherapy|TQB2930 injection is a HER2 bispecific antibody drug； Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
224144884|NCT07047365|DRUG|Trastuzumab+ chemotherapy|Trastuzumab is a HER2-specific targeted drug； Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.
224144885|NCT02664532|OTHER|Miller group|Miller blade was used for laryngoscopy
224144886|NCT02664532|OTHER|Macintosh group|Macintosh blade was used for laryngoscopy
224144887|NCT01635634|OTHER|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
224144888|NCT06762275|DIAGNOSTIC_TEST|Diagnostic strategy|GPs' use of an externally validated cPR followed by CRP-POCT in the medium risk group. See for details: Detailed description - Intervention.
224144889|NCT05266794|DRUG|Alpha lipoic acid|20 patients who received Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.
224144890|NCT05266794|DRUG|Selenium|23 patients who received Selenium 200µg once daily with their routine therapy just a
224163923|NCT03708757|OTHER|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
224163924|NCT02637804|DEVICE|stenfilcon A|contact lens
224163925|NCT02637804|DEVICE|narafilcon A|contact lens
224163926|NCT02637804|DEVICE|delefilcon A|contact lens
224163927|NCT02820558|DRUG|Substance P|
224163928|NCT04803019|COMBINATION_PRODUCT|DEB-TACE|"The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm."
224052534|NCT00665873|DRUG|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
224052535|NCT03395548|DRUG|Macrogol|Used drug: Macrogol (osmotic laxative)
224052536|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
224052537|NCT00349375|DRUG|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
224052538|NCT00349375|DRUG|Simvastatin|Simvastatin 40 mg
224163929|NCT04803019|DEVICE|TAE|"The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy."
224163930|NCT04841850|OTHER|Clinical and biological characteristics|"* Age at beginning of IOT~* Sex~* Atopic and non atopic Comorbidities~* Sensitization to aero-allergens~* Sensitization to trophallergens~* Stage of severity of the elicited reaction~* Hazelnut Specific IgE + Cor a 1,8,9,14 before IOT and during follow up~* Hazelnut skin prick test before IOT and during follow up~* Adverse effects of IOT and their stage (in hospital and at home)~* Use of adrenaline auto-injector (in hospital and at home)~* Maintenance dose"
224163931|NCT00669513|BEHAVIORAL|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
224163932|NCT01789749|OTHER|Snare Tip Soft Coagulation|
224163933|NCT01789749|OTHER|No Snare Tip Soft Coagulation|
223441094|NCT05639686|DRUG|Inhalational isoflurane|Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
223441095|NCT03917979|BEHAVIORAL|Individual GIM|Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.
223566779|NCT06769425|DRUG|HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan|HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
223566780|NCT06769425|DRUG|HS-10502 + Bevacizumab|HS-10502 + Bevacizumab
223566781|NCT02307097|PROCEDURE|Cognitive-Behavioural Bibliotherapy|
223566782|NCT02307097|PROCEDURE|Cognitive-Behavioural Therapy|
223566783|NCT02307097|OTHER|WAIT|
223566784|NCT00059930|DRUG|FOLFOX regimen|
224052539|NCT04507542|BEHAVIORAL|Enriched Music-Supported Therapy|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program is based on musical training, combining self-training sessions of music playing using an app for electronic tablets and music therapy group sessions.
224052540|NCT04507542|BEHAVIORAL|Graded Repetitive Arm Supplementary Program|Home-based rehabilitation program for stroke patients aimed at improving the upper extremity motor function. The program comprises self-training sessions of mass repetition of movements and task-specific exercises for the upper extremity.
224052541|NCT02308631|PROCEDURE|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
224052542|NCT03805945|DRUG|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
224052543|NCT03805945|DRUG|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
224052544|NCT05288218|DEVICE|Leak-free Bronchoscope Adapter|A novel leak-free bronchoscope adapter will connect to the ventilation circuit in place of a standard adapter.
224052545|NCT05288218|DEVICE|Standard Bronchoscope Adapter|Commercially available bronchoscope adapter (Smiths Medical)
224144891|NCT04083456|BEHAVIORAL|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
224163934|NCT01562678|DRUG|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
224163935|NCT01562678|DRUG|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
224163936|NCT00320294|DRUG|irinotecan|
223566785|NCT00059930|DRUG|dexamethasone|
224163937|NCT00320294|DRUG|cisplatin|
224163938|NCT02259946|DRUG|BI 1744 CL|
224163939|NCT02259946|DRUG|Placebo|
224052546|NCT03388359|PROCEDURE|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
224052547|NCT03388359|OTHER|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
224052548|NCT03388359|OTHER|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
224052549|NCT03388359|OTHER|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
224052550|NCT03388359|BIOLOGICAL|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
224052551|NCT03388359|DEVICE|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
224163940|NCT02259946|DRUG|Tiotropium bromide|
224163941|NCT03681834|OTHER|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
224163942|NCT06453863|OTHER|Greater plantar feedback shoes|Shoes providing enhanced plantar feedback
224163943|NCT06453863|OTHER|Neutral gym shoes|Regular gym shoes
223566786|NCT00059930|DRUG|floxuridine|
223441096|NCT03917979|BEHAVIORAL|Waitlist Control|Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
224052552|NCT03388359|BIOLOGICAL|Eosinophils|Eosinophils are isolated from peripheral blood
224052553|NCT03388359|BIOLOGICAL|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
224052554|NCT03388359|BIOLOGICAL|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
224052555|NCT01841944|DRUG|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
224052556|NCT01841944|OTHER|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
224052557|NCT04203732|PROCEDURE|Anesthesia Type|The anesthetic type either general anesthesia or neuraxial anesthesia is the intervention type for patients undergoing primary total joint arthroplasty of the knee or hip.
224052558|NCT04024033|DIETARY_SUPPLEMENT|pine cone extract|pine cone extract capsule
224052559|NCT04024033|OTHER|placebo|placebo capsule
223441097|NCT02217800|DRUG|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
223441098|NCT02217800|DRUG|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
223441099|NCT02217800|DRUG|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
223441100|NCT05195099|OTHER|respiratory treatment|Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
223441101|NCT00632632|DRUG|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
223566787|NCT00059930|DRUG|fluorouracil|
224052560|NCT04436536|OTHER|Treadmill walking training with random speed changes|Participants were asked to walk in different gait speed randomly on the treadmill (80%, 90%, 100%, 110% and 120% of preferred speed). The training speed would be changed in every 15 seconds in 2-minutes-section. 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
224052561|NCT04436536|OTHER|Treadmill walking training with blocked speed changes|Participants were asked to walk in same gait speed on the treadmill per day (80%, 90%, 100%, 110% and 120% of preferred speed, respectively). 2 minutes/ section, 10 sections/ day, 3 days/ week, 2 weeks. 1 minute rest time would be held between sections.
224052562|NCT00169455|BIOLOGICAL|Live attenuated human rotavirus vaccine|
224052563|NCT06087796|DRUG|Betamethasone Valerate 0.1% Cream|Topical treatment modality for alopecia areata.
224052564|NCT06087796|DRUG|Pentoxifylline|Topical treatment modality for alopecia areata.
224052565|NCT06087796|DRUG|Metformin|Topical treatment modality for alopecia areata.
224052566|NCT00971165|DRUG|losartan|Oral losartan up to 100 mg daily fo 18 months
224052567|NCT00971165|DRUG|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
224144892|NCT04083456|OTHER|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
224144893|NCT07080021|DRUG|Standard Reagents, Pancreatic Cancer|This is a non-interventional study. Neoadjuvant therapy regimens and surgical approaches are determined solely by attending physicians according to clinical treatment standards.
224144894|NCT07084870|OTHER|High flow nasal oxygen|Patients in group I then received HFNO. The initial flow rate was adjusted to 50L/min and gradually reduced as tolerated by the patient. The humidification chamber temperature was set at 37°C and gradually reduced to the patient comfort. FiO2 was 100% and then gradually reduced over time according to improvement in oxygenation.
224163944|NCT06453863|OTHER|Barefoot|For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
224052568|NCT05490173|OTHER|Exosomes derived from mesenchymal stromal cells (MSCs)|Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
224052569|NCT00929175|DEVICE|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
224163945|NCT02288442|OTHER|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
224163946|NCT05757024|DEVICE|high power laser therapy|m6 laser therapy of ASA company with multilocked wave system and synchronized emission wave lengths 808 and 905 wave lengths
224052570|NCT00929175|DEVICE|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
224052571|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
224052572|NCT00449670|BIOLOGICAL|H5N1 non-adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)|Two doses of the GSK1562902A non-adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.
224052573|NCT00449670|BIOLOGICAL|H5N1 adjuvanted split virus vaccine (A/Indonesia/05/2005 strain)|Booster administration at Month 6 (and a second booster dose 21 days later for the un-adjuvanted group only) with an adjuvanted split virus pandemic influenza candidate vaccine containing the strain A/Indonesia/5/2005.
224052574|NCT02227732|DEVICE|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
224052575|NCT00234468|DRUG|Iressa (Gefitinib)|
224052576|NCT03059238|DRUG|Celecoxib 200mg oral capsule|
224052577|NCT03059238|DRUG|parecoxib sodium|
223441102|NCT00632632|OTHER|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
223441103|NCT04112550|DRUG|Methadone Hydrochloride|FDA approved medication to treat pain
224052578|NCT03059238|DRUG|controlled-release oxycodone|
224052579|NCT04183790|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
224144895|NCT07084870|OTHER|non invasive BIPAP|Patients in group II received oxygen therapy via intermittent non- invasive positive pressure ventilation, BiPAP mode ventilator using a face mask. BiPAP settings were adjusted as follows: P (low) of 5cm H2O to 10cm H2O and an inspiratory pressure P (high) of 10-20cm H2O . FiO2 was adjusted to 100% and then gradually reduced over time according to improvement in oxygen saturation and PaO2/Fio2 ratio. Respiratory rate was adjusted from 10-12 at then changed according to patient´s respiratory effort and according to ABG.
223441104|NCT04112550|DRUG|Oxycodone-Acetaminophen|FDA approved medication to treat pain
223441105|NCT00846690|DRUG|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
224052580|NCT04183790|DRUG|IVA|Mono tablet for oral administration.
224052581|NCT03716271|DEVICE|Visual Acuity Examination with a novel lens|Visual Acuity Examination with a novel lens set in an ophthalmic trial frame
224052582|NCT01156272|DEVICE|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
224052583|NCT03852251|BIOLOGICAL|AK104|Subjects will receive AK104 by intravenous administration.
224052584|NCT03852251|DRUG|Oxaliplatin|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
224052585|NCT03852251|DRUG|Capecitabine|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
224052586|NCT03410433|DEVICE|Silk 4.0|Silk suture 4.0
224052587|NCT03410433|DEVICE|PG 910 4.0|PG 910 4.0
223441106|NCT00846690|DRUG|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
223441107|NCT01873157|DRUG|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
224052588|NCT03410433|DEVICE|PP 4.0|PP 4.0
224052589|NCT03410433|DEVICE|Silk 5.0|Silk 5.0
224052590|NCT03410433|DEVICE|PG910 5.0|PG910 5.0
224052591|NCT03410433|DEVICE|PP 5.0|PP 5.0
224052592|NCT03410433|DEVICE|APG 5.0|APG 5.0
224052593|NCT03410433|DEVICE|ePTFE 5.0|ePTFE 5.0
224052594|NCT00861120|DRUG|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
224052595|NCT00861120|DRUG|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
224052596|NCT00937937|DRUG|Dinaciclib|Given IV
224052597|NCT06208787|BEHAVIORAL|Neurofeedback training|Neurofeedback training involving auditory feedback upon measurement of non-harmonic alpha-theta ratios during focused attention meditation
224144896|NCT06491641|OTHER|Care based on Kolcaba's comfort theory|During the application process, the babies in the experimental group will receive care based on Kolcaba's comfort theory during their stay in intensive care.
224144897|NCT03196427|DRUG|Vedolizumab|Vedolizumab intravenous infusion
224144898|NCT07088380|DRUG|Ketamine Hydrochloride|Ketamine will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.
223441108|NCT01873157|DRUG|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
223441109|NCT02102672|DRUG|Trimetazidine|
223441110|NCT04957199|OTHER||
223441111|NCT02812225|DEVICE|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
223566788|NCT00059930|DRUG|leucovorin calcium|
224052598|NCT06208787|BEHAVIORAL|Sham Training|Sham neurofeedback involving auditory feedback at random timepoints during focused attention meditation such that no learning can take place
224052599|NCT05238129|OTHER|No intervention - standard care is assessed|No intervention - standard care is assessed
224052600|NCT04989426|OTHER|the state of health of newly arrived migrant patients in the year following their arrival in France|the state of health of newly arrived migrant patients in the year following their arrival in France
224052601|NCT02800408|OTHER|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
224052602|NCT02800408|OTHER|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
223441112|NCT01533688|DRUG|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
224052603|NCT02800408|OTHER|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
223441113|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
223441114|NCT01533688|DRUG|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
223441115|NCT03278847|DIETARY_SUPPLEMENT|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~* Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~* This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~* This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
223441116|NCT03278847|DIETARY_SUPPLEMENT|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
223441117|NCT03278847|DIETARY_SUPPLEMENT|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~* Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~* This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~* This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
223441118|NCT03278847|DIETARY_SUPPLEMENT|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
223441119|NCT02509078|DRUG|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
223441120|NCT05089812|PROCEDURE|Third-molar extraction using platelet-rich fibrin as a filling of the alveolus|see above
223441121|NCT00404716|DRUG|Cilostazol|
223441122|NCT02484768|DRUG|Iron isomaltoside 1000|Intravenous treatment
223441123|NCT02484768|DRUG|Sodium Chloride 0.9%|Intravenous treatment
223441124|NCT06557421|DRUG|Venetoclax|complete discontinuation of Venetoclax
223441125|NCT06557421|DRUG|Azacitidine|complete discontinuation of Azacitidine
224052604|NCT04384484|DRUG|Loncastuximab Tesirine|Intravenous Infusion
224052605|NCT04384484|DRUG|Rituximab|Intravenous Infusion
224052606|NCT04384484|DRUG|Gemcitabine|Intravenous Infusion
224052607|NCT04384484|DRUG|Oxaliplatin|Intravenous Infusion
224052608|NCT05262699|DEVICE|Vibro-tactile stimulation|Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).
224052609|NCT05262699|OTHER|Placebo Control|Devices mounted, no stimulation
224052610|NCT01573871|OTHER|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
223441126|NCT06339827|BEHAVIORAL|Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List|Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
223566789|NCT00059930|DRUG|oxaliplatin|
223566790|NCT00059930|PROCEDURE|adjuvant therapy|
223566791|NCT00059930|PROCEDURE|conventional surgery|
223566792|NCT06838663|PROCEDURE|Robotic assisted Cruciate-Retaining (CR) TKA procedures|Patients who underwent Cruciate Retaining (CR) total knee arthroplasty (TKA)
224052611|NCT00099996|DRUG|SCH-58235|
224052612|NCT00099996|DRUG|Ezetimibe|
224052613|NCT05341479|PROCEDURE|Surgery for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion)."
224052614|NCT05341479|RADIATION|RT for early-stage OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT."
224052615|NCT05341479|RADIATION|CRT for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT."
224144899|NCT07088380|DRUG|Placebo|Placebo will be administered intravenously at a subanesthetic dose of 0.5 mg/kg after a bolus of Propofol, during ECT sessions 2, 4, and 6.
223566793|NCT06838663|PROCEDURE|Robotic assisted Bi-Cruciate Stabilized (BCS) TKA procedures|Patients who underwent Bi-Cruciate Stabilized (BCS) total knee arthroplasty (TKA)
223566794|NCT06860490|DRUG|Sintilimab|Sintilimab will be administered by IV, 200 mg on day 1 of each 21 day cycle.
223566795|NCT06860490|DRUG|Bevacizumab Biosimilar|Bevacizumab biosimilar will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle.
223741009|NCT07191119|BEHAVIORAL|Sleep Quality|Receive Pittsburgh Sleep Quality Index (PSQI); Insomnia Severity Index (ISI); Sleep diaries; Actigraphy via Fitbit Charge 5
223741010|NCT07191119|BEHAVIORAL|Neurocognitive and mental health outcomes|Measured using CNS Vital Signs and DASS-21.
223741011|NCT07190482|DRUG|Olanzapine 5 Mg ORAL TABLET|OLANZAPINE ARM
223741012|NCT07190482|DRUG|Placebo Drug|placebo administered for 8 weeks
223741013|NCT07191379|OTHER|The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting.|The study intervention is self-administration of SC daratumumab by the patient, thereby changing the administration from an outpatient setting to a home setting. To reduce potential bias, patients will function as their own controls by receiving alternating treatments at home and in the outpatient clinic.
223741014|NCT07205965|BEHAVIORAL|Experimental Group|The experimental group will consist of 16 participants and the participants will receive internet-based environment psychoeducation for 6 weeks, each session for 30 minutes.
223741015|NCT07205380|PROCEDURE|Endoscopic Retrograde Cholangiopancreaticography|Anaesthesia or sedation during ERCP for common bile duct stones
223741016|NCT07207291|DRUG|JKN2501|Administration: Intravenous (IV) infusion.
223741017|NCT07207291|DRUG|Placebo|0.9% Sodium Chloride Injection as Placebo. Administration: Intravenous (IV) infusion.
223741018|NCT07206303|BIOLOGICAL|Bifidobacterium probiotics supplementation|"The 10-week research period consists of one prescreening and baseline visit (week -1) and two follow-up visits (week 5 (±7days) and week 10 (±7days)). The participants will be instructed to fast overnight before their visits in the mornings of week -1 and week 10.~The measurements will include documentation of personal and demographic information; three consecutive clinic BP readings; 24-hour ambulatory BP monitoring; a 3-day diet diary to monitor consistency of dietary intake; collection of fecal samples and blood samples for analysis of GM composition and biomarkers, respectively at baseline, and week 5 and 10.~Only participants who are able to provide all the required data and samples within 7 days after the prescreening and baseline visit (week -1) will be eligible to receive the Bifidobacterium supplementation with 20 billion cfu once a day for 10 weeks. They will be instructed to mix the probiotics with water and consume with their dinner."
223741019|NCT07205263|PROCEDURE|AI-assisted robotic-guided endoscopic hematoma evacuation|Surgical removal of hematoma using AI-assisted robotic-guided stereotactic navigation and endoscopic aspiration techniques.
224052616|NCT05341479|OTHER|Surgery for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.~Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion)."
224052617|NCT05341479|PROCEDURE|Neoadjuvant treatment for advanced OPC|"The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.~Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy."
223741020|NCT07205263|PROCEDURE|Conventional craniotomy|Standard open surgical evacuation of hematoma through craniotomy.
223741021|NCT07205263|PROCEDURE|AI-assisted robotic-guided puncture and hematoma evacuation|AI-assisted robotic-guided stereotactic puncture and aspiration of hematoma.
223741022|NCT07205263|OTHER|Standard medical management|Guideline-based conservative therapy without surgical hematoma evacuation.
223741023|NCT07205263|PROCEDURE|AI-assisted robotic-guided endoscopic ventricular hematoma evacuation plus external ventricular drainage|AI-assisted robotic-guided endoscopic evacuation of ventricular hematoma combined with external ventricular drainage.
223741024|NCT07205263|PROCEDURE|External ventricular drainage (EVD)|Conventional ventricular catheter placement for hematoma drainage.
223741025|NCT07207148|DRUG|GLP-1|Glucagon-like peptide-1 agonist agent is the study agent of interest. This study will not supply the GLP-1 drug but depends on the patient's clinical prescription of this drug.
223741026|NCT07207148|DRUG|Ocrelizumab (US)|All participants will be treated with Ocrelizumab for the indication of MS; however, the study will not provide Ocrelizumab as it will be part of the participant's routine clinical care.
223741027|NCT07206407|DIETARY_SUPPLEMENT|Placebo|Four capsules.
224052618|NCT00210808|DRUG|topiramate|
223741028|NCT07206407|DIETARY_SUPPLEMENT|Nutraceutical blend|Four capsules.
224052619|NCT05610904|DIAGNOSTIC_TEST|Prediction model evaluation|a machine learning based anastomotic leakage prediction model
224144900|NCT00184782|PROCEDURE|FDG-PET|
224144901|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
224144902|NCT03522272|DEVICE|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
224144903|NCT03522272|OTHER|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
224144904|NCT06906367|DRUG|migalastat HCl|Non-interventional study of participants receiving migalastat HCl 150 mg
224144905|NCT06906367|DRUG|ERT|Non-interventional study of participants receiving enzyme replacement therapy
223441127|NCT04349046|DEVICE|Total hip arthoplasty (THA)|Total hip arthroplasty (THA) is a common operative treatment where an arthritic, degenerative or fractured hip joint is replaced with a prosthetic device if conservative options are unable to relieve pain and debilitating symptoms. THA was traditionally performed on patients over 60 years old, but now includes young and active patients, as well as very old ones thanks to the continuous improvement in implant design. Major indications of THA include osteoarthritis, rheumatoid arthritis, avascular necrosis and hip fractures. The THA surgical procedure involves replacing the head of the femur and acetabulum or socket with an artificial prosthesis. This system is composed of a femoral stem that is inserted into the femoral canal, a ball that attaches to the femoral stem, and an acetabular component or shell that replaces the acetabulum.
223441128|NCT05684796|DRUG|Anticoagulation|Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)
223441129|NCT05684796|DEVICE|mechanical aspiration thrombectomy|Mechanical aspiration thrombectomy with the Indigo Aspiration System.
223441130|NCT05783466|OTHER|Low-fat dairy products|3-month intervention
223441131|NCT05783466|OTHER|Whole-fat dairy products|3-month intervention
223441132|NCT05783466|OTHER|Milk polar lipid enriched whole-fat dairy products|3-month intervention
223441133|NCT06517797|DRUG|S1B-509 low dose|S1B-509 has multiple neurotransmitter activities
223441134|NCT06517797|DRUG|Placebo|matched pills to S1B-509
223441135|NCT06517797|DRUG|S1B-509 High Dose|S1B-509 has multiple neurotransmitter activities
223441136|NCT05485233|DEVICE|REDSCAR App|"Patients will be discharged after surgery at the time it is considered by the responsible physician. Prior to discharge, patients taking part in the study will follow the same protocol as any other patient treated in our institution. Written consent will be signed after complete explanation of the study protocol by the researcher at this moment. The patient will download the RedScar© application and the researcher will explain how it works and how to answer all the questions about the wound (redness, pain).~At day 3th and 10th after surgery, each patient will upload an image of the surgical wound via RedScar© aplication using their own smartphone device. RedScar© aplication will evaluate the risk of complications of the surgical wound and will assign patients to 2 different groups: potential complications requiring new consultation or satisfactory evolution and discharge."
224052620|NCT05358171|OTHER|HIgh UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet emphasizing UPF (81% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
224052621|NCT05358171|OTHER|No UPF controlled diet|Following a two- week eucaloric lead-in diet, participants will be provided and consume a diet without UPF (0% energy). Diets will be eucaloric (50% carbohydrate, 35% fat,15% protein) matched for dietary soluble and insoluble fiber, added sugar, mono- and polyunsaturated fat, saturated fat, antioxidant nutrients, sodium, pre- and probiotics, and overall diet quality, for 6 weeks.
224052622|NCT01814020|DRUG|MOB015B|
224052623|NCT03197493|DRUG|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
224052624|NCT00182195|PROCEDURE|Control Ventilation Strategy|
224052625|NCT03947489|DRUG|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fasting condition
224052626|NCT04154670|BIOLOGICAL|MGTA-145|MGTA-145 will be given intravenously
224052627|NCT05075070|BIOLOGICAL|Inactivated COVID-19 vaccine|two doses inactivated COVID-19 vaccine
223441137|NCT00253370|DRUG|BAY 43-9006|Given orally
223441138|NCT00253370|DRUG|docetaxel|Given IV
223441139|NCT00253370|DRUG|cisplatin|Given IV
223441140|NCT06187649|PROCEDURE|breast reconstruction|breast expander/implant insertion for breast reconstruction following mastectomy
223441141|NCT06511271|OTHER|relaxation exercises|"The first 10-minute part of the CD audio recordings prepared by the Turkish Psychologists Association is about deep relaxation.~purpose; The second 30-minute part includes instructions for relaxation exercises; The last 30 minutes are just consists of relaxation music"
223441142|NCT06279494|DRUG|Sirolimus|Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT
224052628|NCT01161355|DRUG|AZD9668|Tablets of AZD9668 and IV dose of \[C14\]AZD9668
224052629|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
224052630|NCT02518451|DRUG|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
224052631|NCT00842426|BEHAVIORAL|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
224300540|NCT05485220|OTHER|Aerobic exercise|Aerobic exercise group: Peak workload will be determined by performing an exercise test on the patients. Training will be given at 60-70% of the peak workload for 45 minutes with an arm ergometer 3 days a week for 8 weeks.
223441143|NCT06279494|DRUG|Abatacept|5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT
223441144|NCT06279494|DRUG|MMF|0.5g bid orally, from -3d to +60d post haplo-HSCT
223441145|NCT06279494|DRUG|ATG|2.5 mg/kg, from -5d to -2d
223441146|NCT03576209|BEHAVIORAL|healthy lifestyle program|Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
223441147|NCT03832673|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
223441148|NCT03832673|DRUG|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
224144906|NCT07091890|DEVICE|Fluoride gel|After non-surgical therapy, 6-8 g of a gel containing 12,500 ppm of fluoride was applied for 4 min using a disposable tray appropriately sized for the patient's mouth. As per the guidelines, the patient was asked to briefly rinse their mouth with water. The aim was to remineralize the dental enamel to make it less susceptible to acid attacks caused by low salivary pH and the byproducts of bacterial metabolism
224052632|NCT00842426|BEHAVIORAL|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
223441149|NCT02847910|PROCEDURE|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
223441150|NCT02847910|PROCEDURE|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
223441151|NCT05916131|BEHAVIORAL|Basic Education|2-week text message intervention for providing knowledge about hypoglycemia management and prevention.
223441152|NCT05916131|BEHAVIORAL|Hypoglycemia Symptom Detection Training|10-week text message intervention for providing training on skills of detecting hypoglycemia symptoms.
223441153|NCT05916131|BEHAVIORAL|Education Plus|10-week text message intervention for helping people consider how they think of hypoglycemia.
223441154|NCT06271486|DRUG|Pregabalin 75mg|Group A (pregabalin group) received oral pregabalin treatment administered at 150 mg daily, with 75 mg given every 12 hours.
223441155|NCT06271486|BIOLOGICAL|An epidural blood patch (EBP)|Group B (EBP group) received active therapy in the form of an EBP
224052633|NCT03210389|DRUG|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
224052634|NCT02956954|DRUG|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
224052635|NCT02956954|PROCEDURE|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
224052636|NCT06243042|DIAGNOSTIC_TEST|serum vitamin D|blood sample for serum vitamin D level Vitamin D serum level was measures using the ELISA technique. The Cal Biotech Vitamin D Kit (Mannheim, Germany) was used, which is a solid phase enzyme linked immunoassay (ELISA), based on the principal of competitive binding. Vitamin D deficiency was defined as serum Vit. D below 20 ng/ml.
224144907|NCT07091890|DEVICE|Fluoride varnish|After non-surgical therapy, a fluoride varnish containing 7,700 ppm of fluoride in a homogeneous solution was evenly distributed over the dental surfaces using a micro-brush. Patients were instructed to spit out excess saliva but not to rinse their mouth with water, and to refrain from eating or drinking for at least 60 min afterward. After drying, the varnish formed a fluoride-rich layer on the enamel, increasing the concentration by up to four times. Despite the high concentration of fluoride, the resin component of the varnish allowed for a slow, controlled release of fluoride over time, thus preventing its immediate loss and minimizing the amount ingested by the patient. The purpose was to prevent mineral loss from the enamel and promote its restoration, making the dental tissue more resistant to the acidic pH of saliva caused by the production of organic acids through bacterial metabolism.
224144908|NCT07090408|BEHAVIORAL|Artificial intelligence support|Each student in the intervention group will be asked to solve a given case example using ChatGPT support. However, students in the control group will be asked to analyze the case using their own academic knowledge without ChatGPT support.
223441156|NCT06271486|COMBINATION_PRODUCT|conservative treatment.|Group C (control group) received conservative treatment providing recommendations to the patients, including 24 hours of bed rest, stool softener, and consuming a minimum of 2.0 liters of fluid daily. Analgesics were permitted for pain relief depending on the patient's disease status.
223441157|NCT04404829|OTHER|Manual Therapy|"The first level of IMT was treated in this study: the objective is to harmonize the cranio-sacral and sacro-pelvic systems, as this is fundamental for maintaining good posture. The first therapeutic maneuvers should be focused on releasing of the sacrum and the pelvis. The first is considered a key area for the correct transmission of forces and loads from the lower limbs to the upper limbs and vice versa and shares the role of rigid elements for this purpose (bones) and tensile elements (muscles, ligaments, fascia) in the whole body. In this level. Compensatory injuries that the body has started after a primary injury are treated on this level, through the Fluidic Chains. The diagnosis of this level is performed by cranial somotopias. Practically all the treatment is carried out on the sacrum. The first step are the fuses, which are vibration zones which act as a protection system for the body. These points sometimes stop working, which interrupts the correct movement of the PRM."
223441158|NCT02289105|BEHAVIORAL|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
223441159|NCT04343053|OTHER|SARS-Cov-2 infection|blood sample withdrawal
223441160|NCT03527862|OTHER|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
223441161|NCT00899704|GENETIC|microarray analysis|
224052637|NCT06243042|DIAGNOSTIC_TEST|urine osmolality|"nocturnal urine osmolality: Clear instructions for mothers were to let the child void before sleep and every two hours till 8 am. Short intervals were meant to avoid enuretic episodes during calculation of nocturnal urine volume, and if occurred it mandates the repeat of chart on another day.~Nocturnal urine collected over the night was tested for osmolality, it was measured in mOsm/kg."
224052638|NCT06243042|OTHER|Frequency volume chart|volume and frequency from time of sleep till 8 am
224052639|NCT02248259|DRUG|BI 409306|Oral single dose of BI 409306
224052640|NCT02248259|DRUG|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
224052641|NCT04950179|OTHER|PDRI patients|The study was conducted by retrospective data collection from medical records of 135 continuous ambulatory peritoneal dialysis (CAPD) patients at Phramongkutklao Hospital from January 1, 2016 to December 31, 2020.
224052642|NCT01086462|DRUG|GSK2239633|100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
224052643|NCT02114411|PROCEDURE|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
224052644|NCT02114411|PROCEDURE|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
223441162|NCT00899704|GENETIC|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
223441163|NCT00899704|OTHER|diagnostic laboratory biomarker analysis|
223441164|NCT05381922|OTHER|blood laboratory investigation(coagulation profile- platelet function test)|blood laboratory investigation including ( complete blood count, coagulation profile, platelet function test, level of factor decrease
224052645|NCT06244355|OTHER|Extra blood tubes|Extra blood tubes
224052646|NCT05223868|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
224052647|NCT05223868|DRUG|Placebo|Placebo tablet will be administered orally.
224144909|NCT07090993|BEHAVIORAL|sustainable nutrition education|"The educational intervention applied to the experimental group was carried out in 12 sessions. The knowledge-attitude-behavior education model was adopted in the education sessions. The education program, which was created by obtaining expert opinions, consists of five basic topics and was carried out with the interactive education method.~Sessions;~1. Environmental effects during the production of animal and plant foods~2. Production and environmental effects of processed foods~3. Foods with low environmental impact and nutrition models~4. What are food losses and wastes?~5. Workshops~6. Processing and storage of foods~7. Consumption of local, regional and seasonal fruits, vegetables and fish~8. The importance of sustainable nutrition and alternative protein sources~9. Mediterranean diet model~10. Preparing a shopping list~11. Reading labels and nutritional content~12. Watching a documentary on the harms of packaged foods on living beings and the environment"
224144910|NCT00717262|DRUG|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
223441165|NCT00004866|DRUG|exatecan mesylate|
223441166|NCT03098017|OTHER|Short pasta (dry)|50g available carbohydrate portion of penne (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
223441167|NCT03098017|OTHER|Long pasta (dry)|50g available carbohydrate portion of spaghetti (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
223441168|NCT03098017|OTHER|Couscous|50g available carbohydrate portion of couscous (\~70g uncooked) will be cooked according to package instructions and served with 500mL water
223441169|NCT03098017|OTHER|Glucose|50g available carbohydrate portion of glucose monohydrate (\~55g) will be dissolved in 500mL water
223441170|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a subepithelial connective tissue graft
223441171|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with vascularized interpositional periosteal connective tissue graft
223441172|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a collagen membrane
224052648|NCT02807480|BEHAVIORAL|Exposure-based therapy|Exposure-based therapy
224052649|NCT02807480|BEHAVIORAL|Behavioral Activation therapy|Behavioral Activation therapy
224052650|NCT02807480|BEHAVIORAL|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
224052651|NCT02807480|BEHAVIORAL|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
224052652|NCT02807480|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
224052653|NCT02807480|DEVICE|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
224052654|NCT00641550|OTHER|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
224052655|NCT05104645|OTHER|Analysis of the walk|Gait analysis in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Patients: S0, S1, S2, S4 and S6 Healthy volunteers: 2 times (between 3 and 20 days apart)
224144911|NCT00717262|DRUG|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
223441173|NCT05892016|PROCEDURE|Alveolar ridge preservation|grafted with bone particle and covered with a Cytoplast
223441174|NCT03398239|DEVICE|Noninvasive mechanical ventilation|
223441175|NCT02917824|DEVICE|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
223441176|NCT02917824|DEVICE|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
223441177|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
224052656|NCT05104645|OTHER|Analysis of the race|Analysis of running in 3 dimensions and with inertial measurement units (IMUs) on flat ground and motorized treadmill Healthy volunteers: 2 times (between 3 and 20 days apart)
224052657|NCT05104645|OTHER|Unipodal and bipodal jumps on flat ground|Healthy volunteers: 2 times (between 3 and 20 days apart)
224052658|NCT02369848|DEVICE|Shockwave Lithoplasty System|
224052659|NCT01188200|OTHER|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
224052660|NCT01188200|OTHER|Standard food|Standard meal prior to test time
224052661|NCT04594590|GENETIC|Mutation analysis|The investigators will sequence DNA samples from the patients or their families.
224144912|NCT05174130|DEVICE|RESPIRA device.com® Advanced|Ventilation of patients with continuous monitoring of the patient's clinical parameters and the parameters that the investigational medical device shows.
224144913|NCT05603039|DRUG|QL1706|5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
223441178|NCT00904839|DRUG|BIBF 1120|BIBF 1120 100 and 150 mg capsules
223441179|NCT00904839|DRUG|mFolfox|standard i.v chemotherapy
223741029|NCT07205393|OTHER|Cardiac rehabilitation|"The intervention group underwent the cardiac rehabilitation program from the first day following surgery regarding the clinical guideline for rehabilitation in patients with cardiovascular disease.17 This rehabilitation exercise program formed of breathing exercises, lower and upper extremity exercises in bed, sitting on the edge of the bed, standing at the bedside, and walking around the bed and for 100 m in the ward. The patient performed three sessions per day, with approximately 20 minutes each time. After the rehabilitation exercise, patients continued with gait practice for up to 500 m and carried out endurance training by using a stationary bike in the rehabilitation center of the hospital.~The essions continued until they were discharged from the hospital (approximately 5 to 6 days post operative). The intensity of physical activity was limited by clinical conditions and activity tolerance, and monitored and assessed by physical therapists. Plus routine clinical care"
223741030|NCT07205393|OTHER|Routine clinic care|The control group did not joined any rehabilitation program and only received routine clinical care during the duration of the hospital stay (approximately 5 to 6 days post operative).
223741031|NCT07206979|DIETARY_SUPPLEMENT|Hydration Active Product 1|Participants will use their Hydration Active Product 1 as directed for a period of 1 week.
224144914|NCT05603039|DRUG|QL1604|200mg#D1#Q3W IV
224144915|NCT05603039|DRUG|Bevacizumab|15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
223441180|NCT00904839|DRUG|Bevacizumab|100 mg/Kg solution , IV infusion
223441181|NCT00904839|DRUG|mFolfox 6|IV standard chemotherapy
223441182|NCT00904839|DRUG|bevacizumab|100 mg/4 ml solution
223741032|NCT07206979|DIETARY_SUPPLEMENT|Hydration Active Product 2|Participants will use their Hydration Active Product 2 as directed for a period of 1 week.
223741033|NCT07206979|DIETARY_SUPPLEMENT|Hydration Active Product 3|Participants will use their Hydration Active Product 3 as directed for a period of 1 week.
223741034|NCT07206069|BEHAVIORAL|Standard Care (in control arm)|This Standard Care involves a recorded video education and in-person visit.
223741035|NCT07206069|BEHAVIORAL|Telemedicine Shared Decision-Making|This intervention involves two live telemedicine video visits.
224052662|NCT05073497|OTHER|Finger puppets|In the experimental group, for distraction the researcher will put finger puppets consisting of various animal figures on his finger, and will ask the child to imitate these sounds by making animal-specific sounds that he moves with his finger. The researcher will also draw the child's attention to finger puppets by using methods such as making animals talk to each other and singing before and during venipuncture.
224052663|NCT01979159|BEHAVIORAL|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
224144916|NCT05691829|DRUG|Pembrolizumab|Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
224144917|NCT05691829|RADIATION|Radiation|One-time, up-front radiation delivered at up to five metastatic subsites at a 4 Gy x 5 radiation dose fractionation schedule. Radiation will be delivered within five days before or after initiation of first cycle of pembrolizumab treatment. Radiation modality and technique will be determined at the discretion of the treating radiation oncologist.
224144918|NCT05691829|DRUG|Chemotherapy|Administered alongside pembrolizumab every 3 weeks for 6 cycles per institutional standard of care. For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and paclitaxel or nab-paclitaxel
223441183|NCT00265525|BEHAVIORAL|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
223441184|NCT04344535|BIOLOGICAL|Convalescent Plasma|450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally \> 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.
223441185|NCT04344535|BIOLOGICAL|Standard Donor Plasma|450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
224052664|NCT00906802|PROCEDURE|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
224052665|NCT03281668|BEHAVIORAL|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
224052666|NCT02718781|BEHAVIORAL|Health talk|Health talk on zero-time exercise.
224052667|NCT02718781|BEHAVIORAL|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
224052668|NCT02718781|DEVICE|Handgrip|This is a home-based equipment
223441186|NCT03598582|DRUG|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
223441187|NCT00553358|DRUG|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
223441188|NCT00553358|BIOLOGICAL|Trastuzumab|Therapeutic Monoclonal Antibody
223441189|NCT00553358|DRUG|Paclitaxel|antimicrotubule agent
223441190|NCT05292482|PROCEDURE|pharmacopuncture therapy|This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
223441191|NCT05292482|PROCEDURE|physical therapy|This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
223441192|NCT05840328|DRUG|Dexmedetomidine Injection [Precedex]|interventional drug will be administred either intravenously or epidurally
223441193|NCT05840328|DRUG|Bupivacaine Injection|intervention drug will be administred epidurally
223441194|NCT03887156|DIAGNOSTIC_TEST|Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test|Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
223441195|NCT03946228|BEHAVIORAL|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
223441196|NCT02929966|OTHER|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
223441197|NCT02929966|OTHER|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
223441198|NCT01325194|DRUG|liposomal cytarabine|50 mg intrathecally three times
223441199|NCT06308536|PROCEDURE|bone powder + collagen membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane.
223441200|NCT06308536|PROCEDURE|bone powder + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
223441201|NCT06308536|PROCEDURE|bone powder mixed wih CGF gel + collagen membrane + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder mixed with CGF gel (CGF gel is cutted into granules ), and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
223441202|NCT06308536|PROCEDURE|bone powder + CGF membrane|Fill the extraction socket with Bio-Oss® bone powder and cover the extraction wound with CGF membrane(CGF gel is pressed into a film)
223441203|NCT01840137|OTHER|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
223441204|NCT01840137|OTHER|Exercise|Treadmill and muscle exercises.
223441205|NCT00495599|PROCEDURE|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
224052669|NCT02656459|OTHER|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
223441206|NCT02869841|DRUG|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
223441207|NCT02869841|DRUG|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
224052670|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
224052671|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
224052672|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
224300541|NCT05485220|OTHER|High-intensity interval training|High-intensity interval training Group: Peak workload will be determined by performing an exercise test on the patients and arm ergometer HIIT will be done with a total of 45 minutes, 90-95% of the peak workload for 30 seconds, 60 seconds in between, active recovery at 40-50% workload, 3 days a week for 8 weeks.
224300542|NCT01690221|DRUG|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
224300543|NCT01690221|DRUG|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
223441208|NCT02869841|DRUG|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
223441209|NCT02869841|OTHER|Placebo|No rectus sheath analgesia
223441210|NCT05528484|PROCEDURE|ERAS nursing|Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc
223441211|NCT05528484|PROCEDURE|non eras nursing|Patients were under the routine management without eras protocol
223441212|NCT05456854|DIAGNOSTIC_TEST|Hyperglycemic Clamp|Administration of a hyperglycemic clamp
223441213|NCT05456854|DRUG|Kisspeptin-10|Administration of kisspeptin-10 \* 16 hr
223441214|NCT05456854|DRUG|Placebo|Administration of placebo \*16 hr
224052673|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
224052674|NCT01543152|GENETIC|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
224052675|NCT03479996|DRUG|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
224052676|NCT02932410|DRUG|Macitentan|Dispersible tablet; Oral use
224052677|NCT02932410|OTHER|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and IV/SC prostanoids.
224144919|NCT03457740|DIETARY_SUPPLEMENT|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
224144920|NCT03457740|DIETARY_SUPPLEMENT|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
224144921|NCT03457740|DIETARY_SUPPLEMENT|Placebo|Placebo comparison
224144922|NCT01187134|BEHAVIORAL|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
224144923|NCT05710965|DEVICE|FRx-001|Wearable digital therapy
224300544|NCT06729138|OTHER|Resisted Sprint Training|In this intervention, participants will perform 16 sessions of resisted sprint training with external loads using a sled over eight weeks. In these 16 sessions the intensity will vary in both the distance to be covered and the load to be moved.
224052678|NCT01035775|PROCEDURE|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
224052679|NCT01035775|PROCEDURE|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
224052680|NCT04391348|RADIATION|PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine|Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
224052681|NCT00002142|DRUG|Cidofovir|
224144924|NCT05710965|DEVICE|FRx-003|Wearable digital therapy
224144925|NCT05710965|DEVICE|FRx-004|Wearable digital therapy
224144926|NCT06527508|OTHER|Non-Interventional|This study has a observational design
224144927|NCT06456138|DRUG|Trametinib|Trametinib will be administrated orally every day.
224144928|NCT06456138|DRUG|Anlotinib|Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.
224052682|NCT00002142|DRUG|Probenecid|
224300545|NCT06729138|OTHER|Sprint Training|In this intervention, participants will perform 16 sessions of sprint training over eight weeks. In these 16 sessions the intensity will vary in the distance.
223566796|NCT06860490|PROCEDURE|HAIC|FOLFOX regimen (oxaliplatin, 85 mg/m2 from hour 0-2 on day 1; leucovorin, 400 mg/m2 from hour 2-3 on day 1; and ﬂuorouracil, 400 mg/m2 bolus at hour 3 on day 1 and 2,400 mg/m2 over 24 hours) via infusion via the hepatic artery. HAIC was repeated once every 3 weeks for up to four cycles. Sintilimab plus bevacizumab will be administered 1-3 days after HAIC.
224144929|NCT06456138|DRUG|Tislelizumab|Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.
224144930|NCT04173039|DIAGNOSTIC_TEST|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
223566797|NCT06897176|DRUG|Cerebrolyisin|This intervention uses Cerebrolysin, which is a treatment aimed at improving language abilities and providing neuroprotection for patients with non-fluent aphasia following a stroke. Cerebrolysin is administered via intravenous injection, with the goal of improving language skills and promoting brain function recovery. The treatment is evaluated based on improvements in language abilities, neurological function recovery, and safety.
224052683|NCT02471703|DEVICE|Total hip arthroplasty|Total hip arthroplasty
224052684|NCT03870542|PROCEDURE|kidney transplantation|Kidney transplant for end-stage renal disease from deceased kidney donors
224052685|NCT04193046|OTHER|Blood Sample|Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
224052686|NCT04425291|BIOLOGICAL|4-valent HPV Vaccine|Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.
224052687|NCT04425291|BIOLOGICAL|9-valent HPV Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
224052688|NCT04425291|BIOLOGICAL|GARDASIL®|Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.
224052689|NCT06220539|OTHER|Casting and supervised rehabilitation|casting (8 weeks) followed by supervised rehabilitation
224052690|NCT05021107|OTHER|FDM with isometrics|FDM with isometrics will be done
224144931|NCT01184456|DIETARY_SUPPLEMENT|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
224144932|NCT01184456|DRUG|Placebo|1 capsule per day for 90 days.
224144933|NCT05730374|BEHAVIORAL|Benson's Relaxation technique|Each child in the study group had an individual interview with researchers, who demonstrated the Benson relaxation technique while teaching them. The child was then asked to demonstrate it. sit quietly in a comfortable position in separate room., close eyes, deeply relax all muscles, beginning at the feet and progressing up to the face and breathe through nose. Become aware of breathing pattern. As breathes out, say the word one silently to child. For example, breathe in, and then out, say one, in and out, and repeat one. Breathe easily and naturally. It is Continue for 10 minutes and repeated two times.
224144934|NCT05730374|BEHAVIORAL|Music therapy|"* The child lessen to a Mozart's music, which is played before and throughout the blood transfusion procedure. Ambient noise can be reduced by using headphones. As a result, it is easier to see how the intervention has succeeded.~* This intervention was done using an MP3 player during the blood transfusion procedure and immediately following the completion of the intervention to prevent the transmission of infections headphones were cleaned with disinfectant after each -use."
224144935|NCT00004226|RADIATION|radiation therapy|
224144936|NCT06269718|OTHER|swallowing therapy|oral exercises, tongue movement, and compensatory techniques, swallowing maneuvers and food modifications, will be performed by an experienced speech and language therapist during intervention
223441215|NCT05070143|BEHAVIORAL|RISE-UP Routine|The participants in this condition will be instructed to substitute their current sleep habits with the RISE-UP routine that has been developed by our team (Kaplan, Talavera, \& Harvey, 2018). This involves instructing participants to devise an individually tailored routine that will help them get up each morning (e.g., open blinds, make the bed, head for the shower).
223441216|NCT05070143|BEHAVIORAL|Awareness Training|The participants in this condition will be instructed in dismantling/disrupting the association between the cue and the habit via awareness training from habit reversal approaches (Azrin \& Nunn, 1973; Ladouceur, 1979). This condition involves instructing the participant to develop an awareness of their decisions to stay in bed and snooze.
223441217|NCT05070143|BEHAVIORAL|Vigilant Monitoring|"The participants in this condition will be instructed in vigilant monitoring which involves internal repetition of get up! and don't do it and watching carefully for slipups (Quinn, Pascoe, Wood, \& Neal, 2010)."
223441218|NCT05070143|BEHAVIORAL|Implementation Intentions|"The participants in this condition will be instructed in counter habitual implementation intentions. This involves instructing the participant to engage in implementation intentions in which they imagine replacing snoozing with getting up out of bed (Adriaanse, Gollwitzer, De Ridder, De Wit, \& Kroese, 2011). The structure of this implementation intention is: If I wake up in the morning and I want a sleep-in then I will get up and start my day."
223441219|NCT05070143|BEHAVIORAL|Values-based Approach|The participants in this condition will be instructed in a values-based approach (Anshel, Brinthaupt, \& Kang, 2010; Anshel \& Kang, 2007). This involves asking the participants to reflect on how getting up consistently at the same time each day does or does not align with their values. They are asked to compare the costs and long-term consequences of continuing to engage in the unwanted habit and clearly articulating the disconnect between the habit and their values.
223441220|NCT05070143|BEHAVIORAL|Brief Education|"In this condition, participants only receive the learning module. This condition is included as a minimal intervention comparison condition that controls for the passage of time.~First, education about the importance of regular wake times and sleep inertia that is a normal transitional stage between sleep and wake. The education will be delivered in this video format: https://www.youtube.com/watch?v=P6zcSFA7ymo. Second, after viewing the video, the key points will be summarized. Lastly, participants will be asked to summarize the four key takeaways for good sleep habits."
224052691|NCT05021107|OTHER|FDM without isometrics|FDM without isometrics will be done
224052692|NCT01901575|DRUG|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
224052693|NCT05335356|BIOLOGICAL|Stelara|45 mg , 90 mg at Week 0, 4, 16, 28 and 40;During the study after receiving 2 doses , before dosing at Week 16 patients were re-randomised in a 1:1 ratio to receive either Bmab 1200 or Stelara .
224052694|NCT05335356|BIOLOGICAL|Bmab1200|45 mg , 90 mg at Week 0, 4, 16, 28 and 40
224052695|NCT05109286|BEHAVIORAL|CrossFit|CrossFit training
224144937|NCT06269718|OTHER|IOPI therapy|tongue muscle strengthening and endurance exercises by using 15-min IOPI biofeedback program. The biofeedback will be 50%-60% of maximal strength. (total 1 hour/session for 10 sessions)
224144938|NCT05446974|OTHER|Nursing Competency Enhancement Training Program in PTSD Intervention|This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
224144939|NCT01804257|OTHER|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
224144940|NCT03437291|PROCEDURE|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
224144941|NCT03437291|DEVICE|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
224052696|NCT03503409|DRUG|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
224052697|NCT04702737|DRUG|Tarlatamab|Tarlatamab will be administered as an intravenous (IV) infusion.
224052698|NCT03484286|DEVICE|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
224052699|NCT03484286|OTHER|Standard care|Patients in the control group will be subject to standard heart failure care.
224052700|NCT06378671|PROCEDURE|General treatment|routine bronchoscopy examination, lavage, and mucosal biopsy
224052701|NCT06378671|PROCEDURE|Cryotherapy Treatment|local cryotherapy treatment (around the left and right main bronchi, upper trachea, and carina)
224052702|NCT03256955|DEVICE|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
224052703|NCT03256955|DEVICE|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
224052704|NCT03184077|PROCEDURE|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
224052705|NCT03184077|PROCEDURE|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
224052706|NCT02509806|DRUG|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
224052707|NCT01675635|DRUG|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
223441221|NCT01540084|DRUG|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
223441222|NCT01287975|OTHER|Occupational Therapy|"Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively."
223441223|NCT01287975|DEVICE|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
223441224|NCT01287975|DEVICE|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
224052708|NCT01675635|OTHER|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
224052709|NCT02780674|BIOLOGICAL|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
224052710|NCT02780674|BIOLOGICAL|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
224052711|NCT03159091|DRUG|Rengalin|Oral administration.
224144942|NCT03437291|DEVICE|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
224144943|NCT06252246|DEVICE|Phacoemulsification machine|type of phacoemulsification machine is different
224300546|NCT06727877|DIAGNOSTIC_TEST|Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.|"The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.~The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns."
224300547|NCT06456879|OTHER|extra-coronal restoration type|primary molar crown type
224300548|NCT04441645|OTHER|Acupressure|acupressure once per day, five times per week, a total of 12 weeks
224300549|NCT06785480|DEVICE|Computer Controlled Local Anesthetic Delivery (CCLAD)|Administering local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline) with CCLAD. The CCLAD device is set to 60sec/ml in continuous mode.
224300550|NCT06785480|DEVICE|Conventional metallic syringe|A conventional metallic syringe is used to administers local anesthesia with 1.2ml Septanest normal (4% articaine, 1/200000 adrenaline).
224300551|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
224300552|NCT00321737|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
223441225|NCT05061485|OTHER|Sucrose|The participants consume A) water with 75 g sucrose
224052712|NCT03159091|DRUG|Placebo|Oral administration.
223441226|NCT05061485|OTHER|Sucrose + protein|The participants consume B) water with 75 g sucrose + approx. 100 kcal protein
223441227|NCT05061485|OTHER|Sucrose + fat|The participants C) water with 75 g sucrose + approx. 100 kcal fat
223441228|NCT01612507|DRUG|600 mg Ceftaroline fosamil|1 h infusion
223441229|NCT01612507|DRUG|Placebo|1 h infusion
223441230|NCT01612507|DRUG|600 mg Ceftaroline fosamil|2 h infusion
223441231|NCT01612507|DRUG|Placebo|2 h infusion
224052713|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
224052714|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
224052715|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
224052716|NCT00262522|DRUG|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
224052717|NCT05865535|BIOLOGICAL|AV-380|AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
224052718|NCT03929666|DRUG|ZW25 (Zanidatamab)|"* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~* Part 2: RD identified in Part 1"
224144944|NCT02661620|DEVICE|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
224144945|NCT03219801|BIOLOGICAL|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
224300553|NCT00321737|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
224300554|NCT06928311|OTHER|Exercise Environment|This intervention focused around the environmental design of the exercise room.
224300555|NCT04772391|OTHER|Exercise Sessions|Participant will complete up to 8 exercise sessions
224052719|NCT03929666|DRUG|Capecitabine|Administered orally twice daily (PO bid)
223441232|NCT00208234|DRUG|Omalizumab|0.016 mg/kg IgE
223441233|NCT00208234|DRUG|Placebo for Omalizumab|Placebo
223441234|NCT00208234|DRUG|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
223441235|NCT01010399|DIETARY_SUPPLEMENT|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
223441236|NCT01010399|DRUG|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
223441237|NCT04129775|DRUG|OTO-413|Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
223441238|NCT04129775|DRUG|Placebo|Single intratympanic injection of placebo
223441239|NCT02900261|OTHER|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
223441240|NCT01448603|BIOLOGICAL|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
223441241|NCT01448603|BIOLOGICAL|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
223441242|NCT05538923|OTHER|No intervention was given to the patients|This study was an observational epidemiological study.
224052720|NCT03929666|DRUG|Cisplatin|Administered IV
224052721|NCT03929666|DRUG|Fluorouracil|Administered IV
224052722|NCT03929666|DRUG|Leucovorin|Administered IV
224052723|NCT03929666|DRUG|Oxaliplatin|Administered IV
224052724|NCT03929666|DRUG|Bevacizumab|Administered IV
224052725|NCT03929666|DRUG|Gemcitabine|Administered IV
224052726|NCT04814823|DEVICE|Pulse oximeter|OLV-4202 pulse oximeter (SW version: 01-11)
224052727|NCT04875715|OTHER|Almond Oil|Almond oil
224052728|NCT04875715|DRUG|Hydroquinone Topical|Hydroquinone 2% cream
224052729|NCT02798549|OTHER|blood draw|blood draw of 150ml, twice
224052730|NCT06683937|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file
224052731|NCT03193151|PROCEDURE|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
224052732|NCT03462719|DRUG|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
224052733|NCT03462719|DRUG|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
224052734|NCT03462719|DRUG|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
224052735|NCT03462719|DRUG|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
224052736|NCT03462719|DRUG|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
224052737|NCT06264752|OTHER|Level A|Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician.
224052738|NCT06264752|OTHER|Level B|The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted.
224052739|NCT06264752|OTHER|Passive Alert|Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management.
224052740|NCT03461419|PROCEDURE|Microcannula Harvest Adipose Stroma|Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells
224052741|NCT03461419|DEVICE|Centricyte 1000|Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
224052742|NCT03461419|PROCEDURE|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
224052743|NCT06211569|OTHER|Usual follow-up|Usual follow-up
223441243|NCT00347321|PROCEDURE|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
223441244|NCT05268016|DRUG|ME3183|ME3183 capsule
223441245|NCT05268016|DRUG|Placebo|Placebo capsule
223441246|NCT04122755|DRUG|ALA-1000|Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
223441247|NCT04122755|DRUG|buprenorphine sublingual film|ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
223441248|NCT02742714|DEVICE|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
223441249|NCT03727295|DRUG|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
223441250|NCT01375634|DRUG|Midazolam|2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
223441251|NCT01733823|RADIATION|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
223441252|NCT03579823|DRUG|Adalimumab 100 MG/ML [Humira]|prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
223441253|NCT03579823|DRUG|AVT02 100MG/ML|prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
223566798|NCT06897176|DRUG|Placebo|The placebo is administered alongside standard language therapy to the patients with non-fluent aphasia following a stroke. This allows for comparison with the Cerebrolysin group to assess the impact of the treatment on language abilities and neurological function recovery. The goal is to evaluate the improvements in language skills, neurological function recovery, and safety, comparing the effects between the active treatment and placebo.
223441254|NCT03163459|DRUG|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
223441255|NCT03163459|DEVICE|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
223441256|NCT03900156|OTHER|goal-setting|The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
223441257|NCT06533267|PROCEDURE|Endoscopic nasopharyngectomy followed close follow-up|"Radical resection of primary lesion using nasal endoscopy.~After the treatment, the electronic nasal endoscopy was reviewed every two weeks to determine the healing of the wound, whether there was tumor recurrence, until the surgical wound was completely healed. The patients were followed up at least once every three months from the first year to the third year, at least once every six months from the fourth year to the fifth year, and at least once every year after five years."
223441258|NCT06533267|RADIATION|Intensity-modulated Radiotherapy|"GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy.~After treatment, patients were followed up every 3-6 months from the first year to the third year, every 6-12 months from the fourth year to the fifth year, and at least once a year after five years."
223441259|NCT06135116|DIAGNOSTIC_TEST|Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA|"Gingival crevicular fluid samples collection After removing supragingival plaque, sampling sites were isolated by cotton rolls and dried using air syringe, GCF samples were collected by inserting standardized paper point in the sulcus/ pocket at the proximal-facial line angle of six preselected sites in each patient teeth . Fluid was sucked by paper points for 30 seconds. The samples were immediately placed inside graduated eppendorf vials containing 250µl phosphate-buffered saline (PBS), and transported to the laboratory for subsequent assays .~Blood Samples Collection From control and patient groups and under standard aseptic conditions, the peripheral blood was collected in Ethelene Diamine Tetra Acetic Acid (EDTA) coated vacutainer tubes (K2 EDTA) 5.4mg (BD vacutainer) and transferred immediately to flow cytometric analysis lab."
223441260|NCT05127655|PROCEDURE|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
223441261|NCT00000923|DRUG|Indinavir sulfate|
223441262|NCT00000923|DRUG|Lamivudine|
223441263|NCT00000923|DRUG|Stavudine|
223441264|NCT00000923|DRUG|Zidovudine|
223441265|NCT00000923|DRUG|Didanosine|
223441266|NCT00000923|DRUG|Aldesleukin|
223441267|NCT04579614|BEHAVIORAL|The Impact of Performance Feedback and Variable Goal Setting on Flu Vaccination Success Rates of Providers|"A given provider will be involved in the study for a maximum of 6 months. This will involve, at the most frequent, the delivery of weekly performance feedback.~The performance feedback will be delivered using standard approaches already in place in the organization and there will not be a period of seeking out participants for enrollment.~Providers will receive performance feedback bi-weekly for the duration of the study period."
223441268|NCT05482906|OTHER|eGait|IMU sensor (as part of eGait device) worn at the hip during T25FW
223441269|NCT00404924|DRUG|ZD6474 (vandetanib)|once daily oral tablet
223441270|NCT00404924|OTHER|Best Supportive Care|standard of care
223441271|NCT02215785|OTHER|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
223744853|NCT04889339|DEVICE|Test brace versus control brace: Immediate correction|The trunk surface will be scanned to reconstruct a numerical model of the patient's trunk, this reconstruction will help to produce the optimized brace. The patient skeletal will also be reconstructed from a bilateral radiograph using an EOS imaging system. Each patient will try both the control and the test brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between the immediate correction of the braces. The SRS-22r will be collected. The study protocol requires no additional visits beyond the standard of care. There will be one additional radiograph compared to the standard of care.
224052744|NCT03740165|BIOLOGICAL|Pembrolizumab|IV infusion
224052745|NCT03740165|DRUG|Placebo for pembrolizumab|IV infusion
224052746|NCT03740165|DRUG|Carboplatin|IV infusion
223441272|NCT00394316|DRUG|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
223441273|NCT03887429|DRUG|SXC-2023|SXC-2023 oral capsules
223441274|NCT03887429|DRUG|Placebos|Matching Placebo oral capsules
223441275|NCT00776620|DRUG|Glimepiride 1mg Tablets|
224052747|NCT03740165|DRUG|Paclitaxel|IV infusion
223441276|NCT01197209|BIOLOGICAL|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
223441277|NCT03737266|PROCEDURE|Sonographically assisted breast surgery|Sonography
223441278|NCT03737266|PROCEDURE|Conventional breast surgery|Conventional
223441279|NCT01216046|DRUG|VX-809|capsule, taken once daily
223441280|NCT01216046|DRUG|VX-770|tablet, taken once every 12 hours
223441281|NCT01216046|DRUG|VX-809 placebo|capsule, taken once daily
223441282|NCT01216046|DRUG|VX-770 placebo|tablet, taken once every 12 hours
223441283|NCT05692804|DIAGNOSTIC_TEST|Mini Mental State Examination(MMSE),Montreal Cognitive Assessment ( MoCA),S100B ( protein S100 subunit beta) ,GFAP ( glial fibrillary acidic protein ),NSE ( neuron-specific enolase )|MMSE and MoCA will be applied preoperative,postoperative first day and fourth day S100B,GFAP and NSE will be measured in blood tests preoperative,postoperative second hour,postoperative 24. hour and postoperative 96. hour
223441284|NCT05956522|DRUG|Test Empagliflozin And Linagliptin Tablets|specification: 25 mg/5 mg, manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd
223441285|NCT05956522|DRUG|Reference Empagliflozin And Linagliptin tablets|specification: 25 mg/5 mg, manufacturer: Boehringer Ingelheim International GmbH \& Co. KG
223441286|NCT01129271|DRUG|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
223441287|NCT01129271|DRUG|Matching placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223441288|NCT00951106|DRUG|Pyrimethamine/sulfdoxine (Fansidar)|
223441289|NCT00032630|PROCEDURE|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
223441290|NCT00032630|PROCEDURE|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
223441291|NCT02503371|OTHER|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
223441292|NCT02227719|DEVICE|CTI|CTI is the titanium mesh
223441293|NCT02227719|DEVICE|Collagen membrane|
223441294|NCT03681041|OTHER|Standard treatment|Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
223441295|NCT06041906|PROCEDURE|Shunt Closure|Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.
223441296|NCT03191123|PROCEDURE|hepatic resection|The aim of this intervention is to reach curative resection.
223441297|NCT03191123|PROCEDURE|TACE|The aim of this intervention is one of the palliative treatment.
223441298|NCT00714155|OTHER|Questionnaires, Physical Examination|Questionnaires, Physical Examination
223441299|NCT03439410|OTHER|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
223441300|NCT00869583|BEHAVIORAL|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents \[METS\]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
223441301|NCT05196477|DRUG|Olokizumab|The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
223441302|NCT05196477|DRUG|Standard therapy|Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
223441303|NCT04819477|BEHAVIORAL|Fact box|"All physicians surveyed receive a fact box with numerical information on the benefits and harms of chest CT as a screening method.~In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot."
223441304|NCT04819477|BEHAVIORAL|Cates plot|In addition to the fact box, half of the participants will be randomly assigned to receive the same information in the form of a Cates plot.
223441305|NCT00839787|DRUG|Morphine Sulfate|Morphine Sulfate group: If weight is \<50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
224052748|NCT03740165|DRUG|Olaparib|Oral tablet
223441306|NCT00456261|DRUG|Pemetrexed|pemetrexed 500 mg/m2
223441307|NCT00456261|DRUG|Gemcitabine|gemcitabine 1500 mg/m2
223441308|NCT00456261|DRUG|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
223441309|NCT00456261|DRUG|Carboplatin|carboplatin AUC=5
223441310|NCT05777083|DIAGNOSTIC_TEST|KardiaMobile 6L|Before coronary angiography, all participants will contact both fingers on the two probes at the front side of portable 6-leads electrocardiogram recorder (KardiaMobile 6L), and be recorded all six leads by contacting the other side of probe at lower extremities (left hip bone ridge, thigh, knee, lower abdomen, etc.).
223441311|NCT01322698|BIOLOGICAL|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
223441312|NCT02156063|DRUG|NT100|
223441313|NCT02156063|DRUG|Placebo|
223441314|NCT00624039|OTHER|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
223441315|NCT04217824|PROCEDURE|pilonidal sinus excision|Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
223441316|NCT02195596|OTHER|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
224052749|NCT03740165|DRUG|Placebo for olaparib|Oral tablet
224052750|NCT03740165|BIOLOGICAL|Bevacizumab|IV infusion
224052751|NCT03740165|DRUG|Docetaxel|IV infusion
224052752|NCT04157985|DRUG|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
224052753|NCT04157985|OTHER|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
224052754|NCT06598059|DEVICE|Cochlear implant|CI632D cochlear implant
224052755|NCT06598059|DRUG|Dexamethasone|CI632D, dexamethasone-eluting cochlear implant
224144946|NCT00640146|DRUG|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
224144947|NCT00640146|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
223441317|NCT02195596|OTHER|Low intensity aerobic exercise+strength|"Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~\--------------------------------------------------------------------------------"
223441318|NCT02917655|BEHAVIORAL|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
223441319|NCT02917655|BEHAVIORAL|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
223441320|NCT02917655|BEHAVIORAL|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
223441321|NCT02917655|BEHAVIORAL|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
223441322|NCT02917655|BEHAVIORAL|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
223441323|NCT02917655|BEHAVIORAL|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
223441324|NCT02917655|BEHAVIORAL|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
223441325|NCT02917655|BEHAVIORAL|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
223441326|NCT02917655|BEHAVIORAL|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
223441327|NCT02917655|BEHAVIORAL|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
223441328|NCT02917655|BEHAVIORAL|Sessions with the physical educators team|Participate in a extra session group with the physical educators
223441329|NCT02917655|BEHAVIORAL|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
223441330|NCT02917655|BEHAVIORAL|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
223441331|NCT03485703|DRUG|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
223441332|NCT03485703|DRUG|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
223441333|NCT06070675|DEVICE|Minze Diary Pod|The automated bladder diary utilized in this study consists of the Minze Diary Pod and Minze Flow app. The Diary Pod is a capacitance-based measuring device, that automatically registers voided volumes and time of void. The Diary Pod connects via Bluetooth to the Minze Flow app to request additional information from the patient, such as urge, drinks and leakages.
223441334|NCT06070675|OTHER|Paper bladder diary|The paper bladder diary utilized in this study is a paper timetable that has the patient enter (in the columns of the timetable) drinks in ml, urinations in ml (using a measuring cup) and leakage episodes for the nearest hours (rows of the timetable).
224052756|NCT06582173|OTHER|Face-to-face interviews assisted by a biographical grid|"Face-to-face interviews assisted by a biographical grid.~Healthcare event of the adolescent :~* medical specialist appointment~* general practitioner appointment~* emergency services use~* hospital admission~* diagnostic test~* medication use~* non-pharmacological treatment~* nursing or physical therapy~* alternative care~Biographical of the adolescent :~* Education event~  * Class/level~ * School~ * Attendance~ * Special arrangements~ * Grades~ * Off school education~* Family event~  * Separation/union~ * Birth/death~ * Leave/Arrival~ * Location/Moving~ * Disease/accident~* Peer events~  * Friendships~ * Love interests~ * Bullying~* Leisure \& interests events~  * Activity~ * Frequency"
223441335|NCT01422707|DRUG|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
223441336|NCT03613688|DIETARY_SUPPLEMENT|Deepure|Pu'erh Tea extract
223441337|NCT06139705|OTHER|Walking outdoor|The individuals will walk in park along a pre-designated route 20 min.
223441338|NCT06139705|OTHER|Walking indoor|The individuals will walk in a gym on a treadmill 20 min.
223441339|NCT05008471|DIETARY_SUPPLEMENT|Formula nutrition|The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
223441340|NCT05872659|OTHER|normal saline|iv at D0, D30, D60
223441341|NCT05872659|BIOLOGICAL|Mesenchymal stem cells|iv at D0, D30, D60
223441342|NCT04859309|BEHAVIORAL|ActiveHip+ mobile application|The mobile application with the educational and multidisciplinary tele-rehabilitation program.
223441343|NCT04859309|PROCEDURE|Standard care in a hip fracture|The participants of this group will receive the standard treatment for a hip fracture in the Andalusian healthcare system.
223441344|NCT00187278|DEVICE|Biventricular Pacing|Biventricular Pacemaker implant
223441345|NCT00187278|DEVICE|RV Pacing|Standard Pacemaker implant
223441346|NCT04949204|PROCEDURE|Wearable sensor detection|Empatica E4 wearable wrist sensor
223441347|NCT00803205|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
223441348|NCT00803205|DRUG|Placebo|Placebo matching to ataluren will be provided.
223441349|NCT06730620|DRUG|Test preparation：Methylcholine chloroacetate for inhalation|Cholinergic agonists
223441350|NCT06730620|DRUG|Reference preparation：Methylcholine chloroacetate for inhalation（(Provocholin）|Cholinergic agonists
223441351|NCT04885894|DRUG|Zeposia|Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
223441352|NCT03276468|DRUG|Atezolizumab|1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
223441353|NCT03276468|DRUG|Obinutuzumab|1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
223441354|NCT03276468|DRUG|Venetoclax|800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes\>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
223441355|NCT05604794|COMBINATION_PRODUCT|Ketamine-Assisted Psychotherapy (KAP)|KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
223441356|NCT04116723|DEVICE|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
223441357|NCT02735096|DEVICE|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
223441358|NCT00270231|DRUG|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
223441359|NCT00270231|DRUG|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
223441360|NCT03099772|BEHAVIORAL|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
223441361|NCT00379808|DRUG|montelukast|10 mg tablet (masked by capsule) daily for 1 month
223441362|NCT00379808|DRUG|Placebo|1 lactose-containing capsule daily for 1 month
223441363|NCT04097197|BEHAVIORAL|Brief educational intervention|same as before
223441364|NCT01388504|DRUG|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
223441365|NCT01388504|OTHER|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
223441366|NCT01432561|DRUG|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
224052757|NCT06337357|BEHAVIORAL|Progressive Resistance Training|"Progressive resistance training includes face-to-face education on resistance training:~Resistance exercises with elastic bands include 9 exercises for 1 course. During the first 4 weeks, the patient exercises twice a week with a level of exertion according to Borg's category-ratio 10 (CR10) scale of 4-5 points. For the next 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 6-7 points. In the last 4 weeks, the patient exercises twice a week with Borg's CR10 exertion level of 8-9 points.~The three-month intervention involves twelve weekly calls, with a focus on building rapport (e.g. providing feedback on the baseline assessment); education reinforcement on resistance training; and skill-building (e.g. self-monitoring and resistance training diary). The emphasis is on helping participants to gain the knowledge and skills necessary to achieve targeted intensity. Every 4 weeks, all patients are re-visited by investigators in the hospital."
224052758|NCT06036641|DEVICE|NIRS monitoring|All participants will undergo NIRS monitoring of muscle and cerebral tissue oxygenation intraoperatively.
224052759|NCT06036641|DEVICE|Laser Doppler flowmetry|Cutaneous blood flow will be assessed intraoperatively via Laser Doppler flowmetry in all participants
224052760|NCT06036641|OTHER|Inflammatory and Oxidative stress biomarkers|Blood samples will be taken to measure biomarkers of inflammation and oxidative stress at specific time points
224052761|NCT04815044|OTHER|Pregnancy|Experiences from being pregnant when having a history of eating disorder
224052762|NCT04815044|OTHER|Post-Partum|Experiences from the post-partum period when having a history of eating disorder
223441367|NCT03689101|PROCEDURE|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
223441368|NCT00540904|DRUG|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
223441369|NCT00540904|DRUG|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
224052763|NCT04272892|BEHAVIORAL|Digital cognitive behavioural therapy for insomnia|6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
224052764|NCT04272892|BEHAVIORAL|Sleep hygiene information|A leaflet detailing advice to improve sleep through changes in sleep hygiene
224052765|NCT06557122|DEVICE|SOC and Advanced Bioengineered Skin Substitute|SOC primary dressing with Helicoll®
224052766|NCT06557122|OTHER|SOC and Active Comparator|SOC primary dressing with Epifix® or Grafix®
223441370|NCT02930746|DRUG|BAY987516|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-092)
223441371|NCT02638376|RADIATION|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
223566799|NCT06827327|DIETARY_SUPPLEMENT|LC-Plasma|1 tablet containing 50mg LC-Plasma is taken daily for 24 weeks
223566800|NCT06827327|OTHER|Placebo|1 tablet containing 50mg MCC is taken daily for 24 weeks
224052767|NCT06368921|BIOLOGICAL|VRT106|intratumoral injection
224052768|NCT05208762|DRUG|PF-08046054|Given into the vein (IV; intravenously)
224052769|NCT05208762|DRUG|pembrolizumab|200 mg once every 3 weeks given into the vein (IV; intravenously)
224052770|NCT03977402|OTHER|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
223441372|NCT02638376|PROCEDURE|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
224052771|NCT06370624|DIAGNOSTIC_TEST|MRI-scan|IRM-scan at rest under neonatologist monitoring.
224052772|NCT06553625|DEVICE|Radiofrequency Ablation|Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery
224052773|NCT06012435|DRUG|sigvotatug vedotin|Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle
224052774|NCT06012435|DRUG|docetaxel|75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle
224144948|NCT00609804|DRUG|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
224144949|NCT00609804|DRUG|Erlotinib|Erlotinib 150 mg once daily by mouth
223441373|NCT01904318|DRUG|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
223441374|NCT01904318|DRUG|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
223741036|NCT07206082|DEVICE|Laser atherectomy|"ELCA procedure will be performed using the Spectranetics CVX300 (Spectranetics, Colorado Spring, CO, USA) and the latest generation Philips Laser System Excimer (Philips, San Diego, CA, USA) System, which is based on pulsed xenon-chlorine laser catheters capable of delivering excimer energy (wavelength 308 nm, pulse length 185 ns) from 30 to 80 mJ/mm2 (fluencies) at pulse repetition rates from 25 to 80 Hz.~The ELCA technique will be performed according to current recommendations (18). The laser probe size will be at the operator´s discretion among the available options (rapid exchange concentric 0.9 mm, 1.4 mm, 1.7mm or 2.0mm). The selection of fluence, and repetition rate will be left to the operator. A saline infusion technique will be recommended, although application of laser with blood or contrast will be recommended in resistant lesions. In the event of unsuccessful initial therapy, additional plaque modification techniques may be employed at the discretion of the operator and wi"
223741037|NCT07205315|BIOLOGICAL|GT801 Injection|GT801 Injection
223441375|NCT01904318|DRUG|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
224052775|NCT05089799|BEHAVIORAL|Exposure and interaction with a socially assistive robot|"Description of scenarios involving robot and users~1. welcoming patients and family members l: the robot explains its own functionalities and answers persons 'questions.~2. providing a reminder about sanitary gestures (prevention of virus transmission). In addition, it could mediate a conversation between two or more people so that they keep the appropriate physical distance between them.~3. providing patients with an assistance to prepare the medical consultations : the robot helps patients to fill in paper forms for professionals. The robot also provides information on the course of consultations and the users 'rights in the hospital.~4. providing orientation and guidance to the consultation rooms and the available services : the robot helps people to find their way around the hospital.~5. Providing entertainment to patients and families during the waiting time: the robot offers activities to patients and caregivers"
224052776|NCT06275048|OTHER|Wrist/hand immobilization|Study participants will have their left wrist/hand immobilized with a splint for 7 days. The splint will be worn 24 hours per day.
224052777|NCT05318937|DRUG|SAGE-718-matching placebo|Oral capsules
224052778|NCT05318937|DRUG|SAGE-718|Oral capsules
224144950|NCT04992637|BEHAVIORAL|ClockWork|ClockWork is a behavioral weight loss intervention comprised of coaching sessions as well as digital monitoring and feedback tools. It addresses 4 key behaviors related to the CTS, weight, and health and their Amount, Regularity \& Timing-the ART of ClockWork. Women will receive 12 tailored coaching sessions to review their digital monitoring of each key behavior, learn intervention content, and set goals, which are delivered in-person, by phone, or web to fit women's needs postpartum. Coaches will use women's baseline responses to tailor sessions around the key behaviors. The investigators will protocolize real-time monitoring to increase engagement and adherence, and to facilitate just-in-time adaptive reminders, recommendations, and coaching sessions.
224144951|NCT04992637|OTHER|Usual Care|Usual Care consists of the standard care that postpartum women receive without any additional intervention components.
224144952|NCT04836507|BIOLOGICAL|CRC01|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg.
223441376|NCT01904318|DRUG|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
223441377|NCT01904318|DRUG|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
223441378|NCT01904318|DRUG|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
223441379|NCT01904318|DRUG|Placebo|Placebo single dose administration
224052779|NCT01208792|PROCEDURE|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
224052780|NCT01208792|OTHER|Blood Sample|a blood sample will be collected
224052781|NCT05272150|DRUG|Guselkumab|Participants will receive guselkumab as subcutaneous injection.
224144953|NCT04836507|DRUG|Fludarabine|Administered according to package insert
224144954|NCT04836507|DRUG|Cyclophosphamide|Administered according to package insert
224052782|NCT05272150|DRUG|Placebo|Participants will receive placebo as subcutaneous injection.
224052783|NCT05441488|DRUG|Placebo|treatment per os
224052784|NCT05441488|DRUG|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
224052785|NCT02454140|RADIATION|SBRT|Fixed five-fraction stereotactic radiotherapy
224052786|NCT04209153|OTHER|Transcranial Direct Current Stimulation|tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics
224052787|NCT02479438|OTHER|Diagnosed with GERD|Recording of patient outcomes
224052788|NCT02699645|DRUG|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 pill taken orally once daily for average of 72 months
224052789|NCT02699645|DRUG|Placebo|1 pill taken orally once daily for average of 72 months
224052790|NCT05359679|BEHAVIORAL|Value Champion Training Program|Clinicians from primary care clinic sites randomized to the intervention arm of the study will complete a 6-month clinician value champion training program by participating in a series of 12 web-based training sessions. No intervention will be conducted at clinics in the control arm.
224052791|NCT05359679|OTHER|No Intervention|Usual clinical care - no value champion present at this clinical setting
224052792|NCT06965881|DRUG|Radiprodil with Carbamazepine|Participants will receive oral doses of Radiprodil in the range of 7.5mg to 30mg along with oral doses of Carbamazepine in the range of 100mg to 300mg twice daily over a period of 27 days.
224144955|NCT03926637|OTHER|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
224144956|NCT05308160|DRUG|Dapagliflozin 10Mg Tab|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
224300556|NCT06928428|BEHAVIORAL|Metacognitive therapy, blended format|Blended metacognitive therapy (bMCT): New about this treatment is that it is given both via the internet and through meetings with a therapist. Participants work with the treatment independently via an internet platform and meets their therapist for therapy sessions up to 6 times during the course of the treatment. Key components of the original manual are retained, but adapted to better fit the digital format. A handbook for therapists is developed to facilitate the implementation of the blended format and optimize execution. The digital parts of the treatment for depression and GAD consist of 10 interactive modules located in the Support and Treatment (SoB) platform. The sessions are divided in a flexible way between physical and digital sessions that therapist and patient agree on. The patient has access to all modules but receive instructions from their therapist which module is relevant for each week. During the treatment, the patient can write text messages to his/her therapist.
224052793|NCT06965881|DRUG|Radiprodil with Itraconazole|Participants will receive oral doses of Radiprodil in the range of 7.5mg to 15mg along with oral doses of Itraconazole 200mg twice daily over a period of 21 days.
224052794|NCT06578429|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Active|The study will utilize the H4 coil to administer active Deep Transcranial Magnetic Stimulation (dTMS) to the bilateral insula, a core salience network node.
224052795|NCT06578429|DEVICE|Deep Transcranial Magnetic Stimulation (dTMS) H4 coil - Sham|The study will utilize an identical protocol using the H4 coil to administer a sham condition.
224052796|NCT03320902|BEHAVIORAL|Sudden death counselling|"The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings."
224052797|NCT04221854|DIAGNOSTIC_TEST|Stool-based SDC2 DNA methylation test|Stool-based SDC2 DNA methylation test
224052798|NCT04221854|DIAGNOSTIC_TEST|Fecal immunochemical test|Fecal immunochemical test
224052799|NCT01877915|DRUG|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
224052800|NCT01877915|DRUG|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
224052801|NCT01877915|OTHER|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
224144957|NCT05308160|DRUG|Placebo|This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
224144958|NCT02448017|DEVICE|The Herbst appliance|Orthodontic functional appliance
224144959|NCT02448017|DEVICE|Twin block appliance|Orthodontic functional appliance
224300557|NCT06928701|DIETARY_SUPPLEMENT|omega-3 (n-3 Lc-PUFA), EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) plus a source of palmitoleic acid (hexadecenoic acid)|Nutritional supplements
224144960|NCT05168852|OTHER|Formlabs Permanent CB Resin|Tooth-colored, ceramic-filled permanent resin that can be fabricated with a 3D printer
224144961|NCT02967770|OTHER|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
224144962|NCT02967770|DRUG|Standard of Care Second Line Therapy|
223441380|NCT05999838|DIAGNOSTIC_TEST|HRCT chest visual scoring|"CT-based semi-quantitative scoring will be calculated according to number of lung segments affected on both sides.~The finding on each segment will be given a score from 1 to 4 as follows:~1. for ground glass opacities.~2. for reticulations and fibrotic changes.~3. for bronchiectatic changes.~4. for honeycombing and sub-pleural cysts."
223441381|NCT05521841|PROCEDURE|Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)|"Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side"
223441382|NCT05521841|PROCEDURE|Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)|"Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side."
223441383|NCT03901053|DEVICE|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
223441384|NCT03901053|DEVICE|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
224052802|NCT05269342|BEHAVIORAL|nurse-led counseling and after intervention|the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
223441385|NCT01707251|DRUG|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
223441386|NCT01707251|DRUG|Saline|Placebo control
223441387|NCT03310892|BEHAVIORAL|Generic message|Generic message
223441388|NCT03310892|BEHAVIORAL|Tailored message|Tailored message
224052803|NCT04149015|DRUG|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
224052804|NCT06312943|OTHER|Collection of joint fluid or tissue sample|During a puncture or joint surgery planned as part of the routine care of the patient, a part of the joint fluid or tissue sample will be collected in order to carry out the analyzes planned for the research.
224052805|NCT06275789|PROCEDURE|Alveolar ridge preservation|Premolar tooth will be extracted flapless and ridge preservation procedure with bone grafting material will be done.
224144963|NCT02485613|DRUG|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
224144964|NCT05808023|OTHER|FODMAP powder reintroduction|The FODMAP powders will be reintroduced in three different doses, each for three consecutive days.
224144965|NCT00371813|DRUG|Varenicline tartrate|
224144966|NCT00371813|DRUG|Placebo|
224300558|NCT06927271|OTHER|phone call based intervention|The phone call based intervention seek to educate patients about hypertension and the medications used. It also seeks to remind patients to take their medications. This will be done thrice weekly
223441389|NCT04789928|DRUG|Gentamicins-EDTA|Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.
223441390|NCT00629876|DRUG|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
223441391|NCT01186380|DEVICE|PET-512MC|Transesophageal Transducer
224052806|NCT06393127|DRUG|BI 1015550 Formulation C2|BI 1015550 Formulation C2
224052807|NCT06393127|DRUG|BI 1015550 Formulation C1|BI 1015550 Formulation C1
224052808|NCT03970096|RADIATION|Total-Body Irradiation|Undergo TBI
224052809|NCT03970096|DRUG|Thiotepa|Given IV
224052810|NCT03970096|DRUG|Fludarabine|Given IV
224052811|NCT03970096|DRUG|Tacrolimus|Given IV
224052812|NCT03970096|BIOLOGICAL|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
224052813|NCT03970096|DRUG|Methotrexate|Given IV
224052814|NCT03970096|DRUG|Cyclophosphamide|Given IV
224052815|NCT03970096|BIOLOGICAL|Peripheral Blood Stem Cell|Given IV
224052816|NCT03970096|DRUG|Cyclosporine|Given IV
224052817|NCT03970096|DRUG|Sirolimus|Given IV
224052818|NCT03970096|DRUG|Busulfan|Given IV
224052819|NCT03970096|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
224052820|NCT03970096|PROCEDURE|Echocardiography|Undergo ECHO
223441392|NCT04493151|DRUG|Imipenem, Cilastatin and Relebactam|After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
223441393|NCT00966901|DRUG|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
223441394|NCT00966901|DRUG|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
223441395|NCT00966901|DRUG|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
223441396|NCT00966901|RADIATION|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
223441397|NCT01917604|PROCEDURE|open exposure|the open surgical methods of exposing the canine is compared with control
223441398|NCT01917604|PROCEDURE|closed exposure|closed exposure is compared with control
223441399|NCT00781170|PROCEDURE|allogeneic hematopoietic SCT|
223441400|NCT03661216|DIETARY_SUPPLEMENT|Nephure Oxalate-reducing Enzyme|3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
223441401|NCT03661216|OTHER|Placebo|3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
223441402|NCT02166749|PROCEDURE|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
223441403|NCT04063605|OTHER|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
223441404|NCT04063605|OTHER|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
223441405|NCT02268370|DRUG|Dasatinib|
224052821|NCT03970096|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224052822|NCT03970096|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224052823|NCT06968052|OTHER|Strength and Feldenkrais Exercise|This is a behavioral, non-drug and non-device-based intervention combining somatic awareness through Feldenkrais principles with neuromuscular re-education. Movements emphasize minimal effort, reduced muscle tension, and improved self-perception of posture. The approach supports individualized progression and complements conventional physiotherapy without the use of pharmacological agents or medical equipment.
224052824|NCT06968052|OTHER|Strength Exercise|This is a non-drug, non-device corrective exercise program tailored for adults with forward head posture. It includes postural muscle strengthening and stretching, such as deep neck flexor activation, scapular retraction, and pectoral stretching. Additionally, participants perform diaphragmatic and thoracic breathing exercises.
224052825|NCT03339011|BEHAVIORAL|Motivational SMS text message|Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
224144967|NCT05645653|BEHAVIORAL|Motivational tteaching|A comprehensive assessment of adherence problems will be firstly conducted to identify the factors that affect adherence, including how and why these factors contribute to poor adherence. Medication-related knowledge and skills will be provided based on individual treatments and barriers to adherence. Motivational interviewing techniques will be used for a better understanding of patients' cognitive factors of adherence behavior.
224144968|NCT01894334|DRUG|Ulinastatin|
224144969|NCT01894334|DRUG|Tranexamic acid|
224144970|NCT01894334|DRUG|Edaravone|
224163947|NCT04460365|DIETARY_SUPPLEMENT|10 mg Lutein, 2 mg zeaxanthin, 10 mg meso-zeaxanthin|"This is a lutein (10mg), zeaxanthin (2mg) and meso-zeaxanthin (10mg) one-a-day food supplement which combines all three macular carotenoids.~These three nutrients are found at the back of the eye, at the macula, where they form the macular pigment (yellow colour). Meso-zeaxanthin is particularly concentrated at the centre of this pigment.~Lutein and zeaxanthin can be found in fruits and dark green leafy vegetables and meso-zeaxanthin is present in some species of fish and seafood."
224163948|NCT04460365|OTHER|Placebo|Softgel capsule containing sunflower oil (no active ingredients)
224163949|NCT00321360|DRUG|Propofol|
223441406|NCT02934087|PROCEDURE|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
223441407|NCT02568618|GENETIC|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
223441408|NCT05290480|OTHER|expiratory muscle training|participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
223441409|NCT05290480|DEVICE|Insentive spirometry|participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
223441410|NCT00207792|DRUG|filgrastim|
223441411|NCT00162994|PROCEDURE|adenoidectomy and tymapanostomy|
223441412|NCT05648240|OTHER|Blood test|Venous blood samples taken at the moment of colonoscopy to test for biomarkers
223441413|NCT04779606|DRUG|Ocular gel|3 drops instilled in the right eye
223441414|NCT01561599|DRUG|BB3|Daily intravenous administration of 2mg/kg for 4 days
224163950|NCT00321360|DEVICE|Patient maintained sedation|
223441415|NCT01561599|DRUG|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
223441416|NCT04299048|DRUG|PF-06946860|subcutaneous injection
223441417|NCT02569086|OTHER|Blood draw|
223441418|NCT03914027|BEHAVIORAL|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
223441419|NCT00231439|DRUG|IvIg|
223441420|NCT00001047|DRUG|Ethambutol hydrochloride|
223441421|NCT00001047|DRUG|Clarithromycin|
223441422|NCT00001047|DRUG|Clofazimine|
223441423|NCT00001047|DRUG|Rifabutin|
223441424|NCT03784859|DEVICE|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
223441425|NCT06499012|DIETARY_SUPPLEMENT|All-plant Protein Booster Product Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
223441426|NCT06499012|DIETARY_SUPPLEMENT|Placebo Group|Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
223441427|NCT05716217|OTHER|Arm training|Daily arm training program
223441428|NCT04220086|PROCEDURE|Pediatric massage therapy|Children with ASD will receive pediatric massage therapy twice a week for 12 consecutive weeks by professional pediatric massage doctor. In addition, they will receive parent provided pediatric massage therapy at home after their parents received the professional pediatric massage therapy training. The frequency of pediatric massage will not be more than once every day and each session last about 30 minutes.
223441429|NCT04220086|PROCEDURE|Usual care|Including Applied Behavior Analysis (ABA), Educational intervention, Interpersonal development intervention.
224052826|NCT03521024|OTHER|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
224052827|NCT03521024|OTHER|lithium disilicate|well documented in the literatures as successful restoration modality.
224052828|NCT06404125|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities. Flexion, extension, abduction, adduction, internal and external rotation angles of the shoulder complex will be evaluated in the measurement.
224052829|NCT06404125|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 10 seconds. The test will be repeated for both upper extremities separately.
224144971|NCT04142710|DEVICE|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
224144972|NCT04058158|DRUG|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
224144973|NCT04058158|DRUG|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
224144974|NCT04847141|BIOLOGICAL|C19-IG 20%|Anti-COVID-19 Immune Globulin (Human) 20%
223441430|NCT04220086|OTHER|No intervention|No intervention for healthy controls
223441431|NCT05576441|PROCEDURE|volume stable collagen matrix|Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.
223441432|NCT05576441|PROCEDURE|subepithelial connective tissue graft|SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
223441433|NCT06446349|OTHER|Brief motivational intervention|identification followed by a brief motivational intervention in pharmacies (BMI) based on the mobilisation of patients' psychosocial skills and the integration of tools to help reduce consumption of BZD/Z prescribed over the long term (≥ 6 months).
223441434|NCT02140983|DRUG|Liraglutide|90 days of liraglutide up to 1.8mg/day.
223441435|NCT02140983|DRUG|Placebo|Placebo medication
223441436|NCT05489419|BEHAVIORAL|Multimodal Prehabilitation|Physical and cardiopulmonary training, personalized nutrition and treatment of anxiety and depression.
223441437|NCT06509672|OTHER|Combined Plyometric and Endurance Training|this include Combined Plyometric and Endurance Training for 12 weeks
223441438|NCT06509672|OTHER|Plyometric Training|this include Plyometric Training for 12 weeks
223441439|NCT06509672|OTHER|Endurance training|this include Endurance Training for 12 weeks
223441440|NCT04609241|DRUG|CD79b CAR-T Cells|Each subject receive CD79b CAR-Tcells by intravenous infusion
223441441|NCT02722161|DRUG|[14C]BI 1482694|
223566801|NCT06894069|DRUG|Dexamethasone|a 2 ml solution of dexamethasone (3.3mg/ml) will be flushed in the root canal and intentionally extruded to the periradicular tissues to assess its potnetial sedative effect
223441442|NCT02622087|BEHAVIORAL|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
223441443|NCT03973333|DRUG|IMC-C103C|Weekly IV infusions
223441444|NCT03973333|DRUG|Atezolizumab|IV infusions every 3 weeks
223441445|NCT03973333|DRUG|IMC-C103C|Weekly subcutaneous Injection
223441446|NCT04384770|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT
223441447|NCT04384770|RADIATION|MRI-guided Stereotactic Body Radiation Therapy|Undergo MRI-guided SBRT
223441448|NCT04384770|OTHER|Questionnaire Administration|Ancillary studies
223441449|NCT06731517|PROCEDURE|intubation|Double-Lumen Tube Intubation
224052830|NCT06404125|DIAGNOSTIC_TEST|Numeric Rating Scale|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
224052831|NCT06404125|DIAGNOSTIC_TEST|Pain-Pressure Threshold Measurement With an Algometer|"The measurement will be performed 2 times with 3 min intervals for each region and the average of these applications will be recorded. Before the test, a trial test will be applied to the patient. With the pressure algometer, pressure will be applied to the selected points until it causes pain and the test will be terminated for that region when the patient feels pain.~The measurement includes bilateral shoulder region and left forearm as control region and Wagner manual pressure algometer (1 cm2 probe-10 kg/20 lb) will be used. The selected points will be:~1. Bilateral supraspinatus muscle: 1 cm cranial to the midpoint of the spina scapulae~2. Bilateral infraspinatus muscle: Medial edge of the scapula, intersection of the spina scapula and the inferior scapular angle~3. Bilateral upper trapezius muscle: MidN point of the line joining the acromion and C7 spinous process~4. Left forearm volar face center as control point"
224144975|NCT04847141|DRUG|0.9% Sodium chloride|C19-IG 20% matching placebo
224144976|NCT02215616|DRUG|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
224144977|NCT02215616|DRUG|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
224144978|NCT06295601|OTHER|Traditional rehabilitation|The program consists of a joint treatment in which lower extremity strengthening and balance exercises are carried out synchronously. The program will include a total of 5 minutes of warm-up, 5 minutes of cool-down and 30 minutes of exercises related to the program. The difficulty of the program will increase by changing the number of exercises and increasing the weight in strengthening exercises. Progress in balance and coordination exercises will vary by changing the ground, increasing the standing time, and keeping the eyes open and closed.
224144979|NCT06295601|OTHER|Action observation therapy and motor imagery|In the experimental group, in addition to traditional telerehabilitation, action observation and motor imagery of 4 exercises will be performed in each session. A video will be prepared for 4 exercises. Then, the participant will perform 2 minutes of action observation of each movement, followed by 1 minute of motor imagery. In addition to the traditional telerehabilitation program, a 12-minute combination of action observation and motor imagery will be performed in each session. Exercises will be changed every two weeks, gradually increasing the difficulty.
224144980|NCT00357149|DRUG|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
224144981|NCT00357149|DRUG|Concomitant cisplatin, 5-FU and radiotherapy|
223441450|NCT04172428|DIAGNOSTIC_TEST|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
223441451|NCT03066583|BIOLOGICAL|trephination with placebo|trephination under US guidance and placebo injection
223441452|NCT03066583|BIOLOGICAL|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
223441453|NCT05830669|PROCEDURE|Remote ischemic preconditioning (RIPC)|3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
223441454|NCT05830669|PROCEDURE|Sham RIPC|3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
223441455|NCT00221039|DRUG|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
223441456|NCT02801526|DRUG|CKD-330 16/5mg - A|
224144982|NCT02769078|DRUG|dabigatran|
224144983|NCT02769078|DRUG|rivaroxaban|
224144984|NCT02769078|DRUG|apixaban|
224144985|NCT02769078|DRUG|warfarin|
224144986|NCT02319213|OTHER|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
224144987|NCT02319213|OTHER|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
224144988|NCT02319213|OTHER|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
224144989|NCT02128594|BEHAVIORAL|Serosorting Intervention|Single session, behavioral intervention
223441457|NCT02801526|DRUG|Candesartan 16mg and Amlodipine 5mg|
223441458|NCT05412966|DEVICE|PEAR-002B|PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder
223441459|NCT05412966|DEVICE|reSET-O|reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
223566802|NCT06894069|OTHER|Placebo|2ml of normal saline will be used as placebo to be flushed and extruded through the canals to the periradicular tissues
223566803|NCT04617912|DEVICE|Long AFOV PennPET Explorer|A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
224144990|NCT03623425|DRUG|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
224144991|NCT03623425|DRUG|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
223441460|NCT04292639|DEVICE|The Vital Detect Pulse Oximeter|The Vital Detect is a noninvasive device designed for spot-checking physiological parameters, such as Noninvasive Blood Pressure, Oxygen Saturation, Pulse Rate, Body Temperature, and Respiratory Rate. This device is a finger-cuff technology which is applicable for use at-home or in healthcare facilities in/on individuals 18 years of age and older. It may be used by the individual themselves or an operator. The Vital Detect is not intended for continuous monitoring or for use with high frequency surgical equipment. It is non transit-operable. The Vital USA Vital Detect is composed of a sensor head mounted on a base connected to a phone or computer via Vital Detect App which is free to download.
223441461|NCT00508157|DRUG|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
223441462|NCT00508157|DRUG|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
223441463|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
223441464|NCT02300142|BIOLOGICAL|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
223441465|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
223441466|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
223441467|NCT02300142|BIOLOGICAL|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
223441468|NCT02069093|DRUG|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
224144992|NCT00643344|BEHAVIORAL|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
224144993|NCT05510609|DEVICE|BK 5000 Ultrasound Machine|Both 2D and 3D ultrasound is being used. 3D using optical tracking.
224144994|NCT00003828|DRUG|vinorelbine|
224144995|NCT04578015|DRUG|Metronidazole|Participants in this arm will receive metronidazole 500 mg twice daily, orally for 7 days
224144996|NCT04578015|DRUG|Placebo|Participants in this arm will receive placebo
224144997|NCT03143556|DEVICE|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
224144998|NCT02528253|BIOLOGICAL|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
224144999|NCT02528253|BIOLOGICAL|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
224145000|NCT02528253|BIOLOGICAL|Tanezumab 5 mg SC|Tanezumab 5 mg SC
224145001|NCT02528253|BIOLOGICAL|Tanezumab 10 mg SC|Tanezumab 10 mg SC
223441469|NCT02069093|DRUG|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
223441470|NCT02069093|DRUG|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
223441471|NCT05345444|DEVICE|IRE & MRgRT|Subjects will undergo Irreversible electroporation(IRE) followed by Magnetic resonance guided radiotherapy (MRgRT)
223441472|NCT01982838|PROCEDURE|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
223441473|NCT01982838|PROCEDURE|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
223441474|NCT05167279|BIOLOGICAL|JS026/placebo|Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
224145002|NCT02528253|BIOLOGICAL|Tramadol PR oral|Tramadol PR oral
223566804|NCT05503186|OTHER|Text Message|The intervention consists of a series of text messages aimed to facilitate secure storage and disposal of unused opioid medications.
224145003|NCT03078023|DEVICE|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
224145004|NCT00523653|OTHER|blood test|looking at DNA
224145005|NCT00259246|DRUG|Peptide YY infusion|
224145006|NCT05220371|DIETARY_SUPPLEMENT|Collagen|Participants ingest 15 grams of either specific collagen peptides or Placebo daily
224145007|NCT05220371|OTHER|Concurrent training|Both arms undergo a 12-week trainingintervention 3x/week
224163951|NCT01374191|DRUG|onabotulinum toxin type-A|1 injection of Btx-A
224163952|NCT01374191|OTHER|placebo|1 injection of saline solution
224163953|NCT01374191|DRUG|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
223441475|NCT05167279|BIOLOGICAL|JS016/placebo|Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
223441476|NCT02567864|OTHER|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
223441477|NCT02567864|OTHER|control|participants maintain their daily activities.
223441478|NCT04045080|DEVICE|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
223441479|NCT04045080|OTHER|Training|training
223441480|NCT04045080|OTHER|OT Training|training
223441481|NCT03599856|OTHER|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
223441482|NCT03259828|RADIATION|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
223441483|NCT02183805|DRUG|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
223441484|NCT05556850|BEHAVIORAL|STABL Virtual Rehabilitation|"STABL is a digital health platform that uses computer-vision technology to facilitate at-home post-op recovery for patients while enabling remote monitoring by their surgeon. The platform is fully HIPAA compliant.~STABL analyzes a patient's biomechanics in real time while they perform their recovery exercises to provide them with cues to ensure the exercises are done correctly and track adherence. They then relay all the data to the patient's clinician to allow them to monitor their recovery remotely, address any adherence barriers, and mitigate readmission risks that arise in a more timely manner."
223441485|NCT00083668|DRUG|Paliperidone ER|
223441486|NCT04874532|OTHER|Community Paramedic Program|Patients will be seen for a 1-hr in person evaluation and follow-up will be determined on an individual basis based on patient need. During each visit, CPs will perform health status and social determinants of health assessments, physical exam, medication review/counseling, and goal setting/review.
223441487|NCT04874532|OTHER|Education Material|Participants will be provided with a diabetes resource card, which will provide a list of clinic and community-based diabetes resources, along with a diabetes education packet, which will include information on diabetes self-management, healthy diet, physical activity, glucose self-monitoring, and hypoglycemia.
223441488|NCT06600191|DEVICE|Capstan System transcatheter mitral valve replacement|This is a first human use trial exploring a novel transcatheter mitral valve replacement implant and electro-mechanical delivery system. The device offers a minimally invasive repair for patients who have at symptomatic regurgitation who are otherwise ineligable for surgical intervention, or who have no other prospects for treatment and in whom medical therapy has already been optimised.
223441489|NCT06625983|OTHER|CRC decision tool|CRC decision tool included in the primary care bundle questionnaire
223441490|NCT07014046|OTHER|Simple bed exercises|The participants will be asked to perform exercise by lying flat on bed in supine position with their eyes look towards to the ceiling of the ward and start focusing on deep breathing exercises with slow inhalations and exhalations. These exercises aim to achieve regular pattern of abdominal muscles and improve the coordination between breathing, abdominal muscle contractions and colonic propulsions. After one-minute deep-breathing exercises, intervention group participants will be asked to pull both knees towards chest in return and turning body from one side to another while lying on bed.
223441491|NCT07014631|DRUG|SSS17|The SSS17 treatment arm comprises three dose levels: the first two dose levels will have an 8-week treatment duration, while the third dose level will extend to 24 weeks. At each dose level, participants will be allocated in a 4:1 ratio (SSS17:placebo) for enrollment.
224163954|NCT04021576|OTHER|preventative training program|complementary training of leg-, hip- and core-strength/stability
223441492|NCT07014631|DRUG|Placebo|At each dose level, participants will be allocated in a 4:1 ratio (SSS17:placebo) for enrollment.Placebo recipients will undergo weekly dosing identical to the active treatment group within their assigned dose cohort.
223441493|NCT05537610|BEHAVIORAL|CDT|In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
223441494|NCT05537610|BEHAVIORAL|Control|This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
224163955|NCT05944029|DIETARY_SUPPLEMENT|Pomegranate seed powder|10 g powder / day
224163956|NCT01637857|DIETARY_SUPPLEMENT|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
223566805|NCT05503186|OTHER|Standard of Care|Information provided by the physician and/or pharmacist.
223566806|NCT02902302|DRUG|Ibuprofen 400 mg/10 mL oral suspension|
223566807|NCT02902302|DRUG|MOMENT 400 mg coated tablet|
224163957|NCT01637857|DIETARY_SUPPLEMENT|oligoantigenic diet|oligoantigenic diet associated to life style counseling
224163958|NCT03647748|DEVICE|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
224163959|NCT00422240|DRUG|Adapalene/Benzoyl Peroxide|Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
224052832|NCT06404125|DIAGNOSTIC_TEST|Quick Disabilities of the Arm, Shoulder and Hand (Quick-DASH)|The arm, shoulder and hand problems rapid questionnaire is a shortened version of a questionnaire designed to detect symptoms and loss of function secondary to musculoskeletal problems of the upper extremity. The questionnaire will be used to assess quality of life related to upper extremity function.
224052833|NCT06404125|DIAGNOSTIC_TEST|Short Form-36|The scale was developed by Ware in 1987 and consists of 36 questions in which 8 sub-parameters related to the health status of the person are questioned. These parameters are physical function, pain, limitation due to physical and emotional problems, emotional well-being, social function, fatigue and general health perception. The Turkish validity and reliability of the scale was performed by Pınar et al. It is one of the leading methods used in the evaluation of quality of life in our country as well as all over the world.
224145008|NCT06046547|OTHER|Pulmonary rehabilitation integrating education about palliative care|"PR will include exercise training twice a week, and education and psychosocial support once per week during 12 weeks.~The intervention will include an education session on palliative care, a Peer-to-peer session, a Get-apart session and online sessions.~The education session on palliative care will be facilitated by two specialist healthcare professionals. The main topics that will be discussed are: concept of palliative care, symptom control, disease impact, psychosocial support and planning for the future.~Participants will be the primary communicators in the Peer-to-peer session, and the dialogue will be based on their suggestions. Those who feel more reluctant to reveal private thoughts in front of their loved ones will have the opportunity to discuss their issues in a Get-apart environment.~Individual cases will be referred to a specialist palliative care team or to any other health/social care professional according to the unmet needs identified."
224145009|NCT06046547|OTHER|Pulmonary rehabilitation|"Participants will receive the same PR program as the experimental group besides the education session on palliative care, the Peer-to-peer session, the Get-apart session and the online sessions (i.e. traditional pulmonary rehabilitation)."
224145010|NCT00094835|BIOLOGICAL|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
224145011|NCT00094835|DRUG|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
224145012|NCT00094835|DRUG|Paclitaxel|Paclitaxel 200 mg/m\^2 administered by IV infusion over 3 hours.
224300559|NCT06927271|OTHER|Video based intervention|The video based intervention seek to educate patients about hypertension and the medications used. It also seeks to remind patients to take their medications. This will be done thrice weekly
224300560|NCT06927271|OTHER|Usual Care|The usual care concerns the care the participants receive from the health facility. Participants in this group would neither receive the phonecall or video based interventions.
223566808|NCT06459999|DIAGNOSTIC_TEST|Urine and circulating blood biomarkers|Urine and circulating blood biomarkers in all cohorts
223566809|NCT02860208|PROCEDURE|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
224145013|NCT00094835|DRUG|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
224145014|NCT06565325|BEHAVIORAL|Exercise + Audible Cues|Combined Terminal Knee Extension Exercise with Audible Cues
224145015|NCT06565325|BEHAVIORAL|Exercise|Terminal Knee Extension Exercise
224145016|NCT05461183|OTHER|Retrospective database analysis|This study will review data provided by the BCPDR from April 1, 2008 to March 31, 2021.
224163960|NCT00422240|DRUG|Adapalene Gel, 0.1%|0.1% of adapalene gel topically daily in the evening for 12 Weeks.
224163961|NCT00422240|DRUG|Benzoyl Peroxide Gel 2.5%|2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
224163962|NCT00422240|DRUG|Gel Vehicle|Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
224163963|NCT05328414|DRUG|Prednisolone|intranasal fast dissolving film to be applied intranasal. it contains 0.005 mg Presdnisolone
224163964|NCT05950555|OTHER|Saline|We used 0.9% isotonic sodium chloride.
224163965|NCT05950555|OTHER|Dexmedetomidine|We used the vial containing 200 mcg/2 ml i.v. concentrated infusion solution in 100 ml of 0.9% isotonic sodium chloride.
224163966|NCT05950555|OTHER|Ketamine|We used 500 mg/10 ml solution for injection in 0.9% isotonic sodium chloride.
224163967|NCT04437810|BIOLOGICAL|Albumin|\- Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
223566810|NCT06149221|DEVICE|NTAP|Cold plasma is generated and applied to the scalp area, which was previously soaked with normal saline
224163968|NCT04437810|OTHER|Standard Medical Treatment|standard medical therapy
224163969|NCT00196807|BEHAVIORAL|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
224163970|NCT03627000|OTHER|failure after reimplantation|description of cinical and microbiological failure
224163971|NCT01624467|BIOLOGICAL|Necitumumab|800 mg necitumumab, administered once per week IV
224163972|NCT02349204|BEHAVIORAL|Music - Mozart's sonata for 2 pianos in D-440|
224163973|NCT01953367|DRUG|Vantobra (tobramycin)|Inhalation
224163974|NCT01953367|DRUG|TOBI (tobramycin)|Inhalation
224163975|NCT02201472|DEVICE|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
224163976|NCT06076239|OTHER|ESWT Group|EG were given Extracorporeal Shock Wave Therapy to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles for a total of 5 sessions in 3 weeks (2 sessions in the first week, 2 sessions in the second week, 1 session in the third week) in addition to conventional treatment. 1000 pulses to the trigger point of the patients with a trigger point in one of the supraspinatus, subscapularis and infraspinatus muscles, 500 pulses to the surrounding area, 2 bars, ESWT (GYMNMA Shockmaster 500) was applied for a total of 5 sessions in 3 weeks at 10 Hz, medium energy level (\<0.28 mJ/mm2).
224052834|NCT06404125|DIAGNOSTIC_TEST|Central Sensitization Scale|The central sensitization scale was developed primarily to detect central sensitization findings in patients with chronic pain and consists of two parts, A and B. In part A, 25 somatic and psychosocial symptoms frequently found in patients with central sensitization are questioned. In part B, the presence of diseases with a well-defined relationship with central sensitization is questioned without participating in the scoring. Patients who score 40 points or more out of a total of 100 points are considered to have central sensitization. Düzce et al. stated that the Central Sensitization Scale can be used as a valid method in the Turkish population to screen the presence of central sensitization in patients presenting with chronic pain.
224145017|NCT06087523|OTHER|Multidisciplinary discussion|"Multidisciplinary discussion: Participants will be diagnosed and categorized in regards of pulmonary disease on basis of medical record, PFT, HRCT, and questionnaires.~PFT: Participants will undergo body plethysmography (with diffusion) and six-minute walk test.~Analysis of circulating biomarkers: We will store glasses with serum and glasses with plasma and analyse them for circulating biomarker.~Questionnaires: Participants will complete Danish versions of three questionnaires.~* Saint George's Respiratory Questionnaire Interstitial Pulmonary Fibrosis~* Systemic Lupus Activity Questionnaire~* Lupus Impact Tracker~Review of medical record and clinical investigation with focus on SLE and pulmonary disease.~Thoracic and diaphragmatic ultrasound: The participants will undergo a 14 zone protocol, and be evaluated for b-lines and pleural thickening/irregularities. Diaphragm function will be evaluated according to the M-mode method, area method, and for thickening."
224145018|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
224145019|NCT01378819|PROCEDURE|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
224145020|NCT02391974|DEVICE|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
224145021|NCT00707460|BEHAVIORAL|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
224052835|NCT06404125|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|This scale was developed by Zigmond and Snaith in 1983 to screen anxiety and depression in individuals with physical illness. The scale consists of fourteen questions, seven for anxiety and seven for depression, to be answered on a four-point Likert scale. The Turkish validity and reliability of the scale has been demonstrated and a score above ten for anxiety and seven for depression is considered significant.
224145022|NCT01632176|BEHAVIORAL|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
224145023|NCT01178723|DIETARY_SUPPLEMENT|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
223441495|NCT06618326|DEVICE|Acupuncture|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received acupuncture regardless of the number of acupuncture points, frequency, and courses of treatment in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary fiber consumption to a recommended daily intake of 30 g
223441496|NCT06618326|DEVICE|biofeedback|Twenty patients were suffering from functional constipation. They ranged in age from 7-15 years. All children had reasonable cognitive functions, and a reasonable IQ so as were able to follow the instructions. All received biofeedback training in addition to non-pharmacological treatment advice from health care authorities such as the British Nutrition Foundation includes increasing fluid intake, physical activity and increasing dietary
223441497|NCT02909829|DEVICE|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
224145024|NCT00987636|DRUG|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients \< 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients \>= 18 years will receive a bodyweight-dependent dose:~Patients \>40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
224145025|NCT00987636|DRUG|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: \<9 kg= 1mg/kg BW 9 - \<16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW \>23 - 34 kg= 0.95 mg/kg BW \>34 kg = 0.8 mg/kg BW
224300561|NCT06928181|OTHER|Blood Flow Restriction Training|BFR training involves the application of blood flow restriction during passive or active movement interventions to elicit an additional metabolic stimulus. The cuffs are applied as proximally as possible on the thigh, and a pressure is exerted during the movement that partially restricts venous return from the limb, resulting in venous pooling. Venous occlusion is achieved using a cuff system commonly employed in resistance training (Delfi Medical Innovations Inc., Vancouver, Canada; CE-certified). The pressure applied is individually determined at the start of each training session based on the participant's arterial occlusion pressure, measured via duplex ultrasonography. For this measurement, the participant rests in a supine position while the cuff is gradually inflated until no blood flow is detectable in the limb (i.e., occlusion pressure). For the BFR intervention, 60-80% of this occlusion pressure is subsequently applied. The exercise protocol consists of daily
223441498|NCT02909829|DEVICE|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
223441499|NCT02909829|DEVICE|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
223441500|NCT06618521|DRUG|Anti-hypertensive drug (Methyldopa 250 mg)|Each women in the three groups will receive Medical treatment Anti-hypertensive drug (Methyldopa 250 mg) according to physician instructions.
223441501|NCT06618521|OTHER|Pilates exercise|Each women in the second group will receive Mat Pilates training exercise for 40 minutes/ day, 3 days/week, for 12 weeks beginning 20 weeks' gestation. The Pilates exercise includes pelvic floor exercise, deep tummy strengthening, pelvic tilt, upper back stretch, the cat stretch, thigh stretch, the sword, sword arm, and wagging the tail.
223441502|NCT06618521|OTHER|Circuit exercise training|Each women in group C will receive circuit training exercises in form of single leg curl up and press, sumo squat and row to reverse fly stand for 40 minutes/ day, 3 days/ week, for 12 weeks beginning 20 weeks' gestation. The Circuit exercise training includes sumo squat, quadruped extension, row to reverse fly stand, and single leg curls up.
223441503|NCT05125913|DIAGNOSTIC_TEST|FMD|Measurements will be made by using ultrasound system with a 12-Mhz probe. All vasoactive medications will be withheld for 24 h before the procedure. The participants will remain at rest in the supine position for at least 15 minutes before the examination. Each subject's right arm will be comfortably immobilized in the extended position to allow consistent recording of the brachial artery 2-4 cm above the antecubital fossa. If an arteriovenous fistula is present, the contralateral arm will be used for assessment. Three adjacent measurements of end-diastolic brachial artery diameter will be made from single 2D frames. The maximum FMD diameters will be calculated as the average of the three consecutive maximum diameter measurements after hyperemia and nitroglycerin, respectively.
223441504|NCT05125913|DIAGNOSTIC_TEST|Arterial stiffness|Arterial stiffness assessment will be performed by applanation tonometry with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference-acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
223441505|NCT05125913|DIAGNOSTIC_TEST|Assessment of IMT|A high-resolution B-mode ultrasound of the common carotid arteries with scanning of the longitudinal axis until the bifurcation and of the transversal axis will be performed using ultrasonic pulse with a middle frequency of 12 MHz. For each carotid artery, two longitudinal measurements will be obtained by rotating the vessels at 180o increments along their axis. IMT will be measured at 1 cm proximal to the bifurcation on each side.
223441506|NCT05125913|DIAGNOSTIC_TEST|Echocardiography|Echocardiography will be performed on each patient at baseline; the measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
223441507|NCT05125913|DIAGNOSTIC_TEST|LUS|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
223566811|NCT06112080|DEVICE|RESP™ Biosensor|The RESP™ Biosensor will be placed on all participants for immediate capture and comparison of lung sounds.
223566812|NCT03023774|DRUG|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
223566813|NCT03532854|DRUG|Valsartan|Valsartan P.O
224052836|NCT06851091|DIAGNOSTIC_TEST|Biodex Balance System|Biodex Balance System \[Biodex Balance System SD (Biodex, Inc, Shirley, NY) (BBS)\]:The Biodex Balance System is a computer-assisted device that assesses postural stability. It measures static and dynamic balance, fall risk, and proprioception through different difficulty levels and test protocols. In our study, this system will be used to investigate the relationship between balance and central sensitization. Participants will be evaluated using the postural stability test, fall risk test, athlete single leg test, and limits of stability test protocols, and they will be trained before the testing process.
224052837|NCT06851091|DIAGNOSTIC_TEST|Pressure Pain Threshold (PPT) Measurement with Algometer|Pressure pain threshold (PPT) is defined as the minimum force applied that causes pain. This measurement is commonly used for assessing tender points and has been shown to be useful.
224145026|NCT00987636|DRUG|Treosulfan|12 g/m² d-5 to d-3
224145027|NCT03639922|DRUG|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
224145028|NCT03639922|DRUG|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
224145029|NCT01320956|BEHAVIORAL|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
224145030|NCT01320956|OTHER|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
224145031|NCT05979233|PROCEDURE|staged managment|staged management
224145032|NCT05979233|PROCEDURE|one session ERCP then LC|one session ERCP then LC
224145033|NCT05979233|PROCEDURE|one session LC then ERCP|one session LC then ERCP
224145034|NCT00873288|OTHER|Usual care mailing intervention|routine colposcopy reminder letter
224052838|NCT06851091|DIAGNOSTIC_TEST|Conditioned Pain Modulation (CPM)|According to this protocol, a pressure stimulus, referred to as the test stimulus, will first be applied to the trapezius muscle to induce a pain intensity of 4 on a 10-point Numeric Rating Scale (NRS). Subsequently, a conditioning stimulus will be introduced by immersing the participant's right hand in 7°C water for 20 seconds. Following this conditioning stimulus, the same test stimulus will be reapplied to the trapezius muscle, and participants will be asked to rate their pain using the NRS. If participants are unable to keep their hands in the water for the full 20 seconds, the test stimulus will be applied immediately after hand removal. The CPM score will be calculated as the ratio of the initial NRS score to the second NRS score, multiplied by 100. Scores above 100 are considered indicative of a normal CPM response, with higher scores reflecting greater descending pain inhibition.
223441508|NCT05125913|DIAGNOSTIC_TEST|BIS analysis|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device using specific electrodes. Based on a fluid model using 50 discrete frequencies (5-1000kHz), the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
224052839|NCT06851091|DIAGNOSTIC_TEST|Slowly Repeated Evoked Pain Assessment Protocol (SREP)|"Responses to induced pain indicate the presence of allodynia and hyperalgesia in FMS patients. The Slow Repetitive Evoked Pain (SREP) protocol consists of nine suprathreshold painful stimuli applied to the nail bed for five seconds each, with 30-second intervals. Painful stimulation will be administered using a pressure algometer with a 1 cm² stimulation surface. Nailbed pain stimuli are commonly used to assess pain sensitivity.~The intensity of pain perception from each SREP stimulus will be evaluated using a 10-point Numerical Rating Scale (NRS) (0 = no pain, 10 = extremely painful). The SREP sensitization index will be calculated as the difference between the final and initial pain scores.~Higher positive SREP sensitization index values indicate a greater increase in perceived pain intensity across the nine stimuli, reflecting higher pain sensitization."
224052840|NCT06851091|DIAGNOSTIC_TEST|Central Sensitization Inventory (CSI)|"The Central Sensitization Inventory (CSI) is used by some researchers to investigate pain sensitivity through symptoms associated with central sensitization and related comorbidities. It can help determine the severity of central sensitization.~The scale was developed to detect central sensitization in patients with chronic pain and consists of two sections: Section A and Section B. For scoring purposes, only Section A is used. A score of 40 or higher out of 100 is associated with an increased likelihood of central sensitization.~This scale has been shown to be a reliable and valid tool in the Turkish population with chronic pain (test-retest reliability = 0.92, Cronbach's alpha = 0.93)"
223441509|NCT05125913|OTHER|Biomarkers determination|Biomarkers by ELISA: IL-1, IL-6, VCAM1, Endoglin, NO and ADMA
223441510|NCT02647489|BIOLOGICAL|PAMVAC|
223441511|NCT02647489|BIOLOGICAL|Alhydrogel|
223441512|NCT02647489|BIOLOGICAL|GLA-SE|
223441513|NCT02647489|BIOLOGICAL|GLA-LSQ|
223441514|NCT02647489|OTHER|Placebo|
223441515|NCT03564795|DEVICE|KeraStat Gel|Wound dressing for partial thickness burns
223441516|NCT03564795|DEVICE|Silver Sulfadiazine|Wound dressing for partial thickness burns
223441517|NCT04777448|PROCEDURE|telerehabilitation|24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
223441518|NCT04877158|BEHAVIORAL|Self-Blame and Perspective-Taking Intervention|The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
224052841|NCT06851091|DIAGNOSTIC_TEST|Numeric Rating Scale (NRS)|Numeric Rating Scale (NRS) will be used to determine pain intensity during assessments. Participants will be asked to rate their pain intensity by selecting a value between 0 and 10. Higher scores are associated with increased pain severity.
224145035|NCT00873288|OTHER|CIS support mailing intervention|Mailed reminder plus provider recommendation to call CIS and sample questions to ask
224145036|NCT03418272|DIAGNOSTIC_TEST|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis"
224145037|NCT00329394|DRUG|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
224145038|NCT02001363|DRUG|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
223741038|NCT07206836|OTHER|Enhanced Recovery after Surgery Protocol|reduced fasting, no mechanical bowel prep, early feeding, non-opioid analgesia.
223441520|NCT07012408|OTHER|Return to play program with progressive design|This design has more open objectives than the regressive design. In the progressive design, the duration of the return-to-play program is not determined by a future date, but rather by the player's daily progress. This design is less commonly used for scheduling tasks and planning work. It is intended to be compared with the regressive design to determine which is more appropriate.
224145039|NCT02001363|DRUG|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
223441521|NCT07012408|OTHER|Return to play program with regressive design|Control Group: Subjects with muscle injuries assigned to this group will follow a Return to Play program with a regressive design. This design has fixed times and objectives from the beginning of the program to predict the athlete's exact discharge time. This design is commonly used for scheduling tasks and planning work. It is intended to evaluate the benefits and drawbacks of the design and compare them with those of the progressive design to determine which is more appropriate.
223566814|NCT03532854|DRUG|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
224052842|NCT06851091|DIAGNOSTIC_TEST|Revised Fibromyalgia Impact Questionnaire (FIQ)|Revised Fibromyalgia Impact Questionnaire (FIQ) consists of three sections: function, general, and symptoms, with a total of 21 questions. It evaluates the limitations and functional disability that occur in patients with fibromyalgia. All questions are scored on the Numeric Rating Scale (NRS), ranging from 0 to 10. As the score from the questionnaire increases, it indicates a higher level of disability related to fibromyalgia. In our study, the Turkish version of the questionnaire, which has been validated and shown to be reliable, will be used.
224052843|NCT06851091|DIAGNOSTIC_TEST|S-LANSS Pain Score (Self-administered Leeds Assessment of Neuropathic Symptoms and Signs)|The S-LANSS pain score is a 7-item self-administered scale developed and validated to recognize neuropathic pain in chronic pain patients and distinguish it from nociceptive pain. It evaluates neuropathic symptoms and signs through a series of questions that help identify features like hyperalgesia, allodynia, and paresthesia, which characterize the chronic pain sensation associated with neuropathic pain. These features are often seen in fibromyalgia (FMS) pain. In our study, the Turkish version of the questionnaire, which has undergone validity and reliability testing, will be used.
223441522|NCT07019857|DIAGNOSTIC_TEST|Blood sample collection at surgery time and 12 months later|"each participant undergoes a blood test 1) at surgery time and 2) 12 months after surgery. These 5mL samples include:~* Blood cell count~* TREC dosage~* Complete Lymphocytes immunophenotyping~* Immunoglobulin dosage"
223441523|NCT07015723|PROCEDURE|Living liver donors|Adults who are screened for living liver donation.
223441524|NCT02906033|OTHER|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
223441525|NCT00770133|DRUG|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
223441526|NCT00770133|DRUG|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
223441527|NCT00770133|DRUG|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
223441528|NCT00770133|DRUG|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
224052844|NCT06851091|DIAGNOSTIC_TEST|Tampa Kinesiophobia Scale (TKS)|"The Tampa Kinesiophobia Scale is a 17-item measure designed to assess fear of movement/re-injury. The scale evaluates fear-avoidance behaviors related to work activities, injury/re-injury concerns, and fear-avoidance parameters. It is used in the context of acute and chronic low back pain, fibromyalgia (FMS), musculoskeletal injuries, and whiplash-associated disorders.~The scale uses a 4-point Likert scoring system (1 = Strongly disagree, 4 = Strongly agree). After reversing the scores for items 4, 8, 12, and 16 (for example, if a participant selects 1 for these items, it is counted as 4; 2 is counted as 3, etc.), the total score is calculated. The participant receives a score between 17 and 68. A higher score on the scale indicates a higher level of kinesiophobia. In our study, the Turkish version of the scale, which has undergone validity and reliability testing, will be used."
224052845|NCT06851091|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale (HAD)|"This scale is used to assess anxiety and depression symptoms and consists of 14 items (7 items for anxiety, 7 items for depression). For each subscale, scores range from 0 to 21:~* 0-7 points: No symptoms or very mild symptoms~* 8-10 points: Moderate symptoms~* 11 points or higher: Symptoms likely corresponding to a clinical diagnosis of anxiety and depression According to the 2016 diagnostic criteria for Fibromyalgia Syndrome (FMS), the presence of depression contributes to the diagnosis of FMS. The HAD scale has been shown to be a suitable tool for assessing FMS and related patient education programs.~In our study, the Turkish version of the HAD scale, which has been validated and shown to be reliable, will be used."
224052846|NCT06851091|DIAGNOSTIC_TEST|SF-12 Health Survey (SF-12 Quality of Life Scale)|The SF-12 Health Survey is one of the most widely used scales for assessing health-related quality of life. In our study, the Turkish version of the SF-12, which has been validated and shown to be reliable, will be used. The scores will be calculated using an online calculation tool, and two types of scores-Physical Component Summary (PCS) and Mental Component Summary (MCS)-will be obtained.
224052847|NCT06851091|DIAGNOSTIC_TEST|Fatigue Severity Scale (FSS)|The Fatigue Severity Scale (FSS) is a 9-item questionnaire used to assess the severity, frequency, and impact of fatigue on daily life. Each item is rated on a scale from 1 to 7. A lower score indicates a decrease in fatigue severity. In our study, the Turkish version of the scale, which has been validated and shown to be reliable, will be used.
223441529|NCT06113341|DRUG|IDegLira|Pre-filled pen injection.
223441530|NCT04246502|DRUG|Capecitabine and Pyrotinib|Pyrotinib 400mg orally daily until progressive disease
223441531|NCT04246502|DRUG|Capecitabine,Trastuzumab, and Pertuzumab|as instruction
223441532|NCT04650126|BIOLOGICAL|ATM001|monovalent anti-TNF-receptor 1 antibody format
223441533|NCT04650126|BIOLOGICAL|ATM001 Placebo|ATM001 Placebo
223441534|NCT00006341|OTHER|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
223441535|NCT00546741|DRUG|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
223441536|NCT00546741|DRUG|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
223441537|NCT00546741|DRUG|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
223441538|NCT07026474|OTHER|radiotherapy|single doses of 1.8Gy up to a total dose of 55.8Gy to 63.0Gy
223441539|NCT07026474|DRUG|Cisplatin|40mg/m² BSA weekly concomitant to re-irradiation
223441540|NCT07026474|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w
223441541|NCT07026474|DRUG|cisplatin + 5-fluorouracil (5FU)|Cisplatin: 100mg/m² BSA d1, q3w / 5-FU: 1000mg/m² BSA d1-4, q3w
223441542|NCT07026474|DRUG|Alternative medications: carboplatin + 5-fluorouracil (5FU)|Carboplatin: AUC5 d1, q3w / 5-FU: 1000mg/m² BSA d1-4, q3w
224052848|NCT06851091|DIAGNOSTIC_TEST|Timed Up and Go Test (TUG)|The Timed Up and Go (TUG) test is designed to measure dynamic balance based on the time it takes for participants to stand up and walk. The patient begins by sitting on a standardized chair (height of 46 cm). During the test, the patient is asked to stand up from the chair, walk 3 meters, turn around, and return to sit back on the chair. The time taken to complete this process is measured. Lower values indicate better stability. A cut-off value of 13.5 seconds is used to identify individuals at higher risk of falling.
224145040|NCT01270230|BEHAVIORAL|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
224052849|NCT03970954|DRUG|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
224052850|NCT05505682|BIOLOGICAL|Biological (Male Wolbachia-infected Aedes aegypti)|Releases of male Wolbachia-infected Aedes aegypti mosquitoes
224145041|NCT01270230|BEHAVIORAL|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
224145042|NCT05031429|OTHER|Time Limited Eating|Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
224145043|NCT02521298|OTHER|Strength Training|
224145044|NCT02521298|PROCEDURE|Placebo|
224145045|NCT02521298|DRUG|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
224145046|NCT02521298|PROCEDURE|Dry Needling|
224145047|NCT03583606|BIOLOGICAL|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10\^11 virus particles (vp)).
224145048|NCT03583606|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10\^8 Infectious Units (IU).
224145049|NCT03583606|OTHER|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
224145050|NCT00004916|DRUG|ifosfamide|
223441543|NCT07026474|DRUG|Alternative medications: carboplatin|AUC2 weekly
223441544|NCT07026474|DRUG|Pembrolizumab|i.v., 200mg absolute, q3w, starting within 8-14 days after completion of RCT
223441545|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR and SMV|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate using bone graft mixed with SMV
223441546|NCT05020405|PROCEDURE|Immediate implant placement and ARS with GBR|Implant insertion and GBR for augmentation of the gap between buccal and lingual plate
223741039|NCT07206836|OTHER|Traditional Care Protocol|Participants receive standard peri-operative management for colostomy reversal. This includes three days of mechanical bowel preparation with oral laxatives and clear fluids, overnight fasting before surgery, routine nasogastric tube placement, opioid-based postoperative pain control, and a nil-per-mouth regimen for at least three days after surgery before gradually resuming oral intake.
224052851|NCT06012786|DIAGNOSTIC_TEST|Diagnostic Criteria of Myofascial Pain Syndrome|"Major criteria:~1. The patient's complaint of regional pain~2. Referred pain and sensory change in the specific area of the muscle by palpation of the trigger point~3. Presence of palpable taut band~4. Presence of palpable and tender points along the length of the taut band~5. Restriction of ROM in the area of the affected muscle~Minor criteria:~1. Pain/sensory change with pressure palpation of the trigger point~2. Local twitch response with palpation/injection of the trigger point in the taut band~3. Reduction of pain by inactivation (injection or stretching of the muscle) of the trigger point 5 major and at least 1 minor criteria are required for clinical diagnosis"
224145051|NCT00004916|DRUG|paclitaxel|
224145052|NCT00004916|DRUG|teniposide|
224145053|NCT00004916|PROCEDURE|peripheral blood stem cell transplantation|
224145054|NCT06337162|DRUG|INCB099280|400 mg Tablet
224145055|NCT05693688|DRUG|Atosiban|atosiban i.v. administred for 48 hours. The medication will be administered by a bolus injection of 6.75 mg/0.9 mL in 1 min followed by a continuous infusion of 18 mg/hour for 3 hours followed by a continuous infusion of 6 mg/hour for the remaining 45 hours.
224145056|NCT05942170|DRUG|ICG/ blue dye|The SLN mapping procedure was performed as previously described by using IGC or blue dye. The injection technique of the tracers was the same for both cervical and endometrial cancer. The cervical injection was done by insulin syringe(one ml) inserting full needle length (1 cm) and complete injection at 3, 9 o'clock, or 2,4,8,10 o'clock.
224300562|NCT06928181|OTHER|Sham-BFR|Patients in the control group (CG) follow the same exercise protocol as those in the BFR intervention group; however, the cuff is only inflated to a minimal pressure of 20 mmHg. This pressure does not induce any relevant venous stasis, nor can any local or systemic metabolic effects be expected.
223441547|NCT07027124|DRUG|Darolutamide|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg for 16 weeks prior to RP.
223441548|NCT07027124|DRUG|Pembrolizumab|Administered at the dose of 200 mg intravenously, every 3 weeks, for a total of 5 cycles prior to RP (Neoadjuvant phase, study weeks 1, 4, 7, 10, 13 \& 16), and every 3 weeks, for a total of 12 cycles post-RP (Adjuvant phase, study weeks, 19, 22, 25, 28, 31, 34, 37, 40 43, 46, 49, \& 52). Total Pembrolizumab cycles=17
223441549|NCT07027124|DRUG|Lupron|Androgen deprivation, GnRH agonist Leuprolide will be administered at a dose of 22.5 mg SQ (Eligard)/IM Lupron every 12 weeks prior to RP (Study weeks, 1 and 13).
223441550|NCT07026851|BIOLOGICAL|Blood and bone marrow sampling|"This intervention involves the collection of peripheral blood before and 3 days after coronary artery bypass grafting (CABG), as well as a one-time collection of bone marrow sample during sternotomy.~Samples are analyzed using spectral flow cytometry to characterize the phenotype and maturation stages of circulating and medullary megakaryocytes using a panel of specific surface antibodies."
223441551|NCT07027774|DRUG|Henagliflozin 5 mg Group|Henagliflozin 5 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
223441552|NCT07027774|DRUG|Henagliflozin 10 mg Group|Henagliflozin 10 mg once daily plus KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
223441553|NCT07027774|DRUG|Conventional therapy group|KDIGO-based comprehensive management strategy (e.g., RAAS inhibitors）
224052852|NCT06012786|DIAGNOSTIC_TEST|The Physical Examination of Trigger Points and Pain-Pressure Threshold Measurement With an Algometer|Trigger points in trapezius, infraspinatus, latissimus dorsi, pectoralis major, serratus anterior muscles will be detected bilaterally by physical examination. Algometer (Wagner Force Dial FDK 20) will be used for pain pressure threshold measurement of detected trigger points. Then, the distribution of the trigger points, their frequency and threshold values according to the algometer will be compared between the individual affected-insured extremities and between the groups.
224145057|NCT00880880|OTHER|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
224145058|NCT03825172|DIAGNOSTIC_TEST|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
224145059|NCT05549089|DEVICE|Insignia™ twin brackets|it is metal orthodontic twin brackets with customized base and individual arch-wires for each patient
223441554|NCT01236326|PROCEDURE|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
223441555|NCT01236326|PROCEDURE|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
224145060|NCT05549089|DEVICE|Maestro® 3D Ortho Studio software (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and 3D printing indirect bonding tray
224145061|NCT05549089|DEVICE|Ray set® device (Discovery, Dentaurum®, Ispringen, Germany)|it is conventional metal orthodontic twin brackets will be customizing the bracket base with adhesive composite, individual arch-wires for each patient and double-layer vacuum-formed thermoplastic indirect bonding tray
224145062|NCT00817206|DRUG|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
224145063|NCT00817206|DRUG|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
224145064|NCT02189590|DEVICE|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
224145065|NCT02189590|DEVICE|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
224145066|NCT01511432|DRUG|telaprevir formulation A|A single 1125-mg dose administered orally
224145067|NCT01511432|DRUG|telaprevir Formulation B|A single 1125-mg dose administered orally
224145068|NCT01511432|DRUG|telaprevir Formulation C|A single 1125-mg dose administered orally
224145069|NCT01511432|DRUG|telaprevir Formulation D|A single 1125-mg dose administered orally
224300563|NCT06929013|BIOLOGICAL|Blood sampling|Inclusion (baseline): 28 mL Incision (surgery): 18 mL End surgery: 18 mL H+12 after end surgery: 18 mL H+4 after end surgery: 18 mL H+48 after end surgery: 18 mL H+72 after end surgery: 18 mL D+7 after end surgery: 18 mL D+14 after surgery: 18 mL 4 to 6 weeks after surgery:28 mL
224300564|NCT06928636|BEHAVIORAL|Supper Heroes online environmentally friendly eating intervention for families|Families randomized to the intervention group will complete a 7-week Supper Heroes program that includes activities focused on making more meals at home, reducing food waste, and eating more plant-based foods.
223441556|NCT03438734|DEVICE|Regional cerebral oxygen saturation|Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
223441557|NCT03438734|DEVICE|Bispectral Index (BIS)|The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
223441558|NCT03626324|DEVICE|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
223441559|NCT03092934|DRUG|LY3295668|Oral capsules
223441560|NCT02127736|DRUG|Amitriptyline|
223441561|NCT02127736|DRUG|Placebo|
223441562|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
223441563|NCT03654638|COMBINATION_PRODUCT|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
223441564|NCT03654638|OTHER|Questionnaire Administration|Ancillary studies
223441565|NCT06877572|BEHAVIORAL|Weight loss with pharmacotherapy|Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.
223441566|NCT06877572|BEHAVIORAL|Weight loss without pharmacotherapy|Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits
223441567|NCT06717412|DRUG|Conbercept|Administered as an intravitreal injection
223441568|NCT01468753|PROCEDURE|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
223441569|NCT02535169|BEHAVIORAL|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
223441570|NCT02535169|BEHAVIORAL|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
223441571|NCT06724666|BEHAVIORAL|Transdiagnostic Internet-delivered intervention|The intervention consists of 8 modules based on Rational emotive therapy, delivered via 8 weeks.
223441572|NCT00065767|DRUG|Raloxifene|
223441573|NCT03693469|DEVICE|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
223441574|NCT05056792|OTHER|Isometric strength training for 8 week|Plyometric training for 8 week
223441575|NCT05056792|OTHER|Conventional training|Conventional training for 8 week
223441576|NCT02237924|DRUG|endostar|Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy
223441577|NCT02237924|DRUG|DDP|DDP:100mg/m2 for 2-3 cycles
223441578|NCT02237924|RADIATION|IMRT|IMRT:70-74Gy for 2-3 cycles
223441579|NCT03449992|DIETARY_SUPPLEMENT|nitrate-rich beetroot juice|Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
223441580|NCT03449992|DIETARY_SUPPLEMENT|Placebo|Placebo drink
223441581|NCT07027202|PROCEDURE|Early Left Ventricle unloading|"An Intraortic balloon pump will be systematically inserted as soon as possible, within 12 hours post-randomization.~* A pulmonary artery catheter (PAC) will enable hemodynamic monitoring of cardiac filling pressures, cardiac output and pulmonary artery pressures.~* Doppler Echocardiography will be performed at least daily to monitor LV ejection, LV dimension, appearance of LV blood stagnation, aortic time-velocity integral (VTI) and aortic valve opening.~* Escalation to a microaxial LV venting pump, central ECMO or atrial septostomy will be possible and discussed by the Shock team (as suggested by international recommendations) in case of~* Overt cardiogenic pulmonary edema requiring invasive mechanical ventilation~* Persisting more than 6 hours despite IABP support and optimization of patient's management (titration of ECMO blood flow, inotropes, non-invasive mechanical ventilation with PEEP, diuretics or hemofiltration)."
223441582|NCT03916731|DEVICE|STARgraft AV|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
223441583|NCT03916731|DEVICE|ePTFE AV graft (control)|Implant of standard ePTFE AV shunt as a control in the upper arm and subsequent use for hemodialysis access. After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
223441584|NCT01333956|DRUG|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
223441585|NCT01333956|DRUG|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
223441586|NCT01333956|DRUG|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
223441587|NCT01333956|DRUG|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
223741040|NCT07206732|DEVICE|Ultrasound-Guided Inferior Vena Cava Assessment|This intervention involves bedside ultrasound measurement of the inferior vena cava (IVC) diameter and calculation of the IVC collapsibility/distensibility index. Assessments will be performed both at initial presentation and after fluid resuscitation in shock patients. The procedure is non-invasive, rapid, and performed according to standardized emergency ultrasound protocols, distinguishing it from invasive monitoring methods.
223441588|NCT02240069|BEHAVIORAL|Education (Tx1)|Education on best burn practices
224300565|NCT06928636|BEHAVIORAL|Monthly emails about environmentally friendly habits|Families randomized to the control group will receive monthly emails for 6 months about environmentally friendly habits.
223441589|NCT02240069|DEVICE|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
223441590|NCT02240069|DEVICE|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
223441591|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
223441592|NCT00461760|PROCEDURE|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
223441593|NCT00576810|DRUG|sodium picosulphate|
223441594|NCT06740019|DRUG|JMKX000197|for pleural perfusion
224052853|NCT06012786|DIAGNOSTIC_TEST|Hand Grip Test|The purpose of this test is to test the maximum isometric contraction strength of the hand and forearm muscles. A hand grip dynamometer (Jamar) will be used for the test. While the patient is sitting in the chair, the elbows will be close to the body and at 90 degree flexion, the wrist will be in a neutral position. The patient will be asked to grasp the dynamometer and squeeze it as hard as she can, and the average of 3 measurements made with an interval of 5 minutes. The test will be repeated for both upper extremities separately.
224145070|NCT02570529|DRUG|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
223441595|NCT06740019|PROCEDURE|Tube thoracostomy drainage|Tube thoracostomy drainage
223441596|NCT00236275|DRUG|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
224052854|NCT06012786|DIAGNOSTIC_TEST|VAS|Shoulder pain, feeling of tension and heaviness on the affected arm will be evaluated separately by numerical scale.
223741041|NCT07206719|PROCEDURE|Malone Antegrade Continent Enema (MACE) and Mitrofanoff procedures|"* MACE Split appendix procedure: division of appendix into two segments, so making Mitrofanoff procedure by the distal appendicular segment and Malone procedure by proximal appendicular segment.~* MACE Colonic flap Neoappendecosotomy procedure: creating the colonic flap from the ascending colon, tubularization done. The tip of the neo-appendix was spatulated and sutured with the triangular skin flap of umbilicus, then the silicon catheter in place passing through the neo appendix into the colon~* Mitrofanoff procedure: The appendix was mobilized with its mesentery. The tip of the appendix was incised and a 10-12Fr feeding tube was inserted to confirm patency. Then Opening of the urinary bladder was done. The distal end of the appendix was then inserted into the bladder in a submucosal tunnel. The distal opening of the appendix was sutured to the inner bladder wall and mucosa using absorbable sutures."
223741042|NCT07205640|DEVICE|Low-Level Laser Therapy|A 980 nm diode laser will be applied immediately after extraction of the first permanent molar. The laser will be used in continuous mode at 0.5 W, with a total energy of 300 J, applied for 60 seconds at three points around the extraction socket.
224052855|NCT06012786|DIAGNOSTIC_TEST|Quick DASH|The quick DASH questionnaire which has proven reliable and valid in breast cancer and lymphedema patients in Turkish population, will be used to evaluate the quality of life related to upper extremity function.
224145071|NCT02570529|DRUG|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
224145072|NCT00126581|DRUG|Carboplatin|Given IV
224145073|NCT00126581|DRUG|Erlotinib|Given PO
224145074|NCT00126581|DRUG|Erlotinib Hydrochloride|Given PO
224145075|NCT00126581|DRUG|Paclitaxel|Given IV
224145076|NCT04720495|PROCEDURE|One stage ridge splitting with simultaneous implant placement|"A full mucoperiosteal flap was raised using the sharp periosteal elevator to expose the bone crestally and buccally.~An inverted U-shaped bone cut, down to the cancellous bone, was done in the undercut area with a piezoelectric device.~The horizontal bone cut was made apical to the most concave point in the undercut area with a distance of 3 mm.~The two vertical bone cuts were placed at least 1 mm away from the adjacent roots and extended beyond the undercut area.~The released bone end was minimally elevated using a periosteotome through a greenstick fracture.~All implants were installed with the implant shoulders flush to the bone level using a low-speed drilling procedure."
224145077|NCT04720495|PROCEDURE|Two-stage ridge splitting with implant placement|"The first surgery is the same as one stage ridge splitting Four weeks later, after revascularization between the bone block and the mucoperiosteum, the second surgery will be performed.~A crestal incision was done and the envelope flap slightly elevated to preserve the blood supply.~The implants will be placed in the same manner as one stage ridge splitting"
224145078|NCT02700295|DEVICE|Orthokeratology lens|
224300566|NCT06296654|BEHAVIORAL|Empowerment-Based Interventions|The Empowerment-Based Interventions was used for the study group. It is an integrative educational program under the patient-centered care approach emphasizing collaborative patient interaction. The EBI was implemented through structured (a) small-group d
223441597|NCT02679833|DIETARY_SUPPLEMENT|Placebo|Toothpaste not containing the vitamin.
223441598|NCT02679833|DIETARY_SUPPLEMENT|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
223441599|NCT04527211|DRUG|Ivermectin|Oral administration of ivermectin 200 mcg/kg every week for seven weeks
223441600|NCT03723070|DEVICE|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
224145079|NCT01754207|DEVICE|755nm Alexandrite Laser|755nm Alexandrite Laser
224145080|NCT01754207|DEVICE|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
224145081|NCT03728140|PROCEDURE|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
224145082|NCT03188432|DRUG|Carboplatin|Given IV and IP
224145083|NCT03188432|OTHER|Quality-of-Life Assessment|Ancillary studies
224145084|NCT03188432|OTHER|Questionnaire Administration|Ancillary studies
223441601|NCT00474786|DRUG|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
224145085|NCT03188432|PROCEDURE|Cytoreductive Surgery|Undergo CRS
224145086|NCT02034552|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks x 6 doses intravenous slow bolus
224145087|NCT02034552|DRUG|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
224145088|NCT02034552|DRUG|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
224145089|NCT02034552|DRUG|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
223441602|NCT00474786|DRUG|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
223441603|NCT01863498|OTHER|Epidural|Patients will have an epidural for pain control
223441604|NCT01863498|OTHER|PCA|Patients will have PCA for pain control
223441605|NCT04397471|PROCEDURE|Bone Marrow Harvest|Healthy volunteer bone marrow harvest
223441606|NCT03646305|BEHAVIORAL|Cognitive Defusion|Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, \& Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
223441607|NCT05864573|BIOLOGICAL|ZGGS15|ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
223441608|NCT04624776|DRUG|Methylprednisolone|A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.
223441609|NCT04624776|DRUG|Isotonic saline|A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).
223441610|NCT02971540|DRUG|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
223441611|NCT02971540|DRUG|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
223441612|NCT02971540|DRUG|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
223441613|NCT02971540|DRUG|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
223441614|NCT02971540|OTHER|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
223441615|NCT03417024|DEVICE|Automated Breast Ultrasound|The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.
223441616|NCT03417024|DEVICE|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
223441617|NCT01851187|BEHAVIORAL|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
223441618|NCT01851187|BEHAVIORAL|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
223441619|NCT02742454|PROCEDURE|Standard 30-60 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, the cord is clamped at 30 seconds. If the baby is breathing well, the cord is clamped at 60 seconds. Ventilatory assistance is given after cord clamping.
223441620|NCT02742454|PROCEDURE|VentFirst 120 Seconds Cord Clamping|The infant is stimulated to breathe after birth. If the infant is not breathing well, PPV by face mask is given starting at 30 seconds. If the baby is breathing well, CPAP is given starting at 30 seconds. The cord is clamped at 120 seconds.
223441621|NCT02195427|DEVICE|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
223441622|NCT02195427|DEVICE|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
223441623|NCT04969380|DEVICE|Sofwave|The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.
223441624|NCT05432050|DEVICE|Bispectral index and Patient state index monitoring|The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
223441625|NCT02655419|DRUG|ATM-AVI|"Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
223441626|NCT02655419|DRUG|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
223441627|NCT00431873|DRUG|MGCD0103|MGCD0103 Administered orally three times per week.
223441628|NCT03407547|DIAGNOSTIC_TEST|Electroencephalography|EEG is a device to measure brain activity via surface electrodes
223441629|NCT00756197|DEVICE|Cryo Spray Ablation Group 1|Cryo Spray Ablation
224052856|NCT06012786|DIAGNOSTIC_TEST|Lymqol-Arm|Lymphedema Quality of Life Scale-Arm Turkish form will be used. The lymphedema-specific quality of life scale was developed specifically for the upper extremity and its reliability and validity were proven in Turkish population.
223441630|NCT00756197|DEVICE|Cryo Spray Ablation Group 2|cryo spray ablation
223441631|NCT06617351|DIETARY_SUPPLEMENT|Melatonin|Gummy - 7.5 kilocalories (kCal), 2 g Carbohydrate, 1.5 g total sugars, 7.5 mg sodium, 5 mg melatonin.
223441632|NCT06617351|DIETARY_SUPPLEMENT|Placebo|Gummy - 12.5 kilocalories (kCal), 3g Carbohydrate, 1.875 g total sugars, 1.25 mg sodium.
223441633|NCT00038623|DRUG|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
223441634|NCT00038623|DRUG|Rituximab|250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
223441635|NCT00207727|DRUG|CNTO 1275|
224052857|NCT06012786|DIAGNOSTIC_TEST|Range of Motion of Shoulde Joint|Goniometric measurements will be made for both upper extremities, and the average of 3 consecutive measurements will be taken.
224052858|NCT00881218|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
224052859|NCT02373215|DRUG|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
224052860|NCT05981209|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224052861|NCT05981209|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow biopsy and aspiration
224052862|NCT05981209|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy and aspiration
224145090|NCT02043236|BEHAVIORAL|Healthy bones pamphlet|written educational material
224145091|NCT02043236|BEHAVIORAL|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
224145092|NCT02043236|BEHAVIORAL|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
223441636|NCT02381769|DIETARY_SUPPLEMENT|Soybean based lipid emulsion|
224052863|NCT05981209|PROCEDURE|Computed Tomography|Undergo CT
224052864|NCT05981209|DRUG|Dexamethasone|Given IV or PO
224052865|NCT05981209|PROCEDURE|Echocardiography|Undergo ECHO
224052866|NCT05981209|BIOLOGICAL|Elotuzumab|Given IV
224052867|NCT05981209|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224052868|NCT05981209|BIOLOGICAL|Mezigdomide|Given PO
224052869|NCT05981209|PROCEDURE|X-Ray Imaging|Undergo x-ray imaging
224145093|NCT03278652|OTHER|Consumption of drugs for analgesic use|"* Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)"
224145094|NCT05678842|OTHER|Descriptive|Descriptive
224145095|NCT04243252|BEHAVIORAL|Healthy Pantry Program|Food pantries will receive the Healthy Pantry Program online training, which will be completed by at least one pantry staff member and teaches pantry staff a novel traffic-light nutrition labeling system, a multilingual healthy recipe database, and how to use those and other behavioral economic strategies to implement simple interventions in the food pantry to promote client selection of healthier options. Onsite support by a registered dietitian is included.
224145096|NCT04243252|OTHER|Waitlist Control|Normal food pantry use for duration of the 9-month study period. Control pantries will have access to the Healthy Pantry Program after study is completed.
223441637|NCT02195726|PROCEDURE|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
223441638|NCT02195726|PROCEDURE|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
223441639|NCT05616429|DIETARY_SUPPLEMENT|Alcat based personal diet|Alcat based personalized diet with dietician supervision and follow-up + usual care
224052870|NCT03659851|DRUG|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
224052871|NCT04297085|BIOLOGICAL|Biologic sample|Biological samples will be taken from the subjects included
224052872|NCT01350830|PROCEDURE|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
224052873|NCT01350830|PROCEDURE|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
224145097|NCT00114270|DRUG|letrozole|
224145098|NCT00114270|DRUG|zoledronic acid|
223441640|NCT05616429|DIETARY_SUPPLEMENT|Standard balanced diet|"Sham standard balanced diet with dietician supervision and follow up + usual care."
223441641|NCT05616429|OTHER|usual care|usual care
223441642|NCT00071968|DRUG|temsirolimus|
223441643|NCT00071968|PROCEDURE|conventional surgery|
223441644|NCT00071968|PROCEDURE|neoadjuvant therapy|
223741043|NCT07205640|DRUG|Hyaluronic Acid (HA)|Hyaluronic acid gel will be applied directly into the extraction socket immediately after tooth removal.
224145099|NCT06376370|OTHER|Application of computer-assisted cognitive rehabilitation program|Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
223441645|NCT04861116|BEHAVIORAL|Intervention program for test anxiety|12-week ICT-based manualized, targeted and facilitated individual intervention for adolescent students, that aims to promote compassion, acceptance and mindfulness, in order to help improve test anxiety's regulation (and consequently symptom reduction), as well as increase general and school-related well-being, while promoting valued life action.
223441646|NCT06082882|BEHAVIORAL|Education|Education will be delivered in person in a group education setting or individually by phone. Group education will include a \~1-hour breast and cervical cancer prevention education session delivered with the support of electronic presentations (e.g. PowerPoint presentation ) which will include updated prevention recommendations, such as HPV vaccination recommendations for young adults. For phone education, trained project staff or CHWs will deliver telephone-based education as an alternative to group education sessions for women who missed a scheduled session twice (education materials would be printed and mailed).
224052874|NCT05469555|PROCEDURE|High Resolution Oesophageal Manometry|High Resolution Oesophageal manometry assesses how well the muscles of the oesophagus are working when you swallow. It also checks the relaxation of the valves at the top and bottom of the oesophagus.
223441647|NCT06082882|BEHAVIORAL|Navigation to clinic|Continue telephone based navigation tailored to participants' barriers using the SEMM Cancer Prevention Plan of Action to support, problem solve, assist, and provide reminders to increase utilization of clinic services.
223441648|NCT06910462|BEHAVIORAL|Integrated pest management (IPM) practices|Provide IPM resources to family child care home directors along with information about their exposure to pesticides and use of pesticides to lower their health risks.
223441649|NCT06910501|OTHER|Traditional oral hygiene instruction|Individualized demonstration of proper toothbrushing techniques using a toothbrush and a dental model. Conducted by a trained dental professional.
223441650|NCT06910501|OTHER|Digital slide-based education|Educational session using a PowerPoint presentation on a tablet or projector. The session includes visual aids to explain proper brushing techniques, the importance of oral hygiene, and the effects of poor dental care.
223441651|NCT06910501|OTHER|Brush DJ mobile appliaction|Children use the Brush DJ app, which includes gamified elements such as music, timers, and oral hygiene tips to encourage proper brushing habits. The app provides reminders and engaging content to maintain motivation.
223441652|NCT06911580|PROCEDURE|Graston Massage|The participant was positioned prone on the treatment table with the knee slightly flexed. A small amount of lubricating gel was applied to the entire gastrosoleus complex and the calcaneal tendon. For one minute, sweeping strokes were performed downwards on the gastrocnemius heads using the GT-5 tool. From the second to the fourth minute, the GT-5 was used in an upward direction to ensure that both the gastrocnemius and soleus were treated. Afterward, with the GT-2 tool, one minute of downward sweeping and one minute of upward sweeping were performed on the calcaneal tendon. Following the two minutes of sweeping, GT-3 was used to apply short, perpendicular strokes to the medial and lateral sides of the calcaneal tendon, with 30 seconds for each side. The total application lasted approximately 7 minutes (Palmer et al., 2017).
223441653|NCT03403946|DEVICE|Macintosh blade|Laryngoscopy with C-MAC PM in combination with Macintosh blade
223441654|NCT03403946|DEVICE|D-Blade|Laryngoscopy with C-MAC PM in combination with D-Blade
224052875|NCT04248387|DRUG|Toripalimab|Toripalimab, intravenous drip infusion, a dose of 3 mg / kg once every 2 weeks for a total of two cycles
224052876|NCT05678257|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
224300567|NCT06296654|BEHAVIORAL|Standard Health Education|Patients in the control group received standard health education from SCD clinics in the HC. The clinic employs a multidisciplinary team, including a nurse, a physician, a health record clerk, a laboratory technician, a social worker, and a health promotion specialist, to provide integrated patient health services. It consists of both preventative and curative services. The nurses at the health center provide patients with information regarding factors that may cause vaso-occlusion and precipitate VOCs when to seek emergency care and educate patients on the significance of regular medical examinations and screening using different standardized audiovisual aids.
223441655|NCT03403946|DEVICE|Intubation|Intubation with C-MAC PM in combination with D-Blade
224052877|NCT05678257|DRUG|Leucovorin|Intravenous infusion
224300568|NCT02287129|DRUG|Oxaliplatin|130 mg/m2
223566815|NCT01457014|DEVICE|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
223566816|NCT01457014|DEVICE|Continuous positive airway pressure|continuous positive airway pressure
224052878|NCT05678257|DRUG|Irinotecan|Intravenous infusion
224052879|NCT05678257|BIOLOGICAL|Bevacizumab|Intravenous infusion
224052880|NCT05678257|DRUG|5-FU|Intravenous infusion
224052881|NCT02046096|DEVICE|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
224052882|NCT02046096|DEVICE|Cook Celect® Vena Cava Filters|Temporary or permanent filter placement for the prevention of pulmonary embolism
224052883|NCT03520959|BIOLOGICAL|LV305|Administered via subcutaneous (SC) injection.
224052884|NCT03520959|BIOLOGICAL|G305|Administered via intramuscular (IM) injection.
224052885|NCT03520959|OTHER|LV305-matching placebo|Administered via SC injection.
224052886|NCT03520959|OTHER|G305-matching placebo|Administered via IM injection.
224052887|NCT06518954|OTHER|Interview|The athletes contributes with experience exchange through individual interviews, following a interview template
224145100|NCT00003219|DRUG|perillyl alcohol|
224145101|NCT00001777|DRUG|Sertraline|
224145102|NCT01916707|DRUG|Dosing of enoxaparin for VTE prophylaxis|
224145103|NCT05646654|PROCEDURE|Erector spinae plane block|Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected
224145104|NCT05646654|PROCEDURE|Interscalene brachial plexus block|Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
224300569|NCT02287129|DRUG|Epirubicin|50 mg/m2
224300570|NCT02287129|DRUG|Capecitabine|625 mg/m2
224300571|NCT02287129|DRUG|5-FU|200 mg/m2
223441656|NCT06912425|BEHAVIORAL|Health prevention.|Unlike other projects, this study focuses on an underexplored area in exercise and kidney disease research. Typically, exercise recommendations are directed toward individuals undergoing hemodialysis or peritoneal dialysis. However, in the early stages of the disease, when the kidneys begin to show alterations, there is no established safe training protocol as a preventive measure. This clinical trial will fill that gap by providing references for an exercise program specifically designed for individuals in the early stages of kidney disease. The main objective will be to compare two different exercise strategies to determine potential benefits for renal health.
224052888|NCT03583983|BEHAVIORAL|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
223441657|NCT03410901|BIOLOGICAL|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
223441658|NCT03410901|OTHER|Laboratory Biomarker Analysis|Correlative studies
223441659|NCT03410901|RADIATION|Radiation Therapy|Undergo radiation therapy
223441660|NCT03410901|DRUG|TLR9 Agonist SD-101|Given intratumorally
224052889|NCT03583983|BEHAVIORAL|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
224052890|NCT00626249|DRUG|Technosphere Inhalation Powder|Technosphere Inhalation Powder
224052891|NCT05145998|DIETARY_SUPPLEMENT|Glucola|50 grams of Glucola sugar beverage
224052892|NCT05145998|DIETARY_SUPPLEMENT|Whole pea meal|Whole cooked peas with spaghetti sauce and a slice of bread.
224052893|NCT05145998|DIETARY_SUPPLEMENT|Pea flour meal|Pea flour with spaghetti sauce and a slice of bread.
224052894|NCT05145998|DIETARY_SUPPLEMENT|Whole lentils|Whole cooked lentils with spaghetti sauce and a slice of bread.
224052895|NCT05145998|DIETARY_SUPPLEMENT|Lentil flour|Lentil flour with spaghetti sauce and a slice of bread.
224052896|NCT05338775|DRUG|Talquetamab|Talquetamab will be administered as a subcutaneous (SC) injection.
224300572|NCT02287129|DRUG|Carboplatin|2 mg/ml min
224300573|NCT02287129|DRUG|Paclitaxel|50 mg/m2
223441661|NCT06912230|OTHER|Normoxia|Participants will undergo a 6-hour passive exposure to normoxia in a climate-controlled environmental chamber maintained at 22°C with 30% relative humidity. They will remain in a fasted state throughout the exposure period.
223441662|NCT06912230|OTHER|Hypoxia (simulated altitude of 5000 meters above sea-level)|Participants will undergo a 6-hour passive exposure to a simulated altitude of 5000 meters above sea-level in a climate-controlled environmental chamber maintained at 22°C with 30% relative humidity. They will remain in a fasted state throughout the exposure period.
223441663|NCT06912022|DEVICE|FebriDx Device|Patients suspected of an acute respiratory infection were tested using the FebriDx POC assay.
223441664|NCT06910072|DRUG|paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab|paclitaxel polymeric micelles 300mg/m2, d1 carboplatin AUC=5, d1 iparomilimab and tuvonralimab 5mg/kg, d1 Every 3 weeks (Q3W) is a cycle, a total of 6 cycles.
223441665|NCT03557684|DIETARY_SUPPLEMENT|leucine|amino acid leucine in powder
223441666|NCT03557684|OTHER|PO placebo|maltodextrin
223441667|NCT03557684|BIOLOGICAL|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
223441668|NCT03557684|OTHER|IV placebo|0.9% saline
223566817|NCT01457014|DEVICE|servo ventilation manual|servo ventilation titrated in manual mode
223566818|NCT04741958|DIAGNOSTIC_TEST|Ultrasound Guided Peripheral Thoracic Tumors|Transthoracic ultrasonography: Transthoracic US was done using machine Hitachi 5500 in the Diagnostic Ultrasound Unit - Chest Department- Kasr El-Aini Hospital.on 60 patients that had radiographic evidence of thoracic mass suspected of malignancy
223566819|NCT03698578|OTHER|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
224052897|NCT05338775|DRUG|Teclistamab|Teclistamab will be administered as a SC injection.
224052898|NCT05338775|DRUG|PD-1 Inhibitor|The PD-1 inhibitor will be administered as an intravenous injection.
224052899|NCT04996823|DRUG|Ipilimumab|Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
224052900|NCT04996823|DRUG|Axitinib|Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)
224052901|NCT00806247|DRUG|tapentadol HCl|
224052902|NCT06972225|DEVICE|DEB|Use of DEB to treat coronary lesions
224052903|NCT06970470|DEVICE|Triple-Adjustable Posture Corrector Manufacturer: Mercur®, Santa Cruz do Sul, Brazil|"The Triple-Adjustable Posture Corrector is a thoracic spinal orthosis designed to provide biomechanical support and postural correction in individuals with excessive thoracic kyphosis. It consists of elastic and adjustable non-rigid bands positioned around the shoulders and thorax, allowing individualized tension regulation. The brace promotes scapular retraction and axial alignment by increasing proprioceptive feedback and limiting thoracic flexion.~Participants randomized to this intervention will be instructed to wear the orthosis for a minimum of four consecutive hours per day, during waking hours, for 16 weeks. The orthosis is to be removed during bathing, aquatic activities, and sleep. Individualized fitting will be provided at baseline by trained personnel, following the manufacturer's guidelines. Adherence will be monitored through self-reported daily logbooks. Participants will be advised to report discomfort, adverse effects, or perceived benefits.~The primary clinical obje"
224300574|NCT02287129|RADIATION|radiation|total dosage 41,4 Gy
224300575|NCT02287129|PROCEDURE|Biopsy|translational analysis
223441669|NCT06911281|COMBINATION_PRODUCT|Mesenchymal Stem Cells；755nm picosecond laser treatment|Stem Cell Treatment Group 1 received intravenous infusion of MSCs followed by multi-point injection into the melasma area, combined with 755nm picosecond laser treatment. Stem Cell Treatment Group 2 received multi-point injection of MSCs into the melasma area, combined with 755nm picosecond laser treatment. The Control Group only received 755nm picosecond laser treatment.
223441670|NCT00089700|DRUG|TNX-355|
223441671|NCT06018545|OTHER|Ground truthing|Two Consultant neuroradiologists will independently review the images to establish the 'ground truth' findings on the CT scans which will be used as the reference standard. In the case of disagreement, a third senior neuroradiologist's opinion will be sought for arbitration.
223441672|NCT06018545|OTHER|Reading|All 30 readers will review all 150 cases, in each of two study phases. The readers will provide their opinion on the presence or absence of some acute abnormalities, including intracranial haemorrhage, infarct, midline shift and fracture. They will provide a confidence in their diagnosis (10-point visual analogue scale), and a single click point to mark the location of each abnormality that they consider as being present. The time taken for each scan will be automatically recorded.
223441673|NCT03257241|DRUG|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
223441674|NCT03257241|DRUG|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
223441675|NCT03257241|DRUG|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
223441676|NCT03257241|DRUG|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
223441677|NCT02101749|BIOLOGICAL|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
223441678|NCT01074151|DRUG|duloxetine|any exposure to duloxetine that occurred during pregnancy
223441679|NCT00463840|DRUG|Oxaliplatin|
223441680|NCT00463840|DRUG|5FU|
223441681|NCT00463840|RADIATION|Radiation|
224052904|NCT06970470|DEVICE|Generation Dynamic Osteoporosis Brace Manufacturer: Bort®, Weinstadt, Germany|"The Generation Dynamic Osteoporosis Brace is a semi-rigid thoracic orthosis designed to stabilize the spine and counteract the progression of hyperkyphosis, especially in populations at risk for vertebral fragility. The brace is composed of lightweight, breathable material, with anterior and posterior structural support and adjustable tension straps. It is intended to reduce spinal flexion, improve sagittal alignment, and facilitate back extensor activation.~Participants assigned to this group will wear the orthosis for a minimum of four hours daily during waking hours, excluding sleep and aquatic activities, over a 16-week period. The orthosis will be individually fitted at the initial session by a trained physical therapist, following manufacturer protocols to ensure comfort, stability, and effectiveness. Participants will receive a daily logbook to record usage duration, comfort level, and perceived effects. Adherence will be monitored weekly.~The brace is intended to improve trun"
224052905|NCT06970314|DEVICE|Lokomat|Exoelectric walking aid for patients who have suffered a stroke
224052906|NCT06970314|DEVICE|C-Mill|Exoelectric walking aid for patients who have suffered a stroke
224300576|NCT01769339|DRUG|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
224300577|NCT03801538|DRUG|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
224300578|NCT03801538|DRUG|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
224300579|NCT06919796|BIOLOGICAL|COMIRNATY®|COVID-19 Vaccine, mRNA suspension
223441682|NCT00463840|PROCEDURE|Surgery|
223441683|NCT00463840|DRUG|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
223441684|NCT04812405|DIAGNOSTIC_TEST|Trios4|Examination of occlusal surfaces with 3D scanner and optical criteria
223441685|NCT01653327|DRUG|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
223441686|NCT01653327|DRUG|Placebo|
223441687|NCT00002131|DRUG|Vesnarinone|
223441688|NCT05735912|PROCEDURE|Endoscopic ultrasound-guided radio frequency ablation|Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
223441689|NCT05735912|PROCEDURE|Surgery|Surgical resection of pancreatic insulinoma
223441690|NCT05015543|OTHER|Personal Training Program|One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.
223441691|NCT03194347|DIAGNOSTIC_TEST|molecular genetic analyses|molecular genetic analyses
223441692|NCT05935033|DRUG|Emraclidine|Tablet
223441693|NCT03856333|OTHER|Assigned Interventions|exercises, physical agents
223441694|NCT01689233|DRUG|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
224052907|NCT04445675|OTHER|Support for breastfeeding and the feeding of infants' with breast milk|The content of the support for breastfeeding and the feeding of infants' with breast milk consists of the titles of the importance of breastfeeding and breast milk, the effect of breast milk on preventing jaundice, the importance of early start of breastfeeding, breastfeeding techniques and positions in infants, milking, storage and later use of milk, increasing the quantity and quality of milk, and nutrition of the mother during breastfeeding.
224052908|NCT01449461|DRUG|Brigatinib|Brigatinib tablets and capsules.
224052909|NCT04610021|BIOLOGICAL|i-FactorTM Bone graft|In the i-Factor ™ group it will be placed longitudinally in the intertransverse area. Likewise, in both groups, only autologous and bench bone will be placed in the intersomatic cages. The vertebrae where the i-Factor ™ is placed will be noted on the data collection sheet.
224052910|NCT06970990|PROCEDURE|HFNC:50L/min|Under high-flow oxygen therapy at a flow rate of 50 L/min, record/monitor for 5 minutes
224052911|NCT06970990|PROCEDURE|HFNC:flow=40L/min|Under high-flow oxygen therapy at a flow rate of 40 L/min, record/monitor for 5 minutes.
224052912|NCT06970990|PROCEDURE|HFNC:flow=30L/min|Under high-flow oxygen therapy at a flow rate of 30 L/min, record/monitor for 5 minutes.
224052913|NCT06970990|PROCEDURE|Face mask oxygen:8L/min|Under face mask oxygen at a flow rate of 8 L/min, record/monitor for 5 minutes.
224052914|NCT06970990|PROCEDURE|Face mask oxygen:5L/min|Under face mask oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.
224052915|NCT06970990|PROCEDURE|Nasal cannula oxygen:5L/min|Under nasal cannula oxygen at a flow rate of 5 L/min, record/monitor for 5 minutes.
224052916|NCT06970990|PROCEDURE|Nasal cannula oxygen:3L/min|Under nasal cannula oxygen at a flow rate of 3 L/min, record/monitor for 5 minutes.
224052917|NCT06970756|BIOLOGICAL|26-valent Pneumococcal Conjugate Vaccine|Subjects were treated with a single intramuscular injection of 26-valent Pneumococcal Conjugate Vaccine.
224052918|NCT06970756|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|Subjects were treated with a single intramuscular injection of 13-valent Pneumococcal Conjugate Vaccine.
224052919|NCT05835843|OTHER|In-Person and Remote Disease Assessment|Disease severity will be assessed during the in-person visit and standardized digital photographs of different body regions and/or the full body will be collected for remote evaluations by external dermatologists.
224052920|NCT06647511|DEVICE|Nokia-Withings BPM Connect Blood Pressure Monitor|At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.
224052921|NCT06647511|DEVICE|Smartwatch Devices|Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.
224052922|NCT06233799|DRUG|extended-release naltrexone (XR-NTX)|Once per three weeks injections of extended-release naltrexone
224145105|NCT01853098|BEHAVIORAL|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
224145106|NCT00418210|RADIATION|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
223441695|NCT01689233|DRUG|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
223441696|NCT04607980|DRUG|ABP 654|Participants will receive SC injection of ABP 654.
223441697|NCT04607980|DRUG|Ustekinumab|Participants will receive SC injection of ustekinumab.
223441698|NCT05628298|DEVICE|Soovu Pain Relief System|The Soovu Pain Relief system uses pulses of heat to block the TRPV-1 calcium channel on peripheral pain nerves. The study will determine if the FDA cleared device significantly reduces the subject's pregnancy related pain.
224145107|NCT04188002|BEHAVIORAL|Intervention Physical Activity|4 tailored newsletters focused on improving healthy diet and physical activity delivered at weekly intervals.
224145108|NCT04188002|OTHER|Usual Care|4 non-tailored newsletters focused on issues relevant to cancer survivors (e.g. returning to work)
223441699|NCT00560911|BEHAVIORAL|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
223566820|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
224052923|NCT06233799|DRUG|extended release bupropion (BUP-XL) tablets (BUP-XL)|Daily oral extended release bupropion tablets
224052924|NCT06233799|DRUG|iPLB|Once per three weeks injections of placebo
224052925|NCT06233799|DRUG|oPLB|Daily oral placebo tablets
224052926|NCT06437717|OTHER|application of different topical nasal solutions|each group receives a type of nasal solution to detect if there is a difference in the outcomes in chronic rhinosinusitis patients
224052927|NCT01608152|BEHAVIORAL|Focus Group|Attend a focus group
224052928|NCT01608152|OTHER|Internet-Based Intervention|Have access to the game
224052929|NCT01608152|BEHAVIORAL|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
224052930|NCT05024695|DEVICE|MINIject™ Implant|The MINIject™ SO627 is an integrated system for Minimally Invasive Glaucoma Surgery (MIGS) comprised of a glaucoma drainage implant, the MINIject™ SO627 and the SO Delivery System, designed to deliver the MINIject™ implant into the supraciliary space.
224052931|NCT06046339|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
224145109|NCT06304519|DEVICE|Dynamic ankle-foot orthosis|customized, carbon fiber, passive ankle-foot orthosis
224145110|NCT02904525|DEVICE|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
224145111|NCT02384395|DRUG|Dolutegravir 50 mg|Initial therapy for AHI
224145112|NCT02384395|DRUG|Lamivudine 300 mg|Initial therapy for AHI
224145113|NCT02384395|DRUG|Abacavir 600 mg|Initial therapy for AHI
223441700|NCT00560911|BEHAVIORAL|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
223441701|NCT04651946|DIAGNOSTIC_TEST|DNA methylation testing|Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum
223441702|NCT06911697|DIAGNOSTIC_TEST|18F-TSPF PET/CT|Each subject receives interval imaging of 18F-TSPF PET/CT and 18F-FDG PET/CT, and further follow-up.
223441703|NCT05052606|OTHER|No intervention|This study is an observational study without treatment intervention.
223441704|NCT04747990|PROCEDURE|Early Definitive Treatment|defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
223441705|NCT05988905|OTHER|robot assited gati training|SUBAR® (CRETEM, Korea) is a exoskeletal-robot with a footplate that assists gait movements. The patient's thigh length and lower leg length were measured before training, so that the SUBAR® can be adjusted to patient's size to ensure accurate training. During training, the therapist facilitated the treatment and stood by the patients' side to adjust the direction and speed. RAGT is programmed automatically, and it can be performed regularly over a long period. The patients received 30 min of robot-assisted training using SUBAR® once a day for 5 days a week for 8 weeks. Each training session lasted up to 40 min.
223441706|NCT05988905|OTHER|conventional traiing|Patients also received conventional exercise rehabilitation with the same duration and frequency. Conventional rehabilitation therapy, which consisted of active assistive knee exercises, knee stretching, patellar mobilization exercises, and quadriceps setting exercises, was performed every day throughout the rehabilitation period.
223441707|NCT01833936|DEVICE|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
224052932|NCT06138509|OTHER|Dosage of serotonin and metabolites|The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.
224052933|NCT06138509|OTHER|Blood parameters|The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.
224052934|NCT05002816|DRUG|Elotuzumab|Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
224052935|NCT05002816|DRUG|Belantamab mafodotin|Belantamab mafodotin will be administered via IV infusion on day 1 of each 28 day cycle. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered. Following the dose evaluation, there will be a dose expansion cohort wtih 12 additional subjects. There is no dose escalation planned in this study.
224052936|NCT04590170|BEHAVIORAL|Post-intensive Care unit syndrome|Post-intensive Care unit syndrome after an intensive care unit stay for the COVID19
224145114|NCT05448989|DRUG|1% atropine 5+3|A method for myopia control using high-concentration atropine
224145115|NCT00617318|DIETARY_SUPPLEMENT|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
224145116|NCT00617318|DIETARY_SUPPLEMENT|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
223441708|NCT01833936|DEVICE|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
223441709|NCT02163616|DRUG|Misoprostol|800 mcg of sublingual misoprostol
223566821|NCT00255918|DRUG|Placebo|Placebo dosed to match active medication
224052937|NCT04590170|OTHER|Spatiotemporal measurements of walking|Spatiotemporal measurements of walking in asymptomatic participants from the general population.
224052938|NCT04898933|PROCEDURE|lacrimal deroofing|After infiltration anesthesia, patient underwent proximal lacrimal deroofing. Proper punctal dilatation is done, followed by combined 1 snip punctoplasty with a lateral canaliculotomy/ Punctotomy and posterior canaliculotomy of the lateral third. En-bloc expulsion of the concretion was done in case of canaliculitis.
224052939|NCT04389632|DRUG|sigvotatug vedotin|Administered into the vein (IV; intravenously)
224052940|NCT04389632|DRUG|pembrolizumab|200mg every 3 weeks or 400mg every 6 weeks, given by IV
223441710|NCT04742660|DRUG|Ammonium Glycyrrhizinate|In control group, we assess the incidence and severity of PONV when participants are aministered ramosetron and placebo. In intervention group, the outcomes are assessed as a result of administration of ramosetron and glycyrrhizin.
223441711|NCT04861194|RADIATION|Neurovascular-sparing|Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT
223441712|NCT03728361|BIOLOGICAL|Nivolumab|Given IV
223441713|NCT03728361|DRUG|Temozolomide|Given PO
223441714|NCT04579445|OTHER|Education on tailored Quality Improvement measures|Centers will undergo an education on defined Quality of Care measures, with the aim to implement a standardized pathway which is reproducible, scalable and which will allow increased access. The implementation of these measures will help to reduce resource requirements, intensive care bed occupancy and overall length of hospital stay with uncompromised patient safety.
223441715|NCT05721677|DEVICE|2-octyl cyanoacrylate based topical skin adhesive|Tissue adhesive on CVL exit-site
223441716|NCT03488602|BEHAVIORAL|F-SPS+UC|"Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care."
223441717|NCT03488602|BEHAVIORAL|EUC|"Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care."
224052941|NCT04389632|DRUG|cisplatin|75 mg/m2 every 3 weeks, given by IV
224052942|NCT04389632|DRUG|carboplatin|AUC 5 mg/mL per min every 3 weeks, given by IV
224052943|NCT05574010|DRUG|Cohort 1 in Part A|Dose 1 KAN-101 Intravenous (IV) infusion
224052944|NCT05574010|DRUG|Cohort 2 in Part A|Dose 2 KAN-101 Intravenous (IV) infusion
224052945|NCT05574010|OTHER|Placebo: Group 1 in Part B and Part C|Placebo Intravenous (IV) infusion
224052946|NCT05574010|DRUG|Group 2 in Part B and Part C|Dose 3 KAN-101 Intravenous (IV) infusion
224052947|NCT05574010|DRUG|Group 3 in Part B and Part C|Dose 4 KAN-101 Intravenous (IV) infusion
224052948|NCT05574010|DRUG|Group 4 in Part B and Part C|Dose 5 KAN-101 Intravenous (IV) infusion
224052949|NCT02822846|OTHER|lung ultrasound|
224052950|NCT05314517|DRUG|Namilumab|Namilumab administered subcutaneously
224052951|NCT05314517|DRUG|Placebo|Placebo administered subcutaneously to match namilumab dosing
224052952|NCT04969276|BIOLOGICAL|Quadrivalent Inactivated Influenza High Dose|Sterile suspension for injection in a pre-filled syringe Intramuscular injection
224145117|NCT06531226|OTHER|Fill in personality questionnaires|For patients who need to undergo colonoscopy, we invite them to fill out a personality survey questionnaire after obtaining their informed consent. The questionnaire contains 60 survey questions, which cover the five dimensions of the Big Five personality traits. Each question has five options, corresponding to the five states of very disagree to very agree. The questionnaire was developed based on the Chinese population and has four norms applicable to different age groups to ensure the reliability of the questionnaire.
224145118|NCT02850497|DEVICE|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
224145119|NCT01929213|DRUG|Udenafil|Udenafil is administered
224145120|NCT01929213|DRUG|Bosentan|Bosentan is administered
224145121|NCT01929213|DRUG|Udenafil/Bosentan|Udenafil and Bosentan are administered
224145122|NCT04884672|DEVICE|SMILE|Small incision lenticule extraction, a refractive surgery procedure for the corrcetion of myopia with or without astigmatism
224145123|NCT00886106|DRUG|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
223441718|NCT04441749|DEVICE|Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE)|Patients who are scheduled to undergo Robotic Navigational Bronchoscopy for a peripheral lung lesion will be enrolled. During bronchoscopy, confocal images will be captured using Cellvizio 100 Series Confocal Laser Imaging systems and their Confocal Miniprobes (Mauna Kea Technologies Paris, France). The Cellvizio system and miniprobes are FDA approved by 510(k) for use in through the respiratory tracts by endoscopy or endoscopic accessories. Only images and needle aspiration/ biopsy results from the expansion phase (20 patients) will be analyzed
223441719|NCT02981732|OTHER|Liuwei Dihuang Pill|
223566822|NCT00255918|DRUG|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
223566823|NCT05463744|DRUG|Insulin Efsitora Alfa|Administered SC
224052953|NCT04969276|BIOLOGICAL|COVID-19 mRNA Vaccine (nucleoside modified)|Sterile suspension (white to off-white) in multidose vial Intramuscular injection
224052954|NCT02470299|DRUG|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
224052955|NCT02470299|OTHER|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~* Patients \< 65 years of age: Daily dose of 30 mg for three doses.~* Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
224052956|NCT05424926|OTHER|collection of clinical parameters and blood sample|"* A baseline visit, with collection of clinical parameters and blood sample to measure anti-infliximab antibodies and infliximab trough levels.~* Follow-up visits at 3 months (in outpatient clinic for clinical evaluation), 6 months and 12 months (in day hospitalization for clinical evaluation and blood sample collection for ADA detection and infliximab trough level measurement)."
224052957|NCT05285566|DRUG|Exparel|106mg (8 mL) subcutaneous injection injected after costal cartilage harvest
224052958|NCT05285566|DRUG|Xylocaine|8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site
224052959|NCT04839601|DEVICE|RNS System|The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
224052960|NCT05721846|DRUG|Nivolumab|3 mg/kg (up to 240 mg maximum) as i.v. infusion on day 1 (± 3 days) of each 14-day treatment cycle
224052961|NCT05721846|DRUG|Ipilimumab|1 mg/kg as i.v. infusion on day 1 cycle 1 and subsequently every 6 weeks (± 3 days)
224052962|NCT05721846|RADIATION|SBRT|SBRT: 15 Gy x 1 on a single site of disease on day 1 cycle 1
224052963|NCT05721846|BIOLOGICAL|TGFβ-B-15 peptide|Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51) as s.c. injection on day 1 of the first 6 cycles and subsequently every 4 weeks (± 3 days)
224052964|NCT06517277|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. Relapses will be collected up to 3 months after Haemophilus influenzae pneumonia first episode.
224052965|NCT04551677|BIOLOGICAL|Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: Intramuscular (IM)"
224145124|NCT00886106|DRUG|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
224145125|NCT00343109|BIOLOGICAL|HER-2/neu intracellular domain protein|Given ID
224145126|NCT00343109|PROCEDURE|leukapheresis|Optional correlative studies
224145127|NCT00343109|OTHER|laboratory biomarker analysis|Correlative studies
224145128|NCT00343109|BIOLOGICAL|sargramostim|Given ID
224145129|NCT00343109|OTHER|immunologic technique|Correlative studies
224145130|NCT00343109|BIOLOGICAL|synthetic tumor-associated peptide vaccine therapy|Given ID
224145131|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
224300580|NCT06926725|DEVICE|Cavitation : Study group A only will receive one session per week for three months (total 12 sessions ). Ultrasound treatments are performed using an applicator head with diameter 7 cm . Intensity :|"Cavitation :~Study group A only will receive one session per week for three months (total 12 sessions ).~Ultrasound treatments are performed using an applicator head with diameter 7 cm .~Intensity : 0.1-0.5 w/cm2 (low) Frequency : 30-40 KHZ (low) Duration : 30 minutes"
224052966|NCT04551677|BIOLOGICAL|Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation|"Pharmaceutical form: Suspension for injection in a pre-filled syringe,~Route of administration: IM"
224052967|NCT03289923|DEVICE|Sham TMS + Cognitive therapy|Placebo Transcranial Magnetic Stimulation with cognitive therapy
224052968|NCT03289923|DEVICE|Active TMS + Cognitive therapy|Active Transcranial Magnetic Stimulation with cognitive therapy.
224052969|NCT06976008|OTHER|blood sampling|Blood samples will be taken at different timepoints following CMV viremia to evaluate the impact of CMV viremia over time.
224145132|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
224145133|NCT03807245|BIOLOGICAL|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
224145134|NCT03807245|BIOLOGICAL|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
224145135|NCT00291499|DRUG|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
224145136|NCT00291499|OTHER|Placebo|800 mg placebo/day for 6 months
224145137|NCT05474872|DEVICE|BIS monitoring|The depth of anesthesia will be monitored using Bispectral Index values.
224145138|NCT04220138|PROCEDURE|Anterior chamber illumination in cataract surgery|This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
224145139|NCT06470555|OTHER|A figure-of-eight suture secured with a three-way tap|Femoral haemostasis using a figure-of-eight suture technique
224145140|NCT06470555|OTHER|Shortened bed rest duration of 2-hours|Bed rest duration of 2-hours after initial haemostasis
224145141|NCT06470555|OTHER|Manual compression|Femoral haemostasis using manual compression
224145142|NCT06470555|OTHER|Conventional bed rest duration of 4-hours|Bed rest duration of 4-hours after initial haemostasis
224145143|NCT06247267|DRUG|Fortesta|Primary/secondary untreated hypogonadism patients receive Fortesta injection, gel and transdermal treatment for 12 months with titration for a serum total T level between 300-600ng/dL.
223566824|NCT05463744|DRUG|Insulin Degludec|Administered SC
224052970|NCT06804538|PROCEDURE|Insemination between 42 and 43 hours post hCG|Patients will be stimulated by gonadotropins, ovulation will be blocked by a GnRH antagonist then triggered by hCG allowing IU to occur between 42 and 43 hours post hCG
224052971|NCT06804538|PROCEDURE|Insemination between 36 and 37 hours post hCG|Patients will be stimulated with gonadotropin and GnRH antagonist whose ovulation will be triggered and for which intrauterine insemination will be carried out between 36 and 37 hours post hCG
224145144|NCT06247267|DRUG|Estradiol|Male-to-female (MTF) receive Estradiol orally and transdermal and/or spironolactone-orally) treatment for 12 months for hormonal transition period.
224145145|NCT06247267|DRUG|Fortesta|Female-to-male (FTM) receive Fortesta injection, gel and transdermal treatment for 12 months for hormonal transition period.
224145146|NCT04353973|OTHER|Pre-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
224145147|NCT04353973|OTHER|Standard of Care|Standard of Care with a Genetic Counselor either In-Person or by Remote Services (Telephone or Video Conferencing)
224052972|NCT04187105|DEVICE|Arm1|Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2
224052973|NCT04187105|DRUG|Arm1|"All patients will receive the following standard conditioning regimen:~Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2"
224052974|NCT04187105|DRUG|Arm1|IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.
224052975|NCT04187105|DEVICE|Arm 1|Total body irradiation 2Gy on day -1.
224052976|NCT04187105|OTHER|Arm1|Stem cell infusion on day 0.
224052977|NCT04187105|DRUG|Arm1|Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)
223441720|NCT01599481|BEHAVIORAL|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
223441721|NCT01599481|BEHAVIORAL|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
223441722|NCT04802083|BIOLOGICAL|Eculizumab|Eculizumab 900-1200 mg will be administered intravenously.
223441723|NCT02982148|DEVICE|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
223441724|NCT02982148|DEVICE|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
223441725|NCT01575002|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
223441726|NCT05891717|OTHER|Resistance training|Twice per week for 8 weeks. Total 16 sessions will given.
223441727|NCT05891717|OTHER|Flexibility training|Twice per week for 8 weeks. Total 16 sessions will given.
224052978|NCT04187105|DRUG|Arm1|Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day
224145148|NCT04353973|OTHER|Post-Test Intervention|Secure and accessable by private code only, the web-based intervention will provide users with a the results of their clinical genetic testing results and a detailed summary of what those results mean. Additionally, an individualized summary will also be included.
224145149|NCT05162781|BEHAVIORAL|Speed of Processing Training|"This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors."
223441728|NCT04321941|DIAGNOSTIC_TEST|Lumentin|Contrast agent used in combination with CTE
223441729|NCT04321941|DIAGNOSTIC_TEST|Movprep|Contrast agent used in combination with MRE
223441730|NCT06397209|OTHER|Propioceptive Neuromascular facilitation|Propioceptive Neuromascular Facilitation techniques will be given for 5 days/week,10 repetitions,30 minutes/day for 8 weeks
223441731|NCT06397209|OTHER|Neural Flossing|Neural Flossing exercises will be given for 5 days/week, 3 sets of 10 repetitions in 2 minutes for 30 minutes for 8 weeks
223441732|NCT06199544|DRUG|Metformin|Comparing the effect of drugs on symptoms of PCOS
224052979|NCT04808427|DEVICE|TULSA-PRO|Transurethral MR-Thermometry Guided Ultrasound Ablation of the Prostate
224052980|NCT04655144|DRUG|Dexamethasone|Dexamethasone delivered to the uterine arterial bed, prior to embolization.
224052981|NCT04655144|DRUG|Saline|Saline delivered to the uterine arterial bed, prior to embolization.
224052982|NCT05072977|PROCEDURE|TransPRK|A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.
224052983|NCT05072977|PROCEDURE|Alcohol PRK|A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.
224052984|NCT06082635|DRUG|TGRX-326|Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
224052985|NCT06082635|DRUG|Crizotinib|Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
224052986|NCT00389792|DRUG|ATI-2042|no intervention
224052987|NCT00389792|DRUG|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
224145150|NCT05162781|BEHAVIORAL|Instrumental Activities of Daily Living In-lab Training|The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
223441733|NCT00394394|DRUG|Amiloride 2,5/d or Enalapril/d 10 mg|
223441734|NCT05087446|BEHAVIORAL|Early assessment team|Early assessment team (EAT):The patients receive their first assessment by an early clarification team within a few weeks after the team receiving the referral. The team then decides whether further assessment and/or treatment should be given in the general outpatient clinic, and/or whether any other follow-up may be appropriate. In the first meeting the patient preferably meets two therapists, who conduct a semi-structured interview with focus on health and level of functioning. If considered appropriate, the team may offer a short-term intervention.
223441735|NCT05087446|BEHAVIORAL|Admission to General psychiatric outpatient clinic|Ordinary procedures for admission to an outpatient clinic are followed in accordance with the Norwegian Directorate of Health's national prioritization guide. Referrals are assessed on the basis of severity and placed on a regular waiting list (usually a waiting period of 1-3 months). The patients receive their first personal assessment from a therapist in a general outpatient clinic who takes a position on what is to be initiated and, if necessary, offers further assessment / treatment in accordance with procedures in the outpatient clinics. This is not standardized beyond current practice.
223441736|NCT05230199|BEHAVIORAL|SENSE multisensory program|In order to support parent's ability to implement the daily SENSE program they will be provided with an educational manual reviewing the program, weekly meetings with a therapist, and logs to report their visitation schedule and activities. Parents are able to choose different types of each sensory exposure. All options address the same key principles for that behavior and only include those that have evidence to support their use and are appropriate at each PMA.
223441737|NCT05230199|BEHAVIORAL|Monitored standard of care|Infants who receive sensory exposures only as standard of care but do not recieve the SENSE program
224052988|NCT02484326|OTHER|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
223441738|NCT06118450|OTHER|Non-intervention|non-intervention
224052989|NCT03470584|OTHER|Diet Exposure|Vegetarian diet vs nonvegetarian diet
224052990|NCT06545071|BEHAVIORAL|NEAT-O program|NEAT-O's curriculum is designed to interrupt the cycle of negative emotions and opioid use through a multifaceted approach encompassing physiological, psychological, and behavioral strategies. The program includes interactive modules that capture the core therapeutic components of CBT and teach skills to support OUD recovery.
224052991|NCT01430286|BEHAVIORAL|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
224052992|NCT01430286|BEHAVIORAL|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
224052993|NCT05599672|BEHAVIORAL|Alcohol-targeted Brief Intervention-Medication Therapy Management|Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.
224145151|NCT05162781|BEHAVIORAL|Cognitive Transfer Packagke|This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
224145152|NCT05162781|BEHAVIORAL|Family Caregiver Coaching|One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
224145153|NCT05162781|BEHAVIORAL|Follow-up Phone Calls|After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 5 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
224145154|NCT05162781|BEHAVIORAL|Healthy Lifestyle In-lab Training|This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
224145155|NCT05162781|BEHAVIORAL|Healthy Lifestyle Transfer Package|This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
224145156|NCT05236036|DRUG|Mycophenolate Mofetil|Given PO
224145157|NCT05236036|OTHER|Quality-of-Life Assessment|Ancillary studies
224145158|NCT05236036|RADIATION|Radiation Therapy|Receive radiation therapy
223441739|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
224145159|NCT05236036|DRUG|Temozolomide|Given Orally (PO)
223441740|NCT00858468|BIOLOGICAL|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
223566825|NCT04913168|OTHER|Front Line Worker Pilot Project|13-month intervention targeting workplace policies and programs focused on changes to safety and ergonomics, job enrichment, and work intensity for front line food service workers practices,
224052994|NCT05599672|BEHAVIORAL|Standard medication counseling|Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
224145160|NCT03858270|DRUG|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
223441741|NCT05090306|DIAGNOSTIC_TEST|Routine ultrasound examination|ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
223441742|NCT02119806|DRUG|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
223441743|NCT02119806|DRUG|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
223441744|NCT02119806|DRUG|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
223441745|NCT02060864|DIETARY_SUPPLEMENT|AN-PEP|Two pills are consumed in the morning with a breakfast
223441746|NCT02060864|DIETARY_SUPPLEMENT|Placebo|
223441747|NCT04187716|DRUG|Ferinject|"For patients undergoing chemotherapy, ferinject 1000mg will be injected within 24 hours or 24 hours after day 1 of the next chemotherapy cycle.~Patients using targeted therapies can be dosed at any time after recognizing Hb 8.0-10.5g / dL and injecting 1000 mg of ferinject."
223441748|NCT04767529|DRUG|Efruxifermin|subcutaneous injection
223441749|NCT04767529|DRUG|Placebo|subcutaneous injection
223441750|NCT06464302|PROCEDURE|Surgical stabilisation of rib fractures (SSRF)|Surgical stabilisation of rib fractures using any fixation technique (including but not limited to plate fixation, intramedullary fixation, wire fixation) via any operative approach (including but not limited to open external approach, minimally invasive approach, thoracoscopic approach, thoracotomy approach).
223441751|NCT06464302|OTHER|Non-operative management of rib fractures|Any supportive or specific treatment of rib fractures excluding surgical stabilisation of rib fractures. This includes, but is not limited to analgesia, physiotherapy, non-invasive ventilation, mechanical ventilation, oxygen-supplementation
223441752|NCT01014481|DRUG|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
224052995|NCT03543865|BEHAVIORAL|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
224052996|NCT03543865|BEHAVIORAL|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
224145161|NCT03858270|OTHER|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
224145162|NCT00289549|DRUG|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
223441753|NCT05885061|DEVICE|Spinal cord stimulation turned on (suggestions: off)|Spinal cord stimulation turned on with verbal suggestions of treatment off
223441754|NCT05885061|DEVICE|Spinal cord stimulation turned off (suggestions: on)|Spinal cord stimulation turned off with verbal suggestions of treatment on
223441755|NCT05885061|DEVICE|Spinal cord stimulation turned on with suggestions (suggestions on)|Spinal cord stimulation turned on with verbal suggestions of treatment on
223441756|NCT04350879|OTHER|Data record|Data record
223441757|NCT01716520|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
224145163|NCT00102934|DRUG|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
224145164|NCT00635245|BIOLOGICAL|figitumumab|
224145165|NCT00635245|OTHER|imaging biomarker analysis|
224145166|NCT00635245|OTHER|laboratory biomarker analysis|
224145167|NCT00635245|OTHER|pharmacological study|
224145168|NCT00635245|PROCEDURE|conventional surgery|
223441758|NCT01716520|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
223441759|NCT01716520|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
224145169|NCT00635245|PROCEDURE|magnetic resonance spectroscopic imaging|
224145170|NCT00635245|PROCEDURE|neoadjuvant therapy|
223441760|NCT02370056|DIAGNOSTIC_TEST|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
223566826|NCT01352442|DEVICE|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
223566827|NCT02709551|BEHAVIORAL|HRV_Bfb|
224145171|NCT06269575|BEHAVIORAL|SAFE NUTRITION PROGRAM|"Safe nutrition program:~patient education, caregiver training, behavioral swallowing intervention, position, oral care, swallowing exercises, swallowing assessment"
224052997|NCT03543865|OTHER|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
224145172|NCT03582852|PROCEDURE|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
224145173|NCT05351333|OTHER|placebo|Sugar pill, with an essential-oil smell and of blue color used for conditioning.
224145174|NCT00742807|DRUG|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
224145175|NCT00742807|DRUG|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
224145176|NCT03939637|DRUG|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~* Children 1 to 5 years: Initial: 25 mg once daily~* Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity \[e.g., Chinese, Japanese, Korean, Taiwanese\])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
224145177|NCT03939637|DRUG|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
224145178|NCT03939637|DRUG|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
224145179|NCT03939637|DRUG|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
223441761|NCT02370056|DIAGNOSTIC_TEST|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
223441762|NCT04186897|PROCEDURE|Occlusal reduction|Occlusal contacts on the functional and non-functional cusps were reduced.
223441763|NCT04186897|PROCEDURE|Sham occlusal reduction|The occlusal surface left intact. No actual occlusal reduction.
223441764|NCT02072070|BIOLOGICAL|TissueGene-C|TissueGene-C at 1.8 x 10\^7 cells
223441765|NCT02072070|DRUG|Placebo|Placebo control(Normal Saline)
223441766|NCT02711943|DRUG|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
223441767|NCT03495115|DEVICE|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
223441768|NCT03495115|DEVICE|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
224145180|NCT05886348|DEVICE|Model-A Novel spectacle lens|Model-A Novel spectacle lenses will be given to 1 arm to wear for 36 months
224145181|NCT05886348|DEVICE|Model-B Novel spectacle lens|Model-B Novel spectacle lenses will be given to 1 arm to wear for 36 months
223441769|NCT04480996|DRUG|Drugs Responsible for Cognitive Side Effects|identification of road traffic accidents associated with drugs responsible for psychomotor side effects
223441770|NCT00983541|DRUG|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
223441771|NCT00983541|RADIATION|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
223441772|NCT00983541|DRUG|Gemcitabine|"Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.~Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.~Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.~Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC."
223441773|NCT01937884|DRUG|Parenteral Nutrition|
224052998|NCT06057181|GENETIC|Exome sequencing|Exome sequencing will be completed on each sample submitted.
224145182|NCT05886348|DEVICE|Single vision spectacle lens|Single Vision Spectacle lenses will be given to 1 arm to wear for 36 months
223441774|NCT00401492|DRUG|gemcitabine prolonged continuous infusion|
224145183|NCT03733457|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
224145184|NCT01350713|DRUG|povidone iodine|one local application of 10% povidone iodine ointment
224145185|NCT05224076|OTHER|Home Air Quality|This study will assess the feasibility and usability of ecological momentary assessment (EMA) to capture the context of real time behaviors and environmental exposures that impact indoor environments. In addition, the study will assess the feasibility and usability of providing participants with a readily available indoor home air quality monitor to continuously capture total volatile organic compounds (VOCs) and particulates (PM2.5).
223441775|NCT00401492|DRUG|cisplatin|
223441776|NCT00401492|DRUG|vinorelbine|
223441777|NCT04740996|DRUG|Pembrolizumab|Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
223441778|NCT00004088|BIOLOGICAL|filgrastim|
224145186|NCT05204407|DIETARY_SUPPLEMENT|Luteolin|The luteolin target dose will be 300 mg BID taken over 12 weeks in capsule form
223441779|NCT00004088|BIOLOGICAL|recombinant interferon alfa|
223441780|NCT00004088|DRUG|busulfan|
223441781|NCT00004088|DRUG|cyclophosphamide|
223441782|NCT00004088|DRUG|melphalan|
223441783|NCT00004088|DRUG|pamidronate disodium|
224052999|NCT06967753|DRUG|Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)|Enrolled participants will be switched to a dual therapy regimen consisting of 50-mg DTG plus 300-mg 3TC tablet (as a single pill fixed dose combination) orally administered once daily with or without food. No dose reductions, modifications in dosage, or changes in the frequency of dosing will be allowed in this study.
224053000|NCT06118268|DEVICE|iTBS (Active)|"The present study is a double-blind, randomized clinical trial that will examine if iTBS applied to DMPFC improves social cognitive performance compared to sham stimulation~DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands)."
224053001|NCT06118268|DEVICE|iTBS (Sham)|DMPFC-iTBS will be administered using the MagPro R30 stimulator equipped with a Cool-B70 coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies Enschede, Netherlands).
224053002|NCT04413331|OTHER|Data collection|Medical data collection at M0, M3, M6, M9 and M12 then every 6 months until M60 and at each vascularitis relapse
224053003|NCT04413331|OTHER|Biological samples and data collection|Biological samples at M0, M6, M12, M24 and at each relapse until M60
224053004|NCT06311188|BEHAVIORAL|ITR Healing intervention|This is a nonrandomized test of the culturally adapted ITR healing intervention that is based on the ITR framework. The ITR Healing intervention comprises six 60-minute sessions based on Intersectionality theoretical framework, Healing Centered Engagement (HCE) activities that were integrated into the intervention, as well as participant's feedback about the intervention. Also, the participants' behavioral experiences per the Theoretical Domains Framework targets was used to adapt the intervention activities. HCE focuses on building a holistic approach and empathy for each session, i.e., using music, dance/movement, meditation, breathing and journaling.
224053005|NCT05125601|OTHER|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH)|The Parents' Evaluation of Aural/Oral Performance of Children (PEACH) will be completed once.
224053006|NCT04490018|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine)|Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular
223441784|NCT00004088|DRUG|thalidomide|
223441785|NCT00004088|PROCEDURE|peripheral blood stem cell transplantation|
224053007|NCT04490018|BIOLOGICAL|Meningococcal group A, C, W-135, and Y conjugate vaccine|Pharmaceutical form: Powder and solvent for solution for injection Route of administration: Intramuscular
224053008|NCT04490018|BIOLOGICAL|Human Papillomavirus 9-valent Vaccine (9vHPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224053009|NCT04490018|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine (Tdap-IPV)|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
224053010|NCT02878551|OTHER|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
224053011|NCT03947125|DRUG|Buprenorphine transdermal patch on knee joint|Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
224145187|NCT05204407|DIETARY_SUPPLEMENT|Placebo|The placebo target dose will be 300 mg BID taken over 12 weeks in capsule form
224145188|NCT05976243|DRUG|Remibrutinib|Remibrutinib treated groups and arms
224145189|NCT05976243|OTHER|Placebo|Placebo treated groups and arms
223441786|NCT04402450|PROCEDURE|Ultrasound-guided suprainguinal fascia iliaca nerve block|After an ultrasound-guided insertion of a block needle below the inguinal ligament, the needle will be advance in the plane between fascia iliaca and iliopsoas muscle up to a point cranial to the ligament in order to inject a 40 mL of adrenalized 0.25% levobupivacaine.
223441787|NCT04402450|PROCEDURE|Ultrasound-guided pericapsular nerves group of the hip block|After an ultrasound-guided insertion of a block needle at the level of the inguinal ligament, the needle will be advance into the plane between iliac bone periosteum and the tendon of the iliopsoas muscle in order to inject 20 mL of adrenalized 0.5% levobupivacaine.
223441788|NCT05804253|PROCEDURE|Maxillary sinus augmentation|Maxillary sinus grafting with 2 different xenogenic materials
223441789|NCT04617964|OTHER|Ultrasound|Assessment the intra and interoperator reproducibility of the measurement of the right portal vein diameter at the routine third trimester ultrasound
223441790|NCT02445742|DRUG|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
223441791|NCT01615159|BEHAVIORAL|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
223441792|NCT02806830|DRUG|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
223441793|NCT05979207|DRUG|MMV367|Single dose
223441794|NCT05979207|OTHER|P. falciparum IBSM infection|Induced Blood Stage Malaria
223441795|NCT03807622|DEVICE|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
223441796|NCT03706469|DRUG|TAK-831 T2|TAK-831 T2 Tablets.
223441797|NCT03706469|DRUG|TAK-831 T3|TAK-831 T3 Tablets.
223441798|NCT05812430|DRUG|anlotinib+TQB2450+nab-paclitaxel+cisplatin|"Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles."
223566828|NCT02709551|BEHAVIORAL|MBI|
223566829|NCT02709551|BEHAVIORAL|MBI_HRV_Bfb|
224053012|NCT06227884|OTHER|APN intervention|"Participants with a schedule of a MD consultation (within approximately 2 to 12 months) + an APN intervention halfway between day hospitalization et MD consultation~APN intervention is divided into five main steps:~* clinical and paraclinical examinations,~* appraisal of patient's knowledge,~* health education on hypertension and treatments,~* setting a written medication plan with the patient to invest him in his management with adjusting or renewing treatments identically if necessary~* decision-making balance between the benefits and risks of non-adherence to medication. A time is scheduled at the end of the intervention to let the patient ask questions or express his difficulties if he needs to."
224053013|NCT06227884|OTHER|No APN intervention|Participants with a schedule of a MD consultation (within approximately 2 to 12 months)
224053014|NCT04714073|DRUG|BI 706321|Treatment period 1: Single oral dose of 1 film-coated tablet administered with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) Treatment period 2: On day 1 of period 2 (1 h after the itraconazole administration) a single oral dose of 1 film-coated tablet administered with 240 mL of water after an overnight fast of at least 10 h.
224053015|NCT04714073|DRUG|Itraconazole|Treatment period 2: Administered as an oral solution formulation once daily for 14 days orally with 240 mL of water after an overnight fast of at least 9 h, starting from day -3 up to day 11 of period 2.
224053016|NCT03203551|OTHER|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
224053017|NCT05091983|OTHER|Sensory Processing Scale Inventory (SPSI)|The Sensory Processing Scale Inventory (SPSI) is the main questionnaire. It allows to define over and under sensitive profiles. It's a self-administrated questionnaire
224053018|NCT05091983|OTHER|Autism Spectrum Screening Quotient (ASSQ)|"The ASSQ allows to detect autism spectrum disorders (ASD). This quotient is proposed to the group because the investigators know that ASD are often correlated with sensory integration disorders.~It's answered by the participant's parents."
224053019|NCT05091983|OTHER|GAD 7|"The GAD7 questionnaire allows to detect anxiety disorder. This questionnaire is proposed to the group because the investigators know that anxiety disorders are often correlated with sensory integration disorders.~It's a self-administrated questionnaire."
224053020|NCT05091983|OTHER|Conners abridged|"The Conners abridged questionnaire allows to detect attention-deficit hyperactivity disorder (ADHD). This questionnaire is proposed to the group because the investigators know that ADHD are often correlated with sensory integration disorders.~The questionnaire is answered by the participant's parents."
224053021|NCT05091983|OTHER|EAT 26|"The EAT 26 questionnaire allows to detect anorexia nervosa. It is proposed to the patient with an eating disorder to establish the level of severity of their disease.~It's a self-administrated questionnaire."
224053022|NCT02678143|DRUG|Alemtuzumab|
224053023|NCT02678143|DRUG|Cyclophosphamide|
224053024|NCT02678143|DRUG|Mycophenolate mofetil|
224053025|NCT02678143|DRUG|Sirolimus|
224053026|NCT02678143|DRUG|Fludarabine|
224053027|NCT02678143|RADIATION|Total body irradiation|
224053028|NCT02678143|PROCEDURE|Hematopoietic stem cell transplant|
224053029|NCT04863664|DEVICE|Defibrillation (RV Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
224053030|NCT04863664|DEVICE|Defibrillation (LBBAP Implant)|Required electrical testing for pacing, sensing, impedance and defibrillation will be completed
224053031|NCT02624466|OTHER|CKD progress|CKD progress
224053032|NCT02416752|DRUG|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
224053033|NCT02416752|DRUG|choice of intra-operative opioids were left to the discretion of anesthesiologist|
223566830|NCT02855021|OTHER|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
224053034|NCT00605592|PROCEDURE|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
224053035|NCT00612261|PROCEDURE|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
224053036|NCT00612261|PROCEDURE|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
224053037|NCT00943579|DRUG|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
224053038|NCT04287218|BEHAVIORAL|TG-iConquerFear|The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance \& mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.
224053039|NCT04287218|BEHAVIORAL|aTAU|Active control group
224145190|NCT01082367|DRUG|TOBI|TOBI (tobramycin inhaled solution)
224145191|NCT01082367|DRUG|Placebo|Placebo
223441799|NCT04242485|OTHER|Osteopathic manipulative treatment|Each osteopathic manipulative treatment consisted of a structured evaluation to diagnose somatic dysfunction of the pelvis, abdomen, vertebral spine, and upper and lower limbs (10 min), followed by the therapeutic application of manually guided forces to improve physiological function and homeostasis that has been altered by somatic dysfunction for 20 min, using techniques that were left at the discretion of the osteopath, including the myofascial release and cranial sacrum techniques
223441800|NCT04242485|OTHER|Sham treatment|"The sham treatment consisted only in soft touch of the same body areas involved in the osteopathic manipulative treatment protocol without applying any pressure"
223441801|NCT05437016|BEHAVIORAL|HUBER exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises. HUBER exercises require the synergistic activation of various muscle groups of the lower limbs, trunk and upper limbs to develop low-high force levels against the handles.
223441802|NCT05437016|BEHAVIORAL|Standard exercises|All the exercises involve mobility, flexibility and muscle strengthening exercises. Specifically, these exercises included self-awareness of the lumbo-pelvic-femoral complex and multidirectional mobility of the lumbar spine. We gradually integrated aerobic exercises and muscle strengthening of the lower limbs, trunk and spine extensors with bodyweight exercises.
224053040|NCT04609813|DIAGNOSTIC_TEST|Sponge cytological test|Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
223441803|NCT05952791|OTHER|Surgery|Laparoscopic transabdominal preperitoneal (TAPP) groin hernia repair
224053041|NCT01164566|PROCEDURE|endoscopic procedure|
224053042|NCT01164566|OTHER|questionnaire administration|Ancillary studies
223441804|NCT00564291|OTHER|Examination with an OCT device|
224145192|NCT04325906|DEVICE|high flow nasal cannula (HFNC)|HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher \&Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.
224053043|NCT04672265|OTHER|Mother tongue and Norwegian|The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
223441805|NCT00675337|PROCEDURE|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
223441806|NCT00675337|PROCEDURE|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
223441807|NCT01249586|OTHER|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
223441808|NCT02635009|RADIATION|Three-Dimensional Conformal Radiation Therapy|daily fractions
223441809|NCT02635009|RADIATION|Intensity-Modulated Radiation Therapy|daily fractions
223441810|NCT02838472|DRUG|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
223441811|NCT00000290|DRUG|Cocaine|
223441812|NCT04325867|OTHER|Tele-medicine platform|Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
223441813|NCT02838875|PROCEDURE|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
223441814|NCT02636699|BIOLOGICAL|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
223441815|NCT02636699|BIOLOGICAL|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
223441816|NCT01543737|DEVICE|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
223441817|NCT01543737|DEVICE|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
224053044|NCT06376968|DEVICE|BioLogic Fusion|Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
224053045|NCT06099158|OTHER|HeartLogic|HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
224053046|NCT00784290|DRUG|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
224053047|NCT01212653|DRUG|Simponi|Golimumab 50mg monthly
224053048|NCT01212653|OTHER|0.9ml sodium chloride|0.9ml sodium chloride
224053049|NCT05161390|DRUG|LM-302 Injection|LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.
224053050|NCT01038804|DRUG|YM155|intravenous infusion
224053051|NCT01038804|DRUG|Docetaxel|intravenous infusion
224053052|NCT04636424|OTHER|assesment of gait|speed and weight distribution during gait
224053053|NCT00937261|DRUG|Risperidone|2mg - 8mg per day, for the duration of participation in the study
224053054|NCT00937261|DRUG|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
224053055|NCT06807619|DRUG|Sotorasib|Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care
224053056|NCT03653130|BEHAVIORAL|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
224145193|NCT04325906|PROCEDURE|Prone positioning (PP)|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.
223441818|NCT05164198|BIOLOGICAL|Adalimumab and its biosimilars|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
223441819|NCT05164198|BIOLOGICAL|Biological: Etanercept and its biosimilars|"1. Active substance: Etanercept~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 50mg/mL~4. Route of administration: Subcutaneous injection"
223441820|NCT05164198|BIOLOGICAL|Golimumab|"1. Active substance: Adalimumab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 100mg/mL~4. Route of administration: Subcutaneous injection"
224053057|NCT00002243|DRUG|Calanolide A|
224053058|NCT03181230|OTHER|No intervention|No intervention
224053059|NCT02760979|DRUG|Denosumab|Denosumab treatment one year after surgery
224053060|NCT02760979|DRUG|Placebo|Serum one year after surgery
224053061|NCT04416399|DRUG|Budesonide dry powder inhaler|Budesonide inhaled via dry powder inhaler, 400 micrograms per inhalation, 2 inhalations twice a day
224053062|NCT00887120|DRUG|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"* BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
224053063|NCT00887120|DRUG|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"* BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
224145194|NCT04965870|DRUG|Trifluridine/Tipiracil|Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
224145195|NCT05711199|DRUG|Glyceroltrinitrat|transdermal patch
224145196|NCT06364761|PROCEDURE|Bag in the lens cataract surgery|Cataract surgery using the Morcher 89A intraocular lens
224145197|NCT06145464|BEHAVIORAL|Adhesion to the use of collective shadow|Quantitative evaluation of the use of shadow provided by one or two collective fabric devices, with 6 per 3 metres of size, containing 100% UV blocking filters, that will be installed in the sand on Foz do Lizandro beach, according to the recommendations provided in all groups of the study.
223441821|NCT05164198|BIOLOGICAL|Infliximab biosimilar|"1. Active substance: Infliximab~2. Pharmaceutical form: Prefilled syringe~3. Concentration: 120mg/mL~4. Route of administration: Subcutaneous injection"
224145198|NCT06145464|BEHAVIORAL|Adhesion to the use of sun protector|Quantitative evaluation of the use of sun protector according to the recommendations provided in all groups of the study.
224145199|NCT06145464|BEHAVIORAL|Adhesion to the use of the information disposed in the infographic|Quantitative evaluation of the use of the information disposed in the infographic and provided in all groups of the study.
224145200|NCT06145464|BEHAVIORAL|Adhesion to the health literacy sessions in the interventional groups|Provision of health literacy sessions about skin cancer prevention by two different types of providers in the two interventional groups, 15 days before the use of sun protective interventions implemented at the beach
224145201|NCT00614653|DRUG|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
224145202|NCT00614653|DRUG|Erlotinib|100 mg by mouth Once Daily on days with radiation.
224145203|NCT00614653|DRUG|Capecitabine|400 mg/m\^2 PO Twice Daily on days with radiation.
223441822|NCT03728621|BEHAVIORAL|Normocaloric and balanced diet, physical activity|Promotion of normocaloric \& balanced diet and physical activity
223441823|NCT05301582|DIAGNOSTIC_TEST|Tidal volume challenge test|The purpose of our study is to verify the predictability of TVC test during laparoscopic abdominal surgery for early postoperative AKI and intra-operative hypotension.
223441824|NCT06378866|DRUG|Abiraterone|Given abiraterone
223441825|NCT06378866|DRUG|Apalutamide|Given apalutamide
223441826|NCT06378866|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224053064|NCT05584982|DEVICE|AtbFinder|In the present study, we provided a prospective evaluation of the effectiveness of antibiotics selected with AtbFinder compared to a retrospective analysis of antibiotic efficacy selected with conventional culture-based antibiotic susceptibility tets in patients with cystic fibrosis
224053065|NCT05023408|DRUG|Bleomycin Injection|Intralesional Bleomycin used for treatment of cutaneous warts.
224053066|NCT05023408|PROCEDURE|Cryotherapy|Cryotherapy used for comparison of efficacy.
224053067|NCT04755348|OTHER|Product A|A 4mg nicotine pouch product
224053068|NCT04755348|OTHER|Product B|A 4mg nicotine pouch product
224053069|NCT04755348|OTHER|Product C|A 2mg nicotine lozenge product
224053070|NCT04755348|OTHER|Product D|A 2mg nicotine lozenge product
224053071|NCT04755348|OTHER|Product E|A 2mg nicotine lozenge product
224053072|NCT04755348|OTHER|Product F|A 2mg nicotine lozenge product
224053073|NCT01362361|DRUG|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
224053074|NCT01362361|DRUG|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
224053075|NCT05552222|DRUG|Teclistamab|Teclistamab will be administered as SC injection.
224145204|NCT00614653|RADIATION|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
224145205|NCT05914883|DIAGNOSTIC_TEST|Long-term continuous ECG monitoring|Long-term continuous ECG monitoring with ECG247 Smart Heart Sensor
224145206|NCT04130828|DRUG|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
224145207|NCT04190186|DEVICE|Insertable Cardiac Monitor|Implantable device that provides accurate daily transmission of cardiac electrical data for arrhythmia detection.
224145208|NCT01113554|OTHER|questionnaire administration|
224145209|NCT01113554|BEHAVIORAL|exercise intervention|
224145210|NCT01113554|PROCEDURE|quality-of-life assessment|
224145211|NCT01113554|OTHER|survey administration|
224145212|NCT01113554|PROCEDURE|management of therapy complications|
224145213|NCT01113554|PROCEDURE|psychosocial assessment and care|
224145214|NCT02016898|PROCEDURE|Placement of the sponge|
223441827|NCT06378866|PROCEDURE|Bone Scan|Undergo bone scan
223441828|NCT06378866|PROCEDURE|Computed Tomography|Undergo CT
224053076|NCT05552222|DRUG|Daratumumab|Daratumumab will be administered as SC injection.
223441829|NCT06378866|DRUG|Darolutamide|Given darolutamide
224053077|NCT05552222|DRUG|Lenalidomide|Lenalidomide will be administered orally.
224053078|NCT05552222|DRUG|Dexamethasone|Dexamethasone will be administered either orally or intravenously (IV).
224053079|NCT05552222|DRUG|Talquetamab|Talquetamab will be administered as SC injection.
224053080|NCT02351479|BEHAVIORAL|Hula|
224053081|NCT03337542|BIOLOGICAL|AR101|AR101
224053082|NCT02876120|OTHER|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
224053083|NCT01630655|DRUG|Torrent's Felodipine Extended-Release Tablets|
224053084|NCT01401842|OTHER|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
224053085|NCT01401842|OTHER|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
224053086|NCT00282295|BIOLOGICAL|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
224053087|NCT00282295|BIOLOGICAL|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
224053088|NCT02486848|DRUG|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
224053089|NCT02486848|DRUG|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
224053090|NCT05013190|OTHER|No intervention|This is a non-interventional study.
224053091|NCT00121108|BIOLOGICAL|Motavizumab|Intramuscular dose of motavizumab 15 mg/kg will be administered every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season.
224053092|NCT00121108|OTHER|Placebo|Intramuscular dose of placebo matched to motavizumab will be administered every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the the RSV season.
224053093|NCT04861181|BIOLOGICAL|Pharmacokinetics, Dosage of Niraparib|The biological samples collected during the NIRAPK study will be blood only. The complete biological work-up will be processed in the same way as the usual routine care procedure. Serum niraparib will be measured over 3 courses just prior to treatment (Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1). Close-up kinetic measurements will also be taken at 1 Hour, 2 Hours, 4 Hours, 6 Hours and 24 Hours at Cycle 1 Day 15.
224053094|NCT01380379|BEHAVIORAL|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
224053095|NCT00904800|DRUG|AZD0837|tablet, oral, once daily, 1+5 days
224053096|NCT00904800|DRUG|Placebo|Placebo
224053097|NCT05204823|OTHER|Experimental product|Chocolate milk shakes
224053098|NCT05204823|OTHER|Control product|Glucose
223441830|NCT06378866|DRUG|Degarelix|Given degarelix
223441831|NCT06378866|DRUG|Enzalutamide|Given enzalutamide
223441832|NCT06378866|DRUG|Goserelin|Given goserelin
223441833|NCT06378866|DRUG|Histrelin|Given histrelin
223441834|NCT06378866|DRUG|Leuprolide|Given leuprolide
223441835|NCT06378866|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223441836|NCT06378866|OTHER|Patient Observation|Undergo watchful waiting
224053099|NCT04943081|PROCEDURE|Percutaneous nephrolithotomy|Percutaneous nephrolithotomy (PCNL) is a technique used to remove complex renal stones, or stones resistant to shockwave lithotripsy. A tube is placed through the incision in the kidney, under X-ray guidance, and renal stones are extracted by using nephroscope
224053100|NCT03208764|DRUG|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
224053101|NCT06521775|PROCEDURE|Computed Tomography|Undergo PET/CT
224053102|NCT06521775|OTHER|Electronic Health Record Review|Ancillary studies
224053103|NCT06521775|DRUG|Ga-68 PSMA-11|Given IV
224053104|NCT06521775|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223441837|NCT06378866|PROCEDURE|Positron Emission Tomography|Undergo PET
223441838|NCT06378866|DRUG|Prednisone|Given prednisone
223441839|NCT06378866|OTHER|Questionnaire Administration|Ancillary studies
223441840|NCT06378866|DRUG|Relugolix|Given relugolix
223441841|NCT06378866|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223441842|NCT06378866|DRUG|Triptorelin|Given triptorelin
223441843|NCT04754087|DEVICE|Vivacit-E and Longevity (HXLPE) Liners|This is a dual cohort study in which 150 subjects will receive the Vivacit-E (HXLPE) Liner and 150 subjects will receive the Longevity (HXLPE) Liner.
223566831|NCT00904462|DRUG|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
223566832|NCT00904462|DRUG|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
224053105|NCT05261763|OTHER|Dry Needling|abc
224053106|NCT05261763|OTHER|Sham Dry Needing|xyz
224053107|NCT05199753|DRUG|LM-108|Administered intravenously
224053108|NCT05199753|DRUG|An Anti-PD-1 Antibody|Administered intravenously
224053109|NCT05911295|DRUG|disitamab vedotin|Given into the vein (IV; intravenous) every 2 weeks
224053110|NCT05911295|DRUG|pembrolizumab|400mg given by IV every 6 weeks
224053111|NCT05911295|DRUG|gemcitabine|1000 mg/m\^2 given by IV on days 1 and 8 of every 3-week cycle
224053112|NCT05911295|DRUG|cisplatin|70 mg\^2 given by IV on day 1 of every 3-week cycle
224053113|NCT05911295|DRUG|carboplatin|Area under the plasma concentration-time curve (AUC) 4.5 or 5 given by IV on day 1 of every 3-week cycle
224053114|NCT04335669|DRUG|epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
224145215|NCT02016898|DRUG|Mitomycin-C|
224053115|NCT04335669|DRUG|epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab|Cytotoxic agents.
224053116|NCT03603912|DRUG|Metformin|Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.
223441844|NCT05578131|PROCEDURE|high flow nasal oxygen|In the intervention group, pre-oxygenation was provided using HFNO via Optiflow THRIVE™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) until SpO2 on pulse oximetry was \> 95% and for at least 3 min. A flow of 0.5 l/kg/min-1 was used until induction agents had been administered, and then increased to 2 l/kg/min-1. Nasal oxygenation was continued without ventilation of the lungs while waiting for neuromuscular blockade, and during placing, replacing or repositioning the airway. Anaesthetists were free to carry out bag-mask ventilation of the lungs if they considered this necessary to maintain safe oxygen saturations. After securing the airway, the patient was connected to a circle circuit primed with 100% oxygen and the FIO2 was continued at 100% for a period of at least five more minutes. Relevant times were recorded, including start of pre-oxygenation and start of induction of anaesthesia.
223441845|NCT05578131|PROCEDURE|face mask|In the control group, pre-oxygenation was provided using 100% oxygen via a sealed facemask and a circle-absorber anaesthetic circuit primed with 100% oxygen by installing a ventilation bag to the mouthpiece filter and ventilating the circuit with 100% oxygen. Anaesthetists were free to carry out bag-mask ventilation of the lungs once induction medications had been administered.
224145216|NCT03472794|OTHER|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
223441846|NCT05869864|BEHAVIORAL|Schools Championing Safe South Africa|The intervention consists of 2 parts - a poster campaign with social norms messages on violence and HIV risk, and 2 lessons in life orientation (a health curriculum delivered during school).
223441847|NCT00981058|BIOLOGICAL|Necitumumab|"Administered intravenously.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
223441848|NCT00981058|DRUG|Gemcitabine|"Administered intravenously.~Continues for a maximum of six cycles."
224053117|NCT03603912|BEHAVIORAL|Lifestyle/Risk Factor Modification|Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).
224053118|NCT06031714|OTHER|Saliva sampling|HLA genotyping. The technique should allow to identify, for children's, a paternal HLA antigen not shared with the mothers.
224053119|NCT06031714|OTHER|Blood sampling|"Maternal Blood samples will be incubated with the appropriate antibody, targeting the microchimeric fetal cells of each patient, as well as with a cell viability marker (DAPI). The samples were then be processed through the BD FACS Aria III to sort the fetal cells,~The following steps - RNA extraction, quality control, retrotranscription, preparation of the library, sequencing and transcriptomic analysis - will be carried out according to the Smart-seq3 protocol. The data will be sent for in-depth analysis and confirmation of the results. Additional functional experiments may also be carried out."
224053120|NCT06031714|OTHER|Interviews|V2 and/or V3
224053121|NCT06031714|OTHER|Clinical examination|V2 and/or V3
224053122|NCT04707885|DEVICE|Electrocochleography|"The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions."
224053123|NCT05640193|BIOLOGICAL|Lifileucel (LN-144)|A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
223441849|NCT00981058|DRUG|Cisplatin|"Administered intravenously.~Continues for a maximum of six cycles."
223441850|NCT03846557|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
223441851|NCT03477513|RADIATION|Radation Therapy|Personalized Radiation Therapy
223441852|NCT06189794|OTHER|Rosa damascena oil|Essential oils will used by inhalation
223441853|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
224053124|NCT06477952|DRUG|Dronabinol|Open label Dronabinol treatment for two weeks.
224145217|NCT00159718|DRUG|amlodipine|
223441854|NCT06560008|DIETARY_SUPPLEMENT|Caffeine (200 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
223441855|NCT06560008|DIETARY_SUPPLEMENT|EnXtra® (300 mg) + Caffeine (200 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
223441856|NCT06560008|DIETARY_SUPPLEMENT|Placebo (MCC 300 mg) + Placebo (300 mg)|Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
223441857|NCT02667587|DRUG|Nivolumab|
223441858|NCT02667587|DRUG|Temozolomide|
224053125|NCT04300192|BIOLOGICAL|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
224053126|NCT01734122|OTHER|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
224145218|NCT00159718|DRUG|atorvastatin|
224145220|NCT01267604|DRUG|Recombinant FSH (rFSH)|225IU
224145221|NCT01267604|DIETARY_SUPPLEMENT|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
224145222|NCT03771443|DRUG|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
223441859|NCT02667587|RADIATION|Radiotherapy|
223441860|NCT02667587|OTHER|Nivolumab Placebo|
223441861|NCT05294302|BEHAVIORAL|eSCCIP/eSCCIP-SP|eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
223441862|NCT05294302|BEHAVIORAL|Coping Space|Coping Space is a psychosocial informational website for PCCC.
223441863|NCT03919435|DRUG|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
223441864|NCT06386185|DIAGNOSTIC_TEST|Electrocardiogram|Non-invasive multi-vector voltage/time graph visualising the electrical conduction of the heart
223441865|NCT06386185|DIAGNOSTIC_TEST|Transthoracic echocardiogram|Non-invasive 2 \& 3 dimensional imaging of the heart using ultrasound
223441866|NCT06386185|DIAGNOSTIC_TEST|Right heart catheter|Minimally invasive cardiac chamber pressure measurement using balloon catheterisation
223441867|NCT05841524|DIAGNOSTIC_TEST|Vector flow imaging measurement|Ultrasound measurement, using high framerate measurement techniques.
223441868|NCT04708275|PROCEDURE|PaCT|Manualized Psychoanalytic short-term therapy (PaCT) for children with internalizing disorders, 20-25 sessions (1, 2). PaCT helps the child to resolve rigid conflictual internal representations/ working models by using interpretative and mentalizing techniques and drawing on therapeutic transference relationship with the child and the parent.
223441869|NCT05952817|DEVICE|virtual reality|Virtual reality (VR) technology is a new medical intervention technique founded on the principle of distraction, providing real perceptual stimuli such as visual images, spatial sounds, tactile, and sensory feedback stimuli.(Zhang et al., 2022)
223441870|NCT04687644|BEHAVIORAL|Online education|Education group
223441871|NCT01541761|BEHAVIORAL|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
223441872|NCT04451525|DEVICE|MicroVention Mechanical Thrombectomy Devices as first-line treatment|Patient will be treated with mechanical thrombectomy at the direction of the treating physician
223441873|NCT05739617|OTHER|Comprehensive Respiratory Training Exercise Program|This comprehensive respiratory training exercise program consists of four main components, including oropharyngeal muscle training, respiratory muscle training, aerobic exercise, and sleep hygiene education.
223566833|NCT01838330|DIETARY_SUPPLEMENT|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
223441874|NCT05739617|OTHER|Sleep hygiene education|Sleep hygiene education
224053127|NCT06650059|OTHER|Questionnaire|Self-questionnaire intended to each patient with sickle cell disease seen in consultation in one of the three reference centers participating in the study. Patients will complete the questionnaire once, on site.
223441875|NCT05880342|DRUG|Reboxetine Pill|8 mg
223441876|NCT05880342|DRUG|Methylphenidate Oral Product|20 mg
223441877|NCT00851019|BEHAVIORAL|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
223441878|NCT00851019|BEHAVIORAL|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
224053128|NCT07116837|BEHAVIORAL|Vaping prevention video ads|Participants will view and rate 5 vaping prevention video ads. The vaping prevention video ads cover a variety of different topics and were identified in a previous study activity.
224053129|NCT06977360|OTHER|Routine care|Routine care provided by NCCS
224053130|NCT06977360|OTHER|Routine care + iCareBreast+ mobile app|Routine care provided by NCCS (identical to the control group) along with access to the iCareBreast+ mobile app
224053131|NCT07128329|DRUG|Nicotine Pouches|Nicotine pouches
223441879|NCT04032951|OTHER|Fine Needle Tissue Acquisition|diagnostic
223441880|NCT04856631|DRUG|Toripalimab Injection|240mg once per 3 weeks
223441881|NCT04856631|DRUG|Cetuximab Solution for infusion|First infusion 400mg/m2，Subsequent infusions 250mg/m2。once per week
223441882|NCT01973335|DRUG|Combination therapy with acetazolamide and low-dose loop diuretics|"* Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
223566834|NCT02686151|DRUG|Letrozole|used after oocyte retrieval
223566835|NCT02686151|DRUG|Polygeline|used after oocyte retrieval
223566836|NCT02686151|DRUG|Sodium Chloride|used after oocyte retrieval
223566837|NCT02686151|DRUG|dexamethasone|used after oocyte retrieval
223566838|NCT02320812|BIOLOGICAL|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
223566839|NCT02760173|OTHER|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
223566840|NCT04788797|DRUG|Prolyl Endopeptidase|Two capsules three times a day.
223566841|NCT04788797|OTHER|Placebo|Two capsules three times a day
224053132|NCT05123339|OTHER|Questionnaire|Questionnaire
224053133|NCT06155032|PROCEDURE|Endovascular therapy|"Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment."
224053134|NCT06155032|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
224053135|NCT01071850|DRUG|ipragliflozin|oral tablet
224053136|NCT01071850|DRUG|Metformin|oral tablet
224053137|NCT01071850|DRUG|Placebo|oral tablet
224053138|NCT00878111|DRUG|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
224053139|NCT03372928|DIETARY_SUPPLEMENT|Standard EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
224053140|NCT03372928|DIETARY_SUPPLEMENT|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
224053141|NCT06979674|DRUG|ESG406|Administered via intravenous (IV) infusion.
224053142|NCT03427333|DEVICE|The Rook® Epicardial Access Kit|Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
224145223|NCT04757922|PROCEDURE|Opportunistic salpingectomy / bilateral salpingectomy|An opportunistic salpingectomy refers to removal of the salpinges without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases. Therefore, a so-called opportunistic salpingectomy is a method of female sterilization.
224145224|NCT01287546|DRUG|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
224145225|NCT01287546|DRUG|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
224145226|NCT01287546|DRUG|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
224145227|NCT01287546|DRUG|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
224145228|NCT05425095|OTHER|Buteyko Breathing Technique|Group A will be treated with Buteyko Breathing Technique. Patient in a relaxed sitting position will ask to take a gentle breath in (2 sec), breath out (3sec) followed by pinching the nose with hands to hold the breath. The therapist will count the no. of seconds the patient can comfortably hold the breath until feels the need to breathe in again. Followed by releasing the nose and continue breathing.
224145229|NCT05425095|OTHER|Corpse-Pose Technique|Group B will be treated with Corpse-Pose Technique for 15-20 min.
224145230|NCT03794713|DEVICE|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
224145231|NCT03025152|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
224300581|NCT06926725|OTHER|high intenisty exercise|"type: alternate high intensity exercise (aerobic or strength training) with recovery stages Intensity: high intensity (75%-95% HRmax) or RPE(14-16 hard to very hard ) ( according to patient tolerance), followed by active or passive recovery stage (30%-60% HRmax) or RPE(7-11 extremely light to light) .~frequency : 3 days per week for three months (with no more than 2 consecutive days between sessions) Duration: 10 seconds to 4 minutes high intensity ,12 seconds to 5 minutes active or passive recovery .(according to patient tolerance) 5 minutes warm up pre exercise . 5 minutes cool down post exercise . Progress gradually. total duration :20-40 minutes (according to patient tolerance and progression)"
224300582|NCT06926725|DIETARY_SUPPLEMENT|Diet|In all groups (both study groups A\&B and control group).
223566842|NCT03619928|DEVICE|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
224300583|NCT06927986|DRUG|SYS6010|SYS6010,Q3W
224300584|NCT06927986|DRUG|Pemetrexed|Pemetrexed injection 500 mg/m\^2 administered via intravenous infusion，Q3W
224300585|NCT06927986|DRUG|Cisplatin|Cisplatin 75 mg/m\^2 administered via intravenous infusion，Q3W
224300586|NCT06927986|DRUG|Carboplatin|Carboplatin (AUC=5, Calvert formula) administered via intravenous infusion，Q3W
224300587|NCT06927414|DEVICE|Functional lens|Diffractive Optical Element, D.O.E, technology for controlling myopia progression in children and adolescents. and H.A.L.T, highly aspheric lenslet technology) for controlling myopia progression in children and adolescents.
224300588|NCT00221962|DRUG|Aripiprazole|Open label
224053143|NCT05962853|OTHER|Experimental group (Transcutaneous Electrical Nerve Stimulation)|The application will be applied at 8 hour intervals in the first 24 hours after the surgery.
224053144|NCT06979544|DRUG|LPCN 1154A|Oral LPCN 1154A tablets for 48 hours
224053145|NCT06979544|DRUG|Placebo|Oral Placebo Tablets for 48 hours
224053146|NCT06979804|DEVICE|Semiconducting fabric sleeves|This intervention includes semiconductor embedded sleeves that patients will wear for 4 months post-operatively.
224053147|NCT06979804|DEVICE|Non-semiconducting fabric sleeves|This intervention includes sleeves absent of semiconductors that will be worn for 4 months post-operatively.
223441883|NCT01973335|DRUG|High-dose loop diuretics|"* Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
223441884|NCT01973335|DRUG|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is \>5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
224053148|NCT06980506|DIAGNOSTIC_TEST|MNPR-101-DFO*-89Zr|MNPR-101-DFO\*-89Zr is an antibody radionuclide conjugate intended to image solid tumors expressing uPAR.
224145232|NCT03025152|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
224145233|NCT06380790|PROCEDURE|Laser-aided csf|Laser-aided csf before leveling and alignment
223441885|NCT00047736|DRUG|Tarceva (erlotinib HCl)|
223441886|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) without laser polishing|Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
223441887|NCT04698174|PROCEDURE|Transepithelial Photorefractive keratectomy (tPRK) with laser polishing|Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
223441888|NCT04698174|PROCEDURE|Standard Photorefractive keratectomy (PRK)|Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
223441889|NCT00506714|DEVICE|single point cane|Adjustable single point cane with SureGrip handle
224053149|NCT01357577|BEHAVIORAL|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
224145234|NCT06380790|OTHER|placebo laser-aided csf|placebo laser-aided csf before leveling and alignment
224145235|NCT00630708|DRUG|Benazepril|20 mg per day
223441890|NCT06365450|OTHER|Educational Intervention|Participants will receive hybrid educational intervention on breast and cervical cancer
223441891|NCT05884294|DEVICE|PowerGlide Pro Midline catheter.|The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
224300589|NCT06927232|DRUG|Azacitidine (AZA)|Azacitidine 75mg/m/ day \*5 days, 28 days for 1 course
224300590|NCT06927232|DRUG|Luspatercept|Luspatercept 1.0 mg/kg subcutaneously every 3 weeks, adjusted according to hemoglobin, up to 1.75mg/kg. If hemoglobin ≥120g/L, luspatercept can be discontinued.
224300591|NCT00290251|DRUG|ulipristal acetate 20 mg|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
223441892|NCT04607681|BEHAVIORAL|EDUCATION|WEB BASED EDUCATION
224300592|NCT00290251|DRUG|ulipristal acetate 10 mg|10 mg given daily for three menstrual cycles or 90 - 102 days
224300593|NCT00290251|DRUG|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
224300594|NCT05788575|PROCEDURE|surgery|any surgery that an inpatient has undergone
224300595|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
224300596|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
224145236|NCT00630708|DRUG|Losartan|100 mg per day
224145237|NCT00630708|DRUG|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
224145238|NCT01594567|OTHER|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
224145239|NCT04503512|PROCEDURE|removal of fat pad|Removal removal of fat pad
224145240|NCT04503512|PROCEDURE|non removal of fat pad|non removal of fat pad
224145241|NCT05410197|DRUG|Envofolimab|400mg by subcutaneous injection every 3 weeks
224300597|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
224300598|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
224300599|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
224300600|NCT01512706|BIOLOGICAL|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
223441893|NCT01084395|BEHAVIORAL|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
223441894|NCT01084395|BEHAVIORAL|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
223441895|NCT01084395|OTHER|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
223441896|NCT01084395|OTHER|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
223441897|NCT01164917|DRUG|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
223441898|NCT01164917|DRUG|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
223741044|NCT07207226|DEVICE|Laser doppler vibrometry|Non-invasive CARDIS Technology Demonstrator (CTD) device is a 2 x 6 beam laser Doppler vibrometer (LDV) for non-contact measurement of skin vibrations caused by underlying cardiac action. The CTD device is a split device with a master device and a slave device, which are connected to a data acquisition rack, which again is connected to a computer for signal processing, data presentation and data logging.
224053160|NCT05088902|DIAGNOSTIC_TEST|TERABio Ltd.|Covid- 19 investigational breath test compared to RT- PCR test. TERABio Ltd. has developed a rapid screening tool intended to determine if a tested individual is COVID-19-free (Negative to COVID-19 ).
224145242|NCT05410197|DRUG|Lenvatinib|8 mg orally once a day
224145243|NCT05410197|DRUG|Gemcitabine|1000mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
224145244|NCT05410197|DRUG|Cisplatin|25mg/m2 by intravenous infusions on day 1 and 8 every 3 weeks for up to 24 weeks
224145245|NCT05873699|DRUG|Hyperpolarized 13-C-pyruvate|Given by Injection
224145246|NCT00226278|DRUG|ORG 34517|
224145247|NCT01665768|DRUG|Everolimus|The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
224145248|NCT01665768|BIOLOGICAL|Rituximab|375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
224145249|NCT05386472|DRUG|nirmatrelvir|Nirmatrelvir (tablets) administered by mouth every 12 hours for 5 days (10 doses total)
224145250|NCT05386472|DRUG|ritonavir|Ritonavir (capsules) administered by mouth every 12 hours for 5 days (10 doses total)
224145251|NCT03116373|OTHER|mandible fixation|Intubation device will be fixed on mandible
224145252|NCT03116373|OTHER|Maxilla fixation|Intubation device will be fixed on maxilla
224145253|NCT02453009|DRUG|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
223441899|NCT02305446|BIOLOGICAL|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
223441900|NCT06158009|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223741045|NCT07207304|PROCEDURE|Anesthesia|Patients diagnosed with hepatocellular carcinoma will be randomly assigned to one of four groups. They will receive standard anesthesia with maintenance based on either sevoflurane or propofol. Two of the groups will additionally receive intravenous lidocaine, administered from induction until the end of surgery. Blood samples will be collected preoperatively and six hours postoperatively to measure citrullinated histone H3 (H3Cit), a reliable biomarker of NETosis. Additional inflammatory markers will also be analyzed. All patients will be followed for a period of one year
224053161|NCT03372850|DRUG|HIP1601|Test Drug
224053162|NCT03372850|DRUG|HGP1705|Reference Drug
224053163|NCT04142528|DEVICE|ParkinPal|Wear and periodic recording of motion data during daily wear
224053164|NCT03347331|DRUG|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~\*150 Mbq + 1 MBq/Kg of \[18F\]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
224145254|NCT02453009|DRUG|Prednisone|Pharmaceutical form:tablet Route of administration: oral
224145255|NCT02453009|DRUG|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
224145256|NCT03177265|BEHAVIORAL|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
224145257|NCT03177265|BEHAVIORAL|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
224300601|NCT01512706|BIOLOGICAL|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
224053165|NCT03347331|DRUG|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of \[18F\]F13640 at t=0 min
224053166|NCT04354909|OTHER|s-CD95-L|levels of s-CD95-L (ELISA test)
224053167|NCT06984718|BIOLOGICAL|AK104+lenvatinib|Subjects will receive AK104+lenvatinib until disease progression
224053168|NCT06984718|DRUG|lenvatinib|Subjects will receive lenvatinib until disease progression
224053169|NCT06984549|OTHER|DED diagnosis using PAOSID|A non-invasive diagnostic approach using the Portable Automatic Ocular Surface Imaging Device (PAOSID) to capture anterior segment images and videos for the assessment of dry eye disease (DED).
224053170|NCT06984549|OTHER|DED diagnosis using slit lamp|A non-invasive diagnostic approach using the slit lamp to capture anterior segment images and videos for the assessment of dry eye disease (DED).
224053171|NCT06985771|OTHER|Observational study, with no intervention.|Observational study, with no intervention.
224053172|NCT06984068|DRUG|Vitamin D|4000IU/day vitamin D supplement will be used for 6 months
224053173|NCT06984068|DRUG|Placebo|Placebo will be used for 6 months
224053174|NCT06984874|OTHER|Erector spinae plane block|Patients will receive bilateral erector spinae plane block after the induction of general anesthesia as a study group.
224053175|NCT06984874|OTHER|General anesthesia|Patients will not receive the block after the induction of general anesthesia as a control group.
224053176|NCT06985589|PROCEDURE|Fire needle|At the beginning of the fire needle therapy, the patient was instructed to exposure the lesion in a comfortable position. And the Ashi point (lesion area) was disinfected with iodophor. The 95% alcohol lamp was lit and held by the left hand. Then the needle was held by the right hand in the outer flame of the alcohol lamp to heat the needle body, making the tip of the needle whiten. Subsequently, the needle was quickly and accurately puncted into the base of the herpes at a depth of about 2-5 mm, straight in and out. According to the number of herpes, the early-onset herpes was puncted first, and about 5 to 10 blisters were selected for each puncture. The acupuncture was performed 1-5 times according to the size of the herpes. The treatment was performed once every other day for total 5 sessions.
224053177|NCT06985589|DRUG|Cortex Phellodendri compound fluid wet compress|For the Chinese herbal wet compress treatment, CPCF (Shandong Hanfang Pharmaceutical Co., LTD.) was decocted using forsythia, honeysuckle, phellodendron, dandelion, and centipede. Appropriate amount of liquid was diluted with 5 times the volume of water. Then according to the area of skin lesions, several pieces of medical fat-free cotton gauze with thickness of 8 layers were put into the liquid completely wet. After wringing out to a semi-dry state, the gauze was applied to the lesion for 15 minutes/time, 3 times a day, for 10 days.
224053178|NCT06985589|DRUG|basic treatment|The basic treatment consisted of penciclovir 0.5g/time per day intravenously, mecobalamin 0.5mg/time three times a day orally and pregabalin 75mg/time twice a day orally for 10 days.
224053179|NCT06985394|DIETARY_SUPPLEMENT|Antioxidant cocktail|"Participants will take two doses of antioxidant supplements in capsule form during their overnight shift: the first dose at 7:00 PM, and the second dose 1.5 hour before their morning vascular function visit (post-shift). Each dose will consist of the following concentrations of antioxidants:~600 mg of α-lipoic acid, 1,000 mg of vitamin C, and 600 IU of vitamin E."
224053180|NCT06985394|DIETARY_SUPPLEMENT|Placebo|Participants will take two doses of antioxidant supplements in capsule form during their overnight shift: the first dose at 7:00 PM, and the second dose 1.5 hour before their morning vascular function visit (post-shift). Each dose will consist of placebo pills made from microcrystalline cellulose, designed to match the antioxidants in taste, color, and appearance.
224145258|NCT03177265|BEHAVIORAL|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
224145259|NCT03177265|BEHAVIORAL|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
224145260|NCT03935607|DIAGNOSTIC_TEST|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
224145261|NCT04782986|DIAGNOSTIC_TEST|Pan-intestinal capsule endoscopy|Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn's Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation
224145262|NCT02662413|OTHER|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
224145263|NCT00823940|DRUG|GSK1362885|5 - 100mg of GSK1362885 or placebo
224145264|NCT00823940|DRUG|GSK1362885|100 - 600mg or placebo
224145265|NCT00823940|DRUG|Glucagon|0.5mg IV bolus
224145266|NCT00823940|DRUG|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
224145267|NCT04285944|OTHER|Mavig X-ray Protective Drapes|Mavig X-ray Protective Drapes®
224145268|NCT01403467|DEVICE|Continuous positive airway pressure|CPAP 8 cmH2O
224145269|NCT04563819|GENETIC|Genom-wide association study (GWAS) and biological pathway analyses|
224145270|NCT02976727|DRUG|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
224145271|NCT02976727|DRUG|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
224145272|NCT02976727|DRUG|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
224145273|NCT02976727|DEVICE|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
224300602|NCT01512706|BIOLOGICAL|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
224053181|NCT06984991|DIAGNOSTIC_TEST|fine needle aspiration|Different needle sizes will be used in FNA sampling ; 5ml syringe with 21G needle, 3ml syringe with 23G needle or 22G Quincke tip spinal needle will be used for FNA. Needle insertion will be directed either trans-isthmic or lateral cervical approach. Aspirations will be conducted at different angles and within different nodule regions using a to-and-fro motion till getting blood stain in the needle hub to obtain representative samples. Maximum number of four passes will be performed within the nodule in a single session. Samples will be primarily obtained without suction via the capillary method. However, aspiration with suction will be applied if no aspirates could be obtained in the needle hub after routine capillary method. For mixed cystic solid lesions; FNA will be done from the solid component after aspiration of the cystic component
224053182|NCT06985004|OTHER|PIODO Questionnaire|An original PIODO Questionnaire is a structured protocol that has been developed by the investigators of this study for the preoperative assessment of patients undergoing RARP. It evaluates not only clinical data on the prostate cancer, but also patient characteristics, including anthropometric measurements of the pelvis. The aim is to develope a tool that can be used to predict the risk of operational difficulties and possible outcomes of RARP.
224053183|NCT06984666|BEHAVIORAL|language|Language cues are used to provide participants with psychological suggestions in order to achieve the goal of shifting their focus in gaze patterns.
224145274|NCT02976727|DRUG|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
224145275|NCT02976727|OTHER|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
224145276|NCT02976727|DEVICE|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
224145277|NCT02681185|OTHER|Virtual Care|"Virtual Care consists of the following services and resources:~1. Have a virtual consult through online methods or telephone with one of the study endocrinologists~2. Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~3. Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~4. Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
223441901|NCT06158009|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223441902|NCT00409032|DRUG|Strontium malonate|
224053184|NCT06984796|DEVICE|Photobiomodulation|The irradiated region will cover the lumbar and thoracic spine, specifically from T10 to L4, using the Light Emitting Diode panel in a vertical orientation. Photobiomodulation in the experimental group will be administered using 132 Light Emitting Diodes with wavelengths of 660 nm and 850 nm, applied in contact mode. Each Light Emitting Diode has an emission area of 0.5 cm², with an application time of 20 minutes, an irradiance of 16 mW/cm², and an energy delivery of 4.8 J per Light Emitting Diode, resulting in a radiant exposure of 9.6 J/cm².
224145278|NCT02681185|OTHER|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
224145279|NCT00645918|DRUG|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
224145280|NCT00645918|DRUG|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
224145281|NCT00645918|DRUG|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
224145282|NCT03895112|DRUG|AVID200|dose cohorts of 21-day cycles
224145283|NCT01058733|OTHER|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
223441903|NCT03919344|OTHER|Critical airway closure pressure (Pcrit) measurment|Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
223441904|NCT03919344|OTHER|Acoustic pharyngometry|Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.
223441905|NCT03919344|OTHER|High density surface electroencephalogram neural mapping|Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
223441906|NCT06654297|DRUG|Camrelizumab|Camrelizumab will be given at at a dose of 200 mg intravenously on day 23 of a planned 28-day cycle, and two doses before surgery.
223441907|NCT06654297|DRUG|Palbociclib(100mg)|Palbociclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
223441908|NCT06654297|DRUG|Palbociclib(125mg)|Palbociclib will be given at a dose of 125 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for three cycles.
223441909|NCT01636947|DRUG|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
223441910|NCT01636947|DRUG|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
223441911|NCT01636947|DRUG|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
223441912|NCT01636947|DRUG|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
223441913|NCT01636947|DRUG|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
223441914|NCT01636947|DRUG|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
223441915|NCT02696447|BIOLOGICAL|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
223441916|NCT00957424|BEHAVIORAL|telephone-based intervention|10-15 minute web-based survey on a computer
223441917|NCT00957424|DRUG|nicotine replacement therapy|One week supply
224053185|NCT06984796|OTHER|Simulation of Photobiomodulation|"The researcher responsible for the photobiomodulation application will simulate irradiation by positioning the device in the exact location as in the Photobiomodulation Group; however, the equipment will remain turned off.~To prevent participants from identifying the group to which they belong, the device's activation sound (beep) will be pre-recorded and played during the application."
224053186|NCT06985563|COMBINATION_PRODUCT|HMME-PDT|Prior to treatment, patients or their guardians provided written informed consent. Then patients were then prepared for the procedure by fully exposing the treatment area and shielding the surrounding normal skin with a black cloth. Hemoporfin (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) was administrated intravenously at a dosage of 5.0 mg/kg. Subsequently, patients underwent light radiation at 532 nm (Wuhan Yage Optic and Electronic Technique, Wuhan, China) for 18 to 25 minutes, with a power density randing form 75 to 110 mW/cm2.
224145284|NCT01079286|DRUG|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
224145285|NCT01388868|OTHER|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
224145286|NCT01388868|OTHER|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
223441918|NCT00957424|OTHER|informational intervention|
223441919|NCT00957424|OTHER|internet-based intervention|
223441920|NCT00957424|OTHER|questionnaire administration|Given out week 2, 3 and 4.
223441921|NCT00146913|DRUG|Imatinib mesylate 600mg/day|
223441922|NCT00146913|DRUG|Peg-Interféron at 90 microg/week|
223441923|NCT01840800|DRUG|Ropivacaine|
223441924|NCT01840800|DRUG|placebo|
223441925|NCT02097459|DRUG|Anastrozole|
223441926|NCT02097459|DRUG|Tamoxifen|
223441927|NCT02097459|DRUG|Toremifene|
223441928|NCT02332161|OTHER|surveys, evaluative tests for leg function|See outcome measures
223441929|NCT06192498|OTHER|Virtual Reality Glasses|Virtual Reality(VR) Glasses were introduced to the children pre-procedure. The children were made to watch a video with VR glasses before starting the application and it continued until the end of the Blood Draw procedure.
223441930|NCT06192498|OTHER|Kaleidoscope|Kaleidoscope were introduced to the children pre-procedure. The children were made to watch Kaleidoscope before starting the application and it continued until the end of the Blood Draw procedure.
223441931|NCT06192498|OTHER|Distraction Cards|Distraction Cards were introduced to the children pre-procedure. The children were made to apply Distraction Cards before starting the application and it continued until the end of the Blood Draw procedure.
223441932|NCT05542394|DIETARY_SUPPLEMENT|Curcumin|"water soluble version of turmeric extract standardized to 10% curcuminoids~."
224053187|NCT06985563|DEVICE|Ultrasound examinations|Ultrasound examinations were performed using three types of devices: a Paragon XHD equipped with a L38-22 probe operating at a frequency of 20-30 MHz (Kolo Medical Co., Ltd, Suzhou, China), a DUB Skin Scanner with a 22 MHz probe (Taberna Pro Medicum, German), or a Mindray Resona 7 featuring an L14-5WU linear probe set to a frequency range of 11-12 MHz frequency (Mindray Bio-Medical Electronics Co., Ltd, Shenzhen, China).
224053188|NCT06588621|OTHER|Questionnaire on physical and mental health among healthcare professionnals|Feedback on the results of the questionnaire and toolkit on resources with regard to healthy habits in the professional setting
224145287|NCT01388868|OTHER|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
224145288|NCT04616404|DIETARY_SUPPLEMENT|500 mg of artichoke extract|Tablets containing 500 mg of artichoke extract (triple standardized to contain caffeoylquinic acids ≥ 5.0%; flavonoids ≥ 1.5%; cynaropicrin ≥ 1.0%, by HPLC)
224145289|NCT04616404|OTHER|Placebo|Tablets with no active ingredient
224145290|NCT04766151|DRUG|Transdermal glyceryl trinitrate 10mg patches|Transdermal patches applied to skin 30 minutes before cardiac catheterization
224145291|NCT04766151|DRUG|Placebo patches|Transdermal placebo patches applied to skin 30 minutes before cardiac catheterization
223441933|NCT01713894|OTHER|Decision Aid|
223441934|NCT01713894|OTHER|Standard|
223441935|NCT06731465|DEVICE|Clear aligner therapy|Participants in this group will receive clear aligners (EON Aligner, Minneapolis), designed and customized based on a digital model of each patient's dental structure. Aligners will be worn for at least 22 hours daily, and patients will change to a new aligner depending on treatment progress.
223441936|NCT06731465|DEVICE|Fixed pre-adjusted edgewise orthodontic appliance|Participants in this group will be treated with pre-adjusted fixed orthodontic appliances (Master Series®, American Orthodontics™, WI, USA). This system includes fixed brackets bonded on the labial surface of teeth and a sequence of progressively larger arch wires aimed at achieving alignment over time.
223441937|NCT02370069|BIOLOGICAL|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
223441938|NCT04856397|DRUG|Intravitreal Implant in Applicator|Dexamethasone intravitreal implant
223441939|NCT04856397|DRUG|Eylea|anti-VEGF medication
223441940|NCT04485494|DIAGNOSTIC_TEST|Biochemical Analysis of Blood Biomarkers|Using established biochemical techniques, the bloods will be probed for specific biomarkers s100B, UCH-L1, GFAP, and BDNF. The techniques include individual ELISA kits for each biomarker mentioned and Luminex multiplate assay which will probe for all biomarkers in one plate. Ultimately, these techniques will be able to measure the level of these biomarkers in the blood relative to the participants baseline reading.
224145292|NCT04809272|BEHAVIORAL|ParentChat for parents of children ages 2-17|The programme will include text/audio messages, illustrated comics, videos, and activity assignments for parents to do with their children. Parents will be prompted to give feedback regarding successes and challenges applying these parenting skills via audio or text messages during the week.
223441941|NCT02041052|PROCEDURE|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
224053189|NCT05533034|OTHER|Rehabilitation|"* 1 supervised session of rehabilitation, including a cardiac stress test (to define maximal intensity for aerobic activities), aerobic activity with interval training of moderate and progressive intensity (walking), and respiratory exercise using a volumetric spirometer, and strengthening exercises for lower and upper limbs.~* 3 months of self-managed home exercises. Patients will be asked to use a tracker activity when performing home exercises to self-monitor cardiac frequency and to assess their adherence."
224053190|NCT06985836|OTHER|Mulligan Mobilization and Niel Asher technique|"* Mulligan mobilization technique for shoulder external rotation and abduction as described by Mulligan. 3 sets of 10 repetitions with 1 minute rest between sets, 3 times a week for 4 weeks are performed~* Niel Asher technique provided for 3 sessions a week for 4 weeks"
224053191|NCT06985836|OTHER|Mulligan Mobilization and Conventional physiotherapy.|"* Modalities i.e. heating pad and TENS for ten Minutes~* Postural correction exercises / Scapular retraction~* Therapeutic Exercise : Codman' s, finger ladder, wand exercises~* End Range Gleno-humeral joint stretching Both groups will come four times per week for a total of 4 weeks. Pre and post treatment values of both groups will be analyzed."
224053192|NCT06985849|OTHER|Feldenkrais method|"Activating flexors The pelvic clocktwisting).Side lying lesson for improving the integration of arms, shoulders and spine (reaching motion of shoulders in different directions).Transitioning from supine to side lying to sitting (lying supine involving flexion, extension, and twisting).Twisting on the side Twisting from supine with head fixed to the side (by limiting the movement of the head, the rib cage is forced to participate in the twisting motion) Lengthening the hamstrings Arm circles (lying on side, circling arms in different directions). Rolling from supine to prone via hip rotation"
224053193|NCT06985849|OTHER|Otago exercise protocol.|The study began by completing all 3-outcome measures by first asking about their pain intensity then by checking their balance through Berg Balance Scale and then checking the level of function through ODI questionere. The OEP included the following exercises: knee extension and knee flexion, hip abduction, calf raises, toe raises, sit to stand, semi squats from a standing position, tandem stand, tandem walk, sideways walking, backwards walking, heel walking, toe walking, one leg stand, and walking and turning around. All exercises will be performed with 10-20 repetitions, which will be progressed after 2 week.(12)
224145293|NCT03384628|DEVICE|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
224145294|NCT03384628|DEVICE|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
224300603|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
224300604|NCT01512706|BIOLOGICAL|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
224300605|NCT01512706|BIOLOGICAL|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
224300606|NCT01512706|BIOLOGICAL|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
224300607|NCT01512706|BIOLOGICAL|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
224300608|NCT01512706|BIOLOGICAL|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
224300609|NCT01512706|BIOLOGICAL|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
224145295|NCT03384628|DEVICE|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
224145296|NCT06480188|DEVICE|deep brain stimulation|Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
224145297|NCT02780479|DRUG|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
224300610|NCT00468429|DRUG|Subconjunctival Bevacizumab|
224300611|NCT01745211|DEVICE|755nm Alexandrite Laser|755nm Alexandrite laser with array handpiece
224300612|NCT04062448|DRUG|Ibrutinib|Ibrutinib 420 mg will be administered orally.
224300613|NCT04062448|DRUG|Rituximab|Rituximab 375 mg/m\^2 will be administered intravenously.
224300614|NCT05731713|BEHAVIORAL|Journey of Transformation-Native Youth Health Leadership Program curriculum|Curriculum activities will include traditional storytelling and other Native American cultural arts activities (i.e., drum making, film making), as well as Traditional Ecological Knowledge (TEK) activities and field trips. Curriculum content explains leadership skills and promotes healthy decision-making around substance use and sexual health.
224300615|NCT05178017|DIAGNOSTIC_TEST|Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program|The LEAP program is based on the in-vitro Leukocyte Activation Assay (LAA-MRT) results and initially prepared with the least immune reactive foods and chemicals, and subsequent foods will be added depending on the degree of immune reactivity in a nutritionally balanced manner.
223441942|NCT02041052|PROCEDURE|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
223441943|NCT01851980|OTHER|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
223441944|NCT01851980|DRUG|Furosemide|40 mg and 120 mg
223441945|NCT01851980|DRUG|Placebo|0.9% saline
223441946|NCT00192348|BIOLOGICAL|CAIV-T|
223441947|NCT03582319|OTHER|Biodentine|Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
223441948|NCT03582319|OTHER|Formocresol|Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
223441949|NCT00318175|DRUG|Bosentan (Tracleer)|
223441950|NCT03899207|OTHER|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
224053194|NCT06986135|OTHER|Box Breathing|Box breathing consisted of a 4 second inhale, 4 second hold, 4 second exhale, 4 second hold; for 4 minutes.
224145298|NCT02780479|DRUG|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
224053195|NCT06986135|OTHER|Prolonged Exhalation|Prolonged Exhalation consisted of a deep, 3 second inhale, followed by a slow 6 second exhale through pursed lips, once every 30 seconds for 4 minutes.
224053196|NCT06986135|OTHER|Normal Breathing|This was the placebo, normal breathing group was instructed to breath as they normally would for the entirety of the 4 minute period.
224145299|NCT04225884|OTHER|DTx for pain software|Software with active intervention
224053197|NCT06986213|BEHAVIORAL|Heart Pillow Intervention|"Self-Care:~Teach techniques to perform diminished or dependent self-care. Demonstrate assistive devices for self-care. Teach and train techniques and the use of assistive devices.~Scare Tissue:~Perform massage techniques on scar tissue: gliding and friction. Teach and train massage technique."
224053198|NCT06985082|OTHER|THERE IS NOT A INTERVENTION|THERE IS NOT A INTERVENTION
224145300|NCT04225884|OTHER|Control software|Software without active intervention
224145301|NCT04225884|OTHER|Standard care|Pain medication
224145302|NCT06382337|OTHER|Group A : ice cream cone technique|collagen membrane and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
224145303|NCT06382337|OTHER|Group B : the vestibular socket therapy|cortical lamina fixed by bone tacks and allograft bone for labial plate augmentation simultaneously with immediate implants placements in maxillary anterior region in the defected type 2 socket , custom healing abutment for soft tissue preservation in ice cream cone group
224145304|NCT00570440|DRUG|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
224145305|NCT00618995|DRUG|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
224145306|NCT00618995|DRUG|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
224145307|NCT00618995|DRUG|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
224145308|NCT00618995|DRUG|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
224145309|NCT02420301|OTHER|Tuina exercises|
224053199|NCT06986265|OTHER|Collection of clinical data and biological sampling|Multiple measures relevant to cachexia, such as body weight, body mass index (BMI), muscle mass (handgrip strength using a Jamar hand dynamometer, mid-upper arm muscle circumference), appetite (Functional Assessment of Anorexia/Cachexia Therapy \[FAACT\], Simplified Nutritional Appetite Questionnaire \[SNAQ\], Automated Self- Administered Dietary Assessment Tool \[ASA24\]) will be recorded at inclusion (T0), after 6 months (T6) and after one year of follow-up (T12). Body composition will be assessed by bioelectrical impedance analysis at T0, T6 and T12, and by CT-scan at T0 and T12. In parallel, gut microbiota composition on feces collection will be determined at the two time points (T0 and T12). Markers of systemic and intestinal inflammation will be assessed at T0 and T12. Serum levels of uremic toxins will be measured at T0 and T12. Human muscle biopsies will be performed at the time of a surgical intervention.
224145310|NCT02420301|OTHER|Placebo Tuina exercises|
224145311|NCT04150562|DRUG|rhIL-15|Recombinant human Interleukin-15 (rhIL-15) will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
224145312|NCT04150562|BIOLOGICAL|Avelumab|avelumab (800mg by intravenous (IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
223441951|NCT03899207|OTHER|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
223441952|NCT02401061|DRUG|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
223441953|NCT02508415|OTHER|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
224145313|NCT03316677|PROCEDURE|Intraoperative testing of colorectal anastomoses|"1. Insert a Foley catheter through the anus into the rectum.~2. Insufflate the Foley balloon with 5 cc of air.~3. Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~4. Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~5. Remove the saline from the pelvic space.~6. Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~7. Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
224145314|NCT03316677|PROCEDURE|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
224145315|NCT02988219|DRUG|Bupivacaine-fentanyl|Local anesthetic
223441954|NCT00445744|DRUG|cyclophosphamide|Given IV
223441955|NCT00445744|DRUG|busulfan|Given IV
224145316|NCT02988219|DEVICE|Holter ECG monitor|3-chanel, CM5 leads
224145317|NCT02988219|PROCEDURE|Open kidney cancer surgery|Lateral position
224145318|NCT02988219|PROCEDURE|General anesthesia|
224145319|NCT02988219|PROCEDURE|Epidural Anaesthesia|
223441956|NCT00445744|DRUG|tacrolimus|Given IV or PO
223441957|NCT00445744|DRUG|methotrexate|Given IV
223441958|NCT00445744|GENETIC|cytogenetic analysis|Correlative studies
223441959|NCT00445744|OTHER|flow cytometry|Correlative studies
223441960|NCT00445744|OTHER|pharmacological study|Correlative studies
223441961|NCT00445744|OTHER|pharmacogenomic studies|Correlative studies
223441962|NCT00445744|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBPC transplantation
223441963|NCT00445744|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
223441964|NCT01004718|RADIATION|Fludeoxyglucose F18|Undergo FDG PET/CT scans
223441965|NCT01004718|PROCEDURE|Computed Tomography|Undergo FDG PET/CT scans
223441966|NCT01004718|PROCEDURE|Positron emission tomography|Undergo FDG PET/CT scans
223441967|NCT02245919|OTHER|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
223441968|NCT02343380|OTHER|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
223441969|NCT03394417|DEVICE|StrataXRT|randomized patient allocated to this group will receive StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
223441970|NCT05964010|BEHAVIORAL|Standard Screening|All consented youth age 12-17 years complete a patient-facing, well-validated digital screening tool, the CRAFFT (Knight et al., 2003), which assesses number of days during the past year, and then the past 3 months, during which various formulations of AOD were used. If youth report 0 days of AOD use, the tool asks whether they have ridden in a car whose driver was intoxicated; if this response is negative, they are categorized Low Risk. If youth report \> 0 days of AOD use, the tool asks five additional questions assessing use risk and consequences; also, youth who report nicotine use in the past 30 days complete a nicotine dependence checklist (DiFranza et al., 2002). Screen data are then combined to sort youth into three risk categories: Riding Risk Only (no reported AOD use but indicated rode in car driven by intoxicated person), Distant Use (reported AOD use in past year but not past 3 months), or Recent Use (reported AOD use in past 3 months).
223441971|NCT05964010|BEHAVIORAL|Standard Psychoeducation|In the wait area, youth receive a tablet-delivered brief digital AOD education tutorial that includes advice to abstain from or reduce AOD use. The tutorial focuses on adolescent AOD prevalence rates and related behavioral symptoms; AOD use neurobiology and its relation to adolescent health; and common AOD impacts on developmental milestones (see Meredith et al., 2021). Psychoeducation for AOD has shown positive effects as both a universal and selective prevention strategy (Bröning et al., 2021; Das et al., 2016).
223441972|NCT05964010|BEHAVIORAL|Standard Brief Negotiated Interview (BNI)|In primary care (PC) office, youth and providers together complete a tablet-supported brief negotiated interview (BNI; see Beaton et al., 2016). The BNI is informed by AOD use data gathered during youth screening (O'Grady et al., 2015). The BNI focuses on (a) education about AOD disorders, including youth and family factors that impact AOD use; (b) user-tailored feedback comparing the given youth's AOD use and related problems to national norms, along with information on neurobiological effects and developmental impacts of frequent use (Harris et al., 2012); (c) motivational tools (e.g., reduction readiness rulers) and decisional balance exercises (weighing positive versus negative personal impacts of AOD use) tailored to the youth's use levels (Slavet et al., 2006; King et al., 2009); and (d) AOD reduction goal-setting interventions tailored to the youth's readiness to change AOD use (Walton et al., 2013).
223441973|NCT05964010|BEHAVIORAL|Standard Referral to Treatment (RT)|In primary care (PC) offices providers and youth discuss the value of attending counseling services to address AOD-related problems (Cucciare et al., 2015); counseling referral links that the PC site curates with local services; and the value of youth talking directly with caregivers about their AOD involvement as a first step toward support-seeking and behavior change (Gayes \& Steele, 2014). Providers directly recommend AOD counseling and facilitate a first appointment for youth who agree.
223441974|NCT05964010|BEHAVIORAL|Family Screening|Screening procedures incorporate procedures for youth described for Standard Screening. They also incorporate two sources of caregiver-report data. First is an estimate of youth AOD use based on the Screening 2 Brief Intervention tool (Levy et al., 2016). Second is a 9-item checklist of youth mental health (MH) problems (Achenbach \& Rescorla, 2001). If both youth and caregiver report no AOD use or clinical-level MH problem, the family is categorized Low Risk. Otherwise, screen data are combined to sort families into three risk categories: Hidden SU Risk (youth reports AOD use in past year; caregiver reports no youth AOD use in past year), Named MH Risk (caregiver reports no youth AOD use in past year; caregiver reports clinical-level score for at least one youth MH domain), Named SU Risk (caregiver reports youth AOD use in past year).
223441975|NCT05964010|BEHAVIORAL|Family Psychoeducation|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In the wait area, caregivers receive a tablet-delivered parenting tutorial that covers two AOD risk domains: education about adolescent AOD including prevalence rates, related behavior problems, neurobiological and health effects, and impacts on developmental milestones; and education and video modeling about parenting strategies that reduce or moderate AOD risk, including positive communication, fair and consistent discipline, and non-judgmental conversations about AOD use (Bo et al., 2018). Positive parenting education has been shown effective as a universal and selective prevention strategy in parent-focused AOD prevention trials (Kuntsche \& Kuntshce, 2016; Ladis et al., 2019; Van Ryzin et al., 2017). Tutorials are tailored for each risk category.
224053200|NCT05613517|OTHER|Eye examination|"* orthoptic assessment (visual acuity, refraction, stereopsis test, Cover-test, evaluation of the disparity of fixation and ocular dominance, measurement of the inter-pupillary distance~* ocular biometry~* corneal topography~* monocular photographs in photopic condition"
224053201|NCT06602219|DRUG|LY4100511|Administered orally
224053202|NCT06602219|DRUG|Placebo|Administered orally
224145320|NCT02654275|OTHER|Proprioceptive Intervention|
224145321|NCT04516655|DRUG|chidamide combined with rituximab and high-dose methotrexate|chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
224053203|NCT06984133|BEHAVIORAL|Structured education program|"A structured group educational program culturally adapted from a UK model for adolescents with type 1 diabetes. The program aims to empower adolescents by providing knowledge and tools needed for effective diabetes management.~It is delivered by dietitians, diabetes educators, and a pediatric endocrinologist in small groups. The curriculum targets both caregivers and adolescents: the first day is for parents and covers diabetes basics, management of hypoglycemia and hyperglycemia, insulin dosing, sick day management, and exercise considerations. The following three days focus on adolescents and include interactive sessions on the role of food in diabetes management, the effect of different nutrients on blood glucose levels, carbohydrate sources, reading food labels, advanced carbohydrate counting, and insulin dose adjustment."
224145322|NCT03409029|DIAGNOSTIC_TEST|MRI Scan|Additional imaging using MRI scan
224145323|NCT00992186|DRUG|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
224300616|NCT04008368|DEVICE|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
224300617|NCT02477930|OTHER|No interventions are done|No intervention is done. This is a registry study.
224300618|NCT04450147|BEHAVIORAL|Tai Chi/Qigong vs. Walking/Stretching|Both interventions can be thought of as a form of movement and exercise.
224300619|NCT04990609|DEVICE|Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)|Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) consists of the application of an alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor; which induces the release of large amounts of cellular debris. This cellular debris represents a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
224300620|NCT04990609|DRUG|Neoadjuvant Chemotherapy (NAC)|The NAC regimen will be determined clinically by the participant's physician \[possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)\].
224300621|NCT05913050|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.
224300622|NCT05913050|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
224300623|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5\*10\^10 viral particles on Day 1
223441976|NCT05964010|BEHAVIORAL|Family Brief Negotiated Interview (BNI)|Youth proceed as indicated in the SBIRT-A-Standard condition based on youth screen data. In primary care (PC) offices, caregivers and providers together complete a tablet-supported parenting BNI informed by data from the caregiver screen only that parallels the youth BNI (e.g., AOD education, developmental risks) and also includes motivation, modeling, and goal-setting on positive parenting (e.g., non-judgmental conversations; see above) and effective parent-youth communication about AOD use (Carver et al., 2017).
223566843|NCT03619928|DEVICE|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
224145324|NCT00333697|OTHER|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
224145325|NCT03002103|DRUG|EndoTAG-1|
223566844|NCT00432328|DRUG|Avotermin|
224145326|NCT03002103|DRUG|Paclitaxel|
224145327|NCT03002103|DRUG|Gemcitabine Hydrochloride|
224145328|NCT05961800|BEHAVIORAL|Cutaneous Probe|A computer-controlled probe delivers temperatures to the skin to measure pain, offset analgesia and onset hyperalgesia.
224145329|NCT05961800|BEHAVIORAL|Quantitative Sensory Testing|Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain
224145330|NCT05961800|BEHAVIORAL|Computer Tasks|Quantitative Sensory Testing (QST) and computer tasks are used to measure changes in pain intensity.
224145331|NCT01585896|OTHER|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, \& Steketee, 2007).
224145332|NCT02578472|DRUG|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule\*20 mg) in one of the treatment periods.
224145333|NCT02578472|DRUG|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
224145334|NCT02578472|DRUG|Placebo|Matching Placebo will be administered orally.
224145335|NCT02751021|OTHER|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
224145336|NCT02751021|OTHER|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
224145337|NCT06458257|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
224145338|NCT06458257|DRUG|Chemotherapy|Chemotherapy
223441977|NCT05964010|BEHAVIORAL|Family Facilitated Conversation (FC) & Referral to Treatment (RT)|In PC offices, providers meet separately with youth and caregivers to discuss the value of talking directly with the other family member about AOD risk while practicing positive communication strategies. Whenever both youth and caregiver agree to talk together, providers convene a brief facilitated conversation about AOD risk. In this conversation providers (a) emphasize that a positive youth-caregiver relationship is the strongest protective factor for youth development and (b) follow guidelines for brief triadic risk-reduction interventions focused on positive family communication about AOD risk (Guilamo-Ramos et al., 2020). When indicated, providers directly recommend AOD counseling and facilitate a first appointment for families who agree.
223441978|NCT03943823|DRUG|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
223441979|NCT03943823|DRUG|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
223441980|NCT01544764|OTHER|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
223441981|NCT01189708|DEVICE|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
223441982|NCT01189708|OTHER|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
223441983|NCT02483325|DRUG|Allogeneic transplant conditioning|Allogeneic transplant
223441984|NCT00830635|OTHER|educational intervention|
223441985|NCT00830635|OTHER|informational intervention|
223441986|NCT00830635|OTHER|internet-based intervention|
224145339|NCT06311110|OTHER|Vancouver symptom score for dysfunctional elimination symptoms Questionnaire|Vancouver symptom score for dysfunctional elimination syndrome, Dutch version, validated by 't Hoen et al. 2016. The questionnaire is filled in by the parents of the child.
224145340|NCT06311110|OTHER|Developmental Coordination Disorder Questionnaire|Validated Developmental Coordination Disorder Questionnaire, Dutch version includes assessment of motor functioning. The questionnaire is filled in by the parents of the child.
224300624|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2\*10\^10 viral particles on Day 1
224300625|NCT02543567|BIOLOGICAL|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8\*10\^10 viral particles on Day 1
224300626|NCT02543567|BIOLOGICAL|MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 1\*10\^8 Infectious Unit \[Inf. U.\] once on Day 57
224300627|NCT02543567|BIOLOGICAL|MVA-BN-Filo 5*10^7 Inf. U.|MVA-BN-Filo- live replication incompetent vaccine, IM injection of 5\*10\^7 Inf. U. once on Day 57
224300628|NCT02543567|BIOLOGICAL|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
224300629|NCT05101486|BIOLOGICAL|Ad26.RSV.PreF-based Vaccine|Ad26.RSV.PreF-based Vaccine will be administered as single IM injection.
223441987|NCT00830635|OTHER|questionnaire administration|
223441988|NCT00830635|OTHER|study of socioeconomic and demographic variables|
223441989|NCT00830635|OTHER|survey administration|
223441990|NCT00830635|PROCEDURE|psychosocial assessment and care|
223441991|NCT00830635|PROCEDURE|quality-of-life assessment|
223441992|NCT05048589|DRUG|Standard-Dose Quadrivalent Influenza Vaccine|For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.
223441993|NCT05048589|DRUG|High-Dose Quadrivalent Influenza Vaccine|For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
223441994|NCT02773277|OTHER|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
223441995|NCT04856059|DIAGNOSTIC_TEST|Cardiac MRI, ECG/Holter and Blood Biomarkers|Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
223441996|NCT05182606|BEHAVIORAL|Pilot study of algorithms implementation package|The algorithm implementation package includes a link to the algorithms in the Electronic Health Record, Smartphrases, audited feedback, and instructions.
223441997|NCT05988333|OTHER|Psychoeducational Family Intervention|Supportive intervention administered to families with a member affected by MDD
223441998|NCT05988333|OTHER|Informative intervention|Informative intervention administered to families with a member affected by MDD
223441999|NCT02590874|DRUG|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
223442000|NCT02590874|DRUG|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
223442001|NCT03453281|DRUG|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
223442002|NCT05861102|DRUG|Jaktinib|Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
223442003|NCT05861102|DRUG|Placebo|Participants will receive matching placebo orally twice daily for 16 weeks
223442004|NCT06254235|DRUG|The test octreotide microsphere|A single intramuscular dose of the test octreotide microsphere 30mg,
223442005|NCT06254235|DRUG|The reference octreotide microsphere|A single intramuscular dose of the reference octreotide microsphere 30mg
223442006|NCT01306435|OTHER|Laser|3-week treatment with three Laser sessions per week
223442007|NCT01306435|OTHER|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
223566845|NCT04565444|DIETARY_SUPPLEMENT|Ketone|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* Isocaloric carbohydrate control: dextrose + vanilla flavouring"
224053204|NCT02489136|OTHER|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
224145341|NCT06311110|OTHER|Questionnaire concerning impaired toilettraining and comorbities|Unvalidated, complementary questions concerning impaired toilettraining and comorbidities. Questions were based on ICCS standardisation guidelines (Austin et al., 2015). The questionnaire is filled in by the parents of the child.
224145342|NCT04166656|BIOLOGICAL|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
223442008|NCT01010958|DRUG|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
223442009|NCT06330220|DRUG|Aflibercept Injection [Eylea]|intravitreal injection
224145343|NCT04166656|BIOLOGICAL|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
224145344|NCT00612989|DRUG|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG \& then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle \& every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar \& continue fasting 2 hrs after administration of each Temodar dose."
224053205|NCT06608485|DEVICE|HARMONIC 700 Shears|There is no intervention, beyond necessary clinical care, in this study. HARMONIC 700 Shears for vessel transection were used according to instructions for use.
224053206|NCT04702451|PROCEDURE|Dispersion ablation + PVI|Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation
224053207|NCT04702451|DEVICE|VX1|VX1-based dispersion mapping
224053208|NCT04702451|PROCEDURE|PVI|Pulmonary vein antrum isolation
224053209|NCT06051006|OTHER|ESR and ECAP measurements|"Measurement of electrically evoked stapedial reflexes (ESRT) by stimulation via the cochlear implant. Measurement of the Electric compound action potentials (ECAPs) on the electrodes where the ESRT were performed.~The measurements and tests will be performed during a routine visit to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
224145345|NCT01896856|DRUG|SGI-110 Dose Escalation|"* Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support"
224145346|NCT01896856|DRUG|Regorafenib|160 mg taken orally
223442010|NCT01688141|OTHER|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
224053210|NCT06051006|OTHER|Device setting|"The adjustment will be made by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The purpose of this setting is to modify the comfort thresholds using the ESR via a correction (according to the literature). The cochlear implant (CI) will therefore be set with the setting using the ESR (setting 2). The basic setting (setting 1) will be stored in memory in the CI. If ever the patient does not support setting 2, he/she will have the possibility of returning to the basic setting, without having to return to the Necker hospital for an additional setting.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
224053211|NCT06051006|OTHER|Speech audiometry|"This examination is part of the usual care for a patient with a cochlear implant. Fournier's monosyllabic test will be used. The test will be carried out by an audioprosthetist at the Center for Research in Audiology at Necker Hospital. The measurement will be performed under both setting conditions: setting 1 (current setting) and setting 2 (based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
224145347|NCT01896856|DRUG|TAS-102|35 mg/m\^2 taken orally
224145348|NCT01896856|DRUG|SGI-110|45 mg/m\^2 administered as a subcutaneous injection
223442011|NCT02129634|DEVICE|CB-PTA|
223442012|NCT02129634|DEVICE|DEB-PTA|
224145349|NCT01896856|DRUG|Irinotecan|125 mg/m\^2 administered IV
224145350|NCT06043245|PROCEDURE|Duodenal Switch|Classic Duodenal Switch
224145351|NCT06043245|PROCEDURE|SADI-S|SADI-S with a 300cm common channel
224145352|NCT06043245|PROCEDURE|Minigastric Bypass|Classic minigastric bypass
224145353|NCT01879813|DIETARY_SUPPLEMENT|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
224145354|NCT01879813|DIETARY_SUPPLEMENT|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
224145355|NCT06853496|DRUG|RK-582|"Dosing Frequency:~Do single dose of RK-582 at the dose level specified for the cohort. Seven days after the first dose, Start repeated daily dose and continue until discontinuation criteria were met.~Dose level per dose:~Dose Level 1: 5 mg BID Dose level 2: 10 mg QD Dose level 3: 20 mg QD Dose level 4: 40 mg QD Dose Level 5: 60 mg QD Dose Level 6: 80 mg QD Dose Level 7: 100 mg QD Dose Level 8: 200 mg QD"
224145356|NCT06813014|PROCEDURE|Oral Glucose Tolerance Test|Three hour glucose tolerance test
224145357|NCT02193672|DRUG|[18F] Fluciclatide|\[18F\] Fluciclatide given by vein before PET/CT scan.
224145358|NCT02193672|PROCEDURE|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
223442013|NCT04110717|DEVICE|Vestal Device|Vestibular nerve stimulator
223442014|NCT04110717|DEVICE|Control Device|Control Device
223442015|NCT04110717|BEHAVIORAL|Hypocaloric Diet|Hypocaloric diet
223442016|NCT01167634|BEHAVIORAL|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
224053212|NCT06051006|OTHER|Intelligibility in noise test|"The FraSimat is a measure of speech perception in noise. The test consists of 14 sentences of 3 words, recorded in the presence of background noise, which the child must listen to and repeat. The background noise remains fixed at 65dB HL and the speech intensity adapts according to the patient's responses. The measurement will be performed under two setting conditions: MAP 1 (current setting) and MAP 2 (setting based on ESR). The order of administration will be randomized in order to overcome a training effect.~The measurements and tests will be done during an usual visit of the patient to the Necker hospital for the adjustment of the cochlear implant (visit 1)."
224053213|NCT06051006|OTHER|Cochlear implant datalogging, speech audiometry test, FraSimat test|"The follow-up visit (visit 2) will take place 1 month after visit 1 only for patients with a comfort levels threshold (via the eSRT) different from the current threshold (C-subjective).~At the start of the visit, cochlear implant datalogging will be recorded to determine the use of both settings (setting 2, using the ESR and setting 1, basic setting) while wearing the cochlear implant.~The datalogging will be recorded by an audioprosthetist at the Center for Research in Audiology at Necker Hospital.~If the patient has worn the new program (setting 2), the speech audiometry test and the FraSimat test (Intelligibility in noise test) will be performed again with the setting based on ESR."
224053214|NCT06600542|DEVICE|Inari Medical Commercially Available Devices|Commercially approved Inari Medical devices
224053215|NCT06981806|DRUG|Balixafortide|Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly
224053216|NCT06981806|DRUG|Balixafortide|Dose: 11 mg/kg Route: IV (2hr) Frequency: Weekly
224145359|NCT02193672|BEHAVIORAL|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
224145360|NCT00282867|DRUG|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
224145361|NCT00282867|OTHER|standard care|usual care
224145362|NCT03334474|OTHER||no intervention
224145363|NCT02677220|DEVICE|CI532 cochlear implant|
224145364|NCT05902429|DRUG|Cladribine 10 mg oral tablet|Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
224145365|NCT00553553|DRUG|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
224145366|NCT00553553|DRUG|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
224145367|NCT00965146|DEVICE|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
224145368|NCT00543621|OTHER|daily enteral nutritional product and/or behavioral changes|
224145369|NCT01244958|BIOLOGICAL|Rituximab|1000 mg Rituximab infusion
224145370|NCT01244958|DRUG|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
224145371|NCT02913742|PROCEDURE|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
224145372|NCT06371664|DRUG|Conventional Tray (1 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
224145373|NCT06371664|DRUG|Extended Tray (3 mm)|General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
224145374|NCT02853981|DEVICE|Harmonic scalpel|a method for liver parenchymal transection
224145375|NCT02853981|DEVICE|Kelly clamp crush technique|a method for liver parenchymal transection
224145376|NCT04213937|DRUG|nab-paclitaxel|Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.
224300630|NCT02788045|BIOLOGICAL|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
224145377|NCT04213937|DRUG|Topotecan|Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.
224300631|NCT02788045|BIOLOGICAL|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5mL injection administered intramuscularly.
224300632|NCT02788045|BIOLOGICAL|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
224300633|NCT02788045|DRUG|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
223442017|NCT01167634|BEHAVIORAL|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
223442018|NCT01167634|BEHAVIORAL|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
223442019|NCT00822224|DRUG|MEOPA|inhalation of MEOPA during the painful care
223442020|NCT06260475|PROCEDURE|Aortobifemoral bypass|Open surgery with aortic and iliac reconstruction
223442021|NCT06260475|PROCEDURE|aortoiliac stenting|"Endovascular reconstruction of aortic and iliac arterial obstruction:~Balloon angioplasty may be performed initially to dilate the narrowed segment of the iliac artery.~Subsequently, a stent delivery system is advanced over the wire and positioned across the lesion.~The stent is deployed under fluoroscopic guidance to expand and scaffold the diseased artery, restoring blood flow.~Vascular - iliac dedicated Stent - any brand"
223442022|NCT04548388|OTHER|rehabilitation|"A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions"
223442023|NCT00968188|BEHAVIORAL|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
223442024|NCT00968188|BEHAVIORAL|Information only|Medically fact based HIV information delivered online.
223442025|NCT00438256|PROCEDURE|Proton Beam Radiation|Given over different schedules and duration
223442026|NCT00438256|DRUG|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
223442027|NCT01133288|DEVICE|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (\~30 minutes per day) over a 3 month period.
223442028|NCT04625933|OTHER|No intervention|No intervention
223442029|NCT01555918|DRUG|Isavuconazole|oral
223442030|NCT01555918|DRUG|Isavuconazole (IV)|intravenous (IV)
223442031|NCT00369161|DRUG|Everolimus (RAD001)|
223442032|NCT00369161|DRUG|Tacrolimus|
224053217|NCT06981806|DRUG|Cosibelimab|Dose: 800 mg Route: IV (60 min) Frequency: Weekly
224053218|NCT06981806|DRUG|Balixafortide|Dose: 16 mg/kg Route: IV (2hr) Frequency: Weekly
224053219|NCT06985550|BEHAVIORAL|Multicomponent Exercise|Participants in this group will engage in a 12-week supervised multicomponent exercise program, performed 3 times per week, 90 minutes per session. Each session includes a 10-minute warm-up, 40 minutes of Waltz dance (learning and practicing routines), 30 minutes of resistance band exercises (1-3 sets of 8-12 repetitions, using 10-20RM), and a 10-minute cool-down with stretching. Exercise intensity progresses from 50% to 75% of HRmax (RPE 10-13, 2.0-6.0 METs). The program is designed to improve lipid profile, body composition, cardiovascular fitness, balance, mental health, and cognitive function in postmenopausal women aged ≤65 years with dyslipidemia.
224053220|NCT06985550|OTHER|daily activity|Only daily activities are included.
224300634|NCT06502457|DRUG|painkiller|The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
223442033|NCT00369161|DRUG|Basiliximab|
223442034|NCT00369161|DRUG|Corticosteroids|
223442035|NCT04402359|DRUG|meropenem|meropenem one gram slowly IV infusion every 8 hours for 14 days
223442036|NCT04402359|DRUG|ceftazidime 2 grams and avibactam 500|received ceftazidime 2 grams and avibactam 500 mg every 8 hours for 14 days in solution for injection(sodium chloride 9 mg/mL (0.9%), sodium chloride 4.5 mg/mL, dextrose 25 mg/mL, 0.45% sodium chloride, 2.5% dextrose and/or Lactated Ringer's solution).
223442037|NCT04402359|DEVICE|ventilator|all patients selected to be ventilated for 14 days
224053221|NCT06984614|OTHER|Snoezelen room|'Snoezelen room' is a meaning a room designed to stimulate people's senses. The history of the Snoezelen room dates back to people with mild or severe disabilities. It provides muscle relaxation for people with severe pain. This has become part of complementary medicine that promotes effective comfort and relaxation, which causes the release of endorphins and alleviates a person's capacity to cope with pain. The Snoezelen environment can be used to distract from pain by focusing on various senses, including visual and auditory. Describing multi-sensory therapeutic activity in a special room filled with stimuli that aim to stimulate all senses provides participants with feelings of relaxation and self-control (Nielsen, Overgaard, 2020; Jamshidi Manesh et. al., 2015; Anderson et. al.2011). In the study, the Snoezelen room was designed and the pregnant women in the intervention group will complete their labor in this room, while the control group will complete their labor in the
224053222|NCT06985095|OTHER|Nutrition educational program|"Participants in the intervention group will attend a structured nutrition education program consisting of four monthly sessions, each lasting approximately 40 to 60 minutes. These sessions will be conducted in small groups by the researcher.~Each session includes: A 20-30 minute presentation delivered by the researcher using visual aids, such as slides and educational images. A 20-30 minute interactive discussion to address participants' questions, clarify concepts.~Session Topics:~Treatment Goals in Diabetes Care: Overview of blood glucose targets and the importance of achieving glycemic control.~Key Nutritional Components of Food: Roles of carbohydrates, proteins, fats, fiber, and their impact on blood glucose.~Principles of Meal Planning: Adjusting energy intake based on physical activity levels and BMI.~Understanding the Food Exchange System: Introduction to food exchange lists; selecting the appropriate number of food exchanges to meet individual energy needs."
224053223|NCT06481098|DRUG|HM15275|HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
224053224|NCT06481098|DRUG|Placebo of HM15275|A sterile, matching solution supplied in pre-filled syringes.
223442038|NCT04766099|OTHER|Childbirth Educational Video|Educational video describing techniques for pushing
223442039|NCT01250353|PROCEDURE|pterygium surgery|pterygium was removed surgically
223442040|NCT04606667|OTHER|Exercise Program|Exercise program
223442041|NCT04110496|DRUG|RTX-134|RTX-134 is a cellular therapy containing AvPAL
223442042|NCT05958108|BEHAVIORAL|SinergiAPS intervention|Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
223442043|NCT04727255|BEHAVIORAL|Engaged and Resilient intervention|"Engaged and Resilient is a 3-phase program addressing the promotion of psychological resilience strategies for leaders.~To implement resilience training as a strategic and ethical intervention in the organization, stakeholders from Management/HR will be involved in the final design of the training program based on local institutional data, and the baseline measure result. Local training sessions will be selected from a bag-log of resilience skills structured by three general resilience factors.~To support ownership and internal sustainability, internal trainers will be educated on how to train the resilience skills in the program.~The Engaged and Resilient program consists of 20 short-term sessions for leaders based on cognitive and positive psychology."
223442044|NCT04725123|DIAGNOSTIC_TEST|Microbiome analysis|Stool microbiome analysis of 16S rRNA sequencing to an anticipated number of 8,000,000 reads
223442045|NCT06174818|PROCEDURE|PRF|Pulsed Radiofrequency Current of the Gasserian Ganglion
223442046|NCT05507502|BIOLOGICAL|Influenza vaccination administration|There will be approximately 40 participants who consent; they will be randomized in a 1:1 manner to receiving the influenza vaccination during their heart failure hospitalization versus receiving the vaccine during their first follow-up in the heart failure clinic.
223442047|NCT02290379|DRUG|TNX-201 35 mg|Drug: TNX-201 35 mg
223442048|NCT02290379|DRUG|TNX-201 70 mg|Drug: TNX-201 70 mg
223442049|NCT02290379|DRUG|TNX-201 140 mg|Drug: TNX-201 140 mg
223442050|NCT02290379|DRUG|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
223442051|NCT02290379|DRUG|Placebo|Drug: Placebo
224053225|NCT04276389|DEVICE|OCT-guided paclitaxel drug-coated balloon angioplasty|OCT-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
224145378|NCT02448316|PROCEDURE|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
224145379|NCT02448316|DRUG|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
223442052|NCT04848259|DRUG|Normal saline|Saline will be applied after surgery
223442053|NCT04848259|DRUG|Dexamethasone|Dexamethason will be given IV before surgery
223442054|NCT04848259|DRUG|Honey|Honey will be applied locally after surgery
224053226|NCT04276389|DEVICE|Angiography-guided paclitaxel drug-coated balloon angioplasty|Angiography-guided paclitaxel drug-coated balloon angioplasty in middle-sized de novo coronary artery
224053227|NCT06659588|OTHER|Plasma, urine and stool collection|"During a consultation for follow-up, we will take an extra-volume during a blood sample taken as part of the care. We will also collect stool and urine.~There will be no biological collection for these samples. Organ biopsies carried out as part of the care (liver, kidney, digestive tract, spleen, lymph node) will also be studied as part of this research."
224053228|NCT05926895|DRUG|Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space|Treatment method used in the treatment of subacromial impingement syndrome
224145380|NCT02448316|DRUG|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
224145381|NCT02448316|BEHAVIORAL|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
224300635|NCT06502457|OTHER|hypnosis group|"The hypnosis group will receive a hypnosis session after the fetal heart rate has been recorded. Automated measurement of blood pressure and maternal heart rate will take place during the session in order to objectively assess the impact of the session on the mother.~Patients in the hypnosis group will then have access to the virtual reality headset on request throughout the latency or maturation phase, and will also be able to benefit from a painkiller in accordance with the service protocol if they so request."
223442055|NCT04848259|DRUG|Dexamethasone and honey|Dexamethason will be given IV before surgery and then Honey will be applied locally after surgery
223442056|NCT06038006|DIAGNOSTIC_TEST|Sleep Respiratory Monitoring System|Millimeter-Wave radar-based Sleep Respiratory Monitoring System to be used on each participant undergoing PSG
223442057|NCT02612688|BEHAVIORAL|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
223442058|NCT00506207|DRUG|S-1, Irinotecan, Oxaliplatin|
223442059|NCT03538067|PROCEDURE|Percutaneous coronary intervention (PCI)|Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
223442060|NCT01273662|DRUG|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
224053229|NCT06156215|BEHAVIORAL|Vaccine Messaging|"1. Video clips - short (approximately 3-minute) Public Service Announcement type videos to be viewed by participant using a QR code on their smartphone. If no smartphone is available, the video will be shown to the participant on an iPad.~2. Printed materials - one page information sheets handed to subjects by CRCs.~3. Face to face messaging - short (\< 1 minute), scripted message from the patient's providers in the ED (nurse or provider)~Each site will maintain a library of~A. 5 versions of the videos - the version used in any participant will be tailored to that participant's stated race/ethnicity.~B. 5 versions of printed flyers - likewise, the version will be tailored to the participant's stated race/ethnicity.~C. 1 version of scripted message to be delivered in English or Spanish."
223566846|NCT04565444|DIETARY_SUPPLEMENT|Ketone + Protein|"* Ketone monoester supplement (R)-3-hydroxybutyl (R)-3-hydroxybutyrate based on participants' body weight (0.36g/kg body weight)~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
224053230|NCT06156215|BEHAVIORAL|Vaccine Acceptance Question|"The last question in the Vaccine Acceptance Survey in both the Intervention M and Intervention Q arms of the study is Would you accept the COVID-19 booster vaccine in the emergency department today if your doctor asked you?"
224053231|NCT05816356|DRUG|Decitabine|Oral administration of decitabine as a single dose to healthy male subjects
224053232|NCT05816356|DRUG|Tetrahydrouridine|Oral administration of Tetrahydrouridine as a single dose to healthy male subjects
224053233|NCT03350711|OTHER|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~* Health history and physical examination~* Urinalysis~* Urine or serum pregnancy test~* Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~* Electrocardiogram (EKG or ECG)~* Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
224053234|NCT01410019|OTHER|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
224053235|NCT03996980|DEVICE|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
224053236|NCT05572515|DRUG|Teclistamab|Teclistamab will be administered subcutaneously.
224053237|NCT05572515|DRUG|Pomalidomide|Pomalidomide will be administered orally.
224053238|NCT05572515|DRUG|Bortezomib|Bortezomib will be administered subcutaneously.
224053239|NCT05572515|DRUG|Dexamethasone|Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.
224053240|NCT05572515|DRUG|Carfilzomib|Carfilzomib will be administered intravenously.
224053241|NCT06862986|OTHER|Ear massage|At least one Intervention must be specified for an Interventional study. Patients included in the study group will receive ear massage in addition to the routine treatment and care practices of the clinic. Ear massage application will be started in the evening of the first day after surgical intervention (at 19:30) and will be applied twice a day at least 30 minutes after morning and evening meals (07:30 am, 19:30 pm) for 3 minutes each, similar to the literature (8,9,12). The bowel sounds of the patients will be re-evaluated before and 10 minutes after the ear massage application, and the excretory activities form will be filled out. Ear massage application will be terminated when the patient defecates or when the patient is given an enema.
224053242|NCT05585983|BIOLOGICAL|Vaxigrip Tetra Sanofi Pasteur Europe|We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.
224053243|NCT04892342|DRUG|ESG401|Administered via intravenous (IV) infusion
224053244|NCT07001111|OTHER|kinesio taping|Kinesio taping at the level of the cubital tunnel on the elbow
224053245|NCT07001111|OTHER|Ulnar nerve mobilization exercise|All patients will be provided with information and an exercise sheet containing pictures on ulnar nerve gliding exercises. To monitor whether patients are performing the exercises correctly, they will be asked to come to the hospital once a week, where they will perform the exercises under the supervision of a physiotherapist. In the exercise program, different positions will be held for 30 seconds, with a 1-minute rest between them, and the exercises will be performed twice a day .
224053246|NCT07001111|OTHER|Sham (No Treatment)|It will be applied in the same way as kinesiological taping with adhesive tape.
224053247|NCT07001111|DIAGNOSTIC_TEST|Numeric Rating Scale (NRS)|Description: To demonstrate that kinesiological taping will result in a reduction of pain intensity associated with Cubital Tunnel Syndrome, as measured by the Numeric Rating Scale (NRS) ranging from 0 to 10.
224053248|NCT07001111|DIAGNOSTIC_TEST|the ulnar nerve cross-sectional area measured by ultrasound|The measurements will be taken with the patient in a supine position, the affected arm in shoulder abduction and external rotation, and the elbow flexed at 70°-90°. After applying a generous amount of gel, the lateral edge of the ultrasound probe will be placed on the medial epicondyle, and the medial edge of the probe will be positioned on the olecranon; the ulnar nerve will be directly examined in the retroepicondylar groove. Once the nerve is visualized, the widest point will be identified, and cross-sectional area (CSA) measurements will be taken with the probe perpendicular to the nerve at the center of the screen . The measurements will be repeated twice, and the average will be calculated.
224053249|NCT07001111|DIAGNOSTIC_TEST|Neuropathic pain scale (measured using the DN-4 scale)|"The DN4 questionnaire consists of two main sections and a total of ten questions. The first section includes seven questions related to pain characteristics and sensory information obtained through patient interview. These questions are about burning, electric shocks, coldness, tingling, pricking, numbness, and itching. The second section contains three statements related to physical examination (touch hypoesthesia, pinprick hypoesthesia, and allodynia). For each statement, yes or no responses are given. A score of 1 is assigned for yes answers and 0 for no answers, and the scores are summed. A total score of 4 or more out of 12 is interpreted as neuropathic pain."
223566847|NCT04565444|DIETARY_SUPPLEMENT|Protein|"* Isocaloric carbohydrate control: dextrose + stevia~* 10g Whey Protein~* L-\[ring-2H5\]-phenylalanine tracer (enriched to 4%)"
223566848|NCT02825420|DRUG|trabectedin|
224053250|NCT07001111|DIAGNOSTIC_TEST|SF-12 Quality of Life Scale|The SF-12 Quality of Life Scale is a short form of the SF-36 Quality of Life Scale. While the SF-36 is used for chronic conditions (states), the SF-12 is used for short-term assessments (clinical findings). Similarly, it is also used to gather information about the patient's general health status. The SF-12 provides the same summary component scores as the SF-36, but with fewer items, making it a significant advantage due to its shorter application time. The scale asks the patient about their health opinions, how they feel, and how easily they can perform their usual activities. Scores range from 0 to 100, with higher scores indicating better quality of life.
224053251|NCT07001111|DIAGNOSTIC_TEST|QUICK-DASH|"QUICK-DASH (Shoulder, Arm, and Hand Problems Questionnaire):~This questionnaire assesses both the ability to perform certain physical activities as well as the symptoms of the disease. Each question is answered based on the condition of the past week, and the appropriate score is marked. The answer is given based solely on the ability to perform the physical activity, without considering which hand or arm is injured.~Scoring:~1. = No difficulty~2. = Mild difficulty~3. = Moderate difficulty~4. = Severe difficulty~5. = Unable to perform~QUICK DASH DISABILITY/SYMPTOM SCORE:~(\[(n total score\] - 1) x 25; where n represents the number of questions answered. If more than one question is unanswered, the Quick DASH score cannot be calculated.~SCORE FOR OPTIONAL MODELS:~For each model, divide the total score by 4, subtract 1, and multiply by 25. If more than one question is unanswered, the score for optional models cannot be calculated.~Based on the results of the questionnaire, a score b"
224053252|NCT07001111|DIAGNOSTIC_TEST|Grip strength measured with a hand dynamometer|Grip strength will be measured using a hand dynamometer, with the average of three measurements taken, each followed by a 30-second rest period.
224053253|NCT07002034|DRUG|RE104 for Injection|Single, subcutaneous dose of RE104 for Injection
224053254|NCT07001059|DIAGNOSTIC_TEST|orbital ultrasound|orbital ultrasound at the beginning of the participation, and at 6 months after the inclusion.
224053255|NCT06349733|DRUG|Botulinum toxin type A|Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
224053256|NCT04347226|DRUG|BMS-986253|BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
224053257|NCT06868199|DRUG|LM-168|Q3W,Intravenous Drip
224053258|NCT06868199|DRUG|Toripalimab|Q3W,Intravenous
224053259|NCT06659562|DRUG|HER-096|Administered as a single dose via s.c. injection
224053260|NCT06659562|DRUG|HER-096|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
224053261|NCT06659562|DRUG|Placebo|Administered as multiple doses via s.c. injection. Administered twice a week (2 doses/week) during a 4-week period.
224053262|NCT05027919|DRUG|Hydromorphone|Up to 120mg oral per day in q4 dosing to manage withdrawal
224053263|NCT05027919|DRUG|Naloxone + lofexidine pretreatment|0.2-0.4mg naloxone injection during the Naloxone challenge + pretreatment with oral lofexidine (25% of max daily dose scheduled during lofexidine taper)
224053264|NCT05027919|DRUG|Naloxone + placebo pretreatment|0.2-0.4mg naloxone injection during the Naloxone challenge
224053265|NCT05027919|DRUG|Lofexidine|Oral Lofexidine dosed per FDA label (4 times daily) on days 6 through 10.
224053266|NCT05875129|DEVICE|VAVA prototype|Cognitive behavioral therapy for insomnia
224053267|NCT05077904|DRUG|Staccato alprazolam|"Route of administration: Inhalation~Participants will receive one dose of Staccato alprazolam during the Treatment Period."
224053268|NCT05077904|OTHER|Placebo|"Route of administration: Inhalation~Participants will receive one dose of placebo during the Treatment Period."
224053269|NCT03977974|DRUG|LY3526318|Administered orally
224053270|NCT03977974|DRUG|Placebo|Administered orally
224053271|NCT07017335|DRUG|R1_PBK_M2301(Levocloperastine 60mg)|R1\_PBK\_M2301 is a test drug containing 60mg of levocloperastine per tablet. It is administered orally to evaluate pharmacokinetic characteristics and potential drug-drug interactions with R2\_PBK\_M2301 in healthy adult volunteers.
224053272|NCT07017335|DRUG|R2_PBK_M2301 (Pelargonium sidoides extract)|R2\_PBK\_M2301 is an oral tablet containing 20 mg of Pelargonium sidoides 11% ethanol extract, used as a comparator to evaluate potential pharmacokinetic interactions with R1\_PBK\_M2301.
224163977|NCT06076239|OTHER|Control Group|Both EG and CG were given conventional treatment.Conventional treatment is consist of Ultrasound therapy (Gymna Pulson200) (1 mHz. treatment dose average 1.5 w/cm², intermittent with a small head (50%), 5 minutes (45)) around the glenohumeral joint of the cases in both groups participating in the study; TENS applied at an intensity that the patient can tolerate, covering the painful area (modified biphasic asymmetric pulse, and it was set to a pulse width of 100 μs and a frequency of 100 Hz, 20 min,) (Hometech ht 66b); hotpack and exercises (posterior capsule stretching, wand exercises, mobilization approximately 60 minutes of conventional treatment consisting of exercises and shoulder isometric exercises) was applied once a day, 5 times a week in both groups.
224053273|NCT06717074|DRUG|RBD4059|RBD4059, active drug.
224053274|NCT06717074|DRUG|Placebo|Placebo that is identical in appearance and volume to the doses of active IMP.
224053275|NCT07047144|DRUG|Apitegromab|Apitegromab is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that specifically binds to human pro/latent myostatin with high affinity inhibiting myostatin activation. SRK-015 will be administered every 4 weeks by intravenous (IV) infusion.
224053276|NCT07047144|DRUG|Nusinersen|Nusinersen is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered intrathecally per the prescribing information.
224053277|NCT07047144|DRUG|Risdiplam|Risdiplam is a current standard-of-care SMN therapy that targets the SMN2 gene. It will be administered orally per the prescribing information.
224053278|NCT06731478|DRUG|Trastuzumab Deruxtecan|T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)
224053279|NCT06731478|DRUG|pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg IV Q3W
224053280|NCT06731478|DRUG|Trastuzumab|Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W
224053281|NCT06731478|DRUG|Chemotherapy|"For Arms M1 and E1: 5-FU or capecitabine will be administered.~For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will administered."
223442061|NCT03793374|OTHER|Subcutaneous apocrine glands shaving|A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
223442062|NCT00255320|DRUG|VIP|
223442063|NCT01232374|DRUG|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
223442064|NCT01232374|DRUG|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
224053282|NCT06734741|DIAGNOSTIC_TEST|COVID/Flu Detect™ Rapid Self-Test|The COVID/Flu Detect™ Rapid Self-Test is an investigational qualitative lateral flow immunoassay designed for the detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. It is intended for non-prescription over-the-counter (OTC) use.
224053283|NCT00804531|DRUG|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
223442065|NCT01232374|DRUG|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
223442066|NCT01232374|RADIATION|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
223442067|NCT00256620|PROCEDURE|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
224053284|NCT00804531|DRUG|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
224053285|NCT07059065|DEVICE|FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute|"FIBERGRAFT™ Aeridyan Matrix is a next generation synthetic bone graft that is resorbable, bioactive, and osteoconductive. FIBERGRAFT Aeridyan Matrix is composed of ultra-porous 45S5 bioactive glass granules, boron-based bioactive glass microspheres, and bovine type 1 collagen. The granules are made entirely of 45S5 bioactive glass fibers and feature a porous outer shell encasing an intricate nest of micro- and nano- fibers and microspheres. The nonporous microspheres are made entirely of boron-based bioactive glass and feature essential metallic ions such as zinc, copper, magnesium, and potassium. The highly biocompatible type 1 collagen5 serves as a carrier for the bioactive glass components.~FIBERGRAFT Aeridyan Matrix is designed to have an adequate structural integrity for its application as a bone graft substitute material, while optimizing radiopacity and resorption."
224053286|NCT07059065|DEVICE|Demineralized Bone Matrix|Demineralized Bone Matrix is to be used with bone marrow aspirate and mixed with autograft bone in accordance with approved indications per the IFU
224053287|NCT03084523|DRUG|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
224053288|NCT06757712|OTHER|non linear periodization exercise|The non-linear periodized resistance training program follows a 12-week schedule with varying intensity levels across three training days per week. The intensity fluctuates between very light (VL), light (L), moderate (M), heavy (H), and very heavy (VH) workouts, distributed strategically throughout the week. Each training day implements different intensity levels, and an active rest day follows any workout session.
224053289|NCT06757712|OTHER|linear periodization exercise|The linear periodization exercise program spans 12 weeks with systematically varied training parameters. During weeks 1-2, participants perform 3 sets of 10 repetitions, followed by 3 sets of 8 repetitions in weeks 3-4. The program progresses to 4 sets of 6 repetitions in weeks 5-6, then 3 sets of 6 repetitions during weeks 7-8. The final phases consist of 4 sets of 4 repetitions in weeks 9-10, concluding with 3 sets of 4 repetitions in weeks 11-12. Training loads advance through autoregulatory progression, where participants progress at their individual pace under supervision. While sets and repetitions remain fixed within each phase, load progression is determined by performance in the final set of each exercise, ensuring safe and effective advancement.
224053290|NCT06757712|DRUG|medical treatment|The medical treatment will be received for 12 weeks.
224053291|NCT05907304|DRUG|Naporafenib|Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
223442068|NCT01869569|DRUG|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
223442069|NCT01869569|DRUG|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
223442070|NCT02147067|DRUG|Ranolazine|Ranolazine 1,000 mg twice daily
223442071|NCT02147067|DRUG|Placebo|Placebo
223442072|NCT03737630|DEVICE|Inspiratory muscle training|This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
223442073|NCT00146666|DEVICE|Intermittent compression|
223442074|NCT05484596|PROCEDURE|Measuring VA Coupling|Subjects will undergo clinically indicated investigations and tests. The research part of the study is measuring the VA coupling using high fidelity catheters. That is expected to increase the duration of the cardiac catheterization for 30 minutes.
223566849|NCT04734418|DRUG|Remifentanil|Intravenous pump injection.The initial dose of remifentanil is 0.05 μg/kg/min.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of remifentanil is 0.12 μg/kg/min
224053292|NCT05907304|DRUG|Trametinib|Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
223442075|NCT01768221|BEHAVIORAL|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
223442076|NCT05397340|DEVICE|Deep brain stimulation|active DBS with optimal stimulating parameters
223442077|NCT01179789|BEHAVIORAL|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
223442078|NCT01179789|DIETARY_SUPPLEMENT|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
223442079|NCT01179789|DIETARY_SUPPLEMENT|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
223442080|NCT01179789|DIETARY_SUPPLEMENT|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
223442081|NCT03462992|DIAGNOSTIC_TEST|MonoMark|MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
223442082|NCT05476640|GENETIC|NGS|In the Nation multicenter screening cohort, NGS testing was performed on the basis of conventional NBS to study the relationship between gene variation and disease occurrence;
224053293|NCT05238116|DRUG|PC945|Sterile aqueous liquid for Nebulization
223442083|NCT00346567|DRUG|Zidovudine and Lamivudine (Combivir)|
223442084|NCT00346567|DRUG|Emtricitabine and Tenofovir (Truvada)|
224053294|NCT05238116|DRUG|Placebo|Sterile aqueous liquid for Nebulization
224053295|NCT05645523|DRUG|Indocyanine Green|Given in to the vein (IV)
224053296|NCT07071324|BEHAVIORAL|CF Wellness Program|Intervention modules are 1) Introduction \& Fatigue Explained, 2) Finding Balance between Activity \& Rest, 3) Physical Activity, Self-Review \& Planning, 4) Improving Your Sleep, 5) Managing Emotions, 6) Changing Less Helpful Thoughts, 7) Learning to Relax \& Manage Stress, and 8) Accessing Social Support and Preparing for the Future.
223442085|NCT06171568|OTHER|Tests and questionnaires|"1 year after discharge from neurosurgery department, included patients will answer to the:~* Modified Rankin Scale;~* Instrumental Activities of Daily Living (IADL) questionnaire;~* Montreal Cognitive Assessment (MoCA);~* Frontal assessment battery (BREF);~* Rivermead questionnaire;~* Short Form (36) Health Survey (SF-36)~* Community Integration Questionnaire - Revised (CIQ-R)~* Posttraumatic stress disorder CheckList (PCL-5)"
223442086|NCT06014125|OTHER|psychoeducative program|"The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent."
224053297|NCT07078682|DIETARY_SUPPLEMENT|Elix Daily Harmony|"Each morning, 1-2 hours after their first meal, they will mix the following into room-temperature or warm water and consume:~Elix Daily Harmony: 3 droppers full (approximately 2.5 mL) Elix Cycle Balance: 6 droppers full (approximately 5.0 mL)"
224053298|NCT07072910|DRUG|Cabergoline 0.5 MG|Participants will receive cabergoline 0.5 mg as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. Participants who received cabergoline 0.5 mg during the double-blind phase will continue with the same 0.5 mg dose in the open-label phase.
224053299|NCT07072910|DRUG|Placebo|Participants will receive placebo as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. In the open-label phase, these participants will transition to active cabergoline treatment, receiving either 0.5 mg or 1.0 mg once weekly, depending on their randomized allocation at the start of the open-label phase. The placebo tablets will be formulated to match the cabergoline tablets in size, shape, and color, and should be taken under the same conditions.
224053300|NCT07072910|DRUG|Cabergoline 1 MG|Participants will receive cabergoline 1.0 mg as oral tablets, taken once weekly as an add-on treatment for 12 weeks during the double-blind treatment phase. Participants who received cabergoline 1.0 mg during the double-blind phase will continue with the same 1.0 mg dose in the open-label phase.
224053301|NCT07079904|OTHER|Ultrasound Guided Peripheral Vein Catheterization With or Without Laser-Assisted.|In group T, ultrasound-guided peripheral vein cannulation was performed using dynamic needle tip positioning technique. In group L, ultrasound-guided peripheral vein cannulation was performed using dynamic needle tip positioning technique with laser-assisted.
224053302|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given subcutaneously (dose level 1 )
224053303|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given subcutaneously (dose level 2 )
224163978|NCT01503892|DIETARY_SUPPLEMENT|Metanx|Metanx- one tablet twice daily for twelve months
224053304|NCT07078695|DRUG|SHR-1139 Injection|Single dose of SHR-1139 given intravenously (dose level 3)
224053305|NCT06754462|DRUG|IMVT-1402|Administered once weekly by subcutaneous injection.
224163979|NCT01503892|DRUG|Placebo|Placebo- one tablet twice daily for twelve months.
223442087|NCT02603107|DRUG|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
223442088|NCT02603107|DRUG|ATV|300 mg capsule administered orally once daily with food
223442089|NCT02603107|DRUG|DRV|800 mg tablet administered orally once daily with food
224163980|NCT02090673|DRUG|Exenatide|
223442090|NCT02603107|DRUG|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
223442091|NCT02603107|DRUG|ATV/co|300/150 mg FDC tablet administered orally once daily with food
223442092|NCT02603107|DRUG|DRV/co|800/150 mg FDC tablet administered orally once daily with food
223442093|NCT02603107|DRUG|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
223442094|NCT02603107|DRUG|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
224053306|NCT06754462|DRUG|Placebo|Administered once weekly by subcutaneous injection.
224053307|NCT05753345|BEHAVIORAL|Aquatic therapy|Children receive aquatic occupational therapy twice a week for 10 weeks. 30 minutes of aquatic therapy in a warm water pool to increase upper extremity function and swim skills; 15 minutes of self care training to increase independence with dressing and showering.
224053308|NCT05629546|BIOLOGICAL|Cytokine-induced memory-like natural killer cells|Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
224053309|NCT05629546|BIOLOGICAL|Relatilmab|Standard of care
224053310|NCT05629546|BIOLOGICAL|Nivolumab|Standard of care
224053311|NCT07138807|BEHAVIORAL|Muscle Energy Technique|Participants in this group received Muscle Energy Techniques targeting the upper trapezius trigger points. Treatment was provided 3 sessions per week for 4 weeks. Each session included post-isometric relaxation techniques with stretching, along with baseline TENS therapy.Participants performed Neck Calliet Exercises focusing on cervical flexion, extension, rotation, and lateral flexion. Exercises were done under supervision, 3 times per week for 4 weeks. All participants also received baseline TENS therapy.
223442095|NCT02603107|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
224053312|NCT07138807|OTHER|Neck Calliet exercise|Neck Calliet exercise
224053313|NCT07143578|DEVICE|Operative hysteroscopy using tissue removal device|Operative hysteroscopy using tissue removal device
224053314|NCT07143578|DEVICE|suction curettage|suction curettage using plastic scution curette
224053315|NCT07140211|DRUG|Low-dose low-molecular-weight heparin|"Low-molecular-weight heparin given for 7-10 days after delivery:~* enoxaparin 4000-6000IU o.d.~* nadroparin 3800-5700IU o.d.~* dalteparin 5000-7500IU o.d.~* tinzaparin 4500-7000IU o.d."
224053316|NCT07171385|OTHER|Nordic Hamstring Curl (NHC)|Knee-dominant eccentric hamstring strengthening exercise performed on a padded surface. Participants control the descent of the torso while knees remain fixed, emphasizing eccentric activation of hamstring muscles.
224053317|NCT07171385|OTHER|Kettlebell Swing (KS)|Hip-dominant ballistic movement involving rapid hip flexion-extension using a kettlebell (16-20 kg depending on participant's ability). Each repetition includes concentric, isometric, and eccentric phases standardized by metronome pacing.
224053318|NCT07171385|OTHER|Supine Sliding Single-Leg Curl (SSLC)|Closed-chain exercise performed in supine position with heels placed on sliding discs. One leg is extended while the other leg performs concentric-eccentric sliding curl.
224053319|NCT07171034|DRUG|KLA318-2 Nanocrystal Injection|Intravenous injection, single dose
224053320|NCT07171034|DRUG|Celebrex Capsule|P.O., single dose
224053321|NCT07171671|OTHER|exercises|manuel therapy and exercises
224053322|NCT07171008|OTHER|Ney music|Ney music concert
224053323|NCT07170657|BEHAVIORAL|Peer Support Services Recovery|A program of mental health recovery through one-on-one and small group meetings with a PSS and TP using RES for individuals recently discharged from an acute care psychiatric facility.
224053324|NCT07169799|OTHER|trūFreeze® Spray Cryotherapy System (STERIS Endoscopy)|This treatment consists of performing a diagnostic EGD to identify GAVE lesions. A catheter advances through the therapeutic channel to treat target areas with cryotherapy.
224053325|NCT06156683|OTHER|Multiple sclerosis disease modifying drug|There is no treatment allocation. Women with multiple sclerosis with a recorded pregnancy outcome during the inclusion period will be recruited.
224053326|NCT01593293|DRUG|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
224053327|NCT01593293|DRUG|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
224053328|NCT01781715|DEVICE|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
224053329|NCT04058340|DIETARY_SUPPLEMENT|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
224053330|NCT04058340|OTHER|Placebo|0.9% NaCl solution in nebulization
224053331|NCT04225130|BEHAVIORAL|Written Exposure Therapy -for Suicide|The first session will consist of the therapist educating the participant about common reactions to trauma and providing information regarding the rationale of WET-S as a treatment for PTSD. The participant will then be given general instructions for completing the trauma narratives, specific instructions for completing the first session, and will then complete the first (30 minutes) narrative writing session. Participants will be instructed to write about the same trauma experience during each session. The importance of delving into their deepest emotions surrounding the trauma event is emphasized. All WET-S sessions will take place in a private room and begin with the therapist reading the specific writing instructions for that session and then leaving the instructions with the participant while 30-minute writing session is completed.
224053332|NCT04225130|BEHAVIORAL|Treatment as Usual|The TAU condition consists of daily contact and patient centered care by the acute psychiatric inpatient unit provider team (e.g., psychiatrists, therapists, case managers, behavioral health techs). TAU includes initial stabilization, nurse case management, medication management, psychoeducation groups, and discharge planning. Patients engage with the provider team daily.
224163981|NCT04333992|DRUG|propofol and remifentanil|intravenous propofol and remifentanil using target-controlled infusion (TCI) devices
224163982|NCT04333992|DRUG|sevoflurane and remifentanil|inhalator sevoflurane and remifentanil using target-controlled infusion (TCI) devices
223442096|NCT04170101|PROCEDURE|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC \< 3
223442097|NCT04170101|PROCEDURE|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
223442098|NCT02001272|DRUG|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
223442099|NCT02001272|DRUG|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
223442100|NCT02001272|DRUG|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
223442101|NCT00812500|OTHER|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
223442102|NCT00812500|OTHER|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
223442103|NCT00812500|OTHER|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
223442104|NCT05180981|DEVICE|Transcutaneous vagal nerve stimulation|Noninvasive stimulation vs sham stimulation will be delivered via an auricular device.
223442105|NCT05180981|BEHAVIORAL|Breathing task|Participants will be asked to breathe in specific patterns.
223442106|NCT00537355|BIOLOGICAL|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
224053333|NCT01739985|DRUG|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
224053334|NCT01739985|DRUG|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
224053335|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 1|Probiotic mixture with maltodextrin as a carrier.
224053336|NCT04305522|DIETARY_SUPPLEMENT|Placebo|Placebo comparator with maltodextrin as a carrier.
224053337|NCT04305522|DIETARY_SUPPLEMENT|Probiotic 2|Probiotic mixture with maltodextrin as a carrier.
224053338|NCT04419610|BIOLOGICAL|TRV027|peptide for infusion
224300636|NCT06189118|BEHAVIORAL|Online Mindfulness Based Cognitive Therapy or Health Education Program|12 hours of online group training of Mindfulness Based Cognitive Therapy OR 12 hours of online group training of Health Education Program will be provided via teleconferencing. Additional both groups will perform daily home practice.
224300637|NCT06570928|OTHER|Cannabis|0,2 ml of CBD:THC (50 mg:5 mg)
224300638|NCT06570928|OTHER|Placebo|Product vehicle, medium chain triglycerides (MCT)
224300639|NCT05870800|DRUG|Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2|Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)
224300640|NCT05870800|DRUG|Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)
224300641|NCT05870800|DRUG|Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2|After Surgery, if patients are still considered at high risk (per treating investigator) subjects will be eligible to receive adjuvant chemotherapy with mFOLFOX6 Q2 weeks x 6 cycles (12 weeks) or CAPOX Q3 weeks x 4 cycles (12 weeks)
223442107|NCT00537355|DRUG|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
223442108|NCT01000181|OTHER|PET-CT with CuATSM|PET-CT with CuATSM
223442109|NCT00013923|DRUG|Nutritional Supplement|
223442110|NCT01956864|DRUG|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
223442111|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for two weeks|nutritional intervention received two weeks before surgical intervention
223442112|NCT02475759|DIETARY_SUPPLEMENT|Nutritional perioperative prehabilitation program for one week|nutritional intervention received one weeks before surgical intervention
223442113|NCT02565199|DEVICE|rTMS over Premotor Cortex (Contralateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
224053339|NCT04419610|OTHER|sodium chloride 0.9%|placebo comparator for infusion
224053340|NCT01524198|DRUG|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
224053341|NCT01524198|DRUG|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
224053342|NCT01439282|DRUG|eribulin mesylate|Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
224053343|NCT01439282|DRUG|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
224053344|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
224053345|NCT02232802|DRUG|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
224053346|NCT00350948|DRUG|Telcyta|Day 1 of 28 day Cycle.
223442114|NCT02565199|DEVICE|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
223442115|NCT02565199|DEVICE|rTMS (Control 1)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 400 milliseconds after the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
223442116|NCT02565199|DEVICE|rTMS (Control 2)|"* Location of rTMS: somatosensory cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator"
223442117|NCT02565199|DEVICE|rTMS (Control 3)|"* Location of rTMS: premotor cortex~* Frequency of rTMS: 0.1 Hz~* Time of rTMS: 50 milliseconds before the onset of movement-related EMG~* Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
223442118|NCT02565199|OTHER|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
223442119|NCT01404949|DRUG|Tretinoin and Arsenic Trioxide|See Detailed Description
223442120|NCT01180023|PROCEDURE|Sweeping|Sweeping of membranes during digital exam
223442121|NCT03129295|DRUG|MPC-SHRC|Oral tablet four times a day for 3 days
223442122|NCT03129295|DRUG|Placebo Oral Tablet|Oral tablet four times a day for 3 days
223566850|NCT04734418|DRUG|Dexmedetomidine|Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
223566851|NCT00798460|DRUG|adefovir|adefovir 10mg
224053347|NCT00350948|DRUG|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
224053348|NCT03592706|BIOLOGICAL|IKC (Immune Killer Cells)|
224053349|NCT03592706|PROCEDURE|TACE (Transcatheter Arterial Chemoembolization)|
223442123|NCT05718141|OTHER|COMET-GB|"Online self-guided single session intervention - comprised of 4 modules based on the core principles of CBT, combined with principles from positive psychology. Each module includes short reading exercises, informational videos, and writing exercises.~* Cognitive Restructuring (labelled Flexible Thinking)~* Behavioural Activation (labelled Positive Activities)~* Gratitude~* Self-Compassion~The initial intervention modules and assessment will take participants approximately 60-75 minutes to complete (15-20 minutes for the assessment measures only)."
223566852|NCT00798460|DRUG|clevudine|clevudine 30mg
223566853|NCT00798460|DRUG|lamivudine|lamivudine 100mg
224053350|NCT00751777|BIOLOGICAL|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
224053351|NCT00751777|BIOLOGICAL|Placebo|Travelers' Diarrhea Vaccine System
223442124|NCT02826252|DRUG|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
223442125|NCT02826252|DEVICE|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
223442126|NCT01325571|DRUG|Tacrolimus capsule|oral
223442127|NCT01325571|DRUG|Placebo|oral
223442128|NCT05614583|DEVICE|MORT-PFPS app|The MORT-PFPS, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioural therapy for patients with patellofemoral pain syndrome.
223566854|NCT04027049|DEVICE|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
223566855|NCT02748668|OTHER|Blood specimen collection|
223566856|NCT06910761|PROCEDURE|Biospecimen Collection|Undergo blood and CSF sample collection
223566857|NCT06910761|RADIATION|Craniospinal Irradiation|Undergo photon-VMAT-CSI
223566858|NCT06910761|OTHER|Electronic Health Record Review|Ancillary studies
223566859|NCT06910761|PROCEDURE|Lumbar Puncture|Undergo LP
223566860|NCT06910761|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223566861|NCT06910761|PROCEDURE|Ommaya Reservoir Tap|Undergo Ommaya reservoir tap
223566862|NCT06910761|OTHER|Questionnaire Administration|Ancillary studies
223566863|NCT06910761|RADIATION|Volume Modulated Arc Therapy|Undergo photon-VMAT-CSI
223566864|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Premeal Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for daily water intake timing and volume.
223566865|NCT05843318|BEHAVIORAL|Water intake and weight control in older adults - Total Daily Water + hypocaloric diet|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive specific instructions for total daily water intake.
224053352|NCT03380260|BEHAVIORAL|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
224053353|NCT00634634|DRUG|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
224053354|NCT00634634|DRUG|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
224053355|NCT03775954|DIAGNOSTIC_TEST|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
223442129|NCT05614583|OTHER|treatment as usual (TAU)|In the control group, psychoeducation is delivered and self-exercise is recommended.
223442130|NCT05606770|BEHAVIORAL|Structured Exercise|Participants assigned to Structured Exercise will be provided with twice weekly strengthening exercise classes, delivered through the digital platform. The exercise classes will follow a circuit class style, in order to target a moderate-vigorous exercise intensity. Classes will gradually progress in intensity throughout the program. Classes will include a full body warm up followed by a circuit of eight strengthening exercises. This will be repeated for increasing sets and adding resistance through the use of resistance bands . Exercises will involve simple full body exercises and movements for each major muscle group. This will ensure that exercises that can be completed regardless of possible unilateral weakness or physical impairment. During each session, participants will be reminded to reach their targeted weekly step count goals. The structured exercise component is informed by international clinical guidelines (Kleindorfer et al 2021 and Billinger et al 2021).
223442131|NCT05606770|BEHAVIORAL|Lifestyle Physical Activity|The Lifestyle PA component was developed using the Behaviour Change Wheel (BCW) Guide to Designing Interventions and is underpinned by the COM-B model of behavior change (Michie et al., 2014). This posits that people need capability(C), opportunity(O), and motivation(M) to perform a behavior(B). The aim of the Lifestyle PA component is to increase the capability, opportunity, and motivation of participants to reach their daily step count goals. To achieve this the 3 stages of the BCW intervention design process were followed. The first stage, understanding the behaviour, is done through a review of the literature and primary qualitative research(Cardy et al., 2022). This stage identifies the change objectives of the intervention. Stage 2 requires the selection of intervention functions and the policies that would support them. The final stage is defining the content of the intervention using behaviour change techniques (BCTs) and selecting their mode of delivery.
223442132|NCT03057067|PROCEDURE|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
223442133|NCT01170819|DEVICE|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
223442134|NCT01170819|DRUG|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
223442135|NCT05332717|DIETARY_SUPPLEMENT|Melatonin 5 mg|Participants will be taking one 5 mg tablet of Melatonin 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
223442136|NCT05332717|DIETARY_SUPPLEMENT|Placebo (Vitamin C)|Participants will be taking one placebo tablet 30 minutes before bedtime nightly, for 6 weeks following their knee replacement surgeries.
223442137|NCT04862832|OTHER|Music intervention|"The cold pressor test will consist in the immersion of the participants' arm in 10 degrees circulating water for two minutes.~The music sequences will be all 20 minutes, instrumental, professionally recorded in the studio and composed specifically for the Music Care application and are thus unfamiliar to participants. There will be two music conditions: the most-liked-music (MLM) and least-liked-music (LLM) conditions."
223442138|NCT05410704|OTHER|exercises|Pelvic floor muscle exercises and diaphragmatic breathing exercise
223442139|NCT02634944|DIAGNOSTIC_TEST|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
223442140|NCT00004794|DRUG|cidofovir|
223442141|NCT01841801|DEVICE|Thermal Adhesive Patch|
224053356|NCT02715375|DEVICE|CREON2000A|
224053357|NCT01973777|DEVICE|IUB|intrauterine contraceptive device
224053358|NCT04870242|OTHER|Observational study, non-interventional|observational study for the ERAS protocols in pediatric surgery
223442142|NCT01841801|DEVICE|Marketed Thermal Adhesive Patch|
224053359|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
224053360|NCT01199029|DRUG|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
224053361|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
224053362|NCT01199029|DRUG|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
224053363|NCT01199029|DRUG|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
224053364|NCT01199029|DRUG|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
224053365|NCT01199029|DRUG|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
224053366|NCT00885703|DRUG|Fluconazole|"Step 1: \[For participants randomized to Fluconazole\] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: \[For participants randomized to Ampho B only\] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
224053367|NCT00885703|DRUG|Amphotericin B|Step 1: \[For participants randomized to Ampho B\] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
224053368|NCT00675922|DRUG|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
224053369|NCT00689468|PROCEDURE|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
223442143|NCT01841801|DEVICE|Placebo Patch|
223442144|NCT03668522|OTHER|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
223442145|NCT00814541|DRUG|Bortezomib|
223442146|NCT00814541|DRUG|Doxorubicin|
224053370|NCT00689468|DIETARY_SUPPLEMENT|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
223442147|NCT00814541|DRUG|Dexamethasone|
224053371|NCT00689468|PROCEDURE|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
224053372|NCT00689468|DIETARY_SUPPLEMENT|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
224053373|NCT01183143|DRUG|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
224053374|NCT02834221|DEVICE|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
224053375|NCT02834221|OTHER|Anatomical landmark guided puncture|Anatomical landmark puncture
224145382|NCT05930990|BEHAVIORAL|Mamas in Harmony|Mothers attend 8x 1 hour weekly classes with their infant. Classes take place in a community venue. Mothers sit with their infant on the floor in circle formation on cushioned mats. Group singing facilitated for 40 minutes by the intervention facilitator, a professional musician/choir leader. A mix of songs are introduced that are easy to learn without the need for lyric sheets. Mothers will be encouraged to sing along. Mothers will be encouraged to interact with their infant through various sensory stimuli involving touch, sound and visual. The end of each singing session involves a short period of quiet time, soothing sounds are provided by the intervention facilitator using voice and instruments. 20 minutes of facilitated social support will follow and mothers will be provided with refreshments. Mothers will be encouraged to interact with other mothers to promote social connection.
224145383|NCT03285906|DRUG|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
224145384|NCT00685529|DRUG|Racemic formoterol|12 µg of racemic formoterol fumarate BID
224145385|NCT00685529|DRUG|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
224053376|NCT03045770|DRUG|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
224053377|NCT03045770|DRUG|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
224053378|NCT03045770|DRUG|Irinotecan|Irinotecan was used as first line treatment with AGC.
224053379|NCT03045770|DRUG|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
224053380|NCT03045770|DRUG|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
224145386|NCT00685529|DRUG|Racemic formoterol|24 µg of racemic formoterol fumarate BID
224145387|NCT02855450|DRUG|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
224145388|NCT02855450|DRUG|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
224053381|NCT01502709|DEVICE|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
224053382|NCT01502709|DEVICE|placebo|Matching placebo device
224145389|NCT03383978|BIOLOGICAL|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
224145390|NCT03383978|DRUG|Ezabenlimab|Intravenous infusion of Ezabenlimab 240mg q 3 weeks
224145391|NCT00899210|OTHER|laboratory biomarker analysis|
224145392|NCT00899210|PROCEDURE|cryosurgery|
224145393|NCT00899210|PROCEDURE|radiofrequency ablation|
224145394|NCT00899210|PROCEDURE|therapeutic conventional surgery|
224145395|NCT02881710|OTHER|contrast product used to assess biomarkers variations|
224145396|NCT04402853|DIAGNOSTIC_TEST|Tears swab|rtPCR on tears swabs samples
224145397|NCT05767710|BEHAVIORAL|AI telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
224163983|NCT06059833|DIAGNOSTIC_TEST|Magnesium|The aim of the study is to evaluate serum Mg level in type 2 DM patients.
224163984|NCT01378845|DRUG|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
224163985|NCT01378845|DRUG|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
224163986|NCT05944445|DRUG|Linezolid 600 mg|Linezolid 600mg injection
224163987|NCT01602744|OTHER|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
224163988|NCT05455840|DEVICE|Da Vinci SP surgical platform|using Da Vinci SP platform in thymothymectomy or extended thymectomy
224163989|NCT03148184|DIAGNOSTIC_TEST|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
224163990|NCT02363855|DRUG|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
224163991|NCT00940849|DIETARY_SUPPLEMENT|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
224163992|NCT00940849|DIETARY_SUPPLEMENT|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
224163993|NCT03491280|GENETIC|NGS Diagnostic|Blood take for genetic diagnostic.
224163994|NCT01751360|DRUG|SYR-472|
224163995|NCT03418376|DIETARY_SUPPLEMENT|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
223442148|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
223442149|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
223442150|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
223442151|NCT00700050|DRUG|Hypertonic saline|Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
223442152|NCT04933864|DRUG|Methylene Blue and Photodynamic Therapy|"Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm\^2 energy dose.~For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm\^2 energy dose were performed."
223442153|NCT00460356|OTHER|Laboratory Biomarker Analysis|Correlative studies
223442154|NCT00460356|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
223442155|NCT01621828|OTHER|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
223442156|NCT01621828|OTHER|leaflet|a written leaflet, about the operating room experience and environment.
223442157|NCT01872650|DEVICE|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
223442158|NCT05041660|OTHER|Virtual-reality-based training|Uses virtual reality for the inhibitory control training, rather than a relatively simplistic computerized training.
223442159|NCT05041660|OTHER|Inhibitory Control Training|"Uses an active inhibitory control training which includes a stop signal."
223442160|NCT05041660|OTHER|Sham Inhibitory Control Training|"Uses an inhibitory control training which does not include a stop signal."
223442161|NCT05041660|OTHER|Computerized training|Uses a relatively simplistic computerized training.
223442162|NCT03411902|DRUG|Risedronate Sodium 150 MG|Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
223442163|NCT03411902|OTHER|Placebo|Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
223442164|NCT02256306|OTHER|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
223442165|NCT01464853|OTHER|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
223442166|NCT01464853|OTHER|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
223442167|NCT00190658|DRUG|Somatropin (rDNA origin) for injection|
223442168|NCT01699308|DRUG|Genotropin|
223442169|NCT02205294|OTHER|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
223442170|NCT00618852|DRUG|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
223442171|NCT00618852|DRUG|Saline|1 mg/kg by intravenous bolus injection
224053383|NCT03638154|PROCEDURE|GF+GMSCs carried on β TCP|"surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen"
223442172|NCT03147807|DEVICE|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
223442173|NCT06265571|OTHER|perineural injection|perineural injection of local anesthestetic for postoperative pain management
223442174|NCT02945111|BEHAVIORAL|Real-time view|
223442175|NCT02945111|BEHAVIORAL|No visual support|
223442176|NCT02774187|DRUG|Sorafenib|administration of Sorafenib
224053384|NCT03638154|PROCEDURE|β TCP bone substitute only|surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
224053385|NCT00001764|DRUG|Mycophenolate Mofetil|
223442177|NCT02774187|PROCEDURE|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
223442178|NCT02774187|DRUG|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
223442179|NCT05326256|OTHER|Exercise training- PSSE|Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises
223442180|NCT05326256|OTHER|Exercise training- PSSE with vestibular exercises|Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
223442181|NCT01634568|DRUG|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
224145398|NCT05767710|BEHAVIORAL|general telerehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
223442182|NCT00003703|DRUG|SarCNU|
223442183|NCT05891106|DEVICE|Lotrafilcon A contact lenses|CE-marked silicone hydrogel contact lenses
223442184|NCT02206737|DEVICE|No nicotine e-cigarette|
223442185|NCT02206737|DEVICE|Low dose nicotine e-cigarette|
223442186|NCT02206737|DEVICE|High dose nicotine e-cigarette|
223442187|NCT00419159|DRUG|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
223442188|NCT01981070|BEHAVIORAL|Mindfulness Intervention for Parents|See Study Arms
223442189|NCT01981070|BEHAVIORAL|Support and Information for Parents|See Study Arms
223442190|NCT00093977|DRUG|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
223442191|NCT01017601|BIOLOGICAL|Seneca Valley virus-001|Given IV
223442192|NCT01017601|OTHER|placebo|Given IV
223566866|NCT05843318|BEHAVIORAL|Water Intake and weight control in older adults - hypocaloric diet alone|Individuals will be randomly assigned to one of three groups. All individuals will receive counseling in a structured hypocaloric meal plan (1200-1500 kcal) that is consistent with a healthy dietary pattern as described by the Dietary Guidelines for Americans. This group will receive instructions in the hypocaloric diet, without specific fluid intake recommendations.
223566867|NCT06943807|DIAGNOSTIC_TEST|Fecal sample methylation detection for gastric cancer|Detection of gastric cancer-associated methylation sites in fecal samples
223566868|NCT04910074|DEVICE|Low-level laser therapy|The proposed LLLT protocol will use the Biolase Epic X, an InGaAsP diode laser (940nm) using the pain relief handpiece, a device which has received FDA approval (GUDID 00647529002537) for the treatment of pain, muscle relaxation and healing via increased local circulation. The LLLT will be administered to the experimental group at 30 j/cm2. The laser will be applied extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
223566869|NCT04910074|DEVICE|Dummy LLLT|The Biolase Epic X with pain relief handpiece will be applied with no power extraorally, on the skin overlying the mandible. Application will be for 40 seconds per side, with 10 seconds administered in four places along the jawline, 1 cm apart starting from the gonial angle.
223442193|NCT05005767|PROCEDURE|scaling and root planing|will receive scaling and root planing only
223442194|NCT05005767|PROCEDURE|Frankincense extract gel natural herbal product|will receive Scaling and root planing then. Subgingival application of Frankincense extract gel
223442195|NCT05919355|OTHER|Offer to try Komp|The participants are offered services using the communication solution Komp. If they accept, they will receive one unit at home.
223442196|NCT00274378|DEVICE|ALLOMATRIX injectable putty in distal radius fractures|
223442197|NCT06081491|DIAGNOSTIC_TEST|diagnosis|Pediatric patients within the inclusion criteria will be diagnosed for MIH by the primary investigator and the questionnaire will be filled with face to face interviews with their parents
223442198|NCT06320158|OTHER|clinical evaluation of sarcopenic obesity|completion of scales and questionnaires, venous blood sampling, muscle ultrasound scan
223566870|NCT05176197|OTHER|Almond|Participants will consume almonds every day for 16 weeks.
223566871|NCT05176197|OTHER|Control|Participants will consume pretzels every day for 16 weeks.
223566872|NCT06518317|DRUG|Aspirin|Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
223566873|NCT00349180|DRUG|Enoxaparin sodium|
223442199|NCT03362801|DIAGNOSTIC_TEST|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
223442200|NCT02126124|DEVICE|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
223442201|NCT02126124|DEVICE|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
223442202|NCT00146900|PROCEDURE|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
223442203|NCT00146900|PROCEDURE|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
223442204|NCT00146900|DRUG|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
223442205|NCT00146900|OTHER|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
223442206|NCT01292343|OTHER|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
223442207|NCT01292343|OTHER|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
223442208|NCT04612972|BIOLOGICAL|Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo|This clinical trial is conducted in randomized, blind, placebo controlled design Total sample size is 12 000, which are randomly allocated into investigational vaccine 1, investigational vaccine 2 and placebo control group.
223442209|NCT05571176|DRUG|S-ketamine|S-ketamine infusion 0.29 mg/kg/h for 4 hours
223442210|NCT02503072|BEHAVIORAL|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
223442211|NCT02503072|BEHAVIORAL|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
223442212|NCT01240395|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
224053386|NCT04096274|BEHAVIORAL|Leadership for Organization Change and Implementation (LOCI)|LOCI is a multicomponent implementation strategy that engages organizational executives and first-level leaders (i.e., those who administratively supervise clinicians) to build an organizational climate to support the implementation of a focal evidence-based practice (EBP) with fidelity. In this study, the focal EBP is the OQ-A system. LOCI includes two overarching components: (1) monthly organizational strategy meetings between executives and LOCI consultants/trainers to develop and embed policies, procedures, and practices that support implementation of a focal EBP, and (2) training and coaching for first-level leaders, to develop their skills in leading implementation. The aim of these components is to develop an organizational implementation climate in which clinicians' perceive that use of the OQ-A with high fidelity is expected, supported, and rewarded.
224053387|NCT04096274|BEHAVIORAL|Training and Technical Assistance Only|"All leaders and clinicians in participating clinics will receive standardized OQ-A training and technical assistance provided by the OQ-A purveyor organization. This includes an initial, 6-hr, in-person OQ-A training; two, live, virtual, 1-hr booster trainings, offered 3 and 5 months after the initial training; and, year-round technical assistance from the OQ-A purveyor organization. Technical assistance includes virtual training sessions, online library of training videos, and customer care representative for technical support.~In addition, to encourage participation in the study, a set of four 1-hr, web-based general leadership seminars will be offered to leaders in the control condition. These will cover topics ranging from effective leadership, to giving effective feedback."
224053388|NCT05023356|DEVICE|Non-contact vital signs monitoring with camera|Monitor patients face image by non-contact vital signs monitoring with camera
224053389|NCT02756728|BIOLOGICAL|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
224053390|NCT02756728|OTHER|High dose melphalan|High dose melphalan (HDM)
224053391|NCT02756728|OTHER|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
224053392|NCT04739514|OTHER|Exercises for dysphagia rehabilitation|Diet modifications, postural exercises, compensatory exercises, swallowing exercises
224053393|NCT03724071|BIOLOGICAL|TG6002|"Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
224053394|NCT03724071|DRUG|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms."
223566874|NCT05516030|OTHER|HIFT for people with MRD|12-wk, 3x/week HIFT participation for individuals with MRD
223566875|NCT02264665|DRUG|sunitinib|sunitinib 37.5mg/d orally
223566876|NCT02264665|DRUG|everolimus|everolimus 10mg/d orally
223442213|NCT01587625|DRUG|Oxytocin|
223442214|NCT00944307|DRUG|raltegravir|raltegravir 400mg orally once
223442215|NCT00944307|DRUG|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
223566877|NCT02264665|DRUG|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
223442216|NCT03827551|BEHAVIORAL|Delivery of oral hygiene advices|Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
223566878|NCT03429673|PROCEDURE|Surgeries|Lobectomy or segment/wedge dissection
223566879|NCT05297487|DEVICE|early use of intermittent positive pressure breathing|standard care associated with daily and early use of intermittent positive pressure breathing
223566880|NCT03691818|DRUG|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
223442217|NCT04336813|OTHER|Audience Response system|In the lecture hall, G1 was separated from G2, and both groups completed an assessment of written multiple-choice questions (MCQs) scored out of 20, before the lecture. During L1, phone based (ARS) questions (PB-ARS) secretly displayed on the smart phones of the students in G1, and they were allowed to read the question and answer it, while those in parallel arm of the trial (G2) were blinded to those questions and answers. At the end of L1, both groups completed the same written MCQs assessment
223442218|NCT06621199|DRUG|Mitoxantrone hydrochloride liposome|Mitoxantrone hydrochloride liposome 24 mg/m\^2 on day 1, every 4 weeks
223442219|NCT06621199|DRUG|Cytarabine|Cytarabine 100 mg/m\^2 on day 1-5, every 4 weeks
224053395|NCT04584528|OTHER|Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)|"The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:~* Genotype~* Individual pain plan-preferred analgesic agent, route, dose and dosing interval, last update time~* Name and contact information for the SCD provider~If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits."
224053396|NCT02270619|BIOLOGICAL|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
224053397|NCT02270619|BEHAVIORAL|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
224053398|NCT02270619|OTHER|Placebo|0.9% saline as IV bolus
224053399|NCT02270619|OTHER|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
224053400|NCT01365260|DEVICE|MM-II|Single intraarticular (knee) injection of MM-II
224053401|NCT01365260|DEVICE|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
224053402|NCT02726087|PROCEDURE|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
224053403|NCT02726087|PROCEDURE|Full sternotomy|Conventional full median sternotomy
224053404|NCT00959036|DRUG|ATN-103|10 mg every 4 weeks until week 12
224053405|NCT00959036|DRUG|ATN-103|10 mg every 8 weeks until week 12
224053406|NCT00959036|DRUG|ATN-103|30 mg every 4 weeks until week 12
224053407|NCT00959036|DRUG|ATN-103|80 mg every 4 weeks until week 12
224053408|NCT00959036|DRUG|ATN-103|80 mg every 8 weeks until week 12
224053409|NCT00959036|DRUG|Placebo|Placebo every 4 weeks
224053410|NCT00959036|DRUG|Methotrexate|
224053411|NCT04745871|DIAGNOSTIC_TEST|PSMA PET/CT|The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA or 1,8-2,2 MBq/kg of 68Ga-PSMA-11 will be performed to patient by a single intravenous injection.
224053412|NCT04617938|BEHAVIORAL|TACUNA plus Wellness Circle|TACUNA provides three virtual workshops (one hour each) that use motivational interviewing and a virtual Wellness Circle (WC). The workshops combine a 30-minute discussion of opioid, alcohol and marijuana use, and social networks with another 30 minutes focused on three different traditional practices (one per workshop). TACUNA was adapted from our three-session workshop, MICUNAY (Motivational Interviewing and Culture for Urban Native American Youth) protocol, which was developed and tested for urban AI/AN adolescents and from focus groups conducted in Year 1. For the Wellness Circle, youth will have members of their social network virtually attend these once-a-month gatherings. The WC will bring people together to celebrate health and wellness and tradition. The WC will focus on the importance of social networks in making healthy choices, and provide discussion on the role that AOD use and engagement in traditional practices among members of their social networks affect their choices.
224053413|NCT04617938|BEHAVIORAL|Opioid Education Workshop|The virtual opioid education workshop draws from prevention and education materials supplied and recommended by the National AI/AN Technology and Transfer Center, which is funded by SAMHSA. Materials are culturally relevant educational packages addressing opioid use through recorded webinars, toolkits, and other resources.
224053414|NCT06777641|OTHER|remote supervision|teacher use remote supervision to assist peer training
223442220|NCT06621199|DRUG|Venetoclax|Venetoclax 100 mg on day 2，200 mg on day 3，400 mg on day 4-10, every 4 weeks
223442221|NCT06250179|PROCEDURE|free gingiva graft surgery|For insufficient gingival height in patients, the free gingival graft taken from the palate will be sutured to the relevant area.
223442222|NCT00926640|DRUG|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
223442223|NCT00926640|DRUG|Cisplatin|6 cycles at 60mg/m2 IV on day 2
223442224|NCT00926640|DRUG|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
223442225|NCT05391945|DIAGNOSTIC_TEST|polysomnography|Patient will be assessed by home Polysomnography(PSG), one night, Pulmonary function tests, including respiratory muscle strength, and comprehensive biological assessment of thyroid function.
223442226|NCT05749068|DEVICE|CapScan intestinal sampling device|CapScan is an intestinal collection device used to characterize the regional distribution of sulfasalazine, the metabolic breakdown products of sulfasalazine, and the gut microbiota in the digestive tracts of healthy volunteers.
223442227|NCT00032721|PROCEDURE|Reiki; Subtle energy therapy|
224053415|NCT05251714|DRUG|CFI-402257|Oral once daily in 28 day cycles
224053416|NCT05251714|DRUG|Fulvestrant|500 mg given by IM injection on Day 1 and Day 15 of Cycle 1 and Day 1 of each subsequent cycle
223566881|NCT03691818|DRUG|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
223566882|NCT03691818|DRUG|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
223442228|NCT00574795|BIOLOGICAL|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
223442229|NCT06230666|RADIATION|SBRT|Stereotactic Body Radiation Therapy
223442230|NCT02870842|DEVICE|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
223442231|NCT02870842|OTHER|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
223442232|NCT02638259|DRUG|GP2015|Enbrel comparator
223442233|NCT03910530|DRUG|Retifanlimab|Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.
223442234|NCT03910530|DRUG|INCB001158|Part 1: INCB001158 75 or 100 mg twice daily administered orally.
223442235|NCT03910530|DRUG|Retifanlimab + INCB001158|Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
223442236|NCT01593280|DEVICE|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
223442237|NCT01593280|DRUG|intrathecal morphine|0.3 mg
223442238|NCT05114057|OTHER|Renal Angina Index (RAI)|Risk-stratification tool using measures of risk and presence of injury to predict Acute Kidney Injury
223442239|NCT01925157|BIOLOGICAL|LY3090106 - SQ|Administered SQ.
223442240|NCT01925157|BIOLOGICAL|LY3090106 - IV|Administered IV.
223442241|NCT01925157|BIOLOGICAL|Placebo - SQ|Administered SQ.
223442242|NCT03118791|DIETARY_SUPPLEMENT|anthocyanins|Acute intake of capsules
223442243|NCT06653101|DIETARY_SUPPLEMENT|Probiotic|The trial phase of this study lasted 8 weeks, and each patient will make 3 visits (week 0, week 4, week 8)
223442244|NCT06653101|DIETARY_SUPPLEMENT|Placebo|The trial phase of this study lasted 8 weeks, and each patient will make 3 visits (week 0, week 4, week 8)
223442245|NCT05347134|DRUG|SKB264|"SKB264 ：5 mg/kg, IV (in the vein) on day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Eribulin:1.4mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Capecitabine:1000-1250mg/m2, po,bid, from day 1 to Day 15 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Gemcitabine:800-1000 mg/m2, IV (in the vein) on day 1 and Day 8 of each 281day cycle. Number of Cycles: until progression or unacceptable toxicity develops.~Vinorelbine:25 mg/m2, IV (in the vein) on day 1 and Day 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
224053417|NCT03698942|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
224053418|NCT02715921|OTHER|Tele-exercise|
224053419|NCT04221815|DEVICE|Eagle Eye Platinum digital IVUS catheter with optional SyncVision|IVUS catheter
224053420|NCT04221815|DEVICE|Resolute Onyx Drug Eluting Stent|Stent
224053421|NCT04221815|DEVICE|Onyx Frontier Drug Eluting Stent|Stent
224053422|NCT04221815|DEVICE|Onyx TruStar Drug Eluting Stent|Stent
223442246|NCT05260775|OTHER|Evaluation test: cataract surgery steps|The development datasets were used to train the deep learning model. The validation and test group were used to optimize hyperparameters
223566883|NCT03691818|DRUG|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
223442247|NCT01550016|OTHER|Observation|Clinical follow-up and laboratory investigations.
223442248|NCT01706575|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
223442249|NCT01706575|DRUG|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
223442250|NCT01094782|OTHER|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
223442251|NCT01094782|OTHER|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
223442252|NCT03180424|DRUG|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
223442253|NCT03180424|BEHAVIORAL|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
223442254|NCT03180424|DRUG|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
223442255|NCT03180424|BEHAVIORAL|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
223566884|NCT02937857|DRUG|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
223442256|NCT01968902|BIOLOGICAL|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
223442257|NCT01968902|BIOLOGICAL|Placebo|Saline injection on the day of injection visit
223442258|NCT03738449|DRUG|CKD-387|Test drug
223442259|NCT03738449|DRUG|D484|reference drug
224053423|NCT04221815|DEVICE|Onyx TruCor Drug Eluting Stent|Stent
224053424|NCT06837129|DRUG|A single dose of 4 mg iv nalbuphine|prevention of nausea vomiting
224053425|NCT04712396|DRUG|Capivasertib|Subects will be administered single doses of capiversatib on Day 1 and Day 6.
224053426|NCT04712396|DRUG|Itraconazole|Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
224053427|NCT06959680|OTHER|Exercise and Kinesiotaping|Exercise and Kinesiotaping
224053428|NCT06959680|OTHER|Exercise|only exercise will be performed without any band treatment
223442260|NCT06619028|DEVICE|Weighted vest|During the intervention period, the participants will be exposed to an external load, by means of a weighted vest of 10% of their body weight, for a minimum of 8 hours per day for 4 weeks. In the first phase of the study, participants will be followed without changes in their lifestyle as a control. During the intervention they will be instructed to perform their usual activities with the vest, without further alterations in their lifestyle. This will be followed by a 4-week follow-up period without the use of the weighted vest.
223442261|NCT01190111|BIOLOGICAL|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
223442262|NCT06390761|PROCEDURE|Acupuncture|All acupoints were selected based on traditional Chinese medicine theory and previous articles on PD and constipation.
223442263|NCT02262156|OTHER|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
223442264|NCT02262156|DRUG|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
223442265|NCT03559803|DRUG|Cisplatin|"Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion)."
223442266|NCT02710344|BEHAVIORAL|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
223442267|NCT02918643|OTHER|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
223442268|NCT06059157|DEVICE|Advanced MRI|resting-state functional MRI, diffusion with advanced post-processing (microstructure analysis), myelin mapping
223442269|NCT05932849|DRUG|Benralizumab|Patients were initiated on benralizumab as part of routine clinical practice
223442270|NCT05854043|OTHER|Modified ERAS protocol|"Modified ERAS protocol for OLIF mainly include perioperative analgesic drug management, operation optimization in the anesthetic management, management of gastrointestinal function, and early mobilization management.~Perioperative analgesic usage:~Nonsteroidal anti-inflammatory drugs (NSAIDs) given when Visual Analogue Scale (VAS)\>3. Prehabilitation: Respiratory function exercise; walk at least 200 meters daily. Gastrointestinal function management: Oral lactulose use routinely. Sedation and analgesia: patient status index (PSI) 25-50; analgesia nociception index (ANI) 50-70. Local anesthetic: local infiltration around the psoas muscle. Postop off-bed activity: start mobilization within 24h."
223442271|NCT05854043|OTHER|routine protocol|Perioperative analgesic usage: NSAIDs given follow the patients requirement. Prehabilitation: None. Gastrointestinal function management: None. Sedation and analgesia: bispectral index (BIS) 40-60. Local anesthetic: None. Postop off-bed activity: mobilization follow the patients wish.
223442272|NCT03558841|OTHER|Gait training with the THERA-Trainer Lyra|Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
223442273|NCT03558841|OTHER|Physical therapy|Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
224053429|NCT06959680|OTHER|exercise and sham taping|exercise and sham banding (banding without tension with plaster)
224145399|NCT05767710|BEHAVIORAL|traditional rehabilitation - Tai Chi|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Tai Chi practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Tai Chi practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Tai Chi exercise in each session.
223442274|NCT05556642|OTHER|Biospecimen collection|Clinical information and biospecimens will be collected
223442275|NCT04229199|BEHAVIORAL|simulation|Dyads allocated to the IG were taken into a tour to a simulation operating room accompanied by an expert anesthesia technologist two weeks before the day of surgery. This simulation operating theater is a real operating room equipped with a surgical trolley, sealing surgical lights, anesthesia machine, vital signs monitor, stethoscope, surgical trays, surgical sink, and gas supply pendent. It was prepared with popular cartoon characters, child manikin, and face masks connected to the anesthesia circuit and re-breathing bag. After being assessed by anesthesia clinic doctors, children and their parents in the IG were given a chance to visit the simulation operating room, to receive orientation, education, and demonstration orientation about what they are going to experience in the operating room. Children were encouraged to apply vital signs monitoring, and to simulate providing mask anesthesia induction to a child manikin.
223566885|NCT02937857|DRUG|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
223566886|NCT03883919|DRUG|5-FU|-Standard of care drug
224053430|NCT02863731|OTHER|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
224053431|NCT02863731|OTHER|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
224053432|NCT04615221|OTHER|Specimens|Specimens (blood, biopsy, cervical smear, vaginal swab)
224053433|NCT00794495|DRUG|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
223442276|NCT06230952|OTHER|BASDAI and BASFI reliability|The study will be carried out on volunteer patients who are diagnosed with axial spondyloarthritis and are followed up in the outpatient clinic of Dokuz Eylül University, Department of Internal Medicine, Rheumatology and Immunology Department, and who meet the inclusion criteria. Patients who volunteer to participate in the study will be contacted by phone and BASDAI and BASFI questionaires will be administered.
224145400|NCT05767710|BEHAVIORAL|AI telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
224145401|NCT05767710|BEHAVIORAL|general telerehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
224145402|NCT05767710|BEHAVIORAL|traditional rehabilitation - Yi Jin Jing|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Yi Jin Jing practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Yi Jin Jing practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Yi Jin Jing exercise in each session.
223442277|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
223442278|NCT02668159|DIETARY_SUPPLEMENT|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
224145403|NCT05767710|BEHAVIORAL|AI telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
224145404|NCT05767710|BEHAVIORAL|general telerehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
224300642|NCT05312398|DRUG|Cetuximab|"I LINE:~\- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter~II LINE:~\- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line~THIRD LINE:~\- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
223442279|NCT02668159|DIETARY_SUPPLEMENT|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
223442280|NCT02668159|DIETARY_SUPPLEMENT|Placebo|7 tablets of placebos administered prior to one the OGTT
223442281|NCT00957905|DRUG|Alvocidib Hydrochloride|Given IV
223442282|NCT00957905|DRUG|Fluorouracil|Given IV
223566887|NCT03883919|DRUG|Leucovorin|-Standard of care drug
223566888|NCT03883919|DRUG|Liposomal Irinotecan|-Standard of care drug
223442283|NCT00957905|DRUG|Leucovorin Calcium|Given IV
223442284|NCT00957905|DRUG|Oxaliplatin|Given IV
223442285|NCT02952872|BEHAVIORAL|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
223442286|NCT04047849|DRUG|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
223442287|NCT00755885|DRUG|abiraterone acetate|
223442288|NCT00755885|OTHER|laboratory biomarker analysis|
223442289|NCT00755885|OTHER|pharmacogenomic studies|
223442290|NCT02073656|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223442291|NCT02073656|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223566889|NCT03883919|DRUG|Paricalcitol|-Investigational drug
223566890|NCT03883919|PROCEDURE|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
224053434|NCT00794495|DRUG|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
223442292|NCT03059251|BIOLOGICAL|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
223442293|NCT05245045|PROCEDURE|Shengtaibufen Photodynamic Therapy(STBF-PDT)|Shengtaibufen Photodynamic Therapy(STBF-PDT)
223442294|NCT05245045|PROCEDURE|Red light|Red light
223442295|NCT02638051|DEVICE|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
223442296|NCT02638051|DIETARY_SUPPLEMENT|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
223442297|NCT02638051|DRUG|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
223442298|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
223442299|NCT00523523|BEHAVIORAL|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
224053435|NCT00984490|DRUG|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
224053436|NCT00984490|OTHER|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
224053437|NCT06104982|DEVICE|NeuroTrac MyoPlus Pro single-channel electromyography biofeedback electrotherapy devices|Neuromuscular electrical stimulation (NMES) is applied to intact second motor neurons and target muscles of patients with SCI and provides functional and therapeutic benefits in neurological rehabilitation. Functional electrical stimulation (FES) is a type of NMES that is used for electrical stimulation during exercises such as crunches. Newly used SiFES is a method in which the biofeedback-enabled FES device detects muscle contractions, and this electromyography (EMG) signal triggers the muscle stimulant mode of the device.
224053438|NCT06104982|OTHER|Isometric strengthening exercises|Isometric abdominal strengthening exercises are part of the standard rehabilitation program for individuals with spinal cord injuries.
224053439|NCT05114395|OTHER|Pelvic Floor Telerehabilitation Program|See experimental and active comparator arms.
224053440|NCT05114395|OTHER|Pelvic Floor Face-to-Face Program|See experimental and active comparator arms.
224053441|NCT03584828|BEHAVIORAL|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
223442300|NCT03953157|DIETARY_SUPPLEMENT|Dietary Intervention|Receive dietary intervention
223442301|NCT03953157|BEHAVIORAL|Exercise Intervention|Receive exercise intervention
223442302|NCT03953157|OTHER|Questionnaire Administration|Ancillary studies
223442303|NCT05226234|DEVICE|MRI|Late gadolinium enhancement cardiac magnetic resonance (LGE-MRI)
224053442|NCT00941161|DRUG|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
224053443|NCT00941161|DRUG|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
224053444|NCT00941161|DRUG|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
223442304|NCT03216655|OTHER|phone call|Investigators give a regular follow-up to participants: phone call monthly
224053445|NCT00201968|DEVICE|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
224053446|NCT00201968|DEVICE|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
224053447|NCT00201968|OTHER|Conventional Exercise|An aerobic and resistance training program.
223442305|NCT03216655|OTHER|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
223442306|NCT03218228|PROCEDURE|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
224053448|NCT03926715|OTHER|Nutritional status|
224053449|NCT01490450|BIOLOGICAL|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
224053450|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
224053451|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
224053452|NCT01490450|BIOLOGICAL|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
224053453|NCT04363528|OTHER|Doppler Echo|2 doppler echo will be done at patients hospitalized in ICU and with SARS-CoV-2 pneumopathy at 7 days apart
224053454|NCT02712476|DRUG|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
224053455|NCT02712476|DRUG|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
224053456|NCT02712476|DRUG|placebo|mannitol alone is compared with placebo
223442307|NCT03926468|DIAGNOSTIC_TEST|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
223442308|NCT04875689|OTHER|Group A (Experimental|"Laser therapy is performed on patients in supine lying position. Treatments will be delivered with a diode laser (wavelength 830 nm, continuous wave, power 50 mW) in skin contact at a dose of 6 J/point. Treatment times per point are in the range of 30 seconds to 1 minute. eight points were irradiated per session.~Conventional therapy will include:~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching. Strengthening exercises ,straight leg raising exercise in crook lying position~* Joint mobilizations"
223442309|NCT04875689|DIAGNOSTIC_TEST|Group B (Control)|"1\. Participants of this group will receive only conventional therapy which will include;~* TENS for 15 minutes~* Hot pack for 15 minutes~* Hamstrings muscle stretching and calf muscle stretching.Each stretch was sustained for 30 seconds, with 10-second rest intervals.~* Strengthening exercises include quadricep drills(full knee extension maintained for 5 seconds, followed by a 5-second rest) 20 repetitions per session,straight leg raising exercise in crook lying position(the patients were asked to tense the quadriceps muscle, elevate the limb to 45° and maintain it for 6 seconds, and lower the limb slowly and then relax for 6 seconds; the exercise was performed for three sets of 10 repetitions per session).~* Joint mobilizations (tibiofemoral extension and flexion; patellofemoral medial-lateral and inferior glide)."
223442310|NCT03942003|PROCEDURE|rhomboid blocks|Rhomboid nerve block was performed
224053457|NCT01704040|DRUG|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
223442311|NCT03942003|PROCEDURE|PEC blocks|PEC I-II blocks was performed
223442312|NCT03942003|PROCEDURE|Control groups|Infiltration analgesia was performed
223442313|NCT00082459|BIOLOGICAL|autologous human tumor-derived HSPPC-96|
223442314|NCT05892549|DEVICE|COVOICE application use - initial|Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application
223442315|NCT05892549|DEVICE|COVOICE application use - follow-up|Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
223442316|NCT06366698|DRUG|Venofer 200 MG Per 10 ML Injection|200 mg IV every 2 days until the targeted dose
223442317|NCT06366698|DRUG|Ferrous sulfate|Take 1 tablet every other day with lemon/orange juice
223442318|NCT02536781|DRUG|Anthocyanin|Anti-inflammation gel
223442319|NCT02536781|DRUG|Placebo|Blank gel
224053458|NCT01704040|DRUG|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
224053459|NCT01704040|DRUG|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
224053460|NCT01704040|DRUG|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
224053461|NCT01704040|OTHER|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
224053462|NCT04316377|DRUG|Hydroxychloroquine Sulfate|400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
224053463|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
224053464|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
224053465|NCT00382239|DRUG|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
224053466|NCT00382239|DRUG|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
224053467|NCT05542550|BEHAVIORAL|Voice Rest|Voice rest restricting patient phonation
224053468|NCT05542550|BEHAVIORAL|No Voice Rest|No Voice rest
224053469|NCT03435848|DRUG|BST-236|1 to 4 courses
224053470|NCT04133532|DRUG|Metoprolol|metoprolol 50 mg daily for three months
224053471|NCT04933331|DRUG|Curodont Repair Fluoride Plus|Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
223442320|NCT03834714|DEVICE|Near Infrared Light|NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
224053472|NCT04933331|DEVICE|Silver Diamine Fluoride|Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
224053473|NCT04933331|DEVICE|Glass Ionomer Sealant|A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
224053474|NCT04933331|DEVICE|Fluoride varnish|2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.
224053475|NCT04933331|DRUG|Fluoride toothpaste|Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
223442321|NCT03834714|OTHER|Noise Stimulus|Noise stimulus will be administered, open ear, to continuous broadband noise up to 25% of the allowable daily dose of noise per the AFI 48-127 Occupational Noise and Hearing Conservation Program.
223442322|NCT03834714|DEVICE|Sham Near Infrared Light|Sham NIR Light Therapy will be administered with the Earlight Generation 1.4 device during 2 out of the 4 sessions. It will be administered to each ear individually for 30 minutes per ear.
224053476|NCT00007839|DRUG|beta alethine|
224053477|NCT01841502|DRUG|Paroxetine|paroxetine 20 mg once daily
223442323|NCT05508945|DEVICE|Dermabond Prineo Skin Closure System|synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
223442324|NCT05508945|DEVICE|silk|SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
224145405|NCT05767710|BEHAVIORAL|traditional rehabilitation - Ba Duan Jin|All the participants received a three-month intervention which consisted two stage: the first month was the movement learning and consolidation phase, with 45 minutes of Ba Duan Jin practice per session and three times each week; the last two months were the formal practice phase with 45 minutes of Ba Duan Jin practice per session and three times each week. In the first phase, participants learned four new movements in each session and consolidated these exercises in the next session. After all the movements have been learned, use the remaining time in the first stage to consolidate the exercises. In the second phase, participants performed a complete Ba Duan Jin exercise in each session.
224145406|NCT00285103|DRUG|SPC2996|
224145407|NCT01504971|OTHER|symptom questionaire|GerdQ questionaire
224145408|NCT01504971|PROCEDURE|pH monitoring|24-hour pH monitoring
223442325|NCT05508945|DEVICE|3M Steri-Strip|non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
223442326|NCT03423147|DRUG|2% chlorhexidine gluconate cloth|applied to their abdomen
223442327|NCT03423147|DRUG|4% Chlorhexidine gluconate vaginal scrub|applied as a vaginal cleanse in the operating room prior to cesarean section
224053478|NCT01841502|DRUG|telaprevir|telaprevir 1125 mg twice daily
224145409|NCT01504971|PROCEDURE|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
224145410|NCT01504971|DRUG|rabeprazole|10mg, bid, p.o.
223442328|NCT01048099|PROCEDURE|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
223442329|NCT01048099|DRUG|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
224053479|NCT01262378|PROCEDURE|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
224053480|NCT04155255|OTHER|MyBFF@school|
224053481|NCT01505270|OTHER|Retrospective case study|Retrospective case study
224053482|NCT05755841|OTHER|Outpatient management of preterm prelabor rupture of membranes|"Patients who will be managed as outpatients will be discharged after 48 hours of hospitalization with the following management:~* Twice weekly fetal cardiotocography.~* Complete blood count once a week.~* A weekly clinical and ultrasound examination."
224053483|NCT05755841|OTHER|Inpatient management of preterm prelabor rupture of membranes|In the Inpatient Care Policy group, the same protocol as outpatient group will be applied, but the patient will not be discharged until delivery.
224053484|NCT00019708|DRUG|tanespimycin|Given IV
224053485|NCT03722342|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
224053486|NCT04272671|OTHER|Educational Intervention|The intervention has the following components: 1) alerts given to providers to identify patients taking opioids or benzodiazepines (BZD) and therefore at risk for falls; 2) educational materials to inform providers on best practices for de-prescribing opioids and BZDs in patients at risk; and 3) recommendations on de-prescribing provided by a consultant pharmacist. Impact of the intervention will be evaluated using pre-post surveys evaluating changes in providers' knowledge, confidence, and skills as well as information from the EHR to evaluate impact of the intervention on de-prescribing opioids and BZDs.
224053487|NCT06397755|PROCEDURE|Prostate Biopsy and/or Radical Prostatectomy|Prostate Biopsy: procedure to remove samples of suspicious tissue from the prostate Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
224053488|NCT01424111|DRUG|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
224053489|NCT01424111|OTHER|Healthy Control|No Treatment
224053490|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
224053491|NCT00949832|DIETARY_SUPPLEMENT|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
224053492|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D2|50,000 IU given orally once
224053493|NCT00949832|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3 50,000 IU given orally once
224053494|NCT00540137|DRUG|nevirapine|400mg once daily
224053495|NCT00540137|DRUG|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
224145411|NCT02262234|OTHER|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
223442330|NCT01048099|DRUG|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
223442331|NCT03406624|PROCEDURE|Biopsy|Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
224145412|NCT02262234|OTHER|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
224145413|NCT00936117|DRUG|Posaconazole|200 mg (liquid) by mouth 3 times per day.
223442332|NCT02260349|DRUG|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
223442333|NCT04606875|DIAGNOSTIC_TEST|Campbell Score|The Campbell Score is a blood based assessment of inflammatory and immunologically associated markers that is currently in development as a means of predicting suicidal ideations.
223442334|NCT06811389|BEHAVIORAL|Re-imagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP)|"The RISE-HP intervention consists of three components: peer support (peer coach), cognitive restructuring, and patient education. It consists of 10 weekly one-on-one meetings with a peer coach (a person with lived experience with HP who has been trained to deliver the content of the RISE-HP intervention to another person with HP).~The RISE-HP intervention delivered by peer coaches using the principles of cognitive behavioral therapy combined with theory driven patient education targets the health-related quality of life of patients living with hypersensitivity pneumonitis."
223566891|NCT03883919|PROCEDURE|Tumor biopsy|"* 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~* After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
223566892|NCT03711929|DRUG|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
224053496|NCT01021956|DRUG|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
224053497|NCT04090008|DRUG|PRP gel|The PRP gel is applied on the ulcer twice per week
224053498|NCT04090008|DRUG|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
224053499|NCT02250820|DRUG|Dexmedetomidine|Nasal administration
224053500|NCT02250820|DRUG|Pentobarbital|Oral administration
224053501|NCT02250820|OTHER|Oral Placebo|Oral placebo will be cherry syrup
224145414|NCT04979949|BIOLOGICAL|CoronaVac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
224145415|NCT04979949|BIOLOGICAL|Turkovac|One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
223566893|NCT03711929|OTHER|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
224053502|NCT02250820|OTHER|Nasal Placebo|Nasal placebo will be nasally atomized saline
224053503|NCT02234479|BIOLOGICAL|Hydrophor (Group A)|"* Rehydrates dry, chapped or chafed skin~* May be used alone as a skin lubricant or protectant"
224053504|NCT02234479|BIOLOGICAL|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~* Maintain a balanced environment for healing.~* Aids in reducing dermatitis.~* Reduce affected area pH.2-3"
224053505|NCT05040724|DRUG|Ivermectin|ivermectin placebo
224053506|NCT02177968|OTHER|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
224145416|NCT01577784|DRUG|Pazopanib|800 mg / day of pazopanib in monotherapy.
224300643|NCT05312398|DRUG|FOLFIRI|"I LINE:~\- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter"
223442335|NCT06811389|BEHAVIORAL|Staying Well|The Staying Well intervention consists of 12 weeks of educational sessions. The participants can choose the 10 education sessions out of the 12 they want to cover with the research assistant. Participants will meet weekly with the research coordinator for an estimated 30-45 minutes per session.
223442336|NCT06651892|DRUG|Enema Phosphates Sodium|oral diluted phosphate enema containing as a repletion strategy to replace phosphate in critically ill patients with acute hypophosphatemia.
223566894|NCT03711929|DRUG|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
224053507|NCT04882592|DEVICE|SCiP|Noninvasive spinal cord neuromodulator
224053508|NCT06548919|DRUG|Endocrine therapy|All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
224053509|NCT06548919|DRUG|Chemotherapy Prednisone|All chemotherapy treatment regimens approved for advanced breast cancer
224053510|NCT00820911|DRUG|cyclosporine (reduced exposure) / everolimus|twice daily
224145417|NCT01142453|DRUG|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
223566895|NCT03711929|DRUG|DE-109 Intravitreal Injections (Open Label)|After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
224053511|NCT00820911|DRUG|AEB071 300 mg b.i.d. / everolimus|twice daily
224053512|NCT00820911|DRUG|AEB071 200 mg b.i.d. / everolimus|twice daily
224053513|NCT03066128|DIAGNOSTIC_TEST|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
224053514|NCT03066128|OTHER|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
224053515|NCT04042779|OTHER|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
224053516|NCT04042779|OTHER|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
224145418|NCT06980077|PROCEDURE|Biopsy Procedure|Undergo biopsy
224300644|NCT05312398|DRUG|FOLFOX regimen|"II LINE:~\- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line"
223442337|NCT06651892|DRUG|Glycophos Injectable Product|intravenous sodium glycerophosphate as the standard of care or active control
223442338|NCT05981755|OTHER|Breathing tasks|Breathing tasks include normal breathing through nose or mouth, breathing while resting wakefully, increase and decrease in breathing rate, and breath counting.
223442339|NCT05981755|DEVICE|Brain mapping with stimulation|Electrical stimulation will be used to find specific areas of the brain involved in breathing function. Stimulation will be applied using a Nihon Kohden MEE-1000A neural function measuring system with the MS-120BK extension unit for brain stimulation.
223442340|NCT05538091|DRUG|Vismodegib|A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
223442341|NCT05538091|DRUG|Atezolizumab|Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
223442342|NCT03452241|OTHER|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
223442343|NCT03452241|OTHER|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
224053517|NCT04042779|OTHER|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
224053518|NCT04042779|OTHER|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
224053519|NCT00003535|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
224053520|NCT02672436|DRUG|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
224053521|NCT02672436|DRUG|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
224053522|NCT03573310|DRUG|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
224053523|NCT04788654|DRUG|Celebrex, acetaminophen, and dexamethasone|Pharmacological intervention will be performed. Celebrex 200mg, acetaminophen 1g, and dexamethasone 7 mg will be infused perioperatively.
224053524|NCT04788654|PROCEDURE|Saline irrigation, aspiration of pneumoperitoneum, and low pressure penumoperitoneum|Surgical intervention will be performed. Saline irrigation, aspiration of pneumoperitoneum, and low pressure pneumoperitoneum will be performed.
224053525|NCT01129362|BIOLOGICAL|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
224053526|NCT01129362|BIOLOGICAL|Other Pertussis Vaccines|0.5 mL, Intramuscular
224053527|NCT01776762|DIETARY_SUPPLEMENT|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
224053528|NCT05675943|BIOLOGICAL|Anti-COVID-19 Antibody SA55 for Injection|After the subjects are successfully screened, according to the group they belong to, they will be given the corresponding drug by intramuscular injection once (the dose of SA55 injection for subjects 40kg and above in the test group is 600mg (4ml), and the dose of SA55 injection for subjects in the test group below 40kg is 300mg (2ml), the subjects in the placebo group who are 40kg and above are injected with 4ml of placebo, and those in the test group under 40kg are injected with 2ml of placebo.The injection is allowed in both deltoid muscle of the upper arm or the buttocks muscle.
224145419|NCT06980077|PROCEDURE|Biospecimen Collection|Undergo collection of blood and urine samples
223442344|NCT04306250|PROCEDURE|Apical prolapse fixation - anterior access|The surgery is done in anterior access
223442345|NCT04306250|PROCEDURE|Apical prolapse fixation - posterior access|The surgery is done in posterior access
223442346|NCT01884012|PROCEDURE|long term oxygen therapy|
223442347|NCT00638209|DRUG|Human insulin|
223442348|NCT00638209|DRUG|Saline|
223442349|NCT03274362|BEHAVIORAL|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
224053529|NCT00445874|DRUG|Ketotifen with a Contact Lens (no generic name)|
224053530|NCT01715753|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
224145420|NCT06980077|PROCEDURE|Computed Tomography|Undergo CT
224145421|NCT06980077|BIOLOGICAL|Ivonescimab|Given IV
224145422|NCT06980077|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224145423|NCT06980077|OTHER|Questionnaire Administration|Ancillary studies
224145424|NCT04369755|OTHER|MRI|A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
224145425|NCT03267771|DRUG|Progesterone Suppositories Vaginal|progesterone vaginal suppository
224145426|NCT03267771|DRUG|Dydrogesterone Oral Tablet|oral progesterone drug
224145427|NCT03267771|DEVICE|doppler ultrasound|pulsed doppler ultrasound
224145428|NCT05053126|DRUG|Pregabalin 300mg|Participant will receive an oral dose of pregabalin 300 mg
224145429|NCT05053126|DRUG|pregabalin 450 mg|Participant will receive an oral dose of pregabalin 450 mg
224145430|NCT05053126|DRUG|Pregabalin 300 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg
224145431|NCT05053126|DRUG|pregabalin 450 mg with oxycodone 20 mg|Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg
223442350|NCT02409381|DRUG|Motore|250 mg
223442351|NCT02409381|DRUG|Alivium|600 mg
223442352|NCT02739308|OTHER|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
223442353|NCT02739308|OTHER|Control Group|The control group will not make the intervention and will continue with usual training fencing.
224053531|NCT01715753|BEHAVIORAL|Diet counseling and group education lessons|Individual and group diet counseling to achieve a \>10% weight loss
224053532|NCT02124395|OTHER|Health-related Quality of Life in Rare Kidney Stone Questionnaire|
224053533|NCT05995288|DRUG|Homeopathic Globule|Homeopathic globules were administered after careful anamnesis
223442354|NCT02295761|BEHAVIORAL|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
223442355|NCT02295761|BEHAVIORAL|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
223442356|NCT06731790|OTHER|Blood sampling for inflammatory phenotype analysis|Blood sampling for basal and post-stimulation inflammatory phenotype analysis
224053534|NCT05926700|DRUG|Candonilimab|The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
223566896|NCT03086707|OTHER|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
224145432|NCT05053126|DRUG|oxycodone 20 mg|Participant will receive an oral dose of oxycodone 20 mg
224145433|NCT05053126|DRUG|Placebo|Participant will receive an oral dose of placebo
224300645|NCT05312398|DRUG|Irinotecan|"III LINE:~\- Irinotecan + cetuximab~Irinotecan: 180 mg/ m² irinotecan over 1.30 h, IV infusion every 2 weeks. Cetuximab: as I line"
223442357|NCT06731790|GENETIC|Blood sampling for genetic analysis|Collection of a blood tube for whole exome sequencing of the RANBP2 gene and analysis of the presence of the mutation by RTqPCR.
223442358|NCT03148717|DRUG|Misoprostol|Cytotec
223566897|NCT03723538|DRUG|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
223566898|NCT01338480|OTHER|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
223566899|NCT00408655|DRUG|paclitaxel|Given IV
224053535|NCT06836661|BEHAVIORAL|FDC and TLC and medication adherance|Level 1: Patient 1. Rational FDCs 2. NPHWs and PMs mediated therapeutic lifestyle changes 3. Texts/ WhatsApp reminders Level 2:Physician 1. Reinforcing task sharing 2. Providing evidence on FDCs 3. Theory based behavior modification Level 3: Health administrators 1. Pharmacy - Update drug formulary FDCs 2. CV health days 3. Facility strengthening
224053536|NCT06836661|BEHAVIORAL|Patients will Enhanced Usual Care (EUC)|Patients will Enhanced Usual Care (EUC) with periodic follow ups
223442359|NCT03148717|OTHER|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
223442360|NCT05191368|OTHER|No intervention|No intervention
223442361|NCT05324280|PROCEDURE|Acupuncture|Acupuncture treatment will be performed according to a defined protocol, and includes body and ear acupuncture.
224053537|NCT01154244|OTHER|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
224053538|NCT04878770|DRUG|Topical corticosteroids|Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
223442362|NCT00004358|DRUG|calcitonin|
223442363|NCT03704116|BEHAVIORAL|Expedition|On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
223442364|NCT04819412|BIOLOGICAL|ROTAVAC®|ROTAVAC® with 5 minutes prior administration of 2.5 ml of buffer
223442365|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F1|ROTAVAC 5C formulation BBIL-R2014-1
223442366|NCT04819412|BIOLOGICAL|ROTAVAC 5C -F2|ROTAVAC 5C formulation BBIL-R2014-2
223442367|NCT06730035|OTHER|Blood analysis|This is an experimental analysis on tissues (peripheral blood) and exploratory, which is why the enrollment of a limited number of patients has been planned. The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations. The qualitative and quantitative characteristics of the vesicles and their miRNA content will be analyzed descriptively.
224145434|NCT03442348|DIETARY_SUPPLEMENT|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
224145435|NCT03442348|DIETARY_SUPPLEMENT|Inulin fibre|The participants in the control arm (N\>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
224300646|NCT05703347|BEHAVIORAL|Fixed sleep goal|Investigators will determine if a fixed guideline-based goal (≥9 hours per night) is more efficacious for increasing sleep duration.
223442368|NCT03232164|DRUG|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
223442369|NCT05423366|DEVICE|Extracorporeal Shock Wave Therapy (ESWT)|The ESWT device is product of Elettronica Pagani, Italy.
223442370|NCT04719195|OTHER|Meniscus extrusion ultrasonogrphic evaluation|This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
223442371|NCT01368887|DRUG|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
223442372|NCT01368887|OTHER|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
223442373|NCT01368887|DRUG|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
224053539|NCT04878770|DRUG|Systemic cyclosporine|"Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months."
223442374|NCT01368887|DRUG|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
223442375|NCT03130283|OTHER|Home Hospitalization|Visit every 24 hours
224053540|NCT04878770|DRUG|Systemic dupilumab|Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
224053541|NCT03270189|DEVICE|prism glasses|orthoptic treatment by wearing prisms when writing
224053542|NCT00383084|BEHAVIORAL|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
224053543|NCT00383084|BEHAVIORAL|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
224145436|NCT04591496|BEHAVIORAL|Behavioral change intervention;|Behavioral change intervention: goal setting, regarding child's diet and parental feeding practices; self-monitoring, with observation and recording of the child's food intake and parental feeding practices; individualized feedback, based on preceding week monitoring and according to the defined objectives, regarding child's and parent's behaviors; modeling and direct suggestions by tailored parent figures; positive reinforcement associated to parents' accomplishment of the objectives; prompts, to remember the defined objectives and the main messages of the intervention.
224145437|NCT04591496|BEHAVIORAL|Health Education|Health education: provision of information about preschool children's nutrition guidelines, effective parental feeding practices, strategies to overcome food and feeding-related barriers, and steps to form healthy habits.
224145438|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg|
224145439|NCT01785108|BIOLOGICAL|GAD-Alum (Diamyd) 20 µg X 2|
224145440|NCT01785108|DRUG|Vitamin D|
224300647|NCT05703347|BEHAVIORAL|Personalized sleep goal|Investigators will determine if a personalized goal (≥9 hours per night, but can be lowered to a personalized level, capped at +30 minutes per night above baseline) is more efficacious for increasing sleep duration.
223442376|NCT03130283|OTHER|Conventional Hospitalization|No intervention
223442377|NCT00553293|DRUG|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
223442378|NCT00553293|DRUG|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
223442379|NCT05073861|BEHAVIORAL|STEM learning|"Classes will be randomly assigned to the experimental group and to the control group. As treatment, the experimental group will be assigned to an intervention that uses a STEM blended learning app with gamified videos for content knowledge along with hands-on experiments. The videos are fictitious educational narratives related to the content knowledge and students were asked to step into the shoes of the cartoon scientist (a chipmunk) to solve various problems during the stories. The science experiments will be completed with step-by-step video guidance on the app. The control group will be assigned to read the same content on an e-book and receive an arts-and-craft kit for each lesson that is unrelated to the content knowledge."
223442380|NCT04175431|PROCEDURE|Positron Emission Tomography|Undergo fluciclovine PET/CT
223442381|NCT04175431|PROCEDURE|Lymphadenectomy|Undergo lymphadenectomy
223442382|NCT04175431|RADIATION|Radiation Therapy|Undergo radiation therapy
223442383|NCT04175431|DRUG|Abiraterone Acetate|Given PO
224145441|NCT01785108|DRUG|Ibuprofen|
224145442|NCT05966246|DRUG|Arm I : Experimental (Prucalopride succinate group)|Experimental group taking prucalopride succinate from day 1 to day 5 after surgery
223442384|NCT04175431|DRUG|Prednisone|Given PO
223442385|NCT04175431|PROCEDURE|Computed Tomography|Undergo fluciclovine PET/CT
223442386|NCT04175431|DRUG|Abiraterone|Given PO
223442387|NCT04175431|PROCEDURE|PSMA PET Scan|Undergo PSMA PET scan
223442388|NCT05825651|OTHER|no interventions|This is an observational study without any intervention.
223442389|NCT06365840|DRUG|IMC-001|All participants will receive the study drug, IMC-001, at 20 mg/kg Q2W via IV infusion over 60 minutes.
223442390|NCT06135896|DRUG|Tripegfilgrastim|Tripegfilgrastim to reduce the risk of severe neutropenia in patients with unresectable pancreaticobiliary cancers
223442391|NCT03871725|COMBINATION_PRODUCT|Sonodynamic therapy (SDT)|Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
223566900|NCT00408655|DRUG|carboplatin|Given IV
223566901|NCT00408655|DRUG|temsirolimus|Given IV
224053544|NCT02113436|DRUG|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
224053545|NCT02113436|DRUG|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
224053546|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
224053547|NCT01263483|DRUG|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
224053548|NCT01263483|DRUG|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
224053549|NCT00326209|DRUG|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
224053550|NCT00714285|BIOLOGICAL|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
224053551|NCT00714285|BIOLOGICAL|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
223442392|NCT03854604|OTHER|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
223442393|NCT04164004|OTHER|Kansas City Cardiomyopathy Questionnaire-12|Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
223442394|NCT01222377|PROCEDURE|endoscopic surgery|Undergo endoscopic breast surgery
223442395|NCT01222377|PROCEDURE|quality-of-life assessment|Ancillary studies
224053552|NCT01372384|DRUG|erlotinib [Tarceva]|150 mg orally daily
224053553|NCT01621633|DRUG|LCZ696|
224053554|NCT00507299|BEHAVIORAL|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
224053555|NCT00507299|BEHAVIORAL|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
224053556|NCT01239095|DRUG|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
224053557|NCT00112671|DRUG|sorafenib tosylate|Given orally 400mg orally twice daily
224053558|NCT00112671|OTHER|laboratory biomarker analysis|Correlative studies
224053559|NCT00829179|DRUG|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
223442396|NCT06648720|DRUG|DAPT de-escalation|Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
223442397|NCT03053648|OTHER|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
223566902|NCT00789581|DRUG|Doxorubicin|Doxorubicin 60 mg/m2
223566903|NCT00789581|DRUG|Cyclophosphamide|Cyclophosphamide 600 mg/m2
223566904|NCT00789581|DRUG|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
223566905|NCT00789581|DRUG|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
223566906|NCT00002114|DRUG|Procysteine|
223566907|NCT04538235|PROCEDURE|Thoracic Regional Analgesia|In the TEA group, a thoracic epidural was performed before VATS. In the Bi-block group, a SAP block associated with an ESP block were performed before surgical incision under general anesthesia.
223566908|NCT04350021|DRUG|Capecitabine, Cyclophosphamide|Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
223566909|NCT04449939|DRUG|KY1005|A human anti-OX40 ligand monoclonal antibody
223566910|NCT04338633|DRUG|Conventional calcium hydroxide paste|Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
223566911|NCT04338633|DRUG|Calcium hydroxide nanoparticle|Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
223566912|NCT04338633|DRUG|Combined Calcium hydroxide with silver nanoparticle|Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
223566913|NCT00571246|DRUG|Topiramate|Participants are randomized to take Topiramate (250mg/day) 2 times a day
223566914|NCT00571246|DRUG|lamotrigine|Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day
223566915|NCT00571246|OTHER|Placebo|Participants are randomized to take placebo
223442398|NCT03053648|OTHER|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
223442399|NCT02352987|DRUG|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
223442400|NCT02352987|DRUG|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
223442401|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
223442402|NCT02258334|BIOLOGICAL|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
223442403|NCT02258334|BIOLOGICAL|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
223442404|NCT02258334|BIOLOGICAL|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
223442405|NCT05051800|BEHAVIORAL|Online Program to Support Coping and Communication in Families|Parents and children will access online materials designed to support the use of effective ways to cope with the diagnosis and treatment of cancer and to support open and communication.
223442406|NCT03532815|BEHAVIORAL|Lifestyle Modification|
223442407|NCT06995690|DRUG|Ketamine|Patients receive crystalloid preloading of 15ml/kg (Ringer's lactate) +the sub-anesthetic dose of ketamine of 0.5 mg/kg IV added to the first bottle of ringer for blinding over 20 min before the spinal injection.
223442408|NCT06995690|DRUG|Normal Saline|Patients receive a crystalloid preloading of 15 ml/kg (Ringer's lactate)+ 0.5 mg/kg IV of Normal Saline added to the first bottle of ringer for blinding, over 20 min before the spinal injection.
224053560|NCT01541189|DRUG|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
224053561|NCT03991000|DRUG|Ferric carboxymaltose|Intravenous iron
224053562|NCT03991000|DRUG|Saline|Saline application according to dosing rules of iron.
224053563|NCT03098849|OTHER|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
224053564|NCT00464321|BIOLOGICAL|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
224053565|NCT00464321|BIOLOGICAL|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
223442409|NCT05307185|DIETARY_SUPPLEMENT|Tritordeum-based food|Diets will last 12 weeks with intermediate nutritional checks every four weeks before returning to the final study visit.
223442410|NCT00473785|BEHAVIORAL|Group-based motivational interviewing|
223442411|NCT00473785|BEHAVIORAL|Individual CVD-risk factor feedback|
223442412|NCT00473785|BEHAVIORAL|Education for protective health behavior change|
223442413|NCT01688778|BEHAVIORAL|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
223442414|NCT05724485|DRUG|Branched-chain Amino Acid|12.45 grams of BCAA orally per day before bedtime
223442415|NCT05724485|DRUG|Placebo|12.45 grams of Maltodextrin orally per day before bedtime
223442416|NCT01969084|DRUG|Linagliptin|
223442417|NCT01969084|DRUG|Placebo|
223442418|NCT01969084|OTHER|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
223442419|NCT01969084|OTHER|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
224053566|NCT00464321|BIOLOGICAL|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
224053567|NCT00464321|BIOLOGICAL|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
223442420|NCT01969084|OTHER|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
223566916|NCT00081315|DRUG|Amifostine|
224053568|NCT03419338|PROCEDURE|Sinus lift|Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.
224053569|NCT03419338|PROCEDURE|Surgical alveolus|Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.
224053570|NCT03419338|PROCEDURE|Inorganic bovine bone + newly forming bone|Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.
224053571|NCT03419338|PROCEDURE|Inorganic bovine bone|Maxillary sinus lift will be done with inorganic bovine bone.
224145443|NCT05966246|DRUG|Arm II : Control (Mosapride citrate group)|Control gourp taking mosapride citrate from day 1 day 5 after surgery
223566917|NCT01468207|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223566918|NCT01468207|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
224145444|NCT00139620|DRUG|Tarceva, erlotinib, OSI-774|
224145445|NCT05159362|OTHER|Software Application|Access is granted to participants for 4 weeks to the OARSCM platform which includes reinforcements for meeting MOUD treatment goals.
224145446|NCT01376245|DRUG|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
223442421|NCT06020339|OTHER|The midwife-led continuous care model (MLCC)|"Continuity of midwife-led care has been defined as care in which the midwife is the leading professional in the planning, organization and delivery of care given to a woman from the initial assessment of the pregnant woman to the postpartum period.~ELSBM; It is the same midwife or midwife group providing the care and counseling needed by the woman during pregnancy, childbirth and postpartum period. In this care model, the midwife is the leading health care specialist who is responsible for planning and arranging the care given to women in the antenatal, natal and postnatal period. MLCC is woman-centered and is based on the idea that pregnancy and childbirth are normal life events.~This care model includes education, counseling and care according to the needs of the woman. It promotes vaginal delivery as a normal process and advocates minimal interventions. Continuity of midwifery-led care is associated with superior outcomes for women and infants than other models of care."
223442422|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus Anodic transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Anodal tDCS over DLPFC (20 min) daily for 1 month
223442423|NCT06228872|DEVICE|Cognitive Computerized Training (CCT) plus sham transcranial Direct Current Stimulation (tDCS)|Computerized Cognitive Training (15 min) + Sham tDCS over DLPFC (20 min) daily for 1 month
223442424|NCT06613698|DRUG|GSK4532990|GSK4532990 will be administered
223442425|NCT06613698|DRUG|Placebo|Placebo will be administered
223442426|NCT01037036|DRUG|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
223442427|NCT01037036|DRUG|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
223442428|NCT07004881|PROCEDURE|Group A (Active Comparator) Mulligan's Mobilization With Movement (MWM)|"This group will receive two techniques of mulligan i.e. Medial Patellar Glide relative to femoral trochlea and other is tibial internal rotation relative to femoral condyles.In Medial Patellar Glide; patient is positioned supine with 40 degree knee flexion. Stabilizing hand of therapist stabilizes the posterior aspect of tibia and fibula and with mobilizing hand, the therapist gently glides the patella medially. With that, the patient is asked to actively flex and then extend the knee.~In the tibial internal rotation technique; similarly the patient is positioned supine with 40 degree knee flexion. Stabilizing hand of therapist stabilizes t~After mobilization; following exercises are to be performed all in 3 sets of 7 repetitions:~1. Side-lying hip abduction~2. Clamshell exercises~3. Quadriceps setting exercise~4. Vastus Medialis Oblique strengthening~5. Mini squats~6. Hamstring stretch~7. Iliotibial band stretch"
223442429|NCT07004881|PROCEDURE|Group B(Experimental) Maitland's Patellar Mobilizations|"For all the mobilizations the patient is positioned either in supine or sitting with 30-0 degree knee flexion or full knee extension. The therapist holds patella between his/her thumb and index finger and glides it cranially (Superior Patellar glide), caudally (Inferior Patellar Glide) and medially (Medial Patellar Glide). The fourth one i.e. Patellofemoral Distraction is given by grasping the patella between two fingers and lifting it above/away from underlying femoral trochlea. All 4 of these techniques are repeated 10 times with total 3 sets. 3 sessions are performed in a week on alternate days. Total duration of interventions is 2 weeks.~Both groups receive similar exercises therapy following mobilizations."
223442430|NCT06869551|DRUG|Deucravacitinib|Specified dose on specified days
223442431|NCT06869551|OTHER|Placebo|Specified dose on specified days
223442432|NCT05822648|BEHAVIORAL|Project Health|Project Health will be delivered in six 1-hour group sessions that will be held weekly. In addition, participants will be asked to complete 30 mins of response inhibition and attention trainings once per week between the sessions. This program promotes to retain the gradual lifestyle modification designed to bring energy intake into balance with energy output and the food response inhibition and attention training, but will adapt the dissonance-induction activities to focus on the negative effects of developing T2D in addition to the negative effects of obesity, overeating, and a sedentary lifestyle.
223566919|NCT03396679|OTHER|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
223566920|NCT03727087|OTHER|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
223566921|NCT03994250|OTHER|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
224053572|NCT03419338|DEVICE|Collagen membrane|At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
224053573|NCT00612170|DRUG|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
224053574|NCT00612170|DRUG|Placebo|0 mg oral tablet once a day dosing
224053575|NCT00612170|DRUG|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
224053576|NCT00612170|DRUG|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
224053577|NCT02685423|BEHAVIORAL|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
223566922|NCT03994250|OTHER|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
223566923|NCT05192499|PROCEDURE|Stool test|At inclusion (day 0), stools will be collected with a kit for to remove to 5 mg for each patient.
223566924|NCT05192499|PROCEDURE|Blood test|Blood sample taken during inclusion (day 0) will be collected. There is between 19 and 26 mL for each patient.
224053578|NCT02685423|BEHAVIORAL|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
224053579|NCT06461975|DRUG|Benoxinate Hydrochloride|"The first group had the first examination done using the tear substitute Polyfresh ® eye drops and the second using the Benoxinate HCL drops Benox ® given just before the ROP screening."
224053580|NCT06461975|DRUG|artificial tear (Sodium Hyaluronate 2 mg/ml) eye drops.|"The second group had the first examination done using the Benoxinate HCL drops Benox ® eye drops and the second using the tear substitute Polyfresh ®given just before the ROP screening."
224053581|NCT03000179|DRUG|Avelumab|Avelumab through a vein once every 2 weeks
224145447|NCT01376245|DRUG|Placebo|matching placebo
224145448|NCT03454204|OTHER|Pharmacokinetic|Analysis of blood samples
223442433|NCT05822648|OTHER|Educational Video Control|We selected a T2D management psychoeducational comparison condition. To match Project Health, the educational videos will be delivered in 6 1-hour blocks. The educational group will be instructed to watch videos on nutrition, exercise, and how to maintain general health during the lifespan
223442434|NCT06681896|OTHER|MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice|"MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.~Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week.~Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions.~Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week.~Diet: 30-minute sessions every 5 weeks.~Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week.~Diet: one final 30 minute session after week 3."
224145449|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
224145450|NCT01357889|BIOLOGICAL|albiglutide (GSK716155)|subcutaneous injection administered once a week
224145451|NCT01335698|DRUG|Atazanavir Sulphate|
224145452|NCT01335698|DRUG|Ritonavir|
224145453|NCT00473044|BEHAVIORAL|Sisters in Motion|
224145454|NCT02356640|PROCEDURE|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
224145455|NCT02356640|PROCEDURE|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson \&Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
223442435|NCT07015866|OTHER|Guided therapy group|Participants will engage in guided group discussions over five sessions. Each session will include a guided discussion focusing on self-care topics such as sleep hygiene, dental hygiene, nutrition, and personal interests and hobbies. The first individual session, 'Sleep hygiene, will be used to educate the participants of the importance of sleep and strategies to improve sleep quality. The four other sessions will be group-based (with four participants per group), focusing on dental hygiene, nutrition, personal interests and hobbies and general well-being and reflection. A session will be conducted each week over five weeks, with each session lasting 60 minutes. All sessions will be conducted in a room in the Urology Centre.
224053582|NCT03413111|PROCEDURE|Modified double wire technique|For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
224053583|NCT00381199|DRUG|Amitriptyline Hydrochloride|
224053584|NCT00381199|DRUG|Nabilone|
224053585|NCT02410668|DIETARY_SUPPLEMENT|flaxseed|
224053586|NCT02410668|DIETARY_SUPPLEMENT|Placebo|
224053587|NCT02410668|BEHAVIORAL|Exercise recommendation|
224053588|NCT00217048|DRUG|Yohimbine, oral|
224053589|NCT02738970|DRUG|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
224053590|NCT02738970|DRUG|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
224053591|NCT01299376|DRUG|L50/H12.5/A5|
224053592|NCT01299376|DRUG|L50/H12.5|
224053593|NCT01299376|DRUG|Placebo to L50/H12.5/A5|
224053594|NCT01299376|DRUG|Placebo to L50/H12.5|
224053595|NCT04142775|OTHER|complication versus no complication|development of ICH
224053596|NCT04015453|PROCEDURE|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
224053597|NCT03351920|OTHER|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
224053598|NCT02343159|DRUG|dimethyl fumarate|120 mg and 240 mg delayed release capsules
224053599|NCT02343159|DEVICE|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
224053600|NCT02343159|BEHAVIORAL|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
224053601|NCT05467514|DRUG|Liraglutide|Application of liraglutide 1.8 mg subcutaneous daily for 6 months to evaluate subclinical atherosclerosis, by means of carotid doppler US, lipid profile in patients with type 1 diabetes mellitus
224145456|NCT02356640|DEVICE|Olympus UM 2000|
224145457|NCT02356640|DEVICE|B-D Quincke Type Point|
224145458|NCT02356640|DRUG|Levobupivacaine|
224145459|NCT05764460|DIAGNOSTIC_TEST|Neuropsychological tests|Neuropsychological tests for general cognition, social cognition and language.
224145460|NCT02907671|PROCEDURE|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
224145461|NCT02147509|DRUG|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
224145462|NCT02147509|DRUG|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
224145463|NCT02147509|OTHER|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
224145464|NCT02147509|DRUG|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
223442436|NCT07015866|OTHER|Creative arts therapy|"The intervention will be offered throughout five sessions. Session themes are as follows: 'bridge drawing', 'analogue drawing', 'life-sized body outline', a 'free session' to allow patients to express their feelings, and a final review with the art therapist in which all sessions will be brought to a conclusion.~The first individual session, 'bridge drawing', will be used to introduce the creative arts therapy approach and to elaborate on this project. The four other sessions will be group-based (with four participants per group), providing a supportive and communal environment where participants can engage in creative expression alongside others who may have had similar experiences or challenges. A session will be conducted each week over five weeks, with each session lasting 60 minutes. All sessions will be conducted in a room in the Urology Centre that has been equipped and prepared for the intervention."
223442437|NCT04744259|BEHAVIORAL|Behavioural Activation|A psychological intervention which aims to increase activity and reduce depressive symptoms.
223442438|NCT01288092|DRUG|BEZ235|
224053602|NCT03769246|DEVICE|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
223442439|NCT00862459|DRUG|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
223442440|NCT00862459|DRUG|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
223442441|NCT00862459|DRUG|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
223442442|NCT00862459|DRUG|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
223442443|NCT03139864|PROCEDURE|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
223442444|NCT05188404|BEHAVIORAL|Choice of cannabis product|Participants choose and purchase their own cannabis product
223442445|NCT06624865|OTHER|Blood and stool sampling|Blood and stool sampling
223566925|NCT05192499|PROCEDURE|Induced sputum|At inclusion (day 0), bronchial aspiration after inhalation induction of 4 mL of 6% salt serum administered (after 200 μg of salbutamol via an inhalation chamber during a bronchial drainage session).
224053603|NCT03769246|OTHER|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
224053604|NCT05142475|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
224053605|NCT02512471|DRUG|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
224145465|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
223442446|NCT04296786|DRUG|Sintilimab|200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment
223442447|NCT04296786|DRUG|Chidamide|20mg po per week continuously
223566926|NCT05192499|PROCEDURE|nasale virology|At inclusion (Day 0), patients will be taken nasal swab for virology with swab adapted for nasal swab or with suction trap when blowing the child's nose (depending on center practice)and multiplex PCR.
223566927|NCT04385238|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
223566928|NCT04139577|BIOLOGICAL|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
223442448|NCT01921738|DRUG|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
223442449|NCT01921738|DRUG|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
223566929|NCT05630222|DRUG|Ibuprofen 800 mg|Ibuprofen from Caspian Taamin Company
223566930|NCT05630222|DRUG|Morphine Sulfate|Morphine Sulfate from Darupakhsh Company
223566931|NCT05630222|DRUG|Ibuprofen 400 mg plus Acetaminophen 1000 mg|Both from Caspian Taamin Company
224053606|NCT00825279|DEVICE|Bare Metal Stent|Stainless steel stent
224053607|NCT00825279|DEVICE|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
224053608|NCT00002300|DRUG|Megestrol acetate|
224053609|NCT00914251|DRUG|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
224053610|NCT00914251|DRUG|Placebo|Administration of oral Placebo, 500 mg/daily
224053611|NCT03076385|BIOLOGICAL|VAL-506440|Escalating dose levels
224053612|NCT03076385|OTHER|Placebo|
224053613|NCT00502814|PROCEDURE|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
224145466|NCT00162708|PROCEDURE|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
224145467|NCT00162708|DRUG|CDDP, 5 Fu|
224145468|NCT02670850|OTHER|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
224145469|NCT05297799|DEVICE|Ameda Pearl breast pump|The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
224145470|NCT06218199|DRUG|Furosemide|oral administration
224145471|NCT06218199|DRUG|Torsemide|oral administration
224145472|NCT06218199|DRUG|Bumetanide|oral administration
224145473|NCT06218199|DRUG|sacubitril/valsartan|oral administration
224145474|NCT06218199|DRUG|Hydralazine|oral administration
224145475|NCT06218199|DRUG|Isosorbide Dinitrate|oral administration
223442450|NCT01921738|DRUG|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
223442451|NCT01921738|DRUG|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
223442452|NCT07026604|DRUG|Daratumumab|Participants receive intravenous daratumumab (16 mg/kg weekly for 8 weeks), diluted in 1000 mL (first dose) or 500 mL (subsequent doses) of saline, with infusion rates escalated stepwise from 50 to 200 mL/h under vital sign monitoring. Premedication (antihistamines/analgesics) is administered 30 minutes prior to each infusion to mitigate reactions.
223442453|NCT07026955|OTHER|colorectal cancer in patients over 50 years of age|description
223442454|NCT07026110|DRUG|[68Ga]Ga-NOTA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
223442455|NCT07026110|DRUG|[68Ga]Ga-NOTA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RT4 injection.
223442456|NCT07026110|DRUG|[18F]F-RESCA-T4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
223442457|NCT07026110|DRUG|[18F]F-RESCA-RT4|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-RT4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RT4 injection.
224053614|NCT00502814|PROCEDURE|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
224053615|NCT00502814|PROCEDURE|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
224053616|NCT00502814|PROCEDURE|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
224053617|NCT01353027|DRUG|Placebo|Normal saline
224053618|NCT01353027|DRUG|AVI-6002|Single intravenous administration
224053619|NCT04878003|DRUG|KRT-232|KRT-232, administration by mouth
224053620|NCT04878003|DRUG|TL-895|TL-895, administration by mouth
224053621|NCT06417359|PROCEDURE|Mesh Fixation|That mesh will be fixation with three tackers.
224053622|NCT06417359|PROCEDURE|No Mesh Fixation|That mesh will not be fixation
224053623|NCT04168944|DRUG|Lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation
224053624|NCT04168944|DRUG|Placebo|Sugar pill manufactured to mimic Lenvatinib 10mg tablet
224053625|NCT04168944|DRUG|Immunosuppressive regimen|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
224053626|NCT04585464|DRUG|EDG-5506|EDG-5506 is administered orally as a single dose or once daily
224053627|NCT04585464|DRUG|Placebo|Placebo is administered orally as a single dose or once daily
224053628|NCT00635479|DEVICE|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
224053629|NCT00635479|OTHER|Gauze dressing|Gauze dressing for surgical incision
224053630|NCT00258011|BIOLOGICAL|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
224053631|NCT03387436|BEHAVIORAL|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
223442458|NCT07026110|DRUG|[18F]F-RESCA-EPCD6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]F-RESCA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-EPCD6 injection.
223442459|NCT07026110|DRUG|[68Ga]Ga-NOTA-EPCD6|Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]Ga-NOTA-EPCD6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-EPCD6 injection.
223442460|NCT07027033|OTHER|acid-rich sunflower oil oleic acid|Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of sunflower oil rich in oleic acid
223442461|NCT07027033|OTHER|conventional sunflower oil|Nutritional intervention for 13 weeks ± 2 weeks, including 40 millilitres of conventional sunflower oil
223442462|NCT07027709|DEVICE|BeautiBond Xtreme pretreatment with BeautiLink SA cementation|Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with BeautiBond Xtreme, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were also treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following a standardized clinical protocol.
223442463|NCT07027709|PROCEDURE|HC Primer pretreatment with BeautiLink SA cementation|Laminate veneers fabricated from HC hard blocks were pretreated on the internal surface with HC Primer, then bonded to tooth structure using BeautiLink SA self-adhesive resin cement. The tooth surfaces were treated with BeautiBond Xtreme. Veneers were digitally designed and milled, then cemented following the same clinical protocol used in the experimental grou
223566932|NCT05132998|OTHER|Cardiac Rehabilitation Program|In addition to standard medical care, for an 8-week period, patients will have access to the core components of a CRP, delivered by a multidisciplinary rehabilitation team
224053632|NCT03387436|BEHAVIORAL|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
224053633|NCT01075412|DRUG|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
223442464|NCT07027397|OTHER|Exercise|All participants will conduct a 2-day-a-week resistance training (RT) routine using the velocity-based method in the leg press exercise for one year. A tailored and constant intensity will be performed at 60% of the theoretical maximal isometric strength (F0) during the training intervention. Participants will conduct 3-4 sets, individualizing the repetitions numbers until they reach a velocity loss of 10-20%. A rest of 2 minutes was imposed between sets. A standardized warm-up will preced all RT session as follows: 4 minutes walking at usual gait speed and 6 minutes performing dynamic balance exercises.
223442465|NCT07026006|OTHER|Active Release Technique|Patients will receive Active Release Technique (ART) protocol will be applied to 4 muscles Including; trapezius, levator scapulae, sternocleidomastoid (SCM), and suboccipital muscles (for 15 minutes)
223442466|NCT07026006|OTHER|Strain-counterstrain|Patients will receive Strain-counterstrain (SCS) protocol will be applied to 4 muscles Including the trapezius, levator scapulae, sternocleidomastoid (SCM), and suboccipital muscles for 15 minutes.
223442467|NCT07026019|OTHER|Bruegger's relief exercise|Participant will be in a high sitting position. An elastic resistance band will be wrapped on each hand of the participant leaving the palm open and will be told to abduct and extend of thumb along with fingers, followed by wrist extension and forearm supination, the participant will be instructed to perform scapular retraction with shoulder external rotation, elbow extension, shoulder abduction, and extension and chin tuck. The treatment protocol will be for 4 weeks, having 3 sessions in a week and 4 sets of 12 repetitions in each session. Intervention was started from 10 seconds hold to 30 seconds with 2 seconds increment in every session. Rest time was 30 seconds.
223442468|NCT07026019|OTHER|Multimodal exercise program|Multimodal exercise program including chin tucks, bilateral pectoral stretching, scapular region strengthening exercises and Wand exercises. The training program applied 3 times a week, 50 minutes each time, for 4 weeks
223442469|NCT07027618|BEHAVIORAL|AI-based Software for Personalized End-of-Life Care|This intervention involves the use of an AI-powered software system designed to personalize end-of-life care for elderly patients. The software continuously monitors vital signs and behavior through wearable sensors, sends smart medication reminders, issues preventive alerts to care providers, delivers customized care plans, and provides psychological and social support through communication features.
223442470|NCT07026877|DEVICE|Fenestrated TREO Stent Graft System|"The Fenestrated TREO Stent-Graft System is a modular, endoluminal, over-the-wire system intended for the endovascular treatment of juxtarenal and pararenal to paravisceral aneurysms requiring a fenestrated stent-graft and having suitable morphology. The system is composed of the following components:~Fenestrated TREO Bifurcate Stent-Graft - The main body fenestrated bifurcate provides the following; proximal seal, fenestrations and gates for connection to the leg extensions.~Bridging Stents - The bridging stent connects the main body bifurcated device to the target visceral artery allowing the target anatomy to maintain perfusion while keeping the pathology sealed~TREO Leg and Straight Extension Stent-Grafts: The Leg Extension and Straight Extension stent-grafts are used to complete coverage of the pathology from the main body bifurcated device to the distal landing zones (usually the common iliac artery just proximal to the iliac bifurcation)."
223442471|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space isolated corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
223442472|NCT06493656|PROCEDURE|Ultrasound-guided glenohumeral space concomitant hydrodilatation with corticosteroid injection|Using a 21-gauge spinal needle, the predefined steroid solution with additional 15 mL of normal saline was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach.
223442473|NCT06493656|DRUG|1mL of Triamcinolone (40mg/1mL) Injectable Solution|1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
223442474|NCT06493656|DRUG|4mL of Lidocaine 1% Solution Injectable Solution|4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
223442475|NCT06493656|DRUG|15mL of Normal Saline|15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
223442476|NCT00416689|PROCEDURE|assessment of therapy complications|
223442477|NCT00416689|PROCEDURE|quality-of-life assessment|
223442478|NCT05998317|DRUG|At-night Dexamethasone|Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
223442479|NCT05998317|DRUG|At-induction Dexamethasone|Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
223442480|NCT00889187|RADIATION|Neoadjuvant Short-Course Photon Radiation|
223442481|NCT00889187|DRUG|Capecitabine|
223442482|NCT06614842|BEHAVIORAL|Common Factors Group Psychotherapy|This intervention will not contain active ingredients from established specific forms of psychotherapy (e.g., cognitive-behavioral therapy, dialectical behavioral therapy)
223442483|NCT03283059|DRUG|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
223566933|NCT05132998|OTHER|Community exercise intervention|In addition to standard medical care, for an 8-week period, patients will have access to a community exercise intervention oriented by a sports professional
223566934|NCT00002440|DRUG|Indinavir sulfate|
223566935|NCT00002440|DRUG|Ritonavir|
223566936|NCT00002440|DRUG|Abacavir sulfate|
223566937|NCT00002440|DRUG|Amprenavir|
223566938|NCT00002440|DRUG|Nelfinavir mesylate|
223566939|NCT00002440|DRUG|Saquinavir|
223566940|NCT03693963|DEVICE|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
223566941|NCT03239782|BEHAVIORAL|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
224053634|NCT05479214|DRUG|Metformin|1gm tablet with the 2 main meals
224053635|NCT05479214|DRUG|Insulin|subcutaneous insulin daily administration
224053636|NCT00501371|DRUG|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
224053637|NCT00501371|DRUG|Placebo|soft-gel capsule, Qd, 12 weeks
223442484|NCT03283059|DRUG|Aricept|Aricept 5mg/day, P.O.
223442485|NCT03283059|DRUG|Placebos|Placebo Tablet: P.O. tid
223442486|NCT03784794|DIAGNOSTIC_TEST|Thromboelastometry|devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated
223442487|NCT03784794|DIAGNOSTIC_TEST|Standard Coagulation Test|coagulation tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), to assess blood clotting function in patients. Clauss Fibrinogen.
223442488|NCT03784794|DRUG|Fibrinogen Concentrate Human|To treat acquired fribinogen deficiency investigators will treat with the following doses FIBTEM A5 = 9-11 MM a 2 G FIBRINOGEN CONC. (25 MG/KG); FIBTEM A5 = 4-8 MM a 4 G FIBRINOGEN CONC. (50 MG/KG); FIBTEM A5 \< 4 MM a 6 G FIBRINOGEN CONC. (75 MG/KG)
223442489|NCT03784794|DRUG|Prothrombin Complex Concentrates|to treat acquired factor deficiency investigators will treat as follows PROTROMBIN COMPLEX CONCENTRATE EXTEM CT \> 80 SEC AND FIBTEM A5 ≥ 8 MM 4F-PCC 20 IU/KG (F II, VII, IX and X) GOAL: EXTEM CT ≤ 80 SEC
223442490|NCT03784794|OTHER|Platelets|PLATELETS EXTEM A5 \< 40 MM AND FIBTEM A5 ≥ 12 MM EXTEM A5 \< 40 MM → 1 PLATELET POOL OR APHERESIS; EXTEM A5 \< 30 MM → 2 PLATELET POOL OR APHERESIS GOAL: EXTEM A5: 40-50 MM or PLATELET COUNT \< 100/µL PLT \< 100/µL → 1 PLATELET POOL OR APHERESIS; PLT \> 50/µL → 2 PLATELET POOL OR APHERESIS GOAL: PLT COUNT \> 100/µL
223442491|NCT03784794|OTHER|Red Blood Cells|"Transfuce Red Blood Cells if Hemoglobine levels \< 7 G/DL;~1 unit of FFP for every unit of RBC Transfused GOAL: Hb \> 7.5 G/DL"
223442492|NCT03784794|OTHER|Fresh Frozen Plasma|FRESH FROZEN PLASMA TP AND/OR TTP PATHOLOGICAL INR, 2.0-4.0 → FFP 20 ML/KG GOAL: TP AND TTP NORMAL AND INR \< 2.0
223566942|NCT00785421|DRUG|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS \< 80 % and increased creatinin plasma levels (\>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
223566943|NCT00785421|DRUG|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
223566944|NCT00785421|DRUG|only chemotherapy|observation, no treatment with LMWH
224053638|NCT03959332|DRUG|Baloxavir Marboxil|Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
224053639|NCT00554359|DRUG|I5NP (a small interfering RNA)|Single IV injection of experimental drug
224053640|NCT00554359|DRUG|placebo|Single IV injection of saline
224053641|NCT04278209|OTHER|Breakfast 1|Participant will receive Breakfast 1
224053642|NCT04278209|OTHER|Breakfast 2|Participant will receive Breakfast 2
224053643|NCT04278209|OTHER|Water|Participant will receive water
224145476|NCT04273009|DEVICE|Renew VS PTNS|These will be prescribed and applied as described above.
223442493|NCT03784794|OTHER|cryoprecipitates|FIBRINOGEN (CLAUSS) \< 250 MG/DL FIB 200-250 MG/DL → CRYOS, PACK OF 10 (25 MG/KG); FIB 100-200 MG/DL → CRYOS, PACK OF 20 (50 MG/KG); FIB \< 100 MG/DL → CRYOS, PACK OF 30 (75 MG/KG) GOAL: FIB \> 250 MG/DL
223442494|NCT03164655|DRUG|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil|Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
223442495|NCT03852927|PROCEDURE|Computer guided contouring|Using virtual planing and rapid prototyping a surgical guide will be fabricated, and will be used for bone contouring of the bone lesion.
223566945|NCT00539513|DRUG|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
223442496|NCT00284427|DRUG|vitamin C|IV Vitamin C given 2-3 times a week
223442497|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
223442498|NCT04015518|DRUG|Placebo|Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
223442499|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
223566946|NCT00539513|DRUG|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
223566947|NCT00004206|DRUG|FOLFOX regimen|
223566948|NCT00004206|DRUG|fluorouracil|
223566949|NCT00004206|DRUG|leucovorin calcium|
223566950|NCT00004206|DRUG|oxaliplatin|
224053644|NCT02816307|OTHER|blood samples|
224053645|NCT02431091|OTHER|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
224053646|NCT05055609|DRUG|TRE-515|TRE-515 will be administered orally once daily at least 1 hour prior or 2 hours after eating at approximately the same time each day. Dosing will be continuous with no breaks between cycles. Subjects will continue to receive successive cycles of TRE-515 treatment as long as they do not demonstrate progressive disease, experience an unacceptable toxicity, and both the Sponsor and PI consider additional treatment with TRE-515 to be within the best interest of the subject.
224053647|NCT01954186|DRUG|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
224145477|NCT01812122|DRUG|Glimepiride|
224145478|NCT01812122|DRUG|Vildagliptin|
224145479|NCT02327156|DRUG|dexmedetomidine|adding dexmedetomidine to the local anesthetic
224145480|NCT00105560|RADIATION|radiation therapy|Radiation therapy with proton beam to standard doses
224145481|NCT01200160|DRUG|Niacin|
224145482|NCT01567891|BIOLOGICAL|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
223442500|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
223442501|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
223442502|NCT04015518|DRUG|Spesolimab|Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
223442503|NCT05278338|DRUG|JMT103|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
223442504|NCT05278338|DRUG|Denosumab|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
223442505|NCT05278338|DRUG|Placebo|subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
223442506|NCT03525028|DRUG|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
223442507|NCT03525028|DRUG|Placebo|The investigators use placebo in the control group.
223442508|NCT05995249|DRUG|TAK-279|TAK-279 capsules
223442509|NCT05995249|DRUG|Erythromycin|Erythromycin tablets
223741046|NCT07207304|PROCEDURE|Anesthesia induction with TCI|During induction, patients will receive fentanyl (2-3 µg/kg), propofol (1-1.5 mg/kg) as a bolus or via TCI, and rocuronium (0.5-0.6 mg/kg) to facilitate anesthesia induction and ensure adequate neuromuscular relaxation for endotracheal intubation. Anesthesia will be maintained using TIVA with 1% propofol administered via TCI, guided by the Schneider pharmacokinetic model. The initial target effect-site concentration will be 4 µg/mL and will be titrated intraoperatively to maintain a BIS value between 40 and 59.
224053648|NCT01954186|PROCEDURE|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
224053649|NCT03394144|DRUG|AZD9150, Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
223442510|NCT05995249|DRUG|Phenytoin|Phenytoin capsules
223442511|NCT05995249|DRUG|Efavirenz|Efavirenz tablets
223442512|NCT03499275|DEVICE|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
223442513|NCT03499275|DEVICE|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
223442514|NCT03499275|OTHER|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
223442515|NCT03499275|OTHER|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
224053650|NCT01179464|DRUG|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
224053651|NCT01179464|DRUG|Simvastatin|40 mg once daily
224053652|NCT05239533|DRUG|177Lu-labeled-girentuximab|"The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence."
224053653|NCT05239533|DRUG|Nivolumab|Nivolumab 240mg q2wk
224053654|NCT05239533|DIAGNOSTIC_TEST|89Zr-girentuximab PET/CT|All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
224053655|NCT05239533|DIAGNOSTIC_TEST|177Lu whole body (WB) planar and SPECT/CT scans|177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
223442516|NCT06912035|DRUG|Diacerein 50 mg Capsule|The patients received diacerein capsules
223442517|NCT06912035|DRUG|Placebo|Patients received placebo capsules
223442518|NCT06533852|DRUG|Fecal Microbiome Transplantation (FMT)|"Two doses:~First dose: 24 capsules of FMT at baseline. Second dose: 24 capsules of FMT at 3 months."
224053656|NCT03506035|DIAGNOSTIC_TEST|Research new biomarker for RA|Analyze T and B cell response against new citrullinated peptides
224053657|NCT02772640|DRUG|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -\> evening evening -\> morning"
224053658|NCT04782011|BEHAVIORAL|ATC/DDD|The intervention is the introduction of the ATC/DDD including the training on its importance and usage in monitoring antibiotic use at a given primary care facility.
224053659|NCT04579562|OTHER|No intervention|This is observational, non-interventional study
224053660|NCT04961853|RADIATION|Ultrasound and MRI|Ultrasound examination and magnetic resonance imaging on the hand
224053661|NCT04787094|OTHER|Yoga|Yoga
224053662|NCT04787094|OTHER|Spinal Stabilization Exercise|Spinal Stabilization Exercise
223442519|NCT06533852|OTHER|FMT Placebo|"Two doses:~First dose: 24 capsules of FMT placebo at baseline. Second dose: 24 capsules of FMT placebo at 3 months."
223442520|NCT06911021|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET/CT|A single-dose intravenous injection of the radiotracer 68Ga-FAPI-46 will be administered to participants. Approximately 60 minutes after injection, a whole-body PET/CT scan will be performed. The scan is designed to detect areas of high fibroblast activation protein (FAP) expression in and around pancreatic tumors, providing high-resolution images of tumor margins and potential spread. The goal is to evaluate whether this imaging method offers more accurate and useful information than standard imaging (MRI and CT) for preoperative staging and surgical planning.
223442521|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18，intravenous infusion, once every 2 weeks.
223442522|NCT05584800|BIOLOGICAL|ZGGS18 for Injection|Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18，intravenous infusion, once every 2 weeks.
223442523|NCT00505661|DRUG|Letrozole|2.5 mg PO Once Daily
223442524|NCT06911333|DRUG|AD1208|Up to 6 of cohorts will be applied sequentially in phase Ia part.
224053663|NCT02692365|PROCEDURE|Magnetic Resonance + hemodynamic + infusion of gadolinium|
224053664|NCT06440109|OTHER|Emotional freedom technique (EFT)|İntervention groups will be followed for six months and one of the six EFT therapies will be applied, one session every week.
224053665|NCT06440109|OTHER|Therapeutic touch (TD)|İntervention groups will be followed for six weeks and one of the six TD therapies will be applied, one session every week.
224053666|NCT00812799|DRUG|Oralgen|19.000 BU daily
224053667|NCT00812799|OTHER|placebo control|placebo control
223442525|NCT02795845|DIETARY_SUPPLEMENT|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
224145483|NCT06294041|BEHAVIORAL|Sleep Restriction Therapy (SRT)|SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses
223442526|NCT02795845|OTHER|Placebo|capsule without active ingredient
223442527|NCT03630913|PROCEDURE|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
223442528|NCT05391919|OTHER|Multimodal technology (MT)|"Patients will receive a course of rehabilitation with multimodal correction using BOS-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator SensoRehab, in moderate paresis of the upper limb, the neurointerface Exokist-3 with EEG registration will be used. The program for IS patients includes 15 sessions with the MT: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours."
223442529|NCT05391919|OTHER|Conventional rehabilitation (CR)|The patients will recieve Conventional rehabilitation technology (physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients includes 15 sessions with the CR: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
223442530|NCT05627752|DRUG|Enzalutamide 40 MG|Adding Enzalutamide to Docetaxel chemotherapy
223442531|NCT05627752|DRUG|Docetaxel injection|Docetaxel chemotherapy
223442532|NCT01861873|OTHER|measuring liver function by 18-FDGal PET/CT|
223442533|NCT04291742|DIAGNOSTIC_TEST|cognitive vs software|cognitive vs software
223442534|NCT06442449|BIOLOGICAL|sIPV|vaccination with sIPV
223442535|NCT06442449|BIOLOGICAL|MMR|vaccination with MMR
223442536|NCT06442449|BIOLOGICAL|HepA-I|vaccination with HepA-I
223442537|NCT04353154|DIAGNOSTIC_TEST|Spartan Cube Point-of Care Covid-19 test|Throat and nasal swab for COVID-19 point-of-care test.
223442538|NCT03129711|OTHER|glazed Celtra Duo|zirconia reinforced lithium silicate
223442539|NCT03129711|OTHER|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
224053668|NCT05796375|PROCEDURE|Cystoscopy|Cystoscopy entails direct inspection of the bladder via a cystoscope that is inserted into a patient's urethra.
224053669|NCT05796375|DIAGNOSTIC_TEST|Bladder EpiCheck urine test|The Bladder EpiCheck is a laboratory-developed test for early-stage non-muscle invasive bladder cancer. The Bladder EpiCheck test is a DNA methylation test that is run on DNA extracted from cell pellet from centrifuged urine according to Standardized Operating Procedures. The test has internal controls and a dedicated software to ensure required quality assurance processes and prompt reporting of results.
224053670|NCT05796375|DIAGNOSTIC_TEST|Xpert Bladder Cancer Monitor urine test|A 4.5 ml sample of voided urine is added to Xpert® Urine Transport Reagent, mixed, and then 4ml of treated urine are transferred to the Sample Chamber of the cartridge. In the cartridge, cells in the urine sample are captured on a filter and lysed by sonication. The released nucleic acid is eluted, mixed with dry RT-PCR reagents, and the solution is transferred to the reaction tube for RT-PCR and detection.
223442540|NCT01738191|DRUG|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
224145484|NCT06294041|BEHAVIORAL|Sleep Hygiene Education (SHE)|SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
223442541|NCT01738191|DRUG|Placebo|
223442542|NCT05343091|DEVICE|cardiac ultrasound|Cardiac ultrasound with Pocket ultrasound by expert and non expert physician
223442543|NCT04562220|OTHER|Routine conventional physical therapy plus Vibration session|Routine conventional physical therapy will be applied to patients in the vibration group in 4 weeks and 45 minutes sessions. In addition, right after the sessions, 3 days a week, 30 Hz. frequency vibration will be applied. A vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest.
223442544|NCT04562220|OTHER|Routine conventional physical therapy|Routine conventional physical therapy will be applied to the control group in 4 weeks and 60 minute sessions
223566951|NCT00871039|DRUG|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
223566952|NCT00871039|DRUG|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
223566953|NCT01977443|DRUG|APD-209 Eye drops|
223566954|NCT01977443|DRUG|APD-209 Placebo Eye drops|
223566955|NCT04086797|DIETARY_SUPPLEMENT|IQP-AE-103|1980 mg
223566956|NCT04086797|DIETARY_SUPPLEMENT|Placebo|Placebo
223566957|NCT01225965|DEVICE|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
223566958|NCT01225965|DEVICE|Placebo|Once daily inhalation of Placebo Inhalation Solution
223442545|NCT06910475|OTHER|Resistance training|"The training program will follow a periodized approach, starting with a low total volume (loads x sets x repetitions), ensuring gradual adaptation, patient safety, and performance progression. Strength training will begin 48 hours after muscle strength tests.Sessions will occur 2 to 4 times per week on non-consecutive days. Each session will include 6-12 exercises, with 1-3 seconds for concentric and eccentric actions, 6-20 repetitions, 1-6 sets, and 1-3 minutes of rest. Intensity will be gauged by perceived exertion, ranging from easy to hard, with load adjustments every 2 months based on progress.Patients undergoing hemodialysis may perform the sessions during or between treatments. Portable equipment like free weights, ankle weights, and resistance bands will be used."
223442546|NCT06910475|OTHER|Endurance training|Training sessions will be conducted 2 to 4 times per week on non-consecutive days. Patients will perform aerobic training on different ergometers, namely: bicycle, treadmill, and stair climber. The choice will depend on the patient's needs/abilities and/or equipment availability. The load will be adjusted between 50% and 100% of the ventilatory threshold, according to the patient's cardiorespiratory capacity. The duration of the training will vary between 10 and 60 minutes, always starting with low load and volume, with gradual progression to ensure patient comfort and safety.
223442547|NCT06910475|OTHER|Concurrent training|Training sessions will be conducted 2 to 6 times per week, alternating between strength training one day and aerobic training the next, as described above. As patients improve their physical fitness, strength and aerobic training may be performed on the same day.
223566959|NCT06456229|DIETARY_SUPPLEMENT|Nestle Isocal|Nestle Isocal
223566960|NCT06456229|DIETARY_SUPPLEMENT|Nestle Boost Optimum|Nestle Boost Optimum
224053671|NCT05837351|BEHAVIORAL|Exercise -Running|"At baseline participants will wear a Fitbit for one week and attend the Runner's Assessment. After this the participant will begin to run 3 times per week for eight weeks. Every week, participation in a virtual support group with the physical therapist, research coordinator, and other research staff will be expected. Rest-activity cycles' data will be monitored; if at any point the runner is not able to complete 3 runs per week, participants will be encouraged to contact research staff the issues for this (such as medical problem or scheduling difficulty) and formulate plans to remediate the situation. Participants that would like to continue the treatment for an additional eight weeks will have additional data collected.~Participants will also wear the Fitbit through-out the study and complete surveys during the study and have blood drawn."
224053672|NCT01329679|DIETARY_SUPPLEMENT|Energy Drink|Energy drink, 2oz twice daily for 7 days
224053673|NCT01329679|OTHER|Placebo|Water, lime juice and cherry flavoring
224053674|NCT03980834|BEHAVIORAL|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
224053675|NCT03980834|BEHAVIORAL|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
224053676|NCT03980834|BEHAVIORAL|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
224053677|NCT03980834|BEHAVIORAL|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
224053678|NCT04042168|DIAGNOSTIC_TEST|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
224053679|NCT05885438|BEHAVIORAL|ACT workshop|This workshop is a brief behavioral intervention that teaches acceptance and commitment therapy skills (e.g., values clarification, acceptance, committed action) to approach healthy living.
224145485|NCT04514588|DIETARY_SUPPLEMENT|caffeine consumption|In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
224145486|NCT01457001|DRUG|25-OH-D vitamin|
224145487|NCT02176291|DRUG|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
224145488|NCT02176291|DRUG|Placebo|matched placebo
224145489|NCT03506022|OTHER|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram \[chin\], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
224145490|NCT01086150|PROCEDURE|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
224145491|NCT01086150|DRUG|Lidocaine 5% patches|Subject will apply patches to affected area QD for 12 hours then remove.
223566961|NCT01055665|OTHER|cognitive behavior therapy|6 cognitive behavior therapy groups
223566962|NCT06167005|PROCEDURE|Primary bariatric-metabolic surgery|Primary bariatric-metabolic surgery
223566963|NCT01328041|DRUG|dolutegravir|50 mg twice daily
223566964|NCT06351319|DIAGNOSTIC_TEST|SVM model|Bronchoscopic ultrasound images were analyzed according to SVM mode
223566965|NCT03079401|BIOLOGICAL|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
223566966|NCT05685563|DIAGNOSTIC_TEST|DIERS formetic 4D|Assessment of mentioned tests and their comparison.
223566967|NCT00418431|DRUG|Intravitreal injection of Bevacizumab|
223442548|NCT06910904|COMBINATION_PRODUCT|Constraint-Induced Movement Therapy (CIMT)|CIMT is a intensive training sessions of 6 hours/day for 5 weeks, focusing on functional tasks with the paretic arm while constraining the unaffected arm using a mitt or sling. Implement a constraint on the non-paretic arm to encourage increased use of the affected arm in daily activities. Use shaping techniques to gradually increase the complexity and difficulty of tasks performed with the affected arm (Rahman, 2016). Most commonly, the protocol continues to be 2 weeks in duration but the intensity is adjusted such that the restraint is worn for approximately 6 h per day and therapy is administered for 2 to 3 h per day (MacKenzie \& Viana, 2024). But this study implementing a 2 hour CIMT protocol with 6h restrain for 8 weeks in sub-acute stroke rehabilitation balances therapeutic intensity with practical considerations, potentially enhancing patient engagement and rehabilitation outcomes within clinical settings (Chen et al., 2014; Udoeyop, 2017).
223442549|NCT06910904|COMBINATION_PRODUCT|Mirror Therapy (MT)|A specific intervention that uses a mirror to create a visual illusion of the affected limb, with the goal of improving motor function and quality of life in chronic stroke patients. In mirror therapy, the patient is asked to move the unaffected limb while watching the moving limb being reflected in the mirror. The congruent visual feedback through the mirror affects brain lesions and motor-related areas on the affected side, facilitating motor recovery. Patients with chronic stroke who can benefit from visual feedback to enhance motor recovery (Gandhi et al., 2020; Rothgangel \& Braun, 2013). Mirror therapy sessions should last at least 10 minutes daily, with the option to increase up to 30 minutes for optimal benefits. Practice mirror therapy exercises at least once a day. Perform gentle movements with the intact limb while observing its reflection in the mirror(Crosby et al., 2016).
223442550|NCT01318746|PROCEDURE|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
223566968|NCT02144987|BIOLOGICAL|Bone Marrow CD133+ Stem Cell Transplantation|"1. Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~2. BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~   The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~3. CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~4. Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~5. Hysteroscopy will be performed 2-3 months after stem cell transplantation~6. Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
223566969|NCT06300125|PROCEDURE|Cryoablation|Percutaneous Cryoablation of Breast Cancer
223566970|NCT05134662|DRUG|ALT-801|Injected subcutaneously (SC)
223566971|NCT05134662|OTHER|Placebo|Injected subcutaneously (SC)
224053680|NCT06234150|OTHER|Aerobic dance|Patients assigned to the aerobic dance group will participate in a one-on-one training session before their first chemotherapy session, including aerobic dance instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
224053681|NCT06234150|OTHER|Fast-walking|Patients assigned to the fast-walking group will participate in a one-on-one training session before their first chemotherapy session, including fast-walking instruction, teleconference participation, use of a heart rate bracelet, and use of the Perceived Exertion Rating (PRE) until they master all components. The researchers will also provide participants with instructional videos to view anytime. We will require an exercise log to record the number of workouts, the intensity of the workout using the PRE and heart rate, and the presence of adverse effects. An experienced physical therapist will remotely supervise patients via teleconferencing at home. They will exercise for 50 min three times per week for 12 weeks. The physiotherapist monitors the patient\&amp;#39;s heart rate throughout the exercise program and provides feedback on any problems encountered during exercise.
224053682|NCT00237848|DRUG|D-serine|
224053683|NCT00237848|BEHAVIORAL|Cognitive retraining|
224053684|NCT05139849|DRUG|Vasopressin; Methylprednisolone; Hydrocortisone|"Vasopressin, the vasoconstrictive hypophysal hormone, alone has not shown increased survival when compared to adrenaline. However, animal data have shown increased diastolic pressure, cerebral perfusion pressure and cerebral oxygenation in cardiac arrest treatment with vasopressin, and have when compared to adrenaline been associated with better cerebral blood flow.~Corticosteroids are currently used in septic shock treatment as a means to reduce time to shock reversal and thereby potentially improving mortality. Steroids have therefore also been suggested for cardiac arrest treatment. The potential role in resuscitation includes the catecholaminerg potentiation, vasoconstriction and protection from reperfusion injury."
224053685|NCT05139849|DRUG|Sodium chloride|Sodium chloride 9 mg/ml
224053686|NCT02056054|OTHER|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
224053687|NCT02056054|OTHER|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
224053688|NCT02056054|OTHER|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
224145492|NCT05685576|DEVICE|Piezotomed ridge splitting and osseodensification|Ridge expansion using piezotomed ridge splitting and osseodensification
224145493|NCT01578057|DRUG|tasimelteon|20mg, once
224145494|NCT01578057|DRUG|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
224145495|NCT01578057|OTHER|Placebo tasimelteon|once
223566972|NCT06405737|DRUG|Intranasal oxytocin|Subject assigned to receive intranasal administration of oxytocin (24 IU).
223566973|NCT06405737|DRUG|Intranasal placebo|Subjects assigned to receive intranasal administration of placebo (24 IU).
223442551|NCT01051440|DRUG|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
223442552|NCT01051440|DRUG|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
223442553|NCT05093985|OTHER|Neuromuscular electrical stimulation with blood flow restriction|Neuromuscular electrical stimulation with blood flow restriction
223442554|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
223442555|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
223442556|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
223442557|NCT02109445|DRUG|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
223442558|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
223442559|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
223442560|NCT02109445|DRUG|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
223442561|NCT02109445|DRUG|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
223442562|NCT04291456|DRUG|Minocycline 100mg|Single-arm trial of minocycline 100 mg twice daily
223442563|NCT06911086|DEVICE|3D printed models|A three-dimensional digital model is constructed based on the patient's preoperative CT/MRI images, and a personalized physical model is created using 3D printing. This model has the ability to self-heal after being cut. Surgeons can perform multiple simulated surgeries on the model to plan the optimal surgical path before the authetic surgery
223442564|NCT06911086|OTHER|CT or MRI image|Obtain the patient's CT/MRI images and determine the definitive surgical path based on the two-dimensional images.
223442565|NCT01636648|DEVICE|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
223442566|NCT05380986|DRUG|Camrelizumab combined with apatinib mesylate|Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
223442567|NCT06912282|DEVICE|deep brain stimulation|bilateral single-electrode VO combined with STN target implantation
223442568|NCT00727090|DRUG|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
223442569|NCT00106834|DRUG|Infliximab|
223442570|NCT00157716|DRUG|(MC-1) Pyridoxal-5'-phosphate|
223442571|NCT04077710|RADIATION|Radioactive Iodine-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing template includes information on the path of the implantation needle, characteristics of the surface of the therapy area of the patient, and positioning and orientation effects which can make the operation more accurate.
223442572|NCT04760106|DIAGNOSTIC_TEST|gastric ultrasound|"For the qualitative assessment, every participant was scanned once by both examiners. Each scan session lasted no longer than 5 minutes to mitigate the confounding effect of gastric emptying time.~For the quantitative assessment, the participants were put in a right lateral decubitus position and the antral cross-sectional area (CSA) is measured in the sagittal plane."
223442573|NCT03519100|OTHER|quality of life evaluation|quality of life evaluation post surgery
223442574|NCT01506687|BEHAVIORAL|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
223741047|NCT07207304|PROCEDURE|sevoflurane anesthesia|"During induction, patients will receive fentanyl (2-3 µg/kg), propofol (1-1.5 mg/kg), and rocuronium (0.5-0.6 mg/kg) to facilitate anesthesia induction and ensure adequate neuromuscular relaxation for endotracheal intubation.~For patients in the inhalation anesthesia group, maintenance will be performed using sevoflurane. The end-tidal concentration of sevoflurane (EtSevo) will be maintained between 1.0 and 1.5 MAC, with adjustments in increments or decrements of 0.25-0.5 MAC, depending on the BIS value, which will be maintained between 40 and 59."
224053689|NCT02056054|OTHER|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
224053690|NCT02056054|OTHER|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
224053691|NCT02056054|OTHER|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
224053692|NCT02056054|OTHER|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
224145496|NCT01578057|DRUG|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
224145497|NCT05080959|DRUG|CPL-01|Subjects will receive a single dose
224145498|NCT05080959|DRUG|Naropin 150 MG Per 20 ML Injection|Subjects will receive a single dose
224145499|NCT05080959|DRUG|Placebo|Subjects will receive a single dose
223442575|NCT01506687|BEHAVIORAL|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
223566974|NCT01344681|DRUG|Micafungin sodium|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   \- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~3. Administration Method:~   * Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
224053693|NCT03482687|BEHAVIORAL|Me & You: Building Healthy Relationships|Me \& You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
224053694|NCT05304650|DEVICE|iTEAR100|Controlled Stimulation External Nasal Nerve to stimulate tear production
224053695|NCT01963429|PROCEDURE|radiofrequency ablation|"\* RFA(radiofrequency ablation )~* RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~* performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~* the duration of a single RFA session was 10 min to 15 min."
224053696|NCT01963429|RADIATION|Proton beam therapy|"\* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30\<40%,and/orRLV30\<30%)"
224053697|NCT00865904|DRUG|VX-809|Capsules
224053698|NCT00865904|DRUG|Placebo|Placebo matched to VX-809 capsules.
224053699|NCT00517322|DRUG|ramipril|ramipril 2.5- 5 mg once daily
224053700|NCT00517322|DRUG|irbesartan|irbesartan 150-300 mg once daily
224053701|NCT03625687|DRUG|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks|8 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
224053702|NCT00454038|DEVICE|HYPRO SORB F|resorbable, double layered, collagen membrane
224053703|NCT02372916|DRUG|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
224053704|NCT00941668|DRUG|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
224053705|NCT00941668|DRUG|sodium monofluorophosphate toothpaste|Twice daily usage
224053706|NCT04593667|DEVICE|hm-P bandage|hm-P bandage will be placed over the puncture site with the TR band positioned over the hemostatic bandage. The TR band will then be inflated per device specific instructions and to the group instructions. The arterial sheath will be removed from the body with slight device rotation.
224053707|NCT01396226|DRUG|AZD2927|A single dose of AZD2927 administered as an iv infusion
224053708|NCT01396226|DRUG|Placebo|A single dose of placebo administered as an iv infusion
224145500|NCT01597037|BEHAVIORAL|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
224145501|NCT00354497|OTHER|physiologic testing|
223442576|NCT04304261|DRUG|Canagliflozin|12 weeks of Canagliflozin(100mg/day) treatment
223442577|NCT04304261|DRUG|Sitagliptin|12 weeks of Sitagliptin (100mg/day) treatment
223442578|NCT02192853|DRUG|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
223442579|NCT02192853|DRUG|Placebo|Day 4: placebo tablet
223566975|NCT01344681|DRUG|Itraconazole|"1. Treatment period (active treatment): an average 14 days~2. Dosage:~   \- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~3. Administration Method:~   * Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
223566976|NCT00951236|DRUG|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
223566977|NCT00951236|DRUG|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
224053709|NCT05217121|OTHER|Quadratus Lumborum Block|The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the abdominal muscles, the needle will be punctured and 5 ml of saline will be injected into the postero-lateral border of the quadratus lumborum muscle. After the block location is confirmed, 15 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (30 ml totally).
224145502|NCT00354497|OTHER|study of socioeconomic and demographic variables|
224145503|NCT00354497|PROCEDURE|evaluation of cancer risk factors|
224145504|NCT00354497|PROCEDURE|mutation carrier screening|
224145505|NCT00354497|PROCEDURE|study of high risk factors|
224145506|NCT01191905|DRUG|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
224145507|NCT01191905|DRUG|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
224145508|NCT03242005|DEVICE|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
224145509|NCT03242005|DEVICE|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
224145510|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
224145511|NCT00805545|DRUG|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
224145512|NCT04907591|DEVICE|mHealth App and wearable device|an intervention group (App+IoT device) uses a smart care application tailored to gastric cancer patients created by reflecting the treatment process immediately after surgery and a wearable smart band worn on wrist for 12 months.
223442580|NCT03089853|DEVICE|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
223442581|NCT04857853|OTHER|Exercise Without Rest Break|"Participants in the exercise group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Exercises include shoulder shrugs, neck tilts, wrist and forearm stretch, back and hip stretch, upper body stretch, hamstring stretch, upper back stretch, hand/finger stretch. Side stretch and neck stretch.~Follow up 3 times a week for 5 weeks."
223442582|NCT04857853|OTHER|Exercise With Rest Break|"Participants in the exercise with rest break group will receive 'Exercise Breaks', of 10 minutes, twice a day during the work hours, in addition to the two 'Conventional Rest Breaks' of 15 minutes, twice a day during the work hours.~Participants will also receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation Follow up 3 times a week for 5 weeks."
223442583|NCT04857853|OTHER|Rest Break|"Participants in the rest breaks group will receive 'Supplemental Micro Breaks', of 30 seconds after every 15 minutes of working on a static computer workstation in addition to the two 'Conventional Rest Breaks' of 15 minutes twice a day during the work hours.~Follow up 3 times a week for 5 weeks. During the rest breaks, participants will not perform any exercises."
223442584|NCT01742754|OTHER|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
223442585|NCT00025753|DRUG|rosiglitazone (Avandia)|
223442586|NCT00025753|BEHAVIORAL|Aerobic and weight lifting exercise training|
223442587|NCT05436353|OTHER|Turkish validity and reliability|Contact with developers and formation of steering committee Translation from English to Turkish Back translation from Turkish to English Comparison of translation Review of translated versions. Reaching consensus and development of pilot version Testing in clinical setting Revision of pilot version Testing of final version
223442588|NCT02419651|DRUG|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
223442589|NCT02419651|DRUG|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
223442590|NCT02419651|DRUG|Placebo|Women will receive a placebo 1 hour before the procedure
223442591|NCT02142205|BIOLOGICAL|BG00002|IV Infusion
223566978|NCT03015649|DEVICE|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
223566979|NCT04778163|BEHAVIORAL|Clinical use of humor|"Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being."
223566980|NCT00202709|BEHAVIORAL|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
224145513|NCT06213129|DEVICE|Na and ultrafiltration profiling|Sodium and ultrafiltration profiling are method of dialysis in which dialysate sodium concentration and ultrafiltration rate are altered during the course of the dialysis session
223442592|NCT01957839|DRUG|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
223566981|NCT06457646|GENETIC|Genetic polymorphism|The biological significance of HTR2A and DRD3 in bruxism remains unclear as molecular analyses, including genetic association studies, have not explored the mRNA expression of genes implicated in bruxism. This study aims to evaluate the influence of genetic polymorphisms affecting DRD3 (rs6280) and HTR2A (rs6313) on bruxism to identify potentially associated genotypes. Additionally, it aims to investigate the expression of HTR2A and DRD3 to elucidate their biological significance in bruxism.
223566982|NCT04039711|PROCEDURE|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
223566983|NCT04603781|DIETARY_SUPPLEMENT|CBD Isolate|300 mg. daily dose of CBD Isolate Oil
223566984|NCT04603781|DIETARY_SUPPLEMENT|Full Spectrum CBD Oil|300 mg. daily dose of CBD with full spectrum of other cannabinoids found in the hemp plant
223566985|NCT04603781|DIETARY_SUPPLEMENT|Broad-Spectrum CBD Oil|300 mg. daily dose of CBD with a selected spectrum of other cannabinoids found in the hemp plant
223566986|NCT04603781|DIETARY_SUPPLEMENT|Placebo Oil|MCT Oil with mint flavoring
224145514|NCT03304470|DRUG|ATx201 2% Cream|Anhydrous Cream
223566987|NCT02563535|DEVICE|DEB|angioplasty with Litos drug eluting balloon
223566988|NCT02563535|DEVICE|PTA|angioplasty with conventional balloon
223566989|NCT05418283|BEHAVIORAL|Exercise|1 hour of aerobic exercise will be applied 3 days a week for 12 weeks.
223566990|NCT03860012|DRUG|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
223566991|NCT02200328|DRUG|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
223566992|NCT02200328|DRUG|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
223566993|NCT02916888|OTHER|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
224145515|NCT03304470|DRUG|ATx201 Cream Vehicle|Anhydrous Cream
224053710|NCT05217121|OTHER|Modified-thoracolumbar interfascial plane block|US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 15 mL will be injected in each side (30 ml totally).
223741048|NCT07207304|DRUG|Lidocaine Infusion|During induction, a 1.5 mg/kg intravenous bolus of 1% lidocaine will also be administered. In the maintenance phase of anesthesia, a continuous infusion of 1% lidocaine at 2 mg/kg/hour-up to a maximum of 200 mg/hour-will be administered, starting after endotracheal intubation and continued until emergence from anesthesia.
224053711|NCT00321750|DRUG|1% pimecrolimus cream|
224053712|NCT04315181|DRUG|Opioid Agonist|Abuse liability evaluation.
224053713|NCT04315181|DRUG|Sedatives|Abuse liability evaluation.
224053714|NCT00711425|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
224053715|NCT01023867|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
224053716|NCT05119608|BEHAVIORAL|CBT/ACT|10-session ACT-re-enforced CBT intervention.
224053717|NCT06000995|OTHER|Survey Questions|Thirty questions generally consist of three parts; In the first part, there are 8 questions containing the personal information of the doctors (age, gender, title, institution, etc.). In the second part, 13 questions were included in order to make a general assessment such as the sedative agents used by the doctors before and during the bronchoscopy procedure and the satisfaction with the sedative method used. In the third part, 9 questions were given to determine the preferred follow-up methods during the procedure.
224053718|NCT01944683|OTHER|Placebo|
224053719|NCT01944683|DRUG|GGF2|
224053720|NCT01944683|DRUG|Midazolam|
224053721|NCT00585611|DRUG|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
224053722|NCT00585611|OTHER|placebo|placebo
224053723|NCT05879107|BIOLOGICAL|RSVPreF3 OA investigational vaccine|One dose of RSVPreF3 OA vaccine given intramuscularly in participant's non-dominant arm on Day 1 (in the Coad group) or Day 31(in the Control group).
224053724|NCT05879107|BIOLOGICAL|PCV20|One dose of the 20-valent pneumococcal conjugate vaccine (PCV20) given intramuscularly in participant's dominant arm (Coad group) or non-dominant arm (Control group) on Day 1
224053725|NCT05800340|BIOLOGICAL|Toripalimab|240mg Q3W
224053726|NCT05800340|DRUG|Nab paclitaxel|135 mg/m2, d1, 8 Q3W
224053727|NCT05800340|DRUG|Pemetrexed|500mg/m2, d1 Q3W
224053728|NCT05800340|DRUG|Carboplatin|AUC 5, d1 Q3W
224053729|NCT00376337|DRUG|Micafungin|IV
224053730|NCT00376337|DRUG|Systemic antifungal therapy|IV
224053731|NCT02398708|OTHER|Questionnaires|Both groups will have questionnaires collected and compared.
224053732|NCT02398708|OTHER|Blood Sample|Both groups will have a blood sample collected and compared.
224053733|NCT02398708|OTHER|Stool Sample|Both groups will have a stool sample collected and compared.
224053734|NCT02398708|OTHER|Clinical data|Both groups will have clinical data collected and compared.
224053735|NCT01217398|BIOLOGICAL|bevacizumab|
224053736|NCT01217398|DRUG|temozolomide|
224053737|NCT01217398|GENETIC|polymorphism analysis|
224053738|NCT01217398|OTHER|pharmacogenomic studies|
224053739|NCT05106673|BEHAVIORAL|Optimal pathways to care|The first implementation measure focuses on optimal ways of caring for mentally ill patients who are also parents with children living in the household. The main goals of this intervention are the specific information of the referring physician, the indicated referral of mentally ill parents and the consideration of underage children living in the household in the inpatient referral. The two main components are the evaluation of the attitudes of the medical and psychotherapeutic referrers towards the target group and the intervention as well as the development and implementation of an optimal care pathway. The optimization of the allocation is organized by Silke Pawils (University Medical Center Hamburg-Eppendorf).
224053740|NCT05106673|BEHAVIORAL|Education and training program for the professionals|The second implementation intervention concerns the improvement of the professionals' attitudes, knowledge and skills. The two main components here being the assessment of the current state in all institutions within the clinical centers and the development and implementation of an education and training program. The employees of the randomized clinical centers in the intervention group will get a three-hour training. This intervention is organized by Svenja Taubner (University Hospital Heidelberg, Germany).
224053741|NCT05106673|BEHAVIORAL|Systematic screening|The third implementation intervention includes a systematic screening process to improve detection of mentally ill parents with affected children. Employees of the clinical centers fill out two short questionnaires with the parents. This intervention project is organized by Sibylle M. Winter (Charité, Berlin, Germany).
224053742|NCT05106673|OTHER|TAU|No Intervention: Treatment as usual These clinical centers will be the control group and will not get a specific implementation support during the implementation of CHIMPS.
224053743|NCT03213964|BIOLOGICAL|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~* Dose Level 1: 1 x 10\^7 cells/kg IP~* Dose Level 2: \>1x10\^7 cells/kg to ≤3x10\^7 cells/kg~* Dose Level 3: Complete FATE-NK100 bag (≥3 x 10\^7 to ≤ 10 x 10\^7 cells/kg)"
224053744|NCT03213964|DRUG|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
224053745|NCT00708149|DRUG|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
224145516|NCT00150059|DRUG|Pimecrolimus Cream 1%|
224053746|NCT00708149|DRUG|placebo|takepron placebo
224053747|NCT02485457|PROCEDURE|Volume loading|Volume loading with Ringer Lactate
224053748|NCT02485457|DRUG|Ringer solution|
224053749|NCT00408395|BIOLOGICAL|Influenza vaccine|Seasonal Influenza Vaccine
224053750|NCT05532449|DRUG|Intravenous dizocine|Intravenous dizocine (0.03mg/kg diluted to 5 ml)
224053751|NCT02674542|OTHER|In-depth interviews|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
224053752|NCT02674542|OTHER|Focus Group|"1. Future family planning intentions and beliefs~2. Family planning experiences and beliefs:~3. Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
224053753|NCT05146245|OTHER|Therapeutic Drug Monitoring|Physician receives dosing advice based on risperidone plasma level.
224053754|NCT05146245|OTHER|Risperidone plasma level|Plasma levels of risperidone and 9-OH risperidone are measured in a Dried Blood Spot.
224053755|NCT00247741|DRUG|spinal administration of articaine|
224053756|NCT00247741|DRUG|spinal administration of lidocaine|
223442593|NCT00031772|PROCEDURE|psychosocial assessment and care|Questionnaire and telephone intervention
224053757|NCT01473979|PROCEDURE|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
223741049|NCT07207304|DRUG|Intraoperative analgesia|Intraoperative analgesia will be ensured by administering fentanyl 0.5-1 µg/kg as needed, based on clinical signs of inadequate analgesia (e.g., an increase in blood pressure or heart rate exceeding 20% of baseline, mydriasis, lacrimation, or diaphoresis)
224053758|NCT03120221|DIAGNOSTIC_TEST|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
224053759|NCT01421940|DRUG|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
224053760|NCT01421940|DRUG|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
224053761|NCT05786079|BEHAVIORAL|Footstrike modification|
224053762|NCT05786079|BEHAVIORAL|Control|
224145517|NCT02719470|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
224145518|NCT02810652|OTHER|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
224145519|NCT02810652|OTHER|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
224145520|NCT02680886|DEVICE|Novosyn® Quick|Skin closure
224145521|NCT02252692|DRUG|Enalapril|oral administration
224145522|NCT00152074|BEHAVIORAL|Reduce salt intake|
224145523|NCT03273517|PROCEDURE|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
224053763|NCT03522051|OTHER|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
224145524|NCT03448224|OTHER|Questionnaire Administration|Questionnaire
224145525|NCT03448224|OTHER|Internet-Based Intervention|Intervention
223442594|NCT00153725|DRUG|Aspirin and Pantoloc|
223442595|NCT05964920|DRUG|Saline|Two placebo injections one at baseline and one week 3.
223442596|NCT05964920|DRUG|Testosterone Undecanoate|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3.
223442597|NCT05964920|DRUG|Saline + Resistance exercise training|Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
223442598|NCT05964920|DRUG|Testosterone Undecanoate + Resistance exercise training|Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
223442599|NCT05772507|DEVICE|URGO AWC_008 dressing or URGO AWC_022 dressing|local management of acute or chronic wounds
223442600|NCT05731752|DRUG|HX009|The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
223442601|NCT03236129|PROCEDURE|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
223442602|NCT03236129|PROCEDURE|Standard DLI|The patients in this arm benefit of a standard DLI.
224053764|NCT03351790|OTHER|Questionniare only|A pre-procedure questionnaire will be completed by all participants
224053765|NCT00681174|DRUG|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
224053766|NCT00681174|DRUG|oxycodone|20 mg p.o. 1 h before the start of anesthesia
224053767|NCT00681174|PROCEDURE|Paravertebral block|"* Three injections of 0.5% ropivacaine, 5 ml each~* Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
224053768|NCT00681174|DRUG|Propofol|"* Plasma concentration target-controlled infusion based on bispectral index values~* Acceptable range of concentrations: 2-4 µg/mL~* Target bispectral index values: 40-60~* Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
224145526|NCT04314596|OTHER|Cross Training Course|One day of a supervised, whole body, cross-training course that is meant to produce muscle damage and soreness.
223442603|NCT02578940|DRUG|18F-Fluciclovine PET CT|Radioligand for PET CT scanning
223442604|NCT03127761|OTHER|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
224145527|NCT04314596|DIETARY_SUPPLEMENT|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
224145528|NCT04662216|PROCEDURE|Scaling and root planing|Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes).
224145529|NCT04662216|PROCEDURE|"Scaling and root planing + Perisolv +Hyadent BG gels"|"Scaling and root planing will be accomplished with ultrasonic and hand instruments (Gracey curettes), Perisolv gel will adjectively be applied to all pockets with probing depth(PD) ≥ 5 mm, which will be inserted into periodontal pockets before and during SRP (2 times). The nozzle will be placed in the pocket mesially, lingually, distally and bucally. Afterwards, all teeth will be polished and all treated pockets will be filled with hyaluronic acid gel (Hyadent BG)."
224145530|NCT01021813|DRUG|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
224145531|NCT01021813|DRUG|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
224145532|NCT04578106|BIOLOGICAL|Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination|After 13 weeks of neoadjuvant treatment, a breast MRI will be performed. If a complete response is observed on breast MRI, patients will undergo a stereotactic-guided VAB of the marker area to obtain 12 cylinders of breast parenchyma, which is equivalent to 2 grams of tissue. If no invasive tumor cells and no in situ disease are identified in the stereotactic-guided VAB, patients will be eligible to omit loco-regional surgery.
224145533|NCT01898364|DRUG|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
224145534|NCT02297542|BIOLOGICAL|Flu Vaccine|
224145535|NCT00977015|DRUG|Treatment A|Inhaled, 750/150, single dose
224145536|NCT00977015|DRUG|Treatment B|Inhaled, 750/150, single dose
224145537|NCT05580471|DEVICE|Use 4DryField|Patients randomly use 4DryField in Colorectal resection combined with temporary stomy before fascia closure. We observed the adhesion severity and adhesion extent when stomy closure.
224145538|NCT05101460|DEVICE|XVIVO Perfusion System (XPS™) with STEEN Solution™|XVIVO Perfusion System (XPS™) with STEEN Solution™
224145539|NCT00764478|DRUG|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
223442605|NCT02301845|DRUG|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
223442606|NCT03664921|DRUG|Omnitram Oral Tablet|Administered three times daily for 28 consecutive days.
223442607|NCT03664921|DRUG|Placebo Oral Tablet|Administered three times daily for 28 consecutive days.
223442608|NCT03304275|BEHAVIORAL|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
224053769|NCT00681174|DRUG|Remifentanil|"* 50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~* Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~* Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~* Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
224053770|NCT00681174|DRUG|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
224145540|NCT00764478|DRUG|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
224053771|NCT00681174|DRUG|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).~* 50 mg morphine in 50 ml saline solution (1 mg/ml)~* Incremental dose: 1 mg~* Lock-out time: 8 min~* Limit: 40 mg in 4 h~* Background infusion: none"
224053772|NCT06466538|DRUG|Calcium hydroxide|intracanal medicament
224053773|NCT06466538|DRUG|Leddermix|Leddermix
224053774|NCT06466538|DRUG|Boswellia|Boswellia
224053775|NCT04071743|DEVICE|gammaCore Sapphire|non-invasive vagus nerve stimulator
224053776|NCT04071743|DEVICE|sham gammaCore Sapphire|sham gammaCore Sapphire
224145541|NCT00764478|DRUG|Placebo|placebo sublingual tablet, administered BID for 21 days
223442609|NCT04104997|DRUG|5% GLH8NDE|5% GLH8NDE as eye drops
223442610|NCT04104997|DRUG|Placebos|Placebo as eye drops
223566994|NCT02916888|OTHER|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
223566995|NCT05173948|OTHER|Kinesio taping|Kinesio taping: The tape is measured from the sacrum to the 12th thoracic vertebra with forwarding flexion of the trunk. The base is affixed to the insertion in the resting position. The muscle is elongated and the base anchored with skin displacement. The tape is then affixed with 10% stretch paravertebrally over the muscle bundles up to T12. The tape is rubbed with the muscle in the elongated state.
224053777|NCT00445484|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
224053778|NCT00445484|DRUG|lenalidomide|Given orally
224053779|NCT04607148|DRUG|Galegenimab|Intravitreal (ITV) injections of galegenimab
224053780|NCT03366090|PROCEDURE|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
224053781|NCT03636620|DEVICE|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization
224053782|NCT03636620|DEVICE|radiofrequency ablation/microwave ablation|radiofrequency ablation/microwave ablation
224145542|NCT02270684|DEVICE|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
224145543|NCT00006454|DRUG|carboplatin|
224145544|NCT00006454|DRUG|paclitaxel|
224145545|NCT00006454|DRUG|topotecan hydrochloride|
224145546|NCT04065191|OTHER|High-intensity interval training|Heart rate based high-intensity interval training
224300648|NCT05703347|BEHAVIORAL|Digital sleep health messaging without virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. This group will NOT have virtual psychological visits.
223442611|NCT04513899|BEHAVIORAL|Community health worker (CHW)/ registered nurse (RN) [CHW/RN]|A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
223741050|NCT07207304|DRUG|Non-opioid analgesics|Thirty minutes before the end of surgery, nefopam 40 mg, paracetamol 1 g, and ketoprofen 100 mg will be administered intravenously, depending on the patient's comorbidities, surgical particularities, extent of resection, and residual liver volume.
223741051|NCT07207304|DRUG|Morphine (+)|Postoperative analgesia will be provided with morphine at a dose of 0.1-0.2 mg/kg, administered 30 minutes before emergence from anesthesia. The administration will be performed intravenously, with the dose adjusted based on patient weight and clinical condition. Additional bolus doses may be given in the post-anesthesia care unit (PACU), guided by the patient's reported pain intensity using the Visual Analog Scale (VAS). In the PACU, morphine will be titrated starting with 2-5 mg IV given slowly over 4-5 minutes, with repeated doses every 5-10 minutes if needed, while closely monitoring respiratory rate, level of consciousness, and hemodynamic stability. For ongoing pain management, intermittent IV bolus dosing (typically 0.05-0.1 mg/kg every 4 hours as required) may be used, taking into account factors such as patient comorbidities, type of surgery, and residual hepatic function.
224053783|NCT02933099|DRUG|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
224053784|NCT02933099|DRUG|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
224053785|NCT00817882|OTHER|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
224053786|NCT00817882|OTHER|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
224053787|NCT00110292|BEHAVIORAL|Age-specific parenting newsletters and developmental toys|
224053788|NCT00110292|BEHAVIORAL|Parent-completed Ages & Stages Questionnaires|
224145547|NCT04257084|DIAGNOSTIC_TEST|chromoendoscopy with target biopsy; NBI with target biopsy|"Chromoendoscopy with target biopsy: 0.03% indigo carmine solution based chromoendoscopy (using high-definition colonoscopy) will be fulfilled and target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia.~NBI with target biopsy: After inserting a high definition colonoscopy up to cecum, endoscopists observe the colon in combination of white light and NBI (white light first and then NBI). Target biopsies will be taken at all abnormal mucosal lesions suspected dysplasia/neoplasia."
224145548|NCT00019721|BIOLOGICAL|MART-1 antigen|
224145549|NCT00019721|BIOLOGICAL|aldesleukin|
224053789|NCT00110292|BEHAVIORAL|Clinic-based distribution of children's books|
224053790|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline and at follow up|Subjects will be assessed at baseline (as inpatients) and at 4-6 weeks at follow-up as outpatients according to standard operating procedures. Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Further examinations include measurement of left ventricular ejection fraction by echocardiography at baseline and blood pressure, heart rate, risk scores and health information will be collected at baseline and follow up.
224053791|NCT05843006|DIAGNOSTIC_TEST|Examination and analysis of sweat and blood samples at baseline|Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Blood pressure, heart rate, risk scores and health information will collected.
224053792|NCT02553122|DRUG|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
224053793|NCT02553122|DEVICE|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
224053794|NCT02098720|DRUG|Conbercept|
224145550|NCT00019721|BIOLOGICAL|gp100 antigen|
224145551|NCT00019721|BIOLOGICAL|incomplete Freund's adjuvant|
224300649|NCT05703347|BEHAVIORAL|Digital sleep health messaging with virtual study visit|All participants will receive digital sleep health messaging. Messaging will focus on evidence-based sleep health recommendations, such as regulating evening electronics use, managing extracurricular activities, and setting consistent bedtime routines and sleep-wake schedules. The participants will be randomized to additionally receive virtual study visits where doctoral-level psychology trainees will be trained to implement evidence-based behavioral sleep health guidance.
224300650|NCT05703347|BEHAVIORAL|Inactive Parent-Directed Loss-Framed Incentive|No parental incentive
224053795|NCT03437564|DRUG|Vortioxetine|Vortioxetine tablet
224053796|NCT00151983|DRUG|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
224145552|NCT04441879|BEHAVIORAL|Be a Mom Coping with Depression|Be a Mom Coping with Depression is a blended cognitive-behavioral intervention for the treatment of postpartum depression. It consists of 13 weeks of face-to-face and online sessions, each session targeting a specific thematic content, and providing participants with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content.
224053797|NCT00998270|PROCEDURE|Autologous bone marrow transplantation|"Autologous transplantation:~* Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~* G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~* Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
223442612|NCT04513899|BEHAVIORAL|Clinic-based Standard of Care (cbSOC) Program (control group)|This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
223442613|NCT03370185|DRUG|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
223442614|NCT03955588|DIAGNOSTIC_TEST|aCGH|
223442615|NCT05693025|BEHAVIORAL|Group Exercise|The study evaluates two different approaches for group exercise. Participants in the Standard Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. Participants are guided to learn and perform a series of stretching and strengthening exercises recommended in the base WWE program. Primary BCTs include instruction on how to perform behavior (#4.1) and Graded tasks (#8.7). Participants in the Enhanced Implementation (SI) group complete the standard Walk with Ease intervention as recommended by the Arthritis Foundation. They may perform some of the same exercises as those in the SI group but they are also guided to learn and perform specific exercises prescribed by a physical therapist to improve balance and reduce risks of falling. The primary BCTs include instruction on how to perform behavior (#4.1), Graded tasks (#8.7) from the base program as well as Information on health consequences (#5.1) and Credible source (#9.1).
223442616|NCT05693025|BEHAVIORAL|Behavioral Training|The study evaluates two different approaches for promoting behavior change. Participants in the Standard Training (ST) model follow the standardized Walk with Ease training to support behavior change. Participants are provided with goal setting tools and an online tracker to monitor their progress. Weekly video-based lessons, resource links and eBook content support behavior change. Primary BCTs include Goal Setting (BCT #1.1) and self-monitoring (BCT#2.3). Participants in the Enhanced Training (ET) model access the same basic content as the ST model, but the weekly education-based videos are replaced with lessons focus on habit-formation training. Student coaches are also assigned to individual participants to support behavior change efforts using motivational interviewing strategies. Thus, participants in the ET model also receive two additional theory- and evidence-based BCTs: (1) habit formation training (BCT#1.2, #1.4, #8.3) and (2 health coaching (BCT# 3.3).
223442617|NCT01375452|DRUG|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
223442618|NCT03531476|BEHAVIORAL|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
223442619|NCT00851864|DRUG|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
223442620|NCT02436499|DRUG|Botulinum Toxin-A|
223442621|NCT02614404|DRUG|Imatinib combination therapy|Imatinib plus dihydroartemisinin plus piperaquine
223442622|NCT02614404|DRUG|Dihydroartemisinin-piperaquine|Standard of care
223442623|NCT05205629|DRUG|Donafenib combined with TACE|Donafenib(200mg bid po) combined with TACE
223442624|NCT00086398|BEHAVIORAL|Behavior Therapy|
223741052|NCT07207304|DEVICE|Bispectral Index (BIS)|Bispectral index (BIS) monitoring will be used to guide the depth of anesthesia. The target BIS value will be maintained between 40 and 59 throughout the procedure to ensure adequate hypnosis while avoiding excessive anesthetic depth. BIS values will be continuously recorded and adjustments to anesthetic agents will be made accordingly.
224053798|NCT00998270|PROCEDURE|Allogeneic bone marrow transplantation|"Allogeneic~* Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~* Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
224053799|NCT00916149|DRUG|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
224145553|NCT04441879|BEHAVIORAL|Be a Mom|Be a Mom is an online intervention consisting of 6 modules, each one targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Women will receive biweekly phone calls from a psychologist between completion of each module to provide support.
224145554|NCT05184309|OTHER|ConventioanalExercises|Wand exercises and shoulder wheel exercises to increase the range of motion of the shoulder joint with 10 repetitions will be applied in CEG. Finger ladder exercises will be performed in the abduction and flexion position with 5 repetitions, holding the endpoint for 5 seconds. Stretching exercises with 5 repetitions will be applied in all directions for the limitation of movement, holding it for 20 seconds at the endpoint. Individuals performed conventional exercises twice a week for 6 weeks.
224145555|NCT05184309|OTHER|Serious games|A Serious game program will be applied to the individuals twice a week for 6 weeks in this group. Armrotate, Uball, Balance Surf and Balance Adventure games will be developed by Becure company for shoulder rehabilitation. These games developed for shoulder rehabilitation will be applied to individuals under the supervision of a physiotherapist. Each game will be played for 10 minutes, for a total of 40 minutes.
224145556|NCT03648307|DIAGNOSTIC_TEST|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
224145557|NCT05052528|BIOLOGICAL|Chimeric Antigen Receptor T-Cell Therapy|Given CD19 CAR T cells IV
224145558|NCT05052528|DRUG|Cyclophosphamide|Given IV
224145559|NCT05052528|DRUG|Fludarabine Phosphate|Given IV
223442625|NCT04591015|BEHAVIORAL|Hospital: DD-CA|In the DD-CA group, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with educational, motivational and medication adherence messaging that is currently an arm of our parent DD-ME grant with added COVID support messages that provide information addressing identified barriers in Hispanic underserved communities (e.g. obtaining testing supplies and medications, accessing routine medical care, and completing other important diabetes self-management behaviors such as healthful eating, exercise, social distancing, quarantine, and stay-at-home/lockdown guidelines).
223442626|NCT04591015|BEHAVIORAL|Hospital: Usual Care (UC)|In the UC group, participants will not receive the added COVID support messages, both groups will have a referral placed to the Diabetes Transitions Service (DTS) at the time of discharge as part of usual care. Participants will be contacted by a peer health coach following protocol to coordinate care with outpatient health and other community resources.
223442627|NCT02686814|DEVICE|17mm MDT-2215 aortic valve bioprosthesis|
223442628|NCT04051814|OTHER|Micra Transcatheter Pacemaker System|A miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart
223442629|NCT02401698|OTHER|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
223442630|NCT05124483|BIOLOGICAL|AKS-452X|subcutaneous injection of 90 µg AKS-452X
224053800|NCT00916149|DRUG|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
223442631|NCT02110628|PROCEDURE|Roux-en-Y anastomosis|Roux-en-Y anastomosis
224053801|NCT06441045|DRUG|Double Dose of Third-generation EGFR-TKI|Double Dose of Third-generation EGFR-TKI
224053802|NCT06441045|DRUG|Intrathecal Pemetrexed|Intrathecal Pemetrexed
224053803|NCT01965639|OTHER|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
224053804|NCT05712148|BIOLOGICAL|Stem cell implantation|Suprachoridal mesenchymal spheroidal stem cell implantation
224053805|NCT00907751|DRUG|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
224053806|NCT06119490|DRUG|Abrocitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks
224053807|NCT06119490|DRUG|Tofacitinib|Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks
224053808|NCT00589420|DRUG|docetaxel|
224053809|NCT00589420|DRUG|sorafenib tosylate|
224053810|NCT03025230|OTHER|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
224053811|NCT03025230|OTHER|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
224053812|NCT02761395|PROCEDURE|Al-hijamah|"* Strict sterilization of selected anatomical sites.~* Suction using sterile plastic disposable sucking cups~* Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
224053813|NCT02761395|DRUG|Deferasirox|20-40 mg/kg/day orally
224053814|NCT06508918|DRUG|Betametasona|pressure pain threshold values of the most painful area will be recorded with a manual algometer
224053815|NCT04475575|DEVICE|Aeonose|All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
224053816|NCT00912028|DEVICE|senofilcon A|contact lens
224053817|NCT00912028|DEVICE|lotrafilcon B|contact lens
224053818|NCT00912028|DEVICE|balafilcon A|contact lens
224053819|NCT00912028|DEVICE|methafilcon A|contact lens
224053820|NCT00912028|DEVICE|vifilcon A|contact lens
224053821|NCT06448702|PROCEDURE|wet wrap therapy|Steps for wet wrap therapy After bath/shower with emollients, pat to remove excess water on body and apply the emollient and/ or steroid cream liberally on the affected area to enhance water absorption and seal in moisture Put wet wrap garment in lukewarm water, squeeze water out of the wet wrap garment, take them out without dribbling of water and then apply on the affected area Put on another layer of dry garments/ warm clothing to cover the wet wrap garments and wear usual clothing as needed Check regularly and keep the wet wrap garments underneath damp with water sprayer or wet towel if necessary Patient is suggested to apply emollients frequently throughout the day to maintain the effect
224053822|NCT06448702|DEVICE|External compression counter-pulsation (EECP)|External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.
224053823|NCT04530942|DEVICE|Deep brain stimulation(Active)|DBS On with the optiomal parameters
223442632|NCT02110628|PROCEDURE|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
223442633|NCT02097771|DEVICE|LMA SupremeTM|
224053824|NCT04530942|DEVICE|Deep brain stimulation(Sham)|DBS On with 0V Amplitude
224053825|NCT01214928|DRUG|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
224145560|NCT05052528|BIOLOGICAL|Rituximab|Given IV
224145561|NCT00883220|BEHAVIORAL|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
223442634|NCT02097771|DEVICE|AuraOnceTM|
224145562|NCT03823092|DIAGNOSTIC_TEST|polarization sensitivity|test of polarization vision as described in Study Description
224145563|NCT05344625|DRUG|Ketamine 100 MG/ML|Ketamine Assisted Psychotherapy
224145564|NCT01369212|DRUG|Tenofovir|300 mg daily for 192 weeks (4 years)
224145565|NCT01369212|DRUG|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
224145566|NCT01309438|DRUG|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
224145567|NCT01309438|DRUG|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
224145568|NCT01309438|DRUG|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
224145569|NCT01309438|DRUG|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
224145570|NCT00862121|DRUG|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
224145571|NCT00862121|DRUG|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
224145572|NCT04345497|OTHER|Diabetes-Specific Formula|Diabetes-Specific Formula and Standard of Care
224300651|NCT05703347|BEHAVIORAL|Active Parent-Directed Loss-Framed Incentive|Parents will receive a financial incentive when their child achieves their sleep goal. The incentive will be loss-framed; parents will receive an endowment of $10 at the start of each intervention week, in a virtual bank account; Investigators will deduct $2 each weeknight the sleep duration goal is not met; the funds remaining in the virtual account will be dispensed each Sunday. The weekly endowment-payment approach allows for fresh starts each week. The incentive will be directed at parents as a method to enhance engagement. Investigators will ask parents at baseline and at the end of each month to rate their perceived support in helping their child to meet their sleep duration goal.
223442635|NCT01609088|DIETARY_SUPPLEMENT|Erythritol-containing beverage|Orange flavored beverage containing erythritol
223442636|NCT04665973|BEHAVIORAL|Therapeutic patient education : oral semi-structured interview|The physiotherapist discusses and goes through each page of the booklet and involves the patient as much as possible. He demonstrates the exercises proposed in the booklet and then ask the patient to perform them in front of him. The physiotherapist tries to identify the patient's needs and suggests different ways to ensure that the patient has different opportunities to maintain the best possible level of PA
223442637|NCT04665973|BEHAVIORAL|Therapeutic patient education : booklet (passive)|The booklet (11 pages): explains why it is important to maintain a good level of PA as part of cancer treatment and reviews the most common side effects of cancer therapy and the relative importance of PA in combating these effects (pages 2-3) ; defines PA, its modalities and possible security precautions (pages 4-5), suggests exercises to be performed oneself and a target intensity to be reached (pages 6-8), provides a roadmap to be completed oneself (pages 9-10), and outlines procedures for joining an exercise medicine group (page 11).
223442638|NCT00290693|DRUG|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
224053826|NCT03715699|DRUG|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
224053827|NCT03715699|DRUG|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
224053828|NCT01826110|DRUG|[11C]PIB|Approximately 15 mCI \[11C\]PIB IV x1
224145573|NCT04345497|OTHER|Standard Of Care|Standard of Care
224053829|NCT02431936|DRUG|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
224053830|NCT02431936|DRUG|Placebo|Sugar pill made to look identical to Prazosin intervention.
224053831|NCT00942175|DRUG|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
224053832|NCT00942175|DRUG|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
224145574|NCT02943005|PROCEDURE|Rotator cuff repair|
224145575|NCT04007601|DEVICE|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
224145576|NCT04007601|DEVICE|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
223442639|NCT00290693|DRUG|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
223442640|NCT03797131|OTHER|KB195 (a novel mixture of oligosaccharides)|KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
224053833|NCT00942175|DRUG|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
224053834|NCT00942175|DRUG|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
224053835|NCT00942175|DRUG|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
224145577|NCT03051841|DRUG|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
224145578|NCT00895193|OTHER|Apple pectin|Apple pectin 2000mg
224145579|NCT00895193|DRUG|Aspirin 325 mg|Aspirin 325 mg
223442641|NCT02907619|BIOLOGICAL|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
223442642|NCT01908582|DRUG|Evacetrapib|Administered orally
223566996|NCT05173948|DEVICE|Conventional physical therapy|Transcutaneous electrical nerve stimulation device settings, such as the frequency of 80 Hz, the pulse width of 100 µs, and symmetrical biphasic waveform. Four mediums sized (2 × 2 cm) carbon-impregnated rubber cutaneous electrodes were placed bilaterally in a standard dermatomal pattern over the most painful lumbar region. The current intensity was increased up to the patient's perception of paraesthesia. The supervised exercise therapy management consisted of stretching exercises for the back, iliopsoas, gluteal and hamstring muscles, and strengthening exercises for the abdominal and back muscles. Three sets of stretching exercises, each involving a 30-sec hold and 30-sec of rest repeated three times, were performed in three sessions per week over four weeks. One set of strengthening exercises, consisting of 10 repetitions with a 5-sec hold, was performed in three sessions per week over four weeks.
223566997|NCT01887015|DEVICE|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
224053836|NCT04452474|DRUG|Olokizumab 64 mg|solution for subcutaneous administration 160 mg/mL
224053837|NCT04452474|DRUG|Placebo|Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
224053838|NCT03581266|OTHER|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
224053839|NCT02664272|PROCEDURE|Total Hip Arthroplasty|
224145580|NCT00895193|OTHER|Placebo|Placebo
224145581|NCT02637726|DRUG|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
224145582|NCT02637726|DRUG|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
224145583|NCT02637726|DRUG|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
224145584|NCT02637726|DEVICE|EEG Monitoring|Maintaining a bispectral index between 45 and 55
224145585|NCT02637726|DRUG|Remifentanil|Remifentanil at discretion of the anesthesiologist
224145586|NCT03283618|BEHAVIORAL|Video Conferencing Group|
224300652|NCT05703347|BEHAVIORAL|Inactive Supportive Feedback|No supportive feedback
224300653|NCT05703347|BEHAVIORAL|Active Supportive Feedback|Participants will receive a weekly performance summary message each Sunday during the intervention period, with supportive feedback included to motivate children to maintain their good performance in the week ahead, or to try and improve upon a weak or moderate performance in the week ahead. Investigators will ask children will complete an online survey each Sunday to measure how motivated they are to achieve their sleep goal in the week ahead.
223442643|NCT01908582|DRUG|Rifampin|Administered orally
223442644|NCT00163033|DRUG|estetrol|
223442645|NCT05831306|OTHER|Diet A|Modified Diet A
223442646|NCT05831306|OTHER|Diet B|Modified Diet B
223566998|NCT05290987|DEVICE|nasal spray|2 sprays in each nostril, 6 times a day
224053840|NCT02527525|BEHAVIORAL|Stepped Care|
224053841|NCT03436459|DEVICE|Extracorporeal Shock Wave Therapy|shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
224053842|NCT03436459|DEVICE|Low Level Laser Therapy|LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
224053843|NCT06044207|DIAGNOSTIC_TEST|Pittsburgh sleep quality index|The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
224145587|NCT03879876|DRUG|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
224145588|NCT04176744|OTHER|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
224145589|NCT02797639|OTHER|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
224145590|NCT02797639|OTHER|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
224145591|NCT03860350|DIETARY_SUPPLEMENT|Aged Garlic Extract|
223442647|NCT00431899|BEHAVIORAL|fish oil supplementation|
223566999|NCT01368783|DRUG|atazanavir|400 mg/day for 2 days
224053844|NCT06044207|DIAGNOSTIC_TEST|Self-rating depression scale|The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
224145592|NCT03860350|DIETARY_SUPPLEMENT|Placebo|
224145593|NCT00171314|DRUG|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
223567000|NCT01368783|DRUG|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
223567001|NCT01368783|DRUG|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
223567002|NCT01368783|DRUG|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
224145594|NCT00171314|DRUG|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
224300654|NCT04901429|PROCEDURE|Truncal vagotomy|Truncal vagotomy will be performed in 50% of patients during other routine procedure.
224300655|NCT06135064|DEVICE|Diadem|The device delivers low-intensity ultrasonic waves into specified brain targets.
224300656|NCT02111941|OTHER|Laboratory Biomarker Analysis|Correlative studies
224300657|NCT02111941|BIOLOGICAL|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
223442648|NCT05440721|DEVICE|Treatment A with device Clickotine® (Active intervention)|The intervention regimen around Treatment A is almost entirely user-directed. When a person has a craving, a series of options are available to ease the craving and resist the urge to smoke. The user will also engage with Clickotine® leading up to their quit date to complete a program of 21 Missions, daily activities which help prepare them to quit and keep them off cigarettes. Ideally, the user will open and use Treatment A several times a day.
223442649|NCT05440721|DEVICE|Treatment B with smoking education (control)|The Treatment B app is operated by the National Cancer Institute to provide education and support to smokers seeking to quit. The QG regimen is entirely user-directed. When a user has a craving or wants support or education, they can log into the QG app. The QG app also provides lessons relevant for preparing to quit and beginning to quit.
223442650|NCT00004197|BIOLOGICAL|keyhole limpet hemocyanin|
223442651|NCT00004197|BIOLOGICAL|sargramostim|
223442652|NCT00004197|BIOLOGICAL|tumor cell-based vaccine therapy|
223442653|NCT00004197|DRUG|cyclophosphamide|
223442654|NCT00004197|DRUG|doxorubicin hydrochloride|
223442655|NCT00004197|DRUG|mitoxantrone hydrochloride|
223442656|NCT00004197|DRUG|prednisone|
223442657|NCT00004197|DRUG|vincristine sulfate|
223442658|NCT05254470|DEVICE|Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
223442659|NCT00888290|DRUG|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
223442660|NCT00888290|DRUG|Placebos|Placebo at 3 different doses to match Sodium bicarbonate dosing
223442661|NCT00073645|BEHAVIORAL|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
223442662|NCT00073645|BEHAVIORAL|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
223442663|NCT04886752|DIETARY_SUPPLEMENT|vitamin C without liposome|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
223442664|NCT04886752|DIETARY_SUPPLEMENT|liposomal process A vitamin C|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
223442665|NCT04886752|DIETARY_SUPPLEMENT|liposomal process B vitamin C (Double Nutri™)|subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
224053845|NCT06044207|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
223442666|NCT05509101|OTHER|commercially available control algorithm|Control of the prosthesis/orthosis is based on clinical standard of care using commercially available control algorithms.
223442667|NCT05509101|OTHER|experimental control algorithm|Control of the orthosis is based on residual muscle activity mapped to intended movement using high density electromyography and artificial intelligence control algorithms.
224053846|NCT00585000|DRUG|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
224053847|NCT04629820|DEVICE|Spectacles|Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
224053848|NCT04001075|DRUG|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
224053849|NCT02173860|PROCEDURE|FFR-guided surgical revascularization|
224053850|NCT02173860|PROCEDURE|Angio-guided surgical revascularization|
224053851|NCT03991806|OTHER|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
224053852|NCT02505503|DEVICE|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
224053853|NCT02505503|DEVICE|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
224053854|NCT03263962|DRUG|Canrenone|Evaluation of canrenone therapy in patients with CHF
224053855|NCT03073980|DRUG|IV Acetaminophen|IV Acetaminophen for pain control during procedure
224053856|NCT03073980|DRUG|PO Acetaminophen|PO Acetaminophen for pain control during procedure
224053857|NCT03073980|OTHER|Placebo IV Acetaminophen|Placebo IV Acetaminophen
224053858|NCT03073980|OTHER|Placebo PO Acetaminophen|Placebo PO Acetaminophen
224053859|NCT00812058|DRUG|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
224053860|NCT00812058|DRUG|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
224053861|NCT02895880|BEHAVIORAL|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
224053862|NCT02895880|BEHAVIORAL|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
224300658|NCT02912845|DRUG|KamRAB - HRIG|wound infiltration or IM injection
224300659|NCT01463215|DRUG|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
223442668|NCT02008032|DEVICE|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
223442669|NCT05573438|OTHER|Group fructose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with fructose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of fructose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
223442670|NCT05573438|OTHER|Group Sucrose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with sucrose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of sucrose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
223442671|NCT05573438|OTHER|Group Glucose|Participants will receive a standardized meal of bread, ham, and margarine plus a sweetened drink (200mL) with glucose. The meals will provide 25% of the energy requirements, calculated from the resting energy expenditure measured by indirect calorimetry (KORR®, MetaCheck) multiplied by the activity factor (24) plus 10% referring to the thermal effect of food. The meal will have 15% of protein, 30% of fat, and 55% of carbohydrate (30% of complex carbohydrates and 25% of glucose. The sweetened drinks will have artificial fruit flavor to avoid the identification of the content by the researchers and the volunteers.
223442672|NCT05161572|DRUG|Oxaliplatin|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1.
223567003|NCT04966728|DIAGNOSTIC_TEST|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI|conventional ultrasound diagnosis of the hip joint, contrast-enhanced ultrasound, and high-resolution single hip MRI
223567004|NCT02688088|DRUG|Drug Cocktail|Administered orally
223567005|NCT02688088|DRUG|Abemaciclib|Administered orally
223567006|NCT02252549|DEVICE|SPIES+WLI assisted TURB|
223567007|NCT02252549|DEVICE|WLI assisted TURB|
223567008|NCT03758079|DRUG|Doxepin|10 mg Doxepin for 4 weeks
223567009|NCT03758079|DRUG|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
223567010|NCT02275390|BEHAVIORAL|Nurse-led Psycho-education (or SPBB: self-learning program)|"The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).~\[Note: SPBB consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the \[psychosocial\] effects of the illness; and Module 5: Dealing with \[physical and mental health\] effects of the illness).\]"
224053863|NCT04378530|BEHAVIORAL|Personalized Anchoring Strategy|"The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders.~Participants will be asked to choose a cue to use as an anchoring strategy. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm)."
224053864|NCT04378530|BEHAVIORAL|Non-Anchoring Strategy Control|The study will run for 8 weeks. Control participants will participate in the meditation features in their Calm account. Each participant will receive non-anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The control group will not be provided an anchoring strategy video on the persistence of daily meditation practice and receive non-anchoring strategy specific push notification study reminders. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
224053865|NCT04378530|BEHAVIORAL|Fixed Anchoring Strategy|The study will run for 8 weeks. Intervention participants will participate in the meditation features in their Calm account. Each participant will receive anchoring specific push notifications related to, tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders. The intervention group will be provided an anchoring strategy video on the persistence of daily meditation practice and receive anchoring strategy specific push notification study reminders. Participants will be asked to use a cue given by the research team. Health and well-being measures will be taken at baseline and post-intervention. Participation in the Calm meditations will be tracked (app feature used, time of day used, and time spent in meditation) by the Calm informatics team. Additionally, they will answer one, multiple choice EMA (ecological momentary assessment) question 1x per day (8am, 1pm or 6pm).
224053866|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
224053867|NCT04755075|DRUG|Surufatinib|Subjects to receive Surufatinib 250 mg on Day 1
223442673|NCT05161572|DRUG|Tegafur-Gimeracil-Oteracil|The SOX regimen consists of S-1 and oxaliplatin and is repeated every three weeks. S-1 is administered orally at 40-60 mg twice a day for 14 consecutive days. Then, the patients will have a one-week rest period. The dose of S-1 is according to the body-surface area (BSA): patients with a BSA of less than 1.25 m2 receive 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 receive 100 mg daily; and those with a BSA of 1.5 m2 or more receive 120 mg daily.
223442674|NCT05161572|DRUG|Sintilimab|The immunotherapy includes perioperative treatment and postoperative maintenance treatment. The PD-1 mAb used will be sintilimab, and the dose is 200 mg intravenously every three weeks. Regardless of which arm, the courses of immunotherapy that will be received by the enrolled patients are the same: 3 times preoperatively, 3 times postoperatively, and then maintained until one year after surgery.
223442675|NCT05161572|RADIATION|Concurrent chemoradiation|The radiotherapy (RT) consists of 45 Gy delivered in 25 fractions every five days per week for five weeks. The dose of concurrent ChT is 60 mg/m2 S-1 orally, oral tablets twice daily, days 1-5 of each week.
223442676|NCT05161572|PROCEDURE|D2/R0 gastrectomy|Gastrectomy with standard D2 lymphadenectomy is recommended. The type of gastrectomy performed depends on the location and extent of the primary lesion. For GEJ or upper third tumors, a 3 cm esophageal margin is recommended, and a total gastrectomy or esophagogastrectomy is performed. For middle third tumors, the gastric margin is recommended to be more than 5 cm, and a total gastrectomy is performed. For lower third tumors, a 2 cm duodenal margin is recommended, and a subtotal or total gastrectomy is performed. Billroth I or Roux-en-Y gastrojejunostomy is performed for distal gastrectomy patients. Roux-en-Y esophagojejunostomy is performed for patients receiving total gastrectomy.
223442677|NCT03196375|DRUG|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
223442678|NCT03196375|DRUG|Placebo ODT|Placebo ODT taken three times daily for 28 days
223442679|NCT03267602|DEVICE|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~1. older than 18 years, AHI\> 15 and present obvious symptoms or~2. less than 18 years, AHI still\> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
223442680|NCT03484403|OTHER|Lumbar back brace|A brace that supports the lumbar region of the spine.
224053868|NCT00545064|DRUG|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
224053869|NCT05345535|OTHER|Trampoline exercise|45 minutes of exercises that includes upper and lower extremity movements a trampoline with music
224053870|NCT05345535|OTHER|Walking|45 minutes of moderate tempo walking
223442681|NCT03484403|BEHAVIORAL|Back school|Back school consists of patient education physical therapy exercise instruction.
223442682|NCT01114295|DEVICE|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
223442683|NCT01114295|RADIATION|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
223442684|NCT03699371|PROCEDURE|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
223442685|NCT02263014|BEHAVIORAL|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
224053871|NCT05606367|DEVICE|Non-slip Balloon Catheter of Shanghai MicroPort Rhythm|The principle of Non-slip Balloon Catheter in dilating stenotic lesions is mechanical extrusion of the vessel through the balloon, resulting in irregular rupture of atheromatous plaque and enlargement of the lumen.
224053872|NCT05606367|DEVICE|NSE Coronary Dilatation Catheter|The Lacrosse® NSE is an angioplasty catheter with 3 longitudinal elements attached directly proximal and distal to the balloon that produces 3 endovascular surgical incisions during balloon dilation.
224053873|NCT03113656|OTHER|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
224053874|NCT03113656|OTHER|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
224053875|NCT00868062|OTHER|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
224053876|NCT00081237|DRUG|OSI-7904L|
224053877|NCT00081237|DRUG|oxaliplatin|
224053878|NCT04001621|DRUG|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
224053879|NCT01940471|DRUG|TAF|25 mg tablet administered orally once daily
224053880|NCT01940471|DRUG|TDF|300 mg tablet administered orally once daily
224053881|NCT01940471|DRUG|TAF Placebo|Tablet administered orally once daily
223442686|NCT05946668|PROCEDURE|Biospecimen Collection|Undergo vaginal specimen self-collection via vaginal swab collection kit
223442687|NCT05946668|OTHER|Electronic Health Record Review|Medical records reviewed
223442688|NCT05946668|OTHER|Questionnaire Administration|Complete questionnaires
223442689|NCT05993234|DRUG|Trastuzumab deruxtecan|"This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~T-DXd to be administered according to the SmPC. Conventional therapy (eg. platinum-fluoropyrimidine doublet chemotherapy, nivolumab, ramucirumab-paclitaxel, ramucirumab monotherapy, taxane or irinotecan, and pembrolizumab monotherapy) to be administered according to the SmPC."
223442690|NCT05960357|OTHER|To inform|It includes providing all necessary information about the fetus to the pregnant woman by using the ultrasound monitor during the detailed ultrasound.
223442691|NCT06617546|DRUG|FTX-101|Lyophilized powder for subcutaneous injection
223567011|NCT02275390|BEHAVIORAL|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
223567012|NCT03905317|DRUG|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
223567013|NCT03905317|RADIATION|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
223567014|NCT03905317|DRUG|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
223567015|NCT04378829|DIAGNOSTIC_TEST|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19|Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
224053882|NCT01940471|DRUG|TDF Placebo|Tablet administered orally once daily
224053883|NCT00258674|OTHER|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
224053884|NCT00258674|OTHER|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
224053885|NCT00258674|OTHER|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
224053886|NCT03296085|PROCEDURE|Exam for quantity of edema|There is no intervention
224053887|NCT03715153|DRUG|BUMETANIDE (S95008) for week 0 - 26|Oral solution dosed at 0.5 mg/mL Taken twice daily.
223442692|NCT06617546|DRUG|Placebo|Lyophilized powder for subcutaneous injection
223442693|NCT04624295|DRUG|Early aspirin Therapy|Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
223442694|NCT04624295|DRUG|Non-Early aspirin Therapy|Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
223442695|NCT06251518|BEHAVIORAL|vimida|Participants will receive access to the digital health intervention vimida in addition to TAU.
223567016|NCT00366028|BEHAVIORAL|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
223567017|NCT00366028|BEHAVIORAL|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
223567018|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
223567019|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
223567020|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
223567021|NCT03060395|DIETARY_SUPPLEMENT|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
223567022|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
223567023|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
223567024|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
223567025|NCT03060395|DIETARY_SUPPLEMENT|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
223567026|NCT03843944|DRUG|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
223567027|NCT01768156|OTHER|Experimental arm|"Serum samples are collected:~* at time of diagnosis of recurrence (before 1st chemotherapy)~* during each cycle of chemotherapy~* after the end of chemotherapy~* every 3 month until treatment failure (3-6 samples)~* stop at the progression or after 18 months post chemotherapy"
223567028|NCT05996029|COMBINATION_PRODUCT|Digital Smoking Cessation|The core technology of the study is a smoking cessation assistance practice service driven by a machine learning algorithm. The small programs used by the intervention group in this study included smoking cessation service packages based on cognitive behavioral therapy and online guidance from medical staff on staff, and more digital smoking cessation tools.
223567029|NCT04207918|RADIATION|Radiotherapy|44.94Gy and 37.8Gy in 21 fractions to PGTV and PTV for neoadjuvant treatment. 59.92Gy and 50.4Gy in 28 fractions to PGTV and PTV for definitive treatment.
224053888|NCT03715153|DRUG|PLACEBO for week 0 - 26|Oral solution Taken twice daily.
223567030|NCT04207918|DRUG|Nimotuzumab|400mg, by intravenous infusion once a week in 4-6 weeks.
223567031|NCT04207918|DRUG|S-1|40-60mg/m2/d，orally twice a day concurrently with radiotherapy.
224053889|NCT03715153|DRUG|Open-Label BUMETANIDE (S95008) for weeks 26 - 52|Oral solution dosed at 0.5 mg/mL Taken twice daily.
223442696|NCT05118724|DRUG|Atezolizumab|Atezolizumab 840mg i.v., on Day 1 and Day 15 (q2w) of every 28-day treatment cycle for a total of 12 cycles (24 doses)
223442697|NCT05118724|DRUG|IMM-101|Suspension of Heat-Killed Whole Cell Mycobacterium obuense (NCTC 13365) in Borate Buffered Saline for Intradermal Injection
223442698|NCT05807256|OTHER|collection and analysis of treatments and procedures already performed by normal clinical practice|The patients' anthropometric variables; laboratory test results; PMA techniques (types of fertilization/drugs used for stimulation) and the outcome of the eventual pregnancy (ongoing treatment during the pregnancy itself, development of maternal/fetal complications, such as hypertension, preeclmpsia, thrombotic events, renal failure, disease flare, neonatal outcome) and data on the type of ovarian stimulation drug treatment.
223442699|NCT01450072|DEVICE|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
224145595|NCT01434264|PROCEDURE|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
224145596|NCT02084784|DRUG|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
223442700|NCT01450072|OTHER|Control arm|Venography and sham angioplasty
223442701|NCT04060771|DRUG|Palonosetron|prophylaxis of postoperative nausea and vomiting
223442702|NCT04060771|DRUG|Dexamethasone|prophylaxis of postoperative nausea and vomiting
224053890|NCT02123316|BIOLOGICAL|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
224053891|NCT02123316|BIOLOGICAL|Placebo|Placebo for subcutaneous injection
224145597|NCT02084784|DRUG|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
224145598|NCT04945824|DRUG|Dexamethasone Ophthalmic|Insertion Device: A handheld mechanical device used by the clinician to dilate the punctum and deliver the DEXTENZA insert into the canaliculus; designed to be single-use and pre-loaded with a single DEXTENZA insert.
224145599|NCT04945824|DEVICE|Dilator|Intracanalicular Dilator Device
224145600|NCT04284904|DIAGNOSTIC_TEST|aGVHD biomarker|To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks
223442703|NCT04500678|DRUG|Metformin|Metformin 500 mg Extended Release (ER) qd increasing to 1000 mg ER qd at week 4 and continued to week 48.
223442704|NCT06640946|DRUG|Topical lidocaine|Topical lidocaine cream prior to laser follicle ablation
223567032|NCT00099060|DRUG|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~* Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~* Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
223567033|NCT04021524|DRUG|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
223567034|NCT04021524|DRUG|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
223567035|NCT05275010|DRUG|Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)|A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
223567036|NCT05275010|DEVICE|Handheld Syringe with Hypodermic Needle|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using a handheld manual syringe.
224145601|NCT05052541|DRUG|THC/CBD|Oral solution containing 5mg THC and 50 mg CBD per 1 ml
224145602|NCT05052541|DRUG|THC|Oral solution containing 5mg THC per 1 ml
224145603|NCT05052541|DRUG|Placebo|Oral solution containing no active drug
224145604|NCT05511831|DRUG|Ketotifen Fumarate|Ketotifen treatment for 3 months, 1 mg each time, 1-2 times a day according to the patient's tolerance
224053892|NCT00353834|DRUG|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
224053893|NCT00353834|DRUG|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
224053894|NCT05520645|DRUG|etomidate|use etomidate for anesthesia induction in hysteroscopic surgery
224053895|NCT05520645|DRUG|propofol|use propofol for anesthesia induction in hysteroscopic surgery
224053896|NCT03880032|BEHAVIORAL|Cognitive Behavioral Therapy Intervention for Anxiety|Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
224053897|NCT03675035|DEVICE|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
223442705|NCT06640946|DRUG|Sham cream|Placebo cream without lidocaine will be placed and removed before laser.
223442706|NCT03128034|DRUG|Cyclosporine|Given PO or IV
223442707|NCT03128034|DRUG|Fludarabine Phosphate|Given IV
223442708|NCT03128034|DRUG|Mycophenolate Mofetil|Given PO or IV
223442709|NCT03128034|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
223442710|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 211\^At-BC8-B10 IV
223442711|NCT03128034|RADIATION|Total-Body Irradiation|Undergo TBI
223442712|NCT03128034|RADIATION|Pretargeted Radioimmunotherapy|Given 131\^I-BC8-B10 IV
223442713|NCT03128034|PROCEDURE|Biospecimen Collection|Undergo blood and bone marrow aspirate sample collection
223442714|NCT03128034|PROCEDURE|Single Photon Emission Computed Tomography|Undergo SPECT
224053898|NCT01358760|DRUG|Placebo|Placebo vaginal suppository
224053899|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
224053900|NCT01358760|DRUG|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
224053901|NCT05556278|DIAGNOSTIC_TEST|Ultrasound study|based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)
224053902|NCT05556278|DIAGNOSTIC_TEST|Neurophysiological test|ultrasound protocol described by Chen et al. (2)
224053903|NCT05619302|DRUG|[68Ga]CBP8 PET/MRI|Simultaneous cardiac PET/MRI images will be obtained following injection of \[68Ga\]CBP8
224053904|NCT04311216|OTHER|3D movement analysis with surface electromyography|Single measurement session of 3D movement analysis with surface electromyography for upper limb movements
224053905|NCT02975427|OTHER|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
224053906|NCT02607683|DRUG|XAF5 (concentration A: 0.1%)|
223442715|NCT04542434|DRUG|Niclosamide Oral Tablet|Niclosamide tablets 400 mg 3 times daily for 14 days
223442716|NCT04542434|DRUG|Placebo|Matching placebo tablets 3 times daily for 14 days
223442717|NCT02128334|DRUG|Eligard 45 mg Exposure|Subcutaneous injections
224145605|NCT05511831|DRUG|standard treatment|Standard treatment methods will be determined according to the Guidelines for the Diagnosis and Treatment of Acute ST-segment Elevation Myocardial Infarction (2019) \[19\], including primary PCI, dual antiplatelet, anticoagulation, ACEI/ARB/ARNI, β-receptor blockade drugs, statins, etc.
224145606|NCT04949724|OTHER|translation and adaptation study|translation and adaptation study
223442718|NCT00021645|DRUG|Vitamin E|
223442719|NCT00463034|GENETIC|microarray analysis|
223567037|NCT05275010|DEVICE|On-Body Delivery System|A single 10-mL dose of PH FDC SC will be administered as a subcutaneous (SC) injection using the on-body delivery system (OBDS).
223442720|NCT00463034|GENETIC|polymerase chain reaction|
223442721|NCT00463034|GENETIC|polymorphism analysis|
223442722|NCT00463034|OTHER|high performance liquid chromatography|
223567038|NCT03790358|DRUG|Lysergic Acid Diethylamide|Drug will be administered in solution form.
224053907|NCT02607683|DRUG|XAF5 (concentration B: 0.035%)|
224053908|NCT02607683|DRUG|Matching placebo|
224053909|NCT01565915|DEVICE|Perlane-L|Perlane-L Injection in the midface
224053910|NCT01565915|OTHER|Non-treatment|Non-treatment Arm
224053911|NCT04876755|DRUG|MBM-02|MBM-02 is an HIF-1 and HIF-2 inhibitor.
224053912|NCT00904631|DEVICE|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
224053913|NCT05449990|OTHER|Participation in PFCC-IR|Patient-and-family-centered-care interdisciplinary rounds (PFCC-IR) with the critical care team are standard practice in the ICU but it doesn't usually include family members. The intervention for this study is PFCC-IR that include one family member of the patient.
224053914|NCT01506960|DEVICE|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
224053915|NCT05868551|PROCEDURE|nodulectomy|incision in an onchocerciasis nodule to extract adult worms
223442723|NCT00463034|OTHER|immunohistochemistry staining method|
223442724|NCT00463034|OTHER|laboratory biomarker analysis|
223442725|NCT00463034|OTHER|questionnaire administration|
223442726|NCT00146549|DRUG|Trastuzumab|
223442727|NCT00146549|DRUG|Vinorelbine|
223442728|NCT00146549|DRUG|Paclitaxel|
223442729|NCT00146549|DRUG|Docetaxel|
223442730|NCT04875572|DEVICE|Analgesia Nociception Index (ANI) Monitor|The ANI monitor produces an objective measure of parasympathetic tone through non-invasive electrodes placed on the patient's chest. The patient's standard of care is not affected, and the anesthetist is blinded to the monitor, so as not to affect their anesthetic practice.
223442731|NCT03749499|OTHER|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
223442732|NCT03749499|OTHER|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
224053916|NCT00450723|DRUG|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
224053917|NCT00450723|PROCEDURE|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
224053918|NCT00450723|PROCEDURE|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
224053919|NCT00450723|PROCEDURE|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
224053920|NCT00450723|PROCEDURE|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
224053921|NCT00450723|RADIATION|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
224053922|NCT06090526|DIAGNOSTIC_TEST|"pancreatic stone protein PSP measurement"|Blood samples will be collected for biomarker (PCT, CRP, and PSP) measurements in admission and 24 hours, 72 hours from admission and patients will be followed until death or discharge from the ICU or for 30 days, whichever occurred.
224053923|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions|Conventional impressions for full-arch implant impressions will be digitized and used as a reference for comparison.
224053924|NCT06393582|PROCEDURE|Accuracy of full-arch implant impressions using intraoral scanners|Digital scanners impressions for full-arch implant impressions will be compared to the reference (conventional) impressions
223442733|NCT03749499|OTHER|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
223442734|NCT03749499|OTHER|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
224053925|NCT01905163|PROCEDURE|Tumor Debulking Surgery by laparoscopy|
224053926|NCT01191866|BEHAVIORAL|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
224145607|NCT05508672|OTHER|Community-Centered eHealth Smoking Cessation Intervention (CCeSCI)|We will equip CCeSCI with both core eHealth features and provider-side intervention. Patients assigned to the intervention group will receive a series of online interactive and personalization technologies, including an algorithm-based video curriculum with auto-texting, backstage monitoring system etc. Besides, the patients will also have the face-to-face meetings with community health workers. Provider-side intervention includes training for community workers, WeChat group discussion, and performance-based incentives. The training aims to provide essential skills for community workers so that they can provide face-to-face meetings with smokers during the first 3 months of quitting to prevent or revert relapse in a timely and proactive manner.
224300660|NCT04034537|DIAGNOSTIC_TEST|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
223442735|NCT03208413|DRUG|Thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
223442736|NCT05199935|BEHAVIORAL|Video|Information on violence and safety behaviors. Women are encouraged to share their experience of domestic violence with others.
223442737|NCT05199935|OTHER|Control|Control video on healthy pregnancy
223442738|NCT02958410|BIOLOGICAL|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
223442739|NCT03701685|PROCEDURE|nerve flap|sensory reconstruction via a nerve graft included in the flap
223741053|NCT07207304|PROCEDURE|Intraoperative mechanical ventilation|Intraoperative mechanical ventilation will be performed using a lung-protective strategy. Patients will be ventilated with a volume-controlled mode, using a tidal volume of 6-8 mL/kg of predicted body weight, a respiratory rate adjusted to maintain end-tidal CO₂ (EtCO₂) between 35-45 mmHg, and a positive end-expiratory pressure (PEEP) of minimum 6 cmH₂O. Fraction of inspired oxygen (FiO₂) will be set to maintain peripheral oxygen saturation (SpO₂) above 94%. Recruitment maneuvers may be applied periodically or as clinically indicated.
223442741|NCT04250428|BEHAVIORAL|Demand intervention|"Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals)."
223442742|NCT04250428|BEHAVIORAL|Supply intervention|In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
223442743|NCT00791037|BIOLOGICAL|HER-2/neu peptide vaccine|Given ID
223442744|NCT00791037|PROCEDURE|leukapheresis|Undergo leukapheresis
223442745|NCT00791037|BIOLOGICAL|ex vivo-expanded HER2-specific T cells|Given IV
223442746|NCT00791037|DRUG|cyclophosphamide|Given IV
223442747|NCT00791037|BIOLOGICAL|sargramostim|Given ID
223442748|NCT00791037|OTHER|laboratory biomarker analysis|Correlative study
223442749|NCT05119686|DRUG|AR882 Dose 1|Solid Oral Capsule
223442750|NCT05119686|DRUG|AR882 Dose 2|Solid Oral Capsule
223442751|NCT05119686|DRUG|Placebo|Matching Solid Oral Capsule Placebo
223442752|NCT05626075|DIAGNOSTIC_TEST|Using Oculus Pentacam® which is s a rotating Scheimpflug camera. The rotational measuring procedure generates Scheimpflug images in three dimensions.|Scheimpflug imaging attains a wide and high depth-of-focus , providing sharp images that include information from an anterior corneal surface through to the posterior crystalline capsule
224053927|NCT01806857|DRUG|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
223442753|NCT05647720|PROCEDURE|Distalization combined with upper third molars extraction|After surgical extraction of unerupted upper third molars, the maxillary first molars were distalized using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
224053928|NCT01806857|DRUG|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
224053929|NCT03208387|DIAGNOSTIC_TEST|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
223442754|NCT05647720|PROCEDURE|Distalization without upper third molars extraction|The maxillary first molars were distalized , without extracting upper third molars, using a labial bow with two soldered crimpable hooks distal to the upper lateral incisors. The labial bow fitted in the flying tube of the upper first molar bands. It was anchored bilaterally to the infra-zygomatic mini-implant by closed coil spring that applied a force of 300gm on each side
223442755|NCT05745753|OTHER|sample blood|At the time of enrolment, peripheral blood sampling is expected at the outpatient clinic of the experimental center and the study of the patient's clinical history.
223442756|NCT00998205|DRUG|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
223442757|NCT00998205|DRUG|Atropine bolus|If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
223442758|NCT06543420|PROCEDURE|lateral reconstruction|In lateral reconstruction group, lateral reconstruction is performed by suturing the levator ani muscle to the prostatic collateral ligament and fascia to strengthen the lateral posterior support structure.
223442759|NCT06543420|PROCEDURE|posterior reconstruction|In posterior group, prior to completion of the operation, the posterior fibrous tissues of the sphincter are joined to the residual Denonvilliers fascia on the posterior bladder wall 1-2 cm cephalad and dorsally to the new bladder neck.
223442760|NCT06228495|BEHAVIORAL|Daily Intervention for Active Recovery|"Daily Intervention for Active Recovery - DIARY - is a 28-day intervention during which participants are prompted once daily to engage with intervention content. Each daily intervention interaction includes a short questionnaire with questions regarding sleep quality, current mood (e.g., tense, relaxed), and energy levels. Participants were prompted to open the application through a notification at 18:00 each evening. In case they did not fill out the questionnaire, an additional reminder notification was sent out at 20:00. The questionnaire closed each night at 03:00 am, at which point it was no longer possible to access the questionnaire for that day. The questionnaire took at most 5 minutes to complete. Upon completing the daily questionnaire participants received a prompt - a bit-size amount of information regarding stress and recovery as well as suggestions for a specific recovery strategy."
224053930|NCT03208387|DIAGNOSTIC_TEST|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
224053931|NCT03208387|BEHAVIORAL|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
223442761|NCT02026596|PROCEDURE|Magnetic resonance imaging|
223567039|NCT06024850|OTHER|Datas collected|"Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution"
224053932|NCT03208387|BEHAVIORAL|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
224053933|NCT03208387|BEHAVIORAL|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
224053934|NCT03208387|BEHAVIORAL|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
224053935|NCT03208387|BEHAVIORAL|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
224053936|NCT03208387|DIAGNOSTIC_TEST|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
224053937|NCT03574753|DRUG|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
224053938|NCT04620850|DEVICE|Acupressure|Acupressure after cesarean section 3 hr and then next 3 hr (duration 10 min per time)
224053939|NCT01713751|OTHER|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene \[Prolene®\]
224053940|NCT01713751|OTHER|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene \[Prolene®\]
224300661|NCT01195792|DRUG|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
224300662|NCT01195792|DRUG|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
224300663|NCT01910012|DRUG|ADI-PEG 20|
224300664|NCT02208986|DRUG|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
224300665|NCT00388401|DRUG|Alvimopan|
224300666|NCT03288181|DEVICE|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
224053941|NCT00832520|DRUG|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases \> twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None"
224053942|NCT05365555|PROCEDURE|Fascia Iliaca Compartment Block|Blind technique.
224053943|NCT05365555|PROCEDURE|Femoral Nerve Block|Ultrasound guided.
224300667|NCT06323850|BEHAVIORAL|Intervention Phase|After participants have been enrolled, they will be assigned to one of the trainer-pairs and will work with them to schedule the first two sessions. Most clients will be able to schedule one virtual session per week and one ride along session per week for the first five weeks, with the remaining three weeks allotted to practice ride-along sessions and module repetition (as needed). The additional time also provides a buffer if subjects are unavailable for a week during the intervention phase.
223442762|NCT02026596|PROCEDURE|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
223442763|NCT04063722|PROCEDURE|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
223567040|NCT05706155|BEHAVIORAL|Control Diet|Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
223567041|NCT05706155|BEHAVIORAL|Plant-based Diet|Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
223567042|NCT01397110|OTHER|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
223567043|NCT02355652|DEVICE|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
223567044|NCT02355652|DEVICE|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
223567045|NCT01420692|DRUG|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
223741054|NCT07207304|PROCEDURE|Blood sampling|A total of 10 mL of peripheral venous blood will be collected from each patient at two time points: preoperatively (baseline) and 6 hours after surgery. These samples will be used to quantify the concentration of neutrophil extracellular trap (NET)-associated biomarkers, including myeloperoxidase-DNA complexes (MPO-DNA) and cell-free DNA (cfDNA), which are closely associated with NET formation. Following collection, samples will be centrifuged at 1000 rpm, and the resulting plasma will be aliquoted and stored at -80 °C for later analysis. In parallel, additional inflammatory and metabolic markers will be measured, including C-reactive protein (CRP), total leukocyte count, blood glucose, procalcitonin, and interleukin levels (IL-6, IL-8, IL-10, and IL-17) in selected patients. All participants will be monitored for a period of one year to assess the incidence of postoperative complications and cancer recurrence, including metastasis.
223567046|NCT01420692|DRUG|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
223442764|NCT05906654|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Behavioral intervention to increase physical and social activity. In triads, participants walk 1-mile neighborhood routes three times per week and engage in image-based conversational reminiscence.
223442765|NCT02553798|DRUG|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
223442766|NCT05411601|OTHER|Methodology of attachment of external foot prothesis|establishing the methodology of specific measurements of attachment of external foot prothesis
224053944|NCT05365555|DRUG|Ropivacaine|Ropivacaine dosed according to local guidelines.
224053945|NCT04930809|DRUG|VER-01|standardised cannabis extract (containing 21 mg THC per gram drug product)
224053946|NCT05897814|OTHER|Location of the epidural analgesia catheter|Research of the location of the epidural analgesia catheter using M-mode and color Doppler (cD) ultrasonography.
224053947|NCT03713749|DEVICE|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
224053948|NCT03726606|DEVICE|Intraocular lens|Bilateral implantation of the same intraocular lens.
223567047|NCT01183520|DIETARY_SUPPLEMENT|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
223741055|NCT07205432|DRUG|XTL6001|XTL6001 is a triple-target Glucagon-like peptide-1 receptor （GLP-1R） relevant agonist, intending to manage overweight/obesity and other metabolic diseases
224053949|NCT03389295|RADIATION|Reduced Target Delineation and Radiation Doses|"The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices."
223442767|NCT03099226|DRUG|Placebo|Placebo blue hard gelatine capsules
223442768|NCT03099226|DRUG|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
223567048|NCT00730041|DEVICE|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
223567049|NCT00730041|DEVICE|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
223567050|NCT03564522|PROCEDURE|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
223567051|NCT03564522|RADIATION|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
223567052|NCT06329063|DRUG|Vasopressin|Administration of vasopressin (20 IU) (oral spray)
223567053|NCT06329063|DRUG|Placebo|Administration of placebo (oral spray)
223567054|NCT05526781|DEVICE|Clareon monofocal Intraocular lens (toric and non-toric models)|Bilateral implantation of the Clareon monofocal Intraocular lens (toric and non-toric models) with the Monarch IV inserter
223567055|NCT03679858|OTHER|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
223567056|NCT05128474|OTHER|Neuromuscular Control-Based Exercise Training Group|Exercises for the neuromuscular control of the shoulder will be progressed by starting with the body weight, and in the following phases, a program that progresses to exercises that will improve the dynamic stabilization, coordination and proprioception of the shoulder will be applied to train the sensorimotor system. The exercise program will be performed twice a week for 8 weeks (16 sessions).
223567057|NCT05128474|OTHER|Conventional Exercise Training Group|In this group, which will mainly benefit from conventional open kinetic chain strength exercises, a strengthening exercise program will be applied by advancing from body weight to elastic bands and weights. The exercise program will be performed twice a week for 8 weeks (16 sessions).
223567058|NCT04801459|PROCEDURE|Direction procedure of gastrointestinal anastomosis in Roux-en-Y reconstruction|In this study, intervention methods include two kind directions of gastrointestinal anastomosis in Roux-en-Y reconstruction after distal curative gastrectomy for gastric cancer. One is the isoperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was consistent. The other is the antiperistaltic anastomosis, representing the peristalsis direction of remnant stomach and jejunal efferent loop was opposite.
223567059|NCT04847752|PROCEDURE|carotid artery stenting|common treatments for carotid artery stenosis
223567060|NCT04847752|PROCEDURE|carotid endarterectomy|common treatments for carotid artery stenosis
223567061|NCT04847752|DRUG|Aspirin|the dosage and duration
223567062|NCT04847752|DRUG|Clopidogrel|the dosage and duration
223567063|NCT04847752|DRUG|Anticoagulant|the dosage and duration
223567064|NCT04847752|DRUG|Statin|the dosage and duration
223567065|NCT04847752|DRUG|PCSK9 inhibitor|the dosage and duration
223567066|NCT01309048|DEVICE|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
223567067|NCT00306657|PROCEDURE|Optic nerve sheath fenestration|
223567068|NCT05921682|OTHER|observation|This study is an observational study. Patients will receive conventional cooling measures and organ function support.
223567069|NCT05811520|OTHER|Scapular stabilization exercises with conventional therapy|The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
223567070|NCT05811520|OTHER|Thoracic extension exercises with conventional therapy|Thoracic extension exercises consist of three exercise protocols
223567071|NCT01921218|DRUG|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
223567072|NCT01921218|DRUG|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
223567073|NCT01921218|DRUG|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
223567074|NCT01921218|DRUG|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
223567075|NCT04821102|BIOLOGICAL|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided
223567076|NCT04821102|DRUG|Saline|saline, 1 time injection under ultrasonic guided
223567077|NCT05299996|PROCEDURE|flexible ureterorenoscopy|stone disintegration stricture dilation tumor resection access guidance
223567078|NCT02498886|DIETARY_SUPPLEMENT|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
223567079|NCT02498886|DIETARY_SUPPLEMENT|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
223567080|NCT00297895|PROCEDURE|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
223442769|NCT06307171|DIAGNOSTIC_TEST|In-house Western blot, specific for Leishmania|"Sample will be collected at the collaborating centres and at the DITM, if not already stored at -80°C. The samples will be delivered to the DITM. For the CONTROL groups, two serological tests for Leishmaniasis, based on different antigenic fraction, will be performed on serum samples.~Different strains of Leishmania infantum and Leishmania donovani will be cultivated axenically at the DITM.~Whole soluble fraction of promastigote (WSF), the whole membrane protein fraction (WMF) and the whole soluble fraction secreted by promastigotes (WSFe) of Leishmania spp. will be obtained and the ARPs from WSF, WMF and WSFe, of each Leishmania will be checked trough Western-blot analysis testing at a final dilution of 1/100 each serum sample. The predominant bands detected by Western-blot analysis will be identified by SDS-PAGE separation. Selected bands, corresponding to the immunogenic bands, will be excised, digested and identified with Mass Spectrometry analysis."
223442770|NCT04848246|DRUG|Bupropion|This group received Bupropion 150 mg twice daily for 10 weeks
223442771|NCT04848246|BEHAVIORAL|Behavioural Change Communication|This group will receive Behavioural Change Communication
224053950|NCT03853720|PROCEDURE|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
224053951|NCT05039333|DEVICE|RUS(TM) software : surgical navigation|This clinical trial is a sponsor-led clinical trial, and it is intended to confirm that RUS™, a surgical navigation system certified for level 2 endoscopic imaging treatment planning software, can be applied to real people as a clinical study by using preoperative CT and to confirm the safety of surgery. In addition, the secondary research objective was to examine the accuracy of the intra-abdominal surgical navigation system provided by RUS™ including: 1) the accuracy of the undulation prediction model, 2) the accuracy of the trocar insertion position, 3) the adequacy of 3D reconstruction of the main vessels, 4) the accuracy of the major vessel branching distances, 5) the intraoperative bleeding volume and operating time, and 6) the postoperative hospitalization period and complication rate were compared with the past control group.
224145608|NCT05508672|OTHER|"Traditional smoking is harmful education"|"In the control group, the participants will receive traditional smoking is harmful education video, which is recorded by the clinical physicians."
224145609|NCT02978664|PROCEDURE|Air insufflation|Air insufflation during colonoscopy including insertion phase
224300668|NCT06323850|BEHAVIORAL|Virtual Training Sessions|Virtual sessions will take place over Zoom each session lasting 20-30 minutes. Each of the five virtual sessions will be aligned with the five online modules. For each module, exercises are built in to test comprehension. If the participant does not complete an exercise accurately, the lead trainer will explain why the response was incorrect and prompt them to repeat the video modeling exercise. The support training partner will take notes to support the formative assessment process and complete fidelity checks.
223567081|NCT00297895|PROCEDURE|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
223442772|NCT02211664|DEVICE|Passeo-18 balloon|
223567082|NCT04793451|BEHAVIORAL|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
223567083|NCT04793451|BEHAVIORAL|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
223567084|NCT05465798|DRUG|MC 3x3|Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
223567085|NCT05465798|DRUG|Placebo|Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
223567086|NCT02449889|DRUG|highly purified human chorionic gonadotropin|
224145610|NCT02978664|PROCEDURE|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
224145611|NCT02978664|PROCEDURE|Water exchange|Water will infused and removed during insertion phase of colonoscopy
224145612|NCT01403831|OTHER|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
223442773|NCT02211664|DEVICE|Passeo-18 Lux drug releasing balloon|
223442774|NCT02211664|DEVICE|Pulsar-18 stent|
223442775|NCT03998371|DIAGNOSTIC_TEST|Low-coverage whole-genome sequencing of urine exfoliated cells|The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
223567087|NCT02449889|DRUG|recombinant human chorionic gonadotropin|
223567088|NCT03664791|PROCEDURE|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
223567089|NCT05005845|DRUG|NFX-179 gel|NFX-179 topical gel is the active investigational product being studied
223567090|NCT05005845|DRUG|Vehicle gel|NFX-179 vehicle gel is the placebo comparator for this study
223567091|NCT04553744|OTHER|Survey Administration|Complete survey
223567092|NCT00308412|BIOLOGICAL|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
223567093|NCT00308412|BIOLOGICAL|Placebo|Placebo for rHPIV3cp45 vaccine
224053952|NCT02218242|DEVICE|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
223442776|NCT04889170|OTHER|Intervention|"Intervention: After recording the patient characteristics and the baseline dysphagia characteristics, the intervention begins. The intervention lasts 3 weeks, by extended stay it lasts 5 or 7 weeks.~The intervention has two parts. One part of the intervention is the biofeedback therapy. The biofeedback therapy means that the patient and an SLT watch the video of the FEES together and discuss the findings. The other part of the intervention is a swallow training or a voice training. The frequency of therapy is minimum 3 times a week, the duration of one therapy is minimum 25 minutes.~Allocation to the Groups will be done by a randomization software"
223442777|NCT02722746|DRUG|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
223567094|NCT03336801|PROCEDURE|Back Surgery|All patients undergo basic back surgery.
224053953|NCT04529681|DEVICE|Stroke Riskometer Application|Mobile phone application uses to measure, monitor and manage, it mainly calculates the stroke risk probability within 5 year and 10 years by providing the absolute risk and relative risk which is compared to the normal healthy people with the same age and gender. Not only that, the application purposes to increase general awareness about stroke and its risk factors, and to improve stroke and heart attack prevention on an individual level.
224053954|NCT04529681|OTHER|Informational Leaflets|Informational leaflets consist of the stroke-related leaflet, CVDs-related leaflet and the healthy eating behaviors including; disease introduction, what are the risk factors, early symptoms and also the preventive measures. These materials were developed and published by health education and promotion division Ministry of Health, Malaysia in 2013 - 2016. Usually it will be distributed to public during health screening program and also can be found at all healthcare facilities. All materials were in Malay language only.
224053955|NCT05009927|DRUG|Imatinib tablets|Imatinib interruption
224145613|NCT03729934|DIETARY_SUPPLEMENT|Ketone Ester|This arm receives 25 g ketone ester.
224145614|NCT03729934|DIETARY_SUPPLEMENT|Ketone Salt|This arm receives 25 g ketone salt.
223567095|NCT03336801|DRUG|Propofol|Anesthesia on propofol alone.
223567096|NCT03336801|DRUG|Sevoflurane|Anesthesia on sevoflurane alone.
223567097|NCT03327220|DEVICE|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
223567098|NCT03227952|DEVICE|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
223567099|NCT02762656|DRUG|Lidocaine|Lidocaine drip during surgery
223567100|NCT03857360|DIETARY_SUPPLEMENT|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
223567101|NCT03857360|DIETARY_SUPPLEMENT|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
224145615|NCT04485234|DIAGNOSTIC_TEST|Resting distal coronary to aortic pressure ratio, Fractional flow reserve, Coronary Flow Reserve, Microvascular resistance|Calculation of the resting mean distal coronary to aortic pressure ratio (resting Pd/Pa), fractional flow reserve (Pd/Pa at hyperemia), Coronary flow reserve (peak flow/resting flow), microvascular resistance (Pd/flow).
223567102|NCT00201448|BIOLOGICAL|Hepatitis A Vaccine|Single dose give IM
223567103|NCT00201448|BIOLOGICAL|Towne CMV Vaccine|Single dose given subcutaneously
223567104|NCT00564863|BIOLOGICAL|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
223567105|NCT00551148|DRUG|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
223567106|NCT00551148|DRUG|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
223567107|NCT00551148|DRUG|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
223567108|NCT00551148|DRUG|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
223567109|NCT00551148|OTHER|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
223567110|NCT00651495|BEHAVIORAL|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
223567111|NCT01275612|BIOLOGICAL|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
223741056|NCT07205432|DRUG|Placebo|This intervention contains no active ingredients
224145616|NCT01584258|PROCEDURE|Prostatectomy|Radical prostatectomy: performed open, laparoscopically or using a robotically assisted laparoscopic approach.
224145617|NCT01584258|RADIATION|Conventionally Fractionated Prostate Radiotherapy|"Conventional fractionation delivered to a dose of:~(PACE-B) 78 Gy in 39 fractions or 62 Gy in 20 fractions; (PACE-C) 60 Gy in 20 fractions"
224145618|NCT01584258|RADIATION|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
224145619|NCT05741086|DRUG|Evolocumab|evolocumab (140 mg every 2 weeks)
224145620|NCT05741086|DRUG|Atorvastatin|Atorvastatin 20-40mg
223442778|NCT02722746|DRUG|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
223442779|NCT00682994|BEHAVIORAL|Interview|Interview lasting about 5-10 minutes.
223442780|NCT00682994|BEHAVIORAL|Questionnaire|Questionnaires taking 20-30 minutes to complete.
223442781|NCT00072488|PROCEDURE|computed tomography|
223442782|NCT00072488|PROCEDURE|magnetic resonance imaging|
223442783|NCT00072488|PROCEDURE|positron emission tomography|
223442784|NCT05155449|DIETARY_SUPPLEMENT|Probiotics|Capsule
223442785|NCT05155449|DIETARY_SUPPLEMENT|Placebo|Capsule
223442786|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
223442787|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
223442788|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
223442789|NCT01134263|BIOLOGICAL|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
223442790|NCT01134263|BIOLOGICAL|Placebo: NaCl 0.9%|0.5 ml, SC
223442791|NCT03418194|PROCEDURE|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
223442792|NCT03418194|PROCEDURE|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
223442793|NCT04108780|DEVICE|T-tube|T shaped tube used as stent after CBD exploration
223442794|NCT00290381|PROCEDURE|Oxagen OC000459|
223442795|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg BID x 5 days
223442796|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
223442797|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
223442798|NCT01140412|DRUG|Maraviroc|maraviroc 300 mg QD x 5 days
223442799|NCT01140412|DRUG|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
223442800|NCT01140412|DRUG|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
223442801|NCT02325245|DRUG|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
223442802|NCT02325245|DRUG|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
223442803|NCT00429845|BEHAVIORAL|Nutritional|
223442804|NCT02562092|BEHAVIORAL|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
224300669|NCT06323850|BEHAVIORAL|Ride-Along Training Sessions|The first ride-along session will be the baseline session for assessing level of independence (number of cues needed) and safety. The participant will have up to 8 ride-along sessions to reach full independence (no cues needed) and full marks on the safety assessment. The lead trainer will provide the cues as needed to complete each step of the Rideshare process.
223442805|NCT02562092|BEHAVIORAL|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
223442806|NCT04785040|OTHER|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale|The groups evaluated by The Musculoskeletal Pain Intensity and Interference Questionnaire for Professional Orchestra Musicians, Brief Pain Inventory, QuickDASH and Fatigue Severity Scale
223442807|NCT03945994|OTHER|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
223442808|NCT04790097|RADIATION|Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost|"78Gy in 30 fractions on FET-PET based target volumes;~60Gy in 30 fractions on 2cm margin from MRI based target volumes;~all patients will be treated with concomitant and adjuvant temozolomide"
223442809|NCT00407407|DRUG|ABI-007|80mg/m\^2 to 150mg/m\^2 IV every 3 weeks
223442810|NCT00407407|DRUG|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
223442811|NCT01303614|DRUG|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
223442812|NCT01303614|DRUG|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
223442813|NCT00396916|DEVICE|PET/CT imaging|
223442814|NCT00061750|DRUG|ICL670|
223442815|NCT00061750|DRUG|deferoxamine|
223442816|NCT03905538|DRUG|[18F]FLT-PET/CT|Dose of 0.07 mCi/Kg \[18F\]FLT to max of 5 mCi (± 20%) will be given intravenously.
223442817|NCT02882464|DEVICE|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
223442818|NCT02882464|DEVICE|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
224053956|NCT05651555|BEHAVIORAL|Psycho-educational program EHPAD caregivers / Pact & Pad for caregivers with a parent in an institution|Psycho-educational program EHPAD caregivers / Pact \& Pad for caregivers with a parent in an institution
224053957|NCT06165250|DRUG|BR1018A|One tablet administered alone
223442819|NCT02882464|PROCEDURE|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
223442820|NCT02143934|DRUG|Primaquine|
223442821|NCT02143934|DRUG|Placebo|Sugar pills, appearance identical to Primaquine tablets
223442822|NCT02143934|DRUG|Chloroquine|
223442823|NCT02143934|DRUG|Artemether Lumefantrine|
223442824|NCT05047614|DEVICE|including sham|Repositiong feedback training and biofeedback pressure training unit
223442825|NCT04422964|DEVICE|3D Obturator|Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
223442826|NCT01022216|DEVICE|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
223442827|NCT01022216|DEVICE|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
223442828|NCT04549623|DEVICE|Novel end-tidal CO2 monitoring device|Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.
223567112|NCT02383654|PROCEDURE|Autologous Adipose-Tissue Derived Stem Cells|"1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
224053958|NCT06165250|DRUG|BR1018A-1|One tablet administered alone
224053959|NCT06165250|DRUG|BR1018B|One tablet administered alone
224053960|NCT06165250|DRUG|BR1018B-1|One tablet administered alone
224053961|NCT06165250|DRUG|BR1018C|One tablet administered alone
223567113|NCT00368836|DEVICE|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
224053962|NCT06165250|DRUG|BR1018C-1|One tablet administered alone
223567114|NCT01933438|OTHER|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
223567115|NCT01933438|OTHER|Control|Standard treatment
223567116|NCT04351464|OTHER|physical therapy and reflexology|
223567117|NCT02460354|DRUG|Metformin|Metformin 500 mg pill dispensed once orally
224053963|NCT06148571|DEVICE|left bundle branch area pacing|left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.
224053964|NCT02559297|DRUG|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
224053965|NCT02559297|DRUG|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
224053966|NCT04000789|DRUG|Sodium Hyaluronate, Vitamin A, Vitamin E|Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
224053967|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
224053968|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
223442829|NCT04549623|DEVICE|SpO2 and respiratory motion monitoring|Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
223442830|NCT02741466|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. Formulation number - SR16-01.
223442831|NCT05899712|OTHER|Removable Partial Denture Construction|Construction of class I Removable partial denture by digital workflow
223442832|NCT00404833|DRUG|prednisolone and mycophenolate mofetil|
223442833|NCT00404833|DRUG|prednisolone and chlorambucil|
223442834|NCT06057831|RADIATION|Total Neo-adjuvant Therapy|"* TNT incorporates chemotherapy with concurrent chemoradiotherapy (CRT) in any order.~* Radiotherapy includes 5000 cGy/25 fractions over 5 weeks.~* Chemotherapy regimen for Concurrent CRT: Capecitabine~* Chemotherapy regimens used with TNT are: FOLFIRINOX x 6 cycles, 8-9 courses FOLFOX or 5-6 courses of CAPEOX delivered over 4-6 months.~* The chemotherapy regimen or the order of treatment will be decided at the discretion of the patient's medical oncologist"
223567118|NCT00820794|DRUG|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
223567119|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
223567120|NCT00820794|DRUG|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
223567121|NCT00820794|DRUG|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
223567122|NCT01345513|OTHER|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
223567123|NCT01082874|DRUG|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
223567124|NCT01082874|DRUG|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
224053969|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #45/0.06|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
224053970|NCT05620147|OTHER|Root canal instrumentation EdgeFile X7 to size #35/0.04|Instrumentation will be performed using an endodontic motor at a speed of 300 rpm and a torque of 2 Ncm
223442835|NCT06057831|OTHER|18FDG-PET/MRI scan|18FDG-PET/MRI scan within 4 weeks of commencing chemo-radiation and within 1 - 2 weeks before radical rectal cancer surgery.
223442836|NCT04422730|BEHAVIORAL|Psychological evaluation|Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
223442837|NCT04033211|DEVICE|Novosyn® CHD for fascia and skin closure|Experimental
223442838|NCT04033211|DEVICE|Novosyn® for fascia and skin closure|Comparator
223442839|NCT02736695|DRUG|F-18 AV 1451|Tau binding agent
223442840|NCT06029374|PROCEDURE|Functional Treatment|Patients receiving buddy taping for fingers IV and V and an elastic bandage in terms of a functional treatment. Duration of bandage treatment is determined with 4 weeks.
223567125|NCT01082874|DRUG|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
223741057|NCT07206680|DEVICE|Shockwave therapy|The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.
223567126|NCT01082874|DRUG|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
223741058|NCT07206680|DRUG|Medical treatment|Patients in both groups will receive medical treatment in the form of emollients \& corticosteroids for one month.
223741059|NCT07206745|DRUG|Fei Re Qing Granules|"Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.).~Routine standard treatments：Routine standard treatments according to clinical guidelines."
223741060|NCT07206745|DRUG|Placebo of Feireqing Granules|"Placebo of Feireqing Granules：The placebo granules are prepared using 5% of the active drug combined with pharmaceutical excipients, including starch, dextrin, microcrystalline cellulose, and food-grade coloring and flavoring agents, to ensure consistency in appearance, weight, color, and odor with the Fei Re Qing Granules.~Routine standard treatments：Routine standard treatments according to clinical guidelines."
223741061|NCT07207083|BEHAVIORAL|Immersive Virtual Reality-based Exercise (FitXR, Meta Quest 3s)|"participants assigned to the intervention group will perform a 15-minute immersive virtual reality (VR) exercise program using the FitXR application on the Meta Quest 3s headset.~This program provides interactive, visually immersive exercise tasks designed to engage participants in physical activity while reducing fear of movement and enhancing functional recovery."
223741062|NCT07207083|BEHAVIORAL|Conventional Exercise Program (Matched Exercise, without VR)|"Participants assigned to this arm will perform the same 15-minute exercise program without virtual reality equipment.~This allows comparison between immersive VR-based exercise and conventional exercise of equivalent intensity and duration."
224053971|NCT03591822|BEHAVIORAL|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
223442841|NCT06029374|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
223442842|NCT05723913|DIETARY_SUPPLEMENT|Dietary Supplement: A package containing a mix of functional foods|Participants will be provided with a nutritional strategy based on functional foods to use over the 2 week trial. These will be nopal, chía seeds, inulin, soy protein, agave extract and genistein.
224053972|NCT03591822|BEHAVIORAL|B : Systemic evaluation of the pain|A systematic evaluation of the pain
224053973|NCT01651858|DRUG|Nurigra Chewable tablet|1 tablet of 100mg, once a day
223442843|NCT03724084|DRUG|Cytarabine|Given IV
223567127|NCT04044599|DRUG|Gynoflor|VAGİNAL GYNOFLOR
223567128|NCT02878525|PROCEDURE|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
224053974|NCT06087887|OTHER|no interventions|no interventions
224053975|NCT06185621|DRUG|100mg aspirin|Patients received oral 100mg aspirin, one tablet daily for 2 years
223442844|NCT03724084|DRUG|Daunorubicin|Given IV
223442845|NCT03724084|DRUG|Daunorubicin Hydrochloride|Given IV
223442846|NCT03724084|DRUG|Pinometostat|Given IV
223442847|NCT04799106|BEHAVIORAL|Community Based Strategies for Early Detection of Melanoma|"The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study."
223567129|NCT02878525|PROCEDURE|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
223567130|NCT02128815|OTHER|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
223567131|NCT05181774|DIAGNOSTIC_TEST|Proteomics|Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
223567132|NCT05181774|DIAGNOSTIC_TEST|Metabolomics|Metabolomic data were obtained by UPLC-QTOF/MS platform.
223567133|NCT04700345|DEVICE|Onyx|Embolization of the Middle Meningeal Artery using the liquid embolic material
223567134|NCT04700345|PROCEDURE|Burr-hole|Burr-hole drainage of subdural hematoma
223567135|NCT04700345|OTHER|Medical Management|best medical management
224053976|NCT03762720|DEVICE|Physium treatment|patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.
224053977|NCT00036751|DRUG|imatinib mesylate|Given orally
223442848|NCT03319810|BIOLOGICAL|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
223442849|NCT03395847|BIOLOGICAL|Pembrolizumab|Given IV
224053978|NCT00036751|OTHER|laboratory biomarker analysis|Correlative studies
224053979|NCT01350921|DRUG|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
223442850|NCT03473613|DRUG|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
224053980|NCT01350921|DRUG|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
223442851|NCT03473613|DRUG|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
223442852|NCT06976138|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|This program will focus on changing the participant's sleep patterns, activities, and habits.
223442853|NCT06976138|DEVICE|Bright Light therapy via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer® The participant will be asked to wear the device every morning for about four weeks before surgery, four weeks after surgery and again for 1-week, 3-months after surgery
223442854|NCT06976138|DEVICE|Negative Ion exposure via IonMi Device|This procedure involves wearing a light weight negative ionizer (IonMi Device) around neck for one hour in the morning. An ionizer gives off special negatively charged ions into the air. The participant will be asked to wear the device every morning for about four weeks before surgery, four weeks after surgery and again for 1-week, 3-months after surgery
223442855|NCT06976138|BEHAVIORAL|Sleep / Knee Osteoarthritis Education|This program will focus on increasing The participant's knowledge about sleep, sleep disorders and knee osteoarthritis.
223567136|NCT00634257|BEHAVIORAL|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
223567137|NCT04040595|PROCEDURE|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
223567138|NCT00849706|OTHER|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
223567139|NCT02410473|OTHER|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
223741063|NCT07205224|OTHER|Anesthesia Type|Patients receive either spinal or general anesthesia according to routine clinical decision-making. No investigational drug or device is administered.
224053981|NCT02513849|DRUG|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
224053982|NCT04722770|DEVICE|PhotoniCare OtoSight Middle Ear Scope|PhotoniCare OtoSight imaging using a near-infrared laser
223442856|NCT00191659|DRUG|Atomoxetine Hydrochloride|
223442857|NCT03839875|DRUG|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
223442858|NCT06406634|DRUG|Cadonilimab|Injectable solution
223442859|NCT06406634|DRUG|Lenvatinib|capsule
223442860|NCT05405894|DRUG|Zoledronic acid|Once-yearly infusion of zoledronic acid following denosumab discontinuation
223442861|NCT01425567|DRUG|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
223442862|NCT01087840|DRUG|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
223442863|NCT04935840|DIETARY_SUPPLEMENT|FertyBiotic Pregnancy|DHA, folic acid, Iodine, iron, Lactobacillus rhamnosus, Lactobacillus reuterii, magnesium, zinc, vitamin D3, Vitamin C, Vitamin E, Group B vitamins and Biotin
223442864|NCT04935840|OTHER|Control|400 mcg of folic acid
223442865|NCT01464801|DIETARY_SUPPLEMENT|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
223442866|NCT01464801|DIETARY_SUPPLEMENT|Placebo|Tablet Placebo 3 times daily for 6 months
223442867|NCT05760222|OTHER|Acupuncture|Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
223567140|NCT02410473|OTHER|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
223567141|NCT04378465|OTHER|Enhanced Recovery Program (ERP)|An evidence-based perioperative care approach, involving a multidisciplinary team work including surgeons, anaesthesiologists, dieticians, and nurses, which aim to reduce the surgical stress and metabolic responses as well as organ dysfunction, thus leading to a faster recovery after surgery
223567142|NCT02607917|OTHER|Mass Media plus clinic intervention.|
223567143|NCT02607917|OTHER|Media|
223741064|NCT07206251|BEHAVIORAL|Foiled Windowed room (foil added)|Foiled Windowed room (foil added)
224053983|NCT02802748|DRUG|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
224053984|NCT02802748|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
224053985|NCT06015139|DEVICE|cotton roll-coated viscoelastic polymer pads|relton-hall frame cotton roll-coated viscoelastic polymer pads
224053986|NCT06015139|DEVICE|viscoelastic polymer pads|relton-hall frame viscoelastic polymer pads
224053987|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
224053988|NCT01733979|DIETARY_SUPPLEMENT|Placebo|Placebo (1g/day)
224053989|NCT01733979|DIETARY_SUPPLEMENT|Heme-Iron|Heme-Iron (1g/day)
224053990|NCT01733979|DIETARY_SUPPLEMENT|Organic Iron|Organic Iron (1g/day)
224053991|NCT00417040|OTHER|internet-based intervention|Use the STAR database system
224053992|NCT00417040|OTHER|assessment of therapy complications|Use the STAR database system
223442868|NCT05753059|DRUG|Placebo|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
223442869|NCT05753059|DRUG|Amiloride|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
223442870|NCT05753059|DRUG|Bendroflumethiazide|This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
223442871|NCT05990959|OTHER|No intervention for research purpose|No any intervention will be applied under research purpose. All procedure or drugs would be given to the patient under best clinical judgment, not for research purpose.
223442872|NCT06622863|BEHAVIORAL|Standard oral hygiene instructions will be given verbally by the periodontics resident|Standard oral hygiene instructions will be given verbally by the periodontics resident
223442873|NCT06622863|BEHAVIORAL|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice|Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
223442874|NCT03981965|OTHER|Physical activity|Physical activity as described previously.
223442875|NCT06138002|DEVICE|LumbaCure®|LumbaCure®is a robotic system that systematically moves the spine of affected patients with a complex proprietary algorithm.
223442876|NCT06138002|PROCEDURE|Physical Exercises supervised by the physiotherapist|A set of core stability/active qualitative mobilization exercises have been defined, corresponding to standard exercises proposed in center rehabilitation program
223442877|NCT02174575|DRUG|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
223442878|NCT02174575|DRUG|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
223442879|NCT06286475|DRUG|VRG50635|Specified dose on specified days
223442880|NCT06286475|DRUG|Placebo|Specified dose on specified days
223442881|NCT06270017|DRUG|Chemotherapy drug|rsponse evaluation in zebrafish embryo model
223567144|NCT05190029|DIAGNOSTIC_TEST|Series of questions to parents of children in a virtual form.|A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).
223567145|NCT05190029|OTHER|Intervention by teachers|"The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas."
223567146|NCT05190029|PROCEDURE|Physiotherapeutic evaluation|"A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1)."
223741065|NCT07206472|DRUG|Combination of bempedoic acid and ezetimibe|No drug was administered in this observational study.
223741066|NCT07205718|DRUG|TAK-188|TAK-188 IV infusion
223741067|NCT07202026|BEHAVIORAL|Patient-centered Decision Aid to support long-term opioid therapy tapering|Earlier aims of this study developed a patient-centered Decision Aid (DA) that uses stories of people who benefited from discontinuing and clear explanations of evidence for key choices to decrease stigma; empower patients; increase engagement and productive interaction with providers in decision making; and reduce fear, anger and anxiety about tapering. The DA will be designed to support conversations that providers often find challenging and help providers maintain patient trust and satisfaction. Participants in the pilot test will be asked to: 1) complete a pre-DA survey, 2) review the DA, 3) have a guided conversation with a trained study interventionist with a behavioral health background who is trained on how to use the DA, and 4) complete a post-DA survey.
223741068|NCT07205744|DEVICE|Restylane SkinBoosters Vital|"Restylane® Skinboosters™ Vital (HASBV) is manufactured by Galderma Laboratories. It is a sterile non-animal hyaluronic acid (20mg/mL) based gel that is supplied in a 1mL glass syringe. The syringed is packed with a 29G TW (thin-walled) needle.~For this study, commercial products will be used. The study products are for single use only."
224053993|NCT00417040|OTHER|Questionnaire Administration|Ancillary studies
224053994|NCT01886339|OTHER|SNIF test (Sniff Nasal Inspiratory Force)|
224053995|NCT01436084|DRUG|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
224053996|NCT05664542|OTHER|ESPB (regional Block)|ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine
224053997|NCT05664542|DRUG|ropivacaine and dexmedetomidine|0.2 % ropivacaine and dexmedetomidine
224300670|NCT04649073|BIOLOGICAL|OPC-415|OPC-415 (up to 1×10\^7cells/kg) On 2 days
223442882|NCT06125067|PROCEDURE|no peripheral block|No peripheral block was applied. Standard multimodal analgesia method was applied.
223442883|NCT06125067|PROCEDURE|Fascia Iliaca Compartment Block|Fascia Iliaca Compartment Block is performed with the patient in a supine position. A high-frequency (6-14 MHz) linear ultrasound probe is positioned transversely to locate the femoral artery in the inguinal crease. The hyperechoic femoral nerve is usually visualized lateral to the femoral artery, between the iliopsoas and fascia iliaca. The probe is manoeuvred in a cranial and caudal direction to capture high-quality images of the femoral nerve and fascia iliaca. Identification of the triangular-shaped sartorius muscle and anterior superior iliac spine (ASIS) is achieved by lateral movement of the probe. Post-skin disinfection, the needle tip is directed just beneath the fascia iliaca. Local anaesthetic is administered following negative pressure aspiration into the area. The local anaesthetic spreads towards the femoral nerve medially and towards the iliac process laterally.
223442884|NCT06125067|PROCEDURE|iPACK Block|During the iPACK procedure, the patient assumes a supine position with the lower extremity flexed at the knee and abducted at the hip (in frog-leg position). The ultrasound transducer is placed in the lower third of the medial thigh, and then pushed backward and downward to visualize the gap between the popliteal artery and the femoral shaft, straight above the femoral condyles. After ensuring that the needle tip is placed 2 cm beyond the lateral border of the artery, local anaesthetic solution is administrated in divided doses to infiltrate the tissue space. The needle is then withdrawn after confirming negative aspiration.
223442885|NCT04140240|BEHAVIORAL|intervention group|Parallel Assignment a experimental design with pre test and post test
223442886|NCT05587426|DIETARY_SUPPLEMENT|SFF|Ingestion of 20g of SFF after 10-14 hours of fasting
223442887|NCT05587426|DIETARY_SUPPLEMENT|Glucose|Ingestion of 20g of glucose after 10-14 hours of fasting
223442888|NCT05587426|DIETARY_SUPPLEMENT|SFF chocolate chips|Ingestion of 50g of chocolate chips made with SFF after 10-14 hours of fasting
223442889|NCT05587426|DIETARY_SUPPLEMENT|Regular chocolate chips|Ingestion of 50g of regular chocolate chips after 10-14 hours of fasting
223442890|NCT00002266|DRUG|AS-101|
223442891|NCT03212391|BEHAVIORAL|Diet|52 weeks of Diet supervised by a dietician
223442892|NCT03212391|BEHAVIORAL|Walking|26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
223442893|NCT03212391|BEHAVIORAL|Nordic Walking|26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
223442894|NCT01294748|DEVICE|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
223442895|NCT01294748|DEVICE|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
223442896|NCT02954822|DRUG|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
223442897|NCT02954822|DRUG|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
223442898|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
223442899|NCT01262924|BIOLOGICAL|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
223442900|NCT01262924|BIOLOGICAL|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
223567147|NCT03262766|OTHER|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
223567148|NCT03262766|BEHAVIORAL|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
224300671|NCT04669470|PROCEDURE|bariatric endoscopy, mainly intragastric baloons, plication of stomach too|bariatric endoscopy, mainly intragastric baloons, plication of stomach too
223442901|NCT04520334|OTHER|Zhineng Qigong intervention|"The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD."
223442902|NCT04813913|DRUG|Bevacizumab in combination with chemotherapy based on fluoropyrimidine IV|Enrollement of major patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, naive in antineoplastic treatment and eligible to start a systemic carcinological treatment comprising bevacizumab in combination with chemotherapy based on fluoropyrimidine IV. The main objective is to show that there is an increase in the stiffness of the carotid artery at 4 months in patients with stage IV colorectal cancer exposed to bevacizumab.
223442903|NCT01955109|BIOLOGICAL|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
223442904|NCT04820231|OTHER|intra-articular PRP injection|
223567149|NCT03262766|OTHER|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
223567150|NCT00725348|DRUG|Talarozole|1.0 mg oral dose per day
223567151|NCT01602783|OTHER|11C Acetate Imaging|Single scan
223567152|NCT00090142|DRUG|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
223567153|NCT00090142|DRUG|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
224145621|NCT00603213|PROCEDURE|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
223442905|NCT02600767|DRUG|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
223442906|NCT06044272|OTHER|Factors associated|Factors associated with the type of resistance by microorganisms.
223442907|NCT01323504|OTHER|Music|Patient are listen music during their local care
223442908|NCT01323504|OTHER|no music|There are no music during the local care
223442909|NCT05935995|OTHER|microscopy confocal (Histolog Scanner)|"Surgical margins of tumor samples will be examined by conventional histopathology (H\&E) and confocal microscopy (Histolog® scanner, SamanTree Medical, Switzerland).~Depending on the histopathological result obtained between the two methods, the patient may benefit directly from early surgery if the experimental result confirms the presence of positive margins (excluding the learning curve).~A learning curve will be established over the first fifteen surgeries, enabling surgical teams to gain experience and systematize specimen flattening. This learning curve will also enable reference images to be produced. The procedure will be carried out by the surgeon and the pathologist in the operating room during this phase."
223442910|NCT03884816|OTHER|Determine the Incidence and Retention Rate|Determine the incidence of HIV and the retention rate of MSM/TGW/TGM/Intersex at risk for HIV infection
223442911|NCT05957224|OTHER|Shake 1 then Shake 2|Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake
223442912|NCT05957224|OTHER|Shake 2 then Shake 1|Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
223567154|NCT00338832|BEHAVIORAL|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
223741069|NCT07205744|DRUG|Sculptra Aesthetic|"Sculptra® Aesthetic (PLLA-SCA) is manufactured by Galderma Laboratories. It is a sterile, lyophilized preparation of PLLA that is biocompatible and biodegradable. Each vial contains 367.5 mg of freeze-dried powder, including 150 mg of PLLA. Prior to injection, it will be reconstituted with sterile water for injection (SWFI) and lidocaine hydrochloride (2%).~For this study, commercial products will be used. The study products are for single use only."
224053998|NCT02957591|DIETARY_SUPPLEMENT|Vivomixx®|Streptococcus thermophilus Bifidobacterium breve Bifidobacterium longum Bifidobacterium infantis Lactobacillus acidophilus Lactobacillus plantarum Lactobacillus paracasei Lactobacillus delbrueckii subsp. bulgaricus
224053999|NCT02957591|OTHER|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
224054000|NCT01898936|PROCEDURE|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
224054001|NCT01898936|DEVICE|Only photodynamic therapy|
224054002|NCT04319848|OTHER|TE-EK treatment group|Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
224300672|NCT04158960|BEHAVIORAL|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
223442913|NCT03174678|DRUG|Dexmedetomidine|1µg/kg dexmedetomidine oral
223442914|NCT03174678|OTHER|apple juice|apple juice
223442915|NCT03896672|DEVICE|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
223442916|NCT05157698|DRUG|Naltrexone and Bupropion Combination|Participants in this intervention will take active naltrexone and bupropion pills.
223442917|NCT05157698|BEHAVIORAL|Behavioral Weight Loss|Participants in this intervention will receive behavioral weight loss treatment.
223442918|NCT05157698|OTHER|Placebo|Participants in this intervention will take inactive (placebo) pills.
223442919|NCT05040334|DRUG|Group 1: Antibiotic receiving group|Group 1; receiving antibiotic prophylaxis; single dose of oral doxycycline (200 mg) tablet and metronidazole (500 mg) tablet 2 hours before the surgical evacuation Group B ;receiving placebo 2 hours before the surgical evacuation
223442920|NCT03774134|PROCEDURE|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
223442921|NCT03774134|PROCEDURE|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
223442922|NCT03486119|OTHER|nivolumab|Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.
223442923|NCT04369235|DEVICE|tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. tCES will be applied for 20 minutes at an intensity of 1.0 -1.5 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 6 weeks.
223442924|NCT04369235|DEVICE|Sham tCES|The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham tCES will consist of a 5-second ramp up to 1.0-1.5 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.
223442925|NCT00865241|DRUG|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
223442926|NCT00865241|DRUG|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
223442927|NCT04847102|BIOLOGICAL|SARS-CoV-2 mRNA Vaccine|"The SARS-CoV-2 mRNA Vaccine is formulated by encapsulating the mRNA, which encodes the receptor-binding domain (RBD) of spike glycoprotein (S protein) of SARS-CoV-2 and is transcribed in-vitro by the corresponding DNA template, in lipid nanoparticles (LNPs). This vaccine is presented as a white to off-white dispersion for injection.~Active substances: mRNA encoding the RBD of the S protein of SARS-CoV-2.~The vaccine is supplied in single-dose pre-filled syringe with 0.5 mL dispersion for intramuscular injection. Each dose (0.5 mL) of the vaccine contains:~15 μg of mRNA encoding the RBD of the spike glycoprotein (S protein) of SARS-CoV-2, 0.339 mg of total lipids (including lipid 9001, cholesterol, DSPC, DMG-PEG2000)."
223442928|NCT04847102|BIOLOGICAL|Placebo|0.9% sodium chloride solution, 0.5 mL/vial
223442929|NCT02631902|BEHAVIORAL|Exercise|Community-based exercise program with 3 weekly exercise sessions
223442930|NCT02631902|BEHAVIORAL|Dietary intervention|Community-based dietary intervention program
223442931|NCT02867202|DEVICE|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
223442932|NCT02867202|DEVICE|Intrauterine Contraceptive Device Plus Foley Catheter|After the completion of hysteroscopic adhesiolysis, Intrauterine Contraceptive Device Plus Foley Catheter were inserted into the uterine cavity. Foley Catheter was removed after three days and Intrauterine Device was removed at the second time of hysteroscopy.
223442933|NCT05375084|DRUG|BBP-398 with nivolumab|BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks)
223442934|NCT05961475|DIETARY_SUPPLEMENT|Fruit snack 1|Fruit snacks with original level of sugar
223442935|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 2|Fruit snacks with original level of sugar and mulberry leaf extract
223442936|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 3|Fruit snacks with reduced level of sugar
224054003|NCT02447055|BIOLOGICAL|Tocilizumab|
224054004|NCT02447055|DRUG|Melphalan|
223442937|NCT05961475|DIETARY_SUPPLEMENT|Fruit Snack 4|Fruit snacks with zero added sugar
223442938|NCT05961475|DIETARY_SUPPLEMENT|White Bread|White bread with matched carbohydrate as control
223442939|NCT02735707|DRUG|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
223442940|NCT02735707|DRUG|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
223442941|NCT02735707|DRUG|Piperacillin-tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
223567155|NCT00338832|BEHAVIORAL|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
223567156|NCT01988532|OTHER|No treatment given|Subject will only fill out a questionnaire
223442942|NCT02735707|DRUG|Ceftaroline|"The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.~Note: this intervention is now closed."
223442943|NCT02735707|DRUG|Amoxicillin-clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
223442944|NCT02735707|DRUG|Standard course macrolide|"Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
223442945|NCT02735707|DRUG|Extended course macrolide|"Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).~The dosing of and route of administration is not protocolised, the following guidance is provided:~* Initial IV administration of a macrolide is strongly preferred~* The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~* The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
223442946|NCT02735707|OTHER|No systemic corticosteroid|Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
223442947|NCT02735707|DRUG|Fixed-duration Hydrocortisone|"50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention is now closed."
223442948|NCT02735707|DRUG|Shock-dependent hydrocortisone|50mg IV hydrocortisone every 6 hours while the patient is in septic shock
223567157|NCT05121454|DEVICE|Serenno Sentinel, model Alpha 2.0, software version: 8.0|intra-abdominal pressure measurements compared to a Foley Manometer at different insufflation pressures between 5 and 25 cmH20 at 30seconds intervals.
224054005|NCT02447055|DRUG|Fludarabine|
224054006|NCT02447055|DRUG|Cyclophosphamide|
224054007|NCT02447055|DRUG|Tacrolimus|
224054008|NCT02447055|DRUG|Mycophenolate mofetil|
224054009|NCT02447055|DRUG|Filgrastim|
224054010|NCT04021836|OTHER|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
224054011|NCT04647877|DRUG|phenytoin cream|Phenytoin cream to be applied on the neuropathic pain area
224054012|NCT04647877|OTHER|Placebo cream|Placebo cream to be applied on the neuropathic pain area
224054013|NCT04221698|OTHER|Gait retraining|5 gait retraining sessions of continuous feedback in real time during running sessions; using videotape feedback, a digital metronome to increase step rate, and verbal feedback to reduce the tendency to heel strike upon ground contact. Verbal feedback is offered during the 25- to 30-minute running sessions following a series of drills aimed at improving running mechanics.
223442949|NCT02735707|DRUG|Fixed-duration higher dose Hydrocortisone|"100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.~Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed."
223442950|NCT02735707|OTHER|No antiviral agent for influenza|No antiviral agent intended to be active against influenza infection is to be administered
223442951|NCT02735707|DRUG|Five-days oseltamivir|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
223442952|NCT02735707|DRUG|Ten-days oseltamivir|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
223442953|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
223442954|NCT02735707|DRUG|Lopinavir / Ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Note: this intervention is now closed."
223442955|NCT02735707|DRUG|Hydroxychloroquine|"Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
224054014|NCT01550861|PROCEDURE|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
224054015|NCT01550861|PROCEDURE|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
223442956|NCT02735707|DRUG|Hydroxychloroquine + lopinavir/ritonavir|"Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.~Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).~Note: this intervention is now closed."
223442957|NCT02735707|DRUG|Ivermectin|"Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.~Note: this intervention is now closed."
223442958|NCT02735707|OTHER|No immune modulation for COVID-19|"No immune modulating agent intended to be active against COVID-19 is to be administered.~Note: this intervention is now closed."
223442959|NCT02735707|DRUG|Interferon beta-1a|"IFN-β1a 10 μg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-β1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
223442960|NCT02735707|DRUG|Anakinra|"A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.~In patients with renal impairment, anakinra will be administered on alternate days.~Note: this intervention is now closed."
223567158|NCT02442310|DRUG|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
223567159|NCT02442310|DRUG|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
223567160|NCT05332587|DRUG|Rituximab|The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
223567161|NCT01022957|GENETIC|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
223567162|NCT05055258|DRUG|KVD824|KVD824 300 mg Modified-Release Tablets
223567163|NCT05055258|DRUG|Placebo to KVD824|Placebo to KVD824 300 mg Modified-Release Tablets
223741070|NCT07206212|BEHAVIORAL|A group-based lifestyle intervention for individuals with OCD|Participants will take part in 12 weekly group sessions, consisting of both education on lifestyle habits and physical exercise. Each educational session will focus on a specific topic/lifestyle habit, alternating more informative sessions with sessions discussing how the information can be applied, taking into account specific hinders due to Obsessive-Compulsive Disorder. Between-sessions homework will include, for example, daily registration of physical activity and implementing changes in the lifestyle habits discussed during each session. All homework assignments will be registered in a digital platform. After the 13 weeks of lifestyle intervention, participants will get access to a booster module in the digital platform to help them maintain their behavioral changes.
223741071|NCT07206212|BEHAVIORAL|Medical advice|One individual session with a clinical psychologist on week 1 of about 1 hour of duration. During this session, participants will receive feedback based on the baseline evaluation of their clinical characteristics, lifestyle habits, and cardiometabolic risk.
224054016|NCT02124278|DRUG|PUL-042 Inhalation Solution|
224054017|NCT04952103|OTHER|no intervention|The patient's treatment is determined by the physician in charge according to the patient's clinical situation and relevant guidelines, without additional intervention.
224054018|NCT00787462|DRUG|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
223567164|NCT00481559|DRUG|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
223567165|NCT00688324|DRUG|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
223442961|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.~Note: this intervention is now closed."
223442962|NCT02735707|DRUG|Sarilumab|"Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.~Note: this intervention is now closed."
223442963|NCT02735707|DRUG|Local standard venous thromboprophylaxis|"Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442964|NCT02735707|DRUG|Therapeutic dose anticoagulation|"Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.~Note: this intervention is now closed."
223442965|NCT02735707|DRUG|Conventional low dose thromboprophylaxis|Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
223442966|NCT02735707|DRUG|Intermediate dose thromboprophylaxis|Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
223442967|NCT02735707|DRUG|Continuation of therapeutic dose anticoagulation|"Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442968|NCT02735707|OTHER|No immunoglobulin|No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
223442969|NCT02735707|BIOLOGICAL|Convalescent plasma|Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
223442970|NCT02735707|BIOLOGICAL|Delayed administration of convalescent plasma|Note: this intervention is now closed.
223442971|NCT02735707|OTHER|No vitamin C|"No high dose intravenous vitamin C is to be administered~Note: this intervention is now closed."
223442972|NCT02735707|DRUG|Vitamin C|"Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses~Note: this intervention is now closed."
223442973|NCT02735707|OTHER|No antiplatelet|"No antiplatelet agent or NSAID to be administered.~Note: this intervention is now closed."
223567166|NCT02904005|OTHER|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
223567167|NCT00003946|DRUG|danazol|
223741072|NCT07206212|OTHER|Treatment as usual (TAU)|Written educational information in a digital platform, on healthy lifestyle habits based on national Swedish guidelines issued by the National Board of Health and Welfare. The recommendations include engaging in regular physical activity, dietary guidelines based on Nordic Nutrition Recommendations, and advice to reduce alcohol consumption and quit tobacco use.
224054019|NCT00787462|DRUG|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
224054020|NCT03327012|DRUG|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
224054021|NCT03327012|DRUG|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
224054022|NCT06504537|OTHER|THERAGUN PERCUSSION THERAPY|In Group A, Patients will receive Theragun Percussion therapy along with routine Physical Therapy Treatment. The range of motion of lateral flexion and forward flexion will take by using a bubble inclinometer. Then the patient will place in a sitting position with the shoulder area exposed. Percussion therapy by using the Theragun device will give by a specific order. Treatment will start with the percussion head applied at the origin and insertion heads of the trapezius, Rhomboid and scalene muscle for 3-4 minutes each. Following this the percussive Theragun applicator will applied with circular strokes along the length of the muscle for 3 minutes. The pressure of application will adjust to the subject's tolerance.
223442974|NCT02735707|DRUG|Aspirin|"Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223567168|NCT04265729|DIETARY_SUPPLEMENT|Neocate Infant and Junior marketed products|use of Neocate Infant and Junior marketed products
223567169|NCT00099242|DRUG|rivastigmine transdermal patch|
223567170|NCT05139381|DRUG|Mepolizumab|Treatment with Mepoluzimab
223567171|NCT00006046|BIOLOGICAL|monoclonal antibody hu3S193|
223567172|NCT02850861|DEVICE|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
223567173|NCT00900679|BEHAVIORAL|telephone-based intervention|
223442975|NCT02735707|DRUG|P2Y12 inhibitor|"Site-selected P2Y12 inhibitor:~* Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.~* Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.~* Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442976|NCT02735707|OTHER|No simvastatin|"No simvastatin intended to be active against COVID-19 is to be administered~Note: this intervention is now closed."
223442977|NCT02735707|DRUG|Simvastatin|"Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed."
223442978|NCT02735707|DRUG|Eritoran|"Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital~Note: this intervention is now closed."
223442979|NCT02735707|DRUG|Apremilast|"Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442980|NCT02735707|PROCEDURE|Clinician-preferred mechanical ventilation strategy|Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
223442981|NCT02735707|PROCEDURE|Protocolised mechanical ventilation strategy|Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
223442982|NCT02735707|OTHER|No renin-angiotensin system inhibitor|"No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.~Note: this intervention is now closed."
223442983|NCT02735707|DRUG|Angiotensin converting enzyme inhibitor|"Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442984|NCT02735707|DRUG|Angiotensin Receptor Blockers|"Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442985|NCT02735707|DRUG|ARB + DMX-200|"Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed."
223567174|NCT00900679|OTHER|counseling intervention|
223567175|NCT00900679|OTHER|educational intervention|
223567176|NCT00900679|OTHER|medical chart review|
223567177|NCT00900679|OTHER|questionnaire administration|
223567178|NCT00900679|PROCEDURE|psychosocial assessment and care|
223567179|NCT00900679|PROCEDURE|quality-of-life assessment|
223567180|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with the digital method
223567181|NCT01235364|DEVICE|Foley catheter|The Foley catheter was placed with a speculum
223567182|NCT00832247|GENETIC|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
223567183|NCT05664295|DIAGNOSTIC_TEST|Jenkins Sleep Disorders scale and Epworth Sleepiness scale|Jenkins Sleep Disorders scale and Epworth Sleepiness scale
223567184|NCT03176472|DRUG|ricolinostat|120 mg per dose in 12 mL liquid formulation
223567185|NCT03176472|DRUG|Placebo|12 mL liquid formulation placebo
224054023|NCT06504537|OTHER|COMPRESSION THERAPY|In Group B, Compression therapy will be administered to the patients by migraine relief gel cap for 25 minutes during migraine attacks. The cap will store in a freezer (15-18°C). At the onset of the migraine attacks, patients wore the cap and used it. We will choose 25 minutes as the time for application of the gel cap based on the results of two published studies.(23) Headache severity will measured by Visual Analogue Scale and pain relief will measured on a similar scale. Analgesic treatment will not take within 25 minutes after the onset of cold therapy. If patients did not experience adequate relief from the headache, we will allow them to use analgesics 25 minutes after the onset of cold therapy. The routine physical treatment will be same as in group A.
224054024|NCT02639611|OTHER|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
223567186|NCT05529979|DEVICE|EPIONE® CT-Guided Percutaneous procedures|The EPIONE device is a user controlled, stereotactic accessory intended to assist in the planning and manual advancement of one or more instruments, as well as in verification of instrument position during Computed Tomography (CT) guided percutaneous procedures.
223567187|NCT05105750|DRUG|aspirin 100 mg/d|100mg aspirin for at least 3 days followed by aspirin 100 mg/d
223567188|NCT05105750|DRUG|indobufen 200 mg bid|100mg aspirin for at least 3 days followed by indobufen 200 mg bid
223567189|NCT02568098|DRUG|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
223567190|NCT02568098|DRUG|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
223567191|NCT02568098|DRUG|DHA-PQP|Regimen 6: DHA-PQP
223567192|NCT00912080|GENETIC|genomic signature|genomic signature analysis
223567193|NCT04243018|BEHAVIORAL|Acceptance and Commitment Therapy Group Treatment|The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
223567194|NCT04243018|BEHAVIORAL|Peer Support Group|The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
223442986|NCT02735707|OTHER|No cysteamine|"No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.~Note: this intervention is now closed."
223442987|NCT02735707|DRUG|Cysteamine|"Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed."
223442988|NCT02735707|DRUG|Fixed-duration dexamethasone|6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
223442989|NCT02735707|DRUG|Baloxavir Marboxil|Baloxavir marboxil administered on days 1 and 4 post-randomisation.
223442990|NCT02735707|DRUG|Five-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
223442991|NCT02735707|DRUG|Ten-days oseltamivir + baloxavir marboxil|Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
223442992|NCT02735707|OTHER|No endothelial modulator|No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
223442993|NCT02735707|DRUG|Imatinib|Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
223442994|NCT02735707|OTHER|No Immune Modulator for Influenza|No immune modulating agent intended to be active against influenza is to be administered.
223442995|NCT02735707|DRUG|Tocilizumab|"Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.~Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period."
223442996|NCT02735707|DRUG|Baricitinib|Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
223442997|NCT02735707|OTHER|No antiviral agent for COVID-19|No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
223442998|NCT02735707|DRUG|Nirmatrelvir/ritonavir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
223442999|NCT02735707|DRUG|Remdesivir|Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
223443000|NCT02735707|DRUG|Nirmatrelvir/ritonavir + remdesivir|Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
223443001|NCT02466607|DEVICE|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
223443002|NCT02466607|DEVICE|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
223567195|NCT00596154|OTHER|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
223567196|NCT00037817|DRUG|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
223567197|NCT00037817|BIOLOGICAL|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
223567198|NCT00037817|DRUG|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
223567199|NCT05554978|DRUG|Landiolol|patient receives landiolol in addition to standard-of-care
223567200|NCT05554978|DRUG|Sodium Chloride (NaCl) 0.9%|Placebo
223567201|NCT01665079|DRUG|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS\>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 \> 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS \> 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
223567202|NCT00906139|DRUG|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
223567203|NCT00906139|DRUG|Midazolam|Midazolam dose: 0.1 mg/kg
223567204|NCT00906139|DRUG|Fentanyl|Fentanyl dose: 0.05 mg
223567205|NCT06188650|DRUG|Anlotinib|After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
223567206|NCT06060132|DRUG|Sodium arsenite chloride injection|Patient use of arsenite sodium chloride injection
224054025|NCT02639611|OTHER|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
224054026|NCT04825795|DRUG|DPP4-inhibitor|Prescription of DPP4-inhibitor during the period between the two coronary CT scan
223443003|NCT02466607|OTHER|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
223443004|NCT06417866|OTHER|informed consent|standard verbal and written informed consent
223443005|NCT06417866|OTHER|spine model|standard verbal and written informed consent + visual spine model
223443006|NCT00167401|DRUG|docetaxel|
223443007|NCT00167401|DRUG|cisplatin|
223443008|NCT00167401|PROCEDURE|radiation treatment|
223443009|NCT02893423|DRUG|Ropivacaine|Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
223443010|NCT01861418|OTHER|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
223443011|NCT01861418|OTHER|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
223443012|NCT00458575|DRUG|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
223443013|NCT00232466|PROCEDURE|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
223443014|NCT03602794|PROCEDURE|PECs Block|Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance
223443015|NCT03602794|PROCEDURE|Local infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
223443016|NCT03092336|OTHER|Electrical Stimulation|electrical stimulation training
223443017|NCT03092336|OTHER|Strength training|strength training group
223443018|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation A (light)|Omega-3 monoglyceride based serum and cream of lighter formulation
223443019|NCT06155513|COMBINATION_PRODUCT|Omega-3 monoglyceride based topical Serum and cream of formulation B (rich)|Omega-3 monoglyceride based serum and cream with a richer formulation
223443020|NCT03292471|DEVICE|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
223443021|NCT03324828|DRUG|Hydroxyzine|Hydroxyzine solution
223443022|NCT03324828|OTHER|Clowns intervention|Clowns intervention
223443023|NCT02771925|DRUG|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
223443024|NCT02771925|DRUG|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
223443025|NCT00911586|DRUG|Testosterone undecanoate|
223443026|NCT00676416|DRUG|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
223443027|NCT02397824|OTHER|Salivary and blood samples|
223567207|NCT02840643|BEHAVIORAL|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
223567208|NCT02840643|BEHAVIORAL|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
224054027|NCT04825795|DRUG|No DPP4-inhibitor|No prescription of DPP4-inhibitor during the period between the two coronary CT scan
223443028|NCT02412254|OTHER|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
223567209|NCT03829943|DIAGNOSTIC_TEST|Vitamin D|Blood will be drawn for Vitamin D level
223567210|NCT04264650|BEHAVIORAL|an mHealth intervention|The Care \& Organize Our Lifestyle (COOL) program, a self-regulation theory-based mHealth program
223567211|NCT01944566|BIOLOGICAL|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
224054028|NCT01744665|DRUG|nilotinib|Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
223443029|NCT02412254|OTHER|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
223443030|NCT00279006|PROCEDURE|Percutaneous coronary intervention|
223443031|NCT01051258|DEVICE|AeriSeal System|AeriSeal System for Lung Volume Reduction
223443032|NCT04346771|BEHAVIORAL|Working memory training|Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
223443033|NCT04346771|BEHAVIORAL|Positive ABMT|Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
223443034|NCT03271671|OTHER|NAVA during Non invasive ventilation|NIV during respiratory failure
223443035|NCT03271671|OTHER|PSV during Non invasive ventilation|PSV during respiratory failure
223443036|NCT03423966|DEVICE|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
223443037|NCT02555930|OTHER|No Intervention|No intervention - observational only
223443038|NCT04065581|DRUG|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
223443039|NCT04065581|DRUG|Glucobay|Single dose: 50 mg tablet, oral
223443040|NCT04065581|DRUG|Glucophage|Single dose: 500 mg tablet, oral
223443041|NCT04104087|PROCEDURE|tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.|enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
223443042|NCT05537285|DEVICE|Individualized Accelerated Intermittent Theta Burst Stimulation (Ind-aiTBS)|active side magnetic coil stimulation applied to individualized target in the left dorsal lateral prefrontal cortex.
223443043|NCT05537285|DEVICE|Standard Accelerated Intermittent Theta Burst Stimulation (Std-aiTBS)|active side magnetic coil stimulation applied to standardized target in the left dorsal lateral prefrontal cortex.
223443044|NCT05537285|DEVICE|Sham Accelerated Intermittent Theta Burst Stimulation (Sham)|sham side magnetic coil stimulation applied to the left dorsal lateral prefrontal cortex.
223443045|NCT03039608|DRUG|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
223443046|NCT03039608|DRUG|oral steroid administration（prednisone）|oral steroid
224054029|NCT04354220|DIAGNOSTIC_TEST|capnography monitoring|routinely used capnography monitoring
223443047|NCT05249621|DRUG|MZE001|Small molecule inhibitor of muscle glycogen synthase
223443048|NCT05249621|DRUG|Placebo|Product containing excipients with no active ingredients
223443049|NCT00750919|DRUG|esmirtazapine|
223443050|NCT03994406|DRUG|CLM2 topical gel|Active topical gel for forehead dermal application
223443051|NCT03994406|DRUG|Placebo topical gel|Placebo topical gel for forehead dermal application
223443052|NCT02794506|DRUG|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
223443053|NCT02794506|DRUG|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
223443054|NCT04234594|DRUG|QL1203|6 mg/kg intravenous (IV) infusion only once，on the first day.
223443055|NCT04234594|DRUG|Vectibix®|6 mg/kg intravenous (IV) infusion only once，on the first day.
223443056|NCT06730789|DEVICE|Epicondylitis bandage|A conservative treatment method of lateral epicondylitis.
224054030|NCT04354220|DIAGNOSTIC_TEST|arterial blood gas|Routinely taken arterial blood gas values
223443057|NCT06730789|DEVICE|Wrist dorsiflexion splint|A conservative treatment method of lateral epicondylitis.
223443058|NCT06730789|DEVICE|Kinesio tape|A conservative treatment method of lateral epicondylitis
223443059|NCT03478189|PROCEDURE|use of O-arm surgical imaging|during acetabular fracture surgery , use of O-arm surgical imaging with
223443060|NCT04731077|DEVICE|Avenir Complete Femoral Stem|All enrolled subjects will receive the Avenir Complete Femoral Stem
223443061|NCT03394625|PROCEDURE|Socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
223443062|NCT03394625|PROCEDURE|using Xenograft material|placing xenograft material in gap between the implant and the buccal plate of bone
223443063|NCT06239805|DEVICE|QMR|"A: Treated group (active medical device): intensive protocol B: Treated Group (active medical device): extensive protocol C: Sham/Control group (medical device off)~Patients will be treated as follows:~A- Treated Group: three sessions a week, for a total of 6 sessions, with one session lasting of 30 minutes. The session involves the application of electrodes (adhesive plates), and Q- glove Touch (frequency/intensity)~B- Treated Group: two sessions a week, for a total of 8 sessions, lasting a 20 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove (frequency/intensity)~C- Control/Sham group: three sessions a week, for a total of 6 sessions, lasting a 30 minute session. The session involves the application of electrodes (adhesive plates), e Q-Touch glove with device off."
223443064|NCT03922282|PROCEDURE|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
223443065|NCT03922282|PROCEDURE|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
223443066|NCT06525974|DRUG|Febuxostat|40mg of Febuxostat once daily
223443067|NCT06525974|DRUG|Mesalamine|1 g mesalamine three times daily for 3 months.
224054031|NCT03388918|DEVICE|Telerehabilitation|Blood pressure (A\&D Medical UA 767PBT), weight (A\&D Medical UC-321PBT), step counters(Fitbit Zip \& Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) \& transmitter (Qualcomm Life, QWH-HUB-V1.0E)
224054032|NCT00873340|DRUG|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
224054033|NCT04844684|OTHER|Blood and urine collection|Blood sampling urine collections before RYGP and 1 month and 1 year after.
223443068|NCT02150681|BEHAVIORAL|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
223443069|NCT03763058|OTHER|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
223443070|NCT00005821|DRUG|patent blue V dye|
224054034|NCT06273267|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file. The data collected concerns the first year of follow-up (from the initial PPC intervention to one year to date post-intervention).
223443071|NCT00005821|PROCEDURE|conventional surgery|
223443072|NCT00005821|PROCEDURE|lymphangiography|
223443073|NCT00005821|PROCEDURE|radionuclide imaging|
223567212|NCT04111016|BEHAVIORAL|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
223567213|NCT01937793|OTHER|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
223443074|NCT00005821|PROCEDURE|sentinel lymph node biopsy|
223567214|NCT01937793|OTHER|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
223567215|NCT00622947|PROCEDURE|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
223567216|NCT00622947|PROCEDURE|Sham-rTMS|The coil is angled 90 degrees away from the scalp
223567217|NCT02092051|DEVICE|Continuous glucose monitoring with DexCom G4 platina|
223443075|NCT00005821|RADIATION|Technetium Tc 99m human serum albumin colloid|
223567218|NCT00642369|DRUG|quetiapine fumarate|600-750mg/day
223567219|NCT00642369|DRUG|haloperidol|6-40mg/day
223567220|NCT00727142|PROCEDURE|Surgical treatment|Insertion of a functioning shunt
223567221|NCT04174300|PROCEDURE|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
223567222|NCT00585546|DRUG|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
223567223|NCT01678352|BIOLOGICAL|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
223567224|NCT01678352|DRUG|Imiquimod|Cohort 1 Cohort 2 Cohort 3
223567225|NCT03453762|PROCEDURE|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
223567226|NCT03453762|PROCEDURE|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
223567227|NCT02689739|PROCEDURE|venous duplex ultrasound|Venous duplex ultrasound
223567228|NCT02578966|BEHAVIORAL|Motivational Interview|
223567229|NCT02578966|OTHER|Traditional health education|
223443076|NCT06730659|BIOLOGICAL|CHT101|CHT101: CD 70 UCAR T
223443077|NCT05816759|DRUG|CKD-383|QD, PO
223443078|NCT05816759|DRUG|CKD-501, D744, D150|QD, PO
223443079|NCT05456633|DEVICE|Capri Cervical Static|When used in the cervical spine (C2-T1), CAPRI Static cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
223567230|NCT04867512|DIETARY_SUPPLEMENT|Liquid Tincture|Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
223567231|NCT04867512|DIETARY_SUPPLEMENT|GI Detox|GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
223567232|NCT04867512|DIETARY_SUPPLEMENT|Olivirex|Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
223567233|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
224054035|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
224054036|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
224054037|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
223443080|NCT05456633|OTHER|CAPRI Static Expandable|When used in the cervical spine (C2-T1), CAPRI Static Expandable cages are intended for use in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.
223443081|NCT05456633|DEVICE|Capri Thoracolumbar|Intended for use to replace a collapsed, damaged, or unstable vertebral body due to tumor and trauma (i.e. fracture).
223443082|NCT01455285|DEVICE|transcutaneous electrical nerve stimulation|
223443083|NCT02637388|DIETARY_SUPPLEMENT|Oatwell28 Oatwell Original Powder|
223443084|NCT02637388|DIETARY_SUPPLEMENT|Control Breakfast|Isocaloric breakfast without added beta-glucans
223443085|NCT01827709|OTHER|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.~These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
223443086|NCT01827709|OTHER|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
223443087|NCT01827709|OTHER|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
223443088|NCT01827709|OTHER|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
223443089|NCT01827709|OTHER|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
223443090|NCT03279601|DRUG|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
223443091|NCT03279601|DRUG|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
223443092|NCT00397592|DRUG|Growth Hormone|
223443093|NCT00004901|DRUG|ethynyluracil|
223443094|NCT00004901|DRUG|fluorouracil|
223567234|NCT01129089|DIETARY_SUPPLEMENT|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
223567235|NCT01129089|DIETARY_SUPPLEMENT|Micronutrient powder|Micronutrient powder for infant and young children
223443095|NCT00004901|DRUG|hydroxyurea|
223443096|NCT00004901|RADIATION|radiation therapy|
223567236|NCT06121141|DRUG|Full strength lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000
223443097|NCT03756818|DRUG|Mivavotinib|Given PO
223443098|NCT03756818|DRUG|Paclitaxel|Given IV
223443099|NCT03756818|OTHER|Pharmacokinetic Study|Correlative studies
223443100|NCT04677452|BIOLOGICAL|JWCAR129|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR129. During JWCAR129 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JWCAR129 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JWCAR129 administered intravenously (IV).
223443101|NCT03904316|BIOLOGICAL|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
223443102|NCT03904316|OTHER|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
223443103|NCT00426972|DRUG|estradiol (Zesteem)|
223443104|NCT03103685|DRUG|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
223443105|NCT01773356|DIETARY_SUPPLEMENT|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
223443106|NCT05749406|OTHER|Focus group|Small virtual focus group discussion about experiences/attitudes towards post-operative anal dilatation.
223443107|NCT05749406|OTHER|Semi-structured interview|Individual virtual interview to ascertain participant's experiences of performing anal dilatation post-operatively for their child with an anorectal malformation.
223443108|NCT02051335|DRUG|Roflumilast|Roflumilast tablets
223443109|NCT02051335|DRUG|Roflumilast placebo|Roflumilast placebo-matching tablets
223443110|NCT02051335|DRUG|Donepezil|Donepezil overencapsulated tablets
223443111|NCT02051335|DRUG|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
223443112|NCT02051335|DRUG|Scopolamine|Scopolamine subcutaneous injection
223443113|NCT03174691|DIAGNOSTIC_TEST|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
223443114|NCT02656563|RADIATION|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
223443115|NCT01520194|OTHER|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
223443116|NCT01520194|OTHER|medical records|medical chart review of patients assisted January 2009 to December 2010
223567237|NCT06121141|DRUG|Dilute lidocaine with epinephrine|2% lidocaine with epinephrine 1:100,000 diluted with normal saline (09.% NaCl) in a 1:4 ratio
223567238|NCT05401929|DEVICE|iTBS|Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
223567239|NCT05401929|DEVICE|iTBS|Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
223567240|NCT04372147|PROCEDURE|MMA embolization|Patients in the intervention group will undergo a CT angiography scan of the supra aortic trunks, followed by MMA embolization procedure within 7 days of the burr-hole surgery in addition to standard medical care
223443117|NCT06176313|OTHER|Mandala Group|"The Mandala activity lasts approximately 60 minutes.~• A calm environment is provided during the Mandala activity, and participants are ensured not to be disturbed by external stimuli or individuals unless they request assistance.~Each student's last menstrual date is recorded in an Excel table.~* Two days before the intervention day, students will be contacted and invited to participate in the study.~* Monitoring each student's menstrual cycle, the Mandala activity intervention is scheduled during the late luteal phase of each student's menstrual cycle. The intervention is planned within the 5 days before the expected start of menstrual bleeding on days and hours convenient for the student's class schedule.~* After each session, on the 4th day of the expected menstrual bleeding, students are subjected to PMSÖ.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
223443118|NCT06176313|OTHER|Coping with Premenstrual Symptoms Education Group|"The education will be conducted through face-to-face interviews in the master's course classroom at the Faculty of Health Sciences at Bilecik Şeyh Edebali University. The education was conducted using PowerPoint presentations projected onto a white smartboard.~* One month after the completion of the education, a 1st Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* One month after the 1st Reminder training, a 2nd Reminder training will be provided in the master's course classroom within the Faculty of Health Sciences at Bilecik Şeyh Edebali University, using the face-to-face interview method.~* On the 4th day of the 4th menstrual period bleeding, the research will be concluded by applying the post-test with PMSÖ to the students."
223443119|NCT06176313|OTHER|Control Group|"No intervention will be applied to the control group throughout the research. However, students in this group who cope with premenstrual syndrome using medication or non-medication methods will be monitored during the three-month menstrual cycle.~Each student's menstrual cycle in the control group has been recorded in the Excel table. The estimated end of menstruation for each student has been noted.~* At the estimated end of menstruation, the researcher contacts the students in the control group to inquire whether they have used any medication or non-medication methods to cope with premenstrual syndrome.~* Those who use medication or non-medication methods to reduce premenstrual symptoms are excluded from the study.~* On the 4th day of the 4th menstrual period bleeding, the post-test with PMSÖ will be applied to the students."
223443120|NCT01813513|DRUG|IDX719|50 mg tablet for oral administration
223443121|NCT01813513|DRUG|Simeprevir|150 mg capsule for oral administration
223443122|NCT02912455|DRUG|canagliflozin|encapsulated (gelatin capsule).
223443123|NCT02912455|DRUG|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
223443124|NCT04237558|PROCEDURE|Vaginal hysterectomy|Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse
223443125|NCT04237558|PROCEDURE|Laparoscopic hysterectomy|Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
223443126|NCT05281900|DIAGNOSTIC_TEST|Clinical Tests|Shoulder impingement and instability tests and shoulder normal range of motion measurement.
223443127|NCT05281900|OTHER|MVIC measurements|For the normalization of muscle activation during exercises, muscle activation levels during maximum voluntary isometric contraction (MVIC) of the dominant side Upper Trapezius, Middle Trapezius, Lower Trapezius, Serratus Anterior, Biceps Brachii, Triceps Brachii and Infraspinatus muscles will be recorded. Participants will be asked to stop for 10 seconds at the point where they show resistance. A total of three measurements will be taken and the highest value recorded. The areas where the electrodes will be placed will be prepared by shaving and cleaning with alcohol. The electrode placement will be made parallel to the muscle fibers. A rest period of at least 2 minutes will be allowed between measurements.
223443128|NCT05281900|OTHER|Exercises|"Activation of the scapula and shoulder girdle muscles will be measured during variations of the plank exercise.~* In the tests, participants will be asked to stay in this position for 10 seconds after providing the standardized stance in the plank position. During the test, a video will be taken and incorrect attempts will be repeated.~* Determined plank variations will be done in mixed order. Each exercise will be repeated 3 times and the average of the repetitions will be recorded as the result. A 2 minute rest period will be given between exercises.~* After each exercise, the perceived effort level will be questioned with the BORG scale.~  4 assisted exercises:~ 1. Low plank~ 2. Low plank w/ isometric shoulder external rotation~ 3. High plank~ 4. High plank plus~ 5. Bear plank~  3 assisted exercises:~ 1. Low plank w/ front reach~ 2. High plank w/ shoulder taps~ 3. High plank w/ toe touch~  2 assisted exercises:~ 1. Low plank bird dog~ 2. High side plank"
223567241|NCT04154345|OTHER|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS for 9 weeks, then pain ratings are 0-2 for the remaining 3 weeks. Every physiotherapy session includes also 15 minutes of manual therapy.
223567242|NCT05966363|RADIATION|Nanodot|Radiation measurements using nanodots placed on the eyes, ears, neck and lower abdomen during an imaging examination.
223741073|NCT07207317|PROCEDURE|Laparoscopic ileocecal-reconstruction right hemicolectomy (LIRRH)|The ileocolic vessels are divided at their roots, and lymph nodes of stations 203, 202, and 201 are dissected. The right colic and middle colic vessels are also divided at their roots, and the surrounding lymphatic and adipose tissue (stations 211/212/213 and 221/222/223) is cleared. The transverse colon is transected 10 cm distal to the tumor, and the ileum is divided 10 cm proximal to the ileocecal region. After tailoring the ileal mesentery, an end-to-end ileo-transverse colonic anastomosis is performed. Using a seromuscular suture, the ileum and its tailored mesentery are invaginated into the wall of the transverse colon 2 cm proximal to the anastomosis, thereby reconstructing the ileocecal valve complex.
224054038|NCT00288249|DRUG|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
224054039|NCT00912002|DRUG|MK-0941|A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
224145622|NCT05566821|BEHAVIORAL|STRENGTH Outreach Intervention|The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
223443129|NCT03871959|DRUG|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
223443130|NCT03871959|DRUG|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
223443131|NCT05469022|DRUG|Neoadjuvant lazertinib|Lazertinib 240mg p.o once daily.
223443132|NCT00667797|DRUG|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
223443133|NCT00667797|DRUG|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
223443134|NCT01938989|DEVICE|Clear clip-on glasses|Clip-on glasses with no light filtering properties
223443135|NCT01938989|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
223443136|NCT03592498|DRUG|Sulfadiazine, Silver|Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
223443137|NCT03592498|DEVICE|Skin of Nile tilapia|Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
223443138|NCT06444828|PROCEDURE|Non-operative|Non-operative treatment versus operative treatment (surgery)
223443139|NCT03409445|OTHER|no intervention|no intervention (observational study)
223443140|NCT01835028|OTHER|Echocardiography|Observational Study using Imaging and Biomarkers
223443141|NCT01835028|OTHER|Computed tomography|Observational Study using Imaging and Biomarkers
223443142|NCT01835028|OTHER|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
223443143|NCT01835028|OTHER|Blood biomarkers|Observational Study using Imaging and Biomarkers
223443144|NCT01835028|OTHER|Stress echocardiography|Observational Study using Imaging and Biomarkers
223443145|NCT01207115|DRUG|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
223443146|NCT01207115|DRUG|Placebo|Placebo capsules - twice daily for 8 weeks
223443147|NCT01207115|DRUG|Naproxen|Naproxen capsules - twice daily for 8 weeks
223443148|NCT01057797|BEHAVIORAL|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
223443149|NCT01057797|BEHAVIORAL|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
223443150|NCT01057797|BEHAVIORAL|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
224145623|NCT02067416|DRUG|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
223443151|NCT03634683|BIOLOGICAL|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
223443152|NCT04656366|DIAGNOSTIC_TEST|Coronary Angiography|Diagnostic Coronary angiography for patients that presented angina after a previous CABG operation; eventually interventional procedure with PCI (Percutaneous Coronary Intervention)
223443153|NCT02974205|PROCEDURE|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
223567243|NCT03625869|DEVICE|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
223567244|NCT03984890|DRUG|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
223567245|NCT03984890|DRUG|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
224145624|NCT02067416|DRUG|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
224145625|NCT01033487|DRUG|placebo|oral inhaled formulation, single dose
223443154|NCT02974205|DEVICE|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
223443155|NCT02974205|DEVICE|össur brace|Rehabilitation after acute isolated PCL rupture
223443156|NCT00380666|PROCEDURE|PET/CT scan|
223443157|NCT01878734|DIETARY_SUPPLEMENT|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
223443158|NCT01990872|DIETARY_SUPPLEMENT|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
223443159|NCT01990872|DIETARY_SUPPLEMENT|Placebo|Placebo (0 micrograms vitamin D3/day)
224054040|NCT02411162|DRUG|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.
224300673|NCT04158960|BEHAVIORAL|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
223443160|NCT03851978|BEHAVIORAL|Pharmacist Vaccine Education|When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
223567246|NCT04662775|BEHAVIORAL|HERizon Project|"1\. Participants were asked to complete 3x30-minute physical activity sessions each week \& record their sessions using a logbook. They were given the choice of different types of home-based virtual exercise. 2. Behaviour change support calls - participants were allocated an Activity Mentor (trainee sport and exercise psychologists, was supervised by a HCPC-registered Psychologist). Participants had seven weekly videocalls. Each call was based on a pre-planned session outline and was goal orientated, participant centred and focused on physical activity. 3. No reply SMS - Participants received 3 standardised text messages each week, aimed at providing physical activity -related facts, encouragement and study information."
223567247|NCT02936310|BEHAVIORAL|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
223567248|NCT03085628|DRUG|Oxytocin|40IU
223567249|NCT03085628|DRUG|Placebo|40IU
223567250|NCT02576041|DRUG|Bilastine|Bilastine tablets once a day for 7+3 days
223567251|NCT02576041|DRUG|Placebo|Placebo tablets once a day during 7+3 days run in period
223567252|NCT00970892|DRUG|Warfarin dose titration|Dosage
223567253|NCT03221868|BEHAVIORAL|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
223567254|NCT03221868|BEHAVIORAL|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
223567255|NCT04987996|DRUG|GR-MD-02|Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
223567256|NCT04987996|DRUG|Placebo|Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
223567257|NCT04987996|DRUG|Pembrolizumab|Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
223567258|NCT05587062|BIOLOGICAL|Aflibercept (CinnaGen Co, Iran)|Aflibercept (CinnaGen Co, Iran) by intravitreal injection
223567259|NCT05587062|BIOLOGICAL|Aflibercept (Regeneron, USA)|Aflibercept (Regeneron, USA) by intravitreal injection
223567260|NCT04184414|DRUG|CD19-CART|1-10x106 / kg CD19 CART cells
223567261|NCT03178123|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
223567262|NCT03178123|BIOLOGICAL|high-dose recombinant interferon a-2B|15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
224145626|NCT01033487|DRUG|active comparator|oral inhaled formulation, single dose
224145627|NCT01033487|DRUG|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
224145628|NCT01033487|DRUG|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
223443161|NCT06995053|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223443162|NCT06995053|PROCEDURE|Computed Tomography|Undergo CT
223567263|NCT04740281|BEHAVIORAL|Footwear|Assessment of footwear
223567264|NCT03195244|OTHER|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
223567265|NCT03106844|DRUG|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
223567266|NCT04151927|DEVICE|Normobaric Hypoxia|Low oxygen exposure to mimic \~8500 feet elevation.
223567267|NCT04151927|DEVICE|Normobaric Normoxia|Normal oxygen exposure to mimic \~1000 feet elevation (sham comparator).
223443163|NCT06995053|RADIATION|CT-guided Stereotactic Body Radiation Therapy|Undergo CT-guided SBRT with intrafraction motion monitoring
223567268|NCT06105086|OTHER|Semi-structured interview|Participants will be asked pre-defined questions and are allowed to elaborate on the subject.
223567269|NCT05098964|DEVICE|pedometer home based rehabilitation|Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
223567270|NCT05098964|OTHER|Exercise training|Hospital based exercise training for 6 weeks
223567271|NCT05808946|DRUG|Alpha-Lipoic Acid|1200 mg of ALA daily (given as two 600 mg capsules once daily)
223567272|NCT05808946|DRUG|Sepsis Supportive Care|Appropriate IV fluid, Appropriate antibiotic, Vasopressors if needed, Mechanical ventilation if needed
223567273|NCT03622112|DRUG|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
223567274|NCT03622112|DRUG|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
223567275|NCT03622112|DRUG|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
223567276|NCT03622112|DRUG|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
223567277|NCT03622112|DRUG|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
224145629|NCT01033487|DRUG|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
224145630|NCT00255099|DRUG|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
224145631|NCT00255099|DRUG|Placebo|2 tablets b.i.d. / 96 weeks
224145632|NCT02827279|OTHER|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
223443164|NCT06995053|OTHER|Intrafraction Motion Monitoring|Undergo CT-guided SBRT with intrafraction motion monitoring
223443165|NCT06995053|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224054041|NCT02411162|DRUG|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
223443166|NCT06995053|OTHER|Questionnaire Administration|Ancillary studies
223443167|NCT00486707|BEHAVIORAL|Questionnaire|A questionnaire will be completed.
224054042|NCT04986306|PROCEDURE|SLNB + ALND|Patients who received neoadjuvant chemotherapy will undergo SLNB+ALND to evaluate the feasibility of SLNB
224300674|NCT00640679|DRUG|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
223443168|NCT02905643|OTHER|Study subjects|This study does not include an intervention it is only observational.
224300675|NCT00640679|DRUG|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
223443169|NCT05573529|PROCEDURE|phacoemulsification and intraocular lens implantation|bilateral cataract surgery including phacoemulsification in individuals suffering from age-related cataract and intraocular lens implantation
223443170|NCT05573529|DEVICE|intraocular lens implantation|intraocular lens implantation includes EDOF IOL implantation in the dominant eye and multifocal IOL implantation in the non-dominant eye after phacoemulsification
223443171|NCT01565798|OTHER|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
223567278|NCT03622112|DRUG|Placebo for AZD7594 once daily.|Placebo for AZD7594
223567279|NCT03622112|DRUG|FF 100 µg once daily (open-label)|Fluticasone furoate
223567280|NCT06318806|OTHER|Psychotherapy|Psychotherapy is a type of treatment that can help individuals experiencing mental health conditions and emotional challenges.
223567281|NCT01080066|OTHER|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m\^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m\^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
223567282|NCT01975662|DRUG|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
223567283|NCT01975662|DRUG|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
223567284|NCT03579472|DRUG|Bintrafusp Alfa|Given IV
223567285|NCT03579472|DRUG|Eribulin Mesylate|Given IV
224054043|NCT04266184|OTHER|Kinesio tape (KT)|"For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days."
223443172|NCT05158686|DEVICE|Paclitaxel-coated Balloon dilation angioplasty|Paclitaxel-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
223443173|NCT05158686|DEVICE|Non-coated Balloon dilation angioplasty|Non-coated ballon dilation angioplasty proximal to CTO lesion after failed percutaneous recanalization
223443174|NCT05519072|DRUG|Nitrofurantoin|For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
223443175|NCT07027215|COMBINATION_PRODUCT|Gradual Intermittent pneumatic compression therapy (IPC),Balance excercises.PNF technique|PNF technique
223443176|NCT07027215|COMBINATION_PRODUCT|selected physical therapy program as arm excercises|selected physical therapy program only. The program consisted of (core exercises, AROM exercises, and stretching exercises for LL for 18 sessions every other day, over 6 weeks
223567286|NCT05499455|DEVICE|Positional Sleep Belt|Rematee Positional Sleep Belt
223567287|NCT05499455|DEVICE|Control|Control Device
223567288|NCT03505294|OTHER|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
224054044|NCT04266184|OTHER|Pelvic belt (PB)|The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
224054045|NCT04266184|OTHER|Educational program|This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
223443177|NCT07025876|BIOLOGICAL|low dose PCV24|"The 24-valent pneumococcal polysaccharide conjugate vaccine (low-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~* 3 serotypes (3, 6B, 12F): 4.0 μg per vial each~* 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 2.0 μg per vial each After conjugation with carrier proteins, the polysaccharides of each serotype are adsorbed onto an aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose)."
223443178|NCT07025876|BIOLOGICAL|high dose PCV24|"The 24-valent pneumococcal polysaccharide conjugate vaccine (high-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 serotypes (3, 6B, 12F): 8.0 μg per vial each 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 4.0 μg per vial each After conjugation with carrier proteins, the polysaccharides of each serotype are adsorbed onto an aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose)."
223567289|NCT01901523|BEHAVIORAL|Reporting of discrepancy to journal|
223567290|NCT02210689|DRUG|clindamycin phosphate vaginal cream 2%|
223567291|NCT02210689|OTHER|placebo|vehicle used as placebo
223567292|NCT04401618|OTHER|Retrospective evaluation of RMGI and GIC Class V Restorations|Retrospective evaluation of RMGI and GIC Class V Restorations that were placed by dental students over the last three years were evaluated using the modified USPHS criteria using mirrors and probes.
223567293|NCT04277117|BEHAVIORAL|Waitlist|"Phase 1 (6 months)~• Educational materials on such topics as healthy eating for diabetes."
223741074|NCT07207317|PROCEDURE|traditional laparoscopic right hemicolectomy (TRH)|The ileocolic vessels are divided at their roots, and lymph nodes of stations 203, 202, and 201 are dissected. The right colic and middle colic vessels are likewise divided at their roots, and the surrounding lymphatic and adipose tissue (stations 211/212/213 and 221/222/223) is cleared. The transverse colon is transected 10 cm distal to the tumor, and the ileum is divided 10 cm proximal to the ileocecal junction. An end-to-side or side-to-side ileo-transverse colonic anastomosis is then performed.
223741075|NCT07205146|OTHER|menometrorrhagia|rate of menometrorrhagia at 2 months after treatment
223741076|NCT07205276|DIAGNOSTIC_TEST|Non-contrast multiparametric breast MRI with AI-based radiomics analysis|Participants will receive standardized non-contrast multiparametric breast MRI scans (T2WI, DWI, ADC). Imaging features will be extracted and analyzed using artificial intelligence-based radiomics and deep learning algorithms to improve early detection and diagnosis of breast cancer.
223741077|NCT07205276|DIAGNOSTIC_TEST|Standard radiologist reading of non-contrast multiparametric breast MRI|Imaging data interpreted by trained radiologists following routine clinical practice, without AI assistance.
223741078|NCT07207109|OTHER|Test: Follow-on formula with synbiotics|Intervention description: both products are nutritionally complete follow-on formulas
223741079|NCT07207109|OTHER|Control: Regular follow-on formula|Intervention description: both products are nutritionally complete follow-on formulas
223741080|NCT07206316|OTHER|Individual Placement and Support Model|"The Individual Placement and Support (IPS) model is an employment support program specifically designed for people with severe mental illness (Bond, Drake, \& Becker, 2012). The core philosophy of IPS is that anyone can obtain competitive employment in the open labor market, provided it is the right job combined with appropriate support.~IPS support is delivered by a job coach, specifically trained in this model, who devotes their entire working time to assisting patients in their vocational integration."
223741081|NCT07206316|OTHER|Standard Method|In psychiatric wards, patients who wish to do so are usually offered support to initiate the process of returning to competitive employment in the open labor market. This assistance is provided by the social workers (such as social workers or educators) within the care unit.
223741082|NCT07206498|DRUG|Osimertinib (Tagrisso®)|"Drug: Osimertinib Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: Osimertinib Given PO, 80mg, once daily"
223741083|NCT07206498|DRUG|WSD0922-FU|"Drug: WSD0922-FU Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO"
223741084|NCT07205042|BEHAVIORAL|Supervised Walking Program|A structured walking program consisting of 30 minutes per session, 5 sessions per week, for 12 weeks at 55-65% of age-predicted maximum heart rate. Sessions will be supervised by an exercise physiologist, with adherence monitored by heart rate tracking and attendance logs. Participants will continue their standard levothyroxine treatment but will not begin any new structured exercise programs.
223741085|NCT07205627|OTHER|Rehabilitation program|"Participants will complete an 8-week structured pulmonary rehabilitation program, delivered in 2-3 supervised sessions per week at the Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde. Each session will last 60-90 minutes and include the following components:~Aerobic Training: Walking or cycling at 60-80% of maximum workload, progressively adjusted based on tolerance.~Strength Training: Resistance exercises for major muscle groups (upper and lower limbs), 2-3 sets of 10-15 repetitions, individualized according to baseline strength.~Breathing Techniques: Diaphragmatic and pursed-lip breathing, plus thoracic expansion exercises.~Inspiratory Muscle Conditioning: Threshold device training at 30% of maximal inspiratory pressure (MIP), with progressive increments.~Education Sessions: Information on disease self-management, energy conservation, medication adherence, and lifestyle recommendations."
223741086|NCT07207135|OTHER|Isometric Exercise at 15° and 90° Knee Angles|Participants performed quadriceps and hamstring isometric contractions at 15° and 90° of knee flexion. Each contraction lasted 10 seconds against resistance, three times per week for eight weeks, with progressive repetitions. Hip and ankle strengthening was also included.
223741087|NCT07207135|OTHER|Isometric Exercise at 30° and 105° Knee Angles|Same protocol as Group 1, but at 30° and 105° of knee flexion.
223741088|NCT07207135|OTHER|Isometric Exercise at 45° and 120° Knee Angles|Same protocol as Group 1, but at 45° and 120° of knee flexion.
223741089|NCT07207135|OTHER|Isometric Exercise at 60° and 135° Knee Angles|Same protocol as Group 1, but at 60° and 135° of knee flexion.
223443179|NCT07025876|BIOLOGICAL|PPV23|"The 23-valent pneumococcal polysaccharide vaccine (PPV23) produced by Chengdu Institute of Biological Products is available in vials of 0.5 ml, with a dosage of 0.5 ml per person per administration. It contains the following pneumococcal polysaccharides for each serotype:~Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F: 25 μg per vial for each serotype.~Additionally, it contains sodium chloride and water for injection."
223443180|NCT07025876|BIOLOGICAL|Placebo|"In addition to the antigen components, the 24-valent pneumococcal polysaccharide conjugate vaccine developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. contains the following excipients:~Aluminum phosphate adjuvant (aluminum content: 0.25 mg per dose) Sodium chloride Succinic acid Polysorbate 80 Water for injection It is a liquid formulation, available in vials of 0.5 ml, with a dosage of 0.5 ml per person per administration."
223443181|NCT02927496|DRUG|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)"
223443182|NCT02927496|DRUG|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
223443183|NCT01807416|PROCEDURE|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
223443184|NCT06728657|RADIATION|HFRT targeted to the primary lesion and positive lymph nodes|Hypofractionated radiotherapy (HFRT) targeted to the primary lesion and positive lymph nodes (4Gy × 6 fractions)
223443185|NCT06728657|RADIATION|PULSAR targeted to the primary lesion and positive lymph nodes|Irradiation targeted to the primary lesion and positive lymph nodes (6 Gy/1 fraction)
223443186|NCT06728657|DRUG|Anti-PD-1 monoclonal antibody|The anti-PD-1 mAb is used on day 1 along with each cycle of chemotherapy. There are no restrictions on the choice of anti-PD-1 mAb. Patients can choose commonly used accessible monoclonal antibodies based on their personal preferences and financial status. The commonly used anti-PD-1 mAb usages are as follows: Nivolumab, 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Sintilimab, 200mg solution intravenously once daily, Q3W.
223443187|NCT06728657|DRUG|Chemotherapy|CAPOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks
223567294|NCT04277117|BEHAVIORAL|Medically tailored meals - Daily delivery with human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 MTM a week: mix of hot and frozen, and 5-10 snacks per week. Meals and snacks offer approx. 1200 kcal per day.~* Delivery: 3 to 5x per week. Each delivery day, one meal is warm, the other is frozen. Depending on the participant's availability (3-5 days/week), more frozen meals will be given one day to account for a total of 10 meals every week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (at minimum in-person hand-off \& visual check) with the participant."
224054046|NCT03625050|PROCEDURE|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
224054047|NCT03625050|DRUG|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
224300676|NCT03362918|BEHAVIORAL|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~* High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~* Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
223567295|NCT04277117|BEHAVIORAL|Medically tailored meals - Weekly delivery with no human interaction|"Phase 1 (6 months)~* Educational materials on such topics as healthy eating for diabetes, in addition to materials on meal planning and instructions.~* Food: 10 frozen MTM and 5-10 healthy snacks (with the goal of providing 2 meals and 1-2 snacks for 5 days of the week). Meals and snacks offer approx. 1200 kcal per day. Nutritionally similar and frequently the same meal as that delivered in the daily delivery arm.~* Delivery: 1x per week shipment.~* Engagement: Meals are shipped to the participant's home. No human engagement."
224300677|NCT03362918|BEHAVIORAL|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
224300678|NCT01884311|BIOLOGICAL|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
224300679|NCT01764230|DRUG|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
224300680|NCT02307266|BEHAVIORAL|Standard of care + supplementary education|
224300681|NCT02307266|BEHAVIORAL|Standard of care + additional visits|
224300682|NCT02307266|BEHAVIORAL|Standard of care|
224300683|NCT03034655|DEVICE|CDP|Vestibular rehabilitation using CDP
224300684|NCT03034655|DEVICE|Mobile posturography|Vestibular rehabilitation using mobile posturography
224300685|NCT03034655|OTHER|10 sessions|Vestibular rehabilitation, ten sessions
224300686|NCT03034655|OTHER|5 sessions|Vestibular rehabilitation, five sessions
224054048|NCT05126186|OTHER|haplo-SCT with PTCy|"Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide \>100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1).~Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient~GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 200 à 300ng/l) Mycophenolate mofetyl at 15mg/Kg x2/day from day+5~Prevention of EBV reactivation Rituximab : 150mg/m2 intravenously at Day+5 post Haplo-SCT Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic."
224054049|NCT04170439|DRUG|Clomiphene plus metformin plus N acetyle cysteine in arm number 1|oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
224054050|NCT04170439|DRUG|Clomiphene citrate plus metformin with chromium|oral adminstration of clomiphene citrate plus metformin and chromium
224054051|NCT04170439|DRUG|clomiphene citrate plus metformin|oral adminstration of clomiphene citrate plus metformin
224054052|NCT05390112|BIOLOGICAL|DNA|ctDNA; cfDNA
224054053|NCT03241953|PROCEDURE|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
224054054|NCT04209751|DIAGNOSTIC_TEST|Stool removal|Stool removal; freezing an aliquot at -20 ° C and performing a direct examination. DNA extraction and serial PCR (Polymerase chain reaction).
224054055|NCT04687787|OTHER|Core Stabilization exercises|. Each session will be given for 40 mins (20 mins for TENS and 20 Mins for exercise) Core Stability Exercises include Kegel Exercises, Modified V-sit, opposite Arm Leg Raise, Seated Side bends poses, Dumbell Side bends and Pelvic Tilt. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
224054056|NCT04687787|OTHER|Routinely prescribed exercises|Each session will be given for 40 mins ( 20 mins for TENS and 20 Mins for exercise Routinely prescribed exercises composed of Hamstring stretches, hip flexor stretches, hip extensor stretches, calf stretches, and back extensor stretches. Participants will perform 1 set of exercise having 10 repetitions with hold of 5 seconds. Session would be performed thrice a week.
224054057|NCT06436066|OTHER|Self-Acupressure|"Applications include the following parameters;~1. Patient Information Form (before and after application)~2. Neuropathic Pain Questionnaire - DN4 (before and after application)~3. Neuropathic Pain Questionnaire - Short Form (before and after application)~4. Providing self-acupressure training (before application)~5. Delivery of the self-acupressure training booklet (before application)~6. Sending weekly reminder messages (during implementation)~7. Calling the patient for a check-up after 3 months and re-evaluating with the same scales (After the application)~8. Self-Acupressure - Satisfaction Evaluation Form with Visual Analogue Scale (After application)"
224054058|NCT04592744|DRUG|Angiotensin II|Angiotensin II infusion for Intraoperative management during liver transplantation
223443188|NCT06728657|PROCEDURE|R0 total/subtotal gastrectomy with D2 lymphadenectomy|For resectable participants, gastrectomy with standard D2 lymphadenectomy is commonly used. The type of gastrectomy performed depends on the location and extent of the primary lesion.
223443189|NCT02990351|PROCEDURE|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
223443190|NCT05545345|PROCEDURE|tympanostomy tube placement|An incision will be made in the the tympanic membrane, through which a ventilation tube will be inserted.
223443191|NCT05545345|PROCEDURE|adenoidectomy|The adenoid is resected transorally under a 70° endoscope with microdebrider or coblator until torus tubarius and choanae are completely revealed.
223567296|NCT04277117|BEHAVIORAL|Medically tailored meals - Standard MOWCTX delivery with human interaction|"Phase 2 (6 months)~* Food: 5 MTM a week plus snacks. Planned to offer approx. 600 kcal per day.~* Delivery: 2 to 4x a week (depending on participant availability), including daily delivery of 1 hot MTM plus a cold bag (with healthy snacks), with one day or more (depending on the 2 to 4x a week delivery schedule participant is on) also including 1 frozen MTM to total 5 meals per week.~* Engagement: MOWCTX's trained volunteers and/or paid delivery drivers delivering the meals will have a brief social interaction (check-in) with the participant.~* MOWCTX Standard Wraparounds: Participants will have access to a case manager to assist with additional resources within the community and for additional support if needed (e.g., grocery shopping assistance, home repairs, and pet care)."
223567297|NCT04403243|DRUG|Colchicine|0.5mg twice a day per os during the first three days and then 0.5mg daily per os if weight \< 86 kg or 0.5mg twice a day per os if weight \> 85kg for seven days.
223567298|NCT04403243|DRUG|Ruxolitinib 5 MG|Ruxolitinib - 5mg twice a day per os for ten days
223567299|NCT04403243|DRUG|Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]|Secukinumab - 300mg subcutaneously singly
223567300|NCT04403243|OTHER|standard therapy|standard therapy for COVID 19
223567301|NCT06110858|BEHAVIORAL|Tinkering Activities|Tinkering activities encompass elements of science, art and technology. They emphasize that learning is not simply about teachers imparting knowledge to students, but rather about students actively constructing knowledge themselves. Tinkering activities are characterized by three key elements: active engagement, open-ended exploration and problem-solving. In such activities, participants are provided with products without telling the steps. They are then encouraged to attempt creating it on their own. During this hands-on learning process, participants need to flexibly change their mindset, think outside the box and tackle emerging problems, which challenge their executive functions.
223567302|NCT04851210|OTHER|No intervention|No intervention
223567303|NCT01329276|DRUG|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
223567304|NCT00472316|BEHAVIORAL|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
223567305|NCT02780583|DRUG|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
224054059|NCT04592744|DRUG|Norepinephrine|Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
224145633|NCT00675558|PROCEDURE|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) \& fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
223443192|NCT03647605|BEHAVIORAL|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
223443193|NCT03035006|DRUG|Lipotecan|Lipotecan based concurrent chemoradiotherapy
223567306|NCT02780583|DRUG|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
224054060|NCT06228352|OTHER|Feces collection|"A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers."
223567307|NCT00170768|DRUG|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
223567308|NCT00170768|DRUG|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
223567309|NCT00170768|DRUG|Placebo|Placebo once daily tablet (sham titration)
223567310|NCT04845009|BEHAVIORAL|progressive muscle relaxation|progressive muscle relaxation
223567311|NCT04845009|BEHAVIORAL|Usual care|Usual care
223567312|NCT03228459|DIAGNOSTIC_TEST|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
223567313|NCT03228459|DIAGNOSTIC_TEST|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
223567314|NCT03228459|DIAGNOSTIC_TEST|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
223567315|NCT03228459|DIAGNOSTIC_TEST|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
223567316|NCT03228459|DIAGNOSTIC_TEST|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
223567317|NCT03228459|DIAGNOSTIC_TEST|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
223567318|NCT03228459|DIAGNOSTIC_TEST|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
223567319|NCT03228459|OTHER|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
223567320|NCT03228459|OTHER|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
223567321|NCT03228459|DIAGNOSTIC_TEST|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
224054061|NCT05253651|DRUG|tucatinib|300mg given by mouth (orally) twice daily
224054062|NCT05253651|DRUG|trastuzumab|8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
224054063|NCT05253651|DRUG|bevacizumab|5mg/kg given by IV every 2 weeks
224054064|NCT05253651|DRUG|cetuximab|400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
224054065|NCT05253651|DRUG|oxaliplatin|85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
224054066|NCT05253651|DRUG|leucovorin|400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
224145634|NCT00675558|PROCEDURE|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
224300687|NCT00915928|DRUG|Perindopril|2,5 mg daily for 3 months
223443194|NCT06767423|BEHAVIORAL|Text Message + Automated Caller (Intervention)|Standard text message appointment reminders to English and Spanish-speaking patients. Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment. If patient has not confirmed their appointment after the 3-week and 3-day reminders they will receive an automated caller.
223443195|NCT02149095|DRUG|TransCon PEG treprostinil|
224054067|NCT05253651|DRUG|levoleucovorin|200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
224054068|NCT05253651|DRUG|fluorouracil|400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
223443196|NCT01649310|OTHER|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
223443197|NCT04925284|DRUG|XB002|IV administration of XB002
223443198|NCT04925284|DRUG|Nivolumab|IV administration of Nivolumab
224054069|NCT06162676|BEHAVIORAL|HPV game|A brief health game for parent-child dyads to promote child's HPV vaccination
224054070|NCT05620719|BEHAVIORAL|Cognitive Behavioral Therapy for Posttraumatic Headache|CBT for Posttraumatic Headaches consists of 8 sessions of cognitive behavioral therapy that focus on (1) discussions and exercises that increase awareness of what may be related to headaches, (2) relaxation techniques to manage physiological stress, and (3) problem-solving techniques to manage common stressors. Sessions are delivered weekly and can last between 45 to 75 minutes based on clinical content and patient response to the material.
224054071|NCT05620719|OTHER|Treatment as Usual|Participants will continue to engage in medical care as usual for 8 weeks.
224054072|NCT05620719|OTHER|Telemedicine-based Cognitive Behavioral Therapy (TCBT)|Participants assigned to TCBT will receive 8 sessions of cognitive behavioral therapy using telemedicine rather than face-to face office visits.
224054073|NCT05432323|BEHAVIORAL|Multi-family therapy|8 sessions of Multi-family therapy of 3 hours each during 24 weeks
224054074|NCT02044133|OTHER|Dosage Vitamine D|
224054075|NCT04545814|DEVICE|Stereotactic Radiosurgery|Maximum Tumor Diameter ≤ 2 cm = 20-24 Gy; Maximum Tumor Diameter 2.1-3.0 cm = 18 Gy; Maximum Tumor Diameter 3.1-5.0 cm = 15 Gy
224054076|NCT06948591|DEVICE|Anterior cruciate ligament reconstruction with BioBrace® augmentation|An arthroscopic anterior cruciate ligament reconstruction (ACLR) will be performed and the tissue graft will be augmented with the BioBrace® Reinforced Implant. BioBrace® is intended for use in surgical procedures for reinforcement of soft tissue where weakness exists. It is a bioresorbable, biocomposite scaffold composed of a highly porous collagen sponge and reinforced with poly-L-lactic-acid (PLLA). When used in ACLRs, it is sutured alongside the tissue graft to augment and reinforce the graft construct. BioBrace® is designed to mechanically and biologically augment weakened or torn soft tissue and can be integrated into surgeons' standard of care ACL reconstruction techniques.
224054077|NCT06948591|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction|An arthroscopic anterior cruciate ligament reconstruction is performed using standard surgical procedure.
224054078|NCT04289402|OTHER|Personalized tDCS|The participant will receive 10, 20-minutes sessions of personalized tDCS Monday-Friday, at approximately the same time of day, over two consecutive weeks.
224145635|NCT05341674|OTHER|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.|the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
224145636|NCT04090437|PROCEDURE|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
224145637|NCT02939599|DRUG|QCC374|0.015mg and 0.06mg
224145638|NCT04011748|COMBINATION_PRODUCT|Stem Cell Educator therapy|AA subjects will be recruited and followed by the treatment with SCE therapy.
224145639|NCT05505097|DRUG|Hydroxymethylquinoxalindioxyde|"Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml"
223443199|NCT04925284|DRUG|Bevacizumab|IV administration of bevacizumab
223741090|NCT07197047|OTHER|Neck static stretching|"The static stretching intervention targeted the right posterolateral region of the neck. The stretching protocol consisted of four sets of 45 seconds each, separated by 45-second rest intervals, for a total intervention time of 3 minutes. Seated in a chair, participants performed the stretch by gently flexing their head forward and to the left in an anterolateral direction, using their contralateral (left) hand to assist the movement and ensure selective stretching of the right posterolateral region of the neck. Participants were asked to achieve a subjective discomfort intensity of at least 8 out of 10 on the Numerical Rating Scale (NRS), where 0 represents no pain and 10 indicates the strongest pain imaginable"
224054079|NCT04289402|OTHER|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation Monday-Friday, at approximately the same time of day, over two consecutive weeks.
224145640|NCT03104998|DRUG|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
224145641|NCT01762306|DRUG|Diclofenac Potassium|
224145642|NCT01762306|DRUG|Folic Acid|
224300688|NCT00915928|DRUG|Placebo|Placebo dayli for 3 months
223741091|NCT07206901|DIETARY_SUPPLEMENT|Maharishi Amrit Kalash|
224054080|NCT02258503|OTHER|pain in elderly patients|
223443200|NCT06850857|OTHER|IMPACT-G Module|Administration of the general IMPACT survey module.
223443201|NCT06850857|OTHER|IMPACT-N Module|Administration of the IMPACT-N survey module.
223443202|NCT06850857|OTHER|IMPACT-O Module|Administration of the IMPACT-O survey module.
223443203|NCT06850857|OTHER|IMPACT-J Module|Administration of the IMPACT-J survey module.
223443204|NCT06850857|OTHER|15D Control Survey|Administration of the 15D QOL control survey.
223443205|NCT02360202|PROCEDURE|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
223443206|NCT02360202|DRUG|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
223443207|NCT05029609|DRUG|Intranasal Foralumab Solution|The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
223443208|NCT05029609|DRUG|Placebo|The placebo nasal solution is the acetate buffer vehicle used for foralumab nasal solution. It will be handled in a manner identical to active drug.
223443209|NCT06006143|DRUG|Varenicline|All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
224054081|NCT03232411|OTHER|Questionnaires|Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.
223443210|NCT02770768|DRUG|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
223567322|NCT01748708|DEVICE|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
223567323|NCT01748708|DEVICE|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
223567324|NCT02340208|DRUG|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
223567325|NCT02775591|DRUG|DA-9701|DA-9701 30mg Tablet
223443211|NCT02770768|DRUG|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
223443212|NCT01810783|DRUG|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
223443213|NCT06749392|BEHAVIORAL|Supportive-expressive treatment|Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
223443214|NCT02134353|DRUG|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
223443215|NCT02134353|DRUG|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
223567326|NCT02775591|DRUG|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
223567327|NCT04982328|DIAGNOSTIC_TEST|Th17 cytokine profile|Screening for the components of metabolic syndrome
223567328|NCT04982328|DIAGNOSTIC_TEST|Screening for the components of metabolic syndrome|Anthropometric measures including height, weight, waist circumference and hip circumference will be measured in all patients. Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: CRP, leukocyte count, ratio neutrophils and lymphocytes, hemoglobin, platelet count, urea, creatinine, bilirubin, AST, ALT, GGT, ALP, albumins, fasting glucose.
223741092|NCT07206901|DIETARY_SUPPLEMENT|vitamin C + E|
223741093|NCT07206901|OTHER|Inert Placebo Capsule|placebo is same shape and color as is the active interventions but is inert
224054082|NCT03232411|OTHER|Saliva Samples|Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.
224054083|NCT03232411|OTHER|Tumor Tissue|Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.
224054084|NCT01693354|DEVICE|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
224054085|NCT01693354|DEVICE|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
224054086|NCT04678882|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
224054087|NCT04678882|DRUG|Dupilumab SAR231893|Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
224054088|NCT06973629|BIOLOGICAL|Debamestrocel - MSC-NTF (NurOwn)|MSC-NTF cells suspended in excipient Dulbecco Modified Eagle Medium (DMEM).
224054089|NCT06973629|BIOLOGICAL|Placebo|Dulbecco Modified Eagle Medium (DMEM).
223443216|NCT06905210|DRUG|Placebo of the experimental drug|Subjects randomized to this group will receive one (01) placebo of the experimental drug everyday for 28 weeks.
224054090|NCT01656148|DRUG|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
223443217|NCT06905210|DRUG|Experimental drug|Subjects randomized to this group will receive one (01) experimental drug everyday for 28 weeks.
223443218|NCT06831916|DIETARY_SUPPLEMENT|Active Cannabinoid Product|Participants will be administered a product with minor cannabinoids and terpenes.
223443219|NCT06831916|OTHER|Placebo|Participants will be administered a placebo.
223443220|NCT04735770|PROCEDURE|Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine|Postoperative pain management
223443221|NCT00477607|DRUG|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
223443222|NCT00477607|BEHAVIORAL|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
223443223|NCT00477607|BIOLOGICAL|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
223443224|NCT00477607|DRUG|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
223443225|NCT03542331|DRUG|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
223443226|NCT03542331|DEVICE|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
223443227|NCT00358956|DRUG|ZD6474 (vandetanib)|100 mg once daily oral tablet
223443228|NCT05387681|DRUG|Envafolimab|short course radiotherapy ：5\*5Gy (25Gy/5F) ； Envafolimab：300 mg, subcutaneously, D1, Q3W; Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W; chemotherapy：SOX regimen
223443229|NCT06266156|BEHAVIORAL|Score of anxiety questionnaire|All participants were answered the dental anxiety questionnaire.
223443230|NCT06266156|DIAGNOSTIC_TEST|Heart rate|All participants heart rate were measured with finger type pulse oxymeter.
223443231|NCT06266156|DIAGNOSTIC_TEST|Oxygen saturation|All participants oxygen saturation were measured with finger type pulse oxymeter.
223443232|NCT05432947|DRUG|68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with a dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
223443233|NCT05432947|DRUG|18F-FDG|Intravenous injection of 18F-FDG with a dosage of 5.55 MBq (0.15 mCi)/kg.
223443234|NCT00437827|OTHER|Star*D algorithm|Standard of care based upon the therapies selected in the Star\*D study.
223443235|NCT00437827|OTHER|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
223443236|NCT04761081|BEHAVIORAL|Habitual physical activity assessment|7 days habitual physical activity via accelerometry (ActiGraph GT3x). Specifically steps per day, light physical activity (minutes per day), and moderate to vigorous physical activity (minutes per day).
223567329|NCT04982328|DIAGNOSTIC_TEST|Evaluation of the degree of steatosis|The degree of steatosis will be estimated using the ultrasound and a method for grading steatosis will be measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of steatosis.
223567330|NCT05905224|DEVICE|Invisalign 7-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 7-day wear protocol
223443237|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
223443238|NCT01481584|DIETARY_SUPPLEMENT|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
223567331|NCT05905224|DEVICE|Invisalign 3-day wear protocol|Clear Aligners' (Invisalign, Align technology, San Jose, Calif) 3-day wear protocol
223567332|NCT02779088|OTHER|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
223567333|NCT04104191|DEVICE|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
223567334|NCT00092703|DRUG|MK0663, etoricoxib|
223567335|NCT00092703|DRUG|Comparator: Diclofenac sodium|
223567336|NCT02565264|OTHER|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
224054091|NCT03236220|DRUG|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
224054092|NCT00193089|DRUG|Docetaxel|Docetaxel
224054093|NCT00193089|DRUG|Vinorelbine|Vinorelbine
224054094|NCT00193089|DRUG|Trastuzumab|Trastuzumab
224054095|NCT04170803|DEVICE|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
224054096|NCT04170803|OTHER|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
224054097|NCT00000536|BEHAVIORAL|sodium, dietary|
224054098|NCT04616534|PROCEDURE|Biopsy Procedure|Undergo biopsy (dose expansion cohort only)
223443239|NCT05716854|DRUG|Clarithromycin|"Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD)."
223443240|NCT05716854|DRUG|Pimozide|"Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day."
223443241|NCT05716854|DRUG|Placebo (Part 1)|Subjects receive matching placebo for treatments.
223443242|NCT05716854|DRUG|Moxifloxacin|Subjects receive Moxifloxacin 800 mg orally once on day 1.
223443243|NCT05716854|DRUG|Cobicistat|Subjects receive Cobicistat 450 mg orally once on day 1.
223443244|NCT05716854|DRUG|Moxifloxacin and Cobicistat|Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.
223443245|NCT05716854|DRUG|Placebo (Part 2)|Subjects receive matching placebo for treatments.
223443246|NCT06225154|PROCEDURE|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
223443247|NCT05654428|OTHER|Mckenzie Extension Exercises|The exercises used to create space between under lying structures of lumber spine which help centralization of pain and can be performed in prone lying such as prone press ups, prone on elbow, and head lift in prone.
223443248|NCT05654428|OTHER|William Flexion Exercises|Exercises for strengthening of gluteal and abdominal muscles which help to reduce pressure on the nerve root by promoting flexion at lumber spine such as knee to chest, double knee to chest, bridging(Gluets bridge), and straight leg raise (SLR).
223443249|NCT04776018|DRUG|TAK-981|TAK-981 IV infusion.
223443250|NCT04776018|DRUG|Mezagitamab|Mezagitamab SC injection.
223443251|NCT04776018|DRUG|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj SC injection.
223443252|NCT03005431|BEHAVIORAL|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
223443253|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into nano particles in-situ gel adjunctive to scaling and debridement
223443254|NCT05583643|DRUG|Atorvastatin Calcium|Atorvastatin loaded into in-situ gel adjunctive to scaling and debridement
223443255|NCT05583643|OTHER|Scaling and debridement only|Scaling and debridement only
223443256|NCT02344797|PROCEDURE|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures \>185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
223567337|NCT06345950|DIETARY_SUPPLEMENT|Liposomal Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
223567338|NCT06345950|DIETARY_SUPPLEMENT|Standard Glutathione|A maximum single dose of 500 mg glutathione (hard gel capsules)
223567339|NCT06345950|DIETARY_SUPPLEMENT|New Micellar Glutathione (Lipomicel)|A maximum single dose of 600 mg glutathione (soft gel capsules)
223567340|NCT04463693|DRUG|Etonogestrel implant|Insertion of the contraceptive implant at an alternative insertion site located over the scapula
223567341|NCT04251897|DEVICE|Novel support surface|This is a magnetorheological elastomer that can dynamically redistribute the pressure over a bony prominence to be lower than the critical closing pressure while at the same time providing sufficient support.
223567342|NCT06553300|PROCEDURE|Autotransplantation with PRF|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth with the application of PRF
223567343|NCT06553300|PROCEDURE|Autotransplatation Only|Autotransplantation of Wisdom teeth to the extracted socket of removed broken down posterior teeth.
223443257|NCT03870776|DRUG|MAP4343|Daily oral administration of MAP4343
223443258|NCT03870776|DRUG|Placebo|Daily oral administration of Placebo
223443259|NCT02978391|DEVICE|UI-EWD Hemostatic system|Adhesive endoscopic hemostats, powder type
223567344|NCT02667041|DEVICE|NeuroQore rTMS Device|
223741094|NCT07206524|OTHER|Hemodialysis using dialysate containing citric acid and magnesium at a concentration of 1.0 mmol/L|Change dialysate compositions being used during hemodialysis treatment in each arm.
223443260|NCT02978391|DRUG|epinephrine endoscopic injection (conventional therapy)|endoscopic submucosal injection of epinephrine (1: 10,000)
223443261|NCT02908074|DRUG|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
223443262|NCT06612463|DIETARY_SUPPLEMENT|Caffeine 6mg/kg|In the caffeine trial, participants ingested a capsule containing 3 mg/kg caffeine 60 min prior to each rugby sevens match. There was 2 matches per day. So the total dosage is 6 mg/kg/ day
223443263|NCT06612463|DIETARY_SUPPLEMENT|Placebo|In the placebo trial, participants ingested a capsule containing starch 60 min before each rugby sevens match. There were 2 matches per day
223443264|NCT02602613|DEVICE|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
223741095|NCT07206524|OTHER|Hemodialysis using acetic acid dialysate with magnesium 0.5 mmol/L|Standard dialysate containing acetic acid and magnesium at a concentration of 0.5 mmol/L, used during hemodialysis sessions.
224054099|NCT04616534|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224054100|NCT04616534|PROCEDURE|Diagnostic Imaging Testing|Undergo medical imaging scans
224054101|NCT04616534|DRUG|Elimusertib|Given PO
224054102|NCT04616534|DRUG|Gemcitabine|Given IV
224054103|NCT04623203|OTHER|No intervention|No intervention
224054104|NCT00000421|DRUG|Prednisone|
224054105|NCT00000421|DRUG|Placebo|
224054106|NCT03592966|DIETARY_SUPPLEMENT|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
224054107|NCT03592966|DIETARY_SUPPLEMENT|Placebo|Freeze-dried placebo powder
224054108|NCT05070988|OTHER|Semi-structured interview|Semi-structured interview with the investigating doctor of the study lasting 30 minutes to an hour
224054109|NCT06996080|DRUG|KSI-101|Intravitreal injection
224054110|NCT06996080|OTHER|Sham Comparator|Sham injections
224054111|NCT06857175|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223443265|NCT01827215|BEHAVIORAL|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
223443266|NCT00093847|DRUG|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
223443267|NCT00093847|DRUG|Placebo|Placebo to be taken daily for 6 weeks
223443268|NCT06618846|PROCEDURE|laparoscopic sleeve gastric bypass|This is the observational study that investigate the impact of laparoscopic Sleeve Gastrectomy (LSG) or laparoscopic Roux-en-Y Gastric Bypass on premature aging by the assesment of biological age markers (telomere lenght, IL-6, TNFalpha, total oxidative status, DNA damage, cognitive function)
223443269|NCT05236972|DRUG|Sintilimab|Sintilimab 200mg iv drip Q3W
223443270|NCT05236972|DRUG|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
223443271|NCT05236972|DRUG|capecitabine|1000 mg/m² po twice daily on days 1- 14 repeated every 21 days
223443272|NCT01658592|OTHER|Deep brain stimulation|Stimulator setting is ON
223567345|NCT00759265|OTHER|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
223567346|NCT01694121|BEHAVIORAL|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
224054112|NCT06857175|DRUG|Docetaxel or Paclitaxel|Administration by intravenous infusion for a cycle of 3 weeks.
224054113|NCT04117646|OTHER|Sinus and nasal quality of life survey questionnaire (SN-5)|Subjects respond to the translated questionnaire twice at 15 days apart.
223443273|NCT01658592|OTHER|Placebo|Stimulator setting is OFF
223443274|NCT01458717|DRUG|Neoadjuvant chemoradiation|"* Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
223443275|NCT01458717|PROCEDURE|Upfront surgery|"* Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
223443276|NCT01189734|PROCEDURE|laparoscopic common bile duct exploration|
223567347|NCT01694121|BEHAVIORAL|Comparison|general health intervention for men, not inclusive of HIV or relationship health
223567348|NCT04835220|OTHER|Telehealth Calls|The telehealth nurse will record data in a case report form within the VA REDCap electronic data capture system that is stored within the VA firewall.
223567349|NCT02337998|OTHER|load carriage|
223567350|NCT05958394|BEHAVIORAL|SkillFlix for Parents|A Microskills video training library on communication skills for talking to youth about relationships and sexual health topics.
223567351|NCT01700998|DRUG|Magnesium|
224054114|NCT06043141|DIAGNOSTIC_TEST|Nerve ultrasound|Ultrasonographic evaluation of the median nerve at the carpal tunnel and adjacent levels
223443277|NCT01189734|PROCEDURE|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
223443278|NCT05296200|DEVICE|Hyperbuoyancy Floatation|Subjects are laid supine upon a HBF waterbed encased within a wooden frame partially (50%) filled with water (at 36ºC to maintain thermal comfort) super-saturated with magnesium sulphate. Thus, subjects are buoyant, sinking passively into the bed in proportion to their segmental mass.
223443279|NCT03572361|BIOLOGICAL|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
223443280|NCT00771329|DRUG|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
223443281|NCT00771329|OTHER|Placebo (sterile normal saline)|Single IV dose of Placebo
223443282|NCT02664922|DRUG|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
223443283|NCT02664922|DRUG|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
223443284|NCT02664922|DRUG|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
223567352|NCT01700998|DRUG|Placebo|
223567353|NCT00521599|DRUG|Mometasone furoate dry powder inhaler|
223567354|NCT00521599|DRUG|Placebo|
223567355|NCT01237457|DRUG|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
223567356|NCT02695368|DEVICE|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
223567357|NCT02695368|DEVICE|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
224054115|NCT06043141|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
224054116|NCT06043141|DIAGNOSTIC_TEST|Pressure pain threshold|Pain pressure threshold (PPT) is used to measure deep muscular tissue pain sensitivity.
224054117|NCT03969953|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban is an orally administered selective direct factor Xa inhibitor.
223443285|NCT02664922|DRUG|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
224054118|NCT03969953|OTHER|Placebo|Rivaroxaban matched placebo
223443286|NCT04898972|BEHAVIORAL|Mindfulness-based stress reduction intervention|The 8-group sessions of MBSR will be conducted once a week, lasting two and a half hours, with two additional sessions in the following two months. Between sessions, participants will have to practice at home for 45 minutes a day, 6 days a week. For the practice, patients and caregivers will be provided with audio files containing the meditations proposed in the classroom, readings, and the diary of the practice. During the sessions, the following mindfulness-based techniques will be introduced: body scan; sitting meditation; awareness movement exercises; and walking meditation.The sessions will be held face to face or online using common videoconferencing platforms, such as Skype or Zoom, based on the preferences of the participants. This will facilitate the participation of patients and caregivers, overcoming the obstacles related to travel. The course will be taught by certified mindfulness teachers with experience in MBSR interventions on patients with respiratory diseases.
223443287|NCT04898972|BEHAVIORAL|Information on stress reduction|"COPD patient-caregiver dyads will be delivered by hand, sent by email or by post an information booklet Coping with your chronic disease, targeting COPD patients, to teach them how to manage stress. This booklet, available in Italian, provides simple information on the meaning of stress and anxiety, and suggests some actions that people can implement at home to reduce stress."
223443288|NCT05542667|COMBINATION_PRODUCT|Giomer varnish|* After dryness and isolation are accomplished, Giomer varnish ( PRG coat barrier, by Shofu) will be applied once at the first treatment visit, one drop of PRG Coat Barrier ACTIVE will be added to the container provided in the package containing PRG Coat Barrier BASE the materials will be mixed together with a disposable tip provided by the kit a thin layer is to be applied and left untouched for 3 seconds according to manufacturer instructions and finally varnish is to be light-cured.
223443289|NCT05542667|COMBINATION_PRODUCT|Fluoride varnish|After dryness and isolation are accomplished, fluoride varnish (Biflourid 10, by Voco ) single-use type, the foil in the single-use Bifluorid 10 will be pierced using Micro-Tim brush, then a thin layer of the varnish is to be applied using a micro brush for four sessions at a frequency of one session each week, the varnish will be left undisturbed for 10-20 seconds then air-dried according to manufacturer instructions.
223443290|NCT02660606|OTHER|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
223443291|NCT00874562|DRUG|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
223443292|NCT00874562|DRUG|Rapamycin|Taken orally mixed with water or orange juice
223443293|NCT04477694|PROCEDURE|colonoscopy under sedoanalgesia|Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
223443294|NCT01900431|DRUG|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
223443295|NCT01900431|DRUG|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
223567358|NCT02695368|DEVICE|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
223567359|NCT02867943|OTHER|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
223567360|NCT02949986|BEHAVIORAL|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
223567361|NCT01689870|DRUG|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
223567362|NCT01689870|DRUG|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
223567363|NCT04254367|BEHAVIORAL|Learn-to-Cope|Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
223567364|NCT05824039|DIETARY_SUPPLEMENT|Tea infusion|Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
223567365|NCT00866047|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
223567366|NCT03872830|DRUG|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
224054119|NCT07003282|BEHAVIORAL|"The intervention includes 1) the First Breath app, 2) reminders during the follow-up period and 3) only for women- cotinine concentration measurement (a biomarker of secondhand smoke exposure)"|"The intervention focus on raising knowledge about the health consequences of prenatal secondhand smoke exposure, proposing strategies to avoid exposure at home and in the car, and raising motivation to implement a smoke-free home and car. An exposure score of each participant is calculated, based on his perception of secondhand smoke exposure, smoking rules within the home and strategies used to reduce exposure. Participants are guided in setting specific goals, with a detailed action plan, and receive ongoing feedback throughout follow up. In addition, for pregnant women, urine cotinine measurements at baseline, 4-weeks and 12-weeks study visit are integrated into the intervention and personalized biofeedback provided to them . Participants of the intervention arm also receive remiders (by WhatsApp) to re-use the App during all the follow-up period (3 times during the first week, 2 times/week during the 2nd, 3th and 4th weeks, and then once a week until the end of follow-up)."
224054120|NCT03424460|BIOLOGICAL|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
223443296|NCT01900431|DRUG|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
223443297|NCT01900431|DRUG|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
223443298|NCT01900431|OTHER|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
224054121|NCT03424460|BIOLOGICAL|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
224054122|NCT03424460|GENETIC|RNA extraction|RNA extraction from liver tissue
224054123|NCT06051617|DRUG|Seladelpar|"* Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis."
224054124|NCT06051617|DRUG|Placebo|One capsule daily for up to 36 months.
224054125|NCT06128824|OTHER|MR Imaging|Serial magnetic resonance imaging (MRI)
223443299|NCT05655468|DRUG|Dronedarone|oral administration fed conditions
223443300|NCT05655468|DRUG|Placebo|strictly identical in appearance with dronedarone,oral administration fed conditions
224054126|NCT06707935|BEHAVIORAL|Descriptive social norm nudges|A set of messages with descriptive social norm nudges sent to participants.
224054127|NCT06707935|BEHAVIORAL|Pictorial social norm nudges|A set of messages with pictorial social norm nudges sent to participants.
223443301|NCT02452840|OTHER|No Intervention|No Intervention
223443302|NCT01902355|PROCEDURE|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
223443303|NCT01902355|PROCEDURE|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
223443304|NCT03005613|PROCEDURE|ischial spine fascia fixation|The participants will receive ischial spine fascia fixation.
223443305|NCT03005613|PROCEDURE|sacrospinous ligament fixation|The participants will receive sacrospinous ligament fixation.
223443306|NCT03755518|DRUG|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
223443307|NCT03172364|OTHER|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
223443308|NCT03172364|OTHER|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
223567367|NCT03872830|DRUG|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
223443309|NCT04936659|OTHER|neuromodulation|Palpatory neuromodulation of the V1 and V2 branches of the trigeminal nerve where they exit onto the face.
223443310|NCT04463732|OTHER|Loaded inspiratory muscle test and cardiopulmonary exercise test|This is an observational study. Loaded inspiratory muscle test is setting at 30% of maximal inspiratory pressure. Subjects will perform only 15 breaths under this intensity to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training. Cardiopulmonary exercise test is performed by using bicycle ergometer. These two tests will be performed at least 1 week separately.
223567368|NCT03794206|DEVICE|Vesair Balloon|Treatment with Vesair Balloon for one year
223567369|NCT03371407|OTHER|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
223567370|NCT02928029|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
223567371|NCT02928029|DRUG|Placebo|Matching placebo
223567372|NCT02928029|DRUG|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
224054128|NCT06707935|BEHAVIORAL|Service as usual|Traditional mental health education information disseminated to participants.
224054135|NCT07049848|DRUG|Atezolizumab|Given by IV
224054136|NCT07049848|DRUG|Doxorubicin Hydrochloride|Given by IV
224054137|NCT06715943|DRUG|HRS-5965 capsule|HRS-5965 capsule treatment
224054138|NCT06740968|DEVICE|transcranial alternating current stimulation (tACS)|During each of the 3 stimulation visits, participants will be seated in a comfortable position and a cap will be placed on participant's head similar to a swimming cap. Small electrodes will be placed near the surface of the scalp at certain regions of interest, and a weak electrical current will be passed through the electrodes into speech related brain areas for 20 minutes. The study team will not use current strengths exceeding 2 milliamps (mA).
224054139|NCT06812078|DRUG|TAK-360|TAK-360 tablet.
224054140|NCT06812078|OTHER|Placebo|TAK-360 matching placebo tablet.
224054141|NCT06735833|DEVICE|Middle Meningeal Artery embolization|Bilateral middle meningeal artery embolization using TRUFILL n-BCA liquid embolic system
224054142|NCT06312553|BEHAVIORAL|Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring|Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring described in study arm
223443311|NCT06510387|DEVICE|Ultrasound using suprasternal method|"The research resident will perform suprasternal ultrasound (US) with a curvilinear probe) C6-2) of US machine (Philips Affiniti 50) which will be placed transversely on the suprasternal area just above to the suprasternal notch immediately after intubation, The position of the trachea will be determined by a hyperechoic air-mucosa (A-M) interface with reverberation artifact posteriorly (comet-tail artifact).~The position of endotracheal tube (ETT), when it is placed in trachea, will be defined as observable contour between A-M and comet-tail artifact. If the second contour appears, it will be similar to the second airway which is called double-tract sign which means that the ETT will be in the esophagus. (7) If the position of the esophagus is suspected of being exactly behind the trachea, operator of ultrasound can specify the location of the esophagus by moving the probe to the left and right sides during scan."
223443312|NCT06510387|DEVICE|Ultrasound using subxiphoid method|Immediately after suprasternal sonography, the research resident will perform subxiphoid sonography to detect diaphragmatic motion, and information will be recorded.
223443313|NCT05449938|PROCEDURE|Scaling and root planing|Scaling and root planing involves removal of plaque and calculus on tooth surface.
223443314|NCT03953105|DEVICE|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
223443315|NCT03953105|DEVICE|BT|usind the BT for weight estimation and suggestion of the defined parameter
223443316|NCT04592627|OTHER|Simulated home environment visit|During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
223443317|NCT02732327|DRUG|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
223443318|NCT02732327|DRUG|Vancomycin|15 mg/kg
223443319|NCT02732327|DRUG|Linezolid|600 mg
223443320|NCT02732327|DRUG|Cefepime|2 g
223443321|NCT02732327|DRUG|Meropenem|1 g
223443322|NCT02732327|DRUG|Piperacillin/tazobactam|4.5 g
223443323|NCT04803591|DRUG|Tranexamic Acid|Tranexamic Acid will be administered as an injectable solution (500mg/5ml or 1000mg/10ml).
223443324|NCT04503668|DRUG|Ondansetron|8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
223443325|NCT04503668|DRUG|Dexamethasone|20 mg IV on day 1 pre-chemotherapy
223443326|NCT04503668|DRUG|Neurokinin-1 Receptor Antagonist (NK1-RA)|150 mg IV on day 1 pre-chemotherapy
223443327|NCT04503668|DRUG|Olanzapine|5 mg by mouth on days 1-4 of chemotherapy (taken at night)
223443328|NCT04503668|DRUG|Compazine|5-10 mg by mouth, available as needed, every 6 hours, days 1-5
223443329|NCT04775576|OTHER|Pleth Variability Index|Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.
223443330|NCT04775576|OTHER|Conventional fluid theraphy|8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is \<65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.
224054143|NCT06312553|BEHAVIORAL|Standard Diabetes Self Management Education|Standard Diabetes Self Management Education described in study arm
224054144|NCT06600490|BEHAVIORAL|Behavioral Economic Principles|The control arm will receive no letter to reflect the background vaccination uptake. Intervention arms will test the effects of different letters developed using behavioral economic principles.
224054145|NCT06748417|DEVICE|Acute Cognitive Training|Participants will receive the intervention in person once within in the study for 30 minutes. During the intervention, participants will receive a cognitive training session consisting of an upper extremity, lower extremity, and whole-body reaction time task. The device (5 LED) will be placed in front of participants in all tasks, and participants will be asked to deactivate lights that illuminate for a period of 30 seconds with 30 seconds of rest. For the upper and lower extremity tasks, these will be repeated on both limbs. The purpose of the tasks are to pre-train reaction time in an isolated fashion, requiring participants to use either hands or feet to deactivate the lights, as well as incorporate whole-body movement in the third task along with a decision-making (color-matching) component.
223443331|NCT04775576|OTHER|Anesthesia method|All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
223443332|NCT03788668|PROCEDURE|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
223443333|NCT00902980|OTHER|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
223443334|NCT00603382|DRUG|GW685698X|GW685698X
223443335|NCT00603382|DRUG|Placebo|placebo comparator
223443336|NCT02237560|BEHAVIORAL|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
223443337|NCT02237560|BEHAVIORAL|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
224054146|NCT06748417|OTHER|Non-stimulating Rest|Participants will receive the intervention in person once within the study for 30 minutes. During the intervention, participants will watch, while seated, a 30-minute segment of a nature documentary. The purpose of this intervention is to ensure no additional cognitive or movement training that would improve performance on the dual-task test occurs during the intended rest period.
224054147|NCT06773962|DRUG|TB006|IV infusion.
224054148|NCT06773962|DRUG|Placebo|IV infusion.
224054149|NCT07072819|BEHAVIORAL|Crisis Ready Training|Crisis Ready Training combines Crisis Line Facilitation with Take Home Naloxone training. The intervention is delivered in a group format.
224054150|NCT06895187|DEVICE|VERAFEYE System|VERAFEYE system guidance will be used on all patients undergoing PAF ablation.
224054151|NCT06893302|BIOLOGICAL|Bone Marrow Aspirate (BMA)|Bone marrow aspirate (BMA) is being investigated as an augmentation to arthroscopic debridement surgery of the knee to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.
224054152|NCT06893302|PROCEDURE|Arthroscopic Debridement Surgery|Arthroscopic debridement surgery of the knee is performed to treat conditions such as meniscal injuries, chondral defects, and low-grade osteoarthritis.
224054153|NCT06893302|OTHER|Saline|Patients in the control arm of the study will receive arthroscopic debridement surgery along with a saline injection. This will be compared to the experimental arm, in which patients will receive arthroscopic debridement surgery along with a bone marrow aspirate injection.
223443338|NCT02237560|BEHAVIORAL|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
223443339|NCT03403621|DRUG|Pentamidine Isethionate|Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
223443340|NCT03403621|DRUG|Placebo|No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
223443341|NCT00583102|DRUG|Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
224054154|NCT06746064|DRUG|CHF10073 (Part 1 - SAD)|Single doses of CHF10073 for each cohort
224054155|NCT06746064|DRUG|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF10073 for each cohort
224054156|NCT06746064|DRUG|CHF10073 (Part 2 - MAD)|Multiple doses of CHF10073 for each cohort
224054157|NCT06746064|DRUG|CHF10073 (Part 3)|Single dose of CHF10073
224054158|NCT06746064|DRUG|Placebo (Part 2 - MAD)|Multiple doses of placebo matching CHF10073 for each cohort
224054159|NCT06746064|DRUG|itraconazole (Part 4)|Multiple dose of itraconazole in treatment period 2
224054160|NCT06746064|DRUG|CHF10073 (Part 4)|Single dose of CHF10073 in Treatment Period 1 and 2
224054161|NCT05450354|OTHER|Questionnaires|"Questionnaires will be completed only once :~* Neurodevelopment in children: Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime version (K-SADS-PL-5), the Social Responsiveness Scale (SRS), The Children's Communication Checklist-2 (CCC-2), The Autism-Tics, ADHD and Other Comorbidities Inventory (A-TAC), CONNERS-3, Sensory Profile 2 (DUNN)~* Psychopathological profile of the child by evaluating the presence of psychotic symptoms: K-SADS-PL-5, Prodromal Questionnaire (F PQ16)~* Presence of mood and anxiety disorders: Child Depression Inventory (CDI), Revised Children's Manifest Anxiety Scale (RCMAS)~* Presence of sleep disorders: Children's Sleep Habits Questionnaire (CSHQ). The K-SADS-PL-5 will only be completed by subjects who have attempted suicide after the start of the study; it requires a semi-structured interview of the child by a child psychiatrist and cannot be done remotely. The other scales will be completed by all included subjects."
223443342|NCT00583102|DRUG|Lovastatin|Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
224054162|NCT05450354|OTHER|Questionnaire|Determination of attachment style : Adolescent Relationship Scale Questionnaire (ARSQ). The questionnaire will be completed only once.
224054163|NCT01740076|OTHER|soy nuts|
223443343|NCT06910332|OTHER|Joint mobilization|Participants receive passive shoulder joint mobilization on the dominant-side glenohumeral joint. The mobilization includes inferior, anterior, and posterior glide techniques, each performed for 1 minute at a frequency of 0.5 Hz, with a 30-second rest between each mobilization. The participant is positioned comfortably to support the joint's range of motion.
223443344|NCT06910332|OTHER|Sham|In the sham intervention, the practitioner mimics the technique of shoulder mobilization but does not apply any actual movement or glide effect on the joint. The procedure is designed to closely resemble the real intervention in terms of duration, rhythm, and the practitioner's handling of the participant's shoulder. The practitioner will use superficial touch on the glenohumeral joint without applying any of the mobilizing forces necessary to move the joint.
223443345|NCT01093651|DRUG|Sitagliptin|100 mg sitagliptin daily for 4-6 months
223443346|NCT01093651|DRUG|Placebo|Daily placebo for 4-6 months
223567373|NCT02928029|DRUG|Dexamethasone|Dexamethasone is administered orally at 40 mg
223567374|NCT05154617|DIAGNOSTIC_TEST|Standard surgical monitoring, along with the Flo Trac® system monitoring.|Under standard thoracic anesthesia protocol, extra monitoring will be done by FloTrac® System using a minimally invasive sensor in combination with an advanced monitoring device to derive cardiac output (CO) and cardiac index (CI) parameters through arterial pulse pressure waveform analysis. Intraoperative blood gases collection will be at different intraoperative times. From this data, calculations will be performed to obtain DO2, DO2i, O2ER, and O2ERi.
223567375|NCT00177567|DRUG|lithium carbonate|
223567376|NCT00177567|DRUG|Depakote-ER|
223567377|NCT00177567|DRUG|risperidone|
223567378|NCT00177567|DRUG|olanzapine|
223567379|NCT00177567|DRUG|paroxetine|
224054164|NCT07088640|PROCEDURE|Single-step warming protocol by thawing solution only|Potentially eligible patients' vitrified blastocysts will be thawed by a single-step thawing protocol. For the warming phase, vitrified blastocysts are exposed to the thawing solution of a commercial embryo thawing kit (Irvine Scientific Inc., USA) at 37°C for one minute. Immediately following this, embryos will be rinsed in a 35mm diameter dish of 2ml of pre-equilibrated thawing solution before being placed in culture media in the incubator for at least 2 hours before transfer.
224054165|NCT07088640|PROCEDURE|Standard warming protocol|"For the MS protocol, thawing kits were equilibrated overnight in a 37°C incubator. Warming procedures utilized the kits (Cryotech RtU, Japan). To remove the cryoprotectants, blastocysts were warmed, and cryoprotectants were diluted in a three-step process.~The warming process starts with the exposure of blastocysts to thaw solution (TS) with 1M trehalose for one minute at 37°C. Subsequently, the blastocyst will be transferred to a second well containing a dilution solution (DS) of 0.5M trehalose for a two-minute rinse at room temperature. This is followed by two additional three-minute and 30-second rinses in the wash solution (WS) at room temperature. The timeline for standard warming of blastocysts requires a total of 6.5 min. After thawing, embryo will be placed in the incubator at least 2 hours before transfer."
224054166|NCT07109817|DRUG|Desloratodine|Desloratadine 5mg PO daily for 12 weeks. Desloratadine is a long- acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Desloratadine inhibited histamine release from human mast cells.
224054167|NCT07109817|DRUG|Placebo|Placebo daily PO for 12 weeks. Placebo is a lactose filler covered by a capsule.
224054168|NCT06914141|DRUG|Tirzepatide|New use of tirzepatide dispensing claim is used as the exposure.
224054169|NCT06914141|DRUG|Semaglutide|New use of semaglutide dispensing claim is used as the reference.
223443347|NCT06909903|PROCEDURE|Autogenous drainage of sputum caused by hypertonic saline in adolescents with cystic fibrosis.|"The procedure will be performed at the same session as follows :~* 30 minutes of autogenous drainage, followed by collection of secretions.~* 10 minutes of HSS followed by 30 minutes of autogenous drainage before secretions are collected.~The intervention first step involves verifying patient tolerance to Hypertonic saline solution nebulization (Auscultation, peak flow, saturtion levels), followed by the inhalation of 2 puffs of Ventolin® to prevent bronchospasm. Ten minutes later, the patient undergoes a 10-minute nebulization of 4 mL SSH 6% carried out according to the HAS recommendations.~The patient tolerance to SSH is reassessed. If there are no adverse reactions, the patient continues the protocol. If issues like wheezing, a ≥5% drop in SpO2, or a ≥20% drop in Peak Flow occur, 4 more puffs of Ventolin® are given, and the patient is reassessed.If still intolerant, the patient exits the study.~The session ends with physiotherapy (autogenous drainage) to aid mucus clearance."
223443348|NCT06912503|DEVICE|Device to deliver trial restoration matrix|"Auto-polymerization bisacrylic material (Luxatemp Star, DMG) was used to perform the trial restoration for condensation silicone matrix, addition PVS-silicone matrix with external resin-based shell and CAD/CAM combination matrix. Light-cured flowable composite-resin (Filtek Flow, 3M Dental Products) was used to perform the trial restoration for transparent addition PVS-silicone matrix. The rationale behind using different material stands on the material selection usually chosen by clinicians for each matrix.~In the same appointment 4 trial restorations were performed to each patient using the four different matrixes."
223443349|NCT06911853|OTHER|Virtual Reality Videos|Based on the Phase of Engagement Framework, two online orthopaedic modules focusing on interprofessional and intercultural educations on low back pain (LBP) and adolescent idiopathic scoliosis (AIS) were developed. The students (n=104) were randomized into two groups. In the first module, the Virtual Reality Group as the intervention group received a virtual reality (VR)-enhanced LBP education, while the Case-based Learning Group as the control group engaged with a case study on LBP. After a 3-week washout period, the groups crossed over: the the Virtual Reality Group as the intervention group received the VR-enhanced education on AIS, and the Case-based Learning Group as the control group focused on an AIS case study.
223443350|NCT06912347|OTHER|Intervention Group|Starting 24 hours before pre-treatment, you will receive herbal fumigation of the perianal area twice daily (morning and afternoon), with each session lasting 5 minutes. Additionally, starting 30 minutes after each meal, acupoint application will be performed on five acupoints: Shenque (CV8), Tianshu (ST25), and bilateral Zusanli (ST36). The application will last 4 hours per day.
223443351|NCT06912347|OTHER|control group|Starting 24 hours before pre-treatment, you will receive povidone-iodine warm water fumigation of the perianal area twice daily (morning and afternoon), with each session lasting 15 minutes.
223443352|NCT06910098|DRUG|Rosuvastatin|a dose of 5mg were given and were compared for the cpk, ast and ldl levels
223443353|NCT06910098|DRUG|Rosuvastatin|a dose of 10 mg were given and were compared for the cpk, ast and ldl levels
223443354|NCT06910098|DRUG|Rosuvastatin|a dose of 20 mg were given and were compared for the cpk, ast and ldl levels
223443355|NCT06911528|PROCEDURE|EndoScell Scaner (ES) novel intraoperative cellular probing technology|In this project, we utilize the miniature wide-angle focusing microscope for intraoperative cell-level observation and detection, a technology in which our hospital has conducted extensive research and accumulated rich experience.
224054170|NCT05642507|DRUG|AC01|AC01 microtablets
223443356|NCT06109376|PROCEDURE|hypothermia|In this trial, intra-arterial select cooling infusion is used to reduce brain tissue temperature to 33-35°C.
223443357|NCT06109376|PROCEDURE|thrombectomy|Thrombectomy includes treatment with stent retrievers and/or thromboaspiration, balloon angioplasty, stenting, intra-arterial thrombolysis, or the various combinations of these approaches.
223443358|NCT03611582|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
223567380|NCT00177567|DRUG|bupropion|
223567381|NCT00177567|DRUG|lamotrigine|
223567382|NCT00177567|DRUG|venlafaxine|
224054171|NCT07141888|DIETARY_SUPPLEMENT|Placebo (no active ingredient)|Placebo product containing the same ingredients as the active intervention but without the active compounds
224054172|NCT07141888|DIETARY_SUPPLEMENT|Probiotics|Product contains two probiotic strains
223443359|NCT03611582|DRUG|Placebo (semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
223443360|NCT03376191|DRUG|apatinib|Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
223443361|NCT03723421|OTHER|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
223443362|NCT03723421|OTHER|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
223443363|NCT03127813|OTHER|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
223443364|NCT01783821|DRUG|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
223443365|NCT01783821|DRUG|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
223443366|NCT01783821|DRUG|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
224054173|NCT07141888|DIETARY_SUPPLEMENT|Probiotics plus fibre|Product contains two probiotic strains plus a fibre (beta-glucan)
224054175|NCT05517174|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|For this arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
224054176|NCT05517174|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|Any standard-dose quadrivalent influenza vaccine administered in the Danish governmental influenza vaccine program may be used.
224054177|NCT06945887|PROCEDURE|embolization therapy|Identification of the main vessels afferent to the tumor to be treated. -Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters. - Injection of embolizing material (hydrogel microspheres) - Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
223443367|NCT03669484|DRUG|Remimazolam|Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
223567383|NCT00177567|DRUG|tranylcypromine|
223567384|NCT00177567|DRUG|mirtazapine|
223567385|NCT04248920|BEHAVIORAL|Clinic to Community Education Program|The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
223567386|NCT00336167|DRUG|bezafibrate (drug)|
223567387|NCT04319029|BEHAVIORAL|Pharmaceutical care plan|"The design of the intervention was based on a stepwise approach to address the following point in each participant: set priorities for patient care, assessment of patient's educational needs, and development of a comprehensive and achievable pharmaceutical care plan.~The participants will be educated about their illness and informed about the proper use of their medication in a structured manner (it involved the following items: dyslipidemia as a disease, complications, who therapy reduces its risk and complications, goal of therapy). Behavioral modifications will involve the following: physical exercise, diet, smoking cessation. Patients will obtain this information verbally and provided in a written manner through a brochure that design for this study."
223567388|NCT01610713|DRUG|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
223567389|NCT03893240|DIAGNOSTIC_TEST|Neutralizing Antibody to SPK-3006 capsid|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
223567390|NCT03119181|DRUG|Tymbion Lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution
223567391|NCT03119181|COMBINATION_PRODUCT|Device: Iontophoresis System (IPS) with Drug: Tymbion lidocaine/epinephrine solution|The external ear canal will be filled with Tymbion drug solution. The Iontophoresis System (IPS) will be used to deliver current to the Tymbion solution to facilitate drug penetration into the tympanic membrane (TM) tissue to anesthetize (numb) the TM
223567392|NCT02959827|DRUG|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
223443368|NCT03669484|DRUG|Propofol|Emulsion for infusion, 10 mg/mL in 20-mL glass vials
223443369|NCT03669484|DRUG|Fentanyl|Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
224300689|NCT01453894|BEHAVIORAL|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
223443370|NCT03669484|DRUG|Rocuronium bromide|Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
223443371|NCT01432964|PROCEDURE|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
223443372|NCT02101333|DRUG|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
223443373|NCT01665677|DRUG|Atorvastatin calcium|40 mg PO daily
223443374|NCT02333383|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223443375|NCT04459598|DRUG|Efavirenz|Single oral dose, 600-mg tablet
223443376|NCT04459598|DRUG|Quizartinib|Single oral dose, 60 mg (2 x 30 mg) tablets
223443377|NCT05995405|DRUG|GTX-104|Nimodipine IV infusion
223443378|NCT05995405|DRUG|Nimotop 30 MG Oral Capsule|Oral nimodipine capsules
223443379|NCT00000298|DRUG|Buprenorphine/naloxone|
223443380|NCT04270227|OTHER|Survey study|The questionnaire including Exercise Benefits / Barriers Scale, IPAQ (International Physical Activity Survey), The Bady Awareness questionnaire and demographic information will be filled in one time by face-to-face interview method.
223443381|NCT04956627|DRUG|BMS-986166|Specified dose on specified days
224054178|NCT06948903|DIAGNOSTIC_TEST|Central Sensitization Inventory|The Central Sensitization Inventory is used by some researchers to investigate pain sensitivity through symptoms associated with central sensitization and related comorbidities. It can help determine the severity of central sensitization. The scale was developed to detect central sensitization in patients with chronic pain and consists of two sections: Section A and Section B. For scoring purposes, only Section A is used. A score of 40 or higher out of 100 is associated with an increased likelihood of central sensitization.
224054179|NCT06948903|DIAGNOSTIC_TEST|The Montreal Cognitive Assessment|The Montreal Cognitive Assessment was initially developed as a test for mild cognitive impairment, but has also been determined to match qualities of the mini mental state examination 80. It assesses seven areas of cognition for a total possible score of 30 points. A score of 21 or less is indicative of cognitive impairment in Turkish population.
224300690|NCT00494039|PROCEDURE|Radioactive seed implant to prostate|
223443382|NCT04956627|DRUG|Itraconazole|Specified dose on specified days
223443383|NCT04956627|DRUG|Extended Phenytoin Sodium|Specified dose on specified days
223443384|NCT04956627|DRUG|Gemfibrozil|Specified dose on specified days
223443385|NCT01907217|DEVICE|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
223567393|NCT04231058|DEVICE|TENS and pulmonary rehabilitation|Three treatments with TENS per week for 3 weeks each , lasting 45 minutes
223567394|NCT04852705|BIOLOGICAL|SARS-CoV-2 Vaccine (Vero Cells), Inactivated|2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
223567395|NCT04852705|BIOLOGICAL|Placebo|2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
223567396|NCT05540249|DIETARY_SUPPLEMENT|carbohydrates|Patients will orally consume 355mL CHO after 20:00 the evening before surgery.
223567397|NCT05237791|DRUG|Magnesium sulfate|magnesium sulphate 50mg/kg (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
223567398|NCT05237791|DRUG|Placebo|normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
223567399|NCT01025076|DEVICE|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
223741096|NCT07206524|OTHER|Hemodialysis using citric acid dialysate with magnesium 0.75 mmol/L|Dialysate containing citric acid and magnesium at a concentration of 0.75 mmol/L, used during hemodialysis sessions.
224054180|NCT06948903|DIAGNOSTIC_TEST|Cognitive Symptom Severity Scale-Extended|The Cognitive Symptom Severity Scale extends the scale of the original cognitive symptom severity scale. Participants are asked to rate their cognitive symptoms related to concentration and memory on a single scale ranging from 1-5, rather than the original 1-3, where higher scores indicate greater severity.
223443386|NCT01907217|DRUG|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
223443387|NCT01907217|DRUG|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
223443388|NCT00722163|OTHER|Cognitive Behavioural Therapy|
223443389|NCT00722163|OTHER|befriending|
223443390|NCT00001863|DRUG|Leflunomide|
223443391|NCT06318819|DEVICE|Dental Floss Holders|Dental Floss Holders for flossing purposes
223443392|NCT05658952|OTHER|Microcatheter-derived FFR|FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
223443393|NCT05658952|OTHER|Angiography-derived FFR|FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
223443394|NCT05658952|OTHER|Angiography-guided PCI|Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
223443395|NCT00618709|DRUG|ATX-101|ATX-101 single dose
223443396|NCT05768009|PROCEDURE|Interscalene brachial plexus block (ISB)|• Group A will include 21 patients who will undergo the procedure under general anesthesia and ultrasound guided ISB using 10 ml bupivacaine 0.25%.
223443397|NCT01078298|DRUG|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
223443398|NCT01078298|DRUG|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
223443399|NCT04908202|DRUG|Deucravacitinib|Specified dose on specified days
223443400|NCT04908202|OTHER|Placebo|Specified dose on specified days
223443401|NCT01726621|DEVICE|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
223443402|NCT02314754|DRUG|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
223443403|NCT00866333|DRUG|Entinostat|Entinostat tablets
223443404|NCT03252197|DEVICE|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
223443405|NCT03252197|DEVICE|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
223443406|NCT02095405|DRUG|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
223443407|NCT02095405|OTHER|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
223443408|NCT03632577|DEVICE|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
223443409|NCT03632577|DEVICE|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
223443410|NCT05329727|DRUG|Angiotensin receptor neprilysin inhibitor (ARNI)|The group with ARNI was defined as patients with HFrEF took ARNI more than 3 months
223443411|NCT05329727|DRUG|Renin-Angiotensin System Inhibitor (RAS inhibitor)|The group with RAS inhibitor was defined as patients with HFrEF took RAS inhibitor more than 3 months
223443412|NCT02055274|DRUG|LY03003|
223443413|NCT02055274|DRUG|Neupro|
223443414|NCT01196663|DEVICE|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
223443415|NCT01196663|DEVICE|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
223443416|NCT00005624|DRUG|CI-994|CI-994 as outlined in treatment arm.
223443417|NCT03050112|OTHER|MacNew questionnaire|Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
223443418|NCT00659542|PROCEDURE|cyanoacrylate glue|1 ml glue
223443419|NCT04504175|DRUG|Ketamine|ketamine will be infused using an IV infusion pump at a rate of 0.5 mg/kg of body weight over 40 minutes
223741097|NCT07206186|OTHER|Music|Music as per patient choice
223741098|NCT07204990|PROCEDURE|Endotracheal tube removed awake|Patient will have the ETT removed awake and transferred to PACU breathing independently or with a face mask.
223741099|NCT07204990|PROCEDURE|Laryngeal mask airway inserted following deep extubation|Patient will have LMA inserted following deep extubation of endotracheal tube.
224054181|NCT06948903|OTHER|Fibromyalgia Impact Questionnaire|The Fibromyalgia Impact Questionnaire is composed of 10 items. The first item contains 11 questions related to physical functioning - each question is rated on a 4 point Likert type scale. Items 2 and 3 ask the patient to mark the number of days they felt well and the number of days they were unable to work (including housework) because of fibromyalgia symptoms. Items 4 through 10 are horizontal linear scales marked in 10 increments on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety and depression. The maximum scale score is 100, with higher scores associated with increasing disability.
223443420|NCT05920785|DIAGNOSTIC_TEST|Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile|"comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~* general blood test, general urine test,~* biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~* hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~* glycated hemoglobin,~* \- glucose tolerance test,~* ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~* blood pressure monitoring.~Special laboratory methods:~* Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~* analysis of feces for microbiota by MALDI-TOF mass spectrometry,~* bioimpedance measurement."
223443421|NCT00750256|DRUG|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
223443422|NCT02585388|DRUG|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
223443423|NCT02585388|DRUG|Letrozole|Lestrozole at 2,5 mg every day , per oral
223741100|NCT07207096|COMBINATION_PRODUCT|complementary medicine|Complementary therapies provided include homeopathy, herbalism, hypnosis, and healing. Patients may also be provided with self-help advice for lifestyle changes, mindfulness or meditation techniques, and dietary advice, as indicated for complementary therapy management of their condition.
223741101|NCT05988892|BEHAVIORAL|Physical Activity|Use Exercise to increase physical activity (PA), as measured by cardiovascular endurance, muscular strength, and balance in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address and to increase quality of life (QOL), as measured by physical functioning and fatigue, in underserved cancer survivors \>60 years of age and/or those of any age residing at a rural address.
223741102|NCT06440967|DRUG|Fezolinetant|oral
224054182|NCT06948903|OTHER|Numeric rating scale|Numeric Rating Scale will be used to determine pain intensity during assessments. Participants will be asked to rate their pain intensity by selecting a value between 0 and 10. Higher scores are associated with increased pain severity.
224054183|NCT06948903|OTHER|Hospital Anxiety and Depression Scale|This scale is used to assess anxiety and depression symptoms and consists of 14 items (7 items for anxiety, 7 items for depression). For each subscale, scores range from 0 to 21: • 0-7 points: No symptoms or very mild symptoms • 8-10 points: Moderate symptoms • 11 points or higher
224054184|NCT07154979|DRUG|Oliceridine Injection|"Adult participants receive a single IV bolus of oliceridine (initial dose 45 µg/kg for ages 18-65 y or 40 µg/kg for ≥65 y). Two minutes later, propofol 2 mg/kg IV is administered. Upon loss of consciousness (MOAA/S ≤ 1), rocuronium 0.6 mg/kg IV is given. Direct laryngoscopic tracheal intubation is performed after full muscle relaxation. Blood pressure and heart rate are recorded at baseline, 2 min post-oliceridine, immediately pre-intubation, and for 3 min post-intubation. A positive hemodynamic response is defined as ≥ 20% increase in MAP or HR, HR ≥ 120 bpm, or SBP ≥ 180 mmHg. Subsequent oliceridine doses are adjusted ± 3 µg/kg based on the prior patient's response until seven response crossovers are observed, allowing estimation of ED₅₀ and ED₉₅."
224054185|NCT07151105|DIETARY_SUPPLEMENT|Vitamin C|Participants will receive a vitamin C supplement while following a low vitamin C diet to achieve adequate vitamin C status in a blinded manner. This will be compared to participants receiving a placebo while following a low vitamin C diet that is expected to maintain inadequate vitamin C status.
224054186|NCT07151105|DIETARY_SUPPLEMENT|Placebo + Low Vitamin C Diet|Participants will receive a placebo while following a low vitamin C diet to achieve inadequate vitamin C status in a blinded manner. This will be compared to participants receiving a vitamin C supplement while following a low vitamin C diet that is expected to maintain adequate vitamin C status.
224054187|NCT07155967|DEVICE|Blood Flow Restriction Cuff|Inflatable device that exerts an external pressure above a muscle or joint of the extremities.
224054188|NCT07162675|DEVICE|Huawei Fit 2 Smartwatch|Participants will receive a Huawei Fit 2 smartwatch within the first week of initiating neoadjuvant systemic therapy. The device will be worn throughout the treatment period to continuously monitor step counts, physical activity intensity, sleep duration, and heart rate. It is used solely for non-invasive monitoring and does not alter the standard oncological treatment.
223443424|NCT02585388|DRUG|Anastrozole|Anastrozole at 1 mg every day, per oral
223443425|NCT01559688|BEHAVIORAL|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
223443426|NCT01559688|BEHAVIORAL|Waitlist|Fitness assessment or career counseling
223443427|NCT00696228|DIETARY_SUPPLEMENT|Placebo|Placebo
223443428|NCT00696228|DIETARY_SUPPLEMENT|MUFA|MUFA
223741103|NCT06440967|DRUG|Placebo|oral
223741104|NCT06440967|DRUG|Tamoxifen|oral
223741105|NCT06440967|DRUG|Aromatase inhibitor|oral
223741106|NCT04640142|BIOLOGICAL|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion.
223741107|NCT05948566|BIOLOGICAL|TS23|Monoclonal antibody
223741108|NCT03730948|BIOLOGICAL|DC vaccine|DC vaccine for colorectal cancer
223741109|NCT00330291|DRUG|Xyrem|
223443429|NCT00696228|DIETARY_SUPPLEMENT|PUFA|PUFA
223443430|NCT00696228|DIETARY_SUPPLEMENT|SFA|SFA
223443431|NCT04409015|DEVICE|ROTEM - rotation thromboelastometry testing|The ROTEM® is a simple blood test that provides information about specific components involved in blood clotting and stopping hemorrhage.
223443432|NCT03875976|PROCEDURE|Fast Track Protocol|Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
223443433|NCT03875976|PROCEDURE|Standard Care Protocol|Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
223443434|NCT05731167|BEHAVIORAL|Multidomain frailty prevention method|We use the nutrition, physical training, medication consultation, cognition training to prevent the occurrence of frailty or other adverse outcome.
223741110|NCT06081543|DIETARY_SUPPLEMENT|Ketogenic diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
223741111|NCT06081543|DIETARY_SUPPLEMENT|Low-fat Mixed diet|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff for the first 6 weeks. After that will be a free-living diet period where food will not be supplied but participants will receive educational materials and frequent coaching from a dietitian to help maintain the specified diet. Participants will be asked to exclusively follow the diet in efforts to control any dietary effects.
223741112|NCT05283252|DEVICE|3-D printed Guide|Guided Endodontic micro-surgery
223741113|NCT05283252|OTHER|Conventional Endodontic Micro-Surgery|Free-hand endodontic micro-surgery
224054189|NCT07160660|OTHER|Patients' satisfaction and clinical investigation of removable partial denture anchorage with extracoronal adhesive attachments|"* Completion of a questionnaire by the participant, including patient satisfaction on VAS (visual analogue scale) and prostheses usability, clinical examination of the remaining dentition, the abutment teeth of the extracoronal adhesive attachment and the RPD.~* Evaluation of the attachment's condition, retention, and any signs of biological or technical complications.~* Collection of relevant medical and dental history from patients' records (consent provided)."
224054190|NCT07160660|OTHER|Patients' satisfaction and clinical investigation of removable partial denture anchorage with conventional clasps|"* Completion of a questionnaire by the participant, including patient satisfaction on VAS (visual analogue scale) and prostheses usability, clinical examination of the remaining dentition, the abutment teeth of the clasps and the RPD.~* Evaluation of the clasps' condition, retention, and any signs of biological or technical complications.~* Collection of relevant medical and dental history from patients' records (consent provided)."
224054191|NCT07171632|OTHER|monitoring of clinical and ventilatory variables|Monitoring clinical data
224054192|NCT07171580|OTHER|Remote Home Monitoring - Education|A virtual platform will be used to provide education to ACS patients post discharge.
224054193|NCT07171580|OTHER|Remote Home Monitoring - Education and Support|A virtual platform will be used to provide education and support to ACS patients post discharge.
224145643|NCT05796882|BEHAVIORAL|Whole Food Plant-Based Diet Ad Libitum|"Participants will follow a Low Fat Whole Food Plant-Based Diet Ad Libitum for 8 weeks. It consists of increasing the daily consumption of fruits and vegetables, including sources of vegetable protein such as legumes (beans, lentils, chickpeas, peas, etc), soybeans and their derivatives (tofu, textured soybeans, soymilk), and whole grains. (oats, wheat, rice, quinoa, corn), nuts and seeds high in omega-3 fatty acids (chia, flaxseed, hemp), and minimize processed foods, and foods high in saturated fat. Avoiding animal-sourced foods.~There will be no caloric restriction, however, visual support will be provided, in the form of a traffic light, to distinguish the frequency with which each type of food can be consumed"
224054194|NCT07170111|PROCEDURE|Greater Occipital Nerve (GON) Blockade|The greater occipital nerve block (GONB) will be performed using anatomical landmarks (distal approach). The injection point is located at the medial one-third of the line between the external occipital protuberance and the mastoid process. A 26-gauge insulin needle will be used for the procedure. The block will be administered bilaterally with 0.5% bupivacaine, 1.5 ml per side (total 3 ml). The intervention will be repeated once weekly for a total of four sessions
223443435|NCT05731167|OTHER|Regular follow up|Subjects will receive regular follow up and suggestion in outpatient department.
223443436|NCT01036633|DEVICE|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
224054195|NCT07170839|OTHER|ESWT Aplication|All three groups received a total of five ESWT sessions, once a week for five weeks. All ESWT sessions were administered by the same physiotherapist, and the patients were positioned with their elbows flexed to 90 degrees and supported. ESWT was applied to sensitive points on the lateral epicondyle using a shock wave dose of 2000 pulses/session, with an intensity of 1.6 bar, a frequency of 10 Hz, and 1.6 bar. No analgesics or local anesthetics were administered before, during, or after the treatment.
224145644|NCT05796882|BEHAVIORAL|Nutritional Standard Care|Nutritional Consultation every month for 2 months. Recommendations on healthy eating and lifestyle will be given. Duration 8 weeks
223443437|NCT00300833|DRUG|Tirofiban|pci
223741114|NCT01786629|DRUG|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
223741115|NCT01786629|DRUG|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
223741116|NCT05571059|DRUG|Ifetroban Sodium|Once daily oral ifetroban
223741117|NCT05571059|DRUG|Placebo|Matching oral placebo
223741118|NCT06781619|DIETARY_SUPPLEMENT|Test Product: Plant based high energy high protein ONS|Plant based high energy high protein ONS 2 servings/day for a period of 8 weeks.
223741119|NCT06781619|DIETARY_SUPPLEMENT|Control Product: Dairy based high energy high protein ONS|Dairy based high energy high protein ONS 2 servings equivalent in energy \& protein for a period of 8 weeks.
223741120|NCT06701656|DRUG|Cohort C: bevacizumab|Administered as a single IV dose of 500 mg on Day 1
223741121|NCT06701656|DRUG|Cohort C: placebo|Administered as a single IV dose of placebo on Day 1
223443438|NCT03986554|PROCEDURE|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
224054196|NCT07170839|OTHER|ECCENTRIC EXERCISE|Patients in the eccentric exercise group underwent a protocol consisting of slow-progressive eccentric wrist extensor exercises combined with static stretching exercises three times a week for 5 weeks. Eccentric exercises were performed without any resistance to eliminate gravity in the first week, and the intensity of the resistance was gradually increased using yellow elastic resistance bands in weeks 2-3 and red elastic resistance bands in weeks 4-5. Eccentric exercises were performed with the elbow extended, the forearm pronated, the wrist extended, and hanging down from the support surface. Patients were asked to slowly bend the wrist downward, count to 30, and then return to the starting position. Eccentric contractions were then performed in the same manner, and so on. Patients were instructed to continue the exercise if mild pain occurred but to stop the exercise if the pain increased to the point of preventing movement. Once patients tolerated the exercise, the lo
224054197|NCT07170839|OTHER|COMBINED ISOTONIC EXERCISE|Patients in the combined isotonic exercise group underwent an eccentric-concentric exercise protocol combined with wrist isometric exercises three days a week for 5 weeks. Similar to the eccentric training group, this group completed the training with resistance applied in the first week and elastic bands in subsequent weeks. In the first week, exercise training began with the patients' elbows in full extension, forearms in pronation, wrists in extension, and hanging from the support surface. Participants were asked to slowly bend their wrists for a count of 30, and the wrist extensors were eccentrically exercised. Immediately afterward, patients performed a concentric contraction while returning to the starting position (extension). Then, isometric contraction of the wrist extensors was maintained in the starting position for 30-45 seconds. Once the isometric contraction was achieved, concentric contraction continued, completing the exercise protocol.
224054198|NCT07171697|BEHAVIORAL|Mindfulness and psycho-education|4 week tailored mindfulness and psychoeducation programme for medical interns
224054199|NCT05767593|DEVICE|Wearing Samsung smartwatch and filling out daily surveys|Participants will wear a Samsung smartwatch and fill out daily surveys about their mood and depressive symptoms.
224054200|NCT06789198|DRUG|Vaccination of Fusion-VAC-XS15|"FusionVAC-22 peptide will be administered subcutaneously (s.c.) with the TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1).~A total of two vaccinations are planned, 4 weeks apart from each other. If no sufficient T cell response is achieved at the end of treatment visit (28 days after last vaccination) a booster vaccination at day 56 (+7 days) after the second vaccination can be applied"
224054201|NCT06956651|OTHER|FIT SA|Self Adhesive Flowable giomer restorative material
224054202|NCT06956651|OTHER|Beautifil Flow Plus F00|Conventional Flowable giomer composite
223443439|NCT03986554|PROCEDURE|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (\< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
223443440|NCT06184139|DRUG|Misoprostol|Oral misoprostol for induction of labor in late term pregnancies
223567400|NCT04033887|DIAGNOSTIC_TEST|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
223567401|NCT01267331|PROCEDURE|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
223567402|NCT01267331|PROCEDURE|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
223567403|NCT03770728|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223567404|NCT03770728|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223567405|NCT03770728|DRUG|Background therapy: Metformin alone or in combination with SU|Pharmaceutical form: tablet Route of administration: oral, administered as per investigator and in accordance with local labeling.
224054203|NCT05498350|PROCEDURE|Ovulatory trigger timing|Timing of medication to induce final oocyte maturation
224054204|NCT03820414|BIOLOGICAL|CRV 101|(Different formulations)
224054205|NCT03820414|BIOLOGICAL|Placebo|2 doses administered IM in deltoid region of non-dominant arm
224054206|NCT03516526|DRUG|Natalizumab|Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
224054207|NCT02861768|BIOLOGICAL|Pharyngeal swab|
223567406|NCT00266214|DRUG|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
223567407|NCT00503776|BEHAVIORAL|exercise intervention|Patients undergo low weight resistance training.
224054208|NCT03870438|DRUG|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight \<8 kg; and 50 mg twice a day if weight \>8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
223443441|NCT00350779|DRUG|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
223443442|NCT00350779|DRUG|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
223443443|NCT00350779|DRUG|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
223443444|NCT00350779|DRUG|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
223443445|NCT00350779|DRUG|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
223443446|NCT00760812|BEHAVIORAL|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
223443447|NCT00760812|BEHAVIORAL|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
223443448|NCT03482895|BIOLOGICAL|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
223443449|NCT03482895|BIOLOGICAL|Feces sampling|Intestinal absorption assessment
223567408|NCT00503776|DRUG|amifostine trihydrate|Given subcutaneously
223567409|NCT00503776|PROCEDURE|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
223567410|NCT03144193|OTHER|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
223567411|NCT04876066|DRUG|Ketamine|Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
223567412|NCT04183127|OTHER|No intervention|ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
223567413|NCT04095351|DIAGNOSTIC_TEST|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
224054209|NCT01329445|OTHER|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
223443450|NCT01053338|DRUG|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
223443451|NCT03337906|OTHER|Observation|
223567414|NCT04095351|DIAGNOSTIC_TEST|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
223567415|NCT04095351|BIOLOGICAL|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
223443452|NCT03464474|DEVICE|digital holographic microscopy|Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
223443453|NCT00588939|DEVICE|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
223443454|NCT02094248|DRUG|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection
223443455|NCT02094248|DRUG|control|Normal saline，1ml/day, s.c injection
223443456|NCT00989859|DEVICE|Plethysmographic monitoring|Plethysmographic monitoring
223443457|NCT02087137|BEHAVIORAL|Memory and Aging Program|
223443458|NCT01979237|PROCEDURE|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
223443459|NCT02012959|DRUG|Tolvaptan|
223443460|NCT01865604|DEVICE|Anodal tDCS|
223443461|NCT01865604|DEVICE|Cathodal tDCS|
223443462|NCT01865604|DEVICE|sham tDCS|
223443463|NCT00726258|DRUG|ketamine|ketamine with various concentrations
223443464|NCT00726258|DRUG|placebo|physiological serum
223443465|NCT00642954|DRUG|Vorinostat|Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
223443466|NCT00642954|DRUG|Lenalidomide|Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
223443467|NCT00642954|DRUG|Dexamethasone|Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
223443468|NCT06262022|OTHER|cold therapy|A cold ice pack will be applied to the patient's knee for 20 minutes every hour for three days, starting after total knee arthroplasty.
223443469|NCT03446118|DIAGNOSTIC_TEST|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
223443470|NCT03257761|BIOLOGICAL|Durvalumab|Given IV
223443471|NCT03257761|DRUG|Guadecitabine|Given SC
223443472|NCT01307384|DEVICE|Continuum Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
223443473|NCT00441363|DRUG|Bromocriptine Mesylate|0.8 mg tablet
223443474|NCT01043094|DRUG|Pitavastatin 4mg|Pitavastatin 4mg single dose
223443475|NCT00006087|PROCEDURE|annual screening|
223443476|NCT00006087|PROCEDURE|bronchoscopic and lung imaging studies|
223443477|NCT00006087|PROCEDURE|comparison of screening methods|
223443478|NCT00006087|PROCEDURE|computed tomography|
223567416|NCT05149651|DRUG|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty is a pre-mixed, bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
224054210|NCT03488173|DRUG|Lansoprazole capsules|"Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order."
224054211|NCT03029715|DRUG|Propofol|Total intravenous anaesthesia.
224054212|NCT03029715|DRUG|Remifentanil|Narcotics
224054213|NCT03029715|DRUG|Dexmedetomidine|Total intravenous anaesthesia
224054214|NCT03029715|DRUG|Desflurane|Inhalation anaesthesia.
223443479|NCT00006087|PROCEDURE|radiography|
223443480|NCT00006087|PROCEDURE|study of high risk factors|
223443481|NCT05513755|PROCEDURE|cardioneuroablation|Endocardical radiofrequency ablation of vagal ganglia located close to pulmonary veins antra and interatrial septum.
223443482|NCT01663857|DRUG|LY2228820|Administered Orally
223443483|NCT01663857|DRUG|Carboplatin|Administered IV
223443484|NCT01663857|DRUG|Placebo|Administered Orally
223443485|NCT01663857|DRUG|Gemcitabine|Administered IV
223443486|NCT04974606|DIETARY_SUPPLEMENT|Cherry-flavored still beverage|10 oz bottle
223443487|NCT04974606|OTHER|Placebo cherry-flavored still beverage|10 oz bottle
223443488|NCT04818723|DRUG|Montelukast|We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
224054215|NCT02386436|DRUG|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
224054216|NCT02386436|DRUG|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume \[w/v\] Sodium Chloride) administered as single dose s.c.
224054217|NCT01270308|DRUG|Lansoprazole|Lansoprazole DR Capsules 30 mg
224054218|NCT00960336|DRUG|pegylated liposomal doxorubicin hydrochloride|
224054219|NCT03427047|DEVICE|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
224054220|NCT03427047|DEVICE|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
223443489|NCT04114656|DRUG|Placebo|Placebo will be available as intravenous (IV) infusion of normal saline (0.9 percent \[%\] sodium chloride solution).
223443490|NCT04114656|DRUG|GSK3858279|GSK3858279 will be available as IV infusion and the dose level to be administered is 3 milligrams (mg) per kilogram (kg).
224054221|NCT02554747|DEVICE|Navigated laser|Aflibercept, Navilas®
223443491|NCT02849210|BIOLOGICAL|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
223443492|NCT02061644|OTHER|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
223443493|NCT04755738|COMBINATION_PRODUCT|Almonertinib plus microwave ablation|Patients were treated with almonertinib firstly.When almonertinib achieved the maximal response, microwave ablation was conducted on the primary lung tumors.
223443494|NCT01399398|PROCEDURE|Brain Scan-PET|
223567417|NCT05149651|DRUG|MTA|ProRoot White MTA® is a bioactive calcium silicate cement which used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy.
223443495|NCT01399398|PROCEDURE|Brain Scan-MRI|
223443496|NCT01399398|PROCEDURE|Arterial Line|
223443497|NCT01399398|PROCEDURE|Venous Line|
223443498|NCT01399398|PROCEDURE|Blood Sampling|
223443499|NCT00761371|DRUG|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
223443500|NCT02542137|RADIATION|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
223443501|NCT02542137|DRUG|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
223443502|NCT01473017|BEHAVIORAL|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
223443503|NCT03548350|BEHAVIORAL|HealthyKidz physical activity programme|A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
223443504|NCT00806858|DEVICE|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
223567418|NCT02778555|BEHAVIORAL|Questionnaires|
223567419|NCT05534659|DEVICE|Programmable valve|Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
223567420|NCT05534659|DEVICE|Non-programmable valve|Non-programmable valve used in the study was Medtronic CSF-flow control valve.
224054222|NCT02554747|DEVICE|Conventional laser|Aflibercept, Pascal
223443505|NCT01304290|OTHER|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
223443506|NCT05777564|OTHER|High intensity exercise|High intensity exercise on a indoor aerobic exercise device.
223443507|NCT05319262|RADIATION|Pink noise exposure|Continuous pink noise sound exposure at 45 dBA, throughout the whole night
223443508|NCT05319262|RADIATION|Traffic noise|120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
223443509|NCT01569698|PROCEDURE|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
223443510|NCT05599386|DIAGNOSTIC_TEST|Preoperative test|Patients are subject to quantitative sensory testing, questionnaires, and biomarker analysis prior to surgery.
223443511|NCT05968430|DRUG|lorundrostat|Tablet, administered orally
223443512|NCT05968430|DRUG|Placebo|Tablet, administered orally
223443513|NCT03052920|DEVICE|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
223443514|NCT00488137|DRUG|Prucalopride|2 mg o.d.
223443515|NCT00488137|OTHER|Placebo|o.d.
223443516|NCT00488137|DRUG|Prucalopride|4 mg o.d.
223443517|NCT01156883|DRUG|asparaginase|
223443518|NCT01156883|DRUG|cyclophosphamide|
223443519|NCT01156883|DRUG|cytarabine|
223443520|NCT01156883|DRUG|daunorubicin hydrochloride|
223741122|NCT05591027|DRUG|Centella asiatica product|A sachet of powdered product containing 4 g of a dried hot water extract of Centella asiatica as the active ingredient, combined with inactive ingredients (excipients) for color and taste dissolved in 10 oz of warm or room temperature water and consumed orally.
224054223|NCT00095875|DRUG|carboplatin|Given IV
224054224|NCT00095875|DRUG|cisplatin|Given IV
224054225|NCT00095875|DRUG|docetaxel|Given IV
223443521|NCT01156883|DRUG|dexamethasone|
223443522|NCT01156883|DRUG|doxorubicin hydrochloride|
223443523|NCT01156883|DRUG|ifosfamide|
223443524|NCT01156883|DRUG|mercaptopurine|
223443525|NCT01156883|DRUG|methotrexate|
223741123|NCT05591027|DRUG|Placebo|A sachet of powdered inactive ingredients (excipients) for color and taste identical in volume to those found in the active arm (CAP) dissolved in 10 oz of warm or room temperature water and consumed orally.
223443526|NCT01156883|DRUG|methylprednisolone|
223443527|NCT01156883|DRUG|prednisone|
223443528|NCT01156883|DRUG|thioguanine|
223443529|NCT01156883|DRUG|vincristine sulfate|
223443530|NCT01156883|DRUG|vindesine|
223741124|NCT06458712|DRUG|DSB2455|PARP1 inhibitor
223741125|NCT04629287|DRUG|KPCXM18|KPCXM18,blind,freeze-dried powder,ascending doses，Intravenous route
223741126|NCT04629287|DRUG|Placebo|Placebo,blind,freeze-dried powder,ascending doses，Intravenous route
224054226|NCT00095875|DRUG|fluorouracil|Given IV
224054227|NCT00822731|DRUG|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
224054228|NCT00766038|DRUG|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
223443531|NCT06094543|BEHAVIORAL|Patient Engagement Tool|8 week daily patient education and engagement tool
223443532|NCT00102154|DRUG|MK0928, gaboxadol / Duration of Treatment: 10 months|
223443533|NCT04730752|DIAGNOSTIC_TEST|Appendicitis Inflammatory Response|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
223443534|NCT04730752|DIAGNOSTIC_TEST|Adult Appendicitis Score|A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
223443535|NCT02915822|PROCEDURE|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
223443536|NCT02915822|PROCEDURE|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
223443537|NCT05682274|PROCEDURE|Partial restoration approach combined with CAF+CTG|The location of the CEJ prior to the restorative treatment was identified using the method developed by Zuchelli et al. 2006. The placement of the apical margin of the restoration was performed either at the level of estimated cementoenamel junction (CEJ) or within 1 mm apical to the CEJ. Two weeks after the restorative treatment, all recession defects were treated with CAF combined with CTG.
223443538|NCT03447106|PROCEDURE|laparotomy|This is a kind of traditional surgical method.
223443539|NCT03447106|PROCEDURE|Laparoscopic|laparoscopic surgery
223443540|NCT03447106|PROCEDURE|Robotic|the Da Vinci robot assisted gastric resection
223443541|NCT04465656|DIAGNOSTIC_TEST|Serology test for COVID-19|"In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed in two parts:~1. ELISA test~2. Rapid Diagnostic tests (only if ELISA test is positive)"
223443542|NCT03175315|BEHAVIORAL|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
224054229|NCT00766038|DRUG|Placebo|SC injection daily
224054230|NCT05679128|DIAGNOSTIC_TEST|identification of the cricothyroid membrane using Palpation|identification of the cricothyroid using PALPATION, a procedure used to prepare for front of neck airway access
224054231|NCT05679128|DIAGNOSTIC_TEST|Identification of the cricothyroid membrane using ultrasonography|identification of the cricothyroid membrane, using ULTRASONOGRAPHY, a procedure used to prepare for front of neck airway access
224054232|NCT05651165|DEVICE|Pharmacoactive balloon angioplasty. Lutonix®|Percutaneous transluminal angioplasty with paclitaxel-coated balloon in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
223443543|NCT04303234|OTHER|Artinibsa|local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.
223443544|NCT04303234|OTHER|Artpharma|Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)
223443545|NCT06069895|DRUG|NNC0113-6856|NNC0113-6856 will be administered as oral tablets.
224054233|NCT05651165|DEVICE|Mimetic stent.Supera®|Multiple intertwined nitinol wires that provide greater radial resistance and allow for even stress distribution. Implanted through percutaneous transluminal angioplasty in the arteriosclerosis site to increase blood-flow to the distal arterial areas.
223443546|NCT06069895|DRUG|Placebo|NNC0113-6856 matching placebo will be administered as oral tablets.
223443547|NCT02720159|DEVICE|Percutaneous Osseintegrated Prosthesis|
223443548|NCT03282591|DRUG|5 mg Serlopitant Tablets|Serlopitant Tablets
223443549|NCT03282591|DRUG|Matching Placebo Tablets|Placebo Tablets
223443550|NCT03627715|DRUG|Propagermanium|Immediate release capsule
223443551|NCT03627715|DRUG|Placebo|Placebo capsule
223443552|NCT01254084|DIETARY_SUPPLEMENT|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
223443553|NCT01254084|DIETARY_SUPPLEMENT|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
223443554|NCT01198535|BIOLOGICAL|Cetuximab|Given IV
223443555|NCT01198535|DRUG|Gamma-Secretase Inhibitor RO4929097|Given PO
223443556|NCT01198535|OTHER|Laboratory Biomarker Analysis|Correlative studies
224054234|NCT05049096|DEVICE|focused power ultrasound mediate inferior perirenal adipose tussue modification|"This novel focused power ultrasound is an externally delivered, completely noninvasive focused therapeutic ultrasound device. It is capable of focusing the resulting ultrasound beam to a small cigar-shaped volume and monitoring the temperature of the target area, which leads to the rapid elevation of the peri-renal adipose tissue temperature and the destruction of target tissue eventually."
224054235|NCT05049096|DEVICE|sham-control group|participants will receive the sham control therapy(including peri-renal fat ultrasonic measurement and localization,focused ultrasound treatment parameters setting),however,without initiating the focused ultrasound equipment.
224054236|NCT05566951|OTHER|Psychosocial program|A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.
223443557|NCT01198535|OTHER|Pharmacological Study|Correlative studies
223443558|NCT00442819|PROCEDURE|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
223443559|NCT03937674|BEHAVIORAL|HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
223443560|NCT04425811|OTHER|kinesiological taping|The kinesiological banding applied to the tibialis anterior muscle was applied to improve walking parameters and compared to sham control.
223443561|NCT00312767|DRUG|Fabrazyme (agalsidase beta)|
223443562|NCT00214656|DRUG|Recombinant Activated Factor VII|
223443563|NCT01241331|DRUG|BLI1100|BLI110 topical cream
223443564|NCT01241331|DRUG|Vehicle cream|Vehicle topical cream
223443565|NCT03110081|PROCEDURE|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
223443566|NCT03110081|PROCEDURE|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
224054237|NCT05566951|OTHER|Standart care|Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
223443567|NCT00633490|DRUG|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
223443568|NCT05162430|DRUG|Propofol|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
223443569|NCT03941028|DEVICE|3D printed titanium implant|The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
223443570|NCT02674126|BEHAVIORAL|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
223443571|NCT02674126|BEHAVIORAL|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
223443572|NCT00940576|DIETARY_SUPPLEMENT|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
223443573|NCT00940576|OTHER|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
223443574|NCT02824211|DEVICE|Right Dose System|Automated titration of oxygen system during exertion
223443575|NCT04987931|DRUG|Talazoparib|This retrospective chart review study focuses on patients with HER2- ABC with gBRCA1/2m initiating talazoparib on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
223443576|NCT02435563|DRUG|ticagrelor 180 mg administrated alone|
223443577|NCT02435563|DRUG|Ticagrelor adjusted dose + ritonavir 100mg|
223443578|NCT02624154|PROCEDURE|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
223443579|NCT03090503|DRUG|Aripiprazole|Initial dose: 10 mg.
223443580|NCT03090503|DRUG|Risperidone|Initial dose: 2 mg.
223443581|NCT03038711|DRUG|BMS-986166|Specified dose on specified days
223443582|NCT03038711|OTHER|Placebo matching BMS-986166|Specified dose on specified days
223443583|NCT06397053|PROCEDURE|robotic surgery|robotic surgery
223443584|NCT05382429|PROCEDURE|OWHTO|OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.
223443585|NCT05382429|PROCEDURE|CWHTO|CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
224145645|NCT04260659|DRUG|Dexmedetomidine Hydrochloride [Dexdor]|Initial dosis of dexmedetomidine 1 mcg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 1 mcg/kg IBW / h will be initiated and continued until the end of operation.
223741127|NCT02519920|DRUG|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
223741128|NCT02519920|DRUG|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
223741129|NCT02519920|DRUG|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
223741130|NCT02519920|DRUG|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
223741131|NCT04221685|OTHER|Artpharma|ArtPharma is a unique amide local anesthetic that is currently Used in dentistry Amides has taken over their predecessors esters with their enhanced performance.Each ml Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg
223741132|NCT04221685|OTHER|Artinibsa|"Powerful local anaesthetic with a short latency time.~Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains:~Articaine (D.C.I) 40.00 mg hydrochloride, Epinephrine (D.C.I) (tartrate) 0.01 mg"
223741133|NCT04408846|DEVICE|Lumbar fusion|Patients will receive a single level instrumented fusion using a minimally invasive or open traditional surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either minimally invasive or open.
224054238|NCT03284671|OTHER|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
223443586|NCT01130324|DRUG|VIBATIV|Observational
223443587|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (active)|The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
223741134|NCT03048396|PROCEDURE|Uterus transplantation|
223741135|NCT04884711|OTHER|No Interventions. Participants will be using their everyday digital health technologies.|The investigators will be involving older people to understand the barriers \& facilitators of digital health technology adoption for homebound older people. In this process no interventions will be given by us.
223741136|NCT04884711|OTHER|In depth Interviews|In-depth interviews will be conducted to gather lived experiences of homebound older people.
223741137|NCT04884711|OTHER|Focus Group Discussions|Focus Group Discussions will be used to create avenues to enhance dignity and human perspectives in digital designs for older people.
223741138|NCT05132621|DIAGNOSTIC_TEST|Smear|A smear of the posterior vaginal fornix collected with a gynecological speculum.
224145646|NCT04260659|DRUG|Remifentanil [Ultiva]|Remifentanil TCI Minto Model will be used during induction in dosis 6 ng/ml and intraoperatively appropriately to maintain hemodynamical stability.
223443588|NCT06008431|DEVICE|Transcranial direct current stimulation (tDCS) (Sham)|"The tDCS Acti- Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest."
223443589|NCT04512352|OTHER|Online curriculum|"The psychologist and our advisory team had successfully developed a total of 100 hours of parenting curriculum.~The adopted curriculum had focused on using play to facilitate parents in promoting their children's development in cognitive, motor, emotional and social aspects. Play-based activities are instrumental in improving children's development. Given that parents in poverty had difficulties spending time and money travelling back-and-forth to the training site and their homes, the research team decided to use e-learning as the medium of learning for our parenting programme. Web-based learning has the advantage of cutting time and travelling costs, which are luxuries to many parents in poverty."
223443590|NCT03928275|BIOLOGICAL|Interleukin-2|IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
224054239|NCT02681536|DRUG|Triptorelin|
224054240|NCT02681536|DRUG|Combined oral contraceptive pills|
223443591|NCT03928275|BIOLOGICAL|Combination therapy Interleukin-2 and Bacillus Calmette Guerin|"BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions)."
224054241|NCT02681536|DRUG|HMG|
224054242|NCT04481984|OTHER|Home-based Hand exercise|"Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day."
224054243|NCT04481984|OTHER|Care advice|Patients received care advice including avoiding cold exposure and trauma.
224054244|NCT02998775|DRUG|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
224145647|NCT04260659|DRUG|Ketamine [Ketalar]|Ketamine 0,5mg/kg IBW iv will be administered during induction of general anesthesia.
224145648|NCT04260659|DRUG|Lidocaine [Xylocaine 2%]|Initial dosis of lidocaine 1,5 mg/kg IBW iv will be administered within 10 minutes before general anesthesia induction. Following intubation infusion of 3 mg/kg IBW / h will be initiated and continued until the end of operation.
223443592|NCT02290119|DEVICE|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofemoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
223443593|NCT02290119|PROCEDURE|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
223443594|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
223567421|NCT02379988|RADIATION|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
224054245|NCT06080828|DEVICE|Percutaneous Posterior Tibial Nerve Stimulation|20 minutes of neuromodulation of the posterior tibial nerve of both lower limbs using Physio Go-lite electrical stimulation device (made by ASTAR in Poland, ver 1.0.2 in Poland). Using Transcutaneous Electrical Nerve Stimulation (TENS) current in the device, the positive electrode will be placed posterior to the medial ankle malleolus, and the negative electrode will placed ten centimeters away on the leg along the tibial nerve path. The TENS current parameters will be 200 microsecond pulse width, 10 Hz frequency, and intensity according to participant tolerance ranging between (10 - 50 mA) that increased gradually until visible movement in the big toe or fanning of toes will be noticed. The therapy sessions will be given three times a week, every other day, for a total of twelve sessions.
224054246|NCT06080828|DEVICE|Placebo Percutaneous Posterior Tibial Nerve Stimulation|placebo neuromodulation of the posterior tibial nerve in both lower limbs, much as those in the research group.
224054247|NCT06080828|BEHAVIORAL|Home instructions|they will receive leaflet with information for home instructions on how to properly walk, sleep, maintain good posture, and deal with activities of daily living.
224054248|NCT04701138|DIETARY_SUPPLEMENT|SPM Active|Each capsule contains 145 mg of SPMs (fractionated marine lipids standardized to 18-HEPE, 14-HDHA, and 17-HDHA). All subjects will take 4 capsules orally each day for a total daily dose of 580 mg.
223567422|NCT00260767|DRUG|HEC placebo gel|
223567423|NCT02390440|DRUG|EXPAREL|
223567424|NCT01213459|PROCEDURE|Cervical samples|Human papillomavirus detection and typing in cervical samples.
223567425|NCT01213459|OTHER|Data collection|Questionnaire completion
223567426|NCT03309319|DRUG|Rosiglitazone|rosiglitazone is added to the primary treatment
223567427|NCT03135158|OTHER|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
223567428|NCT06205355|DEVICE|Analgesia/Nociception Index (ANI) monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to ANI monitor.
224054249|NCT01973712|PROCEDURE|Locked Compression Plating|
224054250|NCT01973712|PROCEDURE|Retrograde Intramedullary Nailing (RIMN)|
224054251|NCT00767052|DRUG|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
224054252|NCT00767052|DRUG|Placebo|Placebo tablet matching to the active in multiple dose part.
223567429|NCT06205355|DEVICE|Standard monitoring|intraoperative analgesia was provided by infusion of remifentanil via target controlled infusion mode, which was controlled according to the clinician's decision
223567430|NCT01727648|BEHAVIORAL|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
223567431|NCT01727648|BEHAVIORAL|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
223567432|NCT01727648|BEHAVIORAL|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
223567433|NCT01727648|BEHAVIORAL|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
224054253|NCT00767052|DRUG|AZD1236|75mg single dose will be administered in relative bioavailability part.
224054254|NCT00767052|DRUG|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
224145649|NCT04260659|DRUG|Magnesium Sulphate [Inj. Magnesii Sulfurici Polpharma]|Magnesium Sulphate will be administered in dosis 50 mg/kg IBW iv intraoperatively.
223567434|NCT00639041|DIETARY_SUPPLEMENT|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
223567435|NCT00639041|DIETARY_SUPPLEMENT|Placebo|dairy products without special oils
223567436|NCT00531557|DRUG|Darunavir ritonavir|
224145650|NCT04260659|DRUG|Fentanyl [Fentanyl WZF]|Rescue dosis of 100 mcg iv will be administered if hypertension \> 140/90 mmHg or tachycardia \> 120min occurs. If necessary rescue dosis may be repeated.
224054255|NCT04678570|OTHER|White Noise|"The infants will be listened to a song Called  Bebeginiz Aglamasin from Orhan Osman's colic album which was prepared with the help of Dr. Harvery Karp's ''The Happiest Baby'' album through a portable speaker located at 50 cm away from the infant at 55-decibel frequency.~Listening to this song will start 5 minutes before the insertion of the Orogastric Tube, will continue during the procedure and another 5 more minutes after the procedure is completed. The rest of the noise in the environment will be controlled."
223443595|NCT04404049|BIOLOGICAL|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
223443596|NCT03670511|OTHER|sit-to-stand test|to sit and stand from a chair
223443597|NCT03670511|OTHER|six minute walking test|to walk for six minutes
223443598|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 20 mg|Patients assigned to experimental group are treated with Lipilou® 20 mg
223443599|NCT04511000|DRUG|Lipilou®(generic atorvastatin drug) 10 mg|Patients assigned to comparator group are treated with Lipilou® 10 mg
223443600|NCT03309228|OTHER|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
223443601|NCT05445388|DEVICE|Aurisvue|OCT imaging of the middle ear
223443602|NCT01717157|DRUG|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
223443603|NCT01717157|DRUG|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
223443604|NCT01717157|DRUG|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
223443605|NCT01717157|DRUG|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
223443606|NCT01717157|DRUG|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
223443607|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
223443608|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and absence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the D-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
223567437|NCT06178848|DRUG|propofol group|During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
223567438|NCT06178848|DRUG|remimazolam group|The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
224054256|NCT04678570|OTHER|Swaddling Method|The preterm infants will be placed in the supine position on a 90 cm2 soft cloth. The upper edge of the cloth will be aligned with the infant's shoulder, with the arms placed close to the body, with the horizontal ends of the cloth folded in the opposite direction to cover the top of the body. The arms will be put into flexion and the body will be covered with a cloth. In order not to limit the movements of all limbs of the preterm infant, attention will be paid to leave a finger space between the infant and the cloth cover and to leave a suitable space for the feet to be comfortable before folding the lower part of the cloth cover forward. In the swaddling method, the baby's head can move freely. The swaddling method will be applied approximately 5-10 minutes before the procedure and will be removed from the infant 5 minutes after the procedure. Because swaddling will increase the body temperature of the infant, the standard temperature of the incubator will be lowered.
224054257|NCT04163796|DEVICE|UPnRIDE power wheelchair|The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
224054258|NCT03682679|DIAGNOSTIC_TEST|Sonoelastography|This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly. Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography and the region of interest (ROI) would be divided into four quadrants. The physicians will measure the shear wave velocity at the center point of each quadrant.
223567439|NCT00004495|DRUG|cyanocobalamin|
223567440|NCT00004495|DRUG|folic acid|
223567441|NCT00004495|DRUG|pyridoxine|
224054259|NCT01258244|OTHER|Audiovisual Feedback|EMTs will get audiovisual feedback on CPR technique during CPR
224054260|NCT02950090|BEHAVIORAL|MobilWise|see arm description for MobilWise above
224054261|NCT02950090|BEHAVIORAL|Fitbit Only|see arm description for Fitbit above
223443609|NCT05211908|PROCEDURE|Composite resin restoration with Self Etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SE group, the universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
223443610|NCT05211908|PROCEDURE|Composite resin restoration with Seletive enamel etch adhesive protocol and presence of sclerotic dentin|"The adhesive system Single Bond Universal (3M Oral Care; Brazil) and a nanoparticulate composite resin Z350 XT (3M Oral Care; Brazil), shade A3B, will be the materials used in the restorative procedures.~For the SD-SELETIVE group a 37% phosphoric acid will be applied only at the enamel margin for 15s, then rinsed with water for 20s, and slightly dry. The universal adhesive system will be applied with a disposable microbrush, actively, for 20s and then a gentle stream of air will be used for 5s to solvent evaporation, followed by light curing for 10s using the Valo Cordless light curing (Ultradent Products Inc.), in Standard mode (1000mW /cm2).~All groups will receive the restorations made following the incremental technique of insertion of composite resin (2mm per increment), which will be light cured according to the manufacturer's recommendations."
223443611|NCT01722032|OTHER|Childhood Obesity|
223443612|NCT03326518|DIAGNOSTIC_TEST|Lumentin® 44|Contrast agent
223443613|NCT03326518|DIAGNOSTIC_TEST|Diluted Omnipaque®|Contrast agent
223443614|NCT03326518|DIAGNOSTIC_TEST|Movprep®|Contrast agent
223443615|NCT02400892|OTHER|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
224054262|NCT05549700|OTHER|Neuromodulation|Ultrasound-guided percutaneous neuromodulation will be applied. The protocol used was 5 seconds of stimulation, 55 seconds of rest for 5 minutes at a frequency of 100 Hz and a phase duration of 350 microseconds
224054263|NCT03151863|DRUG|Opioids|The usual opioid treatment used for nursing care
223443616|NCT06124651|PROCEDURE|Total knee replacement with cruciate retaining femoral component|To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate a metallic implants. Implants are fixed to patients' bone with bone cements. Many designs for femoral component designs are available. In the present study, two types of implants, one CR(cruciate retaining), where the posterior cruciate ligaments are retained, and one PS(Posterior cruciate substituting), where the posterior cruciate ligaments are resected, will be compared. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component design remains the same and the tibial component remains the same. Only the cruciate ligament parts are different. For this arm of intervention, CR knee will be used, so posterior cruciate will remain intact after the surgery and still function to aid in the knee stability.
223567442|NCT01242410|DEVICE|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
223567443|NCT01900301|DRUG|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
224054264|NCT03151863|DRUG|Dexmedetomidine|Dexmedetomidine is provided intranasally
224054265|NCT03151863|DRUG|Placebo|Normal saline is either given subcutaneously or intranasally
224054266|NCT03743311|PROCEDURE|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
224054267|NCT03743311|DRUG|Detralex|Conservative treatment of Hemorhoid
224054268|NCT03743311|OTHER|Combined therapy|Surgical + conservative treatment of Hemorhoid
224054269|NCT00003281|DRUG|paclitaxel|
224054270|NCT00003281|DRUG|topotecan hydrochloride|
224054271|NCT00003281|RADIATION|radiation therapy|
224145651|NCT05820620|PROCEDURE|TAP block|The transversus abdominis plane (TAP) block was introduced as a landmark-guided technique via the triangle of Petit to achieve a field block. It involves the injection of a local anesthetic solution into a plane between the internal oblique muscle and transversus abdominis muscle.
223567444|NCT01900301|DRUG|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
223567445|NCT04053946|DEVICE|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
224054272|NCT00748280|PROCEDURE|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
224054273|NCT00748280|PROCEDURE|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
224054274|NCT04272840|BEHAVIORAL|Low Glycemic Index Education|Educational materials layering Glycemic Index education onto Canada's Food Guide and Diabetes Canada recommendations.
224054275|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
224054276|NCT01251653|DRUG|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
224054277|NCT01251653|DRUG|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
224054278|NCT01251653|DRUG|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
224054279|NCT01825291|PROCEDURE|CPAP treatment|
223443617|NCT06124651|PROCEDURE|Total knee replacement with cruciate substituting femoral component|"To perform the total knee replacement, the knee joint is anatomically dissected, and thin portions of bone and cartilage is resected to accommodate metallic implants that has similar contours of a native knee. Implants are fixed to patients' bone with bone cements. This procedure will use the femoral component that sacrifice the posterior cruciate ligament and having a box area with a post, so that cam-post mechanism of implants can mimic the function of the posterior cruciate ligament. To make the comparison more reliable, the same kind of implants will be used, so that the major portions of femoral component remains the same. The tibial component will remain the same design. Therefore, only the cruciate ligament parts will be different."
223443618|NCT06252467|DEVICE|Photobiomodulation Therapy|"Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study."
223741139|NCT05601310|DEVICE|liquid chromatography-mass spectrometry (LC/MS) analysis|To obtain a complete metabolic profile, untargeted metabolomics analysis was conducted by using UPLC-MS. Chromatographic separation was accomplished in an Thermo Vanquish system equipped with an ACQUITY UPLC®HSS T3 (150×2.1 mm, 1.8 µm, Waters, USA) column maintained at 40 ℃. The temperature of the autosampler was 8 ℃. The ESI-MSn experiments were executed on the Thermo Q Exactive mass spectrometer with the spray voltage of 3.5 kV and -2.5 kV in positive and negative modes, respectively. The capillary temperature was 325℃. The analyzer scanned over a mass range of m/z 81-1 000 for full scan at a mass resolution of 70 000. The normalized collision energy was 30 eV(19606840). The detected ions were all under isotopic calibration with the accurate masses of the reference standards.
223443619|NCT06252467|DEVICE|Placebo Photobiomodulation|The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
223443620|NCT02653898|DRUG|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
223443621|NCT02653898|DRUG|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
223443622|NCT02653898|DRUG|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
223567446|NCT04193345|OTHER|Documentation of Maternal blood loss and neonatal outcome|Comparing and monitoring the maternal blood loss and neonatal effect of delayed umbilical cord clamping and early umbilical cord clamping after delivery of the baby durin cesarean delivery in severe preeclampsia
223567447|NCT01794741|DRUG|Dymista Nasal Spray|
223567448|NCT01794741|DRUG|Fluticasone propionate nasal spray|
223567449|NCT02089464|DEVICE|NBS-guided rTMS|
223567450|NCT02089464|DEVICE|Sham rTMS|
223567451|NCT02089464|PROCEDURE|Task oriented rehabilitation|
223567452|NCT05263986|DRUG|MRTX849|"Approximately 18-24 patients to ensure at least 12 PK evaluable patients.~Subjects will be administered a single oral dose of 600 mg MRTX849 in PK lead in D1, and will start the dosing regimen of 600 mg BID orally from C1D1."
223567453|NCT04969965|DRUG|aumolertinib|EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
223567454|NCT05427539|DEVICE|TEST LENS|AO1DfA manufactured with PG hydration
223567455|NCT05427539|DEVICE|CONTROL LENS|AO1DfA manufactured with IPA hydration
223567456|NCT05576168|BIOLOGICAL|overexpression STRA6/miRNA3|RBP4 express in patients with T2DM or not
223741140|NCT04924829|DRUG|Tocilizumab|Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
223741141|NCT04345757|BEHAVIORAL|Structured exercise|The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
223741142|NCT03491618|OTHER|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
224145652|NCT05820620|PROCEDURE|QLB block|"Quadratus lumborum block is a block of the posterior abdominal wall, interfascial plane block, which is performed exclusively under ultrasound guidance. It was described as a variant of the TAP block."
224145653|NCT05820620|OTHER|Control Group|Control Group + Patient Control Analgesia (PCA)
224145654|NCT00984880|DRUG|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
223567457|NCT03103204|COMBINATION_PRODUCT|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
223567458|NCT01317576|BEHAVIORAL|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
223567459|NCT03130387|DEVICE|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
224145655|NCT04955002|OTHER|No intervention|No intervention
224145656|NCT00003091|BIOLOGICAL|aldesleukin|
223443623|NCT02653898|DRUG|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
224054280|NCT04876170|OTHER|Brain-computer-interface: EEG-based musical Neurofeedback task|Neurofeedback training with EEG, in which participants are presented with self-selected music and requested to make the presented music sound better by applying mental strategies. Six repeated training sessions, each composed of five training cycles. Each cycle is composed of 120 sec of 'local baseline' block and 90 sec of 'regulation' block while listening to self-selected music. Participants are instructed to passively listen to their self-selected music during the 'local baseline' block, and to 'make the music sound better' during the 'regulation' block. Participants are instructed to recruit chosen mental strategies, which they find to be most efficient towards this regulatory task. During 'regulation', the quality of the sound varies in real-time (every 3 sec) in proportion to the difference between the current value of VS-EFP and its average value during 'local baseline'.
224054281|NCT02268279|DRUG|solithromycin|
223443624|NCT02030886|DEVICE|Sensimed Triggersfish® (TF)|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
223443625|NCT04786366|OTHER|The study does not have an intervention, but observe the AF incidence of the UK disease-free population|The study does not have an intervention, but observe the AF incidence of the UK disease-free population.
223443626|NCT02303834|DEVICE|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
223443627|NCT01375374|DRUG|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
223443628|NCT01375374|DRUG|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
224054282|NCT03731650|PROCEDURE|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
224054283|NCT04268251|DIAGNOSTIC_TEST|MRI with deep learning based denoising|1-mm coronal contrast-enhanced T1 weighted image with deep learning based denoising
224054284|NCT00847145|BIOLOGICAL|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
224054285|NCT00847145|BIOLOGICAL|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
224054286|NCT00847145|BIOLOGICAL|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
224054287|NCT00847145|BIOLOGICAL|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
224054288|NCT00847145|BIOLOGICAL|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
224054289|NCT00847145|BIOLOGICAL|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
223443629|NCT05948332|BEHAVIORAL|Delphi Rounds to generate consensus opinions among Experts|The Investigators (Steering Committee) will select the experts from across the globe based on pre-specified qualification criteria and will conduct iterative Delphi rounds to generate consensus on the definition and management of acute RVI in patients with receiving V-V ECMO, among the Experts. The selection criteria will be self-assessed through a survey among the potential Experts.
223443630|NCT02550925|BEHAVIORAL|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
223567460|NCT01935583|BEHAVIORAL|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
223567461|NCT04440397|OTHER|xbp-1 - endometriosis patients group|Patients diagnosed with endometriosis by surgery and ultrasound and whose xbp-1 level was examined
223567462|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
223567463|NCT00223977|DRUG|Sodium Ferric Gluconate Complex|250 mg weekly x 4
223567464|NCT00223977|DRUG|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
224054290|NCT00847145|BIOLOGICAL|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
224054291|NCT00847145|BIOLOGICAL|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
224054292|NCT04617951|DIETARY_SUPPLEMENT|Ishige Okamurae extracts group|Ishige Okamurae extracts 300 mg/day for 12 weeks
224054293|NCT04617951|DIETARY_SUPPLEMENT|Placebo group|Placebo 300 mg/day for 12 weeks
224054294|NCT01012791|OTHER|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
224145657|NCT00003091|BIOLOGICAL|recombinant interferon alfa|
224145658|NCT05596786|DRUG|Rituximab|One course of IV rituximab consisting of a first infusion of 1000 mg (500 mL solution) rituximab (day 1), and a second infusion of 1000 mg (500 mL solution) rituximab two weeks later (day 15)
223443631|NCT02550925|BEHAVIORAL|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
223443632|NCT01734083|DEVICE|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
223443633|NCT01734083|BEHAVIORAL|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
223443634|NCT06075043|DRUG|AND017|Oral administration of AND017 capsules three times per week
224145659|NCT05596786|OTHER|Placebo|One course of IV placebo of rituximab consisting of a first infusion of 500 mL of saline (0.9% sodium chloride) infusion (day 1), and a second infusion of 500 mL of saline infusion two weeks later (day 15)
223443635|NCT00621998|DRUG|risperidone|0.5-6 mg/day
223443636|NCT00621998|DRUG|olanzapine|2.5-20 mg/day
223443637|NCT04019262|RADIATION|Radiation Therapy|Radiation
224054295|NCT03075800|BEHAVIORAL|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
223443638|NCT04019262|DRUG|Temozolomide Oral Product|Oral Temozolomide (150mg/m\^2 or 75 mg/m\^2)
223443639|NCT03135574|DIAGNOSTIC_TEST|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
223443640|NCT00039481|BIOLOGICAL|oblimersen sodium|Given IV
223567465|NCT00527683|DRUG|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
224145660|NCT03129412|RADIATION|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
223567466|NCT00527683|DRUG|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
224054296|NCT06206174|DRUG|TGRX-814|Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
224054297|NCT05554484|BIOLOGICAL|Autologous peripheral blood-derived tolerogenic dendritic cells|AMI-DC, autologous dendritic cell product Inject 7.5 x 106 cells hypodermically to 1\~4 sites in the left axillary lymph node between 5-7 days after PCI and 12-14 days after PCI. . The administration must be done within 30 minutes after fully liquified.
224145661|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
224145662|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
223567467|NCT00527683|BEHAVIORAL|Group therapy|Participants attend group sessions once a week
223567468|NCT03267719|DEVICE|laser therapy|Transvaginal erbium-laser treatment
223567469|NCT02864186|DEVICE|control|Women wont use support bra 24 hours a days for six months
223567470|NCT02864186|DEVICE|surgical support bra|Women will use surgical support bra 24 hours a day for six months
223567471|NCT02864186|DEVICE|common support bra|Women will use common support bra 24 hours a day for six months
223567472|NCT04449393|DEVICE|Emdogain® FL|Emdogain® FL is an enamel matrix derivative intended for subgingival and topical application in conjunction with scaling and root planing procedures to provide regeneration of tooth support lost due to periodontal disease. Emdogain® FL has been shown to be effective in residual pockets with probing depths from 5mm to 9mm with no furcation involvement in patients with adequate plaque control. Emdogain® FL has also been shown to enhance the early healing of periodontal soft tissue wounds resulting from the instrumentation of periodontal pockets.
223567473|NCT04449393|OTHER|Scaling and root planing|Scaling and root planing procedures as part of non-surgical periodontal therapy involves mechanical removal of dental plaque and calculus using curettes and sonic scalers.
224054298|NCT02455570|OTHER|No intervention|No intervention
224054299|NCT01798589|DRUG|Ethylenediamine dihydrochloride allergen patch|1 allergen panel containing 2 allergen and 2 control patches
224054300|NCT04161820|BEHAVIORAL|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
224054301|NCT04012554|PROCEDURE|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
224145663|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
224145664|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
224145665|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
224145666|NCT06621654|BIOLOGICAL|Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine|4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
224145667|NCT06621654|BIOLOGICAL|Haemophilus Influenzae Type b Conjugate Vaccine|4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection
224145668|NCT02209649|DRUG|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
224145669|NCT02209649|DRUG|Lacidipine|
224145670|NCT02209649|DRUG|Telmisartan|
224145671|NCT04007913|BEHAVIORAL|teleCBIT|Eight sessions of individual behavior therapy
224145672|NCT04965506|DRUG|IBI362|IBI362 administered subcutaneously (SC) once a week.
224145673|NCT04965506|OTHER|placebo|placebo administered subcutaneously (SC) once a week.
223443641|NCT00039481|DRUG|dexrazoxane hydrochloride|Given IV
223443642|NCT00039481|DRUG|doxorubicin hydrochloride|Given IV
223443643|NCT00039481|DRUG|cyclophosphamide|Given IV
223443644|NCT00039481|BIOLOGICAL|filgrastim|Given SC
223443645|NCT00039481|OTHER|laboratory biomarker analysis|Correlative studies
223443646|NCT00039481|OTHER|pharmacological study|Correlative studies
223443647|NCT00003902|DRUG|capecitabine|
223443648|NCT00003902|DRUG|vinorelbine tartrate|
223443649|NCT06040671|OTHER|Vectra M3 imaging|Study subjects from both arms will undergo Vectra M3 imaging to evaluate the result of the surgery.
223443650|NCT00109941|BIOLOGICAL|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
223443651|NCT00109941|BIOLOGICAL|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
223443652|NCT02776540|DRUG|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
223567474|NCT01715350|DRUG|PM012|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
224054302|NCT04012554|PROCEDURE|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
224054303|NCT02833974|DRUG|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
224054304|NCT02833974|DRUG|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
224054305|NCT06236477|BEHAVIORAL|Personalized Music|Music that is familiar to the child will be played via bluetooth speaker throughout their immediate perioperative care
224145674|NCT04965506|OTHER|Dulaglutide|Dulaglutide administered subcutaneously (SC) once a week.
224145675|NCT01922245|DEVICE|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
224145676|NCT06055127|PROCEDURE|osseodensifiction internal sinus lift / sticky bone graft material|"The osteotomy for the osseodensification internal sinus lift begins with a twist drill advanced at 800 rpm with saline irrigation to within 1-2 mm from the sinus floor. Next, a series of osteotomy drills are used in the same fashion at 800 rpm to widen the osteotomy. The final osteotomy drill is advanced with gentle pressure at 100 rpm counterclockwise without irrigation until a bouncing sensation occurs haptic feedback at this point infracture of the sinus has taken place. After infracture, injection of the graft material into the osteotomy site will occur. The final osteotomy drill is used to guide the graft apically. This process is repeated in an incremental fashion to lift the membrane. Once enough space has been created below the antral membrane, implant insertion will occur then suturing."
223443653|NCT02776540|DRUG|Aspirin|there's another group will receive 400 mg Aspirin
223443654|NCT02065518|DEVICE|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
223567475|NCT01715350|DRUG|Placebo|"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"
223567476|NCT06425809|OTHER|Observation|The data collection will be carried out by the two researchers, in accordance with current data protection regulations, scrupulously complying with the anonymous collection of clinical data, and without collecting any data that could allow the identification of the athletes whose data are collected. The members of the research group will not have access to personal data that could facilitate the identity of any person on the basis of the data collected. The data collected in this study, anonymised from the outset, will be exported to an Excel file. Access to the Excel file will require password access and will be managed from a computer of the University of Oviedo (Department of Surgery and Medical-Surgical Specialities).
223567477|NCT00934947|DRUG|Propranolol|40 mg
223567478|NCT00934947|DRUG|Placebo|sugar pill
223567479|NCT00934947|DRUG|Propanolol|120 mg twice per day
223567480|NCT00410826|DRUG|erlotinib hydrochloride|Given orally
223567481|NCT00410826|DRUG|cisplatin|Given IV
223567482|NCT00410826|RADIATION|3-dimensional conformal radiation therapy|35 fractions
223567483|NCT00410826|RADIATION|intensity-modulated radiation therapy|35 fractions
223567484|NCT00410826|PROCEDURE|quality-of-life assessment|Ancillary studies
223567485|NCT00839462|DRUG|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
223567486|NCT00839462|DRUG|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
223567487|NCT01299857|DRUG|Rituximab|375mg/m2
224054306|NCT06236477|BEHAVIORAL|No Music|Participants will receive standard care without music.
224054307|NCT05068570|OTHER|ARMEROMTERY|ARMERGOMTERY TRAINING FOR UPPERLIMB
224054308|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (1)|Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
224054309|NCT04289337|DIETARY_SUPPLEMENT|Combined probiotics (2)|Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
224054310|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (1)|Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
224054311|NCT04289337|DIETARY_SUPPLEMENT|Combined heat-killed probiotics (2)|Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
224054312|NCT04289337|DIETARY_SUPPLEMENT|Probiotic metabolites|Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
224054313|NCT04289337|DIETARY_SUPPLEMENT|Placebo|Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
223567488|NCT04314999|DIAGNOSTIC_TEST|Examination of stool samples|Tests for diagnosis of parasitic diseases
223567489|NCT01907321|BEHAVIORAL|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
223567490|NCT01907321|BEHAVIORAL|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
223567491|NCT01907321|DRUG|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
223567492|NCT01907321|BEHAVIORAL|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
224054314|NCT06379386|PROCEDURE|Transcatheter aortic valve replacement|A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years
223443655|NCT02065518|BEHAVIORAL|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
223443656|NCT02065518|BEHAVIORAL|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
223443657|NCT05621707|DRUG|chemotherapy combined with PD-1 inhibitors|Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
223443658|NCT04095299|RADIATION|50.4 Gy to the tumor and elective volume|Standard radiotherapy
223443659|NCT04095299|RADIATION|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
223443660|NCT04095299|DRUG|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
223443661|NCT05642572|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223443662|NCT05642572|DRUG|Capmatinib|Given PO
223443663|NCT05642572|PROCEDURE|Computed Tomography|Undergo CT scan
223443664|NCT05642572|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223443665|NCT05642572|DRUG|Osimertinib|Given PO
223567493|NCT01907321|RADIATION|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
224054315|NCT03906097|OTHER|Play and Competition-Based Cognitive Therapy|The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
224054316|NCT02145286|RADIATION|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
224054317|NCT03650842|DEVICE|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
223443666|NCT05642572|BIOLOGICAL|Ramucirumab|Given IV
223443667|NCT04055649|DRUG|Akt/ERK Inhibitor ONC201|Given orally (PO)
224163996|NCT03418376|OTHER|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax\*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
223443668|NCT04055649|DRUG|Paclitaxel|Given IV
223443669|NCT04055649|OTHER|Questionnaire Administration|Ancillary studies
223443670|NCT05429619|OTHER|PeerOnCall|A mobile health peer-to-peer support platform that consists of two inter-connected apps: PeerOnCall and PeerOnCall Support. The apps were co-designed by and for the public safety community in Canada, with customized content for correctional workers, emergency communicators, firefighters, paramedics and police.
223443671|NCT04849416|DRUG|LOXO-305|Administered orally.
223443672|NCT05666479|DEVICE|Dexcom G6 Pro Continuous Glucose Monitor (CGM)|"A DexCom G6 CGM will be implanted on the subject's abdomen contralateral to the surgical site (i.e. left abdomen for right knee or right hip replacements) no less than 30 cm from the surgical site. This CGM shall be termed primary for study purposes. Subjects will wear the primary DexCom G6 CGM for the entirety of the following 10-day timeline: 3/4-days pre-operative, day of hip or knee replacement surgery, and 5/6-day postoperative recovery.~A second CGM will be implanted in subjects postoperatively while in the Post Anesthesia Care Unit (PACU). This CGM, termed secondary for study purposes, will be implanted immediately adjacent to the primary CGM. Subjects will wear the secondary DexCom CGM for the 7 days: day of hip or knee replacement surgery (postoperatively) and 5/6-day postoperative recovery."
223443673|NCT03798327|BEHAVIORAL|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
223443674|NCT06101095|DRUG|Dupilumab|Subcutaneous injection (SC) as per protocol
223443675|NCT06101095|DRUG|Placebo|SC injection as per protocol
223443676|NCT06038149|DIAGNOSTIC_TEST|Transthoracic echocardiogram|A painless ultrasound scan of the heart.
223443677|NCT04716153|OTHER|Multifactorial sensory rehabilitation workshops|A multifactorial sensory rehabilitation Workshops : a multifactorial program in order to optimize the recovery of flavors, focused on smell and taste which integrates several non-drug interventions, which are part of the current recommendations: hydration of the mucous membranes with daily (3 times a day) liposomal sprays (nose and mouth), presentation of visual dishes.
223443678|NCT04716153|OTHER|Usual care|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
223443679|NCT04716153|OTHER|Tests and Questionnaire|fulfillment of Taste Strips Test, Sniffin'sticks test and QGO, FACT-G, HADS, l'EVA des ingesta and GPAQ questionnaires to assess the quality of life of patients
224054318|NCT04171375|DEVICE|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
223443680|NCT06114056|BIOLOGICAL|JWK007 Single intravenous infusion administration|"Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient."
224054319|NCT00790686|PROCEDURE|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
223443681|NCT01690195|DRUG|ABT-126|See arm description
223443682|NCT05560698|OTHER|Motivation-enhancing intervention|The web app is designed as an efficient and easy-to-use app configurable to personal preferences. Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. The questionnaire addresses the same questions as the questionnaire in the standard intervention, but the format is different, and some shortcuts makes it easier to answer. When the questionnaire is answered, the web app gives access to different features. The following features distinct the motivation-enhancing intervention from the standard intervention (1) only complete the entire questionnaire on days with symptoms, (2) integration of grass pollen counts and forecasts, (3) showing personal response rate, (4) access to own data via a graph, (5) advice against grass pollen allergy, (6) status of the study, (7) individually choosing the time of response, (8) option to download an icon for the home screen and (9) contact information. The development is an ongoing iterative process
223443683|NCT05560698|OTHER|Standard intervention|Each day participants receive a text message on their smartphone with a link for the daily cSMS questionnaire. When the questionnaire is answered, the tab needs to be closed.
223443684|NCT04196335|DEVICE|intra-procedural intracardiac echocardiography|use of intra-procedural intracardiac echocardiography during Watchman FLX devices
223443685|NCT02145143|DRUG|Vemurafenib|
224054320|NCT02761304|PROCEDURE|Ultrasound|
224054321|NCT01188889|DRUG|RAD001|"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
224054322|NCT01188889|DRUG|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
223443686|NCT02145143|DEVICE|serial 124I PET/CT|
224054323|NCT00307151|DRUG|Lamivudine|4 mg/kg twice daily
224054324|NCT00307151|DRUG|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
224054325|NCT00307151|DRUG|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily
224054326|NCT00307151|DRUG|Zidovudine|180 mg/m\^2 twice daily
224054327|NCT06439212|DRUG|Ginger powder capsule|Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
224163997|NCT00281567|DRUG|Tiotropium|
223443687|NCT02145143|DRUG|thyrotropin alpha|
223443688|NCT05467813|OTHER|mirror therapy|The mirror therapy (MT) will be done with participants seated at a table. The affected upper-extremity (UE) will be placed behind the mirror and the unaffected UE in front of the mirror. Participants will be asked to do the same movements using both the unaffected and affected UE as possible. Each participant will practice two different MT protocols: unilateral mirror therapy (UMT) and bilateral mirror therapy (BMT). During UMT, the affected hand is static, while during BMT, the affected hand moves in an attempt to duplicate the unaffected hand as best as possible. The MT activities include gross motor movements, fine motor movements, and object manipulation.
223443689|NCT05467813|OTHER|augmented reality (AR)|The training program provides goal-directed exercises designed to be adjustable in order to match the patient's ability to minimize compensatory movements. To ensure safety, the investigators will place a handrail in front of the participant for support. The goal-directed exercise includes balance training (i.e., weight shifting, standing on one leg), activities of daily living training (i.e., reaching), and cognitive enhancement (i.e., memory training). By using the AR system, participants can observe the real performance of motions and interaction between the body and the virtual environment.
223567494|NCT00735826|DRUG|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
223567495|NCT06249698|DIETARY_SUPPLEMENT|meal replacements and supplements|Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
223567496|NCT05476237|BEHAVIORAL|Group Interpersonal Therapy for Adolescents (IPT-AG)|IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.
223443690|NCT05467813|OTHER|control therapy|The control intervention will include practice of upper limb activities, balance activities, activities of daily living, and cognitive enhancement tasks. The protocols of the conventional therapy will be formulated by using occupational therapy techniques, such as neurodevelopmental techniques and functional task training. The therapy will be adapted to the participants' levels of motor deficits and their prioritized goals. The protocol will include affected arm exercise or gross motor training, muscle strengthening of the affected arm, fine motor or dexterity training, and functional tasks of daily life or compensatory techniques to alleviate functional deficits. The therapist will work with the participant to select functionally relevant tasks, such as picking up items from a box, lifting soft drink bottles, hanging clothes, and so on.
223443691|NCT02500771|BEHAVIORAL|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
223443692|NCT02250950|BEHAVIORAL|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
223443693|NCT02250950|BEHAVIORAL|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
223443694|NCT02290145|DRUG|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
223443695|NCT02290145|PROCEDURE|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
223443696|NCT02290145|RADIATION|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
223443697|NCT00119483|DRUG|Nebido (Testosterone Undecanoate)|
223443698|NCT03700918|DEVICE|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
223443699|NCT03894475|DEVICE|AioCare|AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
223443700|NCT03894475|DEVICE|Spirometer USB CPFS/D (MGC Diagnostics)|Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
223443701|NCT04040647|BEHAVIORAL|mobilization and ambulation|6-min walk test (6-MWT)
223443702|NCT04886388|DEVICE|BT-001|BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control.
223567497|NCT05476237|BEHAVIORAL|Treatment as Usual (TAU)|Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
223567498|NCT05097651|DRUG|Cannabidiol oral solution|Cannabidiol 100mg/mL in a sesame seed oil, strawberry flavored solution, taken orally at bedtime in self-titrated dose between 50mg and 600mg. Once a dose that results in relief of symptoms is reached, it will remain as the maintenance dose, not to exceed 600mg.
223567499|NCT05097651|DRUG|Inert sesame seed oil|Placebo will be identical strawberry flavored sesame seed oil-based solution without CBD.
223567500|NCT02178852|DEVICE|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
223567501|NCT06183294|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
223567502|NCT01124123|DRUG|Bilastine|20 mg oral tablet
223567503|NCT01124123|DRUG|Bilastine|10 mg endovenous bilastine
224054328|NCT06439212|DRUG|Placebo|Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
223443703|NCT04886388|OTHER|Physician-guided Standard of Care for type 2 diabetes|Current ADA Standard of Care Guidelines for type 2 diabetes
223443704|NCT02598778|DRUG|Chlorhexidine gluconate (0.12%)|30 second oral rinse of 10mL of solution
223443705|NCT02598778|DRUG|Sodium Fluoride (0.05%)|30 second oral rinse of 10mL of solution
223443706|NCT02598778|OTHER|Paraffin wax chewing gum (sugar-free)|Approximately two minutes of chew time
223443707|NCT02598778|OTHER|Deionized water|30 second oral rinse of 10mL of solution
223443708|NCT04218617|DEVICE|Diagnostic MRI|Diagnostic MRI
223567504|NCT00979342|DEVICE|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
224054329|NCT04046107|BIOLOGICAL|Cemiplimab|Administered as an intravenous (IV) infusion
224054330|NCT05314608|COMBINATION_PRODUCT|IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee|Injection of a biologic mixture (BMC and allograft) into the subchondral bone lesion
224163998|NCT00281567|DEVICE|Respimat SMI|
224163999|NCT00281567|DEVICE|HandiHaler|
224164000|NCT00020449|BIOLOGICAL|recombinant interleukin-12|
224164001|NCT00020449|DRUG|paclitaxel|
224164002|NCT00020449|DRUG|pegylated liposomal doxorubicin hydrochloride|
224300691|NCT02823860|OTHER|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
224300692|NCT00055614|DRUG|topotecan hydrochloride|
224300693|NCT00055614|PROCEDURE|adjuvant therapy|
224300694|NCT02058212|DRUG|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
224300695|NCT01183221|DRUG|Syntocinon|One dose of 24 IU (3 sprays/nostril)
224300696|NCT01183221|DRUG|Placebo|Intranasal Placebo
224300697|NCT05367336|DRUG|Morphine|second group will be receiving morphine
224300698|NCT05367336|DRUG|Fentanyl|third group receiving fentanyl
224300699|NCT00343343|DEVICE|NovoFine® needle 6 mm|
224300700|NCT00343343|DEVICE|NovoFine® needle 4 mm|
224300701|NCT03912441|BIOLOGICAL|BCD-147|Bispecific anti-HER2 monoclonal antibody
224300702|NCT02086630|BEHAVIORAL|Heart to Heart|
224300703|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
224300704|NCT01106664|DRUG|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
223443709|NCT04218617|DEVICE|Planning MRI|Planning MRI: high definition (HD) MRI of the region of interest (1 vertebral level above and below the level(s) being treated)
223443710|NCT04218617|OTHER|Simulation CT|Simulation CT is obtained (1.5 mm slice thickness)
223443711|NCT04218617|OTHER|QOL assessment|QOL assessment
223443712|NCT04218617|OTHER|Brief pain inventory (BPI)|Brief pain inventory (BPI), including narcotic assessment
223443713|NCT04218617|RADIATION|sSRS in 1 fraction|sSRS 18 Gy in 1 fraction
223443714|NCT04218617|RADIATION|sSRS in 2 fraction|sSRS 24 Gy in 2 fractions to be delivered either on consecutive days or one day apart.
223443715|NCT05296447|OTHER|No Intervention|All subjects that previously received RGX-314 in a parent study
223443716|NCT03547232|DRUG|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
223443717|NCT03547232|DRUG|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
223443718|NCT03877588|DIETARY_SUPPLEMENT|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
223443719|NCT06959381|OTHER|Fascial release with instrument assisted soft tissue mobilization|The fascial release group will be treated with the Graston device to the superficial and deep fascia of the hamstrings and the gastro-soleus muscle complex in both extremities for a total of 16 minutes.
223567505|NCT03982719|OTHER|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
223567506|NCT03982719|OTHER|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
223567507|NCT02035436|OTHER|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
224164003|NCT03669107|DRUG|Gum|no gum
224164004|NCT04534049|OTHER|Intensive Strength Training (IST)|
224164005|NCT04534049|OTHER|Strength Endurance Training (SET)|
224164006|NCT04534049|OTHER|Flexibility Training (FT)|
224164007|NCT00901394|DRUG|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
224164008|NCT00901394|DRUG|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
224164009|NCT00901394|OTHER|Placebo|Saline
224164010|NCT00901394|OTHER|oxygen nitrogen|60% air and oxygen mix.
224164011|NCT03607149|DRUG|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
224164012|NCT05097976|DRUG|Methylprednisolone|21 x 4mg tablets beginning on POD 1
224164013|NCT05097976|DRUG|Placebo|21 sugar tablets beginning on POD 1 with standard management
224164014|NCT03144089|DEVICE|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.
224164015|NCT03144089|DEVICE|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
224164016|NCT05187572|BEHAVIORAL|Group intervention|This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
224164017|NCT04306302|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V.
224164018|NCT04306302|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo.
224054331|NCT05988060|OTHER|Experimental Intervention|"Patients who were randomized in the PEI group and accepted the invitation to undergo the experimental intervention receive a PEI for 10 weeks. The PEI will be executed 6 to 7 weeks during and 3 to 4 weeks after (C/B)RT. The PEI consists of a 60 minutes intervention twice a week and will be supervised by a physiotherapist specialized in oncology.~Patients who receive the intervention also have to do home-based aerobic and muscle strength exercises by themselves three times a week."
224054332|NCT04599777|DRUG|TACE combined with sorafenib and tislelizumab|Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
224054333|NCT00586261|DRUG|Pioglitazone|Pioglitazone 30 mg daily for 6 months
223443720|NCT06959381|OTHER|Fascial release with foam roller|Fascial release with a foam roller will be applied to the fascia of the hamstring and gastro-soleus muscle complex with a self-foam roller for a total of 16 minutes.
223443721|NCT01366794|OTHER|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
224054334|NCT00586261|DRUG|Placebo|Placebo 30 mg daily for 6 months
224054335|NCT00586261|DRUG|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
224054336|NCT03223480|DEVICE|EUS-guided gastrojejunstomy|As listed in the arms description
224054337|NCT05348512|OTHER|spectral imaging|non-contact, non-invasive hyperspectral and multispectral imaging without a diagnostic test
224054338|NCT05348512|OTHER|photoplethysmography|non-invasive pulse oximetry without a diagnostic test
224054339|NCT05343286|PROCEDURE|blood sample|blood sample before and after 12 weeks of physical activity
224054340|NCT05343286|OTHER|physical assessement|"physical assessement before and after 12 weeks of physical activity~* Standardized geriatric assessment (physician visit)~* ICOPE Monitor Assessment~* Sit-to-stand Test~* Quantified Gait Analysis (QAM)~* Bone densitometer measurement of body composition"
224054341|NCT05343286|BEHAVIORAL|psychometric assessment|"Psychometric questionnaires~* Cognitive tests (MMSE)~* The long questionnaire of personality traits: Big Five Inventory~* Perceived health and subjective age~* Age group identification~* Attitudes towards aging: French version of the Attitudes Toward Own Aging scale~* Physical self-perception: French version of the Physical Self-Perception Profile~* MOTIVATION SCALE FOR PA FOR HEALTH PURPOSES: Motivation Scale for Physical Activity in a Health Context~* Aging Stereotypes and Exercise Scale"
223443722|NCT00894244|DEVICE|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
223443723|NCT03836456|BEHAVIORAL|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
223567508|NCT02035436|OTHER|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
224054342|NCT03471702|DEVICE|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
224054343|NCT02966509|BEHAVIORAL|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
224054344|NCT00209014|DRUG|Thalidomide|
224054345|NCT04818203|BIOLOGICAL|Clusters of Autologous Dermal Fibroblasts|Dose: 1 x 10\^7 cells/1 mL/vial
223567509|NCT02815046|DRUG|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
223567510|NCT02815046|DEVICE|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
223567511|NCT04742348|DRUG|Carbidopa Levodopa|Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
224054346|NCT04818203|OTHER|Placebo|The injection solution without clusters of autologous dermal fibroblasts
224054347|NCT04737408|DRUG|Rosuvastatin 40mg|Rosuvastatin 40 mg
224054348|NCT00356083|DRUG|Methadone|
224054349|NCT03874663|DEVICE|Directly assisted oral HIV self-testing (HIVST)|"1. To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~2. To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~3. To explore participants attitudes and preferences towards oral HIVST.~4. To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results."
224054350|NCT05745662|DEVICE|Pulse Oximeter|OLV-4202 pulse oximeter (SW version: 01-15)
224054351|NCT06838676|DRUG|ACT001|PO BID at 875 mg/m2 for 28 days
224164019|NCT02023541|RADIATION|Proton beam therapy|
224164020|NCT03864627|DRUG|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
223443724|NCT03836456|BEHAVIORAL|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
223443725|NCT01038752|DRUG|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
223443726|NCT01038752|DRUG|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
223443727|NCT04780243|OTHER|counseling|Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services
223567512|NCT04742348|DRUG|Placebo|Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
223567513|NCT03898466|DRUG|Fluticasone furoate|Inhaled corticosteroid
223567514|NCT03898466|OTHER|Matching placebo|Placebo inhaler
223443728|NCT04034316|OTHER|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
223741143|NCT00804518|OTHER|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at \~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
223741144|NCT05174182|OTHER|A novel treatment approach|A novel treatment approach, as described before.
223741145|NCT05174182|OTHER|Usual care|Usual care, as described before.
223443729|NCT03503734|BEHAVIORAL|Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
223443730|NCT04165135|DRUG|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
223443731|NCT04624178|DRUG|Rucaparib|Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
223443732|NCT04624178|DRUG|Nivolumab|Nivolumab 480mg intravenously on day 1 of every four-week cycle.
223443733|NCT05890274|OTHER|AF and EKG Interpretation Project ECHO|The AF and EKG Interpretation Project ECHO program is delivered via Zoom videoconferencing technology and includes 12, 1-hour long sessions that involve education on best practice management of AF for primary care providers. Each session includes an EKG challenge, case presentation by a participant, didactic presentation, and time for open Q\&A. Supplementary materials are made available to all participants.
223443734|NCT02537652|OTHER|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
223443735|NCT05688254|BEHAVIORAL|FOREST-A|The internet-based psychosocial intervention will be delivered. The intervention comprises six modules: introduction, relaxation, psychological detachment, mastery, control, and summary, within psychoeducation and exercises in each module. The interactions with psychologists will be on demand. The whole intervention duration will be 4 weeks.
223443736|NCT03318679|OTHER|No intervention is planned.|None is planned
223443737|NCT04697212|BEHAVIORAL|Healthcare team- + patient-directed intervention|"Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities, and will also complete a patient prompt list that elicits strategies that they prefer the healthcare team to use during their visit."
223443738|NCT04697212|BEHAVIORAL|Healthcare team-directed intervention|Participants will experience a clinical encounter with a healthcare team that has received training on evidence-based communication strategies for patients with communication disabilities.
223443739|NCT00300443|DRUG|bimatoprost|
223443740|NCT06355843|DRUG|68Ga-PSMA|"PSMA is located in prostate epithelial cells and is converted to a membrane-bound protein in prostate cancer, and PSMA expression is approximately 100 to 1000 times higher in prostate cancer tissue compared to normal prostate tissue. PSMA is expressed at high levels in 95% of prostate cancer patients and is upregulated in castration-resistant prostate cancer (CRPC) and metastatic prostate cancer. PSMA expression was also increased after androgen deprivation therapy (ADT). The use of positronuclide 68Ga-labelled PSMA small molecule inhibitors can be specifically combined with prostate cancer cells, and it is important for the diagnosis of prostate cancer and its metastatic foci through PET/CT and PET/MR visualisation.~With the popularity of integrated PET/MR imaging, combining the higher resolution and morphological performance of MR imaging with the N-staging and M-staging of PET, the specificity of primary prostate cancer diagnosis can be greatly improved."
223443741|NCT02214862|DRUG|[F18]-FDDNP|radiopharmaceutical tracer
223443742|NCT03729323|BEHAVIORAL|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
223443743|NCT03729323|BEHAVIORAL|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
223443744|NCT01618916|DRUG|LY3015014|Administered SC
223443745|NCT01618916|OTHER|Placebo|Administered SC
223443746|NCT04521114|DRUG|Placebo|Placebo will be administered subcutaneously every week for 13 weeks.
223443747|NCT04521114|DRUG|leronlimab 700 mg|700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
223443748|NCT04521114|DRUG|leronlimab 350 mg|350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
223443749|NCT00394134|BEHAVIORAL|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
223567515|NCT00555763|DEVICE|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
223567516|NCT00990431|PROCEDURE|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
223567517|NCT00990431|PROCEDURE|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
224054352|NCT06788587|DRUG|LDX-01 plus TAU|"Participants receive once daily LDX-01 for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25)."
223567518|NCT05718167|DRUG|TQB2450|TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
223567519|NCT05718167|DRUG|Anlotinib hydrochloride capsule|Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
223741146|NCT05027438|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A multimodal psychotherapy that may include stimulus control, sleep restriction, cognitive therapy, psychoeducation, and relaxation strategies
223443750|NCT04674735|DRUG|APSLXR|Oral coated tablets once a day for 60 days.
223443751|NCT03684421|DIAGNOSTIC_TEST|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
223443752|NCT01918072|OTHER|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
223567520|NCT05718167|DRUG|Tislelizumab injection|Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
223741147|NCT05027438|BEHAVIORAL|Deprescribing|The reduction or withdrawal of a medication, through gradual dose reduction, managed by a healthcare professional that aims to reduce harm and improve outcomes
223741148|NCT05882110|PROCEDURE|Cultured autologous epidermal cell membrane|The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
223443753|NCT04151238|BEHAVIORAL|Exercise intervention for cancer patients to increase physical activity during chemotherapy|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
223443754|NCT03555942|DRUG|Follicular phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
223741149|NCT05830487|BEHAVIORAL|Low AGE diet with reduced energy and fat|This group will be given a low AGE diet with reduced energy and fat,.
223741150|NCT05830487|BEHAVIORAL|Energy and fat-reduced normal diet|This group will be given a diet with reduced energy and fat, and AGE levels will not be interfered with
224054353|NCT06788587|DRUG|Placebo plus TAU|"Participants receive once daily LDX-01-matched placebo for 25 weeks, as well as TAU at a clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Days 1 and 2), 150 mg (Days 3 and 4), 200 mg (Days 5, 6 and 7); Weeks 2-21 (Maintenance Phase): 250 mg (or the maximum tolerated for each individual) ; Weeks 22-25 (Taper Phase): 200 mg (Week 22), 150 mg (Week 23), 100 mg (Week 24) and 50 mg (Week 25)."
224054354|NCT05030454|DEVICE|ETHOS|Ring-gantry CT-guided radiotherapy unit, pairing a linear accelerator within a ring-gantry imaging unit.
224054355|NCT05030454|RADIATION|CT-guided stereotactic adaptive radiotherapy|All participants will be initially planned to at least 35 Gy in 5 fractions, subject to hard constraints based on the treatment site.
224054356|NCT04885868|OTHER|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.|This study assess acceptability of autonomous conversation as part of cataract surgery follow up.
224054357|NCT00504907|DRUG|BTA9881|Single oral escalating doses
223443755|NCT03555942|DRUG|Luteal phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
224054358|NCT00504907|DRUG|Placebo|
224054359|NCT05508009|DRUG|Cyclophosphamide 1200 mg/Kg|Cyclophosphamide 1200 mg/Kg will be administered as part of the conditioning regimen A prior to HSCT
224054360|NCT05508009|DRUG|Fludarabine|Fludarabine (starting dose 0.5 mg/Kg and then PK guided to reach an AUC of 18-20) will be administered as part of the conditioning regimen prior to HSCT
224054361|NCT05508009|DRUG|Cyclophosphamide 100 mg/Kg|Cyclophosphamide 100 mg/Kg will be administered as part of the conditioning regimen B prior to HSCT
223443756|NCT04000360|OTHER|High-Intensity Aerobic Exercise (AE)|The home-based exercise group will have a Peloton indoor cycle, heart rate monitor strap, and Garmin activity monitor to track daily activity levels delivered to the home. Participants will be asked to cycle 3x/week for 12 months on this bike with heart rate monitor at aerobic intensity 60-80% of heart rate reserve and target cadence 80-90 revolutions per minute. Study team members will telephone all participants biweekly for similar contact times between treatment groups. During these calls, a study team member reviews fall diary information, inquires about possible adverse events, and reviews participants' activity monitor wear times on the Garmin Connect website (https://connect.garmin.com). For those in the AE group, exercise recommendations, e.g., increase duration, cadence or heart rate, are given based on review of exercise session data on the Peloton portal (onepeloton.com). Compliance barriers or technical challenges with the activity monitor or exercise cycle are addressed.
224054362|NCT05508009|RADIATION|Total Body Irradiation|Total Body Irradiation 200 cGy will be administered as part of the conditioning regimen prior to HSCT
224054363|NCT05508009|DRUG|ATG|ATG 7.5 mg/Kg will be administered as part of the conditioning regimen prior to HSCT
224054364|NCT05508009|DRUG|Rituximab|Rituximab 200 mg/m2 will be administered within 24 hours of the HSCT
223443757|NCT04000360|OTHER|Usual and Customary Care (UCC)|Participants in this group will continue to receive their usual care. They will also receive activity monitors to monitor their daily activity levels, and telephone monitoring throughout the study. Study team members telephone all participants every 2 weeks for similar amounts of contact time between treatment groups. During the calls, a study team member of the reviews fall diary information, inquires about possible adverse events, and reviews participants' activity monitor wear times via the Garmin Connect website (https://connect.garmin.com).
223443758|NCT06241066|OTHER|no-Intervention|no-Intervention
223443759|NCT00744406|BEHAVIORAL|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
223443760|NCT00744406|BEHAVIORAL|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
223567521|NCT03227653|DRUG|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
223567522|NCT03227653|DRUG|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
223567523|NCT03227653|DRUG|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
223567524|NCT05594121|DRUG|Extended Release Subcutaneous Buprenorphine|Monthly subcutaneous injections of long-acting buprenorphine
223567525|NCT05594121|DRUG|Immediate Release Sublingual Buprenorphine|Daily sublingual fast-acting buprenorphine
223567526|NCT04816136|OTHER|Sleep recording (already done)|Sleep recording (already done)
224054365|NCT05508009|DRUG|Melphalan|Melphalan 100 mg/m2 will be administered as part of the conditioning regimen prior to HSCT
224054366|NCT05508009|DEVICE|CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System|CliniMACS® TCRαβ-Biotin and CD19 Systems will be used to create the mobilized peripheral blood stem cells (PBSC) from allogeneic donors depleted of TCRαβ+ T cells and CD19+ B cells to be infused into the patient for the HSCT. The target dose for the number of CD34+ HSC infused is \> 10 x 10\^6 cells/Kg recipient weight. The minimum dose is 2 x 10\^6 cells/Kg. There is no upper limit to the dose of CD34+ HSC infused as long as no more than 1 x 10\^5 TCRαβ+ T-cells/Kg are infused. The target dose of TCRαβ+ T cells/Kg is \< 0.50 x 10\^5.
224054367|NCT05508009|PROCEDURE|Kidney Transplant|In the presence of donor myeloid engraftment, at least 3 months post-HSCT, with \> 95% donor CD3+ chimerism, in the absence of signs of active aGvHD or cGvHD (moderate or severe), at least 4 weeks off of immunosuppression for any previously occurring acute or chronic GvHD (except single agent treatment of mild cGvHD), and with a BMI \>18.5, ambulatory and active in addition to the eligibility for the standard of care KT criteria, patients will undergo a living donor KT using same donor as HSCT
224054368|NCT06794164|PROCEDURE|skin to skin care|skin to skin care of preterm infants with their parents immediately after birth
224054369|NCT06794164|PROCEDURE|Standard Care (in control arm)|skin to skin care within 24 hours after birth
223567527|NCT03651856|DRUG|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
223567528|NCT02042053|DEVICE|PET/CT|
223567529|NCT02042053|DEVICE|PET/MRI|
223567530|NCT01451931|OTHER|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
223567531|NCT01451931|RADIATION|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
223567532|NCT01451931|OTHER|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
223567533|NCT03522038|PROCEDURE|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with \<30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
223567534|NCT01415479|BEHAVIORAL|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
223567535|NCT01415479|BEHAVIORAL|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
224054370|NCT00478465|DRUG|valganciclovir|
224054371|NCT06201897|DRUG|ACTH/Oral Steroids|Injection ACTH or Oral Steroids in children with West Syndrome
224054372|NCT06401122|PROCEDURE|haemodialysis|process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
224054373|NCT02466867|DRUG|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
223443761|NCT00744406|DRUG|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
223443762|NCT02865811|DRUG|Pembrolizumab|"Please see Arms for description."
224054374|NCT02466867|DRUG|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
224054375|NCT00692484|DRUG|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
223443763|NCT02865811|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Please see Arms for description."
223443764|NCT04846816|COMBINATION_PRODUCT|SQIN-01|The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.
223443765|NCT05525780|DRUG|GB-5001|Depending on the cohort, volume will be varied to administer.
224054376|NCT00692484|DRUG|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
224054377|NCT01717287|DRUG|Raltegravir Film-coated Tablet|
224054378|NCT01717287|DRUG|Raltegravir Chewable Tablet|
223443766|NCT05525780|DRUG|Placebo|A matched volume of placebo product will be administered to each subject in each cohort.
223443767|NCT05525780|DRUG|Oral cohort|Single dose of Aricept tablet
223443768|NCT02415062|DRUG|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
223443769|NCT00006220|DRUG|arsenic trioxide|
223567536|NCT01415479|BEHAVIORAL|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
224054379|NCT01717287|DRUG|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
224054380|NCT02520895|BIOLOGICAL|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
224054381|NCT05827159|DRUG|Naltrexone Pill|In the MAUD component, some participants will receive oral Naltrexone in the ED.
224054382|NCT05827159|DRUG|Naltrexone Injection|In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.
224054383|NCT05827159|BEHAVIORAL|Brief Negotiation Interview|Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.
224054384|NCT05827159|DRUG|Gabapentin Pill|In the MAUD component, ancillary treatment with gabapentin will be provided.
224164021|NCT03864627|DRUG|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
223443770|NCT00006220|DRUG|tretinoin|
223443771|NCT01249326|OTHER|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
223443772|NCT04650334|BEHAVIORAL|Collaborative Care|Health services intervention to implement a team based model of care for perinatal depression.
223443773|NCT03245190|DRUG|Chiauranib|50mg, orally once daily
223443774|NCT02454634|DRUG|IDH1 peptide vaccine|
223443775|NCT00576004|PROCEDURE|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
223443776|NCT06730724|OTHER|No intervention|No intervention
223443777|NCT01487239|DRUG|[14C]-GDC-0980|100 uCi of \[14C\]-GDC-0980 in total dose of 10 mg GDC-0980
223443778|NCT02540967|DRUG|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
223443779|NCT04046822|DRUG|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
223443780|NCT04046822|DRUG|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
223443781|NCT03173261|DIAGNOSTIC_TEST|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
223443782|NCT03738761|DRUG|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
223443783|NCT03738761|DRUG|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
223443784|NCT04118777|DRUG|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
223443785|NCT03048071|OTHER|Data collection within medical files|Data collection within medical files
223443786|NCT02104167|DEVICE|ROIC interbody cage with VerteBRIDGE plating|
223443787|NCT00004896|DRUG|busulfan|
223443788|NCT00004896|DRUG|cyclophosphamide|
223443789|NCT00004896|PROCEDURE|allogeneic bone marrow transplantation|
223443790|NCT00004896|PROCEDURE|bone marrow ablation with stem cell support|
224054385|NCT01998620|DRUG|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
223567537|NCT03066700|DEVICE|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
223567538|NCT01263418|DRUG|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
223567539|NCT03321864|PROCEDURE|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
223567540|NCT05909410|OTHER|Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms|This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
223567541|NCT02950155|DRUG|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
223567542|NCT02950155|DRUG|Sodium Chloride solution|A single infusion of Placebo/Sham.
223567543|NCT00964340|DRUG|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
223567544|NCT00964340|DRUG|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
223567545|NCT02165293|DRUG|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
223567546|NCT05666843|BEHAVIORAL|Personalized Dietary Advice|Personalized dietary guidance to increase the intake of fibre-rich foods on top of usual care.The dietary guidance is implemented by dieticians and is personalized based on current adherence to the dietary guidelines, usual dietary intake, gender and personal goals and preferences.
223567547|NCT02979093|DRUG|Oxytocin|All women will receive a nasal spray containing oxytocin.
223567548|NCT02979093|DRUG|Placebos|All women will receive a nasal spray containing a placebo solution.
223567549|NCT02979093|PROCEDURE|Functional MRI scanning|Study participants undergo two functional MRI scans.
223567550|NCT05083091|BEHAVIORAL|Mindfulness and Attention Training|Guided mindfulness meditation with attention monitoring and acceptance skills training
223567551|NCT05083091|BEHAVIORAL|Mindfulness training|Guided mindfulness meditation, no attention monitoring or acceptance skills training
223567552|NCT05083091|BEHAVIORAL|Coping Condition|Guided training focused on coping effectiveness strategies, no monitoring or acceptance instruction
223567553|NCT04315792|DRUG|Endoxifen|Administration of Endoxifen for 3 weeks
224054386|NCT01998620|DRUG|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
223567554|NCT04315792|DRUG|Placebo oral tablet|Administration of Placebo for 3 weeks
223741151|NCT04075565|BEHAVIORAL|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
223741152|NCT04075565|BEHAVIORAL|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
224054387|NCT01998620|DRUG|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
224054388|NCT04541290|DRUG|Protopic 0.1 % Topical Ointment|Applied in a thin layer covering all of the arm including the armpit and hand once a day for six months
223443791|NCT00004896|RADIATION|radiation therapy|
224164022|NCT01388491|DRUG|desogestrel/ethinyl estradiol and ethinyl estradiol|
224164023|NCT01388491|DRUG|desogestrel/ethinyl estradiol|
223443792|NCT01687855|DEVICE|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
223443793|NCT04043208|BEHAVIORAL|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
223443794|NCT04043208|DIETARY_SUPPLEMENT|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
223443795|NCT02599337|DRUG|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
224054389|NCT01976520|BIOLOGICAL|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
223443796|NCT02599337|DRUG|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
223443797|NCT02548715|DRUG|Levothyroxine|
223443798|NCT02548715|DRUG|Placebo|
223443799|NCT05981014|PROCEDURE|Sentinel Lymph Node Biopsy (SLNB)|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
223443800|NCT05981014|DRUG|Doxorubicin|Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
223443801|NCT05981014|DRUG|Epirubicin|Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
223443802|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
223443803|NCT05981014|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
223443804|NCT05981014|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
223443805|NCT05981014|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
223741153|NCT01984008|DRUG|Picosulfate sodium, magnesium oxide, citric acid|
224164024|NCT00802880|DRUG|Dacarbazine|
223443806|NCT05981014|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
223443807|NCT05981014|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
223443808|NCT00164164|DRUG|HalfLytely|
223443809|NCT00164164|DRUG|NuLytely|
223443810|NCT03949738|DIAGNOSTIC_TEST|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
223443811|NCT05298436|OTHER|Follow-up interview|All participants will be followed up at defined time points post-stroke by face-to-face or telephone interview or postal questionnaire.
223443812|NCT01084538|DRUG|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
223443813|NCT05982808|PROCEDURE|CLIF correction|CLIF correction was a novel surgical techqiue of correction of spinal deformtiy with minimal invasive approach
223443814|NCT05982808|PROCEDURE|conventional correction strategy|conventional correction was the classic surgical techqiue of correction of spinal deformtiy with open posterior approach
223443815|NCT04893356|GENETIC|O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients|"Tumor samples of Leiomyosarcoma and Solitary Fibrous Tumours patients, dacarbazine (as single agents or in combination with anthracyclines) treated, will be obtained from and characterized by the Pathology Unit of the Istituto Nazionale Tumori Fondazione Pascale in Naples, Campus Biomedico of Rome, Istituto Oncologico of Bari and University of Palermo.~Glioblastomas control samples will be obtained from CEINGE-Biotecnologie Avanzate, in Naples and characterized by the Pathology Unit of the University of Naples Federico II.~After biopsy or surgical resection, the tissues were fixed in 10% formalin and included in paraffin blocks. All patients partecipating in this study provided informed consent."
223567555|NCT06035393|DRUG|HRG2005 inhalation|Drug 1: dose 1; dose 2; dose 3
223567556|NCT06035393|DRUG|Placebo to match HRG2005 inhalation|Drug 2
223567557|NCT06035393|DRUG|Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 3
224164025|NCT04874350|DRUG|LPCN 1148|LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.
223567558|NCT06035393|DRUG|Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation|Drug 4
223567559|NCT03822598|BEHAVIORAL|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
223567560|NCT03099174|DRUG|Xentuzumab|Once weekly administrated through one hour intravenous infusion
223567561|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
223567562|NCT03099174|DRUG|Letrozole|Once a day
223567563|NCT03099174|DRUG|Anastrozole|Once a day
223567564|NCT03099174|DRUG|Fulvestrant|Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
223741154|NCT03001388|PROCEDURE|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
224054390|NCT01310790|PROCEDURE|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was \>30%.~Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.~Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
224054391|NCT03960775|DRUG|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
224054392|NCT03960775|DRUG|saline|Saline infusion during same time period.
224054393|NCT05472467|DRUG|Camrelizumab|200mg IV Q3W. Every three weeks is a cycle
224054394|NCT05472467|RADIATION|stereotactic body radiation therapy|stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f per week)
224054395|NCT05472467|DRUG|Chemotherapy|"Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles.~Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles."
224054396|NCT03870984|DIETARY_SUPPLEMENT|wNUTS, low-caloric diet plus nuts|15g of nuts and 15g of hazelnuts in association with low caloric diet
224054397|NCT03870984|OTHER|w/oNUTS, low-caloric diet without nuts|low caloric diet
224054398|NCT03095794|OTHER|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
224054399|NCT03095794|OTHER|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
224054400|NCT03095794|OTHER|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
224054401|NCT03095794|OTHER|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
224145677|NCT06055127|PROCEDURE|piezoelectric internal sinus lift / sticky bone graft material|"In the PISE technique, an ultrasonic piezoelectric device (acteon), to which a specialized tip is attached, is used to break the sinus floor. Developed for sinus lift by the crestal approach, the Intralift™ Kit makes it possible to undertake dental non invasive surgery in full safety.~The diamond-coated tips, of increasing diameters (from 1.35mm to 2.80mm), are designed to drill and gradually widen the access canal to the sinus membrane. The sterile spray cools the tips down to avoid any rise in temperature, which could lead to oral tissue damage.The membrane elevation is achieved using the TKW5 by means of microcavitation. Thanks to the ultrasonic frequency modulation, the risk of membrane damage is limited. Moreover, the cavitation effect enables excellent visibility of the operating field."
224145678|NCT04328233|BEHAVIORAL|Time-Restricted Eating|Participants will reduce the amount of time they eat to 10 hours per day over a 12-week monitored intervention followed by a 12-week self-directed intervention and will log their dietary intake using a smartphone application (mCC app). The participants will select a 10-h eating window that best suits their lifestyle. All food/beverages except water must be consumed within the time-interval. No further dietary restrictions will be applied. The participants will be provided with behavioral nutritional counseling by a dietician.
224145679|NCT00676793|DRUG|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
224145680|NCT00532428|DRUG|Raloxifene|60 mg QD
224145681|NCT00532428|DRUG|Raloxifene|120 mg QD
223443816|NCT06314451|OTHER|Cognitive Interview|"The study involves a single cognitive interview with a researcher, either online, by telephone, or face-to-face. People who want to take part will be given information about the study and asked to give written consent. Then they will be asked to talk about the wording of the questionnaire and how relevant it is to them.~Cognitive interviewing is recognized as a significant part of developing questionnaires for patient reported outcome measures (PROMs). The cognitive interviewing process used in PROM development will be adapted in this study to test the Steroid PRO in new disease populations. Cognitive interviewing will be carried out using pragmatic, light-touch interviews, underpinned by think aloud techniques and clean language principles."
223443817|NCT06436391|OTHER|Kinesio taping|Kinesio taping will be applied to the lateral part of the baby's heel to increase blood flow. Blood collection will always be performed by the same nurse
223443818|NCT06436391|OTHER|ShotBlocker|Shotblocker will be applied to the baby's heel average 10-15 seconds with minimal pressure.
223443819|NCT01108419|OTHER|Fermented dairy product|
223443820|NCT01108419|OTHER|milk-based non-fermented dairy product|
224145682|NCT00532428|DRUG|Placebo|Placebo
224145683|NCT05578482|DRUG|Dicloxacillin Oral Capsule|Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
224145684|NCT05578482|DRUG|Elocon 0.1 % Topical Cream|Both groups are treated with elocon for five days.
223741155|NCT05699603|PROCEDURE|Biopsy|Undergo skin biopsy
224054402|NCT02013947|OTHER|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
223443821|NCT06075550|OTHER|single cone technique using TotalFill BC Sealer|Gutta percha cone size X5 (Dentsply, Maillefer) TotalFill BC Sealer (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
223443822|NCT06075550|OTHER|warm vertical compaction technique using TotalFill BC Sealer HiFlow|TotalFill BC Sealer HiFlow (FKG Dentaire SA, La Chaux-de-Fonds, Switzerland)
224054403|NCT00351832|DRUG|Vildagliptin|
223443823|NCT03387501|DRUG|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
223443824|NCT04764084|DRUG|Niraparib|Niraparib 100mg or 200mg, PO, qd，d1-d21
223443825|NCT04764084|DRUG|Anlotinib|Anlotinib 12mg, PO, qd，d1-d14
223443826|NCT01993641|DRUG|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
223443827|NCT01993641|DRUG|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
223443828|NCT01993641|DRUG|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
224145685|NCT06511440|DEVICE|Vision-700|OCT machines used for diagnostic purposes
224145686|NCT04564716|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
223443829|NCT00272870|DRUG|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
223443830|NCT00272870|GENETIC|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
223567565|NCT03099174|DRUG|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
223567566|NCT05015855|OTHER|NP-PC PrEP|All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.
224145687|NCT04564716|OTHER|Placebo|placebo comparator
224145688|NCT06259864|OTHER|EXOPULSE Mollii Suit method|EXOPULSE Mollii Suit method, one of the newest rehabilitation technology products, is a non-invasive neuromodulation approach with a garment that covers the whole body and electrodes placed inside. Designed to improve motor function by reducing spasticity and pain, the method is based on the principle of reciprocal inhibition, which occurs by stimulating the antagonist of a spastic muscle at low frequencies and intensities.
223567567|NCT05015855|OTHER|OBGYN-PrEP|"OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling"
224145689|NCT03071380|DRUG|Repatoxaban|1 tablet contains 10 mg rivaroxaban
224145690|NCT03071380|DRUG|Xarelto|1 tablet contains 10 mg rivaroxaban
223443831|NCT00272870|DEVICE|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
223443832|NCT00087425|BIOLOGICAL|rituximab|
223443833|NCT00087425|DRUG|bryostatin 1|
223443834|NCT02393326|PROCEDURE|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
223741156|NCT05699603|DRUG|Calcipotriene|Applied topically
223741157|NCT05699603|DRUG|Fluorouracil|Applied topically
223741158|NCT05782751|PROCEDURE|GROUPI|10 sites treated with Free connective tissue graft (FCTG) + growth factors enhanced matrix 21 s GEM 21S + coronally advanced flap (CAF)
223741159|NCT05782751|PROCEDURE|GROUP II|10 sites treated withCollagen membrane + GEM 21S + coronally advanced flap (CAF)
223741160|NCT00000751|DRUG|Anti-HIV Immune Serum Globulin (Human)|
223741161|NCT00000751|DRUG|Globulin, Immune|
223741162|NCT00000751|DRUG|Zidovudine|
224054404|NCT03869359|OTHER|Gluten-free diet with gluten powder|The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
224054405|NCT03869359|OTHER|Gluten-free diet with placebo powder|The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
224054406|NCT03600142|BEHAVIORAL|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
224145691|NCT03858608|DIETARY_SUPPLEMENT|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
224145692|NCT03858608|OTHER|Usual asthma care|Usual asthma management
224164026|NCT04874350|DRUG|Placebo|Oral matching placebo capsule
224164027|NCT02147106|OTHER|Videoconsultation|
224054407|NCT02227628|DIETARY_SUPPLEMENT|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
224054408|NCT02227628|DIETARY_SUPPLEMENT|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD\&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
224054409|NCT01357096|BEHAVIORAL|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
224054410|NCT01357096|OTHER|Traditional group|CAD education fryers
224054411|NCT02443363|OTHER|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
224054412|NCT02443363|DEVICE|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
224054413|NCT03662880|RADIATION|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
224054414|NCT03662880|RADIATION|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
224054415|NCT01833637|OTHER|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
224054416|NCT00907348|DRUG|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
224054417|NCT03887533|DRUG|VTS-270|Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
224054418|NCT00516048|DRUG|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
224054419|NCT06470113|DEVICE|simultaneous cognitive training with transcranial magnetic stimulation|simultaneous cognitive training with transcranial magnetic stimulation can enhance the therapeutic effect and improve brain function non-invasively.
224054420|NCT02080247|DRUG|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
224054421|NCT02080247|DRUG|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
224164028|NCT04994886|PROCEDURE|Device implantation|The intervention involves the insertion of 2 lead electrodes (Specify Surescan 5-6-5 Leads, Model 977C190 Medtronic) epidurally over the dorsal aspect of the spinal cord through 2 laminectomies and two implantable pulse generators (Intellis™ with AdaptiveStim™, Model 97715 Medtronic) in the abdomen of the participant.
224164029|NCT01569724|OTHER|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
223741163|NCT05759442|DRUG|Metformin Hydrochloride (HCL)|Tab Metformin HCL 500mg twice per day aimed at improving glycemic indices in Prediabetics
223741164|NCT05759442|DIETARY_SUPPLEMENT|Apple cider vinegar|Apple cider vinegar aimed at improving glycemic indices in Prediabetics
223741165|NCT01908569|OTHER|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
223741166|NCT01908569|OTHER|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
224054422|NCT00639691|BIOLOGICAL|omalizumab|sc
224054423|NCT04620044|OTHER|Kaledo game|Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
224054424|NCT04620044|OTHER|Education|Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.
224054425|NCT04620044|OTHER|No intervention|Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
223443835|NCT02393326|PROCEDURE|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
223443836|NCT06718673|OTHER|virtual delivery room visit|The real-time labour room demonstration video aims to increase participants' awareness of the labour process, reduce unfamiliarity, and facilitate participation for pregnant women with access restrictions. Produced with a 360-degree camera, it shows detailed sections of the labour room, starting from the entrance. Key areas like birthing beds, toilets, bathrooms, and labour materials (mats, pilates balls, TVs) are highlighted. The video also covers baby cots and rest areas for attendants. Narrated by an experienced midwife, the video ensures patient privacy, no interventions, and excludes images or sounds of other pregnant women. Converted to 360-degree format, the video is available on YouTube for repeated viewing. (https://www.youtube.com/watch?v=EyCt-jTDCVs)
223443837|NCT06718673|OTHER|standart of care|Pregnant women in the control group did not receive any intervention other than routine care and counselling.
223443838|NCT05160194|BEHAVIORAL|Positive Parenting Intervention|"The highly interactive GROW Program consists of 5 core modules and 1 optional, supplemental session. Each session is expected to take 15-20 minutes to complete, and at the end of each module, parents record a 5 minute special play time video interacting with their child to demonstrate the skills they learned in the session. Each online module is followed by a meeting with a trained therapist who will discuss their special play time video and the skills they are learning. Parents make their way through the 5 core modules sequentially before accessing the supplemental session that may be relevant to them."
223443839|NCT02860117|DEVICE|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
223443840|NCT02860117|DRUG|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
223443841|NCT01902875|DRUG|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
223443842|NCT01902875|BIOLOGICAL|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
223443843|NCT05330468|DEVICE|Abbott Mechanical Heart Valve (MHV) Regent™|SJM Regent™- Standard cuff (Model number AGN-751); SJM Regent™- FlexCuff™ (Model number AGFN-756)
223443844|NCT04322786|DRUG|ACE inhibitor|Any prescription of ACE inhibitor
223443845|NCT01712308|BIOLOGICAL|Sotatercept|Given SC
223443846|NCT01712308|DRUG|Ruxolitinib|
223443847|NCT04169438|OTHER|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
223443848|NCT04169438|OTHER|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
223443849|NCT03070041|OTHER|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
223443850|NCT03725033|DRUG|Subetta|Oral administration.
223443851|NCT03725033|DRUG|Placebo|Oral administration.
223443852|NCT05270915|BEHAVIORAL|Family supportive care in EOLC|The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
223443853|NCT06614777|PROCEDURE|skin biopsies and blood extraction|"Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area."
223443854|NCT03534115|DIETARY_SUPPLEMENT|NAC|solution containing NAC
223443855|NCT03534115|DIETARY_SUPPLEMENT|Placebo|Placebo
224054426|NCT00916253|DRUG|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
224054427|NCT00916253|DRUG|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
224145693|NCT03693118|BEHAVIORAL|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
223443856|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice with 12% ethanol|
223443857|NCT02613715|DIETARY_SUPPLEMENT|Blackberry juice|
223741167|NCT02126540|DEVICE|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
224145694|NCT00124241|DRUG|telbivudine|
224145695|NCT00124241|DRUG|lamivudine|
224145696|NCT03276013|DRUG|Pembrolizumab|pembrolizumab in combination with doxorubicin
224164030|NCT03079518|DRUG|Ferric Carboxymaltose|single shot infusion
224054428|NCT03012087|BEHAVIORAL|MyHealthyChoices|My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
224145697|NCT03073408|DRUG|Propofol|Closed loop control for propofol administration guided by the BIS.
223443858|NCT06979089|BEHAVIORAL|Doing What Matters in Times of Stress|"DWM is the illustrated guide of the original stress management intervention - Self-Help Plus and can be offered online through a web-based application.~DWM is a low-intensity and transdiagnostic intervention that has been designed to be widely applicable to a variety of mental health problems (depression, anxiety and PTSD). DWM is based on acceptance and commitment therapy (ACT), a modern form (third wave) of cognitive-behavioural therapy with a strong focus on mindfulness practices and identification of values, with exercises which aim to reduce distress and build social support, adaptive coping and resilience.~DWM includes five modules, each of which focuses on a specific skill. The online version of DWM has been designed to release a module every week, so the program is finalized in 5 weeks. In this trial, participants will receive the guided version of DWM: participants will have a short (15 minutes) weekly support call with a helper (6 calls in total)."
223443859|NCT04505449|DIAGNOSTIC_TEST|Left heart catheterization|Patients who underwent left heart catheterization
223443860|NCT00004036|BIOLOGICAL|sargramostim|
223443861|NCT00004036|DRUG|amifostine trihydrate|
223443862|NCT00004036|DRUG|carboplatin|
223443863|NCT00004036|DRUG|cyclophosphamide|
223443864|NCT01499641|DRUG|Methylprednisolone|Epidural methylprednisolone 40 mg or none
223443865|NCT05920668|DRUG|Orelabrutinib|Orelabrutinib monotherapy for CLL/SLL 12 cycles
223443866|NCT04454710|DEVICE|Pulsed Radiofrequency|Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
223741168|NCT06225089|DRUG|pericapsuler nerve block|-Ultrasound Guided pericapsuler nerve block: will be externally rotated and abducted to 45 degrees. The shoulder area will be sterilized with povidone-iodine. High-frequency linear ultrasound perpendicularly between the coracoid and the humeral head probe. The deltoid muscle, subscapular muscle and tendon, and humeral head will be identified on the ultrasound screen. With the in-plane technique, a 22 gauge, 50 millimeter (mm) simplex A peripheral nerve block needle will be used. After passing the deltoid muscle, the needle will contact the tendon of the subscapularis muscle. The needle will be slightly withdrawn and directed between the deltoid muscle and the tendon of the subscapularis muscle and a local injection consisting of will be applied.
224145698|NCT03073408|DRUG|Propofol|Manual control group: Propofol administration adjusted manually.
224145699|NCT06204302|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using Komodo Research Database (KRD)
224145700|NCT06204302|DRUG|Enzalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
224145701|NCT06204302|DRUG|Apalutamide|Retrospective cohort analysis, using Komodo Research Database (KRD)
224145702|NCT06868290|BIOLOGICAL|Rapcabtagene autoleucel|Single infusion of rapcabtagene autoleucel
224145703|NCT06868290|OTHER|Active Comparator|Active comparator option as per protocol
224145704|NCT06868290|DRUG|Glucocorticoids|Concomitant glucocorticoids as per protocol
224145705|NCT02800720|BEHAVIORAL|Meditation Awareness Training|8 Week Meditation Intervention
224145706|NCT02800720|BEHAVIORAL|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
224145707|NCT06526806|OTHER|Kahoot game strategy|"Students in the experimental group will be informed about the Kahoot game strategy. 1-7 and 9-15. After the end of each lesson in the following weeks (except the midterm exam week in the eighth week), students will play the Kahoot game consisting of a total of five questions for approximately 10 minutes in the classroom. The first five minutes will be planned as answering the questions, and the other five minutes will be planned as evaluating the results. Students' answers and score calculations will be automatically recorded in the system, allowing them to see correct and incorrect answers, and learning deficiencies will be identified. Measurements will be made with data collection tools in the first week, ninth (after the midterm exam) and eighteenth weeks (after the final exam) of the course."
224145708|NCT04904003|OTHER|Rehabilitation Intervention|Strength, flexibility, endurance, balance, mobility, (self-efficacy)
223443867|NCT01743118|DRUG|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
223443868|NCT01743118|DRUG|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
223443869|NCT01743118|DRUG|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
223443870|NCT05353634|DIAGNOSTIC_TEST|Effects of mNGS on infected patients|The impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.
223443871|NCT01007292|DRUG|YM155|intravenous infusion
223443872|NCT01007292|BIOLOGICAL|Rituximab|intravenous infusion
223443873|NCT00898326|OTHER|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
223443874|NCT02710916|DEVICE|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
223443875|NCT05935423|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cell transplantation|50 million UC MSC will be transplanted 10-15 days after primary PCI
223443876|NCT02673242|DEVICE|Threshold IMT Philips Respironics|Inspiratory muscle training
223741169|NCT06081868|BEHAVIORAL|Use of toothbrush/toothpaste/fluoride varnish|Children receive information about the use of toothbrush/toothpaste/fluoride varnish.
224145709|NCT01599702|DRUG|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
224145710|NCT01565590|DRUG|Dexmedetomidine|0.2-1.5 mcg/kg/hr
223443877|NCT05040100|OTHER|3D Mediastinum Model|The 3D model cohort was provided with an additional 10-minute interactive lecture reviewing the same focused mediastinal anatomical structures using the 3D model.
223443878|NCT01848509|DEVICE|With teletransmission|Teletransmission of alerts
223443879|NCT00797407|DIETARY_SUPPLEMENT|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
223443880|NCT01299415|DRUG|Vadimezan™|
223443881|NCT03278405|DRUG|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
223443882|NCT02272933|DEVICE|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
223443883|NCT02272933|DEVICE|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
223443884|NCT01786538|DRUG|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
223443885|NCT01786538|DRUG|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
223443886|NCT04554758|PROCEDURE|Sleeve gastrectomy|Bariatric operation will be done by laparoscopic sleeve gastrectomy procedure.
223443887|NCT04554758|PROCEDURE|Roux-en-Y gastric bypass|Bariatric operation will be done by laparoscopic Roux-en-Y gastric bypass procedure.
223443888|NCT07019350|OTHER|Upfront DCB-based hybrid strategy|In upfront DCB-based hybrid strategy group, stepwise provisional strategy with side branch DCB angioplasty will be performed according to the follow standardized procedural steps. In this group, provisional stenting strategy will be performed in accordance with the European Bifurcation Club (EBC) consensus. Bail-out stenting will be performed using operator's preferred technique (e.g. T, TAP, culotte) when there will be one of the following after hybrid strategy: \<TIMI 3 flow in the side branch, severe (\>90%) ostial pinching, or flow-limiting dissection.
223443889|NCT07019350|OTHER|Upfront 2-stenting strategy|In upfront 2-stenting strategy group, systematic planned 2-stenting will be performed according to EBC recommendations. The stent technique will be at the discretion of the operator but could be one of culotte, DK-culotte, mini-crush, DK-crush, T or TAP.
223443890|NCT07026630|DEVICE|Cooking In the Kitchen|"The virtual reality (VR) training tool simulates cooking, an activity of daily living (ADL). The layout of VR environments intentionally place ingredients, tools, and the recipe book far away from the user to require gross upper-limb physical movements. Successful step completion requires reaching to obtain ingredients or turn book pages, grabbing to hold or release objects, and chopping, scooping, stirring, and pouring motions to prepare food items. The VR tool includes three versions of varying graphical complexity: Simple, Standard, and Complex.~Complexity is controlled by stimuli count and detail level. For example, Simple features an empty room with monotone colors, basic shapes, and no extra features. In contrast, Complex resembles a fully-fledged kitchen with color patterns, textures, background details, and sounds."
223443891|NCT07026214|BEHAVIORAL|Vitalis Cancer|Participants receive five free health coaching sessions with a trained student health coach, access to three health education videos, and a free wrist worn activity monitor to keep track of their physical activity and sleep behaviors.
223443892|NCT07026799|OTHER|Exercise|Orthopedic consultation and home-based, individualized, structured resistance training during induction therapy.
223443893|NCT07026799|OTHER|Control group|Orthopedic consultation and stretching exercises/walking. No resistance training.
223443894|NCT04554342|OTHER|V01 candy|candy with sweetener (Isomalt) and apple flavour
223443895|NCT04554342|OTHER|V02 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid)
223443896|NCT04554342|OTHER|V03 candy|candy with with sweetener (Isomalt) and apple flavour and acidifying agent (apple acid + citric acid) and Vitamin C
223443897|NCT04554342|OTHER|V04 candy|candy with sweetener (Isomalt) (control group 1)
223443898|NCT04554342|OTHER|V05 candy|candy with with sweetener (Isomalt) and acidifying agent (apple acid + citric acid) (control group 2)
223741170|NCT06081868|BEHAVIORAL|Education on nutrition/oral hygiene|Children receive education on nutrition/oral hygiene.
224054429|NCT03012087|OTHER|Health Risk Assessment|The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
224054430|NCT01180478|DEVICE|White Light|White Light Cystoscopy
224145711|NCT01565590|DRUG|propofol|5-80 mcg/kg/min
224145712|NCT00082043|DRUG|Dutasteride|
223443899|NCT01507532|OTHER|pharmacokinetic monitoring|pharmacokinetic monitoring
223443900|NCT07025889|DRUG|IBI343|"Subjects in the phase 1b stage will receive IBI343 3/4.5/6mg/kg intravenous infusion (IV) D1 Q3W in 3-week cycles.~Subjects in the phase 2 stage will receive IBI343 RP2D intravenous IV D1 Q3W in 3-week cycles."
223741171|NCT04216342|BIOLOGICAL|Fx-5A peptide complex|subject will receive a slow I.V. infusion of the Fx-5A peptide complex as described in Table 1. Five to 10 mL of blood will be collected at 30min (+/- 5min\*), 1h (+/- 10min\*), 2h (+/- 10min\*), 4h (+/- 15min\*), 8h (+/- 30min\*), 12h (+/- 30min\*), and 24h (+/- 30min\*) for laboratory tests and to be stored for research tests. The patient will be dismissed, as inpatient, 24-36 hours after the beginning of the treatment.
224054431|NCT01180478|DEVICE|Narrow Band Imaging|Narrow Band Imaging
224054432|NCT01993212|DRUG|Androxal 12.5 mg or 25 mg|
224054433|NCT01993212|DRUG|AndroGel 1.62%|
224054434|NCT01993212|DRUG|Placebo Capsules|
224054435|NCT01993212|DRUG|Placebo Gel|
224054436|NCT00054704|DRUG|Riluzole|Riluzole
224054437|NCT00054704|DRUG|Placebo|Placebo
224054438|NCT01018433|BEHAVIORAL|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
224145713|NCT00082043|DRUG|Placebo oral capsule|
223443901|NCT07025889|DRUG|Sintilimab|Subjects will receive sintilimab 200mg IV D1 Q3W in 3-week cycles.
223443902|NCT07025889|DRUG|Oxaliplatin|Subjects will receive oxaliplatin 130mg/m2 IV D1 Q3W in 3-week cycles.
223443903|NCT07025889|DRUG|S-1|Subjects will receive S-1 40-60mg BID PO D1-14 Q3W in 3-week cycles.
223443904|NCT07025941|OTHER|Standard Critical Care Nursing Protocol|"The Standard Critical Care Nursing Protocol encompasses evidence-based, routine nursing practices for critically ill patients in the intensive care unit (ICU). This protocol serves as the control intervention in comparative studies evaluating novel nursing strategies.~Key Components:~Basic Physiological Monitoring:~Continuous assessment of vital signs (heart rate, blood pressure, respiratory rate, SpO₂).~Strict intake/output monitoring and electrolyte balance management.~Airway Management:~Standard oxygen therapy (nasal cannula, face mask) or mechanical ventilation as prescribed.~Scheduled suctioning, positional changes, and oral care (every 4-6 hours).~Infection Prevention:~Aseptic techniques for invasive procedures (e.g., central line care, urinary catheter management).~Ventilator-associated pneumonia (VAP) bundle compliance (e.g., head-of-bed elevation, sedation vacations).~Mobility \& Skin Integrity:~Passive range-of-motion exercises for immobilized patients (2×/day).~Pr"
223443905|NCT07025941|BEHAVIORAL|ICU-PRO Nursing Protocol (Integrated Critical Care Protocol for Rehabilitation Outcomes)|"The intervention group received a standardized 14-day nursing protocol combining three evidence-based components:~Comprehensive Rehabilitation Nursing:~Early mobilization protocol with passive/active exercises (3-4 sessions/day)~Respiratory training using incentive spirometry (Triflo II® devices)~Swallowing rehabilitation with VitalStim® electrical stimulation~Refined Airway Management:~Humidification via Fisher \& Paykel® MR850 systems (33-44 mg/L)~Closed suction systems (Ballard® Trach Care) with strict aseptic technique~Oral care with 0.12% chlorhexidine solution (Peridex®) 4×/day~Nutritional Support:~Enteral feeding using Abbott Nutrition® formulas~Parenteral nutrition via Baxter®/Fresenius Kabi® solutions~Gastric residual monitoring with Kangaroo™ feeding pumps~Key Features:~Implemented by specialized ICU nurses, respiratory therapists, and dietitians~Daily monitoring using Philips® IntelliVue patient monitors~Protocol adjustments based on weekly APACHE II scoring"
223443906|NCT07025928|BEHAVIORAL|Decreased Salt High Potassium Tool (DSHP Tool)|Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
223443907|NCT07026188|OTHER|Ultrasound with SMI|The use of ultrasound allows observation of new bone formation in the distraction gap, also visualize the formation of blood vessels in the distraction gap with SMI, including the velocity and resistance of blood vessels, and can also indicate the environment of new bone formation. All US examination were performed by one US doctor.
223443908|NCT01625689|BIOLOGICAL|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
223443909|NCT01625689|BIOLOGICAL|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
223443910|NCT02901301|DRUG|Pembrolizumab|200mg, IV, q3weeks, Day 1
223443911|NCT02901301|DRUG|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
223443912|NCT02901301|DRUG|Capecitabine|1000mg/m2, PO, BID, Day 1-14
223443913|NCT02901301|DRUG|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
223443914|NCT01162720|PROCEDURE|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
223443915|NCT01162720|PROCEDURE|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
223741172|NCT06153771|OTHER|Collection of brain and kidney NIRS measurements|(recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed
223741173|NCT06153771|OTHER|echocardiography|on day 2, day 4 and day 7 of life
223741174|NCT01829516|DRUG|Oxytocin|Intranasal oxytocin
223741175|NCT01829516|DRUG|Placebo|Intranasal placebo
224054439|NCT01018433|OTHER|Treatment as usual|Can include other psychotherapy and pharmacotherapy
224054440|NCT00362414|DRUG|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
224145714|NCT04546464|BEHAVIORAL|Therapeutic Recreation Program|"The experimental recreation program, which consisted of two sessions per week and lasted approximately~1 hour each session, lasted for 8 weeks between May 2019 and June 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions"
224054441|NCT05414981|DRUG|ABI-H3733|25 mg or 100 mg tablets for oral administration
224054442|NCT05414981|DRUG|Placebo|25 mg or 100 mg tablets for oral administration
224145715|NCT02027415|DIETARY_SUPPLEMENT|Beet juice|2 cups of beet juice will be given before the car ride
224145716|NCT02027415|DIETARY_SUPPLEMENT|Orange juice|2 cups of orange juice will be given before the car ride
224145717|NCT00385463|DRUG|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
224145718|NCT02103881|DRUG|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
224145719|NCT02103881|DRUG|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
224145720|NCT02148211|OTHER|Data collection|Initial and follow-up data was collected using questionnaires.
224145721|NCT05227482|RADIATION|Personalized dosimetry approach|The radionuclide activity to administer is calculated using personalized voxel-based dosimetry approach
224054443|NCT04415957|OTHER|Elastic Tape|The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
223443916|NCT03218267|OTHER|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
223567568|NCT05899595|OTHER|Exercise protocol|"Patients will be randomly assigned to the PERSO or the RECO group. Each week, fatigue status of the patients will be assessed with four evaluations:~* Subjective fatigue (Rate of Fatigue scale)~* Heart rate variability with a holter ECG~* Muscle pain with a visual analogue scale~* Muscle fatigue with muscular electrical stimulations with the Myocene® The two first correspond to an aerobic fatigue score and the two latter to a muscle fatigue score.~The RECO group will perform aerobic and resistance exercises to reach the recommendations for patients with chronic pathologies, with a moderate intensity and an increasing volume.~The PERSO group will perform similar exercises as the RECO group but the training load will be adapted by changing the intensity (with the same volume as RECO) depending on the fatigue scores of the week. The aerobic fatigue score will set the load for the aerobic exercises and the muscle fatigue score for the resistance exercises."
223567569|NCT02378298|DRUG|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
223567570|NCT02378298|DRUG|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
223567571|NCT02378298|DRUG|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
224145722|NCT05227482|RADIATION|Standard dosimetry approach|The radionuclide activity to administer is calculated using standard (BSA or MIRD) dosimetry approach
224145723|NCT00719225|DRUG|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
224145724|NCT04673604|DIAGNOSTIC_TEST|Assessment of ocular surface staining (Oxford score 0-15 scale)|Corneal and conjunctiva staining will be recorded according to the Oxford grading scheme for ocular staining (0-15 score).
224145725|NCT04673604|DRUG|mean diurnal intraocular pressure-lowering|At the end of each 6-month period patients will undergo diurnal intraocular pressure assessment with both therapies.
223443917|NCT03218267|OTHER|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
223567572|NCT04934254|OTHER|Attitude Scale|26-item related to scale will construct and apply to nurses for creating scale
223567573|NCT05671718|OTHER|Nurse-Led Treatment in Primary Care|At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.
223567574|NCT06146946|PROCEDURE|Dissection of the No.253 lymph node|The range of the No.253 lymph node is as follows: medially, it extends from the root of the inferior mesenteric artery to the starting section of the left colonic artery; caudally, from the starting point of the left colonic artery to the intersection with the inferior mesenteric vein; laterally, it is bordered by the outer margin of the inferior mesenteric vein; and cranially, from the horizontal section of the duodenum to the beginning of the jejunum. In the controlled group, the surgery is performed with dissection of the No.253 lymph node.
223567575|NCT06146946|PROCEDURE|Omitting the dissection of the No.253 lymph node|In the experimental group, the surgery is performed without dissection of the No.253 lymph node.
223567576|NCT04173260|DRUG|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
223567577|NCT06002854|DRUG|PRP( platelet rich plasma) and Insulin human|Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
224054444|NCT02329964|DRUG|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
224054445|NCT02329964|DRUG|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
224145726|NCT00250406|DEVICE|Ureteral Stent|triclosan-eluting ureteral stent
224145727|NCT00250406|DEVICE|Ureteral Stent|Percuflex Plus Stent as the control
224164031|NCT03079518|OTHER|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
224164032|NCT01308528|DRUG|Sodium enoxaparin|40 mg/mL
224164033|NCT01308528|DRUG|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
223443918|NCT03657940|BEHAVIORAL|VIVIFRAIL multicomponent exercise training program|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
223443919|NCT07027384|DEVICE|Web-Based Apps PRIMA|Apps PRIMA (posyandu monitoring tools) is delivered using a web-based app accessible through web browsers with basic core functionalities
223443920|NCT07027384|DEVICE|Apps PRIMA Mobile|Enhancement of Apps PRIMA delivered using a standalone mobile app. Enhanced core functionalities include the looping system of children measurements, automatic charts, and GEDSI-sensitive features
223443921|NCT07027384|BEHAVIORAL|Advance GEDSI Training|Additional training to address vulnerabilities in communities and empathetic service from CHWs to caregivers. The training is a follow-up training from a basic GEDSI materials already delivered to CHWs
224054446|NCT00124059|DRUG|Seroquel|400mg/day quetiapine
224054447|NCT00124059|DRUG|Placebo|400mg/day placebo
224145728|NCT01376362|DRUG|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
223443922|NCT03816852|BIOLOGICAL|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
223443923|NCT06884397|PROCEDURE|Abdominal aortic endoprosthesis|An endoprosthesis consisting of a metal spring covered with an impermeable fabric is inserted through an artery and deployed inside the aorta.
223567578|NCT05867836|DIETARY_SUPPLEMENT|IFA vs. MMS during pregnancy|Iron and folic acid, or multiple micronutrient supplements provided during pregnancy
223567579|NCT05389514|DRUG|Cyclophosphamide|Patients will receive a single dose of cyclophosphamide 60 mg/kg IV in 250 ml D5W over 2 hours on Day -3.
224054448|NCT05137548|DRUG|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate oral prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
223443924|NCT00106639|DRUG|CP-690,550|15 mg twice daily
223443925|NCT00106639|DRUG|CP-690,550|30 mg twice daily
223443926|NCT00106639|DRUG|tacrolimus|dose adjusted according to level
224054449|NCT05137548|DRUG|Tenofovir 300Mg Oral Tablet|Tenofovir is an oral nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus. It will be dosed as a tablet by mouth
224145729|NCT01690104|DRUG|Rifampicin|
224145730|NCT01690104|DRUG|Placebo|
223443927|NCT00691639|OTHER|Blood Collection Only|Blood Collection Only
223443928|NCT03904368|PROCEDURE|Open myomectomy|laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
223443929|NCT03904368|DRUG|Gonadotropins|Gonadotropin stimulation of follicular growth
223443930|NCT03904368|DRUG|Human chorionic gonadotropin|HCG triggering of ovulation
223443931|NCT03904368|PROCEDURE|Ovum pick up|34 to 36 hours after HCG triggering
223443932|NCT03904368|PROCEDURE|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
223443933|NCT02105389|BEHAVIORAL|Individualized Yoga Intervention|
223567580|NCT05389514|DRUG|Gemcitabine|Patients will receive a single dose of gemcitabine 600 mg/mg2 IVPB over 30 minutes on Day -2.
223567581|NCT05389514|DRUG|Pembrolizumab|Patients will receive the anti-PD-1 immune checkpoint inhibitor pembrolizumab 200 mg IV over 30 minutes on Day -1 and will be dosed every 3 weeks.
223567582|NCT05389514|BIOLOGICAL|Cell Infusion|"Patient's T cells will be administered at a dose of between 1 x 10\^9 to 5.0 x 10\^10 TCR-transduced lymphocytes, which is a dose of genetically modified T cells that can be safely administered and is capable of mediating tumor regression in some patients with metastatic cancers.~The cells are to be infused intravenously over approximately 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping."
223567583|NCT05473156|DRUG|AP203|"Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses."
223741176|NCT01053364|DEVICE|NL-Prow interspinous spacer implant|Interspinous spacer implant
224054450|NCT02430142|OTHER|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
224054451|NCT04238975|BIOLOGICAL|GC3111 vaccine|0.5mL, Intramuscular
224054452|NCT04238975|BIOLOGICAL|Boostrix® vaccine|0.5mL, Intramuscular
224054453|NCT00883662|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
224054454|NCT05060822|DRUG|HEC585|HEC585 Tablets，once daily
224054455|NCT05060822|DRUG|Pirfenidone|Pirfenidone，three times a day
224054456|NCT05060822|DRUG|Placebo|Placebo，once daily
224054457|NCT03527134|DRUG|Amantadine|patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
224054458|NCT00000570|DRUG|pulmonary surfactant|
224054459|NCT01511276|BEHAVIORAL|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
224054460|NCT01511276|BEHAVIORAL|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
224145731|NCT01692912|OTHER|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28\<2.6
223741177|NCT00712829|DRUG|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
223741178|NCT00712829|DRUG|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
224145732|NCT05945329|DEVICE|GalaFLEX LITE™ Scaffold|Bioabsorbable surgical mesh manufactured from poly-4-hydroxybutyrate (P4HB) and knitted into a surgical scaffold used to reinforce soft tissue
223443934|NCT06750445|DRUG|Fluoxetine|Patients in the fluoxetine group received oral fluoxetine starting at 40 mg/day for six months. Treatment was discontinued if serious adverse reactions developed or if no improvement was observed after dose escalation. Compliance and treatment progress were monitored via telephone follow-ups. For patients unable to have a bowel movement for three consecutive days or experiencing intolerable symptoms, polyethylene glycol (PEG, 10 g) was provided as rescue medication. Bowel movements within 24 hours of rescue medication use were excluded from the count of complete spontaneous bowel movements (CSBM).
223443935|NCT06750445|DRUG|Polyethylene Glycol 400 0.4%|The control group (PEG) used polyethylene glycol as a rescue medication under the same conditions, following similar monitoring and follow-up procedures.
223443936|NCT06759415|OTHER|Exercise|Exercise therapy was applied to individuals in both groups.
223443937|NCT06770933|DRUG|VX-01|There is no physical difference in VX-01 and the placebo. The only difference lies in active ingredient found in VX-01, which is the compound that will be evaluated in the course of this study.
223443938|NCT06770933|DRUG|Placebo|Placebo will be supplied as a tablet identical to test drug but without VX-01. Placebo packaging will be identical to IP in order to keep study personnel and subjects masked.
223443939|NCT06890650|OTHER|Fecal Microbial Transplantation|This will involve colonoscopic instillation of fecal transplant
223443940|NCT06890650|OTHER|Sham transplantation|Sham FMT will involve saline infusion via colonoscopy
223443941|NCT06890650|OTHER|Crohns disease exclusion diet|The modified diet plan will be given to each study participant
223443942|NCT06890650|OTHER|Sham diet|Dietary counselling alone
223567584|NCT05473156|DRUG|AP203|The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
223567585|NCT02308163|DRUG|Peficitinib|oral
223567586|NCT02308163|DRUG|Placebo|oral
223567587|NCT02308163|BIOLOGICAL|Etanercept|subcutaneous injection
223567588|NCT03496792|OTHER|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
223567589|NCT03496792|OTHER|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
223741179|NCT02760446|BEHAVIORAL|CAM-ICU.fr|Neuropsychological testing
223741180|NCT00772772|DRUG|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
223443943|NCT04457934|DRUG|Plenvu|All patients in both Groups will drink will drink 1 Liter of Plenvu and 1 Liter of water or tea in preparation for endoscopy according to endoscopy guidelines
223741181|NCT02570906|DEVICE|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
224054461|NCT01451008|DEVICE|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
224054462|NCT05283759|OTHER|No intervention because it is a patient registry|
224054463|NCT05837156|DRUG|Heptaflurane combined Cyclophenol|Heptaflurane combined Cyclophenol
224054464|NCT05837156|DRUG|Heptaflurane|Heptaflurane only
223443944|NCT00970424|DRUG|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
223443945|NCT00970424|DRUG|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
223443946|NCT04636671|DRUG|Methylprednisolone|Per-protocol methylprednisolone administration and tapering (see arm description)
223443947|NCT04636671|DRUG|Dexamethasone|Per-protocol dexamethasone administration (see arm description)
223443948|NCT06899451|OTHER|systematic desensitization and balance|"1. Systematic desensitization: 2 techniques~   1. Jacobson's technique (progressive muscle relaxation):~  2. Guided imagery training is a relaxation technique~2. Goal-directed paradigm (selected program)"
223443949|NCT04958291|DRUG|CC-99677|CC-99677
223741182|NCT05364723|OTHER||no intervention
223741183|NCT02750592|DRUG|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
223741184|NCT05118451|PROCEDURE|3 d visualization technology|3D visualization technology refers to the conversion of 2d imaging data such as CT and MR into 3D stereoscopic images through computer calculation, analysis and reconstruction, visually separating the shapes and spatial distribution features of targets such as liver, blood vessels and tumors directly, accurately and quickly to present three-dimensional views. Combined with transparency, rotation, scaling and measurement techniques, real-time and interactive 3D dynamic analysis of 3d visual model is carried out. In addition, the computer was used to simulate the operation, and the feasible surgical plan was discussed. The best surgical plan was selected based on the patient's individual data.
223741185|NCT05283187|BEHAVIORAL|Mindfulness Based Cognitive Therapy Group|Mindfulness Based Cognitive Therapy
224054465|NCT05837156|DRUG|Cyclophenol|Cyclophenol only
224054466|NCT01806350|OTHER|questionnaire administration|Ancillary studies
224054467|NCT01806350|PROCEDURE|standard follow-up care|Receive usual care
224054468|NCT01806350|OTHER|educational intervention|Undergo PFMT
224145733|NCT05945329|OTHER|Standard surgery|Surgery performed without the use of a scaffold
223443950|NCT04958291|OTHER|Placebo|Placebo
223443951|NCT04328415|RADIATION|Cerebral scintigraphy|Radioactive tracer 99mTc-DTPA
223443952|NCT06879145|DRUG|SHR-A2102；Adebrelimab|Treatment with SHR-A2102 in combination with fixed dose Adebrelimab
223443953|NCT06762457|DRUG|MT-501|MT-501 Tablets
223443954|NCT01490606|OTHER|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
223443955|NCT01490606|OTHER|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
223443956|NCT06369519|PROCEDURE|Surgery treatment or local tumor destruction.|Surgery treatments mainly include partial nephrectomy and radical nephrectomy. Local tumor destruction mainly includes renal mass ablation.
223567590|NCT03496792|OTHER|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
223567591|NCT03496792|OTHER|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
223567592|NCT05014464|DRUG|Crizotinib|Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
223567593|NCT05517980|DRUG|KP104|Participants will receive loading and/or weekly maintenance subcutaneous (SC) doses of KP104.
223741186|NCT06112951|PROCEDURE|Extracorporeal Photopheresis|Patients randomized into the interventional group will receive ECP. ECP will be started within one week after randomization. Initially a two-day treatment cycle will be performed once every second week for the first two months. Then, a two-day treatment cycle will be performed once a month for 6 months.
223741187|NCT00671307|DRUG|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
224145734|NCT07072195|DRUG|AMC6156 0.1mg|Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.
224145735|NCT07072195|DRUG|AMC6156 0.3mg|Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.
224145736|NCT07072195|DRUG|AMC6156 1.0mg|Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.
223741188|NCT00671307|DRUG|Placebo|Vehicle control given as IV infusion over 1 hour
223741189|NCT00861146|BEHAVIORAL|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
224145737|NCT07072195|DRUG|Placebo|Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.
224145738|NCT04007666|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
224145739|NCT04007666|BEHAVIORAL|Control Group|Coping-focused treatment.
223443957|NCT02973334|OTHER|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
223443958|NCT02973334|OTHER|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
223741190|NCT04430777|DRUG|Tranexamic acid|Administration of tranexamic acid 1 gr either intravenously or subcutaneously
223741191|NCT02981342|DRUG|Abemaciclib|Administered orally
224054469|NCT04026698|BEHAVIORAL|Resident and Family Engagement Intervention|"The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss a care related topic with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for up to 3 months."
224054470|NCT02808754|PROCEDURE|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic \> 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
224145740|NCT07090265|PROCEDURE|non-surgical periodontal therapy|Mechanical Root Instrumentation using Ultrasonic scaling and root debridement using Gracey Curettes
223567594|NCT05787899|OTHER|Hypothermia Protocol|Subject's who will be treated with the hypothermia protocol for Hypoxic Ischemic Encephalopathy as standard of care.
223567595|NCT05434338|DIAGNOSTIC_TEST|HPV detection test|Samples taken from the squamocolumnar junction using swabs (UTM Copan)
223567596|NCT04405128|DIAGNOSTIC_TEST|Transcranial Tissue Doppler (TCTD)|"Doppler ultrasound technique called Brain Tissue Velocimetry (Brain TV), to investigate brain tissue motion over the cardiac cycle."
223567597|NCT04405128|DIAGNOSTIC_TEST|Brain Magnetic Resonance Imaging|Brain MRI for investigation of brain tissue motion in the presence of suspected stroke.
223567598|NCT04414046|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
223567599|NCT05866029|DRUG|Denosumab|Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
223567600|NCT05866029|DRUG|Teriparatide|Teriparatide was sequentially treated with Denosumab
223741192|NCT02981342|DRUG|LY3023414|Administered orally
223741193|NCT02981342|DRUG|Gemcitabine|Administered IV
223741194|NCT02981342|DRUG|Capecitabine|Administered orally
223443959|NCT02973334|OTHER|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
224145741|NCT07090265|PROCEDURE|non-surgical periodontal therapy + I-PRF|Mechanical Root Instrumentation using Ultrasonic scaling and root debridement using Gracey Curettes following by subgingival application of I-PRF
223443960|NCT06906107|PROCEDURE|Cervical Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine facet joints
223443961|NCT06906107|PROCEDURE|Exercise|Therapeutic exercises to the cervical, thoracic, and scapular musculature
223443962|NCT06906107|PROCEDURE|Mobilization|Low velocity, low amplitude movements applied to the cervical spine facet joints (Grade I or II)
223443963|NCT00005817|DRUG|becatecarin|Given IV
223443964|NCT00005817|OTHER|laboratory biomarker analysis|Correlative studies
223443965|NCT05011890|DEVICE|Moovcare® use|Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
223443966|NCT06649279|DEVICE|Oxygen reserve index|Measuring oxygen reserve index during preoxygenation and under general anesthesia
223443967|NCT04040634|DRUG|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
223443968|NCT04040634|DRUG|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
223443969|NCT04791605|OTHER|Gait analysis|Kinematic and kinetic analysis
223443970|NCT03260426|DIETARY_SUPPLEMENT|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
223443971|NCT03260426|DIETARY_SUPPLEMENT|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
223443972|NCT03260426|DEVICE|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
223443973|NCT06083480|DRUG|GlyNAC (combination of glycine and n-acetylcysteine)|GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.
223567601|NCT06482229|PROCEDURE|application for postoperative analgesia|three different methods will be applied to reduce patients' postoperative pain
223741195|NCT02468869|BEHAVIORAL|"Communication skills training empathy skills"|
223443974|NCT06083480|DRUG|Placebo|Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.
223443975|NCT01210144|DRUG|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
223443976|NCT01210144|DRUG|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (\>) 16 millimeter (mm), and with estradiol (E2) \> 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
223443977|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
223443978|NCT01210144|DRUG|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
223741196|NCT02468869|BEHAVIORAL|"Communication skills training information structuring skills"|
223443979|NCT00924391|DIETARY_SUPPLEMENT|phytosterol enhanced soy based beverage|
223443980|NCT00924391|DIETARY_SUPPLEMENT|1% milk|
223443981|NCT02035774|PROCEDURE|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
223567602|NCT05849584|OTHER|Transperineal ultrasound|A 2D scan will be performed of one experienced clinician. The average of 3 2D levator hiatal anteroposterior measurements will be stored. Then, a 3D/4D ultrasound examination of the pelvic floor will be performed using a Voluson S10, E8 or E10 (GE healthcare, Zipf, Austria) device with a RAB 4-8 MHz curved array transducer with the acquisition angle set at 85 degrees. Offline analysis of the ultrasound volumes will be performed using the 4D view (GE Healthcare, Austria) software, blinded to all clinical data. Hiatal anteroposterior diameter will be measured in both 2D and 3D. Hiatal area and hiatal transverse diameter will be measured in the 3D volume
223567603|NCT04356469|BIOLOGICAL|Haploidentical Hematopoietic Cell Transplantation|TCR alpha beta T-cell and CD19 B-cell depleted haploidentical transplantation
223741197|NCT04510779|DEVICE|Apple Watch|Apple Watch is a smartwatch developed by Apple Inc. The heart rate variability function will be used.
223741198|NCT04258345|OTHER|ASB Feeding Study|Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
224054471|NCT00337909|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
224054472|NCT00337909|OTHER|Educational DVDs|
224054473|NCT01469182|BIOLOGICAL|SCH 39641|Rapidly dissolving tablet sublingually once daily
224054474|NCT01469182|DRUG|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
223443982|NCT05159102|OTHER|12-week FMS Intervention|4 sessions, no more than 3 hours per session covering 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) and Sports (during intervention)
223443983|NCT05159102|BEHAVIORAL|Physical Activities & Activity Booklets (via FitFamilies app)|expected to engage in physical activity at least 3 hours per week, parent workshops provide them with resources to engage in Physical activity
223443984|NCT02865603|BEHAVIORAL|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
223443985|NCT05883059|DEVICE|Lower limb robot assisted walking training|The participants in the robot group received lower limb robot assisted walking training combined with routine rehabilitation therapy. Lower limb robot assisted walking training for 30 minutes each time, once a day, 5 times a week, for 4 consecutive weeks; Routine rehabilitation treatment includes lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabilitation treatment once a day, five times a week, for four consecutive weeks.
223443986|NCT05883059|OTHER|routine rehabilitation|The control group participants received routine rehabilitation, including lower limb muscle strength training, stretching training, joint range of motion training, balance training, walking training, functional electrical stimulation, etc. Routine rehabil
223567604|NCT05623319|DRUG|Pembrolizumab/Olaparib|Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
223741199|NCT06024044|BEHAVIORAL|Mobilization Training|"The participants in the training group were given hysterectomy postoperative mobilization training by the researcher (B.K) using presentation and verbal information technique. A Post-Operative Follow-up Chart was given to the participants to fill in the 1st and 2nd postoperative days. The training group participants were followed up by the researcher on the 0th and 1st days after the operation in line with the mobilization training they received. The Post-Operative Follow-up Chart questioning the patients' mobilization times, distances, bowel functions and pain scores was filled in by the researcher in detail by face-to-face interview method. Mobilization time (minutes) and distance (meters) were evaluated by the patients and their relatives, and recorded on the chart, using the stopwatch and pedometer on the personal mobile phones of the patients."
223741200|NCT00087711|DRUG|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
224054475|NCT02613650|DRUG|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
224054476|NCT03118700|OTHER|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
224054477|NCT03118700|OTHER|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
224054478|NCT01432249|DRUG|Enbrel group|will be decided by treating physicians
224145742|NCT07090434|DEVICE|Mobile App + psychoeducation program|"Participants will attend 12 weekly group sessions, each lasting one hour, focused on psychoeducation. In addition to that, participants will receive access to the BEI mobile app, designed to reinforce education and exercise strategies outside clinical sessions. Participants will be instructed to use the app daily, guided by a to-do list including:~* 1 educational module (interactive format) + 3 questions self-exam~* 1 physical activity (video-guided, adapted by fatigue and pain level)~* 1 gamified cognitive task (for memory, attention, speed processing and/or executive function)~* Daily mood and symptom check-in"
224145743|NCT07090434|BEHAVIORAL|Psychoeducation program|Participants will attend 12 weekly group sessions, each lasting one hour, focused on psychoeducation.
223443987|NCT02913027|OTHER|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
223443988|NCT02913027|OTHER|Bimanual Exam|
223443989|NCT02913027|OTHER|Speculum Exam|
223443990|NCT06205173|OTHER|Hot compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
223567605|NCT02517892|PROCEDURE|Biopsy|
223567606|NCT05312749|OTHER|progressive relaxation exercises|progressive relaxation exercises
223741201|NCT00087711|DRUG|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
224054479|NCT00575198|OTHER|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
223443991|NCT06205173|OTHER|Cold compressing|The intervention in this study will commence 15 minutes before the administration of Oxaliplatin and conclude 15 minutes after the injection. Throughout the process, the patient's local site will be checked every 15 minutes for signs of redness, abnormal sensations, and skin temperature measurement to assess potential harm caused by the applied temperature. If any adverse reactions occur, the intervention will be stopped as necessary.
223443992|NCT03969264|OTHER|High Carbohydrate or Tree Nut Food Snacks|Snack consumption
224054480|NCT00575198|OTHER|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
223567607|NCT04990505|DIAGNOSTIC_TEST|lung ventilation/perfusion scintigraphy|"Chest CT-scan will be performed with blocked inspiration.~Lung ventilation/perfusion scintigraphy imaging will be performed within 24hrs after CT pulmonary angiography, 410MBq of Technegas will be inhaled by patients and ventilation tomography performed thereafter. Then, 185MBq 99mTc-macroaggegates will be injected intravenously followed by the perfusion tomography.~A combined CT acquisition will be performed.~The day following lung ventilation/perfusion scintigraphy, 740MBq of Tc99m labeled albumin will be intravenously administered.~Cardiac gated-blood-pool scintigraphy will be then performed in best septal left anterior oblique and left profile according to specific parameters.~45-60 min after injection, a non-gated tomographic acquisition over the lungs will be done, with the same parameters than for PS SPECT, resulting in a late albumin acquisition."
223567608|NCT01894048|DRUG|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
223567609|NCT03526237|BEHAVIORAL|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
224164034|NCT02569645|DRUG|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
223443993|NCT06215300|GENETIC|coronary artery bypass grafting|coronary artery bypass grafting
224054481|NCT06323603|OTHER|Micro and nanoplastic|Biological samples will be obtained to evaluate the different biomarkers selected
223443994|NCT04840459|BIOLOGICAL|BAMLANIVIMAB|n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.
223443995|NCT04840459|BIOLOGICAL|CASIRIVIMAB|CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
223741202|NCT00087711|DRUG|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
224054482|NCT02053168|DEVICE|Resorbable Mesh|Phasix Mesh
223443996|NCT04840459|BIOLOGICAL|IMDEVIMAB|IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
223443997|NCT00494221|DRUG|AZD2171|oral tablet
223443998|NCT00494221|DRUG|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
223443999|NCT00494221|DRUG|Placebo Cediranib|oral tablet
223444000|NCT05922527|PROCEDURE|Combined regenerative technique|Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
223444001|NCT05922527|PROCEDURE|Open flap debridement|Open flap debridement
223444002|NCT06729931|DIAGNOSTIC_TEST|Pleural Fluid Quantitative C-Reactive Protein (Q-CRP) Measurement|The intervention involves the measurement of Quantitative C-Reactive Protein (Q-CRP) levels in pleural fluid obtained from patients presenting with lymphocytic exudative pleural effusion. The Q-CRP test is performed using standardized laboratory methods to quantitatively analyze CRP levels, which are then compared between patients with confirmed tuberculous pleural effusion and those with malignant pleural effusion. This diagnostic approach aims to evaluate the efficacy of pleural fluid Q-CRP as a biomarker to differentiate between these two conditions. No therapeutic or invasive interventions are introduced as part of this study beyond routine diagnostic procedures.
223444003|NCT00732680|DRUG|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
223444004|NCT03040427|DRUG|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
223444005|NCT03526926|DRUG|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
224054483|NCT02853448|DEVICE|Novel Blood Drawing Apparatus|
224054484|NCT04798599|OTHER|Telemonitoring and teleorientation|"Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject."
224054485|NCT04798599|OTHER|Control Group - Waiting list|No intervention (at least, until the time frame for outcome assessment)
223444006|NCT03765424|DIAGNOSTIC_TEST|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
223444007|NCT04527913|BEHAVIORAL|Interdental Oral Hygiene Instruction (Int-OHI)|"Int-OHI will be given focusing on the interdental device of the allocated group for each patient and will be given only once at timepoint T-7. No further formal Int-OH instructions will be given, unless specifically asked by the patient.~Int-OHI will be delivered by trained dental hygienist/periodontist."
224164035|NCT00514592|OTHER|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
223444008|NCT04527913|PROCEDURE|One session of professional supragingival scaling and polishing|A session of professional supragingival scaling and polishing: instrumentation will be performed by a trained dental hygienist/periodontist with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed.
223444009|NCT04527913|PROCEDURE|Oral Hygiene Instruction (OHI)|"OHI will be given focusing on manual toothbrushing and will be given only once at timepoint T-7. No further formal OH instructions will be given, unless specifically asked by the patient.~OHI will be delivered by trained dental hygienist/periodontist."
223444010|NCT00475514|DRUG|Frovatriptan 2.5mg QD|
223444011|NCT00475514|DRUG|Frovatriptan 2.5 mg BID|
223444012|NCT00475514|DRUG|placebo|
223444013|NCT01348113|OTHER|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
223444014|NCT01714609|DRUG|Placebo|Placebo Comparator: Placebo
223444015|NCT01714609|DRUG|Sorafenib|Sorafenib, 400 mg twice daily
223444016|NCT04722952|DRUG|Visilizumab|Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle. Anti-PD-1 mAb 200mg by IV on day 8 of every cycle. Homoharringtonine(HHT) 2mg/(m2.d) by IV on days 1-6 of every cycle Cytarabine 10mg/(m2.d) by SC on days 1-7 of every cycle Granulocyte colony-stimulating factor(G-CSF) 300ug/d by SC on days 1-7 of every cycle，until absolute neutrophil count(ANC) \> 5X109／L or white blood cell（WBC）\> 20X109／L.
223444017|NCT00630747|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
224054486|NCT02687542|DRUG|Placebo|Placebo
224054487|NCT02687542|DRUG|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
224054488|NCT02687542|DRUG|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
224054489|NCT02687542|DRUG|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
223444018|NCT03858894|DRUG|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
223444019|NCT03858894|DRUG|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
223444020|NCT04585620|DRUG|Onabotulinum Toxin A|Series of subcutaneous injections
223444021|NCT04585620|DRUG|Normal saline|Series of subcutaneous injections
224054490|NCT02687542|DRUG|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
223444022|NCT06910722|PROCEDURE|Liver transplant|follow-up of liver transplant patients after selective internal radiotherapy (SIRT) with Yttrium-90 and chemotherapy
223444023|NCT00034944|DRUG|MK0869, aprepitant|
223444024|NCT00034944|DRUG|Comparator: placebo|
223444025|NCT02306694|DRUG|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
223567610|NCT03526237|BEHAVIORAL|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
224054491|NCT02114164|DEVICE|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
223444026|NCT04728373|PROCEDURE|surgery|the need for surgery after aircraft accidents
223444027|NCT04437472|OTHER|CareSignal|The CareSignal software will be programmed to automatically ask a subset of the NCI-PRO-CTCAE questions using SMS depending on patient group as designated by the treating physician: (1) thoracic radiation with chemotherapy, (2) thoracic radiation alone, (3) extremity/body wall sarcoma, and (4) other.
223444028|NCT03782974|DIETARY_SUPPLEMENT|beta glucan|Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
223444029|NCT01500967|OTHER|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
223444030|NCT01500967|OTHER|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
223444031|NCT03802435|PROCEDURE|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
223444032|NCT03802435|PROCEDURE|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
224054492|NCT02114164|DEVICE|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
224054493|NCT00636675|BEHAVIORAL|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~1. In-House Falls Coordinator training on content and falls processes.~2. Case-based modules about fall prevention and tailored for various team members.~3. Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~4. Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~5. Toolbox: Handbook of useful measures and worksheets."
224164036|NCT06183255|OTHER|Observation and evaluation of clinical parameters in the two cohorts|During medical history evaluation, all factors that could negatively affect male fertility, like prevalent comorbidities, previous testis surgery, and any disorder affecting testicular function will be investigated in fertile and infertile men. Moreover, family history will be deeply investigated, including fertility status and prevalence of malignant Non Communicables Diseases. A comprehensive physical examination will be performed on each infertile and fertile man.
223444033|NCT03802435|PROCEDURE|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
223444034|NCT05869279|BIOLOGICAL|CARCIK-CD19|allogeneic cytokine induced killer cells transduced with a transposon CD19-chimeric antigen receptor (CARCIK-CD19) gene
223444035|NCT00395642|DEVICE|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
223444036|NCT01366300|DRUG|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
223444037|NCT01366300|OTHER|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
223444038|NCT01366300|DRUG|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
224054494|NCT00636675|BEHAVIORAL|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~1. In-class learning sessions introduce interaction strategies.~2. Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~3. Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
223444039|NCT01366300|PROCEDURE|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
223444040|NCT04504149|BEHAVIORAL|Patient Readiness for Improvement through Motivation, Engagement, and Decision-making for PTSD|A primary care-based shared decision making intervention
223444041|NCT05202275|DRUG|Olanzapine|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx, 69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. All patients were given orally olanzapine 10mg once on d1-5; intravenously palonosetron 0.25mg once on d1; aprepitant 125 mg once on d1, then 80mg once on d2-5 at every chemotherapy cycle.
223444042|NCT01569256|DRUG|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
223444043|NCT04684875|DEVICE|Radiofrequency Stylus|Low power radiofrequency energy delivered to the posterior nasal nerve area
223444044|NCT05273775|DRUG|HRS5091 Tablets|HRS5091 Tablets once daily
223444045|NCT05273775|DRUG|Midazolam Maleate Tablets|Midazolam Maleate Tablets single dose
224054495|NCT00096785|DRUG|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
224054496|NCT00096785|DRUG|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
224054497|NCT04053868|OTHER|JUUL|Electronic Cigarette
224054498|NCT04053868|OTHER|Tobacco|Tobacco Cigarette
224054499|NCT05807360|DEVICE|Hyaluronic acid eye drops|Hyaluronic acid (HA)-based eyedrops
224054500|NCT01838616|DRUG|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
224054501|NCT01838616|DRUG|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
223444046|NCT05273775|DRUG|Warfarin Sodium Tablets|Warfarin Sodium Tablets single dose
224054502|NCT00956774|PROCEDURE|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
223444047|NCT05273775|DRUG|Omeprazole Enteric Capsules|Omeprazole Enteric Capsules single dose
223444048|NCT05273775|DRUG|Vitamin K1 Tablets|Vitamin K1 Tablets once daily
223444049|NCT05273775|DRUG|Digoxin Tablets|Digoxin Tablets single dose
223444050|NCT05273775|DRUG|Rosuvastatin Calcium Tablets|Rosuvastatin Calcium Tablets single dose
223444051|NCT02119975|BEHAVIORAL|Working memory training|
223444052|NCT02119975|BEHAVIORAL|Placebo training|
223567611|NCT01686659|DEVICE|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin \[SpHb\] and Pleth Variability Index \[PVI\]) to the clinicians in the operating room
224054503|NCT00956774|PROCEDURE|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
224054504|NCT00956774|PROCEDURE|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
224054505|NCT04340375|DIETARY_SUPPLEMENT|AP green tea extracts|AP green tea extracts
224054506|NCT05449197|OTHER|HEMOPHAR e-learning program|training on professional practice by following HEMOPHAR e-learning program
224054507|NCT01912742|BEHAVIORAL|Very-low calorie diet (VLCD)|
224054508|NCT01912742|BEHAVIORAL|Low calorie diet (LCD)|
223444053|NCT06911879|OTHER|Ketogenic diet with caloric restriction|Participants in this group will follow a ketogenic diet with caloric restriction (-550 kcal/day), consisting of approximately 5-10% carbohydrates, 15-25% protein, 70-80% fat. The daily carbohydrate intake will be limited to less than 50g per day. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
223444054|NCT06911879|OTHER|Normal diet with caloric restriction|Participants in this group will follow a normal diet with caloric restriction (-550 kcal/day), consisting of approximately 45-60% carbohydrates, 15-25% protein, 20-30% fat. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
223444055|NCT06911879|OTHER|Normal diet without caloric restriction|Participants in this group will follow a normal diet without caloric restriction, consisting of approximately 45-60% carbohydrates, 15-25% protein, 20-30% fat. The intervention will last for 12 weeks, with regular dietary monitoring and adherence checks every two weeks.
224054509|NCT02021084|DIETARY_SUPPLEMENT|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
223444056|NCT02930161|DRUG|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
223444057|NCT02930161|OTHER|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
223444058|NCT04747951|COMBINATION_PRODUCT|Concurrent Chemoradiotherapy|"50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.~Concurrent chemotherapy:~Capecitabine 1650 mg/m2/d"
223444059|NCT04747951|PROCEDURE|TME|Total mesorectal excision
223444060|NCT04747951|DRUG|consolidation chemotherapy|Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 3 courses, 3 weeks per course
223444061|NCT04747951|DRUG|adjuvant chemotherapy|Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 6-12 cycles
223444062|NCT03090633|DEVICE|Fetoscopy|Minimally invasive in-utero surgery
223444063|NCT00714753|RADIATION|brachytherapy|
223444064|NCT00714753|RADIATION|hypofractionated radiation therapy|
224054510|NCT02021084|DIETARY_SUPPLEMENT|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
224054511|NCT03023527|DRUG|Nivolumab|
223444065|NCT00714753|RADIATION|image-guided radiation therapy|
223444066|NCT00714753|RADIATION|intensity-modulated radiation therapy|
223444067|NCT02993354|DEVICE|The EUM300 (electrical uterine myography)|This study involves monitoring one group of pregnant women for contractions simultaneously using two different devices to determine if one is superior: the usual tocodynamometer commonly used. Women are simultaneously monitored with both devices.
223444068|NCT06233877|DRUG|G-GLIP plus Mitomycin C|G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
223444069|NCT05539261|DEVICE|magnetic resonance image|Imaging data were collected in a strong magnetic field
223567612|NCT05544942|DIETARY_SUPPLEMENT|Lactobacillus plantarum|1 capsule once a day
223567613|NCT05544942|OTHER|maltodextrin|1 capsule once a day
223744854|NCT04889339|DEVICE|Test brace versus control brace: Long-term correction|After comparing the immediate correction of the braces, each patient will be using either the test or the control brace for a period of two years. There will be follow-up visits, between 6 months and 1 year depending on the patient growth. The brace will be renewed using the same procedure to adapt to the patient's growth. The study protocol requires no additional visits beyond the standard of care. There will be no additional radiograph compared to the standard of care. Compliance monitors are installed in each brace.
224054512|NCT03023527|DRUG|Pomalidomide|
224054513|NCT03023527|DRUG|Dexamethasone|
224164037|NCT00782301|DRUG|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
223444070|NCT05539261|DIAGNOSTIC_TEST|Neuropsychological scale|Multi dimensional neuropsychological test
223444071|NCT01578954|DRUG|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
223444072|NCT00409851|DRUG|valsartan+amlodipine|
223444073|NCT06618053|OTHER|cost-effectiveness and audiometry outcomes|Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes
224054514|NCT03023527|DRUG|Elotuzumab|
224054515|NCT01133899|DIETARY_SUPPLEMENT|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
224054516|NCT01133899|DIETARY_SUPPLEMENT|GAA-4|4.8 grams of guanidinoacetic acid
224054517|NCT01133899|DIETARY_SUPPLEMENT|GAA-1|1.2 grams of guanidinoacetic acid
224054518|NCT01133899|DIETARY_SUPPLEMENT|PLACEBO|celulose
224054519|NCT03545763|OTHER|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
224054520|NCT01349868|DRUG|PT005 MDI|PT005 MDI taken as two inhalations
224054521|NCT01349868|DRUG|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
224164038|NCT00782301|DRUG|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
223444074|NCT06469697|BEHAVIORAL|School music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at both school and community levels.
223444075|NCT06469697|BEHAVIORAL|Community music broadcast|An arts-based eye health intervention featuring traditional and contemporary music pieces will be broadcasted at community levels.
223444076|NCT03943927|OTHER|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
223444077|NCT06002776|OTHER|a retrospective study|a retrospective study
223444078|NCT05947227|OTHER|Buteyko breathing technique|Group A : will be treated with manual chest physiotherapy \& Buteyko Breathing exercise
223444079|NCT05947227|OTHER|Diaphragmatic breathing technique.|Group B : will be treated with manual chest physiotherapy \& Diaphragmatic Breathing Treatment evaluation will be done after 8 weeks through 6MWT \& St George respiratory Questionnaire. Patients will perform technique 5 times a weeks for 8 weeks
223444080|NCT03296020|OTHER|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
223444081|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
223444082|NCT04312282|DRUG|Tesetaxel|Tesetaxel orally on Day 1 of a 21-day cycle
223444083|NCT04312282|DRUG|Itraconazole|Itraconazole orally once daily from Day -3 to Day 14 of a 21-day cycle
223744855|NCT01251549|DEVICE|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
224054522|NCT01349868|DRUG|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
224054523|NCT01349868|OTHER|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
224054524|NCT02774512|DRUG|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
224054525|NCT04272684|OTHER|Driving Assessment|Participants will undergo a driving assessment approximately two months after returning home from hospital
223444084|NCT04312282|DRUG|Rifampin|Rifampin orally once daily from Day -6 to Day 14 of a 21-day cycle
223444085|NCT04064580|OTHER|diagnostic test|performing a capnography examination
223444086|NCT06517173|DRUG|Y-3 for injection|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
223444087|NCT06517173|DRUG|Placebo control group|Qualified subjects were randomly divided into groups in a 1:1 ratio and received continuous treatment with Y-3 injection (40 mg/dose, qd) or placebo control drug. The treatment was performed 10 times for 10 days.
223444088|NCT04747873|BEHAVIORAL|e-CBT|The focus of the sessions is placed on the connection between thoughts, behaviours, emotions, physical reactions, and the environment. We work on evaluating negative beliefs and thought processes and their relationship with depression. Our goal is to adjust the negative thinking so that participants can think about and adapt to the things that are happening to them. This allows them to adjust the way they behave and think about their problems in a way that is not as negative and replaces those thoughts and behaviours with potentially more realistic and productive ones. Participants will be offered e-CBT program over 12 weeks with approximately 30 slides in each module. Participants will complete pre-designed modules and homework assignments while receiving personalized feedback and asynchronous interaction with a therapist through the platform.
223444089|NCT04747873|BEHAVIORAL|Stepped Care|Stepped care procedure (see arm/group descriptions).
223444090|NCT04724031|DRUG|PARP inhibitor|use at any line of treatment in patients with advanced ovarian cancer
223444091|NCT04236167|DEVICE|Fractional CO2 laser treatment -|UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
224054526|NCT00829075|DRUG|r-FSH|
224054527|NCT00829075|DRUG|HP-hMG|
223444092|NCT04666844|OTHER|no intervention|Observational Study
223444093|NCT02804867|PROCEDURE|Online questionnaire and self-administered blood spot|
223444094|NCT04910672|OTHER|Control Group|"Bilateral global pelvic manipulation. Lower right limb in extension. The left lower limb in flexion, until the tension on the SPIS was felt. Introduce very little rotation of the spine. ASI anterior slide until crease forms at waist.~We bring the elbow towards our hips. We rotate the patient posteriorly to open the lumbo sacral facet. The thrust is performed by simultaneously increasing these three parameters, with kick and joint compression."
224054528|NCT00829075|DRUG|r-FSH plus HP-hMG|
224054529|NCT02877693|RADIATION|Thoracic MRI Scan|The ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
224054530|NCT00309543|DRUG|Fluorouracil|
224054531|NCT00309543|DRUG|Leucovorin|
224054532|NCT04729985|DEVICE|CGM device with diabetic education, CGM education and a follow up protocol.|Blind CGM placed and recorded for 14 days after discharge and data downloaded
224054533|NCT03677830|DRUG|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
224054534|NCT03677830|DRUG|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
224054535|NCT00379652|BEHAVIORAL|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
224054536|NCT00379652|BEHAVIORAL|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
224054537|NCT00379652|OTHER|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
224054538|NCT05435651|BEHAVIORAL|Multitask game-based digital therapy|To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
224054539|NCT05435651|BEHAVIORAL|Schulte Grid digital game|To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
224054540|NCT02970214|OTHER|no intervention, only observational|no intervention, only observational
224054541|NCT01566773|DRUG|PT001 MDI|Administered as two puffs BID for 14 days
223444095|NCT04910672|OTHER|Experimental Group|"Bilateral Global Pelvic Manipulation and Internal Correction Technique for Laterflexion of the Uterus The technique consists of making contact with the vaginal fingers on the upper and anterior part of the cervix, while the abdominal hand, dragging the skin towards the pubis, tries to make contact as posterior as possible on the fundus of the uterus. The technique consists, while the patient breathes widely, in progressively raising the uterine fundus forward and upward and lowering the cervix until the normal anteversion position is achieved.~At the end of the technique, fixing the correction position of the uterus, we can ask the patient to perform a pelvic anteversion, while the correction is maintained. At the end of the technique, all abnormal tension should have disappeared and the uterus should have recovered a physiological position of anteversion."
223444096|NCT02951572|DEVICE|NIV|
223444097|NCT05690165|BEHAVIORAL|Walking Exercise|Heart rate controlled walking exercise
223444098|NCT01676818|DRUG|eribulin mesylate|Given IV
223444099|NCT02418741|OTHER|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
223444100|NCT05233384|BIOLOGICAL|Blood test|"For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation)."
223444101|NCT06731439|OTHER|Starting feeds within 6 hours of life|Starting feeds within 6 hours of life
223567614|NCT04127799|OTHER|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
223567615|NCT04127799|OTHER|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
223567616|NCT06540703|DIETARY_SUPPLEMENT|Therapeutic Ketogenic Diet (TKD)|2 week induction to establish ketosis followed by 12 weeks therapeutic ketogenic diet
223444102|NCT06731439|OTHER|Standard feeding protocol|Starting feeds based on standard protocol as per primary team
223444103|NCT06460610|OTHER|Blow Bottle technique|Patients sit at a table with comfortable position Hold the bottle with one hand and the tube with the other Put the tube in mouth by holding lips firmly Breath in through nose and out through mouth Blowing enough water is bubbled Short Breaks for 2 to 3 mints When mucus rises up get out of it by coughing or huffing
223444104|NCT06460610|OTHER|Acapella along with Diaphragmatic Breathing|Device which uses a counter weighted plug and magnet to create airway oscillations Acapella combines the effects of PEP therapy and airway vibrations and mobilize to clear pulmonary secretions Facilitates opening of airways in patients with lung disease. Patients instructions to close the mouth piece making surety to no leakage of air. Take a long breath in nose and blow out through the Acapella ,feel vibrations on chest. Duration of performing this technique 3 days a week for 20 mints per day, 4 weeks regular
223444105|NCT01523210|OTHER|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
223444106|NCT01174810|DRUG|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
223444107|NCT03349281|DRUG|Pevonedistat|Administered each cycle on days 1, 3 and 5.
223444108|NCT03349281|DRUG|Vincristine|Administered each cycle on days 2, 9, 16 and 23.
223444109|NCT03349281|DRUG|Dexamethasone|Taken orally each cycle on days 2 through 15.
223444110|NCT03349281|DRUG|PEG-asparaginase|Administered via intramuscular injection (IM) each cycle on days 9 and 23.
223444111|NCT03349281|DRUG|Doxorubicin|Administered via IV each cycle on day 2.
223567617|NCT06423664|BEHAVIORAL|Play and Learn Strategies (PALS) Program|Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
224054542|NCT01566773|DRUG|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
224054543|NCT01566773|DRUG|PT001 Placebo MDI|
224054544|NCT03033537|DRUG|Verapamil|Local treatment of erectile dysfunction
224054545|NCT02751203|BEHAVIORAL|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
224054546|NCT05313451|OTHER|Soluble fiber|15g/day during 2 months
224054547|NCT05313451|OTHER|Placebo|Maltodextrin 15g/day during 2 months
224054548|NCT06243874|PROCEDURE|greater occipital nerve block|greater occipital nerve block
224054549|NCT06243874|PROCEDURE|transnasal sphenopalatine ganglion block|transnasal sphenopalatine ganglion block
224054550|NCT00833053|DRUG|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
224054551|NCT00833053|DRUG|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
223444112|NCT03349281|DRUG|Cytarabine|Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
223444113|NCT03349281|DRUG|Methotrexate|Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
223444114|NCT03349281|DRUG|Hydrocortisone|Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
223444115|NCT06075810|DRUG|MBQ-167|MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42
223444116|NCT01507714|PROCEDURE|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
223444117|NCT05598710|PROCEDURE|Pigtail Insertion|Pigtail is inserted for any reason of ureteral obstruction except for malignant
223444118|NCT06730581|DRUG|Utidelone Capsule 60mg/m2/d|60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223444119|NCT06730581|DRUG|Utidelone capsule 75mg/m2|75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223444120|NCT06730581|DRUG|Utidelone Capsule|Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.
223444121|NCT01029613|DRUG|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
224054552|NCT04483674|DRUG|50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide|"Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL"
224054553|NCT02829307|DRUG|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
224054554|NCT02828553|OTHER|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
224145744|NCT07091188|BEHAVIORAL|Health education, capacity building and economic incentives|"1. Social media platform-based for health education. Pregnant women in the same gestational month will be invited to join specific WeChat group chats tailored to their similar health education and management needs.~2. Capacity building. ANC providers at township hospitals will participate in short-term, small-class training courses designed to cover essential aspects of antenatal care prior to the intervention with the pregnant women.~3. Economic incentives. To encourage ANC attendance, a monetary reward system will be implemented for village doctors every time they successfully identify and invite a newly pregnant woman to initiate her ANC visit."
223444122|NCT06446336|OTHER|HASS Score|Creation of a pre-operative score
223444123|NCT02510313|OTHER|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
223444124|NCT02769936|DRUG|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
223444125|NCT02769936|OTHER|Placebo|Placebo administered orally as encapsulated pill
223444126|NCT05306236|OTHER|LLL therapy , postural correction ex|"study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only."
223444127|NCT05342428|DRUG|TLL018 tablets|Oral tablets administered at different doses BID daily for 12 weeks.
223444128|NCT04849533|DRUG|Belatacept|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
223444129|NCT04849533|DRUG|Everolimus|belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
223444130|NCT04849533|DRUG|mycophenolate mofetil|belatacept with mycophenolate is approved regimen for prevention of rejection
223567618|NCT06650878|PROCEDURE|Desarda|This technique prevent from using a mesh to surgical repair of a inguinal hernia
223444131|NCT04849533|DRUG|corticosteroids|belatacept with chronic steroids is approved regimen for prevention of rejection
223444132|NCT04849533|DRUG|rabbit antithymocyte globulin|rabbit antithymocyte globulin induction for prevention of rejection
223444133|NCT05633277|PROCEDURE|Polidocanol|Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.
223567619|NCT06650878|PROCEDURE|Lichtenstein|This technique implies using a mesh to surgical repair of a inguinal hernia
223567620|NCT06119789|DRUG|Imatinib|imatinib treatment based on molecular alterations
223567621|NCT06119789|DRUG|Trametinib|According to biomarkers
223567622|NCT06119789|DRUG|Dabrafenib|According to biomarkers
223567623|NCT00425997|DRUG|Valsartan/HCTZ|
223567624|NCT00425997|DRUG|amlodipine|
223567625|NCT00425997|DRUG|HCTZ|
223567626|NCT00353808|DRUG|[S,S]-Reboxetine|
224054555|NCT05778058|DEVICE|Unilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
224054556|NCT05778058|DEVICE|Bilateral Stimulation|With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
224054557|NCT05778058|DEVICE|Bilateral Sham Stimulation|Participants were shown that the device was working, but no current was given.
224054558|NCT05778058|DIAGNOSTIC_TEST|Bicycle Ergometer Test|Participants in this group were asked to perform bicycle exercise with maximum performance under 30 watts for 30 minutes.
224145745|NCT07092293|OTHER|occupational therapy|N/A as there is no intervention for this study
223444134|NCT02425033|PROCEDURE|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
223444135|NCT03213197|OTHER|CPR video|Patient watches a short CPR video
223741203|NCT05440279|DEVICE|digital patient support|"Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring."
223741204|NCT00873509|DRUG|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
223444136|NCT04294797|DIAGNOSTIC_TEST|Blood draw|One additional blood sample for study purpose from the day before surgery, postoperative 1, 3 and 8.
223741205|NCT00873509|DRUG|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
223444137|NCT03337035|DRUG|intranasal oxytocin|4-24 IU per day, dosage gradually increases
223444138|NCT03337035|DIETARY_SUPPLEMENT|oral probiotics|200 million cfu per day
223444139|NCT03337035|DIETARY_SUPPLEMENT|oral placebo|2 pills per day
223741206|NCT00873509|DRUG|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
223741207|NCT05333900|BEHAVIORAL|Plant-Based Diet then animal-based diet|Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
223741208|NCT05333900|BEHAVIORAL|Animal-based diet then plant-based diet|Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
224054559|NCT05778058|DIAGNOSTIC_TEST|Lactat Scout|For lactic acid analysis measurement, the middle fingertip of the athlete is disinfected with an alcohol swab and a blood sample is taken by puncturing the finger.The measuring range is 0.5 - 0.25 mmol/L.
224054560|NCT05778058|DIAGNOSTIC_TEST|Polar H10|RR times transferred to computer with Polar H10 are used in heart rate variability analysis. Heart rate data will be transferred to the Kubios program and heart rate variability parameters will be calculated and data on the autonomic nervous system (RMSSD, PNS index, Stress index, SNS index, pNN50, Power LF, Power HF and LF/HF ratio) will be obtained.
224054561|NCT05778058|DEVICE|Vagustim Device|Vagustim Health Technologies Vagus stimulator device is used for this experiment.
224054562|NCT04411485|OTHER|Sexual dysfunction|Sexual dysfunction will be determined with separate scales for women and men
224054563|NCT01408992|PROCEDURE|Audiometry|Standard hearing test performed by audiologists
224054564|NCT01408992|OTHER|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
223444140|NCT03409939|DIETARY_SUPPLEMENT|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
223444141|NCT00001043|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
223444142|NCT03027323|DEVICE|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
223444143|NCT03652584|OTHER|High Protein Diet|
223444144|NCT03652584|OTHER|Control Diet|
223444145|NCT04580537|DRUG|Enstilar|Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
223444146|NCT04580537|DEVICE|Ablative fractional laser|Pre-treatment of affected fingers (nail plates, nail folds)
223444147|NCT06514456|OTHER|no intervention|no intervention
223444148|NCT00774007|DRUG|mesalazine|
223444149|NCT00774007|DRUG|placebo|
223444150|NCT03402347|RADIATION|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
223444151|NCT02342977|DRUG|Placebo|Patients will randomly receive placebo
223444152|NCT02342977|DRUG|Lacosamide|Patients will randomly receive lacosamide
223444153|NCT05106751|DEVICE|Hyaluronic acid dermal filler|Hyaluronic acid dermal filler used for facial volume or wrinkle correction
223741209|NCT06308068|DRUG|Diacerein 50 mg Capsule|Diacerein 50 mg Capsule
223741210|NCT03933787|DRUG|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
224054565|NCT03707067|DEVICE|Compression garments|Made-to-measure compression garments providing high pressures (\> 30 mmHg at the ankle and \>20 mmHg at the thigh - equivalent to European class-2 stockings)
224054566|NCT03707067|OTHER|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
224054567|NCT00522145|DRUG|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
224054568|NCT06496282|DRUG|Lemborexant|The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study
224054569|NCT06496282|DRUG|Placebo|The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
224054570|NCT00637884|DRUG|Fexofenadine HCl|
223444154|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Boost motivation and self-efficacy|"In the boost motivation and self-efficacy dialog, the conversational agent will tell the participant that they can successfully resist smoking, try to take away their self-doubts and assert that the participant can and will succeed. For example, the conversational agent will send text messages such as: Even though the temptation can be high, I have no doubts that you can resist smoking in this situation. If you want something, you can do it. Believe in yourself!."
223444155|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Future-selves and implementation intentions|"In the future-selves and implementation intentions dialog, the conversational agent will first tell the participant to imagine themselves in a future in which they successfully quit smoking (i.e., desired future self). The conversational agent can send text messages such as: Please think about yourself in the future. Imagine that you have quit smoking successfully. Think about the person you will be. What do you look like? What does your life look like? Consider this future image as well as you can.. This procedure will be repeated for a future in which the participant continued smoking (i.e., the undesired future self). Finally, the conversational agent will explain to the participant that it is important to think about how to resist smoking in HRSs (i.e., implementation intentions) to ensure that the participant comes closer to becoming their desired future self as non-smoker and to avoid their undesired future self as a smoker."
223444156|NCT05654545|BEHAVIORAL|Lapse prevention dialog: Identity-related positive self-talk|"In the identity-related positive self-talk dialog, the conversational agent will tell the participant to use positive self-talk focused on their identity to motivate themselves to successfully resist smoking. For example, the conversational agent will send text messages such as: When you feel tempted to smoke, it can help to say positive things to yourself and motivate yourself to resist the temptation. What positive things can you say about yourself to motivate yourself to resist smoking? For instance, 'I am a strong person who can resist smoking' or 'I am a person who is persistent and has control over the urge to smoke'. Now say the sentence(s) you find motivating or your own motivating words to yourself, by thinking it, and repeating it in your head or out loud.."
223444157|NCT05654545|BEHAVIORAL|Attention control dialog: neutral topic|"The neutral dialog will act as an attention control condition. In this dialog, the conversational agent will not provide support using relapse prevention strategies. Instead, the conversational agent will start with a short introduction (e.g., Hi, how are you doing?), ask questions to show interest (e.g., How are you feeling today?) and will talk about a neutral topic (e.g., animals; What is your favorite animal?), and then closes the conversation (e.g., It was nice speaking with you. I hope you have a good rest of the day!)."
223444158|NCT04038554|DIAGNOSTIC_TEST|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
223444159|NCT00986947|DRUG|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
223444160|NCT03362580|DEVICE|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
224054571|NCT04064502|DIAGNOSTIC_TEST|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
223444161|NCT03362580|DEVICE|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
223444162|NCT03362580|DEVICE|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
223444163|NCT03362580|DEVICE|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
223444164|NCT06925854|DRUG|AZD4144|Oral tablet of AZD4144 will be administered.
224054572|NCT02187471|DRUG|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
223444165|NCT06925854|DRUG|Rosuvastatin|Oral tablet of rosuvastatin will be administered.
223444166|NCT01580176|DEVICE|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
223444167|NCT00030680|RADIATION|radiation therapy|
224054573|NCT02187471|DRUG|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
224054574|NCT02187471|DRUG|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
223444168|NCT03667027|DEVICE|Respiratory support|Mechanical ventilation or extracorporeal life support
223741211|NCT03933787|DRUG|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
224054575|NCT02187471|DRUG|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
224054576|NCT04082871|OTHER|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.\[19\] This system was explained in detail and applied successfully in many previous studies.\[10, 14, 20\] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
224054577|NCT02236520|DRUG|Spironolactone|
224054578|NCT02236520|DRUG|Chlorthalidone|
223444169|NCT05083676|BEHAVIORAL|Acceset Intervention|". The intervention comprises of: i) Digital peer support training for youth befrienders to equip them with the knowledge and application of the four active ingredients-Mattering, selfhood, compassion, and mindfulness-to provide effective peer support as they respond to youth seekers' emotional experiences.~ii) Acceset Intervention with features or digital markers of psychological well-being, peer emotional disclosure process and community engagement."
223444170|NCT00701480|OTHER|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
223444171|NCT00701480|OTHER|marketed skin cleanser|face washing 2-3 times/day
223741212|NCT03933787|OTHER|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
224054579|NCT02236520|DIETARY_SUPPLEMENT|Diet|
224054580|NCT02236520|DRUG|Placebo|
224054581|NCT02651168|BIOLOGICAL|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
224054582|NCT01785160|DRUG|Raltegravir|low dose oral administration
224054583|NCT01785160|DRUG|Raltegravir|low dose oral administration
224054584|NCT01785160|DRUG|Faldaprevir|medium dose oral administration
224054585|NCT01539681|DRUG|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
224054586|NCT00820677|BEHAVIORAL|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
224054587|NCT04096209|DEVICE|autograft mixed with xenograft bone|"Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome"
224054588|NCT06022731|DIAGNOSTIC_TEST|Panoramic Radiography|this retrospective study includes analysis of radiographs previously taken from patients for various purposes
224054589|NCT01370720|DIETARY_SUPPLEMENT|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
224054590|NCT01370720|OTHER|Placebo|tablets, 2tablets/day, 12 weeks
224054591|NCT05754385|BEHAVIORAL|Ambulatory monitoring of liver fat|Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.
224054592|NCT05754385|BEHAVIORAL|Standard of care|Subjects will have follow-up every 6 months by hepatologists for routine care
224054593|NCT00957528|DRUG|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
224054594|NCT00957528|DRUG|Placebo|Weekly IM injections of sesame oil.
224054595|NCT02154282|BEHAVIORAL|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
224054596|NCT05823415|PROCEDURE|Laterally Closed Tunnel with CTG|A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.
224054597|NCT05823415|PROCEDURE|CAF with CTG|Gold standard surgical technique
224145746|NCT07090304|DIAGNOSTIC_TEST|FIT|FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
224145747|NCT07090304|DIAGNOSTIC_TEST|FIT-sDNA|FIT-sDNA test combines Fecal Immunochemical Test (FIT) and stool DNA (sDNA) analysis. It detects hemoglobin in stool through FIT to identify occult blood in the gastrointestinal tract and simultaneously analyzes specific DNA mutations or epigenetic alterations (such as methylation changes) in stool DNA to assess the risk of colorectal neoplasms.
223444172|NCT01226680|DRUG|Tasocitinib|0.005% QD for 12 weeks
223444173|NCT01226680|DRUG|Tasocitinib|0.003% QD for 12 weeks
223444174|NCT01226680|DRUG|vehicle for Tasocitinib|vehicle QD for 12 weeks
223567627|NCT04190407|BEHAVIORAL|Intravenous access|A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
223444175|NCT06531629|PROCEDURE|Surgery, radiation therapy and chemotherapy|Surgery, radiation therapy and chemotherapy
223567628|NCT01805908|OTHER|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
223567629|NCT01753869|PROCEDURE|Airways clearance and Hypertonic saline inhalation|
223567630|NCT05129904|OTHER|Double plasma molecular absorption system|DPMAS is an extracorporeal procedure that combines two hemoperfusion machines. During the procedure, toxic plasma is separated and cleansed by perfusion over two absorbers, and the final cleansed plasma is then returned to patients. It does not require large volumes of plasma and nor does it bear the risk of plasma-associated allergic reaction or disease transmissions. DPMAS can attenuate the jaundice in a short term and decrease the bilirubin concentration, which then reduces the toxicities of bile acid and high levels of bilirubin on the hepatocytes
223567631|NCT05712109|OTHER|Follow-up after Anterior cruciate ligament reconstruction|The patients were referred to the sport medicine department for the post ACL-R follow-up including isokinetic knee muscle strength evaluations at 4 months and 8.months after the surgery
223567632|NCT02945358|PROCEDURE|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
223444176|NCT06147960|DIAGNOSTIC_TEST|Immunohistochemistry|Blocks containing formalin-fixed, paraffin-embedded (FFPE) biopsies will be used to analyse the expression of XIAP, cIAP1 and cIAP2 proteins by immunohistochemistry. The antibodies will be selected on the basis of the literature and their validation for this technology (Schnoell et al. 2020). The immunohistochemical techniques will be performed on an automated immunolabelling machine (DakoLink®) after antigen demasking. The specific binding of primary antibodies will be revealed by the application of Flex reagent (Dako Agilent), a dextran polymer coupled on the one hand to anti-mouse and anti-rabbit immunoglobulins, and on the other hand to a large number of horseradish peroxidase (HRP) molecules. 3,3'-Diaminobenzidine (DAB) will be used as a substrate for this enzyme to highlight the specific expression of the biomarker. The use of an automated system will ensure the reproducibility of inter-sample labelling.
223444177|NCT03832504|OTHER|No intervention|The participant will rest in a seated position.
223444178|NCT03832504|OTHER|Fan|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.
223444179|NCT03832504|OTHER|Skin Wetting|Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
223444180|NCT03832504|OTHER|Fan + Skin wetting|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
223444181|NCT03704948|BEHAVIORAL|RCT Treatment -Listening Visits delivered by NICU nurse in person|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
223444182|NCT03704948|BEHAVIORAL|RCT Control Usual mental health care delivered by NICU social workers|RCT Control Usual mental health care delivered by NICU social workers
223444183|NCT03704948|BEHAVIORAL|Open trial: Listening Visits delivered by a NICU nurse via zoom|Open trial: Listening Visits delivered by a NICU nurse via zoom
223741213|NCT06050694|DRUG|glofitamab|Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
224054598|NCT04940104|DRUG|Botox Injectable Product|Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
223444184|NCT06379568|OTHER|No intervention|No intervention
224054599|NCT06119867|PROCEDURE|Japanese pathological investigation|Japanese pathological investigation
224054600|NCT06119867|PROCEDURE|European pathological investigation|The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
224054601|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
223444185|NCT04361214|DRUG|Leflunomide|Tolerability study of leflunomide 100 mg administered once daily for 3 days followed by 30 mg administered once daily for the duration of 2 - 7 days.
223444186|NCT03489941|DRUG|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
223444187|NCT03489941|DRUG|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
223444188|NCT03489941|DRUG|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
223444189|NCT00198913|BEHAVIORAL|lower fat food supplied and education|
223741214|NCT05091437|DIAGNOSTIC_TEST|Observational study|Incidental lung nodules identification
223741215|NCT05856695|DRUG|Carboplatin + Paclitaxel + Durvalumab|Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
223741216|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
223741217|NCT00372268|DEVICE|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
223444190|NCT00198913|BEHAVIORAL|gift cards for grocery foods and written education|
223444191|NCT03001479|DIETARY_SUPPLEMENT|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
223444192|NCT04621838|OTHER|Assigned interventions.|"Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing.~The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited."
223444193|NCT03715387|DRUG|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
223744856|NCT00174655|DRUG|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
224054602|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
224054603|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
224054604|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
224054605|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
223444194|NCT03715387|DRUG|Polysporin Ointment|Polysporin ointment
223444195|NCT03718754|DEVICE|En-Bloc TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
223444196|NCT03718754|DEVICE|Conventional TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
223444197|NCT00659776|DRUG|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
224054606|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
223444198|NCT04332731|DEVICE|Symplicity Spyral™ multi electrode renal denervation system|Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.
223444199|NCT04332731|DIAGNOSTIC_TEST|Renal angiogram|Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
223444200|NCT03972020|BEHAVIORAL|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
224054607|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
223444201|NCT03972020|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
223444202|NCT01180049|DRUG|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
223444203|NCT01180049|DRUG|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
223444204|NCT00182000|DRUG|seromycin|100mg tablet administered 1 hour prior to each therapy session
223444205|NCT00182000|BEHAVIORAL|Behavior Therapy|10 weekly hour-long behavior therapy sessions
223444206|NCT04177888|DEVICE|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
223444207|NCT02004327|DRUG|DW1029M300mg|DW1029M300mg PO Once
223444208|NCT02004327|DRUG|DW1029M600mg|DW1029M300mg 2 tablets Once
223444209|NCT02004327|DRUG|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
223444210|NCT06731231|DRUG|SGLT2 inhibitor|Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
223744857|NCT00174655|DRUG|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
224054608|NCT00677274|PROCEDURE|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
224054609|NCT06361732|OTHER|No intervention|No intervention
224054610|NCT02440360|BEHAVIORAL|PSH|Please see arm description.
224054611|NCT02440360|BEHAVIORAL|Usual Care|Please see arm description.
224054612|NCT04776733|OTHER|prepackaged semisolid nutritional formulations|"The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast."
224054613|NCT04776733|OTHER|restricted diet|"The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast."
224054614|NCT06003114|DRUG|Palbociclib|Participants taking oral palbociclib as prescribed in first-line treatment.
224054615|NCT03854864|OTHER|survey|to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
224054616|NCT02593162|DRUG|Faldaprevir|
224054617|NCT02593162|DRUG|TD-6450|
224054618|NCT02593162|DRUG|Ribavirin|
223444211|NCT04792372|PROCEDURE|Initial periodontal treatment|Conventional periodontal treatment (scaling and root debridement) will be conducted
223444212|NCT04691167|DEVICE|repetitive trans magnetic stimulation|Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.
223444213|NCT04008264|DRUG|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
223444214|NCT00005762|DRUG|Indinavir sulfate|
223444215|NCT00005762|DRUG|Ritonavir|
223444216|NCT00005762|DRUG|Amprenavir|
223741218|NCT05440929|BEHAVIORAL|Clinician Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
224054619|NCT05141760|DIAGNOSTIC_TEST|PSMA-1007 Positron Emission Tomography (PET) scan and 3T Magnetic Resonance Imaging (MRI)|Additional staging PET and MRI scan prior to prostatectomy and lymph node dissection
224054620|NCT00103974|BIOLOGICAL|BHT-3009-01|
224054621|NCT05908682|OTHER|Non-interventional study|This is not an interventional study
224054622|NCT05793671|DEVICE|PPCI in heavy thrombus burden STEMI patients|minimally invasive procedures used to open clogged coronary arteries
224054623|NCT02116556|DRUG|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
224054624|NCT02116556|DRUG|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
224054625|NCT03027362|OTHER|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
224054626|NCT03027362|OTHER|Psychoeducation and medication|
224054627|NCT02081534|DRUG|AZD1722|AZD1722, oral tablet
224054628|NCT02081534|DRUG|Placebo|Placebo bid, double dummy technique
224054629|NCT04911036|OTHER|Questionnaires|Perinatal PTSD Questionnaire State Trait Anxiety Inventory-forme Y-B Early Support Questionnaire Socio-demographic questionnaire
224054630|NCT03553043|BEHAVIORAL|Intervention|Energy label condition.
224054631|NCT03553043|BEHAVIORAL|Control|No label
224054632|NCT02345954|PROCEDURE|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
224054633|NCT02345954|PROCEDURE|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
224054634|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
224054635|NCT00670319|DRUG|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
224054636|NCT00670319|DRUG|Placebo|Placebo one tab orally per day
224054637|NCT03114176|DIETARY_SUPPLEMENT|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
224054638|NCT03269071|DRUG|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
224054639|NCT04182373|DRUG|Antithrombin gamma|Intravenous infusion, once a day, 7 days
224054640|NCT04182373|DRUG|physiological saline|Intravenous infusion, once a day, 7 days
224054641|NCT00837941|DRUG|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
224054642|NCT00837941|DRUG|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
224054643|NCT00837941|DRUG|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
224054644|NCT00483301|DRUG|Sorafenib (BAY 43-9006)|dosage
224054645|NCT00483301|DRUG|ABI-007(Abraxane)|dosage
223444217|NCT00005762|DRUG|Nelfinavir mesylate|
224054646|NCT00518037|BEHAVIORAL|surveys|anxiety surveys
223444218|NCT00005762|DRUG|Efavirenz|
223444219|NCT00005762|DRUG|Saquinavir|
223444220|NCT02968680|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo SLNB
223444221|NCT02968680|DEVICE|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
223444222|NCT02968680|DRUG|Sonazoid|Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
223444223|NCT00427427|DRUG|Trastuzumab|
223444224|NCT04318262|BIOLOGICAL|Determination of the clinical and biological characteristics|"* clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…"
223444225|NCT04318262|BIOLOGICAL|Description of the antibiotic resistance profile|Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
223444226|NCT04318262|BIOLOGICAL|Molecular epidemiology of S. lugdunensis infections|Genome sequencing (Illumina technique)
223444227|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection."
223444228|NCT02972450|BIOLOGICAL|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline."
223444229|NCT02972450|DRUG|Vedolizumab 300 MG [Entyvio]|Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
223444230|NCT02972450|OTHER|Placebo|"Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
223444231|NCT04159324|OTHER|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
223444232|NCT05206786|OTHER|Conventional preventive work out|Female players in the control group will carry out a conventional preventive work that is organised in 3 training days per week. First training session includes preventive strength and proprioception exercises. Junior and senior teams (above 16 years old) will also do plyometrics exercises. In the second training session, players will do preventive strength exercises with an increased load compared to the previous session and proprioception exercises. Junior and senior players will also do anaerobic work. In the third session, players will perform reaction speed exercises.
223444233|NCT05206786|OTHER|Gluteus maximus strengthening specific program|"Female players will carry out a gluteus maximus strengthening work out in addition to the control group programme. Of the following four exercises, the first and the third ones will be done on the first training session and the second and the fourth exercises will be done on the second one. Dosage will be 2 sets of 10 repetitions for each leg.~1. Clam Shell: Lateral decubitus with the knees and hips bend, the working leg placed on top of the other. Separate this knee while feet stay in contact.~2. Unilateral gluteal bridge: Supine decubitus with one foot flat on the floor and bent knee. This leg pushes the ground with the foot until the pelvis is lifted while the other leg remains straight.~3. Quadruped hip extension with knee extension : Quadruped on forearms. Straighten the hip by bringing the whole leg up and back with knee extension.~4. Quadruped hip extension with bent knee: Performed as the previous one, but during this one, the knee of the working leg is bent at 90º."
223444234|NCT03571022|BEHAVIORAL|USE-MI System|"Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s)."
223444235|NCT05059925|OTHER|Structured gym activities|"Planned and structured activities such as Strength training~* Dumbbell Exercises (1kg with 2 sets of 10 repetitions)~* Sit-ups (2 sets of 10 repetitions)~* Stair climbing, (2 sets of 10 stairs up and down)~* Squat (2 sets of 10 repetitions) Flexibility training • Tai chi (Peng. Lu, chi, an Tsai, lieh, chou, Kao (Hold each posture for 20 seconds)) • Pilates (Breathing., Shoulder bridge, Leg lifts (Hold each pose for 20 seconds)) • Stretching techniques (Neck stretch, Shoulder stretch, Side stretch Hold each stretch for 20 seconds))."
223444236|NCT05059925|OTHER|Traditional aerobic activities|"Activities performed such as~* Treadmill Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Cycle ergometer Time: 10 minutes Intensity: 60 to 80% of target heart rate~* Elliptical exercises Time: 10 minutes Intensity: 60 to 80% of target heart rate"
223444237|NCT06040216|OTHER|optical coherence tomography|We observed the postoperative improvement in EIFL severity with optical coherence tomography
223444238|NCT01864252|OTHER|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
223444239|NCT01864252|DRUG|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
223444240|NCT01864252|DRUG|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
223444241|NCT01995864|BEHAVIORAL|CTI-TS|"The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual."
223444242|NCT00482599|DRUG|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
223444243|NCT06101537|DEVICE|Brain temperature-pressure monitoring|An intracranial pressure monitoring device that continuously records brain temperature-pressure data was used during treatment.
223444244|NCT01832909|OTHER|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
223444245|NCT01832909|OTHER|Control Diet|Controlled diet without walnuts.
223444246|NCT06910280|PROCEDURE|conservative surgery for breast cancer with local anesthesia|conservative surgery for breast cancer with local anesthesia
223444247|NCT06910280|PROCEDURE|conservative surgery for breast cancer with general anesthesia|conservative surgery for breast cancer with general anesthesia
223444248|NCT01905592|DRUG|niraparib|300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
223444249|NCT01905592|DRUG|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
223444250|NCT01356329|DRUG|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
223444251|NCT02360748|DIETARY_SUPPLEMENT|Plant based high protein food items|Patients will add high protein plant based food items to their diet
223444252|NCT02946489|DRUG|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
223444253|NCT01358240|DRUG|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
223741219|NCT05402072|PROCEDURE|Autologous matrix-induced chondrogenesis (AMIC)|AMIC is a novel approach in which the microfracture technique has been enhanced by the use of a type I/III collagen matrix (Chondro-Gide®; Geistlich Pharma AG, Wolhusen, Switzerland). In this single-step procedure, the matrix is placed over the defect to stabilize the fragile blood clot that arises from microfracture and to provide infrastructure for repair tissue formation. Essentially, the matrix covers the defect and serves as a protective shield that contains the cells and minimizes the impact of shear forces when moving the hip on the delicate blood clot. At the same time, it functions as the roof of a biological chamber that forms over the defect. The biocompatible collagen material provides an environment for cell growth and is replaced by native tissue over time.
223741220|NCT05621252|DRUG|PLN-74809|160 mg PLN-74809
223741221|NCT05621252|DRUG|Placebo|Matching placebo
224054647|NCT03611855|DEVICE|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
224054648|NCT03611855|OTHER|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
223444254|NCT01358240|DRUG|Vehicle Foam|Vehicle Foam applied once a day for 4 week
223444255|NCT01358240|DRUG|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
223444256|NCT01358240|OTHER|Placebo Cream|Placebo cream applied once a day for 4 weeks
223444257|NCT04137341|DRUG|GLPG1972 - A|Film-coated tablet, formulation A
223444258|NCT04137341|DRUG|GLPG1972 - B|Film-coated tablet, formulation B
223444259|NCT04137341|DRUG|GLPG1972 - C|Film-coated tablet, formulation C
223444260|NCT03996564|DEVICE|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
223444261|NCT03996564|DRUG|Acetaminophen|Acetaminophen 500mg-1000mg,
223444262|NCT03996564|DRUG|Diclofenac|Diclofenac 50mg-75 mg orally
223444263|NCT03996564|DRUG|Diazepam|Diazepam 5mg-10 mg intravenous or oral
223444264|NCT03996564|DRUG|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
223444265|NCT03996564|DRUG|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
223444266|NCT05050500|DRUG|Dapagliflozin 10mg/Tab|patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
223741222|NCT03573479|OTHER|PICU Liber8 Bundle|Bundle of elements for quality improvement
223741223|NCT01394523|DRUG|Bupivacaine|0.25% or 0.5%
223741224|NCT05864469|OTHER|12-week psychosocial dyadic intervention|Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
223744858|NCT00174655|DRUG|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
223744859|NCT00174655|DRUG|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
223744860|NCT04535791|DRUG|Cholecalciferol|4,000 IU orally daily for 30 days
224054649|NCT04539340|BIOLOGICAL|GNR-055|Single intravenous administration
224054650|NCT05289635|PROCEDURE|different suture types|For a wound that is deeper in nature, a mattress stitch can be placed, providing better strength. Mattress sutures can be applied as vertical or horizontal subtypes. So far, various studies have compared the effect of horizontal mattress suture (HMS) with vertical mattress suture (VMS) on wound healing in different wound. However, limited studies have evaluated the effect of the subtype of mattress sutures on the early wound healing and microcirculation changes of peri-implant soft tissues following implant surgery using Laser Doppler flowmetry. The test group use vertical mattress suture and the control group use the horizontal mattress suture.
223444267|NCT05050500|DRUG|Placebo|patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
223444268|NCT00105287|DRUG|OraVescent fentanyl (OVF)|
223444269|NCT02919007|DEVICE|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
223444270|NCT00724802|DIETARY_SUPPLEMENT|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
223444271|NCT00724802|DRUG|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
223444272|NCT01158014|PROCEDURE|Fibrin Glue, Quixil|quixil 0.1 ml
223444273|NCT01158014|PROCEDURE|Suture|vicryl 10/0
223444274|NCT00884845|DRUG|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
223444275|NCT00884845|DRUG|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
224054651|NCT02318667|BIOLOGICAL|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
223444276|NCT04622761|DRUG|Cabazitaxel|"Patients will receive Cabazitaxel 25 mg/m2 \* intravenously over one hour every 21 days (on Day 1 of each cycle). Treatment will be continued for 4 cycles unless disease progression, unacceptable toxicity or patient request. These patients will have surgery (radical prostatectomy) 4-86 weeks following treatment.~\*Cabazitaxel dose should be capped at 50mg (BSA=2)"
223444277|NCT06938477|OTHER|THERA-TRAINER BASED EXERCISES|The interventions will carried out two days a week and 40 minutes for eight weeks
223444278|NCT06938477|OTHER|FUNCTIONAL STROKE TRAİNİNG|he interventions will carried out two days a week and 40 minutes for eight weeks
223444279|NCT02863653|OTHER|observational study|application of several standard instruments in patients with rheumatoid arthritis
223444280|NCT04361097|BIOLOGICAL|Faecal microbiota transplant|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
223444281|NCT04361097|BIOLOGICAL|Placebo|Both groups will receive frozen capsules to be ingested orally (constituted of TMF or placebo according to the randomization) with a frequency of 15 capsules every 12hrs for 4 doses on days 1, 10 and 30 of the study. Each capsule should be ingested in a period no longer than 1 hour.
223444282|NCT05363956|DRUG|salvadora|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
223444283|NCT05363956|DRUG|Eucalyptus Oil|The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
223444284|NCT02116725|OTHER|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
223444285|NCT02116725|OTHER|Plain shower gel|Standard shower gel (Sanex).
223444286|NCT02116725|OTHER|Distilled water|Sterile distilled Water.
223444287|NCT06067581|BIOLOGICAL|SENL103|Patients will be treated with BCMA CAR-T cells
223444288|NCT04316260|BEHAVIORAL|Smoking cessation e-visit|electronic visits (e-visits) for smoking cessation
223444289|NCT04316260|BEHAVIORAL|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
223444290|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
223444291|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
223444292|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
223444293|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
223444294|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
223444295|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
223444296|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
223444297|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
223444298|NCT00160342|DRUG|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
223444299|NCT03015194|DEVICE|Edwards SAPIEN 3 transcatheter heart valve|"Used to relieve aortic stenosis in patients with symptomatic heart disease~In this study it is not used for aortic stenosis-----the device is used in the mitral valve position."
223444300|NCT03015194|DEVICE|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
223444301|NCT02707172|BEHAVIORAL|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
223567633|NCT02684058|DRUG|Dabrafenib|Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
223567634|NCT02684058|DRUG|trametinib|"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"
223567635|NCT02684058|DRUG|Carboplatin|"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."
224054652|NCT01423409|DEVICE|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
223444302|NCT02707172|BEHAVIORAL|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
223444303|NCT02844894|DRUG|Dexmedetomidine|
223444304|NCT02844894|DRUG|Esmolol|
223444305|NCT02844894|DRUG|Placebo|normal saline
223444306|NCT03866629|DRUG|Lifitegrast|Lifitegrast ophthalmic solution 5%
223444307|NCT05633589|BIOLOGICAL|Sc610 cell injection|"Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell product preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and amplification factor, and cell quantity are amplified. The obtained Sc610 is used for one-time intravenous infusion."
223444308|NCT06304402|DEVICE|The Percussive Massage Treatment|In the group where regional vibration is applied, the Hypervolt™ vibrating massage device (HYPERICE Inc, US) will be used. This device is a vibration device with five different speed settings, vibrating at 3,200 percussions per minute (HYPERICE Inc. 'Hypervolt' device. Retrieved from https://hyperice.com/hypervolt-bluetooth, Accessed on: 08.12.2021). The device offers five different head attachment options. For this study, the ball attachment option will be selected as it is the least aggressive option, and the vibration from the device will be applied to the relevant muscle body (Kayoda, 2019). For facilitatory effect, the application will be performed on the posterior deltoid for 5 minutes at a low frequency.
223444309|NCT06304402|BEHAVIORAL|The Proprioceptive Neuromuscular Facilitation Stretching|Among the PNF stretching techniques, the muscle-relaxation technique will be applied. The athlete will be positioned in a side-lying posture on the treatment table with the dominant shoulder in the modified sleeper position, ensuring stabilization of the scapula on the table. The other arm will be positioned in extension along the body with the palm facing upwards. The participant will be instructed to actively bring the arm of the lower limb to the physiological barrier of internal rotation. At this point, they will be asked to perform maximum isometric contraction in external rotation for 7 seconds. After the isometric contraction, the muscle will be relaxed, and active-assisted stretching will be applied in internal rotation for 15 seconds. A 5-second rest will be provided between repetitions, and the exercise will consist of 5 repetitions.
223444310|NCT04191343|DRUG|Toripalimab injection combined with GEMOX|Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
223444311|NCT00433017|DRUG|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.
223444312|NCT00433017|DRUG|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
223444313|NCT00433017|DRUG|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
223444314|NCT03323970|OTHER|semi-structured interviews|individual semi-structured interviews
223444315|NCT03955900|OTHER|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
223444316|NCT05498064|DRUG|Ensartinib|Ensartinib 225 mg administered once daily orally
223444317|NCT04823806|DIETARY_SUPPLEMENT|Spermidine (spermidineLIFE ®) OR Placebo|21 day of 6mg spermidine OR Placebo supplementation per day
223444318|NCT04563637|DIAGNOSTIC_TEST|Computer based vision application by video|patients will be tested by computer based analysis of a video as well as by dexa scan.
223444319|NCT04563637|RADIATION|whole body dual energy x-ray absorptiometry scan|subjects will receive a whole body dual energy x-ray absorptiometry scan to measure their body fat percentage
224054653|NCT01423409|DEVICE|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
224054654|NCT00343421|BIOLOGICAL|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
224054655|NCT00343421|BIOLOGICAL|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
224164039|NCT03182621|BEHAVIORAL|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
224164040|NCT03182621|BEHAVIORAL|SPARK|traditional YMCA program
223444320|NCT04193553|DRUG|Lenvatinib|"Lenvatinib will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for dose reductions will be respected according to BI Lenvatinib.~If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met."
223567636|NCT02684058|DRUG|Vincristine|"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."
224054656|NCT02151955|BEHAVIORAL|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
224054657|NCT02947672|DRUG|Intravenous Dexamethasone|
224054658|NCT02947672|DRUG|Intraperitoneal Dexamesathone|
224054659|NCT05639127|DRUG|Prednisolone|Nebulization of prednisolone
224054660|NCT00136422|BIOLOGICAL|autologous tumor cells|
224054661|NCT01033734|DRUG|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
224164041|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 5 mg
224164042|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
224164043|NCT00412113|DRUG|Amlodipine besylate|Amlodipine besylate 10 mg
224054662|NCT00286273|DRUG|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
224054663|NCT00286273|DRUG|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
223444321|NCT04193553|DRUG|Placebo|"Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm."
223444322|NCT04193553|OTHER|Best supportive care|At any time during the study, patients should receive best supportive care. Best Supportive care as medically indicated for the patient's well-being may be prescribed at the investigator's discretion. Based on the patient's condition, it may consist (but not limited) of analgesics, antibiotics, steroids, blood transfusion, antiemetics, antidepressants/anxiolytics, nutritional counselling, psychological support, palliative radiotherapy…
223444323|NCT00562731|DRUG|ARD-0403|Daily transdermal ARD-0403
223567637|NCT03042650|BEHAVIORAL|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
223567638|NCT03042650|BEHAVIORAL|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
223567639|NCT06090981|DRUG|Bovine surfactant|Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
223567640|NCT03478254|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~\- Received at least one Influenza vaccine dose in the last year."
223567641|NCT03478254|BIOLOGICAL|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
223567642|NCT03478254|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
223567643|NCT04202406|DRUG|Acetaminophen and codeine and caffeine|The patient will receive pretreatment oral single dose of Combination of 1000mg acetaminophen- 16mg codeine- 60mg caffeine 1 hour before treatment.
223567644|NCT04202406|DRUG|Acetaminophen|The patient will receive pretreatment oral single dose of 1000mg acetaminophen alone 1 hour before treatment.
223567645|NCT04202406|DRUG|Placebo|The patient will receive placebo (starch) 1hour before treatment.
223567646|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223567647|NCT05468190|BIOLOGICAL|CD70 CAR-T cells|Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223567648|NCT02879643|DRUG|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
223567649|NCT05924698|OTHER|Electrostimulation|Consisting of the use of NMES (biphasic symmetrical pulse, bipolar mode, 50Hz frequency, pulse duration 300 μs at 1:1 ratio) (S82®; Enraf-Nonius BV, Rotterdam, The Netherlands). The self-adhesive electrodes (8x5 cm2 Pals Platinum © type, Axelgaard Manufacturing Co. Ltd, Fallbrook, CA, USA) were placed on the quadriceps muscle. The positives electrodes placed distally on the rectus anterior and vastus externus and negative electrodes were placed proximally on the rectus anterior and vastus internus. The over current program consisted of 8 seconds (s) of work (ON phase) and 8 seconds of rest (OFF phase). The overcurrent program in the ON phase had a rise time of 2 s, a hold time of 4 s and a fall time of 2 s. The intensity of the electric current was increased to the maximum perceived tolerance, achieving a clear contraction without producing fatigue.
223567650|NCT05924698|OTHER|Blood flow restriction therapy|To attain partial vascular occlusion, a PTS ii portable tourniquet system (Delphi Medical, Vancouver, BC, Canada) with a corresponding size-specific tourniquet was placed around the patient's proximal thigh. This system allows for precise control of cuff pressure throughout training despite the changes in muscle volume that naturally occur while performing exercises. Total limb occlusion pressure (LOP) was identified by determining the pressure required to eliminate a detectable pulse using Doppler ultrasound. Partial vascular occlusion was achieved by setting the tourniquet to 80% of the LOP. This ensured that venous occlusion was obtained while still allowing arterial inflow and was personalized to each patient despite variations in thigh girth, cuff size, and systolic blood pressure. An Easy-Fit Tourniquet Cuff (Delfi Medical, Vancouver, VC, Canada) was used with the PTS ii system.
223567651|NCT02485249|DRUG|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
223567652|NCT06104878|OTHER|No Intervention|No Intervention will be administered in this study.
223567653|NCT06897332|BEHAVIORAL|Real-world manual dexterity task|Participants will perform a manual dexterity task involving the displacement of physical cubes
223567654|NCT06897332|BEHAVIORAL|Immersive virtual reality with controllers|Participants will perform a manual dexterity task in an immersive virtual reality environment, requiring them to move virtual cubes using controllers
223567655|NCT06897332|BEHAVIORAL|Immersive virtual reality with hand-tracking|Participants will perform a manual dexterity task in an immersive virtual reality environment, requiring them to move virtual cubes using the hand-tracking technology
224054664|NCT05376865|DIETARY_SUPPLEMENT|Vitamin D supplement|The intervention group receives 50000 IU of vitamin D every week as vitamin D supplements for 12 weeks, provided monthly.
224054665|NCT01577901|OTHER|Clearblue Advanced|Pregnancy test
223444324|NCT01888653|BEHAVIORAL|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
223444325|NCT01888653|BEHAVIORAL|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
223444326|NCT05000736|DRUG|palbociclib + aromatase inhibitor|palbociclib + aromatase inhibitor therapy
223444327|NCT05000736|DRUG|fulvestrant|fulvestrant monotherapy
223741225|NCT02389998|OTHER|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
223741226|NCT02389998|DRUG|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
223741227|NCT03525574|DRUG|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
224054666|NCT00309634|BIOLOGICAL|4 adjuvanted pandemic influenza candidate vaccines|
224054667|NCT00309634|BIOLOGICAL|4 non-adjuvanted pandemic influenza candidate vaccines|
224054668|NCT06116617|DRUG|SRSD107|SRSD107 is a synthetic, chemically modified double-stranded, small interfering ribonucleic acid (siRNA).
224054669|NCT06116617|DRUG|Placebo|Sodium chloride
224054670|NCT04451915|OTHER|late management strategy|late management strategy of GDM defined as no intervention until GDM screening at 24-28 weeks. Between 24-28 weeks gestation, a 75-g OGTT will be done
224054671|NCT04451915|OTHER|early management strategy|early management of GDM defined as intensive metabolic treatment. Intensive treatment involved the following multidisciplinary approach: lifestyle defined by diet and exercise intervention according to the French guidelines
224054672|NCT03089593|OTHER|Extract of ginger|The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
224054673|NCT03089593|OTHER|Placebo (Cellulose)|The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
224054674|NCT01652183|DRUG|intravenous paracetamol|
224054675|NCT01652183|DRUG|Placebo|
224054676|NCT01347424|DRUG|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3-4h， d1～15，q3w
224054677|NCT01347424|DRUG|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
224054678|NCT03351751|DRUG|Placebo|Placebo
224054679|NCT03351751|DRUG|PF-06372865|PF-06372865
224054680|NCT00657813|DRUG|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
223444328|NCT02875873|DRUG|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
223444329|NCT02875873|DRUG|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
223444330|NCT02875873|OTHER|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
223444331|NCT02875873|OTHER|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
223444332|NCT02004314|DRUG|Chloroquine|
223444333|NCT03952026|PROCEDURE|osteosynthesis of the pelvis|Osteosynthetic Fixation of the pelvic fracture
223741228|NCT03525574|DRUG|IVA|Tablet for oral administration.
224054681|NCT06004414|BEHAVIORAL|App-based Cognitive Behavioral Therapy (CBT)|SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.
224054682|NCT06004414|BEHAVIORAL|Psychotherapy|Psychotherapy with a licensed clinician at one of the study sites.
224054683|NCT04638972|DEVICE|working length determination techniques|A total of 30 infected mandibular primary second molar teeth in twelve children aged between 5 and 8 years were included in this study. Working length determination was performed using tactile sense, radiographic method and two different varieties of electronic apex locators (ProPex Pixi® and Ipex®) separately.
224054684|NCT01409733|DEVICE|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
223444334|NCT06458777|DIAGNOSTIC_TEST|poligraphy|OSA diagnosis
223444335|NCT00335010|DRUG|Nitroglycerin|
224054685|NCT01441830|DEVICE|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
224054686|NCT03976011|DEVICE|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
224164044|NCT00412113|DRUG|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
223444336|NCT01108237|OTHER|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
223444337|NCT01108237|DEVICE|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
223444338|NCT00495690|DRUG|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
223444339|NCT02851316|OTHER|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
223444340|NCT05003830|DEVICE|PET/MR|18F-FDG, 11C-PIB and 18F-PM-PBB3 injection are radiopharmaceuticals used for positron emission tomography (PET) imaging. 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), and used in the assessment of brain glucose metabolism. 11C-PIB dose is about 5-10mCi, and used in the assessment of amyloid deposition. 18F-PM-PBB3 dose is about 5-10mCi, and used in the assessment of tau deposition. Use PET/MR equipment for simultaneous PET and MR collection.
223444341|NCT01829997|DEVICE|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
223444342|NCT05029245|BIOLOGICAL|Comirnaty®|intradermal injection or intramuscular injection
223444343|NCT00370435|DRUG|GW274150|
223444344|NCT05223803|RADIATION|Prostate radiation (XRT)|Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.
223444345|NCT05223803|DRUG|Systemic Therapy|All systemic therapy is provided as best prescribed for patient per their medical oncologist.
223444346|NCT05223803|RADIATION|Stereotactic ablative radiation therapy (SABR)|SABR is delivered to those randomized to Arm 2.
223444347|NCT02446535|OTHER|achievement of the DW by means of the BIA DW (RE.S.T.)|
223444348|NCT04925778|DRUG|monomethyl fumarate|Patients will be prescribed 190 mg (two 95 mg capsules) self-administered twice/day,
223444349|NCT06321497|DEVICE|Extracorporeal carbon dioxide removal|Low flow extracorporeal carbon dioxide removal with PrismaLung+
223444350|NCT01100190|DEVICE|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
223444351|NCT00000888|DRUG|Ritonavir|
223444352|NCT00000888|DRUG|Lamivudine|
223444353|NCT00000888|DRUG|Zidovudine|
223444354|NCT05712837|DRUG|25% TRICHLOROACETIC ACID|Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
223444355|NCT05712837|DRUG|30% salicylic acid|Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
223444356|NCT04185584|OTHER|Not Applicable (Observational Study)|Not Applicable (Observational Study)
223444357|NCT01071434|PROCEDURE|MR Imaging|
223567656|NCT06896760|DRUG|[14C]ABSK011|The standard meal was taken the night before administration, and the patient was fasted for at least 10 h without drinking water overnight. The next morning, eat a low-fat meal, finish the meal within 30 minutes, and take the test drug with warm water 30 minutes (±5 minutes) after the beginning of the meal. The total volume of warm water and suspension liquid is about 240 mL. Except for meals and administration, no water was allowed 1 hour before and 1 hour after medication. No food is allowed for 4 hours after taking the medication. Throughout the study, participants received meals provided by the center at approximately the same time each day.
223567657|NCT06896318|DEVICE|Virtual Reality Therapy|8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR TierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
224164045|NCT00864123|BEHAVIORAL|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
223444358|NCT05742074|OTHER|Faecal microbiota transplantation|25-30 capsules of faecal material
223444359|NCT05742074|OTHER|Placebo|25-30 placebo capsules
223444360|NCT00504543|DRUG|AEB071|oral, twice daily
223444361|NCT00504543|DRUG|Certican|twice daily
223444362|NCT00504543|DRUG|Neoral|twice daily
223444363|NCT04990765|BEHAVIORAL|Virtual Reality Cognitive Behavioral Therapy (CRAVR)|Participants in the intervention group will scheduled for 3 weekly treatment sessions based on manualized cognitive behavioral therapy assisted with alcohol-related high risk situations (6 different scenes from a restaurant) in virtual reality. From scene 1 to scene 6, alchol-related cues increase in intensity in order to perform gradual exposure therapy as a part of CBT. Furthermore, VR scenes are used in CBT to induce craving for coping strategy skill training and cognitive analysis.
223444364|NCT04990765|BEHAVIORAL|CBT|The active comparator receives 3 conventional cognitive behavioral therapy sessions with 1 week intervals.
223444365|NCT00930527|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid|4g per day for 3 weeks
223444366|NCT04457401|DIETARY_SUPPLEMENT|Probiotic|This probiotic is commercially available and contains Bifidobacterium (3 x 10\^9 colony forming units/capsule) as the active ingredient and potato starch, magnesium stearate and ascorbic acid as excipients.
223444367|NCT04457401|DIETARY_SUPPLEMENT|Placebo|The placebo contains potato starch, magnesium stearate and ascorbic acid.
223444368|NCT05273905|DIAGNOSTIC_TEST|Ultrasound derived Avi|Assess the Avi of carotid arteries, hepatic arteries, renal arteries and central retinal arteries.
223444369|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Rind|watermelon rind
223444370|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Flesh|watermelon flesh
223444371|NCT03365960|DIETARY_SUPPLEMENT|Watermelon Seeds|watermelon seeds
223444372|NCT03365960|DIETARY_SUPPLEMENT|Placebo|Control Comparator
223444373|NCT00564278|DRUG|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
223444374|NCT00564278|BEHAVIORAL|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
223741229|NCT06209229|BIOLOGICAL|sodium nucleinate|"* Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy.~* Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy.~* Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy.~* sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months.~* Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days."
224054687|NCT05760443|BEHAVIORAL|Learning to BREATHE|"Learning 2 BREATHE (L2B) is an empirically-supported, manualized mindfulness-based group program (Broderick, 2021). Participants attend 6 sessions of approximately 1.5 hours per session. BREATHE is an acronym: Body, Reflections, Emotions, Attention, Tenderness, Habits, Empowerment; each week's lesson is centered around one of the letters (week 1 encompasses both Body and the overall theme of the sessions, Empowerment). Sample activities of L2B include psycho-education on emotion and self-regulation, body scanning, sitting meditation, non-aerobic yoga, and walking meditation, designed to promote moment-to-moment awareness of mind-body experiences. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants will have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
224054688|NCT01607736|BEHAVIORAL|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
223444375|NCT02333500|OTHER|olfactory workshop|olfactory workshop
223444376|NCT02333500|OTHER|other workshop|other workshop: discussion group, dance and body Expression
223444377|NCT02333500|OTHER|No intervention|control group
223741230|NCT00905554|PROCEDURE|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
224054689|NCT05604495|DIAGNOSTIC_TEST|Sweat Test|In people with cystic fibrosis (CF), there is a problem in the transport of chloride across cell membranes. This results in higher concentrations of chloride (as salt) in sweat compared to those who do not have cystic fibrosis. So, if there is a family history or a possibility of CF, the sweat test is part of the special tests to help make, or exclude, a diagnosis of cystic fibrosis.
224054690|NCT06075589|BEHAVIORAL|Education for Intervention|Participants watch two fifteen-minute educational videos and receive a mental health resource information sheet on study.
224054691|NCT06075589|BEHAVIORAL|Best Practice|Patients receive enhanced treatment as usual and receive a mental health resource information sheet on study.
223444378|NCT05810896|OTHER|AF at Home|The AF at Home education program will be delivered via Zoom videoconferencing technology and will include 6, 1-hour long sessions that involve education on AF self-monitoring and self-management. Each session will include a didactic presentation and open Q\&A. Supplementary educations materials will be made available to participants.
223444379|NCT03714711|PROCEDURE|total hip arthroplasty|Total hip replacement
223444380|NCT03714711|PROCEDURE|total knee arthroplasty|Total knee replacement
223444381|NCT05245422|OTHER|Infant Formula - Partially hydrolyzed protein|Partially hydrolyzed cow's milk protein
223444382|NCT05245422|OTHER|Infant Formula - Intact protein|Intact cow's milk protein
223444383|NCT05603923|BEHAVIORAL|Lumen Coached PST Intervention.|Lumen Intervention Orientation. Participants in the Lumen intervention arm attend a Lumen orientation visit (60 minutes) during which they will be given a Lumen intervention tutorial and receive a study iPad, configured to limit access to only the Lumen intervention enabled on the device. Before leaving, participants are scheduled for the first PST session with Coach Lumen. At the end of each PST session, participants are prompted to schedule their next session with Coach Lumen. They receive automated reminder notifications 1 day prior to their next session, on the session day, and have the opportunity to make up missed sessions. As needed, Lumen intervention orientations can be done remotely.
223741231|NCT00905554|PROCEDURE|air insufflation|air insufflation during the insertion phase of colonoscopy
223444384|NCT05603923|BEHAVIORAL|Human Coached PST Intervention.|Participants in the human coached PST arm will serve as active treatment controls given the demonstrated efficacy of human coached PST in depression and anxiety. They will complete 8 PST sessions with a human coach; first session in-person and remaining sessions via videoconferencing (i.e., Zoom preferred; with phone calls allowed) on the same 4 weekly and then 4 biweekly schedule as that for Lumen participants. Participants will receive a study iPad to use for their PST sessions via zoom. Participants also complete the PHQ-9 and GAD-7 during each session. Participants will receive a certificate of completion.
223444385|NCT05603923|BEHAVIORAL|Optional (delayed) Lumen Coached PST (Waitlist control).|Waitlist control participants will only complete assessments during the 18-week trial period. At the end of their 18-week assessment, they will have the option to complete 8 PST sessions on their assigned iPads.
224054692|NCT04774731|OTHER|Whole Body Vibration|Receiving WBV training three times a week before initiation of dialysis sessions for 12 weeks. Subjects stand on a platform of WBV for 3 minutes in every training session.
223444386|NCT05962788|DRUG|voclosporin|Subjects will receive 2 capsules (15.8 mg) BID (twice daily), 3 capsules (23.7 mg) BID of voclosporin in addition to standard of care with mycophenolate mofetil (MMF) and steroids.
223444387|NCT06439095|GENETIC|Salivary Collection|Expression levels of IL-2, IL-5 and IL-17 in the saliva of individuals aged 3-9 years who underwent stainless steel crown will be recorded before and after the procedure. Before the saliva sample collection procedure, the patient will be asked to rinse their mouth with sterile water and then spit into sterile plastic cups. After collecting approximately 3 ml of saliva, the saliva will be transferred to appropriate eppendorfs and stored at -40 degrees Celsius. For the second post-procedure, the same algorithms will be applied for saliva collection seven days after the crown procedure.
223444388|NCT06439095|DIAGNOSTIC_TEST|Ph and ion level measurement of saliva|Salivary concentration of nickel, chrome ions will be measured using an atomic absorption spectrophotometer.
223444389|NCT06445647|OTHER|core Stability exercise|core stability exercise training
223444390|NCT06445647|OTHER|Breathing exercises|Deep breathing and diaphragmatic breathing exercises
223444391|NCT04544189|DRUG|Alpelisib|300mg (oral) once daily, in a 28-day cycle
223567658|NCT06896318|BEHAVIORAL|Cardiac rehabilitation|A three-week, hospital-based cardiac rehabilitation program for all participants, incorporating structured group exercises and activities. The conventional cardiac rehabilitation program includes morning warm-up exercises, afternoon group sessions, interval training on stationary bikes, and relaxation activities. Morning sessions consist of 20 minutes of standing cardiovascular exercises accompanied by music, while afternoon sessions include 45 minutes of seated activities, divided into cardiovascular, equipment-based, and breathing exercises.
223741232|NCT06018714|DRUG|Fruquintinib|"Drug:~Maintenance treatment regimen:~Fruquintinib 5 mg, qd, po, with three weeks of continuous treatment followed by one week of drug discontinuation. Each treatment cycle lasts four weeks. The treatment will be continued for six months, or until tumor recurrence, metastasis, or intolerable drug toxicities occur within six months.~Adverse drug reactions that occur during the trial will be graded according to the NCI CTCAE version 5.0 and dose adjustments will be made according to the corresponding rules."
224145748|NCT07091240|BEHAVIORAL|Behavioral Parent Training|Family Check-Up® Online is delivered through a secure website that can be accessed via computer or phone at participating caregivers' convenience. Caregivers will complete the Developmental Early Childhood Instrument for Deciding Effectively about Mental Health (DECIDE) tool, a risk calculator that screens for early signs of future mental health challenges, at their child's 24- or 30-month well-check visit with their pediatrician. Clinicians will use the DECIDE tool risk calculator score to refer caregivers of at-risk children to FCU-O. Caregivers may use FCU-O independently, or they may work with a trained coach who will facilitate their use of the program. Participation is open to caregivers who are referred to FCU-O based on their DECIDE risk calculator score by their child's pediatrician and is available in English or Spanish. Participants will also complete assessments via survey and direct observation before beginning FCU-O, and 6- and 12-months after their referral to FCU-O.
224145749|NCT07091305|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|"Induction: QL1706 5 mg/kg IV on Day 1, Etoposide: 100 mg/m² IV on Days 1-3, Cisplatin or Carboplatin: Cisplatin 75 mg/m² IV on Day 1 or Cisplatin 25 mg/m² IV on Days 1-3, Or Carboplatin AUC = 5 IV on Day 1, Q3W, for a total of 2 cycles.~Chemoradiotherapy：Thoracic Radiotherapy（60 Gy in 30 fractions, once daily (2 Gy/fraction), or 45 Gy in 30 fractions, twice daily (1.5 Gy/fraction)），Etoposide 100 mg/m² IV on Days 1-3, Cisplatin either 75 mg/m² IV on Day 1, or 25 mg/m² IV on Days 1-3, Or Carboplatin AUC=5 IV on Day 1 PCI: Patients achieving or approaching complete response, per investigator assessment, 25Gy in 10 fractions.~Consolidation: QL1706 5 mg/kg IV on Day 1, Q3W"
224054693|NCT01489670|DRUG|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
223444392|NCT04544189|DRUG|Fulvestrant|Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
223444393|NCT04544189|DRUG|Placebo|300 mg by mouth once daily, in a 28-day cycle
223444394|NCT03789591|DRUG|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg\*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
223444395|NCT05564689|PROCEDURE|Intracoronary flow and pressure|Measurement of absolute coronary flow and resistance
223444396|NCT05978232|BEHAVIORAL|NAVAH|Patient navigator program that aims to inform African-American prostate and breast cancer patients about their treatment options, specifically radiotherapy
223444397|NCT06216093|BIOLOGICAL|EuRSV|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
223444398|NCT06216093|OTHER|Placebo Comparator|Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
223741233|NCT03794557|DRUG|Sterile Water Injection|Inhaled Sterile Water Injection
224054694|NCT02289742|DEVICE|Nelfilcon A multifocal contact lenses|
224054695|NCT02289742|DEVICE|Nelfilcon A toric contact lenses|
224054696|NCT02289742|DEVICE|Nelfilcon A sphere contact lenses|
224054697|NCT05802654|RADIATION|SBRT|The participants enrolled will receive single fraction of ultra-high dose SBRT(30Gy/1F).
224145750|NCT07091175|BIOLOGICAL|Dupilumab|Subcutaneous injection of Dupilumab for 24 weeks (weight based dosing)
224145751|NCT07091175|DRUG|Placebo|Subcutaneous injection of normal saline placebo (matching dupilumab subcutaneous injection dosing) for 24 weeks
223444399|NCT03341936|DRUG|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
223444400|NCT03341936|DRUG|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
223444401|NCT02368886|DRUG|Clobetasol Propionate|Given topically
223444402|NCT02368886|OTHER|Pharmacological Study|Correlative studies
223444403|NCT02368886|OTHER|Quality-of-Life Assessment|Ancillary studies
223444404|NCT02368886|DRUG|Regorafenib|Given PO
223444405|NCT02339974|DEVICE|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
223444406|NCT05680337|DEVICE|TENS|TENS stimulation will occur within 10 minutes. HRV parameters will be evaluated before stimulation initially at rest, in the first 5 minutes of stimulation, in the second 5 minutes of stimulation and after the end of stimulation.
223444407|NCT06235606|DRUG|Bupivacaine Liposome 13.3 Milligrams/Milliliter [Exparel]|Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
223444408|NCT06235606|DRUG|Dexmedetomidine 0.5milligram (50micrograms)|Dexmedetomidine is a full α₂ adrenergic receptor agonist roughly eight times more selective for the α₂ receptor than clonidine.
223444409|NCT06564428|GENETIC|Suspective gene mutations and family history|To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
223444410|NCT01744171|BIOLOGICAL|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
223444411|NCT01744171|OTHER|Laboratory Biomarker Analysis|Correlative studies
223444412|NCT04460534|DIAGNOSTIC_TEST|diagnostic|The principle of this study is to propose to patients in whom a COVID-19 infection is suspected and who are screened for the disease, the joint search for the virus in the semen.
223444413|NCT04555499|OTHER|Standardized neurological examination|
223567659|NCT04863300|BEHAVIORAL|Collaborative stepped care and peer support|"Case identification will be done through open referral and outreach activities such as street booth, talks, and home visits.~For older adults with mild depressive symptoms (PHQ-9 score 5-9), 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided by the project social workers in DECC. For participants with moderate depressive symptoms (PHQ-9 score 10-14), 6-8 weeks high-intensity clinical intervention, mainly group cognitive behavioral therapy (CBT), would be provided by project social workers from DECC and ICCMW. For those with moderately severe depressive symptoms (PHQ-9 score 15-19), 8-10 weeks individual CBT or group CBT at higher frequency would be provided by the project social workers from ICCMW.~In the progress review when a client is assessed to meet the discharge criteria, a 2-month exit plan involving a Peer Supporter follow-up is invoked."
223567660|NCT06770673|BEHAVIORAL|TOD Great Plains|The adapted TOD intervention is rooted in the original TOD structure, delivery system, and home-visiting teaching schedule. Local enhancements include intervention topics and activities to address local adult caregivers' diabetes management and to promote families' modifiable risk and protective factors targeted by this proposal and informed by the Wicozani wellness concept and measurement. The TOD intervention includes targeted content taught approximately bi-weekly by family health coaches over a 16-week period.
223741234|NCT03794557|DRUG|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
223741235|NCT00373867|BEHAVIORAL|Standard physical therapy|Treatment-based classification physical therapy
223741236|NCT00373867|BEHAVIORAL|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
223741237|NCT00373867|OTHER|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
223741238|NCT04101981|PROCEDURE|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
223741239|NCT03814746|DRUG|Crizanlizumab (SEG101)|"Crizanlizumab was supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion.~IV."
223444414|NCT02485418|DRUG|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
223444415|NCT05056571|BEHAVIORAL|Progressive muscle relaxation|Progressive muscle relaxation exercise is a type of exercise in which tense muscles in your body gradually relax and relax. It is an application that allows you to forcefully stretch every muscle group in your body, hold it tight for 5 seconds, and then relax it. Visualize your tense muscles throughout this exercise and imagine that the feeling of relaxation spreads to all your muscles in the form of a wave and the tension is relieved. Keep breathing throughout the entire exercise.
223444416|NCT02960477|OTHER|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
223444417|NCT02960477|OTHER|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
223444418|NCT06046209|DEVICE|Control Lens|Daily disposable contact lens for 90 minutes
223444419|NCT06046209|DEVICE|Test Lens|Monthly replacement contact lens for 90 minutes
223444420|NCT05461365|DRUG|Insulin|Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
223444421|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
223444422|NCT03944993|DEVICE|Pulsed Electromagnetic Fields Therapy (Non-dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
223444423|NCT03944993|DEVICE|Sham Therapy (Control)|Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
223444424|NCT00111306|DRUG|epratuzumab|
223444425|NCT01824121|BIOLOGICAL|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
223444426|NCT02131636|DRUG|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
223444427|NCT02131636|DRUG|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
223444428|NCT03887624|DRUG|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
223444429|NCT03887624|DRUG|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
223444430|NCT03887624|DRUG|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
223444431|NCT00235248|DRUG|Warfarin|Warfarin
223567661|NCT06770673|BEHAVIORAL|Waitlist Standard of Care|Participants who are waitlisted to receive the TOD intervention will receive Standard of Care.
223567662|NCT06890689|PROCEDURE|Scaling and root planing|Retrospective study to evaluate the outcome of scaling and root planing
223741240|NCT03814746|DRUG|Placebo|Placebo was supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for infusion IV.
223741241|NCT05501184|OTHER|Synchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
223741242|NCT05501184|OTHER|Asynchronous Exercise Program|The exercise program consisted of exercises by recommended guidelines for nonspecific neck pain patients which includes various strengthening, stretching, and proprioceptive exercises with progression.
223741243|NCT04098107|DEVICE|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
223741244|NCT00755157|DRUG|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
223741245|NCT00755157|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
223741246|NCT04344314|DEVICE|Peripheral Intravenous Catheter|Randomised controlled
223741247|NCT04892043|BIOLOGICAL|SQZ-AAC-HPV|Activating antigen carriers (AACs) cell therapy; therapeutic vaccine engineered from red blood cells manufactured with immunogenic epitopes of HPV16
223741248|NCT04892043|DRUG|Ipilimumab|Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
223741249|NCT04892043|DRUG|Nivolumab|Programmed cell death 1 (PD-1) blocking antibody
223741250|NCT05240560|DRUG|BP1.3656|Histamine H3 receptor antagonist/inverse agonist
223741251|NCT04084041|DEVICE|Simeox|Airway clearance device
223741252|NCT04084041|OTHER|CCPT|Conventional chest physiotherapy
223741253|NCT04657614|OTHER|Neutral Alignment|Alignment that is a neutral replicate of the participants prescribed prosthesis.
223741254|NCT04657614|OTHER|Anterior Alignment|Alignment that is anterior displaced pylon.
223741255|NCT04657614|OTHER|Posterior Alignment|Alignment that is posteriorly displaced pylon.
223741256|NCT02444260|DRUG|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
223741257|NCT02444260|DRUG|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
223741258|NCT02444260|DRUG|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
223741259|NCT02444260|DRUG|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
224164046|NCT00864123|DRUG|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
224164047|NCT00864123|DRUG|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
223444432|NCT00235248|DRUG|Clopidogrel-aspirin|Clopidogrel-aspirin
223444433|NCT02173379|DEVICE|Absorb BVS|"* Scaffold diameters: 2.5, 3.0 and 3.5 mm~* Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~* Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~* The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
223444434|NCT02173379|DEVICE|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~* Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~* Stent lengths: 8, 12, 15, 18, 23, and 28 mm~* For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
223444435|NCT04414163|DRUG|IMC-001|Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)
223444436|NCT00674479|DRUG|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
223444437|NCT05989386|PROCEDURE|0.9% saline solution|During emergency laparotomy, after the primary surgical procedure. the sheath will be sutured and the incision site will then be irrigated with three rounds of 1 liter of 0.9% saline solution, which will be completely aspirated before the closure of the incisional wound in experimental group.
223444438|NCT05989386|PROCEDURE|Povidone-iodine Swab|No intra-operative wound lavage done, and wound would be cleaned with povidone doused swab.
223444439|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine
223444440|NCT05280197|PROCEDURE|TAP block|Transversus abdominis plane (TAP) nerve block with normal saline
223444441|NCT05280197|DRUG|liposomal bupivacaine plus free bupivacaine|TAP block using liposomal bupivacaine plus free bupivacaine
223444442|NCT05280197|DRUG|normal saline|TAP block using normal saline
223444443|NCT06347575|DEVICE|Implantation of the caverStim device|Implantation of caverStim in SCI patients.
223444444|NCT02632448|DRUG|LY2880070|Capsules
223444445|NCT02632448|DRUG|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
223444446|NCT01000883|OTHER|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
223444447|NCT01000883|OTHER|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
223444448|NCT01000883|PROCEDURE|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
223444449|NCT04997265|OTHER|Low intensity anticoagulation|Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.
223444450|NCT04997265|OTHER|Moderate Intensity Anticoagulation|"Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers."
223444451|NCT05429008|DRUG|HMPL-A83 injection|Day 1,8,15,22 dose; 28 day treatment cycles.
223444452|NCT04991116|DRUG|TILD sub-cutaneous (SC) injection|1 mL injection of study medication
223444453|NCT04354649|DRUG|Hydroxychloroquine|Hydroxychloroquine 5mg/kg PO daily
223444454|NCT04354649|OTHER|Placebo|Hydroxychloroquine-matching placebo
223444455|NCT05682352|DRUG|LEO 158968|IV infusion or SC injection
223444456|NCT05682352|DRUG|Placebo|IV infusion or SC injection
223567663|NCT06890000|OTHER|Scapular Exercise|"Scapular exercise includes scapular clock exercise (3 sets of 10 repetitions), rowing exercise (3 sets of 10 repetitions), resisted external rotation (3 sets of 10 repetitions), resisted punching exercise (3 sets of 10 repetitions).~The rowing, external rotation and punching exercises will do with theraband. When participants complete the elastic band exercises easily and do not report any muscle fatigue, they will move on to the next level of difficulty. The color order of the bands is yellow, red, green and blue. The exercises will begin with the yellow elastic band, which provides the least resistance.~The intervention will last for 6 weeks, with 2 training sessions per week and each training session lasting 15-20 minutes."
224054698|NCT06549816|DRUG|sigvotatug vedotin|Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6.
224054699|NCT03965676|OTHER|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360μmol/L (baseline DECT is in the domain of usual care).
223444457|NCT05682352|DRUG|LEO 158968|SC injection
223444458|NCT05682352|DRUG|Placebo|SC injection
223444459|NCT01354522|DRUG|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
223444460|NCT01354522|DRUG|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
223741260|NCT02709031|DRUG|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
223741261|NCT02709031|DRUG|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its \~1.8 million patient-years of post-launch experience,
223741262|NCT06260709|DRUG|NNC6019-0001|Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
223741263|NCT05584150|OTHER|Deep Cleansing Gel|daily use
223444461|NCT03307187|BEHAVIORAL|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
223444462|NCT04404985|PROCEDURE|Surgical AVF|"Surgical fistula creation is standard surgical procedures, where a small cut through the skin is made to create a channel directly between a vein and artery .~The study procedures are standard clinical practice, and not considered an experimental procedure."
223567664|NCT06890000|OTHER|Control (Standard treatment)|"Conventional Treatment includes TENS (100 Hz) with hotpack (20 minutes), Stretching exercises (posterior capsule and pectoral muscle), resisted flexion and abduction exercises.~The rowing, external rotation and punching exercises will do with theraband. When participants complete the elastic band exercises easily and do not report any muscle fatigue, they will move on to the next level of difficulty. The color order of the bands is yellow, red, green and blue. The exercises will begin with the yellow elastic band, which provides the least resistance.~The intervention will last for 6 weeks, with 2 training sessions per week and each training session lasting 30-45 minutes."
223567665|NCT01663818|DEVICE|Tack-It Endovascular Stapler|
223741264|NCT05325632|BIOLOGICAL|HER-2 pulsed DC1|Vaccine will be administered weekly for 6 weeks. Boosters will be given at months 6, 9 and 12.
223567666|NCT04309877|DRUG|Theophylline ER|Capsules of theophylline ER
223741265|NCT05325632|DRUG|Trastuzumab|8mg/kg IV Trastuzumab will be given week 1, followed by 6 mg/kg on subsequent cycles every 3 weeks
223741266|NCT05325632|DRUG|Pertuzumab|840 mg IV Pertuzumab will be given week 1, followed by 420 mg on subsequent cycles every 3 weeks.
223741267|NCT05325632|DRUG|Paclitaxel|80 mg/m\^2 IV paclitaxel will be given weekly weeks 7-18
223741268|NCT05325632|PROCEDURE|Resection surgery|After week 18, participants will undergo standard of care resection surgery.
223567667|NCT04309877|OTHER|PO placebo|Capsules of methylcellulose
223567668|NCT04309877|BIOLOGICAL|Lipopolysaccharide (LPS)|Purified bacterial wall component as an inflammatory challenge
223567669|NCT04309877|OTHER|IV placebo|Normal (0.9%) saline
223567670|NCT04710550|DRUG|F18-3F4AP|PET Scan
223567671|NCT03401567|OTHER|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
223567672|NCT04120883|DRUG|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
223741269|NCT03411681|OTHER|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
223741270|NCT06540209|DRUG|Bacillus clausii|Children will be give Bacillus clausii for 5 days
223741271|NCT06540209|DRUG|Saccharomyces boulardii|Children will be give Saccharomyces boulardii for 5 days
223741272|NCT06540209|DRUG|Zinc|Zinc will be given to all children for 5 days
223741273|NCT06540209|DRUG|ORS|ORS will be given to all children for 5 days
223741274|NCT01220947|DRUG|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
223741275|NCT01220947|DRUG|Danoprevir|Danoprevir 50 mg BID
223741276|NCT01220947|DRUG|Danoprevir|Danoprevir 100 mg BID
223741277|NCT01220947|DRUG|Danoprevir|Danoprevir 200 mg BID
223741278|NCT01220947|DRUG|Pegasys|Pegasys 180 microgram sc qw
223741279|NCT01220947|DRUG|Ritonavir|Ritonavir 100 mg
223741280|NCT00518323|DRUG|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
223741281|NCT00518323|DRUG|Placebo|Once daily for 6 weeks
223741282|NCT00518323|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
223741283|NCT00518323|DRUG|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
223741284|NCT01086540|BIOLOGICAL|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
223444463|NCT04404985|PROCEDURE|Endo-vascular AVF|Endovascular fistula creation is a minimally invasive procedure used to create a canal between close artery and vein at the forearm. A magnet attached to a catheter is passed over a guidewire into the artery while another magnet passed over the guidewire into the vein. The two magnets are aligned close to each other, then the radiofrequency electrode is released from the venous catheter and energized for 2 seconds, creating a channel between the vein and the artery.
223444464|NCT06538636|OTHER|PCP-Facing Tools|PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information
223444465|NCT06538636|OTHER|LCS team population management tools|site-specific dashboard and proactive outreach toolkit
223444466|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single-pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post-training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
223444467|NCT00715520|DRUG|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
223444468|NCT00715520|DRUG|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
223444469|NCT00715520|DRUG|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
223444470|NCT00715520|DRUG|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
223444471|NCT00715520|OTHER|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
223444472|NCT00715520|OTHER|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
223444473|NCT04912414|BEHAVIORAL|Brief Family Therapy (BFT)|Patients transferred to the hospital for the treatment of psychosomatic symptoms was randomized (1:1) to receive either Brief Family Therapy (BFT) or a control treatment. Some participants randomized to the BFT arm receive a combination of chemotherapy and BFT and others receive only BFT. BFT comprises 10 sessions using a generic model of problem formation and resolution. This psychotherapy is useful for treating individual, couple, and family problems. Its broad applicability is based on its view that the client's complaint is the problem, not a symptom of something else BFT views behavior, especially a client's problematic behavior, as a function of interaction with other people. After randomization, all participants were asked to complete questionnaires about their psychosomatic symptoms and health at baseline, at the end of the intervention (at 4 months).
223444474|NCT01056913|DEVICE|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
223444475|NCT01056913|OTHER|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
223444476|NCT02139774|BEHAVIORAL|Walk with Ease|A six week walking program by the Arthritis Foundation
223444477|NCT06172790|OTHER|Training|A protocol has been established for the progression of the strengthening and balance training components of the Otago Exercise Program, increasing every two weeks in a four-stage manner. The exercise intensity will be gradually increased based on patient tolerance, ensuring that the perceived difficulty level remains in the range of 4-6 on the Borg dyspnea scale throughout the 8-week period. Supervised walking training is planned to be conducted on a treadmill to ensure standardization. The initial treadmill walking speed for patients will be determined based on the submaximal walking speed in the 6-minute walking test. The progression of the walking program will be carried out every two weeks, similar to the other exercise components of the program, with a 10% increase in walking speed each time.
223444478|NCT03761004|DRUG|carbidopa-levodopa|single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
223444479|NCT02374437|DRUG|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
223444480|NCT02374437|DRUG|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
223444481|NCT02530697|DRUG|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
223444482|NCT02530697|DRUG|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
223444483|NCT02530697|DRUG|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
223444484|NCT00487097|DIETARY_SUPPLEMENT|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
223741285|NCT01086540|OTHER|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
223741286|NCT01086540|DIAGNOSTIC_TEST|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
223444485|NCT02290925|DRUG|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
223444486|NCT02290925|DIETARY_SUPPLEMENT|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
223444487|NCT05048615|DRUG|Venetoclax 100 MG|Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.
223444488|NCT05048615|DRUG|Itraconazole capsule|Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.
223444489|NCT05048615|DRUG|Azacitidine Injection|Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.
223444490|NCT00170352|PROCEDURE|Hyperbaric Oxygen Treatment (HBOT)|
223444491|NCT00170352|PROCEDURE|Enhanced Oxygen Treatment (Enhanced FiO2)|
223444492|NCT00702026|DIETARY_SUPPLEMENT|multispecies probiotic (Ecologic 801)|once daily, 5 gram \[10e9 cfu/gram\]
223444493|NCT00702026|DIETARY_SUPPLEMENT|Placebo|once daily, 5 gram \[10e9 cfu/gram\]
223444494|NCT02342145|DRUG|Basiliximab,|Basiliximab was used on 0d (after transplantation) and +4d (10mg for weight under 35kg, 20mg for over 35kg) .
223444495|NCT02342145|DRUG|Tacrolimus|Specifically Tacrolimus was used by intravenous drip infusion on 0.03mg/kg dosage from -1d and change to 0.1mg/kg oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 5-10 ng/ml.
223444496|NCT02342145|DRUG|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3d,+6d,+11d by intravenous for prevention of graft-versus-host-disease.
223444497|NCT02342145|DRUG|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g per day from -1d to 90d for prevention of graft-versus-host-disease.
223444498|NCT04942210|BIOLOGICAL|Yellow fever vaccine (produced on serum-free Vero cells)|Powder and diluent for suspension for injection Subcutaneous injection
223444499|NCT04942210|BIOLOGICAL|Yellow fever vaccine|Powder and diluent for suspension for injection Subcutaneous injection
223444500|NCT01874418|OTHER|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
223444501|NCT03421275|DRUG|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
223444502|NCT03421275|DRUG|Fentanyl Citrate|intravenous fentanyl given intranasally
223444503|NCT03421275|DRUG|Saline Nasal|intravenous saline given intranasally as placebo
223444504|NCT05697627|DEVICE|Computerized cognitive training (CCT) using EndeavorRx|"The EndeavorRx video game is a digital therapeutic designed to improve attention and related cognitive control processes by training interference management.~\~25 minutes of EndeavorRx video game play per day, for 5 days/week, for up to 4 weeks"
223444505|NCT02570750|BEHAVIORAL|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
223444506|NCT03549065|DEVICE|Brain Stimulation|"Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George \& Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008)."
223444507|NCT02373007|PROCEDURE|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
223444508|NCT01256580|DRUG|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
223444509|NCT01256580|DRUG|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
223444510|NCT04998383|DEVICE|HVNI|High velocity nasal insufflation (Fisher \&Paykel, Auckland, New Zealan High-velocity nasal insufflation (Precision Flow;Vapotherm, Inc, Exeter, NH) (Figure 2) using a smallborenasal cannula was initiated with a flow rate set to 35 L/min, with a starting temperature between 35C and 37C and FiO2 at 1.0. Adjustments in flow (up to 40 L/min) and temperature (typically between 35C and 37C) were made to alleviate respiratory distress and optimize comfort.
223444511|NCT04122625|DRUG|Debio 1143|Administered as capsules.
223444512|NCT04122625|DRUG|Nivolumab|Administered as IV infusion.
223444513|NCT01962246|DRUG|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
223444514|NCT01962246|OTHER|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
223444515|NCT05176925|DRUG|Tislelizumab|Tislelizumab 200mg IV D1, Q3W
223444516|NCT05176925|DRUG|Sitravatinib|The starting dose of sitravatinib in this study is 70 mg, oral once daily. After receiving 2 cycles of starting dose at 70 mg once daily with sitravatinib, if patients were tolerated well with study treatment (without AEs definitely related to sitravatinib nor TRAEs leading to sitravatinib dose reduction and interruption), it is recommended to escalate sitravatinib dose to 100 mg once daily at the discretion of the investigators after discussion with patients.
223444517|NCT00369772|DRUG|darbepoetin alfa|
223444518|NCT05251636|RADIATION|Episcleral Brachytherapy|Minimally invasive, single fraction brachytherapy
223444519|NCT05251636|DRUG|Aflibercept Injection|Standard of Care intravitreal aflibercept injection
223444520|NCT01410240|PROCEDURE|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
223741287|NCT01086540|DRUG|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
223444521|NCT01410240|DRUG|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~\+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
223444522|NCT03425994|DRUG|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
223444523|NCT00002478|DRUG|etoposide|
223444524|NCT02061423|BIOLOGICAL|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10\^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
223444525|NCT02776670|OTHER|Propylene glycol, 0.6% eye drops|
223444526|NCT02776670|OTHER|Lubricant eye drops|
223444527|NCT00323076|DRUG|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
223444528|NCT03402425|DIAGNOSTIC_TEST|18F-FET PET|Patient are investigated with an 18F-FET PET
223444529|NCT06012526|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is done for patients to find any sleep disordered breathing
223444530|NCT02066727|DRUG|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
223444531|NCT02066727|DRUG|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
223444532|NCT01902511|DRUG|G-CSF+Erythropoetin|
223444533|NCT01902511|DRUG|G-CSF|
223444534|NCT00910546|DEVICE|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
223444535|NCT01489852|DRUG|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
223444536|NCT03610321|DRUG|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
223444537|NCT03610321|DRUG|Statin|Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.
223444538|NCT02743065|DEVICE|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
223567673|NCT04120883|DRUG|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
223567674|NCT00437450|DRUG|Epoetin/Atra|
223567675|NCT01925495|OTHER|varied middle-ear pressure|
223741288|NCT01086540|DRUG|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
223741289|NCT01086540|DRUG|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
223741290|NCT01086540|DRUG|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
224164048|NCT06113172|OTHER|Hip flexion|during the delay phase, the patients are asked to bend their knee in order to achieve the maximum degree of hip flexion
223444539|NCT02697591|DRUG|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
223444540|NCT00460863|PROCEDURE|using cool versus warm dialysate during hemodialysis|
223444541|NCT00968357|DRUG|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
223444542|NCT02032771|DEVICE|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
223567676|NCT01925495|DRUG|varied middle-ear gas composition|
223567677|NCT01925495|OTHER|varied ear-canal pressure|
223567678|NCT02601092|PROCEDURE|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
223567679|NCT02601092|PROCEDURE|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
224164049|NCT01149161|PROCEDURE|Routine central neck dissection|Level VI neck node dissection during thyroid operation
223444543|NCT01917695|DRUG|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
223444544|NCT01917695|RADIATION|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
223444545|NCT01917695|RADIATION|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
223444546|NCT01917695|PROCEDURE|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
223444547|NCT05478551|DRUG|Botulinum Toxin|We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.
224145752|NCT07091175|DRUG|Co-intervention of Prednisolone wean during randomised controlled phase|"The Prednisolone wean will commence 2 weeks after receiving the loading dose of Dupilumab/placebo, with each weaning step 2 weeks apart. Prednisolone will be first weaned to the same dose every other day, if the current dosing is daily (or more frequent). The dose will subsequently weaned to 4 pre-determined levels of 30mg/m2, 15mg/m2, 10mg/m2 and 5mg/m2 every other day, rounding up to the nearest 5mg. For instance, if the current dose of prednisolone is 12mg/m2 every other day, the patient will decrease the dose to 10mg/m2 every other day for 2 weeks, followed by 5mg/m2 every other day for 2 weeks, before discontinuing the drug.~If patients enter the trial on Mycophenolate or Levamisole, this will be continued for the duration of the trial at the same dose."
223444548|NCT05478551|DRUG|Normal saline|Normal saline will serve as the placebo control on the contralateral side of the back.
223444549|NCT03630029|DRUG|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
223444550|NCT03923452|BEHAVIORAL|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
223444551|NCT05689008|BIOLOGICAL|UC-MSCs treatment|Participants will receive two doses of UC-MSCs treatment, each dose will contain 1\*10\^6 cells/kg suspended in 100 ml albumin solution.
223444552|NCT06080425|BEHAVIORAL|Medical Nutrition Therapy|Counselling
223444553|NCT05387512|DRUG|Camrelizumab|Patients with EGFR-mutation-negative and ALK-negative advanced non-squamous non-small cell lung cancer were treated with first-line chemotherapy in combination with camrelizumab.
223444554|NCT00495859|DIETARY_SUPPLEMENT|Immunonutrition|food for special medical purpose (FSMP)
223444555|NCT00495859|DIETARY_SUPPLEMENT|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
223444556|NCT00005796|PROCEDURE|filgrastim|GCSF is given after chemo administration
223444557|NCT00005796|BIOLOGICAL|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
223444558|NCT00005796|DRUG|lomustine|chemotherapy is administered every 21 days
223444559|NCT00005796|DRUG|procarbazine hydrochloride|chemotherapy is administered every 21 days.
223444560|NCT00005796|DRUG|vincristine sulfate|chemotherapy is administered every 21 days
223444561|NCT00005796|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
224145753|NCT07091175|BIOLOGICAL|Dupilumab open label extension phase|Upon nephrotic relapse, participants will be unmasked. If they were given placebo, they will be invited to enrol in an open label extension phase to receive dupilumab for 24 weeks (with dosing identical to the experimental arm).
223444562|NCT05061381|BEHAVIORAL|A Lust for Life Schools Programme|A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
223444563|NCT04177966|BEHAVIORAL|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
223444564|NCT04177966|BEHAVIORAL|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
223444565|NCT00596063|BIOLOGICAL|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
223444566|NCT00596063|BIOLOGICAL|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
223444567|NCT03642444|DEVICE|Cane|Assistive walking device
223444568|NCT03642444|DEVICE|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
223444569|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
223444570|NCT04102488|PROCEDURE|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
223444571|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
224164050|NCT04480346|BEHAVIORAL|Challenging Horizons Program|Intervention delivered in high schools provided by school mental health professional over the course of an academic year with twice-weekly meetings with students and 10 evening group meetings with students and 10 group sessions with parents.
224164051|NCT02058251|DRUG|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
223444572|NCT04102488|PROCEDURE|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
223444573|NCT05180890|DRUG|Danavorexton|Danavorexton intravenous infusion.
223444574|NCT05180890|DRUG|Placebo|Placebo intravenous infusion.
223444575|NCT00895934|DRUG|vorinostat|Given orally
223444576|NCT00895934|DRUG|gemtuzumab ozogamicin|Given intravenously (IV)
223444577|NCT00895934|DRUG|azacitidine|Given IV or subcutaneously (SC)
223741291|NCT06150976|BEHAVIORAL|MAAT-YS|MAAT is an evidence-based cognitive-behavioral therapy composed of eight 45-minute telehealth appointments and an accompanying workbook.
223444578|NCT05447026|DEVICE|Control group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, the sites in the control group received only saline irrigation for 1 min.
223444579|NCT05447026|DEVICE|Antimicrobial photodynamic therapy (aPDT) group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, aPDT group received additional application of a diode laser with a wavelength of 810 nm and a power rating of 200 mW (continuous mode). Indocyanine-green (ICG) as a photosensitizer at a concentration of 1 mg/ml was applied at the surgical site on both the buccal and the lingual sides of the flaps. Irradiation was performed in non-contact mode in a constant distance of 1 mm during 30 s per site
223444580|NCT05447026|DEVICE|LED photobiomodulation group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, irradiation was carried out with a LED device with a wavelength of 626 nm in the near-infrared region at a dose of 20 mw/cm2 for 20 min with a total energy of 222 J
223444581|NCT05447026|DEVICE|Topical ozone group|Following local anesthesia, a full-thickness (muco-periosteal) access flap was elevated, granulation tissue was removed and direct instrumentation of the affected root surfaces was performed under the saline irrigation. Intrabony defects were filled with granules of allograft bone material and covered with a native porcine pericardial collagen membrane. The flaps were repositioned and sutured without any tension in order to achieve primary closure of the inter-dental area using a 5-0 mono-filament non-resorbable PTEF suturing material. On the 1st, 3rd, and 7th postoperative days, topical ozone group received ozone application with an ozone generator at 80% concentration using probe #3 for 30 s per site
223444582|NCT00299403|PROCEDURE|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
223444583|NCT00299403|PROCEDURE|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
223444584|NCT04379700|PROCEDURE|Transcatheter arterial embolization|Transcatheter arterial embolization of one or more genicular artery(ies) using Embozene™ Color-Advanced Microspheres. Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer used for embolization.
223444585|NCT04379700|DEVICE|Embozene™ Microspheres|Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter and color-coded by size to allow for easy identification. 250 μm microsphere will be used and are supplied in prefilled yellow syringes.
223444586|NCT05439057|DRUG|Remimazolam|Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
223444587|NCT05439057|DRUG|Control|Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.
223444588|NCT05108987|BEHAVIORAL|Morning Exercise|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the morning.
223444589|NCT05108987|BEHAVIORAL|Afternoon Exercise|Exercise at moderate to hard intensity will be performed in the morning for up to 10 sessions for about 1 hour under supervision in the afternoon.
223444590|NCT00991094|OTHER|Quality-of-Life Assessment|Complete questionnaires
223444591|NCT00991094|OTHER|Questionnaire Administration|Complete questionnaires
224054700|NCT03662165|BEHAVIORAL|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
224164052|NCT02058251|DRUG|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
223444592|NCT06313502|DRUG|75gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
224164053|NCT06882408|DEVICE|Photorefraction device under investigation|Objective refraction measurement with and without cyclopegia
224164054|NCT06882408|DEVICE|Comparator device, Tabletop auto-refractometer|Objective refraction measurement with and without cyclopegia
224164055|NCT06882408|DEVICE|Comparator device, portable photorefraction device|Objective refraction measurement with and without cyclopegia
224054701|NCT03662165|BEHAVIORAL|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
224164056|NCT06882408|OTHER|Distance visual acuity assessments|Distance visual acuity is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.
223444593|NCT06313502|DRUG|100gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
223444594|NCT06313502|DRUG|125gm HDAA|"Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded."
224164057|NCT06882408|OTHER|Subjective refraction and far visual acuity|Subjective refraction is assessed and far visual acuity is assessed with the found refraction measures
223444595|NCT00592592|RADIATION|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
223444596|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan|Porridge rich in arabinoxylan
223444597|NCT01583270|DIETARY_SUPPLEMENT|Rye kernel|Porridge made of rye kernels
223444598|NCT01583270|DIETARY_SUPPLEMENT|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
223444599|NCT01583270|DIETARY_SUPPLEMENT|Semolina|Semoline porridge. control meal.
223444600|NCT02287259|DRUG|olanzapine|
223444601|NCT02287259|DRUG|lithium|
223444602|NCT05290428|DIAGNOSTIC_TEST|DNA methylation testing|All cervical cytology samples will be tested for PAX1 and JAM3 methylation
223444603|NCT04764383|DRUG|L-Histidine|1000 mg capsules taken by mouth (PO) twice daily (BID).
223444604|NCT04764383|DRUG|Placebo|Microcrystalline cellulose (placebo) 1000 mg capsules taken by mouth (PO) twice daily (BID).
223444605|NCT04764383|DRUG|Lodosyn|50 mg capsules taken PO BID.
223444606|NCT03159845|DRUG|Zinc Sulfate Oral Product|
223444607|NCT03159845|DRUG|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
223444608|NCT03159845|DRUG|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
223444609|NCT03159845|DRUG|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
223444610|NCT01935245|DEVICE|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
223444611|NCT01935245|DEVICE|Conventional extracorporeal circulation|
223444612|NCT04953286|OTHER|Measure of visual acuity|ETDRS and Parinaud scale
223444613|NCT04953286|OTHER|Interferometry|Non-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
223444614|NCT04953286|OTHER|Samples of basal tears|Collection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
223444615|NCT04953286|OTHER|Central corneal sensitivity|Central corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
223444616|NCT04953286|OTHER|Slit lamp examination and undilated fundus|Slit lamp examination and undilated fundus
223444617|NCT04953286|OTHER|Conjunctival impression|Conjunctival impression with anesthetic instillation
223444618|NCT04953286|OTHER|Evaluation of the corneal innervation|Contact corneal confocal microscopy
223444619|NCT05765448|OTHER|Soy control|Soy isolate control meal
223444620|NCT05765448|OTHER|Intervention (Laver/nori (Porphyra umbillicus) macroalgae whole biomass)|Laver/nori (Porphyra umbillicus) macroalgae whole biomass treatment meal
223444621|NCT05765448|OTHER|Intervention (Laver/nori macroalgae (Porphyra umbillicus) protein isolates)|Laver/nori macroalgae (Porphyra umbillicus) protein isolates treatment meal
223444622|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) whole biomass)|Chlorella microalgae (Chlorella vulgaris) whole biomass treatment meal
223444623|NCT05765448|OTHER|Intervention (Chlorella microalgae (Chlorella vulgaris) protein isolates)|Chlorella microalgae (Chlorella vulgaris) protein isolates treatment meal
223444624|NCT02109406|DRUG|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
223444625|NCT02109406|DRUG|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
223444626|NCT02109406|DRUG|Placebo MDI|Placebo MDI administered as two inhalations BID
223444627|NCT06281158|DRUG|[14C]-DNL343|Single dose
223444628|NCT03470623|DEVICE|bioabsorbable screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
223444629|NCT03470623|DEVICE|steel screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
224054702|NCT03662165|BEHAVIORAL|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
223444630|NCT03922841|OTHER|Pleural disease management|History, physical examination, pleural drainage, lab/radiographic investigations
223444631|NCT05491395|RADIATION|Hypofractionation|Hypofractionation scheme will comprise 40 Gy in 15 fractions
223444632|NCT02963519|DEVICE|VistaCare®|
223444633|NCT02963519|DEVICE|Dressings|
223741292|NCT05959538|BEHAVIORAL|Building Regulation in Dual Generations (BRIDGE)|The BRIDGE intervention includes 16 weeks of 20-30 minute DBT and parenting skills training videos, delivered asynchronously via an online website requiring a participant login. Video content was drawn from concepts outlined in the DBT Skills Training Manual 2nd Edition (Linehan, 2015). Parenting videos will provide mothers with parenting skills education based on best practices in evidence-based positive parenting interventions (e.g., Parent Management Training, Positive Parenting, Kazdin, 1997; Sanders et al., 2014). The BRIDGE condition also includes weekly synchronous 1-hour virtual group therapy sessions and worksheets to complete weekly (as an opportunity to practice skill use). The clinical team will consist of two Master's or PhD level clinical psychology trainees and a parent peer coach. Mood tracking will be completed using a brief weekly survey, including questions on depression, parenting stress, positive mood, and recent stressful experiences.
223741293|NCT05959538|BEHAVIORAL|Dialectical Behavioural Therapy Skill Training|Participants in the DBT arm will participate in 16 weeks of DBT skills training only led by two Master's or PhD level clinical psychology trainees. Participants in the DBT Skills condition will participate in a skills group which follows the DBT Skills Training Manual 2nd Edition (Linehan, 2015) through weekly, synchronous 1.5-hour virtual group therapy sessions. Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness skill domains will be covered. Participants will be asked to complete worksheets between sessions to practice using skills, and will be asked to complete a Diary Card to track DBT skills use each week (Linehan, 2015). Mood tracking will be completed using a brief weekly survey including questions on depression, parenting stress, positive mood, and recent stressful experiences.
223741294|NCT05962970|DRUG|continuous adductor canal block (CACB) ropivacaine|The CACB group will receive an infusion of 0.2% ropivacaine 5mL/h
223741295|NCT05962970|DRUG|sham continuous adductor canal block - ShACB NaCl|sham continuous adductor canal block - ShACB and ShACB group will receive an infusion of NaCl 0.9% 5mL/h.
223741296|NCT02227589|BEHAVIORAL|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
223741297|NCT02227589|BEHAVIORAL|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
223741298|NCT02227589|OTHER|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
223741299|NCT04056442|DRUG|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
223741300|NCT04056442|DRUG|Placebo|Olive Oil Solution, 5%
223741301|NCT06397352|OTHER|ShotBlocker®|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.
224054703|NCT01868256|OTHER|early discharge (<72 h)|
223444634|NCT02703896|DRUG|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~1. Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~2. Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~3. Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~4. Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~5. Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~6. Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~7. Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~8. Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~9. Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~10. Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
223444635|NCT02703896|PROCEDURE|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
223444636|NCT00530790|DRUG|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
223444637|NCT02499510|DEVICE|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
223444638|NCT04448639|DIAGNOSTIC_TEST|Echocardigraphy (ECHO)|Standar 12 lead electrocardiogram
223444639|NCT04448639|DIAGNOSTIC_TEST|Bloodtest|cardiac biomarkers
223444640|NCT04728984|DRUG|Nalfurafine Hydrochloride|"Nalfurafine Hydrochloride 2.5μg\*2~; Oral administration after dinner, once daily for 14 consecutive days"
223444641|NCT04728984|DRUG|Nalfurafine Hydrochloride+Placebo|Nalfurafine Hydrochloride 2.5μg+ A placebo pill; Oral administration after dinner, once daily for 14 consecutive days
223444642|NCT04728984|DRUG|Placebo|two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
223444643|NCT02419794|PROCEDURE|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
224054704|NCT01868256|OTHER|Conventional discharge|
224054705|NCT02865018|DRUG|cetirizine|
224054706|NCT05336916|BEHAVIORAL|Buddy|Mindfulness-based Cognitive Behavioural Therapy
224054707|NCT04266262|BEHAVIORAL|High-intensity interval training (HIIT)|"Supervised HIIT sessions (2x/week) will comprise cycling 10 x 60 secs at 85-95% maximum heart rate (HRmax) interspersed by 60 secs of low-intensity recovery.~Unsupervised HIIT sessions (1x/week) will involve 10 x 60 secs of walking or alternative (intensity of 7-9 on the 0-10 RPE) interspersed by 60 secs of walking or cycling at low intensity recovery (RPE 3-5)."
223444644|NCT04595084|BEHAVIORAL|Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell|MBCT-R is designed to foster resilience and prevent new-onset anxiety and depression disorders or exacerbation of existing conditions. MBCT-R follows the MBCT structure of eight classes and one half-day retreat, with home practice and specific daily meditation, but is live-online and focuses on specific stressors (COVID-19, its economic and social consequences). Classes of 40-50 participants are led by 2 co-leaders. Participants have CHA MindWell Monitoring and telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
223444645|NCT04595084|BEHAVIORAL|Internet Cognitive Behavioral Therapy plus CHAMindWell|MoodGYM is based on CBT and interpersonal therapy targeting depression, anxiety, stress, and general psychological distress. MoodGYM has 6 sessions with five curriculum modules and a review session that can be completed within an 8-week period. iCBT participants will also be enrolled in CHA MindWell Monitoring and Support (CHA-MW). Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If there are difficulties with accessing iCBT technology or if monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
223444646|NCT04595084|BEHAVIORAL|CHAMindWell|Participants across arms will have CHA MindWell Monitoring and Technician support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants across arms will have CHA MindWell Monitoring and Technician telephone support during weeks 1-8 and then every 4 weeks afterwards for 24 weeks. Participants with severe symptoms or worsening moderate symptoms will be asked if they would like a mental wellness assessment with a clinician. If monitoring with CAT-MH or CAT-DI/ANX-CAT interviews suggests symptomatic worsening, then a CHA MindWell technician will contact the participant and check-in and offer support, including setting up a televisit with a member of a clinical member of the outpatient mental health team if needed.
223444647|NCT04423562|OTHER|No intervention|No intervention
223444648|NCT00670657|DRUG|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
223444649|NCT03693001|DEVICE|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
223444650|NCT01905774|DRUG|Deferasirox|
223444651|NCT03280706|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin 50g in water 500ml
223444652|NCT03280706|DIETARY_SUPPLEMENT|Orange Juice|Orange juice 480ml + 20ml of water
223444653|NCT03280706|DIETARY_SUPPLEMENT|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
223444654|NCT04265300|DIETARY_SUPPLEMENT|Creative Roots|The Creative Roots beverage is a coconut water-based drink with three flavors Mixed Berry, Watermelon Lemonade, and Peach Mango. The ingredients are as follows and are the same for all three flavors: water, coconut water concentrate, citric acid, stevia leaf extract, natural flavor, rosemary extract (to preserve flavor). Contains: coconut
223444655|NCT06356324|OTHER|Music Intervention|Participants assigned to 20 minutes of music listening
223444656|NCT06356324|OTHER|Television Intervention|Participants assigned to 20 minutes of television viewing
223444657|NCT00456781|DEVICE|Augmentation|Rotator Cuff Repair plus Graft Jacket
223444658|NCT00456781|PROCEDURE|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
223444659|NCT05874063|DRUG|Thromboprophylaxis|Thromboprophylaxis in addition of the standard chemotherapy
223741302|NCT06397352|OTHER|Buzzy® Group|All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
223741303|NCT05566990|BIOLOGICAL|LIV-GAMMA SN Inj.10%|LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
223444660|NCT05053035|DRUG|AL001|Administered via intravenous (IV) infusion
223444661|NCT05053035|DRUG|Placebo|Administered via intravenous (IV) infusion
223444662|NCT05258318|PROCEDURE|DK crush|Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).
223741304|NCT04204135|PROCEDURE|LLIF or ALIF procedures|LLIF or ALIF procedures
223741305|NCT04916470|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
224164058|NCT06882408|OTHER|Strabismus assessment|Strabismus is assessed with the refraction measures found by the device under investigation and the comparator device with and without cyclopegia.
223444663|NCT05258318|PROCEDURE|DR crush|Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
223444664|NCT04735159|DEVICE|SCS implanted with Precision SpectraTM|Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
223444665|NCT02623608|OTHER|Reference breakfast|A high fat, high calorie breakfast
223444666|NCT02623608|OTHER|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
223444667|NCT02623608|OTHER|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
223444668|NCT02623608|OTHER|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
224054708|NCT04266262|BEHAVIORAL|High-Intensity resistance training (HIRT)|"Supervised HIRT sessions (2x/week) will comprise 2-3 sets of 6-8 repetitions progressively achieving 85% of 1RM.~Unsupervised HIRT sessions (1x/week) will involve 2-3 sets of 15-20 repetitions using a resistance exercise band when necessary."
223444669|NCT02623608|OTHER|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
223444670|NCT06966765|PROCEDURE|Continuous Veno-Venous Hemodiafiltration|CVVHDF will be delivered following hemoperfusion with a dialysate-to-replacement fluid ratio maintained at 1:1, a blood flow rate of 150-200 mL/min, and a target dialysis dose of 30 mL/kg/h (excluding additional fluid removal). Regional anticoagulation (e.g., heparin or other agent per device requirements) will be used to prevent clotting within the circuit. Once CVVHDF is initiated in either arm, it will not be discontinued until one of the following encountered: (i) death; or (ii) a change in goals of care with withdrawal of life-sustaining interventions; or (3) recovery of kidney function, as determined by treating clinician(s), such that CVVHDF will be no longer required. However, CVVHDF will be reinitiated at the discretion of treating clinician(s), if kidney function comes suboptimal after a period of discontinuation.
223444671|NCT06613542|DIETARY_SUPPLEMENT|4g of taurine daily|Intervention group (4g of taurine/day): 2g of taurine (4 capsules, 500mg each) in the morning and 2g of taurine (4 capsules, 500mg each) in the evening for 6 months
223444672|NCT06613542|DIETARY_SUPPLEMENT|Placebo|Controll group (4g of placebo/day): 2g of placebo (4 capsules, 500mg each) in the morning and 2g of placebo (4 capsules, 500mg each) in the evening for 6 months
223444673|NCT03813134|PROCEDURE|Percutaneous coronary intervention (PCI)|Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis \< 50%. PCI failure will not be an exclusion itself from the trial.
223444674|NCT03813134|OTHER|Pharmacological Support|Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure \>75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
223444675|NCT03813134|DEVICE|VA-ECMO|"Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion."
223444676|NCT03007134|OTHER|Retrospective Chart Review|No intervention.
223444677|NCT06020196|PROCEDURE|surgical rectus sheath block|Local anaesthetic will be administered into the rectus sheath space by the surgeon, towards the end of the operation, at the time of closure of the anterior abdominal wall (before the closure of peritoneum)
223444678|NCT06020196|PROCEDURE|subdermal local anaesthetic infiltration|After closure of the subcutaneous fat, the edges of the skin become more stable; subdermal Infiltration with moving needle technique was done to optimize distribution of the local anesthetic solution
223444679|NCT00315042|DRUG|Telithromycin (HMR3647)|
223444680|NCT00315042|DRUG|Penicillin|
223444681|NCT05857670|BEHAVIORAL|Genetic predisposition to breast cancer|Guilt feelings about procreating
223444682|NCT01656187|DRUG|Memantine 10 mg capsule|"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
223567680|NCT05497050|BEHAVIORAL|Family education|By calling the families in the experimental group by phone; Nursing interventions for family empowerment will last for 10 weeks, they will be invited to the Family Health Center (FHC) or child metabolism polyclinic twice in this process, they will be called once a week (with 2 phone calls) for two weeks after the face-to-face training initiative in the first stage, In the second stage, at the end of the face-to-face training, they will be informed that they will be called once a week for two weeks (4 phone calls in total). The families in the experimental group will be informed that 4 weeks after the completion of the training and phone calls (at the 10th week), they will call the FHC or the pediatric metabolism polyclinic again for the application of the post-tests and that the nursing training for family empowerment will be completed.
223567681|NCT04906967|PROCEDURE|flaps|coverage of soft tissue defect around ankle
223567682|NCT05340634|DIETARY_SUPPLEMENT|Metionac|Metionac is a food suplement composed by 200 mg of SAMe, 100 mg of NAC, 75 mg of ALA and 0,65 mg of vitamin B6 per tablet for 6 months
224054709|NCT03483909|DEVICE|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
224054710|NCT03483909|DEVICE|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
224054711|NCT03483909|DEVICE|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
224054712|NCT02181816|DRUG|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD \& HD
224054713|NCT06037798|OTHER|cranio-cervical flexion test with NOD|testing the anterior neck muscles during a nodding movement and by using a dynamometer
224054714|NCT01365039|DEVICE|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
223444683|NCT01656187|DRUG|Memantine-matched Placebo capsule|"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
223444684|NCT03525782|BIOLOGICAL|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
223444685|NCT03525782|COMBINATION_PRODUCT|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
223444686|NCT03525782|BIOLOGICAL|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
223444687|NCT03525782|DRUG|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
223444688|NCT03525782|OTHER|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
223444689|NCT04224220|OTHER|Adult Medical Care Coordination|Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.
223444690|NCT04224220|OTHER|Remote Patient Monitoring|Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
223444691|NCT01291134|BIOLOGICAL|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
223444692|NCT02074319|DRUG|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
223444693|NCT05266924|DRUG|Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen|fixed-dose of 225 IU/day, subcutaneous (SC), daily, for 5 days. further dosage will be adjusted till adequate follicular development.
223444694|NCT00938587|DRUG|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
223567683|NCT05340634|DRUG|Oral contraceptive|Drospirenone 4 mg once a day
223567684|NCT00750529|DRUG|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
224054715|NCT01365039|DEVICE|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
224054716|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
224054717|NCT00286481|DRUG|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
223444695|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
223444696|NCT00938587|DRUG|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
223444697|NCT00938587|OTHER|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
223444698|NCT00938587|DRUG|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
223444699|NCT00938587|OTHER|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
223444700|NCT00938587|OTHER|Placebo|Placebo tablet every day for 14 days
223444701|NCT00938587|OTHER|Placebo for PF-04171327|Placebo tablet every day for 14 days
223444702|NCT03085771|DRUG|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
223444703|NCT03085771|DRUG|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
223444704|NCT03437161|RADIATION|Radiation Therapy (RT)|Undergo RT either in the supine position with DIBH or in the prone position.
223444705|NCT00001037|BIOLOGICAL|gp160 Vaccine (Immuno-AG)|
223444706|NCT03743402|BEHAVIORAL|Pain self-management training|"This intervention will have 4 components:~1. telephone-delivered evidence-based pain self-management training,~2. web-based video of successfully tapered patients with motivational interviewing debriefing,~3. a voluntary, self-paced opioid taper~4. opioid and non-opioid prescribing guidance for the patient's primary care provider."
223444707|NCT03743402|BEHAVIORAL|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
223444708|NCT03743402|BEHAVIORAL|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they will negotiate details with their primary care provider.
223444709|NCT03743402|BEHAVIORAL|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper. All prescriptions will be written by the primary care provider.
223444710|NCT03743402|OTHER|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses
223444711|NCT02065414|OTHER|Listerine Advance Gum Defense|
223444712|NCT02065414|OTHER|Mouth rinse containing Chlorhexidine|
223444713|NCT02065414|OTHER|Mouth rinse containing 5% Hydroalcohol|
223567685|NCT02094027|BEHAVIORAL|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
223567686|NCT02094027|OTHER|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
223567687|NCT04080986|PROCEDURE|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
223741306|NCT04916470|DRUG|Placebo (Semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
223444714|NCT00466206|DEVICE|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
223444715|NCT00466206|DEVICE|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
223567688|NCT04080986|PROCEDURE|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
223741307|NCT06068933|BEHAVIORAL|K-HEARS Intervention|Tailored aural rehabilitation for participant and care partner
224054718|NCT00286481|DRUG|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
223567689|NCT00230802|DRUG|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
223567690|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
223567691|NCT00230802|DRUG|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
223567692|NCT05179668|DRUG|Dapagliflozin 10 MG|administered orally once daily
223567693|NCT05179668|DRUG|Placebo|administered orally once daily
223567694|NCT00777530|DRUG|Bosutinib (SKI-606)|
223567695|NCT04234087|OTHER|Additional balance and resistance training|Additional exercise program with balance and resistance training three times per week. After completion participants are encouraged to continue exercise training at home according to recommendations and will receive control calls every two weeks.
223567696|NCT01730339|DRUG|PF-06473871|Single dose administered by injection four different times
223567697|NCT01730339|DRUG|PF-06473871|Single dose administered by injection three different times
223567698|NCT03193723|PROCEDURE|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~* Subdermic infiltration. Approximately 8 milliliters~* Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~* Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~* Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~* Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
223567699|NCT03193723|PROCEDURE|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
223567700|NCT06489990|COMBINATION_PRODUCT|combination intervention strategy of [Comorbidity-Co-causes-Joint-prevention]|combination intervention strategy of \[Comorbidity-Co-causes-Joint-prevention\]
223567701|NCT06489990|COMBINATION_PRODUCT|routine health education and mental health knowledge|routine health education and mental health knowledge
223567702|NCT05708781|OTHER|Core strengthening exercise|"1. Isolated lumbar stabilization muscle training:~2. Bridge track:~3. Dead bug track:~4. Quadruped Track:~5. Supine Track:~6. Side-support Track:~7. Prone Track:~8. Standing Track:"
223567703|NCT05708781|OTHER|intensive dynamic back exercise|"1. Trunk lifting Prone on a couch, hips at the edge, upper part of the body free but supported by the hands against the floor. Strap fixation over the calves. With hands on the forehead, the trunk is lifted to the greatest possible extension in hips and spine. If necessary, starting with support from physical therapist. During pauses a chair in front of the couch supports the patient.~2. Leg lifting Standing by the end of the couch, leaning over to a prone position with the hips against the edge in 90 degree flexion, knees 45 degree and feet on the floor. Strap fixation over the chest. Straps around knees to keep legs together. Both legs are straightened and lifted to the greatest possible extension in hips and spine. Again support from physical therapist is necessary.~3. Pull to neck Sitting on a tool with the arms straight and abducted over the head and hands grasping a weight lever. Against sub-maximal resistance the lever is pulled behind neck and shoulders."
223567704|NCT05708781|OTHER|Control group|Hot Pack was given for twenty minutes, slow sustained stretching exercises ( 20 second hold, 10- second relaxation) were given, and isometric exercise of the back((10 repetitions of two sets with 10 seconds hold) alternate days for six weeks.
223567705|NCT04594265|DIETARY_SUPPLEMENT|KetoneAid KE4 Pro Monoester|A dietary supplement containing ketone monoester.
223567706|NCT04594265|DIETARY_SUPPLEMENT|Science in Sport Go Enegy|Dosis isocaloric to the KetoneAid Arm
223741308|NCT06068933|DEVICE|K-HEARS Sound Amplifier Intervention|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
223741309|NCT06960967|OTHER|Chestnut meal|Participants will receive an isocaloric baked meal with chestnut flour.
223741310|NCT06960967|OTHER|Control meal|Participants will receive an isocaloric baked meal without chestnut flour.
223741311|NCT06838273|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223741312|NCT06838273|DRUG|Osimertinib|Oral administration, 80mg daily for a cycle of 3 weeks.
223444716|NCT00466206|PROCEDURE|3MP (Magnetic Mini-Mover Procedure)|"* Subject has EKG performed to measure baseline cardiac activity.~* Magnimplant is implanted.~* After one week, Magnatract is fitted.~* Chest x-ray and 2nd EKG performed 30 days post-implantation.~* Patient and parents complete QoL questionnaire 30d post-implantation.~* Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~* At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~* At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~* Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~* CT scan and third EKG performed after explanation.~* Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
223444717|NCT03726736|DRUG|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
224054719|NCT04871165|DIAGNOSTIC_TEST|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests|S-binding IgG, RBD-binding IgG and N-binding IgG immunoassays and SARS-CoV-2 serum neutralization assay, quantitative serum immunoglobulin tests.
223444718|NCT03726736|DRUG|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
224054720|NCT04871165|DIAGNOSTIC_TEST|Assessment of proinflammatory cytokine production and immunophenotypic analysis after stimulation with overlapping S-peptides in peripheral blood mononuclear cells (PBMC)|Quantitative evaluation of proinflammatory cytokine (IFN-gamma, IL-2 and IL-4) production after stimulation with overlapping S-peptides in peripheral blood mononuclear cells and immunophenotypic analysis (CD45, CD3, CD4, CD8, CD16, CD56, CD14, CD19)
224054721|NCT04871165|DIAGNOSTIC_TEST|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens|Quantitative sequencing for TCR repertoires for SARS-CoV-2-specific antigens
224054722|NCT04345289|BIOLOGICAL|Convalescent anti-SARS-CoV-2 plasma|Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)
224054723|NCT04345289|OTHER|Infusion placebo|Saline 0.9% (600 ml) as an iv single dose infusion
224054724|NCT05650814|DEVICE|ButterfLife|On day 1, the investigator delivers the ButterfLife device at home and explains its use. The patient is recommended to take the measurement once a day, preferably in the morning and to repeat the measurement of parameters during the day if necessary. The doctor will check the data recorded by the patient every day and the trend of the parameters over time by a graphical representation on the electronic medical record (Vitaever®, Nethical S.r.l.). Daily telemonitoring will be conducted in addition to standard home care.
224054725|NCT05650814|OTHER|Control|Patients will receive standard home care: visits will be planned according to the patient's needs. In case of an unstable clinical condition, worsening of symptoms, and alteration of vital parameters, patient can contact by phone the physician or the nurse, who will decide how to intervene.
224054726|NCT00867789|DRUG|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
224054727|NCT00867789|DRUG|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
224054728|NCT05843851|DIAGNOSTIC_TEST|Diagnostic test|Test for two mutations in the CTNS gene and one mutation in the PH1 gene and PH 3.
224054729|NCT02705521|DEVICE|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
223444719|NCT04712513|DIAGNOSTIC_TEST|Dynamic cardiac CT perfusion imaging|Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
223567707|NCT03095027|DEVICE|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
223567708|NCT03095027|DEVICE|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
224054730|NCT00169689|PROCEDURE|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
224054731|NCT00169689|OTHER|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
224054732|NCT01203540|DRUG|NAABAK eyedrops|
224054733|NCT01203540|DRUG|Saline eyedrops|
224164059|NCT04961827|BEHAVIORAL|Self-efficacy based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will utilize concepts in the Theory of self-efficacy to increase dietary self-efficacy among participants and hence improve dietary quality beyond that of conventional nutrition counseling.
223444720|NCT02616718|RADIATION|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
223567709|NCT02346331|OTHER|WHO algorithm of fluid boluses guided by physical examination|
223567710|NCT02346331|OTHER|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
223567711|NCT02346331|OTHER|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
223567712|NCT02346331|OTHER|Oxygen delivery|
224054734|NCT03807349|DEVICE|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
224054735|NCT01399554|BEHAVIORAL|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
224054736|NCT00159757|DRUG|ziprazidone|
224054737|NCT00474396|BEHAVIORAL|Low fat dairy diet|
224054738|NCT01505348|OTHER|Overnight fast|Overnight fast from 21:00 h
224054739|NCT05666336|BIOLOGICAL|Telitacicept|It is necessary and will be given by subcutaneous injection of 160mg/week for 24 weeks.
224054740|NCT05666336|DRUG|Hydroxychloroquine|It is necessary and will be given by oral administration of 0.2g/day for 24 weeks.
223444721|NCT01179438|DRUG|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
223444722|NCT01403506|DRUG|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
223444723|NCT02191046|DEVICE|squeezable bottle|nasal irrigation twice daily for 2 weeks period
223444724|NCT02191046|DEVICE|syringe 20 ml|nasal irrigation twice daily for 2 weeks
223444725|NCT01025375|DIETARY_SUPPLEMENT|inulin|10gram/day inulin for 13-day treatment
223444726|NCT01025375|DIETARY_SUPPLEMENT|inulin|16gram/day inulin for 13-day treatment
223444727|NCT01025375|DIETARY_SUPPLEMENT|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
223444728|NCT02286375|BEHAVIORAL|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
223444729|NCT01592604|DEVICE|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
223444730|NCT01592604|DEVICE|Below knee walking cast|Below knee walking cast for 4 weeks
223444731|NCT03061799|DIETARY_SUPPLEMENT|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
223444732|NCT03061799|DIETARY_SUPPLEMENT|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
223444733|NCT05480553|DRUG|NPC-06|"1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
223444734|NCT05480553|DRUG|Placebo|"1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds."
224164060|NCT04961827|BEHAVIORAL|Knowledge based images through instant messaging|A total of 6 images will be sent to participants via instant messaging. Images will consist of information covered in nutrition counseling sessions, such as those related to serving sizes.
223444735|NCT03104218|OTHER|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
223444736|NCT03104218|OTHER|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
223444737|NCT02781376|OTHER|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
223567713|NCT02346331|OTHER|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
223567714|NCT02346331|OTHER|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
223567715|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
223567716|NCT02387736|BEHAVIORAL|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
223567717|NCT04484896|OTHER|Gain-framed SMS message|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
223567718|NCT04484896|OTHER|Loss-framed SMS message|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
223567719|NCT04484896|OTHER|Information SMS message|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
223567720|NCT02795507|DEVICE|Rehabit-Tec System|Device with visual and kinesthetic feedback
223567721|NCT02795507|DEVICE|Rehabit-Tec System|Device without visual and kinesthetic feedback
223567722|NCT02795507|BEHAVIORAL|conventional exercises|
224164061|NCT01948349|OTHER|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
223444738|NCT02781376|OTHER|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
223444739|NCT03246191|OTHER|blood sample collection|blood sample collection
223444740|NCT01583205|BEHAVIORAL|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
223444741|NCT03316066|PROCEDURE|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
223444742|NCT03316066|PROCEDURE|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
223444743|NCT04374292|BEHAVIORAL|Family intervention|"Topics covered in each session with intervention group mothers.~1. Dietary and physical activity habits and their link to obesity and cardio-metabolic diseases. Children learn about healthy eating habits and health risks at home.~2. Food-preparation processes. Selecting and purchasing food and beverages; importance of food groups and their impact on health; importance of fruit and vegetables. Balance between food groups, source of foods, organic or industrialized. Family menu preparation.~3. Habits and behaviors surrounding eating processes identified as health or risk factors, such as energy density, portion-size control, controlling emotional eating.~4. Beverages. Water versus sugar-sweetened drinks prepared at home or purchased at the store.~5. Preventing the risk of cardiovascular diseases by learning healthy eating habits and practicing these habits at home.~6. Integration. Practicing the skills learned during the intervention in each stage of preparing food and eating"
223444744|NCT04374292|OTHER|Usual nutritional consultation|Control group mothers and children (n = 87) were given the usual nutritional consultation and were prescribed diets that covered their energy requirements according to their age and sex. CG mother/child pairs received information regarding food groups and portion sizes, were trained in the use of the food equivalence system to encourage variation, and were instructed on how to prepare the diet at home.
223444745|NCT01243294|DEVICE|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
223444746|NCT01243294|DEVICE|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
223444747|NCT06033677|PROCEDURE|Distal radial artery cannulation|Interventional application for invasive blood pressure monitoring
223444748|NCT06033677|PROCEDURE|Forearm radial artery cannulation|Interventional application for invasive blood pressure monitoring
223444749|NCT02648464|DRUG|Hydroxychloroquine|
223444750|NCT02648464|DRUG|Placebo|
223567723|NCT05302206|DIETARY_SUPPLEMENT|colonic infusion|colonic glucose or colonic saline infusion
223567724|NCT04143217|DRUG|SPN-812|SPN-812 200 to 600 mg/day
223567725|NCT06456125|DEVICE|amber SEL-P Peripheral Liquid Embolic System|Transcatheter arterial or venous embolization with the liquid embolic agent amber SEL-P embolization across seven different indications for peripheral embolization.
223567726|NCT05397587|BIOLOGICAL|Experimental Vaccine|The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
223741313|NCT06838273|DRUG|Osimertinib|Oral administration, 80mg daily for a cycle of 3 weeks.
223741314|NCT06242249|BIOLOGICAL|Anti-BCMA CAR-NK|"Ten eligible patients with relapsed refractory multiple myeloma will be enrolled based on inclusion criteria and informed consent. After conditioning with Fludarabine and Cyclophosphamide, patients will receive a single infusion of BCMA CAR NK cells with close monitoring using one of the following dose levels:~* Dose Level 1: 1×10\^7/Kg~* Dose Level 2: 5×10\^7/Kg~* Dose Level 3: 1×10\^8/Kg Safety Assessment: Adverse events will be recorded and graded. Laboratory parameters and cytokine release syndrome (CRS) markers will be closely monitored. Efficacy Evaluation: Response assessments will follow IMWG guidelines, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease."
223741315|NCT04117425|BIOLOGICAL|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
223741316|NCT06838208|DRUG|Tislelizumab, Carboplatin /Cisplatin, Etoposide|Induction therapy stage LDRT: lung lesions, 15Gy/5f; Maintenance therapy phase SBRT: The main residual lesions evaluated by the investigators, 30Gy/5f；
223444751|NCT05247346|DEVICE|SENSITIVE system|probe-based integrated Raman spectroscopy and scattering measurements of Barrett's and colorectal tissue during GI endoscopy
223444752|NCT00048997|RADIATION|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
223444753|NCT00048997|OTHER|Observation|
223444754|NCT05072587|BEHAVIORAL|Plant-based diet with no oxysterols|This group will be given 3 prepared plant-based meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
223567727|NCT05397587|BIOLOGICAL|Control Vaccine|The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
223567728|NCT01416103|OTHER|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
223567729|NCT01416103|OTHER|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
224145754|NCT07091175|DRUG|Co-intervention of Prednisolone wean during open label extension phase|Patients will also receive prednisolone 60mg/m2/day as a single daily dose (max 80mg OD) until in remission for 3 days, before prednisolone is weaned to 40mg/m2 every other day for 2 weeks. Doses should be rounded up to nearest 5mg where possible. Prednisolone will then be weaned in steps as per the randomised controlled phase. If patients do not enter full remission after 2 weeks from enrolment into the extension phase, they will be removed from the study. Additional agents, e.g. Mycophenolate, Levamisole, Calcineurin inhibitors should not be started during this time unless there is strong clinical indication.
223444755|NCT05072587|BEHAVIORAL|Standard ADA Diet (SADA)|This group will be given 3 prepared meals a day with macronutrient content: 60% of calories from carbohydrates, 15% protein, and 25% fat. Calories: 25 kcal/kg ideal body weight (IBW). The goal is weight maintenance, but weight loss may occur. 1-5% weight loss will be acceptable and not deemed a potential confounder. Participants will be screened for food allergies and intolerances prior to receiving their research diets. All meals will include culturally familiar foods to enhance adherence. The dietary intervention will be conducted over 4 3-month periods (12 months). Meals will be packaged labeled and distributed to participants once per week. Participants will consume their meals at home.
223444756|NCT02819440|DRUG|Tadalafil|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
223444757|NCT02819440|DRUG|Placebo|100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
223444758|NCT00925197|OTHER|INR self-testing program|
223444759|NCT02252926|DRUG|Bupivacaine|25 mg bupivacaine lozenge
223444760|NCT02252926|DRUG|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
223444761|NCT04644159|OTHER|Human biological samples|Blood , saliva, nasopharyngeal mucosa
223444762|NCT04967859|DRUG|0.1% gentamicin|Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
223444763|NCT04967859|DRUG|Placebo|Patients using placebo ointment at the exit site of the hemodialysis catheter
223444764|NCT02445859|DRUG|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
223567730|NCT06109051|DEVICE|EndeavorOTC|EndeavorOTC™ is an over-the-counter digital therapeutic designed to improve attention function, ADHD symptoms, and quality of life in users 18 years of age and older with primarily inattentive or combined-type ADHD, who have been identified as having a significant attentional impairment. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is not intended to be a replacement for any form of ongoing treatment. EndeavorOTC is deployed on mobile devices and incorporates adaptive, simultaneous cognitive tasks in a consumer-grade action videogame-based platform with high-quality graphics and reward mechanisms.
223567731|NCT02120495|PROCEDURE|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
224164062|NCT01948349|OTHER|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
223444765|NCT05067894|BIOLOGICAL|SARS-CoV-2 Protein Subunit Recombinant Vaccine|intramuscular injection
223567732|NCT04734522|DEVICE|Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating|Subjects will be wearing three different PAL designs with different geometries of the optical progression.
223444766|NCT05067894|BIOLOGICAL|SARS-CoV-2 Inactivated Vaccine|intramuscular injection
223444767|NCT00575510|BEHAVIORAL|Intervention|Multiple component intervention based in the unified theory of behavior
223444768|NCT00575510|BEHAVIORAL|Active control|Partial intervention (full intervention minus cultural-specific component)
223444769|NCT03489200|OTHER|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
223444770|NCT03489200|OTHER|Placebo|No intervention- placebo
223444771|NCT00999700|DRUG|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
223444772|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
223444773|NCT00999700|DRUG|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
223444774|NCT00999700|DRUG|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
223444775|NCT00999700|RADIATION|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
223444776|NCT01267422|DRUG|rAAV2-ND4|injection
224054741|NCT05666336|DRUG|Prednisone|It is permitted which can be interchangeable with methylprednisolone. It will be given by oral administration of 30mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
224054742|NCT05666336|DRUG|Methylprednisolone|It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
224054743|NCT05666336|DRUG|Cyclophosphamide|It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
224054744|NCT05666336|DRUG|Mycophenolate Mofetil|It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
224054745|NCT05666336|DRUG|Tacrolimus|It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
224054746|NCT05354557|DRUG|Iberdomide|Patients will receive 12 cycles of iberdomide as maintenance therapy. Cohort 1: Cycle 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles Cohort 2: Cycles 1-12: Iberdomide 1mg daily Days 1-21 of 28 day cycles
223444777|NCT00459368|BEHAVIORAL|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
223444778|NCT00459368|BEHAVIORAL|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
223444779|NCT02697734|DRUG|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
223444780|NCT02697734|DRUG|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration
223444781|NCT04081116|OTHER|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
223444782|NCT04081116|OTHER|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
223444783|NCT04081116|OTHER|Preinclusion settings|Settings in use at start of study
223444784|NCT03704506|DRUG|Reyanning mixture|Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
223444785|NCT03704506|DRUG|amoxil capsule|amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
223444786|NCT03704506|DRUG|Reyanning mixture simulator|Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
223444787|NCT03704506|DRUG|amoxil capsule simulator|amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
223444788|NCT02651688|DRUG|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
223444789|NCT02651688|DRUG|Enclomiphene|Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
223444790|NCT03174288|OTHER|Exercise|24 weeks of exercise treatment
223444791|NCT03174288|DRUG|Spironolactone|24 weeks of spironolactone
223444792|NCT01194193|DRUG|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
223444793|NCT05576428|BEHAVIORAL|Diet and exercise|diet and exercise in patients of NAFLD
223567733|NCT04363255|DRUG|Etoposide Injection|Etoposide(100mg/m2, d1-3, q3w) combined with platinum was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
223567734|NCT04363255|DRUG|Carboplatin Injection|Carboplatin(AUC 5, d1, q3w) or Cisplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
223567735|NCT04363255|DRUG|Cisplatin injection|Cisplatin(75mg/m2, d1, q3w) or carboplatin combined with etoposide was the first-line chemotherapy in 4-6 cycles, and then JS001 combined with anlotinib as maintenance therapy were followed.
223567736|NCT04363255|DRUG|Toripalimab|After 4-6 cycles of chemotherapy, JS001(240mg, d1, q3w) combined with anlotinib were followed and continued until disease progression.
223567737|NCT04363255|DRUG|Anlotinib hydrochloride|After 4-6 cycles of chemotherapy, anlotinib(12mg qd, d1-14, q3w) combined with JS001 were followed and continued until disease progression.
223567738|NCT04900337|DRUG|AMOR 18 Powder & Inhalation|AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
223567739|NCT04900337|DRUG|Placebo|Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual
223567740|NCT03800342|OTHER|Aerobic Exercise Training|see arm/group description
223567741|NCT06343038|DRUG|Injection, 161Tb-SibuDAB,1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
223567742|NCT06343038|DRUG|Injection, 177Lu-PSMA-I&T, 1GBq|Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
223567743|NCT06343038|DRUG|Injection, 161Tb-SibuDAB, Dose Escalation|"Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed."
223567744|NCT02975414|PROCEDURE|rTARUP technique|obot-assisted rTARUP technique
223567745|NCT03788018|DRUG|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
224164063|NCT05941676|DIAGNOSTIC_TEST|Tumour immunoprofile evaluation|Tumour immunoprofile evaluation will be performed in patients with head and neck cancer.
223444794|NCT05576428|DRUG|NAC with diet and exercise|NAC with diet and exercise in patients of NAFLD
223444795|NCT04477967|OTHER|No intervention|There are no interventions because it is a protocol study
223444796|NCT01648192|DRUG|Losmapimod for single dose|Film coated white tablet
223444797|NCT01648192|DRUG|Losmapimod for repeat dose|Film coated white tablet
223444798|NCT03910140|PROCEDURE|TILA-TACE treatment|TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
223444799|NCT03899012|PROCEDURE|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
223444800|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
223444801|NCT01575730|PROCEDURE|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
223444802|NCT01575730|DRUG|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
223444803|NCT00731731|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
223444804|NCT00731731|PROCEDURE|Cognitive Assessment|Ancillary studies
223444805|NCT00731731|OTHER|Laboratory Biomarker Analysis|Correlative studies
223444806|NCT00731731|DRUG|Temozolomide|Given PO
223444807|NCT00731731|DRUG|Vorinostat|Given PO
223444808|NCT03471806|BEHAVIORAL|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
223444809|NCT03471806|BEHAVIORAL|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
223444810|NCT05232799|OTHER|Care Anywhere with Community Paramedics program|Outpatient management with supportive services provided by the community paramedic team.
223444811|NCT03970200|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
223444812|NCT03970200|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
223444813|NCT03970200|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
223444814|NCT03970200|DRUG|Antibiotics|Standard of care antibiotics
224054747|NCT06399887|OTHER|Exercise|All patients in these groups are taught diaphragmatic breathing, which is the basis for DNS, and are asked to maintain it throughout the exercises. The DNS protocol includes a 5-minute warm-up, 40 minutes of DNS exercises (10 minutes for each of the 4 different body parts) and breathing exercises. The DNS exercises included diaphragmatic breathing, Baby Rock, Roll Over, Lying on the Side, Sitting Down, Sitting Upright, Tripod, Kneeling, Squatting, Prone, and Pull Up (CGU). The focus of the first week is to teach and practice basic DNS exercises.
224054748|NCT06399887|OTHER|Biofeedback|Patients in Group II and Group III will be trained in animated CP using the Aymed Medical Locum Wireless System v.2.69.0.12 device. During CP, 10-second contraction and 30-second relaxation cycles are maintained throughout the animated game. Each session will last approximately 20 minutes. The training protocol will consist of a total of 12 sessions of 20 minutes per week for 3 months.
224054749|NCT06475066|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|"After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.~Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.~* The dosage of iodine contrast agent is calculated as 1.5 mL/kg of iopromide 370 mgI/ml.~* Injecting with high pressure syringe (Stellant, Bayer AG) at an IDR of 3ml/s, followed by 10 ml normal saline."
223444815|NCT01211132|DEVICE|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
223444816|NCT01211132|DEVICE|Standard|Without attaching a transparent cap to the tip of colonoscope.
223567746|NCT03788018|DRUG|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
223444817|NCT04213833|DRUG|Propofol Injection [Diprivan]|patients will be sedated with 50 mg propofol(10 mg/ml) given slowly intravenously over 1 min
223444818|NCT04213833|DRUG|Dexmedetomidine [Precedex]|patients will received 0.5 mcg/ kg dexmedetomidine intravenously followed by syringe containing 50 mg propofol(10 mg/ml).
223567747|NCT02390674|DRUG|Ciclosporin|Comparison between ciclosporin and placebo
223567748|NCT02390674|DRUG|Saline|
223567749|NCT00395291|DRUG|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
223567750|NCT00395291|DRUG|Placebo|Placebo
223567751|NCT02870075|BEHAVIORAL|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
224145755|NCT07091682|DEVICE|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
223444819|NCT04213833|DRUG|Palatable Lidocaine Topical Gel|15 g of palatable lidocaine gel will be gradually applied 3-5 min before the endoscopy at three consecutive 30-s intervals to the base of the tongue, the palate and the peritonsillar areas and the patients will be informed to spread it within their mouth with their tongue and swallow it later to cover the oropharynx and esophagus. Patients will be asked to register the onset of numbness, then patient will receive syringe containing 50 mg propofol (10 mg/ml) intravenously as a sedation.
223444820|NCT00151164|PROCEDURE|donor bone marrow cell injection into thymus gland|
223444821|NCT03183479|DRUG|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
223444822|NCT03183479|DRUG|Normal saline|100mL normal saline will be administered to patients in control group as placebo
223444823|NCT01693185|DRUG|Remifentanil|continuous infusion 0.4 mcg/kg/min
223444824|NCT01693185|DRUG|Midazolam|bolus injection
223444825|NCT01693185|DRUG|Meperidine|bolus injection for 30 sec 1.0 mg/kg
223444826|NCT01693185|DRUG|placebo (for remifentanil)|normal saline mimic diluted remifentanil
223444827|NCT01693185|DRUG|placebo (for midazolam)|normal saline mimic to midazolam injection
223444828|NCT01693185|DRUG|placebo (for meperidine)|normal saline mimic meperidine injection
223444829|NCT04375098|BIOLOGICAL|COVID-19 convalescent plasma|COVID-19 convalescent plasma
223444830|NCT05061901|DRUG|Lisinopril tablet 20 mg|Lisinopril is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 20 mg of lisinopril.
224145756|NCT00805922|OTHER|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
223444831|NCT05061901|DRUG|Zestril® tablet 20 mg|Zestril® is manufactured by Avara Reims Pharmaceutical Services, France. Each tablet contains 20 mg of lisinopril.
223444832|NCT03876496|DEVICE|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
223444833|NCT04331093|DRUG|SHR-1210+Apatinib|"Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression"
223444834|NCT03817099|OTHER|Nutrition Intervention based on My Dia-RNP|Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
223444835|NCT03817099|OTHER|Usual Care|Subjects in the group continue with the usual care
223444836|NCT01429441|DRUG|Ocriplasmin|0.125 mg single intravitreal injection
223444837|NCT01429441|OTHER|Sham injection|Sham injection
223444838|NCT00042653|DRUG|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
223444839|NCT00042653|DRUG|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
223444840|NCT05848596|OTHER|hand hygiene theoretical training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,"
223444841|NCT05848596|OTHER|hand hygiene theoretical + simulation training|"Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,~Hand hygiene simulation training will be carried out by the researcher in an environment with a sink.~* Simulation-based training on standard patients,~* Hand hygiene application and important points to be considered during the application will be emphasized."
223444842|NCT06274710|BEHAVIORAL|ODYSSEE-KH|Automated digital counselling program
223567752|NCT02870075|BEHAVIORAL|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
223567753|NCT05802082|OTHER|The Modified Yale Preoperative Anxiety Scale (m-YPAS) of children|Postoperative 0,5,10,15,30,45,60.and 120 minutes , PAED and WBYAS values
223567754|NCT02562209|DIETARY_SUPPLEMENT|PACER Diet|Pacer diet to be followed for 8 weeks
223567755|NCT02562209|OTHER|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
223567756|NCT02093988|DRUG|Topical TXA|
223567757|NCT02093988|DRUG|Intravenous TXA|
223567758|NCT01762956|OTHER|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
223567759|NCT03876691|OTHER|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
223567760|NCT03876691|OTHER|Physician|The current emergency medical department departments within the preparation of the attending physician
223567761|NCT00199251|DRUG|RUPATADINE|
223567762|NCT02592616|BEHAVIORAL|CON|No exercise intervention.
223567763|NCT02592616|BEHAVIORAL|CW|One hour of continuous walking on a treadmill.
223741317|NCT05301296|DIAGNOSTIC_TEST|Clinical examination of the breast for early detection of Cancer|Participants were invited for 3 rounds of clinical breast examination, conducted 3-years apart. Screening was conducted by health workers trained to perform clinical breast examination for early detection of cancer. Women with abnormal referable lesions underwent CBE by a trained clinician and those women with a confirmed breast lump or any other breast abnormality warranting further investigations were evaluated by triple-testing involving expert physical examination, diagnostic mammography with or without ultrasonography and fine needle aspiration cytology (FNAC) or core biopsy or excision biopsy. Those with confirmed breast cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
223741318|NCT01319903|BIOLOGICAL|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
223741319|NCT01463644|DRUG|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
223741320|NCT01463644|DRUG|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
224145757|NCT02578823|DEVICE|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
223567764|NCT02592616|BEHAVIORAL|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
223567765|NCT01962987|DRUG|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
223567766|NCT01962987|OTHER|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
223444843|NCT00655603|OTHER|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
223444844|NCT02279745|DRUG|Ralinepag|Active
223444845|NCT00003045|DEVICE|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
224054750|NCT05138042|OTHER|Cryotherapy (frozen glove)|"In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes."
224145758|NCT02578823|DEVICE|Arcticgel™|
223444846|NCT00003045|RADIATION|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
223444847|NCT00380718|DRUG|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~\*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade \>2; Skin Grade \>2; Serum bilirubin \>3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase \>10 x ULN; Other non-hematologic toxicities Grade \>2 (except nausea, vomiting)."
223444848|NCT01708720|DRUG|IPV|
223444849|NCT01708720|DRUG|Sabin-IPV|
223444850|NCT01708720|DRUG|Adjuvanted Sabin-IPV|
223444851|NCT05827588|DEVICE|AWAK PD|Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
223444852|NCT00987597|BEHAVIORAL|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
223444853|NCT00987597|BEHAVIORAL|conventional follow-up|nicotinic substitutes
223444854|NCT01300208|DRUG|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
223444855|NCT01300208|OTHER|Placebo|
223444856|NCT01549262|DEVICE|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
223444857|NCT01549262|DEVICE|Observe embryo development|Observe embryo development in the traditional manner
223444858|NCT04447495|DIAGNOSTIC_TEST|iAMP test|The low-cost Atila BioSystems iAMP® COVID-19 Detection kit consists of a reaction buffer mix, primer mix, three sample buffer components, a positive and negative control, nasopharyngeal swabs, and sample collection vials. Each kit is suitable for 100 tests.
223444859|NCT01242501|BEHAVIORAL|60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
223444860|NCT01242501|BEHAVIORAL|20-Min education session|Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
223444861|NCT05207722|BIOLOGICAL|CYNK-101|CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).
223444862|NCT05207722|DRUG|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
223444863|NCT05207722|DRUG|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
223444864|NCT05207722|DRUG|Recombinant Human Interleukin-2|6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.
223444865|NCT05207722|DRUG|Cyclophosphamide|Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
223444866|NCT05207722|DRUG|Fludarabine|Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.
223567767|NCT01214304|OTHER|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
223567768|NCT01214304|OTHER|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
223567769|NCT06176872|DIAGNOSTIC_TEST|Cardiac Computed Tomography Angiography|Non-invasive imaging of the heart, the greater vessels and the coronary arteries using computed tomography.
223567770|NCT02286934|DRUG|Carvedilol|"* Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd"
223444867|NCT05207722|DRUG|Mesna|MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
223444868|NCT00842400|DRUG|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~* metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~* sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~* VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~* 2 g (four 500 mg) probenecid tablets on Day 29."
223444869|NCT03285659|OTHER|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
223444870|NCT05724459|OTHER|Peer education|Training on stem cell transplantation for a total of 12 hours, two days a week for three weeks, two lesson hours a day (60 min. + 60 min.)
223444871|NCT00389051|DRUG|bendamustine hydrochloride|1 cycle; 120 mg/m2/day,2 days concecutively, followed by 19days of oveservation period. (3 to 6 cycles)
224054751|NCT01366547|DRUG|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
224054752|NCT01366547|DRUG|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
224054753|NCT01366547|DRUG|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
224054754|NCT02538874|DRUG|BMS-986171|
223444872|NCT06648954|DEVICE|multisite HD-tDCS|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
223444873|NCT06648954|DEVICE|Conventional tDCS|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
223444874|NCT06648954|DEVICE|Sham stimulation|5-8 MRI compatible electrodes (2 cm diameter) will be placed based on the neuroimaging and computation modelling. The electrodes will be placed inside MRI compatible sponges and affixed to the head using a device matched cap which will be filled with saline to have good contact with the scalp.
223567771|NCT02286934|OTHER|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
223567772|NCT02090049|DIETARY_SUPPLEMENT|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
224054755|NCT02538874|OTHER|Placebo|
224054756|NCT06210074|DEVICE|Daye Diagnostic Tampon|"The DAYE Diagnostic Tampon is a class A in vitro diagnostic device. It has CE certification (self-certified via a declaration of conformity, following the IVDR (EU) 2017/746).~The DDT is constructed entirely from woven cotton and consists of an absorbent core wrapped in a protective sleeve. The DDT is loaded in an applicator to aid with insertion. The DDT needs to be worn for 20 minutes then when removed should be placed immediately in the sterile container."
224054757|NCT02861209|OTHER|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
224054758|NCT00744133|BIOLOGICAL|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
224054759|NCT04223843|DRUG|Tiotropium + olodaterol|Oral Inhalation
224054760|NCT04223843|DRUG|Placebo|Oral Inhalation
224054761|NCT01789762|BIOLOGICAL|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
224054762|NCT01789762|BIOLOGICAL|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
224054763|NCT01789762|BIOLOGICAL|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
223444875|NCT01606748|BIOLOGICAL|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
223444876|NCT01606748|DRUG|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
223444877|NCT01606748|DRUG|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
223444878|NCT02590757|DEVICE|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
223444879|NCT02590757|DEVICE|N-CPAP|Nasal-continuous positive airway pressure
223444880|NCT03150394|DIETARY_SUPPLEMENT|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
224054764|NCT06243198|DRUG|Lebrikizumab|Administered subcutaneously (SC)
224054765|NCT06243198|DRUG|Placebo|Administered subcutaneously (SC)
224054766|NCT05645614|OTHER|EVALUATION OF PAIN|PAIN EVALUATION THANKS TO SCALES
224054767|NCT03651453|BEHAVIORAL|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
224054768|NCT03651453|BEHAVIORAL|Standard care|Standard harm reduction information
224054769|NCT06127160|DRUG|Cephalexin|Cephalexin 1000 mg by mouth 3 times daily for 10 days
224054770|NCT06127160|DRUG|Cephalexin or placebo|Cephalexin 1000 mg by mouth 3 times daily for a minimum of 3 days, once participant reports symptom resolution for 24 hours they will switch to placebo for remainder of 10 days of treatment.
224054771|NCT02159729|DRUG|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
224054772|NCT02159729|DRUG|ATX-101 (1 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
224054773|NCT02159729|DRUG|ATX-101 (2 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
224054774|NCT02159729|DRUG|ATX-101 (4 mg/cm^2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
224054775|NCT06848387|DIAGNOSTIC_TEST|Unbound cloxacillin concentration|Unbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
223444881|NCT03150394|OTHER|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
223444882|NCT02603926|DRUG|Allopregnanolone|Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
223444883|NCT03066219|DRUG|BRM421|A topical solution of BRIM421 ophthalmic drops
223444884|NCT03066219|DRUG|Placebo|vehicle ophthalmic drops
223444885|NCT06289686|PROCEDURE|Rotator cuff repairs with BioEnthesis augmentation|Rotator cuff repair using BioEnthesis allograft patch
223444886|NCT06289686|PROCEDURE|Rotator cuff repairs without BioEnthesis augmentation|Rotator cuff repair using standard of care sutures and anchors
223444887|NCT06368323|BEHAVIORAL|Choir singing|The 12-week intervention will consist of 12 in-person choir-singing sessions (1 session/week, 1,5 h/session, total 18h) conducted by a choir master in addition to home training (3 x 30-minutes-sessions/week, total 18h). In total, participants will undergo the intervention for 3 hours/week for 12 weeks (i.e., 36 hours).
223444888|NCT06368323|OTHER|Usual care|Rehabilitation services received by patients and social activities will be monitored and documented.
223444889|NCT00004759|DRUG|methylprednisolone|
223444890|NCT00004759|DRUG|tirilazad|
223444891|NCT04505202|DRUG|0.12% chlorhexidine gluconate|The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
223444892|NCT04505202|DRUG|Placebo|The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
223444893|NCT04936113|BIOLOGICAL|FB-401|Topical
223444894|NCT02557373|DIETARY_SUPPLEMENT|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
223444895|NCT02557373|DIETARY_SUPPLEMENT|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
223444896|NCT04092829|PROCEDURE|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
223444897|NCT00095589|GENETIC|loss of heterozygosity analysis|
223444898|NCT00095589|GENETIC|microarray analysis|
223444899|NCT00095589|GENETIC|microsatellite instability analysis|
224300705|NCT02475941|OTHER|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
223444900|NCT00095589|OTHER|cytology specimen collection procedure|
223444901|NCT00095589|OTHER|laboratory biomarker analysis|
223567773|NCT02090049|DIETARY_SUPPLEMENT|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
223567774|NCT04008992|DRUG|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
223567775|NCT04008992|OTHER|Placebo|Placebo matching BMS-986259
223567776|NCT04008992|DIAGNOSTIC_TEST|P-Aminohippurate|Diagnostic Agent
223444902|NCT00095589|PROCEDURE|computed tomography|
223444903|NCT00095589|PROCEDURE|cystoscopy|
223444904|NCT05896800|OTHER|Inhaled nitric oxide (NO)|The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
223444905|NCT05896800|OTHER|air|use air（21%O2）as the placebo of inhaled treatment
223444906|NCT02230540|DEVICE|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
223444907|NCT02230540|DEVICE|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
223444908|NCT02230540|DEVICE|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
223444909|NCT05299619|DEVICE|Tixel|a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling fast water evaporation with low thermal damage to the surrounding tissue (such as charring or ablation).
223444910|NCT05800496|DIETARY_SUPPLEMENT|SesZen-Bio™|mode of usage: 1 capsule in the morning and 1 capsule at night. administration: Oral Administration
223444911|NCT05800496|OTHER|Placebo|Mode of Usage: 1 capsule in the morning and 1 capsule at night. Route of Administration: Oral Administration
223567777|NCT04008992|DIAGNOSTIC_TEST|Iohexol|Diagnostic Agent
223567778|NCT06487312|DEVICE|Test equipment: Name: Remote automatic ultrasound diagnostic system (Wuhan Cooper Technology Co., Ltd.) Model: CORUS-A30|A clinical trial to evaluate the effectiveness and safety of a remote automated ultrasound diagnostic system for automated ultrasound examination using a remote automated ultrasound diagnostic system (model: CORUS-A30, Wuhan Cooper Technology Co., Ltd., China).
223567779|NCT05858632|DRUG|Guselkumab|Guselkumab treatment for \~ 9 months
223567780|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
223444912|NCT02671019|BEHAVIORAL|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
223444913|NCT03742258|DRUG|Cyclophosphamide|Given IV
223444914|NCT03742258|DRUG|Doxorubicin Hydrochloride|Given IV
223444915|NCT03742258|DRUG|Prednisone|Given PO
223444916|NCT03742258|BIOLOGICAL|Rituximab|Given IV
223444917|NCT03742258|DRUG|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
223444918|NCT03742258|DRUG|Vincristine Sulfate|Given IV
223444919|NCT06602167|COMBINATION_PRODUCT|True electroacupuncture + True self-administered acupressure|"True electroacupuncture: Participants will receive two electroacupuncture treatments within the first week of each treatment cycle. The acupuncturist inserts the needle into the point and manipulates the needle until the feeling of deqi is achieved and reported by the participant. The electrical stimulation will be administered at a sustained frequency of 2Hz for 30 minutes. True self-administered acupressure: In weeks 2 and 3 of each treatment cycle, participants performed true self-administered acupressure, pressing each acupoint with their thumb to achieve deqi for three minutes."
223444920|NCT06602167|DRUG|Doctor-prescribed treatment|Doctor-prescribed treatment: At the beginning of capecitabine, patients will be treated with doctor-recommended medications, including oral celecoxib, topical diclofenac, and other skin protectants.
224054776|NCT02106052|OTHER|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
224054777|NCT02106052|OTHER|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
224054778|NCT06185829|DRUG|Neurloeptanalgesic treatment|Usual neuroleptanalgesic treatment
224054779|NCT06185829|OTHER|Hypnoanalgesia|Hypnoanalgesia
223444921|NCT06602167|COMBINATION_PRODUCT|Sham electroacupuncture + Sham self-administered acupressure|"Sham electroacupuncture: The sham electroacupuncture comprised a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at body locations not recognized as true acupuncture points and are deemed to not belong to traditional Chinese meridians and have no therapeutic value. Participants will receive acupuncture treatment without electrical stimulation same the intervention group. And avoid deqi sensation. Sham self-administered acupressure: Administered non-acupressure points 1 to 3cm away from the true acupressure points used in the experimental group and away from known meridians. The frequency, course duration, and overall treatment time will be the same as those in the true self-administered shiatsu group. The applied pressure does not cause a feeling of deqi."
223444922|NCT05980143|OTHER|Metacognitive Therapy|The transdiagnostic Metacognitive model suggests that psychological difficulties arise from the activation of a thinking style called the CAS (Cognitive Attentional Syndrome). Metacognitive Therapy (MCT) aims to bring the CAS under control. The therapist helps the patient to learn new ways of relating to stressful thoughts.
223444923|NCT01511003|DRUG|Tacrolimus|oral
223444924|NCT04760379|OTHER|Conventional therapy|Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
223444925|NCT04760379|OTHER|vibration therapy|Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
223567781|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
224054780|NCT02636582|OTHER|Laboratory Biomarker Analysis|Correlative studies
224054781|NCT02636582|DRUG|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
224054782|NCT02636582|BIOLOGICAL|Sargramostim|Given ID
224054783|NCT02636582|PROCEDURE|Surgical Procedure|Undergo surgery
224054784|NCT00777010|OTHER|Ketogenic diet|carbohydrate restricted diet
224054785|NCT00777010|OTHER|Healthy high carbohydrate diet|higher carbohydrate diet
224054786|NCT00272909|DRUG|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
224054787|NCT00272909|DRUG|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
223567782|NCT01457170|DRUG|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
224054788|NCT00272909|DRUG|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
223567783|NCT01457170|DRUG|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
224054789|NCT06545968|BEHAVIORAL|A social media based intervention|WatsApp-based modules to influence retention in care behaviour
224054790|NCT04821544|BEHAVIORAL|Mindfulness-based intervention (with a focus on self-compassion; MBSC)|8-week MBSC intervention with a focus on increasing self-compassion
224054791|NCT04821544|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D at 2,000 IU/day for 8 weeks.
224054792|NCT00390754|BEHAVIORAL|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
224054793|NCT06471829|DRUG|Lu AG13909|Solution for injection/infusion
224054794|NCT03561870|DRUG|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
223444926|NCT02083653|DRUG|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
223444927|NCT02083653|DRUG|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
224145759|NCT02578823|PROCEDURE|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
223444928|NCT02083653|OTHER|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
223444929|NCT02083653|DRUG|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
223444930|NCT02083653|DRUG|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
223444931|NCT05846217|DEVICE|Multiwave Locked System|Multiwave Locked System laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
223444932|NCT03327961|DEVICE|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
223444933|NCT06536322|OTHER|OHS-interRAI|An oral health screening tool is being tested. Former name was the optimized oral health-related section of the interRAI (ohr-interRAI). This was further optimized into the OHS-interRAI. The OHS-interRAI comprises of 3 oral health-related items that are assessed through questioning the resident, and 6 items that require visual inspection of the mouth.
223444934|NCT03742856|COMBINATION_PRODUCT|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
223444935|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. The rectus abdominis and underlying transversus abdominis muscles will be identified. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
223444936|NCT04693156|PROCEDURE|unilateral ultrasound-guided oblique subcostal TAP block with %0.9 NaCl 30ml|In the supine position, after the skin sterilization, ultrasound with a high-frequency linear probe will be placed subcostally and from the xiphoid to the right iliac crest obliquely. %0.9 NaCl 30ml will be injected after negative aspiration to the transversus abdominis plane between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line.
223444937|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound (Esaote MyLab5) probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. The local anesthetic solution (%0.5 Bupivacaine 10ml + %1 Prilocaine 10ml + %0.9 NaCl 10ml) will be injected after negative aspiration.
223444938|NCT04693156|PROCEDURE|unilateral ultrasound-guided posterior TAP block with %0.9 NaCl 30ml|After the oblique subcostal TAP block, the operation table will be slightly turned left laterally for better visualization of the blocking area. The same high-frequency linear ultrasound probe will be placed over the postero-lateral abdominal wall, posterior of the mid-axillary line between the costal margin and iliac crest. After the identification of the internal abdominis, transversus abdominis, and quadratus lumborum muscles, the needle will be advanced into the transversus abdominis plane between the internal abdominis and transversus abdominis muscles, at the aponeurosis of quadratus lumborum and these muscles. %0.9 NaCl 30ml will be injected after negative aspiration.
223444939|NCT00623051|PROCEDURE|Male Circumcision|
223444940|NCT01980745|DRUG|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
223444941|NCT01980745|DRUG|Placebo|
223444942|NCT05076747|BEHAVIORAL|Cardiovascular training|8 weeks of cardiovascular training
223444943|NCT05076747|BEHAVIORAL|Standard Therapy|8 weeks of Standard Therapy
223567784|NCT03232242|DIAGNOSTIC_TEST|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
223567785|NCT06089460|OTHER|Beef|Fresh, locally-sourced, grass-fed, grass-finished ground beef sufficient to meet protein needs based on body weight for 8 weeks
223741321|NCT05931302|DIAGNOSTIC_TEST|68Ga-FAPI-46 PET scan|"68Ga-FAPI-46 is a radiotracer for the detection of Fibroblast Activation Protein (FAP) in cancer patients.~68Ga-FAPI-46 will be administered intravenously at a dose of 2MBq/kg. Patients will be scanned 60 minutes after administration of 68Ga-FAPI-46."
224145760|NCT04407455|DIAGNOSTIC_TEST|Karaduman Chewing Performance Scale|For chewing evaluation, children will be asked to bite and chew a standardized biscuit. Each chewing evaluation will be scored according to the KCPS.
223567786|NCT06089460|OTHER|Meat analogue|Commercially-available and purchased meat analogue sufficient to meet protein needs based on body weight for 8 weeks
223567787|NCT06089460|OTHER|Beans/legumes|Canned beans/legumes sufficient to meet protein needs based on body weight for 8 weeks
223567788|NCT03443479|DEVICE|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
223741322|NCT05813964|DRUG|TDF/FTC 300mg/200mg fixed-dose combination tablets|Event-driven dosing regimen
223741323|NCT05813964|DRUG|TAF/FTC 25mg/200mg fixed-dose combination tablets|Event-driven dosing regimen.
224145761|NCT03143972|DRUG|Dexmedetomidine|Single drug administration
224145762|NCT03143972|DRUG|Remifentanil|Single drug administration
224145763|NCT07091149|BEHAVIORAL|CBT-I|Cognitive behavioral therapy for insomnia
224145764|NCT07091617|OTHER|Telemedicine|Undergo telehealth visit with genetic counselor for pretest genetic education
223444944|NCT04517045|DRUG|Dachengqi decoction|Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
223444945|NCT04517045|DRUG|probiotic L9|L92 2 tablets/time, tid, oral or nasal feeding
223444946|NCT04517045|OTHER|Conventional treatment|Conventional treatment
223444947|NCT01272375|DRUG|Treatment A|PF-04764793 250/50 using inhaler A
223444948|NCT01272375|DRUG|Treatment B|PF-04764793 250/50 using inhaler A
223444949|NCT01272375|DRUG|Treatment C|PF-04764793 250/50 using inhaler A
223444950|NCT01272375|DRUG|Treatment D|PF-04764793 250/50 using inhaler A
223444951|NCT01272375|DRUG|Treatment E|PF-04764793 250/50 using inhaler B
223444952|NCT01272375|DRUG|Treatment F|PF-04764793 250/50 using inhaler B
223444953|NCT01272375|DRUG|Treatment G|PF-04764793 250/50 using inhaler B
224054795|NCT05500274|OTHER|Education|Testimonial videos will be played including those that describe the testing experience and their motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors. The self-affirmation activity will always precede the presentation of the testimonial videos as leading with misinformation correction can be construed by some as a threat to one's self-adequacy.
224054796|NCT05500274|OTHER|Motivational|This is a Type I network intervention that includes specific training on mobilization of network members. Training occurs in a group-based setting of 8-10 enrolled participants facilitated by a community facilitator and Motivational Interviewing trained interventionist. At 30 days, a 15-20-minute phone booster communication session reinforces the intervention content
224054797|NCT06616285|BEHAVIORAL|Self-Guided Multidomain Lifestyle Intervention|Participants will receive guidance on healthy dietary habits, physical activity, mental stimulation, and cardiovascular/metabolic monitoring based on national recommendations and individual consultations with the study physician. Based on this guidance, participants will create their own healthy lifestyle plan. Participants' cardiovascular/metabolic risk factors will be regularly monitored.
223444954|NCT04371211|BEHAVIORAL|Telemedicine Brain Injury Coping Skills|"BICS is a 12 session (one session per week), manualized, cognitive-behavioral treatment group designed to provide support, coping skills, and psychoeducation aimed to improve perceived self-efficacy (PSE) and emotional functioning. PSE has been found to be strongly linked to social participation, increased positive regard toward the caregiving role, and was found to be the greatest contributing factor to predicting life satisfaction.~For this study, the Brain Injury Coping Skills (BICS) group intervention will be administered electronically in a web-based group telemedicine platform, BICS-T. The purpose of this phase is to test the feasibility, participant training protocol, and ease of use of equipment and technology."
223444955|NCT03796715|DIAGNOSTIC_TEST|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
224145765|NCT07091617|OTHER|Genetic Testing|Complete standard of care genetic testing
223444956|NCT03796715|DIAGNOSTIC_TEST|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
223444957|NCT00858715|DRUG|aspirin|100 mg aspirin
223444958|NCT00858715|DRUG|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
223444959|NCT05437237|DIAGNOSTIC_TEST|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. For this purpose the Waveguard touch dry electrode EEG cap and compatible eego mini amplifier (ANT Neuro B.V., Hengelo, Netherlands) are used to record and amplify the EEG signal, respectively. Both products are CE marked as medical devices in the European Union and will be used within the intended use as described in the user manuals.
223444960|NCT06264037|OTHER|semi structured interview|semistructured interview on patient\&#39;s experience of hospitalization.
223444961|NCT00940641|DRUG|AZD7325|IV Dose
223444962|NCT00940641|DRUG|AZD7325|oral dose
223444963|NCT02468713|DRUG|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
223444964|NCT02468713|DRUG|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
223444965|NCT03289299|DRUG|Carfilzomib|56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.
223444966|NCT03289299|DRUG|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
223444967|NCT03289299|DRUG|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
223444968|NCT03289299|DRUG|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
223444969|NCT06295497|DEVICE|Lung-SIGHT|"* The LDCT images will be interpreted by an artificial intelligence-based programme (Lung-SIGHT) for lung nodules.~* LDCT with lung nodules ≥5mm detected by AI programme (AI+) will be sent for reporting by board-certified radiologists.~* Participants with abnormal LDCT reported by radiologists (Rad+) will be followed up at designated clinic. Management of lung nodules will follow the guidelines below for two years.~* Participants with negative LDCT determined by AI programme (AI-) will undergo LDCT thorax and blood taking two years later (T1). Patients with lung nodules detected by AI programme (AI+) will be sent for radiologist reporting and those with abnormal CT reported by radiologists (Rad+) will be followed up in lung nodule clinic as per standard of care. Patients with normal second-round LDCT as determined by AI (AI-) or radiologists (AI+ Rad-) do not require follow up."
223444970|NCT03084315|DEVICE|E-Cig Zero Nicotine|E-Cig Zero Nicotine
223444971|NCT03084315|DEVICE|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
224145766|NCT07091617|OTHER|Telemedicine|Undergo telehealth visit with genetic counselor for disclosure of results
224145767|NCT07091617|OTHER|Internet-Based Intervention|Receive access to Genetic Journey Chatbot
224145768|NCT07091617|OTHER|Educational Intervention|Complete digital pre-test genetic education
224145769|NCT07091617|BEHAVIORAL|Patient Navigation|Utilize chatbot to answer questions, assess barriers, and provide reminders for next steps during the testing period
224054798|NCT06616285|BEHAVIORAL|Folk Dance Multidomain Lifestyle Intervention|"Participants will receive structured, intensive lifestyle intervention with the following components: diet, physical exercise, mental stimulation, cardiovascular/metabolic risk monitoring, social interaction.~One-hour long folk dancing sessions, delivered by professional teachers 3 times weekly, will provide opportunities for physical and mental exercise and social interaction. These sessions were specifically developed to foster physical and mental stimulation through the learning of coordinated movement and different choreographies (rhythmic and gradually more complex movements with folk songs) individually, in pairs, and circles. As such, social stimulation is naturally embedded in the sessions.~Participants will receive advice about diet and cardiovascular/metabolic risk factors based on national recommendations via group sessions and individual consultations. Participants' cardiovascular/metabolic risk factors will be regularly monitored."
224054799|NCT06069934|DRUG|Pridopidine|Pridopidine 45 mg hard gelatin capsules once daily p.o. (or via feeding tube)
223741324|NCT05521412|DRUG|[ 161 Tb]Tb PSMA I&T|During dose escalation, doses of \[161 Tb\]Tb PSMA I\&T will range between 4.4 GBq to 9.5 GBq. The recommended phase 2 dose of \[161 Tb\]Tb PSMA I\&T will be used during dose expansion. \[161Tb\]Tb-PSMA-I\&T dose will be reduced by 0.4 GBq for each subsequent cycles (2 to 6).
223741325|NCT00002631|DRUG|chemotherapy|
223741326|NCT00002631|DRUG|cisplatin|
224054800|NCT05590143|DRUG|Dapagliflozin 10 MG Oral Tablet [Farxiga]|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
223444972|NCT04286334|DEVICE|Bone augmentation with cad-cam laser-sintered mesh|Titanium meshes cad cam laser-sintered were applied in sites with alveolar bone deficiency in order to regenerate the bone volume in need of implant-prosthetic restorations.
223444973|NCT04498039|DEVICE|Portable Neuromodulation Stimulator|Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
223444974|NCT04787614|OTHER|No intervention|No intervention
223741327|NCT00002631|DRUG|fluorouracil|
224054801|NCT05590143|DRUG|Placebo|One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
223444975|NCT03286933|BEHAVIORAL|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
224054802|NCT05230251|DRUG|177Lu-PNT2002|Men randomized to receive 177Lu-PSMA will receive 1 cycle of 177Lu-PSMA at a dose of 6.8MBq administered intravenously 2 weeks prior to the planned HDR administration in the Department of Nuclear Medicine as per local practice for the administration of therapeutic radiopharmaceuticals and consistent with good practices.
224054803|NCT05230251|RADIATION|High Dose Radiation|HDR brachytherapy will be administered as per local practice. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction.
224054804|NCT06798532|OTHER|Collection of data from the patient's medical file.|Collection of data from the patient's medical file.
224054805|NCT00993408|DEVICE|ACT-293987 (NS-304)|
224054806|NCT01555151|DRUG|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
224054807|NCT01555151|DEVICE|Concept 1|A single dose dry powder inhaler (SDDPI)
224054808|NCT01555151|DEVICE|Twisthaler|A single dose dry powder inhaler (SDDPI)
223444976|NCT02862925|PROCEDURE|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
223444977|NCT02507024|OTHER|Online questionnaire|
223444978|NCT02910726|PROCEDURE|Sentinel Lymph Node Biopsy|
223444979|NCT02910726|DRUG|indocyanine green (ICG)|
223444980|NCT03963180|OTHER|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
223741328|NCT00002631|RADIATION|low-LET electron therapy|
223741329|NCT00002631|RADIATION|low-LET photon therapy|
223741330|NCT02596581|OTHER|non-surgical periodontal treatment|scaling and root planing were performed
223741331|NCT03318250|DEVICE|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
223741332|NCT01127412|BEHAVIORAL|Physical activity stimulating program|
223741333|NCT04390204|OTHER|intervenions|"* Motor control exercises~* A supervised home self-rehabilitation program"
223741334|NCT03880019|PROCEDURE|Computed Tomography|Undergo CT
223741335|NCT03880019|PROCEDURE|Core Biopsy|Undergo tumor biopsy
223741336|NCT03880019|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223741337|NCT03880019|DRUG|Olaparib|Given PO
223741338|NCT03880019|DRUG|Temozolomide|Given PO
223741339|NCT00410553|DRUG|Eribulin Mesylate|Given IV
223741340|NCT00410553|DRUG|Gemcitabine Hydrochloride|Given IV
223741341|NCT03752112|DRUG|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
223444981|NCT01952080|DRUG|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
223444982|NCT00413933|PROCEDURE|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
223444983|NCT06614933|DEVICE|Biphasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a biphasic current, continuous at 25 Hz, for 1 hour, in-person.
223444984|NCT06614933|DEVICE|Monophasic transcutaneous auricular vagus nerve stimulation|Transauricular vagus nerve stimulation (taVNS) is a simple technique in which small surface electrodes are placed over the skin of the ear that are thought to be innervated by the auricular branch of the vagus nerve (ABVN). Participants in this group will first receive taVNS with a monophasic current, with a 50% duty cycle at 25 Hz, for 1-hour, in-person.
223741342|NCT03752112|DRUG|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
223741343|NCT03744533|OTHER|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
223741344|NCT03744533|OTHER|guideline-based treatment|guideline-based treatment
223741345|NCT04906551|DEVICE|laser Doppler|A direct measure of blood flow
223741346|NCT02432534|DRUG|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
223444985|NCT06670833|OTHER|Lung ultrasound|Portable lung ultrasound
223741347|NCT02432534|OTHER|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
223741348|NCT00957073|DEVICE|Rheos® system|Implant procedure
224054809|NCT03596866|DRUG|Brigatinib|Brigatinib Tablets.
224054810|NCT03596866|DRUG|Alectinib|Alectinib Capsules.
224054811|NCT05920616|OTHER|Magnetic Resonance Imaging|Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.
223444986|NCT06670833|OTHER|Standard of Care (SOC)|SOC antibiotic treatment
223444987|NCT03979183|BEHAVIORAL|Lumbopelvic, stretching, aerobic and relaxation exercises|Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
223741349|NCT00326950|DRUG|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
223741350|NCT06114147|DEVICE|trans thoracic echocardiography measure|The trans thoracic echography would be carried out with cardiac classic sections to ensure the structural cardiac and valvular normality and then sections repeated 3 times over 10 minutes will be carried out to calculate the cardiac output.
223741351|NCT06114147|DEVICE|ICON measure|The ICON will be placed at the beginning of the consultation and the measurements will be taken at the same time as the trans thoracic ultrasound in the left lateral decubitus position.
223741352|NCT06114147|DEVICE|USCOM|Afterwards, measurements will be made with USCOM in left lateral position and 3 of the best spectra archived according to the Fremantle score.
223444988|NCT04320953|DEVICE|Non-contact MCE system|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
223444989|NCT05669469|PROCEDURE|Bariatric surgery|1\) gastric pouch creation, 2) creation of biliopancreatic limb, 3) jejunojejunostomy creation, and 4) creation of gastrojejunostomy.
223444990|NCT00564395|DRUG|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
223444991|NCT00564395|DRUG|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
224054812|NCT05920616|OTHER|Ultra-High Resolution Computed Tomography (CT) Scan|Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
224054813|NCT04537494|DIETARY_SUPPLEMENT|L. reuteri|Probiotic
224054814|NCT01961349|DRUG|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
224054815|NCT01961349|DRUG|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
224054816|NCT01961349|DRUG|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
224054817|NCT02556996|BIOLOGICAL|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10\^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
224054818|NCT02556996|OTHER|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10\^11 heat-killed bacteria per dose)
224054819|NCT04524702|DRUG|Gemcitabine|Given IV
224054820|NCT04524702|DRUG|Hydroxychloroquine|Given PO
224054821|NCT04524702|DRUG|Nab-paclitaxel|Given IV
224054822|NCT04524702|DRUG|Paricalcitol|Given IV
224145770|NCT07091617|OTHER|Interview|Complete interview
223444992|NCT07026565|BEHAVIORAL|Psychotherapy group for parents|The psychotherapy group will consist of 10 virtual sessions, each lasting 1 hour and 15 minutes. Each session will begin with a mindfulness exercise to bring the participants into the present moment, followed by a pre-determined topic for discussion. At the end of each session, there will be a closing segment to summarize the reflections and teachings of the day, and a homework assignment will be provided. The topics covered will be: Opening, Psychoeducation, Diagnosis Report, Acceptance, Psychological Flexibility, Cognitive Defusion, Self as Context, Values, Committed Action, and Closure.
223444993|NCT07026565|BEHAVIORAL|Control Group|For the parents who will participate in the control group, the steps undertaken will include the administration of the Self-Reporting Questionnaire, Parental Stress Scale, Acceptance and Action Questionnaire, Cognitive Fusion Questionnaire, and Freiburg Mindfulness Inventory, before the intervention, after the intervention, and after 3 months.
223444994|NCT07026357|DEVICE|3D-planimetric measurement|Esophageal stenosis is evaluated by 3D-planimetric measurement
224054823|NCT03677050|OTHER|Smart phone patient education application|Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
224054824|NCT04506814|DEVICE|Endocardial PVI|Catheter based PVI
224054825|NCT04506814|DEVICE|Epicardial Posterior Wall Isolation + LAA Exclusion + Endocardial PVI|Minimally invasive PVI with posterior wall RF ablation + LAA clip + endocardial PVI
224054826|NCT03512795|BIOLOGICAL|Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.
224054827|NCT02576444|DRUG|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
224054828|NCT02576444|DRUG|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
224054829|NCT02576444|DRUG|AZD1775|The recommended dose will be available no earlier than March 2016.
224054830|NCT02576444|DRUG|AZD6738|Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
224054831|NCT04673591|DRUG|Tregalizumab|a monoclonal antibody designed for the treatment of allergic asthma indication
224054832|NCT04673591|OTHER|Placebo|Matched Placebo
224054833|NCT00896779|DRUG|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
224054834|NCT00771823|DRUG|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
224054835|NCT00771823|DRUG|Maraviroc|"* Placebo twice daily for the first 14 days of the study.~* Maraviroc 300 mg twice daily for the last 14 days of the study."
223444995|NCT07026357|RADIATION|Fluoroscopic control|Fluoroscopic control of dilatation therapy
223444996|NCT07026357|DIAGNOSTIC_TEST|Endoscopic control|Macroscopic endoscopic control of dilatation therapy
223444997|NCT07026721|PROCEDURE|Retrograde intrarenal surgery (RIRS)|"The intervention involves Retrograde Intrarenal Surgery (RIRS) performed using a flexible ureteroscope to access the renal collecting system via a retrograde (urethra → bladder → ureter → kidney) approach. Stones are fragmented using a holmium:YAG laser, with or without the use of a ureteral access sheath, depending on the case.~What distinguishes this intervention from others is the integration of preoperative scoring systems-specifically the RIRS Scoring System and the Resorlu Unsal Stone Score (RUSS)-to predict stone-free outcomes and guide case selection and surgical planning. Additionally, all procedures are performed by experienced endourologists following a standardized protocol, including consistent patient positioning, anesthesia, access technique, and post-operative imaging at defined intervals to assess outcomes."
223444998|NCT07027579|OTHER|Nutrineal|"The Education for Thyroid Patients' Nutrition power point presentation prepared by the researcher will also be done using a computer."
223444999|NCT07027410|DEVICE|Intermittent normobaric hypoxia|Participants in the experimental group undergo a single session of intermittent normobaric hypoxia simulated by the iAltitude device. The session consists of breathing air with 12% oxygen concentration (equivalent to 4400 meters altitude) for a specified duration. Cognitive tests are administered before and after the hypoxia exposure to assess executive functions.
223445000|NCT07027410|OTHER|Normoxia|Participants undergo the same cognitive tests without exposure to hypoxia, serving as the control condition.
223445001|NCT07027423|DRUG|BOLD-100|BOLD-100 in combination with Doxorubicin (Escalation)
224054836|NCT03953430|OTHER|Gait analysis|
224054837|NCT06476236|DIETARY_SUPPLEMENT|M4C|Nutraceutical designed to enhance novel metabolic pathway activity.
224054838|NCT03668886|OTHER|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
224054839|NCT03151642|RADIATION|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
224054840|NCT03151642|RADIATION|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
224054841|NCT03151642|PROCEDURE|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
224145771|NCT07091617|OTHER|Survey Administration|Ancillary studies
224145772|NCT07092085|DIAGNOSTIC_TEST|AI model|An AI model provides an objective and rapid assessment of potential mental health risks in students by holistically analyzing their facial expressions, vocal characteristics, and linguistic content from data.
223445002|NCT07027423|DRUG|Doxorubicin 75 mg/m^2|BOLD-100 in combination with Doxorubicin (Escalation)
223445003|NCT07027423|DRUG|BOLD-100|BOLD-100 in combination with Doxorubicin (Expansion)
223445004|NCT07027423|DRUG|Doxorubicin 75 mg/m^2|BOLD-100 in combination with Doxorubicin (Expansion)
223445005|NCT07025980|DIETARY_SUPPLEMENT|The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS|The test product is a ready-to-use preparation PROBalansHepatocare, manufactured by PharmaS d.o.o., which contains 8 strains of live cultures of microorganisms (Bifidobacteriumbreve BBR8, Bifidobacteriuminfantis SP37, Bifidobacteriumlongum SP54, Lactobacillus acidophilus LA1, Lactobacillus bulgaricus LB2, Lactobacillus paracasei IMC502®, Lactobacillus plantarum BG 112, Streptococcusthermophilus SP4) with about 100 billion bacteria (50x109 CFU/capsule) in two capsules per day. In addition, the test product contains 100 mg of fructooligosaccharides, 210 mg of Ca-butyrate, and 10 ug (400 IU) of vitamin D in each capsule.
223445006|NCT07025980|DIETARY_SUPPLEMENT|Placebo Drug|Contains only excipients (cellulose; hydroxypropyl-methyl cellulose) and 10 ug (400 IU) of vitamin D. They do not contain dyes, flavors or preservatives, and contain traces of soy and milk, the levels of which do not affect people who are lactose intolerant.
223741353|NCT02002923|PROCEDURE|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
223741354|NCT02002923|DRUG|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
223741355|NCT02607891|DRUG|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
223741356|NCT02607891|DRUG|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
223741357|NCT05185128|BEHAVIORAL|PEERS social skills intervention|The PEERS treatment program consists of 90-minute sessions, delivered once a week over the course of 16- weeks. Parents and children/adolescents attend separate concurrent sessions that instruct them on key elements about making and keeping friends. Among others, this parent-assisted, social skills intervention provides explicit instruction to target verbal and nonverbal communication skills, appropriate use of humor and resolving peer conflict, as well as expanding and developing friendship networks38. The candidate, Dr. Nair, has been trained on the PEERS social skills intervention extensively for the past five years, and is a certified provider for the adolescent program. The PEERS program will be provided by Dr. Nair's research team (consisting of Dr. Nair, lab co-ordinators, and clinical psychology doctoral students) through the LLU Department of Psychology.
223445007|NCT07026396|OTHER|Creative drama group|In the intervention phase of the study, creative drama training was given to adolescents one day a week for 4 weeks. Before the training, permission was obtained from the families of the individuals, and only voluntary adolescents were allowed to participate. The empty classroom in the school was made suitable for creative drama activities. Adolescents gathered in the empty classroom one day a week, and the models and activity materials prepared by the researcher were taken to the classroom during the implementation week.
223445008|NCT07025863|BEHAVIORAL|Alarm Fatigue Intervention Program|Train nurses in terms of alarm fatigue stressors, coping resources, and cognition. The training content for stress management includes forming a multidisciplinary team, selecting appropriate equipment, replacing accessories and dressings in a timely manner, and comforting the children promptly. The training content for dealing with resources includes standardizing alarm response procedures, increasing manpower allocation, enhancing knowledge, skills, and psychological adjustment, etc. The training content of cognition includes fostering a positive attitude and strengthening responsibility, etc.
223445009|NCT07025798|DIETARY_SUPPLEMENT|Probiotic|Probiotic strips with different strain formulas, Specification: 2g/bag. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
223445010|NCT07026045|OTHER|Post isometric relaxation (Lewit,s)|Post-isometric relaxation technique for the erector spinae, Iliopsoas, Quadratus Lumborum
223445011|NCT07026045|OTHER|Post-Facilitation Stretch Technique (Janda's technique)|Post-Facilitation Stretch Technique for the erector spinae, Iliopsoas, Quadratus Lumborum
223445012|NCT07026175|OTHER|Diet-induced low energy availability|6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing restricted energy intake on the control trial.
223445013|NCT07026175|OTHER|Exercise-induced low energy availability|6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing increased exercise energy expenditure on the control trial.
224054842|NCT03151642|DEVICE|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
224145773|NCT03861195|PROCEDURE|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
224145774|NCT01987349|BIOLOGICAL|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
224145775|NCT01987349|BIOLOGICAL|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
224145776|NCT02769806|PROCEDURE|MRI|
224145777|NCT05009030|DRUG|COVID-19 vaccine|Lung cancer patients will receive an anti-COVID19 vaccine approved by the European Medicines Agency according to the guidelines approved by the regulatory authorities
223741358|NCT03296254|BEHAVIORAL|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
223445014|NCT07026058|OTHER|Sound Wave Treatment|"Sound wave treatment with 6 sessions initially, 3 times a week, followed by the next 6 sessions with a frequency of 2 times a week. Patient's position was analysed through digital X-ray of cervical spine, 80 pulses are typically administered in a session. These pulses are applied generally, targeting the 1st cervical vertebra of the spine. This method aims to achieve spinal alignment through the vibrations generated by the treatment. Before and after the treatment, a patient assessment is conducted to observe visible improvements. A mixed waveform of 8Hz-202 Hz resonated throughout the spine, with intensities ranging from 0.3 to 1. In order to affect the lumbar region, where they are also applied, sound waves are employed to activate C1.~After First 3 sessions vibrations on pain focal points also given to the patient the 40 pulses are typically administrated at pain point."
223445015|NCT07026058|OTHER|Standard physiotherapy|Flexibility Training: Stretching exercises are crucial to improve the flexibility of the spine and surrounding muscles. This includes stretches for the hamstrings, hip flexors, and lower back Strengthening Exercises: Focus on strengthening the core muscles, including the abdominal and back muscles. Common exercises include pelvic tilts, bridging, and lumbar stabilization exercises Postural Training: Education and exercises to correct posture are vital. Proper posture reduces strain on the spine and helps prevent further injury.(31). Techniques such as ergonomic adjustments at work and home, along with exercises like seated squats and calf stretches Manual Therapy: Techniques such as myofascial release (32) and spinal mobilization. Spinal mobilization as one of the most preferable approaches for the management of LBP
223445016|NCT07027241|BEHAVIORAL|Exercise Intervention|"This arm will include and exercise and nutritional intervention in addition to usual postoperative hip fracture care.~The exercise program will be delivered 3-5 times per week, each session lasting between 20-30 minutes depending on patient tolerance. The program will be progressed gradually between sessions and be guided by patient tolerance. The program will involve bed/ chair-based aerobic and resistance training (using an arm crank ergometer, resistance bands and ankle weights). The program will be delivered over the entire length of a patient's hospital stay up to a duration of 6 weeks for prolonged stays.~All patients will undergo baseline assessments including assessment of level of frailty, pre-fracture level of mobility \& function, postoperative mobility, nutritional status/ screening, grip strength and level of pain."
223445017|NCT07027241|OTHER|Usual Care|"This arm will assess all aspects of usual postoperative hip fracture care which will include multidisciplinary team assessment which include physiotherapists, occupational therapists, dieticians as well as specialist nurses and doctors working as part of the orthogeriatric team (falls and bone health assessment). They will receive daily physiotherapy training starting on the first postoperative day which will include mobility, balance, strength and gait training. This group will also receive additional protein supplementation in the form of a nutritional supplement twice daily as part of usual postoperative hip fracture care.~All patients will undergo baseline assessments including assessment of level of frailty, pre-fracture level of mobility \& function, postoperative mobility, nutritional status/ screening, grip strength and level of pain.~All patients will be asked to maintain a three-day food diary to monitor their protein intake."
223445018|NCT07027241|DIETARY_SUPPLEMENT|Nutritional Intervention|The nutritional intervention will take the form of a protein fortified evening snack administered by nursing staff (additional 20g of protein).
223445019|NCT07027566|DRUG|Potassium nitrate and sodium fluoride|Gel with 5% potassium nitrate and 2% sodium fluoride gel of 5% potassium nitrate and 2% sodium fluoride for topical application to teeth before bleaching with hydrogen peroxide
223445020|NCT07027566|DRUG|Cannabidiol (CBD) Gel|Cannabidiol gel for teeth ( 2% cannabidiol oil) before bleaching with hydrogen peroxide
223445021|NCT07027566|DRUG|Natrosol 4% Gel|placebo gel (natrosol-based gel 4%) for topical application to teeth before bleaching with hydrogen peroxide.
223445022|NCT07027085|DEVICE|virtual reality|The intervention group will be applied 14 sessions of virtual reality application, each session lasting 30 minutes and 2 sessions per week. The sessions will be held in a room allocated for this study in the community mental health center. The device on which the application will be made was determined as Meta Quest 3. The contents to be used in the device were determined to be in line with the areas to be examined.
223445023|NCT07026578|PROCEDURE|Blood draw for the laboratory assessment|This is an observational study . The procedures will be carried out in according to clinical practice
223445024|NCT07027371|BEHAVIORAL|Health education|Health education was given in the form of a printed colored brochure designed in easy-to-understand Arabic language. Participants were encouraged to read the brochure thoroughly and as many times as needed and to ask questions to the researchers if they had any.
223445025|NCT07027254|DIAGNOSTIC_TEST|68Ga-pentixafor PET/CT|Diagnostic PET/CT imaging using gallium-68 labeled pentixafor to assess adrenal CXCR4 expression in patients with primary aldosteronism. The imaging is performed prior to treatment allocation and used to assist lateralization of aldosterone production when combined with adrenal venous sampling (AVS).
223567789|NCT03443479|DEVICE|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher\&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
223567790|NCT03324334|DIAGNOSTIC_TEST|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
223567791|NCT03324334|DIAGNOSTIC_TEST|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
223567792|NCT06112288|OTHER|Compressive Myofascial Release|Compressive myofascial release is manual therapy technics.
223567793|NCT06112288|OTHER|Ankle mobilisation|ankle mobilization is manual therapy technics.
223741359|NCT03296254|BEHAVIORAL|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
223741360|NCT05185960|OTHER|ALLSWEET®|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be diluted in water.
223741361|NCT05185960|OTHER|ALLSWEET® and sucrose|ALLSWEET®, is a non-GMO certified allulose developed by the study sponsor. It will be added to sucrose (table sugar) and diluted in water.
223741362|NCT05185960|OTHER|Sucrose|Table sugar. It will be consumed by diluting it in water.
224145778|NCT04707872|DIAGNOSTIC_TEST|MMDx diagnostic test|Microarray test of gene expression in heart biopsies
224145779|NCT04707872|DIAGNOSTIC_TEST|Prospera|Donor derived cell-free DNA in patient blood
223445026|NCT07021352|PROCEDURE|Ear acupuncture|Ear Acupuncture: Participants will receive bilateral NADA ear acupuncture protocol treatment for a one-time insertion in addition to the weekly mindfulness therapy received by participants. The NADA consists of 5 ear acupuncture points inserted bilaterally: shen men, sympathetic, kidney, liver, and lung. Sterile, semi-permanent acupuncture needles (2mm) will be inserted into the participant's ear and left in place until they naturally fall out, typically within 3-7 days.
223445027|NCT07021352|BEHAVIORAL|Mindfulness therapy|Mindfulness: Participants will receive virtual mindfulness therapy weekly for 30 minutes each session via the MS Teams platform.
223445028|NCT07026123|DRUG|Nal-IRI (Onivyde®)-based treatment|Nal-IRI (Onivyde®) combined with 5-FU/LV is used for metastatic pancreatic ductal adenocarcinoma patients who have progressed after treatment with gemcitabine. The recommended dose of Nal-IRI (Onivyde®) is 70 mg/m\^2, administered intravenously for 90 minutes, once every 2 weeks. In patients known to be homozygous for the UGT1A1 \* 28 allele, the recommended starting dose of Nal-IRI (Onivyde®) is 50 mg/m\^2, administered intravenously within 90 minutes. Based on tolerance, increase the dose of Nal-IRI (Onivyde®) to 70 mg/m\^2 in subsequent cycles.
223445029|NCT07026123|DRUG|Other second-line treatment|Other second-line treatment
223445030|NCT07025902|DIAGNOSTIC_TEST|Standardized Psychological Screening Using EPDS and HAM-D|Participants will undergo a standardized psychological screening protocol for postpartum depression within 72 hours after delivery. The protocol includes: (1) completion of the Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-administered questionnaire assessing depressive symptoms; and (2) administration of the Hamilton Depression Rating Scale (HAM-D), a 17-item clinician-administered tool for evaluating the severity of depressive symptoms. The combined use of these tools allows early detection and stratification of postpartum depressive symptoms in a clinical population.
223445031|NCT07027592|OTHER|Survey Study|The injury risk in veteran football players will be assessed based on FIFA 11+.
223741363|NCT05096845|BIOLOGICAL|Recombinant SARS-CoV-2 fusion protein vaccine (V-01)|"Appearance: creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5mL) /vial Vaccination route: intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg Immunization schedule: two doses, one each on Day 0 and 21 (+7 days), respectively.~Storage condition: store at 2\~8°C protected from light Expiry date: 24 months after production date"
223741364|NCT05096845|OTHER|Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
223741365|NCT00530933|PROCEDURE|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
223741366|NCT00530933|PROCEDURE|Transcutaneous tibial nerve stimulation|30 minutes once weekly
223741367|NCT00530933|PROCEDURE|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
223741368|NCT02318511|PROCEDURE|Knee injection|Injection into knee for the treatment of Osteoarthritis
224054843|NCT03151642|OTHER|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
224054844|NCT03606993|OTHER|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one \~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
224145780|NCT04707872|DIAGNOSTIC_TEST|HLA antibody|Centralized measurement of HLA antibodies in patient blood
223445032|NCT07027150|DEVICE|Chest Worn Pulse Oximeter|"The Perin Health Patch is a non-invasive, chest-worn wearable device designed to continuously monitor physiological signals, including photoplethysmography (PPG), oxygen saturation (SpO₂), electrocardiography (ECG), and other health metrics. In this study, the device will be evaluated for its ability to accurately measure SpO₂ during controlled hypoxemia in healthy adult volunteers. The SpO₂ values recorded by the Perin Health Patch will be compared against arterial oxygen saturation values (SaO₂) obtained via co-oximetry, following the UCSF Hypoxia Lab protocol aligned with ISO 80601-2-61 standards.~This device integrates PPG and ECG sensors into a single chest-applied unit, distinguishing it from conventional finger or earlobe pulse oximeters. The intervention in this study is limited to the application and use of the device for data collection under clinically controlled oxygen saturation conditions."
223741369|NCT02318511|OTHER|ReNu amniotic allograft|
223741370|NCT02318511|DEVICE|placebo saline|
224145781|NCT07090057|PROCEDURE|Tendoachilles (TA) lengthening or gastrocnemius (GN) recession, then Plantaris tenotomy|Participants undergo Tendoachilles (TA) lengthening or gastrocnemius (GN) recession surgery before Plantaris tenotomy.
223741371|NCT02318511|DEVICE|Hyaluronic Acid|
223741372|NCT03023969|DRUG|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
223741373|NCT03711487|DRUG|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
223741374|NCT03975855|DEVICE|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
223741375|NCT00519818|DRUG|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
223741376|NCT00519818|DRUG|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
224145782|NCT07090057|PROCEDURE|Plantaris tenotomy, then Tendoachilles (TA) lengthening or gastrocnemius (GN) recession|Participants undergo plantaris tenotomy surgery before Tendoachilles (TA) lengthening or gastrocnemius (GN) recession.
224054845|NCT04526743|BEHAVIORAL|Questionnaire|Psychological and behavioral variables will be collected using questionnaires that have been validated in our setting and will be completed by the patients themselves online.
223445033|NCT07026838|BEHAVIORAL|The Light Building Emotional Awareness and Mental Health (BEAM) Program|"The LightBEAM Program builds on mHealth best practices and evidence-based program design principles with the core objectives of improving parental mental health and fostering supportive parenting. Program content draws on transdiagnostic emotion-focused mental health and third wave Cognitive Behavioural Therapy principles such as Dialectical Behavioural Therapy, Acceptance and Commitment Therapy.~Program delivery will be facilitated through a mobile application. The LightBEAM program consists of four different components; weekly parenting and mental health videos, weekly progress tracking, a group forum, and exercises designed to reinforce skills learned through the video content."
224054846|NCT04798937|OTHER|Motivational interviewing|a health education program based on motivational interviewing provided by a nurse
223445035|NCT07026149|DRUG|Apatinib+Camrelizumab+SOX|Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w
223445036|NCT07026149|RADIATION|Preoperative Radiotherapy|Radiotherapy was administered using IMPT or IMRT. The target volume includes the gastric lesion, and regional lymph nodes. A regimen of 41.4 Gy in 23 fractions is preferred.
223445037|NCT07027761|BEHAVIORAL|Online self-help|Online Self-Help refers to a 24/7 accessible, internet-based platform that offers digital modules grounded in evidence-based approaches, including infant mental health, cognitive-behavioral therapy (CBT), and psychodynamic interventions, aimed at addressing perinatal depression (https://perinatalehulp.be/). Upon logging in, participants receive an overview of the available modules and can select from three distinct treatment trajectories, ideally to be completed over the course of 10 weeks: (a) a self-directed option allowing free choice among all modules; (b) a structured CBT trajectory incorporating both second-wave and third-wave cognitive-behavioral strategies; or (c) a psychodynamic trajectory primarily focused on relational and attachment-related factors contributing to the onset and maintenance of perinatal depression.
223445038|NCT07027761|BEHAVIORAL|Maternal Mental Health Intervention (MaMHI)|A brief, eight-session face-to-face intervention designed for (expectant) mothers and their infants across the perinatal period, consisting of four prenatal sessions (during the second and third trimesters of pregnancy) and four postnatal sessions conducted within the first three months postpartum. The intervention is grounded in psychodynamic principles and informed by mentalization-based approaches
223445039|NCT07027761|OTHER|Usual Care|Prenatal care is provided through follow-up by a general practitioner and a gynecologist and/or a midwife, while postnatal follow-up is conducted by Child and Family Care Services.
223445040|NCT07026461|DEVICE|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique that uses pulsed magnetic fields to activate or suppress specific brain regions. It is used to treat various conditions, including major depressive disorder, by inducing small electrical currents that stimulate nerve cells.
223445041|NCT07026461|DEVICE|intermittent theta burst stimulation|Intermittent theta-burst stimulation (iTBS) is a form of transcranial magnetic stimulation (TMS) used to modulate brain activity. It involves delivering brief bursts of magnetic pulses to specific brain regions, typically the left dorsolateral prefrontal cortex (DLPFC)
224054847|NCT03998111|DIAGNOSTIC_TEST|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
224054848|NCT03062592|DIETARY_SUPPLEMENT|Pine nut oil|Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
224054849|NCT05050708|OTHER|Patient interview|Patient will be interviewed pre-operatively and at 24 hrs post-opartively
224054850|NCT02904915|DRUG|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
224054851|NCT02904915|OTHER|No analgesia|IUD placement without analgesia.
224145783|NCT05481203|BEHAVIORAL|The Kaleidescope|During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
224145784|NCT05481203|BEHAVIORAL|The visual illusion cards|Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
224054852|NCT02904915|DEVICE|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
224054853|NCT00478582|PROCEDURE|Estimation of Hb concentrations with the HemoHue card|
224145785|NCT05018117|DRUG|Nicotine gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
224145786|NCT05018117|OTHER|Placebo gum|The effects of over-the-counter nicotine gum will be compared to a placebo gum
224145787|NCT03897868|DRUG|HCP1803|HCP1803
224145788|NCT03897868|DRUG|Amlodipine|Amlodipine
224054854|NCT04769856|OTHER|State-Trait Anxiety Inventory (STAI) scale|State-Trait Anxiety Inventory (STAI) scale
224054855|NCT04769856|OTHER|Satisfaction scale|Satisfaction scale
224054856|NCT06293040|DRUG|Cannabis|Cannabis will be vaporized using the Mighty Medic
224054857|NCT06293040|DRUG|Alcohol|Alcohol will be orally ingested via a flavored drink
224054858|NCT06293040|DRUG|Placebo Cannabis|Placebo cannabis (i.e., water vapor) will be vaporized using the Mighty Medic.
224054859|NCT06293040|DRUG|Placebo Alcohol|A non-alcoholic, placebo, flavored drink will be orally ingested.
224054860|NCT04354298|BEHAVIORAL|Improvisational Dance Class|Hour long movement classes that meet weekly for 12 weeks.
224145789|NCT03897868|DRUG|Losartan|Losartan
224145790|NCT03897868|DRUG|Placebo|Placebo
224145791|NCT04151095|OTHER|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
224145792|NCT04151095|OTHER|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
224145793|NCT00961922|OTHER|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
224145794|NCT00961922|OTHER|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
224164064|NCT03513250|DRUG|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
223445042|NCT07026097|OTHER|Pilates Exercise - Online|Will receive Pilates exercise protocol online under supervision as patient will instructed to join online meeting and do their exercise 02 times a week along with standard physical therapy protocol for 4 weeks. The Pilates exercise protocol will be of 30 minutes. Repetitions: Exercises started with 6 to 10 reps. and hold time for 30 sec for each exercise. Rest period of 2 mins will be given
223445043|NCT07026097|OTHER|Pilates Exercise - Supervised|Will receive Pilates exercise protocol clinically supervised as patient will instructed to do their exercise 0 times a week along with standard physical therapy protocol for 4 weeks. The Pilates and common standard physical therapy protocol will be the same which is mention in detail in group A description
223445044|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (active)|"This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.~Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function."
223445045|NCT06702137|DEVICE|EXOPULSE MOLLII SUIT (sham)|In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.
224054861|NCT03761875|OTHER|blood sample CHB patients|"During a boold sample at only one follow up visit:~* 3 tubes EDTA 10 ml per patient~* 1 tube Paxgene 1ml~* 1 dry tube per patient"
224054862|NCT03761875|OTHER|boold sample Control group|"* 2 tubes EDTA ideally age and sex matched to CHB patient.~* 1 tube Paxgene 1ml~* 1 dry tube"
224054863|NCT03832179|DRUG|Bevacizumab|Bevacizumab
224054864|NCT03832179|DRUG|Ranibizumab|Ranibizumab
224054865|NCT03832179|DRUG|Aflibercept|Aflibercept
224054866|NCT03832179|DRUG|Ozurdex|Ozurdex
224054867|NCT05364554|DRUG|JNJ-77242113|JNJ-77242113 tablet will be administered orally.
224054868|NCT06501820|DEVICE|Transcranial direct current stimulation|2mA transcranial direct current stimulation, applied bilaterally on the scalp, over the brain vestibular cortex
224054869|NCT06255496|DIAGNOSTIC_TEST|Quantra Hemostasis Analyzer with the QStat Cartridge|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224054870|NCT02639572|BIOLOGICAL|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
224054871|NCT02639572|BIOLOGICAL|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
224054872|NCT01181076|DIETARY_SUPPLEMENT|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
223567794|NCT03100981|BEHAVIORAL|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
223567795|NCT03100981|BEHAVIORAL|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
224054873|NCT02971631|OTHER|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
224054874|NCT02971631|OTHER|Placebo|Infusion of 1% human albumin in normal saline
224054875|NCT01660360|BIOLOGICAL|Tanibirumab|
224054876|NCT04084067|DRUG|Indocyanine Green|IV
224054877|NCT06005610|DRUG|Estradiol|Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
223445046|NCT07026292|PROCEDURE|Immediate Distal Lymphaticovenous Anastomosis (ID-LVA)|ID-LVA (Immediate Distal Lymphaticovenous Anastomosis) is an supermicrosurgical technique performed during axillary lymph node dissection (ALND) to prevent breast cancer-related lymphedema, offering the dual advantages of immediate intervention and radiation-field avoidance. Compared to LYMPHA (Lymphatic Microsurgical Preventive Healing Approach), which utilizes proximal axillary anastomoses within the radiation field with larger vessels and higher venous pressure, ID-LVA creates precise anastomoses between 0.3-0.8mm distal superficial lymphatic vessels and low-pressure venules in the upper arm. In contrast to DD-LVA (Delayed Distal Lymphaticovenous Anastomosis) performed postoperatively (typically 4-12 weeks after ALND) for subclinical lymphedema, ID-LVA provides earlier prevention by utilizing undamaged lymphatics and avoids the need for a second procedure.
223445047|NCT07027540|DRUG|Bupivacaine 0.25% 20ml|Adult patients will take a total 20 ml of Bupivacaine 0.25%
223445048|NCT07027540|DRUG|2mg of dexamethasone|2mg of dexamethasone in the right T7
224054878|NCT07122167|DEVICE|Peripheral Drug-eluting Stent System|Drug-eluting stents (DES) are increasingly used in the treatment of PAD. These stentsare coated with antiproliferative drugs designed to provide mechanical support within the artery while releasing the drug gradually to reduce the risk of restenosis. Commonly used drugs include paclitaxel, sirolimus, and everolimus, which inhibit vascular smooth muscle cell proliferation, thereby reducing the likelihood of re-occlusion.
224054879|NCT06985251|OTHER|gamified mHealth lifestyle app|The CommitFit mHealth app uses gamification techniques to motivate adolescents and caregivers to set and achieve health behavior goals (eat more fruits or vegetables, increase water intake, decrease sugary beverage intake, increase physical activity, or increase overnight sleep). Users are ranked on leaderboard based on their points and can team up with caregivers on a team leaderboard.
224054880|NCT06985251|OTHER|Attention Control|Standard of care healthy lifestyle handouts were emailed monthly to control families.
224145795|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
224145796|NCT04119427|DEVICE|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
223445049|NCT07027540|DRUG|35 ml of Bupivacaine 0.25%|Adult patients will take a total 35 ml of Bupivacaine 0.25%
223445050|NCT07026201|OTHER|colectomy with primary anastomosis|left hemicolectomy or sigmoidectomy, formal resection was carried out following conventional steps of radical resection.with primary anastomosis
223445051|NCT07027501|OTHER|The video based education group|The parents in the intervention group were provided with a video-based educational material on febrile seizures, which they accessed via a QR code.
223445052|NCT07027267|DEVICE|Implantation of Spirair device into the middle turbinates|The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery.
223567796|NCT03213743|DRUG|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
223567797|NCT00258765|DRUG|Zoledronic Acid|
223567798|NCT00258765|DRUG|Docetaxel|
224145797|NCT01234857|DRUG|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
224145798|NCT01234857|DRUG|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
224145799|NCT01234857|DRUG|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
224145800|NCT01234857|DRUG|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
223445053|NCT07027267|DEVICE|TurbAlign|The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery
223445054|NCT07026240|DIAGNOSTIC_TEST|DNA test|a new non-invasive detection method for postoperative monitoring of gastric cancer in the blood
223567799|NCT05897970|DIAGNOSTIC_TEST|Return-to-sport (RTS) follow-up|All sports patients who had a muscle evaluation at 3-4 months after ACLR since January 2017
223567800|NCT05638334|DRUG|89Zr-S095012 tracer and S095012 will be administered via an IV infusion|"Imaging period 1 (Part A and Part B): The tracer will be administered with S095012 at non-therapeutic mass dose. The optimal mass dose of S095012 will be investigated in part A, and used in part B.~Treatment period (Part A to C): S095012 will be administered with multiple 28 days- cycles in a Q2W schedule.~Imaging period 2 (Part C): A second tracer dose will be administered at 1st treatment dose of S095012 in part C."
223567801|NCT02808195|OTHER|Constraint-induced therapy|
224145801|NCT00397176|DRUG|desvenlafaxine succinate sustained release (DVS SR)|
224164065|NCT03513250|DRUG|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
224164066|NCT02859987|PROCEDURE|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
224164067|NCT02859987|PROCEDURE|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
223567802|NCT02808195|OTHER|kinect-based constraint-induced therapy|
223567803|NCT01294306|DRUG|Akt Inhibitor MK2206|Given PO
223567804|NCT01294306|DRUG|Erlotinib Hydrochloride|Given PO
223567805|NCT01294306|OTHER|Laboratory Biomarker Analysis|Correlative studies
223567806|NCT01294306|OTHER|Pharmacological Study|Correlative studies
224054881|NCT06985251|OTHER|gamified mHealth app with financial incentives|The CommitFit mHealth app uses gamification techniques to motivate adolescents and caregivers to set and achieve health behavior goals (eat more fruits or vegetables, increase water intake, decrease sugary beverage intake, increase physical activity, or increase overnight sleep). Users are ranked on leaderboard based on their points and can team up with caregivers on a team leaderboard. CommitFit$ adolescents received an extra $0.05 for each point they earned in the app.
223445055|NCT07027137|DRUG|SRP+ANB+SURG|SRP (scaling and root planing) with ANB (local antibiotic application- 10%doxycycline) and SURG (regeneration procedure according to MIST/M-MIST)
223445056|NCT07027137|PROCEDURE|SRP+SURG|SRP (scaling and root planing) and SURG (regeneration procedure according to MIST/M-MIST)
223445057|NCT07026227|DRUG|Xuebijing Injection|Xuebijing injection (Tianjin Hongri Pharmaceutical Co., Ltd., National Drug Standard Z20040033).
223445058|NCT07026227|PROCEDURE|Conventional Treatment for High-Voltage Electrical Burns and AKI|Standard multidisciplinary care including general burn assessment, wound management (cleaning, debridement, dressings), fluid resuscitation as per burn protocols, management of electrolyte imbalances
223445059|NCT07027436|DRUG|Chemotherapy/Radiation|Combination of radiation and chemotherapy
223445060|NCT07026422|COMBINATION_PRODUCT|Total neoadjuvant therapy integrating iparomlimab/tuvonralimab with chemoradiotherapy|"1. Radiotherapy:~   Radiotherapy location: primary site and the corresponding draining lymph node. Radiotherapy techniques: IMRT/VMRT.~   Radiotherapy dose and fractionation pattern: conventional external irradiation, 50Gy/25 fx/5 weeks or 25Gy/5fx/1 week.~2. Chemotherapy:~Long-course radiotherapy concurrent with chemotherapy: capecitabine 825mg/m2, bid, d1-5/week.~Short-course radiotherapy without concurrent chemotherapy. Consolidation chemotherapy and immunotherapy: QL1706 (iparomlimab and tuvonralimab 5mg/kg, d1) and CAPOX (Oxaliplatin 130mg/m2, d1 + capecitabine 1000mg/m2, bid, d1-14), repeated on a 21-day cycle, for 6 cycles. 3. Surgery or watch-and-wait Total mesorectal excision (TME), or watch-and-wait (for patients with clinical complete response)."
223445061|NCT07027020|DRUG|Oxybutynin Hydrochloride|Pharmaceutical form: solution. Route of administration: Intravesical. Medicinal product unique ID: PRD8074745. EU active substance code: SUB03581MIG.
223445062|NCT07027020|DRUG|Placebo|Pharmaceutical form: solution. Route of administration: Intravesical.
223567807|NCT05981001|PROCEDURE|Surgery for harvesting tumor-draining lymph nodes|A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.
223567808|NCT05981001|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
223567809|NCT05981001|DRUG|Fludarabine|After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
223567810|NCT05981001|BIOLOGICAL|Tumor-draining lymph node-derived lymphocyte (LNL)|"In the dose-escalation portion of phase I study, participants receive ascending dose (1×10\^9\~18×10\^9), single Infusion of LNL on day 0. In the dose-expansion portion of phase I study, participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).~In the phase II study, participants receive single infusion of LNL at the RP2D."
224054882|NCT06984224|DEVICE|Neubie Direct Current Stimulation Device|Pulsed Direct Current Electrical Stimulation Device
224054883|NCT06778005|DIAGNOSTIC_TEST|Ultrasonography|Measurements will be performed using a 7-12 MHz Sonosite M-Turbo device (Fujifilm, USA) with a linear probe by an operator trained in peripheral nervous system ultrasonography. Cross-sectional area (CSA) and echogenicity measurements of the bilateral tibial, common peroneal, and sural nerves will be conducted using the ultrasound device. Tibial nerve assessment will be performed 3 cm proximal to the level of the medial malleolus. Common peroneal nerve assessment will be performed by identifying the nerve at the fibular head and tracking it proximally to image it at the level of the popliteal fossa. Sural nerve assessment will be conducted 10 cm proximal to the upper level of the lateral malleolus. All nerve measurements will be conducted twice in the transverse plane, and the obtained images will be recorded and uploaded into the ImageJ programming system.
223567811|NCT05981001|BIOLOGICAL|Interleukin-2|Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.
223567812|NCT05981001|BIOLOGICAL|Camrelizumab|Camrelizumab will be administered at a fixed dose of 200mg IV on Day 1 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
223567813|NCT05981001|DRUG|Nab-paclitaxel|Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
223567814|NCT05981001|DRUG|Gemcitabine|Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
223567815|NCT05981001|DRUG|Carboplatin|Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
224145802|NCT05108480|OTHER|Experimental group|This study followed the protocol designed for patients with hemophilic knee arthropathy. For its implementation, a 30-cm long15-cm diameter foam roller was used, and a ball 22 cm in length and 8 cm in diameter. The total duration of the intervention was 15 minutes, with 7 sessions per week over a period of 8 weeks. The physiotherapist who supervised the intervention followed up on all patients by telephone on a weekly basis to check for the absence of haemarthrosis during the intervention and to detect the possible need for protocol adaptations depending on the clinical situation of each patient. Each patient was individually provided with instructions as to how perform the exercises during the pretreatment evaluation, customizing the program if necessary. All patients had access to a mobile application, designed ad hoc for the research study (He-Foam®), where they could learn about the exercises through demonstration videos.
224145803|NCT02452801|DRUG|ALKS 5461|Single dose, given orally
224145804|NCT06026007|OTHER|advices|each pregnant woman was advices how to elevate her legs and daily positions to elevate edema
224145805|NCT06026007|OTHER|Traditional physical therapy|each pregnant woman was advised about daily routine in addition to circulatory exercise
224145806|NCT06026007|OTHER|Acupressure|each pregnant woman was advised about daily routine in addition to acupressure therapy
224054884|NCT06778005|DIAGNOSTIC_TEST|Biodex Balance System|"The Biodex is a computer-assisted device with a movement system capable of providing surface inclinations ranging from 360 degrees to 20 degrees. It allows movement in anterior/posterior and mediolateral planes. The device has 12 levels of difficulty, where level 12 represents the highest stability and level 1 represents the lowest stability. It can be used for balance training with different therapy protocols and includes standardized programming systems for evaluating both static and dynamic balance. It provides numerical data for key parameters such as balance, fall risk, and proprioception. In this study, patients will be assessed using the fall risk test and postural stability evaluation test protocols on the Biodex balance system. All participants will be trained and familiarized with the system before the test.~Postural Stability Test: The difficulty level will be set to 8. Fall Risk Test: The difficulty level will progressively decrease from 6 to 2."
223445063|NCT07026747|BEHAVIORAL|Standard Hand Rehabilitation Only|Standard Hand Rehabilitation Program will be delivered over a total duration of six weeks. During the first three weeks, the program will be administered five days per week, and during the following three weeks, it will be performed three days per week. The rehabilitation program will include scar tissue massage, passive and active range of motion exercises for the fingers and wrist, sensory re-education, and edema control using retrograde massage and Coban wrapping. Joint mobilization techniques will be applied to the finger and wrist joints, along with tendon gliding and tendon blocking exercises. Strengthening and stretching exercises targeting the hand and wrist muscles will be progressively introduced throughout the program. Functional training and moderate-level activities will be included as tolerated, particularly in the later stages of the program. The intervention will be structured to gradually increase in intensity and complexity across three phases, each lasting two weeks.
223567816|NCT00619424|DRUG|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
223741377|NCT01165255|DRUG|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
224145807|NCT04417504|OTHER|MobFood breakfast kit|Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood\_PPS4.
224145808|NCT04417504|OTHER|Control isocaloric breakfast|White bread, butter and milk.
224145809|NCT03728712|DIAGNOSTIC_TEST|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
224145810|NCT03521661|PROCEDURE|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
224145811|NCT06554717|DRUG|Tesamorelin|Tesamorelin WR 1.28 mg given subcutaneously daily
223567817|NCT00619424|DRUG|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
224145812|NCT06554717|DRUG|Placebo|Identical placebo injection given subcutaneously daily
224145813|NCT06554717|BEHAVIORAL|Exercise|Home-based semi-supervised exercise program
223567818|NCT00619424|DRUG|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
223567819|NCT00574730|DRUG|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
223567820|NCT00574730|DRUG|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
223567821|NCT00347438|DRUG|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
223567822|NCT01581489|PROCEDURE|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
223567823|NCT04330391|BEHAVIORAL|Remote dietitian supervised weight loss intervention and mobile app|Please see intervention arm description for more details.
223567824|NCT06164496|DEVICE|standart manual toothbrush|Device on plaque removal efficacy
223567825|NCT06164496|DEVICE|360 degree toothbrush|Device on plaque removal efficacy
223567826|NCT00949754|DRUG|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
223567827|NCT05230108|PROCEDURE|Advanced Triage|Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
223567828|NCT00322023|DRUG|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
223567829|NCT00322023|DRUG|D-serine|
223567830|NCT00322023|DRUG|D-serine|
223567831|NCT00322023|DRUG|D-serine|
223567832|NCT01415648|OTHER|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
223445064|NCT07026747|BEHAVIORAL|Supervised Core Stabilization + Standard Hand Rehabilitation|"The second group will receive the same six-week Standard Hand Rehabilitation Program as the control group (5 days per week for the first 3 weeks, and 3 days per week for the last 3 weeks). In addition, participants will perform a Supervised Core Stabilization Exercise Program three times per week for six weeks under a physiotherapist's supervision.The exercises will focus on activating the transversus abdominis and coordinating breathing to improve core stability.Each session will include a warm-up, main core exercises, and a cool-down.In weeks 0-2, the program will include diaphragmatic breathing, transversus abdominis activation, curl-ups, and bridging. In weeks 2-4, it will progress to cross arm-leg extensions, side planks, the hundred exercise, and single-leg bridging. In weeks 4-6, Swiss ball exercises will be introduced, including weight shifting forward and backward, hip flexion, bridging, and contralateral arm.The program will advance in intensity across three phases."
223567833|NCT01415648|OTHER|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
223567834|NCT02937077|DEVICE|Medtronic Reveal LINQ|
224054885|NCT06778005|DIAGNOSTIC_TEST|Douleur Neuropathique 4 (DN4) Pain Scale|"The Douleur Neuropathique 4 (DN4) pain scale score will be used to screen for diabetic peripheral neuropathic pain. The DN4 scale consists of 10 questions, 7 of which inquire about symptoms, and 3 that assess the patient's clinical examination for neuropathy. The symptoms assessed include a burning sensation, pain from cold, electric shock sensations, tingling, pins and needles, numbness, and itching. The sensory exams assess touch hypoesthesia, pin-prick hypoesthesia, and brush allodynia. Each yes response to a question receives 1 point. To calculate the total score, points obtained from the symptom inquiry and clinical examination are added together. The maximum total score is 10, and a score of 4 or higher is considered indicative of neuropathic pain"
224054886|NCT06778005|DIAGNOSTIC_TEST|Numeric Rating Scale|The numeric pain scale will be used to assess the intensity of neuropathic pain. The patient is asked to provide a value between 0 and 10 to indicate the intensity of their pain. Higher scores are associated with an increase in pain severity.
224054887|NCT06778005|DIAGNOSTIC_TEST|Toronto Clinical Neuropathy Score|The Toronto Clinical Neuropathy Score (TCNS) will be used to assess the severity of Diabetic Peripheral Polyneuropathy (DPPN). The Turkish version of the Toronto clinical scoring system is a reliable and valid tool for assessing polyneuropathy in Turkish-speaking patients. The TCNS is preferred in clinical studies because of its ease of use, patient acceptability, ability to classify the severity of DPPN, and its representation of clinical changes related to the progression of DPPN. The scale consists of three sections: symptom scores, sensory test scores, and reflex scores.The first section includes scoring symptoms in the upper and lower extremities .The second section includes scoring the bilateral Achilles and patellar reflexes. The third section involves scoring the sensation in the toe. The total score ranges from a minimum of 0 (no neuropathy) to a maximum of 19 points.
224054888|NCT06778005|DIAGNOSTIC_TEST|Six-Minute Walk Test|Six-Minute Walk Test (6MWT) is a commonly used test to assess functional capacity. The test area should be a corridor with a minimum length of 30 meters, flat, and firm surface. The corridor should be marked every 3 meters. Turnaround points are indicated with objects such as orange traffic cones. A line is drawn for the start and end of the test. Recommended materials for the test include a stopwatch, a device to count laps, cones to mark turning points, a chair placed within easy reach, oxygen support (to be given if necessary), and a blood pressure cuff. The patient should wear comfortable clothing and shoes suitable for walking. They can use any walking aids such as crutches or a walker. Medications or treatments should be taken as usual. The patient should have had a light meal before the test and should not have engaged in heavy physical activity within the 2 hours preceding the test. There should be no warm-up period before the test.
224054889|NCT06778005|DIAGNOSTIC_TEST|SF-12 Quality of Life Scale|The SF-12 Quality of Life Scale will be calculated using an online calculator tool, providing two types of scores: physical and mental scores.
224054890|NCT06778005|COMBINATION_PRODUCT|International Physical Activity Questionnaire-Short Form (IPAQ)|The IPAQ scale was developed to address the general health problem of insufficient physical activity, which necessitates large population studies and allows for cross-country comparisons. Validity studies conducted across multiple countries have proven that this questionnaire is valid and reliable. This survey assesses individuals based on the types of physical activities they perform in their daily lives. The questions asked pertain to the time spent physically active over the past 7 days.
224164068|NCT02859987|DEVICE|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
223567835|NCT04434625|DRUG|Polyethylene glycol|Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
223567836|NCT04845659|DRUG|Doptelet Pill|40 mg or 60 mg Doptelet orally 10-13 days before planned procedure.
223567837|NCT01846676|BEHAVIORAL|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
223567838|NCT01846676|OTHER|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
223567839|NCT00523705|DRUG|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
223567840|NCT00523705|OTHER|placebo|Placebo tablets matched to drug
223567841|NCT00693017|DRUG|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
224054891|NCT06778005|DIAGNOSTIC_TEST|Tuning Fork Vibration Sense|"Vibration sense will be assessed using a traditional 128 Hz tuning fork. When the stem of a 128 Hz tuning fork is placed on the dorsal aspect of the interphalangeal joint of the hallux, a healthy person can feel the vibration as long as it continues (15-20 seconds). In conditions leading to peripheral nerve damage (such as polyneuropathy), vibration sense is impaired. The examiner holds the proximal end of the tuning fork with one hand, while the distal end is struck strongly against the palm of the examiner's other hand. The examiner should try to strike the tuning fork with consistent force for each assessment. After striking, the tuning fork is placed just proximal to the nail bed, on the dorsal aspect of the distal phalanx of the hallux.Before applying the tuning fork, the participant is instructed to verbally respond with yes if they can initially feel the vibration, and they should also indicate now when they stop feeling the vibration."
224054892|NCT06778005|DIAGNOSTIC_TEST|Timed Up and Go Test|The Timed Up and Go (TUG) test is designed to measure dynamic balance based on the time it takes for patients to stand up and walk, providing quantitative results. The patient starts the test by sitting on a standardized chair (46 cm high). During the test, the patient is instructed to stand up from the chair, walk 3 meters away, turn around, and then return to sit back down on the chair. The duration of this process is measured. Lower values indicate better stability. A cutoff value of 13.5 seconds has been used to identify high fall risk in the TUG test.
224145814|NCT03326869|DEVICE|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
223445065|NCT07026747|BEHAVIORAL|Unsupervised Core Stabilization + Standard Hand Rehabilitation|"he third group will receive the same six-week Standard Hand Rehabilitation Program as the control group (5 days/week for 3 weeks, then 3 days/week for 3 weeks). They will also do an Unsupervised Core Stabilization Exercise Program three times a week for six weeks in the same clinic. Exercises will be the same as the supervised group but done alone using videos without a physiotherapist. The exercises will focus on activating the transversus abdominis and coordinating breathing to improve core stability. Each session includes warm-up, main exercises, and cool-down. In weeks 0-2, exercises include diaphragmatic breathing, transversus activation, curl-ups, and bridging. Weeks 2-4 add cross arm-leg extensions, side planks, the hundred, and single-leg bridging.Weeks 4-6 introduce Swiss ball exercises, including weight shifting forward and backward, hip flexion, bridging, and contralateral arm lifts. The program will advance in intensity across three phases."
223445066|NCT07027683|DIAGNOSTIC_TEST|Cardiac MRI|Post-MI cardiac MRI
223445067|NCT06885580|BEHAVIORAL|Education|Students will be provided with digital privacy literacy training designed using the puzzle method, which will consist of 8 sessions over a 12-week period.
223445068|NCT06728722|DIAGNOSTIC_TEST|ultrasound detection of body composition|"Muscle mass and fat thickness The examiner will use a five-site protocol. The protocol includes the examination of quadriceps on four sides and one bicep will be used The technique is reported by USVALID (Arabella, 2020) GRADING OF QUALITY OF ULTRASOUND SCANS - Muscle quality (fat and fibrotic infiltration) grading for each scan~1. = Muscle fascia and bone surface visible~2. = muscle fascia and bone surface still possible to spot~3. = muscle fascia and bone surface not distinguishable; no evaluation possible~The FLUID protocol for edema will be done as follows: MEASURING POINTS 36 points, GRADING OF QUALITY: The examiner will use a 5-point scale of ultrasonic subcutaneous edema grade (USEG) to evaluate subcutaneous edema at each site based on echo intensity, tissue transparency, and fluid properties.~Day zero, day 2 then Every 2 days if extended length."
223445069|NCT06417307|BEHAVIORAL|Supervised exercise training|Participants perform Intradialytic cycling exercise training in the hospital for 6 months (24 weeks) and 3 months (12 weeks) at home. Exercise prescription: 50-60% maximal workload for 20-30 minutes, including low intensity warm-up and cool down (30% of maximal workload).
223445070|NCT06417307|BEHAVIORAL|Control group|Maintain daily lifestyle until the end of the study. Receive no intervention/supplements.
223445071|NCT03193034|DEVICE|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
223445072|NCT06438445|DIETARY_SUPPLEMENT|Real Jelly|Participants will receive 500mg of royal jelly capsules per day for two months.
223445073|NCT06438445|DIETARY_SUPPLEMENT|Placebo|Participants will receive 500mg of placebo capsules per day for two months.
223445074|NCT00594386|DRUG|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
223445075|NCT04192058|DEVICE|Sham transcranial direct current stimulation (tDCS)|For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.
223445076|NCT04192058|DEVICE|Active transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
223567842|NCT00693017|DRUG|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
223445077|NCT02098616|DRUG|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
223445078|NCT02098616|DRUG|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
223445079|NCT03679286|DEVICE|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
223445080|NCT04747444|OTHER|Anti-Gravity Treadmill|Treadmill in which the body weight percent placed on the lower extremities can be controlled
223741378|NCT01165255|DRUG|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
224054893|NCT06778005|DIAGNOSTIC_TEST|Physical Examination|"Manual Muscle Test: Muscle strength is evaluated using the MRC (Medical Research Council) muscle strength scale.~Reflexes:Patellar reflex: The reflex hammer is struck on the patella, and extension of the leg is observed. Achilles reflex: With one hand, the patient's foot is lightly dorsiflexed, and the Achilles tendon is struck; plantar flexion is observed in the ankle."
223445081|NCT05068492|DIAGNOSTIC_TEST|CT|enhanced CT with standard procedure
223445082|NCT05068492|DIAGNOSTIC_TEST|MRI|enhanced MRI with standard procedure
223445083|NCT05068492|DIAGNOSTIC_TEST|HVPG|HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures
223445084|NCT05068492|DIAGNOSTIC_TEST|Ultrasound|Digestive ultrasound with standard procedure
223445085|NCT06454422|OTHER|wu qinxi|"Wuqinxi, also known as the Hundred-step Sweating Exercise, is one of the most emblematic Health qigong exercises. Huatuo, guided by the principle, formulated the 'Wuqinxi':  Running water is never stale and a door-hinge is never gets worm-eaten, and sums up the experiences of the fitness activities of Huatuo's predecessors that imitate the movements of tigers, deer, bears, apes, birds, and other animals, and are associated with human organs, meridians, and 'qi'"
223445086|NCT04687748|DEVICE|Electromographic Biofeedback|Surface EMG biofeedback is an adjunct therapy to standard exercise regime for increasing muscle strength. Electromyographic biofeedback is a specific form of biofeedback. The device records muscle activity through application of vaginal probe will be inserted in vagina and the reference surface electrode would be placed over the right anterior superior iliac spine.
223567843|NCT02764528|BEHAVIORAL|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
223567844|NCT02764528|BEHAVIORAL|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
223567845|NCT02764528|BEHAVIORAL|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
223567846|NCT01620164|OTHER|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
223567847|NCT01748136|DEVICE|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
223567848|NCT01175486|DRUG|Actos (Pioglitazone)|Actos 30 mg for 6 months
223567849|NCT01175486|DRUG|Acarbose|Acarbose 50 mg tid for 6 months
223567850|NCT04185649|BIOLOGICAL|BAT8001 for injection|3.6 mg/kg, q3w, administered intravenously on day 1 of each treatment cycle, 21 days/treatment cycle.
223567851|NCT04185649|DRUG|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
223567852|NCT04185649|DRUG|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
223567853|NCT03784599|DRUG|Trastuzumab emtansine|Infusion
223567854|NCT03784599|DRUG|Osimertinib|Tablet
223567855|NCT00986401|DRUG|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
223567856|NCT00986401|DRUG|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
223567857|NCT00746239|DRUG|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
223567858|NCT00746239|DRUG|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
223567859|NCT06404372|DEVICE|Demetech Barbed PDO Suture|The Demetech Barbed PDO Suture will be used for the correction of midface wrinkles in all patients enrolled in this study.
223567860|NCT02868450|BIOLOGICAL|Blood Sample|
223445087|NCT04687748|OTHER|PFM exercises|Patients would be advised to maximally contract the pelvic floor muscles as forcefully a possible for about 5 seconds. Three attempts would be made with 40 seconds rest in between each contraction. The exercises would be performed with the patient initially in supine position, with hip and knee flexed at 30 and 90 degrees.
224054900|NCT04670965|BIOLOGICAL|E-PRF/rhBMP-2 (similar ratios)|During its preparation, 1.5 mg/ml rhBMP-2 will be incorporated into standardized samples to assure similar E-PRF to rhBMP-2 ratios. To allow for consistency across all samples, standardized E-PRF volume will be established using formation templates. Following its preparation, the E-PRF/rhBMP2 scaffold will undergo a standard in vitro assay to investigate growth factor release over time (ELISA quantification assay). Briefly, the e-PRF/rhBMP2 scaffold will be placed in a shaking incubator at 37 degree Celsius and assessed for growth factor release of rhBMP-2 over time.
223445088|NCT03736330|BIOLOGICAL|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck \& Co., Inc.） and were transferred to participants via intravenous infusion .
223445089|NCT00094536|DEVICE|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
223445090|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
223445091|NCT02153658|PROCEDURE|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
223445092|NCT00684632|DRUG|Placebo|Placebo
223567861|NCT02671539|GENETIC|rAAV2.REP1|single subretinal injection
223567862|NCT05430503|DIAGNOSTIC_TEST|Lung volumes, spirometry and standard single-breath DLCO were measured at rest while combined DLNO and DLCO were measured at rest and post-exercise|DLNO and DLCO were measured at rest and 5-10 s after a bout of treadmill exercise simulating usual walking
223567863|NCT05171309|DRUG|Apatinib|250 mg once daily (QD) oral dosing.
223567864|NCT05171309|DRUG|Camrelizumab|200 mg intravenously every 2 weeks.
223567865|NCT05171309|DRUG|NK cell|Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
223567866|NCT00956137|PROCEDURE|Ultrasound guidance|ultrasound imaging
223567867|NCT00956137|PROCEDURE|Manual palpation|Manual Palpation of vertebra
223567868|NCT01539733|DRUG|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
223567869|NCT01539733|DRUG|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
223567870|NCT01299220|DRUG|Acitretin|Acitretin 10 mg by mouth daily
224054901|NCT04670965|BIOLOGICAL|E-PRF/ACS/rhBMP-2|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. After the addition of the rhBMP-2, the ACS will be cut into 2mm x 2mm pieces and incorporated into the E-PRF membrane. Following its preparation, rhBMP-2 release from the E-PRF/ACS/rhBMP2 scaffold will be quantified using the ELISA quantification assay as described above.
224054902|NCT04670965|BIOLOGICAL|rhBMP-2/E-PRF|rhBMP-2 diluted to account for the additional volume from the E-PRF in other samples will be loaded onto lyophilized absorbable collagen sponges as per the package insert. Rh-BMP2 release will be quantified using the ELISA quantification assay as described above
224054903|NCT04670965|BIOLOGICAL|E-PRF only|E-PRF will be prepared and standardized, but no rhBMP-2 will be added to the material. After preparation, the E-PRF scaffold assayed via ELISA quantification assay as described above to determine the release (if any) of intrinsic BMP-2 from the platelet concentrate scaffold.
224054904|NCT06863610|OTHER|Extension Deficit (>5 degrees)|Patients who had a knee extension ROM deficit of more than 5 degrees will included
223445093|NCT00684632|DRUG|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
224054905|NCT06863610|OTHER|Extension Deficit (<5 degrees)|Patients who had a knee extension ROM deficit of less than 5 degrees will included
224054906|NCT04168827|BEHAVIORAL|Questionnaire|Questionnaire completed by the parents of severe traumatized child, between 3 to 6 months after the leaving of the child out of intensive care unit
224054907|NCT06821698|DRUG|KP-001|KP-001 100 mg dry syrup
224054908|NCT06821698|DRUG|Rosuvastatin calcium10mg|A oral dose of 10 mg tablet
223445094|NCT05501327|DRUG|SLI-F06|Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.
223567871|NCT01180036|DRUG|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
223567872|NCT01180036|DRUG|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine \>30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
223445095|NCT01855282|BEHAVIORAL|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
223445096|NCT00028522|DRUG|R(+)XK469|Given IV
223445097|NCT04564105|BEHAVIORAL|simulation education|Intubation protocol will be trained by simulation exercise.
224054909|NCT06821698|DRUG|Caffeine citrate|100 mg oral solution
223445098|NCT02135705|DRUG|Lomitapide|As prescribed by Physician.
223445099|NCT06954246|DRUG|MHB088C for Injection|2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle
223445100|NCT06954246|DRUG|Topotecan|1.25 mg/m\^2 intravenous dose on Day 1 to Day 5 of each 21-day cycle
223445101|NCT06954246|DRUG|Irinotecan|65 mg/m\^2 intravenous dose on Day 1 and Day 8 of each 21-day cycle
223445102|NCT06954246|DRUG|Paclitaxel|135 mg/m\^2 intravenous dose on Day 1 of each 21-day cycle
223445103|NCT03850691|DRUG|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
223445104|NCT03850691|DRUG|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
223445105|NCT03850691|DRUG|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
223445106|NCT03850691|DRUG|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
223445107|NCT06052644|OTHER|Exercise Dose-Response|"The intervention will last for 12 weeks. Depending on the group, participants will engage in the intervention either four times a week or only two times, with the duration ranging from 30 to 60 minutes per session. Each session will consist of three phases: an initial warm-up phase, a central phase, and a cool-down phase.~The warm-up phase will focus on joint mobility, beginning with flexion-extension, rotation, and lateral neck flexion while maintaining eye contact with a fixed point. This will be followed by trunk mobility exercises, including rotations.~The central phase will consist of aerobic and strength training performed at an intensity of 80-85% of the maximum heart rate. Each exercise will be performed intensely for 20 to 30 seconds, followed by a rest period of 10 to 15 seconds before repeating the exercise."
223567873|NCT04243577|DEVICE|Tele-EaT Sensors|Two iterations of a wearable surface EMG (sEMG) sensors patch we developed will be tested against commercially available wired devices. The first iteration of the wearable sensor patch is an ultrathin patch with a honeycomb-inspired design that included sEMG and strain sensors in order to capture muscle activity and thyroid movement signals from the submental area during swallows and swallow maneuvers/exercises. The second iteration is a more durable slightly thicker flexible, non-stretchable, and double-sided thin sEMG patch. Participants will perform standardized swallow tasks while wearing the device.
224054910|NCT06821698|DRUG|Fluvoxamine|50 mg tablet
224054911|NCT07079839|DEVICE|Transcranial Alternating Current Stimulation (tACS)|A weak electrical current will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 milliamp (mA) sinusoidal current oscillating at individual participants' baseline peak alpha frequencies (PAF; 7-13 Hz), which will be determined by a 3-min resting state EEG recording during the setup. Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
224145815|NCT01630798|DRUG|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
224145816|NCT01025687|DIETARY_SUPPLEMENT|water with noncalorie sweetener|
224145817|NCT01025687|DIETARY_SUPPLEMENT|water with glucose|
224145818|NCT01025687|BEHAVIORAL|TV program showed while feeding|
223445108|NCT01687283|DRUG|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
223445109|NCT01687283|DRUG|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
223445110|NCT03351153|RADIATION|X-ray|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
223445111|NCT03351153|RADIATION|CT|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
223445112|NCT03351153|OTHER|specimen|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
223445113|NCT05581368|OTHER|Chronic Cannabis use|The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
224054912|NCT07079839|DEVICE|Sham for Transcranial Alternating Current Stimulation (tACS)|Stimulation electrodes will be placed on the scalp, but no current will be passed. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
223445114|NCT01469598|DRUG|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
223445115|NCT05176613|DEVICE|HF-rTMS|HF-rTMS stimulated a 70-mm, 8-shaped coil stimulator (The Magstim Company, UK, 2012) on the damaged cerebral cortex. Prior to the application of HF-rTMS, the motor point was identified that stimulates maximum thresholds on the primary motor cortex, causing flexion of the opposite index finger. If the cerebral hemisphere does not show a kinetic response even at the maximum stimulus, the motor point of the opposite hemisphere was found to be symmetrically changed. The intensity of the stimulus was 80% of the resting motor threshold, which means the motor eveked potential above which the first dorsal interosseous muscle can produce 50 μV more than five times out of 10 stimuli. The subject sat on a chair made to hold the head. The stimulation was stimulated at high frequency (10 Hz) for 2 seconds, and the rest was performed for 58 seconds for a total of 200 times for 10 minutes.
223445116|NCT05176613|BEHAVIORAL|ML|Motor learning was conducted for two minutes each in five sessions, and the first is the external rotation training to maximum range of the shoulder joint in sitting position. The second method is to stack cups by transferring them from the non-affected side to the affected side by transferring 25 plastic cups of five colors in sitting position with both hands inserted. Third, by pushing and pulling the ball forward and backward with the hands folded, the subject puts a 55 cm healing ball on the table in a sitting position, and pushes and pulls it forward with the upper limb. The fourth method is to insert and remove pegs from the peg board, and the target uses the affected side hand in sitting position. The fifth method is to tear a newspaper, in which the subject overlaps a newspaper on the table in a sitting position, holds it with the non-affected hand, and tears it with the hands of the damage. A total of 10 minutes of motor learning.
223445117|NCT05176613|DEVICE|Sham-rTMS|Sham rTMS gives a small intensity of 2% of the resting motor threshold that cannot cause excitement in the motor cortex, and is set to listen to the same frequency of noise as HF-rTMS, and motor learning is applied equally. A total of 20 minutes were applied three times a week for four weeks by applying 10 minutes of Sham rTMS and 10 minutes of motor learning.
223445118|NCT04854941|OTHER|Probiotics|Probiotics (10\^9 CFU of each strain: Lactobacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911 and Bifidobacterium longum PDV 2301) 3 times per day in addition to standard treatment regimen for 2 weeks
223567874|NCT04243577|DEVICE|Conventional Sensors|Conventional sensors will include snap-on wired electrodes as the control condition. The same set of standardized swallow tasks will be completed with the conventional and commercially available devices as well.
223567875|NCT02820246|OTHER|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
224145819|NCT01025687|BEHAVIORAL|TV program showed while feeding|
223567876|NCT02172131|DRUG|BI 1744 CL|
223567877|NCT02172131|DRUG|Placebo|
223567878|NCT05148013|OTHER|Pilates exercise|All participants will be given a basic introduction to the Pilates-based exercises and will be taught how to activate the core muscles, which entails isometric contraction of the transverses abdominis, pelvic floor, and multifidus muscles while exhaling during diaphragmatic breathing, before beginning the exercise program. The Pilates exercise program will consist of floor exercises on a mat, including the following exercises: one-leg kick, single leg stretch, shoulder bridge, the hundred, one leg circle, and swimming. All exercises progressed at three degrees of difficulty: basic, intermediate, and advanced. Depending on the patient's tolerance, each exercise will be done for 8-10 repetitions. The treatment plan included a five-minute warm-up, twenty minutes of exercise, and a five-minute cool-down.
223567879|NCT05148013|OTHER|PNF exercise|The PNF techniques utilized in the PNF exercise group will include a combination of isotonics, rhythmic stabilization, and repeated stretch. The exercises which will be performed are; (1) Trunk rotation in sitting position (1a) Chopping to the left and right and (1b) Lifting to the left and right, (2) Rolling activity (2a) Resistance to pelvic anterior patterns 2(b) Resistance to posterior patterns, 2(c) Combination of scapula and pelvis, 2(d) Combination of scapula and pelvis (i.e. asymmetrical exercise for trunk extension: the scapula moves in posterior elevation, the pelvis in posterior depression) and (3) Bridging activity (3a) Stabilize the pelvis in its neutral position, 3(b) Bridging lower trunk rotation and, 3(c) Bridging on two legs in the supine position.
223567880|NCT02059889|DEVICE|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
223567881|NCT02059889|DEVICE|4-dimensional computed tomography|Undergo 4D CT
223567882|NCT02059889|RADIATION|fludeoxyglucose F 18|Undergo FDG-PET
223567883|NCT02059889|DEVICE|FDG-PET|Undergo FDG-PET
223567884|NCT00162747|DRUG|Aquaphor|
223567885|NCT00162747|DRUG|Sunflower Seed Oil|
223567886|NCT06462040|PROCEDURE|Fixation of osteochdral fragments with reabsorbable screws|Arthroscopic or mini-open fixation of free-intrarticular or unstable osteochondral fragments due to osteochondritis dissecans or osteochondral fractures with reabsorbable screws
223567887|NCT06474507|DRUG|Calculus bovis sativus (CBS)|Subjects will orally receive 100mg CBS per day from day 1 to day 84.
223567888|NCT04095663|PROCEDURE|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
223567889|NCT04095663|OTHER|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
224054913|NCT07079839|DEVICE|Transcranial Random Noise stimulation (tRNS)|A weak electrical currents will be passed through the scalp over targeted cortical regions via a transcranial electrical stimulation system (Soterix Medical, Inc), for a span of 10 to 40 minutes at a time. Participants will receive a 2 mA sinusoidal current oscillating at random frequency (1-200 Hz). Current intensities will be modified to address individual participants' subjective reports of discomfort, with a maximum intensity of 2 mA. Stimulation electrodes will be placed within an EEG cap fitted over the participant's head.
223445119|NCT02076347|BEHAVIORAL|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
223445120|NCT02076347|BEHAVIORAL|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
224054914|NCT07080177|PROCEDURE|Free gingival graft simultaneous with delayed implant placement|XCM grafts (of bovine origin)
224054915|NCT07080177|PROCEDURE|Xenogeneic collagen matrix simultaneous with delayed implant placement|A FGG will be harvested from the palate between first premolar and first molar
224054916|NCT05378932|OTHER|Actigraphy|Sleep efficiency recording at home by means of actigraphy during 10 consecutive days.
224054917|NCT05378932|OTHER|Recording of proximal and distal skin temperature and temperature of the bedroom|"Recording of proximal and distal skin temperature at home by data loggers placed on the skin during 10 consecutive days.~Recording of temperature of the bedroom by a data logger during 10 consecutive days."
224054918|NCT05378932|OTHER|Questionnaires assessing subjective sleep quality|"One-off questionnaires assessing subjective sleep quality. The Pittsburgh Sleep Quality Index (PSQI) evaluates sleep quality with questions about sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction during the last month.~The Epworth Sleepiness Scale evaluates daytime sleepiness and comprises 8 items (situations) during which individuals assess how likely they would fall asleep."
224054919|NCT05378932|OTHER|Sweat test|One-off measurement of sweating by a sweat test at the hospital.
224054920|NCT05378932|OTHER|Urine melatonin assay|Two urine melatonin at home during 24 hours, one during a week day and one during the weekend
223445121|NCT05964439|DEVICE|HoloUS app for ultrasound visualization|Study participants will wear HoloLens see-through glasses and use the HoloUS app for ultrasound visualization in the conduct of a vascular access procedure in a phantom.
223445122|NCT00063297|DRUG|R209130|
223445123|NCT04521842|PROCEDURE|Total hip replacement|Total hip replacement in treatment of end-stage osteoarthritis
223445124|NCT04100655|DRUG|GM-CSF|3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
223567890|NCT04683146|DRUG|Hand antisepsis with Propanolol- 1 60%.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using Propanolol-1 60% in both hands.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later"
224054921|NCT05378932|OTHER|Polysomnography|Sleep architecture assessed by a polysomnography during one night at home.
223445125|NCT04100655|DRUG|17-ß estradiol|A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
223445126|NCT04473534|BEHAVIORAL|web based cognitive-behavioral therapy|one web session of psycho-education about sleep
224054922|NCT05378932|OTHER|Standardized psychological and neuropsychological assessment|One-off psychological and neuropsychological assessment of patients with HED during a hospital visit
224054923|NCT06647745|DRUG|THP-00101|Dapagliflozin 10 mg
224054924|NCT06647745|DRUG|THP-00102|Telmisartan 80 mg
224054925|NCT06647745|DRUG|THP-00103|Telmisartan 40 mg
223445127|NCT02330224|OTHER|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~1. Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~2. Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~3. Telephone based follow-up for all patients by nurses"
223445128|NCT01744483|DEVICE|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
223445129|NCT01744483|DEVICE|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
223445130|NCT01744483|DEVICE|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
223445131|NCT00797940|DRUG|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
223445132|NCT03041467|DEVICE|IN.PACT AV DCB|IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
223567891|NCT04683146|DRUG|Hand antisepsis with a solution of alcohol, chlorhexidine digluconate and potassium sorbate.|"* Pre-washing for one minute with neutral soap to remove the transient flora.~* Hand antisepsis using a solution of alcohol, chlorhexidine digluconate and potassium sorbate.~* Bacterial sample collection from right hand.~* Sterile surgical glove in both hands.~* Bacterial sample collection from left hand three hours later."
223567892|NCT00206128|DRUG|Seroquel SR|
223567893|NCT03834610|DRUG|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
223567894|NCT03834610|DRUG|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
223567895|NCT03834610|DIAGNOSTIC_TEST|serum testosterone level|measurement of serum testosterone level
223567896|NCT03834610|DIAGNOSTIC_TEST|HbA1C|measurement of HbA1C levels
223567897|NCT03834610|DEVICE|penile doppler|penile doppler to measure the degree of erection and penile vasculature
223567898|NCT00206050|DRUG|Esomeprazole|
223567899|NCT00206050|DRUG|pantoprazole|
223567900|NCT02713984|BIOLOGICAL|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
223567901|NCT03449940|PROCEDURE|Immediate repair|
223567902|NCT03449940|PROCEDURE|Delayed repair|
223567903|NCT03449940|DRUG|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
223567904|NCT03449940|DRUG|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
223567905|NCT03449940|DRUG|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
223567906|NCT04247009|OTHER|Meal based on red meat, fish products or vegan products|Three meals will be served
223567907|NCT04247009|OTHER|Meal based on red meat|Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
223445133|NCT03041467|DEVICE|Standard Balloon Angioplasty|Standard PTA Balloon
223445134|NCT01190189|BIOLOGICAL|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
223445135|NCT00708474|DEVICE|OsseoFit™ Porous Tissue Matrix™|Bone void filler
223445136|NCT05727748|OTHER|Multimodal exercise with augmented reality|The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.
223445137|NCT05727748|OTHER|Multimodal exercise|"The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed)."
223445138|NCT05727748|OTHER|Control group|The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
223445139|NCT04505254|DRUG|Acalabrutinib|Given PO
223741379|NCT01165255|DRUG|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
223741380|NCT01053819|DRUG|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
223741381|NCT01882374|DRUG|TXA127|Injection, 300mcg/kg/day for 28 days
223445140|NCT04505254|BIOLOGICAL|Obinutuzumab|Given IV
223445141|NCT00274547|DRUG|Tiotropium|
223445142|NCT02528617|DRUG|Velaglucerase alfa|Enzyme replacement therapy
223445143|NCT05614401|OTHER|functional and medical information|1\) functional outcomes(mRS scoring), 2)survival status, 3) date of death in those who died (based on information of the treating physicians), 3) mRS score at the time of the interview, 4) recurrent stroke/TIA, 5) new onset atrial fibrillation, 6) other cardiovascular events, including myocardial infarction, pulmonary embolism, deep venous thrombosis, peripheral arteriopathy.
223741382|NCT01552252|DIETARY_SUPPLEMENT|apple juice|unaltered(0% POs-Ca) commercially available apple juice
223445144|NCT06549881|PROCEDURE|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence|emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
223741383|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
223741384|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
223567908|NCT01877850|PROCEDURE|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
223567909|NCT03389724|DRUG|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
223567910|NCT00000487|DRUG|antihypertensive agents|
223567911|NCT00000487|BEHAVIORAL|smoking cessation|
223567912|NCT00000487|BEHAVIORAL|diet, fat-restricted|
223445145|NCT02732015|DRUG|Dexamethasone|Given IV
223445146|NCT02732015|DRUG|Doxorubicin|Given IV
223567913|NCT00000487|DRUG|diuretics|
223567914|NCT04975412|DIAGNOSTIC_TEST|Whole blood zinc level|whole blood zinc levels determined through ashing acid digestion-inductively coupled plasma (ICP) using Shimadzu ICPS-7510, an inductively coupled plasma emission spectrometer.
223567915|NCT02305472|DEVICE|NeoVas BCS|Subjects receiving NeoVas BCS
223567916|NCT00204594|DRUG|rM28|
223741385|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
223741386|NCT01552252|DIETARY_SUPPLEMENT|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
223741387|NCT03718767|DRUG|Nivolumab|IV Nivolumab
223445147|NCT02732015|DRUG|Fosaprepitant Dimeglumine|Given IV
223445148|NCT02732015|DRUG|Ifosfamide|Given IV
223445149|NCT02732015|OTHER|Laboratory Biomarker Analysis|Correlative studies
223445150|NCT02732015|DRUG|Mesna|Given IV
223445151|NCT02732015|DRUG|Ondansetron|Given IV
223445152|NCT02732015|OTHER|Questionnaire Administration|Ancillary studies
223445153|NCT02732015|DRUG|Rolapitant Hydrochloride|Given PO
223445154|NCT02732015|DRUG|Vincristine Sulfate|Given IV
223445155|NCT01980628|DRUG|ibrutinib|
223567917|NCT00204594|DRUG|autologous PBMCs|
223445156|NCT03550547|OTHER|Educational workshops|1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
223445157|NCT03550547|OTHER|Spa Therapy|Approved Spa therapy of knee osteoarthritis patients
223445158|NCT06955689|OTHER|Non invasive focal vibration with heads|3 sessions over 3 consecutive weeks, with one intervention day per week. Non invasive focal vibration at 120 Hz for 10 minutes while pedaling at 90-100 rpm
223445159|NCT06955689|OTHER|Non invasive focal vibration without heads|3 sessions over 3 consecutive weeks, with one intervention day per week. Non invasive focal vibration at 0 Hz for 10 minutes while pedaling at 90-100 rpm
224054926|NCT06647745|DRUG|THP-00104|Placebo of Dapagliflozin 10mg
223445160|NCT04611282|PROCEDURE|surgical techniques in the treatment of localized gingival recession defects.|Micro or macrosurgical echniques were performed using a coronally positioned flap with a subepithelial connective tissue graft.
223445161|NCT04626700|DEVICE|iNAP|iNAP for the treatment of OSA
223445162|NCT04626700|DEVICE|CPAP|CPAP for the treatment of OSA
223445163|NCT05989919|OTHER|CT scan for nose and paranasal sinuses|CT scan for nose and paranasal sinuses
223445164|NCT04757805|DIAGNOSTIC_TEST|Ultrasound|Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
223445165|NCT02469168|DEVICE|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
223445166|NCT02469168|PROCEDURE|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
223445167|NCT01872806|RADIATION|a dialing smartphone will be placed on the chest and the ear|
223445168|NCT01741350|BEHAVIORAL|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
223445169|NCT01741350|BEHAVIORAL|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
223445170|NCT01383252|PROCEDURE|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
223741388|NCT06698510|DRUG|Arpraziquantel 150mg dispersible tablet|Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
223445171|NCT01383252|PROCEDURE|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
223741389|NCT02255721|BEHAVIORAL|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
224054927|NCT06647745|DRUG|THP-00105|Placebo of Telmisartan 80mg
223445172|NCT02874716|OTHER|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
223445173|NCT04162405|BEHAVIORAL|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
223445174|NCT06257953|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be applied to the patients under real-time ultrasound guidance.
223445175|NCT04099537|BEHAVIORAL|Computerized cognitive training|Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
223741390|NCT02255721|BEHAVIORAL|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
223445176|NCT06543082|DRUG|Colchicine 0.6 mg|Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
223741391|NCT03845907|DEVICE|Gen 1B|Diagnostic Ultrasound and Optoacoustic Imaging
223741392|NCT03845907|DEVICE|Gen 1|Diagnostic Ultrasound and Optoacoustic Imaging
223741393|NCT06555783|DRUG|ALKS 2680|Oral tablet containing ALKS 2680
223741394|NCT06555783|DRUG|Placebo|Oral tablet containing placebo for once daily administration
224054928|NCT06647745|DRUG|THP-00106|Placebo of Telmisartan 40mg
224054929|NCT05763615|OTHER|Tractography MRI|"Addition to the sequences usually done for the care of these patients (CubeT2, Diffusion, CubeT1, CubeT2 fiesta, ASL, T1 injected with gadolinium), of a so-called research tractography sequence benefiting from CE marking and not requiring specific injection.~Search sequence acquisition time: 10 minutes."
224054930|NCT04666610|DRUG|Brivaracetam|"* Pharmaceutical form: Oral solution~* Route of administration: Oral use~Brivaracetam (oral solution \[10 mg/ml, 5 mg/ml or 2.5 mg/ml\] will be administered."
224054931|NCT04666610|OTHER|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding.
223445177|NCT02365038|OTHER|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
223445178|NCT02365038|OTHER|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
223445179|NCT00190398|DEVICE|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
223445180|NCT03959488|DRUG|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
223445181|NCT03959488|DRUG|Palivizumab|Approved anti-RSV monoclonal antibody
223445182|NCT01166711|DEVICE|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type~* BMS needs to be fully embedded in vessel wall~* post-dilation with high pressure is required before treatment with DEB~* DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~* length of DEB should exceed the BMS by 2-3 mm on each side~* if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
223741395|NCT04824170|OTHER|Neural Glide|hot pack and cervical traction is applied for 10-15 min.Group A received Neural mobilization of median nerve which includes gliding and sliding was given,therapist stood on the patient \& affected side besides the patient, patient'S shoulder was depressed with one hand and elbow was moved in 90 degree flexion, forearm supination, extend the wrist and fingers with other hand. Then patient arm was moved into 90 degree abduction and then sliding or gliding of nerve was applied. Sliding was applied with elbow extension and wrist flexion and elbow flexion with wrist extension. 6 sets were performed. Each set was performed for 60 seconds, for alternative days in week for 4 weeks and then progressed to gliding/tensioning technique when symptoms improved
223741396|NCT04824170|OTHER|Rhythmic stabilization technique|"This group was receiving (PNF) Rhythmic stabilization technique with base line treatment.~Subject was lying in spine position on the treatment table and therapist resist an isometric contraction of agonist muscle group.pt maintain this position for 10 sec without trying to move and 12-15 repetitions were performed with 30 sec rest. Each therapeutic session treatment was focused on facilitation of neck stabilizers, improving neck stability, coordination, decreasing pain and improving postural control"
223741397|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
224054932|NCT07107659|DRUG|ONT01 is a small molecule CD11b modulator.|ONT01 will be administered orally twice daily (in the morning and in the evening at approximately 12 hours apart and approximately the same time each day) and should be taken as whole tablets (not crushed) under fasted conditions (2 hours before and 1 hour after each dose) with 8 oz/240 mL of water.
224300706|NCT02475941|OTHER|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
223741398|NCT00874523|DRUG|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
223741399|NCT03777007|DEVICE|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
223741400|NCT06216613|BEHAVIORAL|Sensory Enhanced Aquatics|Sensory Enhanced Aquatics (SEA) utilizes the Sensory Profile to individualize lessons based on children's sensory preferences. The program incorporates evidence-based approaches for autistic children, including: 1) visual supports, 2) sensory supports, 3) communication strategies, 4) behavioral strategies, and 5) modeling to maximize skill acquisition. Lessons will be 1:1 with social opportunities at the beginning and end of each lesson. Like standard swim lessons, skills are taught in progression from water orientation (e.g., blowing bubbles, submerging different body parts) to advanced swimming (e.g., swimming 15 or more yards of different swim strokes). All lessons include instruction of water safety skills. Each skill has been task analyzed by therapists so instruction can be graded according to children's ability. A social story is provided to transition children to lessons. SEA curriculum was reviewed by USA Swimming Foundation and is included as a Swim Lesson Network Provider.
224054934|NCT07127471|DEVICE|Water exchange with AI-assisted detection|The study employs standard high-definition colonoscopy video processors with integrated CADe system (CAD-EYE, EW10-EC02, Fujifilm) The ELUXEO 7000 system (Fujifilm) will be used in this study. During the insertion phase of water exchange (WE) colonoscopy, the air pump will be turned off, and the colon will be irrigated with warm water, using a flushing pump. WE involves simultaneous infusion of distilled water to facilitate luminal expansion and suction of unclean water. Withdrawal will begin with the patient in the left lateral position. Consistent techniques, ensuring adequate luminal distention and comprehensive fold examination, will be used. The CADe device will be activated during the withdrawal phase of the procedures, and it will provide real-time output in the form of a bounding box whenever the CADe device identifies a suspected polyp. All participating endoscopists possess experience and expertise in CADe systems, ensuring readiness before study initiation.
223445183|NCT01166711|DEVICE|Coroflex Please (DES)|"* standard techniques will be used~* maximal vasodilatation after nitro application~* baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~* 6 French guiding catheter at least~* target lesion will be crossed with standard guidewire~* direct stenting at the discretion of the investigator~* if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~* full lesion coverage will be ensured (with one or more stents)~* only insert assigned stent type"
223445184|NCT02975531|OTHER|Simulator's construction|Model to build the mold for the simulator
223445185|NCT02975531|OTHER|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
223445186|NCT02975531|OTHER|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
223445187|NCT02975531|OTHER|Simulator training|Training of pompage technique using the simulator.
223445188|NCT02975531|OTHER|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
223445189|NCT02393131|RADIATION|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
223445190|NCT02393131|RADIATION|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
223445191|NCT01760447|DRUG|Sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
223445192|NCT01760447|DRUG|Placebo to metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
223445193|NCT01760447|DRUG|Metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
223445194|NCT01760447|DRUG|Placebo to sitagliptin plus metformin|Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
223445195|NCT01760447|DRUG|Sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
223445196|NCT01760447|DRUG|Placebo to metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
223445197|NCT01760447|DRUG|Insulin|"Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine."
223445198|NCT01760447|DRUG|Placebo to sitagliptin plus metformin XR|Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
223445199|NCT01760447|DRUG|Metformin XR|Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
223445200|NCT04150536|DRUG|Lidocaine topical system 1.8%|
223445201|NCT00571116|DRUG|Disulfiram|Given PO
223445202|NCT00571116|DRUG|Arsenic trioxide|Given IV
223445203|NCT03996122|OTHER|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
223445204|NCT00068029|DRUG|Pegvisomant/ Sandostatin LAR|
223445205|NCT00068029|DRUG|Sandostatin LAR|
223567918|NCT05073796|DEVICE|Cochlea Implant|"* examination and documentation of vital signs and concomitant medication~* application of an cochlea implant loan processor (external body surface) with varying stimulus pattern for vestibular stimulation by means of basal, medial and apical electrodes~* attraction of an special mask to determine the subjective visual vertical (SVV)~* assessment of the vertical spatial axis with all electrodes turned off~* assessment of the vertical spatial axis with all electrodes turned on~* assessment of the vertical spatial axis while using basal (12-16) and medial (6-11) electrodes~* assessment of the vertical spatial axis while using basal (12-16) and apical (1-5) electrodes~* assessment of the vertical spatial axis while using medial (6-11) and apical (1-5) electrodes"
223567919|NCT03895580|OTHER|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
223567920|NCT03895580|OTHER|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
223567921|NCT05647343|DRUG|Ciclopirox Olamine Oral|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
224145820|NCT00211874|BEHAVIORAL|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
223445206|NCT00068029|DRUG|Pegvisomant|
223445207|NCT02686788|DRUG|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
223445208|NCT03221179|BIOLOGICAL|RO7049665|A single ascending dose (starting dose 1.5 micrograms \[mcg\])of RO7049665 will be administered SC.
223445209|NCT03221179|BIOLOGICAL|Placebo|Matching placebo will be administered SC once.
223567922|NCT05647343|OTHER|Placebo|On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo
223445210|NCT02634619|PROCEDURE|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
223445211|NCT02634619|PROCEDURE|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
223445212|NCT01602679|DRUG|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
223445213|NCT01602679|DRUG|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
223445214|NCT02644447|BIOLOGICAL|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
223445215|NCT02644447|BIOLOGICAL|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
223567923|NCT03892057|BEHAVIORAL|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
223741401|NCT06216613|BEHAVIORAL|Standard Swim Lessons|Standard swim lessons will adhere to USA Swimming Foundation Swim Network Provider requirements ensuring lessons meet or exceed industry best practices. Lessons have up to a 1:5 instructor to child ratio and will focus on stroke development and water-safety with skills advancing from water-orientation to stroke technique and endurance.
223741402|NCT05741411|OTHER|RPM-assisted specialist access|Participants will be prompted to report current symptoms and activity once a day via remote patient monitoring chat technology for up to 28 days following injury. Patients with either escalating or plateauing symptoms will be flagged, with an electronic alert sent via the electronic health record to a nurse navigator. The nurse navigator will have access to the symptom data and facilitate scheduling an in person or telehealth specialist visit as indicated. Symptoms will continue to be monitored through the 28-day acute study period with additional clinical visits occurring according to clinical need.
223741403|NCT03913637|BEHAVIORAL|Strategy Training|Occupational therapists deliver Strategy Training to older adults virtually. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
223741404|NCT03913637|OTHER|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
223741405|NCT02863380|PROCEDURE|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
224145821|NCT03920878|DRUG|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
224145822|NCT03920878|DRUG|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
223445216|NCT00270621|BEHAVIORAL|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
223445217|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
223445218|NCT00255840|BEHAVIORAL|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
223445219|NCT00255840|DRUG|Efavirenz|600 mg tablet taken orally daily
223445220|NCT00255840|DRUG|Lamivudine|150 mg tablet taken orally daily
223445221|NCT00255840|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
223445222|NCT00255840|DRUG|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
223445223|NCT00255840|DRUG|Stavudine|Tablet taken orally daily. Dosage depends on weight.
223741406|NCT02863380|DEVICE|Individualized rTMS (transcranial magnetic stimulation)|
223741407|NCT02863380|DEVICE|Classical rTMS (transcranial magnetic stimulation)|
223741408|NCT02863380|DEVICE|Classical tDCS (transcranial direct current stimulation)|
223741409|NCT05587309|DRUG|BLI5100|Orally via tablet
223741410|NCT05587309|DRUG|PPI Control|Orally via tablet
223741411|NCT02972554|DRUG|Propanolol hydrochloride|One-time dose of 40mg of propranolol
224145823|NCT04327518|DEVICE|TECNIS® Toric II|Toric Intraocular Lens
224054935|NCT07127471|DEVICE|Water exchange with AI-assisted detection and LCI|The study employs high-definition colonoscopy video processors with integrated CADe (CAD-EYE, EW10-EC02, Fujifilm) and LCI systems (Fujifilm).The ELUXEO 7000 system will be used . During the insertion phase of water exchange (WE) colonoscopy, the air pump will be turned off, and the colon will be irrigated with warm water, using a flushing pump. WE involves simultaneous infusion of distilled water to facilitate luminal expansion and suction of unclean water. Withdrawal will begin with the patient in the left lateral position. Consistent techniques, ensuring adequate luminal distention and comprehensive fold examination, will be used. The CADe and LCI devices will be activated during the withdrawal phase of the procedures, and it will provide real-time output in the form of a bounding box whenever the CADe device identifies a suspected polyp. All participating endoscopists possess experience and expertise in CADe and LCI systems, ensuring readiness before study initiation.
224054936|NCT07140705|OTHER|Transformative Virtual Reality Experience and ACT for General Practitioners|"This intervention consists of an individual, in-person session in which each participant engages in a 10-minute transformative Virtual Reality (VR) experience entitled The River and the Leaf, delivered through the Meta Quest 3 headset. Drawing on Acceptance and Commitment Therapy (ACT) metaphors, participants are guided to reflect on key aspects of the experience, their professional challenges, and the personal resources available to them. Following the VR session, participants are supported in clarifying the values that guide their everyday actions. After the in-person session, all participants are encouraged to identify and implement committed actions aligned with their values over the subsequent two weeks, supported by two dedicated audio tracks."
223445224|NCT06473766|DIAGNOSTIC_TEST|RF data extraction|"To will be acquired:~10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.~The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural."
224054937|NCT05934331|DRUG|LM-302|Q2W/Q3W，Administered intravenously
224054938|NCT05934331|DRUG|Toripalimab|Q2W/Q3W,Administered intravenously
224054939|NCT05934331|DRUG|Capecitabine|BID,Oral Administration
224145824|NCT04387929|DIAGNOSTIC_TEST|Detection of anti-COVID-19 antibody level|Detection of anti-COVID-19 antibody level form blood samples. If positive, viral load will be measured by RT-PCR of nasopharyngeal swab.
224300707|NCT06406270|OTHER|Fava|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with fava bean food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
224054940|NCT05934331|DRUG|Tegafur, Gimeracil and Oteracil Potassium Capsules|BID,Oral Administration
223445225|NCT06844617|DEVICE|BathMat|Repositioning patients using the BathMat
223445226|NCT04680832|DIAGNOSTIC_TEST|Electronic nose|First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
223741412|NCT02972554|OTHER|Placebo|Outside casing matching that of active drug
223741413|NCT06287333|DIAGNOSTIC_TEST|Polysomnography in routine care|Children performed a polysomnography in routine clinical care
223741414|NCT02193373|OTHER|Osteopathic Manual Medicine|Osteopathic Manual Medicine
223741415|NCT02193373|OTHER|Sham|Osteopathic Manual Medicine
223741416|NCT02280772|DIETARY_SUPPLEMENT|Glucomannan|
224054941|NCT05934331|DRUG|Nivolumab|Q4W,Administered intravenously
224054942|NCT05934331|DRUG|Apatinib|QD,Oral Administration
224054943|NCT05934331|DRUG|Gemcitabine|Q4W,Administered intravenously
224054944|NCT06161571|DRUG|Efruxifermin|Administered by subcutaneous (SC) injection
224145825|NCT01966263|PROCEDURE|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
223741417|NCT02280772|DIETARY_SUPPLEMENT|Maltodextrin|
223741418|NCT03646461|DRUG|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
223741419|NCT03646461|DRUG|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
224054945|NCT06161571|DRUG|Placebo|Administered by SC injection
224054946|NCT06948799|DRUG|STSP-0902 injection|Subjects will receive the administration dose on Day 1 following protocol requirements
224054947|NCT06948799|DRUG|Placebo|Subjects will receive the administration dose on Day 1 following protocol requirements
224054948|NCT07143513|DRUG|Sotorasib|Participants will have received sotorasib orally daily until disease progression or unacceptable toxicity.
224054949|NCT07141199|DRUG|ABBV-8736|Intravenous (IV) Infusion
224054950|NCT07141199|DRUG|Placebo|IV Infusion
224145826|NCT01966263|PROCEDURE|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
224145827|NCT01966263|PROCEDURE|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
224054951|NCT07101510|BEHAVIORAL|sV-CPR|In the sV-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a video connection with a dispatcher located in another room using a smartphone. To simulate challenging conditions, they must carry out the task in near-total darkness, with the phone's flashlight as the only light source.
223445227|NCT06125535|DIAGNOSTIC_TEST|Sub-phenotyping by biomarkers concentration|Plasma will be collected at ICU admission (i.e., \< 6 hours from graft reperfusion), centrifuged (1500G for 15 min), frozen at -80°c, and then centralized at the Institutional laboratory. The following biomarkers will be assessed: Interleukin-1β, Interleukin-2, Interleukin-6, Interferon-γ, Tumor Necrosis Factor-alpha (TNF-α), chemokine (C-C motif) ligand-2 (CCL-2), Interleukin-15 (IL-15), Ferritin, and D-dimer, by a point-of-care biochip-array device (RANDOX, Multistat)
223445228|NCT04415021|OTHER|Experimental: Diaphragmatic and İliopsoas Myofascial Release Techniques|Subjects in this arm will receive different myofascial release techniques aimed to relaxation the myofascial tension of the diaphragmatic and iliopsoas muscles.
224054952|NCT07101510|BEHAVIORAL|V-CPR|In the V-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a video connection with a dispatcher located in another room using a smartphone.
223445229|NCT04415021|OTHER|Sham Comparator: Sham Myofascial Release Techniques|Subjects in this arm will receive the same manual techniques of the diaphragmatic and iliopsoas myofascial release group, but without the myofascial stimulus.
223567924|NCT01679600|DEVICE|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
223567925|NCT01679600|DEVICE|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
224054953|NCT07101510|BEHAVIORAL|T-CPR|In the T-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a telephone connection with a dispatcher located in another room using a smartphone (vocal communication only).
223567926|NCT05083013|DIAGNOSTIC_TEST|Reverse transcription polymerase chain reaction (RT-PCR)|For SARS Corona Virus 2 (COV2) confirmation
223567927|NCT05083013|DIAGNOSTIC_TEST|Glycated haemoglobin (HbA1C)|Diabetic patients' group will be categorized according to their glycemic control by using their glycated haemoglobin (HBA1C) into good control, fair control and poor control
223567928|NCT05083013|RADIATION|High Resolution Computed Tomography (HRCT)|with the coronavirus disease 2019 Reporting and Data System (CO-RADS) classification grade 5 for SARS COV2 confirmation
223567929|NCT05083013|DIAGNOSTIC_TEST|Routine Laboratory investigations|"* Arterial blood gases (ABGs)~* Routine Laboratory investigations (Urea, Creatinine, Liver function tests, Serum Electrolytes, Prothrombin Concentration)"
224145828|NCT01966263|PROCEDURE|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
223445230|NCT06476431|OTHER|dual task|The intervention program will be a program created by the researcher based on the iPad application Brainilis The tasks (logic, memory, math, and concentration) will be performed using a Type-C cable connected to the smartglasses, and the difficulty level will be adjusted according to the individual's cognitive ability. The experimental group will perform cognitive tasks with the smartglasses while simultaneously performing a walking task on a treadmill. This will be done three times a week for 30 minutes for four weeks. The subjects will not be able to touch the answers, so they will tell the therapist what they think is the correct answer and the therapist will touch the iPad to move on to the next step. The investigators will start with 10 minutes on the treadmill without incline, followed by a 5 minute break, then 10 minutes on the treadmill with incline, followed by a 5 minute break. It will run for 30 minutes, 3 times a week for 4 weeks.
223567930|NCT05083013|DIAGNOSTIC_TEST|Random Blood Sugar (RBS)|Blood Sugar will be measured before each meal and before bed time during hospitalization.
223567931|NCT01018329|PROCEDURE|Magnetic Resonance Imaging|
223567932|NCT01018329|PROCEDURE|Diffusion Tensor Imaging|
223567933|NCT01018329|PROCEDURE|Magnetic Resonance Spectroscopic Imaging|
223567934|NCT01018329|PROCEDURE|Dynamic Contract-Enhanced magnetic resonance imaging|
223567935|NCT01018329|PROCEDURE|Diffusion-weighted magnetic resonance imaging|
223567936|NCT05489172|BEHAVIORAL|Hola Bebe|"Participants will receive the handout It's never too early to prevent diabetes and will meet with the health educator at their CHC and download the Hola Bebe app. The health educator will advise participants to watch one module and complete an action plan for each of the first 12 weeks of study and encourage participants to weigh themselves weekly. The app includes the following features:1) educational/ behavioral audio visual modules, with automatic prompting to complete an action plan at the end of each module; 2) a motivational message library so that participants can chose which motivational texts they wish to receive, how often and time of day; 3) a community forum where participants can interact with each other and ask questions to the health educator; 4) tracking of weights to allow participants to see a graphic of their weight over time by inputting weekly weights; and 5) awards program where participants can earn badges for completing modules."
223741420|NCT03646461|DRUG|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
223741421|NCT06490328|DRUG|DKF-MA102|Administered twice at 12-week intervals
223741422|NCT00988754|BEHAVIORAL|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
223741423|NCT04156568|DRUG|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
223741424|NCT02518555|BIOLOGICAL|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
223741425|NCT02518555|DRUG|Ibrutinib|Given PO
224054954|NCT07101510|BEHAVIORAL|sT-CPR|In the sT-CPR group, participants manage a simulated cardiac arrest scenario alone. They perform CPR while establishing a telephone connection with a dispatcher located in another room using a smartphone (vocal communication only). To simulate challenging conditions, they must carry out the task in higher environmental noises (traffic), generated by a loudspeaker.
223445231|NCT06476431|OTHER|non dual task|No cognitive task, just treadmill walking. Same as the experimental group 1: 10 minutes without treadmill incline, followed by a 5 minute rest period, followed by 10 minutes on the treadmill with incline, followed by a 5 minute rest period. It will run for 30 minutes, 3 times a week for 4 weeks.
223445232|NCT04525131|DRUG|CPX-POM|CPX-POM
223445233|NCT02493530|DRUG|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
224054955|NCT07154433|DRUG|Opioid Analgesic Regimen|Participants will take 5 mg/325 mg of oxycodone - acetaminophen every 6 hours as needed for pain, with a maximum of 4 doses per day. Rescue analgesia protocol: a limited rescue prescription of oxycodone/acetaminophen (containing 5 mg oxycodone), to be taken every 2 hours as needed, with no more than 10 tablets per day, and only if adequate pain relief is not achieved (defined as NRS score ≥ 4).
224145829|NCT02675725|DEVICE|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
224145830|NCT05259930|OTHER|Amino MP9|Name used by Nualtra for their product of BCAA
224145831|NCT04501835|OTHER|Diagnostic and treatment evaluation|No intervention, description of the diagnostic evaluation and the treatment
223445234|NCT02493530|DRUG|ruxolitinib|
223445235|NCT04278924|DRUG|Placebo|TAK-079 placebo-matching SC injection.
223567937|NCT03300271|OTHER|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
223567938|NCT03300271|OTHER|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
223567939|NCT03300271|OTHER|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
223567940|NCT00274859|DRUG|gemcitabine hydrochloride|
224145832|NCT01984736|DRUG|Experimental: EVP-6124|
224145833|NCT03287869|DRUG|Brexpiprazole|Brexpiprazole tablets
223445236|NCT04278924|DRUG|TAK-079|TAK-079 SC injection.
223567941|NCT00274859|DRUG|oxaliplatin|
223567942|NCT04236024|OTHER|Board game|The students in the experimental group will play board game to learn medication about 30-60 minutes.
223567943|NCT04236024|OTHER|Traditional lecture|The students in the comparison group will receive medication lecture using PPT slides about 30-60 minutes.
223567944|NCT06088394|DEVICE|Acupuncture|"Participants will be asked to assume supine lying position on the plinth and the following points will be located then needles will be inserted:~* CV3,4 \&5-40 mm needles at a depth of 1 cun perpendicular insertion.~* ST 25 bilaterally-40 mm needles at a depth of 1 cun oblique insertion.~* SP6 \& 9, K13\&7 bilaterally-25 mm needles at a depth of 0.5 cun perpendicular insertion. A total of 13 needles will be inserted at each session."
223567945|NCT06088394|OTHER|pelvic floor exercises|pelvic floor muscle exercises can help strengthen pelvic floor muscle, which provides better control of urinary urgency by interfering with urethral-detrusor reflexes and inhibiting detrusor contractions
223445237|NCT04220190|BIOLOGICAL|RAPA-501 Autologous T stem cells|Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)
223445238|NCT06226649|BEHAVIORAL|Digital Dyadic Empowerment|"The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers."
223567946|NCT00113399|BIOLOGICAL|filgrastim|
223567947|NCT00113399|DRUG|cisplatin|
223567948|NCT00113399|DRUG|docetaxel|
223445239|NCT06319222|OTHER|DALC Digital Clinic|Providers randomized to the intervention arm will be able to refer their patients with ALD, to the DALC in addition to standard of care. Patients with providers randomized to the intervention arm will be consented by the study team. After appropriate consent, the referred patients will be instructed by our study team to download the RTP application in their smart devices (smartphones or tablets).
223567949|NCT00113399|DRUG|fluorouracil|
223567950|NCT00113399|DRUG|paclitaxel|
223567951|NCT00113399|RADIATION|radiation therapy|
223567952|NCT05482477|OTHER|Transcutaneous acupoint electrical stimulation|Transcutaneous electrical acupoint stimulation (TEAS) is a new type of acupoint stimulation therapy that inputs low-frequency pulse current into human acupoints through electrodes pasted on the skin surface to achieve therapeutic purposes, which combined the preponderances of both acupuncture and transcutaneous electrical nerve stimulation (TENS). TEAS is non-invasive, easy to operate and acceptable to patients. Study showed that TEAS treatment can reduce the consumption of intraoperative anesthetic and improve postoperative nausea and vomiting (PONV) and postoperative recovery.
223445240|NCT04847232|DRUG|Sodium Zirconium Cyclosilicate (SZC)|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the long interdialytic interval (LIDI).
223445241|NCT04847232|DRUG|SZC Placebo|Powder for oral suspension in a sachet. A dose is titrated in 5 g increments during a period of 4 weeks from 5 g up to 15 g qd on non-dialysis days. Afterward, the dose is adjusted monthly (or more frequent based on clinical judgment) depending on the current potassium value as measured after the LIDI.
223445242|NCT06444139|DIETARY_SUPPLEMENT|Probiotics|Probiotics
223567953|NCT00065039|BEHAVIORAL|Promotion of a healthy diet and physical activity|
224054956|NCT07154433|DRUG|Non-opioid analgesic regimen|Immediately after surgery, patients will receive oral acetaminophen 500 mg plus celecoxib 400 mg. Thereafter, celecoxib 200 mg BID and acetaminophen 500 mg Q6H will be administered. Rescue analgesia protocol: a limited rescue prescription of oxycodone/acetaminophen (containing 5 mg oxycodone), to be taken every 2 hours as needed, with no more than 10 tablets per day, and only if adequate pain relief is not achieved (defined as NRS score ≥ 4).
223567954|NCT00065039|BEHAVIORAL|Avoidance of Alcohol, Drugs, and Tobacco|
224145834|NCT04229108|DEVICE|Medopad|Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
223567955|NCT03226379|OTHER|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building"
223567956|NCT03729037|OTHER|CPR self-training|
223567957|NCT03368053|PROCEDURE|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
223567958|NCT03028844|OTHER|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
223567959|NCT04817137|DEVICE|CareTaker PDA Device|Non-invasive blood pressure monitoring
223567960|NCT00321958|DEVICE|CSA System (CryoSpray AblationTM System)|10 second spray times
223567961|NCT00321958|DEVICE|CryoSpray Ablation|10 second spray times
223567962|NCT01779856|DEVICE|REVEAL Insertable Cardiac Monitor (ICM)|
223567963|NCT01535599|DRUG|AL-60371, 0.3% Otic Suspension|
223567964|NCT01535599|OTHER|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
223567965|NCT04660292|OTHER|Maitland's mobilization|Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
223567966|NCT04660292|OTHER|Traditional Physical therapy|BASELINE TREATMENT INCLUDES TENS and Hot PACKS
223741426|NCT02518555|OTHER|Laboratory Biomarker Analysis|Correlative studies
223741427|NCT02518555|OTHER|Pharmacological Study|Correlative studies
224145835|NCT03488238|DEVICE|ORi sensor|Noninvasive pulse oximeter sensor that is placed on the finger for measurement of ORi
224145836|NCT06085287|DEVICE|Electromagnetic therapy|Electromagnetic therapy will be performed using an electromagnetic stimulator (Smart Cap). Chinese medicine practitioners who have at least 3 years of experience will conduct EMT after training. Each session of EMT will take 20-25 min, with 2-3 sessions per week, total of 30 sessions finished within 12 weeks.
224145837|NCT02884518|DEVICE|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
223445243|NCT06444139|DIETARY_SUPPLEMENT|Placebo|Placebo
223567967|NCT03971240|PROCEDURE|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
223567968|NCT00899197|DRUG|tamoxifen citrate|
223567969|NCT00899197|GENETIC|gene expression analysis|
223567970|NCT00899197|GENETIC|protein expression analysis|
223567971|NCT00899197|OTHER|immunoenzyme technique|
223567972|NCT00899197|OTHER|laboratory biomarker analysis|
223567973|NCT02724917|DRUG|APN1125|Oral solid dose form of APN1125
223567974|NCT02724917|DRUG|Placebo|Placebo to match
223567975|NCT03603587|PROCEDURE|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
223567976|NCT03603587|DIAGNOSTIC_TEST|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
223567977|NCT03603587|DIAGNOSTIC_TEST|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
223567978|NCT03603587|DIAGNOSTIC_TEST|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
223567979|NCT03603587|DIAGNOSTIC_TEST|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
223567980|NCT03603587|DIAGNOSTIC_TEST|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
223567981|NCT03603587|DIAGNOSTIC_TEST|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
223567982|NCT03603587|DIAGNOSTIC_TEST|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
223567983|NCT04052763|DIAGNOSTIC_TEST|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
223567984|NCT04052763|DIAGNOSTIC_TEST|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
223741428|NCT02518555|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Given IM
224070839|NCT04647292|OTHER|anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration|"A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy.~Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly."
223445244|NCT06463301|OTHER|Treadmill Training In CP child|"Treadmill training for children should be carefully tailored to their developmental level, physical ability, and specific therapeutic goals. Initial Sessions start with shorter sessions, around 5-10 minutes, especially for children with disabilities.~Progression will be made when the child becomes more accustomed to the treadmill. Aim for a total of 20-30 minutes per session, including breaks if necessary then then Start at a slow walking pace, approximately 0.5 to 1.0 miles per hour (mph) or 0.8 to 1.6 kilometers per hour (kph). Adjust the speed based on the child's comfort and ability to maintain a safe and effective walking pattern.~Older Children (8-12 years Begin with a walking pace of 1.0 to 1.5 mph (1.6 to 2.4 kph). Gradually increase the speed to a brisk walk or light jog, up to 2.0 to 3.0 mph (3.2 to 4.8 kph), depending on the child's progress and comfort level along with conventional physical therapy."
223445245|NCT06463301|OTHER|Conventional Physical Therapy|conventional physical therapy session would typically include gentle stretching, joint mobilization, range of motion exercises for both the upper and lower body, gait training, and standing frame activities. Each component is designed to improve various aspects of physical function, ensuring a comprehensive approach to rehabilitation
223567985|NCT01331343|DEVICE|Guardian RT Telemetered Glucose Monitoring System|
223567986|NCT01835574|BEHAVIORAL|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete \>=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
223567987|NCT05067023|DIAGNOSTIC_TEST|MRI scan|All participants will undergo 1 DCE-MRI scan.
223567988|NCT01825486|BEHAVIORAL|accidental falls|
223567989|NCT02901002|OTHER|Sensory testing in the two hand|spontaneous sensations while watching a hand
224145838|NCT02884518|BEHAVIORAL|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
224145839|NCT05860998|DIAGNOSTIC_TEST|Presence of Toxoplasma gondii IgG Antibodies|Testing for the presence of Toxoplasma gondii IgG Antibodies in participants blood.
224300708|NCT06406270|OTHER|Buckwheat|Participants were instructed to consume only the meals that were provided to them during the study days. The breakfast, lunch and dinner meals of the diets were designed to contain 30% fat, 15% protein, and 55% carbohydrate, and seven different menus (1500, 1750, 2000, 2250, 2500, 2750 and 3000 Kcal) to deliver the closest energy requirements of the volunteers. For the intervention diets, all the meat was replaced with buckwheat food products, serving the same amount of buckwheat and fava bean food products for all the volunteers independently of their energy requirements. During the intervention diets, all the drinks, such as coffee, juice and tea, were restricted and provided by the Human Nutrition Unit at the Rowett Institute; the volunteers were allowed to drink only water ad libitum. Alcoholic drinks were not allowed to be consumed during the intervention diet weeks.
223567990|NCT02901002|OTHER|Neuropsychological evaluation|Score to anxiety-depression scale
223567991|NCT00571870|DRUG|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
223567992|NCT00322296|DRUG|Bexarotene 1% gel|
223567993|NCT04009694|OTHER|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
223567994|NCT03046095|OTHER|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
223567995|NCT03046095|PROCEDURE|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
224145840|NCT06210438|DRUG|SHR-A1921 + Bevacizumab|SHR-A1921 + Bevacizumab
224145841|NCT04435561|OTHER|Standard physiotherapy rehabilitation and dry needling|The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
223741429|NCT02518555|OTHER|Quality-of-Life Assessment|Ancillary studies
223741430|NCT02518555|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
224145842|NCT04435561|OTHER|Standard physiotherapy rehabilitation|This group receives their traditional intervention, without dry needling.
224145843|NCT02670928|BEHAVIORAL|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
224145844|NCT00443937|DRUG|enteric-coated mycophenolate sodium|oral
224145845|NCT00443937|DRUG|everolimus|oral
224145846|NCT00950976|OTHER|citrulline|TID for 5 days
224145847|NCT00950976|OTHER|Lemonade|TID for 5 days
224145848|NCT01376401|DRUG|Bendamustine|
224145849|NCT01376401|DRUG|Velcade|
224145850|NCT01376401|DRUG|Prednisone|
224054957|NCT07153029|BEHAVIORAL|Smartphone based cognitive tasks|"15 days Smartphone/Cellphone tasks: Using NeuroUX smartphone testing software, Cognitive games/tasks lasting approximately 3-4 minutes each will be administered through the a smartphone application and will be prompted via text message twice per day across 15 consecutive days in the morning (8-11am) and evening (5-8). Tasks were chosen to measure aspects of diverse aspects of cognitive that are impaired among patients taking methadone, including N-back task (working memory), the Stroop Task (executive function/cognitive control), and the Variable Difficulty List Memory Test (learning and memory). The 15 days will include two types of task administration: a) Testing Phase: tasks administered at a consistent, fixed difficulty level (days 1-5) b) Remediation Phase: increasing task difficulty in response to participant performance (days 6-15). To encourage adherence, researchers will contact participants to remind them of task completion."
224145851|NCT05906992|BIOLOGICAL|CT-P53|Intravenous(IV) infusion
223445246|NCT01560715|BIOLOGICAL|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
223445247|NCT00631163|DRUG|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
223445248|NCT02750696|DRUG|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
223445249|NCT02750696|DRUG|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
223445250|NCT01300156|DRUG|Oxaliplatin-based chemotherapy (ESHAOx)|"* Etoposide 40 mg/m2, D1-4~* Methylprednisolone 500mg, D1-5~* Cytarabine 2 g/m2, D5~* Oxaliplatin 130 mg/m2, D1"
223445251|NCT05362370|DEVICE|Stryker's PEEK Customized Implant|The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).
223445252|NCT04640155|BEHAVIORAL|Low FODMAP Diet|Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.
223445253|NCT04640155|BEHAVIORAL|Regular Diet|Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
224145852|NCT05906992|BIOLOGICAL|US-Ocrevus|Intravenous(IV) infusion
224145853|NCT05906992|BIOLOGICAL|EU-Ocrevus|Intravenous(IV) infusion
224145854|NCT03199508|DIAGNOSTIC_TEST|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
224145855|NCT03199508|DIAGNOSTIC_TEST|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
223445254|NCT05068011|DEVICE|Spinal Cord Stimulation|differential target multiplexed stimulation
223445255|NCT05352880|DIAGNOSTIC_TEST|serum magnesium level, FEMg|"Blood (serum) for: Magnesium (Mg).Urea, creatinine. Calcium (ca), phosphorus (ph).Sodium (Na), potassium (k), chloride (CL).Fasting blood glucose, cholesterol, triglycerides. Intact PTH, 25OH vitamin D.uric acid, albumin. CBC.~Trough level of cyclosporine or tacrolimus. ii. Urine for:24 hour urinary: Mg, Ca, Ph, Cl and protein. Spot urine sample to calculate fractional excretion of Mg (FEmg)~. Detailed history taking, Thorough Systemic physical examination."
223445256|NCT03900572|BIOLOGICAL|HPV Vaccine|Intramuscular injection, 3 doses
223445257|NCT03900572|DRUG|Placebo|Intramuscular injection, 3 doses
223445258|NCT06276023|BEHAVIORAL|Mindful and Self-Compassionate Care Program (MASC)|"The intervention arm will be comprised of:~Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life."
223445259|NCT06276023|BEHAVIORAL|Health Education Program (HEP)|"The control arm will be comprised of:~Six Virtual Group Sessions. The sessions will discuss caregiver stress, sleep hygiene, nutrition, and ways to stay physically active as a caregiver.~At Home Practice. After each group session, participants will have the opportunity to complete journal exercises that encourage them to integrate the health information that they learn into their daily lives."
223445260|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation A
223445261|NCT06631430|DRUG|BI 3810477|BI 3810477 formulation B
223445262|NCT06631430|DRUG|Placebo|Placebo
223445263|NCT06434727|OTHER|observational study|Observational Study
223445264|NCT03688802|DRUG|OC-01 (varenicline) nasal spray|OC-01 (varenicline) nasal spray
223445265|NCT03688802|DRUG|Placebo (vehicle control) nasal spray|Placebo
223445266|NCT04169997|DRUG|IMP4927|IMP4297 tablet.The starting dose from 100mg QD
223445267|NCT04169997|DRUG|Placebos|Placebos tablet.The starting dose from 100mg QD
223445268|NCT02283320|DRUG|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
223445269|NCT02066077|DRUG|Etomidate|
223445270|NCT02066077|DRUG|Propofol|
223445271|NCT02066077|DEVICE|Bilateral temporal MECT|
223445272|NCT02066077|DEVICE|The right temporal MECT|
223445273|NCT02066077|DEVICE|Bilateral frontal MECT|
223445274|NCT02390713|DEVICE|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
223445275|NCT05394454|PROCEDURE|Bladder stimulation technique|The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins.
223445276|NCT04348500|DRUG|Clazakizumab|IV Infusion
223445277|NCT01124799|DRUG|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
223445278|NCT01124799|DRUG|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
223445279|NCT01124799|DRUG|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
223445280|NCT02542592|DRUG|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
223445281|NCT02542592|DRUG|Isotonic Sodium Chloride|Placebo
223445282|NCT03699540|DRUG|Marijuana|Experimental, non-therapeutic administration of active marijuana dose(s)
223567996|NCT04892550|OTHER|Denneroll traction|The participants will be instructed to lie flat on their back on the ground with their knees slightly bent at 20-30° for comfort and arms gently folded across their stomach. The examiner will position the apex of the Denneroll in one of three regions: lower thoracic (T9-T12), mid-thoracic (T5-T8), and upper-thoracic (T1-T4) depending on the apex of each participant's thoracic kyphosis deformity. For lower thoracic kyphosis (T9-T12) the Denneroll is turned 180° so the peak contacts the lower thoracic spine (T10) while the tapered end supports the mid thoracic region
223741431|NCT05926908|BEHAVIORAL|A Mobilisation Initiative|The Mobilisation Initiative consists of physiotherapists assisting nursing staff in mobilising patients to sit in a chair for breakfast and lunch. This intervention follows the interventions of focus group interviews, formal education, observations of patients and the environment, and awareness of mobilisation survey
224054958|NCT07171606|DRUG|SSGJ-706|PD-1/PD-L1 bispecific antibody
224054959|NCT07171606|DRUG|pemetrexed /carboplatin|chemotherapy
224054960|NCT07171606|DRUG|Carboplatin/Paclitaxel|chemotherapy
224054961|NCT07171606|DRUG|PD-1 Inhibitor + Chemotherapy|control group
223445283|NCT03699540|DRUG|Alcohol|Experimental, non-therapeutic administration of active alcohol dose(s)
223445284|NCT03699540|DRUG|placebo alcohol|Experimental, non-therapeutic administration of inactive alcohol dose(s)
223445285|NCT03699540|DRUG|Inactive marijuana|Experimental, non-therapeutic administration of inactive marijuana dose(s)
223445286|NCT01309750|RADIATION|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
223567997|NCT04892550|OTHER|Multimodal Program|The multimodal program consists of physical pain relief methods, thoracic spine manipulation, myofascial release, and therapeutic exercises.
223567998|NCT05056688|DIAGNOSTIC_TEST|Testicular Model BSE/TSE Training Set|The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
223567999|NCT04170530|DRUG|mFOLFOXIRI|irinotecan\* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
224054962|NCT07170254|GENETIC|BD114VLP, or BD114|"CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression.~A single dosing BD114 injection by topical intraepithelial injection of HSIL lesion."
224054963|NCT07170254|GENETIC|BD114VLP or BD114 plus Gel|"Genetic: BD114VLP or BD114 plus Gel CRISPR/Cas9 instantaneous gene editing therapy, called BD114VLP (also BD114) which is a developing product of gene therapy from modified third-generation integrated defective lentivirus, can deliver gRNA/Cas9 ribonucleoprotein complex (RNP). It works to knock out or knock down HPV-16 E6/E7 genes integrated in HSIL cell genome resulting to lesion clearness or regression.~Multiple dosing BD114 gel (BD114 injection :Gel, 1:1) topical application on HSIL, one time every other day, total 5 times (D0, D2, D4, D6, and D8) ."
223741432|NCT05926908|BEHAVIORAL|Focus Group Interviews|Focus group interviews using a semi-structured interview guide are conducted with health care professionals at the wards to explore the acceptability and demand for the contents of the Mobilisation Initiative, including the identification of facilitators and barriers to mobilisation
223741433|NCT05926908|BEHAVIORAL|Formal Education|Formal education for all nursing staff employed at the two wards includes information on the consequences of immobilisation, with the purpose of enhancing confidence, competencies, and awareness of mobilisation
223741434|NCT05926908|BEHAVIORAL|Self-reported Level of Mobilisation|Patient's self-reported mealtime mobilisation level reported through interview-based surveys, including structured follow-up questions
223741435|NCT05926908|BEHAVIORAL|Observations of Patients and the Environment|During breakfast and lunch, the mobilisation status of all patients in the wards is observed using an observation checklist
223741436|NCT05926908|BEHAVIORAL|Awareness of Mobilisation Survey|To assess the nursing staff's awareness of and confidence in the mobilisation of the patients, a short survey on mobilisation awareness is distributed to the nursing staff at both wards
223741437|NCT03628755|BEHAVIORAL|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
224145856|NCT02591238|OTHER|non-smoker oral placebo|Participants oral placebo last 2 weeks.
224145857|NCT02591238|DRUG|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
224145858|NCT02591238|OTHER|smoker oral placebo|Participants oral placebo last 2 weeks.
224145859|NCT02591238|DRUG|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
224145860|NCT00947934|DEVICE|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
223445287|NCT05460078|BEHAVIORAL|Virtual Psychiatric Transition of Care Program|"Behavioral Health facility or units that have discharged patients meeting inclusion criteria will be randomly assigned as either an intervention or standard care site. Intervention sites will be those using the VPTC program. This evaluation design will integrate into current workflows for the measurement of outcomes. Prior to discharge, patients may be referred to the VPTC program if they report residency or shelter in North Carolina, are 18 years of age or older on the day of discharge and can access virtual care (phone/video).~The VPTC program is defined by:~* Psychiatric consultation~* Medication management services with pharmacological consultation~* following of Health Coaching participation and provide treatment recommendations~* Tracking of behavioral health symptoms and provide treatment recommendations~* Health coaching; Psychoeducational support~* Treatment and safety planning~* Assistance connecting with an outpatient care provider"
223445288|NCT04617483|BIOLOGICAL|Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.
223445289|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.
223445290|NCT04617483|BIOLOGICAL|Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly|The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.
223445291|NCT05732077|DRUG|Dopamine|A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
223445292|NCT05732077|DIAGNOSTIC_TEST|Fractional Flow Reserve, Renal|Renal FFR will be measured based on SOP
223445293|NCT05732077|DEVICE|Renal artery stenting|Renal artery stenting will be implanted based on the protocol
223445294|NCT00560898|DRUG|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
223445295|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
223568000|NCT04043234|DEVICE|RESCU|Retrospectively Supervised Classification Updating (RESCU) is founded on two innovations that promise significant improvement in performance and outcome. The first is a highly robust machine intelligence algorithm, an Extreme Learning Machine with Adaptive Sparse Representation (EASRC), and the second is a novel adaptive learning algorithm and communication interface we call Nessa. We contend that these two technologies allow the prosthetic device to adapt to its user from the initial fitting through continuing, long-term use in the activities of daily living, shifting the paradigm of training from the current prospective data gathering methods to a more dynamic retrospective application.
223568001|NCT04043234|DEVICE|Pattern Recognition|Pattern recognition prostheses associate the patterns of activity of multiple EMG sites to the action of a prosthesis. Such strategies have historically required prospective calibration of the EMG activation patterns.
223741438|NCT03628755|BEHAVIORAL|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
223741439|NCT03628755|BEHAVIORAL|combination Group|combination group intervention of DMT + FST
223741440|NCT05298332|DRUG|ATI-2173 50 mg|ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
223741441|NCT03071978|DEVICE|CRT with LV-only pacing / bi-ventricular pacing|LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
223741442|NCT00749918|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
223741443|NCT06104358|DRUG|HU6|HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
223741444|NCT01902342|DRUG|Oseltamivir 75 mg 1 cap|
223741445|NCT01266460|BIOLOGICAL|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
223741446|NCT01266460|OTHER|Laboratory Biomarker Analysis|Correlative studies
223741447|NCT03756688|DEVICE|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
224145861|NCT04055467|DRUG|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
223445296|NCT00560898|DRUG|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
223445297|NCT00560898|DRUG|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
223445298|NCT01331135|DRUG|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
223445299|NCT00624832|DRUG|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
223445300|NCT00624832|DRUG|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
223568002|NCT03051412|OTHER|No Intervention|No intervention
223568003|NCT04955483|DIAGNOSTIC_TEST|Virtual single energy combined with MAR reconstruction group|combined with MAR reconstruction group
223568004|NCT04372654|DEVICE|Electroducer Sleeve|The device's safety will be assessed at the radial and femoral puncture site
223741448|NCT03756688|DEVICE|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
223741449|NCT04263207|OTHER|No intervention|No intervention
224054964|NCT07170176|DEVICE|Percutaneous Patent Foramen Ovale Closure|Percutaneous transcatheter closure of patent foramen ovale (PFO) is a minimally invasive procedure. Under local anesthesia, a closure device is delivered via a catheter through the femoral vein to the heart to seal the PFO tunnel. The procedure is performed under fluoroscopic and echocardiographic guidance. This intervention aims to eliminate right-to-left shunt, which is hypothesized to improve migraine symptoms and glymphatic function.
223445301|NCT05356650|OTHER|Mulligan Mobilization|The patient will be in a prone position. With one hand, the physiotherapist will fix the sacrum and place the fingers of her other hand under the anterior superior iliac spine. The therapist then pull the ilium on the sacrum and will instruct the patient to do press-ups. Treatment will be given with frequency of 3 sets with 10 repetitions on sacroiliac joint 3 times a week for 6 weeks
223445302|NCT05356650|OTHER|PNF|"PNF stretching will be performed using contract-relax techniques of agonists in supine, prone and side-lying. Contract-relax will be applied with a 6-second contraction with 80% force of the maximal isometric contraction on the muscles (iliopsoas, hamstrings and gluteal muscles) and will be followed by a 15-second passive static stretching in the opposite direction of that muscles. Three sets of stretching of each muscle will be performed for each position with the frequency of 3 times a week for 6 weeks.~Patient will be in supine, prone, side lying. Both groups will receive a baseline treatment (Moist Heat Pack for 10 minutes and 10 minutes of Ultrasound (0.75 MHz, continuous wave)"
223445303|NCT04920097|OTHER|In-person training for seed placement and APA|In-person seed placement and a training for the participant or their caregiver to place the seeds on the ear points.
223445304|NCT04920097|OTHER|Virtual training for seed placement and APA|Self-administer APA by placing the seeds according to the video instruction found in the self-guided smartphone application for understanding and administering APA. Participant and/or a caregiver will follow the video instruction on seed placement.
223445305|NCT04920097|OTHER|Usual Care|Participants will continue with usual care from oncologist.
223568005|NCT04079062|BIOLOGICAL|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
223568006|NCT04079062|BIOLOGICAL|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
223568007|NCT04079062|BIOLOGICAL|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
224054965|NCT07170176|OTHER|No Intervention|This arm does not receive the PFO closure procedure. Patients in this control group are observed under their standard care regimen without any study-specific intervention.
223568008|NCT04079062|BIOLOGICAL|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
223568009|NCT04079062|BIOLOGICAL|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
223568010|NCT03751358|PROCEDURE|Unilateral Erector spinae plane block|Magnetic résonance imaging
223568011|NCT03941457|BIOLOGICAL|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
223741450|NCT01393340|DRUG|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
223741451|NCT01393340|DRUG|Placebo|Placebo
223741452|NCT04923867|DEVICE|Suturable DuraGen™|Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.
224054966|NCT07171489|DEVICE|TNM at a sham-point (AccelBand) - randomized arm|"This will be self-administrated by study participants (or caregivers) for a period of approximately 4 weeks twice a day (once in the morning and once in the evening daily), each lasting 60 minutes. Scheduled weekly phone calls will be provided by the study team member to assure compliance with the TNM administration and answer any questions that a participant may have.~In addition to the treatment period participants will have tests completed (baseline and following treatment), as well as complete surveys during the trial."
224054967|NCT07171489|DEVICE|TNM at a leg point (AccelBand)- randomized arm|"This will be self-administrated by study participants (or caregivers) for a period of approximately 4 weeks twice a day (once in the morning and once in the evening daily), each lasting 60 minutes. Scheduled weekly phone calls will be provided by the study team member to assure compliance with the TNM administration and answer any questions that a participant may have.~In addition to the treatment period participants will have tests completed (baseline and following treatment), as well as complete surveys during the trial."
224054968|NCT07171489|DEVICE|TNM at a leg point (AccelBand)- open-label|After 4 weeks of blinded treatment sham participants will be given the option to continue open-label TNM treatment at a leg point acupoint. Participants that agree to this will be re-trained and allowed to keep the AccelBand for another 2 weeks. During this stage, participants will be asked to complete daily home-based TNM treatment and complete the daily online symptom questionnaires. Participants will complete a visit following this additional treatment.
224054969|NCT07170033|OTHER|Dietary Approach to Stop Hypertension (DASH) Diet|"Dietary intervention: DASH diet Participants in the intervention group will follow the Dietary Approaches to Stop Hypertension (DASH) diet for 12 weeks. The diet plan will be personalized based on each participant's 24-hour physical activity level and basal metabolic rate. Dietary adherence will be monitored through 3-day dietary intake records and DASH diet scores calculated using the Nutrition Information System (BeBiS). The intervention aims to assess the effect of the DASH diet on inflammatory markers, disease activity scores, functional status, and quality of life in adults diagnosed with seropositive rheumatoid arthritis."
223568012|NCT05495841|DEVICE|Pre-oxygenation|Process of administrating oxygen prior to intubation
223445306|NCT04920097|OTHER|Post-training zoom session for seed placement and APA coaching|Zoom session for seed placement and APA coaching, to occur after initial APA and seed placement training (initial training is either in person or guided by the smartphone app videos).
223445307|NCT06012253|OTHER|Home Based Walking Program|"The intervention group will be applied to Home Based Walking Program. It was aimed that the patients should do at least 150 minutes of moderate-intensity physical exercise per week for up to 8 weeks. The content of the program includes a walking information booklet (information notes, activity chart and obstacle avoidance form), exercise diary, face-to-face-telephone counseling, sending text messages, prepared in line with international guides. It was planned to give weekly counseling to the patients included in the intervention group for an 8-week period."
223445308|NCT06205134|DRUG|A: Epinephrine injection|Autoinjector for intramuscular, single-use, 0.3mg
223445309|NCT06205134|DRUG|B: FMXIN002 3.6mg|Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
224054970|NCT07171255|BEHAVIORAL|RemoteEx+ Programming|The exercise program will include video instruction for all exercises, motivational cues, and ADRD risk education throughout the 16-week exercise program to encourage exercise adherence. RemoteEx+ is optimized to enhance exercise knowledge surrounding dementia risk factors to facilitate ADRD risk reduction and overall health improvement. The purpose of this study is to investigate the efficacy of RemoteEx+ on health outcomes associated with dementia risk in underactive rural adults.
223445310|NCT06205134|DRUG|C: FMXIN002 4.0mg|Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril
223445311|NCT01030471|BEHAVIORAL|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
223445312|NCT01028495|DRUG|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
223445313|NCT00285792|BEHAVIORAL|Physical Activity|
223445314|NCT04634032|GENETIC|mRNA expression and SNP analysis|mRNA expression and SNP analysis from samples
224054971|NCT07170618|DEVICE|balloon microcatheter|The balloon microcatheter simultaneously possesses both balloon dilatation and device delivery functions.
224054972|NCT07170436|BEHAVIORAL|Short version of cognitive testing during surgery|Cognitive testing in 3 blocks of 3 minutes during awake surgery
224054973|NCT07170007|OTHER|Physiotherapeutic protocol|"The women randomized to the Intervention Group will receive the following interventions:~During hospitalization: Pelvic Floor Muscle Contraction, observing the participant's ability to contract and advising on how to perform it, associated with cryotherapy and information on physiotherapy in women's health, pelvic floor muscles and its dysfunctions, as well as guidance on the care to be taken during hospitalization and after discharge, including guidance on postures to be adopted or avoided, breathing control, load management, intimate hygiene and the use of cryotherapy at home for pain relief.~After hospitalization, up to 3 months after delivery: Pelvic Floor Muscle Training in weekly online sessions and guidance to carry out the training daily at home, with the same protocols and without supervision. A total of 12 individual online sessions."
223445315|NCT04634032|DIAGNOSTIC_TEST|Blood sampling|Peripheral blood sampling for SNP analysis
223568013|NCT02502669|DRUG|Finasteride 23.5 mg tablets|
223568014|NCT02502669|DRUG|Finasteride 33.5 mg tablets|
223568015|NCT02502669|DRUG|Placebo tablets|
223568016|NCT03090386|OTHER|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
223568017|NCT05709717|PROCEDURE|Regenerative therapy with SVF-PRP to supplement perianal surgery|Regenerative therapy with autologous stromal vascular fraction derived mesenchymal stem cells and platelet-rich plasma to supplement perianal surgery
223568018|NCT01710943|BEHAVIORAL|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
223568019|NCT01165320|DRUG|Caspofungin|
223568020|NCT02938832|BEHAVIORAL|Advice on what food to choose and eat|Dietary advice
223568021|NCT01234805|PROCEDURE|yoga therapy|Participates in yoga classes and yoga at home
223568022|NCT01234805|OTHER|questionnaire administration|Ancillary studies
223568023|NCT01234805|PROCEDURE|quality-of-life assessment|Ancillary studies
223568024|NCT01727115|OTHER|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~* If the challenge is positive: The children continue the assigned formula~* If the challenge is negative: A Follow up formula is given~  * (Nan pro2) if child \> 6 months~ * (Nan pro1) if child \< 6 months"
223568025|NCT04860895|DIAGNOSTIC_TEST|AP-23|AP-23 newly developed point of care system as a well-automated combination of multi-spectral technology and a distributed cloud computing A.I. system which has been developed to detect COVID-19.
223568026|NCT01284478|DRUG|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
223568027|NCT02186054|DEVICE|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
223568028|NCT03826173|BEHAVIORAL|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
223445316|NCT02981563|OTHER|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
223445317|NCT03728998|OTHER|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~* 1\. Starting in semi-succumbed position (45 degree head-up)~* 2\. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
223445318|NCT03728998|OTHER|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
223445319|NCT05409508|OTHER|mindfulness meditation care|mindfulness meditation care
223445320|NCT05409508|OTHER|no mindfulness meditation care|no mindfulness meditation care
223445321|NCT00653978|PROCEDURE|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
223445322|NCT00653978|PROCEDURE|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
223445323|NCT01081405|OTHER|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
223445324|NCT02994641|PROCEDURE|COMA Score Assessment|
223445325|NCT02593955|BEHAVIORAL|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
224054974|NCT07170007|OTHER|Usual maternity care|Participants in the control group will receive standard postpartum care for perineal trauma from the maternity hospital, which includes suturing the injury and oral analgesic medication.
224054975|NCT07170904|OTHER|Not applicable- observational study|This is an observational study; no interventions are administered to participants.
224054976|NCT07170943|OTHER|Blueberry|Daily consumption of blueberries
224145862|NCT04055467|BEHAVIORAL|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
223445326|NCT02593955|BEHAVIORAL|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
223445327|NCT01054313|DRUG|Docetaxel (Taxotere)|Starting dose 30 mg/m\^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
223445328|NCT01054313|DRUG|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
223445329|NCT01054313|DRUG|Prednisone|5 mg by mouth twice a day with prostate cancer.
223445330|NCT06142734|PROCEDURE|pyeloplasty|"* For laparoscopic pyeloplasty:~* Anaesthesia: general~* Position: a 45-degree lateral decubitus position with the concerned side up. Patient is secured to the operating table. Pneumoperitoneum is adopted through a camera port lateral to the umbilicus~* extra operating ports are created at subcostal and at spinoumbilial line.~* the UPJ is transperitoneally accessed by incising the white line of Toldt and the ipsilateral colon is reflected and the proximal ureter and the pelvis are identified an mobilized~* then Anderson- Hynes pyeloplasty is carried out with insertion of nephroureterostomy or pyeloureterostomy tube."
223445331|NCT03013790|DRUG|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
223445332|NCT04691687|DRUG|Furosemide|IV loop diuretic therapy
223445333|NCT04691687|DRUG|IV Solution|IV Placebo comparator
223445334|NCT01522131|PROCEDURE|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
223445335|NCT04801043|DRUG|XNW4107|XNW4107 250mg IV over 60 minutes as a single dose
223445336|NCT04801043|DRUG|Imipenem/Cilastatin|500mg/500mg IV over 60 minutes as a single dose
223445337|NCT04801043|DRUG|placebo|"Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose"
223445338|NCT00650728|PROCEDURE|placing gastric tube|
224054977|NCT07170943|DIETARY_SUPPLEMENT|Freeze-dried blueberry powder|Daily consumption of a freeze-dried blueberry powder
224054978|NCT07170943|DIETARY_SUPPLEMENT|Placebo powder|Daily consumption of a placebo powder
223445339|NCT03339557|DEVICE|NexGen|Comparing two conventional designs and one novel design
223445340|NCT03339557|DEVICE|Persona|Comparing two conventional designs and one novel design
223445341|NCT03339557|DEVICE|PFC|Comparing two conventional designs and one novel design
223445342|NCT00497341|DRUG|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
224054979|NCT07171411|DIETARY_SUPPLEMENT|Whey Protein + Collagen|Participants consumed 30 g/day whey protein isolate (Optimum Nutrition) combined with 10 g/day type I \& III collagen peptides (Vital Proteins). Supplements were provided as single-dose sachets, identical in appearance, and taken twice daily (morning and post-exercise or same time on rest days) for 8 weeks.
224054980|NCT07171411|DIETARY_SUPPLEMENT|Whey Protein|Participants consumed 30 g/day whey protein isolate (Optimum Nutrition), in identical sachets, taken twice daily for 8 weeks.
224054981|NCT07171411|DIETARY_SUPPLEMENT|Collagen Peptides|Participants consumed 10 g/day type I \& III collagen peptides (Vital Proteins), in identical sachets, taken twice daily for 8 weeks.
224145863|NCT00525785|DRUG|5-Fluorouracil|"2.2 Gm/m\^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
224145864|NCT00525785|DRUG|Folinic Acid|200 mg/m\^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
224145865|NCT00525785|DRUG|Oxaliplatin|"100 mg/m\^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m\^2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
223445343|NCT00497341|DRUG|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
223445344|NCT03514056|DIAGNOSTIC_TEST|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
223445345|NCT03514056|DIAGNOSTIC_TEST|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
223445346|NCT05357885|DIAGNOSTIC_TEST|SARS-CoV-2 Antibody test|SARS-CoV-2 antibody test at Jefferson is Roche Elecsys Anti-SARS-CoV-2 immunoassays performed under FDA's Emergency Use Authorization.
223445347|NCT03714776|DRUG|Placebo|Placebo matching solution administered as SC injection.
223445348|NCT03714776|DRUG|ISIS 757456|Administered as SC injection.
223445349|NCT01269099|DRUG|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
223445350|NCT01269099|DRUG|Control|control group (No-PCA group)
223445351|NCT01122069|OTHER|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
223445352|NCT04140084|DEVICE|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
223445353|NCT00423358|DIETARY_SUPPLEMENT|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
223445354|NCT00423358|DIETARY_SUPPLEMENT|placebo|matching placebo
224054982|NCT07171411|OTHER|Maltodextrin (Placebo)|Participants consumed 10 g/day maltodextrin powder (isocaloric to protein supplements), packaged identically, taken twice daily for 8 weeks.
224054983|NCT07169760|BEHAVIORAL|Meta Quest 3 VR Headset with noise cancelling headphones|Wearing the headset and headphones removes all outside audio and visual distractions. One of the groups receives frequent and consistent feedback about work productivity similar to behavioral interventions for ADHD.
224054984|NCT07171359|DEVICE|TMS Low-Dose|one 3-minute session of TMS TBS delivered each morning, prior to commencement of their regularly scheduled daily therapy activities, for 5 days/week, for a total of four-weeks (20 sessions total).
224054985|NCT07171359|DEVICE|TMS High-Dose|One 9-minute session of TMS TBS delivered each morning, prior to commencement of their regularly scheduled daily therapy activities, for 5 days/week, for a total of four-weeks (20 sessions total).
223445355|NCT04279990|OTHER|No intervention: assessment of GI function|"Gastrointestinal function is assessed by the intragastric pressure measurement by a high resolution manometry. This is an examination test considered standard of care for the diagnosis of functional dyspepsia in the university hospital of leuven.~The joint hypermobility syndrome is assess by means of the Brighton criteria."
223445356|NCT06195176|OTHER|Shoulder exercises|"Operational Definition:~* Lift the shoulders as high as possible toward the ears.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
223445357|NCT06195176|OTHER|Hand exercises|"Operational Definition:~* Open and close the hands, making a fist and applying force.~* Maintain this position for 3 seconds.~* Rest.~* Repeat 10 times at the beginning of each hour during the immediate postoperative period on the hospital ward.~* Suspend during the night."
223445358|NCT03636048|DRUG|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
223445359|NCT03636048|DRUG|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
223445360|NCT06965504|DEVICE|Impella 5.5 SmartAssist|The intervention is Impella 5.5 with SmartAssist® support combined with heart failure guideline directed medical therapy (GDMT).
223445361|NCT03517449|DRUG|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
223445362|NCT03517449|DRUG|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
223445363|NCT03517449|DRUG|Paclitaxel|80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
223445364|NCT03517449|DRUG|Doxorubicin|60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
224054986|NCT07171268|BEHAVIORAL|Yoga Asana Chandra Harmoni|"Description: Participants randomized to the intervention group will receive the Yoga Asana Chandra Harmoni program. This program is designed to improve psychological well-being, sleep quality, and self-directed learning readiness.~Components:~Initial Face-to-Face Session: Participants will attend one in-person session led by a qualified yoga instructor. This session will introduce the principles of Yoga Asana Chandra Harmoni and provide instruction on the core asana sequence, breathing techniques (pranayama), and meditation.~Weekly Yoga Sessions: Participants will engage in three 45-minute yoga sessions per week for four weeks, practicing the Yoga Asana Chandra Harmoni sequence.~Video Support: Participants will be provided with a video demonstrating the Yoga Asana Chandra Harmoni sequence to support their home practice. The video will be shared individually via Whatsapp.~Home Practice: Participants are expected to practice the Yoga Asana Chandra Harmoni sequence independently at home,"
224070840|NCT04647292|OTHER|Standard of Care Blood Pressure Management with Antihypertensives|Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.
224070841|NCT01972230|DRUG|Sevoflurane|
224070842|NCT01972230|DRUG|Diprivan + Remifentanil TCI|
224070843|NCT05344456|DEVICE|Change in the device PVC algorithm to ''Off''|PVC algorithm change from Atrial Pace mode to Off
223445365|NCT05835063|BEHAVIORAL|We Chatt communication tool|This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.
223445366|NCT05835063|BEHAVIORAL|Usual/standard care|Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
223445367|NCT06361498|DEVICE|Ultrasound Imaging|Participant will receive ultrasound imaging to evaluate the replaced G-tube placement.
223445368|NCT01245816|DRUG|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
223445369|NCT01245816|DRUG|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
223445370|NCT01245816|DRUG|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
223445371|NCT05008445|BIOLOGICAL|LM-102 Injection|LM-102 Injection with dose escalation stage of 3mg/kg up to 40mg/kg, as well as dose expansion stage with recommended dose level from dose escalation stage.
223445372|NCT05008445|COMBINATION_PRODUCT|LM-102 Injection combined with SOC|LM-102 Injection with appropriate dose level(s), combined with SOC.
223445373|NCT05804227|DRUG|Ulixertinib|Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
223445374|NCT05503875|BIOLOGICAL|adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate|Psoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
223445375|NCT00913224|DRUG|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
223445376|NCT00913224|DRUG|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
223445377|NCT02671734|BEHAVIORAL|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
223445378|NCT05587413|PROCEDURE|periodontal care|periodontal treatment
223445379|NCT00864136|DRUG|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
223445380|NCT00864136|DRUG|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
223445381|NCT00864136|DRUG|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
223445382|NCT04965103|PROCEDURE|SCR|Superior Capsule reconstruction
223445383|NCT04965103|PROCEDURE|Bridging|Tendon repair with graft interposition
223445384|NCT00901979|DRUG|LCQ908A|
223445385|NCT00901979|DRUG|LCQ908A|
223568029|NCT03826173|BEHAVIORAL|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
224054987|NCT07171567|DEVICE|Vacuum erection device|"A vacuum erection device (VED) is a mechanical device designed to enhance blood flow to the corpora cavernosa by creating a vacuum environment. When combined with a constriction ring at the base of the penis, VEDs can promote and sustain an erection.~This is a prospective, uncontrolled, hypothesis-generating pilot study. Eight adult male participants with penile insensitivity will be enrolled and asked to use a VED daily for six months. Monthly self-reported questionnaire data and biweekly follow-up calls will be used to assess feasibility and to collect exploratory outcome data."
224054988|NCT07169981|DRUG|Empagliflozin 10 MG [Jardiance]|This intervention consists of Empagliflozin 10 mg oral tablets administered once daily for a duration of 6 months. The drug is used in this study to evaluate its effect on left ventricular remodeling in patients with heart failure. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes and heart failure. In this trial, it is being investigated specifically for its impact on cardiac structure and function.
224145866|NCT00525785|RADIATION|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
223445386|NCT00901979|DRUG|LCQ908A|
223445387|NCT00901979|DRUG|LCQ908A|
223445388|NCT00901979|DRUG|LCQ908A|
223445389|NCT00901979|DRUG|Placebo|
223445390|NCT00901979|DRUG|Sitagliptin|
223445391|NCT00901979|DRUG|metformin|
223445392|NCT00772187|DRUG|morphine|Single dose: 0.1-0.5 mg
223445393|NCT00772187|DRUG|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
223445394|NCT00772187|DRUG|general anesthesia (fentanyl)|general anesthesia alone
223445395|NCT01069770|DRUG|Sunitinib|50mg daily(4 weeks on \& 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
223445396|NCT03811054|DRUG|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
223445397|NCT02779660|PROCEDURE|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
223445398|NCT02779660|PROCEDURE|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
223445399|NCT00543920|DRUG|MK0777|
223445400|NCT05277350|DRUG|SNIPR001|SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
223445401|NCT05277350|DRUG|Placebo|Matching placebo
223445402|NCT05328284|DEVICE|PASCAL leaflet repair system|transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
223445403|NCT05952713|DRUG|Antidepressant|Treatment with an antidepressant according to Danish register data.
223445404|NCT04851418|DEVICE|Possible NSTE-ACS|As mentioned in the group description
223445405|NCT05590533|OTHER|Cultural adaptation, reliability and validity|Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the F-2-MS
223445408|NCT04412642|DRUG|Methoxyflurane, MEOF|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
223445409|NCT00528632|OTHER|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
223445410|NCT02005627|DRUG|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
223445411|NCT02005627|DRUG|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
223445412|NCT06628388|BEHAVIORAL|Nurse-Led Risk-Based 5As Primary Healthcare Model|The intervention is developed based on the 5As model (ask, advice, assess, assist, arrange). In this model, nurse will play the central role in delivering the service as a case manager. In Ask, all participants will be assessed on the demographics, health related status, and health risk stratification (i.e. 3-tier risk stratification). In Advice, all participants will be given the education booklet. Those assessed to be at low risks will receive general advice, while those at medium risk will receive condition-specific advice instead. High risk participants will be provided with referral suggestions. The assessment of medium or high risk participants willingness and any barriers in seeking changes will be conducted in Assess. In Assist, active referrals will be provided to high risk participants, with weekly advice messages provided to medium and high risk participants. In Arrange, all participants will receive their follow-ups.
223445413|NCT06628388|BEHAVIORAL|Minimal Intervention|Consisting general advice on women health with the education booklet. No risk-based services nor active referral will be offered during the waitlist control exposure. Participants will be switched to receive intervention from 6-month.
223445414|NCT03865394|BIOLOGICAL|Application of allogeneic ADSC stem cells in fibrin gel|Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.
223445415|NCT03865394|PROCEDURE|Standard care in diabetic foot ulcer|Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.
223445416|NCT01054391|DEVICE|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
223445417|NCT00946894|PROCEDURE|Total thyroidectomy|Total thyroidectomy
223445418|NCT00946894|PROCEDURE|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
223445419|NCT00946894|PROCEDURE|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
223445420|NCT05672589|DIAGNOSTIC_TEST|Relaxed Rotational Thromboelastometry|Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
223445421|NCT05672589|DIAGNOSTIC_TEST|Standard Coagulation Tests|Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
223568030|NCT02076308|OTHER|Electroacupuncture and physical therapy|real electroacupuncture
223445422|NCT05948839|DEVICE|active rTMS treatment|Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
223445423|NCT05948839|DEVICE|sham rTMS treatment|The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
223445424|NCT03438058|OTHER|Graft survival and/or Rejection appearance|
223445425|NCT04757324|OTHER|breastfeeding education|
223445426|NCT01192724|DRUG|Cilostazol|100 mg BID, for 3 months
223445427|NCT01192724|DRUG|Aspirin|Aspirin 100 mg QD, for 1 year
223445428|NCT01192724|DRUG|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
223445429|NCT02958332|OTHER|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
223445430|NCT03274752|DRUG|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
223445431|NCT03274752|DRUG|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
223445432|NCT00507832|DRUG|Pimecrolimus|twice daily topical
223445433|NCT00507832|DRUG|Hydrocortisone|twice daily topical
223445434|NCT00507832|DRUG|Pimecrolimus|topical application as a cream twice daily
223445435|NCT00548249|DEVICE|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
223568031|NCT02076308|OTHER|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
223568032|NCT00385944|DRUG|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
223568033|NCT00385944|DRUG|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
223568034|NCT02022215|DRUG|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
223568035|NCT02022215|DRUG|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
223568036|NCT02022215|DRUG|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
223568037|NCT02562508|PROCEDURE|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
223568038|NCT02562508|PROCEDURE|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
223445436|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
223741453|NCT03024307|OTHER|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
224054989|NCT07169981|DRUG|empagliflozin (Jardiance) 25 mg|This intervention consists of Empagliflozin 25 mg oral tablets administered once daily for a duration of 6 months. The drug is used in this study to evaluate its effect on left ventricular remodeling in patients with heart failure. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes and heart failure. In this trial, it is being investigated specifically for its impact on cardiac structure and function.
223445437|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
223568039|NCT05664347|BEHAVIORAL|Verbal teach to goal education|Participants were showed how to use correctly their inhalers and then asked again to show the technique. For each incorrect step, the patients were corrected and asked to repeat the steps until they mastered the technique. This process was repeated a maximum of three times.
223568040|NCT05664347|BEHAVIORAL|Video based teach to goal education|Participants were educated by the a video-based teach to goal method. using a smartphone, an educational video illustrating the correct technique for each of the inhalers used by the patient was displayed. After watching the video, the patients were asked to show again how to use their inhaler and for each wrong step the video was displayed again until mastering the correct technique a maximum of three times. At the end of the interview participants in the intervention group received a copy of the video via WhatsApp and were all invited to watch the video whenever needed.
223568041|NCT01833260|BEHAVIORAL|Music|
223568042|NCT01155466|DRUG|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
223568043|NCT01155466|DRUG|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
223568044|NCT01155466|DRUG|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
223568045|NCT01155466|DRUG|Placebo to Preladenant Tablet|one tablet orally twice daily
223568046|NCT01155466|DRUG|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
223568047|NCT01155466|DRUG|Placebo to Rasagiline capsule|one capsule orally in AM
223568048|NCT02114125|BEHAVIORAL|Physical Activity|group-based physical activity
223568049|NCT02114125|BEHAVIORAL|Cognitive Training|individual-based, multi-domains cognitive training
223568050|NCT01382004|DRUG|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
223445438|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
223445439|NCT00548249|DRUG|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
223568051|NCT01382004|DRUG|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
223741454|NCT06038279|DRUG|INI-2004|INI-2004 (a toll-like receptor \[TLR\]4 agonist) liposomal formulation. INI-2004 is an intranasal (IN) TLR4 agonist that is targeted to prevent AR symptoms in subjects with seasonal AR.
223741455|NCT06038279|DRUG|Placebo|The Placebo for INI-2004 is a clear, colorless solution free of particles supplied in 10 mL glass vials with a 10 mL fill.
223741456|NCT05436925|DEVICE|Dexcom G6 sensor Continuous Glucose Monitor (CGM)|The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
223741457|NCT00859235|DRUG|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
223741458|NCT00859235|OTHER|Plain water|Mouth wash prior to procedure
223741459|NCT01897142|BIOLOGICAL|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
223741460|NCT01897142|DRUG|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
224070844|NCT02896595|DEVICE|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
224145867|NCT00525785|PROCEDURE|Surgery|4-6 weeks after completion of chemoradiotherapy, restaged \& surgical resection of the primary tumor and lymph nodes attempted.
224145868|NCT04005807|DRUG|BPN-14967|BPN-14967 oral capsules
224145869|NCT04005807|DRUG|Placebo|Oral capsules
224145870|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams once daily
224145871|NCT01316939|DRUG|Placebo|Placebo
224145872|NCT01316939|DRUG|GSK1605786A|GSK1605786A 500 milligrams twice daily
223445440|NCT03003000|DRUG|ibuprofen|
223445441|NCT03003000|DRUG|caffeine|
223445442|NCT03003000|DRUG|placebo|
223445443|NCT03464942|RADIATION|SABR|Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.
223445444|NCT03464942|DRUG|Atezolizumab|All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
223445445|NCT01678599|DRUG|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients \> 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
223445446|NCT02527915|OTHER|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
223445447|NCT02527915|OTHER|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
223445448|NCT03998137|DEVICE|AUGMENT® Injectable Bone Graft|AUGMENT® Injectable Bone Graft
224054990|NCT07170605|BEHAVIORAL|Mental health, positive coping strategies promoting self-regulation and adaptive skills|"The BRP manual includes eight modules delivered over eight weeks: introduction to resilience, identifying and communicating emotions, emotional regulation, coping strategies for self-regulation (2 parts), breath awareness/meditation, applying positive coping strategies, and review/group session with caregiver. Sessions utilize play as the primary occupation, introducing resiliency concepts through 40-60 minute sessions three times each week to provide repetition and application of concepts with multiple opportunities to review, repeat and apply.~Each BRP session will be implemented by two occupational therapists, one occupational therapy student, and one YWCA staff member. Group size has been determined to approach therapeutic limits with 8-10 students, requiring this staffing ratio for optimal intervention delivery."
224054991|NCT07170605|OTHER|Standard care/School Readiness Condition|The School Readiness protocol supplements existing preschool curriculum while mitigating positive researcher interaction effects. Sessions start with a song and warm-up, including active listening, sharing and turn-taking while targeting different domains each week: perceptual motor, fine motor (tool use), fine motor (coloring), problem solving, teamwork, coordination and motor planning, problem solving (teams), and gross and fine motor (teams). These skills were selected based on feasibility study observations and designed not to overlap with social-emotional skills embedded in the BRP.
224054992|NCT07171294|PROCEDURE|Minimal invasive hemorrhoidectomy|We propose applying minimally invasive surgery in open excisional hemorrhoidectomy, the most effective technique for treating advanced hemorrhoidal disease. We believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of OEH. Our hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.
224054993|NCT07170293|DRUG|Tunlametinib|Do not chew, dissolve or open the capsule. If you miss a dose of medication, you can take the missed dose 8 hours before the next dose. If the time until the next medication is less than 8 hours, it is not recommended to take it again. Every 21 days for one cycle, subjects will use the investigational drug until the treatment termination criteria specified in the protocol are met. The recommended dosage for the first dose reduction is 9mg, twice daily. The recommended second dose reduction is 6mg, twice daily.
224054994|NCT07171372|OTHER|Device&behavioral|The IoT-HFActive intervention is a 12-month personalized program delivered via a mobile app, integrating patient-centered goal setting, real-time monitoring, and behavioral support. Intervention group participants will first attend two structured education sessions on exercise in HF and the use of the app and smart wristbands. They will then complete 12 supervised group-based sessions (3×50 min/week for 4 weeks) including warm-up, moderate aerobic exercise, and cool-down. Personalized activity goals will be calculated using heart rate reserve (HRR) via the Karvonen formula and exponential weighted moving average (EWMA) based on wristband data. Continuous remote monitoring will display target HR, achieved minutes, calories, and steps, and include daily confirmation prompts. Behavioral support features of the app will provide personalized feedback, motivational messages, visualizations, and monthly goal re-planning to promote adherence and reduce sedentary behavior.
224054995|NCT07170124|OTHER|Obstetric exercises|"The intervention will consist of a structured obstetric exercise program administered by a physiotherapist who is permanently employed at the hospital's prenatal education center, ensuring the reliability and standardization of the intervention. The program will be based on the Pregnancy and Exercise Guide (2012) published by the Turkish Ministry of Health and will be delivered in the pregnancy school of a public hospital in eastern Türkiye.~The exercises will be provided at weekly intervals and will include:~Active joint movements to improve mobility and maintain functional range of motion,~Stretching exercises to enhance flexibility and alleviate musculoskeletal discomfort,~Calisthenic bodyweight exercises to promote muscle strength and endurance,~Relaxation and breathing techniques to reduce stress and improve maternal well-being."
224054996|NCT07169838|OTHER|Perinatal Tissue Collection|Collection of perinatal medical waste (amniotic fluid, amniotic membrane, umbilical cord, placenta) at the time of term delivery for laboratory-based mesenchymal stem cell isolation and analysis. No therapeutic or interventional procedure was performed on participants.
224054997|NCT07171528|PROCEDURE|Secondary Cytoreductive Surgery|"Surgery will only be performed in patients assigned to the experimental arm of the study.~The goal of secondary cytoreductive surgery is to achieve complete tumor reduction by removing all visible residual tumors (Complete cytoreduction with no macroscopic residual disease), and this effort should be the top priority."
224054998|NCT07170995|DRUG|SHR-8068，adebelizumab and platinum-based chemotherapy|SHR-8068，adebelizumab and platinum-based chemotherapy
224054999|NCT07170995|DRUG|tislelizumab, and platinum-based chemotherapy|tislelizumab, and platinum-based chemotherapy
223445449|NCT03998137|PROCEDURE|Standard of Care|Autologous Bone Graft
223445450|NCT01178814|DRUG|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
223445451|NCT01715142|DRUG|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
223445452|NCT01715142|DRUG|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
223445453|NCT04933617|BIOLOGICAL|Rituximab|Rituximab 375 mg/m\^2 intravenous (IV) per protocol on Day 1 of each cycle up to 6 cycles
223445454|NCT04933617|DRUG|Etoposide|Etoposide 50 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
223445455|NCT04933617|BIOLOGICAL|Copanlisib|Copanlisib intravenous (IV) is administered at a fixed dose (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle for up to 6 cycles
223445456|NCT04933617|DRUG|Cyclophosphamide|Cyclophosphamide 750 mg/m\^2 intravenous (IV) on Day 5 of each cycle up to 6 cycles
223445457|NCT04933617|DRUG|Doxorubicin|Doxorubicin 10 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
223445458|NCT04933617|DRUG|Vincristine|Vincristine 0.4 mg/m\^2/day (no cap) continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
223445459|NCT04933617|DRUG|Prednisone|Prednisone 60 mg/m\^2 by mouth (PO) twice a day (BID) Days 1-5 (total 120mg/m\^2/day)
223445460|NCT04933617|DIAGNOSTIC_TEST|ECHO|At screening.
223445461|NCT04933617|DIAGNOSTIC_TEST|EKG|At screening.
223445462|NCT04933617|DIAGNOSTIC_TEST|MRI Brain|At screening.
223445463|NCT04933617|DIAGNOSTIC_TEST|18F-FDG - PET|At screening, baseline, after cycle 1, 3, and 6, and end of treatment.
223445464|NCT04933617|DIAGNOSTIC_TEST|CT Scan|At screening, baseline, after cycle 1, 3, and 6, end of treatment and follow-up.
223445465|NCT04933617|PROCEDURE|Bone Marrow Aspiration|At screening and end of treatment.
223445466|NCT04933617|PROCEDURE|Bone Marrow Biopsy|At screening and end of treatment.
223445467|NCT04933617|DIAGNOSTIC_TEST|Lumbar Puncture (LP)|Baseline and end of treatment.
223568052|NCT00590824|DRUG|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
223568053|NCT00590824|DRUG|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
224145873|NCT03039049|DRUG|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
224145874|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intravenous infusion Subjects will receive conditioning therapy by ludarabine and Cyclophosphamide before cell infusion.
224145875|NCT06126406|BIOLOGICAL|CEA-targeted CAR-T cells|Administration method: intraperitoneal injection Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
223445468|NCT00490672|BEHAVIORAL|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
223445469|NCT00490672|BEHAVIORAL|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
223445470|NCT04344522|PROCEDURE|Descemet membrane endothelial keratoplasty DMEK|DMEK : it involves separating the Descemet membrane from a corneal donor graft , doing a descematorhexis in the recepient cornea , loading and injection of the graft into the anterior chamber , unfolding and fixing the graft to the recepient cornea by intracameral air bubble.
223445471|NCT04344522|PROCEDURE|IOL exchange|IOL exchange : it involves performing a corneoscleral tunnel , freeing the AC IOL from any adhesions and explanting it through the tunnel , then implanting a posterior chamber PMMA lens or iris claw lens if there is no adequate capsular support.
223445472|NCT04344522|PROCEDURE|iridoplasty|iridoplasty : repairing any iris defect by using 10/0 prolene.
223445473|NCT04344522|PROCEDURE|Inferior peripheral iridectomy|Inferior peripheral iridectomy : performed by vannus scissor to avoid postoperative pupillary block due to the intracameral air .
223445474|NCT02658708|OTHER|Bright blue-green light using light visor cap|
223445475|NCT02658708|OTHER|Dim red light using light visor cap|
223445476|NCT02658708|OTHER|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
223445477|NCT02658708|OTHER|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
223445478|NCT02658708|OTHER|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
223568054|NCT00445107|DRUG|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
223568055|NCT04429386|PROCEDURE|Bariatric surgery|Laparoscopic bariatric surgery including gastric bypass and sleeve gastrectomy
223568056|NCT00834990|DRUG|divalproex sodium|delayed-release 500 mg tablet
223568057|NCT00834990|DRUG|Depakote®|delayed-release 500 mg tablet
223568058|NCT04352088|PROCEDURE|Nasal provocation test|Allergen extract under controlled conditions will be applied into nasal mucous.
223568059|NCT00003914|DRUG|dolastatin 10|
223568060|NCT02195999|OTHER|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
223568061|NCT02195999|OTHER|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
223568062|NCT02195999|OTHER|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
223568063|NCT02195999|OTHER|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
223741461|NCT01897142|BIOLOGICAL|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
223741462|NCT01897142|DRUG|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
224145876|NCT01291706|DEVICE|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
224145877|NCT05255341|PROCEDURE|roll pedicle connective tissue graft with bovine bone|rotated pedicle connective tissue graft together with bovine bone applied for socket preservation after tooth extraction
223445479|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
223445480|NCT02658708|OTHER|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
223445481|NCT02658708|DIAGNOSTIC_TEST|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
223568064|NCT03584841|DIAGNOSTIC_TEST|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
223568065|NCT01114971|DRUG|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
223568066|NCT01114971|DRUG|Labetalol|"Labetalol 5 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
223568067|NCT01114971|DRUG|Esmolol|"Esmolol 10 mg/ml boluses will be given:~* at the induction time~* at the time before surgical incision, and~* as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR \> 80 bpm)"
223568068|NCT00791479|DRUG|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
223568069|NCT00791479|DRUG|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
223568070|NCT05525052|OTHER|Trans-Facet fixation|Trans-facet fixation (TFF) under local anesthesia and double fluoroscopic and CT guidance is a minimally invasive technique involving the placement of screws through the posterior facet joints, improving spinal stability.
223568071|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for 120 days
223568072|NCT05308472|DRUG|DISC-1459|Oral dose level 2, once a day for 120 days
223568073|NCT05308472|DRUG|Placebo|Oral dose, once a day for 120 days
223568074|NCT05308472|DRUG|DISC-1459|Oral dose level 1, once a day for up to 8 months
223568075|NCT05978960|OTHER|Nutrition and resistance training exercise intervention|"3 month 2-3 times/week, 60 min exercise regimen utilizes compound movements to focus on body composition, strength, and mobility. Classes are run by certified strength and conditioning specialists and adjusted for linear progression and safety, progressing from compound to isolated movements to maximize safety.~The nutrition intervention focuses on dietary quality by following a healthy low-carbohydrate diet, focusing on nutrient dense foods high and avoiding processed foods and simple carbohydrates to keep totals under 100g/day. Participants will be advised to eat vegetables, avoid snacking, cook all meals with family and friends, avoid eating on the run, and focus on whole foods that require preparation. Calculations and quantification of calories will be avoided, while protein consumption goals are 1.3-1.8 g/kg per. Dietary strategy will be continuously discussed during exercise sessions and the PI will have twice monthly meetings with participants."
223568076|NCT06298617|PROCEDURE|Diagnostic laparoscopy|All women will undergo exploratory laparoscopy under general anesthesia
223741463|NCT01897142|BIOLOGICAL|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
223741464|NCT01897142|DRUG|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
223741465|NCT01897142|BIOLOGICAL|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
223568077|NCT06298617|DIAGNOSTIC_TEST|Full Blood Count (FBC)|Blood samples withdrawn from patients on EDITA tubes and gone through full blood count and differential leucocytic count
223741466|NCT01897142|DRUG|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
223741467|NCT01897142|BIOLOGICAL|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
223741468|NCT01897142|DRUG|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
223741469|NCT01897142|BIOLOGICAL|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
223741470|NCT01897142|DRUG|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
223741471|NCT01132547|DRUG|cyproheptadine hydrochloride|Given orally
223741472|NCT01132547|OTHER|placebo|Given orally
223741473|NCT03407573|BIOLOGICAL|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
223445482|NCT02658708|DIAGNOSTIC_TEST|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
223445483|NCT02658708|OTHER|Horne-Ostberg Morningness-Eveningness Questionnaire|
223741474|NCT05811234|DRUG|CAL/BDP PAD Cream|As provided in real-world clinical practice.
223741475|NCT00259077|DRUG|Omeprazole|
223741476|NCT01224847|DRUG|Tetracaine|1 gtt
223741477|NCT01224847|DRUG|Cocaine|1 gtt
223741478|NCT01224847|DRUG|Lidocaine|Lidocaine soaked pledget
223741479|NCT05875155|DIAGNOSTIC_TEST|Infectious Disease Labwork|Infectious disease labs will be drawn and resulted.
223741480|NCT05875155|DIAGNOSTIC_TEST|Fertility-Based Labwork|Other labwork to understand fertility may be drawn.
223741481|NCT04658537|RADIATION|Radiation Therapy|Cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumours
223741482|NCT04499781|BEHAVIORAL|ACCESS II mHealth Intervention|Participants in the intervention condition will use videoconferencing to connect synchronously with trained HIV+ peer health coaches who will deliver eight weekly, 60-minute cognitive behavioral, motivational sessions for improved ART adherence.
224055000|NCT07160413|DEVICE|Electric and electromagnetic stimulation|Application of electromagnetic and electric stimulation using coils of different designs and electrodes to assess peripheral nerve sensitivity. The stimulation is momentary, non-therapeutic, and performed for basic science research purposes
223445484|NCT02658708|OTHER|Daily Fatigue and Sleep Log|"* Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness~* Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
223445485|NCT00974038|BEHAVIORAL|psychotherapy|1\) cognitive-behavioral therapy or 2) supportive psychotherapy
223445486|NCT03603288|DRUG|idebenone 150 mg film-coated tablets|900 mg idebenone/day
224055001|NCT07169825|DRUG|Lu-177|Given by IV
223445487|NCT02451397|OTHER||This is a cross-sectional study, and we do not assign specific interventions to the subjects of the study.
223445488|NCT04049305|DEVICE|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
223568078|NCT05424978|OTHER|Standardized green channel treatment methods for stroke|The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.
223568079|NCT01684709|BEHAVIORAL|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
223568080|NCT05059821|BIOLOGICAL|Peptide cancer vaccine|Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
223568081|NCT02624063|DRUG|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
223568082|NCT02624063|DRUG|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
224055002|NCT07169825|OTHER|SPECT|SPECT/CT
223568083|NCT01778049|DRUG|BI 10773|Empagliflozin active
223741483|NCT04499781|BEHAVIORAL|ACCESS II control condition|Web-based HIV adherence education. Participants in the control group will connect asynchronously to a web-based HIV ART adherence education condition.
223741484|NCT05481073|DEVICE|UV sensor|Use of UV sensor to be informed about the sun exposure daily through a mobile application
223445489|NCT04049305|PROCEDURE|conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
223568084|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
223568085|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
224055003|NCT07170462|DRUG|Cranberry powder|Cranberry whole powder equivalent to 100 g of fresh cranberries, 525 mg total (poly)phenols), and approximately 3.6 g of fiber.
224055004|NCT07170462|DIETARY_SUPPLEMENT|Placebo|placebo powder (9 g powder, no (poly)phenols, no fibers
224055005|NCT07169617|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224055006|NCT07169617|DRUG|Montanide ISA 51 VG|Given SC
224055007|NCT07169617|OTHER|Questionnaire Administration|Ancillary studies
224055008|NCT07169617|BIOLOGICAL|Sargramostim|Given SC
224055009|NCT07169617|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
224055010|NCT07169955|OTHER|Motivational Interviewing|Implementation of the Research in the Experimental Group Since the patients in the experimental group come from many different cities and regions, the interviews will be conducted online. It was planned to conduct weekly online individual motivational interviews with the patients for 40 minutes on one day of the week for 6 weeks. In the last session of the motivational interview (6th week), Oswetry Low Back Pain Disability Index and World Health Organization Quality of Life Scale - Short Form will be administered. Post-tests will be administered 6 weeks after these forms are administered. Three months (12 weeks) after the first interview, the tests will be administered again.
223568086|NCT01778049|DRUG|BI 10773|Empagliflozin active
224055011|NCT07169643|DRUG|Darbepoetin (DP)|Darbepoetin (DP) 1.5 mcg/kg subcutaneously, monthly (The patients will receive medication monthly until the liver transplant is performed or if it has not yet been transplanted, a maximum of 3 doses)
224070845|NCT02896595|DEVICE|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
224070846|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with the JDome System|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with the JDOME system,"
224070847|NCT05402423|DEVICE|Computerized cognitive training plus aerobic exercise with standard exercise bike|"Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with standard exercise bike"
224070848|NCT02103569|DRUG|FDC of Daclatasvir, Asunaprevir and BMS-791325|
224070849|NCT02103569|DRUG|FDC of Norethindrone and Ethinyl Estradiol|
224070850|NCT02103569|DRUG|BMS-791325|
223445490|NCT04049305|PROCEDURE|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
223445491|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
223445492|NCT03760458|DRUG|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
223445493|NCT05432219|PROCEDURE|endoscopic surgery|endoscopic resection of recurrent nasopharyngeal carcinoma via the transoral retropterygoid nasopharyngectomy approach
223445494|NCT02515084|DEVICE|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
223445495|NCT02515084|DEVICE|MRI imaging|
223445496|NCT03921359|BEHAVIORAL|SMARTfit training|For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
223445497|NCT03921359|BEHAVIORAL|Conventional physical training|For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach \& grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
223445498|NCT06405659|OTHER|correction for pedicle fixation|The patient was diagnosed with idiopathic scoliosis and underwent a posterior idiopathic scoliosis procedure and correction for pedicle fixation.
223445499|NCT05571215|DEVICE|Transcranial Direct Current Stimulation|Five sessions of tDCS will be performed following completions of baseline data collection. This will include 3 sessions during week one and 2 sessions in week 2. A tDCS unit (neuroConn Ilmenau, Germany) will be applied to the left DLPFC with participants in the sitting position for a 20 minutes of tDCS. An anodal 2.0 mA current will be applied to each participant, including a 30-second ramp up at the beginning of stimulation and a 30 second ramp down period and the end of stimulation. The left DLPFC (F3 from EEG 10/20 system) will be located using the Beam F3 measurement system. These parameters are consistent with those used in current literature on tDCS for pain. tDCS procedures will be performed by the PI (CA).
223445500|NCT05571215|BEHAVIORAL|Pain Neuroscience Education|Immediately following completion of each tDCS intervention, participants will be given a one-on-one PNE session provided also by the PT (CA), who is a licensed healthcare provider with expertise in delivery of the content. This educational session will last about 30 minutes. Initial sessions will involve discussion and questioning of participants about their own understanding of their pain and this information will be used to subsequently individualize the forthcoming educational sessions. The educational sessions will follow the content of Explain Pain, a patient booklet, and will include information on the neurophysiology of pain, pain as typical process, the transition from acute to chronic pain, neuroplasticity, central sensitization, factors that promote pain chronicity. Information will be presented verbally along with visuals on paper.
223445501|NCT04006509|BEHAVIORAL|Prenatally Delivered Lactation Educational Program|The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
223445502|NCT04373850|BEHAVIORAL|Home Visit|Physical exam, medication dose titration
223445503|NCT04707560|PROCEDURE|EUS fine needle biopsy with heparin wet suction|"EUS FNB with Heparin wet suction:~Investigator will remove stylet from the FNB device and then infuse Heparin 1ml (5000IU) into device before procedure. The syringe will pre-loaded with 10 ml negative pressure and attach to device upon needle tip insertion into mass lesion.~EUS FNB with Dry suction:~Investigator will remove stylet from the FNB device. Syringe will be pre-loaded with 10 ml negative pressure in syringe and attach to needle tail upon needle tip inserted into target lesion."
223445504|NCT04497974|OTHER|Dietary intervention|Varying the exposure to sweetness via diet manipulation.
224055012|NCT07170163|BEHAVIORAL|¡Iniciando! mHealth App|Participants will undergo 12 weekly, 1-hour virtual group sessions (separate for young adults and parents) and weekly, 30-minute individual virtual coaching sessions for young adults (which parents may attend as appropriate). Participants will also engage with the ¡Iniciando! app modules before and after their virtual group meetings. Throughout the approximately three-month study period, participants will complete (e.g., usability, satisfaction, adherence, app usage data).
224055013|NCT07171437|DEVICE|Doppler ultra sound|\- Doppler Ultrasound (DUS) To evaluate the abdominal aorta and the 3 main splanchnic vessels: Celiac Trunk (CT) Superior Mesenteric Artery (SMA) Inferior Mesenteric Artery (IMA) An ultrasound examination will be performed after a fasting period of at least 8 hours by a single operator blinded to clinical features. For abdominal vessels, the following parameters were measured: caliber, thickness, echogenicity, peak systolic velocity (PSV), end diastolic velocity (EDV), reverse velocity (RV), mean velocity (MV), resistive index (RI), and pulsatility index (PI).
224055014|NCT07171736|BEHAVIORAL|Virtual Reality chairwork exercise|A chairwork exercise from schema therapy, executed in Virtual Reality
223445505|NCT04282720|DEVICE|SurgiMend Mesh|Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
223445506|NCT06333782|DEVICE|Experimental- Genefill Contour®|Genefill Contour® Hyaluronic Acid Injection
223445507|NCT06333782|DEVICE|Marketed comparator - Desirial®Plus|DESIRIAL®PLUS Hyaluronic Acid Injection
223445508|NCT01660802|DRUG|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
223445509|NCT01660802|OTHER|Sham|Sham administered in the study eye on Day 1.
223445510|NCT04384198|PROCEDURE|Sonolysis|Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
223445511|NCT05981404|DIETARY_SUPPLEMENT|β-glucan|Consuming 3g β-glucan with each meal.
223445512|NCT05981404|DIETARY_SUPPLEMENT|Placebo|Consuming 3g Cellulose with each meal.
223445513|NCT02295267|OTHER|walnut allergy provocation|double blind placebo controlled food challenge
223445514|NCT00316329|DRUG|Artesunate + Amodiaquine|
223445515|NCT05250986|DEVICE|GoCheck Kids (iOS)|"Visual Acuity method is used to measure of the sharpness or clearness of vision.~Device: GoCheck Visual Acuity in Office (Windows) Photorefraction method is used to screen amblyopia risk factors."
223445516|NCT05250986|DEVICE|GoCheck Kids (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
223568087|NCT01778049|DRUG|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
224055015|NCT07171736|BEHAVIORAL|Imagination exercise|A regular schema therapy imagination exercise
224055016|NCT07170423|BEHAVIORAL|Automated text message reminder|Participants in the intervention group will receive automated text messages instructing them to obtain hearing aids. The messages will also include basic information on the prevalence and negative effects of hearing loss.
224055017|NCT07170813|OTHER|Spinal hyperextension brace|The Jewett brace is a hyperextension spinal orthosis designed to limit spinal flexion and promote proper posture by applying anterior and posterior forces to the thoracolumbar spine. It is commonly used for spinal fractures, postural disorders, and to reduce spinal load. Participants will wear the Jewett brace during the intervention phase, and spinal mobility and posture will be assessed.
224055018|NCT07171177|DEVICE|Foot Orthoses|To compare the use of handmade plantar orthoses versus the use of splints in the management of low back pain.
224145878|NCT00565019|DRUG|Triamcinolone Acetonide|"* Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~* Doses will range from 60-120 mg depending on extent of the disease.~* Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~* PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: \>10 cm2, dosage 100-120 mg"
224055019|NCT07171658|BEHAVIORAL|Sensitization to Cervical Cancer (CC) screening|Women will receive an awareness letter explaining the importance of cervical cancer screening, the Swiss recommendations and an invitation to schedule an appointment.
224145879|NCT01634113|DRUG|tiotropium-bromide|IMP
224145880|NCT01634113|DRUG|tiotropium-bromide|IMP
224145881|NCT01634113|DRUG|placebo|placebo matching tiotropium
224145882|NCT00324740|DRUG|vorinostat|Given orally
224145883|NCT00324740|DRUG|isotretinoin|Given orally
224145884|NCT00141934|DRUG|AD 452|
223445517|NCT05250986|DEVICE|GoCheck at Home (iOS)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
223445518|NCT05250986|DEVICE|GoCheck at Home (Windows)|Visual Acuity method is used to measure of the sharpness or clearness of vision.
223445519|NCT05943431|DEVICE|paired taVNS|The stimulator will be placed on the left ear of the patient. While the patient performs the action training, the EMG signal feature evoked by the action will trigger an electrical stimulation of the transcutaneous auricular vagus nerve. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
223445520|NCT05943431|DEVICE|Unpaired taVNS|The stimulator will be placed on the patient's left ear. Patients will receive taVNS with pulses every 5-7 seconds. Following the stimulation, motor training will be performed. The motor training will be identical to that of the paired group. The amplitude of the electrical stimulation will be adjusted under the patient's pain threshold. The intervention will be performed daily for 14 days.
223568088|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
224145885|NCT00080184|PROCEDURE|Low Energy Neurofeedback System|
223445521|NCT05943431|DEVICE|Sham taVNS|The stimulator will be placed on the patient's left ear. The amplitude of the electrical stimulation will be adjusted at 0 mA. The intervention will be performed daily for 14 days.
223445522|NCT04309487|DIAGNOSTIC_TEST|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
223568089|NCT01778049|DRUG|BI 10773|Empagliflozin active
223568090|NCT01778049|DRUG|BI 10773|Empagliflozin active
223568091|NCT01778049|DRUG|BI 10773|Empagliflozin active
223568092|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
223568093|NCT01778049|DRUG|BI 10773 Placebo|Empagliflozin placebo
223568094|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
223568095|NCT01778049|DRUG|BI 10773|Empagliflozin active
223568096|NCT01778049|DRUG|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
223568097|NCT04958044|DRUG|Calcium Gluconate|Calcium electroporation
223568098|NCT03094364|BEHAVIORAL|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
223568099|NCT00381511|DRUG|low molecular weight heparin|
223568100|NCT01814098|DRUG|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
223568101|NCT01711489|DRUG|isavuconazole|oral
223568102|NCT01711489|DRUG|Mycophenolate mofetil|oral
223445523|NCT02281240|DRUG|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
223445524|NCT04089878|PROCEDURE|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
223445525|NCT04089878|OTHER|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
223445526|NCT00374257|PROCEDURE|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
223445527|NCT04187274|DEVICE|IKORUS technology|Ikorus technology is a new micro perfusion device measuring via urethral photoplethysmography, the urethral perfusion index (uPI) in patients equipped with an urinary catheter.
223445528|NCT05659303|PROCEDURE|Laparoscopic hysterectomy|Patient having undergone a hysterectomy, planned as an outpatient during the pre-operative consultation, by laparoscopic route.
223445529|NCT04876313|DRUG|Nivolumab + Nab-paclitaxel|4x3 weekly cycles of 360 mg nivolumab + 125 mg/m\^2 nab-paclitaxel IV on days 1 and 8
223445530|NCT04876313|DRUG|Nivolumab|360 mg IV Q3W x 13 cycles
223445531|NCT03585946|DRUG|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
223445532|NCT01490307|BEHAVIORAL|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
223445533|NCT03758105|OTHER|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
223445534|NCT03758105|OTHER|Usual care|Medication and psychotherapy as prescribed in usual care
223445535|NCT01701505|DRUG|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
223445536|NCT01701505|DRUG|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
223445537|NCT01701505|DRUG|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
223445538|NCT05086666|DRUG|AZD4547|"In Phase 1b study, subjects will receive continuous twice daily dosing in 21-day cycles (no matter if missed doses or delays exist), with pre-set dose cohorts of 80 mg BID and 120 mg BID.~In Phase 2, subjects will receive continuous twice daily dosing in 21-day cycles with the RP2D or other doses as determined by the investigator and sponsor."
223445539|NCT00960167|RADIATION|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
223445540|NCT06524167|RADIATION|adjuvant radiotherapy|The patients would receive external radiation therapy within 6 weeks after surgery, using intensity-modulated radiation therapy (IMRT) or volume modulated radiation therapy (VMAT) techniques. 6MV-X-ray irradiation. Conventional segmented irradiation is used, once a day, five times a week, with a segmented dose of 2Gy per dose.
223445541|NCT02443272|PROCEDURE|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
223445542|NCT02443272|PROCEDURE|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
223568103|NCT01480414|BIOLOGICAL|4times injection|bone marrow derived mono nuclear stem cell
223568104|NCT01480414|BIOLOGICAL|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
223568105|NCT01000922|DRUG|Regular Human Insulin|Individual dose of RHI administered subcutaneously
223568106|NCT01000922|DRUG|Lispro|Individual dose of lispro administered subcutaneously
224055020|NCT07171658|BEHAVIORAL|Home-based HPV self-sampling|Women will receive a free-of-charge vaginal self-sampling kit for HPV infection.
224055021|NCT07171450|OTHER|Computerized Cognitive Remediation|"The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Importantly, NeuroFlex personalizes gameplay with adaptive algorithms that adjust difficulty on a trial-by-trial basis. Participants are prescribed a 30-hour dose distributed across 6 weeks. The treatment is completed remotely by the participant within their own home or other private location that is most convenient for the participant."
224070851|NCT04991766|DRUG|[¹⁴C]-LY3484356|Administered orally.
224070852|NCT04991766|DRUG|LY3484356|Administered orally.
223445543|NCT01924104|DRUG|Low molecular weight heparin|2500 mIU/day, subcutaneously
223445544|NCT01924104|DRUG|Low dose aspirin|75 mg/day, orally
224070853|NCT04991766|DRUG|[¹⁴C]-LY3484356 (IV)|Administered IV.
223568107|NCT01000922|DRUG|VIAject|Individual dose of VIAject administered subcutaneously
223568108|NCT01000922|DRUG|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
223568109|NCT01000922|DRUG|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
223568110|NCT01000922|DRUG|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
223568111|NCT02450448|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
223568112|NCT02450448|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
223568113|NCT05573750|BEHAVIORAL|Singing group|Intervention involves singing groups with person with dementia and carer. Please see earlier descriptions.
223445545|NCT01924104|DRUG|Heparin & aspirin|Aspirin (70 mg/day, orally) \& heparin (40 mg/day, subcutaneously)
223445546|NCT01924104|OTHER|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
223445547|NCT06553079|OTHER|Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy|"The intervention in this study involves the administration of the Surgeon Satisfaction Self-Assessment Questionnaire for Shoulder Arthroscopy, a newly developed tool designed to measure various aspects of surgeon satisfaction related to shoulder arthroscopy procedures."
223445548|NCT03012295|OTHER||
223445549|NCT04996836|BIOLOGICAL|Next Generation Sequencing and Network Analysis|Next Generation Sequencing and Network Analysis will profile genetic and epigenetic abnormalities in blood from patients with BC.
223445550|NCT00072059|BIOLOGICAL|methoxy polyethylene glycol epoetin beta|
223445551|NCT01584700|PROCEDURE|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
223445552|NCT02759835|DRUG|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
223445553|NCT02759835|OTHER|Local Ablative Therapy (LAT)|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
223445554|NCT00198432|DRUG|Paclitaxel, vinorelbine, cisplatin|
223445555|NCT05411380|DRUG|Tucidinostat|20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)
223445556|NCT05411380|DRUG|Capecitabine|500mg orally three times a day (continuously)
223445557|NCT05411380|DRUG|Endocrine Therapy|Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
223445558|NCT05999656|BIOLOGICAL|human cord blood-derived mononuclear cells (HCB-MNCs)|All patients received cell therapy for the first time. HCB-MNCs were injected subcutaneously or intramuscularly into the ulcers of the patients' feet, with an interval of about a centimeter between every two points and an injection volume of 0.2ml at each puncture point. The total injection volume required by the patients was the injection needles multiply 0.2ml (about 2ml of suspended cell in total). The remaining suspension was injected on both sides of the center of the main ischemic site. All patients received three injections of umbilical cord blood mononuclear cells at a week interval, with the latter two injections located around the site of the first injection. The adjuvant therapy remained unchanged within two weeks after cell injection. The follow-up period is 12 weeks after treatment to observe safety and efficacy. If the patient does not recover after 12 weeks, the follow-up period can be extended to 24 weeks.
223445559|NCT02007278|DRUG|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
223445560|NCT02007278|DRUG|glimepiride|
223445561|NCT02007278|DRUG|Metformin|
223445562|NCT02080338|DEVICE|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
223445563|NCT00371709|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
223445564|NCT00371709|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
223445565|NCT01530711|DRUG|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase \< 10 mmHg and the creatinine values decrease \<25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
223445566|NCT04539756|BEHAVIORAL|positive psychological intervention|Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
223445567|NCT04539756|BEHAVIORAL|Active control condition|Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
223445568|NCT01593449|BEHAVIORAL|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
223445569|NCT05951920|PROCEDURE|Lymph node aspiration / Blood sampling|Lymph node aspiration / Blood sampling
223445570|NCT03366961|PROCEDURE|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
223445571|NCT00038311|DRUG|PN-152,243)/PN-196,444|
223568114|NCT03773133|DRUG|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
223568115|NCT03773133|DRUG|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
223568116|NCT01500603|DEVICE|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
224145886|NCT01052831|DRUG|Naltrexone|50-100 mg qd for 8 weeks
223568117|NCT01500603|DEVICE|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
223568118|NCT00151710|DRUG|Pioglitazone|
224145887|NCT01052831|DRUG|Placebo|50-100 mg qd for 8 weeks
223445572|NCT06199271|DRUG|Adebrelimab and dalpiciclib|Before surgery, the eligible patients received 3 cycles of adebrelimab (1200 mg intravenously every 3 weeks, Day 1, 22 and 43) and 2 cycles of dalpiciclib (150 mg, po, every 4 weeks, day 1-21 and 29-49). Administration dose adjustments were permitted according to the haematological or non-haematological toxicity.
223445573|NCT00677573|DRUG|Fostimon|450 IU for 4 days then adjusted
223445574|NCT01063231|DEVICE|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
223445575|NCT02028962|BEHAVIORAL|Lifestyle counseling|
223445576|NCT04687566|DRUG|Dextromethorphan|The participants will take dextromethorphan 60 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
223445577|NCT04687566|DRUG|Memantine|The participants will take memantine 5 mg per day, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
223445578|NCT04687566|DRUG|Dextromethorphan and memantine|The participants will take dextromethorphan (60 mg per day) and memantine (5 mg per day) combination, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
223445579|NCT04687566|DRUG|Placebo|The participants will take the placebo pills, once daily, for 12 weeks. The participants will be blind to the assigned treatment group.
223445580|NCT03647072|DRUG|CHOP|CHOP only
223445581|NCT03647072|DRUG|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
223445582|NCT03647072|DRUG|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
223445583|NCT00768339|DRUG|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~* Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~* Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
223445584|NCT02745483|DEVICE|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
223445585|NCT01111422|DRUG|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
223445586|NCT00002525|DRUG|fluorouracil|"Perioperative 5-FU: 600 mg/m\^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m\^2 IV push on days 1-5"
223445587|NCT00002525|DRUG|leucovorin calcium|given after surgery at dose of 20mg/m\^2 IV push on days 1-5
224145888|NCT01594346|DRUG|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
223445588|NCT04221022|OTHER|Light physical activity|Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
223445589|NCT04221022|OTHER|Moderate physical activity|Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
223445590|NCT04221022|OTHER|Vigorous physical activity|Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
223445591|NCT02636803|DRUG|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
223445592|NCT02636803|DRUG|albendazole|group receives one 400 mg dose of albendazole
223445593|NCT05279118|DIETARY_SUPPLEMENT|Ketogenic diet|Children who have consented to the study and have been randomised to ketogenic diet arm will get ketogenic diet under supervision while starting with rapid hiking of lipid to carbohydrate ratio and primary response will be assessed at 6 weeks. Ketogenic diet ratio will be hiked quickly upto a maximum of 4:!. The duration of ketogenic diet can be extended beyond the period of study based on response and parental choice. A minimum period of 6 weeks of diet therapy will be undertaken baring any undue adverse effects when the primary outcome will be assessed
223445594|NCT05279118|DRUG|ACTH|ACTH is the current standard therapy for children with west syndrome. Those who have been randomised to this arm will be started on high dose ACTH for 2 weeks followed by gradual tapering over remaining 4 weeks and primary response documented at 6 weeks of therapy. The high dose ACTh is 150U/m2 or 6U/kg dose administered IM daily for two weeks. After this the doses will be tapered gradually and ACTH will be stopped by 4 weeks for a total treatment duration of strictly 6 weeks.
223445595|NCT02886884|DRUG|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
223445596|NCT02886884|DRUG|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
223445597|NCT03230838|DRUG|Ceftolozane/Tazobactam|12 to \<18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. \<12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.
223568119|NCT02125851|OTHER|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
223568120|NCT02125851|OTHER|Honey|esophageal mucosal contact time of honey vs sucralose slurry
223568121|NCT03371134|BIOLOGICAL|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
223568122|NCT02862483|DRUG|Tamsulosin 0.2mg|
223568123|NCT02862483|DRUG|Tadalafil 5mg|
223568124|NCT02862483|DRUG|Placebo for Tamsulosin|
223568125|NCT05497102|DRUG|Lenalidomide maintenance|Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
223568126|NCT01552785|DEVICE|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
223568127|NCT04960930|DRUG|FMX101|topically once daily
224145889|NCT01594346|DRUG|Sugar Pill|
224145890|NCT01689766|DRUG|Technetium Tc 99m EC20|
224145891|NCT04463238|COMBINATION_PRODUCT|Guided cartilage regeneration membrane|On the basis of microfracture, the blood clot released from the defect area is covered with a guide cartilage regeneration membrane to provide an attached scaffold for the cells in the blood clot.
224145892|NCT04463238|PROCEDURE|Microfracture|Operate in accordance with the clinical microfracture surgery method.
223445598|NCT03230838|DRUG|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
223445599|NCT00002379|DRUG|Indinavir sulfate|
223445600|NCT00002379|DRUG|Levocarnitine|
223445601|NCT00002379|DRUG|Adefovir dipivoxil|
223445602|NCT00002379|DRUG|Lamivudine|
223445603|NCT00002379|DRUG|Stavudine|
223445604|NCT00002379|DRUG|Zidovudine|
223445605|NCT05409755|OTHER|Vivacy|Vivacy and minoxidil
223445606|NCT02372435|PROCEDURE|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
224145893|NCT00520299|DRUG|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
224145894|NCT01352845|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
223445607|NCT01315288|OTHER|One of 6 video presentation by one of 4 presenters|
223568128|NCT01364558|DRUG|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
223568129|NCT01364558|DRUG|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
223568130|NCT02789943|PROCEDURE|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
223568131|NCT05809544|DEVICE|WELT-IP|WELT-IP (an investigational digital therapeutic) is an CBT-I based intervention designed to treat insomnia, conducted in 6 sessions. It is a comprehensive program delivering sleep restriction, stimulation control, muscle relaxation, cognitive treatment, and sleep hygiene education. Main features are sleep diary, sleep reports, daily lessons of CBT-I, muscle relaxation techniques, and cognitive intervention through chatbot.
223568132|NCT05809544|DEVICE|Sham|Sham was downloaded to the subject's phone and was subject was instructed to complete sleep diary and sleep educational contents as needed.
223568133|NCT02168049|DEVICE|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
223568134|NCT02168049|DEVICE|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
223741485|NCT03301142|PROCEDURE|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
224145895|NCT01352845|OTHER|Placebo|0.5 mL dose, given at 0, 2 and 6 months
224145896|NCT01807091|DRUG|Chemotherapy|Receive outpatient induction chemotherapy
223445608|NCT04475718|BEHAVIORAL|Fourth Trimester Mobile Tool|A mobile web-based tool for underserved women in the fourth trimester. The mobile platform teaches self-efficacy, care management, and coping skills to help reduce major health risks and provide tools and resources to maintain mental health.
223445609|NCT04622202|DRUG|Pregabalin 150mg|oral capsule pregabalin 150 mg.
223445610|NCT04622202|DRUG|multivitamin|oral placebo in the form of oral multivitamin capsule.
223445611|NCT05262790|OTHER|This is not an intervention study|
223445612|NCT05262790|OTHER|This is not an intervention study|
223445613|NCT05262790|OTHER|This is not an intervention study|
223445614|NCT04045990|DEVICE|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
223445615|NCT00886964|BIOLOGICAL|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
223445616|NCT00886964|BIOLOGICAL|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
223445617|NCT02865200|OTHER|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
223568135|NCT02168049|DEVICE|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
223568136|NCT01985711|DEVICE|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
223568137|NCT01985711|OTHER|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
223568138|NCT01985711|BEHAVIORAL|usual diabetes outpatient care|
223568139|NCT04002284|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
224145897|NCT03624439|DEVICE|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
224145898|NCT03624439|DEVICE|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
223445618|NCT02865200|OTHER|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
223445619|NCT03604575|DRUG|Insulin Lispro|
223445620|NCT03604575|DRUG|Humalog®|
223445621|NCT05610475|DIAGNOSTIC_TEST|blood cell analysis, blood gas surveillance, chest radiograph and echocardiography|Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.
223445622|NCT01505179|DRUG|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
224055022|NCT07171450|OTHER|Alternative Computer Activities|The active control condition is carefully matched to the experimental condition in duration, computer tablet use, audiovisual stimulation, reward presentation, and interaction with study staff. It involves playing visuospatially-oriented computerized games that do not load on executive functions and watching stimulating educational videos.
223445623|NCT01505179|DRUG|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
223445624|NCT00675870|DRUG|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
223445625|NCT00033878|DRUG|Noni Extract|
223445626|NCT00521885|DRUG|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
223445627|NCT00521885|DRUG|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
223445628|NCT00435188|BEHAVIORAL|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
223445629|NCT01040715|BIOLOGICAL|TNFa Kinoid|TNFa kinoid
223445630|NCT01040715|BIOLOGICAL|TNF kinoid|IM administration 2 or 3 injections within 28 days
223445631|NCT00478907|DRUG|KETAMINE, PROPOFOL, THIOPENTAL|
223445632|NCT02236078|DRUG|High dose isoniazid|See arm description
223445633|NCT04106271|OTHER|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q \& A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
223445634|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
223445635|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
223445636|NCT00978393|DRUG|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
223445637|NCT00978393|DRUG|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
223445638|NCT00978393|DRUG|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
223445639|NCT00978393|DRUG|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
223445640|NCT01915771|DRUG|lomitapide|20 mg dose
223445641|NCT01683877|PROCEDURE|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
223445642|NCT01683877|PROCEDURE|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
223445643|NCT05869877|DEVICE|Bundled|An peripheral intravenous catheter will be inserted by an RN specially trained in PIVC placement, with or without ultrasound. Using best of class medical products, will evaluate dwell time and complications of the PIVC inserted using a bundled approach versus one inserted with the bundle
224055023|NCT07165483|DRUG|Dexmedetomidine|Patients will receive 0.5µg/kg dexmedetomidine (over 10 min) 20 min before induction of anesthesia then saline (over 10 min) 10 min before induction of anesthesia.
224055024|NCT07165483|DRUG|Dexmedetomidine|Patients will receive saline (over 10 min) 20 min before induction of anesthesia then 0.5µg/kg dexmedetomidine (over 10 min) 10 min before induction of anesthesia.
224055025|NCT07165483|DRUG|Saline|Patients will receive saline before induction of anesthesia as a control group.
224055026|NCT07170852|DRUG|Bempedoic acid film coated tablet|1 tablet of 180 mg Bempedoic Acid
224055027|NCT07170852|DRUG|Nilemdo® Film-coated tablets|1 tablet of 180 mg Bempedoic Acid
223445644|NCT03497767|DRUG|Osimertinib|All participants will receive a dose of Osimertinib 80mg once daily
223445645|NCT03497767|RADIATION|Stereotactic Radiosurgery (SRS)|Dose and fractionation depend on lesion size. All SRS must be completed within 21 days of randomisation and all lesions are to be treated within 7 days.
223445646|NCT02700880|DEVICE|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
223445647|NCT00497055|DRUG|Aripiprazole|
223445648|NCT00497055|DRUG|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
223445649|NCT00335855|DEVICE|Auto-injector for IM/SC vaccine administration|
223741486|NCT03301142|PROCEDURE|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
223741487|NCT03935373|DIAGNOSTIC_TEST|DNA Exome sequencing|The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
223741488|NCT03935373|DIAGNOSTIC_TEST|Oral microbiome|The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
223741489|NCT03935373|DIAGNOSTIC_TEST|Proteomics|The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
223741490|NCT03935373|DIAGNOSTIC_TEST|RNA sequencing|The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
224055028|NCT07171047|DIETARY_SUPPLEMENT|Placebo then Verum|Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum
224055029|NCT07171047|DIETARY_SUPPLEMENT|Verum then Placebo|Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum
223445650|NCT01210014|DRUG|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
223741491|NCT03935373|DIAGNOSTIC_TEST|Cytokine|The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
223741492|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pattern|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
223741493|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine tongue diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
223741494|NCT03935373|DIAGNOSTIC_TEST|Traditional Chinese Medicine pulse diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
223741495|NCT03935373|DIAGNOSTIC_TEST|Heart rate variability|Sjögren's syndrome patients and health subjects will take the heart rate variability.
224055030|NCT07170722|DEVICE|Subtreshhold DRG-S|Continuous electrical stimulation delivered through an implanted DRG neurostimulator. Amplitude is set individually to 80% of each participant's perception threshold, ensuring no paresthesia is produced. Frequency and pulse width remain unchanged from the participant's established therapeutic settings. This sub-threshold programming distinguishes the intervention from suprathreshold (paresthesia-based) DRG stimulation used in earlier studies.
224055031|NCT07170722|OTHER|Sham|The implanted DRG stimulator remains switched off for the entire 5-day period. Device interrogation logs are masked to maintain blinding. No electrical stimulation is delivered, allowing a placebo-controlled comparison with active sub-threshold stimulation.
223445651|NCT01210014|DRUG|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
223445652|NCT03582514|RADIATION|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single-fraction radiotherapy.
223445653|NCT00001119|BIOLOGICAL|Tetanus Toxoid Vaccine|
223445654|NCT00001119|DRUG|Indinavir sulfate|
223445655|NCT00001119|DRUG|Lamivudine/Zidovudine|
223445656|NCT00001119|DRUG|Ritonavir|
223445657|NCT00001119|DRUG|Abacavir sulfate|
223741496|NCT03935373|DIAGNOSTIC_TEST|Schirmer's test|Sjögren's syndrome patients will take the Schirmer's test.
224070854|NCT03206697|OTHER|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
223445658|NCT00001119|DRUG|Amprenavir|
223445659|NCT00001119|DRUG|Efavirenz|
223445660|NCT00001119|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
223445661|NCT00001119|DRUG|Lamivudine|
223445662|NCT00001119|DRUG|Zidovudine|
223445663|NCT02907775|DEVICE|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
223445664|NCT02907775|DEVICE|Electrodes|electrodes placed over the radial nerve in radial grove
223445665|NCT01745107|RADIATION|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
223445666|NCT06721637|COMBINATION_PRODUCT|Group A (n = 20): received core stability exercise trained three times a week for 8 weeks.|Woman was in crook lying position with feet flat on the treatment table. The therapist put his two thumbs on the anterior superior iliac spines then, asked the woman to contract the abdominal muscle, hold the contraction for 10 seconds, then, asked her to relax for 10 seconds
223445667|NCT06721637|DEVICE|Group B (n = 20): received whole body vibration trained three times a week for 8 weeks|The woman assumed a full squat position on a vibration platform. The apparatus was set at a frequency of 30 Hz, amplitude of 2 mm, and duration of 5 min. The women were instructed to remain in the squatting position with holding hand rail after turning on the vibration and to report any discomfort that might arise. At the end of 5 min, the vibration turned off automatically. Thereafter, the women took a 1-min rest. They were then asked to stand on the vibration platform for 5 min, with the same parameters as those used in the squatting position. Thus, the total time for the application of WBV in each session was 10 min
223445668|NCT02756598|DRUG|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
223445669|NCT02756598|DRUG|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
223445670|NCT02756598|DRUG|Propofol I|Continued dose of propofol 0.03 mg/kg/min
224055032|NCT05659576|DRUG|Sucralfate|"1. Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion."
224055033|NCT05659576|OTHER|Usual Care|Standard supportive care by using opioids.
224055034|NCT05659576|OTHER|One consent|Patient will sign one consent form.
224055035|NCT05659576|OTHER|Two consent|Patient will sign two consent forms.
223445671|NCT02756598|DRUG|Propofol II|Continued dose of propofol 0.06 mg/kg/min
223568140|NCT02095665|DRUG|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
223568141|NCT02095665|DRUG|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
223568142|NCT02095665|DRUG|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
223568143|NCT03650101|PROCEDURE|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
223568144|NCT02479165|DRUG|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
223568145|NCT02479165|DRUG|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
223445672|NCT02362152|DRUG|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
223445673|NCT02362152|DRUG|5-fluorouracil|Topical field treatment as prescribed by dermatologist
223445674|NCT02362152|DRUG|Imiquimod|Topical field treatment as prescribed by dermatologist
223445675|NCT02362152|DRUG|Diclofenac|Topical field treatment as prescribed by dermatologist
223445676|NCT00657995|DEVICE|Artificial Pancreas (STG-22)|safe tool
223568146|NCT00107315|BIOLOGICAL|bevacizumab|
223568147|NCT00107315|DRUG|capecitabine|
223568148|NCT03477851|DRUG|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
223568149|NCT03477851|DRUG|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
223568150|NCT03087942|DRUG|QAW039|450 mg
224055036|NCT07170345|DIAGNOSTIC_TEST|Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC|This intervention is an artificial intelligence-based computer-aided diagnosis (CAD) system developed to predict microvascular invasion (MVI) in patients with hepatocellular carcinoma using preoperative multiphase CT imaging. The system integrates deep learning, radiomics, and expert-defined imaging features to provide risk assessment and visualization of MVI prior to surgery. In this study, the CAD system will be evaluated retrospectively and prospectively in an observational manner only. The results will not influence clinical decision-making or patient management, and all treatments will follow standard of care.
224070855|NCT01536054|BIOLOGICAL|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
224070856|NCT01536054|DRUG|sirolimus|Given PO
224070857|NCT01536054|OTHER|laboratory biomarker analysis|Correlative studies
224070858|NCT01536054|BIOLOGICAL|sargramostim|Given SC
224070859|NCT00595712|PROCEDURE|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
224070860|NCT00595712|PROCEDURE|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
224070861|NCT04421274|BIOLOGICAL|Bone marrow mesenchymal stem cells transfer|Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times
223445677|NCT06414876|BEHAVIORAL|Hospital dog|The hospital dog always has a well educated dog instructor beside.
223445678|NCT02226848|DRUG|Erythropoeitin|
223445679|NCT01608191|BEHAVIORAL|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
223445680|NCT03420222|DRUG|AVP-786|oral capsules
223445681|NCT03420222|DRUG|Placebo|oral capsules
223445682|NCT00001341|DRUG|ZD1694 (TOMUDEX)|
223445683|NCT04066322|PROCEDURE|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
223445684|NCT04066322|OTHER|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
223445685|NCT01500655|PROCEDURE|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
223445686|NCT01500655|PROCEDURE|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
223445687|NCT03002532|RADIATION|whole brain radiotherapy|
223445688|NCT02483494|OTHER|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
223445689|NCT04785560|DEVICE|Initial shunt setting post-operatively of the Certas Plus shunt valve.|The setting/resistance of the Certas Plus Shunt valve implanted is set according to randomisation and is not changed until the first post-operative MRI is performed 36-48 hours after surgery.
223568151|NCT03087942|DRUG|QAW39A|450 mg
223568152|NCT03087942|DRUG|QAW39A2107|450 mg
223568153|NCT03087942|DRUG|QAW39A2107|450 mg
223568154|NCT02231411|PROCEDURE|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
223568155|NCT02231411|PROCEDURE|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
223568156|NCT02231411|PROCEDURE|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
223568157|NCT02497378|DRUG|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
223568158|NCT02497378|DRUG|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m\^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
223568159|NCT02497378|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
223741497|NCT03935373|DIAGNOSTIC_TEST|Blood function test, liver function test, kidney function test, and immune function test|Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
224055037|NCT06104150|OTHER|Intervallic submaximal exercise test|Intervallic submáximal exercise test on a cycle ergometer: 5 min warm-up at 80% of First Lactate Threshold (LT1), and subsequent sets of 1.5 min at 20% above the Second Lactate Threshold (LT2) alternated with recoveries of 5 min at 80% of LT1, ending with a 20 min recovery at 80% of LT1.
223568160|NCT00236990|DRUG|pentosan polysulfate sodium|
223568161|NCT04589234|DRUG|Salmonella-IL2|Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer
224070862|NCT04421274|DRUG|Best medical treatment|Refer to the latest medication guidelines and give the best medication to the patients
224070863|NCT04421274|PROCEDURE|Percutaneous coronary intervention|Percutaneous coronary intervention
223445690|NCT05808816|DRUG|Lactobacillus Crispatus M247|Oral supplementation of Lactobacillus Crispatus M247 in patients with cervical low grade lesions HPV related
223445691|NCT01077102|OTHER|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
223445692|NCT02334384|BIOLOGICAL|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
223445693|NCT00006378|DRUG|carboplatin|
223445694|NCT00006378|DRUG|paclitaxel|
223568162|NCT04589234|DRUG|FOLFIRINOX Alone (Historical Controls)|We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group
223445695|NCT00006378|RADIATION|radiation therapy|
223568163|NCT04589234|DRUG|Gemcitabine/Abraxane Alone (Historical Controls)|We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group
223445696|NCT05127928|DIETARY_SUPPLEMENT|Dietary Supplement: Vitamin C and vitamin E|Antioxidant supplementation
223445697|NCT05127928|DIETARY_SUPPLEMENT|Placebo|Placebo administration
223741498|NCT04275791|OTHER|Triage|Experimental : Trauma patient orientation in a structured regional health organization, composed of trauma centers hierarchized in several levels according to their capacity to receive severe traumatized persons.
223445698|NCT04971083|BEHAVIORAL|Intervention Group|This study is designed to provide patients a tool with which they can record the nutrition related symptom burden (NRSB) they are experiencing in real time. A pre-defined algorithm then provides them with tailored nutrition information and behavioural tipps based on the severity grade of the symptom recorded. The aim is to increase the chances that such symptoms, when clinically relevant, are addressed in a timely matter and thus the nutrition status is stabilized.
223445699|NCT00441987|DRUG|GSI-953|
223445700|NCT00055497|BIOLOGICAL|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
223568164|NCT02696057|OTHER|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
223568165|NCT02696057|OTHER|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
223568166|NCT00945061|RADIATION|intracavitary balloon brachytherapy|Patients undergo brachytherapy
223568167|NCT00945061|RADIATION|intraoperative radiation therapy|Patients undergo radiotherapy
223568168|NCT02509039|DRUG|CC-122|5 continuous days out of 7 days per week intermittent dosing
223568169|NCT02100020|OTHER|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
223568170|NCT04606589|DEVICE|neoGuard vital signs monitor|The neoGuardTM device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate, respiratory rate and blood oxygen saturation in newborns.
223568171|NCT00412347|DRUG|Insulin Drip Therapy|
224055038|NCT05611346|BEHAVIORAL|Hypnosis|"The experimental group will receive 2 standardized hypnosis sessions via the superhero costume technique performed during this collective therapeutic education program, completed by a reinforcement through the practice of self-hypnosis at home guided by the listening of an audio recording"
223568172|NCT00823433|DRUG|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
224055039|NCT05712278|DRUG|SAR445419|Cell suspension, by intraveneous (IV) injection
224055040|NCT05712278|DRUG|fludarabine|Solution for injection , by IV injection
223445701|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
223445702|NCT00055497|BIOLOGICAL|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
223445703|NCT00055497|BIOLOGICAL|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
223568173|NCT02501317|BEHAVIORAL|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
223568174|NCT02501317|BEHAVIORAL|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
223568175|NCT02398422|BEHAVIORAL|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
223568176|NCT01572363|DRUG|Sildenafil|50 mg once
223568177|NCT00283270|BEHAVIORAL|Brief counselling|
223568178|NCT00283270|BEHAVIORAL|Behavior|
223445704|NCT05383833|DIETARY_SUPPLEMENT|Creatine Monohydrate|Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.
223568179|NCT03797118|DEVICE|FFR|Fractional flow reserve measured during cardiac catheterization
224055041|NCT05712278|DRUG|cytarabine|Solution for injection, by IV injection
224055042|NCT05798221|BEHAVIORAL|Complementary self-help strategies in addition to treatment as usual|The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual
224055043|NCT05798221|OTHER|Treatment as usual|The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
224055044|NCT02516787|OTHER|Parabolic flight|
224055045|NCT02516787|OTHER|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
223568180|NCT04446130|DRUG|Decitabine combined with HAAG Regimen|Decitabine :20mg/m2/d,d1\~5, intravenous infusion; Homoharringtonine :1mg/d,d3\~16,intravenous infusion; Aclarubicin :10mg/d, d3\~d10, intravenous infusion; Cytarabine :10mg/m2,q12h,d3-16, subcutaneous injection; Granulocyte colony-stimulating factor (G-CSF): 50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection
223568181|NCT01371240|DRUG|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
223568182|NCT03136497|DRUG|400mg ABT-199|Oral dose daily until disease progression
223568183|NCT03136497|DRUG|Ibrutinib|Oral dose daily until disease progression
223568184|NCT03136497|DRUG|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
224055046|NCT02516787|OTHER|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
224055047|NCT00268489|BIOLOGICAL|bevacizumab|
223445705|NCT00048165|DRUG|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
224145899|NCT03267589|DRUG|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
224145900|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121 without MF59®
224145901|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241 without MF59®
223741499|NCT03419000|GENETIC|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
224055048|NCT00268489|DRUG|pemetrexed disodium|
224055049|NCT00128479|DRUG|mifepristone|mifepristone 300 mg daily for 7 dats
224055050|NCT00128479|DRUG|mifepristone matched placebo|daily for 7 days
224055051|NCT00128479|DRUG|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
223445706|NCT00048165|DRUG|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
223445707|NCT00048165|DRUG|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
224055052|NCT00128479|DRUG|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
224055053|NCT06365866|DEVICE|"BRAXX Esophageal Brachytherapy Applicator."|The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.
224055054|NCT06365866|RADIATION|Add-on of intraluminal brachytherapy|Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.
224055055|NCT05377788|DRUG|Lazertinib|Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
224055056|NCT00736255|DRUG|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
224055057|NCT00736255|DRUG|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
224145902|NCT05664334|BIOLOGICAL|Placebo|Diluent
224145903|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, without MF59®
223445708|NCT00048165|DRUG|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
223445709|NCT00048165|DRUG|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
223568185|NCT03136497|DRUG|800mg ABT-199|Oral dose daily until disease progression
223568186|NCT00543296|DRUG|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
223568187|NCT01986387|BEHAVIORAL|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
223568188|NCT05459649|DRUG|Cyclosporine Oral Product|A combination of cyclosporin with standard steroid in newly diagnosed ITP patients: cyclosporin was started orally 1 mg/kg/d in two divided doses for 1 week, increased to 1.5 mg/kg/d for 1week, further increased to 2.5 mg/kg/d and then continued for 24 weeks. The therapeutic serum level of cyclosporin was 75 to 150 ug/L. After 26 weeks of cyclosporin treatment, the dose for patients who achieved complete response was reduced by 25 mg/d every 2 weeks to ensure continuing the lowest dose that achieved the targeted serum level of cyclosporin and a safe platelet count; standard steroid regimen included orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
223568189|NCT05459649|DRUG|Prednisone|Standard steroid in newly diagnosed ITP patients: orally prednisone for a total of 10 weeks: 1 mg per kilogram of body weight for 2 weeks followed by 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 mg daily for 2 weeks, 5 mg daily for 1 week and 5 mg every other day for the final week.
223568190|NCT00557310|DRUG|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
224145904|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, without MF59®
224145905|NCT05664334|BIOLOGICAL|IVX-241|225 mcg of IVX-241, without MF59®
224145906|NCT05664334|BIOLOGICAL|IVX-121|75 mcg of IVX-121, with MF59®
224145907|NCT05664334|BIOLOGICAL|IVX-241|75 mcg of IVX-241, with MF59®
224145908|NCT05664334|BIOLOGICAL|IVX-241|150 mcg IVX-241, with MF59®
224145909|NCT05664334|OTHER|MF59®|MF59® as an adjuvant
224145910|NCT01081821|DRUG|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
224145911|NCT01081821|DRUG|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
224145912|NCT01354613|DRUG|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
224145913|NCT01354613|DRUG|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
224145914|NCT06059300|DIAGNOSTIC_TEST|Digital Breast Tomosynthesis|Screening with Digital Breast Tomosynthesis instead of Digital Mammography, for two screening rounds
224145915|NCT03255265|OTHER|no interventions|no interventions
224145916|NCT00250185|DRUG|Sodium Nitrate|
224145917|NCT00250185|DRUG|Acetylcholine|
223445710|NCT03584425|DIAGNOSTIC_TEST|Rasch modified version of the Fugl-Meyer Motor assessment|All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
223741500|NCT00323518|DRUG|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
223741501|NCT00323518|DRUG|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
223741502|NCT05147766|BIOLOGICAL|AlloRx|cultured allogeneic adult umbilical cord derived mesenchymal stem cells
224055058|NCT00736255|DRUG|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
224055059|NCT03278184|DEVICE|tDCS sham motor cortex|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
224055060|NCT03278184|DEVICE|active prefrontal cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
224055061|NCT03278184|DEVICE|active motor cortex stimulation|the intervention 25 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
224145918|NCT01047748|DRUG|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
223445711|NCT03584425|DIAGNOSTIC_TEST|Anatomical image acquisition|High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
223741503|NCT04659967|BEHAVIORAL|Virtual Training|Participants will receive a virtual training that is tailored to age-related hearing loss, use of non-custom personal amplification devices, and communication strategies.
224055062|NCT06320691|PROCEDURE|Total Hip Arthroplasty|Patients that underwent direct anterior approach total hip arthroplasty
224055063|NCT06320691|PROCEDURE|General Anesthesia|Patients that underwent general/systemic anesthesia before surgery
224145919|NCT01047748|DRUG|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
224145920|NCT01760759|BEHAVIORAL|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
224145921|NCT01760759|BEHAVIORAL|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
224145922|NCT02271009|DRUG|AllerT|Ultrafast immunotherapy
224145923|NCT02271009|DRUG|Placebo|placebo control
224164069|NCT02882165|OTHER|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
223445712|NCT03584425|DIAGNOSTIC_TEST|Functional MRI task and acquisition|Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
223445713|NCT06352125|DIAGNOSTIC_TEST|TEG 6s Citrated K, KH, RTH, FFH Cartridge|The TEG® 6s uses the Global Hemostasis with Heparin Neutralization (HN) Cartridge to test the hemostasis properties of citrated blood samples using four different assays/reagents simultaneously, one in each of the four cartridge channels.
223445714|NCT06352125|DIAGNOSTIC_TEST|Clauss Fibrinogen|"Diagnostic Test: Clauss Fibrinogen Fibrinogen, also known as Factor I, is a plasma protein that can be transformed by thrombin into a fibrin gel (the clot). Fibrinogen is synthesized in the liver and circulates in the plasma as a disulfide-bonded dimer of 3 subunit chains. The biological half-life of plasma fibrinogen is 3 to 5 days."
223445715|NCT00279604|BEHAVIORAL|'Problem Profile Intervention' vs. WHO-Brief Intervention|
223445716|NCT04303468|DIETARY_SUPPLEMENT|GABA|The dietary supplement GABA will be taken orally 3 times daily, before each main meal
223445717|NCT04303468|OTHER|Placebo|Gelatin capsule containing powdered cellulose
223741504|NCT05487326|PROCEDURE|Erector spinae plane block|fascial plane injection guided by ultrasound guidance
223741505|NCT05487326|PROCEDURE|cervical epidural injection|cervical epidural injection by fluoroscopy
224055064|NCT06320691|PROCEDURE|Spinal Anesthesia|Patients that underwent spinal/neuraxial anesthesia before surgery
224055065|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
224055066|NCT01141504|DIETARY_SUPPLEMENT|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
223445718|NCT02387424|BEHAVIORAL|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
223445719|NCT02387424|BEHAVIORAL|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
223445720|NCT01812616|DRUG|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
223445721|NCT01812616|DRUG|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
223445722|NCT05715424|OTHER|Six interventions for children and adolescents|"* Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action."
223445723|NCT05216640|DEVICE|High Flow Oxygen Therapy|• The patient will be allocated into 2 groups, patients who will require ventilatory support via HFNC and those who will require HVNI
223445724|NCT05790642|DEVICE|Pulse wave measurement and analysis|Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.
223445725|NCT03521752|OTHER|Specific Exercise Program|4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
223445726|NCT04102332|DEVICE|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
223445727|NCT01139671|DRUG|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
223445728|NCT06485011|PROCEDURE|Paltysma suturing|platysma muscle was sutured in this group with vicryl
223445729|NCT06485011|PROCEDURE|Without Platysma suturing|platysma muscle was not sutured in this group
223445730|NCT04006678|PROCEDURE|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
223445731|NCT02587754|DEVICE|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
223445732|NCT02112877|DEVICE|Veniti Vici™ Venous Stent System|
223445733|NCT03344146|BEHAVIORAL|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
223445734|NCT03344146|BEHAVIORAL|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
223445735|NCT00018421|PROCEDURE|Treadmill Exercise|
223445736|NCT00600158|DRUG|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
223445737|NCT00600158|DRUG|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients \> 70 kg)
223445738|NCT00715871|DRUG|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
223445739|NCT00715871|DEVICE|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
223445740|NCT06055621|DRUG|Dasatinib|Daily orally administration of DASATINIB
223445741|NCT03780972|DRUG|ONL1204|Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
223445742|NCT03780972|PROCEDURE|Intravitreal Injection|Injection of study drug into the eye
223445743|NCT03780972|PROCEDURE|Collection of ocular fluids|vitreous and aqueous fluid collection by a tap and during vitrectomy
223568191|NCT06334081|PROCEDURE|undersized drilling technique|In group A The implant site preparation was made according to the protocol of the manufacturer except that the final drill was omitted. The drilling was done using a low speed reduction, high torque with coolant contra-angle hand piece with surgical motor unit. Speed of drilling was 800-1200 rpm.
223568192|NCT06334081|PROCEDURE|single drilling technique|In group B The implant bed was prepared using the new specially designed drills. First, the use of the guide drill of length 3.5mm with speed of 800 rpm and torque of 35 nm, then the use of the one drill of the same diameter of the selected implant size to the full length of the osteotomy site.
223568193|NCT03429985|BEHAVIORAL|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development and life trajectories of adolescent males.
223568194|NCT04887584|OTHER|Control diet|The control Typical American Diet (TAD) diet pattern will mimic the level of intake of fruits, vegetables, whole grains, added sugars, saturated fats and sodium in the general U.S. population. This diet will feature no servings of pulses per day.
223445744|NCT04159168|BEHAVIORAL|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
223445745|NCT04159168|BEHAVIORAL|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
223445746|NCT00595101|DRUG|PF-03187207|
223445747|NCT00595101|DRUG|Latanoprost 0.005%|
223445748|NCT00595101|DRUG|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
223445749|NCT00595101|DRUG|Latanoprost Vehicle|
223445750|NCT00890240|DRUG|JNJ-31001074|
223445751|NCT04310475|OTHER|Virtual reality assisted CBT|This study uses virtual reality technology to assist cognitive behavioural therapy for social difficulties in people with first episode psychosis.
223445752|NCT04761159|DRUG|Ketamine|Different mixture of ketamin-propofol will apply for anesthesia induction.
223445753|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve radiofrequency denervation.|"While in prone position, lumbar facet joints are identified by fluoroscopy. 18 gauge needles are then advanced aiming to the medial branch of lumbar facet joints. Correct positioning is confirmed by anteroposterior and lateral fluoroscopy. Then, the needles are attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz (hertz), 1ms, 0,6V (volts). In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms (millisecond) and twice the voltage that produced sensitive response. After correct positioning and repositioning the needles if needed, conventional radiofrequency ablation of medial branch nerves is performed using the following settings: 90 seconds, 80º Celsius degrees.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation."
223568195|NCT04887584|OTHER|Low Pulse diet|The Low Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 0.2 cups of pulses per day at 2,000 kilocalories (kcals).
223568196|NCT04887584|OTHER|High Pulse diet|The High Pulse diet will be designed based on the TAD with substitution of pulses for lean meat and grains. This diet will feature 1.5 cups of pulses per day at 2,000 kilocalories (kcals).
223568197|NCT02970630|DRUG|Tacrolimus|once a day
223568198|NCT02970630|DRUG|Everolimus|twice daily
223568199|NCT05725486|DIETARY_SUPPLEMENT|N-3 PUFAs Chicken Meet|Intake of n-3 PUFAs enriched chicken meet for three weeks.
223568200|NCT05725486|DIETARY_SUPPLEMENT|Regular Chicken Meet|Intake of regular chicken meet for three weeks.
224164070|NCT01190020|DRUG|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
223568201|NCT01639573|DRUG|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
223568202|NCT04850391|OTHER|Mobile app|To compare changes induced by the movile app intervention among the three study groups
223568203|NCT03350958|DIETARY_SUPPLEMENT|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
223568204|NCT03350958|OTHER|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
223568205|NCT03273647|RADIATION|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
223568206|NCT05456568|DEVICE|LymphAssistTM Professional|An intermittent pneumatic compression (IPC) device that mimics manual lymphatic drainage. Participants use the device daily for 12 weeks alongside their usual and standard lymphoedema care
223568207|NCT01833728|DRUG|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
223568208|NCT01833728|DRUG|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
223568209|NCT05031091|OTHER|standardised exposure questionnaire|A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
223568210|NCT01180894|DRUG|Iron sucrose|100 mg IV TIW
223568211|NCT01180894|DRUG|Placebo|
223568212|NCT00812409|DIETARY_SUPPLEMENT|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
223568213|NCT00812409|OTHER|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
223568214|NCT01259648|DRUG|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
223445754|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar medial branch nerve injection.|"While in prone position, lumbar facet joints are identified by fluoroscopy. An anteroposterior image of the lumbar vertebrae is obtained. Then, the fluoroscope is tilted between 10 to 20 degrees to the side to inject. 22 gauge needles are then advanced aiming to the medial branch of lumbar facet joints.~The selection of target facet joints is made based on clinical findings. Some patients receive bilateral while other unilateral facet joint denervation. Correct positioning is confirmed with anteroposterior and lateral fluoroscopy. A mixture of 3 ml of ropivacaine 0,2% + 1 ml (40 mg) of triamcinolone (trigon depot) is prepared. 1 ml of the mixture is injected in each lumbar facet joint through the needles. Four facet joints are selected for therapy. Some patients receive bilateral and other unilateral but contiguous medial branch nerve injection."
223445755|NCT04451252|PROCEDURE|Fluoroscopically guided lumbar epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the interlaminar approach using a loss of resistance technique for the identification of the lumbar epidural space. When loss of resistance is encountered, 1 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 4 ml of ropivacaine 0,1%, 2 ml (12 mg) of betamethasone and 2 ml of saline serum is injected in the epidural space. The lumbar level to which it infiltrates depends on each patient.
223445756|NCT04451252|PROCEDURE|Fluoroscopically guided caudal epidural corticosteroid injection.|With the patient in prone position and guided by fluoroscopy, an epidural needle attached to a syringe filled with saline serum is advanced through the sacral hiatus using a loss of resistance technique for the identification of the epidural space. When loss of resistance is encountered, 2 ml of iodinated contrast is injected. After fluoroscopical confirmation of epidural spilling, a mixture of 7 ml of ropivacaine 0,2%, 2 ml (12 mg) of betamethasone and 7 ml of saline serum is injected in the epidural space.
223445757|NCT04451252|PROCEDURE|Fluoroscopically guided pulsed radiofrequency of the lumbar dorsal root ganglion.|With the patient in prone position and guided by fluoroscopy, a 18 gauge needle is advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root. Then, the needle is attached to the radiofrequency device. Correct positioning of the needles is confirmed also by sensitive stimulation (paresthesia evocation) with the following settings: 50 Hz, 1ms, 0,6V. In order to avoid motor lesion, it is confirmed that no motor response is produced with 2Hz, 2ms and twice the voltage that produced sensitive response. After correct positioning is confirmed, pulsed radiofrequency ablation of lumbar dorsal root ganglion is performed using the following settings: 4 minutes, 42ºC (degrees Celsius).
223445758|NCT04451252|PROCEDURE|Fluoroscopically guided transforaminal epidural corticosteroid injection or lumbar selective root block.|With the patient in prone position and guided by fluoroscopy, a 22 french needle is then advanced aiming to the intervertebral foramen. Patient is cautioned about the paresthesia which will be felt along the course of the lumbar root when the needle touches the nerve. A lateral view was taken occasionally to confirm position. 0.5 ml of iodinated contrast is injected to confirm the position of the needle. Then 1 ml of the combination of 12mg of betamethasone and 1ml of ropivacaine 0.2% is injected over the affected root.
223445759|NCT02503254|OTHER|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
223445760|NCT02503254|OTHER|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
223445761|NCT00196430|DEVICE|silver-contained textiles|
223445762|NCT00196430|DRUG|corticosteroid|
223445763|NCT00964015|DRUG|6% Hydroxyethyl Starch 130/0.4|
223445764|NCT00964015|DRUG|0.9% Normal Saline|
223445765|NCT04558489|BEHAVIORAL|IPR + GMI|The IPR + GMI intervention aims to impact reported hopelessness, attitudes to treatment, and view of self as changeable as well as targets treatment attendance and utilization.
223445766|NCT02671656|DEVICE|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
223445767|NCT03142373|OTHER|CV4 technique|
223445768|NCT03142373|OTHER|RR technique|
223445769|NCT03142373|OTHER|Placebo treatment|
223445770|NCT03906851|BEHAVIORAL|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
223445771|NCT05322356|OTHER|Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D|Target dose supplement with the TRINITY® PERINE 3D system
223445772|NCT05350345|OTHER|Root-cause analysis|The first part of this study involves a report with a root-cause analysis done by the students. The second part is a gamification in which they have to evaluate each other and give feedback.
223568215|NCT01259648|DRUG|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
223568216|NCT01259648|DRUG|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
223568217|NCT02539173|OTHER|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
223568218|NCT02135328|BEHAVIORAL|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
223568219|NCT02135328|BEHAVIORAL|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
223568220|NCT02894164|OTHER|No intervention|
223741506|NCT04422054|PROCEDURE|Open Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent open surgical repair.
223741507|NCT04422054|PROCEDURE|Endovascular Surgery|We will retrospectively review patients with abdominal aortic aneurysms that underwent endovascular repair.
223741508|NCT01832870|DRUG|sipuleucel-T|
223445773|NCT05631782|DRUG|Shenkang decoction|Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
223445774|NCT03988972|DEVICE|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
223445775|NCT03988972|DEVICE|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
223445776|NCT01663194|PROCEDURE|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
223445777|NCT04365049|RADIATION|Radiotherapy|Radiotherapy started after two cycles of chemotherapy. External beam radiation therapy was performed using an intensity modulated radiation therapy technique. The gross target volume included the gross primary tumor and positive regional lymph nodes as defined by the multiphasic imaging. A total radiation dose greater than 50 Gy without damaging organ function was the essential requirement.
224055067|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
224055068|NCT01141504|DIETARY_SUPPLEMENT|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
224055069|NCT00764595|DRUG|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
224055070|NCT00900458|BEHAVIORAL|Aerobic Exercise training|aerobic exercise training (cycling)
224055071|NCT00950508|PROCEDURE|High volume plasma exchange|3 high volume plasma exchanges over 3 days
224055072|NCT00950508|PROCEDURE|Standard medical treatment|Standard medical treatment
224055073|NCT02656095|DRUG|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
224055074|NCT02170675|DRUG|Dabigatran etexilate|
224055075|NCT02170675|DRUG|Ketoconazole|
224055076|NCT04169087|OTHER|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
223568221|NCT05285215|PROCEDURE|Integrated psychological program (IPP)|"Patients will listen to the music for 30 minutes before delivery, and resume music listening once they are comfortable after delivery. Upon discharge, they will be asked to have music listening at least 30 minutes per day until 8 weeks postnatal survey.~Mindfulness training via mobile application is administered before delivery. After delivery, they are asked to perform mindfulness training for 10 minutes daily, until last follow-up at 8 weeks post-delivery.~Mobile electronic survey will be used to assess patients' EPDS scores fortnightly, until the last follow-up at week 8 post-delivery. If the EPDS scoring is found to be equal to or more than 10, video counselling and/or face-to-face consultation will be arranged.~Video counselling sessions will be offered if patients are found to have EPDS score of 10-12. For women found to have EPDS≥13, a face-to-face initial psychiatry consultation will be conducted."
223568222|NCT04585269|BEHAVIORAL|Bright IDEAS-YA|Bright IDEAS-YA is a manualized problem-solving skills training intervention conducted by a trainer who teaches the participant the Bright IDEAS stepwise approach to problem-solving and guides the participant through solving their own problems using the Bright IDEAS approach.
223568223|NCT06343350|DEVICE|OPTDR01 software application|Retinal images will be sent to the OPTDR01 software application for mtmDR and vtDR detection
223568224|NCT03782207|DRUG|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
223568225|NCT03324529|DEVICE|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (\<10 breaths/min) with prolonged exhalation.
223741509|NCT01832870|DRUG|ipilimumab|
223445778|NCT04365049|DRUG|Nab-paclitaxel|Eight 21-day cycles of nab-paclitaxel 125 mg/m² by intravenous infusion for approximately 30-45 mins on days 1 and 8.
223741510|NCT00117247|DRUG|darbepoetin alfa|
224055077|NCT04327830|OTHER|Decisional needs assessment|Assessment of decision-making needs
224055078|NCT06001996|PROCEDURE|Pericapsular nerve group (PENG) block|Pericapsular nerve group (PENG) block: Using an in-plane approach with ultrasonographic imaging, the block needle reaches the fascial plane between the psoas muscle and the superior pubic ramus and local anaesthetic solution is injected.
224055079|NCT06001996|PROCEDURE|Suprainguinal fascia iliaca plane block|Suprainguinal fascia iliaca plane block: The needle entering in plane from the caudal end of the ultrasound probe passes through the m. sartorius and into the musculus iliacus and fascia iliaca reaches. The fascia iliaca is passed with the needle and local anaesthetic solution is injected immediately under the fascia.
224055080|NCT03540225|DRUG|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
224055081|NCT03700281|BEHAVIORAL|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
224055082|NCT03700281|BEHAVIORAL|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
223445779|NCT04365049|DRUG|Gemcitabine|Eight 21-day cycles of gemcitabine 1000mg/m² intravenous infusion for approximately 30 mins on days 1 and 8.
223445780|NCT04365049|DRUG|Camrelizumab|Anti-PD-1 antibody (camrelizumab, Hengrui Medicine Co., Ltd) 200 mg was administered intravenously for 30 mins every three weeks. During the chemotherapy-treated period, camrelizumab was administered on day 1 of each 21-day cycle before the infusion of chemotherapy.
223445781|NCT01624402|BEHAVIORAL|Education on Stroke and Depression (ESD)|"* Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~* Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~* Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~* ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
223445782|NCT01624402|BEHAVIORAL|Ecosystem Focused Therapy (EFT)|"1. EFT offers an action-oriented, new perspective about the subject's recovery;~2. It provides an adherence enhancement structure;~3. It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~4. It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~5. It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
223445783|NCT04757233|BEHAVIORAL|GlucoType|GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
223445784|NCT03230136|OTHER|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
223445785|NCT03230136|OTHER|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
223445786|NCT00621517|DRUG|Bupropion|Partipants will receive 150 mg bupropion per night
223445787|NCT00621517|DRUG|Placebo|1 capsule nightly for six weeks
223445788|NCT05376020|DEVICE|Densah Burs|Densah Burs will be used in the intervention group
223445789|NCT05376020|DEVICE|Conventional Burs|Conventional Burs will be used in the control group
223445790|NCT03213418|BEHAVIORAL|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
223445791|NCT02249013|PROCEDURE|Cytoreductive Surgery (CRS)|CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
223445792|NCT02249013|PROCEDURE|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
223445793|NCT02249013|DRUG|Neoadjuvant Chemotherapy (NACT)|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
223445794|NCT02249013|DRUG|Adjuvant Chemotherapy|Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
223445795|NCT02249013|PROCEDURE|Fast-track recovery strategy|A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
223445796|NCT03429283|OTHER|descriptive retrospective epidemiological study|descriptive retrospective epidemiological study
224055083|NCT00404820|DRUG|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
223568226|NCT00709293|DRUG|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
223568227|NCT00709293|DRUG|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
223568228|NCT03501004|DEVICE|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
223568229|NCT03276026|DRUG|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
223568230|NCT03276026|DRUG|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
224055084|NCT00404820|DRUG|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
224055085|NCT00404820|DRUG|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
223445797|NCT00110799|DRUG|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
223445798|NCT00110799|OTHER|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
223445799|NCT02536274|DEVICE|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
223445800|NCT02536274|DEVICE|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
223445801|NCT00073008|DRUG|GW572016 (lapatinib)|tyrosine kinase inhibitor
223445802|NCT03353181|DEVICE|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
223445803|NCT03353181|DEVICE|Biliary stent|Standard placement of biliary stent
223445804|NCT06364202|DIETARY_SUPPLEMENT|Peanut Butter|2 tablespoons of peanut butter
223445805|NCT05569993|DRUG|Glutamine|.3 mg/kg of glutamine
223445806|NCT05569993|OTHER|Placcebo|Patients will recieve placcebo
223445807|NCT03955809|DRUG|Ketamine 0.5|İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
223445808|NCT03955809|DRUG|Ketamine 1|İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
223445809|NCT03955809|DRUG|% 0.9 NaCl|Intraarticular %0.9 NaCl
223445810|NCT02669667|DRUG|MEDI9314|single dose of MEDI9314
223445811|NCT02669667|DRUG|placebo|single dose of placebo
223445812|NCT03713996|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
223445813|NCT03713996|OTHER|Health Education|Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
223741511|NCT04216654|DIAGNOSTIC_TEST|ELISA (enzyme-linked immunosorbent assay)|ELISA Principle. Enzyme-linked Immunosorbent Assays (ELISAs) combine the specificity of antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens coupled to an easily-assayed enzyme. ELISAs can provide a useful measurement of antigen or antibody concentration.
223741512|NCT04723940|DRUG|Bactrim|Bactrim will be given for 6 weeks to treat joint infection
223741513|NCT04723940|DRUG|Cefadroxil|Cefadroxil will be given for 6 weeks to treat joint infection
223445814|NCT00600405|DRUG|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
223445815|NCT00600405|DRUG|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
223445816|NCT00003028|DRUG|sabarubicin|
223445817|NCT04586335|DRUG|CYH33|Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor
223445818|NCT02839876|DRUG|Intravenous acetaminophen|Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
223445819|NCT02839876|DRUG|Oral acetaminophen|Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
223741514|NCT04723940|DRUG|Doxycycline Hcl|Doxycycline HCl will given for 6 weeks to treat joint infection
223741515|NCT04723940|DRUG|Clindamycin|Clindamycin will given for 6 weeks to treat joint infection
223741516|NCT00280956|DRUG|natalizumab|
223741517|NCT00487851|PROCEDURE|surgery|hepaticojejunostomy and gastroenterostomy
223741518|NCT00487851|PROCEDURE|endoscopic strategy|Stent insertion
223445820|NCT03385369|DRUG|MEDI0382|Single dose of MEDI0382
223445821|NCT03385369|DRUG|Placebo|Single dose of placebo
223445822|NCT05392088|OTHER|DATA EXTRACTION|"For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status."
223445823|NCT05392088|OTHER|FOLLOW-UP|All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
223445824|NCT00000997|DRUG|Zalcitabine|
223445825|NCT02414802|DEVICE|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
223445826|NCT02414802|PROCEDURE|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
223445827|NCT02414802|DRUG|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
223445828|NCT02414802|DRUG|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
223741519|NCT00157703|DRUG|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
224055086|NCT03785990|OTHER|adipose tissue|taking a sample of the adipose tissue during operation
224055087|NCT03785990|OTHER|blood|taking a blood sample when a peripheral venous catheter is inserted before operation
224055088|NCT03785990|DIAGNOSTIC_TEST|PEAPOD|Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
223445829|NCT06730178|BEHAVIORAL|relaxation training|The training tapes used were meditation relaxation training tapes translated form Jacobson progressive relaxation technique with copyrights. The tapes were recorded by a male therapist. Participants were instructed to perform the treatment in the evening, preferably just before bedtime, total time was 15 minutes.
223445830|NCT03985488|RADIATION|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
223445831|NCT04261010|PROCEDURE|Global/single cell gene expression profiles obtained from Synovial biopsies|Global/single cell gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug.
224145924|NCT03579225|DEVICE|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
223445832|NCT02721017|DEVICE|Cryoanalgesia|
224055089|NCT06571279|OTHER|Plant-based diet|Standard plant-based meals will be provided directly to participants. The dietary intervention will begin with a one-week Western diet run-in; hereafter, participants will consume plant-based meals for approximately 5 weeks. Total energy provided will be equal to REE X 1.4 to account for light physical activity to support weight maintenance. High-inositol snacks will be provided to meet energy needs. Meals and snacks combined will provide a minimum of 20mg total inositol/kg body weight. For example, a 200lb participant will consume 1.8g daily, which is consistent with doses used in prior studies.
224055090|NCT04184687|PROCEDURE|Nanofractures|anterior cruciate ligament reconstruction will be performed in combination with the nanofractures for the treatment of cartilaginous lesions
223445833|NCT02721017|DRUG|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
223445834|NCT00571753|DRUG|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
223445835|NCT00571753|DRUG|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
223445836|NCT05513768|DIAGNOSTIC_TEST|level of myosin binding protein c in serum|Serum samples will be taken from the participants in the first trimester, transferred to eppendorf tubes after appropriate procedures, and stored at -80 degrees until the time of deliveryParticipants will be divided into two groups according to the timing of birthThe first group is those who gave birth earlier than 37 weeks those who gave birth on time in the other group The mbpc levels will be looked at and compared.
223445837|NCT00430456|PROCEDURE|Exercise|Treadmill Training
224055091|NCT04184687|PROCEDURE|no treatment cartilaginous lesions|patient undergoing to the anterior cruciate ligament reconstruction without treatment of the cartilaginous lesions
224055092|NCT02724254|DRUG|AP611074 5% gel|
223445838|NCT05739656|PROCEDURE|CATARACT SURGERY|Approximately up to 100 subjects (100 eyes) will be successfully implanted with an enVista Toric IOL (Model MX60ET) in one or both eyes.
223445839|NCT01841034|DRUG|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
223445840|NCT04973241|RADIATION|OPG & CBCT|panoramic images , cone beam computed tomography
223445841|NCT01156051|DRUG|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
223445842|NCT01156051|DRUG|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
223445843|NCT06505278|DRUG|Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening|Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
223445844|NCT03963778|BEHAVIORAL|Improving nutritional care|The interventions will be co-designed with the action research team
223445845|NCT01218971|DRUG|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
223445846|NCT01218971|DRUG|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
223445847|NCT03406000|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
223445848|NCT01846806|OTHER|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
223568231|NCT03215303|DEVICE|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
224055093|NCT02724254|DRUG|AP611074 matching placebo|
224055094|NCT01764542|PROCEDURE|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
224055095|NCT03649282|OTHER|HFNC|HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
223445849|NCT03581617|DIAGNOSTIC_TEST|NK cell analysis|"We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~\- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry"
223445850|NCT03581617|DIAGNOSTIC_TEST|Herpesvirus detection|Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
223445851|NCT03581617|DIAGNOSTIC_TEST|sHLA-G analysis|sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
223445852|NCT03581617|DIAGNOSTIC_TEST|HLA-G 14bp INS/DEL typing|Genomic DNA will be genotyped by RealTime PCR
223568232|NCT01169415|DRUG|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
223568233|NCT01169415|DRUG|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
223568234|NCT03263130|OTHER|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
223568235|NCT04275271|BEHAVIORAL|Educational intervention|Skill centered Protocol Training based on IMB model
223568236|NCT06539858|OTHER|massage|General back massage from the base of the neck to the sacrum. Classical massage techniques such as stroking and kneeding will be applied. To be performed by a specialist physiotherapist.
223741520|NCT03019107|DEVICE|Breath synchronized abdominal NMES|VentFree prototype (VF03) that delivers electrical stimulation pulses to the abdominal muscles during exhalation with a frequency of 30 Hz, a pulse width of 350 µs and 90% of the maximum current that the participant can tolerate. These stimulation parameters were selected to cause a tetanic (continuous) contraction of the abdominal muscles, without pain for the patient. Stimulation will be administered for 30 minutes 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
224055096|NCT03649282|OTHER|NCPAP|NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
224055097|NCT06490588|OTHER|sevoflurane|No intervention
224055098|NCT05187546|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
224055099|NCT02366442|OTHER|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
224055100|NCT02590120|DIETARY_SUPPLEMENT|Enteral nutrition|
224055101|NCT02385981|DEVICE|Stivax|
224055102|NCT04022187|OTHER|Observational study : no intervention|Observational study : no intervention, only exporting data
224055103|NCT05915689|OTHER|Myofascial arm pull technique|patient in supine position move the arm passively in abduction to the restricted barrier and pull the arm only enough traction was used to counterbalance the weight of the patient's arm. Stretch was hold until the fibers were released, and then, stretch was given again by increasing traction. This sequence was repeated until an end feel was reached. same procedure for flexion and scapular protraction and Horizontal-adduction. Repetition will be 4-5 reps. per set, 3 times per week for 18 sessions.
224055104|NCT05915689|OTHER|post isometric relaxation technique|The therapist stood in front of the patient, then placed one hand over the top of the subject's involved shoulder. The therapist cups the gleno humeral joint to palpate for motion and the subjects are directed to press the elbow towards therapist hand for shoulder abduction, internal rotation and external rotation. Muscle energy technique was applied for five repetitions per set, five sets per session, one session per day, three days a week for six weeks with each repetition maintained for the duration of 7-10 second
223445853|NCT03581617|DIAGNOSTIC_TEST|sHLA-E analysis|sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
223445854|NCT04660773|DEVICE|NB UVB phototherapy|ultraviolet phototherapy sessions
223445855|NCT04660773|DRUG|Pregabalin|oral medication
223568237|NCT02478697|BEHAVIORAL|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
223568238|NCT02965742|DEVICE|Stratos|A machine made by DMS group.
223568239|NCT02965742|DEVICE|"Hologic QDR 4500A"|A machine made by Hologic inc.
223568240|NCT02965742|DEVICE|"Hologic HORIZON A"|A machine made by Hologic inc.
223568241|NCT01818739|PROCEDURE|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
223568242|NCT01818739|DRUG|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
223568243|NCT01818739|DRUG|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
223568244|NCT01818739|PROCEDURE|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
223568245|NCT04717648|DIAGNOSTIC_TEST|Biochemical test|C Reactive protein and sodium
223568246|NCT04155086|BIOLOGICAL|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
224055105|NCT00177749|DRUG|Posaconazole|
223445856|NCT00347594|DEVICE|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
223445857|NCT00347594|DEVICE|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
224055106|NCT04319575|DRUG|root canal treatment and intracanal medicament|"after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks."
224055107|NCT05099341|OTHER|HDRS-17 depression scale|Measuring the severity of depression
224055108|NCT05099341|BIOLOGICAL|Blood sampling|3 tubes of 5 ml
224055109|NCT03549156|DIETARY_SUPPLEMENT|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
224055110|NCT03549156|DIETARY_SUPPLEMENT|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
224055111|NCT00603460|BIOLOGICAL|DCVax-L and T Cells|"Arm A~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* End of study visit~Arm B~* Optional DCVax-L prior to chemotherapy~* Apheresis~* Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~* Infusion of activated T cells~* DCVax-L vaccine~* Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~* End of study visit"
223445858|NCT07010952|DIAGNOSTIC_TEST|AI-based image analysis|AI-based imaging analysis
223445859|NCT07010952|OTHER|AI-based imaging analysis|AI-based imaging analysis
223445860|NCT07005518|OTHER|No Intervention: Observational Cohort|This is a non-interventional observational study. It will simply look at the data and compare them between the monitors provided.
223445861|NCT06183125|BEHAVIORAL|Traditional Chinese Medicine-based program|"Week1-2: one health talk session(60 mins); three workshops (each workshop will last for 60-90mins) to provide hands-on training in Baduanjin, acupressure techniques, mindful stretching, and effective strategies to combat sedentary behavior in the workplace.~Week 3-4: group practice sessions will take place for one hour every other day throughout the workweek; website support."
223445862|NCT07019831|PROCEDURE|Body positioning|Each subject will breathe in both the supine and prone positions, randomly applied for 15 minutes each. The procedure will be performed twice: once for the assessment of respiratory physiology, and once for computed tomography acquisition.
223445863|NCT07015996|BIOLOGICAL|Tezepelumab|"Monotherapy Period: Participants randomized to tezepelumab will receive two subcutaneous (SQ) injections of tezepelumab 210 mg during the monotherapy period.~Combination Therapy Period: Participants randomized to Tezepelumab will continue to receive Tezepelumab 210 mg every 4 weeks.~Withdrawal Period: Participants will stop receiving Tezepelumab injections."
223445864|NCT07015996|DRUG|Peanut Oral Immunotherapy (OIT)|"Monotherapy Period: Not Applicable. Combination Therapy Period: During combination therapy period, each participant will start peanut OIT. Participants will start on a minimum of 0.1 mg peanut OIT, with starting dose depending on last tolerated dose from screening double-blind placebo-controlled food challenge (DBPCFC) and build to a maximum of 6 mg peanut OIT on the initial dose escalation (IDE) day. Participants will return every 2 weeks for dose escalation to a goal maintenance dose of 2000 mg peanut protein.~Withdrawal Period: Participants will stop peanut OIT."
223445865|NCT07015996|BIOLOGICAL|Placebo for Tezepelumab|"Monotherapy Period: Participants randomized to placebo for tezepelumab will receive two subcutaneous (SQ) injections of placebo 210 mg during the monotherapy period.~Combination Therapy Period: Participants randomized to placebo will continue to receive placebo for Tezepelumab every 4 weeks.~Withdrawal Period: Participants will stop receiving placebo injections."
223445866|NCT03443258|OTHER|Needs assesment tool integrated in nursing consultation.|Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
223741521|NCT03019107|DEVICE|Sham breath synchronized abdominal NMES|Modified VentFree prototype (VF03) that delivers stimulation pulses to the abdominal muscles during exhalation with a frequency of 10 Hz, a pulse width of 100 µs and current set to 10 milliamp. These stimulation parameters were chosen to cause a twitch contraction of the abdominal wall muscles. Stimulation will be administered for 30 minutes, 2 times per day, 5 days per week, for 6 weeks; or until the patient is weaned from mechanical ventilation.
224055112|NCT01914380|DRUG|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
224055113|NCT01360554|DRUG|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
224055114|NCT01360554|DRUG|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
224055115|NCT01360554|DRUG|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
224055116|NCT01360554|DRUG|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
224055117|NCT05939674|DRUG|Flumazenil|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.
224055118|NCT05939674|DRUG|normal saline|During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.9% normal saline according to allocated groups.
224055119|NCT02210065|BIOLOGICAL|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
224055120|NCT04442295|DRUG|STK-001 - Single Ascending Doses|Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
223445867|NCT07022821|DRUG|Dexmedetomidine|"Dexmedetomidine infusion at one of the following doses:~Group A: 0.2 µg/kg/hr Group B: 0.3 µg/kg/hr Group C: 0.4 µg/kg/hr Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period"
223445868|NCT07022821|DRUG|ketamine|"Ketamine infusion at a fixed dose of 0.25 mg/kg/hr administered in all three groups.~Route of Administration: Intravenous Frequency: Continuous infusion during postoperative period"
223445869|NCT07022951|OTHER|Preoperative fasting|This cohort study assesses the duration of preoperative fasting and its clinical effects
223568247|NCT05093595|DEVICE|SFC|The lubricated SFC passed nasally into the oropharynx under the visual guidance of visual laryngoscope to ensure that the cuff had passed through the posterior choanae and reached the oropharynx. The guide wire is removed and the balloon inflated with 5 ml normal saline. The catheter is then pulled slightly until the balloon is fixed and concealed by the soft palate . The ETT is anchored to the SFC with a cable tie .
224055121|NCT04442295|DRUG|STK-001 - Multiple Ascending Doses|Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
223568248|NCT00350363|DRUG|Zymar|zymar qid
223568249|NCT04011826|DEVICE|Device: Trial nasal mask (F&P)|This trial nasal mask will serve as the participant's primary PAP/BPAP therapy mask for the duration of the trial period (from Visit 2 to Visit 3). For participants taking part in the study extension, they will be using the trial nasal mask as their primary PAP/BPAP therapy mask for 6 months after Visit 3.
223568250|NCT03172962|BEHAVIORAL|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
223568251|NCT03172962|BEHAVIORAL|Usual care (control)|Will receive the usual care at the hospital
224055122|NCT05419960|DIAGNOSTIC_TEST|Vestibular Assessment|"During the usual hearing assessment (immittance testing and pure-tone and speech audiometry) carried out by patients, a vestibular assessment will be done for the study to detect vestibular disorders:~* Videonystagmography (VNG) Is the study of eye movement with the help of infrared googles.~* Subjective Visual Vertical (SVV) The patient is asked to orient a line on the vertical axis.~* Video Head Impulse Test (vHIT)~* Cervical and Ocular Vestibular Evoked Myogenic Potential (cVEMP and oVEMP)"
224055123|NCT05419960|DIAGNOSTIC_TEST|Petrous bone Computed Tomography (CT)|"For patients diagnosed with hearing loss, whether conductive, mixed, and/or a vestibular deficit, a CT scan (without injection) will be proposed for their care.~Petrous bone Computed Tomography (CT) is an imaging technique used as the standard method of evaluation of the boney structures in the ear."
224055124|NCT05419960|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|"Patients that have done a CT and for who CT results was abnormal, will additionally require an MRI for their standard care.~Magnetic Resonance Imaging (MRI) is an imaging technique used as the standard method of evaluation of the cochlear, retrocochlear and central and peripheral nervous system. An injection of Gadolinium contrast media will be used to enhance certain recordings."
224055125|NCT05258409|BEHAVIORAL|Media Advocacy (MA)|MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.
224070864|NCT02200315|OTHER|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
224070865|NCT03889561|BEHAVIORAL|Drink Tap|The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
223445870|NCT07026643|DEVICE|active aVNT vs. Sham|Patients in both groups will receive daily stimulation with the Parasym device, temporarily connected to the tragus of the right ear (Fig 2).54 The stimulation parameters will be frequency of 20 Hz, pulse width of 200 µs, and the stimulation amplitude will be titrated to 1 mA below the discomfort threshold, consistent with parameters used in published clinical studies.54-56 With this stimulation at just below the discomfort threshold, people will often feel the stimulation for less than 60 seconds before they lose awareness of the ongoing stimulation. The stimulation will continue for 1 hour daily for 3 months, and we will track its use with a patient diary. Participants can continue their regular activities while wearing the aVNT device, as long as it is not soaked in water. Parasym will obtain Health Canada approval for use of their device in the study.
223445871|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
223568252|NCT02276352|DRUG|Treatment 1|
223568253|NCT02276352|DRUG|Treatment 2|
223568254|NCT02276352|DRUG|Treatment 3|
223568255|NCT04138914|DEVICE|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
223568256|NCT03618732|OTHER|Bilateral movement-based computer training|
223568257|NCT03618732|OTHER|Video-directed conventional training|
223568258|NCT01542697|DRUG|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
223568259|NCT03828903|DEVICE|Cryoprobe|"* The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~* The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~* The frozen tissue is going to be extracted by gently pulling of the probe.~* Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~* The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~* The biopsy sample will be released from the probe by thawing in the saline.~* The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
223741522|NCT03953573|OTHER|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
223445872|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445873|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 1 Hz)|Low frequency stimulation (1 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445874|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% + 10 Hz)|High frequency stimulation (10 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
224070866|NCT01770925|DEVICE|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
223445875|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 10 Hz)|High frequency stimulation (10 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445876|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 10 Hz)|High frequency stimulation (10 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445877|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (90% MT + 25 Hz)|High frequency stimulation (25 Hz) at 90% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445878|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (100% MT + 25 Hz)|High frequency stimulation (25 Hz) at 100% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445879|NCT07026760|DEVICE|Trans-spinal magnetic stimulation (110% MT + 25 Hz)|High frequency stimulation (25 Hz) at 110% of resting motor threshold intensity, delivering a total of 2400 pulses.
223445880|NCT07027358|DEVICE|NETSmart software|Use of NETSmart software by healthcare professionals
223445881|NCT00687882|OTHER|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
223445882|NCT00687882|OTHER|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
223445883|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
223445884|NCT00687882|OTHER|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
223568260|NCT01595230|PROCEDURE|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
223568261|NCT04049266|DRUG|KSI-301|Intravitreal Injection
223741523|NCT05643365|RADIATION|Radioactive Iodine therapy|All the patient need to stop ATD and iodine-containing drugs for 5 days prior to RAI treatment, and followed a low-iodine diet for 2 weeks. After fasting and water deprivation for 8 h, all the patients took RAI orally in the morning. After taking RAI, the patients need to continue fasting and water deprivation for extra 2 h to avoid the effects of food on iodine absorption.
223741524|NCT05305534|DEVICE|QIAstat-Dx® BCID GN and GPF Plus AMR Panels|The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested
223445885|NCT07026500|BIOLOGICAL|EV71 Vaccine|EV71 vaccine of commercial production batch
223445886|NCT07026682|DRUG|Low Osmolar ORS|"Composition: Na⁺ 75 mmol/L, K⁺ 20 mmol/L, Cl- 65 mmol/L, citrate 10 mmol/L, glucose 75 mmol/L; osmolarity 245 mmol/L.~Administered orally in rehydration regimen over 24 hours."
223445887|NCT07026682|DRUG|ReSoMal|"Composition: Na⁺ 45 mmol/L, K⁺ 40 mmol/L, Cl- 76 mmol/L, citrate 7 mmol/L, glucose 125 mmol/L, Mg 6 mmol/L, Zn 300 µmol/L, Cu 45 µmol/L; osmolarity 300 mmol/L.~Administered orally over 24 hours according to rehydration protocol."
223445888|NCT07025967|BEHAVIORAL|Mölkky|The Mölkky group participants receive two-hour weekly or bi-weekly Mölkky training sessions at their elderly community centers. In the sessions, participants are divided into two teams, taking turns throwing a wooden pin called the Mölkky to hit 12 smaller skittles. The fallen skittles are placed upright where they landed after each turn. The first team that reaches exactly 50 points wins.
223445889|NCT07025967|BEHAVIORAL|Home activity|The participants in the home program receive weekly visits by social workers, physiotherapists, or occupational therapists at their homes for an activity regime including closed-skilled exercises and cognitive training. The closed-skilled exercises included stretching, elastic band exercises and functional exercises like tandem standing and bridging. Cognitive training included reality orientation, memory exercises, calculation, and mind-body exercises like Baduanjin.
223445890|NCT02855177|DRUG|Placebo|Placebo as suspension administered every 8 hours, with food
223445891|NCT02855177|DRUG|PF-06427878|500 mg suspension administered every 8 hours, with food
223568262|NCT04049266|DRUG|Aflibercept|Intravitreal Injection
223568263|NCT04049266|OTHER|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
223568264|NCT03315897|DRUG|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
223568265|NCT03315897|DRUG|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
223568266|NCT05088083|DEVICE|Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon|After predilation, using drug-coated balloon catheter to cover the whole treated segment
223445892|NCT06757634|DRUG|Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant|"Drug: Gedatolisib Participants will receive intravenous (IV) gedatolisib once weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off~Other Names:~• PF-05212384 Drug: Palbociclib Participants will receive oral palbociclib on days 1-21 of each 28-day cycle.~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI® Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks~Other Names:~• Faslodex"
223445893|NCT06757634|DRUG|Arm B: Palbociclib or Ribociclib + Fulvestrant|"Drug: Palbociclib Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle~Other Names:~• IBRANCE Drug: Ribociclib Participants will receive oral ribociclib on Days 1-21 of each 28-day cycle~Other Names:~• KISQALI®~Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant approximately every 2 weeks during Cycle 1 then approximately every 4~Other Names:~• Faslodex"
223445894|NCT00653302|DRUG|Lantus (insulin glargine) + Glucophage (Metformin)|
223445895|NCT05447676|DRUG|Dalfampridine|The study drug (4-AP) will be administered as a 10 mg dose.
223445896|NCT05447676|OTHER|Placebo drug|The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.
223445897|NCT05447676|OTHER|STDP stimulation|Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
223445898|NCT05447676|BEHAVIORAL|Exercise training|Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
223445899|NCT02071082|DRUG|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
223445900|NCT02870127|OTHER|blood sample|
223445901|NCT04620954|DRUG|Oregovomab|2mg of Oregovomab is administered through IV on Weeks 1, 5, 9, 17.
223445902|NCT04620954|DRUG|Nivolumab|480mg of Nivolumab is administered through IV every 4 weeks (Weeks 9, 13, 17, 21).
224055126|NCT05258409|BEHAVIORAL|More than Muscles (MTM)|"In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal."
224055127|NCT06464107|DEVICE|PadKit™ from Preprogen|"The interlabial pad is classified as a Class 1 device by the FDA and the device is exempt from requiring a 510(k) approval.~The interlabial pad is worn for 4-6 consecutive hours and collects cells shed from the cervix and uterine cavity. The pad is then removed and placed in the smaller, inner tube that contains the transport solution. After replacing the lid securely, it is then carefully placed back inside the larger outer tube with the outer lid secured and returned to the original box. The entire box is placed in the polybag and mailed back to the lab for analysis."
224055128|NCT00187096|DRUG|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
223445903|NCT04620954|DRUG|Chemotherapy|Pegylated liposomal doxorubicin (PLD) and carboplatin are administered every 4 weeks through IV. The starting dose of PLD and carboplatin are 30mg/m\^2 and 5 AUC (Area Under the Curve) respectively.
223445904|NCT06061211|OTHER|TREADMILL(SIDEA-Germany treadmill ) with TENS|"TENS:~MH8001 Portable tens 45 min. three times/ week 2-120 HZ 200ms~treadmill: SIDEA-Germany treadmill three times/week, 45min, moderate intensity according to claudication pain scale 2MPH(3.5KM/h) 0% grade then increase by 2% every 2min."
223445905|NCT05247892|PROCEDURE|Ultrasound-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance
224055129|NCT00187096|PROCEDURE|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
223445906|NCT05247892|PROCEDURE|Fluoroscopic-guided S1 Radiofrequency stimulation|Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
223445907|NCT00624650|DRUG|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~1. Continuous IV furosemide at 3mg/hour or last known protocol specified dose~2. Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~3. Do not exceed 30mg/hour~Furosemide Bolus:~1. If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~2. By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~3. Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
223445908|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP\<8 or measured PaOP \<12mmHg in addition to concurrent urine output of \<0.5 ml/kg/hr
223445909|NCT00624650|OTHER|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases \> 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map \< 60 or who are on vasopressors that also have a measured GEDI less than goal"
223568267|NCT00851981|OTHER|Placebo|TID
223568268|NCT00851981|DIETARY_SUPPLEMENT|SAMe|300 mg TID
223568269|NCT01703208|DRUG|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
223568270|NCT01703208|DRUG|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
223568271|NCT05449379|OTHER|Respiratory training with the use of resistance set on respiratory muscle trainer|Performing respiratory training with resistance set on respiratory trainer.
223568272|NCT05449379|OTHER|Respiratory training without resistance set on respiratory muscle trainer|Performing respiratory training with no resistance set on respiratory trainer
223445910|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
223445911|NCT00624650|DRUG|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~1. Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~2. Vasopressin - 0.04 international units/hour~3. Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~4. Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of \< 60"
223568273|NCT00948233|BEHAVIORAL|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
223568274|NCT00948233|BEHAVIORAL|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
223568275|NCT00948233|BEHAVIORAL|Surveys|Computer surveys taken at 4 points throughout the study.
223568276|NCT04676841|DEVICE|Conventional ventilation + instrumental tables with integrated laminar airflow|Surgical instruments protected from contamination by local laminar airflow
223445912|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index \< 2.5"
223568277|NCT04676841|DEVICE|Conventional ventilation + standard instrumental tables|Control
223568278|NCT04676841|DEVICE|Laminar airflow ventilation + standard instrumental tables|Control
223568279|NCT00036855|BIOLOGICAL|rituximab|Given IV
223568280|NCT00036855|RADIATION|indium In 111 ibritumomab tiuxetan|Given IV
223568281|NCT00036855|RADIATION|yttrium Y 90 ibritumomab tiuxetan|Given IV
223568282|NCT00036855|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSC transplantation
223568283|NCT00036855|BIOLOGICAL|filgrastim|Given subcutaneously
223568284|NCT00036855|OTHER|laboratory biomarker analysis|Correlative studies
223568285|NCT05215223|DEVICE|whole body vibration|the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session
223568286|NCT05215223|DEVICE|Treadmill|Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
223568287|NCT02131103|OTHER|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
223568288|NCT02585024|DRUG|Cytisine|
223568289|NCT01730365|PROCEDURE|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
223568290|NCT01263678|BEHAVIORAL|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
223568291|NCT01263678|OTHER|Usual Care|Patient views DA and completes post DA survey.
223568292|NCT01077999|DRUG|Carboplatin|Carboplatin AUC = 2 , weekly.
223568293|NCT01077999|DRUG|Paclitaxel|Paclitaxel 50 mg/m2, weekly
223568294|NCT01077999|DRUG|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
223568295|NCT01077999|RADIATION|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
223568296|NCT03404531|BEHAVIORAL|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
223568297|NCT03404531|BEHAVIORAL|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
223568298|NCT00003603|DRUG|cyclophosphamide|
223568299|NCT00003603|DRUG|dexamethasone|
223568300|NCT00003603|DRUG|idarubicin|
223568301|NCT00003603|DRUG|lomustine|
223568302|NCT00003603|DRUG|melphalan|
223568303|NCT00003603|DRUG|prednisolone|
223568304|NCT00924430|DRUG|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
223568305|NCT00924430|DRUG|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
223568306|NCT04491019|OTHER|Balance exercise group|Balance exercises will be carried out with a physiotherapist
223445913|NCT00624650|DRUG|Dobutamine|"1. Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~2. Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~3. If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
223445914|NCT00624650|OTHER|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP \> 60 and off vasopressors for \>12 hours, as well as patients with a measured cardiac index \>2.5 that also have a measured GEDI \> goal."
223445915|NCT00624650|DRUG|Diuresis (furosemide) part II|"Withhold furosemide if:~1. Significant hypokalemia (K+ \<= 2.5 meq/L), or hypernatremia (Na+ \>= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~2. Dialysis dependence~3. Oliguria (less than 0.5ml/kg/hour) with either creatinine \> 3, or clinical suspicion of rapidly evolving ARF~4. More than 800mg has been given in less then 24 hours~5. Creatinine increases \> 1.5 mg/dl in any 24 hour period"
223741525|NCT05567055|DRUG|Capmatinib|Capmatinib is a medication for the treatment of metastatic non-small cell lung cancer tumors that have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR
223445916|NCT00624650|PROCEDURE|Dialysis|"1. Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~2. CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~3. EVLW arm: Fluid balance as per algorithm~4. When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
223445917|NCT02320227|DEVICE|Miami w/o frag Personal lubricant|
223445918|NCT02628509|DEVICE|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
223445919|NCT02086409|DIETARY_SUPPLEMENT|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
223445920|NCT02086409|DIETARY_SUPPLEMENT|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
223445921|NCT00723463|PROCEDURE|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
223445922|NCT00038870|BIOLOGICAL|Dendritic Cell Activated Lymphocyte|
223445923|NCT05096598|DRUG|ZP8396|Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
223445924|NCT05096598|DRUG|Placebo (ZP8396)|Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
223445925|NCT03267459|DEVICE|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
223741526|NCT00684476|DRUG|venom immunotherapy|
224055130|NCT00187096|DEVICE|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
223445926|NCT00840697|BEHAVIORAL|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
223445927|NCT00840697|BEHAVIORAL|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
223445928|NCT00840697|BEHAVIORAL|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
223445929|NCT04561297|DIAGNOSTIC_TEST|TDC differential value|TDC measurements in all patients agreeing to participate who are scheduled for a biopsy of a breast tumor or mass
223445930|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
223445931|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
223445932|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
223445933|NCT01489059|BIOLOGICAL|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
223445934|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
223445935|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
223741527|NCT03394287|DRUG|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
223741528|NCT03394287|DRUG|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
223741529|NCT00644280|DRUG|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
224055131|NCT05954923|OTHER|Amino acid bolus infusion|Equimolar bolus infusions of amino acids or saline (placebo)
223741530|NCT02065960|RADIATION|Stereotactic body radiotherapy (SBRT)|
224055132|NCT03958227|OTHER|Manuel Therapy plus Exercise Intervention|Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
224055133|NCT03958227|OTHER|Exercise Intervention|Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
224055134|NCT00853320|DRUG|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
224055135|NCT00853320|DRUG|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
223445936|NCT01489059|BIOLOGICAL|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
224055136|NCT02422420|BEHAVIORAL|Financial Incentives|Use of financial incentives to promote health behaviors.
224055137|NCT02170883|OTHER|Interactive SMS|
224055138|NCT02170883|OTHER|Usual care|
224145925|NCT01525940|DEVICE|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
223445937|NCT05347290|DEVICE|Rampart IC, M1128|Rampart IC, M1128 aims to address the challenge of radiation protection in the cardiac catheterization laboratory without the burden of wearing a heavy lead apron. Rampart M1128 is a compactly designed, portable, fully adjustable system that provides radiation protection for interventionalists and their technicians. It has independently adjustable flexible panels, allowing interventionalists multiple vascular access points, including right radial, bi-lateral femoral, and bi-lateral pedal. Participants in this arm will conduct catherization procedures using only the Rampart System, and radiation exposure will be measured using real-time dosimeters.
223445938|NCT05347290|DEVICE|Lead Apron and Ancillary Shield|Participating providers in this arm will use conventional skirt and vest, thyroid collar, and 100% use of 2 types of ancillary shields. Most wrap-around skirts and vests were (0.25-0.5 mm) Pb. Thyroid shields were 0.5 mm Pb equivalent. Under the table lead x 2. Radiation exposure will be measured using real-time dosimeters.
223568307|NCT05300230|DEVICE|Neuro Zti cochlear implant and Neuro 2 sound processor|"The study will consist in 3 visits:~* Visit 1: it will be carried out the first contact and learning the measurement procedure.~* Visit 2: it will be evaluated the speech perception and the measurement of the pupil dilatation in silence and noise conditions.~* Visit 3: it will be analysed the effect of the change in the cochlear implant programming parameters."
223568308|NCT03655301|DRUG|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
223568309|NCT03655301|DRUG|Metformin|Single dose of 1000 mg is administered orally.
223568310|NCT00123370|DRUG|Modafinil|
223568311|NCT00835198|DRUG|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
223568312|NCT00835198|DRUG|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
223568313|NCT02523157|OTHER|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
223568314|NCT02523157|OTHER|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
223568315|NCT01862471|DEVICE|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
223568316|NCT01862471|DEVICE|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
223568317|NCT00394602|BEHAVIORAL|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
223568318|NCT00394602|OTHER|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
223568319|NCT02049190|DRUG|onapristone|
223568320|NCT02049190|DRUG|abiraterone|
223568321|NCT00856089|DRUG|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
223568322|NCT03495310|BEHAVIORAL|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
223568323|NCT06095882|OTHER|acupuncture|"Study group: Acupuncture treatment was performed from day 3 to day 14 after surgery. Points include: Zhongwan, Tianshu, Watercourse, Taichong, Sanyinjiao, Zusanli, Yin Lingquan.~Control group: No intervention, the urinary tube was removed until the 14th day after surgery. Patients with urinary retention may receive further acupuncture treatment."
223568324|NCT04416529|BEHAVIORAL|Tele-MBCT|Please see arm/group description.
224055139|NCT01397370|DRUG|GLPG0492|Oral solution
224055140|NCT01397370|DRUG|Placebo|Oral solution
224055141|NCT05726799|PROCEDURE|Cryo myectomy|Extended septal myecotmy using cryo energy
224055142|NCT05726799|PROCEDURE|Myectomy|Classic surgical myectomy
224055143|NCT01534247|DRUG|CAZ-AVI|Infusion
224055144|NCT01534247|DRUG|metronidazole|Infusion
224055145|NCT01534247|DRUG|CAZ-AVI + metronidazole|Infusion
224055146|NCT05726851|DRUG|E2025|E2025 IV infusion.
224055147|NCT05726851|DRUG|Placebo|E2025 matched placebo IV infusion.
224055148|NCT00226109|DRUG|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
224055149|NCT06136377|RADIATION|177Lu-PSMA-617 PET scan|Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
224055150|NCT04663789|PROCEDURE|reinforcement of the staple line|The operator will perform reinforcement of the staple line with a continuous lock stitch.
224145926|NCT02427750|BIOLOGICAL|Aggripal®|TIV
223445939|NCT05347290|DEVICE|Rampart IC, M1128 and Lead Apron|Participating providers will use both the lead apron and the Rampart Shield. Radiation exposure will be measured using real-time dosimeters.
223445940|NCT00003215|BIOLOGICAL|filgrastim|
223445941|NCT00003215|DRUG|CHOP regimen|
223445942|NCT00003215|DRUG|cyclophosphamide|
223445943|NCT00003215|DRUG|cytarabine|
223445944|NCT00003215|DRUG|doxorubicin hydrochloride|
223445945|NCT00003215|DRUG|etoposide|
223445946|NCT00003215|DRUG|leucovorin calcium|
223445947|NCT00003215|DRUG|melphalan|
223445948|NCT00003215|DRUG|methotrexate|
223445949|NCT00003215|DRUG|methylprednisolone|
223445950|NCT00003215|DRUG|mitoxantrone hydrochloride|
223445951|NCT00003215|DRUG|prednisone|
223445952|NCT00003215|DRUG|therapeutic hydrocortisone|
223445953|NCT00003215|DRUG|vincristine sulfate|
223445954|NCT00003215|PROCEDURE|bone marrow ablation with stem cell support|
223445955|NCT00003215|PROCEDURE|peripheral blood stem cell transplantation|
223445956|NCT00003215|RADIATION|radiation therapy|
223445957|NCT00958412|DRUG|Proellex®|one (1) 25 mg capsule daily
223445958|NCT05288855|DRUG|Voclosporin|calcineurin inhibitor
223445959|NCT05288855|DRUG|Placebo Oral Capsule|matching placebo capsule
223445960|NCT06066723|COMBINATION_PRODUCT|19F MRI|Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing.
223445961|NCT04267185|BEHAVIORAL|Physical Activity Together for PwMS and their CGs (PAT-MS)|A dyadic physical activity intervention approach for PwMS and their family CGs affected by moderate-to-severe MS disability.
223445962|NCT05651828|DRUG|Vismodegib 150 MG Oral Capsule|Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
223741531|NCT03185728|OTHER|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
223445963|NCT04121767|DRUG|Edoxaban|oral edoxaban 60mg once daily for 3 months
223445964|NCT04121767|DRUG|Warfarin|oral warfarin once daily for 3 months according to prothrombin time
223445965|NCT03862872|DIETARY_SUPPLEMENT|Anti-Aging Formula|Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
223445966|NCT03862872|DIETARY_SUPPLEMENT|Control Fish Oil|The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
223445967|NCT03862872|OTHER|Inert Placebo|The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
223445968|NCT02227368|DRUG|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
223445969|NCT02227368|DRUG|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
223445970|NCT02411344|DRUG|Pertuzumab|"* Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~* Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~* Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
223445971|NCT04337476|DEVICE|The effects of Pacifier Activated Lullaby in very low birth weigt preterm infants. An italian music therapy intervention|Positive reinforcement is an effective development strategy for improving the feeding skills of preterm infants. A brief intervention with the PAL device with pacifier that reproduces lullabies sung by both parents or by the music therapist could reduce the use of the feeding tube and the length of hospital stay in preterm infants. The aim of this study is not only to evaluate the benefits of positive reinforcement on the nutritional sucking competence of the premature baby, but at the same time to observe its possible effects on its well-being and its clinical stability.
223445972|NCT06045494|DIETARY_SUPPLEMENT|Meiji Yogurt Group|Participants in this arm need to eat assigned product for 12 weeks, one bottle each day.
223445973|NCT00495989|PROCEDURE|saliva sampling + dental calculus collection|
223741532|NCT00822458|DRUG|vismodegib|Given orally
223445974|NCT02175329|DEVICE|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
223445975|NCT02175329|DEVICE|Manually layered veneering|
223445976|NCT03765229|DRUG|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
223445977|NCT03765229|DRUG|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
223445978|NCT01160380|DRUG|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
223445979|NCT01160380|DRUG|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
223445980|NCT02851212|DRUG|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
223445981|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
223445982|NCT02851212|DRUG|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
223445983|NCT02851212|DRUG|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
223445984|NCT04798326|DRUG|MW032|Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.
223445985|NCT04798326|DRUG|Xgeva®|Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
223445986|NCT02524626|PROCEDURE|Sham stimulation|Sham stimulation
223445987|NCT02524626|PROCEDURE|Vagus stimulation|Vagus stimulation
223445988|NCT02510820|DEVICE|comfilcon A|soft contact lens
223445989|NCT02510820|DEVICE|Synergi|Multipurpose solution
224055151|NCT04663789|PROCEDURE|staple only|The operator transect the pancreas with stapler only, without staple line reinforcement.
223445990|NCT02510820|DEVICE|Biotrue|Multipurpose solution
223741533|NCT00822458|OTHER|laboratory biomarker analysis|
224055152|NCT00111800|DRUG|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
224055153|NCT00111800|DRUG|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
224055154|NCT00111800|DRUG|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
224055155|NCT00111800|DRUG|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
224055156|NCT00111800|DRUG|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
223445991|NCT02510820|OTHER|stenfilcon A|daily disposable contact lenses for washout period
223445992|NCT00479830|BEHAVIORAL|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
223445993|NCT00479830|BEHAVIORAL|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
223445994|NCT00479830|BEHAVIORAL|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
223741534|NCT00822458|OTHER|pharmacological study|
224055157|NCT00111800|DRUG|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
223445995|NCT05050422|DIAGNOSTIC_TEST|Trunk Impairment Scale (TIS), PedsQLTM Multidimensional Fatigue Scale (PedsQL-MFS), Pediatric Balance Scale (PBS)|control/study group
223445996|NCT00719940|BEHAVIORAL|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
223445997|NCT00719940|OTHER|Waiting group|No intervention
223445998|NCT06122467|OTHER|EQ Exfoliating Cleanser|Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).
223445999|NCT06122467|OTHER|EQ Gel|Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.
223446000|NCT06122467|OTHER|EQ Moisturizer|Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.
223446001|NCT01512433|PROCEDURE|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
223446002|NCT01512433|PROCEDURE|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
223741535|NCT06637995|DEVICE|Intraoperative Nerve Monitoring|Observational data collection from Locating, Stimulating, and Monitoring target nerves during a surgical procedure (clinician standard of care)
223741536|NCT00002161|DRUG|Adefovir dipivoxil|
223741537|NCT05640102|DRUG|Zanubrutinib|Dosing and treatment duration are at the discretion of the prescribing physician and in accordance with local labeling
223741538|NCT01271920|DRUG|AUY922|
223741539|NCT01271920|DRUG|Trastuzumab|
224055158|NCT02211729|DRUG|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
224055159|NCT02211729|DRUG|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
224055160|NCT03152903|BIOLOGICAL|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
224055161|NCT03152903|OTHER|Placebo|Single dose of Placebo is administered intradermally.
224055162|NCT00475683|OTHER|Mouth wash|Mouth wash with chlorehexidin, three times a day
224055163|NCT00475683|DIETARY_SUPPLEMENT|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
224055164|NCT06414811|OTHER|HYPOTENSİON|MAP below 55 mmHg or long-term (2 minutes or more) hypotensive attacks will be treated with ephedrine 0.1mg/kg.
224055165|NCT02771704|OTHER|Silver Diamine fluoride|
224055166|NCT02771704|OTHER|Potassium iodide|
223446003|NCT03046056|DRUG|Filgotinib|Tablet(s) administered orally once daily
223446004|NCT03046056|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
223446005|NCT03001245|BEHAVIORAL|Interpersonal Counseling|Interpersonal Counseling 1+6 sessions
223446006|NCT03001245|BEHAVIORAL|Standard treatment|Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
223446007|NCT01282333|DRUG|gemcitabine hydrochloride|Given IV
223446008|NCT01282333|DRUG|veliparib|Given orally
223446009|NCT01282333|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223568325|NCT04243902|DEVICE|Fill and Flush Valve|"The fill and flush valve (Figure 1) is an automated valve which is designed to open in response to rising bladder pressure which occurs as the bladder becomes full. The valve is situated between the IDC and the drainage bag as a manual valve would be.~There are three variants of the valve which respond to different degrees of bladder pressure. People's bladders function at different pressure levels. One of the aims of this study is to gain preliminary data on which valve variant works and under which circumstances. Pressure ranges are as follows:~Low: 22 - 49cm H2O Medium: 35 - 61cm H2O High: 53 - 79cm H2O"
224055167|NCT02771704|OTHER|Chlorhexidine|
223568326|NCT00367744|DRUG|Rosiglitazone|Rosiglitazone 4mg BID
223741540|NCT06287983|DEVICE|Inspiratory Muscle Trainer (IMT) (POWERbreathe Medic Classic)|Inspiratory muscle training will be started at an intensity of 50% of the patient's measured PIMAX value and will be increased by 2 cm/H20 per day according to patient tolerance, and will be applied for a total of 6 weeks / 5 days per week / 3 sessions per day / 10 breaths per session.
224055168|NCT02771704|OTHER|Silver diamine fluoride and potassium iodide|
224055169|NCT02771704|OTHER|Physiological saline|
223446010|NCT01282333|OTHER|pharmacological study|Correlative studies
224055170|NCT05698082|DIAGNOSTIC_TEST|Immunohistochemical staining with anti-FOS|The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.
223446011|NCT01282333|DRUG|cisplatin|Given IV
223446012|NCT05683951|DRUG|DWKH|Administration of DWKH three times daily
224055171|NCT04911803|BEHAVIORAL|Anxiety Application|The Intellect mobile app (containing the anxiety application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
224070867|NCT01770925|DEVICE|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
224070868|NCT01770925|DEVICE|NIPPV|The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
224070869|NCT05500625|PROCEDURE|Endoscopic ultrasound-guided coil embolization combined with endoscopic cyanoacrylate injection|Standard diagnostic endoscopy will be done and Fundal varices will be assessed. EUS procedures will be performed using linear endoscope under general anesthesia. Use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. Puncture the gastric fundal variceal vein at the lower esophagus near the cardia and place the coil into the shunt and immediately inject with sclerosant and cyanoacrylate under the guidance of EUS using a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. Use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
223446013|NCT05683951|DRUG|DWKH-R|Administration of DWKH-R three times daily
223446014|NCT05683951|DRUG|Placebo|Administration of Placebo three times daily
223446015|NCT02874833|OTHER|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
223446016|NCT00500253|DEVICE|exhaled nitric oxide measurement|exhaled nitric oxide measurement
223446017|NCT00500253|PROCEDURE|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
223568327|NCT00367744|DRUG|Placebo|Placebo for rosiglitazone
223568328|NCT05100940|PROCEDURE|Cardiac Catheterization|Cardiac Catheterization
223741541|NCT06287983|OTHER|The Sample Spondylitis Exercise Program|The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.
223446018|NCT00500253|PROCEDURE|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
223446019|NCT06320353|DRUG|RPH-075|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
223446020|NCT06320353|DRUG|Keytruda®|"100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)"
223446021|NCT03492905|BEHAVIORAL|Internet-based Cognitive Behaviour Therapy (iCBT)|Guided self-help for 7 weeks. Contact with therapist 2 times per week.
223446022|NCT02913105|DRUG|LMB763|Hard Gelatin Capsules
223446023|NCT02913105|DRUG|Placebo|Hard Gelatin Capsule
223446024|NCT00543998|DEVICE|Optical Measurement transillumination|Optical Measurement of sinus
223446025|NCT02924805|OTHER|Telemedical care|Telemedically guided care based on a standard operating procedure
224055172|NCT04911803|BEHAVIORAL|Procrastination Application|The Intellect mobile app (containing the procrastination application) can be freely downloaded from the App store and Google Play store for free. The app provides access to the different programmes. The mobile app has been pilot tested by Intellect before the release on the App and Google Play store. However, for this research project Intellect is going to provide the the programmes as stand alone applications exclusively for the participants of this research.
223446026|NCT00202891|DRUG|sisomicin|
223446027|NCT01317004|DRUG|Fingolimod|0.5 mg/day oral capsule
224055173|NCT01473342|BEHAVIORAL|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors \& their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting \& participation. During the 9th week (Week 17), participants complete one final survey \& accelerometer wear.
224145927|NCT03749798|PROCEDURE|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
224145928|NCT05516160|DIAGNOSTIC_TEST|diagnostic of optical aberrations|diagnostic of optical aberrations with new device
223446028|NCT01317004|DRUG|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
223446029|NCT03370692|OTHER|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
223446030|NCT00818740|DRUG|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
223446031|NCT04118179|OTHER|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
223568329|NCT03649529|BIOLOGICAL|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
223568330|NCT00793572|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
223568331|NCT00793572|DRUG|Bortezomib|Given SC
223568332|NCT00793572|DRUG|Cyclosporine|Given IV
223568333|NCT00793572|DRUG|Cyclosporine|Given PO
223568334|NCT00793572|DRUG|Fludarabine Phosphate|Given IV
223741542|NCT05805787|OTHER|Acupressure|Acupressure will be applied to the elderly in the experimental group once a day, 5 days a week (Monday-Friday) for a week. The application will last for 2 weeks. A total of 10 sessions of acupressure will be applied. Acupressure application will be applied by researchers who have been trained and certified on this subject. While the elderly are in supine position, pressure will be applied to each acupressure point, respectively, Tianshu (ST25), Guanyuan (CV4) and Hegu (LI4) for 2 minutes for a total of 6 minutes.
223741543|NCT02115711|BEHAVIORAL|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
224145929|NCT00716638|BEHAVIORAL|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
223446032|NCT02727309|DRUG|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
223568335|NCT00793572|OTHER|Laboratory Biomarker Analysis|Correlative studies
223446033|NCT00768573|DRUG|sildenafil|Oral suspension of sildenafil.
223568336|NCT00793572|DRUG|Melphalan|Given IV
223568337|NCT00793572|DRUG|Mycophenolate Mofetil|Given PO
223568338|NCT00793572|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
223568339|NCT00793572|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
223568340|NCT00793572|PROCEDURE|Syngeneic Bone Marrow Transplantation|Undergo transplantation
223446034|NCT04645329|DEVICE|shoulder immovilization sling|immobilization of the arm after surgery
223568341|NCT00793572|RADIATION|Total-Body Irradiation|Undergo radiotherapy
223568342|NCT00309699|DRUG|Placebo|Daily for 3 weeks
223568343|NCT00309699|DRUG|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
223568344|NCT00309699|DRUG|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
223568345|NCT05133622|OTHER|Physical Activity Level|IPAQ-SF assesses the physical activity levels of the individuals. The short form of the questionnaire consists of seven questions and provides information about the time spent sitting, walking, moderately vigorous, and vigorous activities. In scoring, below 600 MET-min/week indicates individuals who are not physically active, 600-3000 MET-min/week values indicate low physical activity levels, and 3000 MET-min/week and above values indicate individuals with high physical activity levels. In our study, sedentary individuals who receive 600-3000 MET-min/week from the questionnaire will be included
223741544|NCT03312972|RADIATION|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 to 2 fractions, Up to 30 Gray (Gy) to target lesion
223741545|NCT02258100|OTHER|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
224145930|NCT00716638|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
224145931|NCT00454272|DRUG|Teicoplanin|
224145932|NCT00454272|DRUG|Vancomycin|
223446035|NCT02379455|OTHER|Comprehensive drug review|1\) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
223446036|NCT04409977|DIAGNOSTIC_TEST|MRI examination|Patient will be scanned in the MRI twice, once at noon (+/- 1 hour), once at 1 a.m. (+/- 1 hour). The investigators will search for any changes in functional connectivity, particular regarding the connection between the hypothalamus and pain-processing networks.
224145933|NCT05535309|DRUG|cefoperazone sulbactam sodium|Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
224145934|NCT01593579|BEHAVIORAL|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
224300709|NCT03591393|DIAGNOSTIC_TEST|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
224300710|NCT03668561|DEVICE|Caligaloc|15 days of wearing of the Caligaloc orthosis
224300711|NCT00299845|DRUG|Lansoprazole|
224300712|NCT02279693|OTHER|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
224300713|NCT02279693|OTHER|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
224300714|NCT02279693|RADIATION|IGRT Associated With IMRT|
224300715|NCT06432049|OTHER|restoration for endodontically treated molar|prefabricated stainless steel crown or endocrown
224300716|NCT01495156|DRUG|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
224300717|NCT01495156|DRUG|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
224300718|NCT05579483|DIETARY_SUPPLEMENT|Prebiotics|The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
224300719|NCT05579483|DIETARY_SUPPLEMENT|Placebo|The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
224300720|NCT05425693|OTHER|Hybrid Warm-up|Dynamic + stretching exercises
224300721|NCT05425693|OTHER|Dynamic Warm-up|Dynamic exercises
224300722|NCT05425693|OTHER|Stretching Warm-up|Stretching exercises
224300723|NCT02470390|DRUG|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
224300724|NCT05157867|OTHER|Amylase trypsin inhibitors|Intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (wheat), dissolved in physiological saline.
224300725|NCT05157867|OTHER|Placebo|Intraduodenal administration of placebo (physiological saline).
224300726|NCT01935466|DRUG|Pioglitazone|Ever users of Pioglitazone
224300727|NCT03865186|BEHAVIORAL|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
224300728|NCT03865186|BEHAVIORAL|no intervention|
224300729|NCT02440022|COMBINATION_PRODUCT|Lutonix DCB|
224300730|NCT02440022|DEVICE|Standard Balloon Angioplasty Catheter|
224300731|NCT02440022|PROCEDURE|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
224145935|NCT01593579|OTHER|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
224145936|NCT05247385|DRUG|Prasugrel|Compared platelet inhibition and adenosine levels at baseline and after 15 days
224145937|NCT05247385|DRUG|Ticagrelor|Compared platelet inhibition and adenosine levels at baseline and after 15 days
224055174|NCT05479942|OTHER|Graded motor imagery training paradigm|"Graded motor imagery is the psychological representation of attention doing movement of a part of body, without actually moving that part, it broken down into three unique stages of treatment techniques:~1. Left/right discrimination (Implicit motor imagery):~2. Explicit motor imagery~3. Mirror Therapy"
224055175|NCT05479942|OTHER|conventional therapy (task-oriented active/passive range of motion training)|"Patient will do 3 tasks as: drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, and combing their hairs.~Practice shoulder flexion and abduction active ROM, and passive ROM training"
224055176|NCT03187938|DIAGNOSTIC_TEST|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
224055177|NCT06480916|PROCEDURE|Maternal-fetal transfers|Prospective and consecutive inclusion of all maternal-fetal transfers during the study period. The teams at the sending and receiving maternity units will complete study-related questionnaires to describe the conditions of the transfer and the outcome of the pregnancy. The study in no way alters the way parturients are cared for.
224055178|NCT02548325|OTHER|Not apply|None. Just registration epidemiology dates
224055179|NCT02070029|PROCEDURE|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~\- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
224055180|NCT03057236|BEHAVIORAL|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
224055181|NCT01273051|DRUG|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
224055182|NCT01273051|RADIATION|radiotherapy|radiation 25x2 Gy
223446037|NCT02995629|PROCEDURE|laser indirect ophthalmoscopy pan retinal photocoagulation|"* Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~* Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~* Target treatment of 250 spots~* Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~* After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength"
223568346|NCT05133622|OTHER|Evaluation of knee extension and elbow flexion muscle strength|"To measure the knee extension strength, the individual brings the knee from 90 degrees flexion to full extension in sitting. To standardize the test, the lower extremities will be fixed of the chair with a belt, allowing full extension of the knee. Three measurements will be performed from the distal tibia with a dynamometer, and the score will be recorded in Newtons.~Elbow flexion will also be measured in a sitting position in a chair. To standardize the given resistance, the upper extremity of the individual will be fixed to the arm support of the chair, allowing elbow flexion with a belt. During the measurement, the individual will try to flex the forearm in supination. Meanwhile, three measurements will be taken from the distal forearm with a dynamometer. The average score will be recorded in Newtons."
223568347|NCT05133622|OTHER|Evaluation of functional strength of trunk muscles|"Sit-ups test: The sit-ups test is a measure the endurance of the abdominal and hip-flexor muscles. The physiotherapist will fix the feet and ask the individuals to do trunk flexion in the knee flexion position. The number of movements performed for 30 seconds will be recorded.~Push-ups test: The test will be in the prone position, with the hands at shoulder level and the elbows flexed, positioned near to the body. Individuals will raise the head, shoulders, and trunk from the ground with their elbows in full extension. The test is performed with the knees in full extension for men and modified knees in flexion for women. The number of movements performed for 30 seconds will be recorded."
223568348|NCT05133622|OTHER|Muscle Endurance|"Lateral bridge test: Lateral bridge test involves static, isometric contractions of the lateral muscles on each side of the trunk that stabilizes the spine.~Modified Biering-Sorensen test: The test measuring how many seconds the individual can keep the unsupported upper body horizontal, while placed prone with the buttocks and legs fixed to the couch by three wide canvas straps and the arms folded across the chest.~Trunk flexors endurance test: Trunk flexion test involving a static, isometric contraction of the anterior muscles, stabilizing the spine until the individual exhibits fatigue. The researcher stops the test when the individual cannot hold the assumed position.~Prone bridge test: The prone bridge test measures the muscular endurance of the abdominal muscles."
224055183|NCT01273051|PROCEDURE|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
224055184|NCT01273051|PROCEDURE|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (\<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
224055185|NCT05244759|DRUG|[14C]-BLU-5937|Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
223446038|NCT02092649|DIETARY_SUPPLEMENT|Omega-3 Complete|
223446039|NCT02092649|DIETARY_SUPPLEMENT|Placebo Pill|
223446040|NCT01526278|DRUG|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
224055186|NCT04282395|BEHAVIORAL|Resilience-Based Diabetes Self-Management Education|"During the group sessions led by professional nurses, participants are provided information and group activities to enable them to more effectively manage their personal diabetes challenges. During the support group sessions, participants discuss personal challenges and solutions to diabetes self-management, using a more informal approach. Booster sessions are held to refresh participants' understanding of how resilience resources can sustain self-management behaviors and maintain improved T2DM health outcomes. The RB-DSME also incorporates cultural characteristics and preferences of African Americans (AAs), to include:~* the location in community-based church settings,~* recognition of cultural dietary preferences, and~* emphasis on cultural/historical significance of resilience in AAs."
224145938|NCT06796985|DRUG|Botulinum neurotoxin|Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm). Participants will receive this drug twice throughout the duration of the study. Approximately 200 units of botulinum neurotoxin will be administered per injection.
224145939|NCT06796985|DEVICE|High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device|A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management. The device will be used five times during the study. Each use will last approximately ten minutes.
224145940|NCT03201848|DRUG|Placebo|Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
224145941|NCT03201848|DRUG|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
224145942|NCT01357980|BIOLOGICAL|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
224145943|NCT01357980|DRUG|Placebo|Intra detrusor injection on Day 1 (single dose)
224300732|NCT02878941|PROCEDURE|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
224300733|NCT03861403|DRUG|TRX518|Administered by IV infusion
224300734|NCT03861403|DRUG|Cyclophosphamide|Administered by IV infusion
224300735|NCT03861403|DRUG|Avelumab|Administered by IV infusion
224300736|NCT02931903|OTHER|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
224300737|NCT02931903|OTHER|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
224300738|NCT02861079|DEVICE|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
224145944|NCT06291506|OTHER|Radiofrequency ablation of heart atrial tissue.|Ablation with radiofrequency, advances techniques: contact force-guided, improved tissue temperature sensors, automark algorithms.
224145945|NCT05953571|PROCEDURE|Dismembered Pyeloplasty|dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
224145946|NCT04507776|DRUG|Etanercept|Patients with spondyloarthrosis as provided in real world practice
224145947|NCT02781350|OTHER|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
224145948|NCT02781350|DIETARY_SUPPLEMENT|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
224145949|NCT00406211|BIOLOGICAL|MMRV|
224145950|NCT00406211|BIOLOGICAL|MMR (Priorix®)|
224145951|NCT00406211|BIOLOGICAL|Varicella (Varilrix®)|
224145952|NCT03994393|DRUG|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
224145953|NCT03994393|DRUG|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
224145954|NCT04849910|BIOLOGICAL|VOR33|Allogeneic, human leukocyte antigen (HLA) matched, genome edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 myeloid protein
224145955|NCT04849910|DRUG|Mylotarg|Infusion of Mylotarg
224145956|NCT06641765|DEVICE|Continous Glucose Monitoring|10 days of real time open access to Continous Glucose Monitoring - either at defined time intervals (Group 2) or continuously for 9 months (Group 3).
224145957|NCT06527677|DRUG|ANT3310|ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.
224145958|NCT06527677|DRUG|Meropenem|meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.
224145959|NCT06638541|RADIATION|Prostate radical radiotherapy|Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac
223446041|NCT00300846|DRUG|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
223446042|NCT00300846|DRUG|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
223446043|NCT04067596|PROCEDURE|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
223446044|NCT04542278|DRUG|Prednisone|used to reduce inflammation
223446045|NCT04835883|BIOLOGICAL|CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)|Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.
223446046|NCT00743847|DRUG|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
223446047|NCT00743847|DRUG|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
223446048|NCT00743847|DRUG|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
223446049|NCT03816618|DRUG|Medihoney Gel in A Tube|TREATMENT1
223446050|NCT03816618|DRUG|Hydrogel|PURLOIN GEL
223446051|NCT03816618|DRUG|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
223741546|NCT04229004|DRUG|Gemcitabine combined with nab-paclitaxel|"Arm is closed to recruitment.~Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
223741547|NCT04229004|DRUG|Dose -mFOLFIRINOX|"Arm is closed to recruitment.~The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
224055187|NCT04282395|BEHAVIORAL|Standard Diabetes Self-Management Education|"Control group sessions, led by professional nurses, cover topics such as:~* causes and symptoms of type 2 diabetes,~* glucose self-monitoring,~* models for and principles of healthy eating, grocery shopping and dining out,~* physical activity,~* diabetes medications,~* managing sick days and stress, and~* community resources."
224055188|NCT03901105|DRUG|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers. IV injection, 240 megabecquerel (MBq) (6.5 mCi), single dose in AZES
224055189|NCT03901105|PROCEDURE|Brain PET Scan|positron emission tomography (PET) scan of the brain
224055190|NCT03609138|DEVICE|Spinal Hardware|Pedicle screws and patient specific rods
224055191|NCT03707548|BEHAVIORAL|BPT|BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
224055192|NCT03707548|BEHAVIORAL|Smartphone-triggered bodily interventions|Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
224055193|NCT03707548|BEHAVIORAL|Smartphone triggered control intervention|The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
224055194|NCT05470751|DEVICE|Intermittent self-catheterisation|Self-catheterising with GC Male and Glide Male with Feelclean technology
224055195|NCT00253643|DIETARY_SUPPLEMENT|green tea catechin extract|Given orally 2 times/day
224145960|NCT01234896|DRUG|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
223446052|NCT02642783|BEHAVIORAL|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
223446053|NCT02642783|BEHAVIORAL|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
224055196|NCT00253643|DIETARY_SUPPLEMENT|fish oil|Given orally 3 times/day
224055197|NCT00253643|OTHER|placebo|Given olive oil placebo orally 3 times/day
224055198|NCT00253643|OTHER|placebo|Given green tea placebo orally 2 times/day
224145961|NCT01234896|DRUG|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
224145962|NCT01234896|DRUG|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
224145963|NCT01234896|DRUG|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
223446054|NCT00532727|DRUG|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
223446055|NCT00532727|DRUG|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
223446056|NCT04664907|OTHER|Videomusic listening|Patients will attend a 8 min videomusic session and questionnaires will be performed before and after this session.
223446057|NCT00038805|DRUG|Mylotarg|
224055199|NCT04660461|DRUG|Lansoprazole 30mg|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
224055200|NCT04660461|DRUG|Placebo|Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
224055201|NCT04152577|DRUG|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
224055202|NCT04152577|DRUG|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
224055203|NCT00524602|PROCEDURE|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
224055204|NCT04035070|COMBINATION_PRODUCT|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
224055205|NCT04035070|COMBINATION_PRODUCT|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
224055206|NCT04035070|COMBINATION_PRODUCT|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
223446058|NCT02132728|OTHER|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
223446059|NCT03092947|OTHER|No intervention|
223446060|NCT00264251|BEHAVIORAL|Weight loss through diet and exercise|
223446061|NCT00264251|DRUG|Rosiglitazone insulin sensitizing agent|
223446062|NCT00640731|DEVICE|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
223446063|NCT01533948|DRUG|axitinib|Given PO
223446064|NCT01533948|OTHER|laboratory biomarker analysis|Correlative studies
223446065|NCT01156909|DRUG|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
223446066|NCT06478082|DEVICE|Home-based virtual reality training|8-week training with an advised frequency of 30 minutes per day, for 5 days per week.
223446067|NCT03726801|OTHER|HEALTH EDUCATION|"The nursing intervention prior to surgery: (breast and colon cancer):~1. First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~2. Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~3. Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort."
223446068|NCT01221558|DIETARY_SUPPLEMENT|lycopene|
223568349|NCT05133622|OTHER|Flexibility|"Back scratch test The back-scratch test evaluates upper extremity flexibility. The individual will externally rotate one arm over her/his shoulder to reach the lowest point on the back with the palm facing the back. The other extremity reaches the highest point on the back with the palm facing forward by internal rotation of the other arm. The distance between the middle fingers of both hands will be measured with a tape measure.~Sit and reach test Sit and reach test evaluates lower extremity flexibility. In the test, a sit and reach board is used. The 0 reference point is taken as the 25 cm inner part where the feet are placed on the sit and reach the board. The part closer to the individual from the reference point shows negative values, and the part towards the far side shows positive values. Individuals will reach as far as with their fingertips by placing their feet on a sit-and-reach board."
224055207|NCT03448068|DRUG|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
224145964|NCT01573403|DRUG|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
224145965|NCT01573403|DRUG|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
223568350|NCT05133622|OTHER|Balance|"Single leg stance test Individuals bend one knee and place the sole on the other thigh and maintain their balance in this position. The test will be performed separately for the right and left extremities with eyes open and closed. The single-leg stance balance time was recorded as seconds (Linda,2013).~Functional reach test The functional reach test evaluates dynamic balance and limit of stability. This test measures the distance between the length of an outstretched arm in a maximal forward reach from standing while maintaining a fixed base of support. The scoring record is centimeter. Higher scores indicate a good level of balance (Lin,2012)."
224145966|NCT01573403|DRUG|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
224300739|NCT02861079|DRUG|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
223446069|NCT01212146|DIETARY_SUPPLEMENT|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10\^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10\^10 CFU.
223446070|NCT01212146|DIETARY_SUPPLEMENT|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
223446071|NCT01859949|DRUG|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
223446072|NCT02664064|BEHAVIORAL|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
223446073|NCT01890759|BIOLOGICAL|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
223446074|NCT01344759|DRUG|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
223446075|NCT01344759|DRUG|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
223446076|NCT01153009|DRUG|Vortioxetine|Encapsulated vortioxetine immediate release tablets
223446077|NCT01153009|DRUG|Duloxetine|Overencapsulated duloxetine delayed-release capsules
223446078|NCT01153009|DRUG|Placebo|Placebo-matching capsules
223568351|NCT05133622|OTHER|Fatigue|"Individuals will score perceived fatigue during walking and running activities with the Modified Borg Scale. According to the scale, 0 indicates no fatigue, and a score of 10 indicates unbearable fatigue (Borg,1987)."
223568352|NCT03494517|DRUG|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
224055208|NCT03448068|DRUG|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
224055209|NCT06959043|DIETARY_SUPPLEMENT|Probiotic Supplementation|Participants will follow the same strict vegetarian diet and regular physical exercise as in Intervention 1. Additionally, they will receive a probiotic supplement, taken twice daily for four weeks. This aims to evaluate the metabolic impact of probiotics in type 2 diabetes.
224300740|NCT03621059|BEHAVIORAL|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
223446079|NCT00347230|DEVICE|Intacs intracorneal ring insertion for the treatment of keratoconus|
223446080|NCT05331105|DRUG|HL-085|"IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen."
223446081|NCT01856998|DRUG|Propofol|
223446082|NCT01856998|DRUG|Diprivan|
223446083|NCT01015105|OTHER|observation|observation
223446084|NCT05309694|COMBINATION_PRODUCT|Paragard® T380A Intrauterine Copper Contraceptive with New Inserter|"Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus."
223446085|NCT01909960|OTHER|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
223446086|NCT01273909|PROCEDURE|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
223446087|NCT01273909|PROCEDURE|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
223446088|NCT02927678|OTHER|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
223446089|NCT02527174|DRUG|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
223446090|NCT02527174|DRUG|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
223446091|NCT02527174|DRUG|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
223568353|NCT02526823|DRUG|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
224055210|NCT06959043|DIETARY_SUPPLEMENT|Placebo Administration|Participants will follow a strictly plant-based diet rich in fiber and bioactive compounds, with controlled macronutrient distribution. Regular physical exercise includes supervised aerobic and resistance training sessions. The intervention lasts four weeks. Instead of probiotic supplementation, participants will receive a placebo, administered in the same manner as the probiotic group to maintain blinding.
223446092|NCT02182986|PROCEDURE|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
223446093|NCT02182986|DRUG|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
223446094|NCT01380652|PROCEDURE|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
223446095|NCT00008125|BIOLOGICAL|filgrastim|
223446096|NCT00008125|DRUG|carboplatin|
223446097|NCT00008125|DRUG|docetaxel|
223446098|NCT00008125|DRUG|gemcitabine hydrochloride|
223446099|NCT03218371|PROCEDURE|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
223446100|NCT06476405|OTHER|Study Product A: Ploom® Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product A: Ploom Non-menthol) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
223446101|NCT06476405|OTHER|Study Product B: Usual Brand Combustible Cigarette (UBCC) Non-Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product B: Non-menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
223446102|NCT06476405|OTHER|Study Product C: Ploom® Menthol Heated Tobacco Product (HTP)|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product C: Ploom® Menthol HTP) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
223446103|NCT06476405|OTHER|Study Product D: Usual Brand Combustible Cigarette (UBCC) Menthol Flavor|Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product D: Menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
223446104|NCT03692637|BIOLOGICAL|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
223446105|NCT05488951|OTHER|Otago Exercise Program|The Otago Exercise Program will be led by a physical therapist in a group setting (5-7 participants/exercise class). The exercise will be 20 min of walking and 30 min of strength and balance exercises (i.e., 50 min exercise class) 3x/week for 6 months. The physical therapist will select suitable exercises for each participant, such that the exercise is individualized and progressive.
223446106|NCT04462328|DRUG|Durvalumab|Durvalumab will be administered over 60 minutes
223446107|NCT04462328|DRUG|Acalabrutinib|Patients will take acalabrutinib orally every 12 hours (+/- 3 hours) daily.
223568354|NCT02526823|DRUG|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
223568355|NCT00123578|DRUG|Lorazepam|Lorazepam
224055211|NCT06493344|OTHER|Applying additional weight|Treadmill training with and without weight (15 minutes of 3 times/ per week for 16 weeks).
223446108|NCT03523312|RADIATION|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
223568356|NCT00123578|DRUG|Pentobarbital|Pentobarbital
223568357|NCT03858335|OTHER|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
223568358|NCT00269503|PROCEDURE|Prone Distraction|
223568359|NCT00269503|PROCEDURE|Side-Posture Manipulation|
223568360|NCT00269503|PROCEDURE|Side-Posture Manipulation & Prone Distraction|
224055212|NCT04335994|DEVICE|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
224300741|NCT04317209|DRUG|SHR0410|administered intravenously
223568361|NCT00269503|PROCEDURE|Usual Care (Control Group)|
223568362|NCT00221806|DEVICE|endothelialised prosthesis|
223568363|NCT00051220|BEHAVIORAL|One-Session Treatment for Specific Phobias|
223741548|NCT04229004|DRUG|Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel|"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
224300742|NCT04317209|DRUG|Placebo|administered intravenously
224300743|NCT05404607|OTHER|Fascial distortion method with neuromuscular inhibition technique|27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
223446109|NCT03523312|DRUG|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
223446110|NCT05788484|DRUG|CDX-585|CDX-585 is administered by infusion every 2 weeks
224055213|NCT04335994|DEVICE|Home Sleep Apnea Test|Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
223446111|NCT02106598|DRUG|fluorescent cRGDY-PEG-Cy5.5-C dots|
223446112|NCT05400486|OTHER|Therapeutic exercise|1.Movements of flexion, extension, inclinations, and rotations of the cervical region at maximum amplitude and without load. 2.Neural mobilization of the cervical nerve roots. 3.Contraction of the deep muscles of the flexors, extensors, and rotators of the cervical region without performing spinal movements, using the movement of the eyes to aid in the accomplishment of these exercises. 4.Isometric contraction of the flexor muscles, inclinators, and rotators against manual resistance of the physiotherapist. 5.Isometric contraction of the cervical extensors of the cervical region against gravity. 6.Contraction of the flexor muscles, extensors, and incliners of the cervical region against the resistance of elastic bands.
223446113|NCT05400486|OTHER|Therapeutic exercise group + high frequency TENS|TENS (Endophasys® - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda) will be applied to the cervical region through 4 silicon-carbon electrodes measuring 4 x 4 cm, with a water-based gel to reduce the impedance at the interface electrode skin. Thus, TENS will be applied with a rectangular, biphasic, and symmetrical pulse, with a pulse width of 100 µm, and a frequency of 100 Hz, at the maximum tolerated sensitive threshold, for 30 minutes (VANCE et al., 2012).
223446114|NCT05400486|OTHER|Therapeutic exercise group + Interferential|In sequence, the interferential current will be applied. Through the Endophasys® device - NMS-0501, KLD Biosistemas® Equipamentos Eletrônicos Ltda). Four electrodes (8x5 cm), two upper and two lower (forming a square) will be positioned around the center of the neck. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (Sweep Mode), 60 Hz Amplitude of frequency modulation (AMF), 30 Hz (Delta AMF), automatic vector mode, with intensity at the motor threshold of sensation, lasting 30 minutes (Albornoz-Cabello et al., 2019).
223446115|NCT00116636|DRUG|Kaletra|
223446116|NCT03276845|DIAGNOSTIC_TEST|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
223446117|NCT03767426|BEHAVIORAL|Sleep Deprivation|Subjects are sleep deprived for an entire night
223446118|NCT03767426|BEHAVIORAL|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
223741549|NCT04229004|DRUG|Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine|"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
224055214|NCT01978782|DRUG|raltegravir|
224055215|NCT01978782|DRUG|citalopram|
224055216|NCT01704586|RADIATION|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
224055217|NCT01704586|RADIATION|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
224300744|NCT05404607|OTHER|Fascial distortion method|27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
223446119|NCT01362023|BEHAVIORAL|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home"
223741550|NCT04229004|DRUG|Drug: Dose -SM-88|"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
223741551|NCT01627821|DEVICE|Jarvik 2000 VAS|Jarvik 2000 LVAD
224055218|NCT01989403|OTHER|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
224055219|NCT00004887|DRUG|carboplatin|
224055220|NCT00004887|DRUG|cisplatin|
224055221|NCT00004887|DRUG|ifosfamide|
224055222|NCT00004887|DRUG|mitomycin C|
224055223|NCT00004887|DRUG|paclitaxel|
224055224|NCT00004887|DRUG|vinblastine sulfate|
224055225|NCT05177120|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
224055226|NCT05177120|OTHER|Short form-36|Standardized questionnaire to investigate the quality of life in patients
224055227|NCT05177120|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
224300745|NCT04848311|PROCEDURE|lymph nodes dissection at 253 station assisted by ICG|In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
223446120|NCT00810498|DEVICE|Trilogy|Exposure for one hour on the Trilogy ventilator
223446121|NCT00810498|DEVICE|Standard of Care|Exposure to participants current ventilator
224055228|NCT05177120|OTHER|Health assessment questionnaire|Standardized questionnaire used to detect the presence of disability
224055229|NCT05177120|OTHER|Hospital anxiety and depression scale|Standardized questionnaire to investigate the depression and anxiety
224055230|NCT05177120|DIAGNOSTIC_TEST|Fibromyalgia rapid screening tool|Standardized questionnaire to determine the presence of fibromyalgia
224055231|NCT05177120|OTHER|Familial Mediterranean Fever Quality of life scale|Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
224055232|NCT00365456|DRUG|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
224055233|NCT00365456|DRUG|Risedronate|Orally once weekly as one 35 mg tablet.
224055234|NCT03668600|DRUG|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
224300746|NCT06037837|PROCEDURE|Robotic Surgery|Surgeons will perform and participants will undergo robotic surgery according to the standard of care. No additional interventions will be performed on participating participants.
224055235|NCT01735253|PROCEDURE|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
224055236|NCT04729036|PROCEDURE|open reduction and internal fixation|The same surgical team have treated all the patients through open reduction via an intra-oral mucosal flap under general anesthesia with insertion and fixation of a 4-6 holes 2.0 miniplate and 5 mm screws at the superior border of the mandible at Champy's osteosynthesis line
224055237|NCT05454371|DEVICE|Colli-Pee UAS devices|Colli-Pee UAS device variants will be evaluated during this study
223446122|NCT05708352|BEHAVIORAL|Keto Diet|The experimental intervention includes a strict and controlled diet that manages daily macronutrient breakdown and increases the ratio of dietary fat relative to protein and carbohydrate consumption.
224055238|NCT01908764|DRUG|AL-60371 otic suspension|
224055239|NCT03260504|BIOLOGICAL|Aldesleukin|Given SC or IV
224145967|NCT04909216|OTHER|Mindful Attention Workshop|The 90-minute workshop will include a 15-minute break and include up to 15 participants. The workshop will be led by peer support staff, fire department psychologists, and/or fire department doctoral psychology practicum students. Each workshop will be facilitate by up to 3 workshop leaders. The workshop will provide (1) psychoeducation regarding common mental health concerns among firefighters, (2) introduction to the concept of mindful attention, why it is relevant to firefighters, and how it can prevent or decrease mental health symptoms, (3) 5 experiential mindful attention training exercises, and (4) discussion. Workshop co-leaders will teach 5 mindful attention exercises, and firefighters will practice each exercise and then engage in discussion about their experiences and provide feedback regarding the utility of the exercise for them personally and for firefighters, generally.
223446123|NCT05708352|BEHAVIORAL|Standard Anti-Cancer Diet|Dietitian sessions will utilize the American Institute for Cancer Research Food resources and will reference foods low in fats such as fruits, vegetables and whole grains, providing key micronutrients and phytonutrients. Sessions will also focus on dietary support to help decrease any treatment related symptoms.
223446124|NCT04136262|DRUG|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
223446125|NCT04136262|DRUG|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
223446126|NCT04136262|OTHER|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
223446127|NCT04122209|OTHER|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
223446128|NCT04122209|OTHER|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
223446129|NCT00088309|PROCEDURE|Eye exam|
223446130|NCT00088309|PROCEDURE|Oral exam|
223446131|NCT00088309|PROCEDURE|CT scan|
223446132|NCT00088309|PROCEDURE|Neuropsychological testing|
224055240|NCT03260504|BIOLOGICAL|Pembrolizumab|Given IV
224055241|NCT04122014|OTHER|Progressive balance training|Progressive balance training program
224055242|NCT04122014|OTHER|Normal daily activities|Usual daily activities
224055243|NCT00873977|DEVICE|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
224055244|NCT03799250|DRUG|Ringer lactate|Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
224055245|NCT03799250|OTHER|standard care|standard care
224055246|NCT01131676|DRUG|BI 10773 low dose|BI 10773 tablets once daily
224055247|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
224055248|NCT01131676|DRUG|BI 10773 high dose|BI 10773 tablets once daily
224055249|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
224055250|NCT01131676|DRUG|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
223446133|NCT00088309|PROCEDURE|Electrocardiogram|
223446134|NCT00088309|PROCEDURE|Echocardiogram|
223446135|NCT04494425|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan by intravenous infusion
223446136|NCT04494425|DRUG|Capecitabine|Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.
223446137|NCT04494425|DRUG|Paclitaxel|Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.
223446138|NCT04494425|DRUG|Nab-Paclitaxel|Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion
223446139|NCT01270321|DRUG|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
223446140|NCT01270321|DRUG|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
223446141|NCT01270321|DRUG|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
223446142|NCT00399711|DRUG|repaglinide and metformin combination tablet|
223446143|NCT00399711|DRUG|rosiglitazone and metformin combination tablet|
223446144|NCT00034047|PROCEDURE|Acupuncture|
223446145|NCT00034047|DRUG|Chinese Products|
223446146|NCT00034047|DRUG|Nafarelin|
223446147|NCT04723589|BIOLOGICAL|Thawed plasma|"Plasma not labeled convalescent plasma is presumed to be free of COVID antibodies, but is not tested for antibodies. To ensure that we are using antibody-free plasma, we will test each unit of plasma with a quick COVID test before it is utilized in this study."
223741552|NCT01627821|DEVICE|HeartMate II|HeartMate II LVAD
224055251|NCT01131676|DRUG|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
223446148|NCT04444336|BEHAVIORAL|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms|Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms
223446149|NCT02822833|PROCEDURE|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
223446150|NCT01613079|DRUG|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
223446151|NCT01613079|DRUG|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
223446152|NCT00910117|DRUG|nimotuzumab|nimotuzumab 400 mg d1
224055252|NCT02954367|DIETARY_SUPPLEMENT|PROTEIN|Immediately (\<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
223446153|NCT00910117|DRUG|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
223446154|NCT04565483|DRUG|Benralizumab Prefilled Syringe|Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
223446155|NCT01342783|GENETIC|DNA analysis|
223446156|NCT01342783|GENETIC|RNA analysis|
223446157|NCT01342783|GENETIC|mutation analysis|
223446158|NCT01342783|GENETIC|nucleic acid sequencing|
223446159|NCT01342783|OTHER|laboratory biomarker analysis|
224055253|NCT02954367|DIETARY_SUPPLEMENT|CARBOHYDRATE|Immediately (\<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
224055254|NCT00004340|DRUG|calcitriol|
223446160|NCT03840408|OTHER|Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation|Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
223446161|NCT03840408|PROCEDURE|Surgery|Patients will be treated with surgery
223446162|NCT02209818|RADIATION|Laser Irradiation One dose|
223446163|NCT02209818|RADIATION|Laser Irradiation Two doses|
223446164|NCT03454386|BEHAVIORAL|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
223446165|NCT03454386|BEHAVIORAL|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
223446166|NCT05624216|DEVICE|BTL-084|Radiofrequency and targeted pressure energy devices for the treatment of cellulite
223446167|NCT03151083|BEHAVIORAL|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
223446168|NCT04003623|DRUG|Pemigatinib|Pemigatinib administered orally once daily.
223446169|NCT03518398|DEVICE|Intense Pulsed Light|E\> Eye (E-SWIN, Paris, France) IPL machine
223446170|NCT03518398|COMBINATION_PRODUCT|Standard treatment|warm compression, lid scrub and non-preservative ocular lubricants
223446171|NCT00623298|BEHAVIORAL|Narrative Exposure Therapy|
224055255|NCT00004340|DRUG|growth hormone|
224055256|NCT03353571|DEVICE|"C3 UMBRELLA CATHETER"|The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
224055257|NCT05959395|DEVICE|VectRx Thermal Therapy|Subjects will receive VectRx thermal treatment added to 2 cycles of chemotherapy regimen. The VectRx device will be used under continuous investigator monitoring of internal tissue temperatures via real-time temperature probe data, as well as clinical signs and symptoms reflecting the objectives described above. Up to 5 study subjects will be treated. They will complete VectRx treatment during day 1 prior to 5-FU based (e.g., mFOLFIRINOX) or Gemcitabine based (e.g., Gemcitabine/Nab Paclitaxel) chemotherapy infusion. Thermal treatment will be carefully ramped-up to achieve staged goals of average tumor temperatures between 38°C and 43°C for total treatment times up to 30-70 minutes. The target temperature will be 41.5°C.
224055258|NCT00859378|DEVICE|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith \& Nephew)
224055259|NCT00859378|DEVICE|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
224055260|NCT03458390|DEVICE|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
224055261|NCT01094769|DRUG|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
224055262|NCT01094769|DRUG|Placebo|lactose capsule taken once daily
224055263|NCT04044131|DRUG|Metabolic Cofactor Supplementation|Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
223446172|NCT00623298|BEHAVIORAL|group IPT|
223446173|NCT00623298|OTHER|6 months-baseline|
224055264|NCT04044131|DRUG|Sorbitol|As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
224055265|NCT03121911|OTHER|Interval Training (IT)|"Each exercise session will consist of:~1. warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~2. interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~3. cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
223446174|NCT02918097|DRUG|Lithium Carbonate|
223446175|NCT02918097|DRUG|Sertraline|
223446176|NCT02918097|DRUG|Nortriptyline|
223446177|NCT02918097|DRUG|Risperidone|
223446178|NCT00703326|BIOLOGICAL|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
224055266|NCT03121911|OTHER|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2."
223446179|NCT00703326|DRUG|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
223446180|NCT00703326|OTHER|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
223446181|NCT00892814|RADIATION|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
223446182|NCT00892814|RADIATION|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
223446183|NCT00063336|BEHAVIORAL|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
223446184|NCT00063336|BEHAVIORAL|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
223446185|NCT02961387|DEVICE|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
223446186|NCT02961387|DEVICE|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
223446187|NCT04927923|OTHER|hope-focused motivational interview|The eight-week hope-focused motivational interview will be applied to each individual individually during dialysis treatment. Within the scope of the study, a hope tree will be created for each individual together with the patients to be used in the evaluation process of the interview sessions. Through the hope tree, it is aimed for the individual to set goals, to discover the obstacles and solutions in achieving these goals.
223446188|NCT03364036|DRUG|Mavenclad®|Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
223446189|NCT01673087|DRUG|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
223446190|NCT01673087|DRUG|Dexamethasone|"Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration."
223446191|NCT01673087|DRUG|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
223446192|NCT01673087|DRUG|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
223446193|NCT02802696|DRUG|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
223446194|NCT02802696|DRUG|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
223446195|NCT04198142|BEHAVIORAL|Imagery Rehearsal Therapy|"The Imagery Rehearsal Therapy (IRT) intervention used in this study is a short version of the treatment, consisting of 1-2 sessions.~The protocol starts with a very brief explanation of the treatment. Then the patient will be guided through an imagery exercise. The next step is to choose a nightmare. This nightmare is then rescripted to a new narrative, which is in no way distressing to the patient anymore. Subsequently, the therapist will guide the patient through an imagery exercise with the new narrative. The new narrative is then either written down or recorded. Lastly, the therapist will explain to the patient, that he or she should rehearse the new narrative daily with imagery exercises."
223741553|NCT00006101|DRUG|eflornithine|Take 500mg of DFMO per day for 12 months
223741554|NCT00006101|DRUG|Placebo|Take placebo per day for 12 months
223741555|NCT04949165|DIETARY_SUPPLEMENT|Iron Supplementation|low dose ferrous sulphate (65mg elemental iron) supplements
223446196|NCT04198142|BEHAVIORAL|Treatment as Usual with dream diaries|Treatment as Usual means that patients in this arm will receive usual inpatient care. Additionally, they will keep a dream diary. It has been shown in previous studies that keeping a dream diary has a positive effect on nightmares.
223446197|NCT03172377|OTHER|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
223446198|NCT01865656|OTHER|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
223446199|NCT01865656|OTHER|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
223446200|NCT01865656|OTHER|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
223446201|NCT01865656|OTHER|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
223446202|NCT01865656|OTHER|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
223568364|NCT05076214|BEHAVIORAL|Aerobic exercise in group|"The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds"
224055267|NCT05100472|BIOLOGICAL|Androgen deprivation therapy (ADT)|ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.
224055268|NCT05100472|RADIATION|Brachytherapy|After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.
224055269|NCT05100472|RADIATION|Hypofractionated pelvic External beam radiation|Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
224055270|NCT04104243|OTHER|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
224055271|NCT05143489|DRUG|Preservative Free Lidocaine|The patient will receive a 1mg/kg IV dose of lidocaine with a max dose of 40mg.
224055272|NCT05143489|DRUG|Saline|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
224055273|NCT05845645|DRUG|UCB0599|Study participants will receive pre-specified doses of UCB0599 in 3 different formulations administered orally in a pre-specified sequence during the Treatment Periods of Part A and B
224055274|NCT05845645|OTHER|Esomeprazole|Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational medicinal product (NIMP) in this study.
224055275|NCT05845645|OTHER|Placebo|Study participants will receive placebo comparator administered orally in a a pre-specified sequence during the Treatment Period of Part B.
224055276|NCT02977650|PROCEDURE|Endoscopic ultrasonography-guided fine needle aspiration|
224055277|NCT01111851|DRUG|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
224055278|NCT01111851|DRUG|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
224055279|NCT01111851|DRUG|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
224145968|NCT03228706|BEHAVIORAL|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
223446203|NCT02242019|DEVICE|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
224055280|NCT01111851|DRUG|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
224145969|NCT01248403|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
223446204|NCT01905332|OTHER|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
223446205|NCT01905332|OTHER|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
223446206|NCT02425462|DRUG|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
223446207|NCT02394119|DRUG|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
224055281|NCT01111851|DRUG|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
224055282|NCT01111851|DRUG|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
223446208|NCT02394119|DRUG|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
223446209|NCT01393106|DRUG|Idelalisib|Idelalisib tablets administered orally
223446210|NCT06427629|DEVICE|Imaging of conjunctival goblet cell|After instillation of moxifloxacin and illuminating with a 405nm light source using confocal fluorescence microscopy, conjunctival goblet cell imaging will be performed in patients with ocular surface disease and patients scheduled for ocular surgery without ocular surface disease
223446211|NCT02157571|DRUG|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
223446212|NCT02157571|DRUG|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
223446213|NCT02157571|DRUG|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
223446214|NCT02157571|DRUG|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
223446215|NCT03510975|DRUG|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
223446216|NCT03510975|BEHAVIORAL|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
223446217|NCT03510975|BEHAVIORAL|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
223446218|NCT02942121|OTHER|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
223446219|NCT02375425|OTHER|no intervention|no intervention-specimen collection study only
224055283|NCT01111851|DRUG|MK0999|I.V. infusion of MK0999 containing \~100 MBq (\~3 mCi) containing ≤ 5 ug of MK0999)
224055284|NCT05362968|DRUG|Freeze-dried strawberry powder|Whole strawberries are freeze-dried to form a powder with improved shelf life that will be used in this research study. Strawberry powder will be provided by the California Strawberry Commission (Watsonville, CA)
224145970|NCT01248403|DRUG|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
224145971|NCT04048629|DEVICE|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
223446220|NCT05805111|DEVICE|endovascular intervention|Covered Endovascular Reconstruction of Aortic Bifurcation (CERAB) is a new, minimally invasive technique, for treating extensive and/or recurrent aorto-iliac occlusive disease. The technique rebuilds the diseased aortic bifurcation and iliac arteries through the use of stent-grafts introduced through the groin or arm arteries.
223446221|NCT03166839|OTHER|Experiencing PPH|No intervention given
223446222|NCT01589588|DEVICE|Open Hudson Mask|Mask type 1 oxygen
223446223|NCT01589588|DEVICE|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
223446224|NCT01589588|DEVICE|Mask 3|Mask type 3 oxygen
223446225|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 oxygen
223446226|NCT01589588|DEVICE|Carnét oxygen demand valve|mask type 3 placebo
223446227|NCT04690335|BIOLOGICAL|MV-012-968|MV-012-968 is a recombinant, live attenuated RSV vaccine.
223446228|NCT04690335|OTHER|Placebo|Saline solution
223446229|NCT02951793|OTHER|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C\>4 versus AUDIT-C of 4 or below.
223446230|NCT02951793|OTHER|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
223446231|NCT02951793|OTHER|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
224055285|NCT06048094|DRUG|18F fluciclovine|Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
224055286|NCT00843388|DRUG|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
224055287|NCT00843388|DRUG|placebo tablet|placebo tablet 25 mg OD
224055288|NCT00239616|DRUG|Iron Sucrose injection|Iron sucrose 100 mg dose
224055289|NCT02263521|OTHER|No intervention employed. Study is based on a cross-sectional observational design.|
224055290|NCT01816061|BEHAVIORAL|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
223446232|NCT02666820|PROCEDURE|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
223446233|NCT02666820|PROCEDURE|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
223446234|NCT05201443|DEVICE|Diode laser|Diode Laser is applied to one group as an adjunctive therapy.
224055291|NCT01816061|BEHAVIORAL|Control - COMPASS|Increased hours of patient-provider interactions Group.
223446235|NCT05201443|DEVICE|Titanium curettes|Non-surgical treatment with titanium curettes were administrated to both groups.
223446236|NCT01084148|DRUG|V0034CR01B|
224055292|NCT00731055|DRUG|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
224055293|NCT00731055|DRUG|Placebo|1 dose of placebo
224055294|NCT03589495|DRUG|N Acetyl L Cysteine|100 mg/kg n acetyl cysteine dissolved in dextrose5%
224055295|NCT03589495|OTHER|dextrose 5%|
224055296|NCT04654481|DEVICE|HCFWO|The Afflovest device is a High Frequency Chest Wall Oscillation (HFCWO) device, a medical vest that uses vibrations to loosen and mobilize mucus in the lung secretions and help clear the airways.
224055297|NCT04654481|OTHER|Standard Care Plus Monitoring|Monitoring via home spirometry, pulse oximetry, temperature checks, telehealth check-in and patient-reported outcome assessments.
224055298|NCT00795249|BEHAVIORAL|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
224055299|NCT01471015|DRUG|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
224055300|NCT01471015|DRUG|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
224055301|NCT01471015|DRUG|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
224055302|NCT03889665|OTHER|Suspension training|Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
224055303|NCT04429165|OTHER|collection of Patient Reported Outcome (PRO) data|collection of Patient Reported Outcome (PRO) data by questionnaires
224055304|NCT04429165|OTHER|collection of anthropometric and clinical functional data|collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
224055305|NCT04429165|OTHER|gait analysis|gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
223446237|NCT01084148|DRUG|V0034CR01B vehicle|
223446238|NCT03971916|DRUG|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
223446239|NCT03971916|DRUG|Placebo|Subcutaneous injection; Single dose on Day 1
223741556|NCT02167607|DIETARY_SUPPLEMENT|Active Comparator|Purple Potato
223741557|NCT02167607|DIETARY_SUPPLEMENT|Placebo Comparator|Placebo Comparator
223741558|NCT01958775|DRUG|GLP-2|single subcutaneous dose of 1500mcg
223741559|NCT01958775|DRUG|Placebo|
224055306|NCT02953340|DRUG|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
224055307|NCT02953340|DRUG|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
224055308|NCT02953340|DRUG|Docetaxel|75mg/m\^2 IV infusion administered on Day 1 of each cycle
224055309|NCT02953340|DRUG|Cyclophosphamide|600mg/m\^2 IV infusion administered on Day 1 of each cycle
224055310|NCT02512406|OTHER|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
224055311|NCT02512406|OTHER|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
224055312|NCT02512406|OTHER|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
224055313|NCT02512406|OTHER|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
224055314|NCT02512406|OTHER|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
223446240|NCT01550523|DRUG|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
223446241|NCT01550523|DEVICE|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
223446242|NCT01904747|DRUG|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
223446243|NCT01904747|DRUG|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
224055315|NCT02512406|OTHER|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
223446244|NCT01904747|DRUG|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
223446245|NCT01904747|DRUG|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
223446246|NCT05437640|BEHAVIORAL|Protein Redistribution Diet|PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.
223446247|NCT05437640|BEHAVIORAL|Protein Consistent Diet|PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
223446248|NCT05206734|OTHER|No specific intervention|Observational analysis of usual care only.
223446249|NCT04250415|PROCEDURE|Surgery|
223446250|NCT04228965|DRUG|Varenicline|Varenicline is a medication approved by the Food and Drug Administration for the treatment of tobacco use disorder among adults (ages 18 and over). In this study, all participants will be administered active medication for the recommended 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
223446251|NCT04228965|BEHAVIORAL|Contingency Management|Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
223446252|NCT04228965|BEHAVIORAL|Counseling|Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
223446253|NCT02330172|OTHER|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
224055316|NCT01376778|DRUG|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
224055317|NCT01376778|OTHER|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
224055318|NCT04745039|DEVICE|Endopatch System|The patch system for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
224055319|NCT02700412|DRUG|Epidiolex|Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
224055320|NCT00928889|DRUG|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
224055321|NCT00928889|DRUG|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
224055322|NCT01835925|GENETIC|Tissue specimen|
224055323|NCT03007368|OTHER|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
224055324|NCT03007368|OTHER|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
224055325|NCT03007368|OTHER|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
224055326|NCT03007368|OTHER|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
223446254|NCT00329589|DRUG|Velcade (bortezomib)|
223446255|NCT04544163|DRUG|Magnesium sulfate- Fentanyl|drug administration before intubation
223446256|NCT04544163|DRUG|Fentanyl 4Mcg/kg|drug administration with induction of anesthesia
224055327|NCT03007368|OTHER|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
224055328|NCT03007368|OTHER|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
224055329|NCT03007368|OTHER|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
224055330|NCT03007368|OTHER|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
224055331|NCT04302194|DIETARY_SUPPLEMENT|phenylalanine restricted diet|Infants with hyperphenylalaninemia on special formula and diet
223446257|NCT04544163|DRUG|Fentanyl 2Mcg/kg|drug administration with induction of anesthesia
223446258|NCT04544163|DRUG|Lidocaine 1.5 mg/kg|drug administaration 90 sec before intubation
223446259|NCT00734656|DRUG|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
224145972|NCT04048629|OTHER|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
223446260|NCT00734656|DRUG|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
224300747|NCT03410251|PROCEDURE|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
224145973|NCT05072756|OTHER|Applying a questionnaire|The participants have to answer a questionnaire addressing their opinion on menopausal hormone replacement therapy
224300748|NCT02433262|OTHER|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
224300749|NCT02433262|OTHER|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
224300750|NCT04162054|OTHER|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
224300751|NCT05533762|DEVICE|arch insole and sham insole|children wear insoles on feet
224145974|NCT06014957|DRUG|spinal anesthesia|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), immediately positioned supine with one pillow supporting the head and shoulders
224300752|NCT04054960|DEVICE|Active tPCS|Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
224300753|NCT04054960|DEVICE|Sham tPCS|For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
224300754|NCT04054960|DRUG|Levodopa tablet|We will give 3 tablets of Levodopa-Carbidopa (100/25).
224055332|NCT01743924|OTHER|raw broccoli|To eat this plant material
224300755|NCT03166423|DRUG|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
224300756|NCT03166423|DEVICE|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
224300757|NCT00662948|DRUG|Rituximab|375 mg/m2 every 8 weeks during 24 months
224300758|NCT00662948|DRUG|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
223446261|NCT00734656|DRUG|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
223446262|NCT00734656|DRUG|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
223446263|NCT04647513|DEVICE|Intradermal injection (superficial dermis for Art Filler Fine Lines / moderately deep to deep dermis for Art Filler Universal and Art Filler Lips)|The function of injectable fillers for the treatment of dermal contour deformities is to smooth dermal depressions formed by the loss of volume and the aging process. These fillers (also known as soft tissue augmentation medical devices) can correct the skin depressions/wrinkles, balance the disproportions or correct topographical anomalies.
223568365|NCT05076214|BEHAVIORAL|Leisure activities in group|The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
224055333|NCT00061165|BEHAVIORAL|School + family changes promoting healthy eating + activity|
224055334|NCT02363348|DIETARY_SUPPLEMENT|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
224055335|NCT02363348|OTHER|Placebo|calcined magnesia
224055336|NCT03141554|DRUG|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
224055337|NCT03141554|DRUG|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
224055338|NCT03141554|DRUG|Normal saline gargle|Normal saline gargle
224145975|NCT06014957|DRUG|saddle block|12.5 mg of 0.5% hyperbaric levobupivacaine (2.5 ml) was given at the level of L4-5 interspaces after the free flow confirming of the cerebrospinal fluid (CSF), placed in the sitting position for ten minutes and then supine with one pillow supporting the head and shoulders
223568366|NCT05680480|BIOLOGICAL|Telitacicept 240 mg|Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.
223568367|NCT05680480|BIOLOGICAL|Telitacicept 160 mg|Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.
223568368|NCT05680480|DRUG|Placebo|Participants will receive placebo weekly in addition to SOC for 48 weeks.
223568369|NCT06264219|BIOLOGICAL|Microbiome restoration - FMT|Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
223568370|NCT06264219|BIOLOGICAL|Microbiome restoration - FVT|Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
223568371|NCT06264219|BIOLOGICAL|Placebo|Inactive solution buffer
223568372|NCT06264219|OTHER|Vaginal birth, untreated control|No intervention. This group is for secondary outcomes comparisons.
223568373|NCT05984407|PROCEDURE|cytokine hemadsorption therapy|Observation of cytokine hemadsorption therapy in critically ill patients who have no microbiological findings and develop vasoplegic shock.
223568374|NCT05996055|DEVICE|improved version_support device|designed the NTUH version\_support device based on the clinical suggestion.
223568375|NCT05996055|DEVICE|the NTUH version_support device|original designed by NTUH
223568376|NCT06230016|OTHER|questionnaires|"human and social science questionnaire (specifically designed by the expert lab of Grenoble) on motivation and restraint perceived by patient and parents, elaborated especially for this study.~Questionnaire administred before the start of current care APA programm and after 4 to 6 months."
223568377|NCT06230016|OTHER|PedsQL quality of life questionnaires|validated PedsQL (The Pediatric Quality of Life Inventory) questionnaires administred to children (if adequate) and parents before the start of current care APA programm and after 4 to 6 months
223568378|NCT03465397|DIAGNOSTIC_TEST|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
223568379|NCT05923931|DEVICE|cooling blanket|On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.
223568380|NCT05923931|DEVICE|non-cooling blanket|Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
223568381|NCT01069159|DRUG|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
223568382|NCT01069159|DRUG|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
223741560|NCT06007599|PROCEDURE|Skin closure using skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures with skin adhesive
224055339|NCT04898270|DRUG|Flupentixol|"Flupentixol tablets are indicated for:~• maintenance therapy of chronic schizophrenic patients whose main manifestations do not include excitement, agitation, or hyperactivity."
224055340|NCT04898270|DRUG|Multi-acting receptor-targeted antipsychotics (MARTAs)|Multi-acting receptor-targeted antipsychotics (MARTAs)
224055341|NCT01676675|BIOLOGICAL|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
224055342|NCT01676675|BIOLOGICAL|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
224055343|NCT01676675|BIOLOGICAL|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
224055344|NCT01676675|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
224055345|NCT03804333|RADIATION|standard treatment|3000 cGy in 10 daily fractions
224055346|NCT03804333|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
224055347|NCT04384562|DRUG|Methylphenidate|A 20 mg methylphenidate (Ritalin®) is administered only once for the dopamine reuptake inhibitor group.
224055348|NCT04384562|DRUG|Reboxetine|A 4 mg reboxetine (Edronax®) is administered only once for the noradrenaline reuptake inhibitor group.
224055349|NCT04384562|DRUG|Nicotine gum|A 2 mg nicotine (Nicorette®) gum is administered only once for the cholinergic receptor agonist group.
224055350|NCT04384562|DRUG|Placebo pill|A placebo pill is administered only once.
224055351|NCT04384562|DRUG|Placebo gum|A placebo gum is administered only once.
224055352|NCT02068742|OTHER|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
224055353|NCT02735395|PROCEDURE|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
224055354|NCT02735395|DRUG|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
224055355|NCT02735395|DRUG|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
224055356|NCT02735395|DRUG|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
224055357|NCT02735395|DRUG|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
224055358|NCT02735395|DRUG|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
224055359|NCT02735395|OTHER|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
224055360|NCT02735395|OTHER|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
223446264|NCT02287688|BIOLOGICAL|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
223446265|NCT04064515|DIAGNOSTIC_TEST|Blood Assayed for CTCs|All study participants will have 15 mL of blood drawn for the purpose of the study.
223446266|NCT04895852|DEVICE|TEAS|The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
224055361|NCT02735395|OTHER|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
224055362|NCT02735395|OTHER|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
224055363|NCT02058030|DEVICE|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
223446267|NCT04895852|DEVICE|Sham TEAS|The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
223446268|NCT02888561|DRUG|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
223446269|NCT02888561|DRUG|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
223446270|NCT01115387|OTHER|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
223446271|NCT01115387|OTHER|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
224055364|NCT03800784|DRUG|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
224055365|NCT04712110|BIOLOGICAL|TAK-019|TAK-019 intramuscular injection
224055366|NCT04712110|BIOLOGICAL|Placebo|Placebo intramuscular injection
224055367|NCT03997435|DRUG|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.
224145976|NCT06167278|OTHER|Indirect bonding with two different digital bracket bonding transfer tray|"To achieve more precise and predictable result is the common aim in contemporary treatment. Digital indirect bonding (IDB) is used for this purpose in orthodontic treatment. The aim of this study is to compare the transfer accuracy of two different IDB trays.~Digital IDB was performed on a total of 30 patients, using one of the two designs: shell and bar trays; with 15 patients in each group. Trays were designed with the Appliance Designer software (3Shape A/S, Copenhagen, Denmark) as shell and bar types."
224145977|NCT04246125|PROCEDURE|Interventional radiology : skin dose measurements|"Therapeutic interventional radiology procedure for the following anatomical regions:~* cerebral (neuroradiology)~* thoracic (cardiology, lungs)~* abdominal~Assessment of peak skin dose and dose mapping with use of Gafchromic film dosimeter and the estimation of the absorbed dose to the skin with use of RDM software program."
224145978|NCT04798846|PROCEDURE|dorsal plating|Spanning Plate inserted dorsally below tendons Spanning External Fixator by rods inserted in distal radius and metacarpals
224145979|NCT03185416|OTHER|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
224145980|NCT00323024|DRUG|NX1011|
224145981|NCT01766219|DRUG|6,8-bis(benzylthio)octanoic acid|Given IV
224145982|NCT03716687|DEVICE|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
224145983|NCT00132314|DRUG|IM risperidone|long-acting injectable risperidone
224145984|NCT00132314|DRUG|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
224145985|NCT00832312|OTHER|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
223446272|NCT00161668|DRUG|Mylotarg|
223446273|NCT02603510|DRUG|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
223446274|NCT02603510|DRUG|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
224055368|NCT03997435|DRUG|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
224055369|NCT05415995|DEVICE|Drug eluting Balloon|Drug eluting Balloon is a kind of the product that has been used for many years. By filling the micropores on the surface of the balloon with anti-proliferative drugs like immunosuppressive agents, the balloon is expanded and contacted with the lesion to rapidly release the drug to the local arterial wall.
224145986|NCT00832312|OTHER|placebo (saline)|Injection of 1cc of saline into the knee joint
224145987|NCT05367557|PROCEDURE|laparoscopic cholecystectomy|removal of the gallbladder by laparoscopy at pneumoperitoneum pressure setting of 12 or 8 mmHg
224145988|NCT06443749|PROCEDURE|appendectomy|the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node
223446275|NCT03214679|OTHER|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
223568383|NCT05807087|PROCEDURE|Conventional osteotomy|The nasal skeleton was accessed using a closed approach or an open approach is done via a transcolumellar and infracartilaginous incision. Osteotomy was made using osteotomes.
223568384|NCT05807087|PROCEDURE|Piezosurgery osteotomy|full exposure of the nasal bony pyramid is needed.
223568385|NCT05655507|DRUG|Zuranolone|Administered as capsules
223568386|NCT02922764|DRUG|RGX-104|
224055370|NCT01982032|PROCEDURE|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
224055371|NCT01982032|DEVICE|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
224055372|NCT01982032|DEVICE|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
224055373|NCT02111161|DRUG|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
224055374|NCT02111161|DRUG|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
224055375|NCT04217187|DEVICE|Neuromuscular Electrical Stimulation|Upper extremity neuromuscular electrical stimulation
224055376|NCT04217187|DEVICE|Sham Electrical Stimulation|Sensory only upper extremity electrical stimulation
224055377|NCT05246436|PROCEDURE|warming saline media|use warm saline as a distention media in office hysteroscopy
224055378|NCT05246436|PROCEDURE|room temperature saline media|use room temperature saline as a distention media in office hysteroscopy
224055379|NCT04417036|DRUG|BAY1097761 Active Dose 1|Participants will receive a lower dose ADM by inhalation
224055380|NCT04417036|OTHER|Placebo to BAY1097761|Participants will receive Placebo to BAY1097761 by inhalation
224055381|NCT04417036|DRUG|BAY1097761 Active Dose 2|Participants will receive a higher dose ADM by inhalation
224055382|NCT03332823|BEHAVIORAL|SME Ambassadors training & program|"* Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc."
224055383|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily
224055384|NCT01197521|DRUG|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
224055385|NCT01197521|DRUG|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
224055386|NCT04993235|BEHAVIORAL|NEPSY-II|Participants with SS and BWS are administered with selected subtests assessing six different neuropsychological domains
224055387|NCT04993235|BEHAVIORAL|CBCL and AQ questionnaires|Parents of participants with SS and BWS are administered with questionnaires assessing behavioral problems and autistic traits
224055388|NCT04993235|BEHAVIORAL|BUT questionnaire and experimental tasks|A questionnaire, a computer-based task, a body-illusion paradigm and two psychophysical tasks assessing diverse levels of body perception and representation. These tasks are administered to adolescents of the three groups
224055389|NCT01517893|DRUG|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
224055390|NCT01517893|DRUG|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
224055391|NCT06275763|DRUG|Phase C: Eplerenone|Participants randomly assigned to this arm take Eplerenone and placebos of Spironolactone and Torasemide
224055392|NCT06275763|DRUG|Phase C: Spironolactone|Participants randomly assigned to this arm take Spironolactone and placebos of Eplerenone and Torasemide
224055393|NCT06275763|DRUG|Phase C: Torasemide|Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
224055394|NCT06275763|DRUG|Phase B: Triplixam / Elestar HCT|Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC) based on optimally combined antihypertensive drugs: perindopril + indapamide + amlodipine (P+I+A) or olmesartan + hydrocholothiazide + amlodipine (O+H+A).
224055395|NCT06275763|DIAGNOSTIC_TEST|Phase A: Confirmation of uncontrolled hypertension|Confirmation of the true ineffectiveness of antihypertensive therapy based on 3 or more antihypertensive drugs (single or dual drug preparations) using ABPM and home BP measurements.
224055396|NCT01489566|DRUG|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
224055397|NCT01489566|DRUG|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
224145989|NCT06221956|BEHAVIORAL|relevis|Participants will receive access to the digital health intervention relevis in addition to TAU.
223446276|NCT03214679|OTHER|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
223446277|NCT05372185|BEHAVIORAL|VA Coordinated Anxiety Learning and Management- Substance Use Version|VA Coordinated Anxiety Learning and Management- Substance Use Version (VA CALM-S) is a cognitive behavior therapy (CBT) program that employs computer assistance to empower providers to deliver CBT with high fidelity. The computer program guides both providers and patients in a course of CBT, and in this study the content will focus on using transdiagnostic treatment elements to address co-occurring anxiety and substance use disorders.
223568387|NCT02922764|DRUG|Ipilimumab|
223568388|NCT02922764|DRUG|Docetaxel|
223568389|NCT02922764|DRUG|Pembrolizumab|
223568390|NCT02922764|DRUG|Carboplatin|
223568391|NCT02922764|DRUG|Pemetrexed|
223568392|NCT04270682|DRUG|Blinded CDCA 250 mg TID|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
223568393|NCT04270682|DRUG|Placebo|Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
223568394|NCT04270682|DRUG|Open-Label CDCA 250 mg TID|Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
223446278|NCT05372185|BEHAVIORAL|Usual care|Veterans will engage in VA care using the standard procedures of their facility.
223446279|NCT02827175|OTHER|blood sample|
223568395|NCT04270682|DRUG|Rescue Medication CDCA 250 mg TID|CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
223568396|NCT04270682|DRUG|CDCA Weight-Based Dose TID|Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
223568397|NCT00822419|DRUG|lidocaine|lidocaine cream 5%
223568398|NCT00822419|DRUG|ketamine|ketamine 5%
224055398|NCT02300948|DRUG|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
223446280|NCT03992677|OTHER|No intervention|No intervention
223446281|NCT01227525|DEVICE|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
223446282|NCT05212584|BIOLOGICAL|CD7CAR T cells|CD7 CAR T cells are used to treat patients. Patient will be administered either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
223446283|NCT02889146|OTHER|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
223568399|NCT00822419|DRUG|non-drug cream|will be put on the skin
223568400|NCT02632669|RADIATION|Hemigland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre-treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine-125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks, 3, 6, 9, 12,18, 24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
223568401|NCT04003207|DRUG|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
224055399|NCT02300948|DRUG|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
224055400|NCT00543075|DRUG|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
223568402|NCT04104815|OTHER|Experimental Thickener|Use to thicken liquids
224055401|NCT01921751|RADIATION|low intensity radiation therapy|50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy
224055402|NCT01921751|DRUG|Capecitabine|825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
224055403|NCT01921751|DRUG|Gemcitabine|1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off \[1 cycle = 4 weeks\]
224055404|NCT01921751|RADIATION|high intensity radiation therapy|63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy
224055405|NCT01921751|DRUG|nab-Paclitaxel|125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week \[1 cycle = 4 weeks\]
224055406|NCT04095650|BEHAVIORAL|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
224055407|NCT02285777|BIOLOGICAL|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
224055408|NCT02285777|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
224055409|NCT03481114|COMBINATION_PRODUCT|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
224055410|NCT03481114|COMBINATION_PRODUCT|Standard chemoradiotherapy|Patients in this arm will receive a standard radiotherapy course.
224055411|NCT04502251|DRUG|Low-Dose Naltrexone|4.5mg daily dose, orally, during 26 days
223446284|NCT02889146|OTHER|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
223568403|NCT01790178|PROCEDURE|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
223568404|NCT03569748|DEVICE|IQOS|IQOS USE FOR 12 WEEKS
224055412|NCT04502251|DEVICE|Transcranial Direct Current Stimulation|An anodal electrode was placed on the scalp above the primary motor cortex (M1), contralateral to the dominant cortex. The cathodal electrode was placed on the supraorbital contralateral area. The current used was 2mA during 20 minutes.
224055413|NCT04502251|DRUG|Placebo|The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
224055414|NCT04502251|DEVICE|Sham Transcranial Direct Current Stimulation|Sham-tDCS stimulation consists of an active current during 30 seconds
224055415|NCT02092012|DRUG|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
224055416|NCT02092012|DRUG|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
224055417|NCT05627414|DRUG|Disitamab Vedotin|2.5mg/kg，IV，Q3W
224055418|NCT05627414|DRUG|Sintilimab|200 mg，IV，Q3W
224055419|NCT05627414|DRUG|S-1|40\~60mg / m2, bid, d1-14, repeated every 3 weeks.
224055420|NCT05627414|PROCEDURE|Intraperitoneal chemotherapy with paclitaxel|Paclitaxel (PTX) was used with a dose of 60mg / m2, Q3W. （Only for patients with peritoneal metastases）
224055421|NCT05129059|OTHER|Logotherapy|Logotherapy is a method of finding meaning with three basic principles. The first principle is that life is meaningful in every situation , even in the most desperate moments. The second principle is that the main source of motivation is the desire to find meaning in life. The third is that an individual is free to choose his own attitude even in the worst conditions.
224055422|NCT02820792|PROCEDURE|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
224055423|NCT02820792|DEVICE|LMA ProtectorTM|
224055424|NCT02820792|DEVICE|Ambu AuraGainTM|
224145990|NCT01271413|BEHAVIORAL|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
224055425|NCT03269435|PROCEDURE|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
224055426|NCT03269435|DRUG|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
224055427|NCT00295711|DRUG|Bicifadine|
224055428|NCT05827939|OTHER|Covid19 Vaccination dose|Participants above or below 2 dose Covid19 Vaccination
224055429|NCT01903707|OTHER|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
223446285|NCT02889146|OTHER|Respiratory therapy|Respiratory therapy according to the service routine.
223446286|NCT03147976|DRUG|AMG 337|6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
224055430|NCT01903707|OTHER|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
224055431|NCT05896085|OTHER|REThink game|The Rethink therapeutic game is an online game developed based on Rational-Emotive Behavioral Therapy and has two versions: for children and adolescents and for adults. The Rethink therapeutic game for adults is available in 3D and VR version and consists of four levels, each of them training a specific emotion regulation ability such as: emotional awareness, mindfulness, cognitive change
224055432|NCT04252053|OTHER|Pilates Based Core Stabilization Training|Pilates-based core stabilization training (PBCST) is a controlled form of exercise provided improvement in stabilization of abdominal and back muscles.
224055433|NCT04252053|OTHER|Home based exercise|Home exercises which include pilates based core stabilization training will be structured for the people with MS according to their physical condition and will perform at home by them.
224055434|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
224145991|NCT03514238|BEHAVIORAL|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
224145992|NCT03514238|BEHAVIORAL|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
223568405|NCT03569748|DEVICE|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
223568406|NCT02254785|DRUG|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
223568407|NCT02254785|DRUG|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
223568408|NCT02254785|DRUG|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
224055435|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
224055436|NCT00761007|DRUG|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
224055437|NCT00761007|DRUG|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
224055438|NCT05085639|BIOLOGICAL|GLS-5130|GLS-5310 DNA plasmid vaccine
224055439|NCT05085639|BIOLOGICAL|Placebo|Placebo
224055440|NCT02713958|OTHER|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
223446287|NCT00645372|DRUG|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
223446288|NCT00645372|DRUG|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
223446289|NCT04469634|DIAGNOSTIC_TEST|Assessing antibody responses, neutralizing capacity and memory B-cell function|Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection
223446290|NCT05155956|OTHER|transcranial Doppler ultrasonography (TCD)|"Transcranial Doppler (TCD) is a non-invasive ultrasound-based technique that facilitates insonation of the cerebral arteries. TCD probe design enables continuous monitoring of cerebral blood flow velocity (CBFv). TCD has a variety of clinical applications, including intraoperative monitoring for detection of microemboli. The TCD probe can be comfortably secured to the patient's head by a headframe in order to maintain continuous vessel insonation. Microembolic signals (MES) can be reliably detected based on standard criteria:~1. Brief in duration (\<300msec)~2. High intensity (amplitude \>3 dB above background)~3. Unidirectional~4. Audible chirp or snap~Further, CBFv monitoring during may inform flow perturbations that occur during cardiac or vascular manipulations."
223446291|NCT04013685|BIOLOGICAL|Orca-T|an allogeneic stem cell and T-cell immunotherapy biologic
223446292|NCT01601067|BEHAVIORAL|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
223446293|NCT01601067|BEHAVIORAL|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
223446294|NCT03231137|COMBINATION_PRODUCT|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
223446295|NCT03231137|DRUG|ATV gel|Atorvastatin gel
223446296|NCT03231137|BIOLOGICAL|PRF|Platelet rich fibrin
223446297|NCT03231137|BIOLOGICAL|PRGF|plasma rich in growth factor
223446298|NCT05922137|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and limiting alcohol consumption
223446299|NCT05922137|BEHAVIORAL|Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
223568409|NCT06356259|DRUG|IRX-010|Administered IV
224055441|NCT02713958|OTHER|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
223741561|NCT06007599|PROCEDURE|Skin closure without skin adhesive|Wound closure using subcuticular running 3-0 monocryl sutures without skin adhesive
223741562|NCT00934739|DRUG|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
224055442|NCT04739254|DIAGNOSTIC_TEST|CardioFlux|Magnetocardiography
224055443|NCT01743755|DRUG|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
224145993|NCT03514238|BEHAVIORAL|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
224145994|NCT03602989|DEVICE|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
224145995|NCT03422640|DRUG|Apremilast|Open label treatment with apremilast
224300759|NCT02427035|BIOLOGICAL|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
223446300|NCT04722536|PROCEDURE|Cervico-isthmic cerclage|There is no intervention in this study. It's an observational retrospective study, before/after.
223446301|NCT00693485|DRUG|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
223446302|NCT00693485|DRUG|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
223446303|NCT00693485|DRUG|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
223568410|NCT06356259|DRUG|Placebo|Administered IV
223568411|NCT06345313|PROCEDURE|Day Group|Patient group that will be operated on between 08.00-12.00
223568412|NCT06345313|PROCEDURE|Night Group|Patient group that will be operated on between 18.00-22.00
223741563|NCT00934739|DRUG|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
224055444|NCT01743755|DRUG|Placebo|Placebo tablet, once daily for four consecutive days
224055445|NCT04533490|DRUG|SHR-1210|After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
224055446|NCT04746352|PROCEDURE|BES-SMFR|For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs. At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive. BES was performed once every 2 days for 4 weeks.
224055447|NCT04746352|PROCEDURE|BES|First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use. Second, patients were required to participate in intensive training regarding myofascial release techniques. Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks. SMFR was confirmed with patients at all their follow up visits.
224055448|NCT03535714|BEHAVIORAL|MANTR-a treatment|MANTR-a treatment
224055449|NCT05024799|DRUG|Fentanyl, propofol|The patients in this group will be administered with fentanyl and propofol
223446304|NCT05612269|DIAGNOSTIC_TEST|interleukin 6|follow up of type 2 diabetes with SGLT2 inhibitors like empagliflozin, canagliflozin, and dapagliflozin for measurement of inflammatory factors like interleukin-6, CRP
224055450|NCT05024799|DRUG|fentanyl and dexmedetomindine|The patients in this group will be administered with fentanyl and dexmedetomindine
224055451|NCT05024799|DRUG|Butorphanol and propofol|The patients in this group will be administered with butorphanol and propofol
224055452|NCT05024799|DRUG|Butorphanol and dexmedetomindine|The patients in this group will be administered with butorphanol and dexmedetomindine
224145996|NCT04939532|BEHAVIORAL|Text-Messaging (TM)|"Patients in the TM condition will receive HIPAA-compliant bidirectional text messages. Texts will include a brief message regarding COVID-19 risk and will screen the participants for COVID testing needs. Participants who reply yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. Patients who reply no will receive a text with the clinic phone number and a note to call if anything changes."
224145997|NCT04939532|BEHAVIORAL|Patient Navigation (PN)|"Patients in the PN condition, who respond yes to accepting testing will receive additional messages with a recommendation to be tested, testing locations/hours/phone, and an offer to receive a free at-home test mailed to their home. In addition they will receive a notice via text message that a Community Health Worker will contact them for patient navigation. At this time, patients will will have the option to opt-out of the phone call from the patient navigator. The Patient Navigation includes advice from navigators to address practical barriers to COVID testing such as logistics, transportation, and expenses as well as behavioral barriers such as hesitancy, fear, and uncertainty."
224145998|NCT04773704|DIAGNOSTIC_TEST|FILMARRAY® Pneumonia Plus Panel technique|FILMARRAY® Pneumonia Plus Panel technique (multiplex PCR) on a respiratory sample
224145999|NCT00926666|DRUG|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
224146000|NCT02347462|DEVICE|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
224146001|NCT02347462|OTHER|Standard care|Standard care according to the hospital severe asthma protocol
224146002|NCT06066359|DRUG|Fludarabine phosphate|Given by (IV) vein
224146003|NCT06066359|DRUG|Cyclophosphamide|Given by (IV) vein
224146004|NCT06066359|DRUG|NY-ESO-1 TCR/IL-15 NK|Given by (IV) vein
223446305|NCT03156569|DIAGNOSTIC_TEST|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
223446306|NCT01712048|PROCEDURE|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
223446307|NCT01712048|PROCEDURE|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
223446308|NCT04901234|RADIATION|Standard radiotherapy +/- chemotherapy|No radiotherapy adaptation unless major dosimetric deviation
223446309|NCT04901234|RADIATION|Experimental radiotherapy +/- chemotherapy|Systemic MRI-based radiotherapy adaptation mid-treatment
223446310|NCT03923049|DIAGNOSTIC_TEST|hybrid PET/MRI|On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
223568413|NCT00579241|PROCEDURE|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
223568414|NCT02388490|DRUG|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
223568415|NCT00603070|OTHER|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
224300760|NCT02427035|OTHER|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
224300761|NCT02203214|DEVICE|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
223446311|NCT01754766|DRUG|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
223446312|NCT01754766|OTHER|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
223446313|NCT05671159|OTHER|Blood sample|A supplementary blood sample will be taken including a 5mL EDTA tube and a paxgene tube
223568416|NCT00603070|OTHER|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
223568417|NCT06067048|DRUG|Zanubrutinib Oral Capsule|36 cycles (1 cycle is 28 days)
223568418|NCT06034951|DIETARY_SUPPLEMENT|Compleat 1.5 HP|Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
224055453|NCT00870766|PROCEDURE|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
224055454|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
224055455|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
224055456|NCT01531322|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
224055457|NCT02512809|DRUG|Isoflurane|
224055458|NCT02512809|DRUG|Dexmedetomidine|
224055459|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
224055460|NCT01431274|DRUG|tiotropium|low dose
224055461|NCT01431274|DRUG|olodaterol|one dose only
224055462|NCT01431274|DRUG|tiotropium|high dose
224055463|NCT01431274|DRUG|tiotropium + olodaterol|fixed dose combination
224055464|NCT01431274|DEVICE|Respimat|Respimat inhaler
224146005|NCT03162094|DRUG|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
224146006|NCT03162094|DRUG|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
224146007|NCT03162094|DRUG|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
224300762|NCT06442423|DRUG|Psilocybin|Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
223446314|NCT03435159|DIAGNOSTIC_TEST|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
223446315|NCT03435159|PROCEDURE|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
223446316|NCT03435159|DEVICE|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
223446317|NCT00559169|DRUG|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
223446318|NCT06020248|OTHER|Wear clothing that has been exposed to cigarette smoke for 3 hours.|Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
223568419|NCT06562660|DEVICE|apnoeic|In group S, High-Flow Nasal Oxygen was performed after the patient lost spontaneous breathing until the end-expiratory oxygen concentration reached 95 %.
223568420|NCT05770934|OTHER|Blood flow restricted low-load resistance exercise|Blood flow restricted low-load resistance exercise
223568421|NCT04200755|DRUG|Dupilumab 300Mg Solution for Injection|First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
224300763|NCT02504671|DRUG|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
223568422|NCT04200755|OTHER|Placebo|First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
223568423|NCT05365568|PROCEDURE|Left Bundle Branch Area Pacing (LBBAP)|Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy
223568424|NCT05365568|PROCEDURE|Biventricular pacing (BiV)|Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
224055465|NCT03429881|PROCEDURE|Stripping versus laser CO2|Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
224055466|NCT03944226|DIETARY_SUPPLEMENT|Beetroot juice|The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
224055467|NCT00003004|DRUG|alvocidib|
224055468|NCT00003004|DRUG|cisplatin|
224055469|NCT00003004|DRUG|paclitaxel|
224055470|NCT04967560|DEVICE|deep brain stimulation|Both group will undergo the DBS surgery. Four weeks after surgery, all patients will visit the clinic with the DBS stimulation in the 'off' state for initial programming of electrical parameters for stimulation. At double-blind visit, the electrical stimulation will be actually 'turned on' immediately after the programming in true-stimulation group, while turn-off in the control group.
224055471|NCT05956730|OTHER|Physical Activity (AUD)|Home training of patients with severe low vision managed through audio-guides (AUD).
224146008|NCT01226589|PROCEDURE|MRS|
224146009|NCT05010772|DRUG|Decitabine and Cedazuridine|Given PO
224146010|NCT05010772|DRUG|Enasidenib|Given PO
224146011|NCT05010772|DRUG|Gilteritinib|Given PO
224300764|NCT02504671|DRUG|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
224300765|NCT02504671|DRUG|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
224146012|NCT05010772|DRUG|Ivosidenib|Given PO
224146013|NCT05010772|DRUG|Venetoclax|Given PO
224146014|NCT06653192|PROCEDURE|Endoscopic biliary drainage|Decompression of the bile duct by endoscopic aproach.
224055472|NCT05956730|OTHER|Physical Activity (SUP)|Training of patients with severe low vision in a gym supervised by a personal trainer (SUP).
224055473|NCT03975621|BEHAVIORAL|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
224055474|NCT05259813|GENETIC|JWCAR029 (Relmacabtagene Autoleucel)|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
224055475|NCT00843518|DRUG|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
224055476|NCT00843518|DRUG|Placebo|Placebo orally twice daily for 12 weeks
224055477|NCT00602095|DRUG|misoprostol|0.025mg tablet vaginally every 4 hour until progress
224055478|NCT00602095|DRUG|dinoprostone|2mg vaginal gel every 6 hours until progress
224055479|NCT00602095|DEVICE|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
224055480|NCT01943513|BIOLOGICAL|BIIB023|Intravenous (IV) infusions
224055481|NCT01943513|BIOLOGICAL|Placebo|Matched placebo
224055482|NCT00754351|DRUG|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
224055483|NCT00754351|DRUG|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
224055484|NCT00754351|DRUG|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
224055485|NCT01811745|BEHAVIORAL|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
224055486|NCT01811745|BEHAVIORAL|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
224055487|NCT04417179|PROCEDURE|transversus abdominis block|transversus abdominis block
224055488|NCT04417179|PROCEDURE|Erector spinae block|Erector spinae block
224055489|NCT04417179|DRUG|Bupivacaine 0.25% Injectable Solution|Local Anesthetic used in both blocks
224055490|NCT04417179|DEVICE|Siemens Acuson x300 3-5MHz Ultrasound|Ultrasound used to aid in the blocks
224055491|NCT00962442|DRUG|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
224146015|NCT06653192|DEVICE|Self-expandable metallic stent (SEMS)|"Self-expandable metallic stent (SEMS) deployment:~Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~Size: 10x40mm or 10x60mm or 10x80mm."
224146016|NCT06653192|DEVICE|Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)|"Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm. DPPS size: 7Fr x 3-7cm."
224055492|NCT00962442|DRUG|placebo|Glucosé 5% perfusion for 14 days, intravenously
224055493|NCT00827606|DRUG|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
224146017|NCT02098499|DRUG|Haloperidol|5mg IV
224146018|NCT02098499|DRUG|Metoclopramide 10mg|10mg IV
224146019|NCT02098499|DRUG|Diphenhydramine|25mg IV
224146020|NCT06248723|OTHER|Nutritional intervention|"The objectives of the dietary intervention will be in accordance with the principles of the Mediterranean diet. Weekly menus will be provided that ensure a balanced intake of the various nutrients, according to the objectives outlined in the study protocol, including a reduction in saturated fatty acids (with proportionately more mono- and polyunsaturated fatty acids), promotion of fiber sources and reduction of sugars, adequate protein and micronutrient intake. They will be accompanied by specific dietary patterns that can be individualized based on weight, comorbidities and personal preferences.~The need for weight loss or gain will be assessed on an individual basis. Dietary interventions will include group and individual sessions, and will be conducted by dietitians and nutritionists in a harmonized manner among the centers. The first meeting will be in-person and will be held at the subject's clinical center of enrollment. Follow-up will be conducted through online meetings."
223741564|NCT00213837|DEVICE|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
224055494|NCT01772901|OTHER|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
224055495|NCT01748942|DRUG|Dexamethasone|Given IV
224055496|NCT01748942|DRUG|Dexamethasone|Given PO
224055497|NCT01748942|OTHER|Placebo|Given PO
224055498|NCT01748942|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
224055499|NCT01748942|OTHER|Questionnaire Administration|Ancillary studies
224055500|NCT01748942|PROCEDURE|Transoral Robotic Surgery|Undergo TORS
224055501|NCT00571844|BEHAVIORAL|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
224300766|NCT02504671|DRUG|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
224055502|NCT00571844|BEHAVIORAL|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
224055503|NCT03574857|DRUG|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
224146021|NCT06248723|OTHER|Physical exercise|The physical activity protocol will be geared to the principles of progressive and individualized loading, in group sessions supervised by a physical therapist within gyms for the strength and balance training portion, and in moderate to intense aerobic activities based on individual preferences and characteristics. The physiotherapist will conduct an individual assessment and develop personalized programs for all participants. Exercise sessions will be held 2-3 times a week.
224146022|NCT06248723|OTHER|Cognitive training|Participants will be evaluated through a Cognitive and Psychological Assessment, which will allow measurement of each participant's cognitive functioning and well-being. Computerized cognitive training (CCT) using Brain HeadQuarter (BrainHQ) or similar software will be used as a cognitive intervention. The CCT includes game-based adaptive exercises that target attention, intelligence, memory, navigation, processing speed and social skills. The training will consist of 72 sessions for 24 weeks (about six months), at least three times a week.
224146023|NCT06248723|OTHER|Oral hygiene|"Participants will be referred for evaluation at dental hygiene offices. As part of the study, participants will also undergo anticholinergic burden calculation, screening for risk factors for oral diseases (smoking, alcohol), and reduction in the frequency of sugar intake through dietary intervention will be sought.~Participants will also undergo the Oral Health Assessment Tool rating scale."
224146024|NCT06248723|OTHER|Sleep quality|"During the visits, participants' sleep will be assessed, either by clinical interview or by scales. Participants will also have the opportunity to assess their own sleep via wearable devices.~If sleep hygiene issues are detected, advice based on currently available scientific evidence will be provided. If, on the other hand, a suspicion of sleep disorders, including, for example, obstructive sleep apnea syndrome, restless legs syndrome, insomnia, or Rapid Eye Movement (REM) sleep disorder, is raised from the medical history, participants will be referred to the relevant specialists for diagnosis and treatment of such problems."
224146025|NCT06248723|OTHER|Control of cardiovascular, metabolic, and infectious risk factors|Measurements of blood pressure, weight, BMI, abdominal circumference, and advice on health promotion and healthy lifestyle will be provided. Recommendations on adherence to the Piano Nazionale di Prevenzione Vaccinale (PNPV) will also be provided.
224146026|NCT06248723|OTHER|Pharmacological evaluation|Evaluation of prescriptive appropriateness (STOP\&START and Beers criteria) and calculation of anticholinergic burden (ACB calculator) will be carried out by a geriatrician, with rationalization of therapy and, where possible, de-prescribing.
224146027|NCT06248723|BEHAVIORAL|Socializing|"To encourage socialization, proposed activities will be carried out as much as possible in groups of 10-12 people, and outdoor group activities will be suggested on a biweekly basis (e.g., walks in parks). On a monthly basis, the nurse and psychologist will organize motivational and check-up meetings (in recreation centers/via telematics) in order to promote adherence to the protocol, collect questions and stimulate participants.~Social activity will also be implemented in the context of all interventions, for example through:~* Physical activity in groups or pairs, including dance or choir activities where possible~* Opportunities for further cognitive stimulation in groups through games (e.g., chess, cards, etc.)~* Proposal to cook, eat or shop together~* Group sessions with dietitian"
224146028|NCT06248723|OTHER|Self-administered interventions|"Subjects in the control group will receive regular health advice in the same domains as the intervention group, via dedicated app and/or access to the dedicated portal on the Age-It website. Such advice and information will be timed to encourage adherence. In addition, participants randomized to the self-guided intervention will receive an initial counseling session of 30-60 minutes on all domains covered by the study, where guidelines for healthy diet, physical and cognitive activity, benefits of social activity, information on cardiovascular risk factors, as well as sleep, oral hygiene will be explained.~Subjects will therefore be treated as per normal clinical practice, albeit with the help of dedicated apps and counseling session."
224146029|NCT02966353|DRUG|ruxolitinib|Ruxolitinib was supplied in 5 mg tablets to be taken orally approximately 12 hours apart (morning and night)
224300767|NCT05526261|PROCEDURE|Hemithyroidectoy|Hemithyroidectomy it is a surgical procedure where half of the thyroid gland is operated.
224300768|NCT02390349|OTHER|Placebo|
224300769|NCT02390349|DIETARY_SUPPLEMENT|Curamin|
224300770|NCT02390349|DIETARY_SUPPLEMENT|CuraMed|
224300771|NCT02242916|RADIATION|Photon therapy versus proton therapy|
224300772|NCT02242916|RADIATION|Photon therapy versus C-ion therapy|
224300773|NCT04842565|DRUG|Sintilimab|Sintilimab (200mg ivdrip D1 Q3W)
224300774|NCT04842565|DEVICE|TACE|TACE will be performed by clinical demand, the interval between two TACEs is not less than 4 weeks.
224300775|NCT02518919|OTHER|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
223741565|NCT04309305|DEVICE|EksoGT™, Ekso Bionics, Berkley, CA, USA|The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
224055504|NCT03574857|DRUG|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
224055505|NCT06428084|DRUG|Ondansetron|4 mg of ondansetron intravenously
223446319|NCT05926466|DRUG|BTZ-043|BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
224055506|NCT06428084|DRUG|Haloperidol|1 mg of Haloperidol intravenously
223446320|NCT05926466|DRUG|Bedaquiline|Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
223568425|NCT06574126|DRUG|Group 1: Dara-VRD followed by apheresis and cilta-cel infusion|In Group 1, 10 eligible participants will undergo a maximum of two 28-day induction cycles with Dara-VRD. Participants in Group 1 are considered enrolled as the date of signing the Informed Consent Form. This will be followed by apheresis according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom apheresis or manufacturing fails will be allowed a second attempt of apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
223741566|NCT04309305|OTHER|Standard of Care|Standard gait therapy provided by licensed physical therapists post stroke.
224055507|NCT05231499|OTHER|nasal irrigation|regular saline nasal rinse
224055508|NCT02748330|DRUG|Ticagrelor|Ticagrelor
224055509|NCT02748330|DRUG|Clopidogrel|Clopidogrel
224055510|NCT02748330|DRUG|Aspirin|Acetylsalicylic acid
224055511|NCT04689581|OTHER|Ultrasound guided bi-level erector spinae plane block|Bi-level ultrasound (US)-guided Erector spinae plane block (ESP) with 30 ml 0.25% bupivacaine at the T2 andT4 vertebral level will performe preoperatively to all patients in the ESP group.
224055512|NCT04689581|OTHER|Ultrasound guided modified pectoral nerve block|Ultrasound (US)-guided modified pectoral nerve block (PECs) with 30 ml 0.25% bupivacaine will performe preoperatively to all patients in the PECs group.
224055513|NCT04037748|DRUG|Puran T4®|Participants who received a single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
224055514|NCT04037748|DRUG|Eutirox®|Participants who received a single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2 under fasting conditions.
224055515|NCT05895682|DEVICE|mobiCARE +Pulse (MP100W)|Volunteers were monitored using end-tidal carbon dioxide partial pressure and fraction of inspired oxygen. Each volunteer was placed in a semi-Fowler's position and connected to a breathing circuit to administer the nitrogen-air-carbon dioxide mixtures. A nose clip was applied to prevent breathing of room air. For frequent blood sampling, an arterial cannula was placed in the radial artery of each volunteer. Pulse oximeter probes were simultaneously attached to each volunteer's fingers. Each volunteer was exposed to various levels of induced hypoxia from 70\~100% of SaO2. Each plateau of oxygen saturation was maintained for at least 30 s until stabilization, after which 1 ml of arterial blood was drawn into a heparinized syringe. The study period consisted of two rounds of hypoxia, and the volunteers were maintained on room air between each round. SaO2 measurements using a CO-oximeter were used as a reference for the SpO2 accuracy.
224055516|NCT05454436|PROCEDURE|sinus tract healing in single or multi visit with single cone technique with bioceramic sealer|Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
224055517|NCT00927654|DRUG|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
224055518|NCT00927654|DRUG|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
224055519|NCT02937025|DEVICE|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
224055520|NCT06159387|DRUG|Cannabis Extract Oil SR Capsule|"After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model"
223446321|NCT05926466|DRUG|Delamanid|Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
223741567|NCT04309305|OTHER|No Intervention|Testing Only
223741568|NCT06320132|OTHER|Treatment of spontaneous intracranial hemorrhage|Data collection of therapeutic approach, including radiological, medical, surgical therapies.
223741569|NCT04784052|DRUG|JSP191|Participants will receive a single IV dose at start of conditioning
224055521|NCT00163202|PROCEDURE|Blood samples|
224055522|NCT00163202|DRUG|Atorvastatin|
224055523|NCT00573989|DRUG|erlotinib hydrochloride|
224055524|NCT00573989|DRUG|pemetrexed disodium|
224055525|NCT00573989|PROCEDURE|quality-of-life assessment|
224055526|NCT00573989|RADIATION|intensity-modulated radiation therapy|
224055527|NCT02069470|BEHAVIORAL|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
224055528|NCT04544475|DEVICE|Revaree|Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
224055529|NCT04544475|DRUG|Estrace|Vaginal estrogen cream, estradiol: 100mcg
224055530|NCT03507920|OTHER|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
224300776|NCT02518919|OTHER|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
224300777|NCT03237949|BEHAVIORAL|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
224300778|NCT03237949|BEHAVIORAL|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
223446322|NCT05926466|DRUG|Moxifloxacin|Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
223568426|NCT06574126|DRUG|Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion|In Group 2, 10 eligible participants will undergo apheresis first, according to institutional standards with the collection target and instructions for processing and shipping apheresis product provided in the Cell Therapy Investigational Product Procedures Manual. Study enrollment is defined as the date of signing Informed Consent Form. The apheresis will be followed by a maximum of two 28-day induction cycles with DARA-VRD. Cilta-cel will be generated from T cells selected from the apheresis. Participants for whom the apheresis or manufacturing fails will be allowed a second attempt at apheresis. Between apheresis and cilta-cel infusion, participants will be allowed to have stem cell collection using GCSF+/-plerixafor. Cilta-cel will be manufactured by transduction of T cells with an LV vector expressing anti-BCMA CAR, followed by T cell expansion.
223568427|NCT01325454|DEVICE|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
224300779|NCT01615237|BEHAVIORAL|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
224300780|NCT01615237|BEHAVIORAL|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
223446323|NCT02309450|DRUG|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
223446324|NCT02222116|DEVICE|MGuard Prime|
223446325|NCT02222116|DEVICE|Control BMS DES|
223568428|NCT02783040|DRUG|Midazolam|
223568429|NCT02783040|DRUG|Warfarin|
223568430|NCT02783040|DRUG|Omeprazole|
223568431|NCT02783040|DRUG|Midazolam|
223568432|NCT02783040|DRUG|Digoxin|
223568433|NCT02783040|DRUG|BI 425809|
223568434|NCT03609385|DIAGNOSTIC_TEST|Coronary angiography|In patients eligible for participation in the study coronary angiography, echocardiography and EKG will be performed systematically.
223568435|NCT06416358|DRUG|ALMB-0168|ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
223568436|NCT03103698|DEVICE|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
224055531|NCT03507920|OTHER|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
224146030|NCT03013257|DEVICE|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
224146031|NCT01029015|PROCEDURE|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
224146032|NCT01029015|PROCEDURE|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
224146033|NCT00445731|BEHAVIORAL|exercise intervention|
224146034|NCT00445731|PROCEDURE|management of therapy complications|
224146035|NCT00445731|PROCEDURE|observation|
224146036|NCT04777474|DIAGNOSTIC_TEST|Enhanced contact endoscopy|The study subjects will undergo enhanced contact endoscopy - studied imaging technique
224146037|NCT04777474|DIAGNOSTIC_TEST|Narrow band imaging|The study subjects will undergo narrow band imaging - comparator procedure
224146038|NCT04777474|DIAGNOSTIC_TEST|IMAGE1S imaging|The study subjects will undergo IMAGE1S imaging - comparator procedure
224146039|NCT05905601|BEHAVIORAL|"NORTH Full"|NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
223446326|NCT03180931|DEVICE|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
224300781|NCT01615237|BEHAVIORAL|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
224300782|NCT00197288|BIOLOGICAL|Influenza|
224300783|NCT03279497|BEHAVIORAL|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
224300784|NCT03279497|BEHAVIORAL|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
224300785|NCT00004151|DRUG|acridine carboxamide|
224300786|NCT04227353|BEHAVIORAL|HEAL ABC|Participants will be assigned their first booklet based on the one they perceive to be the easiest for setting an incremental goal and achieving it. After the participant achieves successful behaviour change, he or she can move more confidently to the next booklet. Support will be provided every two weeks over the phone for 12 weeks. During the follow-up period, participants will use the follow-up booklet which helps them to continue with changes they have made and encourage them to set new goals.
224300787|NCT05250648|DRUG|complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes|In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60
224300788|NCT05250648|PROCEDURE|complete cytoreductive surgery without HIPEC|in the arm without HIPEC, only complete cytoreductive surgery will be performed
224300789|NCT01167322|DRUG|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
224300790|NCT00555386|DIETARY_SUPPLEMENT|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
224300791|NCT05382169|OTHER|Determine the presence of mast cell activation syndrome|"Mast cell activation syndrome will be confirmed if the following three conditions are met (according to Valent et al, 2012) :~* At least two clinical signs compatible with MAS before the first consultation (V1)~* Improvement of symptoms on antihistamines within 2 months of initiation of treatment~* Significant increase in tryptase during crisis~Mast cell activation syndrome will be possible if :~* At least two clinical signs consistent with MAS before the first consultation (V1)~* Improvement of symptoms with antihistamines within 2 months of initiation of treatment~* No significant increase in tryptase during crisis In all other cases, mast cell activation syndrome is unlikely."
224300792|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
223446327|NCT01277432|OTHER|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)"
223446328|NCT01277432|OTHER|Depression screening - control|"All study participants will undergo;~1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~2. a detailed psychological and behavioral assessments using validated questionnaires~3. several specialist questionnaires on depression, self care and quality of life"
223446329|NCT03972501|DRUG|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
223568437|NCT03103698|OTHER|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
223568438|NCT03656848|DIAGNOSTIC_TEST|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
223568439|NCT03656848|DIAGNOSTIC_TEST|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
223568440|NCT03941964|DRUG|Venetoclax|Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing. On the days that the participant received either azacitidine or decitabine, venetoclax was dosed in clinic and administered prior to these agents.
223568441|NCT03941964|DRUG|Azacitidine|The azacitidine infusion was prepared and administered per the package insert and given either subcutaneously or intravenously, per institutional practice.
223568442|NCT03941964|DRUG|Decitabine|The decitabine infusion was prepared and administered per the package insert and given intravenously, per institutional practice.
223446330|NCT03972501|DRUG|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
223446331|NCT04379765|BEHAVIORAL|Exercise and physical therapy|Decompression operation
223446332|NCT01709409|DRUG|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
223568443|NCT01210963|DEVICE|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
223568444|NCT00014989|DRUG|magnesium sulfate|
223568445|NCT03404063|DRUG|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
223446333|NCT01709409|DRUG|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
224300793|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
224300794|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
223446334|NCT02412878|DRUG|Carfilzomib|Carfilzomib was administered as an IV infusion
224055532|NCT06158542|PROCEDURE|Spinal Anesthesia|After standard monitoring, the patient is placed in a sitting position for site marking and administration of anesthesia. The line connecting the upper border of the right and left iliac crests through conventional palpation of anatomical landmarks (Tuffier line) is identified as the entry point at the L3-L4 interspinous space or L2-L3 interspace. For patients in whom spinal entry is successful, spinal anesthesia is provided with the appropriate dose and types of local anesthetics (intrathecal 10-12 mg bupivacaine with the addition of 15-25 mcg fentanyl). After completing the procedure and placing the patient in the supine position, the block level is determined 10 minutes post-procedure using the ice test/pinprick test. Blocks reaching the T4-T6 level are considered successful.
223446335|NCT02412878|DRUG|Dexamethasone|Commercially available dexamethasone was obtained by the investigational site.
223446336|NCT04571385|DRUG|AP30663|Administer by intravenous infusion.
223446337|NCT04571385|DRUG|Placebo|Placebo matched to AP30663.
223446338|NCT03815435|PROCEDURE|Controlled hypotension|Controlled hypotension will be administered according to the clarity of the surgical field.
223446339|NCT02562599|DRUG|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
223568446|NCT03404063|DRUG|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
224055533|NCT06158542|DIAGNOSTIC_TEST|Blood Sampling|Preoperatively, syndecan-1 serum levels will be investigated from the blood sample taken before cesarean section.
223568447|NCT04694755|DRUG|Placebo|On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards
224300795|NCT01160172|BIOLOGICAL|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
224300796|NCT01160172|DRUG|Saline placebo|intramuscular vaccination according to protocol schedule
224300797|NCT06318286|DRUG|Lenvatinib|Induction treatment: lenvatinib, 8 mg QD on Day 1 of a 21-day cycle for 4-6 cycles. Maintenance treatment: Lenvatinib, 20 mg QD may be given for up to a total of 35 cycles.
224300798|NCT06318286|DRUG|Pemetrexed|Pemetrexed, 500 mg/m2 will be given by intravenous (IV) infusion on Day 1 of a 21-day cycle for 4-6 cycles.
224300799|NCT06318286|DRUG|Cisplatin/Carboplatin|Carboplatin (AUC 5 mg/mL/min) or Cisplatin (75 mg/m2) will be given by IV infusion on Day 1 of a 21-day cycle for 4-6 cycles.
223446340|NCT02562599|RADIATION|Intensity-modulated radiotherapy (IMRT)|Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
223446341|NCT02263729|DRUG|Losartan|Cozaar
223446342|NCT02263729|DRUG|Placebo|
223446343|NCT01212159|DEVICE|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
223446344|NCT05475834|DRUG|SIM0417|Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
223446345|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
223446346|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 low dose
223446347|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
223568448|NCT04694755|DRUG|Traditional Chinese medicine prescription|Tianjiang brand formula granules, in line with GMP standards
223568449|NCT05484934|PROCEDURE|Regenerative post mastectomy surgery|Implantation of the Nipple-Areolar Complex (NAC) Reconstruction Using a Decellularized Donor NAC Graft (DCLNAC)
223568450|NCT04823702|BIOLOGICAL|Aldafermin|Biological: Aldafermin (NGM282) Subcutaneous Injection
223568451|NCT00597311|RADIATION|radiotherapy|"1. Short term radiotherapy 5x5 Gy during 5 days~2. Chemoradiotherapy 50 Gy + 5Fu/Lv"
223568452|NCT06606535|DIAGNOSTIC_TEST|validated questionnaires|Validated questionnaires for climacteric symptoms
223568453|NCT06606535|DIAGNOSTIC_TEST|functional MRI|functional MRI
223446348|NCT01306214|DRUG|Placebo|Placebo matching BI 10773 high dose
223446349|NCT01306214|DRUG|BI 10773|BI 10773 low dose once daily
223446350|NCT01306214|DRUG|BI 10773|BI 10773 high dose once daily
223446351|NCT04163926|PROCEDURE|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
223446352|NCT04163926|PROCEDURE|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
223446353|NCT00002255|DRUG|Filgrastim|
223446354|NCT00002255|DRUG|Epoetin alfa|
223446355|NCT00002255|DRUG|Zidovudine|
223446356|NCT06311071|DIAGNOSTIC_TEST|calcium score|Calcium score of coronaries obtained fro coronary CT angiography
223446357|NCT06311071|DIAGNOSTIC_TEST|Invasive coronary angiography|Invasive coronary angiography from radial artery with contrast injection
224300800|NCT06318286|DRUG|Pembrolizumab|Pembrolizumab, 200 mg will be given by IV infusion on Day 1 of a 21-day cycle for up to a total of 35 cycles.
224300801|NCT03465124|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
224300802|NCT03465124|OTHER|Manual Cataract Surgery|conventional cataract surgery as control
224300803|NCT03074123|DIAGNOSTIC_TEST|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
224300804|NCT03429517|DIAGNOSTIC_TEST|Lipogram|liporgram samples
223568454|NCT06606535|DIAGNOSTIC_TEST|Optical Coherent Tomography Angiography|OCT angiography, macular and peripapillary scans
224055534|NCT03710174|RADIATION|Infrared LED photobiomodulation|Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2\~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.
224055535|NCT03710174|DEVICE|Occlusal splint|After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
224055536|NCT03710174|RADIATION|Placebo LED photobiomodulation|The same procedure as LED group with the device turned off.
224055537|NCT05891925|OTHER|Audiobook App|"The intervention will consist of the use of the audiobook application (with poems) for 4 weeks. Here, the application will record the following data autonomously:~* older adult id,~* date, hour and time that the older adult listened to each poem,~* poems listened.~Initially, two questionnaires will be applied to the older adults: one to measure their digital skills (DIGCOMP), and another to assess their well-being prior to the experience with the audiobook application (Part A).~After two weeks of application use, a follow-up will be carried out, in order to answer any questions that may arise from the use of the application, and explain again the objectives of the research, if necessary. This follow-up will be initially done by telephone, and in person if required.~After four weeks, the older adult will be invited to a meeting at the Community Rehabilitation Center at Concepción, Chile, to answer the well-being questionnaire (Part B) and the usability questionnaire (SUS)."
224055538|NCT03089775|DRUG|BBI-2000|Experimental
224055539|NCT03089775|DRUG|Vehicle|Vehicle Comparator
224055540|NCT03089775|OTHER|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
224055541|NCT01378858|DRUG|Varenicline|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
224055542|NCT04534478|DRUG|Prednisone|Patients will be randomized 1: 1 between the two arms of the study
224055543|NCT06338904|BEHAVIORAL|Problem-solving-based psychological intervention|The intervention will include training in the components of the problem-solving model and other behavioral and cognitive skills such as detecting warning signals, monitoring mood, relaxation techniques, self-reinforcement, strategies for acting in crisis situations, engaging in enjoyable activities, mindfulness meditation techniques, or strategies for reframing irrational thoughts. It will be developed from the problem-solving model (D'Zurilla and Nezu, 1982) and will reference the indicated prevention program for depression (Vázquez et al., 2015), which has shown efficacy in reducing depressive symptoms and preventing the onset of depression episodes (Otero et al., 2015; Vázquez et al., 2013), with results on symptomatology maintained at 8 years (López et al., 2020); and the indicated prevention intervention that demonstrated efficacy in reducing suicide risk (Xavier et al., 2019).
224055544|NCT05787873|DRUG|SIPS-2209-1|QD, PO
224055545|NCT05787873|DRUG|SIPS-2209-2, SIPS-2209-3|QD, PO
224055546|NCT01392911|DRUG|Rifampicin|High dose rifampicin
224055547|NCT00113828|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
223446358|NCT00315718|DRUG|Extract from Hintonia latiflora bark|
223568455|NCT06607107|DRUG|mFOLFOX7 combined with Camrelizumab and apatinib|mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally after meals, once a day, for continuous medication.
223568456|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568457|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568458|NCT02298179|BIOLOGICAL|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568459|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568460|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568461|NCT02298179|BIOLOGICAL|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
224055548|NCT00113828|PROCEDURE|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant ."
224055549|NCT03886051|PROCEDURE|Connective Tissue Graft before Orthodontic treatment|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
224055550|NCT03886051|PROCEDURE|Orthodontic treatment only|Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
224055551|NCT04342000|OTHER|Movement education workshop|"30 minutes total:~* 10 minutes sedentary activity (LE injury risk factor and anatomy instruction)~* 10 minutes moderate activity (guided discovery of body segment alignment and stability with squat, lunge, plank, jump, and hop technique assessment and corrective feedback)~* 10 minutes vigorous activity (practical application of body segment alignment and stability including hopping, jumping, and running activities with technique assessment and corrective feedback)~For the month following the athlete workshop, prior to the final assessment, subjects will receive periodic text message instructions. These messages will include key facts and takeaways from the workshop, and reminders about correct form."
223446359|NCT03879551|DEVICE|repetitive Transcranial Magnetic Stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor digiti minimi (ADM), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
223446360|NCT06435078|DEVICE|mPETS(modified-PETS system)|The pressing evaluation and training system (PETS) consists of five force transducers, a pad position-adjustable frame, and biofeedback system. Five force transducers are used to collect the applied normal force from five digits.
223446361|NCT00046540|DRUG|Liposome-encapsulated SN38|
223446362|NCT01089452|DRUG|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
223446363|NCT01089452|DRUG|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
223446364|NCT01089452|DRUG|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
223446365|NCT03671785|DRUG|PRIM-DJ2727|Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
223446366|NCT03671785|DRUG|Placebo oral capsule|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
223446367|NCT02799121|DEVICE|ReGenerCell™ Autologous Cell Harvesting Device|
223446368|NCT05869396|DIAGNOSTIC_TEST|echocardiography|Bedside echocardiography
223446369|NCT05126173|DEVICE|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
223446370|NCT02878096|DRUG|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
223446371|NCT02748759|DEVICE|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
223446372|NCT02748759|OTHER|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
224055552|NCT04342000|OTHER|Sham Education Workshop|"30 minutes total:~* 10 minute sedentary activity (sleep, nutrition, and hydration instruction)~* 10 minutes moderate activity (performance of squat, lunge, plank, jump, and hop activities - no technique assessment or corrective feedback)~* 10 minutes vigorous activity (hopping, jumping, and running activities - no technique assessment and corrective feedback)"
224055553|NCT01035554|OTHER|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
224055554|NCT01035554|OTHER|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
224146040|NCT05905601|BEHAVIORAL|"NORTH Lite"|"NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources."
224055555|NCT01035554|OTHER|Usual Care|Standard care
224055556|NCT01035554|OTHER|Printed Materials|National Institutes of Health Printed Materials on hypertension
224055557|NCT05953558|DEVICE|Patients implanted with Micra AV|The first 1000 patients implanted by the device in France
223446373|NCT03909698|OTHER|Blood and urine sampling|During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
223446374|NCT04056312|BEHAVIORAL|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
223446375|NCT04056312|BEHAVIORAL|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
223446376|NCT02190123|DRUG|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
223446377|NCT00084877|DRUG|triapine|Given IV
223446378|NCT00084877|DRUG|irinotecan hydrochloride|Given IV
223446379|NCT00084877|OTHER|laboratory biomarker analysis|Correlative studies
223446380|NCT00084877|OTHER|pharmacological study|Correlative studies
223446381|NCT02926261|OTHER|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
223446382|NCT00280696|DRUG|Levetiracetam 250 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg~* Route of Administration: Oral Use"
223446383|NCT00280696|DRUG|Levetiracetam 500 mg|"* Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 500 mg~* Route of Administration: Oral Use"
223446384|NCT00280696|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 250 mg and 500 mg~* Route of Administration: Oral Use"
224055558|NCT00949546|DRUG|etanercept|etanercept 50 mg sc twice weekly
224055559|NCT02934308|DEVICE|Skin Conductance Monitor|
224055560|NCT00002117|DRUG|Zidovudine|
224055561|NCT00002117|DRUG|Zalcitabine|
224146041|NCT02693327|OTHER|Biological Sample|A one time sample will be collected.
224146042|NCT02693327|OTHER|Blood Sample|A one time blood sample will be collected.
224146043|NCT05172037|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
224146044|NCT05172037|BIOLOGICAL|Placebo|Saline
224146045|NCT00293150|DRUG|Eplerenone|
223446385|NCT02834832|DEVICE|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
223446386|NCT02502695|OTHER|VATS-associated best practices|
223446387|NCT01026818|DRUG|Tadalafil|Administered by mouth for 9 months
223446388|NCT01026818|DRUG|Placebo|Administered by mouth, daily or on demand for 9 months
223446389|NCT05695118|DIAGNOSTIC_TEST|Non-contrast low-dose abdomen CT|target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.
223446390|NCT05695118|DIAGNOSTIC_TEST|Fibroscan|Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.
223446391|NCT05695118|DIAGNOSTIC_TEST|bioelectrical impedance analysis (BIA)|BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
223446392|NCT02963129|DRUG|Mupirocin|Mupirocin ointment in the nose for 5 days
223446393|NCT02963129|OTHER|Placebo|Placebo ointment in the nose for 5 days
223446394|NCT05274529|BEHAVIORAL|Psychological health and flexibility|A remote coaching programme concentrating on psychological health and flexibility
223446395|NCT05274529|BEHAVIORAL|Work ability|A remote coaching programme concentrating on work ability
223446396|NCT05274529|BEHAVIORAL|Sleep and recovery|A remote coaching programme concentrating on sleep and recovery
223446397|NCT05274529|BEHAVIORAL|Healthy lifestyle|A remote coaching programme concentrating on healthy lifestyle
223446398|NCT05274529|OTHER|No coaching|Participants also have the option to choose no coaching for the coming 3 month period.
223446399|NCT01439490|OTHER|FES-PET|Patients undergo FES-PET prior to obtaining histology
223446400|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts supplemented with L. Rhamnosus GG|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, Lactobacillus Rhamnosus GG ATC53103 HN019 strain and fructooligosaccharides
223446401|NCT04779281|DIETARY_SUPPLEMENT|Oral Rehydration Salts only|A supplement containing sodium chloride, trisodium citrate, potassium chloride, dextrose, microcrystalline cellulose
223446402|NCT00547417|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
223446403|NCT01031004|DEVICE|narafilcon B|contact lens
223568462|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568463|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223446404|NCT01031004|DEVICE|etafilcon A|contact lens
223446405|NCT00311870|DRUG|nisoldipine|
223446406|NCT00311870|DRUG|lisinopril|
223446407|NCT02740790|BIOLOGICAL|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
223446408|NCT02740790|BIOLOGICAL|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
223568464|NCT02298179|BIOLOGICAL|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568465|NCT02298179|DRUG|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
223568466|NCT07033858|DRUG|Rapamune Pill|Rapamiune Tablet 1mg daily plus Advograf plus prednisolone
223446409|NCT00176514|DRUG|Administration of the antineoplastic|
223446410|NCT01641471|DEVICE|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
223446411|NCT01641471|DEVICE|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
223446412|NCT05393687|OTHER|Eccentric exercise|progressive eccentric exercise with elastic band
223446413|NCT02135016|DRUG|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
223446414|NCT02135016|DRUG|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
223446415|NCT02135016|DRUG|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
223446416|NCT00441038|BEHAVIORAL|The Back Guide|Education on postural hygiene and handout of The Back Guide
223446417|NCT00441038|BEHAVIORAL|The Back Book|Education on active management and Handout of The Back Book
223446418|NCT00441038|BEHAVIORAL|Cardiovascular and general health|Education on cardiovascular and general health
223446419|NCT06699381|DEVICE|use of spinal mouse|Spinal Mouse (SM) is an external non-invasive measurement device that evaluates the spinal angle and shape in the frontal and sagittal planes
223446420|NCT06699381|DIAGNOSTIC_TEST|Brunnstrom's Hemiplegia Recovery Staging|According to Brunnstrom's stages of recovery, the individual will be identified at which stage
223446421|NCT06699381|DIAGNOSTIC_TEST|The six minute walking test (6MWT)|It evaluates the functional capacity of the individual and it provides valuable information regarding all the systems during physical activity, including pulmonary and cardiovascular systems, blood circulation, neuromuscular units, body metabolism, and peripheral circulation
223446422|NCT06699381|DIAGNOSTIC_TEST|Functional Reach Test (FRT)|"Functional Reach Test (FRT) is a clinical outcome measure and assessment tool for ascertaining dynamic balance in in simple task.~In standing, measures the distance between the length of an outstretched arm in a maximal forward reach, while maintaining a fixed base of support.~This information is correlated with risk of falling A number of factors exert a major influence on this evaluation: Research revealed that movement strategy and reduced spinal flexibility both affect reach distance."
223568467|NCT03013101|BIOLOGICAL|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
223568468|NCT03643315|BEHAVIORAL|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
223568469|NCT03643315|BEHAVIORAL|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
224055562|NCT01699854|DRUG|capsaicin patch (qutenza)|
223446423|NCT06699381|DIAGNOSTIC_TEST|Mini Balance Evaluation Systems Test (Mini-BESTest)|"This test measures dynamic balance, functional mobility, and gait. It is commonly used in populations who have or have had multiple sclerosis (MS), Parkinson disease (PD), strokes, spinal cord injury (SCI), or cancer.~The Mini-BESTest was developed in 2010 from the Balance Evaluation Systems Test (BESTest), then revised in 2013 to clarify inconsistencies in scoring. The scoring instructions were different in the published and online versions. The revision clarified that the Mini-BESTest should be scored out of 28 points. Explanations for how to score items 3, 6, and 14 were also given.~The Mini-BESTest consists of 14 items, including 4 of the 6 sections (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait) from the BESTest."
223446424|NCT06699381|DIAGNOSTIC_TEST|The five Times Sit to Stand Test (5x Sit-To-Stand Test)|It's used to asses functional lower limbs strength, transitional movements, balance, and fall risk in older adults.
224055563|NCT01699854|DRUG|Placebo|
223568470|NCT01783314|PROCEDURE|MRI of liver|MRI of liver with intravenous gadoxetate disodium
224055564|NCT00150293|DRUG|Pregabalin|
224146046|NCT04270617|BEHAVIORAL|Yoga program|The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
224146047|NCT03024255|DRUG|BBI-4000 gel, 5%|BBI-4000 gel, 5% applied once to each axilla daily
224146048|NCT03024255|DRUG|BBI-4000 gel, 10%|BBI-4000 gel, 10% applied once to each axilla daily
224300805|NCT00866658|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
223568471|NCT05734001|DIAGNOSTIC_TEST|ROTEM Tests|"This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg"
223568472|NCT05734001|DIAGNOSTIC_TEST|Conventional Haemostatic Tests|"To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg"
223568473|NCT03956277|DEVICE|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
223568474|NCT01607333|DRUG|Lamotrigine use|Lamotrigine prescription during the study period
223568475|NCT03496350|BEHAVIORAL|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
223568476|NCT04265157|PROCEDURE|Surgical technique surgical occlusion|Occlusion of hepatoduodenal ligament by clamp or occlusive bands
223568477|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
224146049|NCT03024255|DRUG|BBI-4000 gel, 15%|BBI-4000 gel, 15% applied once to each axilla daily
224055565|NCT00075088|DEVICE|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
224055566|NCT00075088|OTHER|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
224055567|NCT02973087|BIOLOGICAL|von Willebrand factor (Recombinant)|OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.
224055568|NCT02973087|BIOLOGICAL|Antihemophilic Factor (Recombinant)|During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
224055569|NCT00020579|DRUG|entinostat|
224146050|NCT03024255|DRUG|Vehicle (Placebo)|Placebo, applied once to each axilla daily
224146051|NCT02919163|OTHER|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
224146052|NCT04397926|DRUG|Individualized neoantigen peptides vaccine|Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 12 weeks
224146053|NCT02169804|DRUG|Androxal 25 mg|
224146054|NCT06270563|OTHER|Postural advice|The patients received advice about maintaining good posture when sitting, standing, reading, driving, or lifting; taking breaks; sleeping on back or side with a pillow supporting head/neck; avoiding prolonged phone use; adjusting car seat; reading stand for upright posture; keeping objects close when lifting; and using pillows for support when breastfeeding.
224146055|NCT06270563|OTHER|Traditional exercise treatment|The exercise program included strengthening of deep flexor muscles and shoulder retractors while stretching of cervical extensors and pectoral muscles.
224300806|NCT00866658|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
224300807|NCT00866658|DEVICE|Pen auto-injector|
224300808|NCT00866658|DRUG|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
224300809|NCT00866658|DRUG|Basal Insulin|To be continued at a stable dose.
224300810|NCT00267449|DEVICE|SoftScan Optical Breast Imaging System|
224300811|NCT03990597|OTHER|Placebo Administration|Applied topically
224300812|NCT03990597|OTHER|Questionnaire Administration|Ancillary studies
224300813|NCT03990597|DRUG|Wound Dressing Material|Applied StrataXRT topically
224055570|NCT01637909|DRUG|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
224055571|NCT01637909|DIETARY_SUPPLEMENT|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
224146056|NCT06270563|OTHER|Scapular stabilization exercises|Scapular Stabilization exercise was composed of four exercise programs, including scapula retraction exercise, scapula mobilization exercise, and scapula dynamic stabilization exercise I and II.
224146057|NCT06270563|OTHER|High intensity Laser therapy|"There were two phases in every session, the wavelength is 1064 nm, size of spacer is 60 mm in both phases:~Phase I (analgesic phase): the application was made by moving the applicator perpendicular to the skin in continuous circular movements at trigger points detected by acupuncture, power was 8.00 w with a dosage of 5 J/cm2, surface area 50 cm2, frequency 25 HZ, treatment time in this phase was 3 minutes and total energy received at this phase was 250 J.~Phase II (bio stimulation): the application was made at the pain inflicting region by using continuous linear movements and prevent static application, The power was 8.00 w with a continuous frequency, dosage of 50 J/cm2, surface area 50 cm2, treatment time in this phase was 5 minutes and the total energy that was delivered to the patient during this phase was 2500 J."
223446425|NCT06699381|DIAGNOSTIC_TEST|The Postural Assessment Scale for Stroke (PASS)|The Postural Assessment Scale for Stroke (PASS) is an outcome measure specifically designed to assess and monitor postural control after stroke. It was developed in 1999 as an adaptation of the Fugl-Meyer Assessment balance subscale\[1\]. It contains 12 four-level items of varying difficulty for assessing ability to maintain or change a given lying, sitting or standing posture
223446426|NCT06699381|DIAGNOSTIC_TEST|Postural Symmetry Index and Weight Transfer Symmetry|It is a form of measurement in which two scales are used to calculate the weight transferred to the intact and stroke limb. The values obtained as a result of the test are calculated with formulas.
223446427|NCT06699381|DIAGNOSTIC_TEST|Measurement of the craniovertebral angle|Measurement of the craniovertebral angle; the patient is asked to find the most natural position by flexion and extension of the head in the standing position and a photograph is taken with a digital camera from a distance of 1.5 m to the shoulder level of the patient and this process is repeated 3 times. The images obtained are then digitally calculated with the help of an appropriate program.
223446428|NCT06490250|OTHER|Inspiratory Muscle Training|The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other day
223446429|NCT06490250|OTHER|Baduanjin Exercise|The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.
223446430|NCT00285376|DRUG|vilazodone|titration to 40mg tablets qd for 8 weeks
223446431|NCT02625246|BIOLOGICAL|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
224146058|NCT05076097|DRUG|Orelabrutinib in in combination of rituximab and lenalidomide(OLR)|Induction treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: Cycle 1: 15mg QD D1-21, if no dose-limiting toxicity occurred in Cycle 1, cycle 2-6: 20mg QD D1-21; Cycle 1: 375 mg/m2 d1, 8,15,22; Cycle 3, 5: 375 mg/m2 D1 Maintenance treatment phase: Orelabrutinib: 150mg QD D1-28; Lenalidomide: cycle 7-24: 15mg QD D1-21; Cycle 7, 9, 11, 13, 15, 17, 19, 21, 23: 375 mg/m2 D1. 28 days for a cycle.
224146059|NCT05106595|DEVICE|Bimanual Arm Trainer|tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
223446432|NCT03993977|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
223446433|NCT03993977|OTHER|Conventional treatment|Clinical judgement and conventional coagulation tests
223446434|NCT01889732|DEVICE|ROTEM|
223446435|NCT03921632|BEHAVIORAL|Smiles Matter Oral Health Education Series|Three sessions scheduled 2 weeks apart consisting of 15-20 minutes of didactic learning, 10 minutes of a group/personal exercise, and 10 minutes of questions that the patients have on the topic discussed that day
223446436|NCT06148155|RADIATION|[68Ga]Ga-NOTA-RG2 PET Imaging|Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RG2 in a single dose.
223446437|NCT04575584|DRUG|Molnupiravir|Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
223568478|NCT01568450|DRUG|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
223568479|NCT01568450|DRUG|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
223446438|NCT04575584|DRUG|Placebo|Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
223446439|NCT05768997|DRUG|Ferric Derisomaltose Injection|Ferric derisomaltose/iron isomaltoside (as iron) (0 weeks): 20mg/kg, diluted in 250ml of 0.9% physiological saline and injected intravenously over 30-60 minutes
223446440|NCT05768997|DRUG|Darbepoetin Alfa Injection|Darbepoietin alfa (0 weeks, 3 weeks, 6 weeks, 9 weeks): 6.75㎍/kg, subcutaneous or intravenous administration
223446441|NCT03488563|BIOLOGICAL|B244|B244 Suspension
223446442|NCT03488563|BIOLOGICAL|Vehicle|Vehicle Suspension
223741570|NCT04784052|DEVICE|CliniMACS Prodigy System|The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
223446443|NCT02462109|DRUG|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with \<30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with \>30 kg body weight.
223446444|NCT03739801|DRUG|Liposomal Irinotecan|Given IV
223446445|NCT03739801|OTHER|Quality-of-Life Assessment|Ancillary studies
223446446|NCT03739801|OTHER|Questionnaire Administration|Ancillary studies
223446447|NCT03739801|BIOLOGICAL|Ramucirumab|Given IV
223446448|NCT02788188|BIOLOGICAL|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
223446449|NCT02788188|OTHER|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
223446450|NCT05979896|DRUG|Standard age based SPAQ administration for SMC|"Sulfadoxine-pyrimethamine and amodiaquine (SPAQ) is administered in standard WHO approved age based regimens as used in Seasonal Malaria Chemoprevention Programmes.~Sulphadoxine is a slowly eliminated sulphonamide. It is used in a fixed dose combination of 20 parts sulphadoxine with 1 part pyrimethamine given orally or intramuscularly.~Sulphadoxine is readily absorbed from the GIT. It is widely distributed in body tissues and fluids and crosses the placenta into foetal circulation. It is also readily detectable in breast milk. It is excreted predominantly as the unchanged drug. AQ Amodiaquine is a Mannich base 4 amino-quinoline that interferes with parasite haem detoxification. It is more effective than chloroquine in both chloroquine sensitive and resistant P. falciparum infections. However, there is cross-resistance between chloroquine and amodiaquine.~It is readily absorbed in the GIT and rapidly converted in the liver to the active metabolite, desethylamodiaquine."
223446451|NCT00758329|DEVICE|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
223446452|NCT02588729|OTHER|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
223446453|NCT02860962|DRUG|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
223446454|NCT04108741|DEVICE|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.
223446455|NCT06329986|DEVICE|TAMER Lens Spectacle|Regular daily wear of TAMER lens spectacle
223446456|NCT06329986|DEVICE|SV lenses|SV lenses
223446457|NCT05844085|OTHER|Non-polar lipids|The shame comparator lipid intervention product contains no polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of lipids are15g, and the total amounts of available carbohydrates are 50 g.
223446458|NCT05844085|OTHER|No lipids|The placebo comparator contains no added lipids. The product contains a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
223446459|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids low|The experimental intervention product contains 7,5 g plant based lipids polar lipids and 7.5 g plant based lipids non polarlipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. TThe total amounts of available carbohydrates are 50 g.
223568480|NCT05687773|DEVICE|Leap Motion Controller on flat display|The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
223446460|NCT05844085|DIETARY_SUPPLEMENT|Polar lipids high|The experimental intervention product contains15 g plant based polar lipids. The lipids are mixed with a defined amount of glucose and a flavor enhancer and formulated as a spread. The topping is spread on a defined amount of white wheat bread. The total amounts of available carbohydrates are 50 g.
223446461|NCT03738163|DEVICE|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
223741571|NCT04784052|BIOLOGICAL|Depleted Stem Cell Transplant|TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
223741572|NCT04784052|BIOLOGICAL|Rabbit Anti-Thymoglobulin (rATG)|3 consecutive daily doses of rATG will be given by IV during conditioning
224146060|NCT05595551|BEHAVIORAL|"The intervention Aan Tafel in 1, 2, 3 euro"|"The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card."
223741573|NCT04784052|DRUG|Cyclophosphamide|4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
224146061|NCT03101527|DRUG|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
224146062|NCT05402722|DRUG|Eribulin|Eribulin Mesylate，1.4mg/m2，Intravenous infusion，d1，d8，3-week cycle
223446462|NCT03671512|DEVICE|Periodontal Structure Repair (PSR)|Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
223446463|NCT03671512|DEVICE|Standard Root Planing|Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
223446464|NCT05768529|DRUG|U16|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
223446465|NCT01515566|DRUG|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
223446466|NCT01515566|OTHER|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
223446467|NCT01515566|OTHER|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
223446468|NCT01515566|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
223446469|NCT02085070|DRUG|MK-3475|IV MK-3475
223446470|NCT04584840|PROCEDURE|Surgical treatment|"Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal."
224055572|NCT01637909|OTHER|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
224055573|NCT03093753|OTHER|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
224146063|NCT05402722|DRUG|anti-PD-1 antibody|Sintilimab Injection，Intravenous infusion，200mg，3-week cycle
224146064|NCT05337904|DEVICE|On-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is on."
224146065|NCT05337904|DEVICE|Off-Stimulation|"The surgical electrode implanted in target 1 (ACC) or target 2 (NAcc) by a pulse generating device is off."
224146066|NCT01526681|OTHER|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
224146067|NCT01526681|OTHER|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
224300814|NCT04493866|OTHER|Messages to departmental employees to improve quality of consent form completion|All interventions directed to members of the plastic surgery department: Intervention 1: Poster illustration common mistakes on consent forms. Intervention 2: Group message explaining Quality Improvement Project to the department. Intervention 3: Email from Consultant lead in support of project. Intervention 4: Further group message illustrating gains and ongoing goals of the project.
223446471|NCT06135571|PROCEDURE|Laparoscopic colorectal surgery|Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.
223446472|NCT00985933|DRUG|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
223446473|NCT00985933|DRUG|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
224300815|NCT03617757|DIAGNOSTIC_TEST|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
224300816|NCT03617757|DIAGNOSTIC_TEST|HbA1c|2mL blood will be taken for analysis of HbA1c.
224300817|NCT06160700|BEHAVIORAL|Montreal Cognitive Assessment (MoCA)|MoCA is a method for evaluating cognition. This assessment will be conducted at baseline, month 3, and month 6.
223446474|NCT00469248|DEVICE|Intra-aortic balloon pump counterpulsation|
223446475|NCT02104882|RADIATION|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
223446476|NCT04808258|DEVICE|C3+ Holter Monitor|Long-Term ECG monitoring (up to 7 days)
223446477|NCT00812175|DRUG|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
223446478|NCT02769312|DEVICE|Theta burst stimulation|Theta burst transcranial magnetic stimulation
223446479|NCT02769312|DEVICE|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
224055574|NCT03093753|OTHER|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
224055575|NCT03093753|OTHER|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
224146068|NCT01526681|OTHER|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
224146069|NCT01526681|DEVICE|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
224146070|NCT01526681|PROCEDURE|Autologous Breast Reconstruction with Neurotization|
224146071|NCT01526681|PROCEDURE|Autologous Breast Reconstruction without Neurotization|
223446480|NCT02815267|DRUG|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
223446481|NCT02815267|DRUG|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
223446482|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
223446483|NCT00857467|DRUG|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
223446484|NCT01810744|OTHER|capillaroscopy|
223446485|NCT01810744|OTHER|blood pressure measurement|
223446486|NCT04330222|DIAGNOSTIC_TEST|7 Tesla Magnetic Resonance Imaging|Diagnostic Imaging
223446487|NCT04330222|OTHER|Brief Memory and Executive Test|Cognitive Assessment
224146072|NCT03250377|DRUG|Brivaracetam|"* Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg and 50 mg~* Route of administration: Oral use"
223446488|NCT06025201|BEHAVIORAL|Resting State EEG|During this intervention, participants will be asked to not think about anything in particular while EEG is recorded. Resting state will be conducted with either the participants having their eyes open, or eyes closed.
223446489|NCT06025201|BEHAVIORAL|Picture Viewing EEG|During this intervention, participants will view emotionally charged pictures for a short period of time. Afterwards, participants will be asked to rate their emotional reactions to the pictures. EEG will be recorded during this intervention.
223446490|NCT06025201|BEHAVIORAL|Stop Signal EEG|During this intervention, participants will be asked to respond quickly to a visual stimulus with a button press. At times, participants will be asked to inhibit their responses. EEG will be recorded during this intervention.
223446491|NCT01955577|DRUG|Placebo orally everyday|
223446492|NCT01955577|DRUG|Vitamin D3 cholecalciferol|
223446493|NCT03594955|DRUG|SAR440234|Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
223446494|NCT01681095|DRUG|Custodiol HTK|After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
224146073|NCT06042478|DRUG|Remibrutinib|Active treatment
223446495|NCT01681095|DRUG|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
223446496|NCT01680952|DRUG|A) TEST|"1. Extended Release Tacrolimus (Advagraf®)~   ① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~   ② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~2. Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
223446497|NCT01680952|DRUG|B) CONTROL|"1. Extended Release Tacrolimus (Advagraf®)~   : Same as above.~2. Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
223446498|NCT01584505|DRUG|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
223568481|NCT05687773|DEVICE|Leap Motion Controller in Head-Mounted Display|For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
223741574|NCT04784052|DRUG|Fludarabine|4 consecutive daily doses of fludarabine will be given by IV during conditioning
223446499|NCT01584505|DRUG|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
223446500|NCT01584505|DRUG|CHF1535 daily dose|CHF1535 daily dose for 14 days
223446501|NCT06548633|OTHER|Lumbar Vertebral Mobilisation|The participants received Vertebral Lumbar Mobilisations, these were posterior-anterior central vertebral pressures (PACVPs) for four sets of 30 seconds, with up to 30s between each, at a grade III amplitude.
223446502|NCT05369390|DRUG|NNC0487-0111 A|Participants will receive NNC0487-0111 A tablet once daily.
223446503|NCT05369390|DRUG|NNC0487-0111 B|Participants will receive NNC0487-0111 B tablet once daily.
223446504|NCT05369390|OTHER|Placebo B (NNC0487-0111 B)|Participants will receive placebo matched to NNC0487-0111 B tablet once daily.
223446505|NCT05369390|OTHER|Placebo A (NNC0487-0111 A)|Participants will receive placebo matched to NNC0487-0111 A tablet once daily.
224146074|NCT06042478|DRUG|Placebo to remibrutinib|Placebo followed by active treatment
223446506|NCT03271099|OTHER|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
223446507|NCT03152487|OTHER|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
223446508|NCT03152487|OTHER|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
223446509|NCT04159441|OTHER|None intervetion|None intervetion
223446510|NCT01010802|DRUG|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
224146075|NCT06042478|DRUG|Placebo to omalizumab|Placebo followed by active comparator
224146076|NCT06042478|DRUG|Omalizumab|Active comparator
224146077|NCT00859989|BEHAVIORAL|behavioral dietary intervention|
224146078|NCT00859989|BEHAVIORAL|exercise intervention|
224146079|NCT00859989|BEHAVIORAL|telephone-based intervention|
224146080|NCT00859989|OTHER|counseling intervention|
223446511|NCT03984955|DEVICE|Sodium hyaluronate with mannitol (Ostenil Tendon)|1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
223446512|NCT03984955|DEVICE|Platelet-Rich Plasma Injection|Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
223446513|NCT03984955|OTHER|Subcutaneous sham injection|Sham injection will penetrate the skin, but no therapeutic substance will be injected
223446514|NCT04146857|OTHER|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
223446515|NCT04146857|OTHER|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
223446516|NCT04146857|OTHER|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
223446517|NCT05777720|DEVICE|Filtration Fan|Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.
223446518|NCT05777720|BEHAVIORAL|Safe-home pamphlet|The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.
223446519|NCT05777720|BEHAVIORAL|Mid-week phone call|On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.
223446520|NCT05613179|PROCEDURE|Group1 (lever positioning manipulation)|The specific lever positioning manipulation is as follows: the patient lies prone at the mouth-open position with muscles relaxed, waist exposed, knees and hips bent, and ankle joints crossed. The practitioner uses the right elbow olecranon to point at the lumbar vertebrae, then hold the patient's two ankle joints in both hands to cause the lumbar vertebra to make hyperextension and flexion movements through the arms and pull the patient backward and upwards hard. When pulling upwards to the trigger point, the practitioner pulls wit lever quickly with a technique and then senses a clatter or looseness at the positioning point. When the practitioner pulls with lever manipulation, the patient is asked to exhale and then inhale at the end of the manipulation.
223446521|NCT05613179|PROCEDURE|Group2 (placebo group)|The specific sham lever positioning manipulation is as follows: the patient lies prone with his mouth open, muscles relaxed, waist exposed, knees bent at the hip and ankles crossed. The practitioner points to the lumbar spine with the right elbow olecranon, and then holds the patient's two ankles in both hands, so that the lumbar spine through the arm for overextension and flexion, and forcefully pulls the patient back and up. When pulling up to the trigger point, maintain this movement for a short period of time, depending on the patient's endurance, about 1-5 minutes. After finishing, ask the patient to rest in prone position.
223446522|NCT05908487|BEHAVIORAL|AA Communities Speak to Healthcare Professionals|The training program is designed to empower clinicians to improve goal-concordant EoL care delivery by using community-developed storytelling videos to create empathy with experiences of racism in EoL care, guidelines for culturally concordant EoL care delivery, and implicit bias recognition and management training to mitigate bias in goals of care communication.
223446523|NCT05786547|DRUG|Varenicline|Per package dosing, tablet taken orally
223446524|NCT05786547|BEHAVIORAL|Positively Smoke Free Mobile (PSF-M)|Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
223568482|NCT01660672|DRUG|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
224055576|NCT03093753|DIETARY_SUPPLEMENT|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
223446525|NCT05786547|BEHAVIORAL|Standard Care|Brief cessation advice plus referral to local tobacco quitline
223446526|NCT03602196|OTHER|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
223446527|NCT03602196|OTHER|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
223568483|NCT04376047|OTHER|Reverse Trendelenburg position|The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
223568484|NCT04376047|OTHER|Semi-recumbent position|The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
223741575|NCT04784052|DRUG|Rituximab|1 dose of rituximab will be given at the end of conditioning
224055577|NCT03093753|OTHER|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
224055578|NCT03093753|DIETARY_SUPPLEMENT|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
224055579|NCT03093753|OTHER|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
224055580|NCT03093753|DIETARY_SUPPLEMENT|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
224055581|NCT03093753|OTHER|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
224146081|NCT00859989|OTHER|educational intervention|
223446528|NCT03602196|OTHER|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
223446529|NCT05732285|BEHAVIORAL|CRT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
223446530|NCT05732285|BEHAVIORAL|CBT|"Participants that score 1-1.5 standard deviation (SD) below the norm for age and education on 2 cognitive domains will receive an intensive program, 2 CRT sessions per week for 4 weeks in addition to 1 CBT session per week for 8 weeks. Based on clinical experience, those with more severe cognitive deficits require more time to achieve their therapy goals, whereas those with mild deficits can tolerate a more intense therapy.~Participants that score 1.5-2 SD or more below the norm for age and education on 2 cognitive domains will receive 1 CRT and 1 CBT weekly sessions for 8 weeks. All the CRT sessions will be coupled with homework for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
223446531|NCT05732285|BEHAVIORAL|Modifiable lifestyle factors|The therapy sessions are coupled with homework and requires some lifestyle modifications such lifestyle adjustments are using a calendar, a diary, maintaining a sleep schedule and exercise.
223446532|NCT05732285|BEHAVIORAL|Usual care Psychoeducation|"Participants will receive 15 minute psychoeducation session twice per week for 8 weeks.~All research-related sessions will be web-based (on Zoom) and recorded (with approval)."
223446533|NCT00162084|DRUG|apadenoson|
223446534|NCT00766623|DIETARY_SUPPLEMENT|high fat meal|milkshake containing 95g fat
223446535|NCT00766623|DIETARY_SUPPLEMENT|control meal|milkshake comparable with a normal breakfast
224055582|NCT03093753|OTHER|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
223568485|NCT04269577|BEHAVIORAL|SSP training|Participants will practice the Swipe Slide Pattern (SSP) task. On day 1, participants perform two runs of the SSP-task (only one pattern), each lasting approx. 10 min, within an MR scanner. During each run, nine trials of 30s are performed, alternated with rest periods of 14s. In addition, instructions are provided before each trial (i.e. view of the pattern, 4s), as well as an answer option (i.e. participants have circle a random number from zero to nine, 6s). For the following four days (day 2-5), participants will continue practice of the SSP-task at home. During the at-home-sessions, participants will perform nine trials of 12 patterns each, alternated with rest periods of 14s. Instruction are also included. During at home practice, the same pattern as during scans is included, in combination with two new patterns.
223568486|NCT01165112|DRUG|Bendamustine Hydrochloride|Given IV
223568487|NCT01165112|DRUG|Carboplatin|Given IV
223568488|NCT01165112|BIOLOGICAL|Rituximab|Given IV
223568489|NCT01165112|DRUG|Etoposide|Given IV
224055583|NCT03093753|OTHER|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
223568490|NCT01165112|OTHER|Laboratory Biomarker Analysis|Correlative studies
224055584|NCT03093753|OTHER|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
224055585|NCT03093753|OTHER|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
224055586|NCT03093753|OTHER|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
224055587|NCT04572880|PROCEDURE|Trabeculectomy|Trabeculectomy is performed
224055588|NCT04572880|DEVICE|XEN®|Microinvasive Surgery with XEN® is performed
224055589|NCT04572880|DEVICE|Preserflo®|Microinvasive Surgery with Preserflo® is performed
224055590|NCT02163083|PROCEDURE|ICG|Improvement of detection of positive lymphnodes
224146082|NCT00859989|OTHER|immunoenzyme technique|
224146083|NCT00859989|OTHER|laboratory biomarker analysis|
224146084|NCT00859989|OTHER|questionnaire administration|
224146085|NCT00859989|OTHER|study of socioeconomic and demographic variables|
224146086|NCT00859989|PROCEDURE|evaluation of cancer risk factors|
224146087|NCT00859989|PROCEDURE|support group therapy|
224146088|NCT00793182|DRUG|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
224146089|NCT00793182|DRUG|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
224146090|NCT00251875|DEVICE|online health information journal|
224146091|NCT06264349|OTHER|Lifestyle Educational Intervention|The Lifestyle Educational Intervention (LEI) consists of promoting a healthy lifestyle during pregnancy and breastfeeding. In particular, the contents concern: i). macro- and micronutrient requirements during pregnancy/breastfeeding; ii). definition of the concept of the food pyramid and healthy plate also considering aspects of food sustainability; iii). definition of the principles of food safety during pregnancy; iv). importance of maternal and infant sleep quality; v). importance of maternal physical activity during pregnancy and lactation; vi). psychological aspects regarding the mother-child dyad.
224146092|NCT02405806|DIETARY_SUPPLEMENT|low carbohydrate food|low carbohydrate food
224146093|NCT02405806|DIETARY_SUPPLEMENT|standard food|standard food
224146094|NCT02601443|DEVICE|Cervical Pessary|
224146095|NCT00698035|DRUG|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
224146096|NCT00698035|DRUG|Estring|2mg ring inserted vaginally once every 12 weeks
224146097|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
224146098|NCT00795964|OTHER|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
223446536|NCT06147752|BEHAVIORAL|"mobile internet healthcare and co-management of three disciplines"|"co-management of three disciplines:~Endocrinologist:~Assess disease status and rule out secondary obesity; Identify the causes of overweight/obesity and the status and extent of associated diseases; receive patients for return visits. Timely reply to patients' questions on the mobile medical platform, and timely adjust medication plans according to changes in patients' conditions.~Dietitians:~Conduct diet assessment, develop personalized medicine nutrition treatment plan and provide daily real-time guidance and follow up patients' daily diet outside the hospital.~Weight managers:~Establish weight loss record for patients, guide the installation and use of mobile medical Application , including weight monitoring, real-time uploading of daily diet and online interactive consultation; Follow up patients' weight changes; Assist patients in making appointments for follow-up visits."
223446537|NCT06390995|DRUG|TAK-853|TAK-853 intravenous injection
223446538|NCT06343714|DRUG|FB1003|Subcutaneous (SC) injection
223446539|NCT06343714|DRUG|Placebo|Subcutaneous (SC) injection
223446540|NCT06056635|DEVICE|Karl Storz Curved Scope|The curved fetoscope (11508AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the front of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
223446541|NCT06056635|DEVICE|Karl Storz Straight Scope|The straight fetoscope (11506AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the back of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
223446542|NCT05600036|DRUG|ESK-001|Oral tablet
223446543|NCT05600036|DRUG|Placebo|Oral tablet
223446544|NCT05386576|DRUG|Venetoclax|"During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42."
223446545|NCT06187233|OTHER|binaural music|In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
223446546|NCT05187091|RADIATION|Swallowing and submandibular sparing IMRT|Standard IMRT with radical CRT/RT with additional sparing of dysphagia-aspiration related structures \& submandibular gland sparing by SWOAR-IMRT
223446547|NCT02088398|DRUG|ACY-1215|
223446548|NCT06636812|DRUG|Losartan potassium|Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
223446549|NCT06636812|OTHER|Placebo|Single tablet encapsulated identically to placebo
223446550|NCT02714036|DRUG|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
223446551|NCT02714036|DRUG|Ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
223446552|NCT04003272|DEVICE|Comprehensive Reverse Versa-Dial Titanium Glenosphere|Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
223446553|NCT00408187|DRUG|voclosporin|voclosporin 0.4 mg/kg po BID
223446554|NCT00408187|DRUG|Ciclosporin|ciclosporin 1.5 mg/kg po BID
223446555|NCT00408187|DRUG|Placebo|Placebo
223446556|NCT06377332|DIAGNOSTIC_TEST|High density electroencephalogram (HdEEG)|High-density electroencephalography (HdEEG) will be utilised in the investigation of sleep-mediated neuronal functions in controls, OSA, COPD and overlap syndrome and the association with accelerated brain ageing and cognitive impairment.
223446557|NCT06377332|DIAGNOSTIC_TEST|Functional near infrared spectroscopy (fNIRS)|Functional near infrared spectroscopy (fNIRS) is one of the most advanced techniques in measuring brain oxygen content and hemodynamic activity. This information indirectly displays neuronal activity and provides a novel opportunity understand brain oxygenation, neurodegenerative diseases, and cognitive function.
223446558|NCT06377332|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be utilised to assess potential structural neuronal changes associated with neurodegenerative disease in those with COPD, OSA and overlap syndrome. MRI has the capacity to provide vital information regarding neuroimaging standards in cerebral vascular damage such as white matter hyperintensities (WMH), lacunes, cerebral microbleeds, brain atrophy and subcortical infarct. Through the utility of MRI sequences such as T1 and T2 weighted imaging, diffusion weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) and resting-state fMRI (rs-fMRI), the investigators will assess neurodegenerative-related structural brain changes in individuals with COPD, OSA and overlap syndrome and examine the differences between these target groups.
223446559|NCT06377332|BIOLOGICAL|Blood collection|"A fasting 50mL blood sample will be collected at the experimental visit in the morning following the overnight sleep study. Blood samples will be processed after collection and stored at -80 degrees for future batch analyses. Analyses will include markers for inflammation and dementia including but not limited to ptau217 and beta amyloid. Routine blood analyses will be conducted on 17.5mL of the sample collected for baseline measures. Routine blood analyses includes lipid profile, glucose studies, insulin, high-sensitivity C-reactive protein (hs-CRP), iron studies, thyroid function, b12/folate, homocysteine, prolactin, calcium, full blood count and biochemistry panel for the OSA, COPD and overlap syndrome groups.~Routine blood analyses for controls include glucose studies, lipid profile, hs-CRP and biochemistry panel."
223568491|NCT06106724|PROCEDURE|sphincterotomy|cutting the papilla and cannulation with sweeping of common bile duct by ballon and stent insertion
223568492|NCT06106724|PROCEDURE|precutting of the papilla by knife needle|precutting of the papilla by knife needle
224300818|NCT03482700|BEHAVIORAL|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
223446560|NCT06377332|DIAGNOSTIC_TEST|Neuropsychological battery|"A. Montreal Cognitive Assessment (MoCA):~B. Test of Premorbid Functioning (TOPF):~C. Rey Auditory Verbal Learning Test (RAVLT):~D. D-KEFS Colour Word Interference Test (D-CWIT):~E. Trail Making Test (TMT):~F. Symbol Digit Modalities Test (SDMT) - Oral Version:~G. RAVLT 20-minute recall~H. Controlled Oral Word Association Test (COWAT):"
223446561|NCT06377332|OTHER|Questionnaires|"1. Epworth Sleepiness Scale (ESS)~2. PROMIS sleep questionnaire 8a,~3. PROMIS sleep questionnaire 8b~4. EQ-5D-5L~5. Insomnia Severity Index (ISI)~6. Pittsburgh Sleep Quality Index (PSQ-I)~7. St George's Respiratory Questionnaire (SGRQ)~8. COPD Assessment Test (CAT)"
224300819|NCT03482700|BEHAVIORAL|Control Arm|Usual standard of care
223446562|NCT06377332|DIAGNOSTIC_TEST|Pulmonary Function Test (PFT)|Full pulmonary function testing will be conducted in control, COPD, OSA and overlap syndrome groups. Full lung function testing will include spirometry with pre and post bronchodilator, oscillometry, lung diffusion testing (DLCO) and lung volumes.
223446563|NCT06377332|OTHER|Cognitive Assessment|"The following cognitive assessments will be administered using a digital format on CANTAB:~1. Motor Screening Task (MOT) Used to assess sensorimotor function and comprehension and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease. This task acts as a practice trial for the subsequent tasks.~2. Reaction Time (RTI) Used to assess processing and psychomotor speed and is applicable in the assessment of general cognitive function and Alzheimer's disease.~3. Paired Associate Learning (PAL) Used to assess visual episodic memory and is applicable in the assessment of general cognitive function, Alzheimer's disease, Parkinson's disease and cerebrovascular disease.~4. Spatial Working Memory (SWM) Used to assess working memory and strategy and is applicable in the assessment of general cognitive function, Alzheimer's disease and cerebrovascular disease."
223446564|NCT06377332|DIAGNOSTIC_TEST|Polysomnogram (PSG)|During the sleep study, physiological signals are recorded to capture eye movements (electrooculogram, EOG) and chin muscle movements (electromyogram, EMG). A nasal airflow piece, two respiratory inductance plethysmography (RIP) bands and an oximeter probe on the finger will monitor breathing and oxygen levels in the blood. Electrocardiogram (ECG), leg movements, sleeping position and snoring are also recorded.
224055591|NCT02047136|OTHER|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
224055592|NCT02047136|OTHER|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
224055593|NCT05281796|DIAGNOSTIC_TEST|GCF obtaining|GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
224300820|NCT00609518|DRUG|pemetrexed|500 mg/m\^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
223446565|NCT00671047|OTHER|non-interventional|SLE nature history observational
223446566|NCT03534999|DEVICE|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
223446567|NCT03534999|OTHER|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
223446568|NCT00498810|PROCEDURE|complete repair|
223446569|NCT00498810|PROCEDURE|partial repair of the abdominal wall|
223446570|NCT02146820|DEVICE|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
223446571|NCT01006590|DRUG|Saxagliptin|5 mg, oral tablet, once daily
223446572|NCT01006590|DRUG|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
223446573|NCT03332095|DRUG|Doravirine (DOR)|100 mg of DOR administered orally
223446574|NCT03332095|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg) once daily
223446575|NCT03332095|DRUG|Antiretroviral (ARV) medications|Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
223446576|NCT02957487|DEVICE|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
223446577|NCT02649517|PROCEDURE|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
223446578|NCT05627947|DRUG|Mitomycin c|Comparing the effect of Mitomycin C versus Cyclosporine after primary pterygium surgery
223446579|NCT05443503|OTHER|Mobile health applications (mHealth apps) based intervention|Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
223446580|NCT06035211|OTHER|3D model pré-operative education|Before surgery, during a preoperative therapeutic education consultation, 3D models will be presented to the patients according to the allocated study group
223446581|NCT03970226|DRUG|Tocilizumab|"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."
223446582|NCT01660347|BIOLOGICAL|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
223446583|NCT01660347|BIOLOGICAL|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
223446584|NCT01660347|PROCEDURE|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
223446585|NCT02742675|DRUG|Bicalutamide|Given orally
223446586|NCT02742675|DRUG|goserelin acetate|Given subcutaneously or as an injection
223446587|NCT02742675|DRUG|flutamide|Given orally
224055594|NCT05281796|DIAGNOSTIC_TEST|saliva obtaining|Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
224055595|NCT02660203|PROCEDURE|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
224055596|NCT06034171|DEVICE|dental implant|Dental implant surgery in the lower jawbone.
224055597|NCT05381142|DRUG|Elinzanetant (BAY3427080)|Elinzanetant will be administered as a single dose on Study Day 1 and a multiple dose once daily for another 6 consecutive days on Study Day 8 to Study Day 13.
224055598|NCT05381142|DRUG|Placebo|Matching placebo will be administered the same as Elinzanetant (BAY3427080)
224055599|NCT00627653|DRUG|fenofibrate|148mg daily for 30 days
223446588|NCT02742675|DRUG|leuprolide acetate|Given subcutaneously or as an injection
223446589|NCT02742675|DRUG|triptorelin|Given subcutaneously or as an injection
223446590|NCT02742675|PROCEDURE|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
223446591|NCT03848624|DEVICE|Cycling Group|Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
223446592|NCT05988671|DRUG|normal Saline|Intraperitoneal route
224055600|NCT04143009|BEHAVIORAL|Enhanced Friendship Bench|EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
223446593|NCT05988671|DRUG|Dexamethasone|Intraperitoneal route
224146099|NCT06198075|OTHER|Control Group|Subjects will receive 6 weeks of general physical therapy,3 times/week for 30 min each session. The exercise program will include lying to sitting position, moving in the sitting posture, sitting and standing up, posture training for learning a normal gait pattern, weight bearing and weight movement training in the straight posture, walking training on the flat floor and stair walking. Final assessment will be done after 6 weeks
224146100|NCT06198075|DEVICE|Experimental Group|Subjects will watch a video on a screen from 1 meter in front of their chairs while sitting comfortably with their arms resting but they were not allowed to physically follow the video or move. The model of the video motion observation exercises will perform by the therapist and the training video consist of 4 stages that varied by difficulty and the video of each step was watched for the entire week. The participants watched a video of a task presented by the therapist and after completing the assignment they will perform the steps if step will too difficult to perform retraining will be conducted.
223446594|NCT05988671|DRUG|Dexmedetomidine|Intraperitoneal route
223446595|NCT05988671|DRUG|Combination of dexamethasone + dexmedetomidine|Intraperitoneal route
223446596|NCT05859061|DEVICE|cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe|Per manufacturer instructions, the cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. The study team plans to perform each cryoablation (-50°C to -70°C) for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6). The probe will be removed after defrosting to avoid mechanical damage to the intercostal nerve. Cryoablation will be performed once hemostasis is achieved and prior to sternal wire placement and chest closure by a provider from the cardiac surgery team.
223446597|NCT06283680|PROCEDURE|Lung transplantation|Three different groups will be investigated with respect to the effect of NRI, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list.
223446598|NCT03901508|DEVICE|TDCS|20 minutes, 2 electrodes (C3/FP2)
223446599|NCT04104594|DIAGNOSTIC_TEST|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
223446600|NCT04104594|OTHER|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
223446601|NCT04104594|OTHER|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
223446602|NCT04104594|OTHER|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
224055601|NCT04143009|OTHER|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
223446603|NCT04104594|BIOLOGICAL|dosage of 17 cytokines|dosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α
223446604|NCT04701489|DEVICE|Splenic ultrasound|GE LOGIQ E10 device with C1-6 ultrasound probe
223446605|NCT04153968|DIETARY_SUPPLEMENT|β-cryptoxanthin|"Phase 1:~2.0mg of \[13C14\]β-cryptoxanthin, 1.0mg of \[13C10\]β-carotene and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of \[13C14\]β-cryptoxanthin, 0.75mg of \[13C10\]β-carotene, 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of \[13C14\]β-cryptoxanthin, 1.5mg of \[13C10\]β-carotene, and 0.4mg \[2H6\]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21."
223446606|NCT03280316|PROCEDURE|surgery|patients with SVMs receive surgery
223446607|NCT03280316|PROCEDURE|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
223446608|NCT03280316|PROCEDURE|botulinum toxin A injection|BOTOX
223446609|NCT03280316|DRUG|M receptor antagonist|Tolterodine
223446610|NCT05741814|DRUG|Propofol|Gynecologist guided individualised propofol only sedation
223446611|NCT00366652|DRUG|desvenlafaxine SR|
223446612|NCT00366652|DRUG|desipramine|
223446613|NCT00366652|DRUG|duloxetine|
223446614|NCT00819949|DEVICE|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
223446615|NCT01118572|DRUG|YM177|oral
223446616|NCT01118572|DRUG|etodolac|oral
223446617|NCT01118572|DRUG|Placebo|oral
223446618|NCT03867968|BEHAVIORAL|TIPS Intervention|Web-based training for family member.
223446619|NCT03867968|BEHAVIORAL|Control|Traumatic Brain Injury website for family members.
223568493|NCT01518998|DRUG|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
224146101|NCT02278991|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
224146102|NCT03728504|DRUG|ASN002|Daily dose of ASN002 for 32 weeks
223446620|NCT05553535|DIAGNOSTIC_TEST|MRI|retrospective review of shoulder MRI
223446621|NCT04438798|OTHER|F Group|In Group F, pregnant females will be preoxygenated with 100% oxygen using a tight-fitting face mask at a rate of 6 L/min for 3 min with end-tidal gas monitoring.
223446622|NCT04438798|OTHER|H Group|In Group H, high-flow humidified oxygen warmed to 37°C will be delivered through nasal cannula at the rate of 30 L/ min for 30 seconds then 50 liters per minute for a further 150 seconds.
223446623|NCT04505306|PROCEDURE|Macular Laser|All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
223568494|NCT03955250|BEHAVIORAL|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
224146103|NCT03728504|DRUG|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
224146104|NCT00003810|DRUG|docetaxel|
224146105|NCT00003810|DRUG|gemcitabine hydrochloride|
224146106|NCT05616169|DEVICE|Easy Flype/EasyHiFlype|Patients with stenosis or occlusion of the iliac artery, femoral artery and first third of the popliteal artery, implanted with at least one study device, the Easy Flype or the Easy Hi Flype.
224146107|NCT05473104|BEHAVIORAL|Program for the Education and Enrichment of Relational Skills|Social training targeting adolescents with ASD and focused on making and keeping friends
224146108|NCT03628521|DRUG|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
223446624|NCT06498726|DEVICE|transcranial doppler|Demographic and procedural variables will be extracted from medical record assistants , and analysis of recorded images TCD, MRA ,interpretation reports will be assessed , Completeness of protocol components will be assessed Data accuracy and protocol fidelity will be ensured through site monitoring
223446625|NCT01343966|DRUG|MABT5102A|Repeating subcutaneous injection
223446626|NCT01343966|DRUG|MABT5102A|Repeating intravenous infusion
223446627|NCT01343966|DRUG|placebo|Repeating subcutaneous injection
223446628|NCT01343966|DRUG|placebo|Repeating intravenous infusion
223446629|NCT01016574|DEVICE|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
223446630|NCT03299725|DRUG|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
223446631|NCT04290325|DRUG|HMPL-453|HMPL-453 tablet
223446632|NCT00703118|DRUG|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
223446633|NCT00703118|DRUG|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
223446634|NCT00703118|DRUG|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
223446635|NCT00703118|DRUG|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
223446636|NCT05975918|BEHAVIORAL|Motivational İnterview|Participants in the experimental group will be informed about the study through pre-interviews and data (Caregiver Descriptive Characteristics Form, Patient Descriptive Characteristics Form, Depression Anxiety and Stress Scale (DASS-21), Coping Attitudes Assessment Scale) will be collected through pre-tests. A motivational interview intervention consisting of a total of 6 interviews will be conducted.
223446637|NCT05975918|OTHER|Psychoeducation|2 hours of training on coping with stress and problem solving skills will be provided.
223446638|NCT03409484|OTHER|Concord Grape Juice|Concord Grape Juice
223446639|NCT03409484|OTHER|Low flavoniod low essence beverage|Low flavoniod low essence beverage
223741576|NCT04878393|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
224055602|NCT04143009|BEHAVIORAL|Adapted Friendship Bench|Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
224146109|NCT00565214|DIETARY_SUPPLEMENT|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
224146110|NCT00565214|DIETARY_SUPPLEMENT|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
224146111|NCT03625154|PROCEDURE|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
223446640|NCT03409484|OTHER|Low flavonoid beverage|Low flavonoid beverage
223446641|NCT04350931|BIOLOGICAL|intradermal injection of BCG Vaccine|0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds
223446642|NCT04350931|OTHER|placebo|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus
223446643|NCT04384757|PROCEDURE|Distal gastrectomy|Distal gastrectomy and standard D2 lymphadenectomy
223446644|NCT01981148|DEVICE|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
223446645|NCT00431067|DRUG|BIBW 2992|
223446646|NCT01096680|DRUG|SPD489 20 mg|Single oral dose of 20 mg
223446647|NCT01096680|DRUG|SPD489 50 mg|Single oral dose of 50 mg
223446648|NCT01096680|DRUG|SPD489 70 mg|Single oral dose of 70 mg
223446649|NCT01096680|DRUG|Armodafinil|Single oral dose of 250 mg
223446650|NCT01096680|DRUG|Placebo|Single oral dose
223446651|NCT05087121|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F)|The Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F) 6-week training course has been derived from existing Cognitive Behavioral Therapy for Insomnia (CBT-I) group therapy protocols. Participants in this intervention will receive psychoeducation on sleep and practice skills standard of CBT-I including, stimulus control techniques, sleep restriction, counter-arousal skills, cognitive restructuring, sleep hygiene, goal setting, and relapse prevention skills. Weekly sessions will include discussions regarding difficulties specific to occupational barriers and how to mitigate the impact of occupational requirements on sleep quality.
223446652|NCT05087121|DEVICE|Fitbit Inspire HR Wrist Worn Device (NCT04176926)|"The Fitbit Inspire HR wrist worn device will be worn by eligible participants throughout the duration of the intervention and for two weeks following completion of the 6-week intervention to collect objective data on enduring sleep changes. This device is an FDA-registered medical device that is not the object of investigation and is being used on label only to gather data.~501(K) Number: K200948 Device Name: Fitbit ECG App Regulation Number: 870.2345 Classification Product Code: QDA Clinical Trials: NCT04176926"
223446653|NCT00284154|DRUG|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
223446654|NCT04389307|OTHER|Electrical stimulation (IVES)|IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.
223446655|NCT04389307|OTHER|Bladder Training|Bladder Training
223741577|NCT06545331|DRUG|XB010|IV administration of XB010
223741578|NCT06545331|DRUG|Pembrolizumab|IV administration of Pembrolizumab
223741579|NCT06273124|DEVICE|SteadiSet Extended Wear Infusion Set|Each participant will be given 12 Extended Wear Infusion Sets to wear over 12 wear periods up to 168 hours each.
223446656|NCT06146634|BEHAVIORAL|Hazard Perception Training|The hazard perception training is comprised of three modules. Each module is comprised of four scenarios. Each hazard perception scenario has two activities. The entire training is expected to take approximately an hour to complete.
223446657|NCT06146634|BEHAVIORAL|Vehicle Maintenance Training|For participants randomized into the placebo group, they will receive a brief training on vehicle maintenance using a series of short videos. These videos describe regular checks that drivers should do, such as checking windshield wiper fluid levels, and how to change engine oil. Altogether the videos will last approximately 1 hour.
223446658|NCT06146634|BEHAVIORAL|Attention Maintenance Training|The attention maintenance training is comprised of three modules. Each module is comprised of four scenarios, with each scenario corresponding to one activity. The entire training is expected to take approximately an hour to complete.
223446659|NCT01349933|DRUG|Akt inhibitor MK2206|Given PO
223446660|NCT00639392|DRUG|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
223568495|NCT03955250|BEHAVIORAL|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
224055603|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
224055604|NCT02384902|OTHER|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
224055605|NCT02384902|OTHER|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
224055606|NCT00846300|BEHAVIORAL|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
224055607|NCT01268358|DRUG|Lamazym|Lamazym, ERT, infusion weekly
224055608|NCT03755570|DIAGNOSTIC_TEST|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
224055609|NCT03755570|DIAGNOSTIC_TEST|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
224055610|NCT03755570|DIAGNOSTIC_TEST|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
224055611|NCT03755570|DIAGNOSTIC_TEST|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
223568496|NCT00845039|BIOLOGICAL|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
223568497|NCT00845039|DRUG|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
223741580|NCT05230589|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
224055612|NCT03755570|DIAGNOSTIC_TEST|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
223446661|NCT00639392|DRUG|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
223446662|NCT03142256|BEHAVIORAL|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
223568498|NCT00845039|BIOLOGICAL|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
223741581|NCT04625205|BIOLOGICAL|NEO-PTC-01|Administered via intravenous infusion.
224055613|NCT01064674|OTHER|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
224146112|NCT03625154|OTHER|non operative management|closed reduction and splinting followed by progressive weight bearing
223568499|NCT00433160|DRUG|Teriparatide|daily, subcutaneous
223568500|NCT00433160|DRUG|Placebo|daily, subcutaneous
223568501|NCT01261442|PROCEDURE|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
224146113|NCT02197897|DRUG|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
224146114|NCT00430898|DRUG|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
223446663|NCT03142256|DRUG|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
223446664|NCT02033200|DRUG|Stendra 200 mg|
223446665|NCT02033200|DRUG|Placebo|
223446666|NCT02957604|DRUG|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
223568502|NCT03197428|OTHER|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
223741582|NCT04625205|DRUG|IL-2|Administered via intravenous infusion.
224055614|NCT05003622|DRUG|Encorafenib|oral capsule
224146115|NCT00606528|OTHER|No intervention|None. This is an observational study.
223446667|NCT00830518|DRUG|Alisertib|Alisertib capsules
223446668|NCT05971472|PROCEDURE|Arthroscopic Repair|Arthroscopic Repair for medial meniscus posterior Root tears
223446669|NCT05971472|PROCEDURE|High tibial osteotomy|Open Wedge High tibial osteotomy for medial meniscus posterior Root tears
223568503|NCT03197428|OTHER|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
223568504|NCT04294615|OTHER|FMT through a naso-jejunal tube|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a naso-jejunal tube.
223446670|NCT04080089|COMBINATION_PRODUCT|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
223446671|NCT00286065|DRUG|AeroLEF|
224055615|NCT01271192|PROCEDURE|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
223446672|NCT01758159|DIETARY_SUPPLEMENT|Iron supplementation|
224055616|NCT01271192|PROCEDURE|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
224055617|NCT00013208|BEHAVIORAL|Case Management|
224055618|NCT02381405|DIETARY_SUPPLEMENT|Enterade beverage|
224055619|NCT03008850|DRUG|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
224055620|NCT03008850|DRUG|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
224146116|NCT02785146|DRUG|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
224146117|NCT02785146|DRUG|Oxaliplatin|85 mg/m², ivdrip, D1
224146118|NCT02785146|DRUG|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
224146119|NCT02785146|DRUG|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
224146120|NCT00550277|DRUG|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
224146121|NCT02473224|BIOLOGICAL|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
224146122|NCT02473224|OTHER|Placebo|Placebo: 80 ml of sterile water for oral administration
224300821|NCT00609518|DIETARY_SUPPLEMENT|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
224300822|NCT00609518|DIETARY_SUPPLEMENT|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
223446673|NCT01758159|OTHER|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
223446674|NCT04466605|OTHER|Tele-yoga therapy|Each session included combinations of different yoga exercises, postures, yoga breathing, yoga relaxation techniques, yoga counselling and meditative practices based on individualisation.
223446675|NCT04466605|OTHER|Primary care|Patients will follow standard care provided by primary care physicians including analgesics and self care management.
223446676|NCT02949141|DEVICE|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
223446677|NCT02949141|DEVICE|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
223446678|NCT02949141|DEVICE|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
223446679|NCT02779270|DRUG|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
223446680|NCT02779270|DRUG|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
223446681|NCT03063099|OTHER|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
224055621|NCT00890032|BIOLOGICAL|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10\^6, 5x10\^6, and 2x10\^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
224055622|NCT00382746|DEVICE|EarlySense monitoring device|
224055623|NCT06430853|BEHAVIORAL|Step count goal|The step count goal will be discussed at the beginning of the study, and participants will be able to see their step count on the Actigraph watch to facilitate achieving this goal. All participants will receive weekly reminders that are tailored for their intervention arm. Intervention group participants will also receive a step count diary with motivational ideas of how to obtain step goals, which will be reviewed with a study team member every 2 weeks.
224055624|NCT06430853|DEVICE|Actigraph watch|Both groups will wear the watch. Adherence will be assessed via step counts from accelerometer watch.
224055625|NCT04917848|OTHER|Tele-Geriatric Oncology program|Participants will be scheduled to meet with a Geriatric Nurse Practitioner (GNP) or Geriatric Registered Nurse (GRN) via the program's telemedicine platform. The telemedicine encounters with the GNP/GRN may occur every 2 weeks over 3 months, for a total of 6 visits. Visits 1 and 6 are mandatory, and visits 2-5 are on an as needed basis.
224300823|NCT00609518|DIETARY_SUPPLEMENT|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
223446682|NCT01425606|OTHER|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
223446683|NCT03439462|DRUG|nab-sirolimus|nab-sirolimus combined with mFOLFOX6 + bevacizumab
223446684|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
223446685|NCT02155322|BIOLOGICAL|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
223446686|NCT04475770|OTHER|Real Sustained Natural Apophyseal Glides (SNAGS)|"Manual therapists use treatment modalities that include passive techniques such as mobilization and manipulation. Mobilization with movement (MWM) developed by Mulligan involves applying a sustained transverse glide to the spinous process of a vertebra while actively or passively performing. These techniques have gained the name Sustained Natural Apophyseal Glides (SNAGS) as it is maintained at the pain-free range and follows the plane of the apophyseal joints under treatment."
223446687|NCT04475770|OTHER|Sham Sustained Natural Apophyseal Glides (SNAGS)|The participants in the Sham SNAGs group will be positioned same as the SNAG group. Mulligan belt will be used, which included the patient's waist and physiotherapist's hip. The physiotherapist will place the hypothenar region of his hand on the spinous processes of the symptomatic lumbar spine levels and waited a few seconds without no glide will be performed. Sham SNAGs practice consisted of 3 sets of 6 repetitions and a 60-second rest period was given between the sets.
223446688|NCT02800395|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
223446689|NCT03920423|PROCEDURE|improvement of arterial depth|deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
223446690|NCT05194852|PROCEDURE|ultrasound-guided posterior hydrodilatation|Group I was treated through posterior approach; The injection needle is introduced at the skin surface just lateral to the transducer and in an oblique lateral to medial direction. Group II was treated through anterior rotator interval approach. A 21-gauge needle is introduced into the rotator interval using an oblique path within the imaging plane of the transducer; from lateral to medial, the needle tip is imaged in real time throughout its passage from superficial to deep and is positioned in the biceps tendon sheath between the coracohumeral ligament above and biceps tendon below. Both groups were given the same guided stretching and strengthening exercise program
223446691|NCT05194852|DRUG|corticosteroid, saline, and local anesthetic|corticosteroid, saline, and local anesthetic
223446692|NCT05194852|OTHER|guided stretching and strengthening exercise program|guided stretching and strengthening exercise program
223446693|NCT02130700|DRUG|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
223446694|NCT02130700|DRUG|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
223446695|NCT04491526|DRUG|TAMSULOSIN Mepha Ret Depocaps 0.4 mg|"0.4mg/day Tamsulosin hydrochloride (TAMSULOSIN Mepha Ret Depocaps 0.4 mg) from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)"
223446696|NCT04491526|DRUG|Control Intervention|One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)
223446697|NCT00623857|DIETARY_SUPPLEMENT|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
223446698|NCT00623857|DIETARY_SUPPLEMENT|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
223446699|NCT00623857|DIETARY_SUPPLEMENT|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
224055626|NCT03775330|RADIATION|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy \> 2 cm and ≤ 3 cm: 15-18 Gy \> 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions \> 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions \> 15 Gy) when patient is randomized to SRS + WBRT arm"
224055627|NCT03775330|RADIATION|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
224055628|NCT06278935|BEHAVIORAL|Lifestyle-based intervention by an occupational therapist|Participants with diabetic foot ulcers will be offered lifestyle-based treatment sessions virtually for up to 8 sessions (\~8 weeks) with a licensed occupational therapist.
224055629|NCT00050154|DRUG|ZARNESTRA, tipifarnib, R115777|
224055630|NCT06093815|DEVICE|Injection|A pre specified amount will be injected in tissue at selected timepoints
223446700|NCT00623857|DIETARY_SUPPLEMENT|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
223446701|NCT04842552|DRUG|Hydralazine hydrochloride 25mg tablets|Hydralazine hydrochloride 25mg tablets three time daily for 365 days (one year)
223446702|NCT04842552|DRUG|Placebo|Placebo
223446703|NCT04540731|OTHER|This is an observational study without intervention|This is an observational study without intervention
223446704|NCT02392702|DRUG|C-10355|
223446705|NCT02392702|DRUG|C-10358|
224055631|NCT05510700|DEVICE|Acupuncture|All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all points will be lifted, twisted, and stabbed to activate de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
224146123|NCT04673669|DIAGNOSTIC_TEST|Posterior tibial tendon strength mesure|Posterior tibial tendon strength is assessed with a hand-held dynamometer by two independent observer and with an isometric dynamometer by one observer.
223446706|NCT02392702|DRUG|Kalydeco|
223446707|NCT02676635|BEHAVIORAL|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
224146124|NCT00992004|DIETARY_SUPPLEMENT|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
223446708|NCT00808470|DRUG|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
223446709|NCT00808470|OTHER|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
223446710|NCT00523809|DRUG|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
224055632|NCT05510700|DEVICE|Sham acupuncture|"The placebo needles selected for this study are flat-tipped needles without a tip that cannot be pierced into the skin. Also, an external patch device will hold the needles in place and these needles are visually pierced into the skin. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needles being pulled out."
224055633|NCT03497806|BIOLOGICAL|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
223446711|NCT00523809|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
223446712|NCT00523809|DRUG|Fludarabine|25 mg/m\^2 IV Daily Over 30 Minutes for 5 Days
223446713|NCT00523809|DRUG|Melphalan|70 mg/m\^2 IV Daily Over 30 Minutes for 2 Days
223446714|NCT00523809|DRUG|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
223568505|NCT04294615|OTHER|FMT through TET|Prepared feces by automatic methods, then the purified fecal microbiota was delivered into the intestine through a transendoscopic enteral tubing (TET) which is fixed to the cecum with clips under endoscopic guidance.
224055634|NCT02247245|DRUG|Ivabradine|Ivabradine 7.5mg
224055635|NCT02247245|OTHER|Atrial fibrillation|Pacemaker base rate alteration
224055636|NCT02247245|DRUG|Placebo|Placebo
224055637|NCT01045798|DRUG|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
224055638|NCT01045798|DRUG|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
224146125|NCT03842215|DEVICE|smart physical exam|Use smart physical exam to collect functional performance
224055639|NCT01529099|DEVICE|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
224055640|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen low dose vaccine|MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.
224055641|NCT05082285|COMBINATION_PRODUCT|MenABCWY-2Gen high dose vaccine|MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.
224146126|NCT01136863|DRUG|Felodipine|
224146127|NCT01136863|DRUG|Placebo|
224146128|NCT00723671|PROCEDURE|MRI|
223446715|NCT03846128|BIOLOGICAL|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
223446716|NCT00555776|DRUG|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
223446717|NCT00555776|DRUG|placebo|placebo is given with the same definition as Gabapentin
223446718|NCT03337048|DEVICE|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
223446719|NCT05278494|DRUG|Dextromethorphan Hydrobromide|PO
223446720|NCT05278494|DRUG|Placebo|PO
223446721|NCT05687682|BIOLOGICAL|AM-928|AM-928, which is a humanized anti-EpCAM monoclonal antibody developed by AcadeMab Biomedical Inc.
223446722|NCT00649233|DRUG|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
223446723|NCT00649233|DRUG|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
223446724|NCT02791438|DRUG|Azilsartan|Azilsartan granules and tablets
223568506|NCT05565573|DRUG|Medroxyprogesterone Acetate 500 MG Oral Tablet|500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate At a dosage of 500 mg/day
223568507|NCT05565573|DEVICE|Levonorgestrel-Releasing Intrauterine System|Uterine cavity insertion
223568508|NCT03010891|BEHAVIORAL|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes
223568509|NCT03010891|BEHAVIORAL|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
224146129|NCT04798248|BEHAVIORAL|Momentary Affect Regulation - Safer Sex Intervention (MARSSI)|MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
224146130|NCT04798248|BEHAVIORAL|Podcast Health Group|Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
224146131|NCT05989308|BEHAVIORAL|Email|Email message sent to guardian with proxy information.
224146132|NCT05989308|BEHAVIORAL|Text|Text message sent to guardian with proxy information.
224146133|NCT05989308|BEHAVIORAL|Patient Portal Message|Patient portal message (MyChart) to guardian with proxy information.
223446725|NCT02791438|DRUG|Placebo|Placebo-matching azilsartan granules and tablets
223446726|NCT00055679|DRUG|cyclophosphamide|
223446727|NCT00055679|DRUG|epirubicin hydrochloride|
224055642|NCT05082285|COMBINATION_PRODUCT|MenABCWY-1Gen vaccine|MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.
224055643|NCT05082285|COMBINATION_PRODUCT|MenB vaccine|MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
224055644|NCT05082285|COMBINATION_PRODUCT|MenACWY-TT vaccine|MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
223446728|NCT00055679|DRUG|fluorouracil|
223446729|NCT01916902|DRUG|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
223446730|NCT01916902|DRUG|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
223446731|NCT01916902|PROCEDURE|Optical Coherence Tomography|
223446732|NCT00394771|DRUG|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
223446733|NCT00394771|DRUG|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
223446734|NCT00394771|DRUG|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
223446735|NCT02093403|DRUG|decitabine|Given IV
223446736|NCT02093403|DRUG|selinexor|Given PO
223446737|NCT02093403|OTHER|pharmacological study|Correlative studies
223446738|NCT02093403|OTHER|laboratory biomarker analysis|Correlative studies
223446739|NCT00811993|DRUG|RG1507|Starting dose of \>=3mg/kg iv escalating to a maximum dose of \<=16mg/kg iv, depending on dosing schedule in each combination treatment arm
223568510|NCT05332743|DIETARY_SUPPLEMENT|Nutrafol Vegan Women's Hair Supplement|Nutrafol's Vegan Women's Hair Supplement with patented Synergen Complex® is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. These ingredients include Sensoril Ashwagandha, Curcumin, Saw Palmetto, 20% Tocotrienol/Tocopherol complex, and capsaicin in combination with other vegan nutrients used to support hair health such as Pea Sprout Extract, Bamboo, and a new innovative Maldavian Dragonhead flower extract.
223568511|NCT02218073|DRUG|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
223568512|NCT02218073|DRUG|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
223568513|NCT02218073|DRUG|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
223568514|NCT03802344|DRUG|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
223568515|NCT03802344|DRUG|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
223568516|NCT03802344|DRUG|Vehicle|Vehicle cream
223568517|NCT01670786|PROCEDURE|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
223568518|NCT01010568|DRUG|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
223568519|NCT03865745|DIETARY_SUPPLEMENT|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
223568520|NCT05950061|DRUG|Sertraline|Sertraline (200 mg/day) capsule
224055645|NCT05424484|DEVICE|Self-Gripping Resorbable Mesh|Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).
224055646|NCT00487396|DEVICE|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
223568521|NCT05950061|DRUG|Escitalopram|Escitalopram (10 mg/day) capsule
223568522|NCT02793817|DRUG|KPI-121 1% Ophthalmic Suspension dosed BID|
223568523|NCT02793817|DRUG|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
223568524|NCT02489708|BEHAVIORAL|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
223568525|NCT04899258|PROCEDURE|Femtosecond laser assisted LASIK|Refractive surgery
223568526|NCT01895231|DRUG|Iron isomaltoside 1000 (Monofer®)|
223568527|NCT01895231|DRUG|Placebo|
224055647|NCT02920424|DRUG|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
223446740|NCT00811993|DRUG|RO1507|27mg/kg iv, monotherapy
223446741|NCT00811993|DRUG|bevacizumab [Avastin]|as prescribed
223446742|NCT00811993|DRUG|capecitabine [Xeloda]|as prescribed
223446743|NCT00811993|DRUG|carboplatin|as prescribed
223446744|NCT00811993|DRUG|cetuximab|as prescribed
223446745|NCT00811993|DRUG|docetaxel|as prescribed
223446746|NCT00811993|DRUG|erlotinib [Tarceva]|as prescribed
223446747|NCT00811993|DRUG|etoposide|as prescribed
223446748|NCT00811993|DRUG|gemcitabine|as prescribed
224055648|NCT02920424|DRUG|Placebo|Subjects will receive matching placebo.
224146134|NCT06596616|OTHER|Radiology|Radiology - MRI Scans
224146135|NCT06596616|OTHER|Gadopiclenol|Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
224146136|NCT06134414|DRUG|MY008211A tablets|dose 1 (400 mg BID) and dose 2 (600 mg BID) in a 1:1 ratio by central randomization
224146137|NCT00002391|DRUG|Abacavir sulfate|
223446749|NCT00811993|DRUG|irinotecan|as prescribed
223446750|NCT00811993|DRUG|mFOLFOX6|as prescribed
223446751|NCT00811993|DRUG|paclitaxel|as prescribed
223446752|NCT00811993|DRUG|pemetrexel|as prescribed
223446753|NCT00811993|DRUG|sorafenib|as prescribed
223446754|NCT00811993|DRUG|temozolomide|as prescribed
223446755|NCT00811993|DRUG|trastuzumab [Herceptin]|as prescribed
223446756|NCT04832750|DEVICE|intermittent theta burst stimulation (iTBS) or sham stimulation|30 sessions of iTBS over 2 weeks (3 sessions per day, 5 days per week)
223446757|NCT01945294|DRUG|Boceprevir|800 mg three times daily orally
223446758|NCT01945294|BIOLOGICAL|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
223446759|NCT01945294|DRUG|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
223446760|NCT01239836|BEHAVIORAL|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
223446761|NCT01239836|BEHAVIORAL|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
224146138|NCT00002391|DRUG|Lamivudine|
224146139|NCT00002391|DRUG|Zidovudine|
224146140|NCT01532570|DRUG|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
224146141|NCT03646760|BEHAVIORAL|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
223446762|NCT01239836|BEHAVIORAL|General health lecture|Participants will attend a lecture on general women's health issues that does not address urinary incontinence.
223446763|NCT05244434|OTHER|Best Practice|Given standard of care ribociclib + AI or palbociclib + AI
223446764|NCT05244434|PROCEDURE|Biopsy|Undergo biopsy of tumor tissue
223446765|NCT05244434|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223446766|NCT05244434|OTHER|Laboratory Biomarker Analysis|Undergo analysis of previously collected tumor tissue
223446767|NCT05735678|DEVICE|Single-Use Duodenoscopes|Single-Use Duodenoscopes
223446768|NCT00586898|DRUG|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
223446769|NCT00586898|DRUG|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
224055649|NCT01651715|DRUG|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
224055650|NCT00411359|BEHAVIORAL|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
224055651|NCT05555862|DRUG|Artesunate|artesunate formulated as intra-anal suppositories
223446770|NCT00586898|DRUG|Bicalutamide|A pure nonsteroidal antiandrogen
223446771|NCT00586898|DRUG|Testosterone transdermal gel|an androgenic anabolic steroid
223446772|NCT00586898|DRUG|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
223446773|NCT03201393|DRUG|Low-dose naltrexone and acetaminophen combination|Twice a day
223446774|NCT03201393|DRUG|Placebo|Twice a day
223446775|NCT03406988|PROCEDURE|Autologous fat grafting|Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
223446776|NCT03406988|PROCEDURE|Sham procedure|Local injection of 0.5ml saline solution after a simulated liposuction procedure.
223446777|NCT06396013|DRUG|Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
223446778|NCT06396013|DRUG|placebo|"Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use."
223446779|NCT02455713|DEVICE|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
223446780|NCT04641533|PROCEDURE|L-PRF + DPSC|After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
223446781|NCT04641533|PROCEDURE|L-PRF|After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
223446782|NCT03872765|DEVICE|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
224055652|NCT05555862|DRUG|Placebo|placebo intra-anal suppository
224055653|NCT05496868|DRUG|Reparixin 600mg|Reparixin 600 mg tablets, administered crushed through nasogastric tube at the dose of 1200 mg TID (2 tablets TID administered approximately about every 8 hours) as add-on to the standard of care. After extubation and if the patient can swallow, reparixin may be administered orally. Total duration of the treatment: 14 days
223446783|NCT02721303|DIETARY_SUPPLEMENT|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
224300824|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
223446784|NCT02721303|PROCEDURE|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
223446785|NCT02721303|PROCEDURE|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
223446786|NCT00133653|BEHAVIORAL|Observational|
223446787|NCT01313351|DEVICE|RPS InflammaDry Detector™|A noninvasive immunoassay for detecting MMP-9 levels in tears
223446788|NCT00610233|PROCEDURE|deep brain stimulation ON|deep brain stimulation in the ON state
223446789|NCT00610233|PROCEDURE|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
223446790|NCT01892878|PROCEDURE|VerteLoc|Single Arm
223446791|NCT05574907|DIAGNOSTIC_TEST|68Ga-FAPI PET/CT scan|Patients with suspected breast cancer underwent 68Ga-FAPI PET/CT after an injection of 74-148 MBq (2-4 mCi) 68Ga-FAPI to image lesions of breast cancer.
223446792|NCT00540488|OTHER|Adult enteral formula|
223446793|NCT03530319|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
223446794|NCT03530319|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
223446795|NCT00041041|DRUG|imatinib mesylate|Given PO
223446796|NCT00041041|OTHER|laboratory biomarker analysis|Correlative studies
223446797|NCT00478088|DEVICE|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
223446798|NCT00478088|DEVICE|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
223446799|NCT00785902|DEVICE|AtriCure Bipolar System|
223741583|NCT04625205|DRUG|PD-1 Inhibitors|Administered via intravenous infusion.
224055654|NCT05496868|OTHER|Matching Placebo|"Placebo tablets. Administered crushed through nasogastric tube with the same schedule as reparixin as add-on to the standard of care. After extubation and if the patient can swallow placebo may be administered orally.~Total duration of the treatment: 14 days"
224055655|NCT06619522|DRUG|Ruxolitinib|Given orally
224055656|NCT06619522|DRUG|INCB57643|Given orally
224055657|NCT00761618|PROCEDURE|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
223446800|NCT03387345|OTHER|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
223446801|NCT03387345|OTHER|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
223446802|NCT03387345|OTHER|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
223446803|NCT03387345|OTHER|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
224055658|NCT00761618|PROCEDURE|IPC Placement|IPC placed in chest cavity to drain excess fluid
224055659|NCT00761618|RADIATION|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
223446804|NCT03387345|OTHER|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
223446805|NCT03387345|OTHER|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
223446806|NCT01968512|DEVICE|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
223446807|NCT01968512|DEVICE|Sham|Same character of Transcranial Direct Current Stimulation but without current
223446808|NCT01484860|DRUG|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
223446809|NCT06648889|DRUG|Isatuximab|Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.
223446810|NCT06648889|DRUG|Isatuximab|Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
223446811|NCT03070405|DRUG|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
223446812|NCT03070405|DRUG|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
223446813|NCT06216405|PROCEDURE|Colonoscopy|Colonoscopy
223446814|NCT02824588|BEHAVIORAL|Working Memory Training|Training mental flexibility
223446815|NCT02824588|BEHAVIORAL|Internet use|Used as control for time spent on computer
223741584|NCT04849351|DRUG|HMPL-689|All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.
224055660|NCT06805630|DIAGNOSTIC_TEST|Femto Human DNA Quantification Kit|Urine methylation biomarker test
224055661|NCT01739569|OTHER|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
224055662|NCT06026748|DRUG|XJ103 Injection|XJ103 is a humanized monoclonal antibody.
224055663|NCT06026748|DRUG|Placebo|Placebo contains only excipients.
224300825|NCT00609518|DRUG|dexamethasone|4 mg taken orally \[or equivalent\] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
223446816|NCT06915883|DEVICE|Relaxation virtual reality (VR)|A newly developed self-guided app BreezeTrerraVR that helps patients practice relaxation breathing in an immersive virtual environment, using voice prompts, visual cues, and respiratory biofeedback for guidance. The app was developed in the VR center at the National Institute of Mental Health, Czech Republic (supported by THE JOHANNES AMOS COMENIUS PROGRAMME (OP JAC) EXCELLENCE IN RESEARCH, Title: Research of Excellence on Digital Technologies and Wellbeing, Project Registration Number: CZ. 02.01.01/00/22\_008/0004583).
223446817|NCT06915883|DEVICE|Experiential virtual reality (VR)|"The experiential VR intervention will use the VR program Ocean Rift (an experience of the underwater world and its animals). It is a calm experiential and distraction game program that does not require much mobility and interaction and is therefore suitable for pediatric patients and hospital environments. This VR application is also used in available published research."
223446818|NCT02494401|OTHER|Internet-based self-management program|
223446819|NCT02494401|OTHER|Scleroderma book|
223446820|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223446821|NCT05077813|COMBINATION_PRODUCT|9 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D for (MDR-TB)|A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 9 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223446822|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D for (MDR-TB)|Active Comparator: All trans retinoic acid , Minocycline,Chicroic Acid and Vitamin D 50 Subjects will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223568528|NCT02153424|DRUG|Apixaban|
223568529|NCT02226198|DRUG|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
223568530|NCT02226198|DRUG|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
223568531|NCT00534508|DRUG|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
224146142|NCT03646760|BEHAVIORAL|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
224146143|NCT04277832|DIAGNOSTIC_TEST|Questionary|All patients will answer two different questionary (TUPAST, TOPAS 2)
224146144|NCT01545024|DRUG|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
224146145|NCT02565498|RADIATION|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
223568532|NCT04847895|DRUG|Lucentis|There is no treatment allocation. Patients administered Lucentis by prescription that have started before inclusion of the patient into the study will be enrolled.
223568533|NCT05270291|PROCEDURE|rectal swab|rectal swab
223568534|NCT04664530|DRUG|esketamine|The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
223568535|NCT04664530|DRUG|Saline|The titration process in the control group with saline are the same as those in the treatment group with esketamine.
223568536|NCT04126720|DIETARY_SUPPLEMENT|topical corticosteroids and vitamin E suplements|
223568537|NCT04126720|DRUG|Topical corticosteroid and placebo capsules|
223568538|NCT01457677|DRUG|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
223568539|NCT01457677|DRUG|RO4995819|5 mg oral once daily for 6 weeks
223568540|NCT01457677|DRUG|RO4995819|15 mg oral once daily for 6 weeks
223568541|NCT01457677|DRUG|RO4995819|30 mg oral once daily for 6 weeks
223568542|NCT04909892|BIOLOGICAL|COVI-MSC|COVI-MSC are allogeneic culture-expanded adipose-derived mesenchymal stem cells
224055664|NCT01591967|DEVICE|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
223446823|NCT05077813|COMBINATION_PRODUCT|All trans retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized All trans retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223446824|NCT05077813|COMBINATION_PRODUCT|13 cis retinoic acid, Minocycline, Chicroic Acid and Vitamin D For (COVID-19 and MDR-TB)|50 Subjects with confection of COVID-19 and multidrug-resistant tuberculosis (MDR-TB) will be randomly assigned to receive A) Minocycline i.v. 4,5 mg/kg gradual in 2 divided doses increases from 4,5 mg/kg from the first week to 7.5 and 10 mg/kg to the last week. In addition to Aerosolized 13 cis retinoic acid in gradual 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled retinoic acid therapy for 30 days. Moreover, the patients will receive Echinacea Purpurea Extract Capsules Polyphenols Chicoric Acid. Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. Each batch of tablets contain choric acid = 3.4 to 8.5 mg/tablet. Furthermore, the patients will receive Cholecalciferol(Vitamin D) Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
223446825|NCT05077813|OTHER|The standard therapy|The standard therapy 100 infected patients with confection of COVID-19 and MDR-TB will receive the standard therapy for tuberculosis for 30 days
223446826|NCT03646487|DIETARY_SUPPLEMENT|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
223446827|NCT03646487|OTHER|Placebo in capsule form|Daily placebo in capsule form
223446828|NCT03339336|DRUG|BIIB074|Administered as specified in the treatment arm.
223446829|NCT03339336|DRUG|Placebo|Administered as specified in the treatment arm.
223446830|NCT05037084|OTHER|no intervention|no intervention
223446831|NCT05940025|DEVICE|MORT-LBP|The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.
223446832|NCT05940025|OTHER|treatment as usual (TAU)|In the control group, education and physiotherapy is delivered and self-exercise is recommended.
224055665|NCT02988180|OTHER|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
224055666|NCT02988180|OTHER|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
223446833|NCT06326411|DRUG|NST-628|NST-628 is a small molecule non-covalent pan-RAF/MEK dual molecular glue targeting RAF and MEK nodes of MAPK pathway.
223446834|NCT02041780|PROCEDURE|Shearwave electrography|
223446835|NCT02482753|DRUG|Chidamide|30 mg, administered orally twice per week (BIW)
224146146|NCT02565498|RADIATION|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
224146147|NCT06300567|OTHER|data collection|"collection of data of generated by real world follow up"
224146148|NCT05265962|DRUG|Decitabine plus Penpulimab|Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
224146149|NCT01329341|OTHER|Service Dogs|Service dogs will be trained to help Veterans with PTSD
223446836|NCT02482753|DRUG|exemestane|25 mg, PO daily
223446837|NCT02482753|DRUG|placebo|Administered orally twice per week (BIW)
223446838|NCT03438942|DIETARY_SUPPLEMENT|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
223446839|NCT03438942|DIETARY_SUPPLEMENT|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
223741585|NCT05090865|DIETARY_SUPPLEMENT|Liberalized dietary potassium via fruits and vegetables|On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 250 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 2000 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
224055667|NCT03715894|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
224300826|NCT01687478|DRUG|Olanzapine|Administered Orally
224300827|NCT01687478|DRUG|Fluoxetine|Administered Orally
224300828|NCT01687478|DRUG|Placebo|Administered Orally
224300829|NCT00006267|DRUG|rubitecan|
224300830|NCT05479916|DIETARY_SUPPLEMENT|Low glycated milk protein|40 grams of protein dissolved in 600 mL of water
223446840|NCT04322084|OTHER|Wearable Sensors|To develop predictive algorithms that identify early onset of sepsis in children being treated for ALL. This study will use a two-stage design. The initial stage (the feasibility phase) will evaluate the feasibility of data collection, and the second stage (the completion phase) will provide data for the design of predictive models.
223446841|NCT04037800|PROCEDURE|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
223446842|NCT04037800|PROCEDURE|Standard RARP|Robotic-assisted radical prostatectomy with conventional RARP procedures.
223446843|NCT00385827|DRUG|Mitoxantrone|Mitoxantrone 12 mg/m\^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m\^2)
223446844|NCT00385827|DRUG|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
223446845|NCT00385827|DRUG|Prednisone|Prednisone 5 mg orally twice daily
223446846|NCT05525000|DEVICE|Validation|"The validation protocol consists of the following activities:~Activities of daily living, Exercise test on the treadmill, Exercise test on the cycle ergometer, Free-living session"
223446847|NCT01857180|OTHER|Curriculum|
223446848|NCT02374424|DRUG|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
223446849|NCT00410072|DRUG|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
223446850|NCT00410072|DRUG|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
223446851|NCT02414100|OTHER|Laboratory Biomarker Analysis|Correlative studies
223446852|NCT02414100|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223446853|NCT05741242|BIOLOGICAL|Personalized Synthetic Long Peptide Vaccine|Personalized Synthetic Long Peptide Vaccine
223446854|NCT05780749|DIETARY_SUPPLEMENT|DDI-IBS-001|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.
223446855|NCT05780749|OTHER|DDDI-IBS-001 placebo|The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.
223568543|NCT04536948|OTHER|Cooling Gel|Cooling gel (Nelsons Arnicare Arnica Cooling Gel) was applied to the lateral epicondyle region with sponge head 3 times a day. The cooling gel was applied to the painful area around the lateral epicondyle
224055668|NCT06975163|BEHAVIORAL|Mindfulness-Based Stigma Stress Reduction (MBSSR) program|The MBSSR program was developed by modifying elements from the Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT) programs to create a distinct mindfulness intervention targeted at alleviating stigma stress among parents of autistic children. This program consisted of four group sessions, each incorporating mindfulness practices, group discussions, and activities that helped participants apply mindfulness principles to their daily lives.
224300831|NCT05479916|DIETARY_SUPPLEMENT|High glycated milk protein|40 grams of protein dissolved in 600 mL of water
223446856|NCT05295459|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
223446857|NCT05295459|DRUG|Sham procedure control|Sham procedure control
223446858|NCT05295459|OTHER|Background therapy|Daily Saline Irrigation
223446859|NCT05636137|OTHER|Survey application|Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
223446860|NCT04156451|PROCEDURE|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
223446861|NCT04156451|PROCEDURE|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
223446862|NCT06240312|DEVICE|Images of eye at 2 eye pressures|subject images of the eye's optic nerve head are studied
223568544|NCT04536948|OTHER|Cold Pack|Cold pack was applied to the painful area for 15 minutes on a moist towel placed on the painful area around the lateral epicondyle.
223741586|NCT05090865|DIETARY_SUPPLEMENT|Standard dietary potassium restriction|Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake \< 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
223568545|NCT06463353|OTHER|trilinolein cream group|Apply trilinolein cream evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
223568546|NCT06463353|OTHER|cream base group|Apply cream base evenly to the affected skin twice daily. The dosage is calculated using Finger Tip Units (FTU) and should not exceed a maximum of 30 grams per day.
224300832|NCT00742066|DRUG|Irbesartan|Single dose 600mg orally
223568547|NCT01440517|DRUG|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
224055669|NCT05496543|DEVICE|acupuncture|All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.
224300833|NCT00742066|DRUG|Felodipine|single dose 10mg Felodipine ER
224300834|NCT00742066|DRUG|Placebo|Single dose tablet orally
224300835|NCT02180178|OTHER|observational only- no intervention|
224300836|NCT04641078|DRUG|Darolutamide|600 mg BID
223446863|NCT03900247|DEVICE|REMAP EEG based BCI and SEM-Glove BioServo|EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices
223446864|NCT06653400|PROCEDURE|paracervical block|paracervical block with office hysteroscopy
224300837|NCT04641078|RADIATION|metastasis-directed treatment|stereotactic body radiotherapy
223446865|NCT06653400|DRUG|Lidocaine|Dosage: 20 mL of 1% lidocaine
223446866|NCT06653400|DRUG|ketorolac|Dosage: 2 mL (30 mg) of ketorolac
223446867|NCT06034132|OTHER|Stock healing abutments|2ND stage surgery will be performed and stock healing abutment were placed
223446868|NCT06034132|OTHER|Compoiste healing abutments|2ND stage surgery will be performed and composite healing abutment were placed
223446869|NCT06495801|BEHAVIORAL|Frendie PRO mobile application|Frendie PRO mobile application offers employees an environment to manage their social relationships, organize leisure activities, and discuss personal or work-related matters.
223446870|NCT02548884|PROCEDURE|Biliary cannulation|
223446871|NCT03185494|BIOLOGICAL|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
223446872|NCT03234920|DIETARY_SUPPLEMENT|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
223568548|NCT03753100|OTHER|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
223568549|NCT03065842|BEHAVIORAL|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
223568550|NCT03065842|BEHAVIORAL|Usual Standards|Usual standards according to the school curriculum in Kenya.
223568551|NCT04141189|PROCEDURE|weekly|fetal surveillance frequency
223568552|NCT04141189|PROCEDURE|bi-weekly|fetal surveillance frequency
223568553|NCT05920473|DEVICE|rTMS with Magstim Rapid 2 magnetic stimulation device|The study will involve the utilization of the Magstim Rapid 2 magnetic stimulation device to administer rTMS treatment to the participants. The coil will be positioned tangentially on the scalp, specifically targeting the hot spot (thumb movement area) in the ipsilateral cerebral hemisphere. During the stimulation protocol, a 10-Hz stimulation will be applied for 2 seconds, followed by a 10-second rest period. This cycle will be repeated 50 times. The treatment will be administered once daily, from Monday to Friday, for a continuous period of two weeks.
223446873|NCT03234920|OTHER|Placebo|The placebo will be 200 ml of fruit juice given twice daily
223568554|NCT05920473|DEVICE|sham control with Magstim Rapid 2 magnetic stimulation device|In the sham group, patients received sham stimulation using the the Magstim Rapid 2 magnetic stimulation device with the same protocol. The coil was positioned to target the same hot spot, with an angulation parallel to the gyrus to further reduce the potential impact of rTMS.
223446874|NCT06079632|BEHAVIORAL|parent coaching via telehealth|Participants receive 12 weeks of parent-child interaction strategy coaching and sensory processing strategy coaching intervention.
223446875|NCT06079632|BEHAVIORAL|weekly self-learning materials and group discussion session|Participants receive 1-hour self-learning materials, including parent-child interaction and sensory processing strategies, and 1-hour remote group discussion session weekly.
224300838|NCT02381626|DEVICE|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
224300839|NCT02381626|BEHAVIORAL|questionnaires|
224300840|NCT02381626|OTHER|Log-book|PM and biological measurements
224300841|NCT02381626|OTHER|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
223446876|NCT03581955|OTHER|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
223446877|NCT03581955|OTHER|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
223446878|NCT03581955|OTHER|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
223446879|NCT01875263|DRUG|Cloxacilin|2g/4 hours i.v., 5 days
223446880|NCT01875263|DRUG|Cloxacillin|2g/4h 14 days Standard therapy
223446881|NCT01875263|DRUG|Levofloxacin|500 mg v.o./24h, 9 days
223446882|NCT02751619|DRUG|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
223446883|NCT02751619|DRUG|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
223446884|NCT06402877|DIAGNOSTIC_TEST|Saliva obtaining|The patient was asked to sit upright and tilt his/her head forward to collect saliva samples. İn this way, unstimulated saliva was allowed to accumulate in the floor of the mouth. The accumulated saliva was collected in a sterile container. It was then transferred to a propylene tube. The tubes were centrifuged and the clear part at the top of the tube was taken with a sterile syringe and transferred to a different propylene tube with 0.5 ml in each tube. Tubes were stored at -80ºC until the day of analysis.
224146150|NCT03621423|PROCEDURE|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
224146151|NCT05017714|DRUG|Recombinant cytokine gene derived protein injection|"Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care."
224146152|NCT03017846|DRUG|Cantharidin|Application of topical cantharidin
224146153|NCT03539913|BIOLOGICAL|Probiotic : Saccharomyces boulardii|Treatment for 5 days
224146154|NCT03539913|BIOLOGICAL|Probiotic : Bacillus clausii|Treatment for 5 days
224300842|NCT05855616|DEVICE|"Group chlorhexidine dressing"|Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
224300843|NCT05855616|OTHER|"Group solution"|Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
224300844|NCT05032521|BIOLOGICAL|collection of biological data|collection of biological data
224300845|NCT05032521|OTHER|collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data|These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.
224300846|NCT05032521|PROCEDURE|Standard treatment|usual management based on the use of drugs according to international recommendations
223446885|NCT03802734|DEVICE|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
223446886|NCT04554381|BIOLOGICAL|JL1 antigen|we hypothesis that JL1 can be used as an adjunctive marker for the initial diagnosis and the follow up of Acute Lymphoblastic Leukemia.
223446887|NCT03307837|DRUG|CA-008|Local administration during surgery
223446888|NCT03307837|DRUG|Placebo|Local administration during surgery
223446889|NCT04569929|OTHER|(DLP)-printed photo-polymerizable PMMA Nextdent mandibular implant overdenture|The bite registration records with their corresponding master casts were digitalized using an extra oral desktop 3D scanner (3shape D850) and then stored as standard triangulation language (STL) files (Figure 1). The STL files were then imported to Dental system PREMIUM3 design software (3Shape Dental System 2018) for model analysis, surveying and blocking out, designing full permanent denture bases, and for virtual teeth set-up following the recorded inter-arch space
224146155|NCT02317341|DRUG|Ketamine|Single intravenous dose
224146156|NCT02317341|DRUG|Placebo (saline)|Given intravenously over 40 minutes
223446890|NCT00334165|PROCEDURE|Auricular acupuncture (procedure)|
223446891|NCT04310293|OTHER|Femara,Grotwth hormone,HMG|NOVEL THERAPY
223446892|NCT02032615|DIETARY_SUPPLEMENT|Education plus Gudness Nutritional Bar|
223446893|NCT02032615|OTHER|Education|
223568555|NCT04701580|DIAGNOSTIC_TEST|11C-UCB-J PET-CT|Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 11C-UCB-J.
223568556|NCT04701580|DIAGNOSTIC_TEST|18F-FDG PET-MR|Positron Emission Tomography (PET) of glucose metabolism using the radioligand 18F-FDG, and brain MRI performed simultaneously.
223568557|NCT00733057|DRUG|Minocycline|Minocycline as an add-on drug (200 mg/day)
224146157|NCT02317341|DRUG|Ketamine|Single intravenous dose given over 40 minutes
224146158|NCT02317341|DRUG|Midazolam|Given intravenously over 40 minutes
224146159|NCT02317341|DRUG|Midazolam(placebo)|Given intravenously over 40 minutes
224146160|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
223446894|NCT04177992|OTHER|Servo control|FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
223446895|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 LipoMicel® soft gels|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
223446896|NCT05394701|DIETARY_SUPPLEMENT|RxOmega-3 soft gels (Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
223446897|NCT05394701|DIETARY_SUPPLEMENT|Omega-3 Complete soft gels (Non-Enteric)|A maximum single dose of 1260 mg Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
223446898|NCT03074604|PROCEDURE|aortic no-touch OPCABG|(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
223446899|NCT03074604|PROCEDURE|OPCABG with partial clamp applying carbon dioxide|(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
223446900|NCT03074604|PROCEDURE|OPCABG with partial clamp|"(Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp."
223568558|NCT00733057|DRUG|Placebo (200 mg/day)|
224146161|NCT04603391|DRUG|dl-Methylphenidate plus Cannabidiol Placebo solution|Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
224146162|NCT00000450|DRUG|Naltrexone Tablet|
224146163|NCT00000450|DRUG|Matched Placebo Tablet|
224146164|NCT04372043|OTHER|Questionnaire|"Sleep Hygiene Index and demographic questions."
224300847|NCT05032521|PROCEDURE|stratified treatment according to algorithm|management based on arteriovenous CO2 gradient Stratification of drug use
223446901|NCT03714477|PROCEDURE|Extracorporeal shock wave lithotripsy|A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
223446902|NCT00904917|BEHAVIORAL|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
223446903|NCT00904917|BEHAVIORAL|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
223446904|NCT04298879|DRUG|IBI376|IBI376 20 mg po. once daily for 8 weeks ，followed by 2.5mg once daily
223446905|NCT02100735|OTHER|Sedation protocol|Nursing driven sedation protocol
223446906|NCT01127594|DRUG|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
223446907|NCT03915626|DRUG|Rivastigmine (RLD) transdermal patch|brand name patch
223446908|NCT03915626|DRUG|Rivastigmine (generic) transdermal patch|generic patch
223446909|NCT03628833|DEVICE|Incontinence Management System|Incontinence detection device
223568559|NCT00859339|DRUG|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
223568560|NCT00859339|DRUG|Cisplatin|Cisplatin (70 mg/m2) IV day 1
224055670|NCT05496543|DEVICE|sham acupuncture|"The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle."
224055671|NCT03392792|DRUG|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
224146165|NCT05118542|DRUG|Propylthiouracil|PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
224146166|NCT05118542|DRUG|Methimazole|methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
224146167|NCT02151682|DRUG|Tapentadol prolonged release|
224146168|NCT02151682|DRUG|Morphine prolonged release|
224146169|NCT04298190|BEHAVIORAL|Dialectical Behaviour Therapy for Adolescents (DBT-A)|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus \& Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
223446910|NCT06954805|DRUG|Rituximab|Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B cell lysis. 375 mg/m2 Rituximab will be administered to participants by IV.
223446911|NCT06954805|DRUG|Etoposide|Etoposide is a topoisomerase II inhibitor and appears to cause DNA strand breaks. It has been shown to delay transit of cells through S phase and arrest cells in late S or early G2 phase. 50 mg/m2 Etoposide will be administered to participants by IV.
223568561|NCT00859339|DRUG|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
224146170|NCT04298190|BEHAVIORAL|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive family and/or pharmacological treatment as needed.
224300848|NCT03550001|PROCEDURE|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
223446912|NCT06954805|DRUG|Prednisone|Prednisone can prevent or suppress inflammation and immune responses. Prednisone's action may include the inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, and suppression of humoral immune responses. 60 mg/m2 Prednisone will be administered to participants by PO.
223568562|NCT00859339|PROCEDURE|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
223446913|NCT06954805|DRUG|Vincristine|Vincristine is a vinca alkaloid. The mechanism of action of vincristine is thought to be due to inhibition of microtubule formation in the mitotic spindle. This leads to arrest of dividing cells during the metaphase stage. 0.4 mg/m2 Vincristine will be administered to participants by IV.
223568563|NCT05686096|DRUG|MYK-224|Specified dose on specified days
223568564|NCT03889210|OTHER|HVMN Ketone|Water-based, flavoured sport beverage
223568565|NCT03889210|OTHER|Placebo|Water, stevia, malic acid, and thickening agent
223568566|NCT01288612|DEVICE|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
224055672|NCT03392792|PROCEDURE|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
224055673|NCT05097144|DEVICE|Lens A (fanfilcon A)|Daily wear for one month
224055674|NCT05097144|DEVICE|Lens B (asmofilcon A)|Daily wear for one month
224055675|NCT03100071|DRUG|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
224146171|NCT02995122|DRUG|BAY987516|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)"
224146172|NCT02995122|DRUG|SPF Control|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
224300849|NCT01276301|DRUG|Verapamil|single dose verapamil
223446914|NCT06954805|DRUG|Cyclophosphamide|The mechanism of action is thought to involve cross-linking of tumor cell DNA. Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites which are thought to cross-link to tumor cell DNA. These metabolites interfere with the growth of rapidly proliferating susceptible malignant cells. 375 mg/m2 Cyclophosphamide will be administered to participants by IV.
223446915|NCT06954805|DRUG|Doxorubicin|Doxorubicin is an anthracycline, topoisomerase II inhibitor. It is isolated from cultures of Streptomyces peucetius var. caesius. The cytotoxic effect of doxorubicin is related to nucleotide base intercalation and cell membrane lipid binding activities. It blocks nucleotide replication and the action of DNA and RNA polymerases. The interaction between doxorubicin and topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of its cytocidal activity. 10 mg/m2 Doxorubicin will be administered to participants by IV.
223446916|NCT06954805|DEVICE|CAPP-seq|Next generation sequencing (NGS) tool used to detect tiny amounts of cancer DNA in the blood, allowing for early diagnosis and monitoring of cancer in a non-invasive way.
223446917|NCT03166488|DEVICE|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
223446918|NCT05933694|OTHER|Artificial Intelligence-powered Spirometry Interpretation Report|A report generated by artificial intelligence powered software that assessed technical quality of spirometry and estimates the diagnostic probability of six categories: COPD/Asthma/ILD/ Normal/Other obstructive/Other Unidentified
223446919|NCT02603965|RADIATION|Copper Cu 64 TP3805|Given IV
223446920|NCT02603965|PROCEDURE|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
223446921|NCT02603965|PROCEDURE|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
224055676|NCT01530412|OTHER|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
223446922|NCT02603965|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
223446923|NCT02603965|OTHER|Laboratory Biomarker Analysis|Correlative studies
223446924|NCT01142492|DRUG|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
223446925|NCT01051726|OTHER|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
223446926|NCT01051726|OTHER|None essential oil|Baby oil
223446927|NCT00313287|DRUG|clevudine|
223446928|NCT06380933|OTHER|experimental group|first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days
223446929|NCT03083353|DRUG|Isradipine|Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
223446930|NCT03083353|BEHAVIORAL|Cue Exposure|Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
223568567|NCT01288612|DEVICE|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
223568568|NCT00138047|DRUG|zinc supplementation|
223446931|NCT05251064|DEVICE|Suture|Standard suture wound closure device.
223446932|NCT05251064|DEVICE|Clozex|Interlaced adhesive wound closure device.
223446933|NCT05251064|DEVICE|Zipline|Adhesive wound closure device using zip-tie like strips.
223446934|NCT02771860|DRUG|denosumab|60mg sc
223446935|NCT02771860|DRUG|Placebo|identical syringe
223446936|NCT02771860|DIETARY_SUPPLEMENT|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
223446937|NCT06321341|DRUG|Vespireit|Buspirone
223446938|NCT06321341|DRUG|Arlevert|Dimenhydrinate + Cinnarizine
223446939|NCT06174194|DIETARY_SUPPLEMENT|Tulsi Gum|"The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children."
223446940|NCT02163317|RADIATION|stereotactic radiosurgery|Undergo MRI-guided focal SRS
223568569|NCT02714361|DIETARY_SUPPLEMENT|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
223568570|NCT02714361|OTHER|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
223568571|NCT06386341|PROCEDURE|Maxillomandibular Advancement Surgery|Surgery where the upper and lower jaw are repositioned.
223568572|NCT03535285|PROCEDURE|Periodontal ligament distraction|decrease the bony resistant during canine retration
223568573|NCT05599451|OTHER|THS Blade device|Tobacco Heating System (THS) device with Blade technology for Blade tobacco stick use
223568574|NCT05599451|OTHER|THS Induction Mono device|Tobacco Heating System (THS) device with Induction technology (combined Charger-Holder device for Induction tobacco stick use).
223568575|NCT05599451|OTHER|THS Induction Mid device|Tobacco Heating System (THS) device with Induction technology (device with Induction stick Holder for Induction tobacco stick use and separate Charger).
223568576|NCT05599451|OTHER|CIG|Subject's preferred brand of commercially available regular (non-mentholated) cigarettes. (Cigarettes are not provided by the study sponsor.)
224055677|NCT00956267|DRUG|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
224055678|NCT00956267|PROCEDURE|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
224300850|NCT01276301|DRUG|BI 10773|single dose BI 10773
224055679|NCT01484977|DRUG|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."
224146173|NCT04392869|BEHAVIORAL|The CRAFT program (adapted due to COVID-19)|"The CRAFT program was created by P. Posadas, PhD (Posadas 2017). This program aims to cultivate positive emotions toward oneself and others, engaging socio-emotional processes and activating traits such as empathy, motivation and creativity. It has been previously implemented in other Higher Education Institutions (Rull et al 2019, Posadas 2018, 2019).~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: Consciousness, Relaxation-Breathing-Regulation, Mindfulness/Full Attention, Bliss, Transcendence, Communication as Connection, Mindfully, Consciously and Blissfully Living our Daily Lives, My Work of Art My Wonderful Craft Work Here and Now, Time and Energy Management, Passion and Compassion in the COVID context."
224300851|NCT01276301|DRUG|BI 10773|single dose BI 10773
223446941|NCT02163317|DEVICE|magnetic resonance imaging|Undergo staging MRI with contrast
223446942|NCT02163317|OTHER|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
223446943|NCT02163317|PROCEDURE|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
223446944|NCT02163317|PROCEDURE|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
223446945|NCT02163317|BEHAVIORAL|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
223446946|NCT00855699|DRUG|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
223568577|NCT00496483|DRUG|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
223568578|NCT00496483|DRUG|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
223568579|NCT03795207|COMBINATION_PRODUCT|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
223568580|NCT03795207|RADIATION|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
223568581|NCT00227318|DRUG|ATACAND|
223568582|NCT02845947|BEHAVIORAL|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
223568583|NCT02958202|DRUG|BMN 044 IV 6 mg/kg|
223568584|NCT02958202|DRUG|BMN 044 IV 9 mg/kg|
224300852|NCT00871273|DRUG|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
224300853|NCT01906892|OTHER|Group drumming (participatory)|Active participation in group drumming workshops
223446947|NCT05742113|DEVICE|Masimo Radical-7|perfusion index measuring device
223446948|NCT02752711|PROCEDURE|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
223446949|NCT02006433|DEVICE|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
223446950|NCT02190721|DRUG|tbo-filgrastim|5 μg/kg
223446951|NCT04482738|OTHER|High-calorie meal|Intake of a high-calorie meal (2500-3000 calories) within 15 minutes.
223568585|NCT02958202|DRUG|BMN 044 SC 6 mg/kg|
223568586|NCT05492799|DRUG|AX 250|biweekly infusion by intracerebroventricular (ICV) infusion
223568587|NCT01204229|BEHAVIORAL|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
224055680|NCT00930839|DRUG|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
224055681|NCT02441413|RADIATION|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
224055682|NCT03480568|DRUG|Alirocumab 150 MG/ML [Praluent]|Cholesterol-lowering therapy
224055683|NCT03275220|DIAGNOSTIC_TEST|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
223446952|NCT02965508|OTHER|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
223446953|NCT02965508|OTHER|Usual Care|Office based care
223446954|NCT02377128|PROCEDURE|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
223446955|NCT02377128|PROCEDURE|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
223446956|NCT03703674|DRUG|GCSF|Granulocyte-colony stimulating factors (G-CSF)
223446957|NCT04831996|DRUG|parsaclisib|parsaclisib will be administered orally after 8 hours of fasting.
223446958|NCT04046263|DRUG|Sucroferric Oxyhydroxide Chewable Tablet|Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
223446959|NCT01142505|DRUG|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
223446960|NCT01142505|DRUG|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
223446961|NCT05025332|DRUG|NNZ-2591|NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
223446962|NCT02301819|DEVICE|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
223446963|NCT02301819|OTHER|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
223446964|NCT06133959|BEHAVIORAL|The-Optimal-Lymph-Flow (TOLF) Program|TOLF includes training sessions on the lymphatic system, lymphedema, lymphedema diagnosis and measurement, risk of lymphedema, healthy diet, sleep hygiene, and daily lymphatic exercises. It has 8 avatar videos with step-by-step instructions for TOLF lymphatic exercises to promote lymph flow. It is expected that participants will complete initial in-person or telehealth virtual 40-minute session, and 3 virtual telehealth sessions with each session for 20-minute over the course of 8 weeks.
223446965|NCT04663854|DRUG|Trehalose|Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products. In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes.
223446966|NCT00779753|DIETARY_SUPPLEMENT|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
223446967|NCT02954588|DIETARY_SUPPLEMENT|Pyridoxamine|
223446968|NCT02954588|DIETARY_SUPPLEMENT|Placebo|
223446969|NCT04116775|BIOLOGICAL|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
223446970|NCT04116775|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
223446971|NCT04116775|DRUG|Enzalutamide|Daily oral dose.
224055684|NCT01081457|DEVICE|Deep brain stimulation|Comparison ON vs OFF
223446972|NCT01713296|DRUG|Pazopanib|
223446973|NCT00624364|DRUG|biphasic insulin aspart|
223446974|NCT00624364|DRUG|metformin|
223446975|NCT02956707|OTHER|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
223446976|NCT01928199|DRUG|Sitagliptin|
223446977|NCT01928199|DRUG|Placebo|
223446978|NCT03321409|DIAGNOSTIC_TEST|The general population|After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
223446979|NCT03321409|DIAGNOSTIC_TEST|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
223446980|NCT06186596|DEVICE|Triamcinolone delivered via injection assistance device|0.1mL of 1% to 2% triamcinolone solution will be delivered to up to 3 facial inflammatory acne lesions
223446981|NCT03405571|OTHER|No intervention|No intervention
223568588|NCT01204229|BEHAVIORAL|Brief Motivational Intervention (BMI)|Integrate drinking intervention
223568589|NCT03698045|DRUG|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
224055685|NCT00848133|PROCEDURE|mini-midvastus surgical approach for total knee arthroplasty|
224055686|NCT00848133|PROCEDURE|mini-subvastus surgical approach for total knee arthroplasty|
224055687|NCT06317025|DIAGNOSTIC_TEST|Multi-modal Intelligent Anesthesia Monitoring System|To evaluate the sensitivity and specificity of self-developed anesthesia monitoring systems in diagnosing the depth of anesthesia (too deep or too shallow)
224055688|NCT05482074|DRUG|Olaparib|Oral, twice a day, dosage per protocol, per 28 day cycle
224055689|NCT02401321|BEHAVIORAL|Telephone-Based Intervention|Complete Taking Care of Her program
223446982|NCT01502956|DEVICE|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
223568590|NCT01452139|GENETIC|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)
223568591|NCT01452139|DRUG|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
224055690|NCT02401321|OTHER|Caregiver-Assisted Training|Complete Taking Care of Her program
224146174|NCT04392869|BEHAVIORAL|The MBSR program (adapted due to COVID-19)|"The MBSR program is a group-based therapy which teaches mindfulness skills through a range of formal and informal mindfulness practices. Created by Kabat-Zinn (1982), in the current study it is taught by an officially accredited instructor and is compliant with the guidelines established by Brown University and the University of Massachusetts, USA.~It originally consists of 8 weekly classes, 2 hours each (18 hours direct instruction) but it has been adapted and extended due to the situation caused by the COVID19 pandemic.~The resulting 12 week program is structured along the following topics: The Underpinnings of MBSR, The Perception of Reality, Emotion Regulation, Understanding Stress: The Mind-Body Relation, Responding to Stress, Communication and Personal Relations, Daily Life Management, My Personal Plan: The First Week of the Rest of my Life, Time and Energy Management, Emotion Regulation in the COVID context."
224146175|NCT00003077|DIETARY_SUPPLEMENT|omega-3 fatty acid|
224146176|NCT00168064|DRUG|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
224146177|NCT01178346|BIOLOGICAL|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
224146178|NCT01178346|BIOLOGICAL|Placebo|Placebo vaccine given 6 times over 6 months
224146179|NCT00821665|DIETARY_SUPPLEMENT|Sucrose consumption|Sucrose
224146180|NCT00821665|DIETARY_SUPPLEMENT|water consumption|water
224146181|NCT03488394|GENETIC|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10\^6 CD34+ cells/Kg, with a minimum dose of 4x10\^6 CD34+ cells/Kg and a maximum dose of 35x10\^6 CD34+ cells/Kg.~The product will be injected intravenously."
224146182|NCT06976944|DRUG|Pembrolizumab|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Pembrolizumab: Intravenous infusion(400 mg/body, every 6 weeks starting on Day 1 of Cycle 1)"
224146183|NCT06976944|DRUG|Paclitaxel|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Paclitaxel: Intravenous infusion(90 mg/m\^2, on Days 1, 8, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)"
224146184|NCT06976944|DRUG|Bevacizumab|"Protocol treatment will continue until worsening of the participant's underlying disease or unacceptable toxicity is observed or the participant withdraws the consent, or the participant meets other discontinuation criteria.~Bevacizumabl: Intravenous infusion(10 mg/kg, on Days 1, and 15, starting on Day 1 of Cycle 1 with a 28-day cycle)"
223568592|NCT02100163|BEHAVIORAL|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
223568593|NCT02100163|BEHAVIORAL|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
223568594|NCT02100163|OTHER|Standard treatment|
223568595|NCT03310008|BIOLOGICAL|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
223741587|NCT06335810|BEHAVIORAL|Social Network Intervention|Social Network interventions are an intentional effort to modify or use the characteristics of social networks to improve, generate, and maintain healthy behaviors among individuals and populations. This study will focus on implementing a behavioral social-network intervention to promote changes in weight loss behaviors.
224055691|NCT02401321|OTHER|Questionnaire Administration|Ancillary studies
224146185|NCT00318565|DEVICE|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
224146186|NCT01113840|BEHAVIORAL|Exercise|Exercise classes three times per week in a controlled, supervised environment.
224146187|NCT01113840|BEHAVIORAL|Control|Control group continues daily life as prior to randomization.
224146188|NCT04713787|DRUG|Albendazole|Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
223741588|NCT06335810|BEHAVIORAL|Individual Lifestyle Intervention|The individual lifestyle intervention will serve as the control group and will implement the use of DPP based health coaching sessions to promote individual level changes in weight loss behaviors.
224055692|NCT02401321|OTHER|Quality-of-Life Assessment|Ancillary studies
224055693|NCT02113943|DRUG|Citalopram 30mg|
224055694|NCT03760341|PROCEDURE|adenoidectomy - cold method|a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
224055695|NCT03760341|PROCEDURE|adenoidectomy - hot method|a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
224055696|NCT06475313|BEHAVIORAL|plaque index assessment, periodontal probing, Bleeding on probing (BOP), Prosthetic adjacency check, initial occlusal contact, maximum occlusal contact, and filling of the cusps.|oral panoramic radiograph
224055697|NCT04224675|DRUG|Atenolol|Captopril versus atenolol to prevent expansion rate of thoracic aortic aneurysms
224055698|NCT03294525|DRUG|Escitalopram Pill|escitalopram 10\~20mg/day
224055699|NCT03294525|DRUG|Duloxetine|duloxetine 30\~120mg/day
224055700|NCT03294525|DRUG|Mirtazapine Pill|Mirtazapine 15\~45mg/day
224055701|NCT03294525|DRUG|Other Antidepressants|
223741589|NCT06335810|OTHER|Social Network Member|The social network member will serve as the friend, family member, or co-worker nominated to participate in the social network intervention by the social network intervention participant.
223741590|NCT03971188|PROCEDURE|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
223741591|NCT05791383|DEVICE|transcutaneous auricular neurostimulation|All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
223741592|NCT01321515|DRUG|famciclovir|500 mg tablet
223741593|NCT02252198|OTHER|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
223741594|NCT03523754|DRUG|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening \& induction of labor in study group
223741595|NCT03996954|DEVICE|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
223741596|NCT06803485|DRUG|Venlafaxine|Venlafaxine will be started at a dose of 37.5 mg/day in first week and increased to a stable dose of 75 mg/day from second week and will be continued till 8 weeks.
223741597|NCT06803485|DRUG|Dosulepin|Dosulepin will be started at a dose of 25 mg/day in first week and increased to a stable dose of 50 mg/day from second week and will be continued till 8 weeeks.
223741598|NCT03940066|DEVICE|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
224055702|NCT01583933|DEVICE|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
224055703|NCT01583933|DEVICE|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
224055704|NCT04857996|DRUG|UBX1325|Patients will be administered a single 50 μL UBX1325 IVT injection
224055705|NCT04857996|OTHER|Sham|Sham procedure
224055706|NCT00777621|OTHER|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
224146189|NCT04713787|DRUG|Oxfendazole|The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
223741599|NCT03940066|OTHER|No Intervention|No intervention
223741600|NCT03706053|DRUG|Midodrine Hydrochloride|Midodrine Hydrochloride, enteral, 10 or 20 mg
223741601|NCT03706053|OTHER|placebo|investigational pharmacy formulated placebo comparator
223741602|NCT00612924|DEVICE|Anaconda Stent Graft System|Endovascular device
223741603|NCT00612924|DEVICE|Anaconda ONE-LOK Stent Graft System|Endovascular device
223741604|NCT00730912|DRUG|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
224055707|NCT00777621|OTHER|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
224055708|NCT00777621|OTHER|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
224055709|NCT00474110|DRUG|Ketamine & hydromorphone|See Detailed Description
224055710|NCT03321370|DIAGNOSTIC_TEST|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
224055711|NCT06977165|DIAGNOSTIC_TEST|Antibiotic quantification|Piperacillin/tazobactam quantification using liquid chromatography-tandem mass spectrometry
224055712|NCT06978322|PROCEDURE|Immediate surgery|Patients will undergo upfront surgery, then adjuvant chemotherapy.
224055713|NCT06978322|PROCEDURE|Neoadjuvant chemotherapy|Patients will undergo neoadjuvant chemotherapy, then surgery.
224055714|NCT06979024|GENETIC|Triplet-primed PCR or Long-read sequencing|This study involves long-read sequencing in patients with Myotonic Dystrophy Type 1 (DM1) to identify specific motifs, determine the range of repeat numbers, and assess the presence of interruptions in the CTG repeat sequence. The aim is to gain insights into the genetic variability and its clinical implications in DM1.
224055715|NCT06316297|BIOLOGICAL|Acne mRNA vaccine|Pharmaceutical form: Liquid suspension for injection Route of administration: intramuscular
224055716|NCT06316297|OTHER|Placebo|Pharmaceutical form: Liquid solution for injection Route of administration: intramuscular
223741605|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
223741606|NCT00730912|DRUG|loratadine|loratadine 10 mg tablet once daily for 4 weeks
224055717|NCT05229926|DEVICE|CareCube|modular, disposable, negative pressure, isolation patient care system
224055718|NCT01538628|DEVICE|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
224055719|NCT04086004|OTHER|Group I Experimental Motor Imagery|The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks
224146190|NCT04929418|OTHER|10 km continuous running|Trial participants will perform a 10 km continuous running exercise
224055720|NCT04086004|OTHER|Dual task training|group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
223446983|NCT01502956|DRUG|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
223446984|NCT01317498|OTHER|Standard Care|CD4, liver function and CBC every 6 months
223446985|NCT01317498|OTHER|Virological Monitoring|Viral Load test every 6 months
223446986|NCT02501941|DRUG|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
223446987|NCT00639106|PROCEDURE|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
223446988|NCT00639106|PROCEDURE|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
223446989|NCT03453957|OTHER|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
223446990|NCT03574688|DIETARY_SUPPLEMENT|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
223446991|NCT01420341|DRUG|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
223446992|NCT01420341|DRUG|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
223446993|NCT03999528|DIAGNOSTIC_TEST|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
223741607|NCT03999450|BEHAVIORAL|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
224055721|NCT02410304|DEVICE|Xrays|Clinical evaluation
224055722|NCT02410304|DEVICE|Ultrasound (B mode )|
224146191|NCT04929418|OTHER|1.5 km continuous swimming|Trial participants will perform a 1.5 km continuous swimming exercise.
224055723|NCT02410304|DEVICE|Ultrasound (D mode)|
224055724|NCT06978569|DEVICE|Injectable Acellular dermal matrix hydrogel|An injectable, sterile acellular dermal matrix (ADM) gel derived from processed biological tissue, designed to promote healing in chronic wounds. The gel is injected directly onto the wound bed following standard debridement and serves as a biocompatible scaffold to support granulation tissue formation, epithelialization, and wound closure. After application, the wound is covered with a standard secondary dressing. Dressing changes are performed every 2 to 3 days or as clinically indicated.
224146192|NCT00684112|DRUG|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
224146193|NCT00684112|DRUG|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
224146194|NCT02726529|BEHAVIORAL|Brighter Bites|
224146195|NCT02726529|BEHAVIORAL|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
224146196|NCT03933280|DRUG|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
224146197|NCT03933280|DRUG|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
223446994|NCT02830074|BEHAVIORAL|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
223446995|NCT02830074|BEHAVIORAL|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
223446996|NCT00003190|DRUG|cytarabine|Given IV
223446997|NCT00003190|DRUG|daunorubicin hydrochloride|Given IV
223446998|NCT00003190|DRUG|etoposide|Given IV
223446999|NCT00003190|DRUG|valspodar|Given IV
223447000|NCT01059019|DIETARY_SUPPLEMENT|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
223447001|NCT03479138|DIAGNOSTIC_TEST|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
223447002|NCT05600153|PROCEDURE|implant exchange operation|To perform implant exchange via axillary incision.
224055725|NCT06978569|DEVICE|Alginate dressing|A sterile, absorbent alginate wound dressing composed of natural polysaccharide fibers derived from seaweed. Following standard debridement, the alginate dressing is applied directly to the wound bed to manage exudate and maintain a moist wound environment conducive to healing. The dressing is covered with a secondary dressing and changed according to the manufacturer's instructions and clinical protocol.
224146198|NCT03933280|DRUG|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
224146199|NCT03933280|DRUG|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
224055726|NCT06977295|DEVICE|Diagnostic Software Application for CAD Assessment|A novel on-premises diagnostic software integrating automated coronary stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification for evaluation of coronary artery disease (CAD) using coronary computed tomography angiography (CCTA) datasets.
224055727|NCT06978790|OTHER|Generative Artificial Intelligence Nurse Staffing (GAINS) Intervention|The Generative Artificial Intelligence intervention is an industrial engineering and nursing-informed innovation developed to optimize team-based staffing of registered nurses and nursing assistants. We anticipate that the GAINS intervention will enhance staffing efficiency, reduces reliance on travel nurses, minimizes overtime costs, and supports nurse well-being by proactively managing workload distribution and reducing burnout. At the core of GAINS is a generative AI model that predicts future unit-level staffing needs using historical staffing patterns, patient turnover (admissions and discharges), and patient acuity scores (based on ICU versus medical/surgical status, physician orders, charge nurse input, and other clinical factors) reflective of workload. Based on the prediction, the intervention dynamically recommends float pool assignments by evaluating staffing gaps across units and optimally deploying available nurses and nursing assistants to where they are most needed.
224055728|NCT06587243|BEHAVIORAL|Informational Animation Video|The informational animation video will also take several minutes and will cover HPV disease, address specific concerns when identified, and the importance and safety of HPV vaccines.
224055729|NCT06587243|BEHAVIORAL|Personal Narrative Video|Personal narrative videos will consist of someone describing the person's own personal experience with HPV. The investigators have a collection of videos of personal narratives from different people that the investigators have cut to approximate several minutes in length so the investigators can tailor the personal narratives to match each study participant's race/ethnicity and gender as closely as possible.
224055730|NCT01147198|DIETARY_SUPPLEMENT|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
224055731|NCT01147198|DIETARY_SUPPLEMENT|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
224055732|NCT06985173|DEVICE|Occlusal splints manufactured with fully digital workflow.|The intervention involves the fabrication of 3D printed occlusal splint with fully digitalization technique by the aid of Jaw Tracing Device. The acquisition and scanning of the patients are done by using an intra oral scanner and designing them using a designing software. This device will be printed with a 3D printer utilizing printable resin material
224055733|NCT06985173|DEVICE|Occlusal splints manufactured with Conventional workflow|For the comparator group, maxillary and mandibular impressions will be made with Cavex CA37 alginate impression material (Cavex Holland B.V, Holland), models will be poured with gypsum (Kimberlit, Type IV Dental Stone, Protechno Spain), facebow (Bio-art) record and interocclusal registrations will be recorded at centric by using bite registration material after patient deprogramming with Lucia jig. The models will be mounted in a semi-adjustable articulator (Bio-art, A7Plus, Brazil), wax pattern fabrication on surveyed and mounted casts to be invested finally to form a clear, heated-cured acrylic resin splint
224055734|NCT06195488|PROCEDURE|Gastric ultrasound|performing gastric ultrasound to determine gastric contents
224055735|NCT06439082|BIOLOGICAL|Crizanlizumab|Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
224055736|NCT06439082|DRUG|Placebo|Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
224055737|NCT02494258|DRUG|CC-486|The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.
224055738|NCT06985134|DRUG|Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study from Bangladesh|The present study included patients aged \>18 years with inflammatory low back pain fulfilling the Modified New York criteria \[12\], 2014 for moderate to severe ankylosing spondylitis. The criteria include radiographic sacroiliitis (at least grade II bilaterally or grade III unilaterally) along with clinical signs, such as inflammatory back pain for at least 3 months' duration, limitation of lumbar spine in sagittal and frontal planes, or chest expansion decreased relative to normal values for age and sex. Exclusion criteria were non-inflammatory back pain or back pain due to inflammatory causes other than AS, failure to confirm a washout period of four weeks, those who were on DMARDs, allergy to thalidomide, Sulfasalazine, and NSAIDs, known to have kidney diseases or cardiac disease, active peptic ulcer disease, and pregnancy.
224146200|NCT01017887|DEVICE|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
224146201|NCT01017887|DEVICE|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
223447003|NCT05208268|DRUG|Pariet|Pariet Tablets.
223447004|NCT00823485|PROCEDURE|fibrinolysis in situ|intraventricular injection of actilyse
223447005|NCT00823485|PROCEDURE|drainage|drainage
223447006|NCT04295369|BEHAVIORAL|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep, stress management, and Chinese dietary recommendations.
223447007|NCT03157596|OTHER|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD \& methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
223447008|NCT03027245|DRUG|Eribulin|
223447009|NCT01982799|DRUG|Oral placebo|placebo
223447010|NCT01982799|DRUG|Oral ibuprofen|Ibuprofen
223447011|NCT01982799|DRUG|oral naproxen|naproxen
223447012|NCT01982799|DRUG|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
223447013|NCT03451955|OTHER|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
223447014|NCT05861895|DRUG|HF158K1 /Arm 2 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
223447015|NCT05861895|DRUG|HF158K1 /Arm 6 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
223447016|NCT05861895|DRUG|HF158K1 /Arm 15 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
223447017|NCT05861895|DRUG|HF158K1 /Arm 30 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
223447018|NCT05861895|DRUG|HF158K1 /Arm 45 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
223447019|NCT05861895|DRUG|HF158K1 /Arm 60 mg/m²|Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
223447020|NCT03541447|DRUG|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
223447021|NCT03541447|DRUG|Octreotide LAR|A single dose of two 20 mg i.m. injections.
223447022|NCT03541447|OTHER|Placebo|A single dose of two 20 mg i.m. injections.
224146202|NCT04965168|PROCEDURE|phacoemulsification of the lens|all patients underwent phacoemulsification and IOL implantation for immature cataract extraction
224146203|NCT05703698|BEHAVIORAL|Cognitive Behavioural Therapy for Psychosis|CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered in-person. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
224146204|NCT01847261|DIETARY_SUPPLEMENT|Soy Dairy Protein Blend|
224146205|NCT01847261|DIETARY_SUPPLEMENT|Positive Control (Dairy Whey Protein)|
224146206|NCT00830960|DRUG|Prasugrel|Oral, daily, 90 days
224146207|NCT00830960|DRUG|Clopidogrel|Oral, daily, 90 days
223447023|NCT02799914|DEVICE|Sinus-Venous stent (Optimed GmbH)|Stent implantation
223447024|NCT03782129|BIOLOGICAL|blood samples|Blood samples drawn during hospitalisations when needed
223447025|NCT03782129|OTHER|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
223447026|NCT00568893|DRUG|drotrecogin alfa (activated)|
223447027|NCT02634801|DRUG|Fumaric Acid Esters|Administered orally
223447028|NCT02634801|DRUG|Methotrexate|Administered orally
223447029|NCT02634801|DRUG|Ixekizumab|Administered SC
223447030|NCT04705532|DEVICE|tDCS|Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA
223447031|NCT04705532|DEVICE|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
223447032|NCT04705532|OTHER|Music|Subjects will listen to their preferred music for 20 minutes
223447033|NCT04705532|OTHER|White noise|Subjects will listen to a white noise for 20 minutes
223447034|NCT05403840|PROCEDURE|Mitral valve surgery|Surgical mitral valve repair or replacement
223447035|NCT05403840|PROCEDURE|Transcatheter mitral valve intervention|Transcatheter mitral valve repair or replacement
223447036|NCT00280514|DRUG|cefpirome and moxifloxacin administration|
223447037|NCT05481827|GENETIC|GT005|GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
223447038|NCT00528918|DRUG|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
223447039|NCT01756339|DRUG|Solithromycin|
223447040|NCT01756339|DRUG|Moxifloxacin|
223447041|NCT01756339|OTHER|Placebo to match solithromycin|
224146208|NCT03997929|DIAGNOSTIC_TEST|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
224146209|NCT03436771|GENETIC|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
224146210|NCT03436771|GENETIC|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
224146211|NCT02604615|DRUG|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
224146212|NCT02604615|DRUG|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
223447042|NCT03243123|DEVICE|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
223447043|NCT06237608|BEHAVIORAL|Dialectical behavioural therapy (DBT)-informed skills group|16 week 1.5hr DBT-informed skills group facilitated by the lead researcher and two charity facilitators
223447044|NCT05080738|OTHER|Upper Extremity Home Exercises|"The exercises will be performed as follows:~1. Stretching exercises: It will be applied in the form of 10 seconds\*10 repetitions for fingers, wrists, elbows and shoulders.~2. Strengthening exercises: It will be applied as 2 sets\*10 repetitions for fingers, wrists, elbows and shoulders."
223447045|NCT03033160|DRUG|Estradiol Ring|
223447046|NCT02626000|DRUG|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
223447047|NCT02626000|BIOLOGICAL|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
223447048|NCT05745233|DRUG|Nivolumab|Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
223447049|NCT05745233|DRUG|Pembrolizumab|Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
223447050|NCT00791427|DRUG|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
224055739|NCT05796427|BEHAVIORAL|SupporT for ADHD and Related Treatment|Intervention will include 6 modules typically taught over 6-7 weeks. Participants will have up to 3 months to complete the intervention. Modules will provide more knowledge on ADHD, discuss stigma around ADHD, address barriers in receiving care, encourage communication with physician and child, and empower caregivers. Overall, the goal being to improve engagement in ADHD treatment for newly diagnosed or unengaged families. This intervention is mostly targeted towards primary caregivers. However, the last module explicitly includes the child.
223447051|NCT03539484|DRUG|RO7172508|RO7172508 was administered at a dose and as per the schedule specified in the respective arms.
223447052|NCT03539484|DRUG|Obinutuzumab|In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
223447053|NCT03539484|DRUG|Tocilizumab|Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
223447054|NCT02943187|BEHAVIORAL|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
223447055|NCT02943187|DIETARY_SUPPLEMENT|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
223447056|NCT02186899|OTHER|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
223447057|NCT02186899|OTHER|General Anesthesia femoral bolus|
223447058|NCT02186899|OTHER|General anesthesia femoral continuous|
223741608|NCT03999450|BEHAVIORAL|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
223741609|NCT03311659|BIOLOGICAL|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
224055740|NCT07010224|OTHER|Retrospective Medical Record Review|Review of archived medical, surgical, and radiological records of patients diagnosed with elastofibroma dorsi and treated surgically. No active intervention was administered as part of the study.
224055741|NCT07010939|PROCEDURE|blood sampling|At baseline, participants will undergo peripheral blood collection using EDTA tubes. A total of 10 mL of venous blood will be collected and processed into plasma and peripheral blood mononuclear cells (PBMCs). Plasma samples will be stored at -80°C, and PBMCs will be cryopreserved in liquid nitrogen. These samples will be used for future biomarker discovery, multi-omics analysis, and studies of biological mechanisms underlying treatment-related toxicities.
224055742|NCT07013006|OTHER|Collection of data from the patient's medical file|Collection of data from the patient's medical file.
224055743|NCT07016321|DRUG|Emetine Hydrochloride 6mg|To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
224055744|NCT07016321|DRUG|Placebo|Participant take a placebo for 10 consecutive days.
224055745|NCT07016321|DRUG|Emetine Hydrochloride 12mg|To administer Emetine Hydrochloride 12mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic dengue patients.
224055746|NCT02812290|PROCEDURE|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
224055747|NCT07023367|BEHAVIORAL|Parent Navigator Program|Participants in this group will be connected with a parent with lived experience to help get them obtain developmental follow up services and early intervention.
224146213|NCT02604615|RADIATION|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
224300854|NCT01906892|OTHER|Group drumming (live)|Listening to live performances of group drumming
223447059|NCT04923880|OTHER|Implementation of Primary Palliative Care Intervention in CF Centers|"Individuals with CF ages 12 years and above will complete an annual palliative care needs assessment with the CF care team using the IPOS (Integrated Palliative Care Outcome Scale).~Individuals with CF under 12 years of age will complete an annual palliative care needs assessment with the CF care team using IPOS as a conversation guide.~Caregivers of Individuals with CF of all ages will be offered the BASC (Brief Assessment Scale for Caregivers).~In addition to annual needs assessment, palliative care needs assessment will take place when triggered by changes in disease status, such as hospitalization, new diagnosis of CF related Diabetes or referral to transplant."
224300855|NCT01906892|OTHER|Group drumming (recorded)|Listening to recorded performances of group drumming
223447060|NCT00914498|DRUG|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
224055748|NCT07023367|BEHAVIORAL|Standard of Care|The families in the standard care group will have their connections to neurodevelopmental (ND) follow-up and support delivered in the standard fashion which consists of a referral to high-risk infant follow-up (HRIF) by discharge coordinator.
224055749|NCT07029204|DRUG|CycloSPORINE Injectable Product|Intralesional 0.5-2 mL injections of cyclosporine (2.5 mg/ml)
224055750|NCT07029204|DRUG|Saline Solution|Intralesional 0.5-2 mL injections of Saline Solution
224055751|NCT07025187|DRUG|Muscle relaxants tizanidine|All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day for one month .
224055752|NCT07025187|OTHER|integrated neuromuscular inhibition technique|Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month .
224055753|NCT06091306|BEHAVIORAL|Psychotherapy|"Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department."
224055754|NCT07028697|DRUG|Daridorexant|Daridorexant will be taken orally, once daily in the evening as indicated by investigator.
224055755|NCT07028697|DRUG|Placebo|Placebo will be taken orally, once daily in the evening as indicated by investigator.
224055756|NCT06694402|DEVICE|focal muscle vibration combined with exercise|The treatment group will receive a 30-minute intervention in each session. Focal muscle vibration will be applied to the anterior and lateral parts of shoulder to give a sensory stimulation while participants are doing eaercise.
223447061|NCT03634943|OTHER|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
223447062|NCT03591224|OTHER|Pharmacogenomic Testing|pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
223447063|NCT03591224|OTHER|Pharmacist Standard of Care|Pharmacist providing standard of care as per usual practice
223447064|NCT04008797|DRUG|E7386|E7386 dosing.
223447065|NCT04008797|DRUG|Lenvatinib|Lenvatinib, capsules, orally.
224300856|NCT01906892|OTHER|Comparative activity|Taking part in a literary-based activity
223447066|NCT04008797|DRUG|Doxorubicin|Doxorubicin dosing.
223447067|NCT04008797|DRUG|Paclitaxel|Paclitaxel dosing.
223447068|NCT03957590|DRUG|Tislelizumab|Administrated at dose of 200 mg intravenously (IV)
223447069|NCT03957590|DRUG|Placebo|Placebo to match tislelizumab
223447070|NCT03957590|DRUG|Paclitaxel|Administered as 135 mg/m² IV injection
223447071|NCT03957590|DRUG|Cisplatin|Administered as 25 mg/m² IV injection
223447072|NCT03957590|RADIATION|Radiotherapy|Administered at a total dose of 50.4 Gy in 28 fractions
223447073|NCT04697719|DRUG|Aspirin 81mg|81mg oral capsule
223447074|NCT04697719|DRUG|Aspirin 325mg|325mg oral capsule
223447075|NCT04721353|DRUG|Prazosin Hydrochloride|prazosin hydrochloride oral 1-25 mg/day
223447076|NCT02476916|DRUG|AG-348|Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
223447077|NCT06087185|BEHAVIORAL|Mindful Eating|Mindful Eating practices will be taught during a weekly meeting lasting 150 minutes and individuals will be encouraged to integrate the practices learned into their daily lives, for at least 15 minutes a day, being progressively integrated into the other practices that will be taught in subsequent weeks. There will be a WhatsApp group with reminders during the week and audio for guided practice.
223447078|NCT06087185|BEHAVIORAL|Video Group|"Composed of 5 videos sent weekly produced by trained professionals. The topics discussed will be relevant to the management of anxiety in general and lifestyle changes.~Video 1: Psychoeducation of anxiety. Video 2: Healthy eating. Video 3: Sleep hygiene. Video 4: Physical activity. Video 5: Substance use. This protocol used as a control was effective as a Psychoeducation Group in improving anxiety symptoms in patients with generalized anxiety disorder."
223447079|NCT05090384|DRUG|Prednisone|Prednisone starting dose of 0.5 mg/kg; for patients who respond clinically and continue to have low biomarkers will be tapered rapidly; those that are not clinically responding or whose biomarkers increase will be treated per their treating physicians plan or by standard of care
223447080|NCT06961643|DRUG|HRS-7535 Tables|Oral HRS-7535 tables.
223447081|NCT05923359|OTHER|Apple Watch|Apple Watch
223447082|NCT00201318|DRUG|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
223447083|NCT05542277|DEVICE|ClearPlasma|ClearPlasma ClearPlasma™ is an extra-corporeal plasma filtration device, designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma™ is a non-pyrogenic, sterile, single-use medical device
223447084|NCT05355311|DRUG|L-carnitine|L-carnitine is an endogenous precursor of acetylcholine and metabolic intermediate that facilitates the transport of acetyl groups across the mitochondrial membrane and shows promise for treating alcohol use disorder and depression.
223447085|NCT06010732|DRUG|0 ppm F (placebo, negative control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
223447086|NCT06010732|DRUG|1100 ppm F as sodium fluoride (positive control)|• Each subject will use this product during one of the three treatment periods in the crossover study design.
223447087|NCT06010732|DRUG|1100 ppm F as sodium fluoride Test Product|• Each subject will use this product during one of the three treatment periods in the crossover study design.
224300857|NCT01258712|DRUG|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
224300858|NCT01258712|DRUG|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
223447088|NCT06556069|OTHER|Peer-Support Enhanced Agitation Code Team (PACT)|"PACT will address systems challenges experienced by staff, safety threats to ED patients with mental illness and substance use disorders, and known structural biases against marginalized individuals during decisions in use of restraints for behavioral crises in the ED.~The PACT intervention includes a peer support service component to deliver patient-centered, trauma-informed, culturally sensitive care to patients presenting with behavioral complaints in the ED and experiencing distress."
224055757|NCT06694402|OTHER|exercise|The control group will receive 30-minute exercise without focal muslce vibration.
224300859|NCT00037024|PROCEDURE|fatigue assessment and management|
223447089|NCT04752306|OTHER|Interviews|Semi-structured interviews will take place between June and August 2020. Eight individual interviews with healthcare workers, ten individual interviews with residents and two individual interviews with policymakers. Interviews with the healthcare workers and policymakers will take place in a meeting room at the nursing home of employment. One interview with a policymaker will take place online. Interviews with residents will be hold in their personal room.
223447090|NCT04401202|DIETARY_SUPPLEMENT|Nigella sativa oil|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
223741610|NCT05241522|DIAGNOSTIC_TEST|Tc-99m-Tilmanocept|Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
223741611|NCT00503087|PROCEDURE|Saline Injection|
224300860|NCT00037024|PROCEDURE|nutritional support|
224300861|NCT00037024|PROCEDURE|physical therapy|
224300862|NCT00037024|PROCEDURE|psychosocial assessment and care|
223447091|NCT05160298|DRUG|Ropivacaine 0,2% Injectable Solution|Echo-guided bilateral erector spinae block
223447092|NCT05160298|OTHER|Control group|Sham block
223447093|NCT03491397|DEVICE|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
223447094|NCT00561535|DIETARY_SUPPLEMENT|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
223447095|NCT00561535|DIETARY_SUPPLEMENT|placebo (starch)|Once daily
223447096|NCT02233621|OTHER|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with \[18F\]FES before coelioscopy
223447097|NCT05223166|DRUG|Pitolisant|Wakix tablet
223447098|NCT05223166|DRUG|Placebo oral tablet|Matching placebo tablets will be provided for each strength of active pitolisant film-coated tablets.
223447099|NCT05396859|DRUG|Decitabine and Cedazuridine|Given PO
223447100|NCT05396859|DRUG|Entrectinib|Given PO
223447101|NCT05396859|OTHER|Laboratory Biomarker Analysis|Correlative studies
223447102|NCT06564649|DIAGNOSTIC_TEST|CXCL10 Monitoring at clinical frequency|The intervention is the implementation of real-time, serial urinary CXCL10 monitoring, with protocolized further clinical responses in the setting of elevated urinary CXCL10 levels.
223447103|NCT06551298|OTHER|Menggongzi Tibetan Tea Special Drink|Menggongzi Tibetan Tea Special Drink (50ml/time, taken after breakfast and lunch)+Low fat diet
223447104|NCT06551298|DRUG|Atorvastatin Calcium 20Mg Tab|Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
223741612|NCT00503087|DEVICE|Pneumatic Skin Flattening (PSF)|
223741613|NCT05163028|DRUG|HBI-2376|SHP2 Inhibitor
223741614|NCT05737940|DRUG|AZD3427|The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
223741615|NCT05737940|DRUG|Placebo|The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
223741616|NCT05747092|PROCEDURE|gingival graft|"investigators:~Donor site:~* tissue graft harvesting from the palate behind the palatal rugae .~* placement of a palatine hemostatic plaque on the palate in order to reduce the risk of bleeding and to diminish the postoperative pain.~Received site:~* Control: the horizontal incision adjacent to the recession(s) and vertical incisions and split thickness flap. Placement of the graft on the recipient bed and suture.~* Test :connective tissue graft using the  envelope/pouch  technique with two partial thickness incisions (deep and superficial). Placement of the graft inside the envelope"
223741617|NCT04053023|DRUG|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
224300863|NCT00037024|PROCEDURE|quality-of-life assessment|
224300864|NCT06102681|OTHER|intervention group|we will measure, consider and compare patients pain level, quality of life and recovery process. For these aims we will use numeric pain scale, nottingham health profile and postoperative recovery index.
224300865|NCT01859130|DEVICE|Zimmer Persona Total Knee System|
224300866|NCT02960061|DRUG|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
224300867|NCT02960061|PROCEDURE|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
224300868|NCT02960061|DRUG|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
224300869|NCT02960061|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
224300870|NCT04304365|OTHER|Follow-up clinic visit|Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.
223447105|NCT06551298|OTHER|Low fat diet|Low fat diet
223447106|NCT03696199|DRUG|Long-Acting Local Anesthesia|"The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
223447107|NCT03696199|DRUG|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
223447108|NCT05180799|BIOLOGICAL|BA3071|Conditionally active biologic (CAB) antibody that binds to CTLA-4
223447109|NCT05180799|BIOLOGICAL|Nivolumab|Humanized, immunoglobulin G4 (IgG4)-variant mAb against PD-1
223447110|NCT05180799|BIOLOGICAL|Pembrolizumab|Humanized antibody, immunoglobulin G4, with a variable region against the human PD-1 receptor
223447111|NCT05180799|DRUG|Pemetrexed (Alimta)|pemetrexed with either cisplatin or carboplatin
223447112|NCT05353660|OTHER|No intervention|No intervention
223447113|NCT00913302|BEHAVIORAL|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
223447114|NCT01080859|DEVICE|OCT|Optical coherence tomography
223447115|NCT01080859|DEVICE|OCT|Optical coherence tomography
223447116|NCT03141034|DRUG|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
223447117|NCT03141034|DRUG|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
223447118|NCT03141034|GENETIC|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
223447119|NCT03141034|GENETIC|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
223447120|NCT03590223|PROCEDURE|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
223447121|NCT02546596|DEVICE|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
223447122|NCT06046131|OTHER|Standard care|"Extra blood collection for dosages Urine collection for the dosage of non-persistent pollutants, isolation of extracellular vesicles released in urine, analysis of the microbiome, metagenomics to obtain a complete description of the bacterial functions represented as well as other microorganisms present, metabolome profiling and identification and/or assays of any other biological compound of interest strictly related to the specific objectives of the research.~Saliva collection for the extraction of the constitutional DNA. An interview using a structured questionnaire A quality of live auto-questionnaire"
223447123|NCT00329745|BIOLOGICAL|Rotarix™|Oral administration, 2 doses
223447124|NCT00329745|BIOLOGICAL|Placebo|Oral administration, 2 doses
223447125|NCT02486172|BEHAVIORAL|Peer support program|Peer support program as an additional service to the routine clinical service
223568596|NCT06437886|OTHER|opioid-sparing protocol|Patients in the OSA group was administrated with 0.5 to 1 mcg·kg-1 sufentanil and received PIFB combined with RSB after anesthetic induction. Patients in the control group were recommended to receive 2 to 3 mcg·kg-1 opioid-based sufentanil. PIFB was conducted at the T2 to T5 levels under ultrasound guidance. Each side received 20 ml 0.3% ropivacaine containing 2.5 mg dexamethasone. Bilateral RSB was conducted after the PIFB and the needle was inserted into the plane between the rectus abdominal muscle and its posterior sheath using an in-plane approach. After verifying needle placement, 15 ml 0.3% ropivacaine containing 2.5 mg dexamethasone was delivered to each side. In the control group, patients received no procedure and were administrated with traditional anesthetic protocol. Patients received continuous intravenous sufentanil (50 to 100 mg) and tropisetron (5 to 10 mg) at 2 ml·h-1 for the first 48 hours after surgery.
223568597|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
223568598|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
223568599|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
224300871|NCT04304365|OTHER|Text message|Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.
224300872|NCT04304365|OTHER|Low Sensitivity Pregnancy Test (LSPT)|Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
224300873|NCT00322504|PROCEDURE|Accupuncture|
223447126|NCT01597492|BIOLOGICAL|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
223447127|NCT01597492|BIOLOGICAL|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
223447128|NCT03961516|DEVICE|Frequently Sampled Oral Glucose Tolerance Test and CGM|Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.
223447129|NCT03961516|RADIATION|MRI Pancreas and Liver|Patients will undergo an MRI of the pancreas and liver
223447130|NCT00647595|BEHAVIORAL|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
223447131|NCT00178646|DRUG|Botox|Botox 75-150 units, single treatment only
223568600|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
223568601|NCT00979368|DRUG|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
223568602|NCT00979368|DRUG|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
223568603|NCT05093543|BEHAVIORAL|physical rehabilitation/physiotherapy and psychosocial group sessions|physical rehabilitation/physiotherapy and psychosocial group sessions
223568604|NCT04580277|DRUG|Tofacitinib 10 mg|Subjects in this arm will receive tofactinib 10 mg twice daily for 8 weeks
223568605|NCT02978105|OTHER|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
223447132|NCT04269720|BEHAVIORAL|Biofeedback|They will also be taught how to use the biofeedback app and Inner Balance device. Additionally, they will also be educated on the principles of biofeedback and its benefits and taught how to maximize HRV by using self-regulation breathing techniques, guided imagery, and/ or self-talk.They will be given an Inner Balance device, which is an ear sensor that connects to an apple device that measures heart rate variability (HRV) and gives them access to an app that is designed to help them improve their HRV. They will be asked to use this device daily for 10 mins for the duration of the 8-week intervention. Patients and the research coordinator will have access to all of their sessions and results. The research coordinator will monitor compliance via the Heartcloud associated with their device and encourage adherence throughout the 8-week biofeedback intervention.
223447133|NCT03675893|DRUG|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
223447134|NCT03675893|DRUG|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
223447135|NCT03675893|DRUG|LY3023414|LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
223447136|NCT03675893|DRUG|Metformin|Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.
223447137|NCT03675893|DRUG|Zotatifin|Zotatifin is a selective eukaryotic initiation factor 4A (eIF4A) inhibitor.
223447138|NCT03675893|DRUG|Gedatolisib|Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.
223447139|NCT03564093|DRUG|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
223447140|NCT03564093|DRUG|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
223447141|NCT01633970|DRUG|5-FU|Participants will receive 5-FU 400 mg/m\^2 IV q2w.
223447142|NCT01633970|DRUG|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
223447143|NCT01633970|DRUG|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
223447144|NCT01633970|DRUG|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
223447145|NCT01633970|DRUG|Leucovorin|Participants will receive leucovorin 400 mg/m\^2 IV q2w.
223447146|NCT01633970|DRUG|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m\^2 IV qw.
223447147|NCT01633970|DRUG|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m\^2 IV q2w.
223447148|NCT01633970|DRUG|Paclitaxel|Participants will receive paclitaxel 200 mg/m\^2 IV q3w.
223447149|NCT01633970|DRUG|Pemetrexed|Participants will receive pemetrexed 500 mg/m\^2 IV q3w.
223447150|NCT02148315|BEHAVIORAL|garden|
223447151|NCT02288481|DRUG|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
223447152|NCT02288481|OTHER|Placebo|Placebo Suspension
223447153|NCT00332774|DRUG|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
223447154|NCT00332774|DRUG|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
223447155|NCT00332774|OTHER|Nepafenac ophthalmic suspension vehicle|
223447156|NCT04897035|DEVICE|Dayspring Active Wearable Compression System|Dayspring Active Wearable Compression System
223447157|NCT01939223|DRUG|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
223447158|NCT01939223|DRUG|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
223447159|NCT03232268|BIOLOGICAL|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
223447160|NCT01729858|DEVICE|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
223447161|NCT01729858|DEVICE|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
223568606|NCT02978105|OTHER|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
223568607|NCT06198101|OTHER|Myofascial Release Technique|The treatment will be applied by the therapist standing at the side of the patient with different levels according to subject's tolerance for duration of 3 minutes in each sitting. Level one will be performed by longitudinal movements without causing any tension to the tissues. The level two will be performed by longitudinal movements with light pressure to the tensed muscle. The level three will be performed by compressing the treatment area then passively fullest possible range of motion will be performed and then longitudinal movement will be done with same compression. In level four, the patient will actively move the tissue through the fullest possible range of motion. The taut band will palpate and then firm pressure will be maintained and then longitudinal movements will be performed. Treatment will be applied for two intervention sessions per week and a total of 12 sessions over 6 weeks.
223568608|NCT06198101|OTHER|Myofascial Release Technique along with segmental vibrator|this group will receive vibratory stimulations through segmental vibrator along the muscle fibers of upper limb flexors, extensors, and wrist flexors for 10-minutes each session with low amplitude (0.3-0.5 mm peak to peak) at fixed frequency of 150 Hz(23). Along with segmental vibrator group B will also receive myofascial release technique through the same method to the upper limb flexors, extensors, and wrist flexors. Group B will receive both treatments for two intervention sessions per week and a total of 12 sessions over 6 weeks.
223568609|NCT04377802|DIAGNOSTIC_TEST|molecular testing for virus RNA using RT-PCR|Serological testing will be performed using SARS-CoV-2 IgG assay kit (Abbott Diagnostics, US) to check for the immunity. The IgG serology test (200 individuals per run) will be done using ARCHITECT i2000SR system which provides the results within 60 minutes
223568610|NCT04326036|PROCEDURE|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content
223447162|NCT05987059|BEHAVIORAL|SBIRT Intervention|"Project IMPACT intervention will follow a Screening, Brief Intervention, and Referral to Treatment (SBIRT) Model. In the proposed study, staff at community sites will deliver a tailored SBIRT model for people seeking to get pregnant as our Project IMPACT intervention. SBIRT was originally developed as a public health model designed to provide universal screening, secondary prevention (detecting risky or hazardous substance use before the onset of abuse or dependence), early intervention, and treatment for people who have problematic or hazardous alcohol problems within primary care and other health care settings. Morehouse School of Medicine (MSM) has adapted this SBIRT model for people who are seeking to get pregnant to assess their risks and provide early intervention to at-risk people of reproductive age who want to get pregnant. Brief preconception counseling interventions addressing multiple behavioral risk factors have been found to be effective in prior studies."
223447163|NCT06349811|DRUG|BL-M05D1|Administration by intravenous infusion for a cycle of 3 weeks.
223447164|NCT05041075|DEVICE|Weighted Blanket|Weighted blankets provide Deep Pressure Stimulation (DPS) or Deep Touch Pressure (DTP) which has advantages in both physical and psychological domains.
223447165|NCT04786678|DEVICE|Cell phone notification|Habitual bed and wake times will be detected using a wearable for 4 weeks. Using habitual wake time, a minimum bedtime to achieve adequate sleep will be calculated (8 hours). If phone usage is detected after this minimum bedtime, participants will receive a notification informing them they are awake past their minimum bedtime and recommend they go to bed to obtain adequate sleep.
223447166|NCT05977881|OTHER|CHECKIT!|"Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months."
224164071|NCT01190020|DRUG|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
223741618|NCT04053023|DRUG|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
223447168|NCT06634108|DRUG|Genistein|The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
223447169|NCT06484699|PROCEDURE|open repair of perforated peptic ulcer|group (A) includes patients with perforated peptic ulcer that will be operated by open repair approach
223447170|NCT06484699|PROCEDURE|laparoscopic repair of perforated peptic ulcer|group (B) includes patients with perforated peptic ulcer that will be operated by laparoscopic repair approach
223447171|NCT06206954|BEHAVIORAL|MyHealthPath Tool|Tailored, brief online tool to help patients learn about weight treatment options
223447172|NCT06206954|BEHAVIORAL|MyHealthPath Guide|Informational material to help patients learn about weight treatment options
223447173|NCT03624569|OTHER|Bagel|A bagel will be consumed daily for 2 weeks.
223447174|NCT03624569|OTHER|Potato|A potato will be consumed daily for 2 weeks.
223447175|NCT04838457|BEHAVIORAL|Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM)|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
223447176|NCT03965429|OTHER|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
223447177|NCT03965429|OTHER|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
223741619|NCT06561958|DRUG|REKOVELLE|Individualised dosing regiment of REKOVELLE in routine clinical practice.
223741620|NCT02972489|DEVICE|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
223741621|NCT02972489|DEVICE|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
223741622|NCT05996874|DRUG|Semaglutide|Participants will receive Dose 1 oral semaglutide D for the first 5 days followed by Dose 2 of oral semaglutide D for another 5 days.
223741623|NCT03948256|PROCEDURE|Control intervention|Prompt closure of EVD with subsequent observation period
223447178|NCT04577859|DEVICE|ensoETM. Esophageal cooling during AF ablation|Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.
223447179|NCT04577859|DEVICE|Esophageal temperature monitoring probe|An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches \>38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
223447180|NCT02247297|PROCEDURE|Blood collection|Diagnostic blood collection
223447181|NCT03911947|DEVICE|Vibrolung|Device for vibroacoustic respiratory therapy
223447182|NCT01557517|DRUG|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
223447183|NCT01557517|DRUG|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
223447184|NCT05286060|DRUG|GX-188E, GX-I7, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 1200㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
223447185|NCT05286060|DRUG|GX-188E, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
223447186|NCT05286060|DRUG|GX-188E, GX-I7, Pembrolizumab|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa Drug 3: Pembrolizumab pembrolizumab 200mg (100mg/4mL/vial), Intravenous administration Other Name: Keytruda®
223447187|NCT05286060|DRUG|GX-188E, GX-I7|Drug 1: GX-188E GX-188E, 2mg (1.0mg/0.5ml/vial), Intramuscular administration using electroporator Other Name: Tirvalimogene teraplasmid Drug 2: GX-I7 GX-I7 360㎍/kg, intramuscular administration Other Name: NT-I7, rhIL-7-hyFc, efineptakin alfa
223447188|NCT02826577|DRUG|Pregnenolone 175mg|Single Dose 175mg
223447189|NCT02826577|DRUG|Pregnenolone 400mg|Single Dose 400mg
223447190|NCT02826577|DRUG|Placebo|Single Dose
224055758|NCT06728904|BEHAVIORAL|Tai Chi intervention|40-90 minutes per session, 3-5 sessions per week. 6. Each practice mainly includes basic theoretical knowledge, warm-up exercises, standing exercises, Chen style Tai Chi, and relaxation techniques. This study expects to divide the Tai Chi intervention program into three stages: the first stage is the introductory learning of simple high-intensity Chen style Tai Chi, the second stage is the combination of strength training and Chen style Tai Chi courses, and the third stage uses optional high-intensity competitive Chen style Tai Chi or Tai Chi Sword as advanced content to consolidate learning outcomes, such as the 32 style Tai Chi Sword (HR of about 120 times/minute). The intervention plan will be combined with high-intensity interval training (HIIT) to adapt Chen style Tai Chi.
223447191|NCT04081831|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
223447192|NCT04072731|OTHER|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
223447193|NCT03561545|OTHER|weightlessness (parabolic flight)|weightlessness (parabolic flight)
223447194|NCT06187272|BEHAVIORAL|Listening to music|Students listened to background music during a practical examination of 60 bpm.
223447195|NCT04733222|OTHER|Perturbation training|"The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order)."
224164072|NCT06887803|DRUG|Roginolisib|IOA-244: 80 mg (corresponding to 72 mg roginolisib) Ruxolitinib: up to 25 mg BD
223447196|NCT04733222|OTHER|Treadmill walking|Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
223447197|NCT02053259|BEHAVIORAL|Adaptive Goals|
223447198|NCT02053259|BEHAVIORAL|Reinforcement|
223447199|NCT02053259|BEHAVIORAL|Static Goals|
223447200|NCT03850405|DIETARY_SUPPLEMENT|Dark Chocolate|20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
223447201|NCT00591019|DRUG|Modafinil|200 mg/day, morning dose
223447202|NCT00591019|OTHER|Placebo|Sugar pill once per day in the morning.
223447203|NCT02400203|OTHER|Control|
223447204|NCT02400203|OTHER|Hemp foods|
223447205|NCT00441948|DEVICE|Peterio|
223568611|NCT04326036|DEVICE|Centricyte 1000|Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol
223568612|NCT04326036|PROCEDURE|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration
223568613|NCT04326036|DRUG|Liberase Enzyme (Roche)|Sterile Collagenase Blend to separate cSVF from the AD-SVF
223741624|NCT03948256|PROCEDURE|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
224055759|NCT06735404|OTHER|Hybrid care|"The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:~* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant~* Teleconsultation: patients communicate with their healthcare provider(s) remotely~* Personal health portals and self-management applications~* Online prescription requests: patients request prescription online"
224146214|NCT05587634|BEHAVIORAL|Virtual Peer Health Coaching|"Intervention arm: weekly sessions (\~30 min each session) of physical activity counseling with an assigned peer health coach over the course of 12 weeks. The focus of the initial 2 calls is on rapport development and trust building with a focus around PA with discussion of physical activity goals and motives, where possible. The remainder of the call sessions follow a standardized format of a 30-minute call to 1) review the previous week, 2) integrate motivational strategies, and 3) develop action and support plans for the next week. The final call format includes a summary and evaluation of the intervention, discussion of short- and long-term goals, and relapse prevention strategies. Sessions guided by a call tracking form.~These participants receive an adaptive physical activity local guide including information on local adaptive sports opportunities, which the control group also receives."
224146215|NCT02593968|DRUG|Recombinant Human Interferon a-2b Gel|
224146216|NCT02593968|DRUG|Placebo|
224146217|NCT00086736|DRUG|bicalutamide|
224146218|NCT00086736|DRUG|eflornithine|
224146219|NCT00086736|DRUG|oral eflornithine placebo|
224146220|NCT00086736|DRUG|oral bicalutamide placebo|
224146221|NCT03797508|DIAGNOSTIC_TEST|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
224146222|NCT03601793|BEHAVIORAL|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
224146223|NCT03601793|BEHAVIORAL|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
224146224|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
224146225|NCT02171819|BIOLOGICAL|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
224146226|NCT02171819|OTHER|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
224146227|NCT03801811|PROCEDURE|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
224146228|NCT03590704|DEVICE|Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
224146229|NCT00903253|DRUG|LNK-754|
224146230|NCT03086317|DEVICE|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
224146231|NCT03086317|DEVICE|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
224146232|NCT05699317|OTHER|Thermal stimuli|"Thermal stimuli will be delivered delivered using a contact thermal stimulator (TCS model II.1, QST.Lab, Strasbourg, France).~Target temperatures will be set to reach 10°C (CEP) and 60°C (CHEP) at a rate of 300°C/s.~Stimulus duration will be set 200 ms. The stimulator will be manually held against the skin by the experimenter and slightly displaced within the first 10 cm of the distal extremity of the volar forearm being investigated, marked on the skin of the participant, after each stimulus. A total of 30 stimuli per temperature and testing site will be applied."
224146233|NCT00945802|DRUG|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
224146234|NCT00945802|DRUG|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
224146235|NCT03001843|DRUG|Ketamine|Anesthesia of only Ketamine
223741625|NCT01899794|PROCEDURE|TVT-O/Oxytrol|
223741626|NCT01899794|DEVICE|TVT-O|
223741627|NCT01899794|DRUG|Oxytrol|
223741628|NCT02386904|DRUG|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
223741629|NCT00071760|DRUG|GW433908|Fosamprenavir suspension bid
223447206|NCT06201208|BEHAVIORAL|The ST-Facilitation Psychoeducation Program|"One of the important roles of the psychiatric nurse, who helps healthy/sick individuals and their families to improve their mental health, prevent and cope with diseases, is their educational role. The psychiatric nurse determines the psychosocial care needs of the patient and his family and plans, implements and evaluates psychoeducational interventions, which are an evidence-based practice, to meet these needs.~Psychiatric nurses can benefit from existing programs when developing a psychoeducation program, or they can be advised to create programs that include educational and psychosocial goals based on theory specific to the problems of the relevant population. The theoretical basis is of great importance when planning a psychoeducation program. In this study, the psychoeducation program was based on the Self-Transcendence Theory of Pamela G. Reed, a psychiatric nurse."
224300874|NCT03829696|DRUG|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
224300875|NCT03829696|DRUG|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
224300876|NCT03829696|DRUG|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
224300877|NCT03829696|DIAGNOSTIC_TEST|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
224300878|NCT02733315|BEHAVIORAL|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
224300879|NCT01867944|BEHAVIORAL|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
224300880|NCT01867944|BEHAVIORAL|Educational Control|Education on conventional treatment options for chronic constipation.
224300881|NCT01983917|BEHAVIORAL|Diabetes Mobile Application|
224300882|NCT03792724|DRUG|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
224300883|NCT00470457|BIOLOGICAL|Allergen specific immunotherapy|
224300884|NCT01076686|DRUG|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
224300885|NCT01527617|OTHER|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
224300886|NCT01527617|OTHER|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
224300887|NCT04442490|DRUG|SAGE-217|SAGE-217 oral capsules.
223447207|NCT01454219|OTHER|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
223447208|NCT03301935|PROCEDURE|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
223447209|NCT04708496|DRUG|Artemether-lumefantrine|"A three-arm single blind Randomized Clinical Trial in which HIV-malaria co-infected individuals with uncomplicated malaria receiving efavirenz-based ART will be randomized to one of three arms; a standard dose of artemether-lumefantrine, or a double dose of artemether-lumefantrine, or a 5-day course of artemether-lumefantrine for treatment of uncomplicated malaria. Participants will be followed up for 42 days to determine safety, drug pharmacokinetics and malaria treatment outcomes.~The 4th objective focuses on the interaction between Dolutegravir and Artemether Lumefantrine hence this will be a single blind pharmacokinetic trial among HIV-malaria co-infected individuals receiving Dolutegravir based ART and standard dose of artemether-lumefantrine for treatment of uncomplicated malaria."
223568614|NCT04326036|DRUG|Sterile Normal Saline for Intravenous Use|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter
223741630|NCT00071760|DRUG|ritonavir|Ritonavir solution bid
224300888|NCT04442490|DRUG|Placebo|SAGE-217 matched-placebo oral capsules.
224300889|NCT02227147|DRUG|rhNGF 20µg/ml|
224300890|NCT02227147|OTHER|Placebo|Formulation containing antioxidant
224300891|NCT03514641|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
224300892|NCT03514641|DRUG|Placebo|Placebo (inactive) tablet to match the active drug
224300893|NCT01216696|DRUG|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
224300894|NCT01449279|DRUG|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
223447210|NCT03102008|BEHAVIORAL|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
223447211|NCT00005896|DRUG|filgrastim|
223447212|NCT00005896|GENETIC|Autologous stem cells transduced with FACC retroviral vector|
223447213|NCT00005896|PROCEDURE|Autologous Stem Cell Transplantation|
223447214|NCT05881122|BEHAVIORAL|Mad Dog Dietary Consultation|The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
223447215|NCT05388084|BEHAVIORAL|Male peer engagement|Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.
223447216|NCT05388084|BEHAVIORAL|SOC and delayed intervention|Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
223447217|NCT01259674|DEVICE|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
223447218|NCT01259674|OTHER|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
223447219|NCT03132974|DRUG|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
223447220|NCT03132974|OTHER|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
223447221|NCT03132974|OTHER|Placebo with manipulation procedure|Placebo granule with manipulation procedure
223447222|NCT06257160|PROCEDURE|Surgical infiltration|"During surgery, local anesthetics are injected as follow: in the deep plane and in the subcutaneous territory.~Infiltration of the deep plane corresponds to pericotyloid injection, with particular attention to the posterior subcapsular area, the obturator foramen and the psoas muscle. Infiltration of the muscular planes is added, with infiltration of the gluteal and pelvitrochanteric muscles."
223447223|NCT06257160|PROCEDURE|PENG Block ultrasound-guided|"We perform the femoral block under ultrasound after anesthesia (general or rachianesthesia). The PENG block is a peripheral diffusion nerve block that specifically targets the articular divisions of the femoral, obturator and accessory obturator nerves.~The femoral nerve innervates the four parts of the joint capsule, with inconsistency in the anterior inferomedial part of the capsule.~The obturator nerve innervates the inferior part of the anterior face of the capsule.~The accessory obturator nerve innervates the medial half of the hip joint capsule in over 50% of cases."
223447224|NCT00489294|DRUG|Syntropin|
223447225|NCT00528073|DRUG|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
224055760|NCT05114876|OTHER|Multicomponent delirium-risk prevention bundle|"This multidisciplinary intervention will introduce new practices including:~1. Direct-to-Patient Education Program~2. Directly informing anesthesia and surgery teams about high-risk patients by flagging their chart, and providing suggestions for POD mitigation~3. Flag charts as high risk for POD so that nursing staff in both the PACU and the wards are aware, facilitating implementation of CHASM interventions (i.e. evidence-based delirium prevention protocols).~4. Reinforce CHASM best practices with regular educational sessions for nurses."
223741631|NCT04144556|OTHER|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
223741632|NCT04144556|OTHER|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
224055761|NCT07161180|DRUG|PBK_M2301 (levodropropizine + Pelargonium sidoides extract)|A single oral tablet containing levodropropizine 60 mg and Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
224055762|NCT07161180|DRUG|R1_PBK_M2301 (levodropropizine)|A single oral tablet containing levodropropizine 60 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
224146236|NCT03001843|DRUG|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
224146237|NCT03001843|BEHAVIORAL|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
224146238|NCT00212303|BEHAVIORAL|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
224146239|NCT05233982|DRUG|Olaparib Oral Product|Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
223447226|NCT04885790|OTHER|"Respiratory assessment using Spiropalm 6MWT portable spirometry"|"Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry."
223447227|NCT04885790|OTHER|Evaluation of functional exercise capacity|Functional exercise capacity of patients will be evaluated using six-minute walk test.
223447228|NCT04885790|OTHER|Evaluation of peripheral muscle strength|Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.
223447229|NCT04885790|OTHER|Evaluation of chronic cough|The Leicester Cough Questionnaire will be used for evaluating cough.
223447230|NCT01111682|DRUG|Mannitol|0.9% normal saline infusion and boluses of mannitol
223447231|NCT01111682|DRUG|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
223447232|NCT04365673|OTHER|Pharmacist transition of care consultation|Pharmacist-delivered comprehensive medication review
223447233|NCT01404897|OTHER|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
223447234|NCT01404897|OTHER|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
223447235|NCT01404897|OTHER|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
223447236|NCT05057858|DRUG|co-formulated 300 mg TDF/ 200mg FTC|Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
223447237|NCT06217445|DEVICE|high intensity focused ultrasound|High-intensity focused ultrasound (HIFU) therapy is becoming more familiar in medical field because it is non-invasive technique with fewer side effects and provides promising therapeutic results. Several HIFU therapy applications have approved by many approval authorities of deferent countries since last decade
223447238|NCT06217445|OTHER|Doubled chin exercises|1\. Straight jaw jut. 2-ball exercise. 3-Pucker up 4. Tongue stretch 5. Neck stretch 6-bottom jaw jut.
223447239|NCT01204918|DRUG|Riluzole|Riluzole 100mg PO
223447240|NCT01204918|DRUG|placebo|placebo
223447241|NCT02683408|OTHER|placebo|inactive placebo
223447242|NCT02683408|DIETARY_SUPPLEMENT|diosmiplex|diosmiplex is an FDA regulated medical food product
223447243|NCT00004500|DRUG|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
223447244|NCT00004500|OTHER|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
223447245|NCT02976402|RADIATION|SBRT|"Postoperative RT consisting in:~* 31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~* 32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
223447246|NCT05463939|DRUG|Teclistamab|Teclistamab will be administered subcutaneously (SC).
223447247|NCT05903313|DRUG|Chang Gung ECG Abnormality Detection Software|This device is expected to be used for the static 12-lead ECG to detect whether there are abnormal ECG signals related to diseases and outputs the results.
223447248|NCT06972875|DRUG|Fezolinetant|Participants will receive fezolinetant for 28 days at FDA approved dosing and schedule of 45 mg po (per os/by mouth) once daily for treatment of hot flashes in menopausal women.
223447249|NCT06416969|DRUG|Somatostatin|Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
223447250|NCT06416969|DRUG|Epinephrine|Intravenous infusion
223447251|NCT01859962|DRUG|PPI-668|
223447252|NCT01859962|DRUG|BI 207127 Dose 1|
223447253|NCT01859962|DRUG|BI 207127 Dose 2|
223741633|NCT05568147|DRUG|Aspirin tablet|When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
223741634|NCT05568147|DRUG|Placebo|When patients are randomized into the placebo group, they will receive placebo orally once a day.
223741635|NCT05052385|DRUG|Ruxolitinib|As per treating physician's decision - non interventional study
223741636|NCT05052385|DEVICE|Extracorporeal photopheresis|As per treating physician's decision - non interventional study
224146240|NCT00790101|DRUG|Risedronate|
223447254|NCT01859962|DRUG|Faldaprevir|
223447255|NCT01859962|DRUG|Ribavirin|
223447256|NCT01859962|DRUG|BI 207127 Placebo|
223447257|NCT01420042|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
223447258|NCT01420042|DRUG|Placebo|Lemon flavoured cordial and Water for Injection
223447259|NCT00212316|DRUG|sodium phenylbutyrate|
223447260|NCT02109016|DRUG|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
223447261|NCT01853696|DRUG|loteprednol etabonate|
223447262|NCT01853696|DRUG|prednisolone acetate 1%|
223741637|NCT05052385|DRUG|Ibrutinib|As per treating physician's decision - non interventional study
224146241|NCT00790101|DRUG|Raloxifene|
224146242|NCT00790101|OTHER|Placebo|
224146243|NCT02263495|DRUG|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
224146244|NCT02263495|DRUG|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
224146245|NCT02263495|DRUG|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
224146246|NCT02898519|OTHER|cohort|Blood sampling
223447263|NCT04645134|BEHAVIORAL|Brain Health Assessments|The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
223447264|NCT05442541|BEHAVIORAL|not included any interventions(Evaluation of menstrual well-being in women of reproductive age, field survey study)|This is a prospective cross-sectional analytical study conducted through a questionnaire.
223447265|NCT00309790|DRUG|sildenafil|
223447266|NCT03570008|BEHAVIORAL|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
223447267|NCT03570008|BEHAVIORAL|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~* Sp-Ex: spa residential program including physical activity~* Sp-alone: spa residential program alone~* Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
223447268|NCT03266575|BEHAVIORAL|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
223447269|NCT03266575|BEHAVIORAL|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
223447270|NCT03152994|OTHER|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
223447271|NCT01238094|DRUG|Simvastatin|simvastatin 40 mg qd daily until disease progression
223447272|NCT02798120|DRUG|SB204 4%|Open label, topical SB204 4%
223447273|NCT04519762|DRUG|Glycophos (Sodium Glycerophosphate)|Management of hypophosphatemia via Glycophos Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
223447274|NCT04519762|DRUG|Antibiotics|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
223447275|NCT04519762|DRUG|Inotropes|Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
223447276|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
224055763|NCT07161180|DRUG|R2_PBK_M2301 (Pelargonium sidoides extract)|A single oral tablet containing Pelargonium sidoides extract (11% ethanol dried extract, 5.5\~6.6→1) 20 mg. Administered after at least 10 hours of fasting with 150 mL of water at room temperature.
224055764|NCT07161336|DRUG|Methotrexate (MTX)|One group will receive MTX, starting with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated. another group will receive placebo
224055765|NCT07161336|DRUG|Placebo|The investigational drug and the placebo will be formulated to be identical in appearance, packaging, labeling. Blinded study medications will be prepared, packaged, and labeled by the sponsor according to Good Manufacturing Practice (GMP) standards. All packaging will use neutral labeling with unique subject numbers only.
224055766|NCT07159958|OTHER|Simulation-Based Vulvar Cancer and Self-Vulvar Examination Training|The topics covered include the definition of vulvar cancer, risk factors, symptoms, preventive measures to protect against cancer, the definition of KKVM, and the steps involved in performing an examination. The inspection phase of the examination was demonstrated using a light source and mirror on a simulated model of the external genitalia. In addition, the topic was reiterated by explaining on the model how palpation examination is performed, when it should be performed, what signs and symptoms to look for, and in which cases a doctor should be consulted.
224055767|NCT07157852|DRUG|Mirogabalin|For the mirogabalin group, therapy will begin at 5mg twice daily. If the pain will remain inadequately controlled after one week without significant adverse effects, the dose will be escalated in 5 mg per day increments at weekly intervals, with a maximum allowable dose of 15mg twice daily.
224055768|NCT07157852|DRUG|Pregabalin|For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 600 mg daily.
224055769|NCT07160998|OTHER|Digital Lifestyle Therapeutic|Personalized real-time lifestyle recommendations delivered via smartphone/tablet, integrating CGM and wearable data.
224055770|NCT07160998|BEHAVIORAL|Standard Care|Participants receive standard diabetes management including medications and lifestyle recommendations based on guidelines.
224055771|NCT07146880|DRUG|Empagliflozin (EMPA)|Participants will take Empagliflozin once daily, starting at 10 mg. The dose will be increased to 25 mg at monthly follow-ups if participants are non-responders based on ECG ST-segment morphology. The total treatment period is three months.
224146247|NCT06134713|DRUG|cryotherapy with sterile saline at 2.5ºC|In the cryotherapy (experimental group), final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept refrigerated at 2.5ºC and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
224300895|NCT01449279|RADIATION|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
224300896|NCT05579275|BIOLOGICAL|JCXH-212 Injection|Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
224300897|NCT03934320|OTHER|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
224300898|NCT05991830|PROCEDURE|General anesthesia|Older adults during elective surgery under general anesthesia with propofol, frontal EEG will recorded and a baseline plasma sample will be taken
224300899|NCT02717858|DRUG|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
224300900|NCT02717858|DRUG|placebo|Injected s.c./subcutaneously (under the skin) once daily.
224300901|NCT00283790|DRUG|zolpidem tartrate|
224300902|NCT01055132|DEVICE|Etafilcon A toric contact lens|contact lens to correct astigmatism
224300903|NCT01055132|DEVICE|Nelfilcon A toric contact lens|contact lens to correct astigmatism
224300904|NCT01466452|DRUG|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
224300905|NCT01466452|DRUG|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
224300906|NCT01466452|DRUG|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
224300907|NCT02038907|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
224300908|NCT02038907|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
224300909|NCT00805753|DRUG|ACTH|comparison of different dosages of drug
224300910|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
224300911|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
224300912|NCT01003093|BIOLOGICAL|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
224300913|NCT02067429|PROCEDURE|Limbal Relaxing Incisions|
224300914|NCT02067429|DEVICE|Toric Intraocular Lens|
224300915|NCT04670666|DRUG|MADALENA ASSOCIATION|Madalena association coated tablet.
223447277|NCT01025648|DRUG|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
224300916|NCT04670666|DRUG|METFORMIN|Metformin 1000 mg extended-release tablet.
224300917|NCT04670666|DRUG|EMPAGLIFLOZIN + LINAGLIPTIN|Empagliflozin 10 mg + linagliptin 5 mg coated tablet.
224300918|NCT04670666|OTHER|MADALENA ASSOCIATION PLACEBO|Madalena association placebo tablet.
224300919|NCT04670666|OTHER|METFORMIN PLACEBO|Metformin placebo tablet.
224300920|NCT04670666|OTHER|EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO|Empagliflozin + linagliptin placebo tablet.
224300921|NCT03294486|DRUG|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~* Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~* Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~  5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
223447278|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
223447279|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
224300922|NCT00749736|DIETARY_SUPPLEMENT|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
224300923|NCT00749736|DIETARY_SUPPLEMENT|doxercalciferol|1 mcg of doxercalciferol per day
224300924|NCT00749736|DIETARY_SUPPLEMENT|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
224300925|NCT01219413|DRUG|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
224300926|NCT00523536|BEHAVIORAL|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
224300927|NCT00002679|BIOLOGICAL|filgrastim|
224300928|NCT00002679|DRUG|cyclophosphamide|
224300929|NCT00002679|DRUG|doxorubicin hydrochloride|
224300930|NCT00002679|DRUG|paclitaxel|
224300931|NCT00002679|DRUG|tamoxifen citrate|
224300932|NCT00002679|RADIATION|radiation therapy|
224300933|NCT05237518|DEVICE|EarlySense Noomi system|The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
224300934|NCT03477552|DEVICE|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
224300935|NCT03477552|OTHER|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
224300936|NCT02513511|PROCEDURE|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
224300937|NCT01653561|DRUG|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
224300938|NCT00129051|PROCEDURE|Tomotherapy|
224055772|NCT07165444|DRUG|Potassium-Competitive Acid Blocker|Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.
224055773|NCT07165444|DRUG|Proton Pump Inhibitor|Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.
224055774|NCT07161310|DIETARY_SUPPLEMENT|Urolithin A|Patients will receive urolithin A (UA) 1,000mg QD on from day -7 until day 60 (±7) of first-line ICI-based SACT.
224055775|NCT07161310|DIETARY_SUPPLEMENT|Placebo|Patients will receive placebo (PBO) on from day -7 until day 60 (±7) of first-line ICI-based SACT.
224055776|NCT07161310|OTHER|Bio specimens|Bio specimens (PBMC, plasma, stool) will be collected during screening and on days 1, 26 (±7) and 60 (±7) of ICI.
224055777|NCT07160673|DEVICE|VR-based Respite|Caregivers and homebound older adults will receive 4 weeks of VR-based respite sessions. 4 weeks (1 session/week; 30 min/session) of immersive VR sessions using SilVR Adventures platform. Sessions include virtual travel destinations (e.g., cities, natural wonders) and social activities (e.g., group tours). Facilitated by trained research staff, with 5-10 minutes viewing and 20 minutes reflection/discussion.
224146248|NCT06134713|DRUG|control with sterile saline at room temperature|In the control group, final irrigation will be performed with 5 ml of 0.9% physiological sterile saline kept at room temperature and will be delivered for 1 or 4 minutes with a side vented needle inserted at working length for each canal.
224055778|NCT07160673|DEVICE|Video-based Respite|Caregivers and homebound older adults will receive 4 weeks of video-based respite sessions. 4 weeks (1 session/week; 30 min/session) of non-immersive video sessions with content similar to VR themes (e.g., landscapes, cultural events). Facilitated by trained research staff, with post-video discussion. EEG data collected during viewing to assess emotional states.
224055779|NCT07171281|BEHAVIORAL|Early Time-Restricted Eating|"Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately.~During the early TRE intervention, participants will primarily consume their meals in the morning. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction."
224055780|NCT07171281|BEHAVIORAL|Late Time-Restricted Eating|"Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately.~During the late TRE intervention, participants will primarily consume their meals in the evening. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction."
224055781|NCT07170735|DIAGNOSTIC_TEST|Plasma MTB cfDNA assay|Quantitative measurement of MTB cfDNA level in the plasma
224055782|NCT07170020|PROCEDURE|Hyperbaric Oxygen Therapy|Hyperbaric oxygen has been shown in several case studies and retrospective studies to possibly improve mortality and morbidity in this patient population. One limitation of prior studies is many of them are retrospective. This study will be prospective.
224055783|NCT07170644|DRUG|Nirogacestat oral tablet|Nirogacestat tablet
224055784|NCT07171684|DRUG|Insulin glargine alone|Once daily dosing of insulin glargine
224055785|NCT07171684|DRUG|Insulin glargine + insulin lispro|Once daily dosing of insulin glargine + three times daily dosing of insulin lispro with meals
224146249|NCT00123149|DRUG|Epoetin alfa|
224146250|NCT03870256|DRUG|misoprostol|Patient receive 600mic gm sublingual misoprostol
224146251|NCT03870256|DRUG|Carbetocin|Patient receive 100 mic gm carbetocin IV
224146252|NCT03870256|DRUG|TA|The patient receives 1gm oral tranexamic acid
224146253|NCT03659370|OTHER|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
224146254|NCT03659370|OTHER|Acupuncture|Acupuncture
224146255|NCT04697433|DEVICE|Myotonometry|The examiner should exert a slight pressure on the determined point to the necessary depth, which will be indicated by changing the color from red to green light on the device. The device has an automatically controlled preload (0.18 Newton (N)) that will be applied to the contact area by an automatic mechanical pulse, with a duration of 15 milliseconds (ms) and a constant force of 0.4 N , these oscillations will be registered by an accelerometer next to the measurement mechanism inside the device. For each evaluation, a series of 10 consecutive pulses (multiscan mode) will be used with an interval of one second between each pulse. In each shot, the tone, stiffness, elasticity, relaxation time and creep will be calculated.
224146256|NCT02632500|OTHER|Quality of chest compressions|
224146257|NCT05005988|BEHAVIORAL|Actions for Empowered Maternal Neonatal Care|"The intervention includes three 30-minute face-to-face sessions:~Session 1. Recognizing prematurity and the NICU environment: includes definitions of prematurity, characteristics of premature infants, equipment and dynamics of NICU care. Mothers are encouraged to identify their own and contextual resources that can help empower them.~Session 2. Identifying the care of a premature baby: aspects related to the kangaroo method, feeding, thermoregulation, among others, are presented. Knowledge is presented as an empowerment resource.~Session 3: Preparation for the return home. Aspects related to the discharge process and transition to home are described. Includes information on the transition home, warning signs, emergency situations, physical burden, and recognition of sources of personal and professional support.~Session on admission to the out-of-hospital kangaroo program: presents the dynamics of the kangaroo program, as well as the goals in the new care setting."
224146258|NCT01415856|DEVICE|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
224146259|NCT01415856|DEVICE|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
223741638|NCT03488654|DIAGNOSTIC_TEST|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
224055786|NCT07171593|DIETARY_SUPPLEMENT|HMB|EEN+HMB
224146260|NCT02066194|PROCEDURE|Electroacupuncture|
224146261|NCT05243394|OTHER|Gamified virtual reality treadmill gait training with tDCS|Progressive treadmill gait training in a gamified virtual reality environment with tDCS
224146262|NCT05243394|OTHER|Gamified virtual reality treadmill gait training|Progressive treadmill gait training in a gamified virtual reality environment
224146263|NCT05243394|OTHER|Treadmill gait training|Progressive treadmill gait training
223447280|NCT01025648|DRUG|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
223447281|NCT01025648|DRUG|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
223447282|NCT03062995|OTHER|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
223447283|NCT03062995|OTHER|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
223447284|NCT03761225|DRUG|Masitinib|
223447285|NCT03761225|DRUG|Docetaxel|
223447286|NCT03761225|DRUG|Prednisone|
223447287|NCT03761225|DRUG|Placebo|
224055787|NCT07170228|DIETARY_SUPPLEMENT|Micellar Casein|"Participants consumed 30 g of micellar casein powder dissolved in 300 mL of water.~Supplement timing varied by group:~Post-Exercise Casein Ingestion Group (PECIG): Taken 10-15 minutes after completing the standardized high-intensity resistance training session.~Pre-Sleep Casein Ingestion Group (PSCIG): Taken 30-60 minutes before bedtime on the same day as the training session.~The control group received no supplementation. All supplements were prepared and monitored by the research team to ensure dosage accuracy and participant compliance."
224055788|NCT07170488|BEHAVIORAL|Yoga|The LoveYourBrain (LYB) Yoga program is a six-week, evidence-based, light intensity Yoga and meditation curriculum developed for individuals living with TBI. It is delivered online and synchronously, the program is led by experienced instructors with more than a decade of teaching experience in Yoga. Each weekly session is 75 minutes and combines gentle postures, guided breathing exercises (pranayama), Yoga nidra (deep relaxation), and meditation practices. Before each of the Yoga sessions, participants are e-mailed prerecorded tools that focused on a specific theme for the week (resilience, mindfulness etc.)
224055789|NCT07170488|BEHAVIORAL|Yoga for wait list control|After the active Yoga group received the intervention, the wait list control was then assigned to the intervention.
224055790|NCT07171190|OTHER|Lung Cancer Screening Invitation Intervention|Participants are invited to the NHS Lung Cancer Screening to assess lung cancer risk via letter or text message
224055791|NCT07171190|DIAGNOSTIC_TEST|Abdominal scan intervention|Receiving an abdominal CT scan at the same time as the lung scan.
224055792|NCT07169656|DRUG|ETV,TDF,TAF,TMF|treated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)
224055793|NCT07169656|DRUG|Peginterferon α-2b injection|treated with Peginterferon α-2b injection
224055794|NCT07171060|DEVICE|Laplace TTVR System|Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of severe, symptomatic tricuspid regurgitation
224055795|NCT07170358|RADIATION|Radiation Therapy|Radiotherapy for Head and Neck Cancer Patients
224055796|NCT07171476|PROCEDURE|Guided bone regeneration|traditional guided bone regeneration will be done in which a flap will be raised under local anesthesia, followed by atraumatic extraction of the tooth, after which a 3D guided osteotomy will be done and the implant will be inserted, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing
224055797|NCT07171476|PROCEDURE|bone ring technique|bone ring technique will be applied in which the same procedure as group A will be followed till tooth extraction, after which a trephine bure will be inserted through a 3D guide to prepare the site to receive the bone ring. The osteotomy will be done through the bone ring and the implant will be inserted to fix the implant in place, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing.
224055798|NCT07171476|PROCEDURE|Tent pole technique|tent pole technique will be applied in which the same procedure same as group A will be followed till implant insertion. Two monocortical screws will then be inserted using 3D guide, mesial and distal to the implant and extending 3 mm outside the bone, then covered buccally with autogenous bone graft chips and resorbable membrane before flap suturing.
224055799|NCT07170514|PROCEDURE|EIT-guided PEEP titration|"During the PEEP titration procedure, PEEP will be decreased from 18 cmH2O by 2 cmH2O every 20 ventilatory cycles, until a final PEEP of 6 cmH2O.~On each level of PEEP EIT parameters and Cdyn values will be recorded in both groups.~In the EIT-GROUP optimal PEEP is considered as the intersect between the lower percentage of overdistension and collapse, based on the diagnostic tool of the EIT device."
224055800|NCT07170514|PROCEDURE|Cdyn-guided PEEP titration|"During the PEEP titration procedure, PEEP will be decreased from 18 cmH2O by 2 cmH2O every 20 ventilatory cycles, until a final PEEP of 6 cmH2O. On each level of PEEP EIT parameters and Cdyn values will be recorded in both groups.~In the Cdyn-GROUP optimal PEEP is considered as the PEEP value resulting the highest possible Cdyn measured by the ventilator."
224055801|NCT07170449|DIAGNOSTIC_TEST|Nerve conduction studies|Upper extremity nerve conduction studies including median-ulnar sensory and motor responses
224055802|NCT07170449|DIAGNOSTIC_TEST|Median nerve ultrasonography|Median nerve sonographic cross-sectional area and echogenicity measurements
224055803|NCT07170449|DIAGNOSTIC_TEST|Sensory testing|tactile sensory tests
224055804|NCT07171229|PROCEDURE|Pulpotomy|"* Local anesthesia will be administered, and the tooth will be isolated with a rubber dam.~* To minimize further bacterial contamination, carious tissues will be removed progressively, starting from the cavity periphery and then over the pulp chamber roof.~* Before managing the pulpal hemorrhage, a sterile cotton pellet will be placed over the pulp tissue for 30-45 s.~* A fresh sterile bur will be used to remove all coronal pulp tissue down to the root canal orifices, with copious water irrigation~* MTA will be used as medicament of choice for pulpotomy.~* The pulpotomy-treated tooth will be prepared to receive a full-coverage stainless steel crown (SSC) after the procedure."
224055805|NCT07171229|OTHER|Measuring Cytokines level|measuring cytokines level as an indicator for pulp inflammation
224055806|NCT07169916|DRUG|Yueju Pill + Standard Anti-tumor Therapy|Group A (Intervention): Standard therapy + Yueju Pill (6-9 g per dose, twice daily, orally until disease progression or intolerable toxicity).
224055807|NCT07169916|DRUG|Placebo + Standard anti-tumor therapy|Group B (Control): Standard therapy + placebo (identical in appearance, packaging, dosage, and administration frequency to Yueju Pill).
224055808|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
224055809|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
224055810|NCT07169734|DRUG|ALE.P03|ALE.P03, will be administered by IV infusion according to the assigned arms.
224055811|NCT07170683|OTHER|MAIA Microperimetry|Microperimetry (MP) is not performed as part of the current NHS patient pathway. We plan testing 2 MP strategies ('standard' vrs 'fast') to determine whether the fast testing strategy is as robust as the standard test strategy. Adopting the fast strategy will reduce time spent on the MP machine to obtain relevant test results. Healthy volunteers (with no retinal disease) are necessary for comparison, and to establish validity of any new findings.
224055812|NCT07170683|DEVICE|Microperimetry|Two fully automatic MAIA MP (CenterVue, spa; Padova, Italy) examinations (to obtain retinal sensitivity) shall be performed over the 10° diameter central retinal area for the recruited study participants. The first one will be performed with a fast projection, and the second one with the standard full 4-2 staircase projection strategy. Identification of the PRL area will be automatically calculated at the end of each examination. All patient groups will have identical assessment, at all time points. Healthy volunteers will only have assessments at baseline (one examination only)..
224055813|NCT07170683|OTHER|Visual Acuity Measurement (logMAR)|Visual acuity will be measured with the ETDRS chart, and with the participant habitual distance correction, and recorded in logMAR notation
224055814|NCT07170683|DEVICE|OCT-A|OCT and OCT-A examination, as well FAF will be undertaken with the Topcon Triton Plus OCT
224300939|NCT02253030|DEVICE|Optical Coherence Tomography|
224300940|NCT04215848|DRUG|Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide/formoterol (160/4.5 μg/d) as need when they have symptoms.
224300941|NCT04215848|DRUG|Budesonide 200Mcg Inhalation Powder|After the patients who have all criteria, they will be randomized to take Budesonide (200 μg) twice daily
224300942|NCT04814030|DRUG|PD-1 inhibitor|Transarterial hepatic chemoembolization and FOLFOX-based infusion
224300943|NCT04866732|BEHAVIORAL|Physical Activity Cardiac Health Program|The investigators anticipate that the physical activity program will include the following components: a) physical activity component - the investigators propose an incremental physical activity component whereby participants will gradually increase their physical activity ( duration of walk) from baseline to the end of the study; b) weekly informational sessions on various topics related to Cardiovascular disease risk factors prevention; c) daily diary, which will be used to document record about any barriers for completing various components of the intervention; d) problem-solving sessions whereby participants will meet once a week with the investigators to talk about the barriers and facilitators of their weekly activity and any adherence issues.
224300944|NCT03365752|DRUG|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
224300945|NCT03365752|DRUG|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
224300946|NCT03365752|DRUG|General Anesthetics|General anesthetics will be administered intravenously
224300947|NCT03063840|DEVICE|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
223447288|NCT05843032|DIAGNOSTIC_TEST|3D ultrasound, MRI, resected specimen examination by surgeon|3D ultrasound and MR scanning of the resected tongue tumor will be performed. The resected surgical specimen will also be examined by the surgeon to assess the margins. The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
223447289|NCT00849290|BIOLOGICAL|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
223447290|NCT01912352|DRUG|Methylphenidate|
223447291|NCT01687387|DRUG|IPH2102 at 0.1 mg/kg|every 3 months
223447292|NCT01687387|DRUG|IPH2102 at 1 mg/kg|every 4 weeks
223447293|NCT01687387|DRUG|Placebo (normal saline solution)|every 4 weeks
223447294|NCT03992898|OTHER|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
224055815|NCT07160452|DRUG|Levocarnitine Injection|1,000 mg levocarnitine IV (slow IV push or infusion per unit policy) post-hemodialysis, three times weekly for 6 months (\~72 doses). Administered in the dialysis unit in addition to usual ESA-based anemia care.
224055816|NCT07160452|OTHER|Usual ESA-Based Anemia Care|Standard-of-care anemia management using recombinant human erythropoietin (ESA) per unit protocol. Typical initial dosing: 50-100 U/kg/week if Hb \<10 g/dL (in 2-3 doses/week); 50 U/kg/week if Hb 10-11 g/dL; 25-50 U/kg/week as maintenance if Hb 11-12 g/dL. ESA dose adjusted monthly using ERI and Hb/Hct targets (generally Hb 10-12 g/dL).
224300948|NCT02655744|RADIATION|Standard treatment protocol with combined chemoradiation|
224300949|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
224300950|NCT01987973|PROCEDURE|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
224300951|NCT01335386|DRUG|KLYX|
224300952|NCT01335386|DRUG|Glycerine|
224300953|NCT05344430|PROCEDURE|cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy|We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
224055817|NCT07158749|BEHAVIORAL|Episodic Future Thinking (EFT)|Participants will engage in EFT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
224300954|NCT04727814|OTHER|Computer-aided detection system overlaid colonoscopy videos analysis|Analysis of computer-aided detection system overlaid videos from colonoscopies performed with water exchange or air insufflation method.
224300955|NCT00398996|DRUG|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
223447295|NCT06145113|DEVICE|Continuous positive airway pressure (CPAP), ResMed AirMini|Consumer CPAP device, designed for use without medical supervision by patients with obstructive sleep apnea. This device is safely used by unconscious patients for several hours at a time. This will be supplied by face mask to awake patients under direct medical supervision.
223447296|NCT05266859|OTHER|Calcium hydroxide|Calcium hydroxide in the power/liquid form will be used and placed on the exposed pulp
223447297|NCT05266859|OTHER|MTA|Mineral trioxide aggregate will be used as a powder / liquid form and placed over the exposed pulp
223447298|NCT05266859|OTHER|PRF|PRF will be placed directly over the exposed pulp
223447299|NCT02124070|DRUG|rh Growth Hormone|
223447300|NCT05788107|DRUG|HLX51|anti-OX40 tetravalent agonistic humanized monoclonal antibody
223447301|NCT01476397|OTHER|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
223447302|NCT01476397|OTHER|Test infant formula|partially hydrolyzed whey formula with probiotic
223447303|NCT02131116|BEHAVIORAL|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
223447304|NCT02131116|BEHAVIORAL|Treatment as Usual|Treatment as Usual
223447305|NCT00386074|DRUG|NaFeEDTA, Electrolytic Iron|
224055818|NCT07158749|BEHAVIORAL|Episodic Recent Thinking (ERT)|Participants will engage in ERT for 8 weeks, three times a day. Participants will receive three daily text messages. Each prompt will link to a custom web interface that guides participants to read and vividly imagine one of their cues, chosen randomly. Visit times and durations will be recorded.
223447306|NCT04161105|PROCEDURE|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
223447307|NCT01251159|GENETIC|mutation analysis|
223447308|NCT01251159|GENETIC|polymerase chain reaction|
224055819|NCT07158749|BEHAVIORAL|Domain-specific episodic thinking|Content of the episodic thinking intervention will experiencing the symptoms of lung cancer during a broad range of personally meaningful, otherwise positive, events (e.g., social events, celebrations, spending times with friends and family).
223447309|NCT01251159|OTHER|immunologic technique|
223447310|NCT01251159|OTHER|laboratory biomarker analysis|
223447311|NCT05441891|OTHER|Auditory intervention filter-modulated group|"Intervention consisted of listening to classical music modulated by an equalizer for 30 minutes, 2 sessions a day separated by at least 3 hours, for 10 days (Monday to Friday for 2 weeks).~The musical intervention was always performed with the same songs and in the same order using original CDs, heard through headphones (Beyerdynamic, DT 250 / 80 ohm. GMBH \& Co. KG, Theresienstr. 8 D-74072 Heilbronn, Germany). The music was played with a sound system (Panasonic MASH, No. SA-PM24. Hamburg, Germany). and filtered through an equalizer called Earducator (Hollagen Designs, PÍO. Box 43 7864 Bergvliet W.Cape - South Africa) that modulates music by alternating low and high tones with an unpredictable cadence, preventing habituation. It also allows very narrow band complementary filters to attenuate (by about 40 dB) abnormally perceived frequencies (hyper-hearing peaks): filters in: 1 kHz - 1,5 kHz - 2kHz - 3 kHz - 4 kHz - 8kHz."
223447312|NCT05418660|DRUG|Immunotherapy|At least 24 months with Pembrolizumab, Nivolumab or Atezolizumab in any treatment line
223447313|NCT00629538|PROCEDURE|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
223447314|NCT01050335|BEHAVIORAL|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
223447315|NCT02608814|PROCEDURE|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
223447316|NCT02608814|OTHER|Ultrasound|
224055820|NCT07158749|BEHAVIORAL|Generalized episodic thinking|Content of the episodic thinking intervention will include a broad range of personally meaningful, positive, events (e.g., social events, celebrations, spending times with friends and family).
224055821|NCT07160062|BEHAVIORAL|Mandala painting|Each mandala painting process took a total of 35 to 50 minutes, consisting of 30 to 40 minutes for mandala painting and drawing and 5 to 10 minutes for explaining the painted mandala.
224055822|NCT07165860|BEHAVIORAL|Doula Thrive|The intervention will be pairing intimate partner violence survivors with a trained doula
224055823|NCT07165860|BEHAVIORAL|Thrive|The active control arm will include pairing intimate partner violence survivors with IPV advocates
224055824|NCT07171541|DIAGNOSTIC_TEST|OCT ,mFERG,VA test|retinal photography by OCT, VA measurement, and mfERG test
224055825|NCT07171502|DEVICE|AI Annotation|Use the AI model to assist in annotating the target images.
224055826|NCT07171502|OTHER|manual annotation|Use the manual to annotate the target images.
224055827|NCT07170917|DRUG|Brivekimig|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
223447317|NCT04184596|OTHER|Discrete Choice Experiment|An online-based Discrete-Choice Experiment (DCE) using a survey for stated treatment preferences and socio-demographics. Furthermore, the neuropathic pain component will be assessed in all patients with the Numeric Pain Rating Scale instrument.
223447318|NCT04396522|DEVICE|noninvasively Bio-electrical Impedance Analysis (BIA)|By means of noninvasively Bio-electrical Impedance Analysis (BIA) to measure body composition, which divides body weight into different components such as lean body mass and fat mass.
223447319|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
223447320|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
224055828|NCT07170917|DRUG|Placebo|"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"
223447321|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
223447322|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
224055829|NCT07170371|OTHER|patient education|A culturally adapted patient education program designed for individuals with rheumatoid arthritis. The program was developed through a structured needs assessment and based on established health behavior theories. It includes five core modules delivered over six months: understanding rheumatoid arthritis, monitoring disease activity, treatment strategies, nutrition, and stress management. Sessions combine group workshops and individual support, with interactive materials and practical exercises. The program aims to strengthen patients' knowledge, self-management skills, and quality of life compared to usual care.
223447323|NCT02858024|DRUG|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
223447324|NCT03633916|BEHAVIORAL|Classroom sensitization session|"A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems."
223447325|NCT03633916|BEHAVIORAL|School-level sensitization activities|"The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial."
223447326|NCT05158842|DEVICE|Adult bubble CPAP oxygen therapy device|"In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~1. Adaptive version of nasal canula (nasal seal)~2. A nasal canula with connecting circuit system~3. Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source."
223447327|NCT02134392|BIOLOGICAL|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
223447328|NCT01119846|DRUG|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
223447329|NCT01119846|DRUG|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
223568615|NCT05945459|DIETARY_SUPPLEMENT|High-calorie density formula (1 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
223568616|NCT05945459|DIETARY_SUPPLEMENT|Standard formula (0.67 kcal/ml)|The dose is started from 20ml/kg/day divided into 8 feeds and increased by 20ml/kg/day until the feeding goal is reached (120-150ml/kg/day) during hospitalization. The intervention is then continued after discharge for 3 months (ad libitum).
224055830|NCT07170371|OTHER|Usual Care|patients will receive usual care only
224055831|NCT07170059|BIOLOGICAL|herpes zoster vaccine|Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine
224055832|NCT07170696|BEHAVIORAL|nutrition education|dialogic reading-based nutrition education
224055833|NCT07171086|DEVICE|AI-POCUS (BabyChecker, Delft Imaging)|A portable AI-driven ultrasound system developed by Delft Imaging (Netherlands). The device integrates fetal position, amniotic fluid volume, and biparietal diameter measurements, with built-in diagnostic suggestions and risk alerts. Primary healthcare workers, after brief training, use it for antenatal screening, complication detection, and referral decision-making.
223568617|NCT03001700|DEVICE|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
223568618|NCT04736953|DRUG|Sirolimus|Sirolimus
223568619|NCT04736953|OTHER|Placebo|Placebo
223568620|NCT06516263|PROCEDURE|Leukocyte and platelet rich fibrin|Formation of an Leukocyte and platelet rich fibrin clot and placement into the osteotomy site prior to implant placement
223568621|NCT06516263|PROCEDURE|Standard implant placement|Standard implant placement without Leukocyte and platelet rich fibrin
223568622|NCT02333149|DIETARY_SUPPLEMENT|Melatonin|"Children \<40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
224055834|NCT07171086|DEVICE|AI-POCUS (Edan, China)|An AI-POCUS device developed by Edan (China), capable of analyzing blind ultrasound sweeps to extract fetal diagnostic parameters and assist in early risk identification. It supports clinical decision-making for antenatal care.
224146264|NCT00507416|DRUG|Bortezomib|Bortezomib bolus intravenous (IV) injection
224146265|NCT00507416|DRUG|Dexamethasone|Dexamethasone for oral administration
224146266|NCT00507416|DRUG|Melphalan|Melphalan for oral administration
224055835|NCT07171138|DEVICE|Positioning and positioning devices|"Different positioning strategies and positional devices. Measurement of skin interface pressure at key anatomical pressure points (occiput, elbows, sacrum, heels) under different patient positioning strategies and positional devices.~The positions that produce the least amount of pressure are identified and will be implemented and compared with pre-intervention hospital acquired pressure injuries (HAPI)"
224055836|NCT07169968|DEVICE|clear aligners group|patients with lower anterior crowding, after randomization and allocation, will receive intraoral scanning to create a digital model. using computer software, teeth segmentation, setup and stagging of tooth movement will be carried out. models for each stage of tooth movement will be three-dimentionally printed and the aligners will be thermoformed over each model. patients are instructed to wear each aligner for a week then continue to the next aligner till treatment is finished
224055837|NCT07169968|DEVICE|micro-osteoperforations group|patients having lower anteriro crowding, after randomization and allocation, aligners will be produced for them. patients in this group will receive micro-osteoperforation using mini-implants before wearing the first aligner and after one month from starting treatment.
224146267|NCT00507416|DRUG|Prednisone|Prednisone for oral administration
224146268|NCT00507416|DRUG|Thalidomide|Thalidomide for oral administration
224146269|NCT00773565|DIETARY_SUPPLEMENT|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
224146270|NCT04428359|DRUG|Measles-Mumps-Rubella Vaccine|Group A patients will receive intralesional injection of upto 0.5 mL of reconstituted MMR vaccine into a single or a maximum of 5 warts at a time in case of multiple warts. Intralesional injection will be given every three weeks for a maximum of 5 doses or until complete resolution, whichever is earlier.
223447330|NCT01119846|DRUG|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
223447331|NCT01008813|BIOLOGICAL|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (3,8 microgram) adjuvanted with AS 03A
223447332|NCT01008813|BIOLOGICAL|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 \[A/California/7/2009 (H1N1)v\] (15 microgram)
223568623|NCT02333149|DRUG|Placebo|Placebo frequency and volume are identical to the experimental arm
223568624|NCT00393341|PROCEDURE|Blood Draw|Blood sample will be drawn from a vein in the arm.
224146271|NCT04428359|DRUG|Vit D|Group B patients will receive a maximum of 0.5 mL Inj. Vitamin D3 (600,000 IU; 15mg/ml) in each session after injection of IL lignocaine with 31 G insulin syringe. In cases of multiple warts, a maximum of 5 warts will be injected at a time. The session will be done at 3 weekly intervals for a maximum of 5 sessions or until complete resolution of warts, whichever is earlier
224146272|NCT02157506|DRUG|CXL-1427|
223568625|NCT00571207|DEVICE|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
223568626|NCT00571207|BEHAVIORAL|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
223568627|NCT00164385|BEHAVIORAL|Adolescent Impact|
224146273|NCT02157506|DRUG|Placebo|
224146274|NCT03101514|DRUG|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
224146275|NCT03101514|DRUG|chemotherapy|Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
224146276|NCT04905875|PROCEDURE|Prone Position|Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
223447333|NCT00001031|BIOLOGICAL|rgp120/HIV-1MN|
223447334|NCT00001031|BIOLOGICAL|rgp120/HIV-1 SF-2|
223447335|NCT00921713|OTHER|Oncology Nurse Care Management|
223741639|NCT06440538|DEVICE|PCMS + Contralateral Motor Training|PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.
223568628|NCT06519383|PROCEDURE|guided implant surgery|Surgical guide is fabricated and fitted onto the patient's arch and implant is placed with guide in place.
223568629|NCT04827797|DEVICE|balls|Birth balls to exercise
223568630|NCT01336751|DRUG|Insulin glargine|solution for subcutaneous injection
223741640|NCT06440538|DEVICE|PCMS + Rest|PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.
224055838|NCT07171554|DIAGNOSTIC_TEST|µCAN drug screen test|µCAN guided therapy is based on drug screening of patient-derived tumoroids. The patient might be treated with clinically relevant on-label or off-label drugs
224055839|NCT07171554|OTHER|Standard-of-Care Therapy|trifluridine/tipiracil/bevacizumab combination, 28 day cycles
224146277|NCT02790671|DRUG|DS-8500a|DS-8500a 25mg tablet
224146278|NCT02790671|DRUG|Itraconazole|200mg itraconazole
224146279|NCT02322684|DEVICE|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
223447336|NCT00921713|OTHER|Patient-centered materials|
223568631|NCT01336751|DRUG|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
223568632|NCT02031224|BEHAVIORAL|Conventional low protein diet|
223741641|NCT06440538|DEVICE|Sham PCMS + Contralateral Motor Training|360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
224146280|NCT06197542|OTHER|Active Release Technique|active TrP was identified, and sustained and constant pressure was applied .for stretching of the SCM muscle, the patient performed contralateral lateral flexion and ipsilateral rotation of the head to achieve stretching, for trapezius the therapist performed lateral flexion of the neck.
224300956|NCT06478264|DRUG|Etoposide|100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles
223447337|NCT03130270|DRUG|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
223447338|NCT03992833|OTHER|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume \< 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume \> 300 mm3 (positive)."
223447339|NCT03264534|PROCEDURE|limbal relaxing incisions|Manually performed surgical procedure
223447340|NCT03264534|PROCEDURE|astigmatic keratotomy|femtosecond laser guided surgical procedure
223447341|NCT05940766|OTHER|Automated fever alerts|Fever alerts are automated sent to participants if fever is detected
223447342|NCT04592679|DEVICE|FES-C|The participants were submitted to 20 sessions of FES-C three/five times per week. Each session lasted about 30'.
223447343|NCT04592679|OTHER|Standard Treatment|The participants were submitted to 20 sessions of standard rehabilitation for lower limbs with manual mobilization, three/five times per week. Each session lasted about 30'.
223447344|NCT02651649|DEVICE|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
223447345|NCT03646071|DRUG|RX108|RX108
223447346|NCT05401461|OTHER|Evening mobilisation|Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
223447347|NCT01557868|DEVICE|hylan G-F 20|Three 2 cc injections at weekly intervals
224055840|NCT07169994|DRUG|YL202 for injection; Toripalimab injection|"Part 1: YL202 and Toripalimab will be administered intravenously.~Part 3: participants will receive escalating doses of YL202 and fixed dose of Toripalimab until YL202 doses for optimization are determined.~Dose expansion stage: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Toripalimab"
223447348|NCT01557868|DEVICE|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
223447349|NCT01557192|DEVICE|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
223447350|NCT06093971|DRUG|remimazolam|Remimazolam is administered for anesthesia induction.
223447351|NCT06093971|DRUG|Propofol|Propofol is administered for anesthesia induction.
223447352|NCT03739580|DEVICE|DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
223447353|NCT03739580|DEVICE|Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
223741642|NCT06344754|OTHER|Gamified education|Training will be provided with gamification method. Data will be collected with \&#34;Introductory Information Form\&#34; and \&#34;Family Planning Attitude Scale\&#34;. The family planning attitude scale will be administered as both pre and post test.
223741643|NCT04651634|DRUG|MIT-001 plus CCRT|MIT-001 IV-infusion plus CCRT
223741644|NCT01994629|BIOLOGICAL|MenACWY-CRM|MenACWY-CRM
223741645|NCT01994629|BIOLOGICAL|MenACWY-TT|MenACWY-TT
223741646|NCT03945396|DRUG|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
224146281|NCT06197542|OTHER|Instrument Assisted Soft Tissue Mobilization|The therapist applied IASTM strokes for 20 seconds parallel to muscle fibers, followed by strokes for 20 seconds perpendicular to muscle fibers with the tool held at a 45° to the skin. .
224146282|NCT05239364|PROCEDURE|Catheter ablation|Catheter-based ablation of arrhythmias using radiofrequency.
224146283|NCT00466583|DRUG|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
224146284|NCT04904965|DRUG|Propofol Group 1|Propofol 2.0 mg/kg/hr per 10 min
223447354|NCT00795769|DRUG|ondansetron|Given IV
223447355|NCT00795769|OTHER|survey administration|Correlative studies
223447356|NCT00795769|PROCEDURE|management of therapy complications|Ondansetron IV
223447357|NCT00602446|DRUG|deferasirox|20 mg/kg once daily orally for 6 months
223447358|NCT03001466|DRUG|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
223447359|NCT03001466|DRUG|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
223447360|NCT05309239|OTHER|ROX index|observation of ROX index to evaluate the efficacy of non invasive ventilation
223447361|NCT03450616|DEVICE|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
224055841|NCT07169994|DRUG|YL202 for injection; Furmonertinib Mesilate Tablets|"Part 2: YL202 will be administered intravenously，Furmonertinib Mesilate Tablets will be administered orally.~Dose escalation stage: participants will receive escalating doses of YL202 and fixed dose of Furmonertinib Mesilate until YL202 doses for optimization are determined.~Part 4: participants will receive a dose of YL202 not exceeding the maximum dose level achieved during the dose-escalation stage and fixed dose of Furmonertinib Mesilate."
224055842|NCT07170280|PROCEDURE|Direct Infrapectineal Plating in Quadrilateral Plate Acetabular Fractures: A Prospective Cohort Study|This study aims to evaluate the outcomes of direct infrapectineal plate fixation in patients with quadrilateral plate acetabular fractures. A total of 25 adult patients with acute fractures were enrolled between 2021 and 2024 at a university-affiliated hospital. All patients underwent surgical fixation through the ilioinguinal approach. Radiological results were assessed using the Matta scoring system, and functional outcomes were evaluated using the Merle d'Aubigné and Postel scoring system. The study further assessed complication rates, operative time, intraoperative blood loss, and hospital stay.
224055843|NCT07170553|BEHAVIORAL|Digital Game|Parent-child dyads will come to the research site once and participate for up to one hour. Dyads will engage with a digital game prototype. The game involves brief relationship enhancing activities focused on different domains of attachment with the purpose of facilitating appropriate and healthy playful interaction between parents and children.
224055844|NCT07170553|BEHAVIORAL|Control|Parent-child dyads will come to the research site once and participate for up to one hour. Dyads will receive pamphlets with information regarding play based attachment activities and be given the chance to engage in said activities.
224055845|NCT07159061|BEHAVIORAL|Active Closed Loop Real Time fMRI Neurofeedback|Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
224055846|NCT07159061|BEHAVIORAL|Sham Closed Loop Real Time fMRI Neurofeedback|Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)
224055847|NCT07161557|OTHER|No Intervention: Observational Cohort|No intervention involved, participants will fill out some questionnaires and blood samples will drawn for test and analysis.
224055848|NCT07171203|DRUG|Imatinib|Tyrosine kinase inhibitor. Imatinib will be dosed at 400 mg once a day. Dose can be reduced by 100 mg per dose reduction step if clinically indicated.
224055849|NCT07171203|DRUG|Fampridine|Voltage-gated potassium channel (VGKC) blocker. Fampridine will be dosed in a 3+3 design at 10 mg given either every 2 days, or every day, or twice a day.
224055850|NCT07169773|DEVICE|Rezum|Rezum procedure in Rezum group
224055851|NCT07169773|DRUG|Tamsulosin|Tamsulosin were given to Tamsulosin group
224055852|NCT07170319|DRUG|IBI3032|IBI3032. Method of administration: oral, fasted administration.
224055853|NCT07170319|DRUG|placebo|Placebo (without active ingredients). Method of administration: oral, fasted administration.
224055854|NCT07171398|OTHER|Functional Performance Testing Battery|"Participants performed a standardized battery of sport-specific performance tests during a single laboratory session, including:~Countermovement Jump (height, power, flight time)~5-10-5 Pro-Agility Shuttle Test~Acceleration-Deceleration-Acceleration (ADA) Test~Side Jump Test~6-Meter Timed Hop Test~Single-Leg Hop Test~Triple Crossover Hop Test~Lateral Hop Test Performance was assessed using the Deepsport AI program and standard timing/distance protocols. Results compared between CAI and control cohorts."
224146285|NCT04904965|DRUG|Propofol Group 2|Propofol 4.0 mg/kg/hr per 10 min
224146286|NCT04904965|DRUG|Propofol Group 3|Propofol 6.0 mg/kg/hr per 10 min
223447362|NCT03450616|PROCEDURE|Compression Dressing|Standard of Care Compression Dressing
223447363|NCT03304184|DEVICE|Photac-fil|Application of a tooth colored filling in a non-cavitated dental lesion.
223447364|NCT03304184|DEVICE|Biodentine|Application of a white colored filling in a non-cavitated dental lesion.
223447365|NCT05145608|DRUG|Lamotrigine ER tablet 50mg|In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
223447366|NCT00893906|BIOLOGICAL|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
223447367|NCT00893906|BIOLOGICAL|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
223447368|NCT02062775|PROCEDURE|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
223447369|NCT02062775|PROCEDURE|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
224055855|NCT07171645|OTHER|Assessment regarding gender-affirming care|No comparison
224055856|NCT07170215|DEVICE|antigravity treadmill (ALTERG VIA, Lifeward CA, Inc., Milmont Drive, Fremont, CA, U-SA)|Antigravity treadmill training in the experimental group (EG) involved walking in a straight line at a self-selected, com-fortable pace-without running, shortness of breath, or pain. The treadmill's chamber was set to reduce the participant's effective body weight to 20% of their actual body weight (slight unloading was applied to reduce the need for handrail support and to prevent the use of compensatory mechanisms).
224055857|NCT07169682|DRUG|interleukin 17 inhibitor|52 weeks
224055858|NCT07169682|DRUG|interleukin-23 inhibitor|52 weeks
224055859|NCT07169682|DRUG|conventional systemic agent or apremilast|52 weeks
224055860|NCT07171710|DRUG|0.05% Cyclosporine Eye Drops|Cyclosporin A 0.05% eye drops were administered twice daily to both eyes
224146287|NCT04904965|DRUG|Propofol Group 4|Propofol 8.0 mg/kg/hr per 10 min
224146288|NCT02816125|DIETARY_SUPPLEMENT|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
224146289|NCT00740922|DRUG|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
224146290|NCT03866148|DEVICE|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
224146291|NCT02435641|OTHER|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
224146292|NCT04609995|BEHAVIORAL|Incentives|No financial incentive
223447370|NCT02062775|PROCEDURE|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures \>2cm
223447371|NCT03236571|DEVICE|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
223447372|NCT03947502|BEHAVIORAL|Educational intervention in neurobiology of pain|The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
223447373|NCT05987943|PROCEDURE|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula|A Pedicled Buccal Periosteal Flap for the Closure of Oro-antral Fistula
223447374|NCT05529732|OTHER|e-Mobile Application Patient Education for Patients with Thyroidectomy|"Its mobile application is prepared according to the Android Operating System and can be downloaded free of charge from the Google Play Store, it is an application that provides training and consultancy services for patients who have had thyroidectomy surgery."
223447375|NCT02547701|DRUG|P-3058|
223447376|NCT01608516|DRUG|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
223447377|NCT05854849|DRUG|Camrelizumab|200mg, D1, Q3W, iv drip.
223447378|NCT05854849|DRUG|Gemcitabine|1000mg/m2, Day 1 and Day 8, Q3W, iv drip, maximum 6 cycles.
223447379|NCT05854849|DRUG|Cisplatin|80 mg/m2, D1, Q3W, iv drip, maximum 6 cycles.
223447380|NCT05854849|DRUG|Apatinib|250mg, PO, QD
223447381|NCT02940873|BEHAVIORAL|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
224146293|NCT03722914|DRUG|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
223447382|NCT02940873|BEHAVIORAL|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
223447383|NCT02888275|DRUG|Dexmedetomidine|
223447384|NCT02888275|DRUG|normal saline|
223447385|NCT03782532|DRUG|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223447386|NCT03782532|DRUG|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
223447387|NCT03782532|DRUG|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
223447388|NCT03782532|DRUG|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
223447389|NCT05436171|OTHER|No intervention|No intervention
223447390|NCT04553003|DRUG|Glucocorticoids+hepatoprotectant|Participants received glucocorticoids (0.4mg/kg/d po.) and hepatoprotectant for 7 days.
223447391|NCT04553003|DRUG|hepatoprotectant|Participants received hepatoprotectants (i.v.gtt.) for 7 days.
223447392|NCT02693899|OTHER|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
223447393|NCT06074627|DIETARY_SUPPLEMENT|Energy Placebo Control Form 1|Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.
223447394|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.1 Usage|Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.
223447395|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.2 Usage|Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.
223447396|NCT06074627|DIETARY_SUPPLEMENT|Energy Active Study Product 1.3 Usage|Participants will use their Radicle Energy Active Study Product 1.3 as directed for a period of 6 weeks.
224146294|NCT03722914|DRUG|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
223447397|NCT06488872|PROCEDURE|comparison of CT scan with routinely assessed methods of muscle mass and strength|comparison of CT scan with routinely assessed methods of muscle mass and strength
224146295|NCT02029495|DRUG|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
224300957|NCT06478264|DRUG|Cisplatin|25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles
223447398|NCT06222814|PROCEDURE|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft|ACL reconstruction combined with anterolateral ligament reconstruction using peroneus longus autograft
223447399|NCT06222814|PROCEDURE|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)|ACL reconstruction combined with extra-articular tenodesis (Modified Lemaire)
223447400|NCT03292614|DIAGNOSTIC_TEST|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
224146296|NCT02029495|DRUG|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
224146297|NCT02029495|DRUG|Placebo|Placebo administered via subcutaneous injection until week 24.
224300958|NCT06478264|DRUG|Carboplatin|Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;
224300959|NCT06478264|DRUG|Adebrelimab|1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.
224300960|NCT06478264|RADIATION|radiotherapy|Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.
224300961|NCT02865252|OTHER|MWM Treatment|
224300962|NCT02865252|OTHER|MWM Sham|
224300963|NCT01965470|OTHER|Combination Prevention|
224300964|NCT01965470|OTHER|Enhanced Care|
223447401|NCT00212264|BEHAVIORAL|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
223447402|NCT00212264|DEVICE|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
223447403|NCT00212264|BEHAVIORAL|Biofeedback|Pelvic Floor Muscle training via biofeedback
224055861|NCT07171710|DEVICE|Smart plug absorbable lacrimal duct plugs|The lacrimal duct embolization implant is performed by partially sealing the tear discharge duct to increase the lubrication of natural tears on the eye surface.
224055862|NCT07171333|DEVICE|Colonoscopy with CADe system|Patients in the CADe+ arm underwent colonoscopy with CADe DISCOVERY™ (PENTAX Medical, Tokyo, Japan), an AI-driven tool highlighting suspected lesions in real-time, through a light-blue box. The final lesion characterization remained the endoscopist's responsibility.
223447404|NCT00212264|OTHER|No Treatment|No treatment
223447405|NCT05614635|DEVICE|Plastalgin and Plastalgin Fast|Plastalgin and Plastalgin Fast are potassium alginate-based powders designed for dental impression. The powder is mixed with water to obtain an impression material paste, used to imprint the teeth and mouth of the patient. The product is available under two presentations: Plastalgin and Plastalgin Fast. Plastalgin Fast has a shorter mixing time.
223447406|NCT03476902|BEHAVIORAL|Therapist assisted mobile intervention|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
223447407|NCT01605825|DRUG|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
223447408|NCT01605825|DRUG|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
223447409|NCT05152199|PROCEDURE|Cystoscopy - with use of obturator sheath|The intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
223447410|NCT05152199|PROCEDURE|Cystoscopy - without use of obturator sheath|The intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
223447411|NCT00691561|BEHAVIORAL|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
223447412|NCT02740335|DRUG|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
223447413|NCT02740335|DRUG|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
223447414|NCT03418142|BEHAVIORAL|Priovi|Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
223447415|NCT03418142|OTHER|CAU|Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
223447416|NCT03237052|OTHER|model|a model that has been established in advance.
223447417|NCT03237052|OTHER|non-model|real-world psychiatrist decision
223447418|NCT03973697|DRUG|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
223447419|NCT03973697|DRUG|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
223447420|NCT03973697|DRUG|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
223447421|NCT05687409|DRUG|Entecavir 0.5 mg|Orally administered Entecavir 0.5 mg, once a day. For six months
223447422|NCT05687409|DRUG|A 10-g packet of lactulose oral solution and three capsules of probiotics|"A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).~Participants orally administered the contents three times daily after meals. For six months."
223447423|NCT05687409|DIETARY_SUPPLEMENT|A 10-g packet of glucose oral solution and three capsules of starch|A 10-g packet of glucose oral solution and three capsules of starch. Participants orally administered the contents three times daily after meals. For six months.
223447424|NCT02039323|DRUG|Tenofovir|
223447425|NCT02039323|DRUG|Maraviroc|
223447426|NCT00813436|DRUG|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
223447427|NCT00813436|DRUG|Placebo|saline liquid, intranasally administered
224055863|NCT07171346|DEVICE|Zynex NexWave Electrotherapy Device|All participants will use the NMES device in addition to standard rehabilitation
224055864|NCT07170826|OTHER|Self questionnaire|Rosenberg Scale, SF36, MBRSQ
224055865|NCT07170826|OTHER|interview|Semi-structured individual interviews
224055866|NCT07171216|OTHER|Treat to target|"Participants will receive treatment from a toolbox depending on the situation to reach the PTH target. Available medication is mirroring what is used in the outpatient clinic setting already (native vitamin D, activated vitamin D, phosphate binders, calcimetics)."
224300965|NCT02953470|BEHAVIORAL|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
223447428|NCT00550264|OTHER|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
224055867|NCT07169942|DRUG|aleniglipron or placebo|Drug: aleniglipron administered orally Drug: placebo administered orally
223447429|NCT01756248|DRUG|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
223447430|NCT01622725|PROCEDURE|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
223447431|NCT01622725|PROCEDURE|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
223447432|NCT04288817|BIOLOGICAL|Tuberculin purified protein derivative|Intralesional injection of tuberculin PPD in treatment of multiple common warts
223447433|NCT05267223|OTHER|Semi-structured interviews|Semi-structured interviews with individuals with paraplegia
223447434|NCT03362138|DEVICE|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
223447435|NCT05454254|OTHER|Individualised muscle strengthening exercise training protocol.|Based on the results of muscle function tests at baseline an individualised exercise protocol will be designed.
223568633|NCT02031224|DIETARY_SUPPLEMENT|Very low protein diet supplemented with Ketosteril|
223568634|NCT00984607|PROCEDURE|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
223568635|NCT04883840|DRUG|Rosuvastatin 10mg|Daily dose of one medication over 8 week period then switch to another medication over an 8 week period (type of medication during each intervention period is blinded and then randomized).
223568636|NCT06320548|DIETARY_SUPPLEMENT|Low-residue diet|Patients received clear explanations, practical schemes, and a list of allowed foods, tailored to fit individual needs.
224146298|NCT04686019|OTHER|Inspiratory muscle training (IMT)|"IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks."
224146299|NCT01545609|OTHER|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
224146300|NCT06432556|GENETIC|scRNAseq|A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)
224146301|NCT06432556|PROCEDURE|two Skin biopsies|2 skin biopsies from a lesional area
224146302|NCT06432556|PROCEDURE|one Skin biopsies|1 skin biopsies from a lesional area
223568637|NCT06320548|DIETARY_SUPPLEMENT|Free diet|Patients had free diet.
223568638|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
223568639|NCT00983515|DRUG|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
223741647|NCT03945396|OTHER|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
224146303|NCT02986685|DRUG|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
223447436|NCT00214734|DRUG|rAHF-PFM|
223568640|NCT00983515|DRUG|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
223568641|NCT05704907|OTHER|gallbladder ultrasound|gallbladder ultrasound
223568642|NCT02720640|DEVICE|Implant 'on' vs implant 'off'|Single group assignment
223568643|NCT06135636|BEHAVIORAL|Education|Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
223568644|NCT06135636|BIOLOGICAL|Vaccine administration|Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
223741648|NCT03945396|DRUG|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
224055868|NCT07170982|DRUG|Fruquintinib|This study aims to confirm the safety and efficacy of fruquintinib combined with standard chemotherapy, further compare whether first-line standard chemotherapy has superiority, bring better survival benefits to patients with pMMR endometrial cancer, and provide more options for patients with late recurrent and metastatic endometrial cancer.
224055869|NCT07170787|BIOLOGICAL|IMM2510|IMM2510 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM2510 (e.g., 10 mg/kg, 20 mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
224055870|NCT07170787|BIOLOGICAL|IMM01|IMM01 administered intravenously once every 2 weeks (Q2W). Dose escalation cohorts will receive ascending doses of IMM01 (e.g., 1 mg/kg, 2 mg/kg, 3mg/kg, up to maximum tolerated dose or recommended phase 2 dose).
223447437|NCT03244618|DEVICE|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
223447438|NCT03244618|DEVICE|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
223447439|NCT02003456|DRUG|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
223568645|NCT04203069|DEVICE|Control group : Day-time compression sleeve|"In the control group, patients wear only day-time compression garment : lymphatrex during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
223568646|NCT04203069|DEVICE|Intervention group : Day-time compression sleeve and Night-time MOBIDERM® Autofit|"In the intervention group, patients wear a day-time compression garment : lymphatrex and the night-time compression garment : MOBIDERM AUTOFIT during 3 months.~The protocol will require 3 visits during the maintenance phase.~Visit 1 at day 0 (until 5 days after the end of hospital): includes the inclusion visit with the reception of devices and some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group).~Visit 2 at 30 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)~Visite 3 at 90 days after the inclusion : includes some evaluations (clinical examination, lymphedema volume, questionnaires, ultrasound on a patients sub-group)."
223568647|NCT05858450|BIOLOGICAL|Comirnaty|COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
223741649|NCT04364308|OTHER|Fetal Echography|Fetal ultrasound and its parameters
224146304|NCT02986685|DRUG|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
224146305|NCT00928356|PROCEDURE|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
224146306|NCT00928356|PROCEDURE|Off Pump CABG|Standard of Care Off Pump CABG
223447440|NCT02200991|DRUG|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
223447441|NCT02200991|DRUG|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
223447442|NCT02200991|DRUG|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
223447443|NCT02397434|RADIATION|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
224146307|NCT03136952|DEVICE|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
224146308|NCT03498287|DEVICE|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
224146309|NCT03498287|DEVICE|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). \*Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
223447444|NCT01611428|DRUG|Ipragliflozin|Oral and Intravenous (i.v.)
223447445|NCT03086109|OTHER|Risk factors|Risk factors associated bone degenerative diseases
223447446|NCT05268354|OTHER|6-week neuromuscular training program|Training program consisting of three neuromuscular training sessions per week
223447447|NCT02574416|OTHER|There is no intervention|The study is observational and there is no intervention
224146310|NCT00213161|DRUG|iron supplement, iron drops|
224146311|NCT05549648|OTHER|Home oral excrise|The current study aimed to evaluate the efficacy and user experience of mobile phone APP, a mobile application with AI component in facial movement tracking, in improving oral functions of elderly people
223447448|NCT00513890|DEVICE|Infantflow [EME, Brighton, England]|
223447449|NCT05186259|DIAGNOSTIC_TEST|Self-reported signs of central sensitization|Self-reported signs of central sensitization by means of the Central Sensitization Inventory (questionnaire)
223447450|NCT05186259|DIAGNOSTIC_TEST|Objective signs of central sensitization|Objective signs of central sensitization by means of Quantitative Sensory Testing (mechanical and heat detection and pain thresholds, endogenous pain facilitation and inhibition)
223447451|NCT05186259|DIAGNOSTIC_TEST|Audiological outcome measures (audiometry, tinnitus analysis, uncomfortable loudness) in tinnitus patients with and without pain|"* Audiometry Performance of pure tone audiometry according to the modified Hughson-Westlake method~* Tinnitus analysis Measurement of psychoacoustic features of tinnitus, including (1) tinnitus pitch, (2) loudness, (3) masking ability, and (4) residual inhibition.~* Uncomfortable Loudness measures Performance of Uncomfortable Loudness measurements to evaluate the presence of hyperacusis. ."
223447452|NCT05186259|DIAGNOSTIC_TEST|Cognitive functioning|"Evaluation of cognitive functioning by means of:~* Auditory Stroop test~* Detecting letters task~* Letter-number sequencing task"
223447453|NCT05186259|DIAGNOSTIC_TEST|Listening effort|Evaluation of listening effort by means of the modified version of the behavioral listening effort test based on a dual-task paradigm by Degeest, Keppler \& Corthals (2018) .
223447454|NCT05186259|DIAGNOSTIC_TEST|Self-reported psychological factors|"Evaluation of psychological factors by means of:~* Depression, Anxiety and Stress Scale (DASS-21)~* Beck Depression Inventory (BDI)~* Big Five Inventory (BFI)~* Connor-Davidson Resilience Scale"
223447455|NCT05186259|DIAGNOSTIC_TEST|Self-reported lifestyle factors|"Evaluation of lifestyle factors by means of:~Baecke Questionnaire Pittsburg Sleep Quality Index Insomnia Severity Index Stress subscale of the DASS 21"
223447456|NCT05186259|DIAGNOSTIC_TEST|Self-reported measure of pain processing|Evaluation of self-reported pain processing by means of the Pain Catastrophizing Scale
224055871|NCT07170384|BEHAVIORAL|Mediterranean Diet|"A structured Mediterranean diet program designed and supervised by a dietitian. The program emphasizes high consumption of olive oil, vegetables, fruits, legumes, whole grains, and fish; moderate intake of dairy and poultry; and low intake of red meat and processed foods. Adherence will be monitored through 10-day interval follow-up phone calls. Assessments will be conducted at baseline and 3 months"
223447457|NCT05186259|DIAGNOSTIC_TEST|Self-reported quality of life|Self-reported quality of life by means of the SF-36 questionnaire
223447458|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus severity and impact on daily life|Evaluation of self-reported tinnitus severity and impact on daily life by means of the Tinnitus Functional Index
223447459|NCT05186259|DIAGNOSTIC_TEST|Self-reported hyperacusis|Evaluation of self-reported characteristics of hyperacusis by means of the Hyperacusis Questionnaire
223447460|NCT05186259|DIAGNOSTIC_TEST|Self-reported tinnitus characteristics|Evaluation of self-reported tinnitus characteristics by means of the Tinnitus Sample Case History Questionnaire
223447461|NCT05186259|DIAGNOSTIC_TEST|Self reported neck pain related disability|Evaluation of self-reported neck pain related disability using the Neck Disability Index
223447462|NCT04100590|DRUG|Cannabis|Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
223568648|NCT05858450|BIOLOGICAL|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines
223568649|NCT04088981|BEHAVIORAL|Dietary intervention|Low-fat, plant-based diet and a portion-controlled diet
224055872|NCT07170384|BEHAVIORAL|Healthy Eating Advice|Participants will continue their standard medical treatment and will receive general healthy eating advice, as routinely recommended in clinical practice. No additional structured dietary program will be provided. Assessments will be performed at baseline and at 3 months.
223447463|NCT04876976|DRUG|Cyanoacrylate, Isobutyl|using cyanoacrylate in the surgical repair of urethro-cutaneous fistula
223447464|NCT04876976|PROCEDURE|Classic surgical repair|classical repair of urethro-cutaneous fistula without the use of cyanoacryalte
223568650|NCT05125718|DRUG|0.85% synthetic antimicrobial peptide TAPS-18|commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
223568651|NCT05125718|DRUG|0.9% normal saline|commercially available normal saline Sodium Chloride irrigation solution
224146312|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
224146313|NCT00715312|OTHER|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
224146314|NCT03910647|DRUG|pantoprazole|effect of this drug on renal function
224146315|NCT04462757|DRUG|Anakinra 100Mg/0.67Ml Inj Syringe|100 mg interleukin-1 receptor antagonist (r-meth-Hu-IL-1Ra), anakinra; marketed as Kineret® in 0.67 mL prefilled syringe for single use
224146316|NCT01925651|RADIATION|No Bolus|no bolus use
224146317|NCT01925651|RADIATION|Alternate Bolus|0.5cm bolus use in alternate days
224146318|NCT01925651|RADIATION|Continuous Bolus|0.5 cm bolus use in continuous days
224146319|NCT05557734|PROCEDURE|caudal block|injection of local anesthestic through the scral hiatus into the sacral canal to reach caudal epidural space
224146320|NCT05557734|PROCEDURE|perianal block|local anesthestic infiltration in the perianal area to block terminal branches of the nerves supplying the anal canal
224146321|NCT03583320|DIAGNOSTIC_TEST|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
224146322|NCT04985331|DEVICE|W-GenZD|"W-GenZD is a program that delivers evidence based therapy for the symptoms of mild-moderate depression and anxiety in adolescents in brief conversations with a fully automated relational agent."
223447465|NCT01122017|PROCEDURE|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
223447466|NCT01826045|DRUG|Poly-gamma Glutamic Acid|
223447467|NCT01826045|DRUG|Placebo|
223447468|NCT05699785|OTHER|plasma inflammatory markers|Evolution of different plasma inflammatory markers (CRP, IL6, D-Dimers, CD14s, CD163, IL-1, IP-10, MCP-1, IL-18, IFAB)
223447469|NCT05699785|OTHER|CD4/CD8 ratio|Evolution of CD4/CD8 ratio
223447470|NCT02998359|DEVICE|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
223447471|NCT02998359|DEVICE|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
223447472|NCT02336009|DEVICE|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
223447473|NCT04091815|OTHER|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
223568652|NCT02335047|OTHER|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
224146323|NCT05515952|DEVICE|Transcranial Magnetic Stimulation|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
224146324|NCT05515952|DEVICE|Transcranial Magnetic Stimulation (Sham)|TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant. For sham, the side of the coil that does not deliver pulses will be used.
223447474|NCT00913770|BEHAVIORAL|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
223447475|NCT00913770|DRUG|Buprenorphine Initiation|
223447476|NCT00320697|DRUG|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
223447477|NCT00320697|DRUG|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
224055873|NCT07170306|PROCEDURE|transcatheter aortic valve replacement|Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive cardiac interventional procedure that delivers a compressed artificial aortic valve to the diseased aortic valve site via peripheral blood vessels (e.g., the femoral artery) or the apex of the heart through a catheter, releases and deploys the valve to replace the original diseased valve leaflets, thereby restoring normal valve function and treating severe aortic stenosis (AS).
223447478|NCT03260790|BIOLOGICAL|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
224146325|NCT06390631|DEVICE|Continuous Positive Airway Pressure|Patients with COPD were recruited to breath under the atmosphere pressure and different levels of CPAP (4, 6, 8 and 10 cm H2O).
224146326|NCT03411850|BIOLOGICAL|Orencia|FDA approved biologic
224146327|NCT03411850|OTHER|Placebo|
224146328|NCT01452555|BEHAVIORAL|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
224146329|NCT02058758|DEVICE|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
223447479|NCT03260790|BIOLOGICAL|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
223447480|NCT06854809|BEHAVIORAL|Cognitive functional therapy|"The intervention consists of a Cognitive-Functional Therapy (CFT) program for individuals with shoulder pain, conducted by trained physiotherapists (106 hours of training) under the supervision of an expert with over 8 years of experience. CFT adopts a biopsychosocial approach and is structured into three main components:~Making Sense of Pain - A cognitive component aimed at reinterpreting dysfunctional beliefs about pain through a reflective process based on the patient's life history, promoting understanding and self-efficacy.~Graded Exposure with Control - Gradual exposure to functional activities, aiming to modify maladaptive associations between movement and pain, fostering the development of movement confidence.~Lifestyle Change - Discussion and implementation of strategies to promote a healthy lifestyle, including physical activity, sleep habits, and stress management.~All three components are integrated from the first session, with initial focus on building the therapeutic all."
224055874|NCT00000787|BEHAVIORAL|Pre- and post-test counseling|
224055875|NCT01865630|DRUG|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
224055876|NCT03858842|OTHER|epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD|epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
224055877|NCT05241457|DEVICE|Ekso gait training|Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
224055878|NCT05241457|PROCEDURE|Standard physical therapy|Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
224055879|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
224055880|NCT00914927|DRUG|Avatrombopag|Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
224055881|NCT00914927|DRUG|Placebo|Placebo or inactive substance once a day for up to 7 days
224055882|NCT00822965|OTHER|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
224055883|NCT00822965|OTHER|Phone Interviews|2 follow-up phone interviews.
224055884|NCT00822965|BEHAVIORAL|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
224055885|NCT01388660|DRUG|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I \& II Day 1 (crossover manner)
224055886|NCT01388660|DRUG|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I \& II Day 1 (crossover manner)
224055887|NCT03002584|OTHER|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
224146330|NCT01795586|DRUG|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m\^2; Level 2: 1.1 mg/m\^2; Level 3: 1.4 mg/m\^2"
224146331|NCT01795586|DRUG|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
224055888|NCT01648790|DRUG|Prasugrel ODT1 - Tablet|Administered orally as tablet.
223447481|NCT06854809|OTHER|Therapeutic exercise|Participants in the Therapeutic Exercises Group will engage in individualized exercises targeting the scapulothoracic musculature and rotator cuff. The exercises, performed bilaterally, include lateral arm rotation, T, W, wall hand slide, and diagonal arm movement upwards. Each participant will be guided by one of two physiotherapists, randomly assigned. The exercises will follow a protocol consisting of 3 sets of 12 repetitions, with 1-minute rest between sets, using progressively resistant Thera-Bands®. Resistance will increase when pain is ≤2 on the Numerical Rating Scale and perceived exertion is \<3 on the Borg Scale. The protocol was designed based on scientific literature and shoulder pain treatment guidelines to address muscle activation deficits and rotator cuff and scapulothoracic imbalances.
223447482|NCT01531595|DRUG|Bevacizumab plus alternating XELOX/XELIRI|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
223447483|NCT02838589|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
223447484|NCT02838589|DRUG|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
223447485|NCT04938414|DIAGNOSTIC_TEST|Lumbar puncture|Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
223447486|NCT02298413|DEVICE|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
223447487|NCT05310526|OTHER|Training Group|Training for prescribing the Brazilian cardioprotective diet
223447488|NCT04892992|BEHAVIORAL|DFG|
223447489|NCT04714762|DEVICE|eMOM GDM application|"Participants in the intervention group will use the eMOM GDM -application one week/month.~eMOM GDM application includes:~* continuous glucose monitor (CGM, Medtronic)~* diet (digital food tracker) (min 3 days during one application week)~* heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)~* weight measured once a week~The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in)"
223447490|NCT00553852|DRUG|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
223447491|NCT03816007|BEHAVIORAL|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
223447492|NCT03816007|BEHAVIORAL|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
223447493|NCT06863298|OTHER|Podcast|A podcast is content that can be listened to on any digital audio listening device, including a computer, that supports audio file playback.
223447494|NCT06613035|DRUG|Selinexor|Selinexor: 60 mg/day from days -9 to -5.
224146332|NCT04091334|DEVICE|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
224146333|NCT04091334|OTHER|Standard care|Standard care and evaluation and monitoring
223447495|NCT06613035|DRUG|Melphalan|Selinexor: 60 mg/day from days -9 to -5.
223447496|NCT06613035|DRUG|Intravenous Busulfan|3.2 mg/kg on days
223568653|NCT02683070|PROCEDURE|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
223568654|NCT02683070|DRUG|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
224055889|NCT01648790|DRUG|Prasugrel ODT2 - Tablet|Administered orally as tablet.
224055890|NCT01648790|DRUG|Prasugrel ODT2 - Suspension|Administered orally as suspension.
224146334|NCT04408118|DRUG|Atezolizumab|"Atezolizumab (840 mg) will be administered intravenously on Days 1 and 15.~The first infusion of atezolizumab will be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes."
224146335|NCT04408118|DRUG|Paclitaxel|Will be administered on days 1, 8 and 15 via IV infusion over 1 hour.
223447497|NCT06613035|DRUG|Fludarabine|30 mg/m² on days
223568655|NCT01144975|DRUG|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
223568656|NCT01144975|DRUG|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
223568657|NCT03297073|DRUG|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
223447498|NCT00268684|DRUG|Erlotinib, Temozolomide|
223447499|NCT03813641|DRUG|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
223568658|NCT03297073|PROCEDURE|hepatic surgery|
224055891|NCT03329911|DRUG|EU Avastin®|100 mg/4 mL
224055892|NCT03329911|DRUG|BAT1706|100 mg/4 mL
224055893|NCT03329911|DRUG|Paclitaxel|200 mg/m²
224055894|NCT03329911|DRUG|carboplatin|target area under the curve \[AUC\] 6 mg/mL•minute
224055895|NCT02969187|DRUG|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
224055896|NCT02969187|DRUG|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
224055897|NCT02969187|DRUG|Saline|
224146336|NCT04408118|DRUG|Bevacizumab|Will be administered intravenously over 30-90 minutes on Days 1 and 15.
223447500|NCT03813641|DRUG|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
223447501|NCT05006846|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
223447502|NCT01926197|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
223447503|NCT01926197|DRUG|Irinotecan|Irinotecan 180 mg/m² IV over 90 minutes on Day 1 of a 14-day cycle.
223447504|NCT01926197|DRUG|Leucovorin|Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
223447505|NCT01926197|DRUG|5FU|5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.
223447506|NCT01926197|RADIATION|Stereotactic Body Radiotherapy (SBRT)|Radiotherapy treatment starting about 8 weeks after modified FOLFIRINOX induction chemotherapy, administered as 5 fractions of 8 Grey (Gy) each, on 5 separate days.
223447507|NCT03289806|PROCEDURE|Samples of fibroblasts from Tenon's capsule|
223447508|NCT02570035|DRUG|Mirabegron|oral
223447509|NCT07007598|DEVICE|Hemostatic clip|The hemostatic clip is endoscopically applied after a colorectal polypectomy to close the mucosal defect.
224055898|NCT01486927|BIOLOGICAL|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
224055899|NCT01486927|BIOLOGICAL|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
224146337|NCT06161155|COMBINATION_PRODUCT|Protein digestibility|"Two protein sources differing in digestiblity will be used in the dietary intervention to create a difference in protein flow into the large intestine, resulting in different levels of protein fermentation.~Participants will swallow an ingestible that senses biomarkers related to protein fermentation."
224146338|NCT02450734|PROCEDURE|Ultrasound-guided intermediate cervical plexus block|
224146339|NCT04569916|RADIATION|radiotherapy|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
223447510|NCT07006558|DIETARY_SUPPLEMENT|Diamino Oxidase|The investigational product is a dehydrated power of DAO enzyme from green pea (Pisum sativum L.) sprouts (adiDAO®Veg, DR Healthcare, S.L.U., Barcelona, Spain), with an enzymatic activity \> 298 mU/g (\> 14,500 kHDU/g).
223447511|NCT05776914|BIOLOGICAL|Donor Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of freeze-thawed donor stool
223447512|NCT05776914|BIOLOGICAL|Autologous Fecal Microbiota Transplantation|Single fecal microbiota transplantation using 50 gm of stool collected from the same individual
223447513|NCT07009184|DRUG|[111In]In-DOTA-TCO-trastuzumab|\[111In\]In-DOTA-TCO-trastuzumab is a chemically cleavable \[111In\]In-labeled trastuzumab conjugate that is administered first to the patient, it accumulates in HER2-positive tumors and internalizes in HER2-expressing tumor cells.
223447514|NCT07009184|DRUG|Small molecule tetrazine trigger component|TRG001 is a small molecule tetrazine trigger that reacts with \[111In\]In-TGW211-DC in blood and extracellular space thus releasing a fast clearing \[111In\]In-DOTA containing fragment which is rapidly eliminated via the kidney. Because of its non-cell permeable nature, TRG001 does not reach \[111In\]In-TGW211-DC inside tumor cells and therefore the radioactivity inside tumor cells is retained by the tumor.
223447515|NCT03884985|OTHER|Visual stimulation|In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
224146340|NCT04569916|DRUG|irinotecan liposome|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
224146341|NCT04569916|DRUG|apatinib|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
223447516|NCT01781052|DRUG|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
223447517|NCT05960149|DRUG|using Indocyanine Green|Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
223447518|NCT05960149|PROCEDURE|Nerve-sparing robot-assisted laparoscopic radical prostatectomy|Nerve-sparing robot-assisted laparoscopic radical prostatectomy without the use of Indocyanine Green
223447519|NCT03609957|OTHER|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
224146342|NCT04569916|DRUG|PD-1 antibody|radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
224146343|NCT04605536|OTHER|animation videos|watch animation videos about capsule endoscopy
224146344|NCT04605536|OTHER|explanation about endoscopy endoscopy|Give general explanations about endoscopy endoscopy
224146345|NCT01374217|DRUG|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
224146346|NCT01374217|DRUG|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
223447520|NCT03609957|OTHER|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
223447521|NCT07011641|BEHAVIORAL|Structured Online CBT Program|The interventions consisted of eight weekly group sessions (1.5-2 hours each), with each session addressing a specific theme identified through literature as closely related to parental burnout. The sequential themes were the social pressure on parenting, the dynamic balance of parental stressors and resources, parental perfectionism, personal emotional competencies, parent-child relationship quality, co-parenting quality, help seeking, with a last session focused on relapse prevention.
223447522|NCT02393430|DRUG|Rebamipide|Rebamipide is a
224055900|NCT03686436|DEVICE|ocular coherence tomography|imaging by ocular coherence tomography
224055901|NCT03451786|DEVICE|IOL|Intraocular lens
223447523|NCT02393430|BEHAVIORAL|optimization of life style|
223447524|NCT06731400|DIETARY_SUPPLEMENT|EPA supplementation|Six healthy individuals will be supplemented with fish oil contains omega 3 (EPA) for eight weeks, with blood samples collected before and after the intervention.
223447525|NCT02425202|DRUG|Ketamine|Post-operative continuous infusion until 0600 the next day
223447526|NCT02425202|OTHER|Saline infusion|Post-operative continuous infusion until 0600 the next day
223447527|NCT07018232|BEHAVIORAL|Unplanned healthcare encounter|Patient needing to connect with healthcare to fill a medication gap
223447528|NCT07023198|OTHER|Clinical breast examination and Navigation|trained nurses on clinical breast examination and navigation will provide screening for all eligible women and they will follow those women who will have suspicious breast lesions until they have completed their final diagnosis of breast cancer and initiation of breast cancer treatment
223447529|NCT07023146|DEVICE|Moderate to high intensity (PTMH; 65-80% of 1-repetition maximum [1RM]) )|Power training performed at maximum velocity in the concentric phase with moderate to high intensity
223447530|NCT07023146|DEVICE|low to moderate intensity (PTLM; 40-60% of 1-repetition maximum [1RM])|Power training performed at maximum velocity in the concentric phase with lower to moderate intensity
223447531|NCT07026487|OTHER|Music intervention|This group will receive music therapy while performing Needle EMG
223447532|NCT07021937|DRUG|Semaglutide 1.7mg subcutaneous|Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment
223447533|NCT07021937|DRUG|Placebo|Placebo saline solution subcutaneous
223447534|NCT06088368|PROCEDURE|in-plane needle guidance|Ultrasound -guided lumbar plexus block with in-plane needle guidance using the Shamrock method
223568659|NCT01746511|PROCEDURE|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
223568660|NCT01746511|DRUG|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
223568661|NCT02125903|DRUG|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
223741650|NCT06853067|OTHER|Monitoring of body temperature|Body temperature is monitored in the forehead using the Temperature Monitoring Patient Sensors in patients sedated with dexmedetomidine or remimazolam during spinal anesthesia.
224055902|NCT01476475|DRUG|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
224055903|NCT01476475|DRUG|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
223568662|NCT01065051|DRUG|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
223741651|NCT04828785|OTHER|MTM|weekly home meal delivery; an explanation of the medical tailoring of the meals; and a 6-session telephone lifestyle intervention change program designed to complement the period of meal delivery and prepare for the period after meal delivery with behavioral and skill-building approaches to sustain the benefit of the intervention.
223741652|NCT04828785|OTHER|Food Subsidy|$40/month food subsidy
224055904|NCT01476475|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
224055905|NCT05288738|DRUG|Dexmedetomidine 1 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 1 mcg/ml
224055906|NCT05288738|DRUG|Dexmedetomidine 2 mcg/ml|34 patients received PCA morphine 1 mg/ml with combination of dexmedetomidine 2 mcg/ml
224055907|NCT01278745|BIOLOGICAL|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
224055908|NCT01278745|DRUG|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
224055909|NCT02560376|DRUG|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
224055910|NCT04608227|DEVICE|Clearsight monitoring|Non invasive hemodynamic monitoring using a finger cuff Cardiac ultrasound performed to calculate Velocity - Time - integral (VTI) Both intervention are performed before and after a passive leg raising challenge.
224146347|NCT01374217|DRUG|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
223447535|NCT06088368|PROCEDURE|out-of-plane needle guidance|Ultrasound -guided lumbar plexus block with out-of-plane needle guidance using Shamrock method
223447536|NCT07027111|DRUG|NVG-2089|Study drug
223447537|NCT07026136|OTHER|Hybrid Digital Learning with AI Chatbot for Geriatric Communication|A web-based, self-directed learning program integrated with a conversational AI chatbot. The chatbot reinforces learning and allows for flexible post-training practice.
223447538|NCT07026136|OTHER|Traditional Learning: Printed Educational Materials|Traditional teaching materials, printed document including structured readings on aging knowledge, empathy, communication barriers, and case-based communication strategies with older adults.
223447539|NCT07026916|DRUG|GFH375|GFH375 will be administered at the 600mg QD, orally, until disease progression or intolerable toxicity.
224055911|NCT03445871|BIOLOGICAL|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
224055912|NCT03445871|DIAGNOSTIC_TEST|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
223568663|NCT01065051|DRUG|Placebo|Single oral dose
223568664|NCT01888731|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
223568665|NCT01145352|DRUG|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
223568666|NCT00962169|OTHER|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
223568667|NCT00962169|OTHER|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
223568668|NCT00746265|BEHAVIORAL|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
223568669|NCT02830347|DRUG|Amoxicillin|Extraction
223568670|NCT02830347|PROCEDURE|Extraction|Extraction of third molars
223568671|NCT05254275|OTHER|Ozoral Pro and Ozoral gel administration|Peri-implant mucositis sites will receive in-office Ozoral Pro administration after non-surgical therapy. Patients will use Ozoral Gel for the domiciliary administration once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
223568672|NCT05254275|OTHER|Curasept chlorhexidine gel 1%|Peri-implant mucositis sites will receive in-office Curasept chlorhexidine gel 1% administration after non-surgical therapy. Patients will use chlorhexidine gel 1% for the domiciliary application once a day for 14 days after the visits (no rinsing and eating for 30 minutes after gel application).
223568673|NCT05448404|DRUG|18F-PSMA-1007|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
223568674|NCT05448404|DRUG|18F-FDG|Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
223568675|NCT05227599|OTHER|Online survey questionnaire|Participants will complete a brief online survey every morning and evening within 1 hour of waking and 1 hour of going to sleep. The surveys will be a combination of measures used to assess affect, stress, and symptoms
223568676|NCT04607941|OTHER|Questionnaires|Self-administered questionnaires
223568677|NCT04607941|OTHER|Phone interviews|A small amount of subjects will be selected at random for phone interviews.
223568678|NCT01967823|BIOLOGICAL|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
224055913|NCT03627221|BEHAVIORAL|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
224055914|NCT04327583|BEHAVIORAL|IPPACTTO|"The coordinated experimental pharmaceutical path consists of 7 pharmaceutical interviews or consultations. One initial pharmaceutical consultation with the hospital pharmacist. Five follow-up pharmaceutical interviews with the dispensary pharmacist. One follow-up pharmaceutical consultation with hospital pharmacist.~Each pharmaceutical interview or consultation will result in the drafting of a pharmaceutical report to be sent to the other participating health professionals. At each pharmaceutical consultation or interview, the pharmacists requested perform a clinical pharmaceutical analysis of drug prescriptions; Evaluate the patient's understanding; Detect adherence problems, Identify drug related problems; Alert the oncologist and / or the attending physician."
224055915|NCT03086733|DRUG|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
224055916|NCT02789904|OTHER|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
224055917|NCT04730258|DRUG|CFI-400945|The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
224055918|NCT04730258|DRUG|Azacitidine|Azacitidine will be given at its labeled dose and schedule
224055919|NCT05264545|DEVICE|PrimeTaper EV|The PrimeTaper EV Implant is a screw shaped dental implant with a defined surface achieved through grit blasting, followed by a process involving a treatment in diluted hydrofluoric acid. There is a conical connection between the implants and the abutments for a tight and stable connection.
224055920|NCT04427683|BEHAVIORAL|Brief mindful parenting program|Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
223568679|NCT01967823|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223568680|NCT01967823|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
223568681|NCT01967823|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
223447540|NCT00815477|BEHAVIORAL|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
223447541|NCT00815477|BEHAVIORAL|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
223447542|NCT05663944|DRUG|Sirolimus 0.5Mg Tab|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
223447543|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be undertaken at Sir Peter Mansfield Imaging Centre, University of Nottingham at the start of the trial, and at the end, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
224055921|NCT05916105|DRUG|Ciprofloxacin Tablets|Ciprofloxacin antibiotic
224055922|NCT05212506|BIOLOGICAL|vaccinated and unvaccinated|the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
224055923|NCT05735808|BEHAVIORAL|Physician based education|Regular education provided by physician
224055924|NCT05735808|BEHAVIORAL|VR based education|VR based education
224055925|NCT01843842|DRUG|Ergoferon|Safety and Efficiency of liquid dosage form
224055926|NCT01843842|DRUG|Placebo|Safety and Efficiency of liquid dosage form
224055927|NCT02589899|OTHER|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
224055928|NCT06400173|BEHAVIORAL|Cognitive screening|The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.
224055929|NCT06400173|BEHAVIORAL|Audiological Assessment|"Four audiological tests are included in the audiological assessment~1. Tympanometry to assss the middle ear status~2. Pure-tone audiometry with headphone to evaluate the hearing thresholds~3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise~4. The hAVICOP questionnaire to assess the hearing-related quality of life"
224055930|NCT01977599|OTHER|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
224055931|NCT04278963|DRUG|YinHu QingWen Decoction|YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
224055932|NCT04278963|DRUG|YinHu QingWen Decoction(low dose)|This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
224055933|NCT04278963|OTHER|Chinese medicine treatment|This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
224055934|NCT04278963|OTHER|standard western medicine treatment|Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
224055935|NCT06303284|DRUG|subcutaneous Teriparatide injection|20 µg subcutaneous (SC) Teriparatide injection
224055936|NCT06303284|OTHER|placebo|placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
224055937|NCT01605279|DRUG|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
224055938|NCT01605279|DRUG|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
224055939|NCT02615483|OTHER|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
224146348|NCT01374217|DRUG|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
224146349|NCT04306055|OTHER|Questionnaire with precaution information|Ever blood donors in this group would receive a questionnaire which includes some information about how donors can donate safely and how blood center will protect the blood donors during the epidemic of COVID-19.
224146350|NCT04306055|OTHER|Experimental: Questionnaire without precaution information|Ever blood donors in this group would receive a questionnaire which dose not include the information above.
224146351|NCT01913808|DRUG|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
224146352|NCT01913808|DRUG|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
223568682|NCT00746915|DEVICE|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
223447544|NCT05663944|PROCEDURE|1st Percutaneous or Endoscopic Ultrasound guided liver biopsy|After informed consent, participants will undertake up to a 8-week screening period to provide baseline data to ensure eligibility. During this period, participants will undergo blood tests, percutaneous or endoscopic ultrasound-guided liver biopsy, unless the participant has undergone a liver biopsy within the past 3 months, in which case the previous liver biopsy sample will be utilised for this study. They will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate with sirolimus when compared to placebo
223447545|NCT05663944|DRUG|Placebo 0.5mg capsule|"Once randomised, participants will receive either sirolimus or placebo daily for 6 months. The placebo is unmatched. Participants will start on a dose of 1mg daily (2 x 0.5mg capsules) and will have weekly routine bloods including full blood count, renal function and electrolytes and liver function test along with sirolimus trough levels, to maintain blinding of the research team members carrying out blood tests. Placebo doses will be adjusted randomly, in a pattern that mirrors the adjustments made to participants on sirolimus.~All participants will be reviewed by a research clinician at 2, 4 and 6 months."
223447546|NCT05663944|DIAGNOSTIC_TEST|Baseline Blood Tests|"During the initial clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
223447547|NCT05663944|DIAGNOSTIC_TEST|Baseline Clinical Examination|A thorough medical examination will be undertaken at the first clinical visit (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants are clinical stable. This will also serve as a comparator for future clinical examinations once participants have commenced the study drug.
223568683|NCT05608525|DEVICE|transcranial current stimulation|A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
223568684|NCT05608525|BEHAVIORAL|GRASP|A standardized occupational therapy- GRASP will be performed daily together with tDCS over the period between the Pre Assessment and the Post Assessment. GRASP exercise will be administered concurrently with or immediately after tDCS stimulation. GRASP is a self-directed arm and hand exercise program for which is supervised by a therapist, but done independently by the participant (and with their family if possible). GRASP has been shown to improve arm and hand function and strength in stroke patients in community \[22-27\]. The versions of the program- Home GRASP will be used. All occupational tasks will be selected from the GRASP task pool and be progressed according to the GRASP protocol (https://neurorehab.med.ubc.ca/grasp). Each GRASP session will take about 1 hour. A total of 20 GRASP sessions will be administered.
224055940|NCT04664361|DIETARY_SUPPLEMENT|Nicotinamide mononucleotide|Daily supplementation with NMN at 250 and 500 mg for 38 days in total
224055941|NCT04664361|OTHER|Placebo|Daily supplementation with placebo for 38 days in total
224055942|NCT00108394|DRUG|pamidronate|
224146353|NCT05946759|DEVICE|Histolog Scanner|The PMPF study is collecting data that includes the use of the CE Mark IVD Histolog Scanner for the breast lumpectomy margin assessment.
224146354|NCT05627700|DEVICE|AVL200 IOL|The AVL200 is an intraocular lens surgically implanted in the eye after cataract surgery.
223568685|NCT01925911|DRUG|IPI-145|25 mg BID Oral Capsule
223568686|NCT01925911|DRUG|Midazolam|2 mg midazolam syrup
223568687|NCT00841048|DRUG|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
223568688|NCT00841048|DRUG|Placebo|
223568689|NCT03211026|OTHER|No intervention|No intervention
223568690|NCT00966849|OTHER|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~* An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~* All children under 5 years in the household must be up-to-date with vaccinations.~* All children under 5 years must attend a growth monitoring clinic twice per year.~* All children 6-17 years in the household attended school at least 90% of days in the last month.~* At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
223568691|NCT00966849|OTHER|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
224055943|NCT00159991|PROCEDURE|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
224055944|NCT00159991|PROCEDURE|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
224055945|NCT01989312|PROCEDURE|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
224055946|NCT01989312|PROCEDURE|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
224055947|NCT01989312|DEVICE|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
224055948|NCT01989312|DEVICE|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
224055949|NCT01989312|DRUG|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
224055950|NCT01989312|DRUG|Lidocaine|
224055951|NCT01989312|DRUG|Epinephrine|
224055952|NCT01989312|DRUG|Levobupivacaine|
224055953|NCT01547585|OTHER|Standardized soy containing muffin|Standardized muffin containing two levels of soy
223447548|NCT05663944|DIAGNOSTIC_TEST|Week 1 - 5 Titration Blood Tests|"Participants will start on a dose of 1mg daily (2 x 0.5mg tablets) and will have weekly bloods:~* full blood count,~* urea and electrolytes and~* liver function tests to check the study drug is not causing any significant organ damage.~* Sirolimus trough levels will be measured to determine the next dose. The aim will be to achieve a steady state blood trough level of 3-7 ng/ml, which is usually achieved in 3-5 weeks. Therefore, participants will have a minimum of 3 weeks of blood tests during this period, The need for week 4 and 5 blood tests will be decided by the trial pharmacist who will be monitoring results.~Placebo will also be started at 2 capsules daily. All participants will undergo weekly blood tests for the first 3-5 weeks and placebo doses will be adjusted randomly to maintain blinding."
223447549|NCT05663944|OTHER|Month 2 Clinical Examination|A thorough medical examination will be undertaken at Month 2 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
223447550|NCT05663944|DIAGNOSTIC_TEST|Month 2 Blood Tests|"During the Month 2 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
223447551|NCT05663944|OTHER|Month 4 Clinical Examination|A thorough medical examination will be undertaken at Month 4 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants remain clinically stable whilst on the study drug. They will also be asked about potential side effects in detail.
223447552|NCT05663944|DIAGNOSTIC_TEST|Month 4 Blood Tests|"During the Month 4 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
223568692|NCT00966849|OTHER|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
223568693|NCT00966849|OTHER|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
224055954|NCT00820651|DIETARY_SUPPLEMENT|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
224055955|NCT00820651|OTHER|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with \<10% of saturated fatty acids and protein 14%, and exercise)
224055956|NCT01550250|BEHAVIORAL|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
224055957|NCT01550250|BEHAVIORAL|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
224055958|NCT03374189|DEVICE|EZ close|EZ close used.
224055959|NCT03374189|DEVICE|Carter Thomason|Carter Thomason used.
224300966|NCT02953470|BEHAVIORAL|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
224300967|NCT03908762|DEVICE|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
224300968|NCT03908762|BEHAVIORAL|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
224300969|NCT04710966|PROCEDURE|arthroscopic debridement|For the arthroscopic debridement, only stump refreshing and surrounding soft tissue cleaning were performed.
224300970|NCT04710966|PROCEDURE|arthroscopic repair|For the arthroscopic repair, we converted partial tears into full-thickness tears and sutured them.
224300971|NCT05912283|DEVICE|Synthetic Nitrile Condoms (53mm)|53mm width synthetic nitrile condoms
224300972|NCT05912283|DEVICE|Synthetic Nitrile Condoms (56mm)|56mm width synthetic nitrile condoms
224300973|NCT05912283|DEVICE|Control Latex Condom|Commercial natural rubber latex condom
224300974|NCT03762486|OTHER|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
224300975|NCT03762486|OTHER|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
224300976|NCT01186601|DRUG|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of \</= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
224300977|NCT05102214|DRUG|HLX301|A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, HLX301 will be administered as a single intravenous (IV) infusion on Day 1 in each 14-day cycle
224300978|NCT06262802|DEVICE|Active decompression|Intracystic active negative pressure
224300979|NCT03343652|DRUG|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
224300980|NCT03343652|DRUG|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
223568694|NCT02369666|DIETARY_SUPPLEMENT|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
223568695|NCT02369666|DIETARY_SUPPLEMENT|Placebo|Contains MCT oil.
223568696|NCT03259048|DIAGNOSTIC_TEST|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
224055960|NCT02375724|DRUG|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
223568697|NCT04482530|OTHER|fruit paste matrice|Evaluation of the kinetics of the appearance of nutrients and the metabolic response induced by the consumption of fruit pastes (5 different matrices will be tested: 1 Original recipe, 1 maltodextrine recipe, 1 fructose recipe, 1 isomaltulose recipe and 1 mixed recipe comprising fructose and isomaltulose) in elderly healthy volunteers.
223568698|NCT01783574|DRUG|Testosterone|
223568699|NCT01783574|DRUG|Placebo|
224055961|NCT02375724|DRUG|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
224055962|NCT05401084|OTHER|Diet|Macronutrient diet changes.
223568700|NCT02213185|OTHER|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
224055963|NCT06255704|DRUG|Zanubrutinib and RCHOP/RDHAP|"Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。"
224055964|NCT05931237|DIETARY_SUPPLEMENT|Cranberry extract capsules|Cranberry extract capsules (Prebiocran(TM))
224055965|NCT02289170|DEVICE|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
224055966|NCT02289170|DEVICE|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
224055967|NCT03483142|DRUG|Misoprostol|( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
224055968|NCT03483142|DRUG|Placebos|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
224055969|NCT00073216|BIOLOGICAL|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
224055970|NCT00073216|BIOLOGICAL|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
224055971|NCT05775185|RADIATION|Orbital radiotherapy|Low dose fractionated orbital radiotherapy, total dose 20 Gy in 2-week period.
223568701|NCT02608775|DEVICE|Metrodoloris Medical System|Application of a skin electrode
223741653|NCT04957719|COMBINATION_PRODUCT|Selatogrel|"Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
224055972|NCT00494611|DRUG|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
224146355|NCT03889600|OTHER|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
224146356|NCT01766479|RADIATION|CT colonography|
223568702|NCT02608775|DEVICE|Aisys® care station, Acertys|Standard photoplethysmography
223568703|NCT05289271|BIOLOGICAL|Vaxelis™|Vaxelis™ 0.5 mL sterile suspension in prefilled syringe for intramuscular administration.
223568704|NCT06344052|DRUG|SP-002|SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration
223568705|NCT06344052|DRUG|Vismodegib|The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
223568706|NCT06017921|DRUG|Eszopiclone 3 mg|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
223568707|NCT06017921|DRUG|Placebo|Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm
223568708|NCT05223907|DRUG|Etomidate|Etomidate will be used for general anesthesia
223568709|NCT05223907|DRUG|Propofol|Propofol will be used for general anesthesia
223568710|NCT02823054|DEVICE|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
224055973|NCT00562952|DRUG|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
224055974|NCT00562952|DRUG|placebo|no intervention
224055975|NCT01309659|DRUG|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
224055976|NCT01309659|DRUG|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
224055977|NCT03462576|COMBINATION_PRODUCT|Methacetin Breath Test|A breath analyzer will be used to measure changes in carbon 12 to carbon13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.
224055978|NCT03462576|DRUG|Emricasan|Investigational drug for NASH treatment in Main Conatus protocol
224055979|NCT03462576|DRUG|Placebo oral capsule|Placebo versus emricasan in Conatus NASH treatment trial
224055980|NCT01059669|OTHER|diagnostic test|
224055981|NCT02667210|OTHER|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
224146357|NCT05165979|OTHER|Hospitalization due to COVID-19|Hospitalization due to COVID-19
224146358|NCT04240171|DRUG|Dapagliflozin 5Mg Tab|Dapagliflozin 5mg tablets daily
223447553|NCT05663944|OTHER|Month 6 Clinical Examination|A thorough medical examination will be undertaken at Month 6 (cardiovascular, respiratory, abdominal, neurological, musculoskeletal, skin), to ensure participants have remained clinically stable whilst on the study drug. At this visit, they will be asked to finish taking the study drug. They will also be asked about potential side effects in detail.
224055982|NCT03155581|BEHAVIORAL|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
224055983|NCT03155581|BEHAVIORAL|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
223447554|NCT05663944|DIAGNOSTIC_TEST|Month 6 Blood Tests|"During the Month 6 clinical visit, venous blood samples will be taken to ensure that participants have no significant organ dysfunction:~* Full blood count~* Urea and electrolytes~* Liver function tests~* Clotting screen~* Sirolimus trough level will also be repeated to ensure that the previously titrated study drug has remained in steady state~Research bloods will also be taken:~\- 5ml EDTA blood for storage and subsequent fibrosis marker analysis once all participants have complete study"
223447555|NCT05663944|PROCEDURE|2nd Percutaneous or Endoscopic Ultrasound guided liver biopsy|All participants will undergo a second liver biopsy at the end of the study, after taking 6 months of the study drug, to look for any histological change in fibrosis progression rate when compared to their first biopsy.
224055984|NCT06148376|OTHER|Personalized treatment|Discontinue prandial insulin treatment
223447556|NCT05663944|DIAGNOSTIC_TEST|1st MRI scan|If participants opt in for MRI scans, a non-contrast MRI scan will be repeated at the end of the trial, after 6 months of taking trial medication. This is to see whether any radiological features of fibrosis change can be detected to correlate with histological findings.
223447557|NCT02380963|DIETARY_SUPPLEMENT|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
223447558|NCT02380963|BEHAVIORAL|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
223447559|NCT05674877|DRUG|Opioid-based group (OB) (placebo/saline)|Patients in the opioid-based group will receive placebo boluses and infusions of saline.
223447560|NCT05674877|DRUG|"Opioid sparing group (OS) (dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine)"|"Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ dexmedetomidine hydrochloride - Pfizer) and ketamine."
223447561|NCT00524004|BIOLOGICAL|Anti-CsbD Bovine IgG|Three times a day for seven days
223447562|NCT00524004|OTHER|Placebo|Three times a day for seven days
223568711|NCT02555813|DRUG|Abraxane|Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
223568712|NCT02555813|DRUG|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
223568713|NCT01116024|DEVICE|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
223568714|NCT01257568|DEVICE|Rejuvenate Modular Hip|Rejuvenate Modular Hip
223568715|NCT01801748|DIETARY_SUPPLEMENT|oral wheat challenge|
223568716|NCT05662774|DIAGNOSTIC_TEST|Ultrasound contrast agent (Sonovue)|Patients are diagnosed by intravenous injection of ultrasound contrast on the first day of admission and information is collected by diagnostic ultrasound instruments
223568717|NCT00604643|DEVICE|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
224055985|NCT01083004|PROCEDURE|Indocyanine green|Using indocyanine green as intraoperative dye
224055986|NCT01083004|PROCEDURE|Brilliant blue arm|Using brilliant blue as intraoperative dye
224055987|NCT00433108|DRUG|Mitoquinone mesylate (MitoQ)|
224055988|NCT04178759|PROCEDURE|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
224055989|NCT04490863|DEVICE|Rad-67 Pulse oximeter & DCI Mini sensor|Noninvasive pulse oximeter that measures hemoglobin
223568718|NCT00801034|DRUG|Calcium|tablets, 1 tablet 2 times per day in 28 days
223568719|NCT00801034|DRUG|Potassium|Tablets, 5 tablets 2 times per day for 28 days
224055990|NCT00300664|DRUG|Human Growth hormone|
224055991|NCT03962101|DRUG|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
224146359|NCT04240171|DRUG|Glimepiride 4Mg Tab|Glimepiride Tablets daily
224146360|NCT00531245|DRUG|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
224055992|NCT01496131|RADIATION|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
224055993|NCT01496131|DRUG|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
224055994|NCT01496131|DRUG|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
224055995|NCT01496131|DRUG|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
224300981|NCT05493137|OTHER|No intervention will be provided|No intervention will be provided, this is an observational study
224300982|NCT02115932|OTHER|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
224300983|NCT02451332|BIOLOGICAL|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
224300984|NCT01156142|DRUG|doxepin hydrochloride|Oral rinse
224300985|NCT01156142|OTHER|placebo|Oral rinse
224300986|NCT00893737|DRUG|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
224300987|NCT00566007|PROCEDURE|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
224300988|NCT00566007|DRUG|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
224300989|NCT00566007|DRUG|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
224300990|NCT05173675|BEHAVIORAL|Empathy in Action for life with diabetes.|"In Phase 1 (Months 1-6) participants receive (Program):~1. Empathetic communications: A dedicated partner (lightly-trained lay person) who communicates with them via phone with timing and frequency defined by the participant within certain parameters. Two letters mailed during the 6 months that compile anonymized learnings from all participants in the callers panel of 10-20 participants, written as a newsletter to share back with the participant.~2. Material Incentives: One choice of health tool (weight scale or pedometer) selected with the caller in week 1 and expected to be received in weeks 3-5. Two small recognition gifts (valued at US$25) chosen by the caller based on their understanding of the participants preferences, and sent at month 2.5 and 4.5.~3. Educational Materials: Printed DM management educational materials mailed right after enrollment and randomization, and expected to be received in weeks 1-2."
224300991|NCT05173675|BEHAVIORAL|Control Phase 2 Materials Only|"1. Material Incentives:~   a. Choice of health tool (weight scale or pedometer) and 2 health promoting gifts chosen by the caller at the end of their 6 month measurement visit.~   i. Health tool is mailed out within the 7th month ii. Health promoting gifts are mailed out in the 8th and 10th month~2. Educational Materials a. The same educational materials mailed to participants in the intervention arm Program will be mailed to control arm participants after they complete their 6 months visit"
224300992|NCT02140411|DRUG|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
224300993|NCT00002444|DRUG|Nitazoxanide|
224300994|NCT02369991|PROCEDURE|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
224055996|NCT05298891|OTHER|Usual clinical practice + hypoproteic diet|"Diet will be composed by:~* energy equal to daily energy expenditure (estimated by indirect calorimetry \* physical activity factor)~* fats 28-35%~* carbohydrates 50-60%~* proteins 0,7-0,8g/kg of body weight 10-13% Diet will be given to the patient after the first visit and the study will start once the patient begins the diet."
224300995|NCT04709367|OTHER|3D optical scan|The clinical protocol consisted of four test sessions in four different days for an overall duration of 3 weeks. During the 1st session, amputees' residual limb volume was measured 7 times at intervals of 10 minutes after the prosthesis removal. During the subsequent sessions, the residual limb volume was measured immediately after the prosthesis doffing and after the amputee's stabilization time, before and after 15-min of walking on a treadmill, both in the morning and in the afternoon.
224300996|NCT03749486|PROCEDURE|Cataract surgery|Cataract surgery will be done following ArcScan measurement
224300997|NCT01016886|DRUG|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
223447563|NCT00524004|BIOLOGICAL|Anti-CS17 Bovin IgG|Three times a day for seven days
223447564|NCT00777322|PROCEDURE|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15-30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross-linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
223447565|NCT02620384|DRUG|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
224055997|NCT03199664|RADIATION|NB-UVB|NB-UVB given twice weekly for 6 months
224300998|NCT03584724|DRUG|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
224300999|NCT03584724|DRUG|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
224301000|NCT03981419|BIOLOGICAL|GRF6021|for IV infusion
224301001|NCT03981419|OTHER|Placebo|for IV infusion
224055998|NCT03199664|COMBINATION_PRODUCT|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
224055999|NCT03302715|GENETIC|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
224056000|NCT03569709|BEHAVIORAL|Aerobic Exercise|Progressive sub-threshold aerobic exercise
224056001|NCT03569709|BEHAVIORAL|Rest|No structured exercise.
223447566|NCT02620384|DRUG|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
223447567|NCT00366119|DRUG|Ramipril|
223447568|NCT00259974|DRUG|Rituximab|Rituximab
223447569|NCT00691873|DRUG|Placebo|placebo
223447570|NCT00691873|DRUG|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
223447571|NCT06150768|DEVICE|Cobalt Chromium Removable Partial Denture|The patient will receive Removable Partial Denture to restore missing teeth in Kennedy Class II cases.
223447572|NCT06150768|DEVICE|Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture|The patient will receive Implant-Supported Porcelain-Fused-to-Metal-Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
223447573|NCT06150768|DEVICE|Implant-Supported Zirconia Fixed Partial Denture.|The patient will receive Implant-Supported Zirconia Fixed Partial Denture to restore missing teeth in Kennedy Class II cases.
223447574|NCT02101359|DRUG|T2380|200 microlitres of T2380 will be administrated intracamerally
223447575|NCT02101359|DRUG|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
223447576|NCT02101359|DRUG|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
223568720|NCT04288453|BEHAVIORAL|Engagement in a 8-week community-based activity program|"Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.~Other Names:~• Pathways and Resources for Engagement and Participation"
224056002|NCT03569709|BEHAVIORAL|Stretching|Gentle progressive upper and lower extremity stretching program
224056003|NCT00431340|DRUG|PXD101|
223568721|NCT00657839|DRUG|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
223568722|NCT00657839|DRUG|Placebo|Matching placebo
223741654|NCT04957719|COMBINATION_PRODUCT|Placebo|"Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI."
224056004|NCT02921620|BIOLOGICAL|PRX-102|Intravenous
224056005|NCT02921620|OTHER|Placebo|Intravenous
224056006|NCT00662402|OTHER|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
223447577|NCT03093051|DEVICE|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
223447578|NCT04094831|OTHER|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition,Basic health education information about CKD is included in the contents to help patients gain knowledge, awareness, and improve their behaviors. Discussion on basic kidney diseases, risk factors, and preventive measures of CKD is performing by CHWs over a mobile phone call to the study patients. The patients have the liberty to discuss their health-related issues with the CHWs over a period of 10 minutes
223447579|NCT02727426|OTHER|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
223447580|NCT02727426|OTHER|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
223447581|NCT04148963|DRUG|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
223447582|NCT04148963|DRUG|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
223447583|NCT01704001|DRUG|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
223447584|NCT04181268|DEVICE|Percutaneous coronary Intervention|Calcified plaque modification during percutaneous coronary intervention
224056007|NCT00271596|DRUG|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
224056008|NCT00271596|DRUG|Placebo|a daily matching placebo administered over 16 weeks
224056009|NCT05874323|GENETIC|Detection of RAGE gene polymorphism (rs1800625)|Detection of RAGE gene polymorphism (rs1800625) By Molecular analysis (real time PCR)
224056010|NCT04707157|DRUG|LY3556050|given orally
224056011|NCT04707157|DRUG|Placebo|given orally
224056012|NCT01779973|BEHAVIORAL|Remote Observed Dosing|
224056013|NCT06081166|DRUG|Obicetrapib|obicetrapib 10 mg daily
224056014|NCT06081166|DRUG|Atorvastatin Calcium|Atorvastatin 80 mg
224056015|NCT06081166|DRUG|Rosuvastatin Calcium|Rosuvastatin 40 mg
224056016|NCT05993559|RADIATION|Arm I (No PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
223447585|NCT05612802|DIAGNOSTIC_TEST|IGF-1|We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
223447586|NCT02183909|OTHER|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
223447587|NCT02183909|BEHAVIORAL|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
223447588|NCT02183909|OTHER|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
223447589|NCT02183909|DRUG|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
223447590|NCT00065195|PROCEDURE|Moving touch therapy|
223447591|NCT00065195|PROCEDURE|Nonmoving touch therapy|
223447592|NCT02003261|BEHAVIORAL|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
223447593|NCT02003261|OTHER|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
223447594|NCT01240928|DRUG|MSK-2206|Level 1: MK-2206 135mg weekly
223447595|NCT01240928|DRUG|Exemestane|Level 1: Exemestane - 25mg daily
224056017|NCT05993559|RADIATION|Arm II (PMRT)|The purpose of this study is to confirm that in patients with breast cancer who have undergone mastectomy after prior neoadjuvant chemotherapy, omitting radiotherapy is non-inferior to post-mastectomy radiotherapy (PMRT) in terms of 5-year disease-free survival (DFS) in patients with pathologic complete remission and a good response to treatment corresponding to RCB class 0-I, compared to patients treated with PMRT.
224056018|NCT01555047|PROCEDURE|IUI|intrauterine insemination
224056019|NCT01555047|PROCEDURE|IUI|intrauterine insemination
224146361|NCT01740388|DRUG|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
224146362|NCT01740388|DRUG|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
223447596|NCT01240928|DRUG|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
223447597|NCT04268628|OTHER|Serum and plasma samples analysis|This is a non-interventional study and no drug will be given as part of this study. Serum and plasma samples will be collected from the participants with metastatic castration-resistant prostate cancer to evaluate genetic polymorphism and pharmacodynamic parameters.
223447598|NCT00931827|DRUG|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
223447599|NCT00931827|DRUG|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
223447600|NCT06131216|DRUG|SHR-2022 Injection|SHR-2022 Injection is administered by intravenous (IV) infusion
223447601|NCT03077386|BEHAVIORAL|ENCOMPASS Intervention|Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
223447602|NCT02811380|DEVICE|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
224056020|NCT04521036|BIOLOGICAL|Convalescent Plasma as Therapy for Covid-19 patients|Patients in the treatment group will receive 500 ml from COVID-19 recovered donors
224056021|NCT02053324|COMBINATION_PRODUCT|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
224056022|NCT04185753|DIAGNOSTIC_TEST|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing|The prevalence of chronotropic incompetence during maximal cardiopulmonary exercise testing
224056023|NCT00419146|DRUG|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
224146363|NCT03428685|DRUG|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
224056024|NCT00419146|DRUG|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
224056025|NCT00419146|OTHER|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
224056026|NCT00419146|OTHER|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
224146364|NCT03428685|DRUG|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
224146365|NCT02746848|BIOLOGICAL|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
224146366|NCT04113148|OTHER|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
224146367|NCT01241396|OTHER|Any MMY treatment|Any line of treatment for MMY
224301002|NCT06284603|DEVICE|Hyperbaric Oxygen Therapy - HBOT|Each session includes exposure of 60 minutes to 100% oxygen at 2.5 atmosphere absolute (ATA), with 5-minute air breaks every 20 minutes
223447603|NCT02811380|DEVICE|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
224056027|NCT03353974|DEVICE|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
224056028|NCT03353974|DEVICE|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
223447604|NCT00416429|BIOLOGICAL|aldesleukin|
223447605|NCT00416429|BIOLOGICAL|recombinant interferon alpha-2a|
223447606|NCT00416429|DRUG|medroxyprogesterone|
223447607|NCT02927002|DEVICE|Noninvasive brain stimulation|
223568723|NCT03666507|PROCEDURE|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
224056029|NCT00505596|BEHAVIORAL|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
224056030|NCT00433680|BEHAVIORAL|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
224056031|NCT05658016|DRUG|TK-112690|TK112690 treatment Pre \& Post Radiation
224056032|NCT05658016|DRUG|Placebo|TK112690 Placebo treatment Pre \& Post Radiation
224056033|NCT03789851|DEVICE|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
224056034|NCT01069172|DEVICE|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
224056035|NCT01069172|PROCEDURE|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
224056036|NCT05661227|DRUG|Dexmedetomidine|Whether apply DEX or not
224056037|NCT05661227|DRUG|0.9% Sodium chloride|Whether apply DEX or not
224056038|NCT05661227|DEVICE|Tourniquet(Early)|Timing of tourniquet application
224056039|NCT05661227|DEVICE|Tourniquet(Late)|Timing of tourniquet application
223568724|NCT02446704|DRUG|Olaparib|
223568725|NCT02446704|DRUG|Temozolomide|
223568726|NCT00194584|BEHAVIORAL|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
223568727|NCT00303771|DRUG|fluorouracil|
224056040|NCT00332254|DRUG|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
224056041|NCT04206605|OTHER|Placebo|Placebo-matching lanadelumab SC injection.
224056042|NCT04206605|DRUG|Lanadelumab|Lanadelumab solution in a PFS for injection.
224056043|NCT01651351|BIOLOGICAL|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
224056044|NCT01651351|BIOLOGICAL|Placebo: Human albumin 2.5%|Intravenous administration
224056045|NCT03082105|OTHER|Breathing in snow|Breathing in snow with different physical properties
224056046|NCT03641872|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
223447608|NCT06339359|OTHER|Exmainations including clinical measurement, kinetic and kinematic measurmetns. Behavioral assessments|Collection of clinical data including K-Bayley Scales of Infant and Toddler Development Third Edition (K-BSID-Ⅲ), , Beery-Buktenica Visual-Motor Integration, Sixth Edition (VMI-6) and clinical measurement. motor analysis and eye tracking
223447609|NCT04627961|DRUG|TAS-102|Eligible patients who consent to participate will receive oral TAS-102 bid for days 1-5 and 8-12 of a 28 day cycle.
223568728|NCT00303771|DRUG|irinotecan hydrochloride|
223568729|NCT00303771|DRUG|leucovorin calcium|
223568730|NCT01689012|BEHAVIORAL|Facial Exercise|
223568731|NCT02241057|DEVICE|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
223568732|NCT02241057|OTHER|Temperature Probe|
223568733|NCT00996515|DRUG|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
223568734|NCT00996515|DRUG|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
223568735|NCT03392883|BEHAVIORAL|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
223568736|NCT00929188|DRUG|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
224056047|NCT00679510|DRUG|rosuvastatin|tablet 10 mgs once daily
224056048|NCT00679510|DRUG|placebo|placebo
224056049|NCT02403336|OTHER|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
224056050|NCT02403336|BEHAVIORAL|Behavioral group intervention|Intervention on patients (educational workshop).
224301003|NCT00985179|BEHAVIORAL|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
223568737|NCT00929188|DRUG|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
224056051|NCT02403336|OTHER|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
224056052|NCT02964026|DEVICE|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
224056053|NCT03890783|OTHER|Evaluation of phonation quality|"Evaluation of phonation quality by :~* Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~* Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
224056054|NCT03890783|OTHER|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~* Self-evaluation: completion of the Deglutition Handicap Index questionnaire~* Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
224056055|NCT03890783|OTHER|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H\&N35 questionnaires
223447610|NCT05998460|BEHAVIORAL|Glucose-Guided Eating with CGM|The GGE intervention consist of up to four weeks of training to learn to eat when glucose levels are at or below their usual fasting level. Specifically, participants following GGE will self-monitor their glucose levels with an unblinded CGM while using a mobile app (GGE app) that will provide feedback on whether or not to eat. At desired mealtimes participants will enter their current glucose level, rate their perceived hunger, and label the type of hunger they are experiencing (physical, emotional, sensory and practical). Participants following GGE will be instructed by the app to eat when two conditions are met: (a) the desire to eat arises and (b) their glucose levels are at or below a personalized threshold. During the training period, participants are meant to associate feelings of perceived hunger with fasting glucose levels (i.e., physical hunger). After the training period, participants continue to follow GGE without CGM or use of the app.
223447611|NCT05998460|OTHER|CGM only|Comparator participants will use unblinded CGM for up to 4 weeks without the use of the GGE app or any other dietary recommendations.
223447612|NCT00369148|DRUG|nateglinide(drug) mitiglinide(drug)|
223568738|NCT00991328|PROCEDURE|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
223568739|NCT04899375|DEVICE|Floss band|Tissue-flossing, is the use of an elastic band to provide compression on soft-tissue and joints whilst performing active and, or passive range of motion.
223568740|NCT04899375|DEVICE|ACE bandage|An ACE bandage is a cloth wrap used to provide compression
223568741|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
223568742|NCT00801788|DRUG|Oxycodone hydrochloride|Extended release tablet
223568743|NCT03344107|OTHER|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after RIRS
223568744|NCT03676543|PROCEDURE|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
224146368|NCT04490317|DIAGNOSTIC_TEST|Cardiac MRI|"1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients"
224146369|NCT04490317|PROCEDURE|Hyperbaric oxygen therapy|"1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients"
224146370|NCT01025258|BEHAVIORAL|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
224301004|NCT02337959|RADIATION|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
224301005|NCT01330459|DRUG|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
223447613|NCT02518841|DEVICE|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
223447614|NCT02518841|OTHER|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
223447615|NCT01483599|DRUG|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
223447616|NCT01483599|DRUG|CNTO 1959 (15 mg)|SC injections
223447617|NCT01483599|DRUG|CNTO 1959 (50 mg)|SC injections
223568745|NCT02994953|DRUG|Avelumab|Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
224301006|NCT01330459|DRUG|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
223447618|NCT01483599|DRUG|CNTO 1959 (100 mg)|SC injections
223447619|NCT01483599|DRUG|CNTO 1959 (200 mg)|SC injections
223447620|NCT01483599|DRUG|Adalimumab|SC injections
223568746|NCT02994953|DRUG|M9241|Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
223568747|NCT02994953|DRUG|Avelumab (Once weekly)|Participants received avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
224056056|NCT00113776|DRUG|ABX-EGF|
224056057|NCT05188820|PROCEDURE|PRP - platelet rich plasma injection|Facet block using PRP
224301007|NCT01330459|DRUG|Ibuprofen|800 mg oral ibuprofen
223447621|NCT01483599|DRUG|Placebo|SC injections
224056058|NCT05188820|PROCEDURE|Cortisone injection|Facet block using cortisone
224056059|NCT01218464|DRUG|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
223447622|NCT02836951|OTHER|Withdrawal of blood|Withdrawal of blood
224056060|NCT01218464|DRUG|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
224056061|NCT03948100|OTHER|Educational Intervention|Undergo dyadic education program
223447623|NCT01500044|PROCEDURE|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
223447624|NCT01500044|PROCEDURE|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
223447625|NCT05368909|DIETARY_SUPPLEMENT|Sleep Supplement|Proprietary sleep formula containing Tri Factor, Ashwagandha root extract, Lavender, Pyridoxal-5-Phosphate, Melatonin, gamma aminobutyric acid (GABA) and Magnesium.
223447626|NCT05368909|DIETARY_SUPPLEMENT|Placebo|Placebo product
223447627|NCT01630356|BEHAVIORAL|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
224056062|NCT03948100|OTHER|Quality-of-Life Assessment|Ancillary studies
223447628|NCT01630356|DEVICE|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
224056063|NCT03948100|OTHER|Questionnaire Administration|Ancillary studies
223568748|NCT02994953|DRUG|M9241 (MTD)|Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
224056064|NCT03948100|PROCEDURE|Yoga|Undergo dyadic yoga
224056065|NCT03388242|OTHER|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
224056066|NCT03901079|OTHER|single-arm study|single-arm study
224056067|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 16 weeks"
224056068|NCT01056172|DRUG|Peginterferon alfa-2a and Ribavirin|"1. PegIFN alfa-2a (PEgasys) 180 ug/week~2. Weight-based ribavirin (\<65kg: 800mg/day, 65-85kg: 1000mg/day, \>85kg: 1200mg/day)~3. Treatment duration: 24 weeks"
224146371|NCT01025258|BEHAVIORAL|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
223447629|NCT01630356|BEHAVIORAL|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
224146372|NCT01117012|DRUG|Ivacaftor|
224146373|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
224146374|NCT01240408|DRUG|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
223447630|NCT01630356|BEHAVIORAL|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
223568749|NCT02994953|DRUG|Avelumab (Expansion cohort)|Participants in the expansion cohorts received Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
223568750|NCT01792817|DEVICE|GammaCore|Treatment with active gammacore vagus nerve stimulator
224056069|NCT04662944|DRUG|brolucizumab|There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
224056070|NCT04662944|DRUG|ranibizumab|There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
224056071|NCT04662944|DRUG|aflibercept|There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
224056072|NCT00316251|DEVICE|Vibration Plate Therapy|
224056073|NCT02773030|DRUG|CC-220|Specified dose on specified days
224056074|NCT02773030|DRUG|Dexamethasone|Specified dose on specified days
224056075|NCT02773030|DRUG|Daratumumab|Specified dose on specified days
224056076|NCT02773030|DRUG|Bortezomib|Specified dose on specified days
224056077|NCT02773030|DRUG|Carfilzomib|Specified dose on specified days
224146375|NCT03695393|BEHAVIORAL|ACT Therapy|The ACT intervention will consist of three 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations.Participants are recruited from a civil society organization and all other study procedures take place at a rehabilitation center. The ACT sessions will be scheduled to take place at the rehabilitation center following randomization.The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in weekly succession, with a goal of 3 sessions within the first month of study participation.
224146376|NCT02486211|DRUG|Amantadine|100mg twice per day for 7 days at 0600 and 1200
224146377|NCT02486211|DRUG|Placebo|Placebo comparator
224146378|NCT04141553|DRUG|Diltiazem Injection|Randomization to one of to active comparator groups
224146379|NCT04358198|DIAGNOSTIC_TEST|Artificial intelligence|The AI algorithm based on the convolutional neural network (CNN) will be used for analysis the pictures of gastric intestinal metaplasia and normal mucosa. Then AI will be used as a diagnostic tool for GIM during routine endoscopy by using pathology as a gold standard.
223447631|NCT06916312|BEHAVIORAL|High ventilation breathwork|Single guided conscious connected breathing session.
223447632|NCT06916312|BEHAVIORAL|Meditation|Single guided body scan meditation session.
223447633|NCT00966355|DRUG|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
223568751|NCT01792817|DEVICE|Sham GammaCore device|Treatment with sham stimulator
223741655|NCT04601753|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
224056078|NCT03764371|DIAGNOSTIC_TEST|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
223741656|NCT04080440|PROCEDURE|Extubation readiness clinical score|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is \> 9, extubation has to be completed."
224056079|NCT04824820|BEHAVIORAL|Vibrator|Clitoral stimulation
224056080|NCT00874445|DEVICE|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
224056081|NCT03469765|OTHER|does not apply|biological sample taking: urine, blood
224056082|NCT05279248|BIOLOGICAL|HPV+MMR（0d），HPV（6m）|Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
224056083|NCT05279248|BIOLOGICAL|HPV（0d），HPV（6m），MMR（7m）|Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
224056084|NCT05279248|BIOLOGICAL|MMR（0d），HPV（1m），HPV（7m）|Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
224056085|NCT04300699|OTHER|Functional Geriatric Assessment|A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
224056086|NCT03702764|DIAGNOSTIC_TEST|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
224056087|NCT01824992|DRUG|Yallaferon®|
224056088|NCT00927290|DRUG|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
224056089|NCT00927290|DRUG|Placebo|Placebo 45 mg QD (30 mg QD the first month)
224056090|NCT04796051|DEVICE|Neck orthosis - with posterior cervical weight|The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
224146380|NCT00673894|DRUG|Sitagliptin|Glutamine 30g +sitagliptin 100mg
224146381|NCT00673894|DRUG|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
224056091|NCT04796051|OTHER|Deep cervical flexors exercise|The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
224056092|NCT03624933|BEHAVIORAL|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
224146382|NCT02500394|PROCEDURE|Ionosteril|biomarker guided volume substitution with Ionosteril
223447634|NCT00966355|DRUG|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
223447635|NCT00966355|DRUG|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
224146383|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
223447636|NCT03934359|DRUG|DN1508052-01|DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
224301008|NCT01330459|DRUG|Lorazepam|2 mg oral lorazepam
223447637|NCT00777192|BEHAVIORAL|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
223447638|NCT06286020|DEVICE|Virtual Reality Therapy|The therapist begins by assessing the patient's swallowing abilities and creating a personalized treatment plan. This involves determining the appropriate Virtual Reality Therapy scenarios, difficulty levels, and specific swallowing goals tailored to the patient's condition.
223568752|NCT00132691|DRUG|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
223568753|NCT00132691|DRUG|oral corticosteroid with immunosuppressive agents as needed|Prednisone
223568754|NCT01739933|DRUG|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
223741657|NCT04080440|PROCEDURE|Usual Care|"After treatment of the acute neurological condition, eligibility for a spontaneous breathing trial will be assessed once a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to usual care."
223741658|NCT05171231|DEVICE|HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD|"HEMOCOLLAGENE® is an absorbable, sterile and hemostatic sponge, composed of type I undenatured, native and lyophilized bovine collagen (0.027 g per sponge).~HEMOCOLLAGENE® will be inserted into oral sites (mainly the alveoli dental) after post-extraction or post-invasive dental surgical procedure, in case of bleeding not controled by usual hemostatic method. HEMOCOLLAGENE® will be let in place and will undergo a complete and natural absorption after several weeks."
223741659|NCT06829953|BEHAVIORAL|GET ActivE|The GET ActivE health coach will review data from the Vira app and send nudges to the participant with insights encouraging them to engage in activities that bring enjoyment or pleasure.
224056093|NCT03624933|BEHAVIORAL|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
224301009|NCT01330459|DRUG|Lidocaine|20 ml 1% buffered lidocaine, injected
224301010|NCT03562559|OTHER|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
224301011|NCT01231399|DRUG|fluorouracil|Given IV
224301012|NCT01231399|DRUG|leucovorin calcium|Given IV
224301013|NCT01231399|DRUG|oxaliplatin|Given IV
224301014|NCT01231399|DRUG|everolimus|Given orally
224301015|NCT01231399|OTHER|laboratory biomarker analysis|Correlative studies
224301016|NCT01231399|OTHER|immunohistochemistry staining method|Correlative studies
224301017|NCT01231399|GENETIC|microarray analysis|Correlative studies
224301018|NCT00760851|OTHER|probiotic strain Bb-12|10\^9 CFU Bb-12 per 4 oz yogurt
223741660|NCT06829953|BEHAVIORAL|Treatment As Usual|Participants randomized to Treatment As Usual may have access to activity data from an app and receive summary information about activity patterns at the end of their participation.
223741661|NCT01471808|DRUG|CSII|continuous subcutaneous insulin infusion for 2\~4 weeks
223741662|NCT01471808|DRUG|CSII, Metformin, Pioglitazone|CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
223741663|NCT01471808|DRUG|CSII, Sitagliptin|CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months
223741664|NCT04566614|OTHER|ctDNA blood sampling|Screening/baseline blood sample to be analysed for ctDNA
224056094|NCT02512133|DEVICE|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
224056095|NCT02512133|PROCEDURE|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
224301019|NCT00760851|OTHER|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
224301020|NCT01843036|OTHER|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
224301021|NCT04146506|OTHER|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
224301022|NCT04988152|BIOLOGICAL|sotrovimab|sotrovimab IV infusion, single dose
224301023|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
224301024|NCT04988152|BIOLOGICAL|sotrovimab|Sotrovimab IM injection, single dose
224301025|NCT04988152|OTHER|Placebo to Biologic|Sterile 0.9% (w/v) sodium chloride solution
224301026|NCT06458842|DRUG|Ketamine|
224301027|NCT06458842|OTHER|Placebo|
224301028|NCT04746300|PROCEDURE|Biopsy|A biopsy will be taken from metastatic tissue, which will be used for DNA sequencing
224301029|NCT04746300|PROCEDURE|Blood sample|Blood samples will be taken for additional translational research
224301030|NCT02705404|GENETIC|Multifocal Tissue Banking|
224301031|NCT06249776|DEVICE|Supernova revascularization device|Mechanical Thrombectomy
224301032|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire at inclusion in registry
224301033|NCT01578135|DRUG|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
224301034|NCT00000476|DRUG|digitalis|
224301035|NCT01941355|BEHAVIORAL|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
224301036|NCT01941355|BEHAVIORAL|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
224301037|NCT00535587|BEHAVIORAL|Exercise|
224301038|NCT00535587|DRUG|pyridostigmine|
224301039|NCT00535587|DRUG|Placibo|
224301040|NCT00535587|BEHAVIORAL|Attention Control|
223741665|NCT05193656|DIAGNOSTIC_TEST|Al_bladder|Detection of bladder tumor with help of Artificial intelligence
223741666|NCT04759209|DIAGNOSTIC_TEST|Biopsies|
223741667|NCT03424265|DIETARY_SUPPLEMENT|EAA mixture|Dietary supplement intervention for 12-weeks
224301041|NCT01956019|DEVICE|MRI scanning|
224301042|NCT01567748|PROCEDURE|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
224301043|NCT01078129|BEHAVIORAL|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
224301044|NCT01078129|BEHAVIORAL|non-CRT|waiting list
224301045|NCT01168765|BEHAVIORAL|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
224301046|NCT01359644|DRUG|PSI-7977|Tablets, oral, 400 mg, once daily
224301047|NCT01359644|DRUG|Daclatasvir|Tablets, oral, 60 mg, once daily
224301048|NCT01359644|DRUG|Ribavirin|Tablets, oral, 200 mg
224301049|NCT01763814|PROCEDURE|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
224301050|NCT01763814|PROCEDURE|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
224301051|NCT01763814|PROCEDURE|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
224301052|NCT00436904|DRUG|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
224301053|NCT00436904|DRUG|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
224301054|NCT03306953|PROCEDURE|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
224301055|NCT01472328|PROCEDURE|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
224301056|NCT01472328|PROCEDURE|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
224301057|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis|Will be performed education in pain neurosciences and clinical hypnosis, in 4 sessions during 4 weeks
224301058|NCT05042115|OTHER|Education in pain neurosciences and clinical hypnosis plus osteopathic manipulative treatment|Will be performed education in pain neurosciences and clinical hypnosis, and only for this group will be delivered osteopathic manipulative treatment, in 4 sessions during 4 weeks
224301059|NCT02130882|DRUG|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
223568755|NCT01739933|DRUG|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
224301060|NCT02130882|OTHER|Placebo|A sterile solution containing 20 millimolar histidine/histidine-hydrochloride (HCl) 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
224301061|NCT05816369|OTHER|Taste session of five ONS flavors|Patients will taste a small sample (30 mL) of five ONS flavors and report their taste experiences by completing questionnaires of each flavor during the taste session. Participants will also complete a malnutrition risk screening (MST), a three-day food diary, questionnaires of self-reported taste and smell changes (TSS), and quality of life (RAND-36).
224301062|NCT00520286|DRUG|Modafinil|200 mg or 400 mg /daily
224301063|NCT00520286|DRUG|Placebo|Placebo / daily
224301064|NCT06484634|DRUG|Low molecular weight heparin|A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
224301065|NCT03752463|DRUG|DAOI-A group|DAOI with A dose
224301066|NCT03752463|DRUG|DAOI-B group|DAOI with B dose
224301067|NCT03752463|DRUG|DAOI-C group|DAOI with C dose
224301068|NCT03752463|DRUG|Placebo oral capsule|Placebo
224301069|NCT04997941|DRUG|Tamoxifen Oral Product|Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.
224301070|NCT04997941|DIAGNOSTIC_TEST|Assessment of Ki-67|Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.
224301071|NCT04997941|PROCEDURE|Surgery|The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
224301072|NCT01878162|OTHER|Exercise|
223568756|NCT06390696|BIOLOGICAL|Microbial intervention|Children in microbial intervention arm receive an indoor sandbox containing play sand enriched with organic leaf compost, moss and humus substances. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and microbe rich growing medium containing organic leaf compost, moss, biochar and humus substances.
224301073|NCT02109510|DRUG|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
224301074|NCT02109510|DRUG|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
224301075|NCT02109510|PROCEDURE|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
224301076|NCT00227786|BEHAVIORAL|smoking cessation intervention|
224301077|NCT00227786|OTHER|counseling intervention|
224301078|NCT01484613|DEVICE|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
224301079|NCT00856219|DIETARY_SUPPLEMENT|Enteral Continuous|Continuous Tube Feeding for 72 hours
224301080|NCT00856219|DIETARY_SUPPLEMENT|Enteral Intermittent|Intermittent Tube Feedings
224301081|NCT00856219|DIETARY_SUPPLEMENT|Parenteral Continuous|Parenteral Continuously for 72 hours
223447639|NCT06286020|BEHAVIORAL|Conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, etc., 30 min each time, once a day for 14 consecutive days.
223447640|NCT06950762|PROCEDURE|Giomer based injectable composite|Giomers utilize surface pre-reacted glass (SPRG) technology, which involves an acid-base reaction between fluorine-containing glass particles and polymer-containing acid when exposed to water. This reaction results in the formation of a glass ionomer phase, which is then dispersed throughout the resin. Furthermore, the S-PRG fillers present in giomer materials enable the continuous release and replenishment of fluoride, offering long-lasting protection against the recurrence of caries
223447641|NCT06950762|PROCEDURE|Universal injectable resin composite|Conventional injectable resin composite
224301082|NCT01715064|BEHAVIORAL|Exercise|1 hour of moderate-intensity exercise
223447642|NCT04413942|BIOLOGICAL|FB825|Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
223447643|NCT04413942|OTHER|Placebo|Formulation buffer
224301083|NCT03275818|DRUG|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
223447644|NCT06042244|OTHER|Multimodal Exercise Group|Listed in arm/ group descriptions
223447645|NCT06042244|OTHER|Waitlist|listed in arm/group description
223447646|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction
223447647|NCT05124132|BEHAVIORAL|Exercise|Exercise
223447648|NCT05124132|BEHAVIORAL|Mindfulness-Based Stress Reduction + Exercise|Mindfulness-Based Stress Reduction + Exercise
223447649|NCT05124132|BEHAVIORAL|Health Education|Health Education
223447650|NCT02557685|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
223447651|NCT01832883|DEVICE|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
223447652|NCT01962623|OTHER|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
223447653|NCT04930705|DEVICE|Treatment with TempSure Applicator|Subjects will receive up to 5 treatments on the abdomen.
223447654|NCT01421147|DRUG|LY2963016|Administered subcutaneously
223447655|NCT01421147|DRUG|Lantus|Administered subcutaneously
223447656|NCT01421147|DRUG|Insulin Lispro|Administered subcutaneously
223447657|NCT02660684|DRUG|Prograf|Injection or oral
223447658|NCT02660684|DRUG|Methotrexate|Injection
223447659|NCT02660684|DRUG|Cyclosporine|Injection or oral
223447660|NCT04640038|DRUG|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
223447661|NCT03887208|PROCEDURE|Laser therapy|non-ablative fractional laser therapy of skin
223447662|NCT03887208|BIOLOGICAL|Autologous ADSC injection|Subcutaneous injection of autologous ADSC
223447663|NCT03887208|PROCEDURE|Normal saline injection|Subcutaneous Normal saline injection
223447664|NCT01268189|DEVICE|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
223447665|NCT01268189|DEVICE|Standard of care dressing|Xeroform control dressing applied to control wound
223447666|NCT05757362|OTHER|Compliance Questionnaire for Therapeutic Home Exercise Program in Physiotherapy and Rehabilitation (cq-HEPT)|An online application of the developed questionnaire form
223447667|NCT01141166|BEHAVIORAL|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
223447668|NCT03525808|DEVICE|AXIOS|Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
223447669|NCT06406166|DRUG|Lifei Xiaoji Wan|The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on
223447670|NCT06406166|OTHER|Conventional treatment with Western medicine|Conventional treatment with Western medicine
223447671|NCT03308929|DEVICE|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
223447672|NCT02449421|BEHAVIORAL|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
223447673|NCT02449421|BEHAVIORAL|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
223447674|NCT06405802|OTHER|Tele-evaluation|Evaluations will be carried out in two different environments: face-to-face in the clinic and remotely using technology. Face-to-face applications and remote evaluations using technology will be repeated once. Face-to-face applications will be made to individuals with low back pain who come to Bozyaka Training and Research Hospital and volunteer to participate in the study. Then, patients will be video-called at home, asked to perform the tests twice as taught, and recorded as a video.
223741668|NCT03424265|DIETARY_SUPPLEMENT|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
224056096|NCT00213187|BEHAVIORAL|Aerobic and Qi gong Exercise|
224056097|NCT01866384|PROCEDURE|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
223447675|NCT03373747|DIAGNOSTIC_TEST|Reliability of IET|The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.
223447676|NCT03373747|DIAGNOSTIC_TEST|Physiological analysis of IET|The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
224056098|NCT01866384|OTHER|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
223447677|NCT02155309|DRUG|Scopolamine|
223447678|NCT02155309|DRUG|Placebo|
223447679|NCT00833014|DEVICE|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
223447680|NCT03585517|DRUG|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
223447681|NCT03102749|OTHER|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
223447682|NCT03039465|DEVICE|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
223447683|NCT01881698|OTHER|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
223447684|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions
223568757|NCT06390696|OTHER|Placebo|Children in placebo arm receive an indoor sandbox containing visually similar play sand modified with peat with low microbial diversity. Families also receive an indoor cultivation set including growing box, seeds, spray bottle, plant lamp and growing medium containing peat, inorganic fertilizers, and potting gravel with low microbial diversity.
223568758|NCT04098367|DEVICE|VIVITY|Extended vision intraocular lens intended for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism in whom a cataractous lens has been removed by extracapsular cataract extraction
223568759|NCT04098367|DEVICE|SYMFONY|Extended range of vision intraocular lens indicated for primary implantation for the visual correction of aphakia in adult patients with less than 1.00 diopter of pre-existing corneal astigmatism in whom a cataractous lens has been removed
223568760|NCT04098367|DEVICE|AT LARA|Extended depth of focus intraocular lens indicated for implantation for the visual correction of aphakia in patients with and without presbyopia in whom a cataractous lens has been removed by extracapsular cataract extraction
223447685|NCT03589157|DEVICE|drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
223447686|NCT02829502|DRUG|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
223447687|NCT02829502|DRUG|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
223447688|NCT00618124|DRUG|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
223447689|NCT05366296|BIOLOGICAL|A Lyophilized COVID-19 mRNA Vaccine|Active substance: NTD-RBD derived from S protein of Omicron variant Excipient: ALC-0315 (4- hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate), ALC-0159 (2-\[(polyethylene glycol)-2000\]-N, N-ditetradecylacetamide), DSPC \[1,2- distearoyl-sn-glycero-3-phosphocholine\], Cholesterol, Trometamol and Sucrose
223447690|NCT05366296|BIOLOGICAL|Placebo|Normal saline (0.9% sodium chloride solution
223568761|NCT04098367|PROCEDURE|Cataract surgery|Cataract removal by routine small incision surgery
223568762|NCT04829305|DRUG|SHR2285|SHR2285 is a selective inhibition of human FXIa small molecule compound.
223568763|NCT01510015|DRUG|Risperidone|variable dose
223568764|NCT00031655|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
223568765|NCT00031655|BIOLOGICAL|donor lymphocytes|Given IV
223568766|NCT00031655|DRUG|cyclosporine|Given PO
223568767|NCT00031655|RADIATION|total-body irradiation|Undergo TBI
223568768|NCT00031655|DRUG|fludarabine phosphate|Given IV
223568769|NCT00031655|DRUG|mycophenolate mofetil|Given PO
223568770|NCT00031655|OTHER|laboratory biomarker analysis|Correlative studies
224056099|NCT04995055|DEVICE|JJVC Investigational Multifocal Contact Lens TEST Lens|TEST Lens
224056100|NCT04995055|DEVICE|ACUVUE® OASYS Multifocal|CONTROL Lens
223568771|NCT00031655|PROCEDURE|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
223568772|NCT00309712|DRUG|fenofibrate 160 mg and placebo|
223568773|NCT00309712|DRUG|simvastatin 20 mg and placebo|
223568774|NCT00309712|DRUG|fenofibrate 160 mg and simvastatin 20 mg|
223568775|NCT03285087|DRUG|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
224056101|NCT02662036|DRUG|Bupivicaine HCL|
224056102|NCT02662036|DRUG|Liposomal bupivacaine|
224056103|NCT01845922|DIETARY_SUPPLEMENT|Low sodium diet|Low sodium diet
224056104|NCT05014334|DRUG|Berberine|berberine 500 mg, twice daily for 14 days
224056105|NCT05014334|DRUG|Vonoprazan|Vonoprazan 20 mg, twice daily for 14 days
223447691|NCT04938596|COMBINATION_PRODUCT|Respiratory bundle|"* Provision of N95 masks and strong recommendation of use to all household contacts and the index case when sharing a room together, for 2 weeks~* Recommendation to index case to sleep in a room alone, with the door closed and avoid sharing room with others during 2 weeks~* Promotion of strategies to improve house ventilation during 2 weeks~* Provision of a TB leaflet and nurse education about TB transmission."
223447692|NCT01797588|PROCEDURE|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
223447693|NCT01797588|PROCEDURE|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (\~60mL) is used to infiltrate the muscle, subcutaneous tissues.
223568776|NCT04809558|BEHAVIORAL|Tongue resistance exercise|Participant will complete tongue resistance exercises.
223568777|NCT00256815|DRUG|chemotherapy|
223568778|NCT00256815|PROCEDURE|Radiation|
223568779|NCT01842932|DRUG|Phloroglucin|Premedication of colonoscopy
223741669|NCT05442957|BEHAVIORAL|BRIGHT|BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.
223741670|NCT05442957|BEHAVIORAL|Attention Control|AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
223741671|NCT02384707|OTHER|allegic food|"Reintroduction procedure for small doses :~* Administration of the first dose~* Clinical monitoring for 45 minutes~* Administration of the second dose"
223741672|NCT02384707|OTHER|Placebo|
224056106|NCT05014334|DRUG|Amoxicillin|amoxicillin 1000mg, twice daily for 14 days.
224056107|NCT05014334|DRUG|Rabeprazole|Rabeprazole 10mg, twice daily for 14 days.
224056108|NCT05014334|DRUG|Bismuth|Bismuth 220mg, twice daily for 14 days.
224056109|NCT05014334|DRUG|Clarithromycin|clarithromy 500mg, twice daily for 14 days.
224056110|NCT04521023|DRUG|Cantabell Tab|Patients assigned to experimental group are treated with Cantabell Tab
224056111|NCT04521023|DRUG|Candemore Plus Tab|Patients assigned to experimental group are treated with Candemore Plus Tab
223568780|NCT01842932|DRUG|Cimetropium bromide|Premedication of colonoscopy
223568781|NCT01842932|PROCEDURE|Colonoscopy|Diagnostic examination of colon
223568782|NCT01842932|DRUG|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
223568783|NCT04441164|OTHER|Observation of Virtual Actions|If the patient is included in the Virtual Reality group, he/she will be asked to observe Virtual Motor Actions (their own avatar moving in a virtual environment) using a headset once a day for 9 days during 5 minutes, followed by 5 minutes of relaxation performed using soothing music played through headphones.
223568784|NCT04441164|OTHER|Relaxation|If the patient is included in the Relaxation group, he/she will be offered 10 minutes of relaxation performed using soothing music played in headphones once a day for 9 days.
223568785|NCT04441164|OTHER|Acceptability questionnaire|It will be asked to complete an acceptability questionnaire (a priori) concerning the use of a Virtual Reality tool intended to improve walking in the ICU. The duration of filling in this questionnaire is estimated at 30 minutes.
224056112|NCT00061542|DRUG|BETOPTIC S (betaxolol HCl)|betaxolol HC)
224056113|NCT00061542|DRUG|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
224056114|NCT00058812|BIOLOGICAL|EBV specific T cells|One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
224056115|NCT05462964|BEHAVIORAL|Pacifiers Group (İntervention Group 1)|Camera recording was started 2 minutes before OGT placement and only a pacifier was given to the newborn. After the pacifier in the OGT intervention group was placed in the mouth of the given baby in the form of leaking from the mouth, it was inserted by advancing the baby's swallowing reflex from the esophagus to the stomach. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the recording was stopped.
224056116|NCT05462964|BEHAVIORAL|Pacifier group sweetened with 25% dextrose (İntervention Group 2)|Camera recording was started 2 minutes before OGT insertion and the newborn was given a pacifier sweetened with 25% dextrose. After the dextrose-sweetened pacifier in the OGT intervention group was placed in the mouth of the baby in the form of a leak from the mouth, it was inserted by advancing the baby's esophagus and then to the stomach with the swallowing reflex of the baby. It was checked whether the orogastric tube was in the right place. After the evaluation period was completed and the baby was comfortable, the registration was stopped.
224056117|NCT02797340|OTHER|Blood draws and urine samples for metformin concentration measurements|
224056118|NCT02797340|DRUG|Metformin|
224056119|NCT05843734|PROCEDURE|Equia forte HT|Restoration of anterior class III caries lesions
224056120|NCT04927286|BEHAVIORAL|Learning to Breathe|Learning to Breathe is an evidence-based mindfulness curriculum for adolescents
224056121|NCT04927286|BEHAVIORAL|Campus Connections|Campus Connections is a mentoring program for at-risk adolescents
223447694|NCT04010084|RADIATION|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
223447695|NCT04010084|PROCEDURE|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
223447696|NCT00001070|DRUG|Oral Vitamin C|
223447697|NCT00692497|BEHAVIORAL|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
223447698|NCT01830907|DIETARY_SUPPLEMENT|carbohydrates|
223447699|NCT01830907|DIETARY_SUPPLEMENT|vitamins|
223447700|NCT04676152|DEVICE|Masimo Noninvasive Blood Pressure Device|Non-invasive blood pressure device
223447701|NCT00370422|DRUG|Triamcinolone, Bevacizumab|
223447702|NCT01532258|BEHAVIORAL|Go! Foods for You without Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
223447703|NCT01532258|BEHAVIORAL|Go! Foods for You with Weekly MA Support.|"* Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~* In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
224056122|NCT01066585|DRUG|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
224056123|NCT01066585|DRUG|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
223447704|NCT00662987|DRUG|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
223568786|NCT04441164|OTHER|Observation of Virtual Actions (step 4)|If the patient is included in the Observation of Virtual Actions group, he/she will be asked to observe for 10 minutes once a day for 9 days Virtual Motor Actions (avatar moving in a virtual environment) using a Virtual Reality headset.
223568787|NCT04441164|OTHER|Performing Virtual Actions|If the patient is included in the group Performing Virtual Actions, he/she will be asked to perform Virtual Actions of the lower limbs by controlling the legs of his avatar (virtual double) in order to move around in a virtual environment for 10 minutes per day, once a day for 9 days.
224056124|NCT02221531|DRUG|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
224056125|NCT02221531|DRUG|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
223568788|NCT04441164|OTHER|Haptic stimulation|According to the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of step 4 in combination with haptic stimulation (sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
223741673|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
224056126|NCT00884273|DRUG|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
224056127|NCT00884273|DRUG|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
224056128|NCT00884273|DRUG|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
224056129|NCT05032625|PROCEDURE|Surgery|Patients who undergo surgery for NSTI will be followed in hospital and for 1- year in the office. We will asses the quality of life and there functionality. This will help us in determining the predictors of poor outcome.
224056130|NCT02742753|OTHER|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
224056131|NCT03655808|BIOLOGICAL|Bronchial basal cells (BBCs)|Airway epithelial cells were collected in patients of the cell treatment group by a disposable 2-mm brush in order to obtain BBCs. The obtained tissue were washed and enzymatically digested to form a single-cell suspension, which was then cultured under R-Clone system, a patented technique of Regend Therapeutics, Ltd.. For patients in the cell treatment group, on the basis of B-ACT therapy, they were also received autologous BBCs transplantation. Cell suspension was diluted with normal saline. Fibrotic bronchoscopy was guided into the lobular or segmental airways and cells were instilled into lobes.
223447705|NCT00662987|DRUG|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
223447706|NCT03894761|OTHER|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
223447707|NCT01319487|DRUG|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
224146384|NCT01641991|BIOLOGICAL|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
223447708|NCT01319487|DRUG|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
223447709|NCT01319487|DRUG|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
223447710|NCT00675077|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
223447711|NCT00755261|DRUG|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
223447712|NCT00755261|DRUG|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
223447713|NCT03963921|DRUG|HepaStem|Heterologous human adult liver-derived progenitor cells
223568789|NCT04441164|OTHER|Without haptic stimulation|Without haptic stimulation Depending on the superiority or not of the Realization of Virtual Actions or the Observation of Virtual Actions, we will test the most effective condition of Step 4 in combination without haptic stimulation (without sensory feedback through vibrators positioned in the lower limbs to give a feeling of walking), once a day for 10 minutes for 9 days.
223568790|NCT00002839|DRUG|cisplatin|
223568791|NCT00002839|DRUG|fluorouracil|
223568792|NCT00002839|PROCEDURE|conventional surgery|
223568793|NCT00002839|PROCEDURE|neoadjuvant therapy|
223568794|NCT00002839|RADIATION|radiation therapy|
223568795|NCT06353399|PROCEDURE|Intra-marrow penetrations|Intra-marrow penetrations
223568796|NCT06353399|PROCEDURE|No Intra-marrow penetrations|No Intra-marrow penetrations
223568797|NCT04837729|OTHER|Acupressure|acupressure is a non-pharmacological method originating from traditional Chinese medicine. According to the National Cancer Institute, acupressure is defined as pressure / massage applied to certain parts of the body to control symptoms such as pain or nausea. The main purpose of acupressure is to stimulate the regions associated with the specific organ by applying pressure with energy channels called meridians.
224146385|NCT02411526|DRUG|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
224146386|NCT02411526|DRUG|Risperdal Consta|Risperdal Consta administered as a IM injection
224146387|NCT02411526|DRUG|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
224146388|NCT00493974|DRUG|Zileuton|Zyflo tablets, 600 mg, 4 times a day
223447714|NCT05242536|OTHER|Nurse- led program|A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
223447715|NCT02081014|DRUG|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
223447716|NCT05337995|OTHER|Quantified analysis of walking during a task of passage through a horizontal opening|Functional test that reproduce a task of daily living, similar to a doorway
223447717|NCT06196697|BIOLOGICAL|Cadonilimab|Subjects will receive AK104 by intravenous administration
223447718|NCT06196697|BIOLOGICAL|Ivonescimab|Subjects will receive AK112 by intravenous administration
223447719|NCT06196697|DRUG|XELOX|Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
224146389|NCT00493974|DRUG|Placebo|Placebo 4 x daily
224146390|NCT04282057|DEVICE|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
224146391|NCT04282057|DEVICE|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
223447720|NCT06196697|DRUG|SOX|Subjects will receive AK104 and AK112 in combination withSOX(oxaliplatin and Tegafur)
223447721|NCT06218342|DRUG|Henagliflozin|Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.
223568798|NCT00998855|BEHAVIORAL|Exercise|12 wk aerobic or/ resistance exercise program
223568799|NCT01839019|DRUG|ODM-102|Single dose escalation
223568800|NCT01839019|DRUG|Placebo for ODM-102|Single dose escalation
223568801|NCT03824405|DRUG|BTX 1204|BTX 1204 liquid formulation
223568802|NCT03824405|DRUG|Vehicle|Vehicle liquid formulation
223568803|NCT00262678|DRUG|EN3267|
223568804|NCT03201042|DIAGNOSTIC_TEST|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
223447722|NCT06218342|OTHER|Background medication|Participants will only receive lifestyle intervention and background medication.
224056132|NCT03655808|PROCEDURE|Bronchoscopic airway clearance treatment （B-ACT）|The bronchoscopy was performed by board-certified respiratory physicians of Ruijin Hospital using a flexible fiber-optic bronchoscope. B-ACT therapy was performed on all patients in both groups according to the protocol. In brief, continuous suction was performed with the sputum aspirator from the trachea to the subsegmental during the entering of bronchoscope to remove the visible secretions from entire respiratory tract, and then operators used normal saline to collect lavage fluid (the volume various depending on the operator's judgement).
223447723|NCT00104377|BIOLOGICAL|Grass MATA MPL|
223447724|NCT05190965|DEVICE|OCTAngiography .FFangiography|octa.ffa findings in pts with diapetic retinopathy
223447725|NCT04123249|DRUG|Propofol|Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation
223447726|NCT04123249|DRUG|Sevoflurane|Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation；
223447727|NCT04794673|OTHER|brain damage|Have or not have the brain damage and the location of the damage
223447728|NCT04474977|OTHER|Microvascular Decompressive Surgery|Microvascular decompression for hemifacial spasm
223447729|NCT00575471|DRUG|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
223447730|NCT00575471|DRUG|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
223447731|NCT00575471|DRUG|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
223447732|NCT00575471|DRUG|Placebo|Matching placebo tablets once daily for 12 weeks
223447733|NCT02932605|DRUG|Placebo|Placebo
223447734|NCT02932605|DRUG|Cannabidiol|Cannabidiol
223447735|NCT04592796|DEVICE|Xiaomi MiBand2|Recording of sleep and activity data to study their association with age.
223447736|NCT04592796|OTHER|Socio-demographic questionnaire|Self-made questionnaire to be administered at the beginning of the study with the following personal data: age, gender, marital status, residential environment, mobility aids, educational level, occupation, retirement type, socioeconomic status, medical records, treatment.
224056133|NCT05223660|DRUG|Low dose KT07|A single dose of 4 capsules, followed by multiple doses on Days 8-12
224056134|NCT05223660|DRUG|High dose KT07|A single dose of 6 capsules, followed by multiple doses on Days 8-12
224056135|NCT05223660|DRUG|Low dose Placebo|A single dose of 4 capsules, followed by multiple doses on Days 8-12
223447737|NCT04592796|OTHER|EuroQol-5D-5L|Quality of life questionnaire to be administered at the beginning and completion of the study with the following information: severity index, social value index for each health condition. Subjective evaluation of health status from 0 to 100.
223447738|NCT04592796|OTHER|Mini mental State Examination|Questionnaire to be administered at the beginning and completion of the study that measures cognitive impairment.
223447739|NCT04592796|OTHER|Tinetti Scale|Physical test to be administered at the beginning and completion of the study that measures gait and balance of the participants.
223447740|NCT04592796|OTHER|Barthel Index|Questionnaire to be administered at the beginning and completion that evaluates the level of independence in basic activities of life.
223447741|NCT04592796|OTHER|Pittsburgh Sleep Quality Assessment (PSQI)|Questionnaire to be administered whose outcome is the perceived quality, quantity and efficient of sleep. To be given at the beginning and completion of the study.
223447742|NCT00211432|DRUG|Anecortave Acetate Sterile Suspension (15 mg)|
223447743|NCT02295332|DRUG|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
223447744|NCT02295332|DRUG|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
223447745|NCT02796521|OTHER|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
223447746|NCT02796521|OTHER|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
223447747|NCT00077155|DRUG|cilengitide|
223447748|NCT06127758|OTHER|virtual reality glasses application|The experimental group will be given classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower). After 15 minutes video containing nature images and sounds will be shown through virtual glasses.
223447749|NCT06127758|OTHER|classical training|Information about classical training (how to perform the surgery, complications that may occur after the surgery, preparation of fresh blood on the day of surgery, shaving by the barber on the morning of the surgery, how to take care of the mouth after shaving, how to shower with chlorexidine sponges, use of an apron, cap and mask after the shower) will be given.
223447750|NCT01653340|DEVICE|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
223447751|NCT02712918|BEHAVIORAL|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
223447752|NCT02712918|OTHER|Standard Care|Treatment as usual at the ward
223447753|NCT02865629|DRUG|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
224056136|NCT05223660|DRUG|High dose Placebo|A single dose of 6 capsules, followed by multiple doses on Days 8-12
224056137|NCT00488722|DRUG|Zoladex|
224056138|NCT01345396|BEHAVIORAL|Health education about asthma|Three face-to-face appointments (\<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
223447754|NCT01366183|PROCEDURE|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
223447755|NCT01366183|DRUG|Carboplatin|Undergo chemotherapy
224056139|NCT03462420|OTHER|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
224056140|NCT03216096|DRUG|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
223447756|NCT01366183|BIOLOGICAL|Filgrastim|Undergo chemotherapy
223447757|NCT01366183|DRUG|Paclitaxel|Undergo chemotherapy
223447758|NCT01366183|OTHER|Pharmacological Study|Correlative studies
223447759|NCT01366183|OTHER|Quality-of-Life Assessment|Ancillary studies
223447760|NCT01366183|OTHER|Questionnaire Administration|Ancillary studies
223447761|NCT00106158|BIOLOGICAL|protein vaccination|
223447762|NCT04158505|OTHER|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
223447763|NCT01711008|DIETARY_SUPPLEMENT|Cereal|
223447764|NCT01711008|DIETARY_SUPPLEMENT|No breakfast|
223447765|NCT04406116|DEVICE|Microwave coagulation using HS1 Instrument|Microwave therapy at 5.8 GHz
223447766|NCT06472687|OTHER|FIFA 11+ warm-up exercise training|FIFA 11+ warm-up training program was applied to the experimentel group. control group (CG) did their usual warm-up program.
223447767|NCT06472687|OTHER|warm-up exercise training|exercise training
223447768|NCT00292916|BEHAVIORAL|whole body vibration|
223447769|NCT00292916|BEHAVIORAL|resistance exercise|
223447770|NCT00292916|BEHAVIORAL|"wellness"|
223447771|NCT02662335|OTHER|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
223447772|NCT02662335|OTHER|Questionnaire Administration|Ancillary studies
223447773|NCT02662335|PROCEDURE|Standard Follow-Up Care|Undergo standard follow-up care
223447774|NCT03678675|DRUG|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
223447775|NCT02482545|DIETARY_SUPPLEMENT|Meal replacement|
223447776|NCT03020277|OTHER|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
224056141|NCT02512224|DEVICE|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
224056142|NCT02512224|DEVICE|Enteral nutrition|Participants are retrospectively selected with propensity score matching
223447777|NCT00003974|BIOLOGICAL|lung tumor associated antigen|
223447778|NCT00003974|DRUG|DetoxPC|
223447779|NCT00003974|DRUG|chemotherapy|
223447780|NCT00003974|DRUG|cyclophosphamide|
223447781|NCT04394156|BEHAVIORAL|Brief cognitive intervention|See the information provided in the experimental arm description.
223447782|NCT04129112|DRUG|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
223447783|NCT03195322|PROCEDURE|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
223447784|NCT04356599|OTHER|Early dynamic 18F-FDG PET/CT assessment of cerebral glucose uptake|The intervention will consist in a dynamic cerebral 18F-FDG PET study performed at D2+/-1. Kinetic modeling will be performed using in-house software at the global, regional, and voxel level. In addition, cerebral perfusion and blood-brain-barrier permeability will be assessed at D4+/- 1 using perfusion MRI and permeability MRI.
223447785|NCT00198523|DRUG|Prednisolone and Tobramycin|
223447786|NCT00198523|DRUG|Prednisolone|
223447787|NCT01141920|BEHAVIORAL|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
223447788|NCT01141920|BEHAVIORAL|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
223447789|NCT05524727|OTHER|Concept-guided, personalized, motor-cognitive training by means of an exergame|12 weeks, two times per week for 30-40min
223447790|NCT05686460|BEHAVIORAL|ice massage|"After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS)."
223741674|NCT01359657|BIOLOGICAL|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
224056143|NCT05221801|BEHAVIORAL|angle of inclination|The measurement would be done in seat inclination angles of 5,15,30,45 degrees.
224056144|NCT05221801|OTHER|food type|the swallowing was tested with 3 food types
224056145|NCT01050452|DRUG|albendazole|albendazole (400 mg on dose)
224056146|NCT01050452|DRUG|mebendazole|mebendazole (500 mg one dose)
224056147|NCT01050452|DRUG|ivermectin|ivermectin (200 microgram/kg body weight)
224056148|NCT01050452|DRUG|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
224056149|NCT01050452|DRUG|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
224056150|NCT01776736|DEVICE|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
224056151|NCT04960020|OTHER|Retrospective Data Review|Retrospective Data Review
223447791|NCT05686460|BEHAVIORAL|music medicine|After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
223447792|NCT02025933|OTHER|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
223447793|NCT02025933|OTHER|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
223447794|NCT02025933|OTHER|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
224056152|NCT04719494|OTHER|Dynamic balance walking training|Participants in the training group will walk on an elevated treadmill that will move side-to-side in a pseudorandom manner, thereby increasing the difficulty to their balance. Participants are asked to walk independently for 30-minutes per session, for 12 days over 4 weeks.
224056153|NCT02713165|OTHER|Raisins|Participants will consume 84g of raisins per day for 14 days.
224056154|NCT00710736|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
224056155|NCT00710736|DRUG|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
224056156|NCT00578136|DRUG|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
224056157|NCT01677156|DIAGNOSTIC_TEST|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
224056158|NCT03700580|DRUG|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
224056159|NCT03700580|DRUG|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
224056160|NCT02680132|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
224301084|NCT03108092|OTHER|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
224056161|NCT02680132|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
224056162|NCT02047253|DRUG|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
224056163|NCT02047253|DRUG|Dexamethasone|Administered prior to administration of Study drug
224056164|NCT02047253|DRUG|Acyclovir|Administered orally twice daily
224056165|NCT01034592|DRUG|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
223447795|NCT04762563|OTHER|IASTM application|IASTM application .
223447796|NCT04762563|OTHER|Kinesio Tape® Tex Gold)|Kinesio Tape® Tex Gold)
223447797|NCT00501709|DRUG|Belatacept and Raptiva|immunosuppressant agent to prevent rejection in transplant recipients
223447798|NCT06229041|DRUG|Camrelizumab ＋Immunotherapy|Camrelizumab was used in preoperative treatment.
223447799|NCT00143169|DRUG|Parecoxib and placebo|
223447800|NCT03300362|DRUG|Seasonal influenza vaccine|Seasonal influenza vaccine
223447801|NCT03300362|DRUG|MVA-NP+M1|Trial vaccine
223447802|NCT03300362|DRUG|Sodium chloride|Saline placebo
223447803|NCT03543176|OTHER|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
223447804|NCT03543176|OTHER|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
223447805|NCT03543176|OTHER|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
224056166|NCT01037660|DRUG|Metformin|Metformin 1 gram per day
224056167|NCT01987960|DRUG|Placebo|Once daily, tablets, orally
224056168|NCT01987960|DRUG|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
224070710|NCT06855251|BEHAVIORAL|The crossmodal dual-task|"Two main sensory tasks performed together:~1\. the visual task, in which participants are requested to monitor visual stimuli presented on a computer screen and to detect the deviant target as soon as possible. The target changes across blocks: in half of the trials, participants will have to respond to food stimuli presented together with irrelevant non-food stimuli (food target condition); in the other half conditions, participants will have to respond to non-food stimuli presented together with irrelevant food stimuli (non-food target condition). For each participant, we will collect the Reaction Time in milliseconds only for the valid responses, and the level of Accuracy in percentage.~2\) The interoceptive task, in which participants are requested to monitor their heartbeat presented through headphones and registered through pulse oximetry. Participants will judge the level of asynchrony between their heartbeat and the auditory cue."
223447806|NCT03543176|OTHER|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
223447807|NCT03543176|DEVICE|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
223447808|NCT03543176|DEVICE|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
223447809|NCT03961750|OTHER|OTAGO|12 Week exercise class programme
223447810|NCT05009134|BIOLOGICAL|There is no intervention in this study.|There is no intervention in this study.
224056169|NCT02575053|PROCEDURE|assessment of a new latex protocol|"1. All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~   Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~2. Removal of all materials containing latex from the resuscitation carts.~3. Further requirements in case of latex allergic patients:~   * Identification of patients with (suspected) latex allergy.~  * All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~* All staff present in the room should use latex free synthetic gloves.~* Operating tables and supports should be made of latex free material or should be covered with blankets.~* The entire OR staff is thoroughly educated concerning the latex safe protocol."
224056170|NCT00121433|DRUG|leptin|
224056171|NCT00966420|DEVICE|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
224146392|NCT04282057|DEVICE|Shock wave therapy|The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
224146393|NCT05650931|PROCEDURE|Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.|PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
224146394|NCT05650931|PROCEDURE|SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.|SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.
224146395|NCT05650931|PROCEDURE|EEG to search for phantom pain biomarkers|This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
224146396|NCT02555657|BIOLOGICAL|pembrolizumab|
224146397|NCT02555657|DRUG|capecitabine|
224146398|NCT02555657|DRUG|eribulin|
224146399|NCT02555657|DRUG|gemcitabine|
224146400|NCT02555657|DRUG|vinorelbine|
224146401|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg QD|4-mg Leuprolide oral tablet once daily for 28 consecutive days.
224146402|NCT02807363|DRUG|Leuprolide Oral Tablet 4-mg BID|4-mg Leuprolide oral tablet twice daily for 28 consecutive days.
224146403|NCT02807363|DRUG|Leuprolide Depot|3.75 mg intramuscular depot injection
224146404|NCT02807363|DRUG|Leuprolide Oral Tablet 10-mg BID|10-mg Leuprolide oral tablet twice daily for 28 consecutive days.
224146405|NCT06141941|DEVICE|CGM|Continuous glucose monitoring
223447811|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support \& cognitive distortions, social skills \& peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
223447812|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support \& cognitive distortions, social skills \& peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
224056172|NCT02065167|BIOLOGICAL|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
224056173|NCT02241382|DEVICE|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
224056174|NCT02241382|DEVICE|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
224056175|NCT02330822|DRUG|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
224056176|NCT04374760|BEHAVIORAL|SMS-intervention|SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
223447813|NCT03475290|BEHAVIORAL|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
224056177|NCT03422419|DRUG|Heparin|The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
223447814|NCT03475290|BEHAVIORAL|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support \& cognitive distortions, social skills \& peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
223447815|NCT04241822|BEHAVIORAL|Vestibular exercises combined with body awareness exercises and cognitive therapy|The intervention is group based and is a combination of information/education, vestibular exercises (head movements and gaze stability exercises) body awareness exercises and cognitive therapy
223447816|NCT04241822|BEHAVIORAL|Exergaming|The intervention consists of different balance exercises using non-immersive virtual reality
224056178|NCT03422419|DEVICE|TIPS|transjugular intrahepatic portosystemic shunt deployment
224056179|NCT01752660|BEHAVIORAL|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
223447817|NCT03097926|PROCEDURE|Long alimentary limb BPD-DS|BPD-DS with a long strict alimentary limb and a 100-cm common channel.
223447818|NCT06451666|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
224056180|NCT01752660|BEHAVIORAL|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
224056181|NCT00527436|DIETARY_SUPPLEMENT|fish oil|Fish oil pills will be taken daily for 12 weeks
224056182|NCT00527436|DIETARY_SUPPLEMENT|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
224056183|NCT01500122|DRUG|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
224056184|NCT04515225|OTHER|Blood Sample|Blood Sample
224146406|NCT03463096|OTHER|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
224146407|NCT03701217|DRUG|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents.
224146408|NCT03077113|DIAGNOSTIC_TEST|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
224146409|NCT03077113|DIAGNOSTIC_TEST|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
224146410|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
224146411|NCT05019755|DRUG|IN-A002(IN-115314) capsule|Oral Administration of IN-A002(IN-115314), single dose
224301085|NCT03108092|OTHER|Control|Standard care in the department where the trial is conducted
224301086|NCT00725751|BIOLOGICAL|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
224301087|NCT00725751|DRUG|Ribavirin|Ribavirin administered according to European labeling.
223447819|NCT06451666|DRUG|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
223447820|NCT00284011|DIETARY_SUPPLEMENT|SAMe|800 mg dose daily for 4 weeks.
223447821|NCT00284011|OTHER|Placebo|2 placebo pills daily for 4 weeks.
224056185|NCT04066036|OTHER|This is an observational study only.|This is an observational study only.
224301088|NCT02570516|PROCEDURE|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
224301089|NCT01167959|PROCEDURE|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
224056186|NCT00932360|DEVICE|TENS|Active TENS, Placebo TENS and No Treatment TENS
224056187|NCT03371433|OTHER|Soft drinks|Caffeine and Caffeine free soft drinks
224056188|NCT04118270|DEVICE|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
224056189|NCT05896514|DEVICE|ultrasound-guided carotid artery flow time measurement|Ultrasound-guided corrected carotid artery flow time will be measured before anestesia induction.
224056190|NCT01304095|DRUG|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
224056191|NCT04489251|DIAGNOSTIC_TEST|Protein Elisa analysis, microRNA analysis, whole exome sequencing|"ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing."
224146412|NCT00001449|DRUG|gemcitabine|
224146413|NCT00001449|DRUG|fluorodeoxyuridine|
224301090|NCT01167959|BEHAVIORAL|Prodimed dietary intervention|3 months of using the prodimed diet
224301091|NCT02365870|DRUG|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
223447822|NCT05110365|OTHER|Proprioceptive Neuromuscular Facilitation|"The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion"
223447823|NCT01442649|DRUG|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
223447824|NCT01442649|DRUG|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
223447825|NCT01442649|DRUG|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
223447826|NCT01442649|DRUG|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
223447827|NCT01442649|DRUG|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
223447828|NCT01442649|DRUG|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
223447829|NCT00662311|DRUG|vorinostat|Given PO
223447830|NCT00662311|DRUG|paclitaxel|Given IV
223447831|NCT00662311|RADIATION|radiation therapy|Undergo radiation therapy
223447832|NCT06503289|DEVICE|Cytosorb therapy|Extracorporeal treatment with cytosorb filter to patients diagnosed with rhabdomyolysis
223447833|NCT03699072|DEVICE|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
224056192|NCT05627544|PROCEDURE|Anesthesia management/Hip replacement surgery|The effect of anesthesia management on blood transfusion practices in hip replacement surgeries
223447834|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
223741675|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
224056193|NCT05627544|PROCEDURE|Demographic data|The effect of demographic data on blood transfusion practices in hip replacement surgeries
224056194|NCT05627544|PROCEDURE|Chronic diseases|The effect of chronic diseases on blood transfusion practices in hip replacement surgeries
223447835|NCT01293747|DRUG|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
223447836|NCT03615820|DRUG|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
223447837|NCT03615820|DRUG|Oromucoadhesive film|Oromucoadhesive film without PPE control testing which represents Placebo group
223447838|NCT06239025|OTHER|ultrasound-guided Transversus Thoracis Muscle Plane Block|block with ropivacaine 0.5 %, 30 mL
223447839|NCT04392219|DRUG|EIDD-2801|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 2:~Two single oral doses of EIDD-2801 will be administered to participants, in an open-label manner.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
223447840|NCT04392219|DRUG|Placebo|"Part 1:~Participants will be randomized to receive a single oral dose of EIDD-2801 or Placebo.~Part 3:~Participants will be randomized to receive twice daily dosing either EIDD-2801 or Placebo."
223447841|NCT00617747|DRUG|Zolmitriptan|5mg Nasal Spray
223447842|NCT00617747|DRUG|Placebo|
223741676|NCT01359657|BIOLOGICAL|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
223447843|NCT06054763|COMBINATION_PRODUCT|Buyang Huanwu Decoction|Buyang Huanwu Decoction is a common prescription for treating stroke. The possible mechanism is to replenish qi, activate blood circulation, and remove blood stasis.
223447844|NCT06054763|OTHER|Placebo|90% starch and 10% Buyang Huanwu Decoction
223447845|NCT02335346|DRUG|Duloxetine|Administered orally
223447846|NCT01548768|DRUG|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
223741677|NCT01359657|BIOLOGICAL|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
223741678|NCT01359657|BIOLOGICAL|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
223741679|NCT05941507|DRUG|LCB84|TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug
223741680|NCT05941507|DRUG|Anti-PD-1 monoclonal antibody|anti-PD-1 Ab
224056195|NCT05627544|PROCEDURE|Postoperative complication|The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
224056196|NCT04586543|DRUG|Selegiline|10 mg selegiline tablet per day
224056197|NCT04586543|DRUG|Docetaxel|75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
224056198|NCT03223870|DIAGNOSTIC_TEST|Diagnostic|Diagnostic
224056199|NCT02536313|DRUG|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
224056200|NCT02536313|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
224056201|NCT03555513|PROCEDURE|living kidney transplantation|receiving kidney transplantation from living donor
224056202|NCT01555567|DEVICE|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
224056203|NCT01555567|OTHER|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
224056204|NCT06368167|DRUG|SHR2554|SHR2554
224056205|NCT00281645|DRUG|Bicifadine|
223447847|NCT01548768|DRUG|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
224146414|NCT00001449|DRUG|leucovorin|
223447848|NCT02806271|BEHAVIORAL|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
223447849|NCT02806271|BEHAVIORAL|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
223447850|NCT04391777|OTHER|Fourth ventricle compression technique (CV-4)|The participant is in the supine position and the principal investigator is seated at the patient's head, with elbows resting on the table. The main investigator overlaps his hands with the thenar eminences, contacting the occipital bone squamous part, between the external occipital protuberance and the participant's occipito-mastoid suture. The technique begins with a maintained compression on the occipital squamous part during a deep thorax exhalation. Throughout the compression of the occipital bone and the participant's voluntary inspirations, the principal investigator feels a gradual pressure increase at the thenar eminences. The technique will be performed until reaching the still point, in which the mobility of the occipital bone, respiratory rate and muscle tone decrease, or until 5 minutes elapsed.
223447851|NCT04391777|OTHER|Sham|The main investigator uses the technique contact but does not perform any type of tissue traction or compression, maintaining this contact for 5 minutes. At the end of the stipulated time, the contact is removed in a subtle way.
223447852|NCT01176123|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
223447853|NCT04034511|OTHER|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
223447854|NCT00195195|DRUG|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
223447855|NCT03300050|BIOLOGICAL|cH8/1N1 LAIV|"Live-attenuated influenza virus vaccine (LAIV) expressing chimeric hemagglutinin (HA) with the H8 head and H1 stalk and neuraminidase (NA) subtype 1 (N1) (cH8/1N1):~HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1) containing the backbone of the cold-adapted/temperature sensitive of the Russian LAIV A/Leningrad/134/17/1957 (Len17 IDCDCRG46D).~Administered intranasally as drops at a dose of 10⁷·⁵ (plus or minus ⁰·⁵) 50% egg infectious dose (EID50), formulated in a total volume of 0.5 mL sterile saline (0.25 mL per nostril)."
223447856|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV) plus AS03 adjuvant: HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
223447857|NCT03300050|BIOLOGICAL|cH5/1N1 IIV|"Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV):~HA head, A/Vietnam/1203/2004 (H5N1); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
223447858|NCT03300050|BIOLOGICAL|AS03-adjuvanted cH8/1N1 IIV|"Chimeric H8 head with H1 stalk plus N1 (cH8/1N1) inactivated influenza vaccine plus AS03 adjuvant: HA head, A/mallard/Sweden/24/2002 (H8N4); HA stalk, A/California/04/2009 (H1N1); NA, A/California/04/2009 (H1N1).~Administered intramuscularly at a dose of 15 μg of hemagglutinin in a volume of 0.5 mL of phosphate buffered saline (PBS)."
223447859|NCT03300050|BIOLOGICAL|Normal saline|Administered intranasally as 0.25 mL nasal drops per nostril
223447860|NCT03300050|BIOLOGICAL|Phosphate buffered saline (PBS)|Administered intramuscularly as 0.5 mL injection
223447861|NCT03287648|DIAGNOSTIC_TEST|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
223447862|NCT01898052|DRUG|single anaesthetic drug|inject periarticular tissue of the knee after implantation
223447863|NCT01898052|DRUG|multimodal drug injection|inject periarticular tissue of the knee
223447864|NCT03528382|BEHAVIORAL|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
223447865|NCT00603603|OTHER|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
223447866|NCT00603603|OTHER|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
223447867|NCT01024361|DEVICE|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
223447868|NCT04948827|DRUG|SBP-9330|SBP-9330 oral capsules
223741681|NCT01716598|DEVICE|IPS System|TLD Therapy will be achieved bronchoscopically.
224146415|NCT01214941|DRUG|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
224146416|NCT01214941|DRUG|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
224146417|NCT01214941|DRUG|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
224146418|NCT04144075|BEHAVIORAL|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
224301092|NCT02365870|DRUG|placebo|Participants will receive a placebo transdermal patch to be worn daily
223447869|NCT04948827|DRUG|Placebo|Placebo oral capsules
224056206|NCT00281645|DRUG|Standard of Care (pharmacological analgesic treatment)|
224056207|NCT05126108|PROCEDURE|Thyroid and parathyroid surgery|Thyroid and parathyroid surgery
223447870|NCT04377971|BEHAVIORAL|SOC education|Standard participant education from researcher
224146419|NCT04144075|BEHAVIORAL|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
224146420|NCT04144075|OTHER|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
223447871|NCT04377971|BEHAVIORAL|Ask-tell-ask education|Participant education using the ask-tell-ask method. First the researcher will ask a question about participant understanding of wound care and after hearing the participant's answer, the researcher will then proceed to tell the patient how to best take care of their wound using a standardized script. After the educational portion, the researcher will then ask the patient to repeat the information that was shared. If the participant's answer is wrong or incomplete, the researcher will then explain the instructions again to ensure that the participant understands the steps needed.
224146421|NCT05717959|BEHAVIORAL|Oropharyngeal Exercises|Oropharyngeal Exercises
223447872|NCT04377971|OTHER|Participant satisfaction survey|Participant satisfaction survey using components of the 16 item Skindex questionnaire and the 18 item version Patient Satisfaction Survey, adapted for treatment of skin cancer to characterize patient experience administered at two weeks post-operatively in person
223447873|NCT04377971|OTHER|Wound care adherence survey|Wound care adherence survey administered at one week over the phone and at two weeks in person
223447874|NCT00548483|DRUG|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
223447875|NCT03580395|DRUG|Apatinib|500mg, day1-21,neoadjuvant therapy
223447876|NCT03580395|DRUG|paclitaxel|paclitaxel 165mg/m2 day 1
223447877|NCT03580395|DRUG|cisplatin|cisplatin 40mg, day 1-3
223447878|NCT04652518|DRUG|LYT-100|oral administration
223447879|NCT04652518|OTHER|Placebo|oral administration
223447880|NCT00615147|PROCEDURE|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
223568805|NCT03201042|DIAGNOSTIC_TEST|Serology based assay|"1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
223568806|NCT03201042|DIAGNOSTIC_TEST|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
223741682|NCT04964154|BEHAVIORAL|Protect Your Elders Campaign|This is a behavioral intervention where participants will receive cultural appropriate educational information about COVID-19 testing and vaccination.
223741683|NCT01980355|DRUG|Tranexamic Acid|
223741684|NCT01980355|OTHER|Placebo|
223741685|NCT02172742|DRUG|BIA 2-093|BIA 2-093 1200 mg once-daily
223741686|NCT02172742|DRUG|Placebo|matching placebo
223741687|NCT02172742|DRUG|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
224056208|NCT05126108|OTHER|Recurrent nerves monitoring|Recurrent nerves monitoring
224056209|NCT02209298|DEVICE|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
224146422|NCT00966693|DRUG|Dexamethasone|Given PO
224146423|NCT00966693|DRUG|Lenalidomide|Given PO
224146424|NCT00966693|DRUG|Thalidomide|Given PO
223447881|NCT04767971|DEVICE|Standard Colonoscopy|Colonoscopy with a standard colonoscope
223447882|NCT04767971|DEVICE|G-EYE Colonoscopy|Colonoscopy with a G-EYE Colonoscope
224146425|NCT03922633|DRUG|E3112|Intravenous infusion.
224146426|NCT03922633|OTHER|Placebo|Intravenous infusion.
223447883|NCT00429975|DRUG|levofloxacin|
223447884|NCT00429975|DRUG|ceftriaxone|
223447885|NCT02178358|DRUG|LY2157299|Administered orally
223447886|NCT02178358|DRUG|Sorafenib|Administered orally
223447887|NCT02178358|DRUG|Placebo|Administered orally
223447888|NCT02018770|RADIATION|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
223447889|NCT02018770|RADIATION|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
224146427|NCT03517306|OTHER|No Interventions|No Interventions
224146428|NCT01578785|DRUG|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
224146429|NCT01578785|DRUG|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
224146430|NCT00255294|DRUG|Cellulose sulfate vaginal gel|
224056210|NCT05197348|BEHAVIORAL|Meaning-Centered Group Psychotherapy (MCP).|"The MCP program is divided into eight sessions:~Session1: Psychoeducation about Meaning in life, Sources of Meaning, etc. Session 2: Cancer illness and meaning. Session 3: Historical Sources of Meaning (the past) Session 4: Historical Sources of Meaning (present and future). Session 5: Attitudinal Sources of Meaning. Session 6: Creative Sources of Meaning. Session 7: Experimental Sources of Meaning. Session 8: End of psychotherapy, farewell, and facing the future with hope."
223447890|NCT05060107|BIOLOGICAL|Exosomes (sEVs)|Exosomes 3-5x10e11 particles/dose
223447891|NCT00621725|DRUG|AZD2171|Oral dose
223447892|NCT01066663|DRUG|pyrimethamine|Taken orally once a day
223447893|NCT02985021|DRUG|Carboplatin|Chemotherapy
223447894|NCT02985021|DRUG|Docetaxel|Chemotherapy
223568807|NCT02262442|DEVICE|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
223568808|NCT02262442|DEVICE|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
223568809|NCT02362945|DRUG|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
224070711|NCT06654271|DEVICE|Robotic assisted bronchoscopy (RAB)|Participants allocated to the robotic assisted bronchoscopy arm will undergo robotic assisted bronchoscopy with integrated cone beam computed tomography
224070712|NCT06654271|DEVICE|Electromagnetic navigation bronchoscopy (ENB)|Participants allocated to the electromagnetic navigation bronchoscopy arm will undergo electromagnetic navigation bronchoscopy with integrated digital tomosynthesis
224301093|NCT00195234|BIOLOGICAL|HIV CTL MEP 1000 micrograms, 19 months per subject|
224301094|NCT00069836|DRUG|Rosiglitazone/metformin|
224301095|NCT02987101|PROCEDURE|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
223568810|NCT01846195|DEVICE|CM 1500|
224301096|NCT02987101|OTHER|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
224301097|NCT02987101|DRUG|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
223447895|NCT04184011|DEVICE|SRT-100™|SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
223447896|NCT01090050|DRUG|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
223447897|NCT01090050|DRUG|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
223568811|NCT01231321|DRUG|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
223568812|NCT02166645|OTHER|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
224070713|NCT02200185|DRUG|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~* SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
224070714|NCT02200185|DRUG|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
224301098|NCT02546401|DRUG|Insulin Aspart|Injection of Insulin Aspart before or after meals
224301099|NCT01379001|DRUG|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
223447898|NCT02871284|BEHAVIORAL|Exercise|
223447899|NCT06955455|DRUG|Triamcinolone and Bupivacaine Injection|A single injection consisting of 1 cc of 0.25% bupivacaine mixed with 2 cc (20 mg) of triamcinolone (40 mg/mL) is administered under ultrasound guidance. The injection targets the extratemporal portion of the facial nerve approximately 1.5-2 cm distal to the stylomastoid foramen in an inferior and anterior direction. The intervention is designed to reduce inflammation and pain, potentially accelerating facial nerve recovery in acute Bell's palsy.
223447900|NCT05597449|BEHAVIORAL|YouTube videos on care after urologic surgery|Supplemental educational videos regarding care following pediatric urologic surgery
223447901|NCT06336811|DEVICE|passive virtual reality distraction|watching the application by wearing virtual glasses to the child during the phlebotomy
223447902|NCT06336811|DEVICE|active virtual reality distraction|The remote control of the virtual glasses will be given to the hand, and the child will start, slow down or stop the application herself.
223447903|NCT02232061|DRUG|Fingolimod|Fingolimod 0.5 mg tablet
223447904|NCT02256735|DRUG|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
223447905|NCT02256735|DRUG|Treatment B|
223447906|NCT02256735|DRUG|Treatment C|
223447907|NCT02256735|DRUG|Treatment D|
223447908|NCT02256735|DRUG|Placebo|
223447909|NCT02256735|DRUG|Moxifloxacin|
223447910|NCT04378595|OTHER|During COVID-19 Pandemic|Assessing status of food insecurity during the COVID-19 pandemic
223568813|NCT02166645|OTHER|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
223568814|NCT06268327|DRUG|Cisplatin injection and gemcitabine|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with gemcitabine plus cisplatin Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
223447911|NCT04378595|OTHER|After COVID-19 Pandemic|Assessing status of food insecurity after the COVID-19 pandemic
223447912|NCT02878200|BIOLOGICAL|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
223447913|NCT03795285|DIAGNOSTIC_TEST|Expression of neutrophil CD64|Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
223447914|NCT04605718|DRUG|RO7223280|For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
223447915|NCT03108066|DRUG|MK-3795|800 mg twice daily (four 200 mg oral tablets twice daily)
223447916|NCT00144950|DRUG|insertion of a chest drain with urokinase instillation|
223447917|NCT00144950|PROCEDURE|primary video-assisted thorascopic surgery|
223447918|NCT04161521|PROCEDURE|Novel Technique of Placenta Accreta in Menoufia University Hospital|"* Classical CS to decrease haemorrhage from placental bed.~* Delievery of the fetus.~* At the delivery 10 UI of oxytocin IV will be injected.~* The placenta is not attempted to be delievered.~* Opening of the broad ligament via round ligament division and ligation.~* Gentle dissection of the urinary bladder from lateral to medial.~* Bilateral uterine artery clamping at low level below the placental bed .~* Gentle attempt to deliver The placenta.~* If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~* If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~* Intraperitoneal drain insertion."
223447919|NCT04726111|OTHER|Specimens specific for the study|Specimens (blood, umbilical cord, umbilical cord blood, placenta)
223447920|NCT00931112|OTHER|individualized exercise training|Lower extremities resistance exercise and bicycle training
224056211|NCT05197348|BEHAVIORAL|Cognitive Behavioral Psychotherapy (CBT).|"The CBT divided into eight sessions:~Session1: Presentation of psychotherapy, establishing the goals of psychotherapy. Presentation of the participants. Updated information about psychological consequences of cancer.~Session 2. Increase in enjoyable activities. Behavioral activation. Progressive muscle relaxation training. Slow breathing training.~Session 3. Cognitive model of coping with cancer. Psychoeducation on negative thoughts. Training in detecting negative thoughts. Presentation of cognitive distortions Session 4. Training in cognitive restructuring techniques. Session 5. Training in problem-solving skills. Session 6. Being aware of participants needs. Self-care. Assertiveness skills training.~Session 7. Setting goals for the future. Session 8. Summary, relapse prevention, and end of psychotherapy."
224070715|NCT02200185|DRUG|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
224146431|NCT04696874|PROCEDURE||All testes were fixed to the ipsilateral sub-dartos pouch. All epididymides and vasa deferentia were carefully examined, and any observed anomalies were recorded.
224146432|NCT01089829|OTHER|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
223568815|NCT06268327|DRUG|Capecitabine tablets|Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
223568816|NCT02827383|BEHAVIORAL|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
223447921|NCT00560703|DRUG|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
223447922|NCT00560703|DRUG|placebo|sugar capsule
223447923|NCT05723952|OTHER|Barcelona scoliosis physical therapy school|procedure for treating Adolescent Idiopathic scoliosis
223447924|NCT05723952|OTHER|International scoliosis schroth therapy|procedure for treating Adolescent Idiopathic scoliosis
223447925|NCT03244267|BEHAVIORAL|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
223447926|NCT03244267|BEHAVIORAL|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
223447927|NCT02693717|OTHER|Laboratory Biomarker Analysis|Correlative studies
223447928|NCT02693717|DRUG|Pemetrexed Disodium|Given IV
223447929|NCT00156091|DRUG|Olanzapine|5- 20 mg QD
223568817|NCT02860624|DRUG|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
224070716|NCT03809611|DRUG|UNR844-Cl|1.5% Ophthalmic solution for topical ocular administration
224070717|NCT03809611|DRUG|Placebo|placebo
224070718|NCT02093013|OTHER|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
224070719|NCT05442307|BEHAVIORAL|asthma education|A 15 minutes (preferable) one-on-one educational visit about asthma treatment. The main points being: Every person with asthma should be treated with inhaled corticosteroids (ICS). Most patients with asthma should be treated with Bufomix Easyhaler either as needed and/or regularly. Patients should not use short-acting bega2-agonist (SABA) unless they use a medium-ICS-dosis.
224070720|NCT05442307|BEHAVIORAL|Other education|A 15 minutes (preferable) one-on-one educational visit about another topic (NOT asthma).
224070721|NCT00387400|DRUG|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
224070722|NCT00387400|DRUG|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
223447930|NCT00156091|DRUG|Asenapine|5 or 10 mg BID
223447931|NCT00156091|OTHER|Placebo|
223447932|NCT05912075|DRUG|mFOLFIRINOX|prior to tolinapant (ASTX660) for 6 cycles over 12 weeks
223447933|NCT05912075|RADIATION|Pelvic radiotherapy LCRT|50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks
223447934|NCT05912075|DRUG|Capecitabine|800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
223447935|NCT05912075|DRUG|TOLINAPANT (ASTX660)|starting from 14 days before the first dose of radiotherapy, for 10 weeks.
223447936|NCT05912075|RADIATION|Pelvic radiotherapy SCRT|total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)
223447937|NCT05912075|DRUG|FOLFOX4|given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
223447938|NCT05912075|DRUG|CAPOX|every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
223447939|NCT01315522|DEVICE|ComVi stent|Endoscopic insertion of ComVi stent
223447940|NCT01315522|DEVICE|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
223447941|NCT03675529|BEHAVIORAL|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
223447942|NCT00383370|DRUG|VEGF Trap|VEGF Trap formulation 1, ITV-1
223447943|NCT00383370|BIOLOGICAL|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
223447944|NCT00790556|DRUG|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
223447945|NCT00790556|DRUG|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
223447946|NCT04410471|DIAGNOSTIC_TEST|CLIA of IgG and IgM against SARS-Cov-2|Report of clinical data
223447947|NCT04678609|OTHER|Exercise|CKC: exercise with joints fixed on the ground OKC: exercise with joints not fixed on the ground
223447948|NCT01185002|OTHER|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
223447949|NCT01185002|OTHER|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
223447950|NCT01185002|OTHER|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
223568818|NCT02860624|DRUG|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
223568819|NCT02071186|DEVICE|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
224056212|NCT05273476|PROCEDURE|apically repositioned flap+ xenogeneic collagen matrix +free gingival graft|Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
224056213|NCT01753128|DRUG|imipramine|
223447951|NCT05446051|DEVICE|the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)|Phase I Interventions：eRAPID-MV(TRAEs survey)
223447952|NCT05446051|DEVICE|the telephone triage decision support system (TTDSS)|Phase I Interventions：TTDSS
223447953|NCT03247322|OTHER|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
223447954|NCT03730376|OTHER|Cost Information|participants will be given information on the personal and societal costs
223447955|NCT00339833|DRUG|Salsalate|The intervention was salsalate (3g/day) for 7 days.
223447956|NCT00339833|DRUG|Placebo|Identical placebo for 7 days.
223447957|NCT05761119|OTHER|Physical activity|The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
223447958|NCT03891355|DRUG|Carfilzomib|Carfilzomib
223447959|NCT03891355|DRUG|Lenalidomide|Lenalidomide
223568820|NCT02071186|OTHER|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
223568821|NCT02071186|OTHER|Standard of care|
223568822|NCT03675425|OTHER|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
224056214|NCT04662658|DRUG|Hyperpolarized Xenon -129 MRI|e-cigarette sub-study
223447960|NCT03891355|DRUG|Dexamethasone|Dexamethasone
223447961|NCT06185439|BEHAVIORAL|Prenatal Pilates Assisted Childbirth Preparation Training|Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
223447962|NCT00806208|DRUG|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
223447963|NCT00806208|DRUG|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
223568823|NCT03675425|OTHER|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
224056215|NCT01878942|DRUG|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
224301100|NCT01379001|DRUG|Placebo|IM or PO placebo
224301101|NCT01379001|DRUG|Donepezil|donepezil 5mg PO x 1
224301102|NCT01690741|DRUG|Nerofe|Nerofe administered intravenously 3x/week
223447964|NCT00806208|DRUG|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
223447965|NCT00806208|DRUG|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
224056216|NCT01878942|DRUG|LSD|200µg per os, single dose
224301103|NCT05296538|OTHER|Broad-Minded Affective Coping Intervention|The Broad-Minded Affective Coping (BMAC) is a six session intervention that uses mental imagery and rehearsal of memories of past positive experiences to generate positive emotions in the moment. A further follow-up session is provided in the eight weeks following the end of treatment.
224301104|NCT05296538|OTHER|Risk Assessment and Signposting|A therapist will meet with participants over two 50 minute sessions to conduct a comprehensive risk assessment, and develop a collaborative plan with the participant around managing any risk, including identification of sources of support and signposting.
224301105|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
224301106|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
224301107|NCT01120041|BEHAVIORAL|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
223447966|NCT00806208|OTHER|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
223447967|NCT05718440|OTHER|Individualisation of uronephrological complications risk factors|description of pelvic disorders in terms of clinical presentation, electrophysiology/urodynamics/anorectal manometry patterns, urethrocystography/urinary ultrasound/defecography results and urinary complications (infections, vesicoureteral reflux), depending on the dysraphim's type and level of injury and to correlate these parameters to the uronephrological risk factors and complications recorded.
223447968|NCT04504578|PROCEDURE|contact lens assisted corneal cross linking|40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch \& Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
223447969|NCT06101888|DEVICE|TaurusTrio™ Heart Valve System|The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.
223447970|NCT01745614|DRUG|Nimesulide 100 mg tablets|Reference product
223447971|NCT01745614|DRUG|Nimesulide 100 mg tablets|Test product
224301108|NCT01120041|BEHAVIORAL|health education|Traditional health education given during the prenatal phase and the postpartum phase
223568824|NCT04046315|DIAGNOSTIC_TEST|CMR|GLS measurement with CMR
224056217|NCT01252745|DRUG|10.0 mg of Testosterone, 4.0% TID|
224056218|NCT01252745|DRUG|13.5 mg of Testosterone, 4.5% B.I.D|
224056219|NCT01252745|DRUG|11.25 mg of Testosterone, 4.5% T.I.D|
224056220|NCT03163589|DRUG|Erythropoietin|injection
224056221|NCT03163589|DRUG|normal saline|injection
224070723|NCT00387400|GENETIC|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
224070724|NCT00387400|OTHER|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
224070725|NCT02193074|DRUG|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
224070726|NCT02193074|PROCEDURE|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
224070727|NCT02727283|DRUG|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
224070728|NCT02727283|DRUG|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
224070729|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
224070730|NCT00811772|DEVICE|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
224070731|NCT06989671|DRUG|JMT101|JMT101 Q2W or Q3W, intravenous injection
224070732|NCT06989671|DRUG|SYS6002|SYS6002 Q2W or Q3W, intravenous injection
224070733|NCT06989671|DRUG|SG001|SG001 Q2W or Q3W, intravenous injection
224070734|NCT00406302|DRUG|Docetaxel|75mg/m², day 1,22
223447972|NCT03306095|OTHER|Early refeeding group|Food Intake by patient with in 4 hours i.e \<4 hours after the EVL procedure
224301109|NCT03544619|OTHER|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
223447973|NCT03306095|OTHER|Delayed refeeding group|Food Intake by patient after 4 hours i.e \> 4 hours after the EVL procedure
223447974|NCT03621436|DEVICE|TRVD Therapy|A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
223447975|NCT04035525|DIETARY_SUPPLEMENT|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
223447976|NCT04035525|DIETARY_SUPPLEMENT|Rice bran oil + CoQ10|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
224301110|NCT04422353|OTHER|Video Dance classes|The dance program consists of dance lessons inspired by Forró rhythm and Samba rhythm. The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
223447977|NCT04035525|DIETARY_SUPPLEMENT|CoQ10 as powder form|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
223447978|NCT01873118|OTHER|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
223447979|NCT01873118|OTHER|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
223568825|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
223568826|NCT00913991|BEHAVIORAL|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
223568827|NCT02146703|DRUG|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"
223568828|NCT04496375|OTHER|Survey|Self-completed questionnaires
223568829|NCT06255067|DRUG|Minocycline hydrochloride with noisome carrier|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
223568830|NCT06255067|DRUG|Minocycline Hydrochloride only|patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
223568831|NCT00908115|BIOLOGICAL|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
223568832|NCT01377948|BEHAVIORAL|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
223568833|NCT04128397|DEVICE|traditional stimulation site continuous theta burst stimulation (cTBS)|before cTBS treatment, MRI was used to confirm the stimulation site
224056222|NCT01439672|DIETARY_SUPPLEMENT|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to \~100mg/dl at 1100.
224056223|NCT04417764|PROCEDURE|Transcatheter arterial chemoembolization|The patients are plan to operated by Transcatheter arterial chemoembolization(TACE).
224056224|NCT04417764|BIOLOGICAL|PD-1 knockout engineered T cells|The PD-1 knockout engineered T cells are prepared from autologous origin using CRISPR Cas9 technology. The patients are plan to receive 3 or more cycles of PD-1 knockout engineered T cells infusion by percutaneous fine needle liver puncture with a 4-weeks interval. A total of 1 to 3× 10\^9 PD-1 edited T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent.
224070735|NCT00406302|DRUG|oxaliplatin|40mg/m², d1,2,22,23
224301111|NCT04422353|OTHER|Unsupervised physical activities|The classes will be held through a recorded video that must be played twice a week. Each video class lasts 30 minutes.
224301112|NCT02310711|OTHER|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
223447980|NCT01873118|OTHER|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
223447981|NCT00925808|BEHAVIORAL|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
224056225|NCT04843215|PROCEDURE|Type of omentectomy|Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
223447982|NCT03001908|OTHER|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
223447983|NCT03001908|OTHER|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
223447984|NCT06239350|BEHAVIORAL|Counseling|Research staff will provide skills-based counseling at remote weekly visits, starting at Day 0. Counseling sessions will be brief (\~5-10 minutes) and will focus on strategies for preparing for the quit attempt, dealing with triggers, refusal skills, and enhancing motivation.
223447985|NCT06239350|BEHAVIORAL|Contingency management|Contingency management (CM): CM will be provided to all study participants to promote abstinence from all nicotine products. Incentives for abstinence (based on submission of a negative cotinine sample) will be provided on an escalating schedule during treatment (Days 8-84).
223447986|NCT06239350|BEHAVIORAL|Text-based support|All participants will be provided with evidence-based nicotine cessation resources. For those who are vaping nicotine, participants will be provided information for This is Quitting (SMS text-based program). For those who are primarily smoking cigarettes, NCI's QuitSTART (mobile app, web content), as well SmokefreeTXT (SMS-text based program), will be recommended, potentially in addition to This is Quitting for those using multiple products. These resources provide real time monitoring of nicotine use, mood, triggers and lapses.
224056226|NCT01208584|OTHER|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
224056227|NCT05602662|BEHAVIORAL|Music|Music therapy during mechanical ventilation
224056228|NCT01607424|BEHAVIORAL|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
224056229|NCT01460199|DRUG|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
224056230|NCT01460199|DRUG|placebo|tablets
224056231|NCT02034630|DRUG|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
224056232|NCT05824286|OTHER|HbA1c prediction|HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
223447987|NCT05936853|OTHER|Intravenous approach to anaesthetic maintenance|Anaesthetic agents given directly into the bloodstream via a cannula.
223447988|NCT05936853|OTHER|Inhalational approach to anaesthetic maintenance|Volatile-based anaesthetic drugs are breathed in and then absorbed into the bloodstream through the lungs.
223447989|NCT04865679|DEVICE|Axoguard Nerve Cap®|Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
223447990|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and placebo probiotic|the randomized patients will be receive active chlorhexidine rinse and placebo probiotic
223447991|NCT05548361|COMBINATION_PRODUCT|placebo chlorhexidine and active probiotic|the randomized patients will receive placebo chlorhexidine rinse and active probiotic
223447992|NCT05548361|COMBINATION_PRODUCT|active chlorhexidine and active probiotic|the randomized patients will receive active chlorhexidine rinse and active probiotic
223568834|NCT04128397|DEVICE|precise stimulation site cTBS|before cTBS treatment, rs-fMRI was used to confirm the stimulation site
223568835|NCT01728077|DRUG|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
223568836|NCT02948907|OTHER|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
224056233|NCT06186076|DRUG|TRX-221|TRX-221 oral dose as defined
224056234|NCT04754360|OTHER|Evaluation of functional impairment|Symptom burden and functional impairment will be evaluated with EHRA Score, 6-min walk test and 30-second sit-to-stand test
224056235|NCT04754360|OTHER|Evaluation of pulmonary function|Pulmonary function will be evaluated using basic spirometry and respiratory pressure meter.
224056236|NCT04754360|OTHER|Evaluation of quality of life|Quality of life will be evaluated using Short Form-36 Questionnaire.
224056237|NCT04754360|OTHER|Evaluation of physical activity level|Physical activity level will be evaluated using International Physical Activity Questionnaire Short Form
224056238|NCT04296214|DRUG|5-azacitidine|Cycles of 28 days
224056239|NCT01854320|BEHAVIORAL|Acceptance-based treatment|
224056240|NCT01854320|BEHAVIORAL|Standard behavioral treatment|
224056241|NCT05410444|DEVICE|Clean Intermittent Catheterization|Under clean conditions, the method of regularly inserting the urinary catheter into the bladder through the urethra and emptying the urine regularly is called clean intermittent catheterization.
224056242|NCT05410444|DEVICE|Indwelling catheterization|A catheter is inserted into the bladder through the urethra to drain urine. The catheter has been left in the patient's body.
224056243|NCT05147467|DRUG|APG2575|APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
224056244|NCT02602912|DEVICE|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
224056245|NCT01058070|DEVICE|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
223447993|NCT05876429|OTHER|New Standardized Accept Note|A standardized accept note for transfer patients will be implemented, after stakeholder engagement and subsequent finalization.
223447994|NCT05876429|OTHER|Existing Transfer Patient Admission Process|Maintain existing transfer patient admission processes, across GMS, Cardiology, and Oncology services.
223568837|NCT01366612|DRUG|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
223447995|NCT02723994|DRUG|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
223568838|NCT01366612|DRUG|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
223568839|NCT02498990|BEHAVIORAL|Low calorie diet followed by life style intervention|"1. Low calorie diet of 800 kcal/day for 7 weeks.~2. Life style intervention for the remaining study period"
223568840|NCT05928832|OTHER|Follow-up by a case-manager and access to the internet platform|Patients in the intervention group receive an information letter on their discharge presenting the follow-up from which they benefit:call from the case-manager and access to the internet platform. The case-manager meets the patient and/or informal caregiver on the day of discharge from hospital. He recontacts the patient and/or informal caregiver within 7 days after returning home. A follow-up is offered to patients and caregivers following their return home, according to the objectives defined during the initial interview. The total duration of the support is 6 months maximum including at least 4 contacts with the case-manager,but this is refined and adapted with the patient, according to needs. Similarly, the frequency and methods (face-to-face or remote) of contact varies according to the needs of the patients and the stage of support, and is defined by the case-manager and patient. Patients and/or informal caregivers is also able to contact the case-manager 'on request'.
223568841|NCT03813004|DIAGNOSTIC_TEST|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~1. left treadmill belt deceleration for right leg toe off~2. right treadmill belt deceleration for left leg toe off~3. left treadmill belt acceleration for right leg heel strike~4. right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
224056246|NCT06089148|DIAGNOSTIC_TEST|contrast enhanced digital mammography, tomosyntheis and MRI|
224056247|NCT04018794|DEVICE|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
224056248|NCT04007575|DIAGNOSTIC_TEST|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
224056249|NCT02287389|DEVICE|balloon dilation|
224056250|NCT02287389|PROCEDURE|cryotherapy|
224056251|NCT02287389|PROCEDURE|spiculiform electrosurgery|
223447996|NCT02723994|DRUG|Asparaginase Erwinia Chrysanthemi|
223447997|NCT02723994|DRUG|Cyclophosphamide|
223447998|NCT02723994|DRUG|Cytarabine|
223447999|NCT02723994|DRUG|Dexamethasone|
223568842|NCT04870541|DRUG|Ondansetron 8mg|Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
223568843|NCT04870541|DRUG|Nefopam Injectable Solution|Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
224056252|NCT02287389|DRUG|mitomycin C|
224056253|NCT01824511|BEHAVIORAL|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
224056254|NCT05606081|DEVICE|Logistic regression risk model|Logistic regression model to assign risk score, plus time overdue and PROMPT risk category
224056255|NCT05645874|DIAGNOSTIC_TEST|Skin biopsy|Control skin biopsies from children without a chronic underlying disease are drawn from surgical crop margins during elective orthopedic surgery of the lower leg (n\<80). Skin punch biopsies from children with acquired (n\<80) or genetic NDD (n\<80) or unknown etiology (N\<80) are drawn in the setting of elective interventions during sedation or after local anesthesia. IENFD is quantified by immunohistochemistry and compared between the control and NDD group.
224056256|NCT05547880|DRUG|[11C]ER176|Brain PET with \[11C\]ER176. \[11C\]ER176 is a PET ligand that images TSPO.
224056257|NCT03454802|DIAGNOSTIC_TEST|Passive Leg Raising|See above
223448000|NCT02723994|DRUG|Doxorubicin|
223448001|NCT02723994|DRUG|Leucovorin Calcium|
223448002|NCT02723994|DRUG|Mercaptopurine|
223448003|NCT02723994|DRUG|Methotrexate|
223448004|NCT02723994|DRUG|Pegaspargase|
223448005|NCT02723994|DRUG|Prednisone|
223448006|NCT02723994|DRUG|Thioguanine|
223448007|NCT02723994|DRUG|Vincristine Sulfate|
223448008|NCT06536296|OTHER|Music|Arm 1: Music only
223448009|NCT06536296|OTHER|Music and parent voice|Arm 2: Music and parent voice
223448010|NCT06536296|OTHER|Standard Care|Standard Care
224056258|NCT02009436|DRUG|Azacitidine|Given via nebulizer
224056259|NCT02009436|OTHER|Laboratory Biomarker Analysis|Correlative studies
224056260|NCT02009436|OTHER|Pharmacological Study|Correlative studies
224070736|NCT00406302|DRUG|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
224070737|NCT00406302|PROCEDURE|surgery|28 days after end of induction chemotherapy
224070738|NCT04486755|RADIATION|Hypofractionated Radiation Therapy|All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
223448011|NCT04885231|BEHAVIORAL|Perioperative Pain Management Education and Counseling|All patients will receive both verbal postoperative pain management education and counseling as well as a written handout. Multi-modality non-opioid methods of pain control will be thoroughly discussed.
223448012|NCT04977830|DEVICE|Xenon-129|Patients will undergo a hyperpolarized MRI with administered Xenon gas
224056261|NCT01294202|DRUG|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
224056262|NCT02073175|DRUG|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
224056263|NCT03350295|DRUG|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
224056264|NCT05636592|DRUG|immunotherapy|statin combined with immunotherapy
223448013|NCT04264897|DRUG|Metformin|"Metformin (Hunter Pharmacy) following a ramp up dosing protocol with a targeted dose of 1500 mg/day for 12 weeks."
223448014|NCT04264897|DRUG|Placebo oral tablet|Silicified microcrystalline cellulose, Micosolle®, K30 povidone, sodium starch glycolate, and magnesium stearate
223448015|NCT05351749|BEHAVIORAL|New-prescription Alert|An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
223448016|NCT05351749|BEHAVIORAL|New-prescription Alert with referral option|An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
223448017|NCT05351749|BEHAVIORAL|Existing-prescription notification to prescriber|Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
223448018|NCT05351749|BEHAVIORAL|Existing-prescription notification to pharmacist|Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
223568844|NCT01095354|DRUG|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: \>6 years Multiple Breath Washout: Tidal breathing using a facemask \<9 years or mouthpiece \>9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches \<0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects \>10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
223568845|NCT05825924|DEVICE|E-Cigarette|E-cigarettes have been designed to resemble tobacco cigarettes. They include an aerosol generator, sensor, battery and storage area for liquid. They are either disposable or rechargeable. According to a study, e-cigarettes can deliver an average of 1.3 mg (range 0.4 to 2.6 mg) of nicotine from 15 puffs. Average Cmax after e-cigarette use is recorded as 8.4 ng/mL and Tmax achieved between 2 to 5 minutes
223568846|NCT05825924|DRUG|Nicotine patch|The nicotine patches are applied on the skin and nicotine is delivered at a steady rate. After administration, the peak blood levels are achieved within 6-10 hours. The levels remain constant, reducing by 25-40% with use of patches once daily. The patch is typically administered every 24 hours for no longer than 12 weeks. The dose of the patches is often determined by daily cigarette consumption and level of addiction.
224056265|NCT06226350|DRUG|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
223448019|NCT05288946|OTHER|local segmental control and closed kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge
224056266|NCT05945186|DEVICE|Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)|External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
224056267|NCT05883462|COMBINATION_PRODUCT|Airiver Nasal Drug Coated Balloon (DCB) Catheter.|The balloon is coated with a paclitaxel drug (3.5ug/mm2).
224056268|NCT01922687|DRUG|amlodipine plus atorvastatin (Caduet)|
224056269|NCT01922687|DRUG|amlodipine (Norvasc)|
224146433|NCT00861679|PROCEDURE|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~1. Number of Cells:~   * Number of nucleated cells infused exceed 2,5x10\*7/kg recipient BW or~  * Number of nucleated cells collected exceed 3x10\*7/kg BW~  * Number of CD34+ cells infused exceed 2x10\*5/kg Recipient BW~2. GVHD-prophylaxis:~   • MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~   • UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~3. HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~4. If many choices available ABO- major incompatibility should be avoided."
223448020|NCT05288946|OTHER|local segmental control and open kinetic chain|the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.
223448021|NCT05288946|OTHER|traditional therapy|the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
223448022|NCT05367024|OTHER|Broccoli soup|Participants will consume one broccoli soup three times a week for one 12-week intervention period as part of their normal diet.
223448023|NCT05367024|OTHER|Courgette soup|Participants will consume one courgette soup three times a week for one 12-week intervention period as part of their normal diet.
223448024|NCT02671617|OTHER|High intensity interval training (HIIT)|Preoperative HIIT protocol.
223448025|NCT04124328|PROCEDURE|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
223448026|NCT04124328|PROCEDURE|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
223448027|NCT03369626|BEHAVIORAL|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
224056270|NCT05337787|OTHER|flipped classroom approach|The students in the experimental group were trained using the flipped learning model.
224056271|NCT00993265|DRUG|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
224146434|NCT01852695|BEHAVIORAL|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
224146435|NCT00410449|DRUG|Alpha tocopherol|
224146436|NCT02789449|OTHER|assessment of DLNO and DLCO|
224146437|NCT00608452|OTHER|Symptom Assessment Scale|"* Memorial Symptom Assessment Scale~* History and neurologic examination"
223448028|NCT01482234|BEHAVIORAL|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
223448029|NCT01263717|DRUG|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
223448030|NCT01263717|DRUG|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
223448031|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Nab-Paclitaxel|Given by IV, Given by PO
223448032|NCT05075993|DRUG|LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
223448033|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel|Given by IV, Given by PO
223448034|NCT05075993|DRUG|LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide|Given by IV, Given by PO
223448035|NCT05669339|DRUG|Irinotecan|All subjects will be given either 25 mg/m2 (dose level -1), 50 mg/m2 (dose level 0), or 75 mg/m2 (dose level +1) irinotecan intravenously every 7 days.
224056272|NCT00993265|DRUG|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
224056273|NCT01124903|PROCEDURE|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
224056274|NCT01787682|DIETARY_SUPPLEMENT|BOOST High Protein|
224146438|NCT03371732|BEHAVIORAL|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
223448036|NCT05669339|DRUG|Sonidegib|All subjects will take 200 mg sonidegib orally either every 96 hours (dose level -1), every 48 hours (dose level 0), or every 24 hours (dose level +1).
223741688|NCT01927666|DIETARY_SUPPLEMENT|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
224056275|NCT04918030|PROCEDURE|In-hospital staged PCI|After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
224056276|NCT04918030|PROCEDURE|Out-hospital staged PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.
224056277|NCT02479100|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
224056278|NCT05193253|PROCEDURE|Radiofrequency ablation|Treatment-naive patients with solitary HCC \<= 3 cm who received ablation as the first-line treatment
224056279|NCT05193253|PROCEDURE|Liver resection|Treatment-naive patients with solitary HCC \<= 3 cm who underwent liver resection as the first-line treatment
224056280|NCT05193253|PROCEDURE|Liver transplantation|Treatment-naive patients with solitary HCC \<= 3 cm who were listed for liver transplantation as the first-line treatment
223448037|NCT05669339|DRUG|Sorafenib|All subjects will take 200 mg sorafenib orally either every 48 hours (dose level -1), every 24 hours (dose level 0), or every 12 hours (dose level +1).
223448038|NCT06022419|PROCEDURE|Lucerne Cast|Patients receiving reduction of fractured finger and subsequent customization of a lucerne cast. Duration of cast treatment is determined with 4 weeks.
223448039|NCT06022419|PROCEDURE|Forearm Cast and Finger Splint|Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
223448040|NCT02650700|RADIATION|spleen radiotherapy|Radiation: spleen radiation In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
223448041|NCT06300411|DRUG|SRG-514|SRG-514 monotherapy
223448042|NCT01387945|BEHAVIORAL|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
223448043|NCT01234701|OTHER|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
223448044|NCT01234701|PROCEDURE|Liver resection|Hepatectomy with an intention to cure
223448045|NCT01234701|OTHER|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
223448046|NCT05637190|OTHER|Expressive Arts Therapy group intervention|Art is helpful to reduce negative emotions and boost self-worth during the creative process. During the Expressive Arts Therapy workshops, participants experience different art forms, including visual art, body movement, writing, music, and guided imagery to identify the inner self and get in touch with the self to release suppressed emotions and stress.
223448047|NCT02710552|DRUG|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
223448048|NCT02710552|DRUG|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
223448049|NCT03294200|DEVICE|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
223448050|NCT00057005|DRUG|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
223448051|NCT00057005|DRUG|Anti-CD45|Day-5 400 μg/kg
223448052|NCT00057005|DRUG|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
223568847|NCT03879044|DEVICE|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
223568848|NCT05250635|DEVICE|electronic stethoscope|It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
224056281|NCT04086082|DEVICE|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
224056282|NCT06241092|OTHER||
224056283|NCT06040242|OTHER|Exercise|Participants will perform 3 min of the different activities, followed by a 10-min recovery window.
224146439|NCT03371732|BEHAVIORAL|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
224146440|NCT01754675|BEHAVIORAL|Soccer|Watching the soccer match at the time that the favorite team is playing
224146441|NCT01754675|BEHAVIORAL|Movie|Watching a movie at the time that the favorite team is playing
224146442|NCT02492087|DRUG|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
223448053|NCT00057005|DRUG|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
223448054|NCT00057005|DRUG|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
223448055|NCT00057005|RADIATION|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
223448056|NCT01979601|DRUG|LGT209|150 mg lyophilized powder in glass vial
223448057|NCT01979601|DRUG|Placebo|Placebo comparator
223448058|NCT03518502|PROCEDURE|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
223448059|NCT03518502|DRUG|Sorafenib|Standard therapy for advanced HCC
223448060|NCT02582697|DRUG|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
223448061|NCT02582697|DRUG|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
223448062|NCT02582697|DRUG|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
223448063|NCT02582697|DRUG|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
223568849|NCT02388035|DRUG|Cefotaxime|
224056284|NCT05571228|BEHAVIORAL|Self-stigma intervention|Be Outspoken and Overcome Stigmatizing Thoughts (BOOST) is a group-based intervention integrating cognitive behavioural therapy (CBT) and peer support to reduce or prevent the internalization of stigma in early psychosis. The BOOST group will last for 4 weeks and consists of two 1-hour sessions per week. Participants will be assessed prior to the first group, following the final group, six months after the group ends, and twelve months after the group ends.
224056285|NCT02301182|DEVICE|ADM X3-MoP Cup|
224146443|NCT02492087|DRUG|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
224146444|NCT03116308|DRUG|Opicapone (OPC)|50 mg OPC capsules; oral route
224146445|NCT04632537|DRUG|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine|Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
223448064|NCT02582697|DRUG|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles."
223448065|NCT01381380|PROCEDURE|Manual therapy|Manual therapy, once a week for 8 weeks
223448066|NCT03404934|DEVICE|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
223448067|NCT02831946|DEVICE|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
223568850|NCT00605098|DRUG|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
224146446|NCT04632537|DRUG|Preservative-free saline|Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
224146447|NCT04178577|DRUG|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
224146448|NCT02535078|DRUG|Tebentafusp (IMCgp100)|soluble gp100-specific T cell receptor with anti-CD3 scFV
224146449|NCT02312583|BEHAVIORAL|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
224146450|NCT02312583|BEHAVIORAL|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
224146451|NCT04201977|OTHER|Foam Roller Recovery|Myofascial self-release will be developed through the foam roller (FR), where participants will use a custom-made foam roller constructed from a hollow polyvinyl chloride tube that will have an outside diameter of 10cm and a thickness of 0.5cm and will be surrounded by neoprene foam with a thickness of 1cm. Each volunteer will be shown the technique for the 5 muscle groups involved and the technique used for each muscle group. FR will consist of 45s of rolling for each muscle in the left lower extremity, 15s of rest, 45s in the lower right extremity. They will be instructed to begin with the practice on the most distal portion of the muscle. They will be instructed to place as much tolerable body mass on the FR at all times and to roll their body mass back and forth along the roller as smoothly as possible at a rate of 50 beats per minute (ie , 1 rolling motion for 1 to 2s). The total technique time is estimated at 10 to 15min (PEARCEY et al., 2015).
224146452|NCT04201977|OTHER|Active recovery|Active recovery for 20 minutes (MIKA et al., 2016) will consist of pedaling on a stationary bike at a speed of 50 to 60 rpm. The load (49 ± 9 W) will be adjusted individually so that the heart rate is close to 100 bpm (about 50% of the theoretical maximum heart rate). This effort intensity is similar to that used in the literature (CRISAFULLI et al., 2003; FAIRCHILD et al., 2003; VANDERTHOMMED; MAKROF; DEMOULIN, 2010)
224146453|NCT04201977|OTHER|Immersion in cold water|Immersion in cold water will consist of the individual sitting in a plastic pool with water at the water level of the umbilical scar. Water temperature is between 11 and 15ºC, for a period between 10 and 15 minutes immediately after the exercise protocol (MACHADO et al., 2016b; MCDERMOTT et al., 2009). Water temperature will be controlled by adding or removing ice. This method has been applied by studies conducted by our research group (MISSAU; SIGNORI, 2017).
223448068|NCT02831946|DEVICE|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
223568851|NCT00605098|DRUG|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
223568852|NCT05480189|OTHER|Non-intervention|Non-intervention,with real world study
223568853|NCT02873065|DRUG|Ilaprazole|
223568854|NCT02873065|DRUG|Esoprazole|
223741689|NCT05077709|DRUG|IO102-IO103 in combination with pembrolizumab|The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
223741690|NCT01601782|PROCEDURE|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
224056286|NCT02301182|DEVICE|CoC Cup|
224056287|NCT06641999|DEVICE|Tinnitus Implant System|Implanted with Tinnitus Implant System: Active Implantable Medical Device
224056288|NCT06464692|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
224056289|NCT06966726|BEHAVIORAL|Positive Dental Imagery|Children were shown four A4-sized laminated color images depicting positive dental scenes (e.g., children interacting happily with the dentist, smiling after treatment) for 2 minutes prior to the procedure.
224056290|NCT06966726|BEHAVIORAL|Neutral Nature Imagery|Children were shown four A4-sized laminated color images depicting neutral nature scenes (e.g., a beach, sunset, flowers) for 2 minutes prior to the procedure.
224056291|NCT06344351|DRUG|TQB3006 tablets|TQB3006 is an inhibitor protein.
224056292|NCT06971484|DIETARY_SUPPLEMENT|Crystalline glucosamine sulfate|A maximum single dose of 1500mg of glucosamine sulfate in a caplet.
224056293|NCT06971484|DIETARY_SUPPLEMENT|Regular glucosamine sulfate|A maximum single dose of 1500mg of glucosamine sulfate in hard gel capsules.
223448069|NCT00482170|DEVICE|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
224056294|NCT02515383|OTHER|Interview|Complete cognitive debriefing interview
224056295|NCT02515383|OTHER|Quality-of-Life Assessment|Ancillary studies
224056296|NCT02515383|OTHER|Questionnaire Administration|Complete MDASI questionnaire
224056297|NCT06490731|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine
223448070|NCT00482170|DEVICE|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
223448071|NCT02025270|BIOLOGICAL|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
223448072|NCT06149403|GENETIC|Experimental: OTL-203|Experimental: OTL-203: Autologous CD34+ enriched cell fraction that contains hematopoietic stem and progenitor cells transduced ex vivo using lentiviral vector encoding the human IDUA gene
223448073|NCT06149403|GENETIC|Active Comparator: Allo-HSCT|Active Comparator: Allogeneic hematopoietic stem cell transplantation
224056298|NCT06490731|DRUG|Ketamine|patients Will receive ketamine
223448074|NCT05090267|DIETARY_SUPPLEMENT|Probiotic Supplement|Participants will take a probiotic supplement or placebo for 90 days.
223448075|NCT05090267|DEVICE|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
223448076|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Photon Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 50 grays (Gys) delivered in 25 fractions to the Clinical Tumor Volume (CTV).
223448077|NCT06392295|RADIATION|Para Aortic Radiation Therapy: Proton Therapy|Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 60 to 65 Gys delivered in 25 fractions to the Gross Tumor Volume (GTVn).
223448078|NCT06392295|DRUG|Androgen Deprivation Therapy|Androgen deprivation therapy will be administered as per standard of care.
224056299|NCT02874365|PROCEDURE|Endoscopic biopsies|intestinal biopsies
224056300|NCT03779971|OTHER|Control Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.
224056301|NCT03779971|OTHER|Lentil Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
224056302|NCT03779971|OTHER|Chickpea Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
224056303|NCT01671423|DRUG|Prednisone|"See Prednisone arm description"
224056304|NCT01671423|DRUG|Placebo|"See Placebo arm description"
224056305|NCT01839396|DEVICE|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
224056306|NCT03600064|DRUG|Misoprostol|the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
224056307|NCT04201990|DRUG|Camrelizumab and Apatinib|Camrelizumab, iv, Q3W; Apatinib, po, QD
224056308|NCT04694664|OTHER|This is an online survey with no intervention.|As this is an online survey about health and wellbeing, there is no intervention.
224056309|NCT02321930|DRUG|tofacitinib 5mg po bid|
224056310|NCT00545597|DRUG|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
224056311|NCT05071365|OTHER|Early access to virtual resources|Single arm study. Participants are given access to self help videos for the management of plantar fasciitis while they are on the waiting list
224146454|NCT04201977|OTHER|Passive recovery|Volunteers will be seated for 20 min after the resistance exercise session (TEIXEIRA et al., 2014a, 2014b).
223448079|NCT06392295|DRUG|Androgen Receptor Signaling Inhibitor|Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.
223568855|NCT03742999|PROCEDURE|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
223568856|NCT03742999|DEVICE|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
223568857|NCT03742999|COMBINATION_PRODUCT|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
224056312|NCT02130739|PROCEDURE|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
224056313|NCT02130739|PROCEDURE|mastectomy|mastectomy with/without breast reconstruction
224056314|NCT02130739|DRUG|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
224056315|NCT02130739|DRUG|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
224056316|NCT02130739|DRUG|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
224056317|NCT05321069|DRUG|BI 1015550|Participants received film-coated nerandomilast tablets orally twice daily at doses of either 9 mg or 18 mg, with each dose administered at least 12 hours apart and taken with 250 mL of water.
224056318|NCT05321069|DRUG|Placebo|Participants received placebo matching 9 mg or 18 mg nerandomilast film-coated tablets orally twice daily, with doses given at least 12 hours apart and each taken with 250 mL of water.
224056319|NCT04422548|PROCEDURE|AI-assisted Colonoscopy|This is a multi-center prospective randomized controlled study comparing real-time AI-assisted colonoscopy versus standard colonoscopy in a real-life setting.
224056320|NCT04422548|PROCEDURE|Standard Colonoscopy|Standard Colonoscopy
224146455|NCT00095511|DRUG|aripiprazole|
223448080|NCT06318156|DIAGNOSTIC_TEST|Infrared thermal imaging|A well-trained physician donned the Finger TPS tactile pressure measurement system (Finger TPS II, BTLETG03, USA), methodically applying a consistent 60N force with a single thumb vertically downward on the acupoints of the L1 to L5 spinal segments, in accordance with the human cutaneous nerve segment map. Additionally, environmental conditions were meticulously controlled-temperature maintained between 20°C to 25°C, relative humidity at 50% to 60%, with gentle indoor lighting, quiet, and stable airflow. The MESH T-1000 Smart medical infrared thermograph, produced by Wuhan Gewu Optoelectronics Technology Co., Ltd., was utilized to assess the surface temperature of the patient's pressure-sensitive acupoint areas.
223568858|NCT04108845|BIOLOGICAL|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
223568859|NCT01952444|BIOLOGICAL|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
224056321|NCT04224844|OTHER|Erector spinae plane block|The block will be performed before the surgery. The spinous process of T2 or T3 wil be identified by an ultrasound guide, with the probe positioned longitudinally. A block needle will be inserted in the caudo-cephal direction. After the injection site is confirmed by 3 ml of physiological solution and correct position of the needle tip is confirmed, bupivacaine will be injected. The patients assigned to this group will also receive an intravenous patient-controlled analgesia device containing tramadol postoperatively.
223568860|NCT01952444|DRUG|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
223568861|NCT00003044|DRUG|cisplatin-e therapeutic implant|
224056322|NCT04224844|OTHER|Control group|Control group will receive only patient-controlled analgesia device containing tramadol. No block will be performed.
224056323|NCT02987179|OTHER|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
224056324|NCT05843682|DEVICE|Using the Avatr App|The patients will use the mobile application called Avatr, which will monitor their health data, as well as provide individualized care and early intervention through alerts generated for the multidisciplinary team.
224056325|NCT02603471|OTHER|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
224056326|NCT02603471|BEHAVIORAL|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
224056327|NCT00199602|DRUG|warfarine - low molecular heparin|
224056328|NCT00853749|BIOLOGICAL|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
224056329|NCT00853749|PROCEDURE|Blood draw|Collection of 10 mL of blood
224056330|NCT03276312|DEVICE|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
224056331|NCT02450604|GENETIC|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
224056332|NCT04020939|DEVICE|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
224056333|NCT04020939|DRUG|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
224056334|NCT00450242|DRUG|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
224056335|NCT00450242|DRUG|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
224056336|NCT04100681|DEVICE|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
224056337|NCT04100681|DEVICE|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
224056338|NCT05691049|DEVICE|HCC_45|"Dosage form: HCC\_45 is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of hyaluronic acid for intradermal use.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation."
224056339|NCT02917681|OTHER|Two intrathecal MSC injections|
224056340|NCT06118151|BIOLOGICAL|Influenza Hemagglutinin mRNA vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
224056341|NCT06118151|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:Solution for injection-Route of administration:IM injection
224056342|NCT04881071|DEVICE|Scarf|Scarf specifically designed to facilitate mother-neonate skin-to-skin contact
224056343|NCT04881071|OTHER|Usual clinical practice|Participants will receive the usual clinical practice
223448081|NCT06625463|BEHAVIORAL|Home based cardiac rehabilitation|12 week home based cardiac rehabilitation include Physical exercise, dietary management, smoking cessation and stress management
223568862|NCT04881500|OTHER|Motivational interview|Patients will follow motivational interview (2 individual sessions by phone)
223568863|NCT04881500|OTHER|Routine Care|Patients will follow routine care
223568864|NCT02383745|OTHER|Acute EEG with fast EEG electrode|
223568865|NCT04526873|BEHAVIORAL|Postcard|Mailed
223568866|NCT04526873|BEHAVIORAL|Phone call|May be automated or by human
223448082|NCT03489629|DRUG|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if \< 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
224056344|NCT05163470|OTHER|early on filed functional rehabilitation|Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.
224056345|NCT05163470|OTHER|traditional on filed functional rehabilitation|Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
224056346|NCT02269787|BEHAVIORAL|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
223448083|NCT03489629|DRUG|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if \< 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
223448084|NCT03489629|DRUG|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
223448085|NCT03489629|DRUG|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
223448086|NCT03489629|BEHAVIORAL|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
223568867|NCT04526873|BEHAVIORAL|Humor/Salience|Funny cartoon + health risk examples
224056347|NCT04262635|DRUG|Cetuximab, Capecitabine|Maintenance treatment ( ArmA )
224056348|NCT04262635|DRUG|Cetuximab|Maintenance treatment ( ArmB )
224056349|NCT00798135|DRUG|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
224056350|NCT00447512|DRUG|ghrelin|acylated ghrelin
224056351|NCT04260412|DEVICE|medium cut-off (MCO) dialysis membrane|Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
224056352|NCT04260412|DIETARY_SUPPLEMENT|Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)|Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
224056353|NCT04260412|DIETARY_SUPPLEMENT|Sodium propionate|Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
224056354|NCT01803321|DRUG|rilonacept (IL-1 Trap)|
224056355|NCT01803321|OTHER|Placebo|
224056356|NCT04822051|OTHER|The Uncertainty Management Psychoeducation Program|The program is conducted in the form of individual psychoeducation. The training was planned to include a total of five sessions, with 60 minutes for each session once a day, and at least two sessions a week. At least two days of a gap was decided between two consecutive sessions.
224056357|NCT06547658|OTHER|Mouth closure|Closing the mouth during sleep by applying pressure to the mentum until the teeth were in occlusion, without altering the head position.
224056358|NCT05407909|DRUG|SYHX2001|SYHX2001 tablets, oral
223448087|NCT04185272|BIOLOGICAL|analysis of BTN and BTNL status|analysis of BTN and BTNL expression in colon cancer and hepatic metastasis
223448088|NCT06104631|OTHER|BK003|The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.
223448089|NCT06104631|OTHER|Placebo|The placebo product has the same composition in excipient, same form and same posology as BK003.
223448090|NCT05339165|BEHAVIORAL|Psychotherapy|
223568868|NCT04526873|BEHAVIORAL|Telehealth|Information about video visit
223568869|NCT02106624|OTHER|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
223568870|NCT02818374|DEVICE|oral accessibility spatula (SAB)|
223568871|NCT03979456|DRUG|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
223448091|NCT00442481|DRUG|Escitalopram|
223448092|NCT00442481|PROCEDURE|A baseline overnight polysomnography (oPSG)|
223448093|NCT03729622|OTHER|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
223568872|NCT00415428|BEHAVIORAL|Patient adherence to national educational guidelines.|
223568873|NCT00307840|DRUG|paricalcitol|
223568874|NCT00033046|DRUG|Modafinil|
223568875|NCT00950391|DRUG|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
223568876|NCT00742365|DEVICE|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
223568877|NCT00742365|DEVICE|Red light placebo|One hour of exposure to red light.
223568878|NCT04286841|DRUG|Immunotherapy|Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
223448094|NCT04273867|OTHER|Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument|This survey has been developed and revised from prior qualitative research with CHP patients and will be used to better evaluate disease status and quality of life with CHP.
223448095|NCT04358211|BIOLOGICAL|Biological: COVID-19 convalescent plasma|One unit of ABO compatible COVID-19 convalescent plasma
223448096|NCT06145529|OTHER|RT Functional HIIT circuit program (15 minutes) with or without gamification approach|"EG1 (RT Functional HIIT circuit program): This intervention involves a 15-minute Resistance Training (RT) Functional High-Intensity Interval Training (HIIT) circuit program. The focus is on functional movements performed at a high intensity within intervals.~EG2 (RT Functional HIIT circuit program with gamification): This intervention replicates the RT Functional HIIT circuit program from EG1 but incorporates gamification strategies. Gamification involves the application of game-like elements, such as points, rewards, and competition, to make the exercise routine more engaging and enjoyable for the participants.~Control Group (CG): Children in the control group continue with their regular Physical Education (PE) sessions, maintaining their usual routine"
223448097|NCT01785758|DRUG|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
223448098|NCT06482619|DIETARY_SUPPLEMENT|Creatine supplementation|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained creatine monohidrate (Creapure, Crown Sport Nutrition, Arnedo, Spain)
223448099|NCT06482619|DIETARY_SUPPLEMENT|Placebo|The supplements were provided in capsules of 1 g of red color not transparent Guinama S.L.U, 0044634, La Pobla de Valbona, Spain) which were prepared with a Capsunorm 2000 semi-automatic manual capsule filling machine (Miranda del Ebro, Spain). Capsules contained placebo (i.e., sucrose)
223448100|NCT04671355|DRUG|Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg|Pressurized metered dose inhaler
223448101|NCT04671355|DRUG|Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg|Dry powder inhaler
223448102|NCT02349282|DIETARY_SUPPLEMENT|Calcifediol 10ug/day|
223448103|NCT02349282|DIETARY_SUPPLEMENT|Vitamin D3 20ug/day|
223448104|NCT02349282|DIETARY_SUPPLEMENT|Placebo|
223448105|NCT04627558|OTHER|stroke patients, balance assessment|validity relability dubousset functional test
223448106|NCT04698083|DIAGNOSTIC_TEST|Electrocardiography ,Tomographic imaging|Based on electrocardiographic follow-up analyses,the two main groups were compared in terms of rotation condition (i.e., Cwr, normal transition, or CCwr), electrocardiographic intervals, and laboratory findings In our study,CO-RADS5 was considered an advanced tomographic finding(e.g., multifocal ground glass opacities with consolidation, vascular thickening,crazy paving pattern,mixed pattern),while CO-RADS1,2,3, and 4 were considered non-advanced tomographic findings.
223448107|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
223448108|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
223448109|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
223448110|NCT00162097|DRUG|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
223448111|NCT01684124|OTHER|conservative O2 therapy|target lower O2 saturation
223448112|NCT01684124|OTHER|standard care|
223568879|NCT00396136|DEVICE|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
223568880|NCT06482697|PROCEDURE|total colpocleisis|Total colpocleisis refers to the process where, during the dissection of the anterior and posterior vaginal walls to remove the vaginal mucosa, no holes are left. When suturing, the anterior and posterior vaginal walls are completely interrupted with mattress sutures, and no holes are left on either side or at the top of the vagina.
223568881|NCT06482697|PROCEDURE|partial colpocleisis (LeFort)|LeFort involves the removal of a rectangular piece of mucosa from the anterior and posterior walls of the vagina, leaving a strip of mucosa 2 to 3 cm wide on each side of the vagina. The dissection is carried out close to the vaginal mucosa while preserving the vaginal bladder fascia as much as possible, creating channels on both sides of the vagina.
223448113|NCT04170036|DIETARY_SUPPLEMENT|protein supplement|Protein supplement usage for at least three preceding months in varied amounts
223448114|NCT01096498|DRUG|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
223448115|NCT01096498|DRUG|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
223448116|NCT04078724|DIETARY_SUPPLEMENT|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
223448117|NCT04078724|OTHER|Without 5-HTP|Subject will not take 5-HTP
223741691|NCT01601782|DEVICE|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
223448118|NCT00814593|BIOLOGICAL|lymphokine-activated killer cells|Instilled into the tumor bed cavity
223448119|NCT00814593|DRUG|polifeprosan 20 with carmustine implant|Intracranial placement
223448120|NCT01453790|BEHAVIORAL|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
223448121|NCT01453790|BEHAVIORAL|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
223448122|NCT03181685|DRUG|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
223448123|NCT03181685|DRUG|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
223448124|NCT03181685|DRUG|recombinant FSH|Controlled ovarian stimulation (COS)
223448125|NCT03181685|DRUG|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
223448126|NCT03176641|OTHER|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
223448127|NCT03176641|OTHER|control|Meniscus repair surgery only
223568882|NCT01377155|DRUG|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
223568883|NCT01467050|OTHER|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
223568884|NCT01467050|OTHER|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
223568885|NCT03354312|DRUG|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
223741692|NCT02419053|OTHER|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
224146456|NCT05314361|BEHAVIORAL|1-Day Cognitive Behavioural Therapy-Based Workshop|The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
224146457|NCT04217083|DIAGNOSTIC_TEST|Breath sampling|The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
224146458|NCT06005298|BEHAVIORAL|Screening, Brief Intervention, Referral to Treatment (SBIRT)|"SBIRT has been defined by SAMHSA as a comprehensive, integrated, public health approach to the delivery of early intervention for individuals with risky alcohol and drug use and the timely referral to more intensive substance abuse treatment for those who have substance abuse disorders. There is consensus that a comprehensive SBIRT model includes screening, brief intervention/brief treatment, and referral to treatment. In addition there are following characteristics:~* It is brief (e.g., typically about 5-10 minutes for brief interventions; about 5 to 12 sessions for brief treatments)~* The screening is universal.~* One or more specific behaviors related to risky alcohol and drug use are targeted.~* The services occur in a public health non-substance abuse treatment setting.~* It is comprehensive (comprised of screening, brief intervention/treatment, and referral to treatment).~* Strong research or experiential evidence supports the model's effectiveness."
224146459|NCT02521623|DEVICE|SurgiMend® Acellular Dermal Matrix|See arm description.
224146460|NCT02521623|DEVICE|Strattice™ Acellular Dermal Matrix|See arm description.
224146461|NCT01237561|OTHER|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
224146462|NCT01861054|DRUG|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
224146463|NCT01841528|OTHER|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
224146464|NCT01841528|OTHER|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
224146465|NCT05551091|DIETARY_SUPPLEMENT|glycomacropeptide (GMP)|For each of the two baseline visits, women will consume a 300 calorie liquid breakfast meal tolerance test (MTT), eat a standard test lunch ad libitum with recording of food intake, and will then begin the low-dose GMP (25 g BID with meals) or high-dose GMP (25 g TID with meals) for 7 days. On day 7 of each GMP diet, women will come to the Clinical Research Unit (CRU) for a second breakfast MTT followed by lunch. All subjects will stop GMP products for 5-7 days (washout).
224146466|NCT01928992|DEVICE|3D|subjects that underwent 3D mammography
224146467|NCT01928992|DEVICE|2D|those subjects that underwent 2D mammography
223741693|NCT04339764|DRUG|iPSC-derived RPE/PLGA transplantation|iPSC-derived RPE/PLGA transplantation
223568886|NCT03354312|DRUG|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
223568887|NCT03960580|DRUG|OPN-375|OPN-375, BID
223568888|NCT01528891|DRUG|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
223568889|NCT01528891|OTHER|Placebo|
224056359|NCT04967079|DRUG|Trametinib|Trametinib 2 mg given orally, once daily
224056360|NCT04967079|DRUG|Anlotinib|Anlotinib given orally, every two weeks followed by a one-week discontinuation cycle
224056361|NCT04169022|OTHER|Sample collection|Sample collection blood and/or bone marrow
224056362|NCT03778411|DEVICE|VCTE with splenic stiffness measurement|Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
223568890|NCT00914446|PROCEDURE|hepatic biopsies|hepatic biopsies
224056363|NCT06125912|OTHER|Dime Beauty TBT Cream|Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.
224056364|NCT06125912|OTHER|Positive Control|Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
224056365|NCT04644939|OTHER|Phone calls|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions and a telephone call one day before the procedure to re-explain the instructions and the importance of bowel preparation
224056366|NCT04644939|OTHER|Standard bowel preparation|Patients undergoing outpatient colonoscopy will receive the standard bowel preparation instructions
224056367|NCT04644939|OTHER|Colonoscopy|Patients will undergo colonoscopy
224056368|NCT02670070|DRUG|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
224056369|NCT04720781|DRUG|Vonoprazan|Vonoprazan (20mg/day) is prescribed for 4 weeks.
224056370|NCT04720781|DRUG|Esomeprazole|esomeprazole (20mg/day)
224056371|NCT00687440|DRUG|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
224056372|NCT00687440|DRUG|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
224056373|NCT00687440|DRUG|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
224056374|NCT01892592|BEHAVIORAL|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
224056375|NCT02228720|DEVICE|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
224056376|NCT02829242|DEVICE|NIRS Monitoring (SenSmart Monitor)|
224056377|NCT03086395|DRUG|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
224056378|NCT04563273|BIOLOGICAL|BCG vaccine 1（0.025mg/0.1ml/person）|Intradermal injection of 0.025mg/0.1ml/person dose BCG.
224056379|NCT04563273|BIOLOGICAL|BCG vaccine 2 （0.05mg/0.1ml/person）|Intradermal injection of 0.05mg/0.1ml/person dose BCG.
224056380|NCT04563273|BIOLOGICAL|BCG vaccine 3（0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
223568891|NCT04452435|DRUG|C21|C21
223568892|NCT04452435|DRUG|Placebo|Placebo
223568893|NCT03645694|DEVICE|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
223568894|NCT02643563|DRUG|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
223568895|NCT02643563|DRUG|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
223568896|NCT02643563|DRUG|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
224056381|NCT04563273|BIOLOGICAL|BCG vaccine 4 （0.075mg/0.1ml/person）|Intradermal injection of 0.075mg/0.1ml/person dose BCG.
224056382|NCT04563273|BIOLOGICAL|Placebo of BCG vaccine （0.1ml/person）|Intradermal injection of 0.1ml/person dose Placebo.
224056383|NCT00290199|DEVICE|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
223448128|NCT05516771|DEVICE|Tcore™ system|"The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers."
223448129|NCT01963091|DRUG|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
223448130|NCT01963091|DRUG|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
223448131|NCT03585712|DRUG|Norgestrel 0.075 mg|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
223448132|NCT00915603|DRUG|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
223448133|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
223448134|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
223448135|NCT00915603|DRUG|Placebo|Placebo PO daily continuously for all 28 days of a cycle
223448136|NCT00915603|DRUG|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
224056384|NCT00254748|DRUG|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
224056385|NCT00254748|DRUG|Placebo|placebo
224056386|NCT03101774|DEVICE|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
224056387|NCT03101774|DEVICE|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
224056388|NCT03101774|OTHER|Control group|Conventional therapy without any inspiratory muscle training program
223448137|NCT00915603|DRUG|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
223448138|NCT02746094|DEVICE|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule."
223568897|NCT02249299|DRUG|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
223568898|NCT02249299|DRUG|Placebo|
223568899|NCT05113121|DIAGNOSTIC_TEST|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)|, Humphrey visual field (24-2) analysis and optical coherence tomography on retinal nerve fiber layer (RNFL) and ganglion cell complex.(GCC)
223741694|NCT02401594|DRUG|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
224056389|NCT03779308|DEVICE|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
224056390|NCT01392677|DRUG|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
223448139|NCT06822075|BEHAVIORAL|SANTE program|"The intervention will consist of distinct period. Fisrt, 3 complete assessment periods will be realized : pre-intervention (week 1-2) ; mid-intervention (week 8-9) ; post-intervention (week 15 - 16) for evaluate the evolution of the health-related behavior, mental and physical health. Second, the SANTE program intervention will be implemented. Intervention 1 (week 3 and 7) for INT-1 group receive the SANTE program and INT-2 group do noting ; Intervention 2 (week 10-14) for INT-2 group receive the SANTE program and INT-1 do noting.~The SANTE intervention will consist of (at a minimum):~* 1 to 2 group physical activity sessions per week~* 1 outdoor outing (full-day or half-day) per month~* 1 individual meeting with a physical activity and sports expert"
223448140|NCT01230216|DRUG|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
223448141|NCT01230216|DRUG|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
223448142|NCT05742191|OTHER|Daylight Savings time transitions|Daylight Savings time transitions.
223448143|NCT03360214|DRUG|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
223448144|NCT03360214|OTHER|Placebo Drug|For sham drug, 0.9% saline, will be used.
223448145|NCT03360214|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
223448146|NCT03360214|OTHER|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
223448147|NCT03360214|DRUG|Ropivacaine Hydrochloride|For active drug, 0.25% naropin, will be used.
223448148|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Pomegranate extract|Participants will consume 1.5 grams L-carnitine with 1.6 grams pomegranate extract at one visit during one intervention period
223448149|NCT06518343|DIETARY_SUPPLEMENT|L-carnitine + Microcrystalline cellulose|Participants will consume 1.5 grams L-carnitine with 1.5 grams microcrystalline cellulose at one visit during one intervention period
223448150|NCT06192888|DRUG|Glofitamab|IV Glofitamab
223448151|NCT06192888|DRUG|Obinutuzumab|IV Obinutuzumab
223448152|NCT06192888|DRUG|Lenalidomide|Oral Lenalidomide
223448153|NCT06973330|DRUG|SOX regimen combined with Sintilimab and Apatinib|Patients who met the inclusion criteria were treated with SOX regimen combined with Sintilimab plus Apatinib every 3 weeks(4 cycles) followed by sintilimab+apatinib until disease progression or intolerable adverse reactions or death(up to 24 months).
223448154|NCT06055803|BEHAVIORAL|Intake Session|Each of the program components will have an individualized assessment with plan and goals set at the program intake visit.
223448155|NCT06055803|BEHAVIORAL|Individual Sessions|Individual sessions will occur in person or virtual every other week during the 12-week intervention with a health promotion specialist (nurse or exercise physiologist). These sessions will include review of progress towards goals, update exercise prescription, make plan for the next two weeks.
223448156|NCT06055803|BEHAVIORAL|Group Sessions|Group sessions for wellness and education will be delivered by medical multi-disciplinary staff in person or virtual every other week during the 12-week intervention.
223448157|NCT06055803|BEHAVIORAL|Graduation|At the conclusion of the 12-week intervention, there will be a graduation session to honor the participant's achievement and establish a plan for maintenance after the intervention
223568900|NCT02408003|DRUG|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
224056391|NCT01392677|DRUG|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
224056392|NCT01969994|OTHER|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (-)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
224056393|NCT01969994|OTHER|(-)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (-)-epicatechin and a single-carbon-14 radiolabeled (-)-\[2-14C\]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (-)-\[2-14C\]epicatechin.
224056394|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
223448158|NCT06055803|BEHAVIORAL|Exercise|Participants will exercise as part of individual and group sessions. Participants will also be asked to exercise on their own, with a goal of working up to meeting US Physical Activity guidelines (150 minutes per week of moderate to vigorous exercise + 2 episodes of strength training).
223448159|NCT06666335|DRUG|Anakinra|Subcutaneous injections once daily for 6 months
223448160|NCT05169788|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
223568901|NCT02408003|DRUG|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
223568902|NCT00189332|DRUG|852A|
223448161|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-1Gy|1Gy ILDR will be administered to patients in a single fraction. The radiation treatment volume composes both the jejunum and ileum.
223448162|NCT06076135|RADIATION|Intestinal Low Dose Radiotherapy-2-3Gy|ILDR will be administered as single fractions within 10 days. The total dose of radiotherapy will be 2-3 Gy in 2-3 fractions. ILDR design is as above.
223448163|NCT06076135|DRUG|PD-1/PD-L1 Inhibitors|The immunotherapy regimen is the previous ICB therapy regimen or modified by the physician in charge. PD-1/PD-L1 inhibitors will be given 1 day after ILDR at a 3-week interval.
223741695|NCT02401594|DRUG|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
223448165|NCT06949592|DIETARY_SUPPLEMENT|Placebo|Intake of 400 mg placebo (maltodextrin; encapsulated) in the morning (09:00)
223448166|NCT06949592|DIETARY_SUPPLEMENT|M_ML|Intake of 400 mg M\_ML (encapsulated) in the morning (09:00)
223448167|NCT06949592|DIETARY_SUPPLEMENT|M_ML|Intake of 400 mg M\_ML (encapsulated) in the evening (19:00)
223448168|NCT04421014|DIETARY_SUPPLEMENT|Ketone Ester drink|The main ingredient of the Ketone Ester drink \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)\] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices\&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.
223448169|NCT04421014|DIETARY_SUPPLEMENT|Placebo: isocaloric dextrose drink|The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
223448170|NCT04006262|DRUG|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~\- Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
223448171|NCT04006262|DRUG|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
223448172|NCT06383091|BEHAVIORAL|Anterior Neck Manual Therapy|Manual massage applied to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
223448173|NCT06383091|BEHAVIORAL|Pain Neuroscience Education|Description of how the pain system works from a neurobiological level, discussing the biopsychosocial model that influences pain.
223448174|NCT06383091|BEHAVIORAL|Neck Stretches|Bilateral cervical side bending, cervical extension and bilateral rotational neck stretches held for 20 seconds x3.
223448175|NCT06383091|BEHAVIORAL|Scar massage|Digital manipulation of the scar itself in circles.
223448176|NCT06383091|BEHAVIORAL|Voice Exercises|Stemple Voice Exercises
223448177|NCT06383091|BEHAVIORAL|Placebo Anterior Neck Manual Therapy|Will apply extremely light manual contact to the anterior neck, including hyolaryngeal elevators, depressors, sternocleidomastoid.
223448178|NCT06383091|BEHAVIORAL|Placebo Pain Neuroscience Education|Will discuss how pain will as a result of the surgical intervention.
223448179|NCT06383091|BEHAVIORAL|Placebo Neck Stretches|Will ask patient to look down as a neck stretch held for 20 seconds x3.
223448180|NCT06671366|DEVICE|external and internal shoulder rotation using a Cybex dynamometer|"Measurement of the reproducibility, in this precise evaluation position, of the results obtained between the different tests carried out 30 minutes apart, and thus the reliability of each measurement in this test.~measures :~* Concentric internal rotation 60degrees/sec~* Concentric external rotation 60 degrees/sec~* Concentric internal rotation 180 degrees/sec~* Concentric external rotation 180 degrees/sec~* Eccentric internal rotation 60degrees/sec~* Eccentric external rotation 60degrees/sec"
223448181|NCT04296669|DEVICE|Ergotron LearnFit Sit-Stand desk|An adjustable sit-stand desk design for children
223448182|NCT00594074|OTHER|white wine|3.25 ounces of white wine twice a day with lunch and dinner
223448183|NCT01532206|OTHER|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
223448184|NCT05013281|PROCEDURE|Suprachoroidal hemorrhage associated with pars plana vitrectomy|SCH has a higher incidence rate after a second intraocular surgery in a vitrectomized eye which is associated with the lack of vitreous support and easier fluctuation of intraocular pressure. SCH associated with PPV is more localized and has a relatively good prognosis; high myopia and aphakic/ pseudophakic eyes are risk factors. Active treatment can effectively improve visual prognosis.
223448185|NCT01954199|PROCEDURE|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~* In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~* In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~* In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
223568903|NCT05046990|DIAGNOSTIC_TEST|Regular Arrangement of Collecting Venules|This is a prospective, multicentre, international study without a control group.
223568904|NCT04557514|PROCEDURE|platelet rich plasma injection in post burn facial scar|"2 spins\>\>\>~1. st spin (separate plasma from blood) 2500 for 10 minutes~2. nd spin (separate platelet rich part of plasma) 1500 for 10 minutes Taking lower part (platelet rich plasma ) Injection under scar after rigotomy"
223741696|NCT00387439|BEHAVIORAL|standard medical treatment + anoperineal physiotherapy.|
224056395|NCT03996876|DEVICE|RePS (Resolving Psychological Stress) - Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
224056396|NCT00577109|DRUG|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
224056397|NCT00577109|DRUG|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
224056398|NCT00577109|DRUG|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
224056399|NCT00577109|DRUG|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
223448186|NCT03004924|DRUG|SHP640|Instill 1 drop of SHP640 (povidone-iodine \[PVPI\] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
223448187|NCT03004924|DRUG|PVP-I 0.6%|Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
223448188|NCT03004924|DRUG|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
223448189|NCT01173419|DEVICE|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
223448190|NCT01173419|DEVICE|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
223448191|NCT06426160|DRUG|Tocilizumab 20 MG/ML [Actemra]|Tocilizumab 8 mg/kg every four weeks for 24 weeks.
224056400|NCT00577109|DRUG|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
224056401|NCT03072784|PROCEDURE|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
224056402|NCT02726971|DRUG|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
224056403|NCT03180099|DRUG|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
223448192|NCT06426160|DRUG|Sodium Chloride 0.9% Inj|Placebo (Sodium chloride) every four weeks for 24 weeks.
223448193|NCT01280682|DRUG|rituximab|anti-CD20 monoclonal antibody 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
223448194|NCT03103217|BEHAVIORAL|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
223448195|NCT02816541|OTHER|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
223448196|NCT02816541|OTHER|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
223448197|NCT02816541|OTHER|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
223568905|NCT04557514|PROCEDURE|fat injection in post burn facial scar|Anesthesia : general or local Lipoaspirate from abdomen or thigh using adrenaline(1\\1000000) + ringer lactate + zylocaine Liposuction by canula no4 Sediment 3 layers : taking mid layer of fat and omit uppermost and lowermost layers Lipoinjection in fan shaped manner 10-20 cc according to site affected by canula no 1 .
223568906|NCT01841125|DRUG|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
224056404|NCT03180099|DRUG|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
224056405|NCT02324075|BEHAVIORAL|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
224056406|NCT03321227|OTHER|Snack skipping|No snack provided
224056407|NCT03321227|OTHER|Whole eggs|2 whole large eggs scrambled, provided as a snack
224056408|NCT03321227|OTHER|Egg whites|2 egg whites scrambled, provided as a snack
224056409|NCT03321227|OTHER|Egg yolks|2 egg yolks scrambled, provided as a snack
224056410|NCT03321227|OTHER|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
224056411|NCT03588988|DRUG|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
224056412|NCT03588988|DRUG|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
223568907|NCT01841125|DRUG|Placebo|placebo 15mg, QD(once a day), Oral medication
223568908|NCT02604654|DRUG|Yiqitongluo granule|administered after dissolved
223568909|NCT03600766|DRUG|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
223568910|NCT03600766|DRUG|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
223741697|NCT00387439|BEHAVIORAL|Standard medical treatment|
224056413|NCT02170402|BIOLOGICAL|Octocog alfa (recombinant human coagulation factor VIII)|"* Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~* Part 2: On-demand treatment regimen~* Part 3: Prophylaxis treatment regimen"
224056414|NCT01326182|BEHAVIORAL|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
224056415|NCT01326182|BEHAVIORAL|MAAS|Group-based intervention including asthma education and education regarding general child health
224056416|NCT04609735|OTHER|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
224056417|NCT04609735|OTHER|Manual Therapy, Exercise and Ultrasound|Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
224056418|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS)|Assess early and late genito-urinary (GU) toxicities induced assessed via the International Prostate Symptom Score (I-PSS) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
224056419|NCT05820633|RADIATION|"Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite (EPIC-26):"|Assess early and late genito-urinary (GU) and gastro-intestinal (GI) toxicities induced and quality of life assessed via expanded prostate cancer index composite (EPIC-26) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
224056420|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM)|Assess early and late sexual health in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
224056421|NCT05820633|RADIATION|Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE)|Assess early and late toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE) in the experimental UHF group has compared in a non-inferiority analysis to those of patients who received a standard treatment (control group).
224056422|NCT05820633|RADIATION|Report and compare the biochemical disease free survival (bDFS)|Assess the 5 and 10 years biochemical disease-free survival (bDFS) in the UHF group and compare them for non-inferiority to those of the control group.
224056423|NCT05820633|RADIATION|Report and compare the disease free survival (DFS)|Assess the 5 and 10 years disease-free survival (DFS) in the UHF group and compare them for non-inferiority to those of the control group.
224056424|NCT05820633|RADIATION|Report and compare the metastase free survival (MFS)|Assess the 5 and 10 years metastasis-free survival (MFS) in the UHF group and compare them for non-inferiority to those of the control group.
224056425|NCT05820633|RADIATION|Report and compare the overall survival (OS)|Assess the 5 and 10 years overall survival (OS) in the UHF group and compare them for non-inferiority to those of the control group.
223448198|NCT04677387|BEHAVIORAL|Nalox-comm Training Module|The online communication module will be 30-60 minutes. Content will include: 1) using non-judgmental language, 2) how to raise the topic of overdose (OD) and naloxone with patients in a non-threatening manner; 3) videos modeling how to initiate the conversation with patients and caregivers; 4) considerations in how to communicate differently with patients versus caregivers; and 5) addressing pharmacists' perceived barriers to naloxone counseling. Pharmacists can receive continuing education credit (0.1 CEU) for completing the course.
223448199|NCT04677387|BEHAVIORAL|Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists|A 55 minute long online module with videos, didactic content, and quizzes that covers the following topics: risk factors for overdose (OD), how to respond to OD, how naloxone works, types of naloxone, how to administer naloxone, medico-legal issues, how to bill for naloxone, and strategies to address overdose. Pharmacists can receive continuing education credit (0.125 CEUs) for completing the course.
223568911|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
224056426|NCT03865212|DRUG|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
224056427|NCT05264740|BEHAVIORAL|Motivational interviewing|The intervention group will receive motivational interviewing sessions with a trained study nurse plus educational material
224056428|NCT05264740|BEHAVIORAL|Educational materials|The control group will receive educational material only.
224056429|NCT06977659|DRUG|Norepinephrine|Norepinephrine bitartrate (LEVOPHEDR, Pfizer inc.) 4 mg/4ml + 5% Dextrose in water 246 ml (total volume 250 ml, final concentration 16 mcg/ml) infuses intravenously via a central catheter or peripheral line with the rate of 10 ml/h (equivalent to 0.05 mcg/kg/min for a 50-kg patient). The drug will be initiated within 1 hour after randomization, infused for 24 hours after randomization, and then discontinued.
224056430|NCT06977659|DRUG|Placebo|5% Dextrose in water 250 ml infused intravenously at a rate of 10 ml/h. The drug will be initiated within 1 hour after randomization, infused for 24 hours after randomization, and then discontinued.
224056431|NCT06978075|DEVICE|Chest wall tumor resection by the artificial intelgent assistent|we plan to carry out of the research on the application of artificial intelligence (AI) assisted chest wall tumor research combined with a personalized 3D preformed chest wall defect reconstruction system in chest wall tumor surgery. Data will be imported into a computer to draw a 3D model of the tumor and construct an ideal resection range to ensuring sufficient surgical margins while avoiding damage to important nerve and vascular tissues in the chest. Preformed titanium plates will be prepared based on the calculated resection range and the titanium plates will be detachable assembly components through screws, which can be adjusted at any time according to the surgical situation.
224056432|NCT06978777|DRUG|Caffeine (200 mg)|single dose of 200mg caffeine orally in study visit A
224056433|NCT06978777|DRUG|Placebo|single dose of 1 tablet Placebo in study visit B
224056434|NCT06978023|COMBINATION_PRODUCT|JM-LD|Proprietary formula of extracts of Coptidis Rhizoma, Astragali Radix Lonicerae Japonicae Flos (CAL) plus low dose extract of Ophiopogonis Radix
224056435|NCT06978023|COMBINATION_PRODUCT|JM-HD|Proprietary formula of extracts of Coptidis Rhizoma, Astragali Radix, Lonicerae Japonicae Flos (CAL) plus high dose extract of Ophiopogonis Radix
223448200|NCT06402357|DEVICE|Focal One high intensity focused ultrasound device|Participants will be treated with one session of high intensity focused ultrasound using the Focal One device.
223448201|NCT02057432|DEVICE|intra-operative MRI|Patients will undergo an MRI during surgery.
223448202|NCT04427488|OTHER|Morning Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
223568912|NCT05859373|COMBINATION_PRODUCT|TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation|TQB3728 is an inhibitor of apoptosis protein. TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
223448203|NCT04427488|OTHER|Evening Chronotype group|Total of 12 weeks aerobic and strengthening exercises in different timing of the day.
223448204|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223448205|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
224056436|NCT06978023|COMBINATION_PRODUCT|Placebo|Placebo consisting of excipients, coloring and food ingredients to provide a powder mixture of same weight with similar color, texture and odour
224056437|NCT06977906|PROCEDURE|conventional Robotic-assisted radical prostatectomy group|Robotic-assisted radical prostatectomy uses a standard anterior approach with transabdominal or extraperitoneal access. After establishing pneumoperitoneum, the Retzius space is dissected to expose the prostate. The deep dorsal venous complex is ligated to control bleeding, and the bladder neck is carefully dissected while preserving the ureters. Seminal vesicles, vas deferens, and neurovascular bundles are selectively preserved based on tumor characteristics. A tension-free anastomosis of the bladder and urethra is performed using absorbable sutures. Lymph node dissection is done if necessary. The robotic system ensures precise dissection, hemostasis, and suturing, optimizing oncological control while preserving urinary continence and sexual function with reduced bleeding and complications.
223448206|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223448207|NCT00269477|BIOLOGICAL|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
223448208|NCT06572943|OTHER|Moderate intensity physical activity|Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
224056438|NCT06977906|PROCEDURE|Improved Robotic-assisted radical prostatectomy group|The procedure is performed in a head-down, feet-up supine position with an abdominal or extraperitoneal approach. The right peritoneum is opened along the right external iliac vein to clear the obturator nerve, vessels, and lymph nodes. The external and internal iliac lymph nodes are also cleared. The right pelvic fascia is incised to remove prostate fat while preserving the bladder's anterior wall peritoneum. The same approach is used on the left side. The peritoneum is retracted to clear anterior prostate fat, and the deep venous complex is ligated to expose the prostate. Prostatectomy is performed, followed by urethra and bladder anastomosis, and peritoneal suturing with drainage tube placement.
224056439|NCT06977919|BEHAVIORAL|NASM OPT Program|Three 60-minute weekly sessions for 12 weeks, progressing through stabilization (weeks 1-4), strength endurance (weeks 5-8), and hypertrophy (weeks 9-12) phases. Exercises included bench presses, chest flyes, and push-ups.
224056440|NCT06977919|BEHAVIORAL|General Exercise|Three 60-minute weekly sessions of brisk walking and light aerobics without targeted resistance training.
224301113|NCT05237336|BEHAVIORAL|Mindfulness-based Cognitive Therapy|"MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences."
224056441|NCT06977932|DRUG|Carbarmazepine|If patients were on carbamazepine (CBZ) prior to enrollment, the CBZ dose remained unchanged after enrollment; if patients were on oxcarbazepine (OXC) prior to enrollment, they received half of their pre-enrollment OXC dose as CBZ after enrollment. Orally administered for four consecutive weeks.
224301114|NCT05237336|BEHAVIORAL|Counselling as usual|Control group, Counselling as usual
224301115|NCT02189980|OTHER|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
224301116|NCT02189980|OTHER|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
223568913|NCT05859373|COMBINATION_PRODUCT|TQB2450 injection, sequential or concurrent chemoradiation|TQB2450 injection is humanized monoclonal antibody to Programmed Cell Death Protein 1 (PD-1).
223568914|NCT00764257|DEVICE|PREVELLE Shape|
223568915|NCT00764257|DEVICE|Restylane|
224301117|NCT02189980|OTHER|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
223448209|NCT04365075|DEVICE|Excimer Laser Combined with DCB|Using excimer laser combined with drug-coated baloons to treat infrapopliteal lesions in patients with critical limb ischemia.
223448210|NCT04365075|DEVICE|Angioplasty Alone|Using angioplasty alone to treat infrapopliteal lesions in patients with critical limb ischemia.
223448211|NCT05041777|DEVICE|Optical Coherence Tomography|OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. \[2\] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
223448212|NCT03300713|OTHER|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
223448213|NCT03300713|OTHER|usual follow-up|usual follow-up
223568916|NCT05974475|RADIATION|SBRT|State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).
223741698|NCT00326456|DRUG|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
224056442|NCT06977932|PROCEDURE|Sham Electroacupuncture|In this group, superficial needling (0.5-1 mm depth) was performed at non-meridian points located 1 cm lateral to: (1) primary local acupoints ST2 (Sibai), ST7 (Xiaguan), and ST4 (Dicang) on the affected side; (2) branch-specific supplementary points GB1 (Tongziliao) for ophthalmic branch involvement, SI18 (Quanliao) for maxillary branch involvement, and ST6 (Jiache) for mandibular branch involvement; and (3) bilateral distal points LI4 (Hegu) and TE5 (Waiguan). Local acupoint pairs (ST7 adjacent + GB1 adjacent or ST7 adjacent +SI18 adjacent or ST7 adjacent + ST6 adjacent) and distal pairs (LI4 adjacent +TE5 adjacent) were connected to a modified electroacupuncture device with severed output wires (preventing current flow while maintaining indicator function), followed by 60-minute needle retention after parameter adjustment. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
224056443|NCT06977932|DRUG|Carbarmazepine Placebo|CBZ placebo is a tablet with identical packaging and appearance to CBZ but lacks therapeutic effects. If patients were receiving CBZ prior to enrollment, they were transitioned to a CBZ placebo at an equivalent daily dose post-enrollment. For patients previously treated with oxcarbazepine, the post-enrollment regimen consisted of a CBZ placebo administered at half the pre-enrollment oxcarbazepine dose. Orally administered for four consecutive weeks.
224056444|NCT06977932|PROCEDURE|Electroacupuncture|The primary acupoints selected were the affected side's Sibai (ST2), Xiaguan (ST7), and Dicang (ST4). Based on the affected nerve branch, additional acupoints were chosen: for the ophthalmic branch, Tongziliao (GB1); for the maxillary branch, Quanliao (SI18); and for the mandibular branch, Jiache (ST6). Distal acupoints included bilateral Hegu (LI4) and Waiguan (SJ5). Electroacupuncture was applied based on the affected nerve branch. For the ophthalmic branch, the local acupoints selected were Xiaguan + Tongziliao; for the maxillary branch, Xiaguan + Quanliao; and for the mandibular branch, Xiaguan + Jiache. The distal acupoints selected were Hegu + Waiguan. A sparse-dense wave, 2/100Hz, was used, with a treatment duration of 60 minutes. The intensity of the electrical current was adjusted according to the patient's tolerance. Acupuncture was administered 3 times per week (with 1-2-day intervals between sessions) for 4 consecutive weeks, totaling 12 sessions.
223448214|NCT04598308|DIAGNOSTIC_TEST|absolute flow and resistance measurements|"This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine."
224056445|NCT06979271|DRUG|Telitacicept Tofacitinib|One group of D2TRA subjects receive Telitacicept combine Tofacitinib treatment
224146468|NCT04257227|DEVICE|repetitive Transcranial Magnetic Stimulation (rTMS)|"The rTMS intervention will be performed in a dedicated rTMS patient room on the PC unit, where the patient can remain in their bed seated upwards at a 45 degree angle, or seated in a chair.~The stimulation intensity for treatment will be determined by measuring the resting and active motor threshold (rMT and aMT) using single pulse TMS over the motor cortex using standard techniques as in previous trials. Investigators will use left-sided intermittent theta burst stimulation (iTBS). The trained team member will locate the left DLPFC using the BeamF3 technique. For the open-label dose-finding study, this region will be stimulated intermittently at 3 TMS pulses every 200 milliseconds for 2 seconds (i.e. 30 stimulations). This procedure is repeated every 10 seconds for a total duration of 3 minutes during which 600 total pulses are delivered. Participants will receive up to 8 3-minute sessions daily at 45 minute intervals for 5 days (consecutively or in a seven-day window if need be)."
224146469|NCT02581982|OTHER|Laboratory Biomarker Analysis|Correlative studies
223448215|NCT02627482|DEVICE|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
223448216|NCT04350164|DRUG|Romiplostim|romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.
223448217|NCT04050085|BIOLOGICAL|Nivolumab|Given IV
223448218|NCT04050085|RADIATION|Radiation Therapy|Undergo radiation therapy
223448219|NCT04050085|DRUG|TLR9 Agonist SD-101|Given intratumorally
223448220|NCT03611101|COMBINATION_PRODUCT|¹³C-Methacetin Breath Test|A breath analyzer will be used to measure changes in 12C (carbon 12) to 13C (carbon 13) ratio as a result of metabolism of the Methacetin substrate before and after treatment.
223448221|NCT03611101|DRUG|BMS-986036|Investigational drug for NASH treatment in Main BMS protocol
223448222|NCT03611101|DEVICE|BreathID MCS device|The BreathID MCS device is a breath analyzer specifically used for measuring changes in the ratio of 13CO2 and 12CO2 isotopes of carbon dioxide. The device is connected to the subject via a nasal cannula and breath is passively collected before and after ingestion of labelled 13C- Methacetin substrate.
223448223|NCT03838510|BEHAVIORAL|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
223448224|NCT00983138|DRUG|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
223568917|NCT05974475|PROCEDURE|Surgery|State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
223568918|NCT04088240|DIETARY_SUPPLEMENT|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
223568919|NCT04088240|DIETARY_SUPPLEMENT|n-3 control|4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
223568920|NCT04088240|DIETARY_SUPPLEMENT|Placebo|"4 g/d placebo control (light olive oil)"
224056446|NCT06977087|BEHAVIORAL|Psychoeducation|Providing information about social anxiety, role of safety and avoidance behaviors in maintaining social anxiety, rationale for exposure to feared social situations
224056447|NCT06977087|BEHAVIORAL|Prospective Mental Imagery|A standard imagination script is recounted in which participants have successfully mastered the socially feared situation
224056448|NCT06977087|BEHAVIORAL|Verbal Reasoning|Participants are asked to reflect on the pros and cons of facing the socially feared situation
224056449|NCT06340451|DEVICE|iovera° system|subjects will receive ultrasound-guided iovera° system treatment
224056450|NCT06340451|DEVICE|sham iovera° system treatment|subjects will receive ultrasound-guided iovera° sham system treatment
224056451|NCT06977789|DEVICE|S Patch3-Cardio/S-Patch Ex|S Patch3-Cardio/S-Patch Ex for 72 hours
224146470|NCT02581982|DRUG|Paclitaxel|Given IV
224146471|NCT02581982|BIOLOGICAL|Pembrolizumab|Given IV
223448225|NCT01879202|DRUG|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
223568921|NCT05894720|OTHER|Thrower's Ten Exercise Group|"the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs."
223568922|NCT06307522|DRUG|MRG-001|Patients will receive subcutaneous administration of MRG-001 at designated visits.
223568923|NCT02916641|DRUG|Fuzhenghuayu|
223568924|NCT02916641|DRUG|UDCA|
224146472|NCT00599027|DRUG|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
223568925|NCT05577312|DRUG|BRL-101|CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
224056452|NCT06977789|DEVICE|Holter|Holter for 24 hours
224146473|NCT00599027|DRUG|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
224056453|NCT06984601|PROCEDURE|Lateral Internal Sphincterotomy (LIS)|This is a routinely performed surgical procedure for chronic anal fissure. The study is observational and does not assign this procedure to participants.
224146474|NCT05344027|DRUG|Mitotane|Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
224146475|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
224056454|NCT06985667|BEHAVIORAL|Cognitive-Based Behavior Change Training Program|"Parents will be given an 8-session parent training program.~Session 1: Establishing a trusting relationship and informing them about the study Session 2: Informing parents about the cognitive development of 3-6 year old children Theme: Children learn with 'numbers/scales/amounts' Session 3: Parents being consistent in their approach to children Theme: Children learn with the all/or nothing rule Session 4: Reinforcing positive behaviors in children Theme: Children Learn Laterally Session 5: Parents being positive models Theme: Children Learn by Imitation Session 6: Guidance of parents on the principle of 'learning by doing and experiencing' Theme: Children Learn by Action Session 7: This is the last session. Session 8: Application of final tests and saying goodbye."
223568926|NCT00882596|DEVICE|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
224146476|NCT03336827|BEHAVIORAL|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
223448226|NCT01879202|DRUG|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
223741699|NCT00326456|DRUG|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
223741700|NCT00326456|DRUG|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
223741701|NCT06220669|DRUG|LY3541860|Administered IV
224146477|NCT05647629|PROCEDURE|Total hip arthroplasty|hip prosthesis surgery
223448227|NCT00251498|DRUG|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
223448228|NCT02782754|DRUG|Carboplatin|
223448229|NCT02782754|DRUG|Etoposide|
223448230|NCT02782754|DRUG|Cyclophosphamide|
223448231|NCT02782754|DRUG|Bleomycin|
223448232|NCT02782754|RADIATION|Reduced dose of radiotherapy|
223741702|NCT06220669|DRUG|Placebo|Administered IV
223741703|NCT05999994|DRUG|Ramucirumab|Administered IV
223741704|NCT05999994|DRUG|Cyclophosphamide|Administered orally
223741705|NCT05999994|DRUG|Vinorelbine|Administered IV
223741706|NCT05999994|DRUG|Gemcitabine|Administered IV
223741707|NCT05999994|DRUG|Docetaxel|Administered IV
224056455|NCT02963545|OTHER|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
223448233|NCT02394184|PROCEDURE|transcatheter aortic valve replacement|
224056456|NCT02963545|BIOLOGICAL|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
223568927|NCT04308460|PROCEDURE|arthrocentesis|lavage of the temporomandibular joint was done
223568928|NCT04308460|PROCEDURE|operative arthroscopy|operative intervention inside the temporomandibular joint was done using arthroscope
223568929|NCT00453700|PROCEDURE|Trypanosoma cruzi serology|
224056457|NCT02963545|PROCEDURE|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
224056458|NCT02524821|DEVICE|Gelesis100|3 capsules each containing 0.75 mg
224056459|NCT02524821|DRUG|Metformin|1 tablet of 850 mg
224056460|NCT04404998|OTHER|Lower Energy Density|Test meal with lower energy density
224056461|NCT04404998|OTHER|Higher Energy Density|Test meal with higher energy density
224056462|NCT04404998|OTHER|Lower Satiation|Information on lower satiation
224056463|NCT04404998|OTHER|Higher Satiation|Information on higher satiation
224056464|NCT01213420|OTHER|Nivea Cream for scar hydration|3 applications per day during 6 months
224056465|NCT01213420|OTHER|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
224146478|NCT01152489|DEVICE|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
223448234|NCT02344771|PROCEDURE|Elective colon cancer surgery|
223448235|NCT04281628|DRUG|Ketamine group:|Ketamine group: will be administered ketamine in a loading dose of 0.2 mg/kg over 5 min pre incision followed-by an infusion at 0.2 mg/kg/h until the end of surgery.
223448236|NCT04281628|DRUG|Control group|where normal saline was administered as a loading dose then infused with same rate of another group, throughout the whole surgery.
223568930|NCT02010333|DRUG|Ha44 Gel 0.74% w/w|HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
223741708|NCT05999994|DRUG|Abemaciclib|Administered orally
224056466|NCT01213420|OTHER|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
224056467|NCT01213420|OTHER|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
224056468|NCT01637220|BIOLOGICAL|Blood volume collected specifically for this study|"* case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~* Control patients: 20 ml following neuromuscular blocking drug injection"
224056469|NCT06984835|DEVICE|Ellanse S|Ellanse S polycaprolactone and carboxymethylcelluose gel based dermal filler syringe
224146479|NCT01152489|DEVICE|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
224146480|NCT02477722|OTHER|EFP-NF|
223448237|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
223448238|NCT01964716|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
224056470|NCT06984835|DEVICE|Calcium Hydroxylapatite-based filler|Calcium Hydroxylapatite and carboxymethylcellulose based filler
224146481|NCT02477722|OTHER|Sham|
224146482|NCT01205958|PROCEDURE|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
224146483|NCT05321940|BIOLOGICAL|STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|Autologous human ultraviolet (UV)-irradiated (dead) leukemia cells loaded with STAVs administered via intravenous injection. Each treatment will administer 5 ml via syringe.
223448239|NCT05327751|DRUG|Celecoxib 200mg|200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.
223448240|NCT05327751|DRUG|Capecitabine-based chemotherapy|Capecitabine-based chemotherapy
223448241|NCT05677958|DIETARY_SUPPLEMENT|125 mL Fortimel/Nutridrink Compact Protein|125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving).
223448242|NCT05527899|DRUG|Zinc gluconate|30 and 60 mg/d of zinc gluconate
223568931|NCT01926418|BEHAVIORAL|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
223568932|NCT03752190|DRUG|Cosyntropin|intramuscular and intravenous administration
223568933|NCT02359045|DRUG|D1400147|Treatment A
223568934|NCT02359045|DRUG|D14000136|Treatment B
223568935|NCT02359045|DRUG|D14000137|Treatment C
223568936|NCT02359045|DRUG|Epanova®|Treatment D
223741709|NCT05999994|DRUG|Irinotecan|Administered IV
223741710|NCT05999994|DRUG|Temozolomide|Administered orally
224056471|NCT03739476|DRUG|Quetiapine 25 milligrams capsule|Compare the incidence of postoperative delirium.
224056472|NCT03739476|DRUG|Placebo oral capsule|Compare the incidence of postoperative delirium.
224056473|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 1 dose of inactivated Japanese encephalitis vaccine.
224056474|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 28 days.
224056475|NCT06678373|BIOLOGICAL|Liaoning Chengda Inactivated Japanese Encephalitis Vaccine|The patient needs to receive 2 doses of inactivated Japanese encephalitis vaccine, with an interval of 7 days.
224056476|NCT06680934|DIAGNOSTIC_TEST|Molecular genetic testing and audiometry|Genetic testing and audiometry are the interventions of interest
224056477|NCT06875128|DRUG|Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)|Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
224056478|NCT06875128|DRUG|Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)|Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
224146484|NCT05321940|BIOLOGICAL|Dendritic Cell Vaccine|15-20 Million mature dendritic cells per dose administered via intravenous injection.
224146485|NCT03996434|DRUG|Gonadotropin|withholding gonadotropin administration for at least 24 hours
223448243|NCT02535754|BEHAVIORAL|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
223448244|NCT02535754|BEHAVIORAL|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
223448245|NCT02535754|BEHAVIORAL|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
223448246|NCT03386188|DEVICE|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
223448247|NCT03386188|DEVICE|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
223448248|NCT04235842|OTHER|Physical Exercise|Moderate-intensity continuous exercise training performed at cycle ergometer.
223448249|NCT04235842|OTHER|High-intensity interval training performed at cycle ergometer.|High-intensity interval training performed at cycle ergometer.
223448250|NCT01474161|DRUG|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
223448251|NCT01474161|DRUG|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
224056479|NCT03979846|OTHER|Best Practice|Receive usual care
224146486|NCT03996434|DRUG|Antagonist|Cetrorelix acetate 0.25 mg
224146487|NCT05781763|BEHAVIORAL|High intensity interval training (HIIT)|"2 HIIT sessions/week in self-selected activity and type of interval-session with in total 15 minutes interval time (85-90% of MHR) with active rest (50-70% of MHR) between intervals for 12 weeks~1 self-selected session at moderate or high-intensity/week for 12 weeks Standardized physical and digital coaching by a physiotherapist"
224146488|NCT05781763|OTHER|Control group|Continuing with exercise as usual during 12 months
223448252|NCT01474161|DRUG|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
223448253|NCT01474161|DRUG|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
223448254|NCT01474161|DRUG|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
224056480|NCT03979846|OTHER|Computer Application|Use computer-based symptom reporting system
224056481|NCT03979846|OTHER|Questionnaire Administration|Ancillary studies
224056482|NCT03979846|OTHER|Quality-of-Life Assessment|Ancillary studies
224056483|NCT04090580|DIAGNOSTIC_TEST|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks or 2000 mg metformin. Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
224146489|NCT06159348|DIAGNOSTIC_TEST|Anemia Diagnostic Assistant (ADA)|The Anemia Diagnostic Assistant is non-invasive and simultaneously detects two markers of anemia, blood hemoglobin and the End-Tidal carbon monoxide levels. The device comprises an optical sensor module and ETCO breath sampling module.
224146490|NCT06159348|DIAGNOSTIC_TEST|Serum hemoglobin|Venous blood will be drawn on the same day as the ADA was applied and sent to the hospital lab for hemoglobin analysis.
224146491|NCT00002017|DRUG|Interleukin-2, Polyethylene Glycolated|
224146492|NCT01213368|DRUG|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
224146493|NCT01213368|DRUG|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
224146494|NCT02034604|DRUG|Naftofidil|
224056484|NCT06694428|OTHER|Reinterpretation of CMV serology results using the MyCMV tool on the basis of the serology results performed|"The CMV serology results of the patients will have been previously interpreted as part of the care on the basis of the entire virological file according to the reference method.~These results will be reinterpreted using the MyCMV tool on the basis of the serology results performed (IgM, IgG, avidity), CMV PCR, the date of sampling and the date of the start of pregnancy (or last period). This reinterpretation by the tool will be carried out as part of the study and will not be communicated to the patient or to the doctor prescribing the virological analyses."
224056485|NCT07025044|DRUG|onabotulinum toxin type a|All subjects will be scheduled to undergo Onabotulinum toxin type A intradetrusor injection for management of OAB. On Day 0, subjects will undergo Onabotulinum toxin type A injection by a licensed clinical provider and receive a one-time dose of Nitrofurantoin for infection prevention per standard clinic protocol.
223448255|NCT01474161|DRUG|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
224056486|NCT00597753|DRUG|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
223448256|NCT03717649|DEVICE|Conventional 2-stage venous cannula|venous cannula
224056487|NCT00597753|DRUG|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
224146495|NCT02034604|DRUG|Tamsulosin|
224146496|NCT05638906|DEVICE|MINT|Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
223448257|NCT03717649|DEVICE|Conventional 3-stage venous cannula|venous cannula
223448258|NCT03717649|DEVICE|Fenestrated 3-stage venous cannula|venous cannula
223448259|NCT02853071|DRUG|Estramustine|
223568937|NCT02731677|OTHER|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
223568938|NCT02042586|OTHER|Analysis of movement before total hip replacement|
223568939|NCT02042586|OTHER|Analysis of movement after total hip replacement|
223568940|NCT05254132|PROCEDURE|Liquid biopsy|Participants in the aRECIST group will undergo a blood draw for liquid biopsy analysis at baseline and follow up visits
223568941|NCT03798730|BEHAVIORAL|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
223568942|NCT03798730|BEHAVIORAL|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
223568943|NCT01004731|DRUG|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
224146497|NCT04214730|COMBINATION_PRODUCT|NK combined with Chemotherapy|Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months
223448260|NCT02853071|DRUG|standard practice|standard practice
223568944|NCT05055388|OTHER|Multidrug-resistant bacteria|Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.
223568945|NCT04172415|OTHER|Retrospective cohort|Chart Review
223568946|NCT03904953|OTHER|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
224146498|NCT04214730|DRUG|Chemotherapy|Patients will only receive Chemotherapy.
224146499|NCT04376606|PROCEDURE|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
223448261|NCT02202889|BEHAVIORAL|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
223448262|NCT05541913|OTHER|Tele nursing|The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
223448263|NCT01234064|DEVICE|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
223448264|NCT01234064|DEVICE|No Graduated Compression Stockings|No stockings will be applied.
223448265|NCT00121290|DRUG|SJG-136|Given IV
224056488|NCT05133271|OTHER|Clinical hemodynamic and echocardiographic evaluation|"Clinical hemodynamic and echocardiographic evaluation in two stages T1 and T2, before performing the spinal anesthesia, carried out by a doctor different from the doctor in charge of the parturient in the operating room to ensure the blind hemodynamic results before the spinal anesthesia, in particular those of the passive leg raise test (PLR) :~1. T1: clinico-echographic evaluation in dorsal decubitus position (45 °) with cushion under the right buttock.~2. T2: clinico-ultrasound evaluation after performing the PLR.~   Then, clinical hemodynamic evaluation during two periods T3 and T4:~3. T3: conditioning time of the parturient in the operating room during which clinical hemodynamic monitoring is set up and the basic values of arterial pressures (systolic, diastolic and mean) and heart rate are defined.~4. T4: period after performing spinal anesthesia until clamping of the umbilical cord."
224056489|NCT07123272|BEHAVIORAL|Self-guided smartphone application for relaxing acupressure|"Relaxing Acupressure entails applying pressure with either a finger, pencil, or similar object to acupressure points. For the relaxing protocol, there is a total of 9 acupoints (1 unilateral and 4 bilateral). Each point will be stimulated for 3 minutes, yielding a total treatment time of 27 minutes each day. The acupoints are:~1. Yin Tang (Unilaterally): Located on the forehead, between the eyebrows.~2. Anmian (Right and Left/bilaterally): Located on the posterior aspect of the neck, in a slight depression along the bone directly behind the ear.~3. Heart 7 (HT7) (Right and Left/bilaterally): Located on the palmer surface of the hands on the wrist crease; in line with the pinky.~4. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle.~5. Liver 3 (LIV3) (Right and Left/bilaterally): This point is located on the foot, near the big and second toes."
224056490|NCT07123272|BEHAVIORAL|Self-guided smartphone application for relaxing acupressure|"There is a total of 10 acupoints (2 unilateral and 4 bilateral). Each point is stimulated for 3 minutes, yielding a total treatment time of 30 minutes each day. The acupoints are:~1. Du 20 (Unilaterally): Located at the top of the head.~2. Large Intestine 4 (LI4) (Right and Left/bilaterally): Located on the back of the hand, between your thumb and index finger.~3. Conception Vessel 6 (CV6) (Unilaterally): Located two finger widths below the navel on the centerline.~4. Stomach 36 (ST36) (Right and Left/bilaterally): Located on the lower leg below the knee on the outside of the leg.~5. Spleen 6 (SP6) (Right and Left/bilaterally): Located on the inside of the lower leg, approximately 4 fingers width above the bone of the ankle.~6. Kidney 3 (K3) (Right and Left/bilaterally): Located on the inside of the ankle."
224056491|NCT05482516|DRUG|Atezolizumab|Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
224056492|NCT05482516|DRUG|Bevacizumab|Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
224056493|NCT07045155|DRUG|The rHuEPO Monotherapy Group (Control Group)|The rHuEPO Monotherapy Group (Control Group) will be treated with rHuEPO for the first 16 weeks and then switch to Pegmolesatide treatment for the subsequent 8 weeks.
224056494|NCT07045155|DRUG|The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group)|The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group) will receive a combination of Pegmolesatide and roxadustat throughout the entire 24-week treatment period.
223448266|NCT00121290|OTHER|laboratory biomarker analysis|Correlative studies
223448267|NCT00121290|OTHER|pharmacological study|Correlative studies
223448268|NCT02468999|DRUG|human insulin|
223448269|NCT01464619|OTHER|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
223568947|NCT03904953|OTHER|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
223568948|NCT01798173|BIOLOGICAL|Serum, plasma and DNA samples|
223568949|NCT01798173|PROCEDURE|Radiological exploration by CT scan or MRI|
223568950|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
223568951|NCT01381276|OTHER|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
223568952|NCT01381276|OTHER|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
223568953|NCT03627559|PROCEDURE|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
223568954|NCT00996294|PROCEDURE|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
223448270|NCT01464619|OTHER|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
223448271|NCT02540161|DRUG|Sym004 - 18 mg/kg|Sym004 was dosed at 18 mg/kg intravenously every two weeks.
223448272|NCT02540161|DRUG|Sym004 - 24 mg/kg|Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
223448273|NCT00102856|DRUG|Pramipexole|
223448274|NCT00102856|DRUG|Rivastigmine|
223448275|NCT05061602|DIAGNOSTIC_TEST|Evaluation of biomechanics and viscoelastic properties of plantar fascia|The biomechanical and viscoelastic properties of the plantar fascia will be measured with the MyotonPRO device.
223448276|NCT02263378|DRUG|ellagic acid + annona muricata|pills
224056495|NCT07045155|DRUG|The Pegmolesatide Monotherapy Group (Experimental group)|The Pegmolesatide Monotherapy Group (Experimental Group) will receive Pegmolesatide treatment throughout the entire 24-week period.
223448277|NCT05772611|BIOLOGICAL|Genetic and immunology tests|"This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes."
223568955|NCT01168791|DRUG|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
223568956|NCT01168791|DRUG|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
223568957|NCT04728477|DEVICE|OPti BP measurements|measurement of blood pressure with the new smartphone App ( OPTIBP)
223568958|NCT04535713|DRUG|Gemcitabine|600 mg/m2 (Maximum Dose: 1000 mg) i.v. on Day 1 and Day 8 of Cycle 1+
223568959|NCT04535713|DRUG|Doxorubicin|18 mg/m2 (Maximum Dose: 32 mg) i.v. on Day 1 and Day 8 of Cycle 1+
223568960|NCT04535713|DRUG|Docetaxel|25 mg/m2 (Maximum Dose: 42 mg) i.v. on Day 1 and Day 8 of Cycle 1+
223568961|NCT04535713|DRUG|Nivolumab|240 mg i.v. on Day 1 beginnning Cycle 2+
223568962|NCT04617886|OTHER|Sadness induction|"Sadness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
223568963|NCT04617886|OTHER|Happiness induction|"Happiness state will be induced with a Virtual Reality program. Mood induction will be done with an emotional induction procedure in virtual reality (Mood induction parks (Baños et al., 2006)). This technique has proven to be effective in previous studies (e.g., van Strien et al. 2013). Virtual reality software simulates an urban park and includes several methods of sadness induction: Velten's tasks (1968) (sentence formulations with negative content about the self; for example, I am not valuable, I see no future); visualization of a image bank with emotional content from the international system of emotional images (IAPS, Lang et al.,1999); listening to a piece of music and viewing a film scene that demonstrated his effectiveness in inducing positive affect (Donen et al. 1952; Eich and Metcalfe 1989; Gross and Levenson 1995), and an autobiographical memory test."
223568964|NCT04782050|DEVICE|Ultrasound liver assessment|The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
223568965|NCT02511483|DRUG|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
223568966|NCT02511483|DRUG|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
223568967|NCT02511483|DRUG|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
224056496|NCT06926036|BEHAVIORAL|Wake training + TMR|"In this within-participant design, all participants will undergo the same intervention of waking training and TMR.~Waking training - waking training will associate an auditory cue with a specific learned behavioral response (a tongue protrusion and inhalation) during daily sessions for approximately one week, with home sleep monitoring.~TMR - Targeted memory reactivation (TMR) refers to the process of playing learning-associated audio cues quietly during sleep in order to reactivate memories associated with the cue. After completion of waking training, TMR occurs in a laboratory setting, with PSG recording, during a single night."
224146500|NCT04376606|PROCEDURE|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
224146501|NCT04376606|PROCEDURE|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
224146502|NCT00405821|DRUG|Acyclovir|400mg twice daily for 24 months
224146503|NCT00405821|DRUG|Placebo|Placebo tablet twice daily for 24 months
224146504|NCT04819802|OTHER|Measurement of sublingual microcirculation|Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.
224146505|NCT04819802|OTHER|Plasma sampling|Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.
224146506|NCT03277703|BIOLOGICAL|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
223568968|NCT02511483|PROCEDURE|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
224056497|NCT06889012|DRUG|BR1018|One tablet administered alone
224056498|NCT06889012|DRUG|BR1018A|One tablet administered alone
224056499|NCT06889012|DRUG|BR1018B|One tablet administered alone
224146507|NCT05687708|OTHER|Non-Nutritive Sucking|NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
224146508|NCT02320630|DRUG|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
223448278|NCT04085159|BIOLOGICAL|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
223568969|NCT02511483|OTHER|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
223568970|NCT02511483|GENETIC|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
224146509|NCT02320630|DRUG|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
224146510|NCT02320630|DRUG|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
224146511|NCT05530278|DRUG|Galicaftor|Oral
224146512|NCT05530278|DRUG|ABBV-576|Oral
224056500|NCT06734585|DRUG|Gilteritinib|tablet, oral
224056501|NCT06737562|PROCEDURE|Immediatly sequential bilateral cataract surgery|Immediatly sequential bilateral cataract surgery
224146513|NCT05530278|DRUG|Navocaftor|Oral
224146514|NCT05530278|DRUG|Midazolam|Oral
224146515|NCT05474807|BEHAVIORAL|Internet-delivered strengths use intervention|"The online strengths use intervention program, will be based on Miglianico et al.'s (2020) general framework, following the theorized five stages: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation.~As to increase participant engagement and motivation, gamification components will be embedded in several of these stages.~The entire intervention will be delivered online via an LMS software solution."
224146516|NCT02307656|DRUG|Atazanavir|
224146517|NCT02307656|DRUG|Cobicistat|
224146518|NCT02307656|DRUG|Active Pharmaceutical Ingredient|
223448279|NCT02504047|PROCEDURE|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 \& 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
224056502|NCT06737562|PROCEDURE|Delayed sequential bilateral cataract surgery|Delayed sequential bilateral cataract surgery : 3 weeks +/-1 week between the two procedures
224146519|NCT03721237|OTHER|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~1. volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~2. pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~3. PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
224146520|NCT06252766|BEHAVIORAL|Experiment (Clown)|Children included in the intervention group will be accompanied by a clown at the door from the moment they enter the intervention room and The child will be made to sit on the blood collection chair by playing games with them. Meanwhile, the nurse will take blood from the child. lasts for about 2-3 minutes. During this process, the clown is constantly playing games and foam will continue to distract you by blowing up balloons. The child's pain and anxiety score during the procedure the researcher will be evaluated by both the parent and the child. After the procedure is finished, the children will be will be taken out of the room and taken to the waiting area in the next room. Afterwards, the children will be asked how much pain and anxiety they felt during the blood collection procedure. After being allowed to rest for 1-2 minutes a questionnaire form will be applied to the children.
223448280|NCT05735275|DRUG|SHR-A2102|All participants receive SHR-A2102 alone.
224146521|NCT05485259|DIETARY_SUPPLEMENT|DL-alpha lipoic acid|Treatment group recieves 600 mg of DL-alpha lipoic acid daily, per os, for 3 months.
224146522|NCT05485259|OTHER|placebo (rice starch)|Placebo group recieves 600 mg (2x300 mg) of placebo (rice starch) daily, per os, for 3 months
224146523|NCT05948852|PROCEDURE|metabolic surgery (SADIS and OAGB)|TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
224146524|NCT06123910|DIETARY_SUPPLEMENT|Colostrum bovine|Colostrum bovine supplements, 25 kcal per portion, containing 0.25 g fats, 2.0 g CHO and 3 g protein. Lactose reduced.
224146525|NCT06123910|OTHER|Placebo|Dairy comercial product. 25 kcal per portion, 1.3 g fats, 1.95 CHO and 1.3 protein. Lactose based.
223448281|NCT01539928|OTHER|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
223448282|NCT05497817|BEHAVIORAL|Algorithm|Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
224056503|NCT06743022|DIAGNOSTIC_TEST|Chest CT|Repeated chest CT for automated ILD quantification
224056504|NCT06737484|OTHER|APPLYING TOPICAL OLIVE OIL|"1. Preparation phase: Before the application, hand hygiene will be provided, materials will be prepared, and the application will be carried out wearing gloves. The patient bed will be prepared, a stretcher cover and a bed protector will be laid. A screen will be used for patient privacy and only the areas to be applied will be opened in order. Itchy areas will be identified. Before starting the application, olive oil will be tested by applying it to a small area on the inside of the patient's arm in case of any allergic reaction.~2. Application of olive oil: 3 drops of olive oil will be dropped on the itchy areas (excluding the scalp and private areas) for every 25 cm square area and gently spread over the area for 30-60 seconds. Since there is a 5-7 minute absorption period from the skin, the area will be kept open and then a VAS score will be taken.~3. After the application: The procedure will be marked on the patient follow-up form."
223448283|NCT05497817|BEHAVIORAL|Random Match|Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
223448284|NCT00080483|DRUG|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
223448285|NCT00080483|DRUG|testosterone|AndroGel transdermally 5 g a day for two years
223448286|NCT05739305|OTHER|Risk factor|No diagnostic or therapeutic intervention; the characteristics of subgroups will be analyzed by the cause of death certificated in the registry.
223448287|NCT04544839|DEVICE|ADLC attachment system with PEEK inserts|"Each patient will receive 2 implants in the canine region using a guided-surgery protocol and a pre-prepared surgical stent. A healing abutment of an adequate size will be placed on the implant for transmucosal healing. The flaps will be subsequently sutured around the healing abutments. Patients' existing prostheses will be adjusted. Suture removal will be performed one week post implant placement.~Three months later, implant level impressions will be made using the open tray technique. Each patient will be then be randomized using eCRF (electronic Case Report Form) to either ADLC group or LOC group. A final cast of the patients will be obtained and the attachments will be installed using an in-direct technique by a calibrated prosthodontists."
223448288|NCT03801577|DIETARY_SUPPLEMENT|Hepaxa|High concentrate EPA and DHA
223448289|NCT05062720|RADIATION|Local consolidative therapy|Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
223448290|NCT00161694|DIETARY_SUPPLEMENT|sucrose solution|
223448291|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine|The active ingredient of the recombinant herpes zoster vaccine is varicella-zoster virus glycoprotein E fusion protein expressed in CHO cells by gene recombination technology. The LZ901 cell line carrying this gene is cultured in chemically defined medium. The harvest cell culture is purified by multi-step liquid chromatography. After Low pH incubation and virus removal filter package Nanofiltration inactivation/virus removal process, the bulk containing high-purity recombinant herpes zoster virus glycoprotein E is obtained. Finally, an alumina adjuvant is added to the formulated final product.
223448292|NCT06088745|BIOLOGICAL|Recombinant Herpes Zoster Vaccine Placebo|Alumina adjuvant
223448293|NCT02469012|DRUG|Combination #1|Sofosbuvir + Ribavirin
223448294|NCT02469012|DRUG|Combination #2|Sofosbuvir + Daclatasvir
223448295|NCT02469012|DRUG|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
223448296|NCT02469012|DRUG|Combination #4|Sofosbuvir + Ledipasvir
223448297|NCT02469012|DRUG|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
223448298|NCT05415514|OTHER|Instrumented assessment of muscle function|During the instrumented evaluations, we will evaluate the possibility of measuring the passive and active function of the muscle using: - an isokinetic dynamometer, an ultrasound and elastography device, an electrical stimulation of the calf nerve
223448299|NCT05840549|PROCEDURE|TURP|TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.
223448300|NCT05840549|PROCEDURE|UroLift|UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
223448301|NCT03474094|COMBINATION_PRODUCT|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 \& W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
224146526|NCT04218799|DRUG|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
224146527|NCT03807115|OTHER|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
223448302|NCT03474094|COMBINATION_PRODUCT|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 \& W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
224146528|NCT00890071|OTHER|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
224146529|NCT04830228|DEVICE|Ballon expandable stent and PTA|Endovascular treatment for the peripheral artery disease of the Iliac artery
224056505|NCT06474793|OTHER|Aromatherapy Intervention Group-1|For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.
223448303|NCT03474094|COMBINATION_PRODUCT|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 \& W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
223568971|NCT05436587|GENETIC|The whole-exome sequencing|Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.
223568972|NCT04699032|DRUG|Apraglutide|Single dose of apraglutide 5 mg.
223568973|NCT01271712|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
223568974|NCT01271712|DRUG|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
223568975|NCT01271712|DRUG|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
223568976|NCT06493097|BEHAVIORAL|Gut-directed hypnotherapy via audio files|5 audio files 10-15 min each, min 5 times a week for 12 weeks
223568977|NCT00145184|DIETARY_SUPPLEMENT|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
224056506|NCT06474793|OTHER|Aromatherapy Intervention Group-2|For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.
224056507|NCT06474793|OTHER|Aromatherapy Placebo Control Group|For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
223568978|NCT00145184|DRUG|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
223568979|NCT02327390|PROCEDURE|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
223568980|NCT02327390|BIOLOGICAL|X-ACT|Administered as an IV infusion
223568981|NCT00607269|BEHAVIORAL|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol \<0.05) urine sample."
223568982|NCT00096226|DRUG|Induction Carboplatin|
223568983|NCT00096226|DRUG|Induction Paclitaxel|
223568984|NCT00096226|PROCEDURE|Resection|
223568985|NCT00096226|DRUG|Consolidation Carboplatin|
223568986|NCT00096226|RADIATION|Radiation Therapy|
223568987|NCT00096226|DRUG|Consolidation Paclitaxel|
223568988|NCT05752942|BEHAVIORAL|Student Intervention Matching System (SIMS)|"The Student Intervention Matching System (SIMS) is a pre-intervention matching assessment following the behavioral consultation model. The SIMS entails three steps to sequentially assess and then match students' individual characteristics to precise acquisition- or performance-based interventions. The 1st step corresponds to the problem identification stage in behavioral consultation. The 2nd step corresponds to the problem analysis stage of behavioral consultation.The 3rd step of SIMS corresponds to the implementation planning and evaluation stages of behavioral consultation."
223568989|NCT05752942|BEHAVIORAL|group-based social skills training|In the control condition, students received an unconditionally mismatched acquisition-based intervention (group-based social skills training). We selected group-based social skills training for four reasons: (a) participating schools had already been delivering it as their treatment-as-usual, (b) it is a common intervention in US schools, (c) it is only effective for students with acquisition needs, and (d) it represents a counterfactual contrast to the treatment condition because externalizing behaviors driven by performance needs will be reduced more by performance-based interventions than acquisition-based ones.
223568990|NCT05872997|DIAGNOSTIC_TEST|Sensory Motor Training|Mobilization With Movement Along With Sensory Motor Training
223568991|NCT02451683|OTHER|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
223568992|NCT02451683|OTHER|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
223448304|NCT03202732|OTHER|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
223448305|NCT05808270|BEHAVIORAL|Nutrition care process|"According to the randomization and simple blinding, there will be 2 study groups in which group 1 will be operated on Nutrition care process and group 2 with Conventional nutritional intervention.~* The Nutrition Care Process is a standardized model intended to guide RDNs in providing high quality nutrition care. The NCP consists of four distinct, interrelated steps: Nutrition Assessment, Diagnosis, Intervention, and Monitoring/Evaluation (AND, 2023).~* In the case of Conventional nutritional intervention, we will base ourselves on the application of a habitual nutritional clinical history, where information will be obtained on the reasons for consultation and the specific needs of the patient to carry out an intervention based on their priorities."
223448306|NCT04527978|DEVICE|Verofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
223448307|NCT04527978|DEVICE|Nesofilcon A contact lenses|Spherical soft contact lenses for daily disposable wear
223448308|NCT01370616|DRUG|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
223448309|NCT01370616|DRUG|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
223448310|NCT01370616|DRUG|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
223448311|NCT01370616|DRUG|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
223448312|NCT00031044|DRUG|Enfuvirtide|
223448313|NCT00031044|DRUG|Amdoxovir|
223448314|NCT00386230|DRUG|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
223448315|NCT00386230|DRUG|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
223448316|NCT00386230|DRUG|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
223448317|NCT00386230|DRUG|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
223448318|NCT02324699|DRUG|Prednisone|
223448319|NCT02324699|DRUG|Placebo|
223448320|NCT02324699|DRUG|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
224056508|NCT06774846|DRUG|Acetylsalicylic acid/Aspirin (100 mg)|Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
223448321|NCT01614106|BEHAVIORAL|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
223448322|NCT02651493|DEVICE|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
223448323|NCT04538287|DEVICE|AtaCor StealthTrac Lead|Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.
223448324|NCT00462449|DEVICE|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
223568993|NCT02451683|OTHER|Training with some stimulation|motor task combined with real or sham stimulation
223568994|NCT00112411|DRUG|Bronchodilator|
223568995|NCT01063491|PROCEDURE|bypass graft angiography|
224056509|NCT06774846|DRUG|Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride|patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
224056510|NCT06240624|OTHER|No intervention|No intervention will be given.
224056513|NCT06449222|DRUG|BNT327 Dose Level 1 (DL1)|Intravenous (IV) infusion
224056514|NCT06449222|DRUG|BNT327 Dose Level 1 (DL2)|IV infusion
224056515|NCT06449222|DRUG|Nab-placlitaxel|IV infusion
224056516|NCT06449222|DRUG|Carboplatin|IV infusion
224056517|NCT06449222|DRUG|Gemcitabine|IV infusion
224056518|NCT06449222|DRUG|Paclitaxel|IV infusion
224056519|NCT06449222|DRUG|Eribulin|IV infusion
223448325|NCT04779710|OTHER|Staff Survey|A mixed mode survey design comprising of a self-administered electronic survey with a secondary option of a postal survey. The survey population was Speech and Language Therapy (SLT) Clinical Leads for Acute Stroke in Hyper/Acute Hospital Stroke Units in England and Wales. The sample frame was Routinely Admitting, and Non-Routinely Admitting Acute Stroke Hospital Teams registered on the Sentinel Stroke National Audit Programme (SSNAP) register. One hundred and sixty-six hospital teams were included after exclusions. Survey participants were asked to respond about assessment and management of dysphagia and other clinical processes during the first seven days of a person's admission to hospital following a stroke. Respondents were asked to respond about practice on behalf of the Stroke Unit rather than as an individual practitioner.
223448326|NCT04723407|OTHER|questionnaires|Questionnaire completion
223448327|NCT02415231|BEHAVIORAL|humor|
223448328|NCT00464295|DRUG|Capecitabine in HCC|
223448329|NCT03474146|OTHER|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
223568996|NCT01666119|DRUG|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
223568997|NCT03186508|BEHAVIORAL|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
223568998|NCT03186508|BEHAVIORAL|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
223741711|NCT00726804|DRUG|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
223741712|NCT06965751|DRUG|PDI204|PDI204 is a fully human, immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein
224056520|NCT06449222|DRUG|BNT327 Optimized Dose|IV infusion
223741713|NCT06965751|OTHER|0.9 % saline|0.9% saline used as placebo
224056521|NCT06449222|DRUG|BNT327 Equivalent Q3W Dose|IV infusion
224146530|NCT05984797|OTHER|Integrated Short-term Palliative Rehabilitation|"Participants will be offered up to 3 manualised sessions (face to face and/or remotely, via telephone or video-conference) delivered by an expert rehabilitation practitioner (physiotherapist, occupational therapist,).~Core components focus on (i) self-management of symptoms, (ii) physical activities and fitness, and (iii) social participation. Delivery of rehabilitation intervention components will include explicit use of behaviour change techniques including goal setting and action planning to focus on outcomes that are meaningful for the person, their family, and clinicians."
224146531|NCT02392494|DRUG|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
223568999|NCT04444492|DRUG|Ranibizumab Injection|initial three injections of Ranibizumab - afterwards pro re nata monthly
223569000|NCT04444492|DEVICE|Laser photocoagulation|Areas of capillary non-perfusion will be treated with photocoagulation upto 4 times
223569001|NCT04773782|DRUG|avapritinib|oral administration
223741714|NCT06971874|OTHER|No intervention|No intervention
223741715|NCT06967545|BEHAVIORAL|Smartphone-delivered Therapeutic Evaluative Conditioning for Suicide (TEC-S)|Therapeutic Evaluative Conditioning for Suicide (active TEC-S) is a behavioral treatment where participants are given optional access to a computerized task/game where they repeatedly pair suicidal behavior stimuli (pictures, words) with other negative stimuli and self-related stimuli with positive stimuli.
224056522|NCT04117620|OTHER|Pediatric Vestibular Symptom Questionnaire|Subjects respond to the translated questionnaire twice with 15 days interval
224056523|NCT06930781|DEVICE|Ponto implantation|Ponto implantation is a surgical procedure to implant a bone-anchored hearing device, improving hearing by transmitting sound directly to the inner ear through bone conduction.
224056524|NCT06903611|DRUG|CAM-101|fibrinogen depleted human platelet lysate
224056525|NCT06903611|OTHER|Vehicle Control|Plasmalyte-A
224056526|NCT06905925|OTHER|The group receiving counseling|Patients in the experimental group will receive pre-operative stoma care education from the researcher. This training is expected to last approximately 15 minutes. After the training, a brochure will be provided to the patients, which they can use if they need additional information. During the training process, patients will be informed that the researcher will contact them by phone during the 1st, 2nd, 3rd, and 4th weeks after discharge. During these calls, patients will be asked weekly (during weeks 1, 2, 3, and 4) about the color, odor, texture of the wound area, the function of the colostomy, and any complications. Additionally, at the end of the 2nd week, if there are no issues around the wound or sutures, patients will be called to the hospital for suture removal and dressing changes. In other weeks, dietary habits and the condition of the wound will also be inquired. During this four-week period, patients or their relatives will be informed that they can contact the researcher
224056527|NCT07089134|PROCEDURE|reabilitação fisioterapêutica tradicional|Active and passive exercises, and walking
224056528|NCT07089134|PROCEDURE|fisioterapia utilizando realidade virtual imersiva|Use of immersive virtual reality headset for rehabilitation sessions
224056529|NCT06461247|OTHER|Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals|Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy ketogenic breakfast. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
223448330|NCT03474146|OTHER|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
223448331|NCT03474146|OTHER|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
223448332|NCT01578499|DRUG|Brentuximab Vedotin|Brentuximab vedotin intravenous injection.
223448333|NCT01578499|DRUG|Methotrexate|Methotrexate tablets.
223448334|NCT01578499|DRUG|Bexarotene|Bexarotene tablets.
223448335|NCT05403528|BEHAVIORAL|Modality - 3D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
223448336|NCT05403528|BEHAVIORAL|Modality - 2D-3D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
223569002|NCT05082051|DRUG|Part A|"Randomized, double-blind, placebo-controlled dose escalation part to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after single oral dose administration in healthy adult subjects.~Single-dose administration of CDX-7108 at the following anticipated dose levels. 10 000, 50 000, 150 000, 250 000, and 500 000 lipase units will be evaluated in 5 sequential cohorts of 6 subjects each."
223569003|NCT05082051|DRUG|Part B|"Randomized, double-blind, placebo-controlled dose escalation parts to investigate the safety, tolerability, immunogenicity, and PK of CDX-7108 after multiple oral dose administration in healthy adult subjects.~It will evaluate multiple dose administration of CDX-7108 at an appropriate low (50 000 lipase units), mid (150 000 lipase units), and high dose (250 000 lipase units) 4 times a day (QID) for 6 consecutive days in 3 sequential cohorts of 6 subjects each."
223569004|NCT05082051|DRUG|Part C|"Randomized, double-blind, placebo-controlled, single-dose, 2-way crossover part to assess POC of CDX-7108 in terms of PD as well as its safety, tolerability, and immunogenicity in subjects with EPI.~Approximately 10 subjects with severe EPI from partial/total pancreatectomy or chronic pancreatitis will be enrolled. It is anticipated that Part C (POC study) will commence after completion of the third single-dose cohort from Part A (SAD study) and following SRC review of the data from this cohort."
223569005|NCT05487040|DRUG|PF-07321332 (nirmatrelvir)/ritonavir|Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
223569006|NCT05479097|DRUG|Anti-Hypertensive|Based on information entered by the CHWs into the CommCare application designed for this study, the application will provide recommendations (and underlying rationale for these recommendations) for prescription of antihypertensives (amlodipine and/or losartan OR enalapril) and medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated, lifestyle modification, and referral to the supervising physician if indicated for potential complications of hypertension.
224146532|NCT04736329|DRUG|Telmisartan|Telmisartan (20 up to 80mg) for RAAS inhibition, as part of heart failure therapy.
224146533|NCT05202223|BEHAVIORAL|Harmony at HOME (H@H)|H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
224146534|NCT05208723|BEHAVIORAL|Stress and emotion management|The handbook materials and lay helper scripts are based on principles of Acceptance and Commitment Therapy (ACT), and aims to enhance psychological flexibility. Psychological flexibility reflects how a person adapts to fluctuating situational demands, reconfigures mental resources, shifts perspective, and balances competing needs. ACT teaches alternative methods to accommodate difficult thoughts and feelings, primarily through mindfulness techniques. At the same time, ACT also focuses on guiding participants to live in ways consistent with their personal values.
224146535|NCT04152642|DEVICE|Marketed Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
223448337|NCT05403528|BEHAVIORAL|Modality - 2D-2D|Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D
223448338|NCT02670382|DIETARY_SUPPLEMENT|EPA|10 week supplementation
223448339|NCT02670382|DIETARY_SUPPLEMENT|DHA|10 week supplementation
223448340|NCT02670382|DIETARY_SUPPLEMENT|sunflower oil|4-week lead-in
223448341|NCT02972749|BEHAVIORAL|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
223448342|NCT02771600|DEVICE|Buzzy|See arm description
223448343|NCT02771600|DRUG|Topical anaesthetic cream|See arm description
223448344|NCT03112733|DIAGNOSTIC_TEST|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
224146536|NCT04152642|OTHER|Water control|negative control
224146537|NCT04152642|DEVICE|Experimental Dry Mouth Rinse|relieves dry mouth symptoms by physically coating oral mucosal surfaces.
224146538|NCT00852306|PROCEDURE|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
224146539|NCT00361894|DRUG|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
224146540|NCT00361894|DRUG|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
224146541|NCT06224972|DEVICE|Vlab|The study is observational, there is no intervention.
224146542|NCT00643357|DRUG|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
224146543|NCT00643357|DRUG|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
224146544|NCT03579992|BEHAVIORAL|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
224146545|NCT03579992|BEHAVIORAL|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
224146546|NCT03579992|BEHAVIORAL|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
223448345|NCT01354548|DEVICE|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
223448346|NCT02209025|DIETARY_SUPPLEMENT|Theobromine|Theobromine a compound for cocoa
223448347|NCT02209025|DIETARY_SUPPLEMENT|Placebo drink|
223448348|NCT01762449|OTHER|Followup survey|
223448349|NCT02563691|RADIATION|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
223448350|NCT06730165|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Stimulation of the vagus nerve through the tragus and concha in the ear
223448351|NCT06730165|DEVICE|Transcutaneous Auricular Trigeminal Nerve Stimulation|Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
223448352|NCT05459194|DEVICE|RP - TA|randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)
224056530|NCT06461247|OTHER|Standard Care Group|Participants will be provided with liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
224056531|NCT06764875|DRUG|Rilvegostomig|Q3W, intravenous infusion
223448353|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
223569007|NCT01377610|DRUG|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
223569008|NCT01377610|DRUG|Buprenorphine|Following detoxification with buprenorphine \[8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)\] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
224056532|NCT06764875|DRUG|Trastuzumab deruxtecan|Q3W, intravenous infusion
224056533|NCT06764875|DRUG|Trastuzumab|Q3W, intravenous infusion
223448354|NCT01485302|DRUG|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
224056534|NCT06764875|DRUG|Pembrolizumab|Q3W, intravenous infusion
224056535|NCT06764875|DRUG|5-fluorouracil|Q3W, intravenous infusion
224056536|NCT06764875|DRUG|Capecitabine|BID, oral administration
224056537|NCT06764875|DRUG|Cisplatin|Q3W, intravenous infusion
224056538|NCT06764875|DRUG|Oxaliplatin|Q3W, intravenous infusion
224056539|NCT06383845|DRUG|Lido-IV|Intravenous Lidocaine dose loading than a continuous infusion
224056540|NCT06383845|DRUG|ESP Block|ultrasound guided block with injection of Ropivacaine
224056541|NCT06681324|DRUG|AZD7798|AZD7798
223448355|NCT04707365|BIOLOGICAL|Tumor samples|for each patient: liver sampling, blood samples ( serum, plasma, PBMC, whole blood), per-endoscopic bile sampling, stool samples, and materials derived from fresh tumors
223448356|NCT00346736|PROCEDURE|Acupuncture (Procedure)|
223448357|NCT04926506|DRUG|Xiyanping injection|Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
223448358|NCT05912985|OTHER|different oxygenation methods|Different oxygenation methods are used in bronchoscopy procedures under sedation.
223448359|NCT04212832|DRUG|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
223448360|NCT04212832|OTHER|Standard pain|Standard pain follow up and monitorization
223569009|NCT01377610|DRUG|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
223569010|NCT02043912|DRUG|Haloperidol|
223569011|NCT02110680|DEVICE|Sports TENS 2|transcutaneous electric stimulation
223569012|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
223569013|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
223569014|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
223569015|NCT01630252|DRUG|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
223569016|NCT01630252|DRUG|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
224056542|NCT06681324|OTHER|Placebo|Placebo
224056543|NCT04207892|PROCEDURE|Conservative (non-surgical) treatment|Cast Sling Splint Collar
224056544|NCT04207892|PROCEDURE|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) K-Wire External fixation
224056545|NCT05556421|DIAGNOSTIC_TEST|uterocervical angle|uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.
224056546|NCT03354481|BEHAVIORAL|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
223448361|NCT05292612|BEHAVIORAL|iCBT(C&W) for SAD|iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
224056547|NCT03080883|DRUG|Apixaban|Given PO
223448362|NCT00006110|BIOLOGICAL|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
223448363|NCT00006110|DRUG|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
223448364|NCT00006110|DRUG|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
223448365|NCT00006110|DRUG|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
223448366|NCT00006110|PROCEDURE|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
223448367|NCT04350814|BEHAVIORAL|Self-Compassion Step by Step|This is a 6-lesson self-guided audio program by Dr. Kristen Neff (2013)
223448368|NCT04350814|BEHAVIORAL|Self-Reflection Active Control|Participants randomized to this active control condition will be asked to complete study measures at the same intervals as those assigned to the intervention condition. In addition to completing study questionnaires, participants in this arm will also be invited to reflect on their weekly reported symptoms, whether they experienced changed, what they believe these changes are attributed to, etc.
223569017|NCT03269968|DEVICE|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
224056548|NCT07099716|DEVICE|Wearing Hilo band, Ambulatory Blood Pressure Monitor, and Hydrostatic Pressure monitor|During study Visit 1, participants are equipped with tthree devices- the Device Under Test (Hilo band), the reference device (Ambulatory Blood Pressure Monitor), worn on the opposite arm, and a Hydrostatic pressure monitor on the chest. Subjects are instructed to wear the three devices for the next 24 hours to collect blood pressure (BP) and heart rate (HR) data as well as hydrostatic pressure measurements. After Visit 1, subjects return home with the devices in place. Visit 2 takes place at least 24.5 hours later, when participants return to the site to hand back the equipment.
223448369|NCT03469999|DRUG|Dysport Injectable Product|Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
223448370|NCT01724684|OTHER|Telehealth program|
224146547|NCT01214317|PROCEDURE|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
224146548|NCT02839941|DRUG|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
224146549|NCT02839941|DRUG|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
223448371|NCT01724684|OTHER|Usual care|
223448372|NCT02342600|DRUG|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
223448373|NCT02342600|DRUG|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
224146550|NCT02839941|DRUG|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
224146551|NCT02839941|DRUG|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
224146552|NCT00505895|DRUG|Melphalan|Arm 1 = 140 mg/m\^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m\^2 intravenous over 20 Minutes on Day -1.
223448374|NCT01863732|BIOLOGICAL|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
223569018|NCT03269968|DEVICE|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
223448375|NCT01863732|OTHER|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
223569019|NCT04570605|DEVICE|parasacral transcutaneous electrical nerve stimulation (PTENS)|electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
223569020|NCT04570605|OTHER|Standard Urotherapy|standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
223569021|NCT00142805|DRUG|Tricaprilin|Powder formulation will be mixed in a liquid (approximately 8 oz).
224056549|NCT03777722|DEVICE|Tailored Lighting Intervention|Lighting Intervention - active or placebo
224056550|NCT06888050|DRUG|henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ)|henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) (5mg/500mg, once a day, two tablets each time) plus lifestyle intervention
224056551|NCT06888050|DRUG|Metformin|Metformin (500mg, twice a day) plus lifestyle intervention
224146553|NCT00505895|DRUG|Fludarabine|30 mg/m\^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
224146554|NCT00505895|PROCEDURE|Stem Cell Infusion|Stem Cell Infusion on Day 0.
224146555|NCT00505895|DRUG|Rituximab|375 mg/m\^2 intravenous on Day -5, +2 +9 and +16.
224146556|NCT05351710|BEHAVIORAL|Exposure-Based Treatment for Perfectionism|Three tasks focused on exposures are completed. Each treatment session is approximately twenty minutes.
224146557|NCT05351710|BEHAVIORAL|Stress Management|Videos focused on education about healthy habits and relaxation. Each session is approximately twenty minutes.
224056552|NCT06760208|BIOLOGICAL|Pneumococcal 20-valent conjugate vaccine|For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be administered intramuscularly, preferably in the deltoid muscle, with care to avoid injection into or near nerves and blood vessels.
224056553|NCT06905119|OTHER|Digital Transformation of Continuity of Care for Peripherally Inserted Central Catheters|The application is offered to all patients at the time of PICC placement. If they accept, they go to the intervention group. If they do not accept, they go to the control group.
224056554|NCT07097779|BEHAVIORAL|Visual Aids(Photos, Videos, and Pictograms)|Participants will be presented with three types of visual instructional aids: photographs, videos, and pictograms, via a laptop or tablet. Each participant will perform three motor tasks, each paired with a different visual aid, assigned in random order using a Latin Square design. Each task takes approximately 3 minutes, followed by 1 minute of rest. After completing all tasks, participants will complete a 5-minute survey about their understanding, preference, and perceived cognitive load. The total session lasts about 20 minutes.
224056555|NCT04481165|OTHER|Survey|Oral interview and written questions
224056556|NCT05384392|OTHER|Recorded interview|A recorded clinical interview, transcribed verbatim and blinded analyzed
224146558|NCT04929756|BEHAVIORAL|Visual Feedback|Gaze-contingent visual feedback
224146559|NCT02665078|OTHER|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
224146560|NCT01553071|DRUG|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
224146561|NCT04595396|PROCEDURE|Laparoscopic Gastric Bypass|The LGBP was performed using a classic Roux-en-Y procedure. Briefly, a gastric pouch of 30-50 cc was constructed with an antecolic calibrated gastro-jejunal anastomosis (mechanical anastomosis using a 2.5 mm load). The biliary and alimentary limbs measured ≈70 cm and ≈150 cm, respectively, and the jejuno-jejunal anastomosis was also performed in a latero-lateral fashion (mechanical anastomosis using a 2.5 mm load). Mesenteric defects were closed with running non-absorbable sutures and the omentum was divided in every case
224146562|NCT07007780|DRUG|Sacituzumab Tirumotecan|Sacituzumab Tirumotecan monotherapy before surgery at a dose of 5mg/kg, with a dosing schedule of once every 2 weeks for a total of 12 weeks
224146563|NCT05092880|DEVICE|radioembolization|holmium-166 microspheres
224146564|NCT05092880|DRUG|Standard of care first-line systemic therapy|Capecitabine plus anti-VEGF antibody
224146565|NCT05466734|DRUG|Cilostazol Tablet 100 mg|Two oral doses (total daily dose of 200 mg)
224146566|NCT05466734|DRUG|PMR Tablet 135 mg|Single oral dose (total daily dose of 270 mg)
224146567|NCT03479216|DRUG|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
224146568|NCT03479216|DRUG|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
224146569|NCT00798577|DRUG|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
223569022|NCT00142805|OTHER|Placebo|Powder formulation will be mixed in a liquid (approximately 8 oz).
223569023|NCT03325868|DRUG|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
223569024|NCT04627324|DEVICE|The smart toothbrush and smart mirror (STM) system (XiuSolution, Gyeonggi-do, Korea)|"The STM system comprises a smart mirror, which is integrated into a computer monitor, and a 3D motion-capture device inside of a modified toothbrush holder. The computer program displays a toothbrushing animation in the mirror. Toothbrush motions detected by sensors embedded inside the holder are captured and sent to the server for analysis.~(used only during the test visits)~Participants had to brush their teeth at home (using toothbrushes with a flat-trimmed nylon bristle of identical type and length.) for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
224146570|NCT00798577|DRUG|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
224146571|NCT03919838|DIETARY_SUPPLEMENT|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
224146572|NCT03919838|DIETARY_SUPPLEMENT|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
224146573|NCT02586987|DRUG|Selumetinib|Selumetinib oral
224146574|NCT02586987|DRUG|MEDI4736|MEDI4736 IV
224146575|NCT02586987|DRUG|Tremelimumab|Tremelimumab, IV
224146576|NCT06396663|OTHER|Rapid Opioid de-escalation|"Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely"
224146577|NCT06396663|OTHER|Gradual Opioid de-escalation|Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.
224146578|NCT06396663|OTHER|Continuation of opioids|Continue on opioids and review in 1 weeks time.
224146579|NCT02746523|OTHER|Sensory Organization Test|Balance and proprioception test
224146580|NCT02746523|GENETIC|Biomarkers|Blood, urine, and saliva biomarkers
224146581|NCT02746523|OTHER|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
224146582|NCT02746523|OTHER|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
224146583|NCT02746523|OTHER|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
224056557|NCT05384392|OTHER|Clinical scales|Answering to clinical scales : PANSS (Positive and Negative Syndrome Scale); BPRS (Brief Psychiatric Rating Scale); CDSS (Calgary Depression Scale for Schizophrenia); MADRS (Montgomery-Åsberg Depression Rating Scale); Altman; YMRS (Young Mania Rating Scale); GAF (Global Assessment of Functioning); SF-36 (36-Item Short Form Survey); CGI-S (Clinical Global Impression Scale) et CGI-I (CGI-Improvement)
224056558|NCT05384392|BIOLOGICAL|Blood sample|Blood collection of inflammatory markers (IL-1, sIL-2R, IL-4, IL-6, IL-8 and TNF levels) and 2 EDTA tubes and 2 dry tubes for biological collection (plasma bank and serum bank). This blood sample will be taken during routine sampling.
224056559|NCT05251259|DRUG|Atuliflapon|Randomised participants will receive Atuliflapon
224056560|NCT05251259|DRUG|Placebo|Randomised participants will receive matching placebo to Atuliflapon.
224056561|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
223448376|NCT03567161|PROCEDURE|Cavitron ultrasonic surgical aspirator|"Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects ."
223448377|NCT04102683|BEHAVIORAL|Therapeutic recreation activity program|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
223448378|NCT06345014|DRUG|OM-89 [Uro-Vaxom® Capsule]|Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
223448379|NCT06345014|DRUG|OM-89 Placebo [Uro-Vaxom® Capsule Placebo]|Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
223448380|NCT02350088|DRUG|probiotics|probiotics
223448381|NCT02350088|DRUG|placebo|placebo
223448382|NCT03828682|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet \[Envarsus\]
223448383|NCT03828682|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
223448384|NCT03828682|DRUG|Mycophenolic Acid Oral Product|mycophenolic acid tablets
223448385|NCT03828682|DRUG|Tacrolimus|Twice daily tacrolimus
223448386|NCT03828682|DRUG|Methylprednisolone|Methylprednisolone taper
223448387|NCT03828682|DRUG|Prednisone|Prednisone taper
223448388|NCT03828682|DRUG|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
223448389|NCT06330571|DEVICE|Molar distalization by aligners with attachment|"1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner.~4. Aligners will be fabricated on 3d printed models.~5. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~6. Patient will receive the following aligner after 2 weeks.~7. Follow up visits every 4weeks until 6 months."
224146584|NCT01265420|BIOLOGICAL|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
224146585|NCT02667379|OTHER|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
224146586|NCT06884540|DRUG|Dexmedetomidine|"Intravenous bolus: between 0.2 and 0.5 mcg/kg.~followed by~Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."
224146587|NCT06884540|DRUG|lidocaine|"Intravenous bolus: between 0.5 and 1.5 mg/kg.~followed by~Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."
224146588|NCT06884540|OTHER|control group|Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain.
224146589|NCT03589820|OTHER|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
223448390|NCT00460746|DRUG|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
224056562|NCT02500407|DRUG|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
224056563|NCT02500407|DRUG|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
224056564|NCT07109349|DEVICE|Sparrow Link|Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. Participants will self-administer daily active tAN sessions on Days 1 - 28.
224056565|NCT04279847|DRUG|INCB057643|INCB057643 dose escalation and dose expansion.
224056566|NCT04279847|DRUG|Ruxolitinib|Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.
224056567|NCT06430905|BIOLOGICAL|HB-502 and HB-501 alternating 2-vector therapy Dose Level 1|Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.
224056568|NCT06430905|BIOLOGICAL|HB-502 and HB-501 alternating 2-vector therapy Dose Level 2|Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.
223448391|NCT03994237|OTHER|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
223448392|NCT00822328|DIETARY_SUPPLEMENT|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
223448393|NCT00822328|DIETARY_SUPPLEMENT|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
223448394|NCT03518411|OTHER|Cognitive Behavioral Therapy|One-Session Unified Protocol
223448395|NCT00789685|DRUG|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
224056569|NCT06430905|OTHER|Placebo|Administration of placebo to 5 participants.
224056570|NCT07102394|DRUG|Imlygic|intralesional administration of IMLYGIC administered on Days 1 and 21 of each cycle for 4 cycles (8 treatments).
224056571|NCT07106229|BIOLOGICAL|allogeneic human adipose-derived mesenchymal stem cells|The Investigational Product MAG200 is a preparation of 5 mL allogeneic human adipose-derived mesenchymal stem cells (MSCs).
224056572|NCT07106229|OTHER|Placebo|Placebo is commercially available injectable normal saline (0.9% Sodium Chloride in Water for Injection)
223448396|NCT03031041|PROCEDURE|Ultrasound-guided short-axis hydrodissection with 5cc normal saline|Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
223448397|NCT03031041|PROCEDURE|Ultrasound-guided long-axis hydrodissection with 3cc normal saline|Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
223448398|NCT03080480|DRUG|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
223448399|NCT04168840|DIAGNOSTIC_TEST|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
223448400|NCT06366438|BEHAVIORAL|ABC-teen|See above
223448401|NCT06366438|BEHAVIORAL|ParentWeb|See above
223448402|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (2-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W2): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W8): Four weeks after the third treatment, a follow-up assessment will be performed"
224056573|NCT07108166|OTHER|Cigarette|COPD patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
224056574|NCT07108166|OTHER|THS|COPD patients will switch from cigarette smoking to ad libitum THS use, with no flavor variant restrictions.
224146590|NCT00503178|PROCEDURE|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
224146591|NCT03805555|PROCEDURE|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
224146592|NCT03805555|PROCEDURE|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
224146593|NCT00907582|PROCEDURE|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
224146594|NCT02729077|DEVICE|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
224146595|NCT06016790|GENETIC|cfDNA sequencing|Multi-omics sequencing of cfDNA in peripheral venous blood.
224146596|NCT07057986|DEVICE|Trans cervical or abdominal ultrasound|ultrasound assessment before the scheduled upper endoscopy.
224146597|NCT05444348|BEHAVIORAL|Advance consultation concerning your life and treatment (ACT )|The ACT intervention consists of: an 8 h training day for clinicians including clinical materials such as a conversation aid and conversations guide. 6o minutes ACT-intervention sessions in daily clinic. the patients and caregivers will receive preparatory material prior for the ACT-intervention sessions, and a 30 min follow-up telephone call from the nurse within one week after the ACT-session. Clinicians will receive five sessions of followup supervision within the 24 months of intervention. The 60 min ACT-intervention session is an interdisciplinary conversation with nurse, physician, patient, and caregiver discussing issues of importance of patient and caregiver. The issues are based on the preparatory material focusing on information level and prognosis, patient's and caregiver's values, hopes, fears and worries regarding the future care with progressive disease.
224146598|NCT07071376|OTHER|cold dialysis|Patients who meet the inclusion criteria will receive 3 sessions of cold dialysis treatment by reducing the dialysate temperature from 36.5°C to 36°C. Patients will receive this treatment for 1 week, i.e. 3 dialysis sessions. Each dialysis session will last 4 hours. During each dialysis session, the thermal comfort status of the patients will be evaluated by applying the Temperature Comfort Perception Scale at the beginning of dialysis, at the 1st, 2nd and 3rd hours of dialysis and at the end of dialysis. In addition, the day after each session, the patients will be called by phone and the Postdialysis Fatigue Scale will be re-administered and their fatigue levels will be evaluated.
224146599|NCT07077317|OTHER|Airway Assessment Using Standard Clinical Tools|Preoperative airway evaluation using routine physical measurements (e.g., Mallampati score, neck circumference, STOP-Bang questionnaire), and intraoperative/postoperative observation of airway-related parameters.
224146600|NCT07078955|DRUG|BRM421 Ophthalmic Solution, 0.03%|A topical drop of 0.03% BRM421 ophthalmic solution.
224146601|NCT07078955|DRUG|Vehicle Ophthalmic Solution|A topical drop of vehicle (minus active) ophthalmic solution.
224146602|NCT07078955|DRUG|BRM421 Ophthalmic Solution, 0.06%|A topical drop of 0.06% BRM421 ophthalmic solution.
224146603|NCT03862131|DEVICE|MyoStrain®|MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
224146604|NCT07091721|BEHAVIORAL|Mentalization based therapy (MBT)|Mentalization based therapy for conduct disorder
224056575|NCT07112911|DEVICE|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20 sessions of robot-assisted upper limb training combined with central-to-peripheral electrical stimulation, delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of NMES and tsES-assisted robotic training. After a 10-minute break, the session will continue with an additional 20 minutes of robotic-assisted training combined with NMES alone, with tsES turned off during this phase. During the training, patients will perform repeated wrist and finger flexion-extension tasks. The training protocol is designed to activate wrist extension voluntarily (exceeding 10% of their initial MVC), which then triggers NMES and inflation of the robotic hand to assist finger opening.
224056576|NCT07112911|BEHAVIORAL|Occupational Therapy with Electrical Stimulation|The recruited subjects will receive 20 sessions of task-oriented occupational therapy(OT) combined with trans-spinal electrical stimulation(tsES), delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of OT training with tsES. After a 10-minute break, the session will continue with an additional 20 minutes of COT alone, with tsES turned off during this phase. During the OT training, the stroke participants will perform functional daily living tasks, including cylindrical grasp, disc grasp, and tip pinch.
224056577|NCT07112911|BEHAVIORAL|occupational therapy with sham electrical stimulation|The recruited subjects will receive 20 sessions of task-oriented occupational therapy(OT) combined with sham trans-spinal electrical stimulation(tsES), delivered at a frequency of 3 to 5 sessions per week, which will be completed within 4 to 7 consecutive weeks. Each rehabilitation session will begin with a 10-minute preparation phase, followed by 20 minutes of OT training with 0mA-intensity tsES. After a 10-minute break, the session will continue with an additional 20 minutes of COT alone, with tsES turned off during this phase. During the training, the stroke participants will repeatedly practice functional daily living tasks, including cylindrical grasp, disc grasp, and tip pinch.
224146605|NCT07091721|OTHER|Support as usual|Support usually provided by FCAMHS which may include advice/guidance to the professional network around the child/adolescent, psychoeducation, other mental health treatment e.g. CBT
224146606|NCT07090096|OTHER|A whole food plant based diet|A whole food plant based (WFPB) diet
224146607|NCT07091292|BEHAVIORAL|Indoor Cycling|Indoor cycling at 60-70% HR reserve for 30 minutes.
224146608|NCT07091292|BEHAVIORAL|Indoor Cycling|Indoor cycling at 20-30% HR reserve for 30 minutes.
224146609|NCT07092176|OTHER|Steady Strides|"Participants in the control arm will receive a one-time assessment by a trained research assistant at baseline and once more at 2 month follow up. Research assistant will measure and document the specified demographic and clinical variables to be compared between the control and intervention groups.~Participants in the intervention arm will receive a multifactorial intervention, including: Medical Intervention: Provided by physician(s) and/or nurse practitioners (NPs) or physician assistants (PAs) trained in the Steady Strides fall prevention protocol via the hybrid online and in person course on the Steady Strides fall prevention protocol . Rehabilitation Intervention: Provided by occupational therapists (OTs) and physical therapists (PTs) trained through a hybrid online and in person course on the Steady Strides fall prevention protocol"
223448403|NCT05811026|DEVICE|Periorbital rejuvenation with a 1927 nm diode laser treatment (4-week interval)|"* Visit 1 (W0): Clear + Brilliant™ Permea device periorbital treatment~* Visit 2 (W4): Clear + Brilliant™ Permea device periorbital treatment~* Visit 3 (W8): Clear + Brilliant™ Permea device periorbital treatment~* Visit 4 (W12): Four weeks after the third treatment, a follow-up assessment will be performed"
223448404|NCT06263517|DRUG|Clodronate|For Arm 1, patients will be treated with intra articular clodronate 2 mg/2 ml from Baseline to Week 3
223448405|NCT06263517|DRUG|Clodronate|For Arm 2, patients will be treated with intra articular clodronate 5 mg/2 ml from Baseline to Week 3
223448406|NCT06263517|DRUG|Clodronate|For Arm 3, patients will be treated with intra articular clodronate 10 mg/2 ml from Baseline to Week 3
223448407|NCT06263517|DRUG|Placebo|For Arm 4, patients will be treated with Placebo 2 ml from Baseline to Week 3
224146610|NCT07091994|DRUG|edaravone dexborneol injection|The experimental intervention involved twice-daily administration of edaravone dexborneol injection at a dose of 37.5 mg (containing 30 mg edaravone and 7.5 mg dexborneol), with doses spaced exactly 12 hours apart. For each infusion, the study medication was first diluted in 100 mL of normal saline (0.9% sodium chloride solution) and then administered as a controlled intravenous infusion over a precisely timed 30-minute period. This standardized dosing regimen was maintained consistently throughout the 10-14 day treatment course for all participants in the experimental group.
224146611|NCT07091994|DRUG|Standard therapeutic protocol|The standard treatment regimen, which may include antiplatelet therapy, anticoagulation (if indicated), blood pressure management, and other evidence-based interventions, will be administered continuously for 10 to 14 days according to current clinical guidelines.
224146612|NCT07091396|DEVICE|Soterix® tDCS - Home treatment|"Participants will receive transcranial direct current stimulation (tDCS) via the Soterix device at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and ramp-down of the current.~Each participant will be asked to perform tDCS on weekdays for two-weeks (10 sessions total) or every other weekday for four weeks (12 sessions). The research team will decide on a number of therapy sessions depending on the patient's baseline condition and tolerance. Patients who receive 10 sessions of therapy over two weeks will have 4 weeks of washout. Patients who receive 12 sessions over four weeks will have 8 weeks of washout."
224146613|NCT07091396|BEHAVIORAL|Cognitive-linguistic therapy|Participants will be instructed to perform home activity based cognitive-linguistic task-based exercises. Each participant will be asked to perform tDCS concurrently with individualized activity based cognitive-linguistic therapy on weekdays for two-weeks (10 sessions total) or every other weekday for four weeks (12 sessions)
224146614|NCT07091396|DEVICE|Soterix® tDCS - Lab treatment|Participants will receive transcranial direct current stimulation (tDCS) in person, via the same Soterix device the home based participants will use at an intensity of 2 mA for 20 minutes per session, with slow ramp-up and ramp-down of the current. They will undergo 12 sessions over four weeks.
223448408|NCT01195181|DRUG|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
223448409|NCT01438372|DRUG|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
223448410|NCT01438372|DRUG|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
223448411|NCT02423668|PROCEDURE|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
223448412|NCT02423668|PROCEDURE|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
223448413|NCT02423668|PROCEDURE|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
223448414|NCT04765670|OTHER|Instrument Assisted Soft Tissue Mobilization|Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
223448415|NCT04765670|OTHER|Kinesiotape Application|Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
223448416|NCT04938713|DRUG|Ketamine 50 MG/ML|Intravenous Ketalar® 0,30 mg/kg in 1 hour.
224056578|NCT04041232|DRUG|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutyrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
223569025|NCT04627324|DEVICE|Conventional toothbrush|"toothbrushes with a flat-trimmed nylon bristle of identical type and length.~Participants had to brush their teeth at home for 3 min thrice daily, after meals, as recommended by the Korean Dental Association."
223569026|NCT02242136|BEHAVIORAL|FORNET|
224056579|NCT06918834|OTHER|Immediate HSCT Group|Patients undergo direct allogeneic HSCT.
224056580|NCT06918834|OTHER|Bridging Therapy Group|"Patients receive one to two cycles of bridging therapy before undergoing allogeneic HSCT.~o Bridging Therapy Regimen: Hypomethylating agents (HMA) alone or HMA-based combination chemotherapy, e.g., azacitidine (AZA) 100 mg/day + venetoclax (VEN) 400 mg/day for 7 days. Targeted therapies (e.g., IDH1 inhibitors) will be used for eligible patients."
224056581|NCT03451851|DRUG|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
223448417|NCT04938713|DRUG|Esketamine 25 MG/ML|Intravenous Vesierra® 0,15mg/kg in 1 hour.
223448418|NCT00384371|DRUG|Botulinum Toxin A|Botulinum Toxin A
223448419|NCT00384371|DRUG|Placebo|Placebo
223448420|NCT00379171|BEHAVIORAL|Cow's milk with fish oil|
223448421|NCT00379171|BEHAVIORAL|Cow's milk without fish oil|
223448422|NCT00379171|BEHAVIORAL|Formula with fish oil|
223448423|NCT00379171|BEHAVIORAL|Formula without fish oil|
223448424|NCT00636961|DRUG|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
223448425|NCT00636961|DRUG|Placebo|Matching placebo devices and hard gelatin capsules
223448426|NCT03983785|OTHER|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
223448427|NCT03983785|OTHER|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
223448428|NCT01700738|PROCEDURE|gastric ring surgery|
223448429|NCT01700738|OTHER|nutritional help|
223569027|NCT00570011|DRUG|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
223569028|NCT00570011|DRUG|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
223569029|NCT04403152|OTHER|Post-operative rehabilitation|Patients received the exercises programme for five days, 30 minutes, two times per day with supervision by a physical therapist.
223569030|NCT04403152|OTHER|Post-operative mobilization|Patients received usual mobilization programme for 2-5 minutes, two times per day the five days with supervision by a physical therapist.
223569031|NCT01730664|DRUG|ertapenem|single dose of 2000mg ertapenem IV
223569032|NCT01098604|DEVICE|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
224056582|NCT03451851|DRUG|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
224056583|NCT03451851|DRUG|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
224056584|NCT05765474|BEHAVIORAL|Practice Variable|This group receives the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
224056585|NCT05765474|BEHAVIORAL|No Practice Variable|This group does not receive the practice variable. The practice variable being studied will not be disclosed until completion of testing procedures.
224056586|NCT05885737|DRUG|Difelikefalin Injection|Participants receive Difelikefalin three times a week (0.5 micrograms/kg dry body weight). Difelikefalin is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
224056587|NCT05885737|DRUG|Placebo Injection|Participants receive Placebo three times a week (0.5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
223448430|NCT05386732|DEVICE|Micro needling|All patients were treated with a 16 needle, 3mm, 33-gauge surgical grade stainless steel needle cartridge. The operator began treatment using a depth of (1mm) and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occured, the minimum and maximum depth used to create pinpoint bleeding was recorded. The operator began treatment using a minimum depth of 1mm and a frequency setting of 4 (corresponding to 120 Hz). Needle depth and frequency was adjusted until pin-point bleeding occurred.
223448431|NCT06614673|OTHER|text in non-narrative form|Participants will be asked to read a text and complete questionnaires
224056588|NCT05950360|DEVICE|Electromagnetic tracking system, surface electromyography|arm elevation in the scapular plane, overhead reaching to the target 15° backward to the frontal plane, pull-up with overhead reaching forward and backward.
223448432|NCT06614673|OTHER|text in narrative form|Participants will be asked to read a text and complete questionnaires
223448433|NCT06614673|OTHER|animated video in non-narrative form|Participants will be asked to watch a video and complete questionnaires
224146615|NCT07090967|OTHER|Project Planning Course|The Project Planning Course is conducted as a two-hour theoretical class per week. This course is being introduced for the first time in the nursing faculty curriculum. The course was conducted by two faculty members, both of whom have knowledge and experience in research and project writing. Since the goal at the end of the course was for students either to carry out a research project or to apply for a patent/utility model, it was planned for 20 students to enroll; however, 19 students chose the course. The course lasted 14 weeks in total. In the first week, topics such as what a project is, its characteristics, and its components were introduced to the students. As part of the course, students were asked to brainstorm solutions for problems they encountered in clinical settings. During the first seven weeks, theoretical lectures were delivered, and during the following five weeks, students worked with their academic advisors on research projects or patent/utility model topics.
223448434|NCT06614673|OTHER|animated video in narrative form|Participants will be asked to watch a video and complete questionnaires
223448435|NCT06993740|DRUG|NaCl 0,9%|NaCl 0.9% continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively.
223448436|NCT06993740|DRUG|Dexmedetomidine|Dexmedetomidine continuous intravenous infusion during microsurgical reconstruction surgery in cancer patients, started after anesthesia induction and maintained intraoperatively and up to 48 hours postoperatively, titrated to maintain target sedation and hemodynamic stability.
223448437|NCT00572975|OTHER|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
223448438|NCT06616246|BEHAVIORAL|HealthyLifetime|HealthyLifetimeTM \[HL\] seeks to intervene early in the aging process when individuals have the best chance for longer-term benefits of changing their health behavior, staving off functional decline, and minimizing the onset or exacerbation of chronic conditions.
223448439|NCT07007104|BEHAVIORAL|Mindful Eating Intervention|The mindful eating intervention consisted of six structured group sessions delivered over a six-week period, each lasting approximately 60-90 minutes. The sessions were led by a registered dietitian certified in both Mindful Eating (The Center of Mindful Eating, EatRight Certified, 2023) and Mindfulness-Based Eating Awareness Training (MB-EAT, 2019). The curriculum was designed to improve participants' awareness of hunger and satiety cues, reduce emotional eating, enhance eating satisfaction, and foster non-judgmental eating practices. Each session incorporated guided mindfulness practices, cognitive-behavioral techniques, and experiential activities such as sensory-focused eating. The intervention was provided in addition to standard post-treatment care, which included nutritional counseling by an oncology dietitian.
223448440|NCT07007104|BEHAVIORAL|Oncology Nutrition Counseling|Participants in this group received individualized nutrition counseling and education from a registered oncology dietitian as part of standard post-treatment care for breast cancer survivors. The counseling focused on balanced eating, long-term weight management, and general lifestyle guidance based on survivorship needs. No additional behavioral or mindful eating interventions were delivered.
223448441|NCT02572960|DRUG|Valsartan|2 weeks of Valsartan 80 mg per day
223448442|NCT02572960|DRUG|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
223448443|NCT02572960|DIETARY_SUPPLEMENT|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
223448444|NCT02572960|DIETARY_SUPPLEMENT|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
223448445|NCT06338215|BEHAVIORAL|Moderate Alcohol Drinking Pattern|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml).~2. always during meals~3. spread out throughout the whole week, and~4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake."
223569033|NCT01098604|DEVICE|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
224056589|NCT06928480|BEHAVIORAL|Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders|"This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7).~In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows:~* Module 1 (session 1): Setting goals and maintaining motivation.~* Module 2 (sessions 2 and 3): Understanding your emotions.~* Module 3 (sessions 4 and 5): Mindful Emotions Awareness.~* Module 4 (sessions 6 and 7): Flexible thinking.~* Module 5 (session 8): Emotional baheviors.~* Module 6 (session 9): Facing physical sensations.~* Module 7 (sessions 10 and 11): Emotionl exposures.~* Module 8 (Session 12): Relapse prevention."
224056590|NCT06928480|OTHER|Treatment as Usual (TAU)|"This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19.~After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition."
224056591|NCT06939920|OTHER|Non-invasive ventilation mask with airway washout|Non-invasive ventilation mask with airway washout for dual limb ventilators
224056592|NCT06939920|OTHER|non-invasive ventilation|standard state of the art non-invasive ventilation
224056593|NCT06936904|PROCEDURE|injection speed|Patients undergoing CT-guided lung nodule localization were selected for the study, and ultrasound-guided erector spinae plane block was performed before surgery with different injection speed.
224301118|NCT06179927|OTHER|QT voice|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the Experimental Group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes made via tablet. In the scenario, the depictions will be presented in color. They, guided by QT Robot's narrator voice, will have to choose from two or three alternatives the one that represents the appropriate mental state by selecting it on the tablet. Consequently, audio visual feedback will be provided, via the robot, to return information to the subject about the accuracy of the response.
223448446|NCT06338215|BEHAVIORAL|Abstention|"Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~Abstention. Message of 0 alcohol."
223448447|NCT05086341|DEVICE|My COPD|In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
223569034|NCT06289127|BEHAVIORAL|Lower Quarter Y Balance Test|The LQYBT is a widely used test for assessing lower extremity dynamic balance and neuromuscular control. Participants' lower limb balance was performed using The Y Balance Test Kit™ (Move2Perform, Evansville, IN).
223569035|NCT02342457|DEVICE|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
224056594|NCT02520921|DRUG|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
224056595|NCT02520921|DRUG|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
223569036|NCT05045742|OTHER|Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2|We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
224056596|NCT07145190|DRUG|SL-APO|"Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an ON response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better ON response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode."
224056597|NCT07143227|DRUG|XW003 injection|Subcutaneous injection
224056598|NCT07143227|DRUG|placebo with matching volume|Subcutaneous injection
224056599|NCT07144683|PROCEDURE|Patients Undergoing Colorectal Resection with Anastomosis|All eligible patients undergoing elective/emergency colorectal surgery with primary anastomosis (e.g., ileocolic, colocolic, colorectal, or coloanal)
224056600|NCT06946524|DRUG|Risankizumab|Subcutaneous Injection
224056607|NCT06947954|BEHAVIORAL|Nourish intervention then no intervention|Participants will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking. After 9 weeks, participants crossover into the No Intervention group.
224056608|NCT06947954|BEHAVIORAL|no intervention then Nourish intervention|Participants will receive no intervention for 9 weeks. After 9 weeks, they crossover into the Nourish Intervention group where they will attend a weekly in-person class with brief instructional video clips, hands-on cooking and tasting experiences. Participants will work individually and as part of small groups during instructional sessions. At the end of each class, participants will receive a grocery bundle and a kitchen gadget that serves both as an incentive and implementation support to promote improved cooking frequency and confidence. Participants will be asked to post photos of what they made with their groceries to an instant messaging software (GroupMe application) and be encouraged to engage with fellow classmates on GroupMe to encourage social support of cooking.
224146616|NCT07090837|OTHER|Caregiver Support Model|"1. CarePal: A one-stop resource library for caregivers of older adults~2. Nasogastric tube (NGT) webapp: An electronic training platform to learn NGT feeding and management~3. Carer OnBoard programme~4. Caregiver resources in NHG Health App (NHA): Relevant healthcare professionals or TTSH staff will introduce caregivers to the resources they may need in the NHA app.~5. Carer guide, a resource booklet providing information and community resources for caregivers.~6. Group Caregiver Training, for caregivers who are able to attend group caregiver training (instead of learning at the bedside);~7. NHG Care Telephonic team to provide telephonic support to caregivers post-discharge.~8. Nurses or other healthcare professionals providing relevant information on community programmes"
224146617|NCT07090837|OTHER|Standard caregiver support|Participants are provided standard bedside caregiver education as appropriate and information reinforcement through leaflets and booklets
223448448|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
223448449|NCT00718068|DRUG|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
223448450|NCT02929134|DRUG|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)
223448451|NCT02929134|DRUG|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
223448452|NCT05749497|OTHER|NCRT+TME|The eligible patients who voluntarily sign the consent form will undergo NCRT and TME according to treatment guidelines.
223448453|NCT07021560|DEVICE|ZEISS MyoCare spectacle lenses|Spectacle lenses with conventional power profile including myopia control design.
223448454|NCT07021560|DEVICE|ZEISS SV RX SPH 1.5|Commercially available single vision
223448455|NCT07021560|DEVICE|ZEISS Clearview|Commercially available single vision
223448456|NCT07025993|OTHER|Muscle Energy Technique|Eccentric muscle energy technique was applied to subjects' cervical spine. The cervical spine will brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then subjects will asked to push their heads into the direction opposite that of the barrier. The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch.
223569037|NCT04613765|BEHAVIORAL|Measure adherence behaviors|"Conducted in the ambulatory setting of two Brussels hospitals, the MADESIO mixed-method study design combine sequentially a first quantitative explorative questionnaire-based study with a second in depth qualitative approach.~The first 4 visits questionnaire-based survey prospectively measures adherence to OAMs and identify associated risk factors in the two sub-groups of ambulatory patients with various haematological malignancies. A combination of validated self-reported measures able to measure medication taking behaviours, assess both intentional and unintentional adherence, identify associated risk factors was selected.~The second qualitative phase, based on the McGill Illness narrative interview design, deeper address patients' therapeutic adherence and subjective meanings."
223569038|NCT01757223|BIOLOGICAL|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
224146618|NCT07090590|BEHAVIORAL|Thrive Digital Peer Platform (TDPP)|The Thrive Digital Peer Platform (TDPP) is a fully asynchronous, web-based training program designed to support the professional development of Peer Recovery Support Specialists (PRSS). The platform includes 11 interactive modules structured around the Connect, Grow, Apply (CGA) learning model. Content includes peer-led stories, behavioral simulations, scenario-based learning, and formative assessments. The intervention is intended to build competencies in professionalism, communication, and application of recovery-oriented peer support principles.
224146619|NCT07090538|DRUG|Eliglustat|Drug: GM-CSF + Eliglustat Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and GSL Synthetase Inhibitor
223448457|NCT07025993|OTHER|Eccentric muscle energy technique|Eccentric muscle energy technique was applied to subjects' cervical spine. The cervical spine will brought to the barrier of motion in each plane i.e. flexion/extension, lateral bending and rotation. Then subjects will asked to push their heads into the direction opposite that of the barrier. The therapist provided isometric resistance for 3- 5 seconds, after which the subjects relaxed their muscles completely and the therapist applied stretch. Three to five repetitions will performed.
223448458|NCT00581425|BIOLOGICAL|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
224146620|NCT07090421|DIETARY_SUPPLEMENT|Cellulose Powder|Participants consumed an inert cellulose powder dissolved in water, containing no active caffeine. The placebo was ingested orally 60 minutes prior to the rowing performance test. This condition served as the control and was administered once per session in a randomized, double-blind, crossover design.
223448459|NCT00652717|DRUG|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
223569039|NCT01757223|BIOLOGICAL|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
223448460|NCT00652717|DRUG|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
223448461|NCT00752869|DRUG|dutasteride|0.5mg by mouth one time per day for 1 year
223448462|NCT00752869|DRUG|placebo|one tablet per day for 1 year
223448463|NCT03588013|OTHER|Nutritional education|4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
223448464|NCT03588013|DIETARY_SUPPLEMENT|Ready to Use Therapeutic Food|If child remains WHZ \< -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
223448465|NCT03588013|PROCEDURE|Upper gastrointestinal endoscopy with biopsy|If child remains at WHZ \< -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
223448466|NCT04131491|PROCEDURE|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
223448467|NCT05887024|DEVICE|Radial Extracorporeal Shock wave Therapy|Shock wave therapy: (BECO) S/N 16B011375
223448468|NCT05887024|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|EME (Therapic 9400) TENS
223448469|NCT05887024|PROCEDURE|McKenzie Back exercises|Graduated Progressive back exercise program.
223448470|NCT05887024|DEVICE|electric heating pads|electrical conducting heat pack.
223448471|NCT05451953|PROCEDURE|Apneic Oxygenation|Nasal cannula at a rate of 6L/min with 100% FiO2 during laryngoscopy and intubation attempt(s)
223448472|NCT05451953|PROCEDURE|Standard of Care|No respiratory support during laryngoscopy and intubation attempt(s) (current standard of care)
223448473|NCT02223364|DRUG|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
223448474|NCT02223364|DRUG|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
223448475|NCT02223364|DRUG|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
223448476|NCT06026839|OTHER|Conventional nursing|Conventional nursing
223448477|NCT06618573|DRUG|Isoniazid/Pyridoxine|Treatment group received isoniazid 300mg and pyridoxine 10mg/day
223448478|NCT06618573|DRUG|Saccharum Lactis|Control group received placebo
223448479|NCT00701844|BEHAVIORAL|Writing A (Experimental informative writing)|Experimental informative writing
223448480|NCT00701844|BEHAVIORAL|Writing B (Experimental noninformative writing)|Experimental noninformative writing
223448481|NCT00701844|BEHAVIORAL|Writing C (Control informative writing)|Control informative writing
223741716|NCT06969547|DIAGNOSTIC_TEST|dynamic SPECT (two-day rest/stress protocol)|"All nuclear examinations will be performed using a hybrid specialized SPECT/CT Discovery NM/CT570C. At the first stage the passage of the bolus of the radiopharmaceutical through the chambers and the LV myocardium will be recorded at rest. Through a pre-installed intravenous catheter, a bolus of the radiopharmaceutical in a volume of 5 ml (370 MBq) will be injected at a rate of 0,5 ml/sec, after which 30 ml of saline will be injected at a rate of 2 ml/sec. Data acquisition will begin immediately before the introduction of the radiopharmaceutical. Registration of dynamic images will be performed in the List Mode.~At the second day stress test study will be performed (ATP at a dosage of 160 mcg/kg/min over 4 minutes). The bolus volume of the radiopharmaceutical, saline and the rate are equal to the study at rest. The time of data collection at each stage of the study will be 12 minutes. The introduction of the radiopharmaceutical will be performed at 2 minutes of the stress test."
223741717|NCT06969547|DIAGNOSTIC_TEST|gated myocardial perfusion imaging|"Gated MPI will be performed according to a two-day rest-stress protocol. For both stress and rest studies, the acquisition will be performed 60 minutes after the dynamic SPECT. The recording time will be 5 minutes. To correct the attenuation, a low-dose CT scan of the chest, obtained earlier with dynamic recording, will be used. The voltage on the X-ray tube will be 120 kV, the current strength will be 20 mA; tube rotation time 0.8 s; pitch 0.969:1. Radiopharmaceutical administration will be performed only once a day during dynamic SPECT.~Immediately after recording the gMPI at rest, the patient will undergo a series of sequential injections of dobutamine at doses of 5 and 10 µg/kg/min with simultaneous recording. The duration of data collection on each dose of dobutamine will be 5 minutes."
224146621|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 3 mg/kg Oral Powder|Participants consumed caffeine in powder form at a dose of 3 milligrams per kilogram of body weight. The powder was dissolved in water and ingested orally approximately 60 minutes before the start of the 2000-meter rowing ergometer performance test. The intervention was administered once per session in a randomized, double-blind, crossover design.
224146622|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 6 mg/kg Oral Powder|Participants ingested caffeine in powder form, dissolved in water, at a dose of 6 milligrams per kilogram of body mass. The solution was consumed orally 60 minutes prior to the 2000-meter rowing performance test. This intervention was administered once per session as part of a randomized, double-blind, crossover design.
223448482|NCT00701844|BEHAVIORAL|Writing D (Control noninformative writing)|Control noninformative writing
223448483|NCT00742027|DRUG|Panobinostat|Panobinostat hard gelatin capsules.
223448484|NCT00002575|PROCEDURE|conventional surgery|
223448485|NCT00002575|PROCEDURE|laparoscopic surgery|
223448486|NCT06271759|OTHER|Fragrance inhalation|Inhalation of fragranced essential oils
223448487|NCT05616091|DEVICE|painful stimulation by using a laser device (DEKA Stimul 1340, Calenzano, Italy)|In each of the two sessions, 80 experimental painful stimuli of different intensities (2.5 J, 3 J, 3.5 J, 4 J) will be applied using the laser device listed above.
223448488|NCT03863691|DRUG|Amisulpride 300 MG|A single dose of 300 mg amisulpride that looks identical to placebo control capsules.
223448489|NCT03863691|DRUG|Placebo oral capsule|A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
223448490|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management|The children will follow the five-step treatment principle of malnutrition. Diet + nutrition education is the basic way, which is successively promoted to diet + oral nutrition supplement, enteral nutrition, partial enteral nutrition + supplementary parenteral nutrition, and total parenteral nutrition. When a nutritional treatment does not meet 60% of the target energy requirements for 3 to 5 days, the upper step of the treatment can be selected. For infants or newborns, when 75-80% of the target amount cannot be reached for 3-5 days, the upper step of the treatment can be selected.
223448491|NCT06730204|DIETARY_SUPPLEMENT|Standardized nutritional management + short peptide ONS|"During the study period, an additional 3 months of short peptide ONS enteral nutrition intervention is expected to be performed in children enrolled from Dec 1, 2024 to Feb 28, 2025 to explore the improvement of the nutritional status of the children. Short peptide type ONS 30ml/(kg.d) will be taken orally for children under 3 years old, and 20ml/(kg.d) for children over 3 years old. Due to conditional restrictions, standardized nutritional management + short peptide ONS intervention is only carried out in this subgroup.~Inclusion criteria for short peptide ONS enteral nutrition intervention:~1. Male and female, age 1-10 years old~2. Pathological diagnosis is malignant solid tumor with untreated initial onset~3. It is expected to receive enteral nutrition intervention for 3 months~4. Clear consciousness, willing to cooperate, no serious dysfunction of major organ functions"
223448492|NCT01342172|DRUG|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
223448493|NCT03412006|DRUG|Fulacimstat (BAY1142524)|25 mg BAY1142524 are given twice daily over a treatment period of 6 months
223448494|NCT03412006|DRUG|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
223448495|NCT01039805|DRUG|GSK962040 (50 mg)|Cohort 1 = 50 mg
223448496|NCT01039805|DRUG|Placebo|matching placebo
223448497|NCT01039805|DRUG|GSK962040 (75 mg)|Cohort 2 = 75 mg
223448498|NCT03130140|PROCEDURE|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
223448499|NCT03130140|OTHER|Control|Conventional EUS-FNA
223448500|NCT00069563|BEHAVIORAL|Reaching Educators, Children, and Parents (RECAP)|
223448501|NCT06544746|RADIATION|Periapical radiographs|oral radiographs taken with the paralleling technique and film holders at 1- and 3-years post-prosthesis insertion with an X-ray apparatus equipped with a long cone and a Rinn Universal Collimator (Dentsply RINN, York, PA, USA). All radiographs were stored on a PC and analyzed with the software program DBSWIN software. Each radiograph was calibrated using the implant diameter and length as reference measures to correct any distortion before measurement. An image processing program was employed to quantify peri-implant MBL, the EA, EP.
223448502|NCT02872233|DRUG|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
223448503|NCT02872233|DRUG|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
223448504|NCT00002479|DRUG|tretinoin|
223448505|NCT05339919|DIAGNOSTIC_TEST|gait speed; ct scan;grip strength and chair stand test|The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.
223448506|NCT00800111|PROCEDURE|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
224056609|NCT06951919|BEHAVIORAL|Home Based Self- management and Cognitive Training Changes lives in Multiple Sclerosis (HOBSCOTCH-MS)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-MS is an adaptation of the HOBSCOTCH program specifically for people who have multiple sclerosis. It incorporates education about these conditions and cognition into the education module.
224056610|NCT06948500|OTHER|Immersive Virtual Reality|"Participants will wear an HTC Vive Pro head-mounted display with waist, hand and foot trackers during 60-min sessions, 2 times/week for 6 weeks (12 sessions). A gender- and skin-tone-matched first-person avatar will be calibrated to the user's anthropometrics and will mirror all real-time movements. Standardised audio instructions will be played through the headset; a virtual mirror will provide visual feedback.~To facilitate lumbar mobility, two sensorimotor illusions will be applied: (1) Flexion illusion: Avatar upper-limb length will be reduced by ≈20%, encouraging greater trunk flexion; (2) Extension illusion: A virtual bar will rise with lumbar extension but will under-represent real movement by ≈10%. Both manipulations will update continuously throughout each repetition. A physiotherapist will supervise every session and will record adverse events."
224146623|NCT07090421|DIETARY_SUPPLEMENT|Caffeine 9 mg/kg Oral Powder|A powdered caffeine dose of 9 milligrams per kilogram was dissolved in water and consumed orally by participants 60 minutes before a 2000-meter rowing ergometer trial. The intervention was administered once per session under a randomized, double-blind, crossover design.
224146624|NCT04622670|OTHER|Media Intervention|Receive DVD
224146625|NCT04622670|OTHER|Quality-of-Life Assessment|Ancillary studies
224146626|NCT04622670|OTHER|Questionnaire Administration|Ancillary studies
224146627|NCT04622670|OTHER|Survey Administration|Ancillary studies
224146628|NCT04622670|PROCEDURE|Yoga|Attend yoga class
223448507|NCT06695910|DIETARY_SUPPLEMENT|Monoglyceride Eicosapentaenoic acid (omega-3)|515 mg MAG-EPA + 33 mg MAG-DHA per capsule x 3 capsules daily: 1.5g/day (MAG-EPA). Subjects will be treated over a period of 56 days (or 112 days in phase 2) followed by a wash-out period of 28 days.
223448508|NCT06695910|OTHER|Sunflower Oil|698 mg sunflower oil per capsule x 3 capsules: 2.0g/d sunflower oil (Placebo) Subjects will be treated over a period of 112 days followed by a wash-out period of 28 days.
223448509|NCT01501032|DEVICE|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
223448510|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
223448511|NCT01504139|DRUG|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
223448512|NCT01504139|DRUG|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
223448513|NCT01504139|DRUG|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
223448514|NCT01971515|DRUG|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
223569040|NCT04732858|OTHER|Cross sectional e-Survey on surgeons exposed to any educational intervention|"Educational intervention was considered as any procedure or program to facilitate the acquisition of basic skills about the disease, its ramifications and treatment2,6,7:~* Education in infectious disease, including~  * pandemic training for health personnel~ * Personal protective equipment (PPE) and protection.~ * Specific speed-training focusing on environmental control (decontamination area, dressing...), personal protection, hand hygiene, sample management, risky gestures, control measures.~* Intensive care education:~  * mechanical ventilation~ * airways management~ * emergencies and cardiovascular drugs~ * Intensive care monitoring systems~* Basic nurse skills~* COVID-specific clinical management"
223569041|NCT00003406|DRUG|carboplatin|
223569042|NCT00003406|DRUG|docetaxel|
223569043|NCT00003406|DRUG|ifosfamide|
223569044|NCT00003406|PROCEDURE|autologous bone marrow transplantation|
223569045|NCT00003406|PROCEDURE|bone marrow ablation with stem cell support|
223569046|NCT00003406|PROCEDURE|peripheral blood stem cell transplantation|
223569047|NCT00589056|DRUG|cisplatin|
223569048|NCT00589056|DRUG|etoposide|
223569049|NCT00589056|DRUG|nelfinavir mesylate|
223569050|NCT00589056|GENETIC|protein expression analysis|
223569051|NCT00589056|OTHER|immunohistochemistry staining method|
223569052|NCT00589056|OTHER|laboratory biomarker analysis|
223569053|NCT00589056|PROCEDURE|biopsy|
223569054|NCT00589056|RADIATION|radiation therapy|
223569055|NCT03894969|BIOLOGICAL|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
223741718|NCT06969547|OTHER|blood sampling|"Indicators of:~* endothelial dysfunction (specific endothelial cell molecule 1 (endocan, ESM1), endotelin-1)~* severity of inflammatory response (tumor necrosis factor (TNF-α), interleukin-6 (IL-6))~* myocardial fibrosis (matrix metalloproteinase (MMP-9)~* myocardial dysfunction (NT-proBNP)"
223741719|NCT06969547|DIAGNOSTIC_TEST|Low Dose CT-scan|Scanning parameters: tube voltage 120 kV; current 435 mA; tube rotation time 0.4 s; slice thickness 2.5 mm; interslice interval 2.5 mm.
223741720|NCT06969547|DIAGNOSTIC_TEST|CT-coronary angiography|The study will be performed on a 64-slice GE Discovery NM/CT 570С (GE Healthcare, Milwaukee, WI, USA) from the level of the tracheal bifurcation to the diaphragm during breath holding (6-8 s) in the prospective (for HR≤55) or retrospective (for HR\>55) ECG-synchronized mode. To contrast coronary arteries, it is planned to use an intravenous infusion of 85-90 ml (at a rate of 5 ml/s) of an iodine-containing (370 mg iodine/ml) radiopaque substance.Scan will be performed with the following parameters: current strength 120 kV; voltage 300-600 mA with ECG modulation; tube rotation speed 0.4 s; pitch: 0.18-0.22 (depending on heart rate).
223741721|NCT03337074|OTHER|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
223741722|NCT03337074|OTHER|Questionnaire|Participants are asked to complete a questionnaire.
223741723|NCT03337074|OTHER|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
223448515|NCT01971515|DRUG|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
223448516|NCT01971515|DRUG|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
223448517|NCT05163730|DEVICE|COVID-19/ Flu A&B Rapid Panel|Rapid Diagnostic Device
223448518|NCT02584374|OTHER|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
223448519|NCT05627648|DRUG|KP-100LI|Intracordal injection, 20 mcg once per week, 3 weeks
223448520|NCT05627648|DRUG|Placebo|Intracordal injection, once per week, 3 weeks
223448521|NCT03250338|DRUG|Crenolanib|Crenolanib will be administered orally
223448522|NCT03250338|DRUG|Cytarabine|"HAM regimen~FLAG-Ida"
223448523|NCT03250338|DRUG|Mitoxantrone|HAM regimen
223448524|NCT03250338|DRUG|Placebo Oral Tablet|Placebo will be administered orally
223448525|NCT03250338|DRUG|Fludarabine|FLAG-Ida regimen
223448526|NCT03250338|DRUG|Idarubicin|FLAG-Ida regimen
223448527|NCT03250338|DRUG|G-CSF|FLAG-Ida regimen
223448528|NCT01559610|OTHER|Intervention Group|The patients were instructed by a nurse
223448529|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
223448530|NCT02721914|PROCEDURE|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.~In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.~Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
223569056|NCT03894969|BIOLOGICAL|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh\_NTHi-Mcat\_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
223569057|NCT06287593|OTHER|ctDNA monitoring|Patients will receive ctDNA monitoring before and after 3 weeks of neoadjuvant 3rd TKI treatment and optimize the neoadjuvant treatment plan based on this.
223569058|NCT00468676|BEHAVIORAL|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
223569059|NCT00468676|BEHAVIORAL|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
223569060|NCT02198482|DRUG|Volasertib|
223569061|NCT02198482|DRUG|Cytarabine|
223569062|NCT02198482|DRUG|Daunorubicin|
223569063|NCT02198482|DRUG|Mitoxantrone|
223569064|NCT03732326|PROCEDURE|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
223569065|NCT01048307|DEVICE|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~* cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~* placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~* fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
223569066|NCT01893372|DRUG|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
223569067|NCT01893372|DRUG|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
223569068|NCT04566393|DRUG|Ulixertinib (BVD-523)|Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor
223569069|NCT03666897|OTHER|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
223448531|NCT02721914|PROCEDURE|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 30 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.~The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
223448532|NCT05418959|DIAGNOSTIC_TEST|DermTech PLA noninvasive adhesive biopsy|The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
223448533|NCT00458861|BIOLOGICAL|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
223448534|NCT00458861|OTHER|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
223448535|NCT00171158|DRUG|imatinib mesylate|
224146629|NCT02596828|DRUG|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
223448536|NCT01305772|DRUG|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.
223448537|NCT01305772|PROCEDURE|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
223448538|NCT01305772|PROCEDURE|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
223448539|NCT06019026|DEVICE|Tri-Lock|Implant Stem
223448540|NCT06019026|DEVICE|Summit|Implant Stem
223741724|NCT05058443|DRUG|Denosumab 60 mg/ml [Prolia]|denosumab subcutaneously every 6 months (Q6M)
223741725|NCT05058443|DRUG|Placebo|placebo subcutaneously every 6 months (Q6M)
223741726|NCT03064360|OTHER|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
223569073|NCT04261972|GENETIC|Next generation sequencing (NGS)|NGS
223569074|NCT00700544|DRUG|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight \< 60 kgs 20 mg in patients with a weight \> 60 kgs frequency: every day Duration: 2 years"
224146630|NCT02596828|DRUG|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
223448541|NCT03075332|OTHER|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
223448542|NCT02844270|DEVICE|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
223448543|NCT00823602|DRUG|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
223448544|NCT00823602|DRUG|suprefact|GnRH agonist, standard protocol
223448545|NCT04710680|OTHER|no intervention|no intervention
223448546|NCT04230343|BEHAVIORAL|Self-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
223569075|NCT00700544|DRUG|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
223569076|NCT03554941|DEVICE|noise stimulation|noise stimulation
223569077|NCT00099944|DRUG|vildagliptin|
223569078|NCT00099944|DRUG|Glimepiride|Glimepiride 4 mg qd
223569079|NCT00099944|DRUG|LAF237 placebo|
223569080|NCT03526809|DIAGNOSTIC_TEST|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
223741727|NCT03064360|DEVICE|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
223741728|NCT03064360|BEHAVIORAL|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
223741729|NCT04430114|DEVICE|branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms|"Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts."
223741730|NCT06385223|DEVICE|Beam F3 targeted accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
223741731|NCT06385223|DEVICE|Individualized connectome-guided accelerated iTBS|Magpro X100, Axilium Cobot, Localite camera
223741732|NCT03864250|DRUG|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
223448547|NCT04230343|BEHAVIORAL|Other-benefit message|A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
223448548|NCT03536663|DEVICE|Optiflux and Dialyzer with Endexo|Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
223448549|NCT01542086|PROCEDURE|Myocardial SPECT|
224146631|NCT02596828|DRUG|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
223448550|NCT01542086|PROCEDURE|64-channel coronary CT angiography (CCTA)|
223448551|NCT03312465|DEVICE|AS Domelock System|Hemi or Total Shoulder Arthroplasty
223448552|NCT04945174|BEHAVIORAL|Cardiorespiratory exercise combined with patient education and individual follow-up sessions|6 weeks of cardiorespiratory exercise combined with patient education at the hospital, followed by 6 weeks of cardiorespiratory exercise in the local municipality. Subsequently individual follow-up sessions with the aim to facilitate the patients to stay physically active in their everyday life
223448553|NCT03361735|DRUG|Leuprolide Acetate|Intramuscular or subcutaneous injection
223448554|NCT03361735|DRUG|Goserelin Acetate|Subcutaneous injection
223448555|NCT03361735|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
223448556|NCT03361735|RADIATION|Radium Ra 223 Dichloride|Given IV
223448557|NCT03361735|OTHER|Laboratory Biomarker Analysis|Correlative studies
223448558|NCT03361735|DRUG|Degarelix|Subcutaneous injection
224056611|NCT06948500|OTHER|Physical Activity|Participants will undertake a 6-week therapeutic exercise program, consisting of two sessions per week (12 sessions total), with a primary objective of reducing fibromyalgia's impact on daily life. Each session will involve ten exercises performed in one or two sets each, depending on the week of the protocol. Exercise repetitions and intensity will be individualized using the Borg Rating of Perceived Exertion (RPE) scale (6-20), maintaining an intensity range of RPE 13-17. Specifically, intensity will start at RPE 14 (moderate) in Weeks 1-2, increase to RPE 15 (moderate-high) in Weeks 3-4, and peak at RPE 16 (high) in Weeks 5-6. No external load will be applied during the first three weeks to allow participants to adapt to the program, while progressive resistance will be introduced during the final three weeks according to individual capacity, ensuring a safe and gradual overload.
223448559|NCT06955247|OTHER|sensory motor integration|Study group (1) sensory motor integration for 45 minutes/time ,3 days per week for 3 months Treatment program included two parts; tactile sensation and proprioception stimulation programs. Each of them accounted half of the session and in terms of the type of activity it was divided into three categories: active, passive
223448560|NCT06955247|OTHER|bobath technique|"\*study group ( 2) bobath techniquefor 45 minutes/time 3 days per week for 3 months in the form of:~1. Preparation phase~2. Intervention program (Movement facilitation \&Functional training)"
223448561|NCT06956105|DEVICE|Modius Calm|The Modius Calm device is a transdermal neurostimulation product. It consists of a battery-powered headset designed to deliver low-level energy in the form of a neurostimulation waveform that modulates the activity of the vestibular cranial nerve. The active Modius Calm device utilizes a technology called electrical vestibular nerve stimulation (VeNS). In the envisaged configuration the device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current (a maximum of 1.5mA) to the skin behind the ears over the mastoid processes.
223448562|NCT06956105|DEVICE|Sham device|The sham device is identical in appearance. The Modius Calm sham device follows this pattern by applying some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device.
223569081|NCT04920630|BEHAVIORAL|Cognitive Behavioral Therapy - Insomnia (CBT-I)|CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
223569082|NCT02144506|OTHER|T&E|
223569083|NCT02144506|OTHER|OTAGO|
223569084|NCT01360749|DRUG|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
223569085|NCT01360749|DRUG|Placebo|Placebo dose: 2 g for 10 cm2.
223569086|NCT01424748|DIETARY_SUPPLEMENT|Tahitian Noni Juice|noni fruit juice
223569087|NCT01424748|DIETARY_SUPPLEMENT|Placebo|Placebo juice
223569088|NCT06554054|DRUG|GZR18|Oral administered the GZR18 tablet
223569089|NCT03926533|OTHER|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
223569090|NCT00726037|DRUG|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
223569091|NCT02825706|OTHER|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
223569092|NCT06244407|DRUG|Vildagliptin and Metformin Hydrochloride 50mg 1000 mg Film-coated Tablets|Vildagliptin and Metformin Hydrochloride 50/1000 mg Film-coated Tablets
223448563|NCT04433923|DEVICE|Phototherapy with aluminum foil|
223448564|NCT04433923|DEVICE|Phototherapy without aluminum foil|
223448565|NCT00762034|DRUG|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
223448566|NCT00762034|DRUG|Pemetrexed|Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
223448567|NCT00762034|DRUG|Paclitaxel|Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
223448568|NCT00762034|DRUG|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
223448569|NCT00762034|BIOLOGICAL|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
223448570|NCT00762034|BIOLOGICAL|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
223448571|NCT02671552|DRUG|Perflutren Protein-Type A Microspheres|Given IV
223448572|NCT02671552|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
223448573|NCT03685500|DRUG|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
223448574|NCT03685500|DRUG|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
223448575|NCT02442206|DRUG|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
223448576|NCT02442206|DRUG|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
223448577|NCT01883739|OTHER|Parental Presence at Handover Rounds|
223448578|NCT00497146|DRUG|paricalcitol|2 µg capsule
223448579|NCT00497146|DRUG|placebo|placebo capsule
223448580|NCT03016468|DRUG|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
223448581|NCT03016468|DRUG|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
223448582|NCT01471444|DRUG|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
223448583|NCT01471444|DRUG|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
223448584|NCT01471444|DRUG|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
223569093|NCT00118846|DIETARY_SUPPLEMENT|25 gm soy protein supplement|25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
223569094|NCT00118846|OTHER|Placebo|Milk protein administered twice daily
223569095|NCT02392390|PROCEDURE|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
223741733|NCT03864250|DRUG|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
223741734|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
223741735|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
223448585|NCT01471444|DRUG|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
223448586|NCT01471444|PROCEDURE|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
223448587|NCT01471444|DRUG|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
223448588|NCT01471444|DRUG|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
223448589|NCT01225926|DEVICE|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
223448590|NCT01225926|DEVICE|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
223569096|NCT02392390|DRUG|Metvixia cream|
223569097|NCT04338139|PROCEDURE|bone regeneration|bone regeneration using bio-oss collagen
223569098|NCT02471118|DRUG|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
223569099|NCT02471118|DRUG|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
223569100|NCT02668900|BEHAVIORAL|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
223569101|NCT06225375|DEVICE|Restorelle® Flat Mesh|Pelvic organ prolapse repair using Restorelle® Flat Mesh
223569102|NCT00443053|DRUG|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
223448591|NCT06485570|OTHER|creative drama training|"The trainings prepared by the researcher in line with the literature information on Environmental Theory, Self-Care Disability Theory and Adaptation Model will be carried out in 3 sessions with creative drama teaching method to the experimental group. The trainings will be planned in the classroom environment for 4 weeks and 2 lesson hours (100 minutes) for each session. At the end of the trainings, Knowledge Measurement Questionnaire and Perception of Nursing Profession Scale will be applied to the participants as a post-test to measure their level of knowledge about nursing theories. In the third stage of the study, semi-structured interviews will be conducted with the students from the experimental group after the applications in order to reveal the participants' views on teaching methods."
223448592|NCT06485570|OTHER|control|control group
224056612|NCT06955806|DEVICE|The Rexon-Eye, an electrotherapy device utilizing Quantum Molecular Resonance (QMR) technology|The device has received EC certification as a medical device for the treatment of ocular surface disorders. It will deliver a low-intensity alternating electrical current (ranging from 4 MHz to 64 MHz) to targeted biological tissue via contact electrodes. Previous studies have shown the effectiveness of this treatment in alleviating dry eye symptoms, both subjectively and objectively.
223448593|NCT06154720|DRUG|Antibiotics|After the woman had a repaired episiotomy following uncomplicated vaginal birth at 37 weeks or greater with no indication for ongoing antibiotics in the postpartum period. The patients were randomized to receive a co-amoxiclav 625mg (study group) tabs twice daily for 3 days after delivery or no antibiotic arm (control group).
223448594|NCT01956188|DIETARY_SUPPLEMENT|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
223448595|NCT01956188|DIETARY_SUPPLEMENT|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
223448596|NCT02594059|OTHER|endothelial function|measure of reactive hyperemia-peripheral artery tone index
223448597|NCT06062095|PROCEDURE|AI-powered computer-aided diagnosis (CADx)|Real time AI will be used to diagnosis polyps found during colonoscopy.
223448598|NCT03351634|DEVICE|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
223448599|NCT06480019|BEHAVIORAL|Interpersonal psychotherapy|Interpersonal psychotherapy is a first-line treatment and can also be used for the prevention of depression.
223448600|NCT04140812|DIAGNOSTIC_TEST|mass spectrometry (LC-MS/MS)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (\<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
223448601|NCT05977855|OTHER|BPSDiary|The BPSDiary is a diary to register severity, hour, day and triggers of a number of BPSD (namely, agitation, aggression, delusions/hallucinations, insomnia, aberrant motor behavior).
223448602|NCT01619072|OTHER|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
223448603|NCT01619072|OTHER|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
223448604|NCT04198909|DIAGNOSTIC_TEST|Electrocochleography, electrophysiology thet for analyse the wave I generated by the auditory pathways|Electrocochleography is a technique that analyses the functionality of inner ear.
223448605|NCT06291129|PROCEDURE|Periodontal therapy|Supragingival scaling sessions were performed with ultrasonic scalers (Dabi Atlante, Rio de Janeiro, RJ, Brazil) to remove all calculus and biofilms, in addition to oral hygiene guidelines, including brushing technique and interdental cleaning with dental floss.
223448606|NCT05851638|DEVICE|Lung Oxygen measurement with GASMAS system|A specially designed light source probe (2x2cm size) with 2x incorporated laser sources and a detector probe (2x2cm size) will be attached to the torso of the infant in a total of 10 locations to measure lung oxygen.
223448607|NCT04712409|PROCEDURE|Single anastomosis duodeno-ileal bypass|Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion
223448608|NCT04712409|PROCEDURE|Biliopancreatic diversion with duodenal switch|Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.
223448609|NCT04712409|PROCEDURE|SADI-S as a revisional procedure|In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery
223448610|NCT04712409|PROCEDURE|BPD-DS as a revisional procedure|In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
223741736|NCT05075304|DRUG|BDB-001 injection|IV infusions of Injection diluted in sodium chloride
224056613|NCT05735522|DEVICE|Extracorporeal magnetic stimulation|Extracorporeal magnetic stimulation is a technique based on Faraday's law of magnetic induction, approved by the United States Food and Drug Administration in 1998, for conservative treatment of urinary incontinence. It generates electrical activity, which induces controlled depolarization of the nerves, resulting in pelvic muscle contraction and sacral S2-S4 roots neuromodulation. The patient seats in the chair fully clothed.
224056614|NCT05735522|OTHER|Sham|The same chair as is used in the active group with the magnetic field density at the lower 2% resulting in negligible efficacy.
224056615|NCT07145619|OTHER|Spinal Anesthesia with Intrathecal Morphine Only|Elective cesarean delivery performed under spinal anesthesia with the addition of 100 micrograms intrathecal morphine (ITM) as part of standard clinical care. No additional regional block is performed. Postoperative analgesia is maintained with intravenous patient-controlled analgesia (IV PCA) morphine and multimodal analgesia, including scheduled paracetamol and NSAIDs as per institutional protocol.
224056616|NCT07145619|OTHER|Spinal Anesthesia with Intrathecal Morphine plus Bilateral TAP Block|Elective cesarean delivery performed under spinal anesthesia with the addition of 100 micrograms intrathecal morphine (ITM) as part of standard clinical care, plus bilateral ultrasound-guided transversus abdominis plane (TAP) block performed at the end of surgery. The TAP block will be performed in-plane with a high-frequency linear probe, using 0.25% bupivacaine, 20 mL per side, injected between the internal oblique and transversus abdominis muscles. Postoperative analgesia will be maintained with intravenous patient-controlled analgesia (IV PCA) morphine and multimodal analgesia, including scheduled paracetamol and NSAIDs.
224056617|NCT07147816|DEVICE|Transcutaneous electrical stimulation of the cervical spinal cord (tSCS)|All participants enrolled in this group will receive non-invasive transcutaneous electrical stimulation of the cervical spinal cord (tSCS) while performing strength, spasticity and motor control assessment tasks. Researchers will assess the immediate effects of tSCS (within the same experimental session) on arm and hand movements in individuals with motor impairments caused by traumatic brain injury.
223448611|NCT05992402|BEHAVIORAL|ReBOOT program|This is a virtual cognitive intervention led by a clinical neuropsychologist. Participants will attend 2 one-on-one individual sessions and 4 group sessions prior to their epilepsy surgery. Groups will be made up of 3-10 participants. The intervention is designed to provide participants with information about possible changes and/or challenges they may experience after epilepsy surgery, as well as cognitive strategies to implement prior to surgery to increase effectiveness of compensation for any new cognitive difficulties that may be experienced following surgery.
223741737|NCT03079908|OTHER|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
223741738|NCT03079908|OTHER|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
223569103|NCT00541866|DRUG|Voreloxin injection and cytarabine|"Dose-escalation Phase~* Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~* Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous \[IV\] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~* Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~* Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
223741739|NCT03079908|OTHER|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
223741740|NCT03326258|DRUG|Glembatumumab Vedotin|Given IV
224056618|NCT07149844|DRUG|tea tree oil ointment|Petrolatum (petroleum jelly) was sterilized in the oven at 160°C for 90 min, then The ointment was prepared as 10% .
224146632|NCT02596828|DRUG|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
224146633|NCT00062205|DRUG|imatinib mesylate|
224146634|NCT06120465|OTHER|Yoga|Yoga classes
224146635|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with ABV feedback|At the beginning of each session, participants will complete 45 standard dot-probe trials as described above. Participants' ABV on these trials will be calculated and set as their personal baseline (see below for ABV calculation). In the following 165-training trials, participants will receive feedback: when their online-calculated ABV will be below their baseline screen background will be green whereas its color will be red when their online ABV score will be higher than their baseline. Patients will be instructed to try to keep the background green for as long as possible.
224146636|NCT05242263|BEHAVIORAL|Attention Control Training (ACT) with yoked sham feedback|Participants in this group will be exposed to the same task as in the active group but will receive sham feedback that is unrelated to their ABV during task performance. They will be presented with a feedback that is yoked to the one given to a participant in the training group.
224146637|NCT03788967|DRUG|TBPM-PI-HBr|TBPM-PI-HBr tablets administered orally.
224146638|NCT03788967|DRUG|Ertapenem|Antibiotic Therapy for cUTI.
224146639|NCT03788967|DRUG|Dummy Infusion|Dummy intravenous infusion.
224146640|NCT03788967|DRUG|Dummy tablets|Dummy tablets orally.
224146641|NCT00805818|DRUG|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
224146642|NCT00805818|DRUG|Placebo|Sodium Chloride 0.9% Injection
223448612|NCT06955637|DEVICE|dental movement|Possibility to reduce the protrusion of upper incisors
223448613|NCT06956053|DIAGNOSTIC_TEST|Rapid ID/AST method|"1. BioFire® Film Array® Blood Culture Identification 2 BCID2 panel, bioMérieux/BioFire Diagnostics, CE marked (FDA cleared)~2. BioFire® FilmArray® Pneumonia Panels, CE marked (FDA cleared)~3. SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility test (AST) System, bioMérieux/Specific Diagnostics, CE-IVD and -IVDR marked"
223448614|NCT06956053|DIAGNOSTIC_TEST|Conventional biological methods|Usual care
223448615|NCT00437476|DRUG|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
223448616|NCT00437476|DRUG|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
223741741|NCT03326258|BIOLOGICAL|Ipilimumab|Given IV
223741742|NCT03326258|OTHER|Laboratory Biomarker Analysis|Correlative studies
223741743|NCT03326258|BIOLOGICAL|Nivolumab|Given IV
223741744|NCT03326258|OTHER|Pharmacological Study|Correlative studies
223741745|NCT01991457|DRUG|Fludarabine|
223741746|NCT01991457|PROCEDURE|Total Body Irradiation|
223741747|NCT05058300|DEVICE|CT Thorax|CT Thorax (GE Revolution with chest pain algorithm)
223741748|NCT05467436|DRUG|Local anesthetics, IV sedation drugs and analgesics.|Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
223741749|NCT03792867|DRUG|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
223741750|NCT05079295|PROCEDURE|CSDH evacuation|Burr hole for chronic subdural hematomas
224056619|NCT07157917|OTHER|Protocol based|Apply a thirst safety management protocol
224056620|NCT07157917|OTHER|Control|Room air water
224146643|NCT03751969|DRUG|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
223448617|NCT00437476|DRUG|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
223448618|NCT00437476|DRUG|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
223448619|NCT02306369|BEHAVIORAL|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
223448620|NCT02083796|PROCEDURE|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
223448621|NCT02083796|PROCEDURE|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
223448622|NCT02083796|PROCEDURE|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
224056621|NCT07158229|OTHER|Questionnaires|Complete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep.
224056622|NCT07149324|BEHAVIORAL|Single Session for Overevaluation|A single session informed by the principles of Cognitive Behavioural Therapy-Enhanced and motivational intervening.
223448623|NCT02083796|PROCEDURE|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
223448624|NCT02217111|BEHAVIORAL|Adventures in Voice: Pediatric Voice Therapy|
223448625|NCT05496465|DRUG|ARS-1|A single treatment of ARS-1.
223448626|NCT05496465|DRUG|Placebo|A single treatment of placebo nasal spray
223448627|NCT01031017|DRUG|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
224056623|NCT07154992|DIETARY_SUPPLEMENT|Probiotic - Lacticaseibacillus rhamnosus CRL1505|The probiotic product is provided in 2g sticks containing the strain Lacticaseibacillus rhamnosus CRL1505 at a concentration of ≥ 1.0E+8 CFU/g, with corn starch and maltodextrin as excipients.
224056624|NCT07154992|DIETARY_SUPPLEMENT|Placebo|The placebo product is provided in 2g sticks of corn starch and maltodextrin.
224146644|NCT01067313|DEVICE|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
224146645|NCT01067313|DEVICE|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
224146646|NCT04481880|DIAGNOSTIC_TEST|measuring IAP and respiratory parameters|Effect of IAP on respiratory parameters Correlation between IAP and Gastric and urinary bladder pressures
223448628|NCT01031017|DRUG|placebo|placebo
223448629|NCT06323343|OTHER|Video Intervention|Animated video delivered by text message to prepare parents to communicate with physicians at their upcoming appointment for a fetal anomaly concern.
223448630|NCT06323343|OTHER|Webpage links|Links to publicly available webpages about the fetal concerns clinic where the participants' appointments are scheduled.
223448631|NCT04578509|DIAGNOSTIC_TEST|Nasopharyngeal swab|Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test
223448632|NCT04578509|DIAGNOSTIC_TEST|Saliva sample|Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach
223448633|NCT04578509|DIAGNOSTIC_TEST|axillary sweat sample|Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.
223448634|NCT04578509|OTHER|Data collection|Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
223448635|NCT02652559|DEVICE|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
223448636|NCT02652559|DEVICE|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
223448637|NCT02652559|DEVICE|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
223448638|NCT02652559|OTHER|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
223448639|NCT02652559|OTHER|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
223448640|NCT00152243|DRUG|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
223448641|NCT00152243|PROCEDURE|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
223569104|NCT06497062|DRUG|sonrotoclax|"Orally once daily, on D5-14. A 4-day dose ramp-up is required for the first induction. The dosing regimen will be determined in the Safety Run-in phase.~If a second induction is needed, dose ramp-up is not required. In the consolidation therapy phase, subjects in the group with favorable risk and MRD negative do not need to receive Sonrotoclax treatment, and subjects in the group with favorable risk and MRD positive, or with intermediate and adverse risk will receive sonrotoclax on D1-7 at the target dose determined in the safety run-in phase, dose ramp-up is not required.~In the maintenance therapy phase, subjects will receive once daily sonrotoclax on D1-14 at the target dose determined in the safety run-in phase."
224056625|NCT07154784|BIOLOGICAL|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) will be performed at weeks 0 and 4 of study enrollment by administering approximately 250-300 cc of a multi-donor fecal suspension into the colon via sigmoidoscopy, colonoscopy, or by oral administration of an equivalent amount (4 capsules).
224056626|NCT07155122|DRUG|Drug: Serplulimab|serplulimab Serplulimab , 300mg, D1, intravenous drip , Q3W.
224146647|NCT04432376|DRUG|miconazole 2% oil|Drug treatment of otomycosis for 14 days
224146648|NCT04432376|DRUG|vehicle oil|Placebo treatment of otomycosis for 14 days
223448642|NCT03747718|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
223448643|NCT03747718|OTHER|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
224056627|NCT07155122|DRUG|Drug: Etoposide|Etoposide, 60-100 mg/m², D1-3 or D1-5, intravenous drip, Q3W
223448644|NCT04255758|OTHER|Cycle Ergometer Exercise|25 minutes, 70% VO2max steady state cycle ergometry exercise
223448645|NCT03769701|PROCEDURE|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
223448646|NCT01299896|OTHER|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
223448647|NCT01299896|OTHER|Usual Care|Standard therapy to help participants with smoking cessation.
223448648|NCT04652947|DIAGNOSTIC_TEST|MRI diagnostic|no intervention, patient only have MRI
223448649|NCT04663932|PROCEDURE|immediate stenting group(one-step strategy)|Patients assigned to the immediate stenting group will undergo appropriate stent implantation based on characteristics of the lesions.
224056628|NCT07155122|DRUG|Drug: Chemotherapy|Cisplatin, 50-75 mg/m², D2, intravenous drip, Q3W. Or Carboplatin, AUC 5, D2, intravenous drip, Q3W.
224056629|NCT07159503|PROCEDURE|Vortex Intelligence Stone Optimized Removal|Vortex Intelligence Stone Optimized Removal integrates irrigation-suction, pressure monitoring-control, and lithotripsy-stone removal functions, aiming to improve stone clearance efficiency, stabilize intrapelvic pressure, and reduce complications.
223448650|NCT04663932|PROCEDURE|deferred stenting group (two-step strategy)|Patients assigned to the deferred stenting group will be sent back to the ward after PCI to receive standard anticoagulant and antiplatelet therapies, and the CAG will be repeated 5 to 7 days after initial intervention, followed by treatment with stent implantation.
223448651|NCT01269619|DEVICE|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
223448652|NCT01269619|DEVICE|Static back support|A standard wrap-around sacro lumbar support
223448653|NCT05911789|RADIATION|Online adaptive radiation therapy|A dose of 45Gy will be delivered to planning target volume (PTV)
223448654|NCT03139409|PROCEDURE|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
223448655|NCT03139409|OTHER|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
223448656|NCT03181945|OTHER|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
223448657|NCT03181945|OTHER|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
223569105|NCT06497062|DRUG|idarubicin/daunorubicin|idarubicin: On D1-3, intravenously, 10 mg/m\^2 for subjects aged \<60 years, 6 mg/m\^2 for subjects aged ≥60 years daunorubicin: On D1-3, intravenously, 60 mg/m\^2 for subjects aged \<60 years, 40 mg/m\^2 for subjects aged ≥60 years
224056630|NCT07159503|PROCEDURE|Percutaneous Nephrolithotomy (PCNL)|A standard PCNL technique will be performed according to institutional practice guidelines.
224056631|NCT07161648|OTHER|neuromuscular electrical stimulation|The study participants will engage in 100-minutes of neuromuscular electrical stimulation (NMES). NMES pads are sticky pieces of plastic, similar in size to a 25-cent coin. The pads will be placed on the bellies of thigh muscles (the vastus lateralis, vastus medialis), and calf muscles (the long and short head of the gastrocnemius). These skeletal muscles are selected due to their size (thereby promoting a bigger increase for metabolic rate compared with a small muscle), because they are relatively superficial, and because previous published studies of NMES used these anatomical locations.
223448658|NCT01359020|DRUG|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
223569106|NCT06497062|DRUG|Cytarabine|In induction therapy phase: intravenously, 100 mg/m\^2 on D1-7. In consolidation therapy phase: subjects with favorable-risk and MRD negative will receive cytarabine intravenously at 2 g/m\^2/q12h for those aged \<60 years, at 1g/m\^2/q12h for those ≥60 years on D1-3 or 3+7 regimen, and subjects with favorable-risk and MRD positive or intermediate or adverse-risk will receive cytarabine intravenously at 1 g/m\^2/d q12h on D1-3(in combination with sonrotoclax).
223569107|NCT06497062|DRUG|Azacitidine|75 mg/m\^2, subcutaneously, once daily, on D1-7
223569108|NCT06497062|PROCEDURE|allo-HSCT|Per standard of procedure
223448659|NCT03817905|OTHER|Patient navigator|Intervention will utilize staff at the Seidman Cancer Center who are trained in patient navigation and have experience in navigating patients for breast cancer screening as well as sickle cell disease. The staff will undergo training for this study by study principal investigators which will include the target participant population, necessary steps in the navigation process and data that will be collected. In addition, they will receive brief training in supportive, listening technique. They will also be furnished with a telephone script for the initial participant contact.
223448660|NCT01586702|BEHAVIORAL|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~* Measurement of risk factors~* Assessment of medication intake~* Monitoring of antithrombotic therapy~* Joint agreement of an individual target plan~Target values for risk factors:~* Blood pressure \< 140/85 mmHg (\<130/80 in diabetics), normal circadian profile~* HbA1c \<7.5%~* Nicotine abstinence~* LDL \< 100mg/dl (\< 70mg/dl in high risk patients)~* Physical activity ≥ 30min \>2 x / week~Targets for pharmaceutical treatment:~* Platelet inhibitors for strokes / TIA of arterial etiology~* Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~* Cumarins (INR 2-3) or new oral anticoagulants in AF patients~* Statin treatment in patients with LDL \>100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
223448661|NCT03848897|OTHER|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
223448662|NCT03058718|OTHER|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
223448663|NCT03058718|OTHER|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
223448664|NCT02688803|DRUG|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
223448665|NCT02688803|DRUG|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
223448666|NCT02688803|DRUG|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
223448667|NCT05161026|OTHER|Bone osteodensitometry|Evaluation of bone osteodensitometry
223448668|NCT06364436|BEHAVIORAL|Reiki energy therapy|In order to perform distance Reiki application, the practitioner must have completed Reiki II level training according to the Traditional Usui Reiki system and must be attuned by a person with a Usui Reiki Master and Teacher degree. With harmony, the energy channels in the individual's body are opened and the harmonious individual becomes a tool of universal healing energy.
223448669|NCT04769492|OTHER|#ChopViolence/#ChopHIV|Tailored, community-based violence prevention intervention
224146649|NCT04147507|OTHER|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
223448670|NCT00864305|DRUG|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
223448671|NCT00864305|DRUG|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
223448672|NCT00864305|DRUG|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
224146650|NCT04147507|BEHAVIORAL|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
223448673|NCT02107313|DRUG|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
223448674|NCT02107313|DRUG|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
223448675|NCT04515277|DIETARY_SUPPLEMENT|40 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
223448676|NCT04515277|DIETARY_SUPPLEMENT|20 g Gum acacia (FibregumTM)|Applied in 300 mL of orange juice with breakfast (single use at visit)
224056637|NCT07161063|BEHAVIORAL|Brief Family Therapy Program|The Lausanne Family Play - Brief is a video-feedback intervention adapted for families seeking support for a child two to nine years old with a mental health challenge. Feedback focuses on engagement, teamwork, conflict, and child-focused issues.
224056638|NCT07161479|PROCEDURE|Argon Plasma Coagulation (APC)|Ablation of gastric adenoma using argon plasma coagulation.
224056639|NCT07161479|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic resection of gastric adenoma by mucosal resection technique.
223448677|NCT04515277|DIETARY_SUPPLEMENT|0 g Gum acacia (FibregumTM)|300 mL of orange juice with breakfast (single use at visit)
223448678|NCT05253144|RADIATION|Radiotherapy|Radiotherapy
223448679|NCT05253144|PROCEDURE|Surgery|Surgery
223448680|NCT02875717|DRUG|Acetylsalicylic acid|
223448681|NCT02875717|DRUG|low molecular weight heparin|
223448682|NCT00170391|BEHAVIORAL|Quarter of an Hour rule|
223448683|NCT01913574|DEVICE|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
223448684|NCT01913574|PROCEDURE|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
223448685|NCT04027179|DRUG|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
223448686|NCT04027179|PROCEDURE|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
223448687|NCT04027179|DRUG|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
224056640|NCT07159789|DEVICE|Repetitive Transcranial Magnetic Stimulation|Treatment with the rTMS or sham rTMS will be scheduled daily 5x per week for a total of 6 consecutive weeks followed, after a 6 week pause, by another treatment session of 6 weeks where all patients will receive active rTMS treatment
224056641|NCT07169903|PROCEDURE|Pulmonary segmentectomy|Segmentectomy is applied to lung adenocarcinomas with a diameter of 2-3 cm, in which intraoperative frozen pathology confirms a new pathological grade of 1-2.
224056642|NCT07170579|OTHER|Exercise|Participants engaged in High-Intensity Interval Training (HIIT) sessions three times per week, each lasting 60 minutes. Sessions included a 10-minute warm-up, a central HIIT block with cycles of aerobic exercises performed at high intensity (30-60 seconds) alternated with active recovery (60-90 seconds), followed by a 10-minute aerobic functional segment and a 10-minute cool-down with stretching. Exercises included modified jumping jacks, stationary marching, high knees, squats, and functional movements tailored to the participants' physical capacity. Training intensity was monitored using the Borg Rating of Perceived Exertion scale, targeting 13-17 during effort phases and 9-11 during recovery.
224056643|NCT07171619|DRUG|Nirogacestat|oral dose of 150 mg nirogacestat
224056644|NCT07171619|DRUG|Nirogacestat and Famotidine|oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine
224056645|NCT07171619|DRUG|Nirogacestat and Rabeprazole|oral dose of 150 mg nirogacestat and oral dose of 20 mg rabeprazole
224056646|NCT07171463|PROCEDURE|Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation|Pulmonary vein isolation is performed via transseptal access to the left atrium using a point-by-point bipolar pulsed-field ablation catheter
224056647|NCT07171463|PROCEDURE|Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion|Targeted application of radiofrequency energy at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical location of the superior paraseptal parasympathetic ganglion.
224056648|NCT07171021|DRUG|Theophylline 200 mg|taking theophylline (400 mg twice a day) and performing olfactory training for 6 months
224056649|NCT07171021|BEHAVIORAL|olfactory training|performing olfactory training for 6 months
224056650|NCT07170475|DRUG|Febuxostat|Febuxostat tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
224056651|NCT07170475|DRUG|Inosine|Inosine tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.
224056652|NCT07169695|DIAGNOSTIC_TEST|Slit Lamp Examination|The participant will have a slit lamp examination
224146651|NCT00498849|DEVICE|CPAP|
223448688|NCT02357745|PROCEDURE|Non surgical periodontal therapy|scaling and root planing
223448689|NCT00263419|BEHAVIORAL|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
223448690|NCT03625700|DRUG|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
224056653|NCT07169695|DIAGNOSTIC_TEST|Far Best Corrected Visual Acuity (BCVA)|The participant 's BCVA will be evaluated.
223448691|NCT03513471|BIOLOGICAL|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
223448692|NCT03513471|OTHER|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
224056654|NCT07169695|DRUG|T1695|The participant should instill T1695.
224056655|NCT07169695|DRUG|Ciclosporin|The participant should instill Ciclosporin.
224056656|NCT07169695|DIAGNOSTIC_TEST|Corneal fluorescein staining score on modified Oxford scale|One drop of fluorescein will be instilled to assess the fluorescein staining score on the modified Oxford scale.
224056657|NCT07171073|DEVICE|RecoveriX|RecoveriX is a brain-computer interface (BCI) system designed for motor rehabilitation after stroke. It records brain activity using EEG and provides real-time feedback through virtual reality and functional electrical stimulation (FES). Participants imagine hand movements, and the system activates corresponding virtual movements and stimulates the muscles to support motor recovery.
224056658|NCT07171073|DEVICE|Gloreha Aria|Gloreha Aria is a robotic therapy system for upper limb rehabilitation. It combines mechanical assistance with virtual reality tasks to restore hand and finger movements. The device can be used in passive, assistive, or active modes, depending on the patient's abilities, and provides interactive exercises to improve motor function and neuroplasticity.
224056659|NCT07171073|DEVICE|E-Link System|E-Link is an interactive computer-based system for hand and finger rehabilitation. It uses sensors to capture movements and provides individualized motor training through interactive tasks. The system allows both active motor practice and objective assessment of fine motor skills and functional abilities.
224056660|NCT07171073|OTHER|Standard Occupational Therapy|The control group will receive conventional occupational therapy as part of standard rehabilitation. Therapy will include individualized exercises to improve motor, cognitive, and functional abilities, consistent with usual clinical practice.
224056661|NCT07170774|DEVICE|Ischemic Preconditioning|Compression cuff width: 10CM; Compression duration: 5min/5min (ischemia/reperfusion) \*4. 220 mmHg
224056662|NCT07170774|DEVICE|Sham|Compression cuff width: 10CM; Compression duration: 5min/5min (compression/relaxation) \*4. 20 mmHg
224056663|NCT07169864|PROCEDURE|Simple Surgical Glove Compression Technique|Patients will wear surgical gloves of smaller size than the patient's hand, on the dominant hand from 15 minutes before the start of each neoadjuvant chemotherapy infusion until 15 minutes after the end of infusion (total of 90 minutes). The non-dominant hand will serve as the untreated control.
224056664|NCT00285129|DEVICE|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
223741751|NCT06027853|DRUG|CLL1 CAR-NK cell injection|"Drug: CLL1 NK cell therapy Drug: Cyclophosphamid Lympho-conditioning Agent Drug: Fludarabine Lympho-conditioning Agent~Drug: VP-16 Lympho-conditioning Agent"
223448693|NCT03513471|DRUG|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
223448694|NCT06322277|OTHER|Analysis of biological sample|Confermation of type of infection with RT-PCR.
223448695|NCT04098796|DRUG|Anti-PD-1 antibody|Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
223448696|NCT04098796|DRUG|XELOX|Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
223448697|NCT04357938|DEVICE|CT-imaging|Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.
223448698|NCT04886297|DRUG|Mega Resveratrol® capsules|Subjects were orally administered Mega Resveratrol® capsules daily for 8 weeks.
223448699|NCT04886297|DRUG|Mega Resveratrol® Placebo capsules|Mega Resveratrol® Placebo capsules
223448700|NCT00420953|DRUG|Cordarone|
223448701|NCT00888498|OTHER|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
223448702|NCT00888498|OTHER|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
223448703|NCT00888498|OTHER|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
223448704|NCT02228018|DEVICE|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
223569109|NCT04926610|OTHER|proactive clinical ethics consultation|When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
223569110|NCT03638531|DEVICE|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
223569111|NCT03638531|DEVICE|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
223569112|NCT00918320|DRUG|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
223741752|NCT01941641|DRUG|neoadjuvant FOLFOXIRI|
223448705|NCT01088711|DRUG|Omarigliptin|Once-weekly 50 mg capsule
223741753|NCT01941641|DRUG|Capecitabine|
223448706|NCT01088711|DRUG|Placebo|Once-weekly placebo capsule
223741754|NCT04608851|DRUG|E. coli Nissle|1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain
224056665|NCT06275022|PROCEDURE|Inflow occlusion with perforation of septation and sclerotherapy|Inflow occlusion assisted by indocyanine green-fluorescence imaging combined with perforation of septation and sclerotherapy
224056666|NCT06275022|PROCEDURE|Perforation of septation and sclerotherapy|Perforation of septation and sclerotherapy
224056667|NCT06275022|PROCEDURE|Indocyanine green-guided partial resection and sclerotherapy|Indocyanine green-fluorescence imaging-guided partial resection and sclerotherapy
223741755|NCT04608851|OTHER|Placebo control|1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.
223741756|NCT06221514|OTHER|Core Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
223741757|NCT06221514|OTHER|Shoulder Strengthening Programs|"The program will be carried out for 3 weeks, 2 times a week, for approximately 50 minutes.~Each exercise was performed in 3 sets of 15 repetitions."
223741758|NCT00737620|PROCEDURE|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
224056668|NCT06275022|PROCEDURE|Partial resection and sclerotherapy|Partial resection and sclerotherapy
224056669|NCT06410300|RADIATION|Curative Radiotherapy|Radiation dose of 45 Gy or higher
224056670|NCT06410300|DRUG|Immunotherapy|checkpoint inhibitor per PI discretion
224056671|NCT04320108|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy 6 times during 2 weeks
224056672|NCT01605526|DRUG|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
224056673|NCT01605526|DRUG|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
224056674|NCT04162821|DRUG|Hydronidone|Take hydroxynitone capsule
224056675|NCT01054742|DRUG|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
224056676|NCT01054742|DRUG|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
224056677|NCT04754698|BIOLOGICAL|CoronaVac|CoronaVac (Sinovac Biotech Ltd., Beijing, China)
223448707|NCT05050305|DRUG|Marizomib|Intravenous Infusion
223448708|NCT05050305|DRUG|Pomalidomide|Taken orally
223448709|NCT05050305|DRUG|Dexamethasone|Taken orally
223448710|NCT01240902|DEVICE|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
223448711|NCT01240902|DEVICE|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
223448712|NCT00027287|DRUG|Vitamin E|
223448713|NCT04078854|BEHAVIORAL|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
223448714|NCT02085928|OTHER|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"* The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~* The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~* The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
223448715|NCT01441245|DRUG|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
223448716|NCT05573178|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
223448717|NCT00582426|DRUG|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
223448718|NCT00582426|OTHER|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
223448719|NCT03745248|BEHAVIORAL|Aerobic training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
223448720|NCT03745248|BEHAVIORAL|Balance Training|Standard of care
223448721|NCT00373126|DRUG|transdermal nicotine patch|
223448722|NCT06786832|BEHAVIORAL|Cognitive behavioral therapy for persistent fatigue|"The treatment is based on a treatment manual that has previously been evaluated in several randomized controlled trials for persistently fatigued patients with various types of chronic somatic disorders (primarily in specialized healthcare settings).~In this trial we have translated the treatment manual to Swedish and adopted it for implementation in a Swedish primary care setting. The treatment format is blended, meaning that the treatment is administered both via an online platform (where the participant can communicate with the therapist through asynchronous text-messages) and via face-to-face therapy sessions with the therapist."
223741759|NCT01196923|DEVICE|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
224056678|NCT03366298|COMBINATION_PRODUCT|Epipen 0.3mg|Epipen 0.3mg auto-injector
224056679|NCT03366298|COMBINATION_PRODUCT|Emerade 300mcg|Emerade 300mcg auto-injector
224056680|NCT03366298|COMBINATION_PRODUCT|Emerade 500mcg|Emerade 500mcg auto-injector
224056681|NCT02481921|BEHAVIORAL|Group medical visits|Group clinics or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and/or medication management join to manage heart failure in addition to and in support of, the patient's regular individual clinic visits.
224056682|NCT04360551|DRUG|Telmisartan 40mg|Angiotensin Receptor Blocker (ARB)
224056683|NCT04360551|DRUG|Placebo|Placebo once daily
224056684|NCT01443520|DRUG|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
224056685|NCT01443520|DRUG|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
224056686|NCT01443520|DRUG|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
224056687|NCT04640337|OTHER|IPE applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
223448723|NCT06786832|OTHER|Care as usual|Since there are no standardized, structured care programs and guidelines for the patient group, CAU may include a broad variety of psychosocial support, psychological treatment, physiotherapy, occupational therapy, pharmacological treatment, follow-up within specialist healthcare, and/or follow-up by general practitioners. An important aim of the project is to carefully map the content and scope of the care offered to patients in the study within the framework of CAU.
224056688|NCT04640337|OTHER|IPE applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie
223448724|NCT05588934|DIETARY_SUPPLEMENT|Caffeine Gum|Commercially available caffeinated gum that contains 100mg of caffeine per piece of gum.
223448725|NCT05588934|OTHER|Placebo Gum|Commercially available non-caffeinated gum.
223448726|NCT04877899|DEVICE|EchoGo|"EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician.~EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations."
223448727|NCT00872612|PROCEDURE|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
223448728|NCT00872612|PROCEDURE|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
223448729|NCT00762190|DRUG|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
223448730|NCT00762190|DRUG|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
223448731|NCT02164318|OTHER|Handgrip training|
223448732|NCT02164318|DRUG|Nitroglycerin ointment|
223448733|NCT01285778|DRUG|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
223448734|NCT03724019|DRUG|Ketamine|Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
223448735|NCT04321083|DIAGNOSTIC_TEST|INVOS|INVOS monitoring brain o2 saturation
223448736|NCT05233215|BEHAVIORAL|GROW (Glioma Specialists Reaching Out With Support) Support Program|Follow-up survivorship care plan for patients and caregivers
223741760|NCT04776499|DRUG|Propylthiouracil, Riociguat, Perphenazine|"Administration of propylthiouracil, riociguat, and perphenazine in combination~Investigational medicinal product (IMP):~Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg"
223741761|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
223741762|NCT00894322|DRUG|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
224301119|NCT06179927|OTHER|Image stimuli|The subjects will undergo a pre-intervention assessment phase that will consist of administering the Theory Of Mind (TOM) test found in the NEuroPSYcology second edition (NEPSY) battery, part A; the same test will be re-submitted at the end of the intervention. Having ascertained the presence of the inclusion criteria and following randomization of the sample, the control group constituted of 20 children, will be administered the research task, which involves 12 sessions, one per week lasting 45 minutes. the experimental group will view 12 social scenes on paper. They, guided by the narrator's voice of the operator will have to choose from two or three alternatives the one that represents the appropriate mental state by indicating it on the paper. Consequently, feedback will be provided by the operator to return information to the subject on the accuracy of the response.
224301120|NCT04373044|DRUG|Baricitinib|Given PO
224301121|NCT04373044|DRUG|Hydroxychloroquine|Given PO
224301122|NCT04373044|DRUG|Placebo Administration|Given Po
223448737|NCT00572871|OTHER|plyometric exercise|single bout of plyometric exercise
223448738|NCT00572871|OTHER|resistance exercise|single bout of resistance exercise
223448739|NCT00572871|OTHER|No exercise|Will not do any exercise
223448740|NCT04156386|DIETARY_SUPPLEMENT|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
223448741|NCT04156386|DIETARY_SUPPLEMENT|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
223741763|NCT00894322|OTHER|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
223741764|NCT03773705|PROCEDURE|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
223741765|NCT00231725|DRUG|insulin lispro injection [rDNA origin] Low Mix|
223741766|NCT05160454|DEVICE|near infrared spectroscopy|evaluate cerebral blood flow with and without breatholding
224056689|NCT04640337|OTHER|IPE not applied, participants believe they are receiving IPE|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th
223448742|NCT04156386|DIETARY_SUPPLEMENT|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
223448743|NCT04051697|BEHAVIORAL|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
223448744|NCT03837457|DRUG|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
223448745|NCT04069728|OTHER|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
223448746|NCT04069728|OTHER|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
223448747|NCT01675674|OTHER|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
223448748|NCT02446548|DRUG|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
223448749|NCT02446548|DRUG|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
223448750|NCT02446548|OTHER|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
223448751|NCT04624048|DIAGNOSTIC_TEST|COVID-19 survey|Participants should complete a survey to analyze the impact of COVID-19 on University population.
223448752|NCT04145206|BEHAVIORAL|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
223448753|NCT04039425|PROCEDURE|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
223448754|NCT00556257|DRUG|Cyclosporine|Standard of care
223448755|NCT00556257|DRUG|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
223448756|NCT01280071|DRUG|aminophylline|
223448757|NCT05640063|OTHER|Enhanced Delivery and Newborn kit|Under this study enhanced delivery and newborn kits will be provided to the identified pregnant women to utilize at home or at health facility and avoid delays at facility. After the training of community and health care providers, the intervention package will be delivered in the intervention clusters primarily through the LHWs and CMWs.
223448758|NCT01308034|DRUG|sunitinib|"All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
223448759|NCT00874913|DEVICE|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
223448760|NCT05639218|DRUG|Inclisiran|Patients are receiving PCSK9 inhibitors or inclisiran in the context of optimal hypolipidemic pharmacotherapy
223448761|NCT03441685|BEHAVIORAL|Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues|"Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures."
223448762|NCT06679855|DRUG|Milrinone infusion|An intravenous (iv) infusion of milrinone will be administered at an initial dose of 0.33 mcg/kg/min and accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes).
223448763|NCT06679855|DRUG|Placebo infusion|An iv infusion of placebo (0.9% saline) of equivalent volume will be administered. The infusion will be accompanied by an iv bolus of 10 mL/kg of 0.9% NaCl (administered over 60 minutes) to ensure blinding is maintained.
223448764|NCT04126317|DRUG|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
223448765|NCT04126317|DRUG|High-dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
223448766|NCT02696174|OTHER|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
224056690|NCT04640337|OTHER|IPE not applied, participants believe they are receiving placebo|Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
223448767|NCT03229850|DRUG|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
223448768|NCT02293239|OTHER|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
223448769|NCT00985660|DRUG|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
224301123|NCT02450955|OTHER|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
223448770|NCT00985660|DRUG|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
223448771|NCT02204436|OTHER|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
223448772|NCT05121805|PROCEDURE|Snare tip soft coagulation|Thermal ablation of the entire resection margin
223448773|NCT01915901|DRUG|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
223448774|NCT01915901|DRUG|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
223448775|NCT01915901|DRUG|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
223448776|NCT02029482|DRUG|ACT-128800|
223448777|NCT02029482|DRUG|Placebo|
223569113|NCT01327053|DRUG|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
223569114|NCT00385281|BIOLOGICAL|FluMist|
223741767|NCT05872711|OTHER|Low carbohydrate diet|"In order to maintain equal intensity of treatment, each patient will get a cooking workshop and received a personalized diet regime at baseline, based on the randomly assigned diet. Format and quality of the materials are similar.~All diet plans are individualized and matched for energy intake personally . Participants will meet individually with the dietitian for diet instruction and support at week 1,2,4,7,10,12 and thereafter at 24 weeks for a total of seven frontal meetings. Twice during the first 12 weeks the dietician will conduct 10-15-minute motivational telephone calls with all the participants."
223741768|NCT04946539|DIAGNOSTIC_TEST|Ultrasonography|Enthesitis assessment via ultrasonography
223741769|NCT04170114|OTHER|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
223741770|NCT04208594|DRUG|Ivabradine|comparing between both drugs for the effect of hypotensive anesthesia
223741771|NCT04208594|DRUG|Propranolol|comparing between both drugs for the effect of hypotensive anesthesia
223448778|NCT02699827|DRUG|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
223448779|NCT02699827|DRUG|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
223448780|NCT02699827|DRUG|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
223448781|NCT04626258|DRUG|Fluconazole|Fluconazol once a month 150 mg capsule
223448782|NCT04626258|OTHER|L-Mesitran|The first month apply every day one sachet, the next five months apply every week one sachet.
223448783|NCT04325165|DEVICE|DBS Implantation|Bilateral implantation of PPN DBS electrodes
223448784|NCT04786236|DEVICE|"Physiological Control Module for the Medtronic -HVAD Left Ventricular Assist Device"|Software, which sets the device speed according to physiological demand, is activated for the duration of the tests (up to 4 hours). Every patient provides his/her own control, because sequences with active control and with standard pump operation are subsequently performed in randomized order (determined by permutated blocks).
223448785|NCT04186624|DRUG|Subacromial-subdeltoid bursa corticosteroid injection|1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
223448786|NCT01191099|DEVICE|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
223448787|NCT03297021|DRUG|Ondansetron 4 MG|dose as per arm selection
223569115|NCT01574157|DRUG|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
223569116|NCT01574157|DRUG|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
224056691|NCT02916849|OTHER|Safe Step|Strength and balance exercise-digital version
224056692|NCT02916849|OTHER|OEP|Strength and balance exercise -paper version
224056693|NCT02230059|OTHER|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
224056694|NCT01887236|BEHAVIORAL|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
224056695|NCT01887236|BEHAVIORAL|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
223448788|NCT03297021|DRUG|Ondansetron 8mg|dose as per arm selection
224056696|NCT03849417|OTHER|ECT|ECT administered as part of normal clinical management
223448789|NCT03939650|DEVICE|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
224056697|NCT00520884|DRUG|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
224056698|NCT00520884|DRUG|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
224056699|NCT00520884|OTHER|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
224056700|NCT00520884|OTHER|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
224056701|NCT02459327|BEHAVIORAL|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
224056702|NCT02459327|BEHAVIORAL|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
224056703|NCT00633906|BEHAVIORAL|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
224056704|NCT00633906|BEHAVIORAL|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
224056705|NCT05029206|PROCEDURE|Autologous hematopoietic stem cell transplantation|"The therapeutic intervention of AHSCT consists of four parts: the mobilization of hematopoietic stem cells (HSC), the harvest of HSC, the ablation (conditioning) of the immune system and the reinfusion of autologous HSCs.~1. In Sweden, the mobilization of HSCs has been made by a combination of cyclophosphamide (2 g/m2) and granulocyte-colony-stimulating factor.~2. A minimum of 2 × 10\^6 CD34+ cells/kg is harvested and cryopreserved. No in vitro manipulation is done to the stem cells.~3. Two conditioning regimens have been used in Sweden for ablation. The BEAM-ATG protocol include carmustine (BCNU) 300 mg/m2, etoposide 800 mg/m2, cytarabine arabinoside (ARA-C) 800 mg/m2 and melphalan 140 mg/m2 + rATG or hATG. The Cy-ATG protocol include cyclophosphamide 200 mg/kg + rATG/hATG with 1000 mg Metylprednisolone given day -5 to -1.~4. After a minimum of 24 hours after the last administration of chemotherapy have passed, the reinfusion of autologous CD34+ cells is performed."
224146652|NCT03614819|PROCEDURE|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
224301124|NCT02450955|OTHER|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
224301125|NCT06052930|DEVICE|HTC Vive™ Pro|"A commercially available head-mounted display. Each VR session has approximately 20 minutes, performed 3 times per week.~Both groups maintain similar PD specialized physiotherapy sessions throughout the duration of the study (3 times per week, 60 minutes per session)."
223448790|NCT02112019|PROCEDURE|Sialoendoscopy|
223448791|NCT02112019|DRUG|saline|
223448792|NCT02112019|DRUG|hydrocortisone|
223448793|NCT00898755|OTHER|Cytology Specimen Collection Procedure|Correlative studies
223741772|NCT03195543|DIAGNOSTIC_TEST|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
224301126|NCT01642459|OTHER|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
224301127|NCT01642459|OTHER|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
223448794|NCT00898755|OTHER|Laboratory Biomarker Analysis|Correlative studies
224056706|NCT01149889|PROCEDURE|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
224056707|NCT02894853|GENETIC|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
224056708|NCT03193697|DEVICE|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
223448795|NCT03776526|BEHAVIORAL|Fitbit® Alta HR Sleep monitoring|Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
223741773|NCT03195543|DIAGNOSTIC_TEST|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
223741774|NCT03195543|DIAGNOSTIC_TEST|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
223741775|NCT03195543|DIAGNOSTIC_TEST|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
223741776|NCT03659591|BEHAVIORAL|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
223741777|NCT03659591|BEHAVIORAL|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
223741778|NCT02945033|DRUG|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
224056709|NCT03193697|DEVICE|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
224056710|NCT02448602|OTHER|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
224056711|NCT02448602|OTHER|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
224056712|NCT02448602|OTHER|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
224056713|NCT00130585|BEHAVIORAL|Controlled diet|
224146653|NCT03614819|PROCEDURE|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
224146654|NCT06066840|DRUG|Basiliximab|Basiliximab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
223741779|NCT02945033|DRUG|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
223741780|NCT02945033|PROCEDURE|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
223741781|NCT02945033|BIOLOGICAL|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
223741782|NCT02945033|BIOLOGICAL|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
223741783|NCT05863910|DRUG|Medical Cannabis|Any cannabis product that is available to participants through the Medical Cannabis Access Program is eligible to be included in this study.
224146655|NCT06066840|DRUG|Vedolizumab|Vedolizumab is a second-line treatment for steroid-resistant acute graft-versus-host disease.
224146656|NCT06156891|PROCEDURE|Toxicities reduced treatment|"Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-related patients.~Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) combined with concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 70% Partial Response(PR) in HPV-urelated patients."
224301128|NCT02029586|DRUG|MB12066 200mg|oral administration, 100mg bid
224301129|NCT02029586|DRUG|Placebo|oral administration, 100mg bid
224301130|NCT00001586|BIOLOGICAL|Rituximab|Rituxan
223741784|NCT03965533|DRUG|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
224056714|NCT00130585|BEHAVIORAL|folic acid supplement|
224056715|NCT00130585|BEHAVIORAL|13C11-labelled folic acid supplement|
224056716|NCT02522702|OTHER|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
224056717|NCT00388973|DRUG|Quetiapine|
224056718|NCT01497470|DRUG|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
224056719|NCT03138538|DRUG|Part 1: M8891|Participants receives M8891 orally once daily at escalated dose levels under fasting condition for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
224056720|NCT03829930|DRUG|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
224056721|NCT03829930|DRUG|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
224056722|NCT04010500|DEVICE|no mouthguard|Control (not using mouthguard)
223448796|NCT00951158|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
223448797|NCT00951158|DRUG|Conjugated Linoleic Acid|Phase I Dose Escalation Study
223448798|NCT04096001|DEVICE|Woebot-SUDs (W-SUDs)|Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
223448799|NCT00948922|DRUG|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
223448800|NCT00948922|DRUG|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes.
223448801|NCT00948922|PROCEDURE|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
223448802|NCT00948922|DRUG|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
223448803|NCT00948922|PROCEDURE|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
223448804|NCT03105557|DEVICE|Urinary collecting device|Urinary collecting device
223448805|NCT04853966|BEHAVIORAL|Physical activity counseling|Physical activity counseling will be performed using physical activity behavior steps of the transtheoretical model.
224056723|NCT04010500|DEVICE|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
223448806|NCT04755894|DRUG|HDDO-1756|single dose
223448807|NCT04755894|DRUG|HDDO-17561/HDDO-17562|single dose
224056724|NCT04010500|DEVICE|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
224056725|NCT00000742|DRUG|Atevirdine mesylate|
223448808|NCT03183843|DRUG|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
224056726|NCT00000742|DRUG|Zidovudine|
224056727|NCT00000742|DRUG|Didanosine|
223448809|NCT03183843|DRUG|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
224056728|NCT00407095|DRUG|Pardoprunox|12-42 mg/day
224056729|NCT01497639|DEVICE|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
224056730|NCT01497639|DEVICE|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
224056731|NCT02458755|DRUG|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
224056732|NCT01116908|DEVICE|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
223448810|NCT02095197|DRUG|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
224056733|NCT01469338|DRUG|cabazitaxel|Given IV
224056734|NCT01469338|DRUG|prednisone|Given PO
224056735|NCT01469338|DRUG|octreotide pamoate|Given IM
223448811|NCT06052995|DRUG|Elidel 1% Topical Cream|Elidel® 1% is a non-steroid cream for cutaneous use containing pimecrolimus. It is indicated for mild or moderate AD.
223448812|NCT04386161|OTHER|Scheduled exercise program|45 minutes of stretching, strengthening, and balance-coordination exercises and 20 minutes of balance training on the Balance Master® device twice a week for six weeks
223448813|NCT06274242|DIETARY_SUPPLEMENT|Haruna|Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)
224056736|NCT01469338|OTHER|questionnaire administration|Ancillary studies
224056737|NCT01469338|DRUG|octreotide acetate|Given SC
224056738|NCT02530528|DRUG|CHG|Varied application times
224056739|NCT00705211|DRUG|Ezetimibe|Ezetimibe, 10-mg tablets,
224056740|NCT00705211|DRUG|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
224056741|NCT03370783|DRUG|Ethanol|Moderate alcohol consumption
224056742|NCT03729674|DRUG|Biosimilar|Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
224056743|NCT03729674|DRUG|Originator (legacy) drug|Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
224056744|NCT02113085|BEHAVIORAL|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
223448814|NCT06274242|DIETARY_SUPPLEMENT|Placebo Powder|Isolate Soy Protein and Isomalt
223448815|NCT00000548|PROCEDURE|mechanical ventilation|
223448816|NCT04171193|DRUG|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
223448817|NCT04171193|DRUG|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
223448818|NCT03061487|PROCEDURE|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
224056745|NCT00346073|BIOLOGICAL|Boostrix™|Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
223448819|NCT00270504|DEVICE|Memokath stenting|Urethral Stenting
223448820|NCT06163027|DEVICE|Shotblocker|Shotblocher will be administered during spinal needle injection
223569117|NCT03811925|PROCEDURE|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
223569118|NCT03811925|PROCEDURE|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
223569119|NCT05629208|DRUG|Edecesertib|Tablets administered orally
224056746|NCT00346073|BIOLOGICAL|ADACEL®|Sanofi Pasteur
224056747|NCT01202331|DRUG|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
224056748|NCT00239798|DRUG|FTY720|
224056749|NCT01417715|DEVICE|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
224056750|NCT04350853|PROCEDURE|Surgical extrusion|Surgically coronal reposition of the tooth
224056751|NCT02204150|DEVICE|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
224056752|NCT00006476|DRUG|suramin|
224056753|NCT00006476|PROCEDURE|conventional surgery|
224056754|NCT04551937|OTHER|Lactose Free 1% Milk|8 oz of study beverage daily
224056755|NCT04551937|OTHER|Lactose Free 1% Milk + 10 g prebiotic|8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
224056756|NCT00515801|DRUG|glibenclamide|glibenclamide 15 mg single dose
224056757|NCT00515801|DRUG|placebo|placebo capsules, single dose
224056758|NCT00001003|DRUG|Pentamidine isethionate|
224301131|NCT00001586|DRUG|Fludarabine phosphate|Fludara
223448821|NCT06163027|OTHER|Shotblocker(Plasebo)|The back side of the shotblocher will be applied during spinal needle injection
224056759|NCT00001003|DRUG|Zidovudine|
223448822|NCT03140098|DEVICE|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
223448823|NCT02359279|DEVICE|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
223569120|NCT05629208|DRUG|Edecesertib Placebo|Tablets administered orally
224056760|NCT00603109|DRUG|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
224056761|NCT00603109|DRUG|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
224056762|NCT05914168|DEVICE|Breast Tomosynthesis|Three dimensional mammography
224056763|NCT00119535|BEHAVIORAL|Implementation of Proactive Diabetes Eye Care Program|
224056764|NCT04106700|DRUG|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
224056765|NCT02085603|DRUG|Saracatinib|
224056766|NCT02085603|DRUG|Placebo|
224056767|NCT04661709|DRUG|Wen Xin granule|one dose daily, two times per day.
224056768|NCT04661709|DRUG|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
224056769|NCT04661709|DRUG|Atorvastatin Calcium|20 mg tablet, one tablet each night.
224056770|NCT04661709|DRUG|Isosorbide Mononitrate Tab 20 MG|one tablet， twice daily.
224056771|NCT04661709|DRUG|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg, two times daily.
224056772|NCT04661709|DRUG|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
224056773|NCT04661709|DRUG|WXG placebo|one dose daily, two times per day.
224056774|NCT04661709|DRUG|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
224056775|NCT04661709|DRUG|glyceryl trinitrate|be taken when angina pectoris attacks.
224056776|NCT06035900|DRUG|Psilocin|single 4mg dose of psilocin mucate was administered to healthy 10 volunteers
224056777|NCT02728193|PROCEDURE|RFA|
224056778|NCT02728193|PROCEDURE|MWV|
224056779|NCT02728193|PROCEDURE|PEI|Percutaneous ethanol injection
224056780|NCT03711656|DEVICE|isCGM (intermittently scanned Continuous Glucose Monitoring)|Data collection
224056781|NCT03711656|DEVICE|Physical exercise tracker|Data collection
224056782|NCT03053297|OTHER|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
223448824|NCT01488747|DIETARY_SUPPLEMENT|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
223448825|NCT01488747|DIETARY_SUPPLEMENT|Coromega Nectar|660 mg EPA, 436 mg DHA
223448826|NCT01488747|DIETARY_SUPPLEMENT|Barleans Swirl|660 mg EPA, 660 mg DHA
223448827|NCT01488747|DIETARY_SUPPLEMENT|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
223448828|NCT02333994|DEVICE|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
223448829|NCT02333994|OTHER|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
223448830|NCT05765071|BIOLOGICAL|Botulinum toxin A|Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
223448831|NCT05765071|BIOLOGICAL|Normal saline|A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
223448832|NCT04017871|OTHER|MRI|MRI at baseline and J90
223448833|NCT04017871|OTHER|Electro-Encephalography-High Density (children with unilateral PC only)|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
224056783|NCT03703882|DRUG|Edasalonexent|100 mg/kg/day
224056784|NCT03703882|DRUG|Placebo|Placebo
224056785|NCT01617460|DRUG|Aripiprazole|Flexibly dose administered orally once daily
223448834|NCT04017871|OTHER|3D and EMG analysis|3D and EMG analysis at baseline and J90
224056786|NCT02079571|DIETARY_SUPPLEMENT|Coconut water|250 ml Coconut water for each subject
224056787|NCT02079571|DIETARY_SUPPLEMENT|ginger tea|250 ml for each subject
224146657|NCT06156891|PROCEDURE|Conventional treatment|Two cycles toripalimab+docetaxel+cisplatin+capecitabine (TPF) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70.4Gy/32Fx) when responses to induction chemotherapy are less than 70% Partial Response (PR) regardless of HPV status.
223448835|NCT04017871|OTHER|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
223448836|NCT04017871|DEVICE|Accelerometers|During 5 days a sensor at each wrist to quantify their movement.
223448837|NCT04412798|OTHER|orange juice concentrate|250mL of 100% orange juice made from concentrate
223448838|NCT04412798|OTHER|Sugar-sweetened orange-flavoured beverage|Sugar-sweetened orange-flavoured beverage, energy-matched to the orange juice condition
223448839|NCT04412798|OTHER|Whole orange juice with skin removed|Whole orange pieces with skin removed, energy-matched to the orange juice condition
223448840|NCT06373055|OTHER|neoadjuvant chemotherapy followed by radical cystectomy|combination of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) or combination of gemcitabine and cisplatin (GC) followed by radical cystectomy
223448841|NCT01357395|DRUG|Amuvatinib|Amuvatinib 300 mg PO TID
223448842|NCT01537835|OTHER|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
223448843|NCT01345214|DRUG|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
223448844|NCT02829047|DEVICE|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
223569121|NCT00721578|DRUG|voriconazole|Patients must have received (in the Intensive Care Unit \[ICU\] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
223569122|NCT04246775|DEVICE|Peristeen|rectal irrigation
223569123|NCT01828606|DEVICE|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
224056788|NCT05183607|OTHER|Virtual Nutrition Education|4 interventional sessions will be provided using a virtual communication platform and delivered remotely to each participant by a registered dietitian. The virtual counseling sessions will be led by a registered dietitian and delivered to each participant remotely
224056789|NCT05936450|BIOLOGICAL|delivery of placentrex gel after open flap debridement|placentrex gel is placed after open flap debridement only in the test group
224056790|NCT05936450|PROCEDURE|Open Flap Debridement|Open Flap Debridement done in both test and control groups
224056791|NCT04359303|OTHER|Systemic indirect endovenous ozone therapy|200 mL at 40 mcg/mL of medical ozone / oxygen in 200 mL of patients blood mixed in an homologated device for the procedure.
224056792|NCT01140360|DRUG|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA \> 1.8 m2 or 55 mg/m2 twice daily for patients with BSA \< 1.8 m2. For patients with a BSA \> 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA \< 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
223448845|NCT05457179|BEHAVIORAL|Park-based physical activity|The experimental arm will optimize a 12-week intervention 3 days/wk, last approximately 60 minutes, and consist of 10 minutes of warm up, 15 minutes of simple strength training activities, 25 minutes of moderate to vigorous aerobic activities (e.g., walking), and 10 minutes of cool down. The eight full-body strength training exercises will use body weight and/or elastic bands and will include a circuit of chest press, seated row, squat, shoulder press, biceps curl, triceps extension, calf raise, and reverse crunch. Sessions will include education and skill building activities focused on Social Cognitive Theory mechanisms of change including self-efficacy, goal setting, and social support. Under the guidance of trained research staff, certified peer specialists who have experience working with peer groups, will be selected to help deliver the intervention.
223448846|NCT05457179|BEHAVIORAL|Active Control|The active control group will receive information about the importance of park-based PA and a map of local park locations but will not participate in structured park-based PA sessions. Participants in the control group will be invited to participate in park PA sessions after they have completed posttest.
224146658|NCT03263741|DRUG|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) \< 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to \< 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
224146659|NCT02455388|DIETARY_SUPPLEMENT|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
223448847|NCT04441632|BEHAVIORAL|Positive feedback|Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
224146660|NCT02455388|DIETARY_SUPPLEMENT|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
224146661|NCT02471209|DRUG|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
224146662|NCT02747407|BIOLOGICAL|Hepatitis A Vaccine|
224146663|NCT02747407|OTHER|Laboratory Biomarker Analysis|Correlative studies
224146664|NCT02747407|BIOLOGICAL|Tetanus Toxoid Vaccine|
224146665|NCT02747407|BIOLOGICAL|Trivalent Influenza Vaccine|
224146666|NCT03872193|OTHER|Exercise|Virtual Reality Exercies
224146667|NCT01541111|DRUG|Magnesiun|75mg pills; each 12h; 12wk
224146668|NCT02205164|DRUG|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
224146669|NCT02205164|DRUG|Palonosetron|Aloxi 0.25mg
224146670|NCT02150512|DEVICE|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV \>10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still \>10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
224146671|NCT02150512|DEVICE|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
223448848|NCT02680171|BEHAVIORAL|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
224146672|NCT02156752|BEHAVIORAL|ACT|Treatment is based on Acceptance and Commitment Therapy
224146673|NCT02156752|BEHAVIORAL|SR|Treatment is based on Self-Regulation theory.
224146674|NCT02156752|BEHAVIORAL|WLO|Treatment is based on cooking tips and demonstrations.
224146675|NCT05351463|PROCEDURE|papila suture technique|simple interupted vs internal horoizontal matress suture
224146676|NCT00888212|PROCEDURE|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
224146677|NCT01729663|BIOLOGICAL|CSF470 vaccine, BCG, Molgramostim|
224146678|NCT01729663|DRUG|interferon alpha 2b|
224146679|NCT04379960|OTHER|Peptides|Peptides will be added to PBMCs in in vitro cell culture.
224146680|NCT02463136|BEHAVIORAL|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
224146681|NCT02463136|DEVICE|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
224146682|NCT01629901|DEVICE|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
224146683|NCT00745953|DRUG|Valsartan|Valsartan 320mg PO daily for 8 months
223448849|NCT02680171|OTHER|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
223448850|NCT02020135|DRUG|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
223448851|NCT01963507|BEHAVIORAL|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
223448852|NCT03777280|DEVICE|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
223448853|NCT03777280|DEVICE|cobalt chromium framework RPD|standard framework device
223448854|NCT00836446|OTHER|physical activity|physical activity routines 5 times a weeks for 12 weeks.
223448855|NCT01042821|PROCEDURE|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
223448856|NCT01042821|PROCEDURE|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
223448857|NCT04919603|BEHAVIORAL|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
223448858|NCT04919603|BEHAVIORAL|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on diabetes prevention according to \< Guidelines for prevention and treatment of type 2 diabetes in China (2017 edition)
223448859|NCT03077607|DRUG|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
223448860|NCT03077607|DRUG|Itraconazole|100 mg oral dose
223448861|NCT03077607|DRUG|Rifampin|600 mg oral dose
223448862|NCT03055910|DIAGNOSTIC_TEST|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
223448863|NCT00165217|DRUG|Capecitabine|
223448864|NCT00165217|DRUG|Thalidomide|
223448865|NCT01084902|DRUG|Latanoprost|once daily
224146684|NCT00745953|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
223448866|NCT01084902|DRUG|Brinzolamide|Two times daily
223448867|NCT02455453|DRUG|18F-FFNP|
223448868|NCT02455453|DEVICE|CTI/Siemens Biograph 40 PET/CT Scanner|"* Will include (1) 18-FDG-PET/CT scan~* Will include (2) 18F-FFNP-PET/CT scans"
224146685|NCT03194620|OTHER|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
223448869|NCT02455453|DRUG|Estradiol|
223448870|NCT02455453|DRUG|18F-FDG|
223448871|NCT06014164|DIAGNOSTIC_TEST|Interview|An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes
223448872|NCT03169907|RADIATION|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~1. Middle cerebral artery (MCA) peak systolic velocity (PSV):~2. Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~3. Ductus venosus (DV) Doppler:~Cardiac functions:~1. Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~2. Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~3. Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
223569124|NCT01828606|DEVICE|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
224146686|NCT03194620|OTHER|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
224146687|NCT03194620|OTHER|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
224146688|NCT03194620|OTHER|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (-)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
224146689|NCT03194620|OTHER|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (-)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
224146690|NCT03194620|OTHER|(-)-Epicatechin (EC)|Single oral intake of 120 µmol of (-)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
224146691|NCT03194620|OTHER|(-)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (-)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
224146692|NCT03194620|OTHER|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
224146693|NCT00838721|OTHER|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
224146694|NCT00393068|DRUG|Erlotinib|Erlotinib
224146695|NCT00393068|DRUG|Bevacizumab|Bevacizumab
224146696|NCT00393068|DRUG|Paclitaxel|Paclitaxel
224146697|NCT00393068|DRUG|Carboplatin|Carboplatin
224146698|NCT00393068|DRUG|5-FU|5-FU
224146699|NCT00393068|PROCEDURE|Radiation therapy|Radiation therapy
224146700|NCT00393068|PROCEDURE|Surgery|Surgery
224056793|NCT05280678|PROCEDURE|Orthodontic miniscrew insertion in the mandibular buccal shelf|"Each patient received miniscrews in both sizes. The same orthodontist (M.S.) performed all the insertion procedures. Miniscrews were always placed in the mandibular buccal shelf, laterally to the first and second molar interproximal area, with angulation 30 degree to the bone surface, meaning that miniscrew angulation should be approximately the same as the axial inclination of the adjacent molar. Miniscrews were loaded with orthodontic force 2 weeks after the surgery. The investigated factors were:~* long-term success rate of the miniscrews in the buccal shelf of the mandible (miniscrews were considered long-term stable if they served as an anchorage until completion of mandibular distalization, at least 9 months);~* peri-implantitis development (enlargement of the gingiva and/or redness and/or tendency to bleed);~* the patient's report of pain lasting longer than 48 hours after miniscrew insertion."
224056794|NCT01006421|DIETARY_SUPPLEMENT|GINGKO BILOBA|MEMOREX 60 MG BID
223448873|NCT00576862|DRUG|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
223448874|NCT05569369|PROCEDURE|angioplasty and stenting|dilatation of stenotic arteries and insertion of stent
223448875|NCT04339205|OTHER|Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available.|"The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed.~At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium.~The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain.~We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not."
223448876|NCT01996150|DRUG|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
223448877|NCT00032500|DRUG|Echinacea|
223448878|NCT02627456|BIOLOGICAL|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
223448879|NCT02627456|BIOLOGICAL|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
223448880|NCT02627456|DRUG|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
223448881|NCT02627456|OTHER|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
223448882|NCT02627456|DRUG|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
223448883|NCT02627456|DRUG|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
223448884|NCT00412126|DRUG|Insulin|
223448885|NCT02855801|OTHER|constant exercise|
223448886|NCT02855801|OTHER|cryotherapy|
224301132|NCT00001586|OTHER|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
224301133|NCT05033912|DRUG|CST-2032, matching placebo for CST-2032, CST-107|CST-2032 and matching placebo oral liquid; CST-107 white capsules
224301134|NCT00543608|DRUG|iclaprim|
224301135|NCT00543608|DRUG|vancomycin|
223448887|NCT02855801|OTHER|intermittent exercise|
223448888|NCT00411723|DRUG|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
223448889|NCT00411723|DRUG|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
223448890|NCT00301457|DRUG|Anastrozole|1 mg once daily oral dose
223448891|NCT01017081|OTHER|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
223448892|NCT01017081|OTHER|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
223569125|NCT03374800|DRUG|Placebo (0.9% saline)|normal saline
223569126|NCT03374800|DRUG|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
223569127|NCT00169234|BIOLOGICAL|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
223569128|NCT00169234|BIOLOGICAL|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
223569129|NCT06356935|OTHER|RT|Resistance training
223569130|NCT06356935|OTHER|CON|Control group
223569131|NCT05852158|DRUG|Cefazolin 2 GM Injection|Single pre-op dose of 2g IV cefazolin
223569132|NCT05852158|DRUG|Cefazolin Injection|Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
223448893|NCT02875795|PROCEDURE|automatic speech processing tool|
223448894|NCT05386290|DRUG|Infliximab|A TNFα inhibitor in UC and CD treatment
223448895|NCT05386290|DRUG|Vedolizumab|An integrin receptor antagonist in UC and CD treatment
223569133|NCT03233334|BEHAVIORAL|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
223741785|NCT03965533|DRUG|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
223741786|NCT05544331|BEHAVIORAL|Exercise group (written form)|The exercise program will be structUred with core stabilization exercises. Patients will be given the written form of exercises and will be applied as home exercises. Exercise progression will be provided by position changes.
224056795|NCT02708953|PROCEDURE|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
224056796|NCT02708953|PROCEDURE|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
224056797|NCT06197828|OTHER|This study is an observational studie which have no intervention|This study is an observational studie which have no intervention
224146701|NCT05189132|DIAGNOSTIC_TEST|Periodontal Diagnosis|All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
224146702|NCT05189132|DIAGNOSTIC_TEST|Microbiological analysis|"Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum."
224146703|NCT05189132|DIAGNOSTIC_TEST|Inflammatory mediators|"The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α."
224146704|NCT02760160|OTHER|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
224301136|NCT04293978|BEHAVIORAL|CalmPlace|Self-contained VR application allowing the user to build and custom a relaxation session, with options to vary session length (9-20 minutes), music/sound, relaxation exercises, and specific nature environment (three available) including time of day and events (e.g. rain). Delivered using an Oculus Go devices in kiosk-mode.
223448896|NCT05386290|DRUG|Ustekinumab|An IL-12/IL-23 inhibitor in CD treatment
223448897|NCT05386290|DRUG|conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine)|Conventional treatment includes glucocoticoid, immunosupressive drugs and/or mesalazine. Immunosupressive drugs include azathioprine (AZA), methotrexate (MTX) and thalidomide (THA).
223448898|NCT05471960|OTHER|Natural progression over time|Each subject will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
223448899|NCT05520866|BEHAVIORAL|PrehabPal|Web based application
223448900|NCT05789069|DRUG|HFB200603|Participants will be administered HFB200603 as described in the experimental arm.
223448901|NCT05789069|DRUG|Tislelizumab|Participants will be administered tislelizumab as described in the experimental arm.
223569134|NCT05091281|DEVICE|Intubation of the double lumen tube by Macintoch laryngoscope|After induction of anesthesia insertion of the double lumen tube was done by Macintosh laryngoscope
223569135|NCT05091281|DEVICE|Intubation of the double lumen tube by Glidescope videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by GlideScope® videolaryngoscope
223569136|NCT05091281|DEVICE|Intubation of the double lumen tube by C-MAC®(D) videolaryngoscope|After induction of anesthesia insertion of the double lumen tube was done by C-MAC®(D) videolaryngoscope
223741787|NCT05544331|BEHAVIORAL|Exercise group (video based)|The exercise program will be structUred with core stabilization exercises. Patients will be given the exercise videos, which provide visual and auditory feedback, and will be applied as home exercises. Exercise progression will be provided by position changes.
223741788|NCT01074957|DEVICE|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
223448902|NCT03887377|DRUG|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
223448903|NCT03887377|OTHER|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
223448904|NCT05430659|OTHER|observational study|Retrospective observational study
223448905|NCT05885646|DRUG|Sulthiame|Sulthiame add-on according to good clinical practice in these childhood epilepsy syndromes
223448906|NCT05617963|DRUG|Durvalumab|Patients showing a disease control (defined as stable disease \[SD\], partial response \[PR\], or complete response \[CR\] according to RECIST v1.1) at the radiological evaluation performed after the end of thoracic CRT will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months.
223569137|NCT04224714|COMBINATION_PRODUCT|FFR|FFR measurement: Pressure guid wire(radianalyzer Xpress 12711) is produced in Switzerland. After the pressure of the aorta and the pressure guide wire is balanced, Send the pressure guide wire to the distal part of the lesion(more than 20 mm away from the lesion) . Adenosine is injected into the vein,then,record the FFR index 3 times and take the average value as the final measurement index.
223741789|NCT01074957|DEVICE|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
223448907|NCT02387229|DRUG|Rivaroxaban|15 mg
223569138|NCT06605716|PROCEDURE|Enucleation of cysts|Surgical removal of cystic structures larger than 1 cm in patients included in the study arms. Patients were monitored for TCR during the procedure.
223569139|NCT06606093|DRUG|DWP16001 Placebo|1 tablet, Orally, Once daily single dose
223569140|NCT06606093|DRUG|DWP16001 0.3mg|1 tablet, Orally, Once daily single dose
223569141|NCT06654505|BEHAVIORAL|Paired Community Health Workers|Community Health Workers will promote maternal and child health services as paired female and male
223741790|NCT01074957|OTHER|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
223569142|NCT05410171|DEVICE|early warning platform|High risk inpatients will be evaluated by early warning platform
223569143|NCT01944098|DRUG|Lidocaine|
223741791|NCT02144389|DRUG|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
223569144|NCT01944098|DRUG|Placebo|
223741792|NCT02144389|DIETARY_SUPPLEMENT|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
223741793|NCT02144389|DIETARY_SUPPLEMENT|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
223741794|NCT03447990|DRUG|MYK-491|Single Ascending Dose and Multiple Ascending Dose of MYK-491
223741795|NCT03447990|DRUG|Placebo|Single Ascending Dose and Multiple Ascending Dose of placebo
223741796|NCT01627054|DRUG|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
223741797|NCT02533154|DRUG|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
223741798|NCT02533154|DRUG|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
224056798|NCT00017862|DRUG|SCH55700|
224056799|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
224056800|NCT03600779|DEVICE|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
224056801|NCT03415295|OTHER|Plasma TMAO concentration|Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
224056802|NCT03773042|DRUG|HSK3486|For induction and maintenance of sedation.
224056803|NCT03773042|DRUG|Propofol|For induction and maintenance of sedation.
224056804|NCT03762759|PROCEDURE|Computed Tomography|Undergo PET/CT
224056805|NCT03762759|DRUG|Fluciclovine F18|Given IV
224056806|NCT03762759|RADIATION|Gallium Ga68-labeled PSMA-11|Given IV
224056807|NCT03762759|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224056808|NCT01535573|DRUG|Citalopram|20 mg once per day for 9 weeks
224056809|NCT01535573|DRUG|Citalopram|40 mg per day for 9 weeks
223448908|NCT02387229|OTHER|standard of care|
223448909|NCT00604747|OTHER|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
223448910|NCT06305559|DRUG|obicetrapib 10 mg + ezetimibe 10 mg FDC daily|Active treatment
223448911|NCT06305559|OTHER|Placebo|Baseline lipid modifying therapy
223448912|NCT05180565|DEVICE|Colovac|A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)
223448913|NCT03808103|BIOLOGICAL|Placebo|Orally, twice a day, for a period of fifteen days
223448914|NCT03808103|BIOLOGICAL|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
223448915|NCT04686825|DRUG|DA-8010 2.5mg (Fasting)|Test drug l : DA-8010 2.5mg (Fasting)
223448916|NCT04686825|DRUG|DA-8010 2.5mg (Fed)|Test drug ll : DA-8010 2.5mg (Fed)
223448917|NCT04686825|DRUG|DA-8010 5mg (Fasting)|Test drug llI : DA-8010 5mg (Fasting)
223448918|NCT04686825|DRUG|DA-8010 5mg (Fed)|Test drug lV : DA-8010 5mg (Fed)
224056810|NCT01535573|DRUG|Placebo|0 mg per day for 9 weeks
224056811|NCT00625833|DRUG|Placebo|Oral tablet once a day dosing for 10 weeks.
224056812|NCT00625833|DRUG|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
224146705|NCT03628599|DEVICE|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
224146706|NCT03628599|DEVICE|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
224146707|NCT06553365|DRUG|FCN-159|FCN-159 8mg qd po
224146708|NCT04745078|OTHER|Caboxy30|carboxy30 to periorbital dark halos
224146709|NCT04745078|OTHER|Caboxy60|carboxy60 to periorbital dark halos
224056813|NCT01123863|OTHER|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
224056814|NCT01123863|OTHER|Brigance Preschool Screen -II|"Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian."
224056815|NCT06081556|DIAGNOSTIC_TEST|ultrasonic testing|mean gestational sac diameter（mGSD）, crown-rump length （CRL）, mGSD-CRL, D-dimer (DD), adenosine diphosphate (ADP), arachidonic acid (AA), and the ratio of uterine artery peak systolic value to end-diastolic value (UtA-S/D) were collected
224056816|NCT02834468|DRUG|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
224056817|NCT04098770|BIOLOGICAL|Allogeneic Adoptive Immune Therapy|A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
224056818|NCT03339661|DRUG|Group 1_No proph treatment|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
224056819|NCT03339661|DRUG|Group 2A_Proph treatment and γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
224146710|NCT04019210|PROCEDURE|MODIFIED TRABECULECTOMY|Rectangular scleral flap
224146711|NCT02679794|BEHAVIORAL|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
223448919|NCT02629042|PROCEDURE|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
223569145|NCT06661330|OTHER|Behavioral Treatment|Participants followed a 6-month hypocaloric Mediterranean-style diet, reducing energy intake by approximately 600 kcal/day. The diet emphasized fruits, vegetables, whole grains, and fish, while limiting red meat and processed foods. Additionally, participants were required to perform moderate physical activity, including 50 minutes of aerobic exercise, 3 times a wee
223569146|NCT06660953|PROCEDURE|Erector Spinae Plane Block|For ESP, high frequency linear ultrasound probe was planned transversely to the midline and spinous features were visualized. Cervical C7 and T7 vertebrae at the lower end of the scapula, which were accepted as landmarks, were determined and marked with a sterile surgical drawing pen. According to these landmarks, the USG probe was moved 2-3 cm laterally towards the points where kidney transplantation was planned at the T10 vertebral level, and the transverse parts, trapezius, latissimus dorsi, serratus and erector spina muscles were visualized. Using the block needle that can be visualized on USG with in-plane surgery, the skin, subcutaneous tissue and trapezius, latissimus dorsi, serratus and erector spina muscles were passed in a cranio caudal direction and the needle location was confirmed by hydrodissection with 2-5 ml of serum. The distribution of the block procedure and the spread of local anesthetic were linearly visualized with 10 ml bupivacaine and 10 ml 0.9% saline.
223741799|NCT02533154|OTHER|Bacterial culture|bacterial cultures obtained with conjunctival swabs
224056820|NCT03339661|DRUG|Group 2B_Proph treatment and no γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
224146712|NCT02679794|BEHAVIORAL|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
224146713|NCT00908622|PROCEDURE|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
224146714|NCT00908622|PROCEDURE|Cardiac revascularization|Cardiac revascularization
224146715|NCT04101669|DEVICE|RESET Liner|The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
224146716|NCT04101669|OTHER|Sham|Patient receives upper endoscopy but no treatment
224146717|NCT02931526|DRUG|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
223448920|NCT02629042|DRUG|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
223448921|NCT04075136|DRUG|Ranibizumab|Intravitreal injection 0.5 MG Per 0.05 ML Injection.
224056821|NCT03313427|OTHER|Physical Therapy Early Intervention|"At the UCIN:~* Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~* Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
223448922|NCT04075136|DEVICE|Photodynamic laser treatment (PDT)|PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
223448923|NCT04075136|DRUG|Triamcinolone Acetonide|Intravitreal injection of 0.5ml-2mg
223569147|NCT06660953|PROCEDURE|Quadratus Lumborum Block (QLB)|The QL block II was done under aseptic technique, in lateral position with the side intended to block side up. A high frequency ultrasound linear probe covered in sterile sheath was placed anterior and superior to the iliac crest. The three anterior abdominal muscles were visualized. The external oblique muscle was followed posterolaterally until its posterior border was identified. Subsequently, the probe was tilted towards the attachment site of both the internal and external oblique muscles over the quadratus (QL) muscle until the midline of the thoracolumbar fascia was seen as a bright hyperechogenic line located between the posterior border of the quadratus lumborum muscle and the middle thoraco-lumbar fascia (anterior to latissiumus dorsi and erector spinae muscles). A 22-gauge Facet-tip SonoPlex needle of appropriate length estimated from the depth and length of required needle trajectory during scout scanning was inserted via in-plane technique. The needle was directed from a
223569148|NCT06658964|DRUG|Cohort 1: JMKX003142 and itraconazole|"JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD"
223569149|NCT06658964|DRUG|Cohort 2: JMKX003142 and rifampicin|"JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD"
223569150|NCT06658288|OTHER|Rebound Training|12 participants will be in experimental group A giving them rebound training.
223569151|NCT06658288|OTHER|Theraband resistance exercise|12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
224056822|NCT03313427|OTHER|Usual Care|NICU usual care
224056823|NCT05716880|DRUG|Ketosteril|Daily dose = 1 tabl / 5 kg of ideal body weight
224056824|NCT05716880|OTHER|Medium Protein Diet (MPD)|MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
224056825|NCT06355765|DIETARY_SUPPLEMENT|Citicoline blackcurrant supplement|Citicoline, Vitamins A, B, C and E, and Blackcurrant
223448924|NCT04075136|DRUG|verteporfin|Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
223448925|NCT04260568|OTHER|Semi-structured interviews|Patients with a diagnosis of 3PD will be sought from a multidisciplinary balance clinic. Consenting participants will take part in a face-to-face interview about their diagnosis. Data collection will consist of recorded semi-structured interviews, which will be transcribed.
223448926|NCT01658904|DRUG|Carfilzomib|
223448927|NCT01658904|DRUG|Melphalan|
223448928|NCT01658904|DRUG|Filgrastim|
223448929|NCT01459835|BEHAVIORAL|media diet|advice and tips and tools for healthy non violent TV viewing
223569152|NCT06659510|OTHER|education|ACCORDING TO THE RESULTS AFTER THE SURVEY APPLICATION, TRAINING WAS PROVIDED TO THE ADDICTIVE STUDENTS IN THE EXPERIMENT GROUP AND MESSAGES WERE SENT FROM WHATSAPP APPLICATION IN THE FOLLOWING 2 MONTHS AFTER THE TRAINING.
224056826|NCT00355433|PROCEDURE|Urodymanics|
223448930|NCT01459835|BEHAVIORAL|nutritional intervention|advice on healthy eating
223741800|NCT05023265|RADIATION|Stereotactic body radiotherapy|SBRT is a non-invasive treatment approach that delivers precise and highly conformal radiotherapy to the tumour with steep dose gradients that minimize exposure to the surrounding normal tissues.
223741801|NCT01721421|OTHER|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
223448931|NCT05537649|DIETARY_SUPPLEMENT|Oatmeal porridge|Investigation of the impact of enzymatic modification of the molecular structure of starch by amylomaltase on the postprandial glycemic responses of an oatmeal porridge.
223448932|NCT01941836|DRUG|ETC-1002|Patients receive ETC-1002
223448933|NCT01941836|DRUG|Ezetimibe|Patients receive ezetimibe
223741802|NCT01721421|OTHER|Standard treatment time|
224056827|NCT04795232|OTHER|COD45|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
224056828|NCT04795232|OTHER|COD90|Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
224056829|NCT06302907|PROCEDURE|Buffered Local anaesthesia|A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
224056830|NCT06302907|PROCEDURE|Unbuffered Local anaesthesia|an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.
224056831|NCT05453058|DIAGNOSTIC_TEST|plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort|"Biomarker assessments are mandated in this protocol (i.e., they are not expected to be done as part of routine clinical practice).~These assessments will be conducted within the same time window as the observational assessments (at approx. 6-month intervals) and are mandated by protocol if not conducted as per clinical practice."
223448934|NCT06528509|BEHAVIORAL|AI-Generated Informative Videos|"Participants in the experimental arm will receive an AI-generated video designed to provide comprehensive information about cataract surgery. The video will cover key aspects of the procedure, including the nature of the surgery, potential risks, benefits, and postoperative care. The video will be produced in English for Cohort A, and translated into Bengali for Cohort B.~The video will be delivered to participants via a secure link sent to their mobile devices or email. Patients can watch the video at their convenience, and they are encouraged to view it as many times as necessary to fully understand the information provided. The video link will be provided once after the initial clinic appointment, but patients can access and watch the video multiple times.~The videos will be created using the Synthesia platform, which uses artificial intelligence to generate realistic, photo-realistic digital avatars that deliver the information in a personalized and engaging manner."
223448935|NCT06528509|BEHAVIORAL|Standard Written Information Brochures|Participants in the control arm will receive traditional written information brochures about cataract surgery. These brochures are designed to deliver detailed and essential information in a clear and understandable format. The brochures will be handed to participants during their face-to-face clinic appointment. Patients can read the material at their convenience and keep it for future reference. These brochures follow standardized guidelines and recommendations to ensure that all relevant information is included and presented in an accessible manner. The leaflet will be supplied in English for Cohort A, and Bengali for Cohort B.
224056832|NCT02275078|BEHAVIORAL|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
224056833|NCT02275078|DEVICE|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
224056834|NCT02275078|OTHER|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
224056835|NCT01388673|PROCEDURE|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
224056836|NCT00466466|DRUG|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
224056837|NCT00075023|DRUG|Thalidomide Gel|
224056838|NCT00075023|DRUG|Placebo Gel|
224056839|NCT04458142|OTHER|Single buccal infiltration|painless technique for palatal anesthesia,single injection,single puncture given
224056840|NCT04342871|BEHAVIORAL|FACT|Customized communication guidance to help parents with cancer talk about their cancer with their children.
224056841|NCT03670953|DRUG|IR CD-LD|Active comparator - IR CD-LD
224056842|NCT03670953|DRUG|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
224056843|NCT03670953|OTHER|Placebo Matching IPX203|Double dummy placebo capsules
224056844|NCT03670953|OTHER|Placebo Matching IR CD-LD|Double dummy placebo tablets
223569153|NCT06659159|DIAGNOSTIC_TEST|Gastric ultrasound|"The sequence in which the study is conducted will be as follows, the first examination (baseline examination) will take place immediately before the appointment and prescription of GLP-1 Analoga (before the first injection). During the examination the gastric content (quality/quantity) will be determined, secondly, a baseline for gastric emptying time after oral intake of 500ml of water is collected (patient drinks water, the stomach emptying will simultaneously be tracked with gastric ultrasound).~In accordance with the first endocrinological control examination (6-8 weeks after therapy initiation) the same gastric ultrasound examination is performed."
224056845|NCT04179734|DRUG|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
224056846|NCT04179734|DRUG|Placebo|Placebo subcutaenous injection.
223741803|NCT03282188|BIOLOGICAL|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
224056847|NCT06073496|OTHER|Electroacupuncture|Patient receive analgetic medicine will get experimental procedure with needle insertion that attach to eletrostimulator
224056848|NCT04438473|DIETARY_SUPPLEMENT|pectin-supplemented enteral nutrition feeding|sequential supplementation with combination of 90ml pectin and 500ml enteral nutrition formula for 7 days
224056849|NCT04438473|OTHER|enteral nutrition feeding|standard formula enteral nutrition feeding without pectin for 7 days
224056850|NCT04268485|DIAGNOSTIC_TEST|Serum KL-6 level|Serum blood biomarker which has been shown to be of interest in idiopathic pulmonary fibrosis
224056851|NCT04503954|OTHER|Chronic disease self-management program|The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.
224056852|NCT04503954|OTHER|General psychiatric intervention|General psychiatric intervention contains the activities in psychiatric center.
224056853|NCT05378438|OTHER|Microbe literacy Program in the form of workshop|Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
224056854|NCT02229071|DRUG|Donafenib(200mg)|Donafenib 200mg,bid,po
224056855|NCT02229071|DRUG|Donafenib(300mg)|Donafenib 300mg,bid,po
224056856|NCT00899184|GENETIC|polymorphism analysis|
224056857|NCT00899184|OTHER|laboratory biomarker analysis|
224056858|NCT01078831|OTHER|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
224056859|NCT04395339|DRUG|Monosialotetrahexosyl ganglioside (GM1)|Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
224301137|NCT01201941|OTHER|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
224301138|NCT03358784|PROCEDURE|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
224301139|NCT03358784|PROCEDURE|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
224301140|NCT00364806|DRUG|Prochlorperazine|
224301141|NCT00364806|DRUG|Metoclopramide|
224301142|NCT02289235|DRUG|Ginger|Ginger powder capsule 1000 mg twice daily for 3 months
224301143|NCT02289235|DRUG|Placebo|Placebo powder 2 capsules twice daily for 3 months
224301144|NCT01889212|OTHER|11C-erlotinib PET/CT|
224301145|NCT00663767|DRUG|Placebo; oral|dose 1, dose 2
224301146|NCT00663767|DRUG|Placebo; oral|dose 1
224301147|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
224301148|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
224301149|NCT00663767|DRUG|Celecoxib, COX-2 inhibitor; oral|dose 1
224301150|NCT00663767|DRUG|Placebo; oral|dose 2
224301151|NCT00663767|DRUG|ARRY-371797, p38 inhibitor; oral|dose 2
224301152|NCT01355159|DRUG|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
224301153|NCT01355159|DRUG|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
224301154|NCT04819399|DRUG|Catumaxomab|"Procedure: 6 weekly intravesical administration at each dose level; 3 sequential cohorts consisting of 3 patients (part I)~1. cohort 50 µg~2. cohort 70 µg~3. cohort 100 µg~Part II will be treated at recommended dose"
224301155|NCT01194973|DRUG|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
224301156|NCT01131962|PROCEDURE|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
224056860|NCT04395339|DRUG|Control|250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
224056861|NCT03957837|DIAGNOSTIC_TEST|Optical nerve sheath diameter ultrasound measurement|"In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine"
224056862|NCT01683201|PROCEDURE|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
224056863|NCT01683201|PROCEDURE|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
224056864|NCT04509310|DEVICE|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
224301157|NCT02031952|PROCEDURE|hepatectomy combined with lymphadenectomy|
224056865|NCT03740750|DEVICE|Thermacare heat wraps|low level continuous heat wrap
224056866|NCT03740750|DEVICE|TENS|electrical stimulation
224056867|NCT03740750|DEVICE|sham heat|expended heat wrap
224056868|NCT03740750|DEVICE|sham Tens|tens applied but unit not turned on
224301158|NCT02031952|PROCEDURE|hepatectomy alone|
224301159|NCT00015028|DRUG|Buprenorphine/naloxone|
224301160|NCT00074737|DRUG|cenersen|cenersen with standard of care
224301161|NCT00074737|DRUG|Idarubicin|standard of care for AML
224301162|NCT00074737|DRUG|Cytarabine|standard of care Ara-C and High dose Ara-C
224301163|NCT01831453|DRUG|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
224301164|NCT01831453|DRUG|placebo|soft gelatinous capsules filled with isopropylmyristate oil
224301165|NCT04477772|BIOLOGICAL|JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion|Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
223448936|NCT00970515|PROCEDURE|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
223448937|NCT00970515|PROCEDURE|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
223448938|NCT01160094|DRUG|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
223448939|NCT04667533|DRUG|Desidustat|"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg"
223448940|NCT04333225|DRUG|Hydroxychloroquine|Weekly treatment in individuals at high risk
223448941|NCT02444039|DEVICE|SL-D301|Slit Lamp
223448942|NCT02444039|DEVICE|DC-4|Digital Camera Attachment
223448943|NCT02444039|DEVICE|SL-3G|Slit Lamp
223448944|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
223448945|NCT01703559|DRUG|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
223448946|NCT01703559|OTHER|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
223448947|NCT05921240|OTHER|observational study, no intervention|no intervention
223448948|NCT02795936|PROCEDURE|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
224056869|NCT00666458|DRUG|saxagliptin|tablet, per oral, once daily
224056870|NCT00666458|DRUG|sitagliptin|capsule, per oral, once daily
224056871|NCT00290615|BIOLOGICAL|bevacizumab|
223448949|NCT01456364|DRUG|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
223448950|NCT01456364|DRUG|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients \>= 75 years
223448951|NCT03972241|DEVICE|foot insole|arch support and toe extension
223448952|NCT02820181|DEVICE|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
223448953|NCT02820181|DEVICE|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
224146718|NCT01788280|DRUG|Fluciclitite , PET imaging, and Bevacizumab|\[18F\] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
223448954|NCT05911698|DEVICE|Fractional co2 laser|"The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction.~These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes."
223448955|NCT05237739|PROCEDURE|Non-Surgical Periodontal treatment (NSPT)|Participants will receive local anesthesia. Thorough debridement of the root surface will be completed to the depth of the periodontal pocket and of the furcation lesion, by using piezo-electric/ultrasonic devices with specific thin and delicate tips (such as Cavitron, Dentsply Sirona, US) and/or curettes. Treatment chair time will be recorded for each visit.
223448956|NCT05237739|PROCEDURE|Open Flap Debridement (OFD)|Patients will receive local anesthesia and intrasulcular incisions will be made by buccal and lingual/palatal aspects in order to reflect full-thickness flaps. After reflection of the flaps, the granulation tissue around the tooth will be removed with the non-cutting edge of a suitable scaling instrument such as a curette, taking care not to damage the root surfaces. Thorough debridement of the furcation area will be carried out by using piezo-electric/ultrasonic devices with specific thin and delicate tips
223448957|NCT05450406|OTHER|Physical activity|The participants will receive the possibility to attend weekly endurance, resistance and yoga exercise sessions administered by the Healthy Life Center. They will also receive personalized follow-up from the Healthy Life Center, and have the possibility to exercise at the local gym.
223448958|NCT01836185|DRUG|Evacetrapib|
223448959|NCT03078309|DRUG|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
223448960|NCT02811653|DEVICE|Brain MRI|
223448961|NCT02811653|OTHER|neuropsychological evaluation|
223448962|NCT02811653|BIOLOGICAL|Blood|
223448963|NCT01068587|DRUG|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
223448964|NCT01068587|DRUG|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
223448965|NCT01068587|OTHER|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
224056872|NCT00290615|BIOLOGICAL|cetuximab|
224056873|NCT00290615|DRUG|capecitabine|
224056874|NCT00290615|DRUG|oxaliplatin|
224056875|NCT02222207|DRUG|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
224056876|NCT02222207|PROCEDURE|Sham IVT|Sham injections
224056877|NCT02222207|DRUG|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
224056878|NCT02222207|DRUG|Placebo|Placebo eye drops
224056879|NCT03162770|BEHAVIORAL|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
224146719|NCT03466307|DEVICE|Ultrasonography|Ultrasonographic examination of shoulder
224301166|NCT04477772|BIOLOGICAL|Drug：JS001, Intravenous infusion|Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.
224301167|NCT02114476|DEVICE|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
224056880|NCT04027114|BEHAVIORAL|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
224056881|NCT05556499|DIAGNOSTIC_TEST|Biomarker assays|Circulating bone biomarkers assays
224301168|NCT02114476|DEVICE|Placebo|
223448966|NCT02356107|DRUG|5-hydroxytryptophan and Creatine monohydrate|
223448967|NCT01473225|OTHER|Calorie information|Nutrition label featuring calorie information will be provided.
223448968|NCT01473225|OTHER|No calorie information|No nutrition label will be provided in this condition.
223448969|NCT06188845|OTHER|Kinesio taping|Kinesio taping is a non-invasive physical treatment, which is breathable, hypoallergenic and elastic. Because of the mechanical properties and physiological effects, Kinesio taping has been thought to relieve pain, reduce swelling, support and relax soft tissue, promote motor performance, and correct posture or abnormal movement patterns.
223448970|NCT01209247|OTHER|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
223448971|NCT01140828|DRUG|Rabeprazole|Rabeprazole 20mg once daily
223448972|NCT01140828|DRUG|Rabeprazole Placebo|one tab once daily
223448973|NCT01296594|OTHER|Usual Care|Usual Care
223448974|NCT01296594|BEHAVIORAL|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
223448975|NCT00085813|DRUG|Ispinesib|
223448976|NCT02982044|OTHER|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
223448977|NCT02982044|OTHER|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
223448978|NCT02982044|OTHER|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
223448979|NCT05908747|DRUG|surufatinib + gemcitabine + nab-paclitaxel|surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W
223448980|NCT03079076|DRUG|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
223741804|NCT03282188|DRUG|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
223448981|NCT03079076|DRUG|Saline|2 ml saline subcutaneously bilaterally
223448982|NCT03293446|DIAGNOSTIC_TEST|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
223448983|NCT01603394|DRUG|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
223448984|NCT06217744|BEHAVIORAL|Automated Intervention|Participants will receive 6 psychoeducational modules design to increase mental health literacy: Module 1: The Stigma of Mental Illness, Module 2: Understanding Mental Health and Mental Illness, Module 3: Information on Specific Mental Illnesses, Module 4: Experiences of Mental Illness, Module 5: Seeking Help and Finding Support, Module 6: The Importance of Positive Mental Health.
223448985|NCT06217744|BEHAVIORAL|Blended Intervention|Participants will receive the same materials as the Automated Intervention, as well as the possibility to attend psychoeducational sessions held by licensed psychologists.
223448986|NCT01819844|DEVICE|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose \> 2 u/kg).
223448987|NCT04399538|DRUG|PF-06865571|Tablet
223448988|NCT04399538|DRUG|PF-05221304|Tablet
223448989|NCT04399538|DRUG|Placebo|Tablet
223448990|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
223448991|NCT01215435|DRUG|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
224056882|NCT03105687|BEHAVIORAL|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
223448992|NCT05704179|OTHER|Obstetric Quality of recovery score|Patients' quality of recovery will be evaluated with Obstetric Quality of recovery score (ObsQoR-11) on postpartum day 1 and day 2.
223448993|NCT00840034|DRUG|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
224056883|NCT01847482|DEVICE|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
223448994|NCT00840034|DRUG|Placebo|3 tablets PO QD for up to 12 weeks
224056884|NCT02878538|DRUG|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
223448995|NCT03420287|COMBINATION_PRODUCT|MPM Prepared From Allogenic Bone Graft|patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
224056885|NCT02878538|OTHER|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
223448996|NCT03420287|OTHER|Autogenous bone|patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
224056886|NCT02982954|DRUG|Nivolumab|Specified dose on specified day
223448997|NCT05866549|OTHER|Mindfulness-based Childbirth and Parenting Program|Mindfulness-based childbirth and parenting program will be applied to individuals in this group. The program consists of nine sessions, eight of which will take place during pregnancy. Sessions planned during pregnancy will be held once a week, lasting 8 weeks.
224056887|NCT02982954|DRUG|Ipilimumab|Specified Dose on Specified Day
223448998|NCT02870205|DRUG|GSP 301 NS|2 spray in each nostril twice daily for 14 days
223448999|NCT02870205|DRUG|GOM-NS|2 spray in each nostril twice daily for 14 days
223449000|NCT02870205|DRUG|GMM-2 NS|2 spray in each nostril twice daily for 14 days
223449001|NCT02870205|DRUG|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
223569154|NCT06659328|PROCEDURE|Structured Walking Intervention for Children with Autism Spectrum Disorder|"Participants: Thirty children with ASD will participate in the walking sessions.~Conditions: Each child will walk under three different speed conditions:~Normal Speed: 120 beats per minute (bpm) Slow Speed: 100 bpm Fast Speed: 140 bpm~Social Interaction: Each child will walk with two different types of adult companions:~Familiar Adult: A caregiver or individual known to the child. Unfamiliar Adult: An adult not known to the child. Procedure: The walking distance will be 10 meters. The adult will wear a metronome in an earbud to ensure that they maintain the prescribed walking speed, which the child will be instructed to follow. Each child will experience all combinations of walking speeds and social interactions, allowing for a comprehensive assessment of how these factors influence gait parameters.~Gait Parameters: The following parameters will be recorded during each walking session using video analysis software (Kinovea©):~Stride length Step time Cadence Velocity Joint amplitudes"
223569155|NCT06659198|PROCEDURE|total hip replacement|minimally-invasive hip replacement
223569156|NCT06608238|DRUG|D-MNA 200 mcg|D-MNA , (doxorubicin) patch, 200 mcg
223569157|NCT06608238|DRUG|D-MNA 100 mcg|D-MNA (doxorubicin) patch, 100 mcg
223569158|NCT06608238|OTHER|Placebo|P-MNA patch, placebo
223569159|NCT06607380|BIOLOGICAL|TNM002|A single intramuscular (IM) gluteal injection
223741805|NCT02738450|BIOLOGICAL|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
223741806|NCT02738450|BIOLOGICAL|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
224056888|NCT05407259|BEHAVIORAL|Resistance exercise|There will be four conditions (three exercises and one control) on visits 3-6. For the three exercise conditions, all training parameters except intensity will be the same. The sets in high, moderate, and low intensity correspond to the rate of perceived exertion (0-10 scale) 7-9, 5-6, and 3-4, respectively. Therefore, the participants will perform 5 repetitions barbell squat, barbell press, and barbell deadlift with 8RM (78% 1RM), 11RM (72% 1RM), and 16RM (65% 1RM) for 3 sets
224056889|NCT01272310|BIOLOGICAL|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is \< 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is \>= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
223449002|NCT00325624|DEVICE|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
223449003|NCT03557476|DIETARY_SUPPLEMENT|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
223449004|NCT03557476|DIETARY_SUPPLEMENT|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
223569160|NCT06607380|BIOLOGICAL|Adsorbed tetanus vaccine|A single IM deltoid injection
223569161|NCT06607380|BIOLOGICAL|TNM002 + adsorbed tetanus vaccine|A single IM gluteal injection+ a single IM deltoid injection
223569162|NCT06606717|DIETARY_SUPPLEMENT|Creatine Whey Protein|3 grams creatine + 30 grams whey protein
223569163|NCT06606717|DIETARY_SUPPLEMENT|Whey Protein|30 grams Whey Protein
223569164|NCT06607536|OTHER|calcium chloride surface treatment in mini implant|0.1M of Calcium Chloride were used to immersed the orthodontic mini implant
223569165|NCT06607536|OTHER|Acid Etched|Mini implant etched in Hydrochloric acid
223569166|NCT01793337|OTHER|Exposure to cold environmental temperature (-20°C)|
223569167|NCT06730698|OTHER|No intervention|No intervention
223569168|NCT06606379|DEVICE|I1 (Intervention)|Resin ring (DR- Resin ring, Egypt)
223569169|NCT06606379|DEVICE|I2 (Intervention)|Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)
223569170|NCT06606379|DEVICE|I3 (Intervention)|Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)
223741807|NCT02738450|BIOLOGICAL|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
223449005|NCT01420016|OTHER|Prioritized Clinical Decision Support|Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR \>= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
223449006|NCT05572372|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
223449007|NCT03071510|DEVICE|Atlas Genetics io® system|Specimen Collection
223449008|NCT05621967|BEHAVIORAL|Tonation Breathing Techniques|Tonation and Breathing Techniques (TBT): consist of a combination of organic inhalation and controlled exhalation with tonation. This will be guided by a trained facilitator, and the entire exercise will take 20 minutes. This will include guided relaxed breathing, mindful breathing, patterned tonation, nasal tonation, and pursed lip tonation.
223449009|NCT05621967|BEHAVIORAL|Music Driven Vocal Exercises|Music Driven Vocal Exercises (MDVE): A Music Therapy procedure will be implemented by a trained facilitator, utilizing an accompanying instrument (ie, guitar or Autoharp) and moving stepwise up and down within a scale of 8 whole steps. The total length of the procedure is 20-25 minutes. This will include vocal exercises, and melodic exercises alternating with speaking,
223449010|NCT05621967|BEHAVIORAL|Silent Breathing|Patient will sit in a quiet room and focus on silent breathing x 20 min.
223741808|NCT05126784|BIOLOGICAL|AVT03|AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection
224056890|NCT04858945|BEHAVIORAL|Teach-back method|During the trial, women from teach-back group and controlled group will receive three education sessions The topics discussed at the first session included delivery mode, labor process and pain relief, newborn health and care (common health issues and care skills), perinatal die and excises, and perinatal psychological health. The topics discussed at the second session includ postpartum recovery, postpartum maternal health, perineum care (diet, oral care, perineal care, and hygiene), breastfeeding, postpartum blue and depression, neonatal care, neonatal screening tests, newborn vaccination and early child development. At two-week postpartum, the educator answers questions raised by the woman and gives advices on the challenges and difficulties in postpartum recover and caring newborn faced by the woman.
224056891|NCT04772261|DIAGNOSTIC_TEST|13C-Spirulina GEBT|Various lots of 13C-Spirulina GEBT test meals
224056892|NCT02900079|DEVICE|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
224056893|NCT04262687|DRUG|Capecitabine|2000 mg/m²/day, from day 1 to 14 of each cycle
224056894|NCT04262687|DRUG|Oxaliplatin|130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle
224056895|NCT04262687|DRUG|Bevacizumab|7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle
224056896|NCT04262687|DRUG|Pembrolizumab|200 mg by IV infusion over 30 minutes, on day 1 of each cycle
224056897|NCT05058755|DRUG|tislelizumab, azacytidine, lenalidomide|"tislelizumab, 200mg, iv, day 1, every 21 days.~azacytidine, 75mg/m2, ih, days 1-7, every 21 days.~lenalidomide, 25mg, po, days 1-14, every 21 days."
224056898|NCT05058755|DRUG|tislelizumab, etoposide, pegaspargase|"tislelizumab, 200mg, iv, day 1, every 21 days.~etoposide, 100mg, iv, days 1-3, every 21 days.~pegaspargase, 2000U/m2, day 1, every 21 days"
223449011|NCT03602833|DRUG|Compound 451238|Each patient will receive compound 451238 until disease progression unacceptable toxicities.
223449012|NCT04026711|DRUG|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
223449013|NCT04026711|DRUG|Placebo oral tablet|Placebo daily for 12 weeks
223449014|NCT03447964|OTHER|dosing of sphingolipids|\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
223449015|NCT05112159|DRUG|IPG1094|The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.
223449016|NCT05112159|DRUG|placebo|Matching placebo tablets to IPG1094 50mg and 100mg
224056899|NCT04944511|DRUG|Toripalimab Injection|Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
224056900|NCT05086328|BEHAVIORAL|Nonviolent Resistance|Six two weekly sessions of two hours, based on nonviolent resistance Questionnaires pre and post intervention
224056901|NCT04216459|DRUG|oral lactobacillus probiotics plus intramuscular cholecalciferol|According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
224056902|NCT04216459|DRUG|intravenous vitamin C plus thiamine|starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
224056903|NCT03343587|DRUG|LY3375880 IV|administered IV
224056904|NCT03343587|DRUG|LY3375880 SC|administered SC
224056905|NCT03343587|DRUG|Placebo IV|administered IV
224056906|NCT03343587|DRUG|Placebo SC|administered SC
224056907|NCT02603120|DRUG|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
224056908|NCT02603120|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
224056909|NCT02603120|DRUG|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
224056910|NCT02603120|DRUG|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
224056911|NCT03094234|DEVICE|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
224056912|NCT03094234|PROCEDURE|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
224056913|NCT03094234|DRUG|Propranolol|Appropriate dose of propranolol was administered to the patients.
224056914|NCT01645189|BIOLOGICAL|Hunterase|once weekly, 0.5mg/kg IV infusion
224056915|NCT06156982|DRUG|Evusheld|Administration of Evusheld 600 mg
223449017|NCT05358977|BIOLOGICAL|Tisseel|Intraoperatively, the intervention side will receive topical administration of Tisseel to the blepharoplasty incision. A 2mL syringe of Tisseel product will be used as per the product monograph for an area of \< 8cm2. There will be no variation in surgical counselling or technique, with the exception of the use of Tisseel in one eyelid closure. Both eyelids will otherwise receive standard blepharoplasty surgical techniques. There will be no monitoring of compliance necessary, given the Tisseel will be utilized intraoperatively.
223569171|NCT06606379|DEVICE|C (comparator)|Nickel titanium 3D-fusion ring (Garrison, USA)
223569172|NCT03985410|DRUG|ETX2514|intravenous infusion
224056916|NCT03317041|OTHER|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
224056917|NCT01628445|DRUG|liraglutide|liraglutide titrated to 1.8 mg sc daily
224056918|NCT01628445|DRUG|placebo injection|placebo injected sc daily volume equal to active comparator
224056919|NCT06379737|BEHAVIORAL|Multi-systemic Rehabilitation|"Patients in group A underwent a 5-week rehabilitation cycle with two weekly sessions, totaling 10 sessions, in a health resort setting. The patients underwent treatments at two health resort facilities located in the Euganean Basin, Veneto, Italy, equipped with pools of the same depth, size, and water type. Each session was structured into four components:~1. thermal mineral-rich aerosol therapy (10 minutes);~2. dryland motor, respiratory, and proprioceptive rehabilitation in the gym (30 minutes);~3. mineral-rich aquatic aerobic, strengthening, and balance exercises (30 minutes);~4. cognitive enhancement interventions (30 minutes). Inhalation treatments and aquatic exercises utilized thermal mineral-rich water, specifically salsobromoiodic water, naturally springing at approximately 80°C and used in pools at a temperature of around 36°C. The chemical-physical properties of the thermal mineral-rich water employed are reported in Table I.~Patients in group B underwent a 5-week rehabilit"
224056920|NCT04031911|DEVICE|Hydroposturotherapy|"Hydroposturotherapy combines:~* posturotherapy (patient placed upside down with water jets sent to the kidneys)~* lumbar percussion~* hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
224056921|NCT04031911|DEVICE|Standard support in urology|Dispensing of AFU plugs Dietary advice
224056922|NCT00677651|PROCEDURE|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
224056923|NCT00677651|PROCEDURE|Blood sample|Blood will be sampled from an IV line
224056924|NCT00677651|RADIATION|CT Scan|Single image at the level of the liver
224146720|NCT05063617|DEVICE|SCI Step Together|The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
223449018|NCT02181218|DRUG|Romidepsin|
224146721|NCT03771807|DIETARY_SUPPLEMENT|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
224146722|NCT03771807|OTHER|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
223449019|NCT02181218|DRUG|Gemcitabine|
223449020|NCT02181218|DRUG|Oxaliplatin|
223449021|NCT02181218|DRUG|Dexamethasone|
223569173|NCT03985410|DRUG|Placebo|intravenous infusion
223449022|NCT02181218|DRUG|Pegfilgrastim|
223449023|NCT01904630|GENETIC|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
223449024|NCT06618547|DEVICE|TENEO 317 Model 2 excimer laser|TENEO 317 Model 2 excimer laser by Transepithelial Photorefractive Keratectomy
223449025|NCT06645821|DRUG|EVO101|EVO101 topical cream 0.1%
223449026|NCT05799404|DIAGNOSTIC_TEST|ultra-high resolution CT|stapes footplate thickness measurement
223569174|NCT03985410|DRUG|moxifloxacin|oral tablet
223569175|NCT04103541|BEHAVIORAL|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, \[and\] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
223741809|NCT05126784|BIOLOGICAL|Prolia|Prolia (denosumab) will be given as single subcutaneous injection
224056925|NCT00677651|RADIATION|DEXA|Whole body scan
224056926|NCT01973374|BEHAVIORAL|Text Message Intervention|
224056927|NCT06434194|DEVICE|Serranator PTA Serration Catheter|The Serranator PTA Serration Balloon Catheter is an over-the-wire balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
224056928|NCT06434194|DRUG|PTA (Standard of Care)|A percutaneous transluminal angioplasty catheter will be used to treat the target lesion.
224146723|NCT03771807|OTHER|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
224146724|NCT00801892|DEVICE|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
224146725|NCT00801892|DEVICE|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
224146726|NCT05779345|PROCEDURE|surgery|short implant placement
223449027|NCT07010380|DEVICE|PTFinder Dual-Channel NIR Autofluorescence Imaging System|Ex vivo, non-contact imaging of resected thyroid/parathyroid specimens; captures near-infrared autofluorescence and overlays it on white-light video to highlight parathyroid glands (2-5 min per specimen).
223449028|NCT07010380|OTHER|Offline Machine-Learning Algorithm (PTFinder-AI Beta)|training/validation on de-identified NIR/RGB frames.
223449029|NCT04006522|DRUG|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
223449030|NCT04006522|PROCEDURE|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
223449031|NCT07012577|OTHER|GPT-4 Assessment|Diagnostic/Prognostic evaluation of any single case provided by AI (GPT-4). GPT-4 provides diagnosis/treatment recommendations via standardized prompts
223449032|NCT07012577|OTHER|Arthroplasty Fellow Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
223449033|NCT07012577|OTHER|Specializing Resident (4th year) Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
223449034|NCT07012577|OTHER|Junior Resident (3rd year) Assessment|Diagnostic/Prognostic evaluation of any single case provided by an human expert
223449035|NCT07016594|BEHAVIORAL|Aerobic exercise|Aerobic exercise was done with and without neuromuscular electrical stimulation
224056929|NCT04639973|DIAGNOSTIC_TEST|Group 1 (First trimester ultrasound)|A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.
224056930|NCT04639973|DIAGNOSTIC_TEST|Group 2 (Second trimester anatomy ultrasound)|Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
224056931|NCT01572116|DRUG|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
224056932|NCT01572116|DRUG|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
224056933|NCT05091463|DEVICE|Biostim-5/Neostim transcutaneous spinal stimulator|Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
224056934|NCT00838773|BEHAVIORAL|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
224056935|NCT00838773|BEHAVIORAL|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
224056936|NCT00838773|BEHAVIORAL|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
223449036|NCT07015268|DRUG|KLH-2109|"\- KLH-2109 tablet: Oral administration~\- Leuprorelin acetate placebo: Subcutaneous administration"
223449037|NCT07015268|DRUG|Leuprorelin acetate|"\- KLH-2109 placebo tablet: Oral administration~\- Leuprorelin acetate: Subcutaneous administration"
223449038|NCT07016516|DRUG|PRT-064040 nasal spray|A single dose of PRT-064040 nasal spray at one of six dose levels
223449039|NCT07016516|DRUG|Placebo|A single dose of Placebo at one of six dose levels
223449040|NCT07016516|DRUG|PRT-064040 nasal spray|Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
223449041|NCT07016516|DRUG|Placebo|Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days
223449042|NCT00410059|DRUG|Erlotinib|150 mg by mouth daily x 28 days
223449043|NCT01530724|OTHER|Weight-loss diet strategy (+) exercise (PA)|Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training
223449044|NCT01530724|OTHER|weight loss (-) exercise (PA)|Weight-loss diet strategy without exercise
223449045|NCT02470663|DIETARY_SUPPLEMENT|DENSITYTM caplets (marketed as Amorphical)|supplementation
223449046|NCT02470663|DIETARY_SUPPLEMENT|Calcium carbonate 600 mg once daily|supplementation
224146727|NCT05246488|DIAGNOSTIC_TEST|American Orthopedic Foot and Ankle Association Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analog Scale (VAS)|All participants will receive two assessments, 7 days apart. After the demographic data of the patients are recorded with the form prepared by us, they will be evaluated with the AOFAS Midfoot Scale, Foot and Ankle Ability Measure/FAAM, SF-12 Quality of Life Scale, Visual Analogue Scale (VAS).
223449047|NCT07016932|BEHAVIORAL|Education with mobile application|"The I Can Do It Independently mobile application developed by the researchers includes two training videos on hand hygiene and menstruation management. Adolescents will be asked to play the games related to the training after watching the training videos. Thus, it is aimed for the participant to reinforce the training. The mobile application was developed by a multidisciplinary team of special education, nurse, midwife and software engineering academicians specifically for female adolescents with mild intellectual disabilities. Adolescents in the intervention group will be asked to use the mobile application for approximately 30 minutes every day. (https://play.google.com/store/apps/details?id=com.hookey.bagimsizyapabilirim\&pcampaignid=web\_share)"
223449048|NCT07020637|DEVICE|Cheetah NICOM|Bioreactance-based noninvasive cardiac output monitoring device used to measure stroke volume before and after passive leg raising. Used solely for observational measurement. No therapeutic intervention is performed.
224056937|NCT01748175|DRUG|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
223449049|NCT07022171|DEVICE|transcutaneous auricular vagus nerve stimulation|Half of the patients are randomized to the arm receiving transcutaneous auricular vagus nerve stimulation for a period of six weeks. Transcutaneous auricular vagus nerve stimulation will be carried out as an adjuvant, i.e. in addition to the regular treatment of the participants. The intervention will take place three times a day from Monday to Friday. Each of the three daily sessions is going to last 30-60 minutes, depending on patient tolerance.
224056938|NCT02281643|DRUG|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
224056939|NCT01035385|DRUG|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
224056940|NCT04609228|OTHER|Non-acceptance of blood-transfusions|Patients who do not accept blood products transfusions
224056941|NCT04609228|OTHER|Acceptance of blood-transfusions|Patients who accept blood products transfusions
224056942|NCT00529997|DEVICE|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
224146728|NCT01521806|DIETARY_SUPPLEMENT|Dietary Fiber|Dietary fiber will be added to snack foods
223449050|NCT07022171|DEVICE|sham transcutaneous auricular vagus nerve stimulation|Half of the patients are randomized to the arm receiving sham transcutaneous auricular vagus nerve stimulation for a period of six weeks. Sham transcutaneous auricular vagus nerve stimulation will be carried out as an adjuvant, i.e. in addition to the regular treatment of the participants. The intervention will take place three times a day from Monday to Friday. Each of the three daily sessions is going to last 30-60 minutes. The procedures for sham tVNS will be identical to tVNS, with the only exception that the sham tVNS will be performed with no current output
223449051|NCT07022561|BEHAVIORAL|Social Prescribing|A social prescribing intervention is a non-clinical approach to improving health and wellbeing by connecting individuals to community-based services and activities that address social, emotional, and practical needs. These may include arts programs, physical activity, peer support, volunteering, or nature-based activities. Facilitated by a link worker or navigator, social prescribing is tailored to the individual and aims to enhance mental health, reduce isolation, and support overall wellness beyond traditional medical care.
223449052|NCT07021651|PROCEDURE|Erector Spinae Plane (ESP) block admistring|In the ESPB group, the probe was placed longitudinally at the level of the T5 transverse process, 2-3 cm lateral from the midline. The muscles were visualized superior to the transverse process ; then, the needle was inserted in the craniocaudal direction using the in-plane technique. A dose of 2 mL normal saline were injected into the two layers of the interfacial area under the erector spinae muscle, and the proper injection site was confirmed. After visualizing the linear spread of saline in the fascial plane, 20 mL of 0.25% bupivacaine was injected there for the block.
223449053|NCT07021651|PROCEDURE|Thoracic Paravertebral Block administring|In the TPVB group, the probe was placed 2-3 cm laterally and vertically of the T5 spinous process. Once the transverse process, corresponding paravertebral space, internal intercostal membrane, and pleura was identified , the needle was inserted in the lateromedial direction using the in-plane technique. After confirmation of pleural displacement with 2 mL saline, 20 mL of 0.25% bupivacaine was administered for the block.
223449054|NCT06632678|OTHER|behavior, procedure, diet, exercise, device, education, and any other|Any type of intervention except pharmacological interventions (drugs, biologicals, genetics)
223449055|NCT02314312|DRUG|Everolimus + low dose cyclosporin A + prednisolone|
223449056|NCT02314312|DRUG|Standard immunosupressive regimen|
223449057|NCT07027098|PROCEDURE|Perflurocarbon liquid|Used to facilitate surgery of retinal detachment to stabilise macular during surgery.
224056943|NCT00983177|DRUG|Colchicine|0.5 mg twice daily for 4 months
224056944|NCT00983177|DRUG|lactose|lactose capsules twice daily
224056945|NCT00176605|DRUG|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
224056946|NCT00176605|DRUG|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
224056947|NCT02288936|DRUG|Enzalutamide|Enzalutamide 160 mg/day
224146729|NCT02468206|PROCEDURE|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
224146730|NCT02468206|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
223449058|NCT07027098|PROCEDURE|Without Perflurocarbon liquid|Standard retinal detachment surgery (vitrectomy) without the use of Perflurocarbon liquid (PFCL).
223741810|NCT00706407|DEVICE|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
223741811|NCT03043989|DRUG|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
223741812|NCT03043989|DRUG|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
224056948|NCT04552275|DIAGNOSTIC_TEST|Proteomics Analysis|Determine a panel of circulating proteins that discriminates between patients with and without Hypo-Attenuated Leaflet Thickening (HALT)
223741813|NCT03043989|DRUG|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
223741814|NCT03913884|PROCEDURE|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
224056949|NCT01321710|BEHAVIORAL|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
224056950|NCT01321710|BEHAVIORAL|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
224056951|NCT01321710|DRUG|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
224056952|NCT01234974|DRUG|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
224056953|NCT01234974|DRUG|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
224146731|NCT02468206|DRUG|N-butyl-2-cyanoacrylate|
224146732|NCT02468206|DRUG|Lauromacrogol|
224146733|NCT05450744|DRUG|131I-IPA|131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously
224146734|NCT00647972|DRUG|Olanzapine Tablets 20 mg|20mg, single dose fasting
224146735|NCT00647972|DRUG|Zyprexa® Tablets 20 mg|20mg, single dose fasting
223449059|NCT07027332|DIAGNOSTIC_TEST|FibroScan® (Echosens, Paris, France)|A non-invasive liver elastography device used for clinical assessment. Liver steatosis and stiffness are measured in participants using the FibroScan device.
223449060|NCT00194194|BEHAVIORAL|moderate|moderate behavioral management with RD
223449061|NCT00194194|DEVICE|Resting Metablic Rate measurements|intensive behavior management
223449062|NCT07027449|BEHAVIORAL|Screening and Referral Workflow|The Screening and Referral Workflow intervention will include screening eligible patients for employment-related needs and referring those who require support to community-based employment resources.
223449063|NCT07026032|OTHER|Biofeedback tool|Biofeedback tool (tongueometer) will be used for experimental group, where as for control group the intervention used in traditional exercises.
223449064|NCT07026032|OTHER|traditional exercises|traditional exercises were used for the control group
223449065|NCT05443750|BEHAVIORAL|Motivational Behavioral Economic Alcohol Intervention|The intervention combines an alcohol brief motivational intervention (US-THRIVE \[Tertiary Health Research Intervention via Email\]) with the Substance-Free Activity Session (SFAS), shown to reduce drinking and related negative consequences by increasing future orientation and engagement in pro-social alternatives to drinking. The intervention will be delivered using a web-based platform appropriate for the young adult target population whose social networks operate through such communications.
223449066|NCT05443750|BEHAVIORAL|Health Education|Participants view web-based health educational material about alcohol, sleep, and nutrition of a similar length and style to the experimental intervention materials.
223449067|NCT05703464|DRUG|Elobixibat 10mg|Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
223449068|NCT02253576|OTHER|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
223449069|NCT02253576|OTHER|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
223449070|NCT06703034|OTHER|Biological Sampling|"The procedures specifically carried out for the study during a single visit are as follows:~* 1 nasopharyngeal swab for the baseline measurement of the nasal IFN-I score and to check for the presence of infection~* Blood sample collection in:~o1 yellow tube (5mL) for anti-interferon antibody measurement o1 PAXgene tube (2.5mL) for the baseline IFN score without stimulation o3 green heparin tubes (12mL) for performing immune-functional tests o2 large purple tubes (20mL) for biological collection (if the patient provides specific consent) oA total of 39.5mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota."
223449071|NCT03358680|DEVICE|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
223449072|NCT06731881|DEVICE|Nasal PDT|Two two-minute cycles will be provided by a member of the research team in the pre-operative area on the day of surgery. A saturated swab containing 0.01% methylene blue and 0.25% chlorhexidine gluconate will be applied to nares, which is then activated by light.
224056954|NCT03709238|BEHAVIORAL|Thermal stimulation|Thermal stimulation
224056955|NCT01227187|DRUG|Drotrecogin alfa activated (Xigris)|We will test different dose regimens of Drotrecogin alfa activated (Xigris) to determine the optimal dose to achieve PTT between 65 and 100 secs. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via pre-filter arterial drip chamber via a standard IV pump. The PTT will be assessed at baseline,15,30,60,120 and 180 mins. Xigris dose will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains \<65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
224056956|NCT01761292|DRUG|Givinostat|Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
223449073|NCT06731881|COMBINATION_PRODUCT|Photosensitizer formulation only|Nares will be swabbed with Photosensitizer formulation (0.01% methylene blue with 0.25% chlorhexidine solution). Nasal swab cultures will be obtained before control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days). Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic LK Score will also be obtained before treatment at 2 weeks (+/-7 days).
224056957|NCT05913661|DRUG|Pemigatinib|Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.
223569176|NCT05326932|PROCEDURE|Mechanical thrombectomy|Subjects in intervention group will receive MT as soon as possible. Investigators and clinicians should strive to reduce delays of pre-surgery procedure and follow the local standard guideline of MT during the operation and perioperative period. All CFDA approved devices are allowed in this trial. Angioplasty and stent placement can be performed at the discretion of the physicians. Base on site experience, the randomization-operation start period should be within 60 minutes.
223569177|NCT06658262|OTHER|Tai Chi Exercises With Cycling Exercises|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. Participants will be assisted to safely mount the ergometer bicycle. The height of the seat will be adjusted to ensure postural balance, upright seating and firm contact of the feet with the pedals. Treatment for the cycling will last for 30 minutes per session.
223741815|NCT03913884|OTHER|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
224056958|NCT05913661|DRUG|PD-1 Inhibitors|The dosing regimen is 200 mg IV Q3W
224056959|NCT05744089|DEVICE|PCA pump|simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
224146736|NCT06094972|BEHAVIORAL|Adolescent Community Reinforcement Approach, A-CRA|A-CRA consists of eighteen treatment modules/procedures that is delivered in weekly sessions over 12-14 weeks. The overarching goal is to decrease substance use behaviours and other related, problematic behaviours such as acting out when experiencing anger, and to increase prosocial and sober behaviours, relationships and activities. The procedures are: 1) Introduction to A-CRA/treatment agreement, 2) Happiness scale and treatment goals, 3) Homework, 4) Systematic encouragement, 5) Functional analysis of substance use behaviour, 6) Functional analysis of prosocial/sober behaviour, 7) Increasing prosocial activities, 8) Drink/drug refusal, 9) Relapse prevention, 10) Sobriety sampling, 11) Communication skills, 12) Problem-solving, 13) Caregiver sessions, 14) Relationship skills, 15) Couple relationship skills, 16) Job-seeking skills, 17) Anger management, 18) Medication adherence and monitoring. Youths' individual goals and problems guide treatment planning.
223449074|NCT06731881|OTHER|Standard follow-up|All patients will receive standard post-operative wound follow up. This might include being advised to contact the GP or the hospital if there are any wound problems and, or, being invited to an out-patient clinic appointment.
223449075|NCT06731881|DIAGNOSTIC_TEST|Nasal culture|Nasal swab cultures will be obtained before Nasal PDT or control swabbing and converted to colony-forming units to measure bacterial burden at baseline, and after treatment (2 weeks +/- 7 days).
223449076|NCT06731881|DIAGNOSTIC_TEST|Flexible nasendoscopy|Sinonasal mucosal inflammation using the Flexible Nasendoscopy Endoscopic Lund-Kennedy (LK) Score will also be obtained before Nasal PDT or control swabbing and at 2 weeks (+/-7 days).
223449077|NCT06731881|OTHER|In-person review|On Week 2 (±7 days), the participant will undergo an in-person review conducted in the ENT Outpatient department, 2nd floor Southwark wing, Guy's Hospital by the CI, PI or Co-investigator. During this appointment, concomitant medications and use of post-operative antibiotics will be reviewed.
224056960|NCT01880671|DEVICE|Inactive Migraine Medical Device|
224056961|NCT01880671|DEVICE|Migraine Medical Device|
224056962|NCT01407770|GENETIC|DNA analysis|Genetic
224056963|NCT01407770|GENETIC|gene expression analysis|Genetic
224056964|NCT01407770|OTHER|enzyme-linked immunosorbent assay|Genetic
223741816|NCT03169582|DRUG|Avanafil|Drug administration (Avanafil)
223741817|NCT03169582|DRUG|Sildenafil|Drug administration (Sildenafil)
224056965|NCT01407770|OTHER|flow cytometry|Genetic
224056966|NCT01407770|OTHER|laboratory biomarker analysis|Genetic
224056967|NCT01407770|OTHER|questionnaire administration|Genetic
224056968|NCT01407770|PROCEDURE|adjuvant therapy|Genetic
224056969|NCT01407770|PROCEDURE|assessment of therapy complications|Genetic
224056970|NCT01407770|PROCEDURE|quality-of-life assessment|Genetic
224056971|NCT01407770|RADIATION|3-dimensional conformal radiation therapy|Genetic
224056972|NCT01407770|RADIATION|breast irradiation|Genetic
224056973|NCT01407770|RADIATION|external beam radiation therapy|Genetic
224056974|NCT01407770|RADIATION|hypofractionated radiation therapy|Genetic
224056975|NCT01407770|RADIATION|intensity-modulated radiation therapy|Genetic
224056976|NCT01407770|RADIATION|whole breast irradiation|Genetic
224056977|NCT00840086|DRUG|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
224056978|NCT01916837|OTHER|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
224056979|NCT01916837|OTHER|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
224056980|NCT01916837|PROCEDURE|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
224056981|NCT03332498|DRUG|Pembrolizumab|200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
224056982|NCT03332498|DRUG|Ibrutinib|Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
224056983|NCT05311124|DEVICE|Integra Dermal Regeneration template (IDRT)|Integra Dermal Regeneration Template is a two-layer skin regeneration system. The outer layer is made of a thin silicone film that acts as your skin's epidermis. It protects the wound from infection and controls both heat and moisture loss. The inner layer is constructed of a complex matrix of cross-linked fibers. This porous material acts as a scaffold for regenerating dermal skin cells, which enables the re-growth of a functional dermal layer of skin. Once dermal skin has regenerated, the silicone outer layer is removed and replaced with a thin epidermal skin graft.
224056984|NCT03889314|DRUG|Rosuvastatin 20mg|Statin Therapy
224056985|NCT03889314|OTHER|Placebo|Placebo
224056986|NCT02361502|DRUG|mirabegron|
224056987|NCT02361502|DRUG|placebo|
223449078|NCT06731881|OTHER|Telephone Follow-up|"On day 30, the research nurse will telephone participants from the ENT research office.~* Review of adverse events/adverse device effects~* Review of concomitant medications~* Signs and symptoms post-surgery~* Nasal washout~* Record any use of post-operative antibiotics, both local and systemic"
223449079|NCT02336347|DRUG|AVP-786|
223449080|NCT02336347|DRUG|AVP-923|
223449081|NCT05612464|OTHER|No intervention|No intervention
224056988|NCT01750385|DRUG|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
224056989|NCT01750385|DRUG|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
224056990|NCT05953142|DRUG|Dobutamine|Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
224056991|NCT00003283|DRUG|octreotide acetate|
224056992|NCT00003283|DRUG|prednisone|
224056993|NCT00658476|DIETARY_SUPPLEMENT|Fish Oil|Omega-3 fatty acid supplements.
223449082|NCT02467894|OTHER|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
223449083|NCT04672876|DRUG|Telotristat Ethyl Oral Tablet|XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy. The drug is currently FDA-approved for this use but this study has received special approval from the FDA (under an Investigational Drug Application) to study telotristat ethyl in individuals with carcinoid tumors who plan to undergo surgery.
223449084|NCT03795662|OTHER|No intervention|Obervational
223449085|NCT05546320|DRUG|Aspirin 100mg|Anticoagulation or anti-platelet or migraine medication therapy will be provided for different groups.
224056994|NCT00658476|BEHAVIORAL|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
224056995|NCT00658476|OTHER|Placebo|
224056996|NCT01908023|BEHAVIORAL|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
224056997|NCT05627284|PROCEDURE|Stoma reversal with bio-mesh placement|Patients will receive stoma reversal. During the surgery, a bio-mesh is placed beyond the peritoneum on the surgical site to strengthen the abdominal wall.
224056998|NCT05285241|OTHER|Multidirectional stepping exercises|These exercises included stepping of the legs in different directions i.e. sideways, sideways and forefoot (forward), sideways and heel (backward).
224056999|NCT05285241|OTHER|Conventional physiotherapy group|Conventional physiotherapy included a one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min)
224057000|NCT01433237|GENETIC|RNA analysis|
224057001|NCT01433237|GENETIC|gene expression analysis|
224057002|NCT01433237|OTHER|laboratory biomarker analysis|
224057003|NCT01492608|DRUG|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
224057004|NCT04036708|BEHAVIORAL|Wetting method (WTM)|The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.
224057005|NCT04036708|BEHAVIORAL|Mediational Intervention for Sensitizing Caregivers (MISC)|The study team used MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
224057006|NCT01263171|DRUG|Leucovorin|
224057007|NCT01263171|DRUG|fluorouracil|
224057008|NCT01263171|DRUG|leucovorin calcium|
223449086|NCT05546320|DRUG|Metoprolol 25 Mg Oral Tablet|Metoprolol 25mg will be provided for the participants twice a day.
223449087|NCT05546320|DRUG|Clopidogrel 75mg|Clopidogrel 75mg will be provided for the participant once a day.
223449088|NCT05546320|DRUG|Rivaroxaban 20mg|Rivaroxaban 20mg will be provided for the participant once a day.
224057009|NCT01263171|DRUG|oxaliplatin|
224057010|NCT01263171|PROCEDURE|adjuvant therapy|
224057011|NCT01263171|PROCEDURE|neoadjuvant therapy|
224057012|NCT01263171|PROCEDURE|therapeutic conventional surgery|
224057013|NCT01263171|RADIATION|radiation therapy|
224057014|NCT03656679|PROCEDURE|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
224057015|NCT03656679|PROCEDURE|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
224057016|NCT04066582|DEVICE|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
224057017|NCT02131558|PROCEDURE|ICG Dye|ICG Dye injections
224057018|NCT00639483|DRUG|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
224057019|NCT00639483|DRUG|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
224057020|NCT00236834|DRUG|levofloxacin; imipenem/cilastitin|
224057021|NCT02538016|DRUG|Tolvaptan|
224057022|NCT01110616|DRUG|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
224057023|NCT01110616|DRUG|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
224057024|NCT01110616|DRUG|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
224057025|NCT01417598|OTHER|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
224057026|NCT01417598|OTHER|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
224057027|NCT05800548|OTHER|survey application|In data collection; Socio-demographic and obstetric characteristics of puerperant women, descriptive information form including questions about current birth, Postpartum Family Planning Attitude Scale The Health Literacy Scale was used.
224057028|NCT03218098|PROCEDURE|Lobectomy via UVATS|lobectomy with small skin access 4 cm
224057029|NCT05941325|DRUG|fruquintinib|VEGF receptor tyrosine-kinase inhibitor：fruquintinib（4mg), Oral，qd, d1-d14, Q3w，Until disease progression or intolerable toxicity occurs.
224057030|NCT05941325|DRUG|Envafolimab|anti-PD-1 immune checkpoint inhibitor：Envafolimab（400mg), subcutaneous injection, d1, Q3w，Until disease progression or intolerable toxicity occurs.
224057031|NCT04146779|BEHAVIORAL|Yoga Video|A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.
224057032|NCT04146779|BEHAVIORAL|Posture and Strengthening Video|The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.
224057033|NCT04146779|BEHAVIORAL|Relaxation Video|The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes
224057034|NCT04146779|BEHAVIORAL|Breath Work Video|The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.
224057035|NCT04146779|BEHAVIORAL|Satisfaction Survey|Participants will complete a questionnaire addressing satisfaction with the yoga program.
224057036|NCT04146779|BEHAVIORAL|Guided Yoga Session|Instructor guided yoga session twice a week
224057037|NCT04146779|BEHAVIORAL|Written Yoga Instructions|Introduction to Yoga and Yoga poses
224057038|NCT05246020|PROCEDURE|HIPEC|Docetaxel (60-75mg/m2) perfusion solution will be infused into the peritoneal cavity through the tubes within 24 hours after the laparoscopic evaluation. Then, perfusate containing cisplatin (75 mg/m2) will be infused 24 hours later. NHIPEC will be administered at 43°C for a duration of 60min. Saline solution (3000mL) will be used to dissolve the drug, and it will be heated and circulated at a flow rate of 300-500 mL/min.
224057039|NCT05246020|PROCEDURE|intravenous chemotherapy|Patients in the control group will receive three cycles of intravenous NACT. The regimen of intravenous NACT is docetaxel 60-75mg/m2 followed by carboplatin AUC 5 for a 21-day cycle.
224057040|NCT01444742|DRUG|Clofarabine|"Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"
224057041|NCT01444742|DRUG|Cytarabine|"Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)"
224057042|NCT04812431|BIOLOGICAL|Neural precursor cells derived from human embryonic stem cell line|When the Dose Limiting Toxicity (DLT) is not presented in the first three subjects administered with PSA-NCAM(+) NPC, two additional patients are added to the clinical study.
223449089|NCT03373357|OTHER|Patient not SAHOS|"Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~* Cardiovascular events arisen during the duration of the study~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
223449090|NCT03373357|OTHER|Patient SAHOS sailed by the ventilation in PPC and not sailed|"Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~* Questionnaire of evaluation of the global quality of life of the SAHOS~* Appearance of new cardiovascular risk factors~* Cardiovascular events arisen during the duration of the study~* Modification of the current treatments~* Modifications of the lifestyle: alcohol, physical activity~* Weight~* Clinical measure of the PA~* Clinical examination~* The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
223449091|NCT00994799|DRUG|ranibizumab|10mg/ml intravitreal injection
223449092|NCT00994799|RADIATION|macular grid-pattern laser|macular grid-pattern laser therapy
224057043|NCT03151720|DRUG|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
224057044|NCT03151720|DRUG|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
223449093|NCT00573586|DEVICE|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
223449094|NCT01897766|DRUG|Somatropin|0.23 mg to 0.48 mg/kg/week
223449095|NCT02179749|DRUG|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
223449096|NCT02179749|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
223449097|NCT02179749|DRUG|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
223449098|NCT06820723|DRUG|CYB003|synthetic, deuterated isotopomer of psilocin
223449099|NCT06820723|DRUG|Placebo|Placebo orange drink solution
223449100|NCT06811298|OTHER|Breast massage|The breast massage group will receive a 15-minute breast massage administered by the researchers at postoperative Day 0, Hour 3, and Hour 24. The aim of this intervention is to increase lactation. Following the interventions, mothers will be asked to breastfeed their infants, and the infants will be weighed both before and after breastfeeding.
223569178|NCT06658262|OTHER|Tai Chi Exercises Alone|Tai Chai exercises include Ward Off: This movement involves extending and redirecting energy, promoting stability and balance through controlled shifts in weight and posture. Grasp Sparrow's Tail: It comprises a series of movements that emphasize weight shifting, coordination, and maintaining a stable stance, all of which contribute to improved balance and gait. 3.Single Whip: This movement focuses on shifting weight smoothly from one foot to the other while maintaining proper alignment, helping to enhance proprioception and stability. 4.Brush Knee and Twist Step: By incorporating controlled twists and steps, this movement helps to improve coordination, strengthen leg muscles, and refine gait dynamics. 5.Part the Wild Horse's Mane
224057045|NCT06159920|DIAGNOSTIC_TEST|diagnostic accuracy|The aim of this retrospective study is to evaluate the diagnostic and prognostic value of PET/MRI and PET/CT with the use of different radiopharmaceuticals (68Ga-DOTATOC -edotreotide, and 18F-FDG - fluorodeoxyglucose) for the study of patients suffering from neuroendocrine tumors. To this end, both traditional imaging parameters and the contribution of radiomic features will be investigated. The latter are quantitative features extracted from biomedical images, and are believed to be able to provide information, otherwise impossible to investigate, useful for the characterization of various pathologies.
224146737|NCT06094972|BEHAVIORAL|TAU|Standard care is defined as the interventions and treatments adolescents are usually offered and undergo in institutional care in Sweden. These are Motivational Interviewing, MI, Cognitive Behavioral Therapy, CBT, Aggression Replacement Therapy, ART or Acceptance and Commitment Therapy, ACT and PULS, a program for reducing violence and criminal behavior. Also, individually tailored interventions will be included, such as counselling or other psychological interventions. TAU will be thoroughly registered during the study since the sites in the trial differs slightly in what they offer.
223569179|NCT06659107|PROCEDURE|Closed reduction and fixation by K- wires|Fixation by k-wires with mutual linking technique
223741818|NCT02297269|DEVICE|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
223741819|NCT02297269|DEVICE|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
224057046|NCT02690870|DRUG|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
224057047|NCT02690870|DRUG|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
224057048|NCT03494751|DEVICE|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
224057049|NCT03494751|DEVICE|No heart monitor|Standard monitoring by nurses.
224146738|NCT06415162|OTHER|Cooling Pillowcases|No intervention will be given to the patients in the control group.
223569180|NCT06660992|DRUG|HSK31858, tablet|HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis
223569181|NCT06660992|DRUG|Placebo|the placebo comparator of study
224057050|NCT03739398|DEVICE|LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))|1\. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
224057051|NCT03739398|DEVICE|LASEMED laser(The Thulium laser with 1,927nm wavelength)|"2\. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging."
224057052|NCT02535715|DRUG|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
224057053|NCT02535715|DRUG|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
224057054|NCT02535715|DRUG|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
224057055|NCT00909181|DRUG|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
224057056|NCT00909181|DRUG|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
224057057|NCT01227486|DEVICE|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
224057058|NCT01030770|DRUG|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
224057059|NCT01030770|DRUG|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
224057060|NCT00086203|DRUG|Talabostat mesylate (PT-100) tablets|
224057061|NCT00086203|DRUG|Rituximab|
224057062|NCT05950984|OTHER|Drug Infusion Pump Monitoring|Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
224057063|NCT02933034|DRUG|Manganese-enhanced MRI contrast reagent|MRI using manganese-enhanced MRI contrast reagent (manganese 0.28 mL/kg).
224057064|NCT02933034|DRUG|Gadolinium-enhanced MRI contrast reagent|MRI using gadolinium-enhanced MRI contrast reagent (gadolinium 0.2 mmol/kg).
224057065|NCT02506595|BEHAVIORAL|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
224057066|NCT01713842|DRUG|TCZ|Tocilizumab at week 0, 4 and 8.
224057067|NCT02349048|DRUG|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
224057068|NCT02349048|DRUG|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
224146739|NCT01016678|DRUG|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
224146740|NCT01016678|DRUG|Placebo|Dummy pill comparator
224146741|NCT00962754|PROCEDURE|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
224146742|NCT01233700|BEHAVIORAL|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
224146743|NCT01233700|BEHAVIORAL|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
223569182|NCT06659068|DIETARY_SUPPLEMENT|Seluang fish oil (Rasbora argyrotaenia) and synbiotic|The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation
223569183|NCT06659068|DIETARY_SUPPLEMENT|Placebo|Patients received placebo capsules
224057069|NCT02349048|DRUG|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
224146744|NCT01126684|DRUG|Atorvastatin|10 mg of atorvastatin once daily for six months
223449101|NCT06811298|OTHER|Virtual Reality|Postpartum women who undergo virtual reality headset application will watch a 15-minute river and forest video using the headset on postoperative day 0, hour 3, and hour 24. This intervention aims to help them feel in a relaxing and soothing environment and to increase lactation. Following the interventions, mothers will be asked to breastfeed their infants, and the infants will be weighed both before and after breastfeeding.
223449102|NCT02780960|DEVICE|HPV self-testing|Patients will perform HPV testing themselves at home.
223449103|NCT05175950|BIOLOGICAL|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03|SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose
223449104|NCT05175950|OTHER|Normal saline|Normal saline
223569184|NCT06661512|OTHER|Neurorehabilitation program|"Participants will participate in a neurorehabilitation program, consisting in a structured, interdisciplinary approach designed to help individuals improve their functional abilities following acquired brain injury. The goal is to optimize the individual's physical, cognitive, emotional, and social functioning to enhance their quality of life~The neurorehabilitation program includes, physical rehabilitation, occupational therapy, speech therapy and neuropsychological rehabilitation (cognitive, emotional and behavioral)."
223569185|NCT06657885|DRUG|his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi|"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
224057070|NCT02219282|OTHER|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
224057071|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
224057072|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
224057073|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
224057074|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
224057075|NCT00653614|DRUG|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
224057076|NCT00653614|DRUG|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
224057077|NCT00653614|DRUG|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
224057078|NCT00653614|DRUG|Placebo|Placebo administration in each arm
224057079|NCT04070027|PROCEDURE|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
224146745|NCT01126684|DRUG|Placebo|placebo once daily for six months
224146746|NCT04984460|DIAGNOSTIC_TEST|Fluorescence morphological detection of liquid-based thin-layer film-making fungi|"Samples from outpatient or inpatient clinics to be tested for fungal vaginitis. A sample of one or more of the following characteristics. Symptoms: vulva pruritus, burning pain, but also accompanied by pain in urine and sexual pain and other symptoms; Leucorrhea increased.~Physical signs: Vulva flushing, edema, visible scratches or chaps, white membrane attached to the inner side of the labia minora and the vaginal mucosa, more white bean residue like secretions can be seen in the vagina, which can be curd.~Samples are human vaginal secretions. Each sample should be the amount on one swab.~The sample is not in menstrual period. The sample subjects did not have vaginal irrigation, medication or sexual intercourse within 3 days."
224057080|NCT04070027|OTHER|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
224057081|NCT02286414|DRUG|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
224057082|NCT02286414|DRUG|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
224057083|NCT01322464|DRUG|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
224057084|NCT01322464|DRUG|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
224057085|NCT01322464|DRUG|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
224057086|NCT01322464|DRUG|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
224146747|NCT03690947|DRUG|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
224057087|NCT02146508|PROCEDURE|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
224057088|NCT02146508|DEVICE|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
223449105|NCT02756364|DRUG|Fulvestrant|Fulvestrant IM injection.
223449106|NCT02756364|DRUG|Sapanisertib|Sapanisertib capsule.
223449107|NCT00793546|DRUG|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
224057089|NCT00094770|DRUG|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
224057090|NCT00094770|DRUG|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
224057091|NCT04347915|DRUG|Clevudine|Clevudine 120mg once a day for 14 days (up to 21 days)
224057092|NCT04347915|DRUG|Placebo|Matching Placebo once a day for 14 days (up to 21 days)
224057093|NCT00779480|DRUG|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
224146748|NCT03690947|PROCEDURE|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
224146749|NCT03690947|DRUG|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
223449108|NCT00793546|DRUG|exemestane|25 mg tablet once daily
223449109|NCT00793546|DRUG|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
223449110|NCT01334580|BEHAVIORAL|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
223449111|NCT01334580|BEHAVIORAL|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
223449112|NCT00113191|DRUG|Veronate|
223449113|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
223449114|NCT04312594|DRUG|Jaktinib Hydrochloride Tablets|Patients were administered Jaktinib taken orally as tablets twice daily
223449115|NCT04312594|DRUG|Placebo|Patients were administered Placebo taken orally as tablets twice daily
223449116|NCT01841567|DEVICE|Mepilex border post. op|
223449117|NCT01841567|DEVICE|Mepilex border post op|
223449118|NCT01416155|DRUG|natalizumab|
223449119|NCT02841956|OTHER|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
223449120|NCT02841956|OTHER|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis \& building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms \& changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy \& treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
223449121|NCT02841956|OTHER|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
223449122|NCT02841956|OTHER|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
223569186|NCT06659471|DRUG|0.76% Sodium Monofluorophosphate Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
224057094|NCT00825500|DRUG|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
224057095|NCT00825500|DRUG|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
223449123|NCT05400889|DRUG|tofacitinib|Tofacitinib 5mg was taken orally once or twice a day and baricitinib 2mg or 4mg was taken orally once a day for 6 months.
223449124|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
223449125|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
223449126|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
224057096|NCT00825500|DRUG|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
224057097|NCT04773106|DEVICE|ARGOS-SC suprachoroidal pressure sensor|The ARGOS-SC pressure sensor was additionally implanted during routine local intraocular pressure lowering procedures in patients with glaucoma undergoing non-penetrating glaucoma surgery in the earlier ARGOS-SC01 study.
224057098|NCT02877368|OTHER|Computed tomography|
224057099|NCT00053092|BIOLOGICAL|rituximab|
224057100|NCT00053092|DRUG|cyclophosphamide|
224057101|NCT00053092|DRUG|fludarabine phosphate|
224057102|NCT01274819|OTHER|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
224146750|NCT03550365|OTHER|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
224146751|NCT03550365|OTHER|Rye bread intervention|4 week dietary intervention rich in rye bread
224146752|NCT03550365|OTHER|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
224146753|NCT00541736|DRUG|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
223449127|NCT01327313|BIOLOGICAL|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
223449128|NCT02061683|DRUG|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
223449129|NCT01573754|DRUG|Hydroxychloroquine|100 mg by mouth twice weekly
223449130|NCT01573754|PROCEDURE|Phlebotomy|450 mL every 2 weeks
223449131|NCT00829829|OTHER|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
223449132|NCT00829829|DRUG|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
223449133|NCT00829829|DRUG|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
223569187|NCT06659471|DRUG|0.454% Stannous Fluoride Dentifrice|Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
223569188|NCT06660771|PROCEDURE|Functional orthodontic treatment|"The patients were treated with Twin block and Herbst functional appliances. Alginate impressions and a protrusive wax bite were taken for the construction of each appliance. Each device was fitted and then reviewed 4-6 weeks later. First group was treated with Twin block which was manufactured basically according to the original design described by Clark. The overjet was measured from the patients in centric relationship and maximum protrusion position, and construction bite was recorded with 70% of the total advancement capacity of the mandible and 2-4 mm above the freeway space vertically. Overjet measurements were made at each session and active treatment was terminated when a normal overjet in the retracted position was recorded.~Second group was treated with the stainless-steel crown Herbst appliance, included crowned maxillary first molars and mandibular first premolars. The construction bite was recorded with the mandible forward by edge-to-edge incisor position."
224057103|NCT04468542|DRUG|Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)|2-cc injection (mixture consisting of 1-cc of 0.5% Bupivacaine injection and 1cc of 40mg/cc triamcinolone acetonide suspension injection) will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
224057104|NCT04468542|DRUG|Superior laryngeal nerve block - Placebo (saline)|2-cc injection of saline will be delivered percutaneously into the region of the proximal superior laryngeal nerve, every 1-2 weeks, for total of 2 to 3 injections
224057105|NCT03597230|OTHER|Dye|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
224057106|NCT03081442|DRUG|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
224057107|NCT03081442|DEVICE|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
224057108|NCT06399523|DEVICE|VR therapy|Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.
224057109|NCT06399523|DEVICE|VR sham|Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.
224146754|NCT06376188|OTHER|communication training|The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
224057110|NCT00934570|DRUG|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
224057111|NCT00934570|DRUG|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
224057112|NCT00934570|BEHAVIORAL|Placebo Standard exercise|Standard exercise
224057113|NCT00934570|BEHAVIORAL|Intensive exercise|Placebo Intensive exercise
224057114|NCT00003073|DRUG|liposomal cytarabine|
224057115|NCT00000270|DRUG|Cocaine|
224057116|NCT00025051|DRUG|celecoxib|
224057117|NCT00025051|PROCEDURE|anti-cytokine therapy|
224057118|NCT00025051|PROCEDURE|antiangiogenesis therapy|
224057119|NCT00025051|PROCEDURE|biological therapy|
223449134|NCT04068740|PROCEDURE|Surgical treatment of valvular heart disease|Valve replacement or repair
223449135|NCT04068740|DIAGNOSTIC_TEST|Virtual treatment|Virtual valve replacement or repair surgery
223449136|NCT02984267|DEVICE|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
223449137|NCT02984267|OTHER|Palpation|Using palpation only to evaluate the spine prior to epidural placement
223449138|NCT03376217|OTHER|IPTp delivered by HSAs|Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
223449139|NCT00650416|DRUG|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
223449140|NCT00650416|DRUG|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
223449141|NCT00230919|BEHAVIORAL|Diet counseling|
224057120|NCT00025051|PROCEDURE|cancer prevention intervention|
224057121|NCT00025051|PROCEDURE|chemoprevention of cancer|
224057122|NCT00025051|PROCEDURE|growth factor antagonist therapy|
224057123|NCT04343625|BEHAVIORAL|Modified yoga class|Modified yoga was used to see if it would improve pain, fatigue, depression and anxiety, as well as improve sleep quality.
224146755|NCT04748913|DEVICE|Radiographic examination|Standardized bitewing radiographs will be performed by the principal investigator
223449142|NCT05989776|BEHAVIORAL|Informational brochure for patients and brief training for oncologists|For this randomized, stepped wedge trial, the investigators planned a mixed intervention that targets both health professionals and patients. This intervention will be carried out in its entirety thanks to the working groups made up of health professionals and expert patients that took place before the randomized trial. The intervention for health professionals consists of awareness training. They will be trained (or made aware) at different times, defined by randomization. The intervention for patients consists of a pictorial information brochure and tabular patient decision aid given by trained health professionals.
223449143|NCT03631654|DRUG|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
223449144|NCT03631654|DRUG|Placebos|Placebo
223449145|NCT01442727|DRUG|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
223449146|NCT01442727|DRUG|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
223449147|NCT03307122|OTHER|Routine Infant Formula 1|Routine infant formula with probiotic
223449148|NCT03307122|OTHER|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
223449149|NCT03597139|DRUG|Voclosporin Ophthalmic Solution|Investigational Drug
223449150|NCT03597139|DRUG|Restasis®|Comparator
223449151|NCT00520767|DRUG|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
223449152|NCT00520767|DRUG|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
223449153|NCT00520767|DRUG|melphalan|Melphalan 9 mg/m2/day days 1-4
224057124|NCT04508400|DRUG|Fosaprepitant,ondansetron, dexamethasone|Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.
224057125|NCT04508400|DRUG|placebo ondansetron with dexamethasone|placebo plus ondansetron with dexamethasone
224057126|NCT02604316|OTHER|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
224057127|NCT02604316|OTHER|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
224057128|NCT02835001|PROCEDURE|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
224057129|NCT02835001|DEVICE|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
224057130|NCT03283124|PROCEDURE|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
224057131|NCT00527475|DRUG|ranibizumab|0.5 mg. given as an intraocular injection
223449154|NCT00520767|GENETIC|microarray analysis|≤28 days prior to enrollment
223449155|NCT00520767|OTHER|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
223449156|NCT00520767|OTHER|laboratory biomarker analysis|≤28 days prior to enrollment
224057132|NCT00527475|DRUG|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
224057133|NCT01394042|DEVICE|Proxiscan device|All patients will be imaged with the device
224057134|NCT05798091|BEHAVIORAL|Supportive-expressive group therapy|The intervention is based on the evidence-based supportive-expressive (SEGT) approach and was designed by an interprofessional team from psychiatry, social work, physiatry and occupational therapy, along with patient advisors. The SEGT approach fosters mutual support, promotes openness and emotional expression. It has been shown to yield improvements in anxiety, psychosocial functioning, health literacy, and social support in breast cancer survivors. This SEGT approach has been modified, in both content and process, to specifically address the needs of limb loss inpatients.
224057135|NCT05798091|OTHER|Treatment as usual|All patients may be referred to social work and/or a psychiatrist to address their mental health needs. As well, members of the interprofessional team provide psycho-social supports where needed. The types of psycho-social supports provided to patients in the TAU condition will be documented (e.g., referral to psychiatrist, social worker, etc.).
224057136|NCT03594630|DRUG|Chemotherapy|Receive chemotherapy
224057137|NCT03594630|OTHER|Patient Observation|Receive active surveillance
224057138|NCT03594630|OTHER|Questionnaire Administration|Ancillary studies
223449157|NCT00520767|PROCEDURE|quality-of-life assessment|Start of each cycle
223449158|NCT00312104|DRUG|insulin detemir|
223449159|NCT00312104|DRUG|insulin glargine|
223449160|NCT00312104|DRUG|insulin aspart|
223449161|NCT02464644|OTHER|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
223449162|NCT01770067|DRUG|CITA-RNPT|
223449163|NCT01770067|PROCEDURE|Extraction of infected CIED|
223449164|NCT01310244|DRUG|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
223449165|NCT00477204|DRUG|Simvastatin|simvastatin 20 mg daily
223449166|NCT00477204|DRUG|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
223449167|NCT04902079|DEVICE|Device for Cardiac Contractility Modulation Therapy (CCM)|Evaluate the effect from CCM Therapy in HF population
223449168|NCT00001237|DRUG|granulocyte-macrophage colony stimulating factor (GM-CSF)|
223449169|NCT05054699|DEVICE|Magnetic Seizure Therapy|Subjects will receive a train of magnetic pulses (between 600 and 1400 pulses) at 100Hz under general anaesthesia using a Magventure device with a Twin Coil
223449170|NCT05054699|DEVICE|Electroconvulsive Therapy|Subjects will receive a brief-pulse electrical stimulus (between 25 and 1008mC) under general anaesthesia using a ECT device
223449171|NCT01120132|DRUG|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
224057139|NCT03594630|PROCEDURE|Resection of Rectum|Undergo surgical resection
223449172|NCT01120132|DRUG|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
223449173|NCT01120132|DRUG|PA|Suspension of Prednisolone Acetate administered during 28 days
223449174|NCT01120132|DRUG|Placebo|Placebo solution administered during 28 days
224057140|NCT03744351|OTHER|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
224057141|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
223449175|NCT06143787|DRUG|Tranexamic acid|7 days Oral rinsing following tooth extraction
223449176|NCT00382109|DRUG|thiotepa|Given IV
223449177|NCT00382109|DRUG|cyclophosphamide|Given IV
223449178|NCT00382109|DRUG|tacrolimus|Given IV or orally
223449179|NCT00382109|DRUG|methotrexate|Given IV
224057142|NCT03744351|OTHER|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
224057143|NCT03744351|OTHER|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
224057144|NCT02719392|DIETARY_SUPPLEMENT|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
224057145|NCT02719392|DRUG|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
224057146|NCT02719392|OTHER|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
224057147|NCT05085951|DEVICE|20 mm CRE balloon|Endoscopic balloon that is used to dilate pylorus
224057148|NCT05085951|DIAGNOSTIC_TEST|OGD|OGD (No dilatation)
223449180|NCT00382109|DRUG|sirolimus|Given orally
223569189|NCT03474848|OTHER|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
223569190|NCT03474848|OTHER|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
224057149|NCT01265615|DRUG|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
224146756|NCT04748913|DEVICE|Scanning with DIAGNOcam|The surface of the selected teeth will be examined under near infrared light using the DIAGNOcam device
223449181|NCT00382109|RADIATION|total body irradiation|Part of the transplant preparatory regimen
223449182|NCT04441385|DRUG|Maraviroc 300 mg|Patients will receive maraviroc 300 mg twice daily for 14 days
223449183|NCT04441385|OTHER|Standard care therapy|Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
223449184|NCT03131700|BIOLOGICAL|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
223449185|NCT03131700|BIOLOGICAL|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
223449186|NCT01249833|DRUG|Oseltamivir|Oseltamivir 75mg BID for 5 days
223569191|NCT02591758|DEVICE|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
223569192|NCT02591758|BEHAVIORAL|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
223569193|NCT02591758|OTHER|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
223569194|NCT02591758|OTHER|Angina assessment with the angina diary, the SAQ and the SF-36|
224057150|NCT01265615|DRUG|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
223449187|NCT02941354|DRUG|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
223449188|NCT04061733|DEVICE|Hydrogel injection|Hydrogel injection
223449189|NCT00700154|PROCEDURE|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
224057151|NCT01265615|DRUG|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
224057152|NCT01265615|DIETARY_SUPPLEMENT|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
224146757|NCT04748913|DEVICE|Scan with DIAGNOcam and Indocyanine|One the dye has been applied, a new series of images will be taken with Diagnocam
224146758|NCT04748913|DIAGNOSTIC_TEST|Visual-tactile exploration with separation|The point of contact will be open in the corresponding proximal area of the lesion using an elastic orthodontic separator
223449190|NCT06725680|OTHER|Retrolaminar block|Patients will receive retrolaminar block after the induction of general anesthesia.
223449191|NCT06725680|OTHER|Erector spinae plane block|Patients will receive erector spinae plane block after the induction of general anesthesia.
223449192|NCT01900860|DIETARY_SUPPLEMENT|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
223449193|NCT05068479|DEVICE|Bilateral Laser Scleral Microporation procedure|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
223449194|NCT03796676|DRUG|Placebo|Placebo
223449195|NCT03796676|DRUG|PF-04965842|100 mg QD
223449196|NCT03796676|DRUG|PF04965842|200 mg QD
223449197|NCT00535392|DRUG|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if \<50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
223449198|NCT00766844|DEVICE|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
223569195|NCT02591758|OTHER|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
224057153|NCT00842231|OTHER|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
224057154|NCT00304200|DRUG|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
224057155|NCT01141036|DRUG|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
224057156|NCT01141036|DRUG|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
223449199|NCT04588844|DRUG|Polyethylene Glycol Recombinant Human Somatropin|Polyethylene glycol recombinant human somatropin will be injected weekly (3mg/per week) from the beginning of preceding menstruation cycle until the day of ovum pickup.
223449200|NCT05155930|BEHAVIORAL|Internal Family Systems (IFS)|Weekly individual psychotherapy
223449201|NCT04629872|DRUG|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is more than 3 hour prior to mechanical thrombectomy.
223449202|NCT06147323|OTHER|Normal Healthy Diet|Participants aged 18-65 years in general good health will be following the Eatwell booklet advice\*and NICE/NHS guidelines (https://www.nice.org.uk/).
223449203|NCT06147323|DIETARY_SUPPLEMENT|Seaweed Group|Participants aged 18-65 prediabetics will take 2 seaweeds brown extract capsules/day (information detailed in the safety product sheet, total dose of 700 mg before each of the two main meals. All participants will be advised on product storage and use conditions prior to use to ensure product consistency throughout the period of the study.
223449204|NCT06147323|OTHER|Placebo Diet Group|Participants aged 18-65 prediabetics will take 2 capsules/day (750mg Maltodextrin placebo comparator) before each of the two main meals without any advice on the diet to follow.
223449205|NCT02724410|DRUG|home intravenous ertapenem|see arm description
223449206|NCT02724410|DRUG|home oral amoxicillin-clavulanate|see arm description
223569196|NCT02591758|OTHER|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
223569197|NCT06608576|OTHER|Face-to-face standard treatment|Individualized early intervention treatment on physical therapy area as usual in the early intervention facilities once a month for two months. Instructions will be given to the parents for follow-up at home to stimulate the baby's motor development until next face-to-face session.
223569198|NCT06608576|OTHER|Telematic Support|The physiotherapist in charge of the telematic sessions will review and guide in real time through WhatsApp platform, the performance and active participation of the parents in the therapeutic activities being asked to follow-up at home in the face-to-face appointment, correcting, as necessary.
224057157|NCT06414525|OTHER|abdominal massage|It will include patients that will receive abdominal massage; the frequency and duration of the massage will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
224057158|NCT06414525|OTHER|visceral manipulation|It will include patients that will receive visceral manipulation; the frequency and duration of the technique will be arranged as 3 sessions per week, with each session lasting an average of 20-25 minutes for 6 weeks.
224146759|NCT02802072|DEVICE|Enterprise stent implantation|Enterprise stent system (Johnson \& Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
223449207|NCT02724410|DEVICE|peripheral inserted central Catheter|All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
223449208|NCT03284112|BEHAVIORAL|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
223449209|NCT03284112|BEHAVIORAL|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
223449210|NCT04256213|DRUG|Nivolumab and Ipilimumab|"Nivolumab, IV D1C1 and D15C1 (before RT-CT) at 3 mg/kg Every 28 days at 480 mg during 6 months after RT-CT~Ipilimumab, 1 mg/kg, IV D1C1 (before RT-CT)"
223449211|NCT00248833|BIOLOGICAL|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
223449212|NCT00248833|BIOLOGICAL|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
223449213|NCT01163006|OTHER|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
223449214|NCT01900899|PROCEDURE|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
223449215|NCT01329432|PROCEDURE|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
223449216|NCT01329432|PROCEDURE|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
223449217|NCT02006056|DRUG|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
223449218|NCT00723697|DRUG|buprenorphine|0.4, 2, or 8 mg sublingual tablets
223449219|NCT03414905|DEVICE|Aspira Catheter|"* 15.5Fr catheter~* Standard of care"
223449220|NCT03414905|PROCEDURE|Ultrasound|Standard of care
223449221|NCT02546076|DEVICE|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
223449222|NCT02546076|DEVICE|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
223449223|NCT05058092|DEVICE|Immediate Remedee Solution|"* D0 to M3: Remedee Solution + medical care~* M3 to M6: Remedee Solution without personalized support + medical care~* M6 to M9: medical care only"
223449224|NCT05058092|DEVICE|Delayed Remedee Solution|"* D0 to M3: medical care only~* M3 to M6: Remedee Solution + medical care~* M6 to M9: Remedee Solution without personalized support + medical care"
223449225|NCT05292976|OTHER|Methacholine Chloride|Serial Methacholine dilutions
223449226|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Reference)|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols.
223449227|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Reference)|One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
223449228|NCT05292976|DRUG|Albuterol Sulfate HFA 0.09 mg (Test)|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols.
223449229|NCT05292976|DRUG|Albuterol Sulfate HFA 0.18 mg (Test)|One actuation each from two different Test inhalation aerosols and one actuation each from two different placebo Reference inhalation aerosols.
223449230|NCT05292976|DRUG|Placebo|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
224057159|NCT06414525|OTHER|instructions on daily, dietary , toilet , and physical activity habits|It will include patients that will receive behavioral therapy: defecation mechanism and informing about negative attitudes and behaviors towards defecation), lifestyle advice (diet, water consumption, fiber food, etc.), teaching effective defecation posture, and timed toilet training.
223449231|NCT05049473|DRUG|Rituximab|Rituximab 375 mg/m² IV. Day 1. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*. Two additional doses after 6 cycles in case of localized stage patients without CR after four cycles or advanced stage patients.
223449232|NCT05049473|DRUG|Methotrexate|Methotrexate 1500 mg/m² IV 24h-infusion. Day 2. Cycles: A1, B1, C1 (1000 mg/m² if patient in CR) , A2 (1000 mg/m² if patient in CR), B2 (1000 mg/m² if patient in CR) , C2 (1000 mg/m² if patient in CR) Methotrexate 500 mg/m² IV 24h-infusion. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
223449233|NCT05049473|DRUG|Dexamethasone|Dexamethasone 10 mg/m² PO or IV bolus. Days: 2 to 6. Cycles: A1/A1\*, B1/B1\*, C1/A2\*, A2/B2\*, B2/A3\*, C2/B3\*.
223449234|NCT05049473|DRUG|Iphosphamid|"Iphosphamid 800 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1, A2 (500 mg/m² if patient in CR).~Iphosphamid 400 mg/m² IV in 1 hour. Days: 2 to 6. Cycles: A1\*."
223449235|NCT05049473|DRUG|Vincristine|Vincristine 2 mg IV bolus. Day 2. Cycles: A1, B1, A2, B2 Vincristine 1 mg IV bolus. Day 2. Cycles: B1\*, B2\*, B3\*
223449236|NCT05049473|DRUG|Etoposide|Etoposide (VP16) 100 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1, A2. Etoposide (VP16) 250 mg/m² IV in 1 hour. Days: 5, 6. Cycle: C1, C2. Etoposide (VP16) 60 mg/m² IV in 1 hour. Days: 5, 6. Cycle: A1\*, A2\*, A3\*.
223449237|NCT05049473|DRUG|Cytarabine|Cytarabine 150 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1, A2 Cytarabine 2 g/m² IV in 3 hours every 12 hours. Day: 6. Cycle: C1 (1.5 g/m² if patient in CR), C2 (1.5 g/m² if patient in CR) Cytarabine 60 mg/m² IV in 1 hour every 12 hours. Days: 5, 6. Cycles: A1\*, A2\*, A3\*
223449238|NCT05049473|DRUG|Cyclophosphamide|Cyclophosphamide 200 mg/m² IV in 1 hour. Days 1 to 5. Pre-phase. Cyclophosphamide 200 mg/m² IV in 1 hour. Days 2 to 6. Cycles: B1, B2, B1\*, B2\*, B3\*
223449239|NCT05049473|DRUG|Doxorubicin|Doxorubicin 25 mg/m² IV in 15 min. Days 5 and 6. Cycles: B1/B1\*, B2, B2\*, B3\*
223449240|NCT05049473|DRUG|Vindesine|Vindesine 3 mg/m2 (max 5 mg) IV bolus. Day 2. Cycles: C1, C2
223449241|NCT05049473|DRUG|Cytarabine|Cytarabine 30 mg IT. Days 2 and 6. Cycles A1, B1, A2, B2
223449242|NCT05049473|DRUG|Methotrexate|Methotrexate 12 mg IT. Day 1. Pre-phase Methotrexate 12 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2 Methotrexate 15 mg IT. Day 2. Cycles: A1\*, B1\*, A2\*, B2\*, A3\*, B3\*
223449243|NCT05049473|DRUG|Hydrocortisone|Hydrocortisone 20 mg IT. Days 2 and 6. Cycles: A1, B1, A2, B2
224057160|NCT02562079|BIOLOGICAL|Blood samples|"* biological features of the standard follow-up~* 2 more blood tube for the biological collection (serum and PBMC)"
224057161|NCT02562079|BIOLOGICAL|Biopsy|Skin biopsies
224057162|NCT03434340|BIOLOGICAL|Peppermint essential oil|2 drops applied on a nasal strip
224057163|NCT03434340|DRUG|Granisetron|1mg intravenous injection
223449244|NCT05049473|DRUG|Prednisone|Prednisone 60 mg/m2 PO or IV bolus. Days 1 to 5. Pre-phase.
223449245|NCT02770846|PROCEDURE|Immediate loading|
223449246|NCT02770846|PROCEDURE|Delayed loading|
223449247|NCT06371066|OTHER|experimental group|the experimental group was educated by video
223449248|NCT06371066|OTHER|Control group|the control group was educated by traditional formal training
223449249|NCT04291365|DIAGNOSTIC_TEST|Blood pressure measurement|Study subjects will have a total of 9 blood pressure measurements taken (3 on upper arm, 3 on lower arm, and 3 on wrist)
224057164|NCT03434340|DRUG|Dexamethasone|4mg intravenous injection
224057165|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation|Oral, encapsulated FMT
224057166|NCT02801656|DRUG|Vancomycin|Vancomycin po 125 mg qid x 10 days
224057167|NCT02801656|BIOLOGICAL|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
224057168|NCT02801656|DRUG|Vancomycin Placebo|Matching placebo to Vancomycin
224057169|NCT00632099|DRUG|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
224057170|NCT00632099|DRUG|Placebo|matched placebo
224057171|NCT03399136|BEHAVIORAL|Exercise training|Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
224057172|NCT02330575|BEHAVIORAL|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
224057173|NCT02330575|BEHAVIORAL|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
224057174|NCT03078075|DRUG|Naltrexone: Vivitrol®|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks
224146760|NCT02802072|DRUG|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
223449250|NCT06731725|DEVICE|DayDrop®|The patient will administer 1 to 2 instillations each time it is necessary (at least 2 times a day) and will record it in their data collection notebook.
224057175|NCT03078075|DRUG|Placebo (PLB) Injectable|Placebo: 4 intramuscular injections administered every 3 weeks
223449251|NCT05337384|DIAGNOSTIC_TEST|Sonography|Sonographic Venous Doppler Imaging
223449252|NCT02068859|DRUG|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
224057176|NCT03078075|DRUG|Bupropion: Wellbutrin XL®|Bupropion: 450 mg oral dose daily
224057177|NCT03078075|DRUG|Placebo (PLB) Oral|Placebo: once-daily oral placebo tablets
224057178|NCT02840695|DRUG|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
224146761|NCT04961476|DIETARY_SUPPLEMENT|1-MNA|1-MNA supplementation
224146762|NCT00719524|DRUG|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
224146763|NCT05557097|DIAGNOSTIC_TEST|Intrapartum sonography|Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
224146764|NCT00105755|DEVICE|personal dermal thermometer (DT)|
224146765|NCT00105755|DEVICE|Device|
224146766|NCT06062342|BEHAVIORAL|FPI|The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours. At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
224146767|NCT04632407|DIETARY_SUPPLEMENT|"Flax milk"|See above
224146768|NCT04632407|DIETARY_SUPPLEMENT|"Oat fibre milk"|See above
223449253|NCT02068859|DRUG|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
223449254|NCT00607542|DRUG|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
223449255|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
223449256|NCT01417858|PROCEDURE|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
223449257|NCT03374163|DRUG|intralipid 20%|milky soulation for energey supplement.
223449258|NCT03077100|OTHER|Laboratory identification of positive cultures|Laboratory identification of positive cultures
223449259|NCT00239499|DRUG|Tiotropium|
223449260|NCT00239499|DRUG|Salmeterol plus Fluticasone|
223449261|NCT02247271|BEHAVIORAL|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
223449262|NCT04436653|DEVICE|Tricuspid Valve Replacement System|To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.
224057179|NCT04426877|BEHAVIORAL|Experimental group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.
224146769|NCT05037669|BIOLOGICAL|PACE CART19|PACE CART19 cells are allogeneic T cells transduced with a lentiviral vector to express an anti-CD19 scFv TCRz:41BB and electroporated to temporarily express the CRISPR/Cas9 RNA system resulting in beta-2 microglobulin (B2M), Class II Major Histocompatibility Complex Transactivator (CIITA) and TCR-α chain (TRAC) targeted disruption. PACE CART19 cells will be administered by IV infusion.
224057180|NCT04426877|BEHAVIORAL|Control group|The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive the same web-based lifestyle intervention (exercise and nutritional education), but in this case supported by audiovisual instructions given by a doctor outside the patient.
224057181|NCT04592640|OTHER|Human amniotic mesenchymal stem cells|"1. Intravenous infusion of hAMSCs: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance).~2. Injection of hAMSCs to local skin lesions: once every 3 weeks, a total of 6 times (if cured before the end of the planned course of treatment, it will be terminated in advance)."
224057182|NCT01722175|PROCEDURE|ALPPS surgery|
224057183|NCT01722175|PROCEDURE|PVO surgery|
224057184|NCT04200053|OTHER|Reflexology massage|Before the burn dressing, a reflexology massage will be performed for 20 minutes on the right foot and 20 minutes on the left foot. This intervention will continue in the morning for 3 days.
224146770|NCT06123390|OTHER|The Responses to Illness Severity Quantification (RISQ) System|The RISQ System involves: \[1\] the RISQ score: calculated routinely using the \[2\] documentation record and linked to \[3\] score-matched recommendations. Introduction into clinical care is supported by \[4\] the RISQ System implementation package. During the 2 month prior to implementation, front-line staff in the intervention arm will be trained on and will practice the use of the RISQ System .
224146771|NCT03385499|BIOLOGICAL|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
224146772|NCT00093470|PROCEDURE|Clinical Observation|Undergo observation
224146773|NCT00093470|DRUG|Tipifarnib|Given PO
224146774|NCT05289076|DRUG|Chemotherapy drug|Different combinations of chemotherapies will be tested in combination with monoclonal antibodies in zebrafish embryos against inplanted patients livermetastatic tissues.
224146775|NCT02514772|BIOLOGICAL|GP2013 - A Proposed biosimilar rituximab|
224146776|NCT02514772|BIOLOGICAL|Originator rituximab - Rituxan ® or MabThera ®|
224146777|NCT03712800|OTHER|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
223449263|NCT06178562|BEHAVIORAL|systematic therapy|Both groups were given systematic therapy according to the routine treatment plan for PRS for 4 weeks. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223449264|NCT06178562|DEVICE|PNG|In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224146778|NCT03712800|BEHAVIORAL|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
223449265|NCT06178562|DEVICE|IOE|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube (Appendix) was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224057185|NCT04200053|OTHER|Reflexology massage and passive music|Before the burn dressing, a reflexology massage and passive music will be performed for 20 minutes on the right foot and 20 minutes on the left foot. Instrumental music will be played during the massage. This intervention will continue in the morning for 3 days.
224146779|NCT01945268|DRUG|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
224146780|NCT01945268|OTHER|Sterile saline|0.5 ml dose injected intramuscularly
224146781|NCT00381719|DRUG|AGN 203818|3 mg Capsule twice daily for 4 weeks
224146782|NCT00381719|DRUG|AGN 203818|20 mg Capsule twice daily for 4 weeks
224057186|NCT02888015|OTHER|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
224057187|NCT01923285|DEVICE|AXIUM Neurostimulator System|
224057188|NCT01923285|DEVICE|Control Spinal Cord Stimulation Device|
224057189|NCT03880487|DRUG|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
224146783|NCT00381719|DRUG|AGN 203818|60 mg Capsule twice daily for 4 weeks
224057190|NCT03880487|DRUG|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
224057191|NCT03880487|DRUG|Oxycodone oral capsule|10 mg Oxycodone Capsules
224146784|NCT00381719|DRUG|placebo capsule|Capsule twice daily for 4 weeks
224146785|NCT01415908|DEVICE|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
223449266|NCT00072904|DRUG|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
223449267|NCT00072904|DRUG|Repaglinide|0.5mg tab with meals tid
223449268|NCT04516863|DIAGNOSTIC_TEST|German Autobiographical Memory Interview short-form|Diagnostic Test
223449269|NCT01741155|DRUG|SPI-1620|SPI-1620 11 μg/m2 administered intravenously over one minute.
223449270|NCT01741155|DRUG|Docetaxel|Docetaxel: 75 mg/m2 administered as IV infusion.
223449271|NCT03576352|OTHER|a rapid sequence tracheostomy (RST) on rabbit cadaver|"The Rapid Sequence Tracheostomy (RST) consists of the following steps:~1. Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~2. Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~3. Perform a vertical puncture with a tip scissors between the Cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~4. An age adapted tracheal tube is inserted into the trachea and the lungs are ventilated."
223449272|NCT03890978|OTHER|promotional Exclusive breastfeeding text messages|promotional Exclusive breastfeeding text messages will be send to women via mobile phone
223449273|NCT01072747|BIOLOGICAL|bovine heparin|5.000UI/mL bottle with 5mL
223449274|NCT01072747|BIOLOGICAL|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
223449275|NCT06168747|OTHER|Passive Joint Mobilization|Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
223449276|NCT06730841|DEVICE|Dose-Optimized and Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of up to 4 milliamp (mA).~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
223569199|NCT06608719|BIOLOGICAL|The study drug is SHED-CM manufactured by U-Factor|Patients diagnosed with ALS were administered SHED-CM
223569200|NCT06604936|OTHER|Fibromyalgia group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
223569201|NCT06604936|OTHER|Healthy group|Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
223569202|NCT06608784|DIAGNOSTIC_TEST|Electrocardiography|12-lead electrocardiography
223569203|NCT06607042|BEHAVIORAL|Psychotherapy|Psychotherapy according to the Berlin Dissexuality Therapy (BEDIT)
223569204|NCT06586138|OTHER|STAI (State-Trait Anxiety Inventory) Scale : Psychological inventory of 20 self-report items on a 4-point scale|Patient completed STAI Scale in the 24 hours before Maintenance of Wakefulness Test during the hospitalization
224057192|NCT00962572|BEHAVIORAL|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
224057193|NCT02011282|OTHER|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
224057194|NCT00711984|DEVICE|Herkulink renal artery Stent|renal artery stent
223449277|NCT06730841|DEVICE|Spaced Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. Preclinical evidence supports the potential advantage of spaced stimulation with tDCS to maximally engage neuroplasticity. This group will be treated using a stimulation intensity of 2 mA.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
223569205|NCT05032690|DRUG|Bosutinib capsule|Bosutinib four 25 mg capsule taken after a high-fat and high calorie breakfast
223569206|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high calorie breakfast
223569207|NCT05032690|DRUG|Bosutinib|Bosutinib 100 mg capsule taken after an overnight fast of at least 10 hours
223569208|NCT05032690|DRUG|Bosutinib capsule|Bosutinib 100 mg capsule taken after a high-fat and high-calorie breakfast
223569209|NCT05422534|DIETARY_SUPPLEMENT|CoQ10|Participants will receive 1800 mg/day for 12 weeks
223569210|NCT05422534|DRUG|Placebo|Participants will receive placebo or CoQ10/day for 12 weeks
223449278|NCT06730841|DEVICE|Sham Transcranial Direct Current Stimulation|"tDCS, a non-invasive neuromodulation technique that applies low-intensity, direct electrical stimulation to the cortex via scalp electrodes, has been extensively researched as a potential treatment for MDD. tDCS enhances neuroplasticity, which is theorized to be responsible for its therapeutic effects and has been presented as a cost-effective solution for MDD. This group will be treated using sham stimulation.~Participants will first complete an acute intensive induction phase consisting of daily treatment every weekday over 2 weeks (10 days total) followed by a consolidation phase consisting of weekly treatments (once a week) over 4 additional weeks (6 weeks total)."
223449279|NCT01343992|BEHAVIORAL|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
223449280|NCT01343992|BEHAVIORAL|No bedrest|Patients will not rest in bed after the embryo transfer.
223449281|NCT00003178|BIOLOGICAL|filgrastim|
223449282|NCT00003178|DRUG|cladribine|
223449283|NCT00003178|DRUG|idarubicin|
223449284|NCT00467402|DRUG|agomelatine|
223449285|NCT00467402|DRUG|placebo|
223449287|NCT03975725|DEVICE|the use of the WitCard|electrocardiogram (ECG)
223449288|NCT03975725|OTHER|the use of WitDisplayer|a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
223449289|NCT00467558|DRUG|Naltrexone|daily
223449290|NCT00467558|DRUG|Sugar pill|daily
223449291|NCT02254798|OTHER|no intervention|this is a non interventional study
223449292|NCT05761704|DRUG|Dual antiplatelet|Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
223449293|NCT05761704|DRUG|Novel oral anticoagulant|Conventional dose NOAC for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
223449294|NCT05275634|OTHER|Stander treatment|Standard treatment will be (active cervical range of motion exercises, myofascial release to upper trapezius muscle and postural advices at home).
223449295|NCT05275634|DEVICE|Interferential current with carrier frequency 2 KHz|Interferential current treatment parameters will be as following; carrier frequency 2 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
223449296|NCT05275634|DEVICE|Interferential current with carrier frequency 4 KHz|Interferential current treatment parameters will be as following; carrier frequency 4 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
223449297|NCT05275634|DEVICE|Interferential current with carrier frequency 8 KHz|Interferential current treatment parameters will be as following; carrier frequency 8 KHz and beat frequency 15 Hz performed for 45 minutes per session.The intensity will be raised according to the subject's tolerance, remaining in the sensory level.
224057195|NCT00711984|OTHER|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
224057196|NCT00039585|DRUG|imatinib mesylate|
224057197|NCT02543463|DEVICE|Trident X3 Insert with Navigation system|
224057198|NCT02543463|DEVICE|Trident X3 Insert with conventional instrumentation|
224057199|NCT03978507|BEHAVIORAL|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
223449298|NCT05275634|DEVICE|placebo interferential current|Interferential current intensity will not be raised.
223449299|NCT06920797|DIAGNOSTIC_TEST|Reproductive tract microbiome analysis|Assessment of the endometrial and vaginal microbiome in three different samples: endometrial biopsy (EB), endometrial fluid (EF) and vaginal swab (VS).
223449300|NCT05188729|DRUG|Part 1: VP-315 3 Day Dosing/Week|2-8 mg of VP-315 administered via intratumor injection into a single target lesion on W1D1. Each 500-μL dose will be divided into 2 injections given at least 15 minutes and no more than 30 minutes apart, with 30% (150 μL) administered in the first injection and the remaining 70% (350 μL) with the second injection. In all parts of the study, the targeted total volume of delivery is 500 μL daily.
223449301|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - Loading Dose|4mg (halt the target dose) loading dose on W1D1 administered via intratumor injection into a single target lesion, followed by total daily doses at the full target dose of 8 mg on the remaining days of treatment.
223449302|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - No Loading Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 3 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
224057200|NCT03978507|BEHAVIORAL|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
224057201|NCT06272474|OTHER|CAD-CAM zirconia crowns using buccal interocclusal record.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using buccal interocclusal record.~First, scanning the buccal interocclusal record for each patient with the two arches in maximum intercuspation position (MIP) will be performed. The IOS will immediately reproduce the occlusal state of the digital casts; this method is called the buccal bite registration method (BBR)."
224057202|NCT06272474|OTHER|CAD-CAM zirconia crowns using lateral interocclusal records.|"Virtual occlusal interferences adjustment of CAD-CAM zirconia crowns using lateral interocclusal record.~A second scan will be performed for each patient to record lateral mandibular excursion. Then, three STL files will be exported; maxillary arch, mandibular arch at MIP and lateral mandibular excursion"
224057203|NCT02583906|DEVICE|CPAP|Treatment with CPAP for six months in the CPAP arm.
224057204|NCT01041482|DRUG|sorafenib|sorafenib 400mg twice daily
224057205|NCT01244555|OTHER|ultrasound|Twice weekly ultrasound sessions for 6 weeks
224057206|NCT01244555|OTHER|massage|Twice weekly massage sessions for 6 weeks
223449303|NCT05188729|DRUG|Part 2: VP-315 2 Day Dosing/Week - Split Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 2 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
224057207|NCT03489408|DEVICE|Conventus Cage™ PH|Proximal humeral fracture fixation
224057208|NCT00127725|DEVICE|Pulsed electromagnetic field stimulation|
224057209|NCT04334980|BIOLOGICAL|bacTRL-Spike|Each oral dose of bacTRL-Spike contains bacterial medium with either 1 billion (Group 1), 3 billion (Group 2) or 10 billion (Group 3) colony-forming-units of live Bifidobacterium longum, which has been engineered to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.
223449304|NCT05188729|DRUG|Part 2: VP-315 3 Day Dosing/Week - Split Dose|8 mg of VP-315 administered daily via intratumor injection into a single target lesion up to 3 consecutive daily doses/week for up to 2 weeks (W1D1, W1D2, W1D3 and W2D1, W2D2, W2D3 - up to 6 total doses).
223449305|NCT00616876|DRUG|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
223449306|NCT00616876|DIETARY_SUPPLEMENT|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
224057210|NCT02162836|DRUG|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
224057211|NCT00711620|DRUG|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
224057212|NCT02483663|DEVICE|Functional Magnetic Resonance Imaging|Measure brain activity.
224057213|NCT02483663|RADIATION|Dual Energy X-ray absorptiometry|Body composition measurements.
224057214|NCT02483663|OTHER|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
224057215|NCT02483663|OTHER|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
224146786|NCT01415908|OTHER|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
224146787|NCT04518345|DRUG|Azacitidine|Given IV
224146788|NCT04518345|DRUG|Dubermatinib|Given PO
224146789|NCT01770041|OTHER|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
223569211|NCT05422534|BEHAVIORAL|HB-HIIT|Participants will be performed on non dialysis days. It will be video supervised exercise sessions with self directed exercises using pre-recorded bodyweight and strength exercise videos.
223569212|NCT05422534|BEHAVIORAL|Observational|Participant regular activities
223741820|NCT04660448|DIAGNOSTIC_TEST|Bedside lung ultrasound examination|Lung ultrasound exploring 12 areas (6 in each lung) at 12 +/- 6 hours and at 48-72 hours from PICU admission. Clinical and analytical data collection coinciding with ultrasound imaging and during follow-up while admitted to PICU.
223741821|NCT00233896|DRUG|Oral beclomethasone dipropionate (drug)|
224057216|NCT02483663|OTHER|Test Meals|Breakfast, a snack, and lunch provided during study visit.
224057217|NCT02483663|OTHER|Computer Tests|Perform a series of computer tests to determine reaction time.
224057218|NCT02483663|PROCEDURE|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
224057219|NCT00871520|OTHER|no specific interventions|There are no specific interventions in this observational study
224057220|NCT06098612|DRUG|C11-SY08|a PET imaging agent
224146790|NCT00546429|DEVICE|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
224057221|NCT04903925|PROCEDURE|Impacted tooth extraction|All patients will undergo a surgical tooth extraction
224057222|NCT00738153|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
224057223|NCT00468520|DRUG|low dose oxytocin|
224057224|NCT01384227|DRUG|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
224057225|NCT04960982|DIAGNOSTIC_TEST|blood test|blood sample is taken in first, second and third trimester of pregnancy
224057226|NCT03230552|OTHER|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
224057227|NCT02035085|DRUG|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
223449307|NCT01649362|OTHER|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
224057228|NCT03166566|DEVICE|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
223449308|NCT00811980|DRUG|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
223449309|NCT02508103|DRUG|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
223569213|NCT06660511|DRUG|Disitamab Vedotin in Combination With Anlotinib Hydrochloride|"The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)"
223569214|NCT05625789|BEHAVIORAL|Postural control (weight shift) training|Visual cues to improve amplitude of weight shift prior to initiating gait.
223569215|NCT05625789|BEHAVIORAL|Steady state gait training|Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
223569216|NCT06660134|DRUG|Glucagon-like peptide-1 receptor agonists (GLP 1 RA)|In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
223569217|NCT06411977|DIETARY_SUPPLEMENT|Vegetable juice|Vegetable juice (Fa. Fitrabbit, Voglsam)
224057229|NCT00314184|DRUG|quetiapine fumarate|
224057230|NCT02529982|DIETARY_SUPPLEMENT|Curcumin|
224057231|NCT02529982|DIETARY_SUPPLEMENT|Placebo|
224057232|NCT04697238|DEVICE|Weight vest|A vest weighing up to a maximum of 15 kg.
223569218|NCT05893771|DRUG|Methylprednisolone Injection|Ultrasound-guided genicular nerve block comparing Methylprednisolone combined with Bupivacaine to bupivacaine alone. All patients will undergo TKA and will receive spinal anesthesia.
224057233|NCT01784770|DRUG|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
224057234|NCT05932940|PROCEDURE|Gonioscopy-Assisted Transluminal Trabeculotomy|Ab interno angle surgery one of MIGS to lower IOP
224146791|NCT06282419|OTHER|USE OF MOBILE ULTRASOUND|"First stage; Women and their partners who meet the research criteria are at the 32-35th week of pregnancy. was included in the study during the week. First, introductory information forms will be applied to the women and expectant fathers assigned to the experimental and control groups through face-to-face interview technique.~Then, fetal images and fetal heart sounds will be recorded from the pregnant women in experimental group 1 with a mobile phone compatible portable USG device. Fetal USG images and fetal heart sounds taken with the portable USG device of their babies will be sent to the prospective fathers in experimental group 1 by the researcher via WhatsApp application twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp twice a week for 4 weeks after birth."
224146792|NCT06282419|OTHER|ultrasound image taken from the internet|First stage; Fetal USG images and fetal heart sounds, not belonging to their babies, taken from the internet, will be sent to the fathers in experimental group 2 via WhatsApp application by the researcher twice a week until birth (at least 3 weeks). In the second stage of the research; Breastfeeding videos prepared by the researcher will be sent to fathers via WhatsApp application twice a week for 4 weeks after birth.
224146793|NCT04235439|DRUG|Gan & Lee Insulin Lispro Injection|All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
224146794|NCT04799353|DRUG|Budigalimab|Subcutaneous (SC)
224146795|NCT04799353|DRUG|Placebo|Subcutaneous (SC)
224146796|NCT04799353|DRUG|Budigalimab|Intravenous (IV)
223569219|NCT05893771|DRUG|Bupivacaine Hcl 0.5% Inj_#2|Ultasound- guided genicular nerve block using 5 ml bupivacaine 0.5% in 15 ml saline
224146797|NCT04799353|DRUG|Placebo|Intravenous (IV)
224146798|NCT00851253|RADIATION|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
224146799|NCT00043212|DRUG|Dendritic cell immunotherapy|
224146800|NCT04698512|DEVICE|AVFistuloplasty with Sirolimus coated balloon|After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
224146801|NCT03924310|DEVICE|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
224146802|NCT03924310|DEVICE|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
224146803|NCT03154307|DEVICE|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
224146804|NCT02416778|DRUG|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
224146805|NCT00263250|PROCEDURE|watchful waiting or tension-free hernia repair|
224146806|NCT00577915|OTHER|Radiology/MRI scan|MRI spectroscopy
224146807|NCT01705587|DRUG|teriparatide|20 microgram once-daily subcutaneous injection
224146808|NCT05859971|DRUG|SLN mapping using technetium-99m +/- isosulfan blue dye|The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.
224146809|NCT05859971|DEVICE|SLN mapping with ICG fluorescence using the Asimov Platform|2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
224146810|NCT06045728|OTHER|Pilates exercises|Pilates is a group of low impact muscle exercises that strengthen abdominal muscles, back, hips and pelvic floor muscles. the exercise consists of 10 min warm up, 40 min exercise and 10 min cooling down. the exercises that will be included: spine twist, double leg stretch, double leg circles, side leg circle, curl up, shoulder bridges and pelvic curl.
224057235|NCT02591381|PROCEDURE|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
224057236|NCT04502004|DEVICE|App for health=mhealth|Cognitive-Behavioural Therapy and Clinical Practice Guide that recommends 5 Aes: Ask about tobacco, Advise smoking cessation, Assess tobacco consumption, Assist and Arrange (Fiore et alt., 2008)
224057237|NCT02699957|PROCEDURE|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
224146811|NCT06045728|BEHAVIORAL|Mediterranean diet|it is a type of diet used for obesity management based on high vegetable intake, olive oil as a source of fat, the consumption of grains, legumes, and nuts with high amounts of pulp, low-medium consumption of fish, low consumption of red meat.
224146812|NCT05438251|DRUG|Fespixon Cream|"1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (approximately 2 mm in thickness)~5. Dosing schedule: Apply twice a day~6. Duration: up to 12 weeks"
224146813|NCT02293824|DRUG|Caffeine|Given per standard of care.
224146814|NCT01890317|PROCEDURE|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
224146815|NCT01612377|DRUG|Prednisolone-Dipyridamole|Oral, QD
224146816|NCT01612377|DRUG|Prednisone|Oral QD Prednisone 5mg
224057238|NCT05795686|OTHER|"Evaluation of program AVanCer"|Evaluation of program AVanCer with quantitative and qualitative approaches
224057239|NCT05530720|OTHER|Cross-sectional survey|No intervention.
224057240|NCT04275505|OTHER|shortwave diathermy treatment|shortwave diathermy is a deep heating physical therapy agent. It was found efficiaous in carpal tunnel syndrome which is an entrapment neuropathy like ulnar nerve entrapment so it was hypothesised that shortwave diathermy could be an effective treatment method in ulnar nerve entrapment.
224057241|NCT04275505|OTHER|placebo shortwave diathermy treatment|shortwave device was not turned on while participants were asked to put their elbow into the device
224057242|NCT05198336|BIOLOGICAL|Inactivated COVID-19 Vaccine|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
224057243|NCT01761045|DIETARY_SUPPLEMENT|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
224057244|NCT01761045|DIETARY_SUPPLEMENT|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
224057245|NCT01761045|DIETARY_SUPPLEMENT|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
224057246|NCT01499784|BEHAVIORAL|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
224057247|NCT04879667|PROCEDURE|endoscopic management of gastrocutaneous fistula after laparoscopic sleeve gastrectomy|we performed upper GI endoscopy to all cases first to assess the site , size and cause of fistula . we used stents , clips , sutures and ballon dilatation to close the fistula according to size , site and cause of fistula.if the fistula had no track that was proved by CT with oral \& I.V contrast , we used the endoscopic stent. if the fistula had track that was proved by CT with oral \& I.V contrast , we used the OVASCO clip , endo suturing or ballon. Combined maneuvers may be used like ballon dilation and clipping or ballon dilatation and suturing if there was distal narrowing.
224146817|NCT01612377|DRUG|prednisone|Oral, QD prednisone 7.5mg
224146818|NCT02428712|DRUG|FORE8394|
224146819|NCT03845049|OTHER|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
223449310|NCT02508103|DRUG|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
223449311|NCT04849663|BIOLOGICAL|free fat graft|fat harvested from patient will be used to cover exposed root
223449312|NCT04849663|BIOLOGICAL|subepithelial graft|subepitheial graft harvested from palate
223449313|NCT02483988|DEVICE|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
223449314|NCT03017391|DRUG|metoclopramide|metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
223449315|NCT03017391|DRUG|granisetron|granisetron patch 3.1mg/24 hours, use until toxicity
223449316|NCT03017391|DRUG|Dexamethasone|dexamethasone 8 mg, last step in both algorithms
224057248|NCT05672511|BEHAVIORAL|Simulation Teaching Method|Randomly determined experimental group students will perform eight vaginal examination scenarios different in terms of cervical effacement, cervical dilatation, presence of amniotic membrane, presenting fetus part, position of the fetus and fetal descent on the fetal monitoring and labor progress model set in the laboratory. The control group will not receive any simulation training. Both groups will be given a knowledge test after teaching with simulation. Students in both groups will fill out a form evaluating their skills in performing the steps of vaginal examination before each vaginal examination is performed on women in the clinic.
224057249|NCT03506737|OTHER|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
224057250|NCT03506737|OTHER|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
224057251|NCT03946137|OTHER|Chest Therapy|The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)
224057252|NCT03946137|OTHER|Postural Hygiene|Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
224057253|NCT01457391|BEHAVIORAL|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
224057254|NCT01457391|BEHAVIORAL|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
224057255|NCT01457391|BEHAVIORAL|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
224057256|NCT06460675|PROCEDURE|Autogenic Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per weeks for 3 weeks (40 Min per Session)
224057257|NCT06460675|PROCEDURE|Reciprocal Inhibition Muscle Energy Technique|No of repetitions: 1 set with 3 repetitions No of Sessions per week: 2 per week for 3 weeks (40 Min per Session)
224057258|NCT05586048|DRUG|Yiqi Fumai Lyophilized Injection(YQFM)|No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
224057259|NCT02437864|DEVICE|Supplemental oxygen via nasal cannula|
224057260|NCT01833442|BEHAVIORAL|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
224146820|NCT03845049|DRUG|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
224146821|NCT03845049|DRUG|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
223449317|NCT03017391|DRUG|Granisetron 2Mg Tablet|granisetron 2 mg loading dose
223449318|NCT05865158|OTHER|Home-based exercises|Home-based exercises proposed through the CardioSafe+ platform, guided by therapists specialized in cardiovascular disorders, who will try to adapt the sessions to each participant.
224057261|NCT01833442|BEHAVIORAL|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
224057262|NCT01251848|DRUG|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
224057263|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
224146822|NCT03845049|OTHER|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
224146823|NCT03515213|DRUG|Fenofibrate|145mg of fenofibrate
224146824|NCT03515213|DRUG|Placebo|Placebo
223449319|NCT01207011|DRUG|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
223449320|NCT01207011|DRUG|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
223449321|NCT03620526|DRUG|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
224146825|NCT01817114|DEVICE|Auto Remote Ischemic Conditioning (AutoRIC) device|
223449322|NCT03620526|DRUG|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
223449323|NCT05400044|PROCEDURE|Three dimensional maxillary bone augmentation|mixing of bone marrow aspirate concentrate with xenograft to show the bone quality and bone gain compared to the xenografts mixed with autografts
223449324|NCT00620646|DRUG|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
223449325|NCT00620646|DRUG|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
223449326|NCT05798143|DEVICE|Accelerated Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
223449327|NCT02532062|DIETARY_SUPPLEMENT|Cholecalciferol|4,000 IU, oral, once a day for one year
223449328|NCT02532062|DIETARY_SUPPLEMENT|multivitamin|oral, once a day for one year
223449329|NCT02532062|DIETARY_SUPPLEMENT|Placebo|oral, once a day for one year
223449330|NCT02953483|OTHER|Red blood cells|Packed red blood cells to final hematocrit of 14%
223449331|NCT04468893|BEHAVIORAL|Online Intervention Mental Health COVID-19|The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
223449332|NCT00929994|BEHAVIORAL|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
224057264|NCT01251848|DRUG|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
223569220|NCT05893771|DRUG|normal saline|Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
224057265|NCT01251848|DRUG|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
223569221|NCT01915121|BEHAVIORAL|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
223569222|NCT01915121|BEHAVIORAL|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
223569223|NCT05475665|DRUG|Irbesartan/Amlodipine|Irbesartan/Amlodipine once daily for 8 weeks
224057266|NCT04315194|DRUG|clarithromycin-naproxen-oseltamivir|to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir treatment alone for hospitalised paediatric influenza patients.
224057267|NCT05787080|OTHER|Massage|In the second hour of hemodialysis, vibration is applied to both calf muscles of the patients for 10 minutes three times a week for four weeks at low voltages.
224057268|NCT05653622|PROCEDURE|Integrated boost technique (SIB) guided by PET FDOPA|intensity-modulated irradiation scheme with integrated boost technique (SIB) guided by PET FDOPA during the chemo-radiotherapy
224146826|NCT00925145|PROCEDURE|Single Incision Laparoscopic Appendectomy|
224146827|NCT01656811|DRUG|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
224146828|NCT01656811|DRUG|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
224146829|NCT01656811|DRUG|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
224146830|NCT01656811|DRUG|Placebo|Placebo 2 actuations QID
224146831|NCT06119425|DIAGNOSTIC_TEST|blood-based CRC screening|For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
224146832|NCT01226706|DRUG|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
224146833|NCT01226706|DRUG|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
224146834|NCT01165099|PROCEDURE|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
223449333|NCT03096561|DIAGNOSTIC_TEST|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
223449334|NCT04245917|OTHER|Non-interventional|Non-interventional natural history study
223449335|NCT01214668|DRUG|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
223449336|NCT01214668|DRUG|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
223449337|NCT01964989|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
223449338|NCT01964989|BIOLOGICAL|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
223449339|NCT06259149|DRUG|Nardraparin calcium injection|The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
223449340|NCT04868578|DIETARY_SUPPLEMENT|study treatment PPI|patient take PPI every day during 12 months
223449341|NCT04868578|DIETARY_SUPPLEMENT|Placebo comparator|patient take PPI placebo every day during 12 months
223449342|NCT03176121|DRUG|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
223449343|NCT03014141|OTHER|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
224057269|NCT04651621|DEVICE|continuous theta burst stimulation over the SMA|Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.
223449344|NCT03014141|OTHER|Maltodextrin|11 g of Maltodextrin
224057270|NCT04651621|DEVICE|sham continuous theta burst stimulation over the SMA|The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
224057271|NCT05842369|DEVICE|ADVOS|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
224057272|NCT05842369|DEVICE|CVVHD|Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
224057273|NCT03939845|RADIATION|RT|external- beam radiotherapy (EBRT)
224146835|NCT03792451|DRUG|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
224146836|NCT01524237|DRUG|LY2979165|Capsules administered orally
224146837|NCT01524237|DRUG|LY2140023|Tablets administered orally
224146838|NCT01524237|OTHER|Placebo|Administered orally
224146839|NCT01524237|OTHER|Ketamine|Administered intravenously (IV)
223449345|NCT00005872|DRUG|rubitecan|
223449346|NCT01344473|DEVICE|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
223449347|NCT01292707|BEHAVIORAL|Control|Standard national training
223449348|NCT01292707|BEHAVIORAL|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
223449349|NCT01292707|BEHAVIORAL|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
223449350|NCT03908554|OTHER|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
223449351|NCT00104806|DIETARY_SUPPLEMENT|cholecalciferol|100 milligrams orally once a day for 28 days
223449352|NCT00104806|DRUG|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
223569224|NCT05475665|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
224146840|NCT01959399|DRUG|ASP015K|oral tablet
224146841|NCT01959399|DRUG|Rosuvastatin|oral tablet
224146842|NCT02465346|DEVICE|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
224146843|NCT02465346|DEVICE|Control stroke management|Conventional stroke management
224146844|NCT00518401|BIOLOGICAL|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
224146845|NCT05121831|DRUG|DGX-001Dose 1|Dose level 1 of DGX-001
224146846|NCT05121831|DRUG|DGX-001 Dose 2|Dose level 2 of DGX-001
224146847|NCT05121831|DRUG|DGX-001 Dose 3|Dose level 3 of DGX-001
224146848|NCT05121831|DRUG|DGX-001 Dose 4|Dose level 4 of DGX-001
224146849|NCT05121831|DRUG|MAD dose panel of DGX-001|Dose levels confirmed through SAD and MAD
224146850|NCT01213264|OTHER|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
223449353|NCT04829630|BIOLOGICAL|rabies vaccine|"* day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~* day 7 : questionnaire and blood sampling"
223449354|NCT00424593|DRUG|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
223449355|NCT00424593|DRUG|Placebo|every day (QD), by mouth (PO), 13 weeks
223449356|NCT01796301|DRUG|Romozosumab|Administered by subcutaneous injection once a month.
223449357|NCT01796301|DRUG|Teriparatide|Administered by subcutaneous injection once a day.
223449358|NCT00667563|BIOLOGICAL|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
223449359|NCT00667563|GENETIC|DNA analysis|Weeks 0, 2, 10, 26, and 52.
223569225|NCT04644471|DIAGNOSTIC_TEST|CT scanner|1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition
224057274|NCT03939845|PROCEDURE|TACE|transarterial chemoembolization (TACE)
224057275|NCT02754895|OTHER|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
224057276|NCT02754895|OTHER|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
224057277|NCT01080248|DRUG|Gemcitabine|
224057278|NCT01080248|DRUG|Pazopanib|
224057279|NCT00856960|DRUG|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
224057280|NCT00856960|DRUG|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
224057281|NCT00856960|DRUG|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
224057282|NCT00856960|DRUG|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
224057283|NCT00856960|DRUG|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
224057284|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression.
224057285|NCT05533138|BEHAVIORAL|Therapist Guided Internet-CBT for antenatal depression and perinatal extra support.|A 10 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression adapted for antenatal depression. Additionally, up to three supportive contacts with a midwife or perinatal mental health nurse to support ICBT treatment and adress general pregnancy related health problems.
223449360|NCT00667563|GENETIC|polymerase chain reaction|Screening, week 36, and week 52.
224057286|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by chance|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation by chance.
224057287|NCT05533138|BEHAVIORAL|Diagnostic assessment by telephone, video or face-to face - Allocation by choice|Structured diagnostic perinatal psychiatric assessment of women screening positive for antenatal depression (pregnancy week 8-29) by telephone, video or in a face-to-face meeting. Assessment form allocation based on patient preference.
224057288|NCT06220370|OTHER|Observational|There is no clinical intervention as part of this study. Participants will receive treatment as per their clinical treating team.
224057289|NCT04993040|DRUG|Oraxol|"* HM30181 methanesulfonate monohydrate~* Oral paclitaxel capsules"
224057290|NCT00642395|DRUG|Bortezomib|bortezomib-Melphalan
223449361|NCT00667563|OTHER|cytology specimen collection procedure|Screening, week 36, and week 52.
223449362|NCT00667563|PROCEDURE|colposcopic biopsy|Screening, week 36, and week 52.
223449363|NCT00029783|PROCEDURE|Distant Healing|
223449364|NCT02711020|BEHAVIORAL|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
223569226|NCT04644471|DIAGNOSTIC_TEST|Lung MRI|3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence
223569227|NCT02445677|DEVICE|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
224057291|NCT04979689|OTHER|Intensive physical therapy|Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.
223449365|NCT02711020|BEHAVIORAL|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
223449366|NCT03701152|DEVICE|Negative pressure therapy|Negative pressure therapy at sub atmospheric level
223449367|NCT03302507|PROCEDURE|BESS|Biportal endoscopic surgery
223449368|NCT03302507|PROCEDURE|ULBD|Unilateral laminotomy bilateral decompression
223569228|NCT02445677|DEVICE|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
223569229|NCT06888180|OTHER|Non interventional study|"Documentation of Non-Invasive Ventilation Settings at Different Stages of Patient Management"
223569230|NCT06895512|DRUG|HLX15-IV|recombinant anti-CD38 human monoclonal antibody injection
224057292|NCT04979689|OTHER|Non intensive physical therapy|Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
224057293|NCT01853995|DEVICE|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
224057294|NCT04945668|PROCEDURE|Modified technique for pericapsular nerve group block|with the patient in the supine position, ultrasound probe in a transverse plane over the anterior inferior iliac spine (AIIS) and then aligned with the pubic ramus. In this view, the ilio pubic eminence (IPE), the iliopsoas muscle and tendon will be observed. A spinal needle will be inserted from lateral to medial in an in-plane approach to place the tip between the psoas tendon and the pubic ramus. Fluoroscopic image will be taken to confirm the needle tip position in the target site. Following negative aspiration, 15 ml dye will be injected in 5-mL increments while observing for adequate spread using fluoroscopy followed by 15ml local anesthetic
224057295|NCT00821080|DRUG|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
224057296|NCT00821080|DRUG|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
224057297|NCT01043276|DRUG|Treatment A|PF-00258210 220 µg using inhaler A
224057298|NCT01043276|DRUG|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
224057299|NCT01043276|DRUG|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
223449369|NCT05784701|DRUG|TSCV (Full-strength)|TSCV (Full-strength)
223449370|NCT05784701|DRUG|TSCV (Half-strength)|TSCV (Half-strength)
223449371|NCT05784701|DRUG|Typbar-TCV|Typbar-TCV
223449372|NCT05784701|DRUG|Placebo|Placebo
223449373|NCT05172401|DEVICE|Oxulumis® suprachoroidal microcatheterization administration of Triesence®|Suprachoroidally administered Triamcinolone acetonide (Triesence) 2.4mg/60µl
223449374|NCT04403295|BEHAVIORAL|Collaborative Specialty Care|In specialty collaborative care, the specialty provider team will deliver health coaching and problem-solving treatment to GWVs and recommend the primary care team make monthly optimization of analgesics.
223569231|NCT06895512|DRUG|Darzalex|recombinant anti-CD38 human monoclonal antibody injection
223569232|NCT06897306|PROCEDURE|surgery|The patient underwent surgery.
223569233|NCT06572982|DRUG|Azacitidine|300 mg Film coated tablets
223569234|NCT03922594|DIAGNOSTIC_TEST|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
223569235|NCT06379958|DRUG|leramistat 40mg|Oral capsule
223569236|NCT06379958|DRUG|Itraconazole 200 mg|Oral capsule
223569237|NCT06379958|DRUG|Phenytoin 100 Mg Oral Capsule|Oral capsule
223569238|NCT06379958|DRUG|Simvastatin 40mg|Oral capsule
223569239|NCT06379958|DRUG|Upadacitinib 15 MG|Oral Capsule
223569240|NCT06227676|DIETARY_SUPPLEMENT|Cramp Bites by Aunt Flo's Kitchen|Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
223569241|NCT03265002|DIETARY_SUPPLEMENT|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
224057300|NCT01043276|DRUG|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
224057301|NCT01043276|DRUG|Treatment E|PF-00258210 220 µg using inhaler B
224057302|NCT02458521|DEVICE|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
224057303|NCT02458521|DEVICE|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
223449375|NCT04403295|BEHAVIORAL|e-consultation|In e-consultation the specialty provider team will make a onetime recommendation to the primary care team that the GWV locally receive health coaching and problem-solving treatment and analgesic optimization.
223449376|NCT01994707|PROCEDURE|Remote ischemic preconditioning|Blood pressure cuff inflation
223449377|NCT01994707|PROCEDURE|Placebo|Deflated cuff on arm for 30 minutes.
223449378|NCT02855710|OTHER|Rhythm workers training Perceptive timing|Perceptive timing training
223449379|NCT02855710|OTHER|Rhythm workers training sensorimotor timing|Sensorimotor timing training
223449380|NCT02855710|OTHER|No Rhythm workers training|No training
224057304|NCT04455763|PROCEDURE|SVF|Adipose-derived stromal vascular fraction
223449381|NCT04687540|DRUG|Tocilizumab|Baseline: Tocilizumab (infusion of 8 mg/kg bodyweight or a maximum of 800 mg) will be infused over 60 minutes at the end for the study day, therefore study visit 1 (study day 1) measurements are baseline.
223449382|NCT04687540|DRUG|Saline 0.9%|Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
223449383|NCT01155349|BEHAVIORAL|InSight|A cognitive intervention designed to enhance speed of visual processing.
223449384|NCT01155349|OTHER|No contact-control group|No contact-control group.
223449385|NCT04293172|DRUG|Brilinta|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
224146851|NCT01213264|DRUG|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
224146852|NCT01213264|DRUG|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
223449386|NCT04293172|DRUG|Placebo|"Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day"
223449387|NCT02437643|BEHAVIORAL|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
223449388|NCT02437643|DIETARY_SUPPLEMENT|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
223449389|NCT02437643|BEHAVIORAL|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
223449390|NCT00402623|DIETARY_SUPPLEMENT|quercetin|1000 mg quercetin within 24 hours
223569242|NCT03265002|DIETARY_SUPPLEMENT|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
223569243|NCT03265002|DIETARY_SUPPLEMENT|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
223569244|NCT03265002|DIETARY_SUPPLEMENT|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
223569245|NCT03576404|OTHER|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
223449391|NCT00402623|OTHER|placebo|
223449392|NCT04150653|DEVICE|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
223569246|NCT00146809|DRUG|Minocyline|
223569247|NCT05953597|BEHAVIORAL|Nutrition Education|The intervention will consist of 12 monthly nutrition education sessions catered to people with spinal cord injuries. The curriculum is based on the 2020-2025 Dietary Guidelines for Americans such as consuming recommended amounts of fruits/vegetables, whole grains, etc. The sessions will be approximately 30-60 minutes and will be available in-person.
223569248|NCT01543399|DRUG|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
223569249|NCT01543399|DRUG|Placebo|patients of the placebo group will use placebo one a day for 30 days
223741822|NCT00196716|BIOLOGICAL|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
223741823|NCT00399360|DRUG|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
223741824|NCT00399360|DRUG|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
223741825|NCT00399360|BEHAVIORAL|Lifestyle Modification|Lifestyle Modification
223741826|NCT02442960|DRUG|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
223741827|NCT06237595|DEVICE|Vagus nerve stimulation|Electrical stimulation of the vagus nerve.
223741828|NCT06237595|DRUG|Medical treatment|Medical treatment for fibromyalgia patients
224057305|NCT04455763|OTHER|Splint|Thumb brace (Actimove® Rhizo Forte)
223449393|NCT03568383|DRUG|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to \<30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
223449394|NCT03568383|DRUG|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to \<24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
223449395|NCT03568383|DIETARY_SUPPLEMENT|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
223449396|NCT03545633|DEVICE|Treatment with High Intensity Focused ElectroMagnetic system.|"The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area.~Visible contractions will be induced by the device."
223449397|NCT01983163|OTHER|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
223449398|NCT01983163|OTHER|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
223449399|NCT01449864|RADIATION|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
223449400|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
223449401|NCT02187029|OTHER|Placebo|Daily dosing (tablet) for 14 days
223449402|NCT02187029|DRUG|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
224057306|NCT03497585|BEHAVIORAL|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
224146853|NCT02375984|BIOLOGICAL|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10\^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
223449403|NCT02187029|OTHER|Placebo|Daily dosing (tablets) for 14 days
223449404|NCT00012389|DRUG|irinotecan hydrochloride|
223449405|NCT00012389|DRUG|oxaliplatin|
223449406|NCT00815503|DRUG|Ropivacaine|Approved by the Danish Medicines Agency
223449407|NCT00815503|DRUG|Placebo|Saline
224057307|NCT02779959|DRUG|Prochlorperazine|
224057308|NCT06148688|OTHER|Digital Story|"Digital storytelling; It is used in education and training, business marketing, non-profit organizations such as libraries, community centers and museums, and health sciences education. Digital storytelling in health sciences can be a tool for patients and health science professionals to share their experiences, cope with diseases, and add a human element to health problems.~In the study, digital stories were created to increase the self-management of pregnant women with gestational diabetes. In creating a digital story; Qualitative studies involving the self-management experiences of women with gestational diabetes have been examined in the literature. Using the results of the studies, scenarios were created that included factors that facilitate and complicate diabetes self-management. The created scenarios were used in the digital storytelling initiative. A total of four long and four short digital story videos were prepared."
224057309|NCT00807742|DRUG|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
224057310|NCT00807742|BEHAVIORAL|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
224057311|NCT00807742|BEHAVIORAL|Contingency Management|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
223449408|NCT03349489|OTHER|Exercise 1|Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
223449409|NCT03349489|OTHER|Exercise 2|Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
223449410|NCT03349489|DEVICE|Dexcom G4 Platinum|The Dexcom G4 Platinum will be used to measure continuous glucose levels.
223741829|NCT06237595|COMBINATION_PRODUCT|Combined vagus nerve stimulation and medical treatment|Combination of the two interventions
223741830|NCT05321615|DEVICE|Palpator|Palpator for tumor localization
223741831|NCT05321615|DEVICE|Grasper|Atraumatic lung grasper
223741832|NCT05321615|DEVICE|Ultrasound|VATS ultrasound
223741833|NCT05321615|OTHER|Finger palpation|Palpation of the lung/tumour using the surgeon's finger
223741834|NCT06187610|BEHAVIORAL|Digital education|Patients assigned to the experimental group will learn about symptom self-management in a digital learning environment.
224057312|NCT00807742|BEHAVIORAL|Non-Contingent Reinforcement|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
223449411|NCT03349489|DRUG|Insulin|Participant's usual fast-acting insulin analog will be used.
224057313|NCT00492752|DRUG|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
224146854|NCT04789863|DEVICE|SMILe-Integrated Care Model|"Four self-management intervention modules will be delivered by human and technology: 1) monitoring \& follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare."
223741835|NCT04989400|DRUG|Ulipristal Acetate|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal. Then women in had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
223741836|NCT04989400|DRUG|Misoprostol|Group A: received Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal.Group B: received placebo tablet of same shape , texture of that of ulipristal then 12 hours later start misoprostol 100µg every 6 hours buccal. Then women in both groups had rest for 24 hours after 5 doses of misoprostol and restarted misoprostol-only in both groups with the same above regimens, repeating the same sequence for two weeks unless there was excessive bleeding or infection or uterine contractions or cervical changes. If failed, patient proceeded to hysterotomy. If patient aborted, an obstetric US was done to assess the presence of remnants in the uterine cavity. Patient with remnants of conception proceeded suction evacuation.
224057314|NCT00492752|DRUG|Placebo|Matching placebo (orally) twice daily
224057315|NCT03688399|DEVICE|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near
224057316|NCT03688399|DEVICE|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
224057317|NCT04935099|DIETARY_SUPPLEMENT|Wild blueberry powder|22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.
224057318|NCT04935099|DIETARY_SUPPLEMENT|Placebo powder|22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
224057319|NCT00219284|DRUG|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
224057320|NCT01357655|DRUG|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
223449412|NCT03349489|DEVICE|Insulin pump|Participant's insulin pump will be used to infuse insulin.
223449413|NCT04810910|BIOLOGICAL|iNeo-Vac-P01|iNeo-Vac-P01 (peptides)： 300 mcg per peptide
223449414|NCT04810910|OTHER|GM-CSF|GM-CSF: 40 mcg
223449415|NCT03042910|DRUG|Talazoparib|Talazoparib 1 mg orally once daily.
223449416|NCT00639925|BIOLOGICAL|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
223449417|NCT05635877|DRUG|Esmolol|The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump
223741837|NCT00384722|DEVICE|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
223741838|NCT05966168|DEVICE|Medtronic Micra AV Device|Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
223741839|NCT04123288|DRUG|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
223741840|NCT04123288|DRUG|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
223741841|NCT01166178|DRUG|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
223741842|NCT01166178|DRUG|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
224057321|NCT01357655|DRUG|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
223449418|NCT05635877|DRUG|Placebo Comparator: Placebo Comparator:normal saline(0.9%)|The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
223449419|NCT02164071|OTHER|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
223449420|NCT04272047|OTHER|Knee Control+ program|15-20 minute training program to be performed at all team training sessions during the season.
224057322|NCT02098512|DRUG|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
223449421|NCT04272047|OTHER|Adductor strengthening program|Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.
223449422|NCT04272047|OTHER|Knee Control program|15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
223449423|NCT02634632|BEHAVIORAL|Choosing to write advance directives|
223569250|NCT01165788|PROCEDURE|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
223569251|NCT03993990|BEHAVIORAL|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
223569252|NCT02358200|DRUG|BMN-673|
223569253|NCT02358200|DRUG|Carboplatin|
223569254|NCT02358200|DRUG|Paclitaxel|
223569255|NCT05308017|DEVICE|Richard Wolf 24F Laser scope|24F Laser with HoLEP
223569256|NCT05308017|DEVICE|Karl Storz 28F Laser Scope|28 F Laser with HoLEP
223569258|NCT00350272|DRUG|Elvucitabine|Elvucitabine 10 mg orally daily
223569259|NCT00350272|DRUG|Lamivudine|Lamivudine 300 mg orally daily
223569260|NCT00350272|DRUG|Tenofovir|Tenofovir open-label 300 mg orally daily
223569261|NCT00350272|DRUG|Efavirenz|Efavirenze open-label 600 mg orally daily
223569262|NCT03465462|DIETARY_SUPPLEMENT|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
223449424|NCT00151086|DRUG|Estramustine|
223449425|NCT00151086|DRUG|Vinorelbine|
223569263|NCT03465462|DIETARY_SUPPLEMENT|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
223569264|NCT03465462|DIETARY_SUPPLEMENT|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
223569265|NCT03977025|DIAGNOSTIC_TEST|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
223569266|NCT00274898|DRUG|celecoxib|
223569267|NCT00274898|DRUG|docetaxel|
223569268|NCT00274898|PROCEDURE|adjuvant therapy|
223449426|NCT02082769|DRUG|Febuxostat|
223449427|NCT02082769|DRUG|Allopurinol|
223449428|NCT05307003|DRUG|Trazodone|Medication used to treat ICU delirium
223449429|NCT05307003|DRUG|Quetiapine|Medication used to treat ICU delirium
223449430|NCT02756819|DRUG|Azilsartan Medoxomil|Azilsartan medoxomil tablets
223449431|NCT00405340|DRUG|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
223449432|NCT01496417|DRUG|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
223569269|NCT00274898|RADIATION|radiation therapy|
224057323|NCT02098512|PROCEDURE|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
224057324|NCT02098512|DRUG|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
223449433|NCT05582759|BEHAVIORAL|teleCBT-I + SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention
223449434|NCT05582759|BEHAVIORAL|SH/ReadiWatchTM|Participants receive real time feedback on sleep metrics and education on sleep hygiene
223449435|NCT00493506|DRUG|ProAlgaZyme|
223449436|NCT06283433|DIAGNOSTIC_TEST|Finger Prick|Blood sample obtained via drop of capillary blood by finger prick onto filter paper
223449437|NCT06283433|DIAGNOSTIC_TEST|Venipuncture|Blood sample obtained trough venipuncture
223449438|NCT00124085|BEHAVIORAL|Disease Management|
223449439|NCT00124085|BEHAVIORAL|Disease Management + Educational Home Visits|
223449440|NCT05811559|OTHER|No intervention|No intervention
223569270|NCT02070419|PROCEDURE|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
224057325|NCT00609986|DRUG|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
224057326|NCT00609986|DRUG|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
224146855|NCT04789863|OTHER|Usual Care|The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
224146856|NCT04265898|DEVICE|The Digital Virginia Tech Carilion Cognitive Examination|Completion of a newly developed digital cognitive screen
224146857|NCT04938388|DRUG|Semaglutide Pill|All participants will start at a 3 mg dose of OS or matched Placebo. If this minimum dose is not tolerated, the participant will be withdrawn from the study. After 4 weeks, the OS dose (or Placebo) will be adjusted to 7 mg. After a further 4 weeks of study and thereafter, the OS dose (or Placebo) will be adjusted at the study physician's discretion to 14 mg. At each study visit, the current dose of OS (or Placebo) will be maintained, unless participants report moderate-to-severe nausea or vomiting for 3 or more days in the week before the scheduled visit.
224146858|NCT04938388|DIETARY_SUPPLEMENT|Fresh organic vegetables|Prescriptions of organic vegetables
224146859|NCT02287870|DRUG|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
223449441|NCT02889770|OTHER|PEEP titration|Exposure to different PEEP levels
223449442|NCT06400485|DRUG|AMT-676|Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
223449443|NCT02944474|DRUG|Lucerastat|Capsule for oral administration containing lucerastat
223449444|NCT02944474|DRUG|Placebo|Placebo capsules matching lucerastat capsules
223449445|NCT03083808|DRUG|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~\+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8"
223449446|NCT01491841|DRUG|Bendamustine + Rituximab + Pixantrone|Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
223449447|NCT01491841|DRUG|Pegfilgrastim|6mg administered on Day 2 of each 21 day cycle
223449448|NCT05327595|DRUG|LY3549492|Administered orally.
223569271|NCT02070419|RADIATION|stereotactic radiosurgery|Undergo SBRT
223569272|NCT04300517|DRUG|Three sachet of protein supplement to be mixed in with water used daily|Three sachet of protein supplement to be mixed in with water used daily
223569273|NCT04042142|OTHER|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
223449449|NCT05327595|DRUG|Placebo|Administered orally.
223449450|NCT05327595|DRUG|Atorvastatin|Administered orally.
223449451|NCT05327595|DRUG|Midazolam|Administered orally.
223449452|NCT03711136|PROCEDURE|aortic prosthesis|ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
223449453|NCT01138527|OTHER|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
223449454|NCT05799898|OTHER|No intervention for research purposes only|No intervention for research purposes only
223449455|NCT05556941|BEHAVIORAL|Metacognitive Group Intervention|The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
223449456|NCT05556941|BEHAVIORAL|Occupational therapy standard care|Occupational therapy standard care
223449457|NCT02933528|DRUG|DSXS Topical product|once daily for 28 days
223449458|NCT04276077|OTHER|High-frequency electrical muscle stimulation training|High-frequency electrical muscle stimulation training with 50 Hertz during 8 weeks
223449459|NCT04276077|OTHER|Low-frequency electrical muscle stimulation training|Low-frequency electrical muscle stimulation training with 10 Hertz during 8 weeks
223569274|NCT02321189|DRUG|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
223449460|NCT04699370|OTHER|cognition-targeted exercise|"All Standardized physical therapy exercises will be performed in a time-contingent .~Goal setting is essentially done together with the patient, focussing on functionality instead of fatigue relief. Progression to a next level of (more difficult) exercises will be preceded by an intermediate phase of motor imagery.~The treating physical therapist will be advised to address patients' cognitions about their problems during the cognition-targeted exercise training, so that patients will have positive perceptions regarding their illness and treatment outcome.~The treating physical therapist will be advised to discuss the patient's perceptions about each exercise. This include discussion of the anticipated consequences of the exercises and challenging the patient's cognitions in relation to the exercises"
223449461|NCT04699370|BEHAVIORAL|Cognitive behavioral therapy|In the first and second sessions, patients will learn about fatigue-related symptoms as well as Cognitive behavioral therapy and its effectiveness. The third and fourth sessions will be devoted on the introduction of behavioral strategies. The fifth session will introduce cognitive strategies to decrease fatigue. The last three sessions will be about how to adopt the proposed strategies consistently.
223449462|NCT04699370|OTHER|Standardized physical therapy|The standardized physical therapy will consist of eight half-hour individualized face to face physiotherapy sessions, over a 4-week period. this program will consist of twice-weekly supervised general aerobic, strengthening and flexibility exercise sessions .This exercise program is reflective of the general exercises typically undertaken within routine clinical practice.
223449463|NCT00845936|DRUG|Metformin|Metformin 850 mg bid
223449464|NCT01301079|DRUG|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
223449465|NCT01301079|DRUG|Saline|Patients in group N (placebo) was administrated saline during surgery.
223449466|NCT00396474|OTHER|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
223449467|NCT03453814|OTHER|Music Therapy|Subjects will receive one hour of music twice a day for three days.
223449468|NCT01689753|DEVICE|TEGO connector®|
223449469|NCT01689753|DRUG|Trisodium citrate|
223449470|NCT02700425|DEVICE|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
223449471|NCT05621850|OTHER|Blood sample|Based on supplementary blood sampled before embolization procedure and 6 hours and 24 hours after we will be analyzed cytokines concentration (Elisa test) and cortisol
223449472|NCT02477371|PROCEDURE|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values \> 0,8 are deferred.
223449473|NCT02477371|PROCEDURE|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
223449474|NCT00002261|BIOLOGICAL|Smallpox Vaccine|
223449475|NCT00002261|BIOLOGICAL|HIVAC-1e|
223449476|NCT00002261|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223449477|NCT04059939|OTHER|Reading|Small group reading instruction
223449478|NCT04059939|BEHAVIORAL|Anxiety Management|small group anxiety management skills instruction
224146860|NCT02287870|DRUG|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
223449479|NCT04059939|OTHER|Classroom Business as Usual|Classroom Business as Usual
223449480|NCT04059939|OTHER|Attention Control (math practice)|Attention Control (math practice)
223449481|NCT02842008|BEHAVIORAL|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
223449482|NCT02155088|DRUG|BYL719|Dose escalation beginning at 250 mg/day
224057327|NCT03173859|DRUG|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
224057328|NCT03173859|DRUG|Apalutamide|apalutamide 240mg qD orally
224146861|NCT00888069|DRUG|CTAP101 Capsules|Single dose oral administration
224146862|NCT00888069|DRUG|CTAP101 Injection|single IV injection
224146863|NCT02884271|PROCEDURE|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
223449483|NCT02155088|DRUG|Gemcitabine|Dose escalation beginning at 800 mg/m\^2
223449484|NCT02155088|DRUG|(nab)-paclitaxel|125 mg/m\^2 dose
224057329|NCT04355741|OTHER|Exposure|Individuals with SARS-CoV-2 exposure and COVID-19 symptoms.
224057330|NCT06265857|DEVICE|Intermittent Oro-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
224146864|NCT05389384|DEVICE|Passive shoulder exoskeleton|Participants complete overhead working task with support of exo
224146865|NCT05389384|BEHAVIORAL|Fatigue protocol|Participants complete a fatiguing protocol
224146866|NCT05389384|DEVICE|No exoskeleton support|Exoskeleton is worn, but no support provided
224146867|NCT05389384|BEHAVIORAL|No peripheral fatiguing protocol|Participants complete no fatiguing protocol
224057331|NCT06265857|DEVICE|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
224057332|NCT06265857|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
224057333|NCT02921074|OTHER|Computerized Plasticity-Based Adaptive Cognitive Training|
224057334|NCT02921074|OTHER|Commercially available computerized training|
224057335|NCT02384668|DIETARY_SUPPLEMENT|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
223449485|NCT03377062|DIAGNOSTIC_TEST|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
223449486|NCT06060340|DRUG|class II furcation defects management using propolis|"A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect."
223449487|NCT05761457|OTHER|Cryopreserved autologous platelet transfusion|Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20\*10E9/L or severe bleeding occurred.
223449488|NCT02857036|OTHER|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
223449489|NCT02857036|BEHAVIORAL|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
223449490|NCT00479115|DRUG|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
223449491|NCT00479115|DEVICE|AmCell CliniMACs|CD34+ cell selection from peripheral collection
223449492|NCT04369963|PROCEDURE|Esophagogastroduodenoscopy and Colonoscopy with Biopsies|Participants will have an esophagogastroduodenoscopy and colonoscopy with biopsies. Biopsies from esophagogastroduodenoscopy will not exceed 16 pinch biopsies, biopsies from colonoscopy will not exceed 16 pinch biopsies. Participants will have anesthesia for both procedures.
223449493|NCT00264290|DRUG|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
223449494|NCT00264290|DRUG|Placebo|Placebo designed to resemble Valganciclovir
223449495|NCT02496039|DRUG|NUEDEXTA®|NUEDEXTA® only
223449496|NCT02968459|OTHER|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
224057336|NCT02384668|DIETARY_SUPPLEMENT|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
224057337|NCT00004414|DRUG|sincalide|
224057338|NCT01982474|BIOLOGICAL|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
224057339|NCT01982474|OTHER|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
224146868|NCT04914871|BEHAVIORAL|Protocol UN Lifeguard Kids in the Tunja version|"The experimental protocol UN Lifeguard Kids in the Tunja version done by the researcher following the guidelines of International organizations such as the American Heart association and European Resuscitation Council.~The intervention consists of 3 sessions of 60 minutes of theoretical and practical exercises on BLS, developed within the usual class schedule."
224146869|NCT04914871|BEHAVIORAL|Educational session accident prevention and wound management|It will be provided to the control group
224146870|NCT06054503|DEVICE|prototype of sensor|The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
224146871|NCT03260894|DRUG|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
223449497|NCT02968459|OTHER|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
223449498|NCT04472494|BIOLOGICAL|Abatacept|Specified dose on specified days
223449499|NCT04472494|OTHER|Placebo|Specified dose on specified days
223449500|NCT06462170|DIETARY_SUPPLEMENT|Boost Original meal replacement shake|One bottle of Boost Original meal replacement shake.
223449501|NCT00571103|DRUG|acamprosate|Two 333mg tablets taken three times daily.
223449502|NCT05294965|DRUG|Fenoterol|Intravenous infusion
223449503|NCT05294965|OTHER|Mild cold exposure|Body surface cooling
223449504|NCT05345678|DRUG|Durvalumab|Dose: 1500mg Route: IV
223449505|NCT05345678|DRUG|Tremelimumab|Dose: 300mg Route: IV
223569275|NCT02321189|DRUG|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
224146872|NCT03260894|DRUG|Epacadostat|Epacadostat 100 mg administered orally twice daily.
223449506|NCT03954002|DIAGNOSTIC_TEST|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
223449507|NCT05588752|OTHER|TAP block|TAP block under ultrasound
223449508|NCT01728441|DEVICE|Paclitaxel Eluting Stent|
223449509|NCT01728441|DEVICE|Paclitaxel Eluting Balloon|
223449510|NCT02547909|PROCEDURE|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
223449511|NCT02547909|DEVICE|Cellvizio|
223449512|NCT02547909|DRUG|fluorescein 10%|
223449513|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
223449514|NCT02044653|DRUG|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
223449515|NCT02044653|DRUG|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
223569276|NCT02511093|BEHAVIORAL|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~* BP measurements;~* an educational and counselling intervention on patient adherence;~* an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
223449516|NCT02044653|DRUG|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
223569277|NCT05305833|BIOLOGICAL|Stem Cells|ATMP
223569278|NCT03968575|DEVICE|laser treatment|sub-threshold micro-pulse laser treatment
224057340|NCT04076514|PROCEDURE|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
224057341|NCT03129490|DRUG|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
224057342|NCT03129490|DRUG|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
224057343|NCT03129490|DRUG|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
224057344|NCT03129490|DRUG|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
223449517|NCT02044653|DRUG|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
223449518|NCT02641275|OTHER|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
223449519|NCT02624635|OTHER|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
223449520|NCT02624635|OTHER|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ \[1.0278 - (0.0278 x number of repetitions)\] as was used by (Shirazi et al., 2007).
223449521|NCT01308463|DEVICE|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
223449522|NCT02103699|DRUG|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
223449523|NCT05035875|DEVICE|ultrasonography|ultrasound assessment of diaphragm function
223569279|NCT03003221|BEHAVIORAL|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
223569280|NCT03003221|BEHAVIORAL|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
223569281|NCT01728558|OTHER|Early goal Directed Sedation|
223569282|NCT01728558|OTHER|Standard care sedation|
224057345|NCT04643951|BEHAVIORAL|Interview|Interview study using Grounded theory, to investigate dental professionals' and students' perception of child patient's experience and need for treatment regarding procedural and postoperative pain.
224146873|NCT03260894|DRUG|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
224146874|NCT03260894|DRUG|Pazopanib|Pazopanib 800 mg administered orally once daily.
224057346|NCT04738786|PROCEDURE|1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers|"Surgical resection including 1.5 cm normal tissue around the gross tumors~Definition of safety margin: A surgical safety margin is defined as the margin of apparently non-tumorous tissue around a tumor that has been surgically removed (Resected normal-looking tissues from the gross tumor border). The surgical safety margin is applied to all directions of 3-dimensional tumors (mucosal and deep side)."
224057347|NCT04738786|PROCEDURE|1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers|Surgical resection including 1.0 cm normal tissue around the gross tumors
223449524|NCT02477436|DRUG|Avanafil|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks."
223449525|NCT02477436|DRUG|Placebo|"* One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~* Placebos were administered prior to the sexual intercourse for total 8 weeks."
224057348|NCT05066789|DEVICE|Type of stent|1:1 randomization to biodegradable polymer DES (Orsiro Mission) and polymer-free DCS (Biofreedom)
224057349|NCT05066789|DRUG|Duration of DAPT|1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
224057350|NCT05375994|DRUG|avutometinib (VS-6766) and adagrasib|The RP2D of VS-6766 + adagrasib determined in Part A will be used in Part B dose expansion
224057351|NCT02390635|PROCEDURE|Computed Tomography|Undergo 18F-FDG PET/CT
224057352|NCT02390635|PROCEDURE|Diffusion Weighted Imaging|Undergo whole body PET/MRI
224057353|NCT02390635|RADIATION|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
224057354|NCT02390635|DRUG|Gadolinium|Given IV
224057355|NCT02390635|PROCEDURE|Magnetic Resonance Imaging|Undergo whole body PET/MRI
224057356|NCT02390635|PROCEDURE|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
224057357|NCT02390635|PROCEDURE|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
224057358|NCT06216756|PROCEDURE|osteochondral transplant on the femoral condyle|Patients who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 2.0-8.0 cm2 in size, and cystic changes requiring osseous repair present in less than or equal to 12 mm of subchondral bone will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.
224057359|NCT06552312|OTHER|Delphi Questionnaire|"Experts will be asked to rate the importance of each item for ECPR for OHCA using the Grading of Recommendations Assessment, Development and evaluation scale from 1 (strongly disagree) to 9 (strongly agree). Statements will be classified as strong agreement (median score 7-9), neither agree or disagree (median score 4-6), or strongly disagree (median score 1-3). Panel members were also provided an Unable to Score response to use if they did not feel comfortable rating any specific domain. Recipients will be asked to recommend any wording/phrasing changes and to suggest any additional items for inclusion."
224057360|NCT06061250|DIETARY_SUPPLEMENT|Chewing a piece of gum (Xylitol gum, LOTTE WELLFOOD, Korea) before induction of anesthesia|To replicate Xylitol chewing gum, which has been shown to reduce postoperative sore throat in previous studies of single-lumen endotracheal tubes and supraglottic airways, the investigators will use a commercially available gum from South Korea.
224057361|NCT04023422|BEHAVIORAL|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
224057362|NCT04023422|BEHAVIORAL|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
224057363|NCT06383936|PROCEDURE|intensive rehabilitation after uncemented TKA|patients undergoing an intensive rehabilitation protocol after uncemented tka
224057364|NCT03514108|DRUG|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
224146875|NCT04671069|DRUG|MGL-3196|Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
224146876|NCT04671069|DRUG|Clopidogrel|After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
224146877|NCT02539303|DRUG|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
224146878|NCT02098005|OTHER|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
223569283|NCT02910401|BIOLOGICAL|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
224057365|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 3 daily
224057366|NCT03514108|DRUG|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
224057367|NCT03514108|DRUG|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
224057368|NCT02943057|DRUG|2% guttae ganciclovir|2% guttae ganciclovir 5 times a day for 6 weeks
224057369|NCT03318380|PROCEDURE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
224057370|NCT05057949|DRUG|Larotinib|Larotinib Capsules
224057371|NCT05057949|DRUG|Rifampin|Rifampin Capsules
224057372|NCT05057949|DRUG|Itraconazole|Itraconazole Capsules
224057373|NCT04722042|OTHER|place-based mapping|Adjusting the electric frequency filters to align with the cochlear place frequency
224057374|NCT04722042|OTHER|default mapping|Default frequency filter assignments
224057375|NCT01031550|DRUG|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
224057376|NCT01031550|DRUG|propofol|standard of care
223449526|NCT01514877|DRUG|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
223449527|NCT03405168|DRUG|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
223449528|NCT04648657|DEVICE|Lung Ultrasound|Echography of Lungs based on artifacts study
223449529|NCT04648657|DEVICE|Electric impedance tomography|Low alternating electrical currents (usually \<5 milliampere at 50-80 kHz) applied through different pair of electrodes on thorax
223449530|NCT01238419|DEVICE|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
223449531|NCT01238419|DEVICE|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
223449532|NCT03731208|DEVICE|Telerehabilitation|"The telerehabilitation program equipment consists of the following devices:~* a tablet with a keyboard and a fingerprint sensor~* two wearable sensors~* a wireless modem~* measuring tape"
223449533|NCT03401632|OTHER|Enteral nutrition|Enteral nutrition support
223449534|NCT03635008|DEVICE|tDCS|Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
223449535|NCT01912053|RADIATION|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
223449536|NCT02640898|RADIATION|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
223449537|NCT02640898|RADIATION|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
223449538|NCT06832202|DRUG|HLX22|HLX22 15mg/kg Q3W
223449539|NCT06832202|DRUG|Trastuzumab Deruxtecan|Trastuzumab Deruxtecan 5.4mg/kg Q3W
223449540|NCT02777424|DRUG|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S
223449541|NCT02777424|BIOLOGICAL|Fresh Frozen Plasma|Pooled collection of plasma from donors
223449542|NCT03577379|OTHER|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
223449543|NCT04414423|PROCEDURE|bone marrow concentrate alveolar cleft grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft combined with bone marrow concentrate
223569284|NCT00771043|DRUG|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
224057377|NCT06424951|BEHAVIORAL|LKCM(Loving-kindness and Compassion Meditations)|Loving-kindness and Compassion Meditations
224057378|NCT03972787|DEVICE|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
224057379|NCT05742997|DEVICE|PartoSure|Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
224057380|NCT05742997|DEVICE|Fetal Fibronectine|Diagnostic Kit for the Detection of Fetal Fibronectine
224057381|NCT01992133|DIETARY_SUPPLEMENT|Vitamin D3|
224057382|NCT01992133|DIETARY_SUPPLEMENT|Placebo|
224057383|NCT06852274|DIETARY_SUPPLEMENT|Clostridium butyricum CBM588® (Butirrisan®)|Probiotic
224057384|NCT06852274|DRUG|Rifaximin 400 mg Oral Tablet|Antibiotic
224057385|NCT02090413|DRUG|dimethyl fumarate|
224057386|NCT02090413|DRUG|acetylsalicylic acid|enteric-coated capsule
224057387|NCT02090413|DRUG|ASA-Placebo|matched placebo
224057388|NCT03912142|DIAGNOSTIC_TEST|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
223449544|NCT04414423|PROCEDURE|Autogenous alveolar grafting|patients will undergo surgery to repair alveolar cleft with autogenous bone graft
223449545|NCT03597321|BIOLOGICAL|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
223449546|NCT05535426|DEVICE|Tetranite Implant Stabilization Material|Dental adhesive for increased implant stabilization
223569285|NCT02629848|DRUG|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
223569286|NCT02629848|DRUG|Placebo|Motesanib placebo-matching tablets
223569287|NCT02629848|DRUG|Paclitaxel|Paclitaxel IV
223569288|NCT02629848|DRUG|Carboplatin|Carboplatin IV
223569289|NCT02975479|DRUG|ALK Diluent|
224057389|NCT04165226|DEVICE|Low level light therapy|Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
223449547|NCT00475293|DRUG|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
223449548|NCT03594799|OTHER|Bed Rest Control Group|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
223449549|NCT03594799|DIETARY_SUPPLEMENT|Cocktail intervention|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
224146879|NCT02098005|OTHER|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
223449550|NCT04717089|OTHER|overnight intensive recovery / extended post anaesthetic care in PACU|From January 2020, during COVID-19 first pandemics in Hong Kong, a bundle of interim measures was implemented with the joint efforts of the Department of Anaesthesia and Operating Theatre Services (A\&OT) and Intensive Care Unit (ICU), and two ordinary recovery beds were converted into extended post anesthetic care in PACU (ExRR), based on the concept of overnight intensive recovery (OIR) to provide level 2 intensive care to patients undergoing major or ultra-major operations or having multiple comorbidities warranted intensive care in the immediately postoperative periods. This was conducted over 3 pandemic waves in Hong Kong.
223449551|NCT05693753|DEVICE|Use of XCM for the treatment of MAGRs with mCAF technique|After local anaesthesia, mCAF technique will be performed. XCM will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
224057390|NCT04165226|DEVICE|Fractional CO2|"Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~* Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2."
224057391|NCT04165226|DEVICE|Combined fractional CO2 laser and low level light therapy|Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
224146880|NCT06110897|BEHAVIORAL|High Dose Resistance Exercise Training|Progressive resistance exercise training
224146881|NCT06110897|BEHAVIORAL|Low Dose Resistance Exercise Training Group|Progressive resistance exercise training
223449552|NCT05693753|PROCEDURE|Treatment of MAGRs with CTG|After local anaesthesia, mCAF technique will be performed. CTG will be adapted on the root surfaces and positioned at the level of the cemento-enamel junction.
223449553|NCT04319653|DEVICE|Dynamic pelvic MRI with intravaginal probe with pressure sensor|Dynamic pelvic MRI with intravaginal probe and intravaginal and intrarectal opacification gel
223449554|NCT02784288|PROCEDURE|Neck Dissection|All patients will undergo neck dissection of the cervical lymph nodes
223449555|NCT02784288|PROCEDURE|Standard-of-Care (SOC) Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
223449556|NCT02784288|RADIATION|SOC Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
223449557|NCT02784288|DRUG|SOC Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
223449558|NCT02784288|DRUG|SOC Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
224057392|NCT05467956|OTHER|Covid-19|Covid-19 disease
223449559|NCT02784288|PROCEDURE|Videofluoroscopy|All patients undergo a videofluoroscopy procedure one year after completion of therapy to assess swallowing function.
223449560|NCT03336931|DIAGNOSTIC_TEST|Molecular profiling and drug testing|"1. Laboratory analysis including:~   A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~2. Multi-disciplinary Tumour Board case discussion~3. Recommendation of personalised therapy"
223449561|NCT02734862|DRUG|CD101|Intravenous antifungal therapy
223449562|NCT02734862|DRUG|Caspofungin|Intravenous antifungal therapy
223449563|NCT02734862|DRUG|Fluconazole|oral antifungal therapy
223449564|NCT02734862|DRUG|intravenous placebo|normal saline
223449565|NCT02734862|DRUG|oral placebo|microcrystalline cellulose
223449566|NCT03943797|BIOLOGICAL|Cultivated oral mucosal epithelial cell transplantation|Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
224057393|NCT05155202|DRUG|Antihypertensive Agents|Administration of intravenous Nicardipine or Urapidil
224146882|NCT00707343|RADIATION|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-\[F-18\]fluorothymidine, \[F-18\]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
224146883|NCT03779893|COMBINATION_PRODUCT|BioCoat® by Premier®.|Bioactive pits and fissure sealant
223449567|NCT06043492|OTHER|High Intensity Interval Training|10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max
223449568|NCT06043492|OTHER|Coninuous Running|40 min continuous running at lactate threshold
223449569|NCT06043492|OTHER|Control Trial|The participants will perform only the baseline and post acute-training evaluations, without performing exercise
223449570|NCT05969587|COMBINATION_PRODUCT|5% cysteamine cream|5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application
223449571|NCT05969587|COMBINATION_PRODUCT|hydroquinone cream group|4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
223449572|NCT05823103|DIAGNOSTIC_TEST|Shawki Septum Scoring System|Utilising the novel scoring system to facilitate feasibility and safety of hysteroscopic metroplasty for uterine septum
224057394|NCT02902250|PROCEDURE|Decompression|vertebral body decompression in compression fracture
224057395|NCT02902250|PROCEDURE|Conservative Treatment|Conservative Treatment in vertebral compression fracture
224057396|NCT06971705|DEVICE|repetitive transcranial magnetic stimulation, rTMS|Participants underwent rTMS intervention prior to daily ankle stability training. The interventional targets were the key cortical brain regions identified in preliminary studies, with stimulation applied to the contralateral cortical areas corresponding to the affected ankle joint. Parameters included a figure-of-8 coil, 10 Hz frequency, 2-second stimulation duration, 8-second inter-train intervals, 60 repetitions, totaling 1,200 pulses per session, with each session lasting 10 minutes. Ankle stability training commenced within 10 minutes post-rTMS, following the same duration and intensity as the Ankle Stability Training Group + Sham rTMS Group. The treatment was conducted three times per week for a total of 4 weeks.
224057397|NCT06971705|BEHAVIORAL|ankle stability training|The ankle stability training protocol comprised three modalities: neuromuscular training, balance training, and proprioceptive training. Specific exercises included single-leg stance, balance pad training, heel raises, resistive ankle inversion/eversion exercises, MOBO board balance exercises, alphabet tracing (toe-writing), lateral walking, heel walking, toe walking, and jump and landing control drills. The training progressed from stable to unstable surfaces, starting at low intensity and gradually increasing in difficulty and intensity. The training was conducted three times per week for a total of four weeks.
224057398|NCT06971705|DEVICE|Sham repetitive transcranial magnetic stimulation, SrTMS|Before each session of ankle stability training, participants received sham rTMS intervention. The sham stimulation mimicked the sensory experience of real rTMS but did not produce any physiological effects.
224057399|NCT06228326|BIOLOGICAL|KB707|Genetically modified herpes simplex type 1 virus
224057400|NCT06228326|DRUG|Pembrolizumab (KEYTRUDA®)|PD-1 immune checkpoint inhibitor
224057401|NCT06228326|DRUG|Chemotherapy|SOC chemotherapy
223449573|NCT05823103|DIAGNOSTIC_TEST|ESHRE ASRM Classification|Utilising the current classification before performing hysteroscopic metroplasty
223449574|NCT02131233|DRUG|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
223449575|NCT02131233|DRUG|Raltegravir|Raltegravir 400 mg tablet orally twice daily
224057402|NCT04001751|BEHAVIORAL|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
223449576|NCT02131233|DRUG|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
223449577|NCT02131233|DRUG|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
223449578|NCT02131233|DRUG|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
223449579|NCT04893187|DRUG|SSS17|SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH). It is being developed for the treatment of anemia in patients with chronic kidney disease.
223449580|NCT04893187|DRUG|Placebo|Matched placebo.
223449581|NCT02567097|BEHAVIORAL|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
223449582|NCT00230724|BEHAVIORAL|Exercise Counseling|
223449583|NCT06144541|OTHER|Survey administration for Fitzpatrick skin type|Survey administration for Fitzpatrick skin type
223449584|NCT06144541|DEVICE|Measurement of ITA based on SkinColorCatch instrument|Measurement of ITA based on SkinColorCatch instrument
223449585|NCT00463008|DRUG|methotrexate|
223569290|NCT02975479|DRUG|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
223569291|NCT03300024|DEVICE|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
223449586|NCT00463008|OTHER|pharmacological study|
224146884|NCT03779893|COMBINATION_PRODUCT|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
223449587|NCT05667818|DRUG|Amlodipine besylate tablets (trade name: Norfloxacin ®）|Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
223449588|NCT05667818|DRUG|Amlodipine besylate controlled-release tablets|Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9% Expiry date: October 24, 2024 Storage conditions: dark, sealed at room temperature. Manufacturer: Overseas Pharmaceuticals, Ltd. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
224057403|NCT05366933|DRUG|Vitamin B-Complex Supplement|Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
224057404|NCT06968793|PROCEDURE|Pressure support 15|Pressure support of 15 cm H2O will be applied for 5 minutes.
224146885|NCT04800120|OTHER|Hyperbaric Oxygen Therapy|Delivery of 100% oxygen within a hyperbaric oxygen therapy chamber
223449589|NCT03639129|DEVICE|Contrast-enhanced mammography|Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
223449590|NCT03639129|PROCEDURE|Biopsy|Standard of care
223449591|NCT02149563|DEVICE|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
224146886|NCT04828369|PROCEDURE|EUS-guided coil embolization combined with endoscopic cyanoacrylate injection|(1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
223449592|NCT01679028|DRUG|T89 Group A|150mg single dose on day 1
223449593|NCT01679028|DRUG|Placebo Group A|150mg single dose
223449594|NCT01679028|DRUG|Placebo Group B|300mg single dose
223449595|NCT01679028|DRUG|T89 Group B|300mg single dose
223449596|NCT01679028|DRUG|Placebo Group C|225mg bid
223449597|NCT01679028|DRUG|T89 Group C|225mg bid
223449598|NCT06501599|DIAGNOSTIC_TEST|Medical software (AI-based system)|Retrospective analysis of chest CT images with medical software (AI-based system)
224057405|NCT06968793|PROCEDURE|Pressure support 13|Pressure support of 13 cm H2O will be applied for 5 minutes.
224057406|NCT06968793|PROCEDURE|Pressure support 11|Pressure support of 11 cm H2O will be applied for 5 minutes.
224057407|NCT06968793|PROCEDURE|Pressure support 9|Pressure support of 9 cm H2O will be applied for 5 minutes.
223449599|NCT01692522|PROCEDURE|Intubation|visualized blind intubation
223449600|NCT00177866|DRUG|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
223449601|NCT00177866|DRUG|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
223449602|NCT01023425|DRUG|donepezil|from 5mg to 10mg, once a day, 12 months
223449603|NCT04399889|BIOLOGICAL|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.|Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University or University of Miami.
223449604|NCT04399889|OTHER|Placebo|Placebo will be comprised of 40-80 mL of Plasmalyte-A + 1% Human Serum Albumin (HAS) prepared in an identical container to the one used for cell administration. The placebo product will undergo the same process of sterility testing including release inspection, transport and product custodian.
223449605|NCT00771940|DRUG|Ghrelin|Solvent, cont. infusion
223449606|NCT00217581|BIOLOGICAL|Bevacizumab|Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
223449607|NCT00217581|DRUG|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
223449608|NCT00217581|DRUG|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
223449609|NCT00911417|DEVICE|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
223449610|NCT05055154|DEVICE|Very low calorie diet|In hospital patients will eat prepared diet with 567 kcal a day during 3 weeks
223449611|NCT02865694|OTHER|Cascade|
223449612|NCT05161845|BIOLOGICAL|Measles, Mumps and Rubella Combined Vaccine, Live|0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
224057408|NCT06968793|PROCEDURE|Pressure support 7|Pressure support of 7 cm H2O will be applied for 5 minutes.
224057409|NCT06968793|PROCEDURE|Pressure support 5|Pressure support of 5 cm H2O will be applied for 5 minutes.
224057410|NCT05680922|BIOLOGICAL|LB2102|DLL3 directed autologous Chimeric Antigen Receptor T-cells
224057411|NCT00498160|BIOLOGICAL|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
223449613|NCT03513666|COMBINATION_PRODUCT|Drug intervention|anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
223449614|NCT04192890|DEVICE|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
224057412|NCT05696548|DRUG|Lenvatinib|Lenvatinib will be administered at a dose of 24mg as oral dose, one a day
224057413|NCT05696548|DRUG|Nivolumab|Nivolumab will be administered at a dose of 240mg as a 30-minutes IV infusion, every 2 weeks
224057414|NCT01357421|DRUG|TT301|Single iv dose of TT301
224057415|NCT01357421|DRUG|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
224057416|NCT01641328|BEHAVIORAL|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
224057417|NCT01641328|BEHAVIORAL|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
224057418|NCT05166629|BEHAVIORAL|Eatable Alphabet|Eatable Alphabet is a set of kitchen activity cards developed by ChopChop Family, in collaboration with the American Academy of Pediatrics, with funding from the CDC (https://www.chopchopfamily.org/eatable-alphabet/). It includes a series of alphabet cards with family-friendly recipes.
224057419|NCT05166629|BEHAVIORAL|Usual Care|Please see above description of usual care.
223449615|NCT04452552|OTHER|healthy diet|balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
223449616|NCT00248157|DRUG|Octreotide acetate in microspheres|
223449617|NCT04252885|DRUG|Lopinavir and Ritonavir Tablets|As indicated in arm/group descriptions
223449618|NCT04252885|DRUG|Arbidol|As indicated in arm/group descriptions
223449619|NCT02363712|DEVICE|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
223449620|NCT02363712|DEVICE|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
223569292|NCT03300024|DEVICE|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
223569293|NCT01926171|DRUG|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
223569294|NCT05417269|DRUG|IMCY-0141|"The investigational medicinal product (IMP) consists in a small synthetic peptide (23 amino acids - IMCY-0141) combining a known human epitope of MOG flanked with a thioredox motif, presented in the form of a freeze-dried sterile powder and diluent for subcutaneous (SC) administration. The diluent includes the adjuvant aluminium hydroxide (alum) at a concentration of 900 μg/mL. Treatment will be injected within 4h of resuspension of the powder with the diluent.~Treatment will consist of 6 immunizations (separated by 14 days) of the IMP by SC injection in the upper arm, in the region of the triceps (lateral part of the arm, midway between the elbow and the shoulder). Half of the dose to be administered will be injected concomitantly in both arms."
223569295|NCT05417269|DRUG|Placebo|"The placebo will be administered by subcutaneous route, once every two weeks for 6 times. Placebo will be administered to patients randomized in the placebo group during Phase II only."
223569296|NCT05417269|DRUG|Dimethyl Fumarate|"Dimethyl Fumarate (DMF) will be given orally, according to its SmPC for the whole duration of the study.~Dimethyl Fumarate (DMF) will be administered to patients randomized in the active control group during Phase II only."
223569297|NCT06389331|OTHER|closed the defect with barbed suture|In direct hernia, content was reduced, and the fascia transversalis (pseudo sac) was pulled and incorporated into closure with a non-absorbable polypropylene barbed monofilament size-0 suture
223569298|NCT05023473|PROCEDURE|Pericapsular nerve group block|patients will receive pericapsular nerve group block
223569299|NCT05023473|DRUG|Morphine Sulfate|morphine will be given to both groups as patient-controlled analgesia PCA
223569300|NCT03307161|OTHER|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
223569301|NCT03222973|DRUG|BIIB033 (opicinumab)|Administered as specified in the treatment arm
223569302|NCT03222973|DRUG|Placebo|Administered as specified in the treatment arm
223569303|NCT01708265|OTHER|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
224057420|NCT05445401|BEHAVIORAL|Pre-rehabilitation|Triple pre-rehabilitation interventions of exercise, nutrition and psychology
224057421|NCT05445401|BEHAVIORAL|Standard medical care|Traditional care
224057422|NCT04405687|PROCEDURE|Severe head and face deformity reconstructive surgery|Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A\&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
224057423|NCT00074321|DRUG|irinotecan hydrochloride|Given IV
223449621|NCT05300334|DIAGNOSTIC_TEST|adenosine deaminase test|adenosine deaminase deficiency test
223449622|NCT05018676|DRUG|ARX788|1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
223449623|NCT01005901|DRUG|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
223449624|NCT01005901|DRUG|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
223449625|NCT00760487|DEVICE|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
223449626|NCT06583798|PROCEDURE|Resurgery In Silicone Oil Filled Eyes|"* Alcon Luxor Biomicroscope with Non-contact BIOM (binocular indirect ophthalmomicroscope) viewing system was used.~* 2 ports were made in Pars plana.~* Top up of Silicone oil was done whenever needed.~* Membrane peeling with relaxing retinectomy / drainage retinotomy, haemostasis and endolaser were done under Silicone oil as required.~* After the re surgery, the patients were advised to maintain prone position."
224057424|NCT00074321|DRUG|oxaliplatin|Given IV
224057425|NCT00074321|DRUG|capecitabine|Given PO
224057426|NCT00074321|OTHER|laboratory biomarker analysis|Correlative studies
224057427|NCT00074321|OTHER|pharmacological study|Correlative studies
224057428|NCT01245504|OTHER|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
223449627|NCT03157076|DEVICE|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
223449628|NCT06229223|BEHAVIORAL|PALOMA|Partnering with Parents of Adolescent Latinos on Mental Health Assistance
223449629|NCT06845215|PROCEDURE|Transversus abdominis plane (TAP) block|Ultrasound-guided TAP block
223449630|NCT06845215|PROCEDURE|Erector spina plane block (ESP)|Ultrasound-guided ESP block
223449631|NCT05535387|BEHAVIORAL|FamilyNet smart speaker/mobile application|In a 4-week period, families will use a prototype of the FamilyNet integrated and coordinated smart speaker/mobile application designed to provide families with in-situ experiential support for building positive behavior plans. The prototype FamilyNet program will guide families in creating and implementing positive behavior plans to foster positive child behavior, consistent parenting, and promote a positive parent-child relationship.
224057429|NCT00625209|DRUG|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
224057430|NCT00625209|DRUG|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
224057431|NCT00625209|DRUG|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
224057432|NCT00625209|DRUG|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
224057433|NCT06255002|BIOLOGICAL|Fibrinogen concentration by the qLabs®FIB Monitoring system|A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
224057434|NCT04052451|BIOLOGICAL|MET-2|Subjects will take study medication once daily for the duration of the study
224057435|NCT05425004|DRUG|Cabozantinib|Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry® yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
224146887|NCT04828369|PROCEDURE|balloon-occluded retrograde transvenous obliteration|(1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
223449632|NCT03560063|PROCEDURE|Corin Optimised Positioning System|"Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient."
223449633|NCT03560063|PROCEDURE|Standard templating|Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
223449634|NCT03193970|BEHAVIORAL|Post-Operative Recovery Registry|Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
223449635|NCT04099342|DEVICE|FEAST|FEAST with standard electrode configuration and current flow
223449636|NCT04099342|DEVICE|FEAST RP|FEAST with standard electrode configuration and reversed current flow
223449637|NCT06360588|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223449638|NCT06360588|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223449639|NCT06360588|DRUG|Copanlisib|Given IV
223449640|NCT06360588|PROCEDURE|Radiologic Examination|Undergo radiologic evaluation
223569304|NCT01708265|PROCEDURE|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
223569305|NCT02952963|DRUG|Chenodeoxycholic Acid|
223569306|NCT02952963|DRUG|Colesevelam|
223569307|NCT05122260|DRUG|Q-Griffithsin|intranasal spray administered as a single dose
223569308|NCT05122260|OTHER|Placebo|intranasal spray administered as a single dose
223741843|NCT01166178|DIETARY_SUPPLEMENT|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
224057436|NCT04587167|OTHER|Project ECHO|"Using proven adult learning techniques and interactive video technology, the ECHO Model promotes knowledge exchange between experts or specialists at centers of excellence (the hub) and primary care providers (the spokes), typically located in rural settings. Through regular real-time collaborative sessions, the spokes connect with the hub and with other spokes to discuss 1) best practices in care and 2) complex cases managed within their practice."
224057437|NCT04587167|OTHER|Announcement Approach Training|Train physicians and their clinic staff to make strong HPV vaccine recommendations by using presumptive announcements. If parents show vaccine hesitancy, the Training train physicians a 3-step approach (Connect, Clarify, Counsel) to share effective, evidence-based messages about HPV vaccine.
223449641|NCT01067898|DIETARY_SUPPLEMENT|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
223569309|NCT03540537|OTHER|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
223569310|NCT03540537|OTHER|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
223569311|NCT03540537|OTHER|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
223569312|NCT04135560|DRUG|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
224057438|NCT04587167|OTHER|Recall notices|Notify parents that their child is behind for HPV vaccination. Recall notices will include research-tested messages to specifically address parent concerns. Recall notices will be sent to parents via patient portal or email communication.
223449642|NCT01067898|OTHER|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
223569313|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
223569314|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
223569315|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
223569316|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
223569317|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
223569318|NCT04135560|DRUG|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
223569319|NCT04809818|DRUG|LT3001 drug product|Multiple doses of LT3001 drug product administered by intravenous infusion
223569320|NCT04809818|DRUG|Placebo|Multiple doses of Placebo administered by intravenous infusion
223569321|NCT04809818|DRUG|Aspirin|Loading and maintenance doses of Aspirin administered by oral
223569322|NCT04809818|DRUG|Clopidogrel|Loading and maintenance doses of Clopidogrel administered by oral
223569323|NCT04809818|DRUG|Apixaban|Multiple doses of Apixaban administered by oral
223569324|NCT04809818|DRUG|Dabigatran|Multiple doses of Dabigatran administered by oral
223569325|NCT02080481|DEVICE|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
223569326|NCT02080481|DEVICE|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
223741844|NCT03797833|PROCEDURE|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
223741845|NCT05003453|DRUG|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
223741846|NCT05003453|DRUG|Placebo Comparator|A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
223741847|NCT02496455|PROCEDURE|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
223741848|NCT02496455|DRUG|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
223741849|NCT00245674|DRUG|amisulpride|
223741850|NCT00941044|DEVICE|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
223741851|NCT04734509|DEVICE|Silhouette breathing system|The Silhouette is a single-use nasal mask and breathing circuit with lightweight tubing and an adhesive strip across the bridge of the nose to secure the mask in place and create a good seal around the patient's nose.
223741852|NCT01967251|DRUG|Udenafil|Udenafil tablets
223741853|NCT01967251|DRUG|Placebo|Udenafil placebo-matching tablets
223741854|NCT02883634|OTHER|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
224057439|NCT05102370|DRUG|Enasidenib|Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
224057440|NCT03255252|DRUG|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
223449643|NCT01067898|DIETARY_SUPPLEMENT|calcium carbonate|1000 mg calcium per os every day for one year
223449644|NCT05013242|DRUG|Zoladex|evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
223449645|NCT05013242|DRUG|Visanne|valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
223449646|NCT04430088|DRUG|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
223449647|NCT04430088|DRUG|Placebo|IV infusion of 0 mg of VVZ-149
223449648|NCT05012774|BEHAVIORAL|Speech Recognition Training|Training for each training arm takes place over 10 sessions carried out at home. on the participant's own computer without experimenter direct supervision. Pre- and post-training tests are carried out under experimenter supervision.
223449649|NCT00338221|DRUG|alanyl-glutamine|
223449650|NCT00338221|DRUG|glycine|
223449651|NCT04465526|DIAGNOSTIC_TEST|computed tomography perfusion imaging|The new-generation dual-source computed tomography scanner Somatom® Force will be used for all CTP studies. Myocardial perfusion will be evaluated in a stress dynamic CT protocol. The scan range will be determined based on a low-dose non-contrast scan. Subsequently, regadenoson will be administered intravenously at a single dose of 0.4 mg, and followed after 50 seconds delay by 35 mL of the iodinated contrast agent (iohexol, concentration 350 mg I/mL) injected at the flow rate of 5 mL/s. Finally, low-dose non-contrast dual-energy CT scan will be performed 5-6 min after the dynamic scan to assess late enhancement of the myocardium.
223449652|NCT06087497|OTHER|Early mobilization|Z stitch placement is standard of care to achieve vascular hemostasis after EP procedures which is followed by 4 hours of bedrest. In this study, we will compare patient satisfaction and bleeding complications with a shorter bedrest (1 hour instead of 4 hours)
224057441|NCT03255252|COMBINATION_PRODUCT|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
224057442|NCT00981513|BIOLOGICAL|Trivalent live attenuated seasonal influenza vaccine|One dose
224057443|NCT00981513|BIOLOGICAL|Monovalent live attenuated pandemic influenza vaccine|One dose
223449653|NCT02785562|OTHER|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
224057444|NCT00981513|BIOLOGICAL|Saline|One dose
224057445|NCT02237781|DRUG|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
224146888|NCT03689387|OTHER|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
223449654|NCT05811884|DEVICE|Rehabilitation|"The subjects will be provided of the powered exoskeleton for home use. No specific indications will be provided, but using the technology as much as possible.~The subjects will be asked to attend to periodic rehabilitation sessions by the clinical facility. The rehabilitation session will consist in an intense 1-week activities session every three months.~Every six months, the subjects will be asked to attend a single-day session by the clinical facility (follow-up session) consisting on the assessement of a series of qualitative and quantitative measurements."
223449655|NCT05108584|PROCEDURE|PPE Level 3 and Video Laryngoscope|The operator used level 3 PPE and video laryngoscope for the intubation process
223449656|NCT05108584|PROCEDURE|PPE Level 3 and Direct Laryngoscope|The operator used level 3 PPE and direct laryngoscope for the intubation process
223449657|NCT05108584|PROCEDURE|PPE Level 2 and Direct Laryngoscope|The operator used level 2 PPE and direct laryngoscope for the intubation process
223449658|NCT06438419|OTHER|Electrophysiological recordings|"Electrophysiological recordings will be made during a motor task in four different conditions:~1. without pharmacological treatment and without stimulation (Off condition),~2. without pharmacological treatment and during stimulation (DBS condition),~3. during pharmacological treatment and without stimulation (DOPA condition),~4. during pharmacological treatment and stimulation (DOPA+DBS condition)."
223449659|NCT04953715|OTHER|collection of body microbiome|A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
223569327|NCT03935724|BIOLOGICAL|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
223569328|NCT06343870|DRUG|testosterone pellet (100 mg)|Intervention arm: Subdermal implant-bioabsorbable testosterone pellet (100 mg of testosterone)
223569329|NCT06343870|DRUG|Placebo|Pellet of cholesterol (placebo)
223569330|NCT00463463|DRUG|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
223569331|NCT00255138|DRUG|Atomoxetine|
223569332|NCT00000293|DRUG|Nefazodone|
223569333|NCT05538312|DRUG|vepdegestrant|Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
224057446|NCT04837001|DRUG|FDY-5301|FDY-5301 will be administered as a single IV bolus injection.
224057447|NCT04837001|OTHER|Placebo|Placebo will be administered as a single bolus injection.
224057448|NCT01519596|PROCEDURE|quality-of-life assessment|Ancillary studies
224057449|NCT01519596|OTHER|counseling intervention|Receive lifestyle-related counseling
224057450|NCT01519596|BEHAVIORAL|exercise intervention|Undergo physical activity intervention
224057451|NCT01519596|OTHER|educational intervention|Receive educational materials
224057452|NCT01519596|PROCEDURE|standard follow-up care|Undergo usual care
224057453|NCT03129451|DIAGNOSTIC_TEST|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
224057454|NCT00664495|BEHAVIORAL|Diet Weight Loss|
224057455|NCT00664495|BEHAVIORAL|Exercise Weight Loss|
224057456|NCT00664495|BEHAVIORAL|Exercise Without Weight Loss|
223449660|NCT06384053|COMBINATION_PRODUCT|Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined|The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.
223449661|NCT06384053|RADIATION|Radiotherapy (RT)|Radiotherapy is applied.
223449662|NCT06439524|DRUG|40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate|if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
223449663|NCT03079973|DRUG|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
223449664|NCT03079973|DRUG|Vehicle of P-3073|Once daily for 24 weeks.
223449665|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
223449666|NCT02087943|DRUG|Apremilast|Orally twice a day (BID)
223449667|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
223449668|NCT02087943|DRUG|Placebo|Orally twice a day (BID)
223449669|NCT02716506|PROCEDURE|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
223449670|NCT01308996|DEVICE|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft \[recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)\] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
223449671|NCT01308996|PROCEDURE|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
223449672|NCT01690299|DRUG|Apremilast|Apremilast 30 mg tablet orally BID
224057457|NCT03883594|BEHAVIORAL|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
224057458|NCT02594969|OTHER|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
224146889|NCT04261452|DIAGNOSTIC_TEST|isokinetic dynamometer|"Knee flexors and extensors muscles were analysed by an isokinetic dynamometer. Positioning of the subjects (sitting with hips flexed to 75°) was standardized based on the length of the thigh and leg to minimize individual differences. Correction for the effect of gravity on neuromuscular performance was accomplished by incorporating limb mass into the calculation of torque production. Previous warm-up was repeated five time with an angular velocity of 400°/s. All patients randomly performed two maximal isokinetic tests: 6 repetitions at 60°/s and 20 repetitions at 300°/s.~Measurements of torque, work (J), power (W) maximum (peak), and fatigue index were obtained in both tests. In addition, data were analysed at percent of prediction (percent pred) by reference values previously described for the Brazilian population, corrected by muscle mass and peak values."
223569334|NCT05538312|DRUG|Itraconazole|Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
223449673|NCT01690299|DRUG|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
223449674|NCT01690299|DRUG|Placebo tablet|Placebo tablets BID
223449675|NCT01690299|DRUG|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
223569335|NCT00127309|DRUG|Glutathione|
223569336|NCT03637712|DEVICE|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
223449676|NCT02608242|DRUG|YH22189|
223449677|NCT02608242|DRUG|Twynsta 80/10mg|
223569337|NCT00840060|BEHAVIORAL|AMALS|Addressing multiple aspects of language simultaneously
224057459|NCT04196738|OTHER|ventilation strategy|Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
224057460|NCT01293968|DRUG|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
224057461|NCT01293968|DRUG|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
223449678|NCT02608242|DRUG|Crestor 20mg|
223449679|NCT04838847|BIOLOGICAL|CVnCoV Vaccine|Intramuscular (IM) injection
223449680|NCT04648852|OTHER|Heart failure risk estimation|Evaluation by heart failure risk score
223449681|NCT05750173|OTHER|Streamlining of the pre-procedural patient pathway|"Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety."
223449682|NCT03894033|DEVICE|Ascyrus Medical Dissection Stent (AMDS)|The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
223449683|NCT06569030|BIOLOGICAL|spinal orthoses|Evaluation of scoliosis treatment in people using spinal orthoses
223449684|NCT06558526|DIETARY_SUPPLEMENT|Apple pectin (DE 57%)|Dietary intervention with apple pectin. Participants will orally take the supplement once a day, after dissolving it in 100 ml of water, for 6 months.
223449685|NCT06558526|DIETARY_SUPPLEMENT|Placebo|Dietary intervention with maltodextrin. Participants will orally take the placebo (maltodextrin) once a day, after dissolving it in 100ml of water, for 6 months.
223449686|NCT06514573|DIETARY_SUPPLEMENT|Sodium Butyrate|Daily supplementation with 1 sachet per day for 16 weeks
223449687|NCT06514573|DIETARY_SUPPLEMENT|Placebo (cornstarch)|Daily supplementation with 1 sachet per day for 16 weeks
223569338|NCT00840060|BEHAVIORAL|DTA|Discrete Trial Approach
223569339|NCT00871923|DRUG|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
224057462|NCT03817554|DRUG|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
223449690|NCT06391229|BEHAVIORAL|Project Support|"Caregivers will receive up to four, 60- to 90-minute sessions focused on teaching two parenting skills - attentive listening and comforting. Attentive listening involves providing accurate and timely responses to show interest and keep the child engaged until they are ready to end the conversation. Comforting involves using the same attentive listening skills when the child is upset or distressed. Effective mastery of the listening and comforting skills also requires caregivers to withhold any non-listening or non-comforting responses (e.g., interruptions, criticisms).~The program is individually tailored such that caregivers with stronger skills could complete the program in less time (i.e., fewer sessions). Service providers educate caregivers about the skills, then engage in an iterative process of modeling the skills, engaging the caregivers in behavioral practice, and providing tailored, supportive feedback to help caregivers gain mastery."
223449691|NCT04442061|DEVICE|Transcranial magnetic stimulation|"Before the stimulation, identification of a motor hotspot and active motor threshold (AMT) will be performed. The TMS will be applied on the intermittent theta-burst modality (iTBS), i. e., 2 s of TBS trains (30 pulses) repeated every 10 s for 190 s, with a total number of 600 pulses (Huang et al, 2005). The whole TMS session, including preparation, will last up to 1h.~The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue"
223449692|NCT04442061|DEVICE|MRI|Anatomical and functional images will be acquired and review by an experienced neuro-radiologist.
223449693|NCT04442061|DEVICE|Neuronavigation|The neuronavigation system will allow to guide the stimulation using the individual anatomical MRI acquired with MRI, and to record the position and orientation of the coil during successive stimulations
223449694|NCT04442061|DEVICE|Eye-tracking|Eye movements and follow a person's gaze will be recorded during visualization of stimuli presented in the screen by analyzing images of the eye captured by an infrared camera
223449695|NCT04442061|GENETIC|Salivary samples|The DNA will be extracted from the salivary sample to genotyping analyses on the BDNF (Val66Met) and COMT (Val158Met) polymorphism
223449696|NCT04442061|OTHER|Clinical scales|CGI, E-CAR and ABC will be used for behavior and clinical evaluation
224057463|NCT03817554|OTHER|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
224057464|NCT01483742|DRUG|RO5024048|1000 mg orally bid, 24 weeks
224057465|NCT01483742|DRUG|danoprevir|100 mg orally bid, 24 weeks
224057466|NCT01483742|DRUG|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
224057467|NCT01483742|DRUG|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
224057468|NCT01483742|DRUG|ritonavir|100 mg orally bid, 24 weeks
224146890|NCT04261452|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test|"All exercise tests were performed on an electronically braked cycle ergometer. Standard metabolic and ventilatory responses were measured breath-by-breath using a calibrated, computer-based system.~The incremental exercise test started with 2-min unloaded cycling and increments of 3-10 Watts per min until exhaustion. The anaerobic threshold was estimated by the ventilatory equivalents and V-slope methods and it was determined in agreement by a cardiologist and pulmonologist. Heart rate was determined using the 12-lead electrocardiogram. Throughout the experiment, the pulse hemoglobin saturation (SpO2) was assessed with a pulse oximeter and the 'shortness of breath' was asked at exercise cessation using the 0-10 Borg category ratio scale. All measurements were expressed as percentage predicted for the Brazilian population."
223449697|NCT03836209|DRUG|Gilteritinib|"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
223449698|NCT03836209|DRUG|Midostaurin|"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
223569340|NCT00871923|RADIATION|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
223569341|NCT02263911|DRUG|Baricitinib|Administered orally
223569342|NCT01263015|DRUG|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
223569343|NCT01263015|DRUG|Atripla|Atripla once daily on an empty stomach
223569344|NCT01263015|DRUG|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
224057469|NCT03999658|BIOLOGICAL|STI-3031|anti-PD-L1 antibody
224057470|NCT01816412|DEVICE|MD02-LDCB Paclitaxel coated balloon catheter|
224057471|NCT01816412|PROCEDURE|Standard Uncoated Balloon Angioplasty Catheter|
224057472|NCT02449681|DRUG|TH-4000 (Tarloxotinib)|
224057473|NCT02806128|DRUG|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
223449699|NCT03836209|DRUG|Daunorubicin|"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
224057474|NCT03919929|DRUG|Semaglutide 3mg and 7mg [Rybelsus]|Once daily oral tablet of semaglutide for 4 months
224057475|NCT03919929|OTHER|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
224057476|NCT01671813|DRUG|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
224057477|NCT03972579|BEHAVIORAL|Graded exposure therapy|Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.
223449700|NCT03836209|DRUG|Cytarabine|"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (recommend 1.5 g/m² for age ≥ 55 or patients with decreased creatinine clearance) every 12 hours IV Days 1,3,5 or Days 1-3 for 6 doses for up to 4 cycles"
223449701|NCT05350813|PROCEDURE|Measurement of the PCT plasma levels|antibiotic treatment duration will be based on PCT plasma levels
223449702|NCT05350813|PROCEDURE|Usual practice based on guidelines|antibiotic therapy duration will be determined by the type of infection, microbiological results and clinical, biological and/or radiological evolution, according to the usual practice based on guidelines.
224057478|NCT03972579|BEHAVIORAL|Pacing + mindfulness|Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
224057479|NCT05886712|OTHER|Naloxone|Naloxone
224146891|NCT04261452|DIAGNOSTIC_TEST|Functional Capacity Tests|"The six-minute walk test (6MWT) was in accordance with the American Thoracic Society (ATS). The four-minute step test (4MST) consisted of going up and down a 20-cm high, 40-cm wide and 40-cm long step for 4 minutes.~The investigators measured the heart rate and pulse hemoglobin saturation at rest before each test and every minute of both tests. The investigators assessed dyspnoea and leg fatigue at rest and with the modified Borg scale immediately after finishing the test."
224146892|NCT04261452|DIAGNOSTIC_TEST|Lung Function Test|"Spirometry, gas transfer, and static lung volumes were measured in all patients, and airflow was measured using a Pitot-tube based on the American Thoracic Society/European Respiratory Society guidelines. Measurement of maximal inspiratory and expiratory pressures was performed from the residual volume and total lung capacity. Resting blood gases were obtained by samples from the radial artery."
223449703|NCT05679349|OTHER|Survey Administration|Complete survey
223449704|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
223449705|NCT05679349|OTHER|Survey Administration|Complete survey
223449706|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
224057480|NCT05886712|OTHER|Usual intervention|usual administered drug for overdose
224057481|NCT05899881|BEHAVIORAL|Yoga intervention|10 weeks of Hatha yoga, once per week, 60 minutes per class
223449707|NCT05679349|OTHER|Educational Activity|Undergo online shared decision making training and distance learning
223449708|NCT05679349|OTHER|Counseling|Undergo shared decision making counseling
223449709|NCT05679349|OTHER|Survey Administration|Complete survey
223449710|NCT05679349|OTHER|Electronic Health Record Review|Undergo electronic health record review
223449711|NCT03739710|DRUG|Docetaxel|Docetaxel will be administered.
223449712|NCT03739710|DRUG|Feladilimab|Feladilimab will be administered.
223449713|NCT03739710|DRUG|Ipilimumab|Ipilimumab will be administered.
223449714|NCT03739710|DRUG|GSK4428859A|GSK4428859A/EOS884448 will be administered.
223449715|NCT03739710|DRUG|Dostarlimab|Dostarlimab will be administered.
223449716|NCT03739710|DRUG|GSK6097608|GSK6097608 will be administered.
223449717|NCT05054335|OTHER|Functional Assessment|Undergo walking function assessment with optical motion capture
223449718|NCT05054335|PROCEDURE|X-Ray Imaging|Undergo bi-plane dynamic X-ray imaging
223449719|NCT06098235|BEHAVIORAL|Usual Diet advice|The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
223449720|NCT06098235|BEHAVIORAL|ORIENT diet intervention|The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
223449721|NCT03606083|DEVICE|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
223449722|NCT01753115|BIOLOGICAL|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
224057482|NCT05192356|DRUG|CKD-348(3)|QD, PO
224057483|NCT05192356|DRUG|CKD-828, D097, D337|QD, PO
224057484|NCT00255970|OTHER|DFDBA|Demineralized Freeze Dried Allograft bone
224057485|NCT00255970|DEVICE|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
224057486|NCT03926689|BEHAVIORAL|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
223449723|NCT01753115|DRUG|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
223569345|NCT01263015|DRUG|Abacavir/Lamivudine Placebo|matching placebo taken once daily
223569346|NCT01263015|DRUG|Dolutegravir placebo|matching placebo taken once daily
223569347|NCT01263015|DRUG|Atripla placebo|matching placebo taken once daily on an empty stomach
223569348|NCT02723006|DRUG|TAK-580|TAK-580 tablets
223569349|NCT02723006|DRUG|TAK-202|TAK-202 infusion
223569350|NCT02723006|DRUG|vedolizumab|vedolizumab infusion
223569351|NCT02723006|DRUG|nivolumab|nivolumab infusion
223569352|NCT02723006|DRUG|ipilimumab|ipilimumab infusion
223569353|NCT01371149|OTHER|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
223569354|NCT05945771|DIETARY_SUPPLEMENT|Grape seed extract|Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
223569355|NCT00303446|DRUG|Dutasteride|Dutasteride 0.5 mg/day
223569356|NCT00303446|DRUG|Placebo|Matched placebo
224057487|NCT03926689|BEHAVIORAL|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
224057488|NCT03352700|DRUG|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
224057489|NCT03352700|DRUG|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
224057490|NCT02817971|BEHAVIORAL|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
223449724|NCT04146558|DRUG|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
223449725|NCT04146558|OTHER|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
224057491|NCT02817971|BEHAVIORAL|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
224057492|NCT01837030|DIETARY_SUPPLEMENT|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
224057493|NCT01837030|DEVICE|Capsule Endoscopy|GIVEN capsule
224057494|NCT00278642|BIOLOGICAL|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
224057495|NCT05206409|DIAGNOSTIC_TEST|Ultrasound|Fetal head position determination using ultrasound
224146893|NCT04261452|DIAGNOSTIC_TEST|Doppler Echocardiography|The same medical doctor performed all echocardiograms and all patients underwent comprehensive echocardiography.
224146894|NCT04261452|DIAGNOSTIC_TEST|Anthropometry and Body Composition|"Body composition was assessed using a body composition analyzer. Percent body fat was estimated from the resistance and reactance values.~Resistance values and the subject's height (meters), weight (kg), sex, and age (years) were entered into a computer program to estimate percentage of fat, fat mass (FM), and muscle mass (MM)."
224146895|NCT04904588|DRUG|Busulfan|Given IV or PO pre-transplant as part of conditioning regimen
224146896|NCT04904588|DRUG|Busulfan|Given IV pre-transplant as part of conditioning regimen
224057496|NCT04127253|DEVICE|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
224057497|NCT04127253|DEVICE|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
224146897|NCT04904588|DRUG|Fludarabine|Given IV pre-transplant as part of conditioning regimen
224146898|NCT04904588|RADIATION|Total-body irradiation|Administered pre-transplant as part of conditioning regimen
224146899|NCT04904588|DRUG|Cyclophosphamide|Given IV pre-transplant as part of conditioning regimen
224146900|NCT04904588|DRUG|Melphalan|Given IV pre-transplant as part of conditioning regimen
224146901|NCT04904588|PROCEDURE|PBSC Hematopoietic Stem Cell Transplantation (HSCT)|Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0.
224146902|NCT04904588|PROCEDURE|Bone Marrow Hematopoietic Stem Cell Transplantation|Bone marrow graft is infused from a mismatched unrelated donor on Day 0.
224146903|NCT04904588|DRUG|Post-transplant Cyclophosphamide|Cyclophosphamide (50 mg/kg) is administered on Day +3 and on Day +4 post-transplant as an IV infusion over 1-2 hours.
224146904|NCT04904588|DRUG|Mesna|Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide.
224146905|NCT04904588|DRUG|Tacrolimus|Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at 90-100 days post HCT.
224146906|NCT04904588|DRUG|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
224057498|NCT04127253|BEHAVIORAL|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
224057499|NCT06978699|DRUG|XH-S003 Capsule|25mg \& 100mg
224146907|NCT04904588|OTHER|Patient-Reported Outcomes|Survey assessments will be administered to study participants pre- and post-transplant.
224146908|NCT06270602|OTHER|Data collection (retrospective)|Collection of patient data entered in the ROC platform from the beginning activation of the platform (November 2018) until the date on which the study is approved by the local ethics committee
224146909|NCT06270602|OTHER|Data collection (prospective)|Collection of patient data entered in the ROC platform from the date in which the study is approved by the local ethical committee
224146910|NCT05816252|DRUG|SKB264|intravenous (IV) infusion (Q2W or Q3W)
224146911|NCT05816252|DRUG|Pembrolizumab|intravenous (IV) infusion (400mg, Q6W)
224146912|NCT05816252|DRUG|Carboplatin|intravenous (IV) infusion (AUC5, Q3W)
224146913|NCT05816252|DRUG|Osimertinib|80mg, QD
224146914|NCT05038592|DRUG|Decitabine|Given IV
224146915|NCT05038592|BIOLOGICAL|Tagraxofusp-erzs|Given IV
224146916|NCT06533644|PROCEDURE|Partial Oncolysis|Partial tumor oncolysis will be completed by cryolysis.
224146917|NCT06533644|DRUG|SV-102|Intratumoral infusion of SV-102
224146918|NCT03604510|PROCEDURE|Electroencephalographic recordings|24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
223449726|NCT02913781|PROCEDURE|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
223449727|NCT02913781|PROCEDURE|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
223449728|NCT03927326|DRUG|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine
223449729|NCT06364176|DRUG|Losartan|Treatment with losartan through week 12
224057500|NCT06978478|PROCEDURE|Unlabelled PET CT Scan|\[18F\]-FDG-PET CT
224057501|NCT06978478|PROCEDURE|Labelled PET CT Scan|\[18F\]-FBA-A20FMDV2 -PET CT
224146919|NCT05507580|DRUG|Upadacitinib|Oral tablet
224146920|NCT02515708|DEVICE|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
224146921|NCT02891980|BIOLOGICAL|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
223449730|NCT06364176|DRUG|Placebo|Treatment with placebo through week 12
223449731|NCT05800210|DEVICE|Miltenyi CliniMACS Prodigy ® system|Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.
223449732|NCT00949871|OTHER|communication analysis|
223449733|NCT00949871|OTHER|questionnaire administration|
223449734|NCT00949871|PROCEDURE|psychosocial assessment and care|
223449735|NCT00949871|PROCEDURE|support group therapy|
223449736|NCT02748291|OTHER|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months."
223449737|NCT02748291|OTHER|Department of Health Physical Activity Guidelines|"1. Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~2. Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~3. Adults should also undertake physical activity to improve muscle strength on at least two days a week.~4. All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
223449738|NCT01397149|DRUG|Placebo|Dosage form, frequency and duration exactly as experimental arm.
223449739|NCT01397149|DRUG|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to \> 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
223449740|NCT00936676|DRUG|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
223741855|NCT02883634|OTHER|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
224057502|NCT06977412|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of breast cancer|The CT scan is part of the standard treatment protocol.
224146922|NCT02891980|BIOLOGICAL|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
224146923|NCT06968962|DRUG|Tadalafil|Target dose 40 mg OD
224146924|NCT06968962|DRUG|Ambrisentan|Target dose 10 mg OD
224146925|NCT06968962|DRUG|Ambrisentan mimic|Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.
224146926|NCT06968962|DRUG|Tadalafil mimic|Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.
223449741|NCT04438616|PROCEDURE|dome magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia~* A crestal incision is made using No. 15 c blade .~* Full sequential drilling under copious saline irrigation will be made . insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(dome) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure"
223449742|NCT04438616|PROCEDURE|flat magnetic attachment|"* All patients will receive complete denture before implant installation .~* The CBCT examination should be take~* patients received infiltration local anesthesia.~* A crestal incision is made using No. 15 c blade~* Full sequential drilling under copious saline irrigation will be made as indicated by the company guide lines. insertion of two implant by the contra angle handpiece with special adaptor~* We connect magnetic attachment(flat) on complete denture by pick up procedure at day of implant installation.~* Implant stability will be measured using smart peg /osstell at the day of implant installation and after 2,4,8,12 weeks.~* Patient satisfaction measure in 2 weak and after 12 weak by Denture satisfaction questionnaire"
223449743|NCT01784926|PROCEDURE|Intraocular lens repositioning by scleral suturing|
223449744|NCT01784926|PROCEDURE|Intraocular lens exchange with retropupillary iris-claw lens|
223569357|NCT04258995|BIOLOGICAL|Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)|2 formulations at 1 dose level
223569358|NCT03415698|DRUG|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
223569359|NCT03415698|DRUG|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
223741856|NCT01103609|DRUG|Warfarin|Oral tablet od on Day 4
223741857|NCT01103609|DRUG|Placebo|Oral tablet bd, stepwise increased
223741858|NCT01103609|DRUG|AZD1656|Oral tablet bd, stepwise increased
223741859|NCT01730755|DRUG|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
224057503|NCT06979115|DRUG|Indocyanine green (ICG)|Indocyanine green (ICG; National Drug Approval No. H20213567, Ruida Pharmaceuticals) is administered intravenously 24 hours preoperatively at a dose of 2 mg/kg. The drug is dissolved in 250 mL of normal saline using a light-protected infusion set and infused at a constant rate over 60 minutes. Alternatively, a 0.5 mg/kg dose may be administered via IV infusion 1-3 hours before surgery.
224146927|NCT06433375|PROCEDURE|Growth hormone application|Growth hormone application during non-surgical root canal treatment
224146928|NCT06433375|PROCEDURE|Root canal treatment|Teeth undergo conventional root canal treatment without any additional intervention
224070739|NCT05898958|PROCEDURE|thoracic paravertebral block|The block will be performed in the lateral position.After skin sterilization,the ultrasound transducerprobe (6-13-MHz high-frequency linear transducer) is positioned in the vertical plane ∼2.5 cm lateral tomarked spinous process with its orientation directedcranially. T.After local anesthetic infiltration, an 18-gauge Tuohy needle will be inserted into the paravertebral spacein an 'in plane' technique. After a negativeaspiration through the needle, 20 ml of 0.25%bupivacaine with 1: 200 000 epinephrine will be injected slowly over 3 min.A20-G epidural catheter will be threaded through Tuohyneedle and advanced 2-3 cm into the paravertebral space.Anyprocedure-related adverse effects will be noted, and thedermatomal loss of pin prick sensation will be testedover both sides.
223449745|NCT01179932|OTHER|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
223449746|NCT04582201|DRUG|agenT-797|agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
223449747|NCT05857124|DEVICE|Vielight Neuro RX Gamma active device|The Vielight Neuro RX Gamma active device is a home-use photobiomodulation (PBM) device designed to deliver near-infrared (810 nm) light (or photons) to the brain/scalp and nasal tissues.
223449748|NCT05857124|DEVICE|Vielight Neuro RX Gamma sham device|The Vielight Neuro RX Gamma sham device is a home-use device similar to the Vielight Neuro RX Gamma active device, but acting as a sham.
223449749|NCT02265939|DRUG|NPO-13|
223449750|NCT01233752|DRUG|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
223449751|NCT01724944|PROCEDURE|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
223449752|NCT01424241|DRUG|Sandostatin LAR|Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
223449753|NCT05302947|DRUG|Baricitinib Oral Tablet|Baricitinib was administered at a dose of 4 mg once or twice per day for 3-8 days (5 days on average) depending on the individual patients' condition
223449754|NCT05302947|DRUG|Tocilizumab Injection|Tocilizumab was administered by a single intravenous dose of 400 mg
223449755|NCT05302947|DRUG|Netakimab|Netakimab was administered by a single subcutaneous injection of 120 mg
223449756|NCT05302947|OTHER|Standard of care therapy|SOC treatment included hydroxychloroquine (400 mg twice on day 1, followed by 200 mg twice per day on days 5-10), azithromycin (500 mg once per day for 5 days), lopinavir-ritonavir (400/100 mg twice per day for 14 days), and low molecular-weight heparin according to personal indicators
223449757|NCT04624802|BEHAVIORAL|maternal exercise|The maternal exercise is broadly practiced by pregnant women in China. It is designed by a team led by Shen Shanmei, a professor of Maternity Exercises at Department of Obstetrics and Gynecology of First Hospital in Korea.
223449758|NCT02298088|DRUG|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
223449759|NCT02298088|DRUG|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg."
223449760|NCT02258906|DRUG|ulinastatin|
223569360|NCT03274427|DEVICE|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
223569361|NCT03274427|DRUG|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
223569362|NCT03274427|DRUG|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
223569363|NCT03614416|DEVICE|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
223449761|NCT02258906|DRUG|normal saline|
223449762|NCT00496587|DRUG|Capecitabine|800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
223449763|NCT00496587|DRUG|Gemcitabine|900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
223449764|NCT00496587|DRUG|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
223449765|NCT04954417|DIAGNOSTIC_TEST|Radiological scanning|The collected specimens subject to normalized Micro-CT and MSCT image acquisition, image reconstruction using standard algorithms, and bone structure observation using bone algorithms to obtain high-quality, standardized axial images.
223449766|NCT04954417|OTHER|Deep learning|We will use a conditional generation adversarial network-based image mapping technique to train the mapping model between MSCT images and Micro-CT images, find the correspondence between the image information contained in each of MSCT and Micro-CT, and finally obtain high-resolution micro-CT-like images.
223449767|NCT04954417|PROCEDURE|Bio-mechanical testing|we will cut a standardized cubic sample from the vertebral cancellous bone , obtain the bio-mechanical performance index of this cancellous bone sample by mechanical experiments, and analyze the correlation between bone structure of Micro-CT-like images and bio-mechanical index.
223449768|NCT02099383|OTHER|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
224057504|NCT06978205|DEVICE|Urethral Balloon Dilation|Urethral balloon dilation + conventional rehabilitation therapy. 1.A 14-Fr urethral catheter will be prefilled with sterile saline to check for balloon integrity. If intact, the saline will be completely withdrawn. 2.Ultrasound imaging will be used to precisely locate the external urethral sphincter. 3.The catheter will be fully lubricated and gently inserted into the urethra. 4.Under real-time ultrasound guidance, 2-4 mL of sterile saline will be gradually injected into the balloon to expand the external urethral sphincter. 5.Patients will be instructed to attempt urination during the procedure, and changes in voiding patterns will be observed. This procedure will be performed three times per participant. The expansion volume will increase by 0.5-1 mL per session, depending on urethral outlet resistance (urodynamic results) and degree of urethral narrowing (ultrasound assessment）Each session lasts 5 minutes. Strict aseptic techniques will be followed.
223449769|NCT00005049|DRUG|carboplatin|
223449770|NCT00005049|DRUG|cisplatin|
223449771|NCT00005049|DRUG|floxuridine|
223449772|NCT04235322|DRUG|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
223449773|NCT04235322|DRUG|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
223449774|NCT00519584|DRUG|Ropivacaine|30 ml 0.5%
223449775|NCT00519584|DRUG|dex|8 mg (2 ml)
223449776|NCT00519584|DRUG|Bupivacaine|30 ml 0.5%
223449777|NCT00519584|DRUG|Saline|0.9% saline; systemic and local
223449778|NCT01648920|DEVICE|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
224057505|NCT06978205|DEVICE|intermittent catheterization|Intermittent catheterization is based on the results of urodynamic examination to develop a personalized drinking plan and the number of catheterization, and the number of catheterization is selected according to the amount of residual urine.
224146929|NCT06252311|BEHAVIORAL|Mindfulness-Based Breastfeeding Programme|Mindfulness-Based Breastfeeding Programme will consist of structure and anatomy of the breast and milk production, breast milk content, benefits of breast milk, breast care, frequency and duration of breastfeeding, correct and comfortable position for breastfeeding, effects of stress on lactation hormones and milk production, World Health Organization guidelines on duration and continuity of breastfeeding, time to start complementary feeding general information on recommendations, General information about breastfeeding with awareness, mentioning its purpose and programme flow, and it includes formal and informal practices such as breathing awareness exercises, noticing the autopilot, lying/sitting meditation, body scanning exercises and mindful breastfeeding practice.
224146930|NCT06206226|BEHAVIORAL|OHDC-DC|90-minute-weekly cognitive behavioral psycho-education classes using a mobile phone app over a 6-week period
223449779|NCT05644288|OTHER|Help eNursing|"The proposed intervention is a telephonic telenursing program aimed at managing social isolation in the elderly, the HELPeN (Help eNursing) program.~The operational part of the intervention will be carried out by volunteers nursing students from the University of Murcia enrolled in the academic years 2020-2023. To ensure homogeneity in the intervention carried out by the volunteers they will receive a 15-hour training oriented to ensure the acquisition of essential communication skills for the implementation of the intervention and to know the specific interventions of support and counseling for the elderly in social isolation.~Over the 36 weeks of the HELPeN Program, each volunteer is expected to provide intervention to 2 seniors, making 1 call per week to each subject lasting approximately 30 minutes. Students will perform physical and psychosocial assessments of the elders and create individualized care plans based on each subject's needs."
223449780|NCT05259917|DRUG|Placebo|Placebo to KVD900 Tablet
223449781|NCT05259917|DRUG|KVD900 600 mg|KVD900 Tablet 600 mg (2 x 300 mg)
223449782|NCT05259917|DRUG|KVD900 300 mg|KVD900 Tablet 300 mg (1 x 300 mg)
223449783|NCT05133336|DRUG|Saroglitazar Magnesium 1 mg|Subjects randomized to Saroglitazar Magnesium 1 mg arm will receive Saroglitazar Magnesium 1 mg treatment for the entire treatment period up to Week 52.
223449784|NCT05133336|DRUG|Saroglitazar Magnesium 2 mg|Subjects randomized to Saroglitazar Magnesium 2 mg arm are switched to Saroglitazar Magnesium 1 mg treatment up to Week 52
223449785|NCT05133336|DRUG|Placebo|Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
224057506|NCT06978205|DEVICE|Acupuncture treatment|Acupuncture treatment improves the patient's urinary function by acupuncture on the lower abdomen and lumbosacral acupoints.
223449786|NCT06277739|PROCEDURE|Spinal Manipulative Therapy|The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment. If a cavitation (ie, an audible pop) occurred, the treatment was considered complete. If no cavitation was produced, the participant was repositioned and the manipulation was attempted again. A maximum of 2 attempts per side was permitted. If no cavitation was produced after the 4 attempts (ie, 2 per side), the treatment was considered complete.
223569364|NCT03614416|DEVICE|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
223449787|NCT06277739|OTHER|Sham Laser Treatment|The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
223449788|NCT02656511|DRUG|Dolutegravir|Dolutegravir 50 mg PO daily
223449789|NCT02656511|DRUG|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
223449790|NCT05548972|DEVICE|G7 Dual Mobility with Vivacit-E bearing|hip arthroplasty with G7 Dual Mobility Vivacit-E bearing
223449791|NCT05548972|DEVICE|G7 Dual Mobility Longevity bearing|hip arthroplasty with G7 Dual Mobility Longevity bearing
223449792|NCT00916981|PROCEDURE|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
223449793|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 2mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
223449794|NCT05766683|DRUG|onabotulinumtoxinA at a depth of 4mm|One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
223449795|NCT04819841|GENETIC|nula-cel Drug Product|nula-cel is administered via IV infusion following a myeloablative conditioning regimen
223449796|NCT06514911|PROCEDURE|primary closure following Laparoscopic cholodochotomy in management of CBD stones|primary closure of cholodochotomy incision in laparoscopic CBD exploration avoiding T-tube insertion
223449797|NCT06514911|PROCEDURE|T-tube drainage following Laparoscopic cholodochotomy in management of CBD stones|drainage of bile by T-tube insertion in laparpscopic CBD exploration
223449798|NCT04595279|BEHAVIORAL|Smoking sessions|Participants undergo topography and behavioral economic sessions where they can make choices to earn cigarette puffs by pulling plungers on experimental equipment
223449799|NCT03571178|OTHER|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
223449800|NCT06367738|DRUG|Psilocybin|Psilocybin 1-30 mg
223449801|NCT05537428|BEHAVIORAL|Musical Intervention|A trained musician-facilitator will convene a series of four weekly two-hour sessions to which groups of five participants will be invited. The facilitator provides keyboard, professional microphone, recording interface, headphones, guitar, computer and a Digital Audio Workstation (DAW) for recording.
223449802|NCT04008485|DEVICE|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
223449803|NCT06220487|DRUG|Prednisone, Olverembatinib, Blinatumomab, Chidamide|"Phase One. Induction Consolidation, for 1 year. 1.1 Pretreatment ×1 cycle. Prednisone，1mg/kg/d, from day 1 to 14;~1.2 Induction Therapy × 1 cycle. A: OlverembAtinib (at a dose of 40 mg Qod), from day 8 to 42. B: Blinatumomab (at a dose of 28 μg per day), from day 15 to 28. C: Chidamide (at a dose of 10 mg Qod), from day 9 to 41.~1.3 Consolidation Block × 5 cycles. A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42. B: Blinatumomab (at a dose of 28 μg perday) was administered from day 1 to 14. C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Two. Maintenance Therapy, for 3 years. 2.1 A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42.~C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Three. Follow-up, for 5 years."
223449804|NCT02108899|BEHAVIORAL|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
223449805|NCT00694720|DRUG|AVE0657|capsules once a day at bedtime
223449806|NCT00694720|DRUG|placebo|capsules once a day at bedtime
223449807|NCT02641405|DEVICE|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
223449808|NCT02641405|DEVICE|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
223449809|NCT00599742|BEHAVIORAL|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
223449810|NCT00599742|BEHAVIORAL|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
223449811|NCT00002773|BIOLOGICAL|allogeneic tumor cell vaccine|
223449812|NCT00002773|BIOLOGICAL|recombinant interferon alfa|
223449813|NCT00002773|BIOLOGICAL|sargramostim|
223569365|NCT03614416|PROCEDURE|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
223569366|NCT06153433|DRUG|Rosuvastatin Immediate-Release Tablet (IRT) 10mg|Rosuvastatin Immediate-Release Tablet (IRT) 10mg
224057507|NCT06978205|BEHAVIORAL|Pelvic floor function training|The pelvic floor therapist assesses the patient's pelvic floor muscle condition and guides the patient to perform effective pelvic floor muscle contractions and relaxations.
224057508|NCT05351151|PROCEDURE|bilateral ultra-sound guided maxillary and mandibular nerve blocks|Interventional group will receive bilateral ultra-sound guided maxillary and mandibular nerve block with ROPIVACAINE 4,75 mg/ml.
224057509|NCT05351151|PROCEDURE|Infiltration of Lidocaine 1%|Intervention requiring the infiltration of LIDOCAINE 1% at incision sites by surgeon after general anesthesia induction during maxillo-mandibular osteotomy
224057510|NCT02681679|DRUG|0.1% bromfenac ophthalmic solution|
224057511|NCT02681679|PROCEDURE|femtosecond laser cataract surgery|
224146931|NCT03496662|DRUG|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
223449814|NCT00002773|DRUG|cyclophosphamide|
223449815|NCT02652702|PROCEDURE|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
223449816|NCT02652702|PROCEDURE|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
223449817|NCT02383355|DRUG|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
223449818|NCT02383355|DRUG|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
223449819|NCT01183416|DRUG|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are \~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
223449820|NCT01831271|OTHER|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
223449821|NCT01831271|OTHER|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
223449822|NCT02799277|DRUG|Testosterone|Effect of testosterone on moral decision making
223449823|NCT02799277|DRUG|Placebo|Effect of testosterone on moral decision making
223449824|NCT04624607|DEVICE|Transspinal-transcortical paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
223449825|NCT04624607|DEVICE|Transcortical-transspinal paired-associative stimiulation combined with robotic gait training|Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
223449826|NCT01026337|GENETIC|mutation analysis|Correlative study
223449827|NCT01026337|OTHER|pharmacological study|Correlative study
223449828|NCT01026337|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
223569367|NCT06153433|DRUG|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg|Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg
223449829|NCT01026337|DRUG|sunitinib malate|Given orally
223449830|NCT01026337|OTHER|immunohistochemistry staining method|Correlative study
223449831|NCT01026337|OTHER|laboratory biomarker analysis|Correlative study
223449832|NCT01146561|BIOLOGICAL|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
223449833|NCT01146561|OTHER|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
223449834|NCT04231968|DRUG|AK0529|AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
223449835|NCT04231968|DRUG|Matching placebo of AK0529|The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
223449836|NCT03510429|DIETARY_SUPPLEMENT|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
223449837|NCT03510429|OTHER|Routine post-op care|Routine post-operative care
223449838|NCT02295787|DRUG|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
223449839|NCT02295787|DRUG|Placebo|
223449840|NCT01553435|DRUG|Dextromethorphan|The study medicines shall be administered via tube.
223449841|NCT01553435|DRUG|Placebo|The study medicines shall be administered via tube.
223449842|NCT01956760|OTHER|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25\*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20\*8.0mm).attached to skin tape (10.0\*10.0mm). The needles were inserted 3.0\~5.0mm deep and maintained for 48\~72 hours
223449843|NCT01415375|BEHAVIORAL|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
223569368|NCT04810936|DIETARY_SUPPLEMENT|oral nutritional supplements|Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
223569369|NCT06370234|RADIATION|Whole body 18F-FDG Positron Emission Tomography|The subjects enrolling and participating this study will have done PET/MR during pre-operation chemotherapy. But, in normal procedure, they will not have done.
223569370|NCT04624334|OTHER|Elektro-Entero-Graphy procedure|Fasting, after which pre- and postprandial EEnG measurements are performed.
223569371|NCT04624334|OTHER|EEnG Questionnaire|Filling out questionnaire about EEnG procedure.
223569372|NCT04624334|OTHER|Gold Standard Questionnaire|Filling out questionnaire about Gold Standard diagnostic used to diagnose colonic motility disorder.
223569373|NCT00751283|DEVICE|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
223741860|NCT01178593|OTHER|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
223449844|NCT01415375|BEHAVIORAL|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
223741861|NCT01556581|PROCEDURE|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
223741862|NCT01556581|PROCEDURE|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
223741863|NCT03036761|PROCEDURE|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
223741864|NCT04052984|PROCEDURE|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
223449845|NCT06601738|OTHER|Isomeric Hand Grip Exercises|Patients will be instructed to squeeze and sustain the dynamometer for 2 min at 30% M.V.C. The dynamometer pointer which read the scale provided visual feedback to the subjects for the maintenance of the 30% M.V.C. This procedure will be repeated twice for each training session with a 5-minute rest in between.
223449846|NCT06601738|OTHER|Dynamic Hand Grip Exercises|Dynamic handgrip exercise was performed with both-sided, metronome-guided rhythmic hand contractions for 2min. The handgrip ring, closest to 20% of MVC, was chosen for DHE which was performed at a frequency of 30/min, acoustically indicated by a metronome beat.
223449847|NCT00405782|BEHAVIORAL|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
223449848|NCT03628716|BIOLOGICAL|CV301|"Prime with MVA-BN-CV301 (nominal titer 1.6 x 10\^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10\^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10\^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection."
223449849|NCT03628716|BIOLOGICAL|Atezolizumab|Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
223741865|NCT06297109|DEVICE|Patient-specific implants|Application of patient-specific implants for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
223741866|NCT06297109|DEVICE|Conventional mini-plates|Application of conventional mini-plates for Le Fort I osteotomy and genioplasty in bimaxillary orthognathic surgery.
223741867|NCT03527199|DIAGNOSTIC_TEST|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
223741868|NCT06965426|OTHER|Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation|Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
224057512|NCT06977776|BEHAVIORAL|Web-Based Osteoporosis Awareness Training Based on Health Belief Model|This study presents a web-based osteoporosis awareness training based on the health belief model. The training is designed to provide information about the risks of osteoporosis, ways of prevention and healthy lifestyle habits. Participants will be taught about the importance of calcium intake, the benefits of exercise and osteoporosis prevention methods. The training process will be supported by interactive content and individual counseling sessions offered through the website and participants will be provided with the opportunity to consolidate their knowledge.
224057513|NCT06813677|OTHER|In-person health promotion|The results from the initial pre-baseline examination are reviewed during the baseline visit to identify potential risk factors related to the Life's Essential 8 (LE8). Based on these findings, participants receive personalized recommendations to enhance their vascular health and information on local vascular health promotion resources. Additionally, participants receive bi-monthly motivational newsletters designed to support ongoing vascular health improvements.
224057514|NCT06977685|DRUG|Non-selective beta-blockers|Non-selective beta-blockers (NSBB) prescribed at discharge for patients hospitalized with hepatic complications. The study will analyze two types of NSBB: propranolol and carvedilol. The study will also examine potential dosage effects by categorizing NSBB use into low-dose and middle-high dose groups. NSBB use is defined as a prescription for at least 2 days at discharge.
224146932|NCT03496662|DRUG|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
224057515|NCT06501404|DIETARY_SUPPLEMENT|High dose group|A daily high dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x109 CFU of each of the strains
224057516|NCT06501404|DIETARY_SUPPLEMENT|Low dose group|A daily low dose of a mixture of probiotics (Lactobacillus Fermentum CECT 5716 and Bifidobacterium breve CECT 7263), was given orally starting in the first 72 hours of life, until 36+6 weeks of postmenstrual age or discharge The total dose was 1x106 CFU of each of the strains
224057517|NCT06536660|PROCEDURE|Magnesium bone plate and screw fixation in jaw surgery|Participants will undergo jaw surgery based on their clinical indications. High-purity magnesium bone plates and screws will be used for internal fixation during the surgical procedure.
224057518|NCT03303950|DRUG|Busulfan|Given IV
224057519|NCT03303950|DRUG|Cyclophosphamide|Given IV
224057520|NCT03303950|DRUG|Fludarabine|Given IV
224057521|NCT03303950|PROCEDURE|Hematopoietic Cell Transplantation|Undergo HSCT
224057522|NCT03303950|OTHER|Laboratory Biomarker Analysis|Correlative studies
223449850|NCT07006623|BEHAVIORAL|CoMBI-SMI|CoMBI-SMI (Cognitive Model for Behavioral Interventions - Severe Mental Illness) is a structured, team-based behavioral intervention for individuals with severe mental illness. It consists of four steps: (1) analyzing misunderstood behavior and identifying unmet core needs, (2) selecting the most relevant core need, (3) choosing appropriate nursing interventions, and (4) developing a CoMBI care plan. The model is based on cognitive-behavioral principles and personality-based formulations grounded in the DSM. It describes self-image, perception of others, triggers, and problematic behaviors. CoMBI-SMI is implemented by the entire team in a cyclical process, with periodic evaluation and a focus on consistent, team-aligned strategies.
223449851|NCT06866717|OTHER|Hybrid prehabilitation|"Hybrid prehabilitation group (15 sessions in total over 3 weeks): participants will complete 3 center-based sessions and 12 home-based sessions over three weeks. The home-based sessions will mirror those in the center-based group (initiation, training session, final session).~For the home-based component, participants will receive a cycle ergometer, pulse oximeter, activity tracker, and a tablet application for guidance throughout the program, remote monitoring and communication (TELEREHAPP). Home-based sessions include:~* Endurance training on the cycle ergometer (15 to 45 minutes per session).~* Strength training and balance exercises (30 minutes per session).~* Inspiratory muscle training (10 sets of 10 repetitions at 30% of maximal inspiratory pressure).~* Physical activity coaching with daily step count objective;~* Regular remote monitoring and support via the tablet application, with weekly check-ins from healthcare professionals."
223449852|NCT06866717|OTHER|Center-based prehabilitation|"Center-based prehabilitation group (15 sessions in total over 3 weeks): participants will attend 15 sessions in the center, over three weeks, comprising:~* 1 initiation session (approximately 3 hours) including preoperative patient education, instructions on the use of inspiratory muscle training device, endurance training on a cycle ergometer, strength training, and balance exercises.~* 13 endurance training sessions (1.5 to 2 hours each) focusing on endurance training (15 to 45 minutes), strength training (30 minutes), and inspiratory muscle training (10 sets of 10 repetitions at 30% of maximal inspiratory pressure).~* 1 final session (2 to 2.5 hours) with a review of the program and educational reinforcement."
223449853|NCT07016308|DRUG|Sevoflurane|Sevoflurane will be administered via inhalation under low-flow anesthesia conditions. The concentration will be maintained at 2-3% (0.8-1 MAC) with a fresh gas flow of 1 L/min (50% oxygen and 50% air) after induction. Used in Group S (Sevoflurane Low-Flow Anesthesia Arm).
223449854|NCT07016308|DRUG|Desflurane|Desflurane will be administered via inhalation under low-flow anesthesia conditions. The concentration will be maintained at 4-6% (0.8-1 MAC) with a fresh gas flow of 1 L/min (50% oxygen and 50% air) after induction. Used in Group D (Desflurane Low-Flow Anesthesia Arm).
223449855|NCT07015944|OTHER|Non-specialist delivered Low intensity guided self-help (Khushi and Khatoon)|This is a manualised intervention comprising of 8 chapters. This is being further co-adapted to contexualise this for breast cancer survivours. The original manual is focused on stories of two breast cancer survivors , Mrs Khushi, means happiness) and Khatoon, means woman in Urdu, with depression and anxiety, describing how they help themselves using CBT strategies.
223449856|NCT07015944|OTHER|Moving on After Breast Cancer (ABC) plus|This is a high intensity manualised intervention consisting of 12 sessions (60-90 minutes). This manual offers practical support and advice on life after breast cancer, managing difficulties, mindfulness, addressing fatigue, understanding the participant's model of illness, improving personal effectiveness and social relationships. The sessions also include therapist delivered psychoeducation using a CBT model of case formulation and goal setting: identification and formulation of predisposing, precipitating, perpetuating and protective factors of depression and/or anxiety, helping participants to identify core beliefs, where necessary, using downward arrow technique, identifying, and challenging unhealthy thinking patterns at the level of core beliefs using cognitive restructuring, and problem-solving techniques
223449857|NCT07015944|DRUG|Standardised pharmacological treatment (antidepressants)|Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks. After that, flexible titation of sertraline will be permitted, by 50mg increment every 1 to 2 weeks, as clinically indicated and tolerated to a maximum daily dose of 200 mg
223449858|NCT07015944|OTHER|Enhanced Treatment As Usual (E-TAU)|Participants in this arm will continue to follow their routine visits to healthcare facilities. They will be regularly monitored by trained research team and will be assessed at weeks 6,18,30, and 48. In addition to psychological assessment at each follow-up, this will include information leaflets based on a brief psychoeducational module to educate participants and families about the risks, symptoms, management, and referral support information for anxiety and depression
223569374|NCT04695028|OTHER|Data collection|"The following data will be collected by the physician: sociodemographic profile, clinical manifestations, comorbidities, laboratory tests,etc.~Diagnostic performance of different imagery techniques, performance of crystal deposit quantification in ultrasound and Dual-energy computed tomography (DECT), link between co-morbidities and volume of baseline crystal deposits then during monitoring, link between co-morbidities (including cardiovascular events and new diagnoses of co-morbidity) and vascular baseline crystal deposits and during follow-up, link between microcrystalline rheumatism activity and the quantity of crystal deposits in baseline imaging and during follow-up, link between co-morbidities and the evolution of microcrystalline baseline rheumatism and then during follow-up, link between co-morbidities and the evolution of crystal deposition volumes, the concordance of the evaluation of uratic stocks and their evolution between the imagery means."
223569375|NCT05782114|OTHER|Extracorporeal Shockwave therapy|The shockwave will be applied for the experimental group (Group A). The patients will be positioned on a chair, and the hand with the disorder will be placed on a surface with the radio ulnar joint will be in mid position and the thumb will be directed up. will be 1000 impulses with 2 bar pressure at a frequency of 15 Hz on the radial head and focused on the tissue surrounding the maximal pain point.
223569376|NCT05782114|OTHER|Traditional physical therapy program|"1. Instruction to wear Thumb Spica splint:~   The Thumb Spica splint will be used for 4 weeks for both groups of patients.~2. Ultrasound Therapy:~   Therapeutic Ultrasound parameters will be mode: continuous, duration: 5 minutes, intensity: 1.2watt/cm2 and frequency: 1MHZ.~3. Stretching exercise:~1\. Self-stretch of the thenar eminence: 2. Opposition stretches: 3. Wrist stretch:~4\) Strengthening exercise:~1. Resisted exercise for thumb extension:~2. Resisted exercise for thumb abduction:~3. Resisted exercise for thumb opposition:~4. Wrist radial deviation strengthening:~5. Grip strengthening:~6. Finger spring:"
223569377|NCT02691403|DRUG|levo-bupivacaine|
223569378|NCT02691403|DRUG|normal saline|
223449859|NCT07015606|OTHER|Sciatic nerve mobilization with EMS|Patients in both groups will receive electrical muscle stimulation. In addition, the group A will receive sciatic neural mobilization and group B will receive femoral neural mobilization. Patients were not allowed to take medication for pain during the study or to receive any other form of treatment outside the study. EMS device was applied at a pulse frequency of 100 Hz. Placement of 2 surface electrodes will be used for stimulation over a session period of 15 minutes. The repetition of mobilization will be 10 times for 2 sets with 2 minutes rest in between the sets. The frequency of Electrical muscle stimulation and the duration of neural mobilization will be increased after every session up to 10 Hz and 3 mints respectively.
223449860|NCT07015606|OTHER|Femoral neural mobilization with EMS|Patients in both groups will receive electrical muscle stimulation. In addition, the group A will receive sciatic neural mobilization and group B will receive femoral neural mobilization. Patients were not allowed to take medication for pain during the study or to receive any other form of treatment outside the study. EMS device was applied at a pulse frequency of 100 Hz. Placement of 2 surface electrodes will be used for stimulation over a session period of 15 minutes. The repetition of mobilization will be 10 times for 2 sets with 2 minutes rest in between the sets. The frequency of Electrical muscle stimulation and the duration of neural mobilization will be increased after every session up to 10 Hz and 3 mints respectively.
224057523|NCT04134962|DIAGNOSTIC_TEST|3D Imaging FAO measurement and Clinical evaluation of the hindfoot alignment|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
224057524|NCT03577730|DRUG|Caffeine Citrate|Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
224057525|NCT03577730|DRUG|Dextrose Water|Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
224057526|NCT02889406|BEHAVIORAL|Motivational intervention|motivational interviewing schema
224057527|NCT05080023|DEVICE|Enhanced External Counterpulsation (EECP)|Enhanced External Counterpulsation (EECP)
224057528|NCT03974776|BIOLOGICAL|PF-06946860|PF-06946860 administered subcutaneously
223449861|NCT07017660|OTHER|virtual reality glasses|Patients will be asked to wear virtual reality glasses starting three minutes before the procedure and until it is completed. With the virtual reality glasses, the patient will be shown a video of nature scenes and made to listen to the sounds of water and birds. Routine institutional procedures will be applied during the cystoscopy procedure.
223449862|NCT07017660|OTHER|No intervention|Routine institution procedures will be applied during the cystoscopy procedure.
223449863|NCT06618729|OTHER|Pea protein|Ingestion of a meal containing 40 g of protein from pea protein extrudate
223449864|NCT06618729|OTHER|Wheat protein|Ingestion of a meal containing 40 g of protein from wheat protein extrudate
223449865|NCT06618729|OTHER|Soy protein|Ingestion of a meal containing 40 g of protein from soy protein extrudate
223449866|NCT06618729|OTHER|Chicken|Ingestion of a meal containing 40 g of protein from chicken
223449867|NCT03748121|BEHAVIORAL|Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)|The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.
223449868|NCT03748121|BEHAVIORAL|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
223449869|NCT07021469|OTHER|Sound origins|"Parents:~1. Playlists created by parents with lived experience for parents to use as ideas for music they could use for themselves or with baby on the unit.~2. Parent Journal: This journal provides a guide for using music and self-reflection. It also has the link for the playlists.~3. 'Musical gifts' created with the support of a music therapist from external family/ friends to the baby on the unit.~Nursing staff caring for families participating in the study:~1. Nurses shared playlist. Suggested creation of 3 playlists for nursing staff to create their own shared playlist using their music.~2. 'Ask me' badges. These badges are optional for nurses to wear during their shifts but will act as a symbol to parents that their nurse is available to speak to about music."
223449870|NCT07026617|OTHER|Rocabado's approach in addition to LLLT|The patients will recieve Rocabado's non-thrust manipulation: Non-thrust temporo-mandibular joint manipulations consisted of medial glide, lateral glide and anterior glide as described by Rocabado. Each glide was given for 10-15 repetitions for 5-6 times in a session. The grade of mobilization was beginning with Grade-1 or 2 and progressed to Grade-4 depending on subject condition. Total duration of mobilization was lasted for 20 minutes. in addition to low power gallium aluminum arsenide (GaAlAs).
223569379|NCT01863251|DRUG|Atomoxetine|
224146933|NCT03496662|DRUG|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
223569380|NCT05792592|DIAGNOSTIC_TEST|IOS (Impulse Oscillometry)|Small Airways Disease Assessment
224057529|NCT03974776|OTHER|Placebo|Placebo administered subcutaneously
224057530|NCT04311736|BEHAVIORAL|Exergame|Cycling on a recumbent cycle ergometer + Virtual Reality Cognitive Training
224057531|NCT04311736|BEHAVIORAL|Cycling|Cycling on a recumbent cycle ergometer
224057532|NCT04311736|BEHAVIORAL|Stretching|Stretching exercises
224146934|NCT03496662|DRUG|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
224146935|NCT03496662|PROCEDURE|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
224057533|NCT04203745|DEVICE|Nonablative Fractional Diode Laser|The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.
224146936|NCT03496662|PROCEDURE|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
224057534|NCT05764382|BEHAVIORAL|T'ai Chi and Qigong Rehabilitation|T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. Master Yang developed this course based on his own healing journey from severe back pain following a bike accident in 2014.
223449871|NCT07026617|OTHER|control group|The patients will recieve Rocabado's non-thrust manipulation: Non-thrust temporo-mandibular joint manipulations consisted of medial glide, lateral glide and anterior glide as described by Rocabado. Each glide was given for 10-15 repetitions for 5-6 times in a session. The grade of mobilization was beginning with Grade-1 or 2 and progressed to Grade-4 depending on subject condition. Total duration of mobilization was lasted for 20 minutes. in addition to lplacebo ow power gallium aluminum arsenide (GaAlAs).
223449872|NCT07026786|BEHAVIORAL|Mindfulness Intervention|Those in the Mindfulness Intervention group will have a 30-minute Zoom session before surgery to learn simple mindfulness exercises like deep breathing, using senses, and staying focused on the present. After surgery, these participants will receive a refresher on the mindfulness curriculum.
223449873|NCT07022158|OTHER|The patients participating in the study were between 6 and 16 weeks of pregnancy. Height, body weight, and waist circumference were measured at the first antenatal visit at 2 weeks.|170 patients at 6-16th weeks of gestation were prospectively analyzed. Body mass index (BMI) and ABSI were calculated. Patients were analyzed according to the presence of GDM, GHT and preeclampsia at follow-up.
223449874|NCT00247988|DRUG|Weekly Taxotere with weekly carboplatin|
223449875|NCT05690763|OTHER|XP-endo Finisher to use irrigation activation|XPF : The canals were flushed with 2.5 mL 2.5% NaOCl for 30 s and activated by a XPF instrument that was placed in the canal to 1 mm short of the WL and powered by the motor at 800 rpm (1 N-cm torque) for 30 s according to the manufacturer's instructions. Then the canals were rinsed with 2.5 mL of 2.5% NaOCl, followed by activation of the substance with the XPF instrument for 30 seconds, the same way as above. A new XP-endo Finisher file was used for each canal.
223449876|NCT05690763|OTHER|EndoActivator to use irrigation activation|The root canals were irrigated with 2.5 mL of 2.5% NaOCl for 30 s, followed by sonic activation of this solution with EndoActivator red tip size #25/0.04, inserted into the root canal 1 mm short of the WL, at 10,000 cpm/min. for 30 seconds. The EA polymer tip moved vertically from apical to coronal part of the canal during activation.
223569381|NCT03224065|DIAGNOSTIC_TEST|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
223569382|NCT04054804|DIAGNOSTIC_TEST|D-Foot|A digital foot check i assessed by using the software D-Foot.
223741869|NCT06969443|PROCEDURE|Rehabilitation Procedure|"Rehabilitation procedure list :~1. Passive limb mobilization~2. Active (or active-assisted) limb mobilization~3. Passive transfer to chair~4. Active transfer to chair~5. Sitting on edge of bed~6. Standing table (or similar)~7. Standing on legs~8. Walking~9. Cyclo-ergometer (bed or chair)~10. Electrostimulation"
224057535|NCT05764382|OTHER|Usual care|Usual care as per primary care physican, physical therapist.
224057536|NCT05601648|DRUG|Psilocybin|Psilocybin (25mg tablet) plus supportive psychotherapy
224057537|NCT05536310|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|TAVI with the JenaValve Trilogy Heart Valve System
224057538|NCT05087290|OTHER|Cases|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
224057539|NCT05087290|OTHER|Controls|"All performed at baseline, 12 months and 18 months Medical and drug history Anthropometric tests Electrocardiogram Brachial flow mediated dilatation 6 minute walk test Blood sampling Urine sampling 24-hr Ambulatory Blood Pressure Monitor Questionnaires~Optional:~Stool sampling,24-hr Urine collection, Home Blood Pressure Monitor"
224057540|NCT01767454|DRUG|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
224057541|NCT01767454|DRUG|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
224057542|NCT01767454|DRUG|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
224057543|NCT03126942|DEVICE|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
224057544|NCT03126942|DEVICE|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
224057545|NCT01911442|DRUG|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
224057546|NCT01911442|DRUG|Lurasidone|Lurasidone 60 mg once daily
224057547|NCT01911442|DRUG|Placebo|Placebo
224057548|NCT00122681|BIOLOGICAL|Cervarix™|Intramuscular injection, 3 doses
224057549|NCT00122681|BIOLOGICAL|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
224146937|NCT06015932|BEHAVIORAL|Cognitive Behavior Therapy|Participate in CBCSM group sessions
224057550|NCT00073489|DRUG|OSI-461|
224057551|NCT01349465|DRUG|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
224057552|NCT02571296|DRUG|micronized progesterone|Oral
224057553|NCT02571296|DRUG|Placebo|Oral
224057554|NCT02970604|DRUG|Aspirin|Non enteric coated aspirin
224057555|NCT04831489|RADIATION|Imaging|pre and postoperative CT scan of lung
224057556|NCT06073015|DRUG|Esketamine|Group S received a subanesthetic dose of esketamine 0.2mg/kg (2ml/50 mg) 5 minutes before the procedure began.
224057557|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
224146938|NCT06015932|OTHER|Questionnaire Administration|Complete questionnaires
223449877|NCT05700331|PROCEDURE|Fecal Microbiota Transplantation|"FMT performed at week 0, week-2 and week-4: FMT solution will be prepared using stool from a single donor or mixing of stool from multiple donors. Feces will be diluted with sterile saline (0.9%). This solution will be blended and strained with filter. The resulting supernatant will then be used directly as fresh FMT solution or stored as frozen FMT solution for future FMT.~Procedures for Infusion: 100-200 ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via oesophago-gastro-duodenoscopy (OGD). After infusion, subjects will be monitored for 1 hour before discharged.~2 study biopsies in total (from duodenum) will be obtained during FMT infusion via OGD."
224057558|NCT04031742|BIOLOGICAL|IBI306|Administered by subcutaneous injection
224057559|NCT03844984|DRUG|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
224057560|NCT03844984|DRUG|Midazolam|This group will receive midazolam 0.05 mg/Kg
224057561|NCT03844984|DRUG|Normal saline|This group will receive normal saline 10 mL
224057562|NCT03844984|DRUG|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
224057563|NCT03844984|DRUG|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
224057564|NCT05645497|PROCEDURE|Surgery with FACET FIXATION implants|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with FACET FIXATION implants
224057565|NCT05645497|PROCEDURE|Surgery with Pedicle Screw|Surgical treatment of degenerative lumbar spinal stenosis by lumbar decompression with Pedicle Screw
224057566|NCT01589471|DRUG|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
224057567|NCT01859832|OTHER|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
224057568|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
224057569|NCT00381342|DRUG|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
224057570|NCT00381342|DRUG|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
224057571|NCT02879565|OTHER|Semi structured interviews + EEG exams|
224057572|NCT05325905|DIAGNOSTIC_TEST|Gingival crevicular fluid sampling|GCF sampling and clinical periodontal measurements were performed
224057573|NCT03840538|DRUG|Probiotic Product - Cap|probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
224146939|NCT06310824|DRUG|MAB-22|60mg dose of a single subcutaneous injection
224146940|NCT06310824|DRUG|EU-Prolia®|60mg dose of a single subcutaneous injection
223449878|NCT05700331|PROCEDURE|Sigmoidoscopy|Optional sigmoidoscopy will be done at week 0 and week 4, during which 2 study biopsies in total (obtained via sigmoidoscopy) will be obtained from the rectum.
223449879|NCT04735796|DRUG|Drug：LM-102|Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
223449880|NCT00856843|DRUG|BLI800|Solution for oral administration prior to colonoscopy
223449881|NCT00856843|DRUG|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
223569383|NCT03879304|OTHER|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
223569384|NCT03879304|OTHER|traditional physiotherapy program|Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
224057574|NCT06426355|DIETARY_SUPPLEMENT|NMN|NMN capsules (total of 600mg/day) for 2-5 months
224057575|NCT06426355|OTHER|Placebo|NMN-free placebo capsules for 2-5 months
224057576|NCT04892264|BIOLOGICAL|Belantamab Mafodotin|Given IV
224057577|NCT04892264|BIOLOGICAL|Daratumumab|Given IV
224057578|NCT04892264|DRUG|Dexamethasone|Given PO
224057579|NCT04892264|DRUG|Lenalidomide|Given PO
224057580|NCT04892264|OTHER|Quality-of-Life Assessment|Ancillary studies
224057581|NCT04892264|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224057582|NCT04892264|PROCEDURE|Skeletal Survey X-Ray|Undergo X-ray skeletal survey
224057583|NCT04892264|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo whole body low dose CT
224057584|NCT04892264|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224057585|NCT04892264|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224057586|NCT02214966|DRUG|Telmisartan/Ramipril, fixed dose combination tablet|
224057587|NCT02214966|OTHER|high fat, high caloric meal|
224057588|NCT04236063|OTHER|WHODAS 2.0 Questionnaire|36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview
224057589|NCT03243383|OTHER|DiaTOHC Program|"1. Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~2. Peri-discharge coordination of care~3. A1c-based adjustment of diabetes therapy~4. Post-discharge support"
224057590|NCT00338754|DRUG|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
224057591|NCT03891290|OTHER|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
224146941|NCT06310824|DRUG|US-Prolia®|60mg dose of a single subcutaneous injection
224146942|NCT03427866|DRUG|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
223449882|NCT04869111|BEHAVIORAL|Brain Health Training|"1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts.~2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.~3. Brain-Healthy Habits - daily reminders of habits you can track~4. BrainHQ - participants will gain temporary access to the exercise-based cognitive training of BrainHQ after completing their 3rd BrainHealth Index"
223449883|NCT04039321|DRUG|ESPB group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
223449884|NCT04039321|DRUG|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
223449885|NCT04691206|OTHER|briefing objectives, intraoperative teaching, and debriefing feedback|A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
223449886|NCT03825068|PROCEDURE|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
223449887|NCT03825068|DRUG|general anesthetic|patient receive general anaesthetic only
223449888|NCT03376373|BEHAVIORAL|neurofeedback|real-time feedback on accuracy of emotion recognition
223449889|NCT02583867|BEHAVIORAL|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
223449890|NCT05543031|OTHER|Music-Integrated Phonological Awareness training program|We would like to observe the effect of the music integrated phonological awareness program on preschool cochlear implant users and to compare the phonological awareness skills of the study group with the control group before and after the online training. The program is prepared as 10 lessons. Participants were guided through online training for 5 weeks, with 20-minute sessions conducted weekly. The training was carried out via Zoom, a free virtual interview program. Each family had a computer.
223449891|NCT05543031|DIAGNOSTIC_TEST|Spectral-Temporally Modulated Ripple Test (SMRT)|Spectral-Temporally Modulated Ripple Test (SMRT) was used to assess the spectral discrimination ability of the study group.Speech stimuli were presented at a calibrated presentation level of 60 dB SPL in a quiet room. The child was positioned at 0° azimuth and 1-meter from the loudspeaker.
223449892|NCT05543031|DIAGNOSTIC_TEST|The Phonological Awareness Scale of Early Childhood Period (PASECP)|The Phonological Awareness Scale of Early Childhood Period (PASECP) was used to measure the sound awareness and sound discrimination skills of study group pre-post training. The test has 8 sub-dimensions.
223449893|NCT05543031|DIAGNOSTIC_TEST|Mismatch Negativity Test|Mismatch Negativity (MMN) was used to evaluate the central auditory system.The test was used for electrophysiological recordings of the study group.The standard stimulus presented as /ba/ (%80), and the rare stimulus presented as /da/ (%20) frequency. The onset (rise) and offset (fall) times of the stimuli are 10 ms, and the plateau time is 50 ms. The interval between stimuli for both responses was 1.1 ms. A 0.1-30 Hz filter was applied. The speech stimuli intensity was 70 dB SPL. Speech stimuli were presented at a 1-meter distance from the participant, with speakers placed at an angle of 0°.
223449894|NCT05543031|DIAGNOSTIC_TEST|Early Language Development (TELD-3)|Test of Early Language Development (TELD-3) measured children's receptive and expressive language skills both group for inclusion criteria.
223449895|NCT04934982|OTHER|Total Laparoscopic or Robotic Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
223449896|NCT04934982|OTHER|Total Abdominal Radical Hysterectomy|Stage IA1 with lymphovascular interstitial infiltration and IA2 surgical approach was type B (modified radical hysterectomy plus bilateral pelvic lymph node dissection, i.e., resection of 1\~2 cm of the parametrium and 1\~2 cm of the vagina) with abdominal para-aortic lymph node dissection if necessary (surgical staging according to FIGO 2018 and surgical staging according to Querleu-Morrow staging).
223449897|NCT01994902|DEVICE|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
223449898|NCT01994902|DEVICE|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
223569385|NCT04204356|BEHAVIORAL|Language treatment for improving discourse production|All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.
223569386|NCT04204356|DEVICE|Transcranial direct-current stimulation (tDCS)|Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
223569387|NCT03874390|OTHER|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
223569388|NCT05637892|OTHER|No intervention|This is a prospective observational study with no intervention
224057592|NCT00988143|BIOLOGICAL|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
224057593|NCT00988143|BIOLOGICAL|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
224057594|NCT00988143|BIOLOGICAL|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
224057595|NCT04513886|PROCEDURE|Subepithelial connective tissue graft (SCTG) using the single incision technique, with and without suturing the palate|A SCTG was harvested using the single incision technique described by Hürzeler \& Weng. The palatal incisions were standardized to extend between the area between mesial of the canine and mesial of the first molar.In the Suture Group sites a cross- mattress suture and interrupted single sutures were performed using nylon 5-0 when appropriate. In the no Suture Group sites, no suture was performed. In both groups, a CHS was placed after removing the graft to achieve the haemostasis of the palate and subsequent compressed with gauze soaked in saline for 5 minutes.
224057596|NCT02171962|DEVICE|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
224057597|NCT02486978|OTHER|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
224057598|NCT02486978|DIETARY_SUPPLEMENT|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
224057599|NCT02486978|DIETARY_SUPPLEMENT|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
224057600|NCT03370120|DRUG|Padsevonil|"* Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use"
224146943|NCT04643795|DRUG|MGL-3196|Once daily oral dose for 6 days
224146944|NCT05700201|BEHAVIORAL|Lifestyle / Healthy Behavior Intervention|12-session healthy lifestyle program focused on physical activity, nutrition, sleep, and stress management.
224146945|NCT05700201|OTHER|standard care|Standard care (psychotherapy)
224146946|NCT04592237|DRUG|Cabazitaxel|Given IV
224146947|NCT04592237|DRUG|Carboplatin|Given IV
224146948|NCT04592237|BIOLOGICAL|Cetrelimab|Given IV
224146949|NCT04592237|DRUG|Niraparib|Given PO
224146950|NCT06731764|DRUG|Levothyroxine|"Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily."
224146951|NCT06731764|DRUG|Levothyroxine/Liothyronine once daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;
224146952|NCT06731764|DRUG|Levothyroxine/Liothyronine twice daily|Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
224146953|NCT05873205|BIOLOGICAL|Isatuximab|All participants enrolled on the study will receive isatuximab intravenously as a single agent
224146954|NCT02378883|DEVICE|Apollo™ Onyx™ Delivery Micro Catheter|
224146955|NCT05756621|DRUG|Ketamine|"Dual anti-glutamatergic therapy (DUAL) intervention group: patients who received ketamine as a continuous i.v. for 3 days (induction dose 1.5-3 mg/kg, followed by maintenance dose 2-10 mg/kg/h; dose adjustment according to EEG target of ketamine pattern) + oral perampanel via nasogastric tube for 5 days (12 mg if weight \> 60 kg; 9 mg if weight 50-60 kg; 6 mg if weight \< 50 kg), followed by gradual reduction according to clinical evolution."
224146956|NCT05756621|DRUG|Any anti-epileptic and anesthetic therapy, excluding Ketamine and Perampanel|Any antiseizure and anesthetic therapy according to usual clinical practice, excluding the two anti-glutamate drugs Ketamine and Perampanel
223449899|NCT05509010|PROCEDURE|CTCA|CTCA is performed as part of routine care procedure.
223449900|NCT05242133|DRUG|Pegylated interferon beta-1a|Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
223449901|NCT05242133|DRUG|Interferon Beta-1A Prefilled Syringe|Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
223449902|NCT00681265|DRUG|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
223449903|NCT00681265|DRUG|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
223449904|NCT01994473|DRUG|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
223449905|NCT01994473|DRUG|Placebo|single oral dose placebo
223449906|NCT01994473|DRUG|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
224057601|NCT00454857|OTHER|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
224057602|NCT00454857|OTHER|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
224146957|NCT02140619|BEHAVIORAL|multiple health education interventions|
224146958|NCT02220361|DRUG|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
224057603|NCT00454857|OTHER|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
224057604|NCT03185364|DRUG|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
224146959|NCT02220361|DRUG|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
224146960|NCT02220361|DRUG|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
224146961|NCT03064347|DIETARY_SUPPLEMENT|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
224057605|NCT03185364|DRUG|Placebo Oral Tablet|placebos treatment for 12 weeks
224301169|NCT05315635|OTHER|Questionnaire|"Patients treated for substance use disorders and patients treated for eating disorders will have to complete self-questionnaires and a clinical psychiatric (MINI) at the inclusion.~Patients suffering from substance use disorder will be assessed 3 weeks after inclusion.~Questionnaires are :~* Modified Yale Food Addiction (mYFAS 2.0) and Impulsive Behavior Scale (UPPS-P)~* Trait Meta-Mood Scale (TMMS), Hospital Anxiety and Depression Scale (HADs), Emotional Appetite Questionnaire (EMAQ), Perceived Stress Scale (PSS-10), Multidimensional Assessment of Interoceptive Awareness (MAIA) and Five Facet Mindfulness Questionnaire (FFMQ)~* Mini International Neuropsychiatric Interview (MINI), Eating Disorder Examination-Questionnaire (EDE-Q), Rosenberg's Self Esteem (RSE) and Ruminative Response Scale for Eating disorders (RRS-ED)~* Pittsburgh Sleep Quality Index (PSQI) and Montreal Cognitive Assessment (MoCA)"
224301170|NCT03844789|DEVICE|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology \& Dexcom G6 CGM
224301171|NCT03844789|DEVICE|Control Group|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
224301172|NCT06233357|DRUG|treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)|IgG seronegative SARSCoV2-Spike antibody (\< 0,80 U/ml) COVID-19 patients were treated with 1 dose of subcutaneous casirivimab and imdevimab, 1200 mg (600 mg of each). Patients with CRP \> 75 mg/l or IL-6 \> 75 ng/l were treated with one dose of intravenous tocilizumab 8 mg/kg body weight
224301173|NCT00359632|DRUG|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
224301174|NCT00359632|DRUG|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
224301175|NCT02448849|BIOLOGICAL|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
224301176|NCT02448849|OTHER|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
224301177|NCT04328571|DIETARY_SUPPLEMENT|OLE enzymatically treated|OLE (Olive leaf extract ) enzymatically treated + maltodextrin
224301178|NCT04328571|DIETARY_SUPPLEMENT|OLE + probiotic|OLE (Olive leaf extract) co-administered with probiotic
224301179|NCT04328571|DIETARY_SUPPLEMENT|OLE|OLE (Olive leaf extract) + maltodextrin
224301180|NCT00937651|DRUG|Placebo|Placebo
224301181|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
224301182|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
224301183|NCT00937651|DRUG|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
224301184|NCT05801653|DIETARY_SUPPLEMENT|Effects of Oat and Oat Components on Cardiometabolic risk variables|Oat and oat bioactive components consumed as breakfast meal.
224301185|NCT00004153|GENETIC|reverse transcriptase-polymerase chain reaction|
224301186|NCT00004153|PROCEDURE|sentinel lymph node biopsy|
223449907|NCT01491269|BEHAVIORAL|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
223449908|NCT04209439|DRUG|30 ml %0.25 bupivacaine|Ultrasound-guided erector spinae plane block
223449909|NCT04209439|DRUG|Dexketoprofen-trometamol|50 mg Dexketoprofen-trometamol intravenous
223449910|NCT04786665|OTHER|Strawberry|Freeze dried strawberry powder
223449911|NCT04786665|OTHER|Placebo group|Comparative placebo powder
224057606|NCT04026724|DRUG|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
224057607|NCT01886573|DRUG|Azacitidine|Given SC
224057608|NCT01886573|DRUG|Entinostat|Given PO
224057609|NCT01886573|OTHER|Laboratory Biomarker Analysis|Correlative studies
224057610|NCT01886573|OTHER|Pharmacological Study|Correlative studies
224057611|NCT01886573|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224057612|NCT04503304|OTHER|Exercises|already included in arm/group descriptions.
224057613|NCT03533647|OTHER|Observational|none (observational study)
224057614|NCT04206020|DRUG|SkQ1 Vehicle Solution|SkQ1 Ophthalmic Solution Vehicle
224301187|NCT02056470|DEVICE|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
224301188|NCT02056470|DEVICE|Total Knee Replacement|total Knee replacement implant
224301189|NCT02056470|DEVICE|Freedom Total Knee System|Total Knee replacement implant
224301190|NCT05116488|DIAGNOSTIC_TEST|ECG(electrocardigraph)|Detection of electrocardiographic Brugada patterns using high precordial leads positioning as placing the precordial leads in the second intercostal space has been proposed to add sensitivity to the ECG diagnosis of Brugada syndrome.
224301191|NCT03982576|OTHER|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
224301192|NCT03982576|BEHAVIORAL|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
224301193|NCT03982576|BEHAVIORAL|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
224301194|NCT03982576|BEHAVIORAL|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
224301195|NCT03982576|BEHAVIORAL|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
224301196|NCT04700280|DRUG|GLPG3970|GLPG3970 film-coated tablet.
224057615|NCT04206020|DRUG|SkQ1 Ophthalmic Solution|SkQ1 Ophthalmic Solution
223449912|NCT02895139|DEVICE|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
224146962|NCT03064347|DIETARY_SUPPLEMENT|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
224146963|NCT03064347|DIETARY_SUPPLEMENT|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
223449913|NCT02895139|DEVICE|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
224146964|NCT03064347|DIETARY_SUPPLEMENT|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
224146965|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
223569389|NCT06041711|PROCEDURE|General anesthesia with propofol induction and sevoflurane maintenance|Surgical procedure is performed under general anesthesia with propofol induction and mainteined with sevoflurane inhalation.
224146966|NCT03064347|DIETARY_SUPPLEMENT|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
224146967|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
223569390|NCT06041711|PROCEDURE|Regional anesthesia with neuroaxial blockage|Surgical procedure is performed under regional anesthesia. Patients are sedated with 2 mg intravenous midazolam. Combined spinal epidural anesthesia or spinal anesthesia with PENG block is used for anesthesia and analgesia.
224146968|NCT03064347|DIETARY_SUPPLEMENT|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
224146969|NCT03037307|OTHER|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
224146970|NCT03037307|OTHER|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
224146971|NCT03037307|OTHER|Negative Control|No adhesive
224146972|NCT03118453|BEHAVIORAL|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
224146973|NCT03118453|BEHAVIORAL|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
224146974|NCT04786730|DRUG|Centanafadine|Doses of centanafadine will be taken once daily in the morning on Days 1 through 14. The fixed dose strengths will be administered according to body weight. Up to 12 subjects will be enrolled in the 9 to 12 years age cohorts (Cohorts 1 and 6), up to 8 subjects will be enrolled in each of the 6 to 8 years age cohorts (Cohorts 2 and 3), and up to 5 subjects will be enrolled in each of the 4 to 5 years age cohorts (Cohorts 4 and 5).
224146975|NCT06236464|OTHER|Multiparameter analysis of each sample|Retrospective and prospective samples will be collected and analyzed for the study of molecular and viral biomarkers. Simultaneously, fibroblastic tumor-associated cells (CAFs) will be isolated from prospective samples. Through co-cultivation with immortalized cell lines derived from anogenital and head-neck SCCs, these CAFs will enable the production of 3D organoids for use in experiments assessing the response to telomerase and deacetylase SIRT1 inhibitors, both in vitro and in preclinical models.
224057616|NCT05915520|BEHAVIORAL|baduinjuin activities|in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)
224057617|NCT05915520|OTHER|pantoprazole|in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
224057618|NCT05780775|OTHER|HDL2|to perform additional blood samples during acute phase of complications (realized between Day 1 and Day 3) in SCD patients hospitalized for vasoocclusive crisis or priapism.
224057619|NCT00609193|DRUG|lithium|standard clinical care
224057620|NCT00609193|DRUG|quetiapine|standard clinical care
224057621|NCT02462356|PROCEDURE|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
224146976|NCT06212570|DEVICE|KeySuite|KeyScope and KeyLoop will be used to perform biopsies of intra-abdominal masses and cancers.
223449914|NCT02895139|DEVICE|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
223449915|NCT02717442|DRUG|OTO-104|Single intratympanic injection of 12 mg OTO-104
223449916|NCT02717442|DRUG|Placebo|Single intratympanic injection of placebo
223449917|NCT06718387|OTHER|PsychoEducation Program|6 sessions of PsychoEducational Program
223449918|NCT05219097|DIAGNOSTIC_TEST|CBA Assay|Comparsion of specificity, sensitivity and clinical correlation of CBA, ELISA and RIPA assay in autoantibodies detection of myasthenia gravis
223449919|NCT00842777|BEHAVIORAL|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
223449920|NCT00842777|BEHAVIORAL|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
223449921|NCT00538954|DRUG|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
223449922|NCT00538954|DIETARY_SUPPLEMENT|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
223449923|NCT00538954|OTHER|Standard ERAS group|
223449924|NCT02798354|BEHAVIORAL|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
223449925|NCT05872880|PROCEDURE|Modified radical surgery|The modified radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and local extended resection was performed according to the scope of the residual tumor lesions after induction therapy: the incisal margin was 1 to 1.5cm outside the boundary of the residual tumor lesions, and multi-point incisal rapid disease detection was performed intraoperatively to ensure negative incisal margin and complete resection of the residual tumor lesions. Under this premise, the surgical trauma should be minimized, and the organs and appearance of the patient should be preserved. For example, facial skin should not be penetrated, mandible should not be cut off, and tongue tissue should be preserved as much as possible. Direct suture or local tissue flap should be used to repair the defect during the operation. At the same time, improved radical neck dissection was performed on the affected side of the neck.
223449926|NCT05872880|PROCEDURE|Radical surgery|Radical surgery was performed within 4 to 6 weeks after the end of the last chemotherapy, and a wide range of radical surgical resection was performed according to the tumor scope before induction therapy: the incisal margin was 1 to 1.5cm outside the tumor boundary before induction, the lower lip and mandible could be incised if necessary, the facial skin could be excised, the mandibular bone segmentectomy was feasible, and pedicle or free skin (bone) flap was used to repair the defect. At the same time, improved radical neck dissection was performed on both sides of the affected neck.
223569391|NCT00593853|DRUG|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
224057622|NCT02462356|PROCEDURE|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
224057623|NCT03924349|DEVICE|ICG-coated clip|Tumor localization using ICG-coated clip prior to surgery
224057624|NCT04349163|OTHER|Questionnaire|CD-RISC 25 questionnaire
224057625|NCT05141370|DEVICE|cataract surgery with CATSYS|patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS
224057626|NCT02537886|DEVICE|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
224057627|NCT04416555|DEVICE|Placebo comparator: VR googles and the non reality experience|parallel assignment (this arm will receive a static presentation in the same device)
224057628|NCT04416555|DEVICE|Active Comparator: VR googles and the real VR program to enter act with and experience|Parallel assignment (this arm will receive the full immersive virtual reality experience
224057629|NCT02723695|OTHER|Evaluation of postural performances|Postural tests
224057630|NCT02006342|DRUG|Insulin Glargine|
224057631|NCT02006342|DRUG|Regular Insulin|
224146977|NCT04788849|DIAGNOSTIC_TEST|BD Onclarity™ HPV assay|Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
223449927|NCT04401280|DRUG|BiominF|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
223449928|NCT04401280|DRUG|Novamin|in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached
223449929|NCT04401280|DRUG|CPP-ACP|applied in accordance with the manufacturer's specifications
223449930|NCT05032729|OTHER|Trypophan, Theanine and 5'AMP|250 ml beverage consumed at 21:00 hours
223449931|NCT05032729|OTHER|Placebo|250 ml beverage consumed at 21:00 hours, matched in appearance and taste to the active beverages
223449932|NCT03229967|DIAGNOSTIC_TEST|16S rRNA stool microbiome sequencing.|This is an observational cohort that will undergo gut microbiome sequencing.
223449933|NCT00528372|DRUG|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
223449934|NCT00528372|DRUG|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
223449935|NCT00528372|DRUG|Metformin|
223449936|NCT03718169|BEHAVIORAL|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
223449937|NCT02238938|PROCEDURE|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
223449938|NCT02238938|PROCEDURE|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
223569392|NCT00593853|DRUG|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
223449939|NCT06393010|BEHAVIORAL|online rehabilitation program|Participants in the research will undergo a three-week online rehabilitation program, three times a week, lasting 40-45 minutes each session. The program includes posture, stretching, joint range of motion, strengthening exercises, pain education, and discussions. Conducted via Zoom, only the practitioner will be present during sessions. Non-attendance for two consecutive sessions or failure to provide feedback will result in exclusion. Exercises cover various body areas and types, including posture correction, range of motion, stretching, isometric neck and shoulder exercises, stick exercises, and strengthening exercises.
223449940|NCT00973895|BIOLOGICAL|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
223449941|NCT04782414|PROCEDURE|Hot AXIOS® prosthesis|endoscopic trans digestive drainage using of the Hot AXIOS prosthesis in the treatment of pancreatic collections (incompletely fluid or necrotic)
223449942|NCT00006355|DRUG|pyrazoloacridine|
223449943|NCT00006355|PROCEDURE|adjuvant therapy|
223449944|NCT00006355|RADIATION|radiation therapy|
223449945|NCT01187264|DRUG|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
223449946|NCT03818555|OTHER|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
223569393|NCT01952990|DRUG|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
223449947|NCT05271123|DIAGNOSTIC_TEST|Assessment of respiratory function and growth motor function classiffication level|Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
223449948|NCT03965455|DEVICE|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
223449949|NCT03965455|PROCEDURE|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
223449950|NCT06303414|PROCEDURE|Carotid Endarterectomy (CEA)|Carotid endarterectomy (CEA) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
223449951|NCT06303414|PROCEDURE|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, general anesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is advised for all patients who undergo CAS.
223569394|NCT04656795|DRUG|MT-7117|MT-7117
223569395|NCT02624193|BEHAVIORAL|MBSR Program|Mindfulness-based stress reduction, as described previously.
223569396|NCT02624193|BEHAVIORAL|HT Program|Health education curriculum, as described previously
223569397|NCT03823846|DRUG|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
223569398|NCT03823846|DRUG|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
223449952|NCT06303414|PROCEDURE|Hybrid Surgery|Hybrid Surgery Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 5 days before the hybird surgery procedure. If they had stenting procedure, they will receive a daily dose of 100 mg aspirin and 75 mg clopidogrel thereafter. If not, they will take either 100mg aspirin or 75mg clopidogrel daily for life.
223449953|NCT03461302|DRUG|Topical coal tar|Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
223449954|NCT03461302|DRUG|Topical corticosteroids|Clobetasone butyrate 0.05% ointment
223449955|NCT02350699|DEVICE|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
223449956|NCT05210270|RADIATION|Hypofractionation|"Phase 1 (Dose Escalation Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with nSIB 45 Gy (first dose level) and 48 Gy (second dose level); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)~Phase 2 (Efficacy Study):~Pelvic hypofractionated radiotherapy (40 Gy over 15 daily fractions) with (or without) nSIB 45-48 Gy (depending on phase 1 results); to be followed by brachytherapy (6.5-7.5 Gy x 4 fractions)"
223449957|NCT03118479|DRUG|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
223449958|NCT03118479|DRUG|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
223449959|NCT03118479|DRUG|Placebo Oral Tablet|One tablet to be taken daily for 3 months
223449960|NCT00671099|DIETARY_SUPPLEMENT|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
223569399|NCT03823846|DRUG|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
223569400|NCT03823846|DRUG|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
223569401|NCT03823846|OTHER|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
223569402|NCT03823846|DRUG|normal analgesia pump administration|Dose of analgesia pump was added if needed.
223569403|NCT03823846|DRUG|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
224057632|NCT06490835|BEHAVIORAL|High-quality palliative care through consultation-based palliative care services in the ICU|"Family Counseling: Social workers implement a supportive process for families, assessing the individualized psychosocial and decisional support needs of patients and families to provide foundational data for palliative care consultations.~Family Meeting Support: In cases of high medical complexity, uncertainty, value conflicts, or communication issues, the palliative care consultation team supports the facilitation of family meetings.~Consultation: The palliative care team provides consultations to the attending physician based on the palliative care needs assessed during family counseling. Topics include symptom management, understanding treatment options, decisional conflict, emotional and practical support, goal of care setting, resources, and bereavement support.~Palliative Care by attending Physician: The attending physician incorporates the consultations received from the palliative care consultation team to provide high-quality palliative care to patients and their families."
224146978|NCT00691093|DRUG|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
224146979|NCT01707368|DRUG|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
224146980|NCT02294006|DRUG|Everolimus plus Octreotide LAR plus Metformin|Everolimus plus Octreotide LAR plus Metformin
223449961|NCT00671099|DIETARY_SUPPLEMENT|Placebo|Placebo
223449962|NCT05822206|BEHAVIORAL|CBT-TSC|Cognitive Behavioral Therapy for Trauma and Self-Care
224146981|NCT05603754|DRUG|Lorecivivint|One intra-articular injection of 0.07 mg lorecivivint in 2 mL vehicle
223449963|NCT05822206|BEHAVIORAL|Life Steps and Sexual Decision-Making|
223449964|NCT01687842|OTHER|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
223449965|NCT04267159|OTHER|Acute cardioversion|Acute restoration of sinus rhythm by medical or electrical cardioversion in the emergency department
223449966|NCT04267159|OTHER|Delayed cardioversion|Delayed restoration of sinus rhythm by medical or electrical cardioversion in the out-patient clinic
223449967|NCT04282837|DIAGNOSTIC_TEST|AI classification of patients with obesity|Computational modeling techniques will be used for the precise reclassification of obesity into four subgroups, several variables according to the clinical experience and the modeling results will be selected for the cluster analysis.
224146982|NCT05603754|DRUG|Placebo|One intra-articular injection of 0 mg lorecivivint in 2 mL vehicle
223449968|NCT00003037|DRUG|cisplatin|
224146983|NCT00378755|DRUG|velcade|
224146984|NCT00493467|DRUG|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
224146985|NCT00493467|DRUG|Rituximab|250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.
224146986|NCT05489081|BEHAVIORAL|Positive Behavior Management Toolkit|The Positive Behavior Management Toolkit, or the implementation strategy resource package, is a set of resources provided to teachers in the intervention group that aims to support their use of positive behavior management practices in the classroom, particularly with students with hyperactive, inattentive, or impulsive behaviors.
224301197|NCT04700280|DRUG|Placebo|Placebo film-coated tablet.
223449969|NCT00003037|DRUG|docetaxel|
223569404|NCT06303232|OTHER|MANUAL LYMPHATIC DRAINAGE|"MLD was performed after the moist heating of 10 minutes in supine position with both knees bent. It will start from the abdominal lymph drainage followed by the central lymph drainage.~Then, by stimulating the bilateral axillary lymph nodes, the flow of the fluid was directed to the axillary lymph node. Each session lasted for approximately 45 minutes, for 7 days"
223449970|NCT00003037|DRUG|gemcitabine hydrochloride|
223449971|NCT05460637|BEHAVIORAL|No BS just Fitness|The participants receive lessons on the physical activity guidelines, goal setting, physical activity planning, habit development, identity formation, and how to apply all these tools together. In addition, there are numerous resources provided to other existing web resources, including exercise videos and other informational webpages (e.g., USDA nutritional recommendations).
223449972|NCT02860507|DRUG|sugammadex|
223449973|NCT02860507|DRUG|Neostigmine|
223449974|NCT02860507|DRUG|Glycopyrrolate|
223449975|NCT02772809|DEVICE|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
223449976|NCT00479297|DRUG|SAM-531|
223449977|NCT00534105|OTHER|Total Cholesterol|
223449978|NCT00534105|OTHER|Triglyceride|
223449979|NCT00534105|OTHER|HDL|
223449980|NCT00534105|OTHER|LDL|
223449981|NCT04978077|OTHER|Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)|After a night fast participants will drink the test meal
223449982|NCT02774005|DRUG|Idebenone|
223449983|NCT05547776|BEHAVIORAL|Mindfulness app|The mindfulness app contains 6 modules with a variety of features to help caregivers reduce their stress.
223449984|NCT02577627|DEVICE|PrediCare|
223449985|NCT04151966|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for markers of myocardial injury
223449986|NCT03402230|DRUG|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
223449987|NCT03402230|OTHER|Laboratory Biomarker Analysis|Correlative studies
223449988|NCT03402230|OTHER|Questionnaire Administration|Ancillary studies
223449989|NCT02379273|DEVICE|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
223449990|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
223449991|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS03|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
223449992|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS03|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
223449993|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
223449994|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1+AS01|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
223449995|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1+AS01|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
223449996|NCT03275389|BIOLOGICAL|D-SUIV cH8/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
223449997|NCT03275389|BIOLOGICAL|D-SUIV cH5/1N1|1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
223449998|NCT03275389|BIOLOGICAL|D-SUIV cH11/1N1|1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
223449999|NCT03275389|BIOLOGICAL|Placebo|1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
223450000|NCT03275389|BIOLOGICAL|Fluarix Quadrivalent|1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
223450001|NCT00214292|PROCEDURE|fluorescence spectroscopy and diffuse spectroscopy|
223450002|NCT03419130|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
223450003|NCT03419130|OTHER|Laboratory Biomarker Analysis|Correlative studies
223450004|NCT03419130|BIOLOGICAL|Pembrolizumab|Given IV
223450005|NCT03419130|RADIATION|Radiation Therapy|Undergo conventionally fractionated RT
223450006|NCT06730048|OTHER|Experimental Group|An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.
223450007|NCT06730048|OTHER|Control group (placebo)|After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
223450008|NCT05636982|OTHER|Telecare-based intervention program|A 3-month telecare-based intervention program
223450009|NCT05765825|DRUG|serplulimab|Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
223450010|NCT05765825|DRUG|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
223450011|NCT05765825|DRUG|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
224057633|NCT04134182|DRUG|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
223450012|NCT05765825|DRUG|Etoposide|Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
223450013|NCT05765825|RADIATION|Thoracic radiation therapy (TRT)|Participants will receive concurrent low-dose radiotherapy treatment, in once daily fractions, 3 Gy per fraction, to a target dose of 15 Gy in 5 fractions from Day 1-Day 5 in the first cycle, third cycle（ For patients with primary lung lesions (intrathoracic lesions) evaluated as small PR (tumor shrinkage \< 80%)/SD/PD），forth cycle（for subjects evaluated as PD/SD/PR with extrathoracic residual metastases).
223450014|NCT04559425|DRUG|Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
223450015|NCT04559425|OTHER|No Dexamethasone|All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
223450016|NCT00978341|DRUG|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
223450017|NCT00978341|DRUG|Placebo for pregabalin|Placebo capsules BID for 7.5 days
224146987|NCT06270316|DRUG|AMT-191|"A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with Fabry disease."
223450018|NCT00752141|DRUG|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
223450019|NCT00752141|DRUG|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
223450020|NCT00752141|OTHER|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
223450021|NCT05859763|DRUG|99mTc-HFAPI|Each patient receive a intravenous injection of 99mTc-HFAPI, and undergo SPECT/CT scan within specified time.
223450022|NCT01222663|DEVICE|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
223450023|NCT01222663|DEVICE|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
224146988|NCT01213498|DRUG|Atorvastatin|Zarator, 80 mg pr. day for 5 days
224146989|NCT01213498|DRUG|Unikalk|1 tablet Unikalk pr day for 5. days
224146990|NCT05514145|DEVICE|Nance/Transpalatal arch space maintainer|A combined design of both Nance and Transpalatal arch space maintainers as a space maintainer for the maxillary arch in mixed dentition
224146991|NCT05514145|DEVICE|Nance space maintainer|Conventional space maintainer for the maxillary arch used in mixed dentition
223450024|NCT04861441|DEVICE|Aircast Cryo Cuff (Shoulder) and Aircast Cryo Cuff I/C Motorized Cooler|Patient will wear the continuous cryo cuff for a designated period of time and will record their pain and narcotic use post operatively.
223450025|NCT04861441|DEVICE|Icepacks|Standard of care icepacks will be used postoperatively for designated amount of times and patients will record pain and narcotic use post operatively.
223450026|NCT05879224|COMBINATION_PRODUCT|Revised case management package|"1. Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total)(Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management"
223450027|NCT04788186|DRUG|De-prescribe beta blocker therapy|"Participants will be de-prescribed for beta-blocker therapy.~De-prescription will be performed as follows:~* Half of pre-randomization dose for the first 3 days, then~* Half of the above dose for the next 3 days, then discontinue"
223450028|NCT04284163|BEHAVIORAL|Gamification|Teaching through gamification
223450029|NCT04284163|BEHAVIORAL|Traditional teaching|Teaching through master lesson methodology
223450030|NCT00448812|DEVICE|Bronchial Thermoplasty with the Alair System|Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
223450031|NCT06521112|DRUG|Oral care with a solution containing 0.2% chlorhexidine gluconate a frequency determined according to the results of the Intensive Care Oral Care Frequency Rating Scale.|Every day for 10 days, Frequency determined according to Intensive Care Oral Care Frequency Rating Scale, Oral care was applied for 2 minutes a solution containing 0.2% chlorhexidine gluconate.
223450032|NCT03035916|OTHER|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
224146992|NCT00810810|BIOLOGICAL|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
224146993|NCT00810810|BIOLOGICAL|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
223450033|NCT03035916|OTHER|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
223450034|NCT03035916|OTHER|control|The Control group receives standard IV-inhaled general anesthesia.
223450035|NCT06141421|PROCEDURE|procedure|procedure
223450036|NCT00564317|BEHAVIORAL|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
223450037|NCT00564317|BEHAVIORAL|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
223450038|NCT06314412|OTHER|Stoller's Afferent Nerve Stimulation (SANS)|15 sessions of SANS (5 sessions/week for 3 weeks)
224057634|NCT04134182|DRUG|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
224057635|NCT06466447|BEHAVIORAL|Exposure and response prevention therapy|Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by therapists remotely via video. The treatment was augmented by between-session text messaging.
224057636|NCT03528343|DRUG|Non-narcotic pain control|Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
224057637|NCT02691975|DRUG|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
224057638|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
224057639|NCT01118273|DRUG|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
224146994|NCT00810810|BIOLOGICAL|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
223450039|NCT03891823|DEVICE|MitraClip|Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
223450040|NCT03891823|DRUG|Medical Therapy|Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
223450041|NCT05983510|PROCEDURE|Aortic endarteriectomy|Thoraco-phreno-lumbotomy with thoracic aortic cross clamping Longitudinal aortotomy Endarteriectomy of the aorta Direct closure more or less bypass to the visceral arteries and downstream aorta reconstruction.
223450042|NCT02194764|DRUG|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
223450043|NCT02194764|DRUG|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
223450044|NCT02479464|GENETIC|Genotyping results|Genotyping results provided in Phase II
223450045|NCT01135836|PROCEDURE|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
223450046|NCT01135836|PROCEDURE|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
223450047|NCT01135836|PROCEDURE|Control group|CO2 was removed by passive exsufflation through the port site.
223450048|NCT02105649|OTHER|Strengthening exercise + Electrical stimulation of calf muscle|
223450049|NCT02105649|OTHER|selected physical therapy program|
223450050|NCT03885999|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
223450051|NCT02304354|DRUG|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
223450052|NCT01630954|PROCEDURE|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
223450053|NCT01630954|PROCEDURE|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
224146995|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every week
224146996|NCT01101243|RADIATION|Broadband UVB|UVB dose: 4 SED every second week
224146997|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every second week
224146998|NCT01101243|RADIATION|Broadband UVB|UVB dose: 1 SED every month
224146999|NCT01101243|OTHER|Control group|No intervention
224147000|NCT02645591|PROCEDURE|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
224057640|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
224057641|NCT01118273|DRUG|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
224057642|NCT01118273|DRUG|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
224057643|NCT01118273|DRUG|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
224057644|NCT06004843|DRUG|remimazolam|in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
224057645|NCT06004843|DRUG|Propofol|in this group,patients are treated with propofol and remifentanil for reduced sedation.
224057646|NCT03360097|PROCEDURE|Frozen Embryo Transfer|Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
223450054|NCT06274151|DRUG|Naproxen 500 Mg|Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
223450055|NCT06274151|PROCEDURE|Rehabilitation|Rehabilitation after muscle strain injury
223450056|NCT06274151|DRUG|Placebo|Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
223450057|NCT06313554|DRUG|Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin|"The first week dose of Surufatinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC; Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first)."
223450058|NCT02452554|OTHER|Laboratory Biomarker Analysis|Correlative studies
223450059|NCT02452554|BIOLOGICAL|Lorvotuzumab Mertansine|Given IV
223450060|NCT02452554|OTHER|Pharmacological Study|Correlative studies
223450061|NCT02533297|OTHER|Providing clinical skills conditions|
223450062|NCT05740345|DRUG|Metformin|Metformin
223450063|NCT02313805|OTHER|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
223450064|NCT01658397|BEHAVIORAL|Fasting|Ten day fast
223450065|NCT04792047|DIAGNOSTIC_TEST|HRP frequency, plaque compostion and local immune-inflammatory activation|HRP frequency, plaque compostion were detected by CCTA method. Local T cell subsets and their intracellular cytokines levels were detected by Flow Cytometry.
223450066|NCT04891627|DIAGNOSTIC_TEST|Gingival crevicular fluid|GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
223450067|NCT03024827|DRUG|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
223450068|NCT05964127|DEVICE|Air flow device|An air/powder device for surface decontamination
223450069|NCT05964127|OTHER|Hand instruments|Periodontal hand instruments
223450070|NCT05964127|PROCEDURE|Access flap surgery|To improve the surgical access for implant decontamination
223450071|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
223450072|NCT01349127|DIETARY_SUPPLEMENT|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
223450073|NCT01349127|DIETARY_SUPPLEMENT|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
223450074|NCT06234527|OTHER|tested product|application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months
223450075|NCT05535322|DRUG|GLP-1RA|All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period
223450076|NCT05535322|DRUG|SGLT2i|SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA
223450077|NCT05535322|DRUG|Insulin|Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i
223450078|NCT05535322|DRUG|Miscellany|Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
223569405|NCT06303232|OTHER|THERAPEUTIC ULTRASOUND|The participants of group B will receive a treatment of manual lymphatic drainage and ultrasound after the moist heat of 10 minutes. After MLD of 45 minutes, ultrasound will be performed in small circular pattern from periphery to the center towards the areola with following parameters: Mode: pulsed, Frequency: 1MHz, Intensity: 1W/cm2, Time: 8 minutes. Treatment was given for 7 consecutive days
223450079|NCT01665482|OTHER|A 2000 kcal test meal|
223450080|NCT01665482|OTHER|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
223450081|NCT00671125|DRUG|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
223450082|NCT00671125|DRUG|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
223450083|NCT00671125|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
223569406|NCT00389350|DRUG|Extract of Green and Black Tea|
223569407|NCT05671224|OTHER|Visual aid|Handout and video describing different types of induction of labor
224057647|NCT05790382|DRUG|NM-101|"In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts).~In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts)."
224057648|NCT05790382|DRUG|Placebo|Placebo solution for infusion
224057649|NCT04989114|DEVICE|nasal continuous positive airway pressure|positive end expiratory pressure will be applied by nasal continuous positive airway pressure
224057650|NCT03574675|DEVICE|Simulated Altitude (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
224057651|NCT03574675|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
224057652|NCT01392534|DRUG|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
224057653|NCT03014778|DRUG|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
224057654|NCT03014778|DRUG|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
224057655|NCT00754832|DRUG|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
224057656|NCT00754832|DRUG|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
224301198|NCT04594174|PROCEDURE|Fluid administration|"Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase."
224301199|NCT03358160|BEHAVIORAL|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
224301200|NCT01742780|PROCEDURE|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
224301201|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
224301202|NCT02555020|DIETARY_SUPPLEMENT|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
224301203|NCT02555020|DIETARY_SUPPLEMENT|Allocated to MN NPO group,|Patients received NPO from MN.
224301204|NCT04555304|DRUG|KH903 + Paclitaxel|KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
224301205|NCT04555304|DRUG|Placebo + Paclitaxel|Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle； Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
224301206|NCT00352235|DRUG|KRN7000|
224301207|NCT03509714|DIETARY_SUPPLEMENT|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
224301208|NCT03509714|DIETARY_SUPPLEMENT|rice flour (Placebo)|250 mg rice flour (Placebo)
224301209|NCT01908790|DEVICE|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
224301210|NCT01908790|DEVICE|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
224301211|NCT01393184|DRUG|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
224301212|NCT03380533|DRUG|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
224301213|NCT03380533|DRUG|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
224301214|NCT03380533|DRUG|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
224301215|NCT03380533|DRUG|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
224301216|NCT03380533|DRUG|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
224301217|NCT00305552|DRUG|THALIDOMIDE|THALIDOMIDE
224301218|NCT02615171|BEHAVIORAL|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
224057657|NCT05998421|PROCEDURE|acupuncture|The patients in the acupuncture group accepted acupuncture treatment weekly from the second day of menstruation and three times in one cycle. Seirin 0.2-×30-mm acupuncture needles were used. First, needles were inserted into Shenting (GV 24) and bilateral Benshen (G 13) to relieve uneasiness of mind. Then, they were inserted into Chung wan (cv 12), Qihai (CV6), Guan yuan, chung chi (cv 3), bilateral Guiai (S 29) and Zigong (Extra 16) to recuperate energy. Finally, bilateral Tsusanli (st 36), Yinlingch'uan (sp 9) and San yin chiao (sp 6) were used to soothe the liver and tonify the spleen and kidney. Each acupuncture treatment session lasted 30 minutes, with mostly bilateral needle retention over 20-30 minutes for evens techniques.
224057658|NCT05998421|DRUG|routine aspirin and heparin treatment|The patients accepted routine aspirin and heparin treatment. Two months before pregnancy, 50 mg of aspirin (Chenxin Pharmaceutical, China) was taken orally once a day.
224057659|NCT00080028|DRUG|Motexafin Gadolinium Injection|
224057660|NCT02004262|BIOLOGICAL|GVAX Pancreas Vaccine|
224057661|NCT02004262|BIOLOGICAL|CRS-207|
224057662|NCT02004262|DRUG|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
224057663|NCT02004262|DRUG|cyclophosphamide|
224057664|NCT05501561|BIOLOGICAL|Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
223450084|NCT03402672|OTHER|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
223450085|NCT01065363|BEHAVIORAL|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
223450086|NCT01560572|DRUG|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
223450087|NCT03712267|BEHAVIORAL|Electronic Media Enhanced|Research assistants will provide participants' therapists with information from participants' electronic messaging prior to typically scheduled clinical appointments.
224147001|NCT02645591|BIOLOGICAL|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
224147002|NCT02645591|BEHAVIORAL|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
224147003|NCT01429610|DRUG|Rituximab+mVPDL|"1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   \- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT"
224147004|NCT01080144|OTHER|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
224147005|NCT04104295|DIAGNOSTIC_TEST|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
224147006|NCT06978309|OTHER|No Interventions|Observational study.
224147007|NCT06854484|DEVICE|AVEIR™leadless pacemaker|AVEIR™ leadless pacemaker implantation
224147008|NCT01664156|DRUG|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
224147009|NCT01664156|DRUG|Placebo|
224147010|NCT02258867|DRUG|Placebo|Solution for subcutaneous injection
224147011|NCT02258867|DRUG|Gevokizumab|Solution for subcutaneous injection
224147012|NCT00206778|DRUG|Lamotrigine|
224147013|NCT00206778|DRUG|Sodium Valproate|
224147014|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Plasma
224147015|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Serum
224147016|NCT05060783|DIAGNOSTIC_TEST|GaGnostic|Urine
224147017|NCT01700985|DRUG|122-0551|Applied twice daily for two weeks
224147018|NCT01700985|DRUG|Vehicle|Applied twice daily for two weeks
224301219|NCT02615171|BEHAVIORAL|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
224301220|NCT06609252|OTHER|Breast milk odour|On the day of the study, the mothers of the babies will be contacted and fresh breast milk will be obtained from the mother of each baby. In the study, a sterile sponge will be used to smell the breast milk to the baby. Breast milk will be taken as 2 ml, dripped onto a sterile sponge and held 10 cm away from the baby's nose and sniffed 2 minutes before the examination.
224147019|NCT01409993|DRUG|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
224147020|NCT01409993|DRUG|Placebo|Matching placebo three times a day for three months
224147021|NCT01409993|DIAGNOSTIC_TEST|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
224147022|NCT01409993|DIAGNOSTIC_TEST|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
224147023|NCT00249977|DRUG|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
224147024|NCT00609011|DRUG|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
224147025|NCT00141180|DRUG|CP-481,715|
224147026|NCT00163904|BEHAVIORAL|High mono-unsaturated fat/low carbohydrate diet|
224147027|NCT00163904|BEHAVIORAL|High carbohydrate/low fat diet|
224057665|NCT05501561|BIOLOGICAL|Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
224057666|NCT05501561|BIOLOGICAL|Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
224057667|NCT05501561|BIOLOGICAL|Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1|Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
224057668|NCT01209650|DRUG|BIBW 2992|tablets
224057669|NCT04945070|DRUG|IGlarLixi|Switching T2DM subjects from MDI to iGlarLixi
224057670|NCT04945070|DRUG|MDI - Multiple dose insulin injection|Continuing with established MDI regimen
224057671|NCT04863846|OTHER|No intervention, observational study|Exposure of interest: clinical implementation of an algorithm
224057672|NCT00428142|BIOLOGICAL|rituximab|375mg/m2 day 1
224057673|NCT00428142|DRUG|bortezomib|1.3mg/m2 days 1 \& 8
224057674|NCT00428142|DRUG|cyclophosphamide|750mg/m2 day 1
224057675|NCT00428142|DRUG|prednisone|40mg/m2 days 1-5
223450088|NCT03712267|BEHAVIORAL|Treatment as Usual|Research assistants will not review or provide participants' therapists with information from participants' electronic media and will compare with the Electronic Media Enhanced cohort to see if there was a difference in therapy outcomes.
223450089|NCT01317524|DIETARY_SUPPLEMENT|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
224057676|NCT00428142|DRUG|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
224057677|NCT05067322|DEVICE|Minecraft|A game played within the videogame Minecraft
224057678|NCT03823066|DEVICE|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
224057679|NCT04188574|DRUG|BB2603-1|Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
224057680|NCT04188574|DRUG|BB2603-3|Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
224057681|NCT04188574|DRUG|BB2603-10|Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
224057682|NCT04188574|OTHER|Vehicle|Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
224057683|NCT03045679|OTHER|RYGB|laparoscopic RYGB
224147028|NCT06013267|OTHER|Chin tuck against resistance exercise|The experimental group will receive a four-week CTAR protocol and regular dysphagia care, while the control group will only receive routine dysphagia care. The routine dysphagia care is including dysphagia education, dietary precautions, oral hygiene, and swallowing training, etc. The CTAR protocol is first, the study nurses face-to-face teach dysphagia patients to perform CTAR exercises once, then the patient perform CTAR exercises three times a day, five days a week, and for four weeks. The CTAR exercise is to tighten a rubber ball which placed between the chin and the sternum, and to perform 3 cycles of isometric exercise and isotonic exercise.
224147029|NCT00067470|DRUG|Placebo|
224147030|NCT00067470|DRUG|N-acetylgalactosamine 4-sulfatase|
224147031|NCT00019227|DRUG|pentetic acid calcium|
224147032|NCT00019227|RADIATION|yttrium Y 90 daclizumab|
224147033|NCT03859960|DIAGNOSTIC_TEST|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
224147034|NCT03859960|DIAGNOSTIC_TEST|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
224147035|NCT02306239|DRUG|Terlipressin|
224147036|NCT02306239|DRUG|Norepinephrine|
224147037|NCT04869176|DIAGNOSTIC_TEST|Electrocardiogram|Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
224147038|NCT04869176|DIAGNOSTIC_TEST|Monitoring of vital functions|Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
224147039|NCT04869176|DRUG|Caffeine Citrate 5 mg/kg|Caffeine in the form of suspension was given to the newborns.
224147040|NCT00050622|DRUG|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
223450090|NCT01317524|DIETARY_SUPPLEMENT|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
224057684|NCT03045679|OTHER|OAGB/MGB|laparoscopic OAGB/MGB
224057685|NCT03633175|DRUG|Vaginal progesterone|400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
224057686|NCT04512040|BEHAVIORAL|At-Home Yoga|At-home yoga practice over 12 weeks.
224057687|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 20 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
224057688|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 30 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
224057689|NCT04603131|BIOLOGICAL|Inactivated Chikungunya virus vaccine 10 mcg|3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
224057690|NCT04603131|BIOLOGICAL|Placebo|3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
224147041|NCT00050622|BEHAVIORAL|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
224057691|NCT03628053|BIOLOGICAL|Tisagenlecleucel|autologous cellular immunotherapy product
224147042|NCT00050622|DRUG|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
224301221|NCT06609252|OTHER|Mother voice|Mothers of premature babies in the mother voice group will be given a voice recorder on the day of the study and will be encouraged to express their feelings and thoughts and say what they want to say to their babies and will be asked to talk to their babies as they wish. The mother's voice, which is recorded 2 minutes before the procedure, will be placed approximately 30 cm away from the baby's ear and a loudspeaker will be placed at the foot end so that the baby can listen to the sound.
224301222|NCT05617937|OTHER|Massage|The connective tissue massage was started from the lumbosacral region (baseline) and was applied to the lower thoracic, scapular, inter-scapular and cervico-occipital region according to the vascular response of the connective tissue.
223450091|NCT01317524|DIETARY_SUPPLEMENT|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
223450092|NCT05491863|OTHER|conservative physiotherapy plan|Physiotherapy plan consist of following exercises, Postural and Proprioceptive facilitation like weight-bearing actions for the upper and lower extremities. Sit to stand, standing , holding on to stand, free arms standing up, holding on standing and asked the patient to lift one leg, one leg standing, standing on balance board,Straight and sideways parallel bar walk, For the effected body side jumping on stable and dynamic surface,Upstairs and down stair activity performed on staircase.This program was given for 40 minutes with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)
224301223|NCT02617524|DEVICE|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
223450093|NCT05491863|OTHER|trunk stability exercise plan|"trunk stability exercise plan consist of three levels, Proprioception included supine abdominal draw was performed in 1st simple level ,3 sets per 20 repetitions were performed, A double knee to chest abdominal draw was performed with 3 sets per 20 repetition, Supine twist with 3 sets per 20 repetitions was performed.Balance training included pelvic bridging was 2nd complicated level performed with 3 sets per 4-6 repetitions,Twists with a medicine ball were performed with 3 sets per 10-20 repetitions.~for Stability Bridging with head lied on physio ball was performed in 3rd difficult level when holding the position for 4 to 6 seconds, then relaxed slowly for same time with 3 sets per 10 to 20 repetitions, Prone bridging was performed with 3 sets per 4 to 6 repetitions.~There was a 30 seconds to 1 minute break between the sets.This program was given for 1 hour with a rest period of 2 minutes between each group of exercises, 4 days a week for 8 weeks (32 sessions)"
223450094|NCT01422746|DRUG|Metformin|500-1000 mg PO BID (X12 weeks)
223450095|NCT03295175|DIAGNOSTIC_TEST|Hematoxylin-eosin and smooth muscle actin markers|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
223450096|NCT02749799|DRUG|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
223450097|NCT00596999|PROCEDURE|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
224057692|NCT03628053|DRUG|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
224147043|NCT00050622|DRUG|Placebo|
223450098|NCT06255600|OTHER|High Definition-transcranial Direct Current Stimulation|High-Definition transcranial Direct Current Stimulation (HD-tDCS) is a neuromodulation technique, is non-invasive, targeted, safety.
223450099|NCT06255600|DIETARY_SUPPLEMENT|Chlorella Pyrenoidosa|functional food, organically pressed into tablets (Registration with ANVISA/MS: 6.7273.000)
224057693|NCT03628053|DRUG|Inotuzumab|CD22-directed antibody-drug conjugate
224057694|NCT01245582|DRUG|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
224057695|NCT01245582|DRUG|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
224057696|NCT01245582|DRUG|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
224057697|NCT04006886|DIETARY_SUPPLEMENT|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
224057698|NCT03200366|BEHAVIORAL|Tailored DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
224147044|NCT00050622|DRUG|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
224147045|NCT00050622|BEHAVIORAL|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
224147046|NCT02703987|OTHER|Fermented infant milk formula|
224147047|NCT02703987|OTHER|Non-fermented infant milk formula|
224147048|NCT03883490|DIAGNOSTIC_TEST|ECG|A 12-lead ECG will be taken for each participant.
224147049|NCT03883490|DIAGNOSTIC_TEST|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
224301224|NCT06202924|BEHAVIORAL|Static balance assessment|Biodex stabilometer device will be used to evaluate the static balance of the participants.
224301225|NCT06202924|BEHAVIORAL|Dynamic balance assessment:|Individuals' dynamic balance performances were evaluated with the Y balance test. Y balance test is a test method with proven validity and reliability in athletes and healthy subjects. (Intra-class correlation 0.99-1, Inter-class correlation 0.85-0.91).
224301226|NCT06202924|BEHAVIORAL|Isokinetic strength evaluation:|Quadriceps muscle strength of the participants will be evaluated with an isokinetic dynamometer. Isokinetic dynamometers are considered the gold standard in muscle strength measurements. These devices have the ability to objectively report the amount of force produced by individuals at predetermined angular speed and joint range of motion.
224057699|NCT03200366|BEHAVIORAL|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a trained nurse. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
223450100|NCT03552042|BEHAVIORAL|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
223450101|NCT03552042|BEHAVIORAL|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
223450102|NCT03749109|DRUG|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg for daily releases
223450103|NCT03749109|DRUG|Placebo|Matching placebo
223450104|NCT00701571|PROCEDURE|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
223450105|NCT00783328|DRUG|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
223450106|NCT01804153|DRUG|Adipose-derived expanded stem cells|Intralesional application ASC
223450107|NCT05585554|RADIATION|MRIdian|Stereotactic MRI-guided On-table Adaptive Radiation Therapy delivered on MRIdian linac
223450108|NCT00509353|DRUG|irinotecan hydrochloride|
223450109|NCT00509353|DRUG|vincristine sulfate|
223450110|NCT00509353|RADIATION|iobenguane I 131|
223450111|NCT02346994|DIETARY_SUPPLEMENT|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
223450112|NCT02346994|DIETARY_SUPPLEMENT|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
223450113|NCT04418089|DRUG|Simvastatin 40mg|The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
223450114|NCT04418089|DRUG|Placebo oral capsule|The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
223450115|NCT04012346|DEVICE|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
223450116|NCT02273765|DRUG|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~* Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
223450117|NCT02273765|DRUG|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~* Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
223450118|NCT05313646|BIOLOGICAL|batch 1 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
223450119|NCT05313646|BIOLOGICAL|batch 2 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
223450120|NCT05313646|BIOLOGICAL|batch 3 of Ad5-nCoV|The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.
223450121|NCT00427219|DRUG|Ozarelix|Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
223450122|NCT00427219|DRUG|Placebo|Placebo will be administered IM on Day 0 and Day 14.
223450123|NCT01897519|DRUG|Placebo|Placebo infusion
223450124|NCT01897519|DRUG|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
224057700|NCT02221453|DRUG|Triamcinolone Acetonide|
224057701|NCT06281470|DRUG|WS016 Single Dose(6g)|WS016 6g, to be administered orally as a single dose.
224057702|NCT06281470|DRUG|WS016 Single Dose(12g)|WS016 12g, to be administered orally as a single dose.
224057703|NCT06281470|DRUG|WS016 Single Dose(24g)|WS016 24g, to be administered orally as a single dose.
224057704|NCT06281470|DRUG|WS016 Single Dose(36g)|WS016 36g, to be administered orally as a single dose.
223450125|NCT00200941|DRUG|Topiramate|
223450126|NCT03634813|DEVICE|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
223450127|NCT03634813|PROCEDURE|Usual Care|Usual Care
223450128|NCT03757403|DRUG|RDD1609|RDD1609 to be applied on the perianal area BID
223450129|NCT03757403|DRUG|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
223450130|NCT02197442|DRUG|Valsartan|
223450131|NCT00391742|BEHAVIORAL|Brief intervention|
223450132|NCT00047788|DRUG|ZD6474|
223450133|NCT00047788|DRUG|VEGF-receptor tyrosine kinase (KDR)|
223450134|NCT02529098|OTHER|fMRI|functional magnetic resonance imaging
223450135|NCT05427747|DRUG|cefotaxime|"One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture."
224057705|NCT06281470|DRUG|WS016 Single Dose(48g)|WS016 48g, to be administered orally as a single dose.
224057706|NCT06281470|DRUG|SAD matching placebo|Matching placebo, to be administered orally as a single dose.
224147050|NCT03883490|DIAGNOSTIC_TEST|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
224147051|NCT03883490|DIAGNOSTIC_TEST|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
223450136|NCT00005711|BEHAVIORAL|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
223450137|NCT02636439|BEHAVIORAL|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
223450138|NCT02636439|BEHAVIORAL|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
223450139|NCT00650286|DRUG|Modafinil Tablets 200 mg|200mg, single dose fed
223450140|NCT00650286|DRUG|Provigil® Tablets 200 mg|200mg, single dose fed
223450141|NCT04679948|DRUG|Percoffedrinol®|Tablet
223450142|NCT04679948|DRUG|Coumadin®|Tablet
223450143|NCT04679948|DRUG|Antra MUPS®|Gastro-resistant tablet
223450144|NCT04679948|DRUG|Midazolam-ratiopharm®|Oral solution
223450145|NCT04679948|DRUG|BI 730357|Film-coated tablet
224147052|NCT03883490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
223450146|NCT00002267|DRUG|Rifabutin|
223450147|NCT05828316|BEHAVIORAL|Resilience-based intervention|resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
223450148|NCT01263067|BEHAVIORAL|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
223450149|NCT01263067|BEHAVIORAL|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
223450150|NCT02050139|DIETARY_SUPPLEMENT|L-cysteine|
223450151|NCT02050139|OTHER|Placebo|
223450152|NCT03654703|DRUG|Cyclophosphamide|cyclophophamide
223450153|NCT03363308|BEHAVIORAL|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
223450154|NCT01737411|DRUG|solifenacin|
224057707|NCT06281470|DRUG|WS016 Multiple Dose(12g)|WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
224057708|NCT06281470|DRUG|WS016 Multiple Dose(24g)|WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
224057709|NCT06281470|DRUG|WS016 Multiple Dose(48g)|WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
224057710|NCT06281470|DRUG|MAD matching placebo|Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
223450155|NCT01737411|PROCEDURE|cesa/vasa|surgical repair of USL
224057711|NCT02963116|DRUG|AZD5718 IR tablet|
224057712|NCT02963116|DRUG|AZD5718 oral suspension|
224057713|NCT02963116|DRUG|Rosuvastatin tablet|
224057714|NCT00552175|DRUG|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
224147053|NCT06144242|BEHAVIORAL|Feedback on RTD metric|Clinicians in the experimental arm will receive feedback on the RTD metric while clinicians in the No intervention arm will not.
223450156|NCT00926757|DRUG|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
223450157|NCT00926757|DRUG|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
223450158|NCT01637714|DRUG|Multi-strain probiotics|"* B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
223450159|NCT01637714|DRUG|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
223450160|NCT03800680|BEHAVIORAL|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~* Complete all 24 GlycoLeap lessons and quizzes~* Weight Monitoring: Weigh at least once a week.~* Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~* Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~* Medication: Take medications as prescribed."
223450161|NCT03800680|BEHAVIORAL|M-POWER Rewards|A financial incentive program were participants can earn up to 516 M-Points (1 M-Point is equivalent to S$1) over the one-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
223450162|NCT01008774|DEVICE|Paxman Cooling Machine|Scalp cooling procedures
223450163|NCT01008774|DEVICE|Cold Caps|Scalp cooling procedures
223450164|NCT00484926|DRUG|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
223450165|NCT00484926|DRUG|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
223450166|NCT01579669|BEHAVIORAL|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
223450167|NCT04959799|DRUG|Dalbavancin|Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.
223450168|NCT04999943|BIOLOGICAL|DC vaccine|EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
223450169|NCT05105672|DRUG|Sintilimab|IV infusion
224057715|NCT00552175|DRUG|placebo|placebo taken orally every day
223450170|NCT05105672|DRUG|Cisplatin|IV infusion
223450171|NCT05105672|RADIATION|External Beam Radiotherapy (EBRT)|Undergo pelvic EBRT
223450172|NCT05105672|RADIATION|brachytherapy|brachytherapy
223450173|NCT05392595|OTHER|Cawthrone and cooksey exercises,Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Epley repositioning maneuver will be performed, also cervical stretches and Basic Balance exercises Following Exercises will be performed by patient in next session. Caw-Thorne and Cooksey exercise program. Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
223450174|NCT05392595|OTHER|Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.|"Conventional treatment: Epley's repositioning maneuver will be performed also cervical stretches with basic balance exercises.~Frequency: Participants will receive CRM for 6 weeks as needed in each evaluation. Frequency: These exercises will be performed thrice a week on alternate days for 40 min sessions. Post-Intervention Assessment: The patients will be assessed 6 weeks after the beginning of the intervention"
223450175|NCT01624480|DRUG|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
223450176|NCT00527124|DRUG|cediranib maleate|Given orally
223450177|NCT00527124|DRUG|docetaxel|Given IV
223450178|NCT00527124|DRUG|prednisone|Given orally
223450179|NCT00527124|OTHER|laboratory biomarker analysis|Correlative studies
223450180|NCT05488769|DEVICE|Clareon Vivity extended depth of focus (EDOF) intraocular lens|Implantation with the Clareon Vivity extended depth of focus (EDOF) intraocular lens
223450181|NCT05964153|DIAGNOSTIC_TEST|Liquid Biopsy|Analysis of the circulating free DNA in blood patients affected by gliomas
223450182|NCT00679848|DEVICE|RS2 (RESTORe Suturing System)|Suturing in stomach
223450183|NCT02210325|DRUG|solithromycin|
223450184|NCT02210325|DRUG|ceftriaxone|
223450185|NCT02210325|DRUG|azithromycin|
224057716|NCT00552175|DRUG|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
224057717|NCT05768451|OTHER|Ultrasonic image analysis|Preoperative conventional ultrasound (US), elastic ultrasound (UE) and contrast-enhanced ultrasound (CEUS) images were analyzed. Histopathological results were used as the gold standard. The cases were randomly divided into training set and test set with a ratio of 7:3. The US image, UE image and CEUS image of the maximum long-axis section of each lesion were selected, and the region of interest (ROI) of the lesion was manually delineated.
224057718|NCT06493773|BEHAVIORAL|Offer of referral to specialized alcohol use disorder treatment|Patients are offered referral to specialized alcohol use disorder treatment.
224147054|NCT04576247|BEHAVIORAL|Combined aerobic and resistance exercise|"The 12-week intervention will build upon an ongoing resistance exercise program for cancer patients and survivors at the University of Colorado's Anschutz Health and Wellness Center. Resistance exercise will be led by certified cancer exercise specialists who provide individualized exercise programs to cancer patients and survivors. Exercise sessions are progressive, target all major muscle groups, are 50 minutes in duration, and completed 2x/week.~The intervention will also include 3 self-directed moderate-intensity aerobic exercise sessions/week, building to 50 minutes at 60% heart rate maximum (determined at baseline). Target exercise will be achieved by a gradual progression of exercise duration over the first four weeks of the program."
223450186|NCT00828269|PROCEDURE|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
223450187|NCT05044247|PROCEDURE|ESP blocks|ultrasound and fluoroscopy to identify the spread of drug
223450188|NCT03365518|BEHAVIORAL|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
223450189|NCT03365518|BEHAVIORAL|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
223450190|NCT05825963|DIETARY_SUPPLEMENT|Psyllium|The participants select hamburgers randomly by themselves, with or without (control) 12 g of psyllium, each containing 85 g of hamburger bread, 160 g of 20% fat beef, 2.56 g of salt, and 1.28 g of pepper, and asked to consume them with 200 ml of water.
223450191|NCT01556230|PROCEDURE|Surgical intervention for CNFA|(non-experimental) standard procedure
223450192|NCT01556230|RADIATION|Radiotherapy for CNFA|(non-experimental) standard procedure
223450193|NCT00632645|DRUG|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
223450194|NCT00632645|DRUG|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
223450195|NCT00632645|DRUG|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
223450196|NCT02075008|DRUG|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
223450197|NCT04097769|DRUG|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
223450198|NCT05438758|BEHAVIORAL|Almond Therapy|Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.
223450199|NCT05438758|DRUG|Intranasal ketamine (Esketamine)|Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks
223450200|NCT05438758|BEHAVIORAL|Treatment as Usual|Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
223450201|NCT00660595|DRUG|Quetiapine|Oral administration
223450202|NCT00660595|DRUG|Risperidone|Oral administration
223450203|NCT02801799|DRUG|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
223450204|NCT00898872|OTHER|cryopreservation|
223450205|NCT01302210|DRUG|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
223450206|NCT06031675|OTHER|Vigorous intermittent lifestyle physical activity|The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
223450207|NCT05205005|DRUG|Endocalyx|3,712mg (six capsules) of DSGP for eight weeks.
223450208|NCT05205005|DRUG|Placebo|Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg
223450209|NCT03675971|DRUG|Cannabinol|Postoperative pain treatment
223450210|NCT03675971|DRUG|Placebo oral capsule|Placebo comparator
223450211|NCT04565405|OTHER|Detergent|The tracheostomy inner cannulas will be washed with detergent.
223450212|NCT04565405|OTHER|Sterile water|The tracheostomy inner cannulas will be washed with sterile water.
223450213|NCT04866082|OTHER|questionnaire|Members of European Society of Intensive Care and European Society of ANaesthesiology and Intensive care will obtain an electronic survey regarding their routine clinical practice of systemic corticosteroids administration among patients with COVID-19 ARDS
223450214|NCT05868278|OTHER|Training method intervention|Traditional learning method will be used in the control group. In the experimental group, interactive learning method will be used.
223450215|NCT00980733|DIETARY_SUPPLEMENT|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
223450216|NCT00980733|DIETARY_SUPPLEMENT|Yoghurt|Plain yoghurt same as in intervention group without fortification
223450217|NCT06171516|BEHAVIORAL|iCBT|All participants will undergo 10 guided therapy sessions (once-weekly) with each session lasting 20 minutes. The therapy module will be given as an online self-learning source via videos in a website specifically developed for this training. The videos will divide the module content into several parts with each video lasting about 10 minutes.
223450218|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
223450219|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
223450220|NCT01247675|DRUG|ACP-001 (TransCon hGH)|s.c., weekly injection
223450221|NCT01247675|DRUG|Omnitrope|s.c., daily injection
223450222|NCT00954200|DRUG|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
223450223|NCT00954200|DRUG|ibuprofen|10mg/kg syrup - single dose
223450224|NCT00588705|BEHAVIORAL|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
223741870|NCT05237479|PROCEDURE|Suprainguinal fascia ilica block|Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
223450225|NCT04075669|DIAGNOSTIC_TEST|Multiplex Strip PCR|Corneal scraping from patients will have its DNA extracted and eluted in the buffer. The DNA than mixed with the primer strips tube and be analyzed in Real-Time PCR machine. According to the record information from the hospital, the pathogen that usually found from endophthalmitis, keratitis, corneal ulcer diseases in our hospital is Pseudomonas sp., Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter sp., Pseudomonas aeruginosa, Acanthamoeba sp., Aspergillus fumigatus, Aspergillus flavus, Fusarium sp., and Candida albicans. And based on the report from Zhao et al (2014) Herpes Simplex Virus may be detected from patients with keratitis. Therefore in this study, we are trying to detect all of the pathogens simultaneously using the real-time PCR assay from patients corneal scraping who experience eye infections as mention above.
223450226|NCT05886907|DEVICE|Lehfilcon A multifocal toric contact lenses|Investigational silicone hydrogel contact lenses
223569408|NCT06056440|PROCEDURE|Virtual reality|"The VR intervention program for the experimental group will be carried out with a frequency of 3 sessions/week, duration of approximately 45 minutes, and for a total of 12 weeks, being performed in addition to the patient's usual treatment program.~The Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. Specifically, the specific functional rehabilitation program will be used, which comprises exercises that are easy to perform, with a playful component, and which encourage the patient's continuous attention to the task performed, acting as a distractor phenomenon in the face of restrictive movement factors such as fear of pain or movement. This software offers the possibility of adjusting the number of repetitions and characteristics of the exercises, thus allowing an individualized physical rehabilitation"
223569409|NCT06056440|OTHER|Control group|The control group will only receive their usual treatment program for the 12-week duration of the study.
223569410|NCT01713504|BIOLOGICAL|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
223569411|NCT00646321|DRUG|budesonide/formoterol (Symbicort)|
223569412|NCT00646321|DRUG|budesonide|
223569413|NCT01118104|OTHER|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
223569414|NCT00642174|DRUG|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
223569415|NCT00642174|DRUG|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
223569416|NCT02961933|OTHER|Apneic oxygenation|Nasal cannula apneic oxygenation
223569417|NCT02961933|OTHER|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
223741871|NCT05237479|OTHER|Placebo|The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
223741872|NCT00110409|BEHAVIORAL|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
223741873|NCT00110409|BEHAVIORAL|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
223450227|NCT05886907|DEVICE|Samfilcon A multifocal toric contact lenses|Commercially available silicone hydrogel contact lenses
223450228|NCT05886907|DEVICE|CLEAR CARE|Hydrogen peroxide based contact lens cleaning and disinfecting solution
223450229|NCT01763203|BEHAVIORAL|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
223450230|NCT01763203|BEHAVIORAL|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
224147055|NCT00426556|DRUG|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
223450231|NCT02187861|DRUG|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
223450232|NCT02187861|DRUG|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
223450233|NCT02187861|DRUG|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
223450234|NCT04769102|DEVICE|seat cushions|flat versus contoured customized seat cushions
223450235|NCT04084587|DEVICE|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
223450236|NCT06463197|BEHAVIORAL|Self-Administered Acupressure Group|Subjects will attend two weekly 120-minute of self-administered acupressure training according to the group allocation in a classroom at the School Nursing, the Hong Kong Polytechnic University. The subjects will be trained to perform self-administered acupressure by an acupuncturist. To enhance interaction and ensure the quality of teaching, each class will be conducted in a small group of 5 to 7 subjects. Participants in this group will learn the self-acupressure technique and passed fidelity check. The treatment protocol included 6 acupoints, namely, Baihui (GV20) and bilateral Fenchi (GB20), Neiguan (PC6), Shenmen (HT7), Shenxu (BL23) and Yongquan (KI1) (Table 1). Subjects were given an acupressure log to record their practice at home, and they were phoned twice a week to remind their practice during the 4-week treatment period.
223450237|NCT06463197|BEHAVIORAL|Sleep Hygiene Education group|The participants in this group will receive education on sleep hygiene. The treatment duration, frequency, and telephone follow-up schedule for the SHE group will be the same as the self-administered acupressure group (2 sessions, 2 hours each). Sleep hygiene education is often used as a comparison group in randomized controlled trials of self-help and psychological interventions for insomnia. The SHE group will provide subjects with the same amount of contact hours with the healthcare professional (instructor) in order to control the non-specific effects of practitioner-patient interaction in the self-administered acupressure group.
223450238|NCT03735407|DEVICE|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
223450239|NCT02858271|DRUG|AKB-9778 subcutaneous injection|
223450240|NCT02290847|BEHAVIORAL|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
223450241|NCT05326438|BEHAVIORAL|CIRCLE mHealth app|For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
223450242|NCT02757625|DRUG|Dexmedetomidine hydrochloride|"* 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~* 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
223450243|NCT04305860|DIETARY_SUPPLEMENT|Modified starch without flavoring|Each patient of this group receives the thickener during three days of hospitalization
223450244|NCT04305860|DIETARY_SUPPLEMENT|Mofidied starch with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
223450245|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum without flavoring|Each patient of this group receives the thickener during three days of hospitalization
223450246|NCT04305860|DIETARY_SUPPLEMENT|Xanthan gum with Bi1 aromas|Each patient of this group receives the thickener and 5 flavorings during three days of hospitalization
223450247|NCT04838431|OTHER|Blood sample and ultrasound at first trimester|The blood sample and the ultrasound are part of the routine care for the aneuploidy screening at first trimester. We deepened the biochemicals and biophysical markers for predicting the risk for large for gestational age infants
223450248|NCT04421352|DRUG|CS1001|"low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned."
223450249|NCT00888797|DRUG|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
223450250|NCT04854057|OTHER|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.
223450251|NCT04854057|OTHER|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.
223450252|NCT04854057|DEVICE|TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice|Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.
223450253|NCT03917277|DEVICE|Musculoskeletal ultrasound|"Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~1. Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~2. Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~3. Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~4. Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal"
223450254|NCT00824629|PROCEDURE|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
223450255|NCT00824629|PROCEDURE|Direct embryo transfer procedure|Direct embryo transfer procedure
223450256|NCT05750459|DRUG|Artesunate|Artesunate is a succinic ester of artemether.
223450257|NCT02298036|BEHAVIORAL|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
223450258|NCT03519919|DEVICE|somofilcon A multifocal lens|contact lens
223450259|NCT05030571|DEVICE|DPMAS|DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)
223450260|NCT05030571|OTHER|standard treatment|standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
223450261|NCT00645671|DRUG|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
223450262|NCT00645671|DRUG|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
223450263|NCT03475758|DRUG|Goserelin|adding goserelin with chemotherapy
223569418|NCT04623268|DIAGNOSTIC_TEST|Ultrasound and questionnaire|One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
223569419|NCT02409004|DRUG|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
223569420|NCT02409004|DRUG|Rifampin|Capsule 2x3oo mg Oral
223569421|NCT00896363|DRUG|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
223569422|NCT00896363|DRUG|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
223569423|NCT00896363|DRUG|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
223450264|NCT06175039|OTHER|Telerehabilitation exercise program|TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone.
223450265|NCT06175039|OTHER|Control program|KGr will be a pulmonary rehabilitation information brochure will be given after the initial evaluation. They will be asked to do the exercises on the brochure.
223450266|NCT00507520|PROCEDURE|Full dose almonds|
223450267|NCT00507520|PROCEDURE|Half dose almonds+half dose muffin|
223450268|NCT00507520|PROCEDURE|Full dose whole wheat muffin|
223450269|NCT05114564|DEVICE|Lens A (comfilcon A lens)|1 month
223450270|NCT05114564|DEVICE|Lens B (lehfilcon A lens)|1 month
223450271|NCT00493311|DRUG|IV Placebo|IV Placebo
223450272|NCT00493311|DRUG|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
223569424|NCT04644978|OTHER|anonymous online survey|An online questionnaire will be provided for the participants of our study. Participation in the study is voluntary and it can be terminated at any time without having to give any reasons.
223569425|NCT01478802|DEVICE|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
223569426|NCT01478802|DEVICE|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
223569427|NCT02607241|DEVICE|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
223741874|NCT06181890|OTHER|Motivational Interview|The data of the research will be collected between October 2023 and June 2024. Each meeting will last approximately 15-30 minutes.
223741875|NCT04780854|DRUG|Metformin|Participants in the intervention group will be administered metformin tablets 2 gm daily during the chemotherapy treatment duration
223450273|NCT00493311|BIOLOGICAL|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
223741876|NCT04780854|DRUG|Placebo|Participants in the placebo group will be administered metformin free tablet as placebo twice daily
224057719|NCT06116500|DEVICE|Modified twin block appliance with expander|These appliances are myofunctional appliance used for treating class II division growing adolescents.
224057720|NCT06116500|DEVICE|Conventional twin block appliance with expander|These appliances are myofunctional appliances used for treating class II division growing adolescents.
224057721|NCT05479253|DIAGNOSTIC_TEST|Artificial intelligence assistant system|The artificial intelligence assistant system can automatically capture images, prompt abnormal lesions and the parts covered by the examination (the stomach is divided into 26 parts).
224057722|NCT03591640|DIAGNOSTIC_TEST|Blood test|Standard blood test
224057723|NCT00522353|DIETARY_SUPPLEMENT|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
223450274|NCT03999359|OTHER|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
223450275|NCT02779075|DRUG|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
223450276|NCT02779075|DRUG|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
223450277|NCT01462656|DRUG|Non-EZG containing AED polytherapy|AED polytherapy without EZG
223450278|NCT01462656|DRUG|EZG containing AED polytherapy|AED polytherapy including EZG
224147056|NCT00426556|DRUG|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel \& Trastuzumab
223450279|NCT01462656|DRUG|Non-EZG AED monotherapy|AED monotherapy without EZG
223450280|NCT01462656|DRUG|EZG AED monotherapy|Any off-label use of EZG as monotherapy
223450281|NCT04299867|PROCEDURE|Bowel Surgery with Metronidazole|"Metronidazole will be given per standard of care prior to incision. Intraoperative plasma samples will be obtained from pre-existing vascular access catheters at end of bolus, 30, 60, 90 minutes, at time of intestinal excision(s), and at the end of the case in ethylenediaminetetraacetic acid microcontainers, exceeding no more than approximately 5 mL total.~At the time of intestinal excision, the surgeon will cut at least 500 mg of intestine from the specimen, ensuring all layers of bowel are included. If more than one intestinal sample is taken during the surgery, such as in the case of multiple strictures removed, each sample will be obtained and labeled appropriately."
223450282|NCT04714190|DRUG|RC48-ADC|2.5 mg/kg IV every 2 weeks
223450283|NCT04714190|DRUG|Paclitaxel injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
223450284|NCT04714190|DRUG|Irinotecan Hydrochloride Injection|Administered according to label, as one option for Physician's Choice (determined before randomization)
223450285|NCT04714190|DRUG|Apatinib Mesylate Tablets|Administered according to label, as one option for Physician's Choice (determined before randomization)
223450286|NCT05743777|DRUG|Pembrolizumab|400 mg IV q6 weekly for a maximum of 18 cycles
223450287|NCT05743777|DRUG|MET-4|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
223450288|NCT05743777|DRUG|Placebo|Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
223450289|NCT05437614|PROCEDURE|Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation
223450290|NCT05437614|PROCEDURE|Cyclocryoablation in treatment of refractory Glaucoma|Treatment of refractory Glaucoma by cyclocryoablation
223450291|NCT04241016|PROCEDURE|Endoscopic sinus surgery (ESS)|Uncinectomy, middle meatal antrostomy by enlarging the natural maxillary ostium and partial ethmoidectomy or septoplasty according to clinical evaluation of the operator.
223450292|NCT00860080|DRUG|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
224057724|NCT00522353|DIETARY_SUPPLEMENT|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
224057725|NCT03694496|BEHAVIORAL|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
224057726|NCT04652323|DRUG|Biocompatibility of calcium silicate cements|The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
224057727|NCT03899766|OTHER|Animal Assisted Intervention|Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
224057728|NCT03899766|OTHER|Clowns|Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
224057729|NCT03899766|OTHER|Musicians|Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
224147057|NCT00426556|DRUG|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
224147058|NCT05100108|BEHAVIORAL|Dog-assisted therapy|The program will involve 8 sessions, conducted once a week for 8 weeks. Each session will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. In this part, the patients will perform different activities and exercises with the dog. 3) A closing part to relaxation and say goodbye to the dogs.
224301227|NCT06446141|OTHER|Osteopathic technique|Patients will be positioned in a supine position. Osteopathic technique will consist of supoccibital release, soft tissue release of thoracic outlet, mobilization of cervical facet joints, stretching of scalene anterior, scalene medius, upper trapezius, and levator scapula, pectorals major and minor. Subsequently, cost vertebral and cost transverse joint mobilizations will be applied using rib elevation. Then, manipulation of the vertebrae the levels between C6 and T1 will be applied using thrust mobilization technique. Afterwards, mobilization of the first rib will be applied. Finally, mobilization of the upper cervical spine will be performed.
223450293|NCT00860080|DRUG|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
223450294|NCT04824742|PROCEDURE|Neoadjuvant PDT + radical surgery|Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy
223450295|NCT04824742|PROCEDURE|Radical surgery|Patients with cholangiocarcinoma will only receive radical surgery
223450296|NCT02347735|OTHER|No interventions, only data collection|Only data is collected from the subjects in both groups.
223450297|NCT05333796|BEHAVIORAL|gait with leg length discrepancy|After attaching the surface electromyography(EMG) to bilateral back muscles, participants walk at a comfortable speed. The investigators will evaluate the effects of leg length discrepancy on the back muscle activation during gait.
223450298|NCT05905081|OTHER|aerobic exercise|30-minutes aerobic exercise intervention on the bicycle ergometer. The exercise protocol includes 5 minutes of warm-up, 20 minutes of loading and 5 minutes of cool-down. The intensity of the exercise will be adjusted to be between 46% and 63% of the VO2max calculated according to the exercise programming guide published by the American College of Sports Medicine (ACSM), and the perceived effort level on the Borg scale will be 12-13. Warm-up and cool-down periods will be set to 46% of VO2max and Borg perceived exertion level below 9.
223450299|NCT05951361|DEVICE|980nm Diode Laser|300 mW, 4 J/cm2, 2mm non-contact mode up to 10 sessions
223450300|NCT05951361|DRUG|"0.1% topical triamcinolone Acetonide preparation Kenacourt-A Orabase"|three times daily for 4 weeks
223450301|NCT03435627|DRUG|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
223450302|NCT01104987|DRUG|alendronate|One tablet of alendronate à 70 mg once a week during two years.
223450303|NCT04416646|DRUG|Cabozantinib|The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.
224057730|NCT04539561|DEVICE|PiQo4 Laser System|PiQo4 Laser System for treatment of hand pigmentation
224057731|NCT04784182|DIETARY_SUPPLEMENT|probiotic plus prebiotic supplement|Daily consumption of probiotic containing at least 5 billion CFU per day total bacteria including Lactobacillus helveticus and Bifidobacterium longum and prebiotic containing 4 grams of fructooligosaccharides (FOS)
224057732|NCT04784182|DIETARY_SUPPLEMENT|placebo|Daily consumption of visually similar placebo pills
224057733|NCT02069405|OTHER|Relaxation Music|
224057734|NCT01956513|OTHER|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
224057735|NCT03007056|OTHER|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
224057736|NCT01401725|BEHAVIORAL|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
224057737|NCT01401725|BEHAVIORAL|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
224147059|NCT04149847|PROCEDURE|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
224147060|NCT01879254|DEVICE|Deep Brain Stimulation|
224147061|NCT05564442|DRUG|20% benzocaine gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
224057738|NCT01401725|OTHER|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
224057739|NCT05142527|DRUG|ADM03820|ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
224301228|NCT04243408|OTHER|Autologous umbilical cord blood transfusion|single dose of an autologous umbilical cord blood transfusion
224301229|NCT04243408|OTHER|placebo|The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
224301230|NCT04375865|DRUG|AD-2111|celecoxib 200mg
224301231|NCT04375865|DRUG|AD-2112|Tramadol 150mg
224301232|NCT04960306|BIOLOGICAL|Fecal filtrate transplantation|"Patients will receive 5-8 encapsulated lyophilized fecal filtrate transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
224301233|NCT04960306|BIOLOGICAL|Conventional fecal microbiota transplantation|"Patients will receive 5-8 encapsulated lyophilized conventional fecal microbiota transplantations in enterosolvent, size 0 capsules. Before intervention patients will receive proton pump inhibitors and prokinetics. After the preparation, the participants will be instructed to swallow the capsules one by one within 5 minutes with fluid to help to swallow the capsules."
224301234|NCT04712149|DEVICE|Weekly digital follow up|weekly digital follow-up by sending a questionnaire to patients and sending alerts based on the questionnaire to the care team
224301235|NCT00016718|DRUG|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m\^2 up to a maximum of 400 mg once daily
224301236|NCT00016718|DRUG|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
224301237|NCT00016718|DRUG|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
224301238|NCT00621049|DRUG|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
224301239|NCT00621049|DRUG|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
224301240|NCT01593033|DIETARY_SUPPLEMENT|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
224301241|NCT01593033|DIETARY_SUPPLEMENT|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
224301242|NCT01593033|DRUG|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
224301243|NCT00888459|DRUG|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
224301244|NCT00888459|DRUG|placebo NRT|Placebo nicotine lozenges
224301245|NCT05622136|DRUG|Regorafenib Oral Product|Dose escalation strategy
224301246|NCT05736536|BEHAVIORAL|Chance2Act|A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
223450304|NCT05781022|PROCEDURE|endoscopic repair of iatrogenic esophageal perforation|"For patients in EG, we began with assessment of the site \& size of perforation . In this study, In this study, we used a fully covered stent (Mega stent, Taewoong Medical Industries, Gyeonggi-do, South Korea) ultra large and long (length: 24 cm, diameter: 36 mm) stent. We did not experience any complication with Mega stent, particularly migration, thanks to the design of Mega stent that fits well for the post-sleeve anatomy with reduction of migration.~Concurrently, the interventional radiology team subcutaneously drained the intraperitoneal free fluid using 2 intra-peritoneal tubes that were placed under US guidance in the sub-hepatic region and in the pelvis"
223450305|NCT02628158|PROCEDURE|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
223569428|NCT02607241|DEVICE|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR \> 0.8, residual diameter stenosis \< 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis \> 40% or FFR \< 0.8).
224057740|NCT05142527|OTHER|Placebo|Placebo
224057741|NCT04193163|DEVICE|Hip prosthesis - ESOP 2 cementless femoral stem|ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
224057742|NCT03001050|DEVICE|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
224057743|NCT04643756|OTHER|conventional physiotherapy|Classical electrotherapy method consisting of tens, hotpack and ultrasound.
224301247|NCT05811702|OTHER|A randomized acute controlled trial of twenty-eight healthy overweight or obese women|A randomized acute controlled trial of twenty-eight healthy overweight or obese women in Saudi Arabia, aged between 18 and 40 with a body mass index between 25 and 34.5 kg m2 and fat parentage above 30% . The participants have followed ether HFKD or LFD for 12 weeks. Our primary outcome of this study to investigated the effective diets HFKD and LFD on reduction of body weight, the percentage of body fat
223569429|NCT00064766|DRUG|doxycycline|
224057744|NCT04643756|OTHER|conventional physiotherapy plus kinesiotaping|Conventional physiotherapy plus kinesiotaping
224057745|NCT04528862|BEHAVIORAL|Nature slides|participants will view a presentation of nature slides
224057746|NCT04528862|BEHAVIORAL|Urban slides|participants will view a presentation of urban slides
224057747|NCT01195129|DEVICE|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
224057748|NCT01195129|DEVICE|Non-hydrogel coils|Cerecyte or bare platinum coils
224057749|NCT04327687|DEVICE|Remote ischaemic conditioning|5 cycles of 5 minutes of upper limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual sphygmomanometer applied to the upper arm and activated to go through 5 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg. RIC will be completed 1-2 times per day for six months.
224057750|NCT04327687|OTHER|conventional therapy|conventional therapy
224057751|NCT01543828|DRUG|indacaterol|delivered via single-dose dry-powder inhaler
224057752|NCT01543828|DRUG|placebo|delivered via single-dose dry-powder inhaler
224057753|NCT01072305|DEVICE|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
224057754|NCT01072305|DEVICE|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
224301248|NCT02448121|PROCEDURE|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
224301249|NCT06237387|OTHER|Periodontal examination|Determining the patient's oral hygiene status and the severity of gingivitis. For this purpose, the non-invasive Löe-Silness plaque and gingival index system will be used.
224301250|NCT04799678|OTHER|Recording voice samples|A maximum of 9 voice sample recording session will be carried out on their phones and take less than 2 minutes each
224301251|NCT06041841|DRUG|LB54640|LB54640 QD Oral
224301252|NCT03827928|BEHAVIORAL|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
224301253|NCT01045915|BIOLOGICAL|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
224301254|NCT04781036|DRUG|4%Chlorhexidine|4%Chlorhexidine was given to participants with foot odor for 2 weeks
224301255|NCT06922409|DEVICE|Naturalistic Light Intervention|Naturalistic light as an Intervention A 24-hour naturalistic lighting scheme is implemented in all areas and rooms in the unit at Rigshospitalet Glostrup with a computer-controlled lighting scheme (ChromaViso, Denmark). The naturalistic lighting scheme is constantly running. The lighting imitate the sunlight rhythm following the principles of Lucas et al.
224301256|NCT04102631|DIAGNOSTIC_TEST|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
223450306|NCT01825746|OTHER|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
223450307|NCT01765816|BEHAVIORAL|high intensity interval training|
223450308|NCT01765816|BEHAVIORAL|moderate intensity training|
223450309|NCT00257738|BIOLOGICAL|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
223450310|NCT00257738|BIOLOGICAL|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
224057755|NCT03568591|PROCEDURE|Psychosensory Therapy|Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
224301257|NCT04102631|DIAGNOSTIC_TEST|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
224301258|NCT02701231|DEVICE|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
223450311|NCT02460432|DEVICE|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
223450312|NCT02460432|DEVICE|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
223450313|NCT05646732|DEVICE|TMS-fMRI|Participants will undergo simultaneous TMS and fMRI
223450314|NCT03578445|DEVICE|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
223569430|NCT03633630|DRUG|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
224057756|NCT04085679|OTHER|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
223450315|NCT03578445|DIAGNOSTIC_TEST|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
223450316|NCT03416478|DIAGNOSTIC_TEST|ctDNA test|ctDNA test to find some possible mutation.
224057757|NCT00643526|DEVICE|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
224057758|NCT05768945|DRUG|Semaglutide|Semaglutide claim is used as the exposure group.
224057759|NCT05768945|DRUG|DPP-4 inhibitor|DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, and alogliptin) claim is used as the reference group.
224057760|NCT00303147|BEHAVIORAL|Expressive Writing|
223450317|NCT03000322|DEVICE|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
223450318|NCT03456687|DRUG|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
224057761|NCT00029692|DRUG|Ginseng|
224057762|NCT00029692|DRUG|Ginkgo|
224057763|NCT04493021|DEVICE|Dermal Cooling System|Controlled localized cooling will be applied to benign pigmented lesions using the Dermal Cooling System
224057764|NCT04265716|OTHER|Topical L. reeuteri|Tubes with ointment containing L. reuteri DSM17938
224057765|NCT00804570|DRUG|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
224057766|NCT00804570|DRUG|placebo|once daily, orally, 16 weeks
224057767|NCT03467464|OTHER|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
224057768|NCT06405711|DEVICE|frame lens|A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.
224057769|NCT00290342|BIOLOGICAL|DTPa-IPV|3 intramuscular injections
224057770|NCT00290342|BIOLOGICAL|DTPa|3 intramuscular injections
223450319|NCT04153955|BEHAVIORAL|Mobilization|Any movement out of bed
223450320|NCT02117609|DIETARY_SUPPLEMENT|New DELICAL formula|3 months with the option of continuing until 6 months.
223450321|NCT02117609|DIETARY_SUPPLEMENT|Standard DELICAL formula|3 months with the option of continuing until 6 months.
223450322|NCT00699023|DRUG|ezetimibe tablets|ezetimibe tablets 10 mg/die
223450323|NCT00699023|DRUG|simvastatin tablets|simvastatin tablets 20 mg/die
223450324|NCT00699023|DRUG|placebo|placebo
223450325|NCT01460602|DRUG|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
223450326|NCT03440138|PROCEDURE|bariatric surgery (RYGB or SG)|laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
223450327|NCT03051438|PROCEDURE|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
223450328|NCT03051438|PROCEDURE|Three-port VATS|The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
223450329|NCT01057290|GENETIC|gene expression analysis|
223450330|NCT01057290|GENETIC|protein expression analysis|
223450331|NCT01057290|OTHER|fluorescence activated cell sorting|
223450332|NCT01057290|OTHER|immunologic technique|
223450333|NCT01057290|OTHER|laboratory biomarker analysis|
223450334|NCT04324762|BEHAVIORAL|targetted implementation strategies|strategies at the individual and institutional level to promote implementation of an evidenced based innovation and de-implementation of an unnecessary, low value diagnostic test.
223450335|NCT03785314|OTHER|thoracic epidural catheterization|thoracic epidural catheterization with different posture
223450336|NCT05795972|DIETARY_SUPPLEMENT|inulin|patients treated with standard therapy with a supplementation of Inulin 6g twice a day for 3 months.
223450337|NCT05795972|OTHER|standard therapy|control group (patients treated also with standard therapy)
223569431|NCT03633630|DRUG|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
223569432|NCT02068846|DRUG|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
224057771|NCT00290342|BIOLOGICAL|IMOVAX Polio®|3 intramuscular injections
223450338|NCT05867680|BEHAVIORAL|Online Mothers and Babies Course (eMB)|The eMB is an online, asynchronous, self-administered intervention modeled after the efficacious and in-person Mothers and Babies Course. (4) The eight-week course includes psychoeducational modules containing YouTube videos, vignettes, interactive quizzes, homework, guided meditations, and downloadable resources that teach strategies to promote a healthy outcome for mothers and their newborns: 1) overview, 2) thoughts and my mood, 3) fighting harmful and increasing helpful thoughts, 4) activities and my mood, 5) pleasant activities help make a healthy reality, 6) contact with others and my mood, 7) planning for the future and graduation, 8) relaxation exercises.
224057772|NCT03096951|BEHAVIORAL|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
223450339|NCT02296762|DRUG|Sirolimus|Sirolimus tablets 2 mg
223450340|NCT00970671|OTHER|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
223450341|NCT00970671|OTHER|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
223450342|NCT00970671|OTHER|No treatment|No laser treatment
223450343|NCT01951573|DEVICE|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
223450344|NCT01951573|DEVICE|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
224147062|NCT05564442|DEVICE|Transcutaneous electric nerve stimuli|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
223450345|NCT05890014|DIETARY_SUPPLEMENT|Flavonoid-rich diet|Inclusion of foods rich in flavonoids.
223450346|NCT00258193|DRUG|MD-1100 Acetate|
223450347|NCT05644678|DEVICE|Fixed appliances|Metal brackets with a straight-wire prescription will be used. Patients will be treated conventionally.
223450348|NCT05644678|PROCEDURE|Corticotomy|Patients will be treated in conjunction with a surgical intervention using metal brackets with a straight-wire prescription. Corticotomy (alveolar perforation and piezocision) will induce acceleration in canine traction movement during the orthodontic treatment in only one group.
223450349|NCT04407143|DIAGNOSTIC_TEST|IgG test|IgG+ blood test by ELISA method.
223450350|NCT04200183|BEHAVIORAL|iACTwithPain (ACT+compassion)|This intervention will deliver a eHealth ACT and compassion-based therapy (iACTwithPain) designed for chronic pain
223450351|NCT04200183|BEHAVIORAL|ACT-only intervention|This intervention will deliver the iACTwithPain intervention but without the delivery of explicit compassion.
223450352|NCT00707980|DRUG|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
223450353|NCT04116008|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
223450354|NCT01343537|OTHER|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
223450355|NCT03545932|OTHER|exercise program hydrogymnastics|4 months of practice hydrogymnastics
223450356|NCT00734461|DRUG|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
223450357|NCT04404348|BEHAVIORAL|Cognitive Training|Exercises used will be: Mind Bender, Divided Attention, Freeze Frame, Mixed Signals, Target Tracker, To Do List.
223450358|NCT04404348|BEHAVIORAL|Placebo Control|Games are drawn from the set of research control games provided by Posit Science-Brain HQ.
223450359|NCT00190164|PROCEDURE|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
223450360|NCT00190164|PROCEDURE|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
223450361|NCT00428428|DRUG|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
223450362|NCT04061278|DRUG|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
223450363|NCT04061278|DRUG|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
223450364|NCT00680615|BEHAVIORAL|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
223450365|NCT00680615|BEHAVIORAL|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
224057773|NCT03096951|OTHER|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
224147063|NCT05564442|DRUG|Emla gel|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
224147064|NCT05564442|OTHER|Ice application|compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
224147065|NCT03970824|BIOLOGICAL|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
224147066|NCT03970824|BIOLOGICAL|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
224147067|NCT03970824|BIOLOGICAL|EU-approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
223450366|NCT01909973|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
223450367|NCT02479113|PROCEDURE|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
223450368|NCT05849363|PROCEDURE|Posterior fossa decompression|Posterior fossa decompression：Posterior arch of atlas removal, decompression of cerebellum, detection of foramen magnum.
223450369|NCT05849363|PROCEDURE|Posterior Compression-Distraction-Reduction-Fixation|"Posterior Compression-Distraction-Reduction-Fixation：After subperiosteal dissection, the facet joint was exposed. A 2-mm joint scraper with sharp edge was inserted into the joint capsule and rotated to remove the articular cartilage. A blunt-edged rotating distractor was then inserted into the joint space, and the facet was sequentially opened with larger and larger blunt rotating distractors. After distraction on one side, an appropriate-sized trial was placed into the contralateral facet, holding the distraction open. This was repeated back and forth with larger trials. These steps were repeated, and the facet joints were distracted up to the pre-planned distance of the odontoid tip above Chamberlain's line."
223450370|NCT00242515|PROCEDURE|CD8+ T-cell depleted donor lymphocyte infusion|
224057774|NCT06064942|BEHAVIORAL|Multiple Family Narrative Therapy (MFNT)|MFNT consist of 4 weekly group sessions with selected themes from both multiple family therapy (MFT) and narrative therapy (NT) offered in a group format. Parents participates in four mentored sessions, while their children attend the second and fourth sessions. The family is treated as a system through both psychodynamic practices and attachment theories to manage symptoms, to achieve family resilience, and to empower both parents and child to share their unique and lived value-driven experiences. MFNT provides families with therapeutic environments that are conducive to learning and modelling in order to facilitate the process of building healthier parent-child dyads.
224057775|NCT06064942|BEHAVIORAL|School services for families of children with ADHD|Selected school social personnel will deliver services as usual for the control group.
223450371|NCT04724603|OTHER|patients having had avderse event after phagotherapy for bone or joint or implant infection|to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
223450372|NCT00624689|DIETARY_SUPPLEMENT|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
223450373|NCT00297661|DEVICE|Sirolimus-eluting stent|
223450374|NCT00297661|DEVICE|Paclitaxel-eluting stent|
223450375|NCT02247882|OTHER|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
223450376|NCT02247882|OTHER|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
223450377|NCT05916807|OTHER|Stabilization Exercises|It consists of 26 patients who will receive stabilization exercises which will be divided in three components in lying posture, sitting, standing, rolling and kneeling positions to treat posterior, inferior muscles of scapula for 35-45 min for 3 days a week for 4 weeks.
223569433|NCT02068846|DRUG|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
224057776|NCT01045980|DRUG|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
223569434|NCT02273076|DEVICE|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
223569435|NCT04177485|BEHAVIORAL|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
223569436|NCT02465749|DRUG|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
223569437|NCT02465749|DEVICE|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
223569438|NCT02465749|DRUG|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
224057777|NCT01045980|DRUG|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
224057778|NCT01045980|DRUG|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
223450378|NCT05916807|OTHER|Posture Training|It consists of 26 patients who will receive postural training and breast-feeding patterns for the mother and child for 35-45 min in 3 days a week for 4 weeks.
223450379|NCT02695862|DRUG|Terlipressin|
224057779|NCT01045980|DEVICE|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
224057780|NCT03221491|DEVICE|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
223450380|NCT01226017|OTHER|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
223450381|NCT00460239|DRUG|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
223450382|NCT00460239|DRUG|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
223450383|NCT00460239|DRUG|Placebo|Intramuscular; double blind; once per week
224057781|NCT01936636|DRUG|Fentanyl|
223450384|NCT03387969|PROCEDURE|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
223450385|NCT01505231|DRUG|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement.
223450386|NCT01505231|DRUG|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
223450387|NCT05276583|BEHAVIORAL|Motivated Learning Task|"The Motivated Learning Task is split into two parts, the learning phase, and the test phase. During the learning phase participants are presented with 72 landscape images (targets) which they must memorise. Each image which participants are shown is associated with a reward amount. During the test phase participants are shown the 72 images they saw during the learning phase, known as targets, intermixed with 72 new images they did not see during the learning phase, known as lures. Participants must decide whether the image is old (i.e., they saw it during the learning phase) or new (i.e. they did not see it during the learning phase). After they have made their old/new decision, participants rate their confidence in their decision on a 3-point scale (i.e., guess, sure, very sure)."
223450388|NCT06525051|DRUG|Tiotropium|Tiotropium is a long-acting anticholinergic agent and has a bronchodilator effect. According to the COPD Gold 2024 guideline, it is one of the long-acting bronchodilator drugs used as the first choice in the treatment of group A COPD patients.
223450389|NCT01462305|DEVICE|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
223450390|NCT01462305|DEVICE|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
223450391|NCT00348335|DRUG|Cyclosporine 0.05%|
223450392|NCT00348335|DRUG|Ocular lubricant|
223450393|NCT03668665|DRUG|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
223450394|NCT03668665|DEVICE|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
223450395|NCT02225808|BEHAVIORAL|CBT for anxiety in autism|
223450396|NCT04141397|GENETIC|Initiation of POG-related WGTA|POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.
224057782|NCT05054647|OTHER|psychometric questionnaires|Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
223450397|NCT04141397|GENETIC|Usual care|Usual care, not involving the initiation of POG-related WGTA
223450398|NCT06222970|PROCEDURE|Bone lid repositioning in course of sinus lift|"A full-thickness flap was elevated to access the lateral maxillary bone wall. Subsequently, a lateral access window was prepared using a piezoelectric device with specific bone tips, delimitating a trapezoidal bone lid.~Once the antrostomy was completed, the bone lid was gently removed with a Lucas surgical curette and anatomical tweezers, with great care to avoid damages to the Schneiderian membrane. The Schneiderian membrane was detached from the bone layer using specific sinus curettes. In case of sinus membrane perforation, the membrane was raised in all directions. All clinical cases received a cortical bone lamina to avoid graft particles displacement in the maxillary sinus. The elevated space was filled with chips of cortico-spongious bone. The antrostomy was then covered with the bone lid (osteotomy window), previously removed and preserved in physiological solution and fixed in the original anatomical position with a surgical glue. The flap was then repositioned and sutured."
223450399|NCT00866957|PROCEDURE|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
223569439|NCT02465749|DRUG|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
223569440|NCT02465749|DRUG|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
224057783|NCT02535884|DEVICE|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
224057784|NCT06474949|DRUG|Bupivacaine injection|Injection at end of Open Reduction Internal Fixation
224057785|NCT06474949|OTHER|Saline|Injection at end of Open Reduction Internal Fixation
223569441|NCT02465749|DRUG|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
223569442|NCT03790774|BEHAVIORAL|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
224057786|NCT03341975|BEHAVIORAL|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
224057787|NCT01664988|BEHAVIORAL|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
224147068|NCT04066946|DEVICE|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
223450400|NCT03526991|DEVICE|Spinal Cord Stimulator (SCS)|"The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
223450401|NCT00649792|DRUG|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
223450402|NCT00368459|DRUG|raloxifene|Raloxifene is a selective estrogen receptor modulator
223450403|NCT00368459|DRUG|Placebo|Identical appearing placebo
223450404|NCT03610334|DRUG|IFB-088 (2.5-60.0mg) oral capsule|SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
224057788|NCT01664988|BEHAVIORAL|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
223450405|NCT03610334|DRUG|Placebo (2.5-60.mg) oral capsule|SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
223450406|NCT03610334|DRUG|IFB-088 (15.0-50.0mg) oral capsule|MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
223450407|NCT03610334|DRUG|Placebo oral (15.0-50.0mg) capsule|MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
223450408|NCT00412789|DRUG|Patupilone|
223450409|NCT01373034|DIETARY_SUPPLEMENT|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
223450410|NCT01373034|DIETARY_SUPPLEMENT|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
223450411|NCT03989596|RADIATION|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
223450412|NCT03989596|OTHER|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
223450413|NCT00094679|DEVICE|Eye patch|adhesive patch to cover the sound eye
223450414|NCT03653312|DEVICE|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
223450415|NCT04621032|DIAGNOSTIC_TEST|Polygraphy monitoring|All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
224057789|NCT01664988|OTHER|control (routine care)|received routine care of clinic or health center and use drugs if necessary
224057790|NCT01056510|DRUG|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
224057791|NCT01056510|DRUG|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
224057792|NCT01056510|DRUG|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
223450416|NCT04621032|DIAGNOSTIC_TEST|laboratory tests|Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
223450417|NCT00934245|BIOLOGICAL|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
223450418|NCT00934245|BIOLOGICAL|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
224057793|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
223450419|NCT03689153|DRUG|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
223450420|NCT03689153|DRUG|Placebo|Participants will receive matching placebo intravenously.
223450421|NCT06845865|DIETARY_SUPPLEMENT|enteric dyed solution|Oral administration of 0.5 mg/kg of body weight of food coloring dye
224057794|NCT01034735|BIOLOGICAL|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
223450422|NCT02813473|RADIATION|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
223450423|NCT02813473|RADIATION|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
223450424|NCT01073826|BEHAVIORAL|Sport|
223450425|NCT01073826|DRUG|Tocilizumab|
223450426|NCT01073826|DRUG|Sitagliptin|
223450427|NCT00563914|DRUG|ferroquine (SSR97193)|associated with artesunate
223450428|NCT00563914|DRUG|amodiaquine|associated with artesunate
223450429|NCT06844045|BEHAVIORAL|Gonorrhea/chlamydia Point-of-Care Testing|Point-of-care testing for sexually transmitted infections.
223450430|NCT04425681|DRUG|Osimertinib|Treatment of LM With osimertinb
223450431|NCT04425681|DRUG|Bevacizumab|Treatment of LM With Bevacizumab
223450432|NCT06070493|OTHER|classic physiotherapy program|For individuals of control group, a hot pack was applied to the shoulder area for 15 minutes, while the individuals were in the sitting position. The conventional mode of transcutaneous electrical nerve stimulation was used. Frequency was adjusted in the range of 50-100 Hz, and the amplitude intensity was adjusted between 10-30 milliampere with the intensity of mild tingling without causing any excessive discomfort or contractions. Electrodes were placed at the anterior, posterior, superior, and inferior of the shoulder region. In the exercise program of the patients, joint range of motion exercises, stretching, scapular stabilization, rotator cuff, and shoulder muscle strengthening exercises were given.
223450433|NCT06070493|OTHER|Myofascial release|myofascial release technique was applied to the patients in the treatment group besides the control group program. The technique was applied to the lateral neck and shoulder, pectoral region, scapulothoracic area, and arm regions for 5 minutes for optimum benefit.
223450434|NCT05892211|DIAGNOSTIC_TEST|Polysomnography|Polysomnography is performed by 3-channel electroencephalography ((EEG; F4-M1, C4-M1, O2-M1), 2-channel electrooculography (EOG), chin electromyography (EMG), surface EMG recording from tibialis anterior muscles of the right and left leg, body position, oronasal thermal airflow sensor, nasal pressure sensor, thoracic and abdominal respiratory belts for assesing the respiratory effort, electrocardiography (ECG), pulse, recording of respiratory sounds, oxygen saturation and synchronous video recording. The sleep stages are scored by the current criteria of American Academy of Sleep Medicine.
223450435|NCT05892211|DIAGNOSTIC_TEST|Skin conductance|The sympathetic skin response recordings are performed with a four-channel electromyography apparatus (Nihon-Kohden). They are recorded from both sides of the sternum with the active and reference electrodes placed 2 cm apart from the midline.
223450436|NCT05892211|GENETIC|ALU and LINE-1 DNA methylation analysis|2 cc peripheric venous blood is drawn from the participants to the test tubes with EDTA. DNA isolation is done by Nucleospin Blood Kit (REF:740951.250, Macherey-Nagel). Epitect Fast DNA Bisulfite Kit (REF:59824, Qiagen) is used to do DNA bisulfite modification. ALU and LINE-1 site specific methylation primer is designed and the methylation patterns are compared between the groups by Epitect Methylight PCR Kit (Cat. No:59496, Qiagen).
223450437|NCT05892211|DIAGNOSTIC_TEST|The Menopause-Specific Quality of Life Questionnaire (MENQOL)|The Menopause-Specific Quality of Life Questionnaire (MENQOL) is filled by each participant to assess the health related quality of life before the polysomnography test.
223450438|NCT05892211|DIAGNOSTIC_TEST|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is done by each participant to assess the sleep quality and disturbances before thepolysomnography test.
223450439|NCT01438242|DEVICE|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
223450440|NCT05347966|OTHER|Brain Health PRO|BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.
223450441|NCT02145910|DRUG|Vemurafenib|Given PO
223450442|NCT02145910|RADIATION|Whole-brain radiation therapy (WBRT)|Undergo WBRT
224057795|NCT01034735|BIOLOGICAL|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
223450443|NCT02145910|RADIATION|Radiosurgery (SRS)|Undergo SRS
223450444|NCT01349088|DRUG|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
223450445|NCT01349088|DRUG|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
223569443|NCT06326619|PROCEDURE|Primary tumor resection|In addition to systemic therapy a primary tumor resection was performed.
223569444|NCT06326619|PROCEDURE|Systemic Therapy|chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
224057796|NCT03275571|BEHAVIORAL|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
224057797|NCT01898871|DIETARY_SUPPLEMENT|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
224057798|NCT04137120|DRUG|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
224057799|NCT01269762|DRUG|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
224057800|NCT02798055|DRUG|Bosentan group|
223450446|NCT01349088|DRUG|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
224057801|NCT04776473|PROCEDURE|Open treatment|Open (i.e. surgical) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
224057802|NCT04776473|OTHER|Closed treatment|Closed (i.e. conservative) treatment will be performed following the usual practice of the including centre adopting a pragmatic approach.
223450447|NCT06331975|DIAGNOSTIC_TEST|Radiomic signature|Assessment of radiomic signature and tumor genetic profile in patients with Non Small Cell Lung Cancer (NSCLC)
223450448|NCT00000200|DRUG|Methadone|normal maintenance dose
223450449|NCT06101355|OTHER|Telerehabilitation|"Intervention group is home exercise program supplemented with visual and video resources using telerehabilitation. With the exercises, there will be video links, exercise visuals, and written explanations. Videos and visuals of the exercises recorded by the physiotherapist and uploaded to the Rehab My Patient application.~Digital exercise forms will be prepared through the Rehab My Patient application. The intervention group will receive exercises, which prepared from the Rehab My Patient application ,digitally through WhatsApp. In this group, exercise sessions will be conducted with the physiotherapist once a week through video calls. Additionally, there will be one instance of messaging and one phone call for follow-up. Video calls and messaging will be conducted through WhatsApp."
223450450|NCT06101355|OTHER|Standard Home Based Exercise Group|Control group, standard home exercise program group , will receive the program as brochures. Although there will be no video supplement, the brochure will include visuals of the exercises. The control group will be monitored through three weekly voice calls.
223450451|NCT06363292|DRUG|PRO-231|Moxifloxacin 0.5% Ophthalmic solution.
223450452|NCT06363292|DRUG|VIGAMOXI®|Moxifloxacin 0.5% Ophthalmic solution.
223450453|NCT04375904|RADIATION|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)|Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) delivered in 8 fractions of 7.5 Gy. OAR constraints must be respected but a minimum dose coverage to 95% of the PTV will be allowed down to 75% and a minimum dose to 99% of the GTV allowed at 75%. Respiratory monitoring/active respiratory management will be used. Plans will be created and delivered using photon beams with energies between 6-10 MV.
223450454|NCT03345654|OTHER|Hearing Aids|The signal processing of newly fit hearing aids will be evaluated for acceptability based on the toolset, which takes additional patient information beyond hearing threshold (like cognition) to determine the optimal hearing aid signal processing strategies.
223450455|NCT04217317|DRUG|CPI 613|CPI-613 is to be given as 2-hr IV infusion via a central venous catheter. The starting dose of CPI-613 will be 2500 mg/m2 which was determined to be the MTD in the previous phase I clinical trial.
223450456|NCT04217317|DRUG|Bendamustine|Bendamustine at 90 mg/m2 is infused by IV over 10 minutes on Days 1 and 2 of each treatment cycle. Bendamustine is given immediately after CPI-613 administration.
223450457|NCT05515991|OTHER|SUPPORT-DIALYSIS with Access to Output Report and Information Hub|"SUPPORT-Dialysis is a symptom assessment response toolkit, consisting of a screening and response component. Participants will be screened for symptoms and distress using an electronic assessment(ePROMs). Output reports based on ePROMs scores will be provided to patients as well as the clinical care team.~Participants at Toronto General Hospital will complete the screening every 4 weeks for 6 months, and each time the output report will be provided to both patients and the clinical team.The second, response component of the intervention is the information support and self-management hub (https://symptomcare.org). All participants and the clinical team will be given access to this website, which provides information about self-management for patients as well as management advice for healthcare professionals."
224057803|NCT06385730|DRUG|neoadjuvant anti-PD-1|PD-1 inhibitor (toripalimab) 240mg, day 1，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators
224057804|NCT06385730|DRUG|neoadjuvant anti-PD-1 with LDRT|"Radiotherapy: low-dose radiotherapy (LDRT), gross target volume (GTV), DT: 1Gy (day1), 1Gy (day2), every 3 weeks, 2 cycles.~PD-1 inhibitor (toripalimab) 240mg, day 3，every 3 weeks, 2 cycles. Postoperative adjuvant treatment: according to the recommendations of the guidelines and the investigators"
224057805|NCT05148039|BEHAVIORAL|Dietician advice|Personalised dietetic advice
224057806|NCT04944654|DRUG|BIKTARVY 50Mg-200Mg-25Mg Tablet|Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg
224057807|NCT05018039|OTHER|Collaborarive Care Model|"Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care)."
224057808|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
223450458|NCT05515991|OTHER|SUPPORT-DIALYSIS Only|SUPPORT-Dialysis screening will also be implemented at Humber River Hospital, but participants and clinical team will not be receiving the output screening report or be given access to the information hub with symptom management resources.
223450459|NCT05126810|OTHER|Questionnaire Administration|Complete questionnaire
223450460|NCT05419713|OTHER|Visual Stimuli for Space Perception|The visual environment (e.g., target locations and texture backgrounds) will be varied and human behavioral responses (judged distances) will be measured to reveal the space perception and cognitive processes underlying space perception and navigation.
223450461|NCT05499663|BEHAVIORAL|POSTHOC app|The POSTHOC app is a smartphone application that will deliver the Survivorship Care Plan and promote healthy lifestyle behaviors consistent with the individual's Care Plan
223450462|NCT04199923|BEHAVIORAL|Single leg immobilisation|Immobilisation with single leg suspension immobilisation
223450463|NCT06500026|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223450464|NCT06500026|DRUG|Topotecan|Administration by intravenous infusion for a cycle of 3 weeks.
223450465|NCT05997095|OTHER|Neuromuscular electrical stimulation (NMES/0|NMES will be applied for 30 min and will be delivered using an approved, CE-marked device (Premier Combo Plus, Med-Fit Ltd, UK) using two large (7.5 × 13 cm) electrodes placed proximally and distally over the lateral quadriceps. The set protocols will be pre-programmed into to the device and the amplitude value will match the setting that was determined during a familiarisation visit
223450467|NCT05080218|DRUG|Upadacitinib|Hold UPA x 2 weeks at time of COVID booster
223450468|NCT05080218|DRUG|Abatacept|Hold SQ ABA x 2 weeks at time of COVID booster
223450469|NCT05080218|DRUG|Secukinumab|Hold SEC x 2 weeks at time of COVID booster
223450470|NCT05080218|DRUG|Tofacitinib|Hold TOF x 2 weeks at time of COVID booster
223450471|NCT05080218|DRUG|TNF Inhibitor|Hold SQ TNFi x 2 weeks at time of COVID booster
223450472|NCT05080218|DRUG|Canakinumab Injection|Hold CAN TNFi x 2 weeks at time of COVID booster
223450473|NCT05080218|DRUG|Baricitinib|Hold BAR x 2 weeks at time of COVID booster
223569445|NCT03222830|PROCEDURE|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
223569446|NCT04989205|BEHAVIORAL|Cannabis cessation Program|Lundqvist and Ericsson developed the 'Cannabis Cessation Program' (CCP, Nordic abbreviation: HAP) in Sweden in the 1990s. The method uses a combination of cognitive therapy and psychoeducation and covers the normal withdrawal period for cannabis smoking cessation (up to 8 weeks), comprising \~15 individual sessions. It describes a medical, a psychological, and a social phase, in which the participant is helped to recognize and address typical problems related to each phase, e.g., physical and psychological withdrawal problems. The overarching aim of the program is to help cannabis users to reorganize thinking patterns that developed while they were using cannabis and increase their social and psychological coping skills in relation to quitting cannabis use. The CCP manual has been translated into eight languages, e.g., Norwegian.
223741877|NCT05711225|BEHAVIORAL|smoking cessation intervention given according to the web-based transtheoretic model during pregnancy on postpartum smoking relapse.|Smoking cessation videos prepared according to the Web-Based Transtheoretic model A module was created on the web, with 5 sections, prepared by the researcher according to the Web-Based Transtheoretic model, for quitting smoking or for pregnant women who quit smoking to maintain this behavior. The modules are prepared in the form of animated videos in which the researcher is educational. Each module is arranged for an average of 5-10 minutes. Theoretical information about the content has been added under each video.
223741878|NCT02444572|DRUG|Enoxaparin 4000 IU|
223741879|NCT02420054|BEHAVIORAL|Intermittent fasting|Alternate day fasting (ADF) (water permitted) for 3 weeks with double energy intake every other day. Followed by ADF for 3 weeks with ad libitum diet on eating days.
223741880|NCT02420054|OTHER|Time control|Time control period with no change in eating habits.
224057809|NCT00243386|DRUG|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
224057810|NCT02285998|BIOLOGICAL|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
224057811|NCT02285998|BIOLOGICAL|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
224057812|NCT00489814|BEHAVIORAL|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
224057813|NCT05352152|DIAGNOSTIC_TEST|Next generation sequence|Next generation sequence will be used to detect the pathogens in ascites.
223450474|NCT05080218|DRUG|Ixekizumab|Hold IXE x 2 weeks at time of COVID booster
223450475|NCT05197946|DIAGNOSTIC_TEST|MRI|Research unsedated MRI scans (outside of usual care) will be performed using a 3T Philips scanner at the F.M. Kirby Research Center. An MRI scanning protocol will be at the F.M. Kirby Research Center; the protocol will not last more than 1.5 hours. Acquisitions will include a triplanar survey, functional and anatomical multi-slice imaging of the brain as well as MRI of selected spinal levels. Protocols will be used that do not involve use of contrast agents and limit power/tissue absorption as well as otherwise remain within FDA and Kirby Center safety regulations. When possible, MRI will be performed within 3 months of initial survey/interview administration. If MRI is scheduled \>3 months after initial survey/interview administration, a brief survey will be re-administered to screen for changes in pain/clinical status.
223450476|NCT05346484|BIOLOGICAL|CF33-hNIS|CF33-hNIS is a chimeric orthopoxvirus (oncolytic virus) engineered to express the human sodium iodide symporter (hNIS)
223450477|NCT05346484|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200mg administrated IV every 3 weeks (Q3W).
223450478|NCT05346484|DRUG|Modified FOLFOX|"28 day cycle of:~* Leucovorin calcium/folinic acid~* Fluorouracil~* oxaliplatin"
223450479|NCT03642067|DRUG|Nivolumab|Nivolumab was administered IV on day 1 of each 28 day cycle.
223450480|NCT03642067|DRUG|Relatlimab|Relatlimab was administered IV on day 1 of each 28 day cycle.
223450481|NCT04313400|DRUG|1.1% w/w AMTX-100 CF-part1|AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient
223450482|NCT04313400|DRUG|Placebo|Topical cream manufactured to mimic AMTX-100 CF3
223450483|NCT04313400|DRUG|1.1% w/w AMTX-100 CF3-part2|AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient
223450484|NCT03726307|BIOLOGICAL|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
223450485|NCT03726307|BIOLOGICAL|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
223450486|NCT03726307|BIOLOGICAL|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~* mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~* the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
223450487|NCT03326115|BEHAVIORAL|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
223450488|NCT02279290|BEHAVIORAL|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
223450489|NCT02279290|BEHAVIORAL|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
223450490|NCT00608218|DRUG|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
223450491|NCT02839031|BEHAVIORAL|"CBT (Cognitive-Behavioral Therapy)"|
223450492|NCT02839031|BEHAVIORAL|Control (telephonic support without CBT content)|
223450493|NCT05255445|BIOLOGICAL|Red Blood Cell (RBC) Transfusion|Simple RBC transfusion or partial manual exchange
223450494|NCT01461473|DEVICE|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
223450495|NCT01461473|DEVICE|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
223450496|NCT06635850|DRUG|Mosliciguat|Dose level 1, 2, or 3 for inhalation
223450497|NCT06635850|DEVICE|Dry Powder Inhaler|Dry powder inhaler for mosliciguat or placebo delivery
223450498|NCT06635850|DRUG|Placebo|Matching placebo for inhalation
223450499|NCT06203782|PROCEDURE|endoscopic stricturoplasty|Experimental Group: In the experimental group, 51 patients underwent endoscopic stricturoplasty. A transparent cap was mounted on the front end of the endoscope, and a needle knife was inserted through the working channel of the endoscope. Under direct visualization, a radial incision was made at the site of the stricture, with an effort to preserve normal mucosal tissue as much as possible. The stricture was gradually incised until the endoscope could smoothly pass through.
223450500|NCT06203782|PROCEDURE|endoscopic balloon dilation|Control Group: In the control group, 51 patients underwent endoscopic balloon dilation. The endoscope was advanced to the site of the stricture, and a dilation guidewire was inserted. After placing the balloon, it was progressively inflated with pressure, each inflation lasting 1-2 minutes, and this process was repeated 2-3 times until the endoscope and sheath could pass through the narrowed segment and enter the distal colon.
223450501|NCT01637883|DRUG|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
223450502|NCT00667303|OTHER|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
223450503|NCT00667303|OTHER|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
223450504|NCT00667303|OTHER|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
223450505|NCT00003032|BIOLOGICAL|filgrastim|
223450506|NCT00003032|DRUG|cisplatin|
223450507|NCT00003032|DRUG|cyclophosphamide|
223450508|NCT00003032|DRUG|mitoxantrone hydrochloride|
223450509|NCT00003032|DRUG|tamoxifen citrate|
223450510|NCT01014078|DRUG|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
223450511|NCT01014078|DRUG|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
223450512|NCT04292067|BIOLOGICAL|Faecal sampling|Faecal sampling at baseline
224147069|NCT04066946|OTHER|Standard of care|"Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
223450513|NCT04292067|BIOLOGICAL|Blood sampling|Blood sampling at baseline
223450514|NCT03783286|DRUG|Ivacaftor|Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction (2, 3, 4). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity.
223569447|NCT04926207|BEHAVIORAL|Physical Activity Breaks Intervention|Participants will be asked to walk on a treadmill for 3 min at a moderate intensity (55% of heart rate reserve) at an increasing speed and incline to reach and maintain their target heart rate.
223569448|NCT04926207|BEHAVIORAL|Talking Breaks Control|Every 30 min a researcher will start a brief conversation with a participant based on a pre-selected topic, which will change with each break. Topics are standardized across participants and include, for example, pollution, smart clothes, and hydration. A presentation will be followed by questions and answers. The break will last 3 min.
223569449|NCT04134130|DRUG|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
223569450|NCT04134130|DRUG|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
223569451|NCT04134130|DRUG|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
223569452|NCT01909882|OTHER|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
223569453|NCT03183323|BEHAVIORAL|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
223569454|NCT01791881|DRUG|Hugeltox|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
223569455|NCT01791881|DRUG|Botulinum Toxin Type A(Botox®)|1.25U\~2.5U/site, Maximum dosage 12.5U\~60U/person
223569456|NCT03698786|BEHAVIORAL|Exercise|Participants will be required to complete two, 8-hours trials (exercise \& control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
223569457|NCT04650412|OTHER|Bundle of comorbidities care|Pulmonary function tests, blood gas analysis, transthoracic echocardiography, sleep study after stabilization of patient's index clinical condition, thus 1 month after hospital discharge
223569458|NCT06511739|DRUG|SYHX1901|SYHX1901 tablet
223569459|NCT06511739|DRUG|placebo|Oral tablet
224057814|NCT04006496|BEHAVIORAL|Expressive Writing Coaching|For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
224147070|NCT00054236|BIOLOGICAL|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
224147071|NCT00054236|BIOLOGICAL|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
224147072|NCT00054236|DRUG|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
224147073|NCT00054236|DRUG|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
223569460|NCT01344044|DEVICE|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
224147074|NCT00054236|PROCEDURE|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
224147075|NCT00054236|DRUG|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
224147076|NCT00416312|DEVICE|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (\^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by \^131I tositumomab IV over 20 minutes on approximately day 7."
223450515|NCT03683563|OTHER|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
223450516|NCT03683563|OTHER|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
223450517|NCT03570203|DIAGNOSTIC_TEST|Serum Sodium|Measurement of serum sodium.
223450518|NCT03678194|DEVICE|Smartphone Support System|6 weeks smartphone application with daily evaluations
223569461|NCT02676336|DIETARY_SUPPLEMENT|Violet™ Molecular Iodine (I2)|
223569462|NCT02676336|OTHER|Placebo|
223569463|NCT01024582|PROCEDURE|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
223450519|NCT05578677|OTHER|Biopsy technique|"* Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively."
223741881|NCT01946997|OTHER|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
223450520|NCT05186051|DRUG|ZYIL1 capsule|NLRP3 inflammasome inhibitor
223450521|NCT03363893|DRUG|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
223450522|NCT03363893|DRUG|Fulvestrant|Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
223450523|NCT00547924|BEHAVIORAL|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
223450524|NCT02728817|PROCEDURE|End-cephalic vein to side-radial artery fistula creation|"* Circumferential dissection of the cephalic vein (4-5cm long)~* Longitudinal arteriotomy (\~10mm)~* End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
223450525|NCT02728817|PROCEDURE|RADAR fistula creation|"* Dissection of the anterior-medial aspect of the cephalic vein (\~15mm) without grasping or clamping the venous wall~* Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~* Ligation and section of the radial artery (distal)~* Longitudinal venotomy (\~10mm)~* End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
223450526|NCT04442152|BEHAVIORAL|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants were first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
223450527|NCT04041492|DIETARY_SUPPLEMENT|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
223450528|NCT00361803|DRUG|topotecan|topotecan
223450529|NCT03305692|DIAGNOSTIC_TEST|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
223450530|NCT00202943|PROCEDURE|TCRFVR and LAUP|
223450531|NCT04680247|PROCEDURE|VA-LCP|Surgery using the VA-LCP implant
223450532|NCT04680247|PROCEDURE|NCB-PT|Surgery using the NCB-PT implant
223450533|NCT04324528|DEVICE|vv-ECMO + cytokine adsorption (Cytosorb adsorber)|in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
223450534|NCT04324528|DEVICE|vv-ECMO only (no cytokine adsorption)|COVID-19-diseased treated with vv-ECMO
223450535|NCT00441519|DRUG|aspirin|
223450536|NCT00441519|DRUG|omeprazole|
223450537|NCT03454477|PROCEDURE|conventional open surgery|conventional open surgery
223450538|NCT03454477|PROCEDURE|endoscopic thyroidectomy|endoscopic thyroidectomy
223450539|NCT03454477|DEVICE|robotic thyroidectomy|robotic thyroidectomy
223450540|NCT02047994|DRUG|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~* Esomeprazole 40 mg bid for 10 days~* Clarithromycin 500 mg bid for 10 days~* Amoxicillin 1000 mg bid for 10 days"
223450541|NCT03376126|OTHER|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
223450542|NCT06226337|OTHER|listen music|During hysterosalpingography, women were listened to the Acemaşiran maqam as music via MP4 players and headphones.
223450543|NCT03519685|BEHAVIORAL|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
223450544|NCT03519685|BEHAVIORAL|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
223450545|NCT06645769|DRUG|Sodium Phenylbutyrate|will be compared to placebo
224057815|NCT02707380|OTHER|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
224057816|NCT02707380|OTHER|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
224057817|NCT00724997|BIOLOGICAL|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
224057818|NCT00803699|DIETARY_SUPPLEMENT|placebo|daily placebo capsules for 12 months
224057819|NCT00803699|DIETARY_SUPPLEMENT|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
224057820|NCT00133991|BIOLOGICAL|Filgrastim|5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
224057821|NCT00133991|BIOLOGICAL|Rituximab|375 mg/m\^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m\^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
224057822|NCT00133991|DRUG|Cyclophosphamide|1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
224057823|NCT00133991|DRUG|Cytarabine|100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
224057824|NCT00133991|DRUG|Methotrexate|3 g/m\^2 on Day 8 of each cycle of R-CVP.
224057825|NCT00133991|DRUG|Prednisone|100 mg on Days 1-5 of each cycle of R-CVP.
223450546|NCT06645769|OTHER|Placebo|will be compared to NaPB
223450547|NCT06126796|DIAGNOSTIC_TEST|CxBladder Monitor|CxBladder Monitor (CxbM) is an FDA-approved genomic biomarker test specifically designed for patients undergoing surveillance for NMIBC. The non-invasive urine test quantifies 5 measured biomarker genes (MDK, HOXA13, CDC2 (CDK1), IGFBP5, CXCR2) and incorporates this information into an algorithm to detect the presence or absence of bladder cancer.
223450548|NCT06126796|DIAGNOSTIC_TEST|Cystoscopy|Cystoscopy is the most common way surveillance has been performed for NMIBC. Cystoscopy is a procedure that allows your doctor to examine the lining of your bladder and the tube that carries urine out of your body (urethra). A hollow tube (cystoscope) equipped with a lens is inserted into your urethra and slowly advanced into your bladder.
223450549|NCT00770913|DRUG|E3810|20 mg taken orally, once a day for 8 weeks.
223450550|NCT00770913|DRUG|E3810|10 mg, taken orally, twice a day for 8 weeks.
223450551|NCT00770913|DRUG|E3810|20 mg taken orally, twice a day for 8 weeks.
223450552|NCT03919656|DRUG|Dapagliflozin 10 mg|Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
223450553|NCT03919656|DRUG|Placebo Oral Tablet|Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
223450554|NCT04298307|OTHER|Intracoronary lithotripsy (ICL)|ICL using the Shockwave catheter.
223450555|NCT00359294|DRUG|PM00104|Intravenously over 1 hour daily for 5 days, every 3 weeks.
223450556|NCT06621823|PROCEDURE|image-guided surgery technique|The identification of an image-guided surgery technique capable of intraoperatively detecting the presence of lymph node metastases would overcome the disadvantages and complications of extensive staging lymphadenectomies.
223569464|NCT01024582|PROCEDURE|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
223569465|NCT01024582|RADIATION|accelerated partial breast irradiation|
223741882|NCT00631566|DRUG|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
223741883|NCT00631566|DRUG|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
223741884|NCT00060476|DRUG|rofecoxib|
223741885|NCT00060476|DRUG|Comparator: placebo (unspecified)|
224057826|NCT00133991|DRUG|Hydrocortisone|50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
224057827|NCT00133991|DRUG|Vincristine|1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.
224057828|NCT00133991|DRUG|Leucovorin|25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
224057829|NCT04209036|OTHER|0° 3D laparoscopy high-definition camera(Olympus Winter & IBE GMBH, Hamburg - Germany)|total laparoscopic hysterectomy using a 3D laparoscopy high-definition system
224147077|NCT00416312|DEVICE|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (\^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after \^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
223450557|NCT01985061|DRUG|BX2|
223450558|NCT01985061|DRUG|BX3|
223450559|NCT01985061|DRUG|BX4-Suspended|Suspended
224057830|NCT03002155|OTHER|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
224057831|NCT00871182|DRUG|Inhaled PT001|single dose, inhaled
223450560|NCT06968650|BEHAVIORAL|Digital and Coordinated Maternial Care|The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.
223569466|NCT01024582|RADIATION|image-guided radiation therapy|
223569467|NCT00316693|BIOLOGICAL|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
223569468|NCT00316693|BIOLOGICAL|Aimmugen™|Intramuscular injection, 3 doses
223569469|NCT00074529|DRUG|MK0677|
223741886|NCT03727412|DRUG|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
224057832|NCT00871182|DRUG|Inhaled Placebo|single dose, inhaled
224057833|NCT00871182|DRUG|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
224057834|NCT03271398|BEHAVIORAL|EMDR|Eye movement desensitization and reprocessing (intensive format)
224057835|NCT03271398|BEHAVIORAL|PC|Progressive counting (intensive format)
224057836|NCT04998838|DRUG|Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)|Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
224057837|NCT04998838|DRUG|Regular Myanmar treatment|Treated according to normal Myanmar processes for HBV positive patients
224057838|NCT01498198|PROCEDURE|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
224057839|NCT01498198|OTHER|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
224057840|NCT03819348|OTHER|the multiple programs of antifungal therapy for HIV-negative host|the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
224057841|NCT00545298|DRUG|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
224057842|NCT00545298|DRUG|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
224057843|NCT00978029|DRUG|Placebo|Placebo sublingual tablet, once daily
224057844|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
224057845|NCT00978029|BIOLOGICAL|SCH 39641|Allergy immunotherapy tablet (sublingual)
224057846|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
224057847|NCT00333398|BIOLOGICAL|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
224057848|NCT00333398|BIOLOGICAL|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
224057849|NCT04972474|OTHER|Smartphone app in-app components|Insightful notification text, data visualisation, research team contact details.
224057850|NCT00259155|DRUG|Rifaximin|
224057851|NCT05912777|RADIATION|Scanner|Scanner to be performed by patients
224057852|NCT01953575|DEVICE|Mucosal Impedance|A tiny tube will be placed through the endoscope into the esophagus. 5 cm above where the stomach and esophagus meet for 5 seconds. At 10 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds. And at 20 cm above where the stomach and esophagus meet the catheter will be placed for 5 seconds.
224057853|NCT01953575|PROCEDURE|Upper Endoscopy|Esophagogastroduodenoscopy, also called by various other names, is a diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum.
224057854|NCT01931657|DRUG|Mifepristone prior to Mirena|
224057855|NCT01931657|DRUG|Placebo prior to Mirena insertion|
224057856|NCT06470256|PROCEDURE|Palliative Hepatectomy|"Patients will receive TACE, HAIC, or 90Y-SIRT combined with Lenvatinib and Durvalumab. After receiving three months of combined treatment, patients in the SD or PD stage who have poor efficacy evaluated by imaging will undergo palliative hepatectomy.~Palliative Hepatectomy:① Intrahepatic metastasis: complete lesion resection of the main tumor on one side of the liver; ② Extrahepatic metastasis: complete lesion resection of intrahepatic lesions; ③ Merge portal vein tumor thrombus or hepatic vein tumor thrombus: remove the tumor thrombus and completely remove the intrahepatic lesions. And reduce the tumor burden by more than 90% through surgical resection."
224057857|NCT06470256|DRUG|Durvalumab|Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.
224057858|NCT06470256|DRUG|Lenvatinib|Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
224057859|NCT04080947|DRUG|Control group|patients received matching-image placebo once daily at bedtime for 12 weeks.
224057860|NCT04080947|DRUG|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
224057861|NCT04669340|OTHER|E-learning patient education|"The intervention implies patient education through an e-learning program. The program consists of three learning modules covering knowledge of rheumatoid arthritis, medication, examinations, complications and daily living with RA. Module 1 consists of 'need to know' information about disease management, symptoms and medication. Thus, it is mandatory and must be completed before entering module 2 and 3. In module 2 and 3, patients can move around on the basis of their individual needs.~The duration of the full program is approximately two hours, but may vary dependent on the individual user needs. The program may be used as much as needed throughout the study period."
224057862|NCT04669340|OTHER|Standard face-to-face patient education|The intervention implies usual care, i.e. face-to-face patient education in a one-hour session with a nurse at the hospital. This form of patient education is based on the patients individual need for information and guidance in relation to rheumatoid arthritis and medication. Thus, aspects of daily life with the disease is discussed at the beginning and forms the conversation. However, as a standard, information of the disease, disease management, symptoms and medication must be discussed with the patient and relatives.
224147078|NCT06248463|DIAGNOSTIC_TEST|BP measurement in waiting room for 20 minutes|"Measured of BP will be performance in waiting room for 20 minutes every 3 minutes and report by an mobile app. After 24h-ABPM device will be implanted. Results of SBP and DBP obtained in office will be compared with 24-h, diurnal and nocturnal SBP/DBP mean.~BP will be measured automatically and repeatedly every 3 minutes in the waiting room for 20 minutes. Subsequently, a SpaceLab ABPM monitor will be implanted."
224057863|NCT01450449|RADIATION|Radiotherapy|25 Gy in 5 daily fractions over 1 week
224057864|NCT01450449|RADIATION|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
224147079|NCT00004014|DRUG|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
224147080|NCT03498976|PROCEDURE|pulsed radiofrequency|Echoguided technic
223450561|NCT05177549|OTHER|Bilateral knee examination with Lachmeter®|Bilateral knee examination with Lachmeter®. Examination repeated 3 times on each knee
223450562|NCT03860766|OTHER|Photobiomodulation|An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 5 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
223450563|NCT03706716|OTHER|decision aid developed for pelvic organ prolapse|Conversation based upon the inter face in the Electronic patient journal.
224057865|NCT02088970|DEVICE|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
223450564|NCT06315296|BEHAVIORAL|Behavioral Dietary Intervention|Follow a time-restricted diet
223450565|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive interactive positive reinforcement messages
223450566|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
223450567|NCT06315296|BEHAVIORAL|Dietary Counseling and Surveillance|Receive counseling calls
223741887|NCT03727412|DRUG|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
223741888|NCT05220579|DEVICE|"Exposure to TOR device"|"Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity."
224057866|NCT02088970|DRUG|antibiotic treatment|"If not the contact lens wearer -\> Cocci Gram positive cocci~* Vancomycin + Fortum~If contact lens wearer -\> Gram negative bacillus~* Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -\> Fungus.~= Fortum + vancomycin + Fungizone"
224057867|NCT00685880|DRUG|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
224057868|NCT00685880|DRUG|Betamethasone|CELESTONE® SOLUSPAN® \* (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
224057869|NCT01793142|DRUG|Viviant|Viviant (Bazedoxifene) 20mg once daily
224057870|NCT01820364|DRUG|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
224057871|NCT02242578|DEVICE|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
224057872|NCT02242578|DEVICE|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
224147081|NCT02309814|DEVICE|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
223741889|NCT05220579|DEVICE|"Exposure to switched off TOR device"|"The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators."
223741890|NCT04356131|OTHER|progressive relaxation exercises and massage|Progressive relaxation exercises included 30 minute rhythmic breathing and muscle relaxation exercises were demonstrated in the second part of the CD with river sounds and verbal instructions. Massage techniques were performed on the site between upper symphysis pubis and umbilicus with 15 minute effleurage demonstrated in the third part of the CD with nature sound.
224147082|NCT00198458|DRUG|Vitrase|
223450568|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223450569|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223450570|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
223450571|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
223741891|NCT04428996|BEHAVIORAL|Social Cognition and Interaction Training (SCIT)|The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
224057873|NCT00326742|BEHAVIORAL|Trier Social Stress Test|
224057874|NCT03451084|DRUG|ASLAN003|Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
223450572|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
223450573|NCT06315296|OTHER|Interview|Ancillary studies
223450574|NCT06315296|OTHER|Internet-Based Intervention|Use txt4fasting platform
223450575|NCT06315296|RADIATION|Stereotactic Radiosurgery|Undergo SRS
223450576|NCT06315296|OTHER|Text Message-Based Navigation Intervention|Receive text messages about healthy eating habits and food suggestions
223450577|NCT06315296|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223450578|NCT06315296|PROCEDURE|Magnetic Resonance Imaging|Undergo brain MRI
223450579|NCT06315296|OTHER|Neurocognitive Assessment|Ancillary studies
223450580|NCT06315296|OTHER|Questionnaire Administration|Ancillary studies
223450581|NCT06315296|OTHER|Interview|Ancillary studies
224057875|NCT00966342|DRUG|Fluviral 2009/10|single dose given IM .05 mL
224057876|NCT03339206|BEHAVIORAL|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
224147083|NCT06233214|DEVICE|vein imaging device|"During the PIC application attempt, the parents of the children in the experimental group will be ensured to be with their children throughout the procedure.~PIC placement attempt will be performed on the experimental group with the help of a vein imaging device."
224057877|NCT03339206|BEHAVIORAL|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
223450582|NCT00956488|BEHAVIORAL|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
223450583|NCT02891486|PROCEDURE|Spinal surgery|Elective spinal surgery performed
223450584|NCT00892515|BEHAVIORAL|exercise intervention|
223450585|NCT00892515|OTHER|counseling intervention|
223450586|NCT00892515|OTHER|gas chromatography|
223450587|NCT00892515|OTHER|immunoenzyme technique|
223450588|NCT00892515|OTHER|immunologic technique|
223450589|NCT00892515|OTHER|laboratory biomarker analysis|
223450590|NCT00892515|OTHER|mass spectrometry|
223450591|NCT00892515|OTHER|physiologic testing|
223584011|NCT06980311|OTHER|Aerobic Exercise|"Traditional Aerobic Exercise group will undergo treadmill-based aerobic exercise training under the supervision of a physiotherapist twice a week for a total of 8 weeks. For participant safety, they will be instructed to hold onto the handrails while walking, and proper use of the safety key will be ensured during each session.~Using the ULTIMA DC-5000 treadmill, participants will follow an exercise protocol based on the guidelines of the American College of Sports Medicine (ACSM), consisting of: a 10-minute warm-up, a 20-30-minute loading phase at 40-60% of heart rate reserve (moderate-to-vigorous intensity), and a 10-minute cool-down, all performed at 0% incline.~Throughout the sessions, participants' heart rate and oxygen saturation levels will be monitored via a fingertip pulse oximeter. Fatigue and dyspnea levels will also be assessed and recorded using the Modified Borg Scale."
224057878|NCT03339206|BEHAVIORAL|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
224147084|NCT06249009|DEVICE|Non invasive ventilation|CPAP and increasing flows of HFNC will be compared during a 30-minutes period each
224147085|NCT05987189|DIAGNOSTIC_TEST|miLungDx|At study enrollment a blood sample will be drawn prior to any invasive diagnostic study or treatment. On this blood sample a novel lung cancer test relying on small RNA signatures will be performed and evaluated.
224147086|NCT03005041|OTHER|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
224147087|NCT03005041|OTHER|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
224305035|NCT00394524|OTHER|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving \>80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
223450592|NCT00892515|OTHER|questionnaire administration|
223450593|NCT00892515|OTHER|survey administration|
223450594|NCT00892515|PROCEDURE|dual x-ray absorptometry|
223450595|NCT00892515|PROCEDURE|magnetic resonance imaging|
223450596|NCT00892515|PROCEDURE|study of high risk factors|
223450597|NCT02334098|DIETARY_SUPPLEMENT|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
223450598|NCT02334098|DIETARY_SUPPLEMENT|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
223450599|NCT05208580|BEHAVIORAL|Virtual education|Participants undergo virtual education activities on an on-line platform 10-14 days before the surgery
223450600|NCT05208580|BEHAVIORAL|Contact education|Participants attend live educational classes 10-14 days before the surgery
223450601|NCT01808222|DRUG|FACBC|Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
223450602|NCT02254356|DEVICE|Zilver Flex Bare Metal Stent|
223450603|NCT00177645|PROCEDURE|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
223450604|NCT04617405|OTHER|No interventions|No interventions
224057879|NCT00836043|DRUG|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
224057880|NCT05421936|DRUG|Osimertinib|Treatment as the first EGFR-TKI
224057881|NCT02668874|DEVICE|Isolite System|
224057882|NCT02668874|OTHER|Cotton Roll Technique|
224057883|NCT00810004|DRUG|Ferinject|Intravenous infusion of iron
223450605|NCT01961167|DEVICE|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
223450606|NCT00964405|DRUG|GSK233705|Inhaled Long acting muscarinic receptor antagonist
224057884|NCT03418129|DEVICE|Mindfulness|Neuromodulatory intervention for pain management
224057885|NCT03418129|DEVICE|Neurofeedback|Neuromodulatory intervention for pain management
224057886|NCT03418129|DEVICE|Relaxation|Neuromodulatory intervention for pain management
224147088|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy and Famitinib|camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib
223450607|NCT00964405|DRUG|Placebo|Matching placebo
223450608|NCT04979416|BEHAVIORAL|Video messages|video messages aimed at increasing vaccination
223450609|NCT06055153|DRUG|RC48+PD-1+platinum-based|"Phase I: Three subjects with HER2 overexpression (IHC 2+/3+) were initially enrolled. If dose-limiting toxicity (DLT) was observed in two of the three subjects, the study was continued from dose 1 to dose 2. If ≤1 DLT is observed in 3 subjects, continue to enroll 3 patients, and if ≤2 DLT is observed in 6 subjects, proceed to the second phase. If \> 2 cases of DLT are observed in 6 subjects, adjust to dose 2 for phase 2.~Dose 1: RC48 2.5mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~Dose 2: RC48 2.0mg/kg, d1, once every 3 weeks; Camrelizumab 200mg, d1 once every 3 weeks; Platinum: Cisplatin 75mg/m2(or nedaplatin 75mg/m2), d1, once every 3 weeks~The second stage: sample size expansion stage. RP2D obtained at stage 1 continues to be enrolled in up to 20 patients until disease progression or intolerable toxicity occurs."
223450610|NCT04668443|OTHER|Graphical Informed Consent (GIC)|The GIC (set of illustrations that complement the written information and consent form) will be proposed to prospective participants by researchers, systematically during the pre-test (stage 1). If the stage 1 shows no negative impact of the GIC on the consent process, the stage 2 will be implemented and the GIC will be proposed by researchers when they feel it could be beneficial for the participant.
223450611|NCT00098540|DRUG|sorafenib tosylate|Given orally
223450612|NCT00098540|OTHER|laboratory biomarker analysis|Correlative studies
223450613|NCT00802321|DRUG|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
223450614|NCT00275015|BIOLOGICAL|filgrastim|
223450615|NCT00275015|DRUG|carmustine|
223450616|NCT00275015|DRUG|cyclophosphamide|
223450617|NCT00275015|DRUG|cytarabine|
223450618|NCT00275015|DRUG|dexamethasone|
223450619|NCT00275015|DRUG|etoposide|
223450620|NCT00275015|DRUG|fludarabine phosphate|
223450621|NCT00275015|DRUG|melphalan|
223450622|NCT00275015|PROCEDURE|bone marrow ablation with stem cell support|
223450623|NCT00275015|PROCEDURE|peripheral blood stem cell transplantation|
223450624|NCT00275015|RADIATION|radiation therapy|
223450625|NCT02334826|PROCEDURE|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
223450626|NCT02334826|PROCEDURE|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
223450627|NCT01043484|DRUG|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
223450628|NCT01043484|DRUG|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
223450629|NCT04958161|OTHER|Exercise Therapy|Each exercise session will involve 5 to10 minutes of stretching and slow walking followed by a 30 minute stimulus phase of aerobic exercise. Exercise intensity during the stimulus phase will be prescribed based on the graded exercise test results and will be gradually increased with the goal of the participant exercising continuously for 30 minutes at 50% to 85% of symptom-limited maximum heart rate, or maintained at a level below that which causes symptomatic or silent ischemia. Following the aerobic phase of exercise, participants will complete one set of 8 to 12 repetitions of muscle-strengthening activities for all major muscle groups (legs, hips, back, abdomen, chest, shoulders, and arms). Participants will be provided with a home based aerobic exercise program. They will be encouraged to perform this home-based program twice a week on days when they are not attending the center-based program.
224057887|NCT00454103|DRUG|123I-Iodometomidate|
224057888|NCT04267341|OTHER|Timed Up and Go Test|It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again
224057889|NCT04267341|OTHER|10 Meter Walk Test|10 Meter Walk Test measures the time required to complete straight walk of 10 meters distance
224057890|NCT04267341|OTHER|Purdue Pegboard Test|Purdue Pegboard test evaluates the fine manuel dexterity
224057891|NCT05326984|DRUG|Metformin|Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
224070740|NCT05898958|PROCEDURE|rhomboid intercostal and subserratus block|The ultrasound probe will be placed in the obliquesagittal plane orientation, 1-2 cm medial to the medial scapula at theT5-T6 level. The trapezius muscle, rhomboid major muscle, ribs, intercostal muscle and pleura will be visualized respectively using ultrasound.After local anesthetic infiltration, needle will be inserted from the cranial to the caudal direction using the in-plane technique. The needle will be advanced between the rhomboid major and intercostal muscle fascia. The location of the needle will be confirmed with 2 mL saline solution, 10 ml of 0.25% bupivacaine with 1 : 200 000 epinephrine will beinjected slowly over 3min.for the subserratus block 10 ml of 0.25%bupivacaine with 1 : 200 000 epinephrine will be injected betweenthe serratus and intercostal muscle fascia at level of t9.
224147089|NCT05999149|DRUG|Camrelizumab Plus Chemotherapy|Camrelizumab Plus Chemotherapy
224147090|NCT00050960|DRUG|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
224147091|NCT00050960|DRUG|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
224305036|NCT01998724|BEHAVIORAL|Tai Chi|24 week tai chi intervention designed for individuals with COPD
223450630|NCT02193555|DEVICE|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
223450631|NCT04210739|DRUG|Betamethason Sodium Phosphate|Injection of betamethasone in chronic non bacterial prostatitis patients using Trans rectal Ultrasound
223450632|NCT00957489|OTHER|Dynamax appliance|
223450633|NCT00957489|OTHER|Twin-block appliance|
223450634|NCT00779987|DRUG|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
223450635|NCT00779987|DRUG|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
223450636|NCT00524680|DIETARY_SUPPLEMENT|cholecalciferol|Given orally
223450637|NCT05143606|OTHER|3D-printed airway simulator|Two self-directed training on a standard fiberoptic bronchoscope and a custom-made 3D airway simulator.
223450638|NCT05143606|OTHER|virtual reality software, AirwayEx|Two self-directed training on AirwayEx. With additional training as necessary.
223450639|NCT00549471|OTHER|physiotherapy|CG children will undergo a program of intensive physiotherapy
223450640|NCT00549471|OTHER|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
223450641|NCT04280614|BEHAVIORAL|Dialectical behaviour therapy (DBT)|DBT is based on the behavioural therapy principals focusing on four main modules: mindfulness, interpersonal effectiveness, emotional regulation and distress tolerance. The therapy is taught in a group and individual therapy model with coaching during periods of crisis. CBT is a standard model of therapy similar to DBT but is more direct in focusing clients on changing maladaptive behaviours or thoughts to effectively manage difficult emtions.
223450642|NCT01758042|PROCEDURE|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
223450643|NCT04878302|BEHAVIORAL|Combination of Comprehensive Behavioral Intervention for Tics (CBIT) and Evidence-based interventions for co-occurring diagnoses (i.e., Cognitive Behavioral Therapy, Behavioral Parent Training)|Families assigned to the immediate treatment group will receive the telehealth-based Taming Tics Together protocol(created using well-established, evidence-based treatment protocols), which includes group (parent/caregiver-only, child/teen-only) and individualized one-to-one sessions to address tics and co-occurring diagnoses.
223450644|NCT02079298|DRUG|Treatment with fluconazole.|
223450645|NCT02079298|DRUG|2. Treatment with both fluconazole and Ibuprofen.|
223569470|NCT04679922|PROCEDURE|Soft Tissue Enhancement around dental implant|Sixteen sites that are indicated for peri-implant mucosal augmentation at the time of implant placement will be selected. Sixteen sites that were met the subsequent inclusion criteria were eligible to contribute in our study were classified randomly by the sealed envelope technique into two treatment groups, 8 sites in each group. Group I (Control Group): Autogenous SCTGs harvested from the palate +dental implants \*. Group II (Experimental Group): FLA \*\*+dental implants. The allocation was withheld from the surgeon (M.H.) until just before the surgical appointment. The clinical examiner (M.S.) was masked to the treatment group for the extent of the study.Three months after implantation, the sites were located, and the thickness of the mucosa will be evaluated using the customized stent. The operculectomy will be performed following the method of Flatebo et al.,22 collecting biopsy specimens of almost constant quality and evaluating clinical thickness without mucosal distortions
224070741|NCT02540486|OTHER|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
224070742|NCT02540486|OTHER|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
224070743|NCT07009353|DRUG|PF-07054894|"Cohort 1 Period 1 - Oral \[cyclobutenyl-14C\]PF-07054894 under fasted state. Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose.~Cohort 1 Period 2: Oral unlabeled PF-07054894 followed by IV \[cyclobutenyl-14C\]PF-07054894 fusion over approximately 15 minutes at approximately 1.5 hours after the administration of the oral unlabeled dose."
224070744|NCT07009353|DRUG|PF-07054894|Cohort 2 Period 1 - Oral \[Methyl-14C\]PF-07054894 under fasted state.
224070745|NCT02071407|DRUG|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia."
223450646|NCT02079298|DRUG|3. Treatment with ibuprofen.|
223450647|NCT02079298|OTHER|4. No treatment with either fluconazole nor ibuprofen.|
223450648|NCT03124537|BEHAVIORAL|App Experimental condition|This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.
224070746|NCT02071407|DRUG|Placebo|
224070747|NCT00004471|GENETIC|pGT-1 gene lipid complex|
224070748|NCT06877221|PROCEDURE|ultrasound renal denervation|Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device
224070749|NCT07011550|DRUG|Nivolumab|Given by IV
224070750|NCT07011550|DRUG|Bevacizumab|Given by IV
224070751|NCT07011550|DRUG|BMS-986340|Given by IV
224070752|NCT07011550|DRUG|Trifluridine + Tipiracil|Given by PO
223450649|NCT03124537|BEHAVIORAL|App Condition Control|This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
223450650|NCT00123656|DRUG|esomeprazole|esomeprazole dosed qam for 8 weeks
223450651|NCT00123656|DRUG|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
224057892|NCT04532476|DEVICE|Low level laser therapy|"Diode laser (Laser HF, Hager-Werken GmbH \& Co., Duisburg, Germany) was applied to the RIGHT side. Laser was set at PDT mode (660nm) acupuncture therapy. The power of the laser was set at 90 mW in intervals of 80 seconds as recommended by the manufacturer.~The laser was applied perpendicular in contact with the mucosa on 1 point of the buccal and 1 point on the palatal side of the first molar approximately on the middle part of the root, with the 10mm distance from the laser to the mucosa. Each point was treated in 3 intervals, 80s each, in total 240s on vestibular and 240s on the palatal side per tooth. The treated surface was 1cm2. The power of the laser was 90mW, wavelength 660n, beam area 1 cm2, irradiance per target 0.09 W/cm2, during 240 seconds of treatment interval per point- 21.6J/cm2 of energy was delivered.~The same laser treatment was performed the next day, as the pain was noted to be highest within 24 hours after the placement of separators."
224057893|NCT03300674|DRUG|Hydromorphone|Hydromorphone intravenous infusion
224147092|NCT05702970|DRUG|Sucrosomial iron|Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.
224305037|NCT01998724|BEHAVIORAL|Group Walking|24 week group walking intervention
223450652|NCT03171740|DRUG|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
223450653|NCT03171740|DRUG|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
223450654|NCT03171740|DRUG|Oral saline|Oral saline, 0.25ml/kg
223450655|NCT03171740|DRUG|Nasal saline|Nasal saline 0.01ml/kg
223450656|NCT00960973|DRUG|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
223450657|NCT00960973|DRUG|Placebo|Placebo
223450658|NCT02699476|BEHAVIORAL|Psycho-Social Therapy|
223450659|NCT02699476|DEVICE|Cognitive Behavioral Computer Training|
223450660|NCT02699476|BEHAVIORAL|Interactive Trainer-Subject Sessions|
223450661|NCT02699476|DEVICE|Active Control Games|
223450662|NCT02328794|BEHAVIORAL|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
223450663|NCT02328794|BEHAVIORAL|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
223450664|NCT02328794|BEHAVIORAL|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
223450665|NCT02328794|BEHAVIORAL|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
223450666|NCT02328794|BEHAVIORAL|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
223450667|NCT04221568|DRUG|Bupivacaine-fentanyl|local anathetic\&analgesic drugs
223450668|NCT04221568|DRUG|levobupivacaine-fentanyl|local anathetic\&analgesic drugs
223450669|NCT00312117|DRUG|Sodium bicarbonate|
223450670|NCT00307853|DRUG|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
223450671|NCT00307853|OTHER|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
223450672|NCT00307853|OTHER|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
223450673|NCT06369610|DRUG|Abiraterone Acetate|Given abiraterone acetate
223450674|NCT06369610|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223450675|NCT06369610|PROCEDURE|Computed Tomography|Undergo CT
223450676|NCT06369610|BIOLOGICAL|Gonadotropin-releasing Hormone Analog|Given SC or IM
223450677|NCT06369610|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223450678|NCT06369610|PROCEDURE|Positron Emission Tomography|Undergo PET
223450679|NCT06369610|OTHER|Questionnaire Administration|Ancillary studies
223450680|NCT06369610|RADIATION|Radiation Therapy|Undergo radiation therapy
223450681|NCT03681184|DRUG|Placebo|Placebo by SC injection
223450682|NCT03681184|DRUG|Lumasiran|Lumasiran by SC injection
223450683|NCT02509793|DRUG|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
223450684|NCT05318833|DRUG|HRS7415|Drug: HRS7415
223450685|NCT04968522|DRUG|Methylphenidate Hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
223569471|NCT06536205|BEHAVIORAL|psychoeducation|Psychoeducation, psychological difficulties or physical diseases; These are structured educational interventions aimed at teaching people about their illness and their emotional responses to the illness, developing coping skills, ensuring compliance with the illness and cooperation with treatment.
223569472|NCT02194920|PROCEDURE|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
223450686|NCT04968522|DRUG|Placebo|The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
224057894|NCT03300674|DRUG|Lidocaine|Lidocaine intravenous infusion
224057895|NCT03426956|DIETARY_SUPPLEMENT|Glucose|Ingestion of glucose (50 g) dissolved in 200 ml water.
224057896|NCT03426956|DIETARY_SUPPLEMENT|Glucose + Canagliflozin|Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
224057897|NCT02349594|DRUG|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
223450687|NCT04968522|DRUG|Methylphenidate hydrochloride|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
223450688|NCT04968522|DRUG|Methylphenidate Hydrochloride 18 MG|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
223450689|NCT04968522|DRUG|Dexamphetamine sulfate|This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
223450690|NCT00226525|PROCEDURE|skin sensitivity test|
223450691|NCT01627795|DRUG|Oshadi D and Oshadi R|anti cancer agents
223450692|NCT03338244|DRUG|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
223450693|NCT03338244|DRUG|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
223450694|NCT04598295|DRUG|DS-01|synbiotic
223450695|NCT03123003|DEVICE|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
223450696|NCT03123003|DEVICE|Wrist X-ray|Bone age assessment by Wrist X-ray
223450697|NCT02725437|BIOLOGICAL|Clostridium difficile Vaccine|0.5 mL intramuscular injection
223450698|NCT02725437|BIOLOGICAL|Placebo|0.5 mL intramuscular injection
223450699|NCT03326232|DEVICE|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
223450700|NCT04745507|OTHER|Inpatient Equivalent Home Treatment|At-home psychiatric treatment by means of a multiprofessional clinic team (an equivalent to stationary psychiatric care).
223450701|NCT01447641|OTHER|Polysomnography|Overnight physiological recording of sleep
223450702|NCT01447641|OTHER|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
223450703|NCT01607346|DRUG|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
223450704|NCT00343655|DRUG|Atorvastatin|
223450705|NCT04920890|DEVICE|Radiofrequency therapy with manual therapy|Monopolar Capacitive Resistive Radio Frequency at 448 kHz (INDIBA®) (RFMCR) with manual therapy.
223450706|NCT00159952|PROCEDURE|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
223450707|NCT00625183|DIETARY_SUPPLEMENT|selenomethionine|
223569473|NCT03809091|DIAGNOSTIC_TEST|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
223569474|NCT00563095|PROCEDURE|Transcatheter Arterial Chemoembolization (TACE)|
223450708|NCT00625183|DRUG|capecitabine|
223450709|NCT00625183|DRUG|oxaliplatin|
223450710|NCT00625183|OTHER|laboratory biomarker analysis|
223450711|NCT00625183|OTHER|pharmacological study|
223450712|NCT00625183|PROCEDURE|adjuvant therapy|
223450713|NCT00625183|PROCEDURE|neoadjuvant therapy|
223450714|NCT00625183|PROCEDURE|therapeutic conventional surgery|
223450715|NCT00625183|RADIATION|radiation therapy|
223450716|NCT06345391|OTHER|Co-creation|Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.
223450717|NCT06345391|OTHER|Concept Mapping|Concept mapping to create a pain science education intervention for children living beyond cancer.
223450718|NCT03634527|BEHAVIORAL|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
223450719|NCT03634527|BEHAVIORAL|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
223450720|NCT05506514|OTHER|Water immersion|Comparison of 3 different water temperatures
223569475|NCT00563095|PROCEDURE|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
223569476|NCT02858531|OTHER|data retrieval|data retrieval with the Hospital Information System
223569477|NCT03859518|OTHER|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
224057898|NCT02349594|DRUG|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
224057899|NCT02820155|DRUG|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
224057900|NCT02820155|DRUG|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
224057901|NCT04267419|DIAGNOSTIC_TEST|salivary biomarker|MDA and NO as salivary biomarkers
223450721|NCT06653439|PROCEDURE|Bilateral ultrasound guided Subcostal Quadratus Lumborum Block|Bilateral ultrasound-guided subcostal quadratus lumborum block (20 mL, 0.25% bupivacaine, bilaterally) will be performed. All patients will receive multimodal analgesia, including a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated using a PCA device programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum of 0.1-0.15 mg/kg (IBW). Upon arrival in the PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the surgical ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW) in 50-100 mg slow doses, not exceeding 400 mg/day.All patients will receive 8 mg dexamethasone and 0.15 mg/kg ondansetron (IBW) for PONV prophylaxis.
224057902|NCT01553188|DRUG|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
224057903|NCT01553188|DRUG|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
224057904|NCT01553188|DRUG|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
223450722|NCT06653439|PROCEDURE|Control|Patients in this group will not undergo plane blocks. IV morphine PCA multimodal analgesia will be provided: all patients will receive a single dose of IV tenoxicam 20 mg. Additionally, 15 mg/kg IV paracetamol (based on IBW) will be administered at skin closure and continued every 6 hours postoperatively. A standardized IV PCA protocol will be initiated for all patients using a PCA device, programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/kg (IBW). Upon arrival in PACU, patients with a resting NRS ≥4 will receive titrated IV morphine boluses of 0.03 mg/kg (IBW; max 10 mg) every 10 minutes until pain is controlled. In the ward, patients with breakthrough pain (NRS ≥4) despite PCA use will receive IV tramadol 1-1.5 mg/kg (IBW), administered slowly in 50-100 mg doses (max 400 mg/day). All patients will receive IV dexamethasone (8 mg) before induction and IV ondansetron (0.15 mg/kg IBW) near surgery end.
224057905|NCT02445625|DEVICE|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
224057906|NCT02087956|BEHAVIORAL|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
224147093|NCT05702970|DRUG|Vitamin D|administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group
224147094|NCT05702970|DRUG|Ferric Carboxymaltose 50 MG/ML|Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
224147095|NCT04749576|DIETARY_SUPPLEMENT|saffron supplement for IBD|anti inflammatory effect
223569478|NCT01797848|DRUG|Peginterferon alfa 2a|
223569479|NCT01797848|DRUG|Ribavirin|
223569480|NCT01797848|DRUG|Placebo matching Daclatasvir|
223569481|NCT01797848|DRUG|Daclatasvir|
224057907|NCT02087956|BEHAVIORAL|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
224057908|NCT04744207|DRUG|GS-248|120 mg, capsule, once daily for 4 weeks
224057909|NCT04744207|DRUG|Placebo|capsule, once daily for 4 weeks
224057910|NCT03069885|DEVICE|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
224147096|NCT02727660|DRUG|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
224147097|NCT02727660|DRUG|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
224147098|NCT02727660|DRUG|FF MDI (PT005) 9.6 μg|Blinded Treatment
224147099|NCT00305604|DRUG|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
223569482|NCT02502058|DEVICE|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
223569483|NCT02627287|DEVICE|FlexPen®|For subcutaneously (s.c. under the skin) injection.
223569484|NCT02627287|DEVICE|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
223569485|NCT02627287|DRUG|placebo|For subcutaneously (s.c. under the skin) injection
224057911|NCT03069885|OTHER|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
224057912|NCT00547846|DRUG|PDC-748|
224147100|NCT00305604|DRUG|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
224147101|NCT04020406|BIOLOGICAL|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
224147102|NCT00006234|PROCEDURE|peripheral blood stem cell transplantation|
224147103|NCT00006234|RADIATION|holmium Ho 166 DOTMP|
223450723|NCT06653439|DRUG|IV morphine PCA|A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/kg (IBW). No basal infusion will be used.
223450724|NCT06977581|DRUG|PF-07275315|subcutaneous injection
223450725|NCT06977581|OTHER|Placebo|subcutaneous injection
223450726|NCT04978805|BEHAVIORAL|Progressive Relaxation Exercise|In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.
224057913|NCT02403570|OTHER|Brain MRI|
224057914|NCT05973929|OTHER|Screen for movement disorder and correlates it with MRI findings.|"* To determine the prevalence of movement disorders in MS patients.~* To know the clinical type of movement disorders occurring with multiple sclerosis patients and the MRI finding of those patients.~* To find the correlation between the movement disorder and the different types of MS."
224057915|NCT03096730|DRUG|Normal saline|Normal saline is intravenously administrated before anesthesia induction
224057916|NCT03096730|DRUG|Remifentanil|Remifentanil is intravenously administrated
224057917|NCT03096730|DRUG|Sufentanil|Sufentanil is intravenously administrated
224057918|NCT03096730|DRUG|Dexmedetomidine injection|Dexmedetomidine is intravenously administrated before anesthesia induction
224147104|NCT03460925|RADIATION|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
224147105|NCT03684941|DEVICE|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
224147106|NCT03684941|DEVICE|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
224147107|NCT02428972|DRUG|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
223450727|NCT04302480|OTHER|Worksheets for ASP|The ASP intervention will cover the harms and misleading marketing strategies of ASPs and other related information.
223450728|NCT04302480|OTHER|Worksheets for SSB|The SSB intervention will cover the general information on SSBs, such as the sugar content of SSBs, nutrition labels and the harms of SSBs.
224147108|NCT02428972|DRUG|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
224147109|NCT01248364|DRUG|BI 10773|BI 10773 tablets once daily high dose
224147110|NCT04814472|DRUG|BLD-0409|Randomized to active product.
223450729|NCT04302480|OTHER|E-messages for ASP|In the subsequent month after the main intervention, students in the ASP group will receive 4-6 e-messages on ASPs, after which students will be invited to complete a 1-month follow-up assessment.
223450730|NCT04302480|OTHER|E-messages for SSB|In the subsequent month after the main intervention, students in the SSB group will receive 4-6 e-messages on SSBs, after which students will be invited to complete a 1-month follow-up assessment.
223450731|NCT01915524|BIOLOGICAL|CV9202|Intradermal injection of CV9202
223450732|NCT01915524|RADIATION|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
223450733|NCT02704559|DRUG|DWC20155|
223450734|NCT02704559|DRUG|DWC20156|
223450735|NCT01990716|OTHER|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
223450736|NCT03731026|COMBINATION_PRODUCT|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
223450737|NCT03731026|DRUG|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
223450738|NCT04049006|OTHER|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
223450739|NCT00897975|DIETARY_SUPPLEMENT|red yeast rice|600 mg 3 capsules bid
223450740|NCT00897975|DRUG|phytosterol|phytosterol 450 mg 2 tabs bid with food
223450741|NCT00897975|BEHAVIORAL|therapeutic lifestyle program|TLC - 12 weeks
223450742|NCT00897975|DRUG|placebo|placebo
224057919|NCT03096730|DRUG|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
224057920|NCT01617070|DRUG|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
224057921|NCT01617070|DIETARY_SUPPLEMENT|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
224057922|NCT00077363|DRUG|tipifarnib|Given PO
224057923|NCT00077363|DRUG|capecitabine|Given PO
224147111|NCT05733260|BEHAVIORAL|Exercise|10 weeks of resistance training.
224057924|NCT01336582|DRUG|taxotere|70 mg/m2 for age of ≥ 65
224057925|NCT04298775|PROCEDURE|spinal anesthesia with morphine|
224147112|NCT02227472|OTHER|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
224147113|NCT02227472|OTHER|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
224147114|NCT04140604|OTHER|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
223450743|NCT01558713|DRUG|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
224057926|NCT04298775|PROCEDURE|spinal anesthesia without morphine + peripheral nerve block|
224057927|NCT01967355|OTHER|lipid apheresis|
224057928|NCT03906383|OTHER|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
223450744|NCT01558713|DRUG|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
223450745|NCT01558713|DRUG|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
223450746|NCT01558713|DRUG|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
223569486|NCT01603797|BEHAVIORAL|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
223569487|NCT03346551|BEHAVIORAL|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
223741892|NCT04262232|BEHAVIORAL|Adapted Ca-HELP for Geriatric Cancer Patients|Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
224057929|NCT02111642|OTHER|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
224057930|NCT05125055|DRUG|Toripalimab (anti-programmed death-1 inhibitor)|The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
224057931|NCT05125055|DRUG|Albumin paclitaxel|The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
224057932|NCT05125055|DRUG|Cisplatin|The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
224147115|NCT04140604|OTHER|Bifidobacterium animalis subsp. lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
224147116|NCT04140604|OTHER|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
224147117|NCT02920281|OTHER|Polysomnography|
223450747|NCT01558713|DRUG|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
223450748|NCT01558713|DRUG|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
223450749|NCT02024737|OTHER|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
223450750|NCT04318132|DEVICE|Nidek Mirante|The Nidek Mirante Optical Coherence Tomography (OCT) including scanning laser ophthalmoscope (SLO) function is an non-contact system for imaging the fundus and for axial cross sectional imaging of anterior and posterior ocular structures.
223450751|NCT04318132|DEVICE|Optovue RTVue XR Avanti|The Avanti is an optical coherence tomography system indicated for the in vivo imaging,axial cross-sectional, and three-dimensional imaging and measurement of anterior and posterior ocular structures.
223450752|NCT04318132|DEVICE|Optos P200DTx|The P200DTx scanning laser ophthalmoscope (SLO) is indicated for use as a widefield and retinal fluorescence and autofluorescence imaging ophthalmoscope to aid in the diagnosis and monitoring of diseases and disorders that manifest in the retina.
223450753|NCT04638803|DRUG|PRX-P4-003, (-)-FCF|sequential study
223569488|NCT03346551|BEHAVIORAL|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
223569489|NCT01615055|DRUG|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
223569490|NCT01615055|OTHER|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
224147118|NCT02418767|DRUG|MOD-4023|
224147119|NCT02418767|DRUG|Placebo|
224305038|NCT00492986|DRUG|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
224305039|NCT01398514|DRUG|Escitalopram|Escitalopram 10mg/day or matched pill placebo
224305040|NCT04015323|DEVICE|Interferential current|An electrotherapy current with different carrier frequencies
224147120|NCT06305221|DRUG|Opioid-free Analgesics (esketamine, dexmedetomidine)|opioid free group: After infusion of a loading dose of dexmedetomidine, intravenous midazolam 2mg, propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium 0.6-1mg kg-1, and 3min after endotracheal intubation. Intravenous continuous infusion of propofol, esketamine and dexmedetomidine hydrochloride mixture (esketamine 50mg + dexmedetomidine hydrochloride 150 ug + 0.9% saline 50ml in the same 50ml syringe) 0.1ml kg-1 h-1-0.2 ml kg-1 h-1 (equivalent to esketamine 0.1-0.2mg kg-1 h-1; Dexmedetomidine hydrochloride 0.3-0.6 μ g kg-1 h-1) maintains a BIS value between 40-60, 10-20mg / time was added as appropriate.
223450754|NCT01516645|DRUG|KHK2898|injection
223450755|NCT03662815|BIOLOGICAL|iNeo-Vac-P01|Neoantigen peptides
223450756|NCT03662815|OTHER|GM-CSF|immune adjuvant
223741893|NCT05048810|RADIATION|68Ga-DOTA-NT-20.3|In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.
223741894|NCT05431933|BIOLOGICAL|Eupolio|Inactivated Polio vaccine (Sabin strains)
223741895|NCT05677815|PROCEDURE|Underwent Surgery from 2019 to 2022|Surgery was defined as any procedure done by a surgeon in an operating theatre under general, regional, or local anaesthesia
223741896|NCT06367543|DIAGNOSTIC_TEST|Time in therapeutic range of vital parameters|"Treatment adherence on NICU to the following vital parameters:~1. Temperature (T\<37,5°C) (every 4 hours during the first 96 h after admission to neurocritical care unit)~2. systolic blood pressure ICD-10 (International Statistical Classification of Diseases 10th Revision) (I60, 161 \& 162): 100-140 mmHg ICD-10 (I63): 120-180 mmHg (every 4 hours during the first 96 h after admission to neurocritical care unit)~3. Mean arterial blood pressure (MAP: 60-90 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~4. Arterial oxygen partial pressure (paO2: 75 - 100 mmHg) (every 4 hours during the first 96 h after admission to neurocritical care unit)~5. Arterial carbon dioxide partial pressure (paCO2: 35 - 45 mmHg). (every 4 hours during the first 96 h after admission to neurocritical care unit)~6. Blood glucose (BG: 80-180 mg/dL). (every 4 hours during the first 96 h after admission to neurocritical care unit)"
223741897|NCT04537234|BIOLOGICAL|High-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
223741898|NCT04537234|BIOLOGICAL|Standard-Dose Quadrivalent Influenza Vaccine|"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"
223741899|NCT06870539|OTHER|Non-Interventional Study|Non-Interventional Study
223741900|NCT06869122|DEVICE|Ablation|Bronchoscopy and microwave ablation of the lung tumour prior to surgical resection.
223741901|NCT06681220|COMBINATION_PRODUCT|Stenoparib/Temozolomide|Stenoparib at the recommended phase 2 dose +Temozolomide 40mg/day daily will be given in combination x21 days each cycle
223741902|NCT06681220|DRUG|Lurbinectedin|Lurbinectedin 3.2mg/m2 one-hour intravenous (IV) infusion x 21 days each cycle
223741903|NCT06681220|COMBINATION_PRODUCT|Stenoparib/Temozolomide|Patients will be assigned to one of three doses of Stenoparib (200mg po qd, 200mg po BID, and 200mg in am and 400mg in pm). The initial starting dose will be the 200 mg po QD orally daily for 21 days.
223741904|NCT07019129|DIETARY_SUPPLEMENT|Beetroot Juice - Active|Nitrate-rich beetroot juice
223741905|NCT07019129|DIETARY_SUPPLEMENT|Placebo Beetroot Juice Without Nitrate|Nitrate-poor beetroot juice
223741906|NCT06368141|DRUG|Serplulimab|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
223741907|NCT06368141|DRUG|Capecitabine|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
223741908|NCT06368141|DRUG|Oxaliplatin|Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
223741909|NCT06698237|OTHER|immediate cold-water immersion|immediate 10 minute water immersion in 10 degree Celsius
224305041|NCT02771795|DRUG|Herceptin (trastuzumab)|Intravenous administration
224305042|NCT02771795|DRUG|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
223741910|NCT06698237|OTHER|delayed cold-water immersion|3 hour delayed 10 minute water immersion in 10 degree Celsius
223741911|NCT06698237|OTHER|immediate thermoneutral water immersion|immediate 10 minute water immersion in 35 degree Celsius
223450757|NCT00617513|DRUG|Prucalopride|0.5 mg once daily
223450758|NCT00617513|OTHER|Placebo|o.d.
223450759|NCT00617513|DRUG|Prucalopride|1 mg o.d.
223450760|NCT00617513|DRUG|Prucalopride|2 mg o.d.
223450761|NCT02046278|DEVICE|LifeSeal™ Kit|
223450762|NCT04424914|DIAGNOSTIC_TEST|Scintigraphy|scintigraphy
223741912|NCT06880731|BEHAVIORAL|Modeling with Verbal Mediation|Children will watch and listen as a friendly animated character completes shifting task trials while narrating his thoughts and actions, providing a model of verbal mediation.
224305043|NCT01911897|DEVICE|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
224305044|NCT00823121|PROCEDURE|freezing embryos by vitrification|vitrification by Cryotop method
223450763|NCT05138328|DEVICE|Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)|This will use optical coherence tomography (OCT) to assess the margins of basal cell carcinoma. Treatment will be completed by Nd:YAG laser.
223450764|NCT04485637|OTHER|Communication with basic table|Communication showing only the normal range of blood pressure readings, which is often used but may make it hard to interpret numbers outside of the normal range
223450765|NCT04485637|OTHER|Communication with enhanced table|Communication with enhanced table, with reference information showing how combinations of diastolic and systolic blood pressure reflect normal, elevated and hypertension ranges (adapted from the American Heart Association)
223450766|NCT04485637|OTHER|Communication with enhanced graph|Communication with enhanced graph, showing reference information about how to interpret blood pressure readings (adapted from Blood Pressure UK) with diastolic blood pressure on the x-axis and systolic blood pressure on the y-axis
223450767|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
223450768|NCT00629148|DRUG|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
224305045|NCT00823121|PROCEDURE|fresh embryo transfers|fresh embryo transfers
224057933|NCT05125055|DRUG|Docetaxel|The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.
224057934|NCT05125055|DRUG|5-Fluorouracil|The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
223450769|NCT02036541|DEVICE|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
224057935|NCT02718742|OTHER|Laboratory Biomarker Analysis|Correlative studies
224147121|NCT06305221|DRUG|Opioid Anesthetics (sufentanil and remifentanil)|Intravenous midazolam 2mg, propofol 2mg kg-1, sufentanyl 0.3-0.5 μ g kg-1, rocuronium 0.6-1mg kg-1,3min before endotracheal intubation. After successful endotracheal intubation, continuous intravenous infusion of propofol and remifentanil was started to maintain BIS values between 40-60, and rocuronium 10-20mg / time as appropriate. After the start of surgery, 10-20 μ g of sufentanil was added according to blood pressure and heart rate. At the end of the operation, 5mg and 50mg were injected before the end of the operation, and propofol and remifentanil were stopped at the end of the operation
224147122|NCT00764946|DRUG|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
223450770|NCT03173495|DIETARY_SUPPLEMENT|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
223450771|NCT03173495|DIETARY_SUPPLEMENT|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
223450772|NCT03173495|DIETARY_SUPPLEMENT|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
223450773|NCT01778751|BEHAVIORAL|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
223450774|NCT00674895|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
223450775|NCT01047124|OTHER|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
223450776|NCT02787681|DEVICE|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
224147123|NCT03388086|DRUG|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
224147124|NCT04569799|DRUG|Lumason|2.4 mL per lesion
224147125|NCT03552627|DRUG|Oxygen|Medical Oxygen
223450777|NCT05413473|DEVICE|MR guided radiotherapy|MR guided radiotherapy using the Alberta linac-MR P3 system
223450778|NCT06812832|DRUG|Simethicone 80 MG|Patients will receive simethicone 80mg four times per day for 2 weeks post-operatively.
223450779|NCT06812832|DRUG|Placebo|Patients in the control group will receive a placebo pill four times per day for 2 weeks
223450780|NCT05626257|OTHER|Xolair|There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.
223741913|NCT06880731|BEHAVIORAL|Modeling Only|Children will watch as a friendly animated character completes shifting task trials.
223741914|NCT07039526|DRUG|CYTALUX™ (pafolacianine) injection preoperatively|CYTALUX™ (pafolacianine) injection: folate analog ligand conjugated with an indole cyanine green-like dye as a solution in vials containing 1.6 mL at 2 mg/mL. Each subject will be administered a single intravenous dose of not less than 1 hours before and not more than 24 hours before initiation of intraoperative NIR fluorescent imaging.
224147126|NCT04970849|OTHER|observation|IBD doctors who perform the endoscopy perform the questionnaire
224147127|NCT04371627|DRUG|Viaskin Peanut|Daily epicutaneous delivery
224147128|NCT00000937|DRUG|Antibiotics|
223450781|NCT00410618|PROCEDURE|cognitive assessment|
223450782|NCT00410618|PROCEDURE|magnetic resonance imaging|
223450783|NCT00410618|PROCEDURE|management of therapy complications|
223450784|NCT03960424|OTHER|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
223450785|NCT03960424|BEHAVIORAL|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
223450786|NCT06730191|PROCEDURE|soft tissue graft covering immediate dental implant|soft tissue graft covering immediate dental implant
223450787|NCT03850990|BEHAVIORAL|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
223450788|NCT05390385|DIETARY_SUPPLEMENT|KE1 5g|5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces
223450789|NCT05390385|DIETARY_SUPPLEMENT|KE1 10g|10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces
223450790|NCT05390385|DIETARY_SUPPLEMENT|KE4 5g|5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
223450791|NCT05390385|DIETARY_SUPPLEMENT|KE 10g|10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces
224057936|NCT02718742|DRUG|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
224057937|NCT02718742|OTHER|Quality-of-Life Assessment|Ancillary studies
224057938|NCT03231046|DEVICE|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
224057939|NCT03231046|PROCEDURE|Hepatic Biopsy or Ablation|Standard of Care
224057940|NCT03913052|PROCEDURE|Intra-articular Viscosupplement Application|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
224147129|NCT00206011|PROCEDURE|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
224147130|NCT05766436|DRUG|Dexmedetomidine|receive placebo ODF and 3 µ/kg nebulized dexmedetomidine (Precedex™ rxlist) prepared in 0.9% normal saline to a final volume of 3ml. Nebulization was performed using a wall nebulizer and wall oxygen source on 4 l/min.
224147131|NCT05766436|DRUG|Melatonin|will receive placebo nebulizer and 0.4mg/kg of ODF melatonin (metacyst ™ nerhadou) orally allowing the film to dissolve in the patients Oro mucosal lining
223450792|NCT05390385|OTHER|Placebo drink|Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces
223450793|NCT04671056|DRUG|MGL-3196|MGL-3196 100 mg tablet administered orally in the morning for 13 days
223450794|NCT04671056|DRUG|Pioglitazone 15mg|Pioglitazone 15 mg tablet administered orally on 2 separate days, initially on one day alone and again after MGL-3196 has been dosed to steady-state
223450795|NCT04659902|DIETARY_SUPPLEMENT|Protein form|Protein form and absence or presence of calcium manipulated
223450796|NCT01454414|OTHER|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
223450797|NCT04517578|OTHER|Survey|Participants will be asked to fill in an online survey that will be anonimized.
223450798|NCT05681637|OTHER|Breathing mixtures of O2 and N2 and monitoring SpO2 on each finger|Volunteers sequentially inhale three hypoxic gas mixtures each for 2.5 minute. Every measurement will begin with a two-minute stabilization phase, during which the physiological values of the volunteer will be checked. During the experiment, non-invasive SpO2 measurements will be performed continuously on the individual fingers of volunteer hands throughout the experiment.
223450799|NCT03609190|DRUG|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
223450800|NCT03609190|DRUG|Placebo|i.v. infusion of NaCl over 40 min
223450801|NCT04037852|DEVICE|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
223450802|NCT04037852|PROCEDURE|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
223450803|NCT04037852|PROCEDURE|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
223450804|NCT02159885|OTHER|Telemonitoring|
223569491|NCT01242306|DRUG|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
223569492|NCT03690739|DRUG|Carboplatin|Administration according to investigator's discretion
223569493|NCT03690739|DRUG|Gemcitabine|Administration according to investigator's discretion
224147132|NCT05766436|DRUG|Placebo|placebo ODF and 0.9% normal saline nebulizer
224147133|NCT06367972|PROCEDURE|Local Consolidation Therapy|Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.
224147134|NCT06367972|PROCEDURE|Next-line Systemic Therapy|The specific next-line systemic therapy will be determined by your doctor.
224147135|NCT05184127|DRUG|MIR 19 ®|Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
223450805|NCT00019656|DRUG|perifosine|
223450806|NCT01459393|DRUG|5-ALA Photodynamic Therapy|
223450807|NCT01459393|DRUG|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
223450808|NCT00868751|BIOLOGICAL|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
223450809|NCT06612502|BEHAVIORAL|Static stretching|The static stretching protocol comprised eight exercises, performed for 30 seconds per bilateral muscle group (with the exception of the sitting toe touch and butterfly stretch), and included the hip, knee, and ankle. The subjects were instructed to perform the following sequence of stretches: forward lunge, supine knee flexion, lateral quadriceps stretch, sitting toe touch, semi-straddle, straddle, butterfly stretch, and a straight knee ankle extensor wall stretch. Each subject completed each stretch before progressing to the subsequent one. The stretches were maintained until the subject experienced mild discomfort, but not pain.
223450810|NCT06612502|DEVICE|Fascia gun ( Short-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The short time PMT was applied for 2.5 minutes per muscle site for a total of 25 minutes.
223569494|NCT03690739|DRUG|Bevacizumab|Administration according to investigator's discretion
223569495|NCT03690739|DRUG|PLD|Administration according to investigator's discretion
223741915|NCT06697184|DRUG|Sonrotoclax|Administered orally
224305046|NCT00823121|DRUG|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
223450811|NCT06612502|DEVICE|Fascia gun ( Long-time PMT )|The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The long time PMT was applied for 4 minutes per muscle site for a total of 40 minutes.
223450812|NCT06612372|BEHAVIORAL|60-day-6° head-down bed rest|Throughout the bed rest period, subjects carried out all activities of daily living-eating, voiding, recreation, and testing
223450813|NCT05018988|DIETARY_SUPPLEMENT|Oral vitamin D spray|1 spray (10µg) /day for 12 weeks
223450814|NCT05018988|DIETARY_SUPPLEMENT|Placebo|1 spray / day for 12 weeks
223450815|NCT07021378|DIETARY_SUPPLEMENT|Dietary Supplement|"Phase 1 (Neoadjuvant Chemotherapy):~Patients will receive 2 units of Impact oral supplement and 1 sachet of protein module daily, for 7 days prior to each chemotherapy cycle.~During the interval between the end of one cycle and 7 days before the next, 2 sachets of protein module per day will be maintained.~Phase 2 (Surgery):~2 units of Impact once daily, for 7 days prior to surgery.~Phase 3 (Radiotherapy):~2 units of Impact and 1 sachet of protein module daily, for 7 days prior to starting radiotherapy (RT), followed by 1 unit of Impact once daily throughout the course of RT.~Protein module: 13 g/day until the end of treatment."
223450816|NCT07021378|DIETARY_SUPPLEMENT|Dietary Supplement|"2 units of Impact oral supplement and 1 sachet of protein module once daily, starting 1 week before the initiation of radiotherapy (RT).~During RT: 1 unit of Impact and 1 sachet of protein module daily, until 1 week before the end of RT.~2 units of Impact and 1 sachet of protein module daily until the end of treatment, starting from 1 week before the end of RT.~Protein module: 13 g/day throughout the entire treatment period."
223450817|NCT07021378|OTHER|Control Cohort A|Control cohort A: According to the institutional routine nutritional orientation
223450818|NCT07021378|OTHER|Control cohort B|Control cohort B: According to the institutional routine nutritional orientation
223450819|NCT00043563|BEHAVIORAL|Cognitive-Behavior Therapy|
223450820|NCT05954936|OTHER|Risk factor|No therapeutic or diagnostic intervention will be provided; it is an observational study.
223450821|NCT00003418|DRUG|exemestane|
223450822|NCT00003418|DRUG|tamoxifen citrate|
223450823|NCT05297929|DRUG|Irbesartan Tablet|Drug: Irbesartan Oral administration on an empty stomach／fed condition
223450824|NCT05622227|DIAGNOSTIC_TEST|Drug: 68Ga-P16-093|Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of breast cancer by PET/CT.
223450825|NCT00908427|PROCEDURE|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
223450826|NCT00908427|PROCEDURE|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
223450827|NCT03078127|OTHER|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
223450828|NCT03078127|DEVICE|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
223450829|NCT03078127|DEVICE|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
223450830|NCT03078127|DEVICE|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
223450831|NCT02685072|DRUG|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
223450832|NCT02685072|DRUG|Placebo|TNP + Placebo
223450833|NCT03216603|BEHAVIORAL|Health literacy intervention group|In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
223450834|NCT00190112|PROCEDURE|ventral cardiac denervation|
223450835|NCT03268018|DEVICE|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
223450836|NCT03563664|PROCEDURE|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
223450837|NCT03563664|DRUG|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
223450838|NCT03563664|PROCEDURE|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
223450839|NCT04547231|DIAGNOSTIC_TEST|Fractional flow reserve, Coronary CT angiography|"1. Coronary CT angiography (CCTA) and measurement of fractional flow reserve (FFR) will be performed as part of routine clinical practice. The decision to perform CCTA before invasive angiography was at the judgment of the physicians in charge.~2. Physiologic assessment includes delta FFR (lesion-specific) and FFR (vessel-specific) measurement. Delta FFR is defined as a pressure step up across the lesion. Coronary angiography and physiologic assessment will be analyzed by an independent core laboratory (Seoul National University Hospital, Clinical Trial Center, Seoul, South Korea).~3. Stenosis and plaque features on CCTA will be analyzed by an independent CCTA core laboratory (Severance Cardiovascular Hospital, Seoul, Korea), and pericoronary and epicardial fat metrics (fat attenuation index, epicardial fat attenuation index, epicardial fat volume, etc.) will be obtained by an independent cardiac CT fat core laboratory (Tsuchiura Kyodo general hospital, Ibaraki, Japan)."
223569496|NCT03690739|DRUG|Paclitaxel|Administration according to investigator's discretion
223450840|NCT02634710|RADIATION|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
224057941|NCT05480904|OTHER|Neurocognitive (Thinking) Testing|"Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min."
224057942|NCT05480904|DIAGNOSTIC_TEST|CNS Vital Signs (Thinking) Testing|Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
224057943|NCT05480904|OTHER|Health Questionnaires, Sleep Surveys & Sleep Diary|The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
224057944|NCT05480904|DIAGNOSTIC_TEST|Echocardiography/EKG|All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
224057945|NCT05480904|DIAGNOSTIC_TEST|Pulmonary Function|PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
224057946|NCT05480904|DEVICE|Remote Polysomnography|The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
223450841|NCT06909591|OTHER|Self-assessment questionnaire|150 patients aged of 65 or older will pass the Lubben Social Network Scale questionnaire. The Duke Health Profile questionnaire will be also passed by the subject, for the convergent validity.
223450842|NCT04484844|DRUG|TOKUYAMA SHIELD FORCE PLUS|Self-reinforcing (SR) monomer technology
223450843|NCT04484844|DRUG|Sodium Fluoride 5% Dental Varnish|5% NaF
223450844|NCT06729944|DIAGNOSTIC_TEST|NGS|Tissue samples will be processed and analysed at the U.O. of Pathological Anatomy
223450845|NCT03514979|BIOLOGICAL|Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination|Pneumococcal vaccines
223450846|NCT04026932|OTHER|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
223450847|NCT04026932|OTHER|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
223450848|NCT06137209|OTHER|Active Comparator: Study Group A: Blis Q24 Serum at higher dose|Active Comparator: Study Group A: Blis Q24 Serum at 1e7 cfu/ dose (Active)
223450849|NCT06137209|OTHER|Active Comparator: Study Group B: Blis Q24 Serum at lower dose|Active Comparator: Study Group B: Blis Q24 Serum at 1e6 cfu/ dose (Active)
223450850|NCT02620085|PROCEDURE|blood sampling|blood sampling
223450851|NCT03721211|DRUG|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
223569497|NCT03690739|DRUG|PLD|Administration 30 mg/m² q21
224057947|NCT05480904|DIAGNOSTIC_TEST|Physical Function|This is a test of how your heart and lungs respond to exercise.
224057948|NCT00344721|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
224057949|NCT00344721|DIETARY_SUPPLEMENT|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
224057950|NCT06476210|DRUG|BDL regimen|"Drug:bedaquiline 100mg tablets~Other Names:~Bdq TMC-207 bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week~Drug:delamanid 50mg tablets~Other Names:~Dlm OPC-67683 delamanid 100mg 2 times daily~Drug:linezolid Scored 600mg tablets~Other Names:~Lzd linezolid 600mg once daily"
224057951|NCT03280875|OTHER|pedalling exercises|pedalling exercises on a bicycle ergometer
224057952|NCT00881127|DRUG|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
224057953|NCT00881127|DRUG|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
224057954|NCT05376215|DEVICE|Experimental hearing aid|This hearing aid is a receiver-in-canal style hearing aid which can be programmed and adjusted by proprietary software and by use with a mobile application.
224057955|NCT00888550|PROCEDURE|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
224057956|NCT00888550|PROCEDURE|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
224057957|NCT03379272|DEVICE|GOLDSTANDARD|RECORDING WITH EEG GOLDSTANDARD
224057958|NCT03379272|DEVICE|NEURONAUTE|RECORDING WITH NEURONAUTE
223450852|NCT03721211|DEVICE|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
223450853|NCT04467710|PROCEDURE|Laparoscopic common bile duct exploration.|"Laparoscopic common bile duct exploration. ERCP (Endoscopic Retrograde Cholangiopancreatography) with sphincterotomy : : removal of common bile duct stones trought the cystic duct (transcystically) with a Dormia or a choledoscope, or throught the common bile duct with a choledoscope introduced throught an incision of the common bile duct.~ERCP with sphincterotomy: removal of common bile duct stones throught the duodenal papilla, and a sphincterotomy of the oddi sphincter during the same time."
223450854|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
223450855|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
223450856|NCT03126955|DIAGNOSTIC_TEST|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
223450857|NCT02169388|DRUG|Probiotic|Microbial composition using probiotic
223450858|NCT02169388|DRUG|placebo（for probiotic）|microbiota modulation using placebo
223450859|NCT03090451|BEHAVIORAL|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
224305047|NCT00823121|DRUG|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
224305048|NCT00823121|DRUG|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
224305049|NCT00801359|PROCEDURE|Phacoemulsification|
223450860|NCT05131932|PROCEDURE|Endoscopic ablation of inlet patch|Endoscopic ablation of inlet patch using argon plasma coagulation (APC)
223741916|NCT06697184|DRUG|Zanubrutinib|Administered orally
223450861|NCT06220409|OTHER|Dance classes|A 12-week dance class training program two times a week for 3 months
223450862|NCT01612078|DRUG|Droxidopa|200mg/tab 2tablets, po, three times a week
223741917|NCT06717698|DRUG|NNC0519-0130|NNC0519-0130 will be administered subcutaneously.
224305050|NCT00801359|DRUG|BSSPlus solution|
224305051|NCT00801359|DRUG|Lactated Ringer's solution|
223450863|NCT01612078|DRUG|Placebo|200mg/tab, po, three times a week.
223450864|NCT04858360|DRUG|Emla 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.
223450865|NCT04858360|DRUG|EMLA 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 3 hours.
223450866|NCT04858360|OTHER|Vehicle cream for 1 hour|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 1 h.
223450867|NCT04858360|OTHER|Vehicle cream for 3 hours|At the start of each session, the middle forearms of the subject will each be divided into two squared areas (4x4 cm). On each arm, the two areas will be located 4 cm apart. Then two area will be pre-treated with a vehicle cream for 3 h.
223450868|NCT04858360|OTHER|Cowhage|Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.
223450869|NCT04262960|DEVICE|Device: active CPAP|auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients
223450870|NCT04262960|DEVICE|Device: sham-CPAP|The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
223450871|NCT02156973|OTHER|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
223450872|NCT02259829|DRUG|Telmisartan/Amlodipine|Fixed dose combination tablet
223450873|NCT02259829|DRUG|Telmisartan|
223450874|NCT02259829|DRUG|Amlodipine|
223450875|NCT00332631|DRUG|N-acetylcysteine|
223450876|NCT00332631|DRUG|Placebo|
223450877|NCT05144048|OTHER|Inpatient setting|These women stay at the maternity unit
223450878|NCT05144048|OTHER|Outpatient setting|These women leave the maternity unit
223450879|NCT01443325|DRUG|lidocaine patch|1 patch for 12 hours within each 24 hours period
223450880|NCT06731257|OTHER|virtual ward early discharge|Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
223450881|NCT02432144|DRUG|UX003|solution for intravenous (IV) infusion
223450882|NCT03277716|PROCEDURE|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
223450883|NCT03277716|PROCEDURE|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
223450884|NCT03277716|DEVICE|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
223569498|NCT03690739|DRUG|Trabectedin|Administration 1.1 mg/m² q21
223569499|NCT03690739|DRUG|Cisplatin|Administration according to investigator's discretion
223569500|NCT01559922|DRUG|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
223569501|NCT01559922|DEVICE|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
223569502|NCT00712218|PROCEDURE|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
223569503|NCT00712218|PROCEDURE|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions \[24, \].
223569504|NCT03638908|DRUG|Fluoxetine|
223569505|NCT04316806|DIETARY_SUPPLEMENT|Probiotic|Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
223569506|NCT04316806|DRUG|Rifaximin|Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
223741918|NCT06717698|DRUG|Placebo|Placebo matching NNC0519-0130 will be administered subcutaneously.
223741919|NCT06717698|DRUG|Semaglutide|Semaglutide will be administered subcutaneously.
223450885|NCT03277716|DRUG|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
223450886|NCT01451554|BEHAVIORAL|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
223450887|NCT01451554|BEHAVIORAL|Usual Care|self-help booklets
223450888|NCT02348554|BEHAVIORAL|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
223450889|NCT02348554|BEHAVIORAL|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
223450890|NCT00852280|DEVICE|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
223741920|NCT07037420|DRUG|ALXN2420|ALXN2420 will be administered via subcutaneous (SC) injection
224057959|NCT05354011|OTHER|Kinesiotape|Tape with a width of 5 cm and a thickness of 0.5 mm will be utilized. Kinesio Tex I Strip is estimated from elbow to fingertips and cut. It will be collapsed roughly two squares from the end and cut into two triangles on the overlay. The third and fourth fingers are fallen through openings and Kinesio Tex is applied on the dorsum of the hand with no strain. The situation of elbow extension, wrist extension, and radial deviation is given, and Kinesio Tex will be applied from hand to medial epicondyle with 15%-25% tension and end at medial epicondyle with no strain
224057960|NCT05354011|OTHER|Active Release Technique|This group will receive Kinesiotaping with the same method along with Active release technique will be performed on group 2. We will apply profound tension at the region of tenderness while the patient is told to effectively move the injury site from a shortened to lengthened position. The setting of a contact point close to the injury and making the patient move in a way that creates a longitudinal sliding movement of delicate tissues e.g. nerves, ligaments and muscles underneath the contact point.
224057961|NCT00707928|DRUG|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
223450891|NCT00942539|DRUG|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
223450892|NCT01402986|OTHER|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
223450893|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
223450894|NCT01402986|OTHER|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
223450895|NCT01402986|BIOLOGICAL|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
223450896|NCT00280813|BEHAVIORAL|Supportive Treatment in Addiction Recovery (STAR)|
223450897|NCT01997970|BEHAVIORAL|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
223450898|NCT01997970|BEHAVIORAL|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
223450899|NCT02427802|DRUG|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
223450900|NCT02427802|OTHER|Placebo|Matching collagen sponge
223450901|NCT01085084|DRUG|Laquinimod|Laquinimod will be administered per dose and schedule specified in the arm description.
223450902|NCT01085084|DRUG|Placebo|Placebo matching to laquinimod will be administered per schedule specified in the arm description.
223450903|NCT02634983|DRUG|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
223450904|NCT02634983|DRUG|Placebo|Matching placebo
223450905|NCT00269828|DRUG|paclitaxel|
223450906|NCT00269828|DRUG|paclitaxel poliglumex|
223450907|NCT02070978|DRUG|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
223450908|NCT02070978|DRUG|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
223450909|NCT02070978|DRUG|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
223450910|NCT03951753|DRUG|Tirzepatide|Administered SC
223450911|NCT03951753|DRUG|Semaglutide|Administered SC
223450912|NCT03951753|DRUG|Placebo|Administered SC
223450913|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
223741921|NCT07037420|DRUG|Placebo|Placebo will be administered via SC injection.
223741922|NCT07043400|DRUG|Subcutaneous Tislelizumab|Administered by subcutaneous injection
223741923|NCT07043400|DRUG|Intravenous Tislelizumab|Administered by intravenous infusion
223741924|NCT07043400|DRUG|Cisplatin|Administered by intravenous infusion
223741925|NCT07043400|DRUG|Leucovorin|Administered by intravenous infusion
223569507|NCT05296460|DRUG|Dapsone gel|The patients will use topical dapsone gel 7.5% once daily on left side of face ,The patients will use TCA20% peeling as a peeling session every 2 weeks (6 sessions) on right side of face
223569508|NCT03404908|PROCEDURE|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
224057962|NCT00707928|OTHER|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
224057963|NCT00471705|DRUG|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
224057964|NCT00471705|DEVICE|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
224147136|NCT05184127|COMBINATION_PRODUCT|Standard COVID-19 therapy|Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection. This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
223450914|NCT03178851|DRUG|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
223450915|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
223569509|NCT03404908|PROCEDURE|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
223569510|NCT03404908|DRUG|Ropivacaine|In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
223569511|NCT03404908|DEVICE|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
223569512|NCT03404908|DRUG|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
223569513|NCT03404908|DRUG|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
223569514|NCT03404908|DRUG|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
223569515|NCT03404908|DRUG|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
224057965|NCT00471705|DRUG|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
224057966|NCT03666832|DRUG|TEW-7197|"TEW-7197 1cycle 14days~-intake 5days, rest 2days"
224147137|NCT01192204|DRUG|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
223450916|NCT03178851|BIOLOGICAL|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
223450917|NCT00456820|DRUG|Wellbutrin XL|
223450918|NCT04633291|DEVICE|Novel swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
223450919|NCT04633291|DEVICE|Comparator swelling media|Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
223569516|NCT04643639|DEVICE|CytoSorb hemoperfusion|Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
223569517|NCT04376957|BEHAVIORAL|Multinational Association of Supportive Care in Cancer Oral agent Teaching Tool|"This tool was developed by an expert panel of oncology nurses and was further revised following external review of health care providers world-wide. This tools involves four key modules 1) patient's baseline knowledge, 2) patient education of oral cancer drugs 4) patient education tailored to a specific cancer drug 4) evaluation of the educational material.~It was originally studied in 30 patients with lung cancer and was shown to be feasible with acceptable knowledge retention. Similarly, in a single center cohort study of general oncology patients, medication adherence self-efficacy appeared to improve with MOATT. The MOATT interventional tool incorporates key components of patient education and also has the advantage of being a potentially feasible tool that can be incorporated into future routine clinical practise."
223569518|NCT04376957|BEHAVIORAL|Standard of care consisting of standard counselling|Consists of instructions and information on the regimen, common side effects, symptom management, medication safety and how to contact a clinician for any problems encountered.
223569519|NCT03688698|RADIATION|PET/MRI|PET/MRI scans
223569520|NCT04421859|OTHER|EyeCU Mobile Application|Augmented reality glaucoma education mobile phone application
223569521|NCT04266509|DRUG|PF-06651600|50 milligram (mg) tablet
223569522|NCT04266509|DRUG|Rifampin|600 mg provided as two 300 mg capsules.
223569523|NCT03217370|OTHER|education of guidelines|"* Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
223569524|NCT04173195|OTHER|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
224057967|NCT03117075|DEVICE|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
224057968|NCT01068691|PROCEDURE|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"* Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~* Blood pressure~* Obstructive sleep apnea syndrome (OSAS)~* Carotid-to-femoral pulse wave velocity (PWV)~* Biological parameters"
224057969|NCT00426257|PROCEDURE|Secondary debulking|Secondary debulking
224057970|NCT00426257|PROCEDURE|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
224057971|NCT05023759|DIETARY_SUPPLEMENT|Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules|Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.
224057972|NCT06264427|GENETIC|Whole genome sequencing|Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
224147138|NCT01192204|DRUG|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
224057973|NCT06264427|DIAGNOSTIC_TEST|VAGUS|To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
224057974|NCT06264427|DIAGNOSTIC_TEST|NightOwl|Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.
224057975|NCT06264427|DEVICE|CPAP|Participants with an Apnea-Hypoapnea-Index above 30, or above 15 with symptoms of sleep apnea, will be offered treatment with continuous positive airway pressure (CPAP).
224057976|NCT00000475|BEHAVIORAL|health education|
224057977|NCT02336659|DRUG|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
224057978|NCT02336659|DRUG|sitagliptin|DPP-4 Inhibition
224057979|NCT02336659|OTHER|Placebo|Saline
224057980|NCT06029621|PROCEDURE|RATS for Thymectomy|a minimally invasive surgical type for Thymoma: RATS
224057981|NCT06029621|PROCEDURE|VATS for Thymectomy|a minimally invasive surgical type for Thymoma: VATS
224057982|NCT02742428|DEVICE|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
224057983|NCT02742428|PROCEDURE|Acute paracentesis.|Evacuation of a large (\>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
224057984|NCT02742428|BEHAVIORAL|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
224057985|NCT02742428|BEHAVIORAL|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
224057986|NCT02742428|BEHAVIORAL|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
224057987|NCT03259750|OTHER|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
224057988|NCT00141024|BIOLOGICAL|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."
224057989|NCT00141024|BIOLOGICAL|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
224057990|NCT04802525|OTHER|Moderate-intensity aerobic exercise training|The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
223450920|NCT00076258|BEHAVIORAL|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
224057991|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
224147139|NCT04990102|DRUG|CPX-351|Daunorubicin 8.8mg/m2 + cytarabine 20mg/m2
223450921|NCT00076258|BEHAVIORAL|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
223450922|NCT00373802|DRUG|Phenylephrine|
224057992|NCT04702802|DEVICE|Sodium hyaluronate 3%|During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
224057993|NCT01592253|DRUG|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
224057994|NCT00007085|DEVICE|Tomography, X-ray Computed|
224057995|NCT01024010|DRUG|Cyclophosphamide|Given IV
224057996|NCT01024010|OTHER|Laboratory Biomarker Analysis|Correlative studies
224057997|NCT01024010|BIOLOGICAL|Ofatumumab|Given IV
224147140|NCT04879654|PROCEDURE|endoscopic surgery|endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
224147141|NCT02146248|DRUG|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
224147142|NCT02146248|DRUG|DepoProvera|injectable hormonal contraceptive
224147143|NCT05923060|DRUG|Topical Aminolevulinate|Topical Levulan Kerastick is applied to actinic keratoses.
224147144|NCT05923060|PROCEDURE|Photodynamic therapy (PDT)|PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
224147145|NCT05923060|PROCEDURE|Red light illumination|To occur post-PTD; used for activation of ALA during photodynamic therapy.
223450923|NCT02669043|DRUG|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
223450924|NCT03884270|BEHAVIORAL|Hypnotherapy|7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
223450925|NCT04217642|PROCEDURE|Osteosynthesis|The specific surgical technique -osteosynthesis, hemiarthroplasty, or total hip arthroplasty- will depend on the characteristics of the proximal femur fracture in each patient.
223450926|NCT05837793|BEHAVIORAL|Modified frailty index|The mFI includes the following 11 items from the National Surgical Quality Improvement Program (NSQIP): diabetes; functional status (not independent); chronic obstructive pulmonary disease (COPD) or pneumonia; congestive heart failure; history of myocardial infarction; hypertension requiring medication; peripheral vascular disease or rest pain; impaired sensorium; history of either transient ischemic attack or cerebrovascular accident; history of cerebrovascular accident with neurologic deficit; and prior percutaneous coronary intervention, previous coronary surgery, or history of angina.
223450927|NCT03947593|OTHER|No Intervention|No intervention is being administered.
223450928|NCT00661453|DRUG|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
223450929|NCT06197477|DEVICE|OurAir SQ 1750 - Mobile Air Purification System for indoor|Filtration device will be placed in classrooms. Computational Fluid Dynamics simulations will be used to find optimal position and operation mode for air purification systems in classrooms.
223450930|NCT06197477|DEVICE|Sham intervention|Filtration will be turned off in the control part of the study and then will be turned on during the intervention.
223450931|NCT01880905|PROCEDURE|Measure of uteroovarian ligament length during gynecological surgery|
223450932|NCT01158105|DRUG|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
224057998|NCT01024010|DRUG|Pentostatin|Given IV
224057999|NCT01071538|DRUG|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
224058000|NCT04080570|OTHER|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
224058001|NCT03425214|OTHER|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
224058002|NCT03425214|OTHER|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
223450933|NCT04991038|DEVICE|DAISe Device|Thrombectomy using the DAISE device
223450934|NCT04991038|DEVICE|Trevo or Solitaire|Thrombectomy using TREVO or Solitaire device
223450935|NCT01638403|DRUG|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
223450936|NCT01638403|DRUG|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
223450937|NCT01638403|DRUG|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
223450938|NCT01309984|DRUG|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
223450939|NCT01309984|DRUG|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
223569525|NCT05220319|DRUG|Methylprednisolone|250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
223569526|NCT05220319|DRUG|NaCl 0.9%|100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
223569527|NCT00711113|DEVICE|OsseoSpeed™|OsseoSpeed™, all dimensions
223569528|NCT00001812|DRUG|Nystatin|
223569529|NCT00503334|DIETARY_SUPPLEMENT|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
223569530|NCT03963089|PROCEDURE|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
223569531|NCT03963089|PROCEDURE|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
224305052|NCT02328742|BIOLOGICAL|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
224305053|NCT02328742|OTHER|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
223569532|NCT03963089|PROCEDURE|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
223569533|NCT03963089|PROCEDURE|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
223569534|NCT02253056|OTHER|Fasting / Caloric Restriction|
223569535|NCT02253056|OTHER|Healthy Diet|
223569536|NCT03212417|OTHER|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
224058003|NCT03425214|OTHER|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
223450940|NCT02803359|PROCEDURE|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
223450941|NCT06463379|DRUG|Solumedrol|2 days pulse steroid injection 125 mg methylrednisolone
223450942|NCT05047484|DRUG|ALXN2050|Powder-in-capsule (PIC).
223450943|NCT05047484|DRUG|Placebo|PIC.
223450944|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
223450945|NCT05683925|DEVICE|Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
223450946|NCT05683925|DEVICE|Noninvasive transcutaneous earlobe stimulation at 25Hz|Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
223450947|NCT05583786|DIAGNOSTIC_TEST|Tracing intracoronary electrocardiogram|icECG ST-segment shift remission time (τ-icECG) tracing during reactive-hyperemia, obtained immediately after a 1-minute upstream coronary artery balloon occlusion.
223450948|NCT06111001|OTHER|Email use data collection|Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.
223450949|NCT06111001|OTHER|AirEmail Tips and Tricks training|"Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool"
223450950|NCT06111001|OTHER|AirEmail v1 Digital Tool use|Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
223450951|NCT04202315|OTHER|Virtual Reality|Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
223450952|NCT05293873|BIOLOGICAL|autologous bone marrow-derived mononuclear cell transplantation|Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation
223569537|NCT02282800|GENETIC|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
223569538|NCT00780481|DRUG|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
223569539|NCT02057094|DIETARY_SUPPLEMENT|Protein, High-Protein, and Control|
223569540|NCT04866875|BEHAVIORAL|dieting|The minimum amount of caloric intake will be pre-set in 1200 kcal for the both groups, in order to avoid micronutrient deficiencies during the intervention. The diet macronutrient composition will be personalized for each participant based on the results of 2-day energy intake at preliminary session, measured with food items selected from a validated food menu. Individuals will be instructed to maintain the level of energy restriction and macronutrient composition during the diet period, however they will be able to do food exchanges, based on the Canadian Diabetes Association system . This method allows individuals to select foods they enjoy during the weight loss, however in smaller quantities.
223569541|NCT00100230|DRUG|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
224305054|NCT02328742|BIOLOGICAL|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
223450953|NCT05293873|OTHER|Rehabilitation therapy|Rehabilitation therapy
223450954|NCT01438931|DRUG|DA-9501|Dexmedetomidine hydrochloride variable dose
223450955|NCT01438931|DRUG|placebo|
223450956|NCT04544943|DRUG|BioLexa- Cohort 1|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects
223569542|NCT00458042|DRUG|treprostinil sodium|
223569543|NCT01211353|BEHAVIORAL|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
223450957|NCT04544943|DRUG|BioLexa- Cohort 2|Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients
223450958|NCT04544943|DRUG|Placebo|Twice daily (BID) application of placebo for 14 days
223450959|NCT04544943|DRUG|Gentamicin|Twice daily (BID) application of Gentamicin for 14 days
223450960|NCT02552888|DRUG|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
223450961|NCT02552888|DIETARY_SUPPLEMENT|Isoquercetin|Isoquercetin 225 mg by mouth once per day
223450962|NCT02552888|OTHER|placebos|placebos
223569544|NCT01211353|BEHAVIORAL|Education-Only|Educational information about alcohol use
223569545|NCT01332188|DRUG|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
223569546|NCT01332188|DRUG|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
223569547|NCT01332188|DRUG|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
223569548|NCT01332188|DRUG|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
223569549|NCT03927313|DRUG|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
223569550|NCT03927313|DRUG|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
223569551|NCT03927313|DRUG|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
223569552|NCT03927313|DRUG|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
223741926|NCT07043400|DRUG|5-fluorouracil (5-FU)|Administered by intravenous infusion
223741927|NCT07043400|DRUG|Oxaliplatin|Administered by intravenous infusion
224058004|NCT03407638|OTHER|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
224058005|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 and 28 (stage1)
224058006|NCT05007951|BIOLOGICAL|ChAdOx1-S not less than 2.5 × 10^8 infectious units|injection volume of 0.5mL on days 0 and 28 (stage1)
224058007|NCT05007951|BIOLOGICAL|GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|injection volume of 0.5mL on days 0 (stage2)
224058008|NCT03046485|BEHAVIORAL|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
224058009|NCT02238873|DRUG|Pegfilgrastim|
224058010|NCT04597983|DIETARY_SUPPLEMENT|2S-hesperidin|Cardiose® is a natural orange extract that due to its unique manufacturing process, maintains most of the natural hesperidin isomeric form (2S)
224058011|NCT04597983|DIETARY_SUPPLEMENT|Placebo|Microcellulose was used, this molecule was selected to avoid affecting the glycemia, as it can occur with dextrose or maltodextrin.
224058012|NCT04441268|PROCEDURE|primary IOL implantation|implant IOL in capsular bag after cataract extraction
224058013|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen Tab.|
224058014|NCT01776515|DRUG|Tramadol hydrochloride/Acetaminophen SR Tab.|
224058015|NCT02912416|DIETARY_SUPPLEMENT|Probiotics|
224058016|NCT02912416|DIETARY_SUPPLEMENT|Placebo|
224058017|NCT05693168|DEVICE|ANNE Limb Sensor|Pulse Oximeter
224058018|NCT04255446|DEVICE|Thora3DiTM|Not international
224058019|NCT04967781|BEHAVIORAL|autoimmunity|autoimmunity is characterized as self attacking from self immune system, which may involve in the severe progression of COVID-19.
224305055|NCT02328742|BIOLOGICAL|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
223450963|NCT06931431|BEHAVIORAL|Transition of Care Model (TCM)|Key components of the TCM include discharge assessment, care planning, provider communication with outpatient follow-up teams, and community-based follow-up
223450964|NCT05273489|PROCEDURE|Hepatectomy|Neoadjuvant treatment
223450965|NCT02014051|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
223450966|NCT00248976|BEHAVIORAL|Net-present value of individual health behaviors in years|
223450967|NCT01116076|BEHAVIORAL|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
223450968|NCT01732445|DRUG|ruxolitinib phosphate|Given PO
223450969|NCT01732445|DRUG|danazol|Given PO
223450970|NCT01732445|OTHER|quality-of-life assessment|Ancillary studies
223450971|NCT01732445|OTHER|questionnaire administration|Ancillary studies
223450972|NCT03345888|OTHER|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
223450973|NCT02371668|BIOLOGICAL|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
223450974|NCT02371668|BIOLOGICAL|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
223450975|NCT03340298|DIETARY_SUPPLEMENT|fiber|the intervention of different sources of dietary fibers
223450976|NCT04939454|PROCEDURE|quadricipital biopsy|The primary endpoint will be evaluated by histological examination only. The technique of percutaneous biopsy using the modified Bergström needle technique is currently considered the best alternative in the context of research, as it allows sufficient material to be obtained for various analyses and is much less invasive than the reference technique (surgical biopsy). Indeed, unlike surgical biopsy which requires an operating room and is a relatively heavy procedure (two suture planes, skin incision of several centimeters, resting for 48 hours after the procedure...), percutaneous biopsy by the modified Bergström technique can be performed in a consultation room, requires only one stitch, and allows resumption of walking 30 minutes after the end of the procedure.
224058020|NCT01444768|OTHER|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
224058021|NCT03495258|PROCEDURE|Clarion Evolve Laser Vaporization System|
224058022|NCT03495258|PROCEDURE|Olympus TURis Plasma Vaporization|
224058023|NCT01184222|DEVICE|great occipital nerve stimulation|"* Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
224058024|NCT03492528|BIOLOGICAL|blood samples|blood samples
223450977|NCT00401193|DRUG|Tranexamic acid tablets|3900 mg/Day
223450978|NCT00401193|DRUG|Tranexamic acid tablets|1950 mg/Day
223450979|NCT00401193|DRUG|Placebo tablets|
223450980|NCT00398216|DRUG|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
223450981|NCT00289588|DRUG|Mupirocin (drug)|
223450982|NCT02267070|BEHAVIORAL|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
223450983|NCT02267070|BEHAVIORAL|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
223741928|NCT07043400|DRUG|Capecitabine|Administered orally
224058025|NCT04993534|BEHAVIORAL|Stepped-care DWM/PM+|"The DWM program consists of a self-help guide that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. DWM includes five sections (or modules), each of which focuses on a specific skill. In this study, the DWM program will be delivered as an online intervention. The DWM intervention, i.e. both the audios and the self-help guide, have been adapted for use on a smartphone or other device with internet access.~PM+ is a new, brief, psychological intervention program based on cognitive-behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support."
224147146|NCT05090358|DIETARY_SUPPLEMENT|Ketogenic Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
223450984|NCT02267070|BEHAVIORAL|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
223450985|NCT02267070|BEHAVIORAL|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
223450986|NCT01699724|DRUG|JZoloft|50 mg tablet on Day 1 of each period
223450987|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
223450988|NCT01699724|DRUG|sertraline ODT|50 mg tablet on Day 1 of each period
223450989|NCT00415896|DEVICE|positive pressure ventilation|
223450990|NCT00528359|DRUG|quetiapine or olanzapine or risperidone or aripiprazole|
224147147|NCT05090358|DIETARY_SUPPLEMENT|Low Carbohydrate Diet|Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
223450991|NCT00615810|DRUG|Atripla|Open label once daily for oral administration to be taken on an empty stomach
223450992|NCT00615810|DRUG|Kivexa plus Sustiva|Open label once daily for oral administration
223450993|NCT04227405|BEHAVIORAL|Connection to community services through case management|Case managers met with couple and conduct a needs assessment for the couple and their family. Then they developed an Individual and Couple Development Plan to take care of those needs, usually by accessing community services. Case managers met every 5 weeks with the couple to check on progress toward meeting the goals of the plan and assess for the present of any new needs.
223450994|NCT04227405|BEHAVIORAL|TOGETHER Workshop|Couples were required to participate in a 20 hour workshop (8 sessions of 2 1/2 hours each)in groups of 3 to 8 couples. These groups were facilitated by a financial expert and a couples' expert. The workshop is interdisciplinary and psycho-educational. Couples learn about skills to improve their communication about stress and money problems, conflict resolution, individual and couple stress management in general and about money stress in particular, and financial management
223450995|NCT04227405|BEHAVIORAL|Employment Support Services|Only for those participants that were in need of employment support services. If the needs assessment conducted by the case manager indicated an employment or career need. After completion of the TOGETHER workshop, an employment case manager met with the participant, conducted an employment needs assessment and connected the participant with a workforce agency or one-stop employment centers. After doing so, the employment case manager followed through the various steps that the participant had to complete as part of the employment services for a period of 6 months
223450996|NCT00869908|DRUG|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223450997|NCT00869908|DRUG|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223450998|NCT00869908|DRUG|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
223450999|NCT06462742|PROCEDURE|Microwave ablation (MWA) versus Liver Resection (LR)|"Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases.~Liver resection is a surgery to remove part of the liver to eradicate tumors."
223741929|NCT06888453|DRUG|lozenges containing propolis|lozenges containing propolis Participants will be given the test interventions, lozenges containing propolis, and will be asked to chew twice per day and will be instructed to ordinary oral hygiene instruction, No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 7 days
223741930|NCT07047885|DRUG|Ropeginterferon alfa-2b|Will be administered via subcutaneous injection once every 2 weeks
224058026|NCT04993534|OTHER|Psychological First Aid + usual care (CAU)|All participants, both in the treatment and the comparison group, will be offered individual Psychological First Aid (PFA) through a face-to-face or teleconferencing meeting. In addition to PFA, both the treatment and the comparison group will receive care-as-usual (CAU); they will be allowed to receive any usual care. CAU may include community care, social/legal support, and psychoeducation.
223451000|NCT02207400|DRUG|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
223451001|NCT02207400|DRUG|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
223451002|NCT04594655|PROCEDURE|surgery|colectomy
223451003|NCT03367975|OTHER|near infrared spectroscopy|
223451004|NCT03372382|DRUG|Ibuprofen|NSAID
223451005|NCT03372382|DRUG|Acetaminophen|analgesic
223451006|NCT03372382|DRUG|Norco|acetaminophen plus opioid
223569553|NCT03927313|DRUG|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
223569554|NCT01046604|DRUG|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
223569555|NCT05379114|OTHER|INVESTIGATIONAL DEVICE|new medical device for the treatment of head lice infestation: Paranix ®
223569556|NCT05379114|OTHER|Comparator device|well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
223451007|NCT00643981|BIOLOGICAL|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
223451008|NCT00920504|BEHAVIORAL|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
223451009|NCT00920504|OTHER|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
223451010|NCT01393418|OTHER|Cardiac Surgery|
223451011|NCT02834078|DIETARY_SUPPLEMENT|BGG|
223451012|NCT02834078|OTHER|Placebo|
223451013|NCT06552403|DIETARY_SUPPLEMENT|A modified 5:2 intermittent fasting diet|The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
223451014|NCT02757352|DRUG|Ixekizumab|Administered SC
223451015|NCT02757352|DRUG|Placebo|Administered SC
223451016|NCT02112409|PROCEDURE|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
223451017|NCT02112409|PROCEDURE|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
223451018|NCT05581524|DEVICE|VASC|At day 0 the patient will undergo the VASC treatment procedure with VelexTM device. VelexTM venous catheter is inserted in the introducer and pushed in the desired position under echo guidance. At 7 days, 1, 3 and 6 months after the procedure, the patients will undergo a clinical examination and an echo-color doppler assessment.
223451019|NCT03565003|DRUG|JAB-3068|25 mg,100 mg
223451020|NCT06956079|PROCEDURE|EIP-first|EIP is applied for 20 minutes immediately after the initiation of one-lung ventilation, followed by conventional mechanical ventilation.
223451021|NCT06956079|PROCEDURE|EIP-later|Conventional mechanical ventilation is applied for 20 minutes after the initiation of one-lung ventilation, followed by EIP application.
223569557|NCT06508645|DRUG|DWP14012 injection|"1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)"
223569558|NCT04837989|BEHAVIORAL|Diabetes Body Project|Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators
223569559|NCT04837989|BEHAVIORAL|Psychoeducation|Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.
223569560|NCT01606787|DRUG|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
223741931|NCT03423628|RADIATION|Radiation Therapy|35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks)
224058027|NCT03961217|RADIATION|Radiotherapy|Radiotherapy as part of cancer treatment
224058028|NCT00482443|OTHER|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
223451022|NCT06169163|OTHER|Exhaled breath sampling|Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
223569561|NCT01606787|OTHER|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
223569562|NCT03888677|DRUG|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
224058029|NCT00482443|OTHER|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
224058030|NCT01195753|BIOLOGICAL|HHLivC|multiple infusion of liver cells
224058031|NCT02371239|BEHAVIORAL|Physical activity intervention|
224058032|NCT01535495|DRUG|Propranolol|Propranolol XL 120mg by mouth once daily
224058033|NCT00329667|DEVICE|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
224058034|NCT00078325|DRUG|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
224058035|NCT00078325|DRUG|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
224058036|NCT00078325|DRUG|Placebo|Matching placebo tablets once daily in the morning
224058037|NCT00037011|BIOLOGICAL|beta-glucan|
224058038|NCT00037011|BIOLOGICAL|monoclonal antibody 3F8|
224058039|NCT04126083|DRUG|Lofexidine Oral Tablet|lofexidine 0.54 mg 4 times daily
224058040|NCT03054922|DRUG|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
224058041|NCT03054922|DRUG|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
223569563|NCT05614908|OTHER|11 week restrictive regime|"As part of standard care at AUH (until May 2024), patients are immobilized in scotch cast with the foot in plantarflexion during week 0-4. Next, the scotch cast is replaced by a ROM-WALKER in plantarflexion for the next 7 weeks (week 5-11 after injury). The ROM-WALKER is gradually corrected from 30 degrees plantarflexion to 0 degrees. No weight bearing or exercises is allowed and they are not allowed to remove the ROM-WALKER during week 0-10. At week 11, the patients are allowed weight bearing up to 30 kg, after which there is no longer weight bearing restrictions.~From week 12 they are allowed full weight bearing with a 1 cm heel lift i their shoes."
223569564|NCT05614908|OTHER|8 week liberal regime|"The patients are treated with a walker orthosis with 3 wedges in plantarflexion, during week 1-2 with no weight bearing and no exercises. After 2 weeks, the tendon will be examined, and if no defect in the tendon is detected by palpation, the patients will start partially weight bearing in week 3-5, and full weight-bearing week 6-8. They are instructed in unloaded exercises for the calf and anklejoint after 2 weeks, and loaded exercises (elastic) after 5 weeks, with a maximum position til 0 degrees in the anklejoint. Balancetraining and stationary bike training after 7 weeks. The wedges are removed one by one after 3, 5 and 7 weeks, respectively.~If there is a palpable defect in the tendon after 2 weeks, the patient must wait 1 week with partially weight bearing and exercises, and remove the wedges at 4, 5 and 7 weeks after the initiation of treatment.~From week 9, walking i their shoes with a 1 cm heel lift."
223569565|NCT04652375|OTHER|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
224058042|NCT03054922|DRUG|Normosol-R Inj|IV infusion of Normosol throughout surgery.
224058043|NCT02840110|OTHER|ACTR T Cell Product|
224058044|NCT04133454|DRUG|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
224058045|NCT03858036|DRUG|Ricrolin+|1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
224058046|NCT03858036|DEVICE|VEGA UV-A system|The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
224058047|NCT05247814|GENETIC|Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism|All planned interventions are explorative analyses of biological and genetic risk profiles that can contribute to patients' individual risk for adverse drug reactions, i.e. due to variability in drug metabolism
224058048|NCT05247814|OTHER|Adverse Drug Reaction detection|During appointments in the university outpatient clinic, patients will undergo a comprehensive adverse drug reaction (ADR) assessment based on an ADR diary they were handed at enrolment
224058049|NCT05247814|OTHER|Falls Efficacy Scale International (FES-I)|The FES-I wil be obtained to estimate fear of falling
224058050|NCT00959998|OTHER|Self-administered Acupressure|
224058051|NCT02841098|OTHER|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
224058052|NCT02841098|DRUG|Optimal medical therapy alone|Optimal medical therapy alone
224058053|NCT01091584|DEVICE|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
224058054|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Citrate|450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
224058055|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Sulfate|450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
224058056|NCT03632590|DIETARY_SUPPLEMENT|Magnesium Oxide|450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
224058057|NCT03632590|DRUG|Placebo|The placebo capsules will contain starch (Amylum solani) for 24 weeks
224058058|NCT01434589|BEHAVIORAL|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
224058059|NCT00020618|DRUG|morphine sulfate|
224058060|NCT00020618|PROCEDURE|quality-of-life assessment|
224058061|NCT05289050|DRUG|sodium chloride (NaCl; 0.9%)|For patients in the control group,anaesthesia will be maintained with intravenous sodium chloride (NaCl; 0.9%) infusion.while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation,placebo-controlled infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
224058062|NCT05289050|DRUG|S-ketamine|For patients in the s-ketamine group,anaesthesia will be maintained with s-ketamine infusion（0.3mg/kg/h),while anaesthesia will be maintained with propofol infusion(4-12mg/kg/h),analgesia will be maintained with remifentanil(0.15-0.3ug/kg/min).The sufentanil dose at induction and the rate of intraoperative remifentanil and propofol infusions were at the discretion of the anesthesiologist in charge of the patient.The assessment of the depth of anesthesia was based on clinical evaluation.S-ketamine infusion will be stopped 15 minutes before the end of surgery.Propofol and remifentanil infusion will be stopped at the end of surgery.
224058063|NCT05280028|DRUG|Tibolone 2.5 mg|Tibolone 2.5 mg per day
224058064|NCT05280028|DRUG|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg|Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
224058065|NCT06099899|OTHER|interview|conduct in-depth interviews
223451023|NCT06955208|DIAGNOSTIC_TEST|Magnetic Resonance Elastography|Participants will undergo preoperative 3D MRE to quantify tumor stiffness and generate adhesion maps. MRE is performed as an adjunct to standard brain MRI, using 60 Hz vibration frequency and specialized elastogram processing software. The resulting stiffness and adhesion data are made available to the neurosurgical team for surgical planning.
224058066|NCT00445705|DRUG|placebo|Part A: Placebo every 12 hours for 4 weeks
224058067|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
224058068|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
224058069|NCT00445705|DRUG|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
224058070|NCT01582295|DRUG|Cabozantinib|Starting dose 40 mg daily
224058071|NCT02887014|PROCEDURE|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
223451024|NCT06955208|PROCEDURE|Intraoperative Assessment and Recording|During surgical resection, the neurosurgical team will systematically assess and record tumor stiffness, adhesion to surrounding structures, vascularity, resection time, and technical difficulty using a standardized intraoperative scale. These intraoperative findings will be compared to preoperative MRE parameters to evaluate the diagnostic and predictive value of MRE.
223451025|NCT02830399|DEVICE|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
223451026|NCT02830399|DEVICE|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
223451027|NCT02804048|OTHER|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
224058072|NCT01295476|GENETIC|gene expression analysis|
224058073|NCT01295476|GENETIC|microarray analysis|
224058074|NCT01295476|OTHER|laboratory biomarker analysis|
224058075|NCT04613154|DIETARY_SUPPLEMENT|magnesiumcitrate|Magnesiumcitrate 250 mg, Apoteket AB, Sweden
224058076|NCT04613154|DIETARY_SUPPLEMENT|Placebo|Ester-c
224058077|NCT05731258|DRUG|Liposomal doxorubicin containing regimen|Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
224058078|NCT01279850|DRUG|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
224058079|NCT01131520|BEHAVIORAL|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
224058080|NCT01131520|BEHAVIORAL|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
224058081|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
224058082|NCT02787187|PROCEDURE|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
223451028|NCT02804048|OTHER|superficial heat low back|Superficial heat application in the low back
223451029|NCT02804048|OTHER|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
223451030|NCT02804048|OTHER|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
223451031|NCT02804048|OTHER|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
224058083|NCT03762369|DRUG|CKD-351|twice a day
224058084|NCT03762369|DRUG|Latanoprost|once a day
224058085|NCT03762369|DRUG|D930|three times a day
224058086|NCT03762369|DRUG|Placebo of CKD-351|once a day
224058087|NCT03762369|DRUG|Placebo of CKD-351|twice a day
224058088|NCT03762369|DRUG|Placebo of D930|three times a day
224058089|NCT02372565|BEHAVIORAL|Facebook and text Message|Culturally-relevant physical activity promotion program
224058090|NCT02372565|BEHAVIORAL|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
224058091|NCT04960540|OTHER|MRI,|"In this project, multi-modal brain imaging methods, such as resting-state functional MRI, task-state functional MRI, structural MRI and diffusion tensor imaging, will be used to analyze brain structure, gray matter morphology, white matter fibrous brain functional activation mode and brain functional connectivity network, and other dimensions.~In particular, combined with the brain functional activities of ALS patients in the cognitive processing task of language understanding and language use, the brain network damage of ALS patients in motor and executive function was compared, and the neural activities and network mechanism of specific changes in language cognitive processing in ALS patients were investigated. Combined with the clinical neuropsychological behavior evaluation data"
224058092|NCT06443918|BEHAVIORAL|A Just-in-Time Adaptive Intervention for Child and Family Mental Health|Families in the intervention group will download an app on their smartphones. The app will deliver psychoeducational modules and family-based homework activities. It will include a component where AI is used to assess the quality of family-based interactions and provide in-the-moment feedback and coaching to guide the family interaction.
224058093|NCT01147744|DRUG|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
224058094|NCT01147744|DRUG|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
224058095|NCT01147744|DRUG|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
224058096|NCT01147744|DRUG|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
224058097|NCT01147744|DRUG|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
224058098|NCT01147744|DRUG|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
224058099|NCT01147744|DRUG|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
224058100|NCT01147744|DRUG|Placebo montelukast|Placebo capsule once daily in the evening
223451032|NCT02804048|OTHER|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
223451033|NCT05705921|RADIATION|Radiotherapy standard|Standard moderately hypofractionated radiotherapy in prostate cancer
223451034|NCT05705921|RADIATION|Radiotherapy Hypo-FLAME|Ultra-hypofractionated focal lesion ablative microboost in prostate cancer
223451035|NCT06515626|BIOLOGICAL|CAR-T cell reinfusion|Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
223451036|NCT04117542|OTHER|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
223451037|NCT06349239|OTHER|No intervention|Follow-up of disease
223451038|NCT00387972|DRUG|denagliptin (GW823093)|
223451039|NCT01329770|DIETARY_SUPPLEMENT|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"* Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~* Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
223451040|NCT01329770|DIETARY_SUPPLEMENT|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
223451041|NCT02362425|DRUG|N-acetylcysteine|
223451042|NCT02362425|DRUG|Placebo|
223451043|NCT00140036|PROCEDURE|Blood draw|
223451044|NCT06300879|PROCEDURE|Performing totally laparoscopic proximal gastrectomy with esophagogastrostomy by fissure technique|"Surgical Operation:~1. Gastric Resection Range:Proximal gastrectomy, preserving 2/3 of the distal stomach.~2. Lymph Node Dissection Range:D1+ to D2 lymph node dissection.~3. Anastomosis Method: esophagogastrostomy by fissure technique.~4. Anastomosis Risk Management Plan:For a rupture with a maximum diameter less than or equal to 5mm, repair with 4-0/3-0 absorbable sutures and proceed with the anastomosis.For a rupture with a maximum diameter greater than 5mm or failed anastomosis, resect that part of the remaining stomach, change to proximal gastrectomy, and perform double-channel anastomosis.~5. Surgical Approach:Totally laparoscopic proximal gastrectomy."
223451045|NCT00813878|GENETIC|protein analysis|protein analysis
223451046|NCT00813878|GENETIC|protein expression analysis|protein expression analysis
223451047|NCT00813878|GENETIC|proteomic profiling|proteomic profiling
223451048|NCT00813878|OTHER|diagnostic laboratory biomarker analysis|Performed one time on study
224058101|NCT01147744|DRUG|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
224058102|NCT01147744|DRUG|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
224058103|NCT02810847|DEVICE|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
224058104|NCT02293447|DRUG|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
224058105|NCT02293447|DRUG|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
223451049|NCT00813878|OTHER|immunohistochemistry staining method|Performed one time on study
223451050|NCT00813878|OTHER|liquid chromatography|Performed on samples collected one time on study
223451051|NCT00813878|OTHER|mass spectrometry|Performed on samples collected one time on study
223569566|NCT04652375|OTHER|Lactated Ringer's Solution|Participants will receive Lactated Ringer's solution for fluid resuscitation post-surgery.
223569567|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval recess group,we injected 20 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into into the Rotator cuff interval/anterior capsule.
223451052|NCT00813878|PROCEDURE|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
223451053|NCT00813878|PROCEDURE|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
223451054|NCT00813878|PROCEDURE|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
223741932|NCT03423628|DRUG|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0: 1 dose prior to Radiation Therapy. Cycle 1: 2 weeks Intermittent or continuous dosing during Radiation Therapy. Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. Note: the food effect assessment is currently open to recruitment.~Arm A includes the Japan part following the same dosing administration."
223451055|NCT04435899|OTHER|Physical exercise|Multi-modal exercise protocol
223741933|NCT03423628|RADIATION|Radiation Therapy|30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).
223741934|NCT03423628|RADIATION|Radiation Therapy|60 Gy of intensity- modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)
223741935|NCT03423628|DRUG|AZD1390|AZD1390 administered in 1 Cycle. AZD1390 administration concomitantly with RT (2 weeks). Cycle 1 also contains an additional 5 days (post completion of RT with AZD1390 administration). Arm is Closed.
223741936|NCT03423628|DRUG|AZD1390|"AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0: 1 dose prior to Radiation Therapy. Cycle 1: 6 weeks Intermittent or continuous dosing during Radiation Therapy. Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy. Arm is closed."
223741937|NCT06894420|PROCEDURE|Surgeon-Initiated Local Anesthetic|In laparoscopic hernia repairs, patients are positioned supine, and the surgical area is cleansed with povidone iodine and covered with sterile green drapes. A 1-centimeter incision will be made 1 centimeter below the umbilical border. A 10-mm trocar will be inserted into the preperitoneal space. The operation was filmed from the front with a 30-degree camera. After observing the preperitoneal space, two five-mm working trocars will be placed midline, two and six centimeters inferior to the symphysis pubis. Next, the cord structures and Cooper ligament will be exposed and the hernia sac freed from surrounding anatomical structures.Prolene mesh will be spread over the preperitoneal area to cover all hernia defects and secured to the Cooper ligament and abdominal wall with an absorbable fixation device. Group 1 patients undergo desufflation via 50 mg of bupivacaine into the preperitoneal space, followed by 10 mg of bupivacaine into each trocar incision and skin closure with sutures.
223741938|NCT06894420|PROCEDURE|Transversus abdominis plane (TAP) block|After the surgery, the anesthesiologist will use a TAP block under ultrasound guidance. Before the patient wakes up, the Hitachi ultrasound probe will be sterilized and positioned between the iliac wing and the costae. An ultrasound shows the skin, fat beneath it, the six abdominal muscle layers, and a support muscle.A thin needle goes through the skin from one side to the other to reach the muscle layers. The location of the block is confirmed by injecting 1-2 ml of 0.09% NaCl followed by negative aspiration. Patients receive 15-20 ml (40-50 mg per quadrant) of bupivacaine 0.5% concentration in a controlled manner with negative aspiration every 5 ml. The block is performed bilaterally.
223741939|NCT05964829|DEVICE|Cionic Neural Sleeve NS-100|The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.
223451056|NCT04972422|DRUG|ZN-c3|ZN-c3 is a study drug
223451057|NCT02624882|PROCEDURE|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~* Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~* Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
223451058|NCT02624882|PROCEDURE|Negative rapid GAS test|Usual care
223569568|NCT06553716|PROCEDURE|Ultrasound-Guided Hydrodilatation by the Rotator cuff interval and posterior glenohumeral recess|The injection contained 5ml of triamcinolone acetonide (40 mg)mixed with 5ml of 2% lidocaine hydrochloride and 15ml of normal saline in both groups,In the Rotator cuff interval and posterior glenohumeral recess group,we injected 10 mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the Rotator cuff interval/anterior capsule and 10 mL mL lidocaine with 2 mg/mL triamcinolone acetonide (Shincort) into the posterior glenohumeral.
223741940|NCT05964829|BEHAVIORAL|Walking Program|15 minutes of walking for 5 days per week for 6 weeks
224058106|NCT01788033|DRUG|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
224058107|NCT01788033|DRUG|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
224058108|NCT00089050|DRUG|cyclosporine|
224058109|NCT00089050|DRUG|gemtuzumab ozogamicin|
224058110|NCT05369104|BIOLOGICAL|Anti-Staphylococcus aureus Bacteriophages|Single intra-articular injection
224058111|NCT04721470|PROCEDURE|Combined therapy|Patients undergoing combined therapy
224058112|NCT04721470|PROCEDURE|Microwave ablation|Patients undergoing Microwave ablation
223569569|NCT00764543|DEVICE|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
223451059|NCT03190785|OTHER|Benzoic acid washout and exposure|see above
223569570|NCT02258971|DRUG|BEA 2180 BR oral|Oral solution
223569571|NCT02258971|DRUG|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
224058113|NCT04721470|PROCEDURE|Transarterial chemoembolization|Patients undergoing Transarterial chemoembolization
223451060|NCT01456546|DRUG|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
223569572|NCT05264987|OTHER|intensive care follow-up|The need for the mechanical ventilator, the length of stay in the intensive care unit, and outcomes of mothers were recorded. Deceased patients were evaluated in detail.
223569573|NCT04225676|BIOLOGICAL|Tisagenlecleucel|"Tisagenlecleucel Cell Dispersion for Infusion given once during the study.~The approved dose range for tisagenlecleucel is: 0.2 to 5.0×106 CAR positive viable T cells / kg for patients' ≤ 50 kg body weight or 0.1 to 2.5×108 CAR-positive viable T cells for patients \> 50 kg body weight."
223569574|NCT03245736|DRUG|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
223569575|NCT01853579|DRUG|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
223569576|NCT01853579|DRUG|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
223569577|NCT04159987|OTHER|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
223569578|NCT00006042|BIOLOGICAL|filgrastim|
223569579|NCT00006042|DRUG|cyclophosphamide|
223569580|NCT00006042|DRUG|fludarabine phosphate|
223451061|NCT01456546|DRUG|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
223451062|NCT05693324|BEHAVIORAL|Minority stress|Intervention based on Cognitive Behavioural and Compassion Focused Treatments
223741941|NCT06912737|BEHAVIORAL|Group Emotion Focused Behavioral Intervention (G-EFBI)|Group EFBI (G-EFBI) is aimed at assisting people with T2D to gain knowledge about emotions and improve their ability to regulate and manage their emotions.
223741942|NCT06912737|BEHAVIORAL|Group - With Every Heartbeat is Life (G-WEHL)|G-WEHL is an educational intervention designed to increase awareness and prevention of cardiovascular disease.
224058114|NCT02941705|BIOLOGICAL|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
224147148|NCT05090358|DRUG|Alpelisib|The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
223451063|NCT04966650|BEHAVIORAL|5-mins brief nursing advice incorporating with Social Cognitive Theory (SCT)|The protocol is about the relationship between exercise and mental health, the advantages of increase physical activity and regular exercise, and highlight the consequence if not deal with the depressive symptoms.
223451064|NCT04660786|DRUG|triamcinolone acetonide|local immunosuprresent
223451065|NCT04660786|DRUG|vitamin D|local immunomodulator
223451066|NCT06087315|OTHER|Multi-faceted oxygen systems strengthening interventions (different for each country)|The specific approaches are different in each country but broadly include efforts to: (1) strengthening policies, strategies, and governance of medical oxygen production, distribution, maintenance, and use; (2) building capacity of healthcare workers and technicians to use and maintain oxygen well, and (3) strengthening oxygen-related data acquisition and use for forecasting, budgeting, and monitoring.
223451067|NCT00802672|DRUG|Ciclopirox Olamine Cream|topical cream
223451068|NCT00802672|DRUG|Loprox Cream 0.77%|topical cream
223451069|NCT00802672|DRUG|Placebo|topical cream
223569581|NCT00006042|DRUG|mycophenolate mofetil|
223569582|NCT00006042|DRUG|tacrolimus|
223569583|NCT00006042|PROCEDURE|allogeneic bone marrow transplantation|
223569584|NCT00006042|RADIATION|radiation therapy|
223569585|NCT00666497|DRUG|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
223451070|NCT00006244|DRUG|melphalan|Given IV
223451071|NCT00006244|BIOLOGICAL|recombinant interferon alfa|Given SC
223451072|NCT00006244|BIOLOGICAL|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
223451073|NCT00006244|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
223451074|NCT02349139|DRUG|ASN001: Escalating dose Part A|Androgen inhibitor
223569586|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
223569587|NCT00666497|DRUG|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
223569588|NCT04675658|BEHAVIORAL|CBPA + family support|Classroom Based Physical Activity + family support as described in the Arm
223569589|NCT04675658|BEHAVIORAL|CBPA|Classroom Based Physical Activity
223569590|NCT02417116|OTHER|Tear supplement|Application as required to improve comfort
223569591|NCT02417116|OTHER|Tear supplement 2|Application as required to improve comfort
223741943|NCT06337864|OTHER|PreKUnil® LNAA Medical Food for PKU|PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU.
224147149|NCT05090358|DRUG|Fulvestrant|"The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter."
224058115|NCT02941705|BIOLOGICAL|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
224058116|NCT02669966|PROCEDURE|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
224058117|NCT01342484|DRUG|placebo|comparison of different dosages of drug (low vs high) vs placebo
224058118|NCT01342484|DRUG|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
224058119|NCT01342484|DRUG|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
224058120|NCT01840579|BIOLOGICAL|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
224058121|NCT01840579|BIOLOGICAL|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
224058122|NCT01840579|BIOLOGICAL|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
224058123|NCT01840579|DRUG|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
224058124|NCT01840579|DRUG|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
224058125|NCT01840579|DRUG|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
224058126|NCT01840579|DRUG|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
224058127|NCT01840579|DRUG|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
224058128|NCT01840579|DRUG|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
224058129|NCT01840579|BIOLOGICAL|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
224058130|NCT01840579|DRUG|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
224058131|NCT01840579|DRUG|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
224058132|NCT04171479|DEVICE|Epicardial mapping and/or ablation|Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
224058133|NCT00480818|DRUG|SAM-531|
224058134|NCT04350528|DRUG|Chlorpromazine or Pentobarbital|Sedation
224058135|NCT05780255|DEVICE|VV-ECMO|veno-venous extracorporeal membrane oxygenation
223569592|NCT02417116|DIETARY_SUPPLEMENT|Omega 3 nutrition supplement|Taken each day
224058136|NCT01829971|DRUG|MRX34|micro RNA therapy
223569593|NCT02417116|DEVICE|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
223569594|NCT02417116|OTHER|Saline|Application as required to improve comfort
224058137|NCT01671540|DEVICE|intrapulmonary percussive ventilation|
224058138|NCT01671540|OTHER|standard treatment|breathing control exercises
224058139|NCT01889082|BEHAVIORAL|Behavioral Weight Loss Intervention for Young Adults|
223569595|NCT04284735|OTHER|Quantitative ATX and LPA determination in plasma and sputum|"Determination of ATX and LPA levels in plasma and sputum from RA-ILD patients (cases) and in plasma and sputum from RA patients without ILD (controls) after sputum induction using hypertonic saline inhalation"
224058140|NCT01892163|DEVICE|Ozurdex|Dexamethasone implant (Ozurdex)
224058141|NCT04919291|DEVICE|Topoguided LASIK|Topoguided ablation profile on dominant eye
224058142|NCT04919291|DEVICE|Wavefront optimized LASIK|Wavefront optimized ablation profile on non-dominant eye
224058143|NCT00554567|BEHAVIORAL|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
224058144|NCT01289236|DRUG|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
224058145|NCT01289236|DRUG|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
224058146|NCT01289236|DRUG|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
224058147|NCT02361541|PROCEDURE|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
224058148|NCT00262210|DRUG|Cyclophosphamide Epirubicin Etoposide Prednisolone|
224058149|NCT01014325|BIOLOGICAL|Allergen extract|sublingual application
224058150|NCT01014325|BIOLOGICAL|Placebo|sublingual application
224058151|NCT03302975|DEVICE|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
224058152|NCT03493087|DIETARY_SUPPLEMENT|Menakinon 7|Menakinon 7 - One tablet a day against vitamin K deficiency
224058153|NCT03493087|DIETARY_SUPPLEMENT|Diet rich in vitamin K|Diet with large content of vegetables and dairy products
224058154|NCT01552291|DIETARY_SUPPLEMENT|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
224058155|NCT01552291|DRUG|Placebo|30g oral maltodextrin / day for 5 days before surgery
224058156|NCT00542295|DRUG|alverine citrate and simeticone|
224058157|NCT00542295|DRUG|placebo|
224058158|NCT01924182|DEVICE|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
223451075|NCT04077749|BIOLOGICAL|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
223451076|NCT04077749|OTHER|Normal Saline|50 mL normal saline at room temperature
224058159|NCT01924182|OTHER|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
223451077|NCT05903755|DEVICE|speed dependent treadmill training on moderate speed|Experimental group will receive 14 session of speed dependent treadmill training on moderate speed (3 to 6) for 25 minutes along with strengthening, stretching and range of motion exercises.
224058160|NCT01446406|DEVICE|MONARCA|Monitoring affective symptoms entered by the patient every day.
223451078|NCT05903755|DEVICE|speed dependent treadmill training on slow speed|Control group will receive 14 session of speed dependent treadmill training on slow speed (1 to 2) for 25 min along with physiotherapy.
223569596|NCT03110653|DRUG|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
223569597|NCT03110653|DRUG|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
224058161|NCT01446406|DEVICE|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
224058162|NCT04191330|DEVICE|BiovitalsHF|BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
224058163|NCT00037570|DRUG|Pantoprazole|
224058164|NCT02705924|BEHAVIORAL|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
224058165|NCT06262958|BEHAVIORAL|ASSIST|Adolescent psychiatric outpatient will be offered an e-form of ASSIST alcohol and substance use mini-intervention. Results will be compared to those who received TAU.
224058166|NCT06262958|OTHER|Treatment as usual|Psychotherapy and/or psychotropic drug treatment
224058167|NCT02258451|DRUG|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)
224058168|NCT02258451|DRUG|Placebo (saline)|Up to 6 cycles of saline injection
224058169|NCT02258451|DRUG|Exemestane|One 25 mg tablet once daily after a meal.
223569598|NCT03833271|BIOLOGICAL|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
223569599|NCT05143723|DRUG|Gonadotropin-releasing hormone agonist|luteal phase support with gonadotropin-releasing hormone agonist
223569600|NCT02927704|OTHER|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
224058170|NCT02258451|DRUG|Everolimus|"The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice."
224058171|NCT05771220|OTHER|radial extracorporeal shockwave therapy+ evidence-based physical therapy|The experimental group received six sessions of rESWT over six weeks in addition to an EBPT program. The rESWT procedure involved applying shockwaves to the affected area using a radial probe, with sessions lasting 10-15 minutes and consisting of up to 2000 impulses delivered at a frequency of 3-6 pulses per second and an energy intensity level of 1.8 bar, based on patient tolerance. Patients were seated or lying down during the rESWT procedure, with gel or oil applied to facilitate shockwave transmission through the skin. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
224058172|NCT05771220|OTHER|sham radial extracorporeal shockwave therapy+ evidence-based physical therapy|The participants in the control group received six weeks of sham rESWT (radial extracorporeal shock wave therapy) combined with the EBPT (evidence-based physical therapy) program. The sham rESWT involved six sessions with a maximum of 200 impulses delivered at a low intensity, with the applicator placed on the affected area for the same duration as the experimental group. Additionally, participants received a 30-minute exercise program twice a week for 6 weeks, which included hot packs, stretching, range of motion exercises, and isometric shoulder and scapular exercises. They were also instructed to perform the same exercises at home daily.
223451079|NCT01437371|DRUG|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
223451080|NCT04825925|DEVICE|DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)|Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, the Platinum was infused. BAI (Bronchial Arterial Infusion ) chemotherapy was followed by DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with Vinorelbine were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed.
223451081|NCT04424472|DIAGNOSTIC_TEST|Ultrasonography|Abdominal Ultrasonography
223451082|NCT05773339|OTHER|AIMS65 score|"The AIMS65 score consists of five factors:~(i)albumin (1 point for value less than 3.0 g/dL (30 g/L)). (ii)INR (1 point for value greater than 1.5) . (iii)altered mental status (1 point given if Glasgow coma score was less than 14 or if disorientation, lethargy, stupor, or coma was seen) (iv)systolic blood pressure (1 point for value less than 90 mmHg). (v)age (1 point for value greater than 65 years)."
223451083|NCT01616758|DRUG|GTx-024 9mg|
223451084|NCT03116295|DRUG|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
223451085|NCT03067922|OTHER|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
223451086|NCT05325372|PROCEDURE|axillary block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
223451087|NCT05325372|PROCEDURE|infraclavicular block|it will be given using 20 ml of drug 0.25% bupivacaine (10 ml 0.5% bupivacaine + 10 ml normal saline).
223451088|NCT01044368|OTHER|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
223451089|NCT01247389|PROCEDURE|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
223451090|NCT00222014|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
223451091|NCT00222014|PROCEDURE|Paracenthese|Paracenthese
223451092|NCT01137656|DRUG|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
223451093|NCT02904395|OTHER|observational (no intervention)|
223451094|NCT00087464|DRUG|Emtricitabine|
223451095|NCT00087464|DRUG|Nevirapine|
223569601|NCT05358431|OTHER|Neuroimaging and electrophysiology|Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
223741944|NCT07115212|DIETARY_SUPPLEMENT|Bromelain|1 tablet daily with water, for 9 days-starting 2 days before surgery and continuing for 7 days after. Record each dose in the provided log, along with any other medications taken and the time they were taken.
224058173|NCT04991025|DRUG|Cisplatin|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
224058174|NCT04991025|DRUG|Pemetrexed|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
224058175|NCT04991025|DRUG|Gemcitabine|Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
224058176|NCT04991025|DRUG|Carboplatin|Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
224058177|NCT04991025|DRUG|Certolizumab|Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
224058178|NCT04991025|DRUG|Nivolumab|Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
224058179|NCT06321432|BEHAVIORAL|Intensive weight loss intervention|Intensive weight loss intervention, incl. total meal replacements, behavioural support, and weight loss medication.
224305056|NCT05035342|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) capsules|Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
223451096|NCT00087464|DRUG|Tenofovir disoproxil fumarate|
223451097|NCT03026283|DEVICE|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
223451098|NCT02328482|DRUG|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
223569602|NCT03946982|PROCEDURE|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
223741945|NCT07114198|DRUG|Ibuprofen 10 mg/kg|Ibuprofen was administered orally at a dose of 10 mg/kg body weight, 40 minutes before the start of the dental procedure. This intervention was designed to reduce intraoperative pain and pulse elevation associated with reversible pulpitis.
223451099|NCT06224218|PROCEDURE|Single Port Robotic Surgery|Single port Robotic surgery will remove the whole prostate
223451100|NCT06224218|PROCEDURE|Laser Surgery|Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
223569603|NCT03946982|PROCEDURE|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
224058180|NCT06321432|BEHAVIORAL|Usual care|Usual care
224058181|NCT05236556|BEHAVIORAL|Best practice advisory (BPA)|"For patients who are not on oral anticoagulation (AC) but have elevated stroke risk, the practice advisory will fire, which is to say it will be active in the providers workflow during outpatient encounters with a patient's primary care provider (PCP) or cardiology provider."
223451101|NCT05194241|BEHAVIORAL|One MORE|One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into four, 30-minute segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Mindful pain management will be the focus of the second segment and participants will be guided through a mindfulness of pain practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The third segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, and the fourth segment will focus on increasing the positive emotions that can attenuate pain with mindful savoring.
223451102|NCT03403452|DRUG|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
223569604|NCT05160519|RADIATION|Class IV Laser|"30 participants will be irradiated with Class IV laser therapy over the left parasternal area to examine the efficacy of class IV laser on ejection fraction, Cardiac Biomarker and functional outcomes.~Device: Litecure LCT-1000C Class IV laser will be used in contact method over the left parasternal area in 2nd, 3rd intercostal space and apex. Dosage and Parameters for the irradiation will be calculated. Parameters: 1. Wavelength: 980nm, 2. Power/ Energy density: 6W/6J/cm2 3. Frequency: CW 4. Energy delivered at each spot: 360J 5. irradiation spots: 3 6. Irradiation time: 60 sec at each spot.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
224058182|NCT05944926|BEHAVIORAL|Healthy Activity Program (HAP)|HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
224058183|NCT05944926|DRUG|Antidepressant medication (fluoxetine)|Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
224058184|NCT05914766|BEHAVIORAL|PATHWAYS|The PATHWAYS intervention is a psychoeducational intervention comprised of four behavioral coaching sessions and a patient education guidebook.
224058185|NCT05914766|OTHER|Enhanced usual care|The enhanced usual care condition consists of an information resource guide.
224058186|NCT06850766|OTHER|Morning administration of TMZ|Administration of TMZ within 2 hours of waking
224058187|NCT06850766|OTHER|Evening administration of TMZ|Administration of TMZ within 2 hours of bedtime
224058188|NCT03674229|OTHER|Informational Intervention|Receive information about weight management programs
224058189|NCT03674229|OTHER|Questionnaire Administration|Ancillary studies
224058190|NCT03674229|BEHAVIORAL|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
224058191|NCT04630587|PROCEDURE|Indirect restorations|see the Arm description
224058192|NCT02289651|DEVICE|Venner|Video-laryngoscopy
223451103|NCT00005822|DRUG|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
223451104|NCT00005822|DRUG|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
223451105|NCT00005822|PROCEDURE|conventional surgery|Patients undergo a modified radical mastectomy.
223451106|NCT00005822|RADIATION|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
223451107|NCT00005822|DRUG|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
224058193|NCT02289651|DEVICE|Miller|Direct-Laryngoscopy
224058194|NCT05803200|DRUG|No intervention|No intervention was given as this is an observational study.
224058195|NCT03067571|BIOLOGICAL|Daratumumab|Given IV
224058196|NCT06967142|DEVICE|Correcte Carotid flow measurement by USG Doppler|Aim of this study is to investigate the usability of changes in corrected carotid flow time induced by lung recruitment maneuvers during protective lung ventilation (6 ml/kg tidal volume) in patients undergoing elective Coronary Artery Bypass Graft Surgery (CABG) to evaluate fluid responsiveness. The secondary objective is to determine the correlation between measurements taken before and after sternotomy. This study aims to reduce invasive procedures used for assessing fluid responsiveness and develop an alternative method to the use of hard-to-access devices for measurements.
224058197|NCT02836028|DRUG|Talazoparib|Talazoparib monotherapy 1mg/day orally
224058198|NCT02836028|DRUG|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
224070753|NCT03124563|BEHAVIORAL|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
224070754|NCT03124563|BEHAVIORAL|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
224070755|NCT01534533|DIETARY_SUPPLEMENT|Placebo|one gelatine capsule containing starch per day, for 12 months
224070756|NCT01534533|DIETARY_SUPPLEMENT|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
224070757|NCT01534533|DIETARY_SUPPLEMENT|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
224070758|NCT01534533|DIETARY_SUPPLEMENT|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
223451108|NCT04094116|PROCEDURE|ear wax syringing without pre ear oil treatment|Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
223451109|NCT02797145|DRUG|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
223451110|NCT02797145|DRUG|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
223569605|NCT05160519|RADIATION|Sham Class IV Laser|"30 participants in sham control group will be suppose to irradiate with Class IV laser therapy over the left parasternal area, but the radiation will not be delivered.~Device: Litecure LCT-1000C Class IV laser will be placed over the left parasternal area in 2nd, 3rd intercostal space and apex without switching on the instrument.~Both the patient and laser giver will use the laser protected eye wears to ensure standard practice for the laser."
223569606|NCT01247363|DRUG|LY2608204|Administered orally.
223569607|NCT01246479|PROCEDURE|Blood draw|blood draw at Month 12, Month 24 and Month 36.
223569608|NCT01246479|BIOLOGICAL|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
223569609|NCT00001724|DRUG|Flurbiprofen|
223569610|NCT06010381|OTHER|Muscle energy technique|It was applied on the shoulder flexion and the external rotation. An isometric contraction of the agonist muscle (the muscle which requires stretching) for 7 seconds with gentle muscle contraction to avoid the risk of increasing the muscle tone. This contraction started just short of the restrictive barrier. After that, the patient is asked to relax for 2-3 seconds and then the therapist stretches the contracted muscle in the opposite direction for 30 seconds. This is repeated three repetitions for each muscle.
223569611|NCT06010381|OTHER|Maitland mobilization|At the start of each session, the physical therapist examined the patient's ROM in all directions to obtain information about the end-range position and the end feel of the glenohumeral joint. Start with rhythmic mid-range mobilization with the patient in a supine position. The therapist's hands are placed close to the glenohumeral joint, and the humerus is brought into a position of maximal flexion in the sagittal plane. After 10 to 15 repetitions of intensive mobilization techniques in this end-range position, the direction of mobilization will be altered by varying the plane of elevation or by varying the degree of rotation. When alternating the direction of mobilization, other movements such as gliding techniques and distraction in that joint position were (inferior gliding, anterior gliding, and posterior gliding).
223741946|NCT06913192|BIOLOGICAL|CAR-T|All enrolled patients will receive three cycles of induction therapy using either the DVRd regimen (Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone) or the DKRd regimen (Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone). Following induction, patients will undergo high-dose melphalan conditioning followed by autologous hematopoietic stem cell transplantation. On Day 5 after stem cell reinfusion, patients will receive anti-BCMA CAR-T cell infusion. After CAR-T therapy, patients will enter the maintenance phase with lenalidomide monotherapy or lenalidomide in combination with bortezomib until disease progression or intolerable toxicity occurs.
223741947|NCT06913101|DRUG|Trelagliptin 100 mg|Trelagliptin 100 mg was administered orally once weekly before breakfast on the same day of the week.
223741948|NCT06913101|DRUG|Vildagliptin 50 mg|Vildagliptin 50 mg was administered orally once daily.
223741949|NCT06921785|DRUG|Tremelimumab|IV therapy
223569612|NCT06010381|OTHER|Traditional shoulder exercise|Traditional shoulder exercises in the form of shoulder range of motion exercises, stretching exercises and, scapular stabilization.
223569613|NCT02707393|DRUG|Fludarabine|infusion
223569614|NCT02707393|DRUG|Thiotepa|infusion
223569615|NCT02707393|DRUG|Melphalan|infusion
223741950|NCT06921785|DRUG|Rilvegostomig|IV therapy
224058199|NCT03087188|OTHER|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
223451111|NCT05937516|DEVICE|Nasotracheal intubation with conventionally|Nasotracheal intubation will be applied conventionally to patients in this group.
223569616|NCT02707393|DRUG|ATG|infusion
223569617|NCT02707393|DRUG|Cyclosporine A|infusion, orally if possible
223569618|NCT02707393|DRUG|Mycophenolate mofetil|infusion
223569619|NCT02707393|BIOLOGICAL|bone marrow or peripheral blood stem cells|infusion
223741951|NCT06921785|DRUG|Bevacizumab|IV therapy
224058200|NCT01440270|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
223741952|NCT06921785|DRUG|Atezolizumab|IV therapy
224058201|NCT03598816|DRUG|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
224058202|NCT03598816|DRUG|Tremelimumab|-Tremelimumab will be administered first
223741953|NCT06924827|DRUG|Epidiolex 100 mg/mL Oral Solution|The participant's 'artisanal' CBD and Epidiolex dose should be taken consistently with food or consistently without food throughout the entire study. The participant's dosing with or without food should be consistent with their method of dosing of 'artisanal' CBD prior to screening. Oral administration is recommended. When necessary, Epidiolex can be enterally administered via silicone feeding tubes, such as nasogastric or gastrostomy tubes.
224058203|NCT03598816|DEVICE|TDS-IM v1.0 System|-Integrated electroporation device
224058204|NCT03598816|BIOLOGICAL|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
224058205|NCT03598816|PROCEDURE|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
224058206|NCT02281032|OTHER|interRAI PC|"PREPARATORY PHASE~* Step 0: Introductory information~* Step 1: Training on the interRAI PC and the BelRAI webapplication~* Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~* Step 3: Identification of residents with palliative care needs, based on the surprise question~* Step 4: Informed consent signature requirements~* Step 5: Login to the BelRAI webapplication~* Step 6: Definitions of roles and functions~* Step 7: Completion of the interRAI PC~* Step 8: Interpretation of results~* Step 9: Use of results"
223451112|NCT05937516|DEVICE|Nasotracheal intubation with angled ETT using guidewire|a guide wire will be inserted into the ETT before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). The angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. The ETT will be positioned perpendicular to the face and inserted into the nostril. After the angled part of the ETT passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ETT. Meanwhile, the ETT will be moved as a whole to prevent the ETT tip from contacting the posterior wall of the nasopharynx. When the ETT tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.
223451113|NCT03782571|DEVICE|etafilcon a Test 1|1-DAY ACUVUE® MOIST
223451114|NCT03782571|DEVICE|etafilcon A Test 2|1-DAY ACUVUE® MOIST for ASTIGMATISM
223451115|NCT03782571|DEVICE|etafilcon A Test 3|1-DAY ACUVUE® MOIST MULTIFOCAL
223451116|NCT03782571|OTHER|Control|Bare Eye
223569620|NCT06408675|OTHER|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.|Visual Analog Scale (VAS), QOL (36-Item Short Form Survey (SF-36)), and Neck Disability Index (NDI) were used to assess pain, overall quality of life, functional disability respectively.
223741954|NCT07205120|DEVICE|Heart Failure Management Intervention|Participants will receive access to their weight and fluid levels on the Cardiac Scale and through the Bodyport Patient Portal. The provider will receive access to the Congestion Index, alerts, and Clinical Dashboard to support the remote management of the participant. The provider will receive a notice when an alert is generated and twice weekly reminders until the Congestion Index returns below an alert threshold. When an alert is generated, providers will attempt to contact the participant and will be encouraged to follow the recommendations contained within the ARG. Providers will also be encouraged to provide feedback and suggest improvements to the ARG throughout the study. Any changes to medical therapy resulting from an alert will be documented in the Bodyport Clinical Dashboard.
224058207|NCT03375398|DIETARY_SUPPLEMENT|Rice|Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water
224058208|NCT03375398|DIETARY_SUPPLEMENT|Sugardown™|Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
224058209|NCT05693636|PROCEDURE|Total wrist arthroplasty|Two different surgical interventions for treatment of end-stage arthritis are compared
224058210|NCT06304805|DRUG|cycle 1: treatment drug|for cycle 1 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
223451117|NCT01533961|DRUG|SCYX-7158|
223451118|NCT01533961|DRUG|Placebo|
223451119|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
223451120|NCT00786253|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
223451121|NCT03222453|BIOLOGICAL|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
223451122|NCT05165719|DIAGNOSTIC_TEST|Corona-T-test|Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells
223451123|NCT03295032|BEHAVIORAL|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
223451124|NCT00950729|PROCEDURE|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
223451125|NCT00950729|PROCEDURE|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
223451126|NCT00950729|PROCEDURE|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
223451127|NCT03565705|PROCEDURE|Open abdominal prostatectomy|Patients undergo standardized open abdominal prostatectomy.
223451128|NCT02187237|DEVICE|YOLO TOUCH Low Level Laser|
223569621|NCT02978547|DRUG|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
223741955|NCT07205575|DIAGNOSTIC_TEST|Proteomic Biomarker Panel|A blood-based ELISA test measuring circulating ICAM1, CFHR5, and GRN. Index test performance will be evaluated against microbiological gold standards and adjudication.
224058211|NCT06304805|DRUG|cycle 1: reference drug|for cycle 1 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
224058212|NCT06304805|BEHAVIORAL|cycle 1: fasted|for cycle 1 treatment: participants are asked to take the drug fasted
224058213|NCT06304805|BEHAVIORAL|cycle 1: food|for cycle 1 treatment: participants are asked to take the drug after food intake
224058214|NCT06304805|DRUG|cycle 2: treatment drug|for cycle 2 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
224058215|NCT06304805|DRUG|cycle 2: reference drug|for cycle 2 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
223451129|NCT04618991|OTHER|Filling the Quebec Sleep Questionnaire|Filling the Quebec Sleep Questionnaire (QSQ) by the pre-surgery patient, then at 3 months post surgery and 1 year post surgery.
223569622|NCT01106859|DRUG|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
224058216|NCT06304805|BEHAVIORAL|cycle 2: fasted|for cycle 2 treatment: participants are asked to take the drug fasted
224058217|NCT06304805|BEHAVIORAL|cycle 2: food|for cycle 2 treatment: participants are asked to take the drug after food intake
224058218|NCT06304805|DRUG|cycle 3: treatment drug|for cycle 3 treatment: participants are given the oral treatment specification (60 mg \*1 pill)
224058219|NCT06304805|DRUG|cycle 3: reference drug|for cycle 3 treatment: participants are given the oral reference specification (5 mg \*2 pills + 25 mg \* 2 pills)
224058220|NCT06304805|BEHAVIORAL|cycle 3: fasted|for cycle 3 treatment: participants are asked to take the drug fasted
224058221|NCT06304805|BEHAVIORAL|cycle 3: food|for cycle 3 treatment: participants are asked to take the drug after food intake
224058222|NCT05081479|DRUG|N-Acetylcysteine|N-AC infusion will begin the day before CAR T cell infusion and continuously infused over 24-hours for 14 days or until time of discharge whichever is earlier. Interruptions of N-AC infusion for medical reasons are permissible. The dose for patients \<45kg will be adjusted to weight based dosing.
224058223|NCT04730622|DIAGNOSTIC_TEST|SARC-F questionnaire|Assessment of muscle performance based on self-reported information about grip strength, assistance with walking, rising from a chair, climbing stairs, and falls.
223451130|NCT02511132|BIOLOGICAL|Vigil|Vigil 1.0 x 10e7 cells/injection, minimum of 4 to a maximum of 12 administrations.
223451131|NCT02511132|DRUG|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
223451132|NCT02511132|DRUG|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
223569623|NCT01106859|DRUG|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223569624|NCT01106859|DRUG|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
223569625|NCT01106859|DRUG|Placebo|Placebo matching zopiclone
223569626|NCT00438269|DRUG|Site-specific empiric regimens included: Meropenem|
224058224|NCT04730622|DIAGNOSTIC_TEST|Bone tissue histology|Assessment of histomorphology and matrix-structure of tissue samples obtained from the bone resected during the hip prosthesis positioning.
224058225|NCT04730622|DIAGNOSTIC_TEST|Muscle tissue histology|Assessment of histomorphology and ultrastructure of muscle biopsies taken from the upper portion of the vastus lateralis muscle, which is accessed in the surgical procedure of hip replacement.
224058226|NCT04730622|DIAGNOSTIC_TEST|Myostatin serum levels|Quantification of circulating myostatin, a muscle-specific biomarker that suppresses muscle growth and bone formation.
224058227|NCT04730622|DIAGNOSTIC_TEST|Insulin-like growth factor 1 (IGF-1) serum levels|Quantification of circulating IGF-1, a growth factor that promotes muscle growth and osteogenesis.
224058228|NCT04730622|OTHER|Frequency food questionnaire|Assessment of dietary habits based on self-reported information about the monthly- weekly- or daily-frequency consumption of main food groups, including cereals and bread, meat, fish, fruit, vegetable, legumes, dairy products, sweets and snacks, drinks, and dietary supplements.
224058229|NCT04730622|OTHER|Gut microbiota profiling|Assessment of gut microbiome composition on stool samples.
224058230|NCT04473690|BIOLOGICAL|Low Dose of KBP-COVID-19|Low Dose of KBP-COVID-19 and adjuvant
223451133|NCT02511132|DRUG|Gemcitabine|675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
223451134|NCT02511132|DRUG|Docetaxel|75 mg/m2 IV administered on Day 8 and every 21 days
223451135|NCT00240968|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
223451136|NCT04297696|OTHER|Therapeutic exercises|A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
223569627|NCT00438269|DRUG|Piperacillin/tazobactam|
223569628|NCT00438269|DRUG|Ciprofloxacin and cefazolin +/- metronidazole|
223569629|NCT00246051|BEHAVIORAL|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
223741956|NCT07205731|DRUG|Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1|It is the first study which evaluate efficacy and safety of anti PD-1 immune checkpoint inhibitor alone in the first-line treatment of elderly esophageal squamous-cell carcinoma patients who no fit to received chemotherapy with platine
223741957|NCT07205770|OTHER|PNF|Applying to the extensor muscles for 30 seconds
223741958|NCT07205770|OTHER|Passive Stretching|Applying to the extensor muscles for 30 seconds
224058231|NCT04473690|BIOLOGICAL|High Dose of KBP-COVID-19|High Dose of KBP-COVID-19 and adjuvant
224058232|NCT04473690|BIOLOGICAL|Placebo|Buffered saline solution
224058233|NCT00118391|BEHAVIORAL|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
224058234|NCT00118391|BEHAVIORAL|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
224058235|NCT06268444|DEVICE|7-day actimetry sleep recording|7-day actimetry sleep recording
224058236|NCT06268444|OTHER|Determination of environmental pollutants in breast milk|Determination of environmental pollutants in breast milk
224058237|NCT06268444|OTHER|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child|Measurements of environmental pollutants in indoor air deposited on the bracelet worn by the child
224058238|NCT06268444|OTHER|Continuous recording of the child&#39;s temperature for 7 days|Continuous recording of the child\&#39;s temperature for 7 days
223569630|NCT00246051|OTHER|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~1. Positive on the Berlin Questionnaire~2. Clinic visit, exam with a physician, given a home diagnostic device (HDD)~3. High risk on HDD, seen by physician, given a CPAP machine~4. Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~5. Contacted by a sleep health clinic at 3, 6, 12 months~6. After 12 months subject will be referred to their primary care physician"
223569631|NCT00246051|OTHER|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
223569632|NCT00416663|PROCEDURE|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
223569633|NCT01477463|DRUG|Vitamin D3|4,000 IU oral vitamin D3
223569634|NCT01477463|DRUG|placebo and vitamin D|
223569635|NCT04563728|BEHAVIORAL|Surveillance camera(s)|the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
223569636|NCT00354107|BIOLOGICAL|monoclonal antibody SGN-30|Given IV
224058239|NCT06268444|OTHER|Use of a sleep diary for 7 days|Use of a sleep diary for 7 days
224058240|NCT06268444|OTHER|Parental questionnaire of environmental exposure|Parental questionnaire of environmental exposure
223569637|NCT00354107|DRUG|therapeutic hydrocortisone|Given IT
224058241|NCT06460064|BIOLOGICAL|fH1 2 ug|2 administrations at 3-week intervals.
224058242|NCT06460064|BIOLOGICAL|fH1 8 ug|2 administrations at 3-week intervals.
224058243|NCT06460064|BIOLOGICAL|DSP-0546LP 2.5 ug|2 administrations at 3-week intervals.
224058244|NCT06460064|BIOLOGICAL|DSP-0546LP 5 ug|2 administrations at 3-week intervals.
223451137|NCT02561546|DRUG|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
223451138|NCT02561546|DRUG|Trans-catheter embolization|Trans-catheter embolization alone
223451139|NCT06788275|BEHAVIORAL|Aerobic exercise (MIT)|Patients allocated to the MIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will cycle continuously between the first and second ventilatory thresholds. The duration of each exercise session will be set according to the estimated energy expenditure of the long HIIT and short HIIT groups for each training block (energy expenditure-adjusted exercise sessions). All sessions will be supervised, and patients will be asked to avoid additional exercise. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
223451140|NCT06788275|BEHAVIORAL|Aerobic exercise (Short HIIT)|Patients allocated to the Short HIIT group will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-repetition sets of 1-min above the second ventilatory threshold. Patients will perform 1- and 3-min active recovery periods below the first ventilatory threshold between repetitions and sets, respectively. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
223451141|NCT06788275|BEHAVIORAL|Aerobic exercise (Long HIIT)|Patients allocated to the Long HIIT will train on a cycle ergometer three days a week for 12 weeks (36 sessions). They will perform from two to four 4-min high-intensity exercise bouts above the second ventilatory threshold separated by 4-min active recovery periods below the first ventilatory threshold. The total time spent at high intensity will range from eight to 16 min. All sessions will be supervised, and patients will be asked to avoid additional exercise training. They will be allowed to perform extra physical activity (e.g., light walking) according to medical recommendations.
223569638|NCT00354107|DRUG|ifosfamide|Given IV
223569639|NCT00354107|DRUG|carboplatin|Given IV
223569640|NCT00354107|DRUG|etoposide|Given IV
224058245|NCT06460064|BIOLOGICAL|DSP-0546LP 10 ug|2 administrations at 3-week intervals.
224058246|NCT06460064|BIOLOGICAL|Placebo|2 administrations at 3-week intervals.
224058247|NCT06131775|BIOLOGICAL|Blood sampling|One blood sample of 10mL is realized before initiation of immunotherapy
224058248|NCT06131775|BIOLOGICAL|Blood sampling|Three blood samples of 10mL are realized at distinct steps of patients disease management : one before the curative surgery, one after three months and one after six months.
224058249|NCT06614465|OTHER|Multimodal Rehabilitation|The intervention will consist of 4 sessions of education in pain neuroscience, 4 sessions of therapeutic exercise and 4 sessions of manual therapy in the abdominopelvic area.
224058250|NCT04415853|DRUG|Lerotinib|Specification: 50 mg/capsule and 150 mg/capsule
224058251|NCT04415853|DRUG|Irinotecan/Tegafur|Irinotecan:Specification: 2mL: 40mg;5mL:0.1g Tegafur:20mg/capsule
224058252|NCT05419128|BEHAVIORAL|PartnerCHESS|"The following ABCT services, from PartnerCHESS, will be available in the PartnerCHESS app but not in ACHESS:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between identified patient and concerned significant other to follow key principles.~Trigger identification and removal. Cravings discussion. Relapse plan. Reminders."
223451142|NCT01341899|PROCEDURE|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
223451143|NCT06103071|PROCEDURE|Sweeping of membranes|After informed consent all the patients in interventional group will have sweeping of membranes from 37 weeks of pregnancy . It will be repeated weekly till 40 weeks.
223451144|NCT01983826|DIETARY_SUPPLEMENT|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
223451145|NCT01983826|OTHER|Placebo|Microcrystalline cellulose (daily) for 8 weeks
223451146|NCT05122780|PROCEDURE|Coronary angiography|coronary angiography will be performed via the transradial or transfemoral approach with the use of a 6F sheath. Coronary angiography will be performed within 90 minutes from hospital admission in patients presenting with persistent ST-segment elevation, and within 48 hours in patients presenting with non-ST-segment elevation. Unfractionated heparin (initial weight-adjusted intravenous bolus of 60 IU/Kg, with repeat boluses to achieve an activated clotting time of 250 to 300 seconds) was administered in all patients. If evidence of plaque rupture
223451147|NCT05122780|DIAGNOSTIC_TEST|OCT imaging|"OCT imaging will be performed in the culprit artery in all patients randomized to the precision medicine approach. A 0.014-inch guidewire will be placed distally in the target vessel and an intracoronary injection of 200 µg of nitroglycerine will be performed. Frequency domain OCT (FD-OCT) images are acquired by a commercially available system (C7 System, LightLab Imaging Inc/ St Jude Medical, Westford, MA) connected to an OCT catheter (C7 Dragonfly; LightLab Imaging Inc/ St Jude Medical, Westford, MA), which was advanced to the culprit lesion. The FD-OCT run will be performed using the integrated automated pullback device at 20 mm/s. During image acquisition, coronary blood flow will be replaced by continuous flushing of contrast media directly from the guiding catheter at a rate of 4 ml/s with a power injector in order to create a virtually blood-free environment."
223451148|NCT05122780|PROCEDURE|Percutaneous coronary intervention (PCI):|PCI with stent implantation will be considered in selected cases with evidences of plaque rupture
223569641|NCT00354107|DRUG|methotrexate|Given IT
223569642|NCT00354107|DRUG|cytarabine|Given IT
223569643|NCT00354107|OTHER|pharmacological study|Correlative studies
223569644|NCT00354107|OTHER|laboratory biomarker analysis|Correlative studies
224058253|NCT05419128|BEHAVIORAL|ACHESS|ACHESS offers the following, which are also available in PartnerCHESS: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
224058254|NCT04977791|DRUG|Anti-PD-1/PD-L1 monoclonal antibody|Observe a situation before and after immunotherapy
224058255|NCT03834519|BIOLOGICAL|Pembrolizumab|IV infusion
224058256|NCT03834519|DRUG|Olaparib|Oral tablets
224147150|NCT05090358|DRUG|Canagliflozin|Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
224147151|NCT04003337|OTHER|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
223569645|NCT04699292|PROCEDURE|Surgery|Surgery
223569646|NCT04699292|RADIATION|Preoperative RT 36Gy|Preoperative radiotherapy to 36Gy (equivalent)
223569647|NCT04699292|RADIATION|Preoperative RT 50Gy|Preoperative radiotherapy to 50Gy (equivalent)
223569648|NCT04699292|RADIATION|Postoperative RT 50-66Gy|Postoperative radiotherapy to 50-66Gy (equivalent)
223569649|NCT04699292|RADIATION|RT 36Gy|Definitive radiotherapy to 36Gy (equivalent)
224058257|NCT03834519|DRUG|Abiraterone acetate|Oral tablets
224058258|NCT03834519|DRUG|Prednisone|Oral tablets
224058259|NCT03834519|DRUG|Enzalutamide|Oral tablets or oral capsules
224058260|NCT03834519|DRUG|Prednisolone|Oral tablets
224058261|NCT06972485|PROCEDURE|spinal anesthesia|spinal anesthesia with hypobaric and hyperbaric bupivacaine
224147152|NCT00086944|BIOLOGICAL|oblimersen sodium|Given IV
224147153|NCT00086944|BIOLOGICAL|rituximab|Given IV
224305057|NCT05035342|BIOLOGICAL|Placebo capsules|"The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules."
223569650|NCT03279523|DRUG|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
223569651|NCT01311128|DEVICE|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
223569652|NCT02267304|DRUG|50 mL of sodium chloride (0,9%)|
223569653|NCT02267304|DRUG|Morphine 0,05mg/kg|
223569654|NCT02267304|DRUG|Naloxone 10mg|
223569655|NCT00369226|DRUG|Bortezomib (Velcade)|Infusion for a total of 3 doses
223569656|NCT00369226|DRUG|Tacrolimus|Taken until Doctor determines it is not necessary any more
223569657|NCT00369226|DRUG|Methotrexate|Infusion for a total of 4 doses
224058262|NCT06976411|DRUG|MTA|Perforation repair using MTA repair material
224058263|NCT06976411|DRUG|Bioceramic putty|Perforation repair using Bioceramic repair material
224058264|NCT05399888|DRUG|BIIB080|Administered as specified in the treatment arm.
224058265|NCT05399888|DRUG|BIIB080-matching placebo|Administered as specified in the treatment arm.
224147154|NCT00086944|DRUG|ifosfamide|Given IV
224147155|NCT00086944|DRUG|carboplatin|Given IV
224147156|NCT00086944|DRUG|etoposide|Given IV
224147157|NCT00086944|BIOLOGICAL|filgrastim|Given SC
223451149|NCT05122780|DIAGNOSTIC_TEST|Acetylcholine provocative test|ACh will be administered in a stepwise manner into the left coronary artery (LCA) (20-200 μg) or into the right coronary artery (RCA) (20-50 μg) over a period of 3 min with a 2-3 min interval between injections. Coronary angiography will be performed 1 min after each injection of these agents and/or when chest pain and/or ischaemic ECG shifts were observed. The decision of testing with provocative test LCA or RCA as first will be left to the discretion of the physicians; both LCA and RCA will be tested if the first test was negative. Angiographic responses during the provocative test will be assessed in multiple orthogonal views in order to detect the most severe narrowing and/or analysed by using computerized quantitative coronary angiography (QCA-CMS, Version 6.0, Medis-Software, Leiden, The Netherlands).
224058266|NCT06965569|DRUG|ALA-3000|Subcutaneous injection
223451150|NCT05122780|DIAGNOSTIC_TEST|TT-Echocardiography|TT-Echo will be used to calculate left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspidal valve annulus tissue Doppler spectra, ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography.
223569658|NCT00369226|PROCEDURE|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
223451151|NCT05122780|DIAGNOSTIC_TEST|TE/contrast echocardiography|In patients with angiographic evidence or suspicion of distal microembolization, TE-Echo consisting of an echocardiographic probe inserted in to the oesophagus will be used to detect a hidden cardioembolic source (i.e. left atrial thrombus); in patients with suspected left ventricular source of cardioembolism, contrast echocardiography consisting of a 0.3ml solution of SONOVUE will be used.
223451152|NCT05122780|DIAGNOSTIC_TEST|Cardiac magnetic resonance|CMR will be performed during hospital stay on a 1.5-T system equipped with a 32-channel cardiac coil. Patients underwent conventional CMR including cine, T2-weighted, first pass perfusion, and conventional breath-held late gadolinium enhancement (LGE).
223569659|NCT02275715|BEHAVIORAL|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
223569660|NCT06446063|OTHER|Test product|Twice daily applications The product is applied to the entire face.
223569661|NCT06446063|OTHER|Control Product|Twice daily applications The product is applied to the entire face.
223569662|NCT02574650|DEVICE|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
223741959|NCT07205419|DEVICE|Eye-Tracking Interaction System|The eye-tracking interactive interface designed based on evidence-based and co-design principles is installed on tablets or computers equipped with cameras, forming the eye-tracking interactive system.
223741960|NCT07205991|BEHAVIORAL|Phone calls|Participants will receive standard app notifications and be contacted for adherence via two phone calls, a week apart, if they fail to engage with the intervention for more than three consecutive days. The purpose of these calls will be to assess whether participants are experiencing any difficulties using the app or completing the sessions.
223741961|NCT07205991|BEHAVIORAL|Text messages|Participants will receive the standard app notifications and receive a maximum of 2 text messages (SMS) a week apart, if they fail to engage with the intervention for more than three consecutive days.
223741962|NCT07205991|BEHAVIORAL|App notifications|Participants will receive the standard app notifications .
224058267|NCT06965569|DRUG|Placebo|Subcutaneous injection
224058268|NCT06965569|DRUG|escitalopram, sertraline, duloxetine or venlafaxine XR|Newly initiated oral AD selected from SSRI (escitalopram or sertraline) or SNRI (duloxetine or venlafaxine XR) will be given daily
224058269|NCT05103878|DRUG|BT051 100mg|Single oral dose of 100mg BT051
224058270|NCT05103878|DRUG|BT051 300mg|Single oral dose of 300mg BT051
224058271|NCT05103878|DRUG|BT051 700mg|Single oral dose of 700mg BT051
224058272|NCT05103878|DRUG|BT051 1500mg|Single oral dose of 1500mg BT051
224058273|NCT05103878|DRUG|BT051 3500mg|Single oral dose of 3500mg BT051
224058274|NCT05103878|DRUG|Matching Placebo|Placebo Matching BT051
224058275|NCT06144775|OTHER|Kinematics measures|In a single session each child will be video-recorded while performing simple and complex rhythmic actions of the upper limbs with a social partner. The presence of characteristic motor behaviors, practice errors, perseverations, and movement variability will be observed. The study involves the use of three blocks of tasks of the neuropsychological battery (NEPSY-II): Finger Tapping, Visuo-Motor Precision, and Manual Motor Sequences. The order within each block will be randomized.
224058276|NCT00488111|OTHER|Ringer's Lactate|Ringer's Lactate was used 15min before operation
224058277|NCT00488111|OTHER|6% Starch|6% Starch was used 15min before operation
224058278|NCT02652338|DIETARY_SUPPLEMENT|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
224058279|NCT02652338|DIETARY_SUPPLEMENT|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
224058280|NCT01485939|OTHER|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
224058281|NCT01485939|OTHER|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
224058282|NCT05957666|DRUG|Misoprostol Oral Tablet|oral misoprostol 50 microgram repeated after 6 hours if required
224058283|NCT05957666|DRUG|vaginal misoprostol|vaginal misoprostol 50 microgram repeated after 6 hours if required
224058284|NCT04506086|DRUG|Blinatumomab|Participants will receive blinatumomab continuous IV infusion for a maximum of 4 cycles. Each cycle is 6 weeks in duration consisting of 4 weeks of treatment and 2 weeks of rest.
224058285|NCT04506086|DEVICE|Current Wearable Heatlth Monitoring System (CWHMS)|The study will use the CWHMS device to monitor participants' vital signs while they are at home.
224058286|NCT05570539|DRUG|BLU-5937 IR|Each subject will receive two single and multiple administrations of Immediate Release reference formulation
224058287|NCT05570539|DRUG|BLU-5937 ER|Each subject will receive single and multiple oral administrations of Extended Release formulation
224070759|NCT07015528|DRUG|Droperidol|Medication administered as a single intravenous dose.
224070760|NCT07015528|DRUG|Placebo|Matching Placebo given by single intravenous (IV) administration.
223451153|NCT05122780|DIAGNOSTIC_TEST|Circulating biomarkers|Blood sampling for circulating biomarkers and miRNA expression profile at the time or within 12 hours of coronary angiography. Blood sampling will be processed and analysed in the research laboratory of the Department of Cardiovascular Science. Biological aliquots will be preserved at XBiogem Biobank at Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (see section 33).
223451154|NCT05122780|DRUG|Antiplatelet Drug|acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
223451155|NCT05122780|DRUG|Statin|i.e. atorvastatin; dosages titrated on the patient's clinical characteristics
223569663|NCT05162001|DRUG|Disulfiram 250 mg|Disulfiram used qd during nine weeks to observe effects on body weight
223569664|NCT00830713|PROCEDURE|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
223569665|NCT01775579|DRUG|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
223569666|NCT00762138|DEVICE|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
223569667|NCT02312999|DRUG|Plasmalyte|
223569668|NCT02312999|DRUG|Volulyte|
223569669|NCT05158335|DRUG|MBX 2109 (Part A)|Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg
223569670|NCT05158335|DRUG|MBX 2109 (Part B)|Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg
223741963|NCT07205809|PROCEDURE|bioceramic coated gutta percha|"Experimental Arm (Bioceramic-coated GP + Bioceramic Sealer):~Specimens will be obturated using bioceramic-coated gutta-percha cones in combination with bioceramic sealer after canal preparation with ProTaper NEXT files up to size F3."
223741964|NCT07205809|PROCEDURE|conventional(non-coated) gutta percha|"Active Comparator Arm (Conventional GP + Bioceramic Sealer):~Specimens will be obturated using conventional (non-coated) gutta-percha cones in combination with the same bioceramic sealer after canal preparation with ProTaper NEXT files up to size F3."
224058288|NCT03524885|PROCEDURE|Short implant placement|"Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden \& Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated."
223451156|NCT05122780|DRUG|Beta blocker|i.e. bisoprolol; dosages titrated on blood pressure, ECG, heart rate
223451157|NCT05122780|DRUG|ACEi/ARB|i.e. ramipril; dosages titrated on blood pressure, ECG, heart rate
223451158|NCT05122780|DRUG|CCB|i.e. diltiazem; dosages titrated on blood pressure, ECG, heart rate
224058289|NCT03524885|PROCEDURE|Bone regeneration with longer implants|"Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US)."
224058290|NCT05827250|DEVICE|imPulse Tor|"The imPulse-Tor system passively collects audible sounds and inaudible vibrations spanning the infrasound-to-ultrasound frequency range, as well as cardiac electrical signals. The device can be safely placed directly on the chest wall to obtain readings.~imPulse System vibroacoustic recording (VAR) will be performed twice daily till discharge. An attempt will be made to have at least a 6+/-2 hr gap between the two recordings."
224058291|NCT00517751|DEVICE|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
224058292|NCT01441856|PROCEDURE|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
224147158|NCT00086944|BIOLOGICAL|pegfilgrastim|Given SC
224147159|NCT00086944|OTHER|laboratory biomarker analysis|Correlative studies
223451159|NCT05122780|DRUG|Nitrates|i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
223451160|NCT05122780|DRUG|Anticoagulant|i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
223569671|NCT05158335|DRUG|Placebo|Single SC dose or repeated SC doses of placebo.
223569672|NCT01685801|DRUG|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
223569673|NCT01685801|DRUG|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
223569674|NCT01281254|DRUG|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
223569675|NCT01281254|DRUG|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
223569676|NCT00318747|DRUG|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
223569677|NCT04686084|DEVICE|Dual-energy computed tomography scan|Diagnostic CT scan
223569678|NCT00460486|BIOLOGICAL|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
224058293|NCT01441856|PROCEDURE|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
223451161|NCT02696486|BEHAVIORAL|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
223451162|NCT04656301|DRUG|Psilocybin|A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
223451163|NCT05165641|PROCEDURE|segmental spinal anesthesia|Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally \[ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
223451164|NCT00514982|DRUG|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
223451165|NCT00514982|DRUG|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
223451166|NCT00514982|DRUG|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
223451167|NCT00514982|DRUG|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
223451168|NCT00514982|DRUG|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
223451169|NCT00514982|DRUG|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
223451170|NCT03370965|DIAGNOSTIC_TEST|Neuro-ophtalmology examination|"Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment."
223451171|NCT05621395|OTHER|E-OJ-01|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
223451172|NCT05621395|OTHER|Microcrystalline cellulose|1 capsule (400 mg) orally to be taken after breakfast daily for 60 days
223451173|NCT05051891|DRUG|Orelabrutinib and R-CHOP|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
223451174|NCT05051891|DRUG|R-CHOP|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
223569679|NCT04574414|DIAGNOSTIC_TEST|Psychological testing and MRI imaging|"Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI."
223569680|NCT01478685|DRUG|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
224058294|NCT02604953|DIAGNOSTIC_TEST|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
224058295|NCT02604953|DIAGNOSTIC_TEST|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
224147160|NCT01066884|DRUG|erlotinib [Tarceva]|150mg po daily
224305058|NCT00673153|DRUG|gemtuzumab ozogamicin|Given IV
224305059|NCT00673153|DRUG|vorinostat|Given orally
223451175|NCT01528280|BIOLOGICAL|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
223451176|NCT01528280|OTHER|No Intervention|No Intervention
223451177|NCT00469716|DRUG|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
223451178|NCT03140540|OTHER|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta \<20 ,200ml colloid bolus to be administered.
223451179|NCT03140540|OTHER|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV \>10, 200 ml of colloid bolus to be given
223451180|NCT00193583|DRUG|Topotecan|
223451181|NCT00193583|DRUG|Carboplatin|
223451182|NCT05472571|OTHER|Forest bathing|The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
223569681|NCT01478685|DRUG|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
223569682|NCT01478685|DRUG|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
224305060|NCT00673153|OTHER|laboratory biomarker analysis|Correlative studies
224305061|NCT05808153|RADIATION|radiotracer injection|MRI with radiotracer injection
224058296|NCT06025890|OTHER|Functional Training.|"Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children."
223451183|NCT01575418|DRUG|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
224305062|NCT01710553|OTHER|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
223451184|NCT01575418|DRUG|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
223451185|NCT01575418|DRUG|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
223451186|NCT01575418|RADIATION|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
223451187|NCT04153474|PROCEDURE|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
223451188|NCT04153474|PROCEDURE|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
223451189|NCT02801461|DEVICE|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
223451190|NCT06408337|PROCEDURE|implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).|cleft palate repair surgery, all patients in the study will receive the standard treatment (uranostaphyllorrhaphy), with the only difference that patients assigned to the experimental study group will additionally have BIOCLEFT tissue obtained through tissue engineering grafted onto them. the lateral area of the palatine bone exposed when mobilizing the flaps. For the implant, the BIOCLEFT fabric will be placed in the area of exposed bone, sized to the size of the defect and sutured using uncoated, monofilament long-term absorbable synthetic suture.
223451191|NCT03646747|DIAGNOSTIC_TEST|MRI scan|Additional imaging using MRI scan
223451192|NCT00540839|DRUG|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
223451193|NCT00540839|DRUG|Placebo to montelukast|Placebo OG or CT
223451194|NCT00540839|DRUG|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
223451195|NCT00540839|DRUG|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
223569683|NCT04345861|DRUG|Hydroxychloroquine + placebo|hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
223569684|NCT04345861|DRUG|hydroxychloroquine + azithromycin|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
223569685|NCT04050696|DEVICE|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
223569686|NCT04714203|OTHER|sarcopenia assessment|evaluation of sarcopenia status
223569687|NCT05427448|DIAGNOSTIC_TEST|Measurement of amyloid and pTau blood biomarkers|Detection of plasma Amyloid beta 1-40 and 1-42 peptide and phosphorylated tau isoforms.
223741965|NCT07206004|DIAGNOSTIC_TEST|Fibroscan|Fibroscan will be perfomed while the patient receives their usual parenteral support
223741966|NCT07206927|OTHER|Qualitative Study: Semi-structured interview for patients|A semi-structured interview, lasting 20 to 30 minutes, will be conducted by the sociologist and anthropologist. They will use questionnaires (semi-structured interview grids), administered to patients face-to-face or by telephone. Patients will be interviewed only once. The interview grid includes the following sections: personal characteristics such as age, family and professional situation, municipality of residence, and knowledge of clinical research.
223741967|NCT07206927|OTHER|Quantitative Study : Healthcare professionals questionnaires|Questionnaires will be administered by email, in a single session, to healthcare professionals who have agreed to participate in the study.
224305063|NCT01710553|OTHER|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
224058297|NCT06025890|OTHER|Observe.|Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
224058298|NCT01415011|DRUG|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
224058299|NCT04373681|OTHER|patient-administered questionnaires|patient-administered questionnaires
224058300|NCT01188720|BEHAVIORAL|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
224058301|NCT05903729|OTHER|Neurodevelopmental therapy treatment|The group will receive NDT therapy
224058302|NCT05903729|OTHER|conventional physiotherapy|conventional physiotherapy
223451196|NCT03063619|DRUG|Afimoxifene|Applied topically
223451197|NCT03063619|OTHER|Laboratory Biomarker Analysis|Correlative studies
223451198|NCT03063619|OTHER|Placebo|Applied topically
223451199|NCT03063619|OTHER|Questionnaire Administration|Ancillary studies
223451200|NCT02366299|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
223451201|NCT02366299|DRUG|Propofol|Treatment of delirium by Propofol i.v. infusion
223451202|NCT01360788|DRUG|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
223451203|NCT05130996|DEVICE|dental prothesis|5 ranges of implants can be used : IDAll, IDBio, IDCam, IDMax, ID3
223451204|NCT04156243|BIOLOGICAL|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
223451205|NCT00731796|DEVICE|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
223451206|NCT02052297|OTHER|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
223451207|NCT02537600|DRUG|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
223451208|NCT06001853|DRUG|BM-MSC injection|BM-MSCs at the dose 10 x 106 in 1 ml per facet joint for a total of 2 joints
223451209|NCT06001853|DRUG|DSMO Injection|After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
223451210|NCT04331834|DRUG|Hydroxychloroquine|"Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
223451211|NCT04331834|DRUG|Placebos|"Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months"
223451212|NCT00122525|PROCEDURE|Male Circumcision|
224058303|NCT02470026|DRUG|yohimbine|single low dose treatment
224058304|NCT02470026|DRUG|placebo|single control treatment
224058305|NCT01741675|BEHAVIORAL|Questionnaire and monetary incentive|
224058306|NCT01741675|BEHAVIORAL|Questionnaire only|
224058307|NCT00503594|DRUG|Methotrexate and temozolomide|Methotrexate and temozolomide
224058308|NCT00503594|DRUG|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
224058309|NCT06977529|BEHAVIORAL|Algorithm; Algorithm-based maintenance created by researchers:such as falls training, early mobilization|"The Fall Prevention Algorithm prepared by the researchers was applied to the experimental group patients."
224058310|NCT06977464|DEVICE|Wearable Technology and Information Software-Based Psychological Stress Monitoring|The intervention group will additionally use a smartwatch for physiological monitoring and a mobile app for daily to weekly psychological assessments.
223451213|NCT00002917|DRUG|paclitaxel|
223451214|NCT05468983|PROCEDURE|surgical ( implants placement)|4 implants were placed interforamen of the mandibular arch by using the surgical guide
223451215|NCT02360423|DEVICE|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
224058311|NCT06978738|BIOLOGICAL|universal allogeneic anti-CD19/BCMA CAR T-cells|A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
224070761|NCT07023211|BEHAVIORAL|Neo-Functional diaphragmatic breathing|This technique, rooted in the Neo-Functionalist orientation which actively utilizes body contact, involves direct manual assistance from the therapist during different respiratory movements. This hands-on guidance is specifically aimed at promoting and facilitating congruent movements across the thoracic, diaphragmatic, and abdominal regions throughout the breathing cycle, enhancing the targeted respiratory pattern. The intervention will be delivered by a psychotherapist specialized in Neo-Functional techniques.
223451216|NCT02360423|DEVICE|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
224058312|NCT05567575|BEHAVIORAL|Cognitive Behavioral Therapy,|TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).
224058313|NCT06985641|BEHAVIORAL|Khanya-Ekhaya|The Khanya Ekhaya intervention includes an integration of several evidence-based treatment components, including motivational interviewing (MI), problem solving therapy (PST), and behavioral activation (BA), previously tested and adapted for this context in clinic settings, as well as cognitive-behavioral and mindfulness strategies that target rumination and negative thinking patterns. Aims 1-2 will inform Khanya-Ekhaya adaptation, including intervention length, but it is likely to include 3-6 sessions of CHW home visits based on formative work with ongoing supervision and support for CHWs.
224058314|NCT00095355|DRUG|Lithium|
224058315|NCT00095355|DRUG|Divalproex|
224058316|NCT01169220|DRUG|Go-Lytely|Bowel cleansing agent
223451217|NCT02090283|DRUG|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
224058317|NCT01169220|DRUG|Go Lytely|Bowel cleansing agent
224058318|NCT04634396|BEHAVIORAL|ACT Acceptance and Commitment Therapy|6 weeks of 1 hour sessions with a masters prepared research specialist to deliver validated tools
224058319|NCT06984250|RADIATION|Hypofractionated Radiation Therapy|Hypofractionated breast radiotherapy (HFRT) with hybrid techniques combining field-in-field intensity-modulated RT (FIF-IMRT) to the whole breast with inverse-IMRT for concomitant boost
224058320|NCT05060120|DIAGNOSTIC_TEST|biomakers for ovarian torsion|Blood biomarkers analysis using multiplex ELISA: The Luminex system is a magnetic bead-based multiplex ELISA that enable to measure simultaneously multiple proteins within the same sample. Human magnetic Luminex assay will be used for the following analytes: D-Dimer (21.7-5,280 ng/ml), FABP4/A-FABP (0.637-155 ng/ml), GM-CSF (0.012-2.98 ng/ml), ICAM-1/CD54 (6.9-1674 ng/ml), IFN-γ (0.058-14.2 ng/ml), IL-1α (0.005-1.27 ng/ml), IL-6 (0.005-1.2 ng/ml), IL-10 (0.005-1.2 ng/ml), IL-17/IL-17A (0.012-3.1 ng/ml), Park7/DJ-1 (0.26- 63.1 ng/ml), TNF-α (0.01-2.4 ng/ml), TSLP (0.003-0.7 ng/ml), VCAM-1/CD106 (7.8-1891 ng/ml) and VEGF (0.008-2.4 ng/ml). Plasma samples stored at -70°C will be sent to accredited lab at BioTest (Israel) for performing the multiplex ELISA readout assay test using MagPix system.
224058321|NCT05060120|DIAGNOSTIC_TEST|peritoneal fluid proteins analysis|"Western blot for peritoneal fluid proteins analysis~We will look for the relative abundance of proteins involved in the protection of cells against oxidative stress and the regulation of reactive oxygen species (ROS) using western blot. Superoxide dismutase 1 (SOD1, 16kDa) scavenges superoxides (O-2) within cells. Catalase (60kDa) is hydrogen peroxide (H2O2) scavenging enzyme regulate ROS concentrations within cells by reducing H202 into O2 and water. Thioredoxin (12kDa) facilitates the reduction of proteins via cysteine thiol-disulfide exchange. Alpha smooth muscle actin (42kDa) will be used as a loading control. These four proteins will be resolved by western blot given their different molecular weights using western blot cocktail antibodies (abcam # ab179843)."
224147161|NCT03903744|PROCEDURE|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
224147162|NCT01105221|DEVICE|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20\*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
223451218|NCT03132415|BEHAVIORAL|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
223451219|NCT03132415|BEHAVIORAL|HIV Test Locator|The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
223569688|NCT01672463|DRUG|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
224058322|NCT04076254|DRUG|Albumins|albumin 5%
223569689|NCT04549805|DIAGNOSTIC_TEST|Computed Tomography Coronary Angiography|In order to optimise the quality of the Computed Tomography Coronary Angiography scan images, participants might be given tablets or an injection (e.g. beta-blockers, calcium channel antagonist, ivabradine) to slow their heart rate and glyceryl trinitrate (GTN) following local protocol guidance.
223569690|NCT02130830|DRUG|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
223569691|NCT02130830|DRUG|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
223569692|NCT04820634|OTHER|Virtual Reality Job Interview Training|The treatment group (TX) will complete 7 sessions of VR-JIT (1 sessions per week for 7 weeks), designed to teach the skills \& concepts of job interviews. Sessions are approximately 90 minutes long.
223451220|NCT02033707|DRUG|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
223451221|NCT03508349|DIAGNOSTIC_TEST|IST|Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
223451222|NCT01676103|DIETARY_SUPPLEMENT|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
223451223|NCT01676103|OTHER|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
224058323|NCT04076254|DRUG|Fluid|Ringer Lactate
224058324|NCT00940979|PROCEDURE|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
224058325|NCT03332329|DRUG|Entecavir|Entecavir is used for 96 weeks
224058326|NCT03332329|DRUG|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
224058327|NCT03332329|DRUG|Y peginterferon alfa-2b|Y peginterferon alfa-2b is used for 96 weeks
224058328|NCT03332329|DRUG|HBV vaccine|60ug HBV vaccine is used every four week for 24 weeks
224058329|NCT05672472|DRUG|Sivelestat sodium|Continuous infusion of sivelestat sodium for 5 days
224058330|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice|Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.
224058331|NCT05221905|DRUG|BEET IT - Concentrate Beet root juice (nitrate depleted)|Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.
224058332|NCT06611540|PROCEDURE|Biospecimen Collection|Undergo collection of a cervical sample by clinician
223569693|NCT04820634|OTHER|Wonderworks|The control group (CT) will complete 7 sessions of Wonderworks (1 session per week for 7 weeks) using skills in an office environment.
224058333|NCT06611540|PROCEDURE|Cervical Biopsy|Undergo cervical biopsy
224058334|NCT06611540|PROCEDURE|Colposcopy|Undergo colposcopy
224058335|NCT06611540|OTHER|Electronic Health Record Review|Ancillary studies
224058336|NCT06611540|PROCEDURE|Endocervical Curettage|Undergo endocervical curettage
224058337|NCT06611540|PROCEDURE|Excision|Undergo cervical excisional procedure
224058338|NCT06611540|PROCEDURE|HPV Self-Collection|Undertake self-collection of vaginal sample
224058339|NCT06611540|PROCEDURE|Human Papillomavirus Test|Undergo HPV testing of self-collected vaginal samples and cervical samples
224058340|NCT06611540|OTHER|Questionnaire Administration|Ancillary studies
224058341|NCT01383980|DIETARY_SUPPLEMENT|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
224058342|NCT06693856|DRUG|High-Dose Methylprednisolone|Methylprednisolone 500mg, administered intravenously once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
224058343|NCT06693856|DRUG|Low-Dose Methylprednisolone|Methylprednisolone is administered at a dose of 1mg/kg, given as an intravenous injection once daily for 3 consecutive days, repeated every 4 weeks for a total of 24 weeks, followed by a follow-up period.
224058344|NCT05458050|DEVICE|PU sensor|Device to assess microcirculation in sacrum area to find subjects at risk for pressure ulcer
224058345|NCT06763744|DRUG|P2Y12 antagonist monotherapy|CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\*1/\*17 or \*17/\*17) or normal (CYP2C19\*1/\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\*2 or \*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.
224058346|NCT06763744|DRUG|clopidogrel + aspirin|In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).
224058347|NCT06891950|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|Each 0.5 mL dose of the lyophilized formulation of Dengue 1,2,3,4 (attenuated) presents an approximate concentration of 103.0 PFU of each vaccine virus rDEN1Δ30-1545, rDEN2/4Δ30(ME)-1495,7163, rDEN3Δ30/31-7164, rDEN4Δ30-7132,7163,8308.
224147163|NCT01105221|DRUG|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
224058348|NCT00115609|DRUG|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
224058349|NCT00115609|DRUG|tenofovir DF|300mg once a day
224058350|NCT00115609|DRUG|emtricitabine|one pill of 200mg once a day
224058351|NCT03994939|BEHAVIORAL|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
224058352|NCT01183559|DRUG|Vandetanib|Vandetanib 100mg orally escalating to doses of 200 mg daily 7 days a week until completion of radiation therapy
224147164|NCT00979017|DRUG|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
224147165|NCT00979017|DRUG|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
223451224|NCT00288418|DEVICE|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
223451225|NCT01516489|BEHAVIORAL|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
223451226|NCT01516489|BEHAVIORAL|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
223451227|NCT00092976|DRUG|ReFacto|
223451228|NCT06005753|PROCEDURE|Ostheosynthesis of acetabular fractures|The using of plate for fixation of acetabular fractures in surgical treatment
223451229|NCT05269368|PROCEDURE|Wicking|Absorbable or non-absorbable wicking
224058353|NCT01183559|DRUG|5 Fluorouracil (FU)|5-FU 225 mg/m2/day continuous infusion over96 hours during radiation therapy
224058354|NCT01183559|DRUG|Carboplatin|Carboplatin AUC=5 days 1 and 29 during radiation therapy
224058355|NCT01183559|DRUG|Paclitaxel|Paclitaxel 50 mg/m2 days 1, 8, 15, 22, 29 during radiation therapy
224058356|NCT01183559|RADIATION|External Beam Radiation Therapy (RT)|External Beam Radiation Therapy(XRT)to a total dose of 4,500 centiGray (cGy) (180 cGy fractions daily) Monday through Friday for five weeks
224058357|NCT00290485|DRUG|Imatinib mesylate|
224058358|NCT01050309|DRUG|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
224058359|NCT00980200|DRUG|Dose 4 QD|QD once daily
224058360|NCT00980200|DRUG|Dose 3 QD|QD once daily
224058361|NCT00980200|DRUG|placebo|placebo
224058362|NCT00980200|DRUG|Dose 2 QD|QD once daily
224058363|NCT00980200|DRUG|Dose 1 BD|BD twice daily
224058364|NCT04193007|DRUG|molecular targeted therapies|if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
224058365|NCT04193007|RADIATION|Brain Radiotherapy|SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
224058366|NCT00985062|PROCEDURE|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
224058367|NCT00985062|PROCEDURE|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
224058368|NCT00457015|DRUG|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
224058369|NCT00457015|DRUG|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
224058370|NCT01700933|OTHER|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
224058371|NCT01700933|OTHER|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
224058372|NCT00247754|BEHAVIORAL|Cognitive Behaviour Treatment|
224058373|NCT01084070|OTHER|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
224147166|NCT00979017|DRUG|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
224147167|NCT02790710|DRUG|Propanolol|Active treatment
224147168|NCT02790710|DRUG|Placebo|
224147169|NCT03034408|DRUG|Nalmefene|
224147170|NCT03034408|DRUG|Baclofen|
224147171|NCT03034408|DRUG|Placebo Oral Capsule|
224147172|NCT06613100|DRUG|Xaluritamig|Intravenous (IV) infusion
223451230|NCT05269368|PROCEDURE|No wicking|No wicking after surgery
223451231|NCT03283046|DRUG|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
223451232|NCT03283046|DRUG|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
223451233|NCT03283046|DRUG|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
223451234|NCT03283046|DRUG|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
223451235|NCT04026750|DRUG|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
223451236|NCT02421302|DIETARY_SUPPLEMENT|RUTF|This is ready-to-use-therapeutic-food
223451237|NCT04498702|DRUG|APL-1202 treatment|A modified 3+3 design was employed: The dose was started at 300 mg and increased to 450 mg, 600 mg and 750 mg if there was no dose-limiting toxicity (DLT) in 3 subjects after 4-week consecutive administration of APL-1202. When the dose-escalation study was in progress, the doses for any newly enrolled subjects would be the starting dose or the highest dose confirmed with no DLT by the dose-escalation cohort at the time of enrollment. When the MTD or the 750 mg daily dose was attained as a safe dose, the dose for all subjects in the study or subsequently enrolled subjects would be MTD or 750 mg/day.
223451238|NCT05054205|BEHAVIORAL|Motivational İnterviewing|"The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy."
223569694|NCT02614807|DIETARY_SUPPLEMENT|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
223569695|NCT00384423|DRUG|PRX-03140|
223569696|NCT03552536|DRUG|MK-8583|A single oral dose of MK-8583 in capsule form
223569697|NCT03295383|DRUG|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
223569698|NCT03295383|DRUG|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally."
223451239|NCT01653457|DRUG|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~* 1st week: 5 mg daily~* 2nd week: 10 mg daily~* 3rd week: 15 mg daily~* From 4th week up to 24th week: 20 mg daily"
223569699|NCT03295383|DRUG|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
223569700|NCT03295383|DRUG|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
223569701|NCT00011362|DRUG|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
223569702|NCT00011362|DRUG|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was \>=2.4 on treatment day 14, or an additional two weeks of saline
223569703|NCT05434871|OTHER|Yoga training|There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.
223569704|NCT05434871|OTHER|Physiotherapy|The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
223569705|NCT06099470|OTHER|Real-time synchronized telerehabilitation program (STP).|patient education, core stabilization exercises, strengthening exercises, stretching exercises
223569706|NCT06099470|OTHER|Pre-recording non-synchronized telerehabilitation program (NSTP)|Pre-recording non-synchronized telerehabilitation program (NSTP)
223569707|NCT06099470|OTHER|Home non-supervised control group (HCG)|Home non-supervised control group (HCG)
224058374|NCT01084070|OTHER|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
223569708|NCT01929720|BEHAVIORAL|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
224058375|NCT05461911|DIETARY_SUPPLEMENT|Nutrison Advanced Cubison|(20% protein energy 100 kcal, 5.5 g protein, 0.85 g arginine, 38 mg of vitamin C and 2 mg of zinc) in a volume not exceeding 1.5 liters / day and, if necessary, to replenish nutritional needs based on the total daily intake of 30-35 kcal / kg / day and 1.2-1.5 g of protein / kg body weight / day according to the recommendations for nutritional support
224058376|NCT02288585|DIETARY_SUPPLEMENT|Plant sterols|Plant sterols
224058377|NCT02288585|DIETARY_SUPPLEMENT|Placebo product|Placebo product
224058378|NCT05618665|OTHER|Asthma Education|Asthma education about asthma disease, its symptoms, diagnosis, treatment, risk factors, use of medication, use of medication apparatus, vaccination treatment, follow-up of the asthmatic child, precautions to be taken in prevention, what to do during an attack, what to do for adaptation to the disease and things to do in school life.
224058379|NCT05618665|OTHER|Delivery of booklets|The booklets, prepared by the researchers, included information about the content of the education.
224058380|NCT05438316|DRUG|Ramipril tablet 10 mg|Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
224058381|NCT05438316|DRUG|Tritace® tablet 10 mg|Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
224147173|NCT07000058|DRUG|Hyaluronidase and Lidocaine 1% mixture|in group A hyaluronidase is expected to shorten the onset of action and prolong the duration of action of lidocaine 1% mixture than in group B where lidocaine 1% mixture only will be given
223451240|NCT01653457|DRUG|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
223451241|NCT01867515|OTHER|Acoustic distortion of speech|
223451242|NCT00019461|DRUG|carboxyamidotriazole|
224058382|NCT06114173|DRUG|Cardunilizumab|Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.
223451243|NCT00019461|DRUG|chemotherapy|
223451244|NCT01411319|RADIATION|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
223451245|NCT01411319|RADIATION|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
223451246|NCT03609814|DRUG|Clofarabine|Given IV
223451247|NCT03609814|DRUG|Fludarabine Injection|Given IV
223451248|NCT00160121|DRUG|Lanthanum carbonate|
223451249|NCT01005784|DRUG|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
223451250|NCT01005784|DRUG|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
223569709|NCT04844658|DIETARY_SUPPLEMENT|NASAFYTOL®|Dietary supplement presented as green soft gel capsules of 1008 mg, containing a bioactive mixture of turmeric extract or curcumin, natural quercetin from Sophora japonica L. and vitamin D3.
223569710|NCT04844658|DIETARY_SUPPLEMENT|FULTIUM® -D3 800|Vitamin D , FULTIUM® - D3 800 is a blue soft capsule that contains 800 UI (20 µg) of D3 vitamin (cholecalciferol).
224058383|NCT02969057|OTHER|Breakfast with rice bran oil gel|25 grams of rice bran oil gel
224058384|NCT02969057|OTHER|Breakfast with rice bran oil|25 grams of rice bran oil
224147174|NCT07000058|DRUG|lidocaine 1 % mixture|lidocaine 1 % mixture includes; A mixture of ( epinephrine 1:200,000 and lidocaine 1% ) buffered by 1 ml of sodium bicarbonate 8.4% for every 10 ml of the local anesthetic mixture.
224147175|NCT02843295|OTHER|blood samples|
223451251|NCT00003007|BIOLOGICAL|recombinant interferon alfa|
223451252|NCT00003007|BIOLOGICAL|sargramostim|
223451253|NCT00003007|DRUG|cyclophosphamide|
224058385|NCT02969057|OTHER|Breakfast with palm oil gel|25 grams of palm oil gel
224058386|NCT02969057|OTHER|Breakfast with palm oil|25 grams of palm oil
224147176|NCT02575573|OTHER|Factors influencing resuscitation decisions of patients|
224147177|NCT02575573|OTHER|Factors leading to not asking patients about resuscitation preference|
224147178|NCT05371067|OTHER|Fructose respiratory test|Healthy volunteers will performed a fructose respiratory test in order to evaluate if they are or not fructose malabsorbing. The two population will be compared about their feelings and their micriobiote.
224147179|NCT06138561|BEHAVIORAL|Geriatric-8 Survey|A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring \> 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
223569711|NCT04844658|DRUG|Strandard of care treatment|Strandard of care treatment for Covid-19 infection
224058387|NCT05194462|DEVICE|Pericoach® by Analytica|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of home biofeedback .
223451254|NCT00003007|DRUG|dexamethasone|
223451255|NCT00003007|DRUG|melphalan|
223451256|NCT00003007|PROCEDURE|peripheral blood stem cell transplantation|
223451257|NCT02515903|PROCEDURE|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
223451258|NCT02515903|PROCEDURE|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
223451259|NCT01455584|DRUG|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
223451260|NCT02380937|PROCEDURE|ablation for typical atrial flutter|ablation for typical atrial flutter
223451261|NCT02380937|DEVICE|Vision Ablation Catheter|
223451262|NCT05366114|OTHER|No intervention, additional video data collection only|No intervention will be used. Consenting participants will have video recordings taken during their exam of joint hypermobility which will be analyzed at a later time
223451263|NCT03519126|OTHER|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
223451264|NCT03540069|BEHAVIORAL|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
223451265|NCT00214214|DRUG|Campath 1H® (Alemtuzumab)|
223451266|NCT02239445|DRUG|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
223451267|NCT02239445|DRUG|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
223451268|NCT02239445|DRUG|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
223451269|NCT06107855|OTHER|Leg Press Resistance Training Machine|Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.
223569712|NCT03098251|PROCEDURE|3D typing|typing the patient with 3D typing system and give specific treatment
223569713|NCT03098251|PROCEDURE|routine typing|typing the patient with routine typing system and give specific treatment
223569714|NCT05882864|DRUG|6-Gingerol|6-gingerol gel will be applied locally to the participants suffering from oral lichen planus
223569715|NCT05882864|DRUG|Triamcinolone Acetonide 0.1% Oromucosal Paste|Triamcinolone Acetonide 0.1% gel will be applied locally to the participants suffering from oral lichen planus
223569716|NCT05192018|PROCEDURE|Early reversal of a defunctiong ileostomy|Early reversal of a defunctiong ileostomy after 3 weeks of its creation
224058388|NCT05194462|OTHER|Pelvic Floor Physical Therapy|This intervention will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of PFPT.
224058389|NCT01093274|DRUG|Sodium Picosulphate|2 Sachets
224058390|NCT01093274|DRUG|Polyethylene Glycol|3 Liters solution
223451270|NCT05737901|OTHER|Education Booklet|"Training titles and contents were created by listing the most common complications and needs of patients after CABG surgery. In the General Information section of the booklet, the definition of CAD, how CABG surgery is performed, the length of hospital stay, and what can be experienced in the hospital after surgery and in the home environment after discharge were discussed. In the Postoperative Self-Care Practices section, information about the healing process of the breastbone, pain management, medication, respiratory exercises, early nutrition, personal hygiene, protection from coronavirus-19, pulse control, postoperative heart attack, conditions to be reported, compression stockings use for varicose veins, physical activity, travel, sleep and rest, sexual life, and coping with stress and depression was presented. In the Postoperative Life section, training topics on exercise, nutrition, smoking, and alcohol use were included."
223451271|NCT05737901|OTHER|Mobile application|"The logo and content of the Bypass e-Discharge application was visually designed, and the software was developed. In-app transactions were secured with end-to-end encryption by entering the username and password, and internet access was not required to use the application. The application was presented for expert opinion (3 patients, 1 academician, 2 nurses, 2 physicians) in order to investigate the user experience, and edits were made on its interface (such as adding the acceleration feature in videos, an additional button for stopping and starting videos, displaying video total time on the screen, and magnification of all buttons)."
223451272|NCT00640406|DEVICE|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
223451273|NCT00640406|DRUG|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
223451274|NCT01742416|PROCEDURE|Ultrasound|Arterial cannulation facilitated by ultrasound.
223451275|NCT01742416|PROCEDURE|Palpation Method|Arterial cannulation by palpation method.
223451276|NCT03498729|OTHER|Peripheral Blood Sample|30mL peripheral whole blood sample
223451277|NCT01218815|PROCEDURE|IRA stenting in culprit lesion only|stenting
224058391|NCT06407635|DRUG|Psilocybin|The two psilocybin doses will be administered approximately 2 weeks apart in the form of an oral capsule. The first dose will be 25mg. For the second dosing session, participants will either remain on 25 mg of psilocybin, or will receive a dose of 40 mg, depending on the strength of subjective effects experienced during the first dosing session, as well as clinical judgment and participant preference.
224058392|NCT06407635|OTHER|Trauma-focused psychotherapy|Components of trauma-focused psychotherapy will include Cognitive Processing Therapy and in vivo exposure. Such components of evidence-based psychotherapy may lower the safety risk profile for this vulnerable population and enhance the effect size and maintenance of psilocybin therapy.
224058393|NCT06407635|OTHER|Standard psychological support|Standard psychological support involves providing a safe and emotionally supportive environment to participants throughout the course of their participation, and being attentive and responsive to their emotional needs. It includes continued review and discussion of experiences that participants encountered during the psilocybin sessions and the way that those experience relate to the participant's life and clinical status.
224147180|NCT06138561|BEHAVIORAL|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)|Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
224147181|NCT06138561|BEHAVIORAL|Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)|Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
223451278|NCT01218815|PROCEDURE|IRA stenting|Complete IRA revascularization
223451279|NCT01915550|DRUG|Metformin|
223451280|NCT01915550|DRUG|Humulin Insulin Mixtard|
223451281|NCT02915250|DRUG|BioChaperone® Combo|Injection of BioChaperone® Combo
223451282|NCT02915250|DRUG|Humalog® Mix25|Injection of Humalog® Mix25
223451283|NCT02915250|DRUG|Humalog®|Injection of Humalog®
223451284|NCT02915250|DRUG|Lantus®|Injection of Lantus®
224058394|NCT03366688|DRUG|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
224058395|NCT03366688|DRUG|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
224058396|NCT05888727|BEHAVIORAL|"Seated Physical activity INtervention for persons with MS, SPIN program- Intervention Condition"|"The proposed exercise training program is based on Social Cognitive Theory (SCT) for promoting aerobic and strength training in wheelchair users with MS. The 16-week program includes one-on-one video chats with a behavioral coach and various tracks for progressive increases in both strength and aerobic training. The proposed strength training includes 15 exercises with step-by-step instructions using resistance bands and/or wrist weights that were adapted for seated body-position that can be executed in a wheelchair. The proposed aerobic training is arm cycle ergometry; this is a low-cost and modifiable option that fits the needs of both power and manual wheelchair users. Other proposed equipment includes a comprehensive Training Manual, fitness tracker for use during exercise training sessions, and Rate of Perceived Exertion (RPE) scale for guiding individualized exercise intensity. The research team created 12 Newsletters that align with 12 proposed coaching calls."
224147182|NCT00702585|DRUG|Org 36286|Org 36286 single-dose subcutaneous injection
224147183|NCT00702585|DRUG|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
224147184|NCT00194272|DRUG|Methotrexate|Two dose methotrexate
223451285|NCT02915250|DRUG|Placebo|Injection of 0.9% NaCl
223451286|NCT03382405|BIOLOGICAL|mRNA-1647|Escalating dose levels
223451287|NCT03382405|BIOLOGICAL|mRNA-1443|Escalating dose levels
223451288|NCT03382405|OTHER|Placebo|Saline
223451289|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
223451290|NCT06154421|PROCEDURE|Metacarpophalangeal joint prostheses|Observation after implantation of metacarpophalangeal joint prostheses using KeriFlex® or Swanson finger joint implants
223451291|NCT05682599|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
223451292|NCT05682599|DRUG|Placebo|Placebo
223451293|NCT05118763|DRUG|INNA-051|Liquid for intranasal administration
223451294|NCT05118763|OTHER|Placebo|Liquid for intranasal administration
223451295|NCT01041274|DRUG|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
223451296|NCT01041274|DRUG|Placebo|Placebo by mouth daily for 12 months.
223569717|NCT03587025|DRUG|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
224058397|NCT05888727|BEHAVIORAL|WEllness for Longevity Living with MS (WELL)- Control Condition|The attention/contact wellness control condition will mirror the exercise training intervention condition, but focuses on implementing health behaviors other than physical activity (e.g., diet and emotional wellbeing). This program is an adapted version of the WellMS program from Prof. Motl's Phase III clinical trial (NCT03490240). The program is based on SCT principles of behavior change and integrates wellness resources from the National MS Society (NMSS). The research team has created 12 Newsletters that will be delivered on the same chat schedule as the exercise training intervention. All coaching chats and newsletters will occur with the same frequency as in the exercise training intervention condition. Participants will be provided with a participant manual, logbook, and calendar. Participants will work with their behavioral coach on goal setting specific to wellness behaviors.
224058398|NCT03691233|DRUG|Clinical audit on diagnosis and management of neonatal shock|intervenous
224058399|NCT03614754|DIAGNOSTIC_TEST|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
224058400|NCT04002037|DRUG|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
224058401|NCT04002037|DRUG|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
224058402|NCT04002037|DRUG|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
224058403|NCT01429584|DRUG|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
224058404|NCT01429584|DRUG|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
224058405|NCT01568684|OTHER|Citalopram|Treatment
224058406|NCT00747643|DRUG|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
224147185|NCT00186654|PROCEDURE|Acupuncture|
223451297|NCT01041274|BEHAVIORAL|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
224058407|NCT00747643|DRUG|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
224058408|NCT04114292|DRUG|Tauroursoursodeoxycholic acid, brand name Tudcabil|Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
224058409|NCT01987687|BEHAVIORAL|Exercise|Exercise at 55% of maximum power output for 30 min.
224058410|NCT01987687|BEHAVIORAL|Rest|Rest for 30 min
223451298|NCT01041274|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
223451299|NCT01041274|RADIATION|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
223451300|NCT05846568|BIOLOGICAL|GR1801|The injection solution GR1801 does not contain preservatives. The excipients include histidine/histidine hydrochloride (20mM), trehalose (90 mg/mL), disodium EDTA (0.372mg/mL) and polysorbate 80 (0.5 mg/mL). The pH value is 5.8 and each bottle contains 2mg of GR1801 protein. The packaging material is a borosilicate glass tube injection bottle (2mL) with a halogenated butyl rubber stopper for injection and an aluminum-plastic composite cap for antibiotic bottles.
223569718|NCT03587025|DRUG|Placebo|Placebo
223569719|NCT05433051|BIOLOGICAL|buccal miniscrew and TPA|intrusion of molars
223569720|NCT05433051|BIOLOGICAL|vertical holding appliance|intrusion of molars
223569721|NCT02399540|DEVICE|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
223569722|NCT02399540|DEVICE|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
223569723|NCT02399540|DEVICE|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
223569724|NCT02399540|DEVICE|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
224058411|NCT01987687|BEHAVIORAL|Delay|Delay between exercise and OGTT
224058412|NCT03588351|DRUG|chitosan nanoparticles gel|intracanal medicament
224058413|NCT03588351|DRUG|chitosan gel|intracanal medicament
224058414|NCT03588351|DRUG|chlorhexidine gluconate|intracanal medicament
224058415|NCT00750698|DRUG|Entinostat|Entinostat (10 milligrams \[mg\] fixed dose orally \[PO\] every 2 weeks \[Q2W\]) on Days 1 and 15 of a 28-day cycle for up to 6 cycles
224058416|NCT00750698|DRUG|Erlotinib|Erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
224058417|NCT01636973|PROCEDURE|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
224147186|NCT00186654|PROCEDURE|Perinatal massage|
224147187|NCT04699305|DEVICE|ActiGraft|Whole blood clot (WBC) gel
224147188|NCT00027456|DRUG|Leptin A-100|
224147189|NCT02431468|DRUG|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
224147190|NCT02431468|OTHER|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
224147191|NCT05073965|DIETARY_SUPPLEMENT|Vitamin D|Subjects were assigned to receive a 1000IU vitamin D supplement dose
223451301|NCT05846568|BIOLOGICAL|Human Rabies Immunoglobulin(HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin produced by BOYA-BIO, which are derived from human plasma, and then purified and filled in the injectable vial form.
224058418|NCT04715061|OTHER|Resting state (Control)|Participants were asking to sit on a sofa for 50 minutes.
224058419|NCT04715061|OTHER|Moderate Intensity Continuous Exercise (MICE)|MICE condition consisted of 50 minutes of moderate and continuous aerobic exercise on ergocycle. This includes a warm-up and cool-down period at low intensity, and a 40-minute period at moderate intensity (power output is equivalent to an effort perception from 4 to 6/10 and lactate levels from 2 to 4 mmol/L, obtained by submaximal test)
224058420|NCT04715061|OTHER|High Intensity Interval Exercise (HIIE)|HIIT condition consisted of a 30 minutes of aerobic exercise training perform on ergocycle. This includes a warm-up at low intensity, followed by 10 blocks of 1 minute at high intensity (power output corresponding to the highest power reached at the submaximal test and lactate levels \> 4 mmol/L) and 1 minute of active cooldown (effort perception around 1-2/10).
224058421|NCT05947487|BIOLOGICAL|CD70-targeting CAR-T cells|"Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;"
224058422|NCT01426139|DEVICE|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
224058423|NCT03522870|DEVICE|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
224058424|NCT03522870|DEVICE|SMBG|Performing SMBG at least three times/day on Week 2-14 and Week 14-26
223451302|NCT05846568|BIOLOGICAL|Rabies Vaccine|The Chinese licensed freeze-dried rabies vaccine produced by CHENGDA PHARMACEUTICALS for human use (Vero Cells) which is indicated for the rabies Post-exposure Prophylaxis (PEP) .
223451303|NCT02028780|DRUG|Placebo to dose|placebo
223451304|NCT02028780|DRUG|Idarucizumab|short infusion
223451305|NCT02028780|DRUG|Placebo to Idarucizumab|Placebo to Idarucizumab
223451306|NCT02028780|DRUG|dabigatran|2 capsules dabigatran
224058425|NCT02452905|DRUG|Nitazoxanide|
224058426|NCT02452905|DRUG|Placebo (for Nitazoxanide)|
224305064|NCT01916590|DRUG|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
223451307|NCT02028780|DRUG|Idarucizumab|short infusion
223451308|NCT00777335|DRUG|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
223451309|NCT00777335|DRUG|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
223451310|NCT04656184|DRUG|ANAKINRA|The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
223451311|NCT04656184|DRUG|Intravenous immunoglobulin|The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
224058427|NCT02365220|BEHAVIORAL|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
224058428|NCT02365220|BEHAVIORAL|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
224058429|NCT02365220|BEHAVIORAL|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
224058430|NCT02365220|BEHAVIORAL|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
224058431|NCT06219265|BEHAVIORAL|Dance Therapy|"A single-centre prospective randomised controlled trial will be conducted with a minimum of 48 patients with severe mental disorder (SMD) who will be randomised into two groups, 1 intervention group receiving dance therapy (n=24) and 1 control group receiving no intervention or treatment (n=24).~In addition, there will be an intervention group of healthy people who will receive dance therapy (n=20).~All the tests, will be carried out with patients with SMD and only the EEG for healthy people, in order to determine their baseline state. The dance therapy program will last for 20 sessions over 10 weeks.~The 44 people in the two experimental groups will participate in a 10-week intervention program with 2 sessions per week in which they will work for 1 hour on memory, attention and executive functions through dance and movement, ending with 10 minutes of Mindfulness.~The 24 people in the control group will not receive any type of intervention."
224305065|NCT01916590|DRUG|placebo|
224305066|NCT00505089|DRUG|ACZ885|
224305067|NCT00505089|DRUG|ACZ885|
224305068|NCT00505089|DRUG|ACZ885|
224305069|NCT00505089|DRUG|ACZ885|
223569725|NCT06411886|DIAGNOSTIC_TEST|Allergen challenge|Inhaled allergen
223569726|NCT06411886|DIAGNOSTIC_TEST|Saline challenge|Inhaled saline
223569727|NCT04022681|OTHER|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
223569728|NCT06306651|OTHER|High flow nasal cannula therapy group|Patients who will be randomized to high flow nasal cannula therapy. High flow nasal oxygen cannula will be applied at a flow of 20 L/min at FiO2 of 0.4 at a temperature of 36oC
224305070|NCT06493604|DRUG|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days
223451312|NCT01945476|DRUG|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
223451313|NCT01113307|BIOLOGICAL|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
224058432|NCT03321136|DRUG|LSD|0.025 mg LSD per os, single dose
223451314|NCT03637790|DRUG|PF-04965842|single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
223451315|NCT03637790|OTHER|rifampin|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
223451316|NCT00909220|BEHAVIORAL|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis \& Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
223451317|NCT00323843|DRUG|Isoproterenol|
223451318|NCT01148459|BIOLOGICAL|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
223451319|NCT01148459|BIOLOGICAL|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
223451320|NCT01148459|BIOLOGICAL|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
223451321|NCT00694356|BIOLOGICAL|Dalotuzumab|IV infusion
223451322|NCT01994421|OTHER|Kinesiotape|
223451323|NCT05313321|DEVICE|Primary total hip arthroplasty receiving the Insignia Stem|Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
223451324|NCT02399969|OTHER|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
223451325|NCT03278236|BEHAVIORAL|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
223451326|NCT04728698|DRUG|COVI-MSC|1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
223451327|NCT04728698|DRUG|Placebo|Equivalent volume of placebo will be administered
223451328|NCT05587894|DRUG|Paxlovid 5 days|"Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19."
223451329|NCT05587894|DRUG|Paxlovid 10 days|Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
223569729|NCT06306651|OTHER|Conventional oxygen therapy group|Patients who will be randomized to simple oxygen mask therapy. The simple face mask will be applied in a rate range between 6-10 L/min.
223569730|NCT00162500|BIOLOGICAL|Peptide Vaccine (MUC-1)|
224058433|NCT03321136|DRUG|LSD|0.05 mg LSD per os, single dose
223569731|NCT03867786|BEHAVIORAL|Exercise|Participants will complete an acute exercise visit.
224058434|NCT03321136|DRUG|LSD|0.1 mg LSD per os, single dose
223569732|NCT03867786|BEHAVIORAL|Video Control|Participants will complete a video control visit.
223569733|NCT02101801|OTHER|vegetables from fresh or recycled water|
223569734|NCT02101801|OTHER|receives vegetables from fresh water or recycled waste water farms|
223569735|NCT02123238|OTHER|bed positioning|
223569736|NCT03447314|DRUG|GSK1795091|GSK1795091 will be available as solution for injection
223569737|NCT03447314|DRUG|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
223569738|NCT03447314|DRUG|GSK3359609|GSK3359609 will be available as solution for infusion.
223569739|NCT03447314|DRUG|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
224058435|NCT03321136|DRUG|LSD|0.2 mg LSD per os, single dose
224058436|NCT03321136|DRUG|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
224058437|NCT03321136|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
224147192|NCT05073965|OTHER|Placebo|Subject were assigned to receive a placebo
223451330|NCT05587894|DRUG|Veklury|"Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound."
224058438|NCT04964427|DRUG|Methylphenidate|A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
224058439|NCT04964427|DEVICE|anodal tDCS|Anodal electrode will be positioned over the left dlPFC, according to the 10-20 EEG on the sites corresponding F3, whereas the reference electrode will be placed above the contralateral supraorbital area, corresponding to Fp2. In the active tDCS condition, the current will increase slowly during the first 30 seconds to 1 mA (ramp-up) and, at the end of the stimulation, the current will decrease slowly to 0 mA during the last 30 seconds (ramp-down). Between the ramp-up and ramp-down constant current will be delivered for 20 minutes, with a density of 0.04 mA/cm2.
224058440|NCT04964427|DEVICE|sham tDCS|In the sham tDCS condition, the stimulation will be delivered by using the same active tDCS montage, respectively left-anodal dlPFC and right-reference electrode over Fp2. Stimulation intensity will be set at 1 mA, but the current will be applied for 30 seconds and will be ramped down without the participants' awareness.
224058441|NCT04298736|PROCEDURE|Bariatric Surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy
224058442|NCT04298736|BEHAVIORAL|Lifestyle modification|guided low-calorie diet and physical activity.
224058443|NCT03378804|PROCEDURE|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
224058444|NCT03378804|PROCEDURE|Continous epidural analgesia|
224058445|NCT06011148|DEVICE|Perceval S sutureless heart valve|Aortic Valve Replacement with Perceval S sutureless heart valve
224058446|NCT05905120|DRUG|Toludivenlafaxine hydrochloride sustained-release tablets|80 mg/tablet, 2 tablets each time, once a day, for 4 days, orally at 30 min after the start of meals, 200 mL water to take
224058447|NCT02263079|DRUG|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
224058448|NCT02263079|DRUG|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
224058449|NCT02263079|DRUG|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
224058450|NCT01473238|OTHER|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
224058451|NCT00210392|DRUG|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
224058452|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with web-based support|Those in the web-based physio group will access their exercise program online and will be able to leave messages for their physiotherapist on the platform. Physiotherapists will monitor usage and respond to messages every two weeks.
223451331|NCT04168255|PROCEDURE|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
223451332|NCT01152996|DRUG|Vortioxetine|Vortioxetine tablets
223451333|NCT02072941|BEHAVIORAL|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
224058453|NCT03039400|BEHAVIORAL|Physiotherapist-guided home exercise with standard support|Those in the standard care group will receive a written, home-based exercise program. Participants in the usual care group will be asked to keep an exercise diary, in paper format.
224305071|NCT06493604|DRUG|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered six times over two consecutive days
223451334|NCT05982197|DRUG|Curcumin Gel|Curcuma longa oral gel for prevention radiation induced oral mucositis
223451335|NCT05982197|DRUG|Standard Preparation|Standard preparation for prevention radiation induced oral mucositis
223451336|NCT04164797|DRUG|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
224058454|NCT00199550|PROCEDURE|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
223451337|NCT04164797|OTHER|chemoradiotherapy|chemoradiotherapy
224058455|NCT00199550|PROCEDURE|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
224058456|NCT05895942|DRUG|Imatinib|The control group, before and after imatinib treatment, and patients with different efficacy of imatinib treatment were collected, and the correlation analysis was performed to screen the key flora and metabolites that affect the efficacy of imatinib
223451338|NCT01067417|DRUG|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
223451339|NCT01067417|DRUG|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
223451340|NCT04400149|DIAGNOSTIC_TEST|amniocentesis|amniocentesis will be performed to the pregnant women at 16-20 weeks who had a high-risk antenatal test. Furthermore, these women also give a blood sample (at 16-20 weeks) to compare the amniotic fluid and serum progesterone levels in association with pregnancy outcomes. We perform amniocentesis to evaluate genetic disorders in pregnant women who had his risk in the antenal test.
224058457|NCT05823675|DRUG|Itolizumab|Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.
224058458|NCT05823675|DRUG|Methylprednisolone|Methylprednisolone will be taperred as required
224058459|NCT02031562|OTHER|chiropractic|chiropractic
224058460|NCT02031562|OTHER|physical therapy|physical therapy
224058461|NCT05426889|PROCEDURE|subdural hematoma burr hole drainage|For patients with larger hematoma, remove the hematoma by burr hole drainage
224058462|NCT05426889|DRUG|drug conservative treatment|The patient did not receive surgical treatment and chose conservative treatment
224305072|NCT01998672|DRUG|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
224305073|NCT01998672|DRUG|Placebo|Drinking solution
223451341|NCT00401128|DRUG|gemcitabine hydrochloride|
223451342|NCT00401128|DRUG|irinotecan hydrochloride|
223451343|NCT00893074|DRUG|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
223451344|NCT00893074|DRUG|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
223451345|NCT00893074|DRUG|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
223451346|NCT00893074|DRUG|Placebo|placebo dronabinol administered 3x/day for 5 days
224058463|NCT04802993|OTHER|Resection rates|All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
223451347|NCT00744718|DRUG|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
224058464|NCT02700724|OTHER|Immediate Surgery|
224058465|NCT02700724|OTHER|Observation|
224058466|NCT02700724|PROCEDURE|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
224058467|NCT01157221|OTHER|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
223451348|NCT00744718|DRUG|Carboplatin|Carboplatin AUC 5 every 5 weeks
224058468|NCT01157221|OTHER|EMSMTA|end-range mobilization/scapular mobilization treatment approach
224305074|NCT05244395|OTHER|Duchenne Muscular Dystrophy Gait Assessment Scale|a special gait assessment scale for Duchenne Muscular Dystrophy patients
224305075|NCT00003916|RADIATION|radiation therapy|
224305076|NCT00003916|RADIATION|stereotactic radiosurgery|
223451349|NCT04957212|DRUG|Trastuzumab|An initial dose of 8 mg/kg, followed by 6 mg/kg every 3-weeks
223451350|NCT04957212|DRUG|Pertuzumab|An initial dose of 840 mg, followed by 420 mg every 3-weeks
223451351|NCT04957212|DRUG|Carboplatin|A dose of AUC6 (area under the plasma concentration-time curve) every 3-weeks
223451352|NCT04957212|DRUG|Docetaxel|75 mg/m2 every 3-weeks
223451353|NCT02048124|DEVICE|25g standard needle|
223451354|NCT02048124|DEVICE|25d ProCor needle|
223451355|NCT01351454|BEHAVIORAL|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
223451356|NCT01351454|BEHAVIORAL|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
223451357|NCT03131726|DRUG|Simvastatin 40mg|see arm description
223451358|NCT04719598|BEHAVIORAL|congnitive behavioural therapy|CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
223451359|NCT03124160|DRUG|Mona Lisa® NT Cu380 Mini|copper intrauterine device
223451360|NCT03124160|DRUG|ParaGard® TCu380A|copper intrauterine device
223451361|NCT05459337|BEHAVIORAL|MuST AKT|A behavioural intervention designed to help participants identify and communicate with their social network about living kidney donation.
223569740|NCT01485900|DRUG|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
223569741|NCT02694068|OTHER|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
223569742|NCT02694068|OTHER|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
223569743|NCT06490068|DRUG|LTC004+Toripalimab|"LTC004 on D1 of Week 1 and D1 of week 3. IV,90μg/kg. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab.~LTC004:D3,iv,45μg/kg,Q3W. Toripalimab:D1,iv,240mg,Q3W."
223569744|NCT04600076|BEHAVIORAL|BabyCenter site and the community group|Participants will be asked to sign on to the BabyCenter community group for people with pregnancy or infant loss at least 3 times weekly for 6 weeks. Participants may choose to post or comment on the site but are not required to do so.
223569745|NCT02891681|DEVICE|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
223569746|NCT02632201|BIOLOGICAL|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
223569747|NCT02632201|BIOLOGICAL|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
223569748|NCT01382121|BEHAVIORAL|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
223569749|NCT01382121|BEHAVIORAL|Control|watching a video unrelated to the fitness test and self-efficacy
223569750|NCT05636410|DIAGNOSTIC_TEST|Larynx and trachea ultrasound|After meeting enrolment criteria the larynx and trachea ultrasound will be performed at 32 and 42 weeks of gestation.
223569751|NCT06542601|DEVICE|Motor cognitive intervention|Older adults were given cognitive training and motor training for 12 weeks using a tablet computer
224058469|NCT02004496|DEVICE|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
224058470|NCT01467843|BEHAVIORAL|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
224058471|NCT01467843|BEHAVIORAL|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
224058472|NCT03970694|RADIATION|Radiotherapy|"Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy."
224058473|NCT03970694|DRUG|oxaliplatin+capecitabine|Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
223451362|NCT04512950|DRUG|Ringer's lactate|Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.
223451363|NCT04512950|DRUG|0.9% saline|Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.
223451364|NCT05522946|OTHER|Gameplay between parent and child or adolescent with or without a disability|Parent and child or adolescent will play the game using the provided sensors for 10-15 minutes total. Depending on the cognitive and/or physical ability of the child or adolescent, the two may take turns wearing the sensors or if the child or adolescent does not have the physical or cognitive ability to deliberately touch the sensor, then the child or adolescent will wear the sensors and the parent will touch the sensors in order to move the game forward.
223451365|NCT06644079|DRUG|Tranexamic acid|Participants will self-apply topical tranexamic acid to the area where their disease is located 3 times daily for 21-28 days prior to their scheduled Moh's or excision surgery.
224058474|NCT03557281|DRUG|GSK3036656|GSK3036656 will be administered
223451366|NCT03884309|OTHER|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
223451367|NCT01838772|DRUG|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
223451368|NCT00533221|DRUG|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
223451369|NCT00533221|DRUG|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
223451370|NCT03522818|BEHAVIORAL|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
223451371|NCT03522818|BEHAVIORAL|Normal|Will use the alarm as provided by the manufacture.
223451372|NCT06071546|DEVICE|MAIA|MAIA is a visual field testing device combining visual field tests, fixation loss correction by a real-time retinal tracker and confocal TrueColor fundus imaging (P/N AHMACME001)
224058475|NCT03557281|DRUG|Rifafour e-275|Rifafour e-275 will be administered
224058476|NCT00529074|DEVICE|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
223451373|NCT02003755|PROCEDURE|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
223451374|NCT04283435|DRUG|Sildenafil Citrate|Sildenafil Citrate 50 mg tablets taken from the first day of the cycle till the day we start progesterone (we stop 3 days before embryo transfer)
223451375|NCT04283435|OTHER|Placebo|Placebo tablet (multivitamins),Pregnacare vitamins (Vitabiotics,UK)
223451376|NCT04283435|DRUG|Estradiol Valerate|Estradiol valerate tablets 2mg every 8 hours daily starting from the fist day of the cycle till 12th day of the menstrual cycle.
223451377|NCT02472158|DEVICE|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
223451378|NCT02472158|DEVICE|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
223451379|NCT03288545|DRUG|enfortumab vedotin (EV)|Intravenous (IV) infusion on days 1 and 8 every 21 days
223451380|NCT03288545|DRUG|pembrolizumab|IV infusion on day 1 every 21 days
223451381|NCT03288545|DRUG|cisplatin|IV infusion on day 1 every 21 days
223741968|NCT07206576|DEVICE|a percussion massage gun|"Participants assigned to the intervention group will receive a single session of percussion massage therapy (PMT) using the Compex® Fixx™ 2.0 handheld device. The treatment will be applied bilaterally to three major muscle groups: gluteus maximus, quadriceps femoris, and gastrocnemius.~The device will operate at a high intensity setting (Level 4) with a frequency of 41.7 Hz.~A wedge-shaped applicator head will be used to ensure consistent pressure across the treatment area.~Each muscle group will be treated for 3 minutes, following a standardized linear stroke pattern from proximal to distal and back.~The total duration of the intervention will be approximately 18 minutes.~The intervention will be performed once, immediately before the post-test evaluations, and aims to assess acute effects on neuromuscular performance."
224058477|NCT04930055|BIOLOGICAL|COVID-19 Vaccination|Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
223451382|NCT03288545|DRUG|carboplatin|IV infusion on day 1 every 21 days
223451383|NCT03288545|DRUG|gemcitabine|IV infusion on days 1 and 8 every 21 days
223451384|NCT05514457|BEHAVIORAL|visual stimulation with I pad|"At the beginning of the study, for baseline condition, children will do 4 tests (visuo-spatial perception test, visual attention span, visual research, phonology tests).~In the first group of the study, the children will do visual research exercises on I pad 10 minutes per day during one month = remediation. They will also do 4 reading aloud tests, once a month, for 3 months. The remediation exercises will be realized during the first, second or third month."
223569752|NCT01101971|OTHER|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
224058478|NCT02665169|BEHAVIORAL|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
224058479|NCT02665169|OTHER|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
224058480|NCT04216277|DIAGNOSTIC_TEST|Procalcitonin|"In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.~* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml~* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml"
224058481|NCT00402649|BIOLOGICAL|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
224058482|NCT04467424|DRUG|ketamine, propofol|anesthesia with ketofol in pediatric surgery
224058483|NCT04467424|DRUG|ketamine, propofol, lidocaine|anesthesia with ketofol plus lidocaine in pediatric surgery
223451385|NCT05514457|BEHAVIORAL|visual stimulation with lamp|"At the beginning of the study, for baseline condition, children will do the 4 tests like group 1.~In the second group of the study, the children will do reading aloud tests, with lamp adjusted with different parameters = remediation (passive visual stimulation of a specific frequency believed to promote visual processing of written symbols)."
223451386|NCT05753735|DRUG|Piperacillin/Tazobactam|Piperacillin/Tazobactam 3.375 g IV every 6 hours while inpatient following surgery, not to exceed 10 days
223569753|NCT00002319|DRUG|Doxorubicin hydrochloride (liposomal)|
223569754|NCT04889768|DRUG|HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery|"1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles."
223569755|NCT00944736|DIETARY_SUPPLEMENT|VSL#3|1 packet BID
223569756|NCT00944736|DIETARY_SUPPLEMENT|Placebo|1 inactive packet BID
223569757|NCT01745744|OTHER|Mesenchymal stem cells from adipose tissue|\- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
223569758|NCT06121609|DRUG|Remimazolam|Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
224058484|NCT01199042|DEVICE|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
224058485|NCT01999465|DEVICE|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (300 us)~* Ch1 Ramp+ (2 seconds)~* On Time 1 (10 seconds)~* Ch1 Ramp - (2 seconds)"
224058486|NCT01999465|DEVICE|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (48 us)~* Ch1 Ramp+ (0 seconds)~* On Time 1 (0 seconds)~* Ch1 Ramp - (0 seconds)"
224058487|NCT03171220|BIOLOGICAL|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
224058488|NCT03171220|BIOLOGICAL|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
224058489|NCT03171220|DRUG|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
224058490|NCT03171220|DRUG|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
223451387|NCT05753735|DRUG|Amoxicillin/ Clavulanic acid|Amoxicillin/ Clavulanic acid 875/125 mg every 12 hours after discharge to complete 10 days total antibiotics
223451388|NCT01471275|DRUG|Metformin|250 mg or 500mg three times a day
223451389|NCT01471275|DRUG|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
223451390|NCT00770471|DRUG|temozolomide|
223451391|NCT00770471|DRUG|veliparib|
223451392|NCT00770471|GENETIC|DNA methylation analysis|
223451393|NCT00770471|GENETIC|gene expression analysis|
223451394|NCT00770471|GENETIC|mutation analysis|
223451395|NCT00770471|GENETIC|proteomic profiling|
223451396|NCT00770471|OTHER|high performance liquid chromatography|
223451397|NCT00770471|OTHER|immunoenzyme technique|
223451398|NCT00770471|OTHER|laboratory biomarker analysis|
223451399|NCT00770471|OTHER|mass spectrometry|
223451400|NCT00770471|OTHER|pharmacogenomic studies|
223569759|NCT01372072|DEVICE|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
223569760|NCT00534118|BIOLOGICAL|donor lymphocytes|Given IV
223569761|NCT01391572|RADIATION|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
223569762|NCT01391572|RADIATION|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
223569763|NCT01391572|DRUG|cisplatin|
223569764|NCT01391572|DRUG|fluorouracil|
223569765|NCT06459089|BEHAVIORAL|Selection of the parent according to children preference|The children will select the parent who will accompany them during the anesthesia induction
223569766|NCT06459089|BEHAVIORAL|Bringing the favorite toy of the children that will accompany the child during their perioperative period|The children will bring tiheir favorite toy that will accompany them during their perioperative period
223569767|NCT03142724|DRUG|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.
223569768|NCT02589652|DRUG|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
223569769|NCT02589652|DRUG|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
223569770|NCT02589652|DRUG|Entecavir|ETV 0.5mg oral daily for 48 weeks
223569771|NCT00150111|DRUG|Methimazole|
223569772|NCT00150111|DRUG|Rituximab|
223569773|NCT00150111|BIOLOGICAL|Immunization with various vaccines|
223451401|NCT00770471|OTHER|pharmacological study|
223451402|NCT00770471|PROCEDURE|adjuvant therapy|
223451403|NCT00770471|RADIATION|radiation therapy|
223451404|NCT00078845|DRUG|Amifostine|500 mg three times a week.
223451405|NCT06439472|OTHER|Suboccipital Inhibition Technique|"The researcher will place their palms under the patient's head and use their fingers to contact the occipital condyles. Next, the researcher will place the 3rd and 4th fingers of each hand in the space between the occiput and the spinous process of C2. The metacarpophalangeal joints are at 90º flexion, with the base of the skull resting on their hands while they apply constant, non-painful pressure in a postero-anterior direction, keeping the 2nd, 3rd and 4th fingers together in extension. Afterwards, the researcher applies a light and gentle traction in a cephalad direction in order to relieve the suboccipital area. Once the suboccipital muscles have relaxed, the researcher gently removes the contact, leaving the participant's head resting on the table.~This technique is performed for 4 minutes."
223451406|NCT06439472|OTHER|Sham Technique|The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 4 minutes.
223451407|NCT01534416|DRUG|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
223451408|NCT01534416|DRUG|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
223451409|NCT05660668|OTHER|Transbond LR|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond LR will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
223451410|NCT05660668|OTHER|Transbond XT|cleaning the lingual surface using oil free pumice then apply acid etch 35% phosphoric acid for 20 second then rinse then Transbond XT will be applied directly on the fixed retainer and lingual surface of the teeth then light cured.
223451411|NCT03825081|DRUG|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
223451412|NCT04462822|DRUG|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent|2 inhalations of Test and Reference product in each study period
223451413|NCT04462822|DRUG|ADVAIR DISKUS® 250/50|2 inhalations of Test and Reference product in each study period
223569774|NCT00926419|BIOLOGICAL|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
223569775|NCT00926419|BIOLOGICAL|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
223569776|NCT06489821|RADIATION|Stereotactic body radiotherapy|Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
223569777|NCT02239835|DRUG|Tipranavir (TPV) low dose|
223569778|NCT02239835|DRUG|Tipranavir (TPV) high dose|
223569779|NCT02239835|DRUG|Ritonavir low dose|
223569780|NCT02239835|DRUG|Ritonavir high dose|
224058491|NCT03171220|BIOLOGICAL|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
224058492|NCT01439464|DEVICE|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
224058493|NCT01439464|DEVICE|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
224058494|NCT05030012|DEVICE|Automated Control|The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.
224058495|NCT05030012|DEVICE|Manual Control|The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
224058496|NCT00809666|DEVICE|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
224058497|NCT01114503|DRUG|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
224058498|NCT01114503|DRUG|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
223451414|NCT03224624|OTHER|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
223451415|NCT04837287|OTHER|Static Stretching Exercise for 10 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
223451416|NCT04837287|OTHER|Static Stretching Exercise for 30 Seconds|The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
223451417|NCT01884545|BEHAVIORAL|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
223451418|NCT01884545|GENETIC|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
223451419|NCT01884545|BEHAVIORAL|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
223451420|NCT04763616|DRUG|Isatuximab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
223451421|NCT04763616|DRUG|Cemiplimab|The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.
223451422|NCT04037293|DIAGNOSTIC_TEST|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
223451423|NCT04319926|DRUG|lidocaine topical system 1.8%|One topical system is applied to the subject's back for 12 hours.
223451424|NCT04319926|DRUG|lidocaine patch 5%|One generic lidocaine patch is applied to the subject's back for 12 hours.
223569781|NCT02239835|DRUG|Saquinavir|
223451425|NCT02903810|BIOLOGICAL|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
223451426|NCT01761929|RADIATION|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
224058499|NCT01114503|DRUG|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
224058500|NCT01114503|DRUG|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
223451427|NCT05157555|OTHER|Data collection|Description: quality of life assessment
223451428|NCT03489980|OTHER|coloring-type artistic task of a complex form|coloring-type artistic task of a complex form
223451429|NCT03839329|BEHAVIORAL|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
223569782|NCT05066581|DEVICE|Live Chat|Subjects from the intervention group will be able to ask for a medical intervention if needed with the phisycians from the sleep unit. After the following period, we expect to see better sleep habits in this group when compared to the no intervention one
223569783|NCT02856243|DRUG|new antiviral therapy|
223569784|NCT03718572|PROCEDURE|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
223569785|NCT00957944|DRUG|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
224058501|NCT01114503|DRUG|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
224058502|NCT01114503|DRUG|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
224058503|NCT01867060|DEVICE|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
224058504|NCT01867060|DEVICE|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
224058505|NCT03328546|OTHER|Dietary intake|Dietary intake converted into dietary pattern scores.
224058506|NCT01602770|DRUG|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
224058507|NCT04056572|DRUG|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
223451430|NCT02521792|DRUG|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
223451431|NCT05887960|OTHER|CBC and flow cytometry test for monocyte|all groups assigned Cbc with leukocyte differential and flow cytometry for monocyte population
224058508|NCT05798442|OTHER|smartphone health application (Opulse)|The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
224058509|NCT01423162|OTHER|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
224058510|NCT01423162|OTHER|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
224058511|NCT02157675|DIETARY_SUPPLEMENT|Polyherbal capsule|
224058512|NCT02157675|DIETARY_SUPPLEMENT|Placebo capsule|
223451432|NCT00685867|OTHER|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
223451433|NCT00685867|BEHAVIORAL|Hand hygiene promotion|"* Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~* Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~* Isolation precautions according to the hospitals' capacity and strategy~* Additional basic infection control interventions (if necessary)"
223451434|NCT00455676|PROCEDURE|Chevron osteotomy versus Scarf osteotomy|
223451435|NCT00538226|DEVICE|External Electric Muscle Stimulation|
223569786|NCT00977275|RADIATION|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
223569787|NCT00448851|BIOLOGICAL|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
223569788|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
223569789|NCT01510366|BIOLOGICAL|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
223569790|NCT04041466|DIAGNOSTIC_TEST|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
223569791|NCT04915989|DRUG|GX-19N|DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
224058513|NCT02951715|DRUG|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
224058514|NCT02180555|OTHER|Oral glucose tolerance test|
224058515|NCT06320561|OTHER|Longitudinal prospective cohort study|Patients after stroke who meet the in- and exclusion criteria will be examined 4 times during the first 3 months after their stroke.
224058516|NCT02853942|BIOLOGICAL|Autologous adipose stem cell therapy|
224058517|NCT02853942|DRUG|Mecobalamin|
224058518|NCT05722119|DIAGNOSTIC_TEST|FilmArray GI|Rapid multiplex Polymerase Chain Reaction (PCR) assay for digestive infectious agents in stool sample in the baseline diagnostic tests panel
223451436|NCT02571062|DRUG|Fexinidazole|
223451437|NCT05195216|BEHAVIORAL|Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form|Online questionnaires were administered to individuals.
223451438|NCT01188668|DRUG|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
223451439|NCT01188668|DRUG|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
223451440|NCT05538936|OTHER|Baby SPA|"Salus Per Aquam, Sanitas Per Aquam, Salut Per Aqua or Solus Per Aqua (SPA) means health that comes with water. Baby SPA is a physiotherapy method that stimulates the baby's motor movements through water (hydrotherapy) and performs it in an integrated way to balance the body, mind, and emotions. Baby SPA is applied in specially designed bathtubs. The size of the tub is designed in such a way that children can move their hands and feet freely and not be narrow. A neck ring/ring is used to keep the baby on the water surface during SPA treatment."
223569792|NCT04256668|DIAGNOSTIC_TEST|Obtaining one or semen samples|Through staining of semen samples with sets of dyes to measure features of chromatin density, nuclear morphology and mitochondrial status in large numbers of single spermatozoa and to compare differences in the staining results with known fertility outcome. Through comprehensive comparative epigenetic studies we anticipate to explain different efficiencies of sperm from men with seemingly normal semen quality in driving embryonic development.
224058519|NCT02791984|DEVICE|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
224058520|NCT05418400|OTHER|sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X|dental filling materials
224058521|NCT02657395|DEVICE|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
223569793|NCT00003675|DRUG|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
224058522|NCT02554019|BIOLOGICAL|BT063|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
224058523|NCT02554019|BIOLOGICAL|Placebo|Repeated IV infusions over 12 weeks (at weeks 0, 1, 2, 4, 6, 8, 10, 12)
224058524|NCT03603860|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
224058525|NCT06047340|DEVICE|G:DATA, dementia screen videogame|A videogame for screening
224058526|NCT02463409|DRUG|Theophylline|24 hour infusion of IV theophylline
224058527|NCT02835183|DEVICE|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
224058528|NCT02835183|DEVICE|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
224058529|NCT00350051|DRUG|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
223451441|NCT05538936|OTHER|Massage|"The best way to communicate with a baby is to touch it. When babies are born, unlike their other senses, the most developed one is the sense of touch. Because this process begins while in the womb. The baby communicates by touch and begins to recognize his environment. The sense of touch is a priority for the development of all senses. They need to perceive their environment, especially in newborns and infancy periods. Touching the body in a systematic way for a therapeutic purpose is called Massage. Massage is soft touches to body tissues to relax muscles, accelerate circulation, reduce infantile colic symptoms and pain, regulate sleep, and increase its duration. Baby massage has many benefits such as reducing colic symptoms, increasing weight gain, providing motor development and coordination, strengthening the parent and baby bond, supporting growth and development, and reducing stress."
223451442|NCT05292014|DEVICE|ANGIOLITE|Patients in whom treatment with ANGIOLITE has been attempted
223451443|NCT03121794|PROCEDURE|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
223451444|NCT03121794|DEVICE|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
223451445|NCT05601180|OTHER|Respicure®|Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%/0.38%.
223451446|NCT05601180|OTHER|Standard of care|standard treatment is prescribed by the treating physician.
223451447|NCT02424994|OTHER|No intervention|
223451448|NCT01530802|PROCEDURE|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
223451449|NCT00303472|DRUG|Romiplostim|
223451450|NCT02302040|BEHAVIORAL|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
223569794|NCT01482169|DRUG|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
224058530|NCT02281370|DRUG|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
224058531|NCT02281370|DRUG|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
224058532|NCT01308008|BEHAVIORAL|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
223451451|NCT02302040|BEHAVIORAL|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
223451452|NCT00084227|DRUG|Azithromycin/Chloroquine|
223451453|NCT00084227|DRUG|Atovaquone/Proguanil|
223451454|NCT00478075|DRUG|bortezomib|
223569795|NCT01996696|DRUG|Metformin|Metformin 500 mg PO TID x 30-36 months
223569796|NCT01996696|DRUG|Placebo|Identical placebo TID x 30-36 months
223569797|NCT00522418|DEVICE|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
223569798|NCT00522418|DRUG|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
224058533|NCT01308008|BEHAVIORAL|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
224058534|NCT03357731|DRUG|HNO Donor|Infusion
224058535|NCT03357731|DRUG|Nitroglycerin (NTG)|Infusion
223451455|NCT00478075|OTHER|immunologic technique|
223451456|NCT00478075|RADIATION|samarium Sm 153 lexidronam pentasodium|
223451457|NCT02334345|DRUG|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
223451458|NCT02334345|DRUG|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
223451459|NCT00004067|BIOLOGICAL|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
224058536|NCT03357731|OTHER|Placebo|Infusion
224058537|NCT01417195|DRUG|Bravelle|
224058538|NCT01417195|DRUG|Menopur|
224058539|NCT05382351|DRUG|Entecavir|Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
224058540|NCT05382351|DRUG|Entecavir combined with Tenofovir Amibufenamide|Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
224058541|NCT05196126|PROCEDURE|Permament pacemaker implantation|PM implantation
224058542|NCT05196126|PROCEDURE|Cardioneuroablation|Biatrial, binodal CNA procedure with anatomical approach will be performed with pre- and post procedural extracardiac vagal nerve stimulation in general anesthesia.
224058543|NCT00772954|BIOLOGICAL|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
224058544|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
223451460|NCT00004067|DRUG|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
223451461|NCT00004067|DRUG|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
224058545|NCT00772954|BIOLOGICAL|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
224058546|NCT03986489|BEHAVIORAL|Mindfulness-based dance/movement therapy (M-DMT)|M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each online session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
224058547|NCT03986489|BEHAVIORAL|Chronic pain social support group|"The therapist will facilitate online open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive emails with brief information about the topic discussed during the group session."
224058548|NCT06288087|OTHER|VR Based Training with Machine Guidance (MG Group)|The members of both groups will undertake a VR based basic training for ALS. Afterwards MG group were trained with VR based Advanced Training Module, which provides training with full machine guidance. The knowledge level will then be evaluated by the exam mode of the VR based training module
224058549|NCT06288087|OTHER|VR Based Training with Educator Guidance in Metaverse (EG Group)|The members of both groupswill undertake a VR based basic training for ALS. Afterwards EG group will attend at VR based Educator guided training in metaverse. The knowledge level will then be evaluated by the exam mode of the VR based training module
224058550|NCT01958801|OTHER|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
224058551|NCT01958801|OTHER|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
224058552|NCT03238859|DEVICE|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
223451462|NCT00004067|DRUG|taxol|175 mg/m2 IV every 21 days for 4 cycles
223569799|NCT00052091|BEHAVIORAL|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
223569800|NCT00052091|BEHAVIORAL|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
223569801|NCT05257460|DEVICE|Hybrid closed-loop using ultra-rapid insulin lispro|Hybrid closed-loop using ultra-rapid insulin lispro
224058553|NCT03238859|DEVICE|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
224058554|NCT04464395|DRUG|CPI-006|Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.
224147193|NCT01361919|PROCEDURE|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
224301259|NCT02701231|DRUG|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
223569802|NCT05257460|DEVICE|Hybrid closed-loop using standard insulin lispro|Hybrid closed-loop using standard insulin lispro
223451463|NCT03295136|BEHAVIORAL|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
223451464|NCT04850495|DRUG|Cyclophosphamide|Given IV
223451465|NCT04850495|DRUG|Doxorubicin Hydrochloride|Given IV
223451466|NCT04850495|DRUG|Prednisone|Given PO
223451467|NCT04850495|BIOLOGICAL|Rituximab|Given IV
223451468|NCT04850495|DRUG|Vincristine Sulfate|Given IV
223451469|NCT04850495|DRUG|Zanubrutinib|Given PO
223451470|NCT05399316|DIETARY_SUPPLEMENT|Inulin|Natural fiber supplement extracted from chicory
223451471|NCT05399316|DIETARY_SUPPLEMENT|Maltodextrin|Natural non-fermentable sugar
223569803|NCT02193386|OTHER|No intervention, no follow-up, only registration|Usual Care
223569804|NCT02193386|OTHER|Intervention period|Predefined intervention program
223569805|NCT04333186|OTHER|Data from ultrasound measurements|Data from ultrasound measurements and from the electronic patient record will be obtained / analyzed. One additional blood sample will be obtained within 24 hours after inclusion, during planned blood collection (from arterial line or venous puncture).
223569806|NCT01666535|BIOLOGICAL|Influenza vaccination|
223451472|NCT02937636|OTHER|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride \& 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
223451473|NCT02937636|OTHER|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
223451474|NCT00596102|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
223451475|NCT06726122|DEVICE|Profound Matrix|Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).
224058555|NCT04464395|OTHER|Standard of Care|Participants will receive standard of care treatment only.
224058556|NCT02859935|BEHAVIORAL|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
223451476|NCT00583011|DRUG|Local Anesthesia|Local anesthesia: 2 cc of 1% Lidocaine
223451477|NCT00583011|DRUG|Placebo Group|Placebo Group: 2cc Normal Saline
223569807|NCT05143307|BIOLOGICAL|EBT-101|Long term follow up of participants who received EBT-101
223569808|NCT03479177|BEHAVIORAL|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
223569809|NCT03091998|DRUG|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
223569810|NCT03091998|OTHER|Placebo|Participants will receive an \~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
223569811|NCT01441908|DRUG|Pravastatin|40mg or 80mg dose 28 days for 6 month period
223569812|NCT01434394|DRUG|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
223569813|NCT05611229|DRUG|Nivolumab|Nivolumab
223569814|NCT05611229|DRUG|Pembrolizumab|Pembrolizumab
224058557|NCT04824508|BEHAVIORAL|position|teamleaders are instructed to allocated position
224147194|NCT01361919|PROCEDURE|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
223451478|NCT00722683|PROCEDURE|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
223569815|NCT05611229|COMBINATION_PRODUCT|Dabrafenib+Trametinib|Dabrafenib+Trametinib
223569816|NCT05611229|COMBINATION_PRODUCT|Ipilimumab+Nivolumab|Ipilimumab+Nivolumab
223569817|NCT05611229|COMBINATION_PRODUCT|Vemurafenib+Cobimetinib|Vemurafenib+Cobimetinib
223569818|NCT05611229|COMBINATION_PRODUCT|Encorafenib+Binimetinib|Encorafenib+Binimetinib
223569819|NCT00842946|BEHAVIORAL|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
223451479|NCT01396551|DEVICE|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
223451480|NCT04805164|PROCEDURE|Corticotomy and use of the bone substitute : Cerament-G device.|Corticotomy and Cerament-G device
223451481|NCT04805164|PROCEDURE|Corticotomy|Corticotomy
223451482|NCT01883661|BIOLOGICAL|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
223451483|NCT05406271|DIAGNOSTIC_TEST|Intraoperative fluoroscopy|Impantation of hip prosthesis with intraoperative fluoroscopy
224058558|NCT03842423|PROCEDURE|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
223451484|NCT01478607|DRUG|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
223569820|NCT00842946|BEHAVIORAL|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
224058559|NCT05865678|OTHER|Not an intervention study|This is a study administering questionnaire and interviews using mixed quantitative and qualitative methodology with the aim to describe and evaluate musculoskeletal health of adult haematological cancer survivors and its impact to survivors.
224147195|NCT01361919|PROCEDURE|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
224147196|NCT04385914|OTHER|COVID positive via testing|Following pregnancy outcomes whether they are COVID positive or negative
223451485|NCT06041282|PROCEDURE|manipulation under anesthesia|After the anesthesia took effect, the patient was placed in the supine position, and the experienced surgeon stood at the head of the bed to release the affected limb by four angles of forward flexion, abduction, external rotation and internal rotation. After the operation is completed, 1ml de Bosson (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) is injected once.
223569821|NCT00524953|DEVICE|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last \~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
224058560|NCT04187885|BEHAVIORAL|Group/Cohort 2: PAP|"Each experimental session will be carried out over 5 days of a week. Adolescents will take part randomly in four sessions.~Physical activity program will be identical between sessions and groups. 60 min of moderate to vigorous leisure activities and exercises will be proposed each day. Heart rate monitor will be used to control intensity of exercise during the physical activity program."
224058561|NCT05874973|OTHER|Time-controlled adaptative ventilation (TCAV)|Ventilation with TCAV set on the APRV mode on the ventilator.
224058562|NCT05874973|OTHER|Volume-controlled ventilation (VCV)|Ventilation with the VCV mode set on the ventilator.
224058563|NCT01733472|DRUG|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
224058564|NCT01733472|DRUG|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
224058565|NCT00733148|DRUG|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
224058566|NCT01419951|BEHAVIORAL|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
224058567|NCT01419951|OTHER|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
224058568|NCT01419951|BEHAVIORAL|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
224058569|NCT00756145|PROCEDURE|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
224058570|NCT00756145|PROCEDURE|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
224058571|NCT00756145|PROCEDURE|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
223569822|NCT00578877|DEVICE|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
223569823|NCT00578877|COMBINATION_PRODUCT|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
223569824|NCT00578877|COMBINATION_PRODUCT|Buffer Gel|Buffer Gel
223569825|NCT00857831|DIETARY_SUPPLEMENT|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
223569826|NCT02139878|OTHER|Wild blueberry juice|
223569827|NCT02139878|OTHER|Placebo wild blueberry juice|
224058572|NCT02089399|DRUG|Sevikar(amlodipne/olmesartan)|Treatment AB
224058573|NCT02089399|DRUG|crestor(Rosuvastatin)|Treatment AB/Treatment C
224058574|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage survival cohort|consists of surviving patients
224301260|NCT02701231|DEVICE|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
223569828|NCT06357780|OTHER|close-loop synchronization controller with spontaneous mode|30 minutes period where the pressure support of spontaneous effort will be automatically titrated based on pressure and flow waveform analysis obtained from the patient during NIV mode.
223569829|NCT06357780|OTHER|Conventional|30 minutes period where the synchronization of pressure support of patient effort during NIV mode will be manually set.
223569830|NCT06601517|DRUG|Repaglinide|Single dose; Administered orally
223569831|NCT06601517|DRUG|Atorvastatin|Single dose; Administered orally
224058575|NCT06490640|OTHER|Spontaneous subarachnoid haemorrhage mortality cohort|consists of deceased patients
224058576|NCT04782362|OTHER|Brace Treatment|Body image and quality of life of individuals who have used brace will be evaluated
224058577|NCT04550091|DEVICE|Detection of ascites using CT|Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
223569832|NCT06601517|DRUG|Digoxin|Single dose; Administered orally
223569833|NCT06601517|DRUG|Rosuvastatin|Single dose; Administered orally
223569834|NCT06601517|DRUG|HDM1002|Administered orally
223569835|NCT06599710|DIETARY_SUPPLEMENT|AndoSanTM|Fermented water-based exctract of Agaricus subrufesence, Hericum erinacus, and Grifola frondosa
224058578|NCT04640272|DRUG|RBM-007|Intravitreal injection
224058579|NCT06008444|OTHER|Physical Evaluations of post-COVID-19 individuals|In this research, the data of Parkinson's patients who have had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
224058580|NCT06008444|OTHER|Physical Evaluations of non-post-COVID-19 individuals|In this research, the data of Parkinson's patients who have not had COVID-19 will be collected face to face. Chest mobility, cough strength, muscle strength, physical activity and quality of life will be evaluated in all Parkinson's patients. The data to be obtained through all these evaluations will be collected from at one time and in a time lasting maximum of about 1 hour. Step count tracking with pedometer will be done for 3 days for each individual.
224301261|NCT03223948|DEVICE|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
223451486|NCT06041282|PROCEDURE|supervised home rehabilitation|The doctor instructs the patient in exercise training at the outpatient clinic. At each clinic visit, the doctor will guide the different stages of the movement. At the first visit, the doctor guides the patient through the first phase of the rehabilitation program to improve the patient's basic mobility. At the first month of follow-up, the second phase of rehabilitation program was guided, and the recovery of mobility was accompanied by muscle training, including wall climbing and muscle resistance exercises. 1ml Debossone (MSD) +2.5ml sodium hyaluronate (Biochemical Industries Co., LTD.) was injected once at the clinic. All the training required patients to do their best at home to complete 3 sets of 5 each. At the end of each day, the patient will upload a video to the platform, and the doctor will evaluate whether the patient's recovery is in place.
224058581|NCT06469996|OTHER|Connective tissue massage|Connective Tissue Massage will be applied by an experienced physiotherapist for a total of 12 sessions 2 days a week for 6 weeks. While the patients are in sitting position, starting from the lumbosacral region, the lower thoracic, scapular, interscapular and cervical regions will be included in the treatment respectively.
224058582|NCT06469996|OTHER|Self myofascial relaxation|Self myofascial relaxation will be practiced with foam roller in patients with Fibromyalgia.
224058583|NCT00521261|BIOLOGICAL|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
224058584|NCT05785156|OTHER|quick tests|"New quick tests are~* Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and~* Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing"
224058585|NCT00351013|OTHER|Malaria Tropica Nosode D200|5 pellets every four months
224058586|NCT02203825|BIOLOGICAL|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
224058587|NCT02997527|DEVICE|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
224058588|NCT00871845|BEHAVIORAL|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
223451487|NCT02383303|BEHAVIORAL|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
223569836|NCT06657352|DIETARY_SUPPLEMENT|ACS Topical Treatment Group|The topical group applied the ACS cream to the face twice daily (morning and night) for 4 weeks.
223569837|NCT06657352|DIETARY_SUPPLEMENT|Topical Placebo Group|The topical group applied the cream (without ACS) to the face twice daily (morning and night) for 4 weeks.
223569838|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Treatment Group|The combination group used both the topical and oral ACS products for 12 weeks.
224058589|NCT05138016|DEVICE|Soft exosuit|Progressive cardiovascular exercise testing with soft exosuit assistance.
224058590|NCT05138016|BEHAVIORAL|No Soft exosuit|Progressive cardiovascular exercise testing.
223569839|NCT06657352|DIETARY_SUPPLEMENT|ACS Oral Treatment Group|The oral group ingested one ACS capsule twice daily after breakfast and dinner for 12 weeks.
223569840|NCT06657352|DIETARY_SUPPLEMENT|Oral Placebo Group|The oral group ingested one capsule (without ACS) twice daily after breakfast and dinner for 12 weeks.
223569841|NCT06657352|DIETARY_SUPPLEMENT|Oral Treatment + Topical Placebo Group|The combination group used both the topical and oral products without ACS for 12 weeks.
223569842|NCT06656117|OTHER|Elliptical training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
223569843|NCT06656117|OTHER|Resistance training|• Throughout the training, participants' heart rates were monitored, and they were asked to report any discomfort or unusual signs.
223569844|NCT02305017|DRUG|BIA 9-1067|BIA 9-1067 50 mg
223569845|NCT02305017|DRUG|Paracetamol|Paracetamol 1g
223569846|NCT03760887|OTHER|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
224058591|NCT06152445|OTHER|Wheat bread|Different wheat breads
224058592|NCT01647451|DRUG|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
224058593|NCT01647451|DRUG|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
224058594|NCT02094456|PROCEDURE|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
224058595|NCT02094456|PROCEDURE|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
224058596|NCT04866693|OTHER|None - this is an exploratory qualitative study to understand patient safety problems in community-based mental healthcare.|Qualitative study
224058597|NCT05175833|COMBINATION_PRODUCT|Oral probiotics|Oral gel containing streptococcus salivarius K12 and lactobacillus brevis CD2
224058598|NCT05175833|OTHER|Oral placebo|Oral gel containing placebo
224058599|NCT01306448|DEVICE|Vibrant capsule|vibrating capsule
224058600|NCT02568813|BEHAVIORAL|Multiscore Depression Inventory for Children scale|
224058601|NCT00003437|DRUG|asparaginase|
224058602|NCT00003437|DRUG|cyclophosphamide|
224058603|NCT00003437|DRUG|cytarabine|
224058604|NCT00003437|DRUG|daunorubicin hydrochloride|
224058605|NCT00003437|DRUG|dexamethasone|
224058606|NCT00003437|DRUG|doxorubicin hydrochloride|
224058607|NCT00003437|DRUG|mercaptopurine|
224058608|NCT00003437|DRUG|methotrexate|
224058609|NCT00003437|DRUG|pegaspargase|
224058610|NCT00003437|DRUG|prednisolone|
224058611|NCT00003437|DRUG|thioguanine|
224058612|NCT00003437|DRUG|vincristine sulfate|
224058613|NCT00003437|RADIATION|radiation therapy|
224058614|NCT05080465|BIOLOGICAL|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
224301262|NCT02992626|OTHER|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
224058615|NCT05312177|OTHER|Stanford Binet Intelligence Scales, Fifth Edition|The SB-5 is a comprehensive measure of cognitive and intellectual functioning for individuals from age two through 85 years of age. The SB-5 individually assess a child's functioning in five areas of cognitive functioning: Fluid Reasoning, Knowledge, Quantitative Reasoning, Visual Spatial, and Working Memory. The SB-5 is well established in the existing research literature as an assessment tool to evaluate developmental and intellectual abilities in children with ND disorders.
224058616|NCT05312177|OTHER|Vineland Adaptive Behavior Scales Third Edition|The VABS-3 are a parent report, interview style measure of adaptive behavior for individuals ages birth through 90 months. The VABS-3 assesses adaptive behavior in four broad domains of Communication, Daily Living Skills, Socialization, and Motor Skills, and includes a Maladaptive Behavior Domain that assesses problem behaviors.
224058617|NCT05312177|OTHER|Peabody Picture Vocabulary Test, Fifth Edition|The PPVT-5 is a norm-referenced language measure that evaluates single-word receptive vocabulary. The PPVT-5 provides standard scores for individuals ages 2.6 through 90 years.
224058618|NCT05312177|OTHER|Expressive Vocabulary Test, Third Edition|The EVT-3 is a norm-referenced language measure that evaluates single-word expressive vocabulary. The EVT-3 provides standard scores for individuals ages 2.6 through 90 years.
224058619|NCT05312177|OTHER|Leiter International Performance Scale, Third Edition|The Leiter-3 is a nonverbal measure of cognitive functioning and fluid reasoning skills in individuals ages 3 through 75 years. The Leiter-3 measures nonverbal IQ across four subscales, including Sequential Order (SO), Form Completion (FC), Classification and Analogies (CA), and Figure Ground (FG).
224058620|NCT05312177|OTHER|Social Communication Questionnaire, Current Form|The SCQ is a parent-report measure of social communication, social interactions, play, and behavior.
224058621|NCT05312177|OTHER|Aberrant Behavior Checklist|The ABC-2 is a parent report measure of problematic behavior at home and in the community. It measures behavior on five subscales (1) Irritability, (2) Social Withdrawal, (3) Stereotypic Behavior, (4) Hyperactivity/Noncompliance, and (5) Inappropriate Speech.
224058622|NCT05312177|OTHER|Repetitive Behavior Scale, Revised|The RBS-R is a parent report measure that comprehensively surveys for the presence of repetitive behaviors.
224058623|NCT03211221|DEVICE|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (\> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
223451488|NCT05844072|PROCEDURE|Mobilization with movement|All participants will receive the MWM intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. The participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. A licensed physical therapist (PT) will then stabilize the talus for a proper joint mobilization to be performed. The therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range DF reached through a forward lunge, using a Mulligan's mobilization belt around the distal tibia-fibula. The participant will perform 3 sets of 10 repetitions of the forward lunge and the PT will perform a bout of overpressure at end range during each repetition. Two other investigators will be on either side of participant to assist with balance during the intervention if needed.
223451489|NCT01472978|DRUG|metronidazole|Metronidazole, 500 mg three times a for 10 days
223451490|NCT02714556|OTHER|Physiologic measures of lung function|"Respiratory function tests:~Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
223451491|NCT01047111|PROCEDURE|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
223451492|NCT01066702|BIOLOGICAL|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
223451493|NCT01066702|PROCEDURE|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
224058624|NCT02819635|DRUG|Placebo|Film-coated tablet for oral administration
224058625|NCT02819635|DRUG|Upadacitinib|Film-coated tablet for oral administration
224058626|NCT04636827|BIOLOGICAL|sIPV+DTaP+HepA|sIPV+DTaP+HepA at the age of 18 month old
223451494|NCT02094313|DRUG|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
223451495|NCT03577132|DRUG|Neoadjuvant atezolizumab|"Atezolimumab~* At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~* Every 3 weeks, for a total of 3 cycles prior to radical cystectomy"
223451496|NCT03062397|DRUG|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
223451497|NCT03062397|DRUG|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
223451498|NCT03062397|DRUG|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
223451499|NCT03120494|DRUG|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
224058627|NCT04636827|BIOLOGICAL|sIPV|sIPV at the age of 18 month old
224058628|NCT04636827|BIOLOGICAL|DTaP|DTaP at the age of 18 month old
224058629|NCT04636827|BIOLOGICAL|HepA|HepA at the age of 18 month old
224070762|NCT07023211|BEHAVIORAL|Social touch|Participants will receive occasional physical contact applied by the therapist specifically to the right arm. This contact is deliberately non-specific to the breathing process and contrasts with the targeted manual respiratory assistance provided to the experimental group. Participants in this group will not receive breathing instructions.
224058630|NCT04172714|DEVICE|SIR-Spheres microspheres|SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
224058631|NCT01035099|DRUG|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level \<150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level \>350 pg/ml - 7.5 mg;"
224058632|NCT01035099|DRUG|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
224058633|NCT05018247|PROCEDURE|Revascularization by Coronary Artery Bypass Graft or Percutaneous Coronary Intervention|Urgent revascularization via CABG or PCI combined with Optimal Medical Treatment
224058634|NCT00146315|BEHAVIORAL|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
224058635|NCT00146315|BEHAVIORAL|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
224058636|NCT03079206|DIAGNOSTIC_TEST|Food challenge|food challenge with hazelnut
224058637|NCT03079206|DIAGNOSTIC_TEST|skin testing|Skin testing with hazelnut extract
224058638|NCT03079206|DIAGNOSTIC_TEST|blood sampling|blood sampling to perform basophile activation tests
224058639|NCT04214379|PROCEDURE|Ptosis surgery|Frontalis sling surgery using pose-up and Wright's fascia-lata needle
224058640|NCT01795885|BEHAVIORAL|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
224058641|NCT03179891|DRUG|Diazepam Buccal Film 12.5 mg|All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
224058642|NCT02833922|BEHAVIORAL|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
224058643|NCT00530751|OTHER|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool \[GREAT\]) are explored.
224058644|NCT02938884|DEVICE|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
224058645|NCT05233020|DEVICE|robotic|fifteen patients undergo robotic operation
224058646|NCT05233020|DEVICE|hybrid|fifteen patients undergo hybrid operation
223451500|NCT02352376|OTHER|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
223451501|NCT02352376|OTHER|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
223451502|NCT06207760|DRUG|Minocycline|Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
223569847|NCT03760887|OTHER|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
224058647|NCT04058925|DEVICE|NIRS device|Application of NIRS electrode to forehead and thenar eminence.
224058648|NCT05440162|DIAGNOSTIC_TEST|electrolyte|follow up NA
224058649|NCT06372548|DEVICE|Find You! Cure My Animal Friends|Introduced cognitive evaluation theory combined with masking therapy to develop a gamified product that guides amblyopic children to develop habits for the purpose of rehabilitation training.
224058650|NCT06372548|DEVICE|DuoBao Vision Training System|This is a visual training app where participants are required to complete several training tasks.
224058651|NCT00018655|BEHAVIORAL|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
224058652|NCT00018655|BEHAVIORAL|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
224058653|NCT02771509|DRUG|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
224058654|NCT02771509|DRUG|Placebo|Normal saline
223569848|NCT03756155|PROCEDURE|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
224058655|NCT02456844|DRUG|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12."
224058656|NCT02456844|DRUG|Methotrexate, Leucovorin and BMS-986142|"1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10."
224058657|NCT04428463|PROCEDURE|Tachosil|tympanic membrane perforation repair using Tachosil patch under local anesthesia
224058658|NCT04428463|PROCEDURE|fascia and cartilage|tympanic membrane perforation repair using fascia and cartilage under general anesthesia
224058659|NCT03137589|OTHER|Telemedical support|Participating sites will be advised by telemedicine support.
223451503|NCT03706976|DEVICE|Tissue Oxygenation Monitoring|The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
223451504|NCT02801370|DRUG|12 mg ciprofloxacin|Single administration of OTO-201
223451505|NCT02801370|DRUG|Sham Control|Simulated, single adminstration
223451506|NCT01446250|DRUG|Alisporivir|ALV 200 mg soft gel capsules administered orally
223569849|NCT06490653|DRUG|Blood Stopper (Ankaferd)|5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
223569850|NCT02534558|BIOLOGICAL|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
224058660|NCT03078374|DRUG|Warfarin|Reduced dosage to obtain lower INR range
224058661|NCT02572726|DEVICE|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
224058662|NCT02572726|DEVICE|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
224058663|NCT00621699|DRUG|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
223569851|NCT05120765|BEHAVIORAL|The CONNECT Program|The CONNECT Program is a 6-week, group-based, telephone-based, mental health intervention for socially isolated older adults. This group-therapy intervention is based on principles of Acceptance and Commitment Therapy (ACT). The group sessions take place once a week and they last 90 minutes each.
223569852|NCT01696617|DRUG|Aripiprazole 6-week group|
223741969|NCT07205003|DIAGNOSTIC_TEST|Assessment of carotid wall viscosity in patients with vascular dementia|Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
224058664|NCT00621699|DRUG|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
224058665|NCT00621699|DRUG|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
224058666|NCT01528111|DRUG|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
223451507|NCT01446250|DRUG|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
223451508|NCT01446250|DRUG|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
223451509|NCT01446250|DRUG|Ribavirin|RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
223451510|NCT03383692|DRUG|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
223451511|NCT03383692|DRUG|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
223451512|NCT03383692|DRUG|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
223451513|NCT05216458|BEHAVIORAL|Emails and letter intervention|Emails and letters for households assigned to the treatment group
223451514|NCT05216458|BEHAVIORAL|Control group|No outreach during the intervention period.
223451515|NCT03600246|DEVICE|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
223451516|NCT02325921|DEVICE|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
223451517|NCT05559944|BEHAVIORAL|Expressive Writing|Participants will be asked to write about the biggest body image or eating-related stressor they have experienced as a member of the LGBTQ+ community.
223451518|NCT05559944|BEHAVIORAL|Self-Affirmation|Participants will receive one new vignette per day describing a SM young adult experiencing severe body image stress in Alabama. Participants will be asked to write to this person and provide advice based on their own experience as a SM young adult. Vignettes will be identical across participants; however, they will be matched to participants' sexual identity, gender identity, and race/ethnicity.
223569853|NCT01696617|DRUG|Aripiprazole 8-week group|
223569854|NCT02437409|DEVICE|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
224058667|NCT01528111|DRUG|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
224058668|NCT01528111|DRUG|LX7101 Vehicle|Subjects will receive vehicle
224058669|NCT04790877|OTHER|Sub-study 1|Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).
224058670|NCT04790877|OTHER|Sub-study 2|Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
224058671|NCT05352204|PROCEDURE|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization after liver resection
223451519|NCT05559944|BEHAVIORAL|Control|Consistent with prior research participants will write about their routine daily activities since waking up for 20 minutes each day, sans emotional content.
223451520|NCT01555710|DRUG|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
223451521|NCT01555710|DRUG|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
223741970|NCT07205003|DIAGNOSTIC_TEST|Assessment of carotid wall viscosity in patients with Alzheimer's disease|Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
223741971|NCT07205003|DIAGNOSTIC_TEST|Assessment of carotid wall viscosity in patients not presenting dementia.|Carotid wall viscosity will be assessed by simultaneous and continuous measurement by 2 operators of local pressure and diameter at the level of the right and left carotids by coupling echotracking (Vevo 3100®) with applanation tonometry (Millar®). 3 successive measurements will be carried out. These measurements will establish the diameter-pressure relationship and its analysis will allow the calculation of wall viscosity by measuring the area under the curve of this relationship during the cardiac cycle.
224058672|NCT01630473|PROCEDURE|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
224058673|NCT01630473|PROCEDURE|Conventional orthodontics|Conventional orthodontic treatment
224058674|NCT01438489|BIOLOGICAL|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
224058675|NCT01438489|BIOLOGICAL|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
224058676|NCT01438489|OTHER|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
224058677|NCT00751400|DRUG|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
224058678|NCT00573430|DRUG|Candesartan Cilexetil|8 mg oral once daily dose
224058679|NCT00573430|DRUG|Candesartan Cilexetil|16 mg oral once daily dose
224058680|NCT00573430|DRUG|Candesartan Cilexetil 32mg|32 mg oral once daily dose
224058681|NCT02194751|BIOLOGICAL|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
223451522|NCT01555710|DRUG|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
223451523|NCT01555710|DRUG|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
223451524|NCT04184778|DEVICE|Smaller tube size|Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.
223451525|NCT06450093|OTHER|Preformed stainless steel crown.|A well-fitted preformed stainless-steel crown will be chosen by measuring the mesiodistal dimension of the tooth or its contralateral counterpart, using a graduated periodontal probe for guidance. (6) Tooth preparation will be carried out with #835 diamond fissure bur to reduce occlusal surface up to 1 to 1.5 mm. The interproximal reduction will be made mesially and distally using #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. The selected crown size will be checked, and a trial fit will be done before cementation. The crown will be cemented using self-cured RMGI luting cement. The excess will be removed, and proper occlusion will be checked.
223451526|NCT06450093|OTHER|Preformed zirconia crown|The material for crown restoration for this group is the preformed zirconia crown. Tooth preparation will be started by occlusal reduction (1 to 1.5 mm) using #835 diamond fissure bur. The interproximal reduction will be done mesially and distally with #169 L tapered diamond bur in such a way that a straight probe passes freely through the contact area. Rounding of line angles will be done and a knife-edge finish margin of the proximal surface will be obtained avoiding any ledge formation. The selected crown will be placed and checked for a passive fit. Consistent firm finger pressure will be applied during cementation with self-cured RMGI luting cement. Finally, crown placement will be checked.
223741972|NCT00670800|DRUG|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
223741973|NCT06293846|BEHAVIORAL|What I Learned at Home|What I Learned at Home is a self-efficacy intervention intended to build home repair and management skills while improving performance self-efficacy.
223741974|NCT04726982|DRUG|Acetazolamide|250 mg once daily
224058682|NCT00099970|DRUG|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
224058683|NCT06247943|PROCEDURE|Lung Protective Ventilation Strategy|After 10 minutes of pneumoperitoneum, VT 7 ml/kg was used, PEEP 6 cmH2O, FiO2 was 40%, and plateau pressure \<30 cmH2O was maintained throughout.
224058684|NCT06247943|PROCEDURE|regular ventilation|VT 9ml /kg without PEEP, FiO2 of 60%
224058685|NCT03129321|DRUG|Econazole Nitrate Cream, 1%|
224058686|NCT03129321|DRUG|Placebo|
224058687|NCT03559855|BEHAVIORAL|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
224058688|NCT03219242|DEVICE|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
224058689|NCT02152085|DEVICE|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
224058690|NCT02152085|DEVICE|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
224058691|NCT05279547|OTHER|Constant-load bed-cycling exercise|Patients will actively cycle for a minimum duration of 10 minutes and a maximum duration of 20 minutes without breaks.
224058692|NCT05279547|OTHER|Interval bed-cycling exercise|Patients will cycle for the same duration as during constant-load exercise. Interval bed-cycling session will consist of 30 seconds of high intensity exercise alternated by 30 seconds of passive cycling designed so that volume of training will be equal.
224058693|NCT01148537|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.
224058694|NCT01148537|DRUG|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
224058695|NCT01148537|DRUG|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
224058696|NCT02534402|DRUG|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
224058697|NCT03561909|OTHER|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
224058698|NCT06171438|DIAGNOSTIC_TEST|Urine Biomarkers|Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
224058699|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of donor kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
224058700|NCT06171438|DIAGNOSTIC_TEST|Gene expression profiling of recipient kidneys by microarray|Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
224058701|NCT05733871|DIETARY_SUPPLEMENT|meal replacement product- STANDARD PRODUCT|standard product line contains common ingredients and this type of product already exists on world markets
224058702|NCT05733871|DIETARY_SUPPLEMENT|Meal replacement product- INNOVATIVE PRODUCT|innovative product line contains raw materials that are considered better sources of potentially bioactive components
224058703|NCT04003233|DEVICE|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
224058704|NCT04003233|DEVICE|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
224058705|NCT04563429|DIETARY_SUPPLEMENT|Oral Vitamin A|Oral administration of 5000 EU of Vitamin A during first 28 days of life
224058706|NCT02858674|OTHER|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
224058707|NCT02858674|OTHER|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
224058708|NCT01686620|DRUG|BIOD-123|
224058709|NCT01686620|DRUG|Lispro (Humalog)|
223741975|NCT04726982|DRUG|Acetazolamide|500 mg once daily
224058710|NCT05059496|OTHER|Hamstring stretching with Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching with Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
224058711|NCT05059496|OTHER|Hamstring stretching with out Pressure Biofeedback Unit|Hot Pack 15 mins/1 set/ (3 days/week), Hamstring stretching without Pressure Biofeedback Unit 30 secs hold/ 15 secs rest/ 3 sets/ (3 days/week), TENS 15 mins/ 1 set/ (3 days/week). A total of 4 weeks (12 sessions, 3 days/ week) were given each consisting of 35 mins.
224058712|NCT01324232|DRUG|AVP-923-45|AVP-923-45 (dextromethorphan 45 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
224058713|NCT01324232|DRUG|AVP-923-30|AVP-923-30 (dextromethorphan 30 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
224058714|NCT01324232|DRUG|AVP-923-20|AVP-923-20 (dextromethorphan 20 mg/quinidine 10 mg) capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
224058715|NCT01324232|DRUG|Placebo|Matching placebo capsules administered once daily for first 7 days followed by twice daily for 11 weeks of the study to complete 12 weeks of treatment.
224301263|NCT02992626|OTHER|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
224058716|NCT01168661|BEHAVIORAL|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) \>= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
223741976|NCT04726982|OTHER|Placebo|Once daily
223741977|NCT05514067|PROCEDURE|Electro-Acupuncture|A single application of EA at cardiac-related acupoints administered for 30 min prior to CABG surgery.
223741978|NCT06026592|GENETIC|determination of circulating biomarkers of renal origin circulating biomarkers of renal origin|The extracted circulating DNA will be extracted and converted using the methylation kit. Finally, circulating DNA will be analyzed using the PCR mix developed by CGenetix, quantifying tubular and glomerular biomarkers (patented technology).
224301264|NCT02286219|DRUG|FS102|Experimental
224301265|NCT05445726|DEVICE|CPM Device|CPM device used in tangent with reference ECG for validation
224301266|NCT05031247|OTHER|Wellbeing Program|The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
224301267|NCT03977831|PROCEDURE|Radical Cystectomy|Participants are randomly and blinded assigned
224301268|NCT01713231|DIETARY_SUPPLEMENT|standard-dose vitamin D (400IU per day)|
223451527|NCT06450093|OTHER|Preformed BioFlx crown|The prefabricated BioFlx crown will be used in this group. A similar-sized preformed crown will be selected. Tooth preparation will be carried out similarly to traditional SSCs with #835 diamond fissure bur for occlusal reduction by 1-1.5 mm including the central groove. The proximal preparation will be done mesially and distally with #169 L tapered diamond bur around 0.5 mm to clear the contact area creating a feather edge finish line. Placement of the crown will be achieved by a snug fit. Crown cementation will be carried out using self-cured RMGI luting cement and the excess cement will be removed using a floss or an explorer. (13) Finally, crown placement will be checked
223451528|NCT02182154|DRUG|BIBF 1120 ES|
223451529|NCT00405847|DRUG|Dexmedetomidine|
223451530|NCT03116009|DRUG|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
223451531|NCT04910243|OTHER|Questionnaire Survey|Physicians providing care to patients with COVID-19 admitted at ICU in period of COVID-19 pandemic will be questioned by electronic web-based survey within Masaryk University information system.
223451532|NCT00893971|DRUG|PT001|Inhaled PT001, single dose
223451533|NCT00893971|DRUG|PT005|Inhaled PT005, single dose
223451534|NCT00893971|DRUG|PT003|Inhaled PT003, single dose
223451535|NCT00893971|DRUG|PT001 + PT005|Inhaled PT001 + PT005, single dose
223451536|NCT04183166|DRUG|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks
224301269|NCT01713231|DIETARY_SUPPLEMENT|high-dose vitamin D (2000 IU per day)|
224305077|NCT01345175|DRUG|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
223451537|NCT02707900|DRUG|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
223451538|NCT02707900|BIOLOGICAL|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 \& EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
223451539|NCT00004832|DRUG|3,4-diaminopyridine|
223451540|NCT06434688|OTHER|Mental Fatigue:|The Mental Fatigue Scale (MFS) will be used to assess mental fatigue.
223451541|NCT06434688|OTHER|Body Awareness:|"Individuals' general body awareness will be assessed with the Body Awareness Questionnaire (BAQ).~Neck awareness of individuals will be assessed with the Fremantle Neck Awareness Questionnaire (FreBFA).~Short Form of the Five Facet Mindfulness Questionnaire (FFMQ - Short Form) will be used to assess people's mindfulness.~\- In-body awareness:~For the sense of interoception, the Multidimensional Assessment of Interoceptive Awareness Scale, which assesses interoceptive body awareness, will be used.~To evaluate proprioception, a Cervical Range of Motion (CROM) device is used.~The bucket test will be used to assess subjective visual verticality, which is one of the sub-dimensions of verticality perception.~Two scales will be used to assess people's awareness of weight transfer symmetry.~\- Out of Body Awareness:~Right-Left Confusion Hand Test will be used to evaluate the mental rotation skill within the scope of the sense of extroception."
223451542|NCT06434688|OTHER|Neck Disability Level|Neck disability index will be used to assess this parameter.
223451543|NCT06434688|OTHER|Quality Of Life|SF-12 will be used to assess quality of life.
223451544|NCT06434688|OTHER|Pain Assessment:|Pain intensity will be assessed by Visual Analog Scale (VAS). In addition, pain duration and pain frequency will be questioned. The Pain Self-Efficacy Questionnaire will be used to assess the confidence of people with chronic pain to perform certain tasks and behaviors despite their pain.
223451545|NCT06434688|OTHER|Physical Condition:|"Normal range of motion of the cervical region will be evaluated with the Cervical Range of Motion device.~New York Posture Rating Scale will be used to evaluate posture.~Symmetry of weight transfer to both lower extremities of the individuals in standing upright position will be evaluated."
223451546|NCT06434688|OTHER|Anxiety and Depression:|Beck Depression and Beck Anxiety scales will be used to assess depression and anxiety.
223451547|NCT02328573|BEHAVIORAL|Communal singing|
223451548|NCT06673160|BEHAVIORAL|Pumping every 2 hours|The intervention will be pumping every 2 hours.
223451549|NCT06673160|BEHAVIORAL|breast pumping every 3 hours|The intervention will be pumping every 3 hours
223451550|NCT06263426|OTHER|HIV D+/R+|Receipt of kidney transplant from a deceased donor with HIV.
223451551|NCT06263426|OTHER|HIV D-/R+|Receipt of kidney transplant from a deceased donor without HIV.
223451552|NCT00170014|DEVICE|Magnetocardiograph|
223451553|NCT04581018|OTHER|Health supplements|28 days of health supplements (synbiotic), 4g daily
223451554|NCT00623389|DEVICE|IST (Implanted Stimulator-Telemeter)|Pre-surgical exercise with surface electrical stimulation, surgery including electrode and IST- implanted pulse generator insertion, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
223451555|NCT04285216|OTHER|Dry Needling|Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)
223451556|NCT04285216|OTHER|Strain counter strain|Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
223451557|NCT02945696|PROCEDURE|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
223451558|NCT02945696|DRUG|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
223451559|NCT06668103|DRUG|ABSK043 in combination with Firmonertinib|"Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
223451560|NCT04989309|DEVICE|Transcranial Magnetic Stimulation|TMS will be delivered in 10 Hz pulses for 2.5 seconds, with behavioral measures of speech perception and object categorization immediately following each pulse. TMS at this schedule is thought to temporarily disrupt activity at the stimulation site.
223451561|NCT05512741|OTHER|Feces collection|"Feces will be collected, at home, by the patient., by using a collection kit. The stools are collected in the 2 last days before surgery.~After surgery, the first stool is collected, during the hospitalization, by using the same kit. Stools are conserved in the same condition, before being frozen in our local biologic ressources center."
224058717|NCT01168661|BEHAVIORAL|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
224058718|NCT01168661|BEHAVIORAL|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice \>= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
224058719|NCT01527474|DRUG|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
224058720|NCT04564586|BEHAVIORAL|DPPFit|Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
223451562|NCT06080165|DRUG|Sirolimus|Experimental: Sirolimus Participants that are 5 to 12.99 years old will start at 1 mg/m2/dose. Participants that are 13 to 45.99 years old and \< 39.99 kg in weight will also start on 1 mg/day. Participants that are 13 to 45.99 years old and \> 40 kg in weight will start on 2 mg/day. The target blood level will be 5-15 ng/ml with dose adjustment based on clinical labs of sirolimus levels. The target blood level will be 5-15 ng/ml with dose adjustment based on sirolimus levels obtained every 2 to 3 weeks after every dose change.
223451563|NCT06080165|DRUG|Placebo|matching placebo
223451564|NCT03938688|PROCEDURE|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
223451565|NCT07013617|DEVICE|Transcutaneous Electrical Nerve Stimulation Device|Each participant will receive 20 minutes of TENS, Electrodes will be positioned around the patella with a 5 - 7 cm distance in between, The TENS settings include a continuous asymmetric biphasic square-pulse wave, a pulse width of 120 microseconds, and a pulse rate of 180 Hz.
223451566|NCT07013617|OTHER|Strength exercises for lower limb|Each participant will receive progressive strengthening program targeting the hip and knee, begin with 3 sets of 10 repetitions and progress to 3 sets of 20 repetitions.
223569855|NCT06605326|DRUG|Subcutaneous Treprostinil|Patients in this group received subcutaneous treprostinil, starting at a dose of 1.25 to 4 ng/kg/min and gradually titrated according to patient response. The target dose was over 20 ng/kg/min after 3 months of treatment. All patients were referred for lung transplantation during or after treprostinil treatment.
223569856|NCT06605352|DIAGNOSTIC_TEST|The BIOFIRE®FILMARRAY® Pneumonia Panel|"The BIOFIRE®FILMARRAY® Pneumonia Panel is the only FDA approved mPCR test that can test 18bacteria (11 Gram negative, 4 Gram positive and 3 atypical), 7 antibiotic resistance markers, and 9 viruses in one test within 45 minutes.~Using rapid diagnostic test to improve the proportion of antibiotics change, including escalation, de-escalation, discontinuation, or addition of antimicrobial medications in 24 hours within sample collection."
223569857|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + deep sea water|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a supplementation composed by deep sea water
223569858|NCT06600243|DIETARY_SUPPLEMENT|Resistance training + Placebo|A group that will perform a resistance training protocol with variable resistance and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
224058721|NCT03627845|DRUG|PHP-303|Investigational drug
224058722|NCT03627845|OTHER|Placebo|Matching placebo
224058723|NCT00661531|DRUG|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
224058724|NCT00661531|DRUG|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
224058725|NCT02869386|PROCEDURE|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
224058726|NCT02869386|PROCEDURE|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
224058727|NCT00060346|BIOLOGICAL|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
224058728|NCT00060346|DRUG|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
224058729|NCT00060346|DRUG|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
224058730|NCT00060346|DRUG|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
224058731|NCT00060346|DRUG|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
224058732|NCT05493943|DEVICE|Pulsed ElectroMagnetic Field (PEMF) therapy|Application of PEMF using treatment coils in eproximity to the area where treatment is desired.
224058733|NCT05493943|OTHER|Pulsed ElectroMagnetic (PEMF) therapy|Control arm.
224058734|NCT04118816|DIAGNOSTIC_TEST|Polysomnography|overnight polysomnography recording at least six hours
224058735|NCT04118816|DIAGNOSTIC_TEST|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
224058736|NCT04118816|OTHER|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
224058737|NCT03134599|DEVICE|etafilcon A|contact lens
224058738|NCT03134599|DEVICE|methafilcon A - Interozzo|contact lens
224058739|NCT03134599|DEVICE|methafilcon A - CVI (CooperVision)|contact lens
224058740|NCT00916188|DIETARY_SUPPLEMENT|Black Tea Extract|Amount/dose depends on Arm assignment.
224058741|NCT02021045|DEVICE|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
224058742|NCT03553342|DRUG|Corticoids|Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
224058743|NCT03553342|OTHER|Placebo|Patients will receive placebo for seven days.
224058744|NCT02350556|OTHER|Dynamic Avoidance Task|
224058745|NCT02350556|PROCEDURE|physical therapy|
224058746|NCT02350556|DEVICE|3D motion on optoelectronic device|
224058747|NCT05873881|DRUG|Colchicine 0.5 MG|Oral colchicine 0.5 mg daily
224058748|NCT05873881|DRUG|Colchicine placebo|Placebo colchicine daily
224147197|NCT03155295|OTHER|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
224147198|NCT03155295|OTHER|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
224147199|NCT06379867|DRUG|HSK3486|0.4 mg/kg, IV bolus administration
224147200|NCT06379867|DRUG|Placebo|IV bolus administration
223569859|NCT06600243|DIETARY_SUPPLEMENT|Control + deep sea water|A group that will maintain their usual live and at the same time will receive a supplementation composed by deep sea water
224058749|NCT05873881|DRUG|Thiamine Mononitrate 300 mg|Thiamine Mononitrate 300 mg daily
224058750|NCT04417634|DIAGNOSTIC_TEST|RFR|Measurement of resting flow ratio
224058751|NCT04417634|DIAGNOSTIC_TEST|FFR|Measurement of fractional flow reserve
224058752|NCT02887235|OTHER|Home Delivered, Medically Tailored Meals (HDTM)|
224058753|NCT04069195|DIETARY_SUPPLEMENT|DHA supplement|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
224058754|NCT04069195|DIETARY_SUPPLEMENT|Corn Oil: Soybean Oil|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
224058755|NCT02167750|OTHER|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
224058756|NCT03840512|DRUG|CBD|"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."
224058757|NCT00865683|DIETARY_SUPPLEMENT|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
224058758|NCT00865683|DIETARY_SUPPLEMENT|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
224058759|NCT04291443|PROCEDURE|Heavy Force (225g)|Orthodontic Force
224058760|NCT04291443|PROCEDURE|Light Force (25g)|Orthodontic Force
224058761|NCT01568775|DRUG|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
224058762|NCT00250250|DRUG|ZOMACTON|
224147201|NCT06379867|DRUG|Moxifloxacin|0.4 g, Oral administration with 240 mL
223569860|NCT06600243|DIETARY_SUPPLEMENT|Control + Placebo|A group that will maintain their usual live and at the same time will receive a placebo supplementation that have the same tasted than the deep sea water supplementation
224058763|NCT00737191|DRUG|olanzapine|Given orally
224058764|NCT00737191|OTHER|placebo|Given orally
224058765|NCT04828070|OTHER|Observation|all participants followed for clinical data for one year, vital status check at 5 years
224058766|NCT04670614|PROCEDURE|Nerve Block with ropivicaine 0.5% Injectable Solution|Peripheral nerve blocks using 0.5% ropivicaine
224058767|NCT04670614|PROCEDURE|Nerve Block with Placebo sham control of 0.9% Normal Saline|Peripheral Nerve Block with placebo 0.9% normal saline
224058768|NCT01972620|DRUG|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of \~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
224058769|NCT06398548|OTHER|Control Group|Participants continue with their lifestyle as usual, with no modification to lifestyle, or exercise habits.
224058770|NCT06398548|OTHER|Moderate Intensity Continuous Training|This group cycles at 70% of the resistance associated with their first lactate threshold.
223451567|NCT07013617|OTHER|Hamstring Stretch Muscle Energy Technique(MET) (General )|The participant will be supine and the leg will be taken into hip flexion until a tightness is felt then patient will be asked to push down with his lower leg and hold the contraction for 10 seconds then relax for 2 to 3 seconds then the therapist will take the patient's leg into further flexion for 30 seconds this will be repeated for 3 times each session .
223451568|NCT07013617|OTHER|Medial Hamstring Muscle energy technique(MET) stretch|The Participant will be supine' then the therapist will take his leg in flexion, abduction and external rotation at the same time until he feels tightness then he will ask the patient to push his leg down and in or toward him and hold the contraction for 10 seconds then relax for 2 to 3 seconds then therapist will take the patient's leg in more abduction 'external rotation and flexion for 30 seconds, this will be repeated for 3 times each session
223451569|NCT07013617|OTHER|Lateral hamstring Muscle Energy Technique(MET)Stretch|The Participant will be supine' then the therapist will take his leg in flexion, adduction and internal rotation at the same time until he feels a tightness then he will ask the patient to push his leg down and out or away from him him and hold the contraction for 10 seconds then relax for 2 to 3 seconds then therapist will take the patient's leg in more adduction 'internal rotation and flexion for 30 seconds, this will be repeated for 3 times each session
223451570|NCT02380118|DRUG|Olanzapine|Intramuscular injection
223451571|NCT02380118|DRUG|Haloperidol|Intramuscular injection
223451572|NCT02380118|DRUG|Midazolam|Intramuscular injection
223451573|NCT07019441|OTHER|Daily-Activity-Focused, Strategy-Based Educational Program|The proposed Educational Program will have one face-to-face education session and three follow-up telephone support sessions. Strategies to assist the people with dementia with daily activities, developed from our prior work, have been compiled into a Strategies Package. Healthcare professionals will deliver the program and work collaboratively with the carers to identify issues that arise during caregiving and problem-solve using the strategies included in the package. Carers are provided with support and are encouraged to locate an appropriate strategy using the Strategies Package to help them assist in a daily task in which they want their care recipient to engage.
223451574|NCT07019441|OTHER|Usual Carer support|This group will receive emotional support from trainers on the caring issues raised. It will include the same number of sessions as in the experimental group.
223451575|NCT05432895|DEVICE|Dynamic splint|Device treats plantar fasciitis and replacing boot immobilization which is quite benign
223451576|NCT07021625|DEVICE|Kunbot|A chatbot designed based on cognitive behavioral therapy for insomnia
223569861|NCT06606236|OTHER|H2O2 at 35% for 8 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
223569862|NCT06606236|OTHER|H2O2 at 40% for 20 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
223451577|NCT07021625|OTHER|Treatment as usual|Treatment as usual
223569863|NCT06606236|OTHER|H2O2 at 25% plus cold blue light for 15 minutes|The investigators rigorously followed the manufacturer's instructions for all bleaching systems.
223569864|NCT06605521|PROCEDURE|Subclavian lymph node dissection+radiotherapy|The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.
223569865|NCT06605521|PROCEDURE|Simple clavicular region radiotherapy|If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
223741979|NCT04736199|DRUG|Darolutamide (Nubeqa, BAY1841788)|Coated tablet, oral administration
223741980|NCT04736199|DRUG|Placebo|Coated tablet matching Darolutamide in appearance, oral administration
223741981|NCT04736199|OTHER|Androgen deprivation therapy (ADT)|Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
224058771|NCT06398548|OTHER|Heavy Intensity Continuous Training|This group cycles at 10% of the difference between the resistance associated with their lactate threshold, and maximal achieved watts, added to the resistance associated with their lactate threshold.
224058772|NCT00330382|DRUG|Bowman-Birk inhibitor concentrate|Given orally
224058773|NCT00330382|OTHER|placebo|Given orally
224058774|NCT00330382|OTHER|laboratory biomarker analysis|Correlative studies
224058775|NCT05511272|BIOLOGICAL|blood test|four blood samples will be withdrawn from the participants during the day of their frozen embryo transfer cycle
224058776|NCT01356407|DRUG|PICOPREP|
224058777|NCT01356407|DRUG|PEG-ELS|
224058778|NCT04496622|OTHER|WBV technique|"Whole body vibration with frequency of 16-25 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
223451578|NCT07022197|DRUG|BAFF-R CART|"Biological: BAFF-R CART cells Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture BAFF-R CART cells, during which cyclophosphamide will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with BAFF-R CART cells by intravenous (IV) infusion. The initial dose of 0.5×10\^6 CART cells/kg will be infused on day 0.~Drug: Cyclophosphamide and fludarabine Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to BAFF-R CART cells infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 250 mg/m2/day on day -5, -4 and -3, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide."
223451579|NCT07021833|DEVICE|Cryosa Procedure|The purpose of this study is to evaluate the safety and effectiveness of Cryosa System applied to the tongue and soft palate in patients with clinically diagnosed obstructive sleep apnea (OSA).
224058779|NCT04496622|OTHER|Whole body vibration technique|"Whole body vibration with frequency of 26-35 Hz were given from week 1-8 for 10 minutes/10 repetitions. Time were increased weekly Convention therapy were hot pack 10 minutes, stretching exercise (SLR) 10 repetition x 3 sets and quadriceps exercise 10 repetition x 3 sets.~3 session/week for 8 weeks"
224058780|NCT04542759|DRUG|Besifloxacin Ophthalmic|Prophylaxis for endophthalmitis
224058781|NCT04542759|DRUG|Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution|Placebo
224147202|NCT01770691|DEVICE|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
224147203|NCT01721031|PROCEDURE|DPNB|Patients receive DPNB 30min before extubation at the end of operation
224147204|NCT01721031|DRUG|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
223451580|NCT07021755|OTHER|midazolam|
223451581|NCT07022990|OTHER|Educational brochure for deprescribing|"Study participant will be provided information (i.e., educational brochure) about one of the five medication classes participants may be taking that are known to have potential side effects for older adults: proton pump inhibitors (PPIs), benzodiazepine (BZs) and non-benzodiazepine sedative hypnotics (Z-drugs), first-generation antihistamines (FGA), and skeletal muscle relaxants (SMR) to determine their necessity."
223451582|NCT07022288|OTHER|LA ROCHE-POSAY CICAPLAST BALM, Standard cream|"After enrollment, the investigator will generate random serial numbers for grouping through simple randomization.~LA ROCHE-POSAY CICAPLAST BALM：8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period.~Standard cream:8 weeks application It is a leave-on product. It should be applied to the face twice a day during the research period."
223451583|NCT07021391|BEHAVIORAL|Primary care healthy food prescription plus incentive|Primary care healthy food prescription with $40 monthly incentive for four months to purchase 2 and 3 starred (via Guiding Stars) groceries at the supermarket
223451584|NCT07021508|DEVICE|Temporal Interference Stimulation|A non-invasive, non-invasive method of deep brain electrical stimulation utilizing high-frequency electric field interactions to produce a low-frequency envelope to modulate neural activity.
223741982|NCT06552000|DEVICE|NovoTTF-200T System|Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)
224147205|NCT05778019|OTHER|Case Scenarios of complications to be ranked / classified according to classifications (for the severity grading of events)|Test the feasibility, applicability and logic of a novel instrument for the grading of unexpected events in pediatric surgery (Clavien-Madadi classification) compared to the Clavien-Dindo classification for the grading of postoperative complications in general surgery
224147206|NCT03589885|DRUG|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
224058782|NCT03172845|PROCEDURE|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
224147207|NCT03589885|DRUG|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
224058783|NCT03814486|OTHER|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
224058784|NCT02987036|DEVICE|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
224058785|NCT02987036|DEVICE|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
224058786|NCT01699477|DEVICE|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
224058787|NCT03839173|OTHER|Human milk based human milk fortifier|A human milk fortifier with added minerals made from donor human milk
224058788|NCT02810756|DRUG|New Pazopanib formulation|
224058789|NCT01732497|DEVICE|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
224058790|NCT04459182|DIAGNOSTIC_TEST|ENDOPAT|digital plethysmography
224058791|NCT03827824|DEVICE|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
224058792|NCT03827824|DEVICE|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
224058793|NCT02820311|DRUG|TD-4208 175 mcg|via nebulizer
224058794|NCT02820311|DRUG|TD-4208 700 mcg|via nebulizer
224058795|NCT02820311|DRUG|Placebo for TD-4208|via nebulizer
224147208|NCT03589885|DRUG|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
224147209|NCT03589885|DRUG|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
223451585|NCT07021508|DEVICE|Sham Temporal Interference Stimulation|The same machine was used as the temporal Interferenc real stimulus, with current creep only 20 seconds before stimulus onset to simulate the real stimulus sensation.
223451586|NCT07026903|BEHAVIORAL|resistance exercise and calorie restrictive diet|experimental group will be randomized to isCGM during the lifestyle intervention trial while control group will participate in the same lifestyle intervention but will not use isCGM
223451587|NCT02453256|DRUG|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
223451588|NCT02453256|DRUG|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
223451589|NCT07022366|DRUG|Pimavanserin 10mg|Single dose of pimavanserin (10mg)
223451590|NCT07022366|DRUG|Placebo|Sucrose tablet
223451591|NCT07023185|DEVICE|Cold and Compression|External mechanical compression therapy (e.g., compression stockings) has been shown to reduce swelling and risk of deep vein thrombosis in the lower limbs following TKA.12,13 Combining advanced cryotherapy (continuous circulating cold flow) and dynamic compression may offer added benefits than either traditional cryotherapy (e.g., cold packs) or compression (e.g., stockings) alone.
223451592|NCT07023185|OTHER|SOC (Standard of care)|Patients enrolled in this arm will be discharged with 28 hydrocodone/APAP 7.5 mg pills taken every 6 hours as needed (or its MME equivalent), 1 identical refill if patient calls, and cold therapy (bag of ice or gel pack)
223451593|NCT07022301|DRUG|sintilimab combined with anlotinib|Patients who met the inclusion criteria were treated with Sintilimab plus anlotinib every 3 weeks until disease progression or intolerable adverse reactions or death(up to 24 months).
224058796|NCT02820311|DRUG|Moxifloxacin 400 mg|oral
224058797|NCT04004637|DRUG|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg."
224058798|NCT05397626|BEHAVIORAL|Heart Rhythm Biofeedback|Heart rhythm biofeedback is a non-invasive intervention intended to improve heart rate variability and physical resilience that is often limited in chronic fatigue syndrome
224058799|NCT05397626|DIETARY_SUPPLEMENT|Hydrogen Water|Hydrogen water, if ingested daily over several weeks, may have antioxidant and anti-inflammatory effects in chronic fatigue syndrome
224058800|NCT05397626|COMBINATION_PRODUCT|Combined treatment: Heart rhythm biofeedback plus hydrogen water|This treatment is intended to explore the possible additive or synergistic effects of combining heart rhythm biofeedback and hydrogen water.
224058801|NCT04075474|DEVICE|silver diamine fluoride|38% SDF on primary upper anterior teeth
224058802|NCT04075474|DEVICE|sodium fluoride|5% NaF on primary upper anterior teeth
224058803|NCT02192203|DRUG|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
224058804|NCT02192203|DRUG|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
224058805|NCT02192203|DRUG|Menthol Only Gel|3% menthol
224058806|NCT02192203|DRUG|Placebo Only Gel|0.09% menthol
224058807|NCT05704894|BIOLOGICAL|Erythropoietin|Administration of Erythropoietin 150UI/Kg/week divided into 3 doses, IV, for a period of 12 weeks, in patients with hemoglobin between \<12g/dL
224058808|NCT04032600|PROCEDURE|Paracentesis|Full versus partial paracentesis (3 liters)
224058809|NCT03590730|DEVICE|ICD implantation|ICD will be implanted according to current guidelines recommendations.
224058810|NCT00709982|DRUG|Norgestimate; Ethinyl Estradiol; Folic acid|
224058811|NCT02018822|DEVICE|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
224058812|NCT02018822|DEVICE|TPH3|light-cured resin composite for teeth
224058813|NCT02018822|DEVICE|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
224058814|NCT02107638|PROCEDURE|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
224058815|NCT02107638|OTHER|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
223569866|NCT06662370|OTHER|Replacement of the esophagus with a decellularized human esophagus graft|The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
223569867|NCT06660641|DEVICE|TaurolockTMHep100|1.35% taurolidine containing catheter losk solution
224058816|NCT02947035|PROCEDURE|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
224058817|NCT02947035|PROCEDURE|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
224058818|NCT02690155|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
224058819|NCT02690155|DRUG|VKA (Vitamin K antagonist)|As prescribed by treating physicians
224058820|NCT04622332|DRUG|SIR1-365|Route of administration: oral
224058821|NCT04622332|DRUG|Matching Placebo|Route of administration: oral
224058822|NCT05758519|DRUG|QLS1128|QLS1128
224058823|NCT05758519|DRUG|Placebo|Placebo
224058824|NCT03201458|DRUG|Atezolizumab|Given IV
224058825|NCT03201458|PROCEDURE|Biopsy|Undergo tumor biopsy
224058826|NCT03201458|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224058827|NCT03201458|DRUG|Cobimetinib|Given PO
224058828|NCT03201458|PROCEDURE|Computed Tomography|Undergo CT
224058829|NCT03201458|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224058830|NCT01785459|DRUG|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
223451594|NCT07021404|OTHER|Semi-structured interview (Guideline for Suicide care and Evaluation =LOES)|"A semi-structured interview is utilized in general hospitals and other healthcare institutions by clinicians and nurses as part of the psychosocial assessment, with the aim of collecting standardized data on episodes of self-harm and individuals experiencing suicidal ideation.~The interview consists of two parts:~Part 1 is administered shortly after admission to the healthcare facility due to an episode of self-harm or reported suicidal thoughts. It is conducted by a trained nurse or psychologist. This section collects demographic information, characteristics of the self-harm episode, history of self-harm behavior, perceived social support, level of hopelessness, and current suicidal ideation.~Part 2 focuses on a more in-depth exploration of the individual's psychological state. It assesses underlying motives for the self-harm or suicidal thoughts, perceived personal and interpersonal problems, and current and current thoughts of self-harm."
223451595|NCT07021612|DEVICE|JenaValve|JenaValve is a newly developed advanced TAVI system developed by Jenavalve Technology Inc.
223451596|NCT07021612|DEVICE|J-Valve|J-Valve is a newly developed advanced TAVI system developed by Genesis Medtech.
223451597|NCT01239082|PROCEDURE|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
224058831|NCT01785459|DRUG|Standard Care|10 mg Intravenous injection of Prochlorperazine
224058832|NCT00715026|DEVICE|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
224058833|NCT01263821|PROCEDURE|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
224058834|NCT01263821|PROCEDURE|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
224058835|NCT01263821|PROCEDURE|Functional magnetic resonance imaging|Undergo functional MRI
224058836|NCT01263821|PROCEDURE|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
224058837|NCT01263821|PROCEDURE|Therapeutic conventional surgery|Undergo maximal surgical resection
224058838|NCT01263821|PROCEDURE|Quality-of-life assessment|Ancillary studies
223451598|NCT01239082|PROCEDURE|FIT|Annual FIT testing
223451599|NCT02034760|PROCEDURE|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
223451600|NCT02034760|PROCEDURE|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
223451601|NCT02034760|DIETARY_SUPPLEMENT|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
223451602|NCT02034760|DIETARY_SUPPLEMENT|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
223451603|NCT02034760|DIETARY_SUPPLEMENT|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
223451604|NCT06887413|PROCEDURE|THROMBOASPIRATION WITH INDIGO SYSTEM|Subjects randomized to the treatment arm will be treated with the CAT RX as previously described.
223451605|NCT06771102|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
223451606|NCT06771102|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
223451607|NCT00049075|DRUG|fludarabine phosphate|
223451608|NCT01540136|DRUG|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
223451609|NCT01540136|DRUG|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
223451610|NCT04338191|DRUG|mFOLFOXIRI adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
223451611|NCT04338191|DRUG|mFOLFOX6 adjuvant chemotherapy|mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
223451612|NCT03587831|PROCEDURE|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
223451613|NCT03587831|BEHAVIORAL|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
223451614|NCT06258187|DEVICE|Pedi-Cap|The neonatal resuscitation team will include or omit the use of Pedi-Cap during non-invasive positive pressure ventilation (PPV) for infants ≥30 weeks in the delivery room based on the randomized study arm each month.
223451615|NCT05304494|OTHER|Biomarker tests for participant profiling|Combination of digital and physical tests to objectify measures relevant for breathlessness
223451616|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
223451617|NCT01934127|BIOLOGICAL|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
223569868|NCT06660641|DEVICE|0.9 % saline|placebo
224058839|NCT01263821|PROCEDURE|Radiation therapy treatment planning/simulation|Undergo IMRT planning
224058840|NCT01263821|PROCEDURE|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
224058841|NCT01263821|OTHER|Questionnaire administration|Ancillary studies
224058842|NCT00442780|DRUG|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
224058843|NCT00442780|DRUG|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
224058844|NCT00750737|DRUG|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
223451618|NCT01934127|BIOLOGICAL|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
223451619|NCT05112094|DEVICE|peripheral magnetic stimulation|peripheral magnetic stimulation at ipsilateral shoulder ((50-80% output, 20-40Hz, pulse duration 3-5 seconds, for 15 minutes) ) + regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
223569869|NCT06660628|RADIATION|Large Segmentation Radiotherapy|Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold
224058845|NCT00750737|DRUG|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
224058846|NCT01826253|DRUG|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
224058847|NCT03399877|BIOLOGICAL|Combining electromyography with uroflowmetry (group A)|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
224058848|NCT03399877|BIOLOGICAL|Uroflowmetry(Group B)|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
224058849|NCT03399877|BIOLOGICAL|Uroflowmetry-Combining electromyography with uroflowmetry (Group C)|Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
224058850|NCT02614859|DRUG|Observation and Bicalutamide|Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
224058851|NCT02614859|DRUG|Metformin and Bicalutamide|Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
224058852|NCT00068744|DRUG|cisplatin|
224058853|NCT00068744|DRUG|fluorouracil|
224058854|NCT00068744|DRUG|mitomycin C|
224058855|NCT00068744|RADIATION|radiation therapy|
224058856|NCT05112536|DRUG|Trilaciclib|Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
224058857|NCT05112536|DRUG|Cylophosphamide|Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
224058858|NCT05112536|DRUG|Doxorubicin|Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
224058859|NCT05112536|DRUG|Paclitaxel|Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
224058860|NCT05112536|DRUG|Carboplatin (Investigator discretion)|Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
224058861|NCT05112536|BIOLOGICAL|Pembrolizumab (Investigator discretion)|Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
223451620|NCT05112094|OTHER|physical therapy|regular physical therapy(shoulder range of motion exercise and stretching 30-40 minutes per day)
223451621|NCT02787733|DIETARY_SUPPLEMENT|Citrus flavonoid|Daily dose of 500mg divided over two capsules
223451622|NCT02787733|DIETARY_SUPPLEMENT|Placebo|Daily dose of 500mg divided over two capsules
223451623|NCT00429611|PROCEDURE|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
223451624|NCT05903040|DRUG|Lasmiditan|Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
223451625|NCT03203174|DEVICE|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
223451626|NCT03203174|DEVICE|Sham Microneedle|Flat roller with no needles on the roller
223451627|NCT03203174|DRUG|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
223451628|NCT03203174|OTHER|Saline|Saline applied to the palm
223569870|NCT06660628|DEVICE|DIBH|Deep Inspiration Breath Hold
223569871|NCT06660628|DEVICE|Surface guided radiation therapy|The technology uses modern 3D camera technology to help track and monitor patient movements during set-up and treatment.
223569872|NCT06660628|DEVICE|laser alignment|Laser systems for virtual simulation and patient positioning in radiotherapy
224058862|NCT01161264|BIOLOGICAL|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
224058863|NCT04338503|DIAGNOSTIC_TEST|Partial IVC occlusion|Partial balloon occlusion of the inferior vena cava.
224058864|NCT05382975|BEHAVIORAL|CSPAP-T|"Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning"
224058865|NCT02636088|DRUG|Cetuximab|
224058866|NCT00502138|DRUG|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
224058867|NCT00877812|DIETARY_SUPPLEMENT|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
224058868|NCT00877812|DIETARY_SUPPLEMENT|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (\<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
224058869|NCT03098823|DRUG|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
224058870|NCT03098823|DRUG|Prednisone|FDA approved corticosteroid frequently used for SLE.
224058871|NCT01389752|DRUG|LY2216684|Administered orally
224058872|NCT01389752|DRUG|Activated Charcoal|Administered orally
224058873|NCT01063075|DRUG|Cetuximab|Administered Intravenously
224058874|NCT01063075|DRUG|Carboplatin|Administered Intravenously
224058875|NCT01063075|DRUG|5 - FU|Administered Intravenously
224058876|NCT03716401|DIAGNOSTIC_TEST|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
224058877|NCT03716401|DIAGNOSTIC_TEST|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
224058878|NCT03716401|PROCEDURE|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
224058879|NCT03716401|DIAGNOSTIC_TEST|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
223451629|NCT05729581|BEHAVIORAL|The educational programme on sustainable and healthy diet and breastfeeding|In the interventional group the educational programme of sustainable diet and breastfeeding will be provided before the delivery to see the impact on the prevalence of the breastfeeding at 1 and 6 months after delivery (compared with the group of control, without intervention)
223451630|NCT06406413|DIAGNOSTIC_TEST|micro-movement; electroencephalogram; MRI|micro-movement; electroencephalogram; MRI
223451631|NCT05933564|OTHER|No intervention (cross-sectional study)|This is a cross-sectional study examining the association between cognitive reserve, pain catastrophizing, and cognitive function in geriatric patients with chronic pain; no intervention is being implemented or tested.
223451632|NCT01366638|DRUG|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
224147210|NCT03017482|DEVICE|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~* Questionnaires about the utility and impact of the device~* Use of the device in children younger than the current FDA approval range"
224147211|NCT04199208|OTHER|Prehabilitation and Immunonutrition|See study synopsis
224147212|NCT04199208|OTHER|Standard Care Arm|Standard care as per the daily routines of the Hospital at which the study takes place
223451633|NCT01366638|DRUG|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
223451634|NCT01366638|DRUG|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is \> 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is \> 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
223569873|NCT06660628|BEHAVIORAL|free breathing|Patients breathe calmly while radiotherapy instead of holding their breath.
223569874|NCT06608979|BEHAVIORAL|Screening/Referral and Prevention|Session 1: One hour PTSD Screening/referral and Psychoeducation on interpersonal violence (consent, drug-and-alcohol-facilitated assault, intimate partner violence); Session 2: One hour sessions on Protective Behavioral Strategies for interpersonal violence (skills training)
223569875|NCT03200977|OTHER|Non-Interventional|Non-Interventional
223569876|NCT06606145|PROCEDURE|Lymphovenous Anastomosis|LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
223569877|NCT06606145|PROCEDURE|Vascularized Lymph Node Transfer|VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
223569878|NCT06606145|PROCEDURE|Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer|Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
224058880|NCT03716401|DIAGNOSTIC_TEST|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
224058881|NCT02243254|DRUG|high dose remifentanil|high dose remifentanil
224058882|NCT02243254|DRUG|Ibuprofen|intravenous ibuprofen
224058883|NCT02243254|DRUG|low dose remifentanil|low dose remifentanil
224147213|NCT02907320|DRUG|CYCLO 3 ® FORT|
224147214|NCT02907320|DRUG|MPFF|
224147215|NCT02907320|DRUG|placebo CYCLO 3 ® FORT|
224147216|NCT02907320|DRUG|placebo MPFF|
224147217|NCT03472274|DRUG|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
224147218|NCT03472274|DRUG|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
224147219|NCT03472274|DRUG|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~* Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~* Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~* Methotrexate 30mg/m2 intravenously on day 1~* Vinblastine 3mg/m2 intravenously on day 2~* Doxorubicin 30mg/m2 intravenously on day 2~* Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~* Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~* Paclitaxel 80 mg/m2 intravenously on day 1 and 8~* Cisplatin 70mg/m2 intravenously on day 1"
224147220|NCT04149639|DIETARY_SUPPLEMENT|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
224147221|NCT03029481|DRUG|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
223451635|NCT04074382|OTHER|Online Questionnaires|We will use online questionnaires to complete research into functional outcomes after trauma
224058884|NCT03720431|DRUG|TTAC-0001 and pembrolizumab combination|"* Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)"
224058885|NCT00482430|DRUG|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
224058886|NCT00482430|DRUG|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
224058887|NCT01594515|DRUG|BI 1015550|High dose powder for oral solution
224058888|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
224058889|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
224058890|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
224058891|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
224058892|NCT01594515|DRUG|Placebo|Solution for oral administration
224058893|NCT01594515|DRUG|BI 101550|High dose powder for oral solution
223451636|NCT04074382|OTHER|Qualitative Interviews|We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
223569879|NCT06606145|PROCEDURE|Complex Decongestive Therapy|The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
224058894|NCT01594515|DRUG|BI 1015550|Low dose powder for oral solution
223569880|NCT06608810|DRUG|nerve block with 0.5% ropivacaine|General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
223569881|NCT06587334|PROCEDURE|SRP|SRP alone
224147222|NCT01767519|BIOLOGICAL|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
224147223|NCT01767519|DRUG|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
223569882|NCT06587334|PROCEDURE|Nd: YAG Laser Assisted SRP|the patients receive SRP combined with Nd: YAG laser
224147224|NCT01767519|DRUG|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
224147225|NCT01767519|DRUG|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
223451637|NCT01237327|DRUG|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
223451638|NCT01237327|DRUG|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
223451639|NCT04772521|BEHAVIORAL|General health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
223569883|NCT06606548|BEHAVIORAL|comprehensive oral care|including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
224058895|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
224058896|NCT01594515|DRUG|BI 1015550|Medium dose powder for oral solution
224058897|NCT01830504|DRUG|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
224058898|NCT05015088|OTHER|No interventions will be performed in this study|This study will not include any intervention
224058899|NCT04971291|DRUG|AXS-05|AXS-05 taken twice daily for 6 weeks
224058900|NCT04971291|DRUG|Bupropion SR|Bupropion taken twice daily for 6 weeks
224058901|NCT05560282|DRUG|Fenfluramine|"FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5."
224058902|NCT04807855|DEVICE|The cMLP device|There is only one medical device we are testing, so only one intervention.
224058903|NCT05111665|BEHAVIORAL|Mindfulness-based Cognitive Therapy (MBCT)|
224058904|NCT05111665|BEHAVIORAL|Relaxation Group Therapy (RGT)|
224058905|NCT05111665|BEHAVIORAL|Treatment as usual (TAU)|
224147226|NCT00039741|DRUG|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
224147227|NCT00039741|DRUG|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor"
224147228|NCT00039741|DRUG|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor"
223451640|NCT04772521|BEHAVIORAL|Personalized chat-based interactions|Individual chat-based interactions last 3 months and consist of 2 parts. First part is regular message. The schedule will be adjusted according to the participants' quitting and mental health status. The second part includes real-time psycho-behavioral intervention delivered by trained cessation counsellors using the acceptance and commitment therapy (ACT) model for smoking cessation and reliving mental health problems. The conversation is based on participants' socio-demographic characteristics, smoking habit at baseline, and updated smoking status and mental health status assessed during online conversation and the baseline questionnaire.
223451641|NCT04772521|BEHAVIORAL|Text message|Regular messages will be sent twice per month within 3 months. These messages covers simple cessation advice and reminders for follow-ups.
223569884|NCT06608342|BIOLOGICAL|Autologous hematopoietic stem cell transplantation combined with CD19-CART|Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation
224058906|NCT04362280|BEHAVIORAL|ReCHARGE|During their PE class, all participants (both arms) participate in an intensive lifestyle intervention with established efficacy among this population for the academic fall semester. The following semester, participants are randomized to different treatment arms. ReCHARGE increases the intensity of treatment provided in the first semester by increasing social support and addressing common barriers youth have to adhering to intervention.
224058907|NCT04362280|BEHAVIORAL|TAU|PE class as usual led by PE teacher.
224058908|NCT02746133|OTHER|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
224058909|NCT01730508|DRUG|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
224058910|NCT05338177|OTHER|Immunosuppression reduction|participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
224058911|NCT05338177|OTHER|No immunosuppression reduction|participants do not alter immunosuppresion
224058912|NCT05104021|DEVICE|game|"The game is played with a maximum of four people. Beginning points are marked with blue, red, yellow and green colors, the game progress direction is The starting color for the player is determined with the help of arrows. Dice with the biggest number The child who throws starts the game first from the starting point that belongs to him. Play ground Each child who completes a circuit around him reads from his second point. it tries to go inwards (to the world square) in the direction it points. Equivalent to card check box The next child draws one of the face down cards. the instruction written on the back of the card.~implements. Then he puts the card on the back of the other cards. Cards are reward (go forward), penalty (backward) git) cards. Coming second to the same frame during the game The child first starts the game from the starting point of the child in the square. First The child who manages to enter the world square wins the game."
224058913|NCT03957265|PROCEDURE|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
224058914|NCT06386965|OTHER|taking blood sample|A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.
224058915|NCT03048539|PROCEDURE|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
224058916|NCT06273007|OTHER|PartoMa intervention(Locally achievable intrapartum care guideline), in house LDHF trainings|We will implement PartoMa interventions: seminars, LDHF training, and supportive supervision
224058917|NCT03975920|DEVICE|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
224058918|NCT01713621|DRUG|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
224058919|NCT00228995|DRUG|epoetin alfa|
224147229|NCT00946881|DRUG|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
224147230|NCT00293423|BIOLOGICAL|HSPPC-96|25 mcg
223451642|NCT04772521|BEHAVIORAL|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
223451643|NCT04772521|DRUG|Mailed nicotine replacement therapy (NRT)|Full course of NRT treatment (8 weeks) will be provided to all participants who are still smoking at 6-month follow-up and request, or willing to use NRT after advice from counsellors. Medications will be mailed from the smoking cessation clinics.
223569885|NCT06661928|PROCEDURE|Papilla preservation flap|"Surgical access will be obtained using modified papilla preservation techniques and when interproximal space is narrow (less than 3mm in width) incision will be made using the simplified papilla preservation flap. Both flaps buccal and lingual/palatal will be elevated in any case to allow root surface cleaning and defects debridement under direct vision. Minimally invasive flap elevation preventing to damage inter proximal tissues with the preservation of the papilla. Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the pre-surgical level without any tension. Monofilament non-resorbable 5-0 e-PTFE suturing material will be used.~Suturing will be performed with external vertical mattress sutures to achieve primary intention closure."
223741983|NCT04449549|DRUG|Nilotinib and Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
224147231|NCT00293423|PROCEDURE|Standard Surgical Resection|Patients will undergo standard surgical resection of intracranial tumor
224147232|NCT04427436|OTHER|No Intervention|No Intervention
224058920|NCT01371136|PROCEDURE|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
224058921|NCT00321347|DRUG|Lidocaine|
224058922|NCT04035018|PROCEDURE|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
224058923|NCT04035018|PROCEDURE|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
224058924|NCT03885791|DEVICE|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
224058925|NCT04340713|OTHER|information support program|According to the established information support program for prostate cancer patients during hormonal therapy, information support and guidance on disease knowledge, symptom management, life care and other aspects are provided to patients through face-to-face communication, telephone, written information, network and other ways.
224058926|NCT04251910|DRUG|Sublingual film containing Dexmedetomidine|Sublingual film containing Dexmedetomidine
224058927|NCT04251910|DRUG|Sublingual Placebo Film|Sublingual placebo film that matches BXCL501
223451644|NCT04233671|BEHAVIORAL|Mindfulness based relapse prevention and peer mentoring|"Importantly, the treatment will utilize a group format. Group process can serve as a vital agent in breaking down client denial about drug abuse problems. Groups have also been shown to be suitable for treating problems commonly associated with substance abuse, including depression, isolation, and shame.~Additionally, groups intrinsically have many rewarding benefits, including reducing isolation and enabling members to witness the recovery of others. The eight-week group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, then followed by group sessions led by peer mentors for an additional four weeks."
223451645|NCT03350204|PROCEDURE|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
223451646|NCT03350204|OTHER|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
223451647|NCT04517773|OTHER|writting test|Patients will be invitated to fill a questionary about self-autonomy
223451648|NCT02483572|BEHAVIORAL|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
223451649|NCT05837702|PROCEDURE|ESPB|Erector spinae plane block
223451650|NCT05837702|PROCEDURE|PVB|Paravertebral Block
223451651|NCT05837702|PROCEDURE|CONTROL|No block has been done
223569886|NCT06661928|PROCEDURE|Widman flap procedure|"Surgical access will be obtained using the modified Widman flap technique. Intrasulcular incision will be done on both buccal and lingual/palatal sides without attempting to preserve the interdental tissues and interdental tissues will be removed. Both flaps buccal and lingual/palatal will be elevated at full thickness in any case to allow root surface cleaning and defects debridement under direct vision, a vertical releasing incision could be made when needed.~Defects debridement with mini-curettes. Root surface debridement with ultrasonic debridement with periotip and mini-curettes. Flaps will be positioned at the level of the alveolar crest without tension. Monofilament nonresorbable 5 - 0 e/PTFE suturing material will be used. Suturing will be performed with single interrupted sutures."
223741984|NCT06150118|OTHER|CBT+VR (Cognitive behavioral therapy and virtual reality)|The investigators are testing whether this intervention protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
224058928|NCT03436381|OTHER|Questionaire|We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
224058929|NCT03559036|PROCEDURE|Locomotor Training|Body-weight supported stepping on a treadmill.
224058930|NCT06174844|OTHER|No intervention applied|No intervention applied: data will only be collected in the indicated sampling periods from patients admitted to the participating hospitals.
224058931|NCT01722604|DRUG|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
224058932|NCT01722604|DRUG|Azopt 1%|Azopt 1%, RLD
224058933|NCT06033742|DRUG|HS-10374 tablets|Single or multiple dosing of HS-10374 orally in a fasting state
224058934|NCT06033742|DRUG|HS-10374-matched placebo tablets|Single or multiple dosing of HS-10374-matched placebo orally in a fasting state
224058935|NCT04519359|OTHER|Stop NAs therapy|Stop NAs therapy
224058936|NCT03880942|OTHER|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
224058937|NCT03880942|OTHER|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
224147233|NCT00411736|DRUG|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
223451652|NCT01065064|PROCEDURE|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
223569887|NCT04137653|DRUG|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
224058938|NCT03135275|PROCEDURE|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
224058939|NCT03135275|PROCEDURE|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
223741985|NCT06150118|BEHAVIORAL|Control (placebo) group|The investigators are testing whether the placebo control protocol is effective on re-injury anxiety, kinesiophobia, self-efficacy, and adherence problems in athletes who have undergone ACL surgery.
224058940|NCT03135275|DEVICE|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
224058941|NCT03870659|RADIATION|Breast MRI|Magnetic resonance imaging to the breast
224058942|NCT04312685|DEVICE|Prometra II Programmable Pump system - Flowonix Medical|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
224058943|NCT00487136|DRUG|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
224058944|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
224058945|NCT00487136|DRUG|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
224058946|NCT05214612|COMBINATION_PRODUCT|Drug treatment of myasthenia gravis and treatment of crisis|Patients with myasthenia gravis who are receiving medical treatment and treatment of crisis as plasmapheresis
224058947|NCT03837782|PROCEDURE|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
224058948|NCT05171348|DRUG|CM326|a humanized monoclonal antibody
224058949|NCT05171348|DRUG|Placebo|Placebo
224058950|NCT03173729|DIAGNOSTIC_TEST|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
224058951|NCT05675878|BEHAVIORAL|Dietary Intervention|This is a whole food, nutrient-dense diet that aims to remove exposure to specific food additives thought to have negative neurological effects, while also optimizing micronutrient intake.
224058952|NCT00244387|DRUG|SPM 962|
224058953|NCT04638348|DEVICE|New Biofeedback|Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
224058954|NCT05341362|PROCEDURE|LiDCOrapid|According to the illustration of the patient's hemodynamic figures shown on the LiDCOrapid monitor, we decide on the timing of the vasopressor administration. This group aims to maintain the cardiac output within a baseline range.
224058955|NCT05122884|DRUG|Milrinone|Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
224058956|NCT00481286|BEHAVIORAL|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
224058957|NCT00481286|BEHAVIORAL|Standard of Care|Standard of care for diabetes patients
224058958|NCT02227602|DRUG|Mango polyphenolics|Frozen mango pack will be provided (200\~400g per day).
224058959|NCT02777268|DRUG|Infacort|Multi-particulate granules
224058960|NCT02777268|DRUG|Hydrocortisone|Tablet
224058961|NCT01301443|DRUG|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
224058962|NCT04562207|DIAGNOSTIC_TEST|Screening for respiratory virus infection|Nasopharyngeal swab for screening for respiratory virus infection before surgery
223451653|NCT04811664|BIOLOGICAL|Moderna COVID-19 Vaccine|A lipid nanoparticle (LNP) dispersion of a messenger ribonucleic acid (mRNA) encoding the prefusion stabilized S protein of SARS-CoV-2 formulated in LNPs composed of 4 lipids (1 proprietary and 3 commercially available). It is a suspension for intramuscular injection administered as a series of two doses (0.5 mL each) 1 month apart.
224058963|NCT02061670|BIOLOGICAL|Ragweed-SPIRE|Intradermal injection
224058964|NCT02061670|BIOLOGICAL|Placebo|
224058965|NCT04944212|DIAGNOSTIC_TEST|Measuring vitamin D serum level using ELIZA|Venous blood will be obtained from pregnant women at the time of admission and from the umbilical cord veins of the newborns immediately after their delivery. The quantitative measurement of 25OHD in serum will be performed using ELIZA.
224058966|NCT04159220|PROCEDURE|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
224058967|NCT04279275|OTHER|SURVEY|QUESTIONAIRRE
224058968|NCT02348892|OTHER|Coordinator|Patients in complex situation taken care by coordinator
224058969|NCT02348892|OTHER|Classic plan|Patients in complex situation taken care by classic plan
223451654|NCT06719232|DEVICE|Catheter-Free Intravesical Instillation with a special syringe adapter|The intervention involves catheter-free intravesical instillation using a specialized urological adapter. This device is attached to a syringe and inserted approximately 6-8 mm into the urethral opening, allowing the instillation solution to reach the bladder without the need for catheterization.
223451655|NCT02163642|DEVICE|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
223451656|NCT05052697|BIOLOGICAL|mIRV|Intramuscular injection
223451657|NCT05052697|BIOLOGICAL|bIRV AB|Intramuscular injection
223451658|NCT05052697|BIOLOGICAL|qIRV|Intramuscular injection
223451659|NCT05052697|BIOLOGICAL|QIV|Intramuscular injection
223451660|NCT05052697|BIOLOGICAL|bIRV AA|Intramuscular injection
223451661|NCT05052697|BIOLOGICAL|bIRV BB|Intramuscular injection
223451662|NCT01929954|BIOLOGICAL|Gintuit|One time placement of Gintuit over socket graft.
223451663|NCT01929954|DEVICE|Bio-Gide|One time placement of Bio-Gide over socket graft.
223451664|NCT04351477|DEVICE|Massage chair|Mechanical massage chair
223451665|NCT00211627|DEVICE|KEEPASLEEP enhanced breathing device|
223451666|NCT05885633|PROCEDURE|endometrial sampling with pipelle|Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
223451667|NCT03459859|DRUG|Pevonedistat|Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
223569888|NCT04137653|DRUG|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
223569889|NCT06008418|BEHAVIORAL|The LINE Chatbot|The chatbot approach is selected as it uses artificial intelligence to simulate conversations with users. The information can be collected or distributed and even through these conversations trigger human actions. LINE is one of the most widely used freeware applications in Taiwan and its chatbot function is well-organized and relatively easy to modify, adapt, and use. The design of the chatbot aims at the two elements above, ensuring goal alignment and enhancing power sharing, by guiding participants to complete three activities: specifying their goals for today's discussions, providing patient-reported outcomes by self-rating their health-related quality of life, and learning question prompt list based on their needs.
224058970|NCT02618655|OTHER|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
223451668|NCT03459859|DRUG|Cytarabine|Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
223451669|NCT01657656|DIETARY_SUPPLEMENT|Vitamin D|
223451670|NCT06133478|DRUG|NUV001 active cohort 1|6 participants will be assigned to receive active treatment
223451671|NCT06133478|DRUG|NUV001 active cohort 2|6 participants will be assigned to receive active treatment
223451672|NCT06133478|DRUG|NUV001 active cohort 3|6 participants will be assigned to receive active treatment
223451673|NCT06133478|DRUG|NUV001 active cohort 4|6 participants will be assigned to receive active treatment
223451674|NCT06133478|DRUG|NUV001 placebo cohort 1|2 participants will be assigned to receive placebo
223451675|NCT06133478|DRUG|NUV001 placebo cohort 2|2 participants will be assigned to receive placebo
223451676|NCT06133478|DRUG|NUV001 placebo cohort 3|2 participants will be assigned to receive placebo
223451677|NCT06133478|DRUG|NUV001 placebo cohort 4|2 participants will be assigned to receive placebo
223451678|NCT01289574|DRUG|ASC-J9|Cream for twice daily topical application to the face
223451679|NCT03710369|DRUG|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
223451680|NCT03710369|DRUG|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
223451681|NCT01590849|DRUG|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~* Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~* Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
223451682|NCT00262002|BIOLOGICAL|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
223451683|NCT00262002|BIOLOGICAL|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
223451684|NCT00262002|BIOLOGICAL|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
223451685|NCT00262002|BIOLOGICAL|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
223451686|NCT00262002|BIOLOGICAL|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
223451687|NCT00262002|BIOLOGICAL|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
223569890|NCT06264817|DEVICE|MOBIDERM Autofit Armsleeve|"In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks"
223569891|NCT06264817|DEVICE|Compressive bandaging|"In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks.~During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks"
224058971|NCT02582606|OTHER|Regular meal pattern|a 14-day period of eating 6 meal per day
224058972|NCT02582606|OTHER|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
224058973|NCT04928859|DRUG|Albumin|"At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group.~The patients who have no albumin use during their hospitalization in the burn ward consisted the control group."
224058974|NCT00808236|DEVICE|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
224058975|NCT00808236|OTHER|Control|Advanced cardiac life support according to American Heart Association \& European Resuscitation Council 2005 Guidelines
223451688|NCT00262002|BIOLOGICAL|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
223451689|NCT00262002|BIOLOGICAL|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
223569892|NCT06542978|DEVICE|40Hz stimulation|Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
223569893|NCT06605898|OTHER|MIND Diet|Daily meals designed to increase adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) dietary pattern.
223569894|NCT06605898|OTHER|Control Diet|Daily meals designed to increase fruit, vegetable, and whole grain intake consistent with a healthy American diet.
223569895|NCT03483805|DIETARY_SUPPLEMENT|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
224058976|NCT02230384|DRUG|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
224058977|NCT02230384|DRUG|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
224058978|NCT00777101|DRUG|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
224058979|NCT00777101|DRUG|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
224058980|NCT00777101|DRUG|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
224058981|NCT06422975|DRUG|Vasopressin|Patients treated with vasopressin
224058982|NCT04732741|DIAGNOSTIC_TEST|Salivary Gamma-synuclein|Gamma-synuclein salivary levels measured using ELISA assay
224058983|NCT04732741|DIAGNOSTIC_TEST|Incisional biopsy|"A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region."
223569896|NCT03483805|DIETARY_SUPPLEMENT|Placebo|maize maltodextrin in powder form, to be diluted in water
223569897|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
223569898|NCT06607471|OTHER|Support treatment, cardiac medical treatment, aetiology-specific treatment|Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
223741986|NCT06453642|DEVICE|GPX® Embolic Device|Treatment includes distal embolization in the peripheral vasculature of vascular tumors, renal embolization, and portal vein branches
223741987|NCT05635175|OTHER|hip abductors physiotherapy self training|hip abductors self training program during 7 to 10 weeks associate with a PFMT
223741988|NCT05635175|OTHER|Standard pelvic floor muscle training|Standard pelvic floor muscle training
224058984|NCT04732741|DIAGNOSTIC_TEST|Conventional visual and tactile examination|Conventional visual and tactile examination using light and mirror
224058985|NCT05752877|BIOLOGICAL|Targeted IL-13 Rα2 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
223451690|NCT01230099|BEHAVIORAL|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
223451691|NCT03623633|DRUG|denosumab|denosumab 60 milligrams subcutaneously every 6 months
223451692|NCT03623633|DRUG|alendronate|alendronate 70 milligrams weekly
223451693|NCT03623633|DRUG|raloxifene|raloxifene 60 milligrams daily
224058986|NCT05752877|BIOLOGICAL|Targeted B7-H3 UCAR-T cell injection|local administration (intracranial cavity or intravertebral injection after surgery): 1 ampoule (about 2-5 ml, 1-5×10\^7 cells) for 1-2 minutes each time.
224058987|NCT00961220|DRUG|Carmustine|Applied topically
224058988|NCT00961220|OTHER|Laboratory Biomarker Analysis|Correlative studies
224058989|NCT00961220|DRUG|O6-Benzylguanine|Given IV
224058990|NCT03666455|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
224058991|NCT02153528|DRUG|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
223451694|NCT03501654|DEVICE|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
224058992|NCT02153528|DRUG|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
224058993|NCT02031770|DRUG|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
224058994|NCT02031770|OTHER|Control|subjects will receive no treatment
224058995|NCT01908270|BEHAVIORAL|Yoga|
224058996|NCT01908270|OTHER|Usual care|
223451695|NCT01620333|DRUG|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
223451696|NCT01620333|DRUG|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
224058997|NCT00593944|BIOLOGICAL|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
224058998|NCT01301950|OTHER|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
224058999|NCT01301950|OTHER|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
224059000|NCT04948775|OTHER|Cervical stabilization exercises|A progressive home-based cervical stabilization exercise program which is aimed to train deep stabilizer muscles of the cervical spine and improve coordination between superficial and deep cervical muscles will be performed by the patients for 6 weeks. Exercises are going to be delivered by sending messages and video instructions via a freeware and crossplatform messaging service (WhatsApp Messenger) in a weekly basis.
224059001|NCT02651584|DRUG|CAM2038 SC injection|
224059002|NCT02651584|DRUG|SL BPN/NX tabs|
224059003|NCT02651584|DRUG|placebo SC injections|
224059004|NCT02651584|DRUG|SL placebo tablets|
224059005|NCT01711411|DEVICE|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
224305078|NCT01345175|DRUG|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
223451697|NCT05583045|OTHER|Olive Leaf Tea|Olive leaf tea (individual tea bags provided to participants with instructions of preparation)
223451698|NCT05583045|BEHAVIORAL|Lifestyle behavior change program (LBC)|"Lifestyle behavior change program as defined by America Diabetes Association on Standards of Medical Care in Diabetes-2022 Abridged for Primary Care Providers(Association 2022)"
223451699|NCT05583045|OTHER|Placebo tea|Placebo tea containing 2,6g cellulose and a caramel coloring
223451700|NCT06124105|DIAGNOSTIC_TEST|arterial blood gases|measurement of partial oxygen pressure in urine by arterial blood gas device
223451701|NCT04000334|OTHER|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
223569899|NCT06605781|BEHAVIORAL|AR/VR technology-based training|Students will receive AR/VR Technology and OSCE in a Virtual Clinical Environment to learn how to assess and manage patients with auditory hallucination. The course was designed as a diverse and interactive learning experience, integrating a virtual clinical environment for auditory hallucinations with the application of Objective Structured Clinical Examination (OSCE). The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum. Additionally, students will have access to the AR/VR materials for self-practice during the practicum.
223569900|NCT06605781|BEHAVIORAL|traditional vedio and discussion group|Students will receive a traditional course on auditory hallucination assessment, which includes watching educational videos and participating in a general discussion group on auditory hallucinations. The practicum lasts approximately 15 days, with 8 hours per day. The teaching activities of the traditional course will be held 5 times on days 4, 6, 8, 10, and 12 of the practicum.
223741989|NCT05635175|OTHER|Standard pelvic floor muscle training self training|Standard pelvic floor muscle training self training
223741990|NCT04318080|DRUG|Tislelizumab|200 milligrams (mg) intravenously every 3 weeks (Q3W)
224059006|NCT05523037|DRUG|Sevoflurane|For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
224059007|NCT05523037|DRUG|Remimazolam|For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
224059008|NCT01651624|OTHER|Invitation to screening|
224059009|NCT03621332|OTHER|Questionnaire|Online/paper questionnaires
224059010|NCT00841789|DRUG|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
224059011|NCT00841789|DRUG|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
223451702|NCT04000334|OTHER|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
223451703|NCT05699876|DRUG|Melatonin 6 MG|melatonin will be administered orally preoperatively as premedication
223451704|NCT05699876|DRUG|Gabapentin|melatonin will be administered orally preoperatively as premedication
223451705|NCT02278965|DRUG|Metformin|Metformin 850mg, oral, twice a day for 12 months
224059012|NCT03215420|DIAGNOSTIC_TEST|MRI 3T|
223741991|NCT05927376|BEHAVIORAL|Mediterranean diet|All foods, meal plans and instructions provided.
223451706|NCT02278965|DRUG|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
223451707|NCT04774276|OTHER|cardiac rehabilitation protocol without occupational therapist|cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).
223451708|NCT04774276|OTHER|cardiac rehabilitation protocol with occupational therapist|"This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month."
223451709|NCT01891682|OTHER|Observational|Observational, Translational non-treatment study
223741992|NCT05927376|BEHAVIORAL|Western diet|All foods, meal plans and instructions provided.
224059013|NCT01055600|DRUG|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
224147234|NCT00411736|DRUG|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
224147235|NCT04180800|OTHER|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
224147236|NCT05978856|OTHER|Accuracy of computer software in predicting soft tissue profile changes|"Separate analyses will be performed on the initial and final cephalograms.~* All of the cephalometric analyses will be done via computer software,the linear and angular measurements will be done via the software.~* Through the use of software, the initial cephalogram and the initial photograph will be linked.~* Then, the final values of some angles will be tracted from the post-treatment cephalogram.~* These values will be inserted in the treatment simulationsection of the software.~* A post-treatment projected image of the patient will be simulated by the software.~* Then the actual post-treatment photograph will be placed on the simulated image in transparent form.~* From the pupil , real horizontal and vertical reference lines will be drawn.~* Then certain measurements will be taken from referance lines to fixed points on the soft tissue to determine the discrepancies between the real and simulated images."
224147237|NCT05735509|DEVICE|Rubber dam|Intraoral impressions can be taken with rubber dam in place. The care provider will take two impressions, one with the rubber dam in place and one without. The investigator will randomly chose one of the two impressions for crown manufacturing, and the crown will be delivered by the care provider blindly
224147238|NCT02491697|BIOLOGICAL|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
223451710|NCT02179476|DEVICE|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
223451711|NCT01519973|RADIATION|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
223451712|NCT02445131|DRUG|Bendamustine|Debulking: Cycles 1 - 2, d1 \& 2: 70 mg/m2 i.v.
223451713|NCT02445131|DRUG|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 \& 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
223451714|NCT02445131|DRUG|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
223569901|NCT06614647|DIAGNOSTIC_TEST|Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker|"IG patients will receive the following intervention at 3, 12, 24, and 36 months post-surgery:~1\) Recurrence risk stratification by ctDNA analysis of blood samples:~a) Only if ctDNA becomes positive, will imaging be performed. b) If ctDNA is positive, but recurrent disease is not detected by imaging or clinical and endoscopic evaluation, the patient will be referred back to intensified ctDNA measurements repeated every 4 months until either ctDNA becomes negative or recurrence is confirmed by subsequent imaging."
223569902|NCT06614647|BEHAVIORAL|Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)|2\) Collection and analyses of ePROMs to identify whether patients suffer from organ-specific late effects or biopsychosocial late effects and monitor of health related quality of life and the impact of late adverse effects hereon.
223569903|NCT06614647|BEHAVIORAL|Systematic treatment of organ-specific late effects and/or biopsychosocial late effects|3\) When needed, standardized treatment for organ-specific late effects according to newly published national guidelines at specialized centers. Further, online cognitive behavioral therapy is offered to patients suffering from severe biopsychosocial late effects.
223569904|NCT06614647|BEHAVIORAL|Digital care-guide for long-term follow-up after cancer treatment|Use of a digital care-guide from study inclusion to guide the patient trough the follow-up program, in the form of a personalized smart phone app.
223569905|NCT06615817|DIETARY_SUPPLEMENT|Intermittent Fasting|In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.
223741993|NCT06308822|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
223741994|NCT06308822|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223741995|NCT06308822|PROCEDURE|Computed Tomography|Undergo CT
223741996|NCT06308822|DRUG|Erdafitinib|Given PO
223741997|NCT06308822|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223741998|NCT05693909|DRUG|SP-420|Capsules for oral intake
224059014|NCT03573427|DEVICE|Trans-atrial septal placement LV lead for CRT|
224059015|NCT01452763|DRUG|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
224059016|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
224059017|NCT01452763|DRUG|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
224059018|NCT01452763|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
224147239|NCT02491697|DRUG|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
224147240|NCT05096702|DRUG|Tafenoquine|Tafenoquine 300 mg (2x150mg tablets)
224147241|NCT05096702|DRUG|Primaquine|Daily primaquine adjusted by weight (0.5 mg/kg/day for 7 days)
224147242|NCT05096702|DRUG|Primaquine|Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
223451715|NCT02283580|OTHER|Single limb|"Low load, high-repetitive resistance training.~* single limb at a time (e.g., one arm or one leg)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
224059019|NCT01452763|DRUG|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
224059020|NCT01452763|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
224059021|NCT05591118|DRUG|Anticoagulant Therapy|All subjects will receive anticoagulation for a minimum of 3 months.
224059022|NCT05591118|DEVICE|Catheter-Directed Therapy|The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
224059023|NCT05809414|DEVICE|Transcranial Magnetic Stimulation|"TMS is a technique for electrical stimulation of brain tissue by generating a magnetic field, which modulates neural activity at the stimulation site and in interconnected neural networks.~The treatment will be applied to the left dorsolateral prefrontal region. Each patient will receive 3 sessions per week of approximately 10 minutes for 6 weeks.~In the case of TMS sham, a placebo coil will be used, which is indistinguishable from the therapeutic one. In addition, the sessions will be carried out with the same frequency, so the patient will be unaware of the treatment they are receiving."
224059024|NCT05809414|DRUG|Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule|"It will be used at a dose of 100 mg, 1 capsule a day for 1 week, followed by 2 daily doses of 100 mg until completing 6 weeks in total. After completing the treatment phase, the dose will be de-escalated (1 capsule a day for 5 days and discontinued).~In the case of placebo amantadine capsules, they will have the same organoleptic characteristics as amantadine. The start, maintenance and de-escalation pattern will be identical."
224059025|NCT04075838|OTHER|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
224059026|NCT02642445|DEVICE|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
224059027|NCT00452751|PROCEDURE|laparoscopy-assisted distal gastrectomy|
224059028|NCT00452751|PROCEDURE|open distal gastrectomy|
224059029|NCT03009032|DIETARY_SUPPLEMENT|PMT25341|
224059030|NCT03009032|DIETARY_SUPPLEMENT|Placebo|Lactose
224059031|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
224059032|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
224059033|NCT00825162|BIOLOGICAL|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
224059034|NCT01478035|DRUG|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
224059035|NCT01478035|DRUG|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
224059036|NCT02263898|DRUG|Raf kinase inhibitor LGX818|Given PO
224059037|NCT02263898|DRUG|binimetinib|Given PO
224059038|NCT02263898|OTHER|laboratory biomarker analysis|Correlative studies
223451716|NCT02283580|OTHER|Two limb|"Low load, high-repetitive resistance training.~* two limbs at a time (e.g., both arms or both legs)~* elastic bands~* 8 weeks~* 3 times/week,~* each session 60 minutes~* seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~* maximal number of repetitions (RM) \* 3 sets in each exercise."
224059039|NCT03454022|BEHAVIORAL|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
223451717|NCT02570230|OTHER|NSS|NSS infusion
223451718|NCT02570230|DRUG|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
224147243|NCT02288065|DRUG|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
223451719|NCT04699825|OTHER|Cardiovascular and immunological changes|performing cardiac ultrasound, vascular doppler, and immunological study on cord blood sample
223451720|NCT01108692|OTHER|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
223451721|NCT01048086|DRUG|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.
223451722|NCT01048086|DRUG|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
223451723|NCT04091204|DRUG|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
223569906|NCT02030717|DRUG|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
224059040|NCT03454022|BEHAVIORAL|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
224059041|NCT03514342|PROCEDURE|Interscalene brachial plexus block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
224059042|NCT03514342|DRUG|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
224059043|NCT04443543|DRUG|Capecitabine (Xeloda) Pharmacogenetic Test Reagents|CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
224059044|NCT04443543|DRUG|irinotecan|CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1
224147244|NCT03403894|BEHAVIORAL|Asking caregivers in their practice|A questionary is given to caregivers
224305079|NCT05411588|DRUG|PF-07275315|Active drug
224059045|NCT04443543|RADIATION|IMRT|Pelvic Radiation: 50Gy/25Fx
224059046|NCT04443543|DRUG|Oxaliplatin|FOLFIRINOX: 85mg/m2 d1
224059047|NCT04443543|DRUG|5Fluorouracil|FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
224059048|NCT04443543|DRUG|Tislelizumab|200mg iv
224059049|NCT00964743|DRUG|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
224059050|NCT00964743|DRUG|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
224059051|NCT03778619|DRUG|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
224059052|NCT03778619|DRUG|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
224059053|NCT03778619|DRUG|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
224059054|NCT03778619|BIOLOGICAL|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
224059055|NCT03778619|DRUG|Interleukin-2|1 x 10\^6 IU/m2, together with MG4101
224147245|NCT04047758|DRUG|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
223741999|NCT06244784|BEHAVIORAL|effectiveness of a training course on a healthy work environment for nurses and nursing assistants in a hospital|"Once the participants have been included in the study, they will be assigned to each group; control group and intervention group by convenience sampling. Baseline data will be collected in both groups. At this time, questionnaires will be collected in both populations and focus groups will be conducted in the professionals assigned to both groups. Once the data have been obtained, the intervention group will conduct the training course.~After the training, data will be collected again at three different times: 1) Right after the training: questionnaires and focus group will be collected from intervention group professionals; 2) 6 months after the training: questionnaires will be collected from control group and intervention group; 3) 12 months after the training: questionnaires will be collected and focus groups will be conducted in both groups."
223742000|NCT06605599|DRUG|ABBV-932|Oral Capsule
223742001|NCT06605599|DRUG|Placebo for ABBV-932|Oral Capsule
224059056|NCT03455491|DRUG|XC221 100 mg|once daily during 3 days.
224059057|NCT03455491|DRUG|XC221 200 mg|once daily during 3 days.
224059058|NCT03455491|DRUG|Placebo|once daily during 3 days.
224059059|NCT04219176|DIAGNOSTIC_TEST|Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity
224305080|NCT05411588|DRUG|Placebo|Placebo
223742002|NCT02346253|RADIATION|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
223742003|NCT02346253|DRUG|Bicalutamide|Given PO
223742004|NCT02346253|DRUG|Leuprolide Acetate|Given IM or SC
223742005|NCT02346253|DRUG|Goserelin Acetate|Given SC
223742006|NCT02346253|DRUG|Triptorelin Pamoate|Given IM
224059060|NCT05505136|DEVICE|Arrhythmia Management System (AMS)|Retrospective collection of data related to subjects who participated in the MAPS 90D0234 study and had a medication change reported will wearing the AMS device.
224059061|NCT00781911|BIOLOGICAL|Cixutumumab|Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
224059062|NCT00781911|DRUG|depot octreotide|Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
224059063|NCT06416904|DEVICE|archwire stopper mesial to the maxillary first molar group|canine retraction after the extraction of the maxillary first premolars with archwire stoppers is mesial to the maxillary first molars.
224059064|NCT06416904|DEVICE|inter-radicular mini-screw|canine retraction after the extraction of the maxillary first premolars, with the maxillary first molars indirectly anchored to the inter-radicular mini-screw.
224059065|NCT01391286|DRUG|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
224059066|NCT01391286|DRUG|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
224059067|NCT00651417|DIETARY_SUPPLEMENT|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
224059068|NCT00651417|DIETARY_SUPPLEMENT|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
224059069|NCT03424785|OTHER|drug, stent, surgical treatment|drug, stent, surgical treatment
224059070|NCT03212053|BIOLOGICAL|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
224059071|NCT05815407|OTHER|No intervention|No intervention
224059072|NCT00236860|DRUG|topiramate|
224070763|NCT07028099|DEVICE|Expandable OLIF cage with posterior bone grafting|This intervention involves the use of a novel expandable OLIF cage that allows intraoperative height adjustment and posterior bone grafting through a dedicated channel. The device is designed to restore intervertebral height and lumbar lordosis while minimizing endplate injury. Bone grafts (autologous or synthetic) are delivered after expansion to enhance fusion. This design aims to reduce cage subsidence, improve fusion rates, and simplify the surgical workflow compared to conventional OLIF cages with fixed heights.
223451724|NCT03494244|PROCEDURE|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
223451725|NCT03494244|DEVICE|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
223451726|NCT01790516|DRUG|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
224059073|NCT05858021|DIAGNOSTIC_TEST|Physical examination|"Per participant, two colorectal surgeons, will separately and consecutively each perform disease assessment in accordance with the 'usual' clinical approach (direct visualisation with 'naked eye') with the exception that for each lesion identified they will undertake a series of measurements, obtain photographs of each lesion and record their findings on the proforma provided.~Once all lesions identified have been recorded diagrammatically and photographically, EP and PM will confer and collate lesions of suspicion for biopsy. All lesions suspicious for aHSIL will be biopsied/excised in keeping with usual care.~During the study period we anticipate HRA to become available within the LTHTR and incorporated into usual care for the clinical assessment of patients with aHSIL. HRA will be used in addition to direct visualisation such that 'usual care' comprises clinical assessment with direct visualisation and HRA."
224059074|NCT05790109|DEVICE|RF track cautery during percutaneous organ biopsy|After biopsy samples are obtained, the physician operator will place a radiofrequency bipolar cautery electrode through the biopsy introducer needle into the biopsy track and cauterize the track using a standardized protocol.
224059075|NCT04049838|PROCEDURE|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
224059076|NCT01530204|PROCEDURE|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
224059077|NCT01530204|BEHAVIORAL|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
224059078|NCT01530204|OTHER|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
224059079|NCT03317795|DRUG|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
224059080|NCT03317795|DRUG|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
224059081|NCT02918383|DIAGNOSTIC_TEST|Indocyanin Green Dye (ICG)|
224059082|NCT06495034|DEVICE|airwave compression therapy|Airwave compression therapy was given to patients after breast cancer surgery to treat the ipsilateral upper limb
224059083|NCT06495034|OTHER|standard care: health education and routine functional exercise|standard care: health education and routine functional exercise
224059084|NCT06174623|DEVICE|ModulHeart Support|The ModulHeart device will be implanted in the descending abdominal aorta.
224147246|NCT04047758|DRUG|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
223451727|NCT01790516|DRUG|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
223451728|NCT01790516|RADIATION|Radiation|daily radiation for 7 weeks
223451729|NCT04460963|OTHER|Adrenomedullin|Adrenomedullin sample evaluation
224059085|NCT06360991|DEVICE|Deep brain stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (vALIC, BNST, amSTN, VC/VS, or NAc) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
224059086|NCT05754502|DRUG|Trastuzumab emtansine|observational study. After the signature of the Informed Consent Form, all their data reported in the medical charts up to then (as detailed in section 12 of the protocol) will be extracted retrospectively and inserted in the study database. From the end of the washout period following the last treatment with T-DM1, each subject will enter in an observation phase for a maximum of 3 years, or until death whichever happens first. This phase will be prospective after the signature of the Informed Consent Form.
224059087|NCT01628471|DRUG|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
223451730|NCT01554163|DRUG|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
223451731|NCT01554163|DRUG|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
223451732|NCT04239196|DRUG|tocilizumab and IV steroids combination|"Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.~Patients will receive in addition to the reference treatment four subcutaneous injections of tocilizumab 162 mg over one month (1 injection per week)."
223742007|NCT02346253|DRUG|Degarelix|Given SC
223451733|NCT04239196|OTHER|IV steroids combination alone|Every patient will receive the reference treatment for GCA with ocular complication, i.e. high dose corticosteroid therapy (intravenous pulses of 7,5 to 15 mg/kg/day of methylprednisolone with an upper limit of 1000 mg/day for 3 days followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done) and aspirin 75 mg/day. The mean duration of this reference treatment is 18 months.
223569907|NCT02030717|DRUG|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
223569908|NCT04360239|DIETARY_SUPPLEMENT|Fish Oil|Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
223742008|NCT02346253|OTHER|Laboratory Biomarker Analysis|Correlative studies
223742009|NCT02346253|OTHER|Quality-of-Life Assessment|Ancillary studies
224059088|NCT06183840|DEVICE|Glutack|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack
223451734|NCT02922075|BIOLOGICAL|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
223451735|NCT02922075|BIOLOGICAL|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
223451736|NCT02922075|DEVICE|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque \> 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
223451737|NCT02922075|PROCEDURE|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
224059089|NCT06183840|DEVICE|Conventional|Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
224059090|NCT00479284|PROCEDURE|Average volume assured pressure support (AVAPS)|
224059091|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
223451738|NCT02922075|DEVICE|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
224059092|NCT03015571|DEVICE|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
224059093|NCT03015571|DEVICE|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
224059094|NCT03015571|DEVICE|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
224147247|NCT04810234|DEVICE|transcutaneous vagal nerve stimulation (tVNS)|Cervical and auricular transcutaneous stimulation of the vagus nerve
224147248|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (A)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~* Whole Venous Blood"
223451739|NCT02922075|BIOLOGICAL|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
223569909|NCT06869798|DRUG|zinc sulphate|"Group A (intervention) and Group B (non-intervention). The patients in Group A will receive standard therapy along with oral zinc 20mg/day OD for 2 months. While the patients in Group B will receive only Standard therapy.~Then, all the patients of both groups will be trained to maintain diary regarding questionnaire asked in asthma control test, followed up 4 weekly for 8 weeks"
223569910|NCT01054040|OTHER|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
224059095|NCT02386280|BEHAVIORAL|Motivational Interviewing for Change of Parenting Styles|
224059096|NCT02386280|BEHAVIORAL|Psicoeducation|
224059097|NCT06295939|OTHER|social support program|"Group 2, the experimental group, will receive routine nursing care from the assigned nurse and a social support program provided by the researcher, as follows:~Phase 1 (Before Pregnancy Termination)~Phase 2 (After Pregnancy Termination, Before Returning Home):"
224059098|NCT06295939|OTHER|Routine nursing care|The sample group will receive routine nursing care from the assigned nurse.
224059099|NCT00896207|DRUG|Akt inhibitor SR13668|Given orally as a single dose
224059100|NCT04141332|DIAGNOSTIC_TEST|EEG was recorded by EEG Machines|EEG was recorded by EEG Machines
224059101|NCT01549002|DRUG|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
224059102|NCT01549002|DRUG|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
224059103|NCT04655443|OTHER|Standard Care|Standard cardiovascular care
224147249|NCT04408066|DIAGNOSTIC_TEST|Sample Collection/Performance Evaluation (B)|"This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Whole Venous Blood~* Fingerstick Capillary Sample"
224147250|NCT04883658|DRUG|CKD-348(2)|QD, PO
224147251|NCT04883658|DRUG|CKD-828, D097, D337|QD, PO
223451740|NCT02922075|DRUG|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
224059104|NCT02438514|OTHER|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.~Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.~Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
224059105|NCT04066491|DRUG|M7824|Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
224059106|NCT04066491|DRUG|Placebo|Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
224059107|NCT04066491|DRUG|Gemcitabine|Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
224059108|NCT04066491|DRUG|Cisplatin|Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
224059109|NCT06972134|DIETARY_SUPPLEMENT|Sesame Oil (SO) at 100 mg/mL in dissolving fluid.|Pure Sesamum indicum oil (cold-pressed, unrefined) dissolved in BioIVT bile juice at 100 mg/mL. Prepared by homogenization (30 min, 37°C). Used as monotherapy.
224059110|NCT06972134|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil (EVOO) at 100 mg/mL in dissolving fluid.|Pure Olea europaea oil (first cold-pressed, acidity ≤0.8%) dissolved in BioIVT bile juice at 100 mg/mL. Prepared by vortex mixing (15 min, 25°C). Used as monotherapy.
224059111|NCT06972134|DIETARY_SUPPLEMENT|50% Sesame Oil (SO) + 50% Extra Virgin Olive Oil (EVOO).|A 1:1 (v/v) blend of Sesamum indicum oil (AIU-BC-618-1) and Olea europaea oil (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by mechanical stirring (1 hr, 40°C).
224059112|NCT06972134|DIETARY_SUPPLEMENT|50% Psyllium Extract (PE) + 50% Oil Blend (50% SO + 50% EVOO).|50% Plantago ovata mucilage extract (aqueous extraction, 65°C) + 50% AIU-BC-618-3 (SO+EVOO blend). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by sonication (20 min).
224059113|NCT06972134|DIETARY_SUPPLEMENT|Plantago ovata extract (AIU-BC-618-4) + AIU-BC-618-3|50% Taraxacum officinale root extract (ethanol-water extraction, 70°C) + 50% AIU-BC-618-3 (SO+EVOO blend). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by magnetic stirring (30 min, 50°C).
224059114|NCT06972134|DIETARY_SUPPLEMENT|50% Herbal Extract (25% PE + 25% DE) + 50% Oil Blend (25% SO + 25% EVOO).|25% Plantago ovata extract (AIU-BC-618-4) + 25% Taraxacum officinale extract (AIU-BC-618-5) + 25% SO (AIU-BC-618-1) + 25% EVOO (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by homogenization (45 min, 37°C).
223451741|NCT02922075|DEVICE|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
223451742|NCT02922075|OTHER|No soft tissue graft|No soft tissue graft was used
223451743|NCT04833400|DEVICE|ICRS|Patients undergo 30-minute aerobic training with ICRS, 3 sessions a week, for 4 weeks.
223451744|NCT04833400|DEVICE|TAET|Patients undergo 30-minute aerobic training with TAET, 3 sessions a week, for 4 weeks.
223451745|NCT02215499|DRUG|Placebo|
223451746|NCT02215499|DRUG|Sodium Oxybate|
223451747|NCT02215499|DRUG|JZP-386|
223451748|NCT01132300|DEVICE|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
223451749|NCT04884971|DRUG|Intestinal microbiota transplant (IMT)|Two size 00 capsules from a single lot will be taken daily. Approximately 2.0 x 10\^11 bacteria from a healthy donor are contained in each capsule.
223451750|NCT00037037|BIOLOGICAL|MAGE-10.A2|
224059115|NCT06972134|DRUG|Drug: Rowachol® (terpene extract) at 100 mg/mL in dissolving fluid.|25% Plantago ovata extract (AIU-BC-618-4) + 25% Taraxacum officinale extract (AIU-BC-618-5) + 25% SO (AIU-BC-618-1) + 25% EVOO (AIU-BC-618-2). Final concentration: 100 mg/mL in BioIVT bile juice. Prepared by homogenization (45 min, 37°C).
224059116|NCT04173715|BEHAVIORAL|Older Adults Group.|Physical activity and energy expenditure quantification
223451751|NCT00037037|BIOLOGICAL|MART-1 antigen|
223451752|NCT00037037|BIOLOGICAL|NY-ESO-1 peptide vaccine|
223451753|NCT00037037|BIOLOGICAL|sargramostim|
223451754|NCT00037037|BIOLOGICAL|tyrosinase peptide|
223451755|NCT01777737|DRUG|Cotrimoxazole|24 weeks of treatment
223451756|NCT01777737|DRUG|Placebo|Identical capsules to cotrimoxazole
223451757|NCT01894971|DEVICE|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
223451758|NCT03111615|DRUG|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated"
223569911|NCT06625099|OTHER|Mechanical Ventilation (MV) with Low PEEP|Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and 5cmH2o PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.
224059117|NCT04173715|BEHAVIORAL|Low Physical Function Status Group|Physical activity and energy expenditure quantification
224059118|NCT04173715|BEHAVIORAL|Medium Physical Function Status Group|Physical activity and energy expenditure quantification
224059119|NCT04173715|BEHAVIORAL|High Physical Function Status Group|Physical activity and energy expenditure quantification
224147252|NCT02350933|PROCEDURE|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
223451759|NCT01950156|BIOLOGICAL|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
223451760|NCT00784056|DRUG|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH\_DETINLYN Tangerine Mix)
223451761|NCT04273932|DRUG|Lithium|Lithium aspartate of lithium carbonate will be administered by mouth.
223451762|NCT01146028|DRUG|Tizanidine|Tizanidine HCl Tablets 4 mg
224059120|NCT05896449|DIAGNOSTIC_TEST|[68Ga]Ga-PSMA-11 PET/CT|The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of \[68Ga\]Ga-PSMA-11 (2 MBq per kg body weight).
223569912|NCT06625099|OTHER|Mechanical Ventilation (MV) with Optimum PEEP|"Mechanical Ventilation (MV) with Low PEEP During volume controlled ventilation, blood gas values and mechanical power calculations of patients ventilated at 6-8ml/kg tidal volume and optimum PEEP, I/E: 1/2, 10-14 frequency ranges will be recorded.~The optimum PEEP will be adjusted by titrating to the highest compliance with the open lung strategy."
223569913|NCT05396222|DEVICE|3D-printed custom-made non-rigid biomimetic implant|We developed a 3D printed, custom-made, biomimetic prosthesis, with non-rigid structure, which has been tested in biomechanical study and porcine model, showing good bone formation and less stiffness as well. Therefore, we proposed a prospective clinical study to investigate safety, subsidence, and fusion of this prosthesis.
224059121|NCT00668031|DRUG|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
224059122|NCT00668031|DRUG|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
224059123|NCT01855451|DRUG|Cetuximab|
224059124|NCT01855451|RADIATION|RT (70 Gy in 35 fractions)|
224059125|NCT01855451|DRUG|Cisplatin|
223569914|NCT05890170|OTHER|Patient Reported Outcomes Measures|Questionnaires and information extracted from the medical records would be collected.
223569915|NCT05967741|OTHER|Erythritol|Erythritol is a naturally occurring and non-nutritive sugar alcohol that is classified as generally recognized as safe (GRAS)
224059126|NCT04097613|DRUG|Povidone-Iodine|Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
224059127|NCT04097613|DRUG|Budesonide|Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
223569916|NCT05967741|OTHER|Aspartame|Aspartame consists of two amino acids, phenylalanine and aspartic acid, and a methyl group. It does not have metabolic effects and has served as the blinded control beverage in the investigators' completed NIH-funded clinical trials.
224059128|NCT00495820|DRUG|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
224059129|NCT00495820|OTHER|Placebo|Standard inactive pill.
224059130|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
223569917|NCT04465435|OTHER|Web-based self-report questionnaires|Web-based self-report questionnaires based on well established instruments.
223569918|NCT04465435|OTHER|Focus Group Interviews|Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
223569919|NCT01713361|DRUG|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
223569920|NCT01713361|DRUG|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
223569921|NCT01713361|DRUG|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
223569922|NCT01903551|DEVICE|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
223569923|NCT07033091|DIAGNOSTIC_TEST|Self-sampling by gargling kit at dental clinic|Participants will perform a self-sampling at the dental clinic using gargling kit
224059131|NCT00820950|DRUG|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
224059132|NCT00820950|DRUG|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
224059133|NCT00820950|DRUG|Placebo cream|Cream applied once or twice daily for 56 days
224059134|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
224059135|NCT00820950|DRUG|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
223451763|NCT02739451|PROCEDURE|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~* low-flow oxygen \[including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask\]~* or medium-flow oxygen \[Venturi masks and medium-flow facemasks\]"
223569924|NCT07033091|OTHER|Questionnaire|Participants will answer questionnaire online/paper at their home or at the dental clinic
224059136|NCT05901493|BEHAVIORAL|Perceptual category training|Participants complete a forced-choice categorization task with feedback, in order to learn difficult auditory and visual categories
224305081|NCT05752682|DIAGNOSTIC_TEST|Diagnostic pathway|Each included patient will undergo to the faint and fall protocol, to assess the effectiveness of a patients' flow pathways developed in accordance with the most recent guidelines on syncope of the European Society of cardiology and of guidelines on falls of the American and British Geriatrics Societies.
224059137|NCT04888299|DEVICE|Raman spectroscopy (SPECTRA IMDx)|The SPECTRA IMDx comprises a laser system, a spectrometer, a computer with an analysis algorithm installed, and other ancillary parts. The SPECTRA IMDx probe is connected with the main system. The SPECTRA IMDx probe is an assembly of optical fibres and optical components arranged for maximal transmission of light energy. When in use, the laser system will emit a 785nm near infra-red laser that will be transmitted through the SPECTRA IMDx probe to the distal end. When the laser is interrogated upon a tissue surface, the light energy is absorbed and reflected. The reflected energy is then collected from the distal end of the SPECTRA IMDx probe, transmitted back to the main system, and passed through the spectrometer. The collected signal is then processed to obtain the clean Raman signal for diagnostic classification.
224059138|NCT00538798|DRUG|[18F]SP203|
224059139|NCT04207450|OTHER|Placebo gel|Placebo gel application followed by placebo solution application (distilled water)
224304951|NCT06276049|OTHER|custom GPT supported self-directed learning|"The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience."
223451764|NCT02739451|PROCEDURE|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher\&Paykel, Courtaboeuf, France).
223451765|NCT00946127|PROCEDURE|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
223451766|NCT00946127|PROCEDURE|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
224304952|NCT06402370|DIAGNOSTIC_TEST|PET scan|\[18F\]Vizamyl
223451767|NCT06188676|DRUG|Cyclophosphamide|Ciclofosfamida
223451768|NCT06188676|DRUG|Doxorubicin Hydrochloride|Adriamycin
223451769|NCT06188676|DRUG|Etoposide Phosphate|Etopophos
223451770|NCT06188676|DRUG|Prednisolone|Prednisolonum
223451771|NCT06188676|DRUG|Rituximab|Chimeric Anti-CD20 Antibody
223451772|NCT06188676|DRUG|Vincristine Sulfate|Oncovin
223451773|NCT06188676|DRUG|Filgrastim|G-CSF
223451774|NCT06188676|DRUG|Pegfilgrastim|PEG-filgrastim
223451775|NCT06188676|DRUG|Nivolumab 40 mg in 4 ml Injection|Opdivo
223451776|NCT02226120|DRUG|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
223451777|NCT03034135|DRUG|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
223451778|NCT03034135|DRUG|Temozolomide (TMZ)|TMZ is given per standard of care
223451779|NCT04931719|COMBINATION_PRODUCT|PRP+Artz group|The patients in the PRP+Artz group received one intraarticular Artz injection (2.5 ml) followed consecutively by one intraarticular injection of PRP (3ml).
223451780|NCT04931719|COMBINATION_PRODUCT|PRP+ HYAJOINT Plus group|The patients in the PRP+HYAJOINT Plus group received one intraarticular HYAJOINT Plus injection (3ml) followed by one intraarticular injection of PRP (3ml).
223451781|NCT06070753|DRUG|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
223451782|NCT02758197|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
223569925|NCT07033091|DIAGNOSTIC_TEST|Self-sampling by gargling kit at home|Participants will perform a self-sampling at home using gargling kit
223569926|NCT07033091|DIAGNOSTIC_TEST|Blood sampling|Venous blood will be collected from study participants with oral hrHPV positivity, in which the presence of circulating hrHPV DNA will be determined.
223569927|NCT07033091|DIAGNOSTIC_TEST|Self-sampling of the urogenital area|In case of a positive examination in the oropharynx, the tested individuals will be offered a self-collection HPV examination in the urogenital area (cervicovaginal swab in women or external genital swab in men).
223569928|NCT05350228|DIAGNOSTIC_TEST|CNN based model|It is an automatic detector model based on convolution neural network created by computer science expert
223569929|NCT02455661|DEVICE|TR Band (TM)|
223569930|NCT02455661|DEVICE|AngioSeal|
223569931|NCT02455661|DEVICE|StarClose|
223569932|NCT07035054|BIOLOGICAL|low dose-1|PCV24 (low-dose 1) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, and the dosage is 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows: 4.0 μg per vial for serotypes 3, 6B, and 12F; and 2.0 μg per vial for the other 21 serotypes, namely 1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant (aluminum content: 0.125 mg per dose).
223569933|NCT07035054|BIOLOGICAL|low dose-2|"PCV24 (low-dose 2) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 types (3, 6B, 12F): 4.0 μg per vial 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 2.0 μg per vial After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant with an aluminum content of 0.25 mg per dose."
224059140|NCT04207450|OTHER|Placebo Gel + 5% Glutaraldehyde Aqueous Solution|Placebo gel followed by 5% aqueous glutaraldehyde solution
224059141|NCT04207450|OTHER|Phosphoric Acid 37% + Solução aquosa de glutaraldeído a 5%|37% phosphoric acid application followed by 5% aqueous glutaraldehyde solution
224059142|NCT05222256|DRUG|Levosimendan|Patients in this group will receive levosimendan
223451783|NCT05302024|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
224059143|NCT05222256|DRUG|Adrenaline|Patients in this group will receive Adrenaline
224059144|NCT06977126|DRUG|PORPHYSOMES|Pegylated porphyrin-lipid conjugate-containing nanoparticle suspension
224059145|NCT06977126|DRUG|64Cu-PORPHYSOMES|Pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension
224059146|NCT06978933|DRUG|ABSK-011|"Drug: ABSK-011 RP2D according to the results of Phase I trial~Other Names:~• FGFR4 inhibitor Drug: ABSK043 RP2D according to the results of Phase I trial~Other Names:~• Oral PD-L1 inhibitor"
224059147|NCT06977243|BEHAVIORAL|Online MedEd Intern Bootcamp|7 weeks, online training program
224301270|NCT05487365|DEVICE|Comunicare Solutions Smartphone Application|The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
224301271|NCT05487365|OTHER|Completing a quality of life (QOL)-questionnaire|Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
224301272|NCT04161183|DEVICE|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
223451784|NCT00565097|DRUG|Placebo|
223451785|NCT00565097|DRUG|Lanreotide|
224059148|NCT06978387|DEVICE|Minimed 780G|patients aged \>12 years old with T1DM who are on MiniMed 780G
223451786|NCT05584085|BEHAVIORAL|ACT-DE|Acceptance and Commitment Therapy is a third-wave psychological therapy to cultivate participants' acceptance attitude to diabetes and motivate them for a value-driven persistent diabetes self-management, directed by six psychological processes in the ACT hexagonal model, including acceptance, cognitive defusion, the present moment, self-as-context, value clarification and committed action.
223451787|NCT02938234|DIETARY_SUPPLEMENT|High caloric, high protein ONS|
223569934|NCT07035054|BIOLOGICAL|high dose|"PCV24 (high-dose) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation. Each vial contains 0.5 ml, with a dosage of 0.5 ml per person per administration. The polysaccharide content of each serotype is as follows:~3 types (3, 6B, 12F): 8.0 μg per vial 21 other serotypes (1, 2, 4, 5, 6A, 7F, 8, 9N, 9V, 10A, 11A, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F): 4.0 μg per vial After binding to carrier proteins, the polysaccharides of each serotype are adsorbed on an aluminum phosphate adjuvant with an aluminum content of 0.25 mg per dose."
223569935|NCT07035054|BIOLOGICAL|positive control|PPV23 produced by Chengdu Institute of Biological Products is a formulation with each vial containing 0.5 ml, and the dosage is 0.5 ml per person per administration. It contains polysaccharides of the following pneumococcal serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, with each serotype containing 25 μg of polysaccharide. In addition, it contains sodium chloride and water for injection.
223569936|NCT07032428|DEVICE|A new non-invasive brain stimulation tool|kTMP is a magnetic induction method that delivers continuous kHz-frequency cortical electric fields (E-fields) which may be amplitude-modulated to potentially mimic electrical activity at endogenous frequencies which will be tested on anhedonia patients in this study.
224059149|NCT06977607|PROCEDURE|Platelets Rich Fibrin|Repair of facial nerve injury plus Platelets Rich Fibrin will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Nano-fat stem cells)
224059150|NCT06977607|PROCEDURE|Nano-fat stem cells (NFSCs)|Repair of facial nerve injury plus Nano fat derived stem cells will be injected around the repair and measure the out come in comparison with (Repair only) and (Repair Plus Platelets Rich Fibrin).
223569937|NCT07032428|DEVICE|A new non-invasive brain stimulation tool with sham setting selected|This device will counterbalance the active kTMP conditions
223569938|NCT07034911|DRUG|Ketalar|women receiving sub-anesthetic dose of ketamine of 0.5 mg/kg IV bolus in 3 ml of normal saline.
223569939|NCT07034911|DRUG|Ephedrine|women receiving bolus of 15mg of ephedrine
223569940|NCT06881953|OTHER|Questionnaire|The questionnaire will be completed on line by the participants (approx. 10 min).
223569941|NCT05708638|OTHER|Manual anesthesia induction|In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
224059151|NCT06977607|PROCEDURE|Repair only|facial nerve neurorrhaphy only (repair only) after acute facial nerve trauma and measure the out come in comparison with (Repair plus Nano- fat Stem Cells) and (Repair Plus Platelets Rich Fibrin).
224059152|NCT06979063|OTHER|Remote Infertility Education and Counseling|"Patients receive video call counseling covering infertility investigation, non-pharmacological fertility enhancement strategies, and healthcare navigation guidance.~Health professionals review patient records and request missing infertility-related exams according to local protocol.~Additional follow-ups occur approximately every 30 days to assist with pending investigations.~If significant findings arise, patients will receive an explanation and assistance in scheduling primary care consultations."
224059153|NCT06979063|OTHER|Standard Care Arm|Referrals from patients will be avaluated following local protocols in the electronic referral system. Incomplete data will be requested through this system. There will be no direct contact with patients.
224059154|NCT06985264|PROCEDURE|Upper Eyelid Blepharoplasty surgery|Orbicularis oculi excision
223451788|NCT01037816|DRUG|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
223451789|NCT01037816|OTHER|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
223451790|NCT06918808|BIOLOGICAL|DB-3Q|DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.
224059155|NCT01345747|DEVICE|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
224059156|NCT06984731|PROCEDURE|left atrial appendage closure|Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX
224059157|NCT06984731|PROCEDURE|radiofrequency ablation|Patients with atrial fibrillation underwent transcatheter radiofrequency cardiac ablation 1 month after left atrial appendage closure with WATCHMAN FLX
224059158|NCT06442865|DEVICE|AMNIODERM+|"A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC."
224059159|NCT05065931|OTHER|Auxiliary diagnostic system by AI-CDSS|Helping clinicians to make diagnoses by using CDSS based-on AI
223451791|NCT06918808|BIOLOGICAL|Placebo|0.9% NaCl
223451792|NCT06920459|DEVICE|Alliance™ Glenoid|Total Shoulder Arthroplasty using the Alliance™ Glenoid implant
223569942|NCT05708638|OTHER|Anesthesia induction with Target controlled infusions (TCI)|Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
223569943|NCT01940575|DEVICE|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
224059160|NCT00670436|DEVICE|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
224301273|NCT04161183|DEVICE|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
224301274|NCT05571072|OTHER|Opioid calculator|Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.
224301275|NCT05571072|OTHER|Standard opioid prescription|Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
223451793|NCT04736641|OTHER|Survey study|Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) will be applied
223451794|NCT06931691|DRUG|LNP023|Capsules for oral administration
223451795|NCT03973255|BEHAVIORAL|Rehabilitation|Posturography, Whole body vibration
223451796|NCT00817505|DRUG|AZD1656|Single dose oral tablet
223451797|NCT00817505|DRUG|AZD1656|Single dose oral suspension
223451798|NCT02013102|DRUG|Decitabine Injection|Decitabine Injection 20mg/m2/d\*5d, IV\> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d\*8d, IV\> 1h, one cycles per 4 weeks.
224301276|NCT01949948|DRUG|Tenecteplase|0.4 mg/kg single bolus intravenously
224301277|NCT01949948|DRUG|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
223451799|NCT06946992|OTHER|video supported cooperative learning|Video supported cooperative learning will be used in the experimental group. The process will be student-centered. Students will support each other's learning. While practicing on the models in the form of cooperative learning, they will reinforce their practices by watching videos prepared for each psychomotor skill learning.
223451800|NCT06954974|DEVICE|CPAP device|CPAP device
223451801|NCT06954974|DEVICE|CPAP device and exercise|CPAP device
223569944|NCT01940575|DEVICE|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
223569945|NCT03628144|DIETARY_SUPPLEMENT|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
223569946|NCT03628144|DIETARY_SUPPLEMENT|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
224301278|NCT01435226|DRUG|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
224301279|NCT01435226|DRUG|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
224301280|NCT01435226|DRUG|tegobuvir|tegobuvir 30 mg BID
224301281|NCT01435226|DRUG|placebo to match tegobuvir|tegobuvir placebo BID
224301282|NCT01435226|DRUG|placebo to match RBV|Ribovirin placebo BID
224301283|NCT01435226|DRUG|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
223451802|NCT06954974|OTHER|Exercise|"1. Retropalatal level: Phase I: • Open your mouth • Pronounce A for 5 seconds • Stop. Close your mouth. Procedure: 2 sets of 10 repetitions.~2. Retroglossal level: Phase I: • Push the tongue against the front of the palate • Move it back to perform a click sound, Phase II: • Move the tongue from right to left and from up to down The sequence of movement directions can be randomized to increase the challenge for repetitions., Phase III: • In this exercise, the tongue of the patient will scroll • Circle with the tongue on the inside of the lips • Draw 10 circles per set.~   Phase IV: • pressing the back of the tongue firmly on the oral cavity's floor for 8 seconds. Phase V: • Step 1, bite the tongue depressor. • Step 2, push the tongue against the tongue depressor and hold for 8 seconds. Procedure: 2 sets of 10 repetitions.~3. Deglutition level: Phase I: • Gently hold the tongue between the front teeth • Maintain this position Then, close your mouth and swallow. Phase II: • This vers"
223451803|NCT01313013|BEHAVIORAL|question prompt sheet|
224059161|NCT00670436|DEVICE|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
224059162|NCT05015920|GENETIC|BD211 Drug Product|Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.
224059163|NCT06606821|DRUG|Tirzepatide|Investigational drug will be administered as a sc. injection once-weekly.
224059164|NCT06606821|DRUG|Placebo|Placebo containing the same excipients and volume as the active treatment arm but without tirzepatide will be administered as a sc. injection once-weekly.
224059165|NCT06984822|DRUG|Anti-VEGF treatment|Intravitreal anti-VEGF treatment
224059166|NCT06984822|DEVICE|Dexamethasone implant|Intravitreal Dexamethasone implant
224059167|NCT06984822|OTHER|Anti-VEGF treatment or Dexamethasone implant|Intravitreal anti-VEGF treatment or Intravitreal Dexamethasone implant
224059168|NCT03109379|DRUG|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
224059169|NCT03246139|BEHAVIORAL|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
224059170|NCT03246139|BEHAVIORAL|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
224059171|NCT03246139|BEHAVIORAL|Control treatment|The participants will receive UE training without watching videos or imagining movements/tasks.
224059172|NCT06869161|DEVICE|Stabilization splint|Measurements will be taken from the patients with intraoral scans, transferred to the design program and a stabilization splint will be digitally designed. The designed splint will be produced from 3D printers.
223451804|NCT01972464|DRUG|Progesterone|oral micronized progesterone
223451805|NCT01972464|DRUG|Placebo|
224147253|NCT04742270|DEVICE|SIMEOX+ respiratory physiotherapy telecare|"Every 10 days, the patient's expert physiotherapist will contact the patient by video-transmission or telephone call for motivational reinforcement and technical support in the use of the device.~During these phone calls, a quick 3-question questionnaire will be administered to the patient to monitor events of hemoptysis, chest pain and clinical symptoms of gastroesophageal reflux disease: pyrosis.If patients report this type of event, the physiotherapist will inform the patient's physician for management at his/her discretion.~The expert physiotherapist will also conduct this sessions in order to increase the patient's motivation and compliance to the device. In order to do this, he will identify (in collaboration with the patient), the patient's difficulties and obstacles and he will try to find solutions with him."
224147254|NCT01995279|DEVICE|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
224147255|NCT01995279|OTHER|Sham Ultrasound|Ultrasound turned off.
224301284|NCT02170948|DRUG|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
224301285|NCT01506544|DRUG|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
223569947|NCT03628144|RADIATION|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
223569948|NCT03628144|DRUG|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
224059173|NCT06869161|OTHER|Muscle exercises|Muscle exercises prepared by physical therapists will be planned to relieve trigger points in the masticatory muscles.
224059174|NCT00184236|BEHAVIORAL|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
224059175|NCT00184236|BEHAVIORAL|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
224059176|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
224059177|NCT03721510|BIOLOGICAL|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
224059178|NCT06712602|DRUG|alcohol|During the alcohol administration session participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. Participants will consume the drink within 5 min.
224059179|NCT06712602|BEHAVIORAL|Stress-Induction|The stress-induction procedure is the Cold Pressure Test \[CPT\]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (24°C) for 3 minutes.
224059180|NCT06712602|DRUG|PT150|Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.
224059181|NCT06882642|PROCEDURE|Sensory integration therapy|Autistic patients will undergo sensory integration therapy
224059182|NCT05472012|DEVICE|INVSENSOR00057|Noninvasive wearable health monitoring device
223451806|NCT02845531|DEVICE|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
224059183|NCT06727331|DRUG|Tirzepatide|This intervention will consist of the FDA-approved dosing schedule. Participants will receive 2.5mg weekly injections for 4 weeks. IDS will extract tirzepatide and draw the doses into syringes.
224059184|NCT06727331|OTHER|Saline Placebo|Placebo syringes of saline and matching volume will be produced by IDS.
224147256|NCT03771599|OTHER|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
223451807|NCT02845531|DRUG|Optimal Medical Therapy|
223451808|NCT00591929|OTHER|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
223451809|NCT04130074|DEVICE|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
223451810|NCT02526160|BIOLOGICAL|burosumab|solution for SC injection
223451811|NCT02526160|OTHER|Placebo|saline solution for SC injection
224147257|NCT03771599|OTHER|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
224147258|NCT02103452|PROCEDURE|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
224147259|NCT00879606|DRUG|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
224147260|NCT00879606|DRUG|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
224147261|NCT03624764|PROCEDURE|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
224147262|NCT03624764|PROCEDURE|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
224147263|NCT04198896|OTHER|incidece of cancers|With a continuous surveillance system to track all subsequent incidents of cardiovascular diseases and/or non-cardiovascular diseases via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified
224147264|NCT01872091|OTHER|cryotherapy by immersion|
224147265|NCT01872091|OTHER|Control group|
224147266|NCT00808782|DEVICE|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
224147267|NCT00808782|DEVICE|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
224147268|NCT03141372|DEVICE|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
224301286|NCT04691050|PROCEDURE|OrthoMTA (BioMTA)|Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
223451812|NCT04351451|PROCEDURE|thyroidectomy|total thyroidectomy
223451813|NCT04396132|DIAGNOSTIC_TEST|Subjective Visual Vertical with Virtual SVV instrument|The deviation angle will be measured with 15, 30 and 45-degree head tilt to the left and right side while they are standing
223451814|NCT00570960|DRUG|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
223451815|NCT00570960|BIOLOGICAL|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
223451816|NCT02506699|OTHER|analgesic effect of rTMS|
223451817|NCT02820519|DRUG|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
223451818|NCT04579003|OTHER|Mobilization|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
223451819|NCT04579003|OTHER|Mobilization with movement|"Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins."
224059185|NCT06736509|DRUG|AXS-05 (dextromethorphan-bupropion)|AXS-05 tablets, taken twice daily
224059186|NCT03298425|DEVICE|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
224059187|NCT03298425|DEVICE|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
224059188|NCT06889480|DEVICE|New Target DBS|Participants in this arm will receive active DBS targeting a novel brain region identified via electrophysiological brain mapping. A DBS electrode will be implanted at the new target, and stimulation parameters (including frequency, voltage, and pulse width) are individually optimized based on mapping and 24-hour testing. The procedure is performed using a robotic system for precise electrode placement, and the device is provided by Beijing PINS Medical Co., Ltd.
224059189|NCT06889480|DEVICE|CM-DBS|This intervention involves active DBS at the central medial thalamic nucleus (CM) -a widely used target in TS treatment. A DBS electrode is implanted at the CM target, with stimulation settings determined through electrophysiological brain mapping and subsequent 24-hour stimulation. This arm serves as an active comparator, with stimulation administered during a 1-month period in the crossover phase. The same device and robotic-assisted implantation are used to ensure consistency and precision.
224059190|NCT06889480|DEVICE|Sham Stimulation|Participants assigned to the sham stimulation arm undergo the identical surgical procedure and electrode implantation as those in the active arms. However, during the stimulation periods, the device is programmed to deliver no active stimulation. This sham intervention is designed to control for placebo effects and ensure that any observed improvements in TS symptoms are attributable to the active DBS interventions.
224059191|NCT06747260|BIOLOGICAL|Intranasal breast milk|Neonates with hypoxic-ischemic encephalopathy receive their own-mother's fresh breast milk intranasally, starting from the first 48 hours of life and continuing for 28 days. Dose: 2 times daily, 0.4 ml in each nostril (15 minutes apart).
224059192|NCT05957861|BEHAVIORAL|web-based aerobic exercise|Our designed AE program involved core muscle training through movements including marching, step touches, lunges, v-steps, box steps, twists, knee-ups, scoops, and scissors.
224059193|NCT06733155|OTHER|Financial intervention|Participants completing the mammogram within the study end date will receive a $10 voucher.
224059194|NCT06733155|OTHER|Lottery intervention|Participants completing the mammogram within the study end date will receive achance to win a $5000 lottery.
224059195|NCT06733155|OTHER|Health Messages|Participants will receive a less than 5 minute long video from an influential person. The video will be available in four languages (English, Chinese, Malay, Tamil).
224059196|NCT06733155|OTHER|Personal Health Concierge|Participants will be able to call a dedicated hotline for scheduling mammograms with the help of a health concierge over eight weeks of receive the the mailer.
224059197|NCT06733155|OTHER|Only reminder mailer|Receives a mail reminder with basic information about breast cancer and instructions on scheduling a mammogram.
224059198|NCT06756581|OTHER|baked milk product diet|Elimination of none baked cow milk from diet . Baked cow milk containing diet.
224059199|NCT04192344|DRUG|ABSK021|ABSK021 oral capsule
224059200|NCT01423851|DRUG|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
224059201|NCT06929195|DRUG|TQB2210 Injection|TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.
224059202|NCT02984761|RADIATION|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
224059203|NCT02984761|PROCEDURE|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
224059204|NCT06014281|BEHAVIORAL|SOS Meditation|"Focused-attention meditation technique will be used to train participants, specifically the SOS meditation technique. The SOS meditation technique is an easy-to-learn approach where participants are instructed to dissociate their attention from physical awareness, thoughts, and emotions by mentally slowly repeating a calming word or phrase (chosen by the participant themselves).~SOS Meditation Instructions:~* Close your eyes very gently, in a relaxed way, as you do when we go to sleep~* Your attention should be fully alert. Try not to put any strain on your eyes or try to look up.~* Focus your eyes about eight to ten inches into the field of darkness in front of you on the horizontal plane~* Mentally repeat the (chosen) calming word~* Sit lovingly and calmly to see what comes up, as if you were watching a movie screen and waiting to see what appears on it."
224059205|NCT03416153|DRUG|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
224059206|NCT03416153|RADIATION|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
224301287|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
224301288|NCT00759720|DRUG|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
224301289|NCT00759720|DRUG|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
224301290|NCT00145639|DRUG|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
224059207|NCT03416153|DRUG|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
224070764|NCT07028099|DEVICE|Conventional OLIF cage|Participants in the control group will undergo oblique lateral interbody fusion (OLIF) using a standard non-expandable interbody fusion cage. The cage has a fixed height and is inserted via the retroperitoneal approach. Bone grafts are packed into the cage prior to insertion through the anterior or lateral window. This represents the current standard practice for OLIF procedures and does not allow intraoperative height adjustment or posterior graft delivery. The procedure follows conventional OLIF surgical protocols without additional design modifications.
224070765|NCT07029698|DRUG|Vitamin B12, Vitamin B6, Folic acid|A solution for intramuscular injection of fixed vitamin combination (5 mg vitamin B6, 1 mg B12 and 1,05 mg folic acid )
223451820|NCT04501484|PROCEDURE|Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy|Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
224059208|NCT06176638|BEHAVIORAL|RRF4H Combination Intervention|"MFG: is a family strengthening model where children and their parents sit together in groups of 8 to 10 families to discuss important issues. MFG approach provides a social support mechanism and strengthens family relationships by allowing families to share common experiences as well as effective strategies for addressing difficult issues; and focuses on reducing stigma and normalizing common experiences.~TAHC: This is a peer-led program that allows younger students to talk with peers about important issues that they face, gain role models, and identify positive social norms from older peers. It provides age-appropriate lessons and is delivered in a structured fashion. The curriculum consists of sixteen 50-minute lessons spread out over two academic years. Topics delivered in the curriculum include substance use, positive outlook on life, forming a positive self-concept, decision making and problem solving, coping with depression, bullying and social media."
224059209|NCT02628236|DRUG|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
224059210|NCT02628236|DEVICE|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
224059211|NCT05365503|OTHER|Shamiri Intervention|The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
224059212|NCT00143715|DRUG|Phytonadione (Vitamin K1)|1.25 mg given orally
224059213|NCT03446222|PROCEDURE|Catheter ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
224059214|NCT03446222|PROCEDURE|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
224059215|NCT06050174|DRUG|Azadirachta Indica|"Azadirachtaindica L. is a multipurpose medicinal tree of family Meliaceae.Is also named Nimba, holy tree, Vembu, Arishtha, Indian neem tree, Indian lilac, wonder tree. It occurs in tropical and semitropical regions of the world. Almost all parts of this incredible tree have been used as phytomedicines for more than 4,000 years.~Various pharmacological attributes such as antifungal, antiviral, antibacterial, anti-inflammatory, sterilant, antiscabic, antiallergenic and analgesic are attributed to various parts of the tree."
224059216|NCT06050174|PROCEDURE|Non Surgical Periodontal Therapy|The patients will receive full mouth one stage debridement using ultrasonic scalers, manual scalers and curettes with oral hygiene instructions and education.
224059217|NCT02029859|PROCEDURE|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
224059218|NCT05745220|OTHER|Device: silicone hydrogel contact lens|Silicone hydrogel contact lens
224059219|NCT06232070|DEVICE|Lunit INSIGHT MMG|In the Lunit Assisted arm, the radiographers will also be seeing the Lunit INSIGHT MMG reports while reading the mammograms. The standard of care will be followed in all the cases
224059220|NCT01465100|RADIATION|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
224059221|NCT01465100|PROCEDURE|Hepatocyte Transplant|"Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient."
224059222|NCT01465100|DRUG|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
224070766|NCT07029698|DRUG|Vitamin B12 (Cyanocobalamin)|oral tablets of 1mg Vitamin B12
224301291|NCT00145639|PROCEDURE|Limb Sparing|See Detailed Description for treatment plan.
223451821|NCT00536770|DRUG|placebo + gemcitabine + erlotinib|
223451822|NCT00536770|DRUG|Placebo + gemcitabine|
223451823|NCT00536770|DRUG|calcitriol + gemcitabine|
223451824|NCT00536770|DRUG|calcitriol + gemcitabine + erlotinib|
223451825|NCT00720070|PROCEDURE|positron emission tomography/computed tomography|Patients undergo PET/CT scan
223451826|NCT00720070|PROCEDURE|therapeutic conventional surgery|Patients undergo neck dissection
223451827|NCT04959409|DRUG|Topical analgesia (EMLA or AMETOP)|Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
223451828|NCT04237545|DEVICE|T3 short and restoration (prosthesis)|A qualified patient will be treated with a T3 short implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
223451829|NCT04237545|DEVICE|T3 standard length and restoration (prosthesis)|A qualified patient will be treated with a T3 standard length implant according to randomization assignment during implant placement surgery visit. The implant will then be restored with a prosthesis and followed up for yearly visits for a total of 4 years.
224059223|NCT01465100|OTHER|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
223451830|NCT02099253|DRUG|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
223569949|NCT03628144|OTHER|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
223569950|NCT03628144|OTHER|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
223569951|NCT03628144|OTHER|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
223569952|NCT03396367|BEHAVIORAL|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
224059224|NCT01465100|BEHAVIORAL|Neuro-psychological Assessment|Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
224059225|NCT01465100|DIAGNOSTIC_TEST|Whole body Phe oxidation testing|Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
224059226|NCT01465100|PROCEDURE|Liver Biopsy|Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
224059227|NCT04639856|PROCEDURE|Coronary Artery Bypass Grafting|on-pump vs off pump Coronary artery Bypass Grafting
224147269|NCT03553602|RADIATION|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])"
224147270|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 48 weeks
224147271|NCT00245414|DRUG|Pegasys®|180μg for s.c./week for 24 weeks
224147272|NCT03539861|DEVICE|Hemodialysis|Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
224147273|NCT01555905|DEVICE|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
224147274|NCT04528797|DRUG|Levothyroxine|
224147275|NCT04528797|DRUG|Methylprednisolone|
224147276|NCT03638882|BEHAVIORAL|Duolingo|Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.
224147277|NCT03638882|BEHAVIORAL|BrainHQ|Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.
223451831|NCT02099253|DRUG|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
223451832|NCT00329693|DRUG|Norprolac|Placebo
223451833|NCT00329693|DRUG|Norprolac|Quinagolide
223451834|NCT00329693|DRUG|Norprolac|Quinagolide
223451835|NCT00329693|DRUG|Norprolac|Quinagolide
223451836|NCT03169478|PROCEDURE|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
224147278|NCT03638882|BEHAVIORAL|Passive Control|No Intervention.
224147279|NCT02247401|DRUG|2 DAA|ABT-450/r/ABT-267 tablets
223451837|NCT00650819|DRUG|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
223569953|NCT03396367|BEHAVIORAL|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
223569954|NCT06892574|DEVICE|Active-VNS|A neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve.
223569955|NCT06892574|DEVICE|Sham VNS|A neuromodulation treatment that delivers electrical impulses to the brain via the vagus nerve, the actual intensity is 0 mA.
223569956|NCT04657367|OTHER|Observational study - registry|Observational study - registry
223451838|NCT00650819|DRUG|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
223451839|NCT00650819|DRUG|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
223569957|NCT03180437|PROCEDURE|IRE surgery|IRE surgery will be used in local tumor
223569958|NCT03180437|BIOLOGICAL|IRE plus γδ T cells|Combination IRE surgery and γδ T cell will be used in Pancreatic Cancer
223569959|NCT00129610|BEHAVIORAL|Virtual Reality Therapy|
223569960|NCT00129610|BEHAVIORAL|Cognitive Behavior Therapy|
223569961|NCT06896019|DIAGNOSTIC_TEST|Community Pneumonia|The BALF of CAP patients
223569962|NCT06896279|PROCEDURE|TI Stimulation|Participants will accept the TI stimulus for one month
223569963|NCT06896279|PROCEDURE|Sham Stimulation|Participants will accept the sham TI stimulus for one month
223569964|NCT06895590|DEVICE|Philips Advanced Monitoring Cuff (i.e. AMC)|Investigational, non-invasive upper arm cuff
224147280|NCT02247401|DRUG|RBV|Ribavirin tablets
224147281|NCT00553345|DRUG|selenium|
224147282|NCT00553345|DRUG|vitamin E|
224059228|NCT03978455|BEHAVIORAL|Learn, Connect, and Quit Mobile Application|The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
224059229|NCT04411264|DEVICE|virtual reality|Use of a virtual reality headset while caring for chronic wound dressings
224059230|NCT00004231|BIOLOGICAL|aldesleukin|
224059231|NCT00004231|BIOLOGICAL|filgrastim|
224059232|NCT00004231|BIOLOGICAL|recombinant interferon alfa|
224059233|NCT00004231|DRUG|busulfan|
224059234|NCT00004231|DRUG|cyclophosphamide|
224059235|NCT00004231|DRUG|cytarabine|
224059236|NCT00004231|DRUG|doxorubicin hydrochloride|
224059237|NCT00004231|DRUG|leucovorin calcium|
224059238|NCT00004231|DRUG|methotrexate|
224059239|NCT00004231|DRUG|prednisone|
224059240|NCT00004231|DRUG|teniposide|
224147283|NCT00553345|PROCEDURE|chemoprevention|
224059241|NCT00004231|DRUG|vincristine sulfate|
224059242|NCT00004231|PROCEDURE|allogeneic bone marrow transplantation|
224059243|NCT00004231|PROCEDURE|autologous bone marrow transplantation|
224059244|NCT00004231|PROCEDURE|peripheral blood stem cell transplantation|
224059245|NCT02500680|BIOLOGICAL|MER4101|
224059246|NCT02500680|BIOLOGICAL|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
224059247|NCT04749823|OTHER|Blended treatment program|A combined treatment program with specific active neck exercises and general aerobic training in counteractive amount will be executed during 12 weeks. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
224147284|NCT04325776|DRUG|AL2846|AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.
224147285|NCT04325776|DRUG|Zoledronic Acid Injection|Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.
224147286|NCT05753098|DRUG|estrogen therapy|oral estradiol valerate
224059248|NCT04749823|OTHER|Specific strength exercise program|This program includes an individual, patient-tailored exercise program with the aim of retraining the neck musculature. A detailed exercise programme will be constructed in which all exercises are listed with the amount of repetitions and series of each exercise. Strength exercises will be performed by means of dumbbells with different weights and elastic bands with different degrees of resistance. The amount of weight or resistance, and the amount of series and repetitions will be evaluated during the first session. This exercise programme will be re-evaluated repeatedly during the course of the program. Specific strength neck exercises will be performed for 30 minutes. Nine supervised sessions will be supplemented with 1 to 3 weekly unsupervised home exercise sessions.
224059249|NCT04749823|OTHER|General aerobic exercise program|This control group will receive a general aerobic exercise program. Within a 12-week period, patients will be instructed to perform a general aerobic exercise session 3 times a week.
224059250|NCT00916357|DRUG|Humalog|
224059251|NCT00916357|DRUG|Humulin-R|
224059252|NCT00916357|DRUG|Recombinant human hyaluronidase PH20 (rHuPH20)|
224059253|NCT04167046|PROCEDURE|Erector spinae block|Preoperative erector spinae block.
224070767|NCT07027969|PROCEDURE|Roux-en-Y Gastric Bypass or Sleeve Gastrectomy|Patients receive either RYGB or SG. The surgical risk, differential impact of each procedure on body weight and other obesity-related diseases, presence of other medical and mental problems, patient's behavioral factors (e.g., postoperative compliance, active smoking), medications, and goals will be considered when the patient and local medical team make a shared decision about the most appropriate surgical procedure.
224070768|NCT07027969|DRUG|Anti-Obesity Medication (AOM) treatment|Implementation of obesity pharmacotherapy in the nonsurgical group includes initial assessment of side effects and response, followed by achieving a clinically meaningful weight loss (5% weight loss) after three months. Once this goal is reached, AOMs will be continued throughout the study. If a weight plateau is reached within the first AOM, then another AOM may be added in combination in a stepwise fashion. The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.
224147287|NCT05753098|DRUG|Sildenafil|PDE5 inhibitor
224147288|NCT05753098|DRUG|Clomiphene Citrate 50mg|used for ovulation induction
224147289|NCT00380276|DRUG|MPC-7869|800 mg BID Oral dosing
224147290|NCT05293574|DRUG|norethisterone acetate|Norethindrone, a progesterone agonist
224147291|NCT01603030|DRUG|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
224147292|NCT01603030|DRUG|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
224147293|NCT04663139|DRUG|Xla1|Xla1 is a Live Biotherapeutic Product (LBP) containing a strain of the bacteria Christensenella minuta (C. minuta)
224147294|NCT04663139|DRUG|Placebo|Matching placebo
224147295|NCT00238225|DIETARY_SUPPLEMENT|calcitriol|
224147296|NCT00238225|DRUG|dexamethasone|
224147297|NCT00238225|DRUG|ketoconazole|
224147298|NCT04488848|OTHER|bolus glucose|bolus Glucose
224147299|NCT04488848|OTHER|continuous clucose|continuous clucose
224147300|NCT02995330|PROCEDURE|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
224147301|NCT02995330|DRUG|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
224147302|NCT02995330|DRUG|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
224147303|NCT02489565|OTHER|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
224147304|NCT05109130|PROCEDURE|Surgical approach|Different surgical methods for rectal cancer resection
223569965|NCT06805396|BEHAVIORAL|Palliative Care Consult|Patients receive a regular consult (30-45 min) with the hospital palliative care consult team (PCCT) that is tailored to the preferences and needs of the individual patient. The following topics can be discussed: 1) physical symptoms, and, where appropriate, followed by recommendations for symptom management and transfer of handovers to the treating care team, 2) psychological, social and spiritual distress, followed by provision of counseling or referral to another specialist if needed, 3) goals of care to explore participants' values, preferences and needs (advance care planning), and 4) discussion about the needed follow-up of palliative care, and 5) care for caregivers. At baseline, patients receive a validated symptom questionnaire (Utrecht Symptom Diary (USD)-4D), which can be used as input for discussion during the consultation. If necessary, patients may have a follow up.
224059254|NCT04170361|OTHER|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
224059255|NCT04170361|OTHER|Conventional Chest Physiotherapy+Incentive Spirometry|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
224059256|NCT06450652|DRUG|Chinese Herbal Medicine granules|The intervention will be a 4 weeks of Chinese Herbal Medicine (CHM) granules, which will consist of six Chinese herbs. Subjects will take one sachet orally, twice daily after meals for 4 weeks. Way of taking CHM granules is as follow: Add 100ml boiling water into a cup, then pour one pack of granules into the cup and soap it for 2-3 mins. Stir until the granules completely dissolve before drinking.
224059257|NCT01570504|DRUG|Ivermectin|oral formulation
224059258|NCT03069430|BEHAVIORAL|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
224059259|NCT00535561|DRUG|Ferrous sulfate tablets 325 mg, po, TID|
224059260|NCT00535561|DRUG|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
224147305|NCT02682030|DEVICE|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
224147306|NCT02682030|DEVICE|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
224147307|NCT02119234|DRUG|Beclometasone/formoterol/glycopyrrolate|
224147308|NCT02119234|DRUG|Placebo|
224147309|NCT00641524|PROCEDURE|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
224147310|NCT06330285|OTHER|e-learning|"CPET (Cardiopulmonary exercise test) e-learning application The content, planning and design of 4 lessons are as follows:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
224147311|NCT06330285|OTHER|face to face learning|"CPET (Cardiopulmonary exercise test) face to face education. The content, planning and design of 4 lessons are as follows:~Contents:~1. Introduction and CPET Fundamentals:~2. Respiratory function tests~3. Field Field Tests and CPET Results~4. Problems and examples"
224059261|NCT04989283|BIOLOGICAL|Atezolizumab|Given IV
224059262|NCT04989283|PROCEDURE|Biopsy|Undergo tumor biopsy
224059263|NCT04989283|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224059264|NCT04989283|DRUG|Carboplatin|Given IV
224059265|NCT04989283|DRUG|Cisplatin|Given IV
224059266|NCT04989283|PROCEDURE|Computed Tomography|Undergo PET/CT scan
224059267|NCT04989283|DRUG|Etoposide|Given IV
224059268|NCT04989283|RADIATION|External Beam Radiation Therapy|Undergo external beam radiation therapy
224059269|NCT04989283|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224059270|NCT04989283|DRUG|Paclitaxel|Given IV
224059271|NCT04989283|DRUG|Pemetrexed|Given IV
224059272|NCT04989283|PROCEDURE|Positron Emission Tomography|Undergo PET/CT scan
224059273|NCT04989283|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224059274|NCT00000414|BEHAVIORAL|Arthritis Self-Management Program|
224059275|NCT00000414|BEHAVIORAL|SMART Program|
224059276|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
224059277|NCT00784420|DRUG|UK-453,061|UK-453,061 1000 mg once daily for 10 days
224059278|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
224301292|NCT05886439|DRUG|LK101 injection (personlized neoantigen pulsed DC vaccine )|LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations.
224301293|NCT05886439|DRUG|Pembrolizumab|Patients will receive pembrolizumab(200mg IV) Q3W until disease progression (PD), intolerable toxicity.
224301294|NCT05886439|DRUG|Durvalumab|Patients will receive durvalumab (1500mg IV) Q3W until disease progression (PD), intolerable toxicity.
224301295|NCT02243839|DRUG|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
224059279|NCT00784420|DRUG|Raltegravir|Raltegravir 400 mg twice daily for 10 days
224059280|NCT01773109|DRUG|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
224059281|NCT01815307|DRUG|Gemcitabine|1000mg/m2, day 1 every 2 weeks
224059282|NCT01815307|DRUG|S-1|80mg/m2/day, day 1-28, every 6 weeks
224059283|NCT04155138|DEVICE|Naida Hearing Aid|hearing aid
224059284|NCT04155138|DEVICE|Naida Contralateral Routing of Sound Device|This is a device that routes sound to the non-cochlear implanted ear.
224059285|NCT01239342|DRUG|Akt Inhibitor MK2206|Given PO
224059286|NCT01239342|DRUG|Everolimus|Given PO
223569966|NCT06896500|BEHAVIORAL|Kegel Exercises|Kegel exercises performed three times daily in different positions (supine, sitting, and standing) for three weeks, followed by a six-week home program
223569967|NCT06831305|DIAGNOSTIC_TEST|Comparison of microbiological sampling on natural nails|Comparison of microbiological sampling before and after hand desinfection
224059287|NCT01239342|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224059288|NCT00406510|DRUG|Optive, Systane|
224059289|NCT02892474|PROCEDURE|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
224059290|NCT02892474|PROCEDURE|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
224059291|NCT04799392|DEVICE|NOWDx COVID-19 Test|The investigational device is the NOWDx COVID-19 Test.
224059292|NCT03628014|OTHER|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~* Daily orientation and visiting program~* Basic active movements~* Meal assistance~* Recreational activities"
224059293|NCT02011321|DRUG|clevidipine|clevidipine infusion x4 hours
224059294|NCT04156971|DIETARY_SUPPLEMENT|Omega 3|
224059295|NCT04156971|BEHAVIORAL|stage-based lifestyle modification intervention|
224059296|NCT00360594|DRUG|Acamprosate|3 pills (666 mg) for 1998mg/day
224059297|NCT00360594|DRUG|Placebo|3 pills (666mg) for 1998mg/day
224059298|NCT04956380|OTHER|Self-administered Triage|Self-assessment including a self-administered patient joint count and a self-administered Early Inflammatory Arthritis Detection Tool
224147312|NCT03848611|DRUG|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
224147313|NCT04179435|BEHAVIORAL|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
223569968|NCT06831305|DIAGNOSTIC_TEST|Comparison of microbiological sampling on methacrylic nails|Comparison of microbiological sampling on methacrylic nails
223569969|NCT06891469|DIETARY_SUPPLEMENT|Caffeine administration according to body mass (moderate intake- 7 mg/kg)|This randomized, double-blind, crossover study aimed to investigate the acute effects of caffeine consumption on physiological responses and performance during a strength-focused CrossFit workout. Participants will consume either anhydrous caffeine (7.1 ± 0.7 mg/kg of body mass) or placebo, 60 minutes before a CrossFit workout aiming to perform as many repetitions as possible.
224059299|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
224059300|NCT02495844|DRUG|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
224059301|NCT02495844|DRUG|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
224059302|NCT03118232|DRUG|Chlorhexidine gluconate (CHG)|2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
224059303|NCT03118232|DRUG|Iodophor (10% povidone-iodine)|Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
224059304|NCT02325219|DRUG|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
224059305|NCT02325219|DRUG|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
224059306|NCT02325219|DRUG|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
224059307|NCT02325219|DRUG|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
224059308|NCT01136135|OTHER|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
224070870|NCT05500625|PROCEDURE|Ballon-occluded retrograde transvenous obliteration|A balloon occlusion catheter will be inserted into the venous end of the gastro-renal or gastro-caval shunt via the right femoral vein or internal jugular vein. Balloon-occluded retrograde venogram will be done to evaluate degree of retrograde filling of the gastric varices and presence of collateral veins. Any significant large collateral veins seen will be occluded with coils using microcatheter to prevent leakage of the sclerosant into the systemic circulation. Then, sclerosant agent (ethanol-amine oleate, Sodium tetradecyl sulphate, or polidocanol) will be injected into the portosystemic shunt till complete filling of the gastric varices and part of the feeding veins. Finally, the balloon left in place for 2-12 hours then gradually will be deflated when complete occlusion of blood flow of the target shunt is achieved.
223451840|NCT06288243|DIAGNOSTIC_TEST|Clinician-observed assessment tests|Turkish Modified Mann Swallowing Ability Test, which evaluates swallowing skills Standardized Mini-Mental Test assessing Cognitive Status Modified Rankin Scale to evaluate functionality
223451841|NCT03076112|DRUG|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
223451842|NCT03076112|DRUG|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
223569970|NCT06891469|DIETARY_SUPPLEMENT|Placebo (Biotin Capsules)|Consumption of biotin (BIOTIN tablets by Myprotein) at the same time as caffeine.
223569971|NCT06896396|DRUG|Lenvatinib, Pembrolizumab|Pabilizumab: intravenously every three weeks Lenvatinib, with a dosage based on body weight: 8 mg (≤60 kg) or 12 mg (\>60 kg), once daily
223569972|NCT06896396|DRUG|Icaritin soft capsules|Starting 3-5 days after the first TACE treatment, take 6 capsules orally, twice a day, and swallow them with warm water within 30 minutes after breakfast and dinner
223569973|NCT06896396|PROCEDURE|TACE|TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2023 Edition).
223569974|NCT06896292|BEHAVIORAL|Hybrid care model|"Participants will receive usual antenatal care (in-person), plus the digital support tool. A co-design process was used to develop the tool based on consumer feedback.~The tool is based on the recommended Assess/ask, Advise, Help approach to preventive care for smoking, nutrition, alcohol, physical activity and gestational weight gain.~Participants will be prompted (via SMS) to use the digital support tool at regular intervals throughout their pregnancy to self-assess health risks and be reminded of recommendations and available coaching services."
224059309|NCT05705609|OTHER|Mandala art therapy|A mandala is a geometric configuration of symbols. In various spiritual traditions, mandalas may be employed for focusing attention of practitioners and adepts, as a spiritual guidance tool, for establishing a sacred space and as an aid to meditation and trance induction. Mandalas are used effectively in the field of art therapy. The possibility of using mandala in all age groups has contributed to the treatment process of different diseases and disorders, and its effectiveness has been presented to the scientific world with many researches around the globe. As a result of using mandala as an art therapy in adults, mandala has been used both in the treatment of psychiatric disorders and has been a tool used to observe the effects of the treatments. Art therapy which included drawing mandala, significantly reduced the severity of trauma symptoms in individuals with anxiety disorders and post-traumatic stress disorder.
224059310|NCT03426085|DRUG|Liraglutide 6 mg Solution for Injection|
224059311|NCT03426085|OTHER|Placebo|
224059312|NCT00798850|PROCEDURE|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull \& East Yorshire Yospitals NHS Trust.
224147314|NCT04179435|OTHER|brain MRI|Brain MRI scans
224147315|NCT04179435|OTHER|TMS|Measure of the cortical inhibitory capacity using TMS measures
224147316|NCT02624011|BEHAVIORAL|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
224301296|NCT02243839|PROCEDURE|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
223451843|NCT01436487|BIOLOGICAL|MultiStem|single infusion 1-2 days following ischemic stroke
223451844|NCT01436487|BIOLOGICAL|Placebo|single infusion 1-2 days following ischemic stroke
223451845|NCT04418362|OTHER|Neurofeedback training|A home-based self-administered neurofeedback intervention taking place 4-6 times per week for 8 weeks.
223451846|NCT04282629|DRUG|Milrinone Injection|administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14
223451847|NCT04282629|OTHER|Placebo|administration of placebo (intravenous glucose 5%) from Day 4 to Day 14
223451848|NCT01048944|DRUG|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
223451849|NCT01048944|DRUG|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
223569975|NCT06896292|OTHER|Usual Care|Participants will receive usual antenatal care (in-person), which is recommended to include the delivery of preventive care using the AAH model for smoking, nutrition, alcohol, physical activity and gestational weight gain.
224070871|NCT03939507|OTHER|AEP score available to the treating physician|the treating physician knew the AEP score results
224070872|NCT04273178|DRUG|Escalating prophylaxis|For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF). After discharged from LAF units, patients will receive anti-mold prophylaxis in case of haplo-identical or HLA-matched unrelated donor transplantation to d+100 without active acute GVHD (aGVHD). In case of active aGVHD, the prophylaxis treatment will be extended until recovery of aGVHD and tapering of immunosuppression. In case of HLA-matched sibling donor, fluconazole will be continued to d+100 and anti-mold prophylaxis will be given in case of active aGVHD.
224070873|NCT01916265|DRUG|Glucagon|
224147317|NCT00824928|PROCEDURE|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
224147318|NCT01661920|OTHER|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
224147319|NCT01661920|OTHER|Control group|Those antibiotic duration treatments which are not modified by their doctors.
224147320|NCT02636920|OTHER|Therapeutic Education to the Patient (TEP)|"* Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~* Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~* Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~* Assessing of the knowledges acquired by patients."
224147321|NCT01948141|DRUG|nintedanib|Given PO
224147322|NCT04367441|DRUG|608|recombinant humanized anti-IL17A monoclonal antibody injection
224147323|NCT04367441|DRUG|Placebo|auxiliary material of 608 include histidine, histidine hydrochloride, sucrose and polysorbate 80
223451850|NCT01048944|DRUG|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
224059313|NCT00798850|PROCEDURE|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~1. Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~2. Station 2-Exercise bicycles~3. Station 3-Knee extensions with weights(2kg beanbag)~4. Station 4-Heel raises~5. Station 5-Knee bends(Alternating legs after 10 bends)~6. Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
223451851|NCT03727399|OTHER|blood withdrawal|Blood withdrawal
224059314|NCT00798850|PROCEDURE|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
224147324|NCT02188719|BIOLOGICAL|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is \<50/mm\^3 or when the maximal dose of 4.5/mg/kg has been given.
224147325|NCT02188719|BIOLOGICAL|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
224147326|NCT02188719|DRUG|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
224301297|NCT05246033|DRUG|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
224301298|NCT05246033|DRUG|Placebo for TransCon CNP|Weekly subcutaneously injection of placebo.
223451852|NCT05194683|BEHAVIORAL|Relational Letter Writing|The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
223451853|NCT06410417|BEHAVIORAL|Shorten abstinence time|In the experimental group, male ejaculates once on human chorionic gonadotropin trigger day, and can be ejaculated on the second day if ejaculates fail.
223451854|NCT01844817|DRUG|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
223451855|NCT01844817|DRUG|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
223451856|NCT00352625|DRUG|Ketoprofen Topical Patch 20%|
223451857|NCT01997801|DRUG|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
223569976|NCT06895980|PROCEDURE|Non-surgical periodontal treatment, glycated hemoglobin measurement and application of OHIP-14SP survey.|Non-surgical periodontal treatment will be performed, with periodontal maintenance therapy at 3, 6, 9 and 12 months, with measurement of glycated hemoglobin at each time and application of the OHIP-14SP oral health-related quality of life survey.
224059315|NCT02918864|DRUG|Oxytocin|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.
224147327|NCT02188719|DRUG|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~* TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~* EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
224147328|NCT02188719|DRUG|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
223451858|NCT01997801|DRUG|NS infusion|Normal saline will be infused intraoperatively.
223742010|NCT05064956|BIOLOGICAL|Ad26.ZEBOV|"Ad26.ZEBOV is a non-replicating, monovalent vaccine expressing the full-length Mayinga glycoprotein (GP) of the Ebola virus (formerly known as Zaire ebolavirus), and is produced in human cell line.~Participants will receive a 0.5mL intramuscular injection of Ad26.ZEBOV, at a concentration of 1x10\^11 vp/mL, into the anterolateral deltoid muscle."
223742011|NCT06745791|DEVICE|BoneMRI|BoneMRI is a quantitative 3D MRI technique,capable of generating CT-like, quantitative radiodensity bone MRI images to visualize cortical and trabecular bone, allowing to assess bone structure and morphology, in addition to regular clinical MRI images.
223742012|NCT03712904|RADIATION|Stereotactic Body Radiation Therapy|Undergo radiation
223742013|NCT03712904|BIOLOGICAL|Ziv-Aflibercept|Given IV
223742014|NCT03879707|DRUG|Melatonin 5 mg|Melatonin is known to induce sleep
223742015|NCT03879707|DRUG|Placebo Oral Tablet|Placebo
223742016|NCT03879707|DRUG|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
223742017|NCT04674683|DRUG|HBI-8000 in combination with nivolumab|Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight \< 40 kg, nivolumab will be dosed at specific doses on specific days.
223742018|NCT04674683|DRUG|Placebo in combination with nivolumab|Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
223742019|NCT05485974|DRUG|HBI-2438|KRAS G12C Inhibitor
223742020|NCT04536298|DIETARY_SUPPLEMENT|vitamin D|Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28
224059316|NCT02918864|BEHAVIORAL|Social Cognitive Skills Training|Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
224059317|NCT02918864|BEHAVIORAL|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
224059318|NCT02268721|DEVICE|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
224059319|NCT02603874|DEVICE|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
224070874|NCT05134272|DEVICE|Neuromuscular electrical stimulation|Neuromuscular Electrical Stimulation will be applied by the therapist to infant's finger flexors and extensor for 15 min./day, 3x/week.
224070875|NCT05134272|BEHAVIORAL|Modified constraint induced movement therapy|Modified CIMT will consist of constraint 24 hours/day using a splint in addition to therapy two hours/day, 3x/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week.
224301299|NCT06415617|OTHER|Psychoeducation|"The content of psychoeducation is based on Five Ways of Well-being which covers Be active, Connect, Take Notice, Keep learning and Giving . The participants will be engaged in psychoeducation through group discussion, individualised goal setting and reflective exercises."
224301300|NCT06415617|OTHER|Attention control|The content of the sessions mainly focuses on physical health information, such as healthy eating, physical exercise, prevention of falls, and pain management.
223742021|NCT04536298|DIETARY_SUPPLEMENT|Placebo|Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
223742022|NCT05775341|OTHER|No Intervention|This is purely an observational study.
223742023|NCT06019325|PROCEDURE|RIB|After endotracheal intubation, patients will be positioned in lateral decubitus position. A RIB will be performed at the level of T5-T6 by ultrasound guidance. A single shot block will be performed by injecting 30 ml of 0.25% bupivacaine to the interfacial plane between rhomboid major muscle and intercostal muscle.
223742024|NCT01433679|BEHAVIORAL|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
223742025|NCT01852942|DRUG|Losartan|Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
223742026|NCT01852942|DRUG|Placebo|one tablet by mouth daily
223742027|NCT04355325|DEVICE|modified monolithic zirconia crowns|outcomes and complications of implant restoration
223742028|NCT04355325|DEVICE|Metal Ceramic crowns|outcomes and complications of implant restoration
223742029|NCT03346499|BIOLOGICAL|NK cells and IL-2|Natural Killer Cells
223742030|NCT00624494|DEVICE|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
223742031|NCT00624494|DEVICE|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
223742032|NCT01921179|BEHAVIORAL|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
223451859|NCT03679143|DRUG|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
223451860|NCT03679143|DRUG|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
224059320|NCT03551444|DRUG|Administration of DAA-based treatment|"* Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered."
223451861|NCT03679143|DRUG|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
223451862|NCT03679143|DRUG|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
223451863|NCT03679143|DRUG|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
223451864|NCT03679143|DRUG|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
223451865|NCT03679143|DRUG|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
223451866|NCT03679143|DRUG|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
223584012|NCT06980311|OTHER|Aerobic exercise with music therapy|Music Therapy-Based Aerobic Exercise Training group will follow the same treadmill exercise program as the Traditional Aerobic Exercise group. However, during the exercise sessions, music therapy will be applied according to the beats per minute (BPM) ranges specified below: Warm-up (10 minutes, BPM: 80-100): Low-intensity walking accompanied by slow-tempo music Loading Phase (20-30 minutes, BPM: 120-140): Moderate-to-high intensity walking accompanied by rhythmic, motivational music Cool-down (10 minutes, BPM: 80-100): Low-intensity walking accompanied by slow-tempo sedative music Music will be used throughout the exercise sessions to regulate participants' heart rate and blood pressure, reduce perceived fatigue, enhance motivation, and support rhythmic movement patterns. During training, participants' heart rate and oxygen saturation will be monitored using a fingertip pulse oximeter.
224059321|NCT02732769|DEVICE|GammaKnifePerfexion®|neurosurgery
224059322|NCT02732769|DEVICE|GammaKnifeIcon®|neurosurgery
224059323|NCT02732769|DEVICE|Efficast®|Thermoformed mask
224059324|NCT02732769|DEVICE|MRI|
223451867|NCT03679143|DRUG|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
223451868|NCT03679143|DRUG|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
223451869|NCT03679143|DRUG|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
223451870|NCT03679143|DRUG|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
223451871|NCT03679143|DRUG|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
223451872|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
223451873|NCT03679143|DRUG|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
223451874|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
223451875|NCT03679143|DRUG|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
223451876|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
223451877|NCT03679143|DRUG|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
223451878|NCT03679143|DRUG|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
223451879|NCT01133704|BIOLOGICAL|sipuleucel-T|
223451880|NCT01133704|BIOLOGICAL|APC-Placebo|
223451881|NCT04845880|DIAGNOSTIC_TEST|Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2|Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
223451882|NCT00320268|DRUG|Quetiapine fumarate|
223451883|NCT03944278|DEVICE|Thulium Laser|Thulium laser for skin resurfacing procedures
224059325|NCT00198380|DRUG|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
224059326|NCT04870528|DEVICE|pulsed electromagnetic field device|the pulsed electromagnetic field device treatment parameters will be set as 15 Hz frequency, 20 gauss amplitude, and 20 minutes as total treatment duration.
224070876|NCT05134272|BEHAVIORAL|Standard care for infant with asymmetrical hand function|Infants will receive one hour of therapy, one time/week for three weeks. Parents will be trained to carry over home program activities one hour/day, 6 days/week. In addition the infant will wear a sock on their preferred hand during the hour of therapy/home program activity.
224070877|NCT03695003|DIETARY_SUPPLEMENT|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
224070878|NCT03695003|DIETARY_SUPPLEMENT|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
224070879|NCT02787850|DEVICE|CoolSculpting Treatment|The CoolSculpting device will be used to perform treatments.
224070880|NCT01817309|OTHER|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
224070881|NCT02921971|DRUG|SAR156597|Pharmaceutical form: Solution Route of administration: Subcutaneous
224070882|NCT02921971|DRUG|Placebo|Pharmaceutical form: Solution Route of administration: Subcutaneous
224070883|NCT00452699|DRUG|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
224070884|NCT00452699|DRUG|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
224070885|NCT00274131|DRUG|Pramipexole 0.125 mg tablets|
224070886|NCT00274131|DRUG|Pramipexole 0.5 mg tablets|
223451884|NCT00634296|OTHER|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
224059327|NCT04870528|OTHER|Free weights for Strengthening Exercise|"• Parameters of the exercise program: Intensity : The weight or load the patients lifted is set at 50-60% of their individual 1RM , 3 sets of 10 repetitions during the first week. During the second week, the lifting load is increased to 70-75% (3 sets of 10 repetitions) of their individual 1RM and continued for weeks 2-6. After this, training intensity is increased to 80-85% of the 1 RM and implemented from weeks 7-8.~Frequency: 3 sessions per week for 8 weeks. Number of repetitions: 3 sets,10 repetitions in each set. Total treatment duration: 8 weeks"
224059328|NCT06145295|BEHAVIORAL|mobile online support group (experiment group)|The experimental group engaged with the mobile application use for four weeks, with specific tasks including completing the four mandatory courses within one month and submitting at least two health records and online posts every week.
224059329|NCT06145295|BEHAVIORAL|offline support group (control group)|The control group participates in the offline group intervention that last for four weeks. Participants in the control group will participant in four weekly workshop that last between 1 hour to 1.5 hours.
224059330|NCT03563469|OTHER|Salivary bacterial and pH level|"1. Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~2. The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
224059331|NCT02645357|OTHER|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
224059332|NCT02645357|OTHER|Control group|control group
224059333|NCT04766021|DRUG|Mirabegron|Dose-response effect on thermogenesis
224059334|NCT04766021|DRUG|Placebo|Placebo control condition
224059335|NCT02750540|DRUG|Tenofovir enema|
224059336|NCT02750540|OTHER|Saline enema|
224059337|NCT02979665|DRUG|Ranibizumab Ophthalmic|"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."
224059338|NCT04595903|DEVICE|Hemopurifier|Hemopurifier treatments will be one four to six hour treatment session daily for up to 4 days
224059339|NCT05198271|OTHER|Management of risk factors|"* For all patients:~  * Online dietician consultation (45 min 1st consultation with set objectives then 15-20 min for the following ones) then proposal of varied weekly menus, adapted to different cultural and social contexts by email and reassessment at M3 and M6~ * Clinical and radiographic periodontological evaluation at M0 and M6 by a specialist with dental hygiene advice with delivery of equipment and scaling~ * Initial teleconsultation with motivational interview by sports doctor / APA (30 min) with evaluation of initial physical activity, search for contraindications and development of a personalized program with aerobic and resistance training. Provision of filmed sessions and digital exercise materials for regular practice at home and self-assessment using data from the accelerometer with automatic online report.~* Motivational supports on the MyGoodLife / MyGoodCare platform (weight, food questionnaire, pedometer, tobacco consumption)"
224059340|NCT05198271|BEHAVIORAL|Smoking cessation|"\- For active smoking patients:~* Tobacco consultations: S0, S4 and S8 then according to the opinion of the tobacco specialist~* Nicotine substitutes +/- varenicline according to tobacco consumption~* Online notebook to record tobacco consumption and triggers"
224059341|NCT05198271|BEHAVIORAL|weightloss|-For overweight or obese patients: Online dietician consultation every 15 days for 3 months, the consultation based on the online filling of food questionnaires and the weight curve
224059342|NCT05198271|OTHER|periodontal disease treatment|\- For patients with periodontal disease: treatment of periodontal disease (planing, cast splint, tooth avulsion, etc.) between M0 and M3, dental panoramic M0 at inclusion and M6
224059343|NCT05198271|BEHAVIORAL|increased physical activity|\- For patients with low physical activity: Follow-up by level gp session: 45 '/ week for 3 months
224059344|NCT05198271|BEHAVIORAL|Decreased anxiety|"\- For anxious patients:~* Teleconsultation with a psychiatrist specializing in stress management, global assessment, identification of the factors involved and training in the use of cardiac coherence~* Delivery of connected equipment for the practice of cardiac coherence"
224059345|NCT01032304|DRUG|Erdosteine|One 300 mg capsule twice a day
224059346|NCT01032304|DRUG|Placebo|One capsule twice a day
223451885|NCT03271632|BIOLOGICAL|CAR T cells|Infusion of multi-CAR T cells
224059347|NCT03428893|DEVICE|Mobile Application|Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
224059348|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
224059349|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
223451886|NCT00001296|DRUG|melphalan|
223451887|NCT00001296|DRUG|tumor necrosis factor|
223451888|NCT00001296|DRUG|interferon-gamma|
223451889|NCT00001296|PROCEDURE|hyperthermic isolated limb perfusion|
223451890|NCT00073762|DRUG|DVS-233 SR|
223451891|NCT00136214|DIAGNOSTIC_TEST|MR brain and neuropsychiatric tests|
223451892|NCT02841475|OTHER|Charlson comorbidity index|Charlson comorbidity index
223451893|NCT02407847|OTHER|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
224059350|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
224059351|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
224059352|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
224059353|NCT01609907|DRUG|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
224059354|NCT00709215|DRUG|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
224059355|NCT04535479|BEHAVIORAL|Dry Needling|Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
224301301|NCT03903458|DRUG|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
223451894|NCT05420142|DIETARY_SUPPLEMENT|Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey|The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
223451895|NCT03396822|DRUG|Gadoteridol|gadolinium MRI contrast
223451896|NCT00565201|DRUG|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
223451897|NCT00565201|DRUG|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
223451898|NCT04985942|DRUG|Lumateperone|Lumateperone 42 mg capsules administered orally, once daily.
223451899|NCT04985942|DRUG|Placebo|Matching capsules administered orally, once daily.
223569977|NCT05643183|OTHER|Astmakompas|The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
223584013|NCT06592222|DRUG|Elranatamab|BCMA-CD3 bispecific antibody
223584014|NCT06592222|DRUG|Standard of care|Standard of care
224059356|NCT01677533|OTHER|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
224059357|NCT01677533|OTHER|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
224059358|NCT01677533|OTHER|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
224059359|NCT03289650|DRUG|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
223584015|NCT05698745|PROCEDURE|bioespecimen samples|Blood, serum, plasma, urine, stools, small/large bowel tissue.
224059360|NCT03289650|DRUG|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
224059361|NCT02388438|DEVICE|Bongener|
224059362|NCT02872623|RADIATION|Enterography-MRI without enteroclysis|
224059363|NCT02872623|RADIATION|enteroCT with enteroclysis|
224059364|NCT06151171|DIETARY_SUPPLEMENT|CoQ10|"Participants will be randomly and blindly assigned to receive a single dose (200 mg) of one of the preparations (treatments).~Fasting blood samples are taken at baseline (t=0) or pre-dose for CoQ10 baseline determination.~Participants receive treatment at time zero with a glass of water (\~ 125 mL), along with a standardized breakfast-provided immediately after the dose.~Capsules are administered as a single oral dose, with a wash-out period of at least 3-4 weeks between the two Coenzyme Q10 test products.~Capillary blood samples are collected at time points 0, 0.5, 1, 2, 3, 4,5, 6, 8, 10, 12, 24, 48- and 72-hours post-dose. A standardized lunch is provided after the 4hr blood sample, as well as a standardized dinner after the 8-h sample. Identical meals are served to all participants on each test day."
224059365|NCT04753073|PROCEDURE|Non-invasive physical plasma|Treatment with non invasive physical low-temperature plasma
224059366|NCT02266992|BIOLOGICAL|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
224059367|NCT01656031|DRUG|clofarabine|
224059368|NCT01656031|DRUG|cytarabine|
224059369|NCT05651295|BEHAVIORAL|Checking the Facts|Checking the Facts is a form of cognitive reappraisal in which participants identify negatively-valenced automatic thoughts and both generate and consider evidence that challenges the validity of those thoughts.
224059370|NCT05651295|BEHAVIORAL|Opposite to Emotion Action|Opposite to Emotion Action teaches participants to identify their momentary emotion(s), identify the associated behavioral urge(s), and implement a behavior inconsistent with that urge (e.g., approaching a feared stimulus instead of avoiding it).
224059371|NCT05651295|BEHAVIORAL|Mindfulness of Current Emotions|Mindfulness of Current Emotions teaches participants to nonjudgmentally observe the experience of their emotions, including physiological and cognitive responses to those emotions.
224059372|NCT05668624|OTHER|Clean household energy|LPG stoves/fuel for cooking and solar electricity for lighting
224059373|NCT02034890|DRUG|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
224059374|NCT02257372|DRUG|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
224059375|NCT02257372|DRUG|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
223569978|NCT01556048|BEHAVIORAL|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
224059376|NCT02257372|DRUG|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
224059377|NCT02257372|DRUG|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
224059378|NCT00079404|DRUG|tanespimycin|Given IV
224059379|NCT05999188|OTHER|Observational|No interventions will be given to patients.
224059380|NCT00789529|DEVICE|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
224059381|NCT00789529|DEVICE|ReNu MultiPlus®|soft contact lens disinfecting solution
224059382|NCT02634151|DRUG|Gemcabene|Two 300 mg tablets and 1 placebo tablet administered orally, once daily for 12 weeks.
224059383|NCT02634151|DRUG|Placebo|Three placebo tablets administered orally once daily for 12 weeks.
224059384|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
224059385|NCT02492503|DRUG|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
224059386|NCT05940792|OTHER|Nonelastic taping|Non-elastic taping was placed on the ankle of the affected side with a plaster band starting from the middle of the sole of the foot and extending from the lateral side of the foot to the level below the knee to provide eversion support.
224059387|NCT05940792|OTHER|Conservative physiotherapy|The conventional physiotherapy programme included range of motion exercises, balance and gait training and neuromuscular electrical stimulation.
224059388|NCT02289430|DRUG|Crestor+Ezetrol|rosuvastatin+ezetimibe
224059389|NCT02289430|DRUG|Ezetrol|ezetimibe
224059390|NCT02289430|DRUG|Crestor|rosuvastatin
224059391|NCT05143892|DRUG|Avatrombopag|Avatrombopag administered at the described frequency to achieve a target platelet count
224059392|NCT05143892|OTHER|Supportive care|Supportive care other than TPO-RAs or recombinant human thrombopoietin.
223584016|NCT06993480|DRUG|AHB-137|AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).
224059393|NCT00316680|BIOLOGICAL|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
224059394|NCT05008107|OTHER|Virtual reality|Using VR goggles to watch peri-operative instructional video.
224059395|NCT04392115|BEHAVIORAL|The PREPARE program|"A home-based exercise program guided by paper materials, weekly phone calls, and a DVD.~Exercise will be prescribed as one-hour sessions, performed a minimum of three times per week for at least three months, consisting of: 1) strength training; 2) aerobic exercise and 3) flexibility."
224059396|NCT03156920|DRUG|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224059397|NCT03156920|DRUG|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
224059398|NCT02347098|DEVICE|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
224059399|NCT02347098|DRUG|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
224059400|NCT02187172|DRUG|Ustekinumab|
224059401|NCT02187172|DRUG|Placebo|
224059402|NCT00880399|DRUG|orvepitant|Neurokinin-1 (NK-1) antagonist
224059403|NCT00880399|OTHER|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
224059404|NCT04412850|DRUG|Magnesium Sulfate|"Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.~All patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.~Follow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge."
224059405|NCT05710120|OTHER|Hepatitis C Screening Alerts in CHORUS™|"ZS Associates developed a machine learning-based model that provides a numeric % chance of returning a positive hepatitis C test for a patient without diagnosed hepatitis C infection. The data used to develop the model included a US-based large scale data source including electronic medical records, medical claims, and pharmacy claims as well as social determinants of health identified from open-source data.~Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients who have a scheduled appt in the coming week and may require attention. In the after period of this study, the alert will identify patients who are eligible to be screened for hepatitis C infection and provide the % chance of returning a positive hepatitis C infection test."
224059406|NCT05710120|OTHER|Standard of Care|CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients who are eligible to be screening for hepatitis C infection will be disseminated.
224059407|NCT01523496|DRUG|Vitamin D control dose|18,000 IU per month
224059408|NCT01523496|DRUG|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
224301302|NCT02523196|DRUG|HepQuant-SHUNT (Drug and Device) #65,123 (4D-cholate) and IND #65,121 (13C-cholate)|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
224059409|NCT01792921|BEHAVIORAL|COG - FUN|
224059410|NCT04353284|DRUG|Camostat Mesilate|Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.
224059411|NCT04353284|OTHER|Placebo|Placebo taken orally, 4 times daily, for 7 days.
224059412|NCT00145028|DRUG|Carboplatin|
224301303|NCT02523196|DEVICE|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
223451900|NCT06517095|PROCEDURE|improved capsular polishing|In the polished group,utilize the OVDs to partially fill the peripheral capsule, causing the central posterior capsule to bulge, and then employ the double-ended Whitman Shepherd capsular polisher to meticulously polish both the anterior and equator of the capsule. This process also allows for simultaneous polishing of a portion of the posterior capsule. By rotating the polisher 180°along one side, followed by switching ends to cover the remaining 180° range, even the main incision site can be effectively addressed due to its curved tip design.
223451901|NCT06517095|PROCEDURE|the conventional I/A polishing|the conventional I/A polishing the capsule
223451902|NCT03630705|BIOLOGICAL|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|Pharmaceutical form: Liquid solution Route of administration : Intramuscular
223584017|NCT06600308|OTHER|Walk tests|"Performance of the following walking tests using inertial measurement units: TUG; 10 m test at a comfortable and fast speed and TM6 (according to the recommendations of the American Thoracic Society).~At the end of each walking test, measurement of the difficulty of exertion using the Borg scale."
224059413|NCT04096027|DRUG|Cabergoline Pill|0.5 mg cabergoline pill taken orally
224059414|NCT01389375|DEVICE|FemoSeal®|Closure device for femoral artery access closure
224059415|NCT01389375|DEVICE|ExoSeal®|Closure device for femoral artery access closure
224301304|NCT01154959|DRUG|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
224305082|NCT04112173|BEHAVIORAL|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
223451903|NCT03630705|BIOLOGICAL|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
223451904|NCT03630705|BIOLOGICAL|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
223451905|NCT03630705|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223451906|NCT03630705|BIOLOGICAL|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
223451907|NCT03630705|BIOLOGICAL|Hepatitis B Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
223451908|NCT03630705|BIOLOGICAL|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: Oral solution Route of administration: Oral
223451909|NCT03630705|BIOLOGICAL|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
223569979|NCT06641713|PROCEDURE|TACE|TACE was carried out under the guidance of digital subtraction angiography, and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The emulsion of the selected drug and the embolization agents was therefore injected infused into tumor-feeding arteries via the selective microcatheter. A final arteriography confirmed the success of the procedure. The endpoint of the TACE procedure was reached when there was no flow in the tumor-feeding vessels.
223451910|NCT02232477|DRUG|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
223451911|NCT05447455|PROCEDURE|Transversus Abdominis Plane Block|A 22-gauge spinal needle was introduced from medial to lateral in-plane to the ultrasound probe, and 20 mL of bupivacaine 0.25% was injected under visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
223451912|NCT05447455|PROCEDURE|Local anesthetic wound infiltration|40 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (20 mL on each of the upper and lower sides) by the obstetrician before skin closure
223451913|NCT03612479|BEHAVIORAL|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
223451914|NCT03612479|BEHAVIORAL|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
224059416|NCT01389375|OTHER|Manual compression|Conventional manual compression
223451915|NCT06503068|OTHER|Questionnaire|A questionnaire in both digital and written forms in both Arabic and English versions.
223569980|NCT06641713|PROCEDURE|HAIC|HAIC was carried out under the guidance of digital subtraction angiography, 990and hepatic artery angiography was used to assess the location, number, size, and blood supply of the targeted tumor. Then a more selective microcatheter was used to vascularize the tumor. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2. Hepatic arterial infusion chemotherapy administration of oxaliplatin, fluorouracil, and leucovorin via the tumor feeding arteries every 4 weeks
224059417|NCT01875783|DEVICE|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
224059418|NCT04778098|OTHER|Received SMS reminder|telenursing
224147329|NCT02188719|DRUG|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
224147330|NCT02188719|DRUG|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
224305083|NCT03621358|OTHER|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
223451916|NCT02574663|DRUG|TGR-1202|TGR-1202 oral daily dose
223451917|NCT02574663|DRUG|nab-paclitaxel + gemcitabine|IV infusion
223451918|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
223451919|NCT02574663|DRUG|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
223569981|NCT06895824|OTHER|Mindfulness Meditation|Somatic tracking is one aspect of most mindfulness meditation protocols, involving paying attention to the present non-judgementally, and focusing on breath and bodily sensations (e.g., sounds in the case tinnitus). This study employs this approach as a standalone intervention, in the form of a guided meditation recording.
223569982|NCT06766266|DRUG|Irinotecan liposome II combination therapy regimen|In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the neoadjuvant therapy phase before TURBT surgery.
223569983|NCT06766266|DRUG|Irinotecan liposome II combination therapy regimen|In the B arm, the combined therapy with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2 ) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the induction phase after TURBT surgery.
224059419|NCT00128856|DRUG|Gemcitabine|
224059420|NCT00128856|DRUG|Adriamycine|
224059421|NCT00128856|DRUG|Paclitaxel|
224059422|NCT03443076|DIETARY_SUPPLEMENT|EPA + DHA in SMEDS Formulation|A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
224147331|NCT02188719|DRUG|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
224305084|NCT03621358|OTHER|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
223451920|NCT02849704|DRUG|Creon36™|Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
223451921|NCT02731274|OTHER|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
223451922|NCT00559663|DIETARY_SUPPLEMENT|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
223451923|NCT00559663|DIETARY_SUPPLEMENT|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
223451924|NCT01290952|PROCEDURE|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
223451925|NCT01290952|PROCEDURE|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
223451926|NCT02512172|DRUG|Oral CC-486|
223451927|NCT02512172|DRUG|Romidepsin|
223451928|NCT02512172|DRUG|MK-3475|
223451929|NCT05305456|DRUG|Tanreqing capsule|3 capsules per time, 3 times a day
223451930|NCT05305456|DRUG|Tanreqing capsule simulator|3 capsules per time, 3 times a day
223451931|NCT02149407|DRUG|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
223451932|NCT02149407|PROCEDURE|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
223451933|NCT02149407|OTHER|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
223451934|NCT00481364|DRUG|atorvastatin|atorvastatin 40 mg/day
223451935|NCT00481364|DRUG|placebo|1 tb/day
223451936|NCT03603197|DRUG|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
223451937|NCT03603197|DRUG|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
223451938|NCT04482907|DIETARY_SUPPLEMENT|Giving dill by mouth capsule to the study group and placebo capsule by mouth to the control group.|Tests from intravenous blood: TSH, fT3, fT4, anti-TPO, Anti-Tg, CRP
223451939|NCT05119036|RADIATION|44 doses of radiation|Patients will receive 44 gray in 22 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 40 gray in 22 fractions to undissected areas of the neck at low-risk for occult disease.
223451940|NCT05119036|RADIATION|54 doses of radiation|Patients will receive 54 gray in 27 fractions to the operative bed, including the primary tumor site and dissected nodal basin. Patients will receive 50 gray in 27 fractions to undissected areas of the neck at low-risk for occult disease.
224301305|NCT03813693|OTHER|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2\) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3\) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
223451941|NCT06080672|OTHER|Experimental: Group 1 (dental examination-training-tooth brushing) Experimental: Group 2 (dental examination-training-plaque disclosing-tooth brushing)|All participants will be examined and their decay, filling and extracted teeth, plaque index and gingival index measurements will be recorded. Plaque disclosing will be applied to Group 2 after brushing training.
223451942|NCT06581250|BEHAVIORAL|Reminder Messages|Dental clinic staff will use scripts to contact patients 24 and 48 hours before appointments. These scripts will guide staff in confirming the patient will appear for their appointment.
223451943|NCT06581250|BEHAVIORAL|Walk-in Visits|When contacting patients to schedule an appointment (by phone, email, text, or other methods), dental clinic staff will notify patients of times during which patients can walk-in for a dental visit, if convenient for them; otherwise, a regular appointment will be arranged. Scheduled appointments will continue to be available in addition to the walk-in hours.
223451944|NCT06581250|BEHAVIORAL|Motivation-enhanced Communication|Participating clinic site staff will be trained in motivation-enhanced communication techniques using the guide for dental clinic sites and coaching. Topics to be included in the motivation-enhanced communication training are a) to determine what patients hope to gain from their dental care, steps needed to succeed, how the agency and client will work together to attain the goals, and b) to identify patient barriers to attending their visit (e.g., transportation, payment, do not understand need for visit, etc.), and what the agency and patient will do to overcome those barriers. Staff will be instructed to use these techniques with patients at every contact about an upcoming appointment.
223451945|NCT04833426|DRUG|Testosterone gel|Topical gel containing testosterone
223451946|NCT04833426|DRUG|Placebo|Topical gel without active substance
224305085|NCT03621358|OTHER|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
224059423|NCT03443076|OTHER|Lovaza (active comparator; already FDA approved)|A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
223451947|NCT05312138|DEVICE|Repetitive Transcranial Magnetic Stimulation|The treatment will be internally cooled 70 mm double coil and 110 mm round coil, accompanied by a physiotherapist and neurologist. The coil will be placed on the precentral gyrus. Practices will be held, with each session lasting 20 minutes. Cortical excitability will be provided by high frequency (HF) stimulation (5-Hz).
223451948|NCT05312138|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|The treatment parameters will be applied with a pulse current time of 200 μsec, a fixed frequency of 10 Hz, a treatment time of 20 minutes, and a current intensity that the patient can tolerate, which will not cause flexion in the big toe or fan movement in the other fingers. Self-adhesive surface electrodes will be used for stimulation. During the treatment, the patient will lie on his back. The negative electrode will be placed 2 cm posterior to the medial malleolus and the positive electrode will be placed 10 cm proximal.
223569984|NCT01313845|DRUG|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
223569985|NCT01313845|DRUG|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
223569986|NCT04005638|BIOLOGICAL|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
223569987|NCT04005638|BIOLOGICAL|urine sample|12 ml
224059424|NCT02678481|DEVICE|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
224059425|NCT02678481|DEVICE|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
224059426|NCT02464384|PROCEDURE|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
223451949|NCT00574691|DEVICE|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
223451950|NCT05897372|DRUG|ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib|Standard of care for diabetic kidney disease.
223451951|NCT06954779|DRUG|Colgate Cavity Protection|1000ppm fluoride
223451952|NCT06954779|DRUG|TOM's Superior Sensitivity Relief Toothpaste|fluoride free
223451953|NCT06954753|PROCEDURE|Pancreatic surgery|Pancreatic resective surgery performed for pancreatic cystic lesions with high risk of malignant degeneration based on clinical, biochemical, and/or radiological features following current guidelines on pancreatic cystic lesions management.
223451954|NCT02261831|OTHER|obese patients|collection of blood sampling and biopsies
223569988|NCT06895850|OTHER|Eccentric cycling training|The training protocol for the ECC consisted of a 5-minute warm-up on a stationary ergometer (RS1 Go, Life fitness, USA) before completion of the prescribed workout. In the first two weeks, participants completed two sets of 10 minutes of eccentric cycling at an RPE between 9-11 with 2 minutes of inter-set rest. Then, during weeks 3-8, participants completed two sets of 15 min of eccentric cycling at an RPE between 13-15 with 2 min inter-set rest.
224059427|NCT05911542|BEHAVIORAL|Survey|Participants complete survey about pain management practices
224059428|NCT04548726|DEVICE|Sapien 3 Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis via a transcatheter procedure.
224059429|NCT04548726|DEVICE|Myval Transcather Aortic Valve Implant|Implant of a Ballon Expandable Aortic Valve Myval (Meril Life Sciences Pvt. Ltd., India) prosthesis via a transcatheter procedure.
224059430|NCT04382170|DRUG|Dexmedetomidine sublingual film|Dexmedetomidine sublingual film for the management of agitation in hospitalized patients with delirium.
224059431|NCT03891940|PROCEDURE|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
224059432|NCT04715750|DRUG|[18F]-PI2620|\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
223569989|NCT06895850|OTHER|Standar Rehabilitation|The training protocol for STD REHAB consisted of the same 5 min warm-up protocol used in ECC, followed by three sets of 8 repetitions of bicep curls, triceps extensions, shoulder abduction, bodyweight squats, deadlifts, and leg abductions with an elastic band with 2 min inter-set rest. The resistance of the elastic band tension was progressively increased according to the participant's tolerance based on RPE. ECC training was programmed for \~20-30 min, while STD REHAB lasted \~60 min per session.
223569990|NCT06597929|OTHER|Moderate-vigorous physical activity|The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
223569991|NCT06180629|BEHAVIORAL|Music conset|The music modes to be used (Rast and Hüseyni), classical music, nature music, and listening time of 20-30 minutes were determined by taking expert opinion from a faculty member from the Conservatory department and by reviewing the literature. The researcher asked the patients to choose the music genres. After each patient decided on the music they wanted to listen to, the researcher recorded the selected music genres on their smartphones. The music playback application was played to the patients in the experimental group for 20-25 minutes in each session for 4 sessions, i.e. 4 times in total, once a week for a month, until the end of one course. During each session, the patients listened to the music genre they had chosen each week.
223569992|NCT06180629|OTHER|normal treatment routine|normal treatment routine
223451955|NCT02261831|OTHER|diabetic patients|collection of blood sampling and biopsies
223451956|NCT02261831|OTHER|patients free of obesity and diabetes|collection of blood sampling and biopsies
223569993|NCT06454825|DRUG|Intravenous drug|medications were applied intravenously to the groups 30 minutes before end of the procedure
224147332|NCT02188719|DRUG|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
224301306|NCT03813693|OTHER|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
223451957|NCT02261831|OTHER|patients free type 2 diabetes|collection of blood sampling and biopsies
223451958|NCT05714826|OTHER|Preop Intervention and Monitored Recovery|Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care
223569994|NCT00737568|DRUG|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
223569995|NCT00737568|DRUG|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
223569996|NCT00737568|DRUG|TDF Placebo|TDF placebo tablet administered orally once daily
223569997|NCT00737568|DRUG|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
223569998|NCT05694312|DRUG|Ibrutinib 420 mg|Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.
224059433|NCT00291447|BIOLOGICAL|ch806|ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.
224059434|NCT05988268|OTHER|Vibration Foam Rolling|The vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
224059435|NCT05988268|OTHER|Non-Vibration Foam Rolling|The non-vibration foam rolling method will be applied to the gluteal, tensor fascia latae, hamstring, quadriceps femoris, and gastrocnemius muscles of both lower extremities of the participants in the Non-Vibration Foam Rolling Group, in addition to the routine warm-up protocol, 3 days a week for a total of 15 minutes a day for 6 weeks.
224059436|NCT00101751|DRUG|biphasic insulin aspart|
224059437|NCT00101751|BEHAVIORAL|dietary regimen|
223569999|NCT00748397|DEVICE|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
223570000|NCT03317626|DIAGNOSTIC_TEST|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
223570001|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.
223584018|NCT06600308|OTHER|ecological (real-life) assessment of walking ability|Delivery of an actimeter, inertial units and logbook for ecological assessment (in real life) of walking ability for 7 days
224059438|NCT01323725|BEHAVIORAL|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
224059439|NCT05019898|DIAGNOSTIC_TEST|pupillometry|"Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~* The quantification of their anxiety~* An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain."
224059440|NCT00889148|DRUG|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
224059441|NCT00889148|OTHER|Placebo|Half the patients will be randomized to placebo
224059442|NCT00933673|DRUG|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
224147333|NCT02188719|PROCEDURE|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level \>/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level \</=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
224301307|NCT05042934|PROCEDURE|Fine-Needle Aspiration|Undergo fine-needle aspiration
223451959|NCT05714826|OTHER|Usual Care|ERAS, Usual referral and recovery care, and Standard follow-up protocol
223451960|NCT05182749|BIOLOGICAL|bacteriophage|A cocktail of lytic Shigella-specific bacteriophages orally administered with sodium bicarbonate solution
223451961|NCT05182749|OTHER|Placebo|Placebo orally administered with sodium bicarbonate solution
223451962|NCT03638466|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI)|Neural brain activity measured by fMRI
224301308|NCT05042934|DRUG|Irinotecan|Given IV
224301309|NCT05042934|DRUG|Irinotecan Hydrochloride|Given IV
223451963|NCT03638466|DIAGNOSTIC_TEST|Magnetic Resonance Spectroscopy (MRS)|Glutamate and GABA levels measured by MRS
224059443|NCT05015075|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation after pacemaker implantation
223451964|NCT03638466|BEHAVIORAL|Point Subtraction Aggression Paradigm (PSAP) Task|Aggression score measured by the PSAP task
224059444|NCT01710384|DRUG|betamethasone|
223451965|NCT03638466|DRUG|SPN-810|Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score
223451966|NCT03638466|DRUG|Placebo|Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
223451967|NCT00328458|DRUG|EPO906 (epothilone B)|
223451968|NCT02576977|BIOLOGICAL|Pembrolizumab|pembrolizumab 200 mg IV infusion
223451969|NCT02576977|DRUG|Pomalidomide|pomalidomide 4 mg capsules
223451970|NCT02576977|DRUG|Dexamethasone|dexamethasone 40 mg tablets
223451971|NCT06955780|OTHER|Emotional Freedom Techniques|Emotional Freedom Techniques
223451972|NCT04428528|DEVICE|Photoacoustics Imaging System|Characterizing breast masses for photoacoustic markers measurements
223451973|NCT03102957|OTHER|functional MRI|
223451974|NCT00359320|PROCEDURE|pancreaticojejunostomy|
223451975|NCT03251482|DRUG|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
223451976|NCT03251482|DRUG|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
223451977|NCT03251482|DRUG|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
223570002|NCT04332497|OTHER|"Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''"|Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
223451978|NCT03251482|DRUG|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
223451979|NCT03251482|DRUG|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
223451980|NCT03251482|DRUG|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
223570003|NCT03757650|DRUG|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
223570004|NCT04407026|BIOLOGICAL|biofluids|Gingival crevicular fluid, saliva and serum samples were obtained.
224059445|NCT01512602|BEHAVIORAL|DBT|16 weeks DBT treatment
224059446|NCT01512602|BEHAVIORAL|CAMS|CAMS-informed psychotherapy
224059447|NCT01439321|BIOLOGICAL|Eltrombopag|Switched to Eltrombopag
223451981|NCT03251482|DRUG|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
223451982|NCT03251482|DRUG|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
223451983|NCT03251482|DRUG|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
223451984|NCT03251482|DRUG|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
223451985|NCT03251482|DRUG|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
223451986|NCT04481594|DRUG|HPN-01|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
223451987|NCT04481594|DRUG|Placebo|25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
223451988|NCT02016911|DRUG|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
223451989|NCT04508647|DRUG|Ublituximab|"Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes."
223451990|NCT04508647|DRUG|Umbralisib|Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
223451991|NCT01013831|DRUG|Erlotinib Hydrochloride|Given PO
223451992|NCT01013831|OTHER|Laboratory Biomarker Analysis|Correlative studies
223451993|NCT01013831|OTHER|Pharmacological Study|Correlative studies
223451994|NCT04242979|BEHAVIORAL|Questionnaire about albumin use in liver cirrhosis|"1. Permission to carry out the study will be obtained from the Faculty's Ethics Committee.~2. To achieve validity and reliability of the tool. It will be reviewed by two experts in the field of the study and necessary modification will be done.~3. A pilot study will be 10% done to test the clarity and feasibility of developed tool.~4. Each participant involved in the study will be assessed for his or her knowledge using (tool I).~5. Data will be collected by personal interview with participants or via fulfilling online questionnaire taking in consideration data confidentiality.~6. Application of the designed evidence based indications for human albumin use supported by the international guidelines will be done by researcher using (tool II).~7. Evaluate the effect of the designed evidence based indications for human albumin use supported by the international guidelines on physicians' knowledge after 1 month using (tool I) in a random sample of those physicians"
223451995|NCT02447328|DRUG|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
223451996|NCT04481763|DRUG|Camrelizumab|Camrelizumab is 200 mg iv. administered every 2 weeks for 3 cycles with radiotherapy ( 50gy, 25 times for 5weeks)
223451997|NCT04481763|RADIATION|radiotherapy|radiotherapy
223451998|NCT02425735|BIOLOGICAL|DC-CIK cells|DC-CIK cells will be used against tumor cells.
223451999|NCT02425735|BIOLOGICAL|γδ T cells|γδ T cells will be used against breast tumor.
223570005|NCT03900858|DRUG|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
224059448|NCT01439321|BIOLOGICAL|Romiplostim|Switched to Romiplostim
224059449|NCT04082403|PROCEDURE|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
224301310|NCT05042934|DRUG|Lurbinectedin|Given IV
224301311|NCT00161798|BIOLOGICAL|Tick-borne encephalitis vaccine|
223452000|NCT02425735|BIOLOGICAL|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
223452001|NCT00546169|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
223452002|NCT01156493|OTHER|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
223452003|NCT02413671|DIETARY_SUPPLEMENT|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
223452004|NCT02413671|DIETARY_SUPPLEMENT|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
223452005|NCT02413671|OTHER|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
223452006|NCT06955351|OTHER|Survey by Questionnaire|The questionnaire is designed to collect the following information: demographic data (including gender, age, education level, marital status, place of residence, and whether the respondent is a healthcare provider), the respondent's status of basic life support (BLS) training, attitudes and willingness to use an automated external defibrillator (AED), and their knowledge of emergency medical service regulations.
223452007|NCT03970655|DRUG|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1|Group 1 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the LEFT pterygopalatine fossa
223452008|NCT03970655|DRUG|Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2|Group 2 will receive 4 ml of 0.5% Bupivacaine or Ropivacaine with epinephrine in the RIGHT pterygopalatine fossa
223452009|NCT02204644|DRUG|Flumatinib 600mg qd|
223452010|NCT02204644|DRUG|Imatinib 400mg qd|
223452011|NCT01614444|OTHER|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
223452012|NCT01614444|OTHER|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
223452013|NCT05418907|RADIATION|68Ga-NODAGA-exendin-4 PET/CT|PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4
223452014|NCT00787163|PROCEDURE|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
223452015|NCT00035269|DRUG|Antibiotic|
223452016|NCT04639557|BEHAVIORAL|BRIDGE Therapy Program|The BRIDGE Therapy Program is a novel manualized therapy that incorporates key parenting concepts and related Dialectical Behavior Therapy (DBT) modules. The primary aim of the program is to promote self-regulation in the mother-child dyads. There are two components of the program: 1) the DBT section, which will follow the DBT Skills Training Manual 2nd Edition and target maternal mental health symptomology, and 2) the parent skill training materials, which have been designed to correspond to the four core DBT modules (i.e., Mindfulness, Emotion Regulation, Distress Tolerance, and Interpersonal Effectiveness) and to promote self-regulatory skill development and a positive parent-child relationship.
223452017|NCT00596453|DRUG|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
223452018|NCT00596453|DRUG|Placebo|Placebo twice a day for 14 days
223452019|NCT01863719|DRUG|Colistimethate sodium|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
223452020|NCT01863719|DRUG|Colistimethate sodium|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
223452021|NCT06490081|DRUG|Trilaciclib|During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
223452022|NCT00431327|BEHAVIORAL|Peer coach phone call|
223452023|NCT05880095|OTHER|Unrestricted Mediterranean diet|Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.
223452024|NCT05880095|OTHER|Energy-reduced Mediterranean diet|Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.
224059450|NCT04082403|PROCEDURE|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
223452025|NCT05880095|OTHER|Mediterranean diet with time-restricted eating|Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.
223452026|NCT04808414|DRUG|QPX9003 for IV Infusion|antibiotic
223452027|NCT04808414|DRUG|Placebo for IV infusion|Placebo comparator
223452028|NCT03630133|DEVICE|Intracept System Ablation|Radiofrequency ablation using Intracept System
223452029|NCT03417752|OTHER|Exposure to firearm safety PSA|Exposed to firearm safety PSA
223452030|NCT03417752|OTHER|Exposure to health promotion PSA|Exposed to general health promotion PSA
223452031|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System|The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 15-21 days. She receives 3 sessions, in total. 5% Lidocaine cream is applied 30 minutes before each procedure. Each session consists of application of R11 handpiece to the episiotomy scar at Turbo3 Micro Short Pulse mode, with spot size of 2 mm, fluence of 9.5-10 j/cm2, frequency of 2 Hz and 4 pulses per point and 3 passes followed by PS03 handpiece at Basic Long Pulse mode, with spot size of 5 mm, energy of 800 mJ, frequency of 1.4 Hz and 4 pulses per point and 2 passes.
223452032|NCT05793476|DEVICE|Fotona Dynamis Er:YAG Laser System with Sham handpiece|The same procedure is applied above but with a sham handpiece and parameter presentations masked.
223452033|NCT03208894|DRUG|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
223452034|NCT01759719|DEVICE|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
223452035|NCT00409279|BEHAVIORAL|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
223452036|NCT03942367|DEVICE|Active Device (vPatch)|Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.
223452037|NCT03942367|DEVICE|Sham Device (vPatch)|Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
223570006|NCT04348149|DIETARY_SUPPLEMENT|Lindera obtusiloba extract|One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.
223570007|NCT03222154|DEVICE|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
224059451|NCT02328651|DRUG|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg,iv, Bid\~tid）"
224059452|NCT02328651|DRUG|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2\~5ml/kg, iv, Bid\~tid）"
224059453|NCT03677258|DEVICE|Collagen for injections 7%|Injection of medical device
224059454|NCT03677258|DEVICE|Hyaluronic acid for injections 2%|Injection of medical device
224059455|NCT01590940|PROCEDURE|Open inguinal hernia repair with mesh|
224059456|NCT01170520|DEVICE|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
224059457|NCT04164836|DIAGNOSTIC_TEST|rhinoscope|more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
224059458|NCT04075721|DRUG|M3258|Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) or twice per week on Day 1 and Day 4 until disease progression.
224059459|NCT04075721|DRUG|M3258 20 mg|Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.
224059460|NCT00766532|DRUG|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
224059461|NCT04967300|PROCEDURE|Dental treatment|bilateral restorative treatment on the mandibular primary first molars
224059462|NCT00533832|DEVICE|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
224059463|NCT06460402|OTHER|Ice packing|For both arms, participants will self-administer interventions at home per instructions: ice packs every 2 hours for 48 hours (ice pack arm) or sitz baths 2-3 times daily for 7 days (warm water arm). Standardized supplies and daily logs will be provided. All participants receive standard postop care with analgesics and wound care. Adverse events will be monitored closely. Intervention duration: 48 hours (ice), 7 days (sitz bath). Assessments: baseline, 24/48/72 hours (pain, swelling), 1 week (wound separation). Total study duration per participant: \~1 week from surgery.
223570008|NCT03222154|DEVICE|Placebo - Shock wave therapy|Simulation of shock wave therapy
223570009|NCT03408418|PROCEDURE|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
223570010|NCT00248118|DRUG|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
223570011|NCT03020134|DRUG|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
223570012|NCT03020134|DRUG|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
224059464|NCT06460402|OTHER|Warm sitz bath|Participants in this arm will receive standard instructions to perform warm water sitz baths at home, starting from the day of surgery and continuing for 7 days postoperatively. They will be advised to take 2-3 sitz baths per day, with each bath lasting for 15-20 minutes. A standard plastic sitz bath basin will be provided to the participants, along with a thermometer to monitor the water temperature. The recommended water temperature range for the sitz baths is 37-40°C (98.6-104°F). Participants will be instructed to keep a daily log recording the number of sitz baths taken, the duration of each bath, and the water temperature. Proper hygiene and wound care instructions will also be provided to prevent infection.
224070887|NCT00807755|DRUG|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
223452038|NCT00314808|DRUG|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
223452039|NCT00874159|OTHER|No treatment given|Subject will only fill out a questionaire when entering the observational study.
223452040|NCT05676788|DEVICE|Hyperspectral Imaging|Identification of the intersegmental plane
223452041|NCT00964379|PROCEDURE|intraperitoneal or extraperitoneal colostomy|creation of colostomy
223570013|NCT03020134|DRUG|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
223570014|NCT03020134|DRUG|Placebo|Placebo
223570015|NCT00855933|DEVICE|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
223570016|NCT02882867|OTHER|Injuries in Swedish Youth Athletics. The KLUB-study.|
223570017|NCT00656188|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
223570018|NCT00656188|DRUG|Placebo|Matching placebo
224301312|NCT03412786|BIOLOGICAL|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl\_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
224059465|NCT05099627|OTHER|"The questionnaire Cervical myelopathy treatment outcome questionnaire"|"Information gathered through clinical examination and questionnaires performed retrospectively over the phone, pre-operation and at 3- and 6-months post-operation. The questionnaire Cervical myelopathy treatment outcome questionnaire attached records information relating to co-morbidities and symptomology. The examination will be a thorough neurological examination in addition to a focused cardiovascular examination. Biochemical blood markers from existing blood markers or from GP records, which have been or would have been performed regardless of this trial. Radiological findings will be taken from routine MRI and cervical spine X-rays performed as part of the CSM diagnostic work-up"
224059466|NCT05099627|OTHER|"The retrospective questionnaire CSM early diagnosis questionnaire"|To identify early clinical predictors of cervical myelopathy diagnosis based on individual patient-reported symptoms by using a questionnaire and patient characteristics as well as co-morbities, as well as clinical examination findings provided by community musculoskeletal teams.
224059467|NCT05099627|OTHER|JOACMEQ questionnaire and mJOA|Used for prospective cohort via telephone at 3, 6 and 12-months post-operatively to assess treatment outcomes.
224059468|NCT04659265|OTHER|Suspected diagnosis of a pre-treating physician|Participants receive the information that the pre-treating physician thought the patient is suffering from a medical emergency (no diagnosis), an acute myocardial infarction (correct diagnosis) or a pulmonary embolism (wrong diagnosis)
224059469|NCT04777487|DIAGNOSTIC_TEST|GCF obtaining|4 samples of gingival crevicular fluid, 1 from each quadrant of the patient's jaw, were collected by means of paper strips.
224059470|NCT01891500|DRUG|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
224301313|NCT04149886|PROCEDURE|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
224301314|NCT04149886|DEVICE|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
224301315|NCT01372241|BEHAVIORAL|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
223570019|NCT00951080|DEVICE|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
224059471|NCT01891500|DRUG|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
224070888|NCT00807755|DRUG|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
223570020|NCT00951080|DEVICE|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
223570021|NCT05258578|BEHAVIORAL|Tele-CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and problem solving and challenging negative thoughts. Participants are encouraged to complete CBT homework between sessions (i.e., completing food records, pleasurable activities and worksheets).
223570022|NCT05258578|OTHER|Self-Help Resources|Participants will be directed to the CAMH COVID-19 Self-Help webpage (www.camh.ca/covid19) to access coping tools to help with COVID-19 associated stress and anxiety, loss, grief and healing, stigma, and physical isolation.
223570023|NCT06280872|OTHER|Physiological Based Cord Clamping|see Arm Description
223570024|NCT06280872|OTHER|Differed Cord Clamping|see Arm Description
223570025|NCT04562402|PROCEDURE|Phacoemulsification|cataract surgery via phacoemulsification
223570026|NCT04562402|PROCEDURE|Endoscopic cyclophotocoagulation|Endoscopic ablation of the ciliary body
223570027|NCT05496452|DIETARY_SUPPLEMENT|Beta-lactoglobulin|Beta-lactoglobulin (BLG) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
223570028|NCT05496452|DIETARY_SUPPLEMENT|Carbohydrate|Carbohydrate (dextrose monohydrate) will be administered thrice daily during a 7 day period of prehabilitation and 5 day period of immobilisation when the leg is placed in a brace.
223570029|NCT01960998|BEHAVIORAL|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
223570030|NCT01960998|BEHAVIORAL|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
223570031|NCT00811005|RADIATION|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
224301316|NCT03359824|OTHER|Exercise|
224301317|NCT05365841|DRUG|Mepolizumab 100 MG|Patients with SEA eligible to receive anti-IL5 treatment, which is a biologic treatment for SEA
224301318|NCT03639519|DRUG|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
224301319|NCT03639519|OTHER|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
224301320|NCT04586153|DRUG|Meplazumab for Injection|humanized antibody target CD147
224301321|NCT04586153|DRUG|Sterile normal saline (0.9%)|Sterile normal saline (0.9%)
224301322|NCT05814003|DRUG|hydroxylate flavones solid dispersion application|this drug has the antibacterial and anti inflammatory actions could help the palatal donor sites to promote the wound healing
224301323|NCT05814003|OTHER|Placebo|Dough inert material without any therapeutic action
224301324|NCT03322384|DRUG|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
224301325|NCT03322384|DRUG|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
224059472|NCT01891500|DRUG|Crossover iNO|Patients who deteriorate (OI \>20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
224059473|NCT00111280|DRUG|TMC125|
224059474|NCT01918839|DEVICE|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
224059475|NCT01918839|DEVICE|Restylane-L|Restylane-L injected into wrinkle treatment area
224059476|NCT05872802|OTHER|eccentric exercises and electrical stimulation|Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.
224059477|NCT05872802|OTHER|proprioceptive neuromuscular facilitation|proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
224059478|NCT01141088|PROCEDURE|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
224059479|NCT01141088|PROCEDURE|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
224059480|NCT04320732|BEHAVIORAL|Observation of behavior and COVID-19 infection will be conducted.|No intervention, only prospective observation of behavior will be conducted by a questionnaire.
224059481|NCT03821025|DEVICE|Biliary stent|Palliation of malignant biliary obstruction
224059482|NCT05928195|DIETARY_SUPPLEMENT|Acute Moderate-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.
224059483|NCT05928195|DIETARY_SUPPLEMENT|Acute High-Dose Guayusa Extract Supplementation|Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).
224059484|NCT05928195|DIETARY_SUPPLEMENT|Placebo|Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
224059485|NCT01732809|DRUG|AbobotulinumtoxinA (ABO)|Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
224059486|NCT01732809|DRUG|OnabotulinumtoxinA (ONA)|Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
224059487|NCT02424253|DRUG|ZPL-3893787|ZPL-3893787
224059488|NCT02424253|DRUG|Placebo|Matched Placebo
224059489|NCT00091104|BIOLOGICAL|MART-1:27-35 peptide vaccine|
224059490|NCT00091104|BIOLOGICAL|aldesleukin|
224059491|NCT00091104|BIOLOGICAL|filgrastim|
224301326|NCT03322384|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
223584019|NCT06993584|OTHER|Adult patients in cardiogenic shock|evaluate the elimination clearance of levosimendan (LVSMD) in the group without extracorporeal membrane oxygenation (ECMO) and in the group with ECMO.
223584020|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (active)|non-invasive active repetitive stimulation applied to the scalp surface
224059492|NCT00091104|BIOLOGICAL|incomplete Freund's adjuvant|
224059493|NCT00091104|BIOLOGICAL|therapeutic autologous lymphocytes|
224059494|NCT00091104|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
224059495|NCT00091104|DRUG|cyclophosphamide|
224059496|NCT00091104|DRUG|fludarabine phosphate|
224059497|NCT00091104|PROCEDURE|autologous hematopoietic stem cell transplantation|
224059498|NCT00091104|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224059499|NCT00091104|RADIATION|total-body irradiation|
224301327|NCT04320550|DIAGNOSTIC_TEST|abdominal ultra sound|non invasive tests to exclude pathological causes
224301328|NCT04323241|OTHER|Controlled cord traction|In group 2, Spontaneous removal will be performed by massaging on the uterine fundus and applying gentle traction on the umbilical cord.
224301329|NCT04832321|OTHER|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan man with different profiles of illness severity, treatment, and treatment response.
223584021|NCT06155682|DEVICE|repetitive transcranial magnetic stimulation (sham)|non-invasive active repetitive stimulation applied to the scalp surface
223584022|NCT06856668|BEHAVIORAL|Behavioral Activation (Action Brings Change Project 10-Minute Version)|"A behavioral activation SSI where users learn about negative thought spirals, give advice to an imagined peer, then create an action plan of helpful activities to do in the near future. This is a shorter version of the original 15-minute Action Brings Change SSI."
223584023|NCT06856668|BEHAVIORAL|Mindful Acceptance|A clinical psychologist explains a few ways to use mindful acceptance to deal with difficult thoughts and feelings.
223584024|NCT06856668|BEHAVIORAL|Moral Elevation|Users learn about moral elevation, then watch a touching video where a man does good deeds for people in his community (originally a Thai life insurance advertisement). Finally, they plan a positive action they can take to help others in their own life.
223584025|NCT06856668|BEHAVIORAL|Mindful Attention Skills|A series of videos teach mindfulness skills: how to release thoughts and re-evaluate negative interpretations.
223584026|NCT06856668|BEHAVIORAL|5 Habits to Beat Depression|A clinical psychologist and science communicator describes his top 5 one-minute habits to beat depression.
223584027|NCT06856668|BEHAVIORAL|Interactive Cognitive Reappraisal|An interactive SSI where participants learn how to reframe negative thoughts
223584028|NCT06856668|BEHAVIORAL|Expressive Writing (AI-supported)|Participants describe a negative thought they struggle with and an LLM helps them to consider a story in which a peer overcomes that thought.
224059500|NCT02261194|BEHAVIORAL|Self-Care Tools|
224301330|NCT04704141|DRUG|Hormone replacement therapy|A hormone replacement regimen using any medication of a number of standard treatment options
223584029|NCT06856668|BEHAVIORAL|Inner Child Healing Walk|An interactive journey to reconnect and heal one's inner child through breathing exercises, positive affirmations, and supportive animal companions.
224059501|NCT03621514|PROCEDURE|painless indwelling catheter|Catheterization after anesthesia (14 F Foley's urinary catheter), the patient was removed before the anesthesia was awakened and the catheter was removed(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization).
224070889|NCT00807755|DRUG|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
224301331|NCT01193738|PROCEDURE|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
224305086|NCT02984618|PROCEDURE|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
223584030|NCT06856668|BEHAVIORAL|Savoring Strategies|An SSI introducing savoring strategies to improve mood.
223584031|NCT06856668|BEHAVIORAL|Personalized Intervention Recommender|Identifies the kinds of depression one struggles most with and offers a personalized recommendation for future depression support options
223584032|NCT06856668|BEHAVIORAL|Dialectical Behavioral Therapy Skills|Presents videos from dialectical behavioral therapy on various ways to control negative emotions.
223584033|NCT06856668|BEHAVIORAL|All about Trout|An 8-10 minute educational program with information and interactive exercises about trout fish. Intended to capture one's attention and require some effort, while minimizing influence on depressive symptoms.
223584034|NCT06856668|BEHAVIORAL|Reframing Negative Thoughts|An audio-only program in which users are guided to reflect on how they might challenge negative automatic thoughts and beliefs they struggle with.
223584035|NCT01603316|BEHAVIORAL|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form. Need Assessment surveys will be administered via telephone or in person. The content of the needs assessment questionnaire has been informed by themes generated through IHCD's ongoing research and community outreach and service activities with the cancer patient population at our participating institutions. The survey will ask participants about the impact on their cancer care and their socioeconomic needs of the COVID-19 crisis.
223584036|NCT01603316|BEHAVIORAL|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials, via mail, MSK Secure email, or in person and nutrition education sessions.
223584037|NCT06675331|OTHER|Medically Tailored Meal Program with Traditional Navajo Foods|Patients will receive medically-tailored meals incorporating local traditional Navajo foods
223584038|NCT06534424|OTHER|Best Practice|Receive standard care
223584039|NCT06534424|PROCEDURE|Biospecimen Collection|Undergo collection of blood or mouthwash sample
223584040|NCT06534424|OTHER|Counseling|Receive tailored counseling
223584041|NCT06534424|PROCEDURE|Discussion|Participate in phone discussion
223584042|NCT06534424|PROCEDURE|Genotyping|Undergo genotyping
223584043|NCT06534424|PROCEDURE|Molecular Risk Assessment|Undergo enhanced risk assessment
223584044|NCT06534424|OTHER|Questionnaire Administration|Ancillary studies
223584045|NCT03007745|DEVICE|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
223584046|NCT05649514|PROCEDURE|Polysomnography|Polysomnography will be performed for 24 hours at inclusion and 24 months
223584047|NCT05649514|BEHAVIORAL|Neuropsychological assessment|A full neuropsychological assessment will be performed at inclusion, 12 and 24 months
223584048|NCT05649514|BEHAVIORAL|Questionnaires on sleep and behavioural problems|Questionnaires on sleep and behavioural problems
223584049|NCT05649514|PROCEDURE|Actimetrics|Measurement of actimetrics for 14 days at inclusion and at 24 months
223584050|NCT05649514|OTHER|Biomarker assay|Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid
223584051|NCT06616831|DEVICE|Remote Transcutaneous Auricular Vagal Nerve Stimulation Paired with Task-Specific Training|Each participant will complete 2 weeks, 3 times per week, task-specific training paired with transcutaneous auricular vagal nerve stimulation.
223584052|NCT03500588|DIAGNOSTIC_TEST|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
223584053|NCT03500588|DEVICE|Doppler ultrasound|Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
223584054|NCT06860880|OTHER|Exercise|Each patient will receive an individualized exercise prescription that will encompass both aerobic and resistance training, with modifications as necessary to accommodate each patient's needs, abilities, and medical condition. For those not participating in any formal exercise at baseline, the exercise prescription will consist of a basic conditioning program targeting 150 minutes of moderate physical activity weekly with the assistance of a physical therapist if deemed appropriate.
223584055|NCT06860880|OTHER|Diet|Participants will undergo nutritional consultations with a registered dietitian who specializes in oncology. The dietitian will provide tailored dietary recommendations using evidence-based nutrition guidelines. Participants will also be screened ffor ormal nutrition based on American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines as indicated.
223584056|NCT06794255|DIETARY_SUPPLEMENT|Vitamin C|Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
223584057|NCT06794255|OTHER|Placebo|Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
223584058|NCT07042178|OTHER|Meditation video at the beach|A virtual reality video consisting of a 5 minute meditation video at te beach.
223584059|NCT07042178|OTHER|Rollercoaster video|A virtual reality video consisting of a five minute rollercoaster ride.
224059502|NCT03621514|PROCEDURE|indwelling catheter|The patients underwent catheterization(14 F Foley's catheter) after anesthesia,and the catheter was indwelled(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization). The patient was routinely removed for 24 to 72 hours after surgery.
224059503|NCT03998046|BEHAVIORAL|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
224301332|NCT05306171|BEHAVIORAL|Online training for healthcare professionals|"The online training (4 modules) will use the technique of hybrid learning, combining meetings that will require the presence of participants and mediator at the same time and platform (live) with recorded meetings (interviews with experts) that will be watched by the participants at any time (from a distance).~Module 1: Self Care; Module 2: Stress and anxiety management; Module 3: Relationships; Module 4: Communication."
224301333|NCT00041249|DRUG|brostallicin|
223452042|NCT03111277|DEVICE|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
223452043|NCT06344689|OTHER|Surgical treatment|Patients underwent surgical treatment of ectropion were included in this study.
223452044|NCT04304508|DRUG|BAY2433334|Tablet, taken orally once a day.
223452045|NCT04304508|OTHER|BAY2433334 matching placebo|Tablet, taken orally once a day.
223452046|NCT05491681|BIOLOGICAL|intravenous delivery of allogeneic bone marrow-derived MSCs|MSCs
223570032|NCT00811005|RADIATION|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
224070890|NCT00326898|OTHER|Laboratory Biomarker Analysis|Correlative studies
224070891|NCT00326898|OTHER|Placebo|Given PO
224070892|NCT00326898|OTHER|Quality-of-Life Assessment|Ancillary studies
224070893|NCT00326898|DRUG|Sorafenib Tosylate|Given PO
224301334|NCT01484418|BEHAVIORAL|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
223452047|NCT00869310|DRUG|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
223452048|NCT00869310|DRUG|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
223452049|NCT05273229|OTHER|Virtual Gait|Virtual Gait: the patient will be placed in a standing position (with an ad-hoc designed help system) in front of a mirror (from the waist up) and a screen (from the waist down) where a video of legs walking on a treadmill will be projected and overcoming obstacles. Projected legs will be customized based on height, using the tibia length method.
223452050|NCT05273229|OTHER|Physical exercise|"PE: it will be divided into two parts: in the first one, a gait technique training will be carried out and, in the second, a leg strength training, for 30 min. Exercises:~* Coordination exercises: normal and lateral parallel walking and walking with obstacles.~* Functional exercises such as climbing stairs, etc.~* Lower limb strength exercises. Strength exercises will be prescribed according to the guidelines of the American College of Sports Medicine (ACSM). Progression will be customized based on individual abilities."
224070894|NCT00326898|DRUG|Sunitinib Malate|Given PO
223452051|NCT05273229|OTHER|Sham Virtual Gait|only the placebo virtual gait.
223584060|NCT03787810|DIAGNOSTIC_TEST|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
223584061|NCT00841750|PROCEDURE|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
223584062|NCT00841750|PROCEDURE|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
223584063|NCT06876896|DEVICE|Accuryn Foley catheter device|Accuryn foley catheter placed on all subjects after consent who are having treatment for atrial flutter or atrial fibrillation
223584064|NCT01300351|DRUG|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
223584065|NCT01300351|DRUG|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
223584066|NCT02811913|OTHER|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~* session 1 - High frequency rTMS targeting contralesional sensory cortex~* session 2 - Low frequency rTMS~* session 3 - sham rTMS"
223584067|NCT02811913|OTHER|peripheral sensory stimulation|peripheral sensory electrical stimulation and vibration of the stroke-affected hand administered concurrently with each rTMS
223584068|NCT03917069|DRUG|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
223452052|NCT04973709|DIAGNOSTIC_TEST|Confussion assessment method (CAM)|Participants enrolled in the Delirium group according to the CAM.
223452053|NCT04973709|DIAGNOSTIC_TEST|Dementia diagnosis|Participants enrolled in the Dementia group according to the CDR scores and MMSE scores and DSM4/5 criteria
223452054|NCT02688764|DRUG|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
223742033|NCT01921179|BEHAVIORAL|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
223742034|NCT05371574|DRUG|clonidine group|Each participant will be receive 0.2mg of oral clonidine 60 minutes before surgery and 10mls of sterile water (placebo) 10 minutes after skin incision
223742035|NCT05279820|PROCEDURE|Partial pulpotomy|Partial pulp tissue amputation
223742036|NCT05279820|PROCEDURE|Full Pulpotomy|Full Pulpotomy
223742037|NCT02053181|DRUG|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
223742038|NCT01640483|OTHER|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
223742039|NCT06787508|DEVICE|TMS|Continuous high-frequency transcranial magnetic stimulation therapy Targeting the left M1 area, continuous high-frequency stimulation was performed at a frequency of 10Hz with 80-100% TEP for 5 minutes each time, twice a day for a total of 5 days
223742040|NCT06787508|DEVICE|TMS|Consistent with the experimental group protocol, the magnetic stimulation probe is a false stimulation probe that only produces sound but does not actually produce stimulation
223742041|NCT01089088|DRUG|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
223742042|NCT01089088|DRUG|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
223742043|NCT01089088|DRUG|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 \& 8) Sunitinib 37.5mg (po days 2 to 15)"
223742044|NCT00049439|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
223742045|NCT00049439|DRUG|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
223742046|NCT00049439|DRUG|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
223742047|NCT00049439|DRUG|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
224059504|NCT03998046|BEHAVIORAL|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
223452055|NCT02688764|DRUG|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
223452056|NCT04733625|DRUG|Cholecalciferol|single injection of Vitamin D (200000 I.U
223452057|NCT04733625|DRUG|Placebo|placebo medication
223742048|NCT00049439|DRUG|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
223742049|NCT04693507|DRUG|teverelix TFA 120 mg|Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
223742050|NCT04693507|DRUG|teverelix TFA 180 mg|Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
223742051|NCT04991181|DRUG|400 mg BIA 5-1058|Capsules, oral administered to subjects between 08:00 and 09:00 hours in the morning of Day 1after an overnight fast of at least 10 hours. The study drug was swallowed together with 240 mL tap water (room temperature).
224070895|NCT05576571|DIAGNOSTIC_TEST|Met-score|methylation analysis
224070896|NCT03351777|DRUG|PR022|Topical Gel
224070897|NCT02158780|PROCEDURE|Scrotal Orchidopexy|Single incision
224070898|NCT02158780|PROCEDURE|Inguinal Orchidopexy|Double Incision (Standard)
224070899|NCT03847987|DRUG|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
224059505|NCT03998046|BEHAVIORAL|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
224059506|NCT02055105|PROCEDURE|miRNA in Sepsis|miRNA in Sepsis
224059507|NCT02370615|DRUG|TAK-272|TAK-272 tablet.
224059508|NCT02370615|DRUG|Digoxin|Digoxin tablet.
224059509|NCT02370615|DRUG|Itraconazole|Itraconazole oral solution
224059510|NCT02370615|DRUG|Midazolam|Midazolam syrup.
224059511|NCT02290873|DRUG|Remimazolam|For induction and maintenance of sedation
224059512|NCT02290873|DRUG|Midazolam|For induction of maintenance and sedation
224059513|NCT02290873|DRUG|Placebo|Inactive control arm
224059514|NCT04077450|BEHAVIORAL|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
224059515|NCT04509141|OTHER|acupuncture|acupuncture points used were EXHN5 Taiyang, GB20 Fengchi, TE5 Waigun, GB41 Zulinqi
224059516|NCT00267033|PROCEDURE|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
224059517|NCT00685503|DRUG|Ranibizumab|
224059518|NCT02663388|PROCEDURE|gastric bypass, sleeve, gastric banding|
224301335|NCT01484418|BEHAVIORAL|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
223452058|NCT02113007|DRUG|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
224059519|NCT02278900|OTHER|Communication aids|Question Prompt list Audiofile
224059520|NCT04360759|DRUG|Chloroquine or hydroxychloroquine|Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
224059521|NCT03080246|BEHAVIORAL|Strength Training Exercise|
224059522|NCT03045562|DRUG|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
224059523|NCT03045562|DRUG|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
224059524|NCT06036251|OTHER|Questionnaires|Self-reported quality of life (QOL) measures completed online
224059525|NCT01378104|DRUG|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
224059526|NCT01378104|DRUG|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
224059527|NCT01102075|DEVICE|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
224301336|NCT00444457|BIOLOGICAL|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
223452059|NCT02118350|BEHAVIORAL|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
223452060|NCT01331707|DEVICE|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
223452061|NCT01331707|DEVICE|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
223452062|NCT00885378|DRUG|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
223452063|NCT00885378|DRUG|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
223452064|NCT01759394|DRUG|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~* Fed, Fed, Fasted; or~* Fed, Fasted, Fed; or~* Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
223452065|NCT00060372|DRUG|ipilimumab|Given IV
223452066|NCT00060372|DRUG|therapeutic allogeneic lymphocytes|Given IV
223452067|NCT00349193|DRUG|laquinimod 0.3|laquinimod 0.3mg
223452068|NCT00349193|DRUG|laquinimod 0.6|laquinimod 0.6mg
223452069|NCT00349193|OTHER|Placebo|Blinded Placebo
223584069|NCT03917069|DRUG|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
224059528|NCT01102075|DEVICE|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
224059529|NCT01303042|DRUG|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
224059530|NCT01189188|PROCEDURE|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
224059531|NCT01189188|PROCEDURE|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
224059532|NCT03786562|DRUG|Intrathecal Morphine|Group 1
224059533|NCT03786562|DRUG|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
224059534|NCT02847195|DEVICE|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
224059535|NCT04739085|DIAGNOSTIC_TEST|Defocus curves - Monocular distance visual acuity with trial lenses added to the best correction for distance|The monocular distance visual acuity of each participant' eye is evaluated using trial lenses of -3.00 sph, -2.50 sph, -1.75 sph, and -1.25 sph (added to the best correction for distance), which correspond to distances 30 cm, 40 cm, 60 cm and 80 cm, respectively.
224059536|NCT04739085|DIAGNOSTIC_TEST|wDDART - Monocular near visual acuity using the best correction for distance|The same participants undergo visual acuity test via the web-based digital near vision reading test wDDART at 30 cm, 40 cm, 60 cm and 80 cm, having their best correction for distance.
224059537|NCT05796908|DEVICE|Aptis PRUJ Prosthesis|A prosthetic implant for replacement of the proximal radial ulna joint.
224059538|NCT00885274|DRUG|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
224059539|NCT00885274|DRUG|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
224059540|NCT03645993|GENETIC|Genetic Testing|A one time blood sample will be taken.
224059541|NCT02700997|DEVICE|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
224059542|NCT00442052|DRUG|aspirin|
224059543|NCT00442052|DRUG|omeprazole|
224059544|NCT01120392|OTHER|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
223452070|NCT00717795|BEHAVIORAL|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
224059545|NCT01120392|OTHER|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
224059546|NCT05929716|DRUG|Magrolimab|Given by IV (vein)
224301337|NCT00444457|BIOLOGICAL|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
223452071|NCT00717795|BEHAVIORAL|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
223570033|NCT03755674|PROCEDURE|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
223570034|NCT05757154|OTHER|Diet|All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.
223584070|NCT03605069|DRUG|QR-313|QR-313 will be applied topically once daily for 8 weeks of treatment.
224059547|NCT05929716|DRUG|Rituximab|Given by IV (vein)
224059548|NCT05929716|DRUG|CAR T leukapheresis|Given by IV (vein)
224059549|NCT05929716|DRUG|Radiation|Given by IV (vein)
224059550|NCT03186690|OTHER|Biodentine|
224059551|NCT03186690|OTHER|Mineral Trioxide Aggregate|
224059552|NCT06104852|OTHER|Survey|Participants will be surveyed on demographics, medical history, and current memory and cognitive concerns. Vitals signs, urine drug screen, blood draw may be collected.
224059553|NCT06104852|OTHER|Optional Medication Washout|Participants taking memory medications which require a down-taper per the judgment of the study physicians may participate in a medication washout period during study screening.
224059554|NCT03563378|DRUG|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
224059555|NCT03563378|DRUG|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
224059556|NCT04714736|DEVICE|Coronary angiography using DyeVert system|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using DyeVert system.
224059557|NCT04714736|PROCEDURE|Coronary angiography using conventional manual injection syringe.|Invasive diagnostic and/or interventional cardiovascular procedures in the setting of acute coronary syndrome using conventional manual injection syringe.
224059558|NCT05875051|OTHER|Reduced-exertion high intensity training|The intervention of the REHIT group will consist of three parts: i) 3 minutes of warm-up part at 50% of HRmax obtained in the effort test; ii) 3 min 20 sec to 3 min 40 sec of REHIT; and iii) 3 minutes of cool-down at 50% of HRmax obtained in the effort test. The REHIT part will consist of maximum cycling sprints of all-out exercise at 100% of the HRmax, increasing for up to 10 seconds, 15 seconds on week two and 20 seconds on week three. Then, 3 minutes of active rest at 50% of HRmax. Finally, 10 seconds of all-out exercise at 100% of the HRmax, rising to 15 seconds on week two and 20 seconds on week three.
224070900|NCT03847987|DRUG|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
224059559|NCT05875051|OTHER|Short moderate intensity training|The SMIT group will receive a short moderate-intensity training with the same warm-up and cool-down exercises as the REHIT group. In addition, the main part of the session consisted of 6 minutes of moderate intensity exercise at 60-70% HRmax obtained in the effort test. In addition, the main part of the session increases 3 min every week as 6 min for the first 2 weeks, 9 min for the 3rd and 4th weeks, and 12 min for the last two weeks.
223570035|NCT03207321|DIETARY_SUPPLEMENT|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
224059560|NCT00492427|DRUG|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25\~250μg(s.c.)/4week for 24\~26weeks in total.
224059561|NCT00492427|DRUG|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k\~12000IU(s.c.)/2week for 24\~26weeks in total.
224059562|NCT05161533|DRUG|Carboplatin|Given IV
223742052|NCT04377360|RADIATION|Diffusing Alpha-emitter Radiation Therapy|Diffusing Alpha-emitter Radiation Therapy (DaRT) is a method of delivering interstitial brachytherapy, based on the interstitial intratumoral placement of an encapsulated Radium-224 source (3.7 days half-life). These sources release short-lived alpha-emitting atoms into the tumor microenvironment by recoil. As the radioisotope has a short half-life, the majority of radiation absorption happens in the tumor.
224305087|NCT02984618|PROCEDURE|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
223452072|NCT01658254|OTHER|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
224059563|NCT05161533|DRUG|Cisplatin|Given IV
224059564|NCT05161533|BIOLOGICAL|Durvalumab|Given IV
224059565|NCT05161533|DRUG|Etoposide|Given IV
224059566|NCT05161533|RADIATION|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
224059567|NCT05161533|OTHER|Quality-of-Life Assessment|Ancillary studies
224059568|NCT05161533|OTHER|Questionnaire Administration|Ancillary studies
224059569|NCT05501145|PROCEDURE|cesarean section and aortic repair|The timing of aortic repair and delivery have to be determined based on the type of the dissection, the stage of pregnancy (the gestation age), and the status of the fetus, as well as the level of local neonatal service.
223452073|NCT03216369|OTHER|MRI|MRI perfusion imaging
223452074|NCT03011437|OTHER|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
223452075|NCT04750278|DRUG|FP-025 100 mg|FP-025 100 mg BID
223452076|NCT04750278|DRUG|FP-025 300 mg|FP-025 300 mg BID
223452077|NCT04750278|DRUG|Placebo|Placebo BID
223452078|NCT00463489|BEHAVIORAL|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
223452079|NCT00463489|BEHAVIORAL|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
223452080|NCT01220726|DRUG|Botox|Botox injection
223452081|NCT01220726|DRUG|Placebo|Placebo injection
224059570|NCT03463798|DEVICE|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
224059571|NCT03463798|DEVICE|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
224059572|NCT05382247|DEVICE|ultrasonography|"Full history taking, thorough clinical examination, review of participants medical files.~Patients will be typically examined during spontaneous respiration to help assessement of diaphragmatic motion.~The supine position will be used whenever possible to avoid overall variability, side-to-side variability, and for greater reproducibility.~Patients can be examined in quiet respiration and during deep breathing or sniff maneuver.~For uncooperative patients appropriate sedative for age will be used. Assessement of diaphragmatic function: the analysis of the dome excursion with M mode approach Evaluation of diaphragmatic thickness and thickening during inspiration by analyzing the apposition zone."
224059573|NCT01519765|DRUG|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
224059574|NCT01519765|DRUG|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
224059575|NCT01473563|DRUG|Pemetrexed|Administered intravenously
224059576|NCT03610724|BIOLOGICAL|Tisagenlecleucel|Tisagenlecleucel was infused once as an intravenous infustion at a dose of either 0.2 to 5 x 106 CAR-positive viable T cells per kg body weight for subjects ≤ 50 kg or 0.1 to 2.5 x 108 CAR-positive viable T cells for subjects \> 50 kg.
224305088|NCT01736241|DRUG|LY3053102|
224305089|NCT01736241|DRUG|Placebo|
223452083|NCT03883776|DRUG|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
223570036|NCT05947565|DIAGNOSTIC_TEST|Invasive Urodynamic Study|"Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded."
223570037|NCT00759356|DRUG|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
224059577|NCT03610724|DRUG|lymphodepleting chemotherapy|Prior to tisagenlecleucel infusion, each subject underwent lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
224059578|NCT03610724|DRUG|Bridging Therapy|Pre-treatment phase could also include bridging therapy of investigator's choice
224059579|NCT05544188|DIAGNOSTIC_TEST|Differential diagnostic|Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
224059580|NCT02354222|DRUG|Canagliflozin|
223452084|NCT03883776|DEVICE|PET/CT|"Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection."
224059581|NCT02354222|DRUG|Teneligliptin|
224059582|NCT02354222|DRUG|Placebo|
224059583|NCT00786565|DEVICE|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
224059584|NCT00786565|DEVICE|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
224059585|NCT05301868|BEHAVIORAL|Multidomain intervention|For 24 weeks, participants will receive cognitive training twice a week, exercise 3 times a week, nutrition education 12 times, and education about vascular risk factor management every 2 weeks using the tablet PC application.
224059586|NCT01699542|DEVICE|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
224147334|NCT02188719|PROCEDURE|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
224147335|NCT02188719|PROCEDURE|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
223570038|NCT00759356|DRUG|KADIAN|2 x 100 mg, single-dose capsule
223570039|NCT04703608|DRUG|Ivermectin|Ivermectin 0.3-0.4mg/Kg daily for 3 days.
223570040|NCT04703608|DRUG|ASP|Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)
223570041|NCT04703608|DRUG|Placebo|Non-identical placebo
223570042|NCT02666651|DRUG|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
223570043|NCT02666651|OTHER|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
223570044|NCT00791453|BEHAVIORAL|Education|Patients will receive literacy appropriate health information.
223570045|NCT02885480|BEHAVIORAL|questionnaires|
224059587|NCT01699542|DEVICE|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
224059588|NCT06345521|OTHER|No intervention|No intervention
224059589|NCT06388044|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is a third-wave cognitive behavioral therapy. ACT aims to increase psychological flexibility through six core processes: acceptance, cognitive defusion, present-moment awareness, self as context, values, and committed action.
224059590|NCT00753831|PROCEDURE|Aurosling|Silicon rod to be used in frontalis suspension surgery
224059591|NCT00805272|OTHER|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
224059592|NCT05395611|OTHER|EBPcollected using the PExA device.|The PExA device is a non invasive device that collect particles in exhaled air
224059593|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 1mg zoledronic acid once.
224059594|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 2.5mg zoledronic acid once.
224059595|NCT04719650|DRUG|Zoledronic Acid Injection|Infusion 5mg zoledronic acid once.
224059596|NCT04719650|DRUG|Placebo|Infusion normal saline once.
224059597|NCT01395875|DRUG|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
224147336|NCT02188719|PROCEDURE|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
224147337|NCT03780036|DEVICE|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
224147338|NCT04529421|BEHAVIORAL|Online instruction|For some courses and groups of students, instruction is primarily offered digitally, so that the students can participate from outside campus.
224147339|NCT04529421|BEHAVIORAL|In-person instruction|For some courses and groups of students, instruction is primarily offered in-person, on campus (or elsewhere).
223570046|NCT00704483|DRUG|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
223570047|NCT00704483|DRUG|Sevelamer HCl|0.8 g tid
223570048|NCT00704483|DRUG|SBR759|1.5 g tid
223570049|NCT00704483|DRUG|Sevelamer HCl|1.6 g tid
223570050|NCT00373165|DRUG|Ganciclovir|
224059598|NCT01395875|DRUG|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
224059599|NCT00576017|DRUG|Fentanyl-TTS|
224147340|NCT02022956|DRUG|Lorcaserin|
224147341|NCT04297826|BEHAVIORAL|Harvest for Health|Please see previous description
224147342|NCT01164865|DEVICE|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
223452085|NCT03883776|OTHER|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
223452086|NCT02579382|DRUG|TDF|300 mg tablets administered orally once daily
223452087|NCT02579382|DRUG|Vesatolimod|Tablets administered orally once a week (every 7 days) for 12 doses
223452088|NCT02579382|DRUG|Placebo|Placebo administered orally once a week (every 7 days) for 12 doses
223570051|NCT06457230|DEVICE|10Hz rTMS based on cerebellum and FPC|We compare the efficacy of paired-pulse stimulation relative to single-pulse stimulation. Subjects will be randomly assigned to a cerebellar + frontal pole paired-pulse experimental group.
224059600|NCT04474665|DEVICE|Reverse shoulder arthroplasty utilizing Blueprint Software|Reverse shoulder arthroplasty utilizing Blueprint Software
224059601|NCT06648668|DRUG|TMP-301|Once daily \[QD\] × 14 days
224059602|NCT06648668|DRUG|Placebo|Once daily \[QD\] × 14 days
223452089|NCT03818009|OTHER|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
223452090|NCT01730716|DEVICE|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
223452091|NCT03987113|OTHER|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
223452092|NCT04703010|DEVICE|Electroencephalography-Near infrared spectroscopy|Brain activity will be measured using 128-channel EEG and 2 channel NIRS during tactile stimulation (15 minutes sequence of vibrations) while the newborn is asleep.
223452093|NCT04703010|DEVICE|Magnetic resonance imaging|Structural (T1-T2), siffusion tensor imaging and blood-oxygen level dependant signal will be acquired in a subset of 40 subjects (20 minutes while asleep)
223570052|NCT06457230|DEVICE|10Hz rTMS based on cerebellum or FPC|Subjects will be randomly assigned to a cerebellar or frontal pole randomised control group.
223452094|NCT04703010|BEHAVIORAL|Psychometric testing|Cognitive evaluation at age 2 (Parental questionnaires on sensory profiles, executive functions and neurodevelopmental disorders screening, child tests : movement assessment battery, Laby, Head-toes-shoulders-knees)
223452095|NCT01775787|DRUG|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
223452096|NCT00482482|BEHAVIORAL|psychoeducation|on weekly basis for 8 weeks
223452097|NCT00482482|BEHAVIORAL|Yoga|on weekly basis for 8 weeks
223584071|NCT03605069|DRUG|Placebo|Placebo will be applied topically once daily for 8 weeks of treatment.
223584072|NCT02811783|DRUG|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
223584073|NCT02811783|DRUG|Placebo Lotion|Topical TID for 2 weeks
224059603|NCT02282150|DRUG|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
224059604|NCT02282150|DRUG|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
224059605|NCT04360980|DRUG|Colchicine Tablets|1.5 mg loading then 0.5 mg BID P.O
224059606|NCT00248755|PROCEDURE|mucociliary clearance scan|
224059607|NCT03777540|PROCEDURE|Gastric resection|"Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery)."
224059608|NCT05302752|OTHER|Magnetic phrenic nerve stimulation|"The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated."
224059609|NCT03471975|PROCEDURE|direct laryngoscope|the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
224059610|NCT03471975|PROCEDURE|video laryngoscope|the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
224059611|NCT02067195|DRUG|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
224070901|NCT03847987|DRUG|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
224070902|NCT01708980|OTHER|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
224070903|NCT01265459|DEVICE|Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml|Durolane is an intraarticular hyaluronic acid preparation
224070904|NCT04918329|OTHER|Observational study|Non interventional study
224070905|NCT03083340|BEHAVIORAL|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
224070906|NCT02397928|DEVICE|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
224070907|NCT02397928|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
224059612|NCT02067195|DRUG|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP \<13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and \>1.5 ml/kg/hr for LVEDP \>18 mmHg, whereas,0.5 ml/kg/hr for LVEDP \>20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
223452098|NCT02706145|OTHER|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
224147343|NCT01164865|DEVICE|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
223452099|NCT04474054|DEVICE|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation will be performed using catheter ablation
223452100|NCT06414772|OTHER|Use of MARTI application in addition with a classical consultation/support|Participants will use MARTI in order to establish the medical history during their waiting time.
223452101|NCT00208260|DRUG|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
223452102|NCT00208260|DRUG|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
223452103|NCT00208260|DRUG|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
223452104|NCT00208260|DRUG|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
223452105|NCT00208260|DRUG|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
224059613|NCT04402970|DRUG|Dornase Alfa Inhalation Solution|Nebulized dornase alfa
224059614|NCT03499509|OTHER|Low Glycemic Diet|Low Glycemic (LG) diet: The LG diet was made up of foods that do not stimulate insulin secretion and was composed of 20% CHO, 55% fat, and 25% protein. The diet emphasized complex over simple carbohydrates and allowed dairy products, fruits, and vegetables within allowance of the diet.
224059615|NCT03499509|OTHER|High Glycemic Diet|High Glycemic (HG) diet: The HG diet aligned with the United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/) and was composed of 55% CHO, 20% fat, and 25% protein. The diet emphasized complex over simple carbohydrates and allowed dairy products, fruits, and vegetables within allowance of the diet.
224059616|NCT01475175|DEVICE|CRT pacing at rest and during exercise|CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
224059617|NCT02171273|BEHAVIORAL|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
224059618|NCT02171273|BEHAVIORAL|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
224059619|NCT02171273|BEHAVIORAL|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
224059620|NCT05352126|OTHER|Biocide|The product being researched, which is a biocide solution in a spray for atmospheric use without a propellant, will be sprayed in the bedroom of each patient at a rate of 2 sprays per day in the evening (half an hour before going to bed).
224059621|NCT02768090|DEVICE|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
224147344|NCT01164865|DEVICE|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
224147345|NCT04046757|OTHER|Mechanical thrombectomy|Neuroradiological endovascular treatment
224301338|NCT01401049|DRUG|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
224301339|NCT01401049|DRUG|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
223452106|NCT01523834|DRUG|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
223452107|NCT04879706|OTHER|None planned|No intervention planned
223452108|NCT04981197|BEHAVIORAL|Baduanjin exercise|Patients in the intervention group underwent a 12-week Baduanjin exercise programme consisting of 12 weeks of Baduanjin exercise, a 35-min Baduanjin exercise demonstration video, a picture-based educational brochure, and a performance record form.
224059622|NCT05560373|DRUG|Huperzine A injection, operational treatment, the best basic treatment|intramuscular
224059623|NCT05560373|OTHER|operational treatment, the best basic treatment|other
224059624|NCT05560373|DRUG|Huperzine A injection, interventional treatment, the best basic treatment|intramuscular
224059625|NCT05560373|OTHER|Interventional treatment, the best basic treatment|other
224059626|NCT05860842|OTHER|exercise|Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
224059627|NCT04288986|BEHAVIORAL|Keep Achieving|The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
224059628|NCT00725881|DRUG|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
223452109|NCT05725824|DEVICE|BTE hearing aid with compatible earmolds|Hearing aids will be fit with three different types of customized earmolds. They will only wear each earmold group for the duration of the test (total = \~2.5 hours). Hearing aids will be programmed to a simulated mild, flat, sensorineural hearing loss of 30 dB HL from 250-8000Hz. A short washout period will follow completion of testing with ear earmold group.
223452110|NCT00219219|DRUG|Zoledronic acid|
223570053|NCT01388439|DRUG|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants \> 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants \> 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants \> 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
224059629|NCT00725881|DRUG|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
224059630|NCT03105167|PROCEDURE|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
224059631|NCT03105167|PROCEDURE|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
224059632|NCT00432042|BIOLOGICAL|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose \[CCID\]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units \[PFU\]).
224059633|NCT00432042|BIOLOGICAL|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
224059634|NCT05060653|OTHER|SBRT followed by surgical stabilization within 24-48 hours|In a first step, patients will undergo SBRT with active sparing of the surgical site. Patients will receive high dose, single to few fractions radiotherapy consisting of a boost to the metastases exclusively. The bony compartment containing the metastatic lesion will receive an elective dose in order to treat subclinical disease. Treatment planning is performed on the pre-treatment CT and MRI data in radiotherapy position that are mutually registered to yield information on all relevant structures for planning. Dose constraints are set for the organ at risks based on institution specific guidelines. All patients will be treated with on online position verification protocol based on institution specific guidelines. Hereafter, surgical intervention will be performed to the standard of care.
224059635|NCT00455390|PROCEDURE|Post-immediate Psychotherapeutic Intervention|
224059636|NCT02648802|PROCEDURE|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
224059637|NCT02648802|PROCEDURE|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
224059638|NCT02527369|DEVICE|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
224059639|NCT01971021|DEVICE|PICC or subcutaneous venous port|
224059640|NCT00277186|OTHER|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
224059641|NCT02822885|RADIATION|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
224059642|NCT06006234|OTHER|questionnaire survey|questionnaire survey
224059643|NCT05517395|BEHAVIORAL|health nutrition education|The participants in intervention group will receive health nutrition education based on a health belief model including nutrition health education (booklet), and telephone call support.
224059644|NCT05517395|BEHAVIORAL|usual care|Control group will only receive usual care. Usual care is routine measurement of children including height, length, weight, head circumference, monitoring children's activities, and monitoring the immunization status of children.
224059645|NCT02710838|DEVICE|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
224059646|NCT01496729|PROCEDURE|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
224059647|NCT01496729|PROCEDURE|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
224301340|NCT03660436|DRUG|BMS-986165|Specified dose on specified days
223452111|NCT03207490|DEVICE|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
224301341|NCT03660436|DRUG|MMF|Specified dose on specified days
223742053|NCT05310045|BEHAVIORAL|Personalised primary prevention intervention|"Personalised primary prevention intervention~1. Consultation 1~   * Assess caregiver's situation regarding their cancer risk factors~  * Explain the causal links between risk factors and cancer~  * Inform about national recommendations to prevent and limit cancer risk~  * Clarify informal caregiver situation with respect to national screening programs~  * Define a personalised primary prevention program~2. Implementation: personalised primary prevention program~   * Carried out by the informal caregiver~  * Supervised by the coordinating nurse~3. Consultation 2~   * Assess prevention actions realised by informal caregiver in relation to actions defined in the personalised primary prevention program~  * Identify barriers and facilitators to their implementation whether actions or no actions have been done.~  * Adapt the personalised primary prevention program to informal caregiver needs."
223742054|NCT00486694|DRUG|Sulfadoxine-pyrimethamine + artesunate|
223742055|NCT00486694|DRUG|Chloroquine|
223742056|NCT01002755|DRUG|Lenalidomide|Given PO
223452112|NCT04131582|COMBINATION_PRODUCT|Linagliptin + metformin and Empagliflozin + metformin|Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
223452113|NCT04131582|DRUG|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
223570054|NCT04709016|BEHAVIORAL|self-questionnaire|self-questionnaire assessing Chemsex's (drug use in a sexual context) consumption over the last 12 months
224059648|NCT03852862|DRUG|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
224059649|NCT03852862|DRUG|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
223570055|NCT00903136|OTHER|questionnaire administration|
223570056|NCT00903136|PROCEDURE|comparison of screening methods|
223570057|NCT00903136|PROCEDURE|diagnostic endoscopic procedure|
223570058|NCT00903136|PROCEDURE|esophagogastroduodenoscopy|
223570059|NCT00903136|PROCEDURE|tethered capsule endoscopy|
223570060|NCT01817699|OTHER|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
223742057|NCT01002755|BIOLOGICAL|Ofatumumab|Given IV
224059650|NCT01585272|DRUG|ENA713|
224059651|NCT02268903|DRUG|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
224059652|NCT02268903|DRUG|Placebo|Placebo in one single direct intra venous injection
224059653|NCT04444999|PROCEDURE|Carbon Dioxide Angiography|• Automated carbon dioxide angiography: Patients are placed in the Trendelenburg position with the feet elevated of 10 º degrees. Carbon Dioxide automatic injection will be performed by digital Angiodroid injection system
224059654|NCT00404690|PROCEDURE|Bedside Silo|silo placed at bedside on admission
224059655|NCT00404690|PROCEDURE|Operative attempt at closure|go the operating room to attempt closure
224059656|NCT05217485|DEVICE|Zio 14-day cardiac patch|A wearble adhesive cardiac patch (14-day) called Zio
224059657|NCT03189823|DEVICE|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
223452114|NCT00667914|PROCEDURE|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
223452115|NCT00667914|PROCEDURE|Orthopedic care as usual|treatment in ordinary orthopedic unit
223570061|NCT01817699|DIETARY_SUPPLEMENT|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
223570062|NCT02124018|PROCEDURE|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
223570063|NCT02124018|DEVICE|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
223570064|NCT01713283|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
223570065|NCT01713283|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
223570066|NCT00017654|DRUG|anti-thymocyte globulin|
223570067|NCT00017654|DRUG|cyclophosphamide|
223570068|NCT00017654|DRUG|cyclosporine|
223570069|NCT00017654|DRUG|methylprednisolone|
223570070|NCT00017654|PROCEDURE|Allogeneic Bone Marrow Transplantation|
223570071|NCT04077866|DRUG|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
223570072|NCT04077866|BIOLOGICAL|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
223570073|NCT02507180|OTHER|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point"
223570074|NCT03262350|BEHAVIORAL|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
223570075|NCT01743235|DRUG|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
223570076|NCT01743235|DRUG|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
223570077|NCT01743235|DRUG|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
223570078|NCT03786302|DRUG|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
223452116|NCT06454643|DRUG|Flucloxacillin and gentamicin|This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
223452117|NCT06454643|DRUG|Flucloxacillin and ceftriaxone|Control group
223570079|NCT03786302|DRUG|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
223570080|NCT03088748|DEVICE|Journey II posterior cruciate retaining total knee arthroplasty|
223570081|NCT03088748|DEVICE|Journey II posterior bi-cruciate retaining total knee arthroplasty|
223570082|NCT00359944|DRUG|AC-3933|5mg twice daily
223570083|NCT00359944|DRUG|AC-3933|AC-3933, 20 mg twice daily
223570084|NCT00359944|OTHER|Sugar Pill|Sugar Pill twice daily
223570085|NCT03326414|PROCEDURE|Constant PEEP - low tidal volume|The respirator is set according to study protocol
223570086|NCT03326414|PROCEDURE|Constant PEEP - high tidal volume|The respirator is set according to study protocol
224059658|NCT03650920|PROCEDURE|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
224059659|NCT03704142|DEVICE|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
224059660|NCT03704142|DEVICE|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
224059661|NCT03704142|DEVICE|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
224059662|NCT03704142|DEVICE|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
224059663|NCT00996268|DRUG|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
224059664|NCT00996268|DRUG|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
224301342|NCT01121666|DRUG|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
224301343|NCT02881164|OTHER|Low glycemic index|Subjects intake a low glycemic index breakfast
223452118|NCT04736719|DRUG|Apixaban|Apixaban dispensing claim is used as the exposure group
223452119|NCT04736719|DRUG|Warfarin|Warfarin dispensing claim is used as the reference group
223452120|NCT03107559|DIAGNOSTIC_TEST|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
223570087|NCT03326414|PROCEDURE|constant tidal volume - low PEEP|The respirator is set according to study protocol
224059665|NCT00732277|DRUG|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
224059666|NCT00427076|DRUG|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.
224059667|NCT00427076|DRUG|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
224059668|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
224059669|NCT02986503|DRUG|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
224059670|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.5mL dose for intramuscular injection
224059671|NCT00336453|BIOLOGICAL|Influenza Vaccination|0.25mL dose for intramuscular injection
224059672|NCT06356298|OTHER|Airway Management: Flexible Reinforced Laryngeal Mask Airway|In the FLMA group, a FLMA was applied according to the manufacturer's recommendations. After lubrication of the posterior surface with oxybuprocaine hydrochloride gel, the FLMA was inserted after propping the shoulders. Its cuff was fully deflated before insertion, and the pressure was adjusted to 40 cm H2O with a manometer after insertion.
223452121|NCT06323213|DRUG|610|610 subcutaneously injection.
223452122|NCT06323213|DRUG|Placebo|Placebo subcutaneously injection.
223452123|NCT03934918|OTHER|Treatment|Patients for IOL are sent home after placement of intracervical balloon
223570088|NCT03326414|PROCEDURE|constant tidal volume - high PEEP|The respirator is set according to study protocol
223570089|NCT02690428|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
223570090|NCT03663127|DIETARY_SUPPLEMENT|Beauty Drink|"Subjects receive two bottles of Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks."
223570091|NCT03663127|DIETARY_SUPPLEMENT|Placebo|Subjects receive two bottles of placebo of similar appearance per day for 8 weeks of a stage. In addition, anthropometric measurements such as blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]), body weight, body fat, waistline, hips, and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST, and ALT were measured every four weeks.
223570092|NCT02584530|PROCEDURE|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
223570093|NCT00993512|DRUG|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
223570094|NCT00993512|DRUG|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
224059673|NCT06356298|OTHER|Airway Management: Endotracheal Tube|In the ETT group, guided by a visual laryngoscope, a ETT was intubated after lubrication of the surface with oxybuprocaine hydrochloride gel: endotracheal tube size = (16+ age) /4. The cuff pressure of ETT was adjusted to 20 cm H2O with a handheld manometer after inflation.
223452124|NCT01909843|BIOLOGICAL|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
223452125|NCT03004768|DRUG|BMS-986165|Oral solution dose of 24 mg \[14C\] BMS-986165 containing approximately 100 micro Ci of TRA
223452126|NCT03059537|DRUG|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
223452127|NCT05613959|DEVICE|Veress +|The Veress+ safety mechanism was used
223452128|NCT05613959|DEVICE|Conventional Veress|The Conventional Veress Needle was used
223452129|NCT03323697|OTHER|SZ-05|2.5g a day (3 capsules twice a day)
223452130|NCT03323697|DRUG|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
223452131|NCT02417558|BEHAVIORAL|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
223452132|NCT02417558|BEHAVIORAL|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
223452133|NCT00829699|PROCEDURE|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
223570095|NCT00993512|OTHER|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
223570096|NCT00497549|PROCEDURE|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
223742058|NCT04295421|PROCEDURE|adductor canal block|ACB was done in the immediate postoperative period under a high-frequency ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.2% ropivacaine was injected in the canal using a 22-gauge 100-mm short-beveled regional block needle and a catheter was kept for 48H with 4 ml/h ropivacaine 0.2%.
223742059|NCT04295421|PROCEDURE|IPACK block|IPACK block was realized after spinal anesthesia with 40 ml 0.2% ropivacaine and at the end of surgery , patients were given ACB with 20 ml 0.2% ropivacaine and continued with 4 ml/H saline for 48H
223742060|NCT03046199|OTHER|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
224059674|NCT04111640|OTHER|CoRe software|Computer-supported cognitive training (CT)
224059675|NCT04111640|OTHER|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
223452134|NCT00829699|PROCEDURE|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
223452135|NCT00829699|PROCEDURE|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
223452136|NCT00829699|PROCEDURE|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
223452137|NCT03282422|DEVICE|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
223452138|NCT03282422|DEVICE|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
223452139|NCT05917483|DIAGNOSTIC_TEST|Ultrasonography|Collect shoulder rotator cuff tendon ultrasound image during isotonic motion
223452140|NCT01834664|BIOLOGICAL|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell \[MNCs \]Per dose at the interval
223452141|NCT06236854|OTHER|Delirium assessment (observational, not interventional)|As an observational study, we will assess the presence of postoperative delirium in the enrolled patients, which will define their group membership.
223742061|NCT03046199|OTHER|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
224059676|NCT01981655|DRUG|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
224059677|NCT01981655|DRUG|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
224059678|NCT00548015|BEHAVIORAL|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
224059679|NCT02908256|DRUG|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI\>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
223452142|NCT04437797|PROCEDURE|Surgical Extrusion|The next step will be atraumatic extraction which will be initiated by using straight periotome until it is sufficiently luxated and gently pulled out to the amount of sufficient ferrule effect without encroaching the biological width. 90- or 180-degrees rotation of the tooth will be done if needed. The tooth will be supported from palatal side, etching will be done using 37% phosphoric acid, rinsing, drying, bonding agent and then application of 3M Filtek flowable composite on rounded 16mm stainless steel wire for splinting in the middle of the tooth without extension of flowable composite neither to the mesial nor to the distal. This procedure should be followed by occlusal adjustment if needed. Splint will be removed after 2 weeks.
223452143|NCT04437797|PROCEDURE|Immediate Implant Placement|The patient is anaesthetized. Atraumatic extraction of the badly broken-down teeth will be performed using peroiotome. Luxation should be done mesiodistally and not buccolingually, 11 to avoid damaging the buccal plate. After tooth removal, a curette is used to confirm that the location of the buccal plate is intact. Standard drilling procedures are performed according to the manufacturer's instructions. Then the implant is placed in the prepared site. Temporization should be done using composite 3M Filtek Z250 XT material. Finally, a porcelain fused to zirconia crown will be performed. Jumping gap occurring subsequent to atraumatic extraction and immediate implant placement more than 2 mm will be grafted using Xenograft.
223570097|NCT00497549|PROCEDURE|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
224059680|NCT02908256|DRUG|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP\> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
224059681|NCT06341530|DRUG|anlotinib combined with penpulimab|single arm
224059682|NCT03765138|COMBINATION_PRODUCT|PE/Pramipexole|"Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events."
224059683|NCT00164112|DRUG|Cooperstown 5+1 alone|
224059684|NCT00164112|DRUG|Azithromycin plus Cooperstown 5+1|
224059685|NCT00164112|DRUG|Telithromycin plus Cooperstown 5+1|
224059686|NCT00164112|DRUG|Levofloxacin plus Cooperstown 5+1|
223452144|NCT06407492|OTHER|Leech|The leeches used in the treatment were obtained from people producing in culture media. Leech therapy was applied to the patients once a week. Before coming to treatment, patients were warned not to use perfume or apply any chemicals on the skin. While no skin preparation was made before the treatment, in patients with cold legs, the area where the leech would be applied was heated to ensure easy adhesion of the leech. The leeches left on their own after approximately 40 to 38 minutes, but the leeches that did not release on their own until 60 minutes were removed by scraping them from the skin with the help of a gauze. The leeches used in the treatment were used only once and the used ones were disposed of by throwing them into medical waste bags. After the leeches were removed from the patient, the wound was covered with a printed bandage. Patients were instructed to remove the bandage after 10-12 hours.
223452145|NCT06407492|OTHER|Conventional Physiotherapy|Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
223570098|NCT01904149|DRUG|Placebo|Placebo single oral dose (first 8 hours)
223570099|NCT01904149|DRUG|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
223570100|NCT01904149|DRUG|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
224059687|NCT05964374|DEVICE|Goal-directed therapy|Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),
224059688|NCT03034564|DRUG|Northera|
224059689|NCT03034564|DRUG|Placebo Oral Tablet|
224059690|NCT01159028|DRUG|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
224059691|NCT01159028|DRUG|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
224059692|NCT00530985|BEHAVIORAL|Benefits Counseling|Help deciding whether to work
224059693|NCT00530985|BEHAVIORAL|VA Orientation|Orientation to services available at VA
224059694|NCT02428842|PROCEDURE|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
224059695|NCT02428842|PROCEDURE|Blood sampling|Blood sampling will be performed before and after treatment.
224059696|NCT01238016|DEVICE|experimental|
224059697|NCT02701452|OTHER|COAGO|blood samples for haemostasis and hormonal data
223570101|NCT01904149|DRUG|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
224059698|NCT04247633|DRUG|Palbociclib|Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
224059699|NCT03924752|DEVICE|Powered hip exoskeleton|The study team will test a powered hip exoskeleton and its capability to improve locomotion.
224070908|NCT02397928|DRUG|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
224301344|NCT02881164|OTHER|High glycemic index|Subjects intake a high glycemic index breakfast
223570102|NCT01904149|DRUG|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
223570103|NCT01904149|DRUG|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
223570104|NCT01904149|DRUG|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
223570105|NCT03193814|DRUG|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
223570106|NCT00812006|DRUG|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
223570107|NCT00812006|DRUG|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
223570108|NCT04854525|RADIATION|Pre reconstruction Radiotherapy|Previous PMRT
223570109|NCT02638389|DRUG|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
223570110|NCT01358812|DRUG|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL\* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
223570111|NCT01796990|BEHAVIORAL|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
224059700|NCT04600245|PROCEDURE|Evaluation of CARTOSOUND-FAM software for accurate three-dimensional reconstruction of the left atrium in patients referred for atrial fibrillation ablation.|One group will undergo the procedure with assistance from the CartoSound-FAM system and the other with the M-FAM system. Data will be collected from all subjects during the ablation procedure and post procedure for a period of 12 months. Either CartoSound-FAM or M-FAM software systems alongside Carto Merge 3D reconstruction will be used during the treatment for atrial fibrillation. Data will be anonymized by removing patient protected health information, only initials will be used
224059701|NCT02745587|RADIATION|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
223570112|NCT01796990|BEHAVIORAL|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
223570113|NCT00838825|OTHER|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
223570114|NCT00831740|OTHER|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
223570115|NCT00831740|OTHER|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
223570116|NCT00235391|DRUG|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
223570117|NCT02924207|OTHER|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
223570118|NCT00000146|DRUG|Methylprednisolone|
223570119|NCT00000146|DRUG|Prednisone|
223570120|NCT04396769|BEHAVIORAL|FLOW-PA|Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
223570121|NCT04396769|BEHAVIORAL|PE class as usual|PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
223584074|NCT05070910|BEHAVIORAL|Therapy|The intervention performed in the practicum will not be able to be influenced by the study investigators and the intervention may be different for each child based on their needs
223742062|NCT03348085|OTHER|No intervention|No intervention.
223742063|NCT01388075|DRUG|Rifampicin|oral, 450 mg/day , 7 days
224059702|NCT02676089|DRUG|CHF 5993 200/6/12.5 µg|
224059703|NCT02676089|DRUG|CHF 1535 200/6 µg|
224059704|NCT02676089|DRUG|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
224059705|NCT06348485|OTHER|Patients without massive nasal bleeding|No event of massive nasal bleeding after curative radiotherapy
223452146|NCT06407492|OTHER|Kinesiotape|"In this taping technique, skin color, 5cmX5m kinesio tape material was used. Again, the patient standing upright will be prepared in terms of clothing and skin. The standing patient will then be asked to lean forward. Taping will be done using a special muscle technique for this group. When applying tape to the right paravertebral region, first the lower end of the tape will be adhered 7 cm below the sacroiliac joint, at the level of the paravertebral muscles. When applying tape to the left paravertebral region, the same procedure will be done in reverse as on the right, and the tape will not be stretched at all. The third tape will be applied to the patient who is standing upright and bending slightly forward, passing over the sacroiliac joints and parallel to the ground, with the tape stretched by 25%."
223452147|NCT05514613|OTHER|retrospektif study; The effect of tracheostomy tecnique method on complications|retrospektif study; The effect of tracheostomy tecnique method on complications complications and correlation of complications with techniques
224059706|NCT06348485|OTHER|Patients with massive nasal bleeding|Any event of massive nasal bleeding after curative radiotherapy
224059707|NCT03803059|DEVICE|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
223452148|NCT00306410|DRUG|colecalciferol|
223452149|NCT00461929|PROCEDURE|bone marrow aspiration|
223452150|NCT02773420|PROCEDURE|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
223570122|NCT05697289|OTHER|satisfaction survey|Non-comparative longitudinal observational study over 12 months conducted during usual follow-up of patients living with HIV-1 and having changed treatment for an injectable dual therapy with prolonged release cabotegravir-rilpivirine. Decision to change treatment and follow-up of patients are part of routine care. Study is proposed after the doctor has taken the decision to modify treatment, the patient has accepted and injectable dual therapy is prescribed. It is based on self-questionnaires to collect patient perceptions (Patient-Reported Outcomes) and clinical and biological data collected routinely at inclusion and during follow-up visits.
223570123|NCT02181361|DRUG|hirudin plus aspirin|natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
223570124|NCT02181361|DRUG|Warfarin|an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
223570125|NCT02956044|DRUG|Bexagliflozin|Bexagliflozin tablets, 20 mg
223570126|NCT02956044|DRUG|Metformin|1000 mg metformin
223570127|NCT02956044|DRUG|Glimepiride|4 mg glimepiride
223570128|NCT02956044|DRUG|Sitagliptin|100 mg sitagliptin
223570129|NCT05115240|BEHAVIORAL|Body Scan|The body scan intervention aims to raise one's awareness of one's own body. It is considered a relaxation, meditation or mindfulness intervention. During the body scan participants will walk through his or her body by focusing their mind on specific body parts without analyzing, judging or reacting.
223570130|NCT05115240|OTHER|Audio-book|Participants listen to an audio book for the same amount of time as the body scan groups
223570131|NCT04726033|DRUG|64Cu-DOTA-TLX592|TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
223570132|NCT04860934|BEHAVIORAL|Dual Task Training Program Group|Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
223570133|NCT04860934|BEHAVIORAL|Control Group|Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
223570134|NCT06112821|OTHER|Data collection in medical records|Data collection in medical records
223570135|NCT06112821|OTHER|Blood sampling|Blood plasma and serum collection for biobanking. Future laboratory analyses encompass the analysis of endothelial dysfunction markers and other markers implicated in APS.
224059708|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
224059709|NCT03235830|BEHAVIORAL|Enhanced Standard of Care (ESoC)|See above in arm/group description
223570136|NCT03496233|DRUG|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
223570137|NCT01231542|DRUG|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
224059710|NCT01231594|DRUG|GSK2118436|Study Drug
224059711|NCT01231594|DRUG|GSK1120212|Study Drug
223570138|NCT01231542|DRUG|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
223570139|NCT01231542|DRUG|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
223570140|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
223570141|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
223570142|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
224059712|NCT01231594|DRUG|Other approved anti-cancer agent|Study Drug
224059713|NCT05675540|DEVICE|Macusense Assessment Software|Macusense is software designed to assess change in status and response of patients eyes undergoing intravitreal treatment for macular conditions. The output of the Macusense software will be compared with the decision of the treating clinician.
224059714|NCT05462015|BEHAVIORAL|elastic-band exercises|The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
224059715|NCT05462015|BEHAVIORAL|regular rehabilitation|The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
224059716|NCT01325922|PROCEDURE|DFT Testing with a 50/50% tilt|
224059717|NCT03115736|DRUG|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
223452151|NCT03534739|OTHER|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
223452152|NCT03534739|OTHER|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
223452153|NCT03534739|OTHER|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
223452154|NCT03231397|DRUG|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
223452155|NCT03231397|DRUG|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
223452156|NCT03231397|DIAGNOSTIC_TEST|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
223452157|NCT03184779|OTHER|Ski and Snowboard Safety Video|The ski and snowboard safety video (\~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
223452158|NCT04686708|OTHER|Emergency general surgical admissions|All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
223452159|NCT05348954|OTHER|EX-PLISSIT MODEL|The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
224059718|NCT01027819|DEVICE|Mobile bearing|Mobile bearing in total knee arthroplasty
223452160|NCT04076319|BEHAVIORAL|CAPABLE: Community Aging in Place-Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
223452161|NCT02840773|OTHER|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
223452162|NCT02840773|OTHER|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
223452163|NCT02840773|OTHER|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
223452164|NCT02840773|OTHER|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
223452165|NCT02840773|OTHER|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
223570143|NCT00098748|DRUG|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
223570144|NCT00098748|DRUG|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
223570145|NCT00570037|BIOLOGICAL|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
223570146|NCT01868620|DEVICE|Iontophoretic CXL|
223570147|NCT01868620|DEVICE|Standard CXL|
223570148|NCT05372731|OTHER|Recruitment Maneuver|RM after BAL
224059719|NCT01027819|DEVICE|Fixed bearing|Fixed bearing in total knee arthroplasty
224059720|NCT06170424|PROCEDURE|spray skin|The patients who used the autologous skin cell suspension combined with skin grafting.
224059721|NCT06170424|PROCEDURE|Control group|The patients who used skin grafting.
224059722|NCT04013529|BEHAVIORAL|Regret lottery|Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
224059723|NCT04013529|BEHAVIORAL|Way to Health technology enhanced care|Subjects receive text reminders to reach activity goals.
224059724|NCT01763619|DEVICE|Freedom Cervical Disc|
223570149|NCT02777606|DRUG|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
223570150|NCT05404347|DIAGNOSTIC_TEST|Next generation sequencing|NGS is carried out on DNA isolated from paraffin embedded tissue
223570151|NCT01097642|DRUG|Cetuximab|Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.
223570152|NCT01097642|DRUG|Ixabepilone|Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
223584075|NCT05618886|OTHER|Education|The education about urinary incontinence, PFM and PFMT together with lifestyle behavior modifications such as using the knack, maintaining healthy weight, toilet habits, and reducing constipation and intra-abdominal pressure will be provided along with the PFMT instruction.
223452166|NCT01962194|DEVICE|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
223452167|NCT04211558|DRUG|Ozanimod|Ozanimod
223452168|NCT02374619|DIETARY_SUPPLEMENT|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]
223452169|NCT02374619|DIETARY_SUPPLEMENT|Placebo|
223452170|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
223452171|NCT01054222|DRUG|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
223452172|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
223452173|NCT00824655|BIOLOGICAL|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
223452174|NCT06307405|DIAGNOSTIC_TEST|next generation sequencing|All the enrolled patients had undergone fiberbronchoscopy and sputum had been retained. The collected alveolar lavage fluid and sputum were examined for mNGS and routine etiology, respectively
223452175|NCT04711343|DRUG|BAT2306|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
223452176|NCT04711343|DRUG|Cosentyx (US-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
223570153|NCT04715789|BEHAVIORAL|graded exposure and activity|"1. Graded exposure: This approach followed a model where the patient was gradually exposed to previously pain provocative, feared and or avoided tasks. These activities are started at a diminished level that elicits minimal amounts of fear and then gradually increased to situations that elicit larger amounts of fear patients are asked to create a hierarchy of feared activities. The exposure starts with the least feared activity, and the therapist helps the patient appraise the exposure and its consequences and then address irrational and counterproductive beliefs, leading to reductions in the anxiety associated with the activity~2. Graded activity exercises: The new postural and movement behaviors were integrated into each person's nominated pain provocative functional activities linked to their goals in order to generalize learning and build self-efficacy the program focuses on functional activities and progresses in a time contingent manner"
223570154|NCT03264105|OTHER|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
223570155|NCT03264105|OTHER|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
223570156|NCT01728506|BEHAVIORAL|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
223570157|NCT03798054|DRUG|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223570158|NCT03798054|DRUG|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
223452177|NCT04711343|DRUG|Cosentyx (EU-licensed)|150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
223570159|NCT03798054|DRUG|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224301345|NCT01112943|OTHER|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
223452178|NCT06477380|BEHAVIORAL|ACCEPT intervention|"* Training package (1 day)~* A toolkit/manual for clinicians to guide them through the disclosure process~* Trauma-informed changes to the physical environment~* Monthly trauma-focussed reflective group for care co-ordinators"
223452179|NCT05391880|DRUG|BEBT-503 20mg|BEBT-503 capsule
223452180|NCT05391880|DRUG|BEBT-503 40mg|BEBT-503 capsule
223452181|NCT05391880|DRUG|BEBT-503 80mg|BEBT-503 capsule
223452182|NCT05391880|DRUG|BEBT-503 120mg|BEBT-503 capsule
223452183|NCT05391880|DRUG|BEBT-503 180mg|BEBT-503 capsule
223452184|NCT05391880|DRUG|placebo 20mg|placebo capsule
223452185|NCT05391880|DRUG|placebo 40mg|placebo capsule
223452186|NCT05391880|DRUG|placebo 80mg|placebo capsule
223452187|NCT05391880|DRUG|placebo 120mg|placebo capsule
223570160|NCT03798054|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223570161|NCT03798054|DRUG|SGLT2 inhibitor|"Pharmaceutical form:tablet~Route of administration: oral"
223584076|NCT05618886|OTHER|Education and PFMT|Along with education twelve weekly face-to-face sessions of PFMT with exercises individually or in groups with the women's health physiotherapist will be offered. PFMT will be taught on the basis of observation, vaginal palpation and camtech manometry, and will be individualized initially to suit each participant's ability within a protocol encouraging 10 close-to-maximum contractions and 6-8-second hold with a 10-second rest between contractions. During the first two appointments, participant's will be instructed to perform two sessions with rest in between and thereafter three times 10 contractions if possible during each visit. The participant's will be encouraged to perform daily PFMT (10 contraction x 3 10times, 3 sets) at home and will be asked to record their PFMT in an exercise diary.
223584077|NCT05559125|DRUG|STSA-1002 Injection|Intravenous injection
224301346|NCT01112943|OTHER|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
223452188|NCT05391880|DRUG|placebo 180mg|placebo capsule
223452189|NCT06178042|COMBINATION_PRODUCT|MI Paste Plus|Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
223452190|NCT06178042|COMBINATION_PRODUCT|Remin Pro|The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.
223452191|NCT06178042|COMBINATION_PRODUCT|Control|Patients instructed to follow a routine home care.
224301347|NCT01112943|OTHER|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
223452192|NCT01183507|BEHAVIORAL|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
223452193|NCT01183507|BEHAVIORAL|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
224059725|NCT04398875|OTHER|Acupuncture and standard care (ASC)|A semi-standardized treatment protocol and standard care will be employed.
223452194|NCT05345366|OTHER|non-applicable|non-applicable
223452195|NCT00193739|DRUG|NACT|3 cycles of neoadjuvant chemotherapy
223570162|NCT04148196|OTHER|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 27-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
223570163|NCT03104972|DEVICE|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
224059726|NCT04398875|OTHER|Sham acupuncture and standard care (SSC)|Validated non-insertion sham acupuncture (Streitberger sham acupuncture) and standard care will be applied.
224059727|NCT04398875|OTHER|Standard care (SC)|Standard care will be employed.
224059728|NCT04884321|OTHER|Complementary And Alternative Medicine|No intervention was done in the cross-sectional study
224059729|NCT04020601|DRUG|Ropivacaine|Local anesthetic injection
224059730|NCT04020601|DRUG|Dextrose|Sham injection
224059731|NCT05041751|PROCEDURE|Acupuncture Point Injection|Receive trigger point injections
224059732|NCT05041751|PROCEDURE|Massage Therapy|Perform myofascial release
224059733|NCT05041751|OTHER|Quality-of-Life Assessment|Ancillary studies
224059734|NCT05041751|OTHER|Questionnaire Administration|Ancillary studies
224059735|NCT03116698|DRUG|Low dose DFD07 once daily|Low dose DFD07 once daily
224059736|NCT03116698|DRUG|High dose DFD07 once daily|High dose DFD07 once daily
224059737|NCT03116698|DRUG|High dose DFD07 twice daily|High dose DFD07 twice daily
224059738|NCT03116698|DRUG|Placebo twice daily|Placebo twice daily
223452196|NCT00193739|PROCEDURE|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
223452197|NCT00193739|DRUG|Inj.Cisplatin|Concurrent chemo radiotherapy
223452198|NCT00193739|RADIATION|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
223452199|NCT03252145|DEVICE|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
223452200|NCT03252145|OTHER|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
223452201|NCT04168320|RADIATION|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
224059739|NCT00788372|DRUG|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
223452202|NCT04558671|OTHER|asthma exacerbations|to collect the number of asthma exacerbations between the 2 latent classes of patients within the year following bronchoscopy
223452203|NCT03504189|DEVICE|PregSense™|PregSense™ wearable device will be applied for maternal-fetal monitoring
224059740|NCT06317909|OTHER|allergen challenge|Patients will undergo inhaled allergen challenge followed by different measures like MRI and induced sputum. At least 4 weeks later patients will undergo segmental allergen challenge followed by different measures like bronchoalveolar lavage.
224059741|NCT00817232|DEVICE|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
224059742|NCT05071976|DIAGNOSTIC_TEST|ICG-NIR angiography|Capture NIR video of flap site beginning at time of ICG injection. At time of subjective peak intensity, capture video of flap and recipient wound bed. Measure rate of ICG egress from the global flap at 60, 120, and 180 seconds after initial dye injection from intraoperative video
224059743|NCT06046872|BEHAVIORAL|Report-back training|Researchers participate in a report-back training program to evaluate potential impacts on knowledge and future behaviors with respect to sharing personal exposure results with study participants.
224059744|NCT06965140|DEVICE|flat 1-piece open ostomy device|OCT scan and skin measurements of peristomal and abdominal skin
224059745|NCT05962138|BEHAVIORAL|Digital Cognitive Behavioural Therapy for Insomnia|6-10 weeks of digital cognitive behavioural therapy for insomnia (Sleepio) delivered online. In addition participants will receive a booklet published by Versus Arthritis designed for patients with fibromyalgia with general advice, including sleep hygiene.
224059746|NCT04963556|DIETARY_SUPPLEMENT|Red Bull|Drinking of Red Bull before exercise
224147346|NCT00347412|DRUG|Paclitaxel|"Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first."
223452204|NCT03504189|DEVICE|Cardiotocopraphy (CTG)|Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
223452205|NCT04307524|PROCEDURE|laparoscopic repair|laparoscopic suture repair of cesarean scar niche
223452206|NCT04307524|DRUG|medical treatment in the form of combined hormonal contraception|"patient will receive for three months daily without interruption, no pill-free interval drug names is Genera BAYERhealthcare"
223452207|NCT04595929|PROCEDURE|Staging laparoscopy|All patients undergo staging laparoscopy and peritoneal lavage.
224147347|NCT00347412|DRUG|NOV-002|"* Two 60 mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~* For each nominal 21-day paclitaxel and carboplatin cycle:~  * 60 mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~ * followed by 60 mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
224147348|NCT00347412|DRUG|Carboplatin|"Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
223452208|NCT04595929|DRUG|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
223452209|NCT04595929|DRUG|Leucovorin|Day 1 q2w: 200 mg/m² IV over 30 minutes
223452210|NCT04595929|DRUG|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
223452211|NCT04595929|DRUG|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
223452212|NCT04595929|PROCEDURE|Radical surgery|Radical gastrectomy with D2 - lymph node dissection.
223452213|NCT04595929|PROCEDURE|PIPAC|Intraoperative Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin 7,5 mg/m², doxorubicin 1,5 mg/m².
223452214|NCT04595929|DRUG|Adjuvant chemotherapy|Adjuvant chemotherapy according to indications.
223452215|NCT03286621|OTHER|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
223452216|NCT01398657|DRUG|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
223452217|NCT03091738|DRUG|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
223570164|NCT03104972|DEVICE|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
223570165|NCT03104972|DEVICE|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
223570166|NCT01828619|PROCEDURE|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m\^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
223570167|NCT00406705|BEHAVIORAL|Helium-Hyperoxia|
223570168|NCT03762889|DEVICE|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
223570169|NCT03762889|DEVICE|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
223570170|NCT03762889|DEVICE|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
223570171|NCT04763486|DRUG|Cefazolin (Cefamezin)|Cefamezin 2 gr within 6 hour of delivery
223452218|NCT01258478|OTHER|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
223452219|NCT01258478|OTHER|Usual care|Usual care
223452220|NCT04336475|OTHER|orofacial exercise program|combined stretching\&strengthening exercise regimen
223452221|NCT01147562|PROCEDURE|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
223452222|NCT03335683|DRUG|Lenidase|drug per os twice day for 7 days, or for 10 days
223452223|NCT03592849|PROCEDURE|UC-MSCs therapy|After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
223570172|NCT05482815|DEVICE|Provox Vega Voice prosthesis|Voice prosthesis for speech rehabilitation, Provox Vega Voice prosthesis
223570173|NCT03256903|DRUG|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
223570174|NCT03256903|DRUG|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
224059747|NCT06968663|DEVICE|Transcranial Magnetic Stimulation (TMS)|TMS, is a form of non-invasive brain stimulation, that uses magnetic pulses to stimulate specific areas of the brain. In this study we will utilize theta-burst stimulation which uses a higher frequency pulse of 50 Hz delivered for 40 seconds for a total of 600 pulses.
224059748|NCT06968663|BEHAVIORAL|Modified Constraint Induced Language Therapy (mCILT)|Constraint-induced language therapy (CILT) is a treatment approach for aphasia that focuses on forcing the patient to use their impaired language skills, while restricting the use of compensatory strategies like gestures or writing. All participants will receive mCILT.
224147349|NCT06017648|DEVICE|Non Invasive Ultrasound (FUBA5200)|the Focused Ultrasound Fat Reduction device (FUBA5200) is manufactured by Shanghai Carnation Medical Technology Co., Ltd
224147350|NCT06017648|DEVICE|Non Invasive Ultrasound (Contour I V3)|the Focused Ultrasound Fat Reduction device (Contour I V3) is manufactured by Syneron Medical Ltd.
224070909|NCT05079503|DRUG|GEN-001|GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
223570175|NCT03568552|BEHAVIORAL|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
223570176|NCT04676308|OTHER|Artificial Intelligence|Artificial intelligence
223570177|NCT01081301|BEHAVIORAL|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
223570178|NCT06826677|DRUG|Durvalumab|PATIENTS INCLUDED IN AN EARLY ACCESS PROGRAMME TREATED WITH DURVALUMAB IN COMBINATION WITH PLATINUM AND ETOPOSIDE AS FIRST-LINE THERAPY
223584078|NCT05559125|DRUG|STSA-1005 Injection|Intravenous injection
223584079|NCT00343863|DRUG|palonosetron hydrochloride|Given IV
224070910|NCT01256437|DRUG|Threolone ointment|ointment once daily for 1 month
224070911|NCT01256437|DRUG|ointment Synthomycine|ointment once daily for 1 month
224070912|NCT01256437|DRUG|Aqua cream|ointment once daily for 1 month
224070913|NCT01637142|DRUG|LY2140023|Administered orally.
224070914|NCT01637142|DRUG|14C-LY2140023|Administered IV.
224070915|NCT01637142|DRUG|14C-LY404039|Administered IV.
224070916|NCT02111564|DRUG|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (\>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
224070917|NCT02111564|DRUG|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from \>=30 to less than (\<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
224070918|NCT02111564|DRUG|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
224070919|NCT05654844|RADIATION|LC images|Angular and Linear Measurements were compared in mandibular symphysis region using the LC images
224070920|NCT05654844|RADIATION|CBCT images|Angular and Linear Measurements were compared in mandibular symphysis region using the CBCT images
224070921|NCT02852382|DRUG|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
224070922|NCT02852382|DRUG|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
224070923|NCT00687362|BIOLOGICAL|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
224070924|NCT02950519|OTHER|monitoring of cuff pressures|Cuff pressure will be checked per standard and additionally a minimum of every 8 hours.
224070925|NCT03428581|PROCEDURE|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
224070926|NCT03428581|PROCEDURE|ALND|Prospective and retrospective subjects undergoing an ALND.
224070927|NCT06126991|DRUG|Cetirizine|Oral administration of cetirizine at 10mg once daily will be used.
224070928|NCT06126991|DRUG|Midazolam and Fentanyl|Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
224070929|NCT06539598|OTHER|Respiratory Strength Training (RST)|Respiratory Strength training involves inhaling/exhaling against a fix resistant to potentially increase respiratory strength
224059749|NCT06526585|BEHAVIORAL|Cyclic Sighing Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing practice during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the cyclic sighing during the 2 MRI assessments.~The cyclic sighing protocol consists of a breathing pattern that involves inhaling deeply, starting abdominally, inhaling through the nose until lungs feel comfortably filled, immediately followed by a second shorter inhale, also through the nose, to maximally inflate the lungs. Then participants are instructed to slowly exhale through the mouth until their lungs feel empty. This cycle is repeated for 10 minutes."
224059750|NCT06526585|BEHAVIORAL|Box Breathing|"Participants are instructed to be seated or lying down, and can keep their eyes open or closed throughout the 10 minutes of the breathing during the 28 days. Participants are instructed to keep their eyes closed when practicing the 10 minutes of the box breathing during the 2 MRI assessments.~The CO2 tolerance test is done at baseline to determine their comfort level with the duration of each side of the box during box breathing.~The box breathing protocol consists of a four-part breathing technique. The practice involves breathing through the nose in four equally timed parts: inhale, hold, exhale, and hold again, forming a 'box' of breaths (e.g. 4 sec inhale, 4 sec hold, 4 sec exhale, 4 sec hold).This cycle is repeated for 10 minutes."
224059751|NCT06526585|BEHAVIORAL|Hypnosis|Participants are instructed to sit comfortably or lie down during the 28 day at home practice (Participants will be lying down in the scanner during the 2 MRIs). Then participants are asked to look up, slowly close their eyes, take a deep breath, slowly exhale, and let their body float, and then to imagine floating in a bath, a lake, a hot tub, or floating in space. Participants are then asked to picture an imaginary screen and visualize a place where it would naturally feel comfortable and relaxed. The participants then divide the screen in half and picture on the left side one thing that is causing them stress, with the rule that no matter what the participant picture, to keep their body comfortable and relaxed. Then on the right side of the screen the participants are asked to picture one thing that can be done about the problem on the left. At the end the participant will be guided to come out of the state of hypnosis. This exercise will take 10 minutes.
223452224|NCT04762394|BEHAVIORAL|The Child Behavior Checklist (CBCL),|It consists of 113 items; the parents complete it to detect emotional and behavioural problems in children and adolescents aged 6 to 18 years. It is scored on a three-point Likert scale (0=absent, 1= occurs sometimes, 2=occurs often). The time duration for item responses is the past six months.
223452225|NCT01863342|PROCEDURE|CSI score < 40|
223452226|NCT01863342|PROCEDURE|CSI score ≥ 40|
223452227|NCT04240951|OTHER|Sweat patch|Flexible, epidermal, wearable skin patch to collect and analyze sweat
223452228|NCT02456025|DRUG|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
223452229|NCT05660252|OTHER|Collaborative request|The relative is approached by the clinical team and an organ procurement coordinator together.
223452230|NCT02164643|DRUG|Flutemetamol (18F)|
224147351|NCT05457348|PROCEDURE|Planned incisions during phacoemulsification|Planned three (one 2.8 mm and two 2.0mm) on the or near to steep meridian will be performed in the experimental group during phacoemulsification
224147352|NCT05894044|OTHER|Russian current 10%|Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
224147353|NCT05894044|OTHER|Aussie current 10%|Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
224147354|NCT05894044|OTHER|Pulsed current 500 µs phase|Pulsed current, modulated in 50 Hz, 500 µs
224147355|NCT05894044|OTHER|Pulsed current 200 µs phase|Pulsed current, modulated in 50 Hz, 200 µs
223452231|NCT02164643|DRUG|Florbetapir (18F)|
223452232|NCT03743727|DRUG|Combined therapy LDV and SOF|All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
223452233|NCT04418050|PROCEDURE|Shoulder arthroplasty|Surgery consisting in replacement of gleno-humeral joint by a shoulder prosthesis
223452234|NCT03629808|PROCEDURE|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
223452235|NCT03629808|PROCEDURE|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
223452236|NCT03304106|DEVICE|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
223452237|NCT04238338|OTHER|monocyte / lymphocyte ratio|The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
223452238|NCT00510055|PROCEDURE|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
224147356|NCT06182930|OTHER|Within the scope of the research, caregivers will be given face-to-face training in 2 sessions, 15 days apart.|They will receive routine home health care follow-up.
224147357|NCT04209257|DEVICE|Functional Electrical Stimulation.|Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
224147358|NCT04715048|DRUG|PrabotulinumtoxinA|Glabellar line correction
223452239|NCT00510055|PROCEDURE|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
223452240|NCT04649879|BIOLOGICAL|SARS-CoV-2 convalescent plasma|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay \>9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.
223452241|NCT04649879|OTHER|Standard of care|Standard of care as determined by hospital practices for COVID-19 patients.
223452242|NCT03845621|DEVICE|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
223452243|NCT03845621|DEVICE|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
223452244|NCT00030485|DRUG|erlotinib hydrochloride|
223452245|NCT03077425|BEHAVIORAL|Enhanced Usual Care (EUC)|Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.
223742064|NCT02629692|DRUG|Vodobatinib (K0706) capsules|"Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily."
223742065|NCT06308809|OTHER|PNF training|The subjects underwent rehabilitation training for 8 weeks, three times a week (Monday, Wednesday and Friday, 6:00 PM to 10:00 PM in the Physical Education College of Guangxi Normal University), and the rehabilitation training time was about 40-45 minutes per person. Before each rehabilitation training, the subjects warmed up the ankle and lower leg muscles for 5 minutes, followed by the corresponding rehabilitation training for 30-35 minutes, and relaxed the ankle and lower leg muscles for 5 minutes after the training.
223742066|NCT02710890|DRUG|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
223742067|NCT03801564|DEVICE|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
223742068|NCT03801564|DEVICE|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
223742069|NCT03669120|OTHER|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
223742070|NCT03669120|BEHAVIORAL|Telephone-Based Intervention|Receive individualized text based messages
223742071|NCT01150929|DEVICE|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
223742072|NCT04092166|OTHER|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
223742073|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
223742074|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
223742075|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
223742076|NCT01520116|DRUG|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
223742077|NCT01520116|DRUG|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
223742078|NCT01520116|DRUG|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
223742079|NCT01520116|DRUG|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
223742080|NCT01520116|DRUG|Timoptic|0.5%
223742081|NCT03051542|DEVICE|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
223742082|NCT00056030|BIOLOGICAL|cetuximab|
223742083|NCT00056030|DRUG|fluorouracil|
223742084|NCT00056030|DRUG|leucovorin calcium|
223742085|NCT00056030|DRUG|oxaliplatin|
223742086|NCT05351346|DRUG|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
223742087|NCT05351346|DRUG|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
223742088|NCT05351346|DRUG|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
223742089|NCT05351346|DRUG|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
223742090|NCT05351346|DRUG|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
223742091|NCT05351346|DRUG|Orelabrutinib|Orelabrutinib PO will be administered as per the schedule specified in the respective arm.
223742092|NCT05351346|DRUG|Lenalidomide|Lenalidomide PO will be administered as per the schedule specified in the respective arm.
223452246|NCT03077425|BEHAVIORAL|Intervention|Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
223742093|NCT05351346|DRUG|Decitabine|Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
223742094|NCT04968899|DRUG|Neofordex®|Oral dexamethasone (Neofordex®) 40 mg (Day1 to Day 4), ± an additional 4-days cycle of dexamethasone between days 10 and 21.
223742095|NCT04968899|DRUG|Intravenous immunoglobulins|IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))
223742096|NCT03745326|DRUG|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
223742097|NCT03745326|DRUG|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m\^2/day IVPB daily over 30 minutes for 5 days.
223742098|NCT03745326|DRUG|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
223742099|NCT03745326|BIOLOGICAL|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
224059752|NCT06526585|BEHAVIORAL|Audiobook|Participants are instructed to be seated or lying down, and can keep eyes open or closed throughout the 10 minutes of listening to the audiobook during the 28 days. Participants are instructed to keep their eyes closed during the 2 MRI assessments.
224059753|NCT03853603|DIETARY_SUPPLEMENT|Santa herba|Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
224147359|NCT04715048|DRUG|Onabotulinum toxin A|Glabellar line correction
224059754|NCT03853603|DIETARY_SUPPLEMENT|Placebo|Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
224059755|NCT05918575|DEVICE|Noninvasive ventilation alternating with high flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.
224059756|NCT05918575|DEVICE|High flow nasal cannula|A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
224059757|NCT00887237|DEVICE|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
224059758|NCT00887237|DEVICE|Conventional cardiac resynchronization|Conventional cardiac resynchronization
224059759|NCT04048616|DIETARY_SUPPLEMENT|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
224059760|NCT04048616|DIETARY_SUPPLEMENT|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
224059761|NCT04048616|OTHER|microcrystalline cellulose|identical placebo capsule
224059762|NCT04048616|OTHER|maltodextrin powder|isocaloric placebo powder
224059763|NCT06543823|DEVICE|SupraTHEL 250|the membrane is placed onto the wound bed and fixed in place by resorbable interrupted sutures
224059764|NCT06543823|OTHER|Comparator|no membrane is placed onto the wound bed , left bare to heal
224059765|NCT05815719|DRUG|Corifollitropin Alfa|150 micrograms per dose
224059766|NCT05815719|DRUG|Follitropin Alfa|Variable dose.
224059767|NCT05815719|DRUG|Follitropin Alfa Biosimilar|Variable dose.
224059768|NCT05815719|DRUG|Urinary Human follicle stimulating hormone|Variable dose.
224059769|NCT05485155|DRUG|Alpha-proteinase inhibitor|Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.
224059770|NCT02389751|DRUG|Carboplatin|Given IV
224059771|NCT02389751|DRUG|Ganetespib|Given IV
224147360|NCT02633839|DRUG|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
224059772|NCT02389751|DRUG|Paclitaxel|Given IV
224059773|NCT02389751|RADIATION|Radiation Therapy|Undergo radiation therapy
224059774|NCT04071847|DEVICE|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical signals to targeted structures in the brain to modulate neural circuit activity, and has been used successfully for the treatment of various types of movement disorders, including Parkinson's disease (PD), disabling or essential tremor, and dystonia
224059775|NCT05020171|DEVICE|Group of strength training|2x a week during 5 weeks, strengthening of weak muscles with the intensity recommended in the literature, i.e. 3-4x15 repetition at an intensity of 50 to 80% of the maximum force combined with serious games to stimulate patient involvement in strength training
224059776|NCT05020171|OTHER|Group of physiotherapy not focus on strength training|2x a week during 5 weeks, active physical therapy treatment based on movement
224059777|NCT02306109|PROCEDURE|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
224059778|NCT02306109|PROCEDURE|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
224059779|NCT06972173|OTHER|DEEP BREATHING AND PROGRESSIVE MUSCLE RELAXATION EXERCISES|"For deep breathing exercises, students were asked to place their dominant hand on their abdomen and non-dominant hand on their chest in the semi-fowler position. Afterwards, they were instructed to breath deeply through their nose for 4 seconds and exhale through their mouth for 8 seconds. These exercises were performed as 4 repetitions with 2 minutes rest time between the exercises. When the deep breathing exercises were finished, the students lay on their backs and rested for 1 minute and then progressive muscle relaxation exercise was started (10,11).~For the progressive muscle relaxation exercise, the students were asked to contract and then relax the right foot, left foot, right leg, left leg, hip, abdominal muscles, chest muscles and back muscles, right hand, left hand, right arm, left arm, neck and shoulders, and facial muscles respectively. Respectively, from bottom to top, all the major muscles are contracted while inhaling deeply and slowly, and relaxed and r"
224059780|NCT01018628|DRUG|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
224059781|NCT01018628|DRUG|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
224059782|NCT05546125|OTHER|as per Physician's prescription|Participants need to take the Revatio as per Physician's prescription
224059783|NCT03099187|DRUG|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
224059784|NCT03099187|DRUG|Placebo|Matching placebo capsules three times in a day.
224059785|NCT03558984|DRUG|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
224059786|NCT03558984|OTHER|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
224059787|NCT05248295|BEHAVIORAL|Unison speech (vs. solo)|Participants will repeat sentences in four conditions, in a 2x2 design with the factors unison vs. solo repetition, and metrical vs. conversational speech timing. Measures of speech accuracy and timing will be collected.
224059788|NCT05248295|BEHAVIORAL|Metrical timing (vs. conversational)|This is the secondary contrast in the 2x2 design described above.
224059789|NCT01053871|DRUG|propofol|conscious sedation using propofol
224059790|NCT01053871|DRUG|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
224147361|NCT02633839|DRUG|Carbidopa|Administered orally according to the carbidopa dosing schedule.
223452247|NCT05313399|DEVICE|Palatal Crib|An intraoral appliance approach can be used as an adjunct method to stop the habit. Appliances consisting of cribs in the anterior region are very efficient as reminders and physical restrainers. The palatal crib works as an obstacle in non-nutritive sucking and maintains the tongue in a more retruded position, halting its interposition between the incisors.
223452248|NCT05313399|DEVICE|bonded spur|Spur appliances change tongue action, close the open bite, and boost treatment stability, as it induces a permanent modification of the tongue's anterior rest posture by altering orofacial function, resulting in a change in form. Finally, the spur adjusts the sensory input to the brain. This proprioceptive change leads to an altered motor response, resulting in a new normal tongue rest posture (change in function) that allows the incisors to erupt
223452249|NCT06274619|BIOLOGICAL|RSV A Memphis 37|RSV A Memphis 37 challenge agent
223452250|NCT06121531|DEVICE|Soft Contact Lens|Vision Correction
223570179|NCT03551665|BEHAVIORAL|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
224059791|NCT02874456|OTHER|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
224059792|NCT04543799|DEVICE|polysomnography, actigraphy, questionnaires|sleep quality recording
224059793|NCT03650816|OTHER|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
224059794|NCT03650816|OTHER|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
224059795|NCT06650033|RADIATION|Adaptive radiotherapy +/- margin reduction|Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
224059796|NCT06650033|RADIATION|Image guided radiotherapy|Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
224147362|NCT04180995|DRUG|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
223570180|NCT02725112|DRUG|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
223570181|NCT02725112|DRUG|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
223570182|NCT02725112|DRUG|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
223570183|NCT02725112|DRUG|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
223570184|NCT02725112|DRUG|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
223570185|NCT02725112|DRUG|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
223570186|NCT00495924|PROCEDURE|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
223570187|NCT01833234|OTHER|Interviews and questionnaires|
223570188|NCT06286826|PROCEDURE|Postero-lateral thoracotomy|this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture
223570189|NCT06286826|PROCEDURE|Minithoracotomy|Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)
223570190|NCT06024837|OTHER|CT Images|Analysis of CT images of peritoneal and/or liver metastases from colorectal cancer
224059797|NCT03091075|DRUG|Oxandrolone|Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
224059798|NCT03091075|DRUG|Placebo|Placebo group will receive placebo for 12 weeks postoperative
224301348|NCT03082664|DEVICE|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
223570191|NCT06099418|BIOLOGICAL|VB10.16|"Intramuscular (i.m.) administrations of VB10.16 every 3 weeks (Q3W) during a 12-week induction period, followed by a maintenance period with administrations every 6 weeks (Q6W) from Week 13 until Week 49.~A total of up to 11 i.m. administrations will be given. VB10.16 will be administered via Pharma Jet® Stratis 0.5 mL needle free injection system."
223570192|NCT06099418|DRUG|Atezolizumab Injection [Tecentriq]|Intravenous (IV) infusions of atezolizumab (saline solution) every 3 weeks.
223570193|NCT06099418|DRUG|Placebo|Intravenous (IV) infusions of placebo (saline solution) every 3 weeks.
223570194|NCT03526393|DEVICE|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
223570195|NCT03526393|DEVICE|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
223570196|NCT03526393|DEVICE|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
224301349|NCT03546803|OTHER|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
223570197|NCT00045149|BIOLOGICAL|aldesleukin|
223570198|NCT00045149|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223570199|NCT00413894|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
223584080|NCT00343863|DRUG|cyclophosphamide|Given orally
223584081|NCT00343863|DRUG|dexamethasone|Given orally or IV
223584082|NCT00343863|DRUG|doxorubicin hydrochloride|Given IV
223584083|NCT00343863|PROCEDURE|quality-of-life assessment|Ancillary studies
223584084|NCT00343863|PROCEDURE|nausea and vomiting therapy|Given IV
224059799|NCT05909397|DRUG|ARV-471 (PF-07850327)|Pharmaceutical form: Tablets. Route of Administration: Oral
224059800|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
223452251|NCT05467852|DRUG|didroxyprogesterone|Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
223452252|NCT02888990|DRUG|Dasatinib|
223452253|NCT03188523|DRUG|MK-8504|After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
223452254|NCT06365190|OTHER|transcranial magnetic stimulation|During treatment, the patient underwent cTBS targeting the left SMA for 14 consecutive days. Each treatment day comprised three rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
223452255|NCT06365190|DRUG|Pharmacotherapy（antiparkinsonian drugs）|Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
223452256|NCT04230772|PROCEDURE|Natural Orifice Specimen Extraction Surgery|In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
223452257|NCT04230772|PROCEDURE|Traditional Robotic-assisted Surgery|In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
223452258|NCT02665741|DEVICE|Olympus transparent cap|distal colonoscope attachment
224059801|NCT05909397|DRUG|Letrozole|Pharmaceutical form: Capsules. Route of Administration: Orally
224059802|NCT05909397|COMBINATION_PRODUCT|Palbociclib|Pharmaceutical form: Capsules. Route of Administration: Oral.
223452259|NCT02665741|DEVICE|Medivators Endocuff|distal colonoscope attachment
223570200|NCT02491242|OTHER|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
224147363|NCT05652413|BEHAVIORAL|Adapted-Engage-PA|Enhanced motivation strategies for increasing walking using personal values assessment and value-guided goal setting, adapted from Acceptance and Commitment therapy. Strategic activity pacing to increase stamina and reduce pain flares when walking, using the Activity Rest Cycle, from Pain Coping Skills Training. Culturally sensitive elements for older adults who identify as African American such as linking motivation to spirituality, family, community, and other personally-meaningful values.
223570201|NCT04149158|DIETARY_SUPPLEMENT|Placebo|
223570202|NCT04149158|DIETARY_SUPPLEMENT|Sinetrol® Xpur|
223570203|NCT01304069|DRUG|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
223570204|NCT01304069|DRUG|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
224147364|NCT01943318|PROCEDURE|Liver biopsy|Histologic evaluation
224147365|NCT01943318|DEVICE|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
223452260|NCT02665741|DEVICE|Control|No distal colonoscope attachments
223452261|NCT06474572|DEVICE|Direct laryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level
223452262|NCT06474572|DEVICE|Videolaryngoscope and table at xiphoid level|Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level
223452263|NCT06474572|DEVICE|Direct laryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level
223452264|NCT06474572|DEVICE|Videolaryngoscope and table at umbilical level|Participants will be required to intubate the manikin with a videolaryngoscope and table at umbilical level
223570205|NCT01304069|DRUG|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
223570206|NCT01942161|DRUG|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
224059803|NCT06648980|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
224059804|NCT06648980|DIETARY_SUPPLEMENT|Phytoglycogen|Phytoglycogen; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast
224059805|NCT04687813|DRUG|Placebo|Placebo is a tablet with the same appearance as FTP-198
223570207|NCT01942161|DRUG|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
223570208|NCT01942161|DRUG|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
223584085|NCT00343863|PROCEDURE|management of therapy complications|Given IV
223584086|NCT00343863|DRUG|ondansetron hydrochloride|Given IV
223584087|NCT00343863|OTHER|survey administration|Ancillary studies
224059806|NCT06025669|BEHAVIORAL|Nap restriction|There are 2 interventions in the single-arm, that is, the nap rested condition and the nap restriction condition. The sequence of nap intervention followed randomization.
224059807|NCT02958007|BEHAVIORAL|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
224147366|NCT01873443|DRUG|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
224301350|NCT03054259|DRUG|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
224147367|NCT05886179|OTHER|cross-sectional study|analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.
224147368|NCT00192036|DRUG|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
224147369|NCT00192036|DRUG|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
224059808|NCT02958007|BEHAVIORAL|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
224059809|NCT02495155|BEHAVIORAL|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
224059810|NCT03021499|DRUG|Voclosporin|calcineurin inhibitor
224059811|NCT03021499|DRUG|Placebo Oral Capsule|matching placebo capsule
224059812|NCT04410588|DRUG|Fentanyl + Topical Levobupivacaine|in nasal packing
224059813|NCT04410588|DRUG|levobupivacaine|in nasal packing
224059814|NCT04329481|DIETARY_SUPPLEMENT|Mycodigest supplement|"Mycodigest is a dietary supplement which consists of traditional medicinal mushrooms, as essences and grounded powder"
224147370|NCT00192036|RADIATION|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
224059815|NCT06048107|DRUG|Teniposide|Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
224147371|NCT03977350|DEVICE|EEG monitoring|EEG monitoring under general anesthesia
224147372|NCT01310218|OTHER|extended postoperative dressing|2 weeks of bulky dressing
224147373|NCT01310218|OTHER|short postoperative dressing|2 days bulky dressing followed by bandaid
224147374|NCT05424887|DRUG|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
224059816|NCT06350734|OTHER|Non-Interventional Study|Non-Interventional Study
224059817|NCT02959528|OTHER|Working memory training|n-back training program
224147375|NCT05424887|DRUG|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
224147376|NCT04143672|DEVICE|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
224147377|NCT04143672|DIAGNOSTIC_TEST|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
224147378|NCT00000113|OTHER|Progressive Addition Lenses|Varilux comfort with +2.00 addition
224147379|NCT00000113|OTHER|single vision lenses|
224147380|NCT03007121|DRUG|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
224147381|NCT03007121|DRUG|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
223452265|NCT00664365|DRUG|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
223452266|NCT00664365|DRUG|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
223452267|NCT03911076|BIOLOGICAL|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
223452268|NCT03911076|OTHER|Placebo|PBS and PGC
223452269|NCT05883163|DEVICE|Stimit Activator 1|The Stimit Activator 1 System will be used to stimulate the phrenic nerve resulting in diaphragm activation.
223452270|NCT00448214|DRUG|YM150|Oral
223452271|NCT00448214|DRUG|warfarin|Oral
223452272|NCT01267929|PROCEDURE|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
223452273|NCT01267929|PROCEDURE|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
223452274|NCT03970759|DRUG|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
223452275|NCT03970759|DRUG|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
223452276|NCT03970759|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
223452277|NCT04605653|BEHAVIORAL|Weight Management Intervention|Participants attend group and individual dietary education sessions. Participants create a diet plan that satisfies their needs. Participants aim to lose 1 pound weekly until a BMI of 25 is reached. Participants are evaluated through daily self-weighing, dietary records, and food frequency questionnaires.
223452278|NCT03094793|OTHER|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
223452279|NCT01351207|OTHER|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
223452280|NCT06454123|DEVICE|OTX-401|Evidence-based treatments for obesity and binge eating
224059818|NCT02959528|OTHER|perceptual training|visual-perceptual training program
224059819|NCT00361426|DEVICE|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
224059820|NCT00041275|DRUG|megestrol acetate|
224059821|NCT06135649|PROCEDURE|Systematic lymphadenectomy|The nodal dissection protocol included the ISGPS lymphadenectomy stations (5, 6, 8a, 12b-c, 13, 14a-b, and 17) extended to stations contiguous to the regional basin (8p, 12a-p, and jejunal mesentery nodes). Stations embedded in the PD specimen (13, 14a-b, 17 and jejunal mesentery LN) were defined as first nodal echelon, while stations sampled as distinct specimens (5, 6, 8a-p, 12a-b-p-c) were defined as second nodal echelon.
224059822|NCT02462213|OTHER|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
224059823|NCT02462213|OTHER|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
224059824|NCT03988530|DRUG|Scopolamine|Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
224059825|NCT03988530|OTHER|Placebo Nasal Gel|Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
224059826|NCT04858750|DEVICE|Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy|During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
224059827|NCT05539768|BIOLOGICAL|HS-IT101|Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
224059828|NCT00025220|DRUG|Thalidomide|Given PO
224059829|NCT00025220|OTHER|Laboratory Biomarker Analysis|Correlative studies
224301351|NCT03054259|DRUG|Methylprednisolone|100mg infusion on days 1 and 15
224301352|NCT03054259|DRUG|Normal Saline|250ml infusion on days 1 and 15
224301353|NCT00554775|DRUG|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
224301354|NCT00554775|DRUG|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
224301355|NCT00222352|DIAGNOSTIC_TEST|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
224059830|NCT01161290|BEHAVIORAL|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
224059831|NCT00470054|DRUG|dasatinib|Given PO
224059832|NCT00741247|PROCEDURE|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
224059833|NCT04993794|DRUG|XueBiJing Injection|XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.
224059834|NCT04993794|DRUG|Normal saline|Same saline dose as XueBiJing injection is taken intravenously.
224059835|NCT03739905|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
224059836|NCT00870220|DRUG|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
224059837|NCT04519411|DIAGNOSTIC_TEST|Transpulmonary pressure measurements|Transpulmonary pressure measurements
224059838|NCT03497481|BIOLOGICAL|Samples|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
224059839|NCT03459911|DRUG|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)
224059840|NCT03459911|DRUG|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
224059841|NCT04093843|DEVICE|TMS|NeuroStar TMS Therapy
224301356|NCT03176459|DRUG|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
224301357|NCT03176459|DRUG|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
224301358|NCT01668693|OTHER|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
224301359|NCT01668693|OTHER|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
224301360|NCT01668693|OTHER|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
224301361|NCT03235661|DEVICE|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
224059842|NCT03314077|OTHER|GOLD 2017|Standard COPD management according to GOLD 2017, and control the quality of management in one-year follow-up.
224059843|NCT04326712|OTHER|conventional manufactured socket|Presssure disturubition will be measured in conventional manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
223452281|NCT03597191|OTHER|Exercises|Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
223452282|NCT05996822|DRUG|ACF injection|AcF injection 1 month after a DXM injection
223452283|NCT03944863|DRUG|Antibiotics|
223452284|NCT03925337|DEVICE|Computer Aided Diagnostic Software|The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
223452285|NCT04260997|DIETARY_SUPPLEMENT|Lactobacillus gasseri BNR17™ capsule|Once per day (QD), 12 weeks
223742100|NCT04767074|OTHER|Non-pharmacological Cough control Therapy|"Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management.~Session 1 General assessment Prescription and taught of one cough suppression technique.~Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing.~Cough control: identify triggers, use cough suppressions and distractions techniques.~Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education.~Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations."
223742101|NCT06570681|DIAGNOSTIC_TEST|Video call assisted assessment of acute stroke|If the patient is eligible for study inclusion, eight symptoms from the study protocol are evaluated and registered in the Prehospital Patient Journal (PPJ) on the amPHITM Prehospital Health Care Record (Amphi Systems, Hasserisvej 125, 9000 Aalborg, Denmark), on a tablet mounted in each EMT vehicle. Afterwards, the EMS personnel will contact the on-call neurologist and if the vehicle is in the intervention arm a live video stream is initiated. The on-call neurologist then examines the patient via via the video-call and triages the patient.
223452286|NCT04260997|OTHER|Placebo capsule|Once per day (QD), 12 weeks
223452287|NCT02710487|BEHAVIORAL|REMSA|Awakening from REM sleep during the last hour of the sleep period
223452288|NCT02710487|BEHAVIORAL|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
223452289|NCT03835507|DRUG|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
223452290|NCT00134966|DRUG|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
223452291|NCT04445090|DRUG|BI 1569912|BI 1569912
223570209|NCT02422836|OTHER|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
223570210|NCT02762240|OTHER|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
223742102|NCT05443334|DRUG|Semaglutide|Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
223742103|NCT06701682|DRUG|Cohort A: vilobelimab|Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
223742104|NCT06701682|DRUG|Cohort A: placebo|Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)
223742105|NCT03084029|DRUG|Oxytocin|40 international units
223742106|NCT03084029|DRUG|Placebo|40 international units
223742107|NCT03174197|DRUG|Atezolizumab|Given IV
223742108|NCT03174197|RADIATION|Radiation Therapy|Undergo RT
223742109|NCT03174197|DRUG|Temozolomide|Given PO
223742110|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 1|Pharmaceutical form: suspension for injection Route of administration: intramuscular
224059844|NCT04326712|OTHER|3D manufactured socket|Presssure disturubition will be measured in 3D manufactured socket during walking and stairing up and down activities in unilateral transtibial amputees
224059845|NCT01666509|DEVICE|Rossoseq™|
224059846|NCT01666509|DEVICE|Placebo|
223742111|NCT05608005|BIOLOGICAL|Panblok + MF59 Dose 2|Pharmaceutical form: suspension for injection Route of administration: intramuscular
223742112|NCT05608005|BIOLOGICAL|Unadjuvanted Panblok Dose 3|Pharmaceutical form: liquid for injection Route of administration: intramuscular
223742113|NCT02985229|DRUG|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
223742114|NCT02985229|DRUG|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
223452292|NCT04445090|DRUG|Placebo|Placebo
223452293|NCT06548854|DRUG|STC314 Injection/STC314 Injection Placebo|All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
223452294|NCT00071838|DRUG|Daclizumab|
223452295|NCT03803163|DRUG|TransCon Treprostinil|
224059847|NCT02680925|PROCEDURE|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
224059848|NCT02680925|PROCEDURE|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
224059849|NCT00134264|DRUG|torcetrapib/atorvastatin|
224059850|NCT00134264|DRUG|atorvastatin|
224059851|NCT01878526|DRUG|Alginic acid|Algycon 1 tab chew tid after meal
224059852|NCT01878526|DRUG|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
224059853|NCT01878526|DRUG|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
224059854|NCT01878526|DRUG|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
224059855|NCT06037642|BEHAVIORAL|ABC 0-2 years|Four 1 hour meetings and homework
224059856|NCT06037642|OTHER|waiting list|Will be put on hold for four weeks
224059857|NCT02947152|DRUG|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
224059858|NCT03639103|PROCEDURE|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
224059859|NCT03310450|OTHER|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
224059860|NCT00754481|OTHER|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) were maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who were hypothermic (temperature \< 35 ºC) when randomized to the normothermia group were rewarmed slowly using the servo-controlled mattress. Patients who were hyperthermic following randomization to the normothermia group were actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers were administered as needed intravenously in both groups of patients to prevent shivering.
224059861|NCT00754481|OTHER|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) were cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe was placed in the esophagus and its position confirmed using a chest radiograph. Patients were placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reached 34.0ºC, the ice and second cooling blanket was removed and esophageal temperature was maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO were cooled using the extracorporeal circuit cooling-device. Rewarming was done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC was reached. Thereafter temperature was recorded but not controlled by surface cooling.
224059862|NCT01787942|DEVICE|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
224059863|NCT04543058|DEVICE|BeatPark Application|"The participant walks for 30 minutes a day, 5 day a week for 4 weeks. During the walking session, BeatPark Application delivers synchronized music adapted to the patient walking.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
223452296|NCT02352961|OTHER|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
223452297|NCT01466075|DEVICE|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
223452298|NCT06548503|DIETARY_SUPPLEMENT|Si.Pi.Mi product|Assumption of the product as detailed in the protocol
223452299|NCT06548503|OTHER|Placebo|Assumption of placebo
223452300|NCT06171529|DEVICE|CTM|CTM Flow is stored in 1cc vials and is stable at room temperature and does not need to be refrigerated. CTM Flow will be supplied to and stored at the IHTSC Beltway Surgery Center. Product will be stored at room temperature without continued temperature control. All product will be kept in the Beltway Surgery Center and will not be separated from the marketed non-study CTM. Treating Surgeons will remain blinded to the treatment group, but will ensure that only the injection is billed to patients and the CTM or saline are provided at no cost. Lexie Reissaus, CCRP will track drug accountability.
223452301|NCT06171529|OTHER|Placebo|placebo/Saline control injection
223742115|NCT02418923|OTHER|Procedure: Blood specimen collection|Blood specimen collection
223742116|NCT04322253|DRUG|Neladenoson bialanate (BAY 1067197)|10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
223742117|NCT01918904|DRUG|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
223742118|NCT01918904|DRUG|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
224059864|NCT04543058|OTHER|BeatPark Application without synchronized music|"The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application delivers random music at random tempo.~The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts."
224059865|NCT04543058|OTHER|BeatPark Application without music|The participant walks for 30 minutes a day, 5 days a week for 4 weeks. During the walking session, BeatPark Application does not deliver music. The application allows participants to know the progress of their session through graphical representation and voice messages, informs them at the end of the session of their performance and congratulate them for their efforts.
224059866|NCT04869345|BEHAVIORAL|LARKSPUR|This intervention used in our prior research consists of skills training exercises designed to increase the frequency of positive affect. The 6 week intervention (5 weeks of content plus one week of home practice) consists of five components: (1) Positive events and gratitude; (2) mindfulness; (3) reappraisal; (4) strength and goals; and(5) acts of kindness. Participants will have up to 8 weeks to complete this intervention.
224059867|NCT05046847|DRUG|TQB3811|TQB3811 is a second-generation TrkA inhibitor.
224301362|NCT03235661|DEVICE|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
223452302|NCT00199849|BIOLOGICAL|NY-ESO-1 Plasmid DNA Cancer Vaccine|NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.
223452303|NCT05118997|DEVICE|IRRAflow|IRRAflow consists of a control unit and disposables (dual-lumen catheter and tube set) to offer an integrated and synchronized active fluid exchange system. Active fluid exchange is the combination of traditional gravity-driven drainage with periodic, controlled irrigation of the catheter probe to exchange any pathological fluid collection with neutral physiological fluids.
223452304|NCT05118997|DEVICE|EVD|An external ventricular drain (EVD), also known as a ventriculostomy or extraventricular drain, is a device used in neurosurgery to treat hydrocephalus and relieve elevated intracranial pressure when the normal flow of cerebrospinal fluid inside the brain is obstructed.
223452305|NCT01116622|DRUG|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
223452306|NCT01116622|DRUG|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
223452307|NCT02442648|DRUG|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
223452308|NCT02442648|DRUG|Rituximab|Rituximab will be administered for desensitization per study protocol.
224059868|NCT03854136|PROCEDURE|Excision of tumor|Wide margin excision of tumors +/- limb preservation
224059869|NCT00359138|DRUG|desloratadine|5 mg tablet once daily
224059870|NCT00359138|DRUG|levocetirizine|5 mg capsule once daily
224059871|NCT00359138|DRUG|Desloratadine placebo tablet|once daily
224059872|NCT00359138|DRUG|Levocetirizine placebo capsule|once daily
224059873|NCT02716051|DEVICE|MRI|Whole body MRI with cardiac and pulmonary synchronization
223570211|NCT02762240|OTHER|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
223570212|NCT00092872|DRUG|MK0557|
223570213|NCT00000554|PROCEDURE|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
223570214|NCT00000554|PROCEDURE|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
223570215|NCT02029183|DEVICE|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
224059874|NCT02716051|DEVICE|PET|
224059875|NCT04526236|DRUG|Methadone Injectable Product|Perioperative use of placebo for pain management and remifentanil during the surgery.
224059876|NCT05303116|DIAGNOSTIC_TEST|Brainscope modified EEG and cognitive testing|Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
224059877|NCT02277015|DEVICE|Miller Laryngoscope|Direct Laryngoscopy
223452309|NCT04727528|DRUG|Sodium zirconium cyclosilicate|Investigational medicinal product
223452310|NCT04727528|DRUG|Placebo|Plabeco comparator
223452311|NCT05236855|DIAGNOSTIC_TEST|Spectoscropy testing of urine specimen|Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
223452312|NCT02711566|DEVICE|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
223570216|NCT02029183|DEVICE|bi-level positive airway pressure|
223570217|NCT02567370|DRUG|AMG 581|Active drug
223570218|NCT02567370|DRUG|Placebo|Placebo
223570219|NCT03294096|DIETARY_SUPPLEMENT|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
223570220|NCT03294096|OTHER|Routine care|Routine post-op care
223570221|NCT02074345|BIOLOGICAL|TAK-816|TAK-816 intramuscular injection
223570222|NCT03440723|DEVICE|DilaCheck|Measuring device for the measurement of cervical dilation
223570223|NCT03440723|DIAGNOSTIC_TEST|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
223570224|NCT02706275|OTHER|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
224059878|NCT02277015|DEVICE|The Berci-Kaplan DCI|Videolaryngoscope-1
224059879|NCT02277015|DEVICE|The AirTraq|Videolaryngoscope-2
224059880|NCT02277015|DEVICE|GlideScope GVL|Videolaryngoscope-3
224059881|NCT02277015|DEVICE|The Pentax AWS|Videolaryngoscope-4
224059882|NCT00626756|DEVICE|LiDCO technology|non invasive monitoring of cardiac output
224059883|NCT00001075|DRUG|Ritonavir|
224059884|NCT00001075|DRUG|Lamivudine|
224059885|NCT00001075|DRUG|Zidovudine|
224059886|NCT02781909|DRUG|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
224059887|NCT02781909|DRUG|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
224147382|NCT03007121|DRUG|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
224147383|NCT00980421|DIETARY_SUPPLEMENT|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
224147384|NCT03347240|PROCEDURE|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
224147385|NCT03347240|PROCEDURE|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
224147386|NCT03347240|DEVICE|Deep brain stimulation|Bilateral DBS
224147387|NCT03347240|DEVICE|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
224059888|NCT01128127|BEHAVIORAL|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
224059889|NCT01128127|BEHAVIORAL|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
224059890|NCT01128127|BEHAVIORAL|Control|"Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
224059891|NCT05743738|DIAGNOSTIC_TEST|Doppler ultrasound|Control venous Doppler ultrasound
224059892|NCT00528021|DRUG|Placebo|Vehicle Only
224059893|NCT00528021|DRUG|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
224059894|NCT05094791|DEVICE|Telescoping Lag Screw|Intertrochanteric fracture fixation using Arthrex Hip Nail with Telescoping Lag Screw
224059895|NCT05094791|DEVICE|Standard lag Screw|Intertrochanteric fracture fixation using Zimmer Natural Nail Cephalomedullary Nail using standard lag screw
224059896|NCT05094791|DEVICE|Standard lag screw with addition of worm screw|Intertrochanteric fracture fixation using Smith and Nephew TRIGEN INTERTAN with addition of worm screw
224059897|NCT04226690|DRUG|Active CBD/THC Dose 1|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
224059898|NCT04226690|DRUG|Active CBD/THC Dose 2|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
224059899|NCT04226690|DRUG|matched placebo comparator|Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
224059900|NCT04050982|DEVICE|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
224059901|NCT04050982|BEHAVIORAL|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial American Heart Association Life Simple 7 (LS7) assessment and will be provided educational materials and be wait listed for digital app 3 months later
224059902|NCT01246583|DRUG|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
224301363|NCT03597360|RADIATION|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
223742119|NCT01859533|DEVICE|Neopuff|"* Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~* Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
223742120|NCT02989740|PROCEDURE|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
223742121|NCT04708886|DRUG|Romosozumab|Year 1 study drug
223742122|NCT04708886|DRUG|Alendronate|Year 2 study drug
223742123|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
224059903|NCT01246583|DRUG|Vehicle 1|Vehicle 1 twice daily for 4 weeks
224059904|NCT01246583|DRUG|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
224059905|NCT01246583|DRUG|Vehicle 2|Vehicle 2 twice daily for 4 weeks
224059906|NCT05144035|DRUG|PEG-rhGH|the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
224059907|NCT00449501|DRUG|Budesonide/formoterol pMDI|
223742124|NCT02940847|PROCEDURE|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
224147388|NCT04962503|DRUG|Afamelanotide|Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
224147389|NCT00321022|BEHAVIORAL|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
224147390|NCT01273389|DRUG|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
224059908|NCT00449501|DRUG|Budesonide HFA pMDI|
224059909|NCT05054114|DRUG|Interferon gamma human recombinant (IFN-G)|nasal form
224147391|NCT01273389|DRUG|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
224147392|NCT03153020|OTHER|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
224147393|NCT00476996|DRUG|Leflunomide|Oral repeating dose
224147394|NCT00476996|DRUG|Methotrexate|Oral or parenteral repeating dose
224147395|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (200mg)
224301364|NCT05862194|DRUG|Lazertinib|Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
224301365|NCT05862194|DRUG|Platinum-based Chemotherapy|Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
223452313|NCT02711566|DEVICE|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
223452314|NCT03989336|DRUG|Manganese Chloride|Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
223452315|NCT03989336|DRUG|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
223452316|NCT03989336|DRUG|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
223452317|NCT03989336|DRUG|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
223452318|NCT05645302|DRUG|Lidocaine Cataplasms|The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
223452319|NCT00576524|DEVICE|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
223452320|NCT00576524|DEVICE|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
223452321|NCT00022750|BEHAVIORAL|Nurse Case Manager and Community Health Worker Team|
223452322|NCT01662856|BIOLOGICAL|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
223452323|NCT01662856|PROCEDURE|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
223452324|NCT01355562|DRUG|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
223452325|NCT01944644|DEVICE|Active Low Field Magnetic Stimulation|Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
223452326|NCT01944644|DEVICE|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
223452327|NCT01763827|BIOLOGICAL|Evolocumab|Administered by subcutaneous injection
223452328|NCT01763827|DRUG|Ezetimibe|Administered orally once a day
223452329|NCT01763827|BIOLOGICAL|Placebo to Evolocumab|Administered by subcutaneous injection
223452330|NCT01763827|OTHER|Placebo to Ezetimibe|Administered orally once daily
223452331|NCT05006274|DEVICE|Persona Trabecular Metal Tibia|Total knee arthroplasty
223452332|NCT05006274|DEVICE|Verasense technology|Instrumented tibial trial component
223452333|NCT05006274|DEVICE|MUVR|Knee motion and gait sensing wearable device
224059910|NCT06199609|PROCEDURE|Hemodialysis pathway|AVF and TCC are two different vascular pathways for hemodialysis
224059911|NCT06199609|PROCEDURE|AVF|Left atrial changes caused by AVF establishment
224059912|NCT06199609|PROCEDURE|AVF|New onset atrial fibrillation caused by AVF establishment
224059913|NCT00413647|DRUG|CardioPET|
224059914|NCT04465721|BEHAVIORAL|TRE|The TRE intervention will be administered and monitored via the study app. It combines self-monitoring behavior, daily eating window reminders, positive reinforcement based on number of log entries or based on meeting eating widow target, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring, and to reducing the eating window.
224059915|NCT04465721|BEHAVIORAL|HABIT|The HABIT intervention will be administered and monitored via the study app. It combines self-monitoring behavior, positive reinforcement based on number of log entries, and basic lifestyle text messages. It also allows research staff to monitor in real-time, via the backend cloud, adherence to self-monitoring.
224147396|NCT00476996|DRUG|Ocrelizumab|Intravenous repeating dose (500mg)
224147397|NCT00476996|DRUG|Placebo|Intravenous repeating dose
224147398|NCT02618343|DRUG|IPA|IPA Aromatherapy for the experimental arm
224147399|NCT02618343|DRUG|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
224301366|NCT00906984|DEVICE|TheraSphere|Given IV
223452334|NCT03343366|DRUG|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
223452335|NCT03343366|PROCEDURE|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
223452336|NCT03343366|BEHAVIORAL|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
223452337|NCT00168428|BIOLOGICAL|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
223452338|NCT00168428|OTHER|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
223570225|NCT02446470|PROCEDURE|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
223742125|NCT04666233|PROCEDURE|Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
224059916|NCT00199914|DEVICE|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
224059917|NCT00751595|BIOLOGICAL|Tat protein|Biologically active recombinant Tat protein
224059918|NCT01791348|OTHER|d2 test of attention|
224059919|NCT06216431|OTHER|Physical Evaluations of individuals|Participants will be evaluated on posture, chest mobility, cough strength, flexibility, hand grip strength and pinch strength. They will be asked to answer the Modified Medical Research Council Scale, Cornell Musculoskeletal Disorders Questionnaire, International Physical Activity Questionnaire Short Form and Short Form -36. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
224059920|NCT06978374|OTHER|Sonographic examination of thoracolumbar fascia, manual examination of MTrP|"Patients were positioned in the prone position, with a cushion placed under the abdomen to flatten the lumbar lordosis.~A 14-18 MHz linear transducer was used for ultrasonographic (USG) evaluation, performed with a GE Logiq P5 ultrasound device (Serial No: GE-114118SU3).~The USG probe was placed longitudinally at the L2-L3 intervertebral level, 2 cm lateral to the vertical line connecting the spinous processes on both sides, in order to assess the thoracolumbar fascia (TLF)."
224059921|NCT06978504|OTHER|DASH diet|Prospective, single-arm, unblinded clinical trial lasting 90 days. The study population will consist of menopausal women aged between 40 and 60 years who are obese (BMI \> 30) and diagnosed with metabolic syndrome. Volunteers will have an in-person consultation with a nutritionist at t0 to assess their previous habitual food intake and will receive a DASH diet. To minimize losses during the study, in-person consultations with a nutritionist will be held at t0, t30, t60, t90 and online consultations (teleconsultation) at t15, t45 and t75 to answer a questionnaire to assess nutritional adherence that will be applied by the nutritionist. Saliva samples will be collected for genetic panel analysis only at t90. Serum samples for analysis of lipid profile, blood glucose, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), follicle stimulating hormone (FSH), C-reactive protein (CRP) and tumor necrosis factor (TNF) and profile of medications used will be collected at t0 and t90.
224301367|NCT03499002|OTHER|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
223452339|NCT05381454|DRUG|Mitoquinone/mitoquinol mesylate|Mitoquinone/mitoquinol mesylate
223452340|NCT02906579|DRUG|Matching Placebo|
223452341|NCT02906579|DRUG|IW-1973|
223570226|NCT02446470|PROCEDURE|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
223742126|NCT04666233|PROCEDURE|Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection|The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
223452342|NCT01826981|DRUG|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
223452343|NCT01826981|DRUG|SOF|SOF 400 mg tablet administered orally once daily
223452344|NCT01826981|DRUG|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223452345|NCT01826981|DRUG|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
223452346|NCT01826981|DRUG|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
223452347|NCT01826981|DRUG|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
223452348|NCT03701438|BIOLOGICAL|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
223452349|NCT02030119|BEHAVIORAL|Financial Incentives|
223452350|NCT02030119|BEHAVIORAL|Daily feedback|
224059922|NCT06978426|OTHER|Pain Group|Professional e-sports athletes who report wrist pain rated at 3 or higher on a 10-point Visual Analog Scale during gaming activities. These participants play video games professionally for at least 35 hours per week, are between 18-30 years old, and have no history of neurologic or rheumatic disease.
224059923|NCT06978426|OTHER|No-Pain Group|Professional e-sports athletes who report minimal to no wrist pain (less than 3 on a 10-point Visual Analog Scale) during gaming activities. These participants play video games professionally for at least 35 hours per week, are between 18-30 years old, and have no history of neurologic or rheumatic disease.
224059924|NCT06978816|DRUG|Non-Steroidal anti-inflammatory drugs (NSAIDS)|Intravenous infusion of 50 mg dexketoprofen trometamol injection
224059925|NCT06978816|OTHER|Auricular Acupoint Embedding|Concurrently with the intravenous infusion of dexketoprofen trometamol, verum auricular acupoint embedding was performed using disposable sterile press needles at three ipsilateral ear points: thalamus (MA-AT), kidney (MA-SC), and shenmen (MA-TF1), with needle retention for 60 minutes
224059926|NCT06978816|OTHER|Sham Acupoint Embedding|Concurrently with the intravenous infusion of dexketoprofen trometamol, sham auricular stimulation was administered using non-penetrating adhesive patches applied to three ipsilateral ear points: thalamus (MA-AT), kidney (MA-SC), and shenmen (MA-TF1), maintaining the application for 60 minutes.
224059927|NCT06977386|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of gastric cancer|CT scan of the abdomen outside of standard treatment options
224059928|NCT06978517|PROCEDURE|Biodex balance system|Participants assigned to the Biodex balance training group underwent balance rehabilitation using the Biodex Balance System SD, a computerized platform designed to assess and train postural stability. Each participant engaged in training sessions three times per week, with each session lasting approximately 30 minutes, over a total period of six weeks. The intervention began with exercises conducted on a higher stability level (e.g., Level 8), gradually progressing to lower stability levels (e.g., Level 2) to increase the challenge as participants' balance improved. The training included both static and dynamic tasks aimed at enhancing weight shifting, center-of-gravity control, and response to instability. Real-time visual biofeedback was provided via the system's screen, enabling participants to monitor their performance and maintain motivation. All sessions were conducted under the supervision of a qualified physiotherapist to ensure proper technique and safety.
224147400|NCT04269655|DEVICE|Cloud-Based Continuous Glucose Monitoring|The CGM data will be transmitted via bluetooth to a smartphone. The smartphone will automatically transmit values to a secure cloud-based platform, which then populates to the: (1) web-based, CGM data management tool for evaluation purposes (both groups), and (2) Digital Dashboard for monitoring and intervention (intervention only).
224147401|NCT00633308|DEVICE|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
224147402|NCT04791787|OTHER|Standard weight maintaining diet|Diet containing diet approximately 25-35% protein, 45-55% carbohydrate, 20- 30% fat
224147403|NCT04791787|OTHER|Weight maintaining isocaloric ketogenic diet|Isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate,70- 80% fat
224147404|NCT04791787|DIETARY_SUPPLEMENT|Beta-hydroxy butyrate|A supplement of ketone ester of beta-hydroxy butyrate
224147405|NCT01303432|DIETARY_SUPPLEMENT|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
224147406|NCT01303432|DIETARY_SUPPLEMENT|Yogurt|One yogurt (125mL) per day
224301368|NCT04294420|BEHAVIORAL|Patient education program|The education program provides information and guidance concerning aetiology, diagnostics and treatment of pain-predominant functional gastrointestinal disorders. The patient education program will be provided in a group setting and the children will participate along with one of their parents. The participants (n=20) will be divided into two groups consisting of ten child-parent pairs. Two lectures will be held, two weeks apart, two hours per lecture. Represented teachers are physician, psychologist and dietician.
223452351|NCT03681899|OTHER|Questionnaires|"* Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~* Medical and surgical history (Charlson Comorbidity Scale);~* Assessment of oral/dental condition~* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~* Autonomy evaluation (Lawton and Katz scales);~* Mobility assessment (anamnestic evaluation);~* Evaluation of Thyme (GDS 4 items);~* Psycho-behavioral disorders,~* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
223452352|NCT03230435|OTHER|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
223452353|NCT01481883|DRUG|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
223452354|NCT01481883|DRUG|Placebo|1 capsule daily for 12 week trial
223452355|NCT00759655|BIOLOGICAL|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
223452356|NCT00447551|DRUG|Poly-L-Lactic Acid|Deep dermal injection
223452357|NCT02330185|DEVICE|ultrasonography|spinal anesthesia guided with ultrasonography
223452358|NCT05576961|DRUG|RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
223742127|NCT05351242|OTHER|Thermotherapy/sauna bath|Thermotherapy/sauna bath
223742128|NCT02498457|OTHER|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
223742129|NCT00898157|OTHER|laboratory biomarker analysis|
224147407|NCT01208571|OTHER|"Booster session"|Motivational interview
224147408|NCT01519401|DRUG|3 mg drospirenone and 20 µg ethinyl-estradiol|
224147409|NCT01519401|DRUG|3 mg drospirenone and 30 µg ethinyl-estradiol|
224147410|NCT01769469|DRUG|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
224147411|NCT05367219|DEVICE|Air sterilizer|The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
224059929|NCT06978517|PROCEDURE|nintendo Wii fit balance training|Participants in the Nintendo Wii Fit training group engaged in balance exercises using the Nintendo Wii console and Wii Fit balance board. This interactive system includes a variety of balance-focused activities and games that simulate real-life balance challenges in a virtual environment. The training was conducted three times per week, with each session lasting approximately 30 minutes, over a six-week period. Exercises included selected Wii Fit balance games (such as Ski Slalom, Table Tilt, and Tightrope Walk) and yoga-based poses (such as Tree Pose and Warrior), which encouraged participants to engage their core and lower limb muscles while maintaining postural alignment. The difficulty level was gradually increased by introducing more complex tasks and longer balance durations as participants progressed. The system provided immediate visual and auditory feedback, allowing users to track their scores and improvements in real time. All sessions were performed under supervision.
224059930|NCT06979284|PROCEDURE|IVUS-guided strategy|Percutaneous revascularization will be performed using intravascular ultrasound. The operators will follow instructions to modify arteries hardened by calcium and use IVUS to optimize the equipment (balloon and stents) used to unblock the artery.
224070930|NCT02524353|OTHER|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
224070931|NCT03491384|DRUG|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
224070932|NCT05685433|DEVICE|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
224070933|NCT04381390|DIETARY_SUPPLEMENT|Whole egg and resistance training|This intervention consisted of whole egg consumption concomitant with 12 weeks of resistance training. Subject ingested three whole eggs per day immediately after resistance training.
224070934|NCT04381390|DIETARY_SUPPLEMENT|Egg whites and resistance training|This intervention consisted of egg white consumption concomitant with 12 weeks of resistance training. Subject ingested an isonitrogenous quantity of six egg whites per day immediately after resistance training.
224070935|NCT03261622|DEVICE|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
224070936|NCT02386488|DRUG|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
224301369|NCT01179126|PROCEDURE|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
224301370|NCT01179126|PROCEDURE|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
224070937|NCT02386488|DRUG|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
224070938|NCT02386488|DRUG|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
223452359|NCT05576961|DRUG|Mixed bacteria|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
223452360|NCT05576961|DRUG|High dose RX-af01|Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
223452361|NCT05736692|BEHAVIORAL|Brief Sleep Intervention|A \~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.
223452362|NCT06267820|DRUG|Bupivacain|analgesia
223452363|NCT06267820|DRUG|Ketorolac|analgesia
223452364|NCT00004763|DRUG|leuprolide|
223452365|NCT00004763|DRUG|Ethinyl estradiol/norethindrone|
223452366|NCT03457818|DRUG|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
223452367|NCT03457818|OTHER|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
223452368|NCT01727856|DEVICE|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
223452369|NCT01696656|DRUG|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
223452370|NCT00642005|PROCEDURE|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
223452371|NCT00642005|PROCEDURE|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
223452372|NCT01955239|RADIATION|Intensity-modulated Radiotherapy|
223452373|NCT04382716|OTHER|No intervention|No intervention; observation only
223452374|NCT00313833|DRUG|Buprenorphine transdermal delivery system|
224070939|NCT02386488|DRUG|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
224070940|NCT02317666|PROCEDURE|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
224070941|NCT01617837|DEVICE|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
224070942|NCT01617837|OTHER|Placebo band|Comparison between groups 0-48 hours postoperatively
224070943|NCT06134232|DRUG|Sipuleucel-T Injection|Single Infusion
224070944|NCT02800200|PROCEDURE|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
223452375|NCT02213380|PROCEDURE|method of anesthesia|"General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
223452376|NCT00730574|DIETARY_SUPPLEMENT|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
223452377|NCT01314027|DRUG|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
223452378|NCT01314027|DRUG|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
224059931|NCT06977672|OTHER|Down Dog Yoga|In this study, a period of 10 weeks, commencing with a preliminary assessment during the first week, followed by an 8-week intervention phase, and concluding with a final assessment in the last week of the study period. The frequency-intensity-time-type principle will be implemented as follows: sessions will occur 4 times per week, consisting of 2 sessions led by experts and 2 sessions involving parents. The intensity will be 40 to 45 minutes for expert-led sessions and 20 to 25 minutes for parent-led sessions. These sessions will take place 3 or 4 times per week over an 8-week period, focusing on a type of intervention known as dog down yoga
224059932|NCT06977672|OTHER|Traditional|The children took part in group sessions four days a week over a span of 10 weeks, totaling 40 sessions. Each session, lasting around 20 minutes, involved small groups of four to seven children. The aim will be to evaluate the children's writing across four stages of development: pre-phonemic, semi-phonemic, phonemic, and conventional
224059933|NCT06977945|DIAGNOSTIC_TEST|Specific positron imaging agents targeting NTRS-1(FL-091)|This study is diagnostic. Oncologists screen patients with malignant tumors such as head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma who are clinically suspected or confirmed; investigators talk to patients who meet the inclusion criteria, explain the study purpose and study process, sign informed consent forms, and patients can complete 68Ga-FL-091PET imaging and 111In-FL-091SPECT imaging respectively in outpatient or inpatient periods. General information, clinical data, blood routine, urine routine, liver and kidney function and other biochemical indicators, electrocardiogram, radionuclide imaging results and other imaging data of the patients participating in the study were collected and compared with histopathology to evaluate the value of both imaging in the diagnosis of head and neck cancer, colorectal cancer, and pancreatic adenocarcinoma.
224059934|NCT06977893|DRUG|Neoadjuvant Chemotherapy in Combination with Toripalimab|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
224059935|NCT06977893|DRUG|Neoadjuvant Chemotherapy|Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.
224059936|NCT06977217|PROCEDURE|CRT-D implantation|Cardiac resynchronization therapy with a defibrillator (CRT-D). This combination device uses a pacemaker and an implantable cardioverter-defibrillator (ICD). It may be recommended for people with heart failure who also have a risk of sudden cardiac death. It can find dangerous heart rhythms and correct them. It can pace the heartbeat or shock the heart out of a dangerous heart rhythm.
224059937|NCT06977997|OTHER|KAP survey|33 questions to assess knowledge, attitude, and practice of dentists in Egypt regarding TMD
224059938|NCT06978283|BEHAVIORAL|AI-assisted case analysis|Nursing students will perform visual case analyses of pressure injuries using an AI-based platform. The AI system will provide students with case-based feedback.
224059939|NCT06978283|BEHAVIORAL|Traditional case analysis|Participants will be present with written case scenarios and a case analysis will conduct with the instructor. The training process will be carried out with group discussions and the instructor's guidance. No technological or artificial intelligence support will be used.
224301371|NCT06440187|DRUG|Gemcitabine+ nivolumab|Gemcitabine+ nivolumab q 2wks
223452379|NCT02198508|DRUG|DFX(Deferasirox)|
223452380|NCT02198508|DRUG|DFP(Deferiprone)|
223452381|NCT01085708|DRUG|rabeprazole|10 mg normal tablet
223452382|NCT01085708|DRUG|rabeprazole|Type 1 granule containing rabeprazole 10 mg
223452383|NCT01085708|DRUG|rabeprazole|Type 2 granules containing rabeprazole 10 mg
224059940|NCT04070859|PROCEDURE|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes \& Screws, Tension bands. etc)
224059941|NCT02116777|OTHER|Laboratory Biomarker Analysis|Correlative studies
224059942|NCT02116777|OTHER|Pharmacological Study|Correlative studies
224059943|NCT02116777|DRUG|Talazoparib|Given PO
224059944|NCT02116777|DRUG|Temozolomide|Given PO
224301372|NCT01349582|PROCEDURE|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
224301373|NCT01349582|OTHER|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
223452384|NCT01085708|DRUG|rabeprazole|Type 3 granules containing rabeprazole 10 mg
223570227|NCT05379517|DEVICE|Pulsed ectromagnetid field therapy|Pulsed electromagnetic field therapy is an innovative therapy. The technology is based on a high intensity electromagnetic field, which positively influences human tissue. It is a form of non-invasive treatment, with good tolerance by patients. High-intensity electromagnetic fields excite neural and muscle cells, which stimulates the human body.
223570228|NCT05379517|OTHER|Pulmonary rehabilitation program (PRP)|This type of physiotherapy program includes: respiratory muscle training, coughing exercises, diaphragmatic training, aerobic training and strength training.
224059945|NCT03194386|OTHER|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
224059946|NCT03194386|OTHER|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
223452385|NCT01726465|DRUG|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
224059947|NCT04558866|DRUG|Testosterone Cypionate|One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
224059948|NCT04558866|DRUG|Darolutamide|During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
224059949|NCT00085956|DRUG|Arzoxifene|
224059950|NCT00085956|DRUG|Placebo|
223452386|NCT01726465|DRUG|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°-110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
223570229|NCT02476084|OTHER|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
223570230|NCT02476084|OTHER|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
224059951|NCT06978244|DRUG|BL1332 ophthalmic solution|Both arms taken four times a day for 1 day
224059952|NCT06978244|DRUG|BL1332 ophthalmic vehicle|Both arms taken four times a day for 1 day
224059953|NCT06978712|PROCEDURE|Sub-gingival instrumentation|All patients will undergo dental biofilm control through patient motivation, oral hygiene instructions and supragingival professional mechanical plaque removal followed by sub-gingival instrumentation.
224301374|NCT01349582|PROCEDURE|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
223570231|NCT02476084|OTHER|Biological samples collection|Draw of research blood samples.
223570232|NCT02476084|OTHER|Questionnaires|Administration of validated patients' questionnaires.
223570233|NCT02251717|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223570234|NCT04086368|DEVICE|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
223570235|NCT04086368|DEVICE|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
223570236|NCT03780478|DRUG|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
223570237|NCT03780478|DRUG|Placebo Saline Injection|Saline injection, total volume 2ml
224059954|NCT06977438|DRUG|Semaglutide|All participants in this study will receive treatment with Semaglutide
224059955|NCT06979167|DEVICE|midline catheter insertion during general anesthesia|This intervention involves the ultrasound-guided insertion of a midline catheter into a peripheral vein (basilic, cephalic, or brachial vein) during general anesthesia in pediatric patients.
224059956|NCT05016115|BEHAVIORAL|survey|The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
224059957|NCT06984406|DIETARY_SUPPLEMENT|Beet-Derived Inorganic Nitrate-Based Food Product|This intervention consists of an orally administered food product enriched with inorganic nitrates derived from beetroot. Participants in the intervention group will consume a standardized dose of 12 mmol of nitrate per day for 5 days (starting 24 hours before PCI and continuing for 4 days post-procedure). The product is designed to enhance nitric oxide bioavailability, improve renal perfusion, reduce oxidative stress, and lower the risk of contrast-induced nephropathy (CIN).
224059958|NCT06984289|OTHER|Radiomic Analysis of Ultrasound Images|Quantitative analysis of pre-treatment ultrasound images of the primary cervical tumor to extract radiomic features. These features will be used to develop and validate machine learning models for predicting treatment response and disease relapse in patients with locally advanced cervical cancer (LACC).
224301375|NCT01349582|PROCEDURE|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
224301376|NCT01349582|PROCEDURE|surgical clipping|clipping of the aneurysm following invasive brain surgery
224059959|NCT00592033|OTHER|oxygen from a portable concentrator|2 l/minute during exercise
223570238|NCT05010941|DEVICE|Hypotension Prediction Index|Hypotension Prediction Index monitored via radial arterial line
223570239|NCT03989973|DIAGNOSTIC_TEST|Gastroscopy|Gastroscopy
223570240|NCT04233658|DRUG|Placebo|3x2 capsules / day
223570241|NCT04233658|DRUG|Cynara Scolymus|3x2 capsules / day
224059960|NCT03602092|OTHER|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
224059961|NCT05440656|DRUG|Cohort|Participants with Severe Eosinophilic Asthma
224059962|NCT04178174|RADIATION|SABR boost and de-escalated chemoradiation|Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
224301377|NCT03772431|OTHER|Female Voice|The survey was narrated by a female voice
224301378|NCT03772431|OTHER|Motivational Introduction|The survey introduction was worded to include motivational content
224059963|NCT04178174|RADIATION|Standard chemoradiation|Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
223452387|NCT01310127|DRUG|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
223452388|NCT01310127|DRUG|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
223452389|NCT05703334|OTHER|Kinesio tap|Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
223452390|NCT00033319|DIETARY_SUPPLEMENT|folic acid|
224059964|NCT03565575|BEHAVIORAL|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~1. Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~2. Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
224059965|NCT06324448|DEVICE|Transcranial direct current stimulation|tDCS self-administered at home once a day for 28 consecutive days for a total of 28 sessions (one session consists of 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea)).
224059966|NCT06042725|PROCEDURE|Biospecimen Collection|Undergo optional collection of blood samples
224059967|NCT06042725|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224059968|NCT06042725|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224059969|NCT06042725|PROCEDURE|Chest Radiography|Undergo chest x-ray
224059970|NCT06042725|PROCEDURE|Computed Tomography|Undergo PET/CT
224059971|NCT06042725|BIOLOGICAL|Daratumumab|Given SC
224059972|NCT06042725|DRUG|Dexamethasone|Given PO
224059973|NCT06042725|DRUG|Lenalidomide|Given PO
224059974|NCT06042725|PROCEDURE|Low Dose Computed Tomography of the Whole Body|Undergo WBLDCT
224059975|NCT06042725|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223452391|NCT00033319|DRUG|acetylsalicylic acid|
223452392|NCT02073526|DRUG|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
223452393|NCT03498313|DRUG|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
223452394|NCT03498313|DRUG|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
224301379|NCT03772431|OTHER|Male Voice|The survey was narrated by a male voice
224059976|NCT06042725|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224059977|NCT06042725|DRUG|Venetoclax|Given PO
224059978|NCT06042725|PROCEDURE|X-Ray Imaging|Undergo x-rays
224059979|NCT06042725|OTHER|Questionnaire Administration|Ancillary studies
224059980|NCT06872866|DRUG|ASP-001.1|Oral liquid suspension of sildenafil
224059981|NCT06872866|DEVICE|ASP-001.1|Bottle/pump containing ASP-001.1 suspension
224059982|NCT04819256|OTHER|PACE-It mobile application|Care co-ordination platform
224059983|NCT06708312|PROCEDURE|press needle acupuncture|Placement of press needle on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
224059984|NCT06708312|PROCEDURE|sham press needle acupuncture|Placement of adhesive plaster on the ear acupuncture point : MA-TF1 Shenmen, MA-IC4 Heart, and MA-IC4 Sympathetic
224301380|NCT03772431|OTHER|Informational Introduction|The survey introduction was worded to include informational content
224301381|NCT05985733|OTHER|Biochemical analysis|Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
223452395|NCT03498313|DRUG|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
223452396|NCT01439243|DRUG|Donepezil|10 mg Tablet
224059985|NCT00801645|BEHAVIORAL|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
224059986|NCT06904339|BEHAVIORAL|Starting the Conversation|Starting the Conversation includes a 25-minute video with information about sexual health and gynecologic cancer and tips about how to talk to their cancer care team about sexual health concerns. Participants will also fill out a workbook with activities to help them practice communication skills.
224059987|NCT06904339|BEHAVIORAL|Sexual Health Resources|The sexual health resource guide includes institutional resources for patients with sexual concerns (for example, the Women's Survivorship Clinic) and links to reputable websites with information about sexual health after gynecologic cancer.
224301382|NCT00777127|DRUG|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
223452397|NCT01439243|DRUG|Aricept®|10 mg Tablet
223452398|NCT02517736|DRUG|Sorafenib at a dose of 800 mg / day|
223452399|NCT00184002|DRUG|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
223452400|NCT02171429|DRUG|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
224059988|NCT06444217|PROCEDURE|skin biopsy|skin biopsy
223452401|NCT02171429|OTHER|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6, and 8.
223452402|NCT02171429|DRUG|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
224059989|NCT06927466|BIOLOGICAL|B019|B019： Intravenous infusion, 1.0×10\^6 CAR T cell/kg-10.0×10\^6 CAR T cell/kg
224059990|NCT00733954|DRUG|clobetasol propionate spray|Apply twice daily
224059991|NCT00733954|DRUG|clobetasol propionate ointment|Apply twice daily
224059992|NCT02663453|DRUG|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
224059993|NCT02663453|DRUG|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
224059994|NCT05479890|OTHER|ClientBot|ClientBot is an AI-based simulated client that supports skills improvement for providers learning and using Motivational Interviewing
224059995|NCT00218491|DRUG|N-Acetylcysteine|1200mg N-Acetylcysteine
224059996|NCT00218491|DRUG|N-Acetylcysteine|2400mg N-Acetylcysteine
224059997|NCT00218491|DRUG|Matching Placebo|Matching Placebo
223452403|NCT02171429|OTHER|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC once every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
223452404|NCT00392756|DRUG|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
223452405|NCT04628000|OTHER|Vitamin D|Clinical Correlation
223452406|NCT04654715|PROCEDURE|Gracilis flap interposition for rectouretral fistula management|Gracilis flap interposition is a surgery for rectouretral fistula
224301383|NCT00777127|DRUG|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
223452407|NCT03573570|OTHER|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
224059998|NCT02562924|DEVICE|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
223452408|NCT05223790|DEVICE|Pain measurement during care procedures in neonatal reanimation|Pain measurement during care procedures in neonatal reanimation
223452409|NCT02923401|OTHER|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
223452410|NCT02923401|BEHAVIORAL|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
223452411|NCT02923401|BEHAVIORAL|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
223452412|NCT02923401|BEHAVIORAL|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
223452413|NCT02923401|OTHER|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
224059999|NCT02562924|DRUG|Budesonide|Topical steroid
224060000|NCT02562924|DRUG|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
224060001|NCT02562924|DRUG|Prednisone|Post-operatively, 40 mg daily for 7 days
224060002|NCT02562924|PROCEDURE|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
224060003|NCT02562924|DRUG|nasal saline spray|saline nasal mist every hour while awake
224060004|NCT01553630|PROCEDURE|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
224060005|NCT01553630|PROCEDURE|Surgery without bone graft|Plating of fracture without bone graft
224060006|NCT01834092|OTHER|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
224060007|NCT00633659|DRUG|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
224060008|NCT00633659|DRUG|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
224060009|NCT01579188|DRUG|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
224060010|NCT01579188|DRUG|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
224060011|NCT01860924|BEHAVIORAL|exercise|vigorous intensity exercise
224060012|NCT01860924|BEHAVIORAL|health education|education
224060013|NCT05266235|DEVICE|Validation of the Withings bodyscan scale WBS08|Participants will undergo simultaneous recordings of ECGs with the comparator and the study device
223742130|NCT03238404|PROCEDURE|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
223742131|NCT03238404|PROCEDURE|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
224060014|NCT04720235|DEVICE|Lucira COVID-19 All-In-One test kit|"The Lucira COVID-19 All-In-One Test Kit is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 in nasal swab samples. This test is a single-use test kit that determines whether there is active shedding of the virus which causes COVID-19. This test utilizes a molecular amplification technology for the detection of SARS-CoV-2 RNA.~Positive results are indicative of active infection with SARS-CoV-2. Persons who test positive should self-isolate and seek care from their healthcare provider.~Negative results do not preclude SARS-CoV-2 infection. Persons who continue to experience COVID-like symptoms should seek follow up care from their healthcare provider"
224060015|NCT02474433|DRUG|Misoprostol (Cytotec)|
224060016|NCT00937300|BIOLOGICAL|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
224060017|NCT06391671|OTHER|Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)|Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
224060018|NCT01705600|BEHAVIORAL|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
224060019|NCT01556607|DRUG|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
224060020|NCT01556607|DRUG|Placebo|
224060021|NCT00294307|BEHAVIORAL|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners \[low intensity\];
224147412|NCT02750267|DEVICE|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
224147413|NCT04702048|DRUG|Aflibercept Injection|Patients randomized to Arm A will receive 2 mg IVT aflibercept injections every 4 weeks (Q4W) to Week 20, followed by 2-mg aflibercept injections Q8W to Week 52.
223452414|NCT06212284|DRUG|Citalopram 20mg|Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
223452415|NCT06212284|DRUG|Placebo|Doses were gelatine capsules filled with microcrystalline cellulose
223452416|NCT02406963|OTHER|Digital Photograph|A digital photograph sent by the family of the surgical site
223570242|NCT05858957|DRUG|Magnesium sulfate|magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
223570243|NCT05858957|DRUG|Saline|100 ml saline infusion apply to the Group S
223570244|NCT03362788|DRUG|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
223570245|NCT03362788|DRUG|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
223570246|NCT03356977|DRUG|Crisaborole ointment 2%|Applied BID
223570247|NCT03908190|BEHAVIORAL|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
223742132|NCT04608786|DRUG|ZKAB001 5mg/kg|ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
223742133|NCT04608786|DRUG|Capecitabine|Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
223742134|NCT01372501|DEVICE|Endobarrier Liner|Medical device placed endoscopically in the duodenum
223452417|NCT02406963|OTHER|Telephone Call|Standard telephone call with the nurse practitioner
223452418|NCT04332003|DEVICE|Remote Ischemic Conditioning (RIC) Treatment|RIC treatment will be delivered by an automated device that delivers the RIC treatment (manufactured by LifeCuff Technologies).
223452419|NCT05421780|DIETARY_SUPPLEMENT|autoclaved BSG-containing biscuits|Consumption of autoclaved BSG-containing biscuits as breakfast.
223452420|NCT05421780|DIETARY_SUPPLEMENT|bio-transformed BSG-containing biscuits|Consumption of bio-transformed BSG-containing biscuits as breakfast.
223570248|NCT00650455|DRUG|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
223570249|NCT00650455|DRUG|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
223570250|NCT00650455|DRUG|placebo|placebo tablet every morning and capsule every evening for 12 weeks
223570251|NCT04436471|BIOLOGICAL|Gam-COVID-Vac|adenoviral-based vaccine against SARS-CoV-2
224060022|NCT00294307|BEHAVIORAL|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home \[medium intensity\];.
224060023|NCT00294307|BEHAVIORAL|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers \[high intensity\].
223570252|NCT01545232|BIOLOGICAL|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
223570253|NCT01545232|BIOLOGICAL|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
223452421|NCT05421780|DIETARY_SUPPLEMENT|control biscuits|Consumption of plain biscuits as breakfast.
223570254|NCT05739695|DIAGNOSTIC_TEST|Virtual bronchoscopy navigation|It is planned to use VBN as the only navigation technique to compare it with rEBUS
223570255|NCT05739695|DIAGNOSTIC_TEST|radial EBUS|It is planned to use rEBUS as the only navigation technique to compare it with VBN
223570256|NCT06115694|DEVICE|TCI Articulating Introducer|use
223570257|NCT06115694|DEVICE|GlideRite® Rigid Stylet|use
223570258|NCT01884493|DEVICE|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
223570259|NCT01884493|DEVICE|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
223570260|NCT03433820|OTHER|Observation of wound healing|Observation of wound healing after skin biopsy
224060024|NCT03610061|DRUG|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
224060025|NCT03610061|RADIATION|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
224060026|NCT03610061|RADIATION|Radiotherapy (cohort 6 only)|"Cohort 6 patients (only) will receive:~Day 8-Day 10: External Beam Radiotherapy to target site(s)- daily (ie. 5 further fractions to a total of 10 fractions)"
224060027|NCT04760665|BIOLOGICAL|Fecal microbiota transplantation|Patients will receive four fecal microbiota transplantation (FMT) capsules. Microbiota is obtained from healthy patients.
224060028|NCT04760665|OTHER|Placebo|Patients will receive four oral capsules containing placebo. These capsules will have the same shape, weight and colour as capsules containing FMT.
224301384|NCT03274674|OTHER|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
223452422|NCT04716621|OTHER|Early intervention|"The Pain Management Support System for Primary Care (PMSS-PC) generated best practice alerts and gave clinicians access to a pain assessment template, measures of psychological distress and substance use, guidelines for drug and non-drug therapies, and facilitated referrals. At implementation, clinicians at the practices were offered in-person and virtual education through six webinars on best practices for pain."
224060029|NCT04083482|PROCEDURE|continous venovenous hemofiltraion|CVVH
224060030|NCT02263183|DIETARY_SUPPLEMENT|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
224060031|NCT02263183|DIETARY_SUPPLEMENT|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
223452423|NCT04716621|OTHER|Delayed intervention|Delayed wait-list control group. The second arm involved three additional sites receiving the PMSS-PC intervention 6 months after the first arm. Initial outcomes from the PMSS-PC Experimental Intervention arm were compared to those of this Wait-list Control arm.
223452424|NCT04360473|OTHER|General anesthesia|Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
223452425|NCT04360473|DRUG|Ketamine plus general anesthesia|ketamine 0.3 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
223570261|NCT04185974|RADIATION|C12 re-irradiation|51 Gy(RBE) or 54 Gy
223570262|NCT04185974|RADIATION|Photon re-irradiation|54 Gy(RBE) or 60 Gy
223570263|NCT03031392|DIAGNOSTIC_TEST|Sensitivity test|Routine clinical and radiographic examination
223570264|NCT05210634|DIETARY_SUPPLEMENT|THCv|THCv in MCT oil
223570265|NCT01032317|DEVICE|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
223570266|NCT01057056|OTHER|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
223570267|NCT02291393|DEVICE|80 lead ECG|
223570268|NCT00873535|DRUG|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
224060032|NCT01477385|PROCEDURE|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
224301385|NCT03356574|PROCEDURE|Single-ventricle palliation surgery|Single-ventricle palliation surgery
224301386|NCT02441582|OTHER|Telemetry|
224301387|NCT02441582|OTHER|Non-telemetry|
223570269|NCT00873535|DRUG|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
223570270|NCT00937989|OTHER|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
223570271|NCT00937989|OTHER|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
224060033|NCT01477385|PROCEDURE|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
224060034|NCT01477385|PROCEDURE|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
224060035|NCT01477385|PROCEDURE|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
224060036|NCT01477385|PROCEDURE|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
224147414|NCT04702048|DRUG|Sham injection|Patients randomized to Arm B will receive sham intravitreal injections every 4 weeks (Q4W) to Week 20, followed by sham intravitreal injections Q8W to Week 52. Sham means eye will be numbed and a syringe with no needle will be touched to the eye.
223452426|NCT04360473|DRUG|Magnesium sulfate plus general anesthesia|Magnesium sulfate 40 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.
223452427|NCT04360473|DRUG|ketamine plus magnesium sulfate plus general anesthesia|Ketamine 0.15 mg/kg plus magnesium sulfate 20 mg/kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane
223452428|NCT01481402|DRUG|Liothyronine|Liothyronine 40 microgram per day
223452429|NCT01481402|DRUG|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
223452430|NCT02163681|DRUG|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
223452431|NCT02020889|BIOLOGICAL|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
223452432|NCT02020889|DRUG|Placebo|Placebo will be available as 0.9% sodium chloride
223452433|NCT05515237|BEHAVIORAL|Grade 2-5 CI Therapy + Sensory Components|All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
223452434|NCT02768792|DRUG|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
223452435|NCT01438112|BIOLOGICAL|CG0070 Adenovirus Vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
223452436|NCT01438112|OTHER|Control Arm: Quadruple Choice|Quadruple Choice Treatment Options: (same as listed above)
223570272|NCT00937989|OTHER|medical chart review|Baseline, 3, 6 and 9 months after starting the study
223570273|NCT00937989|OTHER|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
223570274|NCT00937989|OTHER|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
223570275|NCT00937989|PROCEDURE|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
223570276|NCT00445939|BIOLOGICAL|adalimumab|160 mg at Week 0, 80 mg at Week 2
223570277|NCT00445939|BIOLOGICAL|adalimumab|80 mg at Week 0, 40 mg at Week 2
224060037|NCT02611154|DRUG|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
223452437|NCT05980013|DEVICE|Whole blood donation supine|Subjects will undergo a 1-unit whole blood donation in a supine position
223452438|NCT05980013|DEVICE|Whole blood donation reclined|Subjects will undergo a 1-unit whole blood donation in a reclined position
223570278|NCT00445939|BIOLOGICAL|placebo|Placebo at Week 0 and Week 2
223570279|NCT06427070|OTHER|Irrigating solution|Saline, sodium hypochlorite, chlorohexidine
224060038|NCT01526512|DRUG|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
224060039|NCT00089908|BIOLOGICAL|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
224147415|NCT04631068|PROCEDURE|Cataract surgery|Small incision cataract surgery with implantation of an intraocular lens
224147416|NCT06356948|DRUG|Tranexamic Acid (TXA)|Study drug administration
224147417|NCT01476748|DEVICE|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
224147418|NCT03089658|DRUG|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
224060040|NCT00089908|BIOLOGICAL|Placebo|Placebo for rDEN1delta30
224060041|NCT03872986|DEVICE|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
224147419|NCT02714504|DRUG|Voriconazole or posaconazole|Azole with activity against molds
224147420|NCT05314881|GENETIC|TNFS4, NCF gene|study the gene polymorphisms from the blood sample of the included SLE patients
224301388|NCT05370755|DRUG|ICP-189|Administered orally
223452439|NCT06099041|DEVICE|Nd-YAG Laser for iris depigmentation|Nd-YAG Laser for iris depigmentation
223452440|NCT06304480|DIETARY_SUPPLEMENT|100g fermented Tofu|"* Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.~* Participants will consume the first Study Product on the day of their Visit 3 (Day 0) and will consume their last Study Product the day prior to Visit 5 (Day 56).~* Participants will be instructed to return any unused Study Product at Visit 5 (Day 56)."
223452441|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.05%|
223452442|NCT00893139|DRUG|AL-38583 ophthalmic solution 0.10%|
223452443|NCT00893139|DRUG|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
223452444|NCT06643585|DRUG|Trastuzumab-Deruxtecan|Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
223452445|NCT06643585|OTHER|Physicians Choice (PhC).|Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
223452446|NCT05964907|DEVICE|Light Source B: Visible Light solar simulator (VL + UVA1)|Patients will be radiated with light source B (Visible light solar simulator)
223452447|NCT05964907|DEVICE|Light Source A: Visible Light solar simulator closer match to sunlight (VL +UVA1)|Patients will be radiated with light source A (Visible light solar simulator closer match to sunlight)
223452448|NCT04095325|DEVICE|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
223452449|NCT00102115|DRUG|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
223452450|NCT03026829|DEVICE|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
223570280|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises and Buerger Allen|Patient will be asked to lie down flat on the plinth with legs elevated from 45 degrees until the skin turns pale, it will take approximately 2 minutes to occur. Then the patient turns to sit at the edge of the plinth with feet hanging and doing the following exercises; dorsiflexion, plantar flexion, inversion, eversion, and flexion the extension of toes, this phase may also be maintained for 2 minutes. Finally, the patient lies flat with his leg rested in a horizontal position and covered with a warm blanket for about 5 minutes
223570281|NCT05878587|OTHER|thermotherapy+ TENS+ low intensity high repetition exercises|The intervention will be repeated 3 times per day and the posttest will be conducted 5th day using KOOS, NPRS and goniometer.
223570282|NCT02154048|DRUG|Ropivacaine|
224060042|NCT03872986|DEVICE|Giomer|Beautifil II dental restorative material
224060043|NCT03872986|DEVICE|GIC|Equia forte dental restorative material
223570283|NCT02154048|DRUG|Dexamethasone|
223570284|NCT02154048|OTHER|Placebo|
223570285|NCT00378599|DRUG|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
223570286|NCT00377559|DRUG|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
223570287|NCT00606398|PROCEDURE|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
223570288|NCT04026360|OTHER|no intervention|
223570289|NCT02984449|BEHAVIORAL|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
223570290|NCT02984449|BEHAVIORAL|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
224060044|NCT03284684|OTHER|Blood test|plasma concentration of circulating DNA of specific genes
224060045|NCT01845012|OTHER|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
224060046|NCT02140697|DIETARY_SUPPLEMENT|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
224060047|NCT02140697|DIETARY_SUPPLEMENT|Placebo (3g/day)|Placebo (3g/day), parallel design
223452451|NCT05266482|OTHER|Personal report|In the intervention group, in addition to receiving the usual care, patients will receive personal reports on multiple time points. These reports include feedback on their PROs including reference scores of patients who previously underwent total knee replacement surgery.
223452452|NCT02388087|DEVICE|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
223452453|NCT02388087|PROCEDURE|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
224060048|NCT06082141|PROCEDURE|Transversus thoracis plane block combined with serratus anterior plane block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 5 ml 0.5% bupivacaine + 5 ml NaCl under US-guidance
224060049|NCT06082141|PROCEDURE|Serratus anterior plan block|SAP block will be made with 10 ml 0.5% bupivacaine + 10 ml NaCl under US-guidance, TTP block will be made with 10 ml NaCl under US-guidance
224060050|NCT05073614|GENETIC|immunohistochemical detection of Heparanase in chronic gastritis|immunohistochemical detection of Heparanase in chronic gastritis specimens.
224060051|NCT01756534|DEVICE|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
224301389|NCT04516512|BIOLOGICAL|Blood draw|For each participants to the research a peripherical blood draw will be performed
224301390|NCT00191633|DRUG|Atomoxetine|
223452454|NCT01768559|DRUG|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
223452455|NCT01768559|DRUG|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
223570291|NCT00489736|DRUG|dronedarone (SR33589)|oral administration
223570292|NCT00489736|DRUG|amiodarone|oral administration
223570293|NCT05110560|BEHAVIORAL|"Stay at Home Take a Step Program (SHTSP)"|The Stay at Home Take a Step Program consisting of video or audio calls four times, sending Short Message Service messages containing reminders to encourage walking, and daily step count and weight tracking will be implemented.
223570294|NCT03333317|DRUG|Lumicitabine|Participants will receive oral administration of lumicitabine.
223570295|NCT03333317|DRUG|Placebo|Participants will receive oral administration of matching placebo.
223570296|NCT03812185|DEVICE|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
223570297|NCT05490589|OTHER|EQUIPE Program|"EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home."
223742135|NCT04020393|PROCEDURE|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
223570298|NCT03952715|DRUG|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
223570299|NCT03952715|DRUG|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
223570300|NCT03262207|OTHER|Extraction genomic DNA|
223570301|NCT03262207|OTHER|Analysis of methylation profiles of numerous GSI and TE|
223570302|NCT03262207|OTHER|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
223570303|NCT03262207|OTHER|Method of protein detection by immunostaining and flow cytometry|
223570304|NCT01127841|DRUG|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
223570305|NCT04172168|DIAGNOSTIC_TEST|Heart rupture|Left ventricular free-wall ruptrue after AMI
223742136|NCT01466348|DRUG|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
223742137|NCT01466348|DRUG|Paracetamol|Paracetamol 1000 mg
223742138|NCT05966324|DRUG|baxdrostat|Baxdrostat is an aldosterone synthase inhibitor
223742139|NCT04139967|RADIATION|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
223742140|NCT05334901|DEVICE|High intensity light cure|Bulk fill resin composite restoration cured with high intensity light curing (2200 mw/cm2)To achieve increased power and a wider spectrum for short exposure time (1 second) to overcome resin composite restoration techniques sensitivity and shorten the clinical procedure
223452456|NCT01768559|DRUG|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
223452457|NCT01768559|DRUG|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
223452458|NCT01768559|DRUG|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
223452459|NCT03486405|OTHER|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
223570306|NCT05175768|OTHER|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
223570307|NCT05175768|OTHER|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
223570308|NCT05175768|OTHER|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
223570309|NCT05025098|DRUG|Standard therapy|"For AML patients: Venetoclax will be administered orally once daily Days 1 through 28, of a 28-day cycle, with a designated dose of 400 mg daily after ramp up in Cycle 1. During Cycle 1 Days 1 - 3, the dose of Venetoclax will ramp up from 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.~For MDS patients: Azacitidine (100 mg/m2) is given once daily for 5 days of every 28 day cycle, starting on day 1 of each cycle."
223570310|NCT05025098|DRUG|Precision therapy|Precision therapy for both AML and MDS patients is standard therapy + tumor board determined precision therapy. The tumor board determined precision therapy can be all available drugs with a marketing authorization in Norway.
223742141|NCT05362747|BEHAVIORAL|Behavioral weight loss and produce vouchers|Participants will receive weekly 30-minute, individual, in-person lifestyle counseling delivered by trained interventionists (e.g., registered dietitians) that consists of behavioral, dietary, and physical activity counseling. ProduceRx vouchers will be in the form of Food Bucks and will be provided at each session.
223742142|NCT04599374|OTHER|no intervention|This study collected data only without any intervention.
223742143|NCT03989440|DRUG|AXER-204|human NoGo Trap fusion protein
223742144|NCT03989440|DRUG|Placebo|Phosphate buffered saline formulation
223452460|NCT03486405|OTHER|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
223570311|NCT02460913|PROCEDURE|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
223742145|NCT05405192|DRUG|Dostarlimab|First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
224060052|NCT04185103|DRUG|Sacubitril-Valsartan|After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.
224060053|NCT01351935|DRUG|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
224060054|NCT04040894|BIOLOGICAL|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
224060055|NCT00867373|BEHAVIORAL|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
224147421|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
224147422|NCT02394795|DRUG|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
223452461|NCT02096562|OTHER|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
223452462|NCT02096562|OTHER|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
223452463|NCT01149031|DEVICE|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
223452464|NCT02589847|BIOLOGICAL|RBX2660|suspension of intestinal microbes
223452465|NCT02589847|DRUG|Standard of Care Antibiotics|Standard of Care Antibiotics
223452466|NCT03110978|BIOLOGICAL|Nivolumab|Given IV
223452467|NCT03110978|RADIATION|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
223452468|NCT05649696|DRUG|Recombinant Staphylokinase|Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
223452469|NCT05649696|DRUG|Normal Saline|Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
223452470|NCT05345847|OTHER|Active Surveillance|Close monitoring of liver enzymes with steroid rescue strategy (watch and wait approach)
223452471|NCT05345847|OTHER|Early initiation|Immediate start of high-dose steroids
223452472|NCT05621837|OTHER|MDSC quantification|Blood sample will be collected at baseline and during therapy, and, optionally, in case of disease progression (PD).
223570312|NCT02460913|DRUG|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
223570313|NCT01684644|BEHAVIORAL|New Forest Parenting Programme|
223570314|NCT01684644|BEHAVIORAL|Treatment as usual|
224060056|NCT03067883|DRUG|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~* These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~* Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~* Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
224060057|NCT02655432|DEVICE|Spot photoscreener|Screening of vision problem through an automated device
224060058|NCT02655432|PROCEDURE|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
224060059|NCT02655432|PROCEDURE|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
224060060|NCT03258112|PROCEDURE|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
224060061|NCT06394713|DRUG|QLF31907|intravenous administration, once every 3 weeks
224147423|NCT04070118|PROCEDURE|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
224301391|NCT04476966|DRUG|Bladogra|1 tablet contains 25 mg Mirabegron
223452473|NCT00440635|DRUG|Bortezomib, tradename Velcade|
223570315|NCT05181202|OTHER|Blood sampling|Collect blood before drug injection. we do not intervene the clinical administration or drug choice or other clinical treatment.
223570316|NCT04134117|BIOLOGICAL|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
224060062|NCT06394713|DRUG|Irinotecan|intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
224301392|NCT04476966|DRUG|Myrbetriq (first dosing)|1 tablet contains 25 mg Mirabegron
224301393|NCT04476966|DRUG|Myrbetriq (second dosing)|1 tablet contains 25 mg Mirabegron
223452474|NCT03816111|BEHAVIORAL|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
223452475|NCT03816111|BEHAVIORAL|Current standard PD training|Current PD training materials and plan
224060063|NCT06394713|DRUG|Docetaxel|intravenous administration, 75mg/m2, d1, every 3 weeks
223452476|NCT06399016|DEVICE|augmented reality book|The story will be presented to the children in this application group in three dimensions. The augmented reality application will be supported by the researcher as it must be used under the supervision of an adult. When the tablet or phone is held to the pages of the book, the animations of these pages are displayed on the screen with sound. While the animation opens automatically when we hold the phone or tablet, the story can be listened to aloud at the same time.
223452477|NCT06399016|DEVICE|book|This group will be asked to just read the book without turning on the augmented reality feature of the book.
223570317|NCT05749003|OTHER|sensorimotor training exercise|Patients will be trained through three stages: static, dynamic and functional. Each exercise will be repeated 3-5 times during a session and with enough periods of rest between each set of exercises. The exercise graduated from easy to more difficult and the patient was not progressed to a more difficult stage until performing the easier one.
224060064|NCT05407584|DRUG|Orevogomab+PLD|"PLD (40 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks (28 days)~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following PLD over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
224060065|NCT05407584|DRUG|Orevogomab+Paclitaxel|"paclitaxel (80 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks on day 1, 8, 15~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following paclitaxel over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7"
224060066|NCT00084123|BEHAVIORAL|Healing Touch Therapy|
224060067|NCT00084123|BEHAVIORAL|Relaxation Therapy|
223452478|NCT01411514|DRUG|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
223452479|NCT01411514|DRUG|Placebo|Placebo tablets. They will be administered during 25 days
224060068|NCT00084123|BEHAVIORAL|Standard Care|Standard Care
224060069|NCT01099852|OTHER|biological sample collection|blood sample collection urine sample cerebrospinal fluid sample
224060070|NCT01099852|OTHER|Quality of life Questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
223452480|NCT05362149|DRUG|Darolutamide (Nubeqa, BAY1841788)|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
223452481|NCT05362149|DRUG|Enzalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
223452482|NCT05362149|DRUG|Apalutamide|Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
223570318|NCT05749003|OTHER|conventional physical therapy program of exercise.|stretching exercise for 30 minutes, then strengthening exercise and usual burn care for the lower extremity. Exercises will be applied for 3 times a week for 8 consecutive weeks.
223570319|NCT01509976|OTHER|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
223570320|NCT04028765|DRUG|Misoprostol|Oral misoprostol 50 mcg every 4 hours for up to 6 doses or until cervical ripening is no longer indicated
223570321|NCT04028765|DRUG|Oxytocin|IV Oxytocin 2 milliunits (mU)/min, increased by 2mU/min q15 minutes per hospital protocol
223570322|NCT06537297|DRUG|Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab|"* Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease."
223570323|NCT00839449|DRUG|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
223570324|NCT02284529|DRUG|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
223570325|NCT02801279|OTHER|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
223570326|NCT02801279|OTHER|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
224060071|NCT01099852|OTHER|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
224060072|NCT01099852|OTHER|Neuropathic Pain Questionnaire (DN4)|Questionnaire used during the follow up
224060073|NCT00234611|PROCEDURE|Echocardiogram guided left ventricular lead placement|
224060074|NCT06188156|PROCEDURE|Anethesia|To assess the effectiveness of thoracic epidural blockage versus ultrasonic guided PECS II block versus ultrasound guided serratus anterior plane block for postoperative pain management in modified radical mastectomy.
223570327|NCT02944357|DRUG|Cisplatin|Given IV
223570328|NCT02944357|DRUG|Gemcitabine Hydrochloride|Given IV
223570329|NCT02944357|PROCEDURE|Radical Cystectomy|Undergo cystectomy
223570330|NCT02944357|BIOLOGICAL|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
223570331|NCT05091697|BEHAVIORAL|Multicomponent treatment VIRTUAL FIBROWALK + TAU|To assess the effectiveness and cost-utility of the virtual multicomponent program (Fibrowalk)
223570332|NCT05787093|DEVICE|transabdominal rectal ultrasound|transabdominal rectal ultrasound to detect megarectum and evaluate the improvements after medical therapy with macrogol
223570333|NCT02576535|PROCEDURE|Fractionated stereotactic radiosurgery|
223570334|NCT02576535|DEVICE|Leskell gamma unit|FDA approved device
224060075|NCT02244216|DRUG|Berotec® N 100 µg Metered-dose Inhaler|
223452483|NCT05088681|OTHER|Rehabilitation program|The exercise intervention will consist of an individualized prescription of resistance training, balance training and cardiovascular exercises delivered for 20 session, one-hour, two/three times per week.
223452484|NCT05977101|BIOLOGICAL|MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
223452485|NCT05977101|OTHER|Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient|Patients who met the inclusion and exclusion criteria were randomly assigned to one of three different cohorts. Subjects in each cohort were randomly assigned in a ratio of 5:1 to two parallel dosing groups, one of which served as the control group. Each cohort was given either an experimental drug or a placebo nasal spray at different doses and intervals, and blood was collected on an empty stomach before the first dose, and left nasal swabs and throat swabs were collected for immunotoxicity and drug concentration testing.
223452486|NCT00565890|DRUG|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
223452487|NCT01679444|PROCEDURE|Magnetic Resonance Spectroscopy|
223452488|NCT05103306|DRUG|Empagliflozin 25 MG|Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor
223452489|NCT05103306|DRUG|INS|Basal insulin add on the background OADs
223452490|NCT00877539|DRUG|PF-03526299|Inhaled, two doses 4 hours apart
223452491|NCT00877539|DRUG|Placebo|Inhaled, two doses 4 hours apart
223452492|NCT00877539|DRUG|Fluticasone propionate|Inhaled
223452493|NCT00002071|DRUG|Epoetin alfa|
223452494|NCT01515696|DRUG|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
223452495|NCT01515696|DRUG|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
223452496|NCT04396379|DEVICE|Implant an epicardial device to reshape the mitral valve annulus|The implant is intended to epicardially reshape the mitral valve annulus and left ventricle without the need for cardiopulmonary bypass (CPB) and open-heart access (atriotomy), in patients with left ventricular dilation and mitral valve insufficiency in patients with ischemic or functional MR.
223452497|NCT05102435|OTHER|Tool Translation & Validation study|In this English version of POMA scale will be translated into Urdu.
223452498|NCT05205980|BEHAVIORAL|Perturbation training|Participants will experience repeated perturbations mixed with non-perturbed trials on the treadmill with the protection by a harness.
223452499|NCT01541072|DRUG|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
223452500|NCT01541072|DRUG|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
223452501|NCT00398047|DRUG|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
223452502|NCT06248684|OTHER|standardized prevention and therapy measures|Patients from the age of 65 years with an additional risk factor for postoperative delirium are assigned to a multidimensional standardized perioperative care protocol.
223452503|NCT03687866|GENETIC|non invasive prenatal testing|
223452504|NCT00114829|PROCEDURE|MR colonography with dynamic contrast uptake|
223570335|NCT02962271|DEVICE|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
223570336|NCT06065319|DEVICE|Wearable Sensors|Participants will wear smartwatches and smartrings and this data will be used to design algorithms which seek to find associations between device data and recovery.
224060076|NCT05447494|DRUG|Low-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
224060077|NCT05447494|DRUG|High-dose CAN103|"Phase 1 is a within-subject dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of two doses of CAN103 in newly treated subjects with GD1.~Phase 2 is a randomized, double-blind, parallel group, dose comparison study to evaluate the efficacy and safety of two doses of CAN103 administered intravenously every other week for 37 weeks in newly treated GD1 or GD3 subjects with significant non-neurological clinical manifestations."
224060078|NCT04667351|DRUG|2400 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 2400 mg/m² 5-FU
224060079|NCT04667351|DRUG|1200 mg/m² 5-fu|Hepatic arterial infusion of oxaliplatin,leucovorin and 1200 mg/m² 5-FU
224060080|NCT02872740|PROCEDURE|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
224060081|NCT02872740|PROCEDURE|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
223452505|NCT02411734|BEHAVIORAL|Rehabilitation|Rehabilitation after hospitalization
223452506|NCT00192777|DRUG|Xeloda|
223452507|NCT00192777|PROCEDURE|External Beam Radiotherapy|
223452508|NCT04506931|OTHER|SMS Survey|Participants will receive a SMS survey
223452509|NCT04506931|OTHER|IVR Survey|Participants will receive an IVR survey
223452510|NCT04506931|OTHER|CATI Survey|Participants will receive a CATI survey
223570337|NCT01842165|DRUG|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
224060082|NCT06410560|OTHER|Training about storytelling and creative writing: 12 hours|Participants in training courses on creative writing and storytelling.
223452511|NCT04017117|PROCEDURE|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
223452512|NCT04726774|BEHAVIORAL|Hypnosis|"Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion."
223452513|NCT04726774|BEHAVIORAL|Rehabilitation program|Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
223452514|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
223452515|NCT00926432|DEVICE|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
223452516|NCT00902746|DRUG|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
223570338|NCT05076916|BEHAVIORAL|The effectiveness of the web-based education programme among cancer patients|The web-based education program was introduced to the patients with cancer in the intervention group during face-to-face interviews. They were asked to examine the program for at least two hours a week for three months. During the follow-up period, the patients in the intervention group were called twice a week and reminded to use the education program. The researchers get in contact with the patients online via the website. The patients contact the research team by calling or writing messages via the website 24/7. An e-mail account was created by the research team using the email system of the university, and it was shared with the patients. The clinical researchers of the team answered the patients' questions via this e-mail account.
223570339|NCT03167970|DEVICE|Pill cam|Patient is asked to swallow the esophageal capsule.
223570340|NCT03167970|OTHER|EGD|Patient will undergo standard EGD
223570341|NCT03010137|PROCEDURE|Incisional Negative Pressure Wound Therapy|
223570342|NCT03010137|PROCEDURE|Standard Closure with Skin Glue|
223570343|NCT03010137|DEVICE|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
223742146|NCT04136054|BEHAVIORAL|Adjusted group CBT-i for Depression, Anxiety and PTSD|Adjusted group CBT-i for Depression, Anxiety and PTSD. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
224060083|NCT06410560|OTHER|Training only about theoretical narrative medicine: 4 hours|Participants in training courses on only theoretical narrative medicine.
224301394|NCT01669473|OTHER|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
224060084|NCT03820622|DEVICE|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
224301395|NCT05480826|GENETIC|study of the transmission of genetic variants|the genetic variants of interest will be investigated by sequencing or genotyping on genomic DNA
224301396|NCT01602965|PROCEDURE|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
223570344|NCT03010137|DEVICE|Dermabond|Final wound closure with skin glue.
224060085|NCT03820622|DEVICE|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
224060086|NCT04022915|DRUG|64Cu-FBP8|Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
224060087|NCT04022915|DIAGNOSTIC_TEST|PET-CT imaging|All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
224060088|NCT03344315|DEVICE|experimental: collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
224060089|NCT03344315|OTHER|Active Comparator: autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
224070945|NCT02800200|DEVICE|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
224301397|NCT01602965|PROCEDURE|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
223742147|NCT04136054|OTHER|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, such as mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
223742148|NCT02974296|DEVICE|transcranial magnetic stimulation|non invasive brain stimulation approach
223742149|NCT01312090|BIOLOGICAL|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
223452517|NCT01385540|BEHAVIORAL|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
223452518|NCT00939588|DRUG|Aliskiren/ Valsartan|
223452519|NCT00939588|DRUG|Telmisartan/ Ramipril|
223452520|NCT02191345|BEHAVIORAL|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
223452521|NCT00638092|DRUG|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
223452522|NCT00638092|DRUG|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
223452523|NCT04878939|OTHER|Power chain used for anterior segment retraction|Elastomeric chain rendering 160 g/side extending between mini-screw implant and a hook crimped on 0.017- by 0.025-inch stainless steel wire distal to the lateral incisor.
223452524|NCT04878939|OTHER|T-loop fabricated to perform anterior segment retraction|In the frictionless group, anterior segment retraction was done using closing T-loops fabricated from 0.017- by 0.025-inch titanium molybdenum alloy (TMA) wire rendering comparable retraction force.
223452525|NCT00351936|DRUG|Aripiprazole|
223452526|NCT00351936|DRUG|placebo|
223452527|NCT06800339|DRUG|Nivolumab|This will be administered intravenously once every 3 weeks for up to 3 cycles (i.e. 9 weeks of total systemic therapy)
223452528|NCT06800339|DRUG|Chemotherapy|Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine
223452529|NCT06800339|RADIATION|SBRT|Three fractions of radiation delivered every other day, for three total days. The final dose of radiation will happen within 7 days of starting chemoimmunotherapy
223452530|NCT06800339|PROCEDURE|Surgical Resection|Post treatment patient will be evaluated for surgical resection
223452531|NCT04504747|OTHER|molecular analysis of blood and tumor|RNAseq, DNAseq, CTCs
223452532|NCT04541212|DIAGNOSTIC_TEST|Cardiac Imaging|Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test
223570345|NCT01529515|DRUG|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
223570346|NCT01529515|DRUG|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
223570347|NCT01529515|DRUG|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
223570348|NCT01529515|DRUG|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
223570349|NCT01529515|DRUG|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
223570350|NCT04597021|DEVICE|use of a wiresless US transducer|to (evaluate the practicability of applying a wireless US transducer for central venous catheter-placement in these patients.
223570351|NCT01706497|DEVICE|Cerebral tissue oxygen saturation monitoring, blinded|
223570352|NCT01536665|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
223742150|NCT01312090|BEHAVIORAL|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
223742151|NCT05725954|BEHAVIORAL|GUT LINK SmartPath|A virtual care delivery and referral support tool for primary healthcare providers.
223742152|NCT03679780|DRUG|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
223742153|NCT03679780|DRUG|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
223742154|NCT03679780|DRUG|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
223452533|NCT04541212|OTHER|Data Collection|Collection of retrospective data
223452534|NCT00305422|DRUG|Quetiapine fumarate|
223570353|NCT01536665|DRUG|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
223452535|NCT00305422|DRUG|Risperidone|
223570354|NCT03334851|DRUG|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
223570355|NCT03334851|DRUG|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
223570356|NCT06163495|BEHAVIORAL|Screen Free Time with Friends intervention|School-based extracurricular intervention focusing on time spent with friends and screen media use
223570357|NCT05467761|DRUG|Oral Psilocybin|25mg orally
223570358|NCT05467761|DRUG|IV Psilocybin|5mg intravenously
223742155|NCT03679780|DRUG|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
223742156|NCT03679780|DRUG|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
223742157|NCT03679780|DRUG|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
223452536|NCT01125085|RADIATION|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"* Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~* Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~* Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~* Total treatment duration is up to 4 weeks"
223742158|NCT06536777|OTHER|Plyometric Exercises|This include Plyometric Training for 8 weeks
224060090|NCT03841071|OTHER|ROM/CFS intervention|The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
224060091|NCT03116646|DIAGNOSTIC_TEST|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
224060092|NCT06177756|BEHAVIORAL|Nutritional and lifestyle counseling|"At risk children Intervention Arm: schedule at least four visits/year with anthropometric monitoring, educate parents on the appropriate diet, active lifestyle from the first year of life, regular self-monitoring of their child's anthropometry and appropriate dietary composition and portion control, provide tailor-made nutritional suggestions.~Not-at-risk children Intervention Arm: educational website with interactive tools for growth self-monitoring and diverse lifestyle suggestions."
224060093|NCT06318910|DEVICE|orthotic wedge|The orthotic wedges with a full length of 3-mm soft foam layer will be provided to each participant under the molded orthoses; the amount of wedge angle will depend on the rearfoot and forefoot angles of the participants. The present study developed 3-degree, 6-degree, and 8-degree wedges for the rearfoot and forefoot. It was made from solid rubber with a cover of thin fabric. There are three sizes for these products which include small (S), medium (M), and large (L) sizes, according to the foot length of participants.
224060094|NCT06318910|DEVICE|CFO|The 3-quarter-length CFO will be made from thermoplastic material (rigid foot orthoses) which consists of four layers i.e. two layers of 0.5-mm polyvinyl chloride (PVC), one layer of 1.5-mm thick fiber to increase strength of foot orthoses in the bottom layers as well as one layer of 1.2-mm genuine leather in the upper layer to increase comfort. It incorporates a heat-molding process to adjust individual foot shape in prone position. The materials will be set within approximately three minutes.
224060095|NCT06465797|DIAGNOSTIC_TEST|Bronchoscopy|No intervention will take place in this study, only image material will be captured from the standard-of-care bronchoscopy
224060096|NCT00034372|DRUG|oregovomab|
224060097|NCT02390011|PROCEDURE|MRI|
224060098|NCT04192487|DRUG|Crofelemer delayed-release tablets 125mg|1 crofelemer delayed-release tablet twice daily at least 8 hours apart for 30 days with or without meals.
224060099|NCT04325542|DIAGNOSTIC_TEST|HBSAg (sure screen test)|Diagnostic test for Hepatitis B
223452537|NCT02347072|DRUG|GFF MDI (PT003)|
223452538|NCT02347072|DRUG|Placebo MDI|
223452539|NCT02347072|DRUG|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
223452540|NCT06442202|DIETARY_SUPPLEMENT|Balanced Nutritional Diet|"Food was provided during the intervention period 3 (three) times each day, i.e. breakfast, lunch and dinner. The food menu used a 30-day menu cycle. The characteristics of the Balanced Nutrition Diet that have been provided based on the distribution of the composition of the macronutrients that will be intervened in are as follows: 45-55% carbohydrates, 15-20% protein, and 20-25% fat (Ministry of Health 2014). The type of diet and portions that were given were the same for each menu unless there were certain food restrictions or allergies, and then the type of food was adjusted specifically to that individual. The calories that will be given range from 300-400 Cal for breakfast, 400-500 Cal for lunch, and 300-500 Cal for dinner.~The choice of carbohydrates should be varied and prioritise complex carbohydrates such as whole grains. The choice of protein type is prioritised from low-fat protein sources and half of it is vegetable protein."
224060100|NCT00928551|DRUG|vabicaserin|
223570359|NCT05791409|DRUG|Epcoritamab|Number of cycles of epcoritamab is either 6 (cycle 1-6) or 12 (cycle 1-12). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
224060101|NCT01849874|DRUG|MEK162, MEK inhibitor; oral|multiple dose, single schedule
224060102|NCT01849874|DRUG|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
223570360|NCT05791409|DRUG|Venetoclax|All patients will receive venetoclax cycle 1-26 (a 5 week ramp-up of venetoclax will precede the first cycle). Patients will be treated until they have received the total number of assigned treatment cycles or until progression, or severe toxicity, whichever comes first.
223742159|NCT06536777|OTHER|Blood Flow Restriction Training|This include Blood Flow Restriction Training for 8 weeks
224060103|NCT02618304|DRUG|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
224060104|NCT04673292|BEHAVIORAL|Fixed site standard of care testing|This arm includes all three Johns Hopkins (JHMI) ambulatory outdoor testing sites across Baltimore City. Each site represents a traditional appointment-based scheduling system. Participants will be given a choice of 1 of 3 outdoor testing locations based on their preferences. Study staff will make an appointment for testing based on testing availability and participant schedule.
223570361|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
223570362|NCT00798239|OTHER|Iliac crest autograft|autograft
223570363|NCT00798239|DEVICE|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
223570364|NCT03172065|DRUG|Normal saline|intravenous flluid
223570365|NCT03172065|DRUG|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
224060105|NCT04673292|BEHAVIORAL|Community-based, mobile van testing|This arm offers the convenience of highly accessible testing and with the flexibility of no fixed appointment time. Each of the 12 geographic strata will have a single, centrally located testing site within the area, providing similar geographic access across households. The testing location will be published on the study website and social media so that participants can visit the location at a time convenient to them.
224060106|NCT04673292|BEHAVIORAL|Self-collected, home-based testing|Individuals will receive a home-based testing kit delivered by a courier service as soon as the randomization of the household is complete. The kit will include provisions for contacting the courier service for pick up. Appropriate biohazard precautions are included. Each of the testing components of this kit will include FDA Emergency Use Authorization approved collection methods. Easy to use instructions with options to view pre-recorded videos and/or virtual 'on demand' coaching sessions with members of the study team via a HIPAA-secure Zoom session will be available.
224060107|NCT01922817|DRUG|Saxagliptin|5mg saxagliptin
224060108|NCT03324906|DEVICE|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
224060109|NCT03687151|OTHER|non intervention / observationnal|non intervention / observationnal
224060110|NCT06475417|DRUG|Adebrelimab combined with DOS|After signing the informed consent, they are screened to meet the inclusion criteria. After receiving the standard dose of adebrelimab combined with DOS regimen for 3 courses of treatment before surgery, and within 3-6 weeks after the completion of the third administration, preoperative imaging examination is used to evaluate the efficacy of new adjuvant treatment and the possibility of radical D2 resection, The patient underwent radical surgical treatment for gastric cancer and observed pCR
224060111|NCT00823628|DRUG|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
224060112|NCT00823628|DRUG|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
224060113|NCT01427998|DIETARY_SUPPLEMENT|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
224060114|NCT01427998|OTHER|placebo|placebo
224060115|NCT00933075|DRUG|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
224060116|NCT04474769|OTHER|Educational intervention for preceptors|
224060117|NCT05939310|PROCEDURE|Fluorescence guided detection of tumor positive margins.|Intraoperative fluorescence imaging detection of tumor positive margins using the targeted tracer bevacizumab-IRDye800CW.
224060118|NCT03239574|DEVICE|MightySat|MightySat - investigational pulse oximeter that will be placed on the subject's right index finger for the duration of the study
224060119|NCT03865173|OTHER|Telephone Interview|Telephone Interview
224060120|NCT02409589|DEVICE|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
224060121|NCT02409589|PROCEDURE|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
224060122|NCT02831413|BEHAVIORAL|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
224060123|NCT02831413|BEHAVIORAL|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
224060124|NCT02960828|PROCEDURE|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
224060125|NCT02960828|DRUG|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
223452541|NCT06442202|BEHAVIORAL|Nutritional Education|Nutritional education is provided via online Zoom meetings with the help of educational media in the form of PowerPoint presentations/videos before entering the intervention period. The educational material that will be provided is regarding Guidelines for Balanced Nutrition, Food Safety, and Healthy Lifestyles (stress management and sleep time). The subject's understanding of the material provided was evaluated using an online quiz platform.
224060126|NCT02960828|DEVICE|Subthreshold Laser|
224060127|NCT05427409|DIETARY_SUPPLEMENT|Beta-alanine supplementation|In a randomized order, two groups (n=7) was randomly assigned to beta-alanine and placebo during a 4-weeks period
224301398|NCT01272726|BEHAVIORAL|Education|Education on the genetics of ADHD and treatment options for ADHD
223452542|NCT05206396|DIAGNOSTIC_TEST|TIL assessment in pre-existing histopathological specimens|TIL assessment in pre-existing histopathological specimens and their relation to complete pathological response and 1-year invasive disease-free interval
223452543|NCT02591030|DRUG|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
224060128|NCT01916876|OTHER|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~1. On day 3 they will be contacted telephonically to:~   i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~2. Reminders via SMS to attend there OPD appointment(s)~3. Medical out-patient review at 2-weeks and 6 weeks if required~4. Medical telephonic hot-line for advice"
224060129|NCT05097703|BEHAVIORAL|Sleep Resource|The sleep resource is a card game to be played by children and caregivers as part of their bedtime routine. It includes exercises to help prepare the child for sleep, including deep breathing, mindfulness and light movement. Caregivers will be asked to use the resource for a minimum of three nights a week over a four week period, and complete pre and post outcome measures as well as sleep and resource use diaries for their children
224060130|NCT01042860|DIETARY_SUPPLEMENT|Lutein|Lutein supplement, 10 mg daily
224060131|NCT01042860|DIETARY_SUPPLEMENT|Placebo|Placebo
224060132|NCT00365521|PROCEDURE|Photodynamic Therapy|
223452544|NCT02591030|DRUG|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
223452545|NCT03056014|DRUG|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
224060133|NCT02744443|DIETARY_SUPPLEMENT|Leucine|
224060134|NCT02744443|DIETARY_SUPPLEMENT|Placebo|
224060135|NCT03914807|OTHER|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
224060136|NCT03914807|OTHER|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
224060137|NCT01082432|OTHER|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
224060138|NCT02531581|DRUG|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc
224060139|NCT02531581|DRUG|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
224060140|NCT02913937|DEVICE|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
224060141|NCT02913937|DEVICE|Endodontic needle|Endodontic irrigation
224060142|NCT02064530|DRUG|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
224060143|NCT02064530|DRUG|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
224060144|NCT02064530|DRUG|serum physiologic|21 ml serum physiologic is applied interfasially
224060145|NCT02952157|DRUG|Lidocaine jelly application|
224060146|NCT02952157|DRUG|Normal saline application|
224060147|NCT06036862|PROCEDURE|Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction|Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
224070946|NCT05967663|DEVICE|PCI-immediate complete revascularisation|In patients allocated to the immediate complete revascularisation group, PCI of the culprit lesion was attempted first and followed by all other lesions deemed to be clinically significant by the operator during the index procedure.
224070947|NCT05967663|DEVICE|PCI-staged complete revascularisation|In the staged complete revascularisation group, only the culprit lesion was treated during the index procedure and PCI of all non-culprit lesions deemed to be clinically significant by the operator was planned at a later stage through an elective re-admission within 15-45 days after randomisation.
224070948|NCT04539730|DRUG|Liposomal bupivacaine|266 mg or 20 ml Liposomal Bupivacaine injectable solution
224070949|NCT04539730|PROCEDURE|Drug: SoC Ropivacaine|0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
224070950|NCT04681170|DRUG|Lomitapide|2mg,5mg, 10mg and 20mg capsules
224070951|NCT04986202|DRUG|AZD4831|AZD4831
224070952|NCT04986202|OTHER|Placebo|Placebo
223452546|NCT03056014|DIETARY_SUPPLEMENT|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
223452547|NCT03056014|DIETARY_SUPPLEMENT|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
223452548|NCT00351559|DEVICE|AlloMap molecular expression testing|
223452549|NCT00351559|PROCEDURE|Right ventricular endomyocardial biopsy|
223452550|NCT04843540|DRUG|CTP-543|Rifampin as oral capsule
223452551|NCT02446847|DRUG|3BNC117|3BNC117 infusions
223452552|NCT02446847|OTHER|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
223452553|NCT03704012|BEHAVIORAL|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
223452554|NCT03466879|DEVICE|SYNUS Pain Relief device|SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
223452555|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
223452556|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
223452557|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
223452558|NCT01351948|BIOLOGICAL|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
223452559|NCT01351948|BIOLOGICAL|AdCh63 AMA1 + MVA AMA1|5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections
223452560|NCT02910934|OTHER|Actellic CS|Indoor residual spray with Actellic CS
223452561|NCT02324621|DRUG|Oral ONC201|Given PO
223452562|NCT02324621|OTHER|pharmacological study|Correlative studies
223742160|NCT03704272|BEHAVIORAL|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
223742161|NCT02207790|DRUG|E2609|
223742162|NCT02207790|DRUG|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
223742163|NCT03970733|BIOLOGICAL|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
223742164|NCT03970733|BIOLOGICAL|Placebo|PBS (Phosphate Buffered Saline)
223742165|NCT03693079|PROCEDURE|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~1. Primary suction; cups are left attached to the skin for 5 minutes.~2. Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~3. Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~4. Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~5. Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
223742166|NCT02341807|BIOLOGICAL|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
223742167|NCT03322488|PROCEDURE|Fistulodesis|"Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
223742168|NCT04834479|DEVICE|Ankle US and Ankle MRI|Ankle US and Ankle MRI
223742169|NCT00822068|DEVICE|anodal tDCS|anodal transcranial direct current stimulation
224070953|NCT02468648|DRUG|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
224070954|NCT02468648|DRUG|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
224070955|NCT02118792|DRUG|AN2728 Topical Ointment, 2%|
224070956|NCT02118792|DRUG|Matching vehicle control|
224070957|NCT05451849|BIOLOGICAL|TC-510|TC-510
224070958|NCT05451849|DRUG|Fludarabine|Fludarabine
223452563|NCT02324621|OTHER|laboratory biomarker analysis|Correlative studies
223452564|NCT05277064|OTHER|Oral FOB|After induction of anesthesia and muscle relaxation, An investigator who has experiences of numerous fiberoptic intubations will measure the optimal preliminary insertion depth of the fiberoptic bronchoscope for oral fiberoptic intubation.
223452565|NCT02157597|OTHER|NIRS based management|"1. Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~2. Deepen anesthesia with volatile or intravenous agent.~3. Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
223452566|NCT02157597|OTHER|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
223452567|NCT05388422|DEVICE|Application of 3D scanner to measure physical size in patients with severe cerebral palsy|Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
223452568|NCT04166292|DEVICE|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
223452569|NCT02205697|BEHAVIORAL|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
223452570|NCT06731062|DEVICE|EF192A|EF192A will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. EF192A will be reapplied to the participants' back in a naive area and removed after 48 hours.
223452571|NCT06731062|DEVICE|Saline solution|The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back in a naive area and removed after 48 hours.
223452572|NCT06006598|DRUG|BI 1584862|BI 1584862
223452573|NCT06006598|DRUG|Placebo matching BI 1584862|Placebo matching BI 1584862
223452574|NCT06006598|DRUG|midazolam|midazolam
223452575|NCT03215407|DRUG|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
223452576|NCT03215407|DRUG|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
223452577|NCT06367777|DEVICE|cervical a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
223452578|NCT06367777|DEVICE|thoracic a-tsDCS|Anodal transcutaneous spinal direct current stimulation (a-tsDCS)
223452579|NCT06367777|DEVICE|sham tsDCS|Sham transcutaneous spinal direct current stimulation (s-tsDCS)
223452580|NCT01529411|DRUG|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min).
223452581|NCT01529411|OTHER|Undefined (standard care)|All the current interventions used by each institution for the study disease.
223452582|NCT03341117|DRUG|Acetylsalicylic acid|Acetylsalicylic acid 300 mg per capsule
223452583|NCT03341117|DRUG|Calcined magnesia|Calcined magnesia 300 mg per capsule
223452584|NCT06756776|DEVICE|Hot pack|The Hot Pack is a therapeutic intervention device designed to deliver localized heat to targeted areas of the body for a duration of 15 minutes. It provides deep, soothing heat that helps to relax muscles, increase blood circulation, and reduce pain and stiffness. The device is typically used to treat conditions such as muscle tension, joint pain, and chronic discomfort. By applying consistent heat, the Hot Pack promotes improved tissue flexibility and alleviates muscle spasms. It is user-friendly, ensuring safe and effective use when applied to affected areas, with adjustable heat settings to accommodate individual needs.
223570366|NCT01761318|DRUG|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
223570367|NCT01761318|DRUG|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
223570368|NCT06289920|DRUG|BR3005|One tablet administered alone, Once a day
223570369|NCT06289920|DRUG|BR3005-1|One tablet administered alone, Once a day
223570370|NCT06289920|DRUG|BR3005-2|One tablet administered alone, Once a day
223742170|NCT00822068|DEVICE|cathodal tDCS|cathodal transcranial direct current stimulation
223742171|NCT00822068|DEVICE|sham stimulation|sham stimulation
223742172|NCT02189473|RADIATION|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
224060148|NCT04546477|DEVICE|Stent implantation|"Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon."
224060149|NCT02217605|DIETARY_SUPPLEMENT|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
224060150|NCT02830880|DRUG|FACBC PET-CT|Anti-3-\[18F\]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
224060151|NCT02830880|OTHER|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or bone scan will be performed to correlate imaging findings.
224060152|NCT03045861|DRUG|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
224060153|NCT03045861|DRUG|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
223570371|NCT01967017|DRUG|Lidocaine|
224060154|NCT04048915|BEHAVIORAL|Long live drama|"The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
224070959|NCT05451849|DRUG|Cyclophosphamide|Cyclophosphamide
223570372|NCT01967017|DRUG|Placebo|
223570373|NCT03920293|BIOLOGICAL|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams \[mg\]/milliliter \[mL\]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
223570374|NCT03920293|DRUG|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
223570375|NCT03804463|PROCEDURE|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
223570376|NCT03804463|PROCEDURE|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
223570377|NCT03804463|PROCEDURE|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
224060155|NCT04048915|BEHAVIORAL|Short live drama|"The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
224060156|NCT01412593|BIOLOGICAL|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
224060157|NCT00019409|DRUG|asparaginase|
224060158|NCT00019409|DRUG|cyclophosphamide|
224060159|NCT00019409|DRUG|cytarabine|
224060160|NCT00019409|DRUG|daunorubicin hydrochloride|
224060161|NCT00019409|DRUG|mercaptopurine|
224060162|NCT00019409|DRUG|methotrexate|
224060163|NCT00019409|DRUG|prednisone|
224060164|NCT00019409|DRUG|therapeutic hydrocortisone|
224060165|NCT00019409|DRUG|vincristine sulfate|
224060166|NCT00019409|RADIATION|radiation therapy|
224060167|NCT05400213|DEVICE|Vallos (DCP)|Demineralized freeze-dried bone allograft (DFBA) in a small particle form
224060168|NCT05400213|DEVICE|Vallomix (DCF)|A combination of cow-derived xenograft and human-derived DFDBA particulate
224301399|NCT06426173|OTHER|Resistance Training Program|The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.
223452585|NCT06756776|OTHER|Sustained Natural Apophyseal Glides (SNAG)|The Mulligan Sustained Natural Apophyseal Glides (SNAG) technique for the lumbar spine will be applied to participants in both groups. Participants will assume a stride standing position. The therapist will stand behind the participant as described by Mulligan, supporting the patient during the application of the technique and ensuring the required movement can be performed easily. The therapist will apply the mobilizing force parallel to the facet joint plane (in the cephalic direction) over the spinous processes of the respective symptomatic spinal levels in a sustained manner while the patient performs trunk flexion. The flexion position will be maintained for a few seconds, after which the participant will return to the starting position, with the therapist continuing to maintain the mobilizing force. Three sets of six repetitions will be performed on each symptomatic lumbar spinal level.
223570378|NCT05306561|PROCEDURE|Systane iLux thermal pulsation treatment|Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
224060169|NCT05400213|DEVICE|Vallos-F (DPX)|Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
224060170|NCT05400213|DEVICE|Vallomix-F (DFX)|A combination of cow-derived xenograft and human-derived DFDBA fibers
224060171|NCT06047041|BEHAVIORAL|EIS Only|"The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~* Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~* Asks teachers and students to report on 7 areas of student social-emotional functioning~* Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~* Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~* Individualized technical assistance for schools to support EIS implementation."
224060172|NCT06047041|BEHAVIORAL|EIS + ECHO|"EIS + ECHO supports include supports from the EIS Only condition plus:~* Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~  * Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Collaboration with colleagues in schools that are also implementing the EIS.~ * Opportunities to consult with university faculty and content experts in school mental health.~* Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions."
224060173|NCT04096911|DRUG|Sintilimab|Sintilimab 200 mg intravenously every 3 weeks
224060174|NCT04096911|DRUG|quadrivalent HPV vaccine|The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
224070960|NCT02787863|BIOLOGICAL|Prevenar-13|Conjugate 13 serotype pneumococcal vaccine
224070961|NCT02787863|BIOLOGICAL|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
224070962|NCT01368835|DEVICE|Ulthera treatment|treatment of cheeks and upper neck area of face
224070963|NCT04644809|DRUG|LY3561774|Administered SC.
224070964|NCT04644809|DRUG|Placebo|Administered SC.
224070965|NCT00963898|DEVICE|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
224070966|NCT04120155|PROCEDURE|Dissection of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.
224070967|NCT04120155|PROCEDURE|Preservation of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
224301400|NCT06426173|OTHER|Standard Treatment Group|Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
224060175|NCT06292936|BEHAVIORAL|Acceptance-Based Behavioral Intervention|"Intervention will evaluate acceptance-based behavioral treatment (ABT) for individuals who are experiencing weight regain after bariatric surgery. ABT builds acceptance and mindfulness skills that increase the capacity to experience uncomfortable internal states (e.g., food cravings, hunger, negative affect). Online treatments include video modules demonstrating session content as well as interactive features. These interventions are particularly desirable, reduced participant burden, and are cost effective.~ABT provides patients unique skills that directly target causes of dietary non-adherence. ABT provides patients specialized skills to directly target causes of dietary nonadherence (rather that solely repeating behavioral strategies they received during preoperative medical weight management required by their third party payers and bariatric surgery programs)."
224060176|NCT03551509|PROCEDURE|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
224060177|NCT03551509|PROCEDURE|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
224060178|NCT03551509|BIOLOGICAL|Alternative Treatment Group|Patients who meet pre-op inclusion criteria where a repair cannot be accomplished due to intraoperative findings will remain in the study. This group will be analyzed separately and still follow study procedures.
224060179|NCT04461262|DEVICE|Camstent Coated Catheter|The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked
224147424|NCT03489681|DEVICE|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
224147425|NCT03451500|DRUG|carbidopa-levodopa|See previous
224147426|NCT02159261|DRUG|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
224147427|NCT05875376|BEHAVIORAL|Couple group therapy|"1. Introduction of I statements~2. Focus of each conversation~3. Emotion acknowledgement~4. Self-assurance and positive feedback~5. teamwork and cooperation~6. Reflection"
224301401|NCT05620602|OTHER|Remedial treatment within 3 months|"The interval between the time of this treatment and the last day of the last therapy is within 3 months.Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
224060180|NCT04461262|DEVICE|Standard Care|Uncoated Foley catheter
224060181|NCT01972048|BEHAVIORAL|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
224060182|NCT01972048|OTHER|Print brochure|Mailed print brochure about breast cancer screening and community resources.
224060183|NCT00806936|DRUG|human insulin|Any kind of human insulin administered at the discretion of the physician
224060184|NCT00806936|DRUG|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
224147428|NCT03258697|DRUG|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
224147429|NCT06372886|PROCEDURE|portal/superior vein resection|portal/superior vein resection
224147430|NCT03371342|DRUG|Meditoxin|Meditoxin (Botulinum toxin type A)
224147431|NCT03371342|DRUG|Botox|Botox(Botulinum toxin type A)
224147432|NCT04911699|BEHAVIORAL|breast adenocarcinoma receiving chemotherapy|for chemotherapy
224301402|NCT05620602|OTHER|Remedial treatment within 3 to 6 months|"The interval between the time of this treatment and the last day of the last therapy is 3-6 months.~Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
224301403|NCT05620602|OTHER|Remedial treatment within 6 to 12 months|"The interval between the time of this treatment and the last day of the last therapy is 6-12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
224147433|NCT04911699|BEHAVIORAL|Control-for|hormonal drug treatment
224147434|NCT02443571|RADIATION|Fluciclovine (18F)|Not applicable. This is an observational study.
223452586|NCT06756776|OTHER|Passive Hamstring (HM) stretching|Passive Hamstring (HM) stretching will be performed by a physical therapist experienced in the treatment of chronic low back pain (CLBP) and trained in the study protocol. The procedure will follow manual therapy stretching standards \[22\]. First, the physical therapist will explain the procedure to the participant and reassure them that the stretching can be stopped if it becomes too difficult to tolerate. With the participant lying supine, the stretched limb will be placed in maximal, pain-free hip flexion with the knee flexed. The physical therapist will then slowly and gradually extend the knee to the maximal pain-free position. In this position, participants should feel an intense stretching sensation in the back of the thigh. If this position causes pain in the lower back, the hip flexion will be reduced to the maximal, pain-free range of motion (ROM). A stopwatch will be used to ensure that the final position is held for 1 minute for each limb.
223570379|NCT06204692|PROCEDURE|dental implant|consisted of 6 patients where computer guided dental implant placement
224060185|NCT04052685|PROCEDURE|Selective removal to soft dentin (SRSD)|In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
224060186|NCT04052685|PROCEDURE|Selective removal to firm dentine (SRFD)|Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
224060187|NCT03443908|DEVICE|CPAP|CPAP therapy 3-4 weeks
224060188|NCT04720482|DIAGNOSTIC_TEST|Somatosensory Evoked Potentials|SSEP performed bilaterally with stimulation of the median nerve
224060189|NCT04720482|DIAGNOSTIC_TEST|Automated Pupillometry|PLR quantified as NPi using a handheld automated pupillometer
224060190|NCT04515693|OTHER|6 Minutes Walking Test|A walkway of 12 meters will be marked with one cone at each end. The patient will be instructed to walk back and forth as many times as possible in six minutes.
224060191|NCT04798469|DRUG|Testosterone Undecanoate 250 MG/ML|Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
224060192|NCT04798469|DRUG|Placebo|Intramuscular administration of placebo at baseline, weeks 4, and week 14.
224060193|NCT01700556|OTHER|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
224060194|NCT01700556|OTHER|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
224060195|NCT01700556|OTHER|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
224060196|NCT01700556|OTHER|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
224060197|NCT04252846|DRUG|Perampanel|Perampanel oral tablets or oral suspension.
224060198|NCT00770614|DRUG|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
224060199|NCT00770614|DRUG|Isotonic saline|0.9% sodium chloride
224060200|NCT00770614|DRUG|Placebo|Placebo
224060201|NCT01040351|PROCEDURE|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
224305090|NCT03123536|DEVICE|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
224060202|NCT04631575|DRUG|SHR6390|SHR6390, PO,single-dose
224060203|NCT01230307|DRUG|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
224060204|NCT01230307|DRUG|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
224060205|NCT04071821|DRUG|cetirizine HCl Gummy|cetirizine HCl 10mg in a gummy formulation
224060206|NCT04071821|DRUG|Zyrtec tablet 10mg|cetirizine HCl 10mg tablet
224147435|NCT05161312|BEHAVIORAL|iACT-BC: Oncovox|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
224147436|NCT04081376|DRUG|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
224147437|NCT01382199|DRUG|Lactoferrin|
224147438|NCT04839991|DRUG|CB307|Tri-specific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin
224147439|NCT05677295|DRUG|duloxetine|Duloxetine 30 mg per day
224147440|NCT05677295|DRUG|Imipramine|Imipramine 25 mg per day
224060207|NCT04527302|COMBINATION_PRODUCT|ERP combined with high-definition active tDCS|"The active tDCS +ERP referred to a period of tDCS applied in the first 20 minutes of the ERP treatment (the tDCS device was activated when ERP began and deactivated automatically while ERP continued). The total treatment phase lasted eight weeks and included ten sessions with experienced psychotherapists following a specific manual for the tDCS+ERP treatment.~The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Anode electrode will be localized in front of the mPFC on the FpZ point according to the EEG international reference. Four cathode electrodes will be placed around (i.e. AF7, AF8, F3, F4)."
224060208|NCT04527302|COMBINATION_PRODUCT|ERP combined with sham tDCS|Patients will get the same CBT setting as the active tDCS group and they were applied the sham tDCS cocurrently with ERP. The sham tDCS device is the same as the active comparator's except that the sham tDCS will only deliver a current stimulation for the first and last 15 seconds in order to produce somatic sensation in patients similar to that induced by the active tDCS.
224060209|NCT04243590|BEHAVIORAL|Hand-Use-at-Home Questionnaire (HUH)|The HUH assesses the amount of spontaneous use of the affected hand in children with unilateral upper limb paresis aged 3-10 years, performing 18 typical bimanual play and self-care activities. Parents rate items using a 5-point rating scale (never-sometimes-regularly-often-always). After completion, the ratings are converted into a 3-point score (i.e. never/sometimes = score 0, regularly/ often = score 1, always = score 2). A sum score can be calculated (range 0-36).
224060210|NCT04243590|BEHAVIORAL|Pediatric Outcome Data Collection Instrument (PODCI)|The PODCI is designed to assess different aspects of daily living in children with musculoskeletal disorders. It has excellent psychometric properties, and it is a widely accepted instrument to provide parent/patient-reported information about upper extremity functioning. A Dutch version is available and it is validated for children with neonatal brachial plexus palsy. It consists of 85 questions and five scale scores and one total score can be calculated (range for all scales and total score 0-100, higher scores indicating better functioning/quality of life). Only the Upper Extremity and Physical Function Scale (8 items) were used in this study since this scale provides information about difficulties performing activities using the arms/hands (score 0-100; lower score, more difficulties).
224147441|NCT03467295|PROCEDURE|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
223452587|NCT06756776|OTHER|Dry needling|"Subjects will be positioned prone on a treatment table with their feet over the edge of the table. Dry needling (DN) will be applied to the hamstring muscles at three locations, each for 1 minute, using a fast in-out, cone-shaped technique.~Subjects will receive DN three times a week. To standardize the approach and optimize the application of DN, the points will be located approximately close to the motor points of the hamstring muscles.~Two of the locations are in the long and short heads of the biceps femoris, at points located at 30% and 60% of a straight line from the ischial tuberosity to the fibular head. For the semitendinosus and semitendinosus muscles, the DN location will be selected at 60% of a straight line from the ischial tuberosity to the medial femoral epicondyle.~Disposable sterilized stainless steel needles (0.3×60 mm; DongBang AcuPrime Ltd, Korea) will be used."
224147442|NCT03467295|PROCEDURE|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
224147443|NCT00587769|DRUG|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
224147444|NCT01064219|DRUG|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
224147445|NCT01055418|DIETARY_SUPPLEMENT|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
224147446|NCT02683018|DRUG|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
224147447|NCT02683018|DRUG|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
224305091|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology Pro|"The Tandem t:slim X2 with Control-IQ Technology Pro is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is very similar to the commercially available t:sli X2 with Control-IQ but modified to accept the lower weight and Total Daily Insulin of the studied population."
223452588|NCT06756776|DEVICE|Transcutaneous Electrical Nerve Stimulation|The TENS (Transcutaneous Electrical Nerve Stimulation) unit is a therapeutic device designed to alleviate pain through the use of electrical impulses. It works by delivering low-voltage electrical currents via electrodes placed on the skin, targeting the affected area. These electrical pulses help to block pain signals sent to the brain and stimulate the production of endorphins, the body's natural pain relievers. The TENS unit is commonly used for managing both acute and chronic pain conditions, including muscle pain, joint pain, and nerve-related discomfort. The device is adjustable, allowing users to customize the intensity, duration, and frequency of the electrical stimulation to meet their individual needs. It is non-invasive, easy to use, and can be applied at home or in clinical settings for effective pain management.
223452589|NCT04084899|DEVICE|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
223452590|NCT06955624|GENETIC|RNA and/or DNA methylation and/or protein analysis|RNA and/or DNA methylation and/or protein analysis from a blood sample or another tissue including dedifferenciation into induced pluripotent stem cells
223452591|NCT04465812|BEHAVIORAL|Self-monitoring and personalized feedback on smartphone app|"1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index \> 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS\>49 or SDS\>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app"
223452592|NCT01251497|BEHAVIORAL|diabetes self-management education|
223452593|NCT04394936|DRUG|Guselkumab|100 mg guselkumab administered subcutaneously
223452594|NCT04394936|DRUG|Placebos|Sodiumchloride 0,9% solution for injection
223452595|NCT06438666|DEVICE|Anodic Transcranial Direct Current Stimulation|This study will apply the anodic transcranial direct current stimulation over 20 children between 14-18 years old. The protocol that it will follow is the next one: 3 days to value the outcome measures, 4 days (1 sessions per day of 17 minutes and 30 seconds) to apply the protocol of anodic transcranial direct current stimulation (0,6 mA of intensity). It will use the EPTE V07 Bipolar System by IONCLINICS ®; 3 days to value the outcome measures studying the effects produced at the affected upper limb. Another evaluation will be realized 3 weeks after the last sessions of anodic transcranial direct current stimulation to know if the effects obtained last at medium-long term.
223570380|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
223570381|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
223570382|NCT00954798|BIOLOGICAL|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
224060211|NCT04243590|BEHAVIORAL|Children's Hand-Use Experience Questionnaire (CHEQ)|"The CHEQ is a questionnaire for children (aged 6-18) with unilateral functional limitations of hand use and is well validated for children with unilateral cerebral palsy. It was only partially validated for use in children with neonatal brachial plexus palsy and has not yet been used in studies. Therefore, it was not used in this group. The questionnaire consists of 29 bimanual activities, typically requiring the use of both hands. It assesses the child's experience using their affected hand when performing the activities and counts how many of the activities are executed independently (with and without using the affected hand).~In the mini-version of the CHEQ some items were deleted or replaced (with more age-appropriate activities for children aged three to eight years) and this version was used for all unilateral cerebral palsy children \<six years in this study."
224060212|NCT02634853|DRUG|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
224060213|NCT02634853|DRUG|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
224060214|NCT00567970|PROCEDURE|quality-of-life assessment|
224060215|NCT00567970|RADIATION|stereotactic body radiation therapy|
224147448|NCT01225978|DEVICE|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
223570383|NCT04007237|DRUG|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
223742173|NCT03664947|OTHER|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
224060216|NCT00577785|OTHER|tissue procurement|No intervention. Tissue procurement study.
224060217|NCT06126432|DIETARY_SUPPLEMENT|Yugart|Yugart 2 bottles per day for 1 month
224060218|NCT02027142|OTHER|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score \> 5 was indicated poor sleep quality."
224060219|NCT02027142|OTHER|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
224060220|NCT02027142|OTHER|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
224060221|NCT02027142|OTHER|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
224147449|NCT02031432|DRUG|Cebranopadol|Film-coated tablet; strengths: 200, 400, or 600 µg
223742174|NCT01955161|DRUG|Placebo|Once daily, matching placebo capsules, orally
223742175|NCT01955161|DRUG|Idalopirdine|Once daily, encapsulated tablets, orally
223742176|NCT06423144|PROCEDURE|TACE/HAIC|TACE/HAIC were performed within 1 month prior/after the first PD-1/PD-L 1 inhibitor/antiangiogenic drug treatment;
224147450|NCT01617187|DRUG|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
223452596|NCT01127048|DRUG|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
223452597|NCT01127048|DRUG|Placebo|Suppositories containing no Ivy leaves dry extract
223452598|NCT05131022|DRUG|NX-5948|Oral NX-5948
223570384|NCT04966494|DIETARY_SUPPLEMENT|BOSB|BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.
224060222|NCT03500432|PROCEDURE|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
224060223|NCT00004262|PROCEDURE|conventional surgery|
224060224|NCT00004262|RADIATION|3-dimensional conformal radiation therapy|
224060225|NCT00004262|RADIATION|stereotactic radiosurgery|
224060226|NCT00004262|DRUG|motexafin gadolinium|Given IV
224060227|NCT00004262|PROCEDURE|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
224060228|NCT00004262|PROCEDURE|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
224060229|NCT00115154|DRUG|Aldara (imiquimod) cream, 5%|
224060230|NCT01523379|DRUG|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
224060231|NCT01523379|DRUG|Placebo|NaCl i.v. two times a day, two days in an row
224060232|NCT02387359|DRUG|Plecanatide|
224060233|NCT02387359|DRUG|Placebo|
224060234|NCT00185081|DRUG|Indium labeled IMP-205xm734|
223452599|NCT00092963|DRUG|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
223452600|NCT00092963|DRUG|Comparator: placebo / Duration of Treatment: 1 day|
223452601|NCT04017715|OTHER|Experimental: warm up|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
223452602|NCT04017715|OTHER|Experimental: cool down|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
223452603|NCT04017715|OTHER|No intervention: control|sprint exercise and general stretching as conventional protocol as follows in star club
223452604|NCT00254215|BEHAVIORAL|high protein & low glycemic index diets|
223452605|NCT03972215|DRUG|Berberine Chloride|Traditional Chinese Medicine
223452606|NCT03972215|DRUG|Placebo|Placebo Control
223452607|NCT01715701|PROCEDURE|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
223570385|NCT01229072|BIOLOGICAL|Heparin sodic|Heparin sodic 150UI/kg
223452608|NCT01715701|PROCEDURE|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
223570386|NCT01229072|BIOLOGICAL|heparin liquemine|Heparin sodic 150UI/kg
223570387|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine|Combination therapy
223570388|NCT05081349|DRUG|Hydroxycarbamide 500 Mg Oral Capsule|Single agent
223570389|NCT05081349|DRUG|L-Carnitine, 250 Mg Oral Capsule|single agent
223570390|NCT03091985|DEVICE|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
223570391|NCT03091985|DEVICE|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
223742177|NCT06423144|DRUG|PD-1/PD-L1 inhibits and anti-angiogenic agents|Agents were administrated based on the instructions recommended
224060235|NCT02511652|DEVICE|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
224060236|NCT02511652|DEVICE|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
224060237|NCT02511652|PROCEDURE|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
224060238|NCT03877562|DRUG|Olanzapine|Olanzapine 10 mg oral tablet
224060239|NCT03877562|DRUG|CORT118335|CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
224060240|NCT03877562|DRUG|Placebo|Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
224060241|NCT03203044|OTHER|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
224060242|NCT00244270|DEVICE|totally implantable vascular access device|totally implantable vascular access device
224060243|NCT01361035|OTHER|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
224060244|NCT03411720|OTHER|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
224147451|NCT01617187|DRUG|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
224147452|NCT01617187|DRUG|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
224060245|NCT02774447|PROCEDURE|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
223742178|NCT01818076|DRUG|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
223742179|NCT01227772|BIOLOGICAL|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
223452609|NCT01715701|PROCEDURE|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
223452610|NCT00003197|DIETARY_SUPPLEMENT|green tea extract|
223452611|NCT03374839|DRUG|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
223452612|NCT02422004|OTHER|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
224060246|NCT00530894|DEVICE|Edwards SAPIEN Transcatheter Heart Valve|
224060247|NCT00530894|DEVICE|Surgical Valve Replacement|
224147453|NCT01617187|DRUG|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
223452613|NCT02422004|OTHER|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
223452614|NCT03963219|DEVICE|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
223452615|NCT03963219|DEVICE|Standard Bolus Calculator|Standard bolus calculator
223452616|NCT02778022|BEHAVIORAL|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
223742180|NCT01059474|DRUG|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
223742181|NCT04136392|DEVICE|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
223452617|NCT03114085|DRUG|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
223452618|NCT03114085|DRUG|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
223452619|NCT04851366|BEHAVIORAL|PROCARE+ (with add-on modules)|The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.
223742182|NCT00565968|DRUG|melphalan|
223742183|NCT00565968|DRUG|sorafenib tosylate|
223742184|NCT00565968|GENETIC|gene expression analysis|
223742185|NCT00565968|GENETIC|protein expression analysis|
223742186|NCT00565968|GENETIC|western blotting|
223742187|NCT00565968|OTHER|pharmacological study|
223742188|NCT01011517|DIETARY_SUPPLEMENT|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
223742189|NCT03852303|DRUG|ivermectin|evaluate effect of ivermectin on frequency of seizures
223742190|NCT01245270|DIETARY_SUPPLEMENT|Bilberry capsule first, then control cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
224060248|NCT00530894|OTHER|medical management and/or balloon aortic valvuloplasty|
224060249|NCT05587855|OTHER|E-group|Participants with Hypertension will be assigned to eCulinary medicine
224060250|NCT03144245|BIOLOGICAL|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
224060251|NCT03144245|COMBINATION_PRODUCT|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
224060252|NCT02332499|DRUG|Anlotinib|Anlotinib p.o. qd
224060253|NCT02332499|DRUG|Placebo|Placebo p.o. qd
224147454|NCT03923439|DEVICE|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
223452620|NCT04851366|BEHAVIORAL|PROCARE (UP-A for selective purposes)|This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
223452621|NCT04851366|BEHAVIORAL|Active control condition|Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
223452622|NCT05686863|DRUG|Remimazolam|Remazolam for sedation in children undergoing bidirectional endoscopy
223452623|NCT05686863|DRUG|Esketamine|Esketamine
223452624|NCT05686863|DRUG|Propofol|Propofol
223452625|NCT05686863|DRUG|remifentanil|remifentanil
223452626|NCT00523770|PROCEDURE|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
223452627|NCT05710146|DRUG|Tranexamic acid|1 injection of 15mg/kg of TXA in 100mL of normal saline
223452628|NCT05710146|DRUG|Placebo|1 injection of 100mL of normal saline
223452629|NCT01684176|BEHAVIORAL|Complex tailored intervention|
223452630|NCT01684176|BEHAVIORAL|Usual care|
223452631|NCT01856738|DRUG|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
223452632|NCT01856738|DRUG|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
223452633|NCT04560868|DEVICE|Control mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.
223452634|NCT04560868|DEVICE|Experimental mHealth program|The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.
223452635|NCT04560868|DRUG|Nicotine patch|Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
223452636|NCT00328588|DRUG|YM155|IV
223452637|NCT00279344|DRUG|Fentanyl (Matrifen)|
223452638|NCT04394702|OTHER|One Shape Single-file rotary system|rotational single file system used for mechanical debridement of root canals
223452639|NCT04394702|OTHER|manual stainless steel K-file|sequential manual filing with stainless steel K-files
223452640|NCT01347593|DRUG|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
223452641|NCT04974229|OTHER|In line with the Dutch guideline for non-specific low back pain, Standard usual care for non-specific low back pain was applied.|In line with the Dutch guideline for non-specific low back pain, Standard usual care or non-specific low back pain was applied.
223452642|NCT00593424|OTHER|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
223452643|NCT00593424|OTHER|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
223452644|NCT01352273|DRUG|MEK162 + RAF265|
223452645|NCT01259934|DRUG|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
223452646|NCT01259934|DRUG|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
223452647|NCT04301739|DRUG|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
223452648|NCT04301739|DRUG|nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide|chemotherapeutics
223452649|NCT04301739|DRUG|Placebo|Placebo
224060254|NCT01788384|DRUG|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
223452650|NCT00187785|BEHAVIORAL|Spanish speaker level|
223452651|NCT06079749|PROCEDURE|Simultaneous BTKA|Simultaneous BTKA
224147455|NCT02601066|DEVICE|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
223452652|NCT06079749|PROCEDURE|Staged BTKA|Staged BTKA
223452653|NCT03559751|OTHER|VLN cigarettes (A)|0.4mg nicotine / g tobacco king size filter cigarette
223452654|NCT03559751|OTHER|Usual Brand Cigarettes (B)|Usual brand king size non-menthol cigarettes
223452655|NCT03559751|DRUG|Nicotine gum (C)|4 mg nicotine gum
223452656|NCT04983290|DIETARY_SUPPLEMENT|weancare-domus|Participants belonging to the experimental group will receive at home a set of foods that allows to receive the right amount of proteins and energy in a modified texture form to be prepared by themselves or by their caregivers
223452657|NCT03321201|PROCEDURE|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
223452658|NCT03321201|PROCEDURE|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
223452659|NCT02793947|DRUG|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
223452660|NCT02793947|DRUG|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
224060255|NCT01788384|DRUG|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
224060256|NCT01788384|DRUG|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
223452661|NCT02793947|DRUG|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
223452662|NCT02793947|DRUG|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
224147456|NCT00780052|DRUG|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
224147457|NCT07036653|DIAGNOSTIC_TEST|spinal ultrasound|Coronal, axial, sagittal scans of the spine using ultrasound
224147458|NCT06710158|DRUG|SC-102|SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.
224147459|NCT01349686|PROCEDURE|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
224147460|NCT01349686|PROCEDURE|Fasting|No intake of fluids during labour.
224147461|NCT06190405|DIAGNOSTIC_TEST|Hemoglobin A1c|Patients with a HbA1c \<5.7% will be considered a normal test, and they will continue their routine prenatal care, including GDM screening at 24-28 weeks. Patients with a HbA1c ≥5.7% and ≤6.4% will be diagnosed with early GDM. Patients with a HbA1c ≥6.5% will be diagnosed with pregestational diabetes. Patient diagnosed with early GDM or pregestational diabetes will be treated as per usual clinical protocol for gestational/pregestational diabetes.
224147462|NCT06190405|DIAGNOSTIC_TEST|Risk-based screening by ACOG with two-step GTT|Patients will be assessed for risk factors for GDM as per ACOG. Patients with a negative screen will continue routine care, including GDM screening at 24-28 weeks. Patients with a positive screen will undergo a two-step GTT screening. Patients with a 1-h GTT \<135 mg/dL will continue with routine care, including GDM screening at 24-28 weeks. Patients with a 1-h GTT ≥185 mg/dL and \<200 mg/dL will be diagnosed with early GDM. Patients with a 1-h GTT ≥200 mg/dL will be diagnosed with pregestational DM. Patients with a 1-h GTT ≥135 mg/dL and \<185 mg/dL will undergo a fasting 3-h GTT. Patient will be diagnosed with early GDM by Carpenter and Coustan criteria. Patients will be diagnosed with pregestational DM if their fasting glucose value is ≥126 mg/dL. If patients pass the 3-h GTT, they will continue routine care, including GDM screen at 24-28 weeks with a 3-h GTT. Patient diagnosed with early GDM/pregestational DM will be treated as per usual clinical protocol for GDM/pregestational DM.
224147463|NCT06466928|PROCEDURE|Total pancreatectomy|Surgical removal of the entire pancreas
223452663|NCT06331832|BIOLOGICAL|IGM2323|Imvotamab is a recombinant monoclonal antibody of the IgM kappa isotype that targets the human CD20 antigen. Its component J-chain is fused to a single chain Fv antibody fragment which targets human CD3ε.
223452664|NCT05074524|DEVICE|Repetitive Transcranial Magnetic Stimulation|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
223570392|NCT04385641|OTHER|Cell infusion for Dose-finding (Group A)|Group A：HLA-I and HLA-II molecular typing were performed at the serological and molecular levels, and the HLA-I and HLA-II molecular antigens of donor and subjects match on 3, 4, 5 or 6 / 6. After the successful matching, the non myeloablative immunosuppressive pretreatment with cyclophosphamide (900 mg / m＾2 / day) and fludarabine (30 mg / m＾2 / day) will be performed 6, 5, 4 and 3 days before the infusion of UCB-NK cells. After the pretreatment, the cell infusion was started on day 0, and the cell infusion could be divided into 50% and 50% for two consecutive days or every other day. To ensure clinical safety, if treatment-related adverse events reach DLT after the first infusion, the cell infusion will stop.
223570393|NCT04385641|OTHER|Cell infusion for Extended research (Group B)|Group B：Non myeloablative immunosuppressive pretreatment and cell transfusion were the same as group A.
223570394|NCT00544453|DRUG|[123I] MNI-308|Injection of \[123I\] MNI-308 and SPECT scanning
223570395|NCT00539383|DRUG|ANG1005|IV infusion once every 21 days
223570396|NCT00504504|DRUG|Rituximab|375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
223570397|NCT00504504|DRUG|Adriamycin|25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
223570398|NCT00504504|DRUG|Bleomycin|10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
223570399|NCT00504504|DRUG|Vinblastine|6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
223570400|NCT00504504|DRUG|Dacarbazine (DTIC)|375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.
223570401|NCT01691885|DRUG|Fluticasone Furoate|100mcg Once daily
223570402|NCT01691885|DRUG|Vilanterol|25mcg Once daily
223570403|NCT05362227|DRUG|Low volume macrogol|Clensia 2 lt
223570404|NCT05362227|DRUG|High volume macrogol|Selg 4 lt
224147464|NCT01905670|DEVICE|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
224147465|NCT06928753|BIOLOGICAL|IXCHIQ|Group of vaccinated arm will be with the IXCHIQ vaccine
224147466|NCT07092007|BIOLOGICAL|NWRD09 administered by intramuscular injection|NWRD09 administered by intramuscular injection according to the study protocol.
224147467|NCT07092358|OTHER|None of intervention|No specific intervention was implemented in this study.
224147468|NCT07089940|PROCEDURE|Biopsy Procedure|Undergo tumor biopsy
224147469|NCT07089940|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224147470|NCT07089940|PROCEDURE|Computed Tomography|Undergo CT
224147471|NCT07089940|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224147472|NCT07089940|DRUG|Myc Inhibitor OMO-103|Given IV
224147473|NCT05452772|DRUG|Psilocybin|Participants will received two psilocybin sessions, 1 week apart
223452665|NCT05074524|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
223452666|NCT00151437|DRUG|Pegvisomant treatment|
223452667|NCT00151437|PROCEDURE|Medical History, demographics|
223452668|NCT00151437|PROCEDURE|Sign and symptoms: questionnaire|
223452669|NCT00151437|PROCEDURE|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
223452670|NCT00151437|PROCEDURE|MRI|
223452671|NCT02868021|DEVICE|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
223452672|NCT02868021|BEHAVIORAL|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
223452673|NCT02868021|BEHAVIORAL|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
223452674|NCT02868021|BEHAVIORAL|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
223452675|NCT02868021|BEHAVIORAL|Self-assessed function|Using the Late Life Function and Disability Instrument.
223452676|NCT02868021|PROCEDURE|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
223452677|NCT02868021|DEVICE|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
223452678|NCT02868021|DEVICE|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
223570405|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
223570406|NCT03517930|DRUG|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
223742191|NCT01245270|DIETARY_SUPPLEMENT|Control capsule first then bilberry cap|"Male subjects aged \>40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
223742192|NCT02654535|OTHER|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
223742193|NCT01321125|BIOLOGICAL|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
223742194|NCT01321125|OTHER|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
224147474|NCT05452772|DRUG|Niacin|Participants will received two niacin sessions, 1 week apart
224147475|NCT06549972|OTHER|Acute Ischemic Stroke|first-ever anterior circulation AIS (Acute Ischemic Stroke)
224147476|NCT05090098|OTHER|None intervention|None intervention
224147477|NCT04884945|PROCEDURE|Open Pyeloplasty (OP)|Open approach for the surgical correction of UPJ obstruction
223452679|NCT02868021|BEHAVIORAL|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
223452680|NCT02179047|PROCEDURE|coronary angiography|percutaneous coronary intervention. coronary angiography.
223452681|NCT04658433|DIETARY_SUPPLEMENT|300 mg of omega3-FA|The participant will receive 1,000 mg of wild salmon and fish oil complex once daily, which contains 300 mg of omega3-FA.
223452682|NCT04911595|DIAGNOSTIC_TEST|exercise oximetry|transcutaneous oxygen pressure is measured at the skin level on chest , buttocks and calves during a walking test 3.2 km\*:h 10% slope. From the test result the decrease from rest of oxygen pressure (DROP) index is calculated to estimate muscle ischemia
223584088|NCT02846246|OTHER|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
223452683|NCT04911595|DIAGNOSTIC_TEST|thallium scintigraphy|Muscle thallium fixation is measured immediately after a walking test 3.2 km\*:h 10% slope and at 4 hours after the test. From the test result the difference of late and early radioactivity is calculated at the buttock and calf level and normalized to total body radioactivity to estimate muscle ischemia
224060257|NCT05319184|OTHER|Myofascial Release Technique and Kinesiology Taping|"Myofascial release is a manual release technique that increases the elasticity and glide between soft tissue layers, reduces this increased muscle activity and pain intensity. Myofascial release is usually characterized by prolonged mechanical forces exerted directly or indirectly on the limited fascial layers with low load. Following the direction of the fascial restraint, the therapist's hands slowly maintain the stretch and allow the fascia to relax on its own.~Kinesio Taping is a non-invasive, painless and less time consuming method with fewer side effects. It is an elastic-cotton adhesive tape that is latex-free and can be used on any joint or muscle. It can stretch significantly (130-140% of its original length), which reduces mechanical movement limitations and mimics skin in thickness and elasticity. It is used in the treatment of LBP to reduce muscle tone and stiffness as a rehabilitative taping technique designed to support the body's natural healing process."
224060258|NCT04776382|OTHER|EMME (Eye Movement Modeling Examples)|Trainees of this group will watch an EMME (Eye Movement Modeling Examples)-recorded video, on where to focus their gaze while performing the epidural procedure in accordance with expert eye-tracking
224060259|NCT02859181|DIETARY_SUPPLEMENT|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
224060260|NCT05513248|PROCEDURE|anatomic lung resection|includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
224060261|NCT02936427|DRUG|Dexamethasone|perineural infiltration of dexamethasone
224060262|NCT01230242|DEVICE|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
224060263|NCT02256540|DRUG|Climara|
224060264|NCT02256540|DRUG|Placebo patch|Placebo patch designed to match active Climara patches.
224060265|NCT02256540|DIETARY_SUPPLEMENT|Resveratrol|
224060266|NCT02256540|DIETARY_SUPPLEMENT|Placebo|Placebo tablets designed to match active resveratrol tablets.
224060267|NCT03578471|DEVICE|Hearing Aid without NR and BF|Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
223452684|NCT00941200|BIOLOGICAL|Blood collection|
224060268|NCT03578471|DEVICE|Hearing Aid with NR|Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
224060269|NCT03578471|DEVICE|Hearing Aid with BF|Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
224060270|NCT00114582|PROCEDURE|family style dinner|
224060271|NCT02605187|OTHER|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
224147478|NCT04884945|DEVICE|Robotic-Assisted Laparoscopic Pyeloplasty (RALP)|Robotic approach with the da Vinci Surgical System for the surgical correction of UPJ obstruction
223452685|NCT01393522|DRUG|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then taper down as appropriate for dose.
224147479|NCT01770145|DRUG|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
224060272|NCT02605187|OTHER|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
224060273|NCT02605187|DRUG|Ibuprofen|Ibuprofen 600mg po q6h
224060274|NCT02605187|DRUG|Acetaminophen|Acetaminophen 650mg po q6h
224060275|NCT02605187|DRUG|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
224060276|NCT02605187|DRUG|Morphine (low)|Intrathecal morphine dose 50mcg
224060277|NCT02605187|DRUG|Morphine (med)|Intrathecal morphine dose 150mcg
224060278|NCT02605187|DRUG|Morphine (high)|Intrathecal morphine 300mcg
224147480|NCT01770145|DRUG|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
223452686|NCT01393522|DRUG|Placebo|Placebo dosing schedule was Day 1-2, 1 tablet daily, Day 3-6 BID, Day 7-14 BID, Day 15 an on through day 90 BID and taper down
223452687|NCT05927168|DEVICE|TENS|TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
223452688|NCT03212014|OTHER|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
223452689|NCT03212014|OTHER|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
223452690|NCT03212014|OTHER|Traditional rehabilitation|traditional exercise models in currently clinical use
223452691|NCT02936089|OTHER|Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)|"For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT."
223452692|NCT02936089|OTHER|Consolidation with auto-HSCT or HLA-matched HSCT|"For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients."
224060279|NCT04315675|BEHAVIORAL|Guided Imagery Intervention|The participant listens to a selected Guided Imagery for 21 consecutive days.
224060280|NCT04315675|BEHAVIORAL|Cognitive Power Intervention|The participant develops a plan to achieve healthy outcomes and reviews plan for 21 consecutive days.
224060281|NCT04315675|BEHAVIORAL|Combined Guided Imagery and Cognitive Power Intervention|The participant completes 21 days of selected Guided Imagery in combination with the development of a plan to achieve healthy outcomes and reviews the plan for 21 days.
224060282|NCT02562560|BEHAVIORAL|Neuropsychological tests|
224060283|NCT02562560|DEVICE|Cerebral imaging (MRI, PET-FDG)|
224060284|NCT05433571|DEVICE|Test Lens|Multifocal Toric Contact Lenses manufactured in Senofilcon A (C3) material with UV/HEV filter
224060285|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with muscle stretching
224060286|NCT00600574|OTHER|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
224060287|NCT01520935|OTHER|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
224060288|NCT05203497|DRUG|SPECT|One single injection of 99mTc-ZHER2:41071, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
224060289|NCT04462562|DIAGNOSTIC_TEST|Quantitative US (Samsung Medison, RS85A)|In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
224060290|NCT06478069|DIAGNOSTIC_TEST|Group A|Group A was treated with Ibuprofen Dosage After breakfast and after dinner for 6 weeks.
224060291|NCT06478069|BEHAVIORAL|Group B|Group B was treated with physical therapy; (Upper limb: The stroke patient warmed up with some gentle stretches for the wrist and fingers to get the muscles ready. They subsequently engaged in resistance training using dumbbells or resistance bands to increase the strength of their upper limbs. Bicep curls, tricep extensions, and shoulder presses were some of these exercises. They tried to complete two to three sets of ten to fifteen repetitions for each exercise, progressively increasing the resistance as their strength increased. Then, to improve dexterity and coordination in daily tasks, functional exercises were included.
224060292|NCT02431065|PROCEDURE|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
224060293|NCT02431065|DRUG|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
224147481|NCT01770145|DRUG|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
224147482|NCT02332798|DRUG|PF-04958242|Administered as specified in the treatment arm
223452693|NCT02936089|OTHER|allogeneic HSCT|For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.
223584089|NCT02846246|OTHER|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
224147483|NCT02332798|DRUG|Placebo|Administered as specified in the treatment arm
224147484|NCT00595868|DRUG|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
224147485|NCT00595868|DRUG|Placebo|same as Varenicline arm
223452694|NCT02080208|DEVICE|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
224147486|NCT03905824|BIOLOGICAL|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
224147487|NCT03905824|PROCEDURE|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
224147488|NCT01221818|DRUG|E6007|E6007 25mg single dose or matching placebo
223570407|NCT02373436|OTHER|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
224060294|NCT02431065|OTHER|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~1. Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~2. Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~3. Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
224060295|NCT02808000|DEVICE|BIP Foley (latex) or BIP Foley -silicone|
224060296|NCT02808000|DEVICE|Standard catheter|
224060297|NCT01910259|DRUG|Amiloride|Comparison with placebo
224060298|NCT01910259|DRUG|Riluzole|Comparison with placebo
224060299|NCT01910259|DRUG|Fluoxetine|Comparison with placebo
224060300|NCT01910259|DRUG|Placebo|Placebo comparator
224060301|NCT00087828|DRUG|Cranberry juice cocktail|
224060302|NCT01601028|DRUG|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
223570408|NCT02373436|OTHER|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
223570409|NCT02180880|DRUG|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
224060303|NCT01601028|DRUG|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
223570410|NCT03555981|OTHER|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
224060304|NCT03586128|DRUG|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
224060305|NCT03586128|DRUG|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
224060306|NCT02238275|DRUG|Micardis® plus|
224060307|NCT04329702|BEHAVIORAL|Coping skills training mobile app with call from CST therapist|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.
224060308|NCT04329702|BEHAVIORAL|Coping skills training mobile app only|The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
224060309|NCT06359873|DIAGNOSTIC_TEST|CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)|"CHA2DS2-VASc Score: Congestive heart failure (HF) \[1 point\], hypertension \[1 point\], age ≥ 75 years \[2 points\], diabetes \[1 point\], prior stroke or transient ischemic attack \[2 points\], vascular disease \[1 point\], age 65-74 years \[1 point\], and female gender\[1 point\].~C2HEST Score: Coronary artery disease or chronic obstructive pulmonary disease \[1 point each, 2 total points\]; hypertension \[1 point\]; elderly \[2 points for age ≥ 75 years\]; systolic HF \[2 points\]; and thyroid disease \[1 point for hyperthyroidism\]\[10\].~LAD: The LAD values of the enrolled patients were extracted by keyword search based on the results of echocardiography in the database."
224060310|NCT03834467|OTHER|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
224060311|NCT03834467|OTHER|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
224060312|NCT00597480|DRUG|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
224060313|NCT00597480|DRUG|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
224147489|NCT01221818|DRUG|E6007|E6007 50mg single dose or matching placebo
224147490|NCT01221818|DRUG|E6007|E6007 100mg single dose or matching placebo
224147491|NCT01221818|DRUG|E6007|E6007 200mg single dose or matching placebo
224147492|NCT01221818|DRUG|E6007|E6007 400mg single dose or matching placebo
224147493|NCT01221818|DRUG|E6007|E6007 600 mg single dose or matching placebo
224147494|NCT03380026|DRUG|Triamcinolone|Apply up to three times daily on select lesions.
224147495|NCT03380026|DRUG|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
224147496|NCT05373082|OTHER|questionnaire completion|Questionnaire to be completed by patients
224147497|NCT06508788|DEVICE|CO2 laser|Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
224147498|NCT00151541|DRUG|Dapsone Topical Gel + adapalene gel 0.1%|
224147499|NCT00151541|DRUG|Dapsone Topical Gel + benzoyl peroxide gel 4%|
224147500|NCT00151541|DRUG|Dapsone Topical Gel + vehicle control|
223452695|NCT01912794|OTHER|Sensory Intervention|"1. full sensory information, whose participants will practice balancing tasks without constraint sensory body;~2. sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~3. control, whose participants will exercise activities involving cognitive and upper limbs."
223452696|NCT02816320|OTHER|Hospitalization|Patients who were hospitalized in acute care
223452697|NCT04136483|BEHAVIORAL|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
223452698|NCT02096276|OTHER|Data collection|Initial and follow-up data will be collected using questionnaires.
223452699|NCT05991960|DEVICE|Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.
223452700|NCT02090777|BEHAVIORAL|Health Coach|
223452701|NCT01923324|BEHAVIORAL|Physician telephone consultation|Pain physician support for family physician treating patient
223742195|NCT01321125|BIOLOGICAL|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
223742196|NCT04572607|DIETARY_SUPPLEMENT|The consumption of avocado honey was analyzed|The subjects of honey group consumed 25 g of honey each day for 4 weeks.
223742197|NCT02157142|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
223742198|NCT02784821|DRUG|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
223742199|NCT02784821|OTHER|Gastric fluid|Microbiome evaluated using gastric aspirate.
223742200|NCT02784821|OTHER|Breast milk|Microbiome will be evaluated using mother's breast milk.
223742201|NCT02784821|OTHER|Stool samples|Microbiome will be evaluated using infant's stool.
223742202|NCT02784821|DRUG|Antibiotics|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
223742203|NCT04122859|DEVICE|Zip Skin Closure Device|The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
223742204|NCT05773547|DEVICE|MSOT measurements|Non-invasive transcutaneous imaging of subcellular muscle components via infrared and near-infrared laser pulses
223742205|NCT04706195|BEHAVIORAL|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
223742206|NCT01277523|DRUG|tiotropium high dose|2 actuations once daily
223742207|NCT01277523|DRUG|placebo|2 actuations once daily
223742208|NCT01277523|DRUG|tiotropium low dose|2 actuations once daily
224060314|NCT05927051|OTHER|Stabilization exercises|Core stability exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
224060315|NCT05927051|OTHER|McKenzie exercises|McKenzie exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
223452702|NCT01923324|BEHAVIORAL|Usual family physician care|Usual family physician care without telephone consultation with pain physician
223452703|NCT00551395|PROCEDURE|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
223452704|NCT00551395|PROCEDURE|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
223452705|NCT03746405|DEVICE|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
223452706|NCT03746405|DEVICE|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
223452707|NCT05205499|DEVICE|Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System|Subjects in this arm will be treated with IBS
223452708|NCT04719845|PROCEDURE|Endoscopic laser resection|Laser resection
223452709|NCT04719845|PROCEDURE|Dilatation|Dilatation
223452710|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
223742209|NCT06032247|BEHAVIORAL|Resistance exercise program- UL|"Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
223742210|NCT06032247|BEHAVIORAL|Resistance exercise program- BL|"Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression."
224060316|NCT05927051|OTHER|Home exercises|Home exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks
223452711|NCT01731327|DRUG|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
223452712|NCT05516238|OTHER|Case management|Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
223452713|NCT04484194|BEHAVIORAL|Check Yourself - Oncology|A validated AYA-targeted electronic health assessment (eHA) screening tool for use in oncology clinics.
223452714|NCT03558685|BEHAVIORAL|Weight loss diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (\> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
224147501|NCT04285372|PROCEDURE|Side branch protection/ballooning|Side branch protection in the context of percutaneous coronary intervention for the treatment of bifurcation lesion
224147502|NCT04285372|PROCEDURE|No side branch protection/ballooning|No intervention on the side branch
224147503|NCT01232192|BEHAVIORAL|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~* Midwife training~* Pregnant women campaigning~* Early detection with self pH detection~* Treatment of bacterial vaginosis"
224147504|NCT04268303|DRUG|Sublingual film containing dexmedetomidine (BXCL501)|Sublingual film containing dexmedetomidine (BXCL501)
224147505|NCT04268303|DRUG|Placebo Film|Placebo Film for BXCL501
224147506|NCT02071641|DRUG|Sunitinib|
224147507|NCT02297646|BEHAVIORAL|Endurance Training|
224147508|NCT05810389|COMBINATION_PRODUCT|Fluoride|Application methods of delivery of topical fluoride
224147509|NCT05141357|DRUG|HBI-8000 in combination with pembrolizumab|Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
223452715|NCT03832829|DEVICE|Indirect composite restoration|Restoration of tooth with extensive substance loss
223452716|NCT00116714|DRUG|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
223452717|NCT06118463|DIAGNOSTIC_TEST|Detection of serum AUNIP expression|The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
223452718|NCT04275453|DRUG|FDG|FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.
223452719|NCT04275453|DIETARY_SUPPLEMENT|Ketone Drink|Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants
223452720|NCT04275453|OTHER|Ketogenetic Diet|Subjects needs to be on Ketogenetic diet
223452721|NCT00677313|DRUG|metreleptin|metreleptin injection
224147510|NCT00259389|BEHAVIORAL|Directly observed therapy (DOT)|
224147511|NCT01340404|PROCEDURE|Stem cell transplantation|Stem cell transplantation
224147512|NCT01340404|PROCEDURE|Transfusion program|Transfusion program
224147513|NCT05223699|BIOLOGICAL|MGTA-117|MGTA-117 will be administered as an IV infusion
224147514|NCT00628225|BEHAVIORAL|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
224147515|NCT00628225|BEHAVIORAL|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
224147516|NCT03927911|DRUG|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
224147517|NCT03927911|DRUG|Standard of Care|Standard of Care
224301404|NCT05620602|OTHER|Remedial treatment after 12 months|"The interval between the time of this treatment and the last day of the last therapy is more than 12 months Patients in Amoxicillin + Tetracycline + Bismuth + Esomeprazole quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Esomeprazole 40mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Vonoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Vonoprazan 20mg bid for 14d.~Patients in Amoxicillin + Tetracycline + Bismuth + Tegoprazan quadruple group will receive Amoxicillin 1000mg bid+ Tetracycline 500mg qid/tid + Bismuth + Tegoprazan 50mg bid for 14d."
223570411|NCT03555981|OTHER|Standard care|Incubator or radiant heater care until stable, off oxygen and \>24h of admission, at which point will start intermittent or continuous kangaroo mother care
223570412|NCT02632279|DIETARY_SUPPLEMENT|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
223570413|NCT02632279|DIETARY_SUPPLEMENT|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
223570414|NCT02632279|DEVICE|Stimulator ON|Participants will be tested while their stimulator is turned ON
223570415|NCT02632279|DEVICE|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
223742211|NCT03669692|BEHAVIORAL|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
223742212|NCT03669692|BEHAVIORAL|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
223742213|NCT03928847|DRUG|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
223452722|NCT03479008|DIAGNOSTIC_TEST|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
223452723|NCT02876861|PROCEDURE|Radical nephroureterectomy|Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
223452724|NCT02876861|PROCEDURE|Distal ureterectomy|Distal ureterectomy.
223452725|NCT02876861|DRUG|Neoadjuvant Chemotherapy|Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
223452726|NCT04811859|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training is a form of resistance (weight) training which strengthens the muscles that you use to breathe. When these muscles are strengthened regularly for a period of a few weeks they adapt, becoming stronger and being able to work for longer.
223452727|NCT06202014|RADIATION|concurrent radiotherapy with envafolimab and capecitabine|Eligibility patients will receive intensity-modulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT) to pancreatic lesions,metastatic lymph nodes and high-risk lymphatic drainage areas,concurrent with and followed by envafolimab and capecitabine.Concurrent and sequential dose of envafolimab is 200mg subcutaneous injection weekly.Capecitabine is with a concurrent and sequential dose of 500-800 mg/m2 bid po , taken orally for 2 weeks and stopped for 1 week (standard concurrent dose is 800 mg/m2 bid po , but for patients ≥70 years of age, 500 mg/m2 bid po depending on physical status ) until progression or intolerance.
223452728|NCT04032795|DIETARY_SUPPLEMENT|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
223742214|NCT00919776|DRUG|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
223742215|NCT00919776|DRUG|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
223742216|NCT01157507|DRUG|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
224301405|NCT00982449|OTHER|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
223742217|NCT01157507|PROCEDURE|Bladder overdistension|Bladder overdistension
223742218|NCT01157507|DRUG|Placebo|One single injection of placebo
223742219|NCT06523036|PROCEDURE|Combined chiropractic care and Tai Chi|Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
223742220|NCT06449807|BEHAVIORAL|crossover point intensity exercise|crossover point intensity exercise
223742221|NCT06155591|OTHER|Community Nurse Case Manager (CNCM)|"Their action protocol has been designed and sequenced according to the circumstances in which the Complex and Pluripathological Chronic Patient finds themself:~* Pre-hospital discharge. The hospital Nurse Case Manager (HNCM) will contact the CNCM to inform of the imminent hospital discharge.~* Hospital discharge: A comprehensive nursing assessment of the CPCP based on Marjory Gordon's functional patterns will be carried out.~* Planned visits: An infographic will be provided to identify signs and symptoms of decompensation/exacerbation and a direct dial telephone number.~* Proactive telephone follow-up: The CNCM will make comfort calls every week for the first month, every 15 days until the 3-months visit and every month until the 6- and 12-months visits.~* Exacerbations/decompensations: An appointment will be arranged with their Primary Care physician.~* Hospital readmission: The CNCM will be kept informed of the process through the HNCM and CPCP's digital clinical history."
223742222|NCT01881230|DRUG|nab-Paclitaxel|nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
223742223|NCT01881230|DRUG|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
224060317|NCT02907294|DRUG|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
224060318|NCT02907294|DRUG|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
224060319|NCT02907294|DRUG|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
224060320|NCT03923543|DIAGNOSTIC_TEST|Neutrophil to lymphosit ratio|
224060321|NCT01761084|BEHAVIORAL|Exercise and behaviour change strategies|"1. cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~2. postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~3. perform muscle strengthening and balance training exercises ≥ 3 days a week~4. the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
224060322|NCT06477874|PROCEDURE|Dental implants placement|implants placed in consolidated bone grafts
224060323|NCT00940589|DRUG|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
224060324|NCT00940589|DRUG|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
224060325|NCT02291120|PROCEDURE|Pulpotomy|
224060326|NCT05699889|OTHER|Data collection|acute kidney injury and tubular dysfunction
224060327|NCT03437382|DEVICE|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
224060328|NCT03915015|DIAGNOSTIC_TEST|MRI|MRI
224060329|NCT00676676|DRUG|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
224060330|NCT00429403|DRUG|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
224060331|NCT03719690|DRUG|Tipifarnib|Tablet for oral administration
224147518|NCT03185923|DRUG|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical \& Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
224301406|NCT00982449|OTHER|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
223452729|NCT04032795|DIETARY_SUPPLEMENT|Placebo|Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
223452730|NCT01302795|DRUG|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
223452731|NCT00412932|DRUG|Olmesartan medoxomil|Tablets
223742224|NCT01881230|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
223742225|NCT00017303|DRUG|carboplatin|
223742226|NCT00017303|DRUG|oglufanide disodium|
224060332|NCT03719690|DEVICE|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
224060333|NCT00004998|DRUG|Lamivudine/Zidovudine|
224060334|NCT00004998|DRUG|Capravirine|
224060335|NCT00004998|DRUG|Nelfinavir mesylate|
224060336|NCT02330159|PROCEDURE|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
224060337|NCT06011343|DRUG|Oral tofacitinib|Association of tofacitinib and meglumine antimoniate
224301407|NCT02216318|OTHER|blue light|
224301408|NCT03828136|DEVICE|Novum Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
224301409|NCT03828136|DEVICE|Allograft Ring or Block|Standard of Care
223452732|NCT00412932|DRUG|Olmesartan medoxomil/hydrochlorothiazide|Tablets
223452733|NCT03534167|BEHAVIORAL|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
223452734|NCT00005959|BIOLOGICAL|filgrastim|
223452735|NCT00005959|BIOLOGICAL|rituximab|
223452736|NCT00005959|DRUG|cyclophosphamide|
223452737|NCT00005959|DRUG|doxorubicin hydrochloride|
223452738|NCT00005959|DRUG|prednisone|
223452739|NCT00005959|DRUG|vincristine sulfate|
223452740|NCT00005587|RADIATION|radiation therapy|
223742227|NCT00017303|DRUG|paclitaxel|
223742228|NCT00017303|PROCEDURE|conventional surgery|
224060338|NCT06011343|DRUG|Parenteral meglumine antimoniate|Meglumine antimoniate
224060339|NCT00643266|BEHAVIORAL|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
224060340|NCT00643266|BEHAVIORAL|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
223452741|NCT04120181|OTHER|There is no intervention.|There is no intervention.
223452742|NCT05704270|BEHAVIORAL|Multi-domain adaptive cognitive training|The multi-domain adaptive cognitive training covers seven aspects of fundamental cognitive function, including sensory perception, cognitive flexibility, attention, memory, language, logic calculation, and emotion recognition and management. A self-adaptive algorithm is embedded in the tablet-based cognitive training platform, which will help deliver suitable tasks at the right difficulty level for each participant according to their personal profile and real-time performance. The intervention dosage is 30 minutes per time, 5 times a week.
223570416|NCT02442791|DRUG|Byetta (Lilly, Exenatide)|See description of Arms
223570417|NCT02442791|OTHER|20% Human Albumin|See description of Arms
223570418|NCT00234481|DRUG|XL844|
223570419|NCT04384445|BIOLOGICAL|Zofin|Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
223570420|NCT04384445|OTHER|Placebo|Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
224060341|NCT05491928|DRUG|Tempol|Tempol will be given as an adjunct to chemotherapy.
224060342|NCT06171451|DIAGNOSTIC_TEST|PET with 11C-Fe-CIT|Use of the PET11C-Fe\_CIT method for the early diagnosis of Parkinson's and in the differential diagnosis between Parkinson's and parkinsonism.
223452743|NCT05704270|BEHAVIORAL|Basic cognitive training with no difficulty change|The basic cognitive training for the control arm will also be delivered via a tablet. The training tasks will be fixed at a primary difficulty level without adaptive algorithm. The intervention dosage is also 30 minutes per time, 5 times a week.
223452744|NCT05114187|OTHER|Education Intervention|"Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. Ten selected multimedia e-learning lessons;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours."
224060343|NCT02749773|DEVICE|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
224060344|NCT01918007|PROCEDURE|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of obstructive sleep-disordered (SDB).
224060345|NCT01609946|DEVICE|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
223452745|NCT05114187|OTHER|Education Control|"Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. One selected multimedia e-learning lesson;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study."
223452746|NCT01945047|DRUG|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
223452747|NCT01945047|DRUG|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
223452748|NCT01490840|OTHER|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
223452749|NCT03331263|DRUG|Chlorhexidine Gluconate|2% CHG
223742229|NCT03562039|PROCEDURE|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
223742230|NCT00112502|DRUG|Celecoxib|400 mg orally twice a day continuous dosing
224060346|NCT01609946|PROCEDURE|Cytology (FNAB) or Surgery|
224060347|NCT05070975|OTHER|Epidemiology|Assessment of the discrepancy of clinical severity of RSV-infections between twin infants.
224060348|NCT00323232|DEVICE|2 Versus 4 Hole DHS|See Detailed Description.
224060349|NCT01334151|DRUG|Insulin LISPRO|Single doses of: 0.15 U/kg
224060350|NCT01334151|DRUG|recombinant human insulin|Single doses of: 0.15 U/kg
224301410|NCT04120584|DEVICE|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
223742231|NCT00112502|DRUG|Isotretinoin|40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
224301411|NCT00712205|DRUG|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
224301412|NCT00712205|DRUG|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
224301413|NCT06925204|OTHER|Observation|Based on the patient's specific clinical condition, the appropriate examination and treatment in accordance with the conventional diagnosis and treatment standards of CP will be performed, including but not limited to: CT, MRI, endoscopic ultrasound (EUS) with or without biopsy, endocrine hormone testing (such as oral glucose tolerance test or mixed meal tolerance testing), pancreatic exocrine function tests (such as fecal elastase-1 test), extracorporeal shock wave lithotripsy (ESWL), endoscopic retrograde cholangiopancreatography (ERCP), and pancreatic enzyme replacement therapy. Patients were followed up regularly.
223742232|NCT00112502|DRUG|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
223742233|NCT00112502|DRUG|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
223742234|NCT00410644|DRUG|OROS Hydromorphone HCI|
223742235|NCT04639609|OTHER|Characterization of Neuromuscular Function and Fatigue|at inclusion
224060351|NCT05630079|DEVICE|Treatment with Metaneb®|"Every patient of this group receive 3 daily treatments of 20 minutes each, performed at approximately 4-hour intervals.~Each treatment with MetaNeb system consists of four cycles: : 5 minutes of Continuous Positive Expiratory Pressure (CPEP) for lung re-expansion (Cycle I), 5 minutes of Chest High Frequency Oscillation (CHFO) for secretion clearance (Cycle II), 5 min of CPEP (Cycle III), 5 minutes of CHFO (Cycle IV). Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It's associated with the administration of aerosols with 10 ml of saline solution 0.9% and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount."
224060352|NCT05630079|DEVICE|Treatment with IPV®|Each treatment with IPV provides 3 daily treatments of 20 minutes with the high percussion frequency tolerated by the patient. and I/E ratio: 1/1.2. Treatments are performed by respiratory physiotherapists and the pressure setted was the highest tolerated by the patient. It is associated with the administration of aerosols with 10 ml of saline solution 0.9% \[-\] and are carried out by connecting the tracheostomy cannula cuffed to the catheter mount.
224060353|NCT00129324|PROCEDURE|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
224060354|NCT00129324|PROCEDURE|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
224060355|NCT01262521|DIETARY_SUPPLEMENT|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
224060356|NCT01262521|DIETARY_SUPPLEMENT|Water|150 ml Chapelle mineral water
224060357|NCT06155370|OTHER|construction of organoids from gynecological tumor|organoids construction
224301414|NCT05524961|DEVICE|Bright light therapy|Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks
223452750|NCT03619655|PROCEDURE|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
223452751|NCT03619655|DRUG|18F-DCFPyL PET/CT|A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
223452752|NCT03619655|DRUG|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
224060358|NCT02448030|OTHER|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
224060359|NCT02448030|OTHER|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
224060360|NCT01930136|BEHAVIORAL|Calorie restriction (25%)|
224060361|NCT01930136|BEHAVIORAL|Ad libitum health diet|
224060362|NCT06096402|PROCEDURE|no intervention, but surgical practice as usual is continued. Its a pragmatic study|no intervention
224301415|NCT05524961|DEVICE|Inactivated negative ion generator|Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
223452753|NCT03619655|PROCEDURE|WB-MRI|Whole body MRI exam (total examination time \< 50 minutes)
223452754|NCT00826566|DIETARY_SUPPLEMENT|Caffeine|2 times 250 mg caffeine per day
223452755|NCT00826566|DIETARY_SUPPLEMENT|placebo|2 times 250 mg per day
223452756|NCT03659123|BEHAVIORAL|standardized geriatric intervention|"Nutritional care is based on:~* A personalized evaluation of nutritional balance and nutritional needs of the patient~* A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~* 2 to 3 times a week: strength exercise~* 2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~* 2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results."
223452757|NCT01581515|DEVICE|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
223452758|NCT01581515|DEVICE|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
223570421|NCT03581539|PROCEDURE|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
223742236|NCT01689129|DRUG|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
224060363|NCT03695575|DEVICE|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
224060364|NCT02838498|DEVICE|ERCP Mechanical Simulator (EMS)|Hands on EMS training
224060365|NCT05266937|COMBINATION_PRODUCT|Atezolizumab,Paclitaxel, Carboplatin|"Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle + Carboplatin area under the curve 2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle + nab-Paclitaxel at a dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle.~In the absence of disease progression or unacceptable toxicity, study treatments will continue until the end of the study (2 years from last patient enrolled or study termination by the Sponsor)."
223742237|NCT01689129|DRUG|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
224060366|NCT04185090|COMBINATION_PRODUCT|ID1803|Amlodipine 10mg/Valsartan 160mg
224060367|NCT04185090|COMBINATION_PRODUCT|ID1801|Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
224060368|NCT04185090|COMBINATION_PRODUCT|ID1803+ID1801|Amlodipine 10mg/Valsartan 160mg Ezetimibe 10mg/Rosuvastatin Ca 20.8mg
224060369|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate|2 FeSO4 supplements containing 27 mg elemental iron/supplements (54 mg total iron)
224060370|NCT05762380|DIETARY_SUPPLEMENT|Ferrous sulfate-enriched Aspergillus oryzae (Ao iron)|2 Ao iron supplements containing 27 mg elemental iron/supplements (54 mg total iron)
224060371|NCT06494852|DIAGNOSTIC_TEST|investigations|laboratory assesment Kidney function test, Urine analysis, Arterial blood gases ,Electrolytes (Na,K,Cl,Ca,phosphorus) and Calcium/creatinine ratio , Total serum IgE Radiological assessment Abdominal ultrasonography
224301416|NCT05524961|DEVICE|Inactivated negative ion generator|Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
224301417|NCT03531398|OTHER|Metabolic test meal challenge|Metabolic test meal challenge
224301418|NCT06928220|PROCEDURE|cystectomy with ileal conduit, using mechanical bowel anastomosis|"An ileal conduit will be the new storage area for urine once the bladder is removed.~GIA Device will be used to perform bowel anastomosis"
223742238|NCT02385266|DRUG|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
224060372|NCT06033573|DIAGNOSTIC_TEST|contrast-enhanced spectral mammography|After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing
223452759|NCT03430908|OTHER|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
224060373|NCT03005795|DEVICE|Headphones|Music can be heard through headphones
224060374|NCT03005795|OTHER|No Headphones|No Headphones will be used.
224060375|NCT00865059|DRUG|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
224060376|NCT00865059|DRUG|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
224060377|NCT05778500|DEVICE|COMPACS|We will modify the current version of the COMPACS software package to implement several guideline-derived algorithms to help the clinician to reduce diagnostic errors and increase the adherence to current guidelines
224060378|NCT02150577|BEHAVIORAL|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
223452760|NCT00362947|DRUG|LMWH parnaparin subcutaneously|
223452761|NCT00818155|DRUG|desvenlafaxine succinate SR|desvenlafaxine succinate SR
223452762|NCT00818155|OTHER|Placebo|
223570422|NCT03581539|PROCEDURE|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
223742239|NCT02385266|DRUG|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
223742240|NCT01280292|DRUG|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
223742241|NCT04504799|DEVICE|Body composition measurement with HAG-BIA scale|Bio-impendance analysis
223742242|NCT03147547|OTHER|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
223742243|NCT03147547|OTHER|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
224060379|NCT00631774|DIETARY_SUPPLEMENT|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
224060380|NCT04066270|DIAGNOSTIC_TEST|video nystagmography|routine test battery applied to all cochlear implant candidates
224060381|NCT00159900|DRUG|Sildenafil Citrate|
224060382|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Roller Coasters, group 1)|During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
224060383|NCT05839054|DEVICE|Virtual Reality audio and visual glass (Wild Dolphins, group 2)|During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
224060384|NCT02830100|OTHER|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
224060385|NCT02830100|DEVICE|MRI|
224060386|NCT01191073|DEVICE|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
224060387|NCT01191073|DEVICE|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
224060388|NCT01222546|DRUG|CH5132799|
224060389|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
224060390|NCT01028092|DRUG|Thymoglobulin + Everolimus|"* Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~* everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
224147519|NCT03185923|DRUG|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical \& Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
224147520|NCT02245230|DRUG|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
223742244|NCT03147547|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
224301419|NCT06928220|PROCEDURE|cystectomy with ileal conduit, using manual bowel anastomosis|"An ileal conduit will be the new storage area for urine once the bladder is removed.~Vycryl suture will be used to perform manual bowel anastomosis"
223742245|NCT03147547|OTHER|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
223742246|NCT05542303|DRUG|ZB001 for injection|Dose Cohort1 (3mg/kg) ZB001 of single IV injection
223742247|NCT05542303|DRUG|ZB001 for injection|Dose Cohort2 (10mg/kg) ZB001 of single IV injection
223742248|NCT05542303|DRUG|ZB001 for injection|Dose Cohort3 (20mg/kg) ZB001 of single IV injection
223742249|NCT05719363|DEVICE|Inogen Rove 6 Portable Oxygen Concentrator|"The Inogen Rove 6 POC is designed to provide a flow of high-purity oxygen. Inogen Rove 6 is a highly versatile and robust concentrator which offers patients the option to use up to 6 different flow settings.~The unit weighs just under 5 pounds. Utilizing an Intelligent delivery technology, the unit can provide patients with required oxygen therapy on a 24/7 basis. The Inogen Rove 6 POC will be used for patients with chronic heart failure as an investigational device. It supplies a high concentration of oxygen and is used with a nasal cannula which channels oxygen from the concentrator to the patient."
224060391|NCT01028092|DRUG|Anti R-IL2 + Cyclosporine then Everolimus|"* anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~* Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~* cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~* corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
224060392|NCT02191254|DRUG|Antistax®|
223742250|NCT01496092|DRUG|Keto Acid|12 tablets per day
223742251|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of anemia.
224060393|NCT02191254|DRUG|Placebo|
224060394|NCT01048762|OTHER|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
224060395|NCT01048762|OTHER|home training|one instruction in home based exercise training
224060396|NCT03298581|DRUG|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
224060397|NCT03420690|OTHER|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (\>1) and the death of patients (\> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
224301420|NCT06927765|OTHER|No abdominal drain is placed|No abdominal drain is placed
224301421|NCT06928688|DIETARY_SUPPLEMENT|Saskatoon berry powder|After oral intake of SB powder, dried whole SB fruit or glucose drink, finger tip blood glucose will be measured 15, 30, 45, 60, 90 and 120 minutes after the consumption.
223452763|NCT04485078|DIAGNOSTIC_TEST|Pressure pain threshold|The PPT assessments of spine will be performed over the spinous process and 2 cm right and left side of the corresponding spinous process. The regional PPT scores will be composed from sum of all PPT values for related segments at spine. The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
223452764|NCT04485078|DIAGNOSTIC_TEST|Temporal summation|TS will be evaluated over the trapezius muscle, sacroiliac joints, C7, T6, and L3 levels at spine with manuel algometer. TS scores will be calculated for each spine level as the sum of three values which measured over the spinous process and 2 cm right and left side of corresponding level. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
223452765|NCT04485078|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 70C water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
223452766|NCT04485078|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
223742252|NCT04474951|DIETARY_SUPPLEMENT|Stinging Nettle|Eligible patients will take 40 drops TID of Fluid Extract of Stinging Nettle for control of fatigue.
223742253|NCT04474951|DIETARY_SUPPLEMENT|Peppermint|Eligible patients will take 40 drops TID of Fluid Extract of Peppermint for control of nausea.
223742254|NCT01195428|DRUG|Simvastatin|Simvastatin 40 mg daily
224060398|NCT02085382|PROCEDURE|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
224060399|NCT02085382|PROCEDURE|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
224060400|NCT04565964|OTHER|change the health behaviors to clean indoor environment|Sheets and all covers should be wash weekly. Clean indoor environment with a vacuum cleaner twice a week
224060401|NCT04006964|DEVICE|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
224060402|NCT04808531|DRUG|NanaBis™|NanaBis™ is a nanoparticle water soluble equimolar solution of d9-THC \& CBD. One dose is equivalent to 2 actuations of the pump delivering 280 µL volume containing 2.5 mg d9-THC and 2.5 mg CBD
224060403|NCT04808531|DRUG|Oxycodone CR|Oxycodone CR tablet is an opioid agonist supplied in 10 mg, 15 mg, 20 mg, 30 mg,40 mg, 60 mg and 80 mg tablets for oral administration. The tablet strengths describe the amount of oxycodone per tablet as the hydrochloride salt.
224060404|NCT04808531|DRUG|Placebo Spray|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
224060405|NCT04808531|DRUG|Placebo Tablet|Placebo comparator used against both NanaBis™ and Oxycodone depending on randomisation of arms.
224060406|NCT04808531|DRUG|Oxycodone IR|Oxycodone immediate release (IR) tablet or capsule or oral solution used as breakthrough analgesia.
224060407|NCT02466152|DRUG|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
224060408|NCT01713023|DIETARY_SUPPLEMENT|Glucose|The same described in Arm description
224060409|NCT01713023|DIETARY_SUPPLEMENT|Fructose|The same described in Arm description
224060410|NCT04989920|BEHAVIORAL|Experimental group: CIMT group (Constraint-Induced Movement Therapy)|2 weeks of intensive therapy delivered 5d/week for 6 hrs/day
224060411|NCT02037295|DRUG|Vancomycin|Vancomycin 125mg orally four times per day for 12 days
224060412|NCT02037295|DRUG|Placebo oral tablet|Placebo pills orally four times per day for 12 days
224060413|NCT02037295|OTHER|Overfeeding diet (OF)|Diet in which the calories are 150% of their weight maintaining energy requirements
224060414|NCT02037295|OTHER|Underfeeding diet (UF)|Diet in which the calories are 50% of their weight maintaining energy requirements
223570423|NCT03581539|PROCEDURE|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
223570424|NCT05835232|OTHER|Survey|Each participant completed an anonymous 62-item online survey.
223570425|NCT03989427|OTHER|Brushing first and Flossing later (BF)|Participants will follow Brushing first and flossing later (BF) sequence for 2 weeks, and after 1 week wash out period, Flossing first and Brushing later (FB) sequence for another 2 weeks.
223570426|NCT03989427|OTHER|Flossing first and Brushing later (FB)|Participants will follow Flossing first and Brushing later (FB) sequence for 2 weeks, and after 1 week wash out period, Brushing first and flossing later (BF) sequence for another 2 weeks.
223570427|NCT06233864|DRUG|Disitamab Vedotin|Disitamab Vedotin
223570428|NCT06233864|DRUG|Gemcitabine|Gemcitabine
223570429|NCT03272828|DEVICE|Nobel Biocare titanium dental implants|
223742255|NCT01195428|DRUG|Placebo|Placebo
223742256|NCT01678963|DRUG|Squalamine lactate|Ophthalmic solution 0.2%
224060415|NCT02891655|OTHER|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
224060416|NCT04174781|DRUG|Sintilimab|Sintilimab: 200mg iv Q3W D1
224060417|NCT04174781|DRUG|DEB-TACE|DEB-TACE(epirubicin 60mg) D1; Additional DEB-TACE procedures were carried out every 4-6 weeks based on tumor response. A treatment cycle was defined as one DEB-TACE procedure plus two doses of sintilimab. The combination of DEB-TACE and sintilimab was continued for a maximum of 3 cycles until surgical resection, radiologic disease progression, unacceptable toxicity, or withdrawal from the study, whichever occurred first.
224060418|NCT03410173|DRUG|Taurine|
224060419|NCT03410173|DRUG|Placebo|
224060420|NCT05710471|DRUG|Brolucizumab|Intravitreal injection
224060421|NCT05710471|DRUG|Aflibercept|Intravitreal injection
224060422|NCT03688932|OTHER|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
224060423|NCT03688932|OTHER|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
224060424|NCT03688932|OTHER|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
224060425|NCT03241914|DRUG|Megestrol Acetate|At a dosage of 160 mg/day
224060426|NCT03241914|DEVICE|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
224060427|NCT06548256|DRUG|Miyarisan-BM (Clostridium Butyricum Miyairi)|probiotics
224147521|NCT02245230|DRUG|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
223570430|NCT05712304|DIAGNOSTIC_TEST|second examination of the proximal colon|For patients in the SE group, the colonoscope was reinserted into the cecum, additional polyps were removed from the proximal colon during the third withdrawall(third pass), and the remainder of the colon from splenic flexure to rectum was examined in a standard manner
223570431|NCT03497546|OTHER|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
223570432|NCT02581462|DRUG|FLOT alone|"Pre-operative therapy:~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43"
223570433|NCT02581462|BIOLOGICAL|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~* Herceptin 8/6 mg/kg, d1, d22, d43~* Pertuzumab 840 mg, d1, d22, d43~* Docetaxel 50 mg/m², d1, d15, d29, d43~* Oxaliplatin 85 mg/m², d1, d15, d29, d43~* Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~* 5-FU 2600 mg/m², d1, d15, d29, d43."
223570434|NCT06151951|OTHER|Cervical Stabilization|Isometric stretching and strengthening exercises of Neck flexor muscle including suboccipitalis, levator scapulae,scalnae anterior and upper trapezius. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.
223570435|NCT06151951|DEVICE|Pressure Biofeedback|"In this method patients in supine position. Sphygmomanometer is used and 100 mmHg pressure will be maintained before the treatment start then cuff will be placed under the occiopit of spine and patient will be asked to press the cuff against the occiopit until gauze show target pressure then hold this position for 6 second and release. Repeated this pressure to 10 times, 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
223570436|NCT06151951|DEVICE|Visual Biofeedback|"In this method Led Head Band light will be used as a visual feedback. Patients in sitting or standing position with neck straight with the alignment of front wall marking followed by control movement training. Patient will be asked to follow the marking through head band light while performing motion control training. Each exercise hold for 6 second and then release and repeated 10 times respectively 3 times in a week for 4 weeks. Therefore, the total exercise time will be 5-10 mints.~Baseline Treatment~Before starting the session participants received moist heat pack and soft tissue massage on cervical for 10 to 15 mints followed by movement control training."
223742257|NCT01678963|DRUG|Vehicle control|Ophthalmic solution vehicle control
223742258|NCT05669560|COMBINATION_PRODUCT|PerioProtect ™= plastic tray +1.7% hydrogen peroxide|Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.
223742259|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
223742260|NCT01030523|DEVICE|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm) in combination with bone grafting
224060428|NCT06500143|DIAGNOSTIC_TEST|Gastric ultrasound|"Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create ring-down artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value."
224060429|NCT01499420|BIOLOGICAL|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
224060430|NCT01499420|BIOLOGICAL|Placebo|Single intravenous doses of normal saline (0.9%)
224060431|NCT01140451|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
224060432|NCT04575558|DRUG|Hydroxychloroquine and Azithromycin|Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
224060433|NCT05433506|DRUG|HU6 Tablet|Six subjects will receive a tablet formulation.
224060434|NCT05433506|DRUG|HU6 Capsule|Six subjects will receive the capsule formulation
224060435|NCT01255527|DRUG|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
224060436|NCT02666339|OTHER|Usual care|Usual care : drug therapy, nurse and physician consultations.
224060437|NCT02666339|BEHAVIORAL|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
224060438|NCT02701543|DEVICE|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
224060439|NCT02701543|DEVICE|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
224060440|NCT03958162|DIAGNOSTIC_TEST|lung biopsy|transbronchial lung cryobiopsy
224060441|NCT00695448|DRUG|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
224060442|NCT00114049|DRUG|GW406381|
224060443|NCT01971073|DEVICE|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
224060444|NCT01971073|DEVICE|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
224060445|NCT04165707|DEVICE|Keyto device + app|Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
224060446|NCT04165707|OTHER|Weight Watchers app|The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
223570437|NCT04358705|OTHER|Aim 1: Online survey|"This survey will evaluate perceptions of flavors on appeal, purchasing and risk perceptions of cigarillo products among young adult and adolescent cigarillo users. This survey will be used to inform survey design for further aims.~As a proxy for biological verification of tobacco use status, data on brand, frequency, and pricing will be collected to confirm user status~Participants will rate the role of flavor and report perceptions of product appeal, health risk, advertising exposure and use intentions. Participants will also complete purchase and substitution tasks."
223570438|NCT04358705|BEHAVIORAL|Eye Tracking Activity|The eye tracking activity consists of a single in-person eye tracking activity that will take place in a private office in Columbus, Ohio where the participant will be seated in a chair within a typical viewing distance from a computer monitor equipped with an infrared camera on the monitor to capture precise eye movements. Participants will have their gaze monitored continuously by the camera on the computer monitor while a randomized set of stimuli (e.g., tobacco product images) are viewed (n=30) for 10 seconds per image. Following each image, an on-screen closed response question will re-center the participant's gaze for standardization prior to the next image.
223570439|NCT04358705|OTHER|Eye tracking survey|Other Names: Participants will complete a survey using Qualtrics immediately after the eye tracking activity and one week following completion of the activity via email to measure recall of brand name, product flavors, perceptions of cigarillo harm, and tobacco use behaviors and intentions.
223570440|NCT04358705|BEHAVIORAL|Online Experimental Marketplace (ETM)|"Administered online via Qualtrics~Participants are given an account balance for use during their assigned ETM based on their average weekly tobacco use calculated from previous interview. Participants will view all four price conditions and all four flavor conditions in random order for a total of 16 rounds~Cigarillo price conditions: 1) market price 2) ½ market price 3) 2X market price 4) 4X market price~Flavor condition: 1) flavored cigarillos and fruit-flavored disposable-cigarettes available 2) unflavored cigarillos and fruit-flavored ecigarettes available 3) flavored cigarillos and tobacco-flavored e-cigarettes available 4) unflavored cigarillos and tobacco-flavored e-cigarettes available.~Participants will purchase cigarillos with their account balance. During all ETM conditions, constant-priced alternative tobacco products (smokeless tobacco, nicotine lozenges, nicotine gum, and the nicotine patch) will be available in addition to the cigarillos and e-cigarettes."
223570441|NCT04358705|OTHER|Aim 3 survey|"Consists of:~* A screener and demographic data collection.~* A tobacco product withdrawal scale~* Upon completion of the ETM, participants will be asked to respond to a quality assurance question regarding the conditions that varied. Participants will be shown a list of 8 possible conditions and must chose one of the three that varied in order to be eligible to receive compensation.~* The tobacco product withdrawal scale again~* Measurements of nicotine dependence and flavor preferences"
223570442|NCT04358705|OTHER|Cognitive Interviews|Cognitive Interviews will be done in-person, using Zoom, or over the phone. Interviews will be video or audio recorded. . The participant will be given a select section of the survey questions from Aim 1. The survey will be uploaded to Qualtrics to reflect the way that survey would be conducted in Aim 1. With the survey questions in front of the participant on the computer screen, research personnel will ask probing questions about each one of the survey questions. If the participant is not able to participate in person or via Zoom, they will be allowed to be interview over the phone with access to the Qualtrics survey or a paper form. If the participant is unable to access the internet, the participant will be read the questions by research personnel. The participant will provide feedback about the questions and walk the research personnel through their thought process for approaching each survey question.
223570443|NCT04358705|OTHER|Supplemental Aim 1 Interviews|Participants from the preceding online survey (who identify as women from Aim 1/supplemental aim 1 survey) who agreed to be contacted for future study will be emailed an invitation to the eligibility screener. Individuals interested will complete a screener to ensure participants identify as women and to verify that they have ever used cigarillos. Eligible participants will be contacted to schedule a 60- to 90-minute Zoom interview about their tobacco, nicotine, and cannabis product use experiences, with particular focus on flavored cigarillo usage initiation, current use, and responses to potential flavor restrictions.
223570444|NCT02104271|PROCEDURE|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
224060447|NCT01505621|OTHER|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L\[ring-13C6\]phenylalanine
224060448|NCT00441974|DRUG|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
224060449|NCT05373654|OTHER|F-SUS Questionnaire|"This F-SUS questionnaire uses a Likert scale including 5 possible responses ranging from  I do not agree at all to  I completely agree  (Celenza A 2011, Croasmun JT 2011). The F-SUS is a short questionnaire with 10 questions (Brooke J 2013). In its original version half of the questions express strong agreement and the other half disagreement. Thus, all the even-numbered items (2, 4, 6, 8, 10) allow the participant to express a very negative opinion (disagreement). On the other hand, the odd-numbered items allow the participant to express a very positive opinion (strong agreement)."
224060450|NCT05373654|OTHER|Interview (only for dissatisfied patients)|"Patients that are dissatisfied with the recharge procedure (Score F-SUS \< 70/100) will be invited to a so-called complementary information interview (an interview after the questionnaire has been completed).~The corpus (the study group that will be interviewed) will naturally be diverse men/women, patients who were improved or not by stimulation, implanted with a rechargeable stimulator directly/replacing a stimulator, different brands of stimulator… The patient must agree to the interview and the way it will be performed (signature of consent form). The interview may be face-to -face at the site or by remote videoconference depending on the wishes and availability of the patient. There is no payment for these interviews but travelling or videoconference expenses are reimbursed All interviews will be audio- taped for further qualitative analysis."
224060451|NCT00984971|DRUG|Tenofovir|Topical gel applied rectally
224060452|NCT00984971|DRUG|HEC Placebo|Placebo gel applied rectally
224060453|NCT00984971|DRUG|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
224060454|NCT00073723|DRUG|ABI-007|
223570445|NCT02104271|PROCEDURE|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
224060455|NCT05363475|DEVICE|ForeSite Intelligent Surface|The ForeSite IS is a continuous bedside pressure mapping system with machine learning and artificial intelligence (ML/AI). It consists of an overlay with over 1500 undetectable integrated sensors and a medical-grade bedside touchscreen monitor. The monitor displays a real-time coloured body pressure image, a turn timer, and a history of previous turns. The ML/AI software tracks 17 body locations and the patient's body position. The system has a centralized dashboard that shows the pressure injury risk and turn history, which can be transmitted to the nursing station. In addition, data is stored in an Amazon Web Services (AWS) secured cloud database, enabling access to individual reports on turn history and compliance and pressure exposure. Data is stored as both, raw pressure data files and real time event information on pressure exposure and turn data.
224060456|NCT03991351|OTHER|Exposure to images|Exposure to images
224060457|NCT00872105|PROCEDURE|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
224147522|NCT02245230|DRUG|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
224147523|NCT03424213|OTHER|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
224147524|NCT01830244|DRUG|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
224147525|NCT05685394|DRUG|Dapagliflozin|Dapagliflozin 10mg P.O. daily
224147526|NCT03122249|BEHAVIORAL|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
224147527|NCT01824693|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
224147528|NCT01824693|DRUG|Busulfan|Given IV
224147529|NCT01824693|DRUG|Cyclophosphamide|Given IV
224147530|NCT01824693|DRUG|Fludarabine Phosphate|Given IV
224147531|NCT01824693|OTHER|Laboratory Biomarker Analysis|Correlative studies
223570446|NCT05202574|DRUG|Intravenous drug|intravenous drug injection
223570447|NCT04070716|PROCEDURE|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
223570448|NCT04070716|PROCEDURE|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
223570449|NCT02780635|BEHAVIORAL|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
223570450|NCT02780635|BEHAVIORAL|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
223570451|NCT06105736|BEHAVIORAL|Behavioral Intervention in a small group platform|RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
223570452|NCT02563860|DRUG|Lovastatin|dose escallating
223570453|NCT01813552|DRUG|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
223570454|NCT01813552|DRUG|Omeprazole|40 mg delayed-release oral capsules, once daily
223570455|NCT01813552|DRUG|Ritonavir|100 mg oral tablets, once daily
223570456|NCT01117740|BEHAVIORAL|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
224147532|NCT01824693|DRUG|Melphalan|Given IV
224147533|NCT01824693|DRUG|Mycophenolate Mofetil|Given IV or PO
224060458|NCT00872105|PROCEDURE|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
224060459|NCT03391271|OTHER|photobiomodulation therapy (PBMT)|"Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)"
224060460|NCT03391271|OTHER|sham laser sessions|• The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
224060461|NCT04608812|DRUG|OS2966|OS2966 is a humanized monoclonal antibody antagonizing CD29 (Beta 1 integrin)
224060462|NCT04608812|DRUG|Gadoteridol|Gadoteridol is a contrast agent which will be added to OS2966 to allow investigators to observe how OS2966 distributes within the brain tumor. Gadoteridol is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
224147534|NCT01824693|OTHER|Pharmacological Study|Correlative studies
224147535|NCT01824693|DRUG|Tacrolimus|Given IV or PO
224147536|NCT06271239|OTHER|Intervention group (ViviFrail)|The participant will be guided to follow a daily exercise routine at home, lasting 30-45 minutes, from Monday to Friday, over six months. A one-week break every six weeks for reassessment, totaling seven months of activities, will be provided. They will be informed that every six weeks, they may receive new exercises in their exercise passport or continue with the same, based on their physical reassessment. Each exercise passport will have a wheel illustrating the exercise circuit for easy reference. An 'Activity Diary' will be provided for tracking progress and frequency. During 'CIRCUIT' sessions, participants should complete the entire circuit, while 'WALKING' sessions should focus solely on walking for that day. They will be motivated to keep this diary updated. The ViviFrail exercise passports cater to various levels of physical frailty and fall risk and can be accessed at https://vivifrail.com/en/materials-2/.
224147537|NCT06271239|OTHER|Group Suggestions for a Healthy Life (CG)|The participants in the group Suggestions for a healthy life (CG) will receive guidance on maintaining a healthy and independent lifestyle for three months. They will also be provided with a booklet containing strength, balance, and flexibility activities, suggesting that participants perform these activities five times a week, for around 30 minutes per day. At the end of the initial three complete months of the intervention (14 weeks), participants in the control group will commence the ViviFrail exercise protocol and will continue until the end of the study. Throughout the entire study period, participants in the control group will receive the same monitoring as the intervention group.
224147538|NCT02979366|DRUG|S64315 once a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
224147539|NCT02979366|DRUG|S64315 twice a week|S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
223742261|NCT04134247|DRUG|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
223742262|NCT04134247|DRUG|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
224060463|NCT02770547|DEVICE|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
224060464|NCT02770547|DEVICE|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
224060465|NCT04245007|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
223452767|NCT04485078|OTHER|Bath Ankylosing Spondylitis Disease Activity Index|Standardized questionnaire to determine the level of disease activity in AxSpa patients
223452768|NCT04485078|OTHER|Ankylosing Spondylitis Quality of Life|Standardized questionnaire to investigate the quality of life in AxSpa patients
223452769|NCT04485078|OTHER|Istanbul Low Back Pain Disability Index|Standardized questionnaire to investigate the disability
223452770|NCT04485078|OTHER|Beck Depression Inventory|Standardized questionnaire to investigate the depression
223452771|NCT04485078|OTHER|Fatigue Severity Scale|Standardized questionnaire to investigate the fatigue
223452772|NCT04485078|OTHER|Pittsburgh Sleep Quality Index|Standardized questionnaire to investigate the sleep quality and disturbance
224301422|NCT06927895|BEHAVIORAL|Educational Intervention|"The research-specific educational intervention is the enhancement of communications and SDM in AE management.~To this end, interventions will include pre-recorded videos that address:~1. SDM methodologies (\~30 minutes)~2. Simulated case role play interactions between a standardized patient actor and clinician participant (\~60 minutes)~3. In depth presentation on AEs associated with HER2-targeted ADC treatments, and the management of these AEs (\~45 minutes)~Clinician participant educational intervention videos and patient participant educational intervention videos will be slightly different, as they are each presented from their specific perspectives."
223452773|NCT04485078|OTHER|Fibromyalgia Rapid Screening Tool|Standardized questionnaire to detect fibromyalgia
223452774|NCT04485078|OTHER|Visual analogue scale|global pain score on a 0 to 10
223452775|NCT03660891|DIAGNOSTIC_TEST|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
223452776|NCT05328453|DIAGNOSTIC_TEST|Fetal prenatal ultrasonographic evaluation.|Routine fetal ultrasonography at 15-24 weeks. All sonographic measurements including 3D fetal thymus calculation was measured.
223452777|NCT01676051|OTHER|Skin culture|Culture swab used to culture skin adjacent to incision
223452778|NCT03013712|BIOLOGICAL|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
223452779|NCT01947101|BIOLOGICAL|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
223452780|NCT00882271|OTHER|Acupuncture|Ten Acupuncture treatments within six weeks
223452781|NCT01898169|OTHER|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
223452782|NCT01704755|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
223452783|NCT01704755|DRUG|Ribavirin (RBV)|Capsule
224060466|NCT03051555|DEVICE|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was \<200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
223452784|NCT03293745|BEHAVIORAL|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
224060467|NCT05341271|OTHER|Experimental: digital reminiscence group (DRG)|Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences
224301423|NCT06928623|OTHER|Surveys|In the present study, no intervention will be carried out, with the recruited subjects only completing the questionnaires set out in the study variables.
224301424|NCT06927479|OTHER|Training about Electronic Decision Support System|"1. System Registration and Usage~2. Pressure Ulcer Prevention~3. Urinary Infection Prevention~4. Nutrition and Hydration Management~5. Physical Activity and In-Bed Mobilization~6. Emergency Management and Reporting~7. Continuous Monitoring and Feedback"
224301425|NCT06928103|OTHER|Dynamic stretching|dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues.
223452785|NCT03293745|BEHAVIORAL|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
223452786|NCT03529708|RADIATION|3D CRT plus SBRT boost|Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
223452787|NCT02974348|DRUG|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
223452788|NCT02974348|DRUG|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
223452789|NCT02974348|DRUG|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
223452790|NCT02974348|DRUG|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
223452791|NCT02974348|DRUG|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
223452792|NCT02974348|DRUG|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
223452793|NCT04105842|DEVICE|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
223452794|NCT02742025|OTHER|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
223742263|NCT00426283|DRUG|Flovent|1760 mcg daily
223742264|NCT00426283|OTHER|Placebo|Placebo
223742265|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
223742266|NCT01630330|PROCEDURE|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
224147540|NCT04797312|DRUG|Opioid Free Anaesthesia protocol|"The OFA protocol begins with a systematic preoperative premedication with clonidine, continues with an adapted intraoperative management without opioid administration, but associating several molecules (clonidine, magnesium, lidocaine, ketamine) and ends with a continued administration of xylocaine up to 1 hour postoperatively in PACU. The use of an opioid in preoperative or intraoperative phases is considered as a deviation from the protocol.~To these different molecules, the use of hypnotic molecules left to the choice of the practitioner and a curare will be systematically associated."
224147541|NCT04797312|DRUG|standard practice protocol based on the use of opioids (sufentanil or remifentanil)|Standard anesthetic practices can be summed up as the combination of a hypnotic, a morphinic (sufentanil or remifentanil) and a curare. The use of ketamine is allowed.
224147542|NCT00436020|DEVICE|TMS|Transcranial Magnetic Stimulation
224147543|NCT00436020|DEVICE|Sham TMS|Sham Transcranial Magnetic Stimulation
224147544|NCT03983460|DRUG|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
224147545|NCT03983460|DRUG|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
224147546|NCT03983460|PROCEDURE|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 \& 3 mm diameter) will be performed according the following schedule:~* Day 0~  * a 5 mm section biopsy from a non-lesional skin~ * a 5 mm section biopsy from an active lesion~ * a 3 mm section microbiopsies from a non-lesional skin~ * a 3 mm section microbiopsies from an active lesion~ * a 2 mm section microbiopsies from a non-lesional skin~ * a 2 mm section microbiopsies from an active lesion~* Day 28~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion~* Day 168~  * a 5 mm section biopsy on improved/healed lesion~ * a 3 mm section microbiopsies on improved/healed lesion~ * a 2 mm section microbiopsies from non-lesional skin identified at V1~ * a 2 mm section microbiopsies on improved/healed lesion"
224147547|NCT03983460|PROCEDURE|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~* Negative control : saline solution~* Positive control : histamine solution~Positive criteria of prick tests results are:~* Positive control's diameter ≥ 3mm~* And negative control's diameter \< 3 mm~* And tested allergen with wheal ≥ positive control, i.e. 3mm"
224147548|NCT03983460|PROCEDURE|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
224147549|NCT03027219|DRUG|Alprostadil|Vasodilator for anastomosis-site of free flap
223742267|NCT06386614|OTHER|Routine treatment|Both groups were given routine treatment
223742268|NCT06386614|OTHER|Transcranial Direct Current Stimulation|The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
223742269|NCT03974815|DEVICE|ACTIVE|"We will use 28.26cm\^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
223742270|NCT03974815|DEVICE|SHAM|"We will use 28.26cm\^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
223742271|NCT00870363|DRUG|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
223742272|NCT00870363|DRUG|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
223742273|NCT00870363|DRUG|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
223742274|NCT02663635|DEVICE|Safe'N'Sound|
223742275|NCT03732885|DEVICE|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
223742276|NCT03732885|DEVICE|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
223742277|NCT05326594|PROCEDURE|Mckenzie Extension Protocol|Mckenzie Extension Exercise Protocol will be performed by participants in prone position
223742278|NCT05326594|PROCEDURE|Lumbar SNAGs|Lumbar SNAGs will be performed in lumbar flexion and extension in standing Position
223742279|NCT05326594|DEVICE|Inferential therapy|4 pole inferential therapy in combination with superficial heating for 20 minutes
223742280|NCT05326594|PROCEDURE|Heat Therapy|superficial heating for 20 minutes
223742281|NCT04260737|OTHER|Decision Aid for Men with Localized Prostate Cancer|The intervention is an interactive decision aid aimed to assist newly diagnosed prostate cancer patients with their treatment management options.
223742282|NCT03911440|DRUG|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
223742283|NCT03911440|DRUG|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
223742284|NCT03409926|DIETARY_SUPPLEMENT|Acacia Gum|dietary supplement will be added to the participant's usual diet
223742285|NCT03096652|PROCEDURE|Approach for cancer resection|
224147550|NCT04510402|DRUG|Povidine iodine nasal swabs|Daily versus twice daily nasal application
224060468|NCT05341271|OTHER|Experimental: general reminiscence group (GRG)|"Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences"
224060469|NCT01157312|DRUG|clomiphene citrate +highly purified uFSH|
224060470|NCT01157312|DRUG|clomiphene citrate|
224060471|NCT01309074|DRUG|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
224060472|NCT01309074|DRUG|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
224060473|NCT05562375|DEVICE|GOCCLES|"Inspection using GOCCLES®. An UV light source will be administered, with polymerization lamp sdi radii xpert, with a potency of 1500 mW/cm2 and a wavelength of 440-480nm, applied at 20cm of the injury.~Notes will be taken on the location and size of the injury observed with the device.~Image register using the GOCCLES® photographic filter for mobile devices. The same light source will be used."
224060474|NCT05562375|DIAGNOSTIC_TEST|Toluidine blue stain|"To value the toluidine blue diagnosis capacity, the sequence described by Mashberg will be followed: The patient will realize a mouthwash with acetic acid at 1% for 20 seconds. Two using water for 20 seconds. Toluidine blue at 1% will be applied for 20 seconds. New mouthwash with acetic acid for 60 seconds and a final mouthwash with water.~Notes on the and pictures will be taken on the location and size of the injury."
224060475|NCT05562375|PROCEDURE|Biopsy|The area to biopsy will be chosen, and, using local anaesthesia, it will be resected. The specimens will be sent to the oral and maxillofacial pathology diagnostic service of the University of Basque Country for anatomopathological study
224060476|NCT04001361|PROCEDURE|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
224060477|NCT03333083|DRUG|Raltegravir|Raltegravir (1200 mg once a day)
224060478|NCT03333083|DRUG|Lamivudine|Lamivudine (300 mg once a day)
224060479|NCT06520735|DEVICE|Transcutaneous electrical nerve stimulation|The pregnant women with emesis gravidarum will be treated by transcutaneous electrical nerve stimulation (TENS) on p6 acupuncture point for 30 minutes daily for 5 consecutive days.
224060480|NCT06520735|OTHER|Capsicum plaster|The pregnant women with emesis gravidarum will be treated with capsicum plaster on p6 acupuncture point for 12 hours per day for 5 consecutive days.
224060481|NCT00393887|DEVICE|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
224060482|NCT00393887|DEVICE|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
224060483|NCT05526690|DRUG|Metformin|1000 mg dose of immediate-release metformin
224060484|NCT05526690|DRUG|CIN-107|10 mg dose of CIN-107
224060485|NCT03016208|DRUG|Misoprostol vaginal insert|
224060486|NCT00312624|PROCEDURE|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
224147551|NCT01011088|OTHER||Not any artificial interventions were given
223452795|NCT02742025|OTHER|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
223452796|NCT02742025|OTHER|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
223452797|NCT02742025|PROCEDURE|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
223452798|NCT02425423|DIETARY_SUPPLEMENT|New thickened formula|
223452799|NCT03566381|DEVICE|Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.|This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
224060487|NCT01966328|DRUG|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
224147552|NCT01482572|PROCEDURE|biopsy|percutaneous lung biopsy and aspiration
224147553|NCT00929136|BIOLOGICAL|USP endotoxin|Continuous intra-arterial infusion
224147554|NCT02558283|DEVICE|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
223452800|NCT05667168|PROCEDURE|physiotherapy approach|The therapy will take place 2-3 times a week; the therapeutic unit will last 45 minutes and will be oriented towards one therapeutic approach from the above list. The total number of therapy sessions will be limited to 3 months (i.e. three months, 2-3 times a week). After completion of the 3-month therapy, a follow-up examination will be performed again by kinesiological analysis, questions about the intensity of tinnitus according to a numerical scale and quality of life by a selected questionnaire.
223452801|NCT01639703|DRUG|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
223452802|NCT02087670|OTHER|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
223452803|NCT02087670|OTHER|exercise protocol no supervised|Exercise program at the community
224060488|NCT01966328|DRUG|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
224060489|NCT03385811|OTHER|no intervention, only questionnaires survey|questionnaires survey
224060490|NCT00224614|PROCEDURE|Allogenic transplantation|
224060491|NCT00492323|DRUG|placebo|twice daily for 4 weeks
224060492|NCT00492323|DRUG|carisbamate|200 mg tablet twice daily for 4 weeks
224060493|NCT02600104|DEVICE|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
224060494|NCT01236690|DRUG|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
224060495|NCT02698267|DRUG|BIIB074|Administered as specified in the treatment arm
224060496|NCT02698267|DRUG|Itraconazole|200 mg twice daily \[BID\] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
223452804|NCT05091996|PROCEDURE|Post-isometric muscle relaxation technique|"1: Therapist (T) abducted the patients' (P) mandible until the functional barrier. P performed isometric tension of the mandibular adductors with about 20% of the maximum force, balanced by the T. After 10 secs of isometric tension, P relaxed his muscles, and T abducted the mandible to a new functional barrier. During one treatment, the cycle was repeated 3 times, each time starting from the previously obtained barrier.~2: T performed passive lateral translation of the mandible until the functional barrier. P performed isometric tension with about 20% of maximum force, as to initiate the movement of the mandible towards the resting position. T balanced the force generated by the P. After 10 secs of isometric tension, P relaxed his muscles and T deepened the lateral movement of the mandible until a new functional barrier was reached. During one treatment, the cycle was repeated 3 times, both to the right and left side, each time starting from the previously obtained barrier."
223452805|NCT05091996|PROCEDURE|Myofascial release technique|The myofascial release procedure was performed successively in the area of: the anterior parts of the temporal muscles , the superficial parts of the masseter muscles and the sternocleidomastoid muscles.During one session, the above cycle was repeated six times on both sides separately. The was lying on his back, with his head turned to the side.The therapist was behind the patient's head, using the pad of the first finger placed on the skin in the area of the initial attachment of a worked muscle, he took out the tissue slack, moving the tissues towards the perceptible limitation of mobility (caudal direction).Reaching the tissue barrier, he kept the tension of the sliding structures, shifting them until the physiological tissue barrier.A single application of the myofascial release procedure consisted of one movement moving the soft tissues along the muscle
223452806|NCT00387283|DRUG|AVI-4020 Injection|
223452807|NCT01272505|PROCEDURE|converntional SILC|
223452808|NCT01272505|PROCEDURE|Harmonic scalpel Single incision laparoscopic cholecystectomy|
223452809|NCT00030628|RADIATION|radiation therapy|
223452810|NCT00030628|PROCEDURE|surgery|
223452811|NCT00030628|RADIATION|WBRT|
223452812|NCT03747783|PROCEDURE|Radical Operation|The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
223452813|NCT01597297|DRUG|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
223742286|NCT03741036|PROCEDURE|Autogenous bone graft as space filling in immidiate implant placment|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
223742287|NCT03741036|PROCEDURE|Deprotinized bovien as space filling in immidate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
224060497|NCT02031497|DIETARY_SUPPLEMENT|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
224060498|NCT02031497|DIETARY_SUPPLEMENT|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
224060499|NCT04531696|PROCEDURE|Blood draw|Blood draw at inclusion
224060500|NCT04531696|PROCEDURE|Post-mortem tissue collection|Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
224060501|NCT04623684|DRUG|Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)]|1 drop (6-7 μL) for 3 doses, 5 minutes' intervals
224060502|NCT04623684|DRUG|Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]|1 drop (28-34 μL) for 3 doses, 5 minutes' intervals
224060503|NCT03503877|DEVICE|EmbryoScope Plus|All embryos will be cultured in the EmbryoScope Plus to obtain morphokinetic data
224060504|NCT03503877|OTHER|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
224060505|NCT03503877|OTHER|SAGE MEDIA|Embryos will be cultured in SAGE media
224060506|NCT00002284|DRUG|Zidovudine|
224060507|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3
224060508|NCT04962022|DRUG|Itraconazole|Administered orally once daily for 8 days from Days 1 through 8
224060509|NCT04962022|DRUG|PF-07321332/ritonavir|Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6
224060510|NCT05988775|BEHAVIORAL|Leg training|Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
224147555|NCT02558283|DEVICE|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
224060511|NCT05988775|BEHAVIORAL|Sequence observation|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
224060512|NCT05988775|OTHER|Nature movie watching|Participants observed 10 blocks of the sequence with the lights alternating automatically, with a 30s break between each block.
224060513|NCT03546530|DRUG|Interferon|Interferon
224060514|NCT03546530|DRUG|Interferon+resveratrol|Interferon+resveratrol
224060515|NCT00006451|DRUG|anti-thymocyte globulin|
224060516|NCT00006451|DRUG|cyclophosphamide|
224060517|NCT00006451|DRUG|cyclosporine|
224060518|NCT00006451|DRUG|methotrexate|
224060519|NCT00006451|DRUG|methylprednisolone|
224060520|NCT00006451|PROCEDURE|allogeneic bone marrow transplantation|
224060521|NCT00006451|PROCEDURE|in vitro-treated bone marrow transplantation|
224060522|NCT00006451|PROCEDURE|radiation therapy|
224060523|NCT05914636|BIOLOGICAL|analysis of foecal microbiota|"An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed."
224060524|NCT02841397|DEVICE|Masimo Pulse CO-Oximeter|Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
224060525|NCT00071695|DRUG|Duloxetine Hydrochloride|
224060526|NCT00071695|DRUG|Venlafaxine Extended Release|
224060527|NCT02690857|DRUG|Docosahexaenoic acid|
224060528|NCT02690857|DRUG|Sunflower Oil|
224060529|NCT03782402|DRUG|Cannabinoids|Cannabinoids with THC and CBD versus placebo cannabinoids
224060530|NCT04240015|OTHER|Oral-Dental Health-Related Quality of Life-United Kingdom (OHRQoL-UK) scale|It consists of 4 different categories and 16 questions evaluating the effects of OHRQoL in positive and negative areas. These categories are as follows; symptoms (2 questions), physical status (5 questions), psychological status (5 questions), social status (4 questions) ' Questions on the OHRQoL-UK scale were scored using the Likert-type scale as 'very bad effect-score 1, bad effect-score 2, no effect-score 3, good effect-score 4, very good effect-score 5. The scores obtained from all questions were summed to give the scores of the 4 sub-categories separately and the total OHRQoL score. A higher total score indicates a higher OHRQoL.
224060531|NCT01146873|DRUG|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
224060532|NCT01146873|DRUG|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
224060533|NCT01146873|DRUG|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
223452814|NCT01597297|OTHER|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
223452815|NCT05100303|DRUG|Mitoxantrone Hydrochloride liposome injection|Mitoxantrone hydrochloride liposome will be administered by intravenous (IV) injections.
223452816|NCT05100303|DRUG|Cytarabine (LoDAC)|Low-dose or high-dose cytarabine (LoDAC) will be administered by intravenous (IV) injections.
223452817|NCT03974529|BEHAVIORAL|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
223452818|NCT03974529|BEHAVIORAL|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
223452819|NCT05972642|DEVICE|HIFU-treatment|The investigator will sedate the subject and perform the HIFU procedure with the investigational medical device according to the pre-established procedure plan (see Table 11 for procedure plan) (procedure may take up to 2 hours). During the procedure, the investigator may modify the pre-established procedure plan by checking in with the subject occasionally to assess the presence of heat and pain at the site of the investigational device application.
223452820|NCT06056453|BEHAVIORAL|Interpersonal Psychotherapy|IPT group-virtual
223452821|NCT04264754|PROCEDURE|Blood collection|Peripheral blood will be collected via routine venipuncture procedure
223584090|NCT03189966|PROCEDURE|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
223452822|NCT03711305|DRUG|SHR-1316|SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
223452823|NCT03711305|DRUG|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
223452824|NCT03711305|DRUG|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
224060534|NCT01146873|DRUG|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
224060535|NCT01152320|BEHAVIORAL|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
224060536|NCT04647591|OTHER|Questionnaires|Use of a questionnaire focused on diver experience and medical history upon inclusion and another questionnaire in case of ENT Barautrauma over a period of two years to standardize Barotrauma assessment.
224060537|NCT03433872|OTHER|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
224147556|NCT02733146|OTHER|cardiac arrest|
224060538|NCT02616549|BEHAVIORAL|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
224147557|NCT04733001|DRUG|HSG4112|Once-daily oral administration
224147558|NCT02846051|PROCEDURE|venous mapping|clinical examination + doppler echo
223452825|NCT03711305|DRUG|Placebo|Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
223452826|NCT02869477|OTHER|Data collection|
223452827|NCT01042392|DRUG|Aliskiren|150 mg Aliskiren as film-coated tablet
223452828|NCT01042392|DRUG|Ramipril|Ramipril 5 mg was given in capsule form.
223452829|NCT01042392|DRUG|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
223452830|NCT01042392|DRUG|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
223452831|NCT05802303|DRUG|17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)|In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
223452832|NCT05802303|DRUG|Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)|In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
223452833|NCT03318367|OTHER|Educational Intervention|Complete virtual reality education module
223452834|NCT00612651|DRUG|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
223452835|NCT04455217|OTHER|data collection from patients with FAI (occuring January 2000 until December 2019)|data collection from patient files (data regarding surgery, adverse events, infections, demographic data)
223452836|NCT06350201|BEHAVIORAL|cognitive behavior therapy|Problem-solving therapy-based holistic emotion management interventions matched to individual symptoms
223452837|NCT06350201|OTHER|control group|Routine psychological care and guidance on mood management
223452838|NCT02146209|DRUG|Metronidazole benzoate|Single oral dose of 400 mg
224060539|NCT01967628|DIETARY_SUPPLEMENT|Vitamin D3 (cholecalciferol)|
224060540|NCT01967628|DIETARY_SUPPLEMENT|Placebo Sugar Pill|
224060541|NCT01545479|DRUG|captopril 25mg|renal blood oxygenation after captopril
224147559|NCT06527261|OTHER|Real-time electronic data input into REDCap|"During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions.~The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation."
224147560|NCT04848415|OTHER|Point-of-Care Ultrasound|Patients admitted to the ED with abdominal pain and suspicion of bowel obstruction : realization of a Point-of-Care Ultrasound after clinical exam by the Emergency Physician in charge as a standard of care. Beside usual findings, the investigators will search for signs of bowel obstruction: dilated and incompressible small bowel loop, back-and-forth peristalsis sign. Determination of probability of small bowel obstruction. Realization of a computed tomography in search of small bowel obstruction.
224147561|NCT02533687|PROCEDURE|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
224147562|NCT02533687|PROCEDURE|Bipolar TURP-2|Bipolar TURP
224147563|NCT02533687|PROCEDURE|Monopolar TURP|Monopolar TURP
224147564|NCT04159818|DRUG|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
224147565|NCT04159818|DRUG|Cisplatin|40mg/m2, weekly for two weeks
224147566|NCT04159818|DRUG|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
224147567|NCT00362050|DRUG|Treatment with 3 dose groups of RBx11160 over 7 days|
223452839|NCT02146209|DRUG|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
223452840|NCT02146209|DRUG|Flagyl 400 mg Tablets|Single oral dose of 400 mg
223452841|NCT00587795|DEVICE|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
223452842|NCT00587795|OTHER|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
223452843|NCT03928379|DRUG|LY3305677|Administered SC
223452844|NCT03928379|DRUG|Placebo|Administered SC
223452845|NCT00700024|DRUG|Testim|50 mg/dose7day
223452846|NCT00700024|BEHAVIORAL|Strength training|three times a week
223452847|NCT00700024|DRUG|placebo|placebo
224060542|NCT04439604|OTHER|regional ventilation monitoring|regional ventilation monitoring
224060543|NCT01826279|DIETARY_SUPPLEMENT|Resveratrol|500mg 3 times daily for 1 month
224060544|NCT01826279|OTHER|Placebo|1 placebo tablet 3 times daily for 1 month
224060545|NCT00841802|DRUG|Prednisone|Prednisone 30mg once daily x 5 days
224060546|NCT03331055|DEVICE|PENS|percutaneous electrical nerve stimulation
224060547|NCT03331055|DEVICE|TENS|transcutaneous electrical nerve stimulation
224060548|NCT03544372|OTHER|Assessment of Concussion History using NIH Concussion History Tool|NIH concussion tool
224301426|NCT06928103|OTHER|Static stretching and dynamic stretching|Static stretching: help patients do the movement that they\&amp;amp;#39;re limited to stretch their soft tissue; Dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues
223452848|NCT00079053|DRUG|erlotinib hydrochloride|
223570457|NCT03760159|DEVICE|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
223570458|NCT02051153|DRUG|Modafinil|Modafinil (2-\[(Diphenylmethyl) sulfinyl\]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg \& Carter, 2008).
223570459|NCT02051153|DRUG|Placebo|
223570460|NCT01173549|DRUG|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
223742288|NCT03741036|PROCEDURE|Nano-hydroxiapatite alloplast in immidiate implant placement|"* The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~* Patients will be subjected to CBCT (diagnostic for upper arch).~* Local anesthesia will be given to the patient.~* Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~* The procedure will be carried out flapless.~* In the study group: Atraumatic extraction~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
223742289|NCT04850846|DRUG|Metformin XR|Orally by mouth
223742290|NCT04850846|OTHER|Placebo|Orally by mouth
223742291|NCT06459648|OTHER|Headache record|The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication.
223742292|NCT06459648|OTHER|Scales|Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.
223742293|NCT06459648|DRUG|Monoclonal antibody anti-CGRP|Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab
223742294|NCT04172246|DRUG|Zanubrutinib|Zanubrutinib at 160 mg orally twice daily
223742295|NCT01447524|BEHAVIORAL|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
223742296|NCT02357901|DRUG|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
223742297|NCT02357901|DRUG|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
223452849|NCT00079053|PROCEDURE|adjuvant therapy|
223452850|NCT04816760|BIOLOGICAL|Peripheral blood samples|Peripheral blood samples at Day 0, Day 7, Day 14, Day 28, Day 90 and Day 180.
223452851|NCT03476642|DRUG|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
223452852|NCT03476642|DRUG|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
223452853|NCT02826161|DRUG|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
223452854|NCT02826161|DRUG|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
223452855|NCT03786900|BIOLOGICAL|Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727|
223452856|NCT05641935|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
223570461|NCT01173549|OTHER|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
223742298|NCT02357901|DRUG|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
224060549|NCT02970825|OTHER|Exercise|Moderate to high intensity physical training
224060550|NCT02970825|OTHER|Relaxation|Low intensity physical activity and relaxation
223452857|NCT05641935|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
223452858|NCT05641935|PROCEDURE|Computed Tomography|Undergo CT
223452859|NCT05641935|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223452860|NCT05641935|OTHER|Electronic Health Record Review|Review electronic medical record
224060551|NCT04331795|DRUG|Tocilizumab|"Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
224060552|NCT04331795|DRUG|Tocilizumab|"Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.~Second dose is provisioned if:~1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND~2. CRP decrease is \< 25% at 24 hours following tocilizumab administration and CRP \> 40mg/L"
223452861|NCT05607316|DRUG|Metformin Hydrochloride|"Consistent with previous studies and clinical recommendations, subjects will initiate treatment at metformin 500 mg twice daily and increase to 1000 mg twice daily only after they have tolerated the treatment (details below).~Study Visit 1 (Week 1) - Study Visit 2 (Week 2) Subjects will be directed to take metformin 500 mg twice daily.~Study Visit 2 (Week 2) - Study Visit 5 (Week 24) If initial metformin dose is tolerated, subjects will be directed to increase the dose to 1000 mg by mouth twice daily for the remainder of the study."
223452862|NCT06404749|DIETARY_SUPPLEMENT|fungal fiber|fungal fiber from mycelium
223452863|NCT06404749|DIETARY_SUPPLEMENT|inulin|long chain, degree of polymerization DP\>23
223452864|NCT05258682|DRUG|Bromelains|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
223452865|NCT05258682|DRUG|Acetylcysteine|Bromelain combined with Acetylcysteine (BromAc), administered simultaneously.
223452866|NCT05100381|OTHER|dry needling|The patients will be placed in a prone position with a pillow under their belly to accommodate lumbar lordosis. Two lengths of sterile, disposable, 0.30 mm x 75 mm and 0.30 mm x 50 mm solid filament needle (Tony, China) will be used in this study. The length of the needle for each participant will be selected based on the size of the participant. The needles will be inserted into the lumbar multifidus muscle, 1.5 - 2 cm lateral to the spinous process of two or three painful segments, perpendicular to lamina (after piercing the skin, needles are directed inferomedially). The needles will be inserted to obtain local twitch response, and this process will continue until no more local twitch response occurs in each session. Then the needles will be left in place for 20 minutes.
223452867|NCT05100381|OTHER|sham (placebo) dry needling|The sham dry needling method includes the insertion of the needles subcutaneously and no local twitch response will be obtained. The needles will be left in the place for 20 minutes.
223452868|NCT05010317|BEHAVIORAL|Mindfulness and acceptance based therapy|This is a behavioral intervention that is aimed at building psychological flexibility among adolescents. It involves careful use of language, metaphors, experiential learning and mindfulness to develop skills that support values guided living. Participants learn to relate with their inner thoughts, feelings and urges in an open and elaborative way as conscious human beings and make choices that improve their lives even in the presence of such difficult experiences.
223452869|NCT05010317|BEHAVIORAL|Standard of care|Usual clinic based counselling offered as routine care to adolescents
223452870|NCT04084002|OTHER|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
223452871|NCT00003115|DRUG|hydromorphone hydrochloride|
223452872|NCT03372642|DEVICE|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
223452873|NCT04990271|DRUG|Conbercept ophthalmic injection|Monthly injection of Conbercept from 0\~5 months
223452874|NCT04053244|BEHAVIORAL|internet-based cognitive behavioural therapy|Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
223452875|NCT01981811|DRUG|Aripiprazole|
223452876|NCT01981811|DEVICE|Ingestible Event Marker (IEM)|
223452877|NCT02869893|DRUG|Secretin|
223452878|NCT03182881|OTHER|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
223452879|NCT03182881|OTHER|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
223452880|NCT04769674|OTHER|Sensory Integration Intervention through the STAR Frame of Reference|The individualized therapy program will be based on the results of the comprehensive evaluation. Intervention aligns with the STAR Frame of Reference fidelity measure and Ayres Fidelity Measure.
223570462|NCT03777709|BEHAVIORAL|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
223570463|NCT01067599|OTHER|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
223570464|NCT01067599|OTHER|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
223570465|NCT01067599|OTHER|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
223570466|NCT04774536|DRUG|CRISPR_SCD001|CRISPR\_SCD001 is administered by IV infusion following myeloablative conditioning with busulfan.
223570467|NCT05959577|PROCEDURE|Stapled hemorrhoidopexy with anoplasty|The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.
224060553|NCT05011929|BEHAVIORAL|Cognitive behavioral therapy|refer to the arm description
224060554|NCT03532594|PROCEDURE|PRODOSE Algorithm|Protamine administered according to PRODOSE algorithm
224060555|NCT03532594|PROCEDURE|Standard Care|Protamine administered according to Standard Care
224060556|NCT00120991|PROCEDURE|Coronary artery bypass grafting|
224060557|NCT04312035|PROCEDURE|end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of increasing extensibility of the periarticular tissues
224060558|NCT04312035|PROCEDURE|Non end-range mobilization|accessory technique applied on the tibiofemoral joint with the aim of alleviating pain
224060559|NCT04312035|PROCEDURE|Control|hands-on cutaneous technique
224060560|NCT02936583|DRUG|BAY987521|"Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-067)"
224060561|NCT01396174|BEHAVIORAL|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
224060562|NCT01396174|BEHAVIORAL|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
224060563|NCT02317861|DRUG|RDEA3170|Oral Treatment
224060564|NCT02317861|DRUG|Febuxostat|Oral Treatment
224060565|NCT02317861|DRUG|Benzbromarone|Oral Treatment
224060566|NCT03851900|OTHER|Teethmate Desensitizer (TM)|Desensitizing agent will be applied to sensitive teeth.
224060567|NCT03851900|OTHER|Clearfil SE Bond 2|Desensitizing agent will be applied to sensitive teeth.
224060568|NCT03851900|OTHER|Distilled water|Placebo will be applied to sensitive teeth as a negative control.
224060569|NCT02055820|DRUG|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
224060570|NCT02055820|DRUG|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
224060571|NCT02055820|DRUG|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
224060572|NCT02055820|DRUG|Rituximab|Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
224060573|NCT02055820|DRUG|Doxorubicin|Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
224060574|NCT02055820|DRUG|Vincristine|Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
224060575|NCT02055820|DRUG|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
224060576|NCT03962374|DEVICE|Frova|Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
224060577|NCT03962374|DEVICE|Stylet|Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
224060578|NCT04428021|DRUG|Standard Therapy Protocol (STP)|Standard Therapy Protocol according to the best evidence treatment recommended by the Regional Health System emergency committee
224060579|NCT04428021|OTHER|STP + Standard Plasma (SP)|Transfusion of three Standard Plasma Units (SP) on day 1,3,5 in addition to STP
224060580|NCT04428021|OTHER|STP + COVID-19 Convalescent Plasma (CP)|Transfusion of three SARS-Cov-2 neutralizing antibodies positive Plasma Units (CP) on day 1,3,5 in addition to STP
224060581|NCT05386901|PROCEDURE|Conventional positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to 5 cmH2O until the end of the operation.
224060582|NCT05386901|PROCEDURE|Lung dynamic compliance guided positive end-expiratory pressure(PEEP)|Positive end-expiratory pressure is the mechanical ventilator that generates positive pressure during the inspiratory phase to pass gas into the lungs. When the airway opens at the end of expiration, the airway pressure remains above atmospheric pressure to prevent the alveoli from shrinking and collapsing.In this intervention arm It will be set to individual value until the end of the operation.The individualized values are obtained by observing the maximum Lung dynamic compliance during PEEP titration.
224060583|NCT01106170|DRUG|Provex CV|dietary supplement, 2 capsules per day by mouth
223452881|NCT04995263|BEHAVIORAL|Sueña component 1: Sleep Hygiene Promotion|The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
224060584|NCT01106170|OTHER|placebo|corn starch, 2 capsules per day by mouth
223452882|NCT04995263|BEHAVIORAL|Sueña component 2: Periodic Anxiety and Pain Screening|Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
224060585|NCT04624711|DRUG|Eribulin Mesylate|Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
224060586|NCT04624711|DRUG|Anlotinib hydrochloride|Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
224060587|NCT03917173|PROCEDURE|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
224060588|NCT03917173|PROCEDURE|Standard surgery|Standard surgery without HIPEC CO2
224060589|NCT03884738|OTHER|Concentric Exercise|"Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg."
224060590|NCT03884738|OTHER|Nordic Eccentric exercise|"1. st week - 1 day - 2 sets of 5 repeats.~2. nd week - 2 days - 2 sets of 6 repeats.~3. rd week - 3 days - 3 sets of 6-8 repeats.~4. th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased."
224060591|NCT03884738|OTHER|Neuromuscular Electrical Stimulation|8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
223742299|NCT04259762|OTHER|Aim 8 (INT, Pilot Test): Breast, Colorectal, and Cervical Cancer Screening Cognitive-Behavioral Interventions|Adult men and women will receive age- and gender-specific INTs. Women age 45-75 years will receive the interventions for breast, colorectal, and cervical cancers screening. Men age 45-75 years will receive the intervention for colorectal cancer screening. Women age 21-49 years will receive the intervention for cervical cancer screening. The cognitive-behavioral INTs on age-gender specific cancers will range from 1-2 hours. The study team will utilize a digital flipchart that will cover each cancer's specific risk/protective factors, incidence, mortality, screening methods, and resources. The study team member delivering the INTs will function as a facilitator linking information with practical skills.
223570468|NCT05959577|PROCEDURE|Ferguson hemorrhoidectomy|Ferguson hemorrhoidectomy
223742300|NCT01203046|DRUG|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
223742301|NCT05719116|BEHAVIORAL|Physical exercise|The physical exercise will be aerobic and strength training. The sessions will last app. 1 hour.
223742302|NCT05623748|PROCEDURE|CTCs isolation/purification and cell number expansion|In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
223742303|NCT04940026|DRUG|amcenestrant|Tablet Oral
224060592|NCT00507390|DIETARY_SUPPLEMENT|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
224060593|NCT00507390|DIETARY_SUPPLEMENT|olive oil|1 capsule day
224060594|NCT00238251|DRUG|gefitinib|Once daily during days 1-28
224060595|NCT00238251|DRUG|temozolomide|Once daily on days 1-21
224060596|NCT00238251|RADIATION|radiation therapy|Whole brain radiotherapy
223452883|NCT04995263|BEHAVIORAL|Sueña component 3: Hypnotics and Caffeine Regulation|The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
223452884|NCT04995263|BEHAVIORAL|Sueña component 4: Sleep Masks and Ear Plugs|Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
223452885|NCT04995263|OTHER|Sueña component 5: Personalized Psychoeducation|Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
223570469|NCT03575065|DRUG|BGB-290|Administered orally
223570470|NCT01003756|OTHER|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
223570471|NCT03617536|DRUG|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
223570472|NCT03617536|DRUG|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
223570473|NCT03617536|DRUG|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
223570474|NCT03617536|DRUG|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
223570475|NCT00196027|DEVICE|PFX Closure System|
223570476|NCT05749666|DRUG|Tofacitinib 5 MG|Tofacitinib 5 MG BID taken orally for 24 weeks
223570477|NCT05749666|DRUG|Prednisolone|Prednisolone taken daily according to preset tapering protocol
223570478|NCT05749666|OTHER|Placebo of tofacitinib 5mg|Placebo of tofacitinib 5mg BID taken orally for 24 weeks
223570479|NCT05749666|OTHER|Placebo of prednisolone|Placebo of prednisolone taken daily according to preset tapering protocol for 24 weeks
223742304|NCT04940026|DRUG|[14C]-SAR439859 microtracer|Solution for infusion Intravenous
223742305|NCT04940026|DRUG|[14C]-SAR439859|Powder for oral solution Oral
223742306|NCT06136871|BEHAVIORAL|CO-OP Procedures|CO-OP is a metacognitive strategy training intervention that will be used in this study. First, five functional, everyday life goals are identified collaboratively by the participant and interventionist. In the second meeting, we introduce the approach to the subject and teach the global cognitive strategy (i.e., GOAL-PLAN-DO-CHECK). In all subsequent sessions, this strategy is used as the main problem-solving framework to facilitate skill acquisition.The subject identifies a GOAL, and then is guided by the therapist to discover a PLAN to potentially achieve the goal. The subject is then asked to DO the plan (if feasible during the therapy session otherwise asked to complete at home prior to the next treatment session), and subsequently to CHECK to see if the plan worked, i.e. the goal was achieved. This process is repeated until satisfactory performance is met for each established goal.
224060597|NCT00913900|BIOLOGICAL|autologous CD133+ cells|Intramuscular injection
224060598|NCT00001014|DRUG|Trimetrexate glucuronate|
224060599|NCT00001014|DRUG|Sulfamethoxazole-Trimethoprim|
224060600|NCT00001014|DRUG|Leucovorin calcium|
224060601|NCT06493968|DRUG|oxytocin|Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
224060602|NCT06493968|OTHER|placebo|IV bolus of normal saline immediately with the uterine incision
224060603|NCT02734160|DRUG|Galunisertib|Administered orally
224060604|NCT02734160|DRUG|Durvalumab|Administered IV
224060605|NCT00976222|DRUG|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
224070968|NCT04550130|DEVICE|TLA Gut™|The medical device to be investigated is named Tailored Leukapheresis (TLA) Gut™. The device comprises a column that has been designed for extracorporeal leukapheresis to specifically remove chemokine (C-C motif) receptor 9 (CCR9) expressing immunological cell populations including human leukocyte antigen DR isotype (HLA-DRhi ) monocytes from the circulation. This is achieved by integrating a strong affinity binding between the gut homing cell receptor, CCR9, and its cognate ligand, thymus-expressed chemokine (TECK) or chemokine ligand 25 (CCL25). Those blood cells that express CCR9 will bind to presented Biotinylated thymus-engineered chemokine (bTECK) on the matrix by a strong receptor ligand interaction, remaining bound to the matrix. Blood cells that do not express the receptor pass through the column unchanged and are returned to the patient.
223452886|NCT04995263|DEVICE|Sueña component 6: Sleep Reports|Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
224060606|NCT04066972|OTHER|Body-weight supported treadmill training in a room cooled to 16°C|A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods \[1 to 5 minutes\] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
223452887|NCT05654064|DRUG|Remifentanil-dexmedetomidine|Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
223452888|NCT05654064|DRUG|Dexmedetomidine-fentanyl|Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
224060607|NCT02362958|DRUG|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
224060608|NCT01628588|DRUG|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
223452889|NCT00289224|BIOLOGICAL|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
223452890|NCT00289224|BIOLOGICAL|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
223452891|NCT04031326|BEHAVIORAL|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
223452892|NCT01734057|DRUG|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day)
223452893|NCT01734057|DRUG|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
223452894|NCT03146741|DRUG|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
223452895|NCT03163316|OTHER|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
223570480|NCT05661864|BEHAVIORAL|Multi-Tiered Systems of Support for Teacher Training|In tier 1 of the intervention, all participants will complete online modules on the target practice and self-monitoring. They will then self-monitor the target practice for approximately three weeks. Non-responders will receive intensified intervention (tier 2) in which they will complete an online module on self-management. They will then self-manage their use of the target practice for approximately 3 weeks. Continued non-responders will receive peer coaching on the target practice (tier 3). Responders to tiers 2-3 will move down a tier after 3 weeks of response.
224060609|NCT04778254|OTHER|PEEK attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
224060610|NCT04778254|OTHER|metalic attachment retained obturator|attachment retained obturator for management of hemi maxillectomy
223452896|NCT01889368|DIETARY_SUPPLEMENT|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
223570481|NCT05058196|RADIATION|Whole breast radiotherapy|Whole breast radiotherapy after surgery
223570482|NCT05058196|RADIATION|Intra Operative Radiotherapy|Intra Operative Radiotherapy
224060611|NCT04778254|OTHER|conventional obturator|clasp retained obturator for management of hemi maxillectomy
224060612|NCT01399788|DRUG|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
224060613|NCT01399788|DRUG|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
223452897|NCT01889368|DIETARY_SUPPLEMENT|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
223452898|NCT04273997|DRUG|Metronidazole 10% ointment|Metronidazole 10% ointment
223452899|NCT04273997|DRUG|Placebo ointment|Placebo ointment
223452900|NCT04814589|DRUG|ezetimibe tablets|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
224060614|NCT00911352|DEVICE|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for \> 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
224060615|NCT02383732|BEHAVIORAL|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention \& Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
224060616|NCT02383732|BEHAVIORAL|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
224060617|NCT02383732|BEHAVIORAL|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
224060618|NCT02919436|DRUG|Tamsulosin|Active drug
224060619|NCT02919436|DRUG|Placebo|Lactose-filled capsules identical to active drug
224060620|NCT05583929|OTHER|GAITRite gaitway system, Bertec Balance System|GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
224060621|NCT04990466|DRUG|IIBR-100|Administration of IIBR-100 vaccine
224060622|NCT04990466|DRUG|Active Comparator|Administration of a currently-approved vaccine for COVID-19
224060623|NCT03699007|BEHAVIORAL|Graded Exposure Therapy (GET Living)|The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.
224060624|NCT03699007|BEHAVIORAL|Multidisciplinary Pain Management (MPM)|The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
224147568|NCT01610908|OTHER|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
224147569|NCT01610908|OTHER|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
224147570|NCT03633591|DRUG|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
224147571|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
224147572|NCT03633591|DRUG|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
224147573|NCT03633591|DRUG|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
224147574|NCT02691481|DIETARY_SUPPLEMENT|Oatmeal breakfast|
224147575|NCT02691481|DIETARY_SUPPLEMENT|Glucerna formula|
224147576|NCT02691481|DIETARY_SUPPLEMENT|Ultra Glucose Control formula|
224147577|NCT01985165|DRUG|Imrecoxib|
224147578|NCT03384004|DEVICE|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
224060625|NCT05808400|BIOLOGICAL|MSC-derived exosomes|The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1\*10\^9 particles/ml.
224060626|NCT04599556|BIOLOGICAL|anti-CD7 CAR-T|Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion
223570483|NCT04697537|DRUG|Ultrasound guided regional anesthesia|Applied perineurally preoperatively ultrasound guided regional anesthesia
224060627|NCT00921232|BEHAVIORAL|Questionnaires|"During a consultation:~* 3 questionnaires (HADS, FRI, CRA)~* and a form for the sociodemographic data"
224060628|NCT04643912|DIAGNOSTIC_TEST|Vibration Device|Device which causes the bone to vibrate and records the spectrum of that vibration
224060629|NCT04718974|OTHER|mHealth call for life system/ tool using IVR ( interactive voice response)|The tool capitalises on a basic mobile phone's core utilities of voice and short messaging services. The system design, development, testing and evaluation was done by Janssen and the Grameen Foundation (http://motechsuite.org/index.php/implementations). In 2015, Janssen Global Public Health Research and Development, in close collaboration with the Infectious Diseases Institute Kampala (IDI), developed Call for Life Uganda (CFLU) tailored to the needs of PLHIV in Uganda
223570484|NCT04697537|DRUG|Local infiltration analgesia|Applied in the wound intraoperatively from the orthopedics
223570485|NCT02323126|DRUG|EGF816|EGF816 150 mg once daily (QD) administered orally as a capsule
223570486|NCT02323126|DRUG|INC280|INC280 400 mg twice daily (BID) administered orally as a tablet
223570487|NCT02323126|DRUG|Nivolumab|Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
223570488|NCT02639169|OTHER|Music Therapy|apply live music through the techniques of music therapy
223570489|NCT04607304|DEVICE|ABCA2 GIRMS|Two systems (ABCA-C and ABCA-D) with run order randomized
223570490|NCT04071015|DEVICE|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line.
223570491|NCT01405352|DIETARY_SUPPLEMENT|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
223570492|NCT01887561|DRUG|dasatinib|
223570493|NCT05377658|DRUG|AK104|10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
223570494|NCT05377658|DRUG|Albumin-Bound Paclitaxel|260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
223570495|NCT05377658|DRUG|Carboplatin|AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
224060630|NCT01923597|DRUG|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
223570496|NCT02178254|DRUG|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
223570497|NCT02178254|DRUG|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
223570498|NCT05977309|DEVICE|Topical ozone therapy|the topical ozone therapy group received a concentration of 30 mg/L at a frequency of 30 minutes per day for 30 days. Participants received ozone therapy topically every three days for eight treatments.
223570499|NCT03350256|DEVICE|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
223570500|NCT02185573|PROCEDURE|Bulk fill|This is one of the composite restoration application techniques
224060631|NCT04220957|OTHER|Digital Impression Technique|Digital impressions of both arches will be taken by using an intraoral scanner (Trios 3, 3Shape, Denmark) by adhering to the scanning pattern recommended by the company for routine diagnosis and recording.
224060632|NCT04220957|OTHER|Conventional Impression Technique|Conventional Impression Technique of both arches will be taken with alginate (Orthoprint, Zhermack) on conventional stainless steel impression trays.
224060633|NCT00315744|DRUG|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
224060634|NCT00315744|DRUG|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
223570501|NCT02185573|PROCEDURE|SonicFill|This is the recent intervention under evaluation
223570502|NCT00134654|DRUG|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
223570503|NCT03208907|DRUG|CQ coadministered with PQ|113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
223570504|NCT03208907|DRUG|DHA-PQP coadministered with PQ|In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
223570505|NCT03208907|DRUG|CQ and PQ starting on Day 42|98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
223570506|NCT03208907|DRUG|DHA-PQP and PQ starting on Day 42|95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
223570507|NCT04126889|OTHER|questionnaire survey|questionnaire survey
223570508|NCT02060994|OTHER|No intervention|No intervention
223570509|NCT05933356|BEHAVIORAL|playing exergames|"will be provided with the individual brain training exergames three times a week and 30 minutes each time"
223570510|NCT05933356|OTHER|scheduled activities|scheduled activities
223570511|NCT02557958|DRUG|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
223570512|NCT02557958|DRUG|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
224060635|NCT00315744|DRUG|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
224060636|NCT00002788|BIOLOGICAL|filgrastim|
224060637|NCT00002788|DRUG|cyclophosphamide|
224060638|NCT00002788|DRUG|dexamethasone|
224060639|NCT00002788|DRUG|etoposide|
224060640|NCT00002788|PROCEDURE|peripheral blood stem cell transplantation|
224060641|NCT00002788|RADIATION|radiation therapy|
224060642|NCT04153721|BEHAVIORAL|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
224060643|NCT04986462|PROCEDURE|shoulder arthroscopy|Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
224060644|NCT02949180|DEVICE|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
224060645|NCT04435509|DIETARY_SUPPLEMENT|1000+ Greek Mountain Tea|Dietary Supplement: Greek Mountain Tea dietary intake of the content of 12 grams (4 grams 3 times per day ) 50 grams per month
224060646|NCT04435509|OTHER|Mediterranean Diet|a Mediterranean dietary protocol
224060647|NCT04243850|DRUG|Empagliflozin 10 MG|Jardiance
224147579|NCT03384004|DEVICE|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
224147580|NCT00457756|DIETARY_SUPPLEMENT|BiosLife Complete|
224147581|NCT00457756|DIETARY_SUPPLEMENT|Placebo|
224147582|NCT01107704|BEHAVIORAL|Family Support Intervention|Multifaceted family support intervention
224147583|NCT00800475|DRUG|Gemfibrozil Tablets|
224147584|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, two days treatment
224147585|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, two days treatment
224060648|NCT04243850|DRUG|Placebo oral tablet|Placebo
224060649|NCT04243850|DIAGNOSTIC_TEST|Caffeine|caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
224060650|NCT03624699|DEVICE|Glaukos iStent inject®|iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
224060651|NCT01157364|DRUG|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
224147586|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, two days treatment
224147587|NCT00700063|DRUG|Vehicle gel|two days treatment
224147588|NCT00700063|DRUG|PEP005 Topical Gel|0.005%, three days treatment
224147589|NCT00700063|DRUG|PEP005 Topical Gel|0.01%, three days treatment
224147590|NCT00700063|DRUG|PEP005 Topical Gel|0.015%, three days treatment
223452901|NCT04814589|DRUG|ezetimibe tablets(Ezetrol ®)|The subjects randomly received single oral administration of ezetimibe tablets 10 mg.
223452902|NCT00837967|DRUG|Symbicort Turbuhaler|160/4.5μg for 3 days
223452903|NCT00837967|DRUG|Terbutaline Turbuhaler|0.4 mg for 3 days
223452904|NCT05098366|DRUG|Furosemide|0.1mg/kg (max 5mg) of IV furosemide
224060652|NCT01157364|DRUG|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
224147591|NCT00700063|DRUG|Vehicle gel|three days treatment
224147592|NCT03105661|DRUG|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
224147593|NCT03105661|DRUG|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
224147594|NCT03105661|DRUG|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
223452905|NCT05098366|DRUG|Normal saline|20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
223452906|NCT05364086|PROCEDURE|Biospecimen Collection|Undergo collection of tumor, blood, saliva and stool samples
223452907|NCT05364086|OTHER|Electronic Health Record Review|Review of medical records
223452908|NCT05364086|OTHER|Interview|Complete an interview
223452909|NCT05364086|OTHER|Quality-of-Life Assessment|Ancillary studies
223452910|NCT05364086|OTHER|Questionnaire Administration|Complete questionnaires
224060653|NCT01157364|DRUG|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
224060654|NCT01157364|DRUG|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
224060655|NCT01157364|DRUG|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
224060656|NCT01157364|DRUG|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
224060657|NCT01157364|DRUG|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
224060658|NCT02891304|OTHER|Quarterly Feedback|Learning curves received quarterly vs. annually
224060659|NCT03259074|BIOLOGICAL|Placebo|Matching placebo to AIN457 150 mg dose administered with AIN457 via pre-filled syringes
224060660|NCT03259074|BIOLOGICAL|GP2017 (adalimumab biosimilar)|40 mg in pre-filled syringes was administered subcutaneously
224060661|NCT03259074|BIOLOGICAL|AIN457 150 mg|150 mg in pre-filled syringes was administered subcutaneously
224060662|NCT00541554|DRUG|Abilify (aripiprazole)|
224060663|NCT02410135|DRUG|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
224060664|NCT02529787|DRUG|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
224060665|NCT02529787|DRUG|Dexilant|1 capsule contains 60 mg Dexlansoprazole
224060666|NCT01780662|DRUG|Brentuximab Vedotin|Given IV
224060667|NCT01780662|DRUG|Gemcitabine Hydrochloride|Given IV
224060668|NCT01233973|OTHER|video decision aid|video
224060669|NCT01653548|BEHAVIORAL|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
224060670|NCT01653548|BEHAVIORAL|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
224060671|NCT01653548|BEHAVIORAL|Habituation|Participants will habituate to personally-relevant stressor.
224060672|NCT01755715|PROCEDURE|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
224060673|NCT05883891|DIAGNOSTIC_TEST|prothrombin time|Prothrombin time at value at diagnosis was used to assess the presence of a correlation with Lille score at day 7 and therefore wether it could predict response to medical treatment.
224060674|NCT00097344|DRUG|Atamestane|
224060675|NCT00097344|DRUG|Toremifene|
224060676|NCT00097344|DRUG|Letrozole|
224060677|NCT00097344|DRUG|Aromatase inhibition|
223452911|NCT03593330|OTHER|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
223452912|NCT02074800|DRUG|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
224060678|NCT00097344|DRUG|Estrogen receptor blocker|
223452913|NCT02074800|DRUG|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
224060679|NCT00097344|PROCEDURE|Hormone therapy|
224060680|NCT00097344|PROCEDURE|Endocrine therapy|
224060681|NCT00097344|PROCEDURE|Antiestrogen therapy|
224060682|NCT03496246|DIAGNOSTIC_TEST|serum total 25 hydroxycholecalciferol 25(OH) vitamin D|Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
223452914|NCT02074800|DRUG|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
223452915|NCT03376113|BEHAVIORAL|the volitional help sheet|A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
223452916|NCT05735639|DRUG|Dalteparin Sodium|Low molecular weight heparin
223452917|NCT05735639|DRUG|Tinzaparin Sodium|Low molecular weight heparin
224060683|NCT03496246|DIAGNOSTIC_TEST|complete blood count (CBC)|for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
224060684|NCT03496246|DIAGNOSTIC_TEST|serum calcium level|measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
224060685|NCT03496246|DIAGNOSTIC_TEST|erythrocyte sedimentation rate (ESR)|it is an indicator of activity in inflammatory bowel disease
224060686|NCT03496246|DIAGNOSTIC_TEST|C-reactive protein (CRP)|it is an indicator for increased possibility of infections
224060687|NCT03496246|DIAGNOSTIC_TEST|serum creatinine|for assessment of renal function
224060688|NCT03496246|DIAGNOSTIC_TEST|serum albumin level|for possibility of malabsorbtion in patients with inflammatory bowel disease
224060689|NCT03496246|DIAGNOSTIC_TEST|seum alanine aminotransferase|for assessment of liver function
224060690|NCT03496246|DIAGNOSTIC_TEST|serum potassium level|indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
224060691|NCT03496246|DIAGNOSTIC_TEST|serum phosphurus level|measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
224060692|NCT01490437|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
224060693|NCT01490437|DRUG|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
224060694|NCT01490437|DRUG|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
224060695|NCT01490437|DRUG|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
224060696|NCT00053417|DRUG|Placebo|Placebo for 15 weeks
224060697|NCT00053417|DRUG|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
224060698|NCT00053417|DRUG|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
224060699|NCT00053417|DRUG|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
224060700|NCT02170285|DEVICE|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
224070969|NCT01228123|OTHER|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
224070970|NCT01228123|OTHER|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
224060701|NCT02170285|DEVICE|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
223452918|NCT05735639|DRUG|Enoxaparin Sodium|Low molecular weight heparin
223452919|NCT05735639|DRUG|Rivaroxaban|Direct oral anticoagulant
223452920|NCT05735639|DRUG|Apixaban|Direct oral anticoagulant
223452921|NCT05735639|DRUG|Dabigatran Etexilate|Direct oral anticoagulant
223452922|NCT06355726|BIOLOGICAL|Plasma Exchange|Plasma exchange session will be done on alternate day to a maximum of 5 sessions. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session,no improvement in clinical condition and Intolerant to PLEX procedure
223452923|NCT06355726|OTHER|Standard Medical Treatment|Standard Medical Treatment
223452924|NCT04003376|DEVICE|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
223452925|NCT04003376|DRUG|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
223452926|NCT04003376|BIOLOGICAL|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
223452927|NCT04003376|DRUG|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
223452928|NCT04499196|DRUG|GlucoCorticoid|Administering glucocorticoid
223452929|NCT00551525|RADIATION|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
223452930|NCT00551525|DRUG|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
224060702|NCT02723500|DEVICE|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223452931|NCT00442234|DRUG|Monteplase|
223452932|NCT03072823|DIETARY_SUPPLEMENT|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
223452933|NCT03072823|DIETARY_SUPPLEMENT|placebo|olive oil ethyl esters
223452934|NCT04676724|DRUG|GSK3228836|Participants will be administered GSK3228836.
223452935|NCT04676724|DRUG|PegIFN|Participants will be administered PegIFN.
223452936|NCT04676724|DRUG|NA therapy|Participants will continue to receive their NA therapy for the duration of the study.
223452937|NCT00287729|DRUG|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
223452938|NCT00287729|DRUG|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
224060703|NCT03719274|DIETARY_SUPPLEMENT|vitamin c depigementation|locally injected vitamin c depigementation
224060704|NCT04368156|DEVICE|gammaCore® (Vagus nerve stimulation)|Vagus nerve stimulation using the gammacore neurostimulation device
223452939|NCT03190980|OTHER|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
223452940|NCT03190980|OTHER|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
223452941|NCT03190980|OTHER|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
223452942|NCT05979480|DIAGNOSTIC_TEST|Dual energy X-ray absorptiometry (DXA)|DXA scan to assess bone mineral density, fat mass and muscle mass.
223452943|NCT04321486|OTHER|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.|The study does not have an intervention, but observe the dementia incidence of the UK disease-free population.
224060705|NCT05032612|DEVICE|PBM Therapy|After the endodontic treatment, PBM therapy will be performed using a 660 nm diode laser (SiroLaser Advance Plus, Dentsply Sirona Inc, Charlotte, NC, USA), with an 8mm tip diameter.The laser tip will be placed on the following external surfaces in a contact mode: mesiobuccal, distobuccal, mesiolingual and distolingual . The power output of the laser will be 50mW and will be verified by Power Meter (PM600 Power/Energy meter, Molectron Detector Inc, Portland, OR, USA). Each site will be irradiated for 25 s with an energy density of 10 J/cm2 .
223452944|NCT05437445|DIAGNOSTIC_TEST|Plasma amino acid assay|Plasma amino acid analysis was performed on all the blood samples received in biogenetics lab at Aga khan university, Karachi during one year period.
223452945|NCT03990311|OTHER|Sodium Restricted Meals|2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period
223452946|NCT03990311|OTHER|Control|Usual Care
223452947|NCT03845244|DEVICE|Flow reduction first|-10L/min q 1hr
223452948|NCT03845244|DEVICE|FiO2 reduction first|\- 0.1 q 1hr
223452949|NCT03845244|DEVICE|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
223452950|NCT04455737|OTHER|injection of indigo carmine|Ex vivo intra-arterial injection of 20 ml indigo carmine solution (10mL, 0.4% indigo carmine with 10mL, 0.9% saline solution) in the transanal total mesorectal excision specimen via the inferior mesenteric artery.
224060706|NCT05032612|DEVICE|PBM Sham|For the PBM sham similar procedure as PBM therapy will be performed without activating the laser.
224070971|NCT02754726|DRUG|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
224070972|NCT02754726|DRUG|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
224301427|NCT06928103|OTHER|Dynamic stretching and foam rolling|Dynamic stretching: teach the participants movements that they can perform to warm up their soft tissues; Foam rolling: Teach the participants how to use a massage ball so that they can perform movements to warm up their soft tissues
224060707|NCT04950257|DEVICE|digital CBT self-help including specific intervention elements to target worry and rumination.|The self-help app includes self-monitoring, psychoeducation and active self-help exercises. The self-monitoring includes daily mood ratings and an ecological momentary assessment option (MoodTracker) for more detailed analysis of mood, worry, activity and situational context. The digital self-help provides psychoeducation, tips, advice, exercises and training for each individual focused on reducing worry and rumination, using strategies from the proven rumination-focused CBT intervention. The app includes text, pictures, audio-recordings, animations, audio-exercises to practice (e.g., self-compassion, relaxation, concreteness exercises), and questionnaires with tailored feedback. The app is designed for iOS and Android use.
224060708|NCT00641589|DRUG|epoetin alfa|
224060709|NCT04081363|DRUG|Centanafadine|Extended-release and immediate-release capsules.
224060710|NCT04756700|DIAGNOSTIC_TEST|DigiCog (BCCAMS app)|Administered as specified in the treatment arm.
224060711|NCT04756700|DIAGNOSTIC_TEST|Konectom Application|Administered as specified in the treatment arm.
224060712|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
224060713|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
224147595|NCT00223652|BEHAVIORAL|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
224147596|NCT00081328|DRUG|Metformin|capsule, 1000 mg bid
224147597|NCT00081328|DRUG|Rosiglitazone|capsule, 4 mg bid
223452951|NCT01150903|OTHER|no intervention|non-interventional study
224060714|NCT01012102|BIOLOGICAL|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
224060715|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
224147598|NCT00081328|BEHAVIORAL|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
224147599|NCT00568620|PROCEDURE|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
224147600|NCT00568620|PROCEDURE|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
224147601|NCT04511780|OTHER|questionnaire filling|assessment of post-traumatic stress, anxiety and burn out
224147602|NCT01188096|DRUG|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
224305092|NCT04796779|DEVICE|Standard Care (SC)|Standard of Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study Dexcom G6 CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump without hybrid closed-loop control capabilities (low-glucose suspend or predictive low-glucose suspend functionality is permitted).
223452952|NCT01150903|OTHER|no intervention|non-interventional study
223452953|NCT02890563|DEVICE|Class II Compression Stockings|
223452954|NCT02078596|DRUG|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
223570513|NCT04081753|DEVICE|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
223570514|NCT00012129|DRUG|liposomal annamycin|
223570515|NCT06030492|DRUG|packing placental site with hydrogen peroxide soaked towels|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution"
224060716|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
224060717|NCT01012102|OTHER|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
223452955|NCT03864523|DRUG|Pioglitazone|
223452956|NCT01537380|DRUG|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
223452957|NCT00657657|BIOLOGICAL|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
223452958|NCT03461783|DEVICE|Zorflex Activated Carbon Dressing|Antimicrobial dressing
223452959|NCT03461783|DEVICE|Standard of Care|foam, calcium alginate, hydrogel, or compressive dressings
223452960|NCT03964259|DRUG|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
223452961|NCT00457288|DRUG|TF 002|
224060718|NCT03525717|DIETARY_SUPPLEMENT|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
224060719|NCT03525717|DIETARY_SUPPLEMENT|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
223742307|NCT06136871|BEHAVIORAL|Inactive Control Group|An inactive control group will be used to control for maturation and testing effects. Weekly contact will be made via teleconferencing to (1) maintain study engagement, (2) introduce weekly social contact with researchers, mimicking some of the potential incidental effects of the experimental group, and (3) ascertain what, if any, additional steps participants have taken to reduce PCS symptoms. The content of each of these meetings will be tracked in intervention notes. Each contact will be recorded for fidelity monitoring to ensure all active ingredients of the CO-OP intervention are avoided.
223742308|NCT04478747|PROCEDURE|TVM|Transvaginal mesh operation using BSC mesh (A.M.I., Feldkirch, Austria)
223742309|NCT04478747|PROCEDURE|Colposacropexy|Colposacropexy using EndoGYNious mesh (A.M.I., Feldkirch, Austria)
223742310|NCT00491387|DRUG|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
223742311|NCT02293655|DRUG|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
223742312|NCT01225575|DRUG|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
224060720|NCT01079273|BIOLOGICAL|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
224147603|NCT06377722|DRUG|Cabozantinib|This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
224147604|NCT01273493|DRUG|Trabectedin|Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
223742313|NCT04473937|RADIATION|Radiotherapy|Radiotherapy at pre-determined dose and schedule
224147605|NCT01273493|DRUG|Dexamethasone|Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
223742314|NCT00217139|DRUG|Celgosivir|
223742315|NCT02166554|OTHER|Saline|On the day of initial surgery
224147606|NCT03909555|OTHER|Complications assessment|Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
224147607|NCT01621854|DRUG|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days
224147608|NCT01277497|DRUG|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
223742316|NCT02166554|DEVICE|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
223742317|NCT01874847|DIETARY_SUPPLEMENT|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
223742318|NCT01874847|DIETARY_SUPPLEMENT|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
223742319|NCT04267991|DRUG|Tacrolimus ointment|Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.
224147609|NCT01277497|DRUG|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
224147610|NCT02062398|DEVICE|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
224147611|NCT03385174|OTHER|Carbon monoxide|Carbon monoxide inhalation
223452962|NCT05622643|OTHER|MRI|Comparison between groups
223742320|NCT04267991|PROCEDURE|phototherapeutic keratectomy|Patients underwent transepithelial PTK for subepithelial infiltrates.
223742321|NCT00121420|DRUG|Motexafin gadolinium|
223742322|NCT03997149|BEHAVIORAL|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
223742323|NCT03997149|BEHAVIORAL|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
223742324|NCT00005888|BEHAVIORAL|Fortified Pasteurized Donor Human Milk supplement|
223742325|NCT00005888|BEHAVIORAL|Preterm Formula supplement|
223742326|NCT02173912|DRUG|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
223742327|NCT02173912|DRUG|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
223742328|NCT03102931|OTHER|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
223742329|NCT03102931|OTHER|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
223742330|NCT04739631|OTHER|acupuncture|use disposable sterile needles to insert to the acupuncture point
224060721|NCT00570973|PROCEDURE|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
224060722|NCT00570973|PROCEDURE|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
224060723|NCT02327052|OTHER|No intervention was performed.|No intervention was performed.
224060724|NCT04277520|PROCEDURE|Root canal therapy|Different types of instrumentation motions during root canal therapy
224060725|NCT00528515|DRUG|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
223742331|NCT04739631|OTHER|minimal acupuncture|The sham-controlled group will be performed with minimal acupuncture(superficial needling) at non- acupoints.
224060726|NCT00528515|DRUG|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
224060727|NCT04303130|DRUG|Camrelizumab|"Carelizumab: PD-1 antibody SHR-1210: SHR-1210 is administered by intravenous infusion, a fixed dose of 200 mg, and intravenous infusion over 30 minutes (the overall infusion time including the flushing time is not shorter than 20 minutes, not longer than 60 minutes), once every 3 weeks, continued medication until the disease progresses intolerable toxicity and receive immunotherapy for a maximum of 2 years (35 cycles); Endo: once a day, 7.5 mg / m2 intravenous infusion, continuous administration for 14 days, rest for a week (or the corresponding dose using a micro-micropump), continued medication until disease progression toxicity intolerance.~The combination regimen is a medication cycle every three weeks (21 days)."
224060728|NCT00006047|DRUG|Oral Etoposide|
224060729|NCT00006047|DRUG|Oral 9-Nitrocamptothecin|
224060730|NCT06466304|BEHAVIORAL|inspiratory muscle training|children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
224060731|NCT06490016|DEVICE|web based education|"The web page will be prepared with professional support in line with the guidelines of the Web Content Accessibility Guide (WCAG / WIEK 2.1) developed by W3C.~1. st meeting: online Informed Consent will be obtained. After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out online.~2. nd interview: Module 1-2.~3. rd interview: Module 3 -4.~4. th meeting: Module 5.They will be asked to fill out the System Usability Scale.~5. th interview: During the first menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online.~6. th interview: During the second menstrual period after the training, the Menstrual Attitude Scale, Menstrual Symptom Scale, and State Anxiety Scale will be completed online."
224060732|NCT06490016|BEHAVIORAL|Face to face|"In face-to-face training, female internal reproductive organ models, female external reproductive organ models, training content prepared with Braille alphabet, menstrual hygiene management kit (underwear, pads, napkins, calendar) materials will be used. Pictures and audio descriptions will be used in web-based training.~1. st interview: Informed Consent . After the meeting, the Personal Information Form, Menstrual Attitude Scale, Menstrual Symptom Scale, State and Trait Anxiety Scale will be filled out.~2. nd meeting: Module 1-2~3. rd meeting: Module 3- 4~4. th meeting: Module 5.~5. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed.~6. th interview: Menstrual Attitude Scale, Menstrual Symptom Scale, State Anxiety Scale will be completed."
224060733|NCT01547169|DRUG|Placebo Comparator|saline, taken twice per day for a 3 week duration
224060734|NCT01547169|DRUG|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
224060735|NCT01547169|DRUG|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
224060736|NCT00841568|DRUG|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
224060737|NCT00763230|DEVICE|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
223742332|NCT00227305|DRUG|quetiapine fumarate|Oral dosing, flexible dosing
224060738|NCT01230281|OTHER|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
224060739|NCT01830751|OTHER|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
224060740|NCT04341220|DEVICE|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation.
224060741|NCT04341220|OTHER|Balance exercises|Specific balance exercises, focused on balance, postural control and control of the center of gravity within the support base.
224060742|NCT04178694|DEVICE|non-invasive ventilation|non-invasive ventilation will be performed on every subjects
224060743|NCT00002364|DRUG|Abacavir sulfate|
224060744|NCT01556139|DEVICE|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~* volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~* increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
224060745|NCT01483716|BEHAVIORAL|Rehabilitation|
224060746|NCT06489496|DIAGNOSTIC_TEST|18F-1007 PSMA PSMA PET/CT|"Each patient will receive an IV injection 18F-PSMA-1007 PET/CT.~PET/CT Imaging will be conducted beginning 90-120 minutes after an injection of 4 MBq/kg (max 400 MBq +/- 15%) 18F-PSMA-1007 in patients."
224060747|NCT05774379|DEVICE|virtual reality and fatigue education|virtual reality distraction for 3 days and fatigue education for children
224060748|NCT05774379|BEHAVIORAL|fatigue education|fatigue education for children
224060749|NCT01087775|BEHAVIORAL|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
223742333|NCT01028339|DRUG|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
223742334|NCT01028339|DRUG|Mannitol|Mannitol
224060750|NCT00454259|DRUG|Fentanyl/Placebo injection|Ultra low dose intravenous injection
224060751|NCT01017003|DRUG|colchicine tablets|0.6mg colchicine tablet
224060752|NCT01017003|DRUG|colchicine tablets|0.6mg q12 hours for 10 days
224060753|NCT04146740|OTHER|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
224060754|NCT04146740|BEHAVIORAL|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
224060755|NCT04699019|OTHER|Four speeds|Four speeds ranging from a set walking speed up to 9 mph
224060756|NCT04699019|OTHER|Foot Strike Pattern|Foot strike sequences (rearfoot strike, midfoot strike, forefoot strike)
224060757|NCT04346589|BIOLOGICAL|Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients|Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.
224060758|NCT04536428|DEVICE|Endoscopic hemostasis with clip|"This intervention is performed as the following orders.~* The tip of endoscope is accessed to a bleeding site.~* The accurate visualization of bleeding site is done.~* A sheath of delivery system of clip is inserted through a working channel of endoscope.~* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.~* The both ends of clip are placed on both sides of a bleeding site.~* If bleeding is still continued, additional placements of clip are tried until bleeding stops."
224060759|NCT00891982|DRUG|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
224060760|NCT00891982|DRUG|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
223452963|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Aptus 2.5|Volar plating of distal radius fracture. Device: Aptus 2.5
223452964|NCT03474445|PROCEDURE|Volar Plate Osteosynthesis Inteos 2.5|Volar plating of distal radius fracture. Device: Inteos 2.5
223452965|NCT00000332|DRUG|Nimodipine|
223570516|NCT06030492|DRUG|normal Saline|"Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution"
223570517|NCT04998539|OTHER|Wheelchair forward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
224060761|NCT03669432|RADIATION|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
224060762|NCT03669432|PROCEDURE|Surgery alone|This intervention is of no interest
224060763|NCT00974246|DRUG|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
224060764|NCT05289570|DRUG|Voxelotor|500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
224060765|NCT03458221|DRUG|Letrozole Oral Product|Letrozole 2.5mg tablet - 2.5mg once dailty until progression of disease.
224060766|NCT03458221|DRUG|Bicalutamide Oral Product|Bicalutatmide 150mg tablet - 150mg once daily until progression of disease.
224060767|NCT03458221|DRUG|Everolimus Oral Product|Everolimus 10mg tablet - 10mg once daily until progression of disease.
224060768|NCT03458221|DRUG|Itraconazole Oral Product|Itraconazole 100mg capsule - 300mg twice daily until progression of disease.
224060769|NCT03043716|OTHER|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
224060770|NCT00272064|DRUG|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
224060771|NCT00272064|DRUG|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
223452966|NCT05413226|DIETARY_SUPPLEMENT|Celastrol|Four increasing doses of Celastrol to each of five men.
223452967|NCT04575532|DEVICE|Use of the pinpointIQ solution (physIQ, Inc.)|Patients are monitored for 28 days post COVID19 diagnosis or COVID19 post-hospitalization discharge using the pinpointIQ solution.
223452968|NCT05073445|BEHAVIORAL|SDNN measurement|SDNN measurement during pediatric simulation
223452969|NCT04204304|DRUG|Isotretinoin|ISO
223452970|NCT02739659|DEVICE|carbon-ion radiotherapy|
223452971|NCT04003051|OTHER|Internet-Based Intervention|Use Project Prepare website
223452972|NCT04003051|OTHER|Quality-of-Life Assessment|Ancillary studies
223452973|NCT04003051|OTHER|Questionnaire Administration|Ancillary studies
223452974|NCT00956332|BIOLOGICAL|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
223452975|NCT00956332|BIOLOGICAL|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
223452976|NCT05311020|DIETARY_SUPPLEMENT|Placebo drink|consume 1 bottle per day
223452977|NCT05311020|DIETARY_SUPPLEMENT|Pitaya Ovule Extract Drink|consume 1 bottle per day
224060772|NCT00272064|DRUG|Metformin|1000 mg b.i.d, since the qualification phase, oral
224060773|NCT00784381|DEVICE|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
224060774|NCT05458765|DRUG|emtricitabine/tenofovir alafenamide|200mg/25mg tablet, once daily dosing for 24 weeks
224060775|NCT05458765|DRUG|Emtricitabine / Tenofovir Disoproxil Oral Tablet|200mg/300mg tablet, once daily dosing for 24 weeks
224060776|NCT03983577|OTHER|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
223452978|NCT01986738|RADIATION|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
223452979|NCT01986738|DEVICE|Active Breathing Control Device (ABC)|
223452980|NCT01986738|DEVICE|Computed Tomography Scan (CT)|
223452981|NCT03060057|DEVICE|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
223452982|NCT01386931|PROCEDURE|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
223452983|NCT01386931|PROCEDURE|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
223452984|NCT01151969|BEHAVIORAL|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
223452985|NCT04408651|BEHAVIORAL|LIIT.CI ACT|4-week online self-management intervention based on Acceptance and Commitment Therapy and adapted to people with chronic medical conditions
224060777|NCT04933175|DRUG|Fluzoparil|Fluzoparil: 150 mg, P.O, BID, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
223452986|NCT04408651|BEHAVIORAL|LIIT.CI CFT|4-week online self-management intervention based on Compassion-Focused Therapy and adapted to people with chronic medical conditions
223452987|NCT00279383|DRUG|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
223452988|NCT02081001|DRUG|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
223452989|NCT02081001|DRUG|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
223452990|NCT06304974|DRUG|BL-B01D1|Administration by intravenous infusion
223570518|NCT04998539|OTHER|Wheelchair backward direction|Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the backward direction. Participants will pull the wheelchair when moving backwards.
223570519|NCT04998539|OTHER|Upright technique|Participants will move the wheelchair across the 5 m soft surface using the upright technique. The upright technique involves the wheelchair being moved with all 4 wheels on the ground.
224060778|NCT04933175|DRUG|Anlotinib|Anlotinib: 8mg, P.O, qd, d1-14, Q3W; Treatment until disease progression or intolerable side effects occur.
224060779|NCT05650801|OTHER|Music Therapy|Therapy using a traditional music originally from Indonesian culture
224060780|NCT05984342|DRUG|Tislelizumab|Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
224060781|NCT06282042|PROCEDURE|Early transcatheter edge-to-edge mitral valve repair (TEER).|TEER will be planned and performed as soon as possible, but within 60 days after index myocardial infarction, and within 30 days of randomisation using the MitraClip device.
224060782|NCT06282042|DEVICE|MitraClip|MitraClip
223452991|NCT06304974|DRUG|Irinotecan|Administration by intravenous infusion
223452992|NCT06304974|DRUG|paclitaxel|Administration by intravenous infusion
223452993|NCT06304974|DRUG|docetaxel|Administration by intravenous infusion
223570520|NCT04998539|OTHER|Wheelie technique|Participants will move the wheelchair across the 5 m soft surface using the wheelie technique. The wheelie technique involves the wheelchair being tipped backward and balanced on the rear wheels. Participant wheelchair occupants will always be upright when being moved using the wheelie technique.
224060783|NCT06282042|OTHER|Optimal medical treatment|Optimal medical treatment
224060784|NCT02725723|DEVICE|Therm-AppTM TH, thermographic camera|
224060785|NCT02725723|DRUG|epidural injection|
224060786|NCT01803984|DEVICE|MRI|
223452994|NCT00665483|OTHER|Skin Prick Test|Skin Prick Test
223452995|NCT01341288|DEVICE|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
224060787|NCT01803984|DEVICE|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
224060788|NCT01803984|OTHER|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
224060789|NCT04294875|DRUG|MPT0B640|PO, every 3 days. dose escalation per MTD
224060790|NCT00534339|DEVICE|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
224060791|NCT04811456|OTHER|multisystem inflammatory syndrome in children (MIS-C)|as in group description
224060792|NCT01298752|DRUG|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
224060793|NCT01298752|DRUG|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
224060794|NCT03741114|PROCEDURE|Foley's Catheter|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
224060795|NCT03741114|DRUG|TA|patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
224060796|NCT03741114|DRUG|Placebo|patients received 100 ml saline just before skin incision
224060797|NCT01880931|DRUG|Remifentanil|The effect site concentration of remifentanil
224060798|NCT02114437|DEVICE|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
224060799|NCT02114437|DEVICE|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
224147612|NCT03230513|OTHER|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
224147613|NCT03230513|OTHER|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
224147614|NCT02646150|PROCEDURE|Magnetic Resonance Perfusion Imaging|
224147615|NCT01779648|DEVICE|DVT-3000|
224147616|NCT01779648|DEVICE|SCD Express|
224147617|NCT02099487|RADIATION|Radiation|hypofractionated IMRT
223452996|NCT05531318|OTHER|Qualitative Interview|Participants will be interviewed about their experiences of substance use, post-traumatic stress and the way they regulate their emotions.
223452997|NCT02548468|DRUG|Fludarabine|Given IV
223452998|NCT02548468|RADIATION|Total-Body Irradiation|Undergo TBI
223452999|NCT02548468|BIOLOGICAL|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
223453000|NCT02548468|DRUG|Cyclophosphamide|Given IV
223453001|NCT02548468|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
223453002|NCT02548468|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
223453003|NCT02548468|DRUG|Mycophenolate mofetil|Given IV
223453004|NCT02548468|DRUG|Tacrolimus|Given IV
223453005|NCT05593770|DRUG|Fostamatinib|Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
223453006|NCT05593770|DRUG|Placebo|Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
223570521|NCT04998539|OTHER|Wheelchair occupant upright body position|The participant occupying the wheelchair (wheelchair occupant) will be seated with a body position that is upright (back is leaning against the wheelchair back rest and arms on wheelchair arm rests) while the wheelchair is being moved.
224060800|NCT04457050|DRUG|Sofosbuvir 400 milligram|single daily dose of 400 milligrams
224060801|NCT04457050|DRUG|Daclatasvir 60 milligram|single daily dose of 60 milligrams for 12 weeks
224060802|NCT04457050|DRUG|Ribavirin 400 milligram|weight based dose, 1200 mg for weight \> 75 kilogram, and 1000 milligram if weight \< 75 kilograms for 12 weeks
224060803|NCT04457050|DRUG|Ledipasvir 90milligram/Sofosbuvir 400 milligram Tab|single daily dose for 12 weeks
224060804|NCT02134483|BIOLOGICAL|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
224060805|NCT05773521|PROCEDURE|SILAP (single incision laparoscopic appendectomy)|Appendectomy performed through transumbilical single access laparoscopy, consisting in the removal of the appendix.
224060806|NCT02982135|OTHER|bypass surgery and indrect bypass surgery|bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
223570522|NCT03349424|DRUG|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
223570523|NCT05868928|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
223570524|NCT05868928|DIAGNOSTIC_TEST|Diffusion-weighted MRI|Diffusion-weighted MRI
223570525|NCT05868928|DIAGNOSTIC_TEST|Arterial spin labeling (ASL)|Cerebral blood flow imaging parameter
223570526|NCT05868928|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-MRI (DSC-MRI)|Cerebral blood volume and vessel architectural imaging parameters
223570527|NCT00096525|DRUG|lenalidomide|
223570528|NCT04591548|DIAGNOSTIC_TEST|proteomic analyses, ELISA validation of peritoneal fluid, blood and uterine fluid sample|All samples were collected during laparoscopy, before any intraabdominal procedure was done. Indication for surgery was clinical (not for research purpose). All sample collection procedures was mimic regular clinical procedures.
223570529|NCT00418275|GENETIC|Recombinant Human Plasminogen Activator (HTUPA)|
223570530|NCT04526717|DRUG|MPT0B640|Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
223570531|NCT02324205|DEVICE|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
224060807|NCT00645593|DRUG|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
224060808|NCT00645593|DRUG|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
224060809|NCT00645593|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
224060810|NCT01579448|BIOLOGICAL|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
224070973|NCT02754726|DRUG|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
223453007|NCT02237040|PROCEDURE|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
223453008|NCT01309451|DRUG|Bevacizumab|intravitreal, 1.25mg., monthly
223453009|NCT01309451|DRUG|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
223453010|NCT06532123|DEVICE|continence muscles resistance device|The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
223453011|NCT04274075|DRUG|GDC-9545 Tablet, Fasted: Treatment A|One dose of the GDC-9545 Phase 1 reference tablet formulation (three 10-mg tablets) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
223453012|NCT04274075|DRUG|GDC-9545 Capsule, Fasted: Treatment B|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water after at least an 8-hour fast.
223453013|NCT04274075|DRUG|GDC-9545 Capsule, Fed: Treatment C|One dose of the GDC-9545 Phase 3 capsule formulation (one 30-mg capsule) administered orally with approximately 240 mL room temperature water within 30 minutes of eating a high-fat meal.
223453014|NCT05934266|DEVICE|Use of n-hexyl cyanoacrylate for mesh fixation|Mesh fixation with tissue adhesive (n-hexyl cyanoacrylate) in open hernia repair
223453015|NCT05040919|OTHER|collection of medical and socio-demographic data|collection of medical and socio-demographic data
223453016|NCT02768922|OTHER|Aphasia telerehabilitation|Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
223453017|NCT02768922|OTHER|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
223453018|NCT04465084|OTHER|Case|Battery of standardised and normalised tests evaluating different cognitive functions Experimental language tasks MRI
223453019|NCT04465084|OTHER|Withness|Experimental language tasks MRI
223453020|NCT04685096|OTHER|Test product creme|twice daily application of creme containing 2% NMN
223453021|NCT04685096|OTHER|Reference creme|twice daily application of reference creme
223453022|NCT03557814|DEVICE|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
223570532|NCT02900638|BEHAVIORAL|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
223570533|NCT01773551|OTHER|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
223570534|NCT03255213|OTHER|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
224070974|NCT02754726|DRUG|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
224070975|NCT02754726|DRUG|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
224070976|NCT00837109|BEHAVIORAL|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
224070977|NCT00837109|BEHAVIORAL|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
224070978|NCT00719927|BEHAVIORAL|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
224070979|NCT00875745|DRUG|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
224070980|NCT02009644|DEVICE|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
224070981|NCT00646542|DRUG|Vildagliptin|
224070982|NCT00646542|DRUG|Placebo|
224070983|NCT01564615|DEVICE|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
224070984|NCT01564615|DEVICE|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
224060811|NCT01579448|BIOLOGICAL|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
224060812|NCT01579448|OTHER|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
224060813|NCT02569814|DRUG|Fimasartan/Amlodipine/Rosuvastatin|
224060814|NCT02569814|DRUG|Fimasartan/Amlodipine|
224060815|NCT02569814|DRUG|Rosuvastatin|
224060816|NCT06978868|OTHER|Sauna Intervention in Clinically Stable Outpatients with HFpEF|Patients were accompanied by study physicians for two sessions weekly, each between 8-15 minutes. We started the first 2 weeks with 8 minutes. Week 3-4: 10 minutes, week 5-6: 12 minutes, week 7-10: 12-15 minutes. Patients were given the freedom to leave the sauna session at any time if they experienced discomfort or were unable to tolerate it. Sessions were done in groups of 5 patients of men or women. The temperature of the sauna was 60°C. After each session, patients were asked to shower with moderate temperature of water and then rest for 20 minutes. Blood pressure and heart rate were measured prior to each session as well as directly after the sauna session and at the end of the rest time.
223453023|NCT03557814|DEVICE|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
224060817|NCT05118802|OTHER|Interview|Attends Interviews
224060818|NCT05118802|OTHER|Survey Administration|Complete Survey
224060819|NCT04218201|BEHAVIORAL|PCP brief advice|Brief advice will be delivered by the patient participant's PCP as part of the medical visit or via phone call. Before the encounter with the patient participant, PCPs will receive a brief printed summary report from the research staff. The summary advises the PCP that their patient participant screened positive for risky opioid use, lists the patient participant's screening results (TAPS Tool +/- COMM) and gives a suggested counseling script. The counseling script will include specific advice on opioid-related risks, will inform patient participants of resources to help them reduce their risk, and will include a recommendation to reduce their risk behavior.
224060820|NCT04218201|BEHAVIORAL|Video doctor|During the baseline visit with the research staff, patient participants will view a video on tablet or desktop computer that reinforces the PCP's counseling. The video is a recording of a provider delivering brief advice about opioid use that includes the same elements covered in the summary report outlined above.
224060821|NCT04218201|BEHAVIORAL|Telephone health coaching|All patient participants in the STOP arm will receive telephonic health coaching sessions at approximately 2- and 4-weeks post-baseline. Patient participants who may benefit from additional coaching (for example, those who do not improve or who experience clinical worsening of unhealthy opioid use) may receive additional coaching sessions (approximately 4 sessions) from the telephone health coach. Coaching is delivered from a centralized call center, by staff that receive standardized training and supervision. To the extent possible, calls will be scheduled at the patient participant's convenience (e.g., evenings, weekends).
224147618|NCT00415519|DRUG|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
223453024|NCT03557814|DEVICE|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
223453025|NCT01826097|DEVICE|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
223453026|NCT01648998|DRUG|Fludrocortisone|single dose 500 mg, capsule
223453027|NCT01648998|DRUG|Placebo|
224060822|NCT04218201|BEHAVIORAL|Nurse Care Manager (NCM) intervention|NCMs will provide health education and counseling on risk reduction, overdose prevention and self-management skills. Patient participants will be asked to participate in a baseline visit with the NCM, which will occur on the same day as the baseline research visit if possible. The NCM continues working with patients in the STOP condition throughout their 12 months of study participation. Following the initial visit with the NCM, the frequency of visits depends on patient participant needs.
224060823|NCT03631836|DRUG|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
224060824|NCT03631836|DRUG|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
224147619|NCT00415519|DRUG|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
223453028|NCT02731547|BEHAVIORAL|Education Against Tobacco School-Based Intervention|
223453029|NCT02609373|BEHAVIORAL|Sleep intervention|"Session 1: Intervener \& participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 \& 10 months: reinforcement, question answering, encouragement and monitoring."
223453030|NCT00328445|BEHAVIORAL|Positive Action|See publications
223453031|NCT05447910|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223453032|NCT04623502|OTHER|13C-Glucose|Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
224060825|NCT03631836|BIOLOGICAL|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
224060826|NCT03631836|DEVICE|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
224060827|NCT04523077|DIAGNOSTIC_TEST|determination of thyroid hormones and antibodies|TSH, fT3, fT4, anti-TPO and anti-Tg were determined from blood sample
224060828|NCT01317342|DEVICE|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
224060829|NCT01677806|PROCEDURE|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
224060830|NCT01677806|OTHER|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
224060831|NCT03189875|OTHER|Standard of Care|Participants will be followed as per local routine clinical practice
224060832|NCT00991523|DIETARY_SUPPLEMENT|protein|protein
224060833|NCT00991523|DIETARY_SUPPLEMENT|placebo|placebo control
223453033|NCT04623502|OTHER|13C-Acetate|Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
223453034|NCT04623502|OTHER|13C-Lactate|Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
223453035|NCT04623502|OTHER|13C-Glutamine|Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
223453036|NCT04623502|OTHER|13C-Fructose|Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
223453037|NCT03596515|OTHER|Sensory Integration|Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
223453038|NCT00889915|DRUG|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
224060834|NCT03581227|OTHER|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
224060835|NCT00113542|DRUG|Tetrathiomolybdate (TM)|
223453039|NCT00889915|DRUG|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
223453040|NCT00889915|DRUG|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
223453041|NCT00889915|DRUG|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
223453042|NCT06226519|DIAGNOSTIC_TEST|11C-MET-PET/RMN|60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.
223453043|NCT01786031|OTHER|metastasis biopsy|
224060836|NCT01531920|DRUG|alcohol + placebo|Part A alcohol + placebo
224060837|NCT01531920|DRUG|alcohol + perampanel|Part A: alcohol + perampanel
224060838|NCT01531920|DRUG|perampanel + alcohol|Part B: perampanel + alcohol
224060839|NCT01531920|DRUG|placebo + alcohol|Part B: placebo + alcohol
224060840|NCT02195024|PROCEDURE|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
224060841|NCT00127907|DRUG|epinephrine (1 mg/1 mL)|
224060842|NCT00127907|DRUG|arginine-vasopressin (40 UI/2 mL)|
224060843|NCT01221064|PROCEDURE|Early drainage removal|Drainage will be removed in postoperative day 1
224060844|NCT01221064|PROCEDURE|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
224060845|NCT03723707|BEHAVIORAL|EQUIPED-ADRD Intervention|(10 clinic sites and \~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
224060846|NCT03723707|BEHAVIORAL|Control (CON)|Will use current guidelines for primary care treatment with Diabetes and Dementia
224060847|NCT02019407|PROCEDURE|PVI, CTI block|"* PVI (pulmonary isolation)~* Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
224060848|NCT02019407|PROCEDURE|PVI|PVI (pulmonary isolation)
224060849|NCT01208350|BEHAVIORAL|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
224060850|NCT01208350|BEHAVIORAL|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
223570535|NCT06320249|OTHER|High-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the high-frequency manipulation group, patients will undergo rotation-traction manipulation three times weekly. A total of 12 treatments for four weeks.
224060851|NCT01208350|BEHAVIORAL|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
224060852|NCT00641251|OTHER|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
224060853|NCT00641251|OTHER|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
224060854|NCT05160259|RADIATION|Radial visualization of the foramen arcuale atlantis|In patients with diagnosed Kimmerle's anomaly, using transcranial Doppler sonography to determine the degree of changes in blood flow in the vertebral arteries
224060855|NCT00897663|GENETIC|gene expression analysis|
224060856|NCT00897663|GENETIC|microarray analysis|
224060857|NCT00897663|GENETIC|protein expression analysis|
224060858|NCT00897663|OTHER|diagnostic laboratory biomarker analysis|
224060859|NCT00897663|OTHER|immunohistochemistry staining method|
224060860|NCT03368651|PROCEDURE|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
224060861|NCT04706039|DIAGNOSTIC_TEST|Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process|"Each patient will be sampled to do a systematic respiratory virus infection screening (SARS-CoV-2 and Flu and RSV). Then each patient will be tested using the Vocus PTR-TOF process.~A self-answering questionnaire will be used to collect symptomatology information and date of onset of symptoms."
224147620|NCT01618422|OTHER|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
224147621|NCT01618422|OTHER|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
224147622|NCT03485222|DRUG|Empagliflozin|6 months
224147623|NCT03485222|DRUG|Placebos|placebo equivalent for 6 months
224147624|NCT03657810|DRUG|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
224147625|NCT03657810|DRUG|Norco|hydrocodone 5 mg/APAP 325 mg
224147626|NCT03657810|DRUG|Placebo|Placebo matching CL-108
224060862|NCT01611974|DRUG|Maribavir|Tablet for oral administration
224060863|NCT01534312|DRUG|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
224060864|NCT01534312|DRUG|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
224060865|NCT03846752|PROCEDURE|radial artery access for complex PCI|Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
224060866|NCT03846752|PROCEDURE|femoral artery access for complex PCI|Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
224060867|NCT01500109|DRUG|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
224060868|NCT01500109|DRUG|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
224060869|NCT01500109|DRUG|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
224060870|NCT04704232|DRUG|ACD440|Double blind, parallel within subject comparison
224060871|NCT04704232|DRUG|PLAC|Double blind, parallel within subject comparison
224147627|NCT02157012|DRUG|The effectiveness of Xeljanz in rheumatoid arthritis patients|
224147628|NCT03983226|PROCEDURE|Surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
223742335|NCT06045195|DRUG|Pembrolizumab|"As induction therapy, all participants will receive one dose of single-agent pembrolizumab (P) followed by two cycles of chemo-immunotherapy consisting of pembrolizumab and BrECADD (P-BrECADD). Response to induction therapy will be measured after 1x P (PET-1) and after 1x P + 2x P-BrECADD (PET-3).~Further systemic treatment is PET-3-guided. Complete metabolic responses will be consolidated with two further cycles of P-BrECADD while participants with a positive PET-3 will receive four further cycles of P-BrECADD. PET-positive lesions after completion of chemo-immunotherapy will be recommended for consolidating radiotherapy according to standard of care."
224060872|NCT05517642|BIOLOGICAL|Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)|Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
224060873|NCT05517642|BIOLOGICAL|mRNA vaccine BNT162b2 (Pfizer)|Subjects will be randomized to receive a second booster dose of BNT162b2.
224147629|NCT03983226|DRUG|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
223570536|NCT06320249|OTHER|Low-frequency rotation-traction manipulation|The procedure for rotation-traction manipulation is as follows: The patient is seated, and their neck is allowed to relax. The physician applies massage techniques to relax the muscles around the neck area for approximately 5 to 10 minutes. The patient is then instructed to rotate their head horizontally, flex it, and then rotate it again to its maximum limit while maintaining a sense of fixation. The physician supports the patient's chin with their elbow and gently pulls upward for 3 to 5 seconds. The patient is then asked to fully relax, and the physician applies a quick, short upward traction with the elbow, which may result in audible sounds. Subsequently, massage techniques are applied to further relax the muscles around the neck and shoulders, with each session lasting approximately 10 to 15 minutes. In the low-frequency manipulation group, patients will undergo rotation-traction manipulation once time weekly. A total of 4 treatments for four weeks.
223570537|NCT06320249|OTHER|Cervical traction|The procedure for cervical traction is as follows: The patient assumes a sitting position, and a cervical traction device with a chin strap is applied. The patient is instructed to slightly flex their head forward, approximately 10-15 degrees, based on their comfort level and symptom relief. Traction force starts at 3 kg and increases gradually in increments of 0.5 kg, with a maximum weight not exceeding 6 kg. The cervical traction group will be subjected to cervical traction three times a week. A total of 12 treatments for four weeks.
223570538|NCT00457977|BIOLOGICAL|Pneumovax (PPSV23)|Injection
223570539|NCT00457977|BIOLOGICAL|Prevnar (PCV7)|Injection
223570540|NCT03354884|DRUG|cabozantinib|cabozantinib 60 mg orally once daily
223570541|NCT05545995|OTHER|embryo selection|The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
223570542|NCT02947165|DRUG|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
223570543|NCT02947165|DRUG|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
223570544|NCT03969056|BEHAVIORAL|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
224060874|NCT04640688|PROCEDURE|Bariatric procedures|510(k) summary K081853 dated June 26, 2008, Endoscopic Sleeve Gastroplasty lecture, Methodist Dallas Medical Center Endobariatric Pathway \& Endoscopic Sleeve Gastroplasty Procedure Description
224060875|NCT04490733|BEHAVIORAL|dual-task walking|Participants in the experimental group will receive 3 times interventions during chemotherapy and 12 weekly phone calls or via LINE to assess barriers of dual-task walking.
224060876|NCT03431155|OTHER|Nursing intervention|Nursing Intervention: Protocol and education booklet were developed according to literature and Theory. There were six modules (10 session) which aimed to personal education for every care givers. Every session took 20 minutes and total 200 minutes. First 5 modules finished within 3 days and aafter one week last module completed (to summarize process). Also individual counseling were made.
224147630|NCT03983226|DRUG|Niraparib|Niraparib maintenance therapy
224060877|NCT04065555|DRUG|TAK-981|Intratumoral microdose injection by the CIVO device.
224060878|NCT04065555|BIOLOGICAL|Cetuximab|Intratumoral microdose injection by the CIVO device.
224060879|NCT04065555|BIOLOGICAL|Avelumab|Intratumoral microdose injection by the CIVO device.
223570545|NCT03969056|BEHAVIORAL|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
223570546|NCT06527248|DIETARY_SUPPLEMENT|Nitrate group|Daily consumption of 70 mL beetroot juice containing \~400 mg nitrate over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
223742336|NCT02627430|DRUG|Hsp90 Inhibitor AT13387|Given IV
224060880|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
224060881|NCT04065555|COMBINATION_PRODUCT|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
224060882|NCT02363140|OTHER|Will undergo a single MRI assessment with intravenous dye|
224060883|NCT02363140|OTHER|pre and post surgery MRI scan|
224060884|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with ACURATE NEO/TF|Transcatheter implantation of the heart valve device ACURATE neo/TF in patients suffering from severe aortic stenosis and are candidates for this operation
224060885|NCT04157920|DEVICE|Transcatheter Aortic Valve Implantation with Medtronic CoreValve /Evolut R/Pro|Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation
224060886|NCT06265675|DRUG|Phenol|Chemical neurolysis
224060887|NCT06265675|DRUG|Celestone|Chemical neurolysis with corticosteroid
224060888|NCT06265675|DRUG|Lidocain|Chemical neurolysis with local anesthetic
224060889|NCT05626270|DEVICE|LunulaLaser OTC|The LunulaLaser™ OTC is a nonthermal and non-invasive procedure designed to restore the growth of clear, healthy nails in clients with onychomycosis.
224060890|NCT03234387|OTHER|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
224060891|NCT02441049|BEHAVIORAL|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
224060892|NCT01023633|DRUG|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
224060893|NCT01089348|DRUG|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
223570547|NCT06527248|DIETARY_SUPPLEMENT|Placebo group|Daily consumption of 70 mL nitrate-depleted beetroot juice (placebo) over an intervention period of 12 weeks concomitant to exercise training, either 3 hours pre-exercise on training days or with breakfast on non-training days.
223570548|NCT04640558|DEVICE|Muscle strength measurement|The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
224060894|NCT01089348|DRUG|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
224060895|NCT02310776|DEVICE|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
224060896|NCT02310776|DEVICE|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
224060897|NCT03257670|DRUG|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
224060898|NCT03257670|DEVICE|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
224147631|NCT03514888|PROCEDURE|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
224147632|NCT00688545|DRUG|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
224147633|NCT00688545|DRUG|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
224147634|NCT02699853|OTHER|Questionnaire Administration|Ancillary studies
223570549|NCT04599959|DIAGNOSTIC_TEST|Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol|Kylt® for detection/confirmation of SARS-CoV-2 cobas® SARS-CoV-2 (PCR) test TaqPath™ COVID-19 CE-IVD RT-PCR kit
223570550|NCT04308434|OTHER|CSD190601-11|Flavor variant CSD190601-11 of a 1.5% nicotine ENDS product
223570551|NCT04308434|OTHER|CSD190601-12|Flavor variant CSD190601-12 of a 1.5% nicotine ENDS product
223570552|NCT04308434|OTHER|CSD190601-13|Flavor variant CSD190601-13 of a 1.5% nicotine ENDS product
223570553|NCT04308434|OTHER|CSD190601-14|Flavor variant CSD190601-14 of a 1.5% nicotine ENDS product
223570554|NCT04308434|OTHER|CSD190601-15|Flavor variant CSD190601-15 of a 1.5% nicotine ENDS product
223570555|NCT04308434|OTHER|CSD190601-16|Flavor variant CSD190601-16 of a 1.5% nicotine ENDS product
223570556|NCT04308434|OTHER|CSD190601-17|Flavor variant CSD190601-17 of a 1.5% nicotine ENDS product
223570557|NCT04308434|OTHER|CSD190601-21|Flavor variant CSD190601-21 of a 3.0% nicotine ENDS product
223570558|NCT04308434|OTHER|CSD190601-22|Flavor variant CSD190601-22 of a 3.0% nicotine ENDS product
223570559|NCT04308434|OTHER|CSD190601-23|Flavor variant CSD190601-23 of a 3.0% nicotine ENDS product
223570560|NCT04308434|OTHER|CSD190601-24|Flavor variant CSD190601-24 of a 3.0% nicotine ENDS product
223570561|NCT04308434|OTHER|CSD190601-25|Flavor variant CSD190601-25 of a 3.0% nicotine ENDS product
223570562|NCT04308434|OTHER|CSD190601-26|Flavor variant CSD190601-26 of a 3.0% nicotine ENDS product
223742337|NCT02627430|OTHER|Laboratory Biomarker Analysis|Correlative studies
223570563|NCT04308434|OTHER|CSD190601-27|Flavor variant CSD190601-27 of a 3.0% nicotine ENDS product
223570564|NCT01517165|DRUG|Pioglitazone|
223570565|NCT01517165|DRUG|Placebo|
223570566|NCT01888133|BEHAVIORAL|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
223742338|NCT02627430|OTHER|Pharmacological Study|Correlative studies
223742339|NCT02627430|DRUG|Talazoparib|Given PO
224060899|NCT00932347|DRUG|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
224060900|NCT00932347|DRUG|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
224060901|NCT00280306|OTHER|No interventions|No intervention
224060902|NCT06211894|PROCEDURE|transobturator tape|transobturator tape :The surgeon makes a small incision in the vagina and small incisions in the right and left groin. The surgical process is similar to the retropubic approach, but the mesh passes through the groin muscles rather than the abdominal wall. transperineal ultrasound: patients who underwent TOT and were evaluated with transperineal ultrasonography, women with incontinence 6 months after the surgery showed discrepancies in the movement of the urethra with the sling compared to continent women, along with asymmetry between the mesh arms, bladder neck descent, and varied sling positions.
224060903|NCT00117429|BIOLOGICAL|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
224060904|NCT02389127|DEVICE|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
224060905|NCT02888093|DEVICE|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
224060906|NCT00530270|DRUG|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
223570567|NCT01888133|BEHAVIORAL|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
223570568|NCT03262571|DIAGNOSTIC_TEST|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
223570569|NCT03240367|OTHER|Coutery|Stapler line bleeding control with coutery
224060907|NCT00530270|DRUG|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
224060908|NCT01397799|DRUG|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
224060909|NCT02975895|DEVICE|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
223453044|NCT04233242|OTHER|Clinical management informed by HIV-1 genotypic resistance testing|"The study intervention will consist of the following components:~1. Genotypic resistance testing (GRT);~2. Review of GRT results by an expert committee providing a treatment recommendation;~3. GRT-based decision on further therapy (switch or maintain current ART regimen; choice of regimen); and~4. GRT-informed adherence support."
223570570|NCT02060630|PROCEDURE|Open surgical revascularization|
223570571|NCT02060630|DEVICE|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
223742340|NCT02940288|OTHER|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
224060910|NCT02975895|DEVICE|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
224060911|NCT02443896|PROCEDURE|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
224060912|NCT02443896|PROCEDURE|No sealant of permanent molars|No sealant applied to permanent molars.
224060913|NCT01169298|DRUG|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
224060914|NCT01823042|DRUG|azathioprine+enteral nutrition|
224060915|NCT01823042|DRUG|Azathioprine|
224060916|NCT00354770|DRUG|Placebo|daily
224060917|NCT00354770|DRUG|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
224060918|NCT02963389|DRUG|Tripegfilgrastim|
224060919|NCT02093806|OTHER|measurment|
224060920|NCT02474212|DRUG|Enoxaparin|
224060921|NCT02757599|OTHER|Ultrasound training|Training on the transvaginal ultrasound simulator.
224060922|NCT00861068|DRUG|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
223453045|NCT06249607|OTHER|storytelling|Storytelling android program: Subjects in group A or the storytelling group will be given headphones to listen to stories for 30 min (i.e., between 9 and 10 pm). While the subject listens to the story, a relative will present in a corner of the room to record when they fell asleep, the relative will present again in the room to record the time of falling asleep. The intervention will be done 7 nights a week for a period of 6 weeks.
224060923|NCT00861068|OTHER|Placebo|Placebo tablets two times a day for 10 weeks
224060924|NCT00283114|DRUG|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
224060925|NCT01757678|PROCEDURE|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography.
224147635|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo RRC
224147636|NCT02699853|PROCEDURE|Radical Cystectomy|Undergo ORC
224147637|NCT00209872|DRUG|Gabapentin|
224147638|NCT00209872|DRUG|Lidocaine|
224147639|NCT00209872|DRUG|S-ketamine|
223570572|NCT02309645|BIOLOGICAL|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
223570573|NCT02309645|OTHER|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
223570574|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
223570575|NCT01502878|DIETARY_SUPPLEMENT|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
224060926|NCT01757678|PROCEDURE|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure.
224060927|NCT01757678|PROCEDURE|cCTA (coronary computed tomography angiography)|Per the protocol, patients will have a coronary computed tomography angiography.
224060928|NCT01757678|OTHER|FFRct Analysis (Fractional Flow Reserve Computed Tomography)|Per the protocol, patients will have a fractional flow reserve computed tomography.
224060929|NCT03589599|OTHER|Flavored tobacco|Effects of flavored tobacco
224060930|NCT03589599|OTHER|Non-flavored tobacco|Effects of non-flavored tobacco
224147640|NCT00209872|PROCEDURE|Epidural analgesia|
224147641|NCT01886885|BEHAVIORAL|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
224147642|NCT05599113|DEVICE|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
224147643|NCT02691364|PROCEDURE|Blood withdrawal|
224147644|NCT02040155|DEVICE|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
224147645|NCT03554850|DEVICE|Trevo® Retriever|Stent retriever procedure
224147646|NCT05441943|PROCEDURE|Lymphovenous anastomosis|"Pre-operative planning prior to lymphovenous anastomosis using ICG lymphography and ultra high frequency ultrasound for mapping of applicable vessels.~During surgery, mapped vessels are freely dissected and anastomosed."
224147647|NCT05951543|OTHER|plyometric exercises|Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
223453046|NCT06249607|OTHER|Mindfulness breathing|"android program: Individuals in group B are instructed to sit upright in a comfortable position with eyes closed, focus on diaphragm movements while breathing in a slow, deep, relaxed manner, and to nonjudgmentally acknowledge and accept unwanted thoughts, ideas or images and return attention to the diaphragmatic breathing. In this exercise, individuals are instructed to notice the physical sensations of breathing, both inhalations and exhalations, with a focus on the natural rate of respiration as opposed to forcibly controlling the breath. Duration: 5 minutes in duration per session, before sleep for 7 days a week for a total duration of 6 weeks"
223453047|NCT06249607|OTHER|Sleep hygiene|"Subjects in all groups will receive tips about healthy sleep~* Maintain a regular sleep routine.~* Avoid daytime naps.~* Don't stay in bed awake for more than 5-10 minutes.~* Don't watch TV, use the computer, or read in bed.~* Drink caffeinated drinks with caution.~* Avoid inappropriate substances that interfere with sleep.~* Clean fresh air.~* Have a quiet, comfortable bedroom."
223570576|NCT01502878|DIETARY_SUPPLEMENT|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
223570577|NCT06243003|RADIATION|HA-WBRT plus SBRT|hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
223570578|NCT03245268|PROCEDURE|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
223570579|NCT03783468|OTHER|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
223570580|NCT06315036|OTHER|Developmental gymnastics|The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
223742341|NCT02940288|OTHER|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
224060931|NCT05514379|BEHAVIORAL|cognitive training|Cognitive training focused on executive function, attention and working memory delivered either by the therapist in a group setting (experimental group) or by a specialized software for cognitive training (Rehacom) at home.
224060932|NCT01487252|BEHAVIORAL|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
224060933|NCT01483391|BEHAVIORAL|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
224060934|NCT01483391|BEHAVIORAL|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
224060935|NCT00150657|DRUG|bevacizumab|
224060936|NCT00150657|DRUG|carboplatin|
224060937|NCT00150657|DRUG|gemcitabine|
224070985|NCT01695473|DRUG|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
224060938|NCT06501651|DRUG|Sacubitril/Valsartan|Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
224060939|NCT06501651|DRUG|Valsartan|Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
223570581|NCT05211921|DEVICE|Multi-Gyn ActiGel Plus|vaginal gel
223570582|NCT02117895|PROCEDURE|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
223570583|NCT02117895|PROCEDURE|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
223570584|NCT06276881|BEHAVIORAL|Visual Stimulation|AI-guided visual stimuli presented on an electronic screen
223570585|NCT01303146|DRUG|rhARSA|intravenous infusion 100U/kg every other week for 18 months
223570586|NCT03664674|DRUG|OTO-104|Single intratympanic injection of 12 mg dexamethasone
223570587|NCT03664674|DRUG|Placebo|Single intratympanic injection of placebo
224060940|NCT06190067|DRUG|Azacitidine Plus PD-1 therapy|Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)
224060941|NCT01870102|DRUG|Pelubiprofen IR (Pelubiprofen 30mg) TID|
224060942|NCT01870102|DRUG|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
224060943|NCT02458963|PROCEDURE|IVF|Women will undergo one IVF cycle
223453048|NCT04813107|DRUG|APL-1202 in combination with tislelizumab|For those assigned to this group (1), each patient will receive 3 cycles of treatment prior to RC and each cycle is 3 weeks. On day 1 of each cycle, a single dose of 200 mg tislelizumab will be administered intravenously. APL-1202 will be administered orally TID daily for 3 weeks at the RP2D defined from Phase I.
223453049|NCT04813107|DRUG|Tislelizumab alone|For patients assigned to this group (2), each patient will receive 3 cycles of treatments with a single dose of 200 mg tislelizumab administered on day 1 of each cycle, followed by RC.
223570588|NCT03434431|OTHER|Reverse dieting|
224060944|NCT02458963|DRUG|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
223570589|NCT03469830|OTHER|SSCP|Insert
223570590|NCT03469830|OTHER|SPMS|Pressure therapy
223570591|NCT02174523|DRUG|40mg lurasidone|
223570592|NCT02174523|DRUG|placebo|
223570593|NCT00856206|BIOLOGICAL|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
224060945|NCT00234689|DRUG|Naltrexone|
224060946|NCT00838331|BIOLOGICAL|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
224070986|NCT05929690|OTHER|Self-acupuncture|Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
223570594|NCT00856206|OTHER|Placebo|Placebo subcutaneous injection once a week
223570595|NCT01839240|DRUG|azacitidine|Given IV or SC
223570596|NCT01839240|DRUG|cytarabine|Given IV
223570597|NCT01839240|DRUG|mitoxantrone hydrochloride|Given IV
223570598|NCT01839240|OTHER|laboratory biomarker analysis|Correlative studies
224070987|NCT03340610|DRUG|Alflibercept|Intravitreal Injection
223570599|NCT05737420|DIAGNOSTIC_TEST|Video call|The on-call neurologist can see and communicate with the patient via live stream video-call.
224070988|NCT04754451|DRUG|Group L|Attach two lidocaine patches for 12 hours, one above and below the incision site.
224070989|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
224070990|NCT02101723|DIETARY_SUPPLEMENT|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
224070991|NCT02101723|DIETARY_SUPPLEMENT|Placebo|Placebo powder without micronutrients
224070992|NCT01484626|DRUG|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m\^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m\^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m\^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m\^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
224070993|NCT02137564|DRUG|gamma secretase inhibitor PF-03084014|Given PO
224070994|NCT02137564|OTHER|pharmacological study|Correlative studies
224070995|NCT02137564|OTHER|laboratory biomarker analysis|Correlative studies
224070996|NCT05730465|BEHAVIORAL|Use of Omron Home Blood Pressure Cuff|Use of an Omron Home Blood Pressure Cuff to monitor blood pressure after discharge
224301428|NCT06928077|BEHAVIORAL|ROC-Stand training with specific environmental features|A licensed, independent therapist along with caregivers will conduct the training program in a public space at the university. The initial phase of the training will concentrate on developing the participants' understanding of cause-and-effect in relation to the control system and the movement of the car, focusing on specific public spaces such as hallways, convenience stores, gardens, and museums. Following this, the therapist will collaborate with caregivers to direct the participants' gaze towards specific physical structures and objects. Furthermore, the therapist will guide and coach caregivers on how to lead the participants in engaging with these environmental features through various exploratory actions, as supported by previous evidence. These actions include touching, hitting, squeezing, pointing, holding objects with one or two hands, object touching own body, fingering, banging, manipulating, and transferring objects.
224301429|NCT06928077|BEHAVIORAL|ROC-Stand training without specific environmental features|The initial phase of training will also focus on teaching participants about cause-and-effect as it pertains to the control system and movement of the car. This phase will include goal-oriented driving activities, such as traveling 200 meters to reach a preferred toy or to interact with someone, and engaging in games like hide-and-seek in various public spaces including hallways, convenience stores, gardens, and museums. The training, without a specific emphasis on environmental features, will highlight the use of upper limbs in functional tasks during driving sessions, and incorporate a range of motor skills to enhance mobility and socialization during natural play sessions. The details of the program will also be established through collaborative discussions between the family and the treating therapist. These discussions will take into account clinical observations of the participant's performance in previous sessions.
224301430|NCT06928077|BEHAVIORAL|Conventional therapy|The overarching goal of this training is to support developmental progress and improve mobility, socialization, and upper limb functionality in everyday tasks. Participants in this group will have the opportunity to walk in the same public space used by the ROC training groups, allowing interaction with both the therapist and caregivers based on their individual motor capabilities.
224060947|NCT00838331|BIOLOGICAL|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (\> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (\> 28 days; washed or rejuvenated) RBC transfusions."
224060948|NCT03096964|OTHER|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
224060949|NCT03096964|OTHER|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
224060950|NCT02641145|RADIATION|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
224060951|NCT02641145|DEVICE|MRI|Cardiac MRI with gadolinium contrast.
224060952|NCT02641145|RADIATION|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
224060953|NCT01314677|PROCEDURE|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
224147648|NCT05951543|OTHER|dynamic balance group control group|Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
224147649|NCT04801641|DRUG|Placebo|Six placebo capsules taken orally twice daily
223570600|NCT01025362|BEHAVIORAL|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
223570601|NCT01025362|BEHAVIORAL|Standard care|Child Health Services offered standard care
224060954|NCT01314677|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT
224060955|NCT04071574|DRUG|Human Chorionic Gonadotropin (hCG)|Administration of hCG (10.000IU) for ovulation triggering
224060956|NCT04071574|DRUG|Gonadotropins|Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
224060957|NCT04071574|DRUG|GNRH-A Triptorelin|Administration of Triptorelin (0.1mg/day)
224060958|NCT04071574|DRUG|GnRH antagonist|Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
224147650|NCT04801641|DRUG|Nabilone|Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
224147651|NCT00367341|DRUG|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
224147652|NCT00367341|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
223570602|NCT00410319|BEHAVIORAL|Fear-reducing Information|
223570603|NCT00410319|BEHAVIORAL|Symptom-based exercise|
223742342|NCT02591355|DEVICE|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
223742343|NCT02591355|DEVICE|Saline solution injection|Placebo is a saline solution
224301431|NCT06928883|DEVICE|Sirolimus drug eluting ballooon therapy|Non-flow limiting vulnerable coronary plaques are treated using sirolimus drug eluting balloon therapy additional to guidelines directed medical therapy.
223453050|NCT06508060|DEVICE|Neosensory Wristband|"The Neosensory wristband consists of four vibratory motors built into the strap of the wristband (Figure 1a). The motors are linear resonant actuators (LRAs), vibrating at 175 Hz, capable of rising from 0 to 50% of their intensity within 30 ms. The motor intensity can be controlled with an eight bit resolution, meaning each motor can be controlled at 256 different intensities. At the highest intensity, each motor vibrates at 1.7 GRMS. The motors are separated from one another at a distance of 18.2 mm and 19.2 mm for the small and large wristband sizes, respectively (center-to-center distances).~The top of the wristband is a module that contains the power button, user setting buttons, a microphone, and a microcontroller. Bluetooth communication is used to create the corresponding vibrations on the wristband. While the study app plays the tones, it also sends a Bluetooth command to the wristband such that the wristband vibrates in the appropriate illusory location."
223453051|NCT06508060|OTHER|Tones only|Tones will be played through an app
223453052|NCT04133597|DEVICE|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
223453053|NCT02091401|DEVICE|Springfusor infusion pump|
223453054|NCT02091401|OTHER|IV administration|
223742344|NCT01867827|OTHER|Neurofeedback and Physical Exercise|
223453055|NCT02091401|DRUG|Magnesium Sulfate|
223453056|NCT00090870|BIOLOGICAL|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
223453057|NCT00090870|BIOLOGICAL|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
223453058|NCT00090870|DRUG|thalidomide|200mg daily by mouth
223453059|NCT02217852|DRUG|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
223453060|NCT02217852|DRUG|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
223453061|NCT02217852|DRUG|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
223453062|NCT02217852|DRUG|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
223453063|NCT01205880|DRUG|Calcitriol ointment|twice daily
223453064|NCT01205880|DRUG|Clobetasol spray|twice daily
223453065|NCT06453915|DRUG|18F-DPA-714|positron emission tomography scan using 18F-DPA-714 as an imaging tracer.
223453066|NCT06453915|DRUG|18F-FDG|positron emission tomography scan using 18F-FDG as an imaging tracer.
223453067|NCT05889572|DRUG|MaaT033|MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.
223453068|NCT00344838|DEVICE|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
223453069|NCT01523327|OTHER|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
223453070|NCT00079885|DRUG|tigecycline|
223453071|NCT01227239|DRUG|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
223453072|NCT01227239|DRUG|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
223453073|NCT01227239|RADIATION|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
223453074|NCT03522207|DIAGNOSTIC_TEST|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
224060959|NCT02164175|DEVICE|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
224060960|NCT04484298|DIAGNOSTIC_TEST|Reference position patient is put in a 30 degree supine position during 5 minutes|Each patient is initially placed in a semi-sitting position at 30° for 5 minutes and then CO is measured (baseline CO)
224060961|NCT04484298|DIAGNOSTIC_TEST|nitroglucerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
224301432|NCT06928883|DRUG|Optimal guidelines-directed medical therapies (GDMT)|Optimal guidelines-directed medical therapies (GDMT) to reduce plaque burden and vulnerability for non-flow limiting vulnerable plaques
223453075|NCT03522207|DRUG|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
223453076|NCT03522207|DRUG|Placebos|placebo per os 30 minutes prior to 2nd PSG
223453077|NCT03522207|DIAGNOSTIC_TEST|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
223453078|NCT03522207|DRUG|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
223453079|NCT03522207|DRUG|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
223453080|NCT03522207|DIAGNOSTIC_TEST|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
223453081|NCT00873067|PROCEDURE|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
223742345|NCT01867827|OTHER|Physical Exercise|
223742346|NCT00099554|DRUG|Etanercept|
224060962|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice1|Apple Juice1
224060963|NCT03846986|DIETARY_SUPPLEMENT|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
224060964|NCT03846986|DIETARY_SUPPLEMENT|Raw Apple|Raw Apple
224060965|NCT04945603|OTHER|Standard management according to international/national guidelines|Standard management according to international/national guidelines. Observational study
224060966|NCT01468584|DRUG|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
223570604|NCT02142517|PROCEDURE|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
223570605|NCT02142517|PROCEDURE|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
223570606|NCT02442453|DRUG|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
223570607|NCT02442453|DRUG|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
223570608|NCT00358332|BIOLOGICAL|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
224060967|NCT01468584|DRUG|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
224060968|NCT01468584|DRUG|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
224060969|NCT00892385|DRUG|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
223453082|NCT00873067|PROCEDURE|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
223570609|NCT00358332|BIOLOGICAL|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
223570610|NCT05834400|BEHAVIORAL|The Optimal Lymph FLow (TOLF)|Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.
223742347|NCT03930043|DIAGNOSTIC_TEST|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
223742348|NCT03832582|DRUG|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
223742349|NCT05892042|DRUG|Rivaroxaban 15 MG [Xarelto]|Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
224060970|NCT00892385|DRUG|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
224060971|NCT04998435|PROCEDURE|Erector Spinae Plain Block|"Using aseptic technique, ultrasound-guided ESPB will be performed with the patient in sitting position. The spinous process of the vertebra and a point 3 cm lateral to it will be marked before performing the block. The needle will be inserted and advanced under sono-visualization to contact the transverse process of the vertebra. After negative aspiration, LA will be deposited into the fascial plane deep to erector spinae muscle.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
224060972|NCT04998435|PROCEDURE|Paravertebral Block|"Using sterile technique, ultrasound scanning of thoracic paravertebral space will be done in sitting position. The transverse process will be identified as hyperechoic structure while pleura will be identified as a mobile hypoechoic structure. The needle will be inserted cranio-caudal and advanced under sono-visualization to the identified thoracic paravertebral space. After negative aspiration, LA will be deposited displacing the pleura.~30 ml of Bupivacaine 0.25% will be used as LA, injected using a 22-gauge spinal needle at the level of T10 which will be identified by counting 3 spinous processes below T7 which is at the level of the inferior angle of the scapula and also rechecked by counting down from C7.~Patients will then receive general anesthesia. All patients will receive paracetamol (1gm/8hrs IV) as a regular analgesia. IV morphine (0.02mg/kg) will be given as a rescue analgesia if the Visual Analogue Scale for pain is ≥ 4."
224060973|NCT00142467|DRUG|Gemcitabine|
224060974|NCT00142467|DRUG|Oxaliplatin|
224060975|NCT00142467|DRUG|Bevacizumab|
224060976|NCT03972969|BEHAVIORAL|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
224060977|NCT03972969|BEHAVIORAL|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
224060978|NCT03972969|BEHAVIORAL|Health education|Provision of general information about a variety of topics
224060979|NCT03927001|DEVICE|NeVa Stent Retrievers|mechanical neurothrombectomy
224147653|NCT00595257|DEVICE|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
224060980|NCT05413382|DIETARY_SUPPLEMENT|Biofresh® 4plus|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
224060981|NCT05413382|DIETARY_SUPPLEMENT|Placebo|Participants will be instructed to use their assigned lozenge three times per day for seven days, preferably after breakfast, lunch, and dinner meals and to avoid eating and drinking for 30 minutes after consuming the lozenge.
224060982|NCT03024554|DEVICE|Implantation of the Bifurcated Multilayer Flow Modulator|
224147654|NCT01155596|BEHAVIORAL|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
223453083|NCT06252155|OTHER|Music|Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing. The mother will be told to feel comfortable, to feel her body relax from head to toe while listening to music, to focus on the music and to free her thoughts.
223453084|NCT04306393|DRUG|Nitric Oxide Gas|"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.~Weaning criteria: maintenance of a PaO2/FiO2 ratio \>/= 300 for at least 24 hours consecutively."
223453085|NCT05816070|DRUG|IVIEW-1201|Four times per day for day 1-2 and three times per day for day 3-7
223453086|NCT05816070|DRUG|Ofloxacin Eye Drops|Four times per day for day 1-2 and three times per day for day 3-7
223570611|NCT05834400|BEHAVIORAL|Daily Monitoring|Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
223570612|NCT04583787|DIAGNOSTIC_TEST|99mTc-sestamibi myocardial perfusion SPECT|82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
223570613|NCT04583787|DIAGNOSTIC_TEST|82Rb-Chloride myocardial perfusion PET with CCTA|stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
224060983|NCT03326076|DIAGNOSTIC_TEST|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
224060984|NCT03326076|OTHER|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
224060985|NCT03326076|DIAGNOSTIC_TEST|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
224060986|NCT03326076|DIAGNOSTIC_TEST|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
224147655|NCT04489927|DEVICE|Tcore|Temperature Measurement of standard care versus the Tcore measurement
224147656|NCT05456152|DRUG|Sublingual Tablet|Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
223453087|NCT05620914|DRUG|Patritumab deruxtecan|Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of brain metastasis
223453088|NCT00505063|BIOLOGICAL|Immunization Schedule patients <7 years.|"* Time 0 months: Prevnar 13 #1, Hib #1~* Time 1 months: Pediarix #1~* Time 2 months: Prevnar 13 #2, Hib #2~* Time 3-4 months: Pediarix #2~* Time 4-6 months: Draw post vaccine titers~* Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
223570614|NCT05555797|DEVICE|308nm Excimer laser|Excimer laser will be (1-2 sessions/ week for 12 sessions according to induration protocol)
223570615|NCT05555797|DRUG|Tazarotene Topical Gel|Tazarotene gel 0.1%(finger tip unit of the gel) will be applied once daily for weeks
223570616|NCT05555797|DRUG|Betamethasone Valerate|.Betamethasone valerate ointment 0.1% will be applied twice daily for 12 weeks.
223570617|NCT03433833|DRUG|Digoxin|Digoxin oral route once daily for 24 weeks.
223570618|NCT01714206|DRUG|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
223570619|NCT01714206|DRUG|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
223570620|NCT01714206|DRUG|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
223742350|NCT06140147|OTHER|Protocolised reduction of non-resuscitation fluids|Maintenance fluid: discontinued if cumulative fluid balance is positive and patient is not dehydrated Intravenous fluid and enteral water: as needed to correct electrolyte disturbances Enteral nutrition (at least 2 kcal/ml): per local practice Glucose (conc. ≥20%, dose ≤1g/kg/day): may be used as nutrition if enteral feeding not tolerated starting 72h after inclusion. May be started earlier in patients with insulin-dependent diabetes or risk of hypoglycemia per local practice Parenteral nutrition: per local practice Intravenous medications: concentrated according to a predefined protocol Patients with neutral or negative cumulative fluid balance receive maintenance and other fluids so the total dose of fluids covers the daily need of water (about 1ml/kg/h)
224147657|NCT02487277|DRUG|PEGPH20|
224147658|NCT02487277|DRUG|Gemcitabine|
224147659|NCT02487277|DRUG|Nab-paclitaxel|
224147660|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
224147661|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
224147662|NCT00589147|DEVICE|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
224147663|NCT01373918|DRUG|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
224147664|NCT01373918|DRUG|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
224147665|NCT04324788|OTHER|Group 1|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
223453089|NCT00505063|BIOLOGICAL|Immunization Schedule patients > or = to 7 years and <11 years of age|"* Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~* Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~* Time 2-3 months: Prevnar 13 #2, Hib #2~* Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
223453090|NCT00505063|BIOLOGICAL|Immunization Schedule patients > or = to 11 years of age|"* Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~* Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~* Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~* Time 3-6 months: IPV, Draw post vaccine titers~* Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
224060987|NCT01155804|BEHAVIORAL|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
224060988|NCT05882448|PROCEDURE|laparotomy|Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion
224147666|NCT04324788|OTHER|Group 2|The patients will be asked to go up and down 9-step stair with the highest speed they can make.
224147667|NCT06027944|OTHER|Light exposure|Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
224147668|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
224147669|NCT00535691|DRUG|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
223453091|NCT03666741|DEVICE|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
223453092|NCT03370406|DRUG|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
223453093|NCT03370406|DRUG|Calcipotriene|Topical application of .005% cream two (2) times daily for four (4) days one (1) day after each of three (3) 5FU injections..
223453094|NCT03473795|BEHAVIORAL|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
223453095|NCT03473795|OTHER|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
223453096|NCT05893888|DRUG|PRV211 (Intraoperative Cisplatin System)|PRV211 system is comprised of two parts, a liquid permeation enhancer (PE) and cisplatin patch. The permeation is brushed onto the resected tumor bed and after 5 minutes the patch can be applied directly over the same area. Apply up to 2 layers of the PRV211 system to the tumor bed post-resection. The duration of the PRV211 treatment takes approximately 10-20 minutes and then the surgeon can continue as planned with the rest of the standard of care procedure. The proposed starting dose is 0.5 mg/cm2 of cisplatin on the tumor bed. This approach can be safe and effective in preventing locoregional recurrence after surgery and eliminating high-risk factors for local recurrence, such as dysplasia at the margins.
223453097|NCT05893888|DRUG|PRV111 (Cisplatin Transmucosal System)|PRV111 (Cisplatin Transmucosal System) is a thin, 2-layer, matrix-type, transmucosal patch consisting of a chitosan matrix layer embedded with cisplatin loaded chitosan particles (CLPs) and a non-woven fabric adhesive unidirectional backing, which is applied to the matrix layer during manufacturing. The patch is self-adhesive. In addition to the PRV111 patch, a separately packaged Permeation Enhancer (PE) Powder for Reconstitution used in conjunction with PRV111. The reconstituted PE Solution is intended to improve the absorption of the cisplatin active ingredient and will be applied prior to patch application.
223570621|NCT02780856|DEVICE|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black \& white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
224147670|NCT03004976|BIOLOGICAL|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10\^7 TNCC/kg.
224147671|NCT03004976|OTHER|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 \[pink\]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
224147672|NCT02194556|DRUG|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
224060989|NCT05882448|PROCEDURE|Laparoscopy|laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes.
224060990|NCT00732303|DRUG|Pemetrexed|Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
223453098|NCT06570694|BEHAVIORAL|OverThinking|OverThinking is a mobile application ecological momentary intervention for iOS and Android, which has been designed for the reduction of experiential avoidance in rumination. The application primarily consists of psychoeducation content and related exercises intended to be delivered over a four-week period. In order to examine the effectiveness of the application during the course of the intervention and to examine user-experiences of using the application for the purpose of rumination intervention, a number of self-report tools are embedded.
224060991|NCT00732303|RADIATION|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
224060992|NCT01074190|DRUG|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
224060993|NCT01074190|DRUG|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
224060994|NCT01074190|DRUG|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
224060995|NCT01614314|OTHER|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
224060996|NCT01614314|OTHER|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
224060997|NCT05632185|BEHAVIORAL|Equine-assisted Therapy|An equine therapy session typically consists of specific tasks and challenges to overcome, with the aid and guidance of horses. There is no riding involved and no specific skills are necessary to take part in these sessions
223453099|NCT06298383|DRUG|Trypsin, Bromelain and Rutoside|Flamogen is a combination of trypsin 48 mgs, bromelain 90mg and rutoside 100 mg in one tablet that provides an anti inflammatory, anti edematous activity. each patient will receive a single dose of 2 tablets one hour before treatment.
223453100|NCT06298383|DRUG|Diclofenac Potassium|Non-steroidal anti inflammatory drug. cataflam is known for its potent anti inflammatory and analgesic properties. each patient will receive one tablet of cataflam 50 mg 1 hour before treatment.
223453101|NCT06298383|DRUG|Prednisolone Oral Tablet|Steroids are potent anti inflammatory drugs, patients are going to receive one tablet of 30 mg solupred one hour before treatment
223453102|NCT06298383|OTHER|Placebo|A tablet of Compacted powdered milk
223453103|NCT05053100|PROCEDURE|Biospecimen Collection|Undergo collection of blood
223453104|NCT05053100|OTHER|Electronic Health Record Review|Undergo electronic health record review
223453105|NCT04006405|DIAGNOSTIC_TEST|GAG score|blood and urine samples to determine GAG scores
223453106|NCT06526676|DEVICE|Cook Alpha TX2 Stent Graft, Cook Zenith TX2, and Cook Zenith Fenestrated Stent Graft|Physician-modified stent grafts that utilizes multiple stent grafts with a combination of fenestrations and/or branches
223453107|NCT06278922|BEHAVIORAL|Seeking Safety + Signs of Safety toolkit|Signs of Safety is a Deaf-accessible toolkit to be used with the Seeking Safety treatment protocol. Seeking Safety is a manualized, non-exposure-based, cognitive behavioral therapy for trauma and addiction.
223453108|NCT06278922|BEHAVIORAL|Treatment as usual|NDT therapists come from a wide variety of training backgrounds, but each works with their clients to build on their existing strengths and provide support as clients develop new strategies and behaviors for overcoming adversity.
223453109|NCT06969274|PROCEDURE|Ultrasound guided sacral erector spinae plane block (SESPB)|Patients will receive an Ultrasound guided sacral erector spinae plane block (SESPB)
223453110|NCT06969274|PROCEDURE|Saddle block.|Patients will receive a Saddle block.
223453111|NCT04109456|DRUG|IN10018|100 mg or 50mg, orally once daily continuously;
223453112|NCT04109456|DRUG|Cobimetinib|60mg , orally once daily from day 1 to day 21 in a 28-day cycle
223453113|NCT04109456|BIOLOGICAL|Atezolizumab|biweekly 840 mg dose will be used in this study starting from Cycle 2.
223453114|NCT05820672|OTHER|No intervention|No intervention
223453115|NCT06852365|DIETARY_SUPPLEMENT|wheat dextrin|participants will take 15 grams per day for 12 weeks
223453116|NCT06852365|DRUG|Oral Contraceptives, Low-Dose|20 micrograms ethinyl estradiol and desogestrel 0.15mg
223453117|NCT06852365|DIETARY_SUPPLEMENT|Maltodextrin|participants will take 15 grams per day for 12 weeks
223453118|NCT05248178|BEHAVIORAL|CO-OP Procedures|CO-OP focuses on learning of a global problem-solving strategy, Goal-Plan-Do-Check (GPDC), within the performance of participant-chosen goals. Use of a broadly applicable strategy and meaningful activity ensures the intervention is salient to the participant and increases likelihood of transfer. Uniquely, therapists applying CO-OP use guided discovery methods to support participants in analyzing their own performance of a given task and generating potential solutions for improving performance. Participants become equipped with these skills through repetitive application of the Goal-Plan-Do-Check process.The intervention focuses on learning GPDC with gradual withdrawal of guided discovery methods.
223570622|NCT00416156|BEHAVIORAL|Lifestyle modification|
223570623|NCT03647410|DEVICE|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
224060998|NCT00264875|DRUG|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
223453119|NCT05248178|DEVICE|tDCS|Each session will begin with 20 minutes of anodal tDCS applied to the ipsilesional dorsolateral prefrontal cortex (DLPFC) at 1.5 mA. The cathode will be placed over the contralesional supraorbital area. Direct current will be applied through two saline soaked sponges placed on the scalp. The tDCS device contains software for double-blinded delivery.
223453120|NCT05248178|BEHAVIORAL|Computer Cognitive Training Procedures|Individuals receiving computerized cognitive training will receive an equal dosage of 12, 45-minute sessions directly following the assigned tDCS condition. The online training software of BrainHQ will be used. BrainHQ is a well-recognized cognitive training program that targets the areas of attention, memory, processing speed, people skills, intelligence, and navigation. BrainHQ tracks progress and automatically grades difficulty as appropriate.
224060999|NCT01381432|DRUG|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
224061000|NCT00779649|OTHER|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
224061001|NCT00779649|OTHER|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
224061002|NCT01432873|DRUG|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
224061003|NCT01432873|DRUG|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
224061004|NCT02983682|DRUG|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
224061005|NCT00959868|DRUG|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
224061006|NCT01441037|DRUG|Danazol|Danazol, 800 mg daily by mouth for 2 years
224061007|NCT00734799|BEHAVIORAL|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
224147673|NCT02194556|DRUG|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
224301433|NCT06927011|BEHAVIORAL|Capscan|"Participants will be asked to swallow 2 small devices (called Capscan), which will collect samples of intestinal fluid as they move through participants small intestine and colon. This device is not FDA approved but has been deemed to have no significant risk. The investigator can explain how it is designed to work. Participants will also answer surveys about participants quality of life.~Participants in this study will be over after all study procedures are completed."
223453121|NCT05248178|DEVICE|sham tDCS group|Sham tDCS will involve the same preparation as in tDCS, but the current will ramp up for only 30 seconds and then return to zero. This method allows for sensations on the scalp associated with tDCS without inducing any neural changes.
223453122|NCT06097871|DIETARY_SUPPLEMENT|Skin Nutraceutical Supplement|The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
223453123|NCT06097871|OTHER|Placebo pill|A placebo pill containing non-active ingredients
223453124|NCT05891886|DRUG|Oxygen Therapy|Study subjects will be asked to breathe supplemental, or extra, oxygen during several time periods.
223453125|NCT05891886|DEVICE|Non-rebreather mask|Non-rebreather mask is a non-invasive oxygen supplementation device that is used to provide continuous oxygen flow, typically in a hospital setting.
224061008|NCT02779374|OTHER|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
224061009|NCT00281398|BEHAVIORAL|Questionnaire|
224061010|NCT00868777|PROCEDURE|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
224061011|NCT01741649|PROCEDURE|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
224061012|NCT01741649|PROCEDURE|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
224147674|NCT04687488|OTHER|Fluorescein|For droplet visualization, we will use fluorescein, which has been used for many years in medicine for diagnostic purposes and is safe upon topical administration, as a tracer. There are no local or systemic side effects of topical sodium fluorescein (5). Fluorescein is routinely used in the mouth to stain dental plaque (6). Through the lacrimal duct, the nasal cavity is exposed to fluorescein when it is used for ophthalmological purposes (7). Allergic reactions have been described to intravenous injection, which is not part of our trial. In the setting of head-and-neck and otolaryngological surgeries, coating the mouth with fluorescein has been used to quantify droplet spread, to assess for risk of transmission of COVID-19 (8). Hence, fluorescein can be safely applied to nasal and oropharyngeal cavities. We will use a similar approach, coating the nasal cavity, to study droplet spread from the nose during naso-gastric intubation for motility or reflux testing.
224061013|NCT04780620|OTHER|Parent Intervention Group|Parents will be involved in 8 weekly sessions.
224147675|NCT04687488|OTHER|Particle measurement|Quantification of aerosol will be done using a medical particle counter, as used for hospital safety measurements.
224147676|NCT01609725|DEVICE|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
224147677|NCT01609725|DEVICE|Oral prophylaxis|One session of supraginigval calculus removal
224147678|NCT05166395|DEVICE|Er:YAG laser|2940 nm Er:YAG laser treatment spread over 3 sessions within 4 weeks on participant's scar on either the head/neck, trunk or extremities.
224147679|NCT05455736|OTHER|Stereotactic salvage radiotherapy for macroscopic prostate bed relapse|Stereotactic prostate salvage radiotherapy administered on prostate bed macroscopic recurrence. Different techniques will be allowed provided that treatment respects doses and fractionation indicated per-protocol (35 Gy in 5 fractions)
224147680|NCT02451488|DRUG|GM-CSF|14 days in a dose of 125 µg/m\^2
224147681|NCT02451488|OTHER|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
224147682|NCT02786836|DRUG|13C-Methacetin|"The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
224147683|NCT02539524|OTHER|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
224147684|NCT02539524|OTHER|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
224147685|NCT05285267|BEHAVIORAL|Behavioral Parent Support|Parent training on effective child management strategies
223453126|NCT05319561|OTHER|Antibiotic Use Report|"The Antibiotic Use Report uses both text and graphics to communicate successes and improvement opportunities specific to the VAMC for which it is prepared. The graphs summarize overall antibiotic use over the previous year, with additional information regarding use of broad- and narrow-spectrum agents. Further, each Antibiotic Use Report compares or benchmarks the individual VAMC for which it is prepared to other VAMCs in the same Medical Complexity Group. This approach adapts and expands peer comparison, which has proven effective at reducing inappropriate antibiotic use in outpatient settings."
223453127|NCT02372942|DRUG|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
224061014|NCT05741255|BEHAVIORAL|Acceptance and Commitment Therapy|type of mindful psychotherapy that helps you stay focused on the present moment and accept thoughts and feelings without judgment. It aims to help you move forward through difficult emotions so you can put your energy into healing instead of dwelling on the negative.
224061015|NCT00704782|DRUG|dimebon|
224061016|NCT02360020|DEVICE|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
224061017|NCT05217745|DIETARY_SUPPLEMENT|MLCT Oil|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
223453128|NCT02372942|DRUG|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
223570624|NCT05901480|GENETIC|OTOV101N+OTOV101C Injections|The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
223570625|NCT00192660|DRUG|Lamivudine|
223570626|NCT00192660|DRUG|Stavudine|
223570627|NCT00192660|DRUG|Didanosine|
223570628|NCT00192660|DRUG|Zidovudine|
223570629|NCT00192660|DRUG|Tenofovir|
223570630|NCT00192660|DRUG|Abacavir|
223570631|NCT00192660|DRUG|Efavirenz (EFV)|
223570632|NCT00192660|DRUG|Nevirapine|
223570633|NCT00192660|DRUG|Indinavir|
223570634|NCT00192660|DRUG|Saquinavir|
224061018|NCT05217745|DIETARY_SUPPLEMENT|LCT Oil (Corn Oil)|1st 12 weeks: frozen ready to eat meals prepared with the oil Last 12 weeks: own diet with provided snacks containing the oil
224061019|NCT03445455|DEVICE|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
224061020|NCT01538654|PROCEDURE|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
224061021|NCT04111029|DIAGNOSTIC_TEST|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
224061022|NCT00188643|DRUG|Venlafaxine and Lamotrigine|
224061023|NCT04868721|PROCEDURE|micro-osteoperforations|three flapless micro-osteoperforations was performed distal to the maxillary canine before starting retraction.
224061024|NCT05598918|PROCEDURE|early active mobilization|In the active rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for active mobilization group.Then, the patients were asked to passively flex the injured side with their healthy hand and hold it in the flexion position for 3-5 seconds.
224147686|NCT05285267|BEHAVIORAL|Shared Parent-Child Activities|Structured parent-child activities
224147687|NCT05285267|BEHAVIORAL|COACHES|This intervention involves practice of parenting strategies with facilitator monitoring and support.
223453129|NCT06245798|PROCEDURE|transarterial chemoembolisation|During transarterial chemoembolisation（TACE）, a vascular catheter was selectively inserted into the tumour-feeding artery with an injection containing a mixture of doxorubicin (10-50 mg) and lipiodol (2-20 mL), followed by embolisation using gelatin sponge particles. TACE was repeated when residual viable tumours were confirmed or new lesions developed in patients with adequate liver function
223453130|NCT05233579|DIETARY_SUPPLEMENT|Sulforaphane|Sulforaphane will be taken one tablet in the morning with breakfast and then every 2 weeks, the dose will be increased by one tablet until a total of 6 tablets are taken in the morning. The supplement should be taken around the same time each day.
223453131|NCT05710510|BEHAVIORAL|Local Care + Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive 6 quarterly clinic visits with their local primary care provider focused on medical management of obesity."
223453132|NCT05710510|BEHAVIORAL|Team Care Model|"Local primary care providers receive training in medical management of obesity prior to the start of the participant intervention.~Participants receive an intensive 18-month group lifestyle intervention (30 total sessions) led by a study lifestyle coach via Zoom, and 6 quarterly 1:1 visits via Zoom with their lifestyle coach. Participants also receive 6 quarterly clinic visits with their local primary care provider; the study lifestyle coach joins the visits via telemedicine. All three parties may meet via telemedicine if needed. The group lifestyle intervention is led by obesity treatment specialists with relevant graduate training and experience."
223453133|NCT06585085|BEHAVIORAL|In person PA sessions|Group B women will have access to a weekly program of 3 face-to-face PA sessions. The face-to-face sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. They will also be offered at one or more times depending on the number of groups. Locations and times will be specified on the online booking software. Women can only register for 3 sessions per week.
223570635|NCT00192660|DRUG|Amprenavir|
223570636|NCT00192660|DRUG|Ritonavir|
223570637|NCT00192660|DRUG|Nelfinavir|
223570638|NCT00192660|DRUG|Tipranavir|
223570639|NCT00192660|DRUG|enfuvirtide (T20)|
223570640|NCT04854031|DEVICE|Cochlear Implants|Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
223570641|NCT02979509|OTHER|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
223570642|NCT00230282|DRUG|Alemtuzumab|3 to 30 mg, IV
223570643|NCT00230282|DRUG|Fludarabine|\[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl\]methoxyphosphonic acid
223570644|NCT00230282|DRUG|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
223570645|NCT03449693|DIETARY_SUPPLEMENT|Magnesium Oxide Supplement|Magnesium Oxide tablet
223570646|NCT03294239|PROCEDURE|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
224061025|NCT05598918|PROCEDURE|early passive mobilization|In the passive rehabilitation group, active extension and passive flexion of the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints were performed with kleinert splint at angles suitable for passive mobilization group.
224061026|NCT03048929|BIOLOGICAL|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
224061027|NCT03048929|BIOLOGICAL|Placebo|The placebo injection will consist of 0.5mL of saline.
224061028|NCT04712929|OTHER|Fluconazole|( Tab Fluconazole 100 mg as a mouthwash ( tablet dissolved in 10 ml of drinking water and used as a rinse for 2 minute and swallowed) once a day for 14 days WHO criteria 5As and 5Rs for tobacco cessation
224147688|NCT00736788|DRUG|AZD1704|single dose oral suspension, 4 different dose levels
224147689|NCT00736788|DRUG|Placebo|single dose oral suspension
224147690|NCT05541523|BEHAVIORAL|cognitive behavioural therapy|The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
224301434|NCT02283294|DRUG|Apixaban|
224301435|NCT02283294|DRUG|Warfarin|
224061029|NCT02409654|OTHER|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
224061030|NCT02409654|OTHER|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
224061031|NCT01805622|BEHAVIORAL|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
224061032|NCT00077792|DRUG|Enoxaparin sodium (XRP4563)|
224061033|NCT02409290|DRUG|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
224061034|NCT02409290|DRUG|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
224061035|NCT02409290|DRUG|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine.
224061036|NCT02409290|DRUG|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
224061037|NCT02409290|DRUG|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
224061038|NCT02409290|DRUG|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
224061039|NCT02409290|DRUG|Prothionamide|Prothionamide has a bacteriostatic action.
224061040|NCT02409290|DRUG|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
224061041|NCT02409290|DRUG|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
224061042|NCT02409290|DRUG|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
223453134|NCT06585085|BEHAVIORAL|Interactive videoconference PA sessions|Women in Group C will have access to a weekly program of 3 PA sessions via interactive videoconferencing. These sessions will have the same format as the face-to-face sessions with visualization of the APA professional, visualization of the participants (who can also choose to be masked). The PA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 3 sessions per week.
223453135|NCT06585085|BEHAVIORAL|In person and by videoconference (mixed format) PA sessions.|Women in Group D will have access to a weekly program of 3 mixed-format PA sessions, with 2 interactive distance learning sessions and 1 in-person session. The in-person sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. Locations and times will be specified on the online booking software. Women can only register for 1 face-to-face session per week. The other 2 sessions will be offered via interactive videoconferencing. These sessions will have the same format as the in-person sessions, with visualization of the APA professional, visualization of the participants. The APA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 2 videoconference's sessions per week.
224061043|NCT04971304|DRUG|Receipt of granulocyte-colony stimulating factor|Receipt of originator or biosimilar
224061044|NCT04026178|DRUG|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
224061045|NCT05021250|PROCEDURE|Lipiodol marking|HCC patients treated with TACE and the tumor marked with lipiodol.
224070997|NCT05493319|OTHER|Exercises|Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
224070998|NCT00557219|DRUG|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
224070999|NCT00557219|DRUG|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
224071000|NCT00557219|DRUG|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
224071001|NCT03824847|DRUG|Clarithromycin 250 MG|Clarithromycin 1 tablet (250mg) twice daily for three days
224071002|NCT03824847|DRUG|Placebos|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
224071003|NCT05056025|DIETARY_SUPPLEMENT|Postbotics and Vitamins|2 capsule 3 times a day, before meals
224071004|NCT05056025|DIETARY_SUPPLEMENT|Vitamins|2 capsule 3 times a day, before meals
223453136|NCT02153151|OTHER|Cytology specimen|Correlative studies
223453137|NCT02153151|OTHER|Laboratory biomarker analysis|Correlative studies
223453138|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with supra-inguinal fascia iliaca block (SIFIC)|Patients will receive pericapsular nerve group (PENG) block with supra-inguinal fascia iliaca (SIFIC) block.
224071005|NCT00874978|DRUG|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
223453139|NCT06577103|OTHER|Pericapsular nerve group block (PENG) with lateral femoral cutaneous nerve block (LFCN)|Patients will receive pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block.
224061046|NCT05679336|DRUG|Rituximab, Cyclophosphamide, and Corticosteroids|"1. Rituximab (RTX) will be given as a single intravenous (IV) dose of 375 mg/m2. Extra RTX infusion at the same dose will be administered on weeks 12, 24, and 36 in the absence of remission and the occurrence of peripheral B-cell reconstitution. Peripheral B-cell reconstitution is defined as total CD19+ cell count \>5 cells/μL;~2. Concurrent with RTX initiation, a single IV infusion of methylprednisolone 500 mg will be administrated, followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1. The dosage will be rapidly decreased by 10 mg/weekly as follows: week 2, 50 mg daily; week 3, 40 mg daily; week 4, 30 mg daily; week 5, 20 mg daily; weeks 6-7, 10 mg daily; weeks 8-48, 5 mg daily; week 49, stop;~3. Four IV infusions of Cyclophosphamide will be administered at a dose of 7.5 mg/kg every other week (on weeks 1, 3, 5, and 7)."
224061047|NCT03401528|DRUG|AVB-S6-500|AVB-S6-500 is an investigational drug.
224061048|NCT03401528|OTHER|Placebo|Matching placebo
224061049|NCT05494021|OTHER|Whole-process management software|Enrolled participants will managed by a pre-designed software. The software would provide helpful assistance, such as lung cancer education, decision-making, assisting in making and attending LCS LDCT appointments, arranging follow-up when needed, tobacco cessation support for smokers, treatment assistance if diagnosed as lung cancer.
224061050|NCT05494021|DEVICE|LDCT detection|LDCT were performed in both arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
224061051|NCT00708500|DRUG|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
224061052|NCT00708500|BIOLOGICAL|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
224061053|NCT00708500|DRUG|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
224061054|NCT00708500|DRUG|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
224061055|NCT03404011|OTHER|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
224147691|NCT05541523|BEHAVIORAL|mindfulness-based therapy|The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
224147692|NCT03277508|DEVICE|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
223453140|NCT03079414|PROCEDURE|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
223453141|NCT04156906|BIOLOGICAL|D+ RH genotype matched red cell units for transfusion|Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
223570647|NCT03294239|PROCEDURE|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
223570648|NCT01643161|BEHAVIORAL|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
223570649|NCT01643161|BEHAVIORAL|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
223570650|NCT04762043|DEVICE|Experimental System: MyoVoice|Person-centric augmentative and alternative communication (AAC) system comprising a user-specific set of wearable sensors for capturing articulatory muscle activity and mobile software that provides real-time audible speech outputs.
223570651|NCT04762043|DEVICE|Reference System: Electrolarynx|Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
224061056|NCT03404011|DEVICE|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
224147693|NCT03277508|DEVICE|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
224147694|NCT00209326|DRUG|FE200440|
224301436|NCT02123212|OTHER|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
224061057|NCT03583151|BIOLOGICAL|Amniotic fluid injection|Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
224061058|NCT03583151|BIOLOGICAL|Steroid injection|Solu-medrol
224061059|NCT01219010|BIOLOGICAL|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
224061060|NCT01242267|DRUG|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 600mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4 days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
224061061|NCT00896922|GENETIC|microarray analysis|
224061062|NCT00896922|OTHER|immunohistochemistry staining method|
224061063|NCT00896922|OTHER|laboratory biomarker analysis|
224061064|NCT00202735|PROCEDURE|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
224061065|NCT00202735|PROCEDURE|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
224061066|NCT02043535|DEVICE|Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing"
224061067|NCT02043535|DEVICE|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
223570652|NCT04132830|OTHER|In Utero HIV Exposure|Born to mother who had HIV infection during pregnancy.
224061068|NCT01758796|PROCEDURE|Non-operative treatment|Below-the-knee cast for six weeks.
224061069|NCT01758796|PROCEDURE|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
224147695|NCT04183946|BEHAVIORAL|Online Cognitive Behavioural Therapy|"The Willkommen Mutterglück program is an 8-session, interactive web-based CBT intervention for prenatal and postpartum depression and anxiety. The sessions are administered online via audio and video images. Each weekly session has a duration of 40-50 minutes during which the participants are asked to actively participate through exercises and quizzes.~A SCID interview for screening will be conducted by a trained clinical psychologist and an experienced psychiatrist from our outpatient clinic will verify the diagnosis. Screened and consented participants will answer baseline questionnaires, provide sociodemographic information and receive a private login to access the program. After completing the 2nd, 4th and 8th intervention session participants will fill in psychological questionnaires.~During the intervention, participants will be contacted three times by telephone by coaches (psychotherapists in training) who follow a manualized script."
223570653|NCT04132830|OTHER|No In Utero HIV Exposure|Born to mother who did not have HIV infection during pregnancy.
223570654|NCT06495840|OTHER|no intervention|no intervention
223570655|NCT06283810|BEHAVIORAL|psychotherapy of interpersonal relationships|"Group KIPT will be 1 session per week and each session will last 90 minutes. There will be 7 sessions in total, and a completion session will be held 2 weeks after the completion of Group KIPT. In order for the students in G1 to understand which group they are in, they will also be informed about the points to be considered regarding laughter therapy. An unstructured laughter intervention will be applied at the beginning or at the end of the sessions in which group IPT is applied.~Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect). Within the scope of work packages 3 and 4, KIPT application and other measurements will be made."
224061070|NCT06254365|BIOLOGICAL|Exogenous LEAP2 hormone|This intervention has never been examined in this type of study before.
224061071|NCT06360250|DRUG|Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation|Each dose (1.0 ml) contained 1.25 mg of human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of human anti-tetanus toxin monoclonal antibody B86.
224061072|NCT06360250|DRUG|Tetanus human immunoglobulin (HTIG)|Tetanus human immunoglobulin (HTIG)
224061073|NCT06360250|DRUG|Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo|There were no active ingredients, and other ingredients were the same
224061074|NCT06360250|BIOLOGICAL|Adsorbed tetanus vaccine (TT)|containing tetanus toxoid titer not less than 40 IU
224061075|NCT00595556|DRUG|zonisamide|flexible dosages of 100-500mg/day
224061076|NCT00595556|DRUG|Placebo|Placebo
224061077|NCT03747211|BEHAVIORAL|Aerobic exercise|High Intensity Interval Training (HIIT)
224061078|NCT00705783|DRUG|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
224061079|NCT00705783|DRUG|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
223453142|NCT05940961|DRUG|Inotuzumab Ozogamicin|intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
223453143|NCT05633810|DRUG|Aspirin|40 mg non-enteric-coated tablet taken twice daily.
223453144|NCT05633810|DRUG|Aspirin Placebo|non-enteric-coated tablet taken twice daily.
223742351|NCT06140147|OTHER|Usual care|"Participants receive non-resuscitation fluids according to local routines, with the following stipulations:~Maintenance fluids (crystalloids and/or glucose and/or enteral water): given at a dose of 1 ml/kg/h unless local protocol states otherwise Glucose: used at maximal concentration of 10% unless local protocol states otherwise.~Medications: concentrated per local protocol"
223742352|NCT00070187|BIOLOGICAL|aldesleukin|Given IV
223742353|NCT00070187|BIOLOGICAL|filgrastim|Given IV
223742354|NCT00070187|BIOLOGICAL|recombinant interferon gamma|Given IV
223742355|NCT00070187|DRUG|carmustine|Given IV
223742356|NCT00070187|DRUG|cyclosporine|Given IV
224061080|NCT02182687|RADIATION|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
224061081|NCT02182687|PROCEDURE|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
223453145|NCT05633810|DRUG|Colchicine|0.5 mg tablet taken once daily
223453146|NCT05633810|DRUG|Colchicine Placebo|tablet taken once daily.
223570656|NCT06283810|BEHAVIORAL|laughter therapy|"Laughter therapy is 1 session per week and each session will last 40 minutes. A total of 8 sessions will continue. Each session will start with warm-up and deep breathing exercises and will continue with applause and childish games. Afterwards, games specific to each session will be added. Unstructured interviews will be conducted with G2 at the beginning or at the end of the session, suggesting that they were subjected to group CIPT. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week (intervention interval), 8th week (end of intervention) and 12th week (long-term effect) when the interviews start."
223570657|NCT06283810|BEHAVIORAL|Plasebo|"After the initial data are collected, unstructured interviews about the interpersonal relationships of the person will be conducted by conducting individual interviews with each student for 2-3 sessions at the beginning of the study in case the student does not understand which group he/she is in. Afterwards, unstructured random interviews and laughter intervention will be conducted for a total of 8 sessions lasting 40 minutes, 1 session per week. Measurements will be made using ANNEX-3, ANNEX-4, ANNEX-5, ANNEX-6 in the 4th week, 8th week and 12th week (long-term effect) when the interviews start."
223570658|NCT04983875|BEHAVIORAL|BAC-Enhanced Letter|The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.
223570659|NCT04983875|BEHAVIORAL|Waitlist Control|Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
223570660|NCT03184493|DRUG|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
223742357|NCT00070187|DRUG|cytarabine|Given IV
223742358|NCT00070187|DRUG|etoposide|Given IV
224061082|NCT02182687|DRUG|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
223453147|NCT02946021|DEVICE|Head and neck garments for pneumatic compression device|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
223742359|NCT00070187|DRUG|melphalan|Given IV
223742360|NCT00070187|PROCEDURE|autologous bone marrow transplantation|
223742361|NCT00070187|PROCEDURE|bone marrow ablation with stem cell support|
224061083|NCT02234154|DEVICE|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
224061084|NCT05365542|OTHER|Hemodialyzer scanning|After the hemodialysis session, the used dialyzer is rinsed and dried before scanning in a Micro Computed Tomography scanner. From cross-sectional images, the number of patent fibers is quantified.
224061085|NCT05365542|OTHER|Bleeding Questionnaires|The ISTH Bleeding Assessment Tool and the HASBLED questionnaires are asked
224061086|NCT05365542|OTHER|Quality of life questionnaire|The EQ5D questionnaire is asked.
224061087|NCT05365542|OTHER|Visual inspection of the limbs|Visual inspection is done of the patient's limbs in order to quantify bruising.
224061088|NCT01029132|DRUG|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
223742362|NCT00070187|PROCEDURE|peripheral blood stem cell transplantation|
223742363|NCT05135520|PROCEDURE|Transvaginal natural orifice specimen extraction (NOSE)|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo Transvaginal NOSE
224061089|NCT06475014|PROCEDURE|Total knee replacement|Mechanical Alignment Using PSI Pre and post-operative CT Scan
224061090|NCT05826756|OTHER|There are no interventions in this study. All participants complete online surveys.|There are no interventions in this study. All participants complete online surveys.
224061091|NCT02788097|PROCEDURE|Progesterone supplementation|artificial frozen embryo transfers
224061092|NCT02184195|DRUG|Olaparib|Tablet -100mg
224061093|NCT02184195|DRUG|Olaparib|Tablet-150mg
224061094|NCT02184195|DRUG|Placebo|Match Olaparib 100mg placebo
224061095|NCT02184195|DRUG|Placebo|Match Olaparib 150mg placebo
224071006|NCT05053295|DRUG|autologous activated T lymphocyte|"Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV"
223742364|NCT05135520|PROCEDURE|Transabdominal specimen extraction|Under general anesthesia, patients who are planned to perform multiport laparoscopic surgery for resection of solid organs including kidney or bladder will undergo transabdominal specimen extraction with incision elongation
223742365|NCT00803868|DRUG|varenicline|up to 1mg po bid for 9 weeks
223742366|NCT00803868|DRUG|placebo|placebo matching study drug up to 1mg po bid
223742367|NCT00483379|BIOLOGICAL|alglucosidase alfa|intravenous infusion
223742368|NCT06801626|COMBINATION_PRODUCT|Famotidine and 4% topical cromolyn sodium|Patients will be instructed to take a 20mg famotidine capsule twice daily, and to use the lotion (4% cromolyn sodium) twice daily.
223742369|NCT06801626|OTHER|Placebo|Treatment with active H1 antihistamine plus administration of placebo famotidine and placebo cromolyn sodium.
223742370|NCT06074237|OTHER|Immersive resident education|Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
223453148|NCT02946021|DRUG|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
223742371|NCT06074237|OTHER|Standardized patient (SP) encounter|"After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant patient and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter."
223742372|NCT03184415|DRUG|DWC20155|tablet
224061096|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - active|The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.
224061097|NCT05570591|DEVICE|2RT subthreshold nanosecond laser - sham|Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant) from the 2RT subthreshold nanosecond laser device.
224061098|NCT03849378|DIETARY_SUPPLEMENT|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
224061099|NCT03849378|DIETARY_SUPPLEMENT|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
224147696|NCT03337425|BEHAVIORAL|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
224147697|NCT03337425|BEHAVIORAL|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
223453149|NCT02588092|DRUG|ADCT-301|Intravenous infusion
223453150|NCT06194058|OTHER|rapid sequence anesthetic induction|Rapid sequence induction and intubation (or crash induction) is a process for inducing general anesthesia when the patient is at a high risk of pulmonary aspiration. It aims at minimizing the time between giving the induction drugs and securing the tube, during which period the patient's airway is essentially unprotected.
223453151|NCT04536272|DRUG|Heparin|Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
224061100|NCT03300895|OTHER|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
223453152|NCT04536272|DRUG|LMWH|Administration of LMWH guided by weight and renal function during ECLS.
223453153|NCT01030718|DRUG|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
223453154|NCT01090141|DRUG|Micafungin|100 mg IV infusion over 1 hour
223453155|NCT01090141|DRUG|Micafungin|300 mg IV infusion over 1 hour
223453156|NCT04564924|RADIATION|DXA|Bone mineral density was examined in all cases and controls
223453157|NCT01294059|DRUG|Milnacipran|50 mg BID Oral x 6 Weeks
223453158|NCT03240185|BEHAVIORAL|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
223453159|NCT00099632|DRUG|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
223453160|NCT00099632|DRUG|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
223742373|NCT03184415|DRUG|DWC20156|tablet
223742374|NCT03184415|DRUG|placebo of DWC20155|tablet
223742375|NCT03184415|DRUG|placebo of DWC20156|tablet
223742376|NCT05031533|RADIATION|Dose-Painting Radiation|"Radiation therapy:~1. Delineation of target area:~   The primary tumor is delineated into different target areas according to the anatomical position of the tumor, including the central area tumor GTV-Tcentral and GTV-Tperipheral.~2. Exposure dose:~1\) GTV-Tcentral: 2.0～2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0～4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy"
223742377|NCT00123864|PROCEDURE|Intensity-modulated radiation therapy|
223742378|NCT03678467|COMBINATION_PRODUCT|EB-CMF|Autologous, anatomically shaped bone graft
223742379|NCT02233322|DIETARY_SUPPLEMENT|Iron|All subjects will receive iron supplementation based on iron levels in the blood
223742380|NCT00188513|PROCEDURE|conformal intensity modulated radiotherapy (IMRT)|
223742381|NCT03202147|DRUG|Cromolyn|Active capsules for inhalation.
223742382|NCT03202147|OTHER|Placebo|Non-active capsules for inhalation.
224061101|NCT03300895|OTHER|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
224061102|NCT05891340|OTHER|Respiratory muscle exercise|respiratory muscle exercise with inspiratory muscle trainer (two times a day)
224061103|NCT05891340|OTHER|Endurance exercise|walking exercise 5000 steps/day
224061104|NCT02997735|BEHAVIORAL|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
224061105|NCT02514616|PROCEDURE|Laparoscopic IPG and lead implant procedure|EST placement
224061106|NCT02514616|DEVICE|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
224061107|NCT02514616|DEVICE|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
223453161|NCT00099632|DRUG|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
223453162|NCT00099632|DRUG|single dose Nevirapine|one 200 mg tablet taken orally
223453163|NCT05435781|DRUG|Hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
223453164|NCT05435781|DRUG|Placebo for hydrocortisone|Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
223453165|NCT00423813|DRUG|placebo|Oral Solution
223453166|NCT00423813|DRUG|Xyrem®|two doses
223453167|NCT03236116|OTHER|Almonds|Participants will consume almonds everyday for 6 months.
223570661|NCT03184493|DRUG|Celebrex|This group patients will receive celebrex.
223570662|NCT03184493|DRUG|Metformin|This group patients will receive metformin.
223570663|NCT05961969|PROCEDURE|Robotic surgery|"1. Patients with rectal cancer.~2. Patients will undergo robotic Transabdominal Top-down Intersphincteric Resection with Double-stapling Coloanal Anastomosis"
223570664|NCT01712997|DRUG|Iloprost|
223570665|NCT01712997|DRUG|Bosentan|
223570666|NCT05569538|DRUG|Bomedemstat|Bomedemstat will be self-administered orally once daily. In both cohorts, the dose of bomedemstat will be adjusted in each patient based on titration of the patient's platelet count to the target range. Ruxolitinib will be self-administered orally. Both medications will continue uninterrupted in 28-day cycles. Subjects will continue combination treatment through the Initial Treatment Period (first 6 cycles), which includes a Qualification Assessment. Those deriving clinical benefit in the opinion of the treating physician may continue receiving combination treatment in the Additional Treatment Period (6 cycles). Qualification Assessments will be performed at the end of each Additional Treatment Period, which is iterative, and may repeat for as long as clinical benefit is sustained, at the discretion of the treating physician.
223570667|NCT04460924|DRUG|Integrase strand transfer inhibitors|Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment
223570668|NCT04142424|DRUG|AZD2693|Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
223570669|NCT04142424|DRUG|Placebo|Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
223570670|NCT03006458|DEVICE|comfilcon A|toric contact lens
223570671|NCT03006458|DEVICE|omafilcon B|toric contact lens
223742383|NCT06807632|DRUG|Valemetostat|"Dose level -1 100 mg po once daily~Dose level 1 150 mg po once daily~Dose level 2 200 mg po once daily"
223453168|NCT03236116|OTHER|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
223570672|NCT05743556|DEVICE|HILT laserotherapy|application of high intensive laser therapy on cervical muscles
223570673|NCT05743556|DEVICE|TRT therapy|application of radiofrekvention therapy on cervical muscles
223570674|NCT00434733|BIOLOGICAL|Pandemic influenza vaccine|
223570675|NCT03011970|DRUG|Oxytocin|
223570676|NCT03011970|DRUG|Placebo|
223742384|NCT06807632|DRUG|Atezolizumab|1680 mg IV q4weeks
223742385|NCT01572506|DRUG|Biotin RBC survival|
224061108|NCT06512012|BEHAVIORAL|yoga and exercise|Technology-Assisted Yoga and Exercise Intervention during 6 months
224061109|NCT04162184|BEHAVIORAL|Sexual Health Initiative for Navigation and Education (SHINE) Health Educator Intervention|a brief health educator-led behavioral intervention focused on educating, identifying reproductive health needs, and linking to services if desired
224061110|NCT01748279|DRUG|Atorvastatin|
224061111|NCT01748279|DRUG|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
224061112|NCT01748279|DRUG|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
224061113|NCT04227509|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
224061114|NCT04227509|DRUG|Placebo|normal saline will be administered as a 30 minute IV infusion every 3 weeks.
224061115|NCT06306521|GENETIC|BeginNGS Test|Genomic sequencing that screens for over 400 genetic diseases.
224061116|NCT00563628|DEVICE|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
224061117|NCT00319774|DEVICE|Hemocontrol Biofeedback System|
224061118|NCT00277511|DRUG|Levofloxacin|
224061119|NCT04966546|DRUG|Memantine Hydrochloride|Active drug arm
224061120|NCT04966546|DRUG|Placebo|Simple syrup with peppermint oil added to match the commercial solution and make it indistinguishable
224061121|NCT05650489|OTHER|assessment|correlation between Autistic features, motor function and quality of life
223453169|NCT01638195|DEVICE|Focused Ultrasound|Focused Ultrasound
223453170|NCT00349635|DRUG|Metformin and Metformin + Fenofibrate|
223453171|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
224061122|NCT01274975|OTHER|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
224061123|NCT02698670|DEVICE|Rhythmia mapping system|A 3-D Cardiac Mapping system
224061124|NCT02698670|DEVICE|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
223453172|NCT02610530|PROCEDURE|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
223453173|NCT02610530|OTHER|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
223453174|NCT00607659|OTHER|No intervention, only observational|No intervention, only observational
223453175|NCT04881279|OTHER|Event|Ransomware attack
223453176|NCT00290654|DRUG|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
223453177|NCT00290654|PROCEDURE|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
223453178|NCT00290654|RADIATION|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
223453179|NCT02343432|DRUG|Triamcinolone|Triamcinolone
223453180|NCT02343432|DRUG|Epidural Volume|Epidural Volume
223570677|NCT02241213|DEVICE|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
223570678|NCT02241213|DEVICE|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
223570679|NCT05482529|OTHER|Integrative omics|Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
223570680|NCT01316757|BIOLOGICAL|cetuximab|Given IV
223570681|NCT01316757|DRUG|paclitaxel|Given IV
224061125|NCT03658265|OTHER|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
223453181|NCT02343432|DRUG|Bupivacaine|Bupivacaine
223453182|NCT05435560|DRUG|Dexmedetomidine|During the imaging scan subjects will receive an initial bolus of dexmedetomidine over 10 minutes. After the bolus has been administered, a constant infusion of dexmedetomidine will be maintained for the remainder of the scan (about 60 minutes).
223570682|NCT01316757|DRUG|carboplatin|Given IV
223570683|NCT01316757|DRUG|erlotinib hydrochloride|Given PO
223453183|NCT05435560|DRUG|Saline|During the imaging scan subjects will receive an initial bolus of saline over 10 minutes. After the bolus has been administered, a constant infusion of saline will be maintained for the remainder of the scan (about 60 minutes).
223453184|NCT02074332|BEHAVIORAL|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight\&obese students Family physical activities Parent involvement
223453185|NCT02074332|BEHAVIORAL|Health education|Knowledge of obesity prevention and control
223570684|NCT01316757|OTHER|laboratory biomarker analysis|Correlative studies
223570685|NCT02381717|OTHER|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
223570686|NCT02381717|DRUG|bupivacaine|
223570687|NCT02381717|DRUG|morphine|
223570688|NCT03172884|DRUG|Copanlisib (ALIQOPA, BAY80-6946)|12mg single dose, intravenous on Day 0
223570689|NCT03232645|DEVICE|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
223570690|NCT00144248|DRUG|nevirapine|
223570691|NCT05897840|DEVICE|Fiber-optic probe CeVOX|Installation of the fiber-optic probe within the existing central venous catheter for continuous monitoring of SvcO2
224061126|NCT03658265|OTHER|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
224061127|NCT03658265|OTHER|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
224061128|NCT03658265|OTHER|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
224061129|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Mivacurium 200µg/kg immediately followed by~3. Fentanyl 2µg/kg"
224061130|NCT01427985|DRUG|Atropine, Fentanyl, Mivacurium|"1. Atropin 10µg/kg~2. Fentanyl 2µg/kg, repeat max. two times~3. Mivacurium 200µg/kg"
224061131|NCT00939783|DRUG|Dimebon|Tablet for oral administration
224061132|NCT02336490|OTHER|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
224061133|NCT03187431|BIOLOGICAL|autologous bone marrow mesenchymal stem cells|intravenous infusion
223453186|NCT05334459|RADIATION|radiotherapy|"Oligometastatic disease (defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems)~* Primary tumor biopsy, Metastatic site biopsy (Bone, liver, etc) (if there is, based on institutional practice)~  o ER / PR /Her2 /Ki67 study)~* Collection of CTC.~* Radiotherapy (RT) to the primary breast tumor (Hypo fractionated)~* All patients will receive the standard of care treatment with CDK4/6 inhibitor + AI for 6 months (at least 26 weeks).~  o Denosumab, Biphosphonate for bone metastasis~* RT to metastatic side (if visible). Continue Systemic therapy~* 12 months, patients will have LRT surgery (BCS/mastectomy + LN evaluation; SLNB+ALND) + RT (based on the institutional practice). Collect CTC and ER/PR/Her 2 in the final specimen~* ST will be continued until progression and/or unmanageable toxicity.~* Radiologic evaluation every 3-6-month based on institutional practice."
223453187|NCT04160637|DIAGNOSTIC_TEST|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
223453188|NCT02840227|PROCEDURE|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
224061134|NCT02189161|DEVICE|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
224061135|NCT01783275|BEHAVIORAL|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
224061136|NCT05939024|OTHER|Muscle Energy Technique plus Conventional Physical Therapy|Post-Isometric Relaxation of the Muscle Energy Techniques will be applied to Spinal Stabilizers and Mechanoreceptors. Hold time will be 7 seconds with 5 seconds rest between two performance x 3 times /session. Whereas, Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
224061137|NCT05939024|OTHER|Conventional Physical Therapy|Conventional Physical Therapy consists of hot pack, TENS, Ultrasonic along with stretching and exercises of back musculature.
224061138|NCT01425827|DRUG|duloxetine HCL|60 mg/day duloxetine for 16 weeks
224061139|NCT01425827|DRUG|placebo|similar looking tablets to the active agent for 16 weeks
224061140|NCT00435838|DRUG|No Intervention -- Observational study|
224061141|NCT00409084|PROCEDURE|endoscopic variceal band ligation|endoscopic variceal band ligation
224061142|NCT02373059|OTHER|Diabetes Issue Cards Decision Aids|
224061143|NCT02373059|OTHER|Usual Pharmaceutical Care|
224061144|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
223742386|NCT06453044|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224147698|NCT03337425|OTHER|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
223570692|NCT01468233|BIOLOGICAL|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223742387|NCT06453044|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224061145|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
224061146|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
224061147|NCT00964535|DRUG|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
224061148|NCT04897477|DRUG|Azacytidine, Bendamustine and Piamprizumab|Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
224061149|NCT04489745|RADIATION|SBRT|
224061150|NCT04489745|DRUG|Androgen deprivation therapy (ADT)|
224061151|NCT02718755|DRUG|Fludarabine|"Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
224061152|NCT02718755|DRUG|Cytarabine|"Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
224061153|NCT02718755|DRUG|Erwinase|"Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
224061154|NCT00905736|PROCEDURE|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
224061155|NCT00905736|PROCEDURE|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
224061156|NCT04004650|PROCEDURE|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7\_vH2\_1ZZc
224061157|NCT03672409|BEHAVIORAL|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
224061158|NCT00713427|DEVICE|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
224061159|NCT06022952|OTHER|Stone MD stent radar|Mobile app
224061160|NCT03297736|DEVICE|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
224061161|NCT03297736|DEVICE|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
224061162|NCT00455689|DRUG|Leuprolide acetate|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
224061163|NCT01824277|OTHER|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
224061164|NCT00638001|DEVICE|custom-molded insoles and custom-molded shoes|"* custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~* custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
223453189|NCT02840227|PROCEDURE|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
223570693|NCT01468233|BIOLOGICAL|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
223570694|NCT03315273|OTHER|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
223570695|NCT00874640|BIOLOGICAL|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
223570696|NCT04074694|PROCEDURE|Sialoendoscopy|Sialoendoscopy
223570697|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
223570698|NCT01271075|DRUG|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
223570699|NCT03325348|DRUG|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
223570700|NCT03325348|DRUG|Labetalol|IV labetalol 20 mg \& mint tablet will be given to patients every 15 min until one hour
223570701|NCT03581695|OTHER|Blood test|Blood test
224061165|NCT03969121|DRUG|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
224061166|NCT03969121|DRUG|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
224061167|NCT05885100|DRUG|Eleveld Model|Target plasma propofol
224061168|NCT04113200|DIETARY_SUPPLEMENT|MerMed One|A 1 kcal per ml enteral feed containing an alginate.
224061169|NCT04113200|DIETARY_SUPPLEMENT|Nutricomp Soy Fibre|A 1kcal per ml enteral feed not containing alginate.
224301437|NCT02123212|OTHER|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
223453190|NCT01173900|BIOLOGICAL|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
223453191|NCT03385551|DRUG|Estradiol|Estradiol or Promestriene depending on the arm
223453192|NCT00135590|DIETARY_SUPPLEMENT|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
223453193|NCT00135590|DIETARY_SUPPLEMENT|Spread diet|Dietary protein was spread over the four meals.
223570702|NCT04015284|PROCEDURE|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
223570703|NCT04015284|PROCEDURE|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
223570704|NCT00653848|DRUG|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
223570705|NCT03537365|DIETARY_SUPPLEMENT|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
223742388|NCT06453044|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223742389|NCT06453044|BIOLOGICAL|Mosunetuzumab|Given SC
224301438|NCT02123212|OTHER|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
224061170|NCT00663988|PROCEDURE|human transplantation|Allograft composite tissue transplantation. procedure. medication
223453194|NCT04883684|OTHER|Personal health wallet service for Chronic Patients in Emergency Department|Patients(caregivers) will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
223453195|NCT04242407|DRUG|DMTS|DMTS applied before surgery and worn for 96 hours
224061171|NCT06290206|BEHAVIORAL|PREVENT - BCT|"Bootcamp Translation (BCT), a method for engaging diverse stakeholders in a consensus-building process, has been used by this research team to actively develop and adapt study interventions. It uses an iterative, flexible schedule of face-to-face meetings combined with short, focused teleconferences. BCT emphasizes no wrong answers and no hierarchy of expertise. The process requires up to nine (9) hours of participant time over 3-6 months. Participants will be surveyed before and after the in-person session to assess learning outcomes and capture basic sociodemographic information.~The BCT process will define the format (mode and frequency) and content of messages to promote vaccine series completion. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings)."
224061172|NCT01664559|DRUG|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
224061173|NCT01664559|DRUG|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
224061174|NCT00864643|DRUG|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
224061175|NCT00864643|DRUG|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
224061176|NCT04168073|OTHER|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
224061177|NCT04168073|OTHER|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
224061178|NCT03334890|DIAGNOSTIC_TEST|plasma mSEPT9 level|the plasma level of methylated SEPT9
224147699|NCT01458496|BEHAVIORAL|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
224147700|NCT03119246|OTHER|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
224147701|NCT02866734|OTHER|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
224147702|NCT02866734|OTHER|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
223453196|NCT04242407|DRUG|Placebo|Matching patches that have no active drug applied before surgery and worn for 96 hours
223453197|NCT02792335|DRUG|apixaban|
223453198|NCT02792335|DRUG|dabigatran|
223453199|NCT02792335|DRUG|rivaroxaban|
223742390|NCT06453044|DRUG|Polatuzumab Vedotin|Given IV
223742391|NCT06453044|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224147703|NCT02866734|OTHER|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
224147704|NCT04263363|DRUG|Sugammadex 100 MG/ML [Bridion]|Sugammadex administered to patients within the clinical best practice pathway.
224147705|NCT03029858|OTHER|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
224147706|NCT03819764|BEHAVIORAL|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
224147707|NCT03819764|BEHAVIORAL|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
223742392|NCT06453044|OTHER|Questionnaire Administration|Ancillary Studies
224301439|NCT05476614|OTHER|Yoga (Robot-instructed)|Yoga that is instructed by a social robot
224301440|NCT05476614|OTHER|Yoga (Human-instructed)|Yoga that is instructed by a human
224301441|NCT05344248|BIOLOGICAL|JS005 (recombinant humanized monoclonal antibody against IL-17A)|Subcutaneous injection
224301442|NCT05344248|BIOLOGICAL|JS005 placebo|Subcutaneous injection
224301443|NCT06926998|DRUG|9MW2821+other anticancer therapy|Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol
224301444|NCT01295866|DEVICE|nasal nitric oxide|
224301445|NCT05102981|PROCEDURE|emergency procedure|The difference between groups is the timing or type ie emergency as opposed to planned
224301446|NCT05801965|DEVICE|A digital solution for patients with Cancer|A digital program that provides holistic lifestyle intervention as well as disease education.
223453200|NCT02792335|DRUG|warfarin|
223453201|NCT00565175|DRUG|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
223453202|NCT00565175|DRUG|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
223453203|NCT00134758|DRUG|Ursodeoxycholic acid|"During 2 years :~* between 40 and 50 kg : 500 mg/day~* between 51 and 75 kg : 750 mg/day~* between 76 and 100 kg : 1000 mg/day"
223453204|NCT00134758|DRUG|Placebo|"During 2 years :~* between 40 and 50 kg : 2 tabs/day~* between 51 and 75 kg : 3 tabs/day~* between 76 and 100 kg : 4 tabs/day"
223453205|NCT04891926|DIAGNOSTIC_TEST|ICIQ FLUTS Questionaires|Questionnaire observing the impact on voiding disfunctions
224061179|NCT00083031|DRUG|bevacizumab|
224061180|NCT00083031|DRUG|cyclophosphamide|
224061181|NCT00083031|DRUG|methotrexate|
224061182|NCT03569800|OTHER|self completed questionnaire|self completed questionnaire
224061183|NCT01509963|OTHER|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
224061184|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
224061185|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Zhifeilongkoma - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
224061186|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 5-dose program|Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
224061187|NCT06078423|BIOLOGICAL|Freeze-dried human rabies vaccine (MRC-5 cells) Kanghua - 4-dose program|Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
224061188|NCT00005832|DRUG|R115777|300mg/dose BID, PO, Days 1-21, q 28days
224061189|NCT01457209|OTHER|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
224061190|NCT02255409|BIOLOGICAL|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
224061191|NCT02255409|BIOLOGICAL|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
224061192|NCT03051360|DRUG|PCSK9 Inhibitor [EPC]|Patients will receive PCSK9 inhibitor by a biweekly injection
224301447|NCT05801965|OTHER|Standard of care for patients with Cancer|Standard of care includes medical treatment at Landspitali University Hospital, and optional cancer rehabilitation at the Ljósið Cancer Rehabilitation Center.
224301448|NCT03928158|DRUG|LCZ 696|50-100-200 mg tablet
223453206|NCT04891926|DIAGNOSTIC_TEST|Frequency Volume Chart|Frequency Volume Chart measures the voided volumes and fluid intake during 3 days in order to observe patients bladder capacity, total and nighttime voided volume and voiding frequency
223570706|NCT03537365|DIETARY_SUPPLEMENT|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
224061193|NCT03051360|DRUG|Placebos|Patients will receive Placebo by a biweekly injection
224061194|NCT01251367|BIOLOGICAL|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
224061195|NCT05505162|DRUG|Zibotentan|Participants will receive two capsules of Zibotentan orally QD from day 6-19.
224061196|NCT05505162|DRUG|EE/LNG|Participants will receive two tablets of EE and LNG once on Day 1 and Day 15 as a combined oral dose.
224061197|NCT01358409|DRUG|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
224301449|NCT03928158|DRUG|Valsartan|40-80-160 mg tablet
224301450|NCT03047473|BIOLOGICAL|avelumab|add on of avelumab 10mg/kg IV to standard therapy
224301451|NCT05468359|DRUG|Atezolizumab|Atezolizumab intravenously, every 3 weeks, Day 1
223570707|NCT02480166|DRUG|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
223570708|NCT02480166|DRUG|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
223570709|NCT03117374|BEHAVIORAL|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
223570710|NCT00530829|DRUG|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
223570711|NCT00998751|DRUG|oral masitinib|7.5 mg/kg/day
224301452|NCT05468359|DRUG|Sorafenib|Sorafenib by mouth every 12 hours, Days 1-21
224301453|NCT05468359|DRUG|Bevacizumab|Bevacizumab intravenously, every 3 weeks, Day 1
223570712|NCT04420572|DRUG|ozone injection|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
223570713|NCT04420572|DRUG|betamethasone|1ml betamethasone will be used for steroid injection.
223570714|NCT00422149|DRUG|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
223570715|NCT00422149|DRUG|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
224061198|NCT01833286|PROCEDURE|TACE+RFA|TACE first, followed by RFA within 2 months
224061199|NCT01833286|PROCEDURE|re-resection|repeat hepatectomy for recurrent small HCC
224301454|NCT05468359|DRUG|Cyclophosphamide|Low-dose cyclophosphamide by mouth once daily, Days 1-21
224301455|NCT05464667|RADIATION|Radiation Therapy (RT)|"Dose Escalation: 4 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 50 Gy in 5 fractions (Par 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)"
224301456|NCT02935686|BIOLOGICAL|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.
224061200|NCT03784976|OTHER|Iyengar Yoga Therapy|2 weekly yoga class (1.25 hours each)
224061201|NCT04839731|DRUG|Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream|Apply twice per day for allotted time
224061202|NCT04839731|DRUG|Nourivan Base Cream|Apply twice per day for allotted time
224061203|NCT00047060|OTHER|A matched peripheral donor stem cells|A matched peripheral donor stem cells
224061204|NCT00047060|DRUG|cyclosporine|cyclosporine
224061205|NCT00047060|DRUG|fludarabine|fludarabine
224061206|NCT00047060|DRUG|Campath|Campath
224061207|NCT01972750|DRUG|Dovitinib|daily oral intake of capsule
224061208|NCT05944315|BEHAVIORAL|Education session|Classroom Education session appropriate for elementary school children
224061209|NCT04067570|RADIATION|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
224061210|NCT01353820|DIETARY_SUPPLEMENT|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( \>10E8 to \<5.10E9 cfu/ml of L. delbruckii lactis )
223453207|NCT04891926|DIAGNOSTIC_TEST|Renal Function Profile|The RFP is a 24-hour urine analysis in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. This RFP was collected on a separated day to the FVC. Daytime samples were taken between 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The night-time samples were taken between 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8), and the volume of each interim void, was noted to calculate the 24h, daytime and night-time urine volume and diuresis rate. On each of this 8 samples, creatinine, osmolality, sodium and urea concentration were analysed. Subsequently, the renal clearance of creatinine, solutes, sodium and potassium (Usubst x Uflow / Psubst) and FWC (urine flow - solute clearance) were calculated.
223453208|NCT04891926|DIAGNOSTIC_TEST|Blood Analysis|Blood analysis in order to observ postmenopausal state, osmolalitity and sodium.
223570716|NCT00422149|DRUG|Placebo treatment|Placebo treatment
223742393|NCT04663607|BEHAVIORAL|Use of PretermConnect App|Participants will receive health education via a mobile app, PretermConnect, in addition to the standard of care, and complete additional surveys on the social determinants of health
224061211|NCT01353820|DIETARY_SUPPLEMENT|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
224061212|NCT02189213|DRUG|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
224147708|NCT04932044|BEHAVIORAL|Early Sleep Facilitation Program|It is divided into two stages. The first stage is to provide sleep circadian rhythm training for preterm infants during hospitalization, and the second stage is to give the caregiver the nursing guidance to promote preterm infants' sleep before preterm infants discharged from the hospital. Moreover, continue to give nursing guidance and follow its implementation status within two months after discharge.
224147709|NCT04932044|OTHER|Routine care|Receives routine care and provide general discharge care and nursing guidance.
223453209|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract|2 capsules, one dose
224061213|NCT03115307|DRUG|Triptorelin|Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
223570717|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
224061214|NCT04936295|DRUG|Fulvestrant plus Anlotinib|Each patient receives Fulvestrant (500mg delivered by intramuscular injection every 4 weeks) plus Anlotinib(20mg taken orally for 14 days and stop for 7 days in one cycle)
224061215|NCT04045288|BEHAVIORAL|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
223742394|NCT06368102|DRUG|Ampicillin|Total 2g vs 3g
224061216|NCT04045288|BEHAVIORAL|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
224061217|NCT01246440|DRUG|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
224061218|NCT03775421|DRUG|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
224061219|NCT03917823|DEVICE|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
224061220|NCT03917823|DEVICE|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
224061221|NCT02679898|OTHER|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
224147710|NCT03381209|DRUG|Sugammadex|sugammadex given based on 3 measurements of body weights
223453210|NCT04946526|DIETARY_SUPPLEMENT|Broccoli seed extract with mustard seed powder|2 capsules, one dose
224061222|NCT02679898|OTHER|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
224061223|NCT03257007|BEHAVIORAL|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
224301457|NCT02935686|BIOLOGICAL|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
224061224|NCT04703556|DEVICE|Devices for deep brain stimulation|Effect of DBS parameters (amplitude, frequency) on gait and balance deficits, and their dynamical evolution over a pre-defined time
224061225|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS (Interactive Voice Response System).
224061226|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
224061227|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS.
224061228|NCT00135668|DRUG|Nitroprusside|Study drug was infused via a dedicated peripheral intravenous catheter or via a dedicated lumen of a multi-orifice central venous catheter. Infusion pumps capable of reliable delivery at low infusion rates (to 0.1 mL/hr) were used.Study drug was dispensed to the sites in 2 mL vials containing 25 mg/mL of sodium nitroprusside. The pharmacist prepared and dispensed the study drug, and supplied blinded study drug for each subject according to a randomization assignment generated by the IVRS
224061229|NCT02016820|DRUG|Omeprazole (suspension)|1 mg/kg/day
224061230|NCT02016820|OTHER|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
224061231|NCT02445807|DRUG|DFD06-Cream|Twice daily topical application for 14 days.
224061232|NCT02445807|DRUG|Vehicle Cream|Twice daily topical application for 14 days.
224061233|NCT01342835|DRUG|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
224147711|NCT06213610|DRUG|Perindopril tablet|Perindopril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril tert-butylamine.
224301458|NCT02935686|BIOLOGICAL|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
223742395|NCT05882565|BEHAVIORAL|A brief (14-day) online mindfulness intervention|The content of the online mindfulness intervention is based on studies by Cavanagh et al. (2013, 2018). There is an approximately 10-minute audio tutorial that participants will listen to daily for 14 days. In the first week, participants will be instructed to apply their learned mindfulness skills to their daily activities. In the second week, they will continue practicing by learning to walk in a mindful manner.
224147712|NCT06213610|DRUG|Prestarium® A tablet|Prestarium® A is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine.
224301459|NCT02935686|OTHER|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
224301460|NCT02935686|BIOLOGICAL|gp140 HIV Bivalent Vaccine|gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
224301461|NCT06228794|OTHER|Peripheral blood test|We will draw 2-5 mL of peripheral blood and utilize multiparameter flow cytometry to measure the level of circulating plasma cells.
223453211|NCT03494049|PROCEDURE|Veil sparring HoLEP|"Early mucosal incision; lateral to the Veru and proximal to the apical bulge of the adenoma, followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
223453212|NCT03494049|PROCEDURE|Standard HoLEP|Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
223453213|NCT04125940|DIETARY_SUPPLEMENT|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
224301462|NCT06330194|DEVICE|2nd Generation Automated Insulin Delivery (AID) system|The AID system will initially commence delivery by insulin pump post-randomisation without the AID in operation and with predictive low glucose suspend activated for a period of two weeks. Once safety has been established, the autocorrect function can be activated and the setpoint reduced to 5.5 mmol/L. Throughout the study insulin pump uploads will be reviewed twice weekly initially and at least weekly thereafter.
223453214|NCT04125940|DIETARY_SUPPLEMENT|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
223453215|NCT04125940|OTHER|Placebo|12oz water + food coloring
223453216|NCT04040465|DRUG|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
224061234|NCT01227044|DRUG|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
224061235|NCT01227044|OTHER|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
224061236|NCT04304716|DRUG|Regional Anesthesia|Block performed is an indwelling wound bed or popliteal catheter placed intraoperatively
224061237|NCT01531309|DRUG|AGO178|AGO178 is administered as a sublingual tablet.
224061238|NCT02199938|OTHER|Identification and characterization of molecular markers in musculoskeletal tumors|
223453217|NCT00154843|DRUG|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
223453218|NCT02496741|DRUG|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
223453219|NCT03848793|DRUG|HS-20004|treatment
223453220|NCT04054674|PROCEDURE|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
223453221|NCT00651144|DRUG|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
223453222|NCT00651144|DRUG|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
223453223|NCT00651144|DRUG|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
223453224|NCT00651144|DRUG|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
223453225|NCT00683306|DRUG|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
223570718|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)|"The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)"
223453226|NCT04150120|DEVICE|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
223453227|NCT01682018|DEVICE|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
223453228|NCT03853291|BEHAVIORAL|PICT Workbook|PICT Workbook: The PICT workbook is a 31-page manual, which includes: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set. Participants in the intervention condition also attended four weekly 30-minute sessions with an interventionist through a combination of online (video observation) and telephone coaching to go over the Workbook.
223453229|NCT03853291|BEHAVIORAL|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
223453230|NCT05007171|DEVICE|Very low calorie diet|During 3 weeks in hospital patients will eat prepared very low calorie diet composed of 50-60% complex carbohydrates with low carbo-glycemic index, 20-25% proteins and 25-30% fat
224061239|NCT04474756|DEVICE|custom-made adjustable mandibular advancement device|a custom-made mandibular repositioning device (MRD), available under medical prescription for the treatment of adult obstructive sleep apnea (OSA) and snoring. It maintains the mandible in an advanced position along the occlusal plane. This ensures patient comfort and treatment efficacy.
224061240|NCT02343172|DRUG|HDM201|
224061241|NCT02343172|DRUG|LEE011|
224061242|NCT06240832|OTHER|Physical therapy exercise|Endurance, strength and stretching training in Chronic liver disease children
224061243|NCT00583362|BIOLOGICAL|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
224061244|NCT01455688|DRUG|early HAART|Initiation of HAART within 5 days of ICU admission
224061245|NCT01455688|DRUG|Late HAART|Initiation of HAART after ICU discharge
224061246|NCT00094978|DRUG|Depsipeptide|
224061247|NCT00094978|DRUG|Flavopiridol (alvocidib)|
224301463|NCT06383052|DRUG|177Lu-NYM032 injection|Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose.
224301464|NCT04100564|DEVICE|Supraglottic airway device|Initial advanced airway management with a supraglottic device
224301465|NCT04100564|OTHER|Standard airway management|Initial advanced airway management with standard care method
224061248|NCT06156956|PROCEDURE|Fecal Microbiota Transplantation|"Fecal Microbiota Transplantation in capsules or suspension obtained from healthy unrelated donor introduced two times per treatment:~for capsules - FMT administration: day 7 (full dose) and days from 9 to 14 (prolonged intake regimen)~for suspension - FMT administration: day 7 and day 14"
224061249|NCT00473343|DRUG|Metvix® cream|
224061250|NCT05234606|DRUG|SBT6290|Escalating doses by subcutaneous (SC) injection in 21-day cycles
224061251|NCT05234606|DRUG|SBT6290|Dose expansion with the recommended Phase 2 dose (RP2D) by SC injection in 21-day cycles
224061252|NCT05234606|DRUG|pembrolizumab|200 mg via intravenous (IV) injection in 21-day cycles
223453231|NCT03883477|DEVICE|Endoscopic Release|Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
223453232|NCT03883477|PROCEDURE|Standard Open Release|Standard open surgical release of the A1 pulley for treatment of trigger finger.
223453233|NCT03610880|DRUG|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
223453234|NCT03610880|DRUG|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
223453235|NCT02069106|DIETARY_SUPPLEMENT|Pro-Omega LDL|
223453236|NCT02069106|OTHER|Placebo|
223453237|NCT00777062|DRUG|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
223453238|NCT00777062|DRUG|Placebo|Placebo injection at the start of weeks 2 and 6.
223570719|NCT04418011|DEVICE|Repetitive Transcranial Magnetic Stimulation (Sham)|Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
223570720|NCT00096148|DRUG|idarubicin|Given IV
223570721|NCT00096148|DRUG|cytarabine|Given IV
223570722|NCT00096148|BIOLOGICAL|bevacizumab|Given IV
223570723|NCT00096148|OTHER|laboratory biomarker analysis|Correlative studies
223570724|NCT00457821|DRUG|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
223742396|NCT05882565|BEHAVIORAL|Psychoeducation online|"The online psychoeducation was modified from the study by Harrer et al (2019, 2021).~This intervention consists of 14 audio tutorials about stress for 14 days, each lasting approximately 10 minutes. Additionally, there is a text version of each audio tutorial, which can be accessed by participants after listening to the audio."
224061253|NCT02008682|DRUG|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
224061254|NCT02008682|DRUG|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
224061255|NCT00400673|BEHAVIORAL|Two-step remission induction and risk-oriented consolidation|
224061256|NCT04247061|OTHER|Educational video|One of two different 10 minute educational videos on smoking cessation will be viewed by participants during a dental cleaning visit. The video that is watched will depend on participants' level of motivation to quit and project needs
224061257|NCT04247061|OTHER|Text-message program|A one-month text message program to motivate and facilitate contact with smoking cessation resources.
224061258|NCT05782621|OTHER|Acupoint focused ultrasound|An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off
224061259|NCT05782621|OTHER|Laserpuncture|"The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min"
224061260|NCT05782621|OTHER|conventional treatment|the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
224061261|NCT05858619|DRUG|Dupilumab|dupilumab 600 mg injection initially and then 300 mg every other week
224071007|NCT01617278|DEVICE|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
223453239|NCT02073539|DEVICE|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
223453240|NCT02073539|DEVICE|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
223570725|NCT00457821|DRUG|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
223570726|NCT00457821|DRUG|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
223570727|NCT00457821|DRUG|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
223570728|NCT04894305|BIOLOGICAL|Ad26.COV2.S|Ad26.COV2.S will be administered as IM injection.
223570729|NCT03548506|DEVICE|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
223570730|NCT03548506|DEVICE|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
223570731|NCT01287390|PROCEDURE|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
223570732|NCT01287390|PROCEDURE|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
223570733|NCT01287390|OTHER|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
223570734|NCT01287390|OTHER|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
223453241|NCT01256099|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
224061262|NCT03961503|DRUG|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
224061263|NCT03961503|DRUG|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
224061264|NCT05107856|DRUG|PRT1419|PRT1419 will be administered by intravenous infusion
223453242|NCT01256099|BEHAVIORAL|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
223453243|NCT01256099|BEHAVIORAL|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
223453244|NCT04966819|OTHER|Survivorship Care Initiative|"The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs."
223453245|NCT03658642|BEHAVIORAL|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
223453246|NCT00098670|BIOLOGICAL|alemtuzumab|Given SC
223453247|NCT00098670|BIOLOGICAL|rituximab|Given IV
223453248|NCT00098670|DRUG|fludarabine phosphate|Given IV
223453249|NCT01397240|DRUG|Albis Tab|2 Tab, twice a day, 12 weeks
224061265|NCT05107856|DRUG|Azacitidine|Azacitidine will be administered by intravenous or subcutaneous
224061266|NCT05107856|DRUG|Venetoclax|Venetoclax will be administered orally
224061267|NCT02989831|DEVICE|Vibrating insoles 'on'|Duration: 30-60 seconds
224061268|NCT00345176|DIETARY_SUPPLEMENT|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
224061269|NCT00345176|DIETARY_SUPPLEMENT|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
224061270|NCT00345176|DRUG|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
224061271|NCT04452903|BEHAVIORAL|communication skills|3-hour communication skill workshop, followed by a month-long period to assimilate and implement the new set of skills, with supervision available by phone from the trainers.
223453250|NCT01397240|DRUG|Placebo|2 Tab, twice a day, 12 weeks
223453251|NCT06224686|OTHER|conventional dysphagia treatment|Conventional dysphagia treatment included oropharyngeal muscle movement training, orofacial alternating hot and cold stimulation, Masako swallowing training, Mendelsohn maneuver, therapeutic ingestion training, intermittent oral-esophageal tube feeding, and low-frequency electrical stimulation of swallowing neuromusculature, etc., 30 min each time, once a day for 14 consecutive days.
223453252|NCT06224686|OTHER|motor imagery based on action observation treatment|First, the therapist explained the purpose and principle of the intervention method to the patient, keeping the surrounding environment quiet and comfortable to avoid the patient's mood fluctuations due to external interference. Then start the treatment, the video recorded in advance was given to the patient to watch, the playback device is a ipad. The content includes lip and tongue muscle relaxation exercises, healthy people eating, chewing, swallowing, drinking and other images. At the same time, the guidance was played, which was consistent with the content in the video. The video was played 3 times consecutively for 30 min each time, once a day for 14 days.
223453253|NCT01187277|BEHAVIORAL|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
223453254|NCT01187277|DEVICE|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
223453255|NCT00232518|PROCEDURE|Infection with hookworm larvae|
223453256|NCT02137226|DRUG|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
223453257|NCT02137226|DRUG|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
223453258|NCT03290391|OTHER|Rapid ART initiation|The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
223453259|NCT03290391|DRUG|Pharmacotherapy for opioid use disorder|Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
223453260|NCT03290391|BEHAVIORAL|Strengths-based HIV case management|Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
223453261|NCT03762681|DRUG|RO7239958|Solution for injection, subcutaneous use (SC).
223453262|NCT03762681|OTHER|Placebo|Sodium chloride solution for injection, SC
223453263|NCT03732222|PROCEDURE|Stretching the diaphragm muscle|Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
224061272|NCT01886365|DEVICE|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
224061273|NCT01886365|OTHER|Conventional therapy with a fixed insulin dosing scheme|Routine care
224061274|NCT03359512|DEVICE|qCON monitor|supervision by qCON monitor of the depth of anesthesia
224061275|NCT00935480|DRUG|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
224061276|NCT00935480|DRUG|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
224061277|NCT00500630|DEVICE|Body fixed 3D sensors|
224061278|NCT01136655|DRUG|80/2.25 μg Symbicort pMDI|inhalation
224061279|NCT01136655|DRUG|80/4.5 μg Symbicort pMDI|inhalation
224061280|NCT01136655|DRUG|Foradil Aerolizer 12 μg|inhalation
224061281|NCT01136655|DRUG|40 μg budesonide HFA pMDI|inhalation
224061282|NCT01136655|DRUG|placebo HFA pMDI|inhalation
224061283|NCT02431572|OTHER|PBR PET|
224061284|NCT02431572|BIOLOGICAL|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
224061285|NCT02431572|RADIATION|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
224061286|NCT05435456|OTHER|Exercise|Strengthening and Relaxation Exercises
223570735|NCT01287390|OTHER|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
224061287|NCT04631146|DRUG|Camrelizumab|PD-1 inhibitors
224061288|NCT02491957|OTHER|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
223570736|NCT02885454|DRUG|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
223570737|NCT02885454|DRUG|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
224061289|NCT02031783|DIETARY_SUPPLEMENT|Mixture of glucose and fructose|
224061290|NCT02031783|DIETARY_SUPPLEMENT|glucose|
224301466|NCT02556372|DRUG|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation from 5mg up to 40mg depending on the monthly response.
224301467|NCT02934763|DRUG|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
224301468|NCT02934763|DRUG|Saline|Saline as placebo
223570738|NCT02885454|DRUG|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
223570739|NCT02885454|DRUG|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
223570740|NCT06601868|DIETARY_SUPPLEMENT|R-Support Prepare & After nutritional supplement|R-Support is a nutritional supplement containing proteins, Vitamine A, Vitamine B6, Vitamine B11, Vitamine B12, Vitamine C, Vitamine D3, Vitamine E, IJzer, Koper, Selenium, Zink, Magnesium, Omega-3 and Beta-glucanen.
223570741|NCT06605976|BEHAVIORAL|DAX CoPilot Group|Participants in this group were given a license for DAX CoPilot and asked to use it for clinical documentation.
223570742|NCT06521515|DIAGNOSTIC_TEST|Lung Ultrasound Morphology Patterns|Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
223570743|NCT06658210|OTHER|soft tissue mobilization with pelvic floor muscle exercises|Group A will receive soft tissue mobilization and pelvic floor muscle exercises. Soft tissue mobilization technique will include abdominal myofascial release/trigger point release and deep scar mobilization to decrease pain and improve scar mobility
223570744|NCT06658210|OTHER|soft tissue mobilization without pelvic floor muscle exercises|Group B will receive soft tissue mobilization technique without pelvic floor exercises.
223570745|NCT06662071|OTHER|Organoid culture|Organoid culture of tumor tissue obtained during patient surgery
223570746|NCT06661772|DIAGNOSTIC_TEST|Vancomycin trough concentration method|A blood sample for VTL was drawn 30 minutes before administration, prior to the fourth dose of vancomycin, under a complete aseptic technique, unless otherwise ordered by the medical team. Vancomycin serum concentrations were measured using a Human vancomycin ELISA Kit.
224061291|NCT02633410|PROCEDURE|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
224061292|NCT01115530|OTHER|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
224061293|NCT01115530|DIETARY_SUPPLEMENT|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
224061294|NCT06036342|DIAGNOSTIC_TEST|MobiCARE test|7-days continuous electrocardiography monitoring using MobiCARE device
224071008|NCT01617278|DEVICE|HD Colon|High definition white light
224071009|NCT01617278|DEVICE|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
223742397|NCT04930848|OTHER|Euphorbia hirta (Dudhiya)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
223742398|NCT04930848|OTHER|PBO(Combined powder of Terminalia arjuna and Terminalia bellerica)|Duration of the intervention was 2 consecutive weeks or 14 days. In each evening, one teaspoon full (3gm) powder should be mixed with two cups of water and boiled. When it becomes half(one cup), have to add one teaspoon of sugar and drink it as tea.
223742399|NCT04743505|DRUG|APL-101|-Provided by Apollomics
223453264|NCT03732222|PROCEDURE|Impulse technique in rotation of cervical level 3 and 4|head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
223453265|NCT03732222|PROCEDURE|Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4|"The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group."
223570747|NCT06659770|DRUG|Zevorcabtagene Autoleucel|Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
224071010|NCT05991856|PROCEDURE|radiofrequency ablation|The subjects is placed in a prone or lateral position under local anesthesia, and the electrodes are placed in the adrenal nodules under ultrasound guidance. A rapidly alternating radiofrequency current (300-500khz) generated around the electrode propagates through the adrenal nodules, causing resistance heating (Joule effect) and inducing cell death through coagulation necrosis. The choice of ablation time and frequency depends on the size, shape and location of the nodules within the adrenal gland.
224147713|NCT05847933|DEVICE|rTMS (cTBS 50Hz experiment)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
223570748|NCT04824768|DEVICE|Tecar Therapy|"CRet is a non-invasive diathermy technique that provides high frequency energy generating a thermal effect on soft tissues. Functional massage (FM) is a non-invasive manual therapy technique that combines rhythmical passive joint mobilization with compression of the muscular belly with the muscle-tendon insertions to be treated.~In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (80-100W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (100-120 W) on the hamstrings. Then a 5 min F.M with passive ankle dorsiflexion and CRet on resistive mode (110-120 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (180-250VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 8.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
223570749|NCT04824768|DEVICE|Sham Tecar Therapy|"In prone position, subjects will get a 7 min preparation massage with CRet on resistive mode (0 W), on the lumbar area, followed by a 5 min preparation massage with CRet on resistive mode (0 W) on the hamstrings. Then a 5 min FM with passive ankle dorsiflexion and CRet on resistive mode (0 W) will be performed on the gastrocnemius medialis and lateralis, followed by a 4 min FM with CRet on capacitive mode (0 VA) on the mentioned area.~In supine position, a 5 min FM with passive knee flexion and CRet on resistive mode 0.~A physiotherapist will monitor the temperature of the patient's treated area every 2 minutes"
223570750|NCT00223405|DEVICE|crown placement|
223742400|NCT04743505|DRUG|Osimertinib|-Given standard of care
223742401|NCT05821699|BEHAVIORAL|LCS (Life Care Specialist)|"The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination"
223742402|NCT05821699|BEHAVIORAL|Standard of Care|Patients will receive the current standard-of-care for pain management in the aftermath of surgery: a standardized prescription protocol, hospital-system approved discharge instructions which provide written instruction on how to taper opioid use, links to written/online resources for opioid misuse, overdose prevention, and State-approved disposal options.
223742403|NCT06501196|DRUG|BH-30236|BH-30236 will be provided as either a 5 mg, 15 mg or 30 mg tablet. Participants will take BH-30236 tablets orally depending on their dose level assignment.
224071011|NCT05991856|PROCEDURE|laparoscopic adrenalectomy|The subjects was placed in a lateral position under general anesthesia. Using harmonic scalpel carefully separates the adrenal vessels and lates them. The adipose tissue around the adrenal gland is dissected carefully, the surrounding tissue is bluntly separated, and the adrenal gland is fully exposed and dissected. After adrenalectomy was completed, hemostasis was rechecked and specimens were removed.
224071012|NCT05991856|DRUG|Hypotensive Drugs|All subjects in the study selected appropriate antihypertensive drugs based on factors such as blood pressure level.
224071013|NCT00005012|DRUG|Peginterferon alfa-2b|
224071014|NCT02078076|DEVICE|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
224071015|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
224071016|NCT01405261|DRUG|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
224071017|NCT01405261|DRUG|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
224071018|NCT01405261|DRUG|oral placebo|Subjects will be randomised to receive a single dose of placebo.
223453266|NCT03632070|BEHAVIORAL|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
223453267|NCT02650492|DEVICE|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
224061295|NCT04455880|OTHER|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity|SWE is a novel noninvasive dynamic ultrasound technique which refers to measurement for quantitative analysis of tissue elasticity. The stiffer the tissue, the higher shear wave velocity is measured. Elastographic examinations were performed by physicians using Samsung HS70A ultrasound system with a Samsung CA1-7A convex transducer and S-Shear wave technique. During the examination, patients were lying in supine position, breathing levels kept steady to prevent noise and artifacts and minimum pressure were applied on the transducer to eliminate misleading tissue compression. A region of interest (ROI) box of 10 × 10 mm was positioned on placenta and six measurements were obtained from central and peripheral zones of placenta while avoiding vascular structures
224061296|NCT05761028|DRUG|CM310|CM310 Recombinant Humanized Monoclonal Antibody Injection
224061297|NCT05761028|OTHER|Placebo|Placebo
224061298|NCT03938779|BEHAVIORAL|Pelvic Floor Muscle Training (PFMT)|PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
224061299|NCT03938779|DIAGNOSTIC_TEST|Pad test|Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
224061300|NCT05880446|OTHER|Bowel symptoms & QoL assessment|QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
223453268|NCT00635986|DRUG|Fentanyl|100 mcg Fentanyl intravenous or epidural route
223453269|NCT00230984|BEHAVIORAL|education|
223453270|NCT00230984|DRUG|Oral dietary supplements (563 kcal/d), RESPIFOR|
223453271|NCT00230984|BEHAVIORAL|exercises on an ergometric bicycle 3 to 5 times a week|
223453272|NCT00230984|DRUG|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
223453273|NCT03148067|PROCEDURE|Intramedullary nailing for fracture fixation|
223453274|NCT02934555|DRUG|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
223453275|NCT02934555|DIETARY_SUPPLEMENT|Ensure|50 mL Ensure
223570751|NCT06599255|PROCEDURE|US-guided RSB and TAPB by one-puncture technique.|The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al
223742404|NCT06501196|DRUG|Venetoclax|Venetoclax will be provided as 10 mg, 50 mg or 100 mg tablets. Participants will take venetoclax orally per label instructions.
223742405|NCT04540770|DRUG|HuL001|Anti-ENO1 monoclonal antibody
223453276|NCT03752060|BEHAVIORAL|Resistance Exercise|Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
223453277|NCT03752060|BEHAVIORAL|Aerobic Exercise|Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
223453278|NCT02583412|BIOLOGICAL|Bexsero®|Multicomponent meningococcal B vaccine
223453279|NCT02583412|BIOLOGICAL|Havrix®|Hepatitis A vaccine
223453280|NCT05202535|OTHER|Aerobic exercise training|"Hospital-based aerobic exercise training for 15-30 minutes including pre and post-vitals assessment.~3x/week on alternate days for 8 weeks at 40-70% of HR Max"
223453281|NCT05202535|OTHER|Conventional therapy|Patient education and counseling with diet plan.Walking 3 days15min/day for 8 weeks
223453282|NCT01330199|OTHER|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
223453283|NCT06443047|DEVICE|TTS suturing system|The use of TTS suturing system could allow a quick, complete endoscopic closure of colonic post-ESD defects, providing relevant clinical and medico-economic benefits.
223742406|NCT05041842|DRUG|Tucatinib|300 mg orally twice daily
223742407|NCT05041842|DRUG|Pertuzumab|Initial loading: 840 mg Maintenance: 420 mg, 3-weekly
224061301|NCT04650373|PROCEDURE|Bariateric surgery|Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
224061302|NCT00627887|PROCEDURE|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
224061303|NCT00627887|DRUG|venlafaxine|extended release target dose of 300mg/day duration of one year
224061304|NCT00627887|DRUG|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
224061305|NCT02752516|DRUG|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
224061306|NCT02555943|DRUG|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
223453284|NCT05420831|PROCEDURE|Vaginal|Sacrospinous hysteropexy using the synthetic mesh
223453285|NCT05420831|PROCEDURE|Laparoscopic|Laparoscopic Sacrohysteropexy
223453286|NCT01270360|DEVICE|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
223453287|NCT03052348|OTHER|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
223453288|NCT03052348|OTHER|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
223453289|NCT02698709|OTHER|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
224061307|NCT02555943|DRUG|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
224061308|NCT02555943|DRUG|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
224061309|NCT02555943|DRUG|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
224061310|NCT02555943|DRUG|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
224061311|NCT03953066|OTHER|The calculation of blood IL-6 and coloctral milk melatonin|Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
224061312|NCT03685539|PROCEDURE|Dual-Energy Computed Tomography|Undergo DECT
224061313|NCT04496401|DRUG|Tacrolimus and Tacrolimus Extended Release Oral Tablet [Envarsus]|"Phase 1: standard dose and frequency tacrolimus, used in accordance with licensing and local protocols. Suitable target trough level should be between 7-14 ng/ml.~Phase 2: ENVARSUS® (LCP Tacro - extended release tacrolimus), used once-daily at an initial dose of 0.17mg/kg, dose adjusted to maintain an appropriate therapeutic blood concentration (measured by trough level). Suitable target trough level should be between 7-14 ng/ml."
223453290|NCT04229771|DRUG|Proparacaine Hydrochloride ophthalmic solution, USP 0.5%|One drop instilled in one eye, randomly chosen, as topical anesthetic
223453291|NCT04229771|DRUG|Balanced salt solution|One drop instilled in one eye, randomly chosen, as control placebo
223453292|NCT02736708|DEVICE|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
223453293|NCT03070756|DEVICE|Minimal-Intervention - Specification of device settings|\- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration \<=15 min, softPAP Level is selected based on patient comfort
223453294|NCT00250809|PROCEDURE|Placement of a central venous catheter|Placement of a central venous catheter
223453295|NCT03210051|DEVICE|Remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
223453296|NCT03210051|PROCEDURE|Endovascular treatment|Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
223453297|NCT05305989|DRUG|Belumosudil 200 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
223453298|NCT05305989|DRUG|Belumosudil 200 mg BID|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
223570752|NCT06599255|PROCEDURE|multipont|", the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution."
223570753|NCT06600282|DRUG|Parecoxib|Pharmacokinetic study under fasting conditions
223570754|NCT06601647|PROCEDURE|adjuvant type|ropivacaine combined with adjuvant
223570755|NCT06608251|DIAGNOSTIC_TEST|white matter lesion|According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
223570756|NCT06608654|DEVICE|endoscope application|Intrauterine bronchoscopy application for fetal distress during labor
223570757|NCT06606392|DEVICE|Biodex balance system|The Biodex Balance System has a wide range of clinical applications and provides objective measures from testing that can be used to establish progressions and discharge criteria, as well as be part of a comprehensive Fall Risk Assessment or Fall Screening Program. Balance ability can be assessed either statically or dynamically, as well as bilaterally and unilaterally. It also allows for bilateral comparisons between involved and uninvolved limbs.
223570758|NCT06606392|OTHER|Short Foot Exercise|Short foot exercise is used as a therapeutic exercise to strengthen intrinsic foot muscles and used as training to create an MLA. It helps improve the balance in functional movement of FF subjects, decreases navicular drop (ND) through intrinsic muscle activation, supports navicular stability, and improves balance
224061314|NCT03518593|OTHER|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
224061315|NCT00768521|DRUG|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
224061316|NCT00768521|DRUG|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
223453299|NCT05305989|DRUG|Belumosudil 400 mg QD|Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
223453300|NCT00275665|DRUG|Valganciclovir|
223453301|NCT02305524|DEVICE|ETView VivaSight SL|Intubation using ETView VivaSight SL
223453302|NCT02305524|DEVICE|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
224147714|NCT05847933|DEVICE|rTMS (cTBS sham)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 0%~* Location: consecutively on the left and right temporo-occipital cortex (MNI coordinates: left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
223453303|NCT00182533|DRUG|Sertraline|25 - 200 mg/day x 16 weeks
223453304|NCT00182533|DRUG|Placebo|25 - 200 mg/day x 16 weeks
224061317|NCT06476522|OTHER|Physiotherapy Program|In the first evaluation, 5 different exercises were shown and the patients were asked to do home exercises in accordance with the given program. The physiotherapist suggested starting with a 10-minute walk 5 times a week and then gradually increasing the walking time. The patients were given a program for balance and sensory training. They were asked to apply the physiotherapy program at least 3 days a week for 12 weeks. Weekly follow-up of the patients was carried out by the physiotherapist over the phone or face to face when they underwent routine treatment.
224061318|NCT06476522|OTHER|To Inform|The patients were informed that they would be evaluated by the physiotherapist when they came to the routine doctor's control in the first week and at the end of the 12 weeks. At the end of 12 weeks, these patients were also given home-based exercise program advice.
224061319|NCT02287623|DRUG|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
224301469|NCT02884349|PROCEDURE|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
224301470|NCT03592342|DRUG|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
223570759|NCT06606964|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
224061320|NCT02287623|DRUG|bupivacaine|patients will receive a tap with bupivacaine
223570760|NCT06606964|OTHER|Isokinetic Strength|The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
223570761|NCT06607601|DRUG|Palbociclib|Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis
223570762|NCT06607601|DRUG|Letrozole|Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
223570763|NCT06608329|DRUG|HDM1002|Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
223570764|NCT06608680|BEHAVIORAL|iTBS|Excitatory stimulation of supramarginal gyrus
223570765|NCT06608680|BEHAVIORAL|cTBS|Inhibitory stimulation to supramarginal gyrus
223570766|NCT06608680|BEHAVIORAL|Sham Stimulation|Sham stimulation of supramarginal gyrus
223570767|NCT00499330|PROCEDURE|lobectomy|
223570768|NCT00499330|PROCEDURE|segmentectomy or wedge resection|
223570769|NCT06607328|OTHER|Assessment of participants in terms of different aspects.|This group was composed of individuals who have the prehypertensive stage.
223570770|NCT06607861|DRUG|saline group|nebulization of 4 mL 0.9% saline twice daily
223570771|NCT06607861|DRUG|dexmedetomidine group|nebulization of 1 µg/kg dexmedetomidine diluted in 4 mL 0.9% saline twice daily
223570772|NCT06607861|DRUG|lidocaine group|bilateral nebulization (60 mg) using a mucosal atomization device twice daily
223570773|NCT06608628|OTHER|Experimental Group|The experimental group students will play a patient safety escape room game. Control group students will be given traditional education. The knowledge level and team cooperation of the two groups will be compared.
223570774|NCT06602388|OTHER|Biological sampling|Collection of biological samples from healthy volunteers: Stool, urine, saliva, buccal swab, nasal swab, superficial skin swab, hair
223570775|NCT06606977|OTHER|Training|"During the detraining period, the athletes did not follow any external (personal) trainer-supported training program and their diet was not altered. Athletes have reported that they have stayed at home as a necessity of the Covid-19 pandemic process, and have done simple home exercises, walking and jogging exercises in a limited way during this time.~The training period included the standard wrestling trainings, which were determined by the national team coaches and realized at different intensities, during the 8 weeks when the training started. Following the period of detraining the level of training intensity was progressively increased throughout the initial 5 weeks. In the 6th and 7th week, training intensity peaked . In the 8th week prior to the competition, the training intensity was reduced in order to prepare and recover for the following competition. After the training period, the wrestlers participated in an international competition."
224061321|NCT02755311|PROCEDURE|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
224301471|NCT01917864|BEHAVIORAL|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
224061322|NCT02755311|PROCEDURE|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
224061323|NCT02755311|DRUG|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
224061324|NCT02755311|DRUG|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
224147715|NCT05847933|DEVICE|rTMS (cTBS 50 Hz active control)|"rTMS using cTBS protocol with the following characteristics:~* Frequency: trains of 50 Hz (3 pulses) every 200ms (frequency of 5 Hz, in the range of theta band)~* Intensity: 80% of resting motor threshold (rMT)~* Location: Right superior frontal cortex~* Duration: 40 seconds for each hemisphere, 80 seconds in total.~* Timing: Immediately before viewing pictures in pictorial memory task (off-line)"
224147716|NCT05847933|DEVICE|rTMS (high frequency)|"rTMS using high frequency protocol with the following characteristics:~* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
223453305|NCT03438864|DEVICE|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
223453306|NCT03438864|OTHER|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
223453307|NCT03162328|DEVICE|PowerSleep Stim|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
223453308|NCT03162328|DEVICE|PowerSleep Sham|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
223453309|NCT05916365|BIOLOGICAL|Lebrikizumab|Lebrikizumab solution for injection administered subcutaneously
223453310|NCT06011824|OTHER|Blood draw|10-12mL of blood will be drawn one time, unless a redraw is needed, in which case up to 24 mL will be drawn (10-12 mL each draw)
223453311|NCT06810167|DRUG|Tenapanor|CF patients with CFrC will ingest one 50 mg tablet of tenapanor twice daily for 4 weeks.
223453312|NCT06650566|DRUG|LM-299|Q2W/Q3W,Intravenous Drip
223453313|NCT04369599|DEVICE|V/Q System|With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
223453314|NCT05000866|BEHAVIORAL|Communication skills training video|The communication skills training video component is designed to be self-delivered. Four couples are depicted in separate scenes discussing HIV testing, drug use, sexual agreements, and drug use during sex. Each scene is viewed twice. In the initial viewing, the couple in the video makes one or more communication errors. The scene is subsequently viewed a second time and the couple utilizes more effective communication skills, resulting in a more adaptive resolution. Each scene is introduced by a narrator who points out communication errors and orients viewers to skills utilized in adaptive versions of each scene.
223453315|NCT05000866|BEHAVIORAL|Drug use module|The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
223453316|NCT06384235|DRUG|LTC004|LTC004,45μg/kg,IV,Day 1,Q3W;
223570776|NCT04611425|DRUG|Remimazolam|Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
223570777|NCT06592014|DIETARY_SUPPLEMENT|Lithium aspartate|Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
224061325|NCT02755311|DRUG|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
224147717|NCT05847933|DEVICE|rTMS (low frequency)|"rTMS using Low frequency protocol with the following characteristics:~* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: temporo-occipital cortex of dominant brain hemisphere (MNI left hemisphere: -50, -72, 4; right hemisphere:50, -66, 0)~* Duration: 30 minutes, continuously~* Timing: Starting 10 minutes before and continuing during the picture viewing and valence rating of the pictures of the memory task (on-line)."
223453317|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
223453318|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
223453319|NCT00693615|BIOLOGICAL|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
223570778|NCT00160017|BEHAVIORAL|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
224061326|NCT02755311|OTHER|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
224061327|NCT03982004|DEVICE|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
224061328|NCT03982004|DRUG|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
223453320|NCT00003513|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223453321|NCT06007937|DRUG|Lorlatinib|Lorlatinib 100 mg orally daily
223570779|NCT06594042|DIAGNOSTIC_TEST|serum preptin|serum preptin level in chronic kidney disease
224305093|NCT04796779|DEVICE|Tandem t:slim X2 with Control-IQ Technology V1.5|"The Tandem t:slim X2 with Control-IQ Technology V1.5 is an artificial pancreas (AP) application that uses advanced closed loop control algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to keep blood glucose in a targeted range. The system components include the t:slim X2 with Control-IQ Technology and the Dexcom G6 CGM. The system is derived from the commercially available t:slim X2 with Control-IQ, with additional features."
223570780|NCT05596487|OTHER|repetitive standardized patient simulation|In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
223453322|NCT06007937|DRUG|Ramucirumab|Ramucirumab 10 mg/kg intravenous infusion once every three weeks is a tolerable and safe dose.
223453323|NCT05880173|DIAGNOSTIC_TEST|FIB4|"Diagnostic procedure :~FIB4 blood tests in medical analysis laboratories. If FIB4 positive, Non invasive spacialized evaluation (transient elastography and FibroMeter) by a specialist and if necessery liver biopsy, endoscopy and/or echography"
223453324|NCT05584878|OTHER|Curodont repair Self- assembling peptide P11-4|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont
223453325|NCT05584878|OTHER|Ph-chi phosphorylated - nano-chitosan|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan
223453326|NCT05584878|OTHER|"CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate"|The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
223453327|NCT04746365|DRUG|ivermectin|ivermectin is anthelmintic
223570781|NCT01632241|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
223570782|NCT01632241|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
223570783|NCT01632241|DRUG|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
223570784|NCT03296137|BIOLOGICAL|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
223570785|NCT03296137|DRUG|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
223570786|NCT03296137|DRUG|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
223570787|NCT03296137|DRUG|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
223570788|NCT03296137|DRUG|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
223570789|NCT03296137|DRUG|Fludara|5 doses (25 mg/m2) prior to TIL infusion
223570790|NCT06183372|DIETARY_SUPPLEMENT|Lemon balm|300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
223570791|NCT06183372|DIETARY_SUPPLEMENT|Placebo|300mg Maltodextrin capsules
223570792|NCT06611345|DEVICE|Tumor Treating Fields|Tumor treating fields will be used each day.
223570793|NCT06611345|DRUG|Durvalumab|Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
223570794|NCT06611345|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
223742408|NCT05041842|DRUG|Trastuzumab|"Intravenous formulation :~Initial loading: 8 mg/kg Maintenance: 6 mg/kg, 3-weekly~Subcutaneous formulation:~600 mg (fixed dose regardless of patient's body weight), 3-weekly"
224061329|NCT03982004|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion
224061330|NCT03982004|OTHER|Dermatologic Quality of Life Index|"* 10 questions about how much skin problems has affected the participant's life over the past week~* The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~* The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
224061331|NCT03982004|OTHER|Functional Assessment of Cancer Therapy|"* 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~* Answers ranging from 0=Not at all to 4 = very much~* Each item is rated on a 5-point Likert scale.~* The higher the score on the social/family well-being and functional well-being indicate higher quality of life~* The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
224061332|NCT03982004|DRUG|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
223453328|NCT04746365|DRUG|hydroxychloroquine|hydroxychloroquine is antimalarial.
223453329|NCT04746365|DRUG|Placebo|Standard treatments
224061333|NCT03982004|DEVICE|Cry-AC|-Device used to give the cryoimmunotherapy
223453333|NCT02261103|DRUG|Pramipexole ER tablets|
224061334|NCT03982004|PROCEDURE|Cutaneous tumor biopsy|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
224061335|NCT03982004|PROCEDURE|Peripheral blood draw for research|-Baseline, week 3 (prior to 1st dose of pembrolizumab), week 9, and at week 18. An optional biopsy can be obtained at the time of disease progression.
224061336|NCT06471400|OTHER|interview|patient relatives or legal authorized representatives will be interviewed
224061337|NCT01131377|DRUG|acetazolamide|"If ABGA is pH ≥ 7.43 \& HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
224061338|NCT01131377|DRUG|Saline|They will receive saline 50ml via IV q 24h.
224061339|NCT02048618|DRUG|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
224061340|NCT02048618|DRUG|Placebo|placebo oral tablets, intake once daily for 20 weeks
224061341|NCT04570501|DRUG|Angiotensin-(1-7)|Ang (1-7) administered by continuous intravenous (IV) infusion
224061342|NCT04570501|DRUG|Placebo|Placebo (normal saline) administered by continuous intravenous (IV) infusion
224061343|NCT04599283|DEVICE|MenHealth Uroflowmeter|MenHealth Uroflowmeter is a mobile application and FDA cleared medical device that analyzes the sound of urine hitting the toilet water when a male urinates and generates voiding data (maximum flow, average flow, and voided volume) and a flow curve. All test results are saved in an automated voiding diary.
224061344|NCT03182270|DIAGNOSTIC_TEST|nCLE|Procedure: EUS-FNA Device: nCLE
224147718|NCT05847933|DEVICE|rTMS (high frequency sham)|"* Frequency: 20 Hz~* Intensity: 10% of MSO~* Location: temporo-occipital cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
224147719|NCT05847933|DEVICE|rTMS (high frequency active control)|"* Frequency: 20 Hz~* Intensity: 120% of rMT for rMT \< 54% \& 65% of MSO for rMT ≥ 54%~* Location: right superior frontal cortex of the dominant brain hemisphere~* Duration: 20 minutes, continuously~* Timing: During the pictorial memory task (on-line) 1 second stimulation and 14 seconds inter-train interval for 76 trains resulting in a total of 1520 pulses."
224147720|NCT05847933|DEVICE|rTMS (low frequency active control )|"* Frequency: 1 Hz~* Intensity: 110% of rMT~* Location: Right superior frontal cortex of the dominant brain hemisphere~* Duration: 6 minutes~* Timing: Starting 1 minutes before and continuing during the memory task (Online)"
224147721|NCT05847933|DEVICE|rTMS ( cTBS 30 Hz active control)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on right superior frontal cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
224304953|NCT05673330|OTHER|Spinal Mobilizations|"1. Headache SNAG: A posteroanterior mobilization of the second cervical vertebrae is sustained for 10 to 30 s with the aim to reduce headache intensity at the time of application. (6)~2. Maitland's C1-C7 PA Glide: A posteroanterior (PA) mobilization of the first till seventh cervical vertebra is achieved by applying a force on to a vertebral segment in a posteroanterior direction (Back to front).~The patients will receive Spinal Mobilizations consisting of 1 set of 6 repetitions once daily thrice per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks"
223453334|NCT02261103|DRUG|Pramipexole IR tablets|
223453335|NCT02261103|DRUG|Placebo matching Pramipexole ER tablets|
223453336|NCT02261103|DRUG|Placebo matching Pramipexole IR tablets|
224061345|NCT02126033|PROCEDURE|take blood samples|
224061346|NCT02870309|BIOLOGICAL|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
223453337|NCT02261103|OTHER|Standard high-fat breakfast|
223453338|NCT01685385|OTHER|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
223453339|NCT06513975|DEVICE|CART BP|A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
223453340|NCT06513975|DEVICE|sphygmomanometer|Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
223453341|NCT06613178|DRUG|acetaminophen|Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
224061347|NCT02227680|OTHER|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
224061348|NCT02227680|OTHER|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
224061349|NCT01505790|DRUG|PRASUGREL|60 mg the first day then 10 mg per day during one month
224061350|NCT01505790|DRUG|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP \<50%. No more than 3 \* 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
224061351|NCT00793260|BEHAVIORAL|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
224061352|NCT00793260|BEHAVIORAL|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
224061353|NCT05252364|DRUG|HP518 - Dose Escalation|"Part 1: Dose escalation~Daily oral dosage with the prescribed dose level based on Cohort assignment."
224061354|NCT05252364|DRUG|HP518 - Dose expansion|"Part 2: Dose expansion~Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1."
224061355|NCT00455013|DRUG|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
224061356|NCT00455013|DRUG|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
224061357|NCT00455013|DRUG|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
224061358|NCT00455013|DRUG|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
224061359|NCT00455013|DRUG|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
224061360|NCT00263029|DRUG|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
224061361|NCT00263029|DRUG|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
224061362|NCT00263029|RADIATION|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
224061363|NCT05295004|BEHAVIORAL|Mindfulness Meditation Training|Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
223453342|NCT05150782|DIETARY_SUPPLEMENT|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
223453343|NCT06337292|DEVICE|Incisional Negative Pressure Wound Therapy (NPWT)|Participants in the treatment group will be standardized and will receive incisional NPWT using the any incisional VAC system that can apply 75-125mmHg continuous suction to the incision. The VAC sponge will be placed over the surgical wound at least 2cm in width and \>3cm in length.
223570795|NCT06611345|DRUG|Cisplatin|Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
223453344|NCT00792116|BEHAVIORAL|Gum Chewing|
223453345|NCT00492232|DRUG|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
223453346|NCT00492232|DRUG|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
223453347|NCT07015307|BEHAVIORAL|Sustainable Diet Program|Intervention based on the Mediterranean sustainable diet. It emphasizes the consumption of fish, fruits, and vegetables, while reducing the intake of meat and meat-derived products. The diet is tailored to the participants' health status, activity level, and nutritional requirements, following the recommendations of the Spanish Society of Cardiology and Endocrinology. Macronutrient and micronutrient goals follow national guidelines and are tracked using specialized dietary software.
223453348|NCT07015307|BEHAVIORAL|Supervised Physical Exercise Program|A 12-week supervised physical exercise program led by certified professionals in Sport Sciences. Exercise prescriptions are tailored individually based on baseline assessments and international guidelines from fields such as cardiology and metabolism. The sessions may include strength, endurance, or combined training. In the supervised period, the instructor guides the sessions, while during the unsupervised period, exercises are followed via an online platform that provides detailed explanations and graphics.
223570796|NCT06661382|BIOLOGICAL|Infiltrative treatment with CB-PRP|Injection of CB-PRP or placebo into the vulvar site. Three treatments are planned four weeks apart. Three and six months after the last treatment with CB-PRP/ placebo each participant will be re-evaluated by vulvoscopy and biopsy, and will be given validated questionnaires to assess satisfaction, symptoms, and quality of life, psychological state, and sexual function.
223570797|NCT06657859|DRUG|GLM101|GLM101 IV infusion
224061364|NCT06086093|DIETARY_SUPPLEMENT|RespireAid TM/placebo|"Direction: Take 1 sachet(5g) 4 times daily~Indication: Externally contracted seasonal epidemic~Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm"
224061365|NCT04901481|DEVICE|Empower Neuromodulation System|Peripheral nerve stimulation with the Empower device. The active and sham treatments only differ by the location of application on the body.
224061366|NCT03792815|DRUG|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
224061367|NCT03792815|DRUG|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
224061368|NCT03792815|DRUG|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
224061369|NCT00503646|OTHER|communication intervention|
223570798|NCT06110715|OTHER|theta tACS stimulation|The low intensity transcranial electrical stimulation will be administered with a battery-powered, current-controlled, multi-channel stimulator from Neuroelectrics® Starstim 8. This device comes with a neoprene headcap to hold the electrodes in place. TACS will be delivered concurrently with the task. The multichannel, current-driven stimulator (Neuroelectrics StarStim 8) will be used to control independent stimulation electrodes on the scalp of the volunteer. The stimulation intensity will be up to 2 mA.
224061370|NCT00503646|OTHER|counseling intervention|
224061371|NCT00503646|OTHER|questionnaire administration|
224061372|NCT00503646|PROCEDURE|psychosocial assessment and care|
224301472|NCT06433635|DRUG|Cariprazine|"1. Cariprazine monotherapy outperformed placebo in improving depressive symptoms in most large randomized control trials (RCT). Pooled data showed higher remission rates (30.2%) with cariprazine (1.5 mg and 3 mg/day) compared to placebo (20.9%). Its efficacy extends to bipolar I depression, including mixed features and anxiety.~2. Common adverse effects include nausea (8%) and akathisia (7%). Somnolence and sedation were slightly more common with cariprazine than placebo.~3. Results from a large RCT evaluating cariprazine for bipolar disorder maintenance treatment (NCT03573297) are awaited. An open-label trial reported reduced manic symptoms over 16 weeks.~4. Cariprazine is a D3-preferring partial agonist for D3 and D2 receptors. It antagonizes 5-HT2A and 5-HT2B receptors and partially agonizes 5-HT1A receptors. Affinity for 5-HT1C and histamine 1 receptors is low to moderate."
224301473|NCT06433635|DRUG|Aripiprazole/Escitalopram combination|"1. 40-70% of bipolar patients use antidepressants, often with antipsychotics or mood stabilizers. Aripiprazole lacks efficacy in bipolar depression but is used for mania. Escitalopram, studied alongside mood stabilizers, showed some efficacy.~2. Aripiprazole in bipolar depression trials led to higher rates of akathisia, insomnia, nausea, fatigue, and impulse control disorders. Escitalopram's is generally safe but adverse effects include nausea, diarrhea, insomnia, dry mouth, ejaculatory dysfunction and dizziness.~3. Aripiprazole monotherapy in bipolar I patients reduced relapse rates and delayed relapse time, but not for depressive episodes.~4. Aripiprazole acts as a partial agonist at D2, D3, 5-HT1A, and 5-HT2C receptors, with antagonistic effects on α1 and possibly H1 receptors. Escitalopram is highly selective for the serotonin transporter, with no significant activity at other receptors."
223453349|NCT07015307|BEHAVIORAL|Combined Sustainable Diet and Exercise Program|This experimental arm combines the dietary intervention based on the sustainable Mediterranean diet with the structured physical exercise program. Both components are personalized and adhere to national and international health and nutrition recommendations. The program includes a 12-week supervised phase and an unsupervised online phase, aiming to maximize improvements in metabolic, physical, and psychosocial health in older women with metabolic alterations.
223453350|NCT07017556|BEHAVIORAL|Views on Information Resources for Kidney Transplantation Patients|"A pilot study to improve kidney transplant patient education. The study explores whether videos help patients to better understand and remember important information regarding the benefits and risks of receiving a kidney transplant.~Currently, patients receive transplant information through written materials, and clinician discussions. However, not everyone has the same level of language literacy and medical understanding, which can lead to critical knowledge gaps, misunderstandings, and misinterpretations.~Patients may also not know about lifelong medication needs, and complications which may follow transplantation, such as diabetes, making patient education and understanding essential.~This study explores whether video materials helps patients feel more informed and satisfied with the clinical information they receive, and whether they can better retain this information. The investigators aim to support more informed patients, making transplant education clearer, and accessible."
223570799|NCT06110715|OTHER|sham tACS stimulation|A placebo control stimulation will use an identical montage to the stimulation montage. However, polarities of the electrodes will be such that only a minimal amount of current reaches the brain, which is achieved through controlled current shunting between neighboring electrodes. This so-called ActiSham protocol is a verified method to imitate the sensations of actual tACS, with minimal stimulation of the brain .
223570800|NCT01310543|BEHAVIORAL|Teens and Toddlers|The T\&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
223570801|NCT05131971|DRUG|GSK3888130B|GSK3888130B will be administered.
223570802|NCT05131971|DRUG|Placebo|Placebo will be administered.
224061373|NCT01271283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
224061374|NCT01271283|DRUG|Lenalidomide|Given orally
224061375|NCT02739620|DEVICE|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
224061376|NCT05069883|DRUG|Steroid Drug|In this group Oral steroid medication after Direct Vision Internal Urethrotomy
224061377|NCT05069883|DRUG|No steroid|In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
224061378|NCT03476941|DRUG|Gentamicin Sulfate Inj 20mg/2ml vial for injection|Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
224061379|NCT03476941|DRUG|Clindamycin phosphate 6 mg/1ml for injection|Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
224061380|NCT03476941|OTHER|Placebo|The placebo group will receive drain irrigation twice/day
224061381|NCT02341638|DRUG|BMS-986141|
224061382|NCT02341638|DRUG|Placebo|
224061383|NCT02341638|DRUG|Aspirin|
224061384|NCT02341638|DRUG|Itraconazole|
224061385|NCT01187186|DRUG|ASP1941|oral
224061386|NCT02905929|DEVICE|ActivPAL inclinometer|Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.
223453351|NCT06613321|DIAGNOSTIC_TEST|Respiratory function tests before introduction of vasodilator therapy|Respiratory function tests before introduction of vasodilator therapy with evaluation of the RV/TLC ratio.
223570803|NCT06609070|DRUG|CHG0521 Oral Coating|The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
224061387|NCT02905929|BEHAVIORAL|Phone counseling call: Breaking up sitting time|Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.
224061388|NCT02905929|BEHAVIORAL|In-person counseling: Breaking up sitting time|Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.
224061389|NCT02905929|BEHAVIORAL|Phone counseling call: Healthy living|Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
223570804|NCT06661447|PROCEDURE|Tridimensional Onlay autologous bone graft|A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
224061390|NCT02905929|OTHER|Tools to prompt standing|Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.
224061391|NCT02905929|BEHAVIORAL|In-person counseling: Healthy living|Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
224061392|NCT05270590|PROCEDURE|minimally invasive rheumatic mitral valve surgery|First, venous and arterial access was established. Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ). The thoracoscope was inserted. Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made. Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently. After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0. Weaning from bypass start
224061393|NCT03309085|PROCEDURE|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
224147722|NCT05847933|DEVICE|rTMS (cTBS 30 Hz)|"* Bilateral continuous theta burst stimulation (cTBS) 30 Hz:~* Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band)~* Intensity: 100% of resting motor threshold (rMT)~* Location: consecutively on left and right temporo-occipital cortex~* Duration: 33.3 seconds for each side~* Timing: Immediately before pictorial memory task (off-line)"
224147723|NCT06216587|DIETARY_SUPPLEMENT|BLa80|Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BLa80.
223453352|NCT06613321|DIAGNOSTIC_TEST|3 month follow up evaluation of response to treatment.|Follow up of patients at least 3 months after introduction of vasodilator therapy to determine response to treatment or absence of response.
223453353|NCT07022470|RADIATION|3-Fraction HDR Brachytherapy|8 Gy per fraction for 3 fractions (total 24 Gy) for patients with locally advanced cervical cancer, based on individualized planning.
223453354|NCT07022470|RADIATION|4-Fraction HDR Brachytherapy|7 Gy per fraction for 4 fractions (total 28 Gy) as the standard-of-care brachytherapy regimen.
223453355|NCT07022145|PROCEDURE|Endovascular repair|Endovascular repair using proximal stent-graft or proximal stent-graft combined with distal stent for TBAD patients
223453356|NCT07022314|DEVICE|FIZE kUO®|FIZE kUO® is a commercially available, non-invasive device used for continuous, minute-by-minute real-time urine output monitoring in patients with an indwelling Foley catheter. In this observational study, the device is used during and after cardiac surgery as part of routine clinical care. Urine output data, along with additional clinical parameters, are collected throughout the study for research analysis.
223453357|NCT07022626|PROCEDURE|CTCA|Computed Tomography Coronary Angiography (CTCA) performed prior to invasive coronary angiography (ICA)
223742409|NCT05041842|DRUG|Hormone therapy|Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
224061394|NCT03309085|DEVICE|CT scan|CT scan
224061395|NCT01737476|PROCEDURE|Transcranial Magnetic Stimulation. PFC|
224061396|NCT04400370|DEVICE|Diaphragm ultrasound|"Diaphragm ultrasound is performed at the following three time points.~1. At the entrance of the operating room before induction of anesthesia~2. 1 hour after surgery~3. 24 hours after surgery"
224061397|NCT01718561|PROCEDURE|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
224147724|NCT02137837|DRUG|Fulvestrant|
224147725|NCT02137837|DRUG|Anastrozole|
224147726|NCT02137837|DRUG|Everolimus|
224147727|NCT02137837|DRUG|Placebo - Anastrozole|
224147728|NCT02137837|DRUG|Placebo - Everolimus|
224147729|NCT02141217|DRUG|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
224147730|NCT02141217|DRUG|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
224147731|NCT02232594|DRUG|Berodual®|
224147732|NCT04806633|DRUG|Dapagliflozin 5mg|Patients randomized in this arm will receive dapagliflozin at a dose of 5mg once daily.
224147733|NCT04806633|DRUG|Placebo|Patients randomized in this arm will receive placebo.
224061398|NCT03990064|OTHER|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
224061399|NCT02577146|DEVICE|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
224061400|NCT05798676|OTHER|overweight/obesity|the consequences of maternal pregestational overweight/obesity on infant´s growth and adiposity will be studied
224061401|NCT01970501|DRUG|bucindolol hydrochloride|
224061402|NCT01970501|DRUG|metoprolol succinate|
224061403|NCT01970501|OTHER|Placebo oral capsule|
224061404|NCT06497348|OTHER|manual therapy and exercises (experimental group) or only exercises (control group) in people with frozen shoulder|They will be divided into two groups, one experimental (they will be mobilized and given exercises to see whether or not they gain joint range in the different movements of flexion-extension, abduction-adduction and internal rotation-external rotation) and another control group ( The patients will be blindly evaluated and they will be given the same exercises as the experimental group)
224061405|NCT04818736|BIOLOGICAL|COVID-19 Vaccination|Dose 1: 0.5 mL at Day 0 Dose 2: 0.5 mL at Day 28
224061406|NCT04818736|OTHER|Usual care|Participants can receive the COVID-19 whenever they are eligible according to local provincial guidelines.
224061407|NCT05818592|OTHER|Self-Pulse Monitoring|Participants will manually monitor pulse for irregularities.
224061408|NCT01361776|BIOLOGICAL|FSME-immune|0.5 ml im as scheduled in the 4 arms
224061409|NCT02354066|DEVICE|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
224061410|NCT02354066|DEVICE|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
224061411|NCT02354066|DEVICE|Retail Shoe|Brake response time measurement before surgery (control run)
224061412|NCT00554242|DIETARY_SUPPLEMENT|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
223570805|NCT06661447|PROCEDURE|Tridimensional Onlay xenogeneic bone graft|A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
224061413|NCT03019042|DIETARY_SUPPLEMENT|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
224061414|NCT03019042|OTHER|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
224061415|NCT06494696|DIAGNOSTIC_TEST|Ga-68 PSMA PET/MRI|The participant will undergo a Ga-68 PSMA PET/MRI scan, and then be followed up for 2 years to see if prostate cancer is diagnosed.
223570806|NCT06661447|PROCEDURE|Tridimensional Onlay allogenic bone graft|A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
223570807|NCT06608043|BEHAVIORAL|Reborn lifestyle adjustment program|"The sessions are based on the 'Do Live Well' model, Kolb's Experiential Learning Theory, and CBT-based problem-solving skills.~Introduction to the Reborn Lifestyle: Core principles of the Reborn Program for building a healthy lifestyle during and after breast cancer.~Physical Activity: The role of physical activity during treatment and exercises to boost energy levels.~Fatigue Management: Scientific methods for managing fatigue during and after treatment.~Pain Management: Effective techniques to reduce pain and improve quality of life.~Mental Health Burden: Strategies to alleviate mental health burdens and cope with stress.~Quality Sleep: Practical methods to improve sleep patterns and achieve quality rest.~Preventive Rehabilitation Approaches: Essential rehabilitation strategies to protect health and reduce recurrence risk.~The study will be conducted online, with evaluations and sessions via Zoom before and after the 12-week modules."
223570808|NCT06608043|PROCEDURE|Conventional Physiotherapy and Occupational Therapy|Patients in the control group will continue conventional medical treatments, occupational therapy and physiotherapy sessions.
224061416|NCT01972867|DEVICE|NanoKnife Procedure|Subjects will be placed in the dorsal lithotomy position, under sterile technique. The NanoKnife procedure will be carried out under general anesthesia. A Foley catheter will be placed to aid in draining the bladder during treatment.
224061417|NCT02971462|DEVICE|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
224061418|NCT04841421|DRUG|89Zr-CD147|The 89Zr-CD147 is a promising positron emission tomography probe and it is possible to select suitable tumor patients with CD147 expression to benefit from anti-CD147 treatment.
224061419|NCT04938583|BIOLOGICAL|Oregovomab|"Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg).~2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes"
224061420|NCT04938583|DRUG|Bevacizumab|15mg/Kg Day 1 (every 21 days) until progression
224061421|NCT04938583|DRUG|Paclitaxel|175 mg/m\^2, Day 1 x 6 cycles (every 21 days)
224061422|NCT04938583|DRUG|Carboplatin|AUC 5 IV Day 1 x 6 cycles (every 21 days)
224061423|NCT05512546|DRUG|Aspir-Low Pill|patients were prescribed 75 mg/day of either aspirin
224061424|NCT05335174|DEVICE|Device: HemoSphere monitor and Acumen IQ sensor.|Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
224061425|NCT05402475|BEHAVIORAL|CBT + Mindfulness|Eight weeks of online CBT intervention combined with mindfulness
224061426|NCT01848184|DEVICE|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
224061427|NCT04206748|DEVICE|iGlucose Smart Meter System|Subjects will have routine care enhanced by use of theThe iGlucose Smart meter system. This is an example of integration of a SMBG system with internet-based technology; including cell phone notifications for reminders, feedback, and communication with clinicians
224061428|NCT04206748|DEVICE|Routine Care-RX meter|Subjects will receive routine care with the insurance prescribed glucose meter. They will self manage with traditional diabetes diary.
224061429|NCT06972641|DRUG|Decitabine|Decitabine 3.5 mg/m2 1-5d for 28 days for 6 cycles of dosing
224061430|NCT06972641|DRUG|Sorafenib (BAY-43-9006)，giritinib|Sorafenib 0.2g 2/day or giritinib 40mg 2/day orally for 2 years
224061431|NCT06972641|DRUG|Avastinib|100 mg 1/day
224061432|NCT06972641|DRUG|Venetoclax;Selenisol|Vinaclat: 50-100mg 1/day orally, d1-14 1/day per month (adjust drug dosage based on blood levels), 28-day cycle; Selenisol: 20mg qw orally (weeks 1 and 2), 28-day cycle If the above treatment is not tolerated, adjust the regimen to decitabine 3.5 mg/m2 1-5 d; 28 days as a cycle of 6 cycles of medication; Vinaclat: 50-100 mg 1/day orally, d1-14 1/day per month orally (adjust the dose of the drug according to the blood concentration), 28 days as a cycle of medication
223570809|NCT06607068|OTHER|None (Observational study)|None (Observational study)
223570810|NCT05403593|OTHER|No Intervention|No intervention, prospective data collection
223570811|NCT04088435|RADIATION|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
223570812|NCT00813605|OTHER|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
224061433|NCT05619510|BEHAVIORAL|PRIME Intervention|Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
224061434|NCT01403818|DRUG|ASP1941|oral
224061435|NCT01403818|DRUG|Mitiglinide calcium hydrate|oral
224061436|NCT05478798|OTHER|ultrasonographic fetal weight estimation|An ultrasonographic estimate will be performed in our ultrasound unit and a calculation by the ultrasound machine is based on Hadlock's formula including measurement of biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL).
224061437|NCT05478798|OTHER|clinical fetal weight estimation|A clinical weight estimate will be performed by using Leopold's maneuvers
224061438|NCT05478798|OTHER|maternal subjective fetal weight estimation|the pregnant woman will tell her subjective estimation of fetal weight estimation
223453358|NCT07022613|OTHER|Mindfulness-Based Stress Reduction Program|"The Mindfulness-Based Stress Reduction (MBSR) program is considered to offer healthcare professionals working under high levels of stress the opportunity to develop knowledge and skills in consciously recognizing their emotions, compassionately accepting painful feelings without suppression, and transforming negative thoughts and emotions into more constructive ones.~In the first and last sessions, the Perceived Stress Scale (PSS), the Mindful Attention Awareness Scale (MAAS), the Self-Compassion Scale (SCS), and the Visual Analog Scale (VAS) will be administered, and saliva samples will be collected.~In the remaining sessions, only the VAS-one of the stress measurement parameters-will be verbally administered. In this way, participants will be informed weekly about the progression of their stress levels.~The program to be implemented in the study will consist of weekly sessions held over eight weeks. Each session will be conducted for groups of 10 participants, three consecutive days"
223453359|NCT07021417|BEHAVIORAL|Workshop|includes a single 4-hour session
223570813|NCT00813605|BIOLOGICAL|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
223570814|NCT00813605|OTHER|Placebo|Inactive dummy agent (to maintain blind)
223570815|NCT00813605|BIOLOGICAL|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
223570816|NCT03836833|DRUG|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
223742410|NCT05041842|DRUG|Pertuzumab/ Trastuzumab|"Initial loading:~1200 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight)~Maintenance:~600 mg Pertuzumab / 600 mg Trastuzumab (regardless of body weight), 3-weekly"
224061439|NCT04918277|DEVICE|Assessment of gastric volume|Measuring the cross-sectional area of stomach in supine and right lateral decubitus
224061440|NCT01439555|DRUG|Simvastatin|Simvastatin, 40 mg per day orally
224061441|NCT01439555|DRUG|L-Arginine|L-Arginine, 2 Gm four times per day orally;
224061442|NCT01439555|DRUG|Tetrahydrobiopterin|Tetrahydrobiopterin 20 mg/kg/day orally
224061443|NCT06369103|DRUG|Dexmedetomidine|Patients will receive dexmedetomidine at a dose of 0.5-1.0 mcg/kg over 5-10 minutes, then a maintenance infusion rate of 0.2-0.5 mcg/kg/min when the bispectral index (BIS) value is between 70 and 80.
224061444|NCT06369103|DRUG|Propofol|Patients will receive propofol at a dose of 0.25-0.5 mg/kg over 5-10 minutes, then a maintenance Infusion rate of 0.5-2 mg/kg/hr when the bispectral index (BIS) value is between 70 and 80.
224061445|NCT00777777|DEVICE|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
224061446|NCT02589691|DRUG|Rocuronium|
224061447|NCT02589691|OTHER|Sodium chloride 0.9%|
224061448|NCT00553709|DRUG|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
224061449|NCT05970874|DEVICE|Hand grip strength measureme|Hand grip strength (HSG) was measured in kg with the CAMRY Digital Hand Dynamometer (Model No. EH101, CAMRY).
224061450|NCT06977763|DRUG|succinylated gelatin injection 1|Nanjing Chia-Tai Tianqing Pharmaceutical Company
224061451|NCT06977763|DRUG|succinylated gelatin injection|Gelofusine
224061452|NCT06977399|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of liver cancer|The CT scan is part of the standard treatment protocol.
224061453|NCT06977698|DIAGNOSTIC_TEST|OCT-Raman|a machine to detect positive margins in lumpectomy specimens
224061454|NCT06977178|BEHAVIORAL|Trier Social Stress Test|Psychosocial stress procedure; 5 minutes of public speaking (preceded by 5 minutes of preparation) and 5 minutes of mental arithmetic.
224061455|NCT04609709|OTHER|Thrust Manipulation, Electric Dry Needling and Exercise|Thrust Manipulation, Electric Dry Needling
224061456|NCT04609709|OTHER|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS|Non-thrust Mobilization, Soft-Tissue Mobilization, Exercise and TENS
224061457|NCT03363087|DEVICE|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
224061458|NCT03363087|DEVICE|Mapping|Omnipolar mapping of left atrial scar and pulmonary vein isolation lines
224061459|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak|After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.
224061460|NCT04943575|DIETARY_SUPPLEMENT|EZC Pak +D|After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.
224061461|NCT04943575|DIETARY_SUPPLEMENT|Placebo|After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.
224061462|NCT06978361|PROCEDURE|Microneedling with autologous Platelet Rich Plasma|Patients in group A will undergo Microneedling with autologous PRP
224061463|NCT06978361|PROCEDURE|Microneedling with topical insulin|Patients in group B will undergo Microneedling with Topical insulin ( regular).
224061464|NCT06978543|DEVICE|A Prototype Device Developed for Flat or Inverted Nipples (DFIN)|This is a non-commercial, researchers-developed prototype breastfeeding aid (DFIN) designed for mothers with flat or inverted nipples. Produced using 3D printing, the device is made of biocompatible material and is not commercially registered. Prior to its application in patients, official approval for use was obtained from the Turkish Medicines and Medical Devices Agency (TITCK). DFIN was developed based on clinical experience and literature. Previous studies showed that warming the breast increases nipple temperature and enhances milk production. DFIN contains a 150-200 mL reservoir of warm water (39-41°C) to apply heat directly. It is anatomically designed to fit the breast and is kept in place for 10 minutes. Then the piston in the DFIN is pulled, with the mother's maximum comfort.
223570817|NCT03836833|DRUG|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
223570818|NCT05772663|OTHER|Personalized program of rehabilitation|"D56: Follow-up visit (D56). Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
223570819|NCT05772663|OTHER|Routine program of rehabilitation|"Assessments: AMPS, MCRO, Satisfaction VAS. Installation of accelerometer wristbands for the sub-sample of 40 people with stroke drawn at random secondary accelerometry analysis.~Between D56 and D112: For 8 weeks, the person does not receive any intervention apart from their usual rehabilitation. At D63, the person returns the accelerometric wristbands.~D112: The assessments carried out by occupational therapist are: AMPS, MCRO. Installation of accelerometer bracelets for the sub-sample of 40 people with stroke, randomly selected for secondary analysis on accelerometers (subjects from the two groups, experimental and control, i.e. 20\*20). At D119, the person returns the accelerometric writbands."
223570820|NCT02458131|BEHAVIORAL|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
224061465|NCT06978543|DEVICE|Modified injector|The syringe method used routinely in the unit was applied by the researcher to mothers immediately after delivery. In this method, the thin part to which the needle is attached is cut with a sharp knife, the plunger is placed in this area and the syringe is applied to the flat or inverted nipple to create a vacuum
224061466|NCT06979310|OTHER|text-based education messages only|Participants will receive text-based education messages
224061467|NCT06979310|OTHER|in-clinic tablet-based multimedia education|Participants will receive tablet-based multimedia education in clinic
224061468|NCT06979310|OTHER|standard of care provider led education|Participants will receive standard of care education from their provider
224061469|NCT06601660|BEHAVIORAL|Morning Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 7 am to 10 am, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
224061470|NCT06601660|BEHAVIORAL|Night Physical Training|A group of women who will perform the combined physical training (CPT) at morning from 6 pm to 9 pm, for 8 weeks and a frequency of 3 times per week (total = 24 sessions) with strength exercises and aerobic endurance exercises, performed in combination. In weeks 1 and 2, the strength training protocol will be performed with 2 sets of 16-20 maximum repetitions (RM). During weeks 3 to 5 with 12-16 RM. In weeks 6 to 8, 4 sets of 8-12 RM, with rests of 60s (weeks 1 and 2), 90s (weeks 3 to 5) and 105s (weeks 6 to 8). The minimum frequency is 90% of the training sessions. With the aerobic resistance protocol, there will be a gradual progression of the duration (volume) of the exercise (from 20 to 30 minutes per training session) and intensity (from 65% to 75% of HRres). In the first two weeks of training, participants will train at an intensity of 65% of HRres during weeks 3 to 5, at 70% of HRres in weeks 6 to 8, the intensity will reach 75% of HRres.
224061471|NCT06601660|OTHER|No intervention|Group of women who will not receive intervention with combined physical training, but will be evaluated before and after 8 weeks, and monitored, without any intervention with physical exercise.
223570821|NCT00790166|DEVICE|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
223570822|NCT00790166|DEVICE|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
223742411|NCT06235788|BEHAVIORAL|Experimental Group ICEMS verbal feedback with pause group|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down and reflecting for 22 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
223742412|NCT06235788|BEHAVIORAL|Experimental Group ICEMS audio feedback with pause and expert video|While performing the simulated procedure, if participants receive real-time verbal feedback based on the intelligent system error detection, they will be instructed to pause the task, putting their instruments down, turning their attention to a 9-second expert-level demonstration video, and reflecting for 13 seconds. A warning will be given when there are 7 seconds remaining in the reflection period so individuals can prepare to resume the task immediately.
223742413|NCT04656145|DEVICE|3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing|On the day of the operation, after the procedure has concluded and the drains have been placed, the surgical drain site that has been randomized to be in the experimental group will receive the chlorhexidine gel dressing. The dressing will remain on the patient until the drain has been removed and the surgical site will be assessed for signs of infection.
223742414|NCT02496832|DRUG|18F-Fluoroazomycin arabinoside|
223742415|NCT02860364|PROCEDURE|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
223742416|NCT03604185|BEHAVIORAL|Choir Singing|A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
224061472|NCT06978400|DRUG|mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy|Dabrafenib 150 mg twice orally daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks or Panitumumab 6 mg/kg (60-minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks, Сalcium folinate 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks.
224061473|NCT06978049|DRUG|Topical Lactic Acid Gel (BAYER)|Lactic acid gel, applied topically once daily to the episiotomy site, starting on postpartum day 7 for a total of seven consecutive days. Commercial product: BAYER (Bucharest, Romania).
224061474|NCT06977373|DIAGNOSTIC_TEST|To explore the value of spectral CT in the diagnosis and treatment of colorectal cancer|The CT scan is part of the standard treatment protocol.
224061475|NCT06978101|OTHER|POAG group|Patients had intraocular pressure (IOP)\>21 mmHg.
224061476|NCT06978101|OTHER|Control group|Patients without family history of primary open-angle glaucoma (POAG), IOP ˂21mm Hg.
224061477|NCT06977308|DRUG|Methylphenidate (MPH)|Each participate will receive one oral dose of 60mg methylphenidate.
223570823|NCT00790166|DEVICE|CPAP + No added humidity|ambient humidity
223570824|NCT05514756|DEVICE|Active t-VNS|Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae
223570825|NCT05514756|DEVICE|Sham t-VNS|Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe
223570826|NCT05514756|OTHER|Baseline assessments|Baselines assessments with no stimulation will serve as control in this three-part crossover design
223570827|NCT02899234|OTHER|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
223570828|NCT02851407|DRUG|Defibrotide|
223570829|NCT02851407|OTHER|Best Supportive Care|
223570830|NCT03647150|DRUG|amoxicillin|At enrollment the child will receive a 1 week course of amoxicillin
224061478|NCT06345963|DEVICE|active H-coil delivered rTMS|Multiple trains of rTMS in a day, for multiple days.
224061479|NCT01810653|DRUG|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
224061480|NCT01810653|DRUG|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
224061481|NCT01650961|DRUG|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
224061482|NCT01650961|DRUG|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
224061483|NCT03401515|DRUG|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
224061484|NCT03401515|OTHER|Normal saline|Normal Saline 1 ml every 6 hrs
224061485|NCT01352832|OTHER|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
224061486|NCT01352832|OTHER|Usual Care|Usual Care
224061487|NCT02682628|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
224301474|NCT06433635|DRUG|Quetiapine|"1. Both immediate and extended-release quetiapine monotherapies showed superiority over placebo in acute BD depression across three 8-week randomized trials, confirmed by meta-analysis. Quetiapine exhibited significantly higher remission rates (52.8%) compared to placebo (34.7%) and improved various aspects of life, including quality of life, clinical global impression, sleep, functioning, and anxiety.~2. Common adverse events of quetiapine include sedation, hypotension, increased appetite, weight gain, dyslipidemia, and elevated glucose levels, particularly in a population already at risk.~3. Four studies examined quetiapine's maintenance effects in patients with manic, mixed, or depressive episodes. Overall, quetiapine prolonged the time to recurrence for both depressive and manic episodes."
223453360|NCT07021417|BEHAVIORAL|Course|Includes four weekly sessions totaling 8 hours (2 hours each)
223453361|NCT07022665|PROCEDURE|Appendicectomy|Appendicectomy for appendicitis
223453362|NCT07022665|PROCEDURE|Cholecystectomy|Cholecystectomy for cholecystolithiasis and/or cholecystitis
223453363|NCT07022665|PROCEDURE|Umbilical hernia repair|Any kind of umbilical hernia repair
223570831|NCT03647150|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
224061488|NCT06977854|OTHER|Removal from study. In case of adverse event, subject treated for the AE.|"The participation of a subject in this study may have been discontinued for any of the following reasons:~* the subject wished to withdraw from study participation;~* if, in the opinion of the Investigator, it was in the best interest of the subject;~* suspected adverse effects from the test article;~* inter-current illness;~* violation of the prohibitions and restrictions;~* development of an exclusion criteria. Subjects were free to withdraw at any time and need not give a reason, however, every reasonable attempt was made to ascertain such reasons. The data for those subjects who were withdrawn was included in the final clinical report but may be excluded from final data analysis."
224061489|NCT06977854|OTHER|removal from study|"The participation of a subject in this study may have been discontinued for any of the following reasons:~* the subject wished to withdraw from study participation;~* if, in the opinion of the Investigator, it was in the best interest of the subject;~* suspected adverse effects from the test article;~* inter-current illness;~* violation of the prohibitions and restrictions;~* development of an exclusion criteria. Subjects were free to withdraw at any time and need not give a reason, however, every reasonable attempt was made to ascertain such reasons. The data for those subjects who were withdrawn was included in the final clinical report but may be excluded from final data analysis."
224061490|NCT06978725|DRUG|Oral Brepocitinib|Drug: Oral Brepocitinib
224061491|NCT06978725|DRUG|Oral Placebo|Drug: Oral Placebo
224061492|NCT06978764|PROCEDURE|Thalamic LIFUP|Patients will receive intervention in Thalamus region by LIFUP
224061493|NCT06984172|PROCEDURE|Remote cardiac rehabilitation|"The patient, following heart valve surgery, is undergoing home-based cardiovascular rehabilitation during the late recovery phase. The rehabilitation is remotely supervised by a therapist through the Open TeleRehab software and includes aerobic exercises, breathing exercises, and lower limb resistance training.~* Aerobic exercise: Performed 3 times per week, each session lasting 20-40 minutes. Activities include walking, stair climbing, or cycling. Exercise intensity is determined based on:~  1. Target heart rate: Set at the anaerobic threshold identified through Cardiopulmonary Exercise Testing (CPET) prior to hospital discharge; heart rate is monitored using a handheld pulse oximeter.~ 2. Borg Rating of Perceived Exertion (RPE) scale for dyspnea: maintained at 12-13 out of 20.~* Lower limb resistance training: Performed 3 times per week, each session lasting 30-40 minutes. Intensity is based on the one-repetition maximum (1RM).~* Breathing exercises: Performed 3 times per week"
224061494|NCT06984172|PROCEDURE|Facility-based cardiac rehabilitation|"After completing inpatient rehabilitation, patients are discharged and continue supervised outpatient rehabilitation three times per week. The program includes aerobic exercise, lower limb resistance training, and breathing exercises.~Aerobic exercise: Each session lasts 20-40 minutes, depending on the patient's condition, and is performed using a Cardiopulmonary Exercise Testing (CPET) device. Exercise intensity is determined based on the target heart rate and the Borg Rating of Perceived Exertion (RPE) scale for dyspnea and fatigue, in accordance with the 2021 guidelines of the Japanese Circulation Society.~Lower limb resistance training: Each session lasts 30-40 minutes.~Breathing exercises: Each session lasts 15-20 minutes"
224061495|NCT06985472|DRUG|ZO|Orelabrutinib 150mg, po, gd, D1-D28, every 28 days, cycle 1-12; Zuberitamab: intravenously administered on day 1 of the cycle at a dose of 375mg/m2 every 28 days, once every cycle for cycles 1-6 and once every 2 cycles for cycles 7-12.
224061496|NCT06986031|DRUG|Vaginal product|Intravaginal application of gel PKB171 with a single-use applicator (syringe)
223453364|NCT07022665|PROCEDURE|Inguinal and/or femoral hernia repair|Any kind of inguinal and/or femoral hernia repair
223453365|NCT07022574|BEHAVIORAL|Low inflammation diet intervention|Autoimmune Protocol Diet intervention
223453366|NCT04673435|DEVICE|PermeaDerm for temporary coverage|See above
223453367|NCT04673435|DEVICE|FHCA for temporary coverage|See above
223453368|NCT04673435|DEVICE|PermeaDerm over autograft|See above
223453369|NCT04673435|DEVICE|FHCA over autograft|see above
223453370|NCT03737565|DEVICE|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
223453371|NCT06703216|DRUG|Anakinra (Kineret®)|Pre-emptive Anakinra at the initial onset of CRS.
223453372|NCT06225791|BEHAVIORAL|MMS (90x2) + BCC or expanded BCC|Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
223453373|NCT06225791|BEHAVIORAL|MMS (180x1) + BCC or expanded BCC|Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
223453374|NCT06715852|BEHAVIORAL|PHYSBI: a 12-week physical exercise program|An individualized 12-week training program including 3 occasions/week of moderate-high intensity.
223453375|NCT06715852|BEHAVIORAL|Modified eHealth Lift: a digital, evidence based lifestyle-intervention for health promotion.|Through questionnaires, the patients answers questions regarding lifestyle habits and the results are converted into a health profile. A care manager will together with the patient decide appropriate health promoting activities to engage in.
224061497|NCT03440450|DRUG|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes
224147734|NCT03506100|OTHER|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
224061498|NCT06655051|DEVICE|endoscopic retrograde biliary drainage (single plastic stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A single plastic stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
224147735|NCT02187341|DIETARY_SUPPLEMENT|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
224147736|NCT02187341|DIETARY_SUPPLEMENT|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
224147737|NCT05651841|DRUG|Tezepelumab|"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
224147738|NCT05651841|OTHER|placebo|"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
224147739|NCT01978600|DRUG|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
224147740|NCT01978600|DRUG|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
224147741|NCT00203255|DRUG|Soy Isoflavones|
224147742|NCT03114423|OTHER|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
224147743|NCT03114423|OTHER|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
224147744|NCT02284945|PROCEDURE|Open fixation|
223453376|NCT03590990|DIAGNOSTIC_TEST|Ultrasonsography, mammography, biopsy|Ultrasonsography of lump in breast Mammography of patents above 35 years Biopsy if indicated
223453377|NCT00312052|DRUG|E5555|50 mg or 100 mg E5555 tablets
223453378|NCT00312052|DRUG|Placebo|50 mg and/or 100 mg placebo tablets
223570832|NCT03647150|BEHAVIORAL|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
223570833|NCT03878030|DRUG|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
223570834|NCT03243578|OTHER|None as this is an observational study|
223570835|NCT02403635|DRUG|Midazolam|
223570836|NCT02403635|DRUG|ASP2151|
223742417|NCT03604185|BEHAVIORAL|Music Appreciation|A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
224147745|NCT02284945|PROCEDURE|Keyhole surgery|
223453379|NCT01216332|DRUG|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
223570837|NCT00075114|BEHAVIORAL|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
223570838|NCT00195520|DRUG|Totelle®|
223570839|NCT03117790|DRUG|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
223570840|NCT03117790|DRUG|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
223570841|NCT00835640|DRUG|Fexofenadine 180 mg tablets|1 x 180 mg
223742418|NCT03429179|DRUG|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
223453380|NCT01216332|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
223570842|NCT00835640|DRUG|ALLEGRA® 180 mg tablets|1 x 180 mg
223742419|NCT03429179|OTHER|Physiological saline|intravenous infusion of the same volume of 0.9% saline
223742420|NCT00060931|DRUG|carvedilol|
223742421|NCT00060931|DRUG|metoprolol|
223742422|NCT06376110|DRUG|Topical Antioxidant Serum|An oil-free vitamin C serum for oily skin and blemish-prone skin that delivers advanced environmental protection, reduces oiliness, refines skin texture, and visibly improves skin clarity and fine lines.
223742423|NCT06376110|DEVICE|AviClear Laser|The AviClear (1726nm) laser is FDA-cleared for use on mild to severe inflammatory acne, with a recommended treatment course comprised of 3 laser procedures each one month apart.
223742424|NCT00375739|DRUG|PEP005|
224061499|NCT06655051|DEVICE|endoscopic retrograde biliary drainage ( fully covered self-expanding metal stent)|Participants will undergo ERCP. A flexible tube is inserted into the duodenum, crossing the sphincter of Oddi to access the biliary system. And the location, diameter, and length of biliary stricture will be evaluated by injection of contrast media. A fully covered self-expanding metal stent is then placed across the biliary stricture, allowing the bile duct to resume drainage. The participants will be observed closely after ERCP and record complications. Imaging evaluation will be conducted 6 months after stenting to confirm spontaneous passage of the biliary duct stent, and the stent will be removed via ERCP if it is still in place.
224061500|NCT02589496|DRUG|pembrolizumab|200 mg every 3 weeks
224061501|NCT05791500|BEHAVIORAL|lifestyle intervention|dietary behavior interventions:through a couple of dietary health education lectures physical activity interventions:through at least an offline teaching and jump rope or jog regularly and quantitatively life schedule and habits intervention group: live in a regular and healthy life habit and last at least 4 months
224061502|NCT02193399|OTHER|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
223453381|NCT02992756|DRUG|Growth Factors|one dose 3-6 mL of PRP obtained by PRGF Endoret
224061503|NCT01088776|DIETARY_SUPPLEMENT|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
224061504|NCT01088776|DIETARY_SUPPLEMENT|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
223453382|NCT03391804|DRUG|ALLN-177|ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
224061505|NCT05847101|PROCEDURE|Tracheoesophageal fistula repair|Tracheoesophageal fistula repair
223453383|NCT01796275|BEHAVIORAL|Core intervention program|
224061506|NCT01127685|DEVICE|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
223453384|NCT01796275|BEHAVIORAL|Booster session|
223453385|NCT01796275|BEHAVIORAL|Control only (Tea gathering)|
223453386|NCT05194943|PROCEDURE|revisional bariatric surgical procedures|Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
223570843|NCT04193761|DIAGNOSTIC_TEST|taurine level|Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
223570844|NCT00068250|DRUG|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
224061507|NCT02544711|DEVICE|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
223453387|NCT01353391|DRUG|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
223570845|NCT00068250|DRUG|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
223570846|NCT00068250|DRUG|temozolomide 100 mg/m^2|Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
223570847|NCT00068250|DRUG|temozolomide 150 mg/m^2|Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
223742425|NCT02614950|OTHER|Treatment interruption|
224147746|NCT05936593|DEVICE|Condylar Stabilizing (CS) insert|During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
223453388|NCT01353391|DRUG|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
223570848|NCT00068250|DRUG|temozolomide 200 mg/m^2|Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
223570849|NCT00068250|RADIATION|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
223570850|NCT00068250|DRUG|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
223570851|NCT04746482|PROCEDURE|single visit root canal retreatment|cases that were subject to root canal retreatment performed in single visit
223742426|NCT05757531|DRUG|[¹⁴C]-LY3437943|Administered SC.
223742427|NCT04735120|DEVICE|iLASE DIODE LASERS|940nm diode laser with 1.5 watts activated in a continuous mode and applied on to the canal orifices during root canal treatment to reduce intraoperative pain and further its effect on post operative pain is assessed
223742428|NCT04407312|DRUG|Cilostazol Tablets|Cilostazol-SR, capsule, 200mg, once daily, 30 days.
223742429|NCT04407312|DRUG|placebo|Placebo, tablet, 200mg, once daily, 30 days.
223742430|NCT04407312|DRUG|Aspirin|Astrix, capsule,100mg, once daily, 30 days.
224061508|NCT02544711|PROCEDURE|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
224061509|NCT03640598|PROCEDURE|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
224061510|NCT03640598|PROCEDURE|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
224061511|NCT00870051|DEVICE|Endurant Stent Graft|Endurant Stent Graft implantation
224061512|NCT03066648|DRUG|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
224061513|NCT03066648|DRUG|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
224061514|NCT03066648|DRUG|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
224147747|NCT05936593|DEVICE|Cruciate Retaining (CR) insert|During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
224147748|NCT03714061|OTHER|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
224147749|NCT03714061|OTHER|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
224147750|NCT04848584|BIOLOGICAL|Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine|prior administration of Pfizer-BioNTech COVID-19 vaccine; vaccine is not administered in this study
224147751|NCT04848584|BIOLOGICAL|BNT162b2 BA.4/5 bivalent|Vaccination with a bivalent booster was defined as receipt of the BNT162b2 BA 4/5 bivalent vaccine ≥8 weeks (≥56 days) since the most recent dose of wild-type COVID-19 mRNA vaccine (BNT162b2 or mRNA-1273) received.
224147752|NCT04848584|BIOLOGICAL|XBB.1.5-adapted vaccinated|Vaccinated with XBB.1.5-adapted vaccine
224147753|NCT02323399|DRUG|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level\]; each initial treatment group will have two PK sampling schedules.
224147754|NCT00448760|DRUG|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
224147755|NCT00448760|DRUG|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
224147756|NCT00448760|DRUG|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
224147757|NCT00448760|DRUG|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
224147758|NCT00448760|GENETIC|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
224147759|NCT00448760|GENETIC|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
223570852|NCT01452230|BEHAVIORAL|Supervised physical activity|Supervised physical activity
223570853|NCT02227173|DRUG|BMS-986020|
224147760|NCT00448760|PROCEDURE|Conventional surgery|Surgical removal of tumor for correlative studies
224147761|NCT03844503|DIETARY_SUPPLEMENT|Cereal Bar no fiber|Cereal Bar no fiber
224147762|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
224147763|NCT03844503|DIETARY_SUPPLEMENT|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
224147764|NCT02489006|DRUG|Olaparib|
223570854|NCT02227173|DRUG|Montelukast|
223570855|NCT02227173|DRUG|Flurbiprofen|
223570856|NCT02227173|DRUG|Digoxin|
223742431|NCT04407312|DRUG|Clopidogrel|Plavix, tablet, 75mg, once daily, 30 days.
224061515|NCT03066648|DRUG|Azacitidine|Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation
224061516|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 320 mg, ACC long 600 mg)
224147765|NCT02489006|DRUG|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
224147766|NCT01916993|DRUG|NBI-98854 50 mg capsule|
224147767|NCT06435182|DRUG|OT202 conc 0.5%|Apply 1-2 drops of OT202 0.5% solution into the conjunctival sac. three times daily
224147768|NCT06435182|DRUG|OT202 conc 0.1%|Apply 1-2 drops of OT202 0.1% solution into the conjunctival sac. three times daily
224147769|NCT06435182|DRUG|Placebo|Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily
224147770|NCT01789346|DEVICE|532nm KTP|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
224147771|NCT01789346|DEVICE|595nm PDL|up to three treatments of 1/2 of Single scar, or one entire, randomized Bilateral scar.
224147772|NCT05003063|DRUG|Donepzil|Test
224061517|NCT04641455|DRUG|Espumisan, N acetylcystein|Administration of mucolytic solution before upper endoscopy (Espumisan 20 mg, ACC long 200 mg)
224061518|NCT04641455|DRUG|Water|Administration of water before upper endoscopy
224061519|NCT04128488|OTHER|Abdominal MR Imaging|Imaging to evaluate visceral adipose tissue and hepatic lipid content
224061520|NCT04128488|OTHER|Cardiac MRI/MRS|Imaging to evaluate cardiac function and structure
224061521|NCT04128488|OTHER|Oral Glucose Tolerance Testing|Blood testing to evaluate changes in glucose and insulin in response to oral glucose load
224061522|NCT04128488|OTHER|Whole Body, Lumbar Spine, and Hip DEXA Imaging|Imaging to evaluate fat and lean body mass as well as bone mineral density
224061523|NCT06586528|OTHER|NGAGE tool|Access to NGAGE tool
224061524|NCT00139945|DRUG|Human acylated ghrelin|5 pmol/kg body weight per min
224061525|NCT05376475|DEVICE|Infrared video-audio camera|Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
224061526|NCT05376475|DEVICE|Level III home sleep apnea test|NightOwl® by Ectosense, Leuven, Belgium
224061527|NCT05376475|DEVICE|Maternal-fetal transabdominal electrocardiographic heart rate monitor|The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
224061528|NCT05376475|DEVICE|Pressure sensing mat|Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
224061529|NCT00102960|DRUG|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
224061530|NCT00102960|DRUG|Didanosine|Second Line Regimen: Either 100 mg/m\^2 or 120 mg/m\^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
224061531|NCT00102960|DRUG|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
224061532|NCT00102960|DRUG|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
224061533|NCT00102960|DRUG|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
224061534|NCT00102960|DRUG|Nevirapine|Second Line Regimen: 150 - 200 mg/m\^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
224061535|NCT00102960|DRUG|Zidovudine|First Line Regimen: 240 mg/m\^2 taken orally twice daily
224061536|NCT05904977|PROCEDURE|Type B resection or type C resection of the anterior leaf of vesicouterine ligament during the radical hysterectomy (type C)|The patients with cervical cancer who underwent abdominal radical hysterectomy（type C）plus pelvic lymph node dissection by the same surgical team at the Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, were included. According to the resection range of the anterior leaf of vesicouterine ligament (VUL), patients were divided into type C resection group (near the bladder wall) and B type resection group (above the ureter).
224061537|NCT02017353|DIETARY_SUPPLEMENT|Curcuphyt|
224061538|NCT06494670|OTHER|No intervention|This study was a cross-sectional study with no intervention for participants
224061539|NCT05367362|DRUG|Minocyclin|200 mg intravenous/oral minocycline hydrochloride for a total of 21 days
224061540|NCT06535841|BIOLOGICAL|MTX-474|MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.
224061541|NCT06535841|OTHER|Placebo|Matching Placebo - Normal Saline
224061542|NCT04914325|COMBINATION_PRODUCT|peek|After tooth preparation, adequate 2ry Impression using non aqueous elastomeric impression materials and bite registration will be taken. 5. Fabrication of the temporary restoration using composite resin temporary material and cemented using non Eugenol Zinc Oxide temporary cement. 11.a.iii. Fabrication and cementation of restoration: Bio-HPP will be supplied in the form of discs to fabricate crown core by CAD/CAM technology then veneered with two veneering techniques; the CAD/ CAM and the manual technique using the visio.lign system of appropriate shade. The finished Bio HPP crown will be cemented by adhesive resin cement according to manufacturer instruction
224061543|NCT03885427|DRUG|Ketamine|evaluate sedative, and analgesic effects of oral or nebulized ketamine
224061544|NCT06872112|DRUG|Artesunate|Participants will receive artesunate capsules. Participants will receive artesunate capsules TID in a dose escalation manner (60 mg, 120 mg, 180 mg total daily).
224061545|NCT05378776|DIETARY_SUPPLEMENT|sucrose|The experimental arm will receive 1.5 ml/kg of the sucrose solution at triage (once). The composition of the homemade sucrose solution used in our emergency department is 3.5 g of table sugar (sucrose) mixed with 10 ml of water. For this double-blind study, we replaced water with diluted juice (see standard arm description) to obtain a solution with the same appearance as the standard arm. With the idea of correcting ketosis, we chose to provide the same amount of sugar as we do in hypoglycemia (0.4-0.5 g/kg of dextrose) to participants in the intervention group, which represents 1.5 ml/kg of the sucrose solution containing 0.4 g of sucrose/mL for a total of 0.6 g/kg of sucrose.
224061546|NCT05378776|DIETARY_SUPPLEMENT|Standard rehydration solution|This group will receive 1.5 mL/kg of diluted juice composed of juice (apple or orange) and water in equal proportion once at triage. This solution contains 0.05 g/ml of sucrose for a total of 0.075 g/kg of sucrose (eight times less than the intervention arm).
224061547|NCT06874010|DRUG|DT-216P2|Active
224061548|NCT06214247|DEVICE|Wedge NC Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using the Wedge NC Scoring Balloon Dilatation Catheter in the test group, subsequently completing the remaining procedure.
224061549|NCT06214247|DEVICE|Scoreflex Scoring Balloon Dilatation Catheter|During PCI, percutaneous transluminal coronary angioplasty is performed on the target lesion using a similar product on the market in the control group, subsequently completing the remaining procedure.
223742432|NCT02456610|BIOLOGICAL|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
224061550|NCT07028112|OTHER|Cohort|Participants undergo one routine visit blood draw and non invasive liver stiffness measurement. Retrospective data are abstracted from medical records.
223742433|NCT05837624|DRUG|Estetrol/Drospirenone|6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
224061551|NCT03789942|PROCEDURE|Oral surgery|Oral surgery procedures
223453389|NCT06359197|DRUG|Caffeine Pill|Participants would take two Wake-Ups 200mg Caffeine tablets to meet the target dose of 400mg of caffeine. These are a registered natural health product with Health Canada (NPN 80003474). They are developed by Adrem Brands, which was established in 1951. Quality control testing is performed at a third-party independent lab, Nucro-Technics, which is audited by Health Canada and the US FDA. This ensures that the caffeine tablets comply with Health Canada standards. The tablets contain caffeine anhydrous-a processed, dehydrated form of caffeine-which allows for a standard dose per tablet. The tablets are sugar-free, which reduces the confounding effect of sugar on our results; thus, the investigators can be more confident that the obtained results are reflective of the association between caffeine and the CVD-related protein biomarkers.
223453390|NCT06359197|DRUG|Placebo|Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
223453391|NCT06359197|DEVICE|TASSO+ Device|TASSO+ is a blood lancet device that uses negative pressure to draw capillary blood from the upper arm into a standard SST tube of volume 500μL. The small volume of blood collected makes this device less invasive than traditional collection methods. It is also safer and easier to use since it offers automated sample collection. TASSO manufactures a number of special devices for capillary blood sampling that have been validated as safe for consumer use, and the Tasso+ device is licensed with Health Canada for research use.
223742434|NCT03338062|DIAGNOSTIC_TEST|Hepatobiliary Iminodiacetic Acid (HIDA) scan|HIDA scan was used as the planning scan for SBRT.
223742435|NCT04622293|DRUG|Solriamfetol Oral Tablet [Sunosi]|Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
223742436|NCT04622293|DRUG|Placebo|A placebo encapsulated to look the same as the experimental drug will be given to the control group.
224061552|NCT06809530|DRUG|QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|Intrathecal injection of PD-1/CTLA-4 bispecific antibody was administered every 2 weeks for 6 weeks during the induction phase, followed by monthly injections during the maintenance phase, until recurrence or death.
224061553|NCT06809530|DRUG|Pemetrexed (Alimta)|Pemetrexed (Alimta, Eli Lilly and Company) was administrated by intrathecal injection, first as induction therapy, twice per week for 2 weeks, followed by consolidation therapy, once per week for 4 weeks, then maintenance therapy, once per month until the patient's death, leptomeningeal metastasis progresses, or intolerable severe adverse events occurred.
223742437|NCT04933539|DRUG|Dexamethasone|Dexamethasone PO/IV (for Cycles 1-4: Dexamethasone 40 mg IV/PO on days 1, 8, 15, 22; for Cycles =5: Dexamethasone 20 mg IV/PO on days 1, 8, 15, 22); for up to 12 cycles
224061554|NCT06640491|DRUG|IO Administration of Cefazolin|Intraosseous injection of cefazolin to guard against infection.
224061555|NCT06640491|DRUG|IO Administration of Vancomycin|Intraosseous injection of vancomycin to guard against infection.
224061556|NCT06640491|DRUG|IV Administration of Cefazolin|Intravenous dose of cefazolin to guard against infection.
224061557|NCT06640491|DRUG|IV Administration of Vancomycin|Intravenous dose of vancomycin to guard against infection.
224061558|NCT05307939|DIAGNOSTIC_TEST|HPV ctDNA Assay|HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
224061559|NCT05307939|DIAGNOSTIC_TEST|MRI Studies|Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
224061560|NCT05307939|BEHAVIORAL|EORTC QLQ H&N 35 and C30|The EORTC QLQ H\&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
224061561|NCT05307939|BEHAVIORAL|MDADI-HN|The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
224147773|NCT05003063|DRUG|Placebo oral tablet|Test
224147774|NCT01899677|OTHER|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
224147775|NCT01899677|DRUG|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
224147776|NCT02316626|DRUG|Subcutaneous progesterone|25 mg daily for 14 days
224147777|NCT02316626|DRUG|Vaginal progesterone|90 mg daily for 14 days
224061562|NCT05307939|BEHAVIORAL|COST-FACIT|Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
224061563|NCT05307939|RADIATION|Intensity-Modulated Radiation Therapy (Arm A)|59.4-60 Gy in 1.8-2 Gy fractions: CTV\_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
224061564|NCT05307939|COMBINATION_PRODUCT|Chemoradiation (Arm B)|30 Gy in 2 Gy fractions: CTV\_primary, CTV\_node-positive neck, CTV\_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons
224061565|NCT04153773|DIAGNOSTIC_TEST|OCT|"The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON)."
224061566|NCT06870799|DEVICE|Surface guided radiation therapy|Radiation therapy will be delivered using no immobilization mask, but a surface guided system with infrared light
224061567|NCT06870799|DEVICE|Closed face mask|Radiotherapy with closed face mask for immobilization
224061568|NCT06666621|DRUG|Normal saline infusion|"After assessment of response to lumbar medial branch block, 8 ml normal saline will be infused through IV over several minutes. 10 minutes will pass, and response to lumbar medial branch block procedure will be re-assessed.~After this step, naloxone infusion will occur (see next intervention)"
224061569|NCT06666621|DRUG|Naloxone infusion|After infusion of normal saline and re-assessment of response to lumbar medial branch block procedure, 8 milligrams of naloxone will be infused over several minutes. Then after 10 minutes, response to lumbar medial branch block procedure will be re-reassessed for the final time.
224061570|NCT04705168|DIAGNOSTIC_TEST|Nevisense electrical impedance spectroscopy|Each participants will undergo Nevisense electrical impedance spectroscopy in order to characterize the electrical impedance spectroscopy scores of nevi in patients with ≥ 100 nevi on the entire cutaneous surface and at least three large acquired nevi (LAN) \> 5 mm in diameter
224061571|NCT02901925|DRUG|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
224061572|NCT06911242|DRUG|ARN-75039|An oral therapy for the treatment of Lassa infection
223453392|NCT06359197|DEVICE|Finger prick and collection on Whatman Protein 903 Saver Cards|The Whatman Protein 903 Saver Card is a specialized filter paper designed for the collection, storage, and elution of biological samples, including blood. It contains five half-inch circles that hold 75 to 80 µL of blood, making it an efficient and reliable method of obtaining dried blood spot (DBS) samples. The participant's finger will be pricked using a sterile, disposable lancet, and drops of blood will be collected on the Whatman 903 Protein Saver Card to fill nine ½ inch discs via capillary action. The blood spots will be allowed to dry at ambient temperature (21°C) for two hours. Whatman Protein 903 Saver Cards undergo strict quality control and GMP manufacturing standards, which ensures high quality and reproducibility.
223570857|NCT04350671|DRUG|Interferon Beta-1A|This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Interferon-β 1a in COVID-19 patients.
223570858|NCT04350671|DRUG|Lopinavir / Ritonavir|This Drug will be used in all arms as mandated by our governmental guidelines.
223570859|NCT04350671|DRUG|Single Dose of Hydroxychloroquine|This Drug will be used in all arms as mandated by our governmental guidelines.
223570860|NCT03349645|BIOLOGICAL|4 mL injection of AMPION™|4 mL injection of AMPION™
223570861|NCT01919047|DRUG|Betanis|Oral
223742438|NCT04933539|DRUG|Carfilzomib|Carfilzomib IV (for Cycles 1-2: 20 mg/m2 IV on day 1, 56 mg/m2 IV on days 8, 15; Cycles =2: 56/m2 IV on days 1, 8, 15); for up to 12 cycles
224061573|NCT04532385|DIETARY_SUPPLEMENT|Green tea extract|400 mg capsule
224061574|NCT04532385|DIETARY_SUPPLEMENT|Placebo|400 mg capsule
224061575|NCT02523066|DEVICE|Magna Ease|This study is non-intervention
224061576|NCT06907849|DRUG|124I-evuzamitide|124I-evuzamitide is an iodine-124 (124I) labeled 45 L-amino acid peptide (also known as p5+14) suitable for single dose PET/CT imaging. The peptide binds many forms of amyloid through multivalent electrostatic interactions with the amyloid fibril and with the ubiquitous amyloid-associated hypersulfated heparan sulfate proteoglycans.
224061577|NCT04342754|DEVICE|Deep Brain Stimulation (DBS)|The device will be ON
224061578|NCT04342754|DEVICE|Sham Stimulation|The device will be OFF
224061579|NCT02014350|DEVICE|DePuy Delta Xtend Reverse TSA|
224061580|NCT03832062|OTHER|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
224061581|NCT05406063|RADIATION|SBRT|Stereotactic multiple fraction radiotherapy
224061582|NCT03228485|DEVICE|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
224061583|NCT06438978|BIOLOGICAL|Tuberculosis Vaccine|"1. Live, attenuated Mycobacterium tuberculosis (M. tb)- MTBVAC (MTBVAC)01 strain~2. 3-17x105CFU (Per dose) Sucrose Sodium glutamate~3. Lyophilized pellet in vials (10doses)~4. 0.1 mL/dose (After reconstitution with 1 mL/vial sterilized water for injection)"
224061584|NCT06949618|DEVICE|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation toward for cancer pain (real and sham control)
224061585|NCT03900273|OTHER|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
224061586|NCT03900273|OTHER|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
224061587|NCT02105545|OTHER|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
224061588|NCT04027400|BEHAVIORAL|computer-assisted rehabilitation|Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
224061589|NCT01409135|DRUG|AGS-22M6E|IV Infusion
224061590|NCT01409135|DRUG|ASG-22CE|IV Infusion
224061591|NCT00037609|DRUG|Capecitabine|1000 mg/m\^2 taken by mouth twice daily.
224061592|NCT00037609|DRUG|Exisulind|125 mg taken by mouth twice daily.
224061593|NCT05121480|DRUG|EDP1815|EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
224061594|NCT05121480|DRUG|Placebo|Placebo oral capsule
224061595|NCT01028664|DEVICE|SENSIMED Triggerfish|2-hour continuous IOP monitoring
224061596|NCT02366611|DEVICE|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
224061597|NCT02658123|OTHER|Pre-operative education (standard of care)|
224061598|NCT02658123|OTHER|Home health care visits (standard of care)|
224061599|NCT02658123|OTHER|Follow-up post-operative visits|
224061600|NCT02658123|OTHER|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
224061601|NCT02658123|OTHER|Healthcare Utilization Form|"* Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~* Form allows patient to record reason for visit and date of visit"
224061602|NCT02658123|OTHER|The City of Hope QOL Survey for Ostomy Patients|"* Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~* Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
224061603|NCT02658123|OTHER|Phone call with CWOCN or PA|
224061604|NCT05541809|OTHER|Aromatherapy|Peppermint aroma inhalation
224061605|NCT05541809|OTHER|Placebo|Water inhalation
224061606|NCT06205888|OTHER|18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT|Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
224061607|NCT04864730|OTHER|No intervention|No intervention
224061608|NCT02822066|PROCEDURE|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
224061609|NCT04124146|RADIATION|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
224061610|NCT00001550|DRUG|IVIg|
224061611|NCT04851951|PROCEDURE|one-shot PRP injection|A single injection of PRP (7% concentrate) ml 4 was made in the Supraspinatus tendon and in the Subacromial space under ultrasound guidance.
224061612|NCT02831673|DRUG|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
224061613|NCT02831673|DRUG|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
223453393|NCT06359197|DEVICE|Intravenous Sampling|Blood will be collected from the medial cubital vein according to the standard venous blood sampling protocol into an EDTA tube with a volume up to 4mL.
223453394|NCT00774072|DRUG|Tobramycin (Gernebcin®)|1 ml / day in each nostril
224071019|NCT02266693|BEHAVIORAL|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
224061614|NCT02831673|DRUG|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
224061615|NCT00919035|DRUG|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
223453395|NCT05140252|BEHAVIORAL|Breast cancer decision aid|The decision aid is tailored from a previously published aid, specific to women ≥70 with early-stage breast cancer. The aid will be delivered via mail or electronically per patient preference before the patient's initial appointment with a surgeon.
224061616|NCT01411748|DIETARY_SUPPLEMENT|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
224147778|NCT03999112|OTHER|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
224301475|NCT06433635|DRUG|Lurasidone|"1. Lurasidone, either alone or with lithium/valproate, proved more effective than placebo for acute BD depression in two 6-week randomized trials. Remission rates were significantly higher with lurasidone monotherapy (40.9%) and in combination (50.3%) compared to placebo (24.7% and 35.4% respectively). Lurasidone also improved anxiety, quality of life, and disability.~2. Common mild adverse events included nausea, headache, akathisia, somnolence, sedation, dry mouth, and vomiting. Weight gain, dyslipidemia, and increased glucose levels were not observed.~3. In a 6-month double-blind discontinuation study post-acute treatment response, lurasidone combined with lithium/valproate prolonged time to depressive episode recurrence compared to placebo (hazard ratio: 0.68). Although not statistically significant due to low placebo recurrence and shorter follow-up, it hints at maintenance efficacy."
224301476|NCT06489457|DRUG|Semaglutide|Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
223453396|NCT06751446|OTHER|Scenario-based Simulation Skill Training|Scenario-based simulation is an educational approach that immerses students in realistic clinical scenarios, allowing them to practice decision-making and problem-solving in a safe, controlled environment. It challenges students to assess patient data, identify priorities, and implement interventions. Through guided debriefing sessions, students reflect on their actions, justify their decisions, and explore alternative strategies.
223453397|NCT06751446|OTHER|Traditional Skill Training|Traditional skill training in nursing education focuses on developing core technical skills through direct instruction, demonstrations, and hands-on practice. It emphasises mastery of essential tasks and conducting patient assessments. Students follow standardized protocols and procedures to ensure patient safety and accuracy in their practice
223453398|NCT01857804|DRUG|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
224061617|NCT01411748|DRUG|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
223453399|NCT01857804|DRUG|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
223453400|NCT01857804|DRUG|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
223453401|NCT03020628|BIOLOGICAL|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
223453402|NCT03020628|BIOLOGICAL|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular \[\* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart\]
223453403|NCT05521152|DRUG|Norepinephrine Bitartrate|"anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.~the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision."
223453404|NCT05521152|DRUG|Placebo|Placebo
223453405|NCT01892904|DRUG|EE20/DRSP(BAY86-5300)|One tablet \[0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone\] / day
223453406|NCT00636636|DRUG|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
223453407|NCT00636636|DRUG|Placebo|Once daily; 300 mg and 600 mg tablets
224061618|NCT02356562|DRUG|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
224061619|NCT02356562|DRUG|Sofosbuvir|tablet
224061620|NCT02356562|DRUG|Ribavirin|tablet
224061621|NCT01469858|DEVICE|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
224147779|NCT01925391|DRUG|Tono-pen XL Applanation tonometer + Ocu-film +|
224301477|NCT06489457|DRUG|Testosterone Undecanoate|Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
224301478|NCT01264731|BIOLOGICAL|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
224061622|NCT03278132|BIOLOGICAL|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
224061623|NCT05453617|BEHAVIORAL|Time-restricted eating|Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
224061624|NCT05453617|BEHAVIORAL|The 5:2 diet|Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
224061625|NCT00412750|DRUG|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
224061626|NCT00412750|DRUG|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
224061627|NCT06457386|PROCEDURE|systematic echocardiography|"transthoracic echocardiography (TTE) will be performed as soon as possible within 14 days following the first blood sample collection for SAB diagnosis, completed, if required, by a transoesophageal (TEE) echocardiography based on the judgment of the echocardiographist.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
224061628|NCT06457386|PROCEDURE|no echocardiography arm|"no echocardiography will be performed unless occurrence of new events evocating IE (extra-cardiac events or positive Staphylococcus aureus blood culture), based on the clinical judgment of the investigator.~SAB in patients of both arms will be treated according to current recommendations, taking into account the result of the echocardiography in the control arm. "
224061629|NCT00126087|DRUG|dopamine|
224061630|NCT03772626|DEVICE|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
224061631|NCT03615183|DRUG|MK-8527|Single oral capsule
224061632|NCT01977781|DRUG|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
224061633|NCT01977781|DRUG|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
224061634|NCT06407180|DRUG|Triamcinolone Acetonide|receive intraarticular triamcinolone injection
224061635|NCT06407180|DRUG|Normal saline|receive intraarticular normal saline injection
224061636|NCT00099190|DRUG|ARQ 501|
224061637|NCT03762070|DEVICE|CL Detect™ Rapid Test|Observational study of a FDA cleared device, the CL Detect™ Rapid Test.
224061638|NCT05069246|OTHER|Nigella Sativa oil|5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.
224061639|NCT05069246|DRUG|Chlorhexidine mouthwash|10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
224061640|NCT02104583|DRUG|Eleclazine|Eleclazine tablets administered orally
224061641|NCT02104583|DRUG|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
224061642|NCT05265403|DRUG|Commercially-available energy storage and return prosthetic foot|Each patient will walk in the Freedom Highlander, a commercially-available energy storage and return prosthetic foot. The foot will be sized based on the patient's foot size and weight.
224061643|NCT05265403|DEVICE|MIT-Lower Leg Trajectory Error (LLTE) customized prosthetic feet|Each patient will walk in prosthetic feet designed by the researchers at MIT. These feet will be customized for the user based on their body size (ie, height, foot length) and weight.
223453408|NCT04777656|DIETARY_SUPPLEMENT|Phase1 : CDED/Modulen™IBD® + Maintenance therapy|from D0 until M2: Phase 1 (2 months run-in phase with CDED protocol + maintenance therapy, with the exception of corticosteroid that have to be tapered and stopped until M2.)
224061644|NCT05360095|BEHAVIORAL|Meaning of Screening|The Meaning of Screening game is a decision making tool that is accessible through the most common web platforms. Users have the ability to explore learn about prenatal screening through multiple approaches, including presentation of facts, personal stories, and values clarification. Users will access the game from their personal phone or computer prior to completing prenatal screening.
224061645|NCT05360095|BEHAVIORAL|Genetic Counseling|This intervention consists of a 45-minute prenatal screening genetic counseling session (in person or online) completed after confirmation of pregnancy and before actual screening.
224061646|NCT05360095|BEHAVIORAL|Usual Care|Participants in the Usual Care group will receive the brochure-based education about prenatal screening that is currently recommended by American College of Obstetrics and Gynecology (ACOG), delivered in an electronic format so they can read it before they complete prenatal screening.
224061647|NCT03095742|DIAGNOSTIC_TEST|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
224061648|NCT03095742|DIAGNOSTIC_TEST|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
224061649|NCT01351389|BEHAVIORAL|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
224061650|NCT01351389|BEHAVIORAL|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
224061651|NCT04136873|DRUG|CVL-231|CVL-231
223453409|NCT04777656|DIETARY_SUPPLEMENT|Phase2 and 3 :|from M2 until M4 CDED phase 2 (introduction of a selected number of additional food). From M4 until end of the study CDED phase 3 (enlargement of number of additional foods and allowance of some initially excluded foods).
224061652|NCT04136873|DRUG|Matching Placebo|Placebo matching CVL-231
224061653|NCT03539744|DRUG|Pomalidomide|capsule, oral
224061654|NCT03539744|DRUG|Dexamethasone|oral, locally available form
224061655|NCT03539744|DRUG|Venetoclax|tablet; oral
224061656|NCT01160757|DEVICE|ultrasound|ultrasound exposure on acute acne lesions
224061657|NCT05950087|OTHER|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy
224061658|NCT05735691|PROCEDURE|High-Intensity Treadmill Training|Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
224061659|NCT05735691|PROCEDURE|Treadmill Training with Perturbations|Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
224061660|NCT05735691|PROCEDURE|Standard Treadmill Training|Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
224061661|NCT04577950|PROCEDURE|Lymphatic drainage of endometrial cancer|Nanocoll® is injected a day before surgery in the cervix at four points. A lymphoscintigraphy is performed 2 or 3 hours afterward. At the beginning of the surgery, the operative field already in place and before the beginning of laparoscopic, 2ml (10mg) of ICG, distributed in four points around the tumor, is injected under the endometrium intra-myometrial under endoscopic control. As ICG spreads slower than blue dye, ICG is always injected first. Then, Bleu Patenté® is injected at two sites in the uterine isthmus, opposite of the uterine arteries. The risk of false negative results, because a tracer migrated too quickly, is reduced when the injection takes place when patients are already anesthetized.
224061662|NCT03113240|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
224061663|NCT03113240|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
224147780|NCT01306032|DRUG|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
224147781|NCT01306032|DRUG|Cyclophosphamide|
223453410|NCT03348098|DRUG|Apatinib|500 mg, po, qd. 12weeks
223453411|NCT03348098|DRUG|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
223453412|NCT04151745|PROCEDURE|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
224147782|NCT03049995|PROCEDURE|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
223453413|NCT01537276|PROCEDURE|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
223453414|NCT00189527|PROCEDURE|respiratory settings|
223453415|NCT00524173|DRUG|Tenofovir & Emtricitabine|
223453416|NCT00524173|DRUG|Tenofovir|
223453417|NCT05475457|BEHAVIORAL|R3|Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
223453418|NCT04583358|DRUG|AMT-101 (oral)|AMT 101 is orally administered biological therapeutic taken once daily
223453419|NCT04583358|OTHER|Placebo (oral)|Orally administered placebo comparator taken once daily
223453420|NCT02464865|DRUG|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
223453421|NCT02464865|OTHER|Non-thiamine|no symptoms and signs of thiamine deficiency
223453422|NCT02464865|DRUG|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
223453423|NCT05638516|BEHAVIORAL|Vira mobile app intervention|The Vira app is installed on the participant's phone. The app passively collects data from phone sensors (i.e., measures of physical activity, sleep patterns, mobility, and language patterns reflecting mood states and cognition) that are indicative of risk-relevant behavioral patterns and psychological states. It also so prompts users to answer a daily check in question. Mobile sensing data are processed to provide an automated assessment of the user's functioning. Users will be asked to use Vira for 12 weeks.
223453424|NCT05638516|BEHAVIORAL|Vira mobile app intervention + coaching|"The Vira app can also be supported by a health coach. The health coach interacts with the user (via an instant messaging platform) and who also schedules just-in-time reminders (i.e., nudges) to arrive in the user's phone at scheduled times to support their behavior change plan. The Vira Health Coach Platform therefore integrates mobile sensing, self-report assessment, and just-in-time nudges and notifications into the coach's workflow."
223453425|NCT04633603|DEVICE|FeverFriend mobile application|Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
224061664|NCT02799407|OTHER|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
224061665|NCT06153251|DRUG|BMS-986453|Specified dose on specified days
224061666|NCT06153251|DRUG|Fludarabine|Specified dose on specified days
224061667|NCT06153251|DRUG|Cyclophosphamide|Specified dose on specified days
224061668|NCT02693561|BEHAVIORAL|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
224061669|NCT02693561|BEHAVIORAL|Self-Help Book|Reading the self-help book.
224061670|NCT02185950|DEVICE|ultrasound|
224061671|NCT02185950|DEVICE|paraffin|
224061672|NCT02185950|DEVICE|endermotherapy|
224061673|NCT03784547|DRUG|Ocrelizumab|already described
224061674|NCT03487575|BEHAVIORAL|Open trial|Integrated electronic support and care support manager contact
224061675|NCT03024489|DRUG|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
224061676|NCT03024489|DRUG|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
224061677|NCT03024489|DRUG|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
224061678|NCT03024489|DRUG|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
224061679|NCT03024489|DRUG|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
223453426|NCT06907355|DRUG|Codeine|Codeine 10mg/5ml + Pseudoephedrine 7.5mg/5ml + Chlorphenamine 0.5mg/5ml: 10ml three times per day during 4 days
223453427|NCT06907355|DRUG|Levodropropizine|Levodropropizine 30mg/5ml: 10ml three times per day during 4 days
223453428|NCT06907355|DRUG|Ivy Leaves Cough Liquid|Ivy Leaf (Hedera Helix Extract) 35 mg/5ml: 10ml three times per day during 4 days
223453429|NCT06907355|DRUG|Placebo|Vitamins: 10ml three times per day during 4 days
223453430|NCT01399476|PROCEDURE|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
223453431|NCT01399476|PROCEDURE|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
223453432|NCT03488069|OTHER|Survey|Submission of survey answers
223570862|NCT01741831|DRUG|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
224061680|NCT03024489|RADIATION|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
224061681|NCT00252343|DRUG|SR58611A|
224061682|NCT02239276|DRUG|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
224061683|NCT06113900|DRUG|Dapagliflozin 10mg Tab orally once daily|Sodium glucose co-transporter 2 inhibitors
224061684|NCT02646982|DRUG|Placebo|A matched placebo will be given once daily for 12 months.
224061685|NCT02646982|DRUG|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
224061686|NCT01671852|DRUG|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
224061687|NCT01671852|DRUG|Placebo|
224061688|NCT00750958|PROCEDURE|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
224061689|NCT00713700|DEVICE|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
224061690|NCT00527579|DRUG|[F-18]FBR|
224061691|NCT01077843|DRUG|Etoricoxib|Cox-2 inhibitor
224061692|NCT01077843|DRUG|Other Cox-2 inhibitors|Cox-2 inhibitor
224061693|NCT01077843|DRUG|Other Non-selective NSAIDs|Non-selective NSAID
224061694|NCT01077843|OTHER|No anti-inflammatory treatment|No anti-inflammatory prescription
224061695|NCT01251809|DRUG|Oncaspar|2000 U/m2 BSA, single infusion
224061696|NCT01251809|DRUG|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
224061697|NCT00528762|BEHAVIORAL|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
224061698|NCT05336071|DRUG|INS068 injection|Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
224061699|NCT05336071|DRUG|INS068 injection|Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
224071020|NCT01660074|OTHER|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
224061700|NCT05231148|PROCEDURE|local debridement and local calcium sulfate loaded by antibiotics|debridement of infected non united fractures and placement of local calcium sulfate loaded by antibiotic then follow up at regular intervals
224061701|NCT06076577|BEHAVIORAL|Prehabilitation Exercise Group|A set of core stabilization exercises and scoliosis specific exercises will be given to patients.
224061702|NCT01464476|DRUG|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
224061703|NCT01464476|DRUG|Placebo|Dose-matched placebo. Once daily, oral administration
224061704|NCT05571787|DRUG|HMPL-523|700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
224061705|NCT05571787|DRUG|Rabeprazole|40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
224061706|NCT05453331|PROCEDURE|bilateral STN deep brain stimulation|bilateral deep brain stimulation of the subthalamic nucleus in people with Parkinson's disease
224061707|NCT02518009|OTHER|Genetic men treated with estrogen|Observational during estrogen treatment
224061708|NCT02518009|OTHER|Genetic women treated with androgen|Observational during androgen treatment
224061709|NCT05580029|DEVICE|Triamcinolone Topical|The treatments will consist of fractional ablative CO2 laser therapies followed by topical application of triamcinolone dosed at 40 mg/ml.
224061710|NCT05580029|PROCEDURE|Fractional Ablative CO2 Therapy|1st pass: 30-40 mJ at 5% density. 2nd pass: 120 mJ at 1% density
224061711|NCT05580029|DRUG|EMLA 5% cream|2 g/10cm2 Topical 30 minutes before each fractional ablative CO2 session
224061712|NCT06137274|RADIATION|Intensity-modulated radiotherapy|All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.
224061713|NCT06137274|OTHER|Magnetic Resonance Guidance|All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
224061714|NCT05942027|DRUG|Placebo|Placebo match Coenzyme Q10 capsules once per day .
224061715|NCT05942027|DRUG|Co-Enzyme Q10|Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
224061716|NCT00253175|DRUG|topiramate|
224147783|NCT03049995|PROCEDURE|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
224147784|NCT03049995|PROCEDURE|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
224147785|NCT03049995|PROCEDURE|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
224147786|NCT03049995|PROCEDURE|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
224147787|NCT03049995|PROCEDURE|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
224147788|NCT03049995|PROCEDURE|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
224147789|NCT04787211|DRUG|BRII-196 and BRII-198|BRII-196 and BRII-198 given by intravenous administration
223570863|NCT02621177|BIOLOGICAL|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
223570864|NCT02621177|BIOLOGICAL|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
223570865|NCT00460954|DRUG|Sinemet® controlled release (Carbidopa/levodopa)|
223570866|NCT04965974|DEVICE|Digital blue light blocking filter|digital blue light blocking filter will be given to 80 dry eye subjects in mobile phones and laptops and 80 individuals will be without filters digital devices users
223570867|NCT00174863|DRUG|SR31747A|
223570868|NCT05423574|PROCEDURE|robotic Trans Abdomino Pre Peritoneal prothesis repair|The treatment of primary and incisional ventral hernia using the robotic assisted laparoscopy technique
223570869|NCT04029389|DEVICE|Injection|Local corticosteroid injection
223570870|NCT04029389|DEVICE|Tibial nerve block|Tibial nerve block
223570871|NCT04029389|OTHER|Conservational therapy|Only exercise and foot insoles
223570872|NCT01703689|BEHAVIORAL|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
223570873|NCT01703689|BEHAVIORAL|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
223570874|NCT05948228|DRUG|giomer based bioactive gel|Application of bioactive gel to prevent white spot lesions in orthodontic patients
223570875|NCT05948228|DRUG|Fluoride gel|Application of fluoride gel to prevent white spot lesions in orthodontic patients
223570876|NCT02080039|DEVICE|Electrical Stimulation|
223570877|NCT05797038|DRUG|Tacrolimus for the treatment of IMN|Remission after tacrolimus treatment of IMN
223570878|NCT01686750|BEHAVIORAL|Integrated care centers|
223570879|NCT00937144|DRUG|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
223570880|NCT00937144|DRUG|placebo|
223570881|NCT02378012|OTHER|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
224061717|NCT01337856|OTHER|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
224061718|NCT04697459|OTHER|chronic phase|1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
224061719|NCT04697459|OTHER|acute phase|30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
224061720|NCT06087653|DRUG|Lenalidomide|Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
224061721|NCT06087653|DRUG|Lenalidomide 25 MG Oral Capsule|Oral lenalidomide for active control
223742439|NCT04933539|BIOLOGICAL|Daratumumab|Daratumumab SC 1800 mg (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); up to 36 cycles total
223742440|NCT03288025|BEHAVIORAL|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
223742441|NCT02826707|BEHAVIORAL|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
223742442|NCT05483179|DIAGNOSTIC_TEST|CPET|Cardiopulmonary exercise test
224061722|NCT03966742|PROCEDURE|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
224061723|NCT05001321|RADIATION|The whole abdomen contrast-enhanced CT scan|All the participants were measured by the whole abdomen contrast-enhanced CT scan.
224061724|NCT05001321|OTHER|H&E stained sections and slides|HE pathological examination was performed on all specimens of enrolled patients.
224061725|NCT02874807|DRUG|Empagliflozin|
224061726|NCT02874807|OTHER|Placebo|
224061727|NCT05815589|OTHER|screw retained prosthesis group|hybrid prosthesis screwed on four mandibular intra-foraminal implants
224061728|NCT01077648|DRUG|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
224061729|NCT05917561|DRUG|Anifrolumab Infusion Product|Anifrolumab 300mg/month infusion for 36 weeks
224061730|NCT05917561|DRUG|Placebo|Placebo once a month, infusion for 36 weeks
224061731|NCT02340585|DEVICE|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
224061732|NCT01563770|DIETARY_SUPPLEMENT|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
224061733|NCT01563770|DIETARY_SUPPLEMENT|Placebo|3 placebo capsules, twice daily for four consecutive weeks
224061734|NCT03923426|OTHER|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
224061735|NCT00769002|BIOLOGICAL|FluShield|Flu vaccine
224061736|NCT00769002|BIOLOGICAL|FluShield - same arm|Flu vaccine
224061737|NCT00769002|BIOLOGICAL|FluShield - opposite arm|Flu vaccine
224061738|NCT00769002|PROCEDURE|Blood Draws|50 cc of heparinized blood and 10 cc of serum at study entry and at 10-12 week post vaccination
224061739|NCT00769002|PROCEDURE|FDG PET-CT Scan|PET scan
223742443|NCT02625155|OTHER|Urine diagnostic testing as SOC, drug regimen changes per SOC|
223742444|NCT02625155|OTHER|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
223742445|NCT00412763|DRUG|Silymarin (Silybum marianum)|
223742446|NCT02528656|DEVICE|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
223742447|NCT02528656|DEVICE|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
223742448|NCT05933577|BIOLOGICAL|Intismeran autogene|IM injection
223742449|NCT05933577|BIOLOGICAL|Pembrolizumab|IV infusion
223742450|NCT05933577|OTHER|Placebo|IM injection
223742451|NCT00941018|DRUG|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
224061740|NCT00769002|GENETIC|Cytokine Profiling|Blood draw for Cytokine Profiling Draw at 2,4 and 6 weeks post vaccination
224061741|NCT04543071|DRUG|Motixafortide|1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly
224061742|NCT04543071|DRUG|Cemiplimab|350 mg intravenous (IV) once every 21 days
224061743|NCT04543071|DRUG|Gemcitabine|1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)
224061744|NCT04543071|DRUG|Nab paclitaxel|125 mg/m2 IV on days 1, 8, 14 (every 28 days)
224061745|NCT02316535|DRUG|Capecitabine|adjuvant chemotherapy;
224061746|NCT03381235|OTHER|Spin exercise|Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
224061747|NCT04697875|OTHER|Normobaric hypoxia (FiO2 15%)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
224061748|NCT04697875|OTHER|Placebo-ambient air (FiO2 21%)|"Inhalation of room air through an altitude simulator (Altitrainer), for approx. 1/2 hour given by a facemask, first at rest and then during exercise."
224061749|NCT03623607|OTHER|Diabetes Survival Skills Education|Application of human factors and education principles to refine and optimize an DSSE program for delivery to inpatients with type 2 diabetes (D2Go - IN) using a table-based e-learning platform ; utilization of implementation science to inform design of implementation processes for delivery within nursing unit workflow; establishment of a D2Go program toolkit; and evaluation of the feasibility and preliminary impact of the program when delivered by nursing unit staff on medical-surgical units (MSUs) to adults with type 2 diabetes. Barriers and facilitators of the D2Go - Inpatient program's reach, effectiveness, adoption, implementation and maintenance (RE-AIM)(31) were explored
224061750|NCT04456179|DEVICE|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
224061751|NCT04456179|DEVICE|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
224061752|NCT04983407|DRUG|batiraxcept|Batiraxcept is experimental drug
224061753|NCT04983407|DRUG|Nab paclitaxel|Nab paclitaxel is active comparator
224061754|NCT04983407|DRUG|Gemcitabine|Gemcitabine is active comparator
223742452|NCT00534274|OTHER|3'-deoxy-3'-[18F]fluorothymidine|
224061755|NCT05779462|OTHER|Dynamic MRI Sequence|Addition of a Dynamic MRI Sequence during the MRI examination performed in routine care
223742453|NCT01558752|DEVICE|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
224061756|NCT00971451|OTHER|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
224061757|NCT00971451|OTHER|TENS|continuous use of TENS during the exercise session
224061758|NCT05059314|OTHER|Brisk walking (moderate physical activity)|"1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6"
224061759|NCT04291950|PROCEDURE|Needle core biopsy|"Blood draws will be done in OR by research staff. Tissue will be obtained at the time of their definitive surgery or at the time of port placement. For women going to surgery first, four (4) 16-gauge core needle biopsies will be obtained by research staff after the tumor has been removed from the patient and the specimen is on the collection table in the OR.~For women who are getting neo-adjuvant therapy prior to surgery, the core needle biopsies will be collected at the time of port placement in the OR. The patient will be under light anesthesia for the port placement. Per standard care, we will also use local anesthetic for the needle core biopsy. Port placement requires ultrasound (US). We will take advantage of the US already available in the OR to guide the core needle biopsy. Within 30 minutes of procurement, the tissue from the biopsies will be flash frozen in liquid nitrogen by staff and taken to the lab."
224061760|NCT05298007|DEVICE|High definition transcranial direct current stimulation|tDCS is described as a non-invasive form of brain stimulation that uses a low-intensity, constant current applied directly to the head through scalp electrodes.
224061761|NCT05298007|DEVICE|sham high definition transcranial direct current stimulation|Sham HD-tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only during the ramp-up and ramp-down periods of 30 and 30 seconds.
224061762|NCT00952497|DRUG|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
224061763|NCT02965495|DRUG|YYD302 2ml|YYD302 2ml
224061764|NCT02965495|DRUG|YYD302 3ml|YYD302 3ml
224061765|NCT02965495|DRUG|Placebo 3ml|phosphate buffered saline 3ml
224061766|NCT02005809|PROCEDURE|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
224061767|NCT05666427|BEHAVIORAL|Pelvic floor muscle training combined with stabilization exercises|While people are doing stabilization exercises, they will also work the pelvic floor muscles. Practices will be combined with breathing.
224061768|NCT05666427|BEHAVIORAL|Pelvic floor muscle training|Exercises that activate the pelvic floor muscles to strengthen and increase endurance.
224061769|NCT00556452|DRUG|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~* 1st dose level: 20 mg/m2/day x 5 days~* 2nd dose level: 30 mg/m2/day x 5 days~* 3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
224061770|NCT00556452|PROCEDURE|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
224061771|NCT00556452|RADIATION|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
224061772|NCT03629457|BEHAVIORAL|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
224061773|NCT05389163|DEVICE|Giomer based injectable resin composite|Giomer material has been introduced as the true hybridization of glass ionomer and resin composite, containing surface pre-reacted glass ionomer (S-PRG) filler particles within a resin matrix. Giomer combines caries protection through fluoride release and recharge of glass ionomers and the esthetics, physical and handling properties of resin composite
224061774|NCT05389163|DEVICE|Resin modified glass ionomer|Resin modified glass ionomer (RMGI) have been developed to combine the advantages of both resin composite and glass ionomer; the good mechanical properties, esthetic of resin composite added to anticariogenic activity and chemical bonding to tooth structure of glass Ionomer.
224061775|NCT02442973|PROCEDURE|Control group (CG): standard practice|Standard practice group
224061776|NCT02442973|PROCEDURE|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
224061777|NCT02442973|DEVICE|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
224147790|NCT04787211|DRUG|Placebo|Placebo given by intravenous administration
224147791|NCT04477915|OTHER|Core exercises|Core stabilization exercise include, plank, lateral plank, swimmer, flutter kick and bridge exercises.
224147792|NCT04477915|OTHER|Auxiliary respiratory exercises|Auxiliary respiratory exercises include, strengthening and stretching exercises for trapezius, sternocleidomastoideus, pectoralis major and serratus anterior muscles.
223742454|NCT01558752|DEVICE|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
223742455|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
224061778|NCT03551223|BIOLOGICAL|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
224061779|NCT00003362|BIOLOGICAL|QS21|
224061780|NCT00003362|BIOLOGICAL|gp100 antigen|
224061781|NCT00003362|BIOLOGICAL|incomplete Freund's adjuvant|
224061782|NCT00003362|BIOLOGICAL|sargramostim|
224061783|NCT00003362|BIOLOGICAL|tyrosinase peptide|
224061784|NCT02353156|OTHER|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
224061785|NCT02353156|OTHER|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
224061786|NCT04423809|OTHER|clinical assessment|assessment of caregivers suffering when a family member is hospitalized
224061787|NCT01836432|DRUG|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours
224061788|NCT01836432|BIOLOGICAL|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
224061789|NCT01836432|RADIATION|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
224147793|NCT05112484|DIAGNOSTIC_TEST|Measurement of concentrations of orally-used DMDs|"For effectiveness - the measured concentrations of orally used DMDs will be correlated with the clinical condition of patients with MS (usual clinical examinations such as physical assessment of clinical condition, evaluation of EDSS scale, MSQOL-54 quality of life questionnaire, and routine magnetic resonance imaging of the brain once a year). At the same time, the relationship between the measured concentrations of orally used DMDs and the concentrations of other biomarkers of MS, such as signs of axonal (so-called plasma neurofilament light chain - pNfL) and glial (so-called chitinase 3-like 1 - CHI3L1) damage, will be analyzed. concentrations of selected cytokines, concentrations of CD4 + and CD8 + T-lymphocytes, and the results of a genetic examination of drug transporters, again with an effect on the clinical condition of the patient."
224147794|NCT05112484|DIAGNOSTIC_TEST|Genetic testing|One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
224147795|NCT05112484|DIAGNOSTIC_TEST|Parameters for routine use of DMDs|"For safety - the usual parameters for routine use of DMDs will be monitored (blood count, liver tests, renal function, etc. according to the specifics of individual drugs)."
224301479|NCT01264731|DRUG|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
224301480|NCT04957836|OTHER|reversal with sugammadex|reversal with sugammadex for immediate extubation in the operating room
223570882|NCT02378012|OTHER|Computer-Assisted Intervention|Receive iPad and instruction manuals.
223570883|NCT02378012|OTHER|Questionnaire Administration|Ancillary studies
223570884|NCT04043754|PROCEDURE|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
223570885|NCT04043754|PROCEDURE|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
223570886|NCT01593995|DRUG|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
223570887|NCT05154136|DRUG|Etrumadenant|Capsule
223742456|NCT02160158|DRUG|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
223742457|NCT02160158|DRUG|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
223570888|NCT05154136|DRUG|Itraconazole|Capsule
223570889|NCT01571050|DRUG|Purified water|Ingestion of 30 mL of purified water
223742458|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
223742459|NCT02160158|DRUG|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
223742460|NCT02160158|DRUG|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
224061790|NCT01836432|DRUG|Gemcitabine|Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
224061791|NCT01836432|DRUG|Capecitabine|Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
224061792|NCT01836432|DRUG|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
224061793|NCT05455853|OTHER|Experimental: bilateral transcutaneous tibial nerve stimulation,exercise and advices|"• First group they will receive morning bilateral transcutaneous tibial nerve stimulation, for 30 minutes, three times per week for 4 weeks, in addition to abdominal muscle training and breathing exercise for 15 minutes three times per week, for 4 weeks and bowel care advices.•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices.~Second group•They will perform abdominal muscle training and breathing exercise, for 15 minutes three times per week, for 4 weeks in addition to bowel care advices."
224061794|NCT03951623|DRUG|HMPL-523|HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
224061795|NCT03951623|DRUG|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
224061796|NCT02554123|DRUG|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
224061797|NCT02554123|DRUG|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
224061798|NCT01143753|DRUG|RO5212054|Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
224061799|NCT00014456|BIOLOGICAL|filgrastim|
224061800|NCT00014456|DRUG|docetaxel|
224061801|NCT00014456|DRUG|gemcitabine hydrochloride|
224061802|NCT00960661|DRUG|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
224061803|NCT00960661|DRUG|insulin lispro|titrated based on pre-meal glucose level; three times a day
224061804|NCT00960661|DRUG|Metformin|
224061805|NCT00960661|DRUG|Insulin/ Glargine|
224061806|NCT03077347|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
224061807|NCT04091529|DEVICE|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
224061808|NCT02699892|DRUG|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
224061809|NCT02989558|DRUG|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
224061810|NCT02989558|DRUG|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
223453433|NCT05433272|BIOLOGICAL|Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain|The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.
223453434|NCT05433272|BIOLOGICAL|COVID-19 Vaccine (Vero Cell), Inactivated|The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.
223453435|NCT00356109|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
223453436|NCT00356109|DRUG|Injectable insulin|patient specific dose, injected, before meals, 6 months
223453437|NCT00356109|DRUG|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
223453438|NCT04214366|RADIATION|Carbon ion irradiation|22 x 3 Gy(RBE) Carbon Ions
223453439|NCT04214366|RADIATION|Bimodal irradiation|25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost
223453440|NCT00594893|PROCEDURE|Mini Incision Approach|Mini Incision Approach
223453441|NCT00594893|PROCEDURE|2 Incision Approach|2 Incision Approach
223453442|NCT01792765|OTHER|Ultrasound guidance|Patient will have intraoperative ultrasound .
223453443|NCT00823030|PROCEDURE|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
223453444|NCT00823030|DRUG|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
223453445|NCT00823030|OTHER|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
223453446|NCT04089501|DIAGNOSTIC_TEST|Stool collection|Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
223453447|NCT04089501|DIAGNOSTIC_TEST|Biopsy collection|3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
223453448|NCT02640313|DRUG|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
223453449|NCT05755646|OTHER|Ice Plant Intensive Cream plus Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome and on the use of the Ice Plant Intensive Cream for the prevention of hand-foot syndrome. The nursing consultation on the standard treatment includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
223570890|NCT01571050|DRUG|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
223742461|NCT02160158|DRUG|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
224061811|NCT02287974|DRUG|Stem cell infusion|Unique stem cell infusion of the randomized group
224061812|NCT01981590|DEVICE|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
224061813|NCT06077266|OTHER|Change of weight class to normal weight|The exposure is the change of weight class from obesity to normal weight during a follow-up period without known intervention.
224061814|NCT00067028|DRUG|Clofarabine 40mg/m^2|40 mg/m\^2 by vein over 1 hour daily for 5 days.
224061815|NCT00067028|DRUG|Idarubicin 10mg/m^2|"10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
224061816|NCT00067028|DRUG|Ara-C 0.75 g/m^2|0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
224061817|NCT00067028|DRUG|Clofarabine 22.5mg/m^2|22.5 mg/m\^2 by vein over 1 hour daily for 5 days.
224061818|NCT00067028|DRUG|Ara-C 1 g/m^2|1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
224061819|NCT00067028|DRUG|Idarubicin 6 mg/m^2|6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
223453450|NCT05755646|OTHER|Standard Care|"This group receives a 30-minute nursing consultation on the standard treatment according to the guideline Supportive Therapy for hand-foot syndrome. The nursing consultation includes recommended basic measures for the prophylaxis of hand-foot syndrome such as the avoidance of mechanical stress and chemical irritants. In addition, treatment of pre-existing skin conditions is recommended. Furthermore, prophylaxis with urea-containing cream (5-10%) should be applied several times a day."
223453451|NCT02800369|BIOLOGICAL|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
223453452|NCT05772117|BEHAVIORAL|Chatbot-delivered interventions tailored to stage of changes|Participants receive Chatbot-delivered interventions tailored to their stage of change regarding PV uptake in a conversational way at Month 0, 1, 2, and 3.
223453453|NCT05772117|BEHAVIORAL|Chatbot-delivered standard interventions|Participants receive Chatbot-delivered general information related to PV at Month 0, 1, 2, and 3.
223570891|NCT01571050|DRUG|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
223570892|NCT01571050|DRUG|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
223570893|NCT01571050|DRUG|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
223570894|NCT00580034|DRUG|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
223570895|NCT00580034|PROCEDURE|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
223570896|NCT01939002|DRUG|BIIB017|
223570897|NCT01939002|DRUG|naproxen|
223570898|NCT05405491|OTHER|PCR based strategy|Early adjustment of antimicrobial therapy according to the results of a multiplex PCR-based testing, used in addition to standard microbiological culture of the tracheal aspirate, in immunocompromised patients with suspected VAP or HAP requiring MV
223570899|NCT05405491|OTHER|Standard care|Broad-spectrum antimicrobial therapy adjustment after results of standard microbiological culture of the tracheal aspirate in immunocompromised patients with suspected VAP or HAP requiring MV
224061820|NCT04309240|DRUG|Rivaroxaban|Rivaroxaban 10mg orally per day for 90days
223453454|NCT03639857|DEVICE|532nm laser|532nm laser will be used to treat the lesion in this study arm.
224061821|NCT05178238|OTHER|Fecal sample|Fecal sample taken to investigate intestinal microbiota
224061822|NCT03303742|OTHER|deep chamfer|finish line marginal design of a full coverage crown preparation
224061823|NCT03303742|OTHER|feather edge|finish line marginal design of a full coverage crown preparation
224061824|NCT05220527|DRUG|Triamcinolone plus hyruan|triamcinolone plus hyruan injections, one time per week, for 3 weeks
224061825|NCT05220527|DRUG|vitagen plus hyruan|vitagen plus hyruan injections, one time per week, for 3 weeks
224061826|NCT05220527|DRUG|normal saline plus hyruan|normal saline plus hyruan injections, one time per week, for 3 weeks
223453455|NCT03639857|DEVICE|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
223453456|NCT03639857|DRUG|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
223453457|NCT01673581|OTHER|Survey|
223453458|NCT02805296|OTHER|Light irradiance|Comparison of double vs. single phototherapy
223570900|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
223570901|NCT00750191|DEVICE|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
223742462|NCT02160158|DRUG|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
224061827|NCT00421668|DRUG|Zinc|zinc
224061828|NCT00421668|DRUG|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
224061829|NCT00421668|DRUG|Placebo|Placebo
224061830|NCT06392646|BEHAVIORAL|self-management education program|Intervention through a self-management education program constructed through evidence summarization and expert correspondence.
224061831|NCT05396742|DRUG|Ravulizumab|Solution for infusion or injection, as applicable
224061832|NCT05396742|DRUG|rHuPH20|Solution for infusion
224061833|NCT02226107|BEHAVIORAL|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
224071021|NCT01406834|BEHAVIORAL|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
224061834|NCT02226107|BEHAVIORAL|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
224061835|NCT02519933|PROCEDURE|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
224061836|NCT02519933|PROCEDURE|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
224061837|NCT05917574|OTHER|n/a (non-interventional)|Non-interventional (Realist Evaluation study)
223453459|NCT04887350|BEHAVIORAL|Student-Senior Isolation Prevention Partnership (SSIPP)|The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
224061838|NCT04485520|OTHER|CARICA PAPAYA MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
224061839|NCT04485520|OTHER|CHLORHEXIDINE MOUTHWASH|Each application was 10 ml. applied for 1 minute, once a day for 8 days
224061840|NCT00630266|DEVICE|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
224061841|NCT06413862|DRUG|Ciprofol|The experimental group was slowly injected with ciprofol for 30 seconds (0.4mg/kg, Haisike Pharmaceutical Co., Ltd., Liaoning, China, batch number 20220911).
224061842|NCT06413862|DRUG|Propofol|The control group was slowly injected with propofol for 30 seconds (2mg/kg, Guorui Pharmaceutical Co., Ltd., Sichuan, China, batch number 22102914).
224061843|NCT00847912|DRUG|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
224071022|NCT04852120|OTHER|No intervention|Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
224071023|NCT02163434|DRUG|Gabapentin|
224071024|NCT02163434|DRUG|Metoclopramide|
223453460|NCT04887350|BEHAVIORAL|Problem Solving Therapy (PST).|Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
223453461|NCT03245320|DEVICE|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
223453462|NCT05619315|OTHER|Charcoal -based whitening toothpaste|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6 hours) for at least 1 minute using charcoal containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
223453463|NCT05619315|OTHER|Calcium carbonate /perlite containing whitening toothpaste.|The labial surface of anterior teeth will be brushed by the circular brushing technique twice daily (morning and after 6hours) for at least 1 minute using (calcium carbonate /perlite) containing toothpaste. Soft bristles toothbrushes will provided to all patients. After 1 month, re-evaluation of the stains will be performed and the data will be recorded.
223453464|NCT05603585|DIETARY_SUPPLEMENT|Optimal protein supplementation to achieve 80% protein adequacy.|Additional protein required and delivered by adding protein powder and given in bolus feeds
223570902|NCT05049213|DRUG|Carrageenan nasal spray and 1% PVP- mouthwash and gargle|"Day1 to Day7~1. Intranasal spray 3 times/day, 2\~3 spray/nostril/per time~2. Oral gargling 3 times/day, 15cc/per time"
223570903|NCT01182805|DEVICE|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
223570904|NCT01182805|DEVICE|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
223742463|NCT02160158|DRUG|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
224061844|NCT00847912|DRUG|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
224147796|NCT05112484|OTHER|Side effects of orally used DMDs|"For tolerability - possible side effects of orally used DMDs will be monitored and the effect of genetic testing of drug transporters will be analyzed."
224147797|NCT06186804|DRUG|ABSK021|Patients in each phase and dose group will receive continuous treatment with oral administration once a day for 28 days/cycle until conditions for treatment termination are met.
224147798|NCT06450353|BEHAVIORAL|Patient Ancestry Questionnaires|Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.
224061845|NCT03306732|DRUG|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
224061846|NCT03306732|DRUG|Normal saline (100ml)|"* After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
224061847|NCT03047070|DRUG|Lidocaine|IV Lidocaine infusion
224061848|NCT03047070|DRUG|Normal saline|IV normal saline infusion
224061849|NCT06377826|OTHER|aerobic exercises|group A will receive aerobic training like walking and cycling for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
224061850|NCT06377826|OTHER|resistance training|this group will receive resistance training like gluteal bridge, calf raise, squats, seated shoulder press for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
223570905|NCT01182805|DEVICE|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
223570906|NCT04715204|OTHER|High Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. Formula with caloric density of \>1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
224061851|NCT06377826|DRUG|medication|This group will be just on medication and no exercise will be given to this group
224061852|NCT00637260|DEVICE|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
224061853|NCT00637260|DEVICE|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
224061854|NCT01256073|DRUG|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
223570907|NCT04715204|OTHER|Standard Energy Oral Nutrition Supplement|Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density \>0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
223742464|NCT02160158|DRUG|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
224071025|NCT04549701|OTHER|CAVAL US-guided Therapy|Patients randomly assigned to this group will receive a daily CAVAL US exam guided decongestive therapy accessible to treating medical team, in addition to the standard care.
224071026|NCT04549701|OTHER|Standard of care|Standard of care will be provided.
224071027|NCT02350803|DEVICE|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
224071028|NCT02652884|DRUG|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
224071029|NCT02652884|DRUG|saline 0.9% NaCl|single dose of intramuscular placebo
224071030|NCT03012074|BEHAVIORAL|Type 2 Diabetes Self-Management|Patients with Type 2 Diabetes
224071031|NCT00554203|DRUG|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
224071032|NCT05381129|OTHER|Detection of Pain, Quality of Life, Sleep and Functioning|All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.
224071033|NCT05381129|OTHER|Temporomandibular joint dysfunction|Patients with jaw complaints will be evaluated for temporomandibular joint dysfunction.
224071034|NCT06500091|DRUG|TQB2916 injection + doxorubicin hydrochloride for injection|"TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40.~The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells."
224071035|NCT06500091|DRUG|TQB2916 injection+penpulimab injection|TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.
224071036|NCT06112106|BEHAVIORAL|Intelligent Physical Exercise Training (IPET)|The intervention group will follow an Intelligent Physical Exercise training (IPET) program delivered via a mobile phone app. The scope of the physical exercise program is 50 minutes per week, and it is individually tailored according to questionnaire responses about work profile, physical capacity, health status and extent of musculoskeletal pain.
224061855|NCT04596475|DRUG|glecaprevir/pibrentasvir (GLE/PIB)|The study intervention consists of a single daily dose of GLE/PIB 100/40 mg (one dose consists of 3 tablets) administered orally; or crushed and administered via a feeding tube if participant is unable to swallow by mouth, for example in the immediate post-operative period. First dose will be administered in the pre-operative period within 4 hours of surgery followed by once daily doses for 7 days total.
223742465|NCT01471106|DRUG|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
224147799|NCT00188968|PROCEDURE|Nasal Continuous Positive Airway Pressure|
223742466|NCT04340362|DRUG|VX-147|Tablets for oral administration.
223742467|NCT00102544|DEVICE|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
224147800|NCT00188968|PROCEDURE|Synchronized Nasal Positive Pressure Ventilation|
224147801|NCT03512470|DEVICE|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
224147802|NCT03512470|OTHER|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
224301481|NCT02579161|DRUG|cephalosporins|Patients were randomly assigned to the interventional arm or the control arm through stratified randomization. In addition to perioperative antibiotics, those in the interventional arm only received antibiotic course for up to 24 hours after procedure, while those in the control arm received antibiotics until external catheters were removed based on surgeon preference. Ancef, a 1st generation cephalosporin, was used as the primary antibiotic, which was started within 60 minutes of the procedure. Dosing was 1 gram IV every 8 hours and was adjusted for renal dosing as needed
223570908|NCT04715204|OTHER|Formula-75/Formula-100|"Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml"
223570909|NCT04048707|DRUG|Angiotensin II|Intravenous
223570910|NCT04048707|DRUG|Midodrine|Pill
223570911|NCT04048707|DRUG|Octreotide|Subcutaneous
223570912|NCT04048707|DRUG|Albumin solution|Intravenous suspension
223570913|NCT02975011|DRUG|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
223570914|NCT02975011|PROCEDURE|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
223570915|NCT02975011|PROCEDURE|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223570916|NCT02975011|PROCEDURE|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
223570917|NCT02975011|PROCEDURE|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223570918|NCT02975011|PROCEDURE|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
223570919|NCT02975011|PROCEDURE|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
223742468|NCT05841563|DRUG|PM54|"PM54 powder for concentrate for solution for infusion (3 mg/vial) is a sterile, preservative-free, lyophilized white to yellowish cake in a single-dose vial for reconstitution prior to intravenous infusion. Each vial contains 3 mg PM54.~Route of administration: Intravenous infusion"
223742469|NCT04669587|DRUG|ZB716|Pharmaceutical form: capsule Route of administration: oral
223742470|NCT04669587|DRUG|Palbociclib|Pharmaceutical form: capsule Route of administration: oral
223742471|NCT05735483|DRUG|Lebrikizumab|Administered SC
223742472|NCT05735483|DRUG|Placebo|Administered SC
223742473|NCT06253507|BIOLOGICAL|Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47|"Cryopreserved autologous CD34+ cells transduced ex vivo with the pCCLCHIM-p47 vector containing the human p47phox (NCF1) gene in final formulation and container closure system, ready for intended medical use.~The minimum cell dose for infusion is 3 x 10\^6 CD34+/kg."
223742474|NCT06466135|DRUG|WAL0921|Investigational drug WAL0921 Participants receive an intravenous infusion of WAL0921 investigational drug once every 2 weeks for 7 total infusions.
224061856|NCT03490305|PROCEDURE|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
224061857|NCT04277845|DRUG|Bortezomib, Lenalidomide, Dexamethasone|Bortezomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone
224061858|NCT05469971|GENETIC|KIR genotyping|DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).
224061859|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
224061860|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
224061861|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
224061862|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
224061863|NCT02517775|DIETARY_SUPPLEMENT|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
224061864|NCT02517775|DIETARY_SUPPLEMENT|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
224061865|NCT06149234|BEHAVIORAL|Fruit leather on the tongue|The patient holds a fruit leather strip on the tongue while being exposed.
224061866|NCT06149234|BEHAVIORAL|Chewing gum strip|The patient holds a banana-tasting gum strip on the tongue while being exposed.
224061867|NCT06149234|BEHAVIORAL|Celluloid matrix group|The patient holds a celluloid matrix stirp gum strip on the tongue while being exposed.
224061868|NCT00117468|DRUG|DR-2011|Administered vaginally from Day 14 to Day 31
224061869|NCT00117468|DRUG|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
224061870|NCT05251402|BEHAVIORAL|Group A - Patient Education|"If you are assigned to this group, you will receive education on asthma and health from an ALOHA health coach.~* In months 1-3, you will attend 3 individual and 8 group sessions. Individual sessions will last \~15 minutes and the first one will be in-person. Group sessions will last \~30 minutes and the first 2 of the 8 will be in person. You and your coach will determine if you may attend the remaining individual and group sessions remotely instead, via Zoom or phone. The purpose of these sessions is to provide you with general information about respiratory health topics, including recommendations for asthma care, inhaler use, and lung health.~* In months 4-12, you will complete 11 phone check-ins for \~10 minutes each. The purpose of these phone calls is to provide you with ongoing support and discuss health topics of your choice."
224061871|NCT05251402|BEHAVIORAL|Group B - Patient Education with Nutrition Counseling|"If you are assigned to this group, you will receive the same patient education as Group A. In addition, you will receive nutrition counseling from your health coach who is a registered dietitian.~* In months 1-3, the duration of the sessions will increase to \~30 minutes each for the 3 individual sessions and to \~60 minutes each for the 8 group sessions. This is because in addition to providing the same information on asthma and health as in Group A, your health coach will also counsel you on how to follow the DASH diet by adopting effective behavior change techniques such as goal setting, self-monitoring, and problem solving.~* In months 4-12, your health coach will review your progress, provide you with personalized feedback, assist you in problem solving as you continue to work towards the DASH dietary goals, and help you maintain the changes you have made over the long term."
224061872|NCT03646851|DIAGNOSTIC_TEST|Questionnaries|patients will have to do a sputum and to complete some questionnaries
224061873|NCT03645928|BIOLOGICAL|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with Lifileucel followed by aldesleukin administration. Lifileucel will be administered to patients once (on Day 0) during the study.
224061874|NCT03645928|BIOLOGICAL|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
224061875|NCT03645928|DRUG|Pembrolizumab|"Humanized antibody.~Pembrolizumab will be administered following tumor resection and will continue every 3 weeks or every 6 weeks thereafter for up to 2 years."
224061876|NCT03645928|BIOLOGICAL|LN-145-S1|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145-S1) followed by aldesleukin administration. TIL will be administered to patients once (on Day 0) during the study.
224061877|NCT03645928|DRUG|Ipilimumab|"Monoclonal antibody~Ipilimumab will be administered as a single dose prior to tumor resection."
224061878|NCT03645928|DRUG|Nivolumab|"Monoclonal antibody~Nivolumab will be administered once prior to tumor resection. The second dose will be administered prior to TIL administration and dosing will continue every 4 weeks for up to 2 years."
224061879|NCT03645928|DRUG|Nivolumab-relatlimab|Nivolumab-relatlimab will be administered following tumor resection and will continue every 4 weeks thereafter for up to 2 years.
224061880|NCT03645928|DRUG|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
224061881|NCT03645928|DRUG|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
224061882|NCT03645928|DRUG|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
224061883|NCT03645928|DRUG|Nab-Paclitaxel|Nab-Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
224061884|NCT03645928|DRUG|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if applicable.
224061885|NCT06276283|DRUG|DZD9008 plus Bevacizumab|DZD9008, 200 mg or 300 mg, once daily plus Bevacizumab 15 mg/kg, once every 3 weeks
224061886|NCT06544161|DEVICE|CPMX2|The CPMX2 is a point-of-care device for non-invasive, real-time, and intermittent monitoring of vascular occlusion pressure.
224061887|NCT01838109|DIETARY_SUPPLEMENT|oral nutritional supplement|
224061888|NCT00142350|DRUG|continuous infusion of 5-fluorouracil|
224301482|NCT02579161|DRUG|Fluoroquinolones|If the patient has an allergy to penicillin or cephalosporin, then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV and would be continued every 12hrs if patient has a normal creatinine clearance
224301483|NCT02579161|DRUG|Clindamycin|If allergic to penicillin, cephalosporins, and fluoroquinolones, 900 mg Clindamycin started within 60 minutes prior to initial surgical incision.
224061889|NCT00142350|DRUG|combination of irinotecan and cisplatin|
224061890|NCT00142350|DRUG|oral administration of S-1|
223742475|NCT06466135|DRUG|Placebo|Placebo product Participants receive an intravenous infusion of placebo once every 2 weeks for 7 total infusions.
224061891|NCT00800293|DRUG|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
223570920|NCT02975011|OTHER|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
223570921|NCT02030197|BEHAVIORAL|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
224061892|NCT03070470|DRUG|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
224301484|NCT02579161|DRUG|Ampicillin/Gentamicin|5 mg/kg as a single dose of Gentamicin within 60 minutes prior to surgical incision; given in combination with 2 grams of ampicillin in cases where allergic to fluoroquinolone and cephalosporin
223570922|NCT02030197|OTHER|Control Group|no treatment
223570923|NCT04673942|BIOLOGICAL|AdAPT-001|Oncolytic virus administered by intratumoral injection
223570924|NCT04673942|DRUG|Checkpoint Inhibitor, Immune|Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
223570925|NCT03372460|DEVICE|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
223570926|NCT03372460|DEVICE|Sham stimulation|For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).
223570927|NCT03372460|OTHER|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
223570928|NCT01863173|DRUG|metoprolol|using B blocker in patient group
223570929|NCT01863173|DRUG|placebo|placebo to control group
223570930|NCT02499900|DRUG|Copaxone®|Subcutaneous Injections
223570931|NCT04532593|PROCEDURE|autologous adipose stem cell injection|Abdominal or buttock fat will be aspirated under local anesthesia or general anesthesia by conventional methods (0.5 ml fat was aspirated per 1 cm2 of skin graft area). The matrix component rich in adipose stem cells will be obtained by chopping, washing and centrifugation. The intervention treatment will be performed after the skin graft sutured. The stem cell components will be injected underneath the skin graft (0.05 ml/cm2).
223570932|NCT04532593|PROCEDURE|saline injection|saline will be injected underneath skin graft (0.05 ml/cm2).
223570933|NCT04074018|OTHER|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
223570934|NCT04074018|OTHER|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
223570935|NCT01608217|DRUG|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
223570936|NCT01608217|DRUG|Placebo|placebo (tablet) three times daily for a period of three weeks.
223570937|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
223570938|NCT01608217|DRUG|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
223570939|NCT04590313|PROCEDURE|Arthrodesis|MTPJ I arthrodesis
223570940|NCT02885857|DRUG|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
223570941|NCT01796119|PROCEDURE|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
224061893|NCT03070470|DRUG|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
224301485|NCT00134043|DRUG|vorinostat|Given orally
224301486|NCT04882423|OTHER|grilled hamburger (7 oz) with no vegetables|Test meal 1: grilled hamburger (7 oz) with no vegetables
224301487|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)|Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
223570942|NCT01796119|PROCEDURE|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
223570943|NCT06468527|DRUG|Diponecaftor|"Diponecaftor is a triple combination of DIR/POS/NES. The combination therapy will be administered orally during 8 weeks. The daily dose contains:~* DIR 300 mg/day~* POS 600 mg/day~* NES 10 mg/day"
223570944|NCT06468527|DRUG|Placebo|Placebo once daily for 8 weeks. Oral administration.
223570945|NCT05648864|DEVICE|Viamigo|Mobile application with the aim to enhance the independent outdoor mobility of the user while a coach (informal caregiver) can monitor the route from a distance.
223570946|NCT00733200|PROCEDURE|Minor or Major Liver Resection|
223570947|NCT01771848|BIOLOGICAL|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
223742476|NCT04299490|BEHAVIORAL|Sleep Fragmentation|Subjects are provided an 8-hour sleep opportunity. Two speakers are placed 12 inches from the head of the bed and four remote-activated mechanical vibrators are placed underneath the mattress. EEG microarousals (\>3 s), as defined according to standard criteria, are elicited at a frequency of 30 or more events per hour.
224061894|NCT03070470|DRUG|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
224061895|NCT03070470|DRUG|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
224061896|NCT03070470|DRUG|Placebo|Placebo (administered orally)
224061897|NCT03070470|DRUG|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
224061898|NCT02709499|DEVICE|0J LLLT|perform with the machine off
224061899|NCT02709499|DEVICE|6J LLLT|irradiation will be perform with 4J
224061900|NCT02371226|DRUG|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
224147803|NCT05666440|PROCEDURE|Visco-Circumferential-Suture-Trabeculotomy in Primary Open Angle Glaucoma.|A superior limbal-based conjunctival flap and a paracentesis. A superficial rectangular scleral flap 4×4 mm was fashioned and dissected forward toward the limbus. A deep sceral flap (2×2 mm) was then created toward the limbus underneath the superficial flap exposing the scleral spur and deroofing SC. Viscoelastic (Healon GV, Pfizer, NY) was injected (using a standard 30 G viscocanalostomy cannula) into the ostia of SC Then, the 5/0 polypropylene suture tip was cauterized into a blunt tip (to ensure atraumatic probing of SC). The tip was inserted into the left ostium of SC using a microsurgical forceps and advanced through the whole circumference of the canal. When the tip presented to the right ostium the AC was filled with a viscoelastic through the paracentesis and traction was applied to approximate both ends of the 5/0 polypropylene suture, thus creating a visco-360-degree trabeculotomy.
224147804|NCT05666440|PROCEDURE|Rigid probe Viscotrabeculotomy in Primary Open Angle Glaucoma.|A fornixbased conjunctival incision followed by creation of a partial thickness (about 50% thickness) triangular (4×4×4 mm) scleral fap, followed by localization of Schlemm's canal by radial incisions straddling the limbus. High viscosity sodium hyaluronate (Healon GV, Pfzer) was then slowly injected into both ends of Schlemm's canal. Trabeculotomy was completed using the standard Harm's trabeculotome (Geuder Instruments), the scleral fap was then secured tightly with interrupted 10/0 Nylon sutures and conjunctival closure ensued.
224147805|NCT04699071|DRUG|pembrolizumab and lenvatinib|"All patients will receive oral lenvatinib daily plus intravenous pembrolizumab 3-weekly.~A cycle is 21 days. Allowances will be made for stepwise dose reductions of lenvatinib due to treatment-related toxicities.~Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, (CTCAE) Version 5.0.~Patients are planned to continue therapy until disease progression, intolerable toxicity, or withdrawal of patient consent."
224147806|NCT04220671|BIOLOGICAL|measles vaccine|Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
224147807|NCT04220671|OTHER|Saline|0.9% NaCl
224147808|NCT04458532|OTHER|Aerobic Training|300 min/wk for 16 weeks
224147809|NCT04458532|OTHER|Aerobic Training|150 min/wk for 32 weeks
224147810|NCT04458532|OTHER|Aerobic Training|300 min/wk for 32 weeks
224147811|NCT04458532|OTHER|Aerobic Training|150 min/wk for 16 weeks
223453465|NCT01054495|DRUG|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
223453466|NCT01054495|DEVICE|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
223453467|NCT01054495|DEVICE|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
223453468|NCT04835064|DRUG|Nab paclitaxel|Albumin combined with paclitaxel 125mg/m2 intravenous infusion, Day 1, 8, 15
223453469|NCT04835064|DRUG|Gemcitabine|Intravenous infusion of 1000 mg/m2 was given for more than 30min on days 1, 8, and 15, and repeated every 4 weeks
224061901|NCT03969849|DRUG|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
224061902|NCT03969849|DRUG|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
224061903|NCT00630656|DRUG|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
224061904|NCT00630656|DRUG|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
224061905|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
224061906|NCT01732796|DRUG|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
224061907|NCT01732796|DRUG|Ribavirin (RBV)|24 weeks of active RBV
224061908|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
224061909|NCT01732796|DRUG|BI 201335 (Faldaprevir)|24 weeks of BI 201335
224061910|NCT01732796|DRUG|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
224061911|NCT01732796|DRUG|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
224061912|NCT01732796|DRUG|Faldaprevir (BI 201335)|24 weeks of 201335
224061913|NCT01732796|DRUG|BI 207127|24 weeks of BI 207127
224061914|NCT02806089|DEVICE|Handheld dynamometer|Evaluation of muscle strength
224061915|NCT02806089|BIOLOGICAL|Creatinine index|Evaluation of muscle mass using plasma creatinine level
224061916|NCT02806089|DEVICE|Electrical bioimpedance analysis|Evaluation of lean body mass
224061917|NCT02806089|OTHER|"Voorrips score questionnaire"|Evaluation of physical activity
224061918|NCT02806089|BIOLOGICAL|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
224061919|NCT01422148|DRUG|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
224061920|NCT01422148|DRUG|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
224147812|NCT06136819|COMBINATION_PRODUCT|RT-310|Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)
224061921|NCT05307484|OTHER|Serious game|This is a serious game in the form of a mobile application, designed to educate adults on dengue prevention.
224061922|NCT05307484|OTHER|Dengue prevention website|This is a website containing information regarding dengue prevention.
224061923|NCT03639870|DEVICE|Model iS3 three-stent trabecular micro-bypass system|Provided in Arm/Group descriptions.
224061924|NCT03147716|OTHER|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
224061925|NCT03147716|OTHER|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
224061926|NCT03147716|OTHER|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
224061927|NCT03147716|OTHER|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
224061928|NCT02376270|DIETARY_SUPPLEMENT|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
224061929|NCT02376270|DIETARY_SUPPLEMENT|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
224061930|NCT05774730|OTHER|Emphysema quantitative analysis software based on chest image AI technology|The participants would undergo lung CT, and the integrity of interlobar fissure will be quantitatively analyses by software based on chest image AI technology.
224061931|NCT05774730|OTHER|artificial analysis of chest image|The participants would undergo lung CT, and the integrity of interlobar fissure will be artificially analyses.
224061932|NCT05774730|PROCEDURE|imported Chartis detection system|The participants would undergo imported Chartis detection system.
224061933|NCT05087550|PROCEDURE|Liver Transplantation|Patients who underwent liver transplantation at Methodist Dallas Medical Center
224147813|NCT05014542|PROCEDURE|Acupuncture|Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
224061934|NCT06125769|PROCEDURE|Liver transplantation|Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver). Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
224061935|NCT05144750|BEHAVIORAL|Fruit and Vegetable Prescription|"The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips."
224061936|NCT05267275|PROCEDURE|extended resection with splenic flexure mobilization|During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
224061937|NCT02854514|PROCEDURE|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
223570948|NCT03385265|BEHAVIORAL|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
224061938|NCT05970198|RADIATION|Total Marrow irradiation，TMI|"TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given.~TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min."
224061939|NCT05970198|PROCEDURE|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation;Porting method melphalan
223570949|NCT03385265|OTHER|Standard of Care|Parents in the standard of care control group will be instructed to manage their child's T1D as recommended by the diabetes team.
223570950|NCT03982264|PROCEDURE|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
223453470|NCT04835064|DRUG|mFOLFIRINOX|Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
224061940|NCT02104986|DRUG|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
224061941|NCT02104986|DRUG|Vepeside-ifosfamide-Cisplatin|
224061942|NCT01858077|DEVICE|ABSORB BVS™|Bioresorbable scaffold
224061943|NCT01858077|DEVICE|XIENCE™|Drug eluting metallic stent
224061944|NCT06264895|BEHAVIORAL|Exercise|three times weekly exercise intervention with protein supplementation
224061945|NCT02324920|DEVICE|DDD-CLS|
224061946|NCT02324920|DEVICE|ODO|
224061947|NCT04240444|DEVICE|drug-coated balloon Catheter|All eligible subjects will be assigned randomly to study group or control group, receive PTCA.
224061948|NCT02767440|BEHAVIORAL|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
224147814|NCT05014542|DRUG|Conventional Medical Treatment|Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
224147815|NCT06226714|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
224147816|NCT06226714|BIOLOGICAL|MPSV4|1 dose of MSPV4 on Day 0
224147817|NCT03239639|BEHAVIORAL|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
224147818|NCT03239639|OTHER|Wait list control|No intervention
224147819|NCT00278096|BEHAVIORAL|occupational therapy|
224147820|NCT03245502|BIOLOGICAL|Blood transfusion|The transfusion of erythrocyte suspension
224147821|NCT01917890|DIETARY_SUPPLEMENT|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
224147822|NCT01917890|DIETARY_SUPPLEMENT|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
224147823|NCT00145912|BEHAVIORAL|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
223453471|NCT02186158|DRUG|Vitamin C|
223453472|NCT02186158|DRUG|Placebo|
223453473|NCT02364297|DEVICE|Early TIPS|TIPS (first 5 days)
223453474|NCT04824937|DRUG|Telaglenastat|Capsule, taken by mouth
223453475|NCT04824937|DRUG|Talazoparib|Capsule, taken by mouth
223570951|NCT03982264|PROCEDURE|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
223570952|NCT04913987|DEVICE|Stryker Triathlon total knee replacement|Knee arthroplasty using a standard care total knee.
223570953|NCT04913987|DEVICE|Zimmer Biomet Persona Partial Knee unicondylar knee replacement|Knee arthroplasty using the Zimmer Biomet Persona Partial Knee (PPK).
224061949|NCT04882306|DEVICE|Bilateral MARIA scan|After consent has been given, the participant's breast will be fitted by the operator using a clear plastic cup to determine their corresponding MARIA® cup insert size. Once this has been determined, participants will be required to lie prone with their breast pendent through an aperture in the MARIA® patient bed. The cup insert will contain a layer of coupling fluid. The hemispherical cup inserts, and array are brought into contact with the breast. Depending on the patient's breast size, one or more cup inserts may be placed in the array to ensure a good but non-compressing fit between the breast and the system interface. The scan sequence will then be performed, this takes a couple of minutes.
224061950|NCT04431570|DEVICE|rTMS|The device is made in London, United Kingdom
224061951|NCT04431570|DEVICE|sham stimulation|the device of sham stimulation was MagStim MC-P-B70 placebo butterfly coil
224061952|NCT06458803|DRUG|Eltrombopag|patients receive oral eltrombopag at 25 to 75 mg once daily according to disease severity，with the treatment of DMARDs at minimal or routine dosages.
224147824|NCT00145912|BEHAVIORAL|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
224147825|NCT00555568|BEHAVIORAL|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
224147826|NCT00555568|BEHAVIORAL|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
224301488|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)|Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
224061953|NCT04219345|DEVICE|Transcranial direct current stimulation|Both groups will undergo the same protocol of twelve sessions of twenty minutes of tDCS associated with mindfulness, where only the type of received electric current is varied (active or simulated sham type). The twelve sessions will be performed in three sessions per week for four weeks, and mindfulness practice at home will be encouraged on days when the intervention is not administered.
224061954|NCT01109875|OTHER|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
224061955|NCT00576459|DRUG|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
224061956|NCT00576459|DRUG|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
224061957|NCT00576459|PROCEDURE|standard of care laser photocoagulation|standard of care laser photocoagulation
223742477|NCT04299490|DRUG|Within-Subject test of blinded study medication (stimulant, benzodiazepine, opioid, cannabinoid, over-the-counter pain medication, or placebo)|On the third day of the in-patient visit participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter pain medications, or placebo (saline).
223742478|NCT04299490|BEHAVIORAL|Sleep Continuity Disruption|An 8-hour sleep opportunity period starting from lights out is divided into eight, one-hour intervals. One of the intervals is randomly determined to be a 60 minute forced awakening, during which no sleep is permitted. Each of the remaining seven, 60-minute intervals are subdivided into tertiles (20 min. blocks). A 20-min forced awakening (FA) is randomly scheduled to occur in either the 1st, 2nd, or 3rd tertile of each hour. During FAs, staff keep subjects awake, either by voice or gentle shaking.
223742479|NCT04299490|BEHAVIORAL|Undisturbed Sleep|Subjects sleep normally for an 8 hour period.
223742480|NCT01519414|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
224061958|NCT00930761|BEHAVIORAL|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
223742481|NCT01519414|OTHER|Placebo|Given PO
223742482|NCT01519414|DRUG|Tivantinib|Given PO
223742483|NCT02883153|DRUG|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
224061959|NCT05988476|OTHER|Exercise|5 day/week, two week, one session stretching exercises consisting of ten repetitions of one minute
224061960|NCT05988476|DEVICE|Pulsed Electromagnetic Field Therapy|5 day/week, two week,two sessions consisting of 180 minutes
224061961|NCT02409849|DRUG|Octreotide lar|
224147827|NCT00638417|BEHAVIORAL|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
223570954|NCT02345772|DRUG|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
223570955|NCT02345772|DRUG|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
223570956|NCT02345772|DRUG|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
224061962|NCT00823407|DRUG|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
224061963|NCT00823407|DRUG|Placebo|Subjects will receive a single oral dose of placebo
224061964|NCT03223064|DIAGNOSTIC_TEST|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
224061965|NCT03223064|DIAGNOSTIC_TEST|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
224061966|NCT02498015|DRUG|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
224061967|NCT02498015|DRUG|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
224061968|NCT03724864|DIETARY_SUPPLEMENT|delivery of snacks|Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
224061969|NCT02824705|PROCEDURE|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
224061970|NCT03949920|DRUG|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
224061971|NCT06279767|DRUG|6-mercaptopurine|6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
223742484|NCT04062331|DEVICE|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
223742485|NCT04062331|DRUG|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
223742486|NCT05848258|DRUG|LY3871801|Administered orally
223742487|NCT05848258|DRUG|Placebo|Administered orally
223742488|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract|2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
223742489|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin|Multivitamin
223742490|NCT02422745|DIETARY_SUPPLEMENT|Cocoa extract placebo|Cocoa extract placebo
224061972|NCT05879042|OTHER|Static Stretching|Participants will be placed in the maximum dorsiflexion position of the ankle of the dominant side lower extremities. At this last point, it will be held in a static position for 30 seconds. A total of 10 repetitions will be done, with 5-10 seconds rest between repetitions.
223453476|NCT05272553|OTHER|Narrative Exposure Therapy|NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.
223453477|NCT06077162|OTHER|Diabetes Nutrition Education Classes|Diabetes nutrition education offered by registered dietitian in group-based classes.
223453478|NCT06077162|OTHER|Healthy Food Security Resource|Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
223453479|NCT02381613|OTHER|Baked beef|A meal based on baked beef
223453480|NCT02381613|OTHER|Baked herring|A meal based on baked herring
223453481|NCT02381613|OTHER|Pickled herring|A meal based on pickled herring
223453482|NCT01025284|DRUG|LY2523355|Administered intravenously as a 1-hour infusion
223453483|NCT01025284|DRUG|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
223742491|NCT02422745|DIETARY_SUPPLEMENT|Multivitamin placebo|Multivitamin placebo
223742492|NCT01147029|DRUG|angiogenesis inhibitor GSAO|
223742493|NCT01147029|OTHER|laboratory biomarker analysis|
224061973|NCT05879042|OTHER|Dynamic Stretching|Participants will be positioned by placing their hands on the edge of the standing wall. They will be asked to try to increase normal ankle motion in a controlled manner using their own body weight. The stretching position will be held for 30 seconds and a total of 10 repetitions will be done. There will be 5-10 seconds rest between repetitions.
223453484|NCT01703169|DRUG|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
223453485|NCT02753816|DRUG|Tranexamic Acid|
223453486|NCT02753816|DRUG|Placebo Comparator|
223453487|NCT01465230|DRUG|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
223453488|NCT00905567|DRUG|Topiramate 2 x 25 mg tablet|
223742494|NCT01147029|OTHER|pharmacological study|
223742495|NCT01147029|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223742496|NCT06073821|DRUG|Sonrotoclax|Administered orally
224071037|NCT02665429|BEHAVIORAL|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
223453489|NCT00905567|DRUG|Topamax® Tablet 2 x 25 mg|
223453490|NCT05482503|DEVICE|12-Lead ECG(I-lead)|All participants will simultaneously record 12-lead ECGs(I-lead)
223453491|NCT03046771|BEHAVIORAL|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
223453492|NCT02542397|GENETIC|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
223453493|NCT04028323|DRUG|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
223742497|NCT06073821|DRUG|Zanubrutinib|Administered orally
223742498|NCT06073821|DRUG|Venetoclax|Administered orally
223453494|NCT04028323|DRUG|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
223453495|NCT02014519|PROCEDURE|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
223453496|NCT02014519|OTHER|Data collection|Active questioning
223453497|NCT04485663|DRUG|ALG-010133|Single or multiple doses of ALG-010133
223453498|NCT04485663|DRUG|Placebo|Single or multiple doses of Placebo
223742499|NCT06073821|DRUG|Obinutuzumab|Administered intravenously
223742500|NCT00391274|DRUG|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
223742501|NCT00391274|DRUG|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
223742502|NCT00210041|DRUG|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
223742503|NCT00210041|DRUG|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
223742504|NCT04837157|DEVICE|Exoskeleton rehabilitation|The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
224147828|NCT00638417|BEHAVIORAL|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (\>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
223453499|NCT03875469|DEVICE|Centargo injector (BPI 1000045)|Contrast-enhanced computer tomography conducted with Centargo injector
223453500|NCT03875469|DEVICE|Stellant MP injector|Contrast-enhanced computer tomography conducted with Stellant MP injector
223453501|NCT04985227|OTHER|Home weight monitoring|Parents will be provided with weighing scales to weigh their infant at home and plug in the weight in the patient portal for review by their primary care provider.
223453502|NCT04241510|DEVICE|Kinesio Taping|Kinesio Taping is a special taping method developed by Dr. Kenzo Kase in 1973. This technique triggers natural healing responses of human body by activating nervous and circulatory systems. The tapes are thin, latex-free, cotton, porous and anti-allergenic, with equal thickness of epidermis. It has elastic properites which allows the tape to elongate to %55-60 of its original lenght. Tape can be used up to 1 week even after sweating or cleaning with water. There are different application techniques for different purposes. Facilitation technique facilitates muscle contractions and supports muscle function. Mechancial correction technique is used for joint positioning and correcting motion of muscle-joint dynamics.
223453503|NCT01164150|RADIATION|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
223453504|NCT00389467|DEVICE|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
223453505|NCT02767778|DEVICE|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
223453506|NCT02767778|DEVICE|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
224147829|NCT06489782|OTHER|Model 1|Model 1 examines the impact of alcohol cues and alcohol availability on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
224147830|NCT06489782|OTHER|Model 2|Model 2 examines the impact of alcohol cues and alcohol availability and a priming dose of alcohol (.04 g/dL) on latency to start drinking and amount consumed of a 0.12 g/dL dose of alcohol during a 2-hour ad-libitum period.
223453507|NCT02208076|DEVICE|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
223453508|NCT02362191|DEVICE|Alternating Current Stimulator|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
223453509|NCT05868681|DEVICE|Delos instrument (computerized balance board)|"Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction."
223453510|NCT02133833|DEVICE|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
223453511|NCT02320708|DRUG|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
223453512|NCT02320708|DRUG|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
223453513|NCT02320708|DRUG|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
223453514|NCT02320708|DRUG|Placebo|2 placebo caplets for acetaminophen taken orally one time
223453515|NCT02320708|DRUG|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
223453516|NCT02320708|DRUG|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
223453517|NCT01738919|PROCEDURE|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
223453518|NCT01738919|PROCEDURE|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
223453519|NCT04566718|DRUG|Metformin|metformin cessation
223453520|NCT00947310|DEVICE|Standard ICD programming|Standard ICD programming
223453521|NCT00947310|DEVICE|High rate cutoff|Programming of a high rate cutoff
223453522|NCT00947310|DEVICE|Long delay|Programming of a prolonged delay
223453523|NCT04632459|DRUG|pembrolizumab plus ramucirumab|"Patients will continue to receive study treatment, until they demonstrate objective disease progression (determined by modified RECIST 1.1) or until they meet any other discontinuation criteria.~* Ramucirumab 8mg/kg on q2W~* Pembrolizumab 200mg on q3W (pembrolizumab first followed by ramucirumab when concurrently administered on the same day)~* If ramucirumab had to be stopped due to intolerable toxicity, pembrolizumab will be continued until unacceptable toxicity, disease progression or upto 35 cycles."
223453524|NCT03200561|DRUG|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
224147831|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
223742505|NCT06371118|DEVICE|Directly mailed self-sampling kit to collect a vaginal sample|"The HPV self-sampling test will be sent by post directly to the woman's address. If the woman does not return the sample within 20 days, she will be sent a SMS reminder.~The returned samples will be analysed. If high-risk HPV is present, women will be invited to be screened for cervical cancer in a clinical setting by their family doctors.~Self-samples in which high-risk HPV is present will also be subjected to HPV DNA methylation test. If an abnormal HPV DNA methylation is detected and the woman has not attended the screening in a clinical setting yet, she will be informed by her family doctor that a new test has indicated the need to attend a medical appointment."
223742506|NCT06371118|DEVICE|Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure|"Women will initially receive an invitation letter in their home addresses to receive the self-sampling kit, as well as a pre-paid envelope to return the answer to this invitation. If the woman does not return the answer within 10 days, she will be sent a SMS reminder. Only those who respond affirmatively to the question will receive the self-sampling kit.~The steps that follow will be the same as in intervention 1."
223742507|NCT06371118|DIAGNOSTIC_TEST|Standard of care - screening in a clinical setting|Corresponds to the standard of care. An invitation to attend the conventional cervical cancer screening (clinician-collected cervical sample for HPV test and reflex cytology) will be sent by post to the woman's address.
223742508|NCT01351844|BEHAVIORAL|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
223742509|NCT01351844|BEHAVIORAL|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
224147832|NCT00844324|DRUG|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
223453525|NCT03200561|BIOLOGICAL|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
223453526|NCT02716792|DRUG|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
223453527|NCT02022046|OTHER|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
223453528|NCT03793647|DEVICE|Electrical muscle devise|evaluate two types of EMS stimulation of legs
223570957|NCT02345772|DRUG|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
223453529|NCT01473940|BIOLOGICAL|ipilimumab|Given IV
223453530|NCT01473940|DRUG|gemcitabine hydrochloride|Given IV
223453531|NCT01473940|OTHER|laboratory biomarker analysis|Correlative studies
223453532|NCT06488898|DRUG|Allogeneic adipose tissue-derived mesenchymal stem cells|"Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention."
223570958|NCT00444704|DRUG|PRA-027|
223570959|NCT00563069|DRUG|Midazolam|
223570960|NCT02439450|BIOLOGICAL|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
223570961|NCT02439450|DRUG|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
223570962|NCT02439450|DRUG|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
223570963|NCT02439450|DRUG|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
223570964|NCT03998670|DEVICE|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
223570965|NCT03998670|DEVICE|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
223453533|NCT06358118|DRUG|Buyuan Zhixiao Formula|Buyuan Zhixiao Formula
223453534|NCT06358118|DRUG|Placebo|The placebo contains 10% of the active ingredients of the Chinese medicine group
223453535|NCT00024440|BIOLOGICAL|filgrastim|
223570966|NCT04959617|DEVICE|Quantitative Fecal Immunochemical Test (qFIT)|The study only included quantitative FIT examination in the general physical examination population over 30 years old.
223570967|NCT03568253|OTHER|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
223570968|NCT03568253|OTHER|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
223570969|NCT03200275|DIAGNOSTIC_TEST|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
223570970|NCT00436423|DRUG|gemcitabine, TS-1|
223570971|NCT00132756|DRUG|Doxil and Estramustine|
223570972|NCT01745523|PROCEDURE|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
223570973|NCT01745523|PROCEDURE|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
224061974|NCT05879042|OTHER|PNF Stretching|For the lateral head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-adduction-external position. For the medial head of the gastrocnemius muscle, the dominant side lower extremities of the participants will be placed in the extension-abduction-internal rotation position. Participants will be asked to actively go as far as they can in the opposite direction from the starting position (flexion-abduction-internal rotation for the lateral head; flexion-adduction-external rotation for the medial head). When the participant returns to the starting position after reaching the final point, the practitioner will apply the hold-relax technique and will be asked to stay in this position for 10 seconds.
224061975|NCT05879042|OTHER|Sham stretching|Sham stretching will be applied to the calf area. While the participant is lying prone, they will wait 30 seconds in a static position without applying any stretching to the calf area before reaching the end point of the joint range of motion.
224061976|NCT03500900|DRUG|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
224061977|NCT03500900|DRUG|Placebo Oral Tablet|Acute administration of placebo tablet
224061978|NCT03627260|BEHAVIORAL|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
224061979|NCT01339806|BEHAVIORAL|Cognitive Rehab|APT-III, Other standard individual and group interventions.
224061980|NCT01339806|BEHAVIORAL|Brainworks|POSIT
224061981|NCT01339806|BEHAVIORAL|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
224061982|NCT03971279|DRUG|Dexamethasone Ophthalmic implant|intravitreal injection of ozurdex implant
224061983|NCT02474732|DEVICE|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
224061984|NCT00397813|DRUG|Cyclosporine|Given PO
224061985|NCT00397813|DRUG|Fludarabine Phosphate|Given IV
223453536|NCT00024440|BIOLOGICAL|oblimersen sodium|
223453537|NCT00024440|DRUG|cyclophosphamide|
223453538|NCT00024440|DRUG|fludarabine phosphate|
223453539|NCT06080542|PROCEDURE|Aerobic|This session will consist of an aerobic training session performed on a cycle ergometer.
223453540|NCT06080542|PROCEDURE|High-intensity interval training|This session will consist of a HIIT performed with elastic bands
224061986|NCT00397813|OTHER|Laboratory Biomarker Analysis|Correlative studies
224061987|NCT00397813|DRUG|Mycophenolate Mofetil|Given PO
224061988|NCT00397813|PROCEDURE|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
224061989|NCT00397813|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
224061990|NCT00397813|RADIATION|Total-Body Irradiation|Undergo TBI
224061991|NCT06460090|BEHAVIORAL|Happy Talk|A targeted selective speech language and communication programme embedded in the community, designed for people livling in social disadvantage.
224061992|NCT03267121|DRUG|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
224061993|NCT03267121|DRUG|Tegafur Gimeracil Oteracil Potassium Capsules|25mg/㎡ bid p.o. every day for 14 days as a cycle
224061994|NCT06330389|PROCEDURE|Burn Injuries Graft Surgery|Burn Injuries Graft Surgery
224061995|NCT03488875|BEHAVIORAL|mMBRT|Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
224071038|NCT06550167|DIETARY_SUPPLEMENT|Nano-PSO, Pomegranate seed oil (omega-5)|"During the intervention, Nano-PSO dietary supplement will be administered to the participants in the assigned group.~Participants will be followed before and after treatment to assess the effects of Nano-PSO on cognitive status, serum concentrations of trophic factors, and other relevant parameters . This randomized, double-blind, controlled clinical trial design allows for a rigorous evaluation of the potential benefits of Nano-PSO in patients with substance use disorders. The study aims to provide valuable insights into the neuroprotective and cognitive-enhancing properties of Nano-PSO in this population."
224147833|NCT04702984|DEVICE|LID021201 contact lenses|Investigational silicone hydrogel sphere contact lenses for frequent replacement daily wear
223453541|NCT05936021|PROCEDURE|Algorithm model-based Aranesp doses|Patients will receive doses calculated by the algorithm instead of by the standard of care procedures. Model-based Aranesp doses will be computed at the same time that doses based on the dialysis anemia protocol are determined. The model-based doses will be administered instead of the protocol-based doses and in the same way and at the same time as the protocol-based doses would have been. The model-based dosing will be more flexible than the protocol-based dosing. Some constraints in the protocol-based dosing were created to prevent patients from achieving high Hb levels. The model-based dosing will also prevent these high Hb values but will do so by predicting a patient's Hb level into the future and then using these predictions to determine doses to reduce Hb variability and to reduce the amount of Aranesp used.
223453542|NCT05936021|PROCEDURE|Standard of care|Current standard of care guidelines are followed for erythropoiesis-stimulating agents to control anemia in dialysis patients
223453543|NCT01147718|BIOLOGICAL|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
223453544|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 60L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
224061996|NCT01974544|DRUG|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
224061997|NCT01974544|PROCEDURE|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
224061998|NCT01974544|PROCEDURE|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
224061999|NCT01974544|DRUG|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
224062000|NCT01974544|DRUG|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration \>4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (\>4.0 mmol/L).
224062001|NCT01974544|BEHAVIORAL|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
224062002|NCT05862181|PROCEDURE|DEB-TACE plus HAIC or HAIC alone|the patients received DEB-TACE plus HAIC or HAIC at least twice during this observational study
224071039|NCT06550167|OTHER|PLACEBO|In this arm of the study the participants will receive a placebo as a control treatment . The placebo is essential in clinical trials to compare the effects of the active intervention (Nano-PSO) with those of an inert substance.
224301489|NCT04882423|OTHER|grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).|Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
223453545|NCT04934163|OTHER|Flow rate setting of high-flow nasal cannula (initially 40L/min)|"The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%."
223453546|NCT03744403|DRUG|CS1001|In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose-expansion part, both dose levels will be expanded.
223453547|NCT00547248|BIOLOGICAL|Synflorix|Intramuscular injection, 1 dose
223453548|NCT00547248|BIOLOGICAL|Tritanrix-HepB|Intramuscular injection, 1 dose
223570974|NCT00581269|BEHAVIORAL|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
224071040|NCT02740088|OTHER|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
224301490|NCT00541970|BIOLOGICAL|Cervarix|Intramuscular injection, different dosing /schedule
224301491|NCT00541970|DRUG|Placebo|Intramuscular injection, different dosing /schedule
224301492|NCT00321828|BIOLOGICAL|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
224301493|NCT00321828|DRUG|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
223453549|NCT00547248|BIOLOGICAL|Hiberix|Reconstituted with Tritanrix-Hep B before injection
223453550|NCT00547248|BIOLOGICAL|Polio Sabin|Oral, 1 dose
223453551|NCT00547248|BIOLOGICAL|Poliorix|Intramuscular injection, 1 dose
223453552|NCT00547248|BIOLOGICAL|Prevenar (Wyeth)|Intramuscular injection, 1 dose
223453553|NCT01754324|DRUG|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
223453554|NCT03999957|OTHER|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
223453555|NCT00197431|DRUG|S-1|
223570975|NCT00581269|DIETARY_SUPPLEMENT|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
223570976|NCT01170065|DRUG|BIBF 1120|Intermediate dose BIBF 1120 twice daily
223570977|NCT01170065|DRUG|BIBF 1120|High dose BIBF 1120 twice daily
224062003|NCT04568278|OTHER|ePRO-CTCAE application|The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
224147834|NCT04702984|DEVICE|OPTI-FREE multipurpose solution|Solution for cleaning, disinfecting, and reconditioning silicone hydrogel contact lenses
224301494|NCT00321828|DRUG|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
224301495|NCT00321828|DRUG|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
223453556|NCT06161714|DRUG|Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml|4% articaine with 1:100,000 epinephrine buccal infiltration
223453557|NCT06161714|DRUG|Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml|2% Lidocaine with 1:100,000 epinephrine buccal infiltration
223453558|NCT02020369|BIOLOGICAL|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
223570978|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 twice daily
223570979|NCT01170065|DRUG|BIBF 1120|Low dose BIBF 1120 once daily
223570980|NCT02538419|BEHAVIORAL|CPAP + Peer Support|
223742510|NCT02467010|DRUG|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
224062004|NCT01674101|OTHER|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
224147835|NCT02590419|DEVICE|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
224147836|NCT03167541|DRUG|Test|RB naproxen sodium tablets (2x220mg)
224301496|NCT01461226|BEHAVIORAL|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
224301497|NCT01461226|BEHAVIORAL|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
223453559|NCT06202703|DRUG|Pneumococcal Vaccine|vaccination with pneumococcal vaccine (PCV13)
223453560|NCT00534248|BIOLOGICAL|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
223453561|NCT00534248|BIOLOGICAL|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
223453562|NCT04221269|BEHAVIORAL|Enhanced Treatment as Usual|Routine community care plus assessment feedback reports to clinicians.
223453563|NCT04221269|BEHAVIORAL|Coping Long-term with Active Suicide Program for Schizophrenia|Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
223453564|NCT02532257|DRUG|Ibrutinib|Given PO
223453565|NCT02532257|OTHER|Laboratory Biomarker Analysis|Correlative studies
223453566|NCT02532257|DRUG|Lenalidomide|Given PO
223453567|NCT02532257|BIOLOGICAL|Rituximab|Given IV
223453568|NCT03319316|DRUG|Durvalumab|Combination of durvalumab + tremelimumab treatment
223453569|NCT03319316|DRUG|Tremelimumab|Combination of durvalumab + tremelimumab treatment
223453570|NCT01534117|BIOLOGICAL|Platelets|1 unit of platelets
223453571|NCT01534117|DRUG|DDAVP|Desmopressin 0.3mcg/kg IV x 1
223453572|NCT02849171|DEVICE|PET scan|
223453573|NCT02849171|RADIATION|C-Choline|
223570981|NCT02538419|BEHAVIORAL|CPAP + Individual Education|
223570982|NCT00118313|BIOLOGICAL|incomplete Freund's adjuvant|
223570983|NCT00118313|BIOLOGICAL|multi-epitope melanoma peptide vaccine|
223570984|NCT00118313|BIOLOGICAL|sargramostim|
223570985|NCT00118313|BIOLOGICAL|tetanus toxoid helper peptide|
223570986|NCT00118313|DRUG|dimethyl sulfoxide|
223570987|NCT00118313|DRUG|imiquimod|
223570988|NCT00118313|PROCEDURE|adjuvant therapy|
223570989|NCT02984241|BEHAVIORAL|eHealth Coping Skills Training|Access to a specialized coping skills training website
223570990|NCT02984241|BEHAVIORAL|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
223570991|NCT02984241|BEHAVIORAL|Coach Support|Access to a professional coach by phone
223570992|NCT00006441|DRUG|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
223570993|NCT00006441|DRUG|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
223570994|NCT00006441|DRUG|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
223570995|NCT00068913|DRUG|Dichloroacetate|
224062005|NCT01674101|OTHER|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
224062006|NCT01674101|OTHER|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
224062007|NCT01674101|OTHER|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
224147837|NCT03167541|DRUG|Reference|Aleve naproxen sodium tablets (2x220mg)
223453574|NCT05833919|DRUG|Eribulin Mesylate|"The dose of Eribulin as the ready to use solution is 1.23 mg/m2 which should be administered intravenously over 2 to 5 minutes on Days 1 and 8 of every 21-day cycle. The amount of Eribulin required (calculated above) will be withdrawn from the appropriate number of vials into a syringe. This may be injected directly as an IV bolus over 2-5 minutes or diluted in up to 100 ml 0.9% sodium chloride (NaCl) for IV infusion over 2-5 minutes.~The dose of Eribulin may be reduced or discontinued during any cycle in accordance with the toxicity modifications described in this chapter. Toxicities will be managed by treatment interruption and dose reduction. Once the dose has been reduced, it cannot be increased at a later date"
223570996|NCT01460355|DRUG|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
223570997|NCT01460355|DRUG|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
223570998|NCT03938220|DEVICE|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON\_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
223570999|NCT05933642|DRUG|Aminophylline|aminophylline 150mg
223571000|NCT05933642|DRUG|Frusemide|frusemide 120mg
223571001|NCT00770042|DRUG|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
223571002|NCT00770042|DRUG|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
223571003|NCT00770042|DRUG|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
223571004|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 8
223571005|NCT00770042|DRUG|Avanafil|Avanafil 50 mg on Days 1 and 6
223571006|NCT00770042|DRUG|Avanafil|Avanafil 200mg Days 1 and 6
223571007|NCT04093765|DIAGNOSTIC_TEST|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~* collection of 3x1cm dried blood spots on filter paper~* administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~* collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~* 1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
223571008|NCT04093765|DRUG|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
223571009|NCT02486991|PROCEDURE|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
223571010|NCT02486991|PROCEDURE|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
224062008|NCT04944160|OTHER|Medical records analysis|To review of medical records to describe diagnosis and severity of the disease.
224062009|NCT04944160|OTHER|Comparison of cohorts|To compare pre and post Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
224062010|NCT03600662|OTHER|TriRec|Trileaflet Reconstruction of the Aortic Valve
224062011|NCT03600662|OTHER|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
224062012|NCT02766738|OTHER|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
224147838|NCT06169995|DRUG|Remimazolam Tosilate|bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
224147839|NCT02565446|PROCEDURE|Magnetic Resolution Elastography (MRE)|Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
224147840|NCT04831567|RADIATION|MIBG-I131|Radiopharmaceutical
224147841|NCT00092482|BIOLOGICAL|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
224301498|NCT06356363|OTHER|Data collection|data collection
223571011|NCT04072601|DRUG|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
223571012|NCT04072601|DRUG|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
223571013|NCT01504633|DIETARY_SUPPLEMENT|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
223453575|NCT05833919|DRUG|Capecitabine|Capecitabine use in breast cancer is registered as monotherapy in advanced breast cancer after failure of a taxane- and anthracycline-containing chemotherapy or for patients for whom an anthracycline is contraindicated. Capecitabine is available in tablets of 150 and 500 mg. The recommended dose as a single agent is 1,250 mg/m2 b.i.d. (twice daily) for 14 days repeated on day 22. The tablets should be swallowed with water within 30 minutes after a meal. Caution is recommended in patients with ischemic heart disease or coronary artery disease and/or in therapy with sorivudine and analogs, coumarins, and phenytoin.
223453576|NCT00988104|BEHAVIORAL|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
223453577|NCT00988104|BEHAVIORAL|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
223453578|NCT05695963|OTHER|Clinical assessment|RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
223453579|NCT05695963|BEHAVIORAL|auto-questionnaires|To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
223453580|NCT05695963|DEVICE|Ecological Momentary Assessment (EMA)|4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
223571014|NCT03602313|DEVICE|Body Weight Support Gait Training|
223571015|NCT03602313|OTHER|Traditional Gait Training|
223571016|NCT02387801|DRUG|Ixekizumab|Administered SC
223571017|NCT05594069|OTHER|triple pre-rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out from the time of enrollment (T0). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
223571018|NCT05594069|OTHER|triple rehabilitation|The triple intervention consisted of exercise, nutrition and psychology. Based on the intervention framework, face-to-face intervention adjustment and intensive intervention measures were carried out at the time of the beginning of radiotherapy (T1), and the middle stage of radiotherapy (T2). Combined with weekly telephone follow-up during the intervention, the intervention content formulated face-to-face last time was reviewed, reinforcement behaviors were performed, and questions were answered during the intervention.
223571019|NCT01529580|BEHAVIORAL|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
223571020|NCT05410847|DRUG|Camrelizumab Nab-Paclitaxel S-1|Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
223571021|NCT00101816|DRUG|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
223571022|NCT03442257|BEHAVIORAL|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
223571023|NCT00686322|DRUG|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
223571024|NCT05585229|DRUG|Psilocybin-assisted Psychotherapy|Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
223571025|NCT06534229|DIAGNOSTIC_TEST|Endoscopic ultrasound-guided fine-needle aspiration|Endoscopic ultrasound-guided fine-needle aspiration for biopsy
223571026|NCT02003066|PROCEDURE|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
223571027|NCT02003066|PROCEDURE|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
223571028|NCT03524287|PROCEDURE|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
224062013|NCT02766738|OTHER|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
224062014|NCT01756131|DRUG|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
224062015|NCT01756131|OTHER|Placebo to match injectable suspension|placebo
224062016|NCT01500278|BIOLOGICAL|Certolizumab Pegol (CZP)|"* Active substance: an injectable volume of 1 ml solution for injection CZP~* Pharmaceutical form: prefilled syringes CZP~* Concentration: 200 mg/ml CZP~* Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal."
224062017|NCT01500278|BIOLOGICAL|Adalimumab (ADA)|"* Active substance: an injectable volume of 0.8 ml solution for injection ADA~* Pharmaceutical form: prefilled syringes ADA~* Concentration: 40 mg/0.8 ml ADA~* Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal."
224062018|NCT01500278|DRUG|Methotrexate (MTX)|"* Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally"
224062019|NCT05590260|DRUG|IV iron infusion|single-dose IV iron infusion
224147842|NCT01989871|BEHAVIORAL|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
224147843|NCT05333640|DEVICE|Sirolimus Drug Coated Balloon|AVFs treated with SDCB
224147844|NCT05333640|DEVICE|Paclitaxel Drug Coated Balloon|AVFs treated with PDCB
224147845|NCT02060968|DEVICE|Promus PREMIER|
224147846|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
224301499|NCT00218166|DRUG|GABA Agonists|GABA drugs administered acutely by mouth
223453581|NCT05695963|DEVICE|activity-rest cycle|To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
223453582|NCT04727736|DRUG|18F-DCFPyL|18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
223453583|NCT04064203|OTHER|Oral glucose tolerance test|50 grams OGTT
223453584|NCT04064203|OTHER|Clamp experiment|insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
223571029|NCT00853125|BIOLOGICAL|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
223571030|NCT00853125|DRUG|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
223571031|NCT00711490|DRUG|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
223571032|NCT00252226|DRUG|Quetiapine|
223571033|NCT03023826|DRUG|LY3202626 (R-Fasting)|Administered orally
223571034|NCT03023826|DRUG|LY3202626 (T1-Fasting)|Administered orally
224301500|NCT04265339|OTHER|Smoking cessation|Participants are required to quit smoking
224301501|NCT04006314|OTHER|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
223453585|NCT03204617|BIOLOGICAL|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 0.5mL at weeks 0, 4 and 8 + Vaccine MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM).
223453586|NCT03204617|BIOLOGICAL|At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
223453587|NCT03204617|DRUG|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
223453588|NCT00459810|DRUG|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
223571035|NCT03023826|DRUG|LY3202626 (T1-Fed)|Administered orally
223571036|NCT06767917|DEVICE|Eyefill® S.C.|Used as viscoelastic devices during cataract surgery
223571037|NCT06767917|DEVICE|Eyefill® M.B.|Used as viscoelastic devices during cataract surgery
223571038|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
223571039|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
223571040|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
223571041|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
223571042|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
223571043|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
223571044|NCT01049165|DRUG|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
223571045|NCT01049165|DRUG|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
223571046|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
223571047|NCT01049165|DRUG|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
223571048|NCT00754091|DEVICE|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
223571049|NCT02869698|PROCEDURE|Spectral Dynamic Imaging|
223571050|NCT02869698|DEVICE|Hybride electrode|
223571051|NCT02869698|DEVICE|Macro electrode|
224062020|NCT05590260|DRUG|Oral iron tablets|60 mg of elemental iron
224062021|NCT00283595|DRUG|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
224062022|NCT00283595|DRUG|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
224062023|NCT05076383|OTHER|Study Group (Motor relearning program)|Task-specific training based on motor relearning program will be performed for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each training session will consist of five training tasks: (1) bed mobility and sitting up over the side of the bed; (2) balanced sitting; (3) standing up and sitting down; (4) balanced standing; and (5) practice of walking.
224147847|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
224147848|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
224147849|NCT04144179|BIOLOGICAL|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
224147850|NCT04144179|BIOLOGICAL|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
224062024|NCT05076383|OTHER|Control Group (Conventional physical therapy program)|The conventional physical therapy program (CPT) exercises will be performed following a standard stroke rehabilitation program for 8 weeks (3 sessions per week; 1 hr. per session; total 24 sessions). Each CPT rehabilitation session will include the following exercises: (1) passive and active-assisted range of motion; (2) stretching; (3) strengthening exercises; (4) balance exercises; and (5) walking.
224062025|NCT02854423|DEVICE|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
224062026|NCT02459795|DRUG|Ingenol Mebutate (Perrigo)|
224062027|NCT02459795|DRUG|Ingenol Mebutate (Reference)|
223453589|NCT00459810|DRUG|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
223571052|NCT05632588|OTHER|Observational study|Observational surveillance study
223571053|NCT03571672|DRUG|DEFINITY|All subjects will receive a single dose of DEFINITY®
223571054|NCT02736513|DRUG|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
223571055|NCT02796872|DIETARY_SUPPLEMENT|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
223571056|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
223571057|NCT02796872|DIETARY_SUPPLEMENT|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
223571058|NCT02796872|DIETARY_SUPPLEMENT|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
223571059|NCT06023628|OTHER|Danish Helicopter Emergency Service|Patients with traumatic cardiac arrest assessed by the Danish HEMS
223571060|NCT06226168|OTHER|exercise and environmental conditions|Participants will perform endurance-strength training for 4 weeks in a variety of environmental conditions. Somatic indices and quantitative indicators of bone mass (bone mineral density) will be measured both before and after the training period. Before the first training day and the day after the last training day, blood will be drawn for biochemical analysis.
223571061|NCT06226168|OTHER|exercise and environmental conditions|Passive exposure to normobaric hypoxia conditions. No training intervention. There will be a measurement of selected somatic indices and a quantitative measurement of bone mass indices (bone mineral density). A blood draw for biochemical analysis will be performed.
223571062|NCT02511600|OTHER|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
223453590|NCT00000757|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223453591|NCT05216445|BEHAVIORAL|Mindfulness Training|The Mindfulness Training will be an 8-week course, with group-based online weekly sessions. The mindfulness training, translated and adapted in Urdu, includes 8 guided audio meditations and one introductory audio recording which gives the participants an overview and introduction of the forthcoming 8-week training (e.g what mindfulness is, some common terms used repeatedly). It also includes 8 chapters, corresponding to each week and a workbook to record home practice. The training will start with an online group session after which the participants will be emailed the 1st week's reading material (chapter 1), audio recordings (for that week), home practice (for that week). At the start of every week, the participants will be emailed the required material for that week. Online sessions will be conducted weekly. The participants will also be sent poems and/or quotations relating to the week's theme and based on the session proceedings.
223571063|NCT02511600|OTHER|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
223571064|NCT02511600|BEHAVIORAL|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
223571065|NCT00428220|DRUG|sunitinib|sunitinib
223571066|NCT04343014|DEVICE|Tongue Root Retractor|Fibroptic endutracheal intubation will be performed with tongue root retractor.
223571067|NCT04343014|DEVICE|Conventional Fibroscope|Fibroptic endutracheal intubation will be performed in conventional way.
223571068|NCT04159584|OTHER|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
223571069|NCT02024880|DEVICE|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
223571070|NCT02024880|DEVICE|Conventional catheter group|A standard embryo catheter
223571071|NCT00357617|DRUG|celecoxib|
223571072|NCT00357617|GENETIC|microarray analysis|
223571073|NCT00357617|GENETIC|protein expression analysis|
223571074|NCT00357617|OTHER|immunoenzyme technique|
224062028|NCT02459795|DRUG|Placebo gel|
224062029|NCT03362021|PROCEDURE|transvaginal oocyte retrieval|sedation for oocyte retrieval
224062030|NCT04013035|PROCEDURE|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
224062031|NCT01709435|DRUG|Cabozantinib S-malate|Given PO
223571075|NCT00357617|OTHER|immunohistochemistry staining method|
223571076|NCT00357617|OTHER|laboratory biomarker analysis|
223571077|NCT00357617|PROCEDURE|biopsy|
223571078|NCT00357617|PROCEDURE|conventional surgery|
223571079|NCT00357617|PROCEDURE|neoadjuvant therapy|
223571080|NCT01748474|PROCEDURE|Supplemental oxygen via a mask|
223571081|NCT04077372|BEHAVIORAL|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
223571082|NCT04077372|BEHAVIORAL|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
224062032|NCT01709435|OTHER|Laboratory Biomarker Analysis|Correlative studies
224062033|NCT01709435|OTHER|Pharmacological Study|Correlative studies
224062034|NCT02981875|OTHER|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
224062035|NCT02981875|OTHER|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
224062036|NCT03294785|PROCEDURE|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
224062037|NCT03294785|DRUG|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
224062038|NCT03294785|PROCEDURE|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
224062039|NCT00730938|DRUG|cefuroxime|intracameral cefuroxime 0.1 ml
224062040|NCT00730938|DRUG|Saline placebo|0.1 ml of Ringers lactate
224062041|NCT04452981|DEVICE|VeNS|The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
224062042|NCT01319695|DRUG|corifollitropin alfa|100 microg for a group of women weighing \<or=60 kg and 150 microg for a group of women weighing \>60 kg
224062043|NCT01319695|DRUG|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
223453592|NCT02259400|DEVICE|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)\< 0.3.
223453593|NCT02259400|DEVICE|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 \< 0.3.
223453594|NCT03905837|DRUG|Lidocaine|Intravenous or paravertebral lidocaine
223453595|NCT03905837|DRUG|Remifentanil|intravenous remifentanil
223453596|NCT04464967|BIOLOGICAL|SNK01|Patient-specific ex vivo expanded autologous natural killer cells
223453597|NCT04464967|DRUG|Trastuzumab|HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
223453598|NCT04464967|DRUG|Cetuximab|EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
223453599|NCT00315614|BIOLOGICAL|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
223453600|NCT02224612|DEVICE|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
223453601|NCT02224612|DEVICE|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
223453602|NCT00697593|DRUG|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
223453603|NCT01618786|OTHER|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
223453604|NCT01618786|OTHER|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
223571083|NCT00030771|DRUG|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
223571084|NCT00030771|RADIATION|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
223571085|NCT00030771|PROCEDURE|Surgery|3-4 weeks after termination of radiotherapy
223571086|NCT00549900|BIOLOGICAL|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
223571087|NCT05942378|DRUG|HRXG-K-1939|HRXG-K-1939
223571088|NCT05942378|DRUG|Adebrelimab|Adebrelimab is a programmed death-ligand 1 antibody
223571089|NCT02982018|DEVICE|senofilcon A with new UV blocker|Investigational Contact Lens
223571090|NCT02982018|DEVICE|senofilcon A|J\&J Marketed Contact Lens
223742511|NCT02467010|DRUG|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
223742512|NCT02467010|DRUG|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
223742513|NCT01306357|DRUG|Somatropin|4 mg or 10 mg delivered by needle-free device
223742514|NCT03051607|DRUG|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
223742515|NCT04366076|DIAGNOSTIC_TEST|Fetal heart rate (FHR) monitoring through computerized cardiotocography (cCTG) analysis antepartum|The investigator conducted antepartum surveillance through computerized cardiotocography (cCTG) analysis antepartum. This is a non-invasive method to study fetal well being. For each patient, a cCTG was attended using a computerized cardiotocography machine. External cCTG was practised for no less than 20 min (max 60 min), two transducers were fixed on the maternal abdomen: one above the fetal heart level and the other at the uterine fundus
224062044|NCT05329376|DEVICE|Smart Speaker Echo Dot|"Participants will receive the Smart Speaker EchoDot 3rd Gen (Amazon Echo®) device (i.e., Alexa) for home use, installed during a home visit following the study enrollment. In addition to the usual functionality of the system, the device will be programmed using a standard model developed by the research team, applied to each patient. The proposed model involves automatic interactions between the device and the patient, comprising:~1. Medication reminders~2. Glucose test reminders:~3. Educational health tips~4. Weekly educational podcasts~5. Good morning and good night routine"
224062045|NCT05329376|OTHER|Usual Care|Participants will maintain usual care during the study period and will receive a booklet with general advice following enrollment
224062046|NCT05914909|BIOLOGICAL|AD-214|AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.
224062047|NCT05914909|OTHER|Placebo|Placebo
224062048|NCT03473496|BIOLOGICAL|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
224062049|NCT05069857|DRUG|Camrelizumab (anti-PD-1 inhibitor)|The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
224062050|NCT05069857|DRUG|Apatinib (anti-VEGFR inhibitor)|The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
224062051|NCT00575809|OTHER|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
224062052|NCT00183274|DRUG|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
224062053|NCT00183274|DRUG|Placebo|six month intervention with placebo drug
224062054|NCT04345744|PROCEDURE|Periodontal surgery|Surgery will be performed following a standardized protocol by a single operator (FG). The procedure consists in the performance of a primary full-thickness flap incision, and of a secondary releasing vertical incision of maximum 3 mm limited to keratinized gingiva. At the end of the surgical procedure, soft tissues will be repositioned by means of a suture involving only the primary incision, while it will not be performed on the releasing incision.
224062055|NCT04345744|DEVICE|Hyaluronic and 0.2% chlorhexidine mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
224062056|NCT04345744|DEVICE|Chlorhexidine 0.2% mouth rinse|The mouth rinse protocol assigned to each study participant included a 10 ml-rinse for 60 seconds twice-a-day (every 12 hours) for 14 days.
224062057|NCT05848154|DIAGNOSTIC_TEST|ctDNA detection|Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.
224062058|NCT02370875|DEVICE|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
224301502|NCT04141358|DIAGNOSTIC_TEST|Advanced ultrasound measurements|"Clinical interventions and procedures:~* Consent at 0 week~* Clinical data collection at 0 week~* Strain for native artery at 0 week~* Young's modulus for native artery at 0 week~* Intimal medial thickness for native artery at 0 week~* Ultrasound blood volume flow measurement at 0 week~* Vessel diameter at 0 week~* Blood pressure at 0 week~* BMI at 0 week~* Intra-operative blood volume flow measurement at AVF surgery time~* Strain for native artery at 6 weeks~* Young's modulus native artery at 6 weeks~* Intimal medial thickness native artery arteries at 6 weeks~* Ultrasound blood volume flow measurement at 6 weeks~* Vessel diameter at 6 weeks~* Blood pressure at 6 weeks~* BMI at 6 weeks"
224301503|NCT04336514|DEVICE|Semi-compressed felt pad (SCF)|Participants with forefoot callus will receive routine treatment of debridement of callus. Along with the debridement, a Plantar Metatarsal Pad (PMP) made of Semi-Compressed Felt (SCF) with appropriate cut outs will be placed in their shoes. The thickness of the SCF would be selected based on the patient weight, and appropriateness of the thickness would be confirmed by the Medilogic pressure measurement. A 50% pressure reduction is the desired outcome.
224301504|NCT01816919|OTHER|collecting breath samples|
224062059|NCT02370875|DEVICE|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
224062060|NCT03847675|BEHAVIORAL|Reach out and Read|"The intervention group will be viewing a video encouraging to read to their children and giving tips on reading methods, in addition will be given a schematic pamphlet highlighting the importance of reading Arabic to children.~After each visit participants will receive an age appropriate book for their child (a total of 3 books). The first book consist of popular nursery rhymes that are usually sung for younger infants. The choice of the 2 other books is based on recommendations from an early child educator according to age specificity.~Focus group conducted by a qualitative researcher will follow the protocol reported by Richard A. Krueger."
224062061|NCT02597569|BEHAVIORAL|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
224062062|NCT05530226|DRUG|Traditional Chinese medicine|Traditional Chinese medicine, oral administration, twice daily
224062063|NCT00015288|DRUG|Buprenorphine/naloxone|
224062064|NCT03673774|DEVICE|cardiac impedancemetry|The cardiac output is measured by impedance measurement at rest and during the walking test.
224062065|NCT02389803|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
224062066|NCT02389803|DIETARY_SUPPLEMENT|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
224062067|NCT05616936|BIOLOGICAL|injectable platelet rich fibrin|injectable platelet rich fibrin
224062068|NCT00320008|BEHAVIORAL|Diet|
224062069|NCT00320008|BEHAVIORAL|Exercise|
224062070|NCT00320008|BEHAVIORAL|Stop smoking|
224062071|NCT00320008|DRUG|Glucose lowering therapy|
224062072|NCT00320008|DRUG|Blood pressure lowering therapy|
224062073|NCT00320008|DRUG|Lipid lowering therapy|
224062074|NCT04363775|DEVICE|The standard Macintosh laryngoscope|intubation with the standard Macintosh laryngoscope and endotracheal tube 7.0 internal diameter with standard tube stylet
224062075|NCT04363775|DEVICE|The Vie Scope laryngoscope|intubation with the Vie Scope laryngoscope with bougie stylet and endotracheal tube 7.0 internal diameter
224062076|NCT05111444|DRUG|Camrelizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion
224062077|NCT05111444|DRUG|Pyrotinib|320mg as continuous oral once daily on every 21 days
224062078|NCT05111444|DRUG|Capecitabine|1000 mg/m\^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of XELOX chemotherapy regimen
224062079|NCT05111444|DRUG|Oxaliplatin|130 mg/m\^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of XELOX chemotherapy regimen and as part of SOX chemotherapy regimen
224147851|NCT06967961|OTHER|For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:|A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.
224147852|NCT06226779|BEHAVIORAL|Baduanjin exercsie|The Baduanjin exercise consists of 8 postures, with emphasis on different body parts. The exercise is commonly practiced as follows: (1) 2 hands holding up the heavens, (2) drawing the bow to shoot the eagle, (3) separating the heaven and earth, (4) wise owl gazing backwards, (5) swaying the head and shaking the tail, (6) 2 hands holding the feet to strengthen the waist, (7) clenching the fists and glaring fiercely, and (8) bouncing on the toes.
224147853|NCT06226779|BEHAVIORAL|Brisk walking|The brisk walking will be gradually increased physical exertion from light to moderate of intensity. During the training period, the heart rate of participants will be monitored.
224301505|NCT02715934|OTHER|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
223571091|NCT03283098|DRUG|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, aqueous solution in a single-use 3 mL glass vial.
224062080|NCT05111444|DRUG|Paclitaxel|80 mg/m\^2 on Day 1 and Day 8 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen
224062081|NCT05111444|DRUG|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): \<1.25 m\^2 BSA =40 mg, 1.25 to \<1.5 m\^2 BSA=50 mg, ≥1.5 m\^2 BSA=60 mg. Administered as part of SOX and TS chemotherapy regimen
224062082|NCT03440099|OTHER|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
224062083|NCT04881825|DRUG|Glepaglutide|Glepaglutide will be delivered in a single-use autoinjector.
224062084|NCT00618410|DEVICE|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
224062085|NCT00618410|OTHER|Placebo|Nasal placebo
224062086|NCT05699161|GENETIC|Adipose-derived stromal vascular fraction cells|Published minimal clinically important differences (MCID) for PDQ-39; MDS-UPDRS; and levo-dopa equivalent dose and changes in the levels of blood proteins (L-1beta, IL-2, IL-6, IL-10, and TNF-alpha) in 10 patients after 12 months of treatment with SVF cells.
224062087|NCT05068466|DRUG|INCB054707|Administered Orally
224062088|NCT05068466|DRUG|Placebo|Administered Orally
224062089|NCT00403676|OTHER|Follow up bu a nurse|Follow up bu a nurse
224062090|NCT00403676|OTHER|Follow up by a medical doctor|Follow up by a medical doctor
224062091|NCT04196075|DRUG|Andrographis Paniculata|AP as palliative treatment
224062092|NCT00951847|DRUG|oxcarbazepine 300 mg/5 mL oral suspension|
224062093|NCT02988570|BEHAVIORAL|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
224062094|NCT00371293|BEHAVIORAL|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
224062095|NCT00371293|DEVICE|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
224147854|NCT06226779|BEHAVIORAL|Health education|Health education will include lecture classes. Video watching will watch videos which were not aim at improving physical exertion, such as sports games or sports related variety shows
224147855|NCT06973902|DEVICE|Cardiac Contractility Modulation (CCM) implant|"Subjects participating in the study carry or will carry the Cardiac Contractility Modulation (CCM) medical device OPTIMIZER Smart Mini by Impulse Dynamics (USA). It is indicated for use in patients over 18 years of age with symptomatic heart failure due to systolic left ventricular dysfunction, despite appropriate medical treatment.~The OPTIMIZER Smart Mini Implantable Pulse Generator is a programmable device with an internal battery and telemetry functions.~The OPTIMIZER Smart Mini is connected to two or three implantable leads, two of which are implanted in the right ventricle and one, optionally, in the right atrium."
224062096|NCT01121133|DRUG|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
224062097|NCT01121133|DRUG|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
224062098|NCT02798536|DRUG|LMB-100|Administered intravenous (IV) on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles (Arms A1 and A2) or 2 cycles (Arms B1 and B2)
224062099|NCT02798536|DRUG|nab-paclitaxel|Arms B1 and B2 only. Administered intravenous (IV) on days 1 and 8 of each 21 day cycle for up to 6 cycles
224062100|NCT01297270|DRUG|BI201335|QD BI 201335
224062101|NCT01297270|DRUG|PegIFN/RBV|
224062102|NCT01297270|DRUG|BI201335|QD (once daily) BI 201335
224062103|NCT01297270|DRUG|Placebo|
224062104|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 5mg
223453605|NCT06008210|BEHAVIORAL|Decision Support Intervention|The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
223453606|NCT06008210|BEHAVIORAL|Health Coaching|The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
223453607|NCT00249418|BEHAVIORAL|Contingency management|Rewards (prizes) for abstinence
223742516|NCT01655550|OTHER|Withhold oral contrast|The intervention is to withhold oral contrast
223742517|NCT01109654|DRUG|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
224147856|NCT05893420|DEVICE|eCARTv5 clinical deterioration monitoring|eCART is a predictive analytic used for the identification of acute clinical deterioration built upon more than a decade of ongoing scientific research and chronicled in numerous peer-reviewed publications. eCART draws upon readily available patient data from the EHR, rapidly quantifies disease severity, and predicts the likelihood of critical illness onset.
224147857|NCT05893420|OTHER|Standard of care control|Standard of care is the health system's clinical best practices and workflows for identifying high-risk patients for clinical deterioration, including other tools already built into the electronic health record (EHR). Hospitals that do not implement eCARTv5 will be compared as a control against hospitals that do implement eCARTv5.
224147858|NCT06220838|DRUG|SC-101|All subjects will receive a single intravenous (IV) infusion of SC-101 once weekly.
223453608|NCT05177640|DRUG|99mTc-Duramycin|This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
223453609|NCT04529239|DEVICE|Abbott Freestyle Libre Pro|Continuous glucose monitoring device to analyze diabetes biomarkers.
223453610|NCT03420430|BIOLOGICAL|GL-ONC1|
224062105|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 10mg
224062106|NCT05416762|DRUG|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg|Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20mg
224062107|NCT00718276|DRUG|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
224062108|NCT00718276|DIETARY_SUPPLEMENT|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
224062109|NCT05468554|DRUG|metformin|Metformin will be used 3 times a day (3x500mg), starting in the first week with 1x1 tablet (1x500 mg for breakfast), in the second week, 2x1 tablet (500 mg for breakfast and 500 mg for dinner), from the 3rd week 3x1 tablet. (3x500mg with main meals). A gradual escalation of the dose is planned to the point of developing drug intolerance or toxicity that is unacceptable to the patient.
224062110|NCT05468554|RADIATION|Radioactive iodine (I-131)|Patients qualified to receive 131I treatment
224062111|NCT04523506|BIOLOGICAL|Botulinum toxin(Botox)|This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
224062112|NCT00121212|PROCEDURE|carbon-11 acetate PET scan|
224062113|NCT01384578|DRUG|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
224062114|NCT01384578|DRUG|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
224062115|NCT02060578|OTHER|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
224062116|NCT04793542|PROCEDURE|lower-limb hot water immersion|For a minimum of 30 minutes, 3 times a week for 8 consecutive weeks, participants will submerge their lower-limbs into 30-32°C (lukewarm) or 39-40°C (hot) water which will be measured with a supplied waterproof thermometer.
224062117|NCT02265770|DRUG|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
224147859|NCT04609280|RADIATION|Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT)|Delivered over 6 weeks in 30 daily fractions in the adjuvant setting and over 6.5 weeks in 33 daily fractions in the definitive setting. In the adjuvant setting, areas with positive surgical margins or nodal stations with pathologic extranodal extension will receive 63 Gy. Margin negative resection bed and involved nodal stations without extranodal extension will receive 54 Gy. Low-risk elective nodal volumes (i.e. ceCTV) will receive 51 Gy. In the definitive setting, gross disease will receive 69.96 Gy, areas at high-risk for subclinical disease will receive 60 Gy, and areas at low-risk for harboring subclinical disease (i.e. ceCTV) will receive 52.8 Gy.
224147860|NCT06000501|DRUG|Serdexmethylphenidate/dexmethylphenidate|Azstarys capsules for once-daily oral use for three weeks. Flexible dose starting at 39.2 mg serd-mph/7.8 mg d-mph and moving up to 52.3 mg serd-mph/10.4 mg d-mph.
224147861|NCT05539807|BEHAVIORAL|Mindful Eating Conscious Living|"MECL is a 8 week mindfulness-based group intervention. Each session is of 2.5-3 hours duration. During the sessions, theories about eating-related difficulties in general are presented, participants are guided in mindfulness practices and participants who want to share their experiences in the group can do so. Topics include: (1) What is mindfulness, why and how can we use mindfulness in relation to eating (2) slowing down, taking breaks and noticing different types of hunger (e.g. physical hunger and the hunger for comfort - heart hunger) (3) working with satiety and satisfaction (4) becoming aware of patterns associated with one's eating behaviors, (5) awareness of feelings and bodily sensations (6) Food and mood (7) craving, and finally (8) working with heart hunger and emotional eating. Six to 10 participants participated in each group."
224147862|NCT06620835|BIOLOGICAL|Blood samples for Hematology|Complete blood count will include erythrocytes, neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, leukocytes, hemoglobin, hematocrit.
224147863|NCT06620835|BIOLOGICAL|Blood samples for Chemistry|Clinical chemistry will include serum electrolytes (sodium, potassium, calcium, corrected calcium for hypoalbuminemia), creatinine, CrCl with local formula, and fasting blood glucose.
224147864|NCT06620835|BIOLOGICAL|Blood sample for liver function tests|Laboratory tests to assess liver function will include Aminotransferase Alanine (ALAT), Aminotransferase Aspartate (ASAT), Phosphatase Alkaline (ALP), Gamma-glutamyl Transferase (GGT), total and conjugated bilirubin.
224062118|NCT02265770|DRUG|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
224062119|NCT02265770|DRUG|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
224062120|NCT02265770|RADIATION|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
224062121|NCT02265770|DRUG|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
224062122|NCT02265770|DRUG|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
224147865|NCT06620835|BIOLOGICAL|Pregnancy test|Pregnancy test will be performed in women of childbearing potential, including women who have had a tubal ligation. Childbearing potential is defined as not having undergone surgical sterilization, hysterectomy, and/or bilateral oophorectomy or not being postmenopausal (≥12 months of amenorrhea). Urine pregnancy tests will be based on the measurement of β-Human Chorionic Gonadotropin (HCG). If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed at screening.
224147866|NCT06620835|PROCEDURE|Tumour assessment|Tumor assessment according to the RECIST v1.1 include the following radiological evaluation: thoracic CT scan, brain MRI or CT scan (MRI is preferred), abdominopelvic scan, PET-CT scan mandatory and at the Investigator's discretion, if needed bone scintigraphy and chest X-ray.
224147867|NCT06620835|PROCEDURE|Local Ablative Therapy (LAT)|Local Ablative Treatment (LAT) (stereotactic body radiotherapy, surgery, thermal ablation)
224147868|NCT04523818|DRUG|Capecitabine|Given PO
224147869|NCT04523818|DRUG|Fluorouracil|Given IV
224147870|NCT04523818|RADIATION|Radiation Therapy|Undergo radiation therapy
224147871|NCT04523818|PROCEDURE|Therapeutic Surgical Procedure|Undergo standard of care surgery
223742518|NCT00035620|DRUG|pegfilgrastim|pegfilgrastim
223742519|NCT00035620|DRUG|filgrastim|filgrastim
223742520|NCT03341533|PROCEDURE|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
223742521|NCT03341533|OTHER|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
223453611|NCT00005033|BIOLOGICAL|trastuzumab|
223571092|NCT03283098|DRUG|Placebo|Placebo supplied to match active intervention.
223742522|NCT04045340|DEVICE|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
223742523|NCT06612437|DEVICE|continuous theta burst stimulation (cTBS)|Standard 600-pulse continuous theta burst stimulation (cTBS) can inhibit the corticomotor excitability. The cTBS will be delivered with an intensity of 70% individual resting motor threshold (RMT) of the hand knob over the contralesional M1.
223742524|NCT06612437|DEVICE|intermittent theta burst stimulation (iTBS)|Standard 600-pulse intermittent theta burst stimulation (iTBS) can increase the corticomotor excitability. The iTBS will be delivered with an intensity of 70% individual resting motor threshold (RMT) of the hand knob over the contralesional M1.
223742525|NCT06612437|DEVICE|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device.
223742526|NCT02786316|OTHER|HIT program|HIT program for the rehabilitation of persons with NSCLBP
224062123|NCT02265770|RADIATION|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
224062124|NCT01707043|DRUG|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
224062125|NCT00019188|DRUG|interleukin-12|
224062126|NCT00105248|BEHAVIORAL|patient-centered communication training|
224062127|NCT00006507|BEHAVIORAL|Occupational Therapy|
224062128|NCT05043571|BIOLOGICAL|CAR T-cell therapy|This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
224062129|NCT02477657|PROCEDURE|Paracentesis|Paracentesis
223571093|NCT05786339|DRUG|Tested Irbesartan Tablet|T
223742527|NCT02786316|OTHER|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
224062130|NCT02477657|DEVICE|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
224147872|NCT03703362|OTHER|Resistance training|30 supervised training-sessions over 12 weeks
224147873|NCT03024840|DRUG|Sevoflurane|Sevoflurane: 1%\~2%
223453612|NCT00005033|PROCEDURE|conventional surgery|
223453613|NCT00112918|BIOLOGICAL|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
223453614|NCT00112918|DRUG|Capecitabine|Film-coated tablets
223453615|NCT00112918|DRUG|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
223453616|NCT00112918|DRUG|Leucovorin calcium|Administered as a 200 mg/m\^2 infusion over 2 hours.
223453617|NCT00112918|DRUG|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
223453618|NCT02964338|DRUG|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
223453619|NCT02964338|DRUG|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
223571094|NCT05786339|DRUG|Reference Irbesartan Tablet|R
223571095|NCT04128982|PROCEDURE|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
223742528|NCT06136702|BEHAVIORAL|Educational session|A community-based researcher will educate women about sexual health and cervical cancer by using the materials that will be developed by the ELEVATE team. Women will be informed about cervical cancer screening (pap smear) and about where they can obtain these services off-site (health facilities). Furthermore, a self-administrated questionnaire is applied to assess current knowledge, willingness to get screened (clinically collected sample) and uptake.
224062131|NCT02477657|DEVICE|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
224062132|NCT05709964|OTHER|Self-reported|Self-reported height, weight, and neck circumference
224062133|NCT05709964|OTHER|Measured|Height, weight, and neck circumference measured by the investigator.
224062134|NCT03013673|OTHER|No intervention|No intervention
224062135|NCT03882970|DRUG|Tirzepatide|Administered SC
224062136|NCT03882970|DRUG|Insulin Degludec|Administered SC
224062137|NCT03831971|DRUG|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
224062138|NCT03820648|DEVICE|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
224147874|NCT03024840|DRUG|Propofol|Propofol: 9-15 mg/kg/h
224147875|NCT00051129|DRUG|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
224147876|NCT00051129|OTHER|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
224147877|NCT02892825|OTHER|Music|headphones with music
224147878|NCT02892825|OTHER|No Music|headphones without music
224062139|NCT03820648|DEVICE|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
224062140|NCT04213105|DRUG|QL1206|subcutaneous injection of 60 mg (1ml) only once,on the first day.
223571096|NCT03411564|OTHER|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
224062141|NCT04213105|DRUG|Prolia®|subcutaneous injection of 60 mg (1ml)only once,on the first day
224062142|NCT03653273|OTHER|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
224062143|NCT03653273|DRUG|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
224062144|NCT02526342|DEVICE|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
224062145|NCT02567253|PROCEDURE|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
224062146|NCT02567253|DRUG|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
224062147|NCT02567253|DRUG|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
224062148|NCT02567253|DRUG|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
224062149|NCT02567253|DRUG|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
224062150|NCT04555824|DRUG|Recombinant Human Thymosin β4|Healthy subjects , were given a single intravenous dose of rh-Tβ4 in Day1.
224147879|NCT03790384|DRUG|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
224147880|NCT01588353|DRUG|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
224147881|NCT02131246|DRUG|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
224147882|NCT02131246|DRUG|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
224147883|NCT05653804|PROCEDURE|tele-visit|The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
223453620|NCT04875910|OTHER|Home-based exercise program|"The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week."
223453621|NCT04761757|OTHER|Booklet of Scripts of Doctors|"The Booklet of Scripts for Doctors was used in the control arm. This tool was developed and tested to encourage shared decision-making in prescribing antidepressants within the Malaysian context."
223571097|NCT02832024|DEVICE|plaque excision system|
224062151|NCT04555824|OTHER|Placebo|Five cohorts, with 10 healthy subjects , were given a single intravenous dose of Placebo. Cohorts received ascending doses of either 0.5, 2,5,12.5 or 25 ug/kg in Day1.
224062152|NCT03070925|DEVICE|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
224147884|NCT06444165|DRUG|Lebrikizumab Pen|Injected into a practice pad.
223571098|NCT02832024|DEVICE|stent|
224062153|NCT05358756|DRUG|SACT-1|Single administartion of 150mg SACT-1
224062154|NCT05358756|DRUG|EDURANT 25Mg Tablet|Single administartion of six EDURANT 25mg tablets (Total 150mg)
224062155|NCT00670670|DEVICE|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
224062156|NCT00670670|DEVICE|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
224062157|NCT04861675|PROCEDURE|Full mouth rehabilitation under general anaesethia|Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
224062158|NCT06268743|OTHER|High intensity|High intensity exercise
224062159|NCT06268743|OTHER|Moderate intensity|Moderate intensity exercise
224062160|NCT04509375|DEVICE|Cranial Doppler Ultrasonography|Before and after the transfusions, flow measurements of middle cerebral arteries will be obtained.
224062161|NCT04509375|DEVICE|Near-Infrared Spectroscopy|Before, during and after the transfusions, regional cerebral oxygen saturation measurements will be obtained.
224062162|NCT05292105|DEVICE|NC Xperience|Coronary dilatation balloon catheter (non compliant)
224062163|NCT05140538|OTHER|SRP + toothpaste + mouthwash|Use of domiciliary products twice a day
224062164|NCT05140538|OTHER|SRP + toothpaste|Use of domiciliary products twice a day
224147885|NCT02600741|OTHER|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
224147886|NCT02600741|OTHER|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
224147887|NCT02600741|DRUG|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
223453622|NCT04761757|OTHER|Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)|"The Booklet of Scripts for Doctors along with the Antidepressant Decision Aid for Major depressive disorder patients, ADAM, was used in the intervention arm. The decision aid was developed as per the International Patient Decision Aid Standards (IPDAS) criteria to enhance patient understanding of risks and benefits of different antidepressants available within the Malaysian context."
224147888|NCT02600741|DRUG|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147889|NCT02600741|DRUG|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
223453623|NCT04812184|DEVICE|Tape Face Mask|Adding tape to face mask
223453624|NCT02630563|DRUG|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
223453625|NCT02630563|DRUG|Cyclosporine|Cyclosporine will be administered as per center practice.
223571099|NCT02832024|DEVICE|Balloon|
223571100|NCT06581731|DRUG|remimazolam combined with remifentanil|Patients in this group will receive a bolus of remimazolam 5 mg intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 mg/kg/h remimazolam via separate syringe pumps.
223742529|NCT06136702|BEHAVIORAL|Self-sampling|Women will receive information about self-sampling and will be instructed by the community-based researcher on how to take a self-sample using an illustrative cartoon. Women will then be invited to take a sample on-site, to measure the uptake of the self-sampling test (% of women who take the self-sample). Furthermore, two self-administrated questionnaires are applied to 1) assess attitudes regarding self-sampling (pre-intervention), and 2) assess users' experience regarding self-sampling (post-intervention). The researcher will collect all samples for analysis by an HPV test in a lab. Sample analysis is expected to take 2 weeks time. All women will be contacted 1-2 weeks after the self-sample taking to inform them on their test result.
224062165|NCT04707742|DRUG|Betadine© bucal 100 mg/ml|15 ml 2% povidone-iodine, one minute rinse.
224062166|NCT04707742|DRUG|Oximen® 3%|15 ml 1% hydrogen peroxide, one minute rinse.
224062167|NCT04707742|DRUG|Clorhexidine Dental PHB©|15 ml 0,12% clorhexidine, one minute rinse.
224062168|NCT04707742|DRUG|Vitis Xtra Forte©|15 ml 0,07% cetylpyridinium chloride, one minute rinse.
224147890|NCT02600741|DRUG|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
223453626|NCT02630563|DRUG|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
223453627|NCT02372383|DRUG|Ethambutol|Anti-mycobacterial oral drug
223453628|NCT02372383|DRUG|Rifampin|Anti-mycobacterial oral drug
223453629|NCT02372383|DRUG|Azithromycin|Anti-mycobacterial oral drug
223453630|NCT02372383|DRUG|Pancrelipase|Pancreatic enzyme replacement therapy
224062169|NCT04707742|DRUG|Distilled Water|15 ml distilled water, one minute rinse.
224062170|NCT03183193|OTHER|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (\<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
224147891|NCT02600741|DRUG|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147892|NCT02600741|DRUG|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147893|NCT02600741|DRUG|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147894|NCT02600741|DRUG|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
223571101|NCT06581731|DRUG|dexmedetomidine combined with remifentanil|Patients in this group will receive a loading dose of dexmedetomidine 1 μg/kg over 10 minutes intravenously, and then a dose of 0.1 μg/kg/min remifentanil and 0.5 μg/kg/h dexmedetomidine via separate syringe pumps.
223571102|NCT06446856|DEVICE|VR application|"The VR application consists of a software (Tree) developed as part of a research project at MIT and legally acquired via the HTC store Viveport. Duration of the VR application: approx. 5 min."
223571103|NCT06141538|OTHER|Observational; No Interventions were given.|Observational; No Interventions were given.
223571104|NCT01926899|DRUG|Bortezomib administration|
223571105|NCT01803178|DIETARY_SUPPLEMENT|Plant Sterols|
223571106|NCT01803178|DIETARY_SUPPLEMENT|Placebo Product|
223571107|NCT05223348|OTHER|Meditation practice|Our intervention will involve two meditation exercises. 1) the experimental condition (body scan meditation). 2) the active comparator condition (listening task)
223571108|NCT02281110|DEVICE|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
223453631|NCT02829658|BEHAVIORAL|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
224062171|NCT03183193|OTHER|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
224062172|NCT00522587|DRUG|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
224062173|NCT00522587|DRUG|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
224062174|NCT00522587|DRUG|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
224062175|NCT00522587|DRUG|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
224062176|NCT00522587|DRUG|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
224062177|NCT00522587|DRUG|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
224062178|NCT00522587|DRUG|Fixed remifentanil dose 1|Dose 1 of remifentanil
224062179|NCT00522587|DRUG|Fixed remifentanil dose 2|Dose 2 of remifentanil
224062180|NCT00522587|DRUG|Fixed remifentanil dose 3|Dose 3 of remifentanil
224062181|NCT00522587|DRUG|Fixed remifentanil dose 4|Dose 4 of remifentanil
224062182|NCT00522587|DRUG|Fixed remifentanil dose 5|Dose 5 of remifentanil
224062183|NCT00522587|DRUG|Fixed remifentanil dose 6|Dose 6 of remifentanil
223453632|NCT02829658|OTHER|No intervention|No intervention
224062184|NCT02385149|OTHER|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
224062185|NCT02385149|OTHER|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
224062186|NCT01112046|PROCEDURE|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
224062187|NCT01112046|PROCEDURE|Laparoscopic resection|Surgical treatment performed under general anesthesia
224062188|NCT03540784|OTHER|WB-EMS|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
224062189|NCT03540784|OTHER|Nutritional support|dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
224062190|NCT00634309|DRUG|Candesartan|
224147895|NCT02600741|DRUG|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147896|NCT02600741|DRUG|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
223453633|NCT00621257|DIETARY_SUPPLEMENT|ergocalciferol|8000 units/ml
224062191|NCT00634309|DRUG|Placebo|
224062192|NCT03643874|DRUG|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
224062193|NCT03643874|DRUG|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
224062194|NCT02334449|DRUG|LML134|LML134 will be administered first as single doses and then as multiple doses
224062195|NCT02334449|DRUG|Placebo|All study cohorts (except food effect cohort) are placebo controlled
224062196|NCT06489587|DIETARY_SUPPLEMENT|Placebo|Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
224062197|NCT06489587|DIETARY_SUPPLEMENT|Creatine|Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
224062198|NCT00336219|DRUG|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
224062199|NCT03724188|PROCEDURE|surgical parathyroidectomy|total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
224062200|NCT05726344|DRUG|Lactulose|4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
224062201|NCT05726344|DRUG|Polyethylene Glycol 3350|4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
224062202|NCT02424032|BEHAVIORAL|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
224062203|NCT02424032|BEHAVIORAL|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
224147897|NCT02600741|DRUG|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147898|NCT02600741|DRUG|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147899|NCT02600741|DRUG|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147900|NCT02600741|DRUG|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
223571109|NCT02174367|DEVICE|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
224062204|NCT02863809|DRUG|Riboflavin|Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
224062205|NCT02863809|DRUG|Dextran|Dextran is used to increase the viscosity of the solution.
224062206|NCT02863809|DEVICE|UVA Light Source|Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
224062207|NCT02709564|DRUG|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
224062208|NCT02709564|DRUG|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
224147901|NCT02600741|DRUG|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147902|NCT02600741|DRUG|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
223571110|NCT04160247|PROCEDURE|Immediate implant placement|Implants are placed in fresh socket
223571111|NCT04160247|PROCEDURE|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
223571112|NCT04160247|PROCEDURE|Cemented crowns placement|To cement the restorations onto the implant abutment
223571113|NCT00617071|OTHER|medical chart review|
223571114|NCT00617071|OTHER|survey administration|
223571115|NCT00617071|PROCEDURE|fecal occult blood test|
223571116|NCT00617071|PROCEDURE|screening colonoscopy|
223571117|NCT04525924|DEVICE|bright light therapy|please see arm description
223571118|NCT00091338|BIOLOGICAL|MART-1 antigen|
223571119|NCT00091338|BIOLOGICAL|gp100 antigen|
223571120|NCT00091338|BIOLOGICAL|incomplete Freund's adjuvant|
223571121|NCT00091338|BIOLOGICAL|recombinant interleukin-7|
223571122|NCT02657681|DEVICE|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
223742530|NCT06136702|BEHAVIORAL|Follow-up assessment|To gauge the knowledge on cervical cancer screening after the educational session and to verify whether they got a pap smear, a 3-month follow-up is proposed for all women receiving an educational session (arm 1) and all women receiving an educational session and a self-sample (arm 2), because all women, whether or not invited for self-sampling, are provided information on where to get screened, although there is no formal referral to screening services.
223742531|NCT00264355|DRUG|cyclosporine A|
223742532|NCT00471848|DRUG|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
223742533|NCT03424174|DEVICE|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
223742534|NCT03424174|DEVICE|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
223742535|NCT05705986|OTHER|Blood Draw|Single blood draw
223742536|NCT00990496|DRUG|Fludarabine|30 mg/m2
223571123|NCT02657681|DEVICE|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
223571124|NCT00607711|DRUG|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
223571125|NCT05683574|DRUG|FDC of etoricoxib + cyclobenzaprine + etoricoxib placebo|Participants randomized to this group will receive one (01) capsule of the investigational drug and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
224062209|NCT02810665|BEHAVIORAL|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
224062210|NCT05106322|OTHER|intraoperative spectrometer scan|intraoperative spectrometer scan (five scans on the left lobe) before clamping the aorta
224062211|NCT05429788|DRUG|Low dose RLS103|3 mg CBD inhaled powder administered before public speaking challenge
224062212|NCT05429788|DRUG|High dose RLS103|6 mg CBD inhaled powder administered before public speaking challenge
224062213|NCT05429788|DRUG|placebo inhaled dry powder|placebo inhaled powder administered before public speaking challenge
224062214|NCT00543426|DRUG|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
224062215|NCT00543426|DRUG|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
224062216|NCT00001990|DRUG|Atovaquone|
224062217|NCT02830776|DRUG|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
224062218|NCT04558411|BEHAVIORAL|Dialectical Behavioral Therapy (DBT) Skills|14 brief videos that teach DBT skills.
224147903|NCT02600741|DRUG|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147904|NCT02600741|DRUG|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147905|NCT02600741|DRUG|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147906|NCT02600741|DRUG|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224147907|NCT02600741|DRUG|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
224301506|NCT02715934|OTHER|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
224062219|NCT05170906|OTHER|Reflex locomotion stimulus|The therapy consists of the application of a stimulating pressure in the pectoral area in the pattern of the locomotion complex of reflex rolling in its first phase. For this, the subject will be placed in a supine position aligned with respect to the axial axis, with the arms along the body, the lower extremities in extension, and the head extended with a rotation of approximately 30º towards one side of the stimulation. The manual stimulation pressure will be exerted in the space between the 6th-7th or the 7th-8th rib under the mammillary line, with a force of about 2 kg.
223453634|NCT00621257|DIETARY_SUPPLEMENT|Cholecalciferol|400 units per drop
224147908|NCT04942119|OTHER|Multifactorial intervention|"1. Correction of magnesium and/or potassium deficit and the underlying disease.~2. Education reinforcing optimal diet and exercise, in addition to, post-nutrition assessment , diabetes self-care activities and adherence will be given at each follow up visit by a specialized dietitian.~3. Comprehensive medication therapy management by clinical pharmacist, and medication adherence will be measured by adherence questionnaire as well as fixed medication possession ratio (FMPR)."
223453635|NCT03575247|DRUG|Glucocorticoids|Long-term use of glucocorticoids
223453636|NCT03419117|PROCEDURE|ESP block|An ESP block will be performed prior to surgery for postoperative pain control
223453637|NCT03419117|PROCEDURE|Placebo|A sham ESP block will be performed before surgery in the placebo group
223453638|NCT01013714|PROCEDURE|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
223453639|NCT01013714|DRUG|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
223453640|NCT01216878|DRUG|losartan potassium|100 mg tablet
223453641|NCT00631982|PROCEDURE|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
223453642|NCT01442012|OTHER|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
223453643|NCT01255904|DRUG|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
223453644|NCT01255904|DRUG|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
223453645|NCT01255904|OTHER|Oral placebo|Oral saline administered
223453646|NCT01255904|OTHER|Intranasal placebo|Intranasal saline administered
223453647|NCT05076604|DRUG|Cardioplegia Solution|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
223453648|NCT05076604|DRUG|Microplegic Solution No. 1|"The microplegia solution that is standard of care for all cardiac surgery patients, and which all study subjects will receive is:~Induction 240 mL Baxter Cardioplegia Solution 10. 5 mL Potassium Chloride 2 meq/ml (21 meq) 250.5 mL total volume~Maintenance 747 mL Baxter Cardioplegia Solution 3.4 mL Potassium Chloride 2 meq/ml (6.75 meq) 750.4 mL total volume~Subjects will be randomly assigned to 4:1 cardioplegia or nondiluted microplegia.~4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.~Nondiluted microplegia consists of all parts human blood."
223453649|NCT03258645|DRUG|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
223453650|NCT04033978|BEHAVIORAL|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
223453651|NCT04033978|BEHAVIORAL|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
223571126|NCT05683574|DRUG|etoricoxib 90 mg (Arcoxia®) +FDC placebo|Participants randomized to this group will receive one (01) etoricoxib 90 mg tablet (Arcoxia®) and one (01) FDC placebo capsule, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
223571127|NCT05683574|DRUG|cyclobenzaprine hydrochloride + etoricoxib placebo|Participants randomized to this group will receive one (01) cyclobenzaprine hydrochloride 15 mg capsule (XL - Mitrul®) and one (01) etoricoxib placebo tablet, respecting a minimum interval of twenty-four (24) hours between doses for 3 days.
223571128|NCT04921085|OTHER|Cross-sectional obeservational survey|Cross-sectional obeservational survey
223571129|NCT06113224|PROCEDURE|Blood collection T0|2 blood samples will be taken in addition to the pre-operative check-up.
223571130|NCT06113224|PROCEDURE|Blood collection 6 months|1 blood sample will be taken 6 months after surgery.
223571131|NCT06507397|DRUG|hyperbaric bupivacaine and fentanyl|Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
223571132|NCT06507397|DRUG|plain bupivacaine and fentanyl|Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
224062220|NCT05170906|OTHER|sham stimulus|The control group will receive an application in an area with low receptor density located on the thigh, with a force of about 2 kg.
224147909|NCT03345732|DIAGNOSTIC_TEST|ICG and SPY system for wound complications|
223453652|NCT06004271|OTHER|exercise|"Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching"
223571133|NCT00798317|DRUG|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
223571134|NCT00798317|DRUG|Placebo|Intravitreal injection placebo.
224062221|NCT03615196|DRUG|USB005 (aclerastide) Ophthalmic Solution|Aclerastide (\[Nle3\]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
224062222|NCT03615196|DRUG|USB005 Ophthalmic Solution Placebo|A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
224062223|NCT04804787|DIAGNOSTIC_TEST|Carrying out a tests and questionnaires battery|The attendees will carry out different questionnaires and tests to evaluate their potential cognitive disorders
224062224|NCT04848558|DRUG|Nipocalimab|Participants will receive IV infusion or SC injection of nipocalimab.
223571135|NCT00380419|BEHAVIORAL|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
224062225|NCT04848558|OTHER|Placebo|Participants will receive IV infusion or SC injection of placebo.
224062226|NCT03029143|DRUG|Vedolizumab IV|Vedolizumab intravenous infusion.
223571136|NCT06260969|DEVICE|balloon dilatation|Direct balloon dilation vs stenting vs embolectomy + tirofiban vs embolectomy + balloon dilation vs embolectomy + balloon dilation + intracranial stenting
223571137|NCT05849818|DEVICE|full-immersive VRapeutic software gaming technology|"* Children of the study group will receive VR training sessions 3 times per week for 8 successive weeks.~* Viblio VRapeutic fully immersive game will be used.~* Manual instructions of the game will be followed and features of the game will be customized.~* The child instructed to put back a pile of books on the floor into their shelves.~* Level II of the game we will use audio visual distractors , repeated parrot sound and the child is required to order the books by colors~* Level III distracting tasks during book ordering~* The complexity of the game depend on task duration, number of books and the nature of distractors"
223571138|NCT01762267|OTHER|nutrition intervention|DASH diet control diet
223571139|NCT00416715|DRUG|letrozole|Given PO
223571140|NCT00416715|DIETARY_SUPPLEMENT|calcium carbonate|Given PO
223571141|NCT00416715|OTHER|laboratory biomarker analysis|Optional correlative studies
223571142|NCT00416715|DIETARY_SUPPLEMENT|calcium citrate|Given PO
223571143|NCT00416715|DIETARY_SUPPLEMENT|calcium glucarate|Given PO
223571144|NCT00416715|DRUG|calcium gluconate|Given PO
223571145|NCT00416715|DIETARY_SUPPLEMENT|cholecalciferol|Given PO
223571146|NCT00416715|PROCEDURE|assessment of therapy complications|Ancillary studies
223571147|NCT00416715|PROCEDURE|musculoskeletal complications management/prevention|Correlative studies
223571148|NCT01495130|PROCEDURE|ultrasound imaging|Undergo transrectal ultrasound
224301507|NCT00062010|BIOLOGICAL|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
223571149|NCT01495130|PROCEDURE|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
223571150|NCT05384418|RADIATION|HDP-Tc99m bone scintigraphy|HDP-Tc99m bone scintigraphy
223571151|NCT04857437|DRUG|PF-07202954 Repeat Dose|10, 30, 100, 300, 600, 1200 milligrams (mg)
223571152|NCT04857437|DRUG|PF-07202954 Single Dose|10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
223571153|NCT04857437|DRUG|Placebo|Matching Placebo
223571154|NCT03515226|BEHAVIORAL|ITS based training|Training using computerized adaptive training in addition to role play
223571155|NCT03515226|BEHAVIORAL|Traditional Training|Training using didactics and role plays
223571156|NCT03563677|OTHER|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
223571157|NCT04907149|DRUG|GLPG3970 film-coated tablet|Participants will receive a single oral dose of GLPG3970.
223571158|NCT04907149|DRUG|[14C]GLPG3970 solution for infusion|Participants will receive an i.v. microtracer microdose.
223571159|NCT04907149|DRUG|[14]GLPG3970 oral solution|Participants will receive a single oral dose \[14C\]GLPG3970.
223571160|NCT02545517|BIOLOGICAL|Rabipur|Participants in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm.
223571161|NCT02545517|PROCEDURE|Blood sampling|Blood samples were drawn from all participants at Day 1 and then at subsequent year intervals from extension study Day 1 onwards.
223571162|NCT02545517|BIOLOGICAL|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM).
223742537|NCT00990496|DRUG|Cyclophosphamide|600 mg/m2
223742538|NCT00990496|BIOLOGICAL|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
224062227|NCT05464706|DIETARY_SUPPLEMENT|Synchrolevels|Supplement therapy to model the recovery after liver surgery
224062228|NCT04572984|PROCEDURE|EBUS-TBMCB|endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy was performed in experimental arm following EBUS-TBNA
224062229|NCT00607386|BIOLOGICAL|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
224062230|NCT01662674|DRUG|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
224062231|NCT01662674|DRUG|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
224062232|NCT04938128|DEVICE|CPAP|Gold standard treatment for obstructive sleep apnea. In this group, patients will be prescribed CPAP treatment according to local policy.
224062233|NCT03203057|OTHER|coronary occlusion|percutaneous coronary intervention
224062234|NCT05738473|DRUG|antibiotic|For pregnant women with GBS colonization, antibiotics are used to prevent infection
224062235|NCT00851539|BEHAVIORAL|Video|Behavioral Intervention Video
224062236|NCT04860570|DEVICE|Double-ring wound-edge protector|Double-ring wound-edge protector: Alexis Applied Medical ®, Rancho Santa Margarita, California.
224062237|NCT00619255|BEHAVIORAL|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
223453653|NCT06004271|OTHER|exercise and taping|When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.
223453654|NCT06004271|OTHER|placebo|In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
224062238|NCT03752775|DEVICE|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
224062239|NCT00974675|BIOLOGICAL|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
224062240|NCT00974675|BIOLOGICAL|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
224062241|NCT00974675|BIOLOGICAL|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
224062242|NCT00974675|OTHER|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
224062243|NCT01250340|DRUG|Aspirin|100 mg/day for 30 days
224062244|NCT01250340|DRUG|Placebo|1 cp day for 30 days
224062245|NCT01669070|DRUG|FF, 50 mcg|Novel dry powder inhaler
224062246|NCT01669070|DRUG|FF, 100 mcg|Novel dry powder inhaler
224062247|NCT01669070|DRUG|FF, 200 mcg|Novel dry powder inhaler
224062248|NCT01669070|DRUG|FF, 250 mcg|Intravenous
223453655|NCT05850702|DRUG|Lidocaine|inhale 5ml of 2% lidocaine by nebulization
223453656|NCT05850702|DRUG|Saline|inhale 5ml of saline by nebulization
223453657|NCT05006456|DEVICE|Catheter ablation|Subjects will undergo catheter ablation using the new technologies, including THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT, QDOT catheter and HELIOSTAR catheter when they are used in conjunction with Carto system for AF ablations.
223453658|NCT02061813|DRUG|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
223453659|NCT02061813|DRUG|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
223453660|NCT02061813|DRUG|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
224147910|NCT03661892|DRUG|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
224147911|NCT03444571|PROCEDURE|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
223453661|NCT02061813|DRUG|Placebo|
223453662|NCT03607877|BEHAVIORAL|Pedometer walking training and positive education|"Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions."
223453663|NCT03607877|BEHAVIORAL|Pedometer walking with training|Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
223453664|NCT03607877|BEHAVIORAL|pedometer walking|Intervention: pedometer walking at least 30 minutes per day and at least three times per week
223453665|NCT03002545|DIETARY_SUPPLEMENT|Magnesium citrate|
223453666|NCT03002545|DIETARY_SUPPLEMENT|Placebo|
223453667|NCT05048043|BEHAVIORAL|Computer-assisted Behavior Intervention|"The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands."
223453668|NCT05048043|BEHAVIORAL|Challenging Horizons Program|The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
223453669|NCT02427854|BEHAVIORAL|Education by animated training video|Training performed by watching an animated educational video.
224062249|NCT02695992|DRUG|Metoprolol|Dosage 100 mg o.d.
224062250|NCT02695992|DRUG|Diltiazem|Dosage 360 mg o.d.
224062251|NCT04123782|DEVICE|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
224147912|NCT01501669|DRUG|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~\+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
224301508|NCT00062010|DRUG|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
224062252|NCT04123782|DEVICE|Placebo F-ESW Treatment|Very low concentration of F-ESW.
224062253|NCT05227521|BEHAVIORAL|Adapted H-GRASP feedback program|Combination of the Home-Graded Repetitive Arm Supplementary Program with in home accelerometer-based feedback
224062254|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
224147913|NCT00553657|DRUG|DETROL LA (drug)|
224062255|NCT01221220|BEHAVIORAL|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
224062256|NCT02121262|DRUG|Dexamethasone|Dexamethasone 700 μg intravitreal injection in the study eye on Day 1, Months 5, and 10.
224147914|NCT04054739|DEVICE|Robot-assisted gait training|intervention with robot-assisted gait training
223453670|NCT02427854|PROCEDURE|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
223453671|NCT03783377|DRUG|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
223453672|NCT03783377|DRUG|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
223453673|NCT00264485|DRUG|E-TRANS Fentanyl hydrochloride; Morphine|
223453674|NCT00350077|DRUG|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
223453675|NCT00350077|DRUG|Vitamin C|IV vitamin C
223453676|NCT01156688|DRUG|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
223453677|NCT01156688|DRUG|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
223453678|NCT02992860|DRUG|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by \> 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
223453679|NCT02992860|PROCEDURE|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
223453680|NCT02992860|OTHER|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
223453681|NCT02992860|OTHER|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
223453682|NCT02992860|PROCEDURE|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
223453683|NCT02992860|GENETIC|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
223453684|NCT02992860|PROCEDURE|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
223453685|NCT02992860|PROCEDURE|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
223453686|NCT02992860|PROCEDURE|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
223453687|NCT00452660|DRUG|Exjade|
223453688|NCT05763914|BEHAVIORAL|Change in the incidence of hand eczema|Assessed by the self-reported cases of newly-developed hand eczema. Change between baseline and 6 months.
223453689|NCT05763914|BEHAVIORAL|Change in severity of hand eczema|Assessed by using the Hand Eczema Severity Index (HECSI). HECSI score: 0-360 points (0 best, 360 worst). Change between baseline and 6 months.
223453690|NCT05763914|BEHAVIORAL|Change in the number of self-reported days with absence from work due to having hand eczema|Self-reported total number of sick days due to having hand eczema. Change between baseline and 6 months.
223453691|NCT05763914|BEHAVIORAL|Change in the number of participants being forced to change their job due to having hand eczema|Self-reported change of job due to having hand eczema. Change between baseline and 6 months.
223453692|NCT05763914|BEHAVIORAL|Change in The Quality Of Life in in relation to hand eczema|Assessed by using Hand Eczema Questionnaire (QolHEQ). Change between baseline and 6 months.
223453693|NCT05763914|BEHAVIORAL|Change in the level of knowledge regarding skin care and protection.|Self-reported level of knowledge regarding skin care and protection. Change between baseline and 6 months.
223453694|NCT00558012|DRUG|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
223453695|NCT00558012|DIETARY_SUPPLEMENT|Vitamin D 800 IU/daily|Daily divided dose
223453696|NCT00558012|DIETARY_SUPPLEMENT|Calcium 1200 mg/daily|supplement plus diet
223571163|NCT02746601|BEHAVIORAL|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
223571164|NCT00751309|OTHER|Non-interventional|Post-transplantation observational study
224062257|NCT02121262|PROCEDURE|Laser Photocoagulation|Laser photocoagulation on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
224062258|NCT04422860|DRUG|Gum Arabic varnish|Powdered exudate from various Acacia species, especially A. senegal (Leguminosae).
224062259|NCT04422860|DRUG|Proflourid Varnish,VOCO|5% NaF varnish
223453697|NCT05470244|OTHER|Routine Physical Therapy and Intra-venous analgesic regimen|ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
223453698|NCT05470244|OTHER|Transcutaneous Electrical Nerve Stimulation along with Routine Physical Therapy and Intra-venous analgesic regimen|High frequency stimulations via Transcutaneous Electrical Nerve Simulator will be applied. ROM Exercises will be performed and analgesics including the NSAIDs and narcotics as per prescription of surgeon/physician will be given to all subjects
223453699|NCT00496158|DRUG|Clevudine|
223453700|NCT00496158|DRUG|Adefovir|
224062260|NCT04422860|DRUG|MI Varnish,GC Japan Inc.|CPP-ACP with fluoride based varnish
224147915|NCT04054739|DEVICE|Treadmill gait training|intervention with treadmill gait training
223453701|NCT02431312|BIOLOGICAL|INO-1800|INO-1800 delivered by EP
223453702|NCT02431312|BIOLOGICAL|INO-9112|INO-9112 delivered by EP
223742539|NCT00077103|BIOLOGICAL|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
223742540|NCT00077103|BIOLOGICAL|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
224062261|NCT04160702|BEHAVIORAL|Motivate-The-Bystander (MTB)|MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
224062262|NCT01898572|OTHER|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
224062263|NCT05298189|BEHAVIORAL|MindBreaks - Audio-visual|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli."
224062264|NCT05298189|BEHAVIORAL|MindBreaks - Auditory-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli."
224062265|NCT05298189|BEHAVIORAL|MindBreaks - Visual-only|"A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli."
224062266|NCT00851201|BEHAVIORAL|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
224062267|NCT00851201|BEHAVIORAL|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
224062268|NCT02601677|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
224062269|NCT02601677|DRUG|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
224147916|NCT04055987|BEHAVIORAL|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
224147917|NCT05474911|DEVICE|Negative pressure therapy|The wound will be cleaned (irrigation with Physiological Serum), the cavity and the perilesional area will be dried with gauze. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing. The cavity will be filled with a sponge. When the depth of the wound is less than 1.5 cm, it will not be necessary to fill the defect. The appropriate dressing will be applied to the size of the incision, reinforcing the edges, and it will be connected to the TPN device, ensuring correct functionality.
223453703|NCT02431312|DRUG|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
223453704|NCT01705080|DEVICE|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
223453705|NCT04846270|DEVICE|TENA SmartCare Change Indicator|Each participating subject will be provided with TENA SmartCare Change Indicator and incontinence products for the duration of the investigation. Each participating subject will be allocated to the incontinence type(s) that are considered most suitable.
223453706|NCT00206427|DRUG|GW572016|Lapatinib, 500 mg
223453707|NCT00206427|DRUG|lapatinib|Lapatinib 500 mg PO
223453708|NCT00003843|DRUG|irinotecan hydrochloride|
223453709|NCT00003843|GENETIC|mutation analysis|
223453710|NCT00003843|GENETIC|polymorphism analysis|
223453711|NCT02348697|BIOLOGICAL|NOVOCART 3D|Autologous Chondrocyte Implantation
223453712|NCT05206383|BEHAVIORAL|Positive message - placebo|"Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo)."
223453713|NCT05206383|BEHAVIORAL|Negative message - nocebo|"Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo)."
223453714|NCT05206383|BEHAVIORAL|Neutral message|"Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message)."
223453715|NCT06955039|OTHER|Sand Activites|Exercises included walking, jogging, striding, bounding, galloping, and short sprints.Exercise intensity (running speed) was controlled using a stopwatch and predefined running distances on the sand-based exercise court.
223453716|NCT06955039|OTHER|Towel Curl Exercises|The experimental group will perform Towel Curl Exercises Sand .In Week 1-4 the exercises will conducted without weights while in weeks 5-8 the exercise included the use of dumbbells weighing 2kg.this exercises will conducted in a sitting position on a slick surface.
223453717|NCT06955039|OTHER|(TCE)|The control group will only perform towel curl exercises In Week 1-4 the exercises will conducted without weights while in weeks 5-8 the exercise included the use of dumbbells weighing 2kg.this exercises will conducted in a sitting position on a slick surface.
223453718|NCT00741598|DRUG|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
223453719|NCT00741598|DRUG|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
223453720|NCT03692923|OTHER|virtual community|
223453721|NCT00313586|DRUG|Azacitidine|Given SC
223453722|NCT00313586|DRUG|Entinostat|Given PO
223453723|NCT00313586|OTHER|Laboratory Biomarker Analysis|Correlative studies
223453724|NCT05084976|BEHAVIORAL|COVID 19 vaccine counseling|After surveys are completed, pulmonary provider (nurse practitioner or physician) will provide counseling via phone or in person about the COVID 19 vaccine. Safety, efficacy and side effects will be reviewed.
224147918|NCT05474911|OTHER|Conventional wound care|The wound will be cleaned with physiological serum irrigation, the cavity will be dried with gauzes and filled with a dressing made of cellulose and silver. A skin protection spray will be applied to avoid irritation of the skin around the wound due to the adhesive of the dressing.
224147919|NCT06290271|OTHER|Intracranial artery flow pattern|the cerebral blood flow patterns observed after the occluded artery has been recanalized.
224147920|NCT05067452|OTHER|Food support|Diabetes-tailored food support. Project Open Hand (POH) will provide intervention participants twelve weeks of supplemental food support. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian. All food support will be home delivered.
224147921|NCT05067452|OTHER|Case-management|"Project Open Hand client services staff will conduct three case management sessions with the participant. The first session will initiate food services and ensure orientation to the intervention and set up delivery; the second session will support the participant with any issues related to the intervention (logistical or nutrition-related, with referral to the POH registered dietitian as needed); the third session will provide transition from the intervention, connect the participant with local food resources, and ensure a warm hand-off to nutrition"
224147922|NCT03380338|BEHAVIORAL|Combined aerobic and strength exercise|
223453725|NCT03076996|BEHAVIORAL|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~* Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~* Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~* Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
223453726|NCT06192238|PROCEDURE|adrenal venous sampling|Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
223453727|NCT02727179|PROCEDURE|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
223453728|NCT03153800|BIOLOGICAL|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
223453729|NCT06142344|DEVICE|Quiremspheres™|The intervention comprises two steps. Initially, the patient will undergo mapping angiography and a Ho-166 scout dose. If deemed eligible, the patient will proceed to 166-Ho radioembolization.
223453730|NCT02494856|DRUG|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
223453731|NCT02494856|DRUG|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
223571165|NCT02421731|DEVICE|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
223742541|NCT00077103|DRUG|cisplatin|cisplatin IV over 30-60 minutes on day 1
224147923|NCT03538132|OTHER|dental regenerative techniques|dental regenerative techniques
224147924|NCT01539785|PROCEDURE|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
223453732|NCT05779787|PROCEDURE|TAVR Aligned|Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
223453733|NCT05779787|PROCEDURE|TAVR Random|TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
223453734|NCT06432101|OTHER|Acupuncture combined with oral hydroxychloroquine sulfate tablets|Acupuncture combined with oral hydroxychloroquine sulfate tablets
223742542|NCT00077103|DRUG|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
224301509|NCT00062010|DRUG|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
224301510|NCT01721811|OTHER|Hyperoxia|
224301511|NCT01721811|OTHER|Glucose|
224301512|NCT00912483|BIOLOGICAL|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
223453735|NCT04026230|DRUG|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
223453736|NCT04026230|DRUG|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
223453737|NCT01247350|DRUG|LY3009104|Administered orally
223453738|NCT01247350|DRUG|Placebo|Administered orally
223453739|NCT03118817|DRUG|HM95573|"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"
223453740|NCT00324662|DEVICE|Implantable cardioverter-defibrillator|
223453741|NCT03059732|OTHER|Treatment|Observe the treatments of gastric cancer in each group
224062270|NCT05933369|BEHAVIORAL|Clincal pharmacist intervention|Patients in the intervention group will receive a protocol-defined intervention at the start of the study and at the 1- , 3 and 6-month follow-up visits for education on disease and treatment 40 minutes, administration and dosage 6 minutes, drug interaction and other drug therapy problems 20 minutes for a total of 66 minutes. The intervention will include education about asthma triggers and the need of minimizing them, asthma symptoms, warning signs, proper inhalation use technique, cigarette smoking cession when appropriate, the need of adherence and they will also counseled to wash their mouth after the use of controller medications. In addition, pharmaceutical care evaluation will be carried out and any drug therapy problems will be addressed accordingly and finally every intervention provided will be recorded.
224062271|NCT06410365|DRUG|Dexmedetomidine injection|Comparison of intravenous and intrathecal route of dexmedetomidine
224062272|NCT02705651|DRUG|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
223571166|NCT02421731|OTHER|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
224062273|NCT04233697|DRUG|Copanlisib|Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.
224062274|NCT04233697|DRUG|Romidepsin|Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
224062275|NCT00153114|DRUG|polyethyleneglycol3350|
224062276|NCT04914689|OTHER|Internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving mirror feedback. Participants will be instructed to perform each functional task in a manner that keeps their knee in line with their toes.
224147925|NCT01539785|PROCEDURE|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
224147926|NCT02156804|DRUG|Nivolumab (BMS-936558)|
224147927|NCT03228394|DRUG|Ganaxolone|Ganaxolone IV
224147928|NCT03228394|DRUG|Placebo|Placebo IV
224147929|NCT01530555|DRUG|Rabbit ATG, Thymoglobuline (Genzyme)|"1. Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~2. Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
224147930|NCT02789826|PROCEDURE|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
224147931|NCT02789826|PROCEDURE|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
224147932|NCT01551472|DEVICE|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
223571167|NCT01069861|DRUG|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
223571168|NCT02760771|OTHER|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
223571169|NCT02760771|OTHER|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
223571170|NCT06358781|OTHER|Whole grain wheat flour|Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
223571171|NCT01304212|DRUG|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
223571172|NCT01304212|DRUG|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
223571173|NCT01304212|DRUG|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
223571174|NCT01304212|DRUG|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
223571175|NCT00308893|GENETIC|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
223571176|NCT04165187|OTHER|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
223571177|NCT04165187|OTHER|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
223571178|NCT00311194|BEHAVIORAL|6 months readmission rate to hospital|
224062277|NCT04914689|OTHER|Visual internal focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving visual feedback via laser. Participants will be instructed to perform each functional task in a manner that does causes the laser to move up and down but not side-to-side.
224062278|NCT04914689|OTHER|Auditory external focus of attention feedback|Participants will complete 12 sessions over a 3-week period of functional movement retraining while receiving auditory feedback. Participants will be instructed to perform each functional task in a manner that does not cause the auditory tool to elicit a noise.
223453742|NCT00565552|DRUG|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
224062279|NCT02588976|DEVICE|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
224147933|NCT04581863|DEVICE|pulse oximeter|Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
224147934|NCT04581863|OTHER|COVID Watch|Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
224147935|NCT02533219|DRUG|18 F-DOPA|Subjects will undergo PET imaging with \[18F\]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of \[18F\]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
224147936|NCT03831737|BEHAVIORAL|stretching exercises|"Head/neck stretches~* Head tilt side to side~* Cross-chest stretch Torso stretches~* Side stretch~* Mid-back stretch Lower limb~* Standing quadriceps stretch~* Standing hamstring stretch"
224147937|NCT03702426|DRUG|GMCSF|GMCSF 1.5mcg/Kg
224147938|NCT03702426|DRUG|Norfloxacin|Tablet Norfloxacin 400 mg
224147939|NCT00436202|BEHAVIORAL|Iron supplement|
224147940|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
223453743|NCT00421109|DRUG|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
223453744|NCT00421109|DRUG|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
223453745|NCT00421109|DRUG|Placebo|Encapsulated tablet. Once daily for 28 days
223453746|NCT03269903|DEVICE|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
223453747|NCT01602705|OTHER|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
224062280|NCT03602079|DRUG|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
223453748|NCT01602705|OTHER|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
223453749|NCT01602705|OTHER|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
223453750|NCT05787743|OTHER|Facial cream with 2% palm tocotrienols extract|Apply on the face twice a day
223453751|NCT05787743|OTHER|Base cream|Apply on the face twice a day
223453752|NCT00003367|DIETARY_SUPPLEMENT|green tea|
223453753|NCT00003367|DIETARY_SUPPLEMENT|soy protein isolate|
223453754|NCT00003367|DIETARY_SUPPLEMENT|vitamin E|
223571179|NCT04018560|BEHAVIORAL|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
223571180|NCT03739489|PROCEDURE|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
223571181|NCT02906215|BEHAVIORAL|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
223571182|NCT00898924|GENETIC|molecular diagnostic method|
223571183|NCT00898924|GENETIC|mutation analysis|
224062281|NCT06009003|DRUG|REL-1017|REL-1017 tablet
224062282|NCT00767091|DRUG|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
224062283|NCT00767091|DRUG|placebo|transdermal patch of placebo
224147941|NCT02584868|DRUG|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
224147942|NCT00875303|BEHAVIORAL|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
224147943|NCT00875303|BEHAVIORAL|Control|Routine primary care.
224147944|NCT04679558|DRUG|Chlorhexidine varnish added to the preventive protocol|Antibacterial agent varnish added to the preventive protocol
224147945|NCT04679558|BEHAVIORAL|Preventive protocol|Preventive protocol
224147946|NCT00453232|BIOLOGICAL|bleomycin sulfate|
224147947|NCT00453232|BIOLOGICAL|pegfilgrastim|
224147948|NCT00453232|DRUG|cisplatin|
224147949|NCT00453232|DRUG|etoposide|
224147950|NCT03165864|DRUG|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
224147951|NCT03165864|OTHER|Placebo|Saline .9%
224147952|NCT01803711|DRUG|Desvenlafaxine|
224147953|NCT01803711|DIETARY_SUPPLEMENT|Omega 3 Fatty acids|
224062284|NCT02988453|OTHER|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
224062285|NCT03292809|DRUG|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
224062286|NCT03292809|DRUG|Vehicle topical ocular, eye drops|Vehicle
224062287|NCT00547170|DRUG|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
224062288|NCT00547170|DRUG|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
224062289|NCT04615754|DIETARY_SUPPLEMENT|Hyperketonemia - use of ketone (3-OHB) infusion|The effect of intravenous ketone supplement
224062290|NCT04615754|DIETARY_SUPPLEMENT|Placebo - use of saline infusion|Saline is infused as an comparator
224062291|NCT05598099|BEHAVIORAL|Concentrated cognitive behavioral therapy|A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
224062292|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
224062293|NCT04566770|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo|Intramuscular other name:Ad5-nCoV
224062294|NCT01765920|DRUG|Ergoferon|5 ml 3 times a day
224062295|NCT01765920|DRUG|Placebo|5 ml 3 times a day
224062296|NCT04335942|OTHER|"Alert AFNOR 3.6."|This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
224062297|NCT04335942|OTHER|"Alertes  AFNOR 3.6  et alertes  Guidelines ."|By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries. For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
224062298|NCT05114200|PROCEDURE|Erector spinae plane block|"Patients will be placed in prone position. Mild sedation will be achieved by using 1-2 mg of midazolam and 50-75 µg of fentanyl iv. The application area will be visualized with General Electrics (GE) Logiq e Ultrasound device using 10-12 MHz linear probe or convex probe. Transverse process and erector spinae muscles will be visualised at the target vertebral level. Following local anesthesia (1-2 cc 2% lidocaine) application to the insertion site, a 20 gauge spinal needle will be inserted using the in-plane technique. The needle will be advanced up to the transverse process under ultrasound guidance. After confirming needle position with hydrodissection, 40 mg triamcinolone, 10 cc 0,5% bupivacaine, 10 cc radiopaque contrast agent solution will be injected. Imaging will performed in AP and lateral positions with fluoroscopy immediately and 30 minutes after the injection to evaluate intectate spread."
224062299|NCT03383445|PROCEDURE|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20, 23 or 26 mm).
224062300|NCT03383445|PROCEDURE|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
224062301|NCT03383445|PROCEDURE|Acurate neo|The TAVR procedure will be performed with the ACURATE neo aortic valve.
224062302|NCT03383445|PROCEDURE|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
224147954|NCT01803711|DRUG|Placebo (for Omega 3 fatty acid supplement)|
223453755|NCT00784589|DRUG|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
223453756|NCT00784589|DRUG|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
223453757|NCT04397549|OTHER|Cervical erector spinae plane block|Cervical erector spinae plane block will be administered before the surgery
223453758|NCT04397549|DEVICE|Intravenous morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
223453759|NCT03023267|BEHAVIORAL|Music therapy and Kangaroo care|Mother holding baby in skin to skin position while singing
223453760|NCT03023267|BEHAVIORAL|Kangaroo Care alone|Mother holding baby in skin to skin position without singing
223453761|NCT01899820|DRUG|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
223453762|NCT01899820|DRUG|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
224062303|NCT04103684|DRUG|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
224062304|NCT04103684|DRUG|Dexamethasone|0.6mg per kg perday for 5 days
224062305|NCT01081249|DRUG|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
224062306|NCT01081249|DRUG|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
224147955|NCT04145713|DIETARY_SUPPLEMENT|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
224062307|NCT05973604|DIAGNOSTIC_TEST|Screening and Confirmatory diagnostic test for primary aldosteronism|Screening for primary aldosteronism will be performed with measurement of aldosterone-to-renin ratio after 2 hours of bed rest. Renin measurement will be performed by estimating plasma renin activity. The screening test will be considered positive when the ratio is \>30, accompanied by elevated aldosterone values (\>15 ng/ml). Patients with a positive result will undergo further confirmatory testing with intravenous sodium test (administration 2 liters of normal saline N/S 0.9%, over a period of 4 hours, while the patient is supine. Considered positive if aldosterone levels are \>5mg/dl at the end of the test). Alternative confirmatory methods are captopril test (Administration of 50 mg of captopril. Considered positive when aldosterone levels are \>8.5 mg/dl 2 hours after the intake) or hydrocortisone test (Administration of 0.1mg of hydrocortisone 4 times a day for a period of 4 days. Considered positive if elevated aldosterone levels (\>6ng/dl) are found at the end of the test).
224062308|NCT04891315|DIAGNOSTIC_TEST|Blood test for soluble VAP-1 (sVAP-1).|\~5ml blood will be taken and sVAP-1 will be measure by Enzyme linked Immunosorbent Assay
224062309|NCT02411539|BIOLOGICAL|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
224062310|NCT02411539|BIOLOGICAL|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
224062311|NCT00282334|DEVICE|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
224062312|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
224062313|NCT02395926|DRUG|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
223453763|NCT02488018|BIOLOGICAL|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
223453764|NCT02537665|OTHER|heating precondition|
223453765|NCT02440048|DEVICE|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
223453766|NCT02440048|DEVICE|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
224301513|NCT00912483|BIOLOGICAL|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
223453767|NCT03571607|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
223453768|NCT00640419|DRUG|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
223453769|NCT00640419|DRUG|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
223453770|NCT04000126|DEVICE|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
223453771|NCT04000126|DEVICE|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
223453772|NCT04000126|DRUG|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
223453773|NCT04000126|DRUG|Placebo|100ml 0,9% NaCl iv 10min before intubation
223453774|NCT04000126|DEVICE|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
223453775|NCT04000126|DEVICE|HR|HR in beats/min will be measured by the electrocardiogram monitor
223453776|NCT04000126|DEVICE|BP|BP will be measured automatically by an occluding upper arm cuff
223453777|NCT04220801|DRUG|ZM-H1505R|Single oral doses of 300, 450, 600, 750, and 900 mg of ZM-H1505R or placebo and multiple oral doses of 450, 600, and 750 mg of ZM-H1505R or placebo will be administered in a fasted state, or in the case of Cohort 3 (Part 1), a second dose of 600 mg will be administered in the fed state. During each SAD and MAD dosing period, 2 subjects in each cohort will receive placebo instead of ZM-H1505R. The dose levels may be adjusted based on the safety and tolerability obtained from the previous cohort.
223571184|NCT00016367|BIOLOGICAL|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
223571185|NCT00016367|DRUG|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
223571186|NCT00016367|DRUG|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
224301514|NCT05643248|DRUG|NEX-20A|Subcutaneous prolonged-release injection
223453778|NCT04715191|GENETIC|CARE T cells|"Four different dosing schedules will be evaluated. The following dose levels will be evaluated:~DL0: 1x10\^7/m\^2 DL1: 3x10\^7/m\^2 DL2: 1x10\^8/m\^2 DL3: 3x10\^8/m\^2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
223453779|NCT04715191|DRUG|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
223453780|NCT04715191|DRUG|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
223453781|NCT05840016|DRUG|AK112, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
223453782|NCT05840016|DRUG|Tislelizumab, Carboplatin, Paxlitaxel|IV infusion,Specified dose on specified days
223571187|NCT03545711|DRUG|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
223571188|NCT05499793|DIETARY_SUPPLEMENT|Zingiber Officinale powder|Ginger powder
224062314|NCT02395926|DRUG|Choline CR 600mg|HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
224062315|NCT00362934|DRUG|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
224062316|NCT00362934|DRUG|Atorvastatin|Atorvastatin 10 mg and 20mg
224062317|NCT01486849|DRUG|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
224062318|NCT01486849|DRUG|Placebo|Matching placebo tablets BID for 21 days
224062319|NCT01486849|DRUG|Riluzole 50 MG|
224062320|NCT06294457|DEVICE|Non-Invasive Neuromodulation NESA|Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
224062321|NCT04245475|BEHAVIORAL|Virtual Reality psychological pain reduction|attention distraction
224062322|NCT04828395|BIOLOGICAL|Camrelizumab|200mg iv Q3W
224147956|NCT04145713|OTHER|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
224147957|NCT02658981|BIOLOGICAL|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
223453783|NCT06342115|DRUG|Ceftolozane-Tazobactam|In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
223453784|NCT06342115|DRUG|Meropenem|The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.
223571189|NCT05499793|DIETARY_SUPPLEMENT|Placebo|Starch powder
223453785|NCT05830539|DRUG|IN10018+PLD|IN10018 orally once daily; PLD 40mg/m2, Q4W
223453786|NCT05830539|DRUG|IN10018+PLD+Toripalimab|IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
223453787|NCT03161522|DRUG|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
223453788|NCT03161522|DRUG|Chemotherapy|Receive induction chemotherapy
223453789|NCT03161522|PROCEDURE|Conventional Surgery|Undergo surgery
223453790|NCT03161522|DRUG|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
223453791|NCT03161522|RADIATION|Radiation Therapy|Undergo RT
223453792|NCT02760524|BEHAVIORAL|NET Intervention|Neuro-emotional Technique
223453793|NCT06346418|GENETIC|WES analysis|"Whole-exome sequencing will be performed as the first approach in all the recruited patients. First, we will analyze different subsets of genes, belonging to:~1. Maternal effect genes as SCMC components and other related genes;~2. Genes essential in the maturation of the oocyte and zygote progression through the early phases of the embryogenesis or highly expressed at different stages of oocyte maturation;~3. Genes with known and potential roles in the establishment and control of genomic imprinting and involved in DNA methylation reactions.~Subsequently, variants with a high pathogenicity score will be analyzed, to identify any genes that may be associated with the phenomenon, but do not belong to the previously described categories of genes. Finally, we will conduct a whole genome sequencing (WGS) analysis on a selected subgroup of BWS mothers with peculiar clinical histories and negative WES analysis, to explore all the noncoding and regulatory regions not targeted by WES."
223571190|NCT02502604|BEHAVIORAL|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
223571191|NCT00293904|BIOLOGICAL|CYT005-AllQbG10|
223571192|NCT05571007|OTHER|True acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
224062323|NCT04828395|DRUG|Fluzoparib|150mg bid
224062324|NCT04828395|DRUG|Cisplatin，Pemetrexed|Cisplatin 75mg/m2 IV and Pemetrexed 500mg/m2 IV Q3W (Day 1 of each cycle of cycles 1-3) (non-squamous cell carcinoma only)
224062325|NCT04828395|DRUG|Cisplatin，Etoposide|Cisplatin 50mg/m2 IV (the 1st and 8th days of the 1st cycle and the 2nd cycle; the 8th and 15th days of the 3rd cycle); Etoposide 50mg/m2 IV (the 1st cycle And the 1st to the 5th day of the 2nd cycle; the 8th to the 12th day of the 3rd cycle).
224062326|NCT04828395|DRUG|Carboplatin, Albumin Paclitaxel|Carboplatin AUC=6, Albumin Paclitaxel 100mg/m2 IV; Days 1, 8 and 15 of cycles 1, 2, and 3.
224062327|NCT04828395|RADIATION|Radiotherapy|60 Gy (total 6 weeks)
224062328|NCT01857284|DRUG|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
224147958|NCT02658981|BIOLOGICAL|Anti-PD-1|Given IV
223571193|NCT05571007|OTHER|Sham acupressure|"Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy."
224062329|NCT01857284|DRUG|Ursodeoxycholic Acid Capsules|250mg.tid.po
224062330|NCT01704352|BEHAVIORAL|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
224062331|NCT03146000|DRUG|lidocaine-prilocaine cream|topical cream
224062332|NCT03146000|DRUG|meloxicam rectal suppository|suppository
224147959|NCT02658981|OTHER|Pharmacological Study|Correlative Studies
224147960|NCT02658981|OTHER|Laboratory Biomarker Analysis|Correlative Studies
224147961|NCT02658981|BIOLOGICAL|Anti-CD137|Given IV
224147962|NCT02706119|DRUG|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
224147963|NCT02706119|DRUG|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
224062333|NCT06171321|DRUG|S-1(Intravenous combined with oral)|Oral combined with intravenous S-1 for ctDNA-positive patients (escalating treatment strategy)
224062334|NCT00413426|DRUG|Darifenacin (DAR328)|
224062335|NCT04041284|DRUG|Fremanezumab|Monthly 225 mg subcutaneous
224062336|NCT04041284|DRUG|Placebo|Matching Placebo
224062337|NCT01148199|DEVICE|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
224062338|NCT01148199|DEVICE|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
224062339|NCT01576770|DEVICE|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
224062340|NCT01576770|DRUG|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
224062341|NCT00829907|DRUG|ORM-12741|Single dose as a capsule, oral administration
224062342|NCT00878371|DRUG|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
224062343|NCT06395831|DIAGNOSTIC_TEST|BREF,ADL,AIS|"1. abbreviated version of the quality of life assessment questionnaire - The World Health Organization Quality of Life (WHOQOL) -BREF~2. scale I - ADL according to Lawton~3. the AIS questionnaire~4. the Zimet Multidimensional Scale of Perceived Social Support - the original version of the MSPSS"
224062344|NCT02086786|DRUG|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
224062345|NCT03412175|BEHAVIORAL|Behavioral Intervention|The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
224062346|NCT05561660|DEVICE|PFO device closure|Participants randomized into this group will take PFO device closure.
224062347|NCT05561660|DRUG|Aspirin|Participants randomized into this group will take aspirin 200mg qd for 6 months.
224062348|NCT02595671|OTHER|Digital Super Coach|Receive Digital Super Coach during 12 weeks
224062349|NCT02595671|OTHER|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
224062350|NCT02595671|OTHER|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
224062351|NCT02595671|OTHER|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
224062352|NCT00882609|DEVICE|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
224147964|NCT04823546|OTHER|activity based therapy|Standing and reaching (2) Sit-to-stand (3) Stepping forward and backward onto blocks (4) Stepping sideways onto blocks (5) Forward step up onto blocks (6) Raising and lowering of heel (7) Standing with the base of support constrained with feet in parallel and tandem conditions Phase 2 started after 3 weeks. Phase 2 included the phase 1 exercise along with below exercise. (10) Walking on a treadmill; (11) Walking over various surfaces and obstacles;
223571194|NCT05623254|OTHER|no comparator - TAU (Treatment-as-usual)|"Learning the ability in mindfulness practice by specific measure (FFMQ) changes in FIVE FACET MINDFULNESS QUESTIONNAIRE (FFMQ) compared to baseline): this questionnaire measures the mindfulness ability of patients before and after the APP application (minimum score 113.7-low mindfulness ability=worse outcome ; maximum score 144.3-high mindfulness ability=better outcome) \[Time Frame: At Three-six months\]~Introduction of the mindfulness program during a preliminary face-to-face session to patients and caregivers~TAU Weekly mindfulness sessions delivered on-line for patients and caregivers (a specific platform for on-line sessions will be used)"
224062353|NCT01923129|DRUG|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
224062354|NCT00886600|DRUG|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
224062355|NCT00886600|DRUG|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
224062356|NCT00886600|DRUG|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
224147965|NCT04823546|OTHER|Strength Training|Strength training included for hip • flexor and extensors and abductors, knee extensors, and ankle dorsi flexors and plantar •flexors. Apart from using body weight, sandbag weights and Therabands of eight different resistances
224147966|NCT02157246|OTHER|Pimonidazole|
224147967|NCT02157246|OTHER|F-MISO PET|
224147968|NCT02157246|OTHER|pCT|
224147969|NCT02157246|OTHER|Functional MRI|
224147970|NCT02157246|PROCEDURE|Biopsy|
224147971|NCT02157246|PROCEDURE|Blood sample|
224147972|NCT02715050|DEVICE|Active or Placebo Phototherapy (MR4)|
224147973|NCT02249026|DRUG|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
224062357|NCT01439204|BIOLOGICAL|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
224062358|NCT00336973|DRUG|efalizumab|Subcutaneous repeating dose
224062359|NCT06358222|PROCEDURE|Blood ctDNA + methylation + PET-CT and Postoperative pathology|A highly sensitive tumor-naïve MRD panel of ctDNA will be employed to detect preoperative blood. Some patients will undergo methylation profiling to prospectively establish LNMs-specific ctDNA methylation signatures.
224062360|NCT06358222|PROCEDURE|MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA|A certain number (depending on the Results of Stage 1) of patients requiring invasive mediastinoscopy or EBUS-TBNA, based on the clinical guidelines, will be included for blood ctDNA mutation/methylation profile (or combined PET-CT), and the detection rate of LNMs will be assessed in patients with negative preoperative blood ctDNA mutation/methylation (or combined PET-CT). The accuracy of predicting LNMs will be compared with that of patients with negative or positive preoperative blood ctDNA mutation/methylation (or combined PET-CT).
224062361|NCT06358222|PROCEDURE|Intraoperative lymph node dissection|For patients with negative preoperative blood negative testing (ctDNA mutation/methylation profiles alone or in combination with PET-CT), systematic lymph node sampling/dissection and no lymph node dissection will be grouped and compared. Regular follow-up is performed to investigate the impact on long-term MRD negative duration and prognosis.
224062362|NCT05772754|GENETIC|study of molecular and protein pathways|42 ml peripheral venous blood sample.
224062363|NCT00730964|DRUG|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
224062364|NCT04234165|DEVICE|TURBT|different power sources ( bipolar vs monopolar)
224062365|NCT00754793|DRUG|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
224062366|NCT00754793|DRUG|placebo|inactive comparator; titrated as per protocol over 12 weeks
224062367|NCT05164107|DEVICE|Globe Mapping and Pulsed Field Ablation System (Globe PF System)|During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
224062368|NCT05775640|BEHAVIORAL|serious game|The forms were applied to the children in the experimental group and the parents of the children on the 0th day of hospitalization. After the forms were applied, a serious game developed by the researchers was played. Children were given access to the game by giving a game link. The game can be played on digital platforms such as computers, tablets, etc. For children who do not have an electronic device, the game was downloaded to the computer in the hospital and the children were allowed to play. On the third day of hospitalization, the children and their parents were surveyed again and the Game Evaluation Questionnaire was filled. Access to the game will be closed at the end of the study.
224062369|NCT01515761|PROCEDURE|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
224062370|NCT01515761|PROCEDURE|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
224062371|NCT03381716|DRUG|drug|Application bracket
224062372|NCT03381716|PROCEDURE|Surgery|Surgery
224062373|NCT01070472|DRUG|Misoprostol|titrated oral misoprostol solution
224062374|NCT01127568|DRUG|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
224062375|NCT04505618|DEVICE|Swept-Source (SS) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
224062376|NCT04505618|DEVICE|Spectral-Domain (SD) OCT Angiography|Non-invasive, minimal risk, ocular imaging study
224062377|NCT04505618|DEVICE|Fundus Imaging|Non-invasive, minimal risk, ocular imaging study
224062378|NCT04505618|DEVICE|Axial Length Measurement Device|Non-invasive, minimal risk, ocular imaging study
224062379|NCT03542006|DRUG|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
224301515|NCT02856880|OTHER|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
224301516|NCT02856880|OTHER|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
224301517|NCT02856880|OTHER|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
224301518|NCT02856880|OTHER|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
223453794|NCT06346418|GENETIC|whole-genome methylation analysis|A whole-genome methylation analysis will be performed to identify methylation changes in women with reproductive problems including those with offspring affected by BWS
223453795|NCT06126640|DRUG|SHR-A1811|Lyophilized powder injection, 100mg / bottle, intravenous drip
224062380|NCT02899689|DEVICE|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
224062381|NCT02899689|DEVICE|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
224062382|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
224301519|NCT02856880|OTHER|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
224301520|NCT05741515|OTHER|Vestibular Balance Therapy|see intervention arm description
224062383|NCT01015651|DRUG|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
224062384|NCT00217204|DRUG|Pancrelipase microtablets|
223453796|NCT06126640|DRUG|Trastuzumab Emtansine|Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
223453797|NCT04831060|PROCEDURE|Periodontal or peri-implantitis treatment|"For Cases :~* Inclusion; Bacterial sampling, gingival fluid and unstimulated saliva collection; Teaching of oral hygiene techniques.~* Non-surgical periodontal or peri-implantal treatment~* At 3 months = periodontal or peri-implantal reevaluation; Bacterial sampling, gingival fluid and unstimulated saliva collection~* If periodontal or peri-implantal pockets greater than 5mm and bleeding persist: surgery and gingival explant sampling~* At 3 months post-surgery = periodontal or peri-implantal re-evaluation; Bacterial sampling, gingival fluid and unstimulated saliva collection~* Maintenance"
223453798|NCT04831060|PROCEDURE|Control treatment|"For Controls:~* Inclusion; Bacterial sampling, gingival fluid and unstimulated saliva collection, teaching of oral hygiene techniques.~* Plastic or pre-prosthetic surgery = gingival explant sampling~* Healing control at 15 days"
223453799|NCT01713062|DEVICE|Vitelene|THA
223453800|NCT01713062|DEVICE|XLPE|THA
223453801|NCT03192410|BEHAVIORAL|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
223453802|NCT03192410|BEHAVIORAL|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
223453803|NCT03192410|BIOLOGICAL|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
223453804|NCT03192410|BIOLOGICAL|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
223453805|NCT03192410|GENETIC|DNA|SNPs (GWAS)
223453806|NCT03192410|BIOLOGICAL|Mental well-being|Cognitive function; dispositional optimism; depression.
223453807|NCT02382809|DRUG|DC071|Mouthwash, twice daily
223453808|NCT02382809|DRUG|Placebo|Mouthwash, twice daily
223453809|NCT06164483|DIAGNOSTIC_TEST|Auditory test|"The patients will perform:~Pure Tone Auditory test + Tympanometry and Stapedial Reflex~* Speech Perception test~* In case of tinnitus: tinnitus questionnaire and acuphenometry~* DPOAEs~* ABR"
223453810|NCT06164483|OTHER|CSF sampling|Cerebrospinal Fluid will be collected by lumbar puncture and analyzed
223571195|NCT00951522|DRUG|GS-9411|Inhaled GS-9411 dissolved in sterile saline
223571196|NCT00951522|DRUG|Placebo|Inhaled placebo in sterile saline
223571197|NCT00162461|DRUG|Phenytoin single dose (300 mg)|
223571198|NCT02128243|DRUG|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
223571199|NCT02128243|DRUG|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
223571200|NCT01189058|PROCEDURE|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
223571201|NCT01189058|PROCEDURE|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for \>90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
223571202|NCT00827281|DRUG|D-cycloserine|Single dosage prior to sessions 3, 4 \& 5
223571203|NCT00827281|DRUG|Placebo|Single dosage prior to sessions 3, 4 \& 5
223571204|NCT03620357|DEVICE|CGM|CGM Group: Dexcom G6 CGM
223571205|NCT03620357|DEVICE|SMBG|SMBG Group: Blood Glucose Meter
223571206|NCT04579172|PROCEDURE|Cervico- isthmic compression suture|Circular isthmic-cervical sutures will be applied . To avoid ureter and bladder injury, the bladder will be reflected downward. A silastic drain will be inserted into internal and through the external os , so as to drain the uterine cavity and to keep the cervical canal open. Firstly, at the left side of the uterus, a Vicryl number two (No..2) stitch will be inserted very close to the cervix from the anterior to the posterior side of the broad ligament.
224062385|NCT04750876|OTHER|Conventional support|"Patients in the Conventional support randomisation arm will follow the usual care of amputee patients in the vascular surgery department. They will be cared for by the surgeon, nurses and nursing auxiliaries, who will provide individualised care (nursing care, mobilisation, pain management, technical care, etc.), listening and support."
224062386|NCT04750876|OTHER|Specific care, including the intervention of a psychologist and a physical therapist.|"In the case where the patient is in the Specific care, including the intervention of a psychologist and a physical therapist. arm, the usual care will be associated with :~* consultations with a psychologist~* The patient will also be cared for on a daily basis by a physical therapist."
224062387|NCT00516542|DRUG|letrozole|A daily dose of 2.5 mg will be used throughout the study.
224062388|NCT00516542|DRUG|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
224062389|NCT00516542|OTHER|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
224062390|NCT04264403|DEVICE|Renal denervation|The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
224062391|NCT03085524|DIAGNOSTIC_TEST|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
224062392|NCT03085524|DIAGNOSTIC_TEST|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
224062393|NCT06926010|OTHER|predictive approach to hemodynamic management|vasoactive drugs and fluids will be given based on the hypotension prediction index
224062394|NCT03748446|DRUG|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
224062395|NCT03748446|DRUG|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
224062396|NCT06776692|DRUG|Qdenga|Administration of Dengue vaccine and blood sample collection
224062397|NCT04507685|OTHER|Lifestyle (Diet and Exercise)|"The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (\<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet.~The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (\<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods.~Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week."
224062398|NCT02558673|OTHER|TMAO dietary precursors|
224062399|NCT02558673|OTHER|Control (or active comparator)|
224062400|NCT06901882|BEHAVIORAL|CONECTEM, Communication based in BCS (basic communication skills) and AAC ( aumentative alternative communicatiton)|"It consists of applying basic and assisted communication techniques, already validated by experts (Happ, et al., 2008) to the critical patient admitted to the ICU. The intervention is divided into 3 strategies according to the level of patient awareness. Each strategy presents both verbal and non-verbal communication skills~Estratègia 3. Glasgow (≤8). Very ill patient, with indications for intubation, sedation and analgesia. We will basically use non-verbal communication, taking into account all external factors that may predispose to a change in the patient's condition.~Modulate your voice, speak softly and slowly, respecting an atmosphere of silence, without intense lights or loud noises. Adjust the temperature of the ICU according to the needs of the patient.~Achieve a relaxing atmosphere, playing calm music during the journey.Make comforting movements for the patient, avoiding abruptness and trying to establish non-verbal communication."
224062401|NCT06897501|DEVICE|bronchial blocker|Lung isolation for robot-assisted esophagectomy will be performed using bronchial blocker in this group.
224062402|NCT06897501|DEVICE|double-lumen endobronchial tube|Lung isolation for robot-assisted esophagectomy will be performed using double-lumen endobronchial tube in this group.
224062403|NCT02909985|OTHER|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
224062404|NCT06820671|OTHER|Recording voice samples|"Voice recording with~* reading the standard text~* repeating the test words~* vowel elicitation of 'a' and 'o' vowels for 5-10 seconds"
224062405|NCT06498713|DRUG|Acetaminophen 650 mg Oral Tablet|650 mg pills
224062406|NCT06498713|DRUG|Acetaminophen 650mg Liquid|650 mg liquid
224062407|NCT06498713|DEVICE|CADD pump|Primed and programmed to delivery 650 mg liquid acetaminophen into a medication cup every 4 hours as needed.
223571207|NCT04579172|PROCEDURE|Anterior wall uterine resection:|After fetal delivery, two corners of the uterine incision and the superior and inferior lips will be clamped immediately by four Mayo clamps. Blunt dissection downward to the bladder-uterus peritoneal reflection will perform, to the partial anterior wall of the uterine myometrium where the placenta was deeply adherent (a myometrium defect, with only the serous layer of the uterus) will be respected, together with the placenta. It is important to ensure that sufficient myometrium above the peritoneal reflection will be available for an optimum closure. Then, as much remaining placenta as possible will be removed piecemeal from the edge of the uterine incision. Clamps and multiple hemostatic sutures will be applied rapidly
223571208|NCT01882010|DRUG|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
223571209|NCT01882010|DRUG|placebo|saline solution daily subcutaneous injection 56 days
223571210|NCT01882010|DIAGNOSTIC_TEST|Sham Comparator: Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
224062408|NCT06774859|DRUG|Baloxavir Marboxil|Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).
224062409|NCT06774859|DRUG|Oseltamivir|Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
224062410|NCT05695950|DRUG|GLPG3667|GLPG3667 capsules will be administered per dose and schedule specified in the arm description.
224062411|NCT05695950|DRUG|Placebo|Placebo matching to GLPG3667 capsules will be administered per schedule specified in the arm description.
224062412|NCT02209077|DEVICE|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
223571211|NCT06276218|DEVICE|Clavicular brace|Clavicular brace for conservative treatment of closed midshaft clavicular fractures
223571212|NCT04035564|DRUG|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
224062413|NCT05441956|DRUG|TGRX-326|Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
224062414|NCT06944041|OTHER|STO3 sensor (Structure Inc., Boulder, CO)|The advent of Apple iPad based 3D scanner opens a new avenue for measuring limb volume. The latest ambient light scanner model was utilized for the current study. 3D scanning technology has gained broad industrial use, including the manufacturing of high-precision tools. A commercially available software package was used for limb volumetry.
224062415|NCT05598593|DRUG|cytarabine+thiotepa+ fludarabine + busulfan|cytarabine+thiotepa+ fludarabine + busulfan intravenous injection
224062416|NCT06953388|DEVICE|transcutaneous auricular vagus nerve stimulation|FDA-cleared Digitimer DS7A Constant Current Stimulator (Digitimer Ltd., USA) will deliver electrical stimulation for 60 mins. Active stimulation will consist of direct electrical stimulation to the inner side of the left tragus (anode on the cymba concha, cathode on the surface of the tragus), thereby stimulating the ABVN. Stimulation parameters will consist of 500μs pulse width, 25Hz frequency, delivered at 200% of each participant's individual perceptual threshold (PT) in 60sec on/off trains.
224147974|NCT02249026|DRUG|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
224301521|NCT05741515|OTHER|Sham Intervention|see sham intervention arm description
224301522|NCT01452711|DRUG|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
224301523|NCT01452711|DRUG|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
224301524|NCT01452711|DRUG|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
224301525|NCT01452711|DRUG|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
223571213|NCT04035564|DRUG|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
223571214|NCT00946725|DRUG|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
223571215|NCT00946725|DRUG|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
223453811|NCT04727593|BEHAVIORAL|Mindfulness Based Cognitive Therapy (MBCT)|Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.
223453812|NCT04727593|OTHER|Treatment as Usual|In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.
223453813|NCT02654158|DRUG|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"
223571216|NCT02002936|DRUG|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
223571217|NCT04447599|OTHER|photography of conjunctival vessels|patient will have photo of their bulbar conjunctival of each eye and photography of fundus without dilatation
223571218|NCT00106600|DRUG|Pixantrone IV infusion|
223571219|NCT00892203|DRUG|BGG492|
223571220|NCT00892203|DRUG|Sumatriptan|
223571221|NCT00892203|DRUG|Placebo|
223571222|NCT00000729|DRUG|Foscarnet sodium|
223571223|NCT02958306|BIOLOGICAL|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
223571224|NCT01689623|DRUG|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
223571225|NCT01689623|DRUG|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
223571226|NCT01689623|DRUG|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
223571227|NCT01640418|DEVICE|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
223571228|NCT04090034|PROCEDURE|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
223571229|NCT02749942|DEVICE|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
223571230|NCT02749942|DEVICE|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
223571231|NCT03132519|DRUG|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
223571232|NCT01024491|DRUG|paroxetine|daily dose of paroxetine 15mg for 12 weeks
223453814|NCT02654158|DRUG|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day"
223453815|NCT02583022|DRUG|PAC-14028 cream 1.0%|Topical application
223453816|NCT02583022|DRUG|PAC-14028 cream vehicle|Topical application
223453817|NCT02583022|DRUG|Elidel cream 1%|Topical application
223571233|NCT01024491|DRUG|paroxetine|active daily treatment with paroxetine 20 mg
223571234|NCT01024491|DRUG|placebo|active daily treatment with placebo
223571235|NCT04672525|DRUG|Rifabutin|2 tablets of 150 mg per day rifabutin tablet daily for 12 weeks in 1 administration with a companion treatment
223571236|NCT04672525|DRUG|Rifampicin|10 mg/kg per day (range 600 mg to 1,200 mg) rifampicin tablet in 1 daily dose for 12 weeks with a companion treatment
223571237|NCT01649544|DEVICE|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
223571238|NCT01649544|DRUG|Amiodarone|
223571239|NCT06350487|DRUG|SGLT2 inhibitor|Enavogliflozin (0.3mg oral tablet once daily) will be administrated.
223571240|NCT05106712|DRUG|Vitamin D3|4000IU per day for around 12 weeks.
223571241|NCT05106712|DRUG|Clomiphene Citrate|"oral Clomiphene citrate using its respective Stair-step dosage protocol as follow: 50 mg, 100 mg, and 150 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively."
223571242|NCT05106712|DRUG|Letrozole|"oral Letrozole using its respective Stair-step dosage protocol as follow: 5 mg, 5 mg, and 7.5 mg, once daily for 5 days, in the 1st, 2nd, and 3rd cycle, respectively, respectively."
223571243|NCT05106712|OTHER|placebo|participants in the control (Placebo) group will be treated with equal amount of placebo tablets per day for the same duration
223742543|NCT00077103|DRUG|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
223742544|NCT00077103|RADIATION|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
223742545|NCT04035161|COMBINATION_PRODUCT|Investigational Product|2%(w/v) Chlorhexidine in 70%(v/v) Isopropyl skin preparation
223742546|NCT04035161|OTHER|Reference Standard|60% (v/v) 1-propanol skin preparation
223742547|NCT04035161|COMBINATION_PRODUCT|Active Comparator|ChloraPrep® SEPP® skin preparation
224062417|NCT06953388|DEVICE|sham transcutaneous auricular vagus nerve stimulation|FDA-cleared Digitimer DS7A Constant Current Stimulator (Digitimer Ltd., USA) will deliver electrical stimulation for 60 mins. Sham will be delivered to the ear lobe. Stimulation parameters will consist of 500μs pulse width, 25Hz frequency, delivered at 200% of each participant's individual perceptual threshold (PT) in 60sec on/off trains.
224062418|NCT06446440|PROCEDURE|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis
224062419|NCT06446440|PROCEDURE|Open adhesiolysis|Open adhesiolysis
224062420|NCT05645406|DRUG|Divigel 0.1% Topical Gel|estradiol topical products
223571244|NCT05043792|DRUG|TT-00920|TT-00920 Tablets
223571245|NCT05043792|DRUG|TT-00920 Placebo|TT-00920 Placebo Tablets
223571246|NCT02130336|BEHAVIORAL|Aerobic interval training|
223571247|NCT02130336|BEHAVIORAL|Continuous moderate-intensity exercise|
223571248|NCT05732584|OTHER|structured family voice stimulation|The structured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death. The content of the recording is developed according to the structured script.
223571249|NCT05732584|OTHER|unstructured family voice stimulation|The unstructured family voice stimulation is played to the patients for the first five days after admission to eicu until transfer out or death.
223742548|NCT04035161|OTHER|Negative Control|0.9% Normal Saline skin preparation
223742549|NCT03849742|OTHER|Quality-of-Life Assessment|Ancillary studies
224062421|NCT05645406|DRUG|Compounded estradiol product|estradiol topical products
224062422|NCT05626998|DRUG|Dexmedetomidine|The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
224062423|NCT05626998|DRUG|Gabapentin|The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
224062424|NCT00006142|BEHAVIORAL|phenylalanine restricted diet|
224062425|NCT01689298|DRUG|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
223453818|NCT02439788|DRUG|cyclophosphamide|500 mg/m2/day x 2 days; for patients \<12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
223453819|NCT02439788|DRUG|Fludarabine|30 mg/m2/day x 3 days; for patients \<12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
223453820|NCT02439788|GENETIC|GINAKIT Cells|"* Dose Level 1 = 3 x 10\^6~* Dose Level 2 = 1 x 10\^7~* Dose Level 3 = 3 x 10\^7~* Dose Level 4 = 1 x 10\^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
223571250|NCT04901442|DEVICE|Aetrex L700 Speed orthotic|An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
223571251|NCT04730778|DIAGNOSTIC_TEST|serum creatinine and estimated glomerular filtration rate, on daily basis|Assess establishing criteria of CIN through a week after primary PCI
223742550|NCT03849742|OTHER|Questionnaire Administration|Ancillary studies
224062426|NCT01689298|DRUG|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
224062427|NCT05332158|BEHAVIORAL|Questionnaires to report barriers to medication adherence|One questionnaire specific to DOACs and one specific to statins have been integrated within the medical records system and will be sent to eligible patients to respond to following written informed consent.
224062428|NCT05912842|BEHAVIORAL|Organizational Partnerships for Healthy Living|Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled.
224062429|NCT05912842|BEHAVIORAL|Standard of Care|Comparison arm health organization will only receive the HIV standard of care (U.S. CDC HIV standard of care) and referral to legal aid.
224062430|NCT00782951|DRUG|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
224062431|NCT00782951|DRUG|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
224062432|NCT00782951|DRUG|Placebo|single IV dose of placebo after dental impaction surgery
224062433|NCT02883946|OTHER|Data collection|
224062434|NCT04765501|OTHER|Survey study|Headache Impact Questionnaire (HIQ) will be applied.
224062435|NCT05649059|DRUG|Cannabidiol|Participants randomized to the cannabidiol arm will receive 3mL of Epidiolex (100mg cannabidiol/mL) in a single-dose.
224062436|NCT05649059|DRUG|Placebo|Participants randomized to the placebo arm will receive 3mL of placebo (sesame seed oil) in a single dose.
224062437|NCT05233137|BEHAVIORAL|PA coaching|PA coaching: Patients receive a step counter together with a coaching application (m-PAC, AppsOnly, KU Leuven) installed on a smartphone. The step counter and coaching application are connected via Bluetooth. The coaching application has the goal of PA promotion as well as detecting any new AECOPD.
224062438|NCT05233137|OTHER|Exercise training|"Each session will include at least the following components:~* Resistance training of the lower limbs: Exercises for 6 muscle groups using minimal (e.g. ankle weights or elastic resistance bands) or no (body weight) equipment are foreseen. Each exercise will be performed in 3 series of 8 repetitions.~* Functional training: Sit to stand exercise and stair climbing. During the first 2 weeks of the exercise training program, at least 3 strength exercises and 1 functional exercise will be performed each session.~Starting from the 3rd week of the exercise training program, whole body exercise training (interval training for walking, cycling, stair climbing and high knees) will be added. From this moment on, at least 1-2 whole body exercises and 2-3 strength and functional exercises will be performed during each physiotherapy session. By doing this, each session will consist of a minimum of 4 exercises in total."
224062439|NCT06834451|DRUG|Revolade®|Tableta 50 mg Reference
224062440|NCT06834451|DRUG|Eltrombopag (EPAG)|Tableta 50 mg
224062441|NCT06047171|BIOLOGICAL|ALE.F02|ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.
224062442|NCT06047171|DRUG|Rituximab|Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
224062443|NCT06047171|DRUG|GlucoCorticoid|Glucocorticoids are a class of corticosteroids, which are a class of steroid hormones that bind to the glucocorticoid receptor. Glucocorticoid effects may be broadly classified into two major categories: immunological and metabolic.
224062444|NCT06047171|DRUG|Cyclophosphamid|Cyclophosphamid is a medication used as chemotherapy and to suppress the immune system
224062445|NCT06047171|DRUG|Placebo|Drug product that will contain no active ingredient
224062446|NCT06047171|DRUG|Immunosuppressive Agents|Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
224062447|NCT05711446|OTHER|Double Voiding|Participant will be instructed to void twice.
223742551|NCT03849742|PROCEDURE|Supportive Care|Receive Uber rides
224062448|NCT05711446|OTHER|Regular Voiding|Participant will void as usual
224062449|NCT06790602|DRUG|Cemiplimab Plus Gemcitabine|Cemiplimab Plus Gemcitabine
224147975|NCT01282567|OTHER|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
224147976|NCT02126813|PROCEDURE|increased interventional threshold for urinary bladder catheterization (800 ml)|
223742552|NCT01328860|BIOLOGICAL|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
224062450|NCT05368571|OTHER|CHOICES-TEEN|This is a four-session hybrid in-person and Telehealth counseling intervention that is designed to reduce the risk of HIV/STI and alcohol- and marijuana-exposed pregnancy for young women who are involved in the juvenile justice system between the ages of 14-19.
224062451|NCT05368571|OTHER|Health and Life Skills Education|This is a four-session psychoeducational intervention that is designed to provide information on time management, sleep, nutrition and exercise, and financial management.
224062452|NCT02432378|BIOLOGICAL|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
224147977|NCT02126813|PROCEDURE|Current used interventional threshold for urinary bladder catheterization (500 ml)|
224147978|NCT02126813|DEVICE|Intermittent bladder catheter|
224147979|NCT00091962|BEHAVIORAL|Psychoeducation; Treatment recommendations|Counseling program
224147980|NCT00091962|DRUG|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
224147981|NCT00091962|OTHER|Usual Care|Physicians' Usual care
224301526|NCT05354830|OTHER|Foot Massage|Foot Massage
224062453|NCT02432378|BIOLOGICAL|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
224062454|NCT04138017|DEVICE|ViviGen|A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
224062455|NCT01292642|BEHAVIORAL|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
224062456|NCT01292642|DRUG|Nicotine Replacement Therapy|"1. 21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~2. 14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
224062457|NCT05376228|DRUG|Oral Vancomycin|As part of standard of care
224062458|NCT04017481|OTHER|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
224062459|NCT04017481|OTHER|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
224062460|NCT01560000|DIETARY_SUPPLEMENT|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
224062461|NCT05682027|DIAGNOSTIC_TEST|ultrasound of the diaphragm|"Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion."
224062462|NCT01851681|DRUG|Amoxicillin|
224062463|NCT00706251|DEVICE|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
224147982|NCT02284022|DEVICE|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
224062464|NCT06534450|DEVICE|Sham|The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.
224062465|NCT06534450|DEVICE|Therapeutic Plasma Exchange|Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.
224062466|NCT06534450|DRUG|IVIG|Intravenous Immunoglobulin
224062467|NCT03312660|DIETARY_SUPPLEMENT|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
224147983|NCT01170221|DRUG|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
224147984|NCT01170221|DRUG|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
224147985|NCT04402619|BEHAVIORAL|Cognitive behavior therapy|"The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future"
224147986|NCT00432562|DRUG|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
223571252|NCT04939181|DEVICE|Non-invasive Neuromodulation|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
223571253|NCT04939181|DEVICE|Placebo Non-invasive Neuromodulation|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
223571254|NCT01471418|DRUG|PET/CT with 18-FDG|FDG uptake
223571255|NCT00996281|DRUG|Azilsartan medoxomil and chlorthalidone|Combination tablet.
223571256|NCT00996281|DRUG|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
223571257|NCT03209076|PROCEDURE|Robotic|Robotic low anterior resection
223571258|NCT03209076|PROCEDURE|Laparoscopic|Laparoscopic low anterior resection
223571259|NCT03036436|BEHAVIORAL|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
223571260|NCT05945056|OTHER|Frog Leg Exercise|The patient lies supine with legs flexed, knees apart and the soles of the feet put together on couch. The physiotherapist stands at the side of the table, moves one arm between the legs to place the hand under the sacrum and cup it. The fingers spread to accommodate the spinous process of the fifth lumbar vertebra. The tips of the fingers contact and grasp the junction of the fifth lumbar vertebra and the base of the sacrum. This hand will give traction in a caudal direction throughout the procedure to move the sacral base posteriorly and the apex interiorly. patient is asked to take a deep breath and hold it, while at the same time they steadily slide the feet downward toward the end of the table.Then patient brings their legs back to the frog leg position, but as they do so the therapist maintains traction preventing the sacrum from moving cephalad. Procedure is repeated for a total of 8 repetitions.
224062468|NCT03312660|DIETARY_SUPPLEMENT|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
224062469|NCT03670875|DIETARY_SUPPLEMENT|Agave inulin|Will be provided in dehydrated apple cubes
224062470|NCT03670875|DIETARY_SUPPLEMENT|Curcumin|Will be provided in capsules
224062471|NCT03670875|DIETARY_SUPPLEMENT|O3FA|Will be provided in capsules
224062472|NCT03670875|BEHAVIORAL|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
224062473|NCT04753827|OTHER|Drug eluting stent|Put a Drug eluting stent in the blood vessel
224147987|NCT02693691|DEVICE|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
224062474|NCT04753827|OTHER|Durg coated balloon|Put a Durg coated balloon in the blood vessel
224062475|NCT01040052|BIOLOGICAL|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
224062476|NCT04043546|BEHAVIORAL|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
224062477|NCT05054972|PROCEDURE|Exclusion of the aortic aneurysm.|Surgical procedure in which an aortic aneurysm is excluded.
224062478|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
224062479|NCT00605423|DRUG|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
224062480|NCT05628220|OTHER|physiotherapy|rehabilitation through using session of virtual reality desensitization
224062481|NCT04071184|DRUG|Alofanib|Five dose cohorts and expanded cohort will be included
224062482|NCT05492929|OTHER|The deep breathing group|The deep breathing group
224062483|NCT05492929|OTHER|4-7-8 breathing technique|4-7-8 breathing technique Group
224062484|NCT04711772|OTHER|whole-genome sequencing|Whole-genome sequencing will be preformed for each participate to explore the potential disease-causing genes of DOR.
224062485|NCT01243710|DEVICE|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
224062486|NCT05208151|OTHER|Creative Drama Education|Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
224062487|NCT01490658|DRUG|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
224062488|NCT01490658|DRUG|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
224062489|NCT01490658|DRUG|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
224062490|NCT00848861|DRUG|propofol (sedation for outpatient colonoscopy)|
223453821|NCT04886245|OTHER|Video sequences|"videos will be made of each participant, during the realization of 5 movements that are the simple closure of the eyelids, the forced closure of the eyelids, the labial protrusion on the sound \[o\], the labial protrusion on the sound \[pu\] and the wide smile uncovering the teeth.~Then, a video sequence will be realized thanks to the dedicated software Tobii Pro Lab®."
224062491|NCT00848861|DRUG|midazolam plus meperidine (sedation for outpatient colonoscopy)|
224062492|NCT03031275|RADIATION|High-resolution computed tomography|HRCT of the thorax
224062493|NCT03031275|RADIATION|Magnetic resonance imaging|MRI of the brain
224062494|NCT03031275|BEHAVIORAL|Cognitive testing|Neuropsychological testing
224062495|NCT05120479|PROCEDURE|Kinesiotape|"Kinesiotape (KT): KT will be placed without any extra tension (in the scientific literature it is called paper off tension). The measure determined in the measurement with a tape measure is cut. The anchor of the KT is placed on the medial epicondyle with the body segments in a neutral position (anchor length: 5 cm). Placement of the active zone of the bandage with the flexor muscles of the fingers in elongation. Origin-insertion placement. Distal anchor in neutral position. Material: Kinesiotape: Kinesiology Tape TEMTEX ® Beige (Towatek Korea Co .; South Korea)."
224062496|NCT05120479|PROCEDURE|Sham tape|Sham tape: exactly the same procedure is followed as above, but an adhesive inelastic tape is used. Material: Omnifix elastic (Laboratorios Hartmann S.A .; Spain).
224062497|NCT04135430|OTHER|Survey|practice of an updated questionnaire at D0, D2 and D7
224062498|NCT03139812|DRUG|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
224062499|NCT03139812|DEVICE|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
224062500|NCT00896675|OTHER|proteomic profiles|blood samples analysis
224062501|NCT00896675|OTHER|proteomic profiles|blood samples analysis
224062502|NCT06042400|BEHAVIORAL|Written Exposure Therapy|An innovative written exposure therapy intervention that addresses psychosocial needs commonly experienced by patients with late stage cancers.
224062503|NCT05957289|BEHAVIORAL|multidimensional rehabilitation|Multidimensional lifestyle interventions
223453822|NCT03826966|DEVICE|reSET|reSET is a mobile app created by Pear Therapeutics, Inc., which has previously been approved by the FDA.
223453823|NCT02966756|DRUG|Venetoclax|Tablet; Oral
224062504|NCT04019132|DIAGNOSTIC_TEST|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
224062505|NCT06297746|PROCEDURE|Subvastus approach|Subvastus approach
224062506|NCT06297746|PROCEDURE|Medial Parapatellar approach|Medial Parapatellar approach
224062507|NCT04479163|BIOLOGICAL|Convalescent Plasma|250 ml Convalescent plasma with an IgG titer against SARS CoV2
224062508|NCT04479163|OTHER|Placebo|Normal Saline 0.9%
224062509|NCT02887391|OTHER|No intervention - observational study|No intervention - observational study
224062510|NCT06194890|OTHER|Distraction technique with comedy video|Women in the intervention group will watch an average of 6 minutes of comedy videos during the active phase, transition phase and latent phase of labor.
224062511|NCT05660720|DRUG|Orelabrutinib and placebo (orelabrutinib tablet simulator)|Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
224062512|NCT05660720|DRUG|Orelabrutinib|Orelabrutinib will be administered as 8 tablets (400mg)
224062513|NCT05660720|DRUG|Placebo (orelabrutinib tablet simulator)|Placebo will be administered as 8 tablets (400mg).
224062514|NCT05660720|DRUG|Moxifloxacin hydrochloride|Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
224062515|NCT01725555|DRUG|Fasted treatment: AXL1717|
224062516|NCT01725555|DRUG|Fed treatment: AXL1717|
224062517|NCT01135498|DRUG|bevacizumab [Avastin]|Intravenous repeating dose
224062518|NCT01135498|DRUG|eloxatin|Intravenous repeating dose
224062519|NCT01135498|DRUG|capecitabine [Xeloda]|Oral repeating dose
224062520|NCT01135498|DRUG|erlotinib [Tarceva]|Oral repeating dose
224062521|NCT01908647|BEHAVIORAL|RT fMRI|Real-time fMRI with neurofeedback.
224062522|NCT01908647|BEHAVIORAL|Cognitive Training|Computer based attention training.
224062523|NCT01908647|BEHAVIORAL|Control RT fMRI|Control condition for real-time fMRI.
224062524|NCT01908647|BEHAVIORAL|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
224062525|NCT03726645|OTHER|Fecal microbiota transplantation|Fecal microbiota transplantation
224062526|NCT02471547|OTHER|BWT with Mitomycin-C prior TURBT|"Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes"
224062527|NCT06490458|COMBINATION_PRODUCT|Balance Training|Balance exercises and cardiac rehabilitation (intervention) for patients for 7 Days, 3 times/week for duration of 25-30 min/ session.
224062528|NCT06312748|DRUG|L-Citrulline|100 mg tablet
223453824|NCT03953599|BIOLOGICAL|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
223453825|NCT02974803|DRUG|Dabrafenib|Dabrafenib 150 mg twice a day until progression or unaccepted toxicity.
223453826|NCT02974803|DRUG|Trametinib|Trametinib 2 mg once daily until progression or unaccepted toxicity.
223453827|NCT06277713|BEHAVIORAL|Standing interruptions|A mobile sit-to-stand desk will be installed at the workplace and participants are instructed to alternate their working position every 30 minutes during two working days (8h).
223453828|NCT06277713|BEHAVIORAL|Exercise bout|Participants will perform a continuous aerobic exercise bout for a duration of 60 minutes at a moderate intensity, which is defined as 60% of their maximal oxygen uptake (VO2max).
223453829|NCT06277713|BEHAVIORAL|Sedentary|Participants are instructed to minimise any behaviour that is not sedentary during two working days (8h).
223453830|NCT02333422|OTHER|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
223453831|NCT05471427|DRUG|Taxane chemotherapy|Patients underwent taxane chemotherapy according to clinical practice for metastatic prostate cancer
224062529|NCT06312748|DRUG|Placebo for L-Citrulline|L-Citrulline-matched Placebo tablet
224062530|NCT06312748|DRUG|BH4|10mg/kg
224062531|NCT06312748|DRUG|Placebo for BH4|BH4-matched Placebo
224062532|NCT06312748|DRUG|Atorvastatin|10 mg tablet
224062533|NCT06312748|DRUG|Placebo for Atorvastatin|Atorvastatin-matched Placebo
224062534|NCT04229745|DEVICE|THRIVE pre-oxygenation|Clinical Trial of Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Oxygen in Women having Planned Caesarean Delivery
224062535|NCT04842084|BIOLOGICAL|Blood samples|sampling of 10 S-Monovette tubes (Sarstedt) 4.3 ml of blood specifically for the study representing a total blood volume of 43 ml
224062536|NCT06229795|DRUG|Green Tea Leaf Extract Decaffeinated|300 mg film coated tablet
224062537|NCT06229795|DRUG|Metformin Hydrochloride 500 MG|500 mg tablet
224062538|NCT04986709|DEVICE|Open repair|Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.
224062539|NCT01594853|BEHAVIORAL|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
224062540|NCT03044340|OTHER|impedance measurement and pain evaluation|Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
224062541|NCT02148380|DRUG|pemetrexed plus carboplatin|
224062542|NCT02148380|DRUG|gefitinib|
224062543|NCT04852107|OTHER|Spinal Cord Stimulation, association of both (DUAL), Dorsal Root Ganglion stimulation|"Lead Implantation which will be conducted in 2 steps:~1. Lead implantation: 8-contact SCS percutaneous lead on SC and 8-contact lead on DRG.~2. Neurostimulation trial phase (Mode DUAL). IPG implantation + Randomization + 1st leads programming (SC, DRG or DUAL stimulation according to randomization sequence).~2nd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). 3rd leads programming (SC, DRG or DUAL stimulation according to randomization sequence). All patients will be switched to Burst waveform for a 1- month follow-up period while keeping the last allocated stimulation type in the randomized crossover arm."
224062544|NCT06425575|BIOLOGICAL|Amniotic suspension allograft|the amniotic suspension allograft consists of fresh amniotic fluid into which micronized amniotic membrane has been added as a suspension.
224062545|NCT04507659|DRUG|Jaktinib Hydrochloride Tablets|Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.
224062546|NCT04507659|DRUG|Jaktinib Hydrochloride Tablets|Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.
224062547|NCT04507659|DRUG|Placebo|Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
224062548|NCT00041093|DRUG|Docetaxel|Given IV
224062549|NCT05043415|PROCEDURE|Immediate endoscopic necrosectomy|In the immediate endoscopic necrosectomy group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent, immediately followed by endoscopic necrosectomy. Endoscopic necrosectomy involves removal of infected necrotic pancreatic tissue via the cystogastrostomy/cystoenterostomy tract using a variety of endoscopic accessories.
223571261|NCT05945056|OTHER|Electrotherapy(Transcutaneous Electrical Nerve Stimulator)|TENS or transcutaneous electrical nerve stimulator is a low voltage electric current to relieve pain. A small battery-operated TENS device which has leads connected to sticky pads called electrodes was used in treatment. Patient in lying position gets pads directly attached to skin of lumbar region. Small electrical impulses delivered to the affected area of the patient's body when the machine is switched on, which patient feel as a tingling sensation.
223571262|NCT05945056|OTHER|Exercise Therapy|Stretching of tight muscles(hip flexors and lower back extensors) Abdominal Curl-Ups and Bridging exercises.
223571263|NCT04229212|DEVICE|hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)|In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System \[HAS\], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.
224062550|NCT05043415|PROCEDURE|Step-up endoscopic interventions|In the step-up endoscopic interventions group, endoscopic ultrasound-guided drainage of the necrotic collection is performed using a lumen-apposing metal stent. Endoscopic necrosectomy is not performed during the index drainage session, but is performed at a later time as needed.
224062551|NCT01019447|OTHER|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
224062552|NCT01019447|OTHER|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
224062553|NCT02505399|DRUG|ticagrelor|"Ticagrelor will be administered orally, according to the following scheme:~* 180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 90 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 90 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
224062554|NCT02505399|DRUG|clopidogrel|"Clopidogrel will be administered orally, according to the following scheme:~* 300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~* 75 mg the following morning (D Day before rotational atherectomy and angioplasty),~* 0 mg the following evening (D Day after rotational atherectomy and angioplasty),~* 75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
223571264|NCT02386215|BEHAVIORAL|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~* One standard OraQuick ADVANCE I/II test kit~* Written pre-test information including test instructions in written and pictorial form~* A phone number that participants can call to obtain additional information~* Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
223571265|NCT06294938|OTHER|Cacao fruit pulp|Cacao pulp puree
223571266|NCT06294938|OTHER|Dextrose|Dextrose beverage
223571267|NCT00403533|DRUG|20 mg of atorvastatin daily|
223571268|NCT00030277|PROCEDURE|high-intensity focused ultrasound ablation|
223571269|NCT01960088|DRUG|HPV vaccine|
223571270|NCT04580758|COMBINATION_PRODUCT|Fractional laser with PRP fluid or PRP gel|20 participants divided into 2 groups of 10 10 participants will do Fractional laser with PRP fluid sessions and 10 participants will do Fractional laser with PRP gel
224062555|NCT04869085|BEHAVIORAL|e-PainSupport|Patients and caregivers assigned to the e-PainSupport condition will download the app on their own device, or they will be given a project tablet with wireless capability if they do not have their own device. All receive specific training for the intervention. They will also receive a hardcopy of the e-PainSupport manual and a trouble-shooting guide. Contact information will be provided in the app and on paper for technical problems. Caregivers complete Education Module, and patients may complete it. Caregiver or patient will fill out Pain Report daily. Pain Summary for Nurses is an automatically generated graphic summary of patients' Pain Reports over time. Nurses have access to this information during the time the patients and caregivers use e-PainSupport.
224062556|NCT06447610|PROCEDURE|Lateral arm free flap|In this study, we present a case series of 8 patients operated for a maxillo-facial defect with a lateral arm free flap.
224147988|NCT04730310|PROCEDURE|NSQIP Lower Extremity Open (LEO) procedure-targeted dataset (i.e. undergoing Lower extremity open revascularization) from 2014-2019|Infrainguinal, open lower extremity revascularization procedures
223571271|NCT02754141|BIOLOGICAL|BMS-986179|Specified dose on specified days
223571272|NCT02754141|BIOLOGICAL|Nivolumab|Specified dose on specified days
223571273|NCT02754141|BIOLOGICAL|rHuPH20|Specified dose on specified days
223571274|NCT03361189|DEVICE|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
223571275|NCT03361189|DEVICE|Standard rate response|Standard rate response is an algorithm to increase heartrate based on movement
223571276|NCT03506919|DRUG|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
223571277|NCT03505788|DRUG|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
223571278|NCT03505788|DRUG|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
223571279|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
223571280|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish AKI from CKD|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
223571281|NCT04404114|DIAGNOSTIC_TEST|Shear wave elastography to distinguish CKD from normal kidney|Record the patient's kidney size, cortical thickness, possible lesion by ordinary renal sonography as well as cortical elasticity by shear wave elastography
223571282|NCT04787783|OTHER|Web based preoperative assessment|Preoperative assessment conducted through a web based application
223571283|NCT04500392|DEVICE|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min
223571284|NCT04500392|DEVICE|Regular nasal cannula|Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
223571285|NCT05709561|PROCEDURE|Acupresur|acupressure application was applied 2 times a week for a total of 12 weeks and 24 times.
224062557|NCT05150379|OTHER|Different exercises with their shoulders|"* Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test"
224062558|NCT05150379|BEHAVIORAL|SI-RSI questionnaire|French version of Shoulder Instability Return-to-Sport after Injury
223453832|NCT05185635|DIAGNOSTIC_TEST|Neuropsychological testing|potential participants will complete the following: Mini-Mental State Examination (MMSE), Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7- item (GAD-7) as part of the screening process. Additionally to the pre-screening instruments, participants will complete the following neuropsychological tests: Bi-dimensional Acculturation Scale, Bilingual Dominance Scale, Verbal Fluency Tests, Boston Naming Test, Symbol Digit Modalities Test, Brief Test of Attention, Who-UCLA Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, Modified Wisconsin Card Sorting Test, Stroop Color and Word Test, Trail Making Test, Word Accentuation Test, Clock Drawing Task, Bells Test, Test of Memory Malingering, and the Five Point Test.
224062559|NCT04997018|RADIATION|Radiation Therapy|"Patients enrolled in this study will undergo ultra-hypofractionated radiation utilizing MR guided, daily online adaptive planning. Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously-delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm, as determined on the pretreatment diagnostic T2 MRI imaging. In the setting of two similarly-sized dominant lesions, both will be boosted."
224062560|NCT05554614|BEHAVIORAL|BTW app with reward-based feedback|Teen drivers will be notified of their weekly driving performance via a driving safety score with information on the types of high-risk driving behaviors committed as well as progress on maintaining and/or improving weekly safe driving behaviors. Educational materials on different driving situations and scenarios associated with the high-risk driving behaviors (e.g. 90-second videos) will be provided for the driver to review at any point and time. Information on these driving behaviors and the education material will be provided via push notifications from the BTW app. Weekly leader boards will show the driver's driving safety score in comparison to other drivers of the same age. Consistently high driver safety scores in certain driving skill areas (e.g., cornering) and a total overall score above 70% of other users on that skill or total score will unlock gamification-based rewards (e.g., driving safety badges, driving safety score leader board, group challenges with winners).
224062561|NCT05554614|BEHAVIORAL|BTW app with situational supervised driving practice|Teen drivers will be provided bi-weekly push-notifications from the BTW app notifying them of situational supervised driving practice activities that are to be completed during the assigned week. There are 12 situational supervised driving activities and six skill-building driving activities (Table 1). Skill-building sessions are assigned for off weeks during the first half of the six months (weeks 2-12), allowing for skills to be further developed when the situations are encountered for a second time (weeks 15-23). Parents will be prompted to directly log situational supervised and skill-building driving activities in the app after the session within the BTW app to obtain the module completion date and duration time.
224062562|NCT05554614|BEHAVIORAL|Sham BTW app|Teens will be provided links to passive education materials and information on car maintenance every week. They will not be given feedback on their driving performances.
224062563|NCT04814251|OTHER|Observationnal cohort|data collection
224062564|NCT04527900|DRUG|carboplatin and paclitaxel|carboplatin and paclitaxel 5-6 cycles (dosage per standard of care according to treating oncologist)
224062565|NCT04527900|RADIATION|pelvic IMPT (Intensity Modulated Proton Therapy)|whole pelvis will receive a total dose of 4500 cGy in 25 fractions to 5040 cGy in 28 fractions
224062566|NCT00003345|DRUG|cisplatin|
224062567|NCT00003345|DRUG|irinotecan hydrochloride|
224062568|NCT06082700|DIAGNOSTIC_TEST|imaging|clinical examination to see missing posterior teeth \& vertical measurements by lateral cephalometric x-ray
224062569|NCT06464250|OTHER|Bundla care group|A care package consisting of foot examination, correct foot care behaviours, and regular blood glucose monitoring was used.
224147989|NCT05204758|DRUG|TCM Formula|three packages of TCM preparations with each meal three times a day
223453833|NCT00567424|DRUG|GW273225|
223453834|NCT01119820|OTHER|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
223453835|NCT00039299|BIOLOGICAL|therapeutic autologous lymphocytes|
223453836|NCT00882661|DEVICE|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
223571286|NCT05709561|PROCEDURE|Mindfulness|Mindfulness practice was applied with the students once a week for 8 weeks, accompanied by a researcher. Then, students were asked to apply for 3 cycles.
223571287|NCT05709561|PROCEDURE|Plasebo|No intervention was applied to the control group.
223571288|NCT03344549|BEHAVIORAL|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
223571289|NCT03344549|BEHAVIORAL|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
223571290|NCT02121769|DRUG|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
223453837|NCT00882661|DEVICE|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
223571291|NCT02454439|OTHER|CRT implantation|
223571292|NCT02441491|DRUG|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
223571293|NCT00397852|PROCEDURE|Kirschner-wires or not|
223571294|NCT03333252|BEHAVIORAL|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
223571295|NCT03333252|BEHAVIORAL|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
223571296|NCT00003434|BIOLOGICAL|carcinoembryonic antigen peptide 1|
223571297|NCT00003434|BIOLOGICAL|hepatitis B antigen peptide|
224147990|NCT05204758|DRUG|Placebo|three packages of placebo preparations with each meal three times a day
223453838|NCT04270695|BEHAVIORAL|blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver.
223453839|NCT04270695|BEHAVIORAL|sham blood flow restriction|an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
223453840|NCT05462236|DRUG|Tinodasertib|MNK inhibitor
223453841|NCT05462236|DRUG|Pembrolizumab|PD-1 Inhibitor
223571298|NCT02615938|DRUG|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
223571299|NCT02615938|OTHER|Placebo|Apply Placebo not to modify lysosomal pH
223571300|NCT03065621|DRUG|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
223571301|NCT00108303|OTHER|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
223571302|NCT01425450|DRUG|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
223571303|NCT01425450|DRUG|HF1020 placebo|Single dose: HF1020 placebo capsule
223571304|NCT04046016|DRUG|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
223571305|NCT00666588|DRUG|idarubicin|Given IV
223571306|NCT00666588|DRUG|cytarabine|Given IV or IT
223571307|NCT00666588|DRUG|bortezomib|Given IV
223571308|NCT00666588|DRUG|etoposide|Given IV
223453842|NCT05462236|DRUG|Irinotecan|Topoisomerase inhibitor
223453843|NCT01398358|BEHAVIORAL|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
223571309|NCT00666588|OTHER|laboratory biomarker analysis|Correlative studies
223571310|NCT02218086|DEVICE|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
223571311|NCT02218086|DEVICE|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
223571312|NCT02218086|DEVICE|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
223571313|NCT02218086|DEVICE|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
223571314|NCT02218086|DEVICE|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
223571315|NCT02218086|DEVICE|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
223571316|NCT02218086|DEVICE|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times \~15minutes within y few weeks.
223571317|NCT02833753|DRUG|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)"
224071041|NCT05916404|OTHER|Upper extremity high-intensity interval aerobic exercise training|"High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate.~In case of desaturation (\<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient."
223571318|NCT03677466|DRUG|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
223571319|NCT03677466|PROCEDURE|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
223571320|NCT02313870|DRUG|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
224147991|NCT00440336|DRUG|Cosopt|
224147992|NCT00440336|DRUG|Xalatan|
224147993|NCT02715999|PROCEDURE|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
224062570|NCT06042218|BEHAVIORAL|Xiaxi intervention program|The Xiaxi sessions will follow the same structure in both intervention groups. First of all, 8-minute warm-up where the participants will work on: postural awareness; active static stretching of the pectoral, hamstring and psoas muscles; and mobility. The main part will include the following blocks of content during the 12 weeks of intervention (46 minutes will be spent on this part in each session): breathing; mobility; active and dynamic static stretching of the tonic muscles with effects on the spine dynamic; strength of the phasic muscles with effects on the spine dynamic, alternating upper limb, lower limb and core; postural awareness; and passive static stretching of the tonic muscles with effects on the spine dynamic. The cool down will be similar in each session (6 minutes) and will focus on: postural awareness and passive static stretching of the pectoral, hamstring and psoas muscles.
224062571|NCT04070742|DRUG|FMX101|
224062572|NCT00721474|DRUG|Bosutinib|Bosutinib fasting
223453844|NCT01398358|BEHAVIORAL|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
223453845|NCT02373137|PROCEDURE|DSAEK|
224062573|NCT00721474|DRUG|Bosutinib|Bosutinib fed
223571321|NCT02313870|DRUG|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
223571322|NCT00211835|BEHAVIORAL|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
223571323|NCT00211835|BEHAVIORAL|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
224062574|NCT02757560|OTHER|SFA diet|SFA versus control diet
224062575|NCT02757560|OTHER|MUFA diet|MUFA versus control diet
224062576|NCT02757560|OTHER|CARB diet|CARB versus control diet
224062577|NCT03548935|DRUG|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
224062578|NCT03548935|DRUG|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
224062579|NCT03571646|BEHAVIORAL|Capnostream 20 monitoring|Continuous monitoring on a general ward
223453846|NCT02373137|PROCEDURE|DMEK|
223453847|NCT02373137|DEVICE|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
223453848|NCT02373137|DRUG|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
223453849|NCT02373137|DRUG|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
223453850|NCT02373137|DRUG|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
223453851|NCT02373137|DRUG|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
223453852|NCT02373137|DEVICE|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
223453853|NCT00003896|DRUG|cisplatin|
223453854|NCT00003896|DRUG|liposomal doxorubicin|
223453855|NCT00003896|DRUG|paclitaxel|
223453856|NCT00507988|BEHAVIORAL|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
223453857|NCT00507988|BEHAVIORAL|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
224062580|NCT03571646|DEVICE|PM1000N-RR monitoring|Continuous monitoring on a general ward
224062581|NCT04677959|DRUG|Fluticasone propionate/salmeterol (FS)|FS administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
224062582|NCT04677959|DRUG|Albuterol|Albuterol administered via electronic multidose dry powder inhaler (eMDPI) Digital System (DS) with component devices including smart device application (App), Digital Health Platform (DHP), and provider-facing dashboard
224062583|NCT04677959|DRUG|Standard of Care Asthma Medication|Current inhaled corticosteroid(ICS)/Long-acting beta agonist(LABA) and any additional controller medication for asthma
224062584|NCT04677959|DRUG|Standard of Care Rescue Medication|Current rescue medication
224062585|NCT06098768|BEHAVIORAL|VR Social Skills|The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group. VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset. The VR interaction will be controlled and operated via linked iPad.
224062586|NCT01253655|DRUG|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
224062587|NCT04529759|OTHER|Control Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
224062588|NCT04529759|OTHER|Experimental Infant Formula|Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
224062589|NCT03403114|BEHAVIORAL|Questionnaire|a 15min questionnaire
224062590|NCT04774835|DIAGNOSTIC_TEST|HIVST|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV self-testing by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
224062591|NCT04774835|DIAGNOSTIC_TEST|Standard aPS|aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV testing at their local HTS location by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
224062592|NCT02057315|DRUG|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
224062593|NCT02057315|DRUG|Placebo|One dose of matching placebo over 3 bilateral applications.
224062594|NCT00763815|DRUG|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
224062595|NCT00763815|DRUG|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
224062596|NCT00763815|DEVICE|Pen auto-injector|
224062597|NCT00763815|DRUG|Pioglitazone|Dose to be kept stable.
224062598|NCT00763815|DRUG|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
224062599|NCT00166608|PROCEDURE|Blood sampling|
224062600|NCT03698435|DRUG|Ganciclovir|Intravenous ganciclovir + TDM
224062601|NCT03698435|DRUG|Valganciclovir|Oral valganciclovir + TDM
224147994|NCT02715999|PROCEDURE|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
224147995|NCT05800509|BEHAVIORAL|Clips Intervention|A website of health education of gestational diabetes mellitus with several short clips of health education (maternity management/counseling, healthy lifestyles, partner support...etc) for participants and their partners will be given right after the questionnaire of 22nd week of pregnancy received from the participants and their partners. There are pretest and posttest questions on the structured questionnaires of 22nd week and 35th week of pregnancy and 3rd month after delivery.
224062602|NCT06044688|DEVICE|EyeQue VisionCheck|Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.
224062603|NCT06044688|DEVICE|Phoropter|Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
224062604|NCT04395664|DEVICE|C3+ Holter Monitor|ECG monitoring
224062605|NCT01362036|DRUG|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
224062606|NCT01970995|OTHER|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
224062607|NCT01970995|OTHER|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
224062608|NCT01970995|OTHER|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
224062609|NCT00678405|BEHAVIORAL|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer \& non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
224062610|NCT00678405|BEHAVIORAL|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
224062611|NCT03535467|OTHER|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
224062612|NCT04309227|OTHER|Strength Training|"Strength training traditionally requires use of high intensity loads to stimulate muscle growth and strength improvements. Some participants will be randomized to a traditional strength training program.~Blood Flow Restriction (BFR) training is used to stimulate muscle hypertrophy and strength improvements in a variety of populations. Results of BFR training are comparable to traditional high intensity training (HIT) despite using weight that are at a low intensity (low percent of 1 repetition maximum). This intervention has not been extensively studies in the rheumatoid or osteoarthritis populations, nor the myositis populations despite idealogical benefit for each group of low-load strengthening."
224062613|NCT01263639|OTHER|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
224062614|NCT01263639|OTHER|Standard of care - No biosketch card|Standard of care
224062615|NCT01576549|DRUG|LY2127399|Administered subcutaneously
224062616|NCT00003715|BIOLOGICAL|BCG vaccine|
224062617|NCT00003715|BIOLOGICAL|autologous tumor cell vaccine|
224062618|NCT00003715|BIOLOGICAL|recombinant interferon alfa|
224062619|NCT00003715|DRUG|chemotherapy|
224062620|NCT00003715|DRUG|cyclophosphamide|
224062621|NCT01485757|DRUG|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
224062622|NCT00199563|DRUG|Viagra|Sildenafil 100mg daily for 12 weeks
223453858|NCT02022735|DEVICE|Deep Brain Stimulator|DBS will provide brain stimulation.
223453859|NCT00100152|DRUG|MK0752, (Notch Inhibitor)|
223453860|NCT00985686|OTHER|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
223453861|NCT04692116|DEVICE|ExAblate treatment|Subthalamotomy using the ExAblate
223453862|NCT00748163|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|
223453863|NCT00748163|DRUG|sunitinib malate|
223453864|NCT01670045|DRUG|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
223453865|NCT04127396|DRUG|Lenvatinib Pill|Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)\>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
223453866|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
223453867|NCT04127396|DRUG|Sorafenib|Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
223571324|NCT06210542|DRUG|ceftazidime avibactam|"Routine treatment dose for patients: the recommended intravenous dose for patients with creatinine clearance rate (eCrCL) \&gt; 50ml/min was 2.5g (2g/0.5g), once every 8 hours, and the infusion time was 2 hours.~Patients with renal injury adjust the dosage according to eCrCL"
224062623|NCT01056627|DRUG|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
224062624|NCT03594188|PROCEDURE|anesthetic methods|Patients will receive standard GA or LA for RF surgery.
224147996|NCT05800509|DEVICE|Structured Questionnaire Only|A website of health education about gestational diabetes mellitus will be given to participants and their partners, then structured questionnaires and regular health service from the hospital continue to be given.
224147997|NCT01488409|DRUG|Acipimox|250 mg by mouth (PO) three times daily
224147998|NCT01488409|DRUG|Placebo|0 mg by mouth (PO) three times daily
223453868|NCT04127396|PROCEDURE|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
223453869|NCT02105519|BIOLOGICAL|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
223571325|NCT02946567|OTHER|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
223571326|NCT02946567|OTHER|Generic Game|Participants will play a generic game without any particular information about hearing health care.
223571327|NCT06149117|DRUG|"test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®"|Take one capsule orally every cycle(T or R)
223571328|NCT01394757|DRUG|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
223571329|NCT04690920|DRUG|Tocilizumab|Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls
223571330|NCT02323841|PROCEDURE|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
224062625|NCT05969509|OTHER|progressive relaxation exercise|applying progressive relaxation exercise to the experimental group after postoperative cholecystectomy and observing the experimental-control groups
224062626|NCT05561517|OTHER|5 K running|The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
224062627|NCT01639677|PROCEDURE|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
224062628|NCT01639677|PROCEDURE|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
224062629|NCT05558878|DRUG|Ambroxol Oral Product|"Drug: Ambroxol (75 mg capsule)~Ambroxol is a mucolytic and expectorant drug. Ambroxol has been approved as lozenges for topical analgesia of sore throat in pharyngitis owing to its local anesthetic properties. Anti-inflammatory properties of ambroxol were confirmed by numerous studies. Ambroxol affect neuronal transduction by blocking (TTX)-resistant Na+ channels (Nav1.8) in small (pain-sensing) dorsal root ganglion neurons more potently than TTX-sensitive channels."
224147999|NCT05603494|DEVICE|NuvoAir|Use of NuvoAir in pulmonary function monitoring during asthma attack
224148000|NCT01020968|BIOLOGICAL|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
224062630|NCT03825770|BEHAVIORAL|"The PEP (Personal Energy Planning) Program"|The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts \~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
224062631|NCT03825770|BEHAVIORAL|General Education about Kidney Disease|"General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference)."
224062632|NCT04254068|BEHAVIORAL|Parent-based prevention|Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
224062633|NCT04742088|DEVICE|ankleSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
224062634|NCT06310980|DEVICE|smartpen|use of a smartpen connected with glucose sensor by an digital application
224062635|NCT02354937|DRUG|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
224062636|NCT01252212|BEHAVIORAL|SMS medication adherence|SMS messages to cell phones.
224062637|NCT01252212|BEHAVIORAL|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
223453870|NCT02494648|DEVICE|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
223453871|NCT02494648|OTHER|Control|
224062638|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg once daily
224062639|NCT01444248|DRUG|Glimepiride/ Metformin|4/1000mg bid
224148001|NCT01020968|OTHER|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
223453872|NCT02538406|OTHER|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
223453873|NCT00501137|BIOLOGICAL|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
223453874|NCT04008888|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
223453875|NCT04008888|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
223453876|NCT04008888|DRUG|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m\^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes
223453877|NCT04008888|DRUG|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
223571331|NCT01430325|DRUG|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
224062640|NCT01382797|DRUG|ALKS 37|Capsules for oral administration
224062641|NCT01382797|DRUG|Placebo|Capsules for oral administration
224062642|NCT03480100|DRUG|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
224062643|NCT03480100|DEVICE|Ectoin Nasal Douche|Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
224062644|NCT04361591|OTHER|Observational only|Observational Study
224062645|NCT05284760|DRUG|Soticlestat|Soticlestat T4 tablets.
224062646|NCT05284760|DRUG|Soticlestat|Soticlestat T3 mini-tablets.
224148002|NCT04327050|PROCEDURE|Magnetic anchored guided endoscopic submucosal dissection|Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
224148003|NCT00790530|BEHAVIORAL|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
224062647|NCT05284760|DRUG|Soticlestat|Soticlestat commercial tablets.
224062648|NCT00492167|BIOLOGICAL|beta-glucan|
224062649|NCT00492167|BIOLOGICAL|monoclonal antibody 3F8|
224062650|NCT00492167|OTHER|immunohistochemistry staining method|
224062651|NCT00492167|OTHER|laboratory biomarker analysis|
224062652|NCT05514314|DRUG|Icotinib|Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
224148004|NCT00790530|OTHER|Usual Care|Usual Care
224148005|NCT01250457|DRUG|topical Timolol|topical Timolol 0.5% solution applied twice daily
224148006|NCT01085604|OTHER|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
224062653|NCT02103998|DRUG|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
223453878|NCT04008888|DRUG|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
223453879|NCT04008888|DRUG|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11\&12 of each 21-day.
224062654|NCT02103998|DRUG|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
224062655|NCT02992340|DRUG|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
224062656|NCT02992340|DRUG|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
224062657|NCT02992340|DRUG|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
224062658|NCT00033410|DRUG|carboplatin|
224062659|NCT00033410|DRUG|paclitaxel|
224062660|NCT00033410|DRUG|tirapazamine|
224148007|NCT02820441|DRUG|Zopiclone|
223453880|NCT03092648|BIOLOGICAL|Bronchial basal cell|autologous bronchial basal cell transplantation
223453881|NCT00537290|DRUG|Rituximab|Rituximab 1000mg IV on Days 0 and 15
223453882|NCT00193557|DRUG|Bortezomib|
223453883|NCT02273128|GENETIC|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
223453884|NCT04326387|DIAGNOSTIC_TEST|SAMBA II (Diagnostic for the Real World)|Point of care Isothermal-PCR Viral RNA Amplication for virus detection
223453885|NCT04326387|DIAGNOSTIC_TEST|Public Health England Gold Standard|Reverse Transcription PCR
223453886|NCT04326387|DIAGNOSTIC_TEST|Cambridge Validated Viral Detection Method|Reverse Transcription PCR
223453887|NCT04326387|DIAGNOSTIC_TEST|Radiological Detection|Chest X-ray \& CT Scan detection of viral infection in the lungs
224062661|NCT00033410|RADIATION|radiation therapy|
224062662|NCT02716987|DRUG|TAK-831|TAK-831 oral suspension.
224062663|NCT02716987|DRUG|[18F]PGM299|\[18F\]PGM299 injection
224148008|NCT02820441|DRUG|Placebo|
224148009|NCT02951897|PROCEDURE|lobectomy|
224148010|NCT02951897|PROCEDURE|segmentecomy|
224148011|NCT02951897|DRUG|chemotherapy（pemetrexed+CISPLATIN）|
224148012|NCT02951897|PROCEDURE|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
223453888|NCT01357005|OTHER|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
223453889|NCT02780271|BEHAVIORAL|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
223453890|NCT02780271|BEHAVIORAL|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
223453891|NCT02780271|BEHAVIORAL|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
223453892|NCT02559570|DRUG|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
224062664|NCT02829138|GENETIC|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
224062665|NCT02829138|BEHAVIORAL|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
224062666|NCT00091715|DRUG|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
224062667|NCT00091715|DRUG|placebo|placebo for 6 months followed by an open-label period
224062668|NCT01394627|DRUG|Eplerenone|100mg x 2
224062669|NCT01394627|DRUG|Placebo|
224062670|NCT00436800|DRUG|Gemcitabine|1000mg/m² over 10mg/m²/min
224062671|NCT00436800|DRUG|Oxaliplatin|100 mg/m² over 2 hours.
224062672|NCT01991990|DRUG|placebo|Single i.v. infusion
224062673|NCT01991990|DRUG|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
224062674|NCT03580252|OTHER|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
224062675|NCT01193855|DRUG|dutasteride|
224062676|NCT01193855|DRUG|gadolinium-chelate|
224062677|NCT01193855|OTHER|active surveillance|
224062678|NCT01193855|PROCEDURE|diffusion-weighted magnetic resonance imaging|
224062679|NCT01193855|PROCEDURE|functional magnetic resonance imaging|
224062680|NCT01193855|PROCEDURE|prostate biopsy|
224062681|NCT01193855|PROCEDURE|ultrasound imaging|
224062682|NCT05877482|OTHER|Short foot exercises|A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.
224062683|NCT05877482|OTHER|Insoles|In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
224062684|NCT03223428|DRUG|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
224062685|NCT03844165|BEHAVIORAL|Diet change (red rice)|This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.
224062686|NCT03844165|BEHAVIORAL|Yoga|All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
224062687|NCT02025907|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
224062688|NCT02025907|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
224062689|NCT02025907|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily.
224062690|NCT01544946|DRUG|88% sucrose po|88% sucrose solution (Syrup B.P.)
224062691|NCT01544946|DRUG|placebo po|sterile water
224062692|NCT03424252|DRUG|FDL169|Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
224062693|NCT04187638|DIETARY_SUPPLEMENT|Olive oil|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
224301527|NCT01289444|BEHAVIORAL|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
224062694|NCT04187638|DIETARY_SUPPLEMENT|Butter|Participants will be randomly allocated to receive daily dose of 30ml of olive oil (OO) as intervention group or a matching control (butter 30g) for 2 weeks each (i.e. two weeks olive oil and two weeks butter), separated by a washout period of 2 weeks between treatments.
223571332|NCT01430325|DRUG|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
223571333|NCT01194843|DRUG|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
223571334|NCT01194843|DRUG|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
223571335|NCT05498233|DRUG|Doxylamine + Pyridoxine|A single dose of R or T drug in each of 2 periods of the study in fasted conditions
223571336|NCT03887065|DRUG|JM-4|Novel small human peptide derived from erythropoietin
223571337|NCT01007123|DRUG|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
223571338|NCT02075047|DRUG|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
224062695|NCT01073332|DIETARY_SUPPLEMENT|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
224062696|NCT01073332|DIETARY_SUPPLEMENT|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
224062697|NCT05514626|DEVICE|3D Holographic Display|3D holographic visualization of the anatomy during the planned interventional procedure. The HOLOSCOPE-i will be used in addition to and will not replace conventional displays that are currently being used during the procedure.
224062698|NCT02319421|OTHER|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
224062699|NCT03681119|BEHAVIORAL|Dementia symptom management at home hospice edition|Quality assurance performance improvement program
224062700|NCT03681119|BEHAVIORAL|Education and Training|Education and training
224062701|NCT00524342|DRUG|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
224062702|NCT04481542|DIAGNOSTIC_TEST|MRI|check MRI quality in aorta
224301528|NCT01289444|BEHAVIORAL|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3\. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
224301529|NCT03416244|DRUG|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
224301530|NCT03416244|DRUG|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
224301531|NCT00573157|DRUG|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
224301532|NCT00573157|DRUG|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
224301533|NCT00573157|DRUG|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
223453893|NCT02559570|DRUG|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
223453894|NCT02559570|DRUG|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
224062703|NCT05676359|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
224062704|NCT05676359|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
224062705|NCT05676359|OTHER|Brief Resilient Coping Scale|Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
223453895|NCT02559570|DRUG|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
223453896|NCT02559570|DRUG|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
223453897|NCT00901082|BEHAVIORAL|Relaxation and information session|Relaxation and information session before the medial branch block
223453898|NCT05022888|DEVICE|regional tissue saturation|tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.
223453899|NCT02738229|DRUG|Valacyclovir|
223453900|NCT02738229|DRUG|placebo|
224062706|NCT05676359|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
224062707|NCT05676359|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
224062708|NCT05676359|OTHER|Rheumatic disease comorbidity index|It is rated from 0 to 9 and comprises 11 comorbid conditions including lung disease, cardio-vascular disease, hypertension, diabetes, fracture, depression, cancer, and gastrointestinal ulcer
224062709|NCT05676359|OTHER|Living will questionnaire|A questionnaire with 17 items about knowledge of the living will.
224301534|NCT00573157|DRUG|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
224301535|NCT05567484|DRUG|Itraconazole|100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
224301536|NCT04317183|DRUG|chamomile topical oral gel|Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
224301537|NCT04317183|DRUG|Miconazole Topical Gel|topical anti fungal agent
224301538|NCT04317183|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
224301539|NCT04317183|DRUG|Oracure gel|Topical analgesic gel
223453901|NCT03397602|BEHAVIORAL|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
223453902|NCT03397602|BEHAVIORAL|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
223453903|NCT04685642|DRUG|Aspirin|Aspirin (100mg/day)
223453904|NCT04685642|DRUG|Atorvastatin|Atorvastatin (20mg/day)
223453905|NCT00043849|DRUG|Quetiapine|
223453906|NCT03021629|OTHER|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay|
223453907|NCT02264938|DIETARY_SUPPLEMENT|Antioxidant|Oral supplemmentation with antioxidants
223453908|NCT04388176|DRUG|C21|C21 as first treatment
224301540|NCT02944383|DRUG|Gemcabene|Gemcabene tablets administered orally once daily, for 12 weeks.
223453909|NCT04388176|DRUG|C21|C21 as second treatment
224301541|NCT02944383|DRUG|Placebo|Placebo tablets administered orally once daily, for 12 weeks.
223453910|NCT04388176|DRUG|Placebo|Placebo as second treatment
223453911|NCT04388176|DRUG|Placebo|Placebo as first treatment
223453912|NCT05387694|OTHER|Thrombotic risk assessment|Collection of symptomatic thrombotic events occurring during the 5 days of hospitalization and then by telephone interview at M1 +/- 3 days. Complete echodoppler (proximal and distal) performed at M1 to highlight asymptomatic thrombotic events.
223453913|NCT04646811|PROCEDURE|Tricuspid valve|Clip for the tricuspid valve implantation on top of best medical therapy
224301542|NCT01632111|OTHER|Lung function measurement|Spirometry
223453914|NCT04646811|OTHER|Best medical treatment|Best medical therapy alone
223742553|NCT04637542|OTHER|Mobile Learning|"The necessary interviews and correspondences were carried out in order to conduct the research. Permission was obtained from Health Sciences University Istanbul Training and Research Hospital Clinical Research Ethics Committee. The purpose of the study was explained to the students as per the sample criteria and their consents were obtained. All of the students participating in the study attended four hours of theoretical lessons in the classroom related to anatomy of the genital system. Following the theoretical training, students were divided into experiment (mobile application) and control (genital organ model) groups. Both groups where then given the Structured Student Presentation Form, Status and trait anxiety inventory and Knowledge Examination (pre-test) on paper.~The didactic content prepared for the institution's standard curriculum (control group) or mobile learning is similar for both training methods."
223742554|NCT04839094|DIAGNOSTIC_TEST|rapid antigen testing versus RT-PCR|Sensitivity of rapid antigen testing and RT-PCR performed on nasopharyngeal swabs versus saliva samples in COVID-19 hospitalized patients.
224062710|NCT05676359|OTHER|Perceptions of Health Outcomes Questionnaire|A questionnaire with 7 items about the probability of quitting the job, getting an infectious disease, requiring emergency medical attention, hospitalization or intensive care, dependence and death.
224062711|NCT06294886|DIAGNOSTIC_TEST|Screening test to detect endometrial cancer and precancer|The device is designed to detect DNA biomarkers for cancer in cells shed from the lining of the uterus into vaginal fluid
224148013|NCT02951897|OTHER|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E\&M-) CTCs.
224148014|NCT03288441|DRUG|Hold|Hold antithrombotic therapy
224148015|NCT03288441|DRUG|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
224148016|NCT03288441|DRUG|Change antithrombotic Drug|Change in type of antithrombotic therapy
224148017|NCT03288441|BIOLOGICAL|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
224148018|NCT03288441|DRUG|Full dose antithrombotics|Continue full dose antithrombotic therapy
224301543|NCT03557528|PROCEDURE|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
224301544|NCT04987242|DRUG|ALLN-346|ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
223742555|NCT05566210|DEVICE|acupuncture|acupuncture
223742556|NCT05566210|DEVICE|Sham acupuncture|Sham acupuncture
224062712|NCT03332563|BEHAVIORAL|Cognitive-behavioral intervention for chronic pain|WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
224062713|NCT02794324|PROCEDURE|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v\_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
224062714|NCT02794324|PROCEDURE|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC\_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC\_DIBH, CT images will be obtained.
224062715|NCT02794324|PROCEDURE|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
224301545|NCT04987242|DRUG|Placebo|Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
223453915|NCT05708040|DEVICE|InPen Medtronic|Patients with DM1 ≥ 18 years of age who initiate Inpen system.
223453916|NCT05708040|DEVICE|Minimed 780G system|Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
223742557|NCT00452829|DRUG|Folic Acid and inositol|Folic Acid and inositol
223742558|NCT00452829|DRUG|Folic acid and placebo|Folic acid and placebo
223742559|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
223742560|NCT00452491|DRUG|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
223742561|NCT02935790|DRUG|ACY-241|tablet
223742562|NCT02935790|DRUG|nivolumab|infusion
223742563|NCT02935790|DRUG|ipilimumab|infusion
223742564|NCT03591016|OTHER|Recording number of IV attempts|Recording number of IV attempts in the operating room
223742565|NCT01276093|PROCEDURE|PVI ablation|Pulmonary Vein Ablation using RF.
224148019|NCT03288441|DEVICE|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
224148020|NCT03288441|DRUG|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
224148021|NCT00002268|DRUG|Sevirumab|
224148022|NCT00897936|GENETIC|DNA methylation analysis|
224301546|NCT05960318|DEVICE|KalobaNaso spray|Nasal spray, 2 puff per nostril, 3 times a day
224301547|NCT05960318|DEVICE|KalobaNaso junior spray|Nasal spray, 1 puff per nostril, 3 times a day
224301548|NCT02646930|PROCEDURE|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
224148023|NCT00897936|GENETIC|comparative genomic hybridization|
224148024|NCT00897936|GENETIC|fluorescence in situ hybridization|
224148025|NCT00897936|GENETIC|microarray analysis|
224148026|NCT00897936|GENETIC|polymerase chain reaction|
224148027|NCT00897936|OTHER|diagnostic laboratory biomarker analysis|
224148028|NCT00897936|OTHER|immunologic technique|
223571339|NCT02075047|DRUG|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects \<45 kg having a target dose range of 60-80 mg/day and subjects \>/= 45 kg having a target dose range of 120-180 mg/day.
223571340|NCT05424263|DRUG|Calcium Acetate Oral Solution|Subjects will be supplemented with calcium acetate (4,000 mg/day), as described in the arm/group descriptions, for 12 weeks.
223571341|NCT05424263|DRUG|Calcium Carbonate Oral Suspension|Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
223571342|NCT00279838|PROCEDURE|Computer Assisted Navigation Knee Replacement|
223571343|NCT05238259|DEVICE|kinesiotaping|Kinesio tape is the name of an adhesive tape created by Kenzo Kase in Japan in 1973. Kinesiotaping is latex-free with 100% cotton fibers that has no pharmaceutical effect, designed to mimic the elasticity properties of the muscle, skin, and fascia. These properties make it resistant and wearable for a long period, in general, 3 to 5 days at a time; it is even water resistant.
223571344|NCT05238259|DEVICE|wrist wheel|Wrist wheel is a therapy aid that exercises muscles in the wrist, forearm and shoulder. It utilizes exercises known as pronation and supination moving from pronation to supination exercises is made easy because of the wheel. It allows the pateint to easily roll wrist back and forth focusing on the wrist and arm
223571345|NCT05731908|DRUG|BI 690517|BI 690517
223571346|NCT06061276|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
223742566|NCT01276093|DRUG|Amiodarone|Amiodarone tablets
223453917|NCT04283253|DEVICE|Robot + TTT exercise|The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
223453918|NCT00420628|DRUG|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
223453919|NCT00420628|DRUG|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
223453920|NCT01830933|OTHER|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
223453921|NCT04690634|PROCEDURE|laparoscopic sleeve gastrectomy (LSG)|Multiple studies have indicated that laparoscopic sleeve gastrectomy (LSG) was superior to nonsurgical approaches for the treatment of obese PCOS patients over both the short and long term
223453922|NCT04786405|BEHAVIORAL|Mindfulness meditation|Participants in the mindfulness meditation condition will practice a breath and body focused meditation.
223453923|NCT04786405|BEHAVIORAL|Clinical hypnosis|Participants in clinical hypnosis will be guided in a hypnosis practice with suggestions tailored towards shifting pain appraisals.
223453924|NCT00001338|DRUG|FLAC chemotherapy with GM-CSF|
223453925|NCT03043963|BEHAVIORAL|Sleep Extension|Lengthen the duration of sleep time.
223571347|NCT06061276|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
223742567|NCT06328153|DEVICE|Fu's Subcutaneous Needling|Operation of the FSN will follow the KOA's Fu's Subcutaneous Needling Treatment Code of Practice24. After routine disinfection, a disposable Fu's subcutaneous needle ( Nanjing-Paifu Medical Technology Co., Ltd., Jiangsu, China ) is inserted parallel into the subcutaneous loose connective tissue of the pathological tight muscles ( gastrocnemius muscle, tibial anterior muscle and quadriceps femoris muscle ). The FSN needle is operated in a swaying movement. The fan angle is approximately 60°; perform a total of 45 round trips in 30 seconds. Swaying is accompanied by reperfusion approach: 20 sweeps with 10 seconds of reperfusion approach as a group, 3 groups for each pathological tight muscle. The reperfusion approach requires active, short and sharp contractions of the pathological tight muscle. The muscle alternates contraction and relaxation. The FSN group is treated 3 times a week for 2 weeks.
224148029|NCT05531968|BIOLOGICAL|BMI2006|IM
224148030|NCT05531968|BIOLOGICAL|BOTOX®|IM
224148031|NCT00953004|DIETARY_SUPPLEMENT|fiber drink and fiber bread|fiber drink or fiber bread three times daily
224148032|NCT00767845|OTHER|questionnaire/survey administration|
224148033|NCT05269641|OTHER|Food: whole almonds|60g of whole almonds will be consumed daily.
224148034|NCT05269641|OTHER|Food: non-nut snack|A non-nut snack will be consumed daily.
224148035|NCT05915936|PROCEDURE|LVMR|laoparoscopic ventral mesh rectopexy
223453926|NCT03043963|BEHAVIORAL|Sleep Timing|Regularize the timing of the sleep period.
224148036|NCT05915936|PROCEDURE|PSR|perineal stapler resection
224148037|NCT05968625|DEVICE|Thermoformed retainers|conventional thermoformed retainers fabricated on stone models.
224148038|NCT05968625|DEVICE|3D-printed retainers|3D-printed retainers fabricated directly by DLP printer.
224301549|NCT02674321|DRUG|SD-809|
224062716|NCT02794324|DEVICE|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
224062717|NCT01236300|DEVICE|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
224062718|NCT06254729|OTHER|Observational study|Our study does not have any exposure factors.
224062719|NCT04474795|BEHAVIORAL|Staff -Educational training|Nurses and community health workers will complete 4 hours of online modules on gestational diabetes - Module 1: GDM Disease, Diagnosis and Complications; Module 2: Nutrition and Physical Activity Management; Module 3: Monitoring, Medications, and Avoiding Hypoglycemia; Module 4: Future Diabetes Risk and Prevention. Effectiveness of the training will be evaluated with pre/post evaluation of diabetes knowledge, attitudes, and self efficacy.
224062720|NCT06392568|OTHER|epidemiological records|Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome
224062721|NCT02305095|DRUG|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
224062722|NCT00872651|DRUG|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
224062723|NCT00872651|DRUG|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
224062724|NCT03009214|DRUG|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
224062725|NCT01833611|DRUG|Entecavir|entecavir 0.5mg qd
224062726|NCT01833611|DRUG|placebo|placebo qd
224062727|NCT03478111|DRUG|CMAB008|the study drug
224062728|NCT03478111|DRUG|MTX|basic therapy drug
224062729|NCT03478111|DRUG|Remicade|active comparator
224062730|NCT02657161|BIOLOGICAL|RABIPUR®|Biological rabies vaccine
224301550|NCT04763564|DRUG|Liraglutide Pen Injector|Treatment will be initiated at 0.6 mg per day for one week. The patient will be instructed to increase the dose to 1.2/day and 1.8 mg /day in week 2 and in week 3, respectively. From week 3 after the start of the drug until week 6 the patient will apply 1.8 mg/day liraglutide. In case of intolerance (e.g. occurrence of refractory nausea) at a higher dose (e.g. 1.8 mg daily, the highest dose in this trial) liraglutide can be reduced to the previous level.
224301551|NCT04763564|DRUG|Placebo Pen Injector|Matching placebo pens used to administer normal saline in the same fashion as for liraglutide
224301552|NCT00003538|BIOLOGICAL|graft versus host disease prophylaxis/therapy|
224062731|NCT02657161|BIOLOGICAL|PIKA rabies vaccine|Biological rabies vaccine
224062732|NCT02657161|BIOLOGICAL|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
224062733|NCT04030923|DEVICE|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
224148039|NCT04054102|OTHER|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
224148040|NCT04054102|OTHER|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
223571348|NCT06061276|DRUG|Camrelizumab|200mg intravenously every 2 weeks
223571349|NCT01235923|DRUG|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
224148041|NCT02178306|DRUG|Telmisartan low dose|
224148042|NCT02178306|DRUG|Telmisartan high dose|patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment
224148043|NCT02178306|DRUG|Placebo|Run-in phase
224148044|NCT05883839|OTHER|Student Group|"Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish."
224148045|NCT06343025|OTHER|Pilates Exercises Group|Individuals will perform clinical pilates exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of basic pilates exercises, 10 minutes of warm-up and 5 minutes of cool-down exercises.
224148046|NCT06343025|OTHER|Tai Chi Exercises Group|Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises.
223571350|NCT01235923|DRUG|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
223571351|NCT05155618|PROCEDURE|INTERVENTION GROUP|Personalized advice to prevent side effect according to their health status will be provided by a dietitian and a physiotherapist.
223571352|NCT06277349|DEVICE|Toric multifocal IOL|Implant of Multifocal toric intraocular lens only
223571353|NCT06277349|DEVICE|Non-toric multifocal IOL|Implant of non-toric multifocal lens plus incisional surgery
223571354|NCT06246019|DIAGNOSTIC_TEST|Early adoption of blood-based biomarkers for Alzheimer's disease|A blood test will be performed to obtain plasma measures of Amyloid-β (Aβ) 42/40, phosphorylated tau (p-tau) 181, p-tau217, p-tau231 and Glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL) and results will be disclosure to the early and late arms at different time points.
223571355|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose
223571356|NCT01098877|DRUG|PF-04634817|Oral solution, 1mg, single dose
223571357|NCT01098877|DRUG|PF-04634817|Oral solution, 3mg, single dose
223571358|NCT01098877|DRUG|PF-04634817|Oral solution, 10mg, single dose
223571359|NCT01098877|DRUG|PF-04634817|Oral solution, 30mg, single dose
224062734|NCT04253275|GENETIC|blood samples|"Blood samples will be taken at inclusion, 12h, 24h, 48h, 7d, 3m and 1y for patients ; at inclusion, 3m and 1y for controls.~Microvesicles samples will be taken at inclusion, 7d and 3M ; at inclusion and 3M for controls."
223453927|NCT02481752|OTHER|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
223453928|NCT02481752|OTHER|SHAM Training|
223453929|NCT01289301|DRUG|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
223453930|NCT01289301|DRUG|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
223453931|NCT03307460|DRUG|68Ga-NOTA-AE105|PET/MRI scan
223453932|NCT00362661|DRUG|Cortisol|Cortisol 10 mg/d for 3 months
223453933|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
223453934|NCT01219192|DRUG|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
223453935|NCT01219192|DRUG|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
223453936|NCT01219192|DRUG|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
223453937|NCT02996890|BIOLOGICAL|MV-ZIKA|MV-Zika vaccine
223453938|NCT02996890|OTHER|Placebo|physiological saline
223453939|NCT01215149|BIOLOGICAL|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10\^10 vp, delivered IM
223453940|NCT01215149|BIOLOGICAL|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10\^10 vp delivered IM
223453941|NCT01215149|BIOLOGICAL|Placebo Control|Colorless 10mm Tris/HCl buffer
223453942|NCT01064362|DRUG|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
223453943|NCT01064362|DRUG|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
223571360|NCT01098877|DRUG|PF-04634817|Oral solution, 100mg, single dose
224062735|NCT04253275|DIAGNOSTIC_TEST|MRI without injection|MRI at inclusion for controls
223571361|NCT01098877|DRUG|PF-04634817|Oral solution, 300mg, single dose
223571362|NCT01098877|DRUG|PF-04634817|Oral solution, 600mg, single dose
223571363|NCT01098877|DRUG|PF-04634817|Oral solution, 900mg, single dose
223453944|NCT01770821|OTHER|Dietary supplement and/or physical training|
223453945|NCT01324921|OTHER|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
223453946|NCT01324921|OTHER|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
223453947|NCT01324921|OTHER|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
223453948|NCT00225108|DRUG|Tinzaparin|
223453949|NCT00040144|DRUG|ACH126, 433|
223453950|NCT04636411|DIETARY_SUPPLEMENT|Oral Magnesium Supplementation|250 mg of elemental magnesium daily for three months
223453951|NCT04636411|OTHER|Standard Care for diabetic patients|Health education, oral antihyperglycemic medications according to American Diabetes Association (ADA) guidelines
223453952|NCT02009371|DEVICE|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
223453953|NCT02009371|DEVICE|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
223453954|NCT02829385|DRUG|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
223571364|NCT01098877|DRUG|PF-04634817|Oral solution, up to 900mg, single dose after food
223571365|NCT01098877|DRUG|PF-04634817 Placebo|Oral solution, placebo, single dose after food
223571366|NCT03221608|PROCEDURE|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
223571367|NCT03221608|PROCEDURE|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
223571368|NCT04394273|OTHER|Exercise|stabilization exercise
224062736|NCT03930719|DIAGNOSTIC_TEST|Stroke screening tools|"Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard."
224062737|NCT04081636|PROCEDURE|Systematic Transrectal biopsy (TR-Bx)|Through the rectum
223571369|NCT03120858|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
223571370|NCT00297102|DRUG|Roflumilast|500 mcg, once daily, oral administration in the morning
223571371|NCT00297102|DRUG|Placebo|once daily
223571372|NCT05705375|OTHER|Waterpipe size|Participants will have 3 lab visits where they are allocated (random order) to smoke a small waterpipe in one visit, smoke a medium waterpipe in a second visit and smoke a large waterpipe in a third visit.
223571373|NCT05719506|OTHER|normal saline without drug|nebulizer session with normal saline only preoperative
223571374|NCT05719506|DRUG|Dexmedetomidine|nebulizer session with dexmedetomidine preoperative
224062738|NCT04081636|PROCEDURE|Targeted Transrectal biopsy (TR-Bx)|Through the rectum
224062739|NCT04081636|PROCEDURE|Systematic Transperineal biopsy (TP-Bx)|Through the perineal skin
224062740|NCT04081636|PROCEDURE|Targeted Transperineal biopsy (TP-Bx)|Through the perineal skin
224062741|NCT05981170|OTHER|Adapted physical activity at home|"The programme will take place over 6 months and will include :~1 consultation with the oncologist who will first assess the need for Adapted Physical Activity and then prescribe the APA with a certificate of no physical contraindication~1 consultation with the ICO's APA coach who will present the APA programme and assess the patient's physical capacity using the Short Physical Performance Battery (SPPB) test in order to adapt the programme to their needs.~13 home-based APA sessions (ideally one session per week) with the EAPA from Departmental Committee for Sport for All in 49~1 telephone call with the EAPA of the ICO to evaluate the programme 3 months after the last session.~Patients will also be asked to complete questionnaires at the first session (S1), halfway through the sessions (S6) and at the last session (S13).~These are FACIT-F 5Functional Assessment of Chronic Illness Therapy - Fatigue ; Ricci and L. Gagnon ; P-GIC (Patients' Global Impression of Change (PGIC) scale)"
224062742|NCT00841594|DRUG|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
224062743|NCT00841594|DRUG|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
224062744|NCT00563186|OTHER|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
224062745|NCT05618821|DRUG|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
224062746|NCT00625469|DRUG|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
224062747|NCT03812640|DEVICE|Vicryl suture|Corneal suture with Vicryl suture
224062748|NCT03812640|DEVICE|Nylon suture|Corneal suture with Nylon suture
224062749|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine|ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.
224062750|NCT06337071|BIOLOGICAL|ACYW135 Meningococcal Polysaccharide Vaccine|ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.
224062751|NCT02776189|DRUG|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
224062752|NCT02776189|DRUG|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
224062753|NCT02776189|DRUG|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
224062754|NCT01661907|PROCEDURE|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.375%-0.5% ropivacaine during surgery. Patient-controlled epidural analgesia will be provided after surgery.
224062755|NCT01661907|PROCEDURE|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
224062756|NCT05970900|DRUG|Imatinib Mesylate|"1. For patients with c-KIT exon 11 mutation, imatinib mesylate, 400mg, qd.~2. For patients with c-KIT exon 9 mutation, imatinib mesylate, 600mg or 800mg, qd."
224062757|NCT05970900|PROCEDURE|Local resection|"According to the characteristics of the location of the tumor, the surgeon decides the surgical approach based on the existing literature and the availability of surgical equipment, including:~1. Local transanal resection (TA)~2. Local resection transsacralapproach~3. Local resection via perineal approach~4. Local resection transvaginal approach"
224062758|NCT06005727|DEVICE|Transanal ice pack|A condom is filled with 100ml of water and frozen to serve as a transanal ice pack. It is covered by sterile plastic dressing and applied to the hemorrhoidectomy wound for 1 minute after surgery is completed.
224062759|NCT01530984|DRUG|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
224062760|NCT01530984|DRUG|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
224062761|NCT03512600|DIETARY_SUPPLEMENT|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
223571375|NCT05719506|DRUG|Ketamine|nebulizer session with ketamine preoperative
223571376|NCT03236259|DIETARY_SUPPLEMENT|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
223571377|NCT03236259|DIETARY_SUPPLEMENT|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
223571378|NCT03236259|DIETARY_SUPPLEMENT|Placebo|Maltodextrin. Daily ingestion of capsule
223571379|NCT02906449|BEHAVIORAL|Meditation Technique|Alertness training or relaxation training
223571380|NCT03960086|OTHER|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
224062762|NCT03512600|DIETARY_SUPPLEMENT|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
224062763|NCT03512600|DIETARY_SUPPLEMENT|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
224062764|NCT03512600|DIETARY_SUPPLEMENT|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
223453955|NCT04626661|DEVICE|COMET measurement system|Photonics Healthcare B.V. has developed an innovative non-invasive bedside monitoring system to measure Cellular Oxygen METabolism (the COMET).The COMET's non-invasive cutaneous mitoPO2 measurements rely on the protoporphyrin IX-triple state lifetime technique (PpIX-TSLT). This technique measures oxygen by oxygen-dependent quenching of delayed fluorescence lifetime of 5-aminolevulinic acid-induced mitochondrial PpIX (protoporphyrin IX). PpIX is the final precursor of haem in the haem biosynthesis pathway and is synthetized in the mitochondria. Administration of exogenous 5-aminolevulinic acid enhances PpIX to detectable levels and enhances mitochondrial origin of the delayed fluorescence signal. Measurements are based on the detection of time of extinction of red light emitted by the tissue following excitation with green light. The technique has been tested and calibrated for use in isolated organs and in vivo.
223453956|NCT01966302|DRUG|BPS-314d-MR|15-150 mcg po BID,
223453957|NCT01615978|DRUG|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
223571381|NCT03960086|OTHER|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
223571382|NCT06364813|OTHER|COMPANION eHealth Program|COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
223571383|NCT05466500|PROCEDURE|Ultrasound guided axillary block with intravenous dexamethasone|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous
223571384|NCT05466500|PROCEDURE|Ultrasound guided axillary block|it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine
223571385|NCT03226756|DRUG|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
223571386|NCT02821377|DRUG|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
223571387|NCT02821377|DRUG|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
223571388|NCT02821377|PROCEDURE|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
223571389|NCT02748434|OTHER|Lipohypertrophy|
224062765|NCT01142102|RADIATION|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~* Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~* Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
223453958|NCT01615978|DRUG|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
223453959|NCT01615978|DRUG|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
223453960|NCT01643278|DRUG|Dasatinib|Given PO
223571390|NCT02748434|OTHER|Normal Subcutaneous Tissue|
223571391|NCT03873961|DEVICE|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
223571392|NCT03873961|DEVICE|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
223571393|NCT00773786|DRUG|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
223571394|NCT00773786|DRUG|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
223571395|NCT02382029|DRUG|Clonazepam|Active medical treatment for burning mouth syndrome
223742568|NCT06328153|DRUG|Celecoxib|Participants in the drug group will receive celecoxib (capsule) 200mg every day continuously for 2 weeks.
223742569|NCT05104567|DRUG|THOR-707|Solution for infusion: intravenous infusion
223453961|NCT01643278|BIOLOGICAL|Ipilimumab|Given IV
223453962|NCT01643278|OTHER|Laboratory Biomarker Analysis|Correlative studies
223453963|NCT01643278|OTHER|Pharmacological Study|Correlative studies
223571396|NCT02382029|OTHER|acupuncture|Traditional chinese acupuncture
223571397|NCT01240525|OTHER|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
223571398|NCT01240525|OTHER|No DLI|Patients will not receive DLI as trial treatment
223571399|NCT04195438|PROCEDURE|CO Testing Pre/Post Hepatic Resection|Monitor CO in exhaled air of patients before liver resection, at 4 hours and 24 hours after PH
223571400|NCT04195438|DIAGNOSTIC_TEST|ABG Testing Pre/Post Hepatic Resection|Monitor carboxyhemoglobin(COHb) in the arterial blood gas of patients before liver resection at 4 hours and 24 hours after PH
223571401|NCT04195438|DIAGNOSTIC_TEST|CT Evaluations|Analyze the relationship between CO production and the extent of hepatic resection assessed by computed scans liver volumetric study at one and three months after PH, size and weight of the resected specimen and operative report
223571402|NCT01774097|BIOLOGICAL|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
223571403|NCT01774097|BIOLOGICAL|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
223571404|NCT01453751|PROCEDURE|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
223571405|NCT04331184|PROCEDURE|RFA using combined bipolar and monopolar energy deliver|RFA technique combining bipolar mode and switching monopolar mode using dual / Twin Cooled-wet electrodes is performed on residual tumors after transarterial chemo-embolization.
223571406|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
223742570|NCT05104567|DRUG|Pembrolizumab|Solution for infusion: intravenous infusion
223742571|NCT05104567|DRUG|Cetuximab|Solution for infusion: intravenous infusion
224062766|NCT00054067|DRUG|cisplatin|
224062767|NCT00054067|PROCEDURE|adjuvant therapy|
224062768|NCT00054067|PROCEDURE|conventional surgery|
224062769|NCT00054067|RADIATION|brachytherapy|
224062770|NCT00054067|RADIATION|radiation therapy|
224062771|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
224062772|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
224062773|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
224062774|NCT00879645|DRUG|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
224062775|NCT02477059|DRUG|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
224062776|NCT02477059|DRUG|saline solution|La saline solution is administered by intravenous infusion.
224062777|NCT02567149|DRUG|Cidofovir|Cidofovir
224062778|NCT03620227|OTHER|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
224148047|NCT06587360|OTHER|fertiShare intervention - sharing bad news eLearning course|"two-hour self-led eLearning course to support fertility staff in sharing bad news (SBN) with their patients~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 offers SPIKES-based step-by-step guidance to ease SBNs. Module 3 offers guidance to cope with common challenges FHPs face: sharing bad news remotely, managing anger and uncertainty, and using good news to lessen the impact of bad news.~Each module offers video content-based lessons, case studies that illustrate guidance and brief quizzes for self-reflection and assessment. Case studies show learners optimal and suboptimal approaches to SBN."
224148048|NCT06587360|OTHER|fertiShare control - basic communication skills eLearning course|"self-led eLearning course branded as fertiShare but designed to emulate the basic communication training healthcare providers receive as they undergo their professional degrees.~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 introduces the communication cycle and associated communication techniques. Module 3 offers guidance regarding other basic communication skills: empathic communication, non-verbal communication, active listening and remote consultations, and communicating the likelihood of positive or negative treatment outcomes.~Each module offers video content-based lessons, case studies, and brief quizzes. All teaching elements remain at the basic level (remembering and understanding instead of analysing and applying)."
224148049|NCT02798562|DEVICE|Native and dynamic contrast-enhanced CT|
224148050|NCT04323150|DEVICE|Closed suction systems|Closed suction systems are using for prevention of the ventilator-associated pneumoniae
224148051|NCT04323150|DEVICE|Conventional suction system|The using of open (conventional) suctioning
224148052|NCT02629536|DRUG|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
224301553|NCT00003538|PROCEDURE|allogeneic bone marrow transplantation|
223453964|NCT02969083|PROCEDURE|RNU|Radical surgical removal by open or laparoscopic access
224062779|NCT03620227|DIETARY_SUPPLEMENT|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
223453965|NCT02969083|DRUG|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
223453966|NCT02969083|DRUG|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
223453967|NCT03472612|OTHER|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA
223453968|NCT04966078|PROCEDURE|liposuction|suction-assisted liposuction
223453969|NCT04966078|PROCEDURE|surgical excision|periareolar surgical excision
223453970|NCT00944632|DRUG|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
223453971|NCT00944632|DRUG|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
223571407|NCT02757443|DRUG|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
224062780|NCT03620227|DIETARY_SUPPLEMENT|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
224062781|NCT01166737|PROCEDURE|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
224062782|NCT03631732|DRUG|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
224062783|NCT03631732|DRUG|NRTIs|"The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)"
224062784|NCT03631732|DRUG|Third Agent|"Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)"
224062785|NCT04827784|PROCEDURE|local anaesthetic injection|The head and neck of the condyle were detected by palpating the pretragal area. Then, the needle was inserted anterior to the junction of the tragus and the lobule. After 0.5 ml the solution was subcutaneously infiltrated, the needle was protruded until it touched the neck of the condyle. Aspiration was performed to avoid intravenous injections, and the remaining solution was injected thereafter.
224062786|NCT00573573|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
224301554|NCT00858143|OTHER|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
224301555|NCT05726175|DRUG|Disitamab Vedotin|Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;
224301556|NCT05726175|DRUG|Penpulimab|Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
224062787|NCT00330902|DRUG|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
224062788|NCT00330902|DRUG|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
224062789|NCT04046432|DIETARY_SUPPLEMENT|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
224062790|NCT04046432|DIETARY_SUPPLEMENT|Placebo|Maltodextrin was used as a placebo.
224062791|NCT04288154|DEVICE|EMS Device On|The EMS Device will turned on during exercise as opposed to it being turned off for control group.
224062792|NCT04288154|OTHER|EMS Device Off|The EMS Device will turned off during exercise as opposed to it being turned off for control group.
224062793|NCT02149940|OTHER|heart-failure related pharmaceutical intervention|
224062794|NCT03521050|DEVICE|defibrillator lead|observation of long-term performance of defibrillator leads
224062795|NCT02873936|DRUG|Filgotinib|Tablet(s) administered orally once daily
224062796|NCT02873936|DRUG|Placebo to match filgotinib|Tablet(s) administered orally once daily
224062797|NCT02873936|DRUG|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
224062798|NCT04568395|OTHER|TCIG|Use a TCIG
224062799|NCT04568395|OTHER|ECIG|Use an ECIG
224062800|NCT04568395|OTHER|sham control|Use a sham control (empty ECIG)
224062801|NCT01561950|DRUG|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
224062802|NCT01561950|DRUG|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
224062803|NCT01561950|DRUG|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
224062804|NCT02860195|OTHER|oral dose of alcohol|
224062805|NCT02860195|DEVICE|alcotest|
224148053|NCT05488704|DIAGNOSTIC_TEST|Stress Parameters Measurement|"Pre-Test (0-2 minutes before NST starts) - Measurement of vital parameters (Pre-Test)~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Starting NST by controlling the noise level Interim Test-(NST 10th minute) - Measurement of vital parameters (Intermediate Test)~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory~  • Termination of NST after 20 minutes Final Test(within 0-2 minutes after NST is over)~* Measurement of vital parameters~* Glucose measurement~* Taking Salivary Cortisol and Saliva ACTH samples~* Filling the Spielberger State Anxiety Inventory After Data Collection - Recording of data~* Centrifugation and analysis of saliva samples taken"
224148054|NCT04324086|DEVICE|Calcium hydroxide with XP-endo Finisher file|XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
224062806|NCT02860195|BIOLOGICAL|blood samples|
224148055|NCT04324086|DEVICE|Calcium hydroxide with Irrisafe Ultrasonic tip|passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
224301557|NCT01551641|OTHER|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
223571408|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
224062807|NCT02860195|DEVICE|Transdermal monitor|
224062808|NCT05563922|COMBINATION_PRODUCT|Total Neoadjuvant Chemoradiotherapy|"Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection"
224062809|NCT02079857|OTHER|Standard protocol|Subjects will receive a standard treatment
224062810|NCT02079857|OTHER|Individualized protocol|Subjects will receive an individualized treatment
224062811|NCT02079857|OTHER|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
224062812|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
224062813|NCT00456105|BEHAVIORAL|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
224062814|NCT00456105|BEHAVIORAL|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
224062815|NCT02166164|OTHER|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
224062816|NCT02166164|OTHER|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
224062817|NCT02166164|OTHER|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
224062818|NCT04060420|OTHER|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
224062819|NCT00742248|DRUG|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
224062820|NCT00742248|DRUG|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
224062821|NCT00742248|DRUG|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
224148056|NCT04324086|DEVICE|Calcium hydroxide with side vented needle|conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide
224148057|NCT01372644|DRUG|SOM 230 / Pasireotide|
224148058|NCT02312115|DRUG|Furosemide|Diuretic
224062822|NCT01669161|DEVICE|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
224062823|NCT01669161|OTHER|Rehab Only|Rehabilitation without device implant and VNS
224062824|NCT00018551|DRUG|Folic Acid|
223453972|NCT01184170|BEHAVIORAL|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
223453973|NCT01337817|OTHER|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
224062825|NCT00318214|DRUG|MRE0094|Gel, 500 mcg/g once each day
224062826|NCT00318214|DRUG|Vehicle gel|Gel administered once per day
224062827|NCT03517891|BEHAVIORAL|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
224062828|NCT02943564|DRUG|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
224062829|NCT02943564|DRUG|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
224148059|NCT02312115|DRUG|Placebo|Saline
224148060|NCT03228498|DRUG|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
223453974|NCT01337817|OTHER|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
224062830|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
224062831|NCT00063570|DRUG|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
224062832|NCT00063570|DRUG|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
224062833|NCT00063570|DRUG|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
224062834|NCT02461550|DEVICE|Irreversible Electroporation Ablation|
224062835|NCT04700839|DRUG|SGLT2 inhibitors|Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
224062836|NCT04700839|DRUG|Metformin|Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
224062837|NCT01073267|RADIATION|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
224062838|NCT01225731|BIOLOGICAL|tildrakizumab|SC administration of tildrakizumab at assigned dose
224148061|NCT03228498|DRUG|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
224148062|NCT01315847|DRUG|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
224148063|NCT01315847|DRUG|[11C]MK-4232|Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
224148064|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|The focused shockwaves are directed at the affected muscles in the upper limb, specifically targeting the subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
223453975|NCT03472001|OTHER|Reflection and feedback|2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
223453976|NCT03472001|OTHER|Lecture|Traditional didactic lecture which uses the same clinical cases
223453977|NCT04528329|DRUG|Early-Dexamethasone|early use of dexamethasone as early as laboratory evidence of high inflammatory markers
223453978|NCT04528329|DRUG|Late dexamethazone|Use of dexamethasone on deterioration of the cases with increased severity
224062839|NCT01225731|DRUG|Placebo|SC administration of Placebo
224062840|NCT01367535|DRUG|SC Methylnaltrexone (MNTX)|
224062841|NCT01367535|DRUG|IV Methylnaltrexone (MNTX)|
224062842|NCT01367535|DRUG|Oral Paroxetine|
224062843|NCT01367535|DRUG|SC Placebo|
224062844|NCT01943526|BIOLOGICAL|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
224062845|NCT00034710|DRUG|Capsaicin Patch|
224062846|NCT04027699|PROCEDURE|Mini-bolus|"* First injection of 2ml/kg (saline solution)~* Second injection of 18ml/kg (saline solution)"
224062847|NCT00513110|GENETIC|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
224062848|NCT00513110|DRUG|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
224062849|NCT00513110|DRUG|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
224148065|NCT06674785|DEVICE|focused extracorporeal shock wave therapy (ESWT)|Placebo shockwave therapy directed at subscapularis, pectoralis major, latissimus dorsi, and teres major muscles.
224301558|NCT01551641|DRUG|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
224148066|NCT06998576|BEHAVIORAL|Animated educational video on antibiotic use|The intervention features a concise animated video on antibiotic use and AMR. The video's content and format will be developed based on the results of a survey conducted among the community residents in the two neighborhoods. Through the survey, the participants evaluated multiple message options including the various delivery formats. The animated video was designed incorporating the community's preferred key message and delivery method. The resulting video uses graphics, voice-overs, captions \[in all 4 official national languages\] to convey key messages about appropriate antibiotic use and AMR.
224062850|NCT05080049|DRUG|Erythropoietin|"Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
224062851|NCT05080049|DRUG|Placebo|"In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection."
224062852|NCT01567657|DRUG|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
224062853|NCT01567657|DRUG|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~\< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
224062854|NCT00977236|DEVICE|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
224062855|NCT00977236|DEVICE|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
224062856|NCT00577642|DRUG|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
223571409|NCT02757443|DRUG|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
224148067|NCT04202549|DRUG|intra-arterial cocktail therapy|Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy.
224148068|NCT07000864|OTHER|No intervention|Lab-based correlative study; no intervention
224148069|NCT00141700|DRUG|Rituximab|
223571410|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
223571411|NCT02757443|DRUG|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
223571412|NCT02757443|DRUG|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
223571413|NCT02757443|DRUG|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
223571414|NCT06116539|DRUG|Cyanoacrylate|In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.
223571415|NCT06116539|PROCEDURE|Suture|After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
223571416|NCT02112682|PROCEDURE|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
223742572|NCT05252611|OTHER|Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8)|The aim of this study is to test the validity of the Turkish version of the Chronic Pain Acceptance Questionnaire-8 (CPAQ-8).
224148070|NCT00461578|DRUG|Chlorproguanil-dapsone + artesunate|
224148071|NCT01142284|DRUG|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
224148072|NCT01458314|OTHER|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
224148073|NCT01458314|OTHER|Rehabilitation without NIV|Training in patients without NIV adoption
224148074|NCT05001061|DRUG|Misoprostol Pill|sublingual versus vaginal Misoprostol in termination of first trimester missed abortion
223571417|NCT05819307|DEVICE|OCT/FLIM|OCT/FLIM imaging of the retina
223571418|NCT06157541|BIOLOGICAL|Allogeneic cytomegalovirus-specific T cells|Allogeneic cytomegalovirus (CMV)-specific T cells generated from the blood of healthy CMV-seropositive donors
223571419|NCT06157541|DRUG|Pembrolizumab|A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
223571420|NCT03117608|BIOLOGICAL|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
223571421|NCT03117608|BIOLOGICAL|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
223571422|NCT01741142|DRUG|ABT-436|Subjects receiving ABT-436
223742573|NCT06059911|DIETARY_SUPPLEMENT|Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)|Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids
224062857|NCT05219942|DRUG|Glargine|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR \> 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.
224062858|NCT05219942|OTHER|normal saline|regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous saline instead of insulin glargine will be given in the control group.
224062859|NCT04341441|DRUG|Hydroxychloroquine - Daily Dosing|"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
224062860|NCT04341441|DRUG|Hydroxychloroquine - Weekly Dosing|"The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day."
224062861|NCT04341441|OTHER|Placebo oral tablet|"Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..~Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.~Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected."
224062862|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Baseline|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
224062863|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 4|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
224148075|NCT00981318|DRUG|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
224148076|NCT00013455|DEVICE|Hearing|
224148077|NCT01714297|DRUG|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
224148078|NCT02275598|DRUG|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
224148079|NCT02275598|DRUG|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
224148080|NCT03219892|DEVICE|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
223453979|NCT03523858|DRUG|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
223453980|NCT02860390|OTHER|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
223453981|NCT02860390|OTHER|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
223571423|NCT01741142|DRUG|Escitalopram|Subjects receiving escitalopram
223571424|NCT01741142|DRUG|Placebo|Subject receiving placebo
223571425|NCT00613925|DEVICE|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
223571426|NCT00613925|DEVICE|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
224062864|NCT04341441|DIAGNOSTIC_TEST|Monitoring Visit - Week 8|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.
224062865|NCT04341441|OTHER|Weekly Assessment|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 \&7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.
224062866|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on AI-guidance|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on AI-guidance
224148081|NCT03219892|DEVICE|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
224148082|NCT02697630|DRUG|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
224062867|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on AI-guidance|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on AI-guidance
224062868|NCT05952440|OTHER|Tapering and/or discontinuation of treatment based on standard of care|After synovial tissue biopsy, pharmacological treatment (cDMARDs or bDMARDs) are tapered first and then bDMARDs and/or cDMARDs are discontinued based on standard of care
224062869|NCT05952440|OTHER|No tapering and/or discontinuation of treatment based on standard of care|Ongoing therapeutic are not changed (tapered or discontinued) after synovial biopsy performance based on standard of care
224062870|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
224062871|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
224148083|NCT02697630|DRUG|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
224148084|NCT01287481|BEHAVIORAL|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
224148085|NCT01287481|BEHAVIORAL|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
224301559|NCT01551641|OTHER|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
224301560|NCT03529578|PROCEDURE|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
224301561|NCT01706237|DEVICE|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
223571427|NCT04346979|OTHER|Telerehabilitation-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. Respiratory exercise was added to the training protocol. Individuals were asked to participate in the study via telerehabilitation system and aimed to do their exercises with a physiotherapist.
223571428|NCT04346979|OTHER|Video-Based|25 volunteers postmenopausal women who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. Online yoga and mindfulness protocol was created for individuals who will participate in the study. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The respiratory exercise was added to the training protocol. Video recordings containing only yoga and mindfulness training were sent to individuals. The participants were supervised by the researcher.
223571429|NCT01524432|DRUG|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
223571430|NCT01524432|DRUG|Placebo|No drug loaded microcapsules socks
223571431|NCT05229211|DEVICE|Cardiac monitoring|Continuous ECG monitoring via VitalConnect patch worn on the chest.
223571432|NCT02308527|DRUG|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
223571433|NCT02308527|DRUG|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
223571434|NCT02308527|DRUG|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
223571435|NCT02308527|DRUG|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
224062872|NCT00917150|DRUG|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
224062873|NCT00917150|DRUG|placebo|oral administration of placebo, once daily for 24months
224148086|NCT01287481|BEHAVIORAL|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
224301562|NCT04785859|DIAGNOSTIC_TEST|BPD prediction|"The following lung ultrasounds will be performed on the patients included in the study: first 24 hours of life, 3rd day of life (DOL) and 7th DOL. At one week of life detection of proteins in nasopharyngeal aspirates will be performed. During the first week of life, an echocardiography will be performed in all patients to evaluate the possibility of a patent ductus arteriosus and its hemodynamic significance.~In the first 20 patients who remain intubated at one week of life, tracheal aspirates will be obtained too, to compare protein determination in both aspirates at the same time."
223571436|NCT02308527|DRUG|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
224062874|NCT01587911|OTHER|Whey|Preload containing complete whey protein.
224062875|NCT01587911|OTHER|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
224062876|NCT01587911|OTHER|Control|Preload control matched for energy to the other 5 preloads.
224062877|NCT01587911|OTHER|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
224062878|NCT01587911|OTHER|MPI|Preload containing whole milk protein.
224062879|NCT01587911|OTHER|CPI|Preload containing sodium caseinate.
224062880|NCT03978195|DEVICE|Non-invasive device for middle ear ventilation|Daily use of the device
224062881|NCT06427200|DRUG|oral Iron|oral iron once daily during or after meals as add-on therapy for 12 weeks.
224062882|NCT06427200|DRUG|Lactoferrin|lactoferrin twice daily before meals as add-on therapy for 12 weeks.
224062883|NCT06427200|DRUG|lactoferrin and oral iron|lactoferrin twice daily before meals and oral iron once daily during or after meals as add-on therapy for 12 weeks.
224062884|NCT03184961|DIAGNOSTIC_TEST|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
224062885|NCT04973475|DRUG|Indocyanine Green|Laparoscopic distal gastrectomy with lymph node dissection for early gastric cancer using Indocyanine Green Tracer
223742574|NCT06059911|DIETARY_SUPPLEMENT|Placebo dietary supplement (97% maltodextrin)|Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin
223742575|NCT03141281|BEHAVIORAL|BrainHQ|BrainHQ
223742576|NCT03141281|BEHAVIORAL|Rise of Nations|Rise of Nations
224062886|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 30|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
224062887|NCT05472766|DRUG|Direct Acting Oral Anticoagulant starting at Day 90|Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
224062888|NCT05520697|BEHAVIORAL|Nutritional intervention|Nutritional treatment with caloric restriction.
223453982|NCT03932916|DRUG|Donepezil Pamoate for Injection 17mg|A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
223453983|NCT03932916|DRUG|Donepezil Pamoate for Injection 34mg|A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
223453984|NCT03932916|DRUG|Donepezil Hydrochloride 5mg|A tablet of 5mg Donepezil Hydrochloride will be administered once.
223571437|NCT02308527|DRUG|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
223571438|NCT02308527|DRUG|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
223571439|NCT02308527|DRUG|Dinutuximab Beta|10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
223571440|NCT02308527|DRUG|Cyclophosphamide|250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
223571441|NCT03828422|DIAGNOSTIC_TEST|imaging|
223571442|NCT03584997|PROCEDURE|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
223571443|NCT03584997|PROCEDURE|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
223453985|NCT00463125|DRUG|Platelet Gel|
223453986|NCT00758134|DRUG|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
223453987|NCT00553527|PROCEDURE|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
223453988|NCT00429650|BEHAVIORAL|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
223453989|NCT00429650|BEHAVIORAL|diet|Use a prescribed diet to maintain weight loss
223453990|NCT00429650|BEHAVIORAL|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
223453991|NCT05558800|PROCEDURE|Implant placement|Implant placement with different surface types
223571444|NCT05981079|DRUG|Piperacillin/tazobactam|Piperacillin Sodium and Tazobactam Sodium for Injection
223571445|NCT05220280|DRUG|Imatinib|Oral imatinib 400 mg tablet once a day for 14 days.
223571446|NCT05220280|DRUG|Infliximab|Infliximab is administered as a single IV infusion with the proposed dosing schedule of 5 mg/kg body weight.
223571447|NCT04136327|DRUG|GLPG1972 film-coated tablets|single oral dose of GLPG1972
223571448|NCT04136327|DRUG|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion \[14C\]-GLPG1972
223571449|NCT04136327|DRUG|[14C]-GLPG1972 oral solution|single oral dose of \[14C\]-GLPG1972
223571450|NCT00098046|DRUG|famciclovir|
223571451|NCT00002858|DRUG|cisplatin|
223571452|NCT00002858|DRUG|cyclophosphamide|
223571453|NCT00002858|DRUG|doxorubicin hydrochloride|
223571454|NCT00002858|DRUG|etoposide|
223571455|NCT00002858|RADIATION|radiation therapy|
223742577|NCT03141281|BEHAVIORAL|IADL Training|IADL Training
223742578|NCT03141281|BEHAVIORAL|Active Control|Puzzle solving
223742579|NCT00714519|DRUG|Xenaderm® Ointment|Topical, BID or as needed
223742580|NCT00714519|DRUG|Placebo Comparator|Topical, BID or as needed
223742581|NCT04990752|DRUG|ulinastatin|In the ulinastatin group, early application of ulinastatin was performed for inflammation management and organ protection before ECMO initiation.The recommended clinical routine dosage of ulinastatin is 300,000 IU, q8h (continuous administration for more than 5 days).
223742582|NCT00001877|DRUG|Pentoxifylline|
223742583|NCT03904758|DIAGNOSTIC_TEST|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
223742584|NCT03322033|DEVICE|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
223742585|NCT00733746|DRUG|erlotinib hydrochloride|oral administration
223742586|NCT00733746|DRUG|gemcitabine hydrochloride|Intravenous administration
223742587|NCT00733746|PROCEDURE|therapeutic conventional surgery|
223742588|NCT01048021|PROCEDURE|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
223742589|NCT05778786|DEVICE|Acuvue Oasys 1 Day for Astigmatism|CONTROL
223742590|NCT05778786|DEVICE|TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore|TEST
223742591|NCT01813084|DRUG|RV1729 single dose|Safety and tolerability of single escalating doses
223742592|NCT01813084|DRUG|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
223742593|NCT01813084|DRUG|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
223742594|NCT01813084|DRUG|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
223742595|NCT02942446|DEVICE|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
224062889|NCT05520697|BEHAVIORAL|Mental exercise.|Mental exercise.
224062890|NCT05520697|BEHAVIORAL|Physical training.|Exercise.
223742596|NCT05487742|DRUG|Dexmedetomidine|dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
223742597|NCT05487742|DRUG|placebo salin infusion|salin infused as aplacebo for 72 hours
223742598|NCT01631058|DRUG|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
223742599|NCT05263154|OTHER|Goal directed low oxygen|Oxygen is titrated until oxygen saturation is 100% in one-minute steps before the induction of anesthesia, with increasing fraction of inspired oxygen (FiO2) from 0.25 to 0.30 to 0.35 and so on. After intubation, the FiO2 is set to 0.25 to achieve a target saturation of 94-96%. Supplementary oxygen after surgery will be given with the same targets and with as little oxygen as necessary.
223742600|NCT05263154|OTHER|High oxygen|FiO2 1.0 before induction until end-tidal oxygen concentrations of 0.80 occur. The FiO2 will be reduced to 0.35 during anesthesia, followed by an increase in FiO2 to 0.80 during 5 minutes before extubating the patient, followed by FiO2 0.40 for at least thirty minutes after anesthesia. Oxgen will then be given at 3 liters a minute with a oxygen saturation goal of 98%
223453992|NCT02308371|DEVICE|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
223742601|NCT02325336|DEVICE|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
224062891|NCT03891264|DRUG|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
224062892|NCT04597736|BIOLOGICAL|Biological collection with nasopharyngeal samples, saliva, blood, stool and urine|"Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel.~For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine.~For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology."
224062893|NCT06210750|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224062894|NCT06210750|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224062895|NCT06210750|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224062896|NCT06210750|DRUG|Calaspargase Pegol|Given IV
223453993|NCT02420483|OTHER|Cardiopulmonary resuscitation chest compressions|
223453994|NCT00396383|DRUG|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
223453995|NCT00029861|DRUG|Rimonabant (SR141716)|
224062897|NCT06210750|PROCEDURE|Computed Tomography|Undergo CT
223453996|NCT03214549|PROCEDURE|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
223453997|NCT03214549|PROCEDURE|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
223453998|NCT03433859|DRUG|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
223453999|NCT03433859|OTHER|Topical Aluminium Chloride (cosmetic product)|Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
223454000|NCT03075189|DIETARY_SUPPLEMENT|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
224062898|NCT06210750|DRUG|Cyclophosphamide|Given IV
224062899|NCT06210750|DRUG|Cytarabine|Given IT, IV or SC
224062900|NCT06210750|DRUG|Daunorubicin|Given IV
224062901|NCT06210750|DRUG|Dexamethasone|Given PO
224062902|NCT06210750|DRUG|Doxorubicin|Given IV
224062903|NCT06210750|PROCEDURE|Echocardiography|Undergo echocardiography
224062904|NCT06210750|PROCEDURE|Lumbar Puncture|Undergo lumbar puncture
224062905|NCT06210750|DRUG|Mercaptopurine|Given PO
224062906|NCT06210750|DRUG|Methotrexate|Given IT
224062907|NCT06210750|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA scan
224062908|NCT06210750|BIOLOGICAL|Navitoclax|Given PO
224062909|NCT06210750|DRUG|Nelarabine|Given IV
224062910|NCT06210750|DRUG|Pegaspargase|Given IV
224062911|NCT06210750|PROCEDURE|Positron Emission Tomography|Undergo PET scan
223454001|NCT02703376|DRUG|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
223454002|NCT03927586|OTHER|cognitive training|We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
223454003|NCT03927586|OTHER|physical exercise training|The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
223454004|NCT03116724|PROCEDURE|central venous catheterization through Rt. IJV|"* insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~* placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~* measurement of the depth of the catheter at insertion point"
223742602|NCT03322254|OTHER|respiratory pathogen panel|lab testing for respiratory pathogens
224062912|NCT06210750|DRUG|Thioguanine|Given PO
223454005|NCT03182491|DIAGNOSTIC_TEST|Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)|Analysis of biomarkers and basophil activation test
223454006|NCT00453830|PROCEDURE|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
223454007|NCT01171469|BIOLOGICAL|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
223454008|NCT01171469|DRUG|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
223454009|NCT04910737|PROCEDURE|extended posterior circumferential decompressive surgery|After the pedicle screws were implanted, laminectomy was performed. Kyphotic correction was done through a temporary rod to reduce the tension of spinal cord. The posterior 1/3 of the vertebral body was resected using a high-speed drill, preserving the anterior wall of the spinal canal to protect the cord from disturbance. The dissection of adhesion at the anterior side of spinal cord was to be done through a posterolateral direction. The region of posterior resection was expanded, including bilateral residual articular processes, transverse processes and pedicles. Slightly press down the ossified lesion, and detach it from the dura mater (perform a sharp dissection if necessary) followed by completely removal. If cerebrospinal fluid leakage was encountered during the process, autologous fat, fascia or gelatin sponge can be applied locally for packaging.
223454010|NCT04542811|OTHER|Acupuncture|Acupuncture is a complementary therapy modality which is used by needle inserted the specific points on the body.
223454011|NCT04618809|BEHAVIORAL|Didactic Session|This session will include an overview of the approach to and management of older mGC patients patients through a case-based presentation.
223454012|NCT04618809|BEHAVIORAL|Comprehensive Geriatric Assessment, including an exploratory analysis to evaluate the use of fitness trackers for evaluation of functional status.|"* The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.~* The patient will receive a FitBit TM to wear for 4 days. Number of steps/day will be recorded."
223454013|NCT02008006|DRUG|BeEAM|"High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0"
223454014|NCT03448172|DRUG|[14C]PF-05221304|a single oral dose of \[14C\]PF-05221304 (50 mg/100 µCi liquid formulation)
223454015|NCT04453410|OTHER|Questionnaire Quality-of-recovery 15 (QoR-15)|Children will use the questionnaire Quality-of-recovery 15 (QoR-15)
223454016|NCT05132790|DRUG|SHR-1316 at a dose 20mg/kg q3w|Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
223454017|NCT05132790|DRUG|SHR6390 at a dose of 150mg orally, daily|SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
223454018|NCT05132790|RADIATION|SBRT|radiation therapy for breast cance before surgery.
223454019|NCT00078910|DRUG|exisulind|
223454020|NCT00078910|PROCEDURE|conventional surgery|
223454021|NCT00078910|PROCEDURE|neoadjuvant therapy|
223454022|NCT00000841|DRUG|Indinavir sulfate|
223454023|NCT00000841|DRUG|Lamivudine|
223454024|NCT00000841|DRUG|Stavudine|
223454025|NCT00000841|DRUG|Zidovudine|
224062913|NCT06210750|DRUG|Venetoclax|Given PO
224062914|NCT06210750|DRUG|Vincristine|Given IV
224062915|NCT06210750|PROCEDURE|X-Ray Imaging|Undergo X-ray
224062916|NCT01112540|DRUG|Morphine|0.1 mg/kg Intravenous bolus
224062917|NCT02308982|DRUG|Immunoglobulins, Intravenous (Privigen)|
224062918|NCT02308982|DRUG|Placebo|
224062919|NCT04674475|DEVICE|Pressure guidewire, optimal coherence tomography|Pressure guidewire, optimal coherence tomography
224062920|NCT01806363|DRUG|Telmisartan 80mg|
224062921|NCT01806363|DRUG|Chlorthalidone 25mg|
224062922|NCT00000299|DRUG|Buprenorphine|
224062923|NCT04808570|DRUG|TQ-B3525 tablets|TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.
224062924|NCT00036075|DRUG|CP-461|
224062925|NCT04778436|DIETARY_SUPPLEMENT|T7082|Patients will take food supplementation for 12 months. For each patient : 5 visits with ophthalmogist and 6 phone call
224062926|NCT05248568|DEVICE|Core training|Core training lasts for 12 weeks, three times a week, one hour each time
224062927|NCT00676390|OTHER|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
224062928|NCT03126695|DRUG|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
224062929|NCT03126695|DRUG|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
224062930|NCT03126695|DRUG|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
224062931|NCT03126695|DRUG|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
224062932|NCT01556425|DRUG|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
224062933|NCT01556425|BEHAVIORAL|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
224062934|NCT01556425|OTHER|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
224062935|NCT04518215|PROCEDURE|Erector Spinae Plain Block|Patients will receive erector spinae plane block (ESP) at the level of T 9-10. Following skin sterilization, high-frequency linear ultrasound probe will be placed 1-2 cm lateral to the midline at the T 9 level. After identification of the erector spinae muscle (ESM) and the transverse process; a 22 G needle will be inserted, in a cranio-caudal direction, deep into the ESM in an in-plane technique. Correct needle placement will be verified with the administration of 0.5-1 ml Normal Saline to view the hydrodissection between the transverse process and the ESM. 0.25% Bupivacaine in a calculated volume of 0.5 ml/kg (with a maximum dose of 20 ml) will be injected deep to the erector spinae muscle for unilateral ESPB.
224062936|NCT04518215|PROCEDURE|Intra-Venous Analgesia|Post-operative rescue analgesic plan will consist of 15 mg/kg Paracetamol IV if the FLACC \[Face, Leg, Activity, Cry, Consolability\] score is 2-4 and 1 mg/kg Tramadol IV if FLACC score \> 4.
223742603|NCT04595513|DRUG|TAVT-18 (sirolimus)|The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.
223742604|NCT06535711|RADIATION|Acute CT|Acute CT (a CT within 24 h)
224062937|NCT05649085|DEVICE|Cobalt-Chromium (CoCr) prosthetic abutments|Cobalt-Chromium (CoCr) prosthetic abutments in single-unit implant-supported prostheses
224062938|NCT05654597|OTHER|CAPTURE tool|CAPTURE 5-item questionnaire and a selected use of peak expiratory flow measurement.
224062939|NCT05654597|OTHER|Spirometry|Spirometry performed with a portable device, used for comparison with the CAPTURE tool.
224062940|NCT03344952|DRUG|Botulinum toxin type A|Repeated injections to hypertonic muscles
224062941|NCT03344952|OTHER|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
224062942|NCT01505634|DRUG|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
224062943|NCT01505634|DRUG|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
224062944|NCT01505634|DRUG|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
224062945|NCT01505634|DRUG|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
224062946|NCT01505634|DRUG|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
224062947|NCT02054897|DRUG|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
224062948|NCT02054897|DRUG|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
224062949|NCT00472264|PROCEDURE|PET imaging|Medical imaging assessment
224062950|NCT04261075|BIOLOGICAL|IPH5201|Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
224062951|NCT04261075|BIOLOGICAL|durvalumab|Durvalumab Q3W for a maximum of 2 years
223742605|NCT06535711|RADIATION|Deferred CT|Deferred CT (a CT within 3-4 weeks)
223742606|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated|Antihypertensive therapy utilizing atrioventricular interval modulation.
224062952|NCT04261075|BIOLOGICAL|oleclumab|Oleclumab Q3W for a maximum of 2 years
224062953|NCT01173224|DRUG|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
224062954|NCT01173224|DRUG|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
224062955|NCT04309942|OTHER|Guided Clinical Pharmacy Consultation|These patients will have the benefit of a Guided Clinical Pharmacy Consultation
223571456|NCT05311449|OTHER|Acupressure|The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.
223742607|NCT06059638|DEVICE|Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated|AVIM therapy is deactivated
224062956|NCT03611192|OTHER|Multicomponent exercise|Aerobic exercise: 15\~20 mins Resistance exercise: 15 mins Balance exercise: 15\~20 mins Flexibility exercise: 10 mins
224062957|NCT03611192|OTHER|Home-program exercise|60 mins exercise
224062958|NCT00794157|DRUG|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
224062959|NCT00794157|DRUG|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
224062960|NCT00794157|DRUG|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
224062961|NCT01673711|DRUG|deuterated phenanthrene tetraol|Given PO
224062962|NCT01673711|DRUG|pharmacological study|Correlative studies
224148087|NCT02626741|DIETARY_SUPPLEMENT|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
224148088|NCT02626741|BEHAVIORAL|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
223742608|NCT03658538|DEVICE|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
224148089|NCT05425719|DRUG|MB-102|18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
224301563|NCT00167687|DRUG|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
223742609|NCT03658538|BEHAVIORAL|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
223742610|NCT03658538|DEVICE|Sham Air Cleaner|The Control arm will receive sham air cleaners
223742611|NCT05554289|DEVICE|Depression Auxiliary Intervention Treatment Software (WL-iCBT)|The Depression Auxiliary Intervention Treatment Software (WL-iCBT) is a mobile application for smartphones that delivers cognitive behavioral therapy (CBT) and cognitive bias modification (CBM) through structured interactive multimedia methods, including animations, videos, audio, and interactive exercises.
224062963|NCT01673711|DRUG|laboratory biomarker analysis|Correlative studies
224062964|NCT02854644|OTHER|additional blood sample|
224062965|NCT01692275|OTHER|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
224062966|NCT01692275|OTHER|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
224062967|NCT02600832|BEHAVIORAL|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
224062968|NCT02600832|BEHAVIORAL|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
224062969|NCT01859728|DRUG|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
224301564|NCT04461561|GENETIC|end-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care|The End-of-Life Nursing Education Consortium (ELNEC) project is a national education initiative to improve nursing education on end-of-life care. The project is administered by the American Association of Colleges of Nursing and City of Hope National Medical Center. The intervention group received training through the Relais Academy website
224301565|NCT00852969|DRUG|Niacin|1000 mg tablets once per day
224301566|NCT00852969|DRUG|Active Placebo|100 mg Niacin tablets once per day
224301567|NCT03853148|BEHAVIORAL|Otago|Exercise program for strength and balance
224062970|NCT01859728|DRUG|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
224062971|NCT01859728|DRUG|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
223454026|NCT03935334|BIOLOGICAL|Biosimilar eptacog alfa, activated (AryoSeven)|A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
224062972|NCT01859728|DRUG|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
224148090|NCT05425719|DEVICE|MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)|On treatment day, participants had a transdermal sensor placed on their upper chest, and the MediBeacon Transdermal GFR Measurement System was initiated to collect background fluorescence. After collection of background fluorescence, participants received a single dose of MB-102.
224148091|NCT03796182|DRUG|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
223454027|NCT03935334|BIOLOGICAL|Eptacog alfa, activated (Novoseven)|A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
223454028|NCT01476306|OTHER|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
223454029|NCT01476306|OTHER|Usual care|Patients in this group will receive care as they usually do with the physician.
223454030|NCT00282152|DEVICE|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
223454031|NCT00282152|DRUG|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
223571457|NCT05311449|OTHER|Plasebo acupressure|In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
223454032|NCT00585325|DRUG|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
223454033|NCT00585325|OTHER|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
223454034|NCT03301831|BEHAVIORAL|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
223571458|NCT02997436|DEVICE|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
223571459|NCT05311995|PROCEDURE|Only different trocar sites|Only different trocar sites in literature
223571460|NCT03061721|DRUG|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
223571461|NCT03061721|DRUG|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
223454035|NCT01350375|DRUG|Botox|
223454036|NCT01350375|DRUG|Saline|
223571462|NCT03061721|DRUG|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
224062973|NCT01300169|BEHAVIORAL|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
224062974|NCT01300169|BEHAVIORAL|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
224062975|NCT02961621|BEHAVIORAL|Stress Reduction Training for 9-1-1 Telecommunicators|
223454037|NCT00614757|DRUG|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
223454038|NCT00614757|DRUG|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
224062976|NCT03446950|PROCEDURE|Vaginal Surgery|Patients will undergo elective surgery on vagina or bladder
224062977|NCT03734835|DIETARY_SUPPLEMENT|hesperidin|1000 mg hesperidin as two capsules
223571463|NCT03061721|DRUG|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
223571464|NCT06102135|DIETARY_SUPPLEMENT|Peptamen 1.3 PHGG|The amount of tube feed will be assess by the health Care Professional.
223571465|NCT00897403|OTHER|biologic sample preservation procedure|
223571466|NCT00897403|PROCEDURE|diagnostic colonoscopy|
224062978|NCT03734835|DIETARY_SUPPLEMENT|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
224062979|NCT03734835|DIETARY_SUPPLEMENT|flaxseed|30 grams flaxseed
224062980|NCT03734835|OTHER|control|no supplementation
224148092|NCT03796182|DRUG|PF-04965842|PF 04965842 100 mg tablets
224148093|NCT04682353|DRUG|TV-46046|SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
224148094|NCT04682353|DRUG|Depo-subQ Provera|SC injection of 104 mg/0.65 mL
224301568|NCT03853148|BEHAVIORAL|Gentle yogic breathing|yogic breathing
224062981|NCT05602038|PROCEDURE|Quadratus laborum block|quadratus lumborum block will be performed using ultrasound machine (Sonosite Portable Ultrasound System, SonoSite, Bothell, Washington, USA). A 5-8 MHZ curved probe will be used with the patient positioned on the lateral side
224148095|NCT03633994|DRUG|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
223454039|NCT03092791|BIOLOGICAL|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
223571467|NCT01920568|BIOLOGICAL|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
224062982|NCT05602038|DRUG|Intrathecal morphine|Intrathecal morphine 100mcg will be added to bupivacaine 0.5% 15mg and fentanyl 20 µg
224062983|NCT05602038|DRUG|intrathecal bupivacaine|intrathecal bupivacaine 0.5% 15mg and fentanyl
224062984|NCT02364089|PROCEDURE|Laparoscopic surgical removal of the adrenal tumor|
224062985|NCT02364089|DRUG|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day."
224062986|NCT00002152|DRUG|WF10|
224062987|NCT06087744|BEHAVIORAL|NeuroN-QI|Skin-to-skin contact (SSC) lasting 2 hours with an auditory sensory stimulation followed by a period of calm and rest of one hour during which the infants will rest in their incubator with breast milk's olfactory stimulation. Light and sound control will be done during the entire intervention.
224062988|NCT06087744|BEHAVIORAL|SSC alone|Skin-to-skin contact (SSC) lasting 2 hours
224062989|NCT05648994|BIOLOGICAL|TCR-T cells|patients will be administration of TCR-T cells
224148096|NCT03633994|DRUG|Normal saline|Normal saline bladder instillation
224148097|NCT05423002|OTHER|Flickering light stimuli|The intervention will be exposed to flickering lights (≤200 lux). More specifically, the participants will be asked to be exposed to a specified flickering light (1Hz, 30 seconds On, and 30 seconds OFF) for 2 hours starting at their habitual bedtime (HBT).
223454040|NCT03092791|BIOLOGICAL|Reference IPV|Reference IPV intramuscular injection
223454041|NCT03092791|BIOLOGICAL|sIPV Placebo|sIPV placebo-matching intramuscular injection
223454042|NCT01124370|DEVICE|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
223454043|NCT03309514|BIOLOGICAL|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
224148098|NCT05423002|OTHER|Constant light stimuli|The intervention will be exposed to constant background lights (≤200 lux). The participants will be asked to be exposed to a specified constant light for 2 hours starting at their habitual bedtime (HBT).
223454044|NCT07002307|OTHER|Warm water at 35 oC|The placebo for the control group
223571468|NCT01920568|DRUG|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
223571469|NCT01920568|DRUG|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
223571470|NCT01920568|DRUG|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
224148099|NCT05423002|OTHER|Dim light|This light condition is the baseline (≤10 lux).
224148100|NCT05406557|PROCEDURE|Partial pulpotomy|In case of partial pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of pulp chamber.
224148101|NCT05406557|PROCEDURE|Miniature pulpotomy|In case of miniature pulpotomy procedure the exposed pulp tissue will be amputated using a sterile bur in the high speed hand piece with water coolant to a depth of superficial 2-3 mm of only affected pulp horn
223454045|NCT07002307|OTHER|Coffee|Instant coffee, Nescafé Gold Blend, manufactured by Nestlé Coffee Brand, Nestlé Global
223454046|NCT07002307|OTHER|Honey-sweetened coffee|Instant coffee plus raw dark amber honey produced by Apis mellifera adansonii
223454047|NCT07002307|OTHER|Green tea|Qualitea Natural Green Tea, packed by Qualitea Ceylon (PVT) LTD
223571471|NCT01920568|DIETARY_SUPPLEMENT|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
223571472|NCT01920568|DIETARY_SUPPLEMENT|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
223571473|NCT04934709|DEVICE|Active PBMT-sMF|PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter. Six different sites of the knee extensor muscles (two medial, two lateral and two central points) were irradiated at the same time.
224062990|NCT05648994|DRUG|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regime
224062991|NCT05648994|DRUG|Cyclophosphamide Capsules|Part of the non-myeloablative lymphocyte-depleting preparative regime
224062992|NCT05648994|DRUG|Albumin-bound paclitaxel|Part of the non-myeloablative lymphocyte-depleting preparative regime
224062993|NCT05648994|DRUG|IL-2|Following cell infusion, the patient will be administration high-dose IL-2.
224062994|NCT03816930|PROCEDURE|mechanical cord usage|Due to the retraction procedures, same preparation conditions will be obtained.
224062995|NCT04041986|DEVICE|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
224062996|NCT03111784|OTHER|Fish consumption and lipid profiles|
224148102|NCT00954837|PROCEDURE|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
224148103|NCT01440907|OTHER|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
223454048|NCT07002307|OTHER|Honey-sweetened green tea|Green tea plus honey
224148104|NCT04284280|DIETARY_SUPPLEMENT|Routine vs Selective use of Human Milk Donor Fortifier|Infants will be randomized to two groups. Both groups will be fed Premature Human Milk (either Maternal own milk or Premature donor human milk). However, one group will get fortified with Donor Human Milk Fortifier once full feed is reached while the second group will get fortified using the same fortifier only when weight gain is suboptimal.
224148105|NCT00102557|DRUG|Hydroxychloroquine|
224148106|NCT04326023|DRUG|PARP Inhibitors|olaparib, rucaparib, niraparib, talazoparib, veliparib
224148107|NCT01324934|DRUG|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
224148108|NCT04997824|PROCEDURE|Artificial Intelligence-based atrial fibrillation catheter ablation|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. AI-guided prediction for poor responder of AFCA in the outpatient clinic~3. Sharing information on the AI prediction with the patient and family member~4. AFCA after consent to the procedure~5. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~6. Monitoring esophageal temperature~7. Evaluation of Procedure and ablation time, and complication afer procedure~8. Post-procedure rhythm follow-up is carried out according to the study design above."
223454049|NCT07002307|OTHER|Black tea|Lipton Yellow Label Black Tea
223454050|NCT07002307|OTHER|Honey-sweetened black tea|Black tea plus honey
223454051|NCT05171660|DRUG|Sintilimab|Sintilimab Injection: 200 mg, i.v., D1, Q3W
223454052|NCT05171660|DRUG|Bevacizumab|intravenous bevacizumab (7.5 mg/kg, day 1) in each 21-day cycle
223454053|NCT05171660|DRUG|Oxaliplatin|intravenous oxaliplatin (130 mg/m2, day 1) in each 21-day cycle
223454054|NCT05171660|DRUG|Capecitabine|oral capecitabine (1 g/m2, days 1-14) in each 21-day cycle
223454055|NCT07022236|DIAGNOSTIC_TEST|Thyroid profile|Thyroid dysfunction in patients undergoing hemogdialysis in sohag university hospital
223454056|NCT07021950|DRUG|AK112|AK112：20mg/kg，Q2W。Administered over 60 minutes (±10 minutes). For intolerable cases, infusion duration may extend up to 120 minutes. During treatment, dosing delays are allowed for up to 12 weeks (calculated from the last dose). AK112 may be resumed after 12 weeks under the following conditions: If treatment is paused due to glucocorticoid tapering for managing immune-related adverse events (irAEs);If treatment is paused due to adverse events unrelated or deemed unrelated to AK112; Resumption is permitted only if the investigator judges continued therapy beneficial, following discussion with relevant medical personnel.
223454057|NCT07021950|DRUG|FOLFIRI|FOLFIRI：Irinotecan, 180 mg/m² IV over 30-90 minutes (Day 1); Leucovorin (LV), 400 mg/m² IV over 2 hours (Day 1); 5-FU, 400mg/m²IV Day1, then 1200 mg/(m².d) ×2 days (total 2400 mg/m² ,IV over 46-48 hours).Q2W.
223454058|NCT07021950|DRUG|Bevacizumab|Bevacizumab：5 mg/kg，Q2W. The initial intravenous infusion should last approximately 90 minutes. If the first infusion is well tolerated, the duration of the second infusion can be reduced to approximately 60 minutes. Should the participant also tolerate the 60-minute infusion well, then all subsequent infusions may be administered over a period of approximately 30 minutes. Continuous monitoring for potential infusion-related reactions during the drip is required; if an infusion-related reaction occurs, the infusion rate should be promptly reduced or the infusion temporarily halted.
224062997|NCT05160961|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
223454059|NCT07021521|DRUG|0 mg/kg Midazolam (Control Group)|"* Intravenous administration of volume-matched normal saline (0 mg/kg midazolam equivalent)~* Administered as single bolus prior to epidural anesthesia~* Served as active comparator for dose-response evaluation"
223454060|NCT07021521|DRUG|0.01 mg/kg Midazolam Group|"* Intravenous midazolam at 0.01 mg/kg (diluted in normal saline)~* Administered as single bolus over 2 minutes~* Manufacturer: Jiangsu Enhua Pharmaceutical Co., Ltd. (Approval H19990027)"
223454061|NCT07021521|DRUG|0.02 mg/kg Midazolam Group|"* Intravenous midazolam at 0.02 mg/kg~* Identical administration protocol as 0.01 mg/kg group~* Primary focus: Intermediate dose efficacy/safety assessment"
224062998|NCT05160961|PROCEDURE|Erector spinae plane block|Erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
224062999|NCT01632995|DRUG|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
224063000|NCT01811875|BIOLOGICAL|Optivate 500IU|
224063001|NCT04605302|DEVICE|MCC/MCC-T|Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract
224063002|NCT04605302|DEVICE|Standard gastroscopy|Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum
224063003|NCT02849561|OTHER|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
224063004|NCT02849561|DEVICE|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
224063005|NCT02849561|OTHER|Electroencephalography|
224063006|NCT02849561|DEVICE|Pupillary light reflex surveillance|With Neurolight® device.
224063007|NCT02849561|DEVICE|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
224063008|NCT05229302|BEHAVIORAL|Reframet IT|The online intervention comprises 8 modules of cognitive behavioral therapy (CBT) delivered at schools by psychologists over 10 weeks. Contents: engagement and problem identification, emotional recognition and distress tolerance, identification of negative automatic thinking, help seeking and activity scheduling, problem solving, and cognitive restructuring, and a wrap up session. Two activities per module. Using a message board, the participant could communicate with research therapists who also check completed activities and respond with personalized messages. The face-to-face intervention comprises 4 CBT-based sessions to help the students in three aspects: i) close support and monitoring in case of an increase of symptomatology; ii) motivation to persist with the CBT; and iii) support the interaction between the students and CBT. Additionally, participants will be referred to a primary care clinic to receive treatment as usual.
224063009|NCT05229302|BEHAVIORAL|Usual care|Treatment as usual consists of identification and assisted referral to a primary care clinic where trained psychologists will assess the symptomatology and propose a course of actions, from initiation of psychotherapy to referral to a General practitioner to initiate medication if needed. Psychoterapy in primary care clinics consists of a range of 4-8 sessions twice a month. Most of the content of the psychotherapy are based on Cognitive-Behavioral Model. When needed, general practioners may suggest using medication, which normally are SSRI anditepressant (e.g., Fluoxetine, Sertraline). Medical check-up is conducted every month or every two months.
224063010|NCT01624662|DRUG|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
224148109|NCT04997824|PROCEDURE|Medical Therapy|"1. Patient selection for Atrial Fibrillation Catheter Ablation(AFCA)~2. Decision for AFCA based on clinical guidelines and the experience of the attending physician~3. AFCA after consent to the procedure~4. Pulmonary vein isolation and additional treatment for non-pulmonary vein triggers~5. Monitoring esophageal temperature~6. Evaluation of Procedure and ablation time, and complication afer procedure"
223454062|NCT07021521|DRUG|0.03 mg/kg Midazolam Group|"* Intravenous midazolam at 0.03 mg/kg (maximum tested dose)~* Special hemodynamic monitoring due to dose-dependent MAP effects~* Primary focus: Optimal dose determination"
223454063|NCT07021924|OTHER|Fu's subcutaneous needling|"A single-use Fu's Subcutaneous Needling (FSN) device was employed. Participants were instructed to lie supine with the tested upper limb extended in a neutral position. After a 15-minute resting period, the FSN needle was fully inserted into the subcutaneous tissue layer at the acupoint Xialian (LI18) along the Large Intestine Meridian, with the needle tip oriented toward the radial styloid process.~The needle core was retracted into the soft tube, and the needle was then manipulated by swinging the handle left and right in a fan-shaped manner, with a sweep angle of approximately 60 degrees (30 degrees in each direction) relative to the insertion axis. The swaying movements was performed 50 times back and forth (100 cycles/min) over a duration of 2 minutes.~The needle was retained in place for 15 minutes before being removed. After needle removal, participants remained resting for 3 minutes before getting up, marking the end of the experimental procedure."
223454064|NCT07021924|OTHER|Acupuncture|"Participants were instructed to lie supine with the tested upper limb extended in a neutral position. According to WHO standard acupoint locations, the acupuncture needle was inserted at Xialian (LI18), located 4 cun below Quchi (LI11) on the line connecting Hegu (LI4) and Quchi (LI11). A 30-gauge, 1.5-inch acupuncture needle was used, and insertion continued until the Deqi sensation was achieved.~The needle was retained for 15 minutes before being removed. After a 3-minute post-removal rest period, participants were allowed to rise, completing the procedure."
224148110|NCT04526119|DRUG|Acotiamide hydrochloride hydrate|A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase
224063011|NCT03691129|BEHAVIORAL|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
224063012|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
224063013|NCT02536989|DRUG|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
224063014|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
224063015|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
224063016|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
224063017|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
224063018|NCT00361270|BEHAVIORAL|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
224063019|NCT00361270|BEHAVIORAL|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
224063020|NCT00361270|BEHAVIORAL|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
224063021|NCT00361270|BEHAVIORAL|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
224063022|NCT03814070|PROCEDURE|Fiber-reinforced framework|Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
224063023|NCT03814070|PROCEDURE|No framework|Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
224063024|NCT04899700|DEVICE|Linked Color Imaging|Inspection of the postpolypectomy scar will be made with Linked Color Imaging
224063025|NCT04899700|OTHER|White light endoscopy|Inspection of the postpolypectomy scar will be made with White light Endoscopy
224063026|NCT02351505|DRUG|Selinexor|Given PO
224063027|NCT02351505|OTHER|Laboratory Biomarker Analysis|Correlative studies
224063028|NCT02351505|OTHER|Pharmacological Study|Correlative studies
224063029|NCT05297942|OTHER|Expansion of Abbreviations and Acronyms|Expansion of Abbreviations and Acronyms
224063030|NCT03276000|PROCEDURE|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
224148111|NCT04526119|DRUG|Placebo|A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
223454065|NCT07022223|DRUG|orelabrutinib combined with rituximab regimen|"All participants will receive induction therapy with the orelabrutinib and rituximab regimen. The treatment cycle is 28 days, with a total of 6 cycles. The induction treatment period is as follows:~Cycle 1: Rituximab, 375 mg/m², on Day 1. Cycles 2-6:Orelabrutinib, 150 mg, once daily orally, from Day 1 to Day 28. Rituximab, 375 mg/m², on Day 1.~Patients who achieve a partial response (PR) or better will enter a 2-year maintenance period with orelabrutinib."
224063031|NCT01513421|PROCEDURE|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
224063032|NCT00272142|DRUG|Zinc|
224063033|NCT00272142|DRUG|Placebo|
224063034|NCT04322851|DIAGNOSTIC_TEST|Lung ultrasound|Lung ultrasound performed at the time of extubation to evaluate B-line in patients with mechanical ventilation due to acute decompensated heart failure
224063035|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 1|Test group 1 will receive investigational product 1 containing collagen (5 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
224063036|NCT04988412|DIETARY_SUPPLEMENT|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 12 weeks.
224063037|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 2|Test group 2 will receive investigational product 2 containing collagen (10 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
224063038|NCT04988412|DIETARY_SUPPLEMENT|Investigational product 3|Test group 3 will receive investigational product 3 containing collagen (10 g/ 25 mL), MSM (1.5 g/ 25 mL) and vitamin C (80 mg/ 25 mL); continuous administration of investigational product for 12 weeks.
224063039|NCT02731261|OTHER|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
224063040|NCT06402708|DRUG|Chemotherapy|paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
224063041|NCT06402708|RADIATION|Radiotherapy|IMRT, 50Gy/25f
224063042|NCT03177421|OTHER|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
224063043|NCT03177421|OTHER|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
223454066|NCT07023133|BEHAVIORAL|Weight loss|All participants will have self selected for bariatric surgery and their weight loss and mitochondrial function will be measured in this study.
224063044|NCT04124913|DRUG|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
224148112|NCT01586806|DRUG|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
224148113|NCT01586806|DRUG|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
224148114|NCT01586806|DRUG|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
224148115|NCT03241238|OTHER|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
224148116|NCT05389059|PROCEDURE|CAF+CM|Periodontal surgery including CAF+CM application
224148117|NCT05389059|PROCEDURE|I-PRF|Periodontal surgery including CAF+CM application with i-PRF
224148118|NCT05684952|DRUG|Shenlingcao Oral Liquid|Shenlingcao oral liquid (200ml/bottle) is comprised of American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos) and fermented Cordyceps powder.
224148119|NCT00862654|DRUG|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
224148120|NCT00862654|DRUG|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo \& ketoconazole shampoo
223454067|NCT07022444|DEVICE|IOL-MASTER 700|patients who were diagnosed cataract would go through tests with IOL-MASTER 700 to achieve ocular biometry parameters.
223454068|NCT07022080|DIAGNOSTIC_TEST|68Ga-grazytracer PET/CT Scan|The imaging agent 68Ga-grazytracer used in this project is synthesised in accordance with the standards for the production of radiopharmaceuticals with reference to the Chinese Pharmacopoeia (18F-FDG quality standard). pH value is between 5.0-8.0; radiochemical purity is not less than 95%, and the content of bacterial endotoxin per mL of solution is less than 15EU; the concentration of radioactivity is not less than 37MBq/mL; the solvent The residual amount of solvent complies with the regulations. Specification: 185\~1850 MBq/ml Characteristics Colourless and transparent, no visible particles. Physical half-life: 68 minutes for 68Ga. Stable for 3 half-lives from the time of labelling. Method of administration: Intravenous. Dose: 0.05Ci/kg, followed by a 5 mL saline flush.
223454069|NCT07022067|DEVICE|Telemonitoring app|periodic measurement of blood pressure and body weight
223454070|NCT07022912|OTHER|educational healthcare intervention|This intervention will be applyed at the beginning of the study
224063045|NCT04124913|DRUG|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
224063046|NCT01553981|DRUG|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
224063047|NCT01553981|DRUG|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
224063048|NCT03449095|DRUG|Alcohol|Alcohol Target BAC .08%
224063049|NCT01986413|DEVICE|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
224063050|NCT01986413|DEVICE|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
223454071|NCT07022912|DIAGNOSTIC_TEST|Objective assessment of GI motility|Objetive assessment of gastrointestinal dysmotility in GI organs (esophagus, stomach, small bowel) will be performed using state of the art tests.
223454072|NCT07022912|DIAGNOSTIC_TEST|Evaluation of GERD severity|Objective evaluation of GERD severity on PPI therapy will be performed.
223454073|NCT07021781|OTHER|MedQuest mobile application|Participants in this group will complete standardized questionnaires and scales using the MedQuest mobile application. Physicians will provide patients with a QR code, allowing them to access assigned digital questionnaires on their personal mobile devices or provided tablets. The application facilitates the digital input of patient responses. Following completion, the MedQuest application automatically processes the questionnaire data and utilizes an integrated artificial intelligence system (Claude 3.5 Sonnet, version from 22.10.2024) to generate recommended International Classification of Functioning, Disability and Health (ICF) codes. The application also provides an integrated calculator for questionnaire scores. This intervention aims to streamline the assessment process, reduce completion time, and enhance the efficiency and accuracy of ICF coding through AI integration.
223454074|NCT07021781|OTHER|Traditional Paper-Based Questionnaires|Participants in this group will complete all standardized questionnaires and scales (e.g. SF-36, Barthel Index, etc.) manually on printed paper forms. Physicians will complete the forms and patients will complete their responses with a pen or pencil. Subsequent evaluation and processing of these questionnaires will be performed by physicians via the Medquest application, followed by manual identification and recording of International Classification of Functioning, Disability, and Health (ICF) codes based on clinical judgment and established guidelines. This method represents the traditional approach to patient assessment and data collection.
223454075|NCT07021534|BIOLOGICAL|NKG2D CAR NK and NKG2D CAR T cells|"* NKG2D CAR-NK cells (hepatic artery infusion, D0 dose: 1×10⁹ cells,D1 dose: 1×10⁹ cells)~* NKG2D CAR-T cells (Over a two-day period, CAR-T cells are administered via intravenous infusion on two consecutive occasions.In the initial phase, rapid titration dose escalation was performed with 1 case per group.The initial dose is set at 1.5×10⁷/kg. If grade 2 or higher cytokine release syndrome (CRS) or related adverse events (AEs) occur, the 3+3 dose escalation protocol will be initiated. If not, the starting dose for escalation will be set at 3×10⁷/kg per administration of-T CAR cells, with subsequent escalations to 5×10⁷/kg per administration and 7×10⁷/kg per administration.)~Chemotherapy:~If you are treated with autologous CAR-NK cells, lymphodepleting chemotherapy with FC is usually not required. If you are treated with allogeneic NKG2D CAR-NK cells derived from umbilical cord blood of a healthy donor, the researchers will adjust the FC chemotherapy dosage or choose another appropriate"
223454076|NCT07022249|DEVICE|Intrasaccular Embolization Device|This is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.The intended therapeutic effect of this device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.
223454077|NCT07021911|RADIATION|Radiotherapy|Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)
223454078|NCT06686654|BIOLOGICAL|Investigational hMPV/RSV vaccine|Investigational hMPV/RSV vaccine administered intramuscularly
223454079|NCT06686654|BIOLOGICAL|Investigational hMPV vaccine (monovalent)|Investigational hMPV vaccine (monovalent) administered intramuscularly
223454080|NCT06686654|BIOLOGICAL|Investigational RSV vaccine (monovalent)|Investigational RSV vaccine (monovalent) administered intramuscularly
223454081|NCT06686654|BIOLOGICAL|Licensed RSV Vaccine|Licensed RSV vaccine administered intramuscularly
223454082|NCT06686654|BIOLOGICAL|Placebo|Placebo administered intramuscularly
224063051|NCT01986413|DEVICE|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
224063052|NCT00203853|DEVICE|pillbox, wristwatch|
223454083|NCT06628453|DEVICE|CGM|Real-time continuous glucose monitoring
223454084|NCT07020572|BEHAVIORAL|Brief Interpersonal Psychotherapy - Adolescent Skills Training (B-IPT-AST)|This is an adolescent depression prevention program consisting of 6 sessions (4 group and 2 individual sessions).
224063053|NCT02812277|OTHER||This is a Non-Interventional Study, so there are no drug or devices included.
224071042|NCT05916404|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
224071043|NCT00575562|DRUG|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
224071044|NCT05075980|DRUG|Cisplatin|Given IV
224071045|NCT05075980|PROCEDURE|Intensity-Modulated Proton Therapy|Undergo IMPT
224071046|NCT05075980|OTHER|Quality-of-Life Assessment|Ancillary studies
224071047|NCT05075980|OTHER|Questionnaire Administration|Ancillary studies
224071048|NCT05075980|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
224071049|NCT05075980|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
224071050|NCT05075980|PROCEDURE|Positron Emission Tomography|Undergo PET/CT or PET/MRI
224071051|NCT05075980|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224071052|NCT05075980|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
224071053|NCT02290314|PROCEDURE|minimally invasive MID-line Lumbar Fusion (MIDLF)|
224071054|NCT02290314|PROCEDURE|Posterior lumbar interbody fusion (PLIF)|
224063054|NCT03270865|DEVICE|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
224063055|NCT03578224|PROCEDURE|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
224063056|NCT03578224|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
224063057|NCT03578224|PROCEDURE|Fine-Needle Aspiration|Undergo FNA
224301569|NCT03853148|BEHAVIORAL|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
223742612|NCT05554289|DEVICE|Placebo Control Software (WL-iHE)|The placebo control software (WL-iHE) is a mobile application that mimics the appearance and usage pattern of the active intervention software but lacks the therapeutic cognitive behavioral therapy components. The software has a similar user interface and time requirements, with participants using it once daily for 10-15 minutes, completing a total of 56 sessions over the 8-week treatment period. Unlike the active intervention, the placebo software does not deliver structured cognitive behavioral therapy content or cognitive bias modification training, instead providing general health education information without specific depression treatment techniques.
223454085|NCT07020572|BEHAVIORAL|Services as usual (SAU)|Services as usual (SAU) involves any mental health services adolescents decide to receive in primary care or in the community. It is possible that adolescents in SAU may decide not to participate in any mental health services.
223454086|NCT07022522|DEVICE|5Hz stimulation on the STN motor subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the motor subregion of the subthalamic nucleus at a low frequency of 5Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the motor subregion using neuroimaging verification.
224071055|NCT00483860|DRUG|Topotecan|once a day
223454087|NCT07022522|DEVICE|5Hz stimulation on the STN associative subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the associative subregion of the subthalamic nucleus at a low frequency of 5Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the associative subregion using neuroimaging verification.
224071056|NCT02085291|DRUG|Norepinephrine|Norepinephrine infusion to titrate MAP to usual level
223454088|NCT07022522|DEVICE|130Hz stimulation on the STN motor subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the motor subregion of the subthalamic nucleus at a high frequency of 130Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the motor subregion using neuroimaging verification.
223454089|NCT07022522|DEVICE|130Hz stimulation on the STN associative subregion|In this experimental arm, Parkinson's disease patients will undergo deep brain stimulation targeting the associative subregion of the subthalamic nucleus at a high frequency of 130Hz, with the primary objective of evaluating its specific effects on cognitive and behavioral outcomes such as inhibitory control and reaction time. The intervention involves precise postoperative programming of DBS electrodes localized to the associative subregion using neuroimaging verification.
223454090|NCT07022522|DEVICE|No stimulation|"In this control arm, Parkinson's disease patients will not receive active deep brain stimulation, with the DBS system maintained in an off state throughout the testing period."
223742613|NCT06040749|OTHER|Virtual group-based handcycling|Virtual group-based handcycling
223742614|NCT05270707|RADIATION|Stereotactic radiosurgery|HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).
224071057|NCT02085291|DRUG|Crystalloid|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
224071058|NCT04734106|DRUG|Desert Harvest Aloe Vera Capsules|600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
224071059|NCT04734106|OTHER|Placebo Capsules|550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
224071060|NCT05857241|DIETARY_SUPPLEMENT|Fasting mimicking diet (FMD)|"D1 will correspond to a pre-fasting phase, with about 800 kcal of intake (approximately 40% of normal caloric intake) from a mono-nutrient diet (fruit, rice or potato according to the patient's preferences). Then D2 and D3 will correspond to the days of actual fasting, with 200-350 kcal of intake (10-18% of normal caloric intake) in the form of 100 ml of broth or vegetable juice (with a teaspoon of linseed oil) three times a day, and vaccination will take place on D4, after returning to a normal diet. 2 to 3 liter of water or unsweetened drink per day is required.Laxatives (unsweetened) will be prescribed and can be taken as during the fasting period."
224071061|NCT02498639|PROCEDURE|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~1. Reduction of the mean aortic gradient ≥50%.~2. Aortic pressure drop during the inflations, indicative of valve orifice sealing.~3. Intraprocedural complication.~4. Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
224063058|NCT03578224|DRUG|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
224063059|NCT05177653|OTHER|Intravenous infusion|GIP receptor antagonist (GIP(3-30)NH2)
224063060|NCT05177653|OTHER|Intravenous infusion|GLP-1 receptor antagonist (exendin(9-39)NH2)
224063061|NCT05177653|OTHER|Intravenous infusion|GIP(3-30)NH2 and exendin(9-39)NH2
224148121|NCT00862654|DRUG|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
223454091|NCT07022431|OTHER|Interval strength training|"The intervention involves interval strength training with biofeedback and real-time decision-making for Alzheimer\&amp;amp;#39;s patients. Participants will complete 24 sessions, each including a circuit of strength exercises using rotational inertial devices (flywheels). Exercises, such as leg press, seated row, and bicep curl, will be randomly ordered, with load progression based on performance stability. Each session includes five sets per exercise, performed in a circuit, with a total of 15 sets over approximately 45 minutes. Real-time monitoring using a rotary encoder will track effort, and participants will continue each set until a 30% drop in average power is detected, ensuring consistent relative effort across sets.~Additionally, participants will engage in cognitively demanding tasks during training by verbally reporting the average power of the previous repetition while performing the next one. This dual-task approach aims to maximize both physical and cognitive engagement."
223454092|NCT07022860|BIOLOGICAL|Platelet-rich fibrin (PRF)|Platelet-rich fibrin (PRF) is an autologous blood-derived material prepared by centrifuging the participant's venous blood without anticoagulants. The PRF clot is then compressed into a membrane and inserted into the extraction socket. It serves as a scaffold rich in platelets and growth factors to support bone regeneration and healing.
223454093|NCT07022873|OTHER|ACT-ED: Acceptance and Commitment Therapy based eating disorder prevention program|This intervention protocol was developed specifically for women who have body dissatisfaction and disordered eating behaviors. Based on the psychological flexibility model (hexaflex), it is designed to improve people's body image flexibility using Acceptance and Commitment Therapy techniques. Interventions related to the dimensions of the hexaflex were made during each session. The first session covers values and goal setting. The second session includes creative hopelessness, acceptance, and self-compassion. The third session covers defusion and mindfulness. The last session focuses on self-as-context exercises and the combined use of skills for committed action.
223454094|NCT07021846|RADIATION|hypofractionated radiotherapy with tumor bed boost|hypofractionated radiotherapy with concomitant/simultaneous tumor bed boost
223454095|NCT07021703|BIOLOGICAL|Freeze-dried Human Rabies Vaccine（Human Diploid Cell）, Essen|"This vaccine is produced by Ningbo Rongyu Biological Pharmaceutical Co., Ltd.. Participants will receive AIM2301 by intramuscular injection.~Receive on the day 0, 3, 7, 14 and 28, a total of 5 doses"
223454096|NCT07021703|BIOLOGICAL|Freeze-dried Human Rabies Vaccine（Human Diploid Cell），Zagreb|"This vaccine is produced by Ningbo Rongyu Biological Pharmaceutical Co., Ltd.. Participants will receive AIM2301 by intramuscular injection.~Receive 2 doses on day 0, 1 dose on day 7 and day 21, a total of 4 doses."
224063062|NCT05177653|OTHER|Intravenous infusion|Saline
224063063|NCT01285115|DRUG|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
224063064|NCT01285115|DRUG|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
224063065|NCT01285115|DRUG|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
224063066|NCT04171518|DEVICE|Catalys Precision Laser System|Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
224063067|NCT04342286|GENETIC|Organoid culture|Organoid culture
224063068|NCT06047652|DEVICE|e-CPD user testing|nurses who meet the criteria will carry out user testing on the e-CPD application via a mobile device. after accessing the e-CPD system the nurse will fill in the System Usability Scale instrument.
224063069|NCT03001089|DRUG|Oral Fludrocortisone (enteral)|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
224063070|NCT03001089|DRUG|Placebo Oral Tablet|oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
224063071|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
224063072|NCT01100437|DRUG|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
224063073|NCT01964014|DRUG|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat."
224063074|NCT01933633|BEHAVIORAL|Exercise|
224148122|NCT00862654|DRUG|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
224148123|NCT04840017|OTHER|rehabilitation exercise|Rehabilitation exercise of intrinsic foot muscles
224148124|NCT01750944|PROCEDURE|Ankle first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPA-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPT-LR are re-measured."
224148125|NCT01750944|PROCEDURE|Toe first|"1. Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~2. A 15 minute walking test (WT) is performed.~3. BBP-LR and BPT-LR are re-measured.~4. 2 hours of rest.~5. BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~6. WT is reperformed.~7. BBP-LR and BPA-LR are re-measured."
224301570|NCT03853148|BEHAVIORAL|Caregiver Gentle yogic breathing|yogic breathing
224301571|NCT02537366|DRUG|Dexmedetomidine|
224301572|NCT02537366|DRUG|Placebo|
224063075|NCT01378234|BEHAVIORAL|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~1. Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~2. Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~3. Supporting caregivers to reduce stress and burden"
224148126|NCT00356395|DRUG|ramipril, candesartan|
224148127|NCT04082702|BEHAVIORAL|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
224063076|NCT00058786|BIOLOGICAL|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
224063077|NCT05413486|OTHER|Observational|"Exposure is defined by group affiliation i.e., Bipolar disorder vs. schizophrenia vs. no disease. Likewise with obesity vs. normal weight.~Biological markers of daytime-circadian rhythmicity is compared across disease and weight groups."
224148128|NCT04082702|BEHAVIORAL|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
224148129|NCT03210779|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
224148130|NCT03210779|DIETARY_SUPPLEMENT|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
224148131|NCT02061579|BEHAVIORAL|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
224301573|NCT00658658|BIOLOGICAL|Panitumumab|Panitumumab administered by intravenous infusion
223454097|NCT07022808|OTHER|Synchronous Group exercise|Participants will participate in the TEEMS biweekly for 8 weeks (synchronous intervention). The synchronous group will attend sessions 2 times per week, with all sessions recorded. The sessions will be 60-minutes total, including 45-minutes of physical activity. Recorded sessions will be made available for participants to use on their own at the end of each week, building a video of 16 videos. The program will be taught by a rehabilitation clinician with expertise in SCI and adapted exercise while our co-instructor will offer peer guidance and demonstrate lived translation of movement with an SCI. Class will take place over a web-based platform (such as Zoom).TEEMS instructors also orient participants to the Borg Rate of Perceived Exertion (RPE, 6-20 scale) to be used as an self-exertion check throughout class and to be recorded in a provided logbook. RPE is used as a self-assessment of moderate-vigorous intensity exercise.
223571474|NCT04934709|DEVICE|Placebo PBMT-sMF|Placebo PBMT-sMF was applied employing the Multi Radiance Medical Super Pulsed Laser MR4 console (Solon, Ohio, USA) with a LaserShower cluster probe as emitter, but without any emission of therapeutic dose. Placebo PBMT-sMF was applied at six different sites of the knee extensor muscles (two medial, two lateral and two central points).
223742615|NCT03671889|DEVICE|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
224148132|NCT04424199|BEHAVIORAL|Rightward Attentional Shift (R-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a rightward attentional shift.
224148133|NCT04424199|BEHAVIORAL|Leftward Attentional Shift (L-PA)|Patients will perform a session of 90 pointing movements toward a visual target presented on the right, the left or at the center of the visual field. This pointing task will be performed with prismatic googles inducing a leftward attentional shift.
224148134|NCT00350311|DRUG|nicotine transdermal patch/lozenge|
224148135|NCT02340468|DEVICE|diffuse optical spectroscopy|diffuse optical spectroscopy
224301574|NCT04335526|DRUG|Cholestyramine Resin|Change bile acid pool by cholestyramine treatment
224301575|NCT05495958|DRUG|Topical Vitamin D eye drop|25 Microgram/cc or 1000 IU
224301576|NCT05495958|DRUG|Topical placebo eye drop|The same-shape packed drop without vitamin D
224148136|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
224148137|NCT00818571|DRUG|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
224148138|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
224063078|NCT01353040|DRUG|AVI-6003|Single intravenous administration
224148139|NCT00818571|DRUG|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
224148140|NCT05711680|DEVICE|Device|To develop an e-health system to remotely monitor patients with chronic HIV infection and conduct early screening for COVID-19 through a telemonitoring, teleconsultation and periodic remote visit system.
224063079|NCT01353040|DRUG|Placebo|Single intravenous administration
224148141|NCT05995925|OTHER|Clinical Observation|Clinical Observation
224148142|NCT05491044|DRUG|orelabrutinib|Orelabrutinib 150mg po qd d1-28, up to 2 years or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).
224063080|NCT02404623|DIETARY_SUPPLEMENT|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
224063081|NCT00476411|BIOLOGICAL|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
224148143|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
224148144|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
224148145|NCT01663844|BEHAVIORAL|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
224148146|NCT01663844|BEHAVIORAL|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
224148147|NCT04377672|BIOLOGICAL|Anti-SARS-CoV-2 Human Convalescent Plasma|"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."
224148148|NCT01300364|DRUG|Reboxetine|8mg/day.
224148149|NCT01300364|DRUG|citalopram (SSRI)|30mg/day
224148150|NCT03954444|DRUG|Oxymetazoline Hydrochloride|Test Comparator
224148151|NCT03954444|DRUG|Rhofade Cream, 1%|Reference Comparator
224148152|NCT03954444|DRUG|Placebo|Placebo Comparator
224148153|NCT02138396|DRUG|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
224148154|NCT02138396|DRUG|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
224148155|NCT02138396|DRUG|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
224063082|NCT00507949|DRUG|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
224063083|NCT00507949|DRUG|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
224148156|NCT02447458|DRUG|MLN3126|MLN3126 tablets
224148157|NCT02447458|DRUG|MLN3126 Placebo|MLN3126 placebo-matching tablets
224148158|NCT01492296|PROCEDURE|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
224148159|NCT01492296|PROCEDURE|conventional fasting|patients were evaluated after fasting for 8 hours
224148160|NCT00546286|DRUG|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
224148161|NCT00546286|DRUG|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
224148162|NCT02602717|OTHER|lymph nodes cyto-punction|
224148163|NCT02133742|DRUG|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
224063084|NCT00616122|DRUG|cyclophosphamide|
224148164|NCT02133742|DRUG|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
224063085|NCT00616122|DRUG|methotrexate|
224063086|NCT00616122|DRUG|sunitinib malate|
224063087|NCT00616122|OTHER|laboratory biomarker analysis|
224063088|NCT03080844|BEHAVIORAL|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
224063089|NCT03080844|BEHAVIORAL|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
224063090|NCT00356850|DRUG|Azithromycin|
224063091|NCT06496815|DRUG|Donafenib|Donafenib will be taken orally twice a day, 0.2g each time.
224063092|NCT06496815|PROCEDURE|transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy|Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).
224063093|NCT06496815|DRUG|PD-1,PD-L1|PD-1/PD-L1 will be used as previous (if have).
224063094|NCT00867321|BIOLOGICAL|bevacizumab|Given IV
224063095|NCT00867321|DRUG|sorafenib tosylate|Given orally
224148165|NCT03096444|DRUG|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
224148166|NCT03096444|DRUG|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
224148167|NCT03096444|DRUG|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
224148168|NCT03096444|COMBINATION_PRODUCT|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
223571475|NCT01028534|DRUG|Olmesartan and Azelnidipine|"1. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~2. Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~3. Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
223571476|NCT00035607|DRUG|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
224063096|NCT06137924|DRUG|Local anesthetic injection Bupivacaine plus dexamethasone|The autonomic neural block is performed with a 25-gauge needle attached to a venous catheter extension introduced through the left 12-mm port. Infiltration of 20 mL of non-diluted 0.5% bupivacaine plus dexamethasone 8 mg is performed at the celiac plexus and vagus nerve trajectory.
223742616|NCT05219435|DRUG|Nivolumab|Nivolumab at 1 mg/kg by intravenous (IV) infusion on D1 of each cycle. Nivolumab at a fixed dose of 480 mg by intravenous (IV) infusion on D1 of each cycle. The maximum duration of treatment with nivolumab will be 2 years, and patients will discontinue treatment at any time in case of unacceptable toxicity, disease progression (PD), investigator ́s decision, patient's consent withdrawal or death by any cause, whichever occurs first.
224063097|NCT06137924|DRUG|Local anesthetic injection bupivacainde plus dexamethasone plus a colloid|bupivacaine plus dexamethasone 8 mg plus a colloid 10 cc (Gelofucin, B. Braun Medical S.A., Crissier, Suiza.) is performed at the celiac plexus and vagus nerve trajectory.
224063098|NCT06137924|DRUG|Local anesthetic injection bupivacaine plus clonidine|bupivacaine 5% plus clonidine (0,150mgs) is performed at the celiac plexus and vagus nerve trajectory
223742617|NCT05219435|DRUG|Ipilimumab|Ipilimumab at 3 mg/kg by intravenous (IV) infusion on D1 of each cycle.
223742618|NCT06399354|DIETARY_SUPPLEMENT|acute intake of medium-chain fatty acids or long-chain fatty acids in patients|The intake of an oil comprising of either medium -chain fatty acids or long-chail fatty acids
223742619|NCT06399354|DIETARY_SUPPLEMENT|Acute intake of medium-chain fatty acids or long-chain fatty acids in healthy individuals|Acute intake of MCT and LCT in healthy individuals in a cross-over design
223742620|NCT05094037|DEVICE|Removable cam walker boot|Standard of care device given to diabetic foot ulcer patients.
224148169|NCT03096444|DRUG|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
224148170|NCT01688635|DRUG|LY2963016|Administered subcutaneously
224148171|NCT01688635|DRUG|US Approved Lantus|Administered subcutaneously
224148172|NCT03351569|DRUG|Intravenous immunoglobulin|Intravenous drip.
224148173|NCT05380713|DRUG|Cyclophosphamide|Cyclophosphamide will be applied in the neoadjuvant setting
223571477|NCT00035607|DRUG|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
223571478|NCT00004552|DRUG|acamprosate (Campral)|
223571479|NCT01367418|DRUG|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
223571480|NCT01367418|DRUG|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
223571481|NCT02056886|PROCEDURE|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
223742621|NCT05094037|OTHER|Counseling|Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
223742622|NCT00213850|PROCEDURE|EFR|
223742623|NCT04173416|BEHAVIORAL|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
223742624|NCT02382822|OTHER|No intervention.|
224063099|NCT03599128|OTHER|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
224063100|NCT03599128|OTHER|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
224148174|NCT05380713|DRUG|Tremelimumab|tremelimumab-durvalumab in adjuvant setting
224148175|NCT05380713|DRUG|Durvalumab|tremelimumab-durvalumab in adjuvant setting
224063101|NCT03599128|OTHER|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
224063102|NCT03599128|OTHER|Placebo|Reconstituted in water and given to subjects
224063103|NCT05063227|DIAGNOSTIC_TEST|Observational: analgesia monitoring indices and changes in heart rate|After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be \< 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
224063104|NCT02122198|DRUG|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
224148176|NCT03752333|DRUG|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
224148177|NCT04228562|OTHER|non-modifiable factor|the presence of an uncontrollable / unremovable risk factor for a disease
224148178|NCT04228562|OTHER|induction of anticipated regret|higher level of elaboration on potential regret
224148179|NCT01499901|PROCEDURE|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
224148180|NCT01499901|PROCEDURE|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
224148181|NCT02016469|OTHER|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
224148182|NCT02016469|OTHER|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
224148183|NCT02016469|DIETARY_SUPPLEMENT|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
224301577|NCT04644835|DEVICE|Low Energy Shock Wave Treatment|The shock wave applicator (Dornier AR2, shock wave device, Dornier MedTech 2010, Wessling, Germany) will be gently placed directly on the ultrasound transmission gel over the skin surface of the suprapubic region above the urinary bladder at the site of the papillary lesion (ultrasound guided) and at other five points. Points 1 and 2 will be at the level of transverse crease 2 cm above the pubic bone and 5 cm from each, points 3 and 4 will 2 cm above points 1 and 2, and point 5 will be centered of points 1-4. A total of 2000 pulses at 0.25 mJ/mm2 will be delivered with a frequency of 3 pulses per second. The position of the shock wave applicator will be changed after every 400 pulses.
223742625|NCT06449469|DRUG|Rivaroxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
224063105|NCT02122198|DRUG|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
224063106|NCT02122198|DRUG|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
224148184|NCT04679441|DEVICE|The Computerized Functional Skills Assessment and Training Program|The CFSAT program provides training on everyday tasks critical to independent living (e.g., financial and medication management). The program currently includes six domain simulations critical to independent living: ATM Banking/Financial Management, Online Banking, Prescription Refill via Voice Menu, Kiosk Ticket Purchase, Online Shopping (and prescription refill), and Medication Management.
224148185|NCT04679441|DEVICE|Brain HQ Double Decision|Cognitive speed training program
224301578|NCT04644835|DEVICE|Sham Treatment|The patients will be exposed to the same therapy head, which will also be fitted with a stand-off without energy transmission.
223454098|NCT07022808|OTHER|Asynchronous exercise (Control)|Participants will participate in the TEEMS biweekly for 8 weeks (asynchronous video library). The asynchronous, control group will be provided with 2 recorded videos weekly that align with the synchronous group sessions, building a 16 video library as well. The sessions will be 60-minutes total, including 45-minutes of physical activity. The program will be taught by a rehabilitation clinician with expertise in SCI and adapted exercise while our co-instructor will offer peer guidance and demonstrate lived translation of movement with an SCI. Class will take place over a web-based platform (such as Zoom).TEEMS instructors also orient participants to the Borg Rate of Perceived Exertion (RPE, 6-20 scale) to be used as an self-exertion check throughout class and to be recorded in a provided logbook. RPE is used as a self-assessment of moderate-vigorous intensity exercise.
224063107|NCT02122198|DRUG|Placebo|placebo
224063108|NCT02883023|OTHER|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
224148186|NCT01319019|DRUG|GSK961081|Comparison of different doses and dosing regimens of the drug
224148187|NCT01319019|DRUG|Salmeterol|Positive control
224148188|NCT01319019|DRUG|Placebo|Placebo arm
224063109|NCT02883023|DRUG|Intralesional bleomycin injection|Local intralesional injections with bleomycin
224063110|NCT02581202|DRUG|lopinavir/ritonavir|tablet
224063111|NCT02581202|DRUG|lamivudine|tablet
224063112|NCT01143727|DRUG|Santyl|Apply one 24-hr period sufficient to cover the wound.
224063113|NCT01143727|DRUG|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
224148189|NCT05278676|DRUG|Dotinurad|Dotinurad oral tablet.
224148190|NCT01655238|OTHER|BMI|Screening guideline to assess body mass index.
224063114|NCT05884931|DEVICE|Nexpowder|Hemostatic powder for endoscopy after colonoscopy polypectomy
224063115|NCT05884931|PROCEDURE|Conventional Treatment|Standard hemostatic procedure
224063116|NCT03295162|DRUG|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
224063117|NCT03295162|COMBINATION_PRODUCT|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
224063118|NCT05062876|DRUG|AD-214|1 tablet administered before the breakfast during 7 days
224063119|NCT05062876|DRUG|AD-2141|1 tablet administered before the breakfast during 7 days
224148191|NCT06006442|BEHAVIORAL|Vaping|Subjects will be smoking the vapnig products that they admitted to using at baseline in the personal life prior to this study
223454099|NCT07022652|PROCEDURE|Esophageal cancer resection|Esophageal cancer resection
223454100|NCT07021677|DRUG|Daratumumab Injection|"Patients will receive intravenous daratumumab (16mg/kg per dose) once weekly for 2 doses. After 2 doses, they will undergo bone marrow examination for flow-cytometric MRD. Those who become MRD negative (less than 0.01% by flow-cytometry), will be off-study and continued on conventional treatment regimen as per institution policy. Hence, total duration in those who become MRD negative will be 3 weeks.~However, those who are still MRD positive (more than or equal to 0.01% by flowcytometry) after two doses, will be given two additional once weekly doses of intravenous daratumumab (16mg/kg per dose). In patients who receive two additional doses, bone marrow aspirate for MRD analysis will be done 7 days after fourth dose of daratumumab. Irrespective of MRD result after fourth dose, patients will be continued on conventional treatment regimen"
223454101|NCT07022834|DRUG|Dabrafenib or Trametinib and Clofarabine|"Drug: Dabrafenib or Trametinib Dabrafenib: 3-5 mg/kg/day; Trametinib: 0.025mg/kg/day~Drug: Clofarabine Consolidation therapy: 25 mg/m2/d, days 1-5 Maintenance therapy: 25 mg/m2/d, days 1-2"
223571482|NCT05482620|PROCEDURE|Nordic walking program|Nordic walking program will consist of three training sessions per week, during eight weeks. Each session will last approximately 60 minutes, including warm-up, the intervention itself and cool-down. Intervention will consist in a 30 minutes Nordic walking, working at 70-85% of maximal heart rate, measured with a Polar pulsometer. Intervention will be delivered in groups (six patients per group as maximum), in designed circuits placed in A Coruña city.
223571483|NCT05482620|PROCEDURE|Educational sessions and usual care|Educational sessions will consist in three classes, about 60 minutes each. In these classes, participants will learn about their pulmonary system, asthma disease, asthma diagnosis, asthma classification, asthma exacerbations and triggers, types of medications, how to take inhalers, how to measure PEF (peak expiratory flow), how to control the environment in order to prevent exacerbations, healthy-lifestyle recommendations and the importance of an active lifestyle, what to do in case of asthma emergency, and how to do required data from patients to note in their Patient's Diary (one of the evaluation tools). Usual care implies following the current therapeutic plan and revisions planned by their specialist/GP.
223571484|NCT02663466|PROCEDURE|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
223571485|NCT03575117|BEHAVIORAL|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
223571486|NCT03575117|BEHAVIORAL|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
223571487|NCT03575117|BEHAVIORAL|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
223571488|NCT01933230|DEVICE|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
223571489|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 lozenges|In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223571490|NCT05375396|DIETARY_SUPPLEMENT|Streptococcus salivarius M18 dairy free lozenges|In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
223571491|NCT02338895|DEVICE|Ultrasound|Ultrasound of inferior vena cava and kidneys
224148192|NCT01305304|OTHER|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
223454102|NCT07022587|DEVICE|Sirolimus-eluting bioresorbable scaffolds|The Firesorb BRS (MicroPort Medical, Shanghai, China) is a balloon-expandable scaffold with a highly crystallized PLLA backbone, abluminally coated with a poly(D, L-lactide) (PDLLA) matrix incorporating sirolimus (4 μg/mm) through highly accurate and precise point spraying techniques. The scaffold thickness is 100 μm for devices with diameters of 2.5 and 2.75 mm, and 125 μm for those ranging from 3.0 to 4.0 mm in diameter. There are two radiopaque markers at each end of the scaffold, which can identify the position of the stent under X-ray monitoring and help to accurately locate the scaffold.
223454103|NCT07022587|DEVICE|Sirolimus-eluting stents|The Firehawk™ stent (MicroPort Medical, Shanghai, China) is a third-generation balloon-expandable L605 cobalt chromium stent with abluminal grooves containing a biodegradable polymer, which provides controlled release of the anti-proliferative medicinal substance sirolimus. The polymer is biodegradable, leaving only the metallic stent as a permanent implant. The stent is mounted on a rapid exchange delivery catheter system. The unique abluminal grooves are scored at the outer surface of the struts (total strut thickness: 86 μm), with an average sirolimus dosage of 3 µg/mm stent lengths.
223454104|NCT07022496|DRUG|Caffeine (200 mg)|caffeine tablets
223454105|NCT07022496|DRUG|triptans|Sumatriptan
223454106|NCT07022496|DRUG|NSAID (Nonsteroidal anti-inflammatory drugs)|Aspirin 250 mg, 81 mg, 75 mg
224148193|NCT01305304|OTHER|Other|No history of endurance sports activity
224148194|NCT05064332|DRUG|PF-06650833|400 mg by mouth (PO) Once daily (QD) for 11 days
224148195|NCT05064332|DRUG|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
224063120|NCT04719143|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Subjects receive 6-8 CBT-I sessions in an individual format.
224063121|NCT05412056|DRUG|Metformin|as in arm/group description
224148196|NCT02625987|PROCEDURE|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
224148197|NCT02625987|PROCEDURE|Separated stitches|Appendectomy wound closure with a separated stitches.
224148198|NCT01672528|OTHER|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
224063122|NCT05412056|DRUG|Placebo oral tablet|as in arm/group description
224063123|NCT02898532|BEHAVIORAL|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
224063124|NCT04141384|DEVICE|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
224063125|NCT06387407|DRUG|Dabigatran Etexilate 150mg|Oral dabigatran etexilate capsules, 150 mg twice a day.
224063126|NCT05169151|OTHER|Smartphone Application|Utilize smartphone application
224063127|NCT02132481|OTHER|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
224063128|NCT02132481|OTHER|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
224148199|NCT01672528|OTHER|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
223571492|NCT01643252|DRUG|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
224063129|NCT02132481|OTHER|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
224063130|NCT02132481|OTHER|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
224063131|NCT03473574|BIOLOGICAL|Durvalumab|immune checkpoint inhibitor
224063132|NCT03473574|DRUG|Gemcitabine|standard chemotherapy
224148200|NCT00372034|DEVICE|Temporary Collagen Inserts|
224148201|NCT04073628|DEVICE|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
224148202|NCT05890313|DIAGNOSTIC_TEST|Mini Mental State Examination|MMSE is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is of three to four years of schooling. It is validated in the general Portuguese population and can discriminate normal cognition from dementia.
224148203|NCT05890313|DIAGNOSTIC_TEST|Montreal Cognitive Assessment|MoCA is a clinically validated cognitive test, broadly used in healthcare and scientific settings, and it is administered to individuals with cognitive complaints suspected of cognitive decline whose educational literacy is, at least, of four years of schooling. It is validated in general Portuguese population and can discriminate MCI from dementia.
224063133|NCT03473574|DRUG|Cisplatin|standard chemotherapy
224063134|NCT03473574|BIOLOGICAL|Tremelimumab|immune checkpoint inhibitor
224063135|NCT02488369|DEVICE|PET / CT|
224301579|NCT00678041|DRUG|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
224301580|NCT00678041|DRUG|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
223454107|NCT07022496|DRUG|Paracetamol (acetaminophen)|Paracetamol 250 mg
223454108|NCT07023263|DEVICE|Schnider+ Mİnto|Patients assigned to the Standart TCI model Group would have Schnider + Minto models throughout the surgery. The patients would be monitorized with anesthesia depth, analgesia monitoring, NIRS, and recovery parameters.
223454109|NCT07023263|DEVICE|Eleveld|Patients assigned to the Eleveld TCI model Group would have Eleveld+Eleveld models throughout the surgery. The patients would be monitorized with anesthesia depth, analgesia monitoring, NIRS, and recovery parameters.
223454110|NCT07021716|OTHER|No Interventions|No Interventions
223454111|NCT07021599|DIAGNOSTIC_TEST|Tailored AI echocardiogram analysis and reporting system|In the AI analysis and reporting pathway, sonographers only need to acquire the echocardiogram images, then the AI algorithm will complete the analysis and report drafting for final endorsement by experienced cardiologists. To ensure blinding of group assignment to the endorsing experienced cardiologists, measurement format and reporting phrases and interface used by AI and sonographers will be standardized.
224063136|NCT04936360|OTHER|questionnaires for clinical assessments|questionnaires for clinical assessments
224063137|NCT06403527|OTHER|Ultrasound guided venous access during AF ablation|Ultrasound guided venous access during AF ablation
224063138|NCT03707600|DEVICE|TMS|MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.
224063139|NCT00621478|DRUG|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
224063140|NCT04894500|DIAGNOSTIC_TEST|Flow fluorescence cytometry|Level of inflammatory markers in body fluid samples
224063141|NCT06248281|OTHER|combination of different rehabilitation strategies|"The psychoeducational program will be conducted through weekly online video-conferencing group sessions that will last for two hours. In addition to these sessions, participants will receive psychoeducational material such as readings, videos, podcasts, worksheets, and homework exercises every week. This material will allow participants to practice at their own pace during the session intervals.~The exercise training program for individuals with MS will be tailored to meet the unique and individual needs of each participant. To achieve this, a head and neck cooling protocol will be implemented using commercially available cooling equipment, specifically the Headcool Power and Neckcool Tie from Inuteq. Participants will need to wear the cooling cup and neck wrap for two hours daily. The equipment will be activated using 10°C tap water. Finally, a nutritionist will provide personalized nutritional guidance including weekly diet observation and recipe videos."
224063142|NCT03412656|DEVICE|SoftHand Pro with CUFF force feedback device|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
224063143|NCT01806779|DRUG|Chantix|
224063144|NCT01806779|DRUG|Zyban|
224063145|NCT01806779|DRUG|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
224063146|NCT01779024|DRUG|Ghrelin|
224063147|NCT01779024|DRUG|Placebo|
224063148|NCT01779024|PROCEDURE|fMRI|
224148204|NCT05890313|DEVICE|Brain on Track (version BOT.0.0.0 03.03.2023)|Brain on Track is a class I web-based software medical device, accessible on most platforms, including desktops and laptops. It is designed to allow periodic self-administered cognitive tests to be performed, enabling a cognitive assessment and continuous monitoring of the cognitive state of the patient remotely. It is based on the classic tests of neuropsychological assessment and allows assessing the main areas of cognition through a test lasting approximately 22 minutes. The stimuli that integrate each subtest are randomized between sessions, which reduces the effect of learning and allows the accomplishment of serial assessments.The test is available in three versions, adapted to different levels of schooling: 1-4 years, 5-9 years and 10+ years. The performance in each test is compared with normative population data and performance over time. For each test performed, Brain on Track presents a cumulative risk score for the presence of cognitive impairment.
224148205|NCT05997017|DRUG|nab-sirolimus|Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
223571493|NCT01643252|DRUG|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
223571494|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
223571495|NCT01741324|DIETARY_SUPPLEMENT|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
223571496|NCT01741324|DIETARY_SUPPLEMENT|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
223571497|NCT05837403|PROCEDURE|Platelet rich plasma injection|venous blood drown from the patient, centrifugation and separation of platelet rich plasma, injection under fissure and edges base.
223571498|NCT05837403|DRUG|Nitroglycerin ointment|application of the ointment twice daily
223571499|NCT06425939|OTHER|Force plate assessment|On Day 1, Day 45 and Day 90: 3x drop jumps, 2 min rest, 3x counter movement jumps, 2 min rest, 3x dynamic push-ups
224148206|NCT05640856|PROCEDURE|intubation|Endotracheal tube placement
224148207|NCT01790009|DIETARY_SUPPLEMENT|Flavanol rich drink|
224148208|NCT01790009|DRUG|Acetaminophen|2x500 mg Acetaminophen
224148209|NCT06396572|PROCEDURE|IVR-Procedure|Using immersive virtual reality to learn urinary catheterisation procedure
223571500|NCT06425939|DEVICE|Whoop wrist band|Whoop wrist worn activity tracker (not a medical device) collects continuous data via smartphone app. This is a marketed device. This is not a device study.
224148210|NCT06396572|PROCEDURE|Nursing Clinical Laboratory practice|Using nursing clinical laboratory sessions to learn urinary catheterisation procedure
223571501|NCT02154100|DIETARY_SUPPLEMENT|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
223571502|NCT02154100|DIETARY_SUPPLEMENT|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
224063149|NCT01779024|DRUG|Alcohol|
224063150|NCT02595450|DRUG|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
223571503|NCT05058573|OTHER|Control group (n=22)|Control group will be received only medical treatment
223571504|NCT02482194|BIOLOGICAL|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
223571505|NCT05292209|DRUG|Riluzole 50 MG|Riluzole 50mg tablets
223571506|NCT06324422|OTHER|Aerobic exercise intervention|Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
224063151|NCT00391573|PROCEDURE|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
224063152|NCT00391573|PROCEDURE|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
224063153|NCT02613390|PROCEDURE|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
224063154|NCT02613390|BEHAVIORAL|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
224063155|NCT02330978|PROCEDURE|Intravitreal transplantation of mesenchymal stem cell|
223454112|NCT07022795|BEHAVIORAL|Educational video combined with daily surveys|Participants will receive the same educational intervention as those in the other arm and will also undergo an ecological momentary assessment (EMA) intervention. This will involve receiving multiple messages per day on their mobile phones, each linking to an online survey designed to capture real-time data on their current oral behaviors. The intervention aims to increase participants' awareness of these behaviors by prompting them to reflect on and report them throughout the day.
223454113|NCT07022795|BEHAVIORAL|Educational video only|"Participants will be provided with an educational video on recognizing and managing oral behaviors such as clenching, prolonged tooth contact, and keeping the jaw tense, etc.~The goal is to increase awareness and promote behavior change to reduce strain to the masticatory muscles and the temporomandibular joint."
223454114|NCT07023250|OTHER|manual dexterity and coordination skills|"The outcomes were assessed by the use of Bruininks-Oseretsky Test scale of motor proficiency (BOT-2) subtests (3,4\&7) for Manual Dexterity, Bilateral Coordination and Upper Limb Coordination respectively. The Bruininks-Oseretsky Examination of Motor Proficiency, Second Edition, evaluates motor performance in various areas such as Manual Dexterity, Bilateral Coordination and Upper Limb Coordination.~It utilizes subtests and complex structures to diagnose developmental and coordination issues among individuals aged four to twenty-one years old. The test is norm-referenced and purpose-oriented to assess motor abilities. The reliability and validity of the test were 0.78 and 0.84, respectively (Kosari et al., 2013; Ebrahimi et al., 2017; Yassin et al., 2020)."
223454115|NCT06698471|OTHER|Community worker training|Training community workers in Self Help Plus intervention, a 5 session self-help intervention based on Acceptance and Commitment Therapy
223454116|NCT06698471|OTHER|Referral to Health System|Referral to Health System of Senegal
223454117|NCT03013413|PROCEDURE|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
223454118|NCT03013413|PROCEDURE|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
223454119|NCT03013413|PROCEDURE|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
223454120|NCT06877650|DRUG|JMT108|Intravenous (IV) administration every two weeks (D1, D15) in a 4-week cycle.
223571507|NCT06324422|OTHER|Resistance exercise intervention|Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
223571508|NCT02480491|OTHER|measuring cell freeDNA|measuring cell free DNA using PCR
223571509|NCT04669938|OTHER|oropharyngeal and intestinal microbiota|analysis of oropharyngeal and intestinal microbiota
223571510|NCT04669938|OTHER|host genotype|analysis of a part of host genotype
223571511|NCT04669938|OTHER|host immune factors|analysis of host immune factors
223571512|NCT04669938|OTHER|viral sequence|analysis of viral sequence
223571513|NCT03350087|DEVICE|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
223571514|NCT03350087|DEVICE|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
223571515|NCT03350087|DEVICE|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
223571516|NCT03350087|DEVICE|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
223454121|NCT06880874|DRUG|Enlicitide|Oral Tablet
224063156|NCT02330978|BIOLOGICAL|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
224063157|NCT05110703|DIETARY_SUPPLEMENT|Supergut|Meal replacement shake
224063158|NCT05110703|DIETARY_SUPPLEMENT|Placebo|Placebo
224063159|NCT05110703|OTHER|Dietary guidelines|Dietary guidelines
224063160|NCT06474442|GENETIC|BD111 Injection (investigational new drug)|BD111: intrastromally injection, single-dosing 10E6 TU/eye, specified injection volume is 0.15mL.
224063161|NCT06474442|COMBINATION_PRODUCT|Triple-drugs therapy of HSV-1 stromal keratitis|"Triple-drugs therapy: Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops for 3 weeks."
224071062|NCT03760926|DEVICE|May Health Kit|The intervention consists in the realisation of the May Health Procedure using the May Health Kit, which comprises two elements: a disposable device (May Health Device) and a radiofrequency (RF) energy generator (May Health System). The May Health Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
224071063|NCT04672759|DRUG|Durvalumab|Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
224071064|NCT04672759|DRUG|Durvalumab|Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
224063162|NCT06978829|DRUG|TP + Cetuximab + Tislelizumab|"Conversion therapy stage:~TP regimen: Albumin-bound paclitaxel+Platinum (Cisplatin or Carboplatin) Albumin-bound paclitaxel: 100 mg/m² by IV infusion, D1/D8, every 3 weeks (Q3W) Platinum: Cisplatin 75 mg/m² by IV infusion or Carboplatin AUC=5 mg/mL/min Q3W Cetuximab: The initial dose is 400 mg/m² by IV infusion for 1 week. Subsequently followed by 250 mg/m² IV infusion, D1/D8, Q3W.~Tislelizumab: 200 mg by IV infusion, Q3W. 3 weeks/cycle, 3 cycles in total.~Patients who have completed conversion therapy undergo efficacy evaluation.~Radical therapy stage:~Evaluated as operable: Undergo surgery, followed by one cycle of adjuvant chemotherapy according to the preoperative regimen.~Evaluated as inoperable: Receive radical radiotherapy.~Maintenance therapy stage:~Tislelizumab for 1 year or until disease progression, intolerable toxicity, or patient refusal to continue treatment."
224063163|NCT06979349|OTHER|Physical Evaluations in Players|Respiratory muscle strength, respiratory muscle endurance, cough strength or balance will be evaluated in adolescent volleyball players.
224063164|NCT03180320|BEHAVIORAL|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies."
224063165|NCT03180320|DRUG|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
224063166|NCT06977542|DRUG|Ivonescimab|"a PD-1/ VEGF Bispecific Antibody, 20mg/kg, every 2 weeks;~Chemotherapy : paclitaxel and carboplatin, followed by epirubicin-cyclophosphamide"
224063167|NCT06978192|DRUG|dexmedetomidine nasal spray group|Experimental group: Long duration high voltage pulse RF therapy plus dexmedetomidine nasal spray group
224063168|NCT06978192|OTHER|long duration high voltage pulse RF therapy group|Experimental group: long duration high voltage pulse RF therapy group
224063169|NCT06977425|DRUG|Magnesium sulphate|Patients received an initial intravenous loading dose of 30 mg/kg of 10% magnesium sulfate solution over 10 min. This will be followed by a continuous infusion of (10mg/kg/hr) for the entire duration of surgery.
224063170|NCT06977425|DRUG|Dexmedetomidine|Patients received dexmedetomidine infusion 0.5 μg/kg over 10 min as a bolus dose, followed by 0.2 μg/kg/h all over the operation.
224063171|NCT06978036|PROCEDURE|Flapless periodontal regeneration with EMD + EASD|Periodontal regneration with EMD in conjuction with Endoscope-assisted subgingival debridement
224063172|NCT06978036|PROCEDURE|Periodontal regeneration with EMD + PPT|Periodontal regneration with EMD in conjunction with periodontal surgery using Papilla Presevation Technique
224063173|NCT06979258|OTHER|Cooling intervention|Infrastructure and/or equipment that cools the house in the hot season
224063174|NCT06978634|OTHER|SBAR training with cases|"The researcher will hold a face-to-face meeting with the students in the intervention group and provide information about the purpose of the study, the content of the training, the Student Guidelines for the SBAR Role Playing Application and the research process. Then, SBAR Training with Cases will be given. In addition, a group will be established via Whatsapp and communication during the process will be provided through this channel. The days and times of the training will be determined by looking at the students' course schedules. The training will be carried out in the Skills Laboratory of the Faculty of Health Sciences at Yüzüncü Yıl University."
224148211|NCT03601208|DIAGNOSTIC_TEST|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
224148212|NCT02447120|DEVICE|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
223454122|NCT06171594|COMBINATION_PRODUCT|Chlorhexidine mouthwash|The proposed study is part of a PhD educational project and will be a double blind, randomised design, crossover trial for the effect of Chlorhexidine (CHX) mouthwash on healthy control and people with dental erosion (PwDE). This study aims to explore mouthwash's effect on oral microbiome recovery in WMS and salivary pellicle and its impact on blood pressure and arterial stiffness in healthy controls PwDE
223454123|NCT05644977|DRUG|Emraclidine|Oral tablets
223454124|NCT05644977|DRUG|Placebo|Oral tablets
223454125|NCT06474273|DRUG|Methylprednisolone|IV Methylprednisolone
224301581|NCT02358343|BEHAVIORAL|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
223571517|NCT03350087|DEVICE|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
223571518|NCT03350087|DEVICE|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
223571519|NCT01588314|DRUG|Gabapentin|gabapentin 100 mg capsules
224148213|NCT06373276|OTHER|multiplanar balance training exercise with education|7 minute daily balance training exercises
223454126|NCT06474273|DRUG|Prednisone|Oral prednisone augmentation
223454127|NCT03207308|DIETARY_SUPPLEMENT|Vitamin A supplementation|200,000 IU of preformed vitamin A
223571520|NCT01588314|DRUG|placebo|compounded placebo capsules
224063175|NCT06978179|PROCEDURE|Ultrasound-Guided Quadratus Lumborum Block For Post-Operative Pain In Lower Abdominal Surgeries In Adult Patients|"Group ( 1 ) QLB Type III: Patients will receive QLB performedwith20ml of diluted bupivacaine 0.25% on each side."
224063176|NCT06978179|PROCEDURE|Ultrasound-Guided Transversus Abdominis Plane Block For Post-Operative Pain In Lower Abdominal Surgeries In Adult Patients|Group ( 2 ) TAP: Patients will receive TAP block performed with 20ml of diluted bupivacaine 0.25% on each side.
224148214|NCT06373276|BEHAVIORAL|education only|5 educational broshures
224063177|NCT06978985|DRUG|Risdiplam|Risdiplam
224063178|NCT06978985|DRUG|Nusinersen Injectable Product|Nusinersen
224063179|NCT04294901|BEHAVIORAL|Direct to patient medication brochure|An EMPOWER medication brochure, adapted to the VA, designed to educate and activate patients. These brochures provide detailed medication information, allow self-testing of indications for use, prompt reflection of experiences with potential side effects, discuss alternative therapies (medication and non-pharmacologic options), and provide a vignette of a patient who successfully stopped the medicine. They were designed for a 6th grade reading level and were based upon theories of patient activation, adult learning, and cognitive dissonance. The visually appealing brochure repeatedly emphasizes that patients should not make any medication changes without first consulting their health care providers.
224063180|NCT03501667|OTHER|Use of decision support tool|use of a decision support software during clinical assessment of a case
224063181|NCT03501667|OTHER|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
224063182|NCT03040375|BEHAVIORAL|Peer counselling|
223571521|NCT02313727|DRUG|Pamidronate|intravenous infusion of pamidronate 60 mg
223571522|NCT02313727|OTHER|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
223571523|NCT00446472|DRUG|Regranex®|Regranex gel will be used for a total of 16 weeks
223571524|NCT00446472|DRUG|Hydrogel|Placebo hydrogel will be applied for 16 weeks
223571525|NCT03164317|OTHER|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
223571526|NCT03164317|OTHER|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
223571527|NCT00793559|DRUG|terlipressin|1 mg of terlipressin one time only
223571528|NCT00793559|DRUG|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
223571529|NCT04210362|BEHAVIORAL|Workshops on responsive caregiving|Caregivers will receive monthly workshops about several dimensions of nurturing care, responsive caregiving and early child development. Workshops will be reinforced through home visits.
223571530|NCT03571802|DRUG|Simvastatin|"* The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~* There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
223571531|NCT03202355|DEVICE|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
223571532|NCT03202355|DEVICE|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
223571533|NCT01880749|DRUG|RAD001|
223571534|NCT00252694|DRUG|candesartan|32 mg oral tablet
223571535|NCT05526976|OTHER|PERISCOPE-care|Patients with planned elective surgery will be asked to complete the PERISCOP3E-Care questionnaire (modified-Althaus \& Kalkman, DN4, HADS, Stait-trait, NRS, MPI, EQ-5D-5L) preoperative. One month and three months post op the patients will be contacted to check if they developed persistend postoperative pain and they will also complete questionnaires (DN4, HADS, Stait-trait, NRS, MPI and EQ-5D-5L).
224063183|NCT02800889|DRUG|Pixantrone|Pixantrone
224063184|NCT02393638|OTHER|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
224063185|NCT02393638|OTHER|Lecture|Lecture
224063186|NCT06977347|DRUG|Piperacillin/Tazobactam|Piperacillin/tazobactam: 4.5g IV q6h (over 3h)
224063187|NCT06977347|DRUG|Piperacillin/tazobactam + Levofloxacin|"Piperacillin/tazobactam: 4.5g IV q6h (over 3h)~\+ Levofloxacin 750mg IV q24h (over 30min)"
224063188|NCT06977477|OTHER|Remote Monitoring for Congestion Management in HFpEF Patients|All patients will undergo baseline tests, including echocardiography (left ventricular ejection fraction, E/e', left atrial volume index, left atrial strain analysis, left ventricular mass index, tricuspid annular plane systolic excursion, right ventricular strain, inferior vena cava index) and blood tests (NT-proBNP, creatinine, GFR, sST2, CA 125, bio-ADM, ALAT, ASAT, complete blood count, and hsCRP). Evaluation of extracellular and total body water volumes in the arms, legs, and trunk will be conducted using the Body Water Scale InBody (South Korea) and daily monitoring of pulmonary pressure through CardioMEMSTM. Bioelectrical impedance analysis (BIA) will be used to assess volume. Additional blood tests will be conducted at weeks 2, 6, 12, and at the final visit, with a focus on NT-proBNP, creatinine, GFR, ALAT, ASAT, hemoglobin, hematocrit, hsCRP, sST2, CA 125, and bio-ADM. At the final visit, a complete set of tests will be repeated to assess overall health and response to the int
223571536|NCT01395121|DRUG|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
223571537|NCT05346965|BEHAVIORAL|Musical training|The musical training intervention comprised songs, rhythm and visual creativity to encourage the children to experience music-making as fun.
223571538|NCT05985213|OTHER|data collection and follow-up|"Main measures and data collection methods:~1. Recording of baseline demographic and clinical information of the participants.~2. Multimodal magnetic resonance imaging~3. blood pressure variability.~4. neuropsychological testing~5. Blood samples collection"
223571539|NCT00831610|PROCEDURE|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
224063189|NCT06978153|DRUG|benmelstobart combined with chemotherapy and anlotinib|Cohort 1: Neoadjuvant therapy (benmelstobart combined with chemotherapy and anlotinib, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day 1. Anlotinib, 10 mg, po, qd, was taken orally for 2 consecutive weeks and stopped for 1 week. Anlotinib was stopped 1 week before surgery. Etoposide, 100mg/m2, day 1\~3. Cisplatin, 75mg/m2，day 1; or Carboplatin, AUC 5, day 1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Patients who achieved R0 resection received adjuvant therapy (benmelstobart combined with anlotinib, 12 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; anlotinib, 10 mg, po, qd, was taken orally for 2 weeks and stopped for 1 week.
224071065|NCT06117319|OTHER|Individual assistance Virtual reality training sessions|5 virtual reality training sessions where feedback will be provided to each individual by the research team
224063190|NCT06978153|DRUG|benmelstobart combined with chemotherapy|Cohort 2: Neoadjuvant therapy (benmelstobart combined with chemotherapy, 3 cycles, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1; Etoposide, 100mg/m2, day 1\~3; Cisplatin, 75mg/m2，day 1; or Carboplatin, AUC 5, day 1. Surgery was performed 4-6 weeks after the final administration of benmelstobart as assessed by the investigator. Adjuvant therapy was evaluated by the investigator 4-6 weeks after surgery. Patients who achieved R0 resection received adjuvant therapy (benmelstobart, every 21 days is a cycle) : benmelstobart, 1200mg, iv, day1.
224063191|NCT06977750|DRUG|succinylated gelatin electrolyte sodium acetate injection 1|Nanjing Chia-Tai Tianqing Pharmaceutical Company
224063192|NCT06977750|DRUG|succinylated gelatin electrolyte sodium acetate injection|Gelaspan
224063193|NCT03092102|DRUG|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
224063194|NCT00349856|DEVICE|Biofinity|Soft contact lens
224063195|NCT03100045|DRUG|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
224063196|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 1|Soft gel capsule
224063197|NCT06665464|DIETARY_SUPPLEMENT|Fish oil supplement 2|Soft gel chewable
224063198|NCT01934556|DRUG|Ranibizumab 0.3 mg intravitreal injection|
224063199|NCT01934556|DEVICE|Guided Laser Photocoagulation|
224063200|NCT02284126|DRUG|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
224063201|NCT02813551|DRUG|Torsemide|
224063202|NCT02813551|DRUG|Placebo|
224063203|NCT04375787|DRUG|Atorvastatin|Patients received 80 mg atorvastatin before elective coronary angiography
224063204|NCT06141369|BIOLOGICAL|individualized mRNA neoantigen vaccine (mRNA-0523-L001)|Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
224063205|NCT06862557|DEVICE|ECHS AD Device|Pulsed electromagnetic therapy device
224063206|NCT06659042|DRUG|Tislelizumab|administered via Intravenous (IV) injection
224063207|NCT06659042|DRUG|Cisplatin|administered via IV infusion
224063208|NCT06659042|DRUG|Carboplatin|administered via IV infusion
224063209|NCT06659042|DRUG|Pemetrexed Disodium|administered via IV infusion
224063210|NCT05039632|OTHER|Hafnium Oxide-containing Nanoparticles NBTXR3|Given intratumorally
224301582|NCT02358343|BEHAVIORAL|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
224063211|NCT05039632|RADIATION|Radiation Therapy|Undergo Abscopal radiation therapy
224063212|NCT05039632|RADIATION|Radiation Therapy|Undergo RadScopal radiation therapy
224063213|NCT04478292|DRUG|Sodium Thiosulfate Injection|Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
224063214|NCT04478292|PROCEDURE|Primary surgery resection|Resection of the primary tumor up-front
224063215|NCT04478292|DRUG|mono CDDP-Group A2|Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
224063216|NCT04478292|DRUG|Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C|All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
224063217|NCT04478292|PROCEDURE|Biopsy|Tumors are deemed unresectable at diagnosis.
224063218|NCT04478292|PROCEDURE|Resection or transplant|Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
224063219|NCT04478292|PROCEDURE|Resection of pulmonary nodules|Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
224063220|NCT04478292|DRUG|mono CDDP- Group B|Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
224063221|NCT04478292|DRUG|Block 1 to 3 (Cisplatin, Doxorubicin) Group D|Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
224063222|NCT04478292|DRUG|Consolidation (Carboplatin, Doxorubicin) -Group D1|Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
224063223|NCT04478292|DRUG|Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2|"Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;"
224063224|NCT06338553|DRUG|Semaglutide (Rybelsus®)|7 mg single dose of Rybelsus® by mouth once before each MMTT
224063225|NCT06338553|DRUG|Placebo|placebo capsule or tablet once before each MMTT.
224063226|NCT03845712|DRUG|doxecitine and doxribtimine|Doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart. Doxecitine and doxribtimine is administered with food.
224063227|NCT07004894|PROCEDURE|Neuromuscular re-education(experimental)|"All participants will receive 4weeks of intervention with a frequency of 2-3 days/week with a period of rest in between. 5 minutes of ultrasound will be given followed by neuromuscular reeducation technique (5-10 minutes duration) which includes for the 1st two weeks; cross friction massage with active movement and for the last two weeks longitudinal friction massage with active movement will be performed and strengthening protocol will be given.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
224063228|NCT07004894|PROCEDURE|Friction massage(standard protocol)|"All participants will receive 4weeks of intervention with a frequency of 2-3 days/week with a period of rest in between. 5 minutes of ultrasound will be given followed by friction massage technique(5-10 minutes duration) which includes for the 1st two weeks; cross friction massage alone and for the last two weeks longitudinal friction massage alone will be performed and strengthening protocol will be given.~The exercise protocol will be taught to the patient by an experienced physiotherapist and supervised on the subsequent sessions. The protocol will be gradually progressed as per the patient's tolerance."
224063229|NCT02450175|DRUG|Everolimus|10 mg of Everolimus daily (by mouth)
224148215|NCT04657653|PROCEDURE|core decompression|:The procedure was performed under general anesthesia with the aid of image intensifier. All patients were positioned in supine position on a fracture table. The core decompression was performed using the direct lateral approach with 2 cm skin incision. A fluoroscope guided large single drill with 8 mm diameter over a guide wire was used to remove the necrotic tissues from the femur head through the lateral cortex distal to trochanteric tubercle. After the removal of the core necrotic bone, the track was filled with 5 ml synthetic bone paste substitute (tricalcium phosphate) and an intraoperative fluoroscope was used to confirm the adequacy of the decompression and grafting.
224148216|NCT06082869|DRUG|Protegera™ toothpaste (NaF)|Plaque Reduction
224148217|NCT06082869|DRUG|Crest™ Cavity Protection toothpaste (NaF)|Plaque Reduction
224063230|NCT02450175|DRUG|Letrozole|2.5mg taken daily (by mouth)
224148218|NCT05698043|DRUG|CKD-386(5)|Test
224148219|NCT05698043|DRUG|D013, D326, D337|Reference
224148220|NCT06712147|BEHAVIORAL|Overcoming Life's Hurdles: Mental health education|The intervention group will cover educational topics around mental health including: mental health literacy, individual coping skills, stigma reduction strategies, resources for mental health support, and mental health rights.
224148221|NCT06712147|BEHAVIORAL|Overcoming Life's Hurdles: Resources in the community|The control group will cover topics including: mental health resources in the community, violence (i.e. domestic violence), employment and education opportunities, housing and tenant rights, immigration and acculturation, and community team building and empowerment.
224148222|NCT01862432|OTHER|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
224148223|NCT02994381|DRUG|RPC1063|
224148224|NCT07044310|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224148225|NCT07044310|PROCEDURE|Bone Mineral Density Test|Undergo BMD
224148226|NCT07044310|OTHER|Questionnaire Administration|Ancillary studies
223571540|NCT00831610|PROCEDURE|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
223571541|NCT06223256|DRUG|NBL-028|Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
223571542|NCT01157325|PROCEDURE|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
223571543|NCT01157325|PROCEDURE|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
224063231|NCT06869265|DRUG|Thiotepa ;busulfan;fludarabine|Eligible patients will receive the following conditioning regimen: thiotepa 5 mg/kg/day on Days -10 to -9; busulfan 3.2 mg/kg/day on Days -8 to -6; fludarabine 30 mg/m²/day on Days -6 to -2; and rabbit anti-thymocyte globulin (rATG) 1.5-2.5 mg/kg/day on Days -5 to -2. Hematopoietic stem cell infusion will be performed on Day 0. Graft-versus-host disease (GVHD) prophylaxis will include cyclosporine A (CsA), mycophenolate mofetil (MMF), and methotrexate (MTX).
224063232|NCT05106309|DRUG|10 mg CVL-231 as IR formulation|Tablets
224063233|NCT05106309|DRUG|30 mg CVL-231 as slow-release MR formulation|Capsules
224063234|NCT05106309|DRUG|30 mg CVL-231 as medium release MR formulation|Capsules
224063235|NCT05106309|DRUG|30 mg CVL-231 as fast release MR formulation|Capsules
224063236|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fasted|Capsules
224063237|NCT05106309|DRUG|30 mg CVL-231 Target Release, Fed|Capsules
224063238|NCT05622344|BEHAVIORAL|Traditional Therapy|Exercises that teaches subjects to move their heads while viewing still or moving targets.
224063239|NCT05622344|DEVICE|SWAN|The SWAN device uses video-oculography to monitor head motion while guiding participants to move their head in yaw, pitch, roll planes for 15 minutes. Feedback is provided regarding frequency and plane of head rotation
224148227|NCT07044310|DRUG|WBF-038|Given WBF-038 PO
224148228|NCT05783453|OTHER|Cosmetic study|"LIPIKAR BAUME LIGHT AP+M~* Formula: 2039055 06~* Aspect: Emulsion~* Batch nº: RAUO0063~* Expiry date: 10/2022~* Application area: Face and Body~* Application mode: Apply to face and body twice a day.~* Quantity of product to be applied: About 1 flask (400g) per month"
224148229|NCT04430283|DRUG|FDY-5301|FDY-5301 is Sodium Iodide administered as an isotonic solution for intravenous injection with a concentration of 7.2 mg/ml.
224148230|NCT04430283|OTHER|Placebo|Placebo is delivered as a single dose, non-reserved liquid parenteral consisting of a formulation matched compendial saline.
224148231|NCT05632224|DRUG|Aprepitant|The drug is given 1 hour before the start of the surgery
224148232|NCT05632224|DRUG|Granisetron|The drug is given 10 minutes before the patients's extubation
224148233|NCT02915952|DEVICE|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
223742626|NCT06449469|DRUG|Acetylsalicylic acid|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
223742627|NCT06449469|DRUG|Clopidogrel|Antiplatelets decrease platelet aggregation and inhibit thrombus formation. In NOTION-4 acetylsalicylic acid (75 mg once a day) is used as first line choice. For participants who are allergic to acetylsalicylic acid, clopidogrel (75 mg once a day) will be used. If the patient has already been prescribed Clopidogrel before the aortic valve intervention e.g. due to apoplexia, the patient will continue this medication following the procedure as an antiplatelet treatment, which is administered according to current guidelines.
224148234|NCT02915952|OTHER|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
223742628|NCT06449469|DRUG|Edoxaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
223742629|NCT06449469|DRUG|Dabigatran|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
223742630|NCT06449469|DRUG|Apixaban|Direct oral anticoagulants (DOAC) treatment will encompass any of the approved drugs: Rivaroxaban, Edoxaban, Dabigatranetexilat, and Apixaban (Table 1). The DOAC dosage will be adjusted according to kidney function (Table 1) and may be adjusted during the study period according to potential changes in guideline recommendations or if new-onset AF would occur in the follow-up period. The specific DOAC prescribed will be determined by the treating physician. If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
223454128|NCT07023237|PROCEDURE|pulsed field ablation|"Pulsed electric fields refer to the generation of high-voltage electric fields with pulse widths ranging from milliseconds to microseconds or even nanoseconds. These fields release extremely high energy in a very short time, creating a large number of irreversible micropores in the cell membrane and even intracellular organelles such as the endoplasmic reticulum, mitochondria, and nucleus. This ultimately leads to apoptosis of the diseased cells, achieving the desired therapeutic effect.~By inserting a pulsed ablation catheter into the patient's body and reaching the target lesion, the pulsed energy is delivered to the ablation catheter via a cardiac pulsed field ablation device, thereby achieving the therapeutic goal of pulsed field ablation."
224063240|NCT06872437|DRUG|Lidocaine Injectable Solution|Infiltration by injections of 6mL of lidocaine (10 mg/mL) per injection site (left ischioanal fossa, right ischioanal fossa right ischioanal fossa, coccyx),
224063241|NCT06872437|DRUG|Saline Solution for Block|Infiltration by injections of 6mL of saline solution per injection site (left ischio-anal fossa, right ischio-anal fossa right ischio-anal fossa, coccyx)
224063242|NCT03471065|DEVICE|SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV|Patients will be implanted with the SAPIEN 3 Ultra THV (20, 23 and 26 mm) or SAPIEN 3 THV (29 mm) using the SAPIEN 3 Ultra Delivery System.
224063243|NCT06112067|DEVICE|deep brain stimulation|DBS electrodes will be implanted into the ALIC and the NAcc, electric stimulation of those areas are used to treat mental disorders and to evaluate the efficacy and safety of DBS system.
224063244|NCT06695429|DIETARY_SUPPLEMENT|Beetroot juice|Supplementation with 500 mL of beetroot juice daily in 2 doses of 250 mL, for 7 days, or until hospital discharge, and a recommendation to maintain a diet rich in vegetables with high nitrate content after discharge.
224063245|NCT06869499|PROCEDURE|Blood sampling for dosage|4ml blood sample to measure acid sphingomyelinase enzyme activity and LysoSM, if required.
224063246|NCT05038020|DRUG|AKST4290|Oral AKST4290
224063247|NCT05038020|DRUG|Placebo|Oral Placebo
224063248|NCT06698939|DRUG|ORKA-001|ORKA-001 is supplied as sterile solution to be administered by SC injection
224063249|NCT06698939|OTHER|Placebo|Placebo solution to be administered at a matching volume by SC injection
224063250|NCT07028879|PROCEDURE|Fatigue management program|Combination of Occupational Therapy and Physiotherapy strategies and sessions.
224063251|NCT07029269|PROCEDURE|ERAS-tubeless group|Nasogastric decompression tube is not placed preoperatively; If necessary, nasogastric decompression tube is placed after anesthesia induction during surgery and removed when the reconstruction is performed; No abdominal drainage and nasojejunal feeding tubes were placed intraoperatively; None of these 3 tubes were present postoperatively.
224071066|NCT06117319|OTHER|Collective assistance Virtual reality training sessions|4 virtual reality training sessions where feedback will be provided to the whole group by the research team and 1 session where feedback will be individual. No participant was ever assigned to this intervention.
224071067|NCT00252057|BEHAVIORAL|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
224071068|NCT05648435|DIAGNOSTIC_TEST|Lithium measures|Measurements of lithium levels in blood and urine
224148235|NCT01096043|DRUG|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
224071069|NCT03248401|DRUG|Cilostazol|Cilostazol 200 mg/day
224071070|NCT03248401|DRUG|Aspirin|Aspirin 100 mg/day
223742631|NCT06449469|DRUG|Warfarin|If the patient has already been prescribed Marevan before the aortic valve intervention, the patient will continue this medication following the procedure as an oral anticoagulant treatment, which is administered according to current guidelines.
223742632|NCT03992729|DRUG|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
223742633|NCT03992729|DRUG|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
223742634|NCT05924802|DIETARY_SUPPLEMENT|Ketone Ester|Added to water or lemonade 3 times per day.
223742635|NCT05924802|DIETARY_SUPPLEMENT|Placebo|Added to water or lemonade 3 times per day.
223742636|NCT05363774|DRUG|NNC0519-0130|"SAD part: Participants will receive up to six dose levels of subcutaneous NNC0519-0130 in a sequential manner with the dose increasing between cohorts.~MAD part: The participants in first cohort will receive NNC0519-0130 subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive NNC0519-0130 up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive NNC0519-0130 up to 6 dose levels."
223742637|NCT05363774|DRUG|Placebo (NNC0519-0130)|"SAD part: Participants will receive up to six dose levels of subcutaneous placebo (NNC0519-0130) in a sequential manner with the dose increasing between cohorts.~MAD part: Participants in first cohort will receive placebo (NNC0519-0130) subcutaneously up to 5 dose levels, and the participants in the second MAD cohort will receive NNC0519-0130 orally up to 4 dose levels.~T2D part: Participants will receive placebo (NNC0519-0130) up to two dose levels with dose escalation within the cohort.~MAD QW part: Participants will receive Placebo up to 6 dose levels."
223742638|NCT05450692|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
223742639|NCT05450692|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion.
224148236|NCT01096043|DRUG|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
224148237|NCT01096043|DRUG|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
223454129|NCT06736899|DEVICE|Orbital Atherectomy System Treatment|Percutaneous coronary intervention of a calcified bifurcation coronary lesion with balloon angioplasty followed by drug eluting stent. Selection of balloon type is at operator´s discretion. Baseline and post dilation OCT will be performed.
223454130|NCT06736899|DEVICE|Balloon System Treatment|Percutaneous coronary intervention of a calcified bifurcation coronary lesion with Orbital Atherectomy followed by drug eluting stent. Baseline and post dilation OCT will be performed.
223454131|NCT00399295|DRUG|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
223454132|NCT06730984|OTHER|Endoscopy-Assisted Tracheal Intubation|Tracheal Intubation Under Endoscopic Guidance
223454133|NCT06730984|OTHER|Traditional Tracheal Intubation|Tracheal Intubation Under Video Laryngoscopy
223454134|NCT00980655|BIOLOGICAL|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
223454135|NCT00980655|BIOLOGICAL|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
223454136|NCT05861206|OTHER|GT-MW group (5% Green tea), WT-MW group (5% White tea),EO-MW group (Listerine mouthrinse)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (5% Green tea, 5% White tea or Listerine mouthrinse) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
223571544|NCT05783921|DRUG|TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"TQB2618 injection is an Anti TIM-3 (T-cell immunoglobulin and mucin domain-3) monoclonal antibody.~Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
223571545|NCT05783921|DRUG|Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin|"Penpulimab injection is a humanized Monoclonal Antibody target Programmed Cell Death Protein 1 (PD-1).~Paclitaxel is a anti-microtubule drug, which promotes tubulin polymerization, inhibits depolymerization, maintains tubulin stability and inhibits cell mitosis.~Cisplatin inhibits DNA synthesis by generating in-strand interstrand crosslinking with DNA. Protein and RNA synthesis can also be inhibited.~Carboplatin is a cyclic nonspecific antitumor agents that cause cross-linking between DNA strands and affect their synthesis to inhibit cancer cells."
223571546|NCT00221715|DEVICE|femoropopliteal artery bypass|Bypass by autologous saphenous vein
223571547|NCT00221715|DEVICE|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
223571548|NCT00434083|DRUG|sumatriptan|
223571549|NCT00434083|DRUG|naproxen sodium|
223571550|NCT05146713|DIETARY_SUPPLEMENT|Propolis nanoparticles extract solution|20 mg/ml propolis nanoparticles in the form of solution prepared from honeybee from various plants.
223571551|NCT05146713|DRUG|sodium hypochlorite|2.5% sodium hypochlorite (household bleaching agent)
223742640|NCT05450692|DRUG|Docetaxel|Participants will received docetaxel as an intravenous infusion.
223742641|NCT05612581|DRUG|VIR-3434|VIR-3434 given by subcutaneous injection
223742642|NCT05612581|DRUG|VIR-2218|VIR-2218 given by subcutaneous injection
223742643|NCT05612581|DRUG|TDF|TDF given orally
223742644|NCT05612581|DRUG|PEG-IFNα|PEG-IFNα given by subcutaneous injection
224063252|NCT07029269|PROCEDURE|ERAS-tube group|Nasogastric decompression tube is not placed preoperatively; If necessary, nasogastric decompression tube is placed after anesthesia induction during surgery and removed when the reconstruction is performed; Nasojejunal feeding tube is not placed intraoperatively; 1 prophylactic abdominal drainage tube is placed at the duodenal stump for LDG and retained postoperatively.
224063253|NCT07029607|DIETARY_SUPPLEMENT|Placebo|Placebo
224063254|NCT07029607|DIETARY_SUPPLEMENT|Dietary Supplement with actives|Dietary Supplement containing magnesium
224063255|NCT07023315|DRUG|Cadonilimab|Anti-PD-1/ CTLA-4 tetrameric bispecific antibody
224063256|NCT07023315|DRUG|SOX chemotherapy|A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium
224063257|NCT05309187|BIOLOGICAL|IO-202|IO-202 given as monotherapy
224063258|NCT05309187|BIOLOGICAL|IO-202 + pembrolizumab combination therapy|IO-202 and fixed dose pembrolizumab combination therapy
224063259|NCT05309187|BIOLOGICAL|RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types|Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
224063260|NCT04340167|BIOLOGICAL|Autologous humanized anti-CD22 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD22 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR T-cell infusion to determine the disease status.
224148238|NCT01096043|DRUG|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
223454137|NCT05861206|OTHER|CHX-MW group (0.12% CHX, as a positive control group)|Subsequently, each patient was instructed to use 15 mL of the mouthwash (0.12% CHX) delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for a week. For the next 3 weeks, at the beginning of each week (8th, 15th and 22nd days), patients were invited to the clinic, oral hygiene instruction was repeated, and the mouthwashes to be used the following week were delivered to them.
223454138|NCT02514200|PROCEDURE|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
223742645|NCT03297281|OTHER|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
223742646|NCT03297281|OTHER|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
224063261|NCT07028450|BEHAVIORAL|Proactive call|The proactive call will be based on the principles of motivational interviewing. The content of the call comprises: 1) Asking the gambler/recipient to reflect on their gambling behavior, 2) providing to the gambler/recipient an overview of their gambling account and financial history, 3) offering to the gambler/recipient information about responsible gambling tools, such as setting lower limits, locking limits, taking a break, or self-exclusion, and 4) providing to the gambler/recipient information about relevant support services and the Gamban tool in cases where a need is expressed.
224063262|NCT07028437|PROCEDURE|Endoscopic-assisted transoral approach for parotid tumor resection|The buccal mucosa was incised in front of the mandibular ligament of the inner wing of the mouth, the submucosal tissue was separated, and important structures such as the buccal nerve, parotid duct, and facial nerve were protected. The tumor was completely resected while preserving the parotid gland.
224063263|NCT07028437|PROCEDURE|Blair S-shaped incision for parotid tumor|The Blair S-shaped incision was made through an anterior auricular incision. After cutting the skin, the flap was reflapped. The greater auricular nerve and facial nerve were separated and protected, and the tumor was completely resected.
224148239|NCT00700895|DRUG|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
224148240|NCT06898099|OTHER|"Standard care control group (without hypnosis)"|"Randomization stratification on insomnia severity. In the Standard care group, the investigating physician will not change his or her current practice as part of the study. Treatment will be the same as usual, whether drug-based or not (psychotherapy, etc.), with the exception of hypnosis. The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study."
224063264|NCT06699342|PROCEDURE|Pacemaker implantation with Left bundle branch area pacing (LBBAP)|"Left bundle branch pacing is a novel pacing modality that can bypass the pathological or disease-vulnerable region in the cardiac conduction system, to provide physiological pacing modality for patients.~The procedure involves the implantation of a permanent pacemaker with a pacing lead positioned at the left bundle branch area to achieve physiological conduction system pacing. LBBAP-Pacemaker device and leads should be implanted according to the physician's standard practice."
224063265|NCT06699342|PROCEDURE|Atrioventricular node ablation (AVNA)|Atrioventricular node ablation uses heat energy, called radiofrequency energy, to destroy the area between the upper and lower heart chambers. This area is called the atrioventricular node.
224063266|NCT06699342|DRUG|Pharmacologic therapy optimized for Atrial Fibrillation management|"Pharmacologic therapy includes rate control with beta-blockers (e.g., bisoprolol), calcium channel blockers (e.g., diltiazem), or antiarrhythmic drugs (e.g., flecainide, propafenone, dronedarone, amiodarone) along with anticoagulation therapy (e.g., apixaban) as per current clinical guidelines (e.g., ESC 2024 or ACC/AHA/HRS 2023) in patients with permanent atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.~Treatment is tailored based on patient tolerance and clinical efficacy."
224063267|NCT06001333|PROCEDURE|fecal microbiota transplantation|Fecal microbiota transplantation will be conducted on patients using donor stool (frozen or capsulized stool) from a stool bank.
224148241|NCT06898099|OTHER|"Experimental group: E2R hypnosis"|"Randomization stratification on insomnia severity. For the patients randomized to the Hypnosis E2R arm, patients summoned within 15 days to 3 weeks of inclusion for their first hypnotherapy session with the hypnotherapist. All patients will receive 4 hypnotherapy sessions over 6 weeks using the E2R method.~The patients will be reviewed at 3 months and 6 months (+/- 1 week) after randomization (D0). The following study information and questionnaires will be completed according to patients' responses: ISI and PSQI self-questionnaires, Record of psychotropic medications, Record of any non-drug therapies implemented, Practice of self-hypnosis requested of the patient (patient diary), Events that could modify sleep, Serious adverse events (EvIG) and non-serious adverse events (EvING) of a neuropsychiatric nature that occurred or worsened during the study."
223454139|NCT02514200|PROCEDURE|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
223454140|NCT02514200|DRUG|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
223454141|NCT02514200|DEVICE|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
223571552|NCT03122353|DRUG|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
223571553|NCT03122353|DRUG|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
223571554|NCT03122353|DRUG|Placebo|vehicle used as placebo
223571555|NCT01552616|PROCEDURE|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
223571556|NCT03216304|DRUG|100 mg safinamide|"Safinamide will be administered as follows:~* Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~* Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~* Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
223571557|NCT03216304|DRUG|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~\- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
223571558|NCT03216304|DRUG|20 mg rosuvastatin calcium period 2|\- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
223571559|NCT00794365|DRUG|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
223571560|NCT04783649|DIAGNOSTIC_TEST|Papanicolaou cytological test|Cervical smear stained using conventional Papanicolaou technique.
223571561|NCT04783649|DIAGNOSTIC_TEST|Local cytological test (H&E stain)|Cervical smear stained using conventional hematoxylin and eosin staining techniques
223571562|NCT04783649|DIAGNOSTIC_TEST|Validated HPV DNA Test|Digene HC2 HPV DNA Test
223571563|NCT04783649|DIAGNOSTIC_TEST|Local HPV test|RealBest DNA HPV HR genotype (differential detection of human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 DNA)
223571564|NCT04783649|DIAGNOSTIC_TEST|Colposcopy|Women with positive cytology results are referred to colposcopy and biopsy
223571565|NCT02131376|PROCEDURE|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
223571566|NCT02131376|PROCEDURE|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
223571567|NCT01274780|DRUG|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
223571568|NCT01274780|DRUG|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
223571569|NCT03071484|DEVICE|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
223571570|NCT06145165|OTHER|Nerve block with ropivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
223571571|NCT06145165|COMBINATION_PRODUCT|Nerve block with liposomal bupivacaine and intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
223571572|NCT06145165|OTHER|Intravenous analgesia|When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
224063268|NCT07027943|DIETARY_SUPPLEMENT|DAO supplement|Gastro-resistant DAO tablets of porcine kidney protein extract. Posology: 3 tablets per day (total 12.6mg of DAO extract/day).
224063269|NCT07027943|DIETARY_SUPPLEMENT|Placebo|Tablets containing microcrystalline cellulose and hydroxypropyl cellulose, with the same shape, size, and color as the DAO-containing tablets. Posology: 3 tablets per day.
224063270|NCT07028476|PROCEDURE|Automated Dynamic Laximetry|Patients are prescribed a Zimmer splint to immobilize the injured limb, and referred to a referring sports physician at the investigating center to perform the LDA as a confirmatory examination (complementary test). Patients arrange their appointment with the sports physician as soon as possible.
224063271|NCT07028476|PROCEDURE|MRI|In the control arm, and in line with standard practice, patients with a suspected ACL injury are prescribed a Zimmer splint to immobilize the injured limb, an MRI as a confirmatory examination, and a consultation with the doctor of their choice. Following the MRI, patients arrange their appointments according to the usual care pathway for their pathology.
224063272|NCT01125150|DRUG|Metformin|Dosage to be determined by Endocrinologist
223742647|NCT05877599|BIOLOGICAL|Autologous, engineered T Cells targeting TP53 R175H|"* Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion TCR T cells~* Post-infusion recombinant interleukin-2 (rIL-2)"
224063273|NCT01125150|BEHAVIORAL|Dietary Modification|To be determined by Endocrinologist
224063274|NCT06718361|OTHER|Oxygen levels measurement (%)|Measuring levels of oxygen in the environment around the patient in %.
224063275|NCT06894433|PROCEDURE|neuroendoscopic surgery|Subjects will receive Neuroendoscopic Surgery followed by standard medical management
224063276|NCT06894433|PROCEDURE|craniotomy|Subjects will receive Craniotomy followed by standard medical management
224063277|NCT00377377|DRUG|EP1572 (ghrelin agonist) oral and duodenal application|
223742648|NCT05012930|OTHER|Baby Foods - Meat|Commercially available baby foods
223742649|NCT05012930|OTHER|Baby Foods - Dairy|Commercially available baby foods
224063278|NCT05213208|DRUG|Propofol|Using \> 200 mg of propofol sedation colonoscopy is performed. 90-120 minutes after colonoscopy subjects go home. Within 1 week patients will be asked about their condition and satisfaction for colonoscopy.
224063279|NCT06829251|BEHAVIORAL|Effective Ear Massage|The intervention consists of a structured ear massage technique administered daily for 2 weeks. Parents will receive training on how to target specific pressure points on the ear to reduce stress and anxiety, and improve sleep quality. This training will be conducted via WhatsApp (What's up Application) for 20 minutes, followed by daily massage practice. The massage will be performed using varying pressure over a 3-minute period on the entire ear, focusing on stress and sleep points.
224063280|NCT06829251|BEHAVIORAL|Sham Ear Massage|The sham intervention involves a 1-minute ear massage on the outer helix rim, helix crest, and helix points 1, 2, and 3, without applying any pressure. The goal of the sham massage is to mimic the process of ear massage while ensuring no physiological effect on stress, anxiety, or sleep quality.
224063281|NCT04161833|DIETARY_SUPPLEMENT|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
224063282|NCT00910793|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
224063283|NCT02821871|DRUG|SP2086|
224063284|NCT02821871|DIETARY_SUPPLEMENT|high fat diet|
224063285|NCT05982405|OTHER|Training group: Inspiratory muscle training|The individuals in the training group will be performed inspiratory muscle training at 30-50% of the maximal inspiratory pressure. Inspiratory muscle training will be done using an inspiratory muscle training device (PowerBreathe®) that works with the threshold loading principle. Inspiratory muscle training will be done for 15 minutes per a session, 2 times per a day or, if tolerated, 30 minutes per a day and 1 time per a day, 5-7 days/week (one session under the supervision and the others at home), for a total of 6 weeks. Applications made at home will be followed with a diary.
224063286|NCT05982405|OTHER|Control group: Thoracic expansion exercise|"Individuals in the control group will be performed thoracic expansion exercises. Thoracic expansion exercises will be applied to individuals in an upright sitting position. In this position, individuals will place their hands on their lower ribs and then perform the cycle of deep breathing + holding the deep breath for 3 seconds + slowly emptying all the breath 3 times in a row. After this cycle, individuals will be asked to rest by taking 3-4 calm breaths. Immediately after, the individual will be asked to repeat the same cycle and repeat the cycle with calm breaths and rest until it reaches 10 repetitions. The individual will do this session 4 times a day. Individuals will do the first session of breathing exercises under supervision. In this way, incorrect exercise will be prevented. Other breathing exercise sessions will be done by individuals as a home program every day and 4 sessions a day during 6 weeks."
224063287|NCT06766916|DRUG|Crisugabalin|"Days 1-14: Crisugabalin 40 mg/day, 20 mg twice daily, orally. Days 15-21: Increase dose to 80 mg/day, 40 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 120 mg/day, 60 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period."
223742650|NCT05012930|OTHER|Baby Foods - Plant|Commercially available baby foods
223742651|NCT05012930|OTHER|Foods from the home|Caregiver will provide participant with usual foods from the home
223742652|NCT04122313|OTHER|Evaluation of Dupuytren's Disease Treatment|There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
223742653|NCT06479876|OTHER|HBCR|Home-based cardiac rehabilitation intervention facilitated by a custom app to deliver education, counseling on healthy living and modification of risk factors, mindfulness, and physical activity guidance. Additionally, there are periodic video calls with an exercise physiologist.
223742654|NCT04862923|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
223742655|NCT06732804|BIOLOGICAL|AVT80|Single subcutaneous injection of AVT80 (108mg)
224063288|NCT06766916|DRUG|Pregabalin|"Days 1-7: Pregabalin 150 mg/day, 75 mg twice daily, orally. Days 8-14: Increase dose to 300 mg/day, 150 mg twice daily. Days 15-21: Increase dose to 450 mg/day, 225 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period.~Days 22-28: Increase dose to 600 mg/day, 300 mg twice daily. If not tolerated, maintain previous dose until the end of the treatment period."
223571573|NCT04584346|DIETARY_SUPPLEMENT|Liquigen MCT oil|MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values
223571574|NCT04584346|OTHER|Standard American Diet|Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
224063289|NCT06938607|DEVICE|Drain|Participants assigned to the drain group will have a surgical drain placed on the surface of the wound during closure. The drain will be removed within 24 hours.
224063290|NCT06938763|DRUG|J4|dry powder capsule
224063291|NCT06938763|DRUG|Placebo|Placebo dry powder capsule
224063292|NCT03087630|BEHAVIORAL|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
224063293|NCT03087630|BEHAVIORAL|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
224063294|NCT03087630|BEHAVIORAL|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
224063295|NCT03087630|BEHAVIORAL|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
224063296|NCT05870267|DEVICE|Power Knee with bone anchored suspension|Motor powered microprocessor controlled prosthetic knee joint
224063297|NCT05870267|DEVICE|C-Leg|Passive hydraulic microprocessor controlled prosthetic knee joint
224063298|NCT05870267|DEVICE|Rheo Knee XC|Passive magneto-rheologic microprocessor controlled knee joint
224301583|NCT02358343|DRUG|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
224301584|NCT05968443|DEVICE|ophthalmic surgery|any ophthalmic surgery using Dafilon® suture
224301585|NCT05447000|BEHAVIORAL|Mindfullness Based Stress Reduction (MBSR) intervention|Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring anxiety levels with mindfulness program
224301586|NCT05447000|BEHAVIORAL|Deep Relaxation Exercises intervention|Deep Relaxation Exercises intervention: Monitoring anxiety levels with deep Relaxation Exercises intervention
223571575|NCT04412733|DEVICE|Therapeutic Pulsed Ultrasound|Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
223571576|NCT04412733|DEVICE|Sham Ultrasound|Control group received sham ultrasound treatment
223571577|NCT05287841|PROCEDURE|Batten batten graft|The batten grafts are autologous grafts from the patients' own tissue, produced from nasal septal quadrangular cartilage. This will be obtained during the septoplasty portion of the procedure. The batten graft will be used to stabilize the internal nasal valve and prevent nasal valve collapse on inspiration.
223571578|NCT05287841|PROCEDURE|Septoplasty|A portion of the quadrangular cartilage of the nasal septum is removed. This will be performed as a standard septoplasty.
223571579|NCT05287841|PROCEDURE|Inferior Turbinate Reduction|The bilateral inferior turbinates will be surgically ablated.
223571580|NCT00633568|DRUG|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
223742656|NCT06732804|BIOLOGICAL|Geographical region 1 Entyvio|Single subcutaneous injection of Geographical region 1 Entyvio (108mg)
224063299|NCT06830499|PROCEDURE|Transcatheter Aortic Valve Replacement (TAVR)|TAVR procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted. Vascular access site will be through transfemoral on the basis of pre-procedural evaluation of access site vessel. The procedure will be performed under local or general anesthesia and per clinical practice standard.
224063300|NCT03770260|DRUG|Ixazomib Citrate|Given PO
224063301|NCT03770260|DRUG|Pevonedistat|Given IV
224063302|NCT05863572|OTHER|Primary care health worker training|Training primary care workers to detect and treat psychosis.
224063303|NCT05863572|OTHER|Community Health Workers Training|training community health workers in detection and referral
224063304|NCT05863572|OTHER|Home visits|home visits conducted by people with lived experience of psychosis
224063305|NCT06547840|DRUG|MOv18 IgE|MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class
224063306|NCT02484911|DRUG|Olanzapine|5mg,twice a day orally on day 1 to day 4
224063307|NCT02484911|DRUG|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
224063308|NCT02484911|DRUG|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
224063309|NCT02484911|DRUG|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
224063310|NCT04194099|DEVICE|20 Hz rTMS (Brain)|Higher frequency (\>5 Hz) trains increase cortical excitability.
224063311|NCT04194099|DEVICE|iTBS rTMS (Brain)|Intermittent theta burst stimulation (iTBS) is a newer rTMS approach.
224063312|NCT04194099|DEVICE|Anode tsDCS (Spinal)|Anodal tsDCS increased the spinal reflex amplitude, as well as corticospinal excitability.
224063313|NCT04194099|DEVICE|20 Hz current square-wave pulses (Spinal)|Higher frequency (\>5 Hz) of current increase cortical excitability.
224063314|NCT04194099|DEVICE|iTBS (Spinal)|Intermittent theta-burst stimulation (iTBS) is a newer approach. it may increase corticospinal excitability.
224063315|NCT04194099|DEVICE|sham|with sham stimulation on brain and spinal.
224063316|NCT01225484|PROCEDURE|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
224063317|NCT01225484|PROCEDURE|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
224063318|NCT01156584|BIOLOGICAL|Toca 511 vector|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
224063319|NCT01156584|DRUG|Toca FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
224063320|NCT05149690|OTHER|Experimental: monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
224063321|NCT05149690|OTHER|Active Comparator: Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
224063322|NCT03801850|DEVICE|3D surface scan|measurement of inter fractional deformations by surface scanning
224063323|NCT05361772|DRUG|colchicine|colchicine 0.5mg per day for 24 months
223571581|NCT00633568|DRUG|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
224063324|NCT05361772|DRUG|Placebo|placebo 0.5mg per day for 24 months
224063325|NCT05182957|DRUG|Anti-PD-1 monoclonal antibody|Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)
224063326|NCT05182957|DRUG|Lenalidomide|Lenalidomide 25mg qd po d1-d10 (/21d)
224063327|NCT05182957|DRUG|Azacitidine|Azacitidine 75mg/m2 i.v d1-d7 (/21d)
223571582|NCT01825395|DRUG|3, 4-Diaminopyridine|
223571583|NCT00301535|DRUG|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
223571584|NCT04216368|BEHAVIORAL|balance training|The training to improve balance is to work on the core muscle groups that help to maintain your posture.,and increase muscular strength.
223571585|NCT04216368|BEHAVIORAL|resistance training|Resistance training is a form of exercise that improves muscular strength and endurance. During a resistance training workout, you move your limbs against resistance provided by your body weight, gravity, bands, weighted bars or dumbbells.
223571586|NCT01389531|PROCEDURE|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
223571587|NCT02850263|DRUG|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
223571588|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
223742657|NCT06732804|BIOLOGICAL|Geographical region 2 Entyvio|Single subcutaneous injection of Geographical region 2 Entyvio (108mg)
224063328|NCT01258504|DRUG|St. Johns Wort|"* Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~* Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
224063329|NCT02372474|BIOLOGICAL|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
224063330|NCT01682135|BIOLOGICAL|Ramucirumab|Administered IV.
224063331|NCT04315519|OTHER|Exercise|Aerobic Exercise
224063332|NCT03632421|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224148242|NCT06762366|BEHAVIORAL|Additional Incentive|During this behavioral intervention, participants will be given additional compensation for correct answers.
224063333|NCT03632421|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224063334|NCT06519786|DRUG|Metformin|Patients will receive metformin immediate-release tablets orally for 24 weeks. Starting dose will be 500 mg once daily for all patients and the dose will be increased by 500 mg weekly until the goal dose is achieved (500 mg twice daily for patients \< 10 years of age, and 1000 mg twice daily for patients 10 years or older)
224063335|NCT05196659|BEHAVIORAL|Integrated comprehensive cardiovascular disease management|"1. Electronic Health Record-Decision Support Software (EHR-DSS):~   * Electronic patient health record storage~  * Management prompts to the clinical team (following algorithms)~  * Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~2. Non-physician health worker-led continuity of care:~   \- individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~3. Text-message based reminders for a healthy lifestyle~4. Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~5. Quarterly audit and feedback to the clinical team"
224148243|NCT06762366|BEHAVIORAL|Response Delay|During this behavioral intervention, participants will not be allowed to respond with their judgements until after a certain amount of time has passed.
223454142|NCT01415726|DEVICE|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.
224063336|NCT04956159|DEVICE|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of depression and anxiety.
224063337|NCT04956159|DEVICE|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
224063338|NCT03065348|DIETARY_SUPPLEMENT|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
224063339|NCT03065348|DIETARY_SUPPLEMENT|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
224063340|NCT03065348|DIETARY_SUPPLEMENT|Carbohydrate Drink|"Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, \< 10mg sodium, 190kcal"
224063341|NCT03065348|OTHER|Preoperative hydration|If urine specific gravity is \>1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
224063342|NCT03065348|OTHER|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
224063343|NCT00187421|PROCEDURE|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
224148244|NCT06762366|BEHAVIORAL|Baseline Performance|In this intervention, the participant completes the task as it is typically administer for a baseline performance measure. The participant can respond at will and does not receive incentive for correct responses.
224148245|NCT07065305|DRUG|Curodont Repair Fluoride Plus (Self-assembling peptide remineralization agent)P11-4 peptide, fluoride, mild acidic buffer (pH ~4.5) , Credentis AG, Switzerland|Pretreatment with Curodont Repair Fluoride Plus (P11-4 + fluoride)
224148246|NCT07065305|DRUG|Beautifil II LS|Application of Giomer restorative material following standard adhesive procedures without pretreatment.
224148247|NCT07067346|DRUG|IR-101|IR-101 Dose Escalation
224301587|NCT05447000|OTHER|No Intervention|No Intervention
224301588|NCT02015559|DRUG|mucoadhesive oral wound rinse|Given PO
223454143|NCT04439058|OTHER|ultrasound guided left stellate ganglion block|"Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli"
223571589|NCT02850263|DRUG|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent \[Ophthalmologicals / Antineovascularisation agents (S01LA05)\] for the treatment of DMO by the patient.according to the prescribing physician.
224063344|NCT00414102|DRUG|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
224063345|NCT00414102|DRUG|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
224063346|NCT01981915|PROCEDURE|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
224063347|NCT01981915|PROCEDURE|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
224063348|NCT01652885|DRUG|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
224063349|NCT00075400|DRUG|imatinib mesylate|Given PO
224063350|NCT00075400|OTHER|laboratory biomarker analysis|Correlative studies
224063351|NCT06130267|OTHER|Endocare|Virtual paradigm (calming environnement)
224063352|NCT00490568|DRUG|Rosiglitazone XR|Experimental drug
224063353|NCT01395394|DRUG|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
224063354|NCT01395394|OTHER|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
224063355|NCT01066364|DRUG|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
224063356|NCT02849795|OTHER|bone densitometry|
224063357|NCT02849795|OTHER|questionnaires|
224063358|NCT02849795|OTHER|biological analyses|
223742658|NCT03813979|DRUG|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
223742659|NCT03842124|OTHER|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
224063359|NCT05347888|OTHER|Nutritional therapy|Either enteral or parenteral nutrition is used for the patient admitted in the ICU
224063360|NCT03574090|DRUG|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
224063361|NCT03574090|DRUG|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
224063362|NCT01876407|DEVICE|Low intensity laser for oral mucositis|
224063363|NCT01876407|DEVICE|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
224063364|NCT03451773|DRUG|M7824|1,200 or 500mg every 2 weeks by intravenous (IV) infusion
224063365|NCT03451773|DRUG|Gemcitabine|Standard (1,000 mg/m\^2) or reduced (600 mg/m\^2 for 4 doses) intravenous (IV) once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
224301589|NCT02015559|OTHER|laboratory biomarker analysis|Correlative studies
223742660|NCT04034420|OTHER|Online training platform|Self-paced training and learning materials in relation to family services
223742661|NCT02446990|DRUG|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
223742662|NCT02446990|DRUG|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
223742663|NCT02409992|BEHAVIORAL|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
224063366|NCT06053515|BEHAVIORAL|Rosie the Chatbot|"Participants in the intervention group will be using the chatbot to ask questions related to the mom and baby's health, provide feedback selecting thumbs up or thumbs down on the questions' response, and use the features (video library, resources page, frequently asked questions (FAQ), and daily syllabus). In addition, participants will be taking a pre-test health survey, mid-test health survey, and post-test health survey."
224063367|NCT02316405|OTHER|Arm and Leg Cycling Exercise for Walking after Stroke|
224063368|NCT05558956|DRUG|illuccix 68Ga-PSMA-11 Total Body PET-CT|Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) 68Ga-PSMA-11
224063369|NCT06309459|DIAGNOSTIC_TEST|Carbonic anhydrase staining levels|CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).
224063370|NCT06519019|PROCEDURE|Dental Implant Surgery - Hydrophilic group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
224063371|NCT06519019|PROCEDURE|Dental Implant Surgery - Conventional group|"A full thickness mucoperiosteal flap was elevated, under Local anaesthesia, osteotomy sites were prepared according to manufactures instructions, and parallel pin was used to confirm position and angulation of osteotomy site. One site received a hydrophilic implant and the other site received a conventional implant.~Ostell ISQ was used to measure primary stability of the dental implant. The surgical wound closure was with mattress and single interrupted sutures, using 4-0 vicryl suture."
224063372|NCT05073809|DIAGNOSTIC_TEST|Photoacoustic Imaging Scan|A relatively novel modality that combines exquisite spatial resolution with the ability to image multiple biological tissues, including blood, water and lipid.
224063373|NCT03468855|DRUG|ATI-50002 topical solution|Topical Solution administered twice daily
224063374|NCT03283189|OTHER|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
224301590|NCT05332028|DRUG|bupivacaine|Block applications
224301591|NCT05332028|DEVICE|22 gauge 100 mm needle|Block applications
224063375|NCT00390546|DRUG|Digoxin|
224063376|NCT00390546|DRUG|Propranolol|
224063377|NCT03670212|DRUG|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
224063378|NCT03670212|DRUG|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
224063379|NCT03670212|DRUG|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
224063380|NCT02241759|DRUG|TA-8995|
224063381|NCT02241759|DRUG|Moxifloxacin|
224063382|NCT02241759|DRUG|Placebo|
224063383|NCT04313127|BIOLOGICAL|Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Intramuscular other name:Ad5-nCoV
224063384|NCT04893642|PROCEDURE|Suture rectopexy|
224063385|NCT04893642|PROCEDURE|resection rectopexy|
224063386|NCT04893642|PROCEDURE|Delorme's operation|
224063387|NCT04893642|PROCEDURE|Altemeier's operation|
224063388|NCT00489567|PROCEDURE|Blood sample collection|
224063389|NCT04117464|BEHAVIORAL|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
224063390|NCT04117464|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
224063391|NCT04117464|BEHAVIORAL|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
224063392|NCT04117464|OTHER|Wait List Group|No psychological intervention
224063393|NCT02836067|BEHAVIORAL|Counseling|Smoking cessation counseling
224063394|NCT02836067|OTHER|Smoking Cessation drugs|Medication to aid smoking cessation
224063395|NCT02836067|PROCEDURE|Bronchoscopy|Bronchoscopy
224301592|NCT05332028|DRUG|Propofol|Routine general anesthesia protocol
224063396|NCT02836067|PROCEDURE|Blood Draw|Screening and research blood draws
224063397|NCT02836067|BEHAVIORAL|Questionnaires|Behavioral questionnaires
224063398|NCT05007275|BIOLOGICAL|1x10^9 vp AZD1222|A single dose of 1x 10\^9 vp AZD1222
224063399|NCT05007275|BIOLOGICAL|5x10^9 vp AZD1222|A single dose of 5x 10\^9 vp AZD1222
224301593|NCT05332028|DRUG|fentanyl|patient-controlled analgesia
224063400|NCT05007275|BIOLOGICAL|1x10^10 vp AZD1222|A single dose of 1x10\^10 vp AZD1222
224063401|NCT01093027|OTHER|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
224063402|NCT01093027|OTHER|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
224063403|NCT05088304|OTHER|no intervention|
224063404|NCT02526706|OTHER|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
224301594|NCT00281671|DRUG|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
224301595|NCT00281671|DRUG|Placebo|0.9% sodium chloride infusion
224301596|NCT03970928|DEVICE|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
224301597|NCT04022928|OTHER|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
223571590|NCT02535299|DRUG|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
224063405|NCT00665457|BIOLOGICAL|filgrastim|
224063406|NCT00665457|DRUG|capecitabine|
224063407|NCT00665457|DRUG|celecoxib|
224063408|NCT00665457|DRUG|cyclophosphamide|
224063409|NCT00665457|DRUG|docetaxel|
224063410|NCT00665457|DRUG|doxorubicin hydrochloride|
224063411|NCT00665457|GENETIC|gene expression analysis|
224063412|NCT00665457|GENETIC|polymorphism analysis|
224063413|NCT00665457|GENETIC|protein expression analysis|
224063414|NCT00665457|GENETIC|reverse transcriptase-polymerase chain reaction|
224063415|NCT00665457|OTHER|imaging biomarker analysis|
224063416|NCT00665457|OTHER|immunohistochemistry staining method|
224063417|NCT00665457|OTHER|laboratory biomarker analysis|
224063418|NCT00665457|OTHER|pharmacogenomic studies|
224063419|NCT00665457|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
224063420|NCT00665457|PROCEDURE|needle biopsy|
224063421|NCT00665457|PROCEDURE|neoadjuvant therapy|
224063422|NCT00665457|PROCEDURE|radiomammography|
224063423|NCT00665457|PROCEDURE|ultrasound imaging|
224063424|NCT05558839|BEHAVIORAL|A 12-week weekly sports and cognitive training intervention.|A 12-week weekly sports and cognitive training intervention was provided to the participants. The training, 2 hours each week, involved 1 hour of sports training and 1 hour of cognitive training.
224063425|NCT01554280|DEVICE|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
224063426|NCT04195321|DRUG|Norepinephrine|infusion will be started after induction of spinal anesthesia
224063427|NCT04195321|DRUG|phenylephrine|infusion will be started after induction of spinal anesthesia
224063428|NCT00291408|PROCEDURE|Skin Prick Test|
224063429|NCT00291408|PROCEDURE|Impulse Oscillometry|
224063430|NCT00291408|PROCEDURE|Exhaled Nitric Oxide|
224063431|NCT00291408|PROCEDURE|Spirometry|
224063432|NCT00291408|PROCEDURE|Reversibility|
224063433|NCT00291408|PROCEDURE|Exhaled Breath Condensate|
224063434|NCT00291408|PROCEDURE|Sputum Induction|
224063435|NCT05348655|OTHER|epidemiology|To review of medical records to describe diagnosis and severity of the disease
224063436|NCT05348655|OTHER|epidemiology|To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
224063437|NCT01526902|DEVICE|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
224148248|NCT06901258|BEHAVIORAL|Genius Pillbox|Participants will be mailed a Genius Pillbox to their home address. Along with the pillbox, they will also receive a detailed written description to orient them to the Genius Pillbox. Participants will be expected to use the Genius pill box organizer daily for four weeks as part of their usual medication routine. Participants are also expected to fill the designated compartments with their daily pills.
224148249|NCT07086092|OTHER|Serum magnesium, uric acid, and vitamin D levels and motor recovery and ambulation stages|Serum magnesium, uric acid, and vitamin D levels, as well as motor recovery and ambulation levels, measured during the patients' rehabilitation stay will be obtained from past medical records.
224148250|NCT07084597|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D ,50000 IU/week will be given for 8 consecutive weeks
224063438|NCT01526902|DEVICE|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
224063439|NCT04578795|DEVICE|Single use flexible ureteroscopy (PUSEN-OLIMPUS)|single use flexible ureteroscopy
224063440|NCT00812214|DRUG|eszopiclone|3 mg tablet every night at bedtime
224148251|NCT07091708|OTHER|Acupuncture|Acupuncture
224148252|NCT07092423|DIETARY_SUPPLEMENT|Semi-elemental formula|Treatment: Semi-elemental enteral nutrition Objective: To assess the efficacy of semi-elemental enteral nutrition in enhancing gastrointestinal tolerance in patients with severe traumatic brain injury.
224148253|NCT07092423|DIETARY_SUPPLEMENT|Standard formula|Treatment: Standard enteral nutrition Objective: To serve as the control for evaluating the efficacy and safety of semi-elemental enteral nutrition versus standard nutritional therapy
224148254|NCT07091084|DIETARY_SUPPLEMENT|MZRW|MZRW herbal formula consists of a 7:1 extract of Huo Ma Ren \[Hemp Seed 33.4%\]; Da Huang (Sheng) \[Rhubarb (Fresh) 22.2%\]; Bai Shao \[Peony (White) 11.1%\]; Zhi Shi \[Aurantium Immaturus 11.1%\]; Hou Po \[Magnolia Bark 11.1%\]; and Xing Ren \[Apricot Kernel 11.1%\] - Taken for 2 weeks intervention and 2 weeks follow-up
224148255|NCT07091812|DEVICE|Ultrasound Vagus Nerve Stimulation (U-VNS)|Ultrasound stimulation of the auricular branch of the vagus nerve using the ZenBud device manufactured by NeurGear (Rochester, New York, USA), a CE-compliant over-the-ear headset. It delivers low-intensity focused ultrasound to the auricular branch of the vagus nerve through several layers of skin (centre frequency 5.3 MHz, pulse repetition rate 41 hertz, 50% duty cycle, average intensity of 1.03 MPa).
224148256|NCT07091812|DEVICE|Sham U-VNS|Sham device, also produced by NeurGear, which is identical in appearance to the true ZenBud device, emits the same sound and warms up slightly where the transducer sits on the skin.
224148257|NCT07090031|DRUG|TAS-102 in combination with oxaliplatin|"Induction : TAS102 35mg/m2, twice a day for 5 days, on 1st, 3rd, 5th week; Oxliplatin 85mg/m2 on 1st and 2nd week; Rectal radiotherapy 50GY/25f in 5 weeks. 2 weeks no treatment.~Consolidation: TAS102 35mg/m2, twice a day for 5 days, every 2 weeks, Oxliplatin 85 mg/m2, every 2 weeks a cycle, for total 3 cycles. 4 weeks no treatment.~Surgery Adjuvant chemotherapy: TAS102 35mg/m2, twice a day for 5 days, every 2 weeks, Oxliplatin 85 mg/m2, every 2 weeks a cycle, for total 16 cycles."
223454144|NCT06386159|OTHER|Comprehensive Intervention or Comprehensive Intervention Combined with Electrical vagus nerve stimulation|Comprehensive intervention includes multidisciplinary collaboration, screening and assessment, oral sensory training, oral motor training, respiratory training, and feeding management. Transcutaneous electrical stimulation of the vagus nerve at the lateral neck was performed by rehabilitation therapists. The cervical vagus nerve accompanies the carotid artery and is located at the groove between the trachea and the sternocleidomastoid muscle, which can be located by touching the carotid pulse. The two electrodes were pasted along the path of the cervical vagus nerve.
223454145|NCT03057717|OTHER|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
223454146|NCT00552890|OTHER|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
223454147|NCT00552890|OTHER|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
223454148|NCT02599064|DRUG|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
223454149|NCT04692272|BEHAVIORAL|Exercise in the XBOX kinect|"The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity)."
224063441|NCT00812214|DRUG|placebo|1 tablet every night at bedtime
224063442|NCT01091701|BIOLOGICAL|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
224063443|NCT01091701|OTHER|Plasmalyte-A|Single IV dose of Plasmalyte-A
224063444|NCT00046774|DRUG|MRA 003 US|
224063445|NCT06090942|OTHER|Smartphone-based cognitive training|Smartphone-based cognitive training
224063446|NCT04176263|BEHAVIORAL|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
224063447|NCT04176263|BEHAVIORAL|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
224063448|NCT00716105|OTHER|Standard infant formula|From 3 to 12 months of age. As per standard requirement
224063449|NCT00716105|OTHER|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
224063450|NCT03724565|PROCEDURE|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
224063451|NCT04603573|DEVICE|fluoride varnish (3M Clinpro White Varnish 5% sodium fluoride )|5% Sodium Fluoride Varnish is a fluoride varnish which is applied to tooth surfaces for sealing dentinal tubules and treatment of hypersensitive teeth. The varnish is applied in a thin layer over the tooth with an applicator brush, and moisture from saliva cures the varnish for adhesion to the tooth surface.
224063452|NCT04603573|DEVICE|Resin based fissure sealant (3M Clinpro sealant )|"teeth will be isolated with coton rolls and saliva ejector then etching for pits and fissure then tooth will be washed then apply resin based fissure sealant on occlusal surface.~resin fissure sealant is a more sensitive for saliva."
224148258|NCT07092449|DRUG|Neoadjuvant chemo-immunotherapy|Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)
224148259|NCT07091136|DRUG|manidipine|study will enrol 100 adults aged 60 to 85 years with MDCT-confirmed mild-to-moderate aortic valve calcification (Agatston score 300-2 000 AU) and preserved left-ventricular ejection fraction to receive manidipine 10 mg, manidipine 20 mg, or matched placebo once daily for 12 months, followed by a 3-month safety observation, with the primary endpoint being the absolute and relative change in aortic valve calcium score at 12 months; secondary endpoints include echocardiographic valve area and transvalvular gradients, six-minute walk distance, peak oxygen uptake, and comprehensive safety outcomes
224148260|NCT07091136|DRUG|Placebo|study will enrol 100 adults aged 60 to 85 years with MDCT-confirmed mild-to-moderate aortic valve calcification (Agatston score 300-2 000 AU) and preserved left-ventricular ejection fraction to receive manidipine 10 mg, manidipine 20 mg, or matched placebo once daily for 12 months, followed by a 3-month safety observation, with the primary endpoint being the absolute and relative change in aortic valve calcium score at 12 months; secondary endpoints include echocardiographic valve area and transvalvular gradients, six-minute walk distance, peak oxygen uptake, and comprehensive safety outcomes
223571591|NCT02535299|DRUG|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
224148261|NCT07091071|DEVICE|CochSyn device|The CochSyn device is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn device records and analyses biopotential waveforms that can be used for hearing screening and diagnostic applications.
224148262|NCT07090291|DIAGNOSTIC_TEST|Colonoscopy|Colonoscopy is used to examine the inner lining of the colon and rectum. During the procedure, if suspicious growths (e.g., polyps) are detected, they will be biopsied and sent for pathological examination.
223454150|NCT03939533|DRUG|CUTAQUIG|Human normal immunoglobulin
223454151|NCT05602740|DEVICE|Harmony|Passive recording of the head pulse
223454152|NCT03191565|OTHER|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
223571592|NCT04239222|DEVICE|Revo-M|Investigational energy storage and return prosthetic foot with using novel elastic elements.
223571593|NCT04239222|DEVICE|Taleo|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transfemoral amputee subjects
223571594|NCT04239222|DEVICE|Proflex XC|Commercially available carbon-fiber energy storage and return foot used as comparative foot for transtibial amputee subjects
223571595|NCT05494736|DRUG|MK-8527|MK-8527 capsule taken by mouth.
224148263|NCT07090291|DIAGNOSTIC_TEST|FIT|FIT stands for Fecal Immunochemical Test, a non-invasive screening tool used primarily to detect hidden blood in the stool, which may indicate colorectal cancer or precancerous polyps. Positive cut-off level: 100 ng/mL.
224148264|NCT07090291|DIAGNOSTIC_TEST|Blood test|Blood test based on cfDNA methylation will be performed.
224148265|NCT07090525|DRUG|Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2|Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2, repeat use on 21st day if the serous effusion not controlled
224148266|NCT07090525|DRUG|cisplatin 40mg/m2 intracavity injection|cisplatin 40mg/m2 intracavity injection
224301598|NCT04132583|DRUG|Deflox®|Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
223454153|NCT03191565|DEVICE|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
223454154|NCT00823758|BEHAVIORAL|Focus Groups|6 to 8 participants per group.
223454155|NCT00823758|BEHAVIORAL|Personal Interviews|Conducted by phone and audiotaped.
223454156|NCT03232216|DIETARY_SUPPLEMENT|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
223454157|NCT03232216|DIETARY_SUPPLEMENT|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
223454158|NCT01472133|OTHER|Recording of 12 lead ECG|Recording of 12 lead ECG
223571596|NCT03029182|OTHER|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
223571597|NCT03029182|BEHAVIORAL|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
223454159|NCT01472133|OTHER|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
223454160|NCT01472133|OTHER|Recording of chest wall movement|Recording of chest wall movement
223454161|NCT01472133|OTHER|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
223454162|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
223571598|NCT01741025|DEVICE|iFuse Implant System|Placement of iFuse implant system via surgery
224063453|NCT06118684|DRUG|EP395 (Part A and B)|"EP395 (test product) oral capsule 125 mg. Part A: Dose: 1 capsule as a single dose on Day 1 and Day 14, total daily dose: 125 mg.~Part B: Dose: 3 capsules once daily on Days 9 to 28, total daily dose: 375 mg."
224063454|NCT06118684|DRUG|Verapamil (Part A)|Verapamil (CYP3A4/Pgp inhibitor), tablet 40 mg. Part A: Dose: 3 tablets twice daily Days 10 to 18, total daily dose: 240 mg.
224063455|NCT06118684|DRUG|Midazolam (Part B)|Midazolam (CYP3A4 substrate) oral solution 1 mg/mL. Part B: Dose: 4 mL as a single dose on Day 1 and Day 24, total daily dose: 4 mg.
224063456|NCT06118684|DRUG|Digoxin (Part B)|Digoxin (Pgp substrate) tablet 0.25 mg. Part B: Dose: 1 tablet as a single dose on Day 1 and Day 24, total daily dose: 0.25 mg.
224063457|NCT04734912|OTHER|gastroscopy in transnasal techique|All patients with indication for gastroscopy in transnasal technique are included.
224063458|NCT01726751|DEVICE|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
224063459|NCT01726751|DEVICE|Spinal cord nerve stimulation|
224063460|NCT03080298|DRUG|BP101|
224063461|NCT03080298|DRUG|Placebo|
224063462|NCT02326870|DEVICE|AutoLap|
224063463|NCT02145741|DRUG|750 milligram Xentuzumab|750 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
224063464|NCT02145741|DRUG|1000 milligram Xentuzumab|1000 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
224063465|NCT02145741|DRUG|1400 milligram Xentuzumab|1400 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.
224063466|NCT00236015|DRUG|Gabitril|
224063467|NCT06406192|DIAGNOSTIC_TEST|Height, Weight, and Blood Pressure Measurement Procedures Improvement|"In the intervention group, the investigators improve the process of measuring blood pressure, height, and weight, requiring timely recording of these measurements. The intervention includes:~i. Enlisting the assistance of nurses and volunteers to improve the accessibility of measurement environments and provide guidance on instrument operation.~ii. Using paper reminders at check-in stations to prompt patients to complete blood pressure and weight recordings before entering examination rooms; providing paper for recording if patients forget their health insurance cards.~iii. Providing alcohol and hand wipes outside examination rooms for disinfecting measurement instruments.~iv. Promoting the recording mode outside the check-in station.~v. Ensuring that physicians or nurses in examination rooms accurately record measurements in the medical order system.~vi. Encouraging patients to ask physicians during consultations, Is my blood pressure and weight okay?"
224063468|NCT01192022|BIOLOGICAL|TachoSil®|Intraoperative application as secondary hemostatic treatment
224063469|NCT01192022|DEVICE|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
224063470|NCT01385020|DRUG|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
224063471|NCT03760549|DRUG|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
223571599|NCT01741025|OTHER|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
223571600|NCT03932864|BIOLOGICAL|MGTA-145|MGTA-145 will be given in various doses intravenously
223571601|NCT03932864|BIOLOGICAL|plerixafor|240 µg/kg subcutaneously
223571602|NCT03932864|BIOLOGICAL|Placebo|Placebo will be given in various doses intravenously
223571603|NCT04067297|OTHER|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of \~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
224063472|NCT06168292|PROCEDURE|ID-RFA and Radiotherapy|The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
224063473|NCT06081803|DRUG|Repatha®|Repatha® 140mg x 3 pens subcutaneous injection
224063474|NCT01692964|DEVICE|InflammaDry|A noninvasive immunoassay for detecting MMP-9 levels in tears.
224063475|NCT00129766|BIOLOGICAL|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
224063476|NCT00129766|BIOLOGICAL|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
224063477|NCT02181829|RADIATION|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
224063478|NCT04459780|BIOLOGICAL|Skin biopsies|3 biopsies on lesion skin (and one more for the first fifteen subjects in group 1)
224063479|NCT04459780|BIOLOGICAL|Blood sample|One blood sample for the group 1 only.
224063480|NCT05075356|DEVICE|The intelligent total body scanner (iToBoS)|"The intelligent total body scanner (iToBoS) device will be an AI diagnostic platform for early detection for melanoma, which includes a novel total-body high-resolution scanner and a Computer Aided Diagnostics (CAD) tool. The prototype iToBoS imaging device used in this study, will not have the integrated CAD system.~The device consists of a horizontal bed on which the participant would lie on. The bed will slide under a series of 5 arc shaped rails that have a total of 15 vision units mounted on rails (3 vision units per arc). The vision units incorporate high-resolution cameras and LED lighting system. When imaging is initiated by an operator, the vision units systematically move along the arch rails taking numerous images capturing majority of the skin surface. The imaging process will take approx. 10 minutes.~Purpose built software will be used to stitch images together to create a body avatar on which skin lesions can be viewed and monitored with."
224063481|NCT04522674|BIOLOGICAL|Autologous platelet rich plasma|0.5 mL autologous platelet rich plasma into a symptomatic osteoarthritic lumbar facet to treat back pain caused by lumbar facet syndrome
224063482|NCT00781456|DRUG|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
224063483|NCT00781456|DRUG|Placebo|1 tablet daily to match experimental arm
224063484|NCT03496909|BEHAVIORAL|Standard OT|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include manual therapy, education, and active and passive range-of-motion, etc.
224063485|NCT03496909|BEHAVIORAL|PhysioTouch|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include use of the PhysioTouch electronic massager in lieu of manual therapy, education, and active and passive range-of-motion, etc.
224063486|NCT04989582|OTHER|The trauma recovery nursing intervention program|The trauma recovery nursing intervention program was for adults who had experienced trauma and consisted of eight sessions, each lasting 30 min. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-help guidelines for clients to develop their mental and physical well-being.
224063487|NCT02631330|OTHER|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
224063488|NCT06010966|DEVICE|rTMS|intermittent theta-burst stimulation (iTBS)
224063489|NCT04803838|OTHER|No intervention|No intervention
224063490|NCT05456477|OTHER|Beef|Beef entrees
224063491|NCT05456477|OTHER|Poultry|Poultry entrees
224063492|NCT04677348|PROCEDURE|Pericapsular nerve group (PENG) block|ultrasound-guided PENG block with 0.3% ropivacaine 20cc
224063493|NCT04677348|PROCEDURE|Fascia iliaca compartment block (FICB)|ultrasound-guided suprainguinal FICB with 0.3% ropivacaine 30cc
224063494|NCT02805777|DEVICE|CPAP mask|A new vent CPAP mask system will be used in this trial
224063495|NCT02598843|OTHER|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB); 2 weeks FWB out of cast, with shoe insert heel raise.~Followed by course of physiotherapy"
224063496|NCT02598843|OTHER|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance; 2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance; 2 weeks in Rebound walking boot with foot in neutral. At 8 weeks, remove boot and allow FWB out of boot.~At 8 weeks after initiation of treatment, physiotherapy is commenced."
224063497|NCT04737577|PROCEDURE|Supramarginal resection|Tissue removal beyond the GAD-enhancing region extending to either at least 1 cm into non-enhancing tissue, or the nearest non-enhancing sulcal boundary/ventricle wall if these structures are closer than 1 cm.
224063498|NCT04737577|PROCEDURE|Conventional (i.e. GTR) resection|Planned resection of ≥95% of the GAD-enhancing regions of tumor without expanding the resection beyond this margin.
224063499|NCT04091087|DRUG|crisaborole ointment|crisaborole ointment
224063500|NCT04091087|OTHER|vehicle ointment|vehicle ointment
224063501|NCT03425032|DEVICE|CT scanner|Regular CT imaging of the abdomen and pelvis
224063502|NCT05217771|OTHER|High tone power therapy group|patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
224063503|NCT03872804|PROCEDURE|Autologous punch mini grafts:|"Under local anesthesia, multiple 1mm holes will be made in the depigmented treatment area using 1mm punch graft instrument inserted to a depth of 2-4 mm to remove a small column of depigmented skin that is to be discarded. The punches will be situated at or very close to the border of the lesion to avoid leaving an achromic fissure and will be separated by 5-8 mm distance from each other.~On the donor area mostly is the gluteal area, punches will be harvested using the same sized punches very close to each other so that maximum number of grafts can be taken from a small area.~Then the harvested-punch minigrafts will be inserted into the recipient chambers, pressed firmly by saline soaked gauge for hemostasis and secured by sterile strips or a compression bandage if applicable."
224063504|NCT03872804|PROCEDURE|Transverse needling|Needling will be done for selected treatment patch using a 30 G disposable insulin syringe, going from the pigmented margins of the lesion into the vitiliginous patch, Position of the needle will be kept close to the dermoepidermal junction and movement will be from normal skin towards the lesion. Needle pricks may lead to oozing of a small drop of blood which will be managed by physical pressure. No dressings will be needed. The procedure will be repeated for selected lesions weekly for a duration of 3 months.
224063505|NCT03872804|PROCEDURE|Punch minigrafts followed by transverse needling|In a third lesion, punch minigrafts will be done as mentioned in line 1 and will be left to stabilize for 3 months then transverse needling will be done weekly for the margins of the lesion as well as the areas of the punch grafts toward the vitiliginous area.
224063506|NCT03872804|OTHER|Oral pulse steroid with narrow band|"* A fourth lesion will be chosen as a control lesion, to which no surgical treatment will ba attempted.~* All lesions will receive NB-UVB therapy according to standard protocol twice weekly and the patients will continue on the oral mini pulse dexamethasone at 2.5 mg dose for two consecutive days weekly all through the study period"
224063507|NCT05440539|OTHER|Written Handouts|The written materials were generated using the collaboration of healthcare communication specialists to generate content that is tailored to a younger age demographic of childbearing age regarding their risk of developing a pelvic floor disorder and what can be done to prevent or treat them in the future.
224063508|NCT05440539|OTHER|Interactive Workshop|Participants logged onto a virtual meeting platform and listened to a live 20 minute presentation by a pelvic floor physical therapist followed by time for questions, which were answered live. Participants anonymity was maintained by not allowing participants to view each other's name and disabling sharing of video feeds.
224301599|NCT04132583|DRUG|Cataflam DD®|Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
224301600|NCT05803928|DRUG|lenvatinib + anti-PD-1 antibodies|A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group
224301601|NCT05803928|PROCEDURE|ablation|radiofrequency ablation or microwave ablation
224063509|NCT03808077|DRUG|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.003 mg/kg/min or 0.18mg/kg/hr).
224063510|NCT03808077|DRUG|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.006mg/kg/min or 0.35mg/kg/hr).
224063511|NCT05634733|OTHER|Treatment of Sepsis|Patients will have standard care of sepsis
224063512|NCT04152161|BIOLOGICAL|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
224063513|NCT04152161|BIOLOGICAL|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
224063514|NCT01409200|DRUG|Antiandrogen Therapy|Given per standard of care
224063515|NCT01409200|DRUG|Axitinib|Given PO
224063516|NCT01409200|PROCEDURE|Radical Prostatectomy|Undergo radical prostatectomy
224063517|NCT01409200|PROCEDURE|Regional Lymph Node Dissection|Undergo pelvic lymph node dissection
224063518|NCT05704933|DRUG|Nivolumab|Nivolumab is a monoclonal antibody o PD-1 protein, which is normally express on the surface of activated T cells. The interaction of PD-1 with its ligand (PD-L1) on T cells decreases their cytotoxic activity, helping protect normal cells in the setting of chronic inflammation. Tumor cells can utilize mechanisms to evade T cell mediated cytotoxicity by expressing PD-L1 on their surface or on the surface of T cells. Nivo, by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, allows T cells to remain active.
224063519|NCT05704933|DRUG|Ipilimumab|Ipilimumab is a recombinant, human antibody to CTLA-4.\[18-20\] CTLA-4 regulates T cell activation by binding with CD80 or CD86 with higher affinity than CD28, resulting in blockage of the co-stimulation signal and preventing further T cell activation. Blockade of CTLA-4 results in further T cell activation.
224063520|NCT05704933|DRUG|Nivolumab + Relatlimab|Opdualag (Nivolumab and Relatlimab-rmbw) is a human monoclonal antibody to LAG-3, currently under investigation.\[6\] Relatlimab is an antibody (IgG4 isotype) that has a stabilizing hinge mutation for attenuated Fc receptor binding to decrease or get rid of the possibility of antibody-mediated and/or complement-mediated target cell killing. Rela binds to an epitope on LAG-3 with high affinity and specificity, with subsequent blockade of LAG-3 and its interaction with its ligand, MHC class II. This antibody displays compelling in vitro functional activity in reversing LAG-3 that facilitates inhibition of an antigen-specific murine T cell hybridoma overexpressing human LAG-3 . Relatlimab was also shown to improve the activation of human T cells in superantigen stimulation assays when added either alone or in combination with Nivolumab.
224063521|NCT05704933|PROCEDURE|Standard of Care Craniotomy|Participants will undergo craniotomy for surgical resection of melanoma brain metastases.
224063522|NCT05701358|PROCEDURE|Physiology-guided NCL PCI|For RFR, PCI will be performed as per local practice for all lesions with RFR ≤0.89. For FFR, PCI will be performed as per local practice for all NCLs with FFR ≤0.80.
224063523|NCT05701358|PROCEDURE|Angiography-guided NCL PCI|PCI will be performed as per local practice
224063524|NCT05937672|DEVICE|Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)|The treatment device in this study generates cold atmospheric plasma. Cold atmospheric plasma has certain properties of plasma, such as ionized gas molecules. To create plasma, a pulse generator supplying 20 kilovolt pulse of 20-ns pulse width at 200 Hz (FPG10-01NM10, FID GmbH, Burbach, Germany) to a 5-mm diameter quartz-covered copper electrode of 10-cm length and 1 - 13mm quartz thickness. These nanosecond pulse parameters were chosen to provide sufficient treatment dose at the high level of plasma uniformity required to avoid any tissue damage. We will treat the lesions for approximately 1 to 2 minutes each, moving the electrode gently over the treatment area.
224063525|NCT06668714|COMBINATION_PRODUCT|Placebo + mixed meal|Placebo (140 mL isoosmotic salt water, NaCl) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = CTR
223454163|NCT01472133|OTHER|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
223454164|NCT06305663|DEVICE|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)|Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
223454165|NCT06305663|DEVICE|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens|CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
223454166|NCT06840041|DIAGNOSTIC_TEST|Vaginal swab and culture|Participants will undergo vaginal swab collection both pre-operatively, immediately prior to the cesarean section, and post-operatively, within a defined timeframe after the procedure. The swabs will be collected using sterile swabs, following standardized procedures to ensure accurate sampling of the vaginal microbiota. The collected samples will then be sent to a designated laboratory for culture and analysis. This process will identify and characterize the bacterial composition of the vaginal microbiota, allowing researchers to investigate potential correlations between specific microbial profiles and the development of post-cesarean section wound infections
223571604|NCT03150576|DRUG|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
223742664|NCT02409992|BEHAVIORAL|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
224063526|NCT06668714|COMBINATION_PRODUCT|Lactate + mixed meal|Lactate (140 mL lactate drink = 25 g D/L-lactate bound to Na) given 30 minutes before a liquid test meal with the addition of 70 MBq 18F-FTHA = LAC The investigators will also use the 18F-FTHA standardized uptake value (SUV) to evaluate dietary fatty acid trapping and distribution, to be able to compare our results with former studies using the 18F-FTHA method.
224063527|NCT06668714|RADIATION|PET-scan|Dynamic whole-body PET scan.
224063528|NCT06668714|COMBINATION_PRODUCT|Mixed meal with 18F-FTHA|Mixed meal test with the addition of 70 MBq 18F-FTHA
224063529|NCT06310434|OTHER|questionnaire|COOL Scale and DAS
224063530|NCT06310434|OTHER|Discussion group|Through discussion groups with students in secondary schools and university separately, a compassionate plan will be designed
224063531|NCT06310434|OTHER|Reflective diary|Students can modify the interventions adapting them to their requirements to get the compassion needed for those in need.
224063532|NCT03246958|DRUG|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
224063533|NCT03246958|DRUG|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
224063534|NCT06280209|DRUG|BMN 351|Anti-sense Oligonucleotide BMN 351 will be administered intravenously.
224148267|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by mechanical articulator|"The therapeutic jaw position will be determined by the following steps:~1. Pre-treatment Jaw Position Recording Participants were seated upright with relaxed posture, eyes facing forward, and the Frankfort plane parallel to the floor. Intercuspal position (ICP) was recorded using silicone registration material. Edge-to-edge position of central incisors was recorded for protrusive position. Left/right lateral positions were recorded with opposing canines aligned.~2. Transfer of Jaw Positions Following the manufacturer's protocol for the Artex CR mechanical facebow (Amann Girrbach, Austria) to transfer Participants' jaw positions.~3. Determination of Therapeutic Position The Glenoid fossa was divided into 7 grids in the oblique-sagittal plane using Gelb's method, identifying grid 4 (Gelb 4/7) as the target condylar position.Condylar displacement knobs were set per VTO analysis.~Incisal pin height was increased to establish vertical dimension."
224148268|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by ai-assisted virtual articulator|"The jaw position was determined by the following steps:~1. AI-Based Segmentation and Reconstruction of Jaw Models CBCT DICOM data was imported into an ai-based craniomaxillofacial bone segmentation system to reconstruct 3D models of the jaws and dentition. The mandibular/maxillary bone models and dental arches were exported as .ply files. These .ply files were then imported into Exocad software.~2. Virtual Transfer of Jaw Positions Bilateral AI-segmented medial pole points of the condyles and the right infraorbital point were annotated in cross-sectional views.A virtual articulator was added and registered to the facebow's reference planes and hinge axis. (3)Determination of Therapeutic Position Sagittal joint spaces (anterior/superior/posterior) were measured on cross-sectional views. The composite mandibular model was repositioned to the target occlusion using the Move Mesh function based on: Optimal mean joint space measurements and physiological condylar position."
224063535|NCT05841043|DRUG|SHR8028 eye drops|SHR8028 eye drops
224301602|NCT00292487|DRUG|Iopamidol 370 mgI/mL|
224301603|NCT05464043|DIAGNOSTIC_TEST|evaluation of second line glucose homeostasis|blood samples, urine samples, genetic test, peptide C stimulation test, OGTT, continuous glucose monitoring and questionnaires
224301604|NCT05326321|OTHER|Study Group|The patients in the intervention group were shown a video with virtual reality glasses for an average of 5 minutes, 2 minutes before the start of the AVF cannulation procedure and 3 minutes throughout the procedure.
223454167|NCT06890143|DRUG|Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks|"①Dapagliflozin+Standard Treatment for 12 weeks. Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg Standard Treatment:standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.),This combined therapy will be administered for 12 weeks.~② Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Standard Treatment alone for an additional 12 weeks. To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
223454168|NCT06890143|DRUG|Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks|"①Standard Treatment for 12 weeks Standard Treatment:Standard renin-angiotensin-aldosterone system inhibitor (RAASi) therapy alone for 12 weeks.(The dosage will be maintained at the pre-enrollment level throughout the entire treatment period, with no adjustments made during therapy.)~②Washout period for 4 weeks Participants should maintenance RAASi therapy while discontinuing dapagliflozin.~③Dapagliflozin+Standard Treatment for 12 weeks Dapagliflozin therapy (Farxiga®, 10 mg tablets) is administered orally once daily,with dose adjustment based on body weight: 5 mg/day for participants ≤30 kg; 5 mg/day initially (first week), then increased to 10 mg/day for participants \>30 kg.This combined therapy will be administered for 12 weeks To ensure compliance, all participants are required to complete a daily medication log.If any adverse events (AEs) occur, appropriate clinical interventions will be promptly implemented"
224063536|NCT05841043|DRUG|Vehicle eye drops.|Vehicle eye drops.
224063537|NCT01527864|DRUG|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
224063538|NCT01527864|DRUG|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
224063539|NCT05569707|DEVICE|Magnetic sentinel lymph node biopsy by use of Magtrace®, in combination with SentiMag® and DiffMag|In addition to the standard procedure, SLNs will be detected using two types of magnetometers (SentiMag® \& DiffMag) in combination with SPIO particles (Magtrace®).
224063540|NCT00808795|DRUG|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
224063541|NCT00808795|DRUG|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
224063542|NCT04922840|BEHAVIORAL|High-intensity exercise (HIIT)|12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
224063543|NCT03465189|DEVICE|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
224063544|NCT01379274|DRUG|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
224063545|NCT03443674|DRUG|SCB-313|Lyophilized powder in a single-use vial
224063546|NCT03767075|DRUG|Atezolizumab|1200 mg, administered IV, once every 3 weeks
224063547|NCT03767075|DRUG|Futibatinib|20 mg administered orally, once daily (QD) continuously in 28-day cycles.
223571605|NCT03150576|DRUG|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
224148269|NCT07090772|PROCEDURE|Repositioning splint therapy with jaw position determined by ai-assisted virtual patient|"The jaw position was determined by the following steps:~1. AI-Based Segmentation and Reconstruction of Virtual Patients:~   CBCT DICOM data was imported into an ai-based craniomaxillofacial bone segmentation system to reconstruct 3D models of the jaws and dentition. The trajectory of mandibular movement was recorded by an electronic facebow.~2. Virtual Transfer of Jaw Positions Bilateral AI-segmented medial pole points of the condyles and the right infraorbital point were annotated in cross-sectional views.A virtual articulator was added and registered to the facebow's reference planes and hinge axis. (3)Determination of Therapeutic Position Sagittal joint spaces (anterior/superior/posterior) were measured on cross-sectional views. The therapeutic position was determined based on: Optimal mean joint space measurements, physiological condylar position and optimal trajectory of mandibular movement."
224148270|NCT07092020|DEVICE|EDF|Extended depth of focus
224148271|NCT07092020|DEVICE|Monofocal IOL|Monofocal
223571606|NCT05875753|DIAGNOSTIC_TEST|68Ga-FAPI-FS PET/CT|"Participants will be administered a single, intravenous bolus of 68Ga-FAPI-FS. The recommended administered activity of 68Ga-NY104 is 1.8-2.2 MBq per kilogram bodyweight, subject to variation that may be required owing to variable elution efficiencies obtained during the lifetime of the 68Ga / 68Ga generator.~The CT and PET imaging session will begin approximately 45 to 75 minutes after 68Ga-FAPI-FS administration."
223571607|NCT04410666|OTHER|Green Tea mouthwash|"an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute."
224063548|NCT03767075|DRUG|Amivantamab|1050 mg administered IV for body weight \< 80 kg and 1400 mg for body weight \>= 80 kg mg once weekly in Cycle 1 (with a split dose on Days 1-2) and then every 2 weeks in subsequent cycles (28-day cycles)
224148272|NCT07090369|DRUG|Olaparib (300 mg BID)|oral tablet
224148273|NCT07090369|DRUG|Pembrolizumab|IV infusion
224148274|NCT07090369|RADIATION|177Lu-PSMA-I&T|PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen. PSMA-I\&T is a small molecule ligand that binds to the extra-cellular domain of the prostatespecific membrane antigen
224148275|NCT07092072|DEVICE|MYOFIX FULL FIELD PERIPHERAL DEFOCUS SPECTACLE|This is a plus peripheral add spectacle with the central part for the myopic correction.
223454169|NCT06039501|BEHAVIORAL|Family Perspective Program|The program involves regular meetings between families and an ICU support counselor. The ICU support counselor is a trained expert in providing culturally competent emotional and/or spiritual support. The ICU support counselor will support families and also learn and summarize family perspectives in a standardized report. ICU care team members will be prompted to perspective take as they review reports prior to regular routine meetings between families and the ICU care team.
223454170|NCT06774807|OTHER|Saline infusion|Saline/NaCl (9mg/ml) intravenous infusion
223571608|NCT04410666|OTHER|Placebo Mouthwash|distilled water
223571609|NCT01465217|BEHAVIORAL|text message medication reminders|daily medication reminders for one month
223571610|NCT00736775|DRUG|anti-Abeta|Intravenous single and multiple doses
223571611|NCT00736775|DRUG|placebo|Intravenous single and multiple doses
223571612|NCT03448666|COMBINATION_PRODUCT|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
223571613|NCT05785533|OTHER|Smartphone App|App that provides recovery guidance based on pain and functional outcomes
223571614|NCT05785533|OTHER|Standard of Care|Paper based discharge instruction that provide information on pain management
223571615|NCT03865108|PROCEDURE|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
224063549|NCT00004873|DRUG|cisplatin|
224063550|NCT00004873|DRUG|docetaxel|
224148276|NCT07090486|DRUG|nirmatrelvir-ritonavir|Paxlovid standard of treatment care
224148277|NCT07089966|OTHER|HTS counselor-led PrEP care model|PrEP delivery ,including HIV testing, eligibility assessment, dispensing, adherence counseling, and provision of refills, provided by an HTS counselor
224148278|NCT07090798|DIAGNOSTIC_TEST|Static Head posture|After the participant sit down and put on the VR glasses, the VR will detect how many degrees the head position has displaced from the neutral position (X= 0, Y = 0, Z = 0). The x, y and z describe the head alignment, and in the table (3.3), they explain the 3D axis (X, Y, Z). Also in fig 3.3 the participant's head is in X=5.027058 Y=2.466827 Z=2.93206, which explains the degree of deviation from the neutral position.
224301605|NCT04920643|PROCEDURE|Ultrafiltration|Ultrafiltration is used during cardiac surgery with cardiopulmonary bypass to remove both fluid and small molecules such as inflammatory cytokines from the patient's circulation.
223454171|NCT06774807|OTHER|Saline injection|Saline/NaCl (9mg/ml) subcutaneous injection
223454172|NCT06774807|OTHER|1nmol antagonist infusion|GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min
224063551|NCT00004873|DRUG|epirubicin hydrochloride|
224301606|NCT02567643|RADIATION|Stereotactic Radiosurgery|
224301607|NCT02254213|OTHER|EEG recording|A short EEG recording is performed 10 times over the span of three months.
224301608|NCT03589586|OTHER|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
224301609|NCT04190810|BEHAVIORAL|Inhibition|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
223454173|NCT06774807|OTHER|4 nmol antagonist infusion|GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min
223454174|NCT06774807|OTHER|Agonist injection|GLP-2(1-33) subcutaneous injection
223454175|NCT00305409|DRUG|Synbiotic (Synergy I / B.longum)|
224063552|NCT00004873|DRUG|fluorouracil|
224063553|NCT04352959|DEVICE|mouthrinse with bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
224063554|NCT04352959|DEVICE|mouthrinse without bêta-cyclodextrin and citrox|3 daily mouthrinses for 7 days
224301610|NCT04190810|BEHAVIORAL|Classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
223571616|NCT03865108|PROCEDURE|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
223571617|NCT06608667|DEVICE|The study was retrospective and did not involve the application of interventions|The study was retrospective and did not involve the application of interventions
223571618|NCT06608953|DEVICE|Enhanced external counterpulsation|A device applying external pneumatic cuff pressure to the lower limbs, thighs, and buttock sequentially in the diastolic phase synchronouslty with electrocardiography to assist the cardiac function via diastolic augmentation mechanism.
223571619|NCT06607133|PROCEDURE|surgery|patients undergo conventional/open thyroidectomy or endoscopic thyroidectomy for large benign thyroid nodules
223571620|NCT06607133|PROCEDURE|staged thermal ablation|patients undergo multiple sessions of thermal ablation for large benign thyroid nodules
223571621|NCT06589050|OTHER|"Toe flexor device experimental group"|This intervention group will perform toe flexion using a toe flexor (TF) device, which facilitates the shortening and stretching of the TF muscle-tendon units (MTUs) against resistance bands. While seated, participants will push a pedal down with their toes over two counts and release it over two counts.
223571622|NCT06589050|OTHER|"Inclined Heel Rise experimental group"|This intervention group will perform single-leg heel rises on an inclined platform. Participants will place their hands against a barre for balance support, lift their heels over two counts, and lower them over two counts.
223571623|NCT02099877|DRUG|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
223571624|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
223571625|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
223571626|NCT01386242|OTHER|Saline Injection|Saline Injection, 1mL, im,three times per week
223571627|NCT01386242|DRUG|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
223571628|NCT06819995|PROCEDURE|Static guided implant placement with a 3D printed guide|3D-printed guides (E-Guide resin, EnvisionTEC®, Germany) (D4K Pro printer, EnvisionTEC®, Germany) performed by acommercial manufacturing center (Archimedes, Spain). All guides will be designed with guide sleeves. Finally, the guide will be post-processed and sterilized according to the manufacturer's recommendations.
224063555|NCT03287219|DRUG|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
224063556|NCT00631020|BEHAVIORAL|CBME|6 weeks of once a week one-on-one CBME
224063557|NCT00631020|DRUG|Optional NRT|NicoDerm CQ nicotine transdermal patch
224148279|NCT07090798|DIAGNOSTIC_TEST|"Angular distance ROM"|"Cervical range of motion assessment is achieved through virtual reality. After detecting the static head posture, Participants will be asked to flex their necks as far as possible toward their chins and anterior chests. Then elevate the head to the neutral and extend the neck to the most tolerable range. Following that, he/she performs maximal neck side-bending in both directions along the coronal plane. Lastly, each participant is required to return the neck to an upright position for the examination of the maximum angle of neck rotation by turning the chin toward the right and then left shoulders without shrugging the shoulders. All of the tests will be repeated three times, and the averaged values of neck movement in each direction will be taken for analysis"
224301611|NCT04190810|BEHAVIORAL|Control|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
224301612|NCT03139786|OTHER|Study the natural history of bicuspid|Study the natural history of bicuspid
223571629|NCT06819995|PROCEDURE|Static guided implant placement with a milled guide|Milled guides (anaxCAM PMMA Clear blanks, Anaxdent, Germany) (CORiTEC 150i PRO miller, Imes-icore®, Germany). All guides will be designed with guide sleeves. Finally, the guide will be post-processed and sterilized according to the manufacturer's recommendations.
223571630|NCT06660784|DRUG|Nitric Oxide|Depending on the indication, the subjects will be given NO treatment or not. In ECMO assisted mechanical ventilation + NO treatment group, the subjects will be randomly assigned to NO treatment via ventilator or membrane oxygenator.
223571631|NCT06662097|DRUG|Bevonescein|Bevonescein is a sterile solution that is intravenously administered
223742665|NCT00865774|BEHAVIORAL|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
224063558|NCT06168032|BIOLOGICAL|Any Chinese government-recommended COVID-19 booster vaccine|Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.
224063559|NCT00002000|DRUG|Valacyclovir hydrochloride|
224063560|NCT00002000|DRUG|Acyclovir|
224063561|NCT06495086|DEVICE|NIV|The NIV group received bilevel-positive airway pressure. During NIV, the tidal volume was set to 6-8 mL/kg, positive expiratory end pressure (PEEP) to 3-5 cm H2O, and pressure support ventilation (PSV) to 8-12 cm H2O by a clinician with 8 years of experience. To reduce potential bias, the clinician was blinded to the null hypothesis.
224063562|NCT06495086|DEVICE|HFNC-30|The HFNC-30 group received HFNC therapy at flow rates of 30 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
224063563|NCT06495086|DEVICE|HFNC-50|The HFNC-50 group received HFNC therapy at flow rates of 50 L/min. During HFNC, the humidifier was set to an open position, the heated air temperature was maintained at 37°C, and the FiO2 was adjusted to maintain an oxygen saturation (SpO2) measured via pulse oximetry of at least 92%.
224063564|NCT02731209|DEVICE|urinary catheter|
224063565|NCT04523311|BEHAVIORAL|Hypnosis.|Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.
224063566|NCT04523311|OTHER|Usual care|Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
224063567|NCT02601521|BEHAVIORAL|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~1. Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~2. The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~3. Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
224063568|NCT02601521|BEHAVIORAL|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
224063569|NCT05959135|DEVICE|Gastric ultrasonography|"It seems like the text you provided is already in Turkish and it appears to be written in an academic style. If you want this text to be translated to English in an academic language, it would be:~Ultrasonographic evaluation of gastric contents in Diabetic and Non-Diabetic term pregnancies"
224063570|NCT03221751|DRUG|prazosin hydrochloride|Prazosin is an oral capsule. It is an alpha-1 antagonists.
224063571|NCT03221751|DRUG|placebo|Placebo is an inert oral capsule identical in appearance to prazosin capsules.
224063572|NCT02086539|OTHER|Large Envelope|
224148280|NCT07090889|DRUG|KM-023|solution for oral administration
223454176|NCT05225415|DRUG|CT1812|Orally administered CT1812
223454177|NCT06795243|PROCEDURE|PAIN NEUROSCIENCE EDUCATION AND THERAPEUTIC EXERCISE PROGRAM|"PAIN NEUROSCIENCE EDUCATION~1\. Introduction to the knowledge of pain in the XXI century. Pain as an alarm system.~Types of pain. Differences between acute and chronic pain. 3. Chronic pain. Concepts of kinesiophobia, catastrophism and fear avoidance, self-determination and neuroplasticity.~4\. Main pain management tools based on scientific evidence. 5. . Transtheoretical model of change. Adherence to treatment, importance as a determinant in health.~6\. Messages for home. Strategies of active coping in the maintenance stage.~THERAPEUTIC EXERCISE PROGRAM 10-min warm-up. Joint mobility exercises with dual task or gamification. 30-min main part. Sequence of balance work between strength and body flexibility dosed according to the specific needs of each participant.~10-min cool down including breathing exercises and motor imagery. Home exercise program: walking (150 minutes in total, 3 days alternating with the face-to-face sessions)."
223454178|NCT06795243|PROCEDURE|USUAL CARE|"The treatment provided is mainly pharmacological, adjusted to the symptomatic profile of theses patients.~Conventional medical care is based on hormonal, pharmacological and/or surgical treatment and is carried out on an individualized basis depending on the severity of the disease and the patient's needs, especially in matters of desire to become pregnant. Surgical treatment is carried out when pharmacological therapy (hormonal or anti-inflammatory) is ineffective or involves adverse events."
223454179|NCT04091386|DRUG|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
223454180|NCT06854185|BEHAVIORAL|Paso Program|The Paso Program is a behavioral weight loss program. It consists of a series of 16 one-hour-long semi-structured group counseling sessions led by a health educator every 1-2 weeks over 26 weeks. Each session has a curriculum with a counselor's guide and patient facing materials, covers specific topics (eating, physical activity, behavioral change strategies). Teaching methods include discussions, practice activities, demonstrations. The program is delivered to groups of 8 to 14 participants, classes are offered primarily in-person with the option of virtual attendance.
223454181|NCT01538849|DRUG|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
223454182|NCT01538849|DRUG|YH4808 A mg|1 tablet = YH4808 A mg
223454183|NCT01538849|DRUG|YH4808 B mg|1 tablet = YH4808 B mg
223454184|NCT01538849|DRUG|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
223454185|NCT00357890|DEVICE|Insulin pump therapy|CSII initiated within 1 month of diagnosis
223454186|NCT00357890|DRUG|Multiple daily injections using insulin glargine + rapid acting analog|MDI as control
223454187|NCT06843785|OTHER|Squat with knees over toes|Participants are instructed to stand comfortably with feet pelvis-width apart and approximately 15-30° to the side with arms extended in front of them. Participants are asked to squat to their most comfortable point, looking straight ahead, without heels leaving the floor, and to hold the position for 2 seconds before returning to the original standing position. The distance between the hips and the floor is measured vertically using a ruler for squat depth. Three trials are performed and the average of the three trials is used for further analysis.
223571632|NCT04942015|DRUG|Honghuaruyi Wan|Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
223571633|NCT04942015|DRUG|Placebo of Honghuaruyi Wan|Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
224063573|NCT02086539|OTHER|Priority Mail|
224063574|NCT02086539|OTHER|Amazon|
224063575|NCT05559489|DRUG|Oral Rehydration Solution|Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
224063576|NCT05559489|DRUG|Lactated Ringer|Standard-of-care Intravenous Fluid resuscitation
224148281|NCT07090889|DRUG|Placebo|solution for oral administration
224301614|NCT00090610|DRUG|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
224301615|NCT00090610|DRUG|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
224063577|NCT06044480|DRUG|Dexamethasone|Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
224063578|NCT06044480|OTHER|Placebo|Administration of the same amount of saline solution instead of dexamethasone
224063579|NCT01250600|BEHAVIORAL|Home exercise|Daily home exercise for 3 months
224063580|NCT03167996|BEHAVIORAL|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
224301616|NCT06060808|GENETIC|gene polymorphism|gene polymorphism of NFKBIA and PTPN22 genes
223454188|NCT06843785|OTHER|Squat where the knee does not pass the toes|In the limited squat exercise, the position of the most anterior part of the knee is not allowed to extend beyond the toes. In the limited squat exercise, a wooden board is placed just distal to the first toe of each foot, and the 60 cm wide wooden board restricts knee movement. Participants are instructed to stand comfortably with their feet pelvis-width apart and approximately 15-30° to the side, and their arms extended in front of them. Participants are asked to squat to 90° of knee flexion, looking straight ahead, without the heels leaving the floor, and to hold the position for 2 seconds, then return to the original standing position. Squat depth is determined by measuring 90° of knee flexion using a goniometer placed on the knee and measured vertically between the hip and the floor using a ruler. Three trials are performed, and the average of the three trials is used for further analysis.
223454189|NCT06843785|OTHER|control|Participants will not be subjected to any intervention and will not be asked to perform any action.
223454190|NCT06880666|PROCEDURE|Minimally invasive laparoscopic pull-through surgery|Conventional laparoscopic pull-through (CLP) surgery utilizes 3-5 small abdominal incisions for the placement of trocars, allowing the insertion of a laparoscopic camera and surgical instruments. After establishing pneumoperitoneum, the aganglionic segment is identified, and the colon is mobilized by dividing the lateral attachments using laparoscopic energy devices. The rectal dissection is performed circumferentially down to the level of the pelvic floor while preserving the mesenteric blood supply. A transanal approach is then used to complete the dissection, pull the mobilized bowel through the anus, and resect the aganglionic segment. A coloanal anastomosis is created, typically with absorbable sutures. Single-incision laparoscopic pull-through (SILS) follows the same principles but is performed through a single umbilical incision using a multi-port device; instruments and a camera are inserted through the same access point.
223454191|NCT06799078|OTHER|Observation while participants receive treatment by their primary care provider|Participants complete a consultation with a psychiatrist who makes some recommendations for the treatment of their depression. The participant's primary care provider decides whether to implement some of these recommendations.
223454192|NCT06745648|PROCEDURE|Arm A - Carotid Sinus Massage + Trendelenburg (CSM+T)|Manual stimulation of the carotid sinus area combined with head-down tilt positioning to activate baroreceptors for headache relief.
223454193|NCT06745648|PROCEDURE|Arm B - Sham CSM+T|Light neck contact, avoiding carotid sinus pressure, paired with identical body positioning to mimic the experimental intervention.
223454194|NCT00845676|DRUG|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
224063581|NCT05395065|DEVICE|Silver Diamine Fluoride/Sodium Fluoride Varnish|Application of dental caries arresting topical medication
224063582|NCT00586495|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
224063583|NCT03891173|DRUG|L-DOS47|L-DOS47 lyophilized powder reconstituted and diluted for iv injection
224063584|NCT03891173|DRUG|Cisplatin|Cisplatin concentrate for solution for iv infusion
224063585|NCT03891173|DRUG|Vinorelbine|Vinorelbine concentrate for solution for iv infusion
224063586|NCT03679533|DIETARY_SUPPLEMENT|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
224063587|NCT03679533|DIETARY_SUPPLEMENT|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
224063588|NCT03247270|BEHAVIORAL|Intervention I|Low intensive physical exercise
224063589|NCT03247270|BEHAVIORAL|Intervention II|High intensive physical exercise
224063590|NCT06308042|OTHER|30 second sit and stand test|The individual sits in the middle of the chair with his back upright, his feet on the ground, and his arms crossed in front of his chest. The individual starts the test with the start command while in this position and takes off as fully as he can for 30 seconds.
224063591|NCT04043325|DIAGNOSTIC_TEST|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
224063592|NCT03459209|OTHER|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
224063593|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
224301617|NCT00807248|DRUG|Escitalopram placebo|Once daily before bedtime for 8 weeks
224301618|NCT00807248|DRUG|Gaboxadol placebo|Once daily before bedtime for 8 weeks
224301619|NCT00807248|DRUG|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
224301620|NCT00807248|DRUG|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
224301621|NCT00807248|DRUG|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
224301622|NCT00788749|DRUG|Prednisolone|tablets 25 mg/day
224301623|NCT00788749|DRUG|Placebo|tablets once daily
224301624|NCT00788749|OTHER|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
224301625|NCT00788749|OTHER|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
223571634|NCT06606678|OTHER|Exercise|supervised exercise training; twice a week for 12 months
224063594|NCT00440947|DRUG|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
224063595|NCT06082388|DRUG|Comparison of atropine and isoprenaline|Comparison of heart conductive system and arrhythmia inducibility after using atropine or isoprenaline
224063596|NCT05576389|DRUG|Camrelizumab+Fluzoparib|Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
224148282|NCT07091045|OTHER|Robot-Assisted Foot-Ankle Training|"Stage 1: Vibration Training Applied for Proper Stepping on the Sole of the Foot and Proper Pressure Distribution: The first step of the training will be constant vibration, and the second step will be sensory localization training with vibration.~Stage 2: Passive Joint Range of Motion Training with Virtual Reality: The platform will move the ankle passively (passive stretching).~Stage 3: Joint Position Sense Training: The platform will bring the patient's ankle to a certain dorsiflexion position, the patient will be asked to feel and be aware of this angle, then the patient will be asked to return to the neutral position and perform ankle dorsiflexion at the angle that the platform initially brought.~Stage 4: Active Joint Range of Motion Training with Virtual Reality: Along with active dorsiflexion, when necessary, assistance will be provided with the Assistance as Needed (AAN) control paradigm, a feature of the robotic device.~Stage 5: It is the same as Stage 1"
224148283|NCT07091045|OTHER|Conventional Foot-Ankle Training|Stage 1: Sensory Training to the Sole of the Foot: In the first step of the training, the physiotherapist will manually apply constant pressure with a blunt object, and in the second step, sensory localization training with a blunt object will be performed. Stage 2: Passive Joint Range of Motion Training: The ankle will be manually moved passively (passive stretching) by the physiotherapist. Stage 3: Joint Position Sense Training: The physiotherapist will bring the patient's ankle to a certain dorsiflexion position, the patient will be asked to feel and be aware of this angle, then the patient will be asked to return to the neutral position and perform ankle dorsiflexion at the angle that the physiotherapist initially brought. Stage 4: Active Joint Range of Motion Training: This stage will be performed with manual assistance provided by the physiotherapist when necessary, along with active dorsiflexion. Stage 5: It is the same as Stage 1
224148284|NCT07092189|OTHER|Pre-colposcopy counseling by a clinical nurse|"In the intervention group, the clinical nurse conducted a structured pre-colposcopy counseling session covering the following topics: verification of the patient's understanding of the reason for the colposcopy referral, explanation of the cervical cytology result, the procedure of the colposcopy, expectations regarding pain, the role of HPV in the development of precancerous and cancerous cervical lesions, counseling on HPV vaccination, and smoking cessation."
224148285|NCT07092189|OTHER|Treatment as usual: regular call to schedule the appointment without pre-procedure conseilling|In the control group, patients simply received a phone call to notify them of their appointment and, upon arrival, were given an information sheet about colposcopy. No pre-colposcopy discussion was conducted.
223454195|NCT00472485|PROCEDURE|eye movement therapy|
223454196|NCT02675270|BEHAVIORAL|Phonological|This treatment involves picture viewing and word repetition.
223454197|NCT02675270|BEHAVIORAL|Orthographic|This treatment involves picture viewing, reading, and writing.
223454198|NCT02675270|BEHAVIORAL|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
223454199|NCT02675270|BEHAVIORAL|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
223454200|NCT02675270|BEHAVIORAL|Untrained|These words are not trained during the treatment phase.
223454201|NCT04135313|DRUG|Capecitabine|2000 mg/m2, bid, per os, days 1-14
224063597|NCT03322189|GENETIC|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
224148286|NCT06908694|DRUG|Semaglutide Pen Injector|The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4mg for the remainder of the trial. Semaglutide dose may be decreased in the case of adverse events to the highest tolerated dose.
224148287|NCT07090915|OTHER|nature sound|Modern audio technology is used to create a 3D natural atmosphere.
223454202|NCT04135313|DRUG|Oxaliplatin|130 mg/m2 iv day 1
223742666|NCT00865774|BEHAVIORAL|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
223454203|NCT04135313|DRUG|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
223454204|NCT04135313|RADIATION|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
223454205|NCT04135313|PROCEDURE|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
223454206|NCT06842953|OTHER|Simulated indoor overheating|Older adults are exposed to a 10-hour simulated exposure
223571635|NCT06609018|DEVICE|Test Lenses (stenfilcon A)|Daily disposable, soft contact lenses worn for one week
223571636|NCT06609018|DEVICE|Control Lenses (omafilcon A)|Daily disposable, soft contact lenses worn for one week
223742667|NCT05755685|DRUG|Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)|5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
223742668|NCT01726153|BEHAVIORAL|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
223742669|NCT03096379|DIAGNOSTIC_TEST|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
223742670|NCT01064401|BIOLOGICAL|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
223742671|NCT01064401|DRUG|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
224063598|NCT02670863|OTHER|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
224063599|NCT02670863|OTHER|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
224063600|NCT00520364|OTHER|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
224063601|NCT03838302|PROCEDURE|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
224063602|NCT03838302|PROCEDURE|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
224148288|NCT07090603|OTHER|Knee extension exercise|Maximum repetitions of knee extension exercise at 20%, 30%, 40%, 50%, 60% and 70% of participants one rep max with and without blood flow occlusion
224148289|NCT07091331|PROCEDURE|Personalized 3D-printed pediatric ceromer crown|After primary molar crown preparation, digital impression using intraoral scanner (i700, Medit, Seoul, South Korea), crown will be designed with CAD software (CliniCAD, medit, South Korea) and fabricated using a 3D printer, (Sonic mini 4k, Phrozen, Taipei, Taiwan). Crown will be cemented by passive seating using a self-adhesive dual cure cement (Beauticem, shofu, San Marcos, CA, USA)
224148290|NCT07091331|DEVICE|Prefabricated stainless steel crown group|Stainless steel crown application: After preparation of the tooth, the crown will be filled and cemented with type-1 glass ionomer cement (Ketac Cem easymix, 3M ESPE, Minnesota, USA)
224148291|NCT07091487|BEHAVIORAL|Diabetes Homeless Medication Support|There will be 10 one-on-one sessions offered within 12 weeks to participants. Sessions will last approximately 30 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors and psychologiccal wellness to the extent that participants are willing. The coach will also help with resource and care coordination. The coach will also provide a tailored tool matched to the patient's needs/goals and tailored diabetes education as needed.
224148292|NCT07091487|BEHAVIORAL|Enhanced Usual Care/ Education|Trained diabetes wellness coaches will provide approximately 15 minutes of instruction about the basic concepts of diabetes. They will use handouts aligned with American Diabetes Association guidelines. They will use the ask-offer-ask method to review these with participants and answer basic questions. Handouts will cover (1) general diabetes knowledge, (2) healthy eating with diabetes, (3) physical activity with diabetes. The coach will also provide a general tool to support medication adherence (e.g. pillbox).
224063603|NCT05115838|DRUG|Islatravir|ISL 47, 52, or 57 mg implantable rod placed subdermally on the upper arm.
224063604|NCT05115838|DRUG|Placebo|Placebo implantable rod placed subdermally on the upper arm.
224063605|NCT02820285|OTHER|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
224063606|NCT02820285|OTHER|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
224148293|NCT07090473|DEVICE|transcutaneous spinal cord stimulation|Transcutaneous spinal stimulation will be delivered using the experimental ARC-EX device (ONWARD Medical), via skin surface electrodes placed over the spine (stimulating electrodes) and bilaterally on the iliac crests (reference electrodes) during the intervention.
224148294|NCT07090473|DEVICE|sham transcutaneous spinal cord stimulation|For sham transcutaneous spinal stimulation electrodes will be placed on the skin surface over the spine and bilaterally on the iliac crests and will be attached to the experimental ARCEX device (ONWARD Medical), however no electrical current will be delivered.
224148295|NCT00257023|DRUG|paliperidone|
224063607|NCT02820285|OTHER|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
224063608|NCT05882955|BEHAVIORAL|Recipes consumption|Participants will eat one or two recipes a day for 17 weeks
224063609|NCT05882955|BEHAVIORAL|Hydroponic unit|Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
224063610|NCT01850485|DEVICE|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
224063611|NCT02681172|DRUG|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
224063612|NCT02681172|PROCEDURE|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
224063613|NCT03417908|PROCEDURE|PNF|The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
224063614|NCT03417908|PROCEDURE|Sham|Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
224148296|NCT07091006|DRUG|VAH|For R/R AML patients, VAH bridging to conditioning regimen for allo-HCT.
224148297|NCT07092241|DIETARY_SUPPLEMENT|microbiota|Bifidobacterium breve and Bifidobacterium longum
224148298|NCT07092241|DIETARY_SUPPLEMENT|microbiota|Bifidobacterium and Lactobacillus
224148299|NCT07092137|DRUG|Nano-crystalline Megestrol Acetate Oral Suspension|Nano-crystalline Megestrol Acetate+PD-(L)1 inhibitor (Q3W, until PD) + chemotherapy (based on guidelines)
224063615|NCT04265885|OTHER|collection of testimonies from transgender people|guided interview
224063616|NCT03622463|DRUG|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
224063617|NCT03622463|OTHER|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
224063618|NCT04424654|DRUG|Testosterone cypionate|Testosterone cypionate 400 mg IM
224063619|NCT05151003|OTHER|Data collection|Collection and analysis of data related to AKI epidemiology, treatment and outcomes
224063620|NCT04510233|DRUG|Ivermectin nasal|Ivermectin nasal spray one ml in each nostril two times daily
224063621|NCT04510233|DRUG|Ivermectin oral|Ivermectin oral (one tablet 6 mg three times daily)
224063622|NCT04510233|OTHER|standard care|oxygen via masks or ventilators
224063623|NCT04317495|OTHER|Computerized Cognitive Training (CCT)|After having four rTMS sessions without CCT, the patients will perform CCT (starting day 5) during the rTMS session, which typically last from 20-40 minutes. A course of rTMS therapy includes from 25-36 treatments, given daily, until the last 5-6 treatments, given as a 'taper' over 2 weeks. CCT will be paired with rTMS up until the taper begins. In addition, they will have assessments prior to and after the therapy.
224063624|NCT03569579|DRUG|Memantine Tab. 10mg|Memantine Tab. 10mg\* 2T/day, QD, PO
224063625|NCT03569579|DRUG|Memantine Tab. 10mg + Donepezil Tab. 10mg|Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO
224063626|NCT05687331|PROCEDURE|knee arthrocentesis|arthrocentesis of the knee joint to gather a synovial fluid sample
224063627|NCT05687331|PROCEDURE|venipuncture|Peripheral venipuncture to gather a blood sample
224063628|NCT05687331|DIAGNOSTIC_TEST|MRI-scan|MRI-scan of the knee
224063629|NCT05687331|DIAGNOSTIC_TEST|Physical examination|Physical examination of the injured knee
224063630|NCT05687331|OTHER|KOOS questionnaire|KOOS questionnaire of the injured knee
223742672|NCT01064401|BIOLOGICAL|Interferon beta-1a|Interferon beta-1a for intramuscular injection
224063631|NCT01963312|PROCEDURE|Transarterial Supraselective Embolization of the prostate|
224063632|NCT01963312|PROCEDURE|Transurethral Resection of the prostate|
224063633|NCT02228291|DIETARY_SUPPLEMENT|Capsule containing citrus flavonoid|
224063634|NCT02228291|DIETARY_SUPPLEMENT|Placebo|
224063635|NCT02555670|OTHER|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
224063636|NCT06012370|PROCEDURE|PRP injection|Injection of PRP and hyaluronic acid
224063637|NCT01834274|DRUG|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
224063638|NCT01834274|DRUG|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
224063639|NCT01834274|DRUG|Sitagliptin|Sitagliptin tablets
224063640|NCT01834274|DRUG|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
224063641|NCT01834274|DRUG|Metformin|Metformin tablets
224063642|NCT03119714|DRUG|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
224063643|NCT03119714|DRUG|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
224148300|NCT07092137|OTHER|Nano-crystalline Megestrol Acetate Oral Suspension placebo|Nano-crystalline Megestrol Acetate placebo+PD-(L)1 inhibitor (Q3W, until PD) + chemotherapy (based on guidelines)
224148301|NCT07090356|OTHER|Instrument-Assisted Soft Tissue Mobilization|IASTM therapy will be provided to participants in whom a specialized instrument will be used to apply controlled pressure over the piriformis muscle as well as surrounding soft tissues.
224148302|NCT07090356|OTHER|Proprioceptive Neuromuscular Facilitation Stretching|PNF stretching (contract relax; hold relax) will be implemented to stretch participants' muscles as flexibly and with as much control as possible.
223742673|NCT01064401|DRUG|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
224063644|NCT01142401|DRUG|Bortezomib|Given IV
224063645|NCT01142401|DRUG|Fulvestrant|Given IM
224063646|NCT01142401|OTHER|Laboratory Biomarker Analysis|Correlative studies
224063647|NCT04082754|BIOLOGICAL|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody
224063648|NCT04082754|DRUG|Placebo|0.9% sodium chloride, same volume and same duration as CSL311
224063649|NCT05872750|DEVICE|theta burst stimulation|Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)
224063650|NCT05872750|DEVICE|sham stimulation|sham stimulation
224063651|NCT02422212|OTHER|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
224063652|NCT02017327|DRUG|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
224063653|NCT02017327|DRUG|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
224063654|NCT02017327|DRUG|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
224063655|NCT06180200|DIAGNOSTIC_TEST|PET for the analysis of mu opioid receptor expression.|PET for the analysis of the expression of mu opioid receptors and to directly measure the distribution of the receptors and enzyme reuptake sites at the brain level.
224063656|NCT01537562|OTHER|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
224063657|NCT03362970|DEVICE|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in \~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
224063658|NCT03362970|OTHER|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
224063659|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
224063660|NCT03880175|BEHAVIORAL|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
224063661|NCT03880175|BEHAVIORAL|Anti Stigma Information|Adults in the households are provided anti-stigma information
223454207|NCT06887777|DRUG|Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]|The patients will orally take a dose of 200 mg/kg/day three times a day during meals: breakfast, lunch or afternoon snack and diner for 6 months.
223742674|NCT03509025|DRUG|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
224063662|NCT03880175|BEHAVIORAL|HIV/AIDS Information|The households receive information about HIV infection and AIDS
224063663|NCT03880175|BEHAVIORAL|ART Information|The households receive information about antiretroviral therapy.
224063664|NCT03880175|BEHAVIORAL|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
224063665|NCT03880175|BEHAVIORAL|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
224063666|NCT00106275|BEHAVIORAL|Mindfulness Based Stress Reduction|
224063667|NCT00626691|BEHAVIORAL|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
224063668|NCT03592940|DIETARY_SUPPLEMENT|Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours
224063669|NCT01956903|GENETIC|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
224063670|NCT02965807|DEVICE|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
223454208|NCT06559228|OTHER|ConnectedNest|Participants will receive a secure message to register and download ConnectedNest's patient app, EmpowerNest. They will be asked to complete a set of modules at baseline through ConnectedNest to understand their health related social needs and programs available to meet those needs. They will receive basic training on the functionality and services available within the app and asked to use the app to identify and connect with needed social and community services for 90 days. Participants will be directed to complete a survey at baseline, 30, 60, and 90 days to collect patient-reported outcomes.
223454209|NCT06559228|OTHER|Standard of care|Participants will be directed to complete a survey at baseline, 30, 60 and 90 days to collect patient-reported demographics, cancer characteristics and outcomes metrics
224063671|NCT04906174|OTHER|Electronic Health Record Review|Medical records are reviewed
224063672|NCT03961815|DRUG|Brazikumab Induction Dose|Participants who met criteria for early termination due to lack of efficacy (rescue treatment criteria) or who did not meet CDAI response at Week 52 in the lead-in study D5121C00001 are considered inadequate/non responders, and will receive IV induction dosing brazikumab at Week 0, Week 4, and Week 8 followed by maintenance dosing of brazikumab subcutaneously every 4 weeks thereafter up to Week 52.
224063673|NCT03961815|DRUG|Brazikumab Maintenance Dose|Responders from Lead-In study D5271C00001 who completed requirements through Week 52 and met CDAI response (CDAI score of \< 150 points or CDAI reduction from Baseline of ≥ 100 points) without ongoing rescue treatment at Week 52 in the lead-in study. will receive maintenance dose of brazikumab administered subcutaneously every 4 weeks through Week 52, starting at Week 0. The subcutaneous dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered
224063674|NCT06090370|DEVICE|N95 Respirator|The participants in this group will be provided with N95 respirator masks to protect from dust and debris while working in the brick kiln and trained on proper usage.
224063675|NCT06090370|DEVICE|Protective Eyewear|The participants in this group will be provided with eye wear to protect the eyes from dust and debris while working in the brick kiln and trained on proper usage
224063676|NCT06090370|OTHER|Baseline Survey|A quantitative, cross-sectional survey will be distributed to enrolled participants to understand baseline worker perceptions on silicosis and personal protective equipment (PPE).
224063677|NCT06090370|OTHER|Design of Workshop|A co-creation human centered design workshop to elicit feedback on PPE training prototypes and types of PPE.
224063678|NCT06090370|OTHER|Training Workshop Pilot|Qualitative workshops will be held to elicit feedback on the piloted PPE training program.
224063679|NCT00356928|DRUG|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
223454210|NCT06843681|DRUG|Trastuzumab combined with taxane neoadjuvant therapy|Trastuzumab combined with taxane neoadjuvant therapy
223742675|NCT03158051|BEHAVIORAL|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
224063680|NCT00356928|BIOLOGICAL|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
224063681|NCT05752253|OTHER|Counseling|Counseling is a process which, through positive orientation and the enhancement of personal resources, is aimed at promoting the improvement of the quality of life in the other.
224301626|NCT02444793|DRUG|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
223454211|NCT06178653|OTHER|Pulmonary Rehabilitation|Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
223454212|NCT06178653|OTHER|Trunk Control Training|Trunk Control Exercises will be based on the neurodevelopmental process. Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
223454213|NCT06408311|COMBINATION_PRODUCT|ENC-201-CED hPI|macro-encapsulated human primary islets
223742676|NCT03158051|BEHAVIORAL|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
224063682|NCT03237104|OTHER|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
224063683|NCT01311037|OTHER|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
224063684|NCT02662257|DRUG|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
224148303|NCT07092111|DEVICE|Auricular acupuncture treatment|Auricular acupuncture is an innovative intradermal acupuncture, which can directly use the meridian system of the ear skin to directly transmit the received stimulation to the lesion. Its stimulation time is long, and the amount of stimulation is strong. Studies have shown that needle pricking continuously delivers an adequate dose of acupuncture stimulation by continuously stimulating Aβ, Aδ, and/or C afferent fibers from the skin and transmitting them to the brain nucleus through the ventrolateral cord of the spinal cord. It is also believed that by stimulating the cranial nerves, especially the auricular branch of the vagus nerve, the effect of sensory afferent peripheral stimulation can be enhanced, and the analgesic effect of the auricular acupoints can be achieved.
224063685|NCT02662257|DRUG|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
224063686|NCT00823355|DRUG|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
224063687|NCT00823355|DRUG|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
224063688|NCT00823355|DRUG|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
224063689|NCT00823355|DRUG|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
224063690|NCT05937178|DRUG|ETV/TAF/TDF/TMF/IFN|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
224148304|NCT07092111|DEVICE|Sham acupuncture group|The treatment regimen is the same as that of the auricular acupuncture treatment group, but with a sham acupuncture (Seirin Pyonex Needles).
224148305|NCT07092098|COMBINATION_PRODUCT|tDCS combined with resistance training|Transcranial direct current stimulation combined with resistance training
224148306|NCT07092098|BEHAVIORAL|Resistance training|low-limb resistance training
224148307|NCT07092098|DEVICE|tDCS|Transcranial direct current stimulation
223454214|NCT05635097|BEHAVIORAL|Motivational Interviewing counseling on the Mediterranean diet and weight checks at regular intervals|Each participant will meet virtually on Zoom with the DNP project leader and receive 1:1 counseling on pairing the Repnho smart scale and tape measure with the Renpho application. The expectations of the weight management program will be explained in detail during the first session, which will last one hour (session one= week zero). The weight loss goal will be at least 1-2 pounds per week as recommended by the Centers for Disease Control and Prevention (CDC) (2022).
224148308|NCT07092098|DEVICE|sham tDCS|Sham transcranial direct current stimulation
224148309|NCT07090161|DRUG|iloperidone|iloperidone
223454215|NCT02559726|PROCEDURE|Echocardiography (TEE)|
223454216|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) with gadolinium enhancement|
223454217|NCT02559726|DEVICE|Magnetic resonance imaging (MRI) without gadolinium enhancement|
223454218|NCT02559726|PROCEDURE|3D electrocardiographic mapping (ECM)|
223454219|NCT03386604|DIETARY_SUPPLEMENT|Whey protein|whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.
223742677|NCT05249361|OTHER|no intervention|no intervention
223742678|NCT00215163|DRUG|Cognitive-behavioral therapy and paroxetine-CR|
223454220|NCT03386604|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin energy value 160 kcal.
223742679|NCT05629390|DRUG|Lotilaner|Lotilaner Ophthalmic Solution
223742680|NCT05629390|DRUG|Vehicle Control|Vehicle of TP-03 ophthalmic solution
223742681|NCT06493695|BEHAVIORAL|Both EGChat and CES intervention|"1. A exercise-promoting chatbot called EGChat, integrated into an established online health promotion platform.~2. Intervention of CES (Cranial Electrotherapy Stimulation) at Home"
223742682|NCT06493695|OTHER|Exercise Chatbot|Exercise Chatbot
223742683|NCT06493695|DEVICE|CES (Cranial Electrotherapy Stimulation)|Intervention of CES (Cranial Electrotherapy Stimulation)
223742684|NCT01518920|DRUG|PF-04958242|PF-04958242 0.35 mg oral solution
223742685|NCT01518920|DRUG|PF-04958242|PF-04958242 0.27 mg oral solution
223742686|NCT01518920|DRUG|Placebo|Placebo oral solution
224063691|NCT05937178|DRUG|ETV/TAF/TDF/TMF|peginterferon alpha or nucleos(t)ide alone are decided by patients' doctors according to their conditions, instead of extra interventions brought by the study
223454221|NCT05524480|BEHAVIORAL|Salud en Mis Manos - Dissemination and Implementation Assistance|The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).
224063692|NCT01100515|OTHER|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
224063693|NCT01100515|OTHER|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
223454222|NCT05524480|BEHAVIORAL|Salud en Mis Manos- Usual Implementation Practice|The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.
223454223|NCT01680653|DRUG|Mini-glucagon|Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age
223454224|NCT01680653|DEVICE|Remote monitoring|Provides real-time continuous glucose monitoring
223454225|NCT01680653|DIETARY_SUPPLEMENT|Carbohydrates|16 grams of carbohydrate
223454226|NCT02706353|DRUG|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
223454227|NCT02706353|DRUG|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
223454228|NCT02394236|OTHER|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
223454229|NCT00311454|DRUG|T.R.U.E.Test|
223454230|NCT06880549|BIOLOGICAL|mRNA-4106|Intramuscular Injection
223454231|NCT06880549|BIOLOGICAL|Nivolumab/Relatlimab|Intravenous infusion
223454232|NCT00199576|DRUG|Methylprednisolone|
223454233|NCT00162227|DRUG|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
223742687|NCT04758819|PROCEDURE|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB)|In vitro Fertilization by ICSI then embryo culture until Day 5/6; all blastocysts with morphological scores compatible with TE biopsy and vitrification will be submitted to Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts (CTTEB) and vitrified.
223742688|NCT02588833|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
224063694|NCT04241211|DRUG|Forsteo|Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery.
224063695|NCT04241211|DRUG|Denosumab Prefilled Syringe [Prolia]|Patients were administered 60mg of denosumab (Prolia) subcutaneously once 6months from the day on before 3months to after 3months about surgery.
224063696|NCT01090466|DRUG|cisplatin|
224063697|NCT01090466|DRUG|gemcitabine hydrochloride|
224063698|NCT01090466|DRUG|temsirolimus|
224063699|NCT01090466|OTHER|pharmacological study|
224063700|NCT01870427|DRUG|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
224063701|NCT05259865|DIAGNOSTIC_TEST|Genetic test for drug response prediction|"There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies.~All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study."
224063702|NCT02739607|BEHAVIORAL|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
224063703|NCT01529437|DRUG|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
224063704|NCT01529437|DRUG|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
224063705|NCT01422915|DRUG|Colestipol|2 grams morning and bedtime for 90 days.
224063706|NCT02813694|DRUG|lefamulin|antibacterial agent
224063707|NCT02813694|DRUG|Moxifloxacin|antibacterial agent
224063708|NCT01265797|DEVICE|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
224063709|NCT01265797|DEVICE|Sham Device|participant wears sham device for 20 minutes daily for 28 days
224063710|NCT00491699|DRUG|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
224063711|NCT00549172|PROCEDURE|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
224063712|NCT00549172|PROCEDURE|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
224063713|NCT06290375|DRUG|HSK21542 tablet|once-daily
224063714|NCT06290375|DRUG|Placebo|once-daily
224063715|NCT00731575|DRUG|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
224063716|NCT05711004|BEHAVIORAL|Education via SMS|Participants in the experimental group will receive three messages per week in the morning (9-10 am) for three months. The investigators will call them every month to ensure that the SMS is delivered.
224063717|NCT02980224|DRUG|OmegaD|OmegaD Softgels
224063718|NCT02980224|DRUG|Placebo|Placebo Softgels
224063719|NCT02942745|BEHAVIORAL|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
224148310|NCT07090161|DRUG|Placebo|placebo comparator
224148311|NCT07091552|DEVICE|CAD/CAM monolithic denture|"Based on the workflow suggested by the Ivoclar digital denture, conventional complete dentures will be scanned by using desktop scanner (Medit T710). The cameo and intaglio surfaces of the complete dentures will be scanned, and the scanned data will be exported as Standard Tessellation Language (STL) file to start the milling process.~For the milling process, monolithic denture will be milled from a bicolored disk (Ivotion). One side is the denture base material made of high impact optimized polymethyl methacrylate (PMMA) while the other is the teeth material made of highly cross-linked PMMA with no filler. The bicolor disk is milled in a 5-axis milling machine in wet condition, through an uninterrupted milling process. Following the fast milling process the dentures will be finished and polished."
224148312|NCT07091552|DEVICE|Conventional denture|The conventional set will be fabricated with the 5-appointment process: preliminary impressions (first appointment); definitive impressions (second appointment); interocclusal records and tooth selection (third appointment), the size of the teeth will be selected according to the library provided by 3Shape Dental System software to match the disc size; wax trial placement (fourth appointment); and denture adjustment and placement (fifth appointment). Conventional CD will be fabricated with the conventional lost wax technique and heat-polymerizing acrylic resin. The heat-polymerized CDs will be finished, and polished before placement. Adjustments will be made for the polished surface, tissue surface, borders, and occlusion. Occlusal errors will be adjusted through clinical remount of the finished dentures.
224148313|NCT07090200|COMBINATION_PRODUCT|Pulmonary Rehabilitation Care Group|participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. The Pulmonary Rehabilitation Care Group received the Pulmonary rehabilitation exercise and usual care for three months. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function of the two groups of patients one year after the intervention.
224148314|NCT07090200|OTHER|The Routine Care (Non-Pharmacological and Pharmacological Treatments ) Group|participants were randomized (1:1) to either the optimized or routine group via a computer-generated random number table. The Routine Care Group received treatment for three months and follow-up with medications prescribed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report. Next, Observe the changes in the improvement of acute exacerbation frequency (times/year/person)，CAT Scoring and St. George's Respiratory Questionnaire (SGRQ), as well as lung ventilation and diffusion function one year after the intervention.
224148315|NCT07089979|DEVICE|Glunovo CGM device|Group 1 (Subjects that will use Glunovo CGM device) will be compared to Group 2 (subject that will use their glucometer)
224148316|NCT07089979|DEVICE|BG-meter|BG-meter
224148317|NCT07091643|BEHAVIORAL|Cognitive Behavioural Therapy|12 weeks of Cognitive Behavioural Therapy (CBT) will be administered. The first session will be accomplished in-person at Baycrest Hospital. After that, therapy will be conducted virtually, via video-conference. Individuals will undergo therapy once a week for approximately 1 hour, for 12-weeks. Following the 12-week period, individuals will receive three follow-up assessments with their therapist at 3, 6, and 9 months.
223454234|NCT06050330|DIAGNOSTIC_TEST|skin biopsy|Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
223742689|NCT02738151|DRUG|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
223742690|NCT02738151|DRUG|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
224063720|NCT02942745|BEHAVIORAL|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
224148318|NCT07091786|DEVICE|Implant supported prosthesis|implant supported full arch prosthesis
224148319|NCT05435066|DIAGNOSTIC_TEST|Harbinger Health Test|This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year
224148320|NCT02992158|BEHAVIORAL|behavioral activation|
224148321|NCT02992158|BEHAVIORAL|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
223454235|NCT03061240|DEVICE|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
223454236|NCT05367882|DIAGNOSTIC_TEST|ELISA|collection of blood samples from critically ill COVID-19 patients, then serum samples are collected after centrifugation measuring IL-6, IL-10 and IP-10 by ELISA
223454237|NCT00481767|BIOLOGICAL|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
223454238|NCT00481767|DRUG|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
224063721|NCT05422807|BEHAVIORAL|BFST for Teens with Type 2 Diabetes|12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
224063722|NCT02331433|DRUG|APN1125|APN1125 orally at ascending doses
224063723|NCT02331433|DRUG|Placebo|Matching Placebo
224063724|NCT04682886|DIAGNOSTIC_TEST|diagnosis|there is no intervention diagnosis or treatment for patients
224063725|NCT01428284|DRUG|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
224063726|NCT00606320|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
224063727|NCT00177333|DRUG|Doxycycline|
224063728|NCT03068442|DRUG|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
224063729|NCT04009863|DEVICE|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
224063730|NCT04009863|RADIATION|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
224063731|NCT03516682|BEHAVIORAL|Reminders|Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
224063732|NCT01152021|DRUG|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
224063733|NCT01152021|DRUG|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
224148322|NCT02293902|DRUG|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
224148323|NCT02293902|OTHER|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
224148324|NCT02293902|DRUG|Methotrexate|Dispensed according to local practice.
224148325|NCT02293902|DRUG|Folic acid|Dispensed according to local practice.
224148326|NCT00225290|DRUG|Thalidomide(Thado)|
224148327|NCT05173961|OTHER|Internet-Based Intervention|Use oncpatient mobile application
224148328|NCT05173961|OTHER|Survey Administration|Complete survey
224148329|NCT06934538|BIOLOGICAL|STC-1010 + IS regimen + SOC therapy|STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)
224148330|NCT03120637|DRUG|Methylene Blue|
223454239|NCT06268496|OTHER|serum formula 2039125 03|application twice a day of the tested product (in the morning and evening) to the face for 3 months
223454240|NCT03601741|OTHER|Daily Antimicrobial Stethoscope Diaphragm Cover|Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
223454241|NCT03601741|OTHER|Uncovered Stethoscopes|Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
223454242|NCT02778841|OTHER|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
223742691|NCT02738151|DRUG|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
223742692|NCT02047747|DRUG|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
224063734|NCT02821507|DRUG|sirolimus and cyclophosphamide|
224063735|NCT02595723|DRUG|Phenytoin 200 mg capsule|Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
224063736|NCT02595723|DRUG|Megestrol 800 mg liquid|Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
224063737|NCT02595723|DRUG|Phenytoin-matched Placebo capsule|Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
224063738|NCT02595723|DRUG|Megestrol-matched liquid Placebo|Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
224063739|NCT01197404|BEHAVIORAL|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
224063740|NCT01197404|BEHAVIORAL|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
224063741|NCT01982929|PROCEDURE|TAP block (Bupivacaine 0.25% with epinephrine)|Ultrasound guided TAP blocks
224063742|NCT01982929|PROCEDURE|Sham block control|A blunt needleless syringe was firmly pressed on either side of the abdomen.
224063743|NCT04952298|PROCEDURE|Mesial temporal lobe epilepsy surgery|"Medial temporal lobe epilepsy surgery including~* selective Amygdalohippocempectomy (SAH) including anterior parahippocampal gyrus / entorhinal cortex~* anteromedial temporal lobe resection including amygdalohippocampectomy~* anterior temporal lobe resection"
224063744|NCT05013762|BEHAVIORAL|Fast intervention|This intervention is based on recent body of evidence that high-speed movements during training are effective at improving arm movements in individuals with chronic stroke.Participants will be rewarded for movements performed within a short amount of time.
224063745|NCT05013762|BEHAVIORAL|Active Monitoring|This is an observation-only group. The training received in this group will be dose equivalent to the active group.
224063746|NCT04839380|DRUG|ruxolitinib cream|ruxolitinib cream 1.5% will be applied twice daily as a thin film
224063747|NCT03336021|OTHER|FAS program|Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
224063748|NCT01087905|DRUG|Nicotine patch|"If \> 10 cigs/day: one 21 mg nicotine patch per day~If \< or = 10 cigs/day: one 14 mg nicotine patch per day"
224063749|NCT01087905|DRUG|Nicotine gum|"If \< 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
224063750|NCT01087905|BEHAVIORAL|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
224301627|NCT02444793|DRUG|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
224301628|NCT01685411|DRUG|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
224301629|NCT01685411|DRUG|Keppra|Day -8 (prior to transplant): Per institutional guidelines
224301630|NCT01685411|DRUG|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
224301631|NCT01685411|DRUG|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
224301632|NCT01685411|DRUG|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
223571637|NCT05118984|DRUG|Azithromycin capsule (Zithromax, Pfizer) (250 mg)|Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
223571638|NCT05118984|DRUG|Placebo|A treatment that has no active properties
223571639|NCT02701777|OTHER|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
223571640|NCT02701777|BEHAVIORAL|Training|The participant will be asked to perform exercises using their hands and arms.
223571641|NCT02701777|OTHER|Sham STDP|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times.
223571642|NCT02701777|OTHER|Multisite-STDP|Paired stimulation will be given to the brain bilaterally, thoracic spine, and several peripheral nerve so that the messages are received at the spinal cord at predetermined time.
223571643|NCT05765149|OTHER|No intervention|This is an observational study, no intervention will be implemented.
223571644|NCT01126658|OTHER|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
224071071|NCT00928538|OTHER|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
224071072|NCT03662425|DRUG|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
224071073|NCT03662425|DRUG|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
224071074|NCT03449823|DIAGNOSTIC_TEST|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
224071075|NCT05287009|PROCEDURE|ILM nonpeeling|ILM is not peeled after ERM removal
224071076|NCT05287009|PROCEDURE|ILM peeling|ILM is peeled after ERM removal
224071077|NCT01660932|DRUG|placebo|
224071078|NCT01660932|DRUG|omega|
224071079|NCT05412680|PROCEDURE|TOETVA|TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH
224071080|NCT05412680|PROCEDURE|conventional thyroidectomy|conventional open thyroidectomy by cervical approach
224071081|NCT02592850|OTHER|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks."
224071082|NCT02592850|OTHER|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks."
224071083|NCT05332483|DRUG|Megestrol Acetate|Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
224071084|NCT04192578|DEVICE|remote ischemic conditioning|RIC is induced by short-term insulting blood-flow of nonvital distant organs intermittently.
224063751|NCT02897700|DRUG|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
224063752|NCT02897700|DRUG|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30\~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
224148331|NCT01929265|DRUG|Bendamustine|"INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1\*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~\*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28"
224148332|NCT00954317|PROCEDURE|epidural placed low|epidural placed low
223454243|NCT02358018|DRUG|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately \~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
224148333|NCT00954317|PROCEDURE|high epidural|high epidural
224148334|NCT00369395|DRUG|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
223454244|NCT00417638|DEVICE|Endovascular cooling by the Celsius Control System|
223454245|NCT00417638|OTHER|Standard of care|
223454246|NCT00000213|DRUG|Fluoxetine|
223454247|NCT05479838|PROCEDURE|Percutaneous coronary intervention|Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
223454248|NCT02578459|DEVICE|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
223454249|NCT02578459|OTHER|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
223454250|NCT01941537|DRUG|ILV-094|IV infusion of ILV-094
223454251|NCT01941537|DRUG|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
223454252|NCT00857961|DRUG|Testosterone MD-Lotion|Administered Topically
223454253|NCT04544553|OTHER|SMS reminder|The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.
223454254|NCT04544553|OTHER|No SMS reminder|The group did not receives any SMS regarding scheduled appoinments.
223454255|NCT03051373|DRUG|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
223454256|NCT03051373|DRUG|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
223454257|NCT03654391|DIETARY_SUPPLEMENT|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
223454258|NCT03654391|DIETARY_SUPPLEMENT|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
223571645|NCT04395638|DIETARY_SUPPLEMENT|3200IU Vitamin D3 per day for 8 weeks|3200IU Vitamin D3 per day for 8 weeks
224301633|NCT01685411|DRUG|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (\> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.
223454259|NCT04272957|DRUG|HMPL-306|HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
223571646|NCT04395638|DIETARY_SUPPLEMENT|20,000IU Vitamin D3 per week for 8 weeks|20,000IU Vitamin D3 per week for 8 weeks
223571647|NCT02633254|DEVICE|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
223571648|NCT05898308|DRUG|RiTUXimab Injection|"Patients assigned to the personalized maintenance treatment will be treated by additional RITUXIMAB injection depending on anti-Dsg Abs levels."
223571649|NCT02028117|BIOLOGICAL|Enadenotucirev|Oncolytic Virus
223571650|NCT05004038|BIOLOGICAL|BCG Vaccine AJVaccines|Single intradermal injection of BCG Vaccine according to published Summary of Product Characteristics
223571651|NCT00481715|BEHAVIORAL|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
223571652|NCT00481715|BEHAVIORAL|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
223571653|NCT00027365|BIOLOGICAL|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
223571654|NCT00027365|BIOLOGICAL|NefTat|
223571655|NCT00027365|DRUG|AS02A Adjuvant|
223571656|NCT00027365|BIOLOGICAL|gp120W61D|
223571657|NCT04384601|DRUG|Chemotherapy|Perioperative chemotherapy will be administered according to description in two arms.
223571658|NCT03641248|DRUG|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
223571659|NCT03641248|DRUG|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
223571660|NCT00075725|DRUG|Cyclophosphamide|Given IV
223571661|NCT00075725|DRUG|Cytarabine|Given IT, SC, or IV
223571662|NCT00075725|DRUG|Daunorubicin Hydrochloride|Given IV
223742693|NCT01975909|DEVICE|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
223742694|NCT00457600|PROCEDURE|patient-driven health IT product|
223742695|NCT05634551|BEHAVIORAL|Questionnaires|Participants will complete 5 questionnaires about any symptoms participants may be having, any anxiety and/or depression participants may be having, your preference in decision-making, and your expectations about your treatment. It should take about 30 minutes to complete all 5 questionnaires
223454260|NCT05635422|DIAGNOSTIC_TEST|isokinetism test|measure of muscular fatigability by isokinetism
223571663|NCT00075725|DRUG|Dexamethasone|Given PO or IV
223571664|NCT00075725|DRUG|Doxorubicin Hydrochloride|Given IV
223571665|NCT00075725|DRUG|Leucovorin Calcium|Given IV
223742696|NCT05634551|BEHAVIORAL|Interview|The interview will last about 30-45 minutes. The interview will be conducted over the phone or remotely over Zoom or FaceTime (based on your preference)
223742697|NCT03333044|BEHAVIORAL|Community Health Worker (CHW)-Led Health Coaching|CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to manage diabetes.
223742698|NCT03333044|OTHER|EHR-Embedded Alerts|An electronic health record (EHR) intervention for primary care providers (PCPs) utilizing embedded alerts to identify South Asian patients with uncontrolled diabetes.
223742699|NCT04820075|BEHAVIORAL|improvement of preoperative shower|Process about preoperative shower
224063753|NCT02897700|DRUG|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
223454261|NCT03865719|BEHAVIORAL|Healthy Habits for Life|Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
223454262|NCT02557516|DRUG|monalizumab|"During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks."
223454263|NCT04293835|DIAGNOSTIC_TEST|Whether to have intestinal-related disease|All patients pathologically diagnosed with sigmoid or rectal cancer in Peking University Third Hospital from January 2010 to December 2018 were included in our study as the cancer group.To evaluate the relationship between the height of the sigmoid take-off and all baseline covariates in normal patients, the results of 200 patients without any intestinal-related abnormalities who underwent pelvic MRI in our center from January 2019 to June 2019 were reviewed as a normal group.
223454264|NCT02530918|DRUG|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
223454265|NCT02530918|DRUG|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
223454266|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)\] given one month apart
223454267|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)\] given one month apart
223454268|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)\] given one month apart
223454269|NCT00707642|BIOLOGICAL|WN-80E|Three injections of the study vaccine \[High Dose WN-80E API (50 µg)\] given one month apart
223454270|NCT05202015|DRUG|MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)|MRI of the liver accoring to our institutional daily routine protocol
223454271|NCT03734445|DIETARY_SUPPLEMENT|Vitamin Supplement|Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
223454272|NCT03734445|OTHER|Placebo|Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
223454273|NCT03280745|DRUG|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
223454274|NCT03280745|DRUG|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
223454275|NCT01623024|DRUG|Vitamin D|20.000 UI/week for 96 weeks
223454276|NCT01623024|BEHAVIORAL|Lifestyle counseling|Lifestyle counseling for 96 weeks
224063754|NCT01347554|DEVICE|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
224063755|NCT01347554|DEVICE|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
224063756|NCT01865409|BEHAVIORAL|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
224063757|NCT03570931|DRUG|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
224063758|NCT06182982|DEVICE|auricolotherapy|Magnetic bal plasters are applied on the ear surface
224063759|NCT00096707|DRUG|2-deoxy-D-glucose (2DG)|
224063760|NCT03228355|DRUG|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
224063761|NCT03228355|DRUG|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
224063762|NCT02534688|DRUG|LNG-IUS|
223454277|NCT01142947|DRUG|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
224063763|NCT02534688|DRUG|DMPA|
224063764|NCT05209633|DRUG|Granules Dendrobii|6g each, 3 times per day, total 18 weeks
224063765|NCT05209633|DRUG|Placebo|placebo
224063766|NCT04893772|DIETARY_SUPPLEMENT|Intermittent fasting|"Three fasting days a week, whereby participants consume 600-800 kcal/day from 4 meal replacement products: breakfast, lunch, a snack and dinner. During the other 4 non-fasting smart days each week, participants are instructed to consume 2 x 300 kcal meals and 2 x 100 kcal snacks, from a selection of recipes, plus one meal of their own choosing."
224063767|NCT00000522|BEHAVIORAL|diet, sodium-restricted|
224063768|NCT00000522|BEHAVIORAL|diet, reducing|
224063769|NCT00000522|BEHAVIORAL|exercise|
224063770|NCT00000522|BEHAVIORAL|alcohol restriction|
224063771|NCT00000522|DRUG|chlorthalidone|
224063772|NCT00000522|DRUG|acebutolol|
224063773|NCT00000522|DRUG|doxazosin|
223571666|NCT00075725|DRUG|Mercaptopurine|Given PO
224063774|NCT00000522|DRUG|amlodipine|
224063775|NCT00000522|DRUG|enalapril|
224063776|NCT04502485|PROCEDURE|Gastric water exchange|Upon entering the fundus of the stomach the air button will be turned off. Air pocket and gastric fluids will be removed by suctioning. Distilled water, delivered by a 50-ml syringe in 10ml-to-20 ml increments, will be infused to dislodge debris and air bubbles adhering the gastric mucosa and open the lumen. The infused water will be removed to keep the lumen almost completely collapsed before the scope advance further.
224063777|NCT04502485|PROCEDURE|traditional air insufflation|Air will be minimally insufflated and residual fluid suctioned during the entire insertion process. Usually, no water will be infused to cleanse the mucosa until the withdrawal phase.
224063778|NCT03027531|BEHAVIORAL|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
224063779|NCT02223260|DRUG|dabigatran|Experimental dose chosen based on age and weight
224063780|NCT00004259|DRUG|BCNU 80mg/m2|BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
224063781|NCT00004259|DRUG|TMZ 200mg/m2|200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
224063782|NCT00004259|RADIATION|radiation therapy|1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
224063783|NCT00004259|DRUG|CCNU|CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
224063784|NCT00004259|DRUG|BCNU 150mg/m2|BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
224063785|NCT00004259|DRUG|BCNU 200mg/m2|BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
224063786|NCT00004259|DRUG|TMZ 150mg/m2 six 6-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
224063787|NCT00004259|DRUG|TMZ 150mg/m2 six 8-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
224063788|NCT05821764|OTHER|Blood sample and data collection|"Solicitation of parturients during a prenatal visit between 22 and 41 weeks of gestation or during their hospitalization in a high-risk pregnancy sector and at the latest on the day of their delivery.~Blood sample :~* Maternal sample within 72 hours before or after delivery during a care-based venipuncture (additional 10 mL sample) ;~* The cord blood sample (10 mL) immediately after delivery.~Data collection :~* A data collection sheet for the attention of the investigator (doctor or midwife) ;~* Additional data relating to the history of vaccination and infection completed by the patients included during their stay in the maternity ward and before their discharge from the hospital (Delay between 0 and 6 days after inclusion)."
224071085|NCT05244681|OTHER|Semi-structured interview|Semi-structured interview to explore the experience of people with chronic non-specific neck pain who used an immersive virtual reality serious game at home
223571667|NCT00075725|DRUG|Methotrexate|Given IT or IV
223571668|NCT00075725|DRUG|Pegaspargase|Given IM
223571669|NCT00075725|DRUG|Prednisone|Given PO or IV
223571670|NCT00075725|RADIATION|Radiation Therapy|Undergo radiation therapy
223571671|NCT00075725|DRUG|Thioguanine|Given PO
223571672|NCT00075725|DRUG|Vincristine Sulfate|Given IV
223571673|NCT00199316|DRUG|spinal morphine|
223571674|NCT01904916|PROCEDURE|Histological biopsy procedure|
223571675|NCT00909545|DRUG|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
223571676|NCT00909545|DRUG|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
223571677|NCT00909545|DRUG|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
224063789|NCT00996944|DRUG|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
223571678|NCT00909545|DRUG|Placebo|4 Placebo to Match (PTM) tablets once daily
223571679|NCT06065059|DRUG|TNG348|Ubiquitin Specific Peptidase 1 (USP1) inhibitor
223571680|NCT06065059|DRUG|Olaparib|PARP inhibitor
223571681|NCT02933073|BIOLOGICAL|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
223571682|NCT02974335|BEHAVIORAL|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
224071086|NCT00312910|DRUG|Probiotics-Bio-plus|
224071087|NCT01022190|DRUG|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
223571683|NCT02023801|DEVICE|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
223571684|NCT00615446|DRUG|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
223571685|NCT06072300|BEHAVIORAL|Physical activity calorie equivalent labelling|Physical activity calorie equivalent labelling on beverage vending machines
223571686|NCT04213781|DEVICE|HappyMed Video Glasses|HappyMed allows the immersion of patients in films, cartoons or concerts.
223571687|NCT04213781|DRUG|Propofol|The dosage is modified according to the Dixon's up-and-down method (using 0.5 µg/ml as a step size). The first patient in each group will start at a dose 3 µg/ml propofol. If patient manifests discomfort then the next patient will receive an increment of 0.5 µg/ml propofol, if patient is comfortable, then the next patient received a decrement of 0.5 µg/ml propofol.
223571688|NCT04213781|DRUG|Sufentanil|0.1 µg/kg
223571689|NCT06438016|BEHAVIORAL|Stress Management Training|The intervention will comprise of 4 sessions delivered over 4 weeks. The training session will be structured as follows: Session 1 - Psychoeducation relating to stress and its effects. Session 2 - Behavioral techniques to cope with stress 1, Session 3 - Cognitive techniques to cope with stress and Session 4- Behavioral techniques to cope with stress. Both verbal and written means will be used to provide this training.
223571690|NCT06232148|DEVICE|Type of surgery|
223571691|NCT04691141|DRUG|ATG-016|59 patients enrolled will be treated with ATG-016, orally, each 4 week (28-day) a cycle
223571692|NCT00384319|DEVICE|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
223571693|NCT02844335|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
223571694|NCT02844335|BIOLOGICAL|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
223571695|NCT02537262|DIETARY_SUPPLEMENT|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
224071088|NCT01903837|DRUG|Samidorphan (Low Dose)|Tablets taken once daily
224071089|NCT01903837|DRUG|Samidorphan (Medium Dose)|Tablets taken once daily
224071090|NCT01903837|DRUG|Samidorphan (High Dose)|Tablets taken once daily
224071091|NCT01903837|DRUG|Placebo|Tablets taken once daily
224071092|NCT01903837|DRUG|Olanzapine|Tablets taken once daily
224071093|NCT03979092|BEHAVIORAL|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~1. Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~2. Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~3. Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~4. Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
224071094|NCT03979092|BEHAVIORAL|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
224071095|NCT00825565|DRUG|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
224071096|NCT01898065|DRUG|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
224071097|NCT02188316|DEVICE|Jumbo forceps|comparison of different polypectomy devices
224071098|NCT02188316|DEVICE|Hot biopsy forceps|comparison of different polypectomy devices
224071099|NCT01992783|DIETARY_SUPPLEMENT|Hi-maize resistant starch|13.5 g/day
224071100|NCT01992783|DIETARY_SUPPLEMENT|Maltodextrin|13.5 g/day
224071101|NCT02750163|DRUG|paracetamol|Paracetamol will be given to febrile septic patients
224071102|NCT03755648|OTHER|Treadmill training|The motorized treadmill treatment parameters considered will be 50 Hertz, 10 Ampere and 220 Volts. The speed of treadmill will be controlled with a single finger tip allowing an individual to exercise in safe environment with sufficient space.The treadmill training will be provided by giving instructions first and then warm up will be given for 5 minutes prior to the training. The children will be upright with the feet flat on treadmill platform. The height of handrails will be adjustable according to every child thus keeping their gaze forward. The training will be ended at cool down period of 5 minutes.The treatment session will be thirty minutes for each group, six times a week for three months.
224148335|NCT03129204|BEHAVIORAL|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
224063790|NCT00996944|DRUG|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
224063791|NCT01688154|DIETARY_SUPPLEMENT|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
224063792|NCT01688154|OTHER|2 empty capsules|
224063793|NCT03910907|DRUG|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
224063794|NCT00769184|DRUG|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
224063795|NCT00769184|OTHER|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
224063796|NCT00769184|DRUG|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
224063797|NCT00034658|DRUG|Posaconazole|
224063798|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 3 mg/kg
224063799|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 15 mg/kg
224063800|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 30 mg/kg
224063801|NCT00578682|BIOLOGICAL|MEDI-557|Single IV dose of 0.3 mg/kg
224063802|NCT00385255|BIOLOGICAL|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
224063803|NCT00385255|BIOLOGICAL|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
224063804|NCT02443883|DRUG|Ramucirumab|Administered IV
224063805|NCT01885611|OTHER|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
224148336|NCT03893773|DEVICE|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
224148337|NCT06954428|COMBINATION_PRODUCT|NT-301 1 mg|unidose of 1 mg apomorphine through nasal spray
224063806|NCT01885611|DIETARY_SUPPLEMENT|Virgin Coconut Oil|cold-processed VCO
224063807|NCT00860210|DEVICE|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
224063808|NCT04325841|BIOLOGICAL|Murine autologous anti-CD19 chimeric antigen receptor T cells|CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In CD19 T cell clinical trials, CAR-T cells was given once. All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
224063809|NCT05266378|PROCEDURE|PECs block|The PECs block is performed immediately after induction of anesthesia, and 0.375% concentration of ropivacaine (carbiropivacaine injection, Fresinius Kavi Korea Co., Ltd.) is used with a 25 G 5 cm (or 8 cm) needle to induce ultrasound-guided pectoralis major (pectoralis major). 10mL (PECs I block) into the fascia between the pectoralis minor muscle) and the pectoralis minor muscle, and 20mL (PECs II block) between the pectoralis minor and serratus anterior muscle.
224063810|NCT05266378|OTHER|Not receiving PECs Block|In this group, the PECs block was not implemented.
224063811|NCT02937818|DRUG|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
224063812|NCT02937818|DRUG|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
224148338|NCT06954428|COMBINATION_PRODUCT|NT-301 2 mg|unidose of 2 mg apomorphine through nasal spray
224148339|NCT06954428|COMBINATION_PRODUCT|Placebo 1 mg|Matching Placebo to NT-301 1 mg
224148340|NCT06954428|COMBINATION_PRODUCT|Placebo 2 mg|Matching Placebo to NT-301 2 mg
223454278|NCT00963976|DRUG|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
223454279|NCT02627573|PROCEDURE|Unrelated allogeneic stem cell transplantation|
223454280|NCT02627573|DRUG|Busulfan|
223454281|NCT02627573|DRUG|Fludarabine monophosphate|
223454282|NCT02627573|DRUG|Tacrolimus|
223454283|NCT02627573|DRUG|Mycophenolate mofetil|
223454284|NCT02627573|DRUG|Cyclophosphamide|
223454285|NCT02627573|DRUG|Thymoglobulin|
223454286|NCT04940663|BEHAVIORAL|EMA|Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
223454287|NCT04646018|OTHER|Lumbar Spine Manipulation|Lumbar non-thrust manipulation is a passive movement that is performed with a rhythm and a grade in a manner in which the patient is able to prevent the technique from being performed.
223454288|NCT04646018|OTHER|Sham Manipulation|Lumbar non-thrust manipulation without force applied
223454289|NCT02939209|DRUG|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
223454290|NCT02939209|DRUG|Placebo|Patients may be randomized to placebo.
224063813|NCT02937818|DRUG|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
224301634|NCT01685411|BIOLOGICAL|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
223454291|NCT00707967|BIOLOGICAL|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
223571696|NCT02537262|DIETARY_SUPPLEMENT|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
224063814|NCT01997411|DRUG|Nasal Glucagon|
224063815|NCT01997411|DRUG|Intramuscular Glucagon|
224063816|NCT03371615|OTHER|Anti-regurgitation infant formula|Anti regurgitation infant formula
224063817|NCT03358888|DRUG|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
224063818|NCT03358888|DRUG|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
224063819|NCT03358888|DRUG|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
224063820|NCT03811457|GENETIC|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
224063821|NCT04922476|DIETARY_SUPPLEMENT|Alflorex®|Each probiotic capsule contains 1 x 10\^9 CFU of B. longum 35624® and corn starch, hydroxypropyl methyl cellulose and magnesium stearate.
224063822|NCT01868048|DRUG|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
224063823|NCT01868048|DRUG|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
224063824|NCT03604965|DRUG|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
223454292|NCT00707967|BIOLOGICAL|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
223454293|NCT00707967|BIOLOGICAL|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
223454294|NCT02319252|DEVICE|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
223454295|NCT02319252|DEVICE|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
223454296|NCT02791529|PROCEDURE|Electrocautery|Skin incision performed by electrocautery
223454297|NCT02791529|PROCEDURE|Scalpel|Skin incision performed by scalpel
223571697|NCT04579302|PROCEDURE|Serratus anterior block (SAB)|Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
224301635|NCT01685411|BIOLOGICAL|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is \>2500 x 10\^9/L or per institutional guidelines.
223454298|NCT01999985|DRUG|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
223454299|NCT01999985|DRUG|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
223454300|NCT01999985|DRUG|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
223454301|NCT01999985|DRUG|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
223454302|NCT03784391|DRUG|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
223454303|NCT06366646|OTHER|Competency-based intervention|90 head nurses and their assistants received the competency-based intervention program
223454304|NCT06357520|DRUG|Baxdrostat|Baxdrostat tablet will be administered orally.
223571698|NCT04579302|PROCEDURE|Erector spinae block|Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
223571699|NCT04579302|DRUG|Saline (as a placebo)|Patients will receive a sham block with 20 ml saline (as a placebo)
223571700|NCT04579302|DRUG|Bupivacaine|bupivacaine
224063825|NCT03604965|DRUG|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
224063826|NCT06006793|DRUG|SY-5933|KRAS p.G12C inhibitor
224063827|NCT02534701|DEVICE|ERIC® and SOFIA™|a self-expanding clot retrieval system
223454305|NCT06357520|DRUG|Itraconazole|Itraconazole capsule will be administered orally.
223454306|NCT01861353|OTHER|Cranberry-lingonberry juice|
223454307|NCT01861353|OTHER|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
223454308|NCT00632125|DRUG|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
223571701|NCT06535022|DIETARY_SUPPLEMENT|Cyclic enteral daytime feeding with ketogenic nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)|Nighttime fasting and ß-hydroxybutyrate supplementation
223571702|NCT03789032|DRUG|Vadadustat|Vadadustat 300 mg
223571703|NCT03789032|DRUG|Rabeprazole|Oral Rabeprazole
224063828|NCT06150235|OTHER|Data collection|Data collection
224063829|NCT03518788|PROCEDURE|Pleur-X|Permanent drainage
224063830|NCT03518788|PROCEDURE|Pleurodesis|Pleurodesis with talc in permanent VATS
224063831|NCT00303914|PROCEDURE|assessment of therapy complications|
224063832|NCT00303914|PROCEDURE|cognitive assessment|
224063833|NCT00303914|PROCEDURE|psychosocial assessment and care|
224301636|NCT01685411|BIOLOGICAL|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
224148341|NCT06954428|COMBINATION_PRODUCT|Placebo 3 mg|Matching Placebo to NT-301 3 mg
224063834|NCT00393107|DRUG|rituximab|
224063835|NCT00393107|DRUG|rituximab,fludarabine, cyclophosphamide|
224063836|NCT00775632|DRUG|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
224063837|NCT00775632|DRUG|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
224063838|NCT02079987|BEHAVIORAL|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
224063839|NCT02079987|OTHER|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
224063840|NCT00205855|DEVICE|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
224063841|NCT00663065|DRUG|PAZ-417|
224063842|NCT06209554|DEVICE|ultrasonic tips and Gracey curettes, airflow with erythritol and diode laser|diode laser and erythritol used as adjunctive method in the treatment of periodontitis in addition to scaling and root planning
224063843|NCT03518879|OTHER|ASTHMA-Educator mobile application|The on-site delivered ASTHMA-Educator mobile application.
224063844|NCT01617330|PROCEDURE|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
224063845|NCT01441570|DRUG|Nebivolol|Subject will take nebivolol daily for 12 weeks.
224063846|NCT01441570|DRUG|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
224063847|NCT02911480|DRUG|Oxytocin|
224063848|NCT03428178|DRUG|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
224063849|NCT01206205|DRUG|Lenalidomide, Bortezomib|"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
224063850|NCT02757664|DEVICE|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
224063851|NCT02757664|OTHER|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
224148342|NCT06954428|COMBINATION_PRODUCT|NT-301 3 mg|unidose apomorphine nasal spray 3 mg
224063852|NCT02757664|DEVICE|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
224148343|NCT06954428|COMBINATION_PRODUCT|NT-301 4 mg|unidose apomorphine nasal spray 4 mg
224148344|NCT06954428|COMBINATION_PRODUCT|Placebo 4 mg|Matching placebo to NT-301 4 mg
224148345|NCT00977587|DRUG|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
224148346|NCT00977587|DRUG|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~* Calcium phosphate, Dibasic 472.0 mg~* Maltodextrin DE14 112.1 mg~* Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
224148347|NCT05406440|DRUG|MK-8189|MK-8189 4 mg and/or 12 mg tablet(s) will be administered orally QD for a total daily dose of 48 mg, 60 mg, 80 mg.
224063853|NCT02940509|DRUG|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~1. Ketamine (0.5mg/kg)~2. Magnesium sulfate (2g)"
224063854|NCT02940509|DRUG|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
224063855|NCT00506883|DRUG|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
224148348|NCT05406440|DRUG|Placebo|MK-8189 dose-matching placebo tablets will be administered orally QD.
224148349|NCT03632668|DRUG|AD-2071 10/20mg|AD-2071 10/20 mg tablet
224148350|NCT03632668|DRUG|AD-2072 80/5mg|AD-2072 80/5mg tablet
224148351|NCT03632668|DRUG|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
224301637|NCT04901598|OTHER|Running anaerobic sprint test and aerobic test|subjects walk a mile with maximum steps and their heart rate will not exceed 180 beats per minute during the test and the execution time will not be less than 9 minutes (RAST test)
223571704|NCT04234789|DIAGNOSTIC_TEST|cardiopulmonary exercise testing with dynamic hyperinflation maneuver|test performed as recommended by ATS guidelines
223571705|NCT04234789|DIAGNOSTIC_TEST|spirometry|test performed as recommended by ATS guidelines
224063856|NCT00506883|DRUG|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
224063857|NCT00506883|OTHER|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
224063858|NCT00823290|DRUG|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
224063859|NCT03147729|RADIATION|Radiofrequency non ablation|Use of radiofrequency
224063860|NCT02224378|PROCEDURE|peep induced CVP|
224063861|NCT02224378|PROCEDURE|passive leg raising(PLR)|
224063862|NCT03747250|DEVICE|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
224063863|NCT03747250|DEVICE|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
224063864|NCT05747911|OTHER||Groups will not be intervened. Only observational data will be used.
224063865|NCT02626195|DIETARY_SUPPLEMENT|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~* Calories: 30-35Kg, via enteral or parenteral~* Protein: 1.2-1.5g/Kg~* Lipid : 1-1.5g/Kg~* Mineral and vitamins supply~* Blood glucose control~* Daily monitoring by dietician and specialized nurse"
224063866|NCT03429192|PROCEDURE|Surgery|Surgeries plus dissection of lymph nodes
224063867|NCT04027998|DIAGNOSTIC_TEST|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
224063868|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
224063869|NCT00399165|DRUG|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
224063870|NCT00399165|DRUG|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
224063871|NCT00399165|OTHER|placebo sesame oil|placebo sesame oil
224063872|NCT00399165|DRUG|Dutasteride|24.5 mg po once (Day 0)
224148352|NCT04345302|BEHAVIORAL|Brief motivational treatment|"The treatment will be delivered by general psychologists with at least three years of experience in primary care. They will receive training and then will demonstrate proficiency in a simulated client session.~During recruitment, therapy sessions will be recorded, and ten percent of them will be reviewed using a proficiency scale. Then, a feedback report will be issued and discussed with each therapist."
224301638|NCT00813566|DRUG|[18F]fluoro-2-deoxy-D-glucose (FDG)|Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.
223454309|NCT04438408|OTHER|questionaires|patients will answer to questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance.
224063873|NCT04173676|DRUG|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
224063874|NCT03777150|OTHER|Postoperative care in Intensive care unit (ICU)|Postoperative care in Intensive care unit (ICU)
224063875|NCT03777150|OTHER|Postoperative care in standard ward|Postoperative care in standard ward
224063876|NCT03636139|DEVICE|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
224063877|NCT03636139|DEVICE|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
224063878|NCT03104894|PROCEDURE|Meibomian Glands Massage|Meibomian gland expression
224063879|NCT03104894|PROCEDURE|Sham Meibomian Glands Massage|Touching the eyelids gently
224148353|NCT04345302|BEHAVIORAL|Enhanced Usual Care|During the trial, participants will continue to receive regular medical and social care at their health centre. These services may include prescriptions for mental health issues and alcohol (Disulfiram, anti-craving, anti-depressants, and other medications), social assistance, and the full spectrum of primary health care. Nevertheless, they will not receive other psychosocial interventions for alcohol use disorder in the health centre.
223454310|NCT00828061|DRUG|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
223454311|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
224301639|NCT00813566|DRUG|3'-deoxy-3'-[18F]fluorothymidine (FLT)|Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors
224301640|NCT00813566|DRUG|[15O]-H2O|Brain scan with imaging agent to determine tumor blood flow
223454312|NCT00828061|DRUG|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
223571706|NCT04234789|DIAGNOSTIC_TEST|pletysmography|test performed as recommended by ATS guidelines
224063880|NCT03104894|DEVICE|Meibomian Massage device|Meibomian glands expression with applicator
224063881|NCT03999762|DEVICE|sample prep|Effectiveness of a sample preparation protocol
224063882|NCT01445951|DRUG|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
224063883|NCT01445951|DRUG|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
224063884|NCT01445951|DRUG|Insulin Aspart in combination with a basal insulin|Injectable insulin
224063885|NCT03857204|DEVICE|SAMPL plain wave algorithm|SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
224063886|NCT06429267|DEVICE|Bioabsorbable Screw|Bioabsorbable screw that redissolves into the bone. Mineral fibers are composed of Silicon Dioxide (SiO2), Sodium Oxide, Calcium Oxide, Magnesium Oxide, Boron Trioxide, and Phosphorous Pentoxide
224301641|NCT00813566|DRUG|[11C]Acetate|Brain scan with imaging agent to determine growth activity of tumor
224063887|NCT06429267|DEVICE|Metal/Titanium Screw|Traditional metal screw used in fracture fixation that requires hardware removal
224063888|NCT06539572|PROCEDURE|Cleft lip repair; palatoplasty; alveolar bone grafting|cleft surgical treatment based on Chang Gung Craniofacial Center Protocol for cleft treatment
224063889|NCT04017143|BEHAVIORAL|HPV app intervention|Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
224063890|NCT00037479|DRUG|ceftriaxone|
224063891|NCT00782548|DRUG|KADIAN (morphine sulfate sustained-release) capsules|Capsules, 30 mg
224063892|NCT00782548|DRUG|Avinza (morphine sulfate sustained-release) capsules|Capsules, 30 mg
224063893|NCT03238105|DRUG|Thioglycolic Acid|Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
224063894|NCT03238105|DEVICE|Intense Pulsed Light|Monthly sessions for 3 months.
224063895|NCT06181942|DEVICE|SP|English name: da Vinci SP Surgical System Model and specification: SP1098 Manufacturer: Intuitive Surgical, Inc.
224148354|NCT02402621|DRUG|fentanyl|fentanyl with antiemetic drug
224148355|NCT04478110|BEHAVIORAL|interactive group education, navigation services and engagement of health care providers for referrals, and linkage to care.|The interactive group education was aimed to increase participant overall understanding of CRC, screening methods, and utilization of available resources such as home test kit and navigation services, with the ultimate goal of increasing screening rates. Clinical partners provided clinical support and ensured successful screening assessment and follow-ups by offering more flexible hours of clinic operation with bilingual medical staff on site. Patient navigation assistance was also offered based on participants' needs. The range of assistance included scheduling appointments with clinical partners for sigmoidoscopy/colonoscopy for screening and diagnosis after a FIT positive result, assisting paper.
224148356|NCT04478110|BEHAVIORAL|Education Session on General Health|Participants in the control group received a group education session in a similar format with that of the intervention group delivered by trained Korean community health educators. Different from the intervention group, the education focused on general health education and primary prevention issues, including routine health examinations and screening for various diseases such as cancer. Korean version of work and communication with a physician, and arranging transportation. standard printed materials and guidelines related to the education contents were also provided, including CRC screening guidelines.
224148357|NCT03249753|DRUG|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
224148358|NCT03249753|DRUG|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
224301642|NCT02689050|DEVICE|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
224301643|NCT03686449|PROCEDURE|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
223454313|NCT05545423|OTHER|instrumented assisted soft tissue mobilization|the appropriate Graston technique instrument will be selected to scan, and then treat the affected area for 30 to 60 seconds per treated area. The procedure will be applied to the superficial cervical fascia and invested the layers of deep cervical fascia that surround all the structures in the neck. Strokes will be applied on the sternocleidomastoids and upper fibers of trapezius muscles. The IASTM technique was applied at a 45° angle in a direction parallel to the treated muscle fibers for 20 seconds, following immediately by an additional 20-seconds application at a 45° angle in a perpendicular direction to the muscle fibers, resulting in a total treatment time of approximately 40 seconds.
223454314|NCT05545423|OTHER|traditional therapy|The exercise program will be in the form of stretching exercises for the sternocleidomastoids (SCM), the scalenes, and upper fibers of trapezius; strengthening isometric exercises for the neck flexors, extensors, lateral flexors, and neck rotators; and postural correction and scapular stabilization exercises
223454315|NCT01824888|DRUG|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
223454316|NCT01824888|DRUG|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
223454317|NCT01400906|DRUG|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
223454318|NCT01400906|DRUG|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
223454319|NCT01400906|DRUG|lactose powder|lactose powder in dry powder device : placebo comparator
223454320|NCT00619372|DRUG|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
223571707|NCT04234789|DIAGNOSTIC_TEST|forced oscillometry technique|test performed as recommended by ATS guidelines
223571708|NCT02674282|PROCEDURE|ACL reconstruction|ACL reconstruction with hamstrings autograft.
224063896|NCT00538395|DRUG|Adriamycin, Taxol and Cytoxan|Chemotherapy
224063897|NCT05513625|DRUG|Pritelivir|oral administration
223454321|NCT00619372|DRUG|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
223454322|NCT00619372|DRUG|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
224063898|NCT05513625|DRUG|ESO and pritelivir|oral administration
224063899|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and / or anal cytology (day 1 and after 36 months)|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (day 1 and after 36 months)
224063900|NCT04735445|DIAGNOSTIC_TEST|Semestral digital rectal exam and / or anal cytology if abnormal → ANOSCOPY with biopsy|For anal screening in MSM man or woman with abnormal cervical cytology, genital warts or having anal sex (semestral)
224063901|NCT04735445|DIAGNOSTIC_TEST|Cervical cytology and cervical sample for HPV detection (day 1 and after 36 months)|For Cervix Screening in sexually active woman (day 1 and after 36 months)
224063902|NCT04735445|DIAGNOSTIC_TEST|Semestral cervical cytology and cervical sample for HPV detection|For Cervix Screening in sexually active woman (semestral)
224148359|NCT06278155|OTHER|Social relation training with social robot|"The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response"
224148360|NCT06278155|OTHER|Traditional social relations training|Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
223571709|NCT02252185|DEVICE|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
224148361|NCT02979444|BEHAVIORAL|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
224148362|NCT02740712|DRUG|Caffeine|200 mg (4 x 50mg) Tablet
224148363|NCT02740712|DRUG|Warfarin|10 mg (2 x 5mg) Tablet
223571710|NCT02252185|DEVICE|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
223571711|NCT00883870|DRUG|mesenchymal stem cells|Intramuscular injection
224063903|NCT04735445|DIAGNOSTIC_TEST|Appointment for mammography (day 1 and after 36 months)|For Breast Screening in woman between 50-70 years old (day 1 and after 36 months)
224063904|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for mammography|For Breast Screening in woman between 45-70 years old (annual)
224063905|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|"For Hepatic Screening:~Cirrhosis or Chronic HBV, and meet any of the following risk factors:~* Asian male\> 40 years old~* Asian woman\> 50 years old~* African man or woman~* HCC family history"
224063906|NCT04735445|DIAGNOSTIC_TEST|Semestral appointment for liver ultrasound|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
224063907|NCT04735445|DIAGNOSTIC_TEST|Semestral blood collection for alpha-fetoprotein and others hepatic biomarkers determination|Having chronic liver disease with fibrosis ≥ F3 or Presents chronic HBV
224063908|NCT04735445|DIAGNOSTIC_TEST|Fecal occult blood test (day 1 and after 36 months)|"For Colon Screening:~Age between 50-70 years old"
224063909|NCT04735445|DIAGNOSTIC_TEST|Annual fecal occult blood test|"For Colon Screening:~Age older than 40 years"
224063910|NCT04735445|DIAGNOSTIC_TEST|Digital rectal exam and PSA determination (day 1 and after 36 months)|"For Prostate Screening:~Man older than 50 years"
224063911|NCT04735445|DIAGNOSTIC_TEST|Annual digital rectal exam and PSA determination|"For Prostate Screening:~Man older than 50 years"
224063912|NCT04735445|DIAGNOSTIC_TEST|Annual appointment for low dose computed tomography for lung screening|"For Lung Screening: should accomplish~ALL the following criteria:~* Age \> 40 years~* Active smoker or former smoker\<3 years, with IPY ≥20. IPY: index of packages-year: nº packages that smoke per day x nº years smoking~* No contraindications for thoracic surgery~* No lung infection in the last 2 months"
224148364|NCT02740712|DRUG|Omeprazole|40 mg Tablet
224148365|NCT02740712|DRUG|Midazolam|5 mg/mL
224148366|NCT02740712|DRUG|digoxin|.25 mg Tablet
224148367|NCT02740712|DRUG|Vitamin K|10 mg Tablet
224148368|NCT02740712|DRUG|Rucaparib|200 \& 300 mg tablet
224148369|NCT00533299|DRUG|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
224301644|NCT03686449|PROCEDURE|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
224063913|NCT04735445|DIAGNOSTIC_TEST|Annual general inspection for skin lesions suggestive of malignancy|"For Skin Screening:~Woman ≥18 years Man ≥40 years"
224063914|NCT02923661|DEVICE|CM LOC|
224063915|NCT02923661|DEVICE|ball attachment|
224063916|NCT06194513|OTHER|Intervention 1: Twice a day for 1 week PIOMI|Preterm babies will receive two sessions of treatment every day for a week, for a total of 14 sessions. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
224063917|NCT06194513|OTHER|Intervention 2: Once a day for 2 weeks PIOMI|Preterm babies will receive a total of 14 sessions of treatment, one every day for two weeks. Each session will be five minutes. The application is done at a time when the baby is peaceful and not very hungry. When the application is performed, the baby is positioned on his back and in a way that feels comfortable.
224063918|NCT02663050|OTHER|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
224063919|NCT02663050|DRUG|NSAID's|twice a daily
224063920|NCT02359630|DEVICE|EasyTube|Insertion for ventilation
224063921|NCT02359630|DEVICE|Endotracheal tube|Insertion for ventilation
224063922|NCT03663426|PROCEDURE|study group|"1. High dose corticoids pre-operative and 24h postoperative~2. Opioid free general anesthesia~3. Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
224063923|NCT03663426|PROCEDURE|control|"1. No corticoids pre-operative.~2. Opioid anesthesia~3. Opioids post-operative after NSAID and paracetamol."
223571712|NCT00883870|DRUG|Plasmalyte A|Intramuscular injection
223454323|NCT00619372|DRUG|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
223454324|NCT00619372|DRUG|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
223454325|NCT00619372|DRUG|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
223454326|NCT02474134|DRUG|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
223454327|NCT00827788|DRUG|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
223454328|NCT00827788|DRUG|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
223454329|NCT03130959|BIOLOGICAL|Nivolumab|Specified dose on specified days
224148370|NCT00533299|DRUG|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
223454330|NCT03130959|BIOLOGICAL|Ipilimumab|Specified dose on specified days
223454331|NCT02418793|DRUG|MOD-5014|Long Acting Factor VIIa
223571713|NCT02752958|DRUG|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
223571714|NCT00845260|BEHAVIORAL|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
223571715|NCT00845260|BEHAVIORAL|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
223571716|NCT01333670|DEVICE|Prontosan wound irrigation solution|"* cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~* dressing with Prontosan Wound Irrigation solution"
223571717|NCT01333670|DRUG|Isotonic solution (saline or lactated ringer)|"* cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~* positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~* dressing with isotonic solution"
223571718|NCT03746600|BEHAVIORAL|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
223571719|NCT01693874|BEHAVIORAL|MBSR|Mindfulness-Based Stress Reduction
223571720|NCT01693874|BEHAVIORAL|control (health education)|health education
223571721|NCT03317093|DRUG|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
224148371|NCT04898868|PROCEDURE|cord blood spontaneous drainage|In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.
223454332|NCT04013295|OTHER|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
223454333|NCT01019460|PROCEDURE|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
223571722|NCT03317093|OTHER|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
223571723|NCT00717522|DRUG|Pomalidomide|
223571724|NCT02182908|OTHER|PET-Scan|PET-Scan
224063924|NCT05508555|PROCEDURE|hyperthermic intrathoracic chemotherapy|application of chemotherapeutic agent intrathoracic under hyperthermic conditions
224063925|NCT02924662|OTHER|There is no intervention.|
224063926|NCT03803072|BEHAVIORAL|time restricted eating (TRE)|Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
224063927|NCT02717884|DRUG|tranylcypromine|"TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
224148372|NCT04898868|PROCEDURE|Umbilical cord miking|In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
224301645|NCT03686449|PROCEDURE|Split skin graft|Traditional method for treatment of post-burn raw area
223454334|NCT00437060|PROCEDURE|Cognitive Assessment|Ancillary studies
223571725|NCT02943356|DRUG|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
223571726|NCT00728520|DRUG|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
223571727|NCT00917072|BEHAVIORAL|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
224148373|NCT04540783|DEVICE|Transcranial direct current stimulation (tDCS)|10 sessions of 2mA and 20 minutes tDCS. Sponges size 5x7 cm. For the sham condition, the patient will receive just 30 seconds of stimulation.
223454335|NCT00437060|PROCEDURE|Diffusion Tensor Imaging|Correlative studies
223454336|NCT00437060|OTHER|Laboratory Biomarker Analysis|Correlative studies
223454337|NCT00437060|OTHER|Pharmacological Study|Correlative studies
223454338|NCT00437060|PROCEDURE|Psychosocial Assessment and Care|Ancillary studies
223454339|NCT04964336|OTHER|Analysis of B cells|B cells from blood and cerebrospinal fluid will be analyzed using RNA-seq
224063928|NCT02717884|DRUG|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
224063929|NCT02717884|DRUG|cytarabine|40mg s.c. (days 1-10)
224063930|NCT04596020|OTHER|Blood Flow Restriction Group (exercise with blood flow restriction using a Delfi unit)|Each group performs the same 4 exercises The BFR group will utilize the Delfi BFR unit
224063931|NCT01015768|DEVICE|ReNu Multiplus multipurpose disinfecting solution|A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
224063932|NCT01015768|DEVICE|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
224063933|NCT00604604|BEHAVIORAL|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
224063934|NCT03154814|DRUG|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
224063935|NCT03154814|DRUG|control|conventional CPB was applied without ulinastatin treatment
224063936|NCT01627860|DRUG|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
224063937|NCT01627860|DRUG|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
224063938|NCT03300999|DIETARY_SUPPLEMENT|ginger tea|"1\. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
224063939|NCT00185952|DRUG|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
224063940|NCT05913570|DRUG|Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody|10mg/kg, Q3W for 4 cycles
224063941|NCT06017570|DIAGNOSTIC_TEST|Radiologic examination on orthopantomogram|Caries examination on the distal side of the adjacent second molar in the orthopantomogram of patients with an appointment for the extraction of mesioangular or horizontal partially impacted third molars
224063942|NCT06017570|DIAGNOSTIC_TEST|Clinical examination after surgery|İnspectional caries examination on the distal side of the adjacent second molar after surgery of patients with mesioangular or horizontal partially impacted third molars
224063943|NCT05873582|DEVICE|Robotic-assisted inguinal hernia repair|Primary transperitoneal unilateral or bilateral inguinal hernia repair with the Dexter robotic system
224063944|NCT05530265|DEVICE|the smart watch and Samsung Health app|Use the smart watch (Galaxy Watch 4, Samsung Electronics Co., Ltd., Korea) and the Samsung Health app (Samsung Electronics Co., Ltd., Korea) for 90 days of positive airway pressure treatment
224063945|NCT05123833|PROCEDURE|Hypospadias repair|surgical repair of hypospadias
224063946|NCT00035022|DRUG|BCX-1777|
224063947|NCT05270070|OTHER|Appointment booking system|Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
224063948|NCT00554502|DRUG|supportive therapy with: ACE-inhibitor / ARB / Statin|"* Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~* ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~* Other antihypertensive medications depending on the clinical decision and following current guidelines.~* Statin therapy~* Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
224063949|NCT00554502|DRUG|supportive and immunosuppressive therapy|"* supportive therapy as outlined above~* depending on GFR:~  * methylprednisolone and prednisolone~ * cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~* Concomitant medication with the immunosuppressive treatment following current clinical practice"
223454340|NCT04053907|OTHER|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
223454341|NCT04053907|OTHER|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
224063950|NCT00001545|DEVICE|Magstim Super Rapid Magnetic Stimulator|
224063951|NCT00001545|DEVICE|Cadwell MES-10|
224063952|NCT03737383|BEHAVIORAL|Narrative Exposure Therapy|brief, trauma-focused treatment.
224063953|NCT01102647|DIETARY_SUPPLEMENT|phytosterol ester|1.6 g phytosterols/day for 29 days
224063954|NCT01747642|DIETARY_SUPPLEMENT|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
224063955|NCT01747642|DRUG|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
224063956|NCT01535456|PROCEDURE|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
224063957|NCT01356082|DEVICE|CNAP|Non-invasive blood pressure monitor
224063958|NCT05105464|DRUG|SYHA1815|Subjects will receive SYHA1815 orally.
224063959|NCT01794611|DEVICE|laryngoscopy|
224063960|NCT03278470|DRUG|HL237|Experimental
224148374|NCT02868164|DRUG|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
224148375|NCT02868164|DRUG|Standard Treatment|Standard Treatment
224148376|NCT02868164|OTHER|Weight Reduction|routine exercise for weight reduction
224148377|NCT03850210|DEVICE|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
224148378|NCT03850210|DEVICE|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
224148379|NCT00574366|DRUG|erlotinib|"Levels:~* 1 Erlotinib 50 mg/d~* 2 Erlotinib 50 mg/d~  * 1 Erlotinib 100 mg/d~ * 2 Erlotinib 100 mg/d~ * 3 Erlotinib 150 mg/d~ * 4 Erlotinib 150 mg/d"
224148380|NCT00574366|DRUG|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~1. RAD001 2.5 mg per day~2. RAD001 5 mg per day~3. RAD001 10 mg per day~4. RAD001 10 mg per day"
224148381|NCT04990531|DIAGNOSTIC_TEST|Low-field magnetic resonance imaging|Imaging of lung parenchyma and function by LF-MRI
224148382|NCT04990531|DIAGNOSTIC_TEST|Blood sample|Blood sample for diagnostic testing
224148383|NCT04366128|DRUG|CAPA indution immunotherapy|"1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1."
224148384|NCT05900466|DRUG|Metformin|500 mg Metformin ER tablets once daily in the morning for 8 weeks
224148385|NCT05900466|DRUG|Placebo|Matching tablets once daily in the morning for 8 weeks
224148386|NCT00529698|BIOLOGICAL|Biologically active recombinant Tat protein|
224148387|NCT04833920|DEVICE|transcranial dirrect current brain stimuation|tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
224148388|NCT05742841|DRUG|moderate- or high-intensity statin/ rosuvastatin|moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
224301646|NCT02562105|PROCEDURE|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
223454342|NCT04053907|OTHER|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
223571728|NCT00917072|BEHAVIORAL|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
223571729|NCT00917072|BEHAVIORAL|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
223571730|NCT00280800|DEVICE|constant CPAP devices|different CPAP mode
223571731|NCT00280800|DEVICE|automatic CPAP devices|different CPAP mode
223571732|NCT01175642|BEHAVIORAL|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
223571733|NCT01175642|BEHAVIORAL|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
223571734|NCT02182440|BIOLOGICAL|recAP|One hour infusions once daily for three days
223571735|NCT02182440|OTHER|Placebo|1 hour IV infusion once daily for 3 days
223571736|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
223571737|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
223571738|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
223571739|NCT01069302|DRUG|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
223571740|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Tilting|Tilt of the patient at 4 angles (22°, 42°, 58° and 80°), the order is randomized for 3 angles (22°, 42°, 58°) while 80° will always be last.
224063961|NCT03278470|DRUG|Placebo Oral Tablet|placebo with same properties except for active ingredient
224063962|NCT00002375|DRUG|Indinavir sulfate|
224063963|NCT00002375|DRUG|Nelfinavir mesylate|
224148389|NCT06153069|DRUG|Short-course regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
224301647|NCT03220061|BEHAVIORAL|music therapy|
224301648|NCT06633718|DRUG|Meropenem and Pralurbactam|3g，q8h，120min infusion
224301649|NCT06633718|DRUG|Saline|100mL，q8h，60min infusion
224301650|NCT06633718|DRUG|Ceftazidime-avibactam|2.5g，q8h，120min infusion
224301651|NCT06633718|DRUG|Metronidazole|0.915g，q8h，60min infusion
223454343|NCT04053907|OTHER|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
223454344|NCT03601156|DEVICE|intraarterial chemoembolization|
223454345|NCT03601156|DEVICE|intravenous chemotherapy|
223571741|NCT06190756|OTHER|Cardiovascular and Baroreflex stimulation by Lower Body Negative Pressure|The patient will undergo 4 level of LBNP (10Torr, 20Torr, 35Torr, 50Torr), the order is randomized for 3 intensities (10Torr, 20Torr, 35Torr) while 50Torr will always be last.
223571742|NCT00314717|BEHAVIORAL|Control diet|
224063964|NCT00004138|PROCEDURE|positron emission tomography|
224063965|NCT00004138|PROCEDURE|radionuclide imaging|
224063966|NCT00004138|RADIATION|fludeoxyglucose F 18|
224063967|NCT02613936|DEVICE|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
224063968|NCT02613936|BEHAVIORAL|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
224063969|NCT00923403|DIETARY_SUPPLEMENT|plant sterol enriched soymilk|plant sterol enriched soymilk
224063970|NCT00923403|DIETARY_SUPPLEMENT|control dairy milk|control dairy milk
224063971|NCT03388411|DIAGNOSTIC_TEST|Gut microbiome profiling|Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
224063972|NCT04442945|DRUG|ANAVEX3-71|Active oral dose of ANAVEX3-71
224063973|NCT04442945|DRUG|Placebo|Oral placebo
224063974|NCT03112889|DRUG|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
224063975|NCT04800562|DRUG|PCS499|PCS499 900mg twice a day with food
224063976|NCT04800562|OTHER|placebo|placebo comparator
224063977|NCT01786096|DRUG|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
224063978|NCT05635799|OTHER|Analysis of walking on flat ground|Analysis of walking on flat ground under different environmental conditions (visit 1)
224063979|NCT05635799|OTHER|Hospital Anxiety Disorder Questionnaire|performed during the inclusion visit
224063980|NCT05635799|OTHER|Analysis of walking on slopes|All assessments will be identical to the flat walking analysis: flat walking will be replaced by slope walking for all environmental conditions
224063981|NCT05635799|OTHER|Group interview with a sociologist|Virtual reality feedback, accompanied by a confrontation of the patients' subjective experiences (group of 5 to 10 people)
224063982|NCT04376320|DEVICE|customised ceramic sheets (Group 1)|guided bone regeneration
224063983|NCT04376320|COMBINATION_PRODUCT|modified sausage technique (Group 2)|guided bone regeneration
224063984|NCT02076997|DRUG|Methotrexate|"Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
224063985|NCT02215876|DRUG|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
224063986|NCT02215876|DRUG|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
224063987|NCT02215876|DRUG|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
224063988|NCT06051682|DEVICE|Artificial intelligence|Artificial intelligence software : Boneview. It analyzes the x-rays, gives an assessment of the presence of fractures at the examination level and locates the fractures on each image by presenting them to the practitioner directly on their screen, without any other logistical constraints for the doctor.
224063989|NCT06051682|PROCEDURE|Emergency physician|the emergency physician analyzes the x-rays
224063990|NCT02533063|DEVICE|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
224063991|NCT06538948|PROCEDURE|Bariatric Surgery|The intervention is not assigned to the participant after recruitment in the study, rather the intervention is an inclusion criteria for participation in the study.
224063992|NCT04588779|OTHER|Graston|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Graston for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
224063993|NCT04588779|OTHER|Manual myofascial release|"Ultrasound for 10 mins/1 set/ (3 sessions/week), Manual myofascial release for 5 mins/1 set/ (3 sessions/week), Piriformis stretching exercises/ 10 reps with 30 sec hold/ 1 set/(3 sessions/week), Hip abductor strengthening/10 reps/1 set/(3 weeks), Hip extensor strengthening/10 reps/1 set/(3 weeks),~A total of 9 sessions for 3 weeks (3 sessions/week) were given each consisting of 20 mins."
224063994|NCT03885310|DEVICE|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
224063995|NCT01012375|DRUG|AZD1446|10 mg capsule, oral dose
224063996|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
224063997|NCT01012375|DRUG|AZD1446|80 mg capsule, oral dose
224063998|NCT01012375|DRUG|Placebo|Matching capsule, oral dose
224063999|NCT04599322|OTHER|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle|Bilateral dry needling in latent trigger points of the Flexor digitorum Brevis Muscle
224064000|NCT05447468|OTHER|Strength of lower trapezius|Ask the patient to raise arm above the head with upper extremity in line with lower trapezius muscle fibers in prone position with the shoulder joint at 135 degrees. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
224064001|NCT05447468|OTHER|Strength of middle trapezius|Shoulder external rotation with the shoulder abducted 90ₒ and elbow flexed 90ₒ in prone position with elbow supported on the table. The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks.
224064002|NCT05447468|OTHER|Strength of serratus anterior|"Ask the patient to raise the arm on a wall in the plane of the scapula in standing position.~The patient will be asked to hold position 6 seconds and perform 3 sets of 10 repetitions and 3times per week for 6 weeks."
223571743|NCT00314717|BEHAVIORAL|Low GI diet|
223571744|NCT03390478|OTHER|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
223571745|NCT00072293|PROCEDURE|Axillary lymph node dissection|Axillary lymph node dissection
223571746|NCT00072293|PROCEDURE|No axillary lymph node dissection|Therapeutic conventional surgery
223571747|NCT01894880|PROCEDURE|early SSC|bonding straight after birth
224064003|NCT05447468|OTHER|Pulsed ultrasound|With a 20% duty cycle, frequency of 1 MHz and intensity of 1.5 w/cm² for 5 minutes 3 times per week for 6 weeks.
224148390|NCT06153069|DRUG|Standard regimen|"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."
224148391|NCT00028418|DRUG|Clofarabine|
223454346|NCT06465771|BEHAVIORAL|Youth-led NCD risk reduction intervention|With the help of Youth (students of grades 9 and 10), their parents and other stakeholders, including teachers, headteachers, and canteen staff through qualitative interviews, we will develop an intervention focuses on NCD risk reduction among younger peers (students of grades 5 and 6). A nutritionist will train the youth on how to deliver the intervention among their younger peers.
223571748|NCT01894880|PROCEDURE|late SSC|bonding after termination of operation
223454347|NCT01960062|DEVICE|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
223454348|NCT01168609|PROCEDURE|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
223571749|NCT03378427|DRUG|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
223571750|NCT04183855|DIETARY_SUPPLEMENT|Generation UCAN supplementation|carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)
223571751|NCT04183855|DIETARY_SUPPLEMENT|Mirexus PhytoSpherix supplementation|carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)
223571752|NCT04183855|BEHAVIORAL|satiety ratings|questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
223571753|NCT03243214|DEVICE|TMS|Real or Sham TMS will be given to the PD-MCI patient
223571754|NCT03243214|DEVICE|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
223571755|NCT01166958|DRUG|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
223454349|NCT01023347|DRUG|Paclitaxel (Genexol®)|
223454350|NCT01023347|DRUG|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
223454351|NCT02384538|BIOLOGICAL|ABT-981|ABT-981 administered by subcutaneous injection
223454352|NCT02384538|BIOLOGICAL|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
223454353|NCT03457324|DRUG|JCM-16021|This prescription with seven ingredients.
223571756|NCT01166958|DRUG|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
223571757|NCT06219837|DRUG|bupivacaine injection by ultrasound guided transversalis fascia plane block|With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
223571758|NCT04218838|DEVICE|CornerLoc SI Joint Stabilization Procedure|CornerLoc minimally invasive SI Joint Stabilization System
223571759|NCT04218838|DRUG|Intra-articular Sacroiliac Joint Steroid Injection|Standard of Care - Steroid injection into the sacroiliac joint
223454354|NCT03457324|DRUG|Placebo|Placebo
223454355|NCT02103023|DRUG|Imiquimod ointment|5% 250mg imiquimod ointment
223571760|NCT01902563|OTHER|Osteopathic Manipulative Treatment|
223571761|NCT04209114|BIOLOGICAL|Nivolumab|Specified dose on specified days
223571762|NCT04209114|PROCEDURE|Radical cystectomy (RC)|Surgical removal of the bladder
223571763|NCT04209114|BIOLOGICAL|Bempegaldesleukin|Specified dose on specified days
223571764|NCT04836416|OTHER|Observational|Observational
223454356|NCT02103023|DRUG|Aqueous cream|aqueous cream
223454357|NCT02103023|BIOLOGICAL|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
223454358|NCT02103023|BIOLOGICAL|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
223454359|NCT01349530|OTHER|Evaluating of usual care|RESEARCH IN CURRENT CARE
223454360|NCT01349530|OTHER|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
223571765|NCT02270762|OTHER|Rest in bed|
223571766|NCT02270762|OTHER|Passive verticalization|
223571767|NCT02270762|OTHER|Rest in bed|
223571768|NCT04177420|DEVICE|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
223571769|NCT04177420|DEVICE|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
223571770|NCT04177420|DEVICE|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
223571771|NCT04177420|DEVICE|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
223571772|NCT04393467|DEVICE|tSMS|tSMS delivered on bilateral motor cortex
223571773|NCT04393467|DEVICE|sham tSMS|sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
223571774|NCT00596245|DRUG|MT400|MT 400, naproxen sodium 550mg
224148392|NCT02500277|DEVICE|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
224148393|NCT02500277|DEVICE|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
224301652|NCT06016036|DRUG|SAL-0951|"SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
224064004|NCT05447468|OTHER|Stretching of extensor carpi radialis brevis muscle|Put the elbow in extension, forearm in pronation and wrist in flexion with ulnar deviation. Hold for 30s and repeat 3 times with 30s rest in between. Three times per week for 6 weeks.
224064005|NCT05447468|OTHER|Eccentric exercises of wrist extensors|Ask the patient to extend elbow, pronate forearm, extend wrist and then flex the wrist slowly until full flexion is achieved. Patients should apply 3 sets of 10 repetitions 3 times per week for 6 weeks.
224064006|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
224071103|NCT03755648|OTHER|traditional physical therapy|Traditional therapy includes hot pack for 15 minutes and stretching for 20 minutes
224071104|NCT03755648|OTHER|Delorme resistance exercise|Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
223454361|NCT02872909|DEVICE|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
223454362|NCT02916953|DEVICE|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
223454363|NCT03259152|DRUG|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
223454364|NCT05689853|DRUG|AK119|AK119 is an anti-CD73 monoclonal antibody.
223454365|NCT05689853|DRUG|AK112|AK112 is a bispecific monoclonal antibody against VEGF and PD-1.
223454366|NCT00179764|PROCEDURE|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
223454367|NCT00179764|PROCEDURE|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
223571775|NCT05440006|DRUG|Fuzuloparib|Fuzuloparib Capsules; 150mg; single dose per cycle.
223454368|NCT00179764|RADIATION|Central Nervous System (CNS) prophylaxis radiation|"* Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~* Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
223454369|NCT02617498|DEVICE|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
223454370|NCT02617498|DEVICE|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
223571776|NCT00901511|PROCEDURE|Baseline WLL|Scheduled bilateral WLL
223571777|NCT00901511|DRUG|Sargramostim|Inhaled GM-CSF
223571778|NCT00901511|PROCEDURE|Rescue WLL|Unscheduled bilateral WLL
223571779|NCT00846989|DRUG|RKI983A|RKI983 0.05 % twice daily
224071105|NCT00369356|DRUG|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
224071106|NCT00369356|DEVICE|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
224071107|NCT00369356|DEVICE|Bare metal coronary stent|Stenting with BMS only
224071108|NCT03105570|PROCEDURE|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
224071109|NCT00705939|DRUG|Taliglucerase alfa|Intravenous infusion every 2 weeks
224071110|NCT02498626|OTHER|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
224071111|NCT05048342|DRUG|LOU064|Each patient took one film-coated tablet in the morning and one film-coated tablet in the evening (except the morning dose at the PK sampling visits, which were to be taken on site during the visit).
224071112|NCT04612998|OTHER|left lateral decubitus position|Comparator group consisted of patients performing CSEA in the left lateral decubitus position.
224071113|NCT04612998|OTHER|sitting position|Active control group consisted of patients performing CSEA in the sitting position.
224071114|NCT04612998|DRUG|The use of intravenous ephedrine.|Intravenous ephedrine (6 mg) was used to treat hypotension (a 30% decrease in systolic blood pressure compared to preoperative values) during surgery.
224071115|NCT04612998|DRUG|The use of intravenous atropine.|Intravenous atropine (1 mg) was given in case of bradycardia (the heart rate \< 45 beats/minute) during surgery.
224071116|NCT04612998|DRUG|The use of intravenous metoclopramide|When nausea and vomiting were observed, intravenous metoclopramide (10 mg) was administered.
224071117|NCT06053424|DRUG|AZD7798|Participants will receive IV infusion of AZD7798 as stated in arm description.
224071118|NCT06053424|DRUG|[11C]AZ14132516|Participants will receive IV bolus dose of radioligand \[11\^C\]AZ14132516 as stated in arm description.
224071119|NCT04393610|DRUG|Lidocaine|Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
224071120|NCT04393610|DRUG|Magnesium Sulphate|Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
224301653|NCT06016036|DRUG|Placebo|"SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks"
224301654|NCT04959591|DRUG|intravenous acetaminophen|experimental(pre): administration of IV acetaminophen
224064007|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
224064008|NCT00677014|DEVICE|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
224064009|NCT02427074|PROCEDURE|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
224064010|NCT02427074|PROCEDURE|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
224064011|NCT00640328|DRUG|Ofatumumab 100|100mg
224064012|NCT00640328|DRUG|Ofatumumab 300|300mg
224064013|NCT00640328|DRUG|Ofatumumab 700|700mg
223454371|NCT01014052|DRUG|QLT091001|oral QLT091001 administered once daily for 7 days
223454372|NCT04215796|DEVICE|ReX-C system|CFTR modulators are dispensed to patients via ReX-C system
223571780|NCT00846989|DRUG|RKI983A|RKI983 0.1 % twice daily
223571781|NCT00846989|DRUG|Latanoprost|Latanoprost 0.005 % once a day
223454373|NCT02966717|DRUG|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
223454374|NCT02966717|DRUG|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
224064014|NCT00640328|DRUG|Placebo|matching placebo
224064015|NCT03761095|DRUG|Unesbulin|Unesbulin will be administered as per the dose and schedule specified in the arm.
224064016|NCT03761095|DRUG|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
224071121|NCT04393610|DRUG|Fentanyl|Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
223454375|NCT02966717|DRUG|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
223571782|NCT00034164|DRUG|S-8184 Paclitaxel Injectable Emulsion|
223571783|NCT03730545|DIETARY_SUPPLEMENT|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
223571784|NCT05189249|OTHER|No intervention performed|No intervention performed. Participants were enrolled retrospectively and medical records were accessed for data.
224071122|NCT01014832|DRUG|Intensive insulin therapy|Intensive insulin therapy
224071123|NCT05248438|BEHAVIORAL|Questionnaire|Questionnaire
224071124|NCT06467890|BEHAVIORAL|Educational programme about vital pulp therapy|An awareness educational material based on the recent AAPD and AAE guidelines on vital pulp therapy will be sent to the participants right after they answer the questionnaire for the first time
224071125|NCT05968729|OTHER|Active Comparator: 0.25 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s.
224071126|NCT05968729|OTHER|Active Comparator: 0.50 m/s asymmetric session first|Participants will first perform an asymmetric walking trial where the between-limb gait speed difference is 0.50 m/s on day one. On the second day, participants will perform an asymmetric walking trial where the between-limb gait speed difference is 0.25 m/s.
224071127|NCT02059200|BEHAVIORAL|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
224071128|NCT02728830|DRUG|Pembrolizumab|Pembrolizumab 200mg IV
224071129|NCT01707615|DRUG|GSPE|GSPE 240 mg/day (120mg bid)
224071130|NCT01707615|OTHER|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
224071131|NCT04795557|DIETARY_SUPPLEMENT|ADAPT-232 oral solution|"One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients"
224071132|NCT04795557|OTHER|Placebo oral solution|Excipients
224071133|NCT06500416|DEVICE|Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL|Tecnis Symfony lens (DXR00V/ZXR00V) has the OptiBlue violet light filter (VLF), which blocks short-wavelength light. Violet light filtration reduces light scatter, improving contrast and reducing nighttime visual disturbances such as halo, glare, and starbursts.
224064017|NCT04686721|DIAGNOSTIC_TEST|Chest CT scan + baseline spirometry|Patients will perform an initial evaluation at 2 months from hospital discharge using a chest CT scan without contrast-enhancing along with a pulmonary function test using spirometry. Based on results and according to current guidelines, further follow-up or intervention will be administered.
223571785|NCT02520258|OTHER|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
223571786|NCT02520258|OTHER|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
223571787|NCT00093886|DRUG|clevidipine|
223571788|NCT00093886|DRUG|nitroglycerin|
223571789|NCT00812201|DEVICE|No intervention is used. Collection of signals only.|Device received per standard of care.
223571790|NCT06252896|OTHER|INSTRUMENTAL-ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE|After all evaluations were made, IASTM was applied to the individuals in the intervention group for five minutes each, for a total of 20 minutes, on the quadriceps and hamstring muscles of both extremities, respectively.
223571791|NCT06252896|OTHER|NO INTERVENTION|The control group waited for 30 minutes after the initial measurements and all measurements were repeated.
223571792|NCT04092907|DRUG|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
223571793|NCT04092907|DRUG|placebo|Ophthalmic Solution
223571794|NCT03889236|OTHER|Fasting mimicking diet Prolon|5-day fasting mimicking diet
223571795|NCT03889236|DIETARY_SUPPLEMENT|Food supplement Endocalyx|Food supplement
223571796|NCT03889236|DIETARY_SUPPLEMENT|Placebo|Placebo
223571797|NCT05736705|PROCEDURE|Endoscopic Submucosal Dissection|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the monopolar electrocautery knife.
223571798|NCT05736705|DEVICE|Bipolar electrocautery knife|Participants randomized in this arm will have the removal of their esophageal lesion utilizing the bipolar electrocautery knife.
223571799|NCT05479344|BEHAVIORAL|A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection|The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
223571800|NCT05285475|OTHER|Exercise and Water Intake|"The exercise protocol for this group will be abdominals, pelvic stretching and kegels exercises (PFM) for three days/week lasting about 30 minutes with approximately 1600-1800ml (8-10 glasses) intake of water for 8 weeks (two consecutive menstrual cycles)~Exercises include:~Piriformis stretching (5 repetitions×20 seconds) Adductor stretching (5 repetitions×20 seconds) Sit-ups (10 repetitions×3 sets) Bridging (10 repetitions×3 sets) Kegels exercises (10 repetions×3 sets) Pelvic elevation (10 repetitions×3 sets) Pelvic rotation (10 repetitions×3 sets) Cobra pose (5 repetitions×20 seconds)"
223571801|NCT02466074|DRUG|Acetazolamide|see arm description
223571802|NCT02466074|DRUG|Placebo|Placebo arm
223571803|NCT01617135|DRUG|CVT-301|
223571804|NCT01617135|DRUG|Placebo|
223571805|NCT01617135|DRUG|Sinemet (carbidopa/levodopa)|
223571806|NCT01617135|DRUG|CVT-301|
223571807|NCT00864669|DRUG|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
223571808|NCT00864669|DRUG|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
223571809|NCT01740544|OTHER|Cathodal tDCS|Cathodal tDCS applied over the right PPC
224064018|NCT04338035|BEHAVIORAL|Expectant management|Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
224064019|NCT00669058|DRUG|Lactic acid (Dermacid)|
224064020|NCT02079103|DEVICE|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
223571810|NCT01740544|OTHER|Sham tDCS|Sham tDCS applied over the right PPC
223571811|NCT00299780|DRUG|Stem cell mobilization|
223571812|NCT01034371|PROCEDURE|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
223571813|NCT01034371|PROCEDURE|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
223571814|NCT01034371|PROCEDURE|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
223571815|NCT04316078|OTHER|patient engagement platform|"1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan."
223571816|NCT04415996|OTHER|HVLA L3/4|"The participant will be lateral decubitus and the investigator will locate the third lumbar vertebra. Then with one hand the investigator will contact the interspinous space underlying L3 and with the other hand he will take the top leg into flexion until the investigator feels tension in L3/L4 joint. Then he puls the tables´s arm until felling tension in the region to be manipulated. Afterwards the investigator will globally rotate the participant in the horizontal plane and will approach to the L3/L4 joint. With one arm the investigator will contact the deltopectoral groove and with the other one will contact the external iliac fossa. Finally, the investigator will compress and rotate the pelvis and will apply an impulse in a rapid rotation, without losing the parameters with a body drop allowed by the flexion of the knees and the contraction of the large pectorals."
223571817|NCT04415996|OTHER|Sham|The participant will be in lateral decubitus and the top leg and knee will be flexed until the foot reaches the popliteal region of the other leg. There won't be applied any tension in no structure. This intervention will be applied during 20 seconds each side.
224064021|NCT02079103|BEHAVIORAL|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
224064022|NCT02374099|DRUG|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
224064023|NCT02374099|DRUG|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
224064024|NCT03898375|OTHER|Walking with different optic flow speeds|Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
224064025|NCT01550146|DRUG|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
224148394|NCT02606396|PROCEDURE|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
224148395|NCT02606396|PROCEDURE|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
224148396|NCT02606396|PROCEDURE|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
224148397|NCT03459157|DRUG|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
224148398|NCT00132158|DRUG|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
224148399|NCT00621010|DRUG|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
224148400|NCT01843634|DRUG|ODSH|
224148401|NCT04983810|DRUG|Fadraciclib|Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
224064026|NCT01550146|DRUG|Placebo|iv. Normal Saline 0.1 ml/kg
224064027|NCT01433575|DRUG|RO4917838|10 mg single oral dose
224064028|NCT01433575|DRUG|RO4917838|20 mg single oral dose
223571818|NCT02087813|DRUG|Alpha1-antitrypsin|
224064029|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
224064030|NCT01033825|DRUG|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
224064031|NCT01033825|DRUG|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
224064032|NCT01033825|DRUG|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
224064033|NCT01033825|DRUG|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
224064034|NCT01033825|DRUG|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
224064035|NCT01033825|DRUG|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
223571819|NCT02087813|DRUG|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
223571820|NCT03204552|OTHER|No intervention (observational study)|No intervention (observational study)
223571821|NCT04348175|DRUG|Setmelanotide|Setmelanotide will be administered as a single SC dose of 2.0 mg on Day 1. A dose higher than 2.0 mg will not be used during the study. Dose may be lowered based on safety data.
224064036|NCT04039893|DIAGNOSTIC_TEST|Systematic axillary ultrasound imaging|Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.
224064037|NCT04039893|DIAGNOSTIC_TEST|Sentinel node|Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.
224064038|NCT04039893|PROCEDURE|Excision of suspicious lymph nodes|Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.
224064039|NCT04039893|PROCEDURE|Two steps axillary node clearance|Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobrachial nerve will be considered the limit defining the border between superior and inferior axilla.
224064040|NCT02913690|DIETARY_SUPPLEMENT|Placebo|2 x 150mg capsules daily
224064041|NCT02913690|DIETARY_SUPPLEMENT|TRF|2 x 150mg capsules daily
224064042|NCT01326546|BIOLOGICAL|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
224064043|NCT01326546|DRUG|entecavir|0.5mg,per day,oral intake.
224064044|NCT01326546|OTHER|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
224064045|NCT01057407|DRUG|ASP1585|oral
224064046|NCT01057407|DRUG|Sevelamer hydrochloride|oral
224071134|NCT05069181|OTHER|Pilates mat exercises|"Pilates mat exercises: Each Pilates session will last for one hour and commence with a 10 minute warm up and finish with a 10 min cool down. The subjects will be taught the 5 key elements of Pilates (lateral costal breathing, centring which is a neutral position of the lumbar spine with activation of the core muscles, ribcage placement, shoulder blade placement and neutral position of the cervical spine with slight upper cervical flexion at the cranio-cervical junction).~Pilates exercise program will consist of warm up exercises, main treatment program (10 level) and cooling down exercises."
224071135|NCT05069181|OTHER|cervical stabilization exercises|training of deep cervical flexor muscles with pressure biofeedback unit, 20 min/day, 3 days/week for 12 weeks.
224064047|NCT04294719|OTHER|Cognitive Adaptation Training (CAT)|Cognitive Adaptation Training (CAT) is a standardized implementation of environmental supports for improving adaptive functioning including medication adherence, grooming, and daily activities in patients with schizophrenia. Environmental supports (signs, checklists) are manual-driven and grounded upon an assessment of neurocognitive function and behaviour. Assessment results yield one of six CAT classifications (Apathy/Poor Executive Functioning, Disinhibited/Poor EF, Mixed/Poor EF, Apathy/Fair EF, Disinhibited/Fair EF, Mixed/Fair EF).The goal will be to improve organization and self-care, modifying the intervention to be more relevant for an inpatient setting. Once an individual's CAT classification has been determined, strategies for specific functional problems are chosen from a series of tables. CAT interventions are maintained in the client's living space during weekly visits. CAT clinicians will encourage team members to assist with the reinforcement of CAT tools and strategies.
224148402|NCT03197350|DIAGNOSTIC_TEST|cMR|cardiac MRI done to complete the diagnosis
224148403|NCT03197350|BIOLOGICAL|biomarker|Biomarker correlation with cMR parameters Prognostic information
224071136|NCT05069181|OTHER|conventional physiotherapy|10 min hot pack on cervical area range of motion exercises and isometric neck exercises as a home program 3 days/week for 12 weeks
223454376|NCT05971264|DIAGNOSTIC_TEST|Near infrared-spectroscopy|Comparison of regional intestinal oxygen saturation (measured with near infrared-spectroscopy) and indirect intraabdominal pressure measurement (bladder pressure) in muscle-relaxed, sedated patients compared to awake, non-sedated patients.
223571822|NCT00951249|BEHAVIORAL|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
224071137|NCT03025958|DRUG|Nimotuzumab|Concomitant nimotuzumab was given weekly at a dose of 200 mg from one week before the start of IMRT.
224071138|NCT03025958|RADIATION|Radiation|Briefly, the dose prescribed was 70.4 Gy, 70.4 Gy, 60.8 Gy, and 54.4 Gy in 32 fractions delivered over 6 weeks at the periphery of the planning target volume (PTV)nx+rn, PTVnd, PTV1, and PTV2, respectively, using the simultaneous integrated boost technique.
224071139|NCT01701739|DRUG|aleglitazar|Multiple doses of aleglitazar
224071140|NCT01701739|DRUG|digoxin|Single dose of digoxin
224071141|NCT01081795|DRUG|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
224071142|NCT01081795|DRUG|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
224071143|NCT01358656|PROCEDURE|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith \& Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
224071144|NCT01358656|PROCEDURE|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
223454377|NCT01853683|PROCEDURE|Conservative Management|
223454378|NCT01853683|PROCEDURE|Operative Management|
223454379|NCT03090061|DIAGNOSTIC_TEST|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
223571823|NCT00951249|BEHAVIORAL|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
223571824|NCT00951249|BEHAVIORAL|Peer health care system navigators|HIV/STI treatment and other medical and social services
223571825|NCT00951249|BEHAVIORAL|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
224071145|NCT03578120|BIOLOGICAL|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
224071146|NCT03398577|DRUG|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
224071147|NCT03398577|DRUG|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
224071148|NCT00136591|DRUG|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
224071149|NCT00136591|DRUG|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
224071150|NCT05758259|DRUG|combination oral and topical vitamin D|combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
224071151|NCT05758259|DRUG|oral placebo and topical cholecalciferol|oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1
224071152|NCT05758259|DRUG|oral placebo and basic ingredient placebo topical vitamin D|oral placebo and basic ingredient placebo topical vitamin D similar to the ointment
223742700|NCT06258837|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
223742701|NCT06258837|PROCEDURE|Adenotonsillectomy|Tonsil and/or adenoid removal
224064048|NCT03065907|OTHER|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
224064049|NCT05088486|GENETIC|DNA analysis|GWAS
224064050|NCT02211027|BIOLOGICAL|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
224064051|NCT04503239|DEVICE|G6|Wear 9 wear periods of the 10-day CGM
224064052|NCT00081159|DRUG|Doxorubicin hydrochloride|Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
224064053|NCT00081159|DRUG|Goserelin acetate|
224064054|NCT00081159|DRUG|Leuprolide acetate|
224064055|NCT00081159|DRUG|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
224064056|NCT00081159|PROCEDURE|orchiectomy|
224064057|NCT00081159|RADIATION|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
224064058|NCT01868880|DRUG|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
224064059|NCT01868880|DRUG|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
224064060|NCT00388700|DRUG|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
224064061|NCT00388700|DRUG|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
224064062|NCT02237521|OTHER|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
224064063|NCT02237521|OTHER|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
224064064|NCT01548339|PROCEDURE|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
224064065|NCT01714687|DEVICE|balloon sinus dilation|
224064066|NCT01714687|OTHER|medical therapy|
224064067|NCT04919642|DRUG|TT-00420|TT-00420 tablet, administered orally once daily
224064068|NCT01553136|DRUG|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
224064069|NCT06973031|DEVICE|Globe Pulsed Field System|Ablation and atrial mapping with the Globe Pulsed Field System
224064070|NCT00214370|DRUG|Propofol-Fentanyl|
224064071|NCT00214370|DRUG|Propofol alone|
224064072|NCT02704338|BIOLOGICAL|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
224064073|NCT02632396|DRUG|Ixazomib|Given PO
224064074|NCT02632396|BIOLOGICAL|Rituximab|Given IV
224064075|NCT00894556|DRUG|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
224064076|NCT00894556|DRUG|Comparator: Placebo|Placebo to Rizatriptan
224064077|NCT00894556|DRUG|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
224064078|NCT02994433|DRUG|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
224064079|NCT02994433|DRUG|Placebo gas|Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
224064080|NCT02994433|DEVICE|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
224064081|NCT05617976|PROCEDURE|caudal block|caudal block
224064082|NCT02284789|OTHER|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
224064083|NCT03209206|DRUG|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
224064084|NCT03209206|DRUG|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
224064085|NCT03926975|DEVICE|Scleral Lens|The contact lens will be worn on one eye.
224064086|NCT03926975|OTHER|No lens|No lens worn on the contralateral control eye
224064087|NCT01223170|BEHAVIORAL|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
224064088|NCT01223170|BEHAVIORAL|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
223571826|NCT01444027|BEHAVIORAL|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
224301655|NCT04959591|DRUG|intravenous acetaminophen|experimental(post): administration of IV acetaminophen
224301656|NCT04959591|DRUG|Placebo|placebo comparator: administration of normal saline
224301657|NCT06227013|BEHAVIORAL|Whistleblowing intervention|the participated nurses will receive session about Whistleblowing
223571827|NCT01485380|DRUG|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
224064089|NCT01223170|BEHAVIORAL|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
224064090|NCT01223170|BEHAVIORAL|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
224064091|NCT00294359|DRUG|Mitomycin C; Capecitabine; Bevacizumab|
224064092|NCT04763642|PROCEDURE|pancreaticoduodenectomy|Robotic Whipple operation Open Whipple operation Laparoscopic Whipple operation
224064093|NCT00868348|DRUG|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
224064094|NCT00868348|DRUG|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
224064095|NCT02993874|DIETARY_SUPPLEMENT|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
224064096|NCT02993874|DIETARY_SUPPLEMENT|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
224064097|NCT03269370|BEHAVIORAL|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
224064098|NCT03269370|BEHAVIORAL|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
224064099|NCT03269370|BEHAVIORAL|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, \& Cobham, 2008)"
224064100|NCT00150826|DRUG|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
224064101|NCT00150826|DRUG|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
224064102|NCT03402984|DRUG|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
224064103|NCT03402984|DRUG|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
224064104|NCT01884259|DRUG|Docetaxel|75 mg/m² on day 1 of 21-days cycle
224064105|NCT01884259|DRUG|Cisplatin|75 mg/m² on day 1 of 21-days cycle
224064106|NCT01884259|DRUG|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
224064107|NCT01884259|BIOLOGICAL|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
224064108|NCT01884259|BIOLOGICAL|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
224064109|NCT01884259|RADIATION|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
224064110|NCT00003351|DRUG|irinotecan hydrochloride|
224064111|NCT06320587|OTHER|Kangaroo care practice by both mother and father|In this group, kangaroo care will be done by both mother and father. Mothers used the Mother-Infant Attachment Scale and the Perceived Maternal Parenting Self-Efficacy Scale as pretests; Fathers will also complete the Postpartum Father-Infant Attachment Survey and the Perceived Father Parenting Self-Efficacy Form. Mothers and fathers in the application group will be provided with kangaroo care for 45 minutes, 2 days a week for 5 weeks. The baby's vital signs will be monitored 30 minutes before each kangaroo care, at the 15th minute of each kangaroo care, and 30 minutes after the kangaroo care, and will be recorded on the Kangaroo Care Monitoring Form. After kangaroo care was completed at the end of 5 weeks, mothers used the Mother-Baby Attachment Scale and the Perceived Mother Parenting Self-Efficacy Scale as posttests; Postnatal Father-Infant Attachment Questionnaire and Perceived Father Parenting Self-Efficacy Form will be filled out by fathers.
224064112|NCT06320587|OTHER|Kangaroo care practice only mother|In the control group, only the mother will care for the kangaroo. The application will be similar to the experimental group.
224064113|NCT03077685|DRUG|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
224064114|NCT00573209|RADIATION|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
224064115|NCT01979536|DRUG|Brentuximab Vedotin|Given IV
224064116|NCT01979536|DRUG|Crizotinib|Given PO
224064117|NCT01979536|DRUG|Cyclophosphamide|Given IV
224064118|NCT01979536|DRUG|Cytarabine|Given IT and IV
224064119|NCT01979536|DRUG|Dexamethasone|Given PO or IV
224064120|NCT01979536|DRUG|Doxorubicin Hydrochloride|Given IV
224064121|NCT01979536|DRUG|Etoposide|Given IV
224064122|NCT01979536|DRUG|Ifosfamide|Given IV
224148404|NCT04134728|BIOLOGICAL|GSK3196165 (Otilimab)|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
223454380|NCT03090061|DIAGNOSTIC_TEST|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
223454381|NCT04252963|DRUG|MUCOLASE tablet (streptokinase • streptodornase)|streptokinase • streptodornase 5mg
223454382|NCT04252963|DRUG|Placebo|Placebo of MUCOLASE tablet
223454383|NCT04806321|OTHER|Project SOLVE|This 30-minute, self-guided, digital program is designed to help adolescents solve, rather than be overwhelmed by, everyday problems.
223454384|NCT04806321|OTHER|Project SUCCESS|This 30-minute, self-guided, digital program is designed to help adolescents develop study skills.
223454385|NCT06479408|OTHER|progressive muscle relaxation (PMR) technique and vestibular rehabilitation exercises|A will be treated by progressive muscle relaxation (PMR) technique as a mean of stress relaxation and vestibular rehabilitation exercises for postural stability through Swiss ball, BOSU ball, balance board etc. Other components of vestibular rehab including gaze stability enhancement, improvement in vertigo and activities of daily living will also be focused.
223454386|NCT06479408|OTHER|virtual reality (VR)|virtual reality (VR) based intervention program where three dimensional-3D environments will be used reduce stress and improve balance. A Simulator Sickness Questionnaire (SSQ) will be filled by participants before and after each session of VR to discriminate whether VR is provoking the symptoms or not.
223454387|NCT05149547|DIAGNOSTIC_TEST|blood culture versus mNGS detection|peripheral 4ml for mNGS detection
223454388|NCT03756597|DEVICE|ReCIVA|The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.
223571828|NCT05648149|BEHAVIORAL|hierarchical multi-dimensional cognitive training scheme based on computer|The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
224064123|NCT01979536|DRUG|Methotrexate|Given IT and IV
223571829|NCT05650138|OTHER|Jacobson's progressive muscular relaxation technique|subjects will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks.
223571830|NCT05650138|OTHER|30 min walk|30 minutes walk twice a week for 4 weeks
223571831|NCT01416441|DRUG|Aripiprazole|Aripiprazole tablets orally once daily.
224064124|NCT00396201|DRUG|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
224064125|NCT03745274|BIOLOGICAL|GHB04L1|Solution
224064126|NCT03745274|OTHER|Placebo|Buffer solution
224064127|NCT03767023|OTHER|cross sectional|
224064128|NCT02594306|DEVICE|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
224064129|NCT02594306|PROCEDURE|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
224064130|NCT02594306|PROCEDURE|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
224064131|NCT02594306|PROCEDURE|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
224064132|NCT04885803|DIETARY_SUPPLEMENT|Softgel Vitamin D3|5000IU vitamin D3 taken as single oral softgel once daily for 30 days
224064133|NCT04885803|DIETARY_SUPPLEMENT|Nano Liquid Vitamin D3|5000IU vitamin D3 taken as liquid oral spray once daily for 30 days
224064134|NCT04885803|DIAGNOSTIC_TEST|25(OH)D Blood Serum Test|A sample of blood is drawn off and processed for 25(OH)D levels at baseline, after 15 days of supplementation, and after 30 days of supplementation
224064135|NCT04885803|OTHER|Placebo Control|Liquid oral spray once daily for 30 days. Solution identical in smell, taste, color, and production process to Nano Liquid D3, but containing no Vitamin D3.
224064136|NCT04158076|DRUG|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
224148405|NCT04134728|BIOLOGICAL|Sarilumab|Sarilumab solution in PFS to be administered SC.
224148406|NCT04134728|DRUG|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
224148407|NCT04134728|DRUG|csDMARDs|Stable dose of csDMARD(s) as SoC.
223454389|NCT03756597|DEVICE|CASPER|Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
223454390|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
223454391|NCT01075919|DIETARY_SUPPLEMENT|Placebo|1 g olive oil taken daily for 12 weeks
223454392|NCT01075919|DIETARY_SUPPLEMENT|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
223454393|NCT03124498|BIOLOGICAL|CIK Cell|Autologous cytokine-induced killer (CIK) cell
223454394|NCT03283332|OTHER|No intervention|
223454395|NCT05916053|DIETARY_SUPPLEMENT|Vitamin D supplementation|50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
224301658|NCT03554213|BIOLOGICAL|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
223454396|NCT01027468|DRUG|Bevacizumab|intraocular bevacizumab injection
223454397|NCT03117361|DRUG|plitidepsin|Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
223454398|NCT03117361|DRUG|Bortezomib|BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
223454399|NCT03117361|DRUG|Dexamethasone|DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks
223454400|NCT01999764|DRUG|QLT091001|QLT091001 administered orally at multiple time points.
223454401|NCT01999764|OTHER|Placebo|Placebo is administered orally at multiple time points.
223571832|NCT01666639|BEHAVIORAL|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
223571833|NCT01666639|BEHAVIORAL|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
223571834|NCT05052437|DRUG|Utidelone Injection; capecitabine|8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle
223571835|NCT05052437|DRUG|Utidelone|8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.
223571836|NCT04627675|DRUG|CORVax|DNA-encodable coronaviral vaccine
223571837|NCT04627675|DRUG|IL-12 plasmid|cytokine
223571838|NCT04627675|DEVICE|Cliniporator|electroporation system
223571839|NCT02653495|BIOLOGICAL|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
223742702|NCT06401668|BEHAVIORAL|Community health worker (CHW) strategy|CHWs will offer participants personalized support to assist in overcoming barriers and leveraging facilitators to PRx uptake. CHWs are trained lay members of the communities they serve. The CHW strategy is an evidence-based.
223742703|NCT06401668|BEHAVIORAL|PRx Program|The PRx Program provides free fruit and vegetables and nutrition education to patients with T2D and food insecurity.
224301659|NCT03760003|DRUG|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
224301660|NCT03760003|DRUG|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
223454402|NCT01869088|DRUG|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0\*1011vp：0.5ml\*3） will be first infused through the target artery
223454403|NCT01869088|PROCEDURE|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
223454404|NCT00988000|OTHER|telephone consultation|alternative to face to face consultation for new referrals
223454405|NCT00988000|OTHER|No intervention|no alternative to face to face consultation
223454406|NCT00701688|DRUG|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
223454407|NCT04611139|DRUG|SP-2577|Daily oral doses
223454408|NCT04611139|DRUG|Pembrolizumab|200mg Q3W by IV infusion
223454409|NCT00095342|DRUG|TMI-005|
223454410|NCT00540644|DRUG|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
223454411|NCT00540644|DRUG|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
223454412|NCT00540644|DRUG|Prednisone|50 mg p.o. Q.O.D.
223454413|NCT06307834|BEHAVIORAL|Neurofeedback - based therapy|This intervention will include mental practice of various hand movements accompanied by guided visual feedback, aimed at regulating brain activation patterns to facilitate the restoration of hand movements. We will also incorporate EMG signals to control a hand exoskeleton.
223571840|NCT01399892|DIETARY_SUPPLEMENT|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
223571841|NCT02648451|DIETARY_SUPPLEMENT|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
223571842|NCT02952482|PROCEDURE|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
223571843|NCT00046163|DRUG|midodrine hydrochloride (ProAmatine®)|
223571844|NCT03251859|DRUG|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
223571845|NCT03251859|DRUG|Ticagrelor 60 mg|Ticagrelor 60 mg daily
223571846|NCT00860834|BEHAVIORAL|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
223571847|NCT00860834|BEHAVIORAL|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
223571848|NCT05079633|BIOLOGICAL|Homologous boost schedule|1st dose mRNA 1273 , 2nd dose mRNA 1273
224064137|NCT04158076|DRUG|Telmisartan|PO, Once daily(QD), 8weeks
224064138|NCT04158076|DRUG|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
223454414|NCT06307834|BEHAVIORAL|Standard hand exercise therapy|This intervention will include engaging in a set of particular hand exercises with the aim of enhancing hand movements.
224064139|NCT03685266|OTHER|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
224064140|NCT02232373|BEHAVIORAL|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
224064141|NCT02232373|DIETARY_SUPPLEMENT|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
224064142|NCT02232373|DIETARY_SUPPLEMENT|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
224064143|NCT03205462|DRUG|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
224148408|NCT04013165|BEHAVIORAL|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
224148409|NCT04013165|BEHAVIORAL|Village-based intervention|"1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
224301661|NCT03760003|DRUG|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
224301662|NCT03760003|DRUG|Placebo|Two capsules of placebo once daily for 16 weeks
224301663|NCT00237913|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
224301664|NCT00237913|DRUG|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
224064144|NCT03205462|DRUG|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
224064145|NCT03205462|DRUG|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
224301665|NCT04498403|DRUG|Crisaborole 2%|Crisaborole 2% ointment
224301666|NCT00599521|DRUG|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
224301667|NCT00599521|DRUG|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
223454415|NCT02957617|DRUG|BIIB074|Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
223454416|NCT00898794|BIOLOGICAL|bevacizumab|
223454417|NCT00898794|OTHER|coagulation study|
223454418|NCT00898794|OTHER|laboratory biomarker analysis|
223454419|NCT00898794|OTHER|platelet aggregation test|
223454420|NCT03280056|BIOLOGICAL|NurOwn® (MSC-NTF cells)|"NurOwn® (MSC-NTF): One course of treatment that includes three separate intrathecal injections of 100-125 x 10\^6 cells every 8 weeks~NurOwn® (MSC-NTF): Autologous, bone marrow-derived, mesenchymal stem cells secreting neurotrophic factors"
223454421|NCT03280056|OTHER|Placebo|"One course of treatment that includes three separate intrathecal injections of Placebo every 8 weeks~Placebo: liquid solution in syringe for injection"
223454422|NCT03280056|OTHER|Bone Marrow aspiration|Bone Marrow aspiration
223454423|NCT03235323|DEVICE|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
223571849|NCT05079633|BIOLOGICAL|Heterologous boost schedule|1st dose mRNA 1273 , 2nd dose MVC COV1901
223571850|NCT02796885|OTHER|no intervention - observational study|
223571851|NCT04125056|DRUG|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
223571852|NCT04125056|DRUG|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
223571853|NCT00313768|DRUG|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
223571854|NCT00313768|DRUG|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
223571855|NCT01696344|PROCEDURE|PVAI|
223571856|NCT01696344|PROCEDURE|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
223571857|NCT00042068|DRUG|Meloxicam|
223571858|NCT04855955|DRUG|Adipose-Derived Mesenchymal Stem Cells|
223571859|NCT05111106|DEVICE|Symfony IOL|Implantation of Intraocular lens with extended depth of focus.
223571860|NCT06127355|DRUG|500 mg of ursodeoxycholic acid (UDCA)|Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
223571861|NCT06127355|OTHER|500 mg of Placebo|Administration of 500 mg of placebo /day
223571862|NCT01209455|DRUG|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
224148410|NCT02483065|OTHER|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
224064146|NCT02922374|DRUG|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
224148411|NCT06305091|DIAGNOSTIC_TEST|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples|Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
223571863|NCT01209455|DRUG|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of \~12 mg/l. To achieve a desired concentration of \~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
224148412|NCT03300258|DEVICE|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
224148413|NCT03300258|DEVICE|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
224148414|NCT03148158|DEVICE|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
224064147|NCT07027930|OTHER|Eye movement desensitization and reprocessing therapy integrative group treatment protocol for Ongoing traumatic stress|EMDR-IGTP-OTS is a group intervention based on EMDR 8-phased protocols with the integration of the Butterfly hug technique.
224148415|NCT02833519|BEHAVIORAL|group exercise|"1. Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~   The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~   The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~2. The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~3. A weekly supportive email."
224148416|NCT05565157|PROCEDURE|Zygomatic implants|A robotic assisted new strategy for positioning zygomatic implants will be performed and its efficacy and accuracy will be assess
224148417|NCT00198094|DRUG|Sertraline and Alprazolam XR|
223571864|NCT01209455|DRUG|Paracetamol|To achieve a local paracetamol concentration of \~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
223571865|NCT02662153|OTHER|Observation only|No intervention.
224064148|NCT06192264|DRUG|ASC40|ASC 40 tablets orally once daily
223571866|NCT00953680|DRUG|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
223571867|NCT00953680|DRUG|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
223571868|NCT00953680|DRUG|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
223571869|NCT03359057|DRUG|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
223571870|NCT03359057|DRUG|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
223571871|NCT00621556|DRUG|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
224064149|NCT04758611|DEVICE|eShunt™ Implant|The eShunt™ Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system as a minimally invasive treatment for communicating hydrocephalus.
224064150|NCT05926830|DEVICE|Sonovein Treatment|The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.
224064151|NCT06039722|DEVICE|Pulse ablation catheter|Pulse ablation catheter is used to ablate the junction of left atrium and pulmonary vein, removing pulmonary vein potential
224148418|NCT02581670|RADIATION|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
224148419|NCT06121362|DIETARY_SUPPLEMENT|Protocatechuic Acid or PCA|PCA 1000 mg capsule
224064152|NCT05804318|DEVICE|Daily adaptive SBRT with urethral sparing|The radiation plan for each daily fraction is adapted from the initial plan based on cone beam CT imaging acquired while the participant is laying on the treatment machine.
224148420|NCT06121362|DIETARY_SUPPLEMENT|Placebo|Placebo capsule
224148421|NCT03277625|PROCEDURE|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
224148422|NCT06302998|DRUG|DEX-PRESSIN|This group will receive vasopressin as the first-line vasopressor. DEX will be started after hemodynamic stabilization if the heart rate is \>90 beats per minute (bpm). NE infusion will be the second-line vasoactive drug.
224148423|NCT06302998|DRUG|Standard of Care|This group will receive conventional treatment according to the SSC 2021 guidelines. This group will receive vasopressin as the second line after NE and will not receive DEX.
224148424|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
224148425|NCT02565732|BIOLOGICAL|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
224148426|NCT02565732|BIOLOGICAL|Placebo comparator|Placebo, Dose C, Topical
223571872|NCT00858741|RADIATION|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
223571873|NCT00858741|RADIATION|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
223571874|NCT05581082|OTHER|Pragmatic, exploratory study of Precision Medicine|This pragmatic, exploratory study consists of individuals with frailty who are referred from routine care to a physical therapy-based strengthening intervention. This specific study will collect ancillary measures to evaluate our outcomes. The study staff will not be conducting any interventions themselves - the physical therapy program is as per usual care.
223571875|NCT05524610|BEHAVIORAL|Sexual Function Screening Approach|"The screening approach will consist of:~1. Standardized use of the PROMIS SexFS Brief in a clinic setting. This tool assesses sexual interest/desire, arousal, discomfort/pain, climax, and satisfaction, among other SD concerns and has comparable sex-specific versions. It has been validated in adult cancer populations.~2. An implementation package to aid in successful implementation. The implementation package will be finalized in the non-trial portion of this study, which will include iterative intervention adaptation. The protocol will be amended as needed to include any relevant updates to the screening approach. Some components may vary per site."
223571876|NCT06137378|BIOLOGICAL|KEYTRUDA®|200 mg KEYTRUDA® i. v. in 3-week cycle (q3w)
224064153|NCT05522608|PROCEDURE|transabdominal preperitoneal hernia repair|It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
224064154|NCT06087926|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes."
224064155|NCT05386992|DIAGNOSTIC_TEST|Anthropometric study|Once the 5 models of lasts have been produced in phase 1, certain shoe models will be designed and manufactured based on these lasts at random and at the free choice of the designers of a footwear company. These models will then be physically tested on children to analyze their effects on walking and walking.
224064156|NCT04649255|DEVICE|Liquid Embolic|Lava Liquid Embolic System (LES)
224064157|NCT06785324|BEHAVIORAL|Nutrition Intervention|"The nutrition intervention will target a 10% caloric deficit calculated from each patient's Basal Metabolic Rate (WHO/Schofield) utilizing a high protein (\>25%), low fat (\<25%), low glycemic index/high fiber (45-55%) diet.~The study registered dietician (RD) will meet with the patient on day of enrollment to go over the menu of dietary options and will re-assess the patient every two days (excluding weekends) for adherence.~My Plate (USDA) will control portion size and eating habits."
224064158|NCT06785324|BEHAVIORAL|Exercise intervention|"The exercise intervention will target 200 minutes of moderate physical activity weekly, as defined by Metabolic Equivalents (METs) of 3-6, made up of aerobic and resistance training activities tailored to the patient's preference by working with the study physical therapist (PT).~Physical Therapist to evaluate patient every 48 hours, excluding weekends."
224148427|NCT04653389|DRUG|Sintilimab Injection|Sintilimab Injection is used as neoadjuvant therapy and adjuvant therapy.
224148428|NCT04653389|DRUG|TACE|The first TACE and Sintilimab Injection will be initiated simultaneously.
224148429|NCT04653389|RADIATION|Radiotherapy|Use Cone Beam computor tomography(CBCT) locates the lession before the therapy.
223454424|NCT02950116|DEVICE|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"* Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)"
224148430|NCT03958318|OTHER|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
224148431|NCT03958318|OTHER|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
223571877|NCT01360398|PROCEDURE|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
224064159|NCT02387255|DEVICE|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
224064160|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
224064161|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
224148432|NCT05823610|DIAGNOSTIC_TEST|ultrasound|The ultrasound parameters to be collected included the angle of progression, head-perineum distance and head-symphysis distance at rest and while pushing during contraction and the data between measurements taken at rest and while pushing. Also anatomical scanning for the episiotomy, perineal tears and obstetric anal sphincter injuries (OASI), also trauma to the levator ani muscle. All demographic, clinical and ultrasound variables were compared between women who had a spontaneous vaginal delivery (SVD) and those who eventually had an operative delivery (OD), vacuum -assisted or cesarean section (CS).
224148433|NCT00519610|OTHER|Chart Review|Patients' charts will be reviewed for relevant medical information.
224148434|NCT03970018|OTHER|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
224148435|NCT03948113|OTHER|Dialysis|
224148436|NCT01711541|DRUG|Carboplatin|Given IV
224148437|NCT01711541|DRUG|Cisplatin|Given IV
224148438|NCT01711541|DRUG|Fluorouracil|Given IV
224148439|NCT01711541|DRUG|Hydroxyurea|Given PO
224148440|NCT01711541|OTHER|Laboratory Biomarker Analysis|Correlative studies
224148441|NCT01711541|DRUG|Paclitaxel|Given IV
224148442|NCT01711541|OTHER|Placebo Administration|Given PO
224064162|NCT00582140|BIOLOGICAL|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
224148443|NCT01711541|RADIATION|Radiation Therapy|Undergo radiation therapy
224301668|NCT04602715|DRUG|MET-2|Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
224301669|NCT04602715|DRUG|Placebo|Placebo Control
224148444|NCT01711541|DRUG|Veliparib|Given PO
224148445|NCT03161171|OTHER|This is an observational study|This is an observational study
224148446|NCT00728936|DRUG|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
224064163|NCT03529266|BIOLOGICAL|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
224148447|NCT00728936|DRUG|Saline placebo|saline placebo given subcutaneously
224148448|NCT04301583|DIETARY_SUPPLEMENT|procyanidin B2 enriched cocoa|Volunteers will intake 5 grams per day of dietary supplement for 10 weeks
224148449|NCT03796234|OTHER|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
224148450|NCT03796234|OTHER|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
224148451|NCT00801346|OTHER|laboratory biomarker analysis|
224148452|NCT00801346|OTHER|metabolic assessment|
224148453|NCT00801346|OTHER|questionnaire administration|
224148454|NCT00801346|PROCEDURE|assessment of therapy complications|
224148455|NCT00801346|PROCEDURE|fatigue assessment and management|
224148456|NCT00801346|PROCEDURE|quality-of-life assessment|
224148457|NCT02911818|BEHAVIORAL|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
224148458|NCT02911818|DRUG|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
224148459|NCT02911818|OTHER|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
223454425|NCT06344559|DEVICE|transcranial magnetic stimulation|"The study intervention involves modulation of cortical excitation to inhibition (E/I) balance in the right frontal eye field (FEF) by means of 2 trains of spaced continuous or intermittent theta burst stimulation (cTBS, iTBS, respectively) using a transcranial magnetic stimulation device. The endpoint of this stimulation will be a decrease (cTBS) or increase (iTBS) in the local E/I ratio that should last at least 60 minutes post-stimulation (Chung et al., 2016).~In separate sessions, all participants will receive either active or stimulation to the FEF. The Investigators will contrast the effects of both iTBS and cTBS to sham stimulation and to each other."
223454426|NCT06452602|DRUG|Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：CR+PR~Adebrelimab plus concurrent chemoradiotherapy:~Adebrelimab：1200mg, IV，q3w, until PD; Nab-paclitaxel：175mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Radiotherapy：50.4Gy/1.8Gy/28f."
223571878|NCT01360398|PROCEDURE|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
223454427|NCT06452602|DRUG|Induction immunochemotherapy followed by concurrent chemoradiotherapy|"Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f."
223454428|NCT04659057|DRUG|Nebulized Lidocaine|will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).
223454429|NCT04659057|DRUG|Nebulized dexmedetomidine|will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).
223454430|NCT04659057|DRUG|Nebulized lidocaine and dexmedetomidine|will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.
223454431|NCT04659057|OTHER|Placebo|will receive nebulized saline 0.9% (5 ml) as control group.
223454432|NCT00000173|DRUG|Donepezil|
223454433|NCT00000173|DRUG|Vitamin E|
223454434|NCT02144077|DRUG|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
223454435|NCT02144077|DRUG|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
223454436|NCT04456400|DIAGNOSTIC_TEST|Multispectral Optoacoustic Tomography (MSOT)|cMSOT-2 system is indicated for measurement of the Multispectral Optoacoustic Tomography (MSOT) values in the bowel wall of patients with an established diagnosis of inflammatory bowel disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The MSOT values provided may be used as an aid to the assessment of inflammatory disease activity in the bowel wall.
223454437|NCT05485714|OTHER|Reviewing records retrospectively of patients undergoing screening endoscopy|Reviewing records retrospectively of patients undergoing screening endoscopy to assess Baveno VI, expanded Baveno VI, Platelet count/spleen diameter and other non-invasive predictors of esophageal varices or varices needing treatment
223454438|NCT00610168|BIOLOGICAL|Boostrix TM|Single booster dose of vaccine
223571879|NCT01360398|PROCEDURE|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
223571880|NCT01360398|PROCEDURE|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
224064164|NCT03529266|PROCEDURE|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
224064165|NCT04129528|DRUG|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
224064166|NCT04129528|OTHER|Placebo|Placebo for active drug
224064167|NCT01316861|DRUG|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
224064168|NCT01316861|DRUG|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
224064169|NCT04185688|OTHER|Functional Reach Test|The Functional Reach Test assesses balance by measuring the limits of stability while the patient reaches forwards as far as possible, having the arms in 90° flexion and without lifting the heels off the floor.
223454439|NCT01038102|OTHER|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
223454440|NCT01038102|OTHER|SFA diet|Diet high in saturated fat (15E%)
224064170|NCT03008356|DIETARY_SUPPLEMENT|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
224064171|NCT03008356|BEHAVIORAL|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
224148460|NCT02911818|DRUG|Placebo Oral Tablet|
224064172|NCT03008356|DIETARY_SUPPLEMENT|Placebo capsules|
224064173|NCT04559958|DIAGNOSTIC_TEST|tongue image|capture tongue images by Automatic Tongue Diagnosis System
224064174|NCT00044577|DRUG|abacavir/lamivudine|
224064175|NCT00044577|DRUG|abacavir|
224064176|NCT00044577|DRUG|lamivudine|
224064177|NCT00044577|DRUG|tenofovir|
224064178|NCT01964352|DRUG|tiotropium|fixed dose combination
224064179|NCT01964352|DRUG|placebo|
224064180|NCT01964352|DRUG|olodaterol|fixed dose combination
224064181|NCT01964352|DRUG|tiotropium|fixed dose combination
224064182|NCT01964352|DRUG|tiotropium|
224064183|NCT01964352|DRUG|olodaterol|fixed dose combination
224064184|NCT02400788|DRUG|Resminostat|
224064185|NCT02400788|DRUG|Sorafenib|
224064186|NCT01908101|DRUG|Eribulin Mesylate|Given IV
224064187|NCT01908101|OTHER|Laboratory Biomarker Analysis|Correlative studies
224148461|NCT02911818|DRUG|Phentermine 15 MG|
223454441|NCT00330694|OTHER|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
223454442|NCT00330694|OTHER|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
223742704|NCT05765058|OTHER|Group A|Application of SDF (silver diamine fluoride) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
224064188|NCT05097807|BEHAVIORAL|smartphone related behaviors|Participants are required to watch specific contents on their own smartphones.
224064189|NCT00371878|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (Prevnar)|
224148462|NCT02911818|BEHAVIORAL|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
224148463|NCT00716339|BEHAVIORAL|motivation|
223454443|NCT04135755|OTHER|no drug intervention|no drug or treatment intervention
223454444|NCT06371690|OTHER|Web-Based Double-Eye Control Program|Web-Based Double-Eye Control Program, a web-based drug dose calculation program, is compatible with smartphones, tablets and computers. On the interface of the website, the nurse is required to enter data such as the age, weight, medications and doses ordered by the physician of the patient. When all these data are entered, the amount of medication that the nurse should give and whether the ordered dose is within the safe dose range for the patient are calculated by the program, so that the nurse can control her own calculations. On the other interface of the website, there are medication instructions uploaded by the researchers. With this interface, nurses access all pharmacological information about especially high-risk drugs (indications, contraindications, interacting drugs and fluids, fluids to be used for diluting, medication route, medication pace, etc.) and information that will enable the medication to be carried out in a standard way.
223742705|NCT05765058|OTHER|Group B|Application of Sodium Fluoride varnish on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
223742706|NCT05765058|OTHER|Group C|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Biosmalto tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
223742707|NCT05765058|OTHER|Group D|Application of Placebo varnish (water-based) solution on the root caries lesions twice yearly in a professional setting. Application of Placebo tooth mousse by the subject twice daily. Regular tooth brushing with standardized fluoridated toothpaste.
224148464|NCT04985240|DIETARY_SUPPLEMENT|Lettuce with no biofortification|Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
224148465|NCT04985240|DIETARY_SUPPLEMENT|Intervention Molibdenum group|Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
223454445|NCT06024811|BEHAVIORAL|supporting nursing care|Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
223454446|NCT00943592|DRUG|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
223454447|NCT00943592|DRUG|Melphalan|Doses ranging from 100 to 140 mg/m2
224148466|NCT06166888|DRUG|AK131|AK131 is an anti-PD-1 and CD73 bispecific antibody
224148467|NCT03079557|DRUG|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
224148468|NCT06104722|OTHER|High-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
224148469|NCT06104722|OTHER|Low-intensity Copenhagen adduction exercise|Copenhagen adduction exercise is an eccentric strengthening protocol of hip adductors and suitable for groin injury prevention and rehabilitation.
223571881|NCT01360398|PROCEDURE|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
223571882|NCT01360398|OTHER|Data collection|Patient interview, diary cards review and questionnaires completion
223571883|NCT01360398|OTHER|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
223571884|NCT00944814|DIETARY_SUPPLEMENT|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
223571885|NCT00944814|DIETARY_SUPPLEMENT|LNS without zinc|LNS containing no zinc
223571886|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-1|Section 1: Deep breathing exercises: A deep breath is taken as far as possible by raising the arms up to the sky. Breathing is held for 4-5 seconds after deep inspiration. Breathing is performed rhythmically and slowly, while the arms are placed in a normal position. After deep inspiration, one can exhale either by forming the lips in the whistling position or by laughing. In each deep breathing exercise technique, the expiration time of the exhalation process should be longer than the inspiration time.
223742708|NCT05497349|OTHER|Leukocyte Rich- PRP injection|Autologous Leukocyte Rich-Platelet Rich Plasma will be injected in the hip joint
224064190|NCT03838679|DIAGNOSTIC_TEST|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
224064191|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
224064192|NCT03838679|DIAGNOSTIC_TEST|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
224064193|NCT03838679|DIAGNOSTIC_TEST|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
223454448|NCT00943592|DRUG|Campath|20mg/d x5
224064194|NCT03838679|DIAGNOSTIC_TEST|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
224148470|NCT05710770|DEVICE|Immunoadsorption|IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
224148471|NCT02356328|DEVICE|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
224148472|NCT05355818|DRUG|Delgocitinib|Cream for topical application
224148473|NCT05355818|DRUG|Cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
224148474|NCT00809861|PROCEDURE|volar locking plating|open reduction and internal fixation
224148475|NCT00809861|PROCEDURE|external immobilisation|closed reduction and external fixation
224148476|NCT03245710|OTHER|Placebos|starch
224148477|NCT03245710|DIETARY_SUPPLEMENT|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
223454449|NCT00943592|PROCEDURE|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
223454450|NCT00500734|PROCEDURE|Blood Sample|One time blood draw of 2 teaspoons.
223454451|NCT02215889|PROCEDURE|Liver transplantation|
223454452|NCT00926341|DRUG|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
223742709|NCT05497349|OTHER|Leukocyte Poor- PRP injection|Autologous Leukocyte Poor-Platelet Rich Plasma will be injected in the hip joint
223742710|NCT07131358|DEVICE|Glass ionomer pit and fissure sealant plus fluoride varnish|Application of glass ionomer pit and fissure sealant plus fluoride varnish
223742711|NCT07131358|DEVICE|Pit and fissure sealant with Giomer® technology|Application of pit and fissure sealant with Giomer® technology
223742712|NCT07131358|DEVICE|Fluoride varnish|Biannual application of fluoride varnish
223454453|NCT00926341|DRUG|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
223571887|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-2|Section 2: Warm-up exercises (10 minutes): Hands are clapped by holding parallel to each other. The fingertips and the palms touch each other, stimulating the acupuncture points on both hands, and the individual's energy level rises. In order to further raise the energy level and synchronize the movements of the group, a rhythm is added in the form of 1-2, 1-2-3. After several rhythmic hand-clapping movements, one more movement is added. Hands are clapped by swinging left and right. Then, an audible rhythm in the form of ho, ho, ha-ha-ha is also added to the hand-clapping movement. People in the group look at each other, and smile.
223742713|NCT04709341|DEVICE|TR Band 60MIN|TR-Band will be in left in place for 15 minutes before it is gradually deflated by 25% at 15 minute intervals
223742714|NCT04709341|DEVICE|TR Band 120MIN|TR-Band is left in place for 60 minutes before it is gradually deflated by 25% at 15 minute intervals
223742715|NCT04994977|DRUG|Melphalan|Given at 0.5 mg/ml.
223742716|NCT04994977|DRUG|Carboplatin|Given at 5 mg/ml.
223742717|NCT04994977|DRUG|Topotecan|Given at 0.2 mg/ml.
223454454|NCT05701540|DRUG|Tegoprazan|Tegoprazan 50mg tablet
223742718|NCT06855264|DRUG|varegacestat|Single oral dose of varegacestat
223742719|NCT06855264|DRUG|Placebo|Single oral dose of placebo
223742720|NCT06855264|DRUG|Moxifloxacin 400 mg|Single oral dose of moxifloxacin
223454455|NCT05701540|DRUG|Esomeprazole|"Esomeprazole 20mg tablet~1. For patients with ERD: two Esomeprazole 20mg tablets~2. For patients with NERD: one Esomeprazole 20mg tablet"
223454456|NCT00169104|DRUG|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
223454457|NCT00169104|DRUG|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
223454458|NCT00169104|DRUG|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
223742721|NCT02849496|DRUG|Atezolizumab|Given IV
223742722|NCT02849496|PROCEDURE|Biopsy Procedure|Undergo a biopsy
223742723|NCT02849496|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223742724|NCT02849496|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223742725|NCT02849496|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223742726|NCT02849496|PROCEDURE|Bone Scan|Undergo a bone scan
224064195|NCT03838679|DIAGNOSTIC_TEST|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
224064196|NCT03838679|DIAGNOSTIC_TEST|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
224064197|NCT03838679|DIAGNOSTIC_TEST|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
224064198|NCT00464412|BEHAVIORAL|Education|
224064199|NCT04245020|OTHER|Text message follow up|A text message will be sent to the patient 6-8 weeks following discharge
224064200|NCT04245020|OTHER|Telephone follow up|The patient will be followed up at 6-8 weeks following discharge with a telephone call
224064201|NCT04245020|OTHER|In person follow up|The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
224064202|NCT04957771|OTHER|Supervise and guide regular exercise|Aerobic exercise, evaluated by cardiopulmonary exercise test, 3-5 times a week
224064203|NCT03746704|DRUG|89Zr˗DFO˗REGN3504|89Zr˗DFO˗REGN3504
224064204|NCT01457742|DEVICE|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
223454459|NCT00169104|DRUG|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
223454460|NCT00169104|DRUG|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
223454461|NCT01457417|DRUG|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
223454462|NCT03646968|DRUG|Anlotinib and Docetaxel|Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
223454463|NCT00715299|BEHAVIORAL|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
223454464|NCT03246022|OTHER|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
223454465|NCT03227731|DRUG|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
223454466|NCT02085265|DRUG|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
223454467|NCT02085265|DRUG|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
223454468|NCT01540981|DEVICE|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
223454469|NCT01540981|OTHER|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
223454470|NCT05624411|DEVICE|CU T380A IUD|post-placental insertion of intrauterine contraceptive device
223454471|NCT05624411|DEVICE|multiload 375 IUD|post-placental insertion of intrauterine contraceptive device
223454472|NCT01222208|DIETARY_SUPPLEMENT|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
223454473|NCT01222208|DIETARY_SUPPLEMENT|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
223454474|NCT06453395|OTHER|Patients were grouped according to tumor location|Patients were grouped according to tumor location
223454475|NCT04348097|DEVICE|Activator instrument|activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
223454476|NCT04348097|DEVICE|dry needle|By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
223454477|NCT02752360|PROCEDURE|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
223454478|NCT02752360|PROCEDURE|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
223454479|NCT05082337|DEVICE|SAVVY guidewire|The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment
223454480|NCT00809094|DRUG|N-acetylcysteine (NAC)|
223742727|NCT02849496|PROCEDURE|Computed Tomography|Undergo a CT scan
223742728|NCT02849496|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223454481|NCT00809094|DRUG|Placebo|
223454482|NCT01114009|PROCEDURE|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
223742729|NCT02849496|DRUG|Olaparib|Given PO
223742730|NCT02849496|PROCEDURE|Positron Emission Tomography|Undergo a PET scan
223742731|NCT02849496|OTHER|Questionnaire Administration|Ancillary studies
224064205|NCT01457742|DEVICE|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
224148478|NCT05256316|OTHER|Previously admitted COVID-19 patients in intensive care units|Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
224148479|NCT01589263|DRUG|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
224148480|NCT01589263|DRUG|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
224064206|NCT03854708|DRUG|3 pmol/kg*min pancreatic polypeptide|PP 3 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
224064207|NCT03854708|DRUG|10 pmol/kg*min pancreatic polypeptide|PP 10 pmol/kg\*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
224148481|NCT02100202|OTHER|Placebo|
224148482|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin (Curcuma longa rhizomes extract)|
224064208|NCT03854708|DRUG|Placebo|Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
224064209|NCT06539013|DRUG|Remifentanil|remifentanil infusion
224148483|NCT02100202|DIETARY_SUPPLEMENT|BioTurmin-WD (Water dispersible curcuminoids)|
223454483|NCT01114009|PROCEDURE|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
224064210|NCT06539013|DRUG|N2O|Use of N2O for analgesia
224064211|NCT06539013|DRUG|Fentanyl|Use of Fentanylfor analgesia
223454484|NCT02812589|OTHER|Diffusion tensor imaging (DTI) in Breast MRI|
223454485|NCT04697290|BIOLOGICAL|CD19/CD20 Dual-CAR-T cells|CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.
223454486|NCT01911754|BIOLOGICAL|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
224064212|NCT00890565|DRUG|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
224148484|NCT02100202|DIETARY_SUPPLEMENT|MaQxan (Tagetes erecta flower extract)|
224148485|NCT03498092|DRUG|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
224148486|NCT03498092|DRUG|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
224148487|NCT03498092|DRUG|General anesthesia|Normal saline in a volume of 0.5 ml/kg
223571888|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-3|"Section 3: Childish games (10 minutes): Childish games are used that will help to laugh for no reason, just like a child. Imagining these games and plays, the arms are raised upwards in the form of a Y with palms facing the sky, motivating the group by saying very good (clap), very good (clap), yes. The leader of laughter yoga speaks out very good (clap), very good (clap), hey (arms to the right and left) to keep the group's energy high and generate enthusiasm in the deep breathing exercises and laughter exercises sections. According to the energy and desire of the group, this section is completed after about 10 minutes."
223742732|NCT02849496|PROCEDURE|X-Ray Imaging|Undergo an x-ray
223742733|NCT03534154|DIAGNOSTIC_TEST|MRI|Magnetic Resonance Imaging
223742734|NCT03534154|DIAGNOSTIC_TEST|Blood Sampling|Sampling of serum
224064213|NCT04090112|DRUG|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
224064214|NCT04090112|DRUG|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
224064215|NCT04806607|PROCEDURE|19G FNB|Biopsy specimen adequacy using the 19G FNB
224064216|NCT04806607|PROCEDURE|22G FNB|Biopsy specimen adequacy using the 22G FNB.
224064217|NCT03269760|DRUG|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
224064218|NCT06543108|DIAGNOSTIC_TEST|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer|The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
224064219|NCT02146612|OTHER|Amino Acid Supplement Group|Group receiving nutritional supplement
224064220|NCT04489966|BEHAVIORAL|Aerobic training|The intervention was aerobic rhythmic training under the guidance and supervision of a professional. The aerobic training program required participants to exercise 3 days/week for 60 minutes/session (including 5-10 minutes of warm-up and 50 minutes aerobic training and 5-10 minutes to relax). All patients received an open class, relate to diabetes health education．
224148488|NCT01234519|DRUG|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
224148489|NCT01234519|DRUG|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
224148490|NCT05474469|OTHER|Diaphragmatic breathing exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
224148491|NCT05474469|OTHER|Abdominal muscle strengthening exercises|12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
224148492|NCT04815538|BEHAVIORAL|the subscale of Health-Promoting Lifestyle Profile II|"Nutritional health behavior included the following nine items: choose a low-fat diet; limit the use of sugars; eat servings of bread, cereal, and rice; eat servings of fruit; eat servings of vegetables; eat servings of meat, poultry, fish, dietary guidelines"
224064221|NCT00166205|DEVICE|Swedish Adjustable Gastric Band|Long term implantable device.
224064222|NCT05712044|DRUG|Folic Acid 5 MG|Folic acid 5mg tablets will be administered orally every 8 hours then samples from buccal mucosa will be taken 15 days and 30 days after suplementation.
224064223|NCT01871961|DRUG|Methotrexate (Metoject® prefilled pen)|
224064224|NCT02806323|OTHER|Yoga practice|
224148493|NCT02320240|DRUG|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224064225|NCT02205749|BEHAVIORAL|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
224148494|NCT02320240|DRUG|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148495|NCT02320240|DRUG|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148496|NCT02320240|DRUG|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148497|NCT02320240|DRUG|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148498|NCT02320240|DRUG|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148499|NCT02320240|DRUG|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
223454487|NCT04849117|PROCEDURE|Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block|"In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously."
223454488|NCT02794688|PROCEDURE|Ductal lavage therapy|"1. Patient lies in supine position, with routine sterilizing and draping procedure.~2. Local anesthesia with 2ml lidocaine (1%) around the nipple.~3. Identification of 4-5 openings of the lactiferous ducts from the nipple.~4. Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~5. Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (\>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~6. The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~7. Repeat step 1-6 every other day for 2 weeks.~8. Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
223454489|NCT02956538|DRUG|Thalidomide|
223454490|NCT02956538|DRUG|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
223454491|NCT02589509|BEHAVIORAL|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
223454492|NCT02589509|BEHAVIORAL|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
223454493|NCT03731949|DIAGNOSTIC_TEST|Ultrasonography|Ultrasonography to assess placental volume
223454494|NCT04009304|BEHAVIORAL|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
223454495|NCT04799262|DRUG|Tofacitinib 5 MG|Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the daily GC dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
223742735|NCT03534154|DIAGNOSTIC_TEST|Microdialysis|Monitoring of cerebral fluid protein levels
223454496|NCT06238219|DRUG|Neuromuscular Blocking Agent|Administration of any neuromuscular blocking agent for surgery under general anesthesia
223454497|NCT05063578|DRUG|Lidocaine 2% Injectable Solution|Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
223454498|NCT01515098|DIETARY_SUPPLEMENT|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
224064226|NCT02205749|BEHAVIORAL|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
224064227|NCT02205749|BEHAVIORAL|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
224064228|NCT03496090|OTHER|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
224148500|NCT02320240|DRUG|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148501|NCT02320240|DRUG|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
224148502|NCT06348758|OTHER|questionnaire|E-Questionnaire will be sent to the students
224148503|NCT01397045|OTHER|VATS|Video-assisted lung segmentectomy
224148504|NCT01397045|PROCEDURE|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
223454499|NCT01515098|DIETARY_SUPPLEMENT|Dextrose Placebo|Placebo developed to closely match blueberry powder.
223571889|NCT05345067|BEHAVIORAL|Experimental: Laughter yoga session parts-4|"Section 4: Laughter exercises (15 minutes): This section contains a variety of laughter exercises that will laugh, such as greetings, laughter cream, exploding balloon laughter, preparing and drinking strawberry milk, bonuses, hot soup, lion, aloha, bird, appreciation, elevator, and cream pie. A laugh is raised by doing only laughter exercises for no reason at all. At the end of this section, relaxation is achieved for about three minutes using deep breathing exercises. The group is given verbal guidance Put your hand on your heart, feel your heartbeat, let's exhale with a smile, make a wish or pray, smile as if we had achieved our wish, and the laughter yoga session is terminated."
223571890|NCT06193408|DRUG|VR-AD-1005|oral capsule
223571891|NCT06193408|DRUG|Placebo|oral capsule
223571892|NCT00737711|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
224064229|NCT03496090|OTHER|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
224064230|NCT04546685|OTHER|Usual Care|Participants who are randomized to the Usual Care group (waitlist for cross-over to ER) will be instructed to continue with their normal pain care. They will receive only study surveys (baseline, 2 weeks, and 1 month). Upon completion of the 1-month study, UC participants will be invited to cross-over and receive ER. Post-class treatment appraisal/satisfaction data only will be collected.
224064231|NCT04546685|BEHAVIORAL|Empowered Relief|The participants will attend an online Spanish Empowered Relief class. The two hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a Spanish binaural relaxation audio file for daily use.
224064232|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens1|CONTROL
224064233|NCT03787472|DEVICE|JJV Investigational senofilcon A Multifocal Lens2|TEST
224064234|NCT04609189|DRUG|Pearlium/EffectiCal|Oral administration of Pearlium/EffectiCal.
224148505|NCT03955055|DEVICE|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
223454500|NCT00397189|DRUG|Circadin|Prolonged release melatonin 2 mg
223571893|NCT04545047|BIOLOGICAL|COVID-19 convalescent plasma|Convalescent plasma collected from individuals who have recovered from COVID-19
223742736|NCT03534154|DIAGNOSTIC_TEST|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
224148506|NCT00756093|OTHER|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
224148507|NCT00756093|OTHER|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
223742737|NCT03534154|DIAGNOSTIC_TEST|MRI (advanced)|Advanced MRI
224064235|NCT04609189|DRUG|Calcium carbonate/vitamin D3|Oral administration of Calcium Carbonate/Vitamin D3
224148508|NCT00756093|OTHER|Blink Tears|Blink Tears one drop each eye one time
224148509|NCT00756093|OTHER|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
224148510|NCT06196619|DIAGNOSTIC_TEST|SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level|Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
224148511|NCT01117025|PROCEDURE|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
224064236|NCT04223960|DRUG|EA1080|EA1080 Formulation A.
224064237|NCT04223960|DRUG|EA1080|EA1080 Formulation B.
223454501|NCT00397189|DRUG|placebo circadin|placebo circadin tablets
223454502|NCT00172445|PROCEDURE|blood sampling, neck lymph node biopsy|
223454503|NCT03472937|PROCEDURE|Transcervical Foley catheter placement for cervical ripening|Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
223454504|NCT02951026|OTHER|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
223454505|NCT02620683|DRUG|Lidocaine|See above
223454506|NCT01788319|PROCEDURE|lasertrabeculoplasty|
223454507|NCT01535443|DRUG|Bromfenac|Drug: Bromfenac Other names: PRO-155
223571894|NCT04591925|DEVICE|Control Device insulin infusion devcie|Control Device - Commercially available insulin infusion device using a soft Teflon indwelling cannula
223571895|NCT04591925|DEVICE|Investigative insulin infusion devcie|Investigative insulin infusion device with coil-reinforced soft polymer indwelling cannula
223571896|NCT00106574|DRUG|Placebo|iv every 4 weeks
223571897|NCT00106574|DRUG|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
223571898|NCT03020017|OTHER|Laboratory Biomarker Analysis|Correlative studies
223571899|NCT03020017|OTHER|Pharmacological Study|Correlative studies
224064238|NCT04223960|DRUG|EA1080|EA1080 Formulation C.
224064239|NCT04223960|DRUG|EA1080|EA1080 Formulation D.
224064240|NCT04223960|DRUG|EA1080-matching placebo|EA1080-matching placebo.
224064241|NCT04223960|DRUG|EA1080|EA1080 Formulation E.
224064242|NCT04223960|DRUG|EA1080|EA1080 Formulation F.
223454508|NCT03703752|DIAGNOSTIC_TEST|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
223454509|NCT05434663|DRUG|SUSTOL|SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
224064243|NCT01610765|DRUG|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
224071153|NCT06299254|OTHER|Placebo-Natural History|"Half of the participants will receive a placebo (i.e., motivational/verbal) cue before and after an experimental session in which they will perform several lifts.~Half of the participants will receive no placebo before and after an experimental session in which they will perform several lifts."
223454510|NCT05924659|OTHER|Cerabral training|1 week of cerebral training (neurofeedback or sham)
223454511|NCT05234268|OTHER|Manual Cervical Traction|"Time: 20 minutes Duration: thrice a week for 4 weeks.~Position:~The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion."
223454512|NCT05234268|OTHER|Passive Accessory Intervertebral Movements|"Time: 20 minutes Duration: thrice a week for 4 weeks~Position:~Patient lying in prone. Therapist stands to side of patient placing their pisiform/ulnar surface of hand over the selected spinous process (SP) with their wrist in full extension.~Other hand placed on top of hand to reinforce. Therapist's shoulders should be directly above the SP with elbows slightly bent. Therapist uses their body weight to apply a PA force to the selected SP by leaning their body over their arms and performing rocking movements to provide oscillatory movements of the vertebra."
223454513|NCT05234268|OTHER|Active Strength Training|"Time: 20 minutes Duration: thrice a week for 4 weeks. The progression of exercises will be done using different colors of Thera-band indicating varied resistance. (A) Resistive lateral flexion of uninvolved side.~Position:~The patient is in sitting position. By the help of thera-band patient will actively flex the neck against resistance on the uninvolved side."
223454514|NCT03216707|DEVICE|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
223454515|NCT03216707|DEVICE|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
223454516|NCT03216707|DEVICE|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
223454517|NCT03216707|OTHER|Capsaicin cream|Capsaicin cream
223571900|NCT03020017|DRUG|Targeted Molecular Therapy|Given NU-0129 IV
223571901|NCT00164957|DEVICE|continuous pump feeding|
223571902|NCT00164957|OTHER|intermittent bolus feeding|
223571903|NCT05770024|OTHER|imaging tests|X-ray radiography (RX); computer tomography (CT); magnetic resonance (MR); positron emission tomography (PET); single photon emission computed tomography (SPECT)
223571904|NCT05953610|DRUG|Acetazolamide 500 MG QHS|Acetazolamide
223571905|NCT05953610|DRUG|Eszopiclone 3 mg QHS|Eszopiclone
223571906|NCT03927287|DIAGNOSTIC_TEST|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
223571907|NCT03527628|DRUG|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
223571908|NCT03527628|DRUG|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
224071154|NCT01146106|DRUG|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
223571909|NCT03527628|DRUG|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
224071155|NCT00143455|DRUG|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
224071156|NCT00143455|DRUG|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
224071157|NCT00123214|DRUG|Controlled Dietary Intervention|
223571910|NCT03527628|DRUG|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
223571911|NCT03527628|DRUG|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
223571912|NCT03527628|DRUG|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
223571913|NCT01514240|DRUG|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
224071158|NCT05268926|DRUG|Dapagliflozin 10Mg Tab|dapagliflozin 10 mg/d or matched placebo
224071159|NCT05268926|DRUG|Placebo|Placebo
224071160|NCT05972460|DRUG|IMM2510|IMM2510 is administered intravenously every 2 weeks, every 28 days for a treatment cycle.
224071161|NCT05484960|OTHER|cognitive assessment|The clinical diagnosis will be made based on the criteria set by the investigators. Clinical history and bedside objective assessment in the form of Montreal Cognitive Assessment-Philippines (MoCA-P) or Mini Mental Status Examination-Philippines (MMSE-P), supported by a neuroimaging study (if neuroimaging is not done, diagnosis will be supported by the Hachinski Ischemic Score).
223454518|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy with and without laryngeal restriction|To reduce the laryngeal movement and St.Eso excursion we will use a device constructed in our laboratory which can induce an adjustable resistance to excursion of the larynx. This handmade device that is worn around the neck consists of a band and a concave plastic disk which serves as a support structure for an inflatable polyethylene bag which is connected to a hand pump and pressure gauge. When worn around the neck the inflatable bag rests in position on the thyroid cartilage with a portion of it hung over above the cartilage creating resistance to its superior excursion when fixed by closure straps. A known external force may be applied to the thyroid by partially inflating the bag to a specific pressure reading on the gauge. The soft and compliant bag conforms to the larynx while applying a resistive force to anterior and superior distraction of the hyolaryngeal complex during swallowing.
223571914|NCT01514240|DRUG|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
223454519|NCT05708885|DEVICE|Concurrent manometry/impedance and fluoroscopy before and after six weeks of using swallow muscle exercising device|Use the previously mentioned wearable device (sRED) and exercise regimen described previously for studying the effect of increase in anterosuperior excursion of the larynx/St.Eso on St.Eso peristaltic function.
223571915|NCT01201616|OTHER|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
224064244|NCT01610765|DRUG|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
223454520|NCT02997605|DRUG|GlucoCorticoid|"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
223454521|NCT05013580|PROCEDURE|Guided bone regeneration (GBR)|Bone grafts will be placed in the patient's jawbone, along with a membrane to cover the bone grafts. A horizontal incision over the edentulous ridge crest will be made along with vertical incisions if indicated. Buccal and lingual full thickness mucoperiosteal flaps will be reflected to expose the alveolar bone. Intra-marrow penetration (decortication of the alveolar bone to increase vascular supply to the bone grafts) at the surgical site alveolar bone will be made with a high-speed hand piece and diamond bur. Bone allograft material will be placed to fill the alveolar bone defect. The bone graft will then be covered with a membrane and secured with sutures.
223454522|NCT03629145|BEHAVIORAL|Live Music Therapy|Investigator will begin play live guitar and voice music.
223454523|NCT03629145|BEHAVIORAL|Recorded Music Therapy|Investigator will play recorded music.
223454524|NCT02170857|DRUG|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
224064245|NCT03442543|DEVICE|preoperative localization of SLN detected by CTLG by either methods|50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.
224064246|NCT05640778|DRUG|Dalpiciclib combined with aromatase inhibitors|Dalpiciclib combined with letrozole or anastrozole
224064247|NCT04278612|OTHER|Quality improvement intervention to strengthen health service provision|Quality improvement intervention comprising of regular improvement meetings based at clinics.
224064248|NCT04220996|DRUG|Vortioxetine|Vortioxetine 10 and 20 mg/day, tablets, orally Patients will receive 10 mg vortioxetine once daily for the first week. At Visit 2, the dose will be increased to 20 mg/day. The dose may subsequently be adjusted to 10 or 20 mg/day at scheduled or unscheduled visits depending on patient's response as per investigator judgment.
223454525|NCT00232557|DEVICE|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
223454526|NCT00232557|DEVICE|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
223454527|NCT01589367|DRUG|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
223454528|NCT01589367|DRUG|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
223571916|NCT01201616|OTHER|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
223742738|NCT04537637|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223742739|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
223742740|NCT01395433|DRUG|Escitalopram|2 x 10 mg, single dose
223742741|NCT01395433|DRUG|Escitalopram|1 x 20 mg, single dose
223742742|NCT03649711|DRUG|Ticagrelor 90mg|Ticagrelor Pill
223742743|NCT03649711|DRUG|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
223742744|NCT03649711|DRUG|Aspirin 81 mg|Aspirin Pill
223742745|NCT01892371|DRUG|Azacitidine|Given SC or IV
224064249|NCT03616678|DEVICE|VenTouch System|"The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester."
224064250|NCT00477165|DRUG|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
224064251|NCT00477165|DRUG|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
224064252|NCT03159858|DEVICE|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70-year-old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
224064253|NCT00846014|DRUG|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
224064254|NCT05118256|DRUG|Pirfenidone Oral Tablet|Patients will be treated with pirfenidone (oral tablets) during 6 months
224064255|NCT03955133|OTHER|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
223454529|NCT05510414|BEHAVIORAL|psychological intervention based on psychological capital|Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
223454530|NCT01059773|DRUG|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients \> 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
223454531|NCT01059773|DRUG|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
223454532|NCT04687111|DRUG|Sacubitril-Valsartan|Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor
223454533|NCT04687111|DRUG|Valsartan|Valsartan is an Angiotensin Receptor Blocker
223454534|NCT01224275|OTHER|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
223454535|NCT03866356|BEHAVIORAL|intervention group|The women in the intervention group were provided care according to SICP
223454536|NCT00004268|DRUG|midodrine|
223454537|NCT04951908|DIAGNOSTIC_TEST|MRI|MRI of TMJ
223454538|NCT04530669|DEVICE|High Tone Power Therapy|"High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort."
223454539|NCT04530669|OTHER|exercise program|physical therapy conventional selected exercise program inform of functional activities of daily living
223742746|NCT01892371|DRUG|Cytarabine|Given SC
223742747|NCT01892371|DRUG|Quizartinib|Given PO
223742748|NCT06149897|DEVICE|tDCS|Non invasive brain stimulation with sham and active comparators
223742749|NCT06349915|BEHAVIORAL|Supporting Wellbeing with Everyday Experiences of Peers (SWEEP)|Each day during a 14-day trial period, participants will receive one narrative featuring lived experience with and recovery from suicidal thoughts and behaviors. These narratives will be presented in audio and text format via a smartphone app. Participants will also complete self-report surveys assessing study outcomes using the same smartphone app five times per day.
223742750|NCT05556447|BEHAVIORAL|Internet delivered pain coping skills training|Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
223742751|NCT03768349|DRUG|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
223742752|NCT03768349|DRUG|F-18 PSMA 1007|F-18 PSMA 1007 PET/CT for detection of tumor location
223742753|NCT06812780|DRUG|AZD2389|Single oral dose of AZD2389 in participants from all cohorts
224064256|NCT00105443|DRUG|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
224064257|NCT00105443|DRUG|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
224064258|NCT03351257|OTHER|observation of surface patterns and colors of polyps|examination of the surface patterns and colors of polyps using Linked color imaging and white-light
224064259|NCT01864278|DEVICE|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
224064260|NCT02135692|BIOLOGICAL|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
224064261|NCT02135692|DRUG|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
224064262|NCT01056250|PROCEDURE|SILS cholangiography|intraoperative
224064263|NCT05842187|PROCEDURE|Biopsy of tumor tissue for organoid culture|By collecting fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) and culturing them into organoids in vitro, this study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment, and the study aims to evaluate the clinical effectiveness of the drug and its consistency with in vitro organoid drug sensitivity.
224064264|NCT00246532|DRUG|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
224064265|NCT00246532|DRUG|Placebo|Patients will receive placebo tablets.
224064266|NCT00144898|PROCEDURE|Sentinel Node Resection|Sentinel Node Resection
224064267|NCT00144898|PROCEDURE|Conventional Axillary Dissection|Conventional Axillary Dissection
224064268|NCT03976037|DRUG|Misoprostol|"Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
224064269|NCT06367881|DRUG|Alveofact|Intratracheal High-dose Alveofact versus Low-dose Alveofact with or without Budesonide
224064270|NCT06367881|DRUG|Budesonide|Budesonide
224064271|NCT01099072|DRUG|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Placebo
224064272|NCT01099072|DRUG|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for \<30 Kg and 30 mg/day for \>30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
224064273|NCT00650910|DRUG|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
224064274|NCT00650910|DRUG|Digoxin|0.5mg on Days 1 and 9
224071162|NCT03537027|DIETARY_SUPPLEMENT|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
224071163|NCT03665142|OTHER|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
224071164|NCT03665142|OTHER|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
224071165|NCT03713944|DRUG|Carboplatin|Carboplatin, AUC 5
224071166|NCT03713944|DRUG|Pemetrexed|Pemetrexed 500mg/m2
224071167|NCT03713944|DRUG|Atezolizumab|Atezolizumab 1200mg
224071168|NCT03713944|DRUG|Bevacizumab|Bevacizumab 15mg/kg
224071169|NCT03768947|OTHER|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of \~12-15 visits (45 min each) of immersion in to a hot tub.
224071170|NCT02184871|OTHER|exposure to different risk factors and molecular assessment|
224071171|NCT03801369|PROCEDURE|Biopsy|Undergo biopsy
224071172|NCT03801369|DRUG|Capivasertib|Given PO (orally)
224071173|NCT03801369|DRUG|Ceralasertib|Given PO (orally)
224071174|NCT03801369|BIOLOGICAL|Durvalumab|Given IV (infusion)
224071175|NCT03801369|DRUG|Olaparib|Given PO (orally)
224071176|NCT03801369|OTHER|Quality-of-Life Assessment|Ancillary studies
224071177|NCT03801369|DRUG|Selumetinib|Given PO (orally)
224071178|NCT04509466|DRUG|Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (12mg/m2, 16mg/m2, 20mg/m2, 24mg/m2) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
224071179|NCT04509466|DRUG|Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
224071180|NCT04509466|DRUG|Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|"Drug: Liposomal mitoxantrone hydrochloride (RP2D defined in Part 1) is administered by an intravenous infusion (IV) on day 1 of each 21-day cycle.~Drug: Pegaspargase (2000IU/m2) is administered by an intramuscular injection (IM) on day 1 of each 21-day cycle."
224071181|NCT03557892|DEVICE|CGM+CSII|Animas Vibe Platinum insulin pump and Dexcom G4 CGM
224071182|NCT03557892|DEVICE|MDI with degludec|Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
224071183|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (sinus lifting)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
224071184|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (ridge augmentation)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
224148512|NCT01117025|PROCEDURE|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
224148513|NCT03439111|DIETARY_SUPPLEMENT|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
224148514|NCT05254652|DRUG|Duloxetine 30mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
224148515|NCT05254652|DRUG|Pregabalin 150mg|Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
224064275|NCT04448587|DRUG|Sitagliptin 100mg|Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
224064276|NCT01157078|DRUG|TC-5214|Tablet, oral, twice daily for 8 weeks
224064277|NCT01157078|DRUG|Placebo|Tablet, oral, twice daily for 8 weeks
224064278|NCT05069987|OTHER|Virtual Reality Immersion|An immersive virtual reality experience will be generated by a head mounted device which shows the user pre-recorded videos (SynVR Relax \& Distract, SyncVR Medical BV, Utrecht, The Netherlands). These videos are recorded in 360 degree views and matched with the users' viewing direction by the head mounted device matches. The user will not be able to see its in vivo surroundings (i.e. the Cathlab) and will be focused on the digital content. The VR immersion will be put into place throughout the entire TAVR procedure starting before femoral access obtainment and ending after access closure.
224148516|NCT05128695|OTHER|there is no intervention; the study is observational|there is no intervention; the study is observational
224148517|NCT00973180|OTHER|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
224148518|NCT01175590|DRUG|Besivance|Ocular administration to affected eye for 7 days
224148519|NCT01175590|DRUG|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
224148520|NCT04775394|OTHER|Bronchoscopy|Bronchoalveolar lavage, mucosal biopsy and bronchial brushes during bronchoscopy
224148521|NCT05137275|BIOLOGICAL|Anti-5T4 CAR-raNK Cells|In the 3+3 dose escalation study, the minimum initial dose is 3.0×10\^9 cells and then escalate to 6.0× 10\^9 and 9.0× 10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 3\\8 of each cycle. In dose extension study, the initial dose will be determined by RP2D determined by the results of dose escalation study, and the other intervention methods are consistent.
223454540|NCT05218200|OTHER|deep breathing and coughing exercises with triflo|patients will be given triflo. A video of the application of deep breathing and coughing exercises with triflo prepared by the researchers will be prepared. The video will be sent to the patients' phones. It will be ensured that the patients do the exercises every hour by watching the video and they will be followed.
223742754|NCT06800313|DRUG|HLD-0915|A treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
224148522|NCT05851092|DRUG|HRS-2189 Tablets|HRS-2189 Tablets
224148523|NCT00092677|DRUG|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
224148524|NCT00092677|DRUG|Comparator: Placebo|matching Placebo
223742755|NCT01864733|OTHER|Physical rehabilitation (exercise).|
223742756|NCT06980649|DRUG|BHV-1300|BHV-1300 is delivered subcutaneously (SC)
223742757|NCT03188094|BEHAVIORAL|CHW-Led Health Coaching|The CHW intervention includes a protocol that consists of 5 monthly 90-minute group health education sessions, providing the tools and strategies to prevent diabetes.
223742758|NCT03188094|OTHER|EHR Alerts|Primary care providers (PCP) treating patients in the intervention group will receive embedded EHR alerts to increase screening and identification of South Asian patients at-risk for T2DM with BMI \>23 kg/m2 and registries to track outcomes.
224064279|NCT03667066|DRUG|Clopidogrel|Patients who were on long-term (more than 3 months) of clopidogrel or received a loading dose more than 4 hours prior to elective percutaneous coronary intervention.
224064280|NCT05689411|DEVICE|Musical Toy|The child and his parents in the experimental group were distracted by playing with the xylophone, a musical toy, 5 minutes before the peripheral vascular access procedure. The xylophone is a percussion wooden toy. There are two wooden bars on the xylophone that make melodious sounds when the metal plates are struck. The xylophone toy was introduced to the child and the parent, and they were given the opportunity to examine it. Before the procedure, one of the wooden sticks of the toy was given to the child and the other to the parent. Before, during and after the procedure, the child and his parents played together by making a melodic sound from the musical toy xylophone. While the child and his parents were playing with the toy, the researcher attached a tourniquet to the appropriate extremity of the child and determined the vein to which the vascular access would be performed.
224064281|NCT04682405|DRUG|Uproleselan|Provided by study
224064282|NCT04682405|DRUG|Placebo|Provided by study
224064283|NCT04682405|DRUG|Melphalan|-Standard of care
224148525|NCT00931294|BEHAVIORAL|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
224148526|NCT00931294|BEHAVIORAL|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
223454541|NCT03212859|BEHAVIORAL|Coach2Move|"Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~* Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~* Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~* The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~* In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions."
224064284|NCT03187769|DRUG|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
224064285|NCT03187769|DRUG|Olanzapine|Daily oral dosing
224064286|NCT03536455|DRUG|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
224064287|NCT03536455|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
224064288|NCT03777644|PROCEDURE|Continuous Paravertebral block with ropivacaine|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg"
224148527|NCT06201169|PROCEDURE|implant placement|All patients received four implants in the lower arch
224148528|NCT05993572|DIAGNOSTIC_TEST|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessments include functional status, fraility comorbidity, cognition, mental health, social support, nutrition, and geriatric syndromes
224148529|NCT04754113|OTHER|prone position|patient was helped into the prone position, patient received instructions of end expiratory occlusion lasting at least 10 seconds and, 1 seconds after the start, a bolus of 10 mL of 5% NaCl solution was injected via the central venous catheter
224148530|NCT05536154|DRUG|Etoposide|Day 1\~Day 2: 75mg/m\^2
224148531|NCT05536154|DRUG|Cytarabine|Day 1\~Day 2: 200mg/m\^2, q12h
224148532|NCT05536154|DRUG|PEG-rhG-CSF|Day 6: 6mg
224148533|NCT01601704|DRUG|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
223454542|NCT03212859|BEHAVIORAL|Usual Care|"Usual care physiotherapy among older adults:~* Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~* Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~* Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~* Collaborate with other disciplines in a multidisciplinary context."
224148534|NCT01601704|DRUG|PBO|Placebo. Administered in addition to the weight management program.
224148535|NCT01601704|BEHAVIORAL|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
224148536|NCT00749268|DEVICE|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
224148537|NCT00749268|DEVICE|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
223454543|NCT02842476|DEVICE|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
223454544|NCT02842476|DEVICE|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
223454545|NCT02842476|DEVICE|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
223454546|NCT02871141|PROCEDURE|electroconvulsive therapy|electroconvulsive therapy
223454547|NCT02871141|DRUG|Antidepressant|Antidepressant
224064289|NCT03777644|PROCEDURE|Continuous Paravertebral Block with Saline|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose"
224148538|NCT02283957|DRUG|CNTX-4975|
224148539|NCT02283957|OTHER|Placebo|
224148540|NCT05784870|DRUG|Shengxuening Tablet|Oral treatment with Shengxuening Tablets 1 week before chemotherapy, usage: 0.5gtid, for 28 consecutive days
223454548|NCT05460949|OTHER|HOLD RELAX STRETCHING OF ILIOPSOAS|"10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks."
224148541|NCT05784870|DRUG|Ferrous succinate|Oral treatment with ferrous succinate 1 week before chemotherapy, usage: 200mgqd, for 28 consecutive days
224148542|NCT00656578|DRUG|4975|Single dose, solution
224148543|NCT00656578|DRUG|Placebo|Single dose, solution
224148544|NCT00877006|DRUG|bendamustine|
224148545|NCT00877006|DRUG|rituximab|
224148546|NCT00877006|DRUG|vincristine|
224148547|NCT00877006|DRUG|prednisone|
224148548|NCT00877006|DRUG|cyclophosphamide|
224148549|NCT00877006|DRUG|doxorubicin|
224148550|NCT01223040|OTHER|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
224148551|NCT01639456|BIOLOGICAL|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
224148552|NCT01639456|BIOLOGICAL|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
224148553|NCT01639456|DEVICE|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
224148554|NCT01639456|DEVICE|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
224148555|NCT01639456|DRUG|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
224148556|NCT01639456|DRUG|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
224148557|NCT01639456|DRUG|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
224148558|NCT04671342|DEVICE|DreamKit|The DreamKit device is a single-use device intended to aid the diagnosis of sleep-disordered breathing.
224148559|NCT05321966|OTHER|Visual video education|The intervention group watched three episodes of a training video a week for 12 weeks. Each session started 90 minutes after the HD treatment
224148560|NCT05982145|OTHER|Individual interviews|Identify the needs and expectations of the users about the compression therapy; Identify the possible facilities and difficulties in link with the management of the venous leg ulcers; Identify care experiences; Identify experiences about the actual compressions systems
224148561|NCT05982145|OTHER|Focus groups|Identify facilities and difficulties in link with the prescription and implementation of the compression therapy everyday
224148562|NCT05982145|OTHER|Questionary and measures|To take measurement of patients who lives in institution or at their home and take measure of hydration and some other measures like the Group Iso Resource (GIR) and the capacity of the person to getting out of the bed.
224148563|NCT03948451|DRUG|[14C]AZD5718 Oral Suspension|200 mg dose of \[14C\]AZD5718 Oral Suspension
224148564|NCT06362447|DRUG|Gentamicin Injectable Solution|Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
223454549|NCT05460949|OTHER|WILLIAM'S PROTOCOL|Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
223454550|NCT00235573|DIETARY_SUPPLEMENT|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
223454551|NCT05474183|DRUG|Ketamine|drug
223454552|NCT02762071|DRUG|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
224064290|NCT03777644|DRUG|Patient-controlled analgesia with morphine|Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
224064291|NCT00250614|DRUG|Saredutant succinate (SR48968C)|
224064292|NCT04987138|DEVICE|Zenflow Spring System|The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
224064293|NCT04987138|DEVICE|Sham Procedure|A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
224064294|NCT01175785|PROCEDURE|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood transplant
224064295|NCT01175785|DRUG|fludarabine phosphate|Given IV
224064296|NCT01175785|DRUG|cyclophosphamide|Given IV
224064297|NCT01175785|BIOLOGICAL|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
224064298|NCT01175785|RADIATION|total-body irradiation|Undergo TBI
224064299|NCT01175785|DRUG|cyclosporine|Given IV
224064300|NCT01175785|DRUG|mycophenolate mofetil|Given IV and PO
224064301|NCT01175785|OTHER|laboratory biomarker analysis|Correlative studies
224064302|NCT04378283|DRUG|LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)|The study is designed to evaluate topical anesthetics
224064303|NCT04378283|DRUG|EMLA plus infiltration as anesthetic for wound repair.|EMLA plus infiltration as anesthetic for wound repair.
224064304|NCT03007173|PROCEDURE|umbilicus preserving surgery|excision of umbilical complex
224064305|NCT05771610|BEHAVIORAL|Activity pattern in CVD|Only individuals who have had a cardiac event within the past twelve months upon recruitment will be included in this study.
224064306|NCT06364449|OTHER|No intervention|No intervention
224064307|NCT06513169|PROCEDURE|Group 1: LEE|"Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)"
223454553|NCT02762071|DRUG|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
223454554|NCT01787669|DRUG|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
223454555|NCT01787669|DRUG|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
223454556|NCT00141518|DRUG|Levodopa-carbidopa intestinal gel (LCIG)|
223454557|NCT00141518|DEVICE|CADD-Legacy® 1400 ambulatory infusion pump|
223454558|NCT00141518|DEVICE|percutaneous endoscopic gastrostomy tube (PEG tube)|
223454559|NCT00141518|DEVICE|jejunal extension tube (J-tube)|
223454560|NCT06135844|DRUG|Purell Hand Sanitizer|Active ingredient. Ethyl alcohol 70%
223454561|NCT06135844|DRUG|Medical Grade Mineral Oil|Inert ingredients: Saturated hydrocarbons, with a purity and chemical structure that differs substantially from food-grade or technical-/industrial-grade mineral oils.
223454562|NCT02821429|OTHER|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
223454563|NCT01101750|BIOLOGICAL|Quadrivalent HPV for types 6, 11, 16 and 18|"Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7."
223571917|NCT03612310|PROCEDURE|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
223571918|NCT04932213|DRUG|Tropicamide Ophthalmic|Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.
223571919|NCT01247532|BEHAVIORAL|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
223571920|NCT02064972|OTHER|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
223571921|NCT04744012|PROCEDURE|Modified Periostal Pocket Flap Technique|"After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes."
224064308|NCT06167785|DRUG|Tislelizumab|Tislelizumab 200mg intravenously every 3 weeks
224064309|NCT06167785|DRUG|Zanubrutinib|Zanubrutinib 160 mg oral twice daily
224064310|NCT06167785|DRUG|Tislelizumab + Zanubrutinib|Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
223454564|NCT04361760|DEVICE|single-puls TMS|Medical Device (MD): MagPro X100
223454565|NCT04361760|DEVICE|sham stimulation|Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
223454566|NCT02816073|DEVICE|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
223454567|NCT01806168|DEVICE|rTMS|Magstim Super Rapid-2
223454568|NCT02725658|DEVICE|DOSI|Breast tissue properties scanning
224064311|NCT01793155|OTHER|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
224064312|NCT01793155|OTHER|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
224064313|NCT02597738|OTHER|Fresh tissue biopsy|Fresh tissue biopsy will be collected.
224064314|NCT02597738|OTHER|Blood/Urine Sample Collection|A one time blood sample will be collected.
224064315|NCT06443970|DEVICE|Exsalta Suction Device|Low flow endotracheal suction device
224064316|NCT02198807|DRUG|Fosmidomycin-Piperaquine|
224064317|NCT05495893|DRUG|Cyclophosphamide|The patients will be divided into two groups randomly. Cyclophosphamide for injection, 750mg/m2 each time, 1g at most, once a month for 6 consecutive months. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
224071185|NCT06154057|PROCEDURE|Dental Implants installed in an grafted area (extraction sites)|The patient will be invited to participate in the clinic to assess radiographic bone loss and clinical follow-up for 12 months.
224071186|NCT00066898|DRUG|AGI-1067|
224064318|NCT05495893|DRUG|Mycophenolate Mofetil|The patients will be divided into two groups randomly. Mycophenolate mofetil, tablets, 30-40mg/ (kg · day), BID, the maximum amount is no more than 2g/d. Steroids : intravenous methylprednisolone, 15\~30mg/kg · day, maximum 1000mg/day, 3 consecutive days a week for 2 weeks; during the interval of methylprednisolone pulse therapy and after:prednisone tablets 2mg/kg · day with a maximum dose 60mg / day. The duration of induction therapy: 6 months.
224064319|NCT04429061|BEHAVIORAL|SKILLZ-Girl curriculum|Participation in the SKILLZ-Girl curriculum and SKILLZ-Club
224064320|NCT02294513|DEVICE|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
223571922|NCT04182061|BEHAVIORAL|The AMTE protocol|The AMTE program is an adaptation of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A; Ehrenreich-May et al., 2018) to be applied as an internet-based protocol. Like the UP-A, the program AMTE implements a set of core principles to address common factors underling youth anxiety and depressive symptoms. It includes the following 10 modules: (1) Understanding emotional problems and disorders, (2) Getting to know your emotions and behaviors, (3) Enjoy your positive activities, (4) Mindful emotion awareness, (5) Being flexible in your thinking, (6) Confronting physical sensations, (7) Situational emotion exposure, (8) How to regulate the emotional avoidance, (9) Respiratory relaxation training, and (10) Relapse prevention.
223571923|NCT03680872|DEVICE|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
223571924|NCT01103063|DRUG|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
223742759|NCT06599879|OTHER|Neuropsychological assessments:|"Several neuropsychological assessments were carried out during the study (at inclusion and 2 years after inclusion), consisting of :~* parental questionnaires (standard questionnaires and questionnaires specifically drawn up for the trial). The aim of these questionnaires will be to assess the patient's neurocognitive level at different times (before and after radiotherapy treatment).~* patient cognitive tests (½ day face-to-face consultation/assessment with a neuropsychologist specialising in paediatrics, followed by a 30-minute telephone call).~Only for patients having received their radiotherapy treatment at the IUCT-O: a multimodal MRI specific to the study (without injection of contrast product) may be performed at inclusion and 2 years after inclusion."
224064321|NCT04314921|OTHER|Yoga trainings|10-week yoga sessions, 2 times per week, 90 min per session.
224064322|NCT06845163|DRUG|Dapagliflozin|Dapagliflozin 10 mg will be given orally once daily for three months.
224064323|NCT06845163|DRUG|Anti-VEGF drug|Aflibercept 2 mg (0.05 ml) will be administered by intravitreal injection every month for three consecutive months.
224064324|NCT03103802|DEVICE|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
224064325|NCT05464303|DRUG|Intravenous Antibodies|Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
224064326|NCT00622648|DRUG|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
224064327|NCT00622648|DRUG|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
224064328|NCT03964961|OTHER|Functional massage|It's a massage combined with a stretching of the muscles.
224064329|NCT03964961|OTHER|Conventional massage|It's a regular massage made with the therapist's hands.
224064330|NCT02586675|DRUG|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
224064331|NCT02586675|DRUG|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
224064332|NCT02586675|DRUG|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
224064333|NCT04500977|BEHAVIORAL|leadership empowerment|In the leadership program, women were taught more about the manner in which to bring about a change in one's health by adapting a healthy life style, leadership and facilitation skills and the development, implementation and evaluation process required to conduct a community program that will impact society. Women learned how to map needs and resources, define goals and objectives, develop, implement and evaluate a community based program.
224064334|NCT03186677|BIOLOGICAL|ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg|ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous
224064335|NCT03186677|BIOLOGICAL|BeneFIX|BeneFIX 75 IU/kg, intravenous administration
224064336|NCT03108313|DRUG|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
224064337|NCT03108313|DRUG|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
224064338|NCT03766048|PROCEDURE|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
224064339|NCT03766048|PROCEDURE|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
224071187|NCT01714986|BEHAVIORAL|Affect School|
224071188|NCT01714986|BEHAVIORAL|Body Awareness Therapy|
224071189|NCT00985400|BEHAVIORAL|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
224071190|NCT00985400|BEHAVIORAL|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
224071191|NCT00985400|OTHER|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
223454569|NCT04335058|DRUG|Lactoferrin + Iron Supplement|Lactoferrin 100 mg twice daily +oral iron
223454570|NCT04335058|DRUG|Iron Supplement|Oral iron supplement alone
223454571|NCT01153217|DRUG|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
223454572|NCT02693262|DEVICE|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
223454573|NCT02693262|DEVICE|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
223454574|NCT03327389|DRUG|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
223454575|NCT03327389|DRUG|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
223571925|NCT01103063|DRUG|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
224064340|NCT05317520|PROCEDURE|Cold vapor|"The Ramsey Sedation Scale was used to assess wakefulness after patients were extubated and arrived at the recovery unit at the 0th hour postoperatively. Sore throat, localization of pain, hoarseness, dry throat, and swallowing difficulty were evaluated in patients with a score of 2 according to this scale. Sore throat of the patients was evaluated with Numerical Rating Scale. Then, cold vapor was applied for 15 minutes with a vapor machine used as a standard in the hospital by the researcher. After the cold vapor application was finished, the patients' sore throat, localization of pain, hoarseness, swallowing difficulty and dry throat were re-evaluated with the same forms.~Sore throat were evaluated before the application of cold vapor at the 2nd and 6th hours. Then cold vapor was applied for 15 minutes. After the cold vapor application was finished, sore throat were re-evaluated.~At the 24th hour, cold vapor was not applied to the patients. Only sore throat were evaluated."
224064341|NCT00879229|DRUG|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
224064342|NCT00879229|DRUG|Placebo|Placebo to match ambrisentan administered orally once daily.
224064343|NCT02085889|OTHER|no intervention: observational study|observational
224064344|NCT05094700|OTHER|Non-marketed Cosmetic Facial Cleanser|Participants will apply non-marketed cosmetic facial cleanser on cleanse facial skin, twice daily for 4 weeks.
224064345|NCT01097746|BIOLOGICAL|Bevacizumab|Given IV
224064346|NCT01097746|DRUG|Carboplatin|Given IV
224064347|NCT01097746|DRUG|Paclitaxel|Given IV
224064348|NCT01227733|OTHER|Breast Tumor Blocks|
224064349|NCT04513002|DIETARY_SUPPLEMENT|Triheptanoin|Triheptanoin is a highly purified, synthetic medium odd-chain triglyceride that is catabolized to heptanoate.
224064350|NCT05186207|OTHER|abnormal pre-pregnancy test results that need clinical intervention|The patients who need clinical intervention before or after pregnancy were divided into observation group. Doctors will formulate a personalized treatment plan according to the international guidelines. Researchers wouldn't interfere with the expert diagnosis and treatment process.
224064351|NCT05071950|OTHER|Control period|"* first 7 days, participants consumed normal meal during iftar (breaking the fast at sunset)~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal"
224064352|NCT05071950|DIETARY_SUPPLEMENT|D-allulose period|"* \[started after 7 days of control period\],~* participants continued with D-allulose period for 7 days continuously~* participants consumed 8.5 g of D-allulose, (dissolve in plain water normal) before start the iftar meal~* participants did not allow to have added sugar/ sweetness drinks before the iftar meal~* flash continuous glucose monitoring system (FreeStyle Libre Pro) was used to measure the glucose~* food diary was used to record the iftar meal~* a questionnaire (multiple choice anwers) was used to record the side effects of D-allulose"
224064353|NCT00446602|DRUG|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
224064354|NCT04129931|DRUG|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
224064355|NCT04129931|DRUG|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
224064356|NCT04129931|DRUG|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
224064357|NCT04129931|DRUG|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
224064358|NCT04129931|DRUG|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
224064359|NCT04129931|OTHER|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks."
224064360|NCT04762537|OTHER|Standard Induction Procedure (SP)|SP includes stabilization on buprenorphine (6-8 mg) on Day 1 followed by a taper over the subsequent 4 days. After the completion of buprenorphine taper, participants will enter a washout period of at least 8 days. On the last day of the washout period, participants will be evaluated for eligibility to receive XR-NTX injection. Once found eligible, an XR-NTX injection will be given.
224064361|NCT04762537|OTHER|Rapid Induction Procedure (RP)|RP includes 1 day of buprenorphine 6-8 mg, followed by a day of washout and 4 days of oral naltrexone titration. If the participant is able to tolerate the last dose of the naltrexone titration, an XR-NTX injection will be given
224071192|NCT00985400|OTHER|Questionnaire administration|
224064362|NCT05461612|DEVICE|Spatial Resynchronization Therapy delivered by the MAX-SRS, external recording and stimulation device|Delivery of algorithmically defined pacing stimuli over a multitude of electrodes placed on the left atrium.
224071193|NCT00985400|BEHAVIORAL|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
223454576|NCT01861769|OTHER|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
223454577|NCT01861769|OTHER|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
223571926|NCT03376685|BEHAVIORAL|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 30 minutes (Week 1-2); 35 minutes (Weeks 3-4); or 40 minutes (Weeks 5-6) at 60% VO2 peak.
223571927|NCT03376685|BEHAVIORAL|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1-2); 5 repetitions (Weeks 3-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2 minutes' rest in between. Exercise will conclude with a 2-minute cool-down.
223571928|NCT06242223|OTHER|Multimodal HIIT|multimodal HIIT protocol followed by sprinting followed by 2 minutes of rest, burpees with 3 minutes rest between sets and push ups 4-5 rep at 80-100% of HR max with a total of 20 minutes exercise per session a day 3 times a week followed by 6 weeks.
223571929|NCT06242223|OTHER|conventional HIIT|conve protocol with 4-5 repetitions of 40 seconds maximum running at 80-100% HR max followed by 20 seconds of walking for 20 minutes exercise per session 3 times a week followed by 6 weeks.
223571930|NCT02340182|DRUG|Vancomycin|250mg 3dd2
223571931|NCT02340182|DRUG|Ciprofloxacin|500mg 2dd1
223571932|NCT02340182|DRUG|Metronidazole|500mg 3dd1
223571933|NCT04021173|DRUG|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
223571934|NCT04021173|DRUG|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
223571935|NCT01415804|DEVICE|endoprosthesis|Thoracic aortic stentgraft
223571936|NCT03115853|DRUG|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
223571937|NCT03115853|DRUG|Placebo|Placebo tablet for Aliskerin
223571938|NCT03115853|DRUG|HCTZ|HCTZ 25mg every day for 18 weeks
223571939|NCT03115853|DRUG|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
223571940|NCT02635139|BEHAVIORAL|Breakfast skipping|18h fasting period in the morning
223571941|NCT02635139|BEHAVIORAL|Dinner skipping|18h fasting period in the evening
223571942|NCT00825058|DRUG|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
223571943|NCT00825058|DRUG|placebo|oral administration 12 hours intervals
223571944|NCT00825058|DRUG|paroxetine|oral 20 mg/day
223571945|NCT00004564|DRUG|Clopidogrel|
223571946|NCT00004564|DRUG|Atorvastatin|
223571947|NCT03981666|OTHER|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~* Ad hoc questionnaire for demographics and medical data;~* Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~* Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
223571948|NCT04539522|BEHAVIORAL|Three-dimensionally corrective exercise for scoliosis|Three-dimensionally corrective exercise for scoliosis is based the theory of physiotherapeutic scoliosis specific exercises, which focus on 3-dimension self-correction and consists of two parts:1)outpatient treatment including stretching, three-dimensional auto-correction(combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.), balance and stability training, combined with manual fascia relaxation therapy, and and breathing training; 2)family rehabilitation: combines self-correcting gymnastics with daily posture management, etc., forming the individual exercise approach for each patient.
223571949|NCT04539522|BEHAVIORAL|Conventional exercise|Conventional exercise consists a series of spine exercises focusing on core strength training.
223584091|NCT03189966|PROCEDURE|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
224071194|NCT03017053|RADIATION|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
224071195|NCT03017053|PROCEDURE|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
223454578|NCT01029262|DRUG|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
223454579|NCT01029262|OTHER|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
223454580|NCT03137277|PROCEDURE|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps \< 5 mm), or conventional polypectomy according to local standards."
223454581|NCT06166017|OTHER|Exposure to minimal amount of lingual keratinized tissue width|measurement of clinical parameters
223454582|NCT03410992|DRUG|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
223454583|NCT03410992|OTHER|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
223454584|NCT05722730|PROCEDURE|Pilates Exercises|The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
224064363|NCT00549458|BEHAVIORAL|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
224064364|NCT00549458|PROCEDURE|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
223454585|NCT02761018|BEHAVIORAL|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
223454586|NCT02761018|BEHAVIORAL|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
223454587|NCT03810157|DEVICE|Laser-assisted hatching system|The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
223454588|NCT04637841|OTHER|Kinesiology Taping Appliying|"Kinesiology tape will be applied to left foot plantar fascia of the participants in diabetes mellitus and control group.~During taping, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position. A Palm Shape taping procedure will be applied to the plantar fascia."
223454589|NCT04637841|OTHER|Myofascial Release Technique Appliying|"Myofascial release technique will be applied (during 5 minutes) to right foot plantar fascia of the participants in diabetes mellitus and control group~During appliying technique, participants will lie in the prone position while the knee joint will be kept 90 degrees of flexion and the ankle joint in a neutral position."
223454590|NCT00338091|DRUG|Benazepril|
223454591|NCT00338091|DRUG|Losartan|
223454592|NCT00336934|DIETARY_SUPPLEMENT|pomegranate juice|Given orally daily.
223454593|NCT00336934|OTHER|placebo|Given orally daily.
223454594|NCT01508247|BIOLOGICAL|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
223454595|NCT01508247|BIOLOGICAL|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
224064365|NCT00208221|DRUG|ramipril|
224064366|NCT00208221|DRUG|ramipril-telmisartan|
224064367|NCT04628637|OTHER|Serum protein level analysis|Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
224064368|NCT05227638|OTHER|exercise|participants were between ages 10-18, volunteered for the study, were diagnosed with adolescent idiopathic scoliosis, were Cobb angle between 10-30 degrees, were 0-3 Risser sign, and were Lenke curve type 1.
224148565|NCT05132595|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
224148566|NCT05132595|DRUG|Esketamine at high dose|After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
223454596|NCT00297700|BEHAVIORAL|Active referral|
223454597|NCT02438280|DEVICE|AcceleDent, Vibrational Device|20 minutes of vibration each day
223454598|NCT02048150|BIOLOGICAL|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
223454599|NCT02048150|PROCEDURE|robot-assisted laparoscopic surgery|Undergo RALP
223454600|NCT02048150|OTHER|diffuse optical imaging|Undergo IOOI
223454601|NCT02048150|OTHER|pharmacological study|Correlative studies
224148567|NCT05132595|DRUG|Esketamine at low dose|After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
224148568|NCT05132595|DRUG|Ketorolac at high dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h Ketorolac until starting skin suture.
224148569|NCT05132595|DRUG|Ketorolac at low dose|After the induction of anesthesia, Ketorolac is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h Ketorolac until starting skin suture.
224148570|NCT03241667|DEVICE|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
224148571|NCT06180616|DRUG|Tirzepatide|"Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study."
224148572|NCT05304000|BEHAVIORAL|Mindfulness Meditation|Participants are informed they should sit down in a chair or, if they preferred, to lie down, and then to set a timer for 5 minutes. Then they are told to close their eyes and to start breathing while focusing their mental attention on their forehead region between their two eyes. They are told that if their focus drifted from that location to re-recenter their attention by focusing back first on their breath and then on the forehead region between their eyes. They are told that as thoughts arise, to recognize that as normal, refocus their attention back to their forehead region and to continue the practice until time has elapsed.
224148573|NCT05304000|BEHAVIORAL|Cyclic Sighing Breathing|Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 minutes. Then they are told to inhale slowly, and that once their lungs are expanded, to inhale again once more to maximally fill their lungs -- even if the second inhale was shorter in duration and smaller in volume than the first, and then to slowly and fully exhale all their breath. They are told to repeat this pattern of breathing for 5 minutes. They are also informed that ideally, both inhales would be performed via their nose and the exhale would be performed via their mouth, but that if they preferred, they are welcome to do the breathing entirely through their nose. They are also informed that it is normal for the second inhale to be briefer than the first.
224148574|NCT05304000|BEHAVIORAL|Box Breathing|"Participants are informed they should sit down in a chair or lie down, and to get a timer. Then they are told to take the CO2 tolerance test as follows: Take 4 breaths through the nose. Then take a maximally deep breath and once your lungs are full, exhale as slowly as possible through your nose or mouth. Time how long it takes to empty your lungs; this will be your C02 discard duration. Use your discard duration to determine how long your inhales, exhales, and breath holds should be (CO2 discard time) by using this table: \<20 sec = 3 - 4 sec, 25 - 45 sec = 5 - 6 sec, 50 - 75+ sec = 8 -10 sec. They are then told to inhale, hold, exhale, hold (for the duration determined by the C02 discard table) and to repeat this pattern for the entire 5 minutes. If at any point they had to strain to reach these times, they should simply reduce the duration of inhales, exhales, and breath holds. We ask participants to perform all breathing through their nose, if possible."
223454602|NCT02048150|OTHER|Laboratory Biomarker|Correlative studies
223454603|NCT02048150|OTHER|Questionnaire|Ancillary studies
223454604|NCT05869370|OTHER|High intensity resistance training|Twelve weeks of resistance training twice a week.
223454605|NCT05869370|OTHER|Low intensity resistance training combined with blood flow restriction|Twelve weeks of resistance training with blood flow restriction twice a week.
223454606|NCT02260817|DRUG|11C-choline Injection|"1. Choline C11 Injection for PET/CT Imaging Protocol:~   * 15 - millicuries (mCi) 11C-choline IV Injection~  * PET images skull base to mid thigh with 3 min per bed position~  * Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~  * Fusion of PET and CT images~2. Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~   * No IV contrast~  * High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~  * Fusion of coronal and PET images"
223454607|NCT03299101|OTHER|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
223454608|NCT02485327|DRUG|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder~Route of administration: oral inhalation"
223584092|NCT05824936|BEHAVIORAL|Pilot study arm for technology-enhanced asthma intervention|Participants will be enrolled in a remote monitoring program using monthly remote study visits which will include the use of a mobile spirometer (device for testing lung function). Participants will complete monthly remote study visits visits using telehealth platform and will complete lung function testing during the visit using a mobile spirometer as well as remote study measures.
223584093|NCT00673881|DRUG|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
223584094|NCT05302362|DEVICE|transcranial direct current stimulation|Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
224148575|NCT05304000|BEHAVIORAL|Cyclic Hyperventilation with Retention|"Participants are informed they should sit down in a chair or, if they prefer, to lie down, and to set a timer for 5 min. Then they are told to inhale deeply (ideally through their nose but if that is not possible, to inhale through their mouth) and then exhale by passively letting the air fall out from the mouth. We inform them that for sake of this protocol, that pattern of a deep inhale through the nose and passively letting the air fall out from the mouth = 1 breath.~Then they are instructed to perform 30 breaths (in and out) in this manner, and after those 30 breaths, to exhale all their air via their mouth and to calmly wait with lungs empty for 15 seconds."
224148576|NCT04137146|DEVICE|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
224148577|NCT03491930|DEVICE|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
224148578|NCT03491930|BEHAVIORAL|Telephone Coaching|Weekly Telephone Coaching
224148579|NCT03491930|BEHAVIORAL|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)"
224148580|NCT00042562|DRUG|duloxetine|
224148581|NCT01089816|BIOLOGICAL|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
224148582|NCT02026518|DIETARY_SUPPLEMENT|Soy isoflavones|
224148583|NCT02026518|DIETARY_SUPPLEMENT|cholecalciferol|
224148584|NCT02026518|DIETARY_SUPPLEMENT|Placebo of soy isoflavones|
224148585|NCT02026518|DIETARY_SUPPLEMENT|placebo of cholecalciferol|
223454609|NCT01100723|OTHER|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
223454610|NCT00347178|PROCEDURE|Laser Peripheral Iridotomy|
223454611|NCT05184348|RADIATION|Narrow band Ultraviolet B phototherapy group|3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
223571950|NCT05504304|PROCEDURE|open reduction and internal fixation plus primary subtalar arthrodesis|they will be scheduled to surgery after resolution of the edema and appearance of wrinkle sign. Lateral position and lateral extensile approach will be used. A 4 mm schanz will be inserted in the calcaneal tuberosity from lateral side to control varus and to restore calcaneal height. Lateral wall of the calcaneus will be lifted keeping it attached inferiorly. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. tricortical iliac bone autograft will be inserted the subtalar joint. A lateral nonlocked plate will be applied to reduce the lateral wall blow out and broadening then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
223584095|NCT02510183|DEVICE|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
223584096|NCT02510183|DEVICE|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
224148586|NCT02122926|OTHER|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge."
224148587|NCT02270801|DRUG|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
223454612|NCT05184348|DRUG|Acitretin group|dose of 0.5-1 mg per kg per day orally for 3 month.
223454613|NCT05184348|COMBINATION_PRODUCT|Acitretin plus Narrow band Ultraviolet B phototherapy group|Acitretin in dose of 0.5-1 mg per kg per day orally plus Narrow band Ultraviolet B phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.
223454614|NCT02937181|DRUG|Ceftaroline|IV Ceftaroline will be given for 72 hours
223454615|NCT05534828|DIAGNOSTIC_TEST|A consultation|A consultation at three months of discharge from the intensive care unit in the population of patients surviving a multivalent intensive care unit stay
223454616|NCT05961631|OTHER|Bio-electrical Impedance Analysis|Variable measured: Fluid accumulation (FA), volume excess (VE), total body weight (TBW), extracellular water (ECW), intracellular water (ICW)
223454617|NCT02904083|BEHAVIORAL|self assessment of adherence|
223454618|NCT01985100|OTHER|hyperbaric oxygen chamber|
223454619|NCT00639262|DRUG|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
223454620|NCT00639262|DRUG|Temozolomide|For Cohort 2 - Gliomas only.
223454621|NCT00639262|RADIATION|Radiotherapy|Radiation Therapy (XRT)
223454622|NCT03147118|DIAGNOSTIC_TEST|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
223454623|NCT03707938|DRUG|Brigatinib|Given PO
224148588|NCT02053558|DRUG|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
224148589|NCT02053558|DRUG|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
224148590|NCT00979719|BEHAVIORAL|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
224148591|NCT00979719|BEHAVIORAL|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. \& Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
224148592|NCT03029676|DRUG|benzodiazepines|sedative
224148593|NCT03029676|DRUG|opioid|analgetic, sedative
223571951|NCT05504304|PROCEDURE|conservative management then calcaneoplasty and subtalar arthrodesis.|they will be assessed upon 1st clinic visit. After at least three months patients will be scheduled for subtalar arthrodesis. A new preoperative ankle CT scan will be done. Lateral position and lateral extensile approach will be used. Lateral wall and plantar exostosis will be resected. Articular surfaces of inferior surface of the talus and posterior facet of the calcaneus will be debrided thoroughly and drilled by 2 mm k-wire. Hind foot deformity (mostly varus) will be corrected through the subtalar joint manually and checked clinically. Loss of calcaneal height will be corrected by tricortical iliac bone autograft to distract the subtalar joint then fixation by two cannulated partially threaded 7.3 screws from the calcaneal tuberosity to the talus. We will check position by fluoroscopy then closure in two layers (subcutaneous and skin) after homeostasis. Below knee slab will be applied and non-weight bearing for six weeks.
223571952|NCT00906451|DRUG|Simvastatin|Simvastatin
224064369|NCT03791788|DIAGNOSTIC_TEST|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
224064370|NCT03373305|DRUG|Brentuximab Vedotin|Given IV
224064371|NCT03373305|DRUG|Lenalidomide|Given PO
224064372|NCT03373305|OTHER|Laboratory Biomarker Analysis|Correlative studies
224064373|NCT03924609|DIAGNOSTIC_TEST|Intensive screening / routine screening|Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
224064374|NCT04179383|OTHER|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients (during RCVS episode and after resolution of RCVS episode) and for control subjects to constitute a biobank, in order to compare different biologic parameters between RCVS patients and healthy volunteers. A specific agreement will be asked to patients and control subjects before collection of samples.~This is why this study is classified as 'interventional' rather than 'observational'."
224064375|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
224064376|NCT00631371|DRUG|Temsirolimus|Temsirolimus 25 mg IV weekly
224064377|NCT00631371|DRUG|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
224064378|NCT00631371|DRUG|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
224064379|NCT05578729|BEHAVIORAL|Single surgical mask group, Double surgical mask group, N95 mask group|Masks were given to the resting pregnant women 30 minutes before the NST, and they were provided to wear masks. After 30 minutes, the vital signs of the pregnant women were measured just before and after the NST, and the images of the NST traces were taken.
224148594|NCT03029676|PROCEDURE|spinal anesthesia|
224148595|NCT03911869|DRUG|encorafenib|taken orally
224148596|NCT03911869|DRUG|binimetinib|taken orally
224148597|NCT01878097|BEHAVIORAL|Green Dot Bystander Intevention|Intervention allocated at the school level
224148598|NCT01878097|BEHAVIORAL|Control|Awareness Education
224148599|NCT04406012|PROCEDURE|paravertebral block|paravertebral block group
224148600|NCT05972395|OTHER|Localized vs Widespread Mechanical Pain Hypersensitivity|Based on pressure pain threshold mapping, participants will be classified as having either localized mechanical pain hyperalgesia (hyperalgesia limited to the lumbosacral region) or widespread mechanical pain hyperalgesia (hyperalgesia extending beyond the lumbosacral region).
224148601|NCT04488081|DRUG|Remdesivir|Participants who receive remdesivir as part of their standard of care will be administered remdesivir by IV for up to ten days. Remdesivir 200mg loading dose on day 1, followed by 100mg IV once daily maintenance doses for 4 or 9 days.
224064380|NCT00636766|DRUG|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
224148602|NCT04488081|DRUG|Imatinib Mesylate|Subjects will be administered 800 mg on Day 1 orally, in divided doses of 400 mg administered twice per day. 400 mg daily will be administered orally for the following 9 days or until discharge, whichever is sooner.
224148603|NCT04488081|DRUG|Dexamethasone|6 mg intravenous of oral dexamethasone once daily up to 10 days or equivalent for alternate corticosteroid if dexamethasone unavailable.
224148604|NCT04488081|DRUG|Cenicriviroc|Oral, loading 300 mg qAM followed by 150 mg qPM, 12 hours apart on day 1, then 150 mg BID for total of 14 to 28 days depending on date of hospital discharge.
224148605|NCT04488081|DRUG|Icatibant|Subcutaneous, a safety run-in for the first 10 subjects was conducted using a regimen of 30 mg q8h × 3 days. All subsequent subjects received drug at 30 mg q8h x 6 days.
224148606|NCT04488081|DRUG|Apremilast|oral, 30 mg bid × 14 days.
224148607|NCT04488081|BIOLOGICAL|dornase alfa|"For Non-intubated subjects: 2.5 mg BID until hospital discharge, improvement to room air (or baseline oxygen use prior to illness) for 24 hours, or total of 14 days of study drug, whichever comes first.~For intubated subjects: 5.0 mg BID in 10 mL normal saline until extubation or 14 days, whichever comes first. If intubated for less than 14 days, extubated subjects received 2.5 mg BID for a total Dornase treatment of 14 days, or until hospital discharge, whichever comes first."
224148608|NCT04488081|DRUG|Celecoxib|Oral: 400 mg BID for 7 days.
224148609|NCT04488081|DRUG|Famotidine|Oral: High dose 80 mg QID for 7 days followed by 40 mg BID for a course of 14 days.
224148610|NCT04488081|BIOLOGICAL|IC14|intravenous, 4 mg/kg on day 1, followed by 2 mg/kg on days 2, 3, 4
224148611|NCT04488081|DRUG|Aviptadil|Inhalation via nebulizer, 100 µg three times (TID) daily for a maximum of 14 days
224148612|NCT04488081|BIOLOGICAL|narsoplimab|Dosed at 4 mg/kg, given as a 30-minute intravenous infusion (up to a maximum of 370 mg per infusion) twice weekly for a total of four weeks (i.e. 9 doses) or until hospital discharge whichever comes first.
224148613|NCT04488081|DRUG|Cyproheptadine|4 mg tablet, with dosing regimen of 8 mg every 8 hours daily for ten (10) days. If the patient weighs less than 48 kg, the regimen is 6 mg every 8 hours daily for ten (10) days. If the participant was discharged before completion of this dosing regimen the drug was not continued.
224148614|NCT04488081|DRUG|Cyclosporine|Modified CsA at an oral dose of 5mg/kg per day administered in two divided doses daily for 5-days.
224148615|NCT02566616|DEVICE|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
224148616|NCT03043846|OTHER|Follow-up every 3 months during 1 year (data collection in eCRF)|
224148617|NCT03043846|OTHER|Follow-up every month to follow the pre-defined strategy|
224148618|NCT00533611|DRUG|MK0524A, /Duration of Treatment : 4 Weeks|
224148619|NCT00533611|DRUG|Comparator : niacin /Duration of Treatment : 1 Weeks|
224148620|NCT06231914|DEVICE|StarWalker® PQX|Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
224148621|NCT05145803|DEVICE|Polyvinylalcohol strip [diagnostic]|The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
224148622|NCT03470311|BIOLOGICAL|Benralizumab|30mg in 1mL pre-filled syringe
224064381|NCT00636766|DRUG|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
224064382|NCT00636766|DRUG|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
224064383|NCT00636766|DRUG|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
224064384|NCT06246565|DRUG|HS-10383|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
224064385|NCT06246565|DRUG|HS-10383 Placebo|HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
224064386|NCT02095535|DRUG|Chlorhexidine gluconate|antiseptic
224064387|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
224064388|NCT00623480|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
224064389|NCT00288093|RADIATION|3-Dimensional Conformal Radiation Therapy|
224064390|NCT00288093|DRUG|Triapine|
224148623|NCT03470311|BIOLOGICAL|Placebo|Matched placebo (1mL) in pre-filled syringe
224148624|NCT00224783|BIOLOGICAL|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
224148625|NCT00224783|BIOLOGICAL|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
224148626|NCT06195943|BEHAVIORAL|Exercise Intervention with use of El-Fit App|Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
224148627|NCT03325556|DRUG|Placebo|Placebo, tablets, once daily by mouth
224148628|NCT03325556|DRUG|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
224064391|NCT06247709|OTHER|Immunohistochemical expression in pitNET cells of KLHL14|Lab essay evaluating the expression of KLHL 14
224064392|NCT01330238|DRUG|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
224064393|NCT03801668|DRUG|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
224064394|NCT03801668|DRUG|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
224064395|NCT03709654|BIOLOGICAL|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
224064396|NCT03709654|OTHER|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
224064397|NCT02056483|OTHER|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
224148629|NCT03325556|DRUG|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
224148630|NCT02119026|DRUG|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
224148631|NCT02119026|DRUG|Capecitabine|1000mg/m2 bid d1-14,
224148632|NCT02119026|DRUG|Bevacizumab|7,5 mg/kg given on d1 q3w
224148633|NCT02119026|DRUG|Oxaliplatin|130mg/m2 iv. d 1 q3w
224148634|NCT02119026|DRUG|Irinotecan|200mg/m2 iv. d 1 q3w .
224148635|NCT00510484|DRUG|Pancrelipase Delayed Release|24000 unit Capsule
224148636|NCT00510484|DRUG|Placebo Comparator|Placebo
223454624|NCT03707938|PROCEDURE|Local Consolidation Therapy|Undergo local consolidative therapy
223454625|NCT04802824|OTHER|PET/CT|18F-fluoropivalate PET/CT scan.
223454626|NCT04120909|DEVICE|Cardiac resynchronization therapy|Biventricular pacing according to current standards.
223454627|NCT01750060|DRUG|Fentanyl|
223454628|NCT01750060|DRUG|Naltrexone|
223454629|NCT02364687|RADIATION|Computed tomography late enhancement imaging|
223454630|NCT05870150|BIOLOGICAL|Salmonella Typhimurium|Salmonella Typhimurium oral challenge. Dose-escalating (1-5x10\^3 CFU, 1-5x10\^4 CFU, 1-5x10\^5 CFU, 1-5x10\^6 CFU)
223454631|NCT04709497|PROCEDURE|viscotrabeculotomy (VT)|viscotrabeculotomy (VT)
223454632|NCT04709497|PROCEDURE|visco-circumferential-suture-trabeculotomy (VCST) .|visco-circumferential-suture-trabeculotomy (VCST)
223454633|NCT04709497|PROCEDURE|combined VT-Trabeculectomy with MMC (VT-Trab).|combined VT-Trabeculectomy with MMC (VT-Trab).
223454634|NCT06114771|OTHER|strepsilis|Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).
223454635|NCT06114771|OTHER|Placebo|Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
223571953|NCT03788447|OTHER|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
224148637|NCT00461422|DRUG|Ganirelix|sc injection of Ganirelix 0.25 mg per day
224148638|NCT00657722|OTHER|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
224148639|NCT03135288|DEVICE|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
224148640|NCT00109005|DRUG|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
223454636|NCT06223308|DRUG|HB0028|Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
223454637|NCT01882803|DRUG|Duvelisib|Phosphoinositide-3-kinase (PI3K) inhibitor
223454638|NCT00502099|DRUG|Pegylated interferon alpha 2a|Injections: 180 ug once per week
223454639|NCT00502099|DRUG|Ribavirin|Tablets, 1000-1200 daily
223454640|NCT00502099|DRUG|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
223454641|NCT02990871|OTHER|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
223454642|NCT02990871|OTHER|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
223454643|NCT01563913|DRUG|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
223571954|NCT03788447|OTHER|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
223584097|NCT00491920|DRUG|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~\+ calcium 500 mg/cholecalciferol 400 IU x2/d"
223584098|NCT00491920|DRUG|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
223454644|NCT01563913|DRUG|Placebo|Sugar Pill, taken for 1.5 years
223454645|NCT00076401|DRUG|Motexafin gadolinium|
223454646|NCT04470479|DRUG|Pilocarpine Hydrochloride|Oral pilocarpine hydrochloride 5mg tablets were administered four times a day for 10 weeks to half the group of selected patients. The other half ingested placebo in the same way. At the end of this period and after two weeks of washing out the medications, the patients had to invert the treatments.
223454647|NCT04470479|DRUG|Placebo|Placebo
223454648|NCT03066778|BIOLOGICAL|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
223454649|NCT03066778|DRUG|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
223454650|NCT03066778|DRUG|Carboplatin|IV infusion on Day 1 of each cycle
223454651|NCT03066778|DRUG|Cisplatin|IV infusion on Day 1 of each cycle
223454652|NCT03066778|DRUG|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
223454653|NCT05361135|DIAGNOSTIC_TEST|PET/CT|Enhanced imaging with PET/CT
223584099|NCT02203955|DRUG|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
223584100|NCT02203955|DRUG|Maltodextrin|4 chews (maltodextrin) daily for 12 months
224064398|NCT01902966|DRUG|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
224064399|NCT01902966|BEHAVIORAL|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
224064400|NCT01902966|BEHAVIORAL|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
224064401|NCT01902966|BEHAVIORAL|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
224064402|NCT00003625|DRUG|cyclosporine|
224064403|NCT00003625|DRUG|etoposide|
224064404|NCT00003625|DRUG|vincristine sulfate|
224064405|NCT00003625|RADIATION|radiation therapy|
224064406|NCT03226145|PROCEDURE|MRI Motility|MRI sequence to assess colonic motility
224064407|NCT03226145|PROCEDURE|High Resolution Manometry|HRM of colon to assess motility
224148641|NCT00340834|DRUG|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
224148642|NCT00340834|DRUG|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
224148643|NCT00340834|DRUG|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
224148644|NCT05320328|DEVICE|Radio frequency ablation|Radiofrequency ablation (RFA) uses heat to kill cancer cells. High-frequency electrical currents are passed through a special needle or probe called a needle electrode. The electrical current from the probe heats a small area containing cancer cells to high temperatures, killing the cancer cells. The area around the tumour is also usually treated because it may contain cancer cells.
224148645|NCT00762268|DRUG|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
224148646|NCT00762268|DRUG|Placebo|
224148647|NCT05868980|OTHER|vital signs by postpartum position|Evaluation of vital signs and NIRS values in 4 different positions after birth
224148648|NCT06157372|DIAGNOSTIC_TEST|targeted next-generation sequencing (tNGS)|To provide rapid etiological diagnosis of patients by means of targeted next-generation sequencing.
224148649|NCT00961441|DRUG|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
224148650|NCT06293365|BIOLOGICAL|VAY736 1ml PFS|Solution for injection.
224148651|NCT06293365|BIOLOGICAL|VAY736 2 ml PFS|Solution for injection
224148652|NCT06293365|BIOLOGICAL|VAY736 2ml AI|Solution for injection.
224148653|NCT04516577|OTHER|Assesssing the severity of pulmonary alveolar proteinosis|Three severity scores will be used to assess the severity of patients with pulmonary alveolar proteinosis.
224148654|NCT03967509|BEHAVIORAL|Comet|
224148655|NCT00432913|DRUG|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
223571955|NCT05945134|OTHER|Visual and auditory feedback STS training|"30 minutes per session, 3 sessions per week, for a total of 3 weeks. The visual and auditory feedback signals will be given throughout the sit-to-stand movement. As the size of circle representing the weight bearing gets more even, and the mobile dot indicating the overall center of pressure moves forward and approaches the midline, the auditory cues will get louder to indicate proximity to the target. It allows the participants to adjust and relearn the correct weight shifting and symmetry.~The intensity will be adjusted based on different chair heights (e.g. 115%, 100%, 80% of lower leg length), various seat materials, and supported level of thigh (progressing from one-third of the length between the greater trochanter of the femur and the knee joint line to full support). The training program will be progressed according to the abilities of the participants."
223571956|NCT05945134|OTHER|Conventional STS training|30 minutes per session, 3 sessions per week, for a total of 3 weeks. All settings will be the same as the experimental group, except for the feedback. In the control group, the verbal cues will be given by the physical therapist and a mirror will be placed in front of the participant for visual feedback. During the sit-to-stand movement, participants will be asked to try to maintain the alignment in the midline.
223571957|NCT00535158|DRUG|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
223571958|NCT05255042|OTHER|organ and tissue sample collection only|Collection of liver segments removed by radical surgery of hepatic lobes, but not submitted to pathology
223571959|NCT01181024|DRUG|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
223571960|NCT01181024|DRUG|RO5303253|Cohorts receiving single ascending doses
223571961|NCT01181024|DRUG|RO5303253|Single dose
223571962|NCT01181024|DRUG|RO5303253|Multiple doses
224148656|NCT00432913|PROCEDURE|Endoscopy|At baseline, month 3 and month 6.
224148657|NCT00432913|PROCEDURE|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
224148658|NCT00432913|PROCEDURE|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
224148659|NCT00432913|PROCEDURE|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
224148660|NCT00432913|PROCEDURE|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
224148661|NCT00432913|PROCEDURE|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
224148662|NCT00432913|PROCEDURE|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
224148663|NCT00432913|PROCEDURE|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
224148664|NCT03617913|DRUG|Avelumab|Given IV
224148665|NCT03617913|DRUG|Cisplatin|Given IV
224148666|NCT03617913|DRUG|Fluorouracil|Given IV
224148667|NCT03617913|DRUG|Mitomycin|Given IV
224148668|NCT03617913|OTHER|Quality-of-Life Assessment|Ancillary studies
224148669|NCT03617913|RADIATION|Radiation Therapy|Undergo RT
224148670|NCT01143714|DRUG|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
223571963|NCT06348914|BEHAVIORAL|Knowledge assessment|survey on knowledge of a group of dental students regarding vital pulp therapy
223571964|NCT06348914|OTHER|Educational Material|An awareness lecture on vital pulp therapy will be given to a group of the students right after they answer the questionnaire for the first time.
224148671|NCT01143714|OTHER|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
224148672|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once on Day 1 and Day 9, respectively
224148673|NCT05063968|DRUG|Placebo|Tablet is administered orally once on Day 1 and Day 9, respectively
224148674|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered fasted orally once on Day 1
224148675|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered after a high-fat meal orally once on Day 9
224148676|NCT05063968|DRUG|XZP-6019 tablet|Tablet is administered orally once daily for 14 Days continuously
224148677|NCT05063968|DRUG|Placebo|Tablet is administered orally once daily for 14 Days continuously
224148678|NCT01721629|PROCEDURE|Sudden wean of nasal CPAP|
224148679|NCT01721629|PROCEDURE|Gradual wean of nasal CPAP|
224148680|NCT00757640|PROCEDURE|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
224148681|NCT02030249|BEHAVIORAL|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview\&rank=1
224148682|NCT02030249|BEHAVIORAL|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
224148683|NCT02030249|BEHAVIORAL|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
224148684|NCT02849184|DRUG|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
224148685|NCT02849184|OTHER|Placebo|Placebo once daily before bedtime.
224148686|NCT01387074|BIOLOGICAL|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
224148687|NCT00853190|DRUG|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
224148688|NCT00853190|DRUG|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
224148689|NCT01865838|DEVICE|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
224148690|NCT01939093|DRUG|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
224148691|NCT01939093|DIETARY_SUPPLEMENT|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
224148692|NCT01939093|DRUG|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
224148693|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, early treatment
224148694|NCT00150345|DRUG|voriconazole (Vfend)|voriconazole, deferred treatment
223454654|NCT01817166|DRUG|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
223454655|NCT01817166|DRUG|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
223454656|NCT01817166|OTHER|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
223454657|NCT01817166|BIOLOGICAL|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
223454658|NCT01817166|BIOLOGICAL|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
223454659|NCT01817166|BIOLOGICAL|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
223571965|NCT03659149|DRUG|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
223571966|NCT03659149|DRUG|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
223571967|NCT03659149|DRUG|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
223454660|NCT04039659|DEVICE|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
223454661|NCT01440985|DRUG|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
223454662|NCT01440985|DRUG|Nicotine|Nicotine gum 4 mg, Lot number GC962A
224148695|NCT06331312|BIOLOGICAL|Secukinumab|2 x 150mg/1mL PFS secukinumab
224148696|NCT03791216|OTHER|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
224148697|NCT02373163|DRUG|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
224148698|NCT02373163|DRUG|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
224148699|NCT02373163|DRUG|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
223454663|NCT01440985|DRUG|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
223454664|NCT00005069|DRUG|arsenic trioxide|
223454665|NCT02448745|DEVICE|Insecticide treated wall lining|Polypropylene non-woven fabric.
223454666|NCT01651754|BIOLOGICAL|Seasonal influenza vaccination|single dose of influenza vaccination
223454667|NCT05995587|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT combines mindfulness meditation with cognitive behavioural therapy (CBT) elements to reduce or prevent recurrent major depressive disorders.
223571968|NCT04506060|OTHER|serum withdrawal|Serum of the transplant patient. In the transplanted patient, the search for the BK virus is traditionally carried out during visits in the first year after transplantation.
223571969|NCT01437098|DEVICE|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
223571970|NCT04518852|COMBINATION_PRODUCT|TACE combined with sorafenib and PD-1 mAb|the combination of local therapy (TACE), anti-angiogenic therapy (sorafenib), and immunotherapy (PD-1 monoclonal antibody)
223571971|NCT04853693|BEHAVIORAL|Mom´s Supporting Mom|A preventive peer consultation intervention for Postpartum Depression.
224064408|NCT03226145|DRUG|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
224064409|NCT03226145|DRUG|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
224064410|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
224064411|NCT04543994|DRUG|Remestemcel-L|An ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory ulcerative colitis
224064412|NCT04543994|OTHER|Placebo|Normal saline
224064413|NCT02321254|DEVICE|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
224064414|NCT02321254|BEHAVIORAL|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
224064415|NCT03741998|DEVICE|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
224064416|NCT02631200|BEHAVIORAL|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
224064417|NCT05086471|DEVICE|NaviCam SB|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
224064418|NCT05086471|DEVICE|PillCam SB3|Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
224064419|NCT00948870|DRUG|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
224148700|NCT02892201|DRUG|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
224148701|NCT00703469|DRUG|MDX1106-02|Single dose
224148702|NCT00703469|DRUG|Placebo|Placebo single dose
224148703|NCT01826526|DEVICE|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
223454668|NCT02091414|DRUG|mycophenolate mofetil (MMF)|1.0 g PO BID
223454669|NCT02091414|DRUG|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
224064420|NCT04583098|OTHER|fecal microbiota transplantation|frozen or capsulized stool from donors who had already finished recommended blood \& stool screening for stool donors
224064421|NCT05939843|BEHAVIORAL|Pain Coping Information|A three minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery)
224148704|NCT02428907|BEHAVIORAL|simulation training|teamtraining of endoscopy staff
224148705|NCT06528730|DIAGNOSTIC_TEST|DCM|Confirm degenerative cervical myelopathy by Orthopaedic surgeon and MRI
224148706|NCT01385319|DEVICE|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
224064422|NCT05939843|BEHAVIORAL|Mindfulness Practice (alone)|A 3-minute audio-guided mindfulness practice.
224064423|NCT05939843|BEHAVIORAL|Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to the practice of mindfulness followed by a 2-minute audio-guided mindfulness practice
224064424|NCT05939843|BEHAVIORAL|Pain Introduction + Mindfulness Introduction + Mindfulness Practice|A 1-minute audio-recorded introduction to pain, followed by a 1-minute audio-recorded introduction the practice of mindfulness, followed by a 1-minute audio-guided mindfulness practice
224064425|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
224064426|NCT05974631|BEHAVIORAL|Dialectical Behavior Therapy Prolonged Exposure protocol|DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
224064427|NCT05974631|BEHAVIORAL|Prolonged Exposure therapy|Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
224064428|NCT05974631|BEHAVIORAL|Suicide risk management|Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
224064429|NCT01081912|DRUG|Placebo|Capsules, no active substance, shells identical to active comparator capsules
224064430|NCT01081912|DRUG|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
224064431|NCT05564143|PROCEDURE|EUS-guided gastroenterostomy (EUS-GE)|Treatment
224064432|NCT05564143|PROCEDURE|Laparoscopic gastroenterostomy (LGE)|Treatment
224064433|NCT02750033|DEVICE|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
224064434|NCT06849076|OTHER|Placebo Talocrural Joint Manipulation|This intervention is a classic method used to evaluate the effect of talocrural joint manipulation.
224064435|NCT06849076|OTHER|Talocrural Joint Manipulation|This technique, aiming to increase ankle dorsiflexion and mechanoreceptor activation, is based on the application of high velocity low amplitude traction to the joint.
224064436|NCT03175900|DRUG|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
224064437|NCT03175900|DRUG|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
224064438|NCT00920673|PROCEDURE|MRI|MRI during 35 to 65 minutes
224064439|NCT01920880|OTHER|Quantitative Sensory Testing analysis|
224064440|NCT03655613|BIOLOGICAL|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
224064441|NCT03655613|DRUG|APL-101|Oral specific c-Met inhibitor
224064442|NCT03655613|BIOLOGICAL|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
224064443|NCT05319171|DEVICE|TAVR|TAVR
224064444|NCT03413280|DRUG|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
224064445|NCT03413280|DRUG|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
224064446|NCT02868242|DRUG|LDV/SOF|Tablet(s) administered orally once daily
224064447|NCT01457807|DRUG|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
224064448|NCT01457807|DRUG|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
224148707|NCT01385319|DEVICE|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
224148708|NCT05034614|DIAGNOSTIC_TEST|Papette brush collection|Cervical cell brush that gathers collects cervical cells during Pap smear collection
224148709|NCT05034614|DIAGNOSTIC_TEST|Spatula/cytology brush collection|Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
224148710|NCT03892707|DRUG|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Milgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
224148711|NCT02835898|OTHER|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
224148712|NCT01807949|DRUG|Placebo|Matching placebo tablet
224148713|NCT01807949|DRUG|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
224148714|NCT01807949|DRUG|Ivacaftor|Film-coated tablet
224064449|NCT01457807|DRUG|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
224064450|NCT04639622|DIAGNOSTIC_TEST|Investigation procedures|All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
224148715|NCT03811171|DEVICE|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
223454670|NCT02091414|DRUG|corticosteroids|As per the practice of each participating center
223454671|NCT03665077|DIAGNOSTIC_TEST|Initial blood draw|At baseline, patients will undergo a blood draw.
223454672|NCT03665077|DIAGNOSTIC_TEST|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
224064451|NCT01493453|GENETIC|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10\*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
224148716|NCT01841918|BIOLOGICAL|Avian Flu Vaccine|
224148717|NCT02996955|BEHAVIORAL|social support|behaviour change intervention
224148718|NCT02996955|BEHAVIORAL|treatment of illness perceptions|educational interview
224148719|NCT02996955|DEVICE|Activ8|wearing a move monitor
224148720|NCT02996955|OTHER|activity advice|walking or cycling 5 days a week during at least half an hour
224148721|NCT06067308|DIAGNOSTIC_TEST|Performance of CTPA|Exposure to CT scan and injection of IV contrast
224148722|NCT04254432|DEVICE|remote ischemic conditioning|RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
224148723|NCT01786863|PROCEDURE|Neuromuscular blockade|
224148724|NCT01288586|DEVICE|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
224148725|NCT01457924|DRUG|Ofatumumab 3mg|3mg of investigational product
224148726|NCT01457924|DRUG|Ofatumumab 30mg|30mg of investigational product
224148727|NCT01457924|DRUG|Ofatumumab 60mg|60mg of investigational product
224148728|NCT01457924|DRUG|Placebo|Placebo
224148729|NCT05018637|DRUG|WJ-MSC|"Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months."
223454673|NCT03665077|DIAGNOSTIC_TEST|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
223454674|NCT03665077|DIAGNOSTIC_TEST|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
223454675|NCT03665077|DIAGNOSTIC_TEST|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
223454676|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
223742760|NCT06712745|RADIATION|Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)|Radiation Therapy Prescription Dose: A dose of 40-50 Gy in 5 fractions prescribed to the PTV will be used for all cases
224148730|NCT05018637|DRUG|Teriparatide|subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
224148731|NCT02988492|DEVICE|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
224148732|NCT01002404|PROCEDURE|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
224148733|NCT02992873|DEVICE|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
224148734|NCT02992873|DEVICE|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
224148735|NCT01877590|DRUG|alpha-lipoic acid|
224148736|NCT02639923|PROCEDURE|Drawing of 7ml peripheral blood|puncture peripheral vein
224148737|NCT04342416|BEHAVIORAL|Visiospatial Interference|Behavioral: Brief cognitive intervention. A one-session intervention with a researcher including a simple cognitive task (a memory cue and 25 minutes of Tetris game play with mental rotation) with instructions to engage in the task self-guided in the subsequent weeks.
223454677|NCT00551174|DRUG|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
223454678|NCT00435461|DRUG|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
223454679|NCT00205660|OTHER|Stayers|Participants remain on their current antipsychotic.
223454680|NCT00205660|OTHER|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
223454681|NCT05335655|DRUG|Dexmedetomidine injection|IV initial bolus and trans operative dexmedetomidine infusion.
223454682|NCT05335655|DRUG|Sodium Chloride 0.9% infusion|IV initial bolus and trans operative infusion of 0.9% saline solution.
223742761|NCT04406727|BIOLOGICAL|UB-421|UB-421 in combination with their ARV
223742762|NCT04406727|OTHER|Antiretroviral (ARV)|Antiretroviral (ARV)
223742763|NCT06862128|DIAGNOSTIC_TEST|OGTT at home using CGM|OGTT at home using CGM
224148738|NCT01181141|DRUG|DU-176b (edoxaban)|
224148739|NCT01181141|DRUG|Enoxaparin sodium 20mg|
224148740|NCT02343419|OTHER|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
224148741|NCT02482649|BEHAVIORAL|EAA/T|bi-weekly for 12weeks
224148742|NCT02482649|DRUG|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
224148743|NCT02482649|DRUG|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
224148744|NCT05786534|DIETARY_SUPPLEMENT|Green Seaweed|400 mg per day
224148745|NCT06382948|DRUG|Everolimus|Patients will receive 7.5 mg of everolimus orally once daily.
224148746|NCT06382948|DRUG|Elacestrant|Patients will receive elacestrant 345 mg orally once daily
224148747|NCT06382948|DRUG|Placebo|Patients will receive placebo orally once daily
224148748|NCT06382948|DRUG|Auxiliary Medicinal Product - Dexamethasone|10 mL of alcohol-free dexamethasone 0.5 mg per 5 mL mouthwashes (swish for 2 min and spit, four times daily for 8 weeks). After 8 weeks, dexamethasone mouthwash could be continued for up to eight additional weeks at the discretion of the clinician and patient. Used for prevention of treatment-induced stomatitis.
224148749|NCT06382948|DRUG|Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues|According to clinical practice (for premenopausal/perimenopausal patients and male patients in both treatment arms). Used to suppress estrogen production.
224148750|NCT02162121|PROCEDURE|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
224148751|NCT02162121|PROCEDURE|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
224148752|NCT02162121|PROCEDURE|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
224148753|NCT02162121|PROCEDURE|Intravenous analgesia|Ketorolac 30mg 3 times a day
224148754|NCT02162121|PROCEDURE|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS\>4
224148755|NCT02162121|DRUG|Mepivacaine 1%|
224148756|NCT02162121|DRUG|Levobupivacaine 0,5%|
224148757|NCT02162121|DRUG|Ropivacaine 0,2%|
224148758|NCT02162121|DRUG|Ketorolac 30mg|
224148759|NCT02162121|DRUG|Buprenorphine 0,2mg|
224148760|NCT02162121|DEVICE|Stimulong, Pajunk, Germany.|
224148761|NCT02162121|PROCEDURE|Continuous lumbar plexus: non-stimulating catheter|
224148762|NCT03296865|DEVICE|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
224148763|NCT03810001|BEHAVIORAL|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
224148764|NCT05200429|DRUG|Trikafta|Highly Effective CFTR Modulator Therapy
224148765|NCT04591145|OTHER|Observational group|Patient receive the standard bowel preparation strategy and routine colonoscopy
224148766|NCT02890043|PROCEDURE|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
224148767|NCT02890043|PROCEDURE|free-hand surgery|traditional free-hand surgery
223454683|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
223454684|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
223454685|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
223454686|NCT01280526|DRUG|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
223454687|NCT02217670|DRUG|Metformin 1000 mg granules|
223454688|NCT02217670|DRUG|Metformin 1000 mg film-coated tablets|
223454689|NCT05631145|OTHER|MT Combined With XKSA|Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.
223454690|NCT05631145|OTHER|MT|Morita therapy (MT) comprised bed rest and light work.
223454691|NCT00004057|DRUG|L-778,123|
223454692|NCT00004057|DRUG|paclitaxel|
223454693|NCT01089010|DRUG|Placebo|Matching placebo in capsules administered as a single oral dose.
223454694|NCT01089010|DRUG|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
223454695|NCT01089010|DRUG|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
223454696|NCT00868647|PROCEDURE|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
223454697|NCT05830890|PROCEDURE|Sentinel lymph node biopsy|After the total mesorectal excision, the indocyanine green was injected around the tumor via the anus. The fluorescence laparoscope was used to visualize and locate the sentinel lymph node, which was then removed and sent for rapid frozen pathological examination. Subsequently, a lateral lymph node dissection was performed.
223742764|NCT06862128|DIAGNOSTIC_TEST|OGTT at the clinic|OGTT at the clinic
224148768|NCT02890043|DEVICE|TiRobot system|a robot-assisted spine surgery system
224148769|NCT01770899|DRUG|Montelukast|
224148770|NCT01770899|DRUG|Placebo|Gelatin capsule given every 24 hours
224148771|NCT02253641|BEHAVIORAL|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
224148772|NCT02253641|BEHAVIORAL|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
224148773|NCT00188357|BEHAVIORAL|Education|
224148774|NCT02722772|DRUG|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
224148775|NCT02722772|OTHER|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
224148776|NCT05060172|DEVICE|Bloomlife MFM-Pro|"Bloomlife MFM-Pro is a non-invasive, wireless, external monitoring system used to measure fetal heart rate, maternal heart rate, and uterine activity during antepartum (non-stress) testing on pregnant women with a singleton pregnancy.~The system acquires biopotential signals from abdominal surface electrodes and measures the fetal electrocardiography, maternal electrocardiography, electrohysterography, as well as accelerometer data."
224148777|NCT02682160|OTHER|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
224148778|NCT06391476|OTHER|Study of the evolution of a cohort of children born between 22 and 25 weeks gestational age|"* Study of mortality in a cohort of children born between 22 and 25 weeks gestational age~* Study of neonatal morbidity~* Description of postnatal growth~* Description of nutrition and breastfeeding at discharge~* Study of the neurological, respiratory and growth outcome at 2 years."
224148779|NCT04767295|DRUG|Camrelizumab, Albumin Paclitaxel, Carboplatin|Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)
224148780|NCT03051828|PROCEDURE|fencing|No intervention: practice fencing
224148781|NCT02189304|DRUG|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
224148782|NCT02189304|DRUG|PT009|PT009 administered as 2 inhalations
224148783|NCT02189304|DRUG|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
224148784|NCT01171287|PROCEDURE|Driving with an Aircast Walker|
224148785|NCT01171287|PROCEDURE|Driving with a walking cast|
224148786|NCT01171287|PROCEDURE|Driving with a running shoe|
224148787|NCT01245205|DRUG|Akt inhibitor MK2206|Given PO
224148788|NCT01245205|DRUG|lapatinib ditosylate|Given PO
223454698|NCT05830890|DRUG|Indocyanine green solution|Indocyanine green was injected around the tumor via the anus to visualize the sentinel lymph nodes under the fluorescence laparoscope.
223454699|NCT05830890|DEVICE|fluorescence laparoscope|The fluorescence laparoscope was used to visualize and locate the sentinel lymph node.
223454700|NCT05830890|DIAGNOSTIC_TEST|pathological examination|The surgical specimens and sentinel lymph nodes were routinely examined for pathology.
223454701|NCT05830890|DIAGNOSTIC_TEST|rapid frozen pathological examination|The lateral green fluorescence imaging sentinel lymph nodes found during surgery was sent to make cryosections. And then a pathologist makes a rapid diagnosis under a microscope。
223454702|NCT05830890|PROCEDURE|total mesorectal excision|"1. Sharply dissect the vascular interface between the pelvic fascia parietal layer and the visceral layer around the mesentery under direct vision to ensure that the rectal mesentery of the resected specimen is intact and tearless.~2. For medium and low rectal cancer: the distal intestinal tube of the tumor should be resected ≥ 2 cm.~3. TME or mesenteric distal resection margin ≥ 5 cm away from the tumor."
223454703|NCT06071741|PROCEDURE|Percutaneous Coronary Intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
223454704|NCT06411210|DRUG|Semaglutide Pen Injector|Escalated to 2.4mg or max tolerated dose
223454705|NCT06411210|DRUG|Placebo|Matched placebo.
223454706|NCT03642600|DIETARY_SUPPLEMENT|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
223571972|NCT04853693|BEHAVIORAL|Enhanced Treatment As Usual|Referral to treatment in the community, clinical monitoring
223571973|NCT01187446|RADIATION|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
223571974|NCT01187446|DRUG|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
223571975|NCT02241330|DIETARY_SUPPLEMENT|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
223571976|NCT02241330|DIETARY_SUPPLEMENT|Fortification|Wheat flour is fortified before testmeal preparation
223571977|NCT02241330|DIETARY_SUPPLEMENT|Control|wheat flour is used as control comparator.
223571978|NCT03000543|BIOLOGICAL|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
223571979|NCT03739957|DEVICE|BPCO Media Kit|Telemonitoring system for patients with COPD
223454707|NCT03642600|DRUG|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
223571980|NCT02574013|DEVICE|Endoractor®|Endoscopic sponge for retraction of small intestine
223571981|NCT00820482|DRUG|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
223571982|NCT00820482|DRUG|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
223571983|NCT03333148|DRUG|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
223571984|NCT03333148|OTHER|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
223571985|NCT02753634|BEHAVIORAL|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
224148789|NCT01245205|OTHER|pharmacological study|Correlative studies
224148790|NCT01245205|OTHER|laboratory biomarker analysis|Correlative studies
224148791|NCT03763799|PROCEDURE|PCR-based microbiological diagnosis strategy|A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
224148792|NCT03763799|PROCEDURE|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
224148793|NCT00290589|DRUG|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
224148794|NCT00290589|DRUG|Placebo|Normal saline intramuscular injection
224148795|NCT02272283|DEVICE|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
224148796|NCT00118911|BEHAVIORAL|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
224148797|NCT00118911|OTHER|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
224148798|NCT05479305|DEVICE|The Valiant Captivia Stent Graft|Aortic arch/Descending aorta Repair
224148799|NCT05656287|OTHER|SMS texts + incentives + Wisepill device for medication monitoring|For the first two months, 54 participants will receive i) daily SMS medication reminders, ii) monthly mobile money for transport to the clinic, and iii) monthly mobile money incentives if \>90% medication adherence. For the remaining four months, the participants will receive: i) weekly medication SMS reminders, ii) monthly mobile money for transport to the clinic, iv) monthly mobile money incentives if \>90% medication adherence.
224148800|NCT05656287|OTHER|SMS texts only + Wisepill device for medication monitoring|For the first 2 months, 54 participants will receive daily SMS medication reminders, ii). For the remaining 4 months, the participants will receive weekly medication SMS reminders. All participants will also receive a Wisepill device for medication monitoring.
224148801|NCT05656287|OTHER|Wisepill device for medication monitoring only|Participants (54) in the Control arm will not receive SMS reminders or mobile money. All participants will also receive a Wisepill device for medication monitoring.
224148802|NCT05128604|DEVICE|Gastroenterostomy|Endoscopic ultrasound guided gastroenterostomy
224148803|NCT01958879|DRUG|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
224148804|NCT01958879|DRUG|ringer without corticosteroid|200 mL Ringer solution
224148805|NCT04122586|DRUG|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
224148806|NCT02204033|DRUG|99mTc - labelled hMAb BIWA 4|
224148807|NCT02204033|DRUG|186 Re - labelled hMAb BIWA 4|
224148808|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - low dose|
224148809|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - medium dose|
224148810|NCT02204033|DRUG|unlabelled hMAb BIWA 4 - high dose|
224148811|NCT01438307|DRUG|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
224148812|NCT01438307|DRUG|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
224148813|NCT02307318|DEVICE|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
224148814|NCT02908633|PROCEDURE|canaloplasty and phacoemulsification|
224148815|NCT03594864|PROCEDURE|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
224148816|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
224148817|NCT00973622|DEVICE|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
224148818|NCT00973622|DEVICE|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
223454708|NCT05534815|BEHAVIORAL|Employment-based abstinence reinforcement|Participants will earn stipends for working with the employment specialist and wage supplements for working in a community job, but the stipends and wage supplements will depend on providing drug-free urine samples.
223454709|NCT03724045|DIETARY_SUPPLEMENT|Back Side of the Moon|"The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.~Follow-up during consultation on pneumology until max. 6 months post-admission on the ICU."
223454710|NCT06803043|BEHAVIORAL|SAH|"SAH is a group trauma informed intervention that uses motivational strategies and self-monitoring of one's thoughts and responses. It provides a unique fusion of interventions for trauma and IPV and consists of 12 two-hour weekly sessions. Throughout the program, group members complete in-session practice exercises and are provided practice assignments to consolidate and apply information learned in group."
223454711|NCT06803043|BEHAVIORAL|TAU|TAU is a court mandated 20 week, psychoeducational/directed program that emphasizes the sharing of power and control in relationships and personal accountability. Topics also focus on equality wheels, substance abuse impacts, culture and socialization impact on gender roles, defense mechanisms versus coping skills, triggers for stress and anger, and healthy versus unhealthy communication.
223454712|NCT05469620|DIETARY_SUPPLEMENT|Meal|Either a meal kit low in sodium, potassium, and phosphorus; or a meal kit low in sodium only is provided based on predefined logic. Meal kits are delivered in bulk twice a week, meant to replace one meal a day.
223571986|NCT05264441|DEVICE|In-Check DIAL G16|Patients will inspire into an In-Check DIAL G16 device.
224148819|NCT05960513|BEHAVIORAL|Breathing Exercises followed by Meditation|Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
224148820|NCT04814407|DIAGNOSTIC_TEST|Blood-derived DNA methylation detection|Up to 20 ml of blood will be collected from each subject, and the blood specimen will be processed to isolate plasma cell-free DNA and immune-derived cells (circulating T cells). Circulating methylated tumor/immune signature will then be identified.
224148821|NCT04436588|GENETIC|Epigenetic signatures|Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
224148822|NCT03991182|OTHER|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
224148823|NCT03991182|OTHER|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
224148824|NCT03991182|BEHAVIORAL|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
224148825|NCT03991182|OTHER|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
224148826|NCT02525887|OTHER|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
224148827|NCT05521971|OTHER|multifaceted pharmacist-led intervention|"* Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone."
224148828|NCT05521971|OTHER|Usual care group|all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
224148829|NCT03948269|BEHAVIORAL|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
224148830|NCT05718453|COMBINATION_PRODUCT|Laboratory Tests|Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
224148831|NCT04517227|DRUG|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
224148832|NCT04517227|PROCEDURE|Transcatheter Hepatic Arterial Chemoembolization (TACE)|TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.
224148833|NCT04517227|PROCEDURE|Ablation|In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).
223454713|NCT05469620|OTHER|Education|Leaflet or video education materials on seven nutrition-related topics are provided, based on predefined logic. Materials are sent throughout the week, via SMS links.
223454714|NCT01592123|PROCEDURE|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
223571987|NCT01546441|BEHAVIORAL|interprofessional assessment|assessment by interprofessional team
223571988|NCT01546441|BEHAVIORAL|usual care|usual care in primary care clinic
223454715|NCT01592123|BEHAVIORAL|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score \>5 is considered to be suggestive of significant sleep disturbance.
223584101|NCT02938273|DRUG|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
223584102|NCT02938273|RADIATION|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
223584103|NCT02938273|DRUG|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
223584104|NCT00413010|DRUG|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
223584105|NCT00413010|DRUG|placebo|placebo + concurrent GAD treatment from the open-label study period
223584106|NCT04494724|DRUG|Clazakizumab|Infusion
224148834|NCT02538939|DRUG|Sodium thiosulfate|
224148835|NCT04649619|PROCEDURE|GASTRIC BYPASS MODIFIED IN ROUX-EN-Y AS A THERAPEUTIC OPTION IN PATIENTS WITH INDICATION OF BARIATRIC AND / OR METABOLIC SURGERY|"Roux-en-Y gastric bypass:~Stapling and reduction of the gastric chamber of approximately 18 cm, followed by anastomosis with a deviated bowel, and another bowel anastomosis with a bowel in a lower portion, for deviation of biliopancreatic secretions. Maintenance of a gastro-gastric communication of approximately 1 cm between the functional gastric pouch and the excluded stomach for endoscopic access."
224148836|NCT00707538|DRUG|BMS747158|2 IV injection of \~11 mCi (total) F-18 labeled compound
224148837|NCT05592041|DRUG|Banaba Leaf Extract|a herbal extract in the form of Bigel
224148838|NCT00702247|PROCEDURE|Hematopoietic Stem Cell Transplantation|
224148839|NCT03123055|DRUG|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
224148840|NCT03123055|DRUG|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
224148841|NCT05431569|DRUG|6MW3211|6MW3211 injection ,30mg/kg,iv drip，Q2W
224148842|NCT01566201|DRUG|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
224148843|NCT01566201|DRUG|placebo|water for injection
224148844|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
224148845|NCT00835003|PROCEDURE|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
224148846|NCT03814005|DRUG|Azacitidine|Azacitidine subcutaneous or intravenous injection.
223454716|NCT01592123|BEHAVIORAL|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
224148847|NCT03814005|DRUG|Pevonedistat|Pevonedistat intravenous infusion.
224148848|NCT06218511|BIOLOGICAL|Peptide-based hepatocellular carcinoma vaccine IMA970A|IMA970A is a lyophilized multi-peptide vaccine consisting of 17 individual peptides (active pharmaceutical ingredients) and 2 excipients (Poloxamer 338 and Mannitol). All peptides have been chemically manufactured by well established solid phase peptide synthesis procedures. All peptides are composed of linear, unmodified L- amino acid chains with chain length in the range of 9 to 21 amino acids.
224148849|NCT06218511|COMBINATION_PRODUCT|Durvalumab|anti-PD-L1
224301670|NCT05903456|PROCEDURE|TACE（transcatheter arterial chemoembolization）|"TACE treatment is strictly in accordance with the Chinese guidelines for clinical practice of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (2018 Edition).~The patients with HCC were selected according to the inclusion criteria (referring to the conditions of the subjects). The subjects who met the inclusion criteria could enter the study after they signed the informed consent. 4-6 weeks after the first TACE treatment, the resectability criteria were evaluated. If not, the next cycle of TACE treatment was carried out. The general principle is to reduce the number of interventional treatment and extend the interval of interventional operation as far as possible under the condition of controlling the tumor and the survival of patients with tumor."
224148850|NCT06218511|OTHER|Montanide (Adjuvant)|Montanide ISA™ 51 is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family with immune stimulatory effect .
224148851|NCT04026971|PROCEDURE|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
223584107|NCT04494724|DRUG|Placebo|Infusion
224148852|NCT03395223|DRUG|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
223584108|NCT01778920|DRUG|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
224148853|NCT05736978|DRUG|Azacitidine|75mg/m2 d1-7
224148854|NCT05736978|DRUG|Venetoclax|d1 100mg, d2 200mg, d3-28 400mg
224148855|NCT05736978|DRUG|Selinexor|if MRD positive in C1D14, selinexor 60mg D15, D22
224148856|NCT00975026|PROCEDURE|Massages ± Stretches|Chair Massage
224148857|NCT01236794|BEHAVIORAL|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
224148858|NCT04503863|DRUG|NPC-22|Single administration of middle dose NPC-22
224148859|NCT04503863|DRUG|NPC-22|Single administration of high dose NPC-22
224148860|NCT04503863|DRUG|NPC-22 Placebo|Single administration of NPC-22 Placebo
224148861|NCT03753815|DEVICE|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
224148862|NCT03753815|DEVICE|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
224148863|NCT02284230|DRUG|Liraglutide|
224148864|NCT02284230|DRUG|Placebo|
224148865|NCT01379170|DRUG|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
224148866|NCT05552807|DRUG|SCT-I10A|Administered intravenously
224148867|NCT05552807|DRUG|SCT200|Administered intravenously
224148868|NCT05552807|DRUG|paclitaxel|Administered intravenously
224148869|NCT05552807|DRUG|docetaxel|Administered intravenously
224148870|NCT01069367|BIOLOGICAL|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
224148871|NCT00895778|OTHER|Neuromuscular blockade with rocuronium and reversal with sugammadex|
224148872|NCT04446299|DRUG|Bowel Prep|Orally ingested liquid bowel preparation
224148873|NCT01267344|DRUG|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
224148874|NCT01267344|DRUG|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
223454717|NCT01592123|BEHAVIORAL|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
224148875|NCT01113190|BEHAVIORAL|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
224148876|NCT01113190|BEHAVIORAL|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller \& Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
224148877|NCT01113190|BEHAVIORAL|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
224148878|NCT01113190|BEHAVIORAL|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
224148879|NCT00035152|DRUG|Paclitaxel and carboplatin|
224148880|NCT02275910|DRUG|E7090|
224301671|NCT05903456|DRUG|lenvatinib|Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
223454718|NCT02999841|DRUG|Acarbose|1-2 week: 50mg tid; 3-24 week: 100mg tid.
223454719|NCT02999841|DRUG|Vildagliptin|1-24 week: 50mg bid
223454720|NCT00552708|DRUG|COREG CR|
223454721|NCT00552708|DRUG|Lisinopril|
223454722|NCT04687826|OTHER|Goal directed fluid therapy|Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.
223454723|NCT04687826|OTHER|Liberal fluid therapy|Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
223454724|NCT01639248|DRUG|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
223454725|NCT01858415|DEVICE|TriPollar|
223454726|NCT02306850|DRUG|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
223454727|NCT00237692|BEHAVIORAL|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
223742765|NCT04104178|DRUG|Clindamycin|Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
223742766|NCT04104178|DRUG|Placebo|Placebo
223742767|NCT06998433|BIOLOGICAL|Platelet-Rich Plasma (PRP) Injections|PRP will be injected into the affected scalp.
224148881|NCT06980350|DRUG|PD-1 Inhibitors|Patients received at least two doses of anti-PD-1 immunotherapy in a neoadjuvant setting.
223454728|NCT00237692|BEHAVIORAL|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
223454729|NCT00237692|BEHAVIORAL|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral \& medication management
224148882|NCT05896046|DRUG|SHR2554+ SHR1701|SHR2554: 350mg/day, PO, twice a day. SHR1701: recommended dose from phase I trial, IV, over 30 minutes.
224148883|NCT05896046|DRUG|SHR-1701|Phase I: 30-150 mg/kg, IV over 30 minutes. Phase II: recommended dose from phase I trial, IV over 30 minutes.
224148884|NCT03819478|BEHAVIORAL|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a \~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
224148885|NCT03819478|BEHAVIORAL|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
224148886|NCT03819478|DIETARY_SUPPLEMENT|NutraBio™ CarboMax Supplement|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (NutraBio™ CarboMax, \~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
224148887|NCT03819478|DIETARY_SUPPLEMENT|6-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 6-month higher protein / lower CHO diet group (6-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
224148888|NCT03819478|DIETARY_SUPPLEMENT|18-month NutraBio™ 100% Whey Protein Isolate Supplement|Participants in the 18-month higher protein / lower CHO diet (18-mo HiProt) will be provided a protein supplement (NutraBio™ 100% Whey Protein Isolate, \~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention and the 12-month follow-up.
224148889|NCT00516412|DRUG|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
224148890|NCT00516412|GENETIC|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
223571989|NCT01512680|BEHAVIORAL|Education to Functional Insulin Therapy|"* Intake of Continuous Glucose Monitor for 5 to 7 days~* Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~* 1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~* 3 months after the training: Blood sampling, vital signs and data on diabetes~* 6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~* 9 months after the training: Blood sampling, vital signs and data on diabetes~* 1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~* 12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
223571990|NCT04303143|BEHAVIORAL|Self-Hypnosis|Self-Hypnosis
223571991|NCT04303143|BEHAVIORAL|Direct Autonomic Experience Control|Direct Autonomic Experience Control. Use of learned mental tool/process to affect outcome measure of SUDS discomfort experience. (eg. Squeeze hand as pre-learned mental anchor to relieve discomfort in lower legs)
223571992|NCT00460278|DRUG|XL418|
223571993|NCT00149994|DRUG|Cyclosporine A|
223571994|NCT00149994|DRUG|Tacrolimus|
223571995|NCT00149994|DRUG|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
223571996|NCT00149994|DRUG|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
223571997|NCT00149994|DRUG|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
223742768|NCT06998433|DRUG|Saline|Placebo saline solution will be injected into affected scalp.
223454730|NCT02420262|DRUG|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
223454731|NCT02420262|DRUG|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
223454732|NCT02420262|DRUG|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
223454733|NCT01456143|DEVICE|High Resolution Microendoscopy (HRME)|High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
223454734|NCT01456143|OTHER|Proflavine hemisulfate|0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
223571998|NCT02280824|PROCEDURE|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
223571999|NCT02280824|DEVICE|Amplatzer Duct Occluder|
223572000|NCT03402971|DIAGNOSTIC_TEST|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
224148891|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
224148892|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
224148893|NCT01080612|DRUG|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
224148894|NCT01080612|DRUG|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
224148895|NCT05876104|BEHAVIORAL|Behavioral therapy|Behavioral and supportive therapy
224148896|NCT00111111|DRUG|Etanercept|
224148897|NCT03965793|DEVICE|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
224148898|NCT01855945|BIOLOGICAL|Swine Influenza|Comparison of different dosages of vaccines
223454735|NCT05050448|DEVICE|Sustained Acoustic Device with 2.5% Diclofenac Patch|Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
224148899|NCT04095468|RADIATION|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
224148900|NCT02967094|DRUG|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
223572001|NCT00504855|OTHER|Casting using Gortex (waterproof) cast padding materials|
224148901|NCT02967094|DRUG|Administration of water before upper endoscopy|
224148902|NCT06325306|BEHAVIORAL|Traditional APA|12 sessions of 1,5 hour are organized (once per week). The first session is primarily focused on the PL assessment, followed by a comprehensive introduction to physical conditioning exercises. Each of the subsequent sessions (n=10), participants will receive an intervention focused on the development of their physical fitness (endurance, strength, flexibility, balance). Each session will commence with a 15 minute warm-up comprising of a blend of cardiovascular and joint mobilization exercises. The core part of each session will be dedicated to session-specific exercises targeting key physical competencies such as endurance, strength, flexibility, and balance, along with other motor skills. . The size of the group will never exceed a number of 15 participants. At the conclusion of each session, participants will be guided through a return-to-calm sequence that included stretching and relaxation exercises.
224148903|NCT06325306|BEHAVIORAL|APA+PL|The general content and duration of this intervention is the same as in the traditional APA intervention, but with an extra particular and explicit emphasis on PL dimensions (6) during the sessions. While the dimension of physical competence is consistently incorporated into the sessions, the remaining 5 dimensions of PL are addressed twicely over the course of the semester with the setting of specific goals and intervention content. This could involve quizzes or games integrated into circuits or exercise workshops, role-play exercises simulating real-life situations, or social interactions between participants with a particular focus on PL-related topics. In addition to the sessions, a follow-up telephone call is scheduled between the educator and each participant during the 2 weeks following the initial PL assessment to share individual PL assessment results and assist participants in setting person-centered goals using a motivational interviewing technique.
223572002|NCT00504855|OTHER|Casting using cotton/cotton-poly cast padding materials|
223572003|NCT01978249|PROCEDURE|Systemic chemotherapy|
223572004|NCT01978249|PROCEDURE|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
223572005|NCT02235675|DEVICE|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
224148904|NCT01824264|DRUG|LIK066|Experimental treatment doses
224148905|NCT01824264|DRUG|Sitagliptin|Active comparator treatment dose
224148906|NCT01824264|DRUG|Placebo|Placebo comparator dose
224148907|NCT04105647|BEHAVIORAL|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
223454736|NCT05050448|DRUG|1% Diclofenac Topical Gel|Topical pain-relief gel
223454737|NCT05391555|DRUG|Remifentanil Hydrochloride|Infusion of 0.2 µg/k/m for 5 minutes, the 0.3 µg/k/m for 5 minutes.
223454738|NCT05391555|DEVICE|Pupillometry measurement|Pupillary measurements were taken at baseline and every 2.5 minutes during the 10-minute infusion and 25-minute recovery period.
223572006|NCT05480215|DEVICE|Cala Device|transcutaneous afferent patterned stimulation (TAPS)
223572007|NCT02681796|DRUG|Bupivacaine|
223572008|NCT05108454|DRUG|Multiple micronutrient supplementation|Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
223572009|NCT03659903|PROCEDURE|pancreaticoduodenectomy|pancreaticoduodenectomy
223572010|NCT06082596|DRUG|BEBT-908 for injection|"Dose escalation phase：10 or 15、22.5、33.75、45mg/m2, intravenous drip, firstly single dose, after the observation period, the drug was administered continuously for 1 cycle (21 days), 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week.~Dose expansion phase：15 or 22.5mg/m2，intravenous drip, 3 times a week, continuous administration for 2 weeks and withdrawal for 1 week，21 days as cycle."
223572011|NCT02031835|PROCEDURE|BWSTT (3 days a week for maximum of 20 minutes session)|
223572012|NCT01789060|OTHER|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
223572013|NCT04316611|DRUG|Potassium chloride|Direct intravenous injection (IVD) 20 mmol potassium chloride
223572014|NCT01872039|DRUG|Perdipine injection|IV
223572015|NCT04881929|DRUG|KN026|KN026 in Combination With Docetaxel
223572016|NCT00369005|PROCEDURE|Red blood cell transfusion guidelines|
223572017|NCT00785551|DRUG|quinine sulfate|2 x 324mg given in one dose to healthy subjects
224148908|NCT04105647|BEHAVIORAL|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
224148909|NCT00909519|DRUG|naproxcinod|naproxcinod 750 mg bid
224148910|NCT00909519|DRUG|Naproxen|Naproxen 500 mg bid
224148911|NCT00909519|DRUG|placebo|placebo
224301672|NCT05903456|DRUG|Icaritin soft capsules|Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
223572018|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
224301673|NCT05211661|DIAGNOSTIC_TEST|Respiratory Muscle Testing|Comprehensive assessment of respiratory muscle function. Comprehensive assessment of respiratory muscle function to the point of its invasive assessment with recordings of twitch transdiaphragmatic pressure in response to magnetic phrenic nerve stimulation and stimulation of the lower thoracic nerve roots.
224301674|NCT03882528|BIOLOGICAL|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
224301675|NCT02385253|BEHAVIORAL|Educational training program|"The educational training program (intervention) consists of four sequential phases:~1. Knowledge Acquisition~2. Skills Assessment~3. Deliberate Practice~4. Clinical Proficiency"
223454739|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
223454740|NCT04032834|COMBINATION_PRODUCT|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
223454741|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
223454742|NCT04032834|COMBINATION_PRODUCT|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
223454743|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
223454744|NCT04032834|COMBINATION_PRODUCT|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
223454745|NCT02238756|BIOLOGICAL|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
223454746|NCT02238756|BIOLOGICAL|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
223454747|NCT02238756|BIOLOGICAL|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
224148912|NCT00909519|DRUG|furosemide|furosemide
224148913|NCT01135017|DRUG|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
224301676|NCT02789397|DRUG|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
223454748|NCT02378974|BIOLOGICAL|Cordstem-ST|
223454749|NCT02378974|BIOLOGICAL|Placebo|
223454750|NCT04708899|BEHAVIORAL|arabic version of differential processing training program|comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).
223454751|NCT04708899|BEHAVIORAL|Arabic computer based auditory traing program(CBAT)|comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
223454752|NCT01630018|DRUG|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
223454753|NCT01630018|DRUG|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
223454754|NCT02580253|DRUG|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
223454755|NCT02580253|DRUG|mFOLFOX6|Oxaliplatin,Fluorouracil
223572019|NCT00785551|DRUG|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
223584109|NCT02179255|DRUG|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
224148914|NCT01135017|DRUG|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
224148915|NCT02136511|DRUG|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
224148916|NCT02136511|DRUG|Rituximab|Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
224148917|NCT01148693|DRUG|gentamicin|10mg per 10ml of contrast media
224148918|NCT01148693|DRUG|Placebo|Distilled water
224148919|NCT01695213|PROCEDURE|uncemented total hip arthroplasty|
224148920|NCT03313856|DRUG|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
224148921|NCT03313856|DRUG|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
223454756|NCT01850394|DRUG|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
224148922|NCT02410096|OTHER|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
224148923|NCT02410096|OTHER|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
224148924|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
224148925|NCT02410096|DIETARY_SUPPLEMENT|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
223454757|NCT01850394|DRUG|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
224148926|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
224301677|NCT02789397|DRUG|Placebos|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
224301678|NCT04731337|DEVICE|Digital Caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)|Measuring the vertical distance between the tip of the upper and lower canine teeth.
223454758|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 1.5T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
223454759|NCT04475627|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR) imaging at 3T|Long and short axis bSSFP cines images, long and short axis tagging images and aortic cine images will be obtained. Participants will be randomised to either have cine or tagging images obtained first.
223454760|NCT00233584|PROCEDURE|Pulmicort (budesonide) pMDI|
223454761|NCT02587767|DEVICE|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
223454762|NCT02587767|DEVICE|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
223454763|NCT00074815|DRUG|Serotonin reuptake inhibitors management|"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."
223454764|NCT00074815|BEHAVIORAL|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
224148927|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
224148928|NCT00033228|BIOLOGICAL|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
224148929|NCT04114344|PROCEDURE|TAPP|Trans Abdominal Pre Peritoneal approach
224148930|NCT04114344|PROCEDURE|TEP|Total Extra Peritoneal approach
224148931|NCT03351439|DRUG|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
224148932|NCT03351439|DRUG|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
224148933|NCT03351439|DRUG|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
224148934|NCT03351439|DRUG|Percocet|Standard of Care
224148935|NCT03351439|DRUG|Naprosyn|Standard of Care
224148936|NCT03076125|BEHAVIORAL|SCORRE|3 components based on the Health Belief Model
224148937|NCT03076125|BEHAVIORAL|Attention-Control Activity|sexual health education
224301679|NCT04830059|BEHAVIORAL|Exercise|Two types of exercise intervention and control group
224148938|NCT03178812|PROCEDURE|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
224148939|NCT03178812|DIAGNOSTIC_TEST|Laboratory Blood test|Laboratory Blood Test
224148940|NCT03688685|DRUG|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
224148941|NCT04099849|DIETARY_SUPPLEMENT|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
224148942|NCT04099849|DIETARY_SUPPLEMENT|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
224148943|NCT04099849|DIETARY_SUPPLEMENT|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
224148944|NCT03048942|DRUG|Cabazitaxel|3 weekly cyctotoxic chemotherapy
224148945|NCT03048942|DRUG|Paclitaxel|Weekly cyctotoxic chemotherapy
224148946|NCT02219711|DRUG|MGCD516|MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
224148947|NCT01074658|DEVICE|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
224148948|NCT03748485|BEHAVIORAL|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
224148949|NCT03748485|DRUG|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
224148950|NCT02879916|DRUG|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
224148951|NCT02879916|DRUG|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
224148952|NCT00229229|OTHER|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
224148953|NCT00229229|OTHER|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
224148954|NCT00229229|OTHER|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
224148955|NCT00229229|OTHER|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
224148956|NCT02899741|DRUG|Omega-3|1000mg every day for 90 days
223454765|NCT00074815|BEHAVIORAL|Instructional cognitive behavioral therapy by a psychiatrist|"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."
223454766|NCT05433545|OTHER|Questionnaire|Adolescents with spinal deformity will be asked to fill out a new questionnaire measuring the quality and quantity of adherence to specific physiotherapy exercises performed at home. Patients will be recruited at an outpatient service dedicated to the treatment of vertebral deformities during the monthly sessions with the physiotherapist
223454767|NCT00954525|DRUG|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
223454768|NCT00954525|DIETARY_SUPPLEMENT|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
223454769|NCT05964283|OTHER|Questionnaire|This questionnaire consists of (five) main parts. The first part is about personal information, the second part is about fluid administration in various settings (emergency room, operating room, and intensive care unit), the third part is about fluid administration behaviors, the fourth part is about workplace location, and the fifth part is about a case study. Filling out this questionnaire will take approximately 60 minutes of your time.
223454770|NCT02234934|BIOLOGICAL|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10\^6 cells per kg of body weight transduced ex vivo with 1 x 10\^8 IG/mL of lentiviral vector to achieve \> 0.3 integrated copies per cell."
223454771|NCT06056830|DRUG|64Cu-SAR-bisPSMA|All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
223454772|NCT02617134|BIOLOGICAL|anti-MUC1 CAR-T cells|
223454773|NCT03905681|DEVICE|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
223454774|NCT00123682|PROCEDURE|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
223454775|NCT00123682|PROCEDURE|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
223454776|NCT00123682|PROCEDURE|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
224148957|NCT02794090|BEHAVIORAL|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
224148958|NCT02794090|BEHAVIORAL|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
224148959|NCT01342952|DRUG|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
224148960|NCT04348994|DEVICE|Non-ablative thermal-only Er:YAG laser therapy|"Each patient will receive 3 sessions of Er:YAG laser treatment for SUI (IncontiLase®).~Single-session treatments will be offered to patients after 18, 24 and 30 months following the initial three sessions."
224148961|NCT00650598|DRUG|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
224148962|NCT00650598|DRUG|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
224148963|NCT05767372|OTHER|Coherent Breathing Exercise|"Step 1: Focus on your natural breathing and count the time of your inhale and exhale.~Step 2: Sit in a comfortable position to practice the coherent breathing technique. Gently place one hand on your stomach.~Step 3: Inhale for four seconds and then exhale for four seconds. Repeat this for one minute.~Step 4: Repeat the above step but lengthen your inhales and exhale for five seconds.~Step 5: Repeat the above step but extend the breaths to six seconds. Once you're able to do this for five minutes, gradually work your way up to 20 minutes.~During this breathing exercise, keep your hand on your stomach. Using diaphragmatic breathing can help you feel your breaths."
224148964|NCT05767372|DEVICE|Inspiratory muscle training|"The patient was in the comfortable sitting position and then put the nose clip on the patient's nose~1. After setting the maximum training; the user recognized the load at which they could effectively execute ten breaths at greatest resistance relying upon the patient's pace of apparent effort.~2. Training was begun with a load at low intensity 20-30% of the patient maximum 10 repetition method using inspiratory muscle training (IMT) device.~3. Progress slowly and monitor carefully.~4. As the inspiratory muscle became stronger the inspiratory load was progressed to 50% of maximum effort over 3 weeks as tolerated.~5. Patient took full breath in (maximal and deep inspiration) then longer and slow expiration. Continue this breathing pattern for 10-20 breath.~6. Repeated step (5), 4-6 times or about 10-15minutes with rest in between 30 seconds.~7. The session was repeated three times per week for 12 weeks."
224148965|NCT04024072|DRUG|Brinzolamide 1% ophthalmic suspension|Test product
224148966|NCT04024072|DRUG|Azopt 1% Ophthalmic Suspension|Reference product
223454777|NCT00123682|PROCEDURE|Self-help|Project staff send out self-help materials for smoking cessation
223454778|NCT00869973|DRUG|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
224148967|NCT04969211|DRUG|VHX-896 and iloperidone|oral tablet
224148968|NCT04969211|DRUG|Iloperidone and VHX-896|oral tablet
224148969|NCT05285033|DRUG|Lurbinectedin|Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).
224148970|NCT03584438|DEVICE|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
224148971|NCT03584438|DEVICE|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
224148972|NCT00167362|BEHAVIORAL|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
224148973|NCT00167362|BEHAVIORAL|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
224148974|NCT04394689|BIOLOGICAL|Measles Rubella Vaccine (MRV-SC)|One dose as subcutaneous injection of a WHO prequalified MR vaccine
224148975|NCT04394689|BIOLOGICAL|MRV-MNP|One standard dose of Measles and Rubella vaccine delivered intradermally as a dissolving microneedle patch
224148976|NCT04394689|OTHER|PLA-MNP|One placebo dose of a dissolving microneedle patch
224148977|NCT04394689|OTHER|PLA-SC|Placebo saline as subcutaneous injection
224148978|NCT05845489|DRUG|Clopidogrel treatment group|Patients assigned to the clopidogrel treatment group will maintain clopidogrel 75mg once a day for at least 5 years.
224148979|NCT05845489|OTHER|No antiplatelet or anticoagulant group|Patients assigned to the no antiplatelet or anticoagulant group will not prescribe antithrombotics for at least 5 years. However, when there is a medical need for antithrombotic therapy during the follow-up, the prescription of antithrombotics is permitted with reporting to the research board.
223454779|NCT00869973|DRUG|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
223454780|NCT05446142|DRUG|Encorafenib capsule formulation (CAP)|A single encorafenib dose of the CAP formulation
223454781|NCT05446142|DRUG|Encorafenib first formulation|first formulation
223454782|NCT05446142|DRUG|Encorafenib second formulation|second formulation
223454783|NCT05446142|DRUG|Rabeprazole tablet|Proton-pump inhibitor
224301680|NCT04830059|BEHAVIORAL|Air purification|Air purification in order to reduce the PM2.5 and PM10
224301681|NCT02755077|PROCEDURE|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
223454784|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
223454785|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
223454786|NCT02098395|DRUG|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
223454787|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
223454788|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
223584110|NCT02179255|DRUG|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
223584111|NCT03825237|DIAGNOSTIC_TEST|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
223584112|NCT04845139|DRUG|Nivolumab|Nivolumab given intraventricularly
223742769|NCT06997198|DRUG|Deutetrabenazine Oral Capsule|Open-label twenty-four-week treatment with Deutetrabenazine oral tablets (up to 24 mg/day) to test the safety and effectiveness of this medication in ameliorating the signs of tardive dyskinesia in persons with intellectual disability.
223742770|NCT07005102|DRUG|Standard of Care|Standard of Care
223742771|NCT07005102|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
223742772|NCT07005102|DRUG|Osimertinib (Osi)|Oral Tablet
223742777|NCT06880848|DRUG|Sonidegib Phosphate Capsules|Sonidegib should be taken 1 hour before or 2 hours after a breakfast
223742778|NCT05478252|DRUG|Semaglutide J|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
223742779|NCT05478252|DRUG|Semaglutide B|Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
224148980|NCT01162304|DRUG|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
223742780|NCT06746805|DIETARY_SUPPLEMENT|CHO+KETONE|Sports drink containing glucose and ketone mono-esters
223742781|NCT06746805|DIETARY_SUPPLEMENT|CHO+PLACEBO|Sports drink containing glucose and placebo
224148981|NCT01162304|DRUG|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
223454789|NCT02098395|DRUG|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
223742782|NCT06400121|DRUG|Apimostinel Infusion, Intravenous|Single injection of Apimostinel (10mg)
223742783|NCT06400121|BEHAVIORAL|Cognitive Training|8 sessions of digital active training
223742784|NCT06400121|BEHAVIORAL|Sham Training|8 sessions of digital sham training
223742785|NCT06400121|DRUG|Isotonic Solution, Intravenous|Single injection of placebo
223742786|NCT06766214|DEVICE|transcranial direct current stimulation|Simultaneous treatment with tDCS and online-based psychotherapy
223742787|NCT06766214|DEVICE|sham transcranial direct current stimulation|Simultaneous treatment with sham-tDCS and online-based psychotherapy
223742788|NCT05171179|PROCEDURE|Breast Reconstruction (Mammaplasty)|Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
223742789|NCT05171179|DEVICE|Pecs blocks|Pectoral nerve (Pecs) blocks I and II function by blocking the pectoral, intercostal, intercostobrachial nerves, and/or long thoracic nerve. These are used primarily for breast surgeries and are gaining momentum as simple administers of local analgesics. Pecs blocks utilize ultrasound to guide injection of local analgesic. It is less invasive and more accurate than most current modes of analgesia administration.
224148982|NCT02608229|DRUG|BVD-523|
224148983|NCT02608229|DRUG|Nab-paclitaxel|
224148984|NCT02608229|DRUG|Gemcitabine|
224148985|NCT02608229|PROCEDURE|Tumor biopsy|
223742790|NCT05171179|DRUG|Exparel|Exparel is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension of multivesicular liposomes (DepoFoam® drug delivery system) containing bupivacaine. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of Exparel, bupivacaine is released from the multivesicular liposomes over a period of time.
224148986|NCT04009746|PROCEDURE|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass|Endoscopic retrograde cholangiopancreatography (ERCP) with Spyglass
224148987|NCT03587870|OTHER|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
224148988|NCT00071851|BIOLOGICAL|VRC-HIVDNA009-00-VP|
224301682|NCT02948153|OTHER|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
223742791|NCT05171179|DRUG|Bupivacaine|This is an anesthetic delivered during breast reconstruction surgery that will be given to participants in both arms.
223742792|NCT06469112|DEVICE|Vibration|The device was used to provide vibration with the participants in this group. This device, designed as a combination of cold application and local vibration to reduce pain experienced during invasive procedures, is frequently chosen for all age groups.
223742793|NCT06469112|OTHER|Placebo|The device was used with participants in this group. The device, at room temperature, was placed by the researcher 5cm proximal to the injection site before the injection was performed. With participants in this group, the device was placed on the procedure site, but no vibration was made. The device was held on the participants for one minute before the injection and throughout the procedure, with the vibration switched off.
223742794|NCT06176352|DRUG|Faricimab|Faricimab 6 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
223742795|NCT06176352|DRUG|Ranibizumab|Ranibizumab 0.5 mg intravitreal (IVT) injection on Day 1 with Q4W PRN treatment thereafter to Week 44. At Week 48, participants will attend a follow-up visit.
224301683|NCT00811356|DRUG|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
224148989|NCT03505749|BEHAVIORAL|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
224148990|NCT03505749|BEHAVIORAL|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
224148991|NCT02288611|DIETARY_SUPPLEMENT|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
224148992|NCT02288611|DIETARY_SUPPLEMENT|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
224148993|NCT03448900|BEHAVIORAL|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
223572020|NCT03618940|BEHAVIORAL|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety \& Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust \&First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical \& Appliances \& Outlets)~4 Firecrackers Safety (Safety around Firecrackers \& Open Flames)~5\. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop \& Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
223572021|NCT02024269|BIOLOGICAL|Adipose Derived Stem Cells|
223572022|NCT02542891|OTHER|Blended CBT|
223572023|NCT02542891|OTHER|Treatment as Usual (TAU)|
223572024|NCT05857033|OTHER|Buccal and direct palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and direct palatal injection
223572025|NCT05857033|OTHER|Buccal and indirect palatal injection with the aid of Buzzy|Children are assigned to local anesthesia after using the Buzzy vibration unit extraorally for 2 minutes using buccal and indirect palatal injection
223572026|NCT05857033|OTHER|Buccal and direct palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and direct palatal injection
223572027|NCT05857033|OTHER|Buccal and indirect palatal injection without Buzzy|Children are assigned to local anesthesia after using topical analgesic gel (benzocaine 20%) intraorally for 1 minute using buccal and indirect palatal injection
223572028|NCT05940545|DRUG|Favipiravir|Small molecule antiviral
223572029|NCT05940545|DRUG|Ribavirin|Small molecule antiviral
223572030|NCT01328834|DRUG|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
223572031|NCT01094353|PROCEDURE|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
224148994|NCT03448900|BEHAVIORAL|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
224148995|NCT05504577|DRUG|Tranexamic acid injection|Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
223572032|NCT01094353|PROCEDURE|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
223572033|NCT01342965|DRUG|Erlotinib|Erlotinib was supplied as tablets.
223572034|NCT01342965|DRUG|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
223572035|NCT04687592|PROCEDURE|reduction and fixation|"* Reduction: one trial of closed reduction under anaesthesia and image control. Open reduction will be done by anterolateral or lateral approach if closed reduction failed~* Fixation: internal fixation of the fracture by appropriate implant according to the fracture state"
223572036|NCT06478797|OTHER|Fluid|Sepsis will be treated with standardized therapy protocol, where participants receive fluids (balanced or non-balanced crystalloids, or colloids) to be resuscitated. Specifically, they will receive 40-60 ml/kg of fluids before the initiation of inotropes.
223572037|NCT06478797|DRUG|Adrenalin|Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
223572038|NCT05335187|DEVICE|micro-macro electrode implantation|One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
223572039|NCT04355533|BIOLOGICAL|serology test|volume according to child weight
223572040|NCT04355533|BIOLOGICAL|nasopharyngeal swab|nasopharyngeal swab for PCR
223572041|NCT04355533|BIOLOGICAL|rectal swab|rectal swab for PCR
223572042|NCT04355533|BIOLOGICAL|saliva sample|for biocollection
223572043|NCT05327634|OTHER|self-questionnaire|Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
223572044|NCT02775942|BIOLOGICAL|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
223572045|NCT02775942|BIOLOGICAL|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
224148996|NCT05504577|DEVICE|apply the QCG|apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
224148997|NCT05504577|DEVICE|apply surgical gauze|apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
224148998|NCT03742206|DEVICE|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
224148999|NCT03742206|DEVICE|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
224149000|NCT05073627|DRUG|Dicloxacillin|Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
224149001|NCT05386927|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled in the first trimester, and blood, urine, saliva and other specimens were collected.
224149002|NCT05205278|OTHER|exercise training|The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
224301684|NCT04131777|DEVICE|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
224301685|NCT00002353|BIOLOGICAL|P3C541b Lipopeptide|
223454790|NCT05717205|DIAGNOSTIC_TEST|technetium scitigraphy|patients will have a technetium scintraphy confirming or ruling out gastroparesis. Then the patients will have a gastroscopy with tissue samples from antrum and fundus. During gastroscopy an endo-flip ballon will meassure the distensibility in pylorus.
223454791|NCT04711694|BEHAVIORAL|Minfulness-based Intervention|"The proposed MBI is an adaptation from the Mindfulness Based Stress Reduction (MBSR) and Mindfulness based Cognitive Therapy (MBCT) programs to youth. This MBI consists of a total of twelve 90 minutes long sessions, the first 8 being the intervention per se and the last 4 a proposition to the transition to regular practice and a chance to better integrate mindfulness in daily life.~A theme regarding mindfulness is addressed in each session, through meditation practices and exercises. Between sessions, participants are invited to practice at home, using an application designed for this study (the MindApp), where participants can find the recorded practices. Investigators have access to participants' use of the meditation recordings and expect that these data will provide a more objective measure of the amount of home practice."
223454792|NCT01310582|DRUG|Desflurane|
223454793|NCT01310582|DRUG|Sevoflurane|
223454794|NCT05942521|BEHAVIORAL|Very brief extinction|"The very brief extinction presents a very short (33ms) repetitive sequence of alcohol cues, followed by a masking stimulus(117ms), which masks the alcohol cues. In the case of repeated exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
224301686|NCT04283201|OTHER|Physical activity|Moderate activity 150 min per week
224301687|NCT04283201|OTHER|Macronutrient modification|Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
224301688|NCT06209411|BEHAVIORAL|Home Based Testing|Community Health Workers (CHWs) will offer at home OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
223454795|NCT05942521|BEHAVIORAL|Clearly visible extinction|"The clearly visible extinction presents a repetitive sequence of alcohol cues(150ms) without a masking stimulus. In the case of repeat exposure to alcohol stimulation, the response to the stimulation is desensitized at the level of conscious processing."
223454796|NCT05942521|BEHAVIORAL|Very brief neutral extinction|"The very brief neutral extinction presents a very short (33ms) repetitive sequence of neutral cues, followed by a masking stimulus(117ms), which masks the neutral cues. In the case of repeated exposure to neutral stimulation, the response to the stimulation is desensitized at the level of unconscious processing."
223454797|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
223454798|NCT00110357|DRUG|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
223454799|NCT04793477|DEVICE|instrumentation technique in pulpectomies|comparison of three file systems for pulpectomies in primary molars
223454800|NCT03382418|BIOLOGICAL|gp145 C.6980 Vaccine|Administered by intramuscular injection in the deltoid.
224149003|NCT03700268|OTHER|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
224149004|NCT05464472|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Guideline/ FDA approved implantation of a Transcatheter Aortic Valve Implantation (TAVI)
224149005|NCT05720767|DRUG|HMPL-523|HMPL-523 is a selective small-molecule SYK inhibitor.
224149006|NCT05720767|DRUG|Itraconazole|Itraconazole is an FDA approved synthetic triazole antifungal agent
224301689|NCT06209411|BEHAVIORAL|Clinic Based Screening|Community Health Workers (CHWs) will offer referral to clinic based OGTT testing to women within the first postpartum year, as well as Type 2 Diabetes education.
224149007|NCT05720767|DRUG|Rifampin|Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
224301690|NCT00798148|DRUG|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
223572046|NCT02775942|BIOLOGICAL|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
223572047|NCT02775942|BIOLOGICAL|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
223572048|NCT02655523|DRUG|Triamcinolone|1 mL of 40 mg of Triamcinolone
223572049|NCT02655523|DRUG|Dexamethasone|1 mL of 4mg of Dexamethasone
223572050|NCT02655523|DRUG|Normal Saline|1 mL of preservative free normal saline
224149008|NCT04491240|DRUG|EXO 1 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the first type.
224149009|NCT04491240|DRUG|EXO 2 inhalation|Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10\^10 of nanoparticles (exosomes) of the second type.
224149010|NCT04491240|DRUG|Placebo inhalation|Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
224149011|NCT02111967|OTHER|Questionnaire administration|
224301691|NCT03659526|DIAGNOSTIC_TEST|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
224301692|NCT01700049|DRUG|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
223454801|NCT03382418|BIOLOGICAL|Placebo|Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.
223454802|NCT03382418|BIOLOGICAL|Aluminum Hydroxide Adjuvant|Administered by intramuscular injection in the deltoid.
223454803|NCT05116371|DRUG|150 mcg levonorgestrel/30 mcg ethinyl estradiol|concurrent use of COC with Nexplanon
223454804|NCT03011177|DRUG|Teneligliptin|teneligliptin 20mg qd
223454805|NCT03011177|DRUG|Linagliptin|linagliptin 5mg qd
223454806|NCT04633226|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL sterile suspension for intramuscular injection.
223454807|NCT01151345|DRUG|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
223454808|NCT01151345|DRUG|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
223454809|NCT02536105|DRUG|Methylphenidate HCl ER tablets 1|
223454810|NCT02536105|DRUG|Placebo|
223454811|NCT02536105|DRUG|Methylphenidate HCl ER tablets 2|
223454812|NCT02536105|DRUG|Methylphenidate HCl ER for suspension|
223454813|NCT06333028|DEVICE|enVista Aspire EA IOLs|Subjects bilaterally implanted with enVista Aspire EA IOLs
223454814|NCT04585243|DEVICE|Evalyn Brush|The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
223454815|NCT02950922|DRUG|RVT-501 0.2% ointment|
223454816|NCT02950922|DRUG|RVT-501 0.5% ointment|
223454817|NCT02950922|OTHER|Vehicle ointment|Placebo comparator
223454818|NCT06289777|PROCEDURE|TEVAR|minimally invasive endovascular intervention to treat aortic dissection
223454819|NCT01083992|DRUG|Galvus (vitagliptin)|Galvus (vitagliptin)
223454820|NCT01083992|DRUG|Galvus + vitamin D|Galvus + vitamin D
223454821|NCT04464408|DRUG|Favipiravir|1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
223454822|NCT04464408|DRUG|Placebo|(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)
223454823|NCT05036798|DRUG|Tislelizumab|"Chemotherapy regimen:~Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2 Tislelizumab 200mg D1 Q3w Lenvatinib 4mg Po QD"
223454824|NCT05687721|DRUG|copanlisib|intravenous infusion (IV) at 60 mg on Day 1, 8 and 15 of each 4-week treatment cycle for up to 26 cycles
223572051|NCT02655523|DRUG|Bupivacaine|2 mL of 0.5% bupivacaine
223572052|NCT01262170|DIETARY_SUPPLEMENT|CigRx Lozenge|lozenge made of dietary supplements
223572053|NCT01262170|OTHER|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
223572054|NCT00226408|DRUG|Interferon-alpha-2b|
223572055|NCT01175434|OTHER|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
223572056|NCT03250078|DIAGNOSTIC_TEST|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
223572057|NCT03887520|DIAGNOSTIC_TEST|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
223572058|NCT02306304|OTHER|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
224149012|NCT02111967|OTHER|Laboratory biomarker analysis|
224149013|NCT00003735|DRUG|topotecan hydrochloride|given by mouth
224149014|NCT01249963|DIETARY_SUPPLEMENT|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
223742796|NCT06176352|PROCEDURE|Sham Procedure|The sham is a procedure that mimics an intravitreal (IVT) injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Participants will undergo the sham procedure at study visits where no study drug is to be administered, in order to maintain masking.
223742797|NCT06880016|DIAGNOSTIC_TEST|Evaluation of serial lung ultrasound data after ENSURE surfactant treatments|Intubating the infant, administering intratracheal surfactant, and then extubating them back to nasal respiratory support (ENSURE method)
223742798|NCT06880016|DIAGNOSTIC_TEST|Evaluation of serial lung ultrasound data after LISA surfactant treatments|Delivering surfactant via a thin catheter (5F) directly into the trachea while the infant remains on existing nasal respiratory support, without disconnecting them from it (LISA method)
223742799|NCT06840834|DRUG|Ivonescimab|Ivonescimab is administered IV Q3W on Day 1 of each cycle. Ivonescimab is given at a dose of 20 mg/kg (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥160 kg). The total duration of ivonescimab treatment is up to 24 months.
223742800|NCT04194736|OTHER|Ultrasound scan|"First ultrasound scan from 1 day to 6 days after the placement of the percutaneous central venous catheter.~Second ultrasound scan from 7 days to 13 days after the placement of the percutaneous central venous catheter if no thrombosis was detected at the first ultrasound scan."
223742801|NCT06913608|COMBINATION_PRODUCT|CLBR001 + SWI019|Investigational switchable CAR-T cell therapy for autoimmune disorders
223742802|NCT06913556|DIAGNOSTIC_TEST|Preoperative dry eyes|In group 1 we access preoperative dry eyes condition and postoperatively we access the condition in 2nd and 4th week with the use of Hylorunic acid lubricant.
223742803|NCT06913556|COMBINATION_PRODUCT|Lipid coated carbomer gel eye drops|In group 2 we prescribe the lipid coated carbomer gel eye drops and access dry eyes condition preoperative and postoperative on 2nd and 4th week and check the curative effect of drop.
223742804|NCT06823167|BIOLOGICAL|IM-1021|IM-1021 is an antibody-drug conjugate
224149015|NCT01249963|DIETARY_SUPPLEMENT|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
223742805|NCT06693310|OTHER|de-escalation or discontinuation of therapy|De-escalation of therapy, defined as a step-down from maintenance with advanced therapy (biologic or synthetic small molecule) to oral aminosalicylate-based therapy or complete discontinuation of therapy if they are allergic or intolerant to aminosalicylate-based therapy. If patients are receiving immunomodulator or oral aminosalicylate maintenance therapy, they will be de-escalated to complete discontinuation of therapy.
223742806|NCT06693310|OTHER|continuation of current therapy|continuation of current maintenance medical therapy for ulcerative colitis
223742807|NCT06744543|DEVICE|SIGHT Prompted Provider Message|Among patients surpassing a 0.30 probability threshold that have a scheduled visit to pediatric primary care at VUMC, 500 will be randomized to the intervention and a SIGHT-prompted provider message will be generated.
223742808|NCT06570798|DRUG|Inebilizumab|Intravenous (IV) Infusion
223742809|NCT06570798|DRUG|Blinatumomab|SC Injection
223742810|NCT07100938|DRUG|BGB-45035|Administered orally
223742811|NCT07100938|DRUG|Placebo|Administered orally
223742812|NCT07109843|DIETARY_SUPPLEMENT|Boswellia serrata extract|Boswellia Serrata 1x day (600mg)
223742813|NCT07109843|OTHER|Placebo|Placebo 1x/day
224149016|NCT03549117|DEVICE|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
224149017|NCT03549117|OTHER|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
224149018|NCT01312324|DRUG|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
224149019|NCT04086602|DRUG|IZD334|Active Drug
223742814|NCT06914791|PROCEDURE|Kegel arm|in this group participants will be followed up for 8 weeks with kegel exercises
224149020|NCT04086602|DRUG|Placebos|Placebo to Match
223742815|NCT06914791|PROCEDURE|De Gasquet arm|in this group participants will be followed up for 8 weeks with de gasquet exercises
223742816|NCT06864208|BEHAVIORAL|Behavioral Weight Management|Prescription of diet and physical activity strategies paired with behavioral strategies for weight management
223742817|NCT06864208|BEHAVIORAL|Weight Bias Internalization|Addressing weight stigma and improving weight-related self-perception through challenging weight-related stereotypes, practicing self-compassion, reducing self-criticism, and coping with weight stigma
223742818|NCT06914817|DEVICE|Brillouin optical scanning system (Intelon Optics) (BOSS)|Brillouin microscopy is a non-invasive optical imaging technique that measures the mechanical properties of tissues, such as stiffness and elasticity, by analyzing light scattering caused by natural acoustic waves within the tissue.
224064452|NCT01854619|DEVICE|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
224064453|NCT01854619|DEVICE|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
224064454|NCT03867578|DIAGNOSTIC_TEST|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
224064455|NCT03867578|DIAGNOSTIC_TEST|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
223742819|NCT06913244|BEHAVIORAL|Multidisciplinary Physiotherapy Program (MD Physio)|"A comprehensive program that integrates:~Specific Exercise Therapy: Supervised stretching and strengthening sessions (30-60 minutes/session, 3× per week for 8 weeks) followed by a prescribed home-based maintenance regimen.~Manual Therapy: Targeted soft-tissue mobilization and myofascial release (20-30 minutes/session, twice per week for 4 weeks).~Education Sessions: Three sessions (both in-person and online) covering pain neuroscience and self-management techniques.~Mind-Body Interventions: Weekly 40-minute sessions of yoga or tai chi for 6 weeks."
223742820|NCT06913244|BEHAVIORAL|Standard Physiotherapy Care|Routine care involves standard follow-up with basic physiotherapy advice as currently provided to breast cancer survivors. This serves as the active comparator in the trial.
223742821|NCT07108114|DRUG|SLV-324 intravenous (IV infusion)|SLV-324 will be administered as an IV infusion
224149021|NCT02205918|OTHER|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
223742822|NCT06921434|DIETARY_SUPPLEMENT|Monk fruit sweetener mouth rinse|monk fruit mouth rinse 10 grams of sweetener powder and 90 ml of distilled water for 30 participants for 1 minute
223742823|NCT06921434|DIETARY_SUPPLEMENT|Splenda (sucralose) sweetener mouth rinse|10 g of splenda powder with 90 ml of distilled water for 30 participants for 1 minute
224149022|NCT02205918|OTHER|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
224149023|NCT03764579|BEHAVIORAL|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
224149024|NCT05142449|DRUG|Amoxilan|Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
224149025|NCT05142449|OTHER|Placebo|Patients receive 8 capsules placebo perioperatively and for the next 3 days 6 capsules per day
224149026|NCT00939939|DRUG|sitagliptin|sitagliptin 100 mg/d for 10 weeks
224149027|NCT00939939|DRUG|glimepiride|glimepiride 1 mg/d for 10 weeks
224149028|NCT00471003|DRUG|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
224149029|NCT02847845|DIETARY_SUPPLEMENT|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
224149030|NCT02847845|DIETARY_SUPPLEMENT|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
223454825|NCT05687721|DRUG|Avelumab|800 mg intravenous infusion on Day 1 and 15 of each 4-week treatment cycle for up to 26 cycles
223742824|NCT06921434|DIETARY_SUPPLEMENT|Sucrose mouth rinse|10 g of sucrose powder dissolved in 90 ml of distilled water as a positive control group for 30 participants for 1 minute
223742825|NCT06916741|DIAGNOSTIC_TEST|Ultrasound with Sacral lift|Intervention includes using a sacral lift during ultrasound to collect femoral vein measurements.
223742826|NCT07181135|DRUG|Finerenone (BAY 94-8862)|Finerenone 10 or 20mg in participants with chronic kidney disease not using renin-angiotensin-system inhibitors
223742827|NCT07181135|DRUG|Placebo|Placebo matching finerenone
224149031|NCT04320290|DRUG|Direct Acting Antivirals|8 weeks of DAA treatment
224301693|NCT05909930|OTHER|Therapeutic resistance exercise|Therapeutic exercise program based on individualized progressive resistance exercises performed during 6 months at home, with a frequency of 1-3 sessions per week at the hospital.
224301694|NCT05909930|OTHER|Education|Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
224064456|NCT03867578|DIAGNOSTIC_TEST|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
223454826|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
224064457|NCT04020250|DEVICE|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
224064458|NCT06849245|BEHAVIORAL|A digital social intervention by primary care clinicians|"* Signposting to the online health community by explaining different sections of the website.~* Introducing norms and values for passive (just reading) and active (writing posts) participation.~* Motivation for engagement with the online health community, emphasising that it could be used ad hoc (e.g. when feeling unwell, or when they need information or emotional support).~* Problem solving with respect to any difficulties/concerns.~* Signing patients up to the online health community, by explaining terms and conditions.~* Explaining the differences between posting publicly and privately (public posts are shared with third parties whereas private messages to other users are not shared).~* Collection of baseline measures. Data will be entered into the study's online database.~Patients will leave the consultation with a leaflet summarising all procedural matters in relation to signing up with the online health community and a reminder of their username and password."
224064459|NCT02344888|DRUG|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
223454827|NCT02083302|BEHAVIORAL|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
223454828|NCT02083302|BEHAVIORAL|SCREAM Theater Dose 4|Booster Session
223454829|NCT06253247|COMBINATION_PRODUCT|NanoChitosan impregnated Calcium Hydroxide|NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days
223454830|NCT01630083|DRUG|epirubicin|Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
223454831|NCT01630083|DRUG|oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
224149032|NCT05836129|BEHAVIORAL|Transcendental Meditation (TM) practice|See previous description
224149033|NCT05836129|OTHER|Stress reduction class (online)|See previous description
224149034|NCT06193694|BEHAVIORAL|Coaching|Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
224149035|NCT06195293|BIOLOGICAL|Neoantigen Polypeptide Vaccine|Deliver neoantigen polypeptide vaccine into patients for anti-ancer therapy.
224149036|NCT03936270|DRUG|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
224149037|NCT03936270|DRUG|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
224149038|NCT01078987|PROCEDURE|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
224149039|NCT04270487|OTHER|IBS Diet|Patients will be randomized to a diet or a mediation treatment
224149040|NCT04270487|DRUG|Otilonium Bromide|Patients will be randomized to a diet or a mediation treatment
224149041|NCT05370742|PROCEDURE|Latarjet surgery|Results of using a screw-only plate for fixation of the corocoid bone in recurrent shoulder dislocations
224149042|NCT02826993|DEVICE|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
224149043|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
223572059|NCT04213144|DEVICE|Magdent Cap MED|Magdent is intended to be used for accelaration of soft tissue and bone healing
223572060|NCT04213144|DEVICE|Sham MED|Sham MED is intended to be used for soft tissue healing
223572061|NCT02868034|BEHAVIORAL|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
223584113|NCT06266104|PROCEDURE|Image Enhanced Endoscopy Filters|Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).
224149044|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
224149045|NCT03015558|DEVICE|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
224149046|NCT02398084|OTHER|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
224149047|NCT02518776|BEHAVIORAL|Neuropsychological tests|Neuropsychological tests
224149048|NCT00005092|DRUG|Cyclophosphamide|IV over 2 hours on days 2 and 3
224149049|NCT00005092|DRUG|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
224149050|NCT00005092|DRUG|Thiotepa|IV over 2 hours on day 1
224149051|NCT00005092|PROCEDURE|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
224301695|NCT00850434|DEVICE|Modified AutoSet Algorithm|"The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm"
224301696|NCT00850434|DEVICE|Standard AutoSet Algorithm|The standard AutoSet used for treatment of OSA
224301697|NCT03534843|PROCEDURE|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
224149052|NCT00005092|PROCEDURE|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
224149053|NCT00005092|RADIATION|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
224301698|NCT03534843|OTHER|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
224301699|NCT06633068|DRUG|Adding perineural Nalbuphine to Bupivacaine in superficial cervical nerve block|Adding nalbuphine as an adjuvant to bupivacaine in superficial cervical plexus block during thyroid surgeries
223584114|NCT02475616|DRUG|PCO371|
223584115|NCT02475616|DRUG|Placebo|
223584116|NCT00958737|DRUG|FOLFOX regimen|6 or 12 treatments of FOLFOX (FOLFOX4 or modified FOLFOX6 (mFOLFOX6))
223584117|NCT00958737|DRUG|CAPOX|4 or 8 cycles
223584118|NCT05605171|PROCEDURE|Posterior reconstruction urethrovesical anastomosis.|Rocco stitch.
223584119|NCT05605171|PROCEDURE|Conventional vesicourethral anastomosis.|Standard of care.
224149054|NCT04451291|BIOLOGICAL|Decidual Stromal Cells (DSC)|DSCs are involved in the immune system during pregnancy. The DSCs used in this study will come from laboratory grown allogeneic human decidual stromal cells obtained from donated placentas.
224149055|NCT06197737|OTHER|Moderate Intensity Interval Training|Participants in this group will perform moderate intensity interval training in which they will perform stair climbing 3 times a week and for every 1 interval I will ask them to take rest for 3 minutes.
224149056|NCT06197737|OTHER|Sprint Interval Training|sprint interval training in which they will do stair climbing 3 times a week with a fast pace.
224149057|NCT06197737|OTHER|pharmacological treatment|They will be on pharmacological treatment as prescribed by their pulmonologist.
224149058|NCT00888615|DRUG|Elesclomol Sodium|Given IV
224149059|NCT00888615|DRUG|Paclitaxel|Given IV
224149060|NCT03714009|BEHAVIORAL|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
224149061|NCT03714009|BEHAVIORAL|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
223454832|NCT01630083|DRUG|capecitabine|The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
223454833|NCT01630083|DRUG|zolbetuximab|Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
223454834|NCT05431491|DEVICE|Ultrafiltration|Ultrafiltration through much smaller intravenous cannula than what has previously been used.
223454835|NCT05471336|PROCEDURE|Enteral Feeding|Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
223454836|NCT00647036|DIETARY_SUPPLEMENT|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
223454837|NCT00647036|DRUG|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
223454838|NCT02450422|OTHER|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
223454839|NCT02450422|OTHER|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
223454840|NCT01480817|DRUG|Sorafenib|Sorafenib 400mg po bid
223454841|NCT01480817|PROCEDURE|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
223454842|NCT03838029|DRUG|Propranolol and etodolac|A perioperative combined drug regimen
223454843|NCT03838029|OTHER|Placebo|Placebo
223454844|NCT03749408|DRUG|bupivacaine plus mannitol|local anesthesia
223454845|NCT03749408|DRUG|bupivacaine alone|local anesthesia
223454846|NCT02394015|DRUG|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
223454847|NCT05535400|BEHAVIORAL|Physical-Psychological Integrative Intervention|The PPI intervention will include eight weekly online group sessions (with each session lasts for 60-90 minutes). At the beginning of each online group meeting, the intervention provider will use motivational interviewing techniques to promote participants' adherence to the physical activity program. And the content of the intervention includes eight different sessions, including Session 1- Orientation and engagement, Session 2- Awareness and Acceptance; Session 3- Non-judgement; Session 4- Stay present and let go; Session 5- Our thoughts are not real \& Response without reacting; Session 6- Empowerment of self-management and discuss pain management; Session 7- Seek out pleasant things and social support and Session 8- Review the intervention and end the programme.
223742828|NCT07183839|BEHAVIORAL|Immersive Virtual Reality|While wearing an immersive VR helmet, participants grabbed virtual objects andd put them into a bowl of virtual water, while memorizing a list of words from the real world.
224149062|NCT05428800|BEHAVIORAL|Progressive Relaxation Exercises|Progressive muscle relaxation (PMR) is a relaxation technique that tenses and relaxes muscles in an unprompted, regular, and consecutive manner until the whole body is relaxed.
224149063|NCT03541655|DRUG|Bupivacaine HCl|0.25% Bupivacaine HCl
224149064|NCT03541655|DRUG|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
224149065|NCT01896908|OTHER|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY \_\_ / \_\_ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
224149066|NCT03657667|PROCEDURE|Ureteroscopy|Endoscopic removal of kidney stones
224149067|NCT03047850|DIAGNOSTIC_TEST|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
224149068|NCT03896113|DRUG|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
224149069|NCT05578235|PROCEDURE|stapled side-to-side anastomosis|Standard procedure for CD
224149070|NCT05578235|PROCEDURE|Handsewn anastomosis|handsewn end-to-end or Kono-s anastomosis
224149071|NCT06874556|BEHAVIORAL|CP-HF Management|Community Paramedics will visit patients up to twice daily. Visits will include patient care discussion with Heart Failure APP, IV placement, lab phlebotomy, heart failure education, and IV medication administration. Community Paramedics will administer up to 120 mg IV furosemide twice daily.
224149072|NCT06882460|OTHER|Low glycemic load|Low glycemic load diet
224149073|NCT06882460|OTHER|Electrical stimulation exercise|Lower-body electrical stimulation exercise for 1-h after eating
224149074|NCT06882460|OTHER|High glycemic load diet|High glycemic load diet
224149075|NCT06876636|DRUG|Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)|zoledronic acid + liposomal doxorubicin + cyclophosphamide followed by zoledronic acid + nab-paclitaxel Concurrent immunotherapy is permitted: pembrolizumab or toripalimab
224149076|NCT05442294|BEHAVIORAL|Juego de Llaves|The main goal of this program is to prevent substance use and engagement in other addictive behaviors. It is intended to be delivered by teachers in a six to twelve session format through different modules that cover the following areas: emotional regulation, cognitive strategies, social interaction, free time, education on drugs and life values
223454848|NCT05535400|DEVICE|Brief online didactic education|Participants in the control group will receive a short video call (approximately 20 minutes each week for eight weeks) from the trained research assistant, i.e., RA 2 to provide general physical and psychological suggestions (e.g., encouragement of performing physical activities, and communication skills with family members/friends, and engagement in the community life). This is to control the contact effects of the PPI intervention.
223454849|NCT01343784|OTHER|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
223454850|NCT03581370|DRUG|1 hour infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
223454851|NCT03581370|DRUG|4 hours infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
223454852|NCT02786706|DEVICE|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
223454853|NCT01348100|DRUG|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
223454854|NCT01348100|DRUG|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
223454855|NCT01348100|DRUG|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
223454856|NCT04292145|BEHAVIORAL|Relaxation Application|The use of an application for relaxation.
223454857|NCT04292145|BEHAVIORAL|Relaxation Only|The individual's personal method to relax.
223454858|NCT03768921|OTHER|PEEP Titriation|The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
223454859|NCT00159107|DRUG|Acamprosate|Acamprosate
223454860|NCT00159107|BEHAVIORAL|Integrative behavior therapy|Integrative behavior therapy
223454861|NCT00159107|DRUG|Placebo|Placebo
223454862|NCT03126253|DIAGNOSTIC_TEST|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
223454863|NCT01129804|BEHAVIORAL|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
223454864|NCT03882957|BEHAVIORAL|Sustained attention|participants will complete a sustained attention task
223454865|NCT03882957|BEHAVIORAL|media multi-task|participants will complete multiple media tasks at the same time
223454866|NCT03882957|OTHER|Video|participants will watch a video of media tasks being completed
223454867|NCT04442698|PROCEDURE|Mini-Gastric Bypass Original Technique|Follow up of the Surgical procedure outcomes in diabetics. Procedure Mini-Gastric Bypass Original Technique
224149077|NCT03032081|OTHER|High intensity exercise|High intensity exercise, defined as an exercise intensity of \> 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
224149078|NCT03032081|OTHER|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
223454868|NCT01608672|BIOLOGICAL|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
223454869|NCT04551768|DRUG|50 mg/mL Virazole|50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
223584120|NCT05039658|DRUG|IBI110 plus sintilimab|Sintilimab is a NMPA approved high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
223454870|NCT04551768|DRUG|100 mg/mL Virazole|100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
224149079|NCT04567446|OTHER|Stool|collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
224149080|NCT04567446|OTHER|Blood sample|20 mL collection at baseline (or before the third injection), at the first evaluation (CT-scan), at ≥ 6 months after the first injection, at toxicity and at relapse, at 1 week after the end of antibiotics treatment
224149081|NCT02091921|DRUG|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
224149082|NCT06723392|DRUG|Oral nitrofurantoin monohydrate/macrocrystals|7-day course of oral nitrofurantoin monohydrate/macrocrystals 100 mg twice daily (total of 14 doses)
224149083|NCT06723392|OTHER|Placebo|7-day course of oral placebo 100 mg twice daily (total of 14 doses)
224301700|NCT01248013|BEHAVIORAL|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
224301701|NCT02154295|DEVICE|Infraredx Test Catheter|
223454871|NCT00543673|OTHER|Milk based formula A|feed as per HCP directions
223454872|NCT00543673|OTHER|#2 Standard formula|Feed as per HCP directions
223454873|NCT00543673|OTHER|#3 Human Milk|Feed as per HCP directions
223454874|NCT00543673|OTHER|Milk based formula C|Feed as per HCP direction
223454875|NCT02897466|OTHER|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
223454876|NCT01134393|DRUG|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
223454877|NCT05042986|DRUG|.[14C]-SKI-O-703|Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
223454878|NCT00013377|PROCEDURE|Low vision|
223454879|NCT01109134|DRUG|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
223454880|NCT01109134|DRUG|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
223454881|NCT00652808|DRUG|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
223454882|NCT00652808|DRUG|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
223454883|NCT04233437|DRUG|MLC1501|MLC1501 capsules (4 capcules (2000 mg) twice a day)
223454884|NCT04233437|DRUG|CYP Cocktail|Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
223454885|NCT04233437|DRUG|Transporter Cocktail|Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
223454886|NCT01590316|DEVICE|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
223454887|NCT00226798|DRUG|Capecitabine (Xeloda)|
223454888|NCT03326297|OTHER|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
223454889|NCT03326297|BEHAVIORAL|Measures to support and education to the family|Pedagogical intervention in parents and health education
223454890|NCT02900664|BIOLOGICAL|PDR001|Powder for solution for infusion
223454891|NCT02900664|BIOLOGICAL|ACZ885|Solution for injection
223454892|NCT02900664|BIOLOGICAL|CJM112|Solution for infusion
224301702|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and delivery of systemic oxygen|CXL is performed using an accelerated protocol (9 mW/ CM2 for 10 minutes) in addition to the delivery of systemic oxygen with a rate of 5 liters/min through a nasal mask for 10 minutes during UV-A ablation
224301703|NCT04343326|PROCEDURE|perform corneal collagen cross linking accelerated and without additional oxygen therapy|corneal collagen cross linking with accelerated protocol without additional oxygen therapy
224301704|NCT04343326|PROCEDURE|perform Conventiona corneal collagen cross linking|Conventional CXL using 30 mW/CM2 UV-A ablation for 30 minutes
223454893|NCT02900664|DRUG|TMT212|Tablets
223454894|NCT02900664|DRUG|EGF816|Tablets
223454895|NCT05212480|DIETARY_SUPPLEMENT|Zinc|For each patient included, a prescription regimen of zinc (in bisglycinate form) is proposed at a dose of 25 mgtwice a day for 15 days for the intervention arm. This dose of zinc is to be taken away from meals.
223454896|NCT05212480|DIETARY_SUPPLEMENT|Placebo|For each patient included, a prescription of an identical to the intervention arm concerning shape, smell, taste and color pill of placebo . This dose of zinc is to be taken away from meals.
223454897|NCT01379105|OTHER|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
223454898|NCT01379105|OTHER|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
223454899|NCT02303197|DRUG|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
223454900|NCT05872061|OTHER|Acceptability of food-to-food fortified (FtFF) instant porridge flours|This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.
223454901|NCT03134911|DRUG|DOAC or VKA|6 months - 2 years
223454902|NCT03134911|DRUG|VKA|6 months - 2 years
224149084|NCT03307629|DRUG|NOX66|NOX66 delivered as rectal suppository.
224149085|NCT03307629|RADIATION|Irradiation Therapy|Radiation per selected tumour lesion.
224149086|NCT04339270|DRUG|Azithropycin according to symptoms|"Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
224149087|NCT04339270|DRUG|Azithromycin according to rheology or symptoms|"Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed."
224149088|NCT01771211|DEVICE|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
224149089|NCT04545099|DRUG|Sugammadex|Administration of Sugammadex for muscle relaxation reversal
224149090|NCT04545099|DRUG|Neostigmine|Administration of Neostigmine for muscle relaxation reversal
224149091|NCT02874183|BEHAVIORAL|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
224149092|NCT03296787|DRUG|TAK-954|TAK-954 intravenous infusion.
224149093|NCT06890013|DIAGNOSTIC_TEST|Observation group|Patients with acute coronary syndrome undergo endothelial function assessment using two methods (flow mediated dilatation of the brachial artery and Cor-Is technology) transthoracic echocardiogram and plasma biomarkers' measurement.
224149094|NCT03229681|BEHAVIORAL|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
224149095|NCT03229681|BEHAVIORAL|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
224149096|NCT02691221|BEHAVIORAL|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
224149097|NCT00325650|DRUG|Rimonabant|Tablet, oral administration
224149098|NCT00325650|DRUG|Placebo (for Rimonabant)|Tablet, oral administration
224149099|NCT06745206|DRUG|Lyophilized Recombinant Human Brain Natriuretic Peptide|rh-BNP is reconstituted to a concentration of 10 μg/mL and administered as an initial intravenous bolus of 2 μg/kg over 15 minutes, followed by a continuous infusion at a rate of 0.01 μg/kg/min. Patients should receive at least the first 500μg dose infusion, with a recommended duration of 72 hours. The specific timing of discontinuation will be determined by the attending physician. Prior to rh-BNP administration, measure: PiCCO indices, hemodynamic parameters, venous return, tissue perfusion, echocardiographic parameters, ultrasound indices, 2-hour averaged urine output and fluid balance. Repeat all above-mentioned measurements at 30 minutes post-initiation.
224149100|NCT00719953|DIETARY_SUPPLEMENT|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
224149101|NCT06728098|DIETARY_SUPPLEMENT|Probiotic|The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
224149102|NCT06728098|DIETARY_SUPPLEMENT|Maltodextrin|The experimental phase of this study had last 30 days and each patient will make 3 visits (d1,d15,d30).
224149103|NCT06159829|BEHAVIORAL|experimental|intervention group used VR with a natural landscape and relaxing musical accompaniment during the upper endoscopy procedure.
223454903|NCT00893529|DIETARY_SUPPLEMENT|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
224149104|NCT04396743|PROCEDURE|Periapical surgery with use of prf-high clot and membrane|Periapical surgery will be done followed by placement of prf-high clot into the defect and membrane over the defect before closure of the flap.
224149105|NCT04396743|PROCEDURE|Periapical surgery with use of prf-medium clot and membrane|Periapical surgery will be done followed by placement of prf-medium clot in the defect and membrane over the defect before closure of the flap.
224149106|NCT01626989|DEVICE|BiPAP auto Advanced|Auto Servo Ventilation Device
224149107|NCT01626989|DEVICE|BiPAP auto SV4|Auto Servo Ventilation Device
223454904|NCT00893529|DIETARY_SUPPLEMENT|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
223584121|NCT05039658|DRUG|IBI110|BI110 is a high-affinity, ligand-blocking, humanized anti- Lymphocyte Activation Gene-3 (LAG-3) IgG4 antibody that blocks the binding of LAG-3 to MHCII.
224149108|NCT07057466|OTHER|Traditional 12-lead Electrocardiogram|12-lead ECG investigation is a standard, non-invasive diagnostic procedure used as an intervention to assess participants' cardiac electrical activity. For the purposes of this study, 12-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
224149109|NCT07057466|OTHER|Apple Watch Series 4 Single-lead Electrocardiogram|Single-lead ECG taken using an Apple Watch Series 4 is a non-invasive, participant-initiated recording of cardiac electrical activity through a wearable device. While more limited than a 12-lead ECG, it can capture rhythm abnormalities-such as atrial fibrillation-and offers a convenient method for remote or continuous heart monitoring during the study. For the purposes of this study, single-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
223454905|NCT00614978|DRUG|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
223454906|NCT00123994|BEHAVIORAL|Tai Chi classes|
223454907|NCT00123994|BEHAVIORAL|Hydrotherapy classes|
223454908|NCT03828214|DEVICE|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R\&D Corporation ®, Japan. The devices computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
223454909|NCT05103800|BEHAVIORAL|invasive interventions|listening the white noise during the invasive interventions
223454910|NCT03143777|DEVICE|Sara Combilizer|Combined tilt table and stretcher chair
223454911|NCT04721639|OTHER|Sphinx Yoga Therapy|Sphinx Pose Yoga is among the best beginner Yoga Poses that relieve Lower Back Pain. It extends the back gently and activates muscles along the spine. The subject will be asked to lay down on their stomach with feet set hip-width apart, the elbows positioned under the shoulders, and the legs held together. The chin should be pointing towards the floor. Next, the subject is required to pull up the kneecaps, squeezing the thighs and buttocks, pressing the pubic bone into the floor and dropping shoulders back away from the neck and pushing the chest forward. In this position, the subject is asked to breathe and hold the pose for two to six breaths. By the end, the subject will be required to exhale, bringing the elbows to the sides and slowly lowering the chest and head to the floor.
223454912|NCT05019573|DIETARY_SUPPLEMENT|Black tea|Black tea twice a day for 4 weeks
223454913|NCT05019573|DIETARY_SUPPLEMENT|Placebo|Placebo tea twice a day for 4 weeks
223454914|NCT04687189|DEVICE|Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)|Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
223454915|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.25 milliamps (mA)
223454916|NCT00305565|DEVICE|VNS Therapy|Received output current of 0.5-1.0 mA
223454917|NCT00305565|DEVICE|VNS Therapy|Received output current of 1.0-1.5 mA
223572062|NCT02868034|BEHAVIORAL|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
223454918|NCT02335385|PROCEDURE|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
223454919|NCT02335385|PROCEDURE|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
223454920|NCT02364076|DRUG|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
223454921|NCT02364076|DRUG|Epacadostat|100mg taken by mouth twice daily
223454922|NCT03056612|OTHER|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
223584122|NCT04070495|DRUG|KW-6356|A single oral dose will be administered at Day 1 and 15
223584123|NCT04070495|DRUG|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
224301705|NCT00307034|BIOLOGICAL|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
223454923|NCT01372540|DRUG|Carfilzomib|Given IV
223454924|NCT01372540|DRUG|Filanesib|Given IV
223454925|NCT01372540|OTHER|Laboratory Biomarker Analysis|Correlative studies
223454926|NCT01290575|DRUG|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
223454927|NCT01290575|DRUG|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
223454928|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
223454929|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
223454930|NCT01290575|DRUG|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
223454931|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
223454932|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
223454933|NCT01290575|DRUG|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
223454934|NCT01290575|DRUG|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
224149110|NCT07057466|OTHER|Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram|Three-lead ECG recorded using the Eko CORE 500 digital stethoscope is a non-invasive, clinician-operated cardiac assessment tool that captures real-time electrical activity of the heart during auscultation. It provides enhanced diagnostic information compared to single-lead recordings, allowing detection of arrhythmias and signs of structural heart disease at the point of care, supporting integrated clinical and digital assessment. For the purposes of this study, 3-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
224149111|NCT07057466|OTHER|AliveCor KardiaMobile Single- and 6-lead Electrocardiogram|A single- or 6-lead ECG recorded using the AliveCor KardiaMobile 6L device which is a portable, non-invasive method for capturing cardiac electrical activity. Operated by the participant or clinician, the device enables rapid rhythm assessment and detection of abnormalities such as atrial fibrillation. The 6-lead configuration offers more comprehensive data than single-lead recordings, supporting enhanced arrhythmia and conduction analysis in both in-clinic and remote settings. For the purposes of this study, single- and 6-lead ECGs will be collected for the application of AI-ECG models for the detection of HF, VHD, and/or PH and will not be used to inform or alter patients' standard NHS care.
224149112|NCT07057466|OTHER|Phlebotomy for N-terminal pro-B-type natriuretic peptide|A minimally invasive biomarker assessment used to evaluate cardiac wall stress and function. Elevated levels can indicate the presence or severity of heart failure and other forms of structural heart disease, making it a valuable tool for diagnosis, risk stratification, and monitoring of cardiac status throughout the study period. For the purposes of this study, NT-proBNP will be collected to assess its accuracy at detecting HF, PH, and VHD with comparison with AI-ECG detections. The investigators will also evaluate the accuracy of AI-ECG detections combined with NT-pro-BNP, for detecting HF, VHD, and PH. The investigators will not be using NT-proBNP results to inform or alter patients' standard NHS care.
224149113|NCT03358654|DRUG|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
224149114|NCT02437487|DRUG|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
224149115|NCT02437487|DRUG|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
224149116|NCT07071415|BEHAVIORAL|Breast cancer screening decision aid -- low risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the low risk of overdiagnosis arm will view a version of the decision aid the describes a low risk of overdiagnosis.
224149117|NCT07071415|BEHAVIORAL|Breast cancer decision aid -- moderate risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the moderate risk of overdiagnosis arm will view a version of the decision aid the describes a moderate risk of overdiagnosis.
224149118|NCT07071415|BEHAVIORAL|Breast cancer screening decision aid -- high risk|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the high risk of overdiagnosis arm will view a version of the decision aid the describes a high risk of overdiagnosis.
224149119|NCT07071415|OTHER|Control condition|Participants in this study will view a video-based decision aid that describes the risks and benefits of breast cancer screening for older women. Participants assigned to the control arm will view a version of the decision aid that does not contain any information about overdiagnosis.
223454935|NCT03457623|OTHER|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
223454936|NCT00210886|DRUG|levofloxacin|
223454937|NCT04633772|DRUG|Angiotensin-(1-7)|Intravenous supplementation of Angiotensin-(1-7)
223454938|NCT04633772|DRUG|Placebo|NaCl 0.9%
223454939|NCT02118259|OTHER|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time."
223454940|NCT00096759|BEHAVIORAL|Tai Chi Chih|
223454941|NCT00096759|BEHAVIORAL|Relaxation training|
223454942|NCT04955613|DEVICE|MyMove/VR system|"The treatment system consists of two lightweight MyMove bands and Virtual-Reality (VR) gear. Proprietary software and content allow tracking of performance in real-time, with feedback to both the patient and treating - personnel.~MyMove is a wearable device that allows patients with loss of upper limb function to operate computers, cellular phones, and similar devices. The technology is non-invasive and does not involve risk to the patient.~Virtual-Reality (VR) gear is a wearable computer running within goggles that project content and allow for interaction using controllers."
223454943|NCT04955613|DEVICE|Mirror therapy|Mirror therapy or mirror visual feedback is a therapy for pain or disability that affects one side of the patient more than the other side
223454944|NCT03605472|OTHER|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
223454945|NCT01738529|DEVICE|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
223454946|NCT02867800|DRUG|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
223454947|NCT02867800|DRUG|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
224301706|NCT00307034|BIOLOGICAL|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
224301707|NCT00307034|BIOLOGICAL|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
223572063|NCT02868034|BEHAVIORAL|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
223572064|NCT02868034|BEHAVIORAL|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
224149120|NCT07075484|DRUG|YTS109 cell|Subjects will receive YTS109 cell, and dose escalation will commence at 5E6 cells/kg or the starting dose may be adjusted based on accumulated data.
224149121|NCT07075991|DRUG|1 μm [14C]-labelled Polystyrene Microplastic|A single test day during which participants will orally ingest a single micro dose of 100 μg 1 µm \[14C\]-labelled PS-MP. Prior to and following ingestion of the labelled PS-MP, biological samples (i.e. blood, urine, faeces) will be collected at regular intervals, throughout the 5-day study period. Participants will spend the first 24h in the clinical laboratory, after which they are allowed to spend the remainder of the 5-day study period at home but with daily visits to the laboratory for blood sampling and home collection of urine and faeces.
224149122|NCT06765161|DRUG|efgartigimod administration|efgartigimod infusion
224149123|NCT06783296|PROCEDURE|Renal Denervation|Renal denervation performed using the Symplicity Spyral™ multi-electrode renal denervation system, which is approved for interventional treatment of hypertension. This procedure involves catheter-based radiofrequency ablation of the renal nerves to reduce sympathetic activity and lower blood pressure.
224149124|NCT06783296|PROCEDURE|Renal Angiography|A sham procedure involving renal angiography without the application of radiofrequency energy. This control intervention is used to maintain blinding.
224149125|NCT06893081|DRUG|MK-8527|Oral Tablet
224149126|NCT06893081|DRUG|CBZ|Oral Extended-release Capsule
224149127|NCT07091695|BIOLOGICAL|Nivolumab + relatlimab|As prescribed by the treating clinician
224149128|NCT07091695|BIOLOGICAL|Nivolumab + ipilimumab|As prescribed by the treating clinician
224149129|NCT07091110|PROCEDURE|laparoscopic appendectomy|laparoscopic appendectomy
223572065|NCT01892787|DRUG|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
223572066|NCT01892787|DRUG|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
223572067|NCT03403985|DRUG|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
223572068|NCT03403985|DRUG|Mineral Trioxide Aggregate|MTA will be used in this group
223572069|NCT04920591|OTHER|doll treatment|"The doll used in the study is the empathy doll; these dolls are designed to obtain an optimal interaction with patients and to arouse empathy."
224149130|NCT07090512|DIAGNOSTIC_TEST|Multimodal Ultrasound|Multimodal ultrasound data collection will be conducted on all organ donors meeting the research criteria.
224301708|NCT02917330|OTHER|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
224301709|NCT01874795|DEVICE|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
224301710|NCT01874795|DEVICE|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
224301711|NCT02667171|BEHAVIORAL|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
223572070|NCT03538444|DEVICE|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
223572071|NCT03538444|DEVICE|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
223572072|NCT01509677|DRUG|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
223742829|NCT07183839|BEHAVIORAL|Plausible control condition|Participant passively viewed the laboratory room they saw while wearing Apple Vision Pro goggles, while memorizing a list of words read to them from the real world.
223742830|NCT07189962|DRUG|SHR8554 Injection|SHR8554 injection.
223742831|NCT07191028|DRUG|MLC 901|Oral capsule, 2 capsules 3 times a day for 12 months
223742832|NCT07191028|DRUG|Placebo|Oral capsule, 2 capsules 3 times a day for 12 months
223742833|NCT07188935|DRUG|ciprofloxacin 500 mg tablet|Administration of oral ciprofloxacin 500 mg twice daily for 7-14 days for the treatment of recurrent urinary tract infections in patients with type 2 diabetes mellitus, following local and international guidelines.
223742834|NCT07190053|OTHER|Secukinumab|This is an observational study, there is no treatment allocation
223742835|NCT07189624|OTHER|Exercise|30-minutes exercise on a bicycle with heart rate monitor and gas exchange analyzer.
224149131|NCT07091474|BEHAVIORAL|Educational Workshops for Parents and Early Educators|A structured series of age-specific educational workshops designed for parents, caregivers, and early childhood educators of children aged 0-36 months. The workshops are organized into three cohorts (0-12 months, 13-24 months, 25-36 months) and focus on typical motor milestones, active play, early stimulation strategies, and recognition of early warning signs of motor delays. Sessions include interactive activities, discussions, and distribution of educational resources. Pre- and post-workshop surveys and semi-structured interviews are conducted to evaluate changes in knowledge and attitudes.
223572073|NCT01509677|DRUG|Placebo|tablet, once daily, oral administration in the morning after breakfast
223572074|NCT02033590|DEVICE|Biodegradable (purified) surgical silk scaffold|
223572075|NCT04165473|BEHAVIORAL|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
223572076|NCT04421872|OTHER|receiving general anesthesia|patients receiving surgery under general anesthesia
223572077|NCT05602675|DRUG|LY3871801|Administered orally.
223742836|NCT02530034|DRUG|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
223454948|NCT02867800|DRUG|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
223454949|NCT02867800|DRUG|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
223454950|NCT02867800|DRUG|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
223454951|NCT02867800|DRUG|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
223454952|NCT02867800|DRUG|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
223454953|NCT02867800|DRUG|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
223454954|NCT02867800|DRUG|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
223454955|NCT02867800|DRUG|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
223454956|NCT02867800|DRUG|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
223454957|NCT02867800|DRUG|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
223454958|NCT02867800|DRUG|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
223454959|NCT02867800|PROCEDURE|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
223572078|NCT05602675|DRUG|Methotrexate|Administered orally.
223572079|NCT05602675|DRUG|Warfarin|Administered orally.
223572080|NCT05602675|DRUG|Dextromethorphan|Administered orally.
223572081|NCT05602675|DRUG|Midazolam|Administered orally.
223572082|NCT05602675|DRUG|Repaglinide|Administered orally.
223572083|NCT01760538|BEHAVIORAL|Exercise training|exercise training
223572084|NCT01760538|BEHAVIORAL|usual care|received usual medical care after heart transplantation
223572085|NCT04694352|OTHER|Jumping Exercises|Jumping in place Jump and clap Jump and reach Jump and twist Jump and turn Half jumping jack Jumping side to side Each exercise done for 1 minute, 5 repetitions is session of 1 hour 15minutes
223572086|NCT04694352|OTHER|Conventional Physical therapy|"Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour"
223742837|NCT02530034|OTHER|Laboratory Biomarker Analysis|Correlative studies
223742838|NCT02530034|OTHER|Pharmacological Study|Correlative studies
223742839|NCT04544449|DRUG|Fenebrutinib|Participants will receive fenebrutinib.
223742840|NCT04544449|DRUG|Ocrelizumab|Participants will receive ocrelizumab.
223742841|NCT04544449|DRUG|Placebo matched to ocrelizumab|Participants will receive ocrelizumab-matching placebo.
223742842|NCT04544449|DRUG|Placebo matched to fenebrutinib|Participants will receive fenebrutinib-matching placebo
223742843|NCT00446953|DRUG|betamethasone|2x12 mg betamethazone c-section at 38 weeks
223742844|NCT00446953|OTHER|placebo|c-section at 39 weeks
223742845|NCT06124378|DRUG|Tislelizumab|200 mg on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The incidence of adverse events with Tislelizumab is relatively low. The Tislelizumab dose adjustment was implemented according to the prescribing information.
223742846|NCT06124378|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2 on Day 1 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for oxaliplatin-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
224149132|NCT07091474|OTHER|Motor Development Assessment in Children 0-36 Months|Comprehensive motor development assessments performed on infants aged 0-36 months using validated tools (Standardized Infant Hand Assessment \[s-HAI\], Hammersmith Infant Neurological Examination \[HINE\], Infant Motor Profile \[IMP\], and Ages and Stages Questionnaire \[ASQ-3\]). These evaluations aim to collect normative data on typical early motor development and to identify early signs of motor delays or neurological conditions, enabling timely referral and intervention. Assessments are conducted annually for typically developing infants and monthly for those identified as at risk.
224149133|NCT07092371|BEHAVIORAL|Digital Multimodal Intervention|Participants will undergo a 6-month multimodal intervention via a digital platform, which includes: (1) Personalized cognitive training; (2) Self-monitoring and management of stroke risk factors including hypertension, dyslipidemia, diabetes, smoking and obesity; (3) Smart wristband-based exercise monitoring and management; (4) Smart wristband-based sleep monitoring and management; (5) Health dietary recording and guidance
224149134|NCT07091656|OTHER|there is no intervention|NO INTERVENTION
224149135|NCT07090707|DRUG|PD-1inhibitor|The PD-1 monoclonal antibody was the same as the neoadjuvant therapy before surgery, and the postoperative level was maintained at Q3\*6.
224149136|NCT07090707|RADIATION|radiotherapy|According to the guidelines, concurrent chemoradiotherapy is required, and carboplatin (50mg/m2) plus concurrent radiotherapy or cisplatin (30mg/m2) plus concurrent radiotherapy is optional.
224149137|NCT07090044|DRUG|Bromfenac Sodium 0.07%|Bromfenac sodium 0.07% is a nonsteroidal anti-inflammatory drug to be administered as one topical drop, one time 5 minutes prior to the regularly scheduled standard of care intravitreal injection.
224149138|NCT07090044|DRUG|Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly|Loteprednol etabonate 0.38% ophthalmic gel is a steroidal drug to be administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.
224301712|NCT02667171|BEHAVIORAL|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
224301713|NCT00653965|DRUG|Rosuvastatin|
224301714|NCT00653965|DRUG|Atorvastatin|
223454960|NCT02867800|DRUG|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
223454961|NCT02867800|DRUG|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
223454962|NCT01392456|PROCEDURE|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
223454963|NCT00143468|BEHAVIORAL|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
223454964|NCT04086381|DIETARY_SUPPLEMENT|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
223454965|NCT04086381|DIETARY_SUPPLEMENT|placebo cellulose|oral ingestion of placebo containing 20 gram cellulose daily
223454966|NCT05111938|BEHAVIORAL|Friends, Family, and Food App (F3A-App)|
223742847|NCT06124378|DRUG|Capecitabine|Oral Capecitabine 1000 mg/m2 twice daily combined with oxaliplatin chemotherapy from Day 1 to Day 14 every 3 weeks and repeat for 2 or 4 cycles. The dose reduction protocol for capecitabine-induced toxicity was implemented according to the study in British Journal of Cancer (2018) 118:1322-1328.
223742848|NCT06124378|PROCEDURE|Colectomy|The specific surgical approach is laparoscopic. The tumor blood supply is ligated and cut at the root of the mesentery, and the margin of resection should be no less than 10cm. Complete resection of the mesocolon (CME) is performed in conjunction.
224149139|NCT07090044|DRUG|Propylene Glycol Preservative-free Artificial Tears|Propylene Glycol Preservative-free Artificial Tears is a placebo compartor administered as one topical drop three times daily on the day of the regularly scheduled standard of care intravitreal injection. The first drop administered 5 minutes prior to the intravitreal injection.
223572087|NCT01483534|DEVICE|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
223572088|NCT03640052|DRUG|Placebo oral capsule|Placebo capsule before sleep
223454967|NCT01603199|DIETARY_SUPPLEMENT|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
223572089|NCT03640052|DRUG|LTM1201L|LTM1201L capsule before sleep
223572090|NCT03640052|DRUG|LTM1201LN|LTM1201LN capsule before sleep
223572091|NCT03640052|DRUG|LTM1201LB|LTM1201LB capsule before sleep
223572092|NCT03640052|DRUG|LTM1201LD|LTM1201LD capsule before sleep
223572093|NCT04422561|DRUG|Ivermectin Tablets|two doses 72 hours apart
223572094|NCT05039671|BEHAVIORAL|Measurement-based care (MBC)|Clinicians will receive a 3-hour interactive MBC training followed by six months of post-training consultation. Training and consultation will include how to collect, score, and use student- and parent-reported progress measures with students and families to inform collaborative progress monitoring and treatment decisions.
223572095|NCT02805400|OTHER|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
223572096|NCT04708132|PROCEDURE|Screw retained restoration|Hybrid prosthesis
223572097|NCT04708132|PROCEDURE|implant-retained ball overdentures|Removable prosthesis
223572098|NCT04685707|DEVICE|Visual feedback monitoring system (HFFS)|Participants will follow the exercise monitoring system's instructions displayed on a TV. Treadmill walking speed will be set at a comfortable walking speed.
223572099|NCT04685707|OTHER|Control|Participants will monitor the intensity of exercise independently using a standard heart rate monitor and control it by adjusting the treadmill speed (walking speed).
223572100|NCT01638052|DRUG|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
223572101|NCT00926133|OTHER|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
223572102|NCT01330979|DRUG|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
224149140|NCT07090954|DRUG|GR1803 injection|Participants will receive GR1803 injection.
223454968|NCT05735405|BEHAVIORAL|Neuropsychological evaluation|Each participant will undergo a complete neuropsychological evaluation, both before and at the end of the clinical trial, with the aim of detecting any changes or improvements.
223454969|NCT05735405|BIOLOGICAL|BDNF evaluation|During the first and last clinical trial session, each participant will undergo two blood samples, one before and one at the end of the ride, to check levels of Brain Derived Neurotrophic Factor (BDNF).
223454970|NCT05735405|BEHAVIORAL|Pedaling as a moderate intensity aerobic exercise|During each session, each participant will perform 30 minutes of pedaling as a form of moderate intensity physical activity.
223454971|NCT05735405|OTHER|Cognitive Training|During each session, each participant will carry out 60 minutes of cognitive training through specific exercises for the attentional, executive and working memory functions.
223454972|NCT05735405|DIAGNOSTIC_TEST|VO2 assessment|"To determine the individual moderate intensity for each patient, a VO2 consumption assessment will be made. The examination will be carried out using an exercise bike and a mask for the calculation of metabolic oxygen consumption.~The 3 MET threshold to reach in pedaling will be calculated (to define it of moderate intensity), in order to elicit the release of BDNF."
223454973|NCT02461056|DRUG|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
223454974|NCT02461056|DRUG|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: \<0.9, antagonism: \>1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
223454975|NCT02614508|DRUG|Buparlisib|Given PO
223454976|NCT02614508|DRUG|Ibrutinib|Given PO
223454977|NCT02614508|BIOLOGICAL|Ofatumumab|Given IV
224149141|NCT07090954|DRUG|Anti-CD38 Monoclonal Antibody|Participants will receive anti-CD38 monoclonal antibody.
223454978|NCT06467539|DRUG|DAOIB plus AO|oral, for 24 weeks
223454979|NCT06467539|DRUG|DAOIB plus placebo|oral, for 24 weeks
223572103|NCT00551915|BIOLOGICAL|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
223572104|NCT00551915|BIOLOGICAL|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
223572105|NCT00551915|BIOLOGICAL|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
223572106|NCT00551915|BIOLOGICAL|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
223572107|NCT00551915|BIOLOGICAL|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
223584124|NCT04070495|DRUG|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
224149142|NCT07090187|DEVICE|LegoPress , Novel assistive device|novel assistive device for rehabilitation using functional electrical stimulation
224149143|NCT06890039|DRUG|Placebo|"Matching placebo for TAK-242: 5% dextrose solution and commercially available 20% intralipid (prepared by hospital pharmacy staff)~Matching placebo for G-CSF: identical to vehicle for filgrastim (prepared for injection by hospital pharmacy staff)"
224149144|NCT06890039|DRUG|TAK-242|"TAK-242 concentrate for solution for infusion (80 mg/ mL in 3 mL ethanol) ): 240 mg TAK-242 per vial. To be reconstituted with 5% dextrose (36 mL) and commercially available 20% intralipid (21 mL).~TAK-242) will be administered as a continuous IV infusion starting with a loading dose of 0.9 mg/kg administered over 30 minutes, followed by a continuous, constant rate infusion of 1.8 mg/kg/day for 10 days.~PLUS placebo for G- CSF"
224149145|NCT06890039|DRUG|G-CSF (Filgrastim)|"Commercially available vials for subcutaneous injection. Quantitative composition (per mL):~Filgrastim: 300 mcg Acetate: 0.59 mg Sorbitol: 50.0 mg Tween® 80: 0.04 mg Sodium: 0.035 mg Water for Injection USP q.s. ad 1.0 mL~G-CSF will be given subcutaneously once daily at a dose of 5 µg/kg for 5 days (Day 1-5) and at Day 8 (6 injections in total)"
224149146|NCT06805617|DRUG|Ivonescimab|An immunoglobulin (Ig) G1 monoclonal antibody (mAb), single-use vial, via intravenous (into the vein) infusion per protocol.
224149147|NCT07091929|DRUG|SGC001|The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
224149148|NCT07091929|DRUG|Placebo|The single dose should be administered within 6 hours after the onset of acute myocardial infarction symptoms, with earlier administration preferred. The intravenous injection should be administered over 10 minutes.
224149149|NCT07090070|PROCEDURE|Cohort 1 Intervention group|Clear margin excision of the lesion under local anesthetic, with re-excision for p53-positive margins.
224149150|NCT07090070|PROCEDURE|Cohort 2 severe/CIS margins clear|Clear margin excision of the lesion under local anesthetic, with re-excision until severe/CIS margins are clear
224149151|NCT07090070|PROCEDURE|Cohort 2 p53 and severe/CIS margins clear|Excision of the lesion ensuring final negative p53 and severe/CIS margins
224149152|NCT07090070|PROCEDURE|Cohort 3 Excision and END|Excision of primary lesions with 5+mm margins and immediate elective neck dissection
223454980|NCT03387657|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
223454981|NCT03387657|DRUG|Hydrochlorothiazide|"Pharmaceutical form: Tablet~Route of administration: Oral"
223454982|NCT04129294|DRUG|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~\[Part 1\] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks \[Part 2\] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
223454983|NCT06351085|BEHAVIORAL|Pre-Visit Planner|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process.
224149153|NCT07090070|PROCEDURE|Cohort 3 Excision and Close follow up|Excision of primary lesion with 5+mm margins and close follow up with salvage elective neck dissection if development of nodal disease
224149154|NCT07092163|DEVICE|QLF Imaging (Qraypen C®)|Fluorescence-based assessment of restoration margins using Qraypen C® device to measure autofluorescence loss (ΔF) and red fluorescence (ΔR). Imaging was performed during routine 18-month follow-up to detect micro-leakage or marginal biofilm activity.
223454984|NCT06351085|BEHAVIORAL|Pre-Visit Planner + MyChart|The study is comparing the implementation of a Pre-Visit Planner to go through the shared decision making process as well as testing if watching educational videos about the Lung Cancer Screening (LCS) process prior to talking to an LVN will help with LCS uptake.
223454985|NCT02787083|DRUG|Mirabegron|
223454986|NCT02787083|DRUG|Placebo|
223454987|NCT03812445|DIETARY_SUPPLEMENT|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8\*10\^9 Colony-Forming Units(CFU) \*2/d for 3 months.
223454988|NCT01454011|DRUG|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
223454989|NCT01454011|DRUG|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
223454990|NCT02710084|DRUG|Oxytocin|Intranasal oxytocin
223454991|NCT02710084|DRUG|Saline|Placebo
223454992|NCT05123352|OTHER|collection of biological samples and clinical data|blood and feces samples
223572108|NCT05166278|BEHAVIORAL|De-escalation training|The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
223572109|NCT01115894|DRUG|Naltrexone|100 mg oral dosage daily for 12 weeks
223742855|NCT06787235|DIETARY_SUPPLEMENT|Modified ketogenic diet|The modified Atkins KD is defined as \<20g carbohydrate per day with freely allowed protein consumption. Recommended protein and fat intake will be calculated for each participant based on their energy needs.
223742856|NCT06787235|OTHER|Individual nutritional consultation|The nutritional consultation will be provided by a dietician to improve individual health
223572110|NCT01115894|BEHAVIORAL|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
223742857|NCT04282252|DRUG|I.V. SOLUTIONS|All i.v. fluids used in an Intensive Care Unit.
223742858|NCT02410382|DRUG|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
224149155|NCT07092163|PROCEDURE|Clinical evaluation|Restorations were evaluated both at baseline (1-week recall) and at 18-month follow-up using the FDI World Dental Federation Clinical Evaluation Criteria, which allow structured and sensitive assessment of indirect restorations across three domains: Functional properties (e.g., marginal adaptation, fracture, retention, occlusion), Biological properties (e.g., recurrent caries, hypersensitivity, pulp status), Esthetic properties (e.g., marginal discoloration, surface texture, shade matching). Each criterion was scored on a 5-point ordinal scale: 1 = Clinically excellent / very good, 2 = Good (minor corrections), 3 = Satisfactory (acceptable with no significant clinical impact), 4 = Unsatisfactory (repair required), 5 = Clinically poor (replacement required). Scores of 1-3 were considered clinically acceptable, while scores of 4 or 5 indicated restorative failure.
224149156|NCT07090720|DRUG|Melatonin|Neonates were given Melatonin.
224149157|NCT07090720|OTHER|Placebo|Neonates received placebo.
224149158|NCT07091773|DEVICE|OLIZ Photobiomodulation Device|OLIZ device utilizes dual-wavelength technology combining specific red (660nm) and near-infrared (850nm) light parameters optimized for post-surgical tissue healing. The device features controlled power density, precise treatment duration protocols, and targeted application to knee arthroplasty surgical sites. Treatment parameters include specific irradiance levels, treatment session duration of 15 minutes, and 3 times of daily application frequency designed.
224149159|NCT07090694|PROCEDURE|Graftless Transcrestal Sinus Floor Elevation with Immediate Implant Placement|This intervention involves a minimally invasive internal (crestal) sinus lift performed without the use of any grafting material. The sinus membrane is elevated using sequential osteotomy drills, and a dental implant is immediately placed into the prepared site. The implant fixture acts as a tent pole, maintaining the lifted membrane and allowing for spontaneous bone regeneration through blood clot formation alone. This graftless method eliminates the need for additional biomaterials and is intended for patients with residual alveolar bone height of 5-7 mm
224149160|NCT07090694|BIOLOGICAL|Platelet-Rich Fibrin (PRF)-Assisted Transcrestal Sinus Floor Elevation with Immediate Implant Placement|This intervention utilizes autologous platelet-rich fibrin (PRF) as the sole grafting material during transcrestal sinus floor elevation. PRF is prepared from the patient's own venous blood using centrifugation and inserted into the osteotomy site after sinus membrane elevation. A dental implant is placed simultaneously to support the sinus membrane and stabilize the graft. The biologically active PRF matrix provides a scaffold rich in growth factors (e.g., TGF-β, PDGF, VEGF), promoting accelerated healing and enhanced bone formation beneath the elevated sinus floor. This technique is performed in a single-stage procedure, eliminating the need for synthetic or allogeneic grafts.
224149161|NCT07091461|DEVICE|HOME Kit Tablet-based Telerehabilitation|Device-based behavioral intervention (motor, cognitive, and communication rehabilitation)
224149162|NCT07091461|OTHER|Conventional Home Physiotherapy|Participants in this arm will follow a conventional home rehabilitation protocol, focusing on upper limb function and postural control. The protocol includes traditional exercises prescribed and explained by a physiotherapist. Follow-up will be conducted through weekly phone calls to reinforce adherence and resolve concerns.
224149163|NCT01165697|OTHER|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
224149164|NCT07092410|DRUG|Encorafenib & Binimetinib Treatment|The SuRage-EB post approval study will evaluate prospectively the potential impact of local treatment of melanoma metastases under encorafenib (E) + binimetinib (B) combination therapy while continuing EB therapy thereafter. It focusses on single melanoma metastases which develop resistance or show no response during EB treatment. These metastases will be treated locally before registration of the patients into the study. Directly after or during local treatment, EB combination therapy will be resumed. Locally treated EB-resistant melanoma cells cannot continue to grow during targeted therapy and the positive response may be prolonged.
224149165|NCT07090824|DRUG|Diluted Humalog U-200 Insulin|Commercially available U-200 Humalog (insulin lispro) diluted 1:1 with a dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
224149166|NCT07090824|DRUG|Diluted U-500 Humulin Insulin|Commercially available U-500 Humulin (regular insulin) diluted 1:4 with dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
224149167|NCT07090824|DRUG|Lyumjev U-100 Insulin|Commercially available U-100 Lyumjev (insulin lispro-aabc) administered unmodified as comparator. Administered as single subcutaneous injection at 0.20 u/kg body weight following mixed meal consumption.
224149168|NCT07090824|DIETARY_SUPPLEMENT|Boost Mixed Meal Test|Standardized mixed meal (Boost drink) administered at 8.0 mL/kg body weight (17.3 g carbohydrates per 100 mL) consumed immediately before insulin injection at each visit.
223454993|NCT00844662|DRUG|Fermagate|Film coated tablet 500mg
223454994|NCT00844662|DRUG|Sevelamer hydrochloride|Tablet 800mg
223454995|NCT05849792|BEHAVIORAL|Exercise and psychological intervention|"Physical Exercise Intervention~Sixty-minute sessions were delivered via internet, three times per week (1 supervised) over the first four weeks of the COVID-19 home confinement. The intervention was a multicomponent exercise program lead by a specialist in fitness composed of aerobic, resistance, balance, coordination, mobility and stretching exercises. Each multicomponent exercise session consisted of a 10 min warm-up, 40 min of moderate to vigorous intensity physical activity, and 10 min cool down.~Psychological intervention~The internet-based-psychological intervention provided to different component of Cognitive Behavioral Therapy (CBT) guided and recorded by a sport neuro-psychologist specialist. The iCBT is based on the protocol for face-to-face CBT for depression. The program consisted of 4 weeks composed of 2 weekly video-guided sessions, with a maximum duration of 30 minutes. iCBT was focused on 4 main axes of action physiological, emotional, behavioral and cognitive."
223454996|NCT04767854|BEHAVIORAL|OA school|Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
223454997|NCT04767854|OTHER|Virtual Training mobile health application|Individually tailored home exercise programs delivered through a mobile health application
223572111|NCT01115894|BEHAVIORAL|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
223454998|NCT04767854|OTHER|Usual care|Individually tailored exercise programs conducted in weekly supervised individual or group sessions
223454999|NCT01538537|DRUG|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
223455000|NCT04697654|DRUG|TLC19|Hydroxychloroquine Liposome Inhalation Suspension
223572112|NCT01115894|DRUG|Placebo|Placebo
223455001|NCT04697654|DRUG|TLC19 Vehicle|Liposome Inhalation Suspension (same formulation as TLC19 but without the active ingredient, HCQ)
223455002|NCT04869852|OTHER|Food|85g mango, 4x/week
223455003|NCT01179646|DRUG|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
223455004|NCT04608890|DIAGNOSTIC_TEST|Eye-tracking video test|An eye-tracking-based test will be administered to patients. It lasts 10 minutes. It consists in several screens passing by to identify objects at a certain time by a mouse clic or touchpad.
223572113|NCT00634712|DRUG|Candesartan|
223572114|NCT00634712|DRUG|Placebo|
223572115|NCT05192629|DRUG|Dexmedetomidine|Premedication by intranasal dexmedetomidine
223572116|NCT05192629|DRUG|Midazolam|Premedication by intranasal midazolam
223572117|NCT00503412|DRUG|AZD2171|oral 14C
223572118|NCT00790647|BIOLOGICAL|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
223572119|NCT00790647|DRUG|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
223572120|NCT00790647|DRUG|melphalan|100 mg/m2/dose D -2, D -1
223572121|NCT00790647|PROCEDURE|Stem Cell Infusion|infusion of previously collected autologous stem cells
223572122|NCT06595823|DRUG|Betadine|To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
223572123|NCT06606184|PROCEDURE|Inspiratory muscle Training|Participants underwent a 12-week program consisting of inspiratory muscle training twice daily, incentive spirometry three times daily, and upper limb exercises along with marching in place for 30 minutes.
223572124|NCT06606184|PROCEDURE|Routine Care|Participants received routine care, which included encouragement to use incentive spirometry three times daily.
223572125|NCT06605274|OTHER|Web-Based Education Program|"Before being discharged from the clinic, the women who experienced perinatal loss filled out the Personal Information Form, Perinatal Grief Scale, Edinburgh Postnatal Depression Scale, Beck Hopelessness Scale, and Stress Coping Styles Scale individually. The women were informed about the use of the website. The discharged women were contacted by phone, given the passwords of the birliktegücleniyoruz.com website, and invited to use the website for the five-week education program. Each week, only one session determined for that week was uploaded to the site. Participants who wished to do so were able to watch the uploaded sessions more than once. Retrospective sessions also remained accessible on the site. Each session lasted an average of 20-30 minutes. Women who completed five sessions were contacted by phone in the sixth week. Women filled out the PGS, EPDS, BHS, and SCSS online a second time"
223572126|NCT06605274|OTHER|Control|Before being discharged from the perinatology clinic, the women filled out the Personal Information Form, PGS, EPDS, BHS, and SCSS individually. Six weeks after discharge, the participants filled out the same measurement tools online again. During this process, the hospital's routine monitoring continued for the control group. The website was opened to the use of participants who wanted to use the site after the completion of the final tests.
223572127|NCT06604819|DRUG|Ozone gel placed after closed sinus lifting then implant placed simultaneously.|The patient received closed sinus lifting using osteotomes then ozone gel is prepared. Pure olive oil was blasted with 25 μ/ml O3 gas for two days, or until the oil changed from a greenish-colored liquid to a whitish gel. The longevity Ext 120 ozone generator executed out this process then implants were placed.
223572128|NCT06604819|PROCEDURE|closed sinus lifting using osteotomes with simultaneous implant placement|The patient received closed sinus lifting using osteotomes with implant placed simultaneously.
223572129|NCT06604988|BEHAVIORAL|Video-feedback intervention to promote positive parenting|"Each session will focus on three parental behaviours (that support child development) that have appeared clearly, frequently and consistently in the video (PICCOLO score of 2) in any of the 4 dimensions (affection, responsiveness, encouragement, teaching). Other aspects of parental behaviours that have scored 1 or 0 on the PICCOLO will also be considered, to increase their frequency or encourage their appearance. It is to be expected that all the behaviours collected in PICCOLO appear in one or more of the recordings, even if only occasionally. Behaviours that do not appear can be introduced through linking strategies with other behaviours in which parents show strength (for example, if a caregiver tends to name objects a lot, a link can be established between naming and asking the child the name of objects, if questions are behaviour that does not appear in the logs).~In each session, the caregiver is shown video clips that clearly show the positive parenting behaviours."
223572130|NCT06605235|PROCEDURE|Local Anesthesia|In Group A, patients received 20 ml of 1% lignocaine (Xyloaid-lignocaine HCl injection) infiltrated in the gall bladder bed after removal of the gall bladder, along with 10 ml of 1% lignocaine infiltration at the port sites at the end of the procedure. Subjects in Group B received 20 ml of 0.25% bupivacaine (Bupicain-Bupivacaine HCl injection) infiltration in gall bladder bed, along with 10 ml of 0.25% bupivacaine at port sites. In Group C patients received 10 ml of 1% lignocaine along with 10 ml of 0.25% bupivacaine infiltrated in gall bladder bed, and then 5 ml of 1% lignocaine along with 5 ml of 0.25% bupivacaine at the port sites
223584125|NCT04485572|DIAGNOSTIC_TEST|Straight Leg Raise test (SLR) and Bragard test (B)|The following neurodynamic and/or orthopedic tension tests were done: the Straight Leg Raise test (SLR), the Bragard test (B) and another test which was the combined test of both (SLR+B)
223584126|NCT04485572|DIAGNOSTIC_TEST|Fajersztajn test (F) and Sicard test (S)|The following neurodynamic and/or orthopedic tension tests were done: the Fajersztajn test (F), the Sicard test (S) and another test which was the combination of both (F+S)
224149169|NCT07091877|BEHAVIORAL|Cognitive Reappraisal|Cognitive Reappraisal (CR) is a cognitive-behavioral technique and will complete the Cognitive Reappraisal task.
224149170|NCT07091877|BEHAVIORAL|Control cue-reactivity task|Participants will complete a control cue-reactivity task.
224149171|NCT07091903|OTHER|Diaphragmatic breathing exercise|Individuals in the respiratory group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. Diaphragmatic breathing exercise was performed with the participants in a supine position with bent knees, 10 repetitions and 3 sets.
224149172|NCT07091903|OTHER|Conventional physiotherapy and post-isometric relaxation technique|Individuals in the respiratory group received a physiotherapy and rehabilitation program for 6 weeks, 3 days a week. The treatment of individuals in this group included conventional physiotherapy and post-isometric relaxation technique. Conventional treatment included an exercise program consisting of Wand, Codman, and finger ladder exercise, in addition to 20 min HotPack, 20 min TENS and 5 min Ultrasound modalities. Each of the exercises was applied as 10 repetitions and 1 sets. Post-isometric relaxation technique was applied with 5 seconds of isometric contraction in the direction of flexion, abduction, internal and external rotation, 5 repetitions, 2 sets.
223455005|NCT03831269|DRUG|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
223455006|NCT03831269|OTHER|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
223455007|NCT04468113|DEVICE|Tumark® Vision clip|Suspicious intramammary lesion is marked with clip
223455008|NCT00082095|DRUG|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
223455009|NCT00082095|DRUG|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
223572131|NCT06606041|PROCEDURE|Dry Needling|This. minimally invasive technique is based on the insertion of a sterile, low-caliber, monofilament needle, without the injection or extraction of any additional substances, into hyperirritable muscle nodules. There are two categories within this technique, based on the depth at which the needle is inserted: superficial needling (or the Baldry technique), in which the needle is inserted up to the subcutaneous cellular tissue overlying the myofascial trigger point (up to 10 mm); and deep needling, where the needle is inserted into the muscle with the intention of reaching the myofascial trigger point. Reaching the trigger point was the investigators goal. Regardless of the technique selected, the aim is to generate controlled micro spasms in the affected muscle area, alternating with periods of muscle relaxation.
223572132|NCT06606041|PROCEDURE|Ischemic Compression|Ischemic compression is a conservative, manual technique used on myofascial trigger points, in which pressure should be exerted between 30 and 90 seconds on these same areas. It is suggested that it leads to the normalization of the biomechanical properties of muscle fibers, restoring the muscle\&#39;s functional condition and probably reducing the risk of injury. Thus, the therapeutic effects include the stimulation of mechanoreceptors, with pain attenuation mainly due to the depletion of specific neurotransmitters and temporary obstruction of local blood flow (local ischemia), followed by a rapid influx of oxygenated blood to the area under pressure relief,(37) which will cause an increase in muscle metabolism.
223572133|NCT06606041|PROCEDURE|Cross Tapes|Cross tapes, as the name implies, based on an equidistant intersection of three or four polyester tapes with a non-elastic adhesive acrylic coating, with the 3 lines oriented in a latero-medial direction. It is recommended that it be applied to the muscle area where the myofascial trigger point has been detected, at a 45º angle to the muscle fibers. Its application may have several purposes, such as muscle support, improving the stability of the fibers; pain relief, especially in areas where muscle tension and/or inflammation are present; aiding lymphatic drainage; promoting blood circulation. Before it is applied, the skin should be clean (disinfecting the area with alcohol) and dry, without any lotion or other ointments and the maximum period of use should not exceed 24 hours due to the risk of changes in position, either due to sweating or direct intervention by the patient himself.
223572134|NCT06606223|DIAGNOSTIC_TEST|serum ammonia test|precaution of withdrawal serum ammonia
223572135|NCT03919968|BEHAVIORAL|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
223572136|NCT03919968|BEHAVIORAL|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
224301715|NCT00580216|DRUG|Idrabiotaparinux sodium|"Pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
224301716|NCT00580216|DRUG|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
223455010|NCT02182830|DRUG|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
223455011|NCT02182830|DRUG|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
223455012|NCT02182830|DRUG|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
223455013|NCT01738256|BEHAVIORAL|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
223742859|NCT02410382|DRUG|Placebo|oral placebo
224149173|NCT07092345|BEHAVIORAL|adaptive intervention|We will utilize an adaptive interventions via Sequential Multiple Assignment Randomized Trial (SMART) design provide a tailored, stepped-care approach for the type, intensity, and dose of treatment, thus, providing the most intensive care to only those who need it, particularly treatment non-response. First, youth and caregivers (dyads) will be randomized to receive 1st-stage interventions in the ED, either the digital psychosocial-only (PS) condition or the psychosocial with digital health communication (PS+text) condition. If identified as non-response at 2-weeks, then dyads will be re-randomized to 2nd-stage intervention(s). Specifically, the PS condition non-responders will be re-randomized to the PS+text condition or the PS+text+FN condition. The 1st-stage PS+text condition non-responders will receive the PS+text+FN condition only.
224149174|NCT07090551|DEVICE|occlusal splint therapy|Patients with myofascial pain will receive occlusal splint therapy, which is a clinically accepted treatment method.
224149175|NCT07092332|BEHAVIORAL|Multimodal treatment|"Vulvodynia Intervention adapted for late adolescents and young adults. A multimodal treatment for provoked vulvodynia~The treatment consists of 11 treatment sessions. Working with goal-directed behavior change that has both physiological and psychosocial components. The treatment sessions will be conducted with various professionals, bot simultaneously and separately.~The intervention is based on physiological and psychosocial components working with goal-directed behavioral change; both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are between 60 to 90 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions."
224149176|NCT06928155|DEVICE|Immersive Virtual Reality with Head Mounted Display|"The intervention will be carried out with an immersive virtual reality device, specifically, with a head mounted display. Specifically, it is the MetaQuest 3 model."
224149177|NCT06928155|OTHER|Aerobic exercise and strength training|The combination of aerobic and strength training is part of the conventional physiotherapy treatment carried out at the center.
223455014|NCT01738256|BEHAVIORAL|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
223455015|NCT01738256|BEHAVIORAL|No intervention|No intervention
223455016|NCT00149032|PROCEDURE|DLI sensitized against antigens expressed by the host.|
223455017|NCT00198809|DRUG|Biolean + Diet education|
223455018|NCT00198809|DRUG|Biolean Free + Diet education|
223455019|NCT00198809|DRUG|Placebo + Diet education|
223455020|NCT05309330|OTHER|No Intervention|This is a non-interventional study.
223455021|NCT02145637|DRUG|Afatinib plus Ruxolitinib combination therapy|
223455022|NCT00154375|DRUG|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
223742860|NCT05311696|OTHER|psychoeducation|The program consists of psychoeducational material regarding PTSD, demonstration of various stress management techniques, and social cohesion activities
223742861|NCT04952870|OTHER|Inhaled NO|Newborn or young infants (\< 3 months) receiving inhaled NO as part of their treatment for severe respiratory failure
223742862|NCT04952870|OTHER|routine care|Patients treated for respiratory failure
223742863|NCT04940052|DRUG|Dabrafenib|Dabrafenib will be administered orally twice daily
223455023|NCT00154375|DRUG|Hydroxyurea|
223455024|NCT00489437|DEVICE|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
223455025|NCT00489437|PROCEDURE|Clinical Prediction Score-HIT Score Card|"1. clinical prediction rule~2. rapid immunoassay"
223455026|NCT02760121|DRUG|Acetazolamide|
223455027|NCT02760121|DRUG|Methazolamide|
223455028|NCT02760121|DRUG|Placebo|
223455029|NCT00797394|DIETARY_SUPPLEMENT|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
223455030|NCT00797394|DIETARY_SUPPLEMENT|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
223455031|NCT02348008|DRUG|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
223455032|NCT02348008|DRUG|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
223455033|NCT02348008|DRUG|MK-3475|Arm B: Phase II Treatment: 200mg IV
223455034|NCT02348008|DRUG|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
223742864|NCT04940052|DRUG|Trametinib|Trametinib will be administered orally once daily
223742865|NCT04940052|DRUG|Trametinib placebo|Trametinib will be administered orally once daily
223742866|NCT04940052|DRUG|Dabrafenib placebo|Dabrafenib placebo will be administered orally twice daily
223742867|NCT06957418|DRUG|AADvac1|AADvac1 tau directed therapy
223742868|NCT06957418|DRUG|Tau2|Tau2 directed therapy
224149178|NCT01091909|PROCEDURE|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
224149179|NCT06393894|DIAGNOSTIC_TEST|Near infrared spectroscopy|Near infrared spectroscopy (NIRS) is an intravascular imaging technique. Patients after coronary angiography with or without angioplasty will undergo NIRS if deemed suitable by the interventionalist. NIRS has a high sensitivity and specificity for lipid core plaque detection.
224149180|NCT06393894|GENETIC|Genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 mutations and niR-126, -145 and -155 expression.|Patients without explicit atherosclerosis risk factors and known genetic disorders will undergo genetic testing for LDLR, APOB, PCSK9 and LDLRAP1 genes in order to evaluate the presence of gene variations as a cause for early atherosclerosis. MiRNA-126, -145 and -155 expression in patients serum samples will be evaluated and correlated with plaque lipid core in near infrared spectroscopy (NIRS) imaging.
224149181|NCT01962285|DRUG|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
224149182|NCT06919614|DIAGNOSTIC_TEST|Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing|Xpert® CT/NG and TV testing
223455035|NCT06015919|BEHAVIORAL|dash diet|"* Group (A): It will include 15 post-menopausal women who will be treated by DASH diet and anti-hypertensive drugs.~* Group (B): It will include 15 post-menopausal women who will be treated by acupuncture and anti-hypertensive drugs.~* Group (C): It will include 15 post-menopausal women who will be treated by DASH diet, acupuncture and anti-hypertensive drugs."
224149183|NCT02005224|OTHER|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
224149184|NCT03516734|DIETARY_SUPPLEMENT|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
224149185|NCT03516734|OTHER|Non Iron-fortified lentils|Non-fortified lentils will be provided
223455036|NCT06015919|DEVICE|Acupuncture|acupuncture
223455037|NCT00616447|DEVICE|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
223455038|NCT00616447|DEVICE|placebo sham|Sham treatment will mimic active treatment mentioned above.
223455039|NCT06179043|BEHAVIORAL|Nutrient warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* Labels that read high in sugars and high in calories~* A label that reads high in sugars"
223455040|NCT06179043|BEHAVIORAL|Text-only health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay"
223455041|NCT06179043|BEHAVIORAL|Graphic health warning labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay"
223455042|NCT06179043|BEHAVIORAL|Control labels|"In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A neutral bar code label~* A neutral quick response (QR) code label (not scannable)"
223455043|NCT01909141|DRUG|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
223455044|NCT01909141|DRUG|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
223455045|NCT01909141|RADIATION|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of \> 18 mm or till day 20 of the cycle
223455046|NCT01909141|OTHER|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
223455047|NCT01909141|OTHER|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
223455048|NCT01909141|OTHER|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
223455049|NCT01909141|OTHER|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
223455050|NCT01909141|OTHER|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
223572137|NCT06605690|DRUG|Dalpiciclib and Letrozole Combined With Anlotinib|Dalpiciclib: 150mg orally, once daily, d1-d21, every 28 days as a cycle (3 weeks / 1 week off) Letrozole: 2.5mg orally once daily (continuous) Anlotinib: 12mg orally, once daily, d1-d14, every 21 days as a cycle (use 2 weeks/stop 1 week). One of the last cycles of the new auxiliary The combination of anlotinib is not included in the treatment regimen to ensure that the time interval between anlotinib withdrawal and surgery is more than 2-3 weeks.
223572138|NCT06602583|DIAGNOSTIC_TEST|Standard Dose Coronary angiography|The radiation exposure of this group would be collected from database of already done studies in the months prior to the initiation of the study (so as to prevent observer bias which may happen once the interventional cardiologist knows his inclusion in study, and may use a shorter or longer cine runs, thus influencing the outcomes). This would best represent the real-world data set, according to the routinely followed standard dose/ older low dose protocol.
224149186|NCT03516734|OTHER|Usual Intake|No lentils will be provided.
224149187|NCT06924814|BEHAVIORAL|Standard of Care|Participant is allowed to use what they will use as a distraction tool while they are receiving treatment.
224149188|NCT06924814|BEHAVIORAL|Immersive technology|Participants will be randomly assigned to one of the following four groups; VR headsets, a bluetooth haptic device (Buddy Guard), a screen and projector (BERT), and a tablets with a game. Participant's anxiety will be assessed and pre- and post-intervention assessments will be completed.
224149189|NCT06829277|COMBINATION_PRODUCT|Sodium fluoride varnish|Sodium fluoride varnish
224149190|NCT06829277|OTHER|Curodont De Senz|Curodont De Senz
224149191|NCT06829277|COMBINATION_PRODUCT|Curodont De Senz plus laser irradiation|Curodont De Senz plus laser irradiation
224149192|NCT06829277|DEVICE|Laser irradiation|Laser irradiation
224149193|NCT02158702|DRUG|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
224149194|NCT01606293|BEHAVIORAL|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
224149195|NCT03801356|DRUG|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
223742869|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
223742870|NCT00708942|DRUG|Placebo|Placebo suppository, for 3-7 hours application
224149196|NCT06300346|DRUG|Propofol|Ondansetron
224149197|NCT06937580|BEHAVIORAL|Peer Support and Baby Box|The intervention consists of five one-on-one peer support sessions and a Baby Box consisting of a woolen hat and socks for infant warmth, a cloth wrap to position the baby securely for skin-to-skin contact and improve comfort, a bar of soap for hygiene, and a real-time continuous temperature monitoring device for hypothermia detection
224149198|NCT06935461|BEHAVIORAL|Families Moving Forward Bridges|Ten, 60-minute manualized FMF Bridges intervention sessions over 3-5 months (approximately every other week)
224149199|NCT05562284|PROCEDURE|intra-arterial thrombolysis|IAT introduces rt-PA directly into the ophthalmic circulation by super-selective microcatheterization.
224149200|NCT05562284|OTHER|conservative treatments|conservative treatments
224149201|NCT03968341|OTHER|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
223455051|NCT01909141|OTHER|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
223572139|NCT06602583|DIAGNOSTIC_TEST|New low dose angiography|a comparative arm where the patients being once eligible for the study; would undergo angiography using the new low dose protocol.
224149202|NCT00472355|DRUG|apomorphine|
224149203|NCT00330525|DRUG|sibutramine|
223572140|NCT06605547|PROCEDURE|Non-surgical periodontal treatment|The non-surgical periodontal treatment (scaling and root planing) was applied under local anesthesia using ultrasonic device and Gracey curettes. After scaling and root planing, periodontal pockets were irrigated using saline solution. Non-surgical periodontal treatment was completed in one or two sessions within 24 hours.
224149204|NCT02947022|DRUG|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
223572141|NCT06605547|DEVICE|Subgingival application of saline|For the subgingival saline application at the control sites, the insulin needle was filled with saline and the 29-gauge needle tip was gently placed into the periodontal pocket. The saline was injected into the periodontal pocket until it was seen to overflow from the gingival margin. Subgingival saline application was repeated on the 7th day.
223742871|NCT00708942|DRUG|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
223742872|NCT00708942|DRUG|Placebo|Placebo ointment for 5 hours application
223742873|NCT03407742|BEHAVIORAL|CAPAS Youth|9-week parenting intervention
223742874|NCT06005922|OTHER|physiotherapy|ultrasound hotpack electrotherapy joint range of motion exercises isometric neck exercises stretching exercises
223455052|NCT06596876|DRUG|HRG2010; Sustained-release Carbidopa/Levodopa administered placebo|Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.
223455053|NCT06596876|DRUG|Sustained-release Carbidopa/Levodopa; HRG2010 placebo|Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.
223455054|NCT04672044|DEVICE|Active rTMS and exercise|active
223455055|NCT04672044|COMBINATION_PRODUCT|Sham rTMS+Exercise|sham
223455056|NCT06137820|DEVICE|Cetilar® (topical cream)|Topical cream twice daily for 30 days. An average amount of 5 g per day.
223455057|NCT06137820|DEVICE|Cetilar Placebo|Cetilar placebo cream matching to Cetilar®. Topical cream twice daily for 30 days. An average amount of 5 g per day
223455058|NCT03040349|BEHAVIORAL|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
223455059|NCT03040349|BEHAVIORAL|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
224149205|NCT02947022|DRUG|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
223455060|NCT03040349|BEHAVIORAL|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
223455061|NCT02868736|DEVICE|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
224149206|NCT06948760|DEVICE|Control-IQ insulin pump with Lyumjev insulin|Control-IQ insulin pump with insulin using settings determined by experimental conversion factor
224149207|NCT06948760|DEVICE|Control-IQ insulin pump with Humalog or Novolog|Control-IQ insulin pump with Humalog or Novolog using optimized insulin settings
224149208|NCT06388330|OTHER|low FODMAP diet|strict low FODMAP diet followed by reintroduction of different FODMAPs and glucose (control)
224149209|NCT04552431|DRUG|Ciprofloxacin|Ciprofloxacin, 500 mg twice daily
224149210|NCT04552431|DRUG|Tamsulosin Hydrochloride|Tamsulosin Hydrochloride, 0.4 mg once daily
224149211|NCT04552431|DRUG|Tamsulosin Hydrochloride Placebo|Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily
224149212|NCT04552431|DRUG|Ciprofloxacin placebo|Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
224149213|NCT01230749|DRUG|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
224149214|NCT01230749|DRUG|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
224149215|NCT01230749|DRUG|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
224149216|NCT00002717|DRUG|cisplatin|
224149217|NCT00002717|DRUG|paclitaxel|
224149218|NCT01017341|DEVICE|PSU hip protector|hip protetor
224149219|NCT04186234|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 30 to 50 Grays in 5 fractions before liver transplantation
224149220|NCT00929045|DRUG|Growth Hormone Replacement|
224149221|NCT04021706|DRUG|Anamorelin Hydrochloride|Ghrelin receptor agonist
224149222|NCT04021706|DRUG|Placebo|placebo is a inert substance
224149223|NCT04008199|OTHER|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
224149224|NCT02999815|PROCEDURE|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
224149225|NCT02999815|PROCEDURE|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
223455062|NCT05887362|BEHAVIORAL|Hand Reflexology|Reflexology is a well-known, safe, and noninvasive alternative medicine technique. It alludes to a treatment that is applied to particular areas of the hands and feet. The compression on the hands or feet serves as a sensor linked to particular body areas. These sensors are activated by the reflexology technique to improve blood flow, energize, relax, and maintain homeostasis.
223455063|NCT03095352|BIOLOGICAL|Pembrolizumab|200 mg Given IV
223455064|NCT03095352|DRUG|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
223455065|NCT03095352|BIOLOGICAL|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
223455066|NCT06655441|DRUG|3% trehalose|ophthalmic solution with 3% trehalose in sterile saline in multi dose preservative free bottles
223455067|NCT02169297|PROCEDURE|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter \[maximum pump infusion rate\]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
223455068|NCT02169297|PROCEDURE|PCA only|Patients received intravenous PCA post-operatively
223455069|NCT00545935|DRUG|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
223455070|NCT00545935|DRUG|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
223455071|NCT00545935|DRUG|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
223742875|NCT06005922|OTHER|TMJ exercises|tongue relaxation position TMJ isometric strengthening exercises Posture exercises Isometric neck extension in neutral position back extension Strengthening the abdominal muscles Supine dorsal stretch pectoral stretch
224149226|NCT02870257|OTHER|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
224149227|NCT02870257|OTHER|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
224149228|NCT05728762|DEVICE|Novel LEDs|LEDs with a continuous spectrum of 430-780 nm.
224149229|NCT01756638|DRUG|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
224149230|NCT01756638|DRUG|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
224149231|NCT01300585|OTHER|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
224149232|NCT01257672|DRUG|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
224149233|NCT01257672|DRUG|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
224149234|NCT01257672|DRUG|placebo|placebo
224149235|NCT01412151|DRUG|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
224149236|NCT04928313|DRUG|Glatiramer Acetate|Cinnomer® was injected subcutaneously 3 times per week at least 48 hours apart.
224149237|NCT00049972|DRUG|paroxetine CR|
224149238|NCT00520650|DRUG|Aripiprazole|
224149239|NCT02811172|OTHER|BEhavior of biomarkers during pregnanCy and lactatiOn|
224149240|NCT00713284|DRUG|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
224149241|NCT03127852|DEVICE|Medly|
224149242|NCT01451866|OTHER|resistance training|hypertrophic resistance training
224149243|NCT01451866|OTHER|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
224149244|NCT01318668|BIOLOGICAL|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
223455072|NCT06240299|PROCEDURE|Neurofeedback|A noninvasive method based on the voluntary modulation of brain activity, with feedback provided through a graphical user interface shown on a computer screen
223455073|NCT06988423|DRUG|CRS3123 200 mg capsule|CRS3123 200 mg capsule given as a single oral dose
223455074|NCT04741646|DRUG|Ferric Citrate|Auryxia® 210 mg ferric iron tablets equivalent to 1 g of FC will be supplied as 200 tablets in 400cc high-density polyethylene bottles.
223455075|NCT04741646|DRUG|Placebo|Placebo to match Ferric Citrate tablets
223455076|NCT06197646|DEVICE|Cartoon characters inhaler mask|Cartoon characters inhaler mask
223455077|NCT00781924|PROCEDURE|biopsy|ultrasound guided biopsy of tumors.
223455078|NCT05817214|DRUG|Cadonilimab|All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1
223455079|NCT05817214|DRUG|Anlotinib|All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.
223455080|NCT05817214|DRUG|Granulocyte-Macrophage Colony-Stimulating Factor|All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.
224149245|NCT00741104|DRUG|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
224149246|NCT02813590|OTHER|Ascitic fluid puncture|
224149247|NCT02813590|OTHER|Skin swaps from puncture side|
224149248|NCT02813590|OTHER|Stool samples|
224149249|NCT01560104|DRUG|Veliparib|
224149250|NCT01560104|DRUG|Carboplatin|
224149251|NCT01560104|DRUG|paclitaxel|
223455081|NCT03601572|OTHER|No intervention|No intervention
223455082|NCT05447767|DEVICE|KIT BMAC|intra-articular infiltration of BMAC
223455083|NCT05447767|DEVICE|KIT BMAC|intra-articular and intra-osseous infiltration of BMAC
223455084|NCT05447767|DEVICE|at-SVF FIDIA|intra-articular infiltration of at-SVF
223455085|NCT05447767|DEVICE|at-SVF FIDIA|intra-articular and intra-osseous infiltration of at-SVF
223572142|NCT06605547|OTHER|Subgingival application of i-PRF|For subgingival application of i-PRF at the test sites, the i-PRF taken into the insulin syringe, the 29-gauge needle tip was gently placed into the periodontal pocket and the i-PRF was injected into the periodontal pocket until it reached the gingival margin (until it overflowed from the sulcus). Subgingival i-PRF application was repeated on the 7th day.
223572143|NCT02141698|DRUG|TAK-438|TAK-438 tablets
223572144|NCT02141698|DRUG|TAK-438 Placebo|TAK-438 placebo-matching tablets
223572145|NCT02141698|DRUG|Esomeprazole|Esomeprazole tablets
223572146|NCT06660329|DRUG|Janus Kinase Inhibitor|Tofacitinib is used according to weight: 5\~\<7kg，2mg；7\~\<10kg，2.5mg；10\~\<15kg，3mg；15\~\<25kg，3.5mg；25\~\<40kg，4mg；≥40kg，5mg. All is twice a day.
224149252|NCT01560104|DRUG|placebo|
224149253|NCT00859573|DRUG|Modafinil|400 mg/day
224149254|NCT00859573|DRUG|Placebo|inactive substance
224149255|NCT00250068|DRUG|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
224149256|NCT03383055|BIOLOGICAL|CMV-MVA Triplex Vaccine|"* CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~* TDap administered on Day 56"
224149257|NCT06206772|DIAGNOSTIC_TEST|Resting state HD-EEG recording|All subjects will be recorded with a resting state HD-EEG recording. 12 minutes in the eyes closed and 12 minutes in the eyes open condition.
224149258|NCT06111404|PROCEDURE|central urinary bladder dissection|A metal catheter was then inserted in the bladder. The catheter was rotated so the tip was pointing upward, to stretch the bladder pillars. The bladder was dissected with monopolar scissors with the catheter in place. Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014). Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides.
224301717|NCT00580216|DRUG|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~* 0.5 mL for the 3.0 mg dosage;~* 0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~* 0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
223742876|NCT06523751|DIAGNOSTIC_TEST|Trabeculopuncture|Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
223742877|NCT03094845|BIOLOGICAL|Placebo solution|15 injections over 7 weeks
224149259|NCT06111404|PROCEDURE|Lateral urinary bladder dissection|The broad ligament is dissected down till the uterine bundle is identified. Once the uterine vascular bundle is identified the space can be dissected just above these vessels to reach the lateral margins of cervix. Any fatty tissue should be moved with the bladder. Uterine vessels are then tackled by desiccation or ligation. Similar procedure is done on the opposite side. Once the bladder is completely dissected and lifted off from the cervix below, midline adhesions of the bladder and pillars can be gradually separated using sharp dissection or Ligasure staying near to cervix (Chen et al., 2007).
224149260|NCT06111404|DEVICE|Wolf laparoscopy tower|set of instruments used for laparoscopic surgery
224149261|NCT06283134|BIOLOGICAL|BioTTT001 hepatic artery infusion|"BioTTT001 monotherapy period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, administered every 2 weeks, for a total of two doses after enrollment.~BioTTT001 in combination with toripalimab and regorafenib period: BioTTT001 5×10\^7 VP/5×10\^8 VP/5×10\^9 VP/1×10\^10 VP hepatic artery infusion, D2 and D16, 4 weeks per cycle， and the dose of BioTTT001 will be determined according to the safety observation results in the monotherapy phase."
224149262|NCT06283134|DRUG|toripalimab|BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
224149263|NCT06283134|DRUG|regorafenib|BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
224149264|NCT00952601|DIETARY_SUPPLEMENT|Modified Atkins diet|Low carbohydrate diet
224149265|NCT03192514|OTHER|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
224149266|NCT00952770|PROCEDURE|transradial coronary intervention|percutaneous coronary intervention with transradial approach
223455086|NCT06608095|BEHAVIORAL|hypothermia group|Minimize the temperature of the thermometric tank or thermometric catheter for rapid temperature control. Use a thermometric catheter to monitor changes in the patient's core body temperature in real time. When the core body temperature drops to 34 ℃, adjust the target temperature of the temperature-controlled water tank to 34 ℃ and adjust the target temperature of the temperature-controlled water tank in real time according to the patient's core body temperature. Keep the core body temperature around 34 ℃. Maintain the body temperature at 34℃ for at least 24 hours after the patient resumes autonomous circulation. After the patient has resumed voluntary circulation for 24 hours, the rewarming process can begin. The target temperature of the temperature control tank will increase at a rate of 0.2°C/h. After reaching 36°C, maintain the current temperature. Once 36°C is reached, the current temperature is maintained until autonomic circulation has been restored for 5 days.
223742878|NCT03094845|BIOLOGICAL|hdmASIT+TM|15 injections over 7 weeks
223742879|NCT06367309|PROCEDURE|Extended totally extraperitoneal repair|The anterior rectus sheath is incised and the retromuscular space is entered through the rectus muscle fibres. The capnopreperitoneum is established and blunt dissection of the retromuscular space is performed. Two additional laparoscopic ports are established 8-10cm lateral to the linea alba caudally to the initial port. The medial border of the rectus sheath is incised and the preperitoneal space below the linea alba is dissected. The hernia orifice is also dissected from peritoneum and preperitoneal fatty tissue. The medial border of the right retromuscular space is then incised and blunt dissection is performed. The hernia orifice is closed with barbed suture and a synthetic mesh is placed on the posterior sheath of the dissected space (intended Mesh-defect ratio 16). The mesh is fixed non-traumatically using glubran glue or no fixation at all.
223742880|NCT06367309|PROCEDURE|Intraperitoneal onlay mesh|Capnoperitoneum is established through left sided subcostal Veress-Needle punction. Three laparoscopic ports are placed 8-10cm lateral to the linea alba usually on the patient's left side. The peritoneum is incised and detached from the umbilical and supraumbilical linea alba. The peritoneum including the hernia sac and preperitoneal fat is resected. The hernia orifice is then closed using a barbed suture. A coated mesh is than placed to the ventral abdominal wall covering the closed hernia orifices (intended mesh-defect-ratio: 16). The mesh is fixed with two transfacial absorbable sutures and several absorbable tackers placed in double crown technique around the hernia orifice. The capnoperitoneum is released, the trocars removed and the fascia closed with an absorbable suture. The skin is sutured with absorbable sutures.
224149267|NCT05596474|DIETARY_SUPPLEMENT|Beet-root juice|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a 400mg nitrate once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third 400mg dose of nitrates at least 150 minutes before forearm endurance testing.
224149268|NCT05596474|RADIATION|red-light therapy|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to 660nm wave length light for 10-minutes.
224301718|NCT00580216|DRUG|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
224301719|NCT00580216|DRUG|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
224301720|NCT00580216|DRUG|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
224301721|NCT05389683|BEHAVIORAL|Elimination Diet|An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
224149269|NCT05596474|DIETARY_SUPPLEMENT|Placebo|Two days prior to the forearm endurance protocol, participants will be provided and instructed to consume a nitrate depleted placebo once per day. On the day of the forearm endurance protocol, the participants will be provided and instructed to consume a third dose of the nitrate depleted placebo at least 150 minutes before forearm endurance testing.
224149270|NCT05596474|RADIATION|sham light|Participants will place their dominant forearm 15 centimeters away from the light source and have their dominant forearm exposed to sham light for 10-minutes.
224149271|NCT04446494|PROCEDURE|Identification and preservation of arm lymphatics (DEPART)|Indocyanine green was utilized to identify arm sentinel nodes, and 0.1 ml MB was injected into the arm sentinel nodes to reveal the subsequent-echelon nodes and lymphatics. Gross arm lymph nodes were examined by intraoperative partial frozen section and were removed if positive.
224301722|NCT00186758|DEVICE|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
223455087|NCT06608095|BEHAVIORAL|normothermia group|Set the temperature of the temperature-controlled water tank or the in vivo cooling catheter to 37°C to maintain the patient's core temperature between 36.5-37.5°C. Real-time monitoring of the patient's core temperature changes through the thermometric urinary catheter, and real-time adjustment of the temperature of the temperature-controlled water tank. The patient's temperature was maintained between 36.5-37.5°C after the patient resumed voluntary circulation until the end of temperature control 5 days after the recovery of voluntary circulation.
223455088|NCT06609031|PROCEDURE|endoscopic mucosal resection|The SSLs less than 10mm in size in this group will be treated by EMR
223455089|NCT06609031|PROCEDURE|Cold snare polypectomy|The SSLs less than 10mm in size in this group will be treated by CSP
223572147|NCT06662331|PROCEDURE|Bilateral Sagittal Split Osteotomy|A surgical procedure to correct dentofacial deformities
223572148|NCT06662266|DEVICE|Induce XT™ is a mixture of human cortical bone fibers and microparticulates that have been processed into Natural Matrix Protein® (NMP®) to which cancellous bone microparticulates have been added|"Bone graft material is required for successful foot and ankle fusion surgery. Current bone grafting materials include autogenous bone, Augment Bone Graft and demineralized bone matrix (DBM), each of which have limitations.~Induce XT is a novel bone graft material that can potentially be used in foot and ankle fusions that may overcome some of these limitations."
223572149|NCT06661096|PROCEDURE|TMJ arthroscopy|level I and level II TMJ arthroscopy
223572150|NCT06658834|DRUG|Dexamethasone Combined with romiplostim N01|Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
223572151|NCT06658834|DRUG|Dexamethasone monotherapy|Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
223572152|NCT06659016|DRUG|Fosfomycin 3 g|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months.
223572153|NCT06659016|DIETARY_SUPPLEMENT|Uroxin 4G|Dietary supplement of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
223572154|NCT06659016|DRUG|Combination of dietary supplement and fosfomycin|Fosfomycin trometamol 3 g administered orally in a single dose every ten days for three months, repeated every three months for a total treatment duration of 12 months, combined with an oral formulation of D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis plus quercetin (Proqutin ®) and Bacillus Coagulans (Uroxin 4G, Pharmasuisse laboratories, Milan, Italy) administered twice daily for seven days in the first month, then once daily for 14 days a month for two months, repeated every three months for a total treatment duration of 12 months.
223742881|NCT05434650|DEVICE|electrophysiology study and ablation with an Abbott Ablation Catheter|During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat
223742882|NCT00846755|DRUG|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
223742883|NCT03455660|OTHER|no intervention|no intervention
223572155|NCT06661018|DRUG|Coenzyme Q 10|participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
223572156|NCT06661018|DRUG|Placebo|participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
223572157|NCT06658678|OTHER|Receiving an educational intervention|Patient not receiving any educational intervention
223742884|NCT04176900|OTHER|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
223742885|NCT04176900|OTHER|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
223742886|NCT00874354|DRUG|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
223742887|NCT05816187|BEHAVIORAL|Education program on healthy habits|6-week supervised educational program.
224149272|NCT02050828|DRUG|AKB-9778|
224149273|NCT02050828|DRUG|ranibizumab|
224149274|NCT02050828|DRUG|Placebo|
224149275|NCT02050828|DRUG|Sham|
224149276|NCT05595135|OTHER|Text Message-Based Navigation Intervention|Receive interactive text messaging.
224149277|NCT05595135|OTHER|Behavioral, Psychological or Informational Intervention|Receive medication reminders via smart pill bottle
224149278|NCT05595135|OTHER|Survey Administration|Ancillary studies
224149279|NCT05595135|OTHER|Quality-of-Life Assessment|Ancillary studies
224301723|NCT00208806|OTHER|congestive heart failure patients|observational echo data on congestive heart failure patients
224301724|NCT04594707|DRUG|PRM-151 (Zinpentraxin Alfa)|"Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo."
224301725|NCT02691793|DRUG|Sunitinib|sunitinib 37.5mg QD
223455090|NCT00334295|DRUG|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
223455091|NCT06517550|OTHER|positive end-expiratory pressure while mechanical ventilation|a parameter in ventilator
223455092|NCT04207944|DRUG|Sulindac 400 MG|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
223455093|NCT04207944|OTHER|Placebo|Patients will be randomized to receive standard radiographic/endoscopic surveillance plus sulindac. The sulindac starting dose is 200 mg by mouth 2x daily. Randomization will be performed at Duke and stratified by (1) the presence of high-grade dysplasia on the operative pathologic report and (2) the use of metformin at the time of enrollment. Patients will be provided the study drugs by a Duke, MSK, MGH, or JHH pharmacist. Patients will continue drug/placebo for 3 years during follow-up.
223455094|NCT06658808|BEHAVIORAL|Promoting Community Conversations About Research to End Suicide|Promoting Community Conversations About Research to End Suicide (PC CARES) trains local community health workers to facilitate a series of five 3-hour Learning Circles (LCs) over \~6 months to develop a 'community of practice' (CoP), whereby trusted adults of youth (a) learn about SPBPs; (b) tailor the SPBPs to their culture and community; (c) build cross-sector relationships (parents, teachers, etc.), and (d) do more to prevent suicide. Each session shares evidence-based, actionable ways to enhance social support, reduce harm/risk, and promote help seeking, which participants adapt and apply in their daily interactions with youth.
223455095|NCT06670365|OTHER|Heat acclimation by warm-water immersion|Participants will be immersed in a whirlpool tub to the shoulder level in a circulated water bath maintained at \~40°C until their core temperature achieves a steady-state of 38.5°C for 60 minutes. The warm-water immersion protocol will be repeated for 6 more consecutive days.
223742888|NCT05816187|BEHAVIORAL|Habitual|The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking
224149280|NCT03349580|BEHAVIORAL|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
224149281|NCT03460470|DRUG|Sildenafil|PDE5 Inhibitor
224149282|NCT03460470|DRUG|Placebo oral capsule|Placebo for Sildenafil
224149283|NCT05571904|PROCEDURE|thick STSG; thin STSG|"For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients."
224149284|NCT01630941|DRUG|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
224149285|NCT01120821|DRUG|Gleevec|400 mg once daily for 12 months
224149286|NCT00124813|DRUG|thalidomide|
224149287|NCT00124813|DRUG|idarubicin|oral idarubicin
224149288|NCT04587921|DEVICE|Digital oximeter monitoring|Digital oximeter and cardiac frequency monitoring.
224149289|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
224149290|NCT01432457|DRUG|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
224149291|NCT01432457|DRUG|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
224149292|NCT02574481|DEVICE|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
224149293|NCT02574481|DEVICE|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
224149294|NCT04059874|DRUG|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
224301726|NCT03080753|DEVICE|Sphinkeeper|Intersphincteric implants in the anal sphincter
224301727|NCT02403453|DEVICE|Rhine Cervical Disc|RHINE Cervical Disc
224301728|NCT00755404|DRUG|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
224301729|NCT00755404|DRUG|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
224149295|NCT04131244|PROCEDURE|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
224149296|NCT02880735|DEVICE|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
224149297|NCT03822702|OTHER|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
224149298|NCT03822702|OTHER|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
224149299|NCT05094076|RADIATION|chest x ray|The chest radiographs obtained will be classiﬁed according to the International Labor Organization (ILO) System for Classiﬁcation of Radiographs for Pneumoconiosis \[ILO, 1980\]. Film quality, profusion, and shape and size of opacities will be evaluated by this method. Radiographic evidence of silicosis was deﬁned as a profusion score of 1/0 or greater
224149300|NCT05333003|DRUG|Semaglutide|The semaglutide dose will start with 0.25 mg/week, and slowly increased every four weeks as tolerated up to a maximal dose of 2 mg/week
224149301|NCT05333003|OTHER|Placebo|Placebo will be provided to participants
224149302|NCT05325398|DIETARY_SUPPLEMENT|HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada|"The cohort will consist of 17 patients with NAFLD. Name of the product that will be the source of molecular hydrogen: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada. It is a nutritional supplement that is a source of molecular hydrogen.~All study participants will drink one tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)."
224149303|NCT05325398|DIETARY_SUPPLEMENT|placebo|"13 probands in the control group who will receive placebo. All study participants will drink one placebo tablet dissolved in 0.33 l of tap water every 8 hours.~They did this for 8 weeks. Blood analysis at study entry and after 8 weeks (end of study)"
224149304|NCT05970068|PROCEDURE|implantation of hydrophobic tubes for edema fluid drainage|1 - A 2-cm-long incision is made at the border of the hypogastrium or lumbar region 10 cm above the inguinal crease; 2- A 1.5-cm-wide and 100-cm-long metal tube tunneling device is introduced under the skin and bluntly passed in the subcutaneous tissue toward the thigh and internal aspect of the calf; 3- Incisions 2 cm long are made in the groin and calf, through which the tunneling device was passed; 4-The hydrophobic tube is passed upward through the tunneling device, after which the tunneling device is removed; 5-The upper and lower ends of the hydrophobic tubes are fixed to the fascia with absorbable sutures.
224149305|NCT05970068|DEVICE|Best Medical Treatment|Compressive therapy, Phisioterapy, venous intervention
224149306|NCT00640276|DRUG|pitavastatin|Pitavastatin 2mg daily once
224149307|NCT00640276|BEHAVIORAL|Lifestyle Modification|conducting mainly exercises and diet
224149308|NCT01943188|RADIATION|stereotactic body radiation therapy|Undergo SBRT
224149309|NCT01943188|DRUG|cyclophosphamide|Given PO
224301730|NCT05665114|DRUG|QN-030a|NK cell therapy
224301731|NCT05665114|DRUG|Cyclophosphamid|Lympho-conditioning Agent
223455096|NCT05817721|DRUG|Proton pump inhibitor|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis will be divided into a PPI/Non-PPI group depending on if they concomitantly were prescribed a PPI or not
223455097|NCT05817721|DEVICE|LAMS-implantation|Patients who received a lumen apposing metal stent (LAMS) for drainage of a walled off necrosis (WON) upon acute pancreatitis
223455098|NCT00743678|DRUG|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
223455099|NCT03268005|DRUG|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
223742889|NCT05791734|OTHER|assessing preoperative skin cleanliness|2 skin swabs on surgical incision sites and direct skin visual observation by a nurse
224149310|NCT01943188|BIOLOGICAL|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
224149311|NCT01943188|OTHER|laboratory biomarker analysis|Correlative studies
224149312|NCT05309733|GENETIC|VOR33|VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
224149313|NCT00905268|DRUG|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
224149314|NCT00905268|DRUG|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
224301732|NCT05665114|DRUG|Fludarabine|Lympho-conditioning Agent
224301733|NCT05665114|DRUG|Cytarabine|Lympho-conditioning Agent
224301734|NCT05665114|DRUG|VP-16|Lympho-conditioning Agent
224301735|NCT04439695|BIOLOGICAL|Low dose|Low dose of KBP-V001
224301736|NCT04439695|BIOLOGICAL|Intermediate dose|Intermediate dose of KBP-V001
224301737|NCT04439695|BIOLOGICAL|High dose|High dose of KBP-V001
224301738|NCT04439695|BIOLOGICAL|Placebo|Buffered Saline Solution
224305094|NCT01070459|BEHAVIORAL|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
223455100|NCT03268005|DRUG|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
223455101|NCT03268005|DRUG|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
223742890|NCT03251573|OTHER|cognitive impairment|one are of patients were exposed to cognitive impairment
223742894|NCT00858442|PROCEDURE|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width \& length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width \& length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
223742895|NCT04298996|DIAGNOSTIC_TEST|taking saliva samples to determine oxidative stress markers TAS and TOS|
223742896|NCT05508971|PROCEDURE|DISE-Directed Surgery|Participants randomized to DISE-directed surgery will undergo one or more potential procedures in a single surgery (i.e. DISE and subsequent sleep surgery performed) concurrently under the same general anesthetic), depending on anatomic assessment.
224149315|NCT06241820|PROCEDURE|Lumbar Sympathetic Ganglion Block|A needle will be inserted at the L3 on the side experiencing pain, either right or left, under fluoroscopy guidance. Once the needle is positioned in front of the desired vertebral body, its location is confirmed using a contrast medium. If the position is well visualized in lateral and anteroposterior (AP) views, 7 mL of 0.5% ropivacaine will be injected.
223742897|NCT05508971|PROCEDURE|Adenotonsillectomy|Tonsil and adenoid removal
223742898|NCT04875182|DIAGNOSTIC_TEST|Evaluation of Delirium development|Postoperative pain scores of the patients will recorded by using a numerical rating scale.
223742899|NCT05791474|DRUG|ATI-2231|Provided by Aclaris Therapeutics, Inc.
223742900|NCT04110132|PROCEDURE|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
223742901|NCT04110132|PROCEDURE|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
224149316|NCT02905825|DEVICE|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
224149317|NCT02905825|DRUG|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
224149318|NCT02905825|DIAGNOSTIC_TEST|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
224149319|NCT00013767|BEHAVIORAL|Individual and Community education|
224149320|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
224149321|NCT01107288|OTHER|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
224149322|NCT03714347|DEVICE|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
224149323|NCT03714347|DEVICE|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
224149324|NCT00045591|DRUG|celecoxib|100 mg PO bid
224149325|NCT00045591|DRUG|Celecoxib|400 mg PO bid
223455102|NCT03268005|DRUG|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
223742902|NCT05838404|BEHAVIORAL|M-O-M-S on the Bayou|Peer and mentor support and meetings across pregnancy
223742903|NCT04371887|OTHER|Local Tailoring|"The guided local tailoring approach will employ a standard structured process, including (1) convening a project team, (2) conducting a local diagnostic process to identify likely barriers using provider/patient survey and interviews with providers/administrators, (3) selecting from a pre-developed menu of implementation strategies categorized by core function (form and function menu), and (4) deploying the selected strategies in collaboration with local implementation and improvement consultants."
223742904|NCT02902185|DRUG|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
223742905|NCT02902185|DRUG|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
223742906|NCT02576561|BIOLOGICAL|TVGV-1|Antigen + Adjuvant
224149326|NCT03507192|DEVICE|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
224149327|NCT00422123|DRUG|Quetiapine fumarate (Seroquel) SR|
224149328|NCT01281189|DRUG|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
224149329|NCT01281189|DRUG|Placebo|Oral tablet twice daily for up to 18 months.
224149330|NCT02883920|OTHER|Allergy and respiratory functional tests|
224149331|NCT01375738|PROCEDURE|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
224149332|NCT01375738|PROCEDURE|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
223455103|NCT02152098|PROCEDURE|Acute Early onset of rehabilitation|Early onset of rehabilitation
223742907|NCT02576561|BIOLOGICAL|GPI-0100|Adjuvant Alone
223742908|NCT02576561|BIOLOGICAL|Placebo|Placebo
224149333|NCT03543527|OTHER|no intervention|no intervention
224149334|NCT05848973|OTHER|Healthy Diet|The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
224149335|NCT05848973|BEHAVIORAL|Mindfulness-based cognitive therapy (MBCT)|MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
224149336|NCT00274066|DRUG|Tiotropium + placebo|
224149337|NCT00274066|DRUG|Tiotropium + ipratropium|
224149338|NCT00274066|DRUG|Tiotropium + fenoterol|
224149339|NCT02228772|DRUG|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
224149340|NCT02228772|DRUG|Vincristine|Standard chemotherapy dosage and duration
224149341|NCT02228772|DRUG|Cytarabine|Standard chemotherapy dosage and duration
224149342|NCT02228772|DRUG|Doxorubicin|Standard chemotherapy dosage and duration
224149343|NCT02228772|DRUG|Mercaptopurine|Standard chemotherapy dosage and duration
223455104|NCT02152098|PROCEDURE|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
223455105|NCT02152098|PROCEDURE|Chronic Exercise|Exercise
223455106|NCT02152098|PROCEDURE|Chronic Control|Control
223572158|NCT05050617|DIAGNOSTIC_TEST|Point-of-care echocardiography|Subjects will undergo point-of-care echocardiography at the time of presentation/enrollment to assess for evidence of right sided heart dilation/strain.
223572159|NCT03537742|BIOLOGICAL|alirocumab|alirocumab 150mg Subcutaneous
223572160|NCT03537742|BIOLOGICAL|placebo|placebo to match alirocumab
223572161|NCT06604416|OTHER|Forward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.
223572162|NCT06604416|OTHER|Backward walking|The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
223572163|NCT06606496|DEVICE|Bispectral index (BIS)|The bispectral index (BIS) monitor is a quantitative electroencephalographic (EEG) device that is widely used to assess the hypnotic component of anaesthesia, especially when neuromuscular blocking drugs are used. If necessary, it may be necessary to increase or decrease MAC (minimum alveolar concentration) in the testosterone group according to the BIS monitoring value.
224149344|NCT02228772|DRUG|Cyclophosphamide|Standard chemotherapy dosage and duration
224149345|NCT02228772|DRUG|Methotrexate|Standard chemotherapy dosage and duration
224149346|NCT05215678|OTHER|Acceptance of invitation to trial participation|Individuals who are eligible for and accept participation in the INKA trial (NCT05172843)
224149347|NCT05215678|OTHER|Declining invitation to trial participation|Individuals who are eligible for participation in the INKA trial (NCT05172843) but decline the invitation to participate
224149348|NCT01135745|DEVICE|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
224149349|NCT01431651|DIETARY_SUPPLEMENT|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
223572164|NCT06607952|OTHER|scenario-based case videos teaching protocol|"Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical"
224149350|NCT03362203|OTHER|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
224149351|NCT03362203|OTHER|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
224149352|NCT05757479|PROCEDURE|Steroid-eluting stent implantation|The sinus cavity with inflammation receives one bioabsorbable steroid-eluting sinus stent.
223455107|NCT03715452|DEVICE|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
223455108|NCT06922448|DRUG|BLU-808|BLU-808 tablets
223455109|NCT06922448|DRUG|Placebo|Placebo tablets
223455110|NCT06918132|PROCEDURE|Biospecimen Collection|Undergo tissue and blood sample collection
223455111|NCT06918132|BIOLOGICAL|Cemiplimab|Given IV
224149353|NCT05757479|DRUG|Steroid nasal spray|1 spray into each nostril once a day.
224149354|NCT05757479|PROCEDURE|nasal saline rinses|The saltwater runs through nasal passages and drains out of the nostril.
224149355|NCT01136746|DRUG|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
224149356|NCT01136746|DRUG|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
224149357|NCT01136746|DRUG|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
224149358|NCT03154294|DRUG|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
224149359|NCT03154294|DRUG|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
224149360|NCT03154294|DRUG|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
224149361|NCT02868255|PROCEDURE|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
223572165|NCT06607952|OTHER|traditional lecture-based teaching method|Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
223455112|NCT06918132|BIOLOGICAL|Fianlimab|Given IV
223455113|NCT06918132|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223572166|NCT06607198|DIAGNOSTIC_TEST|grading &amp; staging|To investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
223572167|NCT06607198|DIAGNOSTIC_TEST|PitNET morphology analysis|Revision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
223455114|NCT06918132|PROCEDURE|Surgical Procedure|Undergo SOC surgery
223455115|NCT06842732|BEHAVIORAL|Maternal Administered Malnutrition Monitoring System - Infant and Young Child Feeding (MAMMS IYCF) intervention|All caregivers randomized to the MAMMS-IYCF arm will be given two MUAC tapes after being trained by skilled study staff and their contact information will be entered into the online MAMMS-IYCF platform. The frequency of messages will be weekly. This will be a two-way SMS system, including health messages on age appropriate IYCF. These messages will also prompt caregivers to measure their child's MUAC, return the color outcome of the measurement to the clinic via the SMS system, and they will also be able to ask any health questions that they may have through the SMS. During follow-up, any caregiver who returns a MUAC measurement via SMS that suggests their child is wasted, will receive an SMS response asking them to come to the clinic with their child as soon as possible. At this visit, the wasting status of the child will be confirmed by a study staff, and if treatment is indicated they will be enrolled into nutritional care provided by MOH nutritionists.
223455116|NCT06842732|BEHAVIORAL|Standard of Care (SOC)|To promote high fidelity to current guidelines, all families randomized to the SOC arm will be enrolled into a one-way SMS service that will send them automated reminders before necessary routine EID or HIV care visits and research clinic appointments on day 90 and 180. During these routine clinic visits, study staff will ensure that the MUAC of SOC children are measured, and that treating clinicians (MOH nutritionists) are made aware if wasting is identified. Staff will ensure that SOC children are enrolled into nutritional care if they are wasted. This additional support means it is likely that SOC children in this study will receive care that is more adherent to current recommendations than is typical for many children. This enhanced SOC is necessary to ensure we are comparing the MAMMS-IYCF to current guidelines. The SMS messaging service will be free of cost to the caregivers as they will not incur any charges to send or receive messages while enrolled in the trial.
223572168|NCT06607198|DIAGNOSTIC_TEST|Radiomics|To investigate radiomics features of PitNETs
223572169|NCT06607198|DIAGNOSTIC_TEST|Molecular test: proteomics|To investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
224149362|NCT05459480|OTHER|the jigsaw technique in web-based distance education|The online training for the intervention group continued for a total of 6 weeks according to the jigsaw technique.
224149363|NCT04251624|BEHAVIORAL|Goal Management Therapy|A cognitive training program aimed at improving cognitive deficits such as in memory, attention, learning, and executive functioning.
223455117|NCT04467983|DRUG|Denosumab Injection|Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.
223455118|NCT04467983|DRUG|Abaloparatide|Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.
223572170|NCT01677598|DRUG|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
223572171|NCT06662344|BEHAVIORAL|Intermittent Oral-esophageal Tube Feeding|The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
223742909|NCT04318990|PROCEDURE|Distal radial artery access|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
223742910|NCT04318990|PROCEDURE|Proximal radial artery surgery|Patients undergoing coronary angiography or angioplasty at The Heart Hospital Baylor Plano will be randomized 1:1 to distal or proximal radial access for cardiac catheterization.
223742911|NCT00391989|DRUG|Dasatinib|
224149364|NCT04251624|BEHAVIORAL|Psychosocial Education|A group therapy program focusing on brain function, neuroplasticity, and lifestyle interventions.
224149365|NCT05116891|DRUG|CAN04 (nadunolimab)|FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
224149366|NCT05116891|DRUG|mFOLFOX|mFOLFOX/CAN04
224149367|NCT05116891|DRUG|DTX|DTX/CAN04
224149368|NCT05116891|DRUG|G/C|G/C/CAN04
224149369|NCT03444467|DRUG|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
224149370|NCT03444467|DRUG|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
224149371|NCT03444467|DRUG|Placebo|Participants will receive single dose of placebo (for double dummy injections).
224149372|NCT05983016|DEVICE|Philips EPIQ-7, Philips Healthcare, Bothell, WA, USA|"All patients had their abdominal aortic aneurysm maximum anterior-posterior diameter estimated with two-dimensional ultrasound using a 5 MHz curved array transducer (Philips® C5-1 transducer, Philips Healthcare, Bothell, WA, USA).~After the acquisition, a three-dimensional ultrasound acquisition was performed with a 3D-matrix transducer (Philips® X6-1 transducers, Philips Healthcare, Bothell, WA, USA)."
224149373|NCT00617617|DIETARY_SUPPLEMENT|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
224149374|NCT00617617|OTHER|Placebo|Control Group - Control Group participants will receive an identical placebo.
224149375|NCT04903886|OTHER|observational|observational
223455119|NCT05407415|OTHER|Kardia Mobile 6L Device|"The KardiaAL is a software analysis library intended to assess ambulatory electrocardiogram (ECG) rhythms from adult subjects. The device supports analyzing data recorded in compatible fonnats from any ambulatory ECG devices such as event recorders, or other similar devices. The library is intended to be integrated into other device software. The library is not intended for use in life supporting, or sustaining systems, or ECG monitors, or cardiac alarm, or OTC use only devices.~The KardiaAI library provides the following capabilities:~* ECG noise filtering,~* heart rate measurement from ECGs,~* detection of noisy ECGs, and~* ECG rhythm analysis for detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, and tachycardia (when prescribed or used under the care of a physician)."
223455120|NCT06954961|DRUG|D-0502|"* Dosage form: Tablet~* Administration route: Oral, once a day"
223455121|NCT06954961|DRUG|Fulvestrant|"* Dosage form: Injection~* Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose"
223455122|NCT04052321|OTHER|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
224149376|NCT05849896|DEVICE|Acquisition of HD sEMG signals using the WPM-SEMG device|The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
224149377|NCT04753749|DRUG|Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)|Subjects will receive DAPT during 1 month post procedure, followed by P2Y12 inhibitor monotherapy (cessation of aspirin) for the next 11 months
224149378|NCT04753749|DRUG|Standard DAPT|Subjects will receive standard treatment: P2Y12 inhibitor and aspirin (DAPT) during 12 months after procedure
224149379|NCT05276765|PROCEDURE|cad/cam socket sealing abutment|Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration
224149380|NCT05276765|PROCEDURE|standard healing abutment|Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
223455123|NCT02480881|DRUG|BMS-663068|Investigational product
223455124|NCT02480881|DRUG|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
223455125|NCT02480881|DRUG|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
223455126|NCT01681953|DRUG|Lamazym|ERT, i.v. infusions weekly
223455127|NCT01681953|DRUG|Placebo|Infusions weekly
223455128|NCT00734708|DRUG|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
223455129|NCT00734708|DRUG|Placebo|Control
223455130|NCT06363019|BEHAVIORAL|Supporting at-risk Mothers Across perinatal period: a Randomized controlled Trial (SMART) mobile application|The intervention is delivered through the SMART mobile application. It contains educational information in audio, visual, article format; on parenting, pregnancy and managing emotional well-being. There is also a peer support feature where participants can speak to experienced mothers via the SMART app. There is also a forum feature where participants can interact with other mothers.
223455131|NCT02477878|BIOLOGICAL|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
223455132|NCT02477878|DRUG|Rimiducid|Rimiducid administered to treat GVHD
223455133|NCT04378569|DRUG|ARQ-252 cream 0.3%|ARQ-252 cream 0.3%
223455134|NCT04378569|DRUG|ARQ-252 cream 0.1%|ARQ-252 cream 0.1%
223455135|NCT04378569|DRUG|ARQ-252 Vehicle Cream|ARQ-252 Vehicle Cream
223572172|NCT06662344|BEHAVIORAL|Nasogastric Tube Feeding|Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
223572173|NCT06662344|BEHAVIORAL|comprehensive rehabilitation therapy|Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
223572174|NCT06669546|OTHER|Phase-locked auditory stimulation (PLAS)|"Intervention: Verum Phase-Locked Auditory Stimulation (PLAS) Using the SleepLoop Device.~The experimental intervention utilizes the SleepLoop device, a home-use, EEG-based system designed for phase-locked acoustic stimulation (PLAS). The device continuously monitors sleep through EEG (Fpz) alongside electrooculogram (EOG) and electromyogram (EMG) channels. The device employs a closed-loop algorithm that detects slow oscillations (SOs) in the EEG and delivers short sound stimuli (50 ms pink noise) during the positive half-waves of slow waves in slow-wave sleep (SWS). These stimuli are delivered through integrated headphones in the SleepLoop device. The intervention is applied during work days for 4 weeks. The algorithm is only active during SWS and does not deliver stimuli when the participant is awake, or in lighter sleep stages (N1, N2) or REM sleep. The intensity and algorithm sensitivity are individually calibrated for each participant to optimize stimulation."
223572175|NCT06669546|OTHER|Sham Phase-Locked Auditory Stimulation|Participants will undergo the same procedure as the real Phase-Locked Auditory Stimulation (PLAS) intervention. However, during the sham condition, the headphones are turned off, and no auditory stimulation is delivered.
223572176|NCT06607614|OTHER|Colorectal Cancer Screening Fecal Immunochemical Test|Fecal Immunochemical Test
223572177|NCT05676151|BEHAVIORAL|Music Therapy|20-minute music-therapy-informed interventions (musical bingo, songwriting, lyric scramble) guided by a music therapist
223572178|NCT04926831|DRUG|capmatinib|150 mg and 200 mg tablets for oral administration
223572179|NCT03738501|OTHER|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
223572180|NCT03738501|OTHER|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
223572181|NCT06607640|BEHAVIORAL|Increase outdoor activity time during specific time periods|"The specific time periods of outdoor activity found to be beneficial for myopia prevention will be used as the intervention target, and a one-year intervention will be initiated."
223572182|NCT00756795|BEHAVIORAL|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
223572183|NCT05272137|DEVICE|Evoke Spinal Cord Stimulation (SCS) System|A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude
223572184|NCT03648489|DRUG|Paclitaxel|Please refer to arm/group description
223572185|NCT03648489|DRUG|TAK228|Please refer to arm/group description
223584127|NCT04485572|DIAGNOSTIC_TEST|Passive Neck Flexion test (PNF)and Kernig test (K)|The following neurodynamic and/or orthopedic tension tests were done: the Passive Neck Flexion test (PNF), the Kernig test (K) and another test which was the combination of both (PNF+K)
223584128|NCT04485572|DIAGNOSTIC_TEST|Slump test (ST) and Dejerine triad (DT)|The following neurodynamic and/or orthopedic tension tests were done: the Slump test (ST), the Dejerine triad (DT) and another test which was the combination of both (ST+DT)
223584129|NCT04485572|DIAGNOSTIC_TEST|MRI scan|All participants will undergo a MRI scan to compare results between the index tests and the Gold Standard
223584130|NCT04976933|BEHAVIORAL|mHealth adherence app|The mHealth app is designed to remind caregivers to give medication in the outpatient setting, track adherence, and capture real time barriers to adherence if medication is missed.
223584131|NCT01533922|DRUG|Placebo|placebo matching tiotropium + olodaterol FDC
223584132|NCT01533922|DRUG|Tiotropium|Tiotropium 5 mcg once daily
223584133|NCT01533922|DRUG|Olodaterol|Olodaterol 5 mcg once daily
223584134|NCT01533922|DRUG|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
223584135|NCT01533922|DRUG|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
223584136|NCT01533922|DEVICE|Respimat|Respimat inhaler
223584137|NCT00799539|DRUG|bortezomib|From cycles 1-4, 1.3mg/m\^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
223584138|NCT00799539|DRUG|bortezomib|From cycles 5-9, 1.3mg/m\^2 on days 1, 8, 22, and 29 of each 6-week cycle
223584139|NCT00799539|DRUG|melphalan|9 mg/m\^2 once daily on days 1-4 of each 6-week cycle
223584140|NCT00799539|DRUG|prednisone|60 mg/m\^2 once daily on days 1-4 of each 6-week cycle
223584141|NCT02942654|DRUG|LY900014|Administered subcutaneously (SC)
223584142|NCT02942654|DRUG|Insulin Lispro|Administered SC
223584143|NCT02338375|BIOLOGICAL|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
223742912|NCT05161169|GENETIC|Genome Sequencing|20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.
223742913|NCT05780619|DIAGNOSTIC_TEST|Transcranial Doppler|Measurement of resistance index on the middle cerebral artery (MCA) (index test) and the Holter (reference test). Patients will be randomized for order of tests
223742914|NCT06493019|DRUG|Pembrolizumab|Chemoradiation Pembrolizumab 200mg IV
223742915|NCT06493019|DRUG|Paclitaxel|Paclitaxel 50 mg/m\^2 IV
224149381|NCT03385694|DIAGNOSTIC_TEST|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
224149382|NCT01090102|DRUG|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
224149383|NCT01090102|DRUG|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
224149384|NCT01607294|DRUG|ETC-1002|ETC-1002 Daily for 4 weeks
224149385|NCT01607294|DRUG|Placebo|Placebo Daily for 4 weeks
224149386|NCT04391088|OTHER|vaccine coverage assessment|vaccine coverage assessment
224149387|NCT05211609|DIAGNOSTIC_TEST|Plasmatic 3-O-Methyldopa dosage|Plasmatic 3-O-Methyldopa dosage
224149388|NCT03341234|DRUG|Bupivacaine|30 ml %0,25 bupivacaine
224149389|NCT03341234|DRUG|Saline|2 ml saline subcutaneously
224149390|NCT03341234|DEVICE|Ultrasound|Ultrasound guided block
224149391|NCT03518034|DRUG|AndroGel®|testosterone administered topically
224149392|NCT03518034|DRUG|Placebo|placebo administered topically
224149393|NCT02814448|DEVICE|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
224149394|NCT02814448|DEVICE|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
224149395|NCT02814448|DEVICE|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
223455136|NCT02658266|BEHAVIORAL|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
223455137|NCT00652847|DRUG|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
223455138|NCT00652847|DRUG|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
223455139|NCT01140971|DRUG|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
223455140|NCT01140971|DEVICE|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
224149396|NCT04655924|DEVICE|Clinical Decision Support System|Clinical Decision Support System using Measurement-Based Care and Digital Decision Support Platform
224149397|NCT03200093|DRUG|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
224149398|NCT03200093|DRUG|Placebo|Ora-Sweet 5mL taken by mouth once daily.
224149399|NCT00010803|DRUG|Ginkgo biloba|120mg twice a day
224149400|NCT00010803|DRUG|Placebo|One pill twice daily
224149401|NCT01283867|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
224149402|NCT00044525|DRUG|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
224149403|NCT00224692|DRUG|Low dose ketamine|
224149404|NCT04381533|BEHAVIORAL|Internet-delivered Adolescent Community Reinforcement Approach (I-A-CRA)|The intervention is a behavioral internet-based intervention based on the Adolescent Community Reinforcement Approach. The program encompasses text, pictures, videos, and written as well as practical assignments (skills training). The main components of the treatment for the young adult with problematic alcohol use consist of psychoeducation and functional analysis, goal formulation, increasing prosocial behaviors, relapse prevention, problem solving, and communication training. The accompanying significant other receives modules containing information focusing on gaining an understanding of the treatment components aimed at the young adult, as well as communication training to improve communication between the young adult and the significant other.
224149405|NCT04381533|BEHAVIORAL|Psychoeducation, information on use of alcohol and its effects|The intervention is a behavioural internet-based intervention including psychoeducation focusing on providing information on alcohol, alcohol use, and its effects. The psychoeducation is provided via texts and pictures, and there is a possibility of asking questions to a therapist if needed however no therapist contact is mandatory. There are separate programs directed towards the young adult and the accompanying significant other. The programmes give brief self-help tips at the end. The intervention approximately corresponds to the information given in a primary care setting for someone with problematic alcohol use.
223455141|NCT01962948|DRUG|paclitaxel|Given IV
223455142|NCT01962948|DRUG|ganetespib|Given IV
223455143|NCT01962948|OTHER|laboratory biomarker analysis|Correlative studies
223455144|NCT03606057|DRUG|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
223742916|NCT06493019|DRUG|Carboplatin|Carboplatin AUC 2 IV
223742917|NCT06493019|RADIATION|Radiation|Delivered as per institutional standards
223742918|NCT06493019|DRUG|Pembrolizumab|Maintenance Pembrolizumab 400mg IV
223742919|NCT05749198|DIAGNOSTIC_TEST|MRE|MRE was performed using a 3T system (Magnetom Skyra; Siemens, Erlangen, Germany) equipped with a combination of a 30-channel body and a 32-channel spine matrix coil.
223742920|NCT05696288|PROCEDURE|Respiratory Gas Delivery System|Oxygen therapy during general anesthesia for ENT panendoscopy
223742921|NCT03338426|DRUG|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
223742922|NCT03338426|DRUG|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
223742923|NCT03338426|DRUG|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
223455145|NCT03606057|DRUG|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
223455146|NCT03606057|DRUG|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
224149406|NCT01019252|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
224149407|NCT02273037|DEVICE|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
224149408|NCT02273037|PROCEDURE|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
224149409|NCT00901381|DRUG|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
224149410|NCT05628155|OTHER|Oral diet including n-3 PUFA intake|menus to cover the recommended intake of n-3 PUFAs (ALA =1% of total energy intake, i.e. 2.1 g/d, and EPA+DHA = 500 mg/d) (n-3 PUFA MENU), based on mass-market products that guarantee the n-3 PUFA RDAs and are available from the catering sector
224149411|NCT01371526|DRUG|depot tetracosactide|1mg, 3x weekly by sc injection
224149412|NCT03696940|DRUG|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
224149413|NCT03696940|DRUG|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
223584144|NCT02634606|DRUG|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
224149414|NCT00162526|DRUG|Tocopherol|
224149415|NCT02678637|OTHER|MRI and muscle dynamometer|
224149416|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
224149417|NCT00806078|DRUG|quinine sulfate|2 x 324 mg capsules (648 mg)
224149418|NCT05690698|DRUG|Quatiapine|Atypical antipsychotic
224149419|NCT05690698|DRUG|Haloperidol|Antipsychotic
224149420|NCT04598711|BEHAVIORAL|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
224149421|NCT04598711|BEHAVIORAL|Sham Conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.
223455147|NCT03606057|DRUG|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
223455148|NCT02475772|DRUG|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
223455149|NCT02475772|PROCEDURE|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
223584145|NCT02634606|DRUG|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
223584146|NCT02634606|DRUG|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
223584147|NCT05740917|DRUG|XZB-0004|XZB-0004 orally Twice daily of every 28-day cycle
223584148|NCT00151788|DRUG|Pactimibe sulfate|
224149422|NCT04598711|BEHAVIORAL|Muscle Power training|All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.
224149423|NCT04598711|BEHAVIORAL|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.
224149424|NCT04598711|BEHAVIORAL|Treadmill Training|All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
224149425|NCT01934933|DRUG|celebrex|
224149426|NCT01934933|DRUG|Enbrel|
224149427|NCT01934933|DRUG|Enbrel plus Celebrex|
224149428|NCT00270413|DRUG|SU11248|sutent 50 mg daily 4w on 2w off
224149429|NCT00028106|DRUG|[131]I-MIBG|
224149430|NCT00028106|DRUG|6-[18F]Fluorodopamine|
224149431|NCT00028106|DRUG|[123]I-MIBG|
224149432|NCT03351478|DRUG|Sotagliflozin|Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.
224149433|NCT03351478|DRUG|Empagliflozin|Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.
224149434|NCT03351478|DRUG|Placebo|Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
224149435|NCT03351478|DRUG|Placebo|Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
224149436|NCT03518632|BEHAVIORAL|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
224149437|NCT03518632|OTHER|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
224149438|NCT04963881|DIAGNOSTIC_TEST|Antibody testing|Blood samples were taken and analyzed for APS antibodies
224149439|NCT03002285|BEHAVIORAL|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
224149440|NCT03002285|BEHAVIORAL|Control group|Group with typical development that performed the Fitts law in a computer task
224149441|NCT02006498|DRUG|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
223455150|NCT05419167|BEHAVIORAL|STEP-COVID|The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
223455151|NCT02252302|OTHER|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
223455152|NCT02252302|OTHER|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
223455153|NCT02252302|DRUG|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
223455154|NCT02252302|DRUG|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
223455155|NCT02252302|OTHER|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
223455156|NCT02252302|OTHER|Filtered air|Participants will be breathing filtered air
223455157|NCT03823820|OTHER|Bioimpedance Analyser|Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
223455158|NCT03413475|BEHAVIORAL|quality of life|
223455159|NCT03351088|PROCEDURE|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
223455160|NCT01572714|BEHAVIORAL|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
223455161|NCT01572714|BEHAVIORAL|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
223455162|NCT01572714|BEHAVIORAL|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
223455163|NCT02759094|DEVICE|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
223455164|NCT03576443|DRUG|Idelalisib|Idelalisib 150 mg x 2 p o
223455165|NCT03249168|DRUG|Duloxetine 60mg|tablet
223455166|NCT03249168|DRUG|Placebo|Tablet
223455167|NCT06487715|DRUG|albumin-bound paclitaxel (260 mg/m2, d1)|260 mg/m2, d1)
224064460|NCT02344888|DRUG|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
224064461|NCT04105374|DRUG|Extended Release Flucytosine|Given PO
224064462|NCT04105374|DEVICE|NovoTTF-100A Device|Receive Optune device
224064463|NCT04105374|OTHER|Quality-of-Life Assessment|Ancillary studies
224064464|NCT04105374|OTHER|Questionnaire Administration|Ancillary studies
224064465|NCT04105374|RADIATION|Radiation Therapy|Undergo radiation
224064466|NCT04105374|DRUG|Temozolomide|Given PO
224149442|NCT02006498|DRUG|Placebo|Placebo capsule with same appearances as study drug
224149443|NCT04991272|OTHER|prewarming and warmed fluid infusion|prewarming with forced air warming system and warmed fluid infusion.
223455168|NCT06487715|DRUG|S-1|80 mg/m2, d1-14
224064467|NCT04105374|PROCEDURE|Therapeutic Conventional Surgery|Undergo standard of care surgery
224064468|NCT04105374|BIOLOGICAL|Vocimagene Amiretrorepvec|Given via intracranial injection
224064469|NCT02098174|DRUG|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
223455169|NCT06487715|DRUG|sintilimab|200 mg, d1
223455170|NCT06487715|DRUG|bevacizumab|First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
223455171|NCT03227393|BEHAVIORAL|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
223455172|NCT03092570|DEVICE|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
224064470|NCT02098174|OTHER|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
224064471|NCT00715832|BIOLOGICAL|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
223742924|NCT03338426|DRUG|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
223742925|NCT04165512|COMBINATION_PRODUCT|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
224149444|NCT05027113|BEHAVIORAL|Mindfulness meditation|Participants use the meditation app 10% Happier to practice mindfulness meditation (see detailed description in arm/group section)
224149445|NCT01174836|OTHER|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
224149446|NCT02583997|PROCEDURE|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
224149447|NCT02583997|PROCEDURE|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
223455173|NCT03092570|DEVICE|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
223572186|NCT06058247|DIETARY_SUPPLEMENT|Active nutritional supplementation|"The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day.~NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active nutritional supplementation arm were protein supplementation at over 1.5 g/kg/day, calorie provision at over 20 kcal/kg/day, and energy adequacy of at least 80%. Energy target was estimated by multiplying the resting energy expenditure using the Harris and Benedict equation by an activity factor of 1.3 and a stress factor of 1.1. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%."
223742926|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
223455174|NCT01008865|PROCEDURE|Studer Pouch orthotopic urinary diversion|
223742927|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
223742928|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
223742929|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
223742930|NCT00457509|BIOLOGICAL|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
224064472|NCT01148446|DRUG|Cyclophosphamide|750 mg/mq IV, day 1
224064473|NCT01148446|DRUG|Cyclophosphamide|50 mg/mq IV, day 1
224149448|NCT02425436|DRUG|Ginkgo Biloba Extract|
224149449|NCT02425436|OTHER|Placebo|
224149450|NCT06047990|DEVICE|Cryobiopsy catheter|Comparison of endobiliary forceps biopsy and cryobiopsy of biliary stenosis during percutaneous transhepatic drainage.
224149451|NCT03636113|DEVICE|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
224149452|NCT00756678|DRUG|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days'
224149453|NCT00756678|DRUG|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
224149454|NCT06185478|DIAGNOSTIC_TEST|MRI scan|MRI scan
223455175|NCT01008865|PROCEDURE|T-Pouch orthotopic urinary diversion|
223455176|NCT05346237|BEHAVIORAL|Quality of life questionnaire|Filling out questionnaires, measuring maximum phonation and diadochokinesis
223455177|NCT06957548|DIAGNOSTIC_TEST|Cardiometabolic disease|Cardiometabolic disease screening
223455178|NCT06955312|BEHAVIORAL|Experimental|Description: After collecting the pre-test data, pregnant women in the experimental group will be informed about the paint-by-numbers activity, and the materials to be used will be introduced. Participants in the experimental group will be asked to choose one of the 40x50 cm paintings. They will then be instructed to complete the painting. Pregnant women will be asked to paint the selected canvas at their convenience over approximately five days. Once the paint-by-numbers activity is completed, participants will be asked to fill out the post-test questionnaires, and final data from the experimental group will be collected, marking the end of the data collection process. After data collection, participants will be gifted their completed paintings, which they can hang in their children's rooms.
223455179|NCT00006929|DRUG|suramin|Given IV
223455180|NCT00006929|DRUG|carboplatin|Given IV
223455181|NCT00006929|DRUG|paclitaxel|Given IV
223455182|NCT00006929|OTHER|pharmacological study|Correlative studies
223455183|NCT00006929|OTHER|laboratory biomarker analysis|Correlative studies
223455184|NCT05306717|OTHER|Questionnaire|The study will compare the rates of isolation and restraint of the two sectoral admission units welcoming people in care without consent for a period of one year. The impact of the QPGE on the satisfaction scores will be systematically evaluated by a self-questionnaire for patients at the end of hospitalization. The QPGE is administered by a nurse during the reception interview of the patient in the unit.
223455185|NCT04655781|PROCEDURE|idiopathic macular hole (MH) surgery|Idiopathic Macular Hole Surgery with Different Internal Limiting Membrane Peeling Patterns
223455186|NCT05678712|DEVICE|Access to CGM data (Dexcom G6)|Acces to CGM data (not blinded CGM)
223455187|NCT03864991|DEVICE|e-device for step count (fit-bit)|Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
224064474|NCT01148446|DRUG|Doxorubicin|50 mg/mq IV, day1
224064475|NCT01148446|DRUG|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
224064476|NCT01148446|DRUG|Prednisone|75 mg/mq IV, days 1-5
224064477|NCT01148446|DRUG|Prednisone|60 mg/mq IV/PO, days 1-5
224064478|NCT01148446|DRUG|Epirubicin|50 mg/mq IV, day 1
224064479|NCT01148446|DRUG|Vinblastine|5 mg/mq IV, day 1
224064480|NCT01148446|DRUG|Rituximab|375 mg/mq IV, day 1
224064481|NCT01148446|DRUG|G-CSF|300 µg tot., SC; days 7-11
224064482|NCT00405197|BEHAVIORAL|Isocaloric diet high in MUFA or Mediterranean diet|
223455188|NCT03864991|BEHAVIORAL|e-messages for log book|Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
223455189|NCT03864991|BEHAVIORAL|e-messages for log book & fit-bit|Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
223455190|NCT05341050|DRUG|TKI|halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
223455191|NCT05606432|OTHER|Instructor-led, one-on-one M2M exercise group|Participants will attend 3 exercise sessions per week for 24 weeks. Each session will last 15 - 40 minutes. Increasing by 5 - 10 minutes each week. Each session will last from 25 to 50 minutes by increasing 5 to 10 minutes each week. The exercise program will focus on improving cardiorespiratory fitness using a series of movement patterns accompanied by music. The program will be tailored to individuals' abilities (e.g., use of arms only vs. truck movement together; slow vs. fast tempo music). The exercise will be prescribed at a moderate intensity level (working somewhat hard with increased heart rate and breathing rate). For the follow-up phase (weeks 25-36), participants will receive the recorded M2M exercise sessions between the M2M instructors and themselves to continue to exercise for the remaining 12 weeks.
223455192|NCT05606432|OTHER|Self-guided control with pre-recorded standard exercise videos|Participants will exercise for 36 weeks using pre-recorded exercise videos. The videos include warm-up, flexibility, muscular strength, aerobic endurance, balance, and cool-down.
223455193|NCT05643989|PROCEDURE|Stoma formation|Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.
223455194|NCT05643989|PROCEDURE|Endoscopic self-expandable metal stent placement|The colonoscope is passed to the distal edge of the tumor and a biopsy of the tumor is performed (if the tumor has not previously been verified). Through the tumor stenosis radioscopically guided metal conductor with atraumatic distal end installs in the proximal colon. A covered or partially covered metal self- expanding stent is placed in the area of tumor stenosis by the conductor, symmetrically in relation to the area of tumor stenosis. Radioscopically and endoscopically guided disclosure of a SEMS is performed immediately after which there is an abundant discharge of gases and intestinal contents. Upon completion of the procedure, the patient is transferred to the patient's room. The next day, a control X-ray of the abdomen is taken.
223455195|NCT03287115|OTHER|Broccoli consumption|All subjects will eat broccoli on day 11
224064483|NCT01312597|OTHER|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
224064484|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 1|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
224064485|NCT02707367|BEHAVIORAL|Recovery Roadmap (RR) Wave 2|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. There are 3 components:~1. Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~2. Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~3. Coaching \& Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
224064486|NCT04434274|DRUG|Micronized Purified Flavonoid Fraction|Based on the (non-)use of adjuvant phlebotropic therapy in the postoperative period.
224064487|NCT02229500|DIETARY_SUPPLEMENT|Inulin|
224064488|NCT02229500|DIETARY_SUPPLEMENT|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
224064489|NCT02229500|DIETARY_SUPPLEMENT|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
224064490|NCT04677712|DRUG|CCH-aaes|Participants were administered CCH-aaes by subcutaneous injection to both buttocks.
224064491|NCT04677712|OTHER|Compression|Participants used a compression garment on both buttocks following subcutaneous CCH-aaes injections.
224064492|NCT04677712|OTHER|Cold Packs|Participants used cold packs applied to the right buttock for 5-10 minutes immediately after subcutaneous CCH-aaes injections.
224064493|NCT04677712|DRUG|Arnica Gel|Participants used Arnica Gel Patches (Arnica montana 50% and Ledum palustre) immediately after the CCH-aaes injection to the right buttock.
224064494|NCT04677712|DRUG|INhance®|Participants used INhance Post-injection Serum topically immediately after the CCH-aaes injection to the right buttock.
224064495|NCT04677712|OTHER|PDL|Investigators applied one treatment with PDL to the right buttock between days 1-7 after injection.
224064496|NCT03608943|OTHER|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
224064497|NCT00711100|OTHER|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
224149455|NCT00004467|DRUG|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
224149456|NCT00004467|DRUG|Placebo|Infusion of 5% dextrose
224149457|NCT03523949|BEHAVIORAL|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
224149458|NCT02104323|DRUG|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
224149459|NCT00017628|DRUG|cyclophosphamide|
224149460|NCT00017628|DRUG|filgrastim|
224149461|NCT00017628|DRUG|methylprednisolone|
224149462|NCT00017628|PROCEDURE|Autologous Stem Cell Transplantation|
224149463|NCT05531513|BEHAVIORAL|Virtual Reality (VR) Meditation|"The VR-Meditation intervention comprises an evidence-based 360-degree high-definition video VR application incorporating elements of nature, mindfulness and compassion. The VR-Meditation intervention is 4 weeks long and includes includes 4 different themes during the course of the program. Each week will focus on a distinct theme and will consist of two 20-minute VR sessions starting with a 10-minute guided meditation related to the weekly theme (one new meditation per week), followed by 10 minutes of open exploration of the virtual environment, for a total of 8 distinct sessions. The weekly themes are as follows:~* Week 1 - Mindfulness of the Environment~* Week 2 - Embodied Mindfulness~* Week 3 - Embodied and Embedded Compassion~* Week 4 - Mindfulness, Compassion, and the External Environment~In addition to baseline measures, participants in the VR Meditation condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
224149464|NCT05531513|BEHAVIORAL|Psychoeducational Pamphlet|"The Psychoeducational Pamphlet intervention is 4 weeks long. Participants receive 1 pamphlet per week for a total of 4 different pamphlets. Handouts will provide information about managing stress and enhancing well-being, without referencing nature, mindfulness or compassion (e.g., eating habits, sleep hygiene, relaxation training, art exercises). The handouts will be based on empirical findings and will be written in accessible language with visual charts and specific practices to facilitate their implementation by participants. At the end of the study (i.e., after follow-up), Psychoeducation Pamphlet participants will receive access to the VR-Meditation program.~In addition to baseline measures, participants in the Psycho-educational Pamphlet condition will be asked to complete measures at mid-point (week 3), post-intervention (week 5), and follow-up (week 9)."
224149465|NCT02589743|DEVICE|Sealant|Application of preventive agent
224149466|NCT02589743|DEVICE|Adhesive and Sealant|Application of preventive agent and technique for control moisture
224149467|NCT04399824|RADIATION|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
223455196|NCT06090968|PROCEDURE|Umbilical cord milking|20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
223455197|NCT06090968|PROCEDURE|Immediate cord clamping|clamping the umbilical cord as soon as possible (average 30 seconds)
223455198|NCT01243918|OTHER|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
223455199|NCT05361967|DEVICE|The Tack Endovascular System|The Tack Endovascular System is designed to treat vascular dissections with Tack implant(s) following angioplasty.
223455200|NCT01443234|OTHER|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
223455201|NCT01443234|OTHER|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
223455202|NCT04565548|OTHER|Educational program for hypertensive patients|The theory-guided program consisted of one session of health education, self-developed leaflet, and weekly text messaging for 12 weeks.
223455203|NCT04565548|OTHER|Usual care|One standardized health education and a leaflet developed by the Health Bureau. As similar as the intervention group, weekly text messaging will be delivered, but the content is not related to the blood pressure control.
223455204|NCT01005862|BIOLOGICAL|PF-04360365|10 mg/kg, single dose administered intravenously
223455205|NCT01005862|DRUG|Placebo|Placebo
223455206|NCT00856791|DRUG|ON 01910.Na|
223455207|NCT00329095|DRUG|travoprost, latanoprost, or bimatoprost|
223455208|NCT00329095|DRUG|Additional ocular hypotensive medication|
223455209|NCT00789607|DEVICE|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
224149468|NCT04399824|OTHER|Quality-of-Life Assessment|Ancillary studies
224149469|NCT04399824|OTHER|Questionnaire Administration|Ancillary studies
223455210|NCT00789607|DEVICE|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
223455211|NCT00455000|BIOLOGICAL|PF-04360365|Monoclonal antibody
223455212|NCT00455000|DRUG|Placebo|Placebo
223455213|NCT02653157|OTHER|MDR-GNB|
223455214|NCT00281697|DRUG|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
223455215|NCT00281697|DRUG|Placebo|
223455216|NCT00281697|DRUG|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~1. Taxane - Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m\^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m\^2 IV every 3 weeks.~2. Gemcitabine (Gemzar) 1250 mg/m\^2 IV on Days 1 and 8 of each 3-week cycle.~3. Vinorelbine (Navelbine) 30 mg/m\^2 IV every week of each 3-week cycle.~4. Capecitabine (Xeloda) 1000 mg/m\^2 orally twice daily on Days 1-14 of each 3-week cycle."
223455217|NCT00568737|DRUG|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
223455218|NCT00568737|DRUG|Placebo|0.9% sodium chloride
223455219|NCT03444259|PROCEDURE|Cardiac surgery|Open heart surgery
223455220|NCT04446429|DRUG|Proxalutamide|200 mg q.d.
223572187|NCT06058247|DIETARY_SUPPLEMENT|Conventional nutritional supplementation|The participants in conventional nutritional supplementation arm received conservative nutritional management without specific protein or caloric targets.
223572188|NCT00445211|DRUG|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
223572189|NCT00445211|OTHER|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
223584149|NCT05335902|DIAGNOSTIC_TEST|ultrasound measurement of the optic nerve sheath diameter|ultrasound measurement of the optic nerve sheath diameter
223584150|NCT05335902|DIAGNOSTIC_TEST|MoCA test|MoCA test is a short bedside test for measuring cognitive disfunction
224064498|NCT00711100|OTHER|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
224064499|NCT00711100|OTHER|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
224064500|NCT00711100|OTHER|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
224064501|NCT00711100|OTHER|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
224064502|NCT05815303|DRUG|Cadonilimab|10mg/kg iv on day 1, every 21 day
224064503|NCT05815303|DRUG|Oxaliplatin|130mg/m2 iv on day 1, every 21 day
224064504|NCT05815303|DRUG|Capecitabine|1000mg/m2 po bid on day 1 to 14, every 21 day
224064505|NCT01117636|DRUG|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter \[mL\]) between 14 hours post dental surgery.
224064506|NCT01117636|DRUG|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
224064507|NCT01117636|DRUG|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
224064508|NCT01065688|PROCEDURE|Roux-en Y reconstruction|surgical procedure
224064509|NCT01065688|PROCEDURE|Billroth-I reconstruction|surgical procedure
224064510|NCT04519892|OTHER|PDRC|Personalized depression risk communication.
224064511|NCT04519892|OTHER|Coach guidance|Coaching service to guide the understanding of PDRC and answer questions.
224064512|NCT04479566|DRUG|Lithium Carbonate 250 MG|Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.
224064513|NCT04479566|DRUG|Calcium Carbonate 500 MG|Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
224064514|NCT00783094|DRUG|Tadalafil 2.5 mg|oral, daily
224064515|NCT00783094|DRUG|Tadalafil 5 mg|oral, daily
224064516|NCT00783094|DRUG|Placebo|oral, daily
224064517|NCT04322773|DRUG|RoActemra iv|single dose treatment with tocilizumab 400 mg intravenously
224064518|NCT04322773|DRUG|RoActemra sc|single dose treatment with tocilizumab 2 x 162 mg subcutaneously
223455221|NCT04446429|OTHER|Standard of Care|Standard of care as determined by the PI
223455222|NCT03061578|DIAGNOSTIC_TEST|Tear Film Imager|Ocular surface imaging assessment by the Tear Film Imager (TFI)
223455223|NCT03061578|DIAGNOSTIC_TEST|Low Humidity Environmental Exposure Chamber (LH-EEC)|Subjects will enter the LH-EEC (\<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
223455224|NCT01671137|OTHER|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
223455225|NCT04747249|OTHER|Psychological support|Psychological care will be based on a monthly interview lasting approximately 45 minutes for 6 months.
223455226|NCT01214993|DRUG|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
223455227|NCT01214993|DRUG|Placebo|Placebo is a tablet with no drug in it.
223455228|NCT01214993|DRUG|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
223455229|NCT01214993|DRUG|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
223455230|NCT06165237|DRUG|BR6001-1|One tablet administered alone, Once a day
223455231|NCT06165237|DRUG|BR6001-2|One tablet administered alone, Once a day
223455232|NCT04188886|OTHER|Practice survey|Practice survey on
224064519|NCT04322773|DRUG|Kevzara sc|single dose treatment with sarilumab 1 x 200 mg subcutaneously
224064520|NCT04322773|OTHER|Standard medical care|management as usual
224064521|NCT05241080|OTHER|Survey|It is a survey based on questionnaire
224064522|NCT01123252|DIETARY_SUPPLEMENT|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
224064523|NCT01123252|DIETARY_SUPPLEMENT|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
224064524|NCT02513329|DRUG|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.10 mL .5% bupivicaine will be administered.
223455233|NCT03839615|PROCEDURE|guided bone regenerations|"intra oral procedures.~* Flap will be done.~* In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~* In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~* The site will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures."
223455234|NCT02706080|OTHER|emergency|
223455235|NCT05567471|BIOLOGICAL|BBV154 Intranasal Vaccine|Administered BBV154 vaccine in form of drops (0.5 mL) via intranasal route
223455236|NCT05567471|BIOLOGICAL|Intramuscular vaccine COVAXIN|Administered BBV152 vaccine via intramuscular route
223455237|NCT05567471|BIOLOGICAL|Covishield|Administered vaccine via intramuscular route
223455238|NCT02256917|BIOLOGICAL|Human cl rhFVIII|
223455239|NCT06277570|OTHER|conventional physiotherapy|Conventional physiotherapy is a treatment method that includes exercise training, hotpack, ultrasound and TENS (electrotherapy) applications.
223455240|NCT06277570|OTHER|NMES|Neuromuscular Electrical Stimulation (NMES) is a non-invasive method that activates intramuscular nerve branches and produces visible contractions through surface electrodes placed on skeletal muscles.
223455241|NCT06277570|OTHER|Superimposed NMES|Superimposed NMES technique is the use of NMES with voluntary muscle contraction.
223455242|NCT02119078|OTHER|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
223455243|NCT02768402|DEVICE|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
223455244|NCT01707628|BIOLOGICAL|influenza vaccination with influenza vaccine|
223455245|NCT04612283|OTHER|NGA-01 gel|NGA-01 is a gel formulation with mostly herbal active ingredients
223455246|NCT04612283|OTHER|Placebo|A Placebo with no active ingredients
223572190|NCT06897397|OTHER|Case Study|Students will be provided with information about the education plan flow chart, education plan content, and environment. 40 students assigned to the intervention group will be provided with information about EFM training based on the case method. Before the application, all groups will be provided with 4 hours of theoretical information about EFM interpretation via a power point presentation.
223572191|NCT06895083|OTHER|self ligating brackets|selfligating are new brackets
223572192|NCT06895304|DEVICE|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the upper limbs.
224064525|NCT02513329|DRUG|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card. 5 mL sterile normal saline will be administered.
224064526|NCT03317756|OTHER|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
224064527|NCT03317756|OTHER|Patient Control|Patients will receive an attention control
224064528|NCT03962205|BEHAVIORAL|cognitive-behavioral life style intervention|Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
224064529|NCT03962205|BEHAVIORAL|wellbeing intervention|This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
224064530|NCT03962205|OTHER|treatment as usual|The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
224064531|NCT02121366|PROCEDURE|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
224064532|NCT05707091|OTHER|Low level laser therapy and conventional therapy|One group treated with low level laser therapy along with conventional therapy
224064533|NCT05707091|PROCEDURE|Conventional therapy|Group B treated with ems and exercises
224064534|NCT01294670|DRUG|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
224149470|NCT04399824|RADIATION|Stereotactic Body Radiation Therapy|Undergo SBRT
224149471|NCT06039150|PROCEDURE|M-TAPA Block|M-TAPA Block; The block will be done by the same experienced anesthesiologist by using ultrasound(USG) after the surgical intervention is completed.The external oblique, internal oblique, and transversus abdominis muscles were shown on the costochondral angle in the sagittal plane at the 10th costal margin by using a high-frequency linear probe. Bilaterally in the midclavicular line at the level of the 10th rib (arcus costarum),0,5 ml/kg 0.25% Bupivacaine (maximum dose 2mg/kg) was administered to between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue.
224149472|NCT06039150|PROCEDURE|Local anesthetic infltration to port sites|Local anesthetic infiltration to port sites; The surgeon infiltrated 0.5 ml/kg of 0.25% Bupivacaine (maximum dose of 2mg/kg) in the skin, subcutaneous tissue, and muscle fascia at each of the three laparoscopic port areas at the end of the surgery.
224149473|NCT02403141|OTHER|Questionnaire|
224149474|NCT00985738|DRUG|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
224149475|NCT00985738|OTHER|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
224149476|NCT02236273|BEHAVIORAL|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
224149477|NCT02236273|BEHAVIORAL|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
224149478|NCT02757404|DRUG|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
224149479|NCT02757404|DRUG|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
224149480|NCT02757404|DRUG|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
224149481|NCT01619488|DEVICE|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
224149482|NCT00116324|DRUG|Montelukast|
224149483|NCT02653352|BEHAVIORAL|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
223455247|NCT05344222|DEVICE|Infrared LED|The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
223455248|NCT05344222|DEVICE|Similar device - Infrared ED|For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
224149484|NCT03736551|BEHAVIORAL|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
224149485|NCT03736551|BEHAVIORAL|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
223455249|NCT04474262|BIOLOGICAL|Albumin|Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
223455250|NCT04474262|DRUG|Midodrine Oral Tablet|Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
223455251|NCT04474262|OTHER|Placebo|Placebo
223455252|NCT02356757|BEHAVIORAL|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
223455253|NCT02356757|BEHAVIORAL|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
223455254|NCT04308876|OTHER|Manual therapy|Manual therapy includes techniques applied to elbow joints and surrounding tissues
223572193|NCT06895304|DEVICE|inspiratory muscle training|The subjects will perform deep inspirations against a threshold device with varying resistances to observe the effect on the diaphragm and the musculature of the upper limbs.
223455255|NCT04308876|OTHER|Strengthening exercises|Strengthening exercises used in this study includes resistant exercises to increase muscle strength of upper extremity
223455256|NCT01299883|OTHER|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
223572194|NCT06753071|DRUG|Pyridostigmine oral tablet|Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months
223572195|NCT06753071|DRUG|Placebo|Placebo oral tablet, twice daily, for 3 months
224064535|NCT02290795|OTHER|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
224064536|NCT03714529|BIOLOGICAL|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
224149486|NCT04148768|DEVICE|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross \& they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
224149487|NCT04148768|DEVICE|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
224149488|NCT02836483|DRUG|LCB01-0371 800mg, QD|Oral administration
224149489|NCT02836483|DRUG|LCB01-0371 400mg, BID|Oral administration
224149490|NCT02836483|DRUG|LCB01-0371 800mg, BID|Oral administration
223455257|NCT01602991|PROCEDURE|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
223572196|NCT00990327|DRUG|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
224149491|NCT02836483|DRUG|Tubes 3~5Tablet, QD|Oral administration
223572197|NCT00990327|DRUG|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
224149492|NCT02836483|DRUG|Zyvox 600mg, BID|Oral administration
224149493|NCT02836483|DRUG|LCB01-0371 1200mg, QD|Oral administration
224149494|NCT05568927|OTHER|SEARCH algorithm|The SEARCH algorithm is a structured, stepwise approach to follow up testing after acute PE that will enable timely diagnosis of post PE sequelae. The test results at each step inform the performance of the subsequent steps. The order of the tests in the algorithm uses the acronym SEARCH: Symptom screen, exercise function, arterial perfusion, resting heart function, confirmatory imaging, and hemodynamics.
224149495|NCT02227849|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
223572198|NCT02240849|DEVICE|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
223572199|NCT02240849|DEVICE|Placebo general pillow|
223572200|NCT00899717|PROCEDURE|Occlusal adjustment|modification of occlusal surfaces
224064537|NCT01871974|DRUG|FK949E|oral
223572201|NCT00899717|PROCEDURE|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
223572202|NCT06411912|DRUG|NIDO-361|Tablets containing 100mg of NIDO-361 for oral administration.
223572203|NCT06411912|DRUG|Placebo|Placebo oral tablets
223572204|NCT03549871|DRUG|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223572205|NCT03549871|DRUG|BPA prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
223572206|NCT03549871|DRUG|Factor (FVIII or FIX) prophylaxis|Pharmaceutical form: solution for injection Route of administration: Intravenous
223572207|NCT01827774|DEVICE|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
224064538|NCT00186550|BEHAVIORAL|Supportive Expressive Group Psychotherapy|
224064539|NCT00186550|BEHAVIORAL|Education|
224064540|NCT04852848|BEHAVIORAL|Connect2Test Intervention|Brief assessment based feedback and motivational interviewing intervention
224064541|NCT02042937|OTHER|Exercise|Exercise to improve gluteus maximus recruitment
224064542|NCT00517595|DRUG|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
224064543|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
224064544|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
224064545|NCT02083380|DRUG|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
224064546|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
224064547|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
224149496|NCT02227849|DRUG|GLP-1 analogue|
224149497|NCT03982238|DRUG|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
224149498|NCT03982238|DRUG|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
223584151|NCT04286672|DIAGNOSTIC_TEST|Metadherin|study alterations of MTDH gene expression in the serum of bladder cancer patients
223584152|NCT05226091|BEHAVIORAL|Letter|Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
224149499|NCT03982238|DRUG|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
224149500|NCT00812604|DRUG|Ping On Ointment|Ping On Ointment
224149501|NCT00812604|DRUG|Vaseline|Placebo
224149502|NCT05420415|OTHER|CSTME|Tumor microenvironment collagen signature
224149503|NCT05953207|OTHER|Medical hypnosis|Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
224149504|NCT05953207|OTHER|Standard Of Care|Sleep hygiene and safety education session
224305095|NCT01070459|BEHAVIORAL|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
223455258|NCT01602991|PROCEDURE|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
223455259|NCT02870192|PROCEDURE|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
223455260|NCT02720276|OTHER|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
223455261|NCT04642417|OTHER|dietary fiber literacy|education
223455262|NCT04642417|OTHER|routine care|routine care
223455263|NCT04635930|OTHER|Taping plus Traditional exercises|The children will be taped 6 days per week for a total a period of 08 weeks. The tape will be used and keep the scapula in position for 3 days and the region will then be left to rest for 24 hours. Kinesio Taping will then be re-applied by the same experienced research assistants for another 3 days.
223455264|NCT06300099|DRUG|Dexamethasone|Dexamethasone as adjunct to serratus anterior plane block.
223455265|NCT06300099|DRUG|Dexmedetomidine|Dexmedetomidine as adjunct to serratus anterior plane block.
223455266|NCT01427270|DRUG|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
223455267|NCT01427270|DRUG|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
223455268|NCT01427270|DRUG|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
223455269|NCT05888480|OTHER|The end-of-life communication skills training|Training methods include lectures, video demonstrations, and simulation in small groups (4-5 trainees per group with multidisciplinary roles). Written and audiovisual learning materials will be offered. Each session will be 150 minutes, including lectures and video demonstration (90 min/session) and simulation and feedback (60 min/session). One session will be conducted in two weeks. Totally there will be four sessions completed in 8 weeks.
223455270|NCT05888480|OTHER|Routine training activity|Routine training activities arranged by relevant departments in hospitals
223455271|NCT02106780|DRUG|14C-labeled ASP1707|oral
223455272|NCT00959465|BIOLOGICAL|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
223455273|NCT06133998|DEVICE|incentive spirometer with aerobic exercises|"Group A: Aerobic exercise (running, jugging, cycling, walking) will be given to the group A for the checking the effect of incentive spirometer~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung. This schedule will be following supervised exercise training for a minimum 60 minutes 3 days a week in moderate patient,75 minutes in moderate to vigorous patients and 150 minutes in healthy patients~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire."
223572208|NCT03193086|DRUG|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
223572209|NCT01644695|PROCEDURE|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
223572210|NCT01133626|DRUG|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
223572211|NCT01133626|DRUG|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
224064548|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
223572212|NCT01133626|DRUG|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
223572213|NCT01133626|DRUG|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
223572214|NCT04285866|DRUG|Durvalumab|Durvalumab after chemoradiotherapy
223584153|NCT02679820|DEVICE|Copper T intrauterine device|
224064549|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
223584154|NCT04794764|DEVICE|McGrath Mac|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
224064550|NCT01365663|DRUG|SPC4955|3 Weekly SC injections
224064551|NCT01365663|DRUG|Saline 0.9%|3 Weekly SC injections
224064552|NCT05576402|PROCEDURE|colonoscopy|endoscopic exploration of colonic mucosa to evaluate inflammatory activity in patients with either Crohn's disease or ulcerative colitis
223455274|NCT06133998|DEVICE|incentive spirometry without aerobic exercises|"Group B: In group B we will check the effects of incentive spirometer without the aerobic exercise.~* In aerobic exercise following treatment protocol will be involve~* In sitting position, for the relaxation of body, patient will take a deep breath.~* In sitting position, patient will sit on the chair, placed both feet on the floor while bending knee at 90 degree and use the incentive spirometer for the deep breath and check the volume of lung.~* We will check the dyspnea of the patient by the borage scale~* We will check the exercise capacity by the endurance training of respiratory muscles and use the 6 mint walk test~* We will check the quality of life by the questionnaire.~* We will check the chest expansion by measuring tap."
223455275|NCT02768168|DRUG|dezocine|receive dezocine 0.1 mg/kg
223455276|NCT02768168|OTHER|normal saline|receive matching placebo (equal volume of normal saline)
223455277|NCT00660296|OTHER|Air insufflation use in colonoscopy|Air insufflation for colonic distension
223455278|NCT00660296|OTHER|CO2 use in colonoscopy|Co2 insufflation for colonic distension
223455279|NCT05102669|OTHER|analysis of immunological response|collection and analysis of SARS-CoV2 Spike specific blood cells
223455280|NCT05102669|DIAGNOSTIC_TEST|analysis of serum antibodies|analysis of anti-SARS-CoV2 Spike specific antibodies
223455281|NCT01753713|DRUG|dovitinib|Given PO
223455282|NCT01753713|OTHER|laboratory biomarker analysis|Correlative studies
223455283|NCT03301987|OTHER|Therapeutic exercise|30 minutes per day of therapeutic exercise
223572215|NCT04266964|PROCEDURE|Manual examination|"With the patient in a supine position, squeeze the skinfold between your thumb and pointfinger on the inner aspect of the middle third of the thigh and on the inner aspect of the middle third of the calf.~Place your hand under the proximal calf and the heel and move the leg into maximum flexion at the hip and knee joints. After the response, if any, is completed, move the limb back into full extension. Each of these movements lasts for one second."
223572216|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
223572217|NCT00561002|BIOLOGICAL|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
223572218|NCT03298984|DRUG|Alvocidib|IV bolus followed by IV infusion
223572219|NCT03298984|DRUG|Cytarabine|continuous infusion
223572220|NCT03298984|DRUG|Daunorubicin|IV bolus
224064553|NCT06786936|DRUG|Secukinumab|Initial dosing of Secukinimab at week 0, 1, 2, 3, 4 and maintenance doses will be determined by the standard care team. This will be 150mg or 300mg. This will be administered by the study team once confirmed and randomisation has occurred for secukinimab/ placebo allocation.
223455284|NCT06434675|OTHER|No intervention done|No intervention done
223572221|NCT05730543|DRUG|Volbella or Juvederm Ultra XC filler|Hyaluronic acid filler
223572222|NCT00294645|OTHER|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
223572223|NCT00294645|OTHER|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
223572224|NCT05950516|DRUG|Semaglutide|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
223572225|NCT05950516|DRUG|Semaglutide Pen Injector [Ozempic]|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks
223572226|NCT01766895|OTHER|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
223572227|NCT01778335|PROCEDURE|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
223572228|NCT01549808|OTHER|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
224064554|NCT06786936|DRUG|Bimekizumab|Initial dosing of bimkizumab at week 0 \& 4 and maintenance doses will be determined by the standard care team. This will be 160mg or 320mg. This will be administered by the study team once confirmed and randomisation has occurred for bimekizumab/ placebo allocation.
224064555|NCT06786936|DRUG|Ixekizumab|Initial dosing of Ixekizumab at week 0 \& 4 or week 0, 2 \& 4, maintenance doses will be determined by the standard care team. The initial dose will be 160mgs then 80mg dose will either be given 2 or 4 weekly. This will be administered by the study team once confirmed and randomisation has occurred for Ixekizumab/ placebo allocation.
224064556|NCT06786936|DRUG|Placebo|Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.
223455285|NCT03436017|OTHER|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
223455286|NCT01699334|BEHAVIORAL|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
223572229|NCT01549808|OTHER|mobilization|sitting, standing and walking
223572230|NCT00336011|DEVICE|Magnetic resonance imaging|
223572231|NCT00091130|BIOLOGICAL|HspE7|Given SC
223572232|NCT00091130|OTHER|placebo|Given SC
223572233|NCT00091130|OTHER|laboratory biomarker analysis|Correlative studies
223572234|NCT02966964|DRUG|DWPUR001|
223572235|NCT02966964|DRUG|Placebo|
224149505|NCT01590212|OTHER|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
224149506|NCT01590212|OTHER|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
224149507|NCT00192595|DRUG|Tenofovir|
224149508|NCT00192595|DRUG|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
224149509|NCT03858296|BEHAVIORAL|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
224149510|NCT03858296|BEHAVIORAL|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
224149511|NCT03858296|BEHAVIORAL|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
224149512|NCT00978224|DIETARY_SUPPLEMENT|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
224149513|NCT00978224|DIETARY_SUPPLEMENT|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
224149514|NCT02533401|DRUG|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
224149515|NCT02533401|DRUG|Fludarabine|Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
224149516|NCT02533401|DRUG|Rituximab|Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
224149517|NCT00799760|DRUG|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
224149518|NCT00799760|DRUG|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
224149519|NCT00799760|DRUG|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
224149520|NCT04570514|PROCEDURE|PCI|percutaneous coronary intervention (PCI)
223455287|NCT01699334|OTHER|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
223455288|NCT06459713|DIAGNOSTIC_TEST|multiplex respiratory polymerase chain reaction test|According to our hospital policy, nasopharyngeal swab samples are collected by the clinicians and transported to the Clinical Microbiology Laboratory of the hospital in 10 minutes. The samples are analyzed in 2 hours and the samples were measured by Thermo Fisher / Applied Biosystems Quant Studio-5 for reverse transcription-polymerase chain reaction (RT-PCR) testing to detect multiplex respiratory agents
223455289|NCT02104427|DRUG|TG-0054 combined with G-CSF|
223572236|NCT00521430|BIOLOGICAL|anti-thymocyte globulin|
223572237|NCT00521430|DRUG|busulfan|
223572238|NCT00521430|DRUG|cyclosporine|
223572239|NCT00521430|DRUG|fludarabine phosphate|
224064557|NCT00001379|BIOLOGICAL|Interferon|For lymphomatoid granulomatosis (LYG) Grade 1 and 2: Interferon starting at 7.5 million Units subcutaneous (subQ) 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond complete remission (CR).
224064558|NCT00001379|DRUG|Rituxan and EPOCH|For lymphomatoid granulomatosis (LYG) Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) every 3 weeks for 6 cycles.
224064559|NCT00001379|PROCEDURE|Tumor biopsy|Baseline (optional).
224064560|NCT00001379|PROCEDURE|Bone marrow biopsy|Baseline.
224064561|NCT00001379|BIOLOGICAL|Bone marrow aspirate|Baseline.
224064562|NCT00001379|PROCEDURE|Lumber puncture|Baseline.
224149521|NCT00129740|DRUG|Nilotinib|400 mg orally twice daily
224149522|NCT00081939|DRUG|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m\^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m\^2. Maintenance year one 1.0mg/m\^2 1,4,8,11 q 28 days.
224149523|NCT00081939|DRUG|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
224149524|NCT01752725|DEVICE|BiCision®|
223455290|NCT06172231|PROCEDURE|Instrument Assisted Soft tissue mobilization|The treatment processes consist of Four phases: warm up (heat), Graston Technique®, passive stretching and cryotherapy.6\_10 long strokes on Hamstring and Rectus femoris by using G1 instrument .Brief bouts (30 - 60 s) of deeper and more specific. Frequency: 4 sessions in 4-week period. Duration: 15\_35 min each session.
223455291|NCT06172231|PROCEDURE|Conventional therapy|5 min moist Hot pack ,Patellar joint mobilizations and Tibiofemoral ,Maitland grades III and IV (5 oscillations in first week) ,PROMs of knee joint ( 5 reps) ,Quad sets ( 5 reps with 5 sec hold)Progression: 5 repetition of each exercise would be add in every week ,Frequency: 4 sessions in 4-week period Duration: 15\_ 35 min each session.
223455292|NCT01896193|DRUG|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
223455293|NCT01896193|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223455294|NCT05104385|OTHER|Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines|Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
223455295|NCT06435767|DRUG|Adjuvant chemotherapy|In the Cancer Hospital, postoperative chemotherapy regimens and doses were planned by oncologists, with adjustments made based on drug toxicities or tumor responses.
223455296|NCT04533789|OTHER|selected physical therapy program|strengthening muscles of upper and lower limbs, balancing exercise, gait training in open environment, stretching for elbow flexors and forearm pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
223572240|NCT00521430|DRUG|methotrexate|
223572241|NCT00521430|DRUG|methylprednisolone|
223572242|NCT00521430|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223572243|NCT00521430|PROCEDURE|peripheral blood stem cell transplantation|
223572244|NCT04265508|OTHER|Assessment of hemostatic profile|To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
223572245|NCT05502159|DRUG|M-TAPA|Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
223572246|NCT05502159|DRUG|EOB|In the supine position, a high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the midaxillary line between the spina iliaca anterior superior and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected under the external oblique muscle of the block needle and the block location will be confirmed. After the block location is confirmed, 20 ml of 0.25% bupivacaine will be administered. The same procedure will be applied to the other side (40 ml of 0.25% bupivacaine in total).
223572247|NCT00219882|DRUG|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
224064563|NCT00001379|DIAGNOSTIC_TEST|CT|Arm 1: At baseline, then every 4 weeks until on stable dose of interferon or a maximum of 6 monthly scans, then every 3 months while receiving interferon, and following completion of interferon. In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years. Arm 2: At baseline, following cycle 4, and following cycle 6 of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years.
224064564|NCT00001379|DIAGNOSTIC_TEST|Brain MRI|"Arm 1: At baseline, then every 4 weeks until on stable dose of interferon or a maximum of 6 monthly scans, then every 3 months while receiving interferon, and following completion of interferon. In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years (patients with central nervous system (CNS) disease only).~Arm 2: At baseline, following cycle 4, and following cycle 6 of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R). In surveillance, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year and yearly thereafter for 2 years (patients with CNS disease only)."
224064565|NCT00001379|DIAGNOSTIC_TEST|Echocardiogram|For participants receiving \> 450 mg/m\^2 doxorubicin.
224064566|NCT00001379|DIAGNOSTIC_TEST|FDG-PET|Arm 1: Baseline and following completion of interferon. Arm 2: Baseline and following completion of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R).
224064567|NCT03299348|BEHAVIORAL|AgingPLUS|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.
224064568|NCT03299348|BEHAVIORAL|Active Control Group|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) four major health conditions that affect the lives of many middle-aged and older adults (e.g., cardiovascular disease, cancer, type 2 diabetes; clinical depression); and (b) how these conditions can be managed successfully.
224064569|NCT06223828|DRUG|Azithromycin|10mg/kg/dose (max dose 500mg) once daily for 3 days
224064570|NCT05525533|BEHAVIORAL|Harnessing prosocial and social image motivations for behavior change|The investigators will collect AGYW customer feedback using a short USSD-based survey and randomize whether shopkeepers receive 1) No feedback; 2) Private feedback; or 3) Public feedback
224064571|NCT04278859|BIOLOGICAL|Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion|Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion
224064572|NCT06145724|BEHAVIORAL|Maternal Sepsis Safety Bundle|Maternal sepsis safety bundle implemented at Columbia, Lincoln, Harlem, and Allen hospitals.
224064573|NCT02339064|DRUG|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
224071196|NCT06420973|DRUG|RC48+carboplatin±bevacizumab|RC48 (2.5mg/kg iv on d1 , every 21d for 6 cycles) + Carboplatin (AUC5 iv on d1 every 21d for 6 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for 6 cycles) for treatment followed by RC48 (2.5mg/kg iv on d1 , every 21d for 8 cycles)±Bevacizumab (7.5-15mg/kg iv on d1 every 21d for progress ) maintenance therapy.
224071197|NCT03657251|GENETIC|liquid biopsy|Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
224071198|NCT04196868|DRUG|Metformin treatment|1500 mg once a day, per os, during six months
224071199|NCT04196868|OTHER|Placebo|per os, during six months
224071200|NCT04196868|DRUG|Methotrexate treatment|per os
224071201|NCT02577861|PROCEDURE|Biopsy from donor eye|Corneal biopsy from undamaged limbus
223455297|NCT01793038|DRUG|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
223455298|NCT01793038|DRUG|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
223455299|NCT00652912|DRUG|Clonazepam|ODT, 1 mg
223455300|NCT00652912|DRUG|Klonopin Wafers|ODT, 1 mg
223584155|NCT04794764|DEVICE|Macintosh Laryngoscope|in a randomized order we evaluate the first pass success rate of the tracheal tube into the trachea.
223584156|NCT02633553|RADIATION|adjuvant radiotherapy|50Gy/25Fx
223584157|NCT01020708|DRUG|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
223584158|NCT01020708|DRUG|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
223584159|NCT01020708|DRUG|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
224071202|NCT02577861|PROCEDURE|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
224071203|NCT02577861|PROCEDURE|Ophtalmologic examination|"The following assessments are performed:~Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia."
224071204|NCT02577861|PROCEDURE|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
224071205|NCT02577861|PROCEDURE|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
224071206|NCT02577861|PROCEDURE|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
224071207|NCT02577861|BEHAVIORAL|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
224071208|NCT02577861|PROCEDURE|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
224071209|NCT05688878|DEVICE|Threshold electrical stimulation|Threshold stimulation (EDS) is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes. Threshold stimulation provides a natural proprioception by depolarizing the sensory and motor nerves without causing any muscle contraction.This treatment will be applied for 4 weeks, 3 days a week, for 1 hour.
224071210|NCT01990287|DEVICE|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
224071211|NCT01990287|DEVICE|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
224071212|NCT02090400|DRUG|Bazedoxifene|20 mg Oral daily for 12 months
224071213|NCT02090400|DRUG|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
224071214|NCT05533983|OTHER|fecal microbiota transplantation with Nivolumab|This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
224071215|NCT05920876|DRUG|QLS32015|Participants will receive subcutaneous (SC) injection of QLS32015. Eight dose groups were proposed, 21 days as a treatment cycle.
224071216|NCT01739179|PROCEDURE|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
224071217|NCT01739179|PROCEDURE|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
224071218|NCT05034965|DRUG|hyaluronic acid filler injection|quantitative surface electromyography before injection(baseline) and one week after injection
224071219|NCT03847610|DRUG|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
224071220|NCT03847610|DEVICE|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
224071221|NCT01074138|DRUG|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
224071222|NCT02421237|BEHAVIORAL|Narrative Enhancement and Cognitive Therapy|
224071223|NCT02421237|BEHAVIORAL|Supportive Group Therapy|
224071224|NCT01254279|DRUG|CABAZITAXEL|Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
224071225|NCT06170398|DIAGNOSTIC_TEST|Wideband tympanometry|Wideband tympanometry
224071226|NCT06170398|DIAGNOSTIC_TEST|Electrocochleography|Electrocochleography
224071227|NCT06170398|DIAGNOSTIC_TEST|Vestibular Evoked Myogenic potentials|Vestibular Evoked Myogenic potentials
224071228|NCT05769179|OTHER|Massage group|Massage group will be applied classic massage and cervical stabilisation exercises 3 days a week for 4 weeks
224071229|NCT05769179|OTHER|Connective tissue massage group|Connective tissue massage group will be applied connective tissue massage and cervical stabilisation exercises 3 days a week for 4 weeks
224071230|NCT05769179|OTHER|Mobilization group|Mobilization group will be applied cervical mobilization techniques and cervical stabilisation exercises 3 days a week for 4 weeks
224071231|NCT01325012|PROCEDURE|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
224071232|NCT01325012|PROCEDURE|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
224149525|NCT01752725|DEVICE|Ultracision® Har-monic Scalpel(Ethicon)|
224149526|NCT02925559|DRUG|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
224149527|NCT02925559|DRUG|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
224149528|NCT00154193|DRUG|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
224149529|NCT01767181|OTHER|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
224149530|NCT01767181|OTHER|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
224149531|NCT00338260|DRUG|MK0954, /Duration of Treatment : 5 Years|
223455301|NCT02134795|DEVICE|TNM Device|The noninvasive device is worn like a music headset and the patient lies back on a wedge pillow while the device is active. Each session lasts under 20 minutes.
223455302|NCT02027077|BEHAVIORAL|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
223455303|NCT02027077|BEHAVIORAL|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
223455304|NCT05051046|PROCEDURE|Colonoscopy under hypnosis|The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
223455305|NCT01300247|DRUG|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
223455306|NCT01300247|DRUG|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
223455307|NCT01300247|DRUG|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
223455308|NCT01300247|DRUG|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
223455309|NCT02815033|DRUG|Enzalutamide|
223455310|NCT02815033|PROCEDURE|11C or 18F-Choline PET/CT|
223455311|NCT02815033|PROCEDURE|Whole body MRI|
223455312|NCT02815033|PROCEDURE|Bone scan|
223455313|NCT05359952|BEHAVIORAL|Starting the Conversation|The Starting the Conversation intervention consists of a brief educational video and accompanying workbook with activities to help prepare patients to discuss sexual and menopausal types of health concerns effectively with gynecologic cancer providers, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback. In addition, participants receive a list of sexual and menopausal resources.
223455314|NCT05359952|BEHAVIORAL|Sexual and Menopausal Health Resources Only|A list of resources on sexual/menopausal health both within and outside the institution, including websites.
223455315|NCT01858207|PROCEDURE|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
223455316|NCT01858207|PROCEDURE|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
223455317|NCT01858207|DRUG|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
223455318|NCT03478085|OTHER|Oxygen guided exercise therapy|Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
223455319|NCT06382129|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223455320|NCT06382129|DRUG|Docetaxel|Administration by intravenous infusion for a cycle of 3 weeks.
223455321|NCT03547037|DRUG|JNJ-63723283|JNJ-63723283 will be administered intravenously.
223455322|NCT03547037|DRUG|Erdafitinib|Erdafitinib will be administered orally.
223455323|NCT06248307|DIETARY_SUPPLEMENT|Barrita experimental|Nutritional advice, as well as administration of protein bars.
223455324|NCT06248307|DIETARY_SUPPLEMENT|Barrita Placebo|Nutritional advice, as well as administration of placebo bars.
223455325|NCT01930916|DEVICE|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
223455326|NCT01930916|OTHER|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
224149532|NCT00338260|DRUG|Comparator : atenolol /Duration of Treatment : 5 Years|
224149533|NCT01752075|DRUG|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
224149534|NCT01463124|BEHAVIORAL|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
224149535|NCT01463124|BEHAVIORAL|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
224149536|NCT05796349|DIAGNOSTIC_TEST|multifrequency EIT-based for detecting intracranial abnormalities|For subjects who received clinical trials, 16 electrodes were placed equidistantly in their head, and brain EIT data were measured at 9 frequencies in the range of 21 kHz to 100 kHz by applying a current RMS of 176 microamps.MFEIT image sequences were obtained according to certain imaging algorithms.
224149537|NCT04897594|DRUG|TERN-201|Investigational drug
224149538|NCT04897594|OTHER|Placebo|Matching placebo
224149539|NCT03387891|DEVICE|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
223572248|NCT01359761|BEHAVIORAL|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
223572249|NCT06396715|DEVICE|Transcranial direct current stimulation|tDCS is a type of non-invasive brain stimulation that in a standard paradigm, low intensity current (1-2 mA) is applied continuously through a battery connected to two 20 to 35 cm2 surface electrodes located on the scalp: an anode and a cathode. In the interhemispheric competition model, tDCS can serve as a means to increase ipsilesional cortical excitability through anodal stimulation, to decrease contralesional cortical excitability through cathodal stimulation, or to do both through a montage of bi-hemispheric electrodes.
224071233|NCT02236052|BIOLOGICAL|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
223455327|NCT00371475|DEVICE|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
223455328|NCT00371475|DEVICE|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
224071234|NCT02236052|BIOLOGICAL|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
224071235|NCT02236052|BIOLOGICAL|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
224071236|NCT02236052|BIOLOGICAL|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
224071237|NCT02236052|BIOLOGICAL|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
223455329|NCT05128591|DRUG|Rivaroxaban 18mg Oral Tablet|AD-109 (Rivaroxaban 18mg) Oral Tablet
223455330|NCT05128591|DRUG|Rivaroxaban 20 MG Oral Tablet|AD-1091 (Rivaroxaban 20mg) Oral Tablet
223455331|NCT02378948|DIETARY_SUPPLEMENT|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
223455332|NCT05385341|OTHER|Telerehabilitation (Tele RCV)|20 home-based sessions monitored by the REMOTE-ACS device and containing 2 hours/day 5 days/7 of exercise training associated with educative sessions.
223455333|NCT05385341|OTHER|Rehabilitation (RCV)|20 sessions of cardiac rehabilitation will be realized in a rehabilitation center containing exercise training during 2 hours/day 5 days/7 and educative program.
223455334|NCT03864003|BEHAVIORAL|Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care|In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (\>50 years) from a rural area that has been identified as under-resourced for hearing health care.
223455335|NCT00933985|DRUG|dexrazoxane hydrochloride|Given IV
223455336|NCT00933985|DRUG|doxorubicin hydrochloride|Given IV
223455337|NCT00933985|DRUG|obatoclax mesylate|Given IV
223455338|NCT00933985|DRUG|liposomal vincristine sulfate|Given IV
223455339|NCT00933985|OTHER|pharmacological study|Correlative studies
224071238|NCT02236052|BIOLOGICAL|Placebo|A single dose of placebo
224071239|NCT01029067|BEHAVIORAL|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
224071240|NCT01029067|BEHAVIORAL|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
224071241|NCT01861405|BEHAVIORAL|neuropsychological testing and quality of life assessments|
224071242|NCT01861405|RADIATION|Standard of Care WBRT or SRS|
224071243|NCT01861405|DEVICE|Functional magnetic resonance imaging|
224071244|NCT00096863|DRUG|Ziprasidone|
224071245|NCT00096863|DRUG|Haloperidol|
224071246|NCT00096863|OTHER|Placebo|
224071247|NCT03099707|BEHAVIORAL|Treatment Ambassador|"This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support."
224071248|NCT01445769|DRUG|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 \& 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10\^9/L at wk 12 or ≥ 150 x 10\^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets \<100 x 10\^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level \< 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
224071249|NCT03056118|DRUG|6-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
224071250|NCT03056118|DRUG|12-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
224071251|NCT03056118|DEVICE|Zotarolimus eluting stent|Zotarolimus eluting stent is applied to coronary stenotic lesion
224071252|NCT03056118|DEVICE|Biolimus eluting stent|Biolimus eluting stent is applied to coronary stenotic lesion
224071253|NCT01552044|DRUG|Spironolactone|25mg tablet once a day for 1 month
224071254|NCT01552044|DRUG|Placebo|one tablet once a day for 1 month
224071255|NCT01843855|DRUG|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
224071256|NCT01843855|DRUG|Placebo|A saline infusion will be given to match the study drug infusion.
223572250|NCT01990430|BEHAVIORAL|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
223572251|NCT00119912|PROCEDURE|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
223572252|NCT00119912|PROCEDURE|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
223572253|NCT02593422|BEHAVIORAL|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
223742931|NCT04409743|BEHAVIORAL|Remote Cognitive Behavioral Therapy for Insomnia|Participants will meet with a psychologist through telehealth once a week for four weeks to complete a brief CBT-I intervention. Cognitive Behavioral Therapy for Insomnia consists of a cognitive therapy and a behavioral therapy. The cognitive therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The behavioral therapy increases sleep quality by limiting excessive time spent in bed to increase homeostatic sleep drive and sleep consolidation.
224301739|NCT03311035|PROCEDURE|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
223742932|NCT00245141|BIOLOGICAL|dactinomycin|
224064574|NCT03930654|BEHAVIORAL|iPrEP|"* iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~* Women will receive the iPrEP intervention on an iPAD Air tablet device~* iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~* iPrEP uses qualitative themes~* iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~* Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~* Scales were modified (in some cases) for cultural competency and tailoring to women"
224064575|NCT03930654|BEHAVIORAL|Usual Care|"* Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies"
224064576|NCT02510027|OTHER|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
224064577|NCT00918034|DRUG|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
224064578|NCT00918034|DEVICE|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
224064579|NCT00918034|PROCEDURE|Placement|Placement of device in prostate urethra
224064580|NCT05427552|DEVICE|Intermittent theta-burst stimulation (iTBS)|The iTBS will be applied over lDLPFC with three different intensities. The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007. The equation is AdjMT% = MT + 2.8 \* (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8\*6=16.8(%) were added to the normal intensity.
224064581|NCT03405259|DEVICE|Super Seal® Desensitizer|Single dose professional application.
224064582|NCT03405259|DEVICE|Acclean® Fluoride Varnish|Single dose professional application.
224064583|NCT03703102|DRUG|KHK4083|Anti-OX40 Monoclonal Antibody KHK4083
224064584|NCT03703102|DRUG|Placebo|Matching placebo
224064585|NCT05033470|DEVICE|Dabir Mattress Overlay System|Dabir Surface mattress overlay system consists of a controller and a low-profile alternating pressure (AP) surface (placed over a non-powered mattress) with hundreds of air-filled geometric nodes arranged in rows. . The multiple rows of nodes inflate and deflate in alternating sequence every five minutes. During deflation phase, the skin and soft tissues experience reduced pressure/loading and enhanced perfusion. In conjunction with Standard of Care: Debridement, Proper moisture balance, off-loading, reduce bacterial burden and nutritional counseling.
224064586|NCT01220895|BIOLOGICAL|CMV-specific T-cells, single infusion following single positive CMV PCR result|"1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily"
224064587|NCT00876187|BIOLOGICAL|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
224064588|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
224149540|NCT04319640|BEHAVIORAL|Cognitive behaviour therapy for insomnia|CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
224149541|NCT04319640|BEHAVIORAL|psychoeducation for ASD|psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
224149542|NCT03703960|OTHER|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
224149543|NCT03703960|OTHER|music|calm music conducive to relaxation
224149544|NCT01242254|BIOLOGICAL|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
224149545|NCT03980626|BEHAVIORAL|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
224149546|NCT04526067|BEHAVIORAL|CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home on weekly visits to cue adaptive behaviors and establish healthy habits.
224149547|NCT04526067|BEHAVIORAL|R-CAT|An evidence-based psychosocial treatment using environmental supports such as signs, alarms, pill containers, and the organization of belongings established in a person's home using remote weekly visits to cue adaptive behaviors and establish healthy habits.
224149548|NCT01661868|DRUG|Olaparib|Tablet formulation will be used.
224149549|NCT01324128|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
224149550|NCT01324128|DRUG|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
224149551|NCT01324128|DRUG|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
224149552|NCT03729661|BEHAVIORAL|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
224149553|NCT06481020|DIETARY_SUPPLEMENT|Plant sterols 2g/day|PS-containing dietary supplement Sachet containing a powdered microencapsulated free plant sterols (2 g ingredient/day) during 8 weeks
223572254|NCT02593422|BEHAVIORAL|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
224149554|NCT06481020|DIETARY_SUPPLEMENT|Placebo|Sachet containing the powdered excipients of the dietary supplement during 8 weeks
223572255|NCT03263923|BEHAVIORAL|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
223572256|NCT03263923|BEHAVIORAL|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
223572257|NCT01094314|OTHER|embryo culture medium|comparison between two types of embryo culture medium
223572258|NCT01690546|DRUG|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
223572259|NCT01690546|DRUG|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
223572260|NCT01690546|DRUG|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
223572261|NCT05734053|OTHER|Nilotinib|There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
223572262|NCT02627547|BEHAVIORAL|Normal training|5-10 hours of endurance training each week
223572263|NCT02627547|BEHAVIORAL|De-training|No training
223572264|NCT01122342|DRUG|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
223572265|NCT03908372|DRUG|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
223572266|NCT03908372|DRUG|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
223742933|NCT00245141|DRUG|cyclophosphamide|
223742934|NCT00245141|DRUG|vincristine sulfate|
223742935|NCT00245141|RADIATION|radiation therapy|
224149555|NCT04687007|BEHAVIORAL|SMART-ALD|At the beginning of SMART-ALD, a multi-professional team evaluates participant's current health status and develops an individual treatment plan together with the participant. The SMART-ALD intervention offers medical, psychological, and social counseling, as well as a physical fitness and disease-specific nutritional program carried out via video consultation. Thus, scope and intensity of SMART-ALD intervention is initially tailored to individual needs and continuously adapted to changes during intervention.
224149556|NCT04687007|BEHAVIORAL|Waiting list|At the beginning of the study, patients of the waiting list (WL) control condition receive one medical consultation via video consultation, including recommendations to contact their local treating physician if necessary. Individuals are instructed not to seek any other medical or psychological treatment for X-ALD symptoms without informing the study staff. All WL patients are guaranteed 6 months of SMART-ALD intervention after a waiting period of 6 months.
224149557|NCT02456792|PROCEDURE|IVF|Women will undergo one IVF cycle
224149558|NCT02456792|PROCEDURE|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
224149559|NCT05823870|DRUG|DW6014|"Drug: DW6014 Single oral administration of DW6014 after an overnight fast~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast"
224149560|NCT05267418|DEVICE|Automated nasal O2 titration with FreeO2|The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
224149561|NCT01229891|DIETARY_SUPPLEMENT|plain yogurt drink|daily intake of two bottle of plain yogurt drink
224149562|NCT01229891|DIETARY_SUPPLEMENT|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
224149563|NCT01229891|DIETARY_SUPPLEMENT|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
224149564|NCT00003250|DRUG|fenretinide|
224149565|NCT03299036|DEVICE|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
224149566|NCT04030949|OTHER|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
224149567|NCT03810378|BEHAVIORAL|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
224149568|NCT03810378|BEHAVIORAL|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
224149569|NCT00028639|DRUG|bortezomib|
224149570|NCT05378048|DRUG|PDO-guided treatment|"A biopsy of the tumour will be performed for PDO culture and Genome-guided drug screening.~An Multidisciplanary Tumour Board will review the drug screen results and recommend the use of a drug with a response in a PDO."
224149571|NCT05378048|DRUG|standard of care|the standard of care will include all treatments that have been reported to improve survival or quality of life in randomized trials.
224149572|NCT03970707|OTHER|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25\*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
224149573|NCT03970707|OTHER|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25\*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
224149574|NCT02264171|DRUG|Tamsulosin HCl|
224149575|NCT02264171|DRUG|Ketoconazole|
224149576|NCT04694625|OTHER|Structured Rehabilitation Program|Early Function Phase (Protective phase) week 1 Progressive Function Phase (Recovery Phase) 2nd and 3rd week Advance Function Phase (Activity Phase) 4th week
224149577|NCT04694625|OTHER|Conventional Physical Therapy|• Rapid post-operative mobilization • Range of motion exercises started • Passive extension by placing pillow under foot • Flexion-by dangling the leg over the side of bed • Muscle strengthening exercises • Weight bearing is allowed on 1st post-operative
224149578|NCT00352066|DRUG|apricitabine|
224149579|NCT04090268|OTHER|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
224149580|NCT04860011|DRUG|Dapagliflozin 10 MG Oral Tablet|Dapagliflozin 10mg once daily
224149581|NCT04860011|DRUG|Metolazone Tablets|Metolazone 5MG or 10MG once daily
224149582|NCT04762953|DRUG|Paclitaxel|Intraperitoneal Paclitaxel
224305096|NCT01070459|BEHAVIORAL|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
223742936|NCT03329690|DRUG|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
224149583|NCT04762953|DRUG|Paclitaxel|IV Paclitaxel
224149584|NCT04762953|DRUG|Leucovorin|IV Leucovorin
224149585|NCT04762953|DRUG|Fluorouracil|IV 5-FU
224149586|NCT04593875|DEVICE|Active LIFUP Treatment|Low intensity focused ultrasound pulsation will be administered to the internal globus pallidus in 20 sonications at 650kHz, ispta.3 720mW/cm, pulse repetition frequency 100Hz, duty cycle 5%, duration 30s with 30s spacing between sonications. For active LIFUP, the device will be used with a gel pad that allows the ultrasound to pass through.
224149587|NCT04593875|DEVICE|Sham LIFUP Treatment|The device will be aimed at the internal globus pallidus and turned on with the same settings as the active condition; however, in this case, the device will be used with a gel pad that blocks the ultrasound from passing through, such that no ultrasound is actually being administered to the brain.
224149588|NCT06539338|GENETIC|INT2104|INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
224149589|NCT03909672|OTHER|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
224149590|NCT01118715|DEVICE|Compression glove|A compression glove worn during recovery from distal radius fracture
224149591|NCT02241928|BIOLOGICAL|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
224149592|NCT02904187|OTHER|Positron Emission Tomography (PET)|
224149593|NCT02904187|OTHER|Electroencephalogram (EEG)|
224305097|NCT01070459|BEHAVIORAL|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
223455340|NCT00933985|OTHER|laboratory biomarker analysis|Correlative studies
223455341|NCT00467207|DRUG|Botulinum Toxin A|
224064589|NCT00876187|BIOLOGICAL|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
224064590|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
223455342|NCT00467207|BEHAVIORAL|Resistance training|
223455343|NCT01556932|DRUG|ABH gel|Given topically
223455344|NCT01556932|OTHER|placebo|Given topically
223455345|NCT06635252|DRUG|STA 4783|Use of statins will be identified from Prescribed Drug register within 6 months before dementia diagnosis or each follow-up date
223455346|NCT02434159|OTHER|Heart scan|
223455347|NCT05552742|OTHER|Conservative rehabilitation|The conservative rehabilitation program includes a patient-specific conservative exercise program comprising exercises that strengthen the paralyzed side, increase joint range of motion and strengthen muscles, stretch spastic muscles, and ensure balance rehabilitation that enhances balance performance and coordination. The patients in both groups received conservative rehabilitation program for 8 weeks, 4 days a week for 1 h.
223455348|NCT05552742|DEVICE|Virtual Balance Training|Virtual balance training program using the Thera-Trainer Balo device was applied 4 times a week for a total of 8 weeks, and each session lasted for 20 min. The center of mass of each patient was determined using sensors and displayed on the screen. The patients were encouraged to move their mass by swiping in all directions via the apple picking game displayed on the screen
223455349|NCT04388124|DRUG|Bosentan|vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
223455350|NCT04388124|DRUG|Placebo|Placebo
224064591|NCT00876187|BIOLOGICAL|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
224064592|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
224064593|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
224064594|NCT00876187|DRUG|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
224064595|NCT00876187|BIOLOGICAL|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
224064596|NCT00876187|DRUG|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
224064597|NCT01186575|OTHER|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
224064598|NCT05392686|DRUG|PD-1 inhibitor|Tirelizumab
224064599|NCT05392686|DRUG|PARP inhibitor|Fluzopari capsule
224064600|NCT04503499|OTHER|Manuel Therapy|"The manual therapy protocol will consist of 45-60 minutes and the following techniques;~* suboccipital decompression~* cervical mobilization (in the posterior-anterior direction)~* sternocleidomastoid release~* scalene release~* trapezoidal release~* scalene release~* pectoralis tractus~* sternoclavicular joint mobilization~* sternum mobilization~* parasternal circumference intercostal and paravertebral release~* diaphragm release~* rib reasing~* scapulothoracic joint mobilization~* thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times."
224064601|NCT02742038|OTHER|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
224064602|NCT01068028|DRUG|ORM-12741|Ascending multiple doses to sequential panels
224064603|NCT01068028|DRUG|Placebo for ORM-12741|
224064604|NCT05349929|DRUG|Gelofen (generic name of Ibuprofen in Iran)|Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
224064605|NCT05349929|DRUG|Anahil ( generic name of Bromelain in Iran)|Anahil capsules,200 mg Bromelain, Permon Amin Health Company,every 6hours
224064606|NCT05349929|PROCEDURE|Root Canal Therapy|all the participants go under RCT.
224064607|NCT00893724|DRUG|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
224064608|NCT00893724|DIETARY_SUPPLEMENT|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
224064609|NCT00893724|DRUG|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
224064610|NCT02081040|OTHER|Not applicable (observational study with no active intervention)|
224064611|NCT05241730|OTHER|Training intervention|The training intervention will be a 10 week training plan for endurance runners. The plan consists of five sessions per week (three basic endurance sessions and two interval sessions)
224064612|NCT05241730|OTHER|High Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from high glycaemic index carbohydrates per day, the other E-% are fats and proteins.
224064613|NCT05241730|OTHER|LCHF|The subjects eat ≥ 65 E-% fats and a maximum of 50 g carbohydrates per day.
224064614|NCT05241730|OTHER|Low Glycaemic Index|The subjects eat 55-60 E-% carbohydrates with ≥ 65 % from low glycaemic index carbohydrates per day, the other E-% are fats and proteins.
224064615|NCT00405067|DRUG|BMS-201038 (AEGR-733)|
224064616|NCT00405067|DRUG|Ezetimibe|
224064617|NCT00404014|DRUG|AL-208|1 dose of 300 mg
224064618|NCT00404014|DRUG|Placebo|1 dose of placebo
224064619|NCT00945776|BEHAVIORAL|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
224064620|NCT00945776|BEHAVIORAL|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
224149594|NCT02721654|DRUG|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution \& when administered intravenously it is a source of water, electrolytes \& calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
223455351|NCT02328937|DEVICE|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
223455352|NCT02328937|DEVICE|lotrafilcon B|
223455353|NCT02328937|DEVICE|comfilcon A|
223455354|NCT00494429|DRUG|Morphine|Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
223455355|NCT00494429|DRUG|Morphine|Gestational Age\>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
223455356|NCT02006199|BEHAVIORAL|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
223455357|NCT04730401|BIOLOGICAL|Convalescent plasma from COVID-19 donors|Convalescent plasma from COVID-19 donors
223455358|NCT04730401|BIOLOGICAL|Placebo|200mL saline
223455359|NCT01888250|DRUG|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
223455360|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
223455361|NCT00825838|DIETARY_SUPPLEMENT|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
223455362|NCT00000809|BIOLOGICAL|Aluminum hydroxide|
223455363|NCT00000809|BIOLOGICAL|QS-21|
223455364|NCT00000809|BIOLOGICAL|MN rsgp120/HIV-1|
223455365|NCT01727362|OTHER|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
223455366|NCT01727362|OTHER|Usual care|Patients of this group receive usual care only
223455367|NCT00057525|BIOLOGICAL|Anthrax|Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
223455368|NCT00057525|BIOLOGICAL|Alhdryogel or PBS|Doses will range from 5 \_g to 100 \_g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
223572267|NCT03908372|RADIATION|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
223572268|NCT00033709|DRUG|temozolomide|
223455369|NCT03058471|DRUG|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
223455370|NCT03058471|DRUG|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
223455371|NCT03058471|DRUG|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
223572269|NCT00033709|DRUG|thalidomide|
223572270|NCT00005631|BIOLOGICAL|filgrastim|
223572271|NCT00005631|BIOLOGICAL|rituximab|
223572272|NCT00005631|DRUG|carboplatin|
223572273|NCT00005631|DRUG|etoposide|
223455372|NCT04931771|DEVICE|vFFR guided revascularization|3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
223455373|NCT04931771|DEVICE|FFR guided revascularization|Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
223455374|NCT00417521|BEHAVIORAL|Family-Based Treatment|
223455375|NCT06078644|OTHER|respiratory exercise diary|Patients in the intervention group will be asked to perform breathing exercises in the form of using a spirometer 10 times every hour during the preoperative period while they are awake for three days, starting from the first day after the surgery. Patients in this group will be given a breathing exercise diary.
223455376|NCT01625442|DRUG|Saffron tablet|Saffron tablets 100 mg
223455377|NCT01625442|DRUG|Barberry tablet|Barberry tablets 200 mg
223455378|NCT01625442|DRUG|Placebo|Placebo tablets received daily for 45 days
223455379|NCT03887585|PROCEDURE|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
223455380|NCT00403026|DRUG|Bevacizumab ( Avastin)|
223455381|NCT02604030|OTHER|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
223572274|NCT00005631|DRUG|ifosfamide|
223572275|NCT00908869|DRUG|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
224305098|NCT01070459|BEHAVIORAL|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
224305099|NCT06394843|OTHER|Ultrafiltration|Patients are selected depending on need of ultrafiltration
224305100|NCT02208232|PROCEDURE|cataract surgery|cataract surgery with implantation of intraocular lens
224305101|NCT04603170|OTHER|DRUG|taking drug medication prescribed by psychiatrists for at least one month
223572276|NCT01991223|DRUG|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
223572277|NCT01991223|DRUG|NS infusion|Normal saline will be infused during surgery
223742937|NCT03329690|DRUG|Physician's Choice|"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
224064621|NCT00945776|BEHAVIORAL|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
223572278|NCT01633515|PROCEDURE|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
224064622|NCT00816426|DRUG|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
224064623|NCT00816426|DRUG|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
224064624|NCT00816426|DRUG|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
224064625|NCT00816426|DRUG|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
224064626|NCT00816426|DRUG|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
224064627|NCT02676492|OTHER|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
224064628|NCT02676492|OTHER|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
224064629|NCT01599403|PROCEDURE|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
224064630|NCT01599403|PROCEDURE|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
224064631|NCT01599403|PROCEDURE|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
224064632|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
224064633|NCT01650636|BEHAVIORAL|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
224064634|NCT01224626|DRUG|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
224064635|NCT00334022|DRUG|enfuvirtide|1ml BID
224064636|NCT01560780|DRUG|Prasugrel|one 10 mg tablet by mouth daily
224064637|NCT01560780|DRUG|Placebo|placebo similar in appearance to prasugrel
224071257|NCT04534777|OTHER|repeated neurological, behavioral assessments and conventional, quantitative and functional brain imagery|Based on the collected data, we will evaluate the respective diagnostic accuracy of all the markers acquired in clinical practice regarding the clinical outcome at 2 years.
224071258|NCT00440505|DRUG|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
224301740|NCT03311035|PROCEDURE|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
224305102|NCT02570113|DEVICE|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
224305103|NCT02894437|OTHER|qualitative interviews|semi-structured interviews as a conceptual frame work
223455382|NCT05926843|PROCEDURE|Spinal cord stimulation surgery (device) and motor rehabilitation|The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
223455383|NCT03426943|BIOLOGICAL|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
223455384|NCT03426943|BIOLOGICAL|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
223455385|NCT03426943|DEVICE|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
224071259|NCT00440505|DRUG|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
223455386|NCT03426943|DEVICE|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
223455387|NCT00558805|BEHAVIORAL|FISP + Usual Care|
223455388|NCT00558805|BEHAVIORAL|Usual Care|
223455389|NCT03850834|DRUG|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
224071260|NCT00440505|DRUG|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
224071261|NCT05220605|DRUG|BromAc|Bromelain and acetylcysteine are combined in various concentrations (either 100ug, 150ug or 200ug of bromelain, with 20mg of acetylcysteine). This is then delivered by a nebuliser to up to 12 healthy volunteers. The primary aim is determining safety.
224071262|NCT01459705|BEHAVIORAL|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
224071263|NCT01459705|BEHAVIORAL|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
224071264|NCT01459705|BEHAVIORAL|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
224071265|NCT01090882|DRUG|Bupivocaine|20ml 0.25% at beginning of operation
224071266|NCT01090882|DRUG|0.9% normal saline solution|20ml 0.9% NaCl
224071267|NCT03658486|OTHER|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
224071268|NCT00144482|DRUG|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
224071269|NCT00144482|DRUG|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
224071270|NCT02525159|DIETARY_SUPPLEMENT|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
224071271|NCT02525159|OTHER|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
224071272|NCT03039842|DRUG|Dextromethorphan|
224071273|NCT03039842|DRUG|Memantine|
224071274|NCT03039842|DRUG|dextromethorphan+memantine|
224071275|NCT03039842|DRUG|placebo+valproate|
224071276|NCT03721666|OTHER|CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.
224071277|NCT03021902|DRUG|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
224149595|NCT02721654|DRUG|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile \& non-pyrogenic solution \& is indicated for extracellular fluid replacement \& in the management of metabolic alkalosis in the presence of fluid loss, \& for restoring or maintaining the concentration of sodium \& chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
224149596|NCT04630964|DRUG|Psilocybin|psilocybin 25 mg Single Oral Dose
224149597|NCT04630964|DRUG|Niacin|niacin 100mg Single Oral Dose
224149598|NCT03459404|COMBINATION_PRODUCT|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
224149599|NCT00436293|DRUG|Docetaxel|75 mg/m²
224149600|NCT00436293|DRUG|Cisplatin|75 mg/m²
224149601|NCT03838003|PROCEDURE|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
224149602|NCT01395641|DRUG|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
224149603|NCT05789849|DEVICE|Collecting blood pressure measurements with noninvasive blood pressure device|Noninvasive blood pressure measurements will collected based on the recommendations of the International Organization for Standardization (ISO) 81060-2:2018+A1:2020 Non-invasive sphygmomanometers -Clinical investigation of intermittent automated measurement type. This study has only 1 arm; investigational NIBP measurements will be collected using a NIBP Auscultatory Algorithm with alternating NIBP measurements collected using a reference sphygmomanometer.
224149604|NCT02842788|PROCEDURE|Prone positioning|Turning the patient face down for several consecutive hours
224149605|NCT05390307|DRUG|Liraglutide / Semaglutide|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection for 6 months.
224149606|NCT05390307|DRUG|Dapagliflozin|Dapagliflozin 5-10 mg once daily for 6 months.
223455390|NCT03850834|DRUG|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
223455391|NCT01643486|OTHER|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
223455392|NCT01643486|OTHER|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
223455393|NCT03210012|DIAGNOSTIC_TEST|Transthoracic echocardiography|Diagnostic test done prior and after the dive
223455394|NCT03210012|DIAGNOSTIC_TEST|Blood samples|Diagnostic test done prior and after the dive
223455395|NCT05714540|DRUG|Ketamine Hydrochloride ,Magnesium sulphate and saline 0.9%|The Effect of Oropharyngeal Pack Soaked with Ketamine or Magnesium Sulphate on Post Operative Sore Throat after Nasal Surgeries
223455396|NCT03821766|DEVICE|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
223455397|NCT03672344|DEVICE|Lookware TM|Lookware TM is a computer-based video game that requires the subject engage in social skills related exercises that include certain visual behaviors. These exercises combine techniques from applied behavior analysis (ABA) and use of gaze-contingent eye tracking technology during simulated social interactions with 3D animated characters to target certain social skills deficits in children with autism spectrum disorder (ASD). The game is delivered through a laptop computer, eye tracker, and game controller.
224149607|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin|Combined treatment with Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months.
224149608|NCT05390307|DRUG|Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition|Liraglutide 3mg once daily or semaglutide 1mg once weekly subcutaneous injection plus Dapagliflozin 5-10 mg once daily for 6 months combined with intensive lifestyle changes.
224149609|NCT05390307|OTHER|Usual care|Usual standard care
223455398|NCT03672344|DEVICE|Lookware TM Control Module|Lookware TM Control Module is a version of the Lookware TM computer-based video game that excludes the social skills related exercises. The game is delivered through a laptop computer, eye tracker, and game controller.
224149610|NCT02253017|OTHER|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
224149611|NCT05544071|DEVICE|Transcranial Magnetic Stimulation (TMS)|Compare active coil with sham coil.
224149612|NCT00134017|DRUG|Busulfan|Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)
224149613|NCT00134017|DRUG|Cyclophosphamide|Days -3, -2, +3, +4: 50 mg/kg IV daily
224149614|NCT06377072|DRUG|Shenqi Sherong Pill|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
224149615|NCT06377072|DRUG|Placebo|two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks
224149616|NCT00540306|DEVICE|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
224301741|NCT02521935|DEVICE|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination \& diagnosis \& initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
224149617|NCT04296916|DRUG|IOP lowering eye drops|"1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops."
224149618|NCT05816291|DIETARY_SUPPLEMENT|Time to Exhaustion at velocity at VO2max|During a familiarization trial prior to supplementation and before and after each supplementation period at the beginning of each study visit, participants will complete a standardized warm-up consisting of walking on a treadmill for 5 minutes, a series of whole-body dynamic movements (high knees, butt kicks, walking lunges, straight-leg marching, etc.), and a self-prescribed period of jogging on the treadmill for no more than ten minutes. The speed on the treadmill will then be set at the velocity upon which 100% VO2Peak was achieved. Participants will be instructed to run at this velocity for as long as they can. No feedback in terms of duration, pacing, etc. will be provided, and participants will be provided verbal encouragement to run for as long as possible.
224149619|NCT00739960|DRUG|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
224149620|NCT00169039|DRUG|Clozapine|
224149621|NCT00169039|DRUG|Chlorpromazine|
224149622|NCT00763243|BEHAVIORAL|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
224149623|NCT00636441|DRUG|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
224149624|NCT05774613|DIETARY_SUPPLEMENT|Effect of a Hibiscus sabdariffa beverage|Hibiscus sabdariffa concentrate 60 mL from improved Mexican variety , administered on a single occasion
224149625|NCT02163772|PROCEDURE|Intracordal hyaluronate injection|
224149626|NCT00439504|DRUG|Lobeline|
224149627|NCT05228080|DIAGNOSTIC_TEST|enzyme-linked immunosorbent assay(ELISA)|Peripheral blood samples will be drawn from each patient at study entry (before reperfusion therapy) and at 12,24 hours after reperfusion therapy.Serum will be immediately separated by centrifugation at 3000 rpm for 15 minutes and stored at -80°C. Endocan,ICAM-1,VCAM-1,MMP-9 levels will be determined in duplicate by commercially available enzyme-linked immunosorbent assay (ELISA).
224149628|NCT05452824|OTHER|Tai Chi Prehabilitation|The intervention arm will be oriented to a WaQi (youthful vitality) program 8 weeks prior to their scheduled surgery date. The WaQi program uses a Tai Chi curriculum previously successfully implemented in older adults, and at the Memorial Sloan Kettering Cancer Center (MSKCC). It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting or standing. Intervention participants will also receive printed materials from Prostate Cancer Canada about prostate cancer management. These materials include information about how to cope with prostate cancer including pelvic floor exercise, physical activity, healthy eating, and mental wellbeing.
224149629|NCT05452824|OTHER|Usual care|Control arm participants will receive printed materials identical to intervention arm participants with general information on a healthy lifestyle. The control arm will receive an 8-week online Tai Chi teaching module subscription at the end of the study.
223455399|NCT03958110|DIAGNOSTIC_TEST|OCT A|OCT (Optical Coherence Tomography) and Retinophotography made at the beginning and end of the Rugby season.
223455400|NCT00996034|BIOLOGICAL|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
223455401|NCT00996034|RADIATION|[123I]5-IA-85380|up to 10 mCi of \[123I\]5-IA-85380, I.V. on each of two SPECT Scan days
223455402|NCT00996034|DRUG|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
223455403|NCT01602497|DEVICE|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
223455404|NCT01602497|DEVICE|sham rTMS|Patients will undergo ten session of sham rTMS.
223455405|NCT03508180|BEHAVIORAL|INTERVIONNAL|"Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient."
223455406|NCT03508180|OTHER|CONTROL|None intervention.
223455407|NCT00670722|DRUG|insulin aspart|Intervention at the discretion of the physician
223455408|NCT00670722|DRUG|insulin detemir|Intervention at the discretion of the physician
223455409|NCT00670722|DRUG|biphasic insulin aspart 30|Intervention at the discretion of the physician
223572279|NCT04929925|DIAGNOSTIC_TEST|serum procalcitonin in acute bacterial meningitis|Serum Procalcitonin estimation will be done by Cobas e411Roch diagnostic,Switzerland apparatus by immunoassay method (electrochemiluminescence immunoassay) by using sample serum or plasma heparin or EDTA with reference range less than 0.5ng/ml ( no sepsis) but 0.5-2ng/ml)follow up is recommended) and more than 2 (sepsis)
223572280|NCT04503161|DEVICE|Duragen with Collagen Hydrodel and ASCs|Duragen combined with collagen hydrogel and patient's stem cells
223572281|NCT05385081|OTHER|genomic profiling|next generation sequencing
223572282|NCT00481325|DRUG|pexacerfont|Tablets \& Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
224149630|NCT04926844|DRUG|Levetiracetam|Intravenous levetiracetam 60 mg/kg (max 4500 mg) over 5 minutes (diluted with isotonic saline to a concentration of 50 mg/ml).
224149631|NCT04926844|DRUG|Midazolam|Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes
224149632|NCT04926844|DRUG|Placebo|Intravenous isotonic saline (1.2 ml/kg) over 5 minutes
224149633|NCT00807300|RADIATION|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
224149634|NCT00807300|PROCEDURE|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
224149635|NCT06609317|DEVICE|Digital therapeutic motion-based device|This intervention includes use of a digital therapeutic motion-based device for pelvic floor muscle training
224149636|NCT03499340|BEHAVIORAL|text-only PWL|control condition (no image)
224149637|NCT03499340|BEHAVIORAL|low arousal graphic PWL|pictorial warning
224301742|NCT02521935|DEVICE|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, \& tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
224301743|NCT01593696|BIOLOGICAL|Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)|Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
224301744|NCT00002785|BIOLOGICAL|filgrastim|
224301745|NCT00002785|DRUG|asparaginase|
224149638|NCT03499340|BEHAVIORAL|high arousal graphic PWL|pictorial warning
224301746|NCT00002785|DRUG|cyclophosphamide|
223455410|NCT01570257|PROCEDURE|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
224149639|NCT03499340|BEHAVIORAL|absolute risk|Percentage risk information for smoking-related diseases for smokers
224149640|NCT03499340|BEHAVIORAL|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
223572283|NCT00481325|DRUG|escitalopram|Tablets \& Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
223572284|NCT00481325|DRUG|placebo|Tablets \& Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
224149641|NCT05238987|DIETARY_SUPPLEMENT|Ferrous sulphate|Single dose of ferrous sulphate (120 mg of elemental iron)
224149642|NCT00425100|DRUG|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
224149643|NCT01884168|BIOLOGICAL|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
224149644|NCT03603834|DRUG|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
224149645|NCT04000087|OTHER|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
224149646|NCT04580823|DIETARY_SUPPLEMENT|Fasting with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan.
224149647|NCT04580823|DIETARY_SUPPLEMENT|Post-Prandial with exogenous ketone salt supplement|Participants will have to take 2 doses of supplement, one 75 minutes before the scan and one 30 minutes before the scan and they will have a liquid meal 20 minutes before the scan.
224301747|NCT00002785|DRUG|cyclosporine|
224301748|NCT00002785|DRUG|cytarabine|
224149648|NCT04158986|BEHAVIORAL|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~* Filling in the Chronic Liver Disease Questionnaire.~* Therapeutic conversations including drawing and review of genogram and eco-map.~* Information about- and help to initiate contact to relevant municipal offers.~* Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
224149649|NCT03335618|OTHER|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
224301749|NCT00002785|DRUG|daunorubicin hydrochloride|
224301750|NCT00002785|DRUG|dexamethasone|
224301751|NCT00002785|DRUG|etoposide|
224301752|NCT00002785|DRUG|leucovorin calcium|
224301753|NCT00002785|DRUG|mercaptopurine|
224301754|NCT00002785|DRUG|mesna|
224301755|NCT00002785|DRUG|methotrexate|
224301756|NCT00002785|DRUG|methylprednisolone|
224301757|NCT00002785|DRUG|pegaspargase|
224301758|NCT00002785|DRUG|prednisone|
224301759|NCT00002785|DRUG|therapeutic hydrocortisone|
224301760|NCT00002785|DRUG|vincristine sulfate|
224301761|NCT00002785|PROCEDURE|allogeneic bone marrow transplantation|
224301762|NCT00002785|RADIATION|low-LET cobalt-60 gamma ray therapy|
224301763|NCT00002785|RADIATION|low-LET photon therapy|
224301764|NCT04921020|OTHER|Photography|Facial photographs and blinking videos are taken
224149650|NCT03335618|OTHER|Passive Activity Monitoring|Passive step tracking without check-ins
224149651|NCT02042339|DRUG|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
224301765|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
224301766|NCT04006223|DIAGNOSTIC_TEST|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
224301767|NCT01936623|BEHAVIORAL|Computerized Brief Intervention|No additional information needed.
224301768|NCT01374295|OTHER|video|watch a 3 minute video
224301769|NCT01374295|OTHER|standard education|Receives standard verbal education from healthcare provider
224301770|NCT04873765|BIOLOGICAL|Pegfilgastrim Megalabs|Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose
224301771|NCT04873765|BIOLOGICAL|Pegfilgastim Amgen|Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
224071278|NCT03021902|DEVICE|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
224071279|NCT01428817|DRUG|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
224071280|NCT01428817|DRUG|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
224071281|NCT01428817|DRUG|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
224071282|NCT01428817|DRUG|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
224071283|NCT01428817|DRUG|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
224071284|NCT02656602|OTHER|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
224071285|NCT01903499|OTHER|Other: Bean patty|
224071286|NCT01903499|OTHER|Other: Beef patty|
224071287|NCT00042887|DRUG|mitomycin C|
224071288|NCT00042887|PROCEDURE|conventional surgery|
224071289|NCT03127384|DEVICE|Restylane Lidocaine|Hyaluronic acid based filler
224071290|NCT03127384|OTHER|No-treatment control|No-treatment control
224071291|NCT06287970|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|In the experimental group, bilateral auricular point Xin (CO15) and auricular point Shen (CO10) will be stimulated, on where the vagus nerves distributed.
224071292|NCT06287970|DEVICE|Sham Transcutaneous Auricular Vagus Nerve Stimulation|In the control group, bilateral earlobes will be stimulated with no vagus nerve distribution.
224071293|NCT01063374|DIETARY_SUPPLEMENT|low glycemic diet instruction|
224071294|NCT01063374|DIETARY_SUPPLEMENT|high cereal fibre diet instruction|
224071295|NCT00355173|DEVICE|Lubo cervical collar|
224071296|NCT03926663|DRUG|Dexmedetomidine|"Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa."
224071297|NCT03926663|DRUG|Bupivacaine|patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
224071298|NCT01168648|BEHAVIORAL|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
224071299|NCT01168648|OTHER|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
224071300|NCT03496428|DEVICE|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
224071301|NCT04812132|PROCEDURE|One-anastomosis gastric bypass|One group is planned to have one-anastomosis gastric bypass (also known as mini-bypass)
224071302|NCT04812132|PROCEDURE|Long biliary limb Roux gastric bypass|Other group is planned to receive a long biliary limb Roux gastric bypass
224071303|NCT00002753|RADIATION|iodine I 131 monoclonal antibody 81C6|
224071304|NCT05499949|DIAGNOSTIC_TEST|NASH screening|Evaluate liver steatosis and elasticity using transient elastography in the FONS group
224071305|NCT05499949|DIAGNOSTIC_TEST|Cardiac dysfunction screening|Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography
224071306|NCT05499949|DIAGNOSTIC_TEST|Liver biopsy|For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
224071307|NCT04349774|DRUG|Control Group - ESP block with SAP block|None - Control Group
224071308|NCT04349774|DRUG|Treatment Group - ESP block with SAP normal saline|Substitution of normal saline in place of 0.375% Bupivacaine in SAP block
224149652|NCT02855320|OTHER|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
224149653|NCT03332472|OTHER|Telemedicine group|
224149654|NCT03332472|OTHER|Conventional group|
224149655|NCT00615251|DRUG|DR-2011|Progesterone vaginal ring for approximately 10 weeks
224149656|NCT00615251|DRUG|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
224149657|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
224149658|NCT02052934|BIOLOGICAL|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
224149659|NCT06430710|DEVICE|Intrusion|2 different methods for incisor intrusion
224149660|NCT04419818|BEHAVIORAL|Virtual Reality|Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Participants will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
224149661|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
224149662|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
224149663|NCT01112423|DRUG|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
224149664|NCT01112423|DRUG|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
224149665|NCT03495817|DRUG|ATI-50002|ATI-50002 Topical Solution
224149666|NCT03833375|OTHER|Decision Aid|Shared-decision making tool
224149667|NCT02293096|DRUG|metoprolol succinate|
224149668|NCT02293096|GENETIC|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
224149669|NCT02293096|PROCEDURE|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
224149670|NCT02616016|DEVICE|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
224149671|NCT03071003|DRUG|SENS-401|Oral Administration
224149672|NCT03071003|DRUG|Placebo|Oral Administration
224149673|NCT02602171|OTHER|Oldenburger sentence test, localization test|
224149674|NCT04169061|DRUG|Acthar|Acthar gel for subcutaneous injection
224149675|NCT02781454|DRUG|Mexiletine|
223455411|NCT03910881|OTHER|Open-platform patient support system (PSS) app|The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
223455412|NCT02812082|OTHER|web-based patient education|
224149676|NCT02781454|DRUG|Placebo|
224149677|NCT04196205|BIOLOGICAL|Anti-CD19 CAR-T|1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh
224149678|NCT04585451|DIAGNOSTIC_TEST|ALGOS System|A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
223455413|NCT02812082|BEHAVIORAL|questionnaire|
223455414|NCT02008136|DRUG|Botulinum Toxins|intramuscular injections
224149679|NCT00326417|DRUG|Fludarabine|Doses of 30 mg/m\^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
224149680|NCT00326417|DRUG|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
224149681|NCT00326417|DRUG|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
224149682|NCT00326417|DRUG|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
224149683|NCT00593658|DRUG|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
224149684|NCT01867814|PROCEDURE|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
224149685|NCT00096590|OTHER|coagulation study|
224149686|NCT00096590|OTHER|immunoenzyme technique|
224149687|NCT00096590|OTHER|laboratory biomarker analysis|
224149688|NCT00096590|OTHER|physiologic testing|
224149689|NCT00096590|PROCEDURE|study of high risk factors|
224149690|NCT05510206|DEVICE|Leveling and alignment|"Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires"
224149691|NCT00844285|DRUG|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
224149692|NCT04693689|OTHER|RNA vaccine|We elicit subjects' willingness to receive RNA COVID-19 vaccine
224149693|NCT04693689|OTHER|20% adoption rate|We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
224149694|NCT04693689|OTHER|40% adoption rate|We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it
224149695|NCT04693689|OTHER|60% adoption rate|We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it
224149696|NCT04693689|OTHER|80% adoption rate|We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it
224149697|NCT04693689|OTHER|Conventional vaccine|We elicit subjects' willingness to receive conventional COVID-19 vaccine
224149698|NCT04693689|OTHER|0% adoption rate|We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
224149699|NCT01352065|DRUG|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
224149700|NCT01352065|DRUG|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
224149701|NCT01352065|DRUG|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
224149702|NCT04045626|PROCEDURE|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
224149703|NCT01648829|DRUG|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
224149704|NCT01648829|DRUG|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
224149705|NCT03485092|DRUG|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
224149706|NCT03485092|DRUG|Placebo Oral Tablet|placebo tablets for oral self administration once a day
224149707|NCT01682070|BIOLOGICAL|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
224149708|NCT01682070|BIOLOGICAL|Placebo|
224149709|NCT01995812|BEHAVIORAL|Hula and heart health education|
224301772|NCT03816566|DEVICE|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
224301773|NCT01340768|DRUG|Sitagliptin|One 100 mg tablet taken orally once daily
224149710|NCT01562704|DRUG|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
224149711|NCT05937217|OTHER|myofascial induction and direct scar release techniques|Manual therapy techniques used to reduce chronic lower transverse abdominal scars pain and improve quality of life of the affected women
224149712|NCT05937217|DEVICE|therapeutic ultrasound|Ultrasound petron (model SM 500) specifications: output frequency:1Mhz, output power:5W/cm², power intensity:5 degree (0.8-1.2-1.6-2.0-2.5), time intensity:5-30(step by 5 min) . It will be applied for both groups for 10 minutes
224149713|NCT02490917|DEVICE|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
224149714|NCT02490917|DEVICE|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
224149715|NCT00965406|DRUG|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
224149716|NCT00091923|DEVICE|Eye patch|
224149717|NCT00091923|DEVICE|Spectacles|
224149718|NCT02183623|DRUG|Simvastatin|
224149719|NCT02183623|DRUG|10 mg BI 1356 BS|
223455415|NCT03231306|DRUG|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
223455416|NCT02540122|DEVICE|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
224149720|NCT02140203|OTHER|Yoga Training|one-year experimental training (three times per week and one hour per session)
224149721|NCT02372097|DRUG|SYR-472|SYR-472 25mg, 50mg
224149722|NCT01097148|DRUG|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
224149723|NCT00931060|DIETARY_SUPPLEMENT|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
224149724|NCT01644981|OTHER|blood sampling|blood sampling
224149725|NCT04163640|OTHER|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
224149726|NCT02220946|DEVICE|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
224149727|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Plan + CHW|"* Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~* Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
224301774|NCT01340768|DRUG|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
224301775|NCT01340768|DRUG|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
224301776|NCT02620150|DRUG|Escitalopram|10 week trial
224301777|NCT02620150|OTHER|Placebo|10 week trial
224301778|NCT00997568|DEVICE|PET-511BTM|Transesophageal Transducer
224301779|NCT02203422|DRUG|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
224149728|NCT02190617|BEHAVIORAL|Enhanced Clinic+ Unified Management Plan|"* Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~* Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
224149729|NCT02190617|BEHAVIORAL|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
224149730|NCT00467714|PROCEDURE|rhinoplasty|COLUMELLA STRUT PLACEMENT
224149731|NCT02201355|RADIATION|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
224149732|NCT00555906|DRUG|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
224149733|NCT00555906|DRUG|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
224149734|NCT00555906|DRUG|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
224149735|NCT00477555|DEVICE|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
224149736|NCT00001911|DRUG|Interleukin-12|
224301780|NCT02203422|DRUG|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
224149737|NCT03400137|DIAGNOSTIC_TEST|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
224149738|NCT05693870|DEVICE|Fixed space maintainer|Appliance bonded with composite resin or/banded and cemented with glass ionomer cement
224149739|NCT06281405|DRUG|PD-1 antibody|PD-1 antibody (Toripalimab): 240mg d1 q3w
224149740|NCT06281405|DRUG|Capecitabine|Capecitabine: 1000mg/m2 bid d1-14 q3w
224149741|NCT06281405|RADIATION|Short-course radiotherapy|Short-course radiotherapy: 25Gy/5Fx
224149742|NCT04019769|DRUG|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
224149743|NCT05260892|DEVICE|Narrow GM implants|Rehabilitation of superior lateral incisors or inferior central and lateral incisors with narrow implants supporting single unit or partial prostheses
224149744|NCT01292044|OTHER|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
224149745|NCT03219567|DEVICE|Optical Coherence Tomography (OCT)|"Optical coherence tomography (OCT) is a non-contact, micrometer scale imaging technique, it provides clinicians and researchers with high resolution in vivo images sufficient to visualize layered microanatomy in 3D.~The study team will develop the hardware systems and software algorithms necessary to enable simultaneous OCT imaging of all the refractive surfaces of the eye."
224149746|NCT03219567|DEVICE|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) is a medical imaging technique that uses a magnetic field and computer-generated radio waves to create detailed images of the organs and tissues in the body.
224149747|NCT05912712|OTHER|Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment|10 mL PRP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PRP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PRP leakage. The outflow was observed, and the amount of outflow was recorded.
224149748|NCT05912712|OTHER|Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment|10 mL PPP and thrombin coagulum gel was administered every night for seven consecutive days by the same IBD specialist. Before the intervention, the patients had to defecate. The prepared PPP gel was injected into the external opening of the rectum using the same syringe, and the patient was kept in the Trendelenburg position to ensure that the therapeutic drug remained in place under gravity. The normal supine position was returned after 15 minutes to minimize PPP leakage. The outflow was observed, and the amount of outflow was recorded.
224301781|NCT02878486|DEVICE|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
224301782|NCT02878486|BEHAVIORAL|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
224149749|NCT05912712|DRUG|Mesalazine Suppository Treatment|For patients receiving mesalazine suppositories, the intervention was inserted through the anus with a disposable sanitary finger to the point of slight loss of resistance. To facilitate intervention, moisturize with water or cream. If the drug drains within 10 minutes, it should be re-inserted. The swelling at the local injection site on each group's intervention day was recorded.
224149750|NCT05912712|BIOLOGICAL|Infliximab Treatment|Patients, in every arm, all receive infliximab (300 mg iv at 0, 2, 6 weeks, and then every eight weeks).
224301783|NCT02878486|DEVICE|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
223455417|NCT02540122|DEVICE|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
224301784|NCT02815449|OTHER|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
224149751|NCT06431178|OTHER|General Anesthesia|"General anesthesia will be induced by 6% sevoflurane with a face mask. An intravenous line(22-g cannula )will be inserted then fentanyl 1mcg-kg will be given . Endotracheal tube will be used to intubate the patient .Anesthesia will be maintained by 2%sevoflurane inhalation in an oxygen air compination 1:1 throught the operation . Crystalloid solution was used to replenish fluid according 4/2/1-rule. Monitoring during the procedure include , ejection fraction (EF),blood pressure, heart rate, respiratory rate, and O2 saturation are measured at baseline, after induction, 10 min after catheter insertion,30 min during procedure and post emergence."
224149752|NCT06431178|OTHER|Local anesthesia|A nasal cannula was placed and oxygen delivered at 2 to 3 L/minute. An intravenous line will be inserted (22-g cannula). The sedation regimen will include loading dose of dexmedetomidine (1 mcg/kg) and ketamine (1mg/kg) over 10 minutes . The patient will receive an infusion of dexmedetomidine at 0.7 mcg/kg per hour and ketamine 0.5 mg/kg/hr as maintenance sedation .Local infilteration of xylocaine 2% at dose 2mg/kg will be given for vascular access in cardiac catheterization . After completion of the procedure the infusion pump will be stopped to ensure that the patient is fully awake and vitally stable
224149753|NCT03941691|DEVICE|Fully Absorbable VSD Occlusion System|Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
224301785|NCT02815449|OTHER|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
224301786|NCT02815449|OTHER|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
224301787|NCT01713049|DRUG|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
223455418|NCT02540122|DEVICE|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
223455419|NCT02540122|DEVICE|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
224071309|NCT06216639|DRUG|Bismuth Subcitrate|Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.
223455420|NCT00920413|DIETARY_SUPPLEMENT|Vitamin C|vitamin C 500mg orally once a day
223455421|NCT00920413|DIETARY_SUPPLEMENT|placebo|
224071310|NCT06216639|DRUG|Esomeprazole|Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.
224071311|NCT06216639|DRUG|Metronidazole|Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.
224071312|NCT06216639|DRUG|Amoxicillin|Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.
224071313|NCT06216639|DRUG|Clarithromycin|Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
224071314|NCT06216639|DRUG|Levofloxacin|Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
224071315|NCT05243264|BEHAVIORAL|Empower@Home|The intervention is a 10-week course of internet-based cognitive behavioral therapy. During the active intervention phase, participants will receive a weekly check-in call to see how they are doing. The weekly check-in call is intended to be brief and last no more than 10 minutes on average.
224071316|NCT05223946|DIAGNOSTIC_TEST|Microwave Radiometry|The MWR 2020 (former RTM-01-RES) device is a unique commercially available CE marked device. The device is already registered in Russia and Kyrgyzstan for diagnostics of different diseases. There were several works on identification of excess of microwave emission due to inflammatory, process, cancer and other disorders.
224071317|NCT05223946|DEVICE|SCENAR-CHENS-01|Percutaneous electroneurostimulation (TENS) using the Self Controlled Energy Neuro Adaptive Regulator SCENAR-CHENS-01 device (ZAO OKB RITM, Taganrog, Russia)
224071318|NCT05223946|COMBINATION_PRODUCT|Traditional Combination Therapy|ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )
224071319|NCT04055714|DEVICE|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
224071320|NCT06424028|OTHER|Right Ventricular Infarct|Consecutive patients presented with isolated inferior, infero-posterior and inferolateral wall MI with or without acute right ventricular infarction.
224071321|NCT00326352|DRUG|Sedation with propofol and remifentanil|
224071322|NCT03081520|BEHAVIORAL|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
224071323|NCT03081520|BEHAVIORAL|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
224071324|NCT03081520|BEHAVIORAL|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
224071325|NCT00619073|DRUG|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
224149754|NCT03941691|DEVICE|VSD Occluder|Under echocardiography guided treatment of VSD with commercially available occluder.
224149755|NCT02849626|DRUG|Perampanel|E2007
224149756|NCT05057143|DEVICE|Implants|3D printed implants
224149757|NCT05057143|DEVICE|Plates|Titanium plates
224149758|NCT05589844|PROCEDURE|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo standard of care allogeneic hematopoietic stem cell transplant
224149759|NCT05589844|PROCEDURE|Biospecimen Collection|Correlative studies
224149760|NCT05589844|BIOLOGICAL|CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine|Given intradermally
224149761|NCT05079763|OTHER|Bacterial cellulose-monolaurin hydrogel|Hydrogel containing Komagataeibacter bylines-derived bacterial cellulose, virgin coconut oil monolaurin, cucumber fragrance and distilled water
224149762|NCT05079763|OTHER|Placebo cream|Cream containing distilled water, white petrolatum, steady alcohol, propylene glycol, sodium laurel sulphate, methylparaben and propylparaben
224149763|NCT01654523|DEVICE|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
224149764|NCT01313208|DRUG|etanercept|Administered by subcutaneous injection once weekly.
224149765|NCT01313208|DRUG|Placebo|Placebo subcutaneous injection
224149766|NCT01313208|DRUG|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
224149767|NCT03865459|OTHER|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
224149768|NCT01270100|BEHAVIORAL|Recovery management|
224149769|NCT00159159|DRUG|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
224149770|NCT00159159|DRUG|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
223572285|NCT01789983|BEHAVIORAL|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
224149771|NCT02855242|BEHAVIORAL|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
224149772|NCT02855242|OTHER|Controls Group|Subjects not participating in any lifestyle counseling
224149773|NCT06268587|COMBINATION_PRODUCT|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &amp;gt; 3/10 on day one and who did not take analgesics.|Measure the impact of the home analgesia protocol on the proportion of patients with a VAS \&amp;gt; 3/10 on D+1 and who did not take analgesics. The protocol consists of providing the patient with instructions at the time of discharge, analgesics for a maximum of two days with dosages and an explanatory booklet on pain management
224149774|NCT03231215|DRUG|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
224149775|NCT01957787|DEVICE|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
224149776|NCT04176445|DEVICE|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
224149777|NCT04176445|OTHER|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
224149778|NCT03013829|BEHAVIORAL|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
224149779|NCT04393077|BEHAVIORAL|Emotional Freedom Technique|EFT application was started by showing the meridian points to the participants through the picture. It was advised that these points should be clicked with the index finger and middle finger without hurting, but with certain strokes, and it was ensured that they understood the regions by showing and applying them. Then, the following basic steps, which should be followed by the EFT session (four in total lasting 20 minutes), were carried out in succession with the researcher.
224149780|NCT02877849|DEVICE|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
224149781|NCT01148316|DRUG|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
224149782|NCT01148316|BEHAVIORAL|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
224149783|NCT04571918|PROCEDURE|Biodegradable spacer|Implantation of a biodegradable balloon used as a subacromial spacer.
224149784|NCT04571918|PROCEDURE|Debridement and biceps tenotomy|Surgery with arthroscopic debridement and biceps tenotomy
224149785|NCT00538746|DEVICE|BIPAP|
224149786|NCT00538746|DEVICE|PSV|
224149787|NCT00538746|DEVICE|PSV + CPAP|
224149788|NCT05137886|DRUG|PD-1 inhibitor|decitabine 10mg on d1-5, Tislelizumab 200mg on d8，21 days as one cycle.
224149789|NCT04922034|DRUG|Amoxicillin|Outcome of patients with negative oral challenge to amoxicillin
224149790|NCT02195934|OTHER|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
224149791|NCT02195934|OTHER|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
224149792|NCT02496117|PROCEDURE|Electrical mapping, nerve stimulation checked renal denervation procedure|
224149793|NCT02496117|PROCEDURE|Electrial mapping, nerve stimulation guided renal denervation procedure|
224149794|NCT03076918|DEVICE|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
224149795|NCT03076918|DEVICE|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
224149796|NCT01829217|DRUG|Sunitinib|
224149797|NCT02581618|OTHER|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
224149798|NCT00013481|PROCEDURE|Stroke Rehabilitation|
224149799|NCT05113719|OTHER|Exercise|Both groups will perform bridge exercise
224149800|NCT04046341|BEHAVIORAL|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. Session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine) via text message.
224149801|NCT01713855|BIOLOGICAL|Inactivated Trivalent Influenza vaccine|
224149802|NCT02679495|BEHAVIORAL|Active measures of lifestyle modification|
224149803|NCT00226395|DRUG|Oxymorphone immediate release|
224149804|NCT03173612|DRUG|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
224149805|NCT01572818|PROCEDURE|phlebotomy|7 ml/kg without exceeding 500 mL
224149806|NCT01572818|BEHAVIORAL|dietary and lifestyle counseling|dietary and lifestyle counseling
224149807|NCT05486936|RADIATION|hypofractionated radiation|Eligible breast cancer patients will receive hypofractionated radiotherapy of 2.67 Gy for 16 fractions (and sequential tumor bed boost of 2.67 Gy for 4 fractions in patients with intact breast) to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) at the discrection of radition oncologists.
224149808|NCT00440895|DRUG|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
224149809|NCT04077736|DRUG|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
224149810|NCT05163717|COMBINATION_PRODUCT|INP105|A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
224149811|NCT05163717|COMBINATION_PRODUCT|Placebo|A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
224149812|NCT01536106|OTHER|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
224149813|NCT01536106|OTHER|Placebo control|Intracoronary infusion of autologous peripheral blood.
224149814|NCT04552717|OTHER|My Grief|The app will build on principles of cognitive behavioural theory and therapy (CBT) and contains four main sections: Learning, Self-assessment, Manage symptoms and Find support.
224149815|NCT01557764|DRUG|lapatinib ditosylate|Given PO
224149816|NCT01557764|BIOLOGICAL|trastuzumab|Given IV
224149817|NCT05575284|PROCEDURE|Robot-assisted urological surgery|Patient with programmed robot-assisted urological surgery
224149818|NCT05650515|OTHER|Co-creation|The development of a technology-based exercise intervention based on ideas of older adults and experts in the field of geriatric rehabilitation/research/medicine
224149819|NCT06528015|DRUG|probiotics combined with enteric-coated budesonide capsule|"In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
224149820|NCT06528015|DRUG|probiotics placebo combined with enteric-coated budesonide capsules|"In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules."
224149821|NCT00920478|OTHER|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
224149822|NCT00920478|OTHER|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
223455422|NCT05937620|DIAGNOSTIC_TEST|99mTC nanocolloid albumin injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
224149823|NCT04796428|DRUG|Canagliflozin|Canagliflozin If the patient is already on metformin, the fixed combination Canagliflozin / Metformin can be used.
224149824|NCT04796428|DRUG|Dapagliflozin|"Dapagliflozin If the patient is already on metformin, the fixed combination dapagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination dapagliflozin / saxagliptin can be used."
224149825|NCT04796428|DRUG|Empagliflozin|"If the patient is already on metformin, the fixed combination empagliflozin / metformin can be used.~If the patient is already on a DPP-4 inhibitor, the fixed dose combination empagliflozin / linagliptin can be used."
224149826|NCT04180501|COMBINATION_PRODUCT|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
224149827|NCT05893667|DIAGNOSTIC_TEST|Inflammatory markers|analysis of inflammatory scores
224149828|NCT00232440|DEVICE|BodyFIX|
224149829|NCT05181904|OTHER|Gastric ultrasound|Assessment of gastric content with gastric ultrasound monitoring: gastric ultrasounds will be performed in eligible children, when enteral feeding is stopped for planned extubation, and repeated 6 hours after, at extubation and every hour between feeding interruption and extubation. The stomach will be classified as empty or full according to PERLAS criteria. In total, 8 gastric ultrasounds will be performed over a period of 12 hours.
224149830|NCT03859492|DEVICE|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
224149831|NCT05165992|DRUG|Nebulized Fentanyl|Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
224149832|NCT02780596|OTHER|Item1|Does CHILD NAME often wake one or more times during the night?
224149833|NCT02780596|OTHER|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
224149834|NCT02780596|OTHER|Item3|Do you think CHILD'S SLEEP is a problem?
224149835|NCT02780596|OTHER|Item4|Do you think CHILD NAME has a sleep problem?
224149836|NCT02780596|OTHER|Item5|Do you have any concerns about CHILD NAME'S sleep?
224149837|NCT04914117|DRUG|RC118 for injection|RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.
224149838|NCT06044519|BIOLOGICAL|different types of dressings|different types of dressings were compared ti see the effectiveness for for STSG donor site wound
224149839|NCT04715412|OTHER|patient counseling and adherence support|"Technical interventions include; identification of possible reasons for non-adherence, adherence support by developing simplified schedules for taking medications that were customized to individualized patient's lifestyle. Reminders for dose as well as tools/strategies the RTR may use to follow the dosing schedules if needed as pillbox were provided as needed~Clinical pharmacists' guided patient training was individualized, repetitive, covered 6 months, and included more aspects and provided practical hints and strategies for medication management.~Initial clinical pharmacist face-to-face session will be up to 60-minute then 30-minute follow-up sessions will be conducted monthly for 6 months during the scheduled post-transplant clinic visits as coordinated with the transplant physician to allow for single office visits for transplant related issues and comorbidities."
224149840|NCT04282681|OTHER|Accelerometer Live-Streaming Tool|The only 'intervention' that will take place is the placement of the XLS tool(s) on the upper left chest and/or left wrist of the patient.
224301788|NCT03052959|BEHAVIORAL|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
224301789|NCT03052959|OTHER|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
224301790|NCT05385159|DRUG|AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION|Adipose tissue removal, ADSVF production and injection of ADSVF will be done on the same day during a short hospital stay
223455423|NCT05937620|DIAGNOSTIC_TEST|ICG injection|All patients will receive an injection of both tracers in order to detect the sentinel lymph node
223455424|NCT00685360|DRUG|Delamanid|Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
223455425|NCT00685360|DRUG|Optimized Background Regimen (OBR)|"Selection and administration of the treatment medications (i.e., OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.~Study Investigator could change OBR for a participant based on participant's tolerability and drug susceptibility testing (DST) results."
223455426|NCT00685360|DRUG|Placebo|Placebo tablets matching 50-mg tablets of delamanid
223455427|NCT02646319|OTHER|Laboratory Biomarker Analysis|Correlative studies
223455428|NCT02646319|DRUG|Nanoparticle Albumin-Bound Rapamycin|Given IV
223455429|NCT02646319|OTHER|Quality-of-Life Assessment|Ancillary studies
223455430|NCT02447471|DEVICE|Nexfin|Nexfin cuff placed on finger to measure blood pressure
223455431|NCT05261243|DIAGNOSTIC_TEST|EEG / questionnaires / working memory task|EEG resting state measurements and analysis of frequency bands (gamma, beta, alpha, theta), peak frequencies and connectivity measures / questionnaires for depression, anxiety, social activities, cognition, pain, sleep, fatigue / digitalized block-tapping task
223455432|NCT01358786|PROCEDURE|quilting suture|"* quilting sutures and drains~* quilting sutures but no drains"
223455433|NCT05573256|BEHAVIORAL|Lavender oil inhalation|Lavender oil inhalation;During the trial, the participants will be asked to practice lavender oil inhalation as follows: Every night before going to bed (21:00-24:00), the participants will drop two drops of 2% lavender essential oil on a 2x2 cm cotton gauze pad in a bowl, place it at a distance of 15-20 cm from their pillows, and breath normally for 20 minutes. The participants will be instructed to repeat this process by dripping lavender oil onto a new gauze pad every night for four weeks.
223455434|NCT05573256|BEHAVIORAL|Sleep hygiene education|Sleep hygiene education;The participants assigned to Groups 1 and 2 will receive sleep hygiene education using the sleep hygiene education brochure, which has been prepared by the researchers based on the literature concerning the improvement of general sleep quality in individuals with a stoma.
223572286|NCT01789983|OTHER|Collect Blood, GA and Other Survey Tools|"* Geriatric Assessment (GA) (Version 5)~* Functional Assessment of Cancer Therapy-General (FACT)~* Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~* Outcome Expectations for Exercise (OEE) scale29~* Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~* Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~* Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
224301791|NCT05385159|DRUG|Placebo|Adipose tissue removal, ADSVF production, cryopreservation of ADSVF and injection of placebo will be done on the same day during a short hospital stay.
224071326|NCT00619073|DRUG|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
223455435|NCT05762809|DIAGNOSTIC_TEST|Tampa Scale of Kinesiophobia (TSK-17)|The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.
223572287|NCT01921374|BIOLOGICAL|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
224071327|NCT00619073|DRUG|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
224071328|NCT05171257|DRUG|IV antibiotic treatment from prior|patients receiving same IV antibiotic treatment from prior
224071329|NCT05171257|DRUG|differing IV antibiotic treatment|patients receiving differing IV antibiotics from prior
224071330|NCT04543643|DRUG|Carvedilol|As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.
224071331|NCT04543643|DRUG|Berberine|Berberine can regulate the intestinal flora, which is safe and effective in clinical application.
224071332|NCT01967537|DRUG|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
224071333|NCT01967537|PROCEDURE|Radio-guided surgery|Using 68Gallium DOTATATE
224071334|NCT04985903|BEHAVIORAL|Clinician Communication Intervention|The focus of the communication program is to help clinicians increase their use of the 5 A's by improving knowledge, self-efficacy, outcome expectations, and communication skills. Training modules include didactic information with video clips of sample conversations showing specific communication skills, feedback on clinician's usage of the 5A's, and audio clips from their Pre-Intervention recorded conversations.
224071335|NCT04985903|OTHER|5A's lecture|a lecture on general information about smoking cessation for pregnant patients and smoking cessation counseling.
224071336|NCT02827864|BEHAVIORAL|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
224071337|NCT02827864|BEHAVIORAL|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
224071338|NCT02827864|BEHAVIORAL|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
224071339|NCT06411626|OTHER|PNH-relevant therapies|This is an observational study. There is no treatment allocation. The decision to initiate PNH-relevant therapies (such as eculizumab, ravulizumab, pegcetacoplan, iptacopan, and others) will be based solely on clinical judgement.
224071340|NCT04324372|DRUG|HEC68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
224071341|NCT02517164|OTHER|Measurement of serum 25-hydroxyvitamin D|
224071342|NCT02517164|OTHER|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
224071343|NCT03263507|DRUG|Placebo|Saline .9%
224071344|NCT03263507|DRUG|Donidalorsen|Donidalorsen administered subcutaneously
224071345|NCT04417894|DRUG|dupilumab|Solution for subcutaneous (SC) injection administration
224071346|NCT04417894|DRUG|Placebo|Solution for SC injection administration
224071347|NCT01783327|BEHAVIORAL|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
224071348|NCT01783327|BEHAVIORAL|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
224071349|NCT05093400|OTHER|no intervention|saliva collection
224149841|NCT04377269|OTHER|Taping and Bandaging|Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
224149842|NCT00276770|OTHER|fluorine F 18 fluorothymidine|
224149843|NCT00276770|PROCEDURE|positron emission tomography|
224149844|NCT02305875|OTHER|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
224149845|NCT05200052|DRUG|Colchicine 0.5 mg Oral Tablet|Colchicine loading dose 1 mg and maintenance dose 0.5 mg for 6 months in addition to standard anti ischemic treatment.
224149846|NCT00405652|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
224149847|NCT04014270|DEVICE|Self-modulated functional electrical stimulation (SM-FES)|"The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks."
224149848|NCT04014270|OTHER|Standard Care|"The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks."
224149849|NCT04376099|DIAGNOSTIC_TEST|Transcutaneous oxygen pressure measurement during the treadmill test|"Calculation of the decrease from rest of oxygen pressure (DROP) throughout the period of rest exercise and recovery.~The DROP is calculated as chanegs on each limb probe minus changes on a chest reference probe from rest.~Analysis of the recovery period of the recordings will be done to seach for recovery 50% and 90% from the minimal DROP observed Evaluation of calf and non calf pain during the tests. Evaluation of calf and non calf (buttock or thigh) ischemia during the tests. Ischemia being defined as a monimal DROP lower than minus 15 mmHg."
224149850|NCT01637870|DEVICE|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
224149851|NCT01887106|DRUG|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
224149852|NCT01887106|DRUG|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
224149853|NCT01887106|DRUG|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
224149854|NCT01887106|DRUG|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
224149855|NCT01176370|DEVICE|C-Pulse™ (Implantable Counterpulsation Therapy)|C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
224149856|NCT05808842|OTHER|CeraVe|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* CeraVe lotion (CeraVe; New York, NY) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
224149857|NCT05808842|OTHER|CeraVe and Calecim|"* CeraVe gentle facial cleanser (CeraVe; New York, NY) to be used morning and evening~* Calecim® Professional Serum (CellResearch Corporation; Singapore) to be used morning and evening~* Calecim® Restorative Hydration Cream (CellResearch Corporation; Singapore) to be used morning and evening, reapply as needed for dry skin~* A mineral CeraVe sunscreen (CeraVe; New York, NY) to be applied in the morning and reapplied every 2 hours if going outside"
224149858|NCT01090219|PROCEDURE|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
224149859|NCT00435994|DRUG|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
224149860|NCT00435994|OTHER|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
224149861|NCT03823599|BEHAVIORAL|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
224149862|NCT03823599|BEHAVIORAL|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
224149863|NCT02941289|PROCEDURE|visual search performance of everyday objects in realistic scenes|
224149864|NCT00772694|DRUG|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
224149865|NCT05757089|DIETARY_SUPPLEMENT|ALCOFILTRUM|ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
224149866|NCT04183894|BEHAVIORAL|Personalized Intervention|Participants will receive a personalized intervention based on their personalized network.
224149867|NCT02155348|PROCEDURE|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
224149868|NCT02155348|PROCEDURE|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
224149869|NCT02155348|DEVICE|Lentis LS-313|
224149870|NCT04794946|BIOLOGICAL|Covishield|2 IM doses (0.5 mL) of AZD1222(Covishield) at Day 0 and after 6-8 weeks of first dose (Day 42-56 days). This schedule will be followed for the first 100 participants, following which vaccination schedule as per the prevailing Government protocols shall be followed as a part of Adaptive Clinical Trial.
224149871|NCT04649762|BEHAVIORAL|activating consciousness technique (hypnosis)|activating consciousness technique (hypnosis)
224149872|NCT04078334|OTHER|MATCH|In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.
224149873|NCT04078334|OTHER|PATH|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can be completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions.
224149874|NCT04078334|OTHER|PATH 2.0|"In the first days of hospitalization, the physiotherapist determines the score linked to the patient's mobility profile using of a decisional tree. The PA program has 2 or 3 exercises to be done with or without supervision 3 times per week day during hospitalization. These daily exercises are prescribed by the doctor and taught by the physiotherapist.~In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decisional tree. When returning home after hospitalization, each PA program includes a daily walk as well as 3 or 4 exercises that can completed in a 12 to 20 minutes timeframe. These daily exercises are prescribed by the doctor and taught by the physiotherapist in 2 sessions."
224149875|NCT02790463|BEHAVIORAL|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
224149876|NCT00181935|DRUG|risperidone (Risperdal)|
224149877|NCT00181935|DRUG|olanzapine (Zyprexa)|
224149878|NCT03404635|DRUG|Apixaban|Apixaban as standard of care for VTE
224149879|NCT03404635|DRUG|Rivaroxaban|Rivaroxaban as standard of care for VTE
224149880|NCT00886717|DRUG|carboplatin|
224149881|NCT00886717|DRUG|paclitaxel-loaded polymeric micelle|
223455436|NCT05762809|DIAGNOSTIC_TEST|Knee injury and Osteoarthritis Outcome Score (KOOS)|The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.
223455437|NCT05762809|DIAGNOSTIC_TEST|Oxford Knee Score (OKS) scoring|OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.
223455438|NCT05762809|DIAGNOSTIC_TEST|Quadriceps and hamstring muscle isokinetic strength|Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.
223455439|NCT05762809|DIAGNOSTIC_TEST|Single-leg hop test|The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.
223455440|NCT05762809|DIAGNOSTIC_TEST|Y-balance test|The Y-balance test (YBT) (Move2Perform, United States) for anterior reach was used to measure dynamic balance. Participants performed three trials to familiarize themselves with the test, and then undertook three tests. The test started with the participant standing barefoot on the testing kit. The patients had to push a wooden box with the contralateral leg as far as possible with continuous movement and return to their starting position without losing balance. The longest distance achieved was used in the statistical analysis.
223455441|NCT05762809|DIAGNOSTIC_TEST|Anthropometric measurements|Body mass (kg) and height (cm) were measured, and the body mass index (BMI) was calculated as kg/m2.
223455442|NCT05153083|PROCEDURE|Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
223455443|NCT06382142|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223455444|NCT06382142|DRUG|Eribulin|Administration by intravenous bolus for a cycle of 3 weeks.
223455445|NCT06382142|DRUG|Vinorelbine|Administration by intravenous infusion for a cycle of 3 weeks.
223455446|NCT06382142|DRUG|Gemcitabine|Administration by intravenous infusion for a cycle of 3 weeks.
223455447|NCT06382142|DRUG|Capecitabine|Oral administration for a cycle of 3 weeks.
223455448|NCT04912479|DEVICE|connected watch|connected watch that provide to patients with information on their sleep quality and their performed activities
223455449|NCT04513145|DRUG|Ropivacaine injection|Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.
223455450|NCT04513145|DRUG|Saline Injection|Saline will be used as a placebo injection
224149882|NCT03288324|DRUG|Tofacitinib|Tofacitinib 5 mg twice daily
224149883|NCT01125618|OTHER|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
223455451|NCT04513145|PROCEDURE|Total Knee Arthroplasty|All subjects participating in this study will undergo primary total knee arthroplasty
223455452|NCT06778525|OTHER|Exercise|Personalized neuromuscular exercises, according to the patient's specific needs.
223455453|NCT06778525|OTHER|SmartPose|Virtual reality application containing rehabilitative games developed for individuals in need of exercise.
224064638|NCT03992976|OTHER|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
224064639|NCT06027359|OTHER|Therapeutic play hospital fear and nursing interventions|"Children assigned to the study group will be divided into 5 groups, with a maximum of 8 children. The researcher will perform a therapeutic play activity with each group consisting of maximum 8 children one day of the week in the room and time determined by the school. Each activity will last an average of 30 minutes. Therapeutic play activities will be completed in 4 weeks.~* Therapeutic play activities will not be performed with the children in the control group.~* One week after the completion of the therapeutic play intervention, the researcher will re-fill the Child Nursing Interventions and Fear of Materials Scale-uncommon materials sub-dimension face-to-face with the children in the study and control groups."
224064640|NCT05200078|DEVICE|Deep inspiration breath-hold technique|Selective application of deep inspiration breath-hold technique
224064641|NCT03798964|OTHER|Placental analysis|Analysis of placenta to determine expression of heparanase
224064642|NCT03676621|DRUG|Misoprostol|buccal tablets
224064643|NCT03676621|DRUG|Oxytocin|intravenous drip
224064644|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
224064645|NCT01032915|BIOLOGICAL|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
224064646|NCT01032915|BIOLOGICAL|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
224064647|NCT01032915|DRUG|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
224064648|NCT03363321|BIOLOGICAL|PF-06741086|PF-06741086 subcutaneous injection
224064649|NCT06424782|OTHER|medicinal water|Medicinal water treatment in bath tub once daily.
224064650|NCT01577186|DRUG|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
224064651|NCT05074251|DIAGNOSTIC_TEST|HIV self test|For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use \& importance of partner testing, to take home to their partner(s).
224064652|NCT05074251|BEHAVIORAL|Counseling and referral for partner testing|Counseling and refer participant's partner for facility based HIV testing
224064653|NCT01897285|DEVICE|AQUACEL® foam adhesive dressing|
224064654|NCT02783703|DIETARY_SUPPLEMENT|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
224064655|NCT00883207|BEHAVIORAL|Psychotherapy|Narrative and dialogical approach for couples
224064656|NCT05886790|BIOLOGICAL|Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation|Containing two adenovirus type 5-based vaccines delivering the spike proteins of SARS-CoV-2 wild type and Omicron BA.4/5 mutant, respectively
224064657|NCT05886790|BIOLOGICAL|Bivalent COVID-19 mRNA Vaccine|Containing two mRNA-based vaccines delivering the spike proteins of SARS-CoV-2 Beta and Omicron BA.4/5 mutant, respectively
224064658|NCT05886790|BIOLOGICAL|Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation|Containing adenovirus type 5-based vaccine delivering the spike proteins of SARS-CoV-2 wild type
224064659|NCT03882814|DRUG|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
224149884|NCT01125618|OTHER|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
224149885|NCT00525408|BIOLOGICAL|Mycobacterium w.|Immunomodulator
224149886|NCT00525408|DRUG|Docetaxel|Chemotherapeutic agent
224064660|NCT03882814|DRUG|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
224064661|NCT02915523|DRUG|entinostat|An orally available histone deacetylases inhibitor (HDACi).
224064662|NCT02915523|DRUG|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
224064663|NCT02915523|DRUG|Placebo|A pill containing no active drug ingredient.
224064664|NCT04658901|DEVICE|ERA-C70,ERA-C30 and ERA-G5|use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
224064665|NCT04658901|DEVICE|ClosureFast™ and ClosureRFG™|use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
224064666|NCT00005648|DRUG|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
224064667|NCT00005648|DRUG|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
224064668|NCT05623579|BEHAVIORAL|Pain Neuroscience Education|8 Sessions of different pain education interventions
224301792|NCT04183075|DIETARY_SUPPLEMENT|FontActiv Superprotein/Hypercaloric Fiber|The product under study has a liquid presentation, in 200 ml bottles, ready to take
224064669|NCT05623579|BEHAVIORAL|Exercise|12 Sessions of Aerobic Exercise
224064670|NCT03141736|OTHER|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
224064671|NCT03141736|OTHER|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
224064672|NCT03141736|OTHER|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
224064673|NCT03141736|OTHER|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost \[3 cents per bag\]
224064674|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
224064675|NCT00977951|DRUG|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
224064676|NCT00977951|DRUG|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
224064677|NCT00977951|DRUG|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
224064678|NCT00915681|DRUG|Silibinin|20 mg/kg continuous IV is over 24 hours
224064679|NCT05910866|DEVICE|Left bundle branch area pacing (LBBAP)|Pacing of the conduction system of the heart to obtain physiological activation
224064680|NCT05910866|DEVICE|Right ventricular pacing (RVP)|Conventional ventricular pacing
224064681|NCT00811135|DRUG|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
224064682|NCT00811135|DRUG|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
224064683|NCT00811135|DRUG|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
224064684|NCT03147781|DEVICE|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
224064685|NCT03147781|DEVICE|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
224064686|NCT02817321|PROCEDURE|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
224064687|NCT02817321|DEVICE|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
224064688|NCT02817321|DEVICE|PAJUNK Contiplex S Catheter|
224064689|NCT02817321|DRUG|single dose ropivacaine|"* 2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~* given immediately after the correct position of the tip of the needle has been confirmed"
224064690|NCT02817321|DRUG|continuously infusion of ropivacaine|"* 0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~* given through the catheter inserted in the T8 paravertebral space following the single dose"
224064691|NCT02817321|DRUG|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
224064692|NCT04158622|PROCEDURE|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
224064693|NCT04158622|PROCEDURE|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
224149887|NCT02990455|DRUG|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
224149888|NCT04370912|DIAGNOSTIC_TEST|Bed side Ultrasound|Handgrip strength will be measured using a digital grip strength dynamometer (Sammons Preston, Nottinghamshire, UK). This measurement is carried out three times using the subject's dominant hand, and then averaged
224149889|NCT04665414|DIAGNOSTIC_TEST|MRI|preoperative MRI
224149890|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound|preoperative transvaginal ultrasound
224149891|NCT04665414|DIAGNOSTIC_TEST|transvaginal ultrasound elastography|preoperative transvaginal ultrasound elastography
224064694|NCT03220542|DRUG|Probiotics|Saccharomyces boulardii
224064695|NCT03220542|DIETARY_SUPPLEMENT|Broccoli|Broccoli sprouts extract
224064696|NCT03220542|DRUG|Esomeprazole|Esomeprazole
224064697|NCT03220542|DRUG|Amoxicillin|Amoxicillin
224064698|NCT03220542|DRUG|Clarithromycin|Clarithromycin
224064699|NCT01685463|DEVICE|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
224064700|NCT01685463|DEVICE|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
224064701|NCT01226550|PROCEDURE|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
224064702|NCT04931784|DRUG|Nitrate|Administration of intra-coronary nitrate before percutaneous coronary intervention
224064703|NCT00746980|DRUG|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
224149892|NCT03846219|DRUG|IMU-838 (30 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 15 mg tablet IMU-838 daily) and then start taking the full assigned dose from Day 7 onwards (two 15 mg tablets IMU-838 once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 30 mg/day dose will take the full assigned dose which consists of two 15 mg tablets IMU-838 once daily."
224149893|NCT03846219|DRUG|IMU-838 (45 mg/day)|"* Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 22.5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 22.5 mg tablets once daily).~* Optional extended treatment period (optional): Participants who were re-randomized to a 45 mg/day dose will take the full assigned dose of two 22.5 mg tablets IMU-838 once daily."
224149894|NCT03846219|DRUG|Placebo|"* Main treatment period (Cohort 1 and Cohort 2): All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~* Optional extended treatment period: Placebo not applicable as participants were re-randomized to a 30 mg/day dose or a 45 mg/day dose."
224149895|NCT03846219|DRUG|IMU-838 (10 mg/day)|"* Main treatment period for Cohort 2: All patients will receive half the assigned dose during the first 7 days of the main treatment period (one 5 mg tablet per day) and then start taking the full assigned dose from Day 7 onwards (two 5 mg tablets once daily).~* Optional extended treatment period (not applicable to Cohort 2): IMU-838 10 mg/day not applicable."
224149896|NCT04413721|PROCEDURE|RBC transfustion|When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
224149897|NCT06190743|OTHER|Prevention events organized by participating centers|Cardiovascular disease primary prevention events organized by centers participating in the study where capillary sampling will be performed on subjects to quantify plasma levels of cardiovascular risk factors and validated questionnaires will be administered
224149898|NCT02366390|BEHAVIORAL|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
224149899|NCT05109702|DRUG|0.25% Tanfanercept Ophthalmic Solution|Tanfanercept ophthalmic solution.
224149900|NCT05109702|DRUG|Placebo|Placebo vehicle solution.
224149901|NCT01396902|BEHAVIORAL|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
224149902|NCT01396902|BEHAVIORAL|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
224149903|NCT03812588|DRUG|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
224149904|NCT03812588|DRUG|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
224149905|NCT06049615|DEVICE|CLAAS® System|The CLAAS® System delivers a plug to the ostia of the Left Atrial Appendage (LAA) and is designed to occlude the appendage to eliminate blood flow. It is designed to conform to the geometry of the LAA. The implant is designed to permanently seal off the LAA from the LA with an endothelial layer that forms across the LA face of the implant. The implant is available in two different sizes; Regular (27mm) and Large (35mm) to accommodate patient anatomy. Angiography and/or echocardiography may be used to determine the LAA ostium diameter to properly select the Implant size. The implant has an inner, cylindrical, Nitinol endoskeleton that provides the mechanical base structure. The Nitinol endoskeleton contains 10 face struts and 20 anchors (Regular) and 12 struts and 24 anchors (Large) facing proximally to engage the tissue to resist movement. The endoskeleton also provides the conformable structure to enable the foam cylinder to compress against the LAA tissue to facilitate sealing.
224149906|NCT00475800|DRUG|Lumiracoxib|
224149907|NCT05099237|DEVICE|OURA Ring|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
224149908|NCT05099237|DEVICE|WithingsScan Watch|All participants will be asked to wear an OURA ring and WithingsScan Watch both at home and whilst in hospital. These devices can record activity, sleep type and duration, resting heart rate and heart rate variability along with a range of other vital signs.
224301793|NCT04183075|DIETARY_SUPPLEMENT|Carbohydrates and C Vitamin|The control product will be prepared with equal presentation and taste as similar as possible tan study product
224301794|NCT01194518|BEHAVIORAL|Lifestyle Intervention Program|
223455454|NCT06347900|DIAGNOSTIC_TEST|Pentacam (corneal topographic changes detection), Polysymnography|Pentacam for recording corneal parameters in different stages of OSA patients. Polysymnography for for detction of hyponea, oxygen saturation and desaturation and staging of OSA in different patients.
223455455|NCT04252547|OTHER|Kangaroo Care|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before the first feeding hour when they are included in the study and then they will be held on their mothers' chest for skin-to-skin kangaroo care for half an hour. Their heart rate and oxygen saturation will be recorded for half an hour. At the end of the kangaroo care, the infant will be breastfed by his/her mother. A chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. The infant's heart rate and oxygen saturation will also continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weight is measured without a diaper change and his/her weight will be recorded. Then he/she will be taken back in the incubator to sleep.
223572288|NCT01921374|BIOLOGICAL|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
223572289|NCT01921374|BIOLOGICAL|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
223455456|NCT04252547|OTHER|Control|The preprocedural measurements (weight, heart rate, and oxygen saturation) will be recorded before feeding when they are included in the study and then they will be breastfed by their mothers. The chronometer will be started at that moment he/she begins sucking and terminated when he/she stops. Also, the infant's heart rate and oxygen saturation will continue to be recorded during the breastfeeding process. When the breastfeeding process is over, the infant will be allowed to rest in his/her mother's arms for two minutes and his/her physiological parameters will be recorded. Following the breastfeeding process, the infant will be weighed without a diaper change and his/her weight will be recorded. When the care process is over, it will be taken back in the incubator to sleep.
223455457|NCT05130216|OTHER|Genicular Nerve Radiofrequency Ablation|Radiofrequency Ablation (RFA)
223455458|NCT04865419|DRUG|AZD0466|AZD0466 powder for concentrate for solution for infusion will be administered by IV infusion.
223455459|NCT04865419|DRUG|Voriconazole|Voriconazole film-coated tablet will be administered orally.
223572290|NCT01921374|BIOLOGICAL|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
223572291|NCT01921374|BIOLOGICAL|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
223572292|NCT02061397|DRUG|Simvastatin|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
223572293|NCT02061397|DRUG|Sirolimus Oral Product|Eligible patients on sirolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
223572294|NCT02061397|DRUG|Everolimus Oral Product|Eligible patients on everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
223572295|NCT03342573|DRUG|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
223572296|NCT05308498|DIAGNOSTIC_TEST|ESView software with proscan|Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
224064704|NCT02381639|BEHAVIORAL|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
224064705|NCT01119300|OTHER|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
224064706|NCT01119300|OTHER|Standard care|Standard care
224064707|NCT04522089|BIOLOGICAL|AdimrSC-2f|AdimrSC-2f is a candidate vaccine against COVID-19 developed by Adimmune Corporation (Adimmune). Using the baculovirus-insect cells expression system, the recombinant receptor binding domain (RBD) of SARS-CoV-2 spike (S) protein is amplified and purified. AdimrSC-2f is formulated in the different dosages of Spike (S) protein without/with aluminum content as adjuvant.
224064708|NCT01643629|BIOLOGICAL|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
224064709|NCT01643629|OTHER|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
224064710|NCT01179009|DRUG|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
224064711|NCT01179009|DRUG|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
224064712|NCT01179009|DRUG|placebo|IV saline (i.e. placebo ketamine)
224064713|NCT02243215|OTHER|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
224064714|NCT04788121|DRUG|Tranexamic acid|The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
224064715|NCT04788121|OTHER|Standard of care|For management, initial priority will be given to secure airway, breathing and circulation. To ensure hemodynamic stability, crystalloids infusion will be given as and when required. Blood transfusion will be initiated at the threshold hemoglobin (Hb) of 7g/dl, to maintain the target Hb of 7-9g/dl or with signs of hemodynamic instability despite fluid resuscitation. Intra venous (IV) PPI and antibiotic will be started promptly in all cases and IV splanchnic vasoconstrictor will be given in all suspicious case of Variceal hemorrhage before definitive therapeutic and diagnostic endoscopic procedure is done.
224064716|NCT02337374|DEVICE|Midurethral sling mesh|
224064717|NCT01297335|DRUG|clonidine|Intrathecal Clonidine
224064718|NCT05780307|DRUG|IMM2520|IMM2520 will be administered once a week intravenously at Day 1, Day8, Day 15 and Day 22 each cycle for up to 48 weeks.
224064719|NCT06373809|BIOLOGICAL|Transplantation of Placenta Derived Stem Cells|Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients
224064720|NCT04793295|DRUG|MT-7117|MT-7117
224064721|NCT02573363|DRUG|Cytarabine|Given per standard of care
223455460|NCT05192395|DRUG|DWJ1525|DWJ1525
223455461|NCT05192395|DRUG|DWP16001|DWP16001
224064722|NCT02573363|DRUG|Mitoxantrone Hydrochloride|Given per standard of care
224064723|NCT02573363|DRUG|Selinexor|Given PO
224064724|NCT03119792|OTHER|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
224301795|NCT01584206|DRUG|Ezetimibe|10mg ezetimibe/day, at least 4 months
224301796|NCT00145275|DRUG|zoledronic acid|
224149909|NCT05099237|DRUG|Isansys Patient Status Engine|Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
224149910|NCT05099237|OTHER|Quality of Life Surveys|On a weekly basis participants will be asked to complete satisfaction surveys for the devices they are wearing (ring and watch) and report on their quality of life through standardised questionnaires. These surveys will be delivered electronically to participants via their smartphone or tablet device. There will be an option for participants to report adhoc symptoms via an app on their smartphone or tablet device.
224149911|NCT05099237|DIAGNOSTIC_TEST|Blood Samples|"COHORT 3 ONLY~Participants in Cohort 3 only will be asked to provide a series of blood samples to measure inflammatory molecules during the study. These will be requested at various intervals during face-to-face visits and whilst the patient is in hospital:~* Baseline blood sample during study enrolment~* Post-lymphodepletion and prior to CAR T-cell infusion (this may be on day -1 or day 0 as needed)~* Post CAR T-cell infusion:~  * Day 1~ * Day 3~ * Day 6~ * Day 9~ * Day 14 (if the participant remains in hospital)~A sample of blood will be taken at baseline and a further sample post lymphodepletion and prior to CAR T-cell infusion. Post CAR T-cell infusion, samples will be taken at two timepoints (morning and afternoon) on each of the sampling days."
224149912|NCT05099237|OTHER|Daily Weights|"COHORT 3 ONLY~During their inpatient stay, up to a maximum of 28 days, participants in Cohort 3 will be supported to weigh themselves daily using a Withings Body Scale."
224149913|NCT00180271|DEVICE|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
224149914|NCT00180271|DEVICE|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
224149915|NCT02679807|BIOLOGICAL|Bifidobacterium animalis subsp. lactis Bl-04|
224149916|NCT02679807|OTHER|sucrose|
224149917|NCT02747771|BEHAVIORAL|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
224149918|NCT01725256|DRUG|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
224149919|NCT05121909|OTHER|Colgate (R) Cavity Protection Toothpaste|Participants will use Colgate (R) Cavity Protection Toothpaste for brushing teeth twice daily.
224149920|NCT05121909|DEVICE|Colgate (R) Cello Toothbrush|Participants will use Colgate (R) Cello Toothbrush for brushing teeth twice daily.
224149921|NCT05121909|OTHER|Prototype 1 Mouthwash|Participants will use 20 mL of Prototype 1 Mouthwash for 30 seconds after brushing twice daily.
224149922|NCT05121909|OTHER|Prototype 2 Mouthwash|Participants will use 20 mL of Prototype 2 Mouthwash for 30 seconds after brushing twice daily.
224301797|NCT03886987|DEVICE|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
224301798|NCT04351048|PROCEDURE|Stepwise Excavation|"* stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall."
224301799|NCT04351048|PROCEDURE|One Step Excavation|\*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
224301800|NCT01476592|DIETARY_SUPPLEMENT|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
224301801|NCT02743234|OTHER|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
224301802|NCT02743234|DRUG|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
224301803|NCT02743234|DRUG|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
224301804|NCT00185666|PROCEDURE|Stereotactic radiosurgery|
224301805|NCT04296058|OTHER|microvessel density|the vessel numbers in high power field with Anti-CD31 staining in tumor specimen
224301806|NCT05806619|OTHER|histopathological analysis; morphological and non-morphological magnetic resonance|The surgical material removed during surgery was subjected to histological analysis. Morphological and non-morphological magnetic resonance examination before the neurosurgical surgery, according to clinical practice.
223455462|NCT05192395|DRUG|DWC202101|DWC202101
223455463|NCT00261898|PROCEDURE|Increase sleep|
223455464|NCT04792060|PROCEDURE|Hook plate|We used titanium 2.4 mm hooked distal ulnar locked plate used for fixation of distal ulna fractures , this plate have low profile which is anatomically precontoured
223455465|NCT02895191|DRUG|ulinastatin|Patients will receive the study drugs for 7 to 14 days
223455466|NCT02895191|DRUG|placebo|Patients will receive the placebo for 7 to 14 days
223455467|NCT02255071|DEVICE|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
223455468|NCT02255071|DEVICE|Sham wristband|A wristband over wrist but no acupressure for seven days.
223455469|NCT05163938|DEVICE|REThink Therapeutic Game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
223455470|NCT05163938|DEVICE|Treatment as Usual|Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
223455471|NCT00547157|DRUG|Panitumumab|Arm 2 consists of panitmumab plus RT
223572297|NCT05308498|DIAGNOSTIC_TEST|Rapid software with SBI|Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
223572298|NCT02145104|DRUG|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
223572299|NCT04341545|OTHER|Placebos|Placebo 4 tablets a day for one week.
223455472|NCT00547157|DRUG|Cisplatin|Cisplatin
223572300|NCT04341545|DRUG|Letrozole tablets|Letrozole 10mg daily for one week.
224064725|NCT03119792|OTHER|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
224064726|NCT00091806|DRUG|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
224064727|NCT00091806|DRUG|Panitumumab|9 mg/kg once every 3 weeks
224064728|NCT03729063|OTHER|Twice-daily expired carbon monoxide (CO) measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
224064729|NCT03729063|OTHER|Minimal control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
224064730|NCT01724658|DRUG|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
224064731|NCT01724658|DRUG|placebo|placebo orally twice a week with progynova 1 mg oral daily
224064732|NCT04377711|DRUG|Ciclesonide|160mcg Inhaler
224064733|NCT04377711|DRUG|Placebo|Matching Placebo Inhaler
224064734|NCT01748539|DRUG|KHK4827|
224064735|NCT01748539|DRUG|Placebo|
224064736|NCT02702765|PROCEDURE|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
224064737|NCT02702765|PROCEDURE|Ultrasound|Ultrasound is a non-invasive procedure
224064738|NCT02702765|DRUG|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
224064739|NCT02702765|PROCEDURE|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
224064740|NCT02702765|PROCEDURE|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
224064741|NCT02231554|OTHER|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
224064742|NCT02231554|OTHER|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
224064743|NCT00002278|DRUG|Diclazuril|
224064744|NCT05246137|BIOLOGICAL|COVID-19 Vaccine 40 ug/dose|Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V
224064745|NCT03937583|DRUG|Fludeoxyglucose 18F|"The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously."
224064746|NCT00401375|DRUG|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
224064747|NCT00401375|DRUG|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
224064748|NCT03461328|DRUG|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
224064749|NCT00950768|PROCEDURE|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
224064750|NCT05417724|OTHER|Battlefield Acupuncture|Battlefield Acupuncture
224064751|NCT04116385|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224064752|NCT03152019|DRUG|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
224064753|NCT03152019|DRUG|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
224064754|NCT00350142|RADIATION|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
224064755|NCT00350142|DRUG|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
224064756|NCT00350142|OTHER|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
223455473|NCT02482883|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
224149923|NCT05121909|OTHER|Prototype 3 Mouthwash|Participants will use 20 mL of Prototype 3 Mouthwash for 30 seconds after brushing twice daily.
224149924|NCT05121909|OTHER|Listerine (R) Cool Mint (R) Antiseptic Mouthwash|Participants will use 20 mL of Listerine (R) Cool Mint (R) Antiseptic Mouthwash for 30 seconds after brushing twice daily.
224149925|NCT05121909|OTHER|5% Hydroalcohol Mouthwash|Participants will use 20 mL of 5% Hydroalcohol Mouthwash for 30 seconds after brushing twice daily.
224149926|NCT04001309|OTHER|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
224149927|NCT02322411|DEVICE|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
224149928|NCT02322411|BEHAVIORAL|Compensatory approaches|
224149929|NCT01025011|DEVICE|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
224149930|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149931|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149932|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
224149933|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149934|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149935|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
224149936|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149937|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149938|NCT01392378|DRUG|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
224149939|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149940|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149941|NCT01392378|DRUG|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
224149942|NCT01392378|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149943|NCT01392378|BIOLOGICAL|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
224149944|NCT04172337|BEHAVIORAL|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
224149945|NCT04172337|BEHAVIORAL|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
224149946|NCT02610205|OTHER|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
224149947|NCT04029324|PROCEDURE|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
224149948|NCT04029324|PROCEDURE|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
224149949|NCT04029324|PROCEDURE|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
224149950|NCT04029324|PROCEDURE|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
224149951|NCT04564066|BIOLOGICAL|efgartigimod IV|intravenous infusions of efgartigimod
224149952|NCT04564066|BIOLOGICAL|efgartigimod PH20 SC|subcutaneous injections of efgartigimod PH20 SC
224301807|NCT05298319|DEVICE|high flow nasal cannula|The patients were randomized into 6 groups, each group received different flow of oxygen, to observe the incidence of hypoxemia between different groups.
224301808|NCT02903719|DRUG|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
224149953|NCT00431821|BEHAVIORAL|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
224149954|NCT00431821|OTHER|Stroke education|Stroke education program with matched attention phone calls
224149955|NCT01338935|DRUG|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage \*.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage\*.~\*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
224149956|NCT01338935|DRUG|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
224149957|NCT01338935|DRUG|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
224149958|NCT03788863|DRUG|Diflucortolone valerate (BAY866146)|Follow clinical administration
224149959|NCT02461394|DEVICE|Blood glucose monitoring systems for self-testing|
224149960|NCT02713789|DRUG|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
224149961|NCT02713789|DRUG|Placebo (PBS-20% sucrose)|
224149962|NCT03674333|DIETARY_SUPPLEMENT|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
224149963|NCT03674333|OTHER|Placebo|Placebo - a sugar pill
224149964|NCT00061503|DRUG|Travoprost|
224149965|NCT00387270|DRUG|Dimebon|Dimebon 10 or 20 mg TID x 7 days
224149966|NCT00610285|OTHER|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
224149967|NCT00615797|BIOLOGICAL|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
224149968|NCT00615797|DRUG|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
224149969|NCT00014911|PROCEDURE|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
224149970|NCT00014911|DRUG|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
224149971|NCT00014911|DRUG|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
224149972|NCT00014911|DRUG|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
224149973|NCT00014911|DRUG|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
224149974|NCT00014911|DRUG|Ganciclovir|An antiviral used to kill viruses and stop viral replication
224149975|NCT00014911|DRUG|Trimethoprim|An antibacterial used to prevent opportunistic infections
224149976|NCT00014911|DRUG|Pentamidine|An antiprotozoal used to prevent disease
224149977|NCT04711499|BEHAVIORAL|Fatigue|The intervention will be assessing the participant in a fatigued state compared to a non fatigued state
224149978|NCT01924299|DRUG|Baricitinib|Administered orally
224149979|NCT01924299|DRUG|Ketoconazole|Administered orally
224149980|NCT01924299|DRUG|Fluconazole|Administered orally
224149981|NCT00871091|PROCEDURE|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
224149982|NCT00871091|PROCEDURE|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
224149983|NCT00871091|PROCEDURE|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
224149984|NCT05611515|PROCEDURE|TORS|"* Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~* Arm 2: Trans-oral Laser Microsurgery (TLM)~* Arm 3: Trans-oral Robotic Surgery (TORS)"
223572301|NCT02217371|OTHER|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
223572302|NCT02670798|PROCEDURE|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
223572303|NCT05597644|PROCEDURE|Trans-arterial uterine artery embolization|transarterial angioembolization of uterine artery
223572304|NCT00000344|DRUG|Buprenorphine/naloxone|
223572305|NCT01567592|DEVICE|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
223572306|NCT01635673|OTHER|Exercise intervention|Whole body vibration exercise 3 times per week
223572307|NCT05536089|DIAGNOSTIC_TEST|a multi-locus blood-based assay|Colorectal tumor-specific plasma ctDNA methylation markers detection
223572308|NCT02737553|PROCEDURE|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
223572309|NCT02737553|PROCEDURE|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
223572310|NCT03937648|DRUG|COL-144 50mg|COL-144 50mg
223572311|NCT03937648|DRUG|COL-144 100mg|COL-144 100mg
223572312|NCT03937648|DRUG|COL-144 200mg|COL-144 200mg
223572313|NCT03937648|DRUG|COL-144 400mg|COL-144 400mg
223572314|NCT03937648|DRUG|Placebo|Placebo
223572315|NCT04600505|DRUG|Treatment A|Participants will receive 2 inhalations of BGF MDI with propellant 1.
223572316|NCT04600505|DRUG|Treatment B|Participants will receive 2 inhalations of BGF MDI with propellant 2.
223572317|NCT04600505|DRUG|Treatment C|Participants will receive 2 inhalations of BGF MDI with HFA propellant.
223572318|NCT01683006|DRUG|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
223742938|NCT04243187|OTHER|Chilean Native Beans|"In each visit the participant would have to:~1. Fill a survey of gastrointestinal symptoms and basal bowel movements (THE GASTROINTESTINAL SYMPTOM RATING SCALE (GSRS))~2. Fill a survey of food consumption~3. Bean plate intake~4. Expired hydrogen test, which consists of exhaling air in a syringe every 20 minutes for 12 times (4 hours in total). During this time the participant can do quiet activities (not physical activity).~5. Fill surveys of gastrointestinal symptoms (online or on paper), during the hydrogen test, at 12 and 24 hours (3 times). During this time (1 day before and 2 days later) the participant cannot eat other bloating foods (legumes, cauliflower, broccoli, lettuce, cabbage, artichokes, onions, topinambur and others described in the food survey)."
223742939|NCT06271252|DRUG|OriCAR-017|Anti-GPRC5D CAR-T cell product
224149985|NCT03341611|BEHAVIORAL|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
224149986|NCT05877703|OTHER|close kinetic chain exercises|CKC include mini squats, leg press, step-up and step-down, wall slides etc along with their respective modality as quadriceps drill and static cycle ergometer respectively on grade-3 knee OA patients
224149987|NCT05877703|OTHER|open kinetic chain exercises|The distal segment of the body components can move freely during OKC exercise.OKC exercises include quadriceps setting, knee extension in sitting and straight leg raise in lying position; it also includes quadriceps drills as part of OKC exercises
224301809|NCT03895671|DRUG|Ponatinib|"Induction phase (first three cycles)~\- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~* Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~* Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day"
224301810|NCT03895671|DRUG|Azacitidine|"Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~\- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%\<MR4≤0.01%;"
224301811|NCT05492253|OTHER|Infant fruit|Infants will be fed prune puree
224301812|NCT05492253|OTHER|Infant vegetable|Infants will be fed carrot puree
224301813|NCT05492253|OTHER|Infant meat|Infants will be fed beef puree
224301814|NCT05492253|OTHER|Infant grain|Infants will be fed oatmeal cereal
223455474|NCT05285059|BEHAVIORAL|ASRT task|"The ASRT (Alternating Serial Reaction Time) task is a computerized behavioral task measuring implicit learning. This task consists of 20 series of trials lasting 2 minutes each.~In each trial, a stimulus is displayed on the screen in one of the four possible predefined locations. The participant must press a button to indicate the position of the stimulus on the screen. Response content and response time are recorded.~At the end of every trial, the participant can take a break and resume the task whenever ready. The task lasts about 45 to 50 minutes."
224301815|NCT03850951|DEVICE|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
223455475|NCT04293484|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223455476|NCT04293484|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223455477|NCT00015652|DRUG|Ribavirin|
223455478|NCT00015652|DRUG|Aldesleukin|
223455479|NCT00015652|DRUG|Peginterferon alfa-2b|
223455480|NCT01836146|DEVICE|EnligHTN™ Renal Artery Ablation Catheter|
224301816|NCT03850951|DEVICE|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
224149988|NCT06106243|PROCEDURE|The conventional heat pressing temporary flexible maxillary removable partial denture|An intraoral scan will be made for each patient's maxillary and mandibular jaws in addition to digital bite registration using (Medit i700; Medit corp.) the resultant data will be exported in the form of a Standard Tessellation Language (STL) file. The denture base and the teeth will be designed using computer-aided design software (Partial Cad, Dental CAD software). Each patient will receive two RDPs, fabricated with two different manufacturing techniques. Based on randomization, the patients will start by receiving either partial denture that is fabricated by conventional heat pressing technique of 3D printed castable resin (Cast V1resin) followed by partial denture that is fabricated by 3D printing of printable resin (Flexo denture base, resin) and teeth (permanent crown,resin) or the other way around. In 3D-printed RDP, the artificial teeth will be attached to the fabricated denture bases using printable denture base resin material
224149989|NCT06106243|PROCEDURE|3D-printed and digitally designed temporary flexible maxillary removable partial denture|3D-printed and digitally designed temporary flexible maxillary removable partial denture
224149990|NCT01095068|BEHAVIORAL|Physical exercise|
224149991|NCT02584777|BIOLOGICAL|Pacritinib|QD (Once a day)
224149992|NCT01061320|DRUG|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
224149993|NCT01061320|DRUG|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
224149994|NCT06151860|OTHER|Static stretching|Stretching exercises performed by maintaining the point of muscular discomfort without changing position for a certain period of time.
224149995|NCT06151860|OTHER|Pilates stretching|Stretching exercises performed dynamically, following the six basic principles of Pilates: concentration, control, center, precision, breathing and fluidity.
224149996|NCT01576120|OTHER|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
224149997|NCT01576120|OTHER|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
224149998|NCT05744323|OTHER|Functional training|Physical and motor function training for children,may use BOSU balls, medicine balls, balance mats, fitness steps, and other training equipment to improve gradually
224149999|NCT03108625|DRUG|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
224150000|NCT01003613|DRUG|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
224150001|NCT01003613|OTHER|Beriplast P|0.1 ml to attach graft
224150002|NCT00004999|DRUG|Lamivudine/Zidovudine|
224150003|NCT00004999|DRUG|Capravirine|
224150004|NCT00004999|DRUG|Nelfinavir mesylate|
224150005|NCT00002257|DRUG|Ganciclovir|
224150006|NCT01608607|OTHER|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
224150007|NCT03481569|OTHER|Blood and cerebrospinal fluid pharmacocinetic samples on one of the nine antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
224150008|NCT04101734|DEVICE|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
224150009|NCT04101734|DEVICE|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
224150010|NCT00618904|DIETARY_SUPPLEMENT|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
224150011|NCT00618904|DIETARY_SUPPLEMENT|Placebo|Placebo administered bid for 6 weeks.
224150012|NCT03825510|RADIATION|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
224150013|NCT01768234|OTHER|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
224150014|NCT05976477|OTHER|educational intervention|"1. four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~2. Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~3. Four recipes for tasty easy-to-prepare meals, avoiding added salt."
224301817|NCT04603235|BEHAVIORAL|Manual-based Art Therapy|This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
223455481|NCT03003169|OTHER|Medical questionnaire|"* quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~* Hospital Anxiety and Depression scale~* satisfaction care questionnaire (IN-PATSAT32)"
223572319|NCT01683006|DRUG|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
224150015|NCT03217201|DEVICE|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
224150016|NCT03217201|DEVICE|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
224150017|NCT02130154|OTHER|18-FDG PET CT scan and 123I-MIBG SPECT scan|
224150018|NCT07090980|OTHER|epilepsy education via podcast|Epilepsy education via podcast has never been provided in any clinical study in Turkey before. By providing education via podcast, we have made health education more accessible and repeatable.
224150019|NCT07090902|BEHAVIORAL|Progressive Relaxation-Based Childbirth Preparation Program|This intervention consists of a childbirth preparation program that integrates progressive muscle relaxation (PMR) exercises. Participants receive face-to-face education by trained health professionals, a printed booklet explaining both childbirth preparation and PMR techniques, and an audio CD with guided relaxation sessions produced by the Turkish Psychological Association. The participants are instructed to perform the relaxation exercises daily at home until delivery. The goal of this intervention is to reduce labour pain, support informed mode of delivery preference, and enhance breastfeeding comfort in the early postpartum period.
224150020|NCT04690257|OTHER|Trace Image and Coloring for Kids-Book (TICK-B)|A collection of pictures designed as a book contains and given to children during the procedure and they take a picture as they favored.
224150021|NCT02504697|OTHER|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
224150022|NCT03040817|PROCEDURE|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
224150023|NCT03040817|DRUG|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
224150024|NCT02354092|PROCEDURE|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
224150025|NCT02354092|PROCEDURE|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
224150026|NCT02354092|PROCEDURE|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
224150027|NCT02354092|PROCEDURE|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
224150028|NCT02354092|BEHAVIORAL|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
224150029|NCT02354092|DRUG|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
224150030|NCT01923571|OTHER|intraoperative BGC measure|
224150031|NCT05031572|OTHER|dietary intervention|Chronic caloric restriction diet vs intermittent fasting on energy sensing metabolites and metabolic homeostasis
224150032|NCT00355134|DRUG|Fingolimod|Fingolimod capsules for oral administration
224150033|NCT00355134|DRUG|Placebo|Matching placebo capsules for oral administration.
224301818|NCT04419792|OTHER|Assessment of physical performance variables|"Other:~Assessment of physical performance indices using the following outcome measures:~Cardiopulmonary fitness: YMCA submaximal bike test Upper Body: ACSM press up test, Dynamometry Lower body: Wall squat test, Countermovement jump test"
224301819|NCT00950963|BEHAVIORAL|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
223455482|NCT06038500|OTHER|Multicomponent intervention of resistance exercises, dancing sessions and nutritional education|The intervention consisted of two sets of ten repetitions of resistance exercises, the second month four sets of eight repetitions, and the third month four sets of fifteen repetitions. It was estimated that each session (dance + resistance exercise) generated a caloric expenditure of 270.85 calories corresponding to 4.5 and 3.5 METs per activity. The resistance exercises and the dance sessions began and with a warm-up and stretching session 10 min, followed by the resistance exercises 30 min and dancing practice 30 min. The session ended with a cooling down session 10 min. The nutritional education offered included weekly topics lasting 20 min, on basic concepts of nutrition and recommended diet for the maintenance of skeletal muscle mass. Reinforcement of the topics was carried out through triptychs that were provided throughout the 12 sessions.
223455483|NCT01491867|DRUG|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
223572320|NCT03305081|DEVICE|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
224150034|NCT05912348|BEHAVIORAL|Low Physical Activity and Added Carbohydrate Group|Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.
224150035|NCT05912348|BEHAVIORAL|Low physical Activity Control|Young men and women will transition into a low physically active lifestyle for 10 days.
224150036|NCT05912348|BEHAVIORAL|High Physical Activity and Added Carbohydrate Group|Young men and women will transition into a high physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group.
224150037|NCT05610241|DEVICE|Compression Therapy System Prototype|A device designed to deliver compression therapy at a pre-set level to the lower leg for legs with a circumference between 30-50 cm. The device provides compression through a series of three air bladders and is controlled by a battery-powered electronic module that controls compression levels by monitoring bladder pressure.
224150038|NCT05610241|DEVICE|Standard Compression|Coban 2 represents the standard of care 2-layer compression wrap used to treat venous leg ulcers. The device consists of a comfort layer and a compression layer. A clinician applies the device to establish compression therapy.
224150039|NCT00041704|DRUG|Anidulafungin, VER002|
224150040|NCT02123394|OTHER|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
224150041|NCT02123394|OTHER|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
223455484|NCT01383018|DEVICE|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
223455485|NCT03101384|OTHER|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
223455486|NCT05828368|PROCEDURE|Non surgical periodontal therapy|"Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed."
223455487|NCT02719002|DEVICE|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
223455488|NCT03021317|DRUG|ACTHar|The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
224064757|NCT00350142|RADIATION|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
224064758|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
224064759|NCT00755274|BIOLOGICAL|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
224064760|NCT03763071|OTHER|Patient-reported scales to measure sleep disorders|"Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters"
224064761|NCT04286204|OTHER|Basic Life Support training based on ICTs|This intervention is defined as a self-training course consisting of a 5-minute educational video in basic life support and a Kit with the elements to build the home dummy and the home DEA allowing integrally students to develop the steps as the video. The Kit will be delivered at the beginning of the study and every month the necessary materials will be complemented. The strategy will be carried out by the students every month and supervised by their teachers. Students will have constant access to an educational platform based on ICTs.
224064762|NCT04286204|OTHER|Classic Basic Life Support training|It is defined as a module carried out by trained personnel in basic resuscitation (pre-hospital care program staff of the UdeA medical school), which includes two subcomponents of the conventional BLS course that are basic resuscitation and DEA in adults. The duration of the subcomponents is a theoretical part of 30 minutes and a practical part in a low fidelity simulator with 1.5 hours duration.
224150042|NCT02717676|PROCEDURE|Episiotomy|episiotomy will be done after crowning of the fetal head
224150043|NCT03968081|BEHAVIORAL|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
224150044|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
224150045|NCT03665493|DRUG|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
223572321|NCT00270088|DRUG|epoetin alfa|
223572322|NCT00203112|DRUG|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
223572323|NCT00203112|DRUG|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
223572324|NCT06163183|DEVICE|Edi catheter|
223572325|NCT01774253|DRUG|Vismodegib|
224064763|NCT03757286|PROCEDURE|FSF with CAD\CAM customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction."
224064764|NCT03757286|PROCEDURE|FSF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed."
224064765|NCT06220331|DEVICE|Intra Ocular Lens|Intensity SL Intra Ocular Lens
224064766|NCT02721680|OTHER|Internal Awareness Training Program|
224064767|NCT02721680|OTHER|External Awareness Training Program|
224064768|NCT01743911|OTHER|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
224064769|NCT01743911|DRUG|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
224064770|NCT00610987|DRUG|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
224064771|NCT00610987|DRUG|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
224064772|NCT00385502|DRUG|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
224064773|NCT00424424|DRUG|MK0719|
224064774|NCT03060135|BEHAVIORAL|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
224064775|NCT03060135|BEHAVIORAL|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
224064776|NCT00254501|BEHAVIORAL|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
224064777|NCT00254501|BEHAVIORAL|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
224064778|NCT03022695|DEVICE|High Intensity Focused Ultrasound|
224150046|NCT03665493|BEHAVIORAL|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
223455489|NCT03163719|DIAGNOSTIC_TEST|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
223455490|NCT03517241|DIAGNOSTIC_TEST|functional magnetic resonance imaging (fMRI)|Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
223455491|NCT03517241|DIAGNOSTIC_TEST|Microperimetry (MP)|MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
223455492|NCT03517241|DIAGNOSTIC_TEST|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
223455493|NCT03517241|DIAGNOSTIC_TEST|Blue light fundus autofluorescence imaging (FAF)|Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.
223455494|NCT03517241|DIAGNOSTIC_TEST|Visual testing|Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
223455495|NCT04527042|DRUG|Rivaroxaban|It is determined by the clinician's routine clinical prescription.
223455496|NCT02279615|DRUG|Mirabegron|50mg of mirabegron per day will be given.
223455497|NCT02279615|DRUG|Tamsulosin|0.4mg of flomax per day.
223455498|NCT01765569|DRUG|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
223455499|NCT01765569|DRUG|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
224064779|NCT01509196|DRUG|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
223742940|NCT00151320|DRUG|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
224150047|NCT03665493|DRUG|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
224150048|NCT03665493|DRUG|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
224150049|NCT06380348|DRUG|JMT101 Injection|JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
224150050|NCT06380348|DRUG|Osimertinib tablet|Osimertinib 160mg once po everyday
224150051|NCT06380348|DRUG|Cisplatin injection|Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
224150052|NCT06380348|DRUG|Pemetrexed injection|Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
224150053|NCT00769236|OTHER|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
224150054|NCT00769236|OTHER|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
224150055|NCT00769236|OTHER|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
224150056|NCT01746810|RADIATION|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
224150057|NCT05586815|DRUG|Colistin|150 mg every 8 hours intravenously for at least 7 and up to a maximum of 28 days
224150058|NCT05586815|DRUG|Minocycline|200 mg every 12 hours orally for at least 7 and up to a maximum of 28 days
224150059|NCT05586815|DRUG|Placebo|Capsule without active compound
224150060|NCT04088565|OTHER|Paired-Associative Stimulation (PAS)|Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
224150061|NCT04088565|OTHER|Vagus Nerve Stimulation (VNS)|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
224150062|NCT04088565|OTHER|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
224150063|NCT03393689|DRUG|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
224150064|NCT03221712|BEHAVIORAL|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
224150065|NCT03648463|PROCEDURE|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
224150066|NCT02944669|DEVICE|ReWalk Personal Device|
224150067|NCT00653094|DEVICE|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
224150068|NCT05477446|BIOLOGICAL|CD207 CAR-T cells|Single dose of CD207 CAR-T cells administered IV
224150069|NCT00409916|DEVICE|BioZ Dx|
224150070|NCT01441518|OTHER|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
224150071|NCT01441518|OTHER|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
224150072|NCT04714944|DIETARY_SUPPLEMENT|Placebo|Supplementation period 12 weeks
224150073|NCT04714944|DIETARY_SUPPLEMENT|Whole fiber product|Supplementation period 12 weeks
224150074|NCT04569617|OTHER|Resistance Training - UL endurance protocol|UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
223742941|NCT01555268|BIOLOGICAL|trebananib|Given IV
224150075|NCT04569617|OTHER|Resistance Training - UL strength protocol|UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
224150076|NCT04569617|OTHER|Resistance Training - LL endurance protocol|LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).
224150077|NCT04569617|OTHER|Resistance Training - LL strength protocol|LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
223742942|NCT01555268|DRUG|cytarabine|Given SC
223742943|NCT01555268|OTHER|laboratory biomarker analysis|Correlative studies
223742944|NCT01555268|OTHER|pharmacological study|Correlative studies
223742945|NCT00540345|DRUG|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
224064780|NCT01317862|DEVICE|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
224064781|NCT06060964|OTHER|Breathe Easier Progressive Web Application|The Breathe Easier Progressive Web Application is an 8-week, mindfulness based cancer recovery training program consisting of breathing retraining exercises, mindfulness meditation, gentle yoga, and cancer-specific educational activities, guided by a combination of written instructions, video, and audio. The progressive web application can be downloaded onto any mobile device.
224064782|NCT00923130|DRUG|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
224064783|NCT00923130|DRUG|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
224064784|NCT01402609|DEVICE|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
224064785|NCT01402609|DEVICE|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
224064786|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
224064787|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
224064788|NCT00650702|DRUG|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
224064789|NCT03063710|DRUG|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
224064790|NCT03921021|DRUG|Telomelysin|OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
224064791|NCT04594967|OTHER|Patient-centred care home (PCMH)|New model of care defined by care provision by a team of people centered in the community that is both proactive and coordinated to improve the health and wellness of the people in that community.
224064792|NCT00823498|BEHAVIORAL|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
224064793|NCT00823498|BEHAVIORAL|Interview|Interview with a member of study staff at housing development site.
224064794|NCT00823498|OTHER|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
224064795|NCT04841707|DEVICE|uEXPLORER/mCT|Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
224064796|NCT01744600|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
224064797|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators"
224064798|NCT06080451|OTHER|Integrated Diabetes and Hypertension Primary Care Model - Providers|"The intervention consists of five components that align with the World Health Organization Technical Package for Cardiovascular Disease Management in primary Health Care.~1. Training health workers on diabetes and hypertension treatment protocols~2. Team-based care and task sharing~3. Strengthening access to medications and diagnostics~4. Electronic medical record system and registry~5. Systems monitoring and feedback of key indicators~Health care providers will administer this intervention to patient participants and will report on their experience."
224064799|NCT06573112|DIAGNOSTIC_TEST|ultrasound assessment for catheter-related thrombosis.|Patients with newly inserted central venous catheter will be assessed with vascular ultrasound for the presence of catheter-related thrombosis
224064800|NCT02775396|DEVICE|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
224064801|NCT03641963|DEVICE|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
224064802|NCT05428891|PROCEDURE|Abrams' needle pleural biopsy (IG-ANPB) versus medical thoracoscopy in the diagnosis of pleural diseases.|We compare the diagnostic efficacy and safety of imaging-guided Abrams needle biopsy with medical thoracoscopy.
224064803|NCT02967874|PROCEDURE|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
224064804|NCT02967874|DRUG|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
224064805|NCT02258828|DRUG|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
224064806|NCT02258828|DRUG|Placebo|Matched placebo
224064807|NCT00872807|BEHAVIORAL|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
224064808|NCT00872807|BEHAVIORAL|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
223572326|NCT00571636|DRUG|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
224150078|NCT00083304|DRUG|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
224150079|NCT00083304|RADIATION|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
223572327|NCT00571636|DRUG|5% glucose solution|ev continuous infusion
223572328|NCT00554619|DRUG|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
223572329|NCT05415592|DEVICE|DePuy Synthes Radial Head Replacement System|DePuy Synthes Radial Head Replacement System will be used for radial head replacement or partial replacement of the elbow joint.
224150080|NCT00083304|OTHER|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
224150081|NCT01089166|DRUG|Metformin|
224150082|NCT02848313|DRUG|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
224150083|NCT01544478|BIOLOGICAL|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
224150084|NCT04814511|DRUG|InfectoScab 5 % Creme|InfectoScab 5 % Creme is the already approved standard therapeutic agent, containing the active ingredient permethrin in 5 % concentration. In this study, it is used for topical treatment in the first treatment cycle (standard therapy) as well as in the second treatment cycle (escalation therapy).
224150085|NCT04814511|DRUG|Permethrin 10 % Creme|Permethrin 10 % Creme also contains permethrin as the active ingredient, but in 10 % concentration. Permethrin 10 % creme is used exclusively for topical treatment in the second therapy cycle (escalation therapy).
223455500|NCT04653259|OTHER|LYFE MD app|"LyfeMD app is a digital health platform for patients living with both Crohn's disease (CD) and Ulcerative colitis (UC). LyfeMD is meant to help people live and thrive while managing their inflammatory disease with holistic, easy-to-implement, evidence based lifestyle therapies. LyfeMD is one app with multiple features - ranging from customized diet using anti-inflammatory principles identified from recent research, exercise plans to mindfulness and stress reduction programs. It helps patients make therapeutic diet choices to treat inflammation and provides stress reduction strategies when they feel unwell. The LyfeMD app also supports patients to maintain remission even when they're feeling well with trusted resources designed to keep them symptom free.~In addition to delivering personalized and interactive support, the app uses behaviour science to help patients change their habits, improve their health and reduce the burden IBD places on their lives."
223455501|NCT02902042|DRUG|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
223455502|NCT02902042|DRUG|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
223455503|NCT02902042|DRUG|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
223455504|NCT02902042|DRUG|Pembrolizumab alone|200 mg q3w
223455505|NCT06525558|PROCEDURE|Intestinal resection|This study does not add additional risks for patients as the resected specimen is collected during the surgery in accordance with standard clinical practice.
223455506|NCT05395624|DRUG|18F-OP-801|18F Hydroxyl Dendrimer
223455507|NCT06183424|PROCEDURE|Transcranial Direct Stimulation|2 mA, 20 min, 5 days
223455508|NCT01911702|OTHER|Standard fluidic resuscitation.|"Goals:~1. arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~2. diuretic rhythm ≥ 1 ml / Kg / h~3. venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~4. BE\> - 3~5. Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
223572330|NCT03866785|DIAGNOSTIC_TEST|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
223572331|NCT03866785|DIAGNOSTIC_TEST|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
223572332|NCT03866785|DEVICE|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
224150086|NCT04814511|DRUG|Driponin 3 mg Tabletten|Driponin 3 mg Tabletten are approved for the treatment of scabies, containing ivermectin as the active ingredient. Driponin is used as a supplementary, peroral add-on combination treatment in addition to topical permethrin therapy and is used exclusively in the second treatment cycle (escalation therapy).
224150087|NCT03874416|OTHER|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
224150088|NCT03874416|OTHER|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
224150089|NCT00761358|DRUG|Z-338|Oral
224150090|NCT00761358|DRUG|Placebo|Oral
224150091|NCT04592848|OTHER|Questionnaires|"Four Questionnaires in French will be sent to participants :~* 1 questionnaire about sexual and urinary symptoms before and after the surgery ;~* 1 validated questionnaire Female Sexual Function Index to assess sexual function over the past 4 weeks ;~* 1 validated questionnaire Body Image Scale to assess body image during the past week ;~* 1 validated questionnaire Stoma Quality of Life, only for patients with incontinent urostomy.~If the questionnaires are not returned 15 days after sending, a follow-up phone call will be made by one of the investigators.~The data collection will include both the answers to the questionnaires and the patients' computerized medical data:~* Pathology responsible for the urological disorders and date of onset of the disorders~* Date and Type of surgery performed~* Patient's age at the time of surgery~* Post-operative complications within one month of surgery"
224150092|NCT04518722|RADIATION|CT Scan|Dual-energy mid-tibia CT, high-resolution single energy MDCT imaging of the distal tibia (ankle), and low radiation hip CT scans
223572333|NCT03866785|OTHER|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~* Skills in physical activity advice~* Knowledge of functional signs (symptoms)~* Knowledge to examine heart rate and perceived effort rate"
223572334|NCT03866785|OTHER|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
223572335|NCT00343369|DRUG|asparaginase|
223572336|NCT00343369|DRUG|cyclophosphamide|
223572337|NCT00343369|DRUG|cytarabine|
223572338|NCT00343369|DRUG|daunorubicin hydrochloride|
223572339|NCT00343369|DRUG|dexamethasone|
223572340|NCT00343369|DRUG|doxorubicin hydrochloride|
223572341|NCT00343369|DRUG|mercaptopurine|
223572342|NCT00343369|DRUG|methotrexate|
223572343|NCT00343369|DRUG|pegaspargase|
223572344|NCT00343369|DRUG|prednisolone|
223572345|NCT00343369|DRUG|teniposide|
223572346|NCT00343369|DRUG|thioguanine|
223572347|NCT00343369|DRUG|vincristine sulfate|
223572348|NCT00343369|RADIATION|radiation therapy|
224064809|NCT01750112|DEVICE|Macrolane VRF20|Injection treatment with Macrolane VRF20
224064810|NCT00986700|DIETARY_SUPPLEMENT|late night meal|Three different kinds of late night meal each for 2 days.
224064811|NCT02062788|DIETARY_SUPPLEMENT|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
224064812|NCT06333834|DRUG|Traditional scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the classification proposed by the Mexican Clinical Practice Guideline to decide the dose of scorpion antivenom. Scorpion antivenom will be administered to all patients. Patients in this group will receive between one and three vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade I, two vials for patients classified as grade II, and three vials for patients classified as grade III)
224064813|NCT06333834|DRUG|Serial dose of scorpion antivenom regimen|All patients will be classified according to two severity scales. The pharmacist, who is the only team member aware of which group each patient was assigned to, will consider the classification corresponding to the American classification to decide the dose of scorpion antivenom. Scorpion antivenom will be administered only in the presence of signs and/or systemic symptoms of intoxication, excluding signs and symptoms at the sting site. Patients in this group will receive between one and two vials every 30 minutes, depending on the severity of the condition (one vial for patients classified as grade III and two vials for patients classified as grade IV)
224064814|NCT03071614|OTHER|News items with spin|Interpretation of news items with spin
224064815|NCT03071614|OTHER|News items without spin|Interpretation of news items without spin
224064816|NCT04933604|PROCEDURE|laparoscopic partial nephrectomy|Nephron sparing minimally invasive surgery
224064817|NCT04933604|PROCEDURE|Laparoscopic radical nephrectomy|Completely removal of kidney by using laparoscopic surgery
224064818|NCT04523636|DEVICE|Splinting|Pre-fabricated or custom resting hand splints
224064819|NCT00389428|DRUG|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
224064820|NCT00003936|DRUG|bryostatin 1|
224064821|NCT05543577|OTHER|Questionnaire|Questionnaire
224064822|NCT04674020|DRUG|Erenumab|Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
224064823|NCT06037733|RADIATION|CTV omitted or delineated|Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
224064824|NCT05677555|DRUG|Colchicine 0.5 MG|A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
224064825|NCT05677555|DRUG|Placebo|A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
224064826|NCT04010214|OTHER|No intervention|No intervention
224064827|NCT04234906|DRUG|Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
224064828|NCT04234906|DRUG|Magnesium Sulfate|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
224064829|NCT04234906|DRUG|Amiodarone|I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
224064830|NCT04234906|DRUG|Procainamide|IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
224064831|NCT02838966|DIETARY_SUPPLEMENT|Nestle IMPACT Advanced Recovery|
224064832|NCT02838966|DIETARY_SUPPLEMENT|Nestle Boost High Protein Drink|
224064833|NCT01290874|DRUG|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
224064834|NCT01290874|DRUG|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
224064835|NCT01290874|DRUG|Formoterol|Formoterol 12 mcg twice daily for one year
224064836|NCT02094690|DEVICE|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
224064837|NCT02094690|DEVICE|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
224150093|NCT04518722|RADIATION|DXA Scan|Basic DXA scans will be performed to measure areal BMD and body composition measures at the whole body, spine, and hip
224150094|NCT04518722|OTHER|Steroid Intake Questionnaire|Questionnaire designed to quantify lifetime oral glucocorticoid intake
224150095|NCT01461824|DRUG|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
223572349|NCT02154620|PROCEDURE|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
223572350|NCT02154620|DEVICE|Synthes TCP volar plate|
223572351|NCT05897190|BIOLOGICAL|SARS-CoV-2 mRNA vaccine (RBMRNA-405)|Dose A
223572352|NCT05897190|BIOLOGICAL|CoronaVac®|Dose B
223572353|NCT01192269|DIETARY_SUPPLEMENT|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
223572354|NCT00908648|PROCEDURE|Narrow Band Imaging|Narrow Band Imaging
223572355|NCT04073784|DRUG|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
223572356|NCT02810301|OTHER|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
223572357|NCT02810301|OTHER|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
223572358|NCT01571284|DRUG|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
223742946|NCT00540345|DRUG|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
224150096|NCT02168712|OTHER|Moderate continuous exercise training|
224150097|NCT02168712|OTHER|Interval exercise training|
224150098|NCT01791790|DEVICE|Stimulation|
224150099|NCT01791790|DEVICE|SHAM|no stimulation
223572359|NCT01571284|DRUG|FOLFIRI|irinotecan, 5-FU and leucovorin
223572360|NCT02470143|BEHAVIORAL|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
223572361|NCT03867565|OTHER|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
223572362|NCT00096499|DRUG|ispinesib|Given IV
223742947|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
224064838|NCT05796102|PROCEDURE|PET-MRI|"A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position.~Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment"
224064839|NCT04194528|DRUG|Oxycodone/acetaminophen 5/325 mg|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
224064840|NCT04194528|DEVICE|Proteus digital medicine program|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
224064841|NCT04501185|DEVICE|total hip arthroplasty|The indication for total hip arthroplasty is mainly osteoarthritis.
224064842|NCT04571411|OTHER|CBC|The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.
224064843|NCT04926051|DRUG|BMS-986172|Specified dose on specified days
224064844|NCT04926051|OTHER|Placebo|Specified dose on specified days
224064845|NCT02589444|DIETARY_SUPPLEMENT|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
224150100|NCT02519062|OTHER|No intervention|This is a retrospective study
224150101|NCT02114489|DRUG|ibandronate|Unique perfusion of ibandronate 3 mg IV
224150102|NCT02114489|DRUG|Placebo|
224150103|NCT03382262|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
224150104|NCT03382262|DRUG|TAcs 40 mg|Immediate-release 40mg TAcs IA injection
224150105|NCT01596192|OTHER|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
224150106|NCT02310360|RADIATION|Fallypride|
224150107|NCT01802268|DRUG|Conversion from Tacrolimus to Sirolimus|
224150108|NCT01802268|DRUG|Maintenance on tacrolimus|
224150109|NCT00227968|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
224150110|NCT00227968|BEHAVIORAL|Clinical Status and Symptom Response Therapy (CSSRT)|
224150111|NCT05498025|OTHER|Deterra activated charcoal pouch|drug disposal pouch
223572363|NCT00096499|OTHER|pharmacological study|Correlative studies
223572364|NCT00096499|OTHER|laboratory biomarker analysis|Correlative studies
223572365|NCT02101684|DRUG|Orteronel 300mg BID|
223572366|NCT01394224|DRUG|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
223572367|NCT01394224|DRUG|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
224150112|NCT03404219|BEHAVIORAL|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
224150113|NCT06067724|OTHER|Pelvic and trunk control exercises|Patients in this group will be treated by the traditional physical therapy program in addition to a 18 sessions of pelvic and trunk control exercises for 40 min included abdominal drawing in maneuver for contraction of transversus abdominis pelvic tilting exercises and pelvic stabilization exercises from different positions. Pelvic tilting exercises included; anterior, posterior, lateral pelvic tilting and pelvic rotation on a therapeutic ball. Pelvic stabilization exercises include bridging, half bridging, clamshell from supine and side lying, quadribed exercises, weight shifting on the affected limb from standing by forward and diagonal reach out, ball bridging and rhythmic stabilization exercises
224150114|NCT01736709|BIOLOGICAL|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
224150115|NCT01072240|DRUG|rituximab [Mabthera/Rituxan]|As prescribed by physician
224150116|NCT01318421|DRUG|ELND002|
224150117|NCT02038790|DRUG|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
224150118|NCT02038790|DRUG|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
224150119|NCT06338813|DEVICE|Digital Manometry|"The Compass Lumbar Puncture Pressure Transducer (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer. After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted."
224150120|NCT01089751|DRUG|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
224150121|NCT01089751|DRUG|placebo|Placebo once daily on an empty stomach for 14 weeks.
224150122|NCT01818986|DRUG|Sipuleucel-T|
224150123|NCT01818986|RADIATION|Stereotactic Ablative Body Radiation|
224150124|NCT03121066|DEVICE|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
224150125|NCT03121066|DEVICE|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
224150126|NCT03487887|DEVICE|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
224150127|NCT00250081|PROCEDURE|Upper Extremity Tendon transfer|
224150128|NCT00250081|PROCEDURE|Botulinum Toxin injections in Upper Extremity|
223572368|NCT01230515|OTHER|Individual patient interview, focus group and structured survey|
224150129|NCT00250081|PROCEDURE|Regularly ongoing therapy|
224150130|NCT02942706|DRUG|Cetuximab|anti-EGFR monoclonal antibody
224150131|NCT02942706|DRUG|mFOLFOX6|Oxaliplatin+LV5FU2
224150132|NCT02942706|DRUG|FOLFIRI|Irinotecan+LV5FU2
224150133|NCT01027104|OTHER|Education|Firearm injury prevention anticipatory guidance curriculum
224150134|NCT01726816|DRUG|Probucol 250mg/day|Probucol 250mg + Placebo
223572369|NCT01230515|OTHER|interview, focus group and structured survey|
223572370|NCT01230515|OTHER|interview, focus group and structured survey|
223572371|NCT01230515|OTHER|interview, focus group and structured survey|
223572372|NCT03352557|DRUG|BIIB092|Administered as specified in treatment arm.
223572373|NCT03352557|DRUG|Placebo|Administered as specified in treatment arm.
223572374|NCT02070393|RADIATION|Proton|14-24 Radiation treatments using Protons
224150135|NCT01726816|DRUG|Probucol 500mg/day|Probucol 500mg + Placebo
223572375|NCT04065074|DRUG|FX006 32 mg|Extended-release 32 mg FX006 IA injection
223572376|NCT02739529|DRUG|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
223572377|NCT02241811|DRUG|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
223572378|NCT02241811|DRUG|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
223742948|NCT00540345|DRUG|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
223742949|NCT03822676|DEVICE|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
224150136|NCT01726816|DRUG|Placebo|Probucol matching placebo
224150137|NCT02031198|DRUG|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
224150138|NCT00690417|DIETARY_SUPPLEMENT|Cholecalciferol (vitamin D3)|low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
224150139|NCT03949543|OTHER|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
223742950|NCT06326294|DEVICE|Thermal ablation|Thermal ablative uses heat (100°C to 120°C) to cause localized tissue damage at the cervical transformation zone and destroy the abnormal epithelium.
224150140|NCT03949543|OTHER|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
224150141|NCT00438464|DRUG|Finasteride|Given PO
224150142|NCT00438464|OTHER|Placebo|Given PO
224150143|NCT00438464|PROCEDURE|Prostatectomy|Undergo prostatectomy
224150144|NCT00438464|OTHER|Laboratory biomarker analysis|Correlative studies
224150145|NCT03537092|DEVICE|Vaginal Film|"2 x 2 vaginal film with no active drug"
224150146|NCT03943446|DRUG|TAK-018|TAK-018 immediate-release tablets.
224150147|NCT03943446|DRUG|TAK-018 Placebo|TAK-018 placebo-matching tablets.
224150148|NCT03057912|BIOLOGICAL|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
224150149|NCT03057912|BIOLOGICAL|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
224150150|NCT03055572|OTHER|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
224150151|NCT03055572|OTHER|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
224150152|NCT00392119|DEVICE|MR-guided Laser Interstitial Thermal Therapy System|
224150153|NCT03214328|DIAGNOSTIC_TEST|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
223455509|NCT01911702|OTHER|Volemic small treatment|"Goals of the treatment:~1. arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~2. diuretic rhythm ≥ 0.5 ml / kg / h~3. venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~4. BE\> - 5~5. PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be \> 10-15 ml / kg / h an infusion of furosemide should be initiated"
223455510|NCT04245618|DRUG|neoadjuvant chemotherapy ( cisplatin - gemcitabine)|Neoadjuvant chemotherapy before TURBT
224150154|NCT01759160|PROCEDURE|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
224150155|NCT01759160|PROCEDURE|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
224150156|NCT02394418|DRUG|Sevoflurane|Treatment of delirium by inhaled sevoflurane
223455511|NCT05645107|DRUG|Xembify|SC infusion pump
223455512|NCT05645107|DRUG|Placebo|SC infusion pump
223742951|NCT06326294|PROCEDURE|LOOP ELECTROSURGICAL EXCISION PROCEDURE|Cervical tissue excision
224150157|NCT02394418|DRUG|Propofol|Treatment of delirium by propofol i.v. infusion
223455515|NCT04208412|DRUG|KVD900|KVD900 tablet 600 mg
224150158|NCT02394418|DRUG|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
224150159|NCT05745025|DEVICE|Repeated Transcranial Magnetic Stimulation|rTMS will be delivered using a commercially available magnetic stimulator (Rapid2, Magstim Inc., Eden Prairie, MN) with a figure-of-8 Air Film coil at 10 Hz. Coil orientation will be optimized for stimulation of the abductor pollicis brevis. Stimulation targeting will be identified using motor-evoked potentials (MEP) of the first dorsal interossei that will be monitored using electromyography (EMG) (Motion Lab Systems Inc., Baton Rouge, LA). The motor threshold (MT) of the muscle will then be identified by systematically adjusting the pulse intensity. The MT will be considered the lowest stimulation intensity at which 5 out of 10 MEPs have a peak-to-peak amplitude of at least 50 microvolts. rTMS will be performed at the identified optimal location at 10Hz using an intensity that is 80% of the MT. Pulse trains will be delivered for 10 seconds, with a 30-second rest for 20 repetitions.
224150160|NCT05745025|DEVICE|Sham Repeated Transcranial Magnetic Stimulation|Sham rTMS will be performed using the same methods as the active group, but a sham Air Film coil (Magstim Inc., Eden Prairie, MN) will be used. This coil looks and sounds like the active coil, but it does not deliver magnetic pulses.
224301820|NCT00950963|OTHER|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
224150161|NCT05745025|OTHER|Rehabilitation|"Rehabilitation will consist of education, value-based goal setting, Graded Motor Imagery (GMI) (3 components described below), and graded activity. Subjects will complete activities at treatment sessions and be asked to perform certain treatment activities at home.~Week 1: Pain education, functional value-based goal setting, laterality training (first component of GMI), one task for graded activity (task-based on patient goals)~Week 2: Continue week 1 activity, add graded motor imagery (second component of GMI), progress 1st graded activity, and initiate 2nd graded activity exercise.~Week 3- Mirror therapy (third component of GMI), assess knowledge and update education as needed, progress graded activity 1 and 2, and add 3rd graded activity if appropriate based on patient goals.~Week 4- Continue with week 3 activities. Discuss experience with meditation and progress graded activity as tolerated"
224150162|NCT04658810|OTHER|Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)|Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder
224150163|NCT05460390|OTHER|Therapeutic drug monitoring (TDM)|Serum trough level of adalimumab and anti-adalimumab antibody will be obtained at time of enrollment and every 3 months until the end of the study. Adalimumab dose optimization goal will be to achieve trough drug level in the range of 5 -8 μg/mL.
224150164|NCT02509611|OTHER|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
224150165|NCT03786406|OTHER|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
224064846|NCT02589444|OTHER|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
224064847|NCT02589444|OTHER|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
224150166|NCT01309373|OTHER|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
224064848|NCT02589444|OTHER|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
224064849|NCT02589444|PROCEDURE|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
224064850|NCT01255644|DRUG|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
224064851|NCT02325284|DEVICE|Pressure Algometer Testing|
224064852|NCT01311050|DRUG|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
224064853|NCT01934686|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
224064854|NCT04227366|BIOLOGICAL|BCD-089|BCD-089 162 mg SC
224064855|NCT04227366|BIOLOGICAL|Placebo|Placebo
224064856|NCT04227366|DRUG|Methotrexat|15 to 25 mg/week
224064857|NCT00485602|PROCEDURE|"orthodontic treatment with Rafenalign appliance"|
224064858|NCT03587220|DRUG|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
224064859|NCT03587220|RADIATION|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
223455516|NCT04208412|OTHER|Placebo|KVD900-matched Placebo Tablet
223455517|NCT02733341|DRUG|Cangrelor|
223455518|NCT02733341|DRUG|Ticagrelor|
224064860|NCT03587220|OTHER|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
223455519|NCT05415462|BIOLOGICAL|mRNA-1010|Sterile liquid for injection
223455520|NCT05415462|BIOLOGICAL|Fluarix Tetra|Sterile suspension for injection
223455521|NCT00288444|DRUG|Lonafarnib|
223455522|NCT00288444|DRUG|Docetaxel|
223455523|NCT03621241|DIAGNOSTIC_TEST|Flow cytometry|Flow cytometry
223455524|NCT04342013|OTHER|Electronic Clinical Decision Support Application|Robust, real-time medication-related clinical decision support application for use in the operating room. The application is fully integrated with existing clinical systems. It provides visual alerts for medication errors and adverse medication events at the point-of-care.
223455525|NCT03616392|DRUG|D308, CKD-501|"1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg"
223455526|NCT04819750|DEVICE|MusicCare® device|The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
223455527|NCT04819750|DEVICE|Headphones with noise reduction|Headphones with noise reduction without music
224064861|NCT03587220|DRUG|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
224064862|NCT03200132|DIAGNOSTIC_TEST|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
224064863|NCT04867473|BEHAVIORAL|Teleyoga|12 weekly 75 minute therapist-led teleyoga sessions
224064864|NCT06020586|OTHER|hair lotion|ECOHAIR
223455528|NCT03463252|DRUG|Progesterone|MPA oral 250mg-500mg qd for 3 months per cycle
223455529|NCT03463252|DEVICE|Mirena®|levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
223455530|NCT03463252|DRUG|GnRH agonist|GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
223455531|NCT01038154|DRUG|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
224064865|NCT05004636|DRUG|Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty|Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate (0.3mL) in the block and the other half will receive 0.3 mL of saline in the block.
224064866|NCT02159703|PROCEDURE|TORS|
224064867|NCT02159703|RADIATION|Adjuvant Radiation Therapy|
224064868|NCT03921424|BIOLOGICAL|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
224064869|NCT03921424|BIOLOGICAL|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 mL dose.
224064870|NCT03921424|BIOLOGICAL|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
224064871|NCT05422560|PROCEDURE|Embolization of the inferior mesenteric artery|"The procedure is performed in a dedicated angiography room. After local anesthesia, a common femoral arterial approach is performed according to the Seldinger technique with the placement of a 4 French valve introducer.~Catheterization of the superior mesenteric artery with a Cobra 4F catheter and angiography to confirm patency of the border arcade.~Catheterization of the inferior mesenteric artery with a 4F cobra/shepherd hook catheter and angiography. Microcatheterization of the artery with a 2.7F or 2.8F microcatheter and embolization with microcoil leaving the first centimeters of the IMA in order not to interfere with the surgery.~Catheterization of the superior mesenteric artery and final angiography to confirm the reinjection of the inferior mesenteric by the border arcade.~Removal of the material and manual compression of femoral access. Clinical monitoring for 6 hours and discharge the same day of the procedure."
224064872|NCT00005039|BIOLOGICAL|recombinant fowlpox-prostate specific antigen vaccine|Given IM
224064873|NCT00005039|BIOLOGICAL|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
224064874|NCT00005039|OTHER|laboratory biomarker analysis|Correlative studies
224064875|NCT05489731|DRUG|VIC-1911|VIC-1911 tablets for oral administration
224064876|NCT05489731|DRUG|Osimertinib Mesylate Tablets|Osimertinib tablets for oral administration
224064877|NCT02587650|DRUG|Capmatinib|Given PO
224064878|NCT02587650|DRUG|Ceritinib|Given PO
224064879|NCT02587650|DRUG|Entrectinib|Given PO
224064880|NCT02587650|OTHER|Laboratory Biomarker Analysis|Correlative studies
224064881|NCT02587650|DRUG|Regorafenib|Given PO
224064882|NCT04772495|GENETIC|miRNA|miRNA effect on Multiple sclerosis pathology
224064883|NCT03853239|PROCEDURE|face mask ventilation crossover nasal ventilation|Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.
224064884|NCT03853239|PROCEDURE|nasal ventilation crossover face mask ventilation|Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
224064885|NCT05785468|DRUG|Caplacizumab|description and quantification of clinical response in terms of platelet count recovery in patients with aTTP treated t with caplacizumab
224064886|NCT01766960|OTHER|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
224150167|NCT06849427|OTHER|multicomponent exercise intervention|"Multicomponent Exercise Program~A. Flexibility B. Targeted Strength Training C. Balance and Mobility~1. Center of Gravity Control Training~2. Multisensory Training~3. Postural Strategy Training~4. Gait Pattern Development Variation Training~5. Dual Task Exercises . D. Cardiovespiratory Fitness"
223455532|NCT03873311|DRUG|Azacytidine, HAG Regimen|Azacytidine（75mg/m2 QD for 7 days）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) for 14 days), Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L)
224064887|NCT01766960|DRUG|Morphine|Five milligrams of intravenous morphine will be administered.
224064888|NCT01473082|DEVICE|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
224064889|NCT01473082|DEVICE|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
224064890|NCT04030221|OTHER|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
224064891|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
224064892|NCT00579865|BEHAVIORAL|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
224150168|NCT00821145|PROCEDURE|conventional surgery|AAA patients operated using a conventional incision
223742952|NCT05732194|DRUG|ITI-333|ITI-333 oral solution
224064893|NCT01076049|DEVICE|Standard of Care (SoC)|The preferred irrigation solution and method was chosen by the site's emergency department physician(s) and could vary between subjects. The type of SoC was recorded in the source document and the same solution and irrigation method were used during the initial treatment and 48-hour follow-up visits.
224064894|NCT01076049|DEVICE|Irrisept Delivery System|"Irrisept is a manual, self-contained irrigation device capable of producing 7-8 psi of pressure for effective wound cleansing and irrigation. Irrisept contents include the Chlorhexidine Gluconate (CHG) solution, a 450 mL bottle, and Irriprobe applicator or an abscess irrigation tip. The bottle design allows users to control the pressure of the solution through manual bottle compression.~Irrisept was recorded in the source document and used during the initial treatment and 48-hour follow-up visits."
224064895|NCT00826124|PROCEDURE|Epidural steroid injection|Injection based solely on history and physical exam
224064896|NCT00826124|PROCEDURE|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
224064897|NCT00826124|PROCEDURE|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
224064898|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 weeks of symptoms|Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms
224064899|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 3 months of symptoms|Microscope assisted lumbar discectomy done at 3 months of starting symptoms
224064900|NCT04538027|PROCEDURE|Lumbar Microdiscectomy at 6 months of symptoms|Microscope assisted lumbar discectomy done at 6 months of starting symptoms
224064901|NCT04994119|DRUG|BIA 5-1058|Oral BIA 5-1058 (Zamicastat) 100 mg tablets
224064902|NCT04994119|DRUG|Warfarin|Oral Warfarin (Coumadin) 5 mg film coated tablets
224064903|NCT05462847|DRUG|Ringer acetate|8ml/kg Ringer acetate over 10 minutes
224064904|NCT04197115|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
224064905|NCT04197115|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
224064906|NCT04197115|DRUG|Complex B|Complex B ((Thiamine 100mg, Pyridoxine 5 mg and Cyanocobalamin 50 mcg) 1 tablet enteral route every 6 horas for 4 days or until ICU discharge
224064907|NCT05531175|OTHER|Reiki apply|The intervention group is the group in which reiki is applied. They receives 3 sessions of hemodialysis per week.
223455533|NCT03873311|DRUG|Azacytidine|Azacytidine 75mg/m2 QD for 7 days.
223455534|NCT03603561|DEVICE|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
224064908|NCT06512974|BEHAVIORAL|NeuroTrainer|Virtual reality based cognitive training
224064909|NCT06977958|BEHAVIORAL|NASM OPT Group|Three 60-minute weekly sessions for 12 weeks, progressing through stabilization (weeks 1-4), strength endurance (weeks 5-8), and hypertrophy (weeks 9-12) phases. Exercises included hip thrusts, squats, and glute bridges.
224064910|NCT06977958|BEHAVIORAL|General Exercise Group|Three 60-minute weekly sessions of brisk walking and light aerobics without targeted resistance training.
224064911|NCT06978959|BEHAVIORAL|FN+ Intervention|Participants will attend 5 one-on-one sessions over the course of 5 weeks; they will meet with a family navigator over video conferencing software (e.g., Zoom). The purpose of each sessions are as follows: 1) Provide an overview of the program and help parents understand their perceptions of child behaviors, 2) Train parents to find, access, and overcome barriers to mental health services, 3) Build parent capacity in understanding how mental health treatment works and how to communicate with providers, 4) Help parents understand the common function of child behaviors, and 5) Train parents to find, evaluate, and use online mental health tools. Participants will complete measures of child symptoms, parent activation, barriers to treatment, and/or satisfaction with the program before the intervention, immediately after the intervention, and 3 months after completing the intervention.
224064912|NCT06982469|RADIATION|Brachytherapy|HDR brachytherapy
224064913|NCT04769960|DIAGNOSTIC_TEST|MRI Studies|MRI scans will be performed on a 1.5T MRI scanner. Department of Radiology MRI SafetyGuidelines will be followed except regarding breast tissue expanders. Conventional MRIstudies will be performed using the standard of care clinical sequences.
224071350|NCT06106464|OTHER|Aerobic exercise+6.5 h of prolonged sitting|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then sit in the chair for 6.5 hours. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
224071351|NCT06106464|OTHER|Aerobic exercise+2 minutes of walking breaks every 30 minutes|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 2-minute walks at 35-40% of their heart rate reserve every 30 minutes for 6.5 hours after moderate-intensity aerobic exercise. They will make a twelve interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
224071352|NCT06106464|OTHER|Aerobic exercise+4 minutes of walking breaks every 1-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 4-minute walks at 35-40% of their heart rate reserve every 1 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
224150169|NCT00821145|PROCEDURE|laparoscopic AAA resection|laparoscopic AAA resection
224150170|NCT00821145|PROCEDURE|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
224150171|NCT00599170|DRUG|Rituximab|375 mg/m2 IV
224150172|NCT00356668|DEVICE|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
224150173|NCT04456595|BIOLOGICAL|Adsorbed COVID-19 (inactivated) Vaccine|Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
224150174|NCT04456595|BIOLOGICAL|Placebo|Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
224150175|NCT01454479|DRUG|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
224150176|NCT04209530|DRUG|EN3835|Collagenase Clostridium Histolyticum (CCH)
224150177|NCT03588611|DRUG|Bivalirudin|0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
224150178|NCT03588611|DRUG|Bivalirudin|0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
224150179|NCT01192711|DEVICE|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
224150180|NCT06043401|OTHER|Neuroimaging with Magnetic Resonance Imaging (MRI)|MRI will be used to observe brain states over time.
224150181|NCT04368897|DIAGNOSTIC_TEST|CAG length <22|CAG repeat length in exon 1 of AR gene
224150182|NCT04368897|DIAGNOSTIC_TEST|CAG length >=22|CAG repeat length in exon 1 of AR gene
224150183|NCT04814524|DEVICE|Fitbit|Wear Fitbit
224150184|NCT04814524|OTHER|Questionnaire Administration|Ancillary studies
224150185|NCT04814524|DEVICE|Virtual Reality Device|Use VR
224150186|NCT00706394|DEVICE|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
224150187|NCT03030768|DRUG|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
224150188|NCT03030768|BEHAVIORAL|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
224150189|NCT00666380|BIOLOGICAL|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
224150190|NCT04258293|DIAGNOSTIC_TEST|Blood sampling|fasting venous glycemia, venous glycemia after sugar loading, glycated hemoglobin and platelet count
224150191|NCT03504462|PROCEDURE|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
224150192|NCT02708615|OTHER|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
223455535|NCT03603561|DEVICE|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
223455536|NCT04932343|DIAGNOSTIC_TEST|cohort study|no intervention
223455537|NCT00355511|BEHAVIORAL|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
224150193|NCT04675697|DRUG|Platinum-etoposide+Anlotinib|Platinum-etoposide regiment consisted of etoposide 100mg/m2, d1\~3 of 21-day cycle, with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W). Anlotinib treated of 12mg Qd from day 1 to 14 of a 21-day cycle. Eligible patients received anlotinib plus platinum-etoposide for 4\~6 cycles, and followed by maintenance therapy with Anlotinib. The efficacy was evaluated every 6 weeks (2 cycles) through treatment.
224150194|NCT01529814|DEVICE|Implant with new abutment connection|New abutment connection implant system
224150195|NCT01529814|DEVICE|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
224150196|NCT01201707|PROCEDURE|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
224150197|NCT01201707|OTHER|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
224150198|NCT05267197|OTHER|3D Telemedicine|3D Telemedicine system
224150199|NCT05267197|OTHER|2D Telemedicine|2D Telemedicine system
224150200|NCT00574457|OTHER|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
224150201|NCT05815680|DRUG|metformin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
224150202|NCT05815680|DRUG|digoxin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
224150203|NCT05815680|DRUG|IBI362|Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
224150204|NCT05815680|DRUG|warfarin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
224150205|NCT05815680|DRUG|atorvastatin|For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
224150206|NCT04950842|BIOLOGICAL|JB-101|induced T cell with suppressive function
223455538|NCT02259699|OTHER|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
224150207|NCT02302144|BEHAVIORAL|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
224150208|NCT01084109|OTHER|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
224150209|NCT01084109|OTHER|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
224150210|NCT03290170|PROCEDURE|Measured Resection|Bony landmarks are used to set femoral component rotation.
224150211|NCT03290170|PROCEDURE|Gap Balancing|Relies on ligament releases prior to bone cuts.
224150212|NCT02135900|DRUG|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
224150213|NCT01467661|DRUG|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
224150214|NCT02549248|OTHER|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
224150215|NCT02549248|OTHER|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
224150216|NCT02549248|OTHER|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
224150217|NCT02549248|OTHER|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
224150218|NCT02549248|OTHER|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
224150219|NCT03673956|DRUG|Mupirocin|30mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
224150220|NCT03673956|DRUG|Tobramycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
224150221|NCT03673956|DRUG|Levofloxacin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
224150222|NCT03673956|DRUG|Vancomycin|240mg capsules dissolved in a standard 240mL saline irrigation rinse and self-administered through nasal saline irrigation twice per day over 30 days.
224150223|NCT02533778|DEVICE|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
224150224|NCT04636320|DEVICE|Contrast-enhanced CMR|Cardiac Magnetic Resonance Imaging (MRI) examinations will be performed at Day 0 visit on clinical systems 1.5 equipped with specific antennas for cardiac imaging. The imaging protocol will last approximately 50 minutes.
224150225|NCT04636320|DIAGNOSTIC_TEST|Exercise test ECG|"A treadmill exercise test with 12 lead ECG monitoring will be performed at M3 visit.~Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls."
224150226|NCT04636320|BIOLOGICAL|Blood sample|"A blood sample will be taken at Day 0 visit for COVID-19 serology, hematocrit measurement, ultra-high sensitive troponin test, low grade markers of inflammation, genetic profiling.~An other blood sample will be taken at M3 visit for a control COVID-19 serology for 30 healthy volunteers."
224150227|NCT04636320|DIAGNOSTIC_TEST|Resting 12 lead ECG|A resting 12 lead ECG will be performed at Day 0 visit.
224150228|NCT04636320|DIAGNOSTIC_TEST|24 hour Holter ECG|A 24 hour Holter ECG will be performed at M3 visit. Maximum expected enrollment 30 MRI+ patients and 30 healthy volunteers MRI- matched controls.
224150229|NCT05982834|DRUG|Disitamab Vedotin combined with fruquintinib and Tislelizumab|Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w
224150230|NCT00270998|BEHAVIORAL|Behavioral Therapy|Pelvic muscle training and exercises
224150231|NCT00270998|DEVICE|Intravaginal Pessary|Intravaginal pessary
224150232|NCT00270998|DEVICE|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
224150233|NCT04876586|PROCEDURE|Lumbar fusion|Transforaminal Lumbar Interbody Fusion of the SPECT/CT positive degenerative disc disease
223455539|NCT04186221|DEVICE|OCS Liver System|OCS Liver System for preserving and assessing donor livers for transplantation
223455540|NCT02393235|OTHER|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
223455541|NCT05624190|DRUG|Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)|The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.
223455542|NCT05624190|OTHER|Best Medical Management|Best Medical Management
223742953|NCT05732194|OTHER|Placebo|Matching placebo
223742954|NCT03447808|BIOLOGICAL|Daratumumab|Given IV
224150234|NCT03242161|DIAGNOSTIC_TEST|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
224150235|NCT02366793|OTHER|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
224150236|NCT02366793|OTHER|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
224150237|NCT01204307|DRUG|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
224305104|NCT03627507|BIOLOGICAL|Hepa-B|Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
224150238|NCT01204307|DRUG|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
224150239|NCT05913518|DEVICE|Neurofeedback active|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Active neurofeedback group aims at enhancing the sensorimotor rhythm (12-15 Hz).
224150240|NCT05913518|DEVICE|Neurofeedback placebo|Neurofeedback uses real-time displays of brain activity to teach self regulation of brain function. People can learn to control their own brain activity through operant conditioning, where they receive feedback on their brainwaves and learn to modify them to achieve a desired state. Placebo feedback group (PFT) : patients enhance random frequency bands
224150241|NCT05318040|DRUG|CMS121|CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
224150242|NCT05318040|DRUG|Placebo|Placebo will be provided as visually matching placebo capsules.
224150243|NCT01100294|BIOLOGICAL|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
224150244|NCT00453661|BEHAVIORAL|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
224150245|NCT00453661|BEHAVIORAL|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
224150246|NCT04414488|PROCEDURE|Thoracic paravertebral block (ThPVB)|Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process. A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura. An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA). The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification). Plain bupivacaine (0.3 ml\*kg-1) was then injected after a negative aspiration test for air or blood. The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer. Testing was symmetrical on both sides of thorax. A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
224150247|NCT04889612|PROCEDURE|hand motor coordination in a sitting positin|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
223455543|NCT02158377|DEVICE|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
223455544|NCT02158377|DEVICE|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
223455545|NCT01654263|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
223455546|NCT01904032|DRUG|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
223455547|NCT01904032|DRUG|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
223455548|NCT00147511|DRUG|linezolid|
223455549|NCT01340742|PROCEDURE|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
223455550|NCT01340742|PROCEDURE|Control|Cuff placed on arm uninflated for 30 minutes.
223455551|NCT00437372|DRUG|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
223455552|NCT00437372|RADIATION|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
223455553|NCT02635256|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
223455554|NCT03367234|BEHAVIORAL|Individual Therapy Sessions|One-on-one sessions with a counselor
223455555|NCT03367234|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
223455556|NCT03367234|BEHAVIORAL|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
223455557|NCT03367234|BEHAVIORAL|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
223455558|NCT03367234|BEHAVIORAL|Group Therapy Sessions|Group therapy sessions
223455559|NCT03367234|BEHAVIORAL|Psychiatric Consultation|Access to psychiatric consultation
223455560|NCT03367234|BEHAVIORAL|Contingency Management|Rewards for engagement in specified recovery behaviors
223455561|NCT00531947|DRUG|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
223455562|NCT00531947|DRUG|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
224150248|NCT04889612|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and hand free). After putting the Hand Tutor glove on, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
224150249|NCT00466024|BEHAVIORAL|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
224150250|NCT00466024|BEHAVIORAL|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
224150251|NCT00395837|BEHAVIORAL|Aerobic exercise|
224150252|NCT03963804|DEVICE|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
224150253|NCT06173609|PROCEDURE|CABG|"During coronary artery bypass surgery, the surgeon removes a piece of blood vessel from the leg, chest, arm, or belly. Then, the surgeon uses that piece of blood vessel (called a graft) to reroute blood around the blocked artery."
224150254|NCT02253472|DEVICE|Deep Brain Stimulation|
223455563|NCT03775967|DIAGNOSTIC_TEST|sialic acid|sialic acid level estimation in salivary samples
223455564|NCT03775967|DIAGNOSTIC_TEST|IL10|IL10 estimation in salivary samples
223455565|NCT03240276|OTHER|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
223455566|NCT03240276|DEVICE|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
223455567|NCT03240276|OTHER|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
223455568|NCT01800799|DRUG|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
223455569|NCT01800799|DRUG|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
223455570|NCT00596050|DRUG|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
223455571|NCT00596050|DRUG|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
223455572|NCT03513783|OTHER|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~* A clinical exam is performed by the Physical Medicine \& Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~* Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~* The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
223455573|NCT04615078|DEVICE|ETAPES Program|"The Chronic Care Connect Pneumology is a remote medical monitoring solution, combining:~* A technical solution for the transmission and analysis of ventilator data, leading to alerts generated by an algorithm ;~* An organizational solution relying on a nurse call center."
223455574|NCT00282685|PROCEDURE|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
224150255|NCT04461028|DRUG|Liposomal bupivacaine|20 ml mixture of 10 ml of Liposomal Bupivacaine 1.3% and 10 ml of Bupivacaine HCl 0.5%.
224150256|NCT04461028|DRUG|Bupivacaine with Dexamethasone Solution|20 ml of Bupivacaine HCl 0.5% with 4 mg of preservative-free dexamethasone.
224150257|NCT00388167|DRUG|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
224150258|NCT01463657|DEVICE|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
223455575|NCT00529178|DRUG|Pravastatin|
223572379|NCT04260763|BEHAVIORAL|Social Cognition Group|Each session lasts 90 minutes and includes three 20-minute work packages tapping different social cognition skills; specifically affect recognition and theory of mind/mental state attribution in this study. Examples of the work packages include guessing the emotions of others based on their facial expressions, activities such as indicating how confident participants feel about guessing emotions when looking at more ambiguous pictures, and watching/discussing video clips with content relevant to the group.
223572380|NCT04260763|DEVICE|Novel Mobile App|"The novel homework app was designed to deliver tasks to the participants between group therapy sessions. Three types of task were delivered by the app; 'Stories', 'Emotions', and 'Facts and Guesses'. The 'Stories' task was designed to encourage participants to think about how thoughts, emotions and actions interact. Participants were presented with a short vignette and asked to identify the emotion or behaviour of a character. 'Emotions' aimed to target affect perception by presenting faces of different emotion presentations and asking clients to select the correct emotion from a list of three, whilst 'Facts and Guesses' aimed to address difficulties with jumping to conclusions in social situations by showing clients a photograph of a social situation and asking them to determine whether a given statement about the photo was a fact or a guess. Confidence in answers was also assessed in order to encourage flexible thinking."
223572381|NCT00916058|DRUG|Bendamustine|30 mg/m\^2 given on day 2 of melphalan
223572382|NCT00916058|DRUG|Melphalan|100 mg/m\^2 for 2 days (70 mg/m\^2 for patients with Creatinine Clearance \<70 ml/min)
223572383|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 2nd day of melphalan
223572384|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 2nd day of melphalan
223572385|NCT00916058|DRUG|Bendamustine|60 mg/m\^2 given on the 1st and 2nd day of melphalan
223572386|NCT00916058|DRUG|Bendamustine|90 mg/m\^2 given on the 1st day of melphalan and 60 mg/m\^2 given on the 2nd day of melphalan
223455576|NCT02018302|DRUG|Triheptanoin|
224150259|NCT01463657|DEVICE|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
224150260|NCT04795492|BEHAVIORAL|remote intervention|Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.
224150261|NCT04795492|BEHAVIORAL|Routine outpatient follow-up|Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.
224150262|NCT05462457|PROCEDURE|Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)|Intraoperative excision of TAD lymph nodes followed by ALND in the same surgical session or secondary surgical intervention
224150263|NCT00446758|DIETARY_SUPPLEMENT|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
224150264|NCT05660889|OTHER|Blood sampling.|Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
224150265|NCT03295604|PROCEDURE|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
224150266|NCT03295604|PROCEDURE|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
223455577|NCT04529317|DIETARY_SUPPLEMENT|Quinoa and quinoa-based food|"Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records."
223455578|NCT02611765|DRUG|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
223455579|NCT02611765|DRUG|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
223455580|NCT04087369|OTHER|Bundled NCD WHO PEN Intervention|In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
223455581|NCT02432209|OTHER|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
223455582|NCT02432209|DRUG|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
223455583|NCT02432209|OTHER|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
223455584|NCT06222177|DIAGNOSTIC_TEST|Pathophysiologic evaluation|High-resolution manometry and pH study
223455585|NCT06099925|DRUG|Hetrombopag|All the recruited 48 patients will take hetrombopag 5mg/day within 24 hours after chemotherapy
223455586|NCT00311922|BEHAVIORAL|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
223455587|NCT00311922|BEHAVIORAL|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
223455588|NCT05295199|OTHER|Progressive relaxation exercise|Progressive relaxation exercise is a type of exercise that involves voluntary stretching and relaxation of major muscle groups in the human body, from the hands to the feet.
223572387|NCT00916058|DRUG|Bendamustine|125 mg/m\^2 given on the 1st day of melphalan and 100mg/m\^2 given on the 2nd day of melphalan
223572388|NCT01984645|OTHER|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
223572389|NCT03267173|DRUG|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
223572390|NCT00871117|BIOLOGICAL|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
223742955|NCT03447808|DRUG|Ibrutinib|Given PO
224150267|NCT03746067|DRUG|TS-134|5 mg, 10 mg, or 20 mg oral solution
224150268|NCT03746067|DRUG|Placebo|Matched Placebo oral solution
224150269|NCT00000196|DRUG|Naltrexone|
224150270|NCT05366530|OTHER|Biomarkers, electrocardiographic imaging, intracardiac electrograms, cardiac magnetic resonance imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
224150271|NCT03718702|OTHER|ePain|Electronic pain management programme (ePain)
224150272|NCT05135351|DIETARY_SUPPLEMENT|Resistant Starch|A prebiotic nutritional supplement available at commercial grocery and health food stores. Specifically, we will be using Bob's Red Mill® potato starch.
224150273|NCT05135351|DIETARY_SUPPLEMENT|Maltodextrin|A starch commonly used as a placebo in prebiotic trials that is digested in the stomach and rapidly absorbed
224150274|NCT03009812|PROCEDURE|Longitudinal uterine incision|
224150275|NCT03009812|PROCEDURE|Transverse uterine incision|
223572391|NCT00871117|BIOLOGICAL|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
223572392|NCT00871117|BIOLOGICAL|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
224064914|NCT04769960|BEHAVIORAL|Patient Reported Outcomes|Participants will fill out questionnaires before, immediately after, and approximately 3 months following the MRI examination +/- 1 month to evaluate for any pain or perceived changes with the breast tissue expander. The first questionnaire will obtain background participants information as well as establish a baseline pain level, the second questionnaire will evaluate any changes in pain after undergoing the MRI examination, and the last questionnaire will evaluate long term changes in pain. The patient reported outcome questionnaire will be optional at 3 months post-MRI +/-1 month.
224064915|NCT06675617|DEVICE|Allay Aortic Stent|Endovascular treatment of an aortic dissection
224064916|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
224064917|NCT01260012|OTHER|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
224064918|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
224064919|NCT01260012|DIETARY_SUPPLEMENT|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
224064920|NCT07006454|PROCEDURE|Ventro-Cephalic Translatoric Glide|"Participants of group A will receive ventro-cephalic translatoric glides, total of 3 sets with 15 repetitions per set.~PROCEDURE:~1. Patient sits on low chair with back straight and therapist stand facing the patient's right side.~2. Therapist's stable hand: with the thumb and index finger of left hand fixate caudal vertebra.~3. Therapist's moving hand: therapist will place his/her right hand on left side of patient's head and cervical spine than place little finger around cranial vertebra of segment to be moved.~4. Apply glide in ventro-cranial direction in the right angle of the treatment plane of the facet joint."
224064921|NCT07006454|PROCEDURE|Dorso-Caudal Translatoric Glide|"Participants of group B will receive Dorso-caudal translatoric glides, total of 3 sets with 15 repetitions per set.~PROCEDURE:~1. Patient sits on low chair with back straight and therapist stand facing the patient's left side.~2. Therapist's stable hand: with the thumb and index finger of right hand fixate caudal vertebra.~3. Therapist's moving hand: therapist will place his/her left hand on right side of patient's head and cervical spine than place little finger around cranial vertebra of segment to be moved.~4. Apply glide in dorso-caudal direction in the right angle of the treatment plane of the facet joint."
224064922|NCT07020858|DIAGNOSTIC_TEST|FAPl lmaging|Studies have shown that imaging with radionuclide-labeled fibroblast activation protein inhibitor (FAPl) is a reliable technique for detecting myocardial fibrosis and activated CFs in arteries. Preliminary evidence suggests that FAPl imaging can assess plaque characteristics and the status of myocardial fibrosis in various cardiovascular diseases.
224064923|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） Low Dose|
224064924|NCT01411254|DRUG|Betamethasone Microsphere (DE-102） High Dose|
224064925|NCT01411254|DRUG|Sham|
224064926|NCT06099964|BEHAVIORAL|Pain Coping Information|A 4-minute audio recording providing common pain coping techniques (e.g., ice, rest, medication, surgery).
224064927|NCT06099964|BEHAVIORAL|Mindful Pain Management|A 4-minute audio recording consisting of a 1-minute introduction to mindfulness followed by a 1-minute and 30-second mindful breathing practice and a 1-minute and 30-second mindfulness of pain practice.
224064928|NCT06692075|PROCEDURE|extracorporeal life support|ECMO supported life support for cardiopulmonary resuscitation in refractory OHCA
224064929|NCT06692075|PROCEDURE|standard ACLS|Standard ACLS in cardioplumonary resuscitation of refractory OHCA
224064930|NCT06629753|BEHAVIORAL|Differentiated service delivery model|The differentiated service delivery (DSD) intervention is a clinic-level intervention in which PMTCT clients are differentiated into those who are clinically stable or unstable, with each group offered a different package of services to meet their needs. The DSD model that is being tested in this study is an individual-focused, facility-based model designed for implementation within maternal-child health clinics offering integrated HIV services.
224064931|NCT07027904|DEVICE|Implant|The immediate implant was placed, and the surrounding cavity was filled with xenograft bone material, along with the application of hyaluronic acid or platelet-rich fibrin (PRF) to enhance healing and bone integration.
224064932|NCT07028892|DEVICE|A gamified mobile learning|There will be a gamified environment in a mobile application with case scenarios on pressure injury prevention designed by researchers.
224064933|NCT07028892|OTHER|Booklet training|Nurses will receive training via a booklet about prevention of pressure injuries.
224064934|NCT07029867|DRUG|Yishen Daluo Yin granuls|The patient takes YSDLY granules or placebo twice a day.
224064935|NCT07029867|DRUG|Placebo|The patient takes placebo (YSDL mimetic granules) twice a day.
224064936|NCT07030023|OTHER|Non intervention|Non intervention
223742956|NCT03447808|OTHER|Laboratory Biomarker Analysis|Correlative studies
223742957|NCT03447808|OTHER|Pharmacological Study|Correlative studies
224064937|NCT07029893|BEHAVIORAL|Independent Life Skills Program (ILSP)|The ILSP runs for 14 weeks, covering six areas of independent living skills and 14 weekly sessions lasting 2 hours each. The program will run in a group format with 4 participants in each group. The ILSP will be run by occupational therapists who are trained in the program delivery.
224064938|NCT07029893|OTHER|Wait-list control|Participants do not receive the experimental treatment and will be put on a waiting list to receive the intervention after the active treatment group does.
224064939|NCT07029243|BEHAVIORAL|HEAL-ME digital app|HEAL-ME is a digital prehabilitation app that provides semi-guided nutrition/exercise prehabilitation
223572393|NCT06488612|PROCEDURE|Minced skin grafts for donor site|"After harvesting of STSG using watson's knife and coverage of the recipient site, the excess graft edges will be trimmed and together with any unused graft pieces will be collected in saline filled plate to prevent graft dissecation. Graft pieces will be placed over a rigid surface such as dorsum of a stainless steal jar or pot. Mincing of these small grafts will be done manually using large blade (no. 25) and sharp scissors. The resulting pasty graft mass composed of a large number of minced skin graft particles and a small amount of saline solution will be spread onto one half of the donor site using small dressing forceps.~Minced skin grafts will not be used on the other half (control side). The entire donor site will be covered with non-adherent absorbable dressing in the form of Vaseline gauze and sterilized cotton-filled dressing followed by elastic compression bandage."
223742958|NCT02882555|BEHAVIORAL|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
224064940|NCT07029243|DIETARY_SUPPLEMENT|Creatine supplementation|Patients will take 5g creatine supplementation daily for 13 weeks
224064941|NCT07029243|DIETARY_SUPPLEMENT|Whey protein supplementation|Patients will take 35g whey protein supplementation daily
224064942|NCT07029243|DIETARY_SUPPLEMENT|Placebo|Patients will be administered daily placebo supplementation.
224064943|NCT07028203|DEVICE|Treatment with BTL-785 with the applicator BTL-785-7-11|The treatment administration phase will consist of four (n=4) treatments, delivered 2 -14 days apart. The applicator will be placed outside the orbital rim, on the subject's inferior orbital portion of the orbicularis oculi muscles and lateral canthal edge-temporal area. Therapy time is set to 20 minutes.
224064944|NCT07029074|DEVICE|Sham inspiratory muscle training (MIP 0%)|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
224064945|NCT07029074|DEVICE|MIP 30% inspiratory muscle training|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
224064946|NCT07029074|OTHER|MIP 70% inspiratory muscle training|POWERbreathe Wellness (POWERbreathe International Ltd.., England, UK) device will be used for inspiratory muscle training.
224064947|NCT07029477|DEVICE|Incentive Spirometry|Participants received incentive spirometry therapy using a standard device beginning within 2 hours post-laparoscopic cholecystectomy. They were instructed to take 10 deep breaths every 2 hours for 12 hours.
224064948|NCT07029477|BEHAVIORAL|Massage Therapy|Participants received manual massage therapy at regular intervals of 4, 8, and 12 hours after laparoscopic cholecystectomy.
224064949|NCT07028216|BEHAVIORAL|Mindful Self-Compassion|The course teaching mindfulness meditation skills relevant to cultivating self-compassion.
224064950|NCT07029880|OTHER|full veneered metal ceramic dental prosthesis cemented with resin cement|full veneered metal ceramic dental prosthesis cemented with resin cement
224064951|NCT07028580|OTHER|Diet based on animal proteins|Ιntervention with a diet based on animal proteins.
224064952|NCT07028580|OTHER|Diet based on plant proteins.|Ιntervention with a diet based on animal proteins.
224064953|NCT07028580|OTHER|General instructions for patients with liver disease.|Α brochure with general instructions was designed for patients with liver disease.
224064954|NCT07029191|OTHER|Progressive standing test|Progressive raising test in successive steps in a healthy subject
224064955|NCT07029256|OTHER|Non-Interventional Study|Non-interventional study
224064956|NCT07029958|DRUG|recombinant humanized anti-CD25 monoclonal antibody|"For children at high risk of GVHD, one of the following conditions must be met (haploidentical donors must meet one condition, while unrelated donors must meet two conditions):~1. The donor is ≥40 years old;~2. The donor is an unrelated donor with ≥1 locus mismatch, a haploidentical female donor, or collateral consanguinity (e.g., cousin, uncle/aunt);~3. Pre-transplant CD3 count ≥4 x 10\^8/kg;~4. The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase;~5. ATG (or biologically equivalent doses of ATLG \[1:2\] or ALG \[1:20\]) \<10mg/kg. Combining recombinant anti-CD25 humanized monoclonal antibody with conventional pretreatment regimen, before peripheral blood stem cell transfusion (i.e. 0d) and+3d, 1mg/kg，\<40kg the maximum dose should not exceed25mg/dose, ≥40kg 1mg/kg, and the maximum dose should not exceed 50mg/dose."
224064957|NCT07027852|BEHAVIORAL|My Lung Health Coach|Virtual education and self-management program with companion application
224064958|NCT07029386|DEVICE|tES|"his study employs a randomized controlled trial (RCT) design, randomly dividing eligible participants into a neuromodulation group and a sham neuromodulation group.~Neuromodulation Group:~Receive individualized transcranial electrical stimulation (tES) treatment Combined with cognitive training~Stimulation parameters:~Total current: approximately 2mA Duration: 21 minutes Electroencephalogram (EEG) and functional MRI (fMRI) monitoring before and after electrical stimulation"
224064959|NCT07029386|DEVICE|tES|Use the same device and procedure as the neuromodulation group Stimulation device automatically turns off after 30 seconds Maintain device connection Design creates similar initial sensations to actual stimulation Maintains the double-blind nature of the study
224064960|NCT07028814|OTHER|Risk-informed obesity care plan|A risk-informed obesity care plan, implemented through pediatric primary care provider training via a Virtual Learning Collaborative (VLC) will be deployed.
224064961|NCT07028255|DIETARY_SUPPLEMENT|Qualia Testosterone|Qualia Testosterone manufactured by Qualia Life Sciences
224064962|NCT07028255|DIETARY_SUPPLEMENT|Placebo|Rice Flour
224064963|NCT06706245|BEHAVIORAL|SET-VR (computer)|Low-immersive version of the SET-VR program
224064964|NCT06706245|BEHAVIORAL|SET-VR (headset)|High-immersive version of the SET-VR program
224064965|NCT07028060|DEVICE|PulseNmore MC™|novel mobile Self-scan ultrasound device, Pulsenmore MC™
224150276|NCT06437145|OTHER|Type of Exercise|The high-intensity interval training session consists of 5-min warm-up and 5-min cool-down periods. The main part has 7 cycles. Each cycle consists of 1.5 min of 80-90% of HRpeak and 3 min of 65-70% of HRpeak. The moderate-intensity continuous training session consists of 5 min warm-up and 3-min cool down period. The main part consists of 32 min of 75% of HRpeak.
224150277|NCT02958904|OTHER|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
224150278|NCT02993458|OTHER|DASH diet|DASH style diet rich in fruits, vegetables, and low-fat dairy foods and low in saturated fat and total fat
224150279|NCT02993458|OTHER|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
224150280|NCT02993458|OTHER|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
223455589|NCT02106741|BEHAVIORAL|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
223455590|NCT02106741|BEHAVIORAL|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
223455591|NCT04877418|PROCEDURE|TeleCIMT|Mode applied remotely, through the principles and components of the CIMT protocol.
223455592|NCT01486823|DRUG|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
223455593|NCT01486823|DRUG|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
223455594|NCT04035122|OTHER|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
223455595|NCT04035122|OTHER|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
223455596|NCT01720485|DRUG|Desloratadine + Prednisolone|1 tablet 3 times a day
223455597|NCT01720485|DRUG|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
223455598|NCT01087203|BIOLOGICAL|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
223455599|NCT01087203|BIOLOGICAL|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
223455600|NCT06272825|OTHER|Virtual reality|VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.
223455601|NCT06272825|OTHER|conventional rehabilitation|The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
223455602|NCT05720429|OTHER|Psychoeducational program|"A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art."
223742959|NCT02882555|DRUG|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
224064966|NCT07028931|BEHAVIORAL|Visualization technique|In GROUP A, i.e., visualization technique Athletes will be shown a video of stretching protocols and then will be asked to visualize those exercises, the total session time will be approximately 20 minutes which will be divided into three phases: pre-Session visualization (5-10 minutes) which will begin with 1-2 minutes of deep breathing and mental preparation to start visualization technique then players will be asked to visualize dynamic stretching (leg swings, arm circles, and lunges) and static stretching (hamstring and shoulder stretch) for 2-3 minutes each. Then begins the during session visualization phase (1-2 minutes per stretch) the players will be asked to pause before each stretch to visualize the movements, muscle engagement and the feeling of stretch and the transit between the stretches and then last comes the post session phase of visualization (5 minutes) this will involve visualization of cool down exercises like spinal twist, bicep stretch, triceps and hip stretch.
224064967|NCT07028931|OTHER|Combined Stretching Protocol|GROUP B will receive Combined stretching training protocol. The overall duration will be 20 minutes starting from warm up (5-7 minutes) which will include light jogging arm swings, leg swings and lunges, hamstring and shoulder stretches then followed by combined stretching movements (8-10 minutes) this will include hip flexor and hamstring combo, calf and Achilles stretch and spinal twist and arm extension movements and ending with a cool down protocol (5-7 minutes) which will include hip flexor stretch, quadriceps stretch and calf stretch, bicep and triceps stretch.
224064968|NCT07027891|DEVICE|AI-ECG|The patients in AI-ECG group would be managed with the information of the myocardial infarction risk score in AI-ECG in addition to the usual care.
224150281|NCT02993458|OTHER|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
224150282|NCT03258632|BEHAVIORAL|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
224150283|NCT03169049|DEVICE|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224150284|NCT03169049|DEVICE|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
224150285|NCT05647018|PROCEDURE|Primary Percutaneous coronary angiography|Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries in patients presenting with myocardial infarction, through which installment of stents or intracoronary injection of drugs can take place.
224150286|NCT03082053|DRUG|varlitinib|IMP
223572394|NCT04994782|BEHAVIORAL|GAME-EOL|The GAME-EOL involves Hello game booklets as well as meetings with an interventionist. Players (ICD recipient and their family member or friend dyad) take turns asking the questions in their booklet and providing their answers to the question. The gameplay continues until all questions are answered or the dyad wishes to stop. Following the completion of the game play, participants will be offered the opportunity to complete advance directives using the conversation guide and advance directive form included in the conversation guide that accompanies the questionnaire booklet.
224150287|NCT03082053|DRUG|capecitabine|Companion Medication
224150288|NCT01241019|DRUG|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
224150289|NCT03486210|BEHAVIORAL|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
224150290|NCT03486210|OTHER|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
224150291|NCT04871581|DEVICE|NTI-tss|FDA cleared device for prophylactic treatment of medically diagnosed migraine pain
224150292|NCT04871581|DEVICE|Placebo|Similar to Device, but having no influence on clenching intensity
224150293|NCT03094832|DRUG|Miransertib|Miransertib capsules administered orally at an initial dose of 15 mg/m\^2 or 25 mg/m\^2 QD and then titrated up to 25 mg/m\^2 or 35 mg/m\^2 QD at the investigator's discretion.
224150294|NCT03780491|OTHER|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
223572395|NCT01702090|DRUG|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
224150295|NCT04350905|OTHER|Mosquito Feeding|Mosquito feedings will be conducted with Aedes aegypti colonies raised at the CNM (National Malaria Center) Malaria and Vector Research Laboratory (MVRL), an established state of the art insectaries for mosquitoes was built in 2014 to ACL2 (arthropodcontainment level 2)-level specifications.
224150296|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01|high brightness LED light box
224150297|NCT04721574|DEVICE|Philips EnergyUp Energy light HF3418/01 with filter|high brightness LED light box with filters that reduced lamp output to less than 50 lux
223455603|NCT00768287|BIOLOGICAL|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
223455604|NCT00768287|BIOLOGICAL|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
223455605|NCT03731390|DRUG|GR1405 injection|Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
223455606|NCT04285905|OTHER|Access to Fast Track TB clinic|Male partner can attend clinic with dedicated services for men
223455607|NCT04285905|OTHER|Information leaflet for male partner|Female participants will be provided with a letter asking their male partner to attend the clinic for tuberculosis screening
223455608|NCT04285905|OTHER|Home sputum collection|Female participants will be provided with sputum cups to take home and collect a sample of sputum from their male partner
223455609|NCT04285905|OTHER|Home HIV testing|Female participants will be provided with an oral HIV self-test kit to be given to their male partner with instructions for use
223455610|NCT04285905|OTHER|Financial incentive|Female participants will be provided with a voucher for MKW5000 which can be redeemed when the male partner attends the clinic for TB testing
223455611|NCT01462864|BEHAVIORAL|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
223455612|NCT01816932|PROCEDURE|Home Visit|The intervention is the location of the insertion visit.
224064969|NCT07028307|OTHER|Breathing Exercises|"Ujjai: While the mouth is closed, a hissing sound is made until the space between the throat and lungs is filled with breath, and a slow and deep inhalation is made. Then, without holding the breath, a long and full exhalation is made through a partially closed glottis and a slight laryngeal muscle contraction, and the same sound is made. In each session, two sets of ujjayi technique were applied, with an inhalation:exhalation ratio of 1:2 and 10 respiratory cycles, with a 1-minute rest period between sets.~Sukha Pranayama: Applied for 5 minutes with a 5:5 inhalation:exhalation ratio of 6 breaths per minute.~Nadi Shodhana: After closing the right nostril with the thumb of the right hand, a slow and deep inhalation is performed through the left nostril. After maximum inhalation, without holding the breath, the left nostril is closed with the fourth finger of the right hand and a full exhalation is performed through the right nostril. Maintaining the closed position of the left nostr"
223455613|NCT01816932|PROCEDURE|Office visit|
223455614|NCT01789801|PROCEDURE|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
223455615|NCT01789801|PROCEDURE|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
223455616|NCT00065273|DRUG|risperidone|
223455617|NCT00065273|DRUG|clozapine|
223455618|NCT00065273|DRUG|olanzapine|
223455619|NCT00470561|DRUG|Aspirin|Two 325 mg doses of aspirin per day for 6 months
223455620|NCT00470561|DRUG|Placebo|Two placebo pills per day for 6 months
224064970|NCT07028307|OTHER|Breathing Exercises + Kinesio Taping Group|The tape was not removed for 5 days from the day of the procedure, but was removed after the 5th day, allowing the skin to rest for 2 days, and then repeated for 4 weeks with a new kinesio tape application. The tapes of those who stated that there was wear or tear on the tape were renewed within a week. After the skin was cleaned with alcohol, the kinesio tape application was applied bilaterally as an I tape with 25-50% tension on the paraspinal muscles from the 7th cervical vertebra to the 12th thoracic vertebra. The I tape was applied horizontally with 50% tension to the point where the kyphotic area was clearly observed. All strips were rubbed to increase adhesion to the skin and activate the tape.
224064971|NCT07029165|OTHER|Acute exercise|Participants will lie in a semi-supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise at steady state for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
224064972|NCT07029165|OTHER|Cold pressor test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
224064973|NCT07029165|OTHER|Mental stress test|Participants will lie in a semi-supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will be instructed to state their answers as quickly and accurately as possible. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
224064974|NCT06737627|OTHER|no intervention|no intervention
224064975|NCT06744296|OTHER|Blood Draws and Tissue Sample(s)|All participants on the study, regardless of arm, will be getting blood draws, and tissue samples.
224064976|NCT06833502|OTHER|CT Scan|Participants will undergo a screening CT thorax, abdomen, pelvis at baseline prior to adjuvant radiation therapy and additional screening CT thorax, abdomen, and pelvis at 6 months if the baseline CT is found to be negative.
224064977|NCT06895993|DRUG|Ferric Carboxymaltose Injection|For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 2 mL: 100 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 1 min, with a speed of 2 mL/min.
224064978|NCT06895993|DRUG|Ferric Carboxymaltose Injection [Injectafer®]|For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Injectafer®) (R, 2 mL: 100 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 1 min, with a speed of 2 mL/min.
224064979|NCT02433652|BIOLOGICAL|Recombinant live attenuated trivalent dengue vaccine|Contains 10\^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10\^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10\^3.0 PFU of each component.
224064980|NCT02433652|BIOLOGICAL|Placebo|
224064981|NCT02433652|BIOLOGICAL|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10\^3 PFU
223455621|NCT02748629|DEVICE|Covidien Parietex ProGrip Self-Fixating Mesh|
224150298|NCT00788697|DRUG|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
224150299|NCT00788697|OTHER|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
224150300|NCT01998880|DRUG|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
224150301|NCT01998880|DRUG|rituximab|375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
224150302|NCT01998880|DRUG|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
224150303|NCT01473329|OTHER|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
224150304|NCT02745301|OTHER|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
224150305|NCT03949140|PROCEDURE|Laser hair removal|Those who consent to participate in the study will be treated with up to 8 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
224150306|NCT03655392|BEHAVIORAL|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
224150307|NCT03655392|DIAGNOSTIC_TEST|Induced sputum collection|All participants performed induced sputum collection
224150308|NCT03655392|DIAGNOSTIC_TEST|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
224150309|NCT03655392|DIAGNOSTIC_TEST|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
224150310|NCT03655392|OTHER|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
224150311|NCT03655392|OTHER|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
224150312|NCT03655392|DIAGNOSTIC_TEST|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
223455622|NCT02748629|DEVICE|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
223455623|NCT05450172|OTHER|QoR-15 questionnaire|The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
223455624|NCT06048393|DRUG|SA55 nasal spray|"The novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray (SA55 nasal spray) is provided by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The main component of this product is the novel coronavirus broad-spectrum neutralizing antibody, which is a colorless to pale yellow solution. Each milliliter contains 5mg of broad-spectrum neutralizing antibody against novel coronavirus. Excipients include histidine hydrochloride, arginine hydrochloride, histidine, sucrose, polysorbate 80 (II), hydroxypropyl cellulose, glycerol, and benzalkonium chloride (concentration 0.005%).~20 sprays per bottle, approximately 100 sprays per bottle μ L. Containing 0.5 mg of broad-spectrum neutralizing antibody against novel coronavirus."
223455625|NCT02984644|DRUG|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
223455626|NCT02984644|DRUG|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
223455627|NCT01547052|BEHAVIORAL|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
223455628|NCT01547052|BEHAVIORAL|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
223455629|NCT00360009|PROCEDURE|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
223455630|NCT00360009|PROCEDURE|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
223455631|NCT02414217|BEHAVIORAL|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
223455632|NCT02414217|BEHAVIORAL|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
223455633|NCT04074330|DRUG|TAK-981|TAK-981 intravenous infusion.
224150313|NCT03655392|DIAGNOSTIC_TEST|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
224150314|NCT01977339|DRUG|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
224150315|NCT01977339|DRUG|Bupivacaine|20 cc of 0.25% bupivacaine
224150316|NCT04588831|DEVICE|Mouthguard|Protective device for orofacial complex for patients playing contact sports
224150317|NCT03384524|DRUG|Bromocriptine 2.5 MG|Administered daily
224150318|NCT03384524|DRUG|Metoprolol 25 MG|Administered daily
224150319|NCT03384524|DRUG|Tamsulosin 0.4 MG|Administered daily
224150320|NCT03384524|OTHER|Placebo|Three pills, matching active drugs to be administered daily
224150321|NCT06524596|DRUG|tartaric acid butorphanol|The group received 0.02 mg/kg tartaric acid butorphanol intravenously over 5 minutes, 30 minutes before anaesthesia induction
224150322|NCT06524596|DRUG|normal saline|The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
224301821|NCT06295848|BEHAVIORAL|Exercise|An individual program will be organized for each patient according to the exercise test result. Since the patients have both arthritis and HTN, aerobic exercises will be given at moderate intensity (40-60% VO2 reserve) according to ACMS recommendations. Xrcise Runner Med treadmill and Xrcise Care 2.5.8.3 software will be used for aerobic exercises. Resistant exercises will be given under the supervision of a physiotherapist, calculating 1 repetitation maximum (1-RM) in the main muscle groups.Patients will perform isotonic exercises with 3 sets of 15 repetitions with a resistance of 60% of 1-RM. The education sessions will be conducted by a multidisciplinary team of health professionals (nurse, physiotherapist and dietician) under the leadership of a clinician experienced in CR. Education topics will consist of 60-minute sessions covering heart-healthy eating, setting health-related goal, exercise, diet, healthy weight loss, smoking cessation, and stress/coping.
224301822|NCT02175316|DEVICE|Enhanced External Counterpulsation|Enhanced External Counterpulsation
223572396|NCT06225024|DEVICE|ESWT|Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
224150323|NCT06524596|DRUG|propofol and remifentanil|Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
224150324|NCT05317013|DRUG|CBD|CBD
224150325|NCT05317013|OTHER|Placebo|Placebo
223455634|NCT04074330|DRUG|Rituximab|Rituximab intravenous infusion.
223455635|NCT03643302|DEVICE|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of airway clearance and bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
223455636|NCT04110886|DRUG|HSK21542|Single dose, injection, starting dose of 0.2ug escalating up to 20ug
223455637|NCT04110886|DRUG|Placebo|Single dose, injection matching placebo
224150326|NCT04613999|DRUG|Ralinepag|"Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose."
224150327|NCT02266732|DEVICE|Stimuplex HNS 12|
224150328|NCT05606978|BEHAVIORAL|FASTb|FAST blended
223455638|NCT04288427|DRUG|Finasteride|Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
223455639|NCT00184093|DRUG|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
223455640|NCT05056155|OTHER|Systane Complete|Propylene glycol 0.6% eye drops for replenishing deficiencies in both the lipid and aqueous layers of the tear film
223455641|NCT03620383|PROCEDURE|Topical Heat|Warm heat pack applied topically in participant hand.
223455642|NCT00005802|BIOLOGICAL|aldesleukin|
223455643|NCT00005802|BIOLOGICAL|filgrastim|
223572397|NCT06225024|DRUG|BoNT A|BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
223572398|NCT02125916|OTHER|oxygen therapy|
223572399|NCT00869804|BEHAVIORAL|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
224150329|NCT05606978|BEHAVIORAL|FASTr|FAST regular
224150330|NCT02671461|DRUG|BMS-986141|
224150331|NCT02671461|DRUG|Aspirin|
224150332|NCT02671461|OTHER|Placebo|
224150333|NCT03831893|OTHER|Nopal food product 1|Dried Nopal incorporated in a food product
224150334|NCT03831893|OTHER|Nopal food product 2|Dried Nopal incorporated in a food product
224150335|NCT03831893|OTHER|control|Food Product without nopal
224301823|NCT02447796|DRUG|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
224301824|NCT02447796|DRUG|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
224301825|NCT02894281|DEVICE|pupillary light reflex|measure with infra-red cameras
224150336|NCT05657951|DEVICE|ArcScan Insight 100 very high-frequency digital ultrasound|The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
224150337|NCT00517283|DRUG|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
224150338|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
224150339|NCT00517283|DRUG|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
224150340|NCT02562183|DRUG|kallikrein|Using kallikrein
224150341|NCT02037451|PROCEDURE|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
224150342|NCT01412060|DRUG|Placebo|Placebo was supplied in capsules.
224150343|NCT01412060|DRUG|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
224150344|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
224150345|NCT01892644|OTHER|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
224150346|NCT01892644|DRUG|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
224150347|NCT01043848|PROCEDURE|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
224150348|NCT04712266|DRUG|Glucagon|calculated IV insulin:Glucagon molar ratio
224150349|NCT04712266|DRUG|Insulin|calculated IV Insulin dose infused at a constant rate
224150350|NCT00048789|PROCEDURE|Extracorporeal Photopheresis|
224150351|NCT01752439|DEVICE|Anodal transcranial direct current stimulation|
224150352|NCT01752439|DEVICE|Sham transcranial direct current stimulation|
224150353|NCT04643665|PROCEDURE|Double-lung transplantation|
224150354|NCT00629525|DRUG|RAD001|RAD001 at a dose of 10 mg PO daily
224150355|NCT01469572|DRUG|Pasireotide|Pasireotide is given as an injection.
224150356|NCT01469572|PROCEDURE|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
224150357|NCT01469572|DRUG|Everolimus|Given orally every day for the duration of the study
224150358|NCT02219841|PROCEDURE|radiofrequency catheter ablation|
224150359|NCT06206902|DRUG|After preconditioning with chemotherapy, F01 will be evaluated.|Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
224150360|NCT03159806|DEVICE|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
224150361|NCT03303287|BEHAVIORAL|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
224150362|NCT00004732|PROCEDURE|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
224150363|NCT00004732|DEVICE|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
224150364|NCT04696237|OTHER|Questionnaire|a questionnaire to provide data about the management of cleft lip and palate patients in Egypt will be designed
224301826|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
223455644|NCT00005802|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223455645|NCT00005802|DRUG|cytarabine|
223455646|NCT00005802|DRUG|etoposide|
223455647|NCT00005802|DRUG|fludarabine phosphate|
223455648|NCT00005802|DRUG|methotrexate|
223455649|NCT00005802|DRUG|mitoxantrone hydrochloride|
223455650|NCT00005802|DRUG|therapeutic hydrocortisone|
223572400|NCT00869804|BEHAVIORAL|Attention control|
223572401|NCT04480190|DRUG|Gemcitabine|IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
223572402|NCT04480190|DRUG|Cisplatin|IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
223572403|NCT04480190|DRUG|Fluorouracil|Infusional 5-FU 225 mg/m2/d via Continuous IV infusion, to be given Days 1-5 and 8-12 during RT
223572404|NCT04480190|RADIATION|Short course ChemoRT|"Radiation Therapy:~Sim: All patients will undergo 4D-CT simulation with 3 hours fasting with or without IV contrast. Compression may be used depending on the tumor motion.~Radiation Target Volume: The gross tumor volume (GTV) will be defined on all relevant imaging datasets including diagnostic CT, MRI, MRCP and/or ERCP data. An iGTV will be generated using the 4D datasets. The clinical target volume (CTV) will include the entire iGTV as well as portal lymphatic and celiac nodal space for all patients with selective treatment of the SMA and pancreaticoduodenal depending on the tumor location. A 5 mm margin will be added to the CTV to generate the planning target volume (PTV).~Radiation Dose: The dose will be 30 Gy in 10 fractions (3 Gy per fraction) for all patients using either 3D Conformal or Intensity Modulated Radiation Therapy techniques."
223572405|NCT01108432|OTHER|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
223572406|NCT04775927|OTHER|education|premarital education
223572407|NCT00391677|BEHAVIORAL|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
223572408|NCT00391677|BEHAVIORAL|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
223572409|NCT03897296|DIAGNOSTIC_TEST|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
223572410|NCT03933410|DRUG|KB195|KB195 is a novel glycan
223572411|NCT01317537|OTHER|Electronic personal health record|
223572412|NCT05785637|PROCEDURE|Polygraphy diagnostic at home|Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.
223572413|NCT03444766|DRUG|Nivolumab|specified dose on specified days
223572414|NCT01767493|DRUG|[18F]Florbetapir PET imaging|\[18F\]Florbetapir and PET imaging
224064982|NCT06862752|PROCEDURE|erector spine plane (ESP) block|Bilateral ultrasound guided erector spine plane (ESP) block will be performe preoperatively at T5 level. 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL serum physiologic % l) will be injected deep to the erector spinae muscle.
224064983|NCT06862752|PROCEDURE|Serratus Anterior Plane Block|Bilateral ultrasound guided serratus plane block with 20 ml %0,25 bupivacaine at the midaxillary 5. Rib
224064984|NCT06883747|DRUG|BMS-986504|MTA cooperative PRMT5 inhibitor
224064985|NCT05202106|BEHAVIORAL|Home visits|Home visits entail a visit a children's home every two weeks. During this visit, trained child development agents will engage parents in activities with the child and provide basic toys and learning materials.
224064986|NCT05202106|OTHER|Afini App|Afini is an app designed to help parents provide nurturing environments and stimulation to their young children. Most caregivers currently connect to the platform via Facebook Messenger; once they sign up, the platforms start engaging the caregiver by recommending age-specific health- and development-promoting activities. Rather than just hoping that caregivers will later engage in these activities, the virtual assistant directly observes whether caregivers access the materials for the recommended activity, and asks caregivers to provide feedback on each task.
224064987|NCT06845423|DRUG|Low molecular weight heparin|"Pharmacological thromboprophylaxis using LMWH at preventive dosage. The choice of subcutaneous LMWH depends on the practice of each center:~* Enoxaparine 4000 UI (weight \> 90 kg 6000 UI)~* Tinzaparine 3500 UI (weight \> 90 kg 4500 UI)~* Dalteparine 5000 UI (weight \> 90 kg 7500 UI)~* Nadroparine 2850 UI (weight \> 90 kg 3800 UI)."
224064988|NCT03744390|DRUG|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
224064989|NCT00202787|DRUG|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
224064990|NCT00202787|DRUG|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
224064991|NCT00240409|DRUG|Pramipexole|
224064992|NCT00240409|DRUG|Bromocriptine|
224064993|NCT04044300|PROCEDURE|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
224064994|NCT04044300|OTHER|Conservative|Continued pain management and physical therapy.
224064995|NCT03837639|OTHER|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
224150365|NCT03742115|DRUG|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
224150366|NCT03742115|DRUG|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
224150367|NCT03742115|DRUG|Etoposide|150 mg/m2 weekly
224150368|NCT03742115|DRUG|IVIG|0.5 g/kg, once every 4 weeks
224150369|NCT01183312|DRUG|Flumazenil|Sublingual flumazenil
224150370|NCT00442767|DRUG|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
224150371|NCT00442767|DRUG|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
224150372|NCT05279716|DRUG|Eybelis ophthalmic solution 0.002%|Ophthalmic eye drop
224150373|NCT00532714|DRUG|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
224150374|NCT03159819|GENETIC|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
224150375|NCT05247541|DRUG|Definity|Definity (Lantheus Medical Imaging, N Billerica, MA) in 50 mL of saline infused over 5-10 minutes
224150376|NCT01052519|OTHER|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
224150377|NCT04373785|RADIATION|Intensity-modulated radiation therapy|Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
224150378|NCT04373785|DRUG|Temozolomide|"Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy.~1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles."
224150379|NCT04373785|DRUG|NG101m|Oral NG101m capsule continuously twice daily.
224150380|NCT04097015|DEVICE|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
224150381|NCT05950971|DRUG|Amiodarone, diltiazem or esmolol|Intravenous continuous infusion after loading or bolus dose of amiodarone, diltiazem or esmolol.
224150382|NCT04011800|PROCEDURE|Catheter ablation|Pulmonary vein isolation, or additional left or right-sided atrial lesions.
224150383|NCT04011800|COMBINATION_PRODUCT|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake with antiarrhythmic drugs
224150384|NCT02013128|DRUG|Ublituximab|Ublituximab (IV infusion)
224150385|NCT02013128|DRUG|Ibrutinib|Ibrutinib oral daily dose
224150386|NCT04457128|BEHAVIORAL|Just-in-Time Adaptive Intervention|Randomized factorial design
224150387|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
224150388|NCT03428451|DRUG|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
224150389|NCT03428451|DRUG|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
224150390|NCT01593228|DRUG|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
224150391|NCT01593228|DRUG|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
224150392|NCT01593228|DRUG|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
224150393|NCT01593228|DRUG|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
224150394|NCT01593228|DRUG|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
223455651|NCT00005802|RADIATION|radiation therapy|
223455652|NCT05095311|DRUG|Cetirizine HCl|Eight participants will be administered 10 mg of cetirizine HCl to examine whether this drug can improve their oxyhemoglobin saturation during exercise.
223455653|NCT05095311|OTHER|Placebo|The placebo pill is a sugar-free gelatin pill casing. The placebo inhaler contains isotonic saline.
223455654|NCT05838911|OTHER|Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)|The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.
223455655|NCT05838911|OTHER|Control Group Chest physical therapy|The patients in this group were received the chest physiotherapy program for 20 min each day, for five days a week for three consecutive weeks
223455656|NCT03328598|BEHAVIORAL|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
223455657|NCT03328598|BEHAVIORAL|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
223455658|NCT03328598|OTHER|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
223455659|NCT03941145|BEHAVIORAL|Reduced-Exertion High-Intensity Interval Training (REHIT)|REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
223455660|NCT02130388|DIETARY_SUPPLEMENT|Zinc|
223455661|NCT01925976|BEHAVIORAL|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
223455662|NCT00205998|DEVICE|Locking Compression Plate 2,4mm|
223455663|NCT00205998|DEVICE|Locking Compression Plate 3,5mm|
223455664|NCT05451394|OTHER|ROAF|"Use of the method Ressource Optimisation of Armed Forces (ROAF). 6 one-hour workshops"
224150395|NCT01593228|DRUG|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
224150396|NCT01593228|DRUG|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
224150397|NCT05500183|BEHAVIORAL|Cognitively enriched walking program|The PA+CA program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
223455665|NCT05451394|OTHER|Active Comparator|6 one-hour workshops on cognitive process
224150398|NCT05500183|BEHAVIORAL|walking program|The PA only program is group-based and will have a duration of six months (i.e. 24 weeks), with a frequency of two group sessions a week. All group sessions will last for approximately one hour and take place in groups of twelve or thirteen people supervised by a certified coach. Participants will be encouraged to do one individual session every week, as well.
224150399|NCT04286828|OTHER|Position Sense|Knee position sense was evaluated with a Acumar dual digital inclinometer. Each participant was asked to wear shorts and to lie down in supine position treatment table. The lower extremity of the participant was positioned in neutral for the knee flexion movement. The placement of the digital inclinometer's attachment was the lateral ridge of the femur and tibia. We actively assisted the participant's knee to the target angle and asked the participant to hold it there for 5 seconds before returning the knee to the starting position. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. This procedure was repeated 3 times for each limb (non-dominant and dominant). We measured the absolute difference between the target angle and the observed angle and calculated the absolute error score by averaging the 3 trials.
224150400|NCT04286828|OTHER|Balance|"To measure postural stability and Limits of Stability this study used a balance device, the Biodex Balance System.~Postural Stability: The participants were focused on a characteristic dot (COP, centre of pressure) on the monitor screen. The participant's task was to balance the body in such a way that the dot was in the centre of a circle displayed on the monitor at the point of intersection of the coordinate axes. Test consisted of three 20-second trials, each separated by 10-second breaks. Measurements were repeated three times while their eyes were open/close and analyzed by calculating the average value of measurements.~Limits of Stability: The participants are asked to complete the directional tasks displayed on a screen as quickly as possible, with the directions displayed at random. A total of 3 tests were performed, at intervals of 10 s."
224150401|NCT04286828|OTHER|Dual Task Performance|"The timed up and go test (TUG) was used in the evaluation of dual task performance. For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. TUG test was performed initially without task, and then with cognitive and motor tasks, respectively. Cognitive task given during the test is counting three backwards from 100 or counting the names starting with the letter A, and motor task given is to carry three glasses of water on a tray. The time elapses between standing up from the chair and sitting back to chair was recorded as the test result. As time increases, dual task performance decreases."
223455666|NCT00007995|BIOLOGICAL|filgrastim|
223455667|NCT00007995|BIOLOGICAL|recombinant interferon alfa|
224150402|NCT05622357|RADIATION|short course radiation therapy followed by 6 cycles of CAPOX then surgery|Short course RT 5 x5 Gy followed by 6 cycles CAPOX then surgery
224150403|NCT00815204|PROCEDURE|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
224150404|NCT00815204|PROCEDURE|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
224150405|NCT01530282|OTHER|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
224150406|NCT01530282|OTHER|Non invasive method|Non\_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
224150407|NCT02289274|DRUG|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
224150408|NCT02289274|DRUG|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
224150409|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
224150410|NCT01294982|DRUG|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
224150411|NCT01294982|DRUG|Placebo|Placebo Oral Capsules twice daily
224150412|NCT01441791|PROCEDURE|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
224150413|NCT02072382|DRUG|Metformin|metformin 850mg twice a day for eight weeks
224150414|NCT02072382|DRUG|Placebo|
224150415|NCT01564667|BEHAVIORAL|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
224150416|NCT05082506|BEHAVIORAL|Acupressure|Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher without lifting the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief.
224150417|NCT00897052|GENETIC|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
224150418|NCT00897052|OTHER|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
224301827|NCT05367518|DIETARY_SUPPLEMENT|Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)|Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
223455668|NCT00007995|BIOLOGICAL|sargramostim|
223455669|NCT00007995|DRUG|busulfan|
223455670|NCT00007995|DRUG|cyclophosphamide|
223455671|NCT00007995|DRUG|melphalan|
223455672|NCT00007995|PROCEDURE|autologous bone marrow transplantation|
223455673|NCT00007995|PROCEDURE|bone marrow ablation with stem cell support|
223455674|NCT00007995|PROCEDURE|peripheral blood stem cell transplantation|
223455675|NCT05859308|OTHER|Virtual Reality Pixel Plucker|A virtual reality task where participants wear the Virtual Reality headset and respond to targets.
223455676|NCT05859308|OTHER|Rock Steady Boxing|An in-person boxing class designed for individuals with Parkinson's disease.
224305105|NCT03627507|BIOLOGICAL|Engerix B|.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
224150419|NCT03161782|OTHER|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
224150420|NCT03161782|OTHER|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
224150421|NCT03161782|OTHER|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
224150422|NCT03161782|OTHER|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
224150423|NCT00960713|DRUG|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
224150424|NCT05569564|PROCEDURE|Ridge splitting followed by ossedensificaion|Ridge splitting followed by ossedensificaion with osseodensifying burs.
224150425|NCT05569564|PROCEDURE|Osseodensification|Pilot drill is used to make the initial osteotomy to the desired depth, then osseodensifying burs will be used in sequence, gradually wider diameter in a counterclockwise rotation and bouncing motion under profuse saline irrigation
224150426|NCT01683084|DRUG|Telmisartan|
224150427|NCT01683084|DRUG|Placebo|
224150428|NCT00191737|DRUG|Atomoxetine|
224150429|NCT00367432|DRUG|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
224150430|NCT03950999|OTHER|Placebo|Sugar pill
224150431|NCT00903370|PROCEDURE|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
224150432|NCT00903370|DEVICE|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
224150433|NCT02963415|BEHAVIORAL|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
224150434|NCT03683056|BEHAVIORAL|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
224150435|NCT02452177|DRUG|Vitamin D|
224150436|NCT04000347|DRUG|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
224150437|NCT04000347|DRUG|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
224150438|NCT05594433|DRUG|Lenograstim|Injection sub cutaneous of Lenograstim during 4 days, once per day
224150439|NCT00744848|DRUG|Bupivacaine HCl|100 mg Bupivacaine HCl
224150440|NCT00744848|DRUG|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
224150441|NCT02165345|DRUG|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (\<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (\>=) 30 kg: every 2 weeks; sJIA participants \<30 kg: every 2 weeks; sJIA participants \>/= 30 kg: once weekly
224150442|NCT03256409|OTHER|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
224150443|NCT03256409|OTHER|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
224150444|NCT05113498|DIETARY_SUPPLEMENT|(-)-Epicatechin|Administration of a capsule with 150 mg of pure (-)-epicatechin after 48h low-flavanol diet.
224150445|NCT05599698|OTHER|Chemotherapy|Standard chemotherapy protocols for adjuvant \& neoadjuvant treatment for different types of solid malignancies
224305106|NCT00842478|PROCEDURE|Toothbrushing|
224305107|NCT03279211|OTHER|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
224305108|NCT03279211|OTHER|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
224150446|NCT04391972|DEVICE|SAV|SAV multifocal intraocular lens is a implantable IOL which offers multifocal vision.
224150447|NCT00002544|DRUG|docetaxel|
224150448|NCT00002544|DRUG|mitoxantrone hydrochloride|
224150449|NCT00976248|DRUG|RAD001|Taken orally once a day
224150450|NCT00806689|PROCEDURE|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
224150451|NCT00806689|DEVICE|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
224150452|NCT03174613|DRUG|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
224150453|NCT03174613|DRUG|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
224150454|NCT00884715|DRUG|Octreotide|short acting octreotide
224150455|NCT05803369|BEHAVIORAL|Regulating Together (RT)|Regulating Together is an intensive outpatient group treatment targeting emotion dysregulation. It engages both caregivers and children and utilizes evidence-based intervention techniques including cognitive behavioral therapy (CBT), visuals, reinforcements, and scaffolding, and newer interventions such as mindfulness and acceptance-based therapy.
224150456|NCT05803369|BEHAVIORAL|Achieving Independence and Mastery in School (AIMS)|AIMS is a school-based program developed to help students with social-communication challenges (such as autism spectrum disorder) achieve academic success. It is well-established and has been used with autistic youth, both in schools and in outpatient settings.
224150457|NCT02278081|DRUG|lansoprazole|the lansoprazole will be taken orally.
224150458|NCT02278081|DRUG|placebo|the lansoprazole placebo will be taken orally.
224150459|NCT03615118|OTHER|IVR/SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes
224305109|NCT03279211|OTHER|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
224150460|NCT03615118|OTHER|SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale
224150461|NCT06063239|OTHER|Test Group|Subjects will receive orally administred probiotics based on L. plantarum and L. rhamnosus for 90 days
224150462|NCT06063239|OTHER|Positive Control|Subjects will receive orally administred probiotics based on placebo 90 days
224150463|NCT06063239|OTHER|Negative Control|Subjects will receive esclusively instruction to perform oral hygiene procedures properly.
224150464|NCT05448599|DRUG|6MW3211 injection with Intravenous Infusion|phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.
224150465|NCT01560611|DEVICE|Near infrared spectroscopy|
224150466|NCT04199793|DEVICE|Lavare On|"For the patients randomized to Lavare On group, the Lavare™ cycle will be turned on upon device interrogation after patients return to intensive care unit from the operating room."
224150467|NCT04199793|DEVICE|Lavare Off|"For the patients randomized to Lavare Off group, the Lavare™ cycle will be turned off upon device interrogation after patients return to intensive care unit from the operating room."
224150468|NCT02687932|DRUG|LCZ696|
224150469|NCT02687932|DRUG|Valsartan|
224150470|NCT01011218|BEHAVIORAL|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
224150471|NCT01011218|BEHAVIORAL|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
224150472|NCT01011218|DRUG|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(-)-enantiomer of the racemic modafinil.
224150473|NCT03820726|DRUG|Nintedanib|Bid
224150474|NCT00568282|PROCEDURE|phlebotomy|Standard of care
224150475|NCT00605072|DRUG|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
224150476|NCT00605072|DRUG|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
224150477|NCT00605072|DRUG|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
224150478|NCT00605072|DRUG|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
224150479|NCT00605072|DRUG|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
224150480|NCT03345992|DRUG|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
224150481|NCT03345992|DRUG|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
224150482|NCT06383689|OTHER|Seizure placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG
224150483|NCT06383689|OTHER|Well-being placebo pill|patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG
223455677|NCT01319942|OTHER|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
223455678|NCT00561691|DRUG|nimotuzumab|monoclonal antibody
223455679|NCT05441553|GENETIC|VGB-R04|A novel, bioengineered adeno-associated viral (AAV) vector carrying human factor IX variant
224150484|NCT00345540|DRUG|NOV-002|60 mg / mL / day / 20-23 Days
224150485|NCT00345540|DRUG|Carboplatin|AUC 5 following IV bolus administration of NOV-002
224150486|NCT05130372|OTHER|Static Stretching Method Group|Static stretching has been the most common stretching method applied to the ankle in healthy older adults, and different protocols have proven to increase ankle range of motion. In this study, the static stretching method was actively applied while standing.
224150487|NCT05130372|OTHER|PNF Stretching Method Group|The contract-relax technique was used in the PNF stretching method.
224150488|NCT05130372|OTHER|Myofascial Relaxation Method Group- Roller Massage|A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
224150489|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
224150490|NCT01272817|PROCEDURE|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
224150491|NCT00206401|DRUG|Lantus and short acting analogs Vs NPH and short acting analogs|
224150492|NCT01406652|PROCEDURE|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
224150493|NCT04384432|OTHER|Routine Physical Therapy with Thoracic mobility exercise|Combınatıon of routıne Routine Physical Therapy with Thoracic mobility exercise
224150494|NCT04384432|OTHER|Routıne Physıcal therapy|Exercise for Chronic Neck Pain
224150495|NCT03164785|DRUG|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
224301828|NCT00628537|DEVICE|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
224150496|NCT01383187|PROCEDURE|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
224150497|NCT01383187|PROCEDURE|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
224150498|NCT00141037|DRUG|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
224150499|NCT00141037|DRUG|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m\^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m\^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
224150500|NCT00141037|DRUG|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing \<40 kg and 1.5 mg/kg/day in subjects weighing \>40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
224150501|NCT00141037|DRUG|Tacrolimus|Taken orally from immediately preoperatively to those\>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects \<age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) \&5-7 ng/mL \>= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 \& 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
224150502|NCT00141037|DRUG|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
224150503|NCT00141037|DRUG|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
224301829|NCT02895607|PROCEDURE|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
224301830|NCT00807677|DRUG|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
224305110|NCT04100785|BEHAVIORAL|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
223455680|NCT05219604|DRUG|DiphenhydrAMINE Injectable Solution|Intravenous infusion of diphenhydramine 50 mg.
223572415|NCT06391281|OTHER|Education|The patient receiving hemodialysis treatment will be given fistula self-care training in 2 sessions. An educational booklet will be provided after the training.And routine care
223572416|NCT04333511|DEVICE|TPS (NEUROLITH)|6 treatments of TPS over 2 weeks
224150504|NCT00141037|DRUG|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
224150505|NCT03292393|BEHAVIORAL|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
224150506|NCT03292393|BEHAVIORAL|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
224150507|NCT03292393|DEVICE|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
224150508|NCT03292393|DEVICE|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
224150509|NCT03255811|DRUG|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
224150510|NCT03379896|OTHER|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
224150511|NCT04041141|DIAGNOSTIC_TEST|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
224150512|NCT04041141|DEVICE|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
224150513|NCT04404803|OTHER|questionnaire|Patients will be asked to complete a questionnaire about the reasons why they agree / decline to take part in research.
224150514|NCT04179786|BIOLOGICAL|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
224150515|NCT00393003|DEVICE|Closed-loop anesthesia system|
224301831|NCT02941757|BEHAVIORAL|Mediterranean diet Intervention|"1. Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~2. Peer-education and support~3. Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~4. Email or text message encouragement and reminders during the intervention."
224301832|NCT02161822|DRUG|simvastatin|simvastatin 80mg qd for 5weeks
224301833|NCT02435095|DRUG|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
224301834|NCT02435095|DRUG|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
224301835|NCT05965115|DIAGNOSTIC_TEST|Sample of Blood|All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests to determine their accurate diagnosis. Patients with monoclonal gammopathy of undetermined significance (MGUS) would be carefully assessed and followed up.
224301836|NCT05134753|BIOLOGICAL|Advanced PRF|Advanced PRF will be placed for patients undergoing sinus augmentation
223455681|NCT02362737|BEHAVIORAL|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be \~16 weekly meetings of \~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
223455682|NCT00311753|DRUG|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
224150516|NCT04559087|PROCEDURE|Laparoscopic Surgery|"NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall."
224150517|NCT05082064|DIAGNOSTIC_TEST|arterial blood gases and serum electrolytes|arterial bloog gases parameters serum potassium serum sodium serum calcium
224150518|NCT04117399|OTHER|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
224150519|NCT00001127|BIOLOGICAL|Influenza virus vaccine (CAIV-T)|
224150520|NCT03638557|OTHER|Nutritious Lunch|"The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
224150521|NCT01938001|DRUG|Rituximab|Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
224150522|NCT01938001|DRUG|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
224150523|NCT01938001|DRUG|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
224150524|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
224150525|NCT03310580|DRUG|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
224150526|NCT03310580|DRUG|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
224150527|NCT03056729|DRUG|BIIB076|Administered as single intravenous (IV) infusion
224150528|NCT03056729|DRUG|Placebo|Administered as single IV infusion
224301837|NCT05134753|BIOLOGICAL|Control|PRF will be placed for patients undergoing sinus augmentation
224301838|NCT01041183|DRUG|intravenous ramosetron|0.3 mg IV ramosetron (group I)
224301839|NCT01041183|DRUG|oral ramosetron|0.1 mg oral ramosetron (group II)
224150529|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
224150530|NCT01548794|PROCEDURE|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
224150531|NCT01548794|PROCEDURE|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
224150532|NCT02326389|BEHAVIORAL|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
224150533|NCT02326389|BEHAVIORAL|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
224150534|NCT03139929|DIAGNOSTIC_TEST|MSFP|MSFPhold and MSFParm
224150535|NCT03162029|OTHER|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
224150536|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using 3D photogrammetry technique.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
224150537|NCT05755022|PROCEDURE|Maxillary Segment Repositioning|"* Le-Fort I osteotomy will be made using the cutting guide.~* Mobilization of the maxilla will be done.~* The osteotomized segment will be positioned using the positioning guide that will be fabricated utilizing the reverse engineering technology using the commercial scanners.~* While the guide in place, the plates will be fixed into their intended position.~* After fixation of the plates, the guide will be removed."
224150538|NCT00002577|RADIATION|radiation therapy|
224150539|NCT02626364|DRUG|crenolanib|single-agent crenolanib at 100 mg PO TID
224150540|NCT04258007|DRUG|Reversal Neostigmine|Patients will receive 0.02 mg/ kg atropine and 0.04 mg/ kg neostigmine following observing the second response on stimulating the ulnar nerve on the TOF watch
224301840|NCT01041183|DRUG|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
224301841|NCT05803174|DIAGNOSTIC_TEST|blood sample|"Blood collection Circulating serum concentrations of melatonin and dopamine were determined from fasting blood samples. Participants were required to fast from 10 pm the previous evening. A 5 mL serum blood sample was collected from the antecubital vein between 8.30 am and 10 am.~Tear collection Tear samples were collected using Schirmer's strip without anesthesia between 8:30-10:00am. Tears were extracted in 200 μl of 1 X Phosphate Buffered Saline with 0.1% Tween-20 (PBST).~Saliva collection Saliva samples were collected via the passive drool method with subjects in a seated position. Subjects were asked to rinse their mouth with water 10 minutes prior to saliva collection and to refrain from using lip makeup during the sampling period."
224301842|NCT01141244|DRUG|temsirolimus|Given IV
224301843|NCT01141244|DRUG|temozolomide|Given orally
224301844|NCT01141244|DRUG|irinotecan hydrochloride|Given IV
224301845|NCT01141244|OTHER|laboratory biomarker analysis|Correlative studies
224301846|NCT06436040|OTHER|Pathological response assessment|The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
224301847|NCT02437240|BEHAVIORAL|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
224301848|NCT02437240|BEHAVIORAL|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
224301849|NCT02928367|OTHER|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
224150541|NCT04258007|DRUG|Reversal Sugammadex|Interventional Arm Patients undergoing cardiac catheterization will receive sugammadex 4 mg/ kg when the T2 is observed on the TOF watch
224150542|NCT04466072|DIAGNOSTIC_TEST|Stool test for microbial analysis|Fecal samples will be analyzed by shotgun metagenomics and sample from the high ventricular arrhythmia burden will be compared with those from comparable control patients with low ventricular arrhythmia burden.
224150543|NCT06372808|OTHER|The Plyometric Exercise|The training group will perform plyometric exercises for eight weeks in addition to their regular training program.
224150544|NCT06372808|OTHER|The Regular Training|The control group's regular training includes basic strength training, cardiovascular training, technical and tactical training, and match-style wrestling.
224150545|NCT04537754|DEVICE|bleaching device|activated bleaching
224150546|NCT06184542|BIOLOGICAL|DTacP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on Day 0
224150547|NCT06184542|BIOLOGICAL|DTacP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine of 0.5mL on the M3-M4-M5, M2-M3-M4, or M2-M4-M6 immunization schedule
224150548|NCT06184542|BIOLOGICAL|DT (one-dose booster)|Diphtheria-Tetanus Combined Vaccine of 0.5mL on Day 0
224150549|NCT06184542|BIOLOGICAL|DTaP (one-dose booster)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on Day 0
224150550|NCT06184542|BIOLOGICAL|PENTAXIM (one-dose booster)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on Day 0
224150551|NCT06184542|BIOLOGICAL|DTaP (three-dose primary vaccination)|Diphtheria-Tetanus-acellular Pertussis Vaccine of 0.5mL on an M3-M4-M5immunization schedule
224150552|NCT06184542|BIOLOGICAL|PENTAXIM (three-dose primary vaccination)|Diphtheria, Tetanus, acellular Pertussis, inactivated Polio, conjugate Haemophilus influenzae type b Combined Vaccine of 0.5mL on the M3-M4-M5 or M2-M3-M4 immunization schedule
224150553|NCT01258517|DEVICE|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
224150554|NCT03731546|PROCEDURE|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
224150555|NCT03001323|DRUG|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
224150556|NCT03001323|DRUG|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
224150557|NCT03738189|OTHER|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
224150558|NCT06076772|DRUG|Palbociclib|The investigator will follow the patients after starting treatment to follow and observe the outcome of the treatment side effects and risk factors
224150559|NCT05521646|OTHER|Quality Improvement Collaborative|Explore if a Quality Improvement Collaborative can increase the proportion of immigrant women who choose an effective postpartum contraceptive method
224150560|NCT02190630|DEVICE|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
224150561|NCT04614350|BIOLOGICAL|Markman Biologics Microsurfaced ADM|an ADM which has been scored (microsurfaced)
223455683|NCT00311753|DRUG|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
223455684|NCT01998347|DRUG|Paclitaxel liposome|
224150562|NCT04614350|BIOLOGICAL|AlloDerm|AlloDerm tissue matrix
224150563|NCT02877667|DEVICE|planar acoustic wave device|accessory to laser treatment
224150564|NCT01670812|DRUG|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
224150565|NCT03010267|DRUG|DP-R213|Investigational product is prescribed to all of randomized subjects
224150566|NCT03010267|DRUG|Raloxifene|Investigational product is prescribed to all of randomized subjects
224150567|NCT03010267|DRUG|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
224150568|NCT01496170|DRUG|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
223455685|NCT01998347|DRUG|Cisplatin|
223455686|NCT01998347|DRUG|5-fluorouracil|
223455687|NCT02932813|BEHAVIORAL|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
223572417|NCT04333511|DEVICE|Sham-TPS (NEUROLITH)|6 treatments of Sham-TPS over 2 weeks
224150569|NCT01496170|DRUG|Placebo|Placebo capsules, orally, once per day for 7 days
224150570|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 5µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
224150571|NCT05542693|BIOLOGICAL|RNA MCTI CIMATEC HDT 10µg|Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)
224150572|NCT05542693|BIOLOGICAL|Covishield® - AstraZeneca|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer)
224150573|NCT05542693|BIOLOGICAL|Comirnaty® - Pfizer|Adults previously immunized will be randomized to receive a single booster vaccine comparator (Comirnaty - Pfizer and (Covishield - Oxford/Astrazen).
224150574|NCT00000440|DRUG|naltrexone (Revia)|
223455688|NCT04932135|DIAGNOSTIC_TEST|Continuous heart rate monitoring|Continuous heart rate monitoring with a wrist worn fitnesstracker
224150575|NCT00000440|DRUG|sertraline (Zoloft)|
224150576|NCT01386892|OTHER|No intervention|There is no intervention for this study
224150577|NCT03519841|DEVICE|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
223572418|NCT00867776|BEHAVIORAL|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
223572419|NCT03598205|COMBINATION_PRODUCT|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
223572420|NCT03800589|PROCEDURE|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
223572421|NCT03800589|PROCEDURE|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
224150578|NCT02677623|DRUG|Pyridium|
224150579|NCT02677623|DRUG|Sodium Fluorescein|
224150580|NCT02677623|DRUG|Mannitol|
224150581|NCT02677623|OTHER|Normal Saline|
224150582|NCT00430547|DRUG|Carbimazole, radio-active iodine (I131)|
224150583|NCT04888351|OTHER|Comparison of complications between mastectomies with IBR and mastectomies without IBR|"Precocious complications (less than 3 months after surgery) are classified with Clavien's classification : hematoma, seroma, stitches, antibiotics, transfusion.~Tardive complications (after 3 months until 1 year) are more specifics : hematoma, seroma, tardive infections, asymmetry, removing of implant, breaking up of implant, skin necrosis, capsular contractures, implant loss, chronic pain."
224150584|NCT04888351|OTHER|To analyze variations of number of patients eligibles to IBR|Including patients with differents classic risk factors : T3, T4, tobacco, diabetes, overweight and obesity, hypertension, age over 70, thoracic irradiation in the past
224150585|NCT00829127|DRUG|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
224150586|NCT00829127|DRUG|Placebo|Oral suspension
224150587|NCT05387798|DRUG|RAD011|Cannabidiol Oral Solution (containing synthetic cannabidiol)
224150588|NCT05805670|OTHER|Yoga and Mindfulness|"Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery"
224150589|NCT00370890|DRUG|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
224150590|NCT01882244|BEHAVIORAL|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
223572422|NCT01129037|OTHER|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
224150591|NCT01882244|BEHAVIORAL|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
224150592|NCT02715492|DRUG|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
224150593|NCT02715492|PROCEDURE|TACE|Trans arterial chemoembolization
224150594|NCT04213040|DIAGNOSTIC_TEST|Serum levels of Procalcitonin, C-reactive protein, lactate|"Serum PCT, CRP, and lactate values were collected postoperatively every day starting on postoperative 12 hours, postoperative days 1 through 5.~After the operation, all postoperative complications were recorded during the first seven days period.~The relations between diagnostic tests and postoperative complications are sought by the use of the statistical analysis methods."
223455689|NCT00717652|DRUG|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
223455690|NCT00717652|DRUG|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
223455691|NCT05858866|OTHER|Piper Fatigue Scale|The Piper Fatigue Scale (PFS) was developed by Piper et al. to measure fatigue in a multi-dimensional manner. The scale assesses the behavioural, affective, sensory and cognitive/mood attributes of fatigue and contains 22 items and 5 open-ended questions. Each item is scored between 0 and 10 using a Visual Analogue Scale. Sub-scale scores are obtained by dividing the scores from the sub-scale items by the number of the items in the sub-scale. The same method is used to calculate the total score
224150595|NCT05418569|DEVICE|Intervention arm - A new smartphone application for pediatric type 1 DM|An evidence-based locally tailored Chinese smartphone application for pediatric type 1 DM
224150596|NCT05418569|OTHER|Standard diabetic eduction|Received standard diabetic care (diabetic nurse education and regular follow-ups) with optional use of an existing smartphone application for general diabetic
224150597|NCT06034015|DRUG|APL-1202 and APL-1501 (Single ascending dose)|Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.
224150598|NCT06034015|DRUG|APL-1202 and APL-1501 (Multiple Ascending dose)|Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
224150599|NCT04492878|DRUG|IKERVIS®1mg/mL|One drop of study medication once daily in each eye at bedtime during 90 days.
224150600|NCT00336778|DRUG|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
224150601|NCT02417896|DRUG|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
224150602|NCT04378699|OTHER|SMR (12-15 Hz)|SMR training sessions (12-15 Hz) C4 unipolar placement, central region
224150603|NCT04378699|OTHER|alpha band (8 -12Hz)|3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
224150604|NCT04124055|DIAGNOSTIC_TEST|Therapeutic drug monitoring (TDM)|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
224150605|NCT01005199|DRUG|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
224150606|NCT01005199|DRUG|sorafenib tosylate|Sorafenib 2 x 400 mg daily
224150607|NCT02318745|BEHAVIORAL|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
224150608|NCT02318745|BEHAVIORAL|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
224150609|NCT04397315|PROCEDURE|Pulpotomy to the level of canal orifices|Pulp tissue will be removed till the level of canal orifices.
224150610|NCT04397315|PROCEDURE|Pulpotomy up to superficial 2-3 mm of pulp chamber|Only superficial pulp from the chamber will be removed
224150611|NCT01582958|PROCEDURE|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
223455692|NCT02579317|BEHAVIORAL|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
223455693|NCT02579317|BEHAVIORAL|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
224150612|NCT01582958|OTHER|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
224150613|NCT05799209|DEVICE|Float Pool|Participant floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
223572423|NCT04072367|DEVICE|NeVa Stent Retrievers|thrombus removal
224150614|NCT05799209|DEVICE|Float Chair|Participant floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
224150615|NCT05564676|DIETARY_SUPPLEMENT|flaxseed oil and pomegranate dry extract|The flaxseed oil were yellow capsules with 1.0 g each and the pomegranate dry extract capsules were green with 0.6 g each.
224150616|NCT05564676|DIETARY_SUPPLEMENT|sunflower oil and microcrystalline cellulose|The sunflower oil were yellow capsules with 1.0 g each and the microcrystalline cellulose capsules were green with 0.6 g each.
224150617|NCT02583516|DRUG|vemurafenib and cobimetinib|Comparison between different treatment regimens
224150618|NCT01781663|DEVICE|KAM2904 Face Cream|
224150619|NCT01781663|DEVICE|KAM3008 Body Lotion|
224150620|NCT01781663|OTHER|petrolatum-based moisturizer|
224150621|NCT04283357|OTHER|Exercise|Short Foot Exercises
224150622|NCT04283357|DEVICE|Virtual Reality|Exercise with virtual reality
224150623|NCT04959604|PROCEDURE|ICG-marking endoscopically|Preoperatively the participants will receive an endoscopic marking at four points around the tumour with the fluorescent dye indocyanine green.
224150624|NCT00500812|DRUG|Cethrin|
224150625|NCT04186663|DRUG|Silver Diamine Fluoride|38% aqueous silver diamine fluoride \[Ag(NH3)\]2F, CAS RN 33040-28-7
224150626|NCT01569087|BIOLOGICAL|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
223572424|NCT04072367|DEVICE|Solitaire Stent Retrievers|thrombus removal
223572425|NCT04829799|DRUG|1% preservative-free lidocaine|Instillation of intracameral lidocaine after initial paracentesis incision.
223572426|NCT04829799|DRUG|Phenylephrine 1.0%/ Ketorolac 0.3%|Instillation of Omidria irrigation solution after paracentesis incision and in irrigation solution.
223572427|NCT05703620|DEVICE|Renal Denervation|All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
223572428|NCT03692351|DEVICE|Uncemented acetabular cup with screw holes|
224150627|NCT01569087|BIOLOGICAL|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
224150628|NCT00005015|DRUG|Fluoxetine|
224150629|NCT02033655|DIETARY_SUPPLEMENT|Protein supplementation|\> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
223572429|NCT03692351|DEVICE|Uncemented acetabular cup without screw holes|
224064996|NCT03837639|OTHER|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
224064997|NCT03837639|OTHER|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
224150630|NCT02033655|BEHAVIORAL|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
224150631|NCT03649334|DRUG|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
224150632|NCT03649334|DRUG|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
224150633|NCT02608034|DRUG|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
224150634|NCT02608034|DRUG|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
224150635|NCT02608034|DRUG|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
224150636|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
223572430|NCT04686760|DRUG|Nitroglycerin|2 mg/ml solution of nitroglycerin used for nebulization four hourly
224064998|NCT05696522|RADIATION|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy will be delivered to a volume of ventricular myocardium responsible for the clinical ventricular tachycardia.
224064999|NCT00659204|DRUG|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
224065000|NCT00659204|DRUG|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
224065001|NCT00000859|DRUG|Indinavir sulfate|
224065002|NCT00000859|DRUG|Ritonavir|
224065003|NCT00000859|DRUG|Nelfinavir mesylate|
224065004|NCT01178775|BEHAVIORAL|walking|use a pedometer for records steps.
224065005|NCT05619198|BEHAVIORAL|High Intensity Interval Exercise|"High Intensity Interval Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of interval work consisting of eight bouts of 1-minute cycling at a power output corresponding to \~85% of VO2max interspersed with 4-minute recovery periods at 20 watts.~* 5 minutes resting phase @ 0 watts."
224065006|NCT05619198|BEHAVIORAL|Moderate Intensity Continous Exercise|"Moderate Intensity Continous Exercise:~* 5 minutes resting phase @ 0 watts.~* 5-minute warm up phase @ 20 watts.~* 40 minutes of MICE 65% VO2max.~* 5 minutes resting phase @ 0 watts."
224065007|NCT03157427|DEVICE|CRYOBEAUTY MAINS|CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (\<1g) and during a predetermined short duration (3 seconds)
224065008|NCT04210609|DEVICE|Vaporous Hyperoxia Therapy|55 minutes of treatment, 2 times per week
224065009|NCT00522431|DRUG|Testosterone|2% gel
224065010|NCT03637933|PROCEDURE|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
224065011|NCT00643695|BEHAVIORAL|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
224065012|NCT00643695|OTHER|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
224150637|NCT00967109|OTHER|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
223572431|NCT05341999|OTHER|cold saline (cryotherapy)|using 20ml of 2.5°C cold saline for 5 min
223572432|NCT05341999|DRUG|Ibuprofen 400 mg|patients will be prescribed ibuprofen medication as a single dose immediately after completion of root canal treatment.
223572433|NCT05341999|OTHER|Final irrigation with normal saline|final irrigation will be done using normal saline at room temperature.
223572434|NCT02275117|BIOLOGICAL|ALD403|
223572435|NCT02275117|BIOLOGICAL|Placebo|
223572436|NCT00297973|PROCEDURE|Blood pressure measurements|
223572437|NCT00297973|PROCEDURE|Blood samples|
224065013|NCT01495442|DEVICE|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
224065014|NCT01495442|DEVICE|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
224065015|NCT03378076|DRUG|FX006 32 mg|Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
224150638|NCT03118011|OTHER|No smoking|No smoking
224150639|NCT03118011|OTHER|Smoking|Ability to go out to smoke
224150640|NCT05833971|DRUG|cadonilimab+chemotherapy|cadonilimab plus cisplatin and Nab-PTX, Q3W
224301850|NCT02928367|OTHER|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
224301851|NCT02928367|OTHER|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
224301852|NCT00655876|DRUG|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m\^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m\^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
224065016|NCT03378076|DRUG|TAcs 40 mg|Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
224301853|NCT00655876|DRUG|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
223572438|NCT05184465|PROCEDURE|spinal anesthesia|"The anesthesiologist, who was not involved in the study, prepared the anesthetic solution immediately before the injection.~Intrathecal injections were performed with a 24G or 25G Pencil point needle in the L3-L4 interval. Spinal puncture was performed while the patient was sitting on the table. Then the patient was placed on his back."
224065017|NCT02249650|DRUG|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
224065018|NCT05331014|DRUG|LivaloVA|For 8 weeks(PO, QD)
224065019|NCT05331014|DRUG|LivaloV|For 8 weeks(PO, QD)
224065020|NCT05331014|DRUG|VA|For 8 weeks(PO, QD)
224065021|NCT04238390|DRUG|Ceftolozane-Tazobactam|Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
224065022|NCT04238390|DRUG|Meropenem|Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
224065023|NCT02342795|OTHER|e-cigarette|
224065024|NCT02342795|OTHER|cigarette substitute|
224065025|NCT02823691|DRUG|Lanreotide and Metformin|Lanreotide and Metformin
224065026|NCT00216411|BIOLOGICAL|Botulinum toxin type A|
224065027|NCT00216411|DRUG|Placebo|
224065028|NCT04690400|OTHER|Experimental: Active care group|Stretching exercise program remotely supervised. Total of approximately 40 minutes per session by WhatsApp, individually and supervised by a professional (physiotherapist or physical education teacher). As recommended for flexibility improving, 30 seconds of stretching in each exercise will be perform fractionated (3 series of 10 seconds of static position at the point of moderate discomfort, with 10 seconds interval between series). There will be two stretching protocol models with exercises variations, but for the same muscle groups, intensity, volume, and duration. The position at the point of moderate discomfort will be self-adjusted by subjective perception over 12 weeks of intervention. The protocol model will change after seven weeks. In order to make the interventions more similar, the guide and videos of control group will be also sent to experimental group
224065029|NCT04690400|OTHER|Active Comparator: Self-care group|The participants will receive counseling to stretching by guide and explanatory video that will be send by WhatsApp. The stretching exercise protocols will be the same performed by the experimental group. In addition, participants will receive recommendation to perform the protocol with the same weekly frequency, intensity, volume, and duration perform by the experimental group After the guide and explanatory video are sent, participants will receive a call for clarification. As well as in the experimental group, the protocol model will change after seven weeks; so, other guide and explanatory video will be sent for participants.
224065030|NCT04842201|DRUG|CM326|subcutaneous injection
224065031|NCT04842201|DRUG|Placebo|subcutaneous injection
224065032|NCT00774462|DRUG|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
224065033|NCT04286061|OTHER|Assisted soft tissue mobilization|It will be done for 60 seconds, making a total of 30 strokes with the tool in the longitudinal direction to the muscle fibers. The physiotherapist will previously apply some massage cream to the area to be treated (adductor musculature) so that the tool slides at a 45º angle. Landslides will be made from the femoral condyle to the groin, and vice versa, exerting a pressure with the instrument of 3 over 10 on the analog visual scale that the subject feels
224065034|NCT03992508|DEVICE|intermittent pneumatic compression|
224065035|NCT03992508|PROCEDURE|complex decongestive therapy|
224065036|NCT06073600|DRUG|Metformin / Vildagliptin Reference Film Coated Tablets (1000 mg / 50 mg) (Galvumet®)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
224065037|NCT06073600|DRUG|Metformin / Vildagliptin Test Film Coated Tablets (1000 mg / 50 mg)|The subjects randomly received a single oral administration of Metformin / Vildagliptin Film Coated Tablets (1000 mg / 50 mg).
224150641|NCT04223063|BEHAVIORAL|Exercise program|As per the intervention arm
224301854|NCT00655876|DRUG|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
224301855|NCT00655876|RADIATION|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
224301856|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
224150642|NCT04368468|OTHER|biomarker evolution|analysis of a list of biomarkers on triple negative breast tumors samples before and after neoadjuvant therapy
224150643|NCT04868747|DRUG|Lidocaine|The participants receive perioperative lidocaine infusion with general anesthesia for gastrectomy.
224150644|NCT04868747|DRUG|normal saline|The participants receive perioperative normal slaine infusion with general anesthesia for gastrectomy.
224301857|NCT01831765|DRUG|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
224301858|NCT01831765|DRUG|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
224301859|NCT01831765|DRUG|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
224150645|NCT04586556|DIAGNOSTIC_TEST|Polyps detection by Artificial Intelligence|The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
224150646|NCT03291158|DRUG|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
224150647|NCT01781871|BIOLOGICAL|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
224150648|NCT01781871|BIOLOGICAL|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
224150649|NCT03328585|BEHAVIORAL|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
224150650|NCT03328585|BEHAVIORAL|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
224150651|NCT03328585|OTHER|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
224150652|NCT06700148|BIOLOGICAL|MCV4|1 dose of MCV4 on Day 0
224150653|NCT06700148|BIOLOGICAL|MPSV4|1 dose of MPSV4 on Day0
224150654|NCT00897091|GENETIC|comparative genomic hybridization|
224150655|NCT00897091|GENETIC|microarray analysis|
224150656|NCT00897091|GENETIC|reverse transcriptase-polymerase chain reaction|
224150657|NCT00897091|OTHER|diagnostic laboratory biomarker analysis|
224150658|NCT06079034|PROCEDURE|Venovenous ECMO|Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
224150659|NCT06079034|PROCEDURE|Venoarterial ECMO|Initial support type of venoarterial ECMO
224150660|NCT01184846|BIOLOGICAL|10% liquid formulation of human immunoglobulin|
224301860|NCT00859586|DEVICE|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
224150661|NCT04019652|DRUG|CS-3150|Single, oral administration; 10-mg or 40-mg dose
224150662|NCT04019652|DRUG|Moxifloxacin|Single, oral administration; 400 mg-tablet
224150663|NCT04019652|DRUG|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
224150664|NCT04019652|DRUG|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
224150665|NCT00816855|DRUG|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
224150666|NCT00554138|DRUG|placebo|1 dd for 7-10 days
224150667|NCT00554138|DRUG|rosuvastatin|1 dd 20 mg for 7-10 days
224150668|NCT00892957|BIOLOGICAL|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
224150669|NCT00892957|OTHER|Surgical gauze pads|Manual compression with surgical gauze pads
224150670|NCT01999946|DRUG|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
224150671|NCT02595840|DRUG|Afatinib|
224150672|NCT02595840|DRUG|Pemetrexed|
224150673|NCT06876012|OTHER|Tai Chi Program|Twelve sessions (six weeks) of a Tai Chi Program to assist with balance and fall risk.
224150674|NCT04144855|DRUG|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
224150675|NCT04261049|DRUG|Triamcinolone Acetonide Extended-Release Injectable Suspension|A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.
224301861|NCT04877886|DIAGNOSTIC_TEST|Ultrasound with IV contrast|To compare the efficiency over the ultrasound scan within contrast
224150676|NCT04213508|DRUG|Isotonic Saline ( 0.9% Sodium Chloride Saline)|0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
224150677|NCT04213508|DRUG|Hypertonic Saline ( 3% Sodium Chloride Saline)|3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
224150678|NCT02850952|OTHER|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
224301862|NCT04877886|DIAGNOSTIC_TEST|CT with IV contrast|CT with IV contrast
224301863|NCT04877886|DIAGNOSTIC_TEST|Ultrasound without IV contrast|Ultrasound without IV contrast
224301864|NCT04877886|DIAGNOSTIC_TEST|CT without IV contrast|CT without IV contrast
223572439|NCT03281330|BEHAVIORAL|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
223572440|NCT00858260|GENETIC|blood sample|Searching for Klotho variants in DNA
223572441|NCT02376101|PROCEDURE|Surgery less than 60 minutes|
223572442|NCT01056003|OTHER|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
223572443|NCT00386477|PROCEDURE|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
224150679|NCT05737407|OTHER|LUS-guided choice of Peep|Choice of Peep guided by lung ultrasound to avoid atelectasis
224150680|NCT05737407|OTHER|Standard choice of Peep|Choice of Peep according to standard practice
224150681|NCT01894763|DEVICE|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
224301865|NCT00374426|DRUG|sertraline|
224301866|NCT05040438|BIOLOGICAL|Vax-NK/HCC|autologous NK cells expanded ex vivo.
224301867|NCT04099550|DEVICE|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
224150682|NCT05904353|PROCEDURE|Ambulant nurse-assisted administration of zoledronic acid|Patients from the intervention regions will be followed by the protocol of ambulant nurse-assisted administration of zoledronic acid.
224150683|NCT05904353|PROCEDURE|Usual care|General practitioners are requested to take care of the follow-up, through the patients and the discharge summary, with annual infusions of zoledronic acid.
224150684|NCT03052387|OTHER|assigned intervention|"\* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~* Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~* The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~* Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~* Using fissure bur to harvest the graft for the defect.~* Closure using vicryl 3-O sutures."
224150685|NCT05963295|DIAGNOSTIC_TEST|toxoplasma igG|Dignosis of toxoplasma
224150686|NCT01549223|DRUG|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
224150687|NCT01549223|DRUG|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
224150688|NCT05884359|DIAGNOSTIC_TEST|3D Electroanatomical Mapping (NavX)|To utilize 3D mapping as a tool to explore electro-anatomical and electrocardiographic characteristics of the Left Bundle Branch Area. Patients will undergo placement of standard Left Bundle Area pacing leads for routine indications, during the implantation procedure electro-anatomical map of the target area and neighboring tissues will be created. Map characteristics will be analyzed and used intra-operatively to assist with lead placement along with standard pacing metrics and standard X-ray criteria. We plan on prospectively reviewing the data found from 3D mapping the left bundle branch implantation cases.
224301868|NCT04099550|OTHER|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
224301869|NCT04120090|DRUG|low dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
224065038|NCT05883644|DRUG|Durvalumab|Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion
224065039|NCT05883644|DRUG|Tremelimumab|Participants will receive single dose of 300 mg through IV infusion at Day 1
224065040|NCT03962439|BEHAVIORAL|High-Demand Photography|The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
224065041|NCT03962439|BEHAVIORAL|Moderate-Demand Photography|The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
224065042|NCT03962439|BEHAVIORAL|At-Home Engagement|The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
224065043|NCT03489382|OTHER|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~1. Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~2. Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~3. The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
224065044|NCT00513409|BIOLOGICAL|Synflorix|Intramuscular injection, 1 or 2 doses
224065045|NCT00513409|BIOLOGICAL|Infanrix Hexa|1 Intramuscular injection
224065046|NCT00513409|BIOLOGICAL|Havrix|1 Intramuscular injection
224065047|NCT05736900|DIAGNOSTIC_TEST|Blood sampling|One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
224065048|NCT01049035|BIOLOGICAL|Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate|0.5 milliliter (mL), Intramuscular (IM) injection
224065049|NCT01049035|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)|0.5 mL, IM injection
224301870|NCT04120090|DRUG|high dose ruxolitinib|The dose for adult patients(Age\>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight \>=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
224301871|NCT01570803|DEVICE|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of \>15 mmHg, residual stenosis of \>30%, and flow-limiting dissection.
223572444|NCT05979636|OTHER|Novamin containing toothpaste|children's teeth will be brushed using Novamin containing toothpaste.
223572445|NCT05979636|OTHER|Fluoride containing toothpaste|children's teeth will be brushed using Fluoride containing toothpaste.
223572446|NCT04349748|BEHAVIORAL|Health education, and regular HIV and STDs testing prompting service|Health education through app for once a week, and regular HIV and STDs testing prompting service (every month through app) are given to the participants at the beginning of the study and last for the whole five observation periods.
224301872|NCT01570803|DEVICE|Complete SE Stent|same to SMART CONTROL Stent
224301873|NCT00787059|DRUG|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10\^9 vp to 10\^12 vp in 5 dose groups
224301874|NCT00787059|DRUG|Sucrose (3%)|
224065050|NCT01049035|BIOLOGICAL|M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live|0.5 mL, Subcutaneous (SC) injection
224065051|NCT01049035|BIOLOGICAL|Varicella Virus Vaccine Live|0.5 mL, SC injection
224065052|NCT01049035|BIOLOGICAL|Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
224065053|NCT01049035|BIOLOGICAL|Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)|0.5 mL, IM injection
224065054|NCT01049035|BIOLOGICAL|Rotavirus Vaccine|oral
224065055|NCT01049035|BIOLOGICAL|Hepatitis B Vaccine|0.5 mL, IM injection
224065056|NCT06307912|OTHER|Video placebo communication|The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
224065057|NCT06307912|OTHER|Video nocebo communication|The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.
224065058|NCT01735487|OTHER|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
224065059|NCT01735487|OTHER|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
224065060|NCT01735487|OTHER|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
224065061|NCT01735487|OTHER|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
224065062|NCT01735487|OTHER|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
224065063|NCT04716790|PROCEDURE|Ultrasound Debridement|Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.
224065064|NCT04716790|PROCEDURE|Conventional Treatment|Conventional Treatment based on international guidelines for diabetic foot
224065065|NCT01088074|DEVICE|Histoacryl Tissue Adhesive|
224065066|NCT01088074|DEVICE|Dermabond|
224065067|NCT01088074|DEVICE|Staples|
224065068|NCT01088074|DEVICE|Monocryl 4-0|
224065069|NCT01312246|DEVICE|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
224065070|NCT01564355|DEVICE|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
224065071|NCT01564355|DRUG|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
224301875|NCT03216018|BEHAVIORAL|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
223455694|NCT01918657|DRUG|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at \~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
224065072|NCT03066427|DRUG|Sunitinib|Sunitinib 50 mg/d
224065073|NCT00180310|DEVICE|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
224065074|NCT00180310|DEVICE|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
224065075|NCT02289222|DRUG|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
224065076|NCT02289222|DRUG|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
224065077|NCT02289222|DRUG|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
224065078|NCT04462952|DRUG|Adavosertib (AZD1775)|Adavosertib taken orally
224065079|NCT02491814|OTHER|1% M.F. Milk|
224065080|NCT02491814|OTHER|Yogurt Beverage|
224065081|NCT02491814|OTHER|Soy Beverage|
224065082|NCT02491814|OTHER|Almond Beverage|
224065083|NCT02491814|OTHER|Water|
224065084|NCT02491814|OTHER|Breakfast cereal|
224065085|NCT03189446|RADIATION|Vaginal Cuff Brachytherapy|Within 12 weeks of surgery. Either LDR or HDR brachytherapy will be permitted
224065086|NCT03189446|DRUG|Carboplatin|Carboplatin IV on day 1 of a 21 day cycle for 3 cycles
224065087|NCT03189446|DRUG|Paclitaxel|Paclitaxel IV on days 1,8 and 15 of a 21 day cycle for 3 cycles
224065088|NCT03315767|DIAGNOSTIC_TEST|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
224065089|NCT03315767|DIAGNOSTIC_TEST|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
224065090|NCT05931809|BEHAVIORAL|Serqual tool|The SERVQUAL scale will be applied with the questionnaire of expectations in the first 24 hours after admission and perception questionnaire within the first 24 hours after discharge.
224065091|NCT06124482|DEVICE|Total Knee arthroplasty|The FHK-CK prosthesis (non CE-Marked, class III) is to be implanted with the use of FHK-CK instruments. The surgery has to be performed in accordance with the practice/guidelines, FHK-CK Instruction For Use (IFU) and surgical techniques documents.
224065092|NCT05634577|DRUG|Mitotane|Given by PO
224065093|NCT05634577|DRUG|Pembrolizumab|Given by vein (IV)
224065094|NCT06490913|DRUG|Capecitabine|1000mg/m2, bid, d1-d14，q3w，1cycle
224065095|NCT06490913|DRUG|oxaliplatin|130mg/m2, ivgtt, d1，q3w，1cycle
224305111|NCT05190809|PROCEDURE|Goldilocks mastectomy and fat transfer|Skin sparing mastectomy (Goldilocks mastectomy), then autologous fat grafting in the medial and lateral breast pillars as well as the inferior dermal flap
224305112|NCT06358170|BEHAVIORAL|Circuit Training Combine with Square-Stepping Exercise|Circuit Training Combine with Square-Stepping Exercise
224305113|NCT05944601|BEHAVIORAL|Virtual and computer-based cognitive remediation training|Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
224065096|NCT06490913|DRUG|Cetuximab|cetuximab 500mg/m2, q2w
224065097|NCT06490913|DRUG|Oxaliplatin|85mg/m2, d1,q2w
224065098|NCT06490913|DRUG|Leucovorin|400mg/m2, d1,q2w
224065099|NCT06490913|DRUG|5-FU|400mg/m2，d1,q2w
224065100|NCT04839978|BEHAVIORAL|Connect Program|The Connect program includes school-based screening, brief intervention and referral, and will be treated as part of the participating schools' prevention programs. A computer-based screening and brief intervention will be supported by Cherokee Nation Behavioral Health (CNBH) supervised Connect coaches universally, to reduce potential stigma associated with speaking to a Connect coach and to reinforce drug free norms among all students. Follow-up of moderate to high-risk youth will be conducted by a Connect Coach through Zoom, other electronic communication, or in-person visits, with referral to Cherokee Nation or community services if deemed necessary.
224065101|NCT04839978|BEHAVIORAL|Communities Mobilizing for Change and Action (CMCA)|The community-level intervention Communities Mobilizing for Change and Action (CMCA) will involve educating and organizing of adult volunteers and consent will be assumed by their participation. Trainings and tools will be provided, including Family Action Kits, to support local families, community organizations and citizens, including information on national and local opioid and other drug use, evidence-based policies, programs and practices, and how to motivate and create family and local action for drug prevention.
224065102|NCT03865706|DRUG|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
224065103|NCT03865706|DRUG|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
224065104|NCT03865706|DRUG|Broad-spectrum antibiotics|Standard of care treatment for infections
224065105|NCT06046261|OTHER|ACP board game for life|The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
224065106|NCT00278421|BIOLOGICAL|rituximab|
224065107|NCT00278421|DRUG|cyclophosphamide|
224065108|NCT00278421|DRUG|doxorubicin hydrochloride|
224065109|NCT00278421|DRUG|prednisone|
224065110|NCT00278421|DRUG|vincristine sulfate|
224065111|NCT00568646|DRUG|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
224065112|NCT00658554|DRUG|ARQ 197|Treatment with ARQ 197
224065113|NCT03628170|OTHER|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
224065114|NCT03628170|OTHER|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
224065115|NCT02916355|DRUG|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
224065116|NCT02916355|DRUG|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
224065117|NCT02027103|DRUG|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
224065118|NCT02027103|DRUG|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
224305114|NCT00910091|DRUG|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
223455695|NCT01918657|DRUG|walnut powder|escalating doses of walnut powder
223455696|NCT02009423|DRUG|Masitinib|
223455697|NCT02009423|DRUG|Placebo|
224065119|NCT04835636|BEHAVIORAL|Diabetes Prevention Program|This program is a 1 year lifestyle modification program focused on reducing calories and fat calories and increasing physical activity to achieve a 7% weight loss. This study utilized the first 16 sessions (6 months) of the program
224065120|NCT05681507|DRUG|Transversus thoracic muscle plane block|Ultrasound guided bilateral parasternal injection of bupivacain 0.375%, 20ml, at 4th thoracic vertebral level.
224065121|NCT05681507|PROCEDURE|Standard postoperative analgesia|Standard of postoperative ICU analgesic care, per institutional protocol
224065122|NCT02642133|PROCEDURE|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
224065123|NCT01515787|DRUG|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1, leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
224065124|NCT01515787|OTHER|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m\^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m\^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
224065125|NCT01515787|PROCEDURE|surgery|low anterior resection with total mesorectal excision
224065126|NCT01515787|PROCEDURE|magnetic resonance imaging or endorectal ultrasound|
224065127|NCT03174132|DEVICE|Restylane Perlane Lidocaine|Intradermal injection
224065128|NCT03174132|DEVICE|Restylane Perlane|Intradermal injection
224065129|NCT05374252|DRUG|PD-1 inhibitor|Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
224065130|NCT05374252|RADIATION|concurrent chemoradiotherapy|Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
224065131|NCT01166022|OTHER|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
224065132|NCT03875898|OTHER|150 g bread fortified (15 g mix fibre)|Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
224065133|NCT03875898|OTHER|150 g unfortified bread|Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
224065134|NCT02486198|DRUG|placebo|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
224065135|NCT02486198|DRUG|GM|"1. For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~2. For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
224065136|NCT02486198|DRUG|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
224065137|NCT00773812|DRUG|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
224065138|NCT00773812|DRUG|placebo|One pill is taken once daily.
224065139|NCT04407559|OTHER|Serological analyses to be lead on a pre-existing biobank|"3 immunoassays will be used according to the procedure described (Demey-2020; Tuaillon-2020) :~* WuHan UNscience Biotechnology Co., Ltd (Chine). COVID-19 IgG/IgM Rapid Test Kit, (Wuhan, China), will be refered as UNscience~* Chongqing iSIA BIO-Technology Co., Ltd (Chine). 2019-nCoV IgM/IgG Diagnostic Test Kit ; (Chongqing, China), will be refered as iSIA~* Xiamen Biotime Biotechnology Co. Ldt (Chine). (SARS-CoV-2) IgM/IgG Rapid Qualitative Test Kit, will be refered as Biotime."
224065140|NCT03981783|BEHAVIORAL|Best available care (BAC)|Eligible patients are assigned to a standard pulmonary rehabilitation program
224065141|NCT03981783|BEHAVIORAL|Telerehabilitation (TH)|Eligible patients are assigned to a pulmonary telerehabilitation program
224065142|NCT06888830|DRUG|JS212 for Injection|JS212 for Injection is administered on the first day of the first cycle and every 3 weeks thereafter.
224065143|NCT02412787|DRUG|Idursulfase-IT|Participants received 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who were younger than 3 years of age received an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).
224065144|NCT02412787|DRUG|Elaprase|Participants received intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
224065145|NCT05836103|BEHAVIORAL|Smartphone-based intervention messages|Intervention messages in the proposed trial will address specific high-risk situations for smoking and smoking urges. Messages will focus on two key situational triggers for message matching: 1. Stress (high/low) and 2. Presence of other smokers (yes/no). For each situation, characterized by a combination of these characteristics, several messages were developed. To improve user engagement with the intervention, all messages contain visual content in form of pictures.
224065146|NCT05829135|DEVICE|Acuvue Oasys with Transitions|soft contact lenses with darkening technology
224065147|NCT05930548|OTHER|Low Shrinkage Giomer|Low shrinkage giomer resin composite shows both sustained fluoride release and recharge, and low volumetric shrinkage of less than 1% with low resultant polymerization shrinkage stress. Such remarkable feature is due to the novel SRS (Steric Repulsion Structured) molecule which is designed to decrease polymerization shrinkage through molecular steric repulsion resulting in a stable restoration microstructure (AlQranei MS et al, 2021). Thus, low shrinkage giomers are best indicated in class V cavities where the dentin bonding agent does not have high strength (Algailani U, et al 2022).
224065148|NCT00622674|BIOLOGICAL|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
224065149|NCT00622674|DRUG|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
224065150|NCT03945526|DRUG|Astaxanthine|
224065151|NCT03945526|DRUG|Placebo Oral Tablet|
223455698|NCT06408779|PROCEDURE|mitral valve repair|coronary artery bypass grafting concomitant mitral valve repair
224065152|NCT00455234|DRUG|Intramuscular Olanzepine 10 mg|
224065153|NCT00455234|DRUG|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
224065154|NCT02788942|PROCEDURE|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
224065155|NCT02730585|BIOLOGICAL|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
224065156|NCT05044208|DIAGNOSTIC_TEST|ECG monitoring|After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
224065157|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.
224065158|NCT00071071|DRUG|HuMax-CD4|HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.
224065159|NCT02311153|DEVICE|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
224305115|NCT00910091|DRUG|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
224301876|NCT06452875|PROCEDURE|Primary Needle Knike Fistulotomy|"After verifying the eligibility of the papillary morphology (excluding flat or diverticular papillae according to Viana's classification), access to the bile duct will be initiated using the primary needle knife fistulotomy technique. After the first contact of the needle knife with the papilla, the endoscopist will have a total of 8 minutes, after which he can change to other cannulation techniques (eg standard cannulation methods through the papillary orifice) or even stop the procedure.~During ERCP all patients will be submitted to PEP prophylaxis with indomethacin. Also as a prophylactic PEP measure a pancreatic stent will be placed whenever there is cannulation or opacification of the Wirsung duct. For the purpose of this study, a dedicated form (attached) will be created with the various variables to be analyzed."
224301877|NCT01987037|BEHAVIORAL|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
223572447|NCT04349748|BEHAVIORAL|Health status inquiry through app (partner notification)|The permission to query health status through app (partner notification) is given to participants (participants can query their potential sexual partner's status of HIV, syphilis, hepatitis B, and hepatitis C respectively through app) at the specific observation period,and the permission is retained until the end of study.
224065160|NCT02311153|DEVICE|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
224065161|NCT05194085|DIAGNOSTIC_TEST|POC viral load testing|POC viral load testing- women randomized to have POC VL at enrollment, delivery and 6 months post-partum, will have a finger prick to obtain whole blood for the Cepheid Xpert HIV-1 RNA cartridge on the Xpert IV machine with results in 90 minutes. Women who are randomized to POC VL who have VL \>200 c/ml will receive additional adherence counseling, following the STREAM protocol, \[26\] to address the challenges that they are having with ART use. At the delivery visit, infants of women in the POC VL arm will also have viral load testing done.
224065162|NCT05194085|OTHER|Wellness visit services for male partners|Wellness visits for men- additional prevention services for men randomized to the intervention arm, including dual syphilis and HIV testing, blood pressure, visual acuity screening, and COVID-19 screening as part of wellness
224065163|NCT04086823|DRUG|RZL-012|Subcutaneous injection to the submental fat area
224065164|NCT04086823|DRUG|Placebo|Placebo
224065165|NCT06535243|BEHAVIORAL|Lifespan Integration Therapy (LI)|same as above
224065166|NCT01535170|DIETARY_SUPPLEMENT|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) \[16\] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori \[17\].
224065167|NCT03742180|DRUG|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
224065168|NCT03742180|DRUG|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
224065169|NCT04010396|OTHER|Blood sampling|Blood sampling: 1 EDTA and 1 Serum vial
224065170|NCT02550886|OTHER|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
224065171|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
224065172|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
224065173|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
224065174|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
224065175|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
223742960|NCT02882555|DRUG|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
223742961|NCT01463371|DRUG|Azithromycin|250 mg three times a week during three months
224065176|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
224065177|NCT00848055|DRUG|AbGn168 intravenous infusion|single dose intravenous infusion
224065178|NCT00848055|DRUG|AbGn168 subcutaneous injection|single dose subcutaneous injection
224065179|NCT06377787|OTHER|ELDOA and conventional therapy|hot pack and TENS for10 min, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4rep with 6 sec hold once a day) and ELDOA method C0-C1-C2, C2 \& C3 positions for cervical spine (2 sets of five repetitions with 45 sec hold and 15sec rest between each set once a day).
224065180|NCT06377787|OTHER|conventional therapy|include hot pack and TENS for 10 minutes, cervical PIR (MET) in flexion, extension, side bending and rotation (single set of 4 reps with 6 seconds hold once a day).
224065181|NCT03255681|PROCEDURE|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
224065182|NCT00957008|BEHAVIORAL|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
224150689|NCT05891691|BEHAVIORAL|Music Activities, Yoga, Massage|The program begins with music and dance movements using percussion instruments (rhythm stick, stone triangle, drum, cymbal, tambourine, maracas, etc.) and body percussion. In this phase, the children will follow the instructions of the researcher. The goal is to warm up the bodies and musically experience the beginning of the program After the warm-up, yoga postures are combined with breathing techniques that focus on developing awareness of body sensations and feelings.The daily program ends with massage. During the massage application, the children sit in a circle. The massage is performed by the children observing the movements of the researcher on their arms and legs and applying them on their own arms and legs.Yoga postures, breathing techniques, and massage practices are accompanied by stories to ensure children's active participation, encourage their development, and facilitate their acquisition of new approaches.
224150690|NCT06894862|DRUG|NYR-BI03|Participants receive NYR-BI03 nanosuspension formulated for continuous intravenous infusion to be given over 3 hours or 6 hours.
224150691|NCT06894862|DRUG|Matching placebo (all cohorts)|Administered as a continuous intravenous infusion over 3 hours or 6 hours
224150692|NCT01930240|DRUG|TRIA-662|1-MNA Chloride
224150693|NCT01930240|DRUG|Placebo|Double-blind placebo
224150694|NCT03944070|DRUG|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
224150695|NCT04876599|BEHAVIORAL|IN FOCUS|Adapted Resiliency Group Intervention
224150696|NCT04876599|BEHAVIORAL|Usual Care|Referral to Virtual Group Support
224150697|NCT04409652|PROCEDURE|Head on bed|During emergence, head is kept on bed without pillow.
224150698|NCT04409652|PROCEDURE|Head on pillow|During emergence, head is kept on pillow.
224150699|NCT00889980|OTHER|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
224150700|NCT03175562|OTHER|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
224150701|NCT03175562|OTHER|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
224150702|NCT07090850|BEHAVIORAL|Puzzle education group|It was evaluated the effect of using puzzles as a teaching technique in a nursing practice course.
224150703|NCT07090941|PROCEDURE|Endovascular Treatment|The vascular access route is selected based on the patient's anatomical characteristics and operator discretion. Endovascular treatment (EVT) procedures must adhere to each participating center's standardized operating protocols. Upon confirmation of vascular occlusion, EVT may be performed using devices approved by China's National Medical Products Administration (NMPA). Based on lesion-specific features and operator judgment, permissible techniques include stent retriever thrombectomy, aspiration thrombectomy, balloon angioplasty with or without stenting, or intra-arterial thrombolysis. Investigational devices are strictly prohibited.
224150704|NCT07090109|BEHAVIORAL|Genetic testing education video|patient education video about genetic testing for hereditary cancers
224150705|NCT07091799|DIAGNOSTIC_TEST|P2X4 receptors in blood samples|This is an interventional study designed to assay P2X4 receptors in blood samples from ALS patients and healthy volunteers by comparing the mean levels of P2X4 expression.
224150706|NCT07092319|PROCEDURE|deferred cord clamping|DCC: deferred cord clamping successfully for 60 seconds;MISA: Surfactant administration by minimally invasive methods that allow for spontaneous breathing.
224150707|NCT07091019|OTHER|TKIs|There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled.
224150708|NCT07091825|DEVICE|LACRIFRESH OCU-DRY 0.3% OSD|Use LACRIFRESH OCU-DRY 0.3% OSD as the daily contact lens lubricant product.
224150709|NCT07091825|DEVICE|Rigid contact lens lubricant|Use Rigid contact lens lubricant as the daily contact lens lubricant product.
224150710|NCT07091227|DRUG|AK112+oxaliplatin+capecitabine|participants will receive standard dose treatment of AK112 combined with oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery.
224150711|NCT07091227|DRUG|oxaliplatin+capecitabine|participants will receive standard dose treatment of oxaliplatin+capecitabine every 3 weeks for 4 cycles before surgery
224150712|NCT07091760|OTHER|Su Jok Application|The patient's hands will be preferred for the application due to the comfort and convenience of the woman after cesarean section. Su Jok therapy, massage and seed will be applied to the reflection points on the hand based on the area to be treated.
224150713|NCT07091760|OTHER|Placebo Application|"Placebo Intervention:~The placebo group will be massaged and seed will be applied to an area where there is no reflection of the Su Jok organ."
224150714|NCT07091266|DEVICE|Sacral Neuromodulation (SNM)|A standardized two-stage implantation protocol was used. In Stage 1, a temporary lead (InterStim 3093, Medtronic) was implanted at the S3 sacral foramen under fluoroscopic guidance. Patients with ≥50% improvement in urinary symptoms over a 7-day test period proceeded to Stage 2, where a permanent neurostimulator (InterStim 3058, Medtronic) was implanted subcutaneously. Stimulation parameters were adjusted (amplitude: 0.5-10 V; frequency: 14 Hz; pulse width: 210 μs) to optimize symptom control.
224301878|NCT00706511|DEVICE|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
224301879|NCT01312571|BEHAVIORAL|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
224305116|NCT03102801|DRUG|Humulin S|Humulin S used to induce hypoglycaemia
223455699|NCT02509975|DEVICE|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
223455700|NCT00108290|DRUG|Chemotherapy|
223455701|NCT00332306|DRUG|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients \<60kg, 400mg patients \> 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
224150715|NCT07091266|PROCEDURE|Hyperbaric Oxygen Therapy (HBOT)|Patients received two 20-session courses (5 sessions/week) in a hyperbaric chamber at 2.0 atmospheres absolute (ATA). Each session consisted of 60 minutes of 100% oxygen inhalation, bracketed by compression and decompression periods.
224150716|NCT07091526|DIAGNOSTIC_TEST|serum uric acid test|Detect the serum uric acid in blood sample
224150717|NCT07092059|DEVICE|Smartphone digital therapeutic system|This intervention is composed of a smartphone app (Apple iOS or Android type) that prompts patients with Stimulant Use Disorder to (1) complete self-assessment questionnaires in the app about their health, health care needs and the services they receive and other health-related functions in life, (2) read educational modules about health and wellness and answer questions about these readings, (3) speak periodically with a Guide about their use of the app, and (4) take periodic saliva substance tests using video-selfies with their smartphone camera. The intervention includes testing and interviews with the study staff over a 12 month period. There is a follow-up period to measure the longer-term results at 15 months, as well.
224150718|NCT02146833|DRUG|Selinexor|Comparison of different dosages and dosing schedules of drug.
224150719|NCT07092306|DRUG|Irinotecan Hydrochloride Liposome Injection Combined with Temozolomide and Vincristine (NALIRI-VT)|（NALIRI-VT，Nanoliposomal Irinotecan，Vincristine，Temozolomide）， Nanoliposomal Irinotecan：35 mg/m2/d，iv，D1，8，15， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；
224150720|NCT07092306|DRUG|Irinotecan Combined with Temozolomide and Vincristine (VIT)|（VIT，Vincristine，Irinotecan，Temozolomide） Irinotecan：50 mg/m2/d，iv，D1-5， Temozolomide：100 mg/m2/d，po，D1-5， Vincristine：1.4 mg/m2/d，iv，D1，最大剂量2mg；
224150721|NCT07090733|OTHER|Interscalene brachial plexus block|Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.
224150722|NCT07090733|OTHER|Suprascapular nerve block|Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.
223742962|NCT01824186|PROCEDURE|SILC|Underwent single-incision laparoscopic cholecystectomy
224150723|NCT07090733|OTHER|Anterior glenoid block|Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.
224150724|NCT07090733|OTHER|Suprascapular nerve block + Anterior glenoid block|Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.
224150725|NCT07092124|DEVICE|test visionumVR|Two evaluation sessions with VisionumVR one month apart
224150726|NCT07090928|DRUG|5 ml of 0.5% bupivacaine infiltrated at each port site|5 ml of 0.5% bupivacaine infiltrated at each port site after the arthroscopic procedures
224150727|NCT07090928|DRUG|Placebo|5ml 0.9%normal saline infiltrated at port site
224150728|NCT07091383|OTHER|Exercise|Static stretching
224150729|NCT07091383|OTHER|Exercise|Soft Tissue Mobilization
224150730|NCT07091383|OTHER|Exercise|Functional soft tissue mobilization
224150731|NCT07092202|DRUG|Firmonertinib|Firmonertinib 160mg po qd
224150732|NCT07092202|DRUG|Intrathecal injection of pemetrexed|Intrathecal injection of pemetrexed. Weight above 50kg: Induction period: 40mg/time, d1, d5 (q3w, x 4 cycles); Consolidation period: 40mg/time, q4w (pause when cerebrospinal fluid ctDNA is negative); Weight below 50kg: Induction period: 30mg/time, d1, d5 (q3w, x 4 cycles); Consolidation period: 30mg/time, q4w (pause when cerebrospinal fluid ctDNA is negative)
224150733|NCT07090343|DRUG|Wegovy ®|Semaglutide 2.4 mg subcutaneous once-weekly starting 3 months prior TAVR and continued 24 months post-TAVR. During the first 16 weeks, the dose of semaglutide or placebo will be gradually escalated from 0.25 mg once weekly until target dose as an add-on to standard-of-care. The treatment will continue until the 'end of treatment' visit followed by a 8 weeks follow-up period.
224150734|NCT07090343|DRUG|Placebo|Matching placebo subcutaneous once-weekly.
224150735|NCT06910202|BEHAVIORAL|Manipulation of nicotine/tobacco product price and availability|"This study does involve experimental manipulation of nicotine/tobacco product price and availability to understand consumers' behavior. Participants will be provided with a commercially available e-cigarette to use during the study, if they wish.~Every participant will purchase tobacco products in an online store under four different scenarios: a) cigarette flavor restricted and e-cigarette flavor restricted, b) cigarette flavor unrestricted and e-cigarette flavor restricted, c) cigarette flavor restricted and e-cigarette flavor unrestricted, d) cigarette flavor unrestricted and e-cigarette flavor unrestricted."
223742963|NCT01824186|PROCEDURE|LC|Underwent conventional 4-port laparoscopic cholecystectomy
224150736|NCT07089953|OTHER|Questionnaire|Complete 3 questionnaires about your emotions and your trust in doctors.
224150737|NCT07089953|OTHER|Video|Four (4) videos, each 4 minutes long, have been made for use in this study.
224150738|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF neutral pH|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
224150739|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF acidic pH|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
224150740|NCT07092215|DRUG|Synthetic interstitial fluid (SIF) / SIF acidic pH + BCTC 1 µM|Intradermal injection of SIF at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
224150741|NCT07092215|DRUG|LPS 5 ng / SIF neutral pH|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
224150742|NCT07092215|DRUG|LPS 5 ng / SIF acidic pH|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7)
224150743|NCT07092215|DRUG|LPS 5 ng / SIF acidic pH + BCTC 1 µM|Intradermal injection of LPS 5 ng at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to pH 5.7), containing BCTC 1 µM
224150744|NCT07092215|DRUG|LPS 5 ng + Azeliragon 100 µM / SIF neutral pH|Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
224150745|NCT07092215|DRUG|LPS 5 ng + Azeliragon 100 µM / SIF acidic pH|Intradermal injection of LPS 5 ng + Azeliragon 100 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with acidic pH (pH 7.4 to 5.7)
224150746|NCT07092215|DRUG|LPS 5 ng + Resatorvid 10 µM / SIF neutral pH|Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4)
224150747|NCT07092215|DRUG|LPS 5 ng + Resatorvid 10 µM / SIF acidic pH|Intradermal injection of LPS 5 ng + Resatorvid 10 µM at time point -4.5h, followed by laser speckle imaging, mechanical stimulation and intradermal injection of SIF with neutral pH (pH 7.4 to pH 5.7)
224150748|NCT04482244|DRUG|Cannabidiol|Liquid taken orally
224150749|NCT04482244|OTHER|Placebo|Liquid taken orally
224150750|NCT06928922|BIOLOGICAL|BMD006 monotreatment|After receiving the first dose of BMD006 treatment on Day 1, the patient will complete a single-treatment DLT observation (14 days). If the treatment is deemed safe and tolerable by the investigator, the patient will proceed to multiple-treatment DLT observation (14 days), with BMD006 treatment administered on Day 15 and Day 22. On Day 28, if the treatment is again assessed as safe and tolerable by the investigator, the patient will continue treatment at the current dose level following a QW (once weekly) regimen for 6 doses. After that, starting from Week 11, the treatment schedule will change to Q3W (once every 3 weeks) until 52 weeks after the first treatment or until the treatment discontinuation criteria are met.
224150751|NCT06928922|BIOLOGICAL|BMD006 in combination with PD-1 antibody|Once the dose escalation of BMD006 monotreatment is completed and the MTD (Maximum Tolerated Dose) is determined (i.e., the RP2D for this study), a dose escalation exploration of BMD006 in combination with PD-1 antibody will be conducted. On Day 1, patients will receive BMD006 in combination with PD-1 antibody treatment, followed by BMD006 treatment on Days 8 and 15. The DLT observation period will be 21 days. On Day 21, if the treatment is assessed as safe and tolerable by the investigator, the patient will continue treatment at the current dose level according to the QW (once weekly) regimen for 6 doses. After Week 10, the treatment schedule will change to Q3W (once every 3 weeks) until 52 weeks after the first treatment or until the treatment discontinuation criteria are met.
224150752|NCT04984512|DRUG|Mitizodone Phosphate tablets|Mitizodone Phosphate tablets will be administered with food.
224150753|NCT04984512|DRUG|Placebo-matching tablets|Placebo will be administered with food.
224150754|NCT06921473|DRUG|Norepinephrine|Intravenous bolus of norepinephrine (5-10 µg) to treat spinal anesthesia-induced hypotension during cesarean section.
224150755|NCT06921473|DRUG|Ephedrine|Intravenous bolus of 5-10 mg ephedrine administered as needed to treat maternal hypotension following spinal anesthesia during elective cesarean section. The drug is prepared in identical, unlabeled syringes to ensure blinding.
224150756|NCT03258463|OTHER|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
224150757|NCT01379924|BEHAVIORAL|Parenting/Life Skills Intervention|Modules adapted from the Ansell-Casey Life Skills Assessment Curriculum, the Women's Negotiation Project Curriculum for Teen Mothers and the Nurturing Curriculum. Goal is to help teen mothers develop positive parenting skills, decrease repeat pregnancy and acquire skills of daily living. The series of five, one-hour long, structured, one-on-one interactive modules aims to help teens build positive, empathetic relationships with their children, while enhancing self-efficacy and increasing the sense of self- worth for parents and children. Domains addressed include child development/discipline, safety, house/money management, social relationships, career planning, substance abuse and community and interpersonal violence.
224150758|NCT01379924|OTHER|Teen-tot medical home|Medical, mental health, and social services provided to teen parents and their children
224150759|NCT03700736|BEHAVIORAL|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
224150760|NCT00315978|DEVICE|Heart-to-Heart Decision Aid|
224150761|NCT04329494|PROCEDURE|Biopsy|Undergo biopsy
224150762|NCT04329494|DRUG|Cisplatin|Given via PIPAC
224150763|NCT04329494|DRUG|Doxorubicin|Given via PIPAC
224150764|NCT04329494|DRUG|Fluorouracil|Given IV
224150765|NCT04329494|DEVICE|Intraperitoneal Chemotherapy|Undergo PIPAC
224150766|NCT04329494|DRUG|Irinotecan|Given IV
224150767|NCT04329494|DRUG|Leucovorin|Given IV
224150768|NCT04329494|DRUG|Mitomycin|Given via PIPAC
224150769|NCT04329494|DRUG|Oxaliplatin|Given via PIPAC
224150770|NCT04329494|OTHER|Quality-of-Life Assessment|Ancillary studies
224150771|NCT04329494|OTHER|Questionnaire Administration|Ancillary studies
223455702|NCT00332306|DRUG|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients \< 60kg, 400 mg OD patients \> 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
223455703|NCT01766908|OTHER|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
223455704|NCT03655600|OTHER|Self-administered acupressure|Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
224150772|NCT00642018|DRUG|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
224150773|NCT00642018|DRUG|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
224150774|NCT00642018|DRUG|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
224150775|NCT05740579|PROCEDURE|laparoscopic cryopreservation of one ovary|Laparoscopic removal of one ovary as child. In adulthood cortical tissue is replaced in the abdomen in order to improve fertility and pregnancy rates in Turner syndrome women.
223455705|NCT05030636|PROCEDURE|Acute moderate to vigorous exercise performed at a specific moment of the day|Treadmill (30 minutes) at 70% of maximal aerobic capacity
223455706|NCT01540513|DRUG|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
223455707|NCT01540513|DRUG|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
223455708|NCT02510612|DRUG|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
223455709|NCT02510612|DRUG|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
223455710|NCT04030234|DRUG|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
224065183|NCT00957008|OTHER|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
224065184|NCT00957008|DEVICE|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
224065185|NCT01118351|DRUG|sunitinib malate|Given orally
224065186|NCT01118351|OTHER|immunohistochemistry staining method|Correlative studies
224065187|NCT01118351|OTHER|TdT-mediated dUTP nick end labeling assay|Correlative studies
224065188|NCT01118351|OTHER|light microscopy|Correlative studies
224065189|NCT01118351|OTHER|laboratory biomarker analysis|Correlative studies
224065190|NCT02413112|BEHAVIORAL|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
224065191|NCT04016480|DEVICE|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
224065192|NCT04016480|DEVICE|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
224065193|NCT01515137|DRUG|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
224065194|NCT01515137|DRUG|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
224065195|NCT01515137|DRUG|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
224065196|NCT05372523|DIAGNOSTIC_TEST|CAPS-5 Assessment|A validated, semi-structured clinical interview to assess core PTSD symptoms
224065197|NCT05372523|DIAGNOSTIC_TEST|Senseye OBCI|Using a machine learning algorithm, Senseye's DT will record a series of visual tasks, pupil light reflex, vascular function and heart rate measurement throughout.
224065198|NCT00518154|DRUG|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
224065199|NCT05654389|OTHER|Application of teleconsultation for a patient with a provisional diagnosis of myocardial infarction at the district hospital|Using teleconsultation for a patient with a provisional diagnosis of myocardial infarction during referral from the district hospital to the cardiac centre
224065200|NCT00919100|DEVICE|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
224065201|NCT00919100|OTHER|vapocoolant|venipuncture with vapocoolant spray offered
224065202|NCT04200261|DRUG|Banapenem|2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed
224150776|NCT06935591|PROCEDURE|Pulmonary Vein Isolation|Subjects will receive treatment for Atrial Fibrillation with Pulmonary Vein Isolation per standard of care.
224150777|NCT06935591|DEVICE|vMap® + Pulmonary Vein Isolation|Subjects will receive treatment for Atrial Fibrillation with the use of the vMap® system and Pulmonary Vein Isolation.
224150778|NCT04532918|DRUG|Verinurad|The subjects will receive single oral dose of extended release capsule verinurad 7.5 mg on Day 1 of each treatment period under fasted condition.
223455711|NCT04030234|DRUG|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
223455712|NCT03541707|DEVICE|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
224065203|NCT04200261|DRUG|sodium chloride|sodium chloride
224065204|NCT06076421|OTHER|Fact box|Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.
224065205|NCT01536600|DRUG|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
224065206|NCT04052659|DRUG|Sintilimab|200 mg IV, every 3 weeks, d1
224065207|NCT04052659|DRUG|Chidamide|30 mg PO, 2 times every week, d1 and d4
224065208|NCT04052659|DRUG|Azacidine|100 mg SC, every 3 weeks, d1 to d7
224065209|NCT03345108|DEVICE|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
224065210|NCT03345108|DEVICE|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
224065211|NCT03345108|OTHER|No Adhesive|No adhesive applied.
224065212|NCT02317120|GENETIC|NGS BRCA 1 and BRCA 2 full sequencing|
224065213|NCT02317120|GENETIC|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
224065214|NCT02785250|OTHER|DPX-Survivac|SubQ injection
224065215|NCT02785250|DRUG|Cyclophosphamide|PO BID
224065216|NCT02785250|DRUG|Epacadostat (INCB024360)|PO BID
224065217|NCT01849302|DIETARY_SUPPLEMENT|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
224065218|NCT05000385|OTHER|Assesment of masticatory efficiency with optical scanning method|Participants will chew a standardized silicone tablet controlled by the examiner for 20 masticatory strokes. By scanning the comminuted particles, data on each particle size will be obtained. Enhanced masticatory performance is presented by a decrease in the chewed particle areas and an increase in the number of chewed particles.
224065219|NCT05000385|DIAGNOSTIC_TEST|body mass index|as an indication of nutritional status
224065220|NCT01867281|DRUG|aspirin|
224065221|NCT05104580|DEVICE|Quantitative Flow Ratio derived PPG|"From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2."
224065222|NCT02712567|DRUG|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
224065223|NCT05160155|PROCEDURE|Serratus Anterior Plane Block|Serratus anterior plane block will be performed unilaterally, under US guidance.
224065224|NCT05160155|PROCEDURE|Intercostal Block|Intercostal Block will be performed unilaterally, under US guidance.
224065225|NCT05284942|DRUG|Mycophenolate mofetil combined with oral prednisone|Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108
224065226|NCT03853785|BIOLOGICAL|MMR vaccine|Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.
224065227|NCT03853785|BIOLOGICAL|Candida antigen|Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.
224065228|NCT03853785|DRUG|Topical Podophyllin|It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
224065229|NCT01437852|BIOLOGICAL|StrataGraft Skin Tissue|
224150779|NCT04532918|DRUG|Allopurinol|The subjects will receive single oral dose of tablet allopurinol 300 mg on Day 1 of each treatment period under fasted condition.
224150780|NCT04532918|DRUG|Cyclosporine|The subjects will receive single oral dose of soft capsule cyclosporine 600 mg on Day 1 of treatment period 2 under fasted condition.
224150781|NCT04532918|DRUG|Rifampicin|The subjects will receive single oral dose of film coated tablets rifampicin 600 mg on Day 1 of treatment period 3 under fasted condition.
224301880|NCT01312571|BEHAVIORAL|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
224301881|NCT06035471|DIAGNOSTIC_TEST|MeD-seq|MeD-seq analyse: DNA treatment bisulfite --\> unmethylated C-nucleotide trabsformed in uracil.--\> PCR --\> next generation sequencing (NGS) --\> localization methylated nucleotides (enzym LpnPI).
224150782|NCT03427138|BEHAVIORAL|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
224150783|NCT03427138|BEHAVIORAL|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
224150784|NCT04639908|OTHER|Interview|interview with patient
224150785|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
224150786|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
224150787|NCT01336166|BIOLOGICAL|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
224150788|NCT01336166|BIOLOGICAL|Placebo control|120 adults were assigned to receive 1 dose of placebo.
224150789|NCT05508399|OTHER|DNA panel and RNA Sequencing|"Interventions include collecting samples, DNA panel test and full transcriptome sequencing.~Before collecting samples, obtaining written informed consent from patient in advance.~1. Blood cell samples;~2. Paraffin sample of residual tumor tissue of biopsy;~3. Paraffin sample of residual tumor tissue and paracancer tissue after gastrectomy."
224150790|NCT05435742|BIOLOGICAL|SON-080|Recombinant human interleukin-6 (rhIL-6)
224150791|NCT05243277|OTHER|Oculomotor tests|"There will be four visits. Each visit is associated with a different exposure in terms of level of oculomotor conflict.~At each visit, several oculomotor tests will be performed, followed by a comfort questionnaire. The oculomotor tests are subjective tests during which the participant will be asked to fix his/her eyes on one or more targets that can move in space and to indicate the way he/she perceives this/these target(s). Depending on the test, lenses may be inserted between the participant and the target to modify his/her perception.~The comfort questionnaire consists to rate on a scale of 1 (not at all) to 5 (very much) the presence of visual symptoms, such as burning, watering or dryness.~The participant will then have to perform four different perceptual tasks. His/her level of accommodation (i.e. focus) will be monitored throughout the tasks.~Each exposure is followed again by eye tests and a comfort questionnaire."
224150792|NCT02564029|DRUG|PF-06372865|Single dose
224150793|NCT02564029|DRUG|Placebo|Placebo for PF-06372865 and placebo for lorazepam
224150794|NCT02564029|DRUG|Lorazepam|2 mg single oral dose
224150795|NCT01520584|DIETARY_SUPPLEMENT|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
224150796|NCT02235402|DRUG|Lacidipine|
224301882|NCT01386151|DRUG|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
224150797|NCT02235402|DRUG|Bendrofluazide|
224150798|NCT02235402|DRUG|Placebo|
224150799|NCT04126031|DRUG|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
224150800|NCT04126031|DRUG|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
224150801|NCT01736631|BEHAVIORAL|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark \& Wells (Clark \& Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
224301883|NCT01386151|DRUG|Saline placebo|Normal (0.9%) saline will be used as a placebo.
224301884|NCT00077545|DRUG|triapine|Given IV
223455713|NCT00511485|DRUG|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
224301885|NCT00077545|DRUG|cisplatin|Given IV
224301886|NCT01041066|DRUG|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
224301887|NCT01041066|DRUG|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
224301888|NCT00121472|DEVICE|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
224301889|NCT02711735|BIOLOGICAL|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
224301890|NCT02711735|BIOLOGICAL|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
224305117|NCT00622466|DRUG|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
224305118|NCT00622466|DRUG|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
224305119|NCT01659866|DRUG|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
223455714|NCT00511485|DRUG|Etarfolatide|
223455715|NCT03327038|BEHAVIORAL|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
224150802|NCT03118076|DRUG|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
224150803|NCT03118076|DRUG|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
224150804|NCT02859896|DRUG|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
224150805|NCT02859896|DRUG|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
224150806|NCT01769144|DEVICE|Acticoat Absorbent|wound dressing
224150807|NCT01769144|DEVICE|BCT|wound dressing
224150808|NCT00002511|RADIATION|low-LET photon therapy|
224150809|NCT00617656|DRUG|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
224150810|NCT00617656|DRUG|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
224150811|NCT00617656|DRUG|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
224150812|NCT00617656|DRUG|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
224150813|NCT03789890|DRUG|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
224150814|NCT03789890|DRUG|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
224150815|NCT01344252|DRUG|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
224150816|NCT00176124|PROCEDURE|leukocyte depletion of whole blood|
224150817|NCT00176124|OTHER|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
224150818|NCT00131664|DRUG|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
224150819|NCT00131664|DRUG|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
224301891|NCT00654758|DRUG|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
224301892|NCT02080013|OTHER|radiofrequency|ClosureFAST
224150820|NCT00131664|DRUG|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
224150821|NCT00326157|DRUG|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
224150822|NCT05264558|DEVICE|Xpert HCV Viral load finger stick point of care test (Cepheid)|Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
224150823|NCT05264558|DRUG|Epclusa 400Mg-100Mg Tablet|Same day HCV test and treatment
224150824|NCT05264558|OTHER|Standard of care|Clinical services will receive additional education and have the option of providing incentives to attendees of service.
224150825|NCT02952833|DRUG|Saline|Sodium chloride solution.
224150826|NCT02952833|BIOLOGICAL|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
224150827|NCT01855841|DRUG|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
224150828|NCT01855841|DRUG|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
224150829|NCT01201304|BEHAVIORAL|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
224150830|NCT01201304|BEHAVIORAL|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
224150831|NCT01201304|BEHAVIORAL|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
224150832|NCT01201304|BEHAVIORAL|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
224301893|NCT02934659|DEVICE|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
224301894|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
224301895|NCT02117700|DIETARY_SUPPLEMENT|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
224301896|NCT02117700|OTHER|Placebo twice/day|Placebo capsules twice/day for 16 weeks
224301897|NCT01334983|BEHAVIORAL|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
224301898|NCT01398215|PROCEDURE|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
224301899|NCT06504420|DRUG|Sirolimus|Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen
224301900|NCT06504420|DRUG|Placebo|Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
224301901|NCT06024889|DRUG|Furosemide Injection|Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS\*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis. These measurements are repeated at multiple time points until 6 hours have elapsed.
224301902|NCT04849962|OTHER|Control|Participants in this group received a traditional muffin with butter as the predominant source of fat.
224301903|NCT04849962|OTHER|Pecan|Participants in this group received a muffin in which part of the butter was substituted out for pecans.
224301904|NCT02008786|DRUG|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
223455716|NCT03327038|OTHER|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
224065230|NCT04408690|PROCEDURE|Immediate anterior cruciate ligament reconstruction|"No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury."
224065231|NCT04408690|OTHER|Rehabilitation|All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
224065232|NCT04408690|PROCEDURE|Optional delayed anterior cruciate ligament reconstruction|"If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury."
224065233|NCT03114514|BIOLOGICAL|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
224065234|NCT06308276|OTHER|Aerobic Training|Aerobic Training: Brisk walking, jogging, cycling, or low-impact aerobics
224065235|NCT06308276|OTHER|Resistance Training|Resistance Training: Full body resistance exercise targeting major muscle groups, including squats, lunges, chest presses, rows, and core exercises
224065236|NCT06378814|PROCEDURE|Selective Caries Removal (No Pulp Exposure)|Caries excavation technique where clinician leaves carious tissue so close to pulp
224065237|NCT06378814|PROCEDURE|Non-Selective Caries Removal (No Pulp exposure)|Complete caries removal even in areas so close to pulp
224065238|NCT06378814|PROCEDURE|Partial Pulpotomy (Pulp Exposed)|In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue
224065239|NCT04853784|PROCEDURE|intracorporeal anastomosis|intracorporeal anastomosis
224065240|NCT04648384|DIETARY_SUPPLEMENT|Blend Protein Supplementation|Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
224065241|NCT04648384|DIETARY_SUPPLEMENT|Placebo Supplementation|Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
224065242|NCT04648384|OTHER|Resistance Exercise|10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise
224065243|NCT01816009|OTHER|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
224065244|NCT05234970|OTHER|Wysa|Participants in the intervention arm will be able to log into the Wysa app at any time of day. They can chat with the AI-based bot, Wysa, or choose to complete different self-care exercises. These exercises are grouped into tool packs, which include dealing with relationships, overcoming loneliness, managing mood, among many others. Users can engage in simple, therapeutic exercises including mindfulness and cognitive re-structuring for negative thinking.
224065245|NCT05234970|OTHER|Harvard College App|Participants in the control arm will be given instructions on how to download and utilize the Harvard College App. Students assigned to this app receive instructions on how to utilize the app to navigate resources on campus to support their mental health including professional and peer support groups and how to make an appointment at the Counseling and Mental Health Services. Participants cannot send messages or share any information through the app.
224065246|NCT04517747|DRUG|Ramucirumab|chemotherapy i.v.
224065247|NCT04517747|DRUG|TAS 102|p.o. twice daily
224065248|NCT04962360|DIETARY_SUPPLEMENT|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
224065249|NCT04962360|DIETARY_SUPPLEMENT|Placebo|Low caloric formula (Powder added to water) without added vitamins and minerals
224065250|NCT04131335|DRUG|AEONTM Repair|Lubricating eye drops
224065251|NCT04131335|OTHER|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
224065252|NCT04971876|DEVICE|HLR-1|Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
224065253|NCT04971876|DEVICE|HLR-2|Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
224065254|NCT04971876|DEVICE|HLR-3|Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
224301905|NCT02008786|DRUG|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
224301906|NCT02008786|DRUG|placebo|Placebo
224301907|NCT03906396|DEVICE|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
224305120|NCT01659866|DRUG|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
224150833|NCT05551260|OTHER|Neuropsychological assessments (tests allowing to measures attentional, executive and emotional performances) and experimental protocol assessing moral cognition|"Day 0: sending of the information notice~Day 1 : signing the consent form + neuropsychological tests assessing reasoning and abstraction abilities, attentional processes, executive functions (including inhibition and mental flexibility) and social cognitive functions, including facial emotion recognition, theory of mind and perception and social knowledge (duration 1h30-2h). Experimental protocol: vignettes of moral offenses manipulating variables of intention and consequence. This systematic manipulation, commonly used in the field of moral judgment, usually leads to 3 combinations of variables: intentional harm (present intention; present consequence); attempted harm (intent present; consequence absent); accidental harm (intention absent; consequence present). Another form of accidental harm will also be constructed (positive intention; present consequence) (duration : 1h)~Between day 1 and day 21 : second part of the Day 1 tests"
224150834|NCT03770676|DIETARY_SUPPLEMENT|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
224150835|NCT04441554|DIAGNOSTIC_TEST|7 Tesla MRI|7 Tesla MRI of cervical spine
224150836|NCT03815123|DIAGNOSTIC_TEST|cardiac CT|The cardiac CT examinations are indicated by the referring physician. The participation in this study has no influence on the further diagnostic and therapeutic regimen.
224150837|NCT04673812|DRUG|Bupivacaine-fentanyl|"Bupivacaine-Fentanyl (BF) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and (0.5 mL) normal saline added in the same syringe in a total volume of 3.5 mL.~Bupivacaine-Fentanyl-Naloxone (BFN) group (46 patients): will receive spinal anaesthesia with 12.5 mg hyperbaric Bupivacaine 0.5% (2.5 mL) plus 25 µg Fentanyl (0.5 mL) and 20 µg Naloxone (prepared in 0.5 mL normal saline) added in the same syringe in a total volume of 3.5 mL."
224150838|NCT03611998|BEHAVIORAL|Occupation-based programming|Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
224150839|NCT00003777|DRUG|amifostine trihydrate|
224150840|NCT00003777|DRUG|cisplatin|
224150841|NCT00003777|DRUG|fluorouracil|
224150842|NCT00003777|PROCEDURE|surgical procedure|
224150843|NCT00003777|RADIATION|radiation therapy|
224301908|NCT03791723|DRUG|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
224301909|NCT03791723|DRUG|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
224301910|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate and Vitamin C|28 mg iron 240 mg vitamin C
224301911|NCT04469010|DIETARY_SUPPLEMENT|Iron Bis-Glycinate Chelate|28 mg iron
224301912|NCT04469010|DIETARY_SUPPLEMENT|Placebo|Matched placebo
224305121|NCT01659866|DRUG|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
224065255|NCT00601068|OTHER|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
224065256|NCT03986385|DRUG|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
224065257|NCT03986385|DRUG|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
224065258|NCT04536688|DRUG|RGLS4326|Solution for subcutaneous injection
224065259|NCT04413253|DRUG|Lifitegrast 5% Ophthalmic Solution|To reduce signs and symptoms of dry eye disease
224065260|NCT04413253|DRUG|Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution|To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.
224065261|NCT00655031|DIETARY_SUPPLEMENT|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
224065262|NCT00655031|DIETARY_SUPPLEMENT|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
224065263|NCT00919503|PROCEDURE|Allogeneic Bone Marrow Transplantation|Infused IV
224065264|NCT00919503|BIOLOGICAL|Anti-Thymocyte Globulin|Given IV
224065265|NCT00919503|DRUG|Cyclosporine|Given IV or PO
224065266|NCT00919503|DRUG|Fludarabine Phosphate|Given IV
224065267|NCT00919503|OTHER|Laboratory Biomarker Analysis|Correlative studies
224065268|NCT00919503|DRUG|Methotrexate|Given IV
224065269|NCT00919503|DRUG|Mycophenolate Mofetil|Given IV or PO
224065270|NCT00919503|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Infused IV
224065271|NCT00919503|DRUG|Tacrolimus|Given IV or PO
224065272|NCT00919503|RADIATION|Total-Body Irradiation|Undergo total body irradiation
224065273|NCT00919503|DRUG|Treosulfan|Given IV
224065274|NCT00919503|PROCEDURE|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
224065275|NCT04833088|OTHER|Focus group discussions|Focus group discussions will be organized to investigate the needs and requirements of the participants in terms of three pre-defined user scenarios.
224065276|NCT00801879|DRUG|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
224065277|NCT00801879|DRUG|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
224065278|NCT00649532|DRUG|Ondansetron Tablets 24 mg|24mg, single dose fasting
224065279|NCT00649532|DRUG|Zofran® Tablets 24 mg|24mg, single dose fasting
224065280|NCT01324258|DRUG|GSK1120212|Part1 and Part2
224065281|NCT01324258|DRUG|Gemcitabine|Part2
224305122|NCT01659866|DRUG|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
223455717|NCT03327038|BEHAVIORAL|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
223455718|NCT03327038|OTHER|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
224065282|NCT03923569|DIAGNOSTIC_TEST|Overnight polysomnography|Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
224065283|NCT03923569|DIAGNOSTIC_TEST|blood sample|blood sample for genetic testing of the Apolipoprotein E
224065284|NCT03923569|DIAGNOSTIC_TEST|high-resolution MRI scan|Evaluation of anomalies in brain structure and functional resting state connectivity
224065285|NCT03923569|BEHAVIORAL|neuropsychological evaluation|neuropsychological evaluation including episodic memory tests before an overnight polysomnography
224065286|NCT05945953|OTHER|Incentive spirometer as visual feedback|"Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
224065287|NCT05945953|OTHER|Diaphragmatic breathing exercise (Mirror mediated therapy)|"Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen)."
224065288|NCT03659682|DRUG|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
224065289|NCT03227900|DRUG|Lidocaine|Intragastric infusion of lidocain
224065290|NCT03227900|DRUG|Placebos|Intragastric infusion of water for injections
224065291|NCT01072214|DRUG|pazopanib|gw786034
224065292|NCT01072214|DRUG|pazopanib|gw786034
224065293|NCT01072214|DRUG|pazopanib|gw786034
224065294|NCT01072214|DRUG|Placebo|placebo
224065295|NCT04654494|PROCEDURE|Total proctocolectomy|excision of the whole large bowel including colon and rectum and end ileostomy fashioning
224065296|NCT04654494|PROCEDURE|Total colectomy|excision of the colon with preservation of the rectum
224065297|NCT04654494|PROCEDURE|Segmental colectomy|excision of a segment of colon
224065298|NCT04925232|DEVICE|Transcranial Magnetic Stimulation device|Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
224065299|NCT03725748|OTHER|irrigation|irrigation the edges of the cs scar before closure
224065300|NCT04840160|DIETARY_SUPPLEMENT|Cherry juice|A tart cherry juice intervention
224065301|NCT04840160|DIETARY_SUPPLEMENT|Placebo|A tart cherry juice placebo
224065302|NCT03641066|DEVICE|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions \[1\] un-braced, \[2\] Active Ankle 329 Ankle Sleeve, \[3\] AS1Pro (a lace-up brace), \[4\] Eclipse 1 (single-upright brace), and \[5\] Eclipse 2 (double upright brace)
224065303|NCT02368054|DRUG|Bupivacaine|Infiltration anesthesia
224065304|NCT02368054|DRUG|Adrenaline|Infiltration anesthesia
224065305|NCT03094871|BEHAVIORAL|FACE-PC|
224065306|NCT01018498|BEHAVIORAL|Restricted FODMAPs diet|Restricted fermentable substrate diet
224065307|NCT04921735|DRUG|Cisatracurium|0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
224065308|NCT05097456|DEVICE|carbon dioxide laser|carbon dioxide laser
224065309|NCT05097456|DEVICE|sham laser|sham laser
224065310|NCT02305355|DRUG|Omega-3-acids ethylesters 90 4g|
224065311|NCT02305355|DRUG|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
224065312|NCT00072735|PROCEDURE|Electrocardiogram|
224065313|NCT05070221|DRUG|Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)|less than 8mL/time，Q2W，i.t.；
224065314|NCT05070221|DRUG|Recombinant humanized anti-PD-1 monoclonal antibody for injection|200mg/time，Q3W，i.v.；
224065315|NCT05070221|DRUG|Axitinib|5mg，bid，p.o.；
224065316|NCT05224583|PROCEDURE|Simultaneous Liver-Kidney Transplant|Simultaneous Liver-Kidney Transplant
224065317|NCT03422315|DRUG|Propofol|injection;2mg/kg;single-dose
224065318|NCT00886301|PROCEDURE|liver biopsy|liver biopsy
224065319|NCT00414453|DRUG|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
224065320|NCT00414453|DRUG|Extended-release oxycodone|extended-release oxycodone titrating schedule
224065321|NCT00414453|DRUG|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
224065322|NCT00414453|DRUG|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
224065323|NCT01231100|OTHER|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
224150844|NCT05441540|DEVICE|Internal Jugular Vein Compression Collar|The current FDA approved internal jugular vein compression collar, marketed as the Q collar, is manufactured by Q30 Innovations Home. It is designed to be worn around the neck of individuals aged 13 and older. It functions by lightly compressing the internal jugular vein's bilaterally, safely increasing intracranial volume and intracranial pressure. The FDA approved neck collar device is made of a thermoplastic elastomer that is specifically fitted to an individual to provide mild internal jugular vein compression. The product was developed and confirmed with ultrasonography to confirm appropriate fit and compression of the vein based on an athlete's neck circumference.
224150845|NCT04402346|PROCEDURE|Radiofrequency-assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a radio frequency device
224150846|NCT04402346|PROCEDURE|Stapler assisted pancreas transection|Transection of the pancreas in distal pancreatectomy by applying a stapler device with/without seamguard
224150847|NCT05855681|OTHER|therapeutic exercises|strengthening exercise and stretching exercise
224150848|NCT03040765|DRUG|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
224150849|NCT03040765|DRUG|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
224150850|NCT05491447|DRUG|BMX-010|Ointment
224150851|NCT05491447|DRUG|Placebo|Ointment
224150852|NCT01624688|PROCEDURE|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
224150853|NCT00456833|DRUG|RAD001|
224150854|NCT00456833|DRUG|erlotinib|
224150855|NCT00979108|OTHER|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
224150856|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
224150857|NCT00979108|OTHER|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
224150858|NCT05096546|OTHER|No intervention|No intervention will be applied for the observational study.
224150859|NCT00472017|DRUG|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
224150860|NCT03607071|DRUG|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
224150861|NCT00971542|BIOLOGICAL|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
224150862|NCT03862495|DIAGNOSTIC_TEST|C. trachomatis and N. gonorrhoeae|In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
224150863|NCT03862495|DRUG|Azithromycin|Azithromycin 1g administered as a single oral dose
224150864|NCT03862495|OTHER|Partner notification and treatment|Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
224150865|NCT00182507|DRUG|Olanzapine|
224150866|NCT06342648|DRUG|Sterile Water Injection|Injection of intracutaneous sterile water
224150867|NCT06342648|DRUG|Diclofenac Sodium injection|Injection of intramuscular diclofenac sodium
224150868|NCT04383613|OTHER|Prone positioning|The intervention is prone positioning (i.e., instructing a patient to lie on their stomach while they are in bed) for 7 days or until the first of study hospital discharge or not requiring supplemental oxygen for \>24 hours or study outcome. Patients will be asked to aim for prone positioning four times per day for at least two hours each time, and will be encouraged to sleep on their stomach at night.
224150869|NCT06366334|DRUG|Ketamine Hydrochloride|See arm description
224150870|NCT06366334|DRUG|Normal saline|See arm description
224150871|NCT03853304|OTHER|+ Folic acid|Salt fortified with folic acid
224150872|NCT03853304|OTHER|+ Vitamin B12|Salt fortified with vitamin B12
224150873|NCT03853304|OTHER|DFS|Salt fortified with iron and iodine
224150874|NCT02120144|OTHER|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
224150875|NCT02120144|OTHER|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
224150876|NCT03554304|DRUG|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
224150877|NCT03554304|DRUG|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
224150878|NCT03554304|DRUG|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
224150879|NCT02525952|PROCEDURE|Hepatectomy|Surgical removal of all lesions
224150880|NCT02525952|PROCEDURE|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
224150881|NCT00425113|DRUG|Metronidazole|
224150882|NCT00425113|PROCEDURE|Blood Draw|
224150883|NCT00425113|PROCEDURE|CT Scan|
224150884|NCT00425113|PROCEDURE|PET Scan|
224150885|NCT05019651|DEVICE|Apollo Wearable System|Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
224150886|NCT04989088|DEVICE|ProComp5 Infiniti System w/BioGraph Infiniti Software|Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)
224150887|NCT04989088|DEVICE|ProComp5 Infiniti System w/recorded videos|Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
224150888|NCT01969513|PROCEDURE|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
224150889|NCT01969513|PROCEDURE|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
224150890|NCT00864344|DRUG|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
224150891|NCT00864344|DRUG|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
224150892|NCT04280406|DRUG|Azithromycin|azithromycin 500mg one hour before implant placement
224150893|NCT04280406|DRUG|Placebo oral tablet|identical placebo one hour before implant placement
224150894|NCT00879437|DRUG|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
224150895|NCT00879437|DRUG|Bevacizumab|All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
224150896|NCT00879437|RADIATION|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
224150897|NCT01423955|DRUG|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
224150898|NCT01423955|DRUG|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
224150899|NCT02964988|DRUG|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
224150900|NCT02964988|DEVICE|PET/CT|Whole body PET/CT
223455719|NCT03327038|OTHER|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
224150901|NCT01039636|DRUG|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
224150902|NCT03000686|BIOLOGICAL|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
224150903|NCT03000686|OTHER|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
224150904|NCT00129207|DRUG|bortezomib|
223455720|NCT04633499|BEHAVIORAL|Social Cognition Task|Two paradigms will be tested: visual perspective taking and reading the mind in the eyes.
223455721|NCT04633499|DEVICE|tDCS|tDCS either over the dmPFC or the rTPJ.
223455722|NCT04411758|DIETARY_SUPPLEMENT|Propolis|Four capsules (400mg/day) containing dry EPP-AF® green propolis extract for 2 months and after washout, more two months crossover
224150905|NCT00948038|DIETARY_SUPPLEMENT|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
224150906|NCT00948038|DIETARY_SUPPLEMENT|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
224150907|NCT00683007|OTHER|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
224150908|NCT00683007|OTHER|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
224150909|NCT05316480|DRUG|Nimotuzumab|nimotuzumab 200mg/week
224150910|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
224150911|NCT02291445|DRUG|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
224150912|NCT03212807|DRUG|Durvalumab|Investigational Medicinal Product
224150913|NCT03212807|DRUG|Lenalidomide|Investigational Medicinal Product
224150914|NCT00100646|BEHAVIORAL|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
224150915|NCT00100646|DRUG|Lamivudine|300 mg tablet taken orally daily
224150916|NCT00100646|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
224150917|NCT00100646|DRUG|Stavudine|Dosage dependent on weight
224150918|NCT00100646|BIOLOGICAL|Rabies de novo antigen|Vaccine injected intramuscularly
224301913|NCT02444923|DEVICE|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
224301914|NCT02444923|DEVICE|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
223455723|NCT04411758|DIETARY_SUPPLEMENT|Placebo|Four capsules (400mg/day) containing magnesium stearate, silicon dioxide and microcrystalline cellulose for 2 months and after washout, more two months crossover
223455724|NCT01341093|BEHAVIORAL|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
223455725|NCT01341093|BEHAVIORAL|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
223455726|NCT00972283|DRUG|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
223455727|NCT00972283|DRUG|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
223455728|NCT00972283|DRUG|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
223455729|NCT02893046|OTHER|No intervention|
223455730|NCT02721498|PROCEDURE|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
224065324|NCT02120014|PROCEDURE|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
224065325|NCT02120014|PROCEDURE|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
224065326|NCT06079450|OTHER|artificial intelligence based mobile application|Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
224065327|NCT05837637|DIAGNOSTIC_TEST|The Vietnamese Smell Identification test (VSIT), the Brief Smell Identification test (BSIT)|"* The VSIT: Odorants used in the VSIT are odorous liquids commercially available in Vietnam. Cotton buds are dipped in diluted odor solution and are used as test materials. The cotton swab is then packaged in a sterile and non-volatile sachet. Participants tore the cotton swab-containing sachet in the direction of the arrow to reveal the bud of the cotton swab and place it approximately 2 cm from the nostrils for 2-3 seconds. The score based on the number of correct answers ranges from 0 to 12.~* The BSIT: BSIT will be purchased from Sensoics, Inc. and used according to the manufacturer's instructions. Odorants are microencapsulated on the paper and odors are released when the subject uses a pencil to scratch the microcapsule coating. Odorants are placed 2 cm from the both nostrils and participants selected the smell from the answer card containing four options for each odorant. The score based on the number of correct answers ranges from 0 to 12"
224065328|NCT00845728|DRUG|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
224065329|NCT00845728|DRUG|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
224065330|NCT02907385|DEVICE|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
224065331|NCT02206646|DRUG|Metalyse|
224065332|NCT02919878|DRUG|Gemcitabine|Nucleoside analog- Chemotherapy
224065333|NCT02919878|RADIATION|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
224065334|NCT02919878|DRUG|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
224065335|NCT00941876|BEHAVIORAL|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
224065336|NCT00822757|BIOLOGICAL|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
224065337|NCT00822757|BIOLOGICAL|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
224065338|NCT04457804|BEHAVIORAL|Virtual ACT Workshop for Emotional Eating|"This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
224065339|NCT06537960|PROCEDURE|18FDG PET-CT|"18FDG PET-CT will be performed in 2 phases:~1. st standard phase: Standard acquisition (vertex to mid-thigh) at 1 hour post-injection of radiotracer~2. nd phase: Complementary abdomino-pelvic acquisition at 2.5 hours post radiotracer injection."
224065340|NCT05990673|DRUG|Remimazolam|remimazolam is given intravenously
224065341|NCT05697601|DIAGNOSTIC_TEST|Artificial-Intelligence Based Screening Tools|Artificial-Intelligence Based Screening Tools build on machine learning models
224065342|NCT05697601|DIAGNOSTIC_TEST|Pathology analysis|Pathology assessment of cells and tissues from respective organs
224065343|NCT02419560|DRUG|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
224065344|NCT04646759|DRUG|Fulvestrant combined with Pyrotinib|Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily
224065345|NCT04646759|DRUG|Capecitabine combined with Pyrotinib|Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
224065346|NCT06359509|BIOLOGICAL|BCMA Targeted CAR T-cells|Each patient will receive BCMA Targeted CAR T-cells by intravenous infusion.
224065347|NCT03150771|DRUG|Aripiprazole|Injection
224065348|NCT05725616|PROCEDURE|Coronary angiography|Snuff Box Approach or radial Arterial Approach at wrist for coronary angiography.
224301915|NCT02053935|DRUG|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
224301916|NCT04425135|DRUG|Camrelizumab|200mg,D1,ivgtt, Q3w.
224150919|NCT05806112|BEHAVIORAL|Resiliency Training|"The Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) has been shown to be effective in improving resilience and reducing distress among individuals across different populations and settings. The SMART-3RP enhances resilience by 1) teaching tools to elicit the relaxation response (RR) to offset negative effects of chronic stress; 2) improving stress management and awareness; and 3) promoting growth enhancement and agency to effect positive change. It blends stress coping principles from mind-body, cognitive-behavioral, and positive psychology theory to teach skills to advance each of these resiliency processes. The training will be delivered in six 50-minute virtual group sessions with 2 optional booster sessions available for those who desire additional sessions to further consolidate the core resiliency skills."
224150920|NCT05806112|BEHAVIORAL|Task Sharing|"Task Sharing is a process involving health care workers in partnership with others in which workers retain many of their primary tasks, but some tasks are completed collaboratively or by other workers or volunteers in a shared effort. Study coaches will work with the group home directors and RCWs to identify shared tasks that may be conducted by peers or resident volunteers by task co-assignment with supervision and support. Task co-assignments will be discussed in routine house meetings occurring on a weekly basis and incorporated into a jointly developed house plan. The house plan will engage staff and residents to identify shared activities to reduce the burden on RCWs through task co-assignment and team-based efforts aimed at tasks that create unnecessary burden and stress for RCWs, yet do not require RCWs to complete them."
224150921|NCT05806112|BEHAVIORAL|Workplace Improvement Learning Collaborative|The Workplace Improvement Learning Collaborative (WILC) consists of identifying major sources of RCW burnout across the system and then instituting an organizational (agency-wide) measure to address the identified sources of burnout by restructuring tasks (e.g., reducing administrative burdens, increasing workflow efficiencies) through a virtual earning collaborative with group home leaders. Learning collaboratives commonly use a structured framework within which teams learn about research and best practices, apply quality-improvement methods, and exchange their experiences in making improvements with the widespread use of such collaboratives. Program Directors will participate in a learning collaborative facilitated by trained and certified study coaches to identify and collaboratively develop and implement effective strategies to address root causes of RCW burnout across group homes and program directors assigned to the WILC intervention.
224150922|NCT02843750|BEHAVIORAL|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home"
224150923|NCT02843750|OTHER|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
224150924|NCT00228033|DRUG|Elemental calcium (as carbonate)|
224150925|NCT01604096|OTHER|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~* brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~* posters (same distribution as brochures)~* short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~* radio-spots transmitted in local radio stations~* advertisements in local newspapers~* banners on websites of local newspapers~* newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~* training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
224301917|NCT04425135|DRUG|Apatinib|250mg,Qd,Q3W.
224301918|NCT04425135|DRUG|Pemetrixed|500 mg/m2,D1,ivgtt, Q3w.
223455731|NCT02721498|OTHER|Rest period|A 30-60 minute of resting
224301919|NCT04425135|DRUG|Carboplatin|AUC=5\~6,D1,ivgtt, Q3w.
224301920|NCT06138236|DRUG|Collagen hydrolyzed peptides|infiltration near the heal spur of 2ml of Arthrys
223455732|NCT03482908|BEHAVIORAL|Early healthy lifestyles|Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future
223455733|NCT03482908|BEHAVIORAL|Responsive parenting curriculum|Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby
223455734|NCT03482908|BEHAVIORAL|Data sharing/coordination|Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
223455735|NCT01390571|DRUG|olaparib|
223455736|NCT01390571|DRUG|temozolomide|
223455737|NCT01390571|GENETIC|gene expression analysis|
223455738|NCT01390571|GENETIC|protein expression analysis|
223455739|NCT01390571|OTHER|laboratory biomarker analysis|
223455740|NCT01390571|OTHER|pharmacological study|
223455741|NCT01390571|PROCEDURE|diffusion-weighted magnetic resonance imaging|
223455742|NCT01390571|PROCEDURE|dynamic contrast-enhanced magnetic resonance imaging|
223455743|NCT01390571|PROCEDURE|therapeutic conventional surgery|
223455744|NCT01634308|DRUG|Novosis(bongros/BMP-2)|
223455745|NCT01634308|DRUG|Bio-oss|
223455746|NCT00019357|BIOLOGICAL|aldesleukin|
223455747|NCT00019357|BIOLOGICAL|therapeutic autologous lymphocytes|
223455748|NCT00019357|BIOLOGICAL|therapeutic tumor infiltrating lymphocytes|
223455749|NCT03145051|OTHER|Saline solution|a nasal irrigation care
223455750|NCT03145051|OTHER|Respimer Netiflow|a nasal irrigation care
223455751|NCT00502853|DRUG|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
223455752|NCT00502853|DRUG|Methotrexate|10-25mg/week
223455753|NCT02382315|BEHAVIORAL|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
223455754|NCT05096962|DIAGNOSTIC_TEST|Quantitative analysis of SARS-CoV-2 antibodies|The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).
224301921|NCT00003960|DRUG|busulfan|
224301922|NCT00003960|DRUG|cyclophosphamide|
224301923|NCT00003960|DRUG|methylprednisolone|
224301924|NCT00003960|PROCEDURE|allogeneic bone marrow transplantation|
224301925|NCT00003960|PROCEDURE|in vitro-treated bone marrow transplantation|
224301926|NCT05759936|DIETARY_SUPPLEMENT|500mg seaweed|4 week supplementation of 1 capsule per day of seaweed
223455755|NCT05096962|DIAGNOSTIC_TEST|Cellular immunity|Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
224065349|NCT05012956|PROCEDURE|Laparoscopic sacrocolpopexy|During laparoscopic sacrocolpopexy, the anatomical position of the vaginal vault and cervix (if present) is restored by suturing a surgical mesh to the vaginal cuff or cervix and variable portions of the anterior and posterior vagina, while connecting the other end of the mesh to the anterior longitudinal ligament over the sacrum.
224065350|NCT05012956|PROCEDURE|gynecologic laparoscopic surgery|Gynecologic laparoscopic surgery at UZ Leuven, other than sacrocolpopexy
224065351|NCT04951037|BEHAVIORAL|Fully Asynchronous Online Savvy Program|"The intervention is a fully online, self-administered psychoeducational program designed to enhance caregiver mastery for family and friends providing unpaid care for living with Alzheimer's and similar dementia disorders. Participants will be asked to engage with a fully online version of Tele-Savvy for 42 days.~Participants will receive a series of daily video lessons related to caregiving. These lessons are generally 8-15 minutes in length and are emailed to participants. Participants can watch the lessons whenever and as often as they wish over the course of the study. There will also be self-guided learning strategies and exercises to accomplish skill and mastery related to the caregiving role. The lessons cover a variety of topics including:~* Facts about dementing Illnesses~* Caregiving Strategies - guiding the person through days that are as safe, calm, and pleasant as possible~* Self-Care for the Caregiver"
224065352|NCT05630937|DRUG|NMS-01940153E|Route of administration: intravenous (IV) solution
224065353|NCT05949905|BEHAVIORAL|Stage-matched interventions|The intervention would be using the Processes of Change that match each Stage of Change.
224065354|NCT05137327|BEHAVIORAL|Classroom Behavior Support (CBS) Condition|An individualized teacher consultation program that includes observation and performance feedback and techniques borrowed from Motivational Interviewing and Cognitive Behavioral Therapy (CBS). It is designed to address barriers to implementation and improve teacher practices and student outcomes.
224065355|NCT05137327|BEHAVIORAL|Standard Problem Solving Consultation|A standard problem solving approach to teacher consultation that includes observation and brief performance feedback. It represents current best practice in teacher consultation.
224065356|NCT00500084|DRUG|Liprotamase|Administered orally
224065357|NCT04677244|PROCEDURE|Blood sample in portal vein|A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
224065358|NCT04319978|DRUG|Dexamethasone injection|Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
224065359|NCT02500524|DRUG|Cocamide diethanolamine|Topical lotion
224065360|NCT02500524|DRUG|Permethrin|Topical creme rinse
224065361|NCT03946709|OTHER|Action Observation|Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
224065362|NCT00514865|DRUG|ONO-2333Ms Experimental 2|5-10 mg QD(once a day) for 8 weeks
224065363|NCT00514865|DRUG|Placebo|0 mg QD(once a day) for 8 weeks
224065364|NCT00514865|DRUG|ONO-2333Ms Experimental 1|1-2 mg QD(once a day) for 8 weeks
224065365|NCT00003460|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
224065366|NCT00331474|BIOLOGICAL|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
224065367|NCT04719182|OTHER|Adjunctive therapies|Determine and compare practice of adjunctive and supportive treatments for COVID-19
224065368|NCT03616938|PROCEDURE|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
224065369|NCT02214238|DEVICE|PAP device|
224065370|NCT05985031|DIAGNOSTIC_TEST|Tendon tap|While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.
224065371|NCT05985031|DIAGNOSTIC_TEST|Tibial nerve stimulation|H-reflex responses were examined by tibial nerve stimulation
224065372|NCT00849732|BIOLOGICAL|V520|Intentionally Blank
224065373|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^9 vp/d given at Day 1, Week 4, and Week 26
224065374|NCT00849732|BIOLOGICAL|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10\^10 vp/d given at Day 1, Week 4, and Week 26
224065375|NCT00849732|BIOLOGICAL|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
224065376|NCT03432078|OTHER|Hypnotherapy|Non-pharmacological treatment
224065377|NCT00397826|DRUG|MK0733|Duration of Treatment: 12 Weeks
224065378|NCT01173991|BEHAVIORAL|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
224065379|NCT00273975|DRUG|Nevirapine|
224065380|NCT00273975|DRUG|Lamivudine|
224065381|NCT00273975|DRUG|Zidovudine|
224065382|NCT01717209|DRUG|Nitric Oxide|inhaled nitric oxide
224065383|NCT01717209|DRUG|Prostacyclin|inhaled prostacyclin
224065384|NCT02833012|DRUG|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
224065385|NCT02833012|DRUG|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
224150926|NCT01647425|BEHAVIORAL|physician assessment|"* Socio-economic conditions and general features: educational level, professional status...~* Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~* in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~* Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~* Assessment of current use of cannabis using the Cannabis Abuse Screening Test~* Psychiatric assessment using the MINI 5.0"
224150927|NCT02867722|DRUG|aminolevulinic acid HCl|Drug will be administered to consented patients
224150928|NCT00054444|DRUG|Topotecan Hydrochloride Liposomes|Given IV
224150929|NCT00054444|RADIATION|3-Dimensional Conformal Radiation Therapy|
224150930|NCT00054444|DRUG|Cisplatin|Given IV
224150931|NCT06349850|DIAGNOSTIC_TEST|serum uric acid level to plasma HDL-c level ratio (UHR)|high UHR is considered to be a risk factor for development of DKI in type 2 DM
224150932|NCT02672618|OTHER||The IRS system is capable of precisely measuring and storing real-time thermal images with a resolution of 320×240 pixels (IRS S6md Shanghai,China). The camera has Focal Plane Array (FPA), Uncooled microbolometer detector, with a thermal sensitivity of 0.05 ℃ at 20℃ to 30℃. The thermal images were captured at a distance of one meter from the various body regions namely face and the images were analyzed by thermal software（version 1.0）.
224150933|NCT05446922|OTHER|Diffusion MRI|All procedures will be performed during a single visit. Subjects will be invited to lie on the scanning bed that will be moved head first into the scanner such as the head lie under the scanner magnets. Hearing protection will be provided to each subject to muffle the noise produced by the MRI scanner. Subjects will also be provided with pillows and blankets to keep them comfortable. They will also be given a call button that they can push to stop the procedure at any time. MRI acquisition will be performed on 1.5T or 3.0T MRI scanners depending on centre's equipment. Acquisition protocol will include the following sequences with the best parameters chosen by local radiologist and technical BrainTale team.
224150934|NCT06149754|DEVICE|BraiN20(R) monitoring of N20 somatosensory evoked potential|N20 monitoring will be carried out using the BraiN20 medical device and appropriate electrodes. The device measures one N20 wave per 33 seconds. Scalp electrodes will be located on band and wrist electrodes on a globe. The device provides an automatic reading of N20 and outcome prediction and do not require a specific training.
224150935|NCT01112982|OTHER|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
224150936|NCT01112982|DRUG|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is \> 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
224150937|NCT01112982|DRUG|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
224150938|NCT05512312|PROCEDURE|Conventional Esthetic crown lengthening|Conventional Surgical Esthetic Crown Lengthening
224150939|NCT05512312|PROCEDURE|Computer guided Esthetic crown lengthening|Computer guided Esthetic crown lengthening
224150940|NCT02336048|DRUG|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
224150941|NCT02336048|DRUG|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
224150942|NCT02336048|DRUG|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
224150943|NCT02336048|OTHER|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
224150944|NCT02336048|DRUG|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
224150945|NCT01244204|DIETARY_SUPPLEMENT|Vitamin D|Daily dose of 800IU of vitamin D
224150946|NCT01244204|DIETARY_SUPPLEMENT|Placebo|Identically appearing capsules
224150947|NCT04242459|RADIATION|Adaptive Radiotherapy|Determining the radiotherapy dose delivered to organs at risk (OAR) or to the target volume (dependent on what arm the participant is assigned to) through adaptive radiotherapy volume adaption planning
224301927|NCT05759936|OTHER|Placebo|4 week placebo supplement of 1 capsule per day
223572448|NCT05832112|PROCEDURE|VATS/RATS lobectomy|"Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner."
223572449|NCT01693380|BIOLOGICAL|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~* From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~* 9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
223572450|NCT01693380|BIOLOGICAL|Control vaccine|"Schoolchildren from 6 to 8 years of age:~\- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
223572451|NCT04373408|PROCEDURE|ACL repair without anterolateral repair|Surgical repair of the ACL using semitendinous autograft
224150948|NCT04777604|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as neoadjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within patients with resectable pancreatic cancer after neoadjuvant chemotherapy, the investigators aim to strategize appropriate neoadjuvant chemotherapy before surgery, thus developing a platform to predict the outcomes of each patient.
224150949|NCT06359704|BEHAVIORAL|Caregivers Of dementia Processing Emotions (COPE) program|a dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) program
224150950|NCT00361023|DRUG|losartan|
224150951|NCT00294684|DRUG|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
224150952|NCT00294684|DRUG|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
224150953|NCT02726334|DRUG|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
224150954|NCT02726334|DRUG|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
224150955|NCT05171881|OTHER|Intervention for cerebral hypoxia|For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.
224150956|NCT06364384|COMBINATION_PRODUCT|PD-1 and CRT|Chemotherapy (/3w): 1)DDP 75 mg/m2, d1, intravenous infusion; 2)5-FU 1000 mg/m2, d1-4, continuous pumping intravenously; Immunotherapy (/3w): PD-1 monoclonal antibody(sintilimab) 200mg, d1, intravenous infusion; Radiotherapy (at 3rd week after first time of chemotherapy):Daily single dose of 2Gy, with a total dose of 50-54GY.
224150957|NCT03528824|OTHER|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
224150958|NCT03528824|DRUG|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
224150959|NCT02025049|DRUG|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
224150960|NCT02025049|DRUG|Placebo|mannitol-based DP-b99 look-alike
224150961|NCT01085019|DIETARY_SUPPLEMENT|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
224150962|NCT01085019|DIETARY_SUPPLEMENT|Oregano|2.8g/day of oregano in capsules during 4 weeks.
224150963|NCT01085019|DIETARY_SUPPLEMENT|Ginger|2.8g/day of ginger in capsules during 4 weeks.
224150964|NCT01085019|DIETARY_SUPPLEMENT|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
224150965|NCT01085019|DIETARY_SUPPLEMENT|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
224150966|NCT01085019|DIETARY_SUPPLEMENT|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
224150967|NCT00095719|DRUG|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
224150968|NCT00095719|DRUG|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
224150969|NCT00649168|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
224150970|NCT00649168|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
224150971|NCT00314041|BIOLOGICAL|Meningococcal C|
224150972|NCT00314041|BIOLOGICAL|DTP/Hib|
224150973|NCT00389441|DRUG|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
224150974|NCT00088114|DRUG|STA-4783/paclitaxel|
224150975|NCT02591043|PROCEDURE|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
223572452|NCT04373408|PROCEDURE|ACL repair with anterolateral repair|Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
223572453|NCT02116647|BEHAVIORAL|Psychoanalytic therapy|
223572454|NCT04413903|PROCEDURE|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations|The Effect of Different Mechanical Ventilator Modes on Optic Nerve Diameter and Cognitive Functions in Laporoscopic Cholecystectomy Operations
223572455|NCT00612547|DRUG|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
223572456|NCT02577770|DEVICE|acupuncture|therapeutic acupuncture treatment with actual needles
223572457|NCT02577770|DIETARY_SUPPLEMENT|200mg caffeine|8g coffee, po
223572458|NCT02577770|DIETARY_SUPPLEMENT|400mg caffeine|16g coffee, po
223572459|NCT02577770|DIETARY_SUPPLEMENT|Decaffeinated|decaffeinated coffee, po
223572460|NCT06079060|DEVICE|Synthetic Nitrile Condom (61mm)|61mm width Synthetic Nitrile Condoms
223572461|NCT06079060|DEVICE|Control Latex Condom|61mm width Natural Rubber Latex Condom
223572462|NCT04854967|OTHER|Rescind home oxygen order|A note will be entered in the medical record describing the participants randomization into the intervention group. The note will be signed by study staff and will accompany the discontinuation of the patient's home oxygen by a study clinician.
224065386|NCT02833012|DRUG|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
224065387|NCT02833012|DRUG|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
224065388|NCT04442230|BIOLOGICAL|NasoVAX|NasoVAX consists of replication-deficient adenovirus vectors in suspension
224065389|NCT04442230|OTHER|Placebo|Normal saline
224065390|NCT05026307|PROCEDURE|Excision of pterygium|Simple surgical excision of pterygium with bare sclera
224065391|NCT01604265|DRUG|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
224065392|NCT01604265|DRUG|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
224065393|NCT04492683|COMBINATION_PRODUCT|DBV1605|"Ready-to-use atopy patch test for diagnostic use containing 2 distinct patches:~* One active patch containing a dry deposit of 180 μg of cow's milk proteins~* One control patch with the same design as the active patch but devoid of any formulation."
224065394|NCT05984238|DEVICE|ReCET|Investigational product.
224065395|NCT05984238|DRUG|Semaglutide, 1.0 mg/mL|Already registered medicine for type 2 diabetes
224065396|NCT05984238|OTHER|Sham procedure|The sham control for the ReCET procedure.
224065397|NCT06072521|DRUG|Lactoferrin Bovine|Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.
224065398|NCT03807804|BIOLOGICAL|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
224065399|NCT01821651|DEVICE|HeartNavigator|Procedure with software
224065400|NCT01821651|DEVICE|EchoNav|Procedure with software
224065401|NCT01821651|OTHER|Control-Group EN|Procedure without software
224065402|NCT01821651|OTHER|Control-group HN|Procedure without software
224065403|NCT01578733|DIETARY_SUPPLEMENT|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
224065404|NCT05300191|DIAGNOSTIC_TEST|Effluent dialysate|Effluent dialysate samples evaluated for evidence of peritonitis
224065405|NCT02706873|DRUG|Placebo to Upadacitinib|Tablet; Oral
224065406|NCT02706873|DRUG|Methotrexate|Capsule or Tablet; Oral
224065407|NCT02706873|DRUG|Placebo to Methotrexate|Capsule or Tablet; Oral
224065408|NCT02706873|DRUG|Upadacitinib|Tablet; Oral
224065409|NCT00657891|DRUG|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
224065410|NCT00657891|DRUG|Placebo|Placebo Injection
224065411|NCT04242082|DIAGNOSTIC_TEST|GLUT 1 gene expression|"GLUT 1 gene expression will done on blood samples taken from three groups using real time PCR.~Pigment epithelium derived factor will used on keratinocytes cell line and compare GLUT 1 gene expression before and after treatment."
224065412|NCT00210093|DRUG|denufosol tetrasodium (INS37217)|
224065413|NCT02630758|BEHAVIORAL|Mindfulness-based Yoga|See study arm description.
224065414|NCT02630758|BEHAVIORAL|Walking Control Condition|See study arm description.
224065415|NCT03187665|DEVICE|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
224065416|NCT03187665|DEVICE|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
224065417|NCT05028400|DEVICE|Laser speckle contrast imaging (LSCI)|LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
224065418|NCT05875675|DRUG|Drug: Pioglitazone Oral Tablet|Dietary Supplement: Pioglitazone 30 mg by mouth daily
224150976|NCT04656288|DRUG|BI 764198 - Formula A|BI 764198
224150977|NCT04656288|DRUG|BI 764198 - Formula B|BI 764198
224150978|NCT04656288|DRUG|BI 764198 - Formula C|BI 764198
223572463|NCT04854967|BEHAVIORAL|Provider Education|A note will be entered in the medical record informing the patient's individual medical providers (i.e. primary care provider, pulmonologist) of their randomization into the intervention group. The note will include the evidence-base for oxygen use among patients with COPD.
223572464|NCT04854967|BEHAVIORAL|Patient Education|"The patient will receive a patient education page about discontinuation of home oxygen after recovery from a hospitalization that was developed by Consumer Reports in conjunction with the Choosing Wisely Campaign."
223572465|NCT04854967|BEHAVIORAL|Teach-to-goal inhaler training|Teach-to-goal (TTG) inhaler training is a patient-centered education strategy that has been shown to decrease inhaler misuse and decrease acute care utilization. The training is tailored to the patient and meets guideline recommendations for assessment and instruction of inhaler technique. The rounds of assessment and demonstration can be completed until acceptable skill level is attained and tailored to the specific medication prescribed.
223572466|NCT04854967|BEHAVIORAL|Pursed lip breathing|Pursed lip-breathing will be taught to the participants randomized to the intervention arm. This simple technique relieves breathlessness and has been shown to improve functional capacity in patients with COPD. Participants will be given an instructional handout to refer to after the visit.
223572467|NCT03008902|PROCEDURE|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
223572468|NCT05270330|OTHER|This is an observational study, we don't have any interventions.|No intervention
223572469|NCT00147862|DRUG|Tranexamic Acid|
223572470|NCT00025428|DRUG|carboplatin|
223572471|NCT00025428|DRUG|cyclophosphamide|
223572472|NCT00025428|DRUG|doxorubicin hydrochloride|
223572473|NCT00025428|DRUG|etoposide|
223572474|NCT00025428|DRUG|vincristine sulfate|
223572475|NCT00025428|PROCEDURE|adjuvant therapy|
223572476|NCT00025428|PROCEDURE|conventional surgery|
223572477|NCT00025428|PROCEDURE|neoadjuvant therapy|
223572478|NCT03986580|DEVICE|Annular closure device|Annular closure, following limited discectomy procedure at a single LS level between L4 and S1
223572479|NCT01184833|DRUG|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
223572480|NCT04504890|DEVICE|EYE-SYNC|Nystagmograph used to measure eye movement
223572481|NCT00594542|DRUG|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
223572482|NCT00420810|DRUG|MK0928 / Duration of Treatment : 8 Weeks|
223572483|NCT04804631|DEVICE|Enteral feeding tubes|Families within Great Ormond Street Hospital are offered the choice of two enteral feeding tubes prior to admission for bone marrow transplant. Some families choose a gastrostomy to be placed prophylactically in the weeks prior to admission, others choose a nasogastric tube to be placed during the admission.
223572484|NCT01545882|DRUG|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
223572485|NCT02599649|DRUG|Lirilumab|3 mg/kg by vein every 4 weeks.
223572486|NCT02599649|DRUG|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
223572487|NCT02599649|DRUG|Azacitidine|75 mg/m\^2 by vein for 7 days of a 28 day cycle.
223572488|NCT05615987|DRUG|Onabotulinumtoxina for Injection|200iu/2ml in both groups
223572489|NCT06372522|DRUG|Pitocin Injectable Product|The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
223572490|NCT00150358|DRUG|Sildenafil Citrate|
223572491|NCT00977938|DRUG|Placebo & Aspirin|
223572492|NCT00977938|DRUG|Clopidogrel & Aspirin, Prasugrel & Aspirin|
223572493|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
223572494|NCT04046354|DEVICE|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
223572495|NCT02109874|BIOLOGICAL|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
223572496|NCT02109874|BIOLOGICAL|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
223572497|NCT05008575|BIOLOGICAL|anti-CD33 CAR NK cells|6×10\^8, 12×10\^8, 18×10\^8/KG Treatment follows a lymphodepletion
223572498|NCT05008575|DRUG|Fludarabine|recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
224150979|NCT04656288|DRUG|BI 764198 - Formula D|BI 764198
224150980|NCT02937688|DEVICE|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
224150981|NCT02357888|DRUG|V0018|Oromucosal - Single dose
224150982|NCT02357888|DRUG|Placebo|Oromucosal - Single dose
224150983|NCT02979028|DEVICE|TEAS|Transcutaneous electrical acupoint stimulation
224150984|NCT05134168|PROCEDURE|bone marrow mononuclear cell injection|bone marrow mononuclear cells were injected in the intersphincteric space and around the internal opening after ligation and division of the tract
224150985|NCT05134168|PROCEDURE|LIFT|The fistula tract is ligated in the intersphincteric space
224150986|NCT04430790|DRUG|Doxapram|Loading dose and continuous doxapram infusion.
224150987|NCT04430790|DRUG|Placebo|Loading dose and continuous placebo infusion.
224301928|NCT01912274|DRUG|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
223572499|NCT05008575|DRUG|Cytoxan|recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
223572500|NCT04161963|DEVICE|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
223572501|NCT04161963|DEVICE|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
223572502|NCT02142283|DEVICE|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
223572503|NCT02142283|OTHER|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
223572504|NCT00832130|DEVICE|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
223572505|NCT00832130|DEVICE|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
223572506|NCT04913181|DIAGNOSTIC_TEST|Artificial intelligence sepsis prediction model|The main purpose of this paper is to evaluate the accuracy of the sepsis prediction model established in the early stage. The occurrence of sepsis is determined by the daily clinical judgment of doctors, and the results of sepsis prediction model are matched and corrected.
223742964|NCT01808053|DEVICE|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
224065419|NCT05875675|DIETARY_SUPPLEMENT|Placebo|Dietary: Supplement: Placebo
224065420|NCT03824808|DRUG|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
224065421|NCT03824808|DRUG|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
224065422|NCT05461950|PROCEDURE|Extrauterine placental transfusion and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
224065423|NCT05461950|PROCEDURE|Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping|Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
224065424|NCT05461950|PROCEDURE|Delayed umbilical cord clamping|Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
224065425|NCT05138081|OTHER|PNF stretching|"Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion."
224065426|NCT05138081|OTHER|Stabilization|Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
224065427|NCT00000848|DRUG|Indinavir sulfate|
224065428|NCT00000848|DRUG|Saquinavir|
224065429|NCT00464334|BIOLOGICAL|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
224065430|NCT00464334|BIOLOGICAL|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
224065431|NCT00464334|BIOLOGICAL|Placebo to V950|
224065432|NCT04232579|OTHER|Therapeutic strategy|Therapeutic strategy compatible with the guidelines and development of predictive biomarkers of the response to treatment.
224065433|NCT02467933|OTHER|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
224065434|NCT02467933|OTHER|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
224065435|NCT02467933|OTHER|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
224065436|NCT02569762|DIETARY_SUPPLEMENT|Sucralose-Aspartame|Sucralose or aspartame
224065437|NCT02569762|DIETARY_SUPPLEMENT|Aspartame-Sucralose|Aspartame or sucralose
224065438|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 without adjuvant
224065439|NCT05903183|BIOLOGICAL|IVX-A12|IVX-A12 with adjuvant
224065440|NCT05903183|BIOLOGICAL|Placebo|Diluent
224065441|NCT02173574|DRUG|DEB025|
224065442|NCT02173574|DRUG|EDP239|
224065443|NCT04321759|BEHAVIORAL|Cognitive Enhancement Therapy|CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.
224150988|NCT05263349|OTHER|Typical Dreams Questionnaire|"Each of the dreams was classified according to its thematic content (e.g., being involved in a chase, flying through the air, falling, being lost, losing one's teeth, drowning) in order to in a chase, flying through the air, falling, being lost, losing teeth, drowning) in order to determine the most determine the most frequent themes emerging from our sample. The instrument used used to carry out this classification is the Typical Dream Questionnaire of Zadra and Nielsen (1999), which has been validated with more than 600 patients suffering from sleep disorders and and 1200 adults (Nielsen et al., 1999; 2003)."
224150989|NCT05263349|OTHER|HAD Questionnaire|"The HAD scale is an instrument that screens for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D).~two scores (maximum score for each score = 21)."
224150990|NCT05263349|OTHER|Dream Booklet|The patient is asked to write down in a notebook every morning the description of the dreams made during the night and to comment on it if necessary
224150991|NCT05392166|DIAGNOSTIC_TEST|blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound|blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
224150992|NCT00004234|PROCEDURE|management of therapy complications|
224150993|NCT00004234|RADIATION|radiation therapy|
224150994|NCT00300534|DEVICE|Abbott Laboratories Determine test for syphilis|
224150995|NCT00300534|DEVICE|Investigational syphilis immunochromatographic strip test|
223572507|NCT04127357|PROCEDURE|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
224150996|NCT05678270|DRUG|ICP-192|ICP-192 is a round, uncoated tablet, 5mg, orally.
224150997|NCT00587834|DEVICE|Gintuit|Application of Gintuit at Day 0 to the gingival bed
224150998|NCT00587834|OTHER|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
224150999|NCT05800834|DRUG|Morphine Sulfate|"For the preparation of the gel formulated for the intervention, the proportion of an ampoule of dimorf® (morphine sulfate) in the injectable presentation of 10mg/ml will be used. Morphine sulfate is a strong, systemic opioid analgesic used for the relief of severe pain.~For the base of the compound, Curatec Hidrogel with Alginate® will be used. A transparent and viscous hydrogel, which provides a moist environment, preventing the dressing from adhering to the skin, preventing additional injuries generated by difficulty removing the dressing."
223572508|NCT02460783|OTHER|Boost (R) 5-2 diet|Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
223572509|NCT02460783|OTHER|Healthy Living Diet|Counseling and educational material on diet portion, consistency
224151000|NCT05800834|DRUG|Lidocaine Hcl 2% Jelly|The control group will receive lidocaine® in gel (2% sterile jelly lidocaine hydrochloride) alone. Because it is a homogeneous, transparent gel, free of lumps and impurities, it has similar characteristics to the hydrogel (Curatec Hidrogel with Alginate®) used in the preparation of morphine gel, guaranteeing the blinding of the study.
224151001|NCT03504436|DEVICE|LEO +|LEO +: self-expanding intracranial stent
224151002|NCT00003408|BIOLOGICAL|aldesleukin|
224151003|NCT00003408|BIOLOGICAL|recombinant interferon alfa|
224151004|NCT00003408|BIOLOGICAL|sargramostim|
224151005|NCT04994704|DRUG|Propfol group|Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
224151006|NCT04994704|DRUG|Remimazolam group|Remimazolam group will be started total intravenous anesthesia with remiamazolam at 6 mg/kg/h for induction, and maintained at 0.5-1.5 mg/kg/h and remifentanil under TCI model.
224151007|NCT02252757|DEVICE|CoVa|
224151008|NCT02295800|OTHER|Standard of care|
224151009|NCT02295800|OTHER|Semi-structured interviews|
224301929|NCT01912274|DRUG|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
223572510|NCT04490980|DRUG|butorphanol|Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
223742965|NCT06639607|BIOLOGICAL|PEP-CMV vaccine|Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.
223742966|NCT06639607|BIOLOGICAL|Tetanus booster|Td 5 flocculation units, Lf
224151010|NCT03251872|DRUG|Olaparib|Olaparib tablets
224151011|NCT00049504|DRUG|cyclophosphamide|Given IV
224151012|NCT00049504|DRUG|fludarabine phosphate|Given IV
224151013|NCT00049504|DRUG|tacrolimus|Given IV or orally
224151014|NCT00049504|DRUG|mycophenolate mofetil|Given orally
224151015|NCT00049504|GENETIC|polymerase chain reaction|Correlative studies
224301930|NCT00067899|DRUG|Vitamin E with and without Vitamin C|
224301931|NCT03249337|DRUG|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
224301932|NCT01732484|PROCEDURE|intraocular lens implantation|
224301933|NCT04005365|DRUG|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
224301934|NCT05006768|DRUG|Barcimiant|1 tablet contains 4 mg Barcitinib
224151016|NCT00049504|GENETIC|fluorescence in situ hybridization|Correlative studies
224151017|NCT00049504|GENETIC|polymorphism analysis|Correlative studies
224065444|NCT04321759|BEHAVIORAL|Social Skills Training|"The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises."
224065445|NCT04821037|BEHAVIORAL|ACT|Acceptance and Commitment Therapy
224065446|NCT04019730|OTHER|diet|low carbohydrate diet (\< 10 EN% carbs) vs high carbohydrate diet (\>50 EN% carbs)
224065447|NCT00855985|PROCEDURE|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
224065448|NCT02941016|DRUG|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
224065449|NCT04370080|DEVICE|Silver Diamine Fluoride 38%|Dental caries arrest medication
224065450|NCT02631525|DRUG|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
224065451|NCT02631525|DRUG|Propofol|Total intravenous anesthesia based on propofol
224065452|NCT03196076|DRUG|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
224065453|NCT00820495|BEHAVIORAL|Web + Phone|Web + Phone
224065454|NCT00820495|BEHAVIORAL|Web Only|Web Only
224065455|NCT00820495|BEHAVIORAL|Phone Only|Phone Only
224065456|NCT00820495|BEHAVIORAL|Usual Care|Usual Care
224065457|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
224065458|NCT01418183|PROCEDURE|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
224065459|NCT01418183|PROCEDURE|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
224065460|NCT05362318|DRUG|Nicotine patch and lozenges|Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke \>10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
224065461|NCT05362318|BEHAVIORAL|Telephone counseling sessions|Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
224065462|NCT05362318|BEHAVIORAL|Access to a web-based video|"Participants will be given web-based access to the relapse prevention video Surviving Smokefree."
224065463|NCT05362318|BEHAVIORAL|Florida Tobacco Quitline|Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
224065464|NCT02424526|OTHER|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
224065465|NCT02424526|DEVICE|Treadmill|
224065466|NCT00794677|DRUG|ezetimibe|Blinded study medication (ezetimibe 10 mg in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
224065467|NCT00794677|DRUG|placebo|Blinded study medication (matched placebo) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
224065468|NCT02461992|DRUG|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
224065469|NCT06443866|DIAGNOSTIC_TEST|Disease status detection|RAI dose determination
224065470|NCT06443866|DIAGNOSTIC_TEST|Theranostic dosimetry|Theranostic dosimetric evaluation for optimization of RAI therapy of thyroid cancer
224065471|NCT06443866|DRUG|I-124 PET/CT imaging|Theranostic dosimetry for optimization of RAI therapy for Thyroid Cancer
224065472|NCT03788720|PROCEDURE|Suture of the ovarian cortex|Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).
224065473|NCT03788720|PROCEDURE|No suture of the ovarian cortex|Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
224065474|NCT01699945|OTHER|This is an observational study being conducted as a substudy of antoher trial.|
224065475|NCT02911532|PROCEDURE|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
224065476|NCT03444285|OTHER|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
224065477|NCT03444285|OTHER|Hot Pack|20 minutes of hot-pack on both hamstring
224065478|NCT02151474|DRUG|INCB047986|
224065479|NCT02151474|DRUG|Placebo|
224065480|NCT03302845|DRUG|Omeprazole 40 MG|Omeprazole 40 mg capsule
224151018|NCT00049504|GENETIC|gene expression analysis|Correlative studies
224151019|NCT00049504|RADIATION|total-body irradiation|Undergo total-body irradiation
224301935|NCT05006768|DRUG|Olumiant (first dose)|1 tablet contains 4 mg Barcitinib
223742967|NCT06639607|BIOLOGICAL|Nivolumab|Administered intravenously
224065481|NCT03302845|DRUG|Famotidine 40 mg|Famotidine 40 mg tablet
224065482|NCT03302845|DRUG|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
224065483|NCT04684446|BIOLOGICAL|AZD1222|Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
224065484|NCT04684446|BIOLOGICAL|rAd26-S|Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29
224065485|NCT04411355|DIETARY_SUPPLEMENT|control by dietitian|
224065486|NCT04411355|OTHER|Exercise programs|In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
224065487|NCT04411355|BEHAVIORAL|control by psychiatrist|The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
224065488|NCT05377047|RADIATION|SABR|Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
224065489|NCT01710449|DRUG|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
224065490|NCT01471457|DRUG|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
224065491|NCT00909558|BIOLOGICAL|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
224065492|NCT00641498|BEHAVIORAL|Psychotherapy|Individual supportive
224065493|NCT00708578|DRUG|Glimepiride|Once a day before breakfast
224065494|NCT00708578|DRUG|Metformin|After breakfast and supper
224065495|NCT00708578|DRUG|Insulin Glargine|Injection in the morning
224065496|NCT04858165|PROCEDURE|MY GERYFS PROTOCOL|The MY GERYFS will be introduced through a guideline document, dissemination through the department of nursing, notices on the intranet and provision of large signs indicating that MY GERYFS are in progress and the times of meals for each ward. The developed protocol in phase 1 and 2 will be tested in single-centre in a before and after study for its feasibility and safety. In the pre-study, patients will be given usual care. In the post-study, patients will care according to the developed protocol. Clinical outcomes such as malnutrition risk, medical background, anthropometry data, nutrition-focused physical findings, dietary intake, mealtime barrier, Hospital Foodservices satisfaction will be recorded.
224065497|NCT06074874|OTHER|Intestinal tissue analysis|Intestinal tissue analysis
224065498|NCT02905565|DRUG|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
224065499|NCT02905565|DRUG|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
224065500|NCT03840655|PROCEDURE|Near-Infrared Imaging Thoracoscopy|Sympathicotomy performed by near-infrared imaging thoracoscopy
224065501|NCT03891511|DEVICE|MRI scann|MRI will be performed in the TMJ of participants affected with TMD
224065502|NCT05318391|DIAGNOSTIC_TEST|Gene expression profile|"Diagnostic Test:~The Canhelp-COO Assay (Canhelp Genomics CO., Ltd) for differentiating COO subtypes using gene expression analysis by real-time PCR (RT-PCR)"
224065503|NCT06089642|DEVICE|Virtual reality|Virtual reality based on distraction and Virtual Reality based on focussed attention
224065504|NCT02958488|DEVICE|High Flow Nasal Cannula|
224065505|NCT03759626|BEHAVIORAL|Impulsive intervention|"As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions."
224065506|NCT03759626|BEHAVIORAL|Reflective Intervention|"This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study."
224065507|NCT02504021|BEHAVIORAL|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
224065508|NCT00428532|DRUG|Licorice root extract or Pomegranate juice|
224065509|NCT04440995|PROCEDURE|pectoral nerve block|Patients received standardized general anesthesia. PECS block were applied under vision using blunted tip cannula(27G, 30mm) after surgical resection of breast by operator. 0.25% ropivacaine 10ml was injected into fascia between pectoralis major and minor muscles. 0.25% ropivacaine 20ml was injected into fascia between pectoralis minor and serratus anterior muscles at the level of the third rib. Breast reconstruction is performed after PECS block
224301936|NCT05006768|DRUG|Olumiant (second dose)|1 tablet contains 4 mg Barcitinib
224151020|NCT00049504|PROCEDURE|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
224151021|NCT00049504|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
224151022|NCT00702728|DRUG|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
224151023|NCT00702728|DRUG|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
224151024|NCT04717895|DIAGNOSTIC_TEST|Rocking environment forward (B) followed by a translation environment|Start by the virtual reality session by viewing a rocking environment followed by a translation environment
224151025|NCT04717895|DIAGNOSTIC_TEST|Translation environment followed by a rocking environment|Start by the virtual reality session by viewing a translation environment followed by a rocking environment
224151026|NCT00736593|DRUG|Nexagon™ or Nexagon™ vehicle|
224151027|NCT00126672|DRUG|Rapamycin|
224151028|NCT00334204|DEVICE|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
224151029|NCT00045357|BIOLOGICAL|therapeutic autologous lymphocytes|
224151030|NCT04702204|DRUG|Denosumab 60 MG/ML|"Denosumab, another antiresorptive agent, is a fully human monoclonal IgG2 antibody that binds to the receptor activator of the nuclear factor-kB ligand (RANKL) with high specificity and affinity. Denosumab inhibits bone resorption by affecting the development, activation, and survival of osteoclasts.~Denosumab 60 mg subcutaneously was administered to the patients whose consent forms were obtained, once every 6 months."
224151031|NCT03781388|DRUG|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
224151032|NCT02378493|BIOLOGICAL|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
224151033|NCT04432467|BIOLOGICAL|Autologous mesenchymal stem cells|Autologous adipose tissue-derived mesenchymal stem cells
223455756|NCT04792307|OTHER|Neuromuscular electrical stimulation , no high protein ice cream supplementation|"A trained operator applies Neuromuscular electrical stimulation treatment to one leg, for approximately 30 minutes per session, three sessions per week with or without high protein ice cream. Treatment can stimulate the nerve controlling the vastus lateralis muscle in the thigh or the nerve controlling the tibialis anterior muscle in the lower leg, or both. In our study, we will aim to stimulate both nerves and muscle groups, on the basis that the maximal effect with result from the maximal amount of muscle stimulated.Treatment is adjusted to generate a specific force and maintained for up to 5 minutes, followed by a rest period and then repeated three times over the typical 30-minute session. The stimulation can vary according to the frequency (pulses per second, typically 10-50Hz).~Additional protein supplementation: high protein ice cream :a single doses of a high protein supplement after each bout of neuromuscular electrical stimulation,"
224151034|NCT04432467|OTHER|standard treatment|standard treatment according to clinical protocols
224151035|NCT05229991|DRUG|Lonafarnib|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
224151036|NCT05229991|DRUG|Ritonavir|once-daily dosing of lonafarnib 50 mg with ritonavir 200 mg over a 48-week treatment period.
224151037|NCT01082588|DRUG|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
224151038|NCT01082588|DRUG|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
224151039|NCT00660075|DRUG|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
224151040|NCT00660075|DRUG|Placebo|Placebo for 6 weeks
224151041|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
224151042|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
224301937|NCT04422119|PROCEDURE|Multi-Foam dressing|Application of a multi-layer foam dressing with Safetac in surgical wound
224151043|NCT01001234|DRUG|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder \[moderate or severe pain 15 minutes after dose\] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those \<40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
224151044|NCT01001234|DRUG|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
224151045|NCT01045434|DRUG|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
224151046|NCT05428449|DRUG|GT20029 Gel|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
224301938|NCT04422119|PROCEDURE|Usual care|Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
224151047|NCT05428449|DRUG|GT20029 Gel Placebo|Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
224151048|NCT00905372|DRUG|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
224151049|NCT00905372|DRUG|Placebo|intravenously (IV) every 4 weeks for 80 weeks
224151050|NCT03689868|BEHAVIORAL|Virtual Reality|Virtual Reality headset with calming scenery
224151051|NCT02842541|DRUG|EBI-031|
224151052|NCT00385034|DEVICE|Interactive computer based health-risk survey before doctor's visit|
224151053|NCT00125372|DRUG|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
224151054|NCT00596804|DRUG|veltuzumab|once weekly intravenous dosing for 4 weeks
224151055|NCT00000339|DRUG|Risperidone|
224151056|NCT01652937|DRUG|BIIB057|Oral
224151057|NCT01652937|DRUG|Placebo|Oral
224151058|NCT04489004|PROCEDURE|Driver ablation+CPVI|Patients receive driver ablation and CPVI (circumferential pulmonary vein isolation).
224151059|NCT04489004|PROCEDURE|Stepwise ablation|Patients receive stepwise ablation.
224151060|NCT00756704|BEHAVIORAL|Smoking cessation guideline implementation|"1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff"
224151061|NCT03994276|DIETARY_SUPPLEMENT|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
224151062|NCT02657876|BIOLOGICAL|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
224151063|NCT04463225|OTHER|Internet-Delivered Brief Intervention|The internet-delivered brief intervention developed for the study can be accessed via computers and mobile devices.. The intervention will employ assessment data to give study participants feedback on their drinking behavior and offer strategies to avoid risky behavior.
224151064|NCT05480839|PROCEDURE|M-IBCS|Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant
224151065|NCT05480839|PROCEDURE|ReLA-IBCS Early|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia
224151066|NCT05480839|PROCEDURE|ReLA-ISBCS|Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia
224151067|NCT02656901|DEVICE|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
224151068|NCT02656901|DEVICE|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
224151069|NCT02656901|DEVICE|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
224151070|NCT02656901|DEVICE|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
224151071|NCT05168176|DRUG|Dotilavir sodium tablet|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
224301939|NCT05402774|DIAGNOSTIC_TEST|point-of-care ultrasound|point-of-care ultrasound
224301940|NCT01087489|DRUG|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
223455757|NCT01937585|BEHAVIORAL|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
223455758|NCT01937585|BEHAVIORAL|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
223742968|NCT06639607|DRUG|Temozolomide|Administered orally
224305123|NCT01659866|DRUG|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
224305124|NCT01659866|DRUG|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
224151072|NCT05168176|DRUG|Dotilavir sodium tablet(Tivicay@)|The subjects randomly received single oral administration of Dotilavir sodium tablet 50mg.
224151073|NCT00993304|DRUG|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
224151074|NCT00993304|DRUG|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
224151075|NCT00424034|DRUG|GSK1325760A|
224151076|NCT06060704|DRUG|Envafolimab|150mg Qw, delivered as a single 1.5ml subcutaneous injection in under 30s , every 4 weeks for one cycle(Q4w).
224151077|NCT06060704|DRUG|Trifluridine/Tipiracil|35 mg/m2 (maximum single dose of 80 mg), po, on days 1-5 and 8-12 of each treatment cycle, twice daily for 28 days, within 1 hour after breakfast or dinner take medicine.
224151078|NCT06060704|DRUG|Bevacizumab|ivgtt, 5mg/kg, d1, d15, every 4 weeks for one cycle (Q4w). The subjects will receive Trifluridine/Tipiracil plus Bevacizumab and Envafolimab until disease progression, intolerable toxicity, initiation of other anti-tumor therapy, death, withdrawal of informed consent, or loss of follow-up.
224151079|NCT02076334|OTHER|Far Infrared Fabric|
224151080|NCT02076334|OTHER|Spandex|
223455759|NCT05515510|OTHER|FU-APP|"FU-APP is a web-based application using the guidelines and oral health recommendations provided by the current German Ratgeber 2020. It provides information related to oral health care for the parents of children between 6 to 72 months of age. An account was made on a certified online web-development platform and an application was developed on it.~This application serves as a practical guide for the parents of children under 6 years of age. It provides all the essential German guidelines related to first dental visits, expected dental findings, practical brushing technique steps, plaque disclosing activity, motivational brushing video, nutritional facts and behavioral habits to be avoided. It is a complete package of essential information and with high quality content that promotes prevention of ECC at an early age."
223455760|NCT05515510|OTHER|Oral health recommendations|"Oral health recommendations provided as usual (verbal/oral) according to the current German Ratgeber 2020"
223455761|NCT02516956|OTHER|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
223742969|NCT00678821|OTHER|Aerobic exercise|Supervised aerobic exercise and educational lectures for 10 weeks
223742970|NCT02592746|DRUG|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
224065510|NCT00092430|BIOLOGICAL|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
224065511|NCT04840680|OTHER|No Intervention|This is a non-interventional study.
224065512|NCT05383027|BEHAVIORAL|Music Listening Control (MLC)|MLC participants will engage in assigned music listening in the presence of their loved one with ADRD via a selected online platform (pandora or Spotify) for 10 minutes a day 5-7 days a week.
224065513|NCT05383027|BEHAVIORAL|Heart Focused Breathing|Heart-focused breathing participants will engage in heart-focused breathing using the inner balance device (shipped to their home), they will be asked to do this in the presence of their loved one with ADRD for 10 minutes a day 5-7 days per week.
224065514|NCT05472727|OTHER|reaction time test|Reaction time tests consist of 3 sub-parameters as simple reaction time, selective reaction time and distinctive reaction time. Participants will do these tests on the computer.
224065515|NCT05472727|OTHER|Physical fitness test|The physical fitness test will be evaluated with the senior fitness test used for geriatrics and the 8 meter walking speed test.
224065516|NCT04847973|OTHER|Medically-Tailored Meals (MTMs)|12 weeks of home-delivered MTMs, delivered weekly, containing food for 3 meals per day on 5 days of the week
224065517|NCT04847973|DIETARY_SUPPLEMENT|Protein supplementation shakes|12 weeks of 1 bottle of Ensure Max Protein shake every day, in addition to partcipants' standard diet
224065518|NCT04476888|BIOLOGICAL|Convalescent Plasma (CP)|500 ml of Convalescent plasma in a single dose will be transfused over a period of 1- 2 hours.
224065519|NCT04476888|OTHER|Drugs and supportive care|This will include drugs like steroids, tocilizumab, azithromycin and supportive care
224065520|NCT02135718|DEVICE|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
224065521|NCT02135718|DEVICE|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
224065522|NCT05458076|DRUG|QLS1128 A-Dose 1~5 and Ritonavir|"Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo"
224065523|NCT05458076|DRUG|QLS1128 C-Dose 1~3 and Ritonavir|"Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days"
224065524|NCT05458076|DRUG|QLS1128 D-Dose 1 and Ritonavir|"Cohort 9:~Group A:QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 1. QLS1128 D-Dose 1 plus Ritonavir under fatty food condition, on day 5~Group B: QLS1128 D-Dose 1 plus Ritonavir under fatty food condition , on day 1. QLS1128 D-Dose 1 plus Ritonavir under fasting condition, on day 5"
224065525|NCT04952064|DRUG|Monosialoganglioside GM1|Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
224065526|NCT00796315|DRUG|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
224065527|NCT04516928|DIAGNOSTIC_TEST|Anti-SARS-CoV2 Serology|The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
224065528|NCT04516928|OTHER|Questionnaire|A questionnaire on socio-demographical status, health status and lifestyle habits during the pandemic will be filled by the participants at Day 0.
224065529|NCT02342002|DRUG|Mifepristone|Mifepristone for treatment of missed abortion
224065530|NCT02342002|DRUG|Misoprostol|Misoprostol for treatment of missed abortion
224065531|NCT00194545|BEHAVIORAL|Medication diaries|Caregivers expected to complete medication diaries daily
224151081|NCT01209806|DRUG|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
224151082|NCT03790072|BIOLOGICAL|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
224151083|NCT00778713|DRUG|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
224151084|NCT03379376|OTHER|Questionnaire Administration|Receive questionnaire
224151085|NCT03379376|PROCEDURE|Supportive Care|Undergo eHealth mindful moving and breathing
224151086|NCT00735761|DRUG|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
224305125|NCT01659866|DRUG|aztreonam|500 mg intramuscularly 2 hours before the procedure
224305126|NCT01659866|DRUG|imipenem|500 mg intramuscularly 2 hours before the procedure
224151087|NCT00735761|DRUG|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
224151088|NCT04300881|DRUG|Eplerenone|Following intravitreal ocriplasmin therapy
224151089|NCT01611298|BIOLOGICAL|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
224151090|NCT02372110|DRUG|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
224151091|NCT02372110|DRUG|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
224151092|NCT01270724|DRUG|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
224151093|NCT01923649|DRUG|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
224301941|NCT01087489|DRUG|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
224301942|NCT01113944|BEHAVIORAL|Program 1|
224301943|NCT01113944|BEHAVIORAL|Program 2|
224301944|NCT05076240|PROCEDURE|FilmArray® analysis|FilmArray® multiplex PCR analysis to diagnose ventilator associated pneumonia in COVID-19 ARDS
224301945|NCT02808949|DRUG|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
224301946|NCT02890836|DRUG|Antihypertensiva, mainly Metyldopa|
223742971|NCT02592746|DRUG|Exemestane|Exemestane 25mg, orally once daily
224065532|NCT01975012|DRUG|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules \[2.5 mg/g\]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
224065533|NCT00802243|DRUG|leflunomide|
224065534|NCT04689776|BEHAVIORAL|Dual-Task Training|The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
224065535|NCT02072031|DRUG|Anlotinib|Anlotinib p.o. qd
224065536|NCT02072031|DRUG|Sunitinib maleate|Sunitinib 50 mg p.o. qd
224065537|NCT04015154|DEVICE|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
224065538|NCT02223572|RADIATION|hip Xray|
224065539|NCT06517134|DRUG|Antihypertensive Agents|use of antihypertensive drugs
224065540|NCT05634863|DEVICE|Implantable Doppler probe manufactured by COOK Medical Company.|The continuous audible Doppler signals produced by the monitoring device represent the blood flowing in the renal artery. This is an indicator of graft perfusion. Cessation of audible Doppler signals is the key that may suggest hampered blood flow due to vascular complications. In the intervention group, the monitoring device will be used as an added mechanism to monitor graft perfusion.
224065541|NCT04126382|PROCEDURE|Intubate-Surfactant-Extubate(INSURE)|Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
224065542|NCT04126382|PROCEDURE|less invasive surfactant administration(LISA)|Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
224151094|NCT01923649|DRUG|Placebo|Placebo for somatuline slow release 90 mg
224151095|NCT00753623|DRUG|Ramelteon|ramelteon (8 mg)
224301947|NCT00015340|DRUG|Buprenorphine/naloxone|
224301948|NCT00737763|DRUG|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
224301949|NCT00737763|DRUG|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
224301950|NCT04804865|OTHER|prognostic assessment|determination of a prognostic score with 3 clinical and 5 biological parameters.
224301951|NCT05941455|DEVICE|Venus-Neo Surgical Aortic Valve|Implant of a Venus-Neo Surgical Aortic Valve
223742972|NCT02592746|DRUG|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
223455762|NCT02516956|OTHER|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
223455763|NCT02516956|OTHER|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
224151096|NCT00753623|DRUG|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
224151097|NCT03332303|DRUG|Estrace® Cream|Estrace® Cream
224151098|NCT03332303|DRUG|Estradiol Vaginal Cream|Estradiol Vaginal Cream
224151099|NCT03332303|DRUG|Vehicle Cream|Vehicle Cream
224151100|NCT04177875|DRUG|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
224151101|NCT05678478|OTHER|semi-directed interview concerning the experience of adolescents and their parents on Lyme borreliosis and on the tick.|"semi-structured interview on the experience of adolescents and their parents on Lyme borreliosis and the tick.~The interviews will be semi-directed in physical presence. Three interviews will be conducted.~The minor will be questioned first, then the parent(s). And finally, the whole family in one interview. All interviews will be audio recorded with parallel note taking in order to best transcribe the visual expressions. The interviews will be transcribed in writing and pseudonymised."
224151102|NCT05172531|DRUG|Cisatracurium Besylate|Participants in the test group received Cisatracurium Besylate 0.12mg/kg/hr continuous infusion during intubation。
224151103|NCT05172531|DRUG|saline 0.12ml/kg/hr|saline 0.12ml/kg/hr
224151104|NCT04673344|DEVICE|Regeneten Collagen Patch|Partial rotator cuff repair surgery with the addition of the Regeneten scaffold
224151105|NCT04974190|DEVICE|Nasal Spray Device|A Nasal Spray apparatus containing a liquid
224151106|NCT03907449|DIAGNOSTIC_TEST|Preview Rapid Strep A test|Rapid assay for the detection of type A streptococcal infection of the throat.
224151107|NCT03504267|OTHER|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
224151108|NCT00107822|DRUG|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
224151109|NCT00001890|DRUG|Estrogen therapy|
223455764|NCT02516956|OTHER|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
223455765|NCT02516956|OTHER|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
223455766|NCT02485756|OTHER|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
223455767|NCT05061433|OTHER|Mobile Integrated Healthcare/Community Paramedicine (MIH/CP) Support|MIH/CP provider and their team will offer additional support and connection to resources after patient is discharged from hospital.
223742973|NCT02592746|DRUG|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
223742974|NCT03176992|DRUG|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
223742975|NCT03458533|PROCEDURE|Bariatric surgery|
223742976|NCT03458533|BEHAVIORAL|Diet and lifestyle changes|
224151110|NCT01679522|PROCEDURE|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
224151111|NCT01679522|PROCEDURE|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
224151112|NCT00460629|PROCEDURE|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
224151113|NCT02872324|OTHER|Procurement questionnaires|
224151114|NCT03365336|DRUG|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
224151115|NCT03365336|DRUG|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
224151116|NCT03549819|DRUG|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
224151117|NCT03549819|DRUG|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
224151118|NCT03623022|DRUG|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
224301952|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
224301953|NCT00928707|DRUG|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
224301954|NCT00132028|DRUG|vorinostat|Given orally
223742977|NCT04564612|DRUG|BIIB091|Administered as specified in the treatment arm
224151119|NCT03623022|DRUG|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
224151120|NCT03395327|OTHER|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
224151121|NCT05146934|RADIATION|high resolution CT|Ground glass，honeycomb，reticulation, consolidation
224151122|NCT06071780|OTHER|organic product - Virgin Coconut Oil|A commercially available sterilized contact lens was soaked in VCO for 4 hours in a sterile condition to allow absorption of VCO into the contact lens polymer. The contact lens here is a vehicle to transport the VCO into the eye.
224151123|NCT05609383|OTHER|assessment|An exit evaluation was initiated immediately upon recovery from anesthesia
224151124|NCT03250156|BEHAVIORAL|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
224151125|NCT03250156|BEHAVIORAL|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
224151126|NCT04995900|OTHER|Community education|Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
224151127|NCT01091051|DRUG|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
224151128|NCT01091051|DRUG|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
224151129|NCT00640952|DRUG|acamprosate|333 mg 2 tabs tid
224151130|NCT01296698|DRUG|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
224151131|NCT01296698|DRUG|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
224151132|NCT04322240|DRUG|Alpha lipoic acid|Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
224151133|NCT00716326|DEVICE|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
224151134|NCT00716326|DEVICE|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
224151135|NCT05934721|OTHER|Questionnaire and physical assessments|Participants will complete self-report questionnaires assessing pain (CSI) and RA severity (patient global VAS), as well as undergoing physical assessments of RA severity (physician global VAS, swollen/tender joint counts) and cognition (MoCA).
224151136|NCT01605201|BIOLOGICAL|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
224151137|NCT03639987|DRUG|Aducanumab|Administered as specified in the treatment arm.
224151138|NCT03639987|DRUG|Placebo|Administered as specified in the treatment arm.
224151139|NCT05380908|OTHER|None of any intervention|The patients did not have any intervention.
224151140|NCT04150354|BEHAVIORAL|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
224151141|NCT01816256|PROCEDURE|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
224151142|NCT06334172|DRUG|Oxytocin|Oxytocin
224301955|NCT00132028|OTHER|laboratory biomarker analysis|Correlative studies
224301956|NCT02041156|OTHER|aerobic and resistance training|
224301957|NCT02041156|OTHER|aerobic combined with balance training|
223742978|NCT04564612|DRUG|Rabeprazole|Administered as specified in the treatment arm
223742979|NCT04564612|DRUG|Itraconazole|Administered as specified in the treatment arm
223742980|NCT02302651|DEVICE|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
224151143|NCT06334172|OTHER|Placebo|Saline
224151144|NCT02077803|DRUG|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
224301958|NCT04467801|DRUG|Ipatasertib|Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
224305127|NCT01659866|DRUG|ceftriaxone|2000 mg intravenously 1 hour before the procedure
224305128|NCT01659866|DRUG|gentamicin|2 mg/kg intravenously 1 hour before the procedure
224305129|NCT01659866|DRUG|amikacin|5 mg/kg intravenously 1 hour before the procedure
224151145|NCT02077803|DRUG|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
224151146|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
224151147|NCT02077803|DRUG|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
224151148|NCT01012349|DRUG|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
224151149|NCT01012349|DRUG|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
224151150|NCT06065904|BEHAVIORAL|Nutrilect|This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
224151151|NCT00776321|DRUG|Eprotirome|
224151152|NCT00776321|DRUG|Placebo|
224151153|NCT01224587|DRUG|D1000078|Oral, one single dose
224151154|NCT01224587|DRUG|D1000082|Oral, one single dose
224151155|NCT01224587|DRUG|D1000083|Oral, one single dose
224151156|NCT01224587|DRUG|D1000085|Oral, one single dose
224151157|NCT06526598|PROCEDURE|PMI-targeted pressure support setting and adjustment|During PSV, the pressure support is set and adjusted to a PMI target between 0 and 2 cmH2O.
224151158|NCT06526598|PROCEDURE|VT/RR-targeted pressure support setting and adjustment|During PSV, pressure support is set and adjusted according to a VT/RR target of VT between 6 and 8 ml/kg predicted body weight, RR between 20 and 35 breaths/min, and no signs of respiratory distress.
224151159|NCT03079245|OTHER|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
224151160|NCT03079245|OTHER|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
224151161|NCT03079245|OTHER|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (\>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
224151162|NCT05190107|DIAGNOSTIC_TEST|DASS-21 scale|"Each construct consists of 7 questions. The participants must select the answer that better represents their feelings over the last week in each scenario. Each question has a Likert scale of 4 options where 0 represents did not apply to me to 3 applied to me very much."
224151163|NCT00621088|PROCEDURE|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
224151164|NCT05110599|DRUG|Bryophyllum 50% chewable tablets|Each 350 mg tablet corresponds to 170 mg of leave press juice from Bryophyllum pinnatum, dried down to 17 mg by mixing with lactose; 100 mg dried BP matter in 1 g
224151165|NCT05110599|OTHER|Placebo|Lactose with adaption in appearance and tast
224151166|NCT02157168|BEHAVIORAL|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
224151167|NCT01614912|DRUG|SM-13496|40 or 80 mg once daily orally
224151168|NCT06282536|DRUG|Iruplinalkib|60 mg on days 1-7, if tolerable, 180 mg from day 8 onwards.
224151169|NCT06282536|PROCEDURE|surgery|Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
224151170|NCT04798313|DRUG|MW031|Subjects would receive a single 60mg (1 mL) of MW031 through subcutaneous injection, on the first day of treatment.
224151171|NCT04798313|DRUG|Prolia®|Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
224151172|NCT04406389|DRUG|Enoxaparin sodium|"Intermediate Dose Prophylaxis Arm:~0.5 mg/kg subcutaneously every 12 hours if creatinine clearance greater than or equal to 30 ml/min --OR-- 0.5 mg/kg subcutaneously every 24 hours if creatinine clearance less than 30 ml/min~Therapeutic Dose Anticoagulation Arm:~1 mg/kg subcutaneously every 12 hours"
224151173|NCT04406389|DRUG|Unfractionated heparin|"Intermediate Dose Prophylaxis Arm:~7,500 units subcutaneously every 8 hours~Therapeutic Dose Anticoagulation Arm:~Dosed to target anti-Xa level 0.3 - 0.7 IU/mL or activated partial thromboplastin time (aPTT), according to institutional protocol"
224151174|NCT04406389|DRUG|Fondapariniux|"Intermediate Dose Prophylaxis Arm:~2.5 mg daily subcutaneously~Therapeutic Dose Anticoagulation Arm:~Dose by weight:~* If greater than or equal to 100 kg: 10 mg daily~* If less than 100 kg but greater than or equal to 50 kg: 7.5 mg daily~* If less than 50 kg: 5 mg daily"
224151175|NCT04406389|DRUG|Argatroban|"Therapeutic Dose Anticoagulation Arm:~Dosed according to institutional protocol"
224151176|NCT03292341|OTHER|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
224151177|NCT03292341|OTHER|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
224305130|NCT01659866|DRUG|aztreonam|2000 mg intravenously 1 hour before the procedure
224305131|NCT01659866|DRUG|imipenem|1000 mg intravenously 1 hour before the procedure
223572511|NCT01646645|BIOLOGICAL|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
224065543|NCT01638780|DIETARY_SUPPLEMENT|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
224065544|NCT01638780|DIETARY_SUPPLEMENT|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
224151178|NCT03292341|OTHER|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
224151179|NCT03292341|OTHER|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
224305132|NCT01908816|DRUG|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
224065545|NCT05182554|BEHAVIORAL|Doctor Videos|Receive ads on Facebook or through our website with videos in which health professionals tell people to get the Covid-19 vaccine. The health professionals answer common questions about the Covid-19 vaccine, such as how mRNA vaccines work, and what types of side effects to expect.
224065546|NCT05182554|BEHAVIORAL|Sharing Videos|Receive ads on Facebook with videos in which health professionals tell people to encourage their unvaccinated friends to get the Covid-19 vaccine.
224065547|NCT05182554|BEHAVIORAL|Sharing Videos (Influencers)|Receive ads on Facebook with videos in which health professionals tell people to get their most influential friends to encourage their unvaccinated friends to get the Covid-19 vaccine.
224065548|NCT05182554|BEHAVIORAL|Vaccine Ambassador|"Adults in participating geographic areas can sign up to be a vaccine ambassador on a website that the study team has built. The study team will send updates to vaccine ambassadors when new content has been posted to the website (e.g. a new video) and/or to remind the vaccine ambassadors to encourage their friends to get vaccinated. The study team will incentivize vaccine ambassadors by entering participating ambassadors into a lottery for a prize."
224065549|NCT05182554|BEHAVIORAL|Video framing|"The same videos will be displayed using two different frames: a myth frame and a fact frame. Visitors to the vaccine content website will randomly receive one framing of each video."
224065550|NCT05182554|BEHAVIORAL|Video order|The order in which videos appear on the vaccine content website will be randomized.
224065551|NCT03385603|DEVICE|Dilator|Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
224065552|NCT03385603|BEHAVIORAL|Fear-Based Questionnaires|Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
224065553|NCT01230541|DRUG|Placebo|Daily, oral tablet
224065554|NCT01230541|DRUG|Udenafil|Daily tablet
224065555|NCT03260088|DIAGNOSTIC_TEST|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
224065556|NCT00453726|PROCEDURE|Non invasive mechanical ventilation|
224065557|NCT03234244|DRUG|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
224065558|NCT03234244|DRUG|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
224065559|NCT03234244|DRUG|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
224065560|NCT01778439|DRUG|OMP-52M51|
224065561|NCT00002106|DRUG|Ranitidine hydrochloride|
224065562|NCT03519763|DIAGNOSTIC_TEST|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
224065563|NCT04296370|DRUG|Fluzoparib; Apatinib|Fluzoparib Orally twice daily; Apatinib Orally once daily
224065564|NCT04296370|DRUG|Fluzoparib|Fluzoparib Orally twice daily
224065565|NCT04296370|DRUG|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine Vinorelbine"
224065566|NCT01962571|DRUG|Erythropoietin alfa|
224065567|NCT01962571|DRUG|Placebo|
224065568|NCT01666431|DRUG|Lapatinib|
224065569|NCT00309309|DRUG|Rosiglitazone|
224065570|NCT01157975|DRUG|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
224065571|NCT01157975|DRUG|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
224065572|NCT03831074|DEVICE|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
224065573|NCT02249143|DEVICE|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
224151180|NCT05452109|OTHER|Blood Flow Restriction|Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
224151181|NCT05452109|OTHER|Classical Training Alone|Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
224151182|NCT05705895|PROCEDURE|CENTRAL VENOUS CATHETER CARE PROTOCOL|"Catheter care is provided in line with the CVC care protocol developed by the researcher:~* For subsequent catheter care, a transparent sterile catheter cover impregnated with 2% chlorhexidine gluconate will be used.~* The entry point of the catheter will be wiped with a disposable sterile skin cleaning applicator containing 2% Chlorhexidine Gluconate and 70% Isopropyl Alcohol, which will be provided by the researchers, and wait for it to dry.~* Vein valve/needleless connector will be used.~* Effective manual disinfection of needle-free connectors (hubs) will be ensured before each intervention.~* Needle-free connectors will be replaced every 96 hours at the latest.~* If necessary, the catheter lumen will be washed with a disposable, positive-pressure sterile washing system containing 10 ccs 0.9% sodium chloride to be provided by the investigators.~* Pulsatile give stop give stop technique will be used in the washing process."
224151183|NCT02644148|PROCEDURE|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
224151184|NCT02644148|PROCEDURE|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
224151185|NCT01249534|OTHER|gastroesophageal cancer surgery|gastroesophageal cancer surgery
224151186|NCT02451540|RADIATION|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
224151187|NCT02451540|DRUG|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
224151188|NCT02451540|DRUG|Roflumilast|Roflumilast, once a day in the morning during 3 months
224151189|NCT01227304|DEVICE|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
224151190|NCT04312438|DIAGNOSTIC_TEST|oral food challenge with cow's milk proteins|in children with diagnosed Cow's Milk Allergy open oral food challenge test with cow's milk protein (milk formula in children up to 3 yo, cow,s milk after 3 yo) will be carried out
224151191|NCT03277768|DEVICE|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
224151192|NCT03157440|DIAGNOSTIC_TEST|Ring oxymetry|a new type oxymetry wear on index finger like a ring
224151193|NCT03249948|PROCEDURE|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
224151194|NCT03249948|PROCEDURE|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
224151195|NCT05161637|DRUG|TLC590|TLC590 490mg or 588mg
224151196|NCT05161637|DRUG|Bupivacain|Bupivacaine 75mg
224151197|NCT05161637|DRUG|Ropivacaine|Ropivacaine 150mg
224151198|NCT05161637|DRUG|Normal saline|Normal saline 20mL or 24mL
224151199|NCT01478893|BIOLOGICAL|SEL-068|Sub-cutaneous injection, multiple dose
224151200|NCT01478893|BIOLOGICAL|Saline|Sub-cutaneous injection, multiple dose
224151201|NCT04664140|OTHER|QFR-based virtual PCI|Procedural planning of PCI based on the pullback trace given by the QFR systems in order to obtain an optimized functional result after PCI
224151202|NCT04664140|OTHER|angiography-based PCI|PCi according to international guidelines, local protocols and practice
224151203|NCT04075773|BEHAVIORAL|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
224151204|NCT03686865|DEVICE|dental implants|extraction sockets regenerated with xenograft
224151205|NCT02559713|DRUG|Vedolizumab|Vedolizumab IV infusion
224151206|NCT05487313|PROCEDURE|Erector spinae plane block|fascial plane injection guided by fluoroscopic device after ultrasound guidance
223455768|NCT01633099|DRUG|Decitabine|"1. Number of Cycles: 4 cycles.~2. Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,\>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells\<5%, the following cycle:decitabine 20 mg/m2, (iv,\>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,\>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（\<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,\>1h, on d1-3 of each 28day cycle)."
223455769|NCT02600611|DRUG|iclaprim|Experimental treatment
224151207|NCT00219232|DRUG|Rivastigmine Transdermal Patch|
224151208|NCT00983359|RADIATION|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
224151209|NCT03306485|OTHER|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
224151210|NCT06092853|OTHER|Gingival crevicular fluid (GCF) and serum samples|Gingival crevicular fluid (GCF) and serum samples were collected from all participants for biochemical analyses
224151211|NCT02680405|PROCEDURE|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
224151212|NCT02680405|PROCEDURE|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
224151213|NCT02680405|PROCEDURE|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
224151214|NCT04637971|OTHER|Coaching|Participants will receive 4 sessions of group coaching intervention within 6 weeks. Each session is in a group of 3-4 women and lasts for approximately 1.5 hours. The sessions will be conducted by experienced social workers.
224151215|NCT04637971|OTHER|Self-help tips plus telephone support|Participants will receive 4 self-help tips sent via SMS and 4 phone call from a social worker in 6-week of time. During the telephone call, the social worker will advise the client to make use of the tips we sent to her.
224151216|NCT03694041|DRUG|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
224151217|NCT03694041|DRUG|SAD: Placebo|Drug: Placebo Placebo for 1day
224151218|NCT03694041|DRUG|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
224151219|NCT03694041|DRUG|MAD: Placebo|Matching study drug will be repeatedly administered.
224151220|NCT03694041|OTHER|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
224151221|NCT03694041|OTHER|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
224151222|NCT04350736|DRUG|TD-0903|Study drug to be administered by inhalation
224151223|NCT04350736|DRUG|Placebo|Placebo to be administered by inhalation
224151224|NCT03357913|OTHER|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
224151225|NCT02011867|DEVICE|Cork Electrode|
224151226|NCT02303171|DRUG|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
224151227|NCT02303171|DRUG|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
224151228|NCT03418051|OTHER|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
224151229|NCT03418051|OTHER|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
224151230|NCT05684653|DRUG|Orelabrutinib Tablets|50 mg, single oral dose
224151231|NCT02441855|DEVICE|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
224151232|NCT01678716|BEHAVIORAL|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
224151233|NCT01678716|DIETARY_SUPPLEMENT|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
224151234|NCT01678716|BEHAVIORAL|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
224151235|NCT01907841|OTHER|Ischemic Preconditioning|
223455770|NCT02600611|DRUG|vancomycin|Active comparator
224301959|NCT02909946|BEHAVIORAL|Multi-modal Infection Control Program|"1. Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~2. Hand hygiene education to residents and families (resident-level intervention).~3. Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~4. Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~5. Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
223455771|NCT02147392|DRUG|[11C]ER-176|
223455772|NCT00630201|DRUG|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
223455773|NCT03189069|DRUG|Apixaban|Treatment for NVAF patients
223455774|NCT03189069|DRUG|Dabigatran|Treatment for NVAF patients
223455775|NCT03189069|DRUG|Rivaroxaban|Treatment for NVAF patients
223455776|NCT03189069|DRUG|Warfarin|Treatment for NVAF patients
224151236|NCT04587960|PROCEDURE|Delayed primary closure of skin incision in Caesarean section in experimental group|Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
224151237|NCT04587960|PROCEDURE|Primary closure of skin incision in Caesarean section in active comparator group|Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
224151238|NCT00103597|DRUG|Fludrocortisone|
224151239|NCT00103597|DRUG|Domperidone|
224151240|NCT00103597|BEHAVIORAL|Conservative Measures for Orthostatic Hypotension|
224151241|NCT06362460|DRUG|[14C] RAY1216|400 mg suspension containing 100μCi of \[14C\]RAY1216
224151242|NCT03198780|OTHER|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
224151243|NCT01928563|DRUG|Dapoxetine|
224151244|NCT01928563|DRUG|Udenafil|
224151245|NCT01928563|DRUG|Udenafil+Dapoxetine|
224151246|NCT00002718|BIOLOGICAL|anti-thymocyte globulin|
224151247|NCT00002718|BIOLOGICAL|filgrastim|
224151248|NCT00002718|DRUG|cyclophosphamide|
224151249|NCT00002718|DRUG|cytarabine|
224151250|NCT00002718|DRUG|methylprednisolone|
224151251|NCT00002718|DRUG|thiotepa|
224151252|NCT00002718|PROCEDURE|in vitro-treated bone marrow transplantation|
224151253|NCT00002718|PROCEDURE|in vitro-treated peripheral blood stem cell transplantation|
224151254|NCT00002718|RADIATION|radiation therapy|
224151255|NCT03628950|PROCEDURE|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
224151256|NCT03628950|PROCEDURE|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
224151257|NCT03046342|DIAGNOSTIC_TEST|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
224151258|NCT02487888|OTHER|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
224151259|NCT02487888|OTHER|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
224151260|NCT02193828|BIOLOGICAL|Collagenase clostridium histolyticum|Single injection into nodule
224151261|NCT02193828|BIOLOGICAL|Placebo|Single injection into nodule
224151262|NCT03587571|PROCEDURE|Surgical intervention|Open reduction and plate osteosynthesis.
224151263|NCT06460597|OTHER|Papworth Technique|The Papworth breathing technique is used by respiratory physiotherapists to control and correct breathing. Instead of using the chest, Papworth technique encourages to take more relaxed breathing by using the abdomen. Breathing in slowly through the nose and breathing out through pursed lips as if blowing out a candle. Repeat this cycle for 3-5 times
224151264|NCT06460597|OTHER|Pranayama|Pranayama is an ancient breath technique that originates from yogic practices in India. Sitting comfortably, slowly inhale through the nose and count to five. Direct the breath across the back of the throat as you inhale so the air makes a slight hissing sound keeping the lips sealed, breathe out through the nose and try to match the length of your inhale. The breath should make a noise like waves crashing as you exhale. Continue to inhale and exhale using the same process for 5 to 8 minutes. Aim to do this exercise for 10 to 15 minutes as become more practiced.
224151265|NCT00717535|OTHER|cryopreservation|
224151266|NCT00717535|OTHER|questionnaire administration|
224151267|NCT00717535|OTHER|study of socioeconomic and demographic variables|
224151268|NCT06155240|BEHAVIORAL|Therapeutic yoga|Yoga interventions include yoga poses, breathing, and meditation
224151269|NCT06386172|OTHER|Clinical decision support trigger|Investigation of CDS-triggers effect on primary care physicians detection and management of chronic kidney disease
224151270|NCT00226967|DRUG|Sandostatin|Calculated per patient
224151271|NCT05101395|OTHER|Giemsa stain|Giemsa special stain was employed for detection of H. Pylori microorganisms.
224151272|NCT03106012|PROCEDURE|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
224151273|NCT03106012|PROCEDURE|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
224151274|NCT04250012|BEHAVIORAL|Internet-based ACT intervention|The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
224151275|NCT04250012|BEHAVIORAL|Psychoeducation|The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
224151276|NCT00889681|DEVICE|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
224151277|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period \[S0\]) until r-hCG day (at least 2 follicles \>=17 mm)
224151278|NCT01185704|DRUG|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period \[S6\]) until r-hCG day (at least 2 follicles \>=19 mm)
224151279|NCT01185704|DRUG|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
224151280|NCT01185704|DRUG|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period \[S1\]) until r-hCG day
224151281|NCT01383967|DRUG|LY2979165|Administered orally
224151282|NCT01383967|DRUG|placebo|Administered orally
224151283|NCT02790333|PROCEDURE|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
224151284|NCT02790333|PROCEDURE|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
224151285|NCT01671956|BIOLOGICAL|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
224151286|NCT01671956|BIOLOGICAL|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
224151287|NCT03165942|OTHER|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
224151288|NCT03165942|OTHER|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
224151289|NCT03165942|DRUG|Ethanol|
224151290|NCT03864809|BEHAVIORAL|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
224151291|NCT00212485|PROCEDURE|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
224151292|NCT00212485|PROCEDURE|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
224151293|NCT00680160|DRUG|AN2690|AN2690 7.5% Solution, once daily for 28 days
224151294|NCT04101435|BIOLOGICAL|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
224151295|NCT01686958|DEVICE|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
224151296|NCT02993055|DRUG|Ulimorelin|
224151297|NCT02993055|OTHER|Placebo|
224151298|NCT05998655|OTHER|tele nursing|"In the research, tele-nursing applications based on technological competence theory will be applied to the experimental group. In the content of the application, training, consultancy and follow-up will be made on breast cancer, the problems experienced in the treatment process of breast cancer, the most frequently experienced chemotherapy symptoms and management strategies. Technology knowledge will be based on the concepts of collaborative design and participant interaction. A five-week group training will be implemented once a week. The training will be applied to all the participants in the experimental group and will be held over Google Meet. Educational program; pre-prepared powerpoint presentations, oral narration, discussion and group training will be made using e-booklets."
224151299|NCT02675738|OTHER|good clinical practice|
224151300|NCT02486367|DRUG|Clopidogrel|Standard ADP receptor blockade
224151301|NCT02486367|DRUG|Ticagrelor|High potency ADP receptor blockade
224151302|NCT02832596|DRUG|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
224151303|NCT02832596|PROCEDURE|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
224151304|NCT03162458|DRUG|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
224151305|NCT03162458|DRUG|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
224151306|NCT02741219|DRUG|Normal saline|Control Group receives normal saline bolus after delivery
224151307|NCT02741219|DRUG|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
224151308|NCT02741219|DRUG|Sufentanil|sufentanil PCA after surgery
223455777|NCT04798872|OTHER|Web-based educational program|The mothers and fathers will be provided a website that consist of 6 session. at the end of the session, the lactation consultant will do video call to the mothers to discuss the questions from mothers and fathers. after delivery, telephone counseling will be conducted by lactation consultant to mothers at 2, 4, and 6. weeks postpartum
223455778|NCT03167255|DRUG|NS-065/NCNP-01|Received during weekly intravenous infusions
224151309|NCT02741219|DRUG|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
224151310|NCT01151540|DRUG|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
224151311|NCT06327620|COMBINATION_PRODUCT|Daivobet ointment, topical steroids|"Daivobet Ointment: This intervention involves the topical application of Daivobet ointment, which is a combination of calcipotriol and betamethasone. The application is to be done three times daily for four weeks.~Topical Steroid: This intervention entails the topical application of a steroid ointment three times daily for four weeks. The specific steroid and its details are not disclosed in the provided information."
224151312|NCT01213693|DRUG|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
224151313|NCT01213693|DRUG|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
224151314|NCT00003893|DRUG|CMF regimen|
224151315|NCT00003893|DRUG|cyclophosphamide|
224151316|NCT00003893|DRUG|doxorubicin hydrochloride|
224151317|NCT00003893|DRUG|epirubicin hydrochloride|
224151318|NCT00003893|DRUG|fluorouracil|
224151319|NCT00003893|DRUG|methotrexate|
224151320|NCT00003893|DRUG|mitomycin C|
224151321|NCT00003893|DRUG|mitoxantrone hydrochloride|
224151322|NCT00003893|PROCEDURE|adjuvant therapy|
224151323|NCT00003893|RADIATION|radiation therapy|
224151324|NCT02248857|OTHER|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
224151325|NCT02248857|OTHER|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
224065574|NCT05893407|DIAGNOSTIC_TEST|Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging|Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
224065575|NCT01555528|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
224065576|NCT00689871|DEVICE|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
224065577|NCT02084303|OTHER|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
224065578|NCT01783080|BEHAVIORAL|Behavioral Activation for return to work|See Arm Description
224065579|NCT06365203|PROCEDURE|Through knee amputation|Amputation Technique
224065580|NCT06365203|PROCEDURE|Above knee Amputation|Amputation Technique
224065581|NCT05273034|PROCEDURE|1-hour sepsis bundle|"The sepsis management will be delivered in a timely manner within 60 minutes of ED triage including~* usual test and treatment~* blood culture~* lactate measurement~* broad spectrum antibiotics~* In case of hypotension or lactate \> 4, rapid administration of 30ml/kg crystalloid fluid resuscitation will be mandated~* In case of initial elevated lactate (\> 2 mmol/l), a second lactate measurement should be done after initial fluid resuscitation."
224065582|NCT02185404|DEVICE|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
224065583|NCT04169880|DEVICE|HILT|HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
224065584|NCT04169880|COMBINATION_PRODUCT|HILT & EXERCISE|HILT\&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
224065585|NCT00363948|DRUG|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
224065586|NCT00363948|DRUG|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
224065587|NCT02845570|OTHER|68Ga-DOTANOC PET/MRI|
224065588|NCT02845570|OTHER|18F-FDG PET/MRI|
224065589|NCT00956670|OTHER|Quality-of-Life Assessment|Ancillary studies
224065590|NCT00956670|OTHER|Questionnaire Administration|Ancillary studies
224065591|NCT00956670|PROCEDURE|Study of High Risk Factors|Undergo lymphedema assessment
224065592|NCT00956670|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224065593|NCT00956670|PROCEDURE|Therapeutic Laparoscopic Surgery|Undergo surgery
224065594|NCT00956670|PROCEDURE|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
224065595|NCT00326807|DRUG|Naltrexone|
224065596|NCT00542269|DRUG|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
224065597|NCT00542269|DRUG|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
224065598|NCT00542269|DRUG|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
224065599|NCT00889265|DEVICE|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
224065600|NCT06364111|DEVICE|Vibrabot capsule|Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks.
224065601|NCT06364111|DRUG|polyethylene glycol|Subjects in the control group received polyethylene glycol for 6 weeks
224065602|NCT00867399|DRUG|ABT-126|See arm for details
224065603|NCT04450680|OTHER|Beta-lactam Therapeutic Drug Monitoring|Monitoring serum beta-lactam levels to individualise beta-lactam doses and ensure therapeutic target attainment
224065604|NCT03363750|BEHAVIORAL|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
224065605|NCT04618159|OTHER|lactobacillus reuteri DSMZ 17648|to evaluate if this product can eradicate helicobacter pylori
224065606|NCT04455529|OTHER|ESUS|Embolic stroke of undetermined source (ESUS) designates patients with nonlacunar cryptogenic ischemic strokes in whom embolism is the likely stroke mechanism.
224065607|NCT02075099|OTHER|tensing exercises|Donors will do tensing exercises during blood donation
224065608|NCT02075099|OTHER|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
224065609|NCT01228370|DRUG|silodosin|silodosin 8mg once a day for 12 weeks
224151326|NCT03453918|DIETARY_SUPPLEMENT|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
224065610|NCT01732302|OTHER|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
224065611|NCT03357679|PROCEDURE|Tracheal intubation|Intubation of the trachea with endotracheal tube
224065612|NCT03357679|DEVICE|Glidescope assisted tracheal intubation|With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
224065613|NCT03357679|DEVICE|Bed up head elevated tracheal intubation|Use of the Macintosh laryngoscope blade size 3
224065614|NCT04455646|BEHAVIORAL|CBT-based, mobile-delivered, intervention platform|App of this platform have been shown to be associated with reduced psychopathology symptoms,including depressive symptoms, following treatment (i.e., relapse prevention). GGDE, which was specifically designed to address MDD related maladaptive beliefs and symptoms,includes different CBT-based intervention modules (nine active and one sham), as well as means for data collection and response monitoring. The active treatment modules will differ in the proportion of adaptive vs. maladaptive statements and the emphasis on particular content (e.g loneliness vs. hopelessness).
224065615|NCT02135211|BEHAVIORAL|Lifestyle counseling|
224065616|NCT04350775|OTHER|RE-IADL|RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.
224065617|NCT04350775|OTHER|General community rehabilitation|General community rehabilitation contains the activities in psychiatric rehabilitation center.
224065618|NCT02404259|DRUG|TDF (Tenofovir)|
224065619|NCT02404259|DRUG|Efavirenz|
224065620|NCT02404259|DRUG|lopinavir/ritonavir, atazanavir/ritonavir|
224065621|NCT00524407|DRUG|Epoetin alfa|
224065622|NCT05656677|BEHAVIORAL|Passive parental involvement|One parent watching a procedural painful intervention, two nurses executing facilitated tucking
224065623|NCT05656677|RADIATION|Active parental involvement|One parent watching a procedural painful intervention and at the same time executing facilitated tucking
224065624|NCT00127738|PROCEDURE|Angiographic renal revascularization|
224065625|NCT06190652|DRUG|Chemotherapy combined with immunotherapy|chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors
224065626|NCT06190652|RADIATION|radiotherapy|Intensity-modulated radiation therapy
224065627|NCT04055792|DRUG|Sintilimab|Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
224065628|NCT04514523|OTHER|QBSAfe Toolkit|The QBSAfe toolkit focuses on palliating symptoms, alleviating burden of treatment, facilitating social connections, and optimizing treatment safety.
224065629|NCT02690662|BEHAVIORAL|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
224065630|NCT04648605|OTHER|Post traumatic stress disorder questionnaire|Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
224065631|NCT04777136|OTHER|Home visit and comprehensive geriatric assessment|Home-visit from the geriatric team, who will do a full geriatric assessment and targeted interventions
224065632|NCT04777136|OTHER|Control group, no designated follow up|Only follow-up on patients own initiative with contact to the general practitioner
224065633|NCT03275194|PROCEDURE|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
224065634|NCT03817775|OTHER|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
224065635|NCT02799823|DEVICE|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
224065636|NCT03955302|BEHAVIORAL|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
224065637|NCT02572674|OTHER|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
224065638|NCT02572674|GENETIC|Genetic sample|Blood samples
224065639|NCT01888029|DEVICE|transcranial direct current stimulation|
224065640|NCT01888029|DEVICE|sham stimulation|
224151327|NCT03453918|OTHER|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
224151328|NCT02261883|DRUG|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
224151329|NCT02261883|DRUG|Placebo|Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
224151330|NCT04527276|OTHER|Oral care with 0,12% Chlorhexidine|0, 12 % CHX, and standard oral care with 0,9% NaCl were compared to assess VAP rates. Both solutions were applied to critically ill children who were intubated.
224151331|NCT01390480|DRUG|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
224151332|NCT06187948|OTHER|Video|All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
224151333|NCT01343017|OTHER|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
224151334|NCT04889963|BIOLOGICAL|adypose mesenchymal conditioned medium and ligament derived conditioned medium|rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture and ligament derived conditioned medium
224151335|NCT02576886|DEVICE|Gamma Camera|All images acquired with the General Electric Discovery 530c
224151336|NCT02576886|PROCEDURE|Prone Imaging|
224151337|NCT06281379|PROCEDURE|Total mesogastrectomy|More extended resection type with better oncological outcomes when compared to standard technique
224151338|NCT00661102|DRUG|Corticosteroids|As prescribed
224151339|NCT00661102|DRUG|Placebo|As prescribed
224151340|NCT00661102|DRUG|capecitabine [Xeloda]|As prescribed
224151341|NCT00661102|DRUG|dexpantenol [Bepantol]|As prescribed
224151342|NCT00353184|DRUG|Montelukast 5-mg orally added to standard therapy|
224151343|NCT00505102|DRUG|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
224151344|NCT00170742|DRUG|Octreotide, 30 mg i.m. LAR formulation|
224151345|NCT02729805|DRUG|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
224151346|NCT02729805|DRUG|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
224151347|NCT02729805|DRUG|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
224151348|NCT03574415|DRUG|DWP14012|DWP14012 tablets
224151349|NCT03574415|DRUG|Placebo|DWP14012 placebo-matching tablets
224151350|NCT04403854|DIAGNOSTIC_TEST|MRI|If possible with spectroscopy
224151351|NCT04403854|PROCEDURE|Spinal Tap|together with CSF pressure estimate
224151352|NCT03487393|DEVICE|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
224151353|NCT03441347|BEHAVIORAL|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
224151354|NCT03441347|OTHER|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
224151355|NCT00860119|DRUG|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
224151356|NCT00860119|DRUG|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
224151357|NCT04863937|DEVICE|Distal Thigh Compression Garment, Knee Sleeve|Randomized Comparison of Knee Sleeve, Distal Thigh Compression Garment and No Device
224151358|NCT05075707|OTHER|Electromagnetic therapy.|Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
224151359|NCT05075707|OTHER|Low level laser therapy (LLLT)|Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
224151360|NCT05883007|RADIATION|Accelerator-based BNCT with borofalan(10B)|Patients will be treated with BNCT regulated as 12, 15, or 18 Gy-Eq of the mucosal maximum dose.
224151361|NCT02915887|OTHER|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
224151362|NCT02414971|OTHER|There is no intervention|There is no intervention
224151363|NCT01425229|DRUG|Bosentan|"* Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
224065641|NCT03439202|OTHER|Hypoxia|Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
224065642|NCT01445821|BIOLOGICAL|Peripheral Blood Stem Cells|Mobilized leukapheresis product
224065643|NCT01445821|DRUG|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
224065644|NCT01445821|DRUG|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
224065645|NCT01445821|DRUG|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
224065646|NCT01445821|DRUG|Methylprednisolone|Steroid
224065647|NCT01445821|DRUG|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
224065648|NCT01445821|DRUG|Fludarabine|Purine analog which inhibits DNA synthesis or repair
224065649|NCT05145907|BIOLOGICAL|TJ107 +Pembrolizumab|TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV
224065650|NCT04821466|DEVICE|Virtual Reality Headset to provide a Virtual Reality Experience|Participants will utilise a Virtual Reality experience for distraction therapy via a Virtual reality headset. Participants will wear the Virtual reality headset to be immersed in a multimedia experience.
224065651|NCT06264882|DRUG|Degarelix|After first undergoing a pregnancy test, a clinician will administer an 80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ) to the women. A second injection will occur at 10 weeks. Compliance to the intervention will be ensured by having participants receive injections in the Clinical and Translational Research Center (CTRC), where all study visits will take place.
224065652|NCT06264882|DRUG|Transdermal Estradiol Patch|Treatment will be a weekly transdermal patch (0.075 mg) administered in a double-blinded manner. This estradiol dose increases serum estradiol to \~90 pg/mL. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
224065653|NCT06264882|DRUG|Transdermal Placebo Patch|Treatment will be a weekly transdermal patch (placebo inactive) administered in a double-blinded manner. Compliance to the intervention will be monitored by having participants keep a log that tracks patch use.
224065654|NCT03804203|RADIATION|standard treatment|3000 cGy in 10 daily fractions
224065655|NCT03804203|RADIATION|short course treatment|2000 cGy in 4 fractions administered twice a day
224065656|NCT00814892|BIOLOGICAL|allogeneic tumor cell vaccine|Given intradermally
224065657|NCT00814892|BIOLOGICAL|therapeutic autologous dendritic cells|Given intradermally
224065658|NCT00845650|BIOLOGICAL|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
224065659|NCT00845650|BIOLOGICAL|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
224065660|NCT00845650|BIOLOGICAL|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
224065661|NCT00845650|BIOLOGICAL|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
224065662|NCT00845650|BIOLOGICAL|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
224065663|NCT00845650|BIOLOGICAL|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
224065664|NCT03116074|BEHAVIORAL|Interactive Digital Health Tools|Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
224065665|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
224065666|NCT00531752|DRUG|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
224065667|NCT00531752|DRUG|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
224065668|NCT00385957|DRUG|AZT+3TC+IDV+RTV|
224065669|NCT00385957|DRUG|AZT+3TC+EFV|
224065670|NCT04540042|DRUG|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
224065671|NCT04540042|DRUG|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
224065672|NCT04540042|DRUG|SelK2 (Part 2)|I.V., single-dose (Day 1)
224065673|NCT04540042|DRUG|Placebo (Part 2)|I.V., single-dose (Day 1)
224065674|NCT00950664|DRUG|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
224065675|NCT00950664|DRUG|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
224065676|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using locator attachment|
224065677|NCT02952274|DEVICE|mandibular overdenture retained with single midline implant using ball attachment|
224065678|NCT02821715|DRUG|Active comparator: Modafinil + placebo|
224065679|NCT02821715|DRUG|THN102 300/3|
224065680|NCT02821715|DRUG|THN102 300/27|
224065681|NCT02526459|BEHAVIORAL|Birth plan|Patient will receive a birth plan
224065682|NCT03609307|DRUG|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
224065683|NCT03609307|DRUG|Intravitreal bevacizumab|these patients receive only Bevacizumab
224065684|NCT02302482|OTHER|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
224065685|NCT04155671|DRUG|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
224065686|NCT04155671|DRUG|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
224065687|NCT03793712|DRUG|Lu AF11167 (1-2 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
224065688|NCT03793712|DRUG|Lu AF11167 (3-4 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
224065689|NCT03793712|DRUG|Placebo|Placebo oral dose, tablets. Once daily. 12 weeks.
224065690|NCT05303545|OTHER|standard of care for patients with poliomyelitis sequelae|clinical examination, radiological, biological and physiological examinations.
224065691|NCT01359709|DRUG|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
224065692|NCT06339528|PROCEDURE|Vojta's Reflex Locomotion|"Reflex locomotion according to Vojta's therapy is a neurorehabilitative concept originally used for diagnostics and treatment of infants who were at risk of non-physiological psychomotor development, especially spastic cerebral palsy. This concept utilizes stimulation of specific zones described by Vojta to evoke global motor and non-motor response.~Trigger zones are specific body zones that are stimulated with pressure during reflex locomotion stimulation. They are pressure stimulated in order to induce reflex response. Variations of stimulation of different trigger zones (spatial summation) causes multiplication of afferent impulses. Sufficiently long stimulation of trigger zones (temporal summation) induces isometric contraction in muscle groups described by Vojta."
224065693|NCT06339528|PROCEDURE|Sham stimulation|Control group received sham stimulation by physicians at zones outside of the pressure zones, specifically 4-5 cm above the patella and on the lateral malleolus.
224065694|NCT05170243|DRUG|9MW1911 Injection|Single dose intravenously on day 1
224065695|NCT05170243|DRUG|9MW1911 Injection Placebo|Single dose of matching placebo intravenously on day 1
224065696|NCT05022797|DRUG|Glucarpidase 1000 UNT [Voraxaze]|2 vials of 1000 units per vial
224065697|NCT02222259|PROCEDURE|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
224065698|NCT04797065|PROCEDURE|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 2 minutes then in 3 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 2 minutes, then reentered the cecum and withdrawn to the splenic curvature in 3 minutes."
224065699|NCT04797065|PROCEDURE|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 3 minutes then in 2 minutes during each colonic segment.~In actual performance, withdrawal of the right colon, transverse colon and the left colon can be operated in segmental tandem colonoscopy. Taking the right colon as an example, after the endoscope reaches the cecum, it can be withdrawn to the splenic curvature in 3 minutes, then reentered the cecum and withdrawn to the splenic curvature in 2 minutes."
224065700|NCT00159861|DRUG|Sildenafil citrate|
224065701|NCT05954442|DRUG|Everolimus|Everolimus is a kind of mTOR inhibitors which has been approved to use in several kinds of cancers, especially in metastatic breast cancer .
224065702|NCT05954442|DRUG|Investigator's Choice of Chemotherapy|Investigator's choice of chemotherapy means the chemotherapy chosen by investigators/doctors to treat metastatic triple negative breast cancer, including nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone.
224065703|NCT02686515|DEVICE|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
224065704|NCT02686515|DEVICE|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
224065705|NCT00418353|DRUG|Betamethasone(Celestone soluspan) and Dexamethasone|
224065706|NCT02463175|DRUG|Plasmalyte|Boluses of 5ml/kg of plasmalyte
224065707|NCT02463175|PROCEDURE|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
224065708|NCT05799456|DIAGNOSTIC_TEST|Free glycosaminoglycan profiling|Free glycosaminoglycan profiling (GAGome) analysis was performed at a single blinded central laboratory using commercial kits wherein the concentration (in µg/mL) of 17 chondroitin sulfate (CS), heparan sulfate (HS), hyaluronic acid (HA) disaccharides were detected and quantified using a UHPLC-MS/MS system.
224065709|NCT02735369|DRUG|2% OC-10X|2% OC-10X
224065710|NCT02735369|DRUG|Placebo Comparator|Placebo
224065711|NCT05266066|OTHER|Clinical observation without antibiotic therapy for VAT|Patients will receive standard care plus antibiotic if new organ dysfunction or new infections other than VAT.
224065712|NCT05266066|OTHER|7 day antibiotic course for VAT|Patients will receive standard care plus 7 day course of antibiotic.
224065713|NCT02319187|DRUG|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
224065714|NCT02319187|DRUG|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
224065715|NCT02319187|DRUG|irinotecan|irinotecan 160mg/m2 d1, every 14 days
224065716|NCT04319133|BEHAVIORAL|Fasting|Doing fasting 2 days a week within 8 weeks
224065717|NCT02401828|DRUG|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
224065718|NCT01650025|DIETARY_SUPPLEMENT|VSL#3 active probiotic|
224065719|NCT01650025|OTHER|VSL#3 placebo|
224065720|NCT02260115|DEVICE|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
224065721|NCT02260115|PROCEDURE|Surgical Control|Surgery only
224065722|NCT00288756|PROCEDURE|lv injection of contrast|
224065723|NCT06632184|DRUG|Ondansetron Intraperitoneal Lavage|A single dose of 8 mg of ondansetron diluted in 500 mL of 0.9% saline solution will be administered as an intraperitoneal lavage at the end of elective laparoscopic cholecystectomy. The solution will remain in the abdominal cavity for 5 minutes and then be fully aspirated before surgical closure. This intervention aims to evaluate the local analgesic and antiemetic effects of ondansetron when used via the peritoneal route.
224151364|NCT03059472|BEHAVIORAL|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
224151365|NCT03059472|BEHAVIORAL|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
224151366|NCT04777318|OTHER|Conventional physiotherapy|A total of 12 sessions of conventional physiotherapy program for 4 weeks were applied 3 days a week. The conventional physiotherapy program included 20 min hotpack , 10 min ultrasound, 20 min conventional (Transcutaneous electrical nerve stimulation) TENS application.
224151367|NCT04777318|OTHER|Conventional physiotherapy and Muscle Energy Technique|In addition to conventional therapy, the muscle energy technique was applied to the individuals in the second group at the same frequency. Muscle energy technique was applied to the upper trapezius, sternocleidomastoideus , scalene (anterior-medius-posterior) and levator scapula muscles. According to the MET post-isometric relaxation method, each muscle was applied as one set (each set includes three repetitions). The patient was asked to perform a 7-second isometric contraction corresponding to 20% of the maximum isometric contraction force in the area where the restriction was felt. After the application, the patient was asked to breathe and relax, and the neck was brought back to the barrier point and the technique was repeated.
224151368|NCT04777318|OTHER|Conventional physiotherapy and Cervical Mobilization Techniques|Cervical mobilization techniques were also applied to the individuals in the third group in addition to conventional physiotherapy at the same frequency. In the first few sessions, bridging and manual traction techniques were applied in 3-5 repetitions. In the next sessions, in addition to these techniques, rotation with 3-5 repetitions of manual traction, anteroposterior sliding with traction and cervical lateral shift techniques were applied. Vertebrobasilar InsufficiencyTest was applied to all participants to determine the appropriateness of cervical mobilization. Before mobilization, a deep friction massage was applied on painful spasmic nuchal muscles for 3-4 minutes in order to increase blood circulation and relax tense tissues.
224151369|NCT02920606|PROCEDURE|Pulpotomy|
224151370|NCT02920606|PROCEDURE|Endodontic treatment|
224151371|NCT05955079|OTHER|Whole blood|3 samples (before, after surgery and before chemotherapy)
224151372|NCT02333006|OTHER|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
224151373|NCT00554476|DRUG|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
224151374|NCT03855033|BEHAVIORAL|Media Aware Sexual Health - High School|Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
224151375|NCT05652972|OTHER|Ketogenic diet|1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
224151376|NCT05652972|OTHER|Control diet|1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
224151377|NCT00546234|DRUG|tiotropium|18 mcg daily via Handihaler
224151378|NCT00546234|DRUG|long acting beta agonist|Turbohaler, 6 \& 12 mcg
224151379|NCT01664858|OTHER|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
224151380|NCT01664858|OTHER|SPECT|SPECT: Single Photon Emission Computed Tomography
223455779|NCT02588664|OTHER|COMPASS Intervention|"* A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~* Patient will receive a follow-up telephone call two days after having been discharged.~* 7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~* Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services."
224151381|NCT01664858|OTHER|CT calcium score|CT calcium score
224151382|NCT01664858|OTHER|CT coronary angiography|CT coronary angiography
224151383|NCT01664858|OTHER|X-Ray coronary angiography|X-Ray coronary angiography
224151384|NCT05520918|DIAGNOSTIC_TEST|the LIT test|The retained functional capacity of leukocytes (primarily neutrophils) to produce ROS in response to PMA in whole blood samples could provide a rapid 10-minute detection method for objectively determining onset or occurrence of severe COVID-19 and monitoring progression and treatment of COVID-19.
224151385|NCT02073903|BEHAVIORAL|Patient Survey|
224151386|NCT02073903|BEHAVIORAL|Provider Survey|
224151387|NCT03751423|DRUG|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
224151388|NCT03751423|DRUG|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
224151389|NCT03751423|DRUG|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
224151390|NCT03751423|DRUG|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
224151391|NCT03751423|DRUG|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
224151392|NCT02661464|BIOLOGICAL|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
224151393|NCT02661464|BIOLOGICAL|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
224151394|NCT00860990|OTHER|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
224151395|NCT06528808|OTHER|Simple reality simulator application|Women in the intervention group will be given an application aimed at breast cancer awareness with a simple valid simulator.
224151396|NCT00737685|DRUG|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
224151397|NCT05840978|DIETARY_SUPPLEMENT|Probiotics|Oral capsules
224151398|NCT05840978|DIETARY_SUPPLEMENT|Placebo|Oral capsules
224151399|NCT01634945|DRUG|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
224151400|NCT01634945|DIETARY_SUPPLEMENT|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
224151401|NCT01634945|DRUG|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
224151402|NCT01634945|DIETARY_SUPPLEMENT|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
224151403|NCT01634945|OTHER|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
224151404|NCT04477109|DEVICE|low level laser in addition to diet recommendations|The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt
223455780|NCT04565821|DEVICE|IPD Probe via TNIT|A total of 10 healthy adult volunteers will be enrolled in this study. All consented participants will be receive the same intervention. A Nasal tube will be inserted through nares until reaching the small intestine. This will be confirmed by m-mode OCT. Once secured, we will start infusing Ionic solution into the intestine so that IPD Probe can measure the potential difference between this and the control reading. The control reading is measured by infusing the same ionic solution subcutaneously on large muscle groups.
223455781|NCT02317484|DRUG|Ipragliflozin (SGLT2 inhibitor)|
223455782|NCT01315795|DRUG|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
224151405|NCT04477109|OTHER|sham laser application in addition to diet recommendations|sham laser application in addition to diet recommendations
224151406|NCT03069898|BEHAVIORAL|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
224151407|NCT00671983|PROCEDURE|Neurocognitive Testing|
224151408|NCT01236859|DRUG|Gabapentin|Neurontin®, Pfizer
224151409|NCT03947567|DRUG|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
224151410|NCT04262622|DEVICE|Group TEA: thoracic epidural analgesia group|in this group TEA will be performed by the insertion of transthoracic epidural catheter before induction of general anesthesia. Analgesia will be started on wound closure by injecting local anesthetic mixture into the epidural catheter
224151411|NCT04262622|DEVICE|Group RSB: rectus sheath block group|Two sets of epidural catheters which have multiple perforations at the end of the tubing will be surgically applied bilaterally into the rectus sheaths for each patient in this group on wound closure. By the end of surgery,injection of local anesthetic mixture will be started.
224151412|NCT04780945|DIAGNOSTIC_TEST|Functional RAD51 assay|ex vivo functional assay (RAD51 assay also known as Repair Capacity (RECAP) assay ) to test homologous recombination deficiencie (HRD) in viable tumor tissue
224151413|NCT04780945|DRUG|Olaparib Oral Product|300 mg bid
224151414|NCT00738829|DRUG|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
224151415|NCT00738829|DRUG|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
224151416|NCT00738829|BIOLOGICAL|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
224151417|NCT00357422|PROCEDURE|Operation|No drug needed
224151418|NCT00357422|PROCEDURE|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
224301960|NCT02951468|PROCEDURE|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed \[14\]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
224301961|NCT00437840|DRUG|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
224301962|NCT00437840|DRUG|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
223455783|NCT04400981|PROCEDURE|Remote ischemic conditioning|Remote ischemic conditioning will be applied immediately after randomization in the Emergency Department, through a standard blood pressure cuff placed around the non-paretic arm. The protocol includes 4 cycles of intermittent manually induced upper limb ischemia, alternating 5 minutes of inflation (20mmHg above systolic blood pressure) and 5 minutes of deflation.
223455784|NCT04400981|OTHER|standard medical therapy|"Standard medical therapy comprises single antiplatelet therapy, either aspirin given in a total dose ranging between 100 to 300 mg per day on days 1-5 and followed by aspirin 100mg/day on days 1-5 followed by aspirin 100mg/day, or Clopidogrel 75mg/day (at the discretion of the patient's attending physician), unless an indication for early anticoagulation (e.g. atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state) or dual antiplatelet therapy (e.g. early carotid stenting) is present.~All patients will receive standard deep venous thrombosis (DVT) prevention therapy together with appropriate treatment for blood pressure control, glycemic control and cholesterol reduction."
224151419|NCT02213822|OTHER|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
224151420|NCT02407912|DRUG|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
224151421|NCT05456412|OTHER|JAK inhibitor treatment|Standard care
224151422|NCT03279341|DRUG|polyethylene glycol|osmotic laxative
224151423|NCT03279341|DRUG|Bisacodyl|stimulant laxative
224151424|NCT03279341|DRUG|Prucalopride|prokinetic
224151425|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
224151426|NCT03138018|DIAGNOSTIC_TEST|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
224151427|NCT04103775|BEHAVIORAL|Cognitive Remediation|See Cognitive Remediation Arm description.
224151428|NCT04103775|BEHAVIORAL|Active Control|See Active Control Arm description.
224151429|NCT02638870|DRUG|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
224151430|NCT00334152|DRUG|casopitant|
224151431|NCT04101578|DRUG|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
224151432|NCT01753388|DEVICE|Liberty Stent|
224151433|NCT00113178|DEVICE|Catheter-based cardiac cryoablation|
223455785|NCT00002823|DRUG|cisplatin|
223455786|NCT00002823|DRUG|etoposide|
224151434|NCT03412500|DRUG|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
224151435|NCT03412500|DRUG|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
224151436|NCT05567393|DRUG|TAK-951 Placebo|TAK-951 placebo-matching SC injection
224151437|NCT05567393|DRUG|TAK-951|TAK-951 SC injection
224151438|NCT02030470|OTHER|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
224151439|NCT03148756|DRUG|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
224151440|NCT03148756|DRUG|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
224151441|NCT03583788|BEHAVIORAL|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
224151442|NCT03583788|OTHER|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
224151443|NCT02540772|BEHAVIORAL|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
224151444|NCT03374644|DEVICE|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
224151445|NCT01125540|DEVICE|Acuvue (Standard Daily Disposable Contact Lens)|
224151446|NCT01125540|DEVICE|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
224151447|NCT01867567|PROCEDURE|abdominal bandage|
224151448|NCT00358501|DRUG|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
224151449|NCT05493540|DRUG|Ibuprofen oral suspension|"The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
224151450|NCT05493540|DRUG|Placebo|"Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen"
224151451|NCT01899586|OTHER|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
224151452|NCT01899586|OTHER|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
224151453|NCT01874873|DRUG|Anlotinib|
224151454|NCT04688216|OTHER|risk factors of infection with multidrug-resistant organisms|"1. General information: age, gender, length of stay in ICU, method of admission, tubes taken at the time of admission, APACHEⅡ score, surgery, laboratory tests (PCT, CRP, WBC), pressure sores, etc.~2. Iatrogenic factors: days of using ventilator, days of using antibacterial drugs, types of antibacterial drugs, use of glucocorticoids, use of immunosuppressants, days of central venous intubation, days of indwelling catheters, days of arterial catheterization, and other indwelling catheters.~3. The patient's own related factors: diagnosis, whether complicated with hypertension or diabetes; whether exist malignant tumor, primary lung infection, hypoproteinemia; whether antibiotic treatment before admission; fever and fever days, whether diarrhea occurs"
224151455|NCT02255643|DEVICE|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
224151456|NCT00765713|DEVICE|Nasal continuous positive airway pressure|Nocturnal
224151457|NCT05386264|OTHER|Expanded autologous T regulatory cells|A 3+3 dose escalation design with expanded T regulatory cells administered on Day 1 and Day 15
224151458|NCT03120364|BIOLOGICAL|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
224151459|NCT03120364|BIOLOGICAL|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
224151460|NCT00429390|BEHAVIORAL|Ramadan Fasting|
224151461|NCT04021459|PROCEDURE|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~* One on the arm vein (peripheral)~* One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
223455787|NCT00002823|DRUG|vinblastine sulfate|
223455788|NCT00002823|DRUG|vindesine|
224151462|NCT02177175|DRUG|Carvedilol|
224151463|NCT02177175|OTHER|placebo|
224151464|NCT06397742|OTHER|Physical activity|"Patients received a set of exercises to execute at home. The home exercise program comprised 12 exercises conducted in sequence:~1. Symmetrical shoulder raises with retraction~2. Rolling upper extremities using a ball~3. Symmetrical shoulder raises~4. Band exercises strengthening the upper girdle and arm~5. Exercise of the shoulder joint flexors~6. Side arm raises in supine position~7. Lateral arm raises in supine position~8. Head raises with rotation in supine position~9. Side arm raises in prone position~10. Front arm raises in prone position~11. Rising and lowering the upper girdle in prone position~12. Neck muscles stretches"
224151465|NCT06397742|OTHER|Physical therapy - myofascial techniques|"Physical therapy program comprised five parts. I. Fascial manipulation targeted three most active center of coordination - center of fusion points within head, neck, shoulder, shoulder blade, or chest - during each session, time depending on the patients' adaptability.~II. Manual mobilization of the scar area with each training session including: active myofascial stretching; manual scar mobilization by stretching perpendicularly and in parallel with the scar; soft tissue mobilization by rolling and pulling the surface tissues; myofascial relaxation by breaking through restrictions.~III. Relaxation of muscle contractures using post-isometric muscle relaxation of the scalene muscle, sternocleidomastoid muscle, and neck muscles - until the sessions provided no muscle elongation.~IV. Neuromuscular stimulation with proprioceptive neuromuscular facilitation - included scapula movement patterns, dynamic reversal, stabilizing reversal, upper extremity movement patterns."
224151466|NCT03755999|OTHER|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
224151467|NCT05832099|RADIATION|Radiation|The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
224301963|NCT01517230|BEHAVIORAL|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
223455789|NCT00002823|DRUG|vinorelbine tartrate|
223455790|NCT00002823|RADIATION|radiation therapy|
223455791|NCT02720861|GENETIC|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
224065724|NCT06632184|DRUG|Saline Intraperitoneal Lavage|At the end of elective laparoscopic cholecystectomy, a peritoneal lavage will be performed using 500 mL of 0.9% saline solution (normal saline). The solution will be maintained in the peritoneal cavity for 5 minutes and then fully aspirated before surgical closure. This intervention serves as the comparator to assess the added effect of ondansetron in the experimental group.
224065725|NCT04499443|DRUG|GST-HG131 tablets|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
224065726|NCT04499443|DRUG|Placebo|This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
224065727|NCT05232838|DEVICE|eShunt Implant|The eShunt System is intended to shunt cerebrospinal fluid from the intracranial subarachnoid space to the venous system for the treatment of patients with normal pressure hydrocephalus, reducing disability due to symptoms including one or more of gait disturbance, cognitive dysfunction and urinary incontinence.
224065728|NCT04489888|DRUG|Pembrolizumab|Pembrolizumab 200 mg IV infusion given on Day 1 of each 21-day cycle
224065729|NCT04489888|DRUG|Carboplatin|Carboplatin AUC 5 mg/mL/minute IV infusion given on Day 1 of each 21-day cycle
224065730|NCT04489888|DRUG|Paclitaxel|At investigator's choice, paclitaxel 100 mg/m\^2 IV infusion given on Day 1 and Day 8 of each 21-day cycle or paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each 21-day cycle
224065731|NCT06047600|OTHER|Uroconnect Follow Up Group|Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
224065732|NCT03349099|DEVICE|Cook Flexor|ureteral access sheath
224065733|NCT03349099|DEVICE|Boston Scientific Navigator|ureteral access sheath
224065734|NCT02727985|PROCEDURE|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
224065735|NCT01805531|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
224065736|NCT05422820|DIAGNOSTIC_TEST|Diagnostic high-definition white-light (HDWL) colonoscopy|All participants will undergo to colonoscopy examination performed by competent/junior or expert/senior endoscopists (\>150-400 or \>400 previous colonoscopies, respectively). Bowel preparation was performed using different solutions, according to the clinical discretion of the attending, who indicated colonoscopy. After deep sedation by intravenous propofol with or without fentanyl or midazolam administration, a water-assisted colonoscopy was performed using a high-definition (HD) scope with white light (WL). Colonoscope trademark differs among participant centres.
224065737|NCT01070732|DRUG|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
224065738|NCT02285621|OTHER|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
224065739|NCT01685827|DRUG|Fexinidazole|
224065740|NCT01685827|DRUG|Nifurtimox|
224065741|NCT01685827|DRUG|Eflornithine|
224065742|NCT06493474|OTHER|Education|PEER ASSISTED BREASTFEEDING EDUCATION PROGRAM
224065743|NCT06493474|OTHER|Routine Care|Non education program only routine care
224065744|NCT05941078|BEHAVIORAL|ICF-based post-stroke rehabilitation program|Patients completed an intake interview with a case therapist for an initial assessment and setting of personal treatment goals. The therapist assisted the patient with setting goals that were related to their life roles and functional gaps in terms of body function and activity and participation. Patients' personalized treatment plans were composed in case conferences. The treatment program contents were organized as ICF-based body function and activity and participation intervention modules. Each of the occupational therapy, physiotherapy, and speech therapy disciplines set the aims and developed the training contents, intensities, durations, and upgrading and completion criteria.
224065745|NCT04080193|BEHAVIORAL|Smartphone-based interventional trial|According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
224065746|NCT00278993|DRUG|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
224301964|NCT01921621|BEHAVIORAL|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
224301965|NCT01921621|BEHAVIORAL|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
223455792|NCT04848753|COMBINATION_PRODUCT|Toripalimab combined with cisplatin and paclitaxel|Specified doses on specified days.
223455793|NCT04848753|COMBINATION_PRODUCT|Placebo combined with cisplatin and paclitaxel|Specified doses on specified days.
224151468|NCT04154371|DEVICE|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
224151469|NCT05716594|COMBINATION_PRODUCT|Plant enteral-extended anti-reflux stents|Plant enteral-extended anti-reflux stents in EUS-guided drainage of pancreatic pseudocysts
224151470|NCT05716594|COMBINATION_PRODUCT|Plant traditional stents|Plant traditional stents in EUS-guided drainage of pancreatic pseudocysts
224151471|NCT04110860|DRUG|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
224151472|NCT04110860|DRUG|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
224151473|NCT04110860|DRUG|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
224151474|NCT00143962|BEHAVIORAL|Low Carbohydrate Diet|
224151475|NCT03297333|OTHER|Resistance training|The resistance training group
224151476|NCT03297333|OTHER|Aerobic interval training|The aerobic interval training group
224151477|NCT05138237|PROCEDURE|endoscopy or surgery|"we choose the proper intervention surgery or endoscopy for management of the indeterminate common bile duct stricture according to its nature benign or malignant"
224151478|NCT04186715|DEVICE|Near-infrared spectroscopy|The Near-infrared spectroscopy probes will be placed in the frontal region.
224151479|NCT02535637|OTHER|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
224151480|NCT03457311|DRUG|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
224151481|NCT02629328|DEVICE|CardioCel|Treatment with CardioCel implant
224151482|NCT03965871|DRUG|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
224151483|NCT03965871|DRUG|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
224151484|NCT03965871|DRUG|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
224151485|NCT03965871|DRUG|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
224151486|NCT00260429|BIOLOGICAL|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
224151487|NCT00861380|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
224151488|NCT00861380|BIOLOGICAL|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children \< 12 months of age at the time of first study vaccination."
224151489|NCT00861380|BIOLOGICAL|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children \>= 12 months of age at the time of first study vaccination.
224151490|NCT02481063|OTHER|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
224151491|NCT02481063|OTHER|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
224151492|NCT00628758|DRUG|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
224151493|NCT00628758|DRUG|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
224301966|NCT03893435|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
223455794|NCT01429298|DRUG|Hydromorphone|2 mg IV hydromorphone over to 2-3 minutes
224151494|NCT06391658|OTHER|Functional Training|Functional training was performed for eigth weeks. The group participated on the supervised training once a week and twice a week at home. The training was arranged in a circuit method, consisting of three to four blocks with two to three exercises each, with an execution time of two minutes and recovery of thirty seconds between exercises and one minute between each block. The exercises emphasized integrated, functional and multi-joint movements for mobility, flexibility, strength, power and muscular endurance with overload, as well as agility, speed and balance exercises.
224151495|NCT01619163|DRUG|Placebo|
224151496|NCT01619163|DRUG|Prednisolone|low dose, 7.5 mg/day
224151497|NCT04447534|DRUG|Chloroquine or hydroxychloroquine|Chloroquine or hydroxychloroquine
224151498|NCT04447534|DRUG|zinc|Zinc tablets
223455795|NCT01429298|DRUG|Usual care|Attending administers IV opioid of his choosing
223455796|NCT02852057|DRUG|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
224151499|NCT05454397|OTHER|Observational study, no intervention|Observational study, no intervention
224151500|NCT04504461|OTHER|Analysis of feasibility and costs|Analyze the feasibility and costs of performing laparoscopic inguinal hernioplasty in an ambulatory surgery center
224301967|NCT04259983|OTHER|Maximal exercise test|The maximal exercise test will be performed on an electronically braked bicycle ergometer.
224301968|NCT04259983|OTHER|Endothelial dysfunction assessment|Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
224301969|NCT04259983|OTHER|Arterial stiffness assessment|Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
224301970|NCT01921530|PROCEDURE|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
223455797|NCT03592784|BEHAVIORAL|Food Order Therapy|Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.
224065747|NCT04828057|DRUG|Tafluprost, timolol maleate|Patients prescribe PG mono who occurs OSD or I IOP lower insufficient. patients switch to combination therapy.
224065748|NCT05613764|BEHAVIORAL|COVID Booster text messages|Participants will receive text messages per descriptions listed in the arms
224065749|NCT05678036|DRUG|Opioid maintenance treatment|A reform dramatically expanding access to opioid maintenance treatment (with methadone or buprenorphine) in the region.
224065750|NCT06503575|OTHER|Assesment|All assessments will be made
224065751|NCT02317211|DIETARY_SUPPLEMENT|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
224065752|NCT02317211|DIETARY_SUPPLEMENT|placebo|starch
224065753|NCT02114320|DEVICE|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
224065754|NCT00456989|DRUG|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
224065755|NCT00456989|DRUG|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
224065756|NCT04666779|OTHER|Chiropractic care|Care provided by chiropractors, based on manual therapy, exercise prescription and patient advice/education/reassurance
224065757|NCT02386228|GENETIC|collection of CSF and blood|collection of CSF and blood
224065758|NCT02598375|OTHER|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
224065759|NCT02408471|DEVICE|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
224065760|NCT05035615|DIAGNOSTIC_TEST|IUO Acute Leukemia Panel|This Investigational Panel , comprised of 6 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of immature hematopoietic cell populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell acute lymphoblastic leukemia or acute myeloid leukemia.
224065761|NCT03829657|DRUG|ampreloxetine|Oral tablet, QD (Daily)
224065762|NCT03829657|DRUG|Placebo|Oral tablet, QD
224065763|NCT05216679|DEVICE|Night splints|A night splint is a brace the patient wears on their foot to keep it in a dorsiflexed position while they sleep. It is the first line treatment for plantar fasciitis.
224065764|NCT05216679|DEVICE|Triceps Surae Stretching and Flexibility Assessment Device (TESS)|The TESS device is a slant board with a bar added for balance that the participant will stand on in 5 minute intervals throughout the day to stretch their calves, and potentially treat their plantar fasciitis symptoms.
224065765|NCT02121600|OTHER|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an \[F-18\]-Fluorocholine injection in the arm.
224065766|NCT02121600|RADIATION|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
224065767|NCT02121600|RADIATION|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
224065768|NCT00948363|OTHER|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
224065769|NCT00948363|OTHER|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
224065770|NCT02304107|DRUG|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
224065771|NCT02304107|DRUG|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
224065772|NCT06043232|BIOLOGICAL|DC vaccine|DC vaccine produced by the Team
224065773|NCT02188875|BEHAVIORAL|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
224065774|NCT02188875|BEHAVIORAL|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
224065775|NCT05559190|OTHER|Pulsed electromagnetic field|Pulsed electromagnetic field therapy was applied directly over the abdominal muscle from a supine position after the removal of metals or things that can be affected by a magnetic field will be assured prior to magnetic field application. The treatment parameters were set as 15 Hz frequency, 20 gauss amplitude with a rectangular waveform for 20 minutes.
224065776|NCT05559190|OTHER|Graduated abdominal strengthening exercises|Four specific muscle core exercises were performed
224065777|NCT00116350|DRUG|Misoprostol|800 mcg sublingual misoprostol
224065778|NCT00116350|DRUG|Oxytocin|40 IU Oxytocin IV
224065779|NCT01014689|DRUG|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
224065780|NCT01014689|DRUG|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
224151501|NCT06040307|PROCEDURE|SPI (Surgical Pleth Index)|Elective surgery in patients having trauma and orthopedic surgery with a combination of general and regional anesthesia. Opioid titration is guided by SPI during general anesthesia in the experimental arm.
224151502|NCT00378976|DRUG|valacyclovir|500 mg twice-daily oral
224151503|NCT00378976|DRUG|matching placebo|twice daily as per experimental drug
224151504|NCT02425280|BEHAVIORAL|Narrative Exposure Therapy|
224151505|NCT02425280|BEHAVIORAL|Treatment as Usual|
224151506|NCT00637377|DRUG|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224151507|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224151508|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224151509|NCT00637377|BIOLOGICAL|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
224151510|NCT01340391|DEVICE|Omnicast|dorsal splint 2-5 weeks
224151511|NCT05082402|DIAGNOSTIC_TEST|Swept Source Optical Coherence Tomography Angiography|The PLEX Elite 9000 is an FDA cleared research device for use in ocular imaging obtained by Northwestern University by way of a purchase agreement with the manufacturer, Carl Zeiss Meditec, Inc. It is currently unavailable outside of participation in the ARI Network, a cloudbased storage and image processing platform using deidentified information shared between academic institutions. The ARI Network is managed by a group of physicians and scientists from around the world that are working to better understand eye diseases.
224151512|NCT04104373|OTHER|Observational Cohort|
224151513|NCT03254862|PROCEDURE|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
224151514|NCT03254862|PROCEDURE|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
224151515|NCT04804280|GENETIC|DNA methylation of target genes|The methylation status of target genes (BDNF, SLC6A4, OXTR, NR3C1) will be investigated. Cord blood will be collected at birth for PT and FT, only for PT a peripheral blood sample will be collected at hospital discharge, during routine clinical procedures. Genomic DNA will be extracted from aliquots of 0. 2 ml of each blood sample with the GeneElute Blood Genomic DNA kit (Sigma) and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated.
224301971|NCT01921530|PROCEDURE|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
224301972|NCT02166814|DRUG|Fimasartan and Rosuvastatin|
224301973|NCT02166814|DRUG|Fimasartan|
224301974|NCT02166814|DRUG|Rosuvastatin|
224301975|NCT03473626|DRUG|Alicaforsen|Alicaforsen tablet
223455798|NCT03592784|BEHAVIORAL|Medical Nutrition Therapy|Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
223455799|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 1|Carbohydrate based food
223455800|NCT01734590|DIETARY_SUPPLEMENT|Carbohydrate based food mix 2|Carbohydrate based food
223455801|NCT01734590|DIETARY_SUPPLEMENT|Control carbohydrate based food|Carbohydrate based food
223455802|NCT00619125|OTHER|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
223455803|NCT00696995|DRUG|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
223455804|NCT04839432|BEHAVIORAL|implementation of albumin solution in the priming of the cardiopulmonary bypass machine|In March 2019, the investigators initiated a new priming fluid policy strategy aiming at replacing our traditional pure crystalloid fluid administration for an albumin one in order to decrease the relatively high-rate of observed pulmonary complications
223455805|NCT04324515|PROCEDURE|Robotic gastric bypass with or without cholecystectomy|Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
223455806|NCT00002073|DRUG|Epoetin alfa|
223455807|NCT06004323|BEHAVIORAL|Digital health literacy intervention|Participants from the intervention group will be invited to join virtual or face-to-face training, watch short videos on social media, participate in virtual bi-weekly group discussion, and fill in questionnaires for five times during the course of the study
223455808|NCT02226263|DIETARY_SUPPLEMENT|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 \[CFU\] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
223455809|NCT05709405|OTHER|Reading intervention|"The intervention will use a reading program called Lesing for alle (Reading for all) based on the research of Accessible Literacy Learning (ALL) which is an evidence-based approach, designed to teach reading skills to students with various intellectual disabilities, including autism spectrum disorders"
223455810|NCT02983253|OTHER|blood sample|none, only laboratory tests on blood serum
224065781|NCT03283826|BIOLOGICAL|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
224065782|NCT03283826|DRUG|Placebo|Placebo matching to ATA188
224065783|NCT00432614|DRUG|SR58611A|oral administration
224065784|NCT00432614|DRUG|escitalopram|oral administration
224065785|NCT00432614|DRUG|placebo|oral administration
224065786|NCT00003462|DRUG|busulfan|
224065787|NCT01632462|DRUG|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
224065788|NCT05353699|OTHER|Implementation strategies|We will adopt implementation strategies,which include Capacity-building strategies, Supervision, Integration strategies, Implementation process strategies, Dissemination strategies, Scale-up strategies.Firstly,Capacity-building strategies include:recruit, designate, and train for leadership; work with educational institutions.Secondly,Supervision includes provide clinical supervision;Thirdly,Integration strategies include: remind clinicians; use data warehousing techniques.Fourthly,Implementation process strategies include: identify and prepare champions; identify early adopters; inform local opinion leaders; involve patients/consumers and family members; obtain and use patients/consumers and family feedback.Fifthly,Dissemination strategies include: make training dynamic.Finally,Scale-up strategies include: use train-the-trainer strategies;place innovation on fee for service lists/formularies.
224065789|NCT01547455|DRUG|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
224065790|NCT01547455|DRUG|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
224065791|NCT00544609|DRUG|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
224065792|NCT00544609|PROCEDURE|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
224065793|NCT03565627|DEVICE|Exercise app: 7 Minute Workout Challenge|7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
224065794|NCT03565627|DEVICE|Running app: One You Couch to 5K|One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
224065795|NCT00718783|OTHER|Tissue samples taken from retinoblastoma|Tissue banking
224065796|NCT00718783|OTHER|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
224065797|NCT03813537|OTHER|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
224065798|NCT00609791|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
224065799|NCT00609791|OTHER|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
224065800|NCT00609791|OTHER|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
224065801|NCT00609791|OTHER|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
224065802|NCT00609791|OTHER|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
224065803|NCT00609791|PROCEDURE|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
224065804|NCT00609791|PROCEDURE|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
224065805|NCT00274027|DRUG|tiotropium bromide|
224065806|NCT04226820|OTHER|examination: blood pressure assessment|blood pressure measurement for 30 minutes, dominant side
224065807|NCT04226820|OTHER|examination: Flow Mediated Dilatation (FMD)-test|Flow Mediated Dilatation (FMD)-test for measuring the endothelial functionality
224065808|NCT04226820|OTHER|examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring|participant does a maximal exercise test by a handgrip strength test with simultaneously monitoring of the muscular oxygenation
224065809|NCT04226820|OTHER|examination: measurement of glucose by a finger prick|follow-up of blood sugar (glucose) during examinations by a finger prick
224065810|NCT01347151|DEVICE|The glidescope video laryngoscopy|
224065811|NCT01347151|DEVICE|The Pentax airwayscope|
224065812|NCT02091570|OTHER|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
224065813|NCT01920204|DRUG|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
224065814|NCT06116825|OTHER|1450ppm Fluoride toothpaste|1450ppm Fluoride toothpaste
224065815|NCT06116825|OTHER|1000Pppm Fluoride toothpaste|1000Pppm Fluoride toothpaste
224065816|NCT04201925|PROCEDURE|upper blepharoplasty|excision of excess eyelid skin with or without strip of orbicularis muscle ; with or without upper orbital fat
224065817|NCT02098564|OTHER|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
224065818|NCT02098564|OTHER|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
224065819|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
224301976|NCT02731326|DEVICE|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
224301977|NCT02731326|BEHAVIORAL|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
224301978|NCT02272634|DRUG|YPL-001 80 mg|twice daily \[BID\]
224301979|NCT02272634|DRUG|YPL-001 160 mg|twice daily \[BID\]
224065820|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
224065821|NCT00938314|DRUG|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
224065822|NCT00938314|DRUG|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
224065823|NCT04652271|PROCEDURE|Pancreatic surgery|Open, laparoscopic or robotic surgery of the pancreas
224065824|NCT01826552|DEVICE|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
224065825|NCT01826552|DEVICE|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
224065826|NCT04979507|OTHER|Uninterrupted sleep followed by functional neuroimaging.|2 within-subject sleep conditions: uninterrupted sleep; selective REM sleep reduction, followed by functional neuroimaging with emotion reactivity and regulation tasks the following morning
224065827|NCT01394939|BIOLOGICAL|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
224065828|NCT01394939|DRUG|Irinotecan|180 mg/m2 IV every 2 weeks.
224065829|NCT03379662|DEVICE|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
224065830|NCT03379662|DEVICE|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
224065831|NCT06263569|PROCEDURE|Total hip arthroplasty|Unilateral primary total hip arthroplasty procedure.
224065832|NCT05928455|BIOLOGICAL|LYB001|Experimental: The LYB001 vaccine was administered through intramuscular injection at doses of 30ug or 60ug in a 0.5mL volume.
224065833|NCT05928455|BIOLOGICAL|CoronaVac|Active Comparator: The CoronaVac vaccine was administered through intramuscular injection in a 0.5mL volume.
224065834|NCT00150592|DRUG|SPD503 (Guanfacine HCl)|
224065835|NCT00150592|DRUG|Placebo|
224065836|NCT02288507|DRUG|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
224065837|NCT02288507|RADIATION|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
224065838|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
224065839|NCT01281462|DRUG|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
224301980|NCT02272634|DRUG|Placebo|twice daily \[BID\]
224301981|NCT03670290|PROCEDURE|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
224065840|NCT01281462|DRUG|Doripenem|500 mg doripenem IV q8h;
224065841|NCT01281462|DRUG|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
224065842|NCT00002350|BIOLOGICAL|APL 400-003|
224065843|NCT02227693|DRUG|avatrombopag|E5501 (avatrombopag) 20-mg tablets
224065844|NCT02227693|DRUG|Placebo|Placebo matching 20-mg tablets
224065845|NCT03504878|PROCEDURE|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
224065846|NCT03504878|PROCEDURE|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
224065847|NCT00874120|DRUG|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
224065848|NCT00874120|DRUG|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
224065849|NCT01096563|DRUG|AZD9164|"Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose."
224065850|NCT01096563|DRUG|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
224065851|NCT01823679|DRUG|Capecitabine|Given orally
224065852|NCT03706287|DRUG|anlotinib 8mg + AP/PC|anlotinib 8mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
224065853|NCT03706287|DRUG|anlotinib 10mg + AP/PC|anlotinib 10mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
224301982|NCT03670290|PROCEDURE|epidural catheter|Patient will evaluate and if VAS score \>3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS\>3 or patient enounce pain.
224301983|NCT03670290|PROCEDURE|patient controlled analgesia|Patient will evaluate and if VAS score \>3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
224301984|NCT00150943|DEVICE|Renal artery stent|
224301985|NCT02344719|DRUG|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
224301986|NCT02344719|PROCEDURE|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
224301987|NCT02344719|PROCEDURE|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
224301988|NCT02344719|DRUG|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
224301989|NCT03667209|OTHER|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
224301990|NCT03667209|OTHER|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
224301991|NCT03821870|DIAGNOSTIC_TEST|Inditreat|Tumoroid formation and drug sensitivity analysis
224301992|NCT03821870|DRUG|Experimental drug|Second line treatment based on drug sensitivity analysis
224301993|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
224301994|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
223455811|NCT06005090|PROCEDURE|Far Cortical Locking Technique|Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
223455812|NCT02903420|DEVICE|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
223455813|NCT00227019|DRUG|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
223455814|NCT00227019|DRUG|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
223455815|NCT00227019|DRUG|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
223455816|NCT00227019|DRUG|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
223455817|NCT00227019|DRUG|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
223455818|NCT02555085|BIOLOGICAL|BIIB063|Single ascending IV dose
223455819|NCT02555085|OTHER|Placebo|Single dose
223455820|NCT03510897|DRUG|teprasiran|IV injection
223455821|NCT03510897|DRUG|Placebo|isotonic saline
224065854|NCT03706287|DRUG|anlotinib 12mg + AP/PC|anlotinib 12mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
224065855|NCT03706287|DRUG|anlotinib + AP/PC|anlotinib doses to be determined following the completion of Phase I of the study, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
224065856|NCT00225511|DRUG|Effexor XR|
224065857|NCT00225511|DRUG|Milnacipran|
224065858|NCT04743102|PROCEDURE|multi-points and full-thickness Biopsy|Four points around the tumor site and center of the tumor site full-thickness Biopsy
224065859|NCT04743102|DIAGNOSTIC_TEST|traditional cCR|diginal examination, endoscopy test, rectal MRI, and serum CEA level
224301995|NCT01471119|BIOLOGICAL|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
224301996|NCT01471119|BIOLOGICAL|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
224301997|NCT05828576|DIAGNOSTIC_TEST|MRI|Patients will be asked for two additional control visits in the hospital. Overview of measurements: Included subject will visit the UMCU at two occasions. The first MRI scan will be the baseline MRI, and the second MRI will take place after 2 years of follow-up. Additional follow-up data will be collected through medical records reporting on regular follow-up.
224301998|NCT06010537|DRUG|polysaccharide superparamagnetic iron oxide injection|Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
224301999|NCT06022900|BEHAVIORAL|Online training group|online health education with video call
224302000|NCT06022900|BEHAVIORAL|Face-to-face training group|Face-to-face health education with home visit
224065860|NCT01107678|OTHER|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
224065861|NCT04342221|DRUG|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate is an anti-malarial and anti-rheumatic drug and seems to be a potential candidate for the treatment of COVID-19 since it is able to block virus infection by increasing the endosomal pH, required for virus/cell fusion, it affects the activation of p38 mitogen-activated protein kinase (MAPK), involved in the replication of HCoV-229E and can interfere with the terminal glycosylation of ACE2, thus inhibiting SARS-CoV-2 infection.
224065862|NCT04342221|DRUG|Placebo|Placebo capsules
223455822|NCT03786185|BEHAVIORAL|MusicPlast|"Each subject will receive 20 sessions of the computerized training based on a simplified music reading protocol. The training will be provided via a smartphone or a tablet. Each training session will last for 20 minutes and the log file will be directly available to the researcher, allowing him/her to follow subject's timely participation. The stimuli used in the training protocol will consist of a visual image showing a circle on top of a background of 5 horizontal lines. The auditory part of the stimulus will consist of piano melodies of known songs. The position of the circle within the five lines will either follow the rule the higher the pitch of the tone, the higher the position of the circle or it will violate the above rule. The task requires audiovisual integration."
224151516|NCT04804280|DIAGNOSTIC_TEST|Functional Magnetic Resonance Imaging (fMRI) acquisition|Infants will undergo an MRI exam with a 3 Tesla Philips Achieva scanner and a 32-channel head coil. a trained experimenter will apply tactile stimulation associated with affective touch characteristics to the child with a soft brush on the right anterior tibial region in proximal and distal directions. The length of the stimulated area will be measured to cover approximately 15 cm, and tactile stimulations will be applied at a rate of 5 cm/s for 15s, with randomized intervals between stimuli of 10-15s (resulting in 5 stimulations in a 15s block). A regular audio signal will help the researcher to keep a constant stroke velocity. Audio commands will also be used to direct the experimenter. Infant must be asleep (natural sleep) during the fMRI acquisition.
224151517|NCT00755872|DRUG|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
224151518|NCT00755872|DRUG|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
224151519|NCT00755872|DRUG|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
224151520|NCT00755872|DRUG|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
224151521|NCT02992301|DRUG|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
224151522|NCT04712799|DRUG|Otrivin|oxymetazoline nasal spray
224151523|NCT05320380|DRUG|Anti-CD123 ADC IMGN632|Given IV
224151524|NCT05320380|PROCEDURE|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration/biopsy
224151525|NCT05320380|DRUG|Cytarabine|Given IT and IV
224151526|NCT05320380|DRUG|Fludarabine Phosphate|Given IV
224151527|NCT05320380|DRUG|Hydrocortisone Sodium Succinate|Given IT
224151528|NCT05320380|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
224151529|NCT05320380|DRUG|Methotrexate|Given IT
224151530|NCT05320380|DRUG|Prednisolone|Given IT
224151531|NCT00110474|DRUG|Glucosamine sulfate|
224151532|NCT00110474|DRUG|Acetaminophen|
224151533|NCT06229067|DRUG|Adebrelimab|Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
224151534|NCT06229067|DRUG|Vinorelbine|Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
224151535|NCT06229067|DRUG|Cyclophosphamide (tablet)|Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
223455823|NCT03786185|BEHAVIORAL|MusicPlast Control|Each subject will receive 20 sessions of the computerized training within a period of 4 weeks, aiming to train visual search via spot-the-difference tasks and identification of dissonance in music. Auditory and visual stimuli are concurrently presented, but do not require audiovisual integration.
223455824|NCT05078749|OTHER|Exercise training group|A regular advanced exercise program will be given and followed.
223455825|NCT05078749|OTHER|Control training group|Basic exercises will be given at the beginning and will do the same exercises
223455826|NCT02005900|DRUG|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
224151536|NCT06229067|DRUG|Capecitabine|Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
224151537|NCT05715944|DRUG|AZD 1222|Vaccine
224151538|NCT05953324|OTHER|Kiwifruit|2 kiwifruit for 6 weeks
224151539|NCT03998904|PROCEDURE|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
224151540|NCT03998904|PROCEDURE|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
224151541|NCT01676792|DRUG|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon \& before bed time. Medication should be reapply after bathing or cleaning.
224151542|NCT01990755|BEHAVIORAL|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
224151543|NCT01990755|OTHER|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
224151544|NCT01990755|DRUG|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
224065863|NCT03891589|BEHAVIORAL|Nutritional education program|These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
224065864|NCT03891589|DIETARY_SUPPLEMENT|Home fortification (Taburia)|Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.
224151545|NCT01990755|DIETARY_SUPPLEMENT|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
224151546|NCT01990755|DRUG|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
224151547|NCT03644108|DRUG|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
224151548|NCT06530108|BEHAVIORAL|PLISSIT model based sexual health education|the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
224065865|NCT03927105|DRUG|Nivolumab|Nivolumab is a human monoclonal antibody (HuMAb; immunoglobulin G4 \[IgG4\]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens. Nivolumab will be delivered intravenously at a fixed dose of 240 mg on day 1 of 14 day cycles.
224065866|NCT03927105|DRUG|cabiralizumab|Cabiralizumab is a recombinant, humanized Immunoglobulin G4 (IgG4) monoclonal antibody that binds to human colony stimulating factor 1 receptor (CSF1R; c-fms). Cabiralizumab will be delivered intravenously at a dosage of 4 mg/kg on day 1 of 14 day cycles.
224065867|NCT00529256|BEHAVIORAL|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
224065868|NCT03402607|PROCEDURE|Percutaneous Local Ablation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
224151549|NCT02969538|OTHER|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
224151550|NCT02969538|OTHER|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
224151551|NCT02836132|BEHAVIORAL|Weight Watchers Online|
224151552|NCT02836132|BEHAVIORAL|Experience Success Virtual Reality Platform|
224151553|NCT06175442|DEVICE|Intraoperative intestinal decompression|Insertion the tubes of various lengths (nasogastral, short and long nasointestinal) into the gastrointestinal tract during operations in patients with acute small intestinal obstruction
224151554|NCT04559269|OTHER|No intervention|patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
224151555|NCT00828503|DRUG|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
224151556|NCT00828503|DRUG|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
224151557|NCT06044129|DEVICE|Mri scan of fetal head and pelvis|The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.
224151558|NCT00271934|BIOLOGICAL|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
224151559|NCT03707262|BIOLOGICAL|Donor CD34+ and CD3+ cells|Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
224065869|NCT03402607|RADIATION|Hypofractionated Image Guided Radiation Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
224065870|NCT01657409|DRUG|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
224065871|NCT01657409|DRUG|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
224065872|NCT01657409|DRUG|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
224065873|NCT06268691|OTHER|Insecticide Coating INESFLY|The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.7%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
224065874|NCT01133587|OTHER|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
224065875|NCT01133587|BEHAVIORAL|admissions contract|"contract regarding patient-guided admissions starting immediately"
224065876|NCT05748093|DRUG|Cobicistat|Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.
224065877|NCT05931146|OTHER|MyNetDiary app group|MyNetDiary will be used to track calories, and exercise while motivating for living a healthier life each day.The intervention period would last for three months. Total energy expenditure (TEE) of every participant enrolled into the study would be calculated at the start of the study and an exercise and diet plan with a calorie deficit of around 1000 kcal per week would be provided to the participant. The diet and exercise plan would be modified according to the new TEE of the participant. MyNetDiary app has built-in food and exercise activities with their respective calories' count. Moreover, customized foods and exercises can also be added into the application
224065878|NCT05931146|OTHER|Paper diary group|Paper Diary will be used to track calories and exercise. The nutritional intake and exercise would be recorded for three months. The diet and exercise plans would be modified according to the new Total Energy Expenditure of the participants.
224065879|NCT04569721|DEVICE|CT Guided Splanchnic Cryoablation|The patient will be sedated and continuously monitored by the anesthesia team, who will be present for the entire procedure. The puncture site will be anesthetized with 1% Lidocaine infiltration. Following tract anesthesia, and utilizing fluoroscopic CT guidance, four cryoablation probes (Ice Rods®) will be advanced, 2 on each side. In addition, a temperature monitoring probe (Boston Scientific, Multipoint 1.5 Thermal Sensor®) will be advanced on each side. The cryoablation process will include a 10-minute freeze, followed by a 3-minute passive thaw, and a brief active thaw to facilitate probe removal. A final scan will be obtained following removal of the probes. After the procedure, a sterile dressing will be applied, and subjects will be monitored for at least 12 hours in an observation bed in the hospital post-procedure.
224065880|NCT03640039|PROCEDURE|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
224065881|NCT02755857|DRUG|Lozanoc|65 mg
224065882|NCT03470493|DIAGNOSTIC_TEST|ApneaLink Air|ApneaLink Air to be used on each participant undergoing PSG
224065883|NCT04816812|BEHAVIORAL|Exercise intervention|A 12-week aerobic exercise program tailored to the individual patients by physiotherapists using the principles of Frequency, Intensity, Time, and, Type (FITT) aiming to increase or maintain the physical activity level to a weekly moderate activity level. This includes two supervised exercise sessions of 60 minutes per week, combined with one weekly home training session. The type of exercise is planned by a physiotherapist to fit each patient during sessions. We monitor the intervention by training diaries including frequency, intensity, time, and type of exercise (FITT) and the verbal BORG 15-point scale and heart rate monitors. We will also monitor the overall seven days' physical activity level by accelerometry using the AX3 device from the company Axivity at weeks 0 and 12.
224065884|NCT04816812|BEHAVIORAL|Lifestyle - online lesson intervention|The investigators offer one online lesson of 15-25 minutes on lifestyle guidance including general advice on healthy living.
224065885|NCT02289183|PROCEDURE|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
224065886|NCT02289183|PROCEDURE|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
224065887|NCT02510768|DEVICE|ELAPR002f|Intradermal implant
224065888|NCT02510768|DEVICE|ELAPR002g|Intradermal implant
224065889|NCT02510768|DEVICE|Saline|Intradermal implant
224065890|NCT04660162|DEVICE|Iontophoresis|By using the PeriIont (Perimed, Jarfalla, Sweden) device, 0.5 mL of a 10 mg/ml Sodium nitroprusside solution was used transdermally and ionised with a current strength of 200 µA for 1 minute.
224065891|NCT04660162|OTHER|Stepwise occlusion|The upper arm was occluded for 30 seconds with a pneumatic cuff up to 50 mmHg, 80 mmHg, 110 mmHg, 140 mmHg, and 170 mmHg. The volunteer had rest for 5 minutes between each occlusion procedure.
224065892|NCT00316563|DRUG|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
224065893|NCT00316563|OTHER|Placebo|
224065894|NCT05655338|DEVICE|antimicrobial photodynamic therapy|
224065895|NCT05655338|DRUG|systemic antibiotics|
224151560|NCT05754801|DRUG|Yunzhi Essence|Yunzhi Essence capsule
224151561|NCT05754801|OTHER|Placebo|Placebo capsules
224065896|NCT05493020|OTHER|Questionnaires set|"At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital."
224065897|NCT01858181|BIOLOGICAL|ocaratuzumab|
224151562|NCT01620450|DRUG|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
224151563|NCT00527969|DRUG|HT1001 extract of Panax quinquefolius L|
224151564|NCT02539914|OTHER|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
224151565|NCT02539914|OTHER|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
224151566|NCT02762708|PROCEDURE|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
224151567|NCT02762708|BEHAVIORAL|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
224151568|NCT02762708|DRUG|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
224151569|NCT02762708|DRUG|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
224151570|NCT01495923|PROCEDURE|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
224151571|NCT01495923|PROCEDURE|Sham epidural steroid injection|Injection of saline into the back muscles
224151572|NCT01495923|DRUG|Gabapentin|Titration of gabapentin to effect
224151573|NCT01495923|DRUG|Placebo gabapentin|Titration of placebo gabapentin
224151574|NCT05216913|BEHAVIORAL|Lifestyle modification|Could include all/some of the following: weight loss, increased physical activity, smoking cessation and reduction in alcohol intake
224151575|NCT05216913|DRUG|Cardiovascular Agents, Other|Could include all/some of the following: statins, antihypertensives, diabetic medication, levothyroxine
224151576|NCT05216913|OTHER|QRISK 3 Score|Could include a combination of lifestyle measures and/or cardiovascular agents as described above
224151577|NCT01062009|DRUG|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
224151578|NCT01115088|DIETARY_SUPPLEMENT|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
224151579|NCT01115088|DIETARY_SUPPLEMENT|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
224151580|NCT01115088|DIETARY_SUPPLEMENT|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
224151581|NCT03776097|OTHER|observational study|Observational study
224151582|NCT03145597|DEVICE|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
224151583|NCT03145597|DEVICE|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
224151584|NCT00217009|PROCEDURE|Narrowband Ultraviolet B (TL-01UVB) Therapy|
224151585|NCT00217009|PROCEDURE|Topical Psoralen plus ultraviolet A (PUVA)|
224151586|NCT05199883|OTHER|TI.VA algorithm: decision support system|TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
224151587|NCT04100291|OTHER|Faecal microbiota transplantation|FMT by daily enema with donor faeces
224151588|NCT04100291|OTHER|Placebo|Placebo by daily enema with placebo mixture
224151589|NCT00821860|OTHER|talc|Talc pleurodesis
224151590|NCT00821860|PROCEDURE|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
224151591|NCT00821860|PROCEDURE|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
224151592|NCT04501757|BIOLOGICAL|Naxitamab/GM-CSF|naxitamab/GM-CSF for 5 Cycles
224151593|NCT00419367|DRUG|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
224151594|NCT02577367|DRUG|Levothyroxine|Administer Levothyroxine
224151595|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
224151596|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
224151597|NCT01068717|DRUG|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
224151598|NCT01068717|DRUG|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
224302001|NCT05310162|BEHAVIORAL|Food, fun and family|"The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun \& Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home."
224151599|NCT01822223|DEVICE|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
224151600|NCT04429412|BEHAVIORAL|MCT+|Metacognitive training
224151601|NCT02758119|OTHER|Serious Game|
224151602|NCT02758119|OTHER|Online course|
224151603|NCT06338007|DEVICE|Hand Dynamometer|Hand grip strength will be measured using a hand dynamometer. Research has demonstrated that hand grip strength is correlated with muscle strength in the upper extremities, as well as overall body and pulmonary muscle strength.
224151604|NCT06338007|DIAGNOSTIC_TEST|Pulmonary Function Test|Spirometry is a physiological test that measures the ability to inhale and exhale air relative to time. Spirometry is a diagnostic test of several common respiratory disperses such as asthma and chronic obstructive pulmonary disease (COPD). It is also instrumental in monitoring the progression of various respiratory disorders. The main results of spirometry are forced vital capacity (FVC), forced expiratory volume exhaled in the first second (FEV1), and the FEV1/FVC ratio. Pulmonary Function Test analysis values (FEV1, FVC and FEV1 /FVC) will be used.
224151605|NCT06338007|OTHER|Modified Frailty Index|The modified frailty index is a valuable preoperative risk assessment tool that can be used to assess the risk of both morbidity and mortality in patients undergoing surgery. It is calculated based on 11 parameters.
224151606|NCT02439736|OTHER|Blood draw within 12 hours of head injury|
224151607|NCT06042192|DRUG|TK-254RX|Two TK-254RX per day to predetermined application site
224151608|NCT04366713|DRUG|Neratinib|Administered orally once daily as a single daily dose of 240 mg
224151609|NCT04366713|DRUG|Capecitabine|Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
224151610|NCT04366713|DRUG|Loperamide|Administered orally for prophylaxis for 28 days and then as needed
224151611|NCT03717636|OTHER|medical evaluation|return of medical evaluation after discharge
224151612|NCT02733679|DRUG|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
224151613|NCT02733679|DRUG|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
224151614|NCT04348539|OTHER|Balance training|32 sessions will be held twice a week, with each session taking an average of 45 minutes
224151615|NCT00264446|DRUG|ADH300004|
224151616|NCT05704439|DRUG|Neurologist Initiated Treatment|Neurologist Initiated Treatment for Hypertension or Hyperlipidemia
224151617|NCT05704439|OTHER|Placebo|Usual care
224151618|NCT04950140|PROCEDURE|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia|Robot Assisted Laparoscopic Surgery for the Treatment of Parastomal Hernia of the Oncology Patient
224151619|NCT04950140|PROCEDURE|Laparoscopic Surgery for the Treatment of Parastomal Hernia|Laparoscopic Surgery for the Treatment of Parastomal Hernia in Cancer Patients
224151620|NCT02532387|OTHER|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
224151621|NCT01721512|OTHER|Breastfeeding|
224151622|NCT01721512|OTHER|Infant formula|
224151623|NCT00063310|DRUG|Leuprolide acetate|
224151624|NCT04458363|BIOLOGICAL|Convalescent Plasma (CP)|Once the patient meets criteria for CP infusion (severity of disease and risk factor determination and absence of exclusion criteria), an ABO compatible product will be identified. The CP dose administered will be 10mL/kg/dose (up to 2 units per dose) times two doses per patient for a total dose of 20 mL/kg. Patients will be followed for adverse events and clinical response. Research blood testing will be obtained prior to infusion (baseline) and serially weekly afterwards until clinical resolution. Patients will receive 2 doses equaling 20 mL/kg (if available) of ABO compatible CP over 24-48 hours if they do not experience grade 3-5 adverse events that are possible, probably, or definitely attributed to CP after the first dose. Patients will be followed for adverse events for a minimum of 28 days after the last infusion of CP.
224151625|NCT04458363|DRUG|Standard COVID-19 therapies|If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
224151626|NCT06112912|OTHER|REAL Essentials Advance|"REA is a relationship education curriculum developed by the Center for Relationship Education for high school-age youth. REA teaches youth critical relationship skills and practical approaches for navigating the social dynamics of friendship and love. The curriculum draws on several theories of behavior change, including social cognitive theory, theory of planned behavior, social inoculation theory, social norms theory, and behavior change theory.~REA includes 87 lessons organized into 10 units. The units cover topics such as healthy relationships, effective communication, commitment, planning for the future, job readiness, and sexual health."
224151627|NCT05865210|OTHER|Kegel Exercise|Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
224151628|NCT05865210|OTHER|Myofascial release technique|Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
224151629|NCT02062476|DIETARY_SUPPLEMENT|Lactobacillus GG|
224302002|NCT05310162|BEHAVIORAL|Counseling|"Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping."
224302003|NCT02802774|OTHER|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
224302004|NCT02802774|OTHER|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
224302005|NCT02802774|OTHER|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
223455827|NCT01084213|DRUG|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
223455828|NCT01084213|DRUG|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
223455829|NCT05398705|DRUG|Cepharanthine|Low-dose: Day 1\~5: 20mg, Q8H X 5 days (60mg/day)+SMT
223455830|NCT05398705|DRUG|Placebo|"Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc."
223455831|NCT05398705|DRUG|Cepharanthine|"High-dose: Day 1\~5: 40mg, Q8H X 5 days (120mg/day) +SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor and Chinese traditional medicine, etc."
223455832|NCT04093557|OTHER|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
223455833|NCT04093557|OTHER|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
223455834|NCT04649970|PROCEDURE|Antegrade double-J stent|After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position.
223455835|NCT04013880|DRUG|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
223455836|NCT04013880|DRUG|IDH-1 Inhibitor FT-2102|Given by mouth
223455837|NCT02151214|OTHER|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
223455838|NCT06266949|DIAGNOSTIC_TEST|SONDA|Perimetry based visualfield analysis
223455839|NCT03247881|OTHER|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
224065898|NCT02454166|OTHER|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
224065899|NCT02454166|OTHER|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
224065900|NCT00647556|DRUG|adapalene gel, 0.3%|applied topically once daily in the evening
224065901|NCT00647556|DRUG|tretinoin 0.05% emollient cream|applied topically once daily in the evening
224065902|NCT05594173|OTHER|Food texture modification|Food prepared in three different consistencies: minced and moist, soft and bite-sized and regular, as defined by the International Dysphagia Diet Standardisation Initiative
224065903|NCT01877187|DRUG|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
224065904|NCT03669302|OTHER|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
224065905|NCT03669302|DEVICE|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
224065906|NCT03669302|DEVICE|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
224065907|NCT03124823|DEVICE|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
224065908|NCT03776175|DRUG|PF-05221304 Monotherapy|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
224065909|NCT03776175|DRUG|PF-06865571 Monotherapy|Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
224065910|NCT03776175|DRUG|Placebo|Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
224065911|NCT03776175|DRUG|PF-05221304 and PF-06865571 Combination|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
224302006|NCT05097313|DIETARY_SUPPLEMENT|Yeast β-glucan fiber|The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.
224302007|NCT05097313|OTHER|Placebo|oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
224302008|NCT04732910|DRUG|Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor|observational
224302009|NCT04647721|DEVICE|Radiesse injectable implant (dermal filler)|Subdermal injection.
224302010|NCT04647721|DEVICE|Restylane injectable implant (dermal filler)|Subdermal injection.
224302011|NCT05070546|BIOLOGICAL|Ad26.RSV.preF-based Vaccine|Participants will receive a single IM injection of an RSV vaccine.
224302012|NCT05070546|OTHER|Placebo|Participants will receive a single IM injection of matching placebo.
224302013|NCT04824248|BEHAVIORAL|Pain Neuroscience Education|Increase pain coping skills and educating the patients that pain is in the brain, and that hypersensitivity of the central nervous system rather than local tissue damage contributes to their symptoms.
224302014|NCT04824248|BEHAVIORAL|Cognition-targeted exercise therapy|Daily (physical) activity and exercise therapy. To confront the patient with movements and activities that are feared, avoided and/or painful using a gradual and cognition-targeted approach.
224065912|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2 in orange juice|1000 IU dose
224065913|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3 in orange juice|1000 IU
224065914|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D2|capsule, 1000 IU
224065915|NCT01778114|DIETARY_SUPPLEMENT|Vitamin D3|capsule, 1000 IU
224065916|NCT01778114|OTHER|Placebo|Placebo
224065917|NCT01489839|OTHER|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
224065918|NCT05261022|BEHAVIORAL|Love Together, Parent Together (L2P2)|Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.
224065919|NCT04464161|DIETARY_SUPPLEMENT|Ensure|Ensure protein is a complete nutritional drink with 10g, 240 calories, and 27 vitamins and minerals. It is often used as a nutritional supplementation in many hospitals.
224065920|NCT02475798|DEVICE|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
224065921|NCT02852031|OTHER|Collaborative Learning Network|
224065922|NCT05702528|DEVICE|Apollo Neuro|The group will complete daily use of the Apollo Neuro, a wrist-worn consumer wellness device
224065923|NCT01303094|DRUG|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
224065924|NCT01303094|OTHER|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
224065925|NCT02855528|DEVICE|Tin Filter|
224065926|NCT04351984|DEVICE|MitraClip|Transcatheter Mitral Valvuloplasty with MitraClip
224065927|NCT02414386|OTHER|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
224065928|NCT02738983|DRUG|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
224065929|NCT02738983|RADIATION|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
224065930|NCT02868697|DRUG|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
224065931|NCT02868697|DRUG|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
224065932|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally(once daily) on Day 1
224065933|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally(once daily) on Day 1
224065934|NCT05345964|DRUG|GST-HG151|Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
224065935|NCT05345964|DRUG|Placebo|Subjects will take Placebo orally (once daily) from day 1 to day 7
224065936|NCT05345964|DRUG|GST-HG151|Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
224065937|NCT05345964|DRUG|GST-HG151|Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
224065938|NCT03166033|OTHER|the disease|Observation the patients and non-patients
224065939|NCT02562456|PROCEDURE|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
224151630|NCT01153477|BEHAVIORAL|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
224151631|NCT00719862|DRUG|Placebo nasal spray|Placebo
224151632|NCT00719862|DRUG|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
224151633|NCT04446871|DRUG|0.9% sodium chloride|Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
224151634|NCT04446871|DRUG|Methylene Blue|Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.
224151635|NCT02669199|BIOLOGICAL|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
224151636|NCT03264833|OTHER|TempTraq|no intervention
224151637|NCT06098196|DRUG|Aminophyllin|Patients will be observationally included in the Elveld TCI or Schnider TCI group and recevied or not Aminiophylline bolus. The TCI model, such as the aminophylline delivery or not, is chosen at anesthesiologist's discretion, as suggested in literature
224151638|NCT04759313|BEHAVIORAL|Image Narrative|Each participant will take part in a 5-week program of weekly 1-hour telehealth sessions with the PI or a social work PhD student facilitator trained in the INI by the PI.
224151639|NCT02899806|OTHER|Written Information|A written information on peridural anesthesia is delivered
224151640|NCT02899806|OTHER|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
223455840|NCT03247881|OTHER|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
223455841|NCT01284751|OTHER|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
224151641|NCT04030676|PROCEDURE|Biopsies|Two more biopsies in inflammatory zone will be collected.
224151642|NCT04030676|BIOLOGICAL|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
224151643|NCT06837792|DRUG|Experimental treatment arm|"Trastuzumab deruxtecan (T-DXd) 5.4mg/kg intravenous infusion every 3 weeks.~(1 cycle = 3 weeks)"
224151644|NCT06837792|DRUG|Control treatment arm|"1. Fulvestrant intramuscular injection of two 250mg injection every 4 weeks (every 2 weeks for the first cycle, 1 cycle = 4 weeks)~2. Fulvestrant (administered same as above) + alpelisib 300mg oral administration every day~   (1 cycle = 4 weeks)\*~3. Exemestane 25mg oral administration every day (1 cycle = 4 weeks)~4. Exemestane 25mg + everolimus 10mg oral administration every day (1 cycle = 4 weeks)~5. Tamoxifen 20mg oral administration every day (1 cycle = 4 weeks)~6. Fulvestrant (administered same as above) + Capivasertib 400mg oral administration twice a day(dosed on Days 1 to 4 in each week of a 28-day treatment cycle)~   * fulvestrant + alpelisib can be selected in PIK3CA activating mutation positive patients~  * Fulvestrant + Capivasertib can be selected in 1 or More mutation positive of PIK3CA/AKT1/PTEN"
224151645|NCT00556621|DRUG|cisplatin|
224151646|NCT00556621|DRUG|gemcitabine hydrochloride|
224151647|NCT00556621|PROCEDURE|biopsy|
224151648|NCT00556621|PROCEDURE|cystoscopy|
224151649|NCT00556621|PROCEDURE|therapeutic conventional surgery|
224151650|NCT00556621|RADIATION|radiation therapy|
224151651|NCT01060098|DRUG|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
224151652|NCT05440487|OTHER|Iron chelator|There is no treatment allocation. Patients administered approved Iron chelators by prescription that have started before inclusion of the patient into the study will be enrolled.
224151653|NCT01499797|OTHER|The CareWell programme|"The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions"
224151654|NCT02979561|DRUG|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
224151655|NCT02979561|DRUG|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
224151656|NCT01819441|DRUG|Azelnidipine|8mg or 16mg
224151657|NCT01819441|DRUG|Perindopril|4mg or 8mg
224151658|NCT01819441|DRUG|hydrochlorothiazide|12.5mg or 25mg
224151659|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine QIV 0.5mL|
224151660|NCT02480998|BIOLOGICAL|IL-YANG Flu Vaccine TIV 0.5mL|
223455842|NCT03743844|BEHAVIORAL|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
223455843|NCT04539548|DRUG|Dextenza Ophthalmic Insert|0.4mg insert for intracanalicular use
224151661|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
224151662|NCT00774956|PROCEDURE|Exercise training program|A 6 week shoulder exercise training program
224302015|NCT04824248|BEHAVIORAL|Behavioral weight reduction program|Changes in diet, behavior and a physical exercise to reach weight loss. It will include a lifestyle approach, incorporating behavioral theories and constructs to assist and facilitate healthy energy balance related behavior.
224151663|NCT06318260|DRUG|Dobutrex|Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.
224151664|NCT00005905|DRUG|hu Leptin (A-100)|
224151665|NCT00107172|PROCEDURE|surgery|
224151666|NCT00107172|RADIATION|brachytherapy|
224151667|NCT02688153|DEVICE|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR \& CABG.
224151668|NCT02688153|DEVICE|Stented aortic bioprostheses|In comparison to control valves available on the market.
224151669|NCT01840436|DEVICE|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
224151670|NCT01840436|DEVICE|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
224151671|NCT02152150|OTHER|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
224151672|NCT02152150|OTHER|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
224151673|NCT01102140|DRUG|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
224151674|NCT01102140|DRUG|Sugar Pill|Matching sugar pill
224151675|NCT03199144|DRUG|Chemotherapy|3 cycles of Gemzar-Abraxane
224151676|NCT03199144|RADIATION|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
224151677|NCT03199144|PROCEDURE|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
224151678|NCT04640753|PROCEDURE|Endoscopic procedure for achalasia|POEM procedure will have a high technical feasibility, with effective clinical resolution of symptoms both in the short and long term.
224151679|NCT03823898|BEHAVIORAL|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
224151680|NCT03823898|BEHAVIORAL|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
224151681|NCT03823898|BEHAVIORAL|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
224151682|NCT02540876|DRUG|Ilorasertib|Given PO
224065940|NCT02562456|PROCEDURE|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
224065941|NCT03389035|BIOLOGICAL|CARCIK-CD19|Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
224065942|NCT04583033|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
224065943|NCT05086536|OTHER|no intervention|This is a retrospective and observational study.
224065944|NCT02599961|DRUG|UX007|UX007 is a liquid intended for oral (PO) administration.
224065945|NCT03127371|DRUG|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
224065946|NCT03127371|DRUG|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
224151683|NCT02540876|OTHER|Laboratory Biomarker Analysis|Correlative studies
224151684|NCT01209975|PROCEDURE|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
224151685|NCT03674307|OTHER|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
224151686|NCT03674307|OTHER|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
224151687|NCT03596970|DRUG|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
224151688|NCT03596970|DRUG|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
224151689|NCT03582267|DIETARY_SUPPLEMENT|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
224151690|NCT03682055|DRUG|VK-2019|EBNA1 inhibitor
224151691|NCT03526341|DEVICE|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
224151692|NCT02816476|DRUG|Daratumumab|
224151693|NCT03596255|DIAGNOSTIC_TEST|Estimated level of DA|the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
224151694|NCT03596255|DIAGNOSTIC_TEST|MDAS|The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
224151695|NCT04691557|OTHER|Mobile Health Application|YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
224151696|NCT04691557|OTHER|Usual Care|Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
224065947|NCT06438484|BEHAVIORAL|multimodal prehabilitation program|"Patients performed physical exercise training and/or received dietary counseling for five weeks, provided by a trained physiotherapist and dietitian (both \>15 years experience). The physical exercise training consisted of high-intensity interval training (HIIT) three times a week and functional strengthening exercises. Patients visited the hospital two times a week and performed home exercise training five times a week on a stationary cycle ergometer (Corival Home+, Lode BV, Groningen, The Netherlands).~The dietary intervention consisted of optimization of energy and protein intake, optimization of timing of eating protein-rich products, and if necessary additional protein and vitamin supplements. Individual protein requirements were set at 1.5-1.9 g/kg fat free mass. Patients used the eiFIT-application or a food diary to track their protein intake."
224065948|NCT00143312|DRUG|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
223455844|NCT04539548|DRUG|Prednisolone acetate ophthalmic suspension USP 1%|"1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week"
223455845|NCT00104793|DRUG|carboplatin|
223455846|NCT00104793|DRUG|irinotecan hydrochloride|
223455847|NCT02491970|DRUG|Fluticasone/Formoterol|
223455848|NCT02491970|DRUG|Fluticasone/Salmeterol|
223455849|NCT02589834|OTHER|Quran group|
224065949|NCT03048903|DRUG|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
224065950|NCT03048903|DRUG|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
224065951|NCT05956106|DIETARY_SUPPLEMENT|Black Mulberry Fruit Powder|Anthocyanin plays a major role in preventing symptoms of metabolic syndrome.
224065952|NCT01029366|BIOLOGICAL|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
224065953|NCT05210530|COMBINATION_PRODUCT|VCTX210A unit|CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device
224065954|NCT02244567|DRUG|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
224065955|NCT02244567|PROCEDURE|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
224065956|NCT02244567|OTHER|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
224065957|NCT05387811|COMBINATION_PRODUCT|Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy|Adherence to International Club of Ascites recommendations for the management of AKI
224065958|NCT03721094|OTHER|Immersive virtual reality|In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
224065959|NCT05428787|PROCEDURE|Left Bundle Branch Area Pacing|The patients will be allocated by randomization to receive the intervention of Left Bundle Branch Area Pacing
224065960|NCT05428787|PROCEDURE|CRT|The patients will be allocated by randomization to receive the intervention of CRT.
224065961|NCT05428787|PROCEDURE|AV node ablation|AV node ablation after 4 weeks of CRT implant or LBBAP implant.
224065962|NCT01479543|OTHER|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
224065963|NCT01479543|OTHER|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
224065964|NCT01479543|OTHER|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
224065965|NCT01479543|OTHER|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
223455850|NCT01860144|DRUG|Bevacizumab|
223455851|NCT06294444|OTHER|Constraint Induced Movement Therapy|Group A: This group patients will be treated with mCIMT, the forced use of the affected arm by restraining the unaffected arm, with a sling or a hand splint, during dedicated exercise sections or usual ADLs (90% of waking hours).Massed practice (eight hours of exercise) of the affected arm through a shaping method, where shaping involves a commonly operant conditioning method in which a behavioural objective (in this case 'movement') is approached in small steps of progressively increasing difficulty. The participant is rewarded with enthusiastic approval for improvement, but never blamed or punished for failure. This therapy will be given 4hrs daily for 6 weeks. The results will be based upon pre and post evaluation.
224065966|NCT01479543|OTHER|Placebo|Placebo capsule for 28 days.
224065967|NCT06212245|DRUG|Inebilizumab|Participants will receive IV inebilizumab 300 mg
224065968|NCT00906087|DRUG|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
224065969|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
224065970|NCT01086891|DEVICE|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
224065971|NCT03837470|DRUG|0.9% Sodium Chloride|Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
224065972|NCT03837470|DRUG|Furosemide 40 mg|Bolus intravenous injection of 40 mg furosemide
224065973|NCT02127190|DRUG|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
224065974|NCT02127190|DRUG|Placebo|
224065975|NCT05892809|OTHER|use an incubator cover|Vital signs of term and preterm newborns were measured separately and with and without an incubator cover.
224065976|NCT00331045|DRUG|alvimopan|0.25 mg/day
224065977|NCT00331045|DRUG|Placebo|
224065978|NCT00331045|DRUG|Alvimopan 0.5 mg/day|
224065979|NCT00331045|DRUG|Alvimopan 1 mg/day|
224065980|NCT00370279|PROCEDURE|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
224065981|NCT01957358|BEHAVIORAL|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
224065982|NCT02898259|DRUG|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
224065983|NCT02898259|DRUG|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~* Starting lenalidomide Dose (20mg)~* Calculated Creatinine Clearance: \>=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~* Calculated Creatinine Clearance: \>= 30 and \< 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
224065984|NCT02898259|DRUG|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
224065985|NCT01856881|DRUG|AMG 876|Ascending multiple doses of study drug administered SC
224065986|NCT03442634|OTHER|Early Hydration|this group will start oral hydration within 1 hour after cesarean section
224065987|NCT03442634|OTHER|Traditional Oral Hydration|this group will start oral hydration 6 hours after cesarean section
224065988|NCT01225679|DEVICE|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
224065989|NCT03341962|DRUG|IMU-838|IMU-838 tablet
224065990|NCT03341962|DRUG|Placebo|Tablets manufactured to mimic IMU-838 tablets
224065991|NCT01576692|BIOLOGICAL|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~* Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~* Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~* Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m\^2)/dose, over 4 hours daily~* NK Cell dosage: minimum of 0.1 \* 10\^6 cells/kg; maximum of 400 \* 10\^6 CD45+ cells/kg, given once"
224065992|NCT01576692|DRUG|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3"
224065993|NCT01576692|OTHER|Cytokines|"Cytokines may be given at the following dosages:~* interleukin-2: 1 million units/m\^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~* GM-CSF: 250 mcg/m\^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC \>2,000/mm\^3"
224065994|NCT01576692|BIOLOGICAL|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy \& Procedure Manual.
224065995|NCT01576692|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
224065996|NCT01109784|DRUG|prasugrel|prasugrel 10 mg/day
224065997|NCT01109784|DRUG|clopidogrel|clopidogrel per os 150mg/day
224065998|NCT02936700|BEHAVIORAL|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
224065999|NCT02936700|BEHAVIORAL|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~* decreasing the tendency to try to escape unpleasant mental experiences~* increasing psychological flexibility~* developing acceptance of psychological events and engagement in valued actions"
224066000|NCT01796327|DRUG|dacomitinib oral|Dacomitinib 45 mg oral tablet
224066001|NCT01796327|DRUG|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
224066002|NCT01046877|DEVICE|Tympanostomy Tube Delivery System|Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
224066003|NCT00084201|DRUG|Cranberry juice|
224066004|NCT00084201|DRUG|Amoxicillin|
224066005|NCT00001133|DRUG|Indinavir sulfate|
224066006|NCT00001133|DRUG|Ritonavir|
224151697|NCT04746157|OTHER|Nurse intervention|Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
224151698|NCT00290303|BIOLOGICAL|DTPw-HBV/Hib-MenAC conjugate vaccine|
224151699|NCT03621189|DEVICE|intermittent theta burst stimulation|stimulatory protocol
224151700|NCT01069094|DRUG|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
224151701|NCT01069094|DRUG|Progenta|25 mg, administered as a once daily oral dose for 90 days.
224151702|NCT01069094|DRUG|Progenta|50 mg, administered as a once daily oral dose for 90 days.
223455852|NCT06294444|OTHER|Mirror therapy|Group B: These patients will be treated with mCIMT and mirror therapy. Children were taught repetitive symmetrical upper limbs exercises: with modelling-clay in each hand to elicit bilateral thumb-finger pinch and grasping. They performed these during a 15-minute daily routine at home with mCIMT (forced use of arm and massed practice 4hrs of exercise of affected arm). This combination of therapy will be given for 6 weeks. The results will be seen through pre and post evaluation.
223455853|NCT05168072|DEVICE|m-Health app|M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise
223455854|NCT05168072|OTHER|conventional outpatient obesity management|Diet and exercise guidance
223455855|NCT03679819|DEVICE|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
223455856|NCT03852498|GENETIC|Lenti-D|Participants received a single IV infusion of Lenti-D Drug Product.
223455857|NCT04532411|OTHER|Personal Protective Testing Booth|Health personnel who utilize the Hexapod will remain in the booth and utilize durable gloves attached to ports through a plexiglass wall in order to administer a nasal swab for SARS-CoV-2 (COVID-19) testing. Patient escorts and housekeeping/sanitation staff perform additional tasks outside of the booth such as escorting the patient to the correct testing bay and dropping off testing vials and printed information, collect samples and deposit in the appropriate location after testing is complete, and sanitizing the patient bay before a subsequent patient is tested there.
223455858|NCT03025347|OTHER|Control|Participants complete a resting control condition instead of a run.
223455859|NCT03025347|OTHER|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
223455860|NCT02115061|DEVICE|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
224066007|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem \& Delta-TT cup with a polyethylene insert
224066008|NCT03093038|DEVICE|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert
224066009|NCT03093038|DEVICE|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
224066010|NCT01108146|DRUG|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
224066011|NCT01108146|DRUG|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
224066012|NCT03869528|DRUG|5 sprays of 10% lignocaine|5 sprays of 10% lignocaine
224066013|NCT03869528|DRUG|10 sprays of 10% lignocaine|10 sprays of 10% lignocaine
224066014|NCT01888042|DRUG|Everolimus|10 mg (1 tablet of 10 mg)
224066015|NCT03831594|DEVICE|Galvanic Vestibular Stimulation|Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
224151703|NCT01069094|DRUG|Lucron Depot|3.75 mg IM monthly
224151704|NCT01069094|DRUG|Placebo|Administered as a once daily oral dose for 90 days.
224151705|NCT05278936|OTHER|The cataract surgery and the anterior vitrectomy|Surgical
224151706|NCT04430868|BEHAVIORAL|lifestyle redesign program|In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
224066016|NCT03831594|OTHER|Standard Physiotherapy|45 minutes of standard physiotherapy treating impairments and functional problems
224066017|NCT00712699|DRUG|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
224066018|NCT00712699|DRUG|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
224066019|NCT02866474|DIETARY_SUPPLEMENT|population living at home with meals on wheels|
224066020|NCT02866474|DIETARY_SUPPLEMENT|population living in an EHPAD|
224066021|NCT04280900|BEHAVIORAL|Virtual Reality-Enhanced Cognitive Behavioral Therapy (VR-CBT)|use of cybertherapy (8 sessions) in addition to cognitive behavioral therapy (4 sessions) (pharmacological treatment are note modified)
224066022|NCT04280900|BEHAVIORAL|Treatment as usual|Treatment as usual is a cognitive behavioral therapy I (4 sessions) (pharmacological treatment are note modified)
224066023|NCT01515384|DRUG|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
224066024|NCT03836391|BEHAVIORAL|Nudge|Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
224066025|NCT06466226|PROCEDURE|Multiple central venous lines in two sites separately|Patients with two central venous lines in two sites separately (two central venous sites).
224066026|NCT06466226|PROCEDURE|Multiple central venous lines in one site (internal jugular vein)|Patients with two concomitant central venous lines in a single internal jugular vein (one central venous site).
224151707|NCT04412772|DRUG|Tocilizumab|Participants will receive 1 dose of IV TCZ. 1 additional dose may be given if clinical symptoms worsen.
224151708|NCT04412772|DRUG|Placebo|Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
224151709|NCT01135394|DRUG|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
224151710|NCT01614340|BEHAVIORAL|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
224151711|NCT02839811|PROCEDURE|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
224151712|NCT00191386|DRUG|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
224151713|NCT02443051|BEHAVIORAL|Attention Bias Modification|Computer delivered modification in 80% of trials
224151714|NCT01191424|DRUG|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
224151715|NCT01191424|DRUG|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
224151716|NCT00125229|DRUG|Mannitol|
224151717|NCT00125229|DRUG|Hypertonic Saline|
224151718|NCT03552900|BEHAVIORAL|7cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
224151719|NCT03552900|BEHAVIORAL|Bliss|Participants who receive the Bliss app will get access to an app that that provides access to important community, health, wellness, academic, and support resources.
224151720|NCT03422744|PROCEDURE|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
224151721|NCT03422744|PROCEDURE|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
224151722|NCT01970735|BIOLOGICAL|Blood test|
224302016|NCT03262506|OTHER|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
224302017|NCT06036888|OTHER|questionaries completion|Answer to the DASH and SF-12 questionaries, for an estimated duration of 15 minutes.
224302018|NCT00853086|DRUG|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
224302019|NCT00043758|DRUG|Tolvaptan|
224066027|NCT03413189|OTHER|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
224066028|NCT03413189|OTHER|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
224066029|NCT03413189|OTHER|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
224066030|NCT05209503|OTHER|AccuFFRangio-guided strategy|In this study, the AccuFFRangio-guided strategy will be applied to in the AccuFFRangio group in which calculation of the AccuFFRangio values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to PCI revascularization will be carried out. If AccuFFRangio ≤ 0.80, then simultaneous PCI revascularization of target blood vessels will be carried out. If AccuFFRangio \> 0.80, then no PCI revascularization of target blood vessels will be carried out.
224066031|NCT05209503|OTHER|Angiography-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 70% (visual estimation) and suited for PCI revascularization will undergo PCI revascularization.
224066032|NCT05020873|OTHER|Crizanlizumab|Prospective observational study. There is no treatment allocation. Patients administered crizanlizumab, that have started before inclusion of the patient into the study will be enrolled.
224066033|NCT05965284|DRUG|Azathioprine|All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
224066034|NCT05965284|DRUG|Telitacicept|Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
224066035|NCT03350217|DRUG|Eleview|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
224066036|NCT03350217|DRUG|Hetastarch|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
224066037|NCT05828693|BEHAVIORAL|SysLife©|Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
224066038|NCT05828693|BEHAVIORAL|SysLife©, as intervention after closing the RCT-design|Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
224151723|NCT00462488|DRUG|Vicinium|Intravesical administration of Vicinium
224151724|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
224151725|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
224151726|NCT02866903|DRUG|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
224151727|NCT02187133|DRUG|Carfilzomib|"Given IV; Dose Level (DL)~Twice Weekly:~DL -1 and DL 1: 15 mg/m\^2~Weekly:~DL 1.5: 20,27,27 mg/m\^2, DL 2: 20,36,36 mg/m\^2, DL 3: 20,56,56 mg/m\^2 DL 4: 20,70,70 mg/m\^2"
224151728|NCT02187133|DRUG|Bendamustine|"Given IV; Dose Level (DL)~DL -1: 75 mg/m\^2 DL 1,1.5, 2, 3, and 4: 90 mg/m\^2"
224151729|NCT02187133|DRUG|Rituximab|Given IV; 375 mg/m\^2
224151730|NCT00590941|PROCEDURE|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
224151731|NCT00733473|DRUG|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
224151732|NCT00733473|DRUG|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
224151733|NCT00134342|OTHER|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
224151734|NCT03592927|DEVICE|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
224151735|NCT03592927|DEVICE|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
224151736|NCT05395728|OTHER|Deflate the tracheostomy cuff early|The tracheostomy cuff will be early deflated, on beginning the weaning mechanical ventilation
224151737|NCT05395728|OTHER|Deflate the tracheostomy cuff after complete weaning mechanical ventilation|The tracheostomy cuff will be deflated onl twenty four hours after complete weaning mechanical ventilation
224151738|NCT01450475|PROCEDURE|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
224066039|NCT00800332|DRUG|CYT003-QbG10|subcutaneous injection
224066040|NCT00800332|DRUG|Placebo|subcutaneous injection
224066041|NCT03027986|BEHAVIORAL|postural rehabilitation program|This program is based on sensory-motor control
224151739|NCT00184652|DRUG|somatropin|
224151740|NCT00030030|DRUG|Silymarin (milk thistle)|
224151741|NCT04984564|OTHER|None. As this was an observational study.|Observational study.
224151742|NCT01256320|OTHER|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
224151743|NCT01256320|OTHER|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
224151744|NCT05711862|DRUG|suvorexant (SUVO)|Participants will receive 20mg of SUVO for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
224151745|NCT05711862|DRUG|Placebo|Participants will receive 0mg of placebo for 7 days. Participants will be directed to take the medication between 9:30 PM and 10:00PM.
224151746|NCT02061748|DRUG|Observational|Retrospective Chart Review
224151747|NCT04059991|BIOLOGICAL|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
224151748|NCT01742091|DRUG|LY2541546 - SC|Administered SC
224066042|NCT01040559|DRUG|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
224066043|NCT04267874|PROCEDURE|Biospecimen Collection|Undergo collection of nasal swabs, blood, urine, and stool
224066044|NCT04267874|DIETARY_SUPPLEMENT|Nutritional Supplementation|Given black raspberry nectar PO
224066045|NCT04267874|DRUG|Placebo Administration|Given PO
224066046|NCT04267874|OTHER|Questionnaire Administration|Ancillary studies
224066047|NCT03016325|DRUG|HNO Donor|Infusion
224066048|NCT03016325|DRUG|Placebo|Infusion
224066049|NCT01323426|PROCEDURE|Periurethral injection|Periurethral injection of autologous muscle fibers
224066050|NCT05473403|OTHER|Corticosteroid therapy|Administration of high doses of corticosteroids as early as possible. Patient non-responder to treatment should lead to listing for emergency liver transplantation (LT).
224066051|NCT02970292|DRUG|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
224066052|NCT02970292|DRUG|Placebo|Placebo, taken as two tablets, once daily by mouth
224066053|NCT05213377|PROCEDURE|Preoperative warming|Patients enrolled in surgery who will not receive 30 minutes of pulsed air thermal blanket warming prior to induction of anesthesia (3M™ Bair Hugger™ Adult Integral Blanket, Model 300 Dimensions: 213 cm x 91 cm)
224066054|NCT05532774|DEVICE|AI defocusing frame glasses|AI defocusing frame glasses have the function of eye behavior management, which can delay the progression of myopia through scientific management of eye behavior including outdoor light exposure (≥2 hours/day), duration of continuous close eye use (30 seconds rest every 30 minutes) and close eye distance (one punch, one foot and one inch), etc.
224151749|NCT01742091|DRUG|LY2541546 - IV|Administered IV
224151750|NCT01742091|DRUG|Placebo - SC|Administered SC
224151751|NCT01742091|DRUG|Placebo - IV|Administered IV
224151752|NCT01072968|DRUG|BF2.649|1 capsule per day in the morning before the breakfast
224151753|NCT01072968|DRUG|Placebo|1 capsule per day in the morning before the breakfast
224151754|NCT05227768|DRUG|VV116 25mg Group|4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
224151755|NCT05227768|DRUG|VV116 200mg Group|6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
224151756|NCT05227768|DRUG|VV116 400mg Group|6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
224151757|NCT05227768|DRUG|VV116 800mg Group|6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
223455861|NCT02115061|DEVICE|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
223455862|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
223455863|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 50 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
223455864|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 100 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
223455865|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 200 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
224066055|NCT01774578|DRUG|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
224066056|NCT01774578|BIOLOGICAL|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
224066057|NCT01774578|DRUG|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
224066058|NCT01774578|DRUG|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
224066059|NCT00947180|BEHAVIORAL|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
224066060|NCT00947180|OTHER|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
224066061|NCT00947180|BEHAVIORAL|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
224066062|NCT03757208|DIETARY_SUPPLEMENT|carbohydrate rich drink|The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
224066063|NCT04096196|BEHAVIORAL|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
224066064|NCT04096196|OTHER|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
224066065|NCT03617991|OTHER|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
224066066|NCT03761615|DEVICE|Dexcom G6 CGM|All women in the study will be given Dexcom G6 CGM and a study glucometer.
224066067|NCT03464656|DRUG|Fairhaven Pro for men|"Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)"
224066068|NCT03464656|DIAGNOSTIC_TEST|Semen analysis|"Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010)."
224066069|NCT03464656|DIAGNOSTIC_TEST|Sperm DNA fragmentation|Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
224066070|NCT03464656|DIAGNOSTIC_TEST|Static Oxidation reduction potential in semen|Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
224066071|NCT00757250|DRUG|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
224066072|NCT00814775|DEVICE|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
224302020|NCT00045175|DRUG|7-hydroxystaurosporine|
224302021|NCT00045175|DRUG|topotecan hydrochloride|
223455866|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 300 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
223455867|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 450 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
224151758|NCT05227768|DRUG|VV116 1200mg Group|6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
224151759|NCT04681924|OTHER|Diet intervention|Low carb diet group are compared to low fat diet group and followed up for 6 months
224151760|NCT01909609|OTHER|AAP Documents|
224151761|NCT01909609|OTHER|Parent Survival Guide|
224151762|NCT05286567|DRUG|RGRN-305|Heat shock protein 90 inhibitor
224151763|NCT05286567|DRUG|Placebo|Placebo (blinded)
224151764|NCT02069249|BEHAVIORAL|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
223455868|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 600 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
223455869|NCT03994484|DRUG|HA121-28 tablets|Participants will receive oral HA121-28 at a dose of 800 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle
223455870|NCT01181947|DEVICE|TEVAR|Thoracic endovascular aneurysm repair
224151765|NCT02069249|BEHAVIORAL|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
224151766|NCT00247559|BIOLOGICAL|Botulinum toxin type A|
224151767|NCT05488418|OTHER|Clinical, cognitive and biological tests|"Evaluations at 1, 3, 6 and 12 months post-inclusion will be performed, during which the subject will complete various clinical and cognitive tests.~A blood sample will be collected at each visit to study biological processes including the regulation of genetic and epigenetic expression, in particular the expression of the GPR56 and ELK1 genes in the blood.~For eligible subjects a brain MRI will be proposed at the first visit."
224151768|NCT00531908|DRUG|furosemide|furosemide
224151769|NCT04764968|DRUG|Dasiglucagon|Abdominal s.c. administration using a multi-dose reusable pen injector
224151770|NCT01340560|PROCEDURE|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
224151771|NCT05243004|OTHER|Phone Nurse consultation|"A phone call will be made by the nurse 72 hours before the surgery. During this phone call, the nurse :~* underlines the preoperative preparation instructions (skin preparation, fasting period, specific medical instructions given by the anesthesiologist, administrative instructions)~* ensures that the reason for hospitalization is understood~* answers the patient's questions."
224151772|NCT04544124|BEHAVIORAL|Contingency management|Incentives will be provided for treatment attendance over a 12-week period.
224151773|NCT03706040|BIOLOGICAL|Placebo|subcutaneous (SC) injection
224151774|NCT03706040|BIOLOGICAL|Risankizumab|subcutaneous (SC) injection
224151775|NCT02226419|DIETARY_SUPPLEMENT|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
224151776|NCT03658317|DIAGNOSTIC_TEST|renal arterial resistive index|done by dupplex on renal arteries
224151777|NCT03658317|DIAGNOSTIC_TEST|uric acid level|serum sample for doing the test
224151778|NCT03658317|DIAGNOSTIC_TEST|serum urea and creatinine|serum samples for doing the test
224151779|NCT03658317|DIAGNOSTIC_TEST|24 hours urinary proteins|urine collected over 24 hours for doing the test
224151780|NCT03658317|DIAGNOSTIC_TEST|lipogram|serum sample for doing the test
224151781|NCT03658317|DIAGNOSTIC_TEST|HbA1c level|serum sample for doing the test
224151782|NCT03658317|DIAGNOSTIC_TEST|urine analysis|urine sample for doing the test
224151783|NCT03658317|DIAGNOSTIC_TEST|abdominal ultrasonography|done by the ultrasonography device
224151784|NCT01475318|DRUG|mifepristone|200 mg mifepristone on day 1
224151785|NCT01475318|DRUG|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
223455871|NCT05211141|DEVICE|HLS KneeTec Deep Dish|total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
223455872|NCT06363448|PROCEDURE|Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia|Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.
224151786|NCT01475318|DRUG|Misoprostol|misoprostol 800mcg PV on day 3
224151787|NCT02508519|PROCEDURE|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
224151788|NCT04260841|DEVICE|bed in 45 degrees for passive leg raising test|fluid responsiveness is tested by the passive leg raising test
224151789|NCT04545034|OTHER|water aerobic exercise|The EP would be formed by continuous session of dynamic water aerobic exercise which consisted of a dynamic warm-up period (5 minutes), an active exercise period at the established intensity of HR (35 minutes), and a cooldown period (5 minutes) to total 45 minutes, with a intensity of 75%HR.
224151790|NCT01668134|RADIATION|Stereotactic radiation|
224151791|NCT03068936|RADIATION|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
224151792|NCT03068936|DRUG|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
224151793|NCT03010904|OTHER|Dietary intervention|
224151794|NCT04181957|DRUG|Placebo oral tablet|Participants take one dose of placebo (lactose) tablet.
224151795|NCT04181957|DRUG|Lisdexamfetamine Dimesylate|Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
224151796|NCT02099760|DEVICE|STD testing (GC/Ct/trich)|
224151797|NCT03077243|RADIATION|Intensity Modulated Radiotherapy (IMRT)|60- 70 Gy at 2 Gy/fx
224151798|NCT03077243|DRUG|Cisplatin (or alternative)|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 -7 total doses.
224151799|NCT03077243|PROCEDURE|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
224151800|NCT03030183|DRUG|Zilucoplan (RA101495)|0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
224151801|NCT03788616|DRUG|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
224151802|NCT03788616|DRUG|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
224151803|NCT04061941|BEHAVIORAL|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
224151804|NCT00212758|DRUG|Nutropin AQ|Nutropin AQ
224151805|NCT04936204|DEVICE|ConnettivinaBio Plus cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
224151806|NCT04936204|DEVICE|ConnettivinaBio cream|The Un-blinded Investigator will perform the first application of medication. He will also instruct the patient or his/her caregiver to the self-application of the treatment which will be covered by a secondary dressing according to the site's standard care.
224151807|NCT00141310|DRUG|Sildenafil citrate|
224151808|NCT03510910|DRUG|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
224151809|NCT03510910|DRUG|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
224302022|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
224151810|NCT01105936|DRUG|Paracetamol|665 mg sustained release paracetamol caplets
224151811|NCT01105936|DRUG|Placebo|Placebo caplets
224151812|NCT01673490|DRUG|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
224151813|NCT02338856|DRUG|MB12066 200mg|100mg bid (multiple dose, day 8)
224151814|NCT02338856|DRUG|Placebo|100mg bid (multiple dose, day 8)
224151815|NCT00110591|DRUG|PRO 140|Monoclonal antibody to CCR5
224151816|NCT02244229|DRUG|Tamsulosin|
224151817|NCT02244229|DRUG|Finasteride|
224151818|NCT02244229|DRUG|Placebo|
224151819|NCT02506491|OTHER|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
224151820|NCT02506491|OTHER|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
224151821|NCT02506491|OTHER|Control Group|No exercise
224151822|NCT03062267|OTHER|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
224302023|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
224302024|NCT00302081|BIOLOGICAL|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
224302025|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
224302026|NCT00302081|DRUG|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
224302027|NCT00763438|DRUG|Sertindole|Flexible dose
224302028|NCT05789693|BEHAVIORAL|Physical activity changes|Previously an initial measure (qualitative and qualitative) will be made to know the little active adolescents. At the end of the physical activity program a retention measure will be carried out to know the scope and persistence of the variables analyzed. The intervention will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where there will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all.
224302029|NCT06276036|OTHER|Identification of specific markers|Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.
224066073|NCT00814775|DEVICE|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
224066074|NCT02012985|BIOLOGICAL|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
224066075|NCT02012985|DRUG|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
224066076|NCT06549569|PROCEDURE|TFS|burn coverage with TFS
224066077|NCT01811251|DRUG|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
224066078|NCT06475833|DIAGNOSTIC_TEST|Prone plank test, Side plank test, The Awareness of Sports Injuries Scales|"Prone Plank Test: For the prone bridge test, athletes will position themselves in a plank position with their elbows shoulder-width apart and directly under their shoulders. Using a stopwatch, the duration for which they can maintain this position without breaking form will be recorded.~Side Plank Tests: For the side bridge test, athletes will position themselves in a side plank position, ensuring that the shoulder is directly above the elbow. The duration for which they can maintain this position will be recorded using a stopwatch.~The Injury Prevention Awareness Scale for Athletes will be used to evaluate athletes' awareness and attitudes towards preventing sports injuries. A high score indicates a good level of awareness of injury prevention in sports."
224066079|NCT04759651|OTHER|Functional Outcome of Sleep Questionnaire Turkish version (FOSQ-TR)|Sleep related quality of life questionnaire.
224066080|NCT04759651|OTHER|Epworth Sleepiness Scale (ESS)|Subjective level of daytime sleepiness.
224066081|NCT04759651|OTHER|Berlin Questionnaire|Evaluation of high-risk for Obstructive Sleep Apnea.
224066082|NCT04759651|OTHER|Stop-Bang Questionnaire|Evaluation of high-risk Obstructive Sleep Apnea.
223455873|NCT07018791|DIAGNOSTIC_TEST|Standard TMD Assessment|This is the conventional diagnostic and management approach for TMD, focusing on physical evaluation and symptom tracking without the use of any visual or art-based tools. It serves as the baseline for comparison in this study.
223455874|NCT07018791|DIAGNOSTIC_TEST|Artistic Pain Exploration (APE) Method|This approach involves showing patients three expressive paintings and asking them to select the one that best resonates with them. A guided interview follows, using the artwork to explore the patient's pain characteristics, emotional impact, and functional limitations. This method aims to provide a richer, more personalized understanding of the patient's pain experience.
223455875|NCT07022327|DRUG|Ivacaftor 150 MG (milligrams)|Ivacaftor is a CFTR potentiator approved for the treatment of cystic fibrosis in patients with specific gating mutations. In this observational, single-patient study, Ivacaftor is being used off-label in an adolescent without a cystic fibrosis-associated CFTR mutation to evaluate its potential impact on chronic pancreatitis. The intervention is not assigned by the study team but is part of the participant's ongoing medical care. The study monitors clinical outcomes and wearable health data over a 12-month period.
224066083|NCT04759651|OTHER|Insomnia Questionnaire|Subjective evaluation of insomnia.
224066084|NCT04759651|OTHER|Restless Leg Syndrome Questionnaire|Subjective evaluation of Restless Leg Syndrome.
224066085|NCT04759651|OTHER|Zung Self-rating Depression Scale (SDS)|Subjective test for evaluation of depressive mood.
224066086|NCT04759651|OTHER|Beck Anxiety Inventory|Subjective test for evaluation of anxiety.
224066087|NCT03353870|OTHER|qualitative interview|individual qualitative interview
224066088|NCT03579784|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
224066089|NCT03579784|DRUG|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
224066090|NCT03579784|DRUG|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
224066091|NCT02820129|DEVICE|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
224066092|NCT02820129|DEVICE|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
224066093|NCT04586283|OTHER|Maternal prone position|Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
224066094|NCT02671136|DEVICE|Hyperbaric Oxygen therapy|
224066095|NCT02671136|OTHER|Conventional Wound Therapies|
224066096|NCT04383860|PROCEDURE|5-0 suture|5-0 suture administration during surgery
224066097|NCT04383860|PROCEDURE|4-0 suture|4-0 suture administration during surgery
224066098|NCT02327637|BEHAVIORAL|Moderate Activity|Ambulation 150 feet, two times per day
224066099|NCT03643380|DEVICE|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
224066100|NCT02547350|DRUG|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
224066101|NCT01565070|DRUG|Biofreeze|Use of Biofreeze ointment
224066102|NCT01565070|OTHER|Placebo|Use of placebo ointment
224066103|NCT04572477|DRUG|[18F]THK-5351|F-18 THK PET Imaging
224066104|NCT04572477|DRUG|[18F]AV-45|F-18 AV45 PET Imaging
224066105|NCT00806559|OTHER|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
224066106|NCT00806559|OTHER|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
224066107|NCT05409261|BIOLOGICAL|Ad26.COV2.S|Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
224066108|NCT04937556|DIETARY_SUPPLEMENT|Probiotic: Lactobacillus salivarius + Vit D + Zinc|A mixture of 1\*10E9 colony forming unit (CFU) of Lactobacillus salivarius + Vit D + Zinc citrate in 1 capsule will be daily administrated during 28 days.
224066109|NCT04937556|DIETARY_SUPPLEMENT|Placebo|Placebo in 1 capsule will be daily administrated during 28 days.
224066110|NCT03766529|PROCEDURE|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
224066111|NCT02982343|BEHAVIORAL|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
224066112|NCT02982343|BEHAVIORAL|Falls management only|Participants will undergo a session of falls management and education.
224066113|NCT04251637|OTHER|Cardiac output monitoring with Starling SV.|Intraoperative monitoring of cardiac output by esophageal Doppler, NICOM Starling SV and collection of values for each patient at at least 7 predefined intraoperative times.
224066114|NCT03730155|OTHER|CCT intervention.|8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
224066115|NCT00279825|DRUG|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
224066116|NCT00279825|DRUG|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
224066117|NCT00279825|DRUG|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
224066118|NCT00279825|DRUG|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
224066119|NCT00279825|DRUG|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
224066120|NCT00279825|DRUG|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
224066121|NCT00279825|DRUG|CD-LD IR Placebo|Placebo to match CD-LD IR
224066122|NCT00279825|DRUG|CD-LD CR Placebo|Placebo to match CD-LD CR
224151823|NCT02940860|DRUG|Iron isomaltoside/ferric derisomaltose|"Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes."
224151824|NCT02940860|DRUG|Iron sucrose|Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
224151825|NCT02802956|OTHER|Daily Life Promotion Program|Daily Life Promotion Program
224151826|NCT02802956|OTHER|general rehabilitation treatment|general rehabilitation treatment
224151827|NCT03587467|OTHER|collect fecal specimens|collect fresh fecal specimens of participants
224151828|NCT03820908|DRUG|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
224151829|NCT03665207|DRUG|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
224151830|NCT02715804|OTHER|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
224151831|NCT02715804|DRUG|Placebo|Matching placebo for PEGPH20
224151832|NCT02715804|DRUG|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
224151833|NCT02715804|DRUG|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
224151834|NCT04524091|OTHER|Positive end expiratory pressure|Initially, the patients will be ventilated using pressure support ventilation with an inspiratory pressure adjusted to achieve 6 - 8 ml/kg of PBW with a minimal esophageal pressure swing of 5 cmH2O and a PEEP of 5 cmH2O. After 5 minutes, we will measure five IPSexp and five IPSinsp in random order and considering a resting period between each occlusion in order to avoid learning effect and disconfort. The IR will be calculated using the average of the measured IPSexp and the average of the IPSinsp. Besides, we will register the average of esophageal pressure and transpulmonary pressure swings continuously. The same procedure will be carried out with 10 and 15 cmH2O of PEEP. Inspiratory pressure will be kept constant throughout the protocol.
224151835|NCT04053218|COMBINATION_PRODUCT|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
224151836|NCT04053218|DIETARY_SUPPLEMENT|Placebo|Olive oil placebo
224151837|NCT04671095|DEVICE|ERCP procedure with single use duodenoscope|ERCP is an endoscopic procedure done to relieve bile duct obstruction. It is done either under conscious sedation or deep sedation. The endoscope is inserted thorough the mouth and is taken to the second part of duodenum (small bowel). The ampulla is identified and the bile duct is cannulated. Biliary obstruction is relieved either by placing a stent or removing the stone/s
224151838|NCT00836524|PROCEDURE|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
224151839|NCT00948194|DRUG|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
224151840|NCT03875872|DRUG|Propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
224151841|NCT03875872|DRUG|inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
224151842|NCT02431793|BEHAVIORAL|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
224151843|NCT02431793|BEHAVIORAL|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
224151844|NCT00233324|DRUG|Surfactant|Intubation and administration of surfactant by 1 hour of age.
224151845|NCT00233324|DEVICE|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
224151846|NCT00233324|DRUG|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
224151847|NCT00233324|DRUG|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
224151848|NCT04838639|DRUG|NO-13065|"Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065."
224302030|NCT04771403|DEVICE|FMPD AP algorithm|The Fading Memory Proportional Derivative (FMPD) insulin infusion algorithm determines insulin delivery rates based on proportional error, defined as the difference between the current CGM level and the target CGM level, and the derivative error, defined as the rate of change of the CGM. The FMPD algorithm utilizes derivative and proportional glucose errors to determine delivery rates of insulin.
224151849|NCT04838639|DRUG|Placebo|Two subjects per cohort will take a matched placebo.
224151850|NCT00680966|BEHAVIORAL|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
223455876|NCT07021820|DIAGNOSTIC_TEST|MSOT|Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.
223455877|NCT07021729|DRUG|Clarithromycin|Drug regimens will be given for 14 days, and omeprazole for 6weeks
223455878|NCT07021729|DRUG|Levofloxacin|Drug regimens will be given for 14 days, and omeprazole for 6weeks
223455879|NCT07022691|DEVICE|Lafayette dynamometer:|Lafayette dynamometer will be used for assessment of muscle strength Flexible tape measurement will be used for assessment of WC and hip circumference.
223455880|NCT07021768|DEVICE|Laser Auriculotherapy|French Laser Auriculotherapy using the ECCO REABILITY device and dual pen with red laser with 660 nm wavelength, both manufactured by Ecco Optical Fibers and Devices, using the ideal Nogier Frequency for each region with application of 2 J per point with 100 mW power. For the active group, a 120 mW active tip, red laser with 660 nm, pulse width of 1.2 milliseconds will be used.
223455881|NCT07023068|DIAGNOSTIC_TEST|68Ga-DPA PET/CT|Use 68Ga-DPA PET/CT in the diagnosis of lung cancer
223455882|NCT07023159|OTHER|Demographics|The demographic profile of each patient was documented, including age and sex, to examine potential associations with survival and neurological outcomes.
224066123|NCT00513500|DRUG|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
224066124|NCT00513500|DRUG|Coartem|Give Coartem without RDT and refer fast breathing
224151851|NCT02827370|BEHAVIORAL|Behavioral Dietary Intervention|Receive dietary counseling
224151852|NCT02286726|OTHER|Laboratory Biomarker Analysis|Correlative studies
224151853|NCT02286726|DRUG|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
224151854|NCT03267407|OTHER|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
224151855|NCT04705610|OTHER|Video-oculography / Social cognition tasks / Neuropsychological evaluations|"* Recording of eye movements with a video-oculography device during oculomotor paradigms (Fixations, horizontal and vertical reflex saccades, horizontal and vertical smooth pursuit, anti-saccades)~* Recording of eye gaze with a video-oculography device during emotions recognition tasks (Reading the Mind in the Eyes test (Baron-Cohen 2001); Ekman Faces task (1976))~* Neurological evaluation~* Neuropsychological evaluations~* Social cognitions tasks~* Behaviour assessment"
224151856|NCT02683707|OTHER|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
224151857|NCT02683707|DRUG|Fentanyl|IV peri-procedural analgesia
224151858|NCT02683707|DRUG|Lidocaine|Local Anesthetic
224151859|NCT02683707|DRUG|Midazolam|IV sedation
224151860|NCT04112771|DRUG|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
224151861|NCT04112771|OTHER|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
224066125|NCT06494137|OTHER|inulin|inulin from chicory root
224066126|NCT02585505|PROCEDURE|stem cells|stem cell will be injected
224066127|NCT02248727|DEVICE|somofilcon A|somofilcon A lens
224066128|NCT05852535|PROCEDURE|Exploration|abdominal exploration
224066129|NCT03216356|BEHAVIORAL|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
224066130|NCT03216356|BEHAVIORAL|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
224066131|NCT03216356|DRUG|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
224066132|NCT03216356|DRUG|Placebo|polyethylene glycol 3350 powder
224066133|NCT03216356|DRUG|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
224066134|NCT04639583|DEVICE|Near-infrared spectroscopy (NIRS) utilization|The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
224066135|NCT04326335|OTHER|Felt-tip marking|Marking the location of the future stoma with a felt pen
224066136|NCT04326335|OTHER|Felt-tip marking + 3D printed ostomy button|Marking the location of the future stoma with a felt pen + 3D printed ostomy button placed on the future stoma location
224066137|NCT02613598|DRUG|Bortezomib|
224066138|NCT02613598|DRUG|Ruxolitinib|
224066139|NCT00749996|DEVICE|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
224066140|NCT00749996|PROCEDURE|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
224066141|NCT04687579|OTHER|Screening|Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
224066142|NCT04687579|PROCEDURE|Preoperative optimization|Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin \< 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia \< 150 10\^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio \> 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
224151862|NCT03170258|DEVICE|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired \~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
224151863|NCT00753597|DRUG|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
224151864|NCT05633680|DIAGNOSTIC_TEST|Peripheral blood sampling for circulating tumor cells|Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
224151865|NCT00779363|DEVICE|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
224151866|NCT01626534|DRUG|Clopidogrel|600mg loading dose then 75mg/day
224151867|NCT01626534|DRUG|trigagrelor|180 mg loading dose then 90 mg Twice a day
224151868|NCT02556970|PROCEDURE|Single port VATS|Performing video-assisted thorascopic surgery through a single port
224151869|NCT02556970|DRUG|Paracetamol|1g intraoperatively
224151870|NCT02556970|DRUG|Diclofenac|75mg intraoperatively
224151871|NCT02556970|DEVICE|Camera (5mm diameter 30 degree videothoracoscope)|
224151872|NCT02556970|DEVICE|Forceps grasper|
224151873|NCT02556970|DRUG|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
224151874|NCT03375970|OTHER|TCM|oral chinese herb, chinese topical ointment
224151875|NCT03375970|OTHER|Western medicine|oral steroid, oral antihistamine, topical steroid
224151876|NCT04447924|DIETARY_SUPPLEMENT|Bif195|Daily intake of Bif195 dietary supplement
224151877|NCT04447924|OTHER|Placebo|Daily intake of Placebo
224151878|NCT01883219|DRUG|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
224151879|NCT01563107|RADIATION|Plasma Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
224151880|NCT01563107|PROCEDURE|Exercise Capacity Test - Bicycle|subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
224151881|NCT01563107|PROCEDURE|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
224151882|NCT01427114|DRUG|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
224151883|NCT01470365|PROCEDURE|quality-of-life assessment|Ancillary studies
224151884|NCT01470365|RADIATION|intensity-modulated radiation therapy|Undergo IMRT
224151885|NCT01470365|RADIATION|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
224151886|NCT03955497|OTHER|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
224151887|NCT03955497|DRUG|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
224151888|NCT03955497|PROCEDURE|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
224151889|NCT05702372|OTHER|Glucose as reference food|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
224151890|NCT05702372|OTHER|Cracker made by wheat flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by wheat flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
224151891|NCT05702372|OTHER|Cracker made by rye flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from cracker made by rye flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
224151892|NCT05702372|OTHER|Cracker made by sunflower flour|Eleven healthy, normal weight subjects after 10-14 hours fast, consumed 50g available carbohydrates from sunflower flour, along with 300ml water, tested once, within 10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
224151893|NCT03825445|DRUG|GnRHa (Fertipeptil 0.1mg)|Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
224151894|NCT03825445|DRUG|hCG (Pregnyl 5000IU)|hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
224151895|NCT03696446|BEHAVIORAL|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
224151896|NCT03696446|BEHAVIORAL|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
224151897|NCT00662389|DEVICE|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
224151898|NCT03562624|DRUG|BAY98-7443|"Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5"
224151899|NCT03562624|DRUG|Levonogestrel (Skyla, BAY86-5028)|Comparative LNG dose
224151900|NCT05526625|OTHER|Ultrasound-based measurements of IVC & IJV.|Ultrasound-based measurements of IVC \& IJV.
224151901|NCT01117805|BEHAVIORAL|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
224151902|NCT06020768|OTHER|the bed-head was raised to an angle of 0, 20, 30 and 45 degrees|With each patient in the supine position, the bed-head was raised to an angle of 0, 20, 30 and 45 degrees without a pillow, and the haemodynamic parameters of central venous pressure, systolic and diastolic blood pressure, heart rate, breathing rate and peripheral oxygen saturation were recorded after 0 and 10 minutes.
224151903|NCT00398125|DRUG|GSK364735|
224151904|NCT00095810|DRUG|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
224151905|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Experimental Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. Intensity will depend on subjet's tolerance but without generate visible muscle twitches.~5. Session duration: 25 minutes"
224151906|NCT04483128|DEVICE|Electrical stimulation: Interferential Current (IFC): Control Group|"Application of IFC with Sonopuls 692® (Enraf-Nonius BV, Rotterdam, The Netherlands) device. Parameters:~1. Carrier frequency of 4000 Hz~2. Amplitude modulated frequency of 65 Hz (AMF)~3. Sweep frequency of 95 Hz of modulation with a 1:1 swing pattern, in a quadripolar technique.~4. NO intensity (0 mA)~5. Session duration: 25 minutes"
224151907|NCT05480501|BIOLOGICAL|IM19 CAR-T cells|IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
224151908|NCT05559073|PROCEDURE|Radiofrequency ablation|pulmonary vein isolation using radiofrequency ablation.
224151909|NCT04914767|DRUG|Nigella|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
224151910|NCT04914767|DRUG|Placebo|"The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days."
224151911|NCT01783470|DRUG|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
224151912|NCT00247273|DRUG|risedronate|tablet, 5 mg risedronate, once a day for 2 years
224151913|NCT00247273|DRUG|risedronate|oral, 150 mg risedronate, once a month for 2 years
224151914|NCT03111342|DRUG|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
224151915|NCT03111342|PROCEDURE|Dry-needling|A placement of thin needle into the cervix without substance injection
224151916|NCT01510834|BEHAVIORAL|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
224151917|NCT04238572|DEVICE|Audiovisual distraction device|Evaluate the impact of an audiovisual distraction device on the peroperative opioid consumption
224151918|NCT04238572|DEVICE|Analgesia nociception index|ANI (Analgesia Nociception Index) will be used for peroperative overall comfort measurement
224151919|NCT05059938|BEHAVIORAL|MyFitnessPal user|Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
224151920|NCT04492787|DRUG|Changkang Granule|Take Changkang granule before meals twice a day , one bag for each time
224151921|NCT04492787|DRUG|Changkang Placebo Granule|Take Changkang Placebo granule before meals twice a day , one bag for each time
224151922|NCT02977533|DRUG|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224151923|NCT02977533|DRUG|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
224151924|NCT02977533|DRUG|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
224151925|NCT00001753|PROCEDURE|Magnetic resonance imaging|
224151926|NCT01419015|DEVICE|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
224151927|NCT04861519|OTHER|Collecting invasive FFR measurements.|Invasive FFR measurements from the patient's hospital records will be collected.
224151928|NCT06552923|OTHER|ECHO Tele-Education|A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
224151929|NCT01225120|OTHER|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
224151930|NCT05884281|DRUG|Roflumilast|0.5 mg once daily for treatment period
224151931|NCT05884281|DRUG|Placebo|Placebo for treatment period
224151932|NCT02972957|BIOLOGICAL|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
224151933|NCT02972957|DRUG|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
224151934|NCT00601146|PROCEDURE|chest computed tomography scan|Once a year for three years
224151935|NCT01174888|DRUG|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
224151936|NCT01174888|DRUG|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
224151937|NCT01174888|DRUG|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
224151938|NCT01174888|DRUG|etoposide|Patients receive etoposide IV over 1 hour
224151939|NCT01174888|DRUG|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
224151940|NCT02268071|DRUG|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
224151941|NCT05200728|DRUG|SIM1910-09|"Part A-single ascending doses， SIM1910-09 will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, SIM1910-09 will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
224151942|NCT05200728|DRUG|Placebo|"Part A-single ascending doses， placebo will be administered by IV bolus infusion over a 30-min. The test doses are including of : 2mg/kg, 4mg/kg, 6mg/kg, 8mg/kg, which will be tested sequentially from low dose to high dose.~Part B-multiple ascending doses, placebo will be administered as an initial bolus dose over 30-min, plus subsequent continuous infusion over 72 hours, the test doses are including of : 4mg/kg IV bolus infusion+0.03mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.1mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.3mg/kg/h continuous infusion；4mg/kg IV bolus infusion+0.6mg/kg/h continuous infusion，which will be tested sequentially from low dose to high dose."
224151943|NCT01999907|DIETARY_SUPPLEMENT|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
224151944|NCT01999907|DIETARY_SUPPLEMENT|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
224151945|NCT01999907|OTHER|Placebo|placebo given in a 2ml dose by mouth at baseline.
224151946|NCT06347783|DEVICE|Insulin pump|Continuous subcutaneous insulin therapy.
224151947|NCT03276572|DRUG|225Ac-J591|225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
224151948|NCT04491214|OTHER|quality of live assessment|quality of live assessment 3 moth and 6 moth after ointensive care hospitalisation using SF36.
224151949|NCT00602381|DRUG|Lithium|
224151950|NCT04238611|DEVICE|Microneedle|Lactate microneedle applied on the skin of participant
223455883|NCT07023159|OTHER|Comorbidities|Data on pre-existing chronic conditions were recorded, such as hypertension, diabetes mellitus, coronary artery disease, chronic kidney disease, and malignancy, in order to assess their potential impact on prognosis following OHCA.
224151951|NCT04238611|DIAGNOSTIC_TEST|Blood lactate measurement|Serum lactate testing through conventional laboratory methods
224151952|NCT04238611|OTHER|Exercise regimen|Standardised aerobic exercise regimen
224151953|NCT02822651|BIOLOGICAL|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
224151954|NCT02822651|OTHER|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
224151955|NCT01192841|OTHER|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
224151956|NCT02784977|DEVICE|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
224151957|NCT02784977|DEVICE|Intraoral device (IOD)|Treatment of OSA with IOD
224151958|NCT02784977|PROCEDURE|Uvuloplasty|Uvuloplasty
224151959|NCT02784977|OTHER|Conservative treatment|No active intervention
224151960|NCT00048490|DEVICE|transcranial magnetic stimulation (TMS)|
224151961|NCT00586638|BEHAVIORAL|Video game based training|36 one-hour sessions over 12 weeks
224151962|NCT02580240|DRUG|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
224151963|NCT02580240|DRUG|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
224151964|NCT02053519|DRUG|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
224151965|NCT02053519|DRUG|Mygliol Oil|Matched placebo comparator
224151966|NCT03625492|BEHAVIORAL|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
224151967|NCT03625492|BEHAVIORAL|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
224151968|NCT00607919|DRUG|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
224151969|NCT00607919|DRUG|Placebo|oral, daily, for 16 weeks
224151970|NCT01660230|BIOLOGICAL|3K3A-APC, diluted in 0.9% sodium chloride in water|
224151971|NCT01660230|DRUG|0.9% NaCl in water|
224151972|NCT01395355|BEHAVIORAL|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
224151973|NCT01395355|BEHAVIORAL|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
224151974|NCT00760045|DRUG|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
224151975|NCT00760045|DRUG|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
224151976|NCT04933409|PROCEDURE|3D printed replica of the donor tooth|3D printed replica of the donor tooth.
224151977|NCT04933409|PROCEDURE|Conventional Autotransplantation of tooth|Conventional Autotransplantation of tooth without using the 3D printed guide
224302031|NCT04771403|DEVICE|MPC AP system|The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
224302032|NCT04771403|DEVICE|Dexcom G6 Continuous Glucose Monitoring (CGM) System|The Dexcom G6 CGM measures interstitial glucose through a sensor transmitter. This glucose value is reported to the MPC algorithm during this intervention.
224151978|NCT04466787|DIAGNOSTIC_TEST|Spectral Photon Counting Computed Tomography (SPCCT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~The SPCCT scanner is a prototype spectral photon-counting computed tomography system derived from a modified clinical CT system with a field of View (FOV) of 168 mm in-plane, and a z-coverage of 2 mm."
224151979|NCT04466787|DIAGNOSTIC_TEST|Dual Energy CT (DECT)|"The acquisition for the assessment of the brain parenchyma and for the evaluation of the cervical and intracranial arteries will be performed without and with iodine based contrast media, respectively. The same parameters will be used for both conditions but for a large volume, from the aortic arch to the top of the head. The iodinate contrast agent's injection (Iomeron 400, Bracco Imaging France) will be performed at 5mL/s into an 18G catheter, followed by a 20 mL saline flush that will be injected at the same rate. The bolus volume will be determined according to the patient's body weight : 70 mL for patients \< 80 kg and 1 mL/kg for patients \> 80 kg, with a maximum of 90 mL.~DECT : IQon, Philips"
224151980|NCT00646581|DRUG|Placebo|Placebo
224151981|NCT00646581|DRUG|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
224151982|NCT01444508|DRUG|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
224151983|NCT01444508|DRUG|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
224151984|NCT01714713|DRUG|EVP-6124|Arm 1, 2
224151985|NCT06516458|DIAGNOSTIC_TEST|Camera Based Kinematic Analysis|Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
224151986|NCT05143918|OTHER|assessment of quality of life using questionnaire|assessment of quality of life in hypothyroid patients using SF 36 questionnaire
224151987|NCT05281068|DRUG|Iguratimod|Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
224151988|NCT05281068|DRUG|Danazol|Oral danazol (200 mg twice daily) for 12 weeks.
224151989|NCT00527072|BIOLOGICAL|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
224151990|NCT02007252|DRUG|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
224151991|NCT02007252|DRUG|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
223572512|NCT00688246|OTHER|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture \[Lønning 2005\]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk \[Looker 2000\]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
224151992|NCT02396693|DEVICE|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
224151993|NCT02396693|DEVICE|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
224151994|NCT02396693|DEVICE|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
224151995|NCT02657434|DRUG|Atezolizumab|Participants received IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
224151996|NCT02657434|DRUG|Carboplatin|Participants received IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
224151997|NCT02657434|DRUG|Cisplatin|Participants received IV infusion of 75 mg/m\^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
224151998|NCT02657434|DRUG|Pemetrexed|Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
224151999|NCT02080494|DRUG|Tranexamic Acid|
224152000|NCT02699697|RADIATION|External Beam Radiation Therapy|Undergo EBRT
224152001|NCT02699697|RADIATION|Palliative Radiation Therapy|Undergo EBRT
224152002|NCT02699697|OTHER|Quality-of-Life Assessment|Ancillary studies
224152003|NCT02699697|OTHER|Questionnaire Administration|Ancillary studies
224152004|NCT05463172|OTHER|abdominal strengthening exercises|abdominal strengthening exercises
224152005|NCT05463172|OTHER|pelvic floor muscles strengthening exercises|to strengthen pelvic floor muscles
224152006|NCT00003760|DRUG|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
224152007|NCT01576666|DRUG|LDE225|
224152008|NCT01576666|DRUG|BKM120|
224152009|NCT05247983|PROCEDURE|"Tension-free repair of inguinal hernia with Undissociate Spermatic cord"|"patient undergoing Tension-free repair of inguinal hernia with Undissociate Spermatic cord"
224152010|NCT00257868|DRUG|Rivastigmine prevention of delirium|
224152011|NCT04827940|OTHER|Progressive relaxation exercise with music|"The progressive relaxation technique includes exercises for the muscles in the body to consciously contract and relax together with deep breathing exercises while sitting comfortably or lying down accompanied by music.~Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients did the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music.Relaxing relaxation music for sleep, prepared by the Turkish Psychologists Association, has been installed on the mobile phones of the patients.~The patients were taught to do the relaxation exercises for an average of 30 minutes before going to bed for a week and every day with music."
224152012|NCT02116738|PROCEDURE|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
224152013|NCT00805610|BIOLOGICAL|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
224152014|NCT02402712|DRUG|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
224152015|NCT02402712|DRUG|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
224152016|NCT02402712|DRUG|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
224152017|NCT05579119|DRUG|Sitagliptin 100mg|Sitagliptin 100 mg po once daily.
224152018|NCT05579119|DRUG|Glargine|Glargine once daily.
224152019|NCT05579119|DRUG|Lispro|Correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI).
224152020|NCT06507761|OTHER|Sham|An unrefrigerated room temperature Cold Pack will be wrapped in a towel and applied to the patient's posterior neck and back for 15 minutes while the patient is lying face down.
224152021|NCT06507761|OTHER|Hot Pack|Hot pack (55-60 degrees) application will be wrapped in a towel and applied to the back side neck and back of the patient for 15 minutes while the patient is lying face down.
224152022|NCT06507761|OTHER|Cold Pack|Cold pack application (2-4 degrees) will be wrapped in a towel and applied to the patient's back side neck and back for 15 minutes while the patient is lying prone.
224152023|NCT05157776|DRUG|PD-1 and chemotherapy|Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
224152024|NCT01639391|PROCEDURE|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
224152025|NCT02394327|DEVICE|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
224152026|NCT02394327|DEVICE|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
224152027|NCT01581996|DRUG|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
224152028|NCT01785498|BEHAVIORAL|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
224152029|NCT04759222|DIAGNOSTIC_TEST|vascular occlusion test|The VOT was performed five times in each patient, before the induction of general anesthesia (baseline, T0), 30 min after the induction of general anesthesia (T1), 30 min after applying CPB (T2), 10 min after injection of protamine (T3), and after sternal closure (T4). Before induction of anesthesia, an NIRS sensor was placed on the thenar eminence and an automated tourniquet was placed around the upper arm. The arterial catheter was placed in the contralateral radial artery and the baseline blood pressure was measured. When the baseline tissue oxygen saturation (StO2) was stabilized, the automatic tourniquet was inflated to 50 mmHg over the patient's baseline systolic blood pressure and maintained for 5 min. After the 5-min ischemic period, the tourniquet rapidly deflated to 0 mmHg. StO2 data were continuously recorded during the VOT procedure.
224152030|NCT00533169|DRUG|ZD6474|Part A = Starting dose 50 mg/m\^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m\^2 by mouth daily on days 2-28.
224152031|NCT00533169|DRUG|Retinoic Acid|Part B, C = 80 mg/m\^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
224152032|NCT01216345|DRUG|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
224152033|NCT00469872|PROCEDURE|Context-focused compared to child-focused interventions|
224152034|NCT00720824|BEHAVIORAL|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
224152035|NCT00720824|BEHAVIORAL|Office routine|Standard vaccine administration
224152036|NCT02001688|DRUG|Kamada-AAT for Inhalation, 80mg|
224152037|NCT02001688|DRUG|Placebo|
224152038|NCT02001688|DRUG|Kamada-AAT for Inhalation, 160mg|
224152039|NCT06445569|DIETARY_SUPPLEMENT|KH-1|3 capsules and one stick packet consumed daily around the same time
224152040|NCT06445569|OTHER|Placebo|3 capsules and one stick packet consumed daily around the same time
224152041|NCT00052936|BIOLOGICAL|filgrastim|
224152042|NCT00052936|BIOLOGICAL|rituximab|
224152043|NCT00052936|DRUG|CHOP regimen|
224152044|NCT00052936|DRUG|cyclophosphamide|
224152045|NCT00052936|DRUG|doxorubicin hydrochloride|
224152046|NCT00052936|DRUG|prednisone|
224152047|NCT00052936|DRUG|vincristine sulfate|
224152048|NCT00052936|RADIATION|radiation therapy|36Gy on BULK and extranodal involvement
224152049|NCT04989881|DEVICE|da Vinci Simulator|Single training session
224152050|NCT04989881|DEVICE|Laparascopic training box|Single training session
224152051|NCT02273414|DRUG|BIIL 284 BS - rising dose|
224152052|NCT02273414|DRUG|Placebo|
223742981|NCT04626869|OTHER|Evaluation of Diaphragm Movement|Diaphragmatic movement will be evaluated with ultrasonography and a 5-2 MHz convex transducer will be used. The ultrasound probe is placed between the mid-clavicular line and the anterior axillary line by directing it vertically and slightly cranially. During quiet breathing and deep breathing, diaphragm movement will be measured. The reduction in diaphragm motion will be calculated as the difference (in percent) in diaphragm motion measured before and 30 minutes after the block. Each test will be done 3 times and the values will be averaged. A decrease between 75% and 100% will be defined as complete paresis, a decrease between 25% and 75% as partial paresis, and less than 25% decrease in diaphragmatic movement will be defined as no paresis. In order to investigate the effect of continuous local anesthetic drug administration on diaphragm movement via nerve catheter, the same procedure will be repeated 24 hours after surgery.
224152053|NCT01089569|DRUG|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
224152054|NCT01089569|DRUG|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
224152055|NCT01956266|BEHAVIORAL|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
224152056|NCT02527941|DRUG|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
224152057|NCT05838209|DRUG|test|Ozone oil used as an adjunctive of scaling and root planing and control,
224152058|NCT05838209|DRUG|Control|saline solution 0.09% used as an adjunctive as scaling and root planing
224152059|NCT01989754|DRUG|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
224152060|NCT01989754|DRUG|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
224152061|NCT01989754|DRUG|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
224152062|NCT02516150|DRUG|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
224152063|NCT02516150|DRUG|Glucagon|injection of 50 micrograms of glucagon
224152064|NCT05856669|DEVICE|Virtual reality gaming|This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
224152065|NCT04391855|DRUG|Tramadol with ropivacaine|A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
224152066|NCT04391855|DRUG|Dexmedetomidine with ropivacaine|A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
224152067|NCT04391855|DRUG|Magnesium with ropivacaine|A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
224152068|NCT04391855|DRUG|Ropivacaine plus normal saline|A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
224152069|NCT01313832|OTHER|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
224152070|NCT00347477|DRUG|HyperHAES vs. RA-solution/NaCl|
224152071|NCT04705987|DRUG|Colchicine 0.5 MG|Colchicine 0.5 mg/24h Treatment 8 weeks
224152072|NCT04705987|DRUG|Placebo|Placebo 1c/24h Treatment 8 weeks
224152073|NCT05572346|OTHER|Home-based telerehabilitation program delivered through digital devices|To evaluate the effects of digital home-based telerehabilitation program on functional and spirometric measures as well as on quality of life in patients with chronic respiratory disease
224152074|NCT01994317|OTHER|Algorithm|IV sedation dosing calculated by algorithm
224152075|NCT01994317|OTHER|Standard care|IV sedation dosing calculated by standard care.
224152076|NCT01659268|OTHER|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
224152077|NCT01659268|OTHER|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
224152078|NCT00858936|DRUG|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
224152079|NCT00858936|DRUG|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
224152080|NCT00813917|DRUG|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
224152081|NCT00813917|DRUG|placebo|12 weeks of placebo (double blinded) by mouth twice per day
224152082|NCT03902041|DRUG|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
224152083|NCT03350841|PROCEDURE|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
224152084|NCT03350841|PROCEDURE|root canal treatment|conventional root canal treatment and obturation with guttapercha
224152085|NCT02595268|DRUG|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
224152086|NCT02595268|DRUG|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
224152087|NCT04857788|OTHER|Pandah Application smartphone only|Patients will have an application on their smartphone to help them do their homework
224152088|NCT01080456|DRUG|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
224152089|NCT02227056|DRUG|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
224152090|NCT05381207|DRUG|Montelukast Oral Tablet|Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
224152091|NCT01349972|DRUG|alvocidib|Given IV
224152092|NCT01349972|DRUG|daunorubicin hydrochloride|Given IV
224152093|NCT01349972|DRUG|mitoxantrone hydrochloride|Given IV
223455884|NCT07023159|OTHER|Prehospital Variables|Several prehospital factors were evaluated, including whether the cardiac arrest was witnessed, whether bystander CPR was performed, the time from collapse to the initiation of CPR, and the time from collapse to EMS arrival. Additionally, the durations of no-flow (i.e., time without any CPR) and low-flow (i.e., time with CPR but without ROSC) were noted. The initial cardiac rhythm was categorized as ventricular fibrillation or pulseless ventricular tachycardia (VF/pVT), asystole, or pulseless electrical activity (PEA). Airway management methods used in the field were documented and classified as bag-valve-mask (BVM), supraglottic airway devices (SGAs), or endotracheal intubation (ETI). Other recorded interventions included prehospital defibrillation, administration of epinephrine (including total dosage), and use of mechanical chest compression devices. Whether ROSC was achieved prior to arrival at the emergency department was also noted.
223455885|NCT07023159|DIAGNOSTIC_TEST|Hematological Parameters|These included white blood cell count (WBC), hemoglobin level, platelet count, mean platelet volume (MPV), and differential counts such as neutrophils, monocytes, and eosinophils.
223455886|NCT07023159|DIAGNOSTIC_TEST|Biochemical Parameters|Measurements included creatinine, urea, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), sodium, potassium, chloride, calcium, and troponin-I levels.
223455887|NCT07023159|DIAGNOSTIC_TEST|Arterial Blood Gas Parameters|The primary clinical outcomes recorded for each patient included return of spontaneous circulation (ROSC), 28-day survival or mortality, and neurological status, which was later assessed using the Cerebral Performance Category (CPC) scale.
223742982|NCT01687491|DRUG|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
223742983|NCT01687491|DRUG|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
224152094|NCT01349972|DRUG|cytarabine|Given IV
224152095|NCT06357884|PROCEDURE|Callus debridement|Eligible patients will be seated on a podiatry couch. Standard skin preparation procedure will be done with 2% Chlorhexidine gluconate in 70% isopropyl cleansing to all areas of feet. The same researcher will perform sharp debridement in all participants to minimize the variance between procedures. The procedure will comply with Infection Control Guideline (Podiatry) . A sterile scalpel handle loaded with a single-use No. 15 blade will be used to carry out sharp debridement using aseptic technique. Hyperkeratotic tissue will be debrided until smooth transition with adjacent skin is achieved and underlying pinkish normal skin is visible. Used scalpel will be unloaded and disposed by a QlickSmart ® BladeFLASK scalpel blade remover.
224152096|NCT02137707|DRUG|Gilenya|All patients will receive Gilenya
224152097|NCT03043807|DRUG|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
224152098|NCT03043807|DRUG|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
224152099|NCT03043807|DRUG|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
224152100|NCT03043807|RADIATION|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
224152101|NCT03043807|DRUG|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
224152102|NCT03670498|DEVICE|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
224152103|NCT03670498|DEVICE|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
224152104|NCT01489267|OTHER|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10'7 cells).
224152105|NCT00105183|BIOLOGICAL|Placebo|placebo infusion, single
224152106|NCT00105183|BIOLOGICAL|EZ-2053|single IV infusion, 9 mg/kg
224152107|NCT00105183|BIOLOGICAL|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
224152108|NCT00493441|DRUG|AVN944|150, 200, 250, 300, or 400 mg q12h
224152109|NCT06277583|BEHAVIORAL|Urban care farming|An intervention curriculum has been designed using horticulture therapy combined with urban farming techniques. The sessions will use plants and interaction with nature to engage and rehabilitate participants. Both the intervention and control group participants will undergo the intervention. But the intervention group will start with the urban care farming intervention first, and the control group will follow once the intervention group completes the program.
224152110|NCT02274415|BIOLOGICAL|Vaccination with the combined vaccine (Prevenar13 ®)|
224152111|NCT02274415|BIOLOGICAL|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
224302033|NCT06973512|DEVICE|deep brain stimulation and stereoelectroencephalography|Deep brain stimulation guided by stereoelectroencephalography
224152112|NCT03286296|BIOLOGICAL|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
224152113|NCT02108834|PROCEDURE|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
224152114|NCT02108834|PROCEDURE|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
224152115|NCT00695513|DIETARY_SUPPLEMENT|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
224152116|NCT03157843|DRUG|low-molecular-weight heparin|
224152117|NCT04724681|DEVICE|WARD CSS|Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well
224152118|NCT00430885|DRUG|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
224152119|NCT05224817|OTHER|Necrotizing soft tissue infections (NSTIs)|There will be no direct interaction with subjects and involves no interventions; study is conducted completely via review of electronic health records. Our site will only collect data from the Methodist Dallas Medical Center.
224152120|NCT01153906|OTHER|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
224152121|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
224152122|NCT00545480|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
224152123|NCT00646568|DRUG|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
224152124|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 50μg group|50μg/person
224152125|NCT05352867|BIOLOGICAL|SARS-CoV-2 (LVRNA009) 100μg group|100μg/person
224152126|NCT05352867|OTHER|Placebo|0.5ml/person
224152127|NCT03027843|DRUG|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
224152128|NCT00792701|DRUG|cisplatin|Given IV
224152129|NCT00792701|DRUG|gemcitabine hydrochloride|Given IV
224152130|NCT01788150|DEVICE|Coronary Stenting|
223455888|NCT07022509|OTHER|proceduder surgery|"The single-incision lateral sulcus mammoplasty is a breast-conserving surgical technique that involves making a single incision along the lateral aspect of the inframammary fold or within the natural skin crease of the lateral sulcus. This approach provides direct access to the lateral quadrants of the breast, which are commonly affected in breast carcinoma, allowing for effective tumor excision while preserving the breast contour.~In SILSM, the incision is carefully planned to align with natural anatomical lines, ensuring optimal cosmetic results and minimal visible scarring. Through this lateral access point, the surgeon performs both tumor resection and glandular reshaping. The technique often involves mobilization and rearrangement of the remaining breast tissue to fill the defect left by the tumor excision, thereby maintaining breast symmetry and volume.~This techn"
223455889|NCT07022509|OTHER|Technique surgery|"The matrix rotation flap is a versatile oncoplastic surgical technique employed in the reconstruction of partial breast defects following tumor excision. This method involves the creation of a rotational skin and glandular flap, mobilized from adjacent breast tissue, typically using an inferolateral or inferomedial pedicle. The flap is designed in a curvilinear or semicircular fashion, allowing it to rotate into the defect site while maintaining adequate vascular supply.~The MRF technique is particularly useful for defects in the lower quadrants of the breast, where direct tissue advancement may be limited. The surgeon carefully outlines a skin paddle adjacent to the resection cavity and undermines the surrounding breast parenchyma. The flap is then rotated and inset into the tumor bed to fill the defect, with the skin paddle contributing to both volume replacement and skin resurfacing if required.~This approach provides robust coverage of the surgical cavity, helps restore breast co"
224152131|NCT03943888|DRUG|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
224152132|NCT03943888|DRUG|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
224152133|NCT03943888|DRUG|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
224152134|NCT03943888|DRUG|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
224152135|NCT05657509|OTHER|Functional training|Functional training Length: 12 weeks; Training duration: 60 minutes; Intensity: 60 to 95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-2 minute rest between sets.
224152136|NCT05657509|OTHER|No intervention|The Control group continues regular traditional training exercises for 12 weeks with a training duration of 60 minutes and three days per week.
224152137|NCT03368326|DIAGNOSTIC_TEST|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
224152138|NCT02690324|BEHAVIORAL|cognitive stress (serial 7)|
224152139|NCT05561894|OTHER|pulse pressure variation index guided fluid therapy|maintainence intraoperative fluid therapy (ringer's acetate) will be given guided by either two goals of pulse pressure variation index, either \>12% or \>16%
223742984|NCT05044754|PROCEDURE|Local treatment of the prostate (SCAP or HIFU)|Once the local involvement of the recurrent prostate cancer is confirmed, patient will undergo local treatment of the prostate (SCAP or HIFU)
224152140|NCT01769495|OTHER|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
224152141|NCT02641314|DRUG|metronomic therapy|"* Propranolol 0.5 mg/kgxd p.o. day 1,~  1. mg/kgxd p.o. day 2,~ 2. mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~* Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~* Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~* Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~* Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
224152142|NCT05251298|OTHER|"Coordination through the online platform JamesAKTIV"|"Coordination of the treatment through the online platform JamesAKTIV that allows neurologists and therapists to select specialised therapies for the predominant symptoms of the patients and communicate easily about problems during the treatment"
224152143|NCT01062919|PROCEDURE|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
224152144|NCT01062919|PROCEDURE|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
224152145|NCT01229514|OTHER|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
224152146|NCT03990090|DRUG|TG103|Administered SC
224152147|NCT03990090|DRUG|Placebo|Administered SC
223455890|NCT06630858|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.
223455891|NCT06630858|PROCEDURE|Intrathecal Morphine|Intrathecal morphine will be performed (a total of 0.2 mg of morphine sulfate + 7.5 mg isobaric bupivacaine).
224152148|NCT03257618|DRUG|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
223455892|NCT06630858|DRUG|Patient Controlled Analgesia (IV PCA)|IV morphine-PCA will be applied postoperatively for 24 hours . IV-PCA: The requested dose will be 1mg morphine, the lock-in time will be 6 minutes, the 4-hour limit will be 20 mg morphine.
223455893|NCT07022977|BIOLOGICAL|MET233|For subcutaneous administration
223455894|NCT07022977|BIOLOGICAL|Placebo|Sterile 0.9% (w/v) saline for subcutaneous administration
223455895|NCT07021690|OTHER|High glyceamic index meal|Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with high glycemic index.
223455896|NCT07021690|OTHER|Low glyceamic index meal|Meal sizes are standardized regarding the amount of carbohydrate, always 50 g. The composition of these meals focuses on selecting carbohydrates with low glycemic index.
223742985|NCT05219929|DRUG|Tetracycline 500 Mg|500 mg three times daily
223742986|NCT05219929|OTHER|Placebo|Placebo for Tetracycline given same way as Tetracycline.
223742987|NCT06268561|OTHER|Visual acuity analysis|Collection of information on visual acuity from the medical file concerning the surgery
223742988|NCT06268561|OTHER|Intraocular pressure analysis|Collection of information on intraocular pressure from the medical file concerning the surgery
224152149|NCT03257618|OTHER|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
224152150|NCT03568695|DIAGNOSTIC_TEST|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
224152151|NCT02143141|DRUG|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
224152152|NCT02143141|DRUG|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
224152153|NCT03140124|BEHAVIORAL|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
224152154|NCT03140124|BEHAVIORAL|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
224152155|NCT00064077|DRUG|Cisplatin|Given IV
224152156|NCT00064077|DRUG|Gemcitabine Hydrochloride|
224152157|NCT00064077|DRUG|Paclitaxel|Given IV
224152158|NCT00064077|OTHER|Quality-of-Life Assessment|Ancillary studies
224152159|NCT00064077|DRUG|Topotecan Hydrochloride|Given IV
224152160|NCT00064077|DRUG|Vinorelbine Tartrate|Given IV
223455897|NCT07021638|OTHER|EMMVIES program|Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health
224152161|NCT01179867|OTHER|Electronic Medication Reconciliation|"1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
224152162|NCT04042012|OTHER|Eccentric exercise|soleus eccentric exercise
224152163|NCT04042012|OTHER|PNE|the application of galvanic current
224152164|NCT04042012|OTHER|Combined|soleus eccentric exercise and PNE
224152165|NCT00563368|DRUG|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
224152166|NCT00563368|DRUG|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
224152167|NCT00563368|DRUG|topiramate|topiramate 46 mg, po once daily
224152168|NCT00563368|DRUG|topiramate|topiramate 92 mg, po once daily
224152169|NCT00563368|DRUG|phentermine|phentermine 7.5 mg, po once daily
224152170|NCT00563368|DRUG|phentermine|phentermine 15 mg, po once daily
224152171|NCT00563368|DRUG|VI-0521|placebo, po once daily
224152172|NCT00398307|DRUG|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
224152173|NCT03620253|DRUG|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
224152174|NCT03620253|DRUG|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
224152175|NCT03431909|DRUG|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
224152176|NCT03431909|DRUG|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
224152177|NCT00520637|DRUG|EZN-2208|
224152178|NCT04138212|DRUG|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
224152179|NCT04138212|RADIATION|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d\*23
224152180|NCT02623491|DRUG|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
224152181|NCT02623491|DRUG|Placebo|Participants will receive matching placebo.
223455898|NCT06006377|OTHER|electrotherapy|hotpack electrotherapy ultrasound exercises
223455899|NCT06006377|OTHER|Backup therapy|The backup spine health device is in the form of a mat and provides segmental electrical stimulation to the spines. At the same time, the mat can heat up to 40 degrees during the treatment process. Backup spine health device is very effective in both reducing pain and strengthening the muscles with electrical stimulations by reaching even the deep muscles around the spine. Sessions consist of 30 minutes
223455900|NCT00814723|DRUG|fluvastatin|80 mg MR, 12 weeks
223455901|NCT00814723|DRUG|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
223455902|NCT00622492|OTHER|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
223455903|NCT06821087|DRUG|Ketamine only|Participants in this arm will receive four intramuscular (IM) ketamine injections over a two-week period. The initial dose will be 0.5 mg/kg during the first session, increasing to 0.65 mg/kg in the second session, and 0.75 mg/kg for the third and fourth sessions. Injections will be administered at least three days apart.
223455904|NCT03516708|DRUG|Epacadostat|Drug provided.
223455905|NCT03516708|RADIATION|Short-course radiation therapy|Short-course pelvic radiation therapy, 5 Gy x 5 fractions over 1 week
223455906|NCT03516708|DRUG|CAPOX chemotherapy|Standard of care
223455907|NCT03516708|DRUG|FOLFOX chemotherapy|Standard of care
223455908|NCT06766136|BEHAVIORAL|Asthma education program|An educational program based on the Roy Adaptation Model in addition to standard asthma treatment.
223742989|NCT06268561|OTHER|Analysis of optical coherence tomography (OCT) images|Collection and analysis of optical coherence tomography (OCT) images of the medical file concerning the surgery
224152182|NCT02135549|DIETARY_SUPPLEMENT|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
224152183|NCT02135549|DRUG|Placebo Oral Tablet|Placebo comparator
224152184|NCT02716662|DIETARY_SUPPLEMENT|Axona|medical powder, supplement food
224152185|NCT04323423|BEHAVIORAL|interrupting sedentary behaviour with light physical activity|replacing sitting with light walking bouts at different frequencies/durations
224152186|NCT03497611|PROCEDURE|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
224152187|NCT02321072|DRUG|Oxygen|
224152188|NCT00117728|DRUG|nevirapine|
224152189|NCT04995614|DRUG|Radium-223|Prospective observational cohort study investigating patient-reported outcomes
224152190|NCT01699295|BEHAVIORAL|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
224152191|NCT01699295|BEHAVIORAL|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
224152192|NCT04840368|OTHER|Dancing|Participants randomized to the dance group will take part in a dance intervention programme for 12 weeks, including 3 sessions per week (non-consecutive days), each lasting 60 min. Dance classes will be performed individually at home, guided by an expertise instructor, as live sessions online. They will include a variety of rhythms such as salsa, merengue, jazz dance, aerobics, etc. The dance sessions will include a warm up of approximately 10 min (posture, join mobility and dance technique), a main part of 40 min (practicing isolated dance moves and learning of specific choreographic routines), and a cool down of 10 min (muscle stretching and relaxation).
224152193|NCT01616784|OTHER|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
224152194|NCT01616784|OTHER|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
224152195|NCT02822157|DRUG|Olaparib|
224152196|NCT02822157|DRUG|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
224152197|NCT04140370|OTHER|There is no intervention|There is no intervention
224152198|NCT01627223|DRUG|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
224302034|NCT06969313|OTHER|Structured Questionnaire on Telemedicine Needs|Participants will complete a structured questionnaire designed to assess their telemedicine needs, expectations, and current knowledge. The questionnaire includes items on demographics, osteoporosis management, and telemedicine service expectations. No clinical or pharmacological intervention will be applied.
224302035|NCT05841732|OTHER|Usual Care|Education; Pain Medication, imaging, referrals to other health services, other health care appointments
224302036|NCT05841732|OTHER|MyBack Program|A tailored exercise and behavioural change program
224302037|NCT04180176|OTHER|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
224302038|NCT04944719|DIAGNOSTIC_TEST|nasopharyngeal aspirate|nasopharyngeal aspirate to determinate colonization by streptococcus pneumoniae
224302039|NCT02689245|DRUG|Tenofovir|
224302040|NCT02689245|DRUG|Fecal Microbiota Transplantation (FMT)|
224302041|NCT00183885|DRUG|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
224302042|NCT05314114|PROCEDURE|No axillary surgery|No axillary surgery
224302043|NCT05249530|OTHER|Chiropractic spinal adjustment|Chiropractic spinal adjustment
223455909|NCT06929481|DEVICE|Cell free DNA (cfDNA) blood test|"The intervention is a novel blood test that evaluates circulating cell free tumor DNA (cfDNA) and detects colorectal cancer (CRC). Recently, the cfDNA test has been shown to have 83% sensitivity and 90% specificity for CRC detection, and 13% sensitivity for advanced polyp detection, heralding a new screening strategy postulated to be highly convenient and acceptable. The cfDNA test is made by Guardant Health, FDA approved for average risk colorectal cancer screening, and marketed with the brand name Shield. Patients opting for the cfDNA test will also be requested to complete an at home FIT."
223455910|NCT06929481|OTHER|At home Fecal Immunochemical Test (FIT) or Colonoscopy|The usual care group will be offered standard colorectal cancer screening options to choose from: at home FIT or colonoscopy.
223455911|NCT06618963|DRUG|Omalizumab Injection|Omalizumab is a monoclonal antibody FDA-approved for treatment of food allergy.
223455912|NCT04030325|BEHAVIORAL|Sequential Personalized Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
223455913|NCT04030325|BEHAVIORAL|Simultaneous Personalized Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
223455914|NCT04030325|BEHAVIORAL|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking events
223455915|NCT01124292|PROCEDURE|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
223455916|NCT01124292|DEVICE|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
223455917|NCT04565899|OTHER|Practice facilitation implementation intervention|6 months during which practice facilitation is implemented to support the primary care clinic in improving routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs.
223572513|NCT00688246|PROCEDURE|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
223572514|NCT06276452|BEHAVIORAL|Psychoeducation|Psychoeducation is the therapeutic management of illness through the increase of related knowledge, skills, and motivation.
223572515|NCT00509860|DRUG|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
223572516|NCT02030080|BEHAVIORAL|Financial incentives|
223572517|NCT02030080|BEHAVIORAL|Teams|
223572518|NCT02030080|BEHAVIORAL|Framing of feedback|
223572519|NCT02030080|BEHAVIORAL|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
223572520|NCT02279849|OTHER|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
223572521|NCT02279849|OTHER|Pricing|The pricing incentives were used to help promote sales of healthier food items.
224152199|NCT01627223|DRUG|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, \< 4 sec / 4-6 sec / \> 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
224152200|NCT01803113|DEVICE|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
224152201|NCT02095990|DRUG|Hydroquinone|
224152202|NCT02095990|DRUG|Placebo|
224152203|NCT04308954|DRUG|[18F]flumazenil|\[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
224152204|NCT04466813|DEVICE|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times."
224152205|NCT04466813|DEVICE|Control-Dry Needling|Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
223572522|NCT02279849|OTHER|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
224152206|NCT00490867|DRUG|Alpha lipoic acid|
224152207|NCT01386567|DRUG|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
224152208|NCT01386567|DRUG|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
224152209|NCT03477669|DIETARY_SUPPLEMENT|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
224152210|NCT03477669|DIETARY_SUPPLEMENT|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
224152211|NCT05275452|OTHER|No intervention|No intervention
224152212|NCT01306851|DRUG|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
224152213|NCT01235728|DRUG|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
223572523|NCT01760330|DRUG|IV acetaminophen|
224152214|NCT01235728|DRUG|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm\^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
224152215|NCT01235728|DRUG|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm\^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
223742990|NCT06268561|OTHER|Analysis of retinograms|Collection and analysis of retinography images of the medical file concerning the surgery
223742991|NCT02935608|DRUG|BIIB074|Administered as specified in the treatment arm
223742992|NCT02935608|DRUG|Placebo|Matched placebo
223742993|NCT05494450|DEVICE|ExufiberAG+|confirm performance and safety of the Exufiber Ag+ dressing in medium to high exuding chronic wounds
224152216|NCT01808404|BEHAVIORAL|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
224152217|NCT05494749|OTHER|zirconomer|teeth meeting the inclusion criteria are assigned to receive Zirconomer® restorations
224152218|NCT05494749|OTHER|HVGI-Equia Forte|teeth meeting the inclusion criteria are assigned to receive HVGI-Equia Forte® restorations.
224152219|NCT05150834|OTHER|This is observational study|We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.
223572524|NCT01760330|DRUG|Placebo|
224152220|NCT01729650|BEHAVIORAL|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
224152221|NCT00234208|PROCEDURE|Medical thoracoscopy|
223572525|NCT05807100|DIAGNOSTIC_TEST|Baseline Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
223572526|NCT05807100|DIAGNOSTIC_TEST|6th month Standardized Mini Mental Test|Cognitive status assessment was done with Standardized Mini Mental Test.
223572527|NCT03620552|DRUG|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
223572528|NCT04053400|DRUG|Ketamine|
223572529|NCT01384448|PROCEDURE|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
224152222|NCT00234208|PROCEDURE|Simple chest tube drainage|
224152223|NCT05568498|DIETARY_SUPPLEMENT|Probiotic|Oral probiotic delivered in powdered form.
224152224|NCT05568498|DIETARY_SUPPLEMENT|Placebo|Oral placebo delivered in powdered form.
224152225|NCT00022152|DRUG|vinorelbine tartrate|
224152226|NCT05626244|BEHAVIORAL|Being a Parent|Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
224152227|NCT01104363|PROCEDURE|Snow white plaster 2|Test. Plaster impression not splinted.
224152228|NCT01104363|PROCEDURE|Primopattern LC gel + PVS|Control PVS impression
224152229|NCT05002699|DIAGNOSTIC_TEST|Alzheimer's disease CSF biomarkers|Measurement of amyloid beta peptide 1-42, amyloid beta peptide 1-40, and total tau in cerebrospinal fluid.
224152230|NCT01575899|DRUG|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
224152231|NCT01575899|DRUG|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
224152232|NCT04294095|OTHER|My Baby My Move +|This is a community-based, peer-led 12-week wellness intervention to decrease excessive gestational weight gain.
224152233|NCT04294095|OTHER|Control|This is a 12-week basic prenatal education class.
223572530|NCT01384448|PROCEDURE|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
223572531|NCT01238770|DRUG|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
223572532|NCT03736993|OTHER|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
223572533|NCT02881112|DEVICE|Provant Therapy System|Treatment with the Provant Therapy System
224152234|NCT00034203|DRUG|efalizumab|
224152235|NCT02873364|DRUG|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
223572534|NCT02374814|DRUG|Rabies vaccine|Compare dose schedule and route of administration
223572535|NCT02374814|DRUG|Placebo|Placebo
224152236|NCT02873364|DRUG|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
224152237|NCT00036062|DRUG|Sivelestat|
224152238|NCT06202001|DRUG|Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab|This study followed a classic 3+3 design, in which patients received escalating doses of TAS-102 (20, 25, 30, or 35 mg/m2/dose, administered twice daily for days 1-5) and irinotecan (135, 150, 165, or 180 mg/m2 on day 1) with a fixed dose of bevacizumab (5 mg/kg on day 1), repeated every 14 days.
224152239|NCT05315141|OTHER|No Intervention|No Intervention
224152240|NCT02379611|PROCEDURE|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
224152241|NCT00830154|DRUG|pagoclone|0.30 mg BID, 0.60 mg BID
224152242|NCT00830154|OTHER|placebo|placebo
224302044|NCT05249530|OTHER|Non-force simulation|Non-force simulation
223572536|NCT00712530|BIOLOGICAL|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
223572537|NCT00712530|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
223572538|NCT01426984|DRUG|methylphenidate|a capsule containing 20 mg
223572539|NCT05783076|DRUG|Stereotactic body radiation therapy|Details have been shown in arm descriptions.
223572540|NCT05783076|DRUG|adoptive cell therapy with vNKT cells|Details have been shown in arm descriptions.
223572541|NCT01887821|DRUG|Chloroquine|
223572542|NCT01887821|DRUG|Dihydroartemisinin/Piperaquine|
224152243|NCT02766907|DEVICE|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
224152244|NCT00375960|DRUG|V3381|
224152245|NCT00375960|DRUG|Placebo|
224152246|NCT04454580|DRUG|Venetoclax|treatment with azacitidine or decitabine in combination with venetoclax
224152247|NCT01360229|PROCEDURE|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
224152248|NCT01360229|OTHER|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
224152249|NCT02017886|DIETARY_SUPPLEMENT|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
224152250|NCT02017886|DIETARY_SUPPLEMENT|Placebo|Placebo tablet twice daily for three weeks
224152251|NCT02640118|DRUG|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
224152252|NCT02640118|DRUG|Lixisenatide-Placebo|
224152253|NCT02640118|OTHER|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
224152254|NCT02829008|DRUG|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
224152255|NCT02829008|DRUG|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
224152256|NCT05419414|DEVICE|Shear wave elastography|Both groups were examined with shear wave elastography.
224302045|NCT00816361|DRUG|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
224302046|NCT05028049|DRUG|Sufentanil injection|Sufentanil 0.3 μg/kg is intravenously administrated to maintain intraoperative analgesia
224302047|NCT05028049|DRUG|Remifentanil Hydrochloride|Remifentanil 0.3ug/kg/min is intravenously administrated to maintain intraoperative analgesia
224302048|NCT05028049|OTHER|plain areas|Patients should be long staying residents in plain areas (altitude level below 1,000 meters above sea level)
224152257|NCT05334550|OTHER|Home Based Early Intervention by Parent|Through a video communication program called ZOOM, the parents of intervention group are educated once every two weeks for three months. Parent education consists of a program developed by our pediatric rehabilitation therapist to help premature infants develop motor skills. Parents provide daily exercise training to their children as educated.
224152258|NCT04085042|DEVICE|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
224152259|NCT06216197|DRUG|FENT group|Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).
224152260|NCT06216197|DRUG|DEX group|The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).
224152261|NCT01451151|BIOLOGICAL|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
223572543|NCT03292939|DIAGNOSTIC_TEST|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
223572544|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
224152262|NCT03205982|BEHAVIORAL|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
224152263|NCT03205982|BEHAVIORAL|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
224152264|NCT03355404|OTHER|standing patient|patient goes standing to the surgery room
224152265|NCT00002941|DRUG|carmustine|
224152266|NCT00002941|DRUG|cyclophosphamide|
224152267|NCT00002941|DRUG|etoposide|
224152268|NCT00002941|DRUG|mesna|
224152269|NCT00002941|PROCEDURE|peripheral blood stem cell transplantation|
223455918|NCT00348036|BEHAVIORAL|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
223455919|NCT00348036|OTHER|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
223455920|NCT03373461|DRUG|LNP023|LNP023 5, 25, 100 mg capsles
223572545|NCT02052726|BIOLOGICAL|Placebo|Placebo administered at Month 0, 1, and 3.
223572546|NCT02052726|BIOLOGICAL|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
223572547|NCT02052726|BIOLOGICAL|placebo|Placebo administered at Day 1, 8, and 30.
223572548|NCT03717792|OTHER|no intervention|no intervention
223572549|NCT02839226|DRUG|AR/101|
223572550|NCT02839226|DRUG|Placebo|
224152270|NCT05153447|BEHAVIORAL|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
224152271|NCT05153447|OTHER|Usual Care|Participants randomized to the usual care arm will receive standard of care.
224152272|NCT05176860|DEVICE|CBCT Imaging|Two research CBCT images will be acquired per subject.
224152273|NCT06161857|OTHER|No intervention|There is no intervention this is an observational study to develop a diagnostic test
224152274|NCT00994162|DEVICE|EZCare/V1STA Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
224152275|NCT00655161|BIOLOGICAL|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
224152276|NCT05765292|DIETARY_SUPPLEMENT|Probiotic|The multiprobiotic which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the pa
224152277|NCT05765292|DIETARY_SUPPLEMENT|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
224152278|NCT03253133|DRUG|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level"
224152279|NCT03253133|DRUG|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
224152280|NCT03253133|DRUG|Oxycodone|Oxycodone
224152281|NCT00976729|DRUG|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
224152282|NCT00976729|DRUG|NOX-E36|single SC doses, at safe and tolerable dose level
224152283|NCT00976729|DRUG|Placebo|
224152284|NCT00660777|BEHAVIORAL|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
224152285|NCT00660777|BEHAVIORAL|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
224152286|NCT00185354|DRUG|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
224152287|NCT00185354|DRUG|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
224152288|NCT05713825|PROCEDURE|Endovascular embolization or surgery|"* Endovascular embolization may be done with coils, remodeling technique (coils and balloon), stent and coils, flow-diverter, endosaccular devices. The access is through the femoral or radial artery.~* Surgery is considered the standard neurosurgical procedure of aneurysm clipping."
224152289|NCT02824848|BEHAVIORAL|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
224152290|NCT02824848|BEHAVIORAL|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
224152291|NCT00455936|DRUG|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
224152292|NCT00455936|PROCEDURE|chemotherapy|gemcitabine(1250mg/m2 iv on D1 \& 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
224152293|NCT06011980|DRUG|Growth Inhibitor|growth inhibitors for 250-500μg/h, ivgtt. for 5 days
224152294|NCT04490304|OTHER|durability of posterior soft tissue repair|how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
224152295|NCT02194517|DEVICE|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
224152296|NCT06388135|DRUG|Serplulimab Combined With Nab-paclitaxel and Cisplatin|Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
224152297|NCT06388135|DRUG|nab-paclitaxel，Cisplatin|nab-paclitaxel，Cisplatin
224152298|NCT05211258|DEVICE|a novel portable upper gastrointestinal endoscopy system|Patients arrived at the hospital in the morning after an overnight fast (\>6 hours). The patients took oral dyclonine glue 15 mins before their examination. The doctors prepared the portable endoscopy system so that it was in working status and the disposable sheathed system was placed on the endoscope optical probe.
224152299|NCT01349296|DRUG|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
224152300|NCT06402786|DEVICE|Kitea ICP Sensor|Kitea ICP Sensor placed in brain during shunt surgery.
224152301|NCT01955395|BEHAVIORAL|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
224152302|NCT01170312|BIOLOGICAL|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
224152303|NCT01170312|OTHER|Normal saline|Normal saline injection
224152304|NCT04673955|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and cetuximab
224152305|NCT04673955|DRUG|Cetuximab|Observation of real-life treatment with encorafenib and cetuximab
224152306|NCT01425749|BIOLOGICAL|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
224152307|NCT01277913|DRUG|Vitamin D3|1000 IU once daily for 12 months
223455921|NCT03373461|OTHER|Placebo|Matching placebo to LNP023
223455922|NCT02893111|DRUG|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
223455923|NCT03300180|BEHAVIORAL|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
223455924|NCT03300180|OTHER|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
223455925|NCT01475032|DRUG|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
224152308|NCT01277913|DRUG|Vitamin D3|500 IU once daily for 12 months
224152309|NCT06117917|DRUG|S-ketamine and pregabalin|"* Drug: Pregabalin~* 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)~* Drug: S-ketamine infusion~* 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
224152310|NCT06117917|DRUG|Normal saline and placebo capsule|"* Drug: Placebo capsules~* Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~* Drug: Normal saline~* 0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours"
224152311|NCT01293084|DRUG|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
224152312|NCT01293084|DRUG|7% saline|5mL 7% saline inhaled once over 20 minutes
224152313|NCT00246064|DRUG|infliximab|
224152314|NCT04110184|OTHER|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
224152315|NCT06154499|PROCEDURE|Radical prostatectomy|Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
224152316|NCT01797315|DRUG|Sirolimus|
224152317|NCT02983799|DRUG|OLAPARIB|300 mg olaparib tablets taken orally twice daily
224152318|NCT00845507|DRUG|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
224152319|NCT00845507|DRUG|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
224302049|NCT05028049|OTHER|plateau areas|Patients should be long staying residents in plateau areas (altitude level\>3000 meters above sea level)
224152320|NCT03406715|DRUG|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
224152321|NCT03406715|DRUG|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
224152322|NCT03406715|BIOLOGICAL|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
224152323|NCT04820153|DEVICE|Physical Activity Monitoring Device|Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
224152324|NCT04820153|BEHAVIORAL|Lifestyle Redesign Coaching|Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
224152325|NCT02794623|DEVICE|Tinnitus masking|Tinnitus masking via CI system
224152326|NCT03713606|PROCEDURE|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
224152327|NCT04486989|BEHAVIORAL|Cardiovascular Conditioning Protocol|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
224152328|NCT04486989|OTHER|Voice Production Exercises|Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
224152329|NCT01105780|DRUG|Placebo|Matching placebo
224152330|NCT01105780|DRUG|JNJ-41443532|250mg tablet once daily for 1 day
224152331|NCT03450993|OTHER|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
224152332|NCT05102331|OTHER|Lavender Oil Aromatherapy|"Participants will be given a dental bib to wear. Three drops of the lavender oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~The lavender oil is produced by doTERRA and has Gas Chromatography Mass Spectrometry analysis showing 35.66% linalool without any contaminants"
224152333|NCT05102331|OTHER|Placebo oil|"Participants will be given a dental bib to wear. Three drops of the placebo oil will be placed on the fabric of the bib and the participant will be instructed to relax for 20 minutes.~Refined jojoba oil which has no color or smell"
223455926|NCT01475032|DRUG|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
223455927|NCT01475032|DRUG|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
223455928|NCT01636089|DRUG|bicarbonates|sodium bicarbonates 1,4%
223455929|NCT01636089|DRUG|saline|sodium chloride 0,9%
223455930|NCT03157726|PROCEDURE|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
223455931|NCT03157726|PROCEDURE|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
223572551|NCT01128348|BEHAVIORAL|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
223572552|NCT02707081|DRUG|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
223572553|NCT02707081|DRUG|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
223572554|NCT02707081|DRUG|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
224152334|NCT05102331|PROCEDURE|BMAB procedure|SOC BMAB procedure. The procedure takes approximately 20 minutes to complete and is performed on the posterior superior iliac crest of the pelvic bone. Between 5 and 10 mL of 1% lidocaine will be injected into the site of the BMAB 5 minutes prior to the procedure beginning. No systemic premedications will be allowed including opioids or benzodiazepines. If during the procedure, participants continue to report severe anxiety or pain, the practitioner may consider providing 1mg of lorazepam or morphine as a rescue medication. The aspirate needle and core biopsy needle will be the standard needle provided by the BMAB kit
224152335|NCT02382757|DRUG|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
224152336|NCT00607126|DEVICE|Lokomat|locomotor training using body weight support on a treadmill
224152337|NCT00607126|PROCEDURE|resistive training|resistive training using theraband and/or weights
224152338|NCT06178757|DRUG|TAPB|As soon as the surgical procedure is completed, TAPB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed at the level of the anterior axillary line between the 12th rib and the iliac crest, and the external oblique abdominal muscle, internal oblique abdominal muscle, and transverse abdominis muscle will be visualized. Then, using the in-plane technique, the needle will be advanced with the help of ultrasound until the needle tip reaches the space between the internal oblique and transversus abdominis muscles. After negative pressure aspiration, 5ml saline will be injected and the block location will be confirmed. Once the block location is confirmed, 20ml 0.25% bupivacaine (40ml total for each side) will be injected bilaterally.
224152339|NCT06178757|DRUG|EOIB|As soon as the surgical procedure is completed, EOIB will be applied before extubation. After aseptic conditions are ensured, the high-frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath in the supine position, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed on the 6th rib in the mid-axillary line, at the line between the anterior superior iliac spine and the umbilicus. Using the In-Plane technique, 5 ml of saline will be injected between, the external oblique muscle and the rib, and the block location will be confirmed. After confirming the block location, 20 ml 0.25% bupivacaine will be applied to the plane between 6.,7., and 8. ribs and the muscles. The same procedure will be applied to the other side (a total of 40 ml 0.25% bupivacaine).
224152340|NCT00005808|DRUG|motexafin lutetium|Given IV
224152341|NCT00005808|DRUG|photodynamic therapy|Undergo laser therapy
224152342|NCT00005808|PROCEDURE|loop electrosurgical excision procedure|Undergo LEEP
224152343|NCT00005808|OTHER|laboratory biomarker analysis|Correlative studies
224152344|NCT02249208|DEVICE|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
224152345|NCT02249208|DEVICE|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
224152346|NCT02249208|DEVICE|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
224152347|NCT00308321|DRUG|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
224152348|NCT00308321|DRUG|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
224152349|NCT05235100|DRUG|Apatinib Mesylate|Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT
224152350|NCT05430672|DEVICE|The Thoracic Aortic Stent Graft System (Zylox-Tonbridge Medical Technology Co., Ltd. )|This is a objective performance criteria-controlled study, all subjects meet the criteria will receive the same treatment using the thoracic aortic stent graft system (Zylox-Tonbridge Medical Technology Co., Ltd. ).
224152351|NCT00293046|BIOLOGICAL|ALK Grass tablet - use of compliance device|
224152352|NCT03328624|DEVICE|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
224152353|NCT04034043|DEVICE|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
224152354|NCT04949555|OTHER|Primary congenital glaucoma evaluation|long term evaluation of primary congenital glaucoma management
224152355|NCT01760187|DRUG|lomitapide|
224152356|NCT01794013|BEHAVIORAL|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
223572555|NCT02707081|DRUG|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
224152357|NCT01794013|BEHAVIORAL|Routine care|routine care
223572556|NCT04281225|BEHAVIORAL|Attention to Variability (ATV)|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and behavior that occur throughout the day, and to notice changes they experience with their hearing loss symptoms; noticing if it is better or worse and to ask why it may be.
223572557|NCT04281225|OTHER|Placebo|Participants are told that the device they will be testing will improve their hearing, when in fact the device is not a hearing aid but just a metallic earring.
223572558|NCT00884039|DRUG|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
223572559|NCT00884039|DRUG|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
224302050|NCT00546572|BIOLOGICAL|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
224302051|NCT00546572|BIOLOGICAL|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
223572560|NCT02675192|OTHER|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
223572561|NCT06333743|PROCEDURE|laser ablation|Research has confirmed that laser ablation treatment of cervical HSIL is effective and feasible.
224152358|NCT06329999|DRUG|CMGV|"Initial treatment induction therapy: CMG+Vineclavone regimen Mitoxantrone liposomes 15mg/m2, iv, d1; Cytarabine 10mg/m2, H, q12h, d1-7; G-CSF starts at 5ug/kg, H, d0, WBC ≥ 30 × 109/L, stop G-CSF; Vinecla 100mg, 2200mg, 3400mg, d4-10. Every 4 weeks is a cycle, for a total of 2 cycles. For patients with CR/CRI/MLFS/PR in the first cycle, repeat this regimen for consolidation treatment once (the second course of treatment is Vineclavone 400mg d1-7).~Follow up treatment: Patients who meet the transplantation criteria will undergo hematopoietic stem cell transplantation, while those who do not undergo transplantation will continue to receive CMG+Vineclavone consolidation for 4-6 courses."
224152359|NCT01989182|DEVICE|Spiration Valve System|
224152360|NCT01989182|OTHER|Medical Management|
224152361|NCT02483078|DRUG|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
224152362|NCT02483078|DRUG|Placebo|
224152363|NCT02483078|DRUG|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
224152364|NCT02853955|DEVICE|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
224152365|NCT02853032|DEVICE|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
224152366|NCT02853032|DEVICE|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
224152367|NCT02853032|DEVICE|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
224152368|NCT04591210|DRUG|Angiotensin converting enzyme inhibitor|The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, including renal function, potassium assessment, and dose adjustments as appropriate.
224152369|NCT04591210|DRUG|Angiotensin II Receptor Blockers|The study recommends physicians to select evidence-based ARBs such as candesartan or valsartan or losartan. Lab values will be obtained during baseline. The patient will be followed by the physician clinically, with recommended laboratory testing in one week, and dose adjustments as appropriate.
224152370|NCT05942729|OTHER|Determine the etiology of hypokinetic and hypertrophic heart disease on transthoracic echocardiography data alone|The origin of the pathology will have been previously diagnosed for each patient thanks to complementary examinations performed as part of routine care (e.g. cardiac CT, cardiac MRI, coronary angiography, thorough biology, nuclear medicine). This information will be used (i) to guide the learning of the AI method developed during the project from a sub-population (80% of the collected database will be used to train the algorithms); (ii) to serve as an evaluation criterion from a test sub-population (remaining 20% of the collected database)
223455932|NCT00222222|PROCEDURE|vein puncture|comparison of different inflammatory markers in the blood of septic patients
223455933|NCT01486186|DRUG|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
223455934|NCT01486186|DRUG|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
223455935|NCT03922204|DRUG|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
223455936|NCT03922204|DRUG|Pembrolizumab (Keytruda)|Group B patients will be treated in combination with MCLA-145 and pembrolizumab 200mg Q3W.
223455937|NCT00220233|DRUG|olmesartan medoxomil|
223455938|NCT00220233|DRUG|amlodipine|
223455939|NCT00220233|DRUG|hydrochlorothiazide|
223455940|NCT00461097|DRUG|Egg oral immunotherapy|Egg white solid powder
223455941|NCT00461097|DRUG|Control Group|Placebo for egg white solid
223455942|NCT03818776|DRUG|Durvalumab|Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg \>30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).
223572562|NCT06333743|PROCEDURE|LEEP or Conization|The most common treatment for HSIL is LEEP or conization of the cervical lesion, but there are several perinatal complications involved in this surgery.
223742994|NCT01742741|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
223455943|NCT03818776|RADIATION|Proton beam therapy RT|Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
223455944|NCT05977088|DEVICE|Repetetive Transcranial Magnetic Stimulation|".Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system.~A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group."
224152371|NCT06229587|PROCEDURE|furlow with buccinator flap|Assessment of speech and the middle ear function of patients between the age of 3 and 7 years surgically treated by ARC (Furlow z-palatoplasty with a buccinator myomucosal flap) was done
224152372|NCT06202209|PROCEDURE|Circumferential Pulmonary Vein Isolation|Circumferential pulmonary vein isolation (CPVI) is a type of cardiac ablation procedure. Cardiac ablation procedures involve creating small scars in the heart using thermal or cold energy to block irregular electrical signals and restore normal heart rhythm. CPVI specifically creates small scars in the area where the four pulmonary veins connect to the left atrium of the heart. The pulmonary veins carry oxygen-rich blood from the lungs to the heart.
224152373|NCT04747522|DRUG|SARS-CoV-2 vaccine|SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
224152374|NCT01963754|DEVICE|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
224152375|NCT01963754|DRUG|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
224152376|NCT01963754|DRUG|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
224152377|NCT00006372|DRUG|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
224152378|NCT00006372|DRUG|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
224152379|NCT00006372|DRUG|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
224152380|NCT07089927|PROCEDURE|Art Therapy|Complete virtual art therapy sessions. When complete the participant will receive a 3D printed replica of the avatar.
223455945|NCT04298827|OTHER|Unimodal|Patients will receive physical therapy alone.
224152381|NCT07089927|OTHER|Interview|Ancillary studies
224152382|NCT07089927|OTHER|Survey Administration|Ancillary studies
224152383|NCT00676208|BEHAVIORAL|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
224152384|NCT01330563|DRUG|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
224152385|NCT00236522|DRUG|levofloxacin|
224152386|NCT05867199|BEHAVIORAL|Motor Imagery and Action Observation Training|The training consists of watching videos of actions performed with the hand. At the end of the video the subject is subsequently asked to imagine performing the action just seen
224152387|NCT04370730|OTHER|clinical, neuroimaging and DNA assessments|Selected assessments, including evaluation of treatment response to specific antipsychotic drugs, will be performed at follow-up visits after 1, 3 and 5 years
224152388|NCT03716453|PROCEDURE|Standard protocol|Give narcotic according to vital signs
224152389|NCT03716453|PROCEDURE|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score \> 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given."
224152390|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg lorlatinib
224152391|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
224152392|NCT03726333|DRUG|lorlatinib|continued daily administration of 100 mg QD lorlatinib
223455946|NCT04298827|OTHER|Trimodal|Patients will receive physical therapy, nutrition counseling, and cognitive behavioral therapy in the form of group counseling.
224152393|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
224152394|NCT03726333|DRUG|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
223455947|NCT06955052|OTHER|"Minds In Motion The Maze"|"Minds in Motion the Maze is a program that combines physical activity with cognitive training. Research suggests that MIM can positively impact balance and gait in children with Down syndrome. Some potential benefits include:~* Improved balance and stability~* Enhanced gross motor skills~* Better coordination and overall physical function~* Increased confidence in physical abilities~The program's effectiveness may vary depending on individual needs and program implementation."
224152395|NCT01206790|BEHAVIORAL|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
224152396|NCT03157921|RADIATION|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
224152397|NCT03157921|DIAGNOSTIC_TEST|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
224152398|NCT00881790|OTHER|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
224152399|NCT01410799|DRUG|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
224152400|NCT06063512|OTHER|sweet orange oil inhalation|sweet orange oil with inhalers will be carried out in an open clinical setting. Three drops of sweet orange oil will be dispensed into a cotton wick of the inhaler, The children will be asked to inhale the aroma from the inhalers for 2 minutes followed by an induction period of 15 minutes
224152401|NCT00030095|DRUG|2-methoxyestradiol|
224152402|NCT01946412|DRUG|Ivacaftor|
224152403|NCT00428376|DEVICE|Building Blocks|
224152404|NCT05124262|OTHER|Low- FODMAPdiet group intervention|Diet intervention
224152405|NCT01062828|DIAGNOSTIC_TEST|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
224152406|NCT00014170|DRUG|gefitinib|Given orally
224152407|NCT00014170|OTHER|pharmacological study|Correlative studies
224152408|NCT00014170|OTHER|laboratory biomarker analysis|Correlative studies
224152409|NCT00014170|OTHER|questionnaire administration|Ancillary studies
224152410|NCT00014170|PROCEDURE|quality-of-life assessment|Ancillary studies
224152411|NCT05182424|BEHAVIORAL|Myndlift BPT App & As-Needed Therapist Support|"BPT is based on social learning and operant conditioning principles in which parents are instructed to utilize methods to facilitate positive behaviors in their child and reduce challenging behaviors. Myndlift BPT translates established content and processes into a digital format to be delivered through a mobile app. Myndlift content consists of 10 components, designed to be completed in a self-directed manner by parents, over the course of approximately 10 weeks (total weeks depends upon parent's pace through the program).~In this project, trained and supervised doctoral- and masters-level students will serve as study therapists and meet with parents via a secured, password-protected Zoom platform to introduce parents to the Myndlift BPT (first session before start of the BPT), to support and problem solve BPT skills acquisition (during the Myndlift BPT), and at the end of the Myndlift BPT (to review the intervention content and consider the maintenance of skills)."
224152412|NCT02542813|DRUG|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
224152413|NCT02542813|DRUG|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
224152414|NCT02542813|DRUG|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
224152415|NCT02542813|DRUG|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
224152416|NCT02542813|DRUG|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
224152417|NCT02542813|DRUG|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
224152418|NCT03556982|BIOLOGICAL|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
224152419|NCT03750240|DIAGNOSTIC_TEST|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~1. FLORET without Inversion Recovery (IR), and~2. FLORET with IR"
224152420|NCT03750240|DIAGNOSTIC_TEST|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
224152421|NCT00927758|DRUG|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
224152422|NCT02479295|DEVICE|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
224152423|NCT03125018|DEVICE|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
224152424|NCT00439725|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
224152425|NCT00439725|DRUG|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
224302052|NCT04629261|BEHAVIORAL|Use of ECOBICI (public bicycle sharing program)|Use of ECOBICI program with and without incentive.
223455948|NCT06955052|OTHER|conventional treatment|"Document any specific motor challenges or deficits typical in children with down syndrome.~walk for 10 to 20 minutes warm up for 5 minutes cool down for 5 minutes rest period as per the subject convenience 6 stretching exercise performed during the warm and cool down period ,standing with feet together, standing with feet shoulder apart sitting with feet together ,sitting with feet shoulder width apart standing with only on leg extended , sitting with only one leg standing extended"
223455949|NCT06955585|DEVICE|Proluxx Artificial Tear Spray|Topical artificial tear spray applied to closed eyelids four times daily for 28 days.
224152426|NCT01444183|BEHAVIORAL|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
224152427|NCT01444183|BEHAVIORAL|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
224152428|NCT01755325|DRUG|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
224152429|NCT01755325|DRUG|placebo|
224152430|NCT04988321|PROCEDURE|Prolonged continuous theta burst stimulation (pcTBS)|Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
224152431|NCT00439894|PROCEDURE|Blood draw|blood draw at baseline, week 12 and week 24
224152432|NCT00379236|DEVICE|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
224152433|NCT00379236|DEVICE|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
224302053|NCT02902783|OTHER|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
224302054|NCT00044967|GENETIC|microsatellite instability analysis|
224302055|NCT01634282|DRUG|OPC-262|Orally administered once daily
224152434|NCT06119555|DIETARY_SUPPLEMENT|Cinnamon Capsules|The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
224152435|NCT01877031|DEVICE|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
224152436|NCT01877031|DEVICE|Ultrasound|Standard of Care - Ultrasound guided intervention
224152437|NCT04573192|DRUG|L19TNF|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
224152438|NCT04573192|DRUG|Lomustine|Cohort 1: 10 µg /kg L19TNF i.v. plus 90 mg/m2 lomustine Cohort 2: 10 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine Cohort 3: 13 µg /kg L19TNF i.v. plus 110 mg/m2 lomustine
224152439|NCT06198218|OTHER|Scapular mobilization|Group A: will be treated with manual scapular mobilization in upward rotation and downward rotation, adduction and abduction of scapula.Sets of 10 repetitions were applied with a rest interval of 30 seconds between set for 20 minutes, activity based scapular mobilization(Codman pendulum exercises, scapular pushups, band wall apart ,wall ball circles and advance study wall pushups) along with conventional physical therapy program(heating,EMS,stretching for tight muscles , strengthening exercises and graduated active exercises) for 25 min
224152440|NCT06198218|OTHER|Conventional physical therapy program|Group B:will receive conventional physical therapy program including (heating to improve circulation and release muscle tension,EMS,stretching for stiff muscle,weight bearing, strengthening exercises \& graduated active exercises)for 20 min along with activity based scapular mobilization (Codman pendulum exercises,band wall apart,wall ball circles, scapular pushups and advance study wall pushups)for 20 min with 5 min resting interval.
224152441|NCT03346291|BEHAVIORAL|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
224152442|NCT03700346|DEVICE|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
224152443|NCT02451189|DIETARY_SUPPLEMENT|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
224152444|NCT02451189|DIETARY_SUPPLEMENT|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
224302056|NCT05143151|BIOLOGICAL|CD276 CAR-T cells|CD276 CAR-T cells infusion
224302057|NCT01254682|DEVICE|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
223572563|NCT02648022|BEHAVIORAL|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
224152445|NCT02451189|DIETARY_SUPPLEMENT|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
224152446|NCT01279967|DRUG|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
224152447|NCT01301404|DIETARY_SUPPLEMENT|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
224152448|NCT05637957|DEVICE|active transcranial direct current stimulation|Device: 20 minutes of up to 2.0 mA active anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
224152449|NCT05637957|DEVICE|sham transcranial direct current stimulation|Device: 1 minute of 1.0 mA anodal tDCS (anode positioned at C3/4, cathode positioned at Fp1/2 as per 10-20 electrode placement guidelines) and 19 minutes with unit turned off and electrodes remaining in place Behavioral: Physiotherapy motor skills based physiotherapy intervention (representative of typical goal-focused intervention in the clinical ABI program at Holland Bloorview), 45 minutes in duration
224152450|NCT00866060|DRUG|Memantine|20mg memantine
224152451|NCT00866060|DRUG|Donepezil|10mg donepezil
224152452|NCT00866060|DRUG|Placebo donepezil|Placebo donepezil
224152453|NCT00866060|DRUG|Placebo memantine|Placebo memantine
224152454|NCT02047968|BEHAVIORAL|wake therapy|
224152455|NCT06422572|OTHER|No Intervention|No Intervention
224152456|NCT04914819|BEHAVIORAL|Online Behavioral Weight Loss Program|Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.
224152457|NCT04914819|BEHAVIORAL|Virtual weigh-in|Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
224152458|NCT01500863|DRUG|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
224152459|NCT01500863|DRUG|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
224302058|NCT01254682|PROCEDURE|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
224302059|NCT04627480|DEVICE|Fisher Wallace Neurostimulation Device|a Cranial Electrotherapy Stimulator Device (CES).
224302060|NCT06273787|OTHER|diaphragmatic release|diaphragmatic myofascial release for 1 months 3 sessions per week
224302061|NCT02907541|OTHER|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
224302062|NCT02907541|OTHER|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
224152460|NCT01500863|DRUG|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
224152461|NCT01500863|DRUG|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
224152462|NCT01500863|DRUG|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
224152463|NCT01500863|DRUG|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
224152464|NCT04410913|DRUG|Psilocybin plus Visual Healing Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist who will guide and accompany participants before, during, and after the psychedelic session. In addition, participants will have the chance to view nature-themed videos before and after the psychedelic sessions. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
224152465|NCT04410913|DRUG|Psilocybin plus Standard Set and Setting|Psychedelic session (psilocybin 25 mg) with a therapist will guide and accompany participants before, during, and after the psychedelic session. Four weeks later, a second psychedelic session (psilocybin 25 mg) with either Visual Healing or standard Set and Setting procedures (patient's choice).
224152466|NCT06450808|DIETARY_SUPPLEMENT|Dried Microalgae biomass|The products to be tested are pestos enriched with different amounts of the microalgae Phaeodactylum tricornutum (3, 4 and 5%). After drying, the microalgae Phaeodactylum, which has already been used in two previous applications (application german ethic F-2020-001), is added to the pesto. Three different pestos will be produced and enriched with different amounts of the microalgae Phaeodactylum.
224152467|NCT00215813|DRUG|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
224152468|NCT00033059|DRUG|Tolcapone|
224152469|NCT01413828|DRUG|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
224152470|NCT01413828|DRUG|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
224152471|NCT04090697|DRUG|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
224152472|NCT02164604|DRUG|intravitreal injection of 0.03ml ranibizumab|
224152473|NCT05837507|OTHER|Telerehabilitation solution (m-Rehab)|"Patients in the experimental group will have access to a multimodal digital platform (m-Rehab®). The solution includes a website and an application available on smart phones for the patient and caregivers. Patients and caregivers will have access to educational content about the condition and its treatments, NIV compliance data, digital group educational workshops, secure messaging and video conferencing.~All the professionals forming the patient's circle of care will be able to have access to the solution, after the patient's authorization. The circle of care, in a non-exhaustive way, includes specialist doctors, the general practitioner, the staff of the reference center of the Montpellier University Hospital, the physiotherapist, the speech therapist, the dietician and the psychologist."
224152474|NCT05837507|OTHER|Usual management including NIV.|Usual management including NIV.
224152475|NCT03582436|PROCEDURE|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
224152476|NCT04816786|OTHER|no intervention will be administered, this is a retrospective observational study.|no intervention will be administered, this is a retrospective observational study.
224152477|NCT04506281|DRUG|neoadjuvant treatment|PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
224152478|NCT05287724|DRUG|N-acetyl cysteine|1,500 mg twice daily for seven days
224152479|NCT05287724|DRUG|Placebo|Placebo taken twice daily for seven days
224152480|NCT02550119|DRUG|Aprepitant|Given PO
224152481|NCT02550119|DRUG|Dexamethasone|Given PO or IV
224152482|NCT02550119|DRUG|Dolasetron Mesylate|Given PO or IV
224152483|NCT02550119|DRUG|Placebo|Given PO
224152484|NCT04038385|BEHAVIORAL|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers at farmers' markets.
224152485|NCT04431141|DRUG|Teneligliptin|Teneligliptin alone
224152486|NCT04431141|DRUG|Empagliflozin|Empagliflozin alone
224152487|NCT04431141|DRUG|Teneligliptin and Empagliflozin|Teneligliptin and empagliflozin
224152488|NCT02435394|BEHAVIORAL|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
224152489|NCT02435394|BEHAVIORAL|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
224152490|NCT02435394|BEHAVIORAL|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
224152491|NCT02656862|OTHER|No intervention|
224302063|NCT02907541|OTHER|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
223572564|NCT04793997|BIOLOGICAL|Microbiome spray|Throat spray containing 3 beneficial lactobacilli strains
223572565|NCT04793997|BIOLOGICAL|Placebo spray|Throat spray
223572566|NCT05235958|OTHER|non-linear periodized exercise (NLPE)|Aerobic training derived from professional sports, that is characterized by variable periodization of training frequency, volume and intensity according to individual factors, such as physical and mental readiness, training progress and performance level
224152492|NCT00005792|DRUG|etoposide phosphate|Etoposide phosphate 1363 mg/m\^2/day IV over 4 hours (total dose 2726 mg/m\^2, or 2400 mg/m\^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
224152493|NCT00005792|DRUG|melphalan|Melphalan 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2), followed immediately by topotecan. Days -7, -6, -5
223455950|NCT06955078|OTHER|Visual Motor Integration|"The Beery Visual Motor Integration will be used to measure the integration of visual perception and motor skills as the participant children imitated and copied a developmentally sequential series of geometric forms using pencil and paper. As the task progressed, the levels of difficulty in geometric forms increased.~VP task will be used to measure an individual's visual abilities without the integration of fine motor skills. Children will be asked to point to the item in the array, which was identical to the target figure. The choices will be written on answer sheets by experimenters or children themselves. Elapsed time will be recorded beginning with Item 7, and the task discontinued after 3 minutes. Children will be told to connect dots and to draw within provided borders. Elapsed time was recorded beginning with Item 7 and the task ended up after 5 minutes."
223455951|NCT06956092|BIOLOGICAL|Glofitamab treatment|eceive Glofitamab treatment as per the instructions in the package insert.
224152494|NCT00005792|DRUG|topotecan|Topotecan 3.3 mg/m\^2/day (starting total dose = 10 mg/m\^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
224152495|NCT00005792|PROCEDURE|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
224152496|NCT02866773|BEHAVIORAL|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
224152497|NCT02866773|BEHAVIORAL|PA2: Education sessions, Reminders|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
224152498|NCT02866773|BEHAVIORAL|PA3: Education sessions, Whataps group|"The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
224152499|NCT02866773|BEHAVIORAL|PA4: Education sessions|"The intervention includes one component only:~\- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
224152500|NCT02866773|BEHAVIORAL|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~\- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~\- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
224302064|NCT00630890|RADIATION|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
224302065|NCT02581007|DRUG|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
224302066|NCT02581007|DRUG|Melphalan|
224302067|NCT02581007|DRUG|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
223455952|NCT06955897|OTHER|Observational|Observational
223455953|NCT06954922|BEHAVIORAL|memory-based exercise and training intervention|The experimental group will be given memory-based exercises that will last approximately 15-20 minutes every day for 2 months. Four sessions of epilepsy training will be given, one session per week.
223455954|NCT06954922|BEHAVIORAL|educational initiative about epilepsy|This group will be given 4 sessions of epilepsy training, one session per week.
223455955|NCT03052569|DRUG|RXDX-105|Oral Capsules
223455956|NCT06465745|DEVICE|AltaValve System.|Transcatheter Mitral Valve Replacement.
223455957|NCT05483075|BEHAVIORAL|HCP-Guided Exercise Training Program|"Individually tailored exercise program consisting of aerobic training (5 days per week for a minimum of 30 minutes at moderate intensity) and strength training (2 days per week at moderate intensity).~Two days per week the participant will receive their exercise program at NYU Langone Health. When at NYU, the training will be supervised by a physical therapist and will consist of the following: warm-up of 5 minutes, 30 minutes of aerobic exercise on either a stationary bike or treadmill at 60-70% of maximum heart rate. Following aerobic training, strength training will be carried out. Strength training will consist of 1 exercise per major muscle group, 8-12 reps, 1-3 sets at moderate intensity.~The remaining three days a week the participant will perform aerobic training at home by exercising on a bicycle or by walking fast for a minimum of 30 mins at moderate intensity (60-70% of max HR)."
223455958|NCT02546128|DEVICE|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
223455959|NCT02546128|OTHER|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
223455960|NCT04051541|OTHER|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
223455961|NCT03233815|DRUG|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
223455962|NCT03233815|DRUG|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
223455963|NCT02271217|DRUG|Placebo|
223455964|NCT02271217|DRUG|dalfampridine-ER 7.5mg|
224152501|NCT02866773|BEHAVIORAL|HD2: Education sessions, Reminders|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
224152502|NCT02866773|BEHAVIORAL|HD3:Education sessions, Whataps group|"The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
224152503|NCT02866773|BEHAVIORAL|HD4: Education sessions|"The intervention includes one component only:~\- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
224152504|NCT04687436|DEVICE|mechanical cervical ripening|mechanical cervical ripening with a foley catheter or double-balloon catheter or Cook cervical ripening balloon
224152505|NCT01507623|DEVICE|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
224152506|NCT04376424|DIAGNOSTIC_TEST|Hand Held Ultrasound|Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
224152507|NCT01124513|PROCEDURE|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm\^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
224302068|NCT02581007|PROCEDURE|peripheral blood stem cell transplant|
224152508|NCT01625611|DRUG|Naltrexone|Naltrexone 100 mg titrated over one week
224152509|NCT00829777|DRUG|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
224152510|NCT02915289|PROCEDURE|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
224152511|NCT02915289|PROCEDURE|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
224152512|NCT03006900|OTHER|Pilates|Pilates
224152513|NCT03006900|OTHER|Massage|Massage
224152514|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
223455965|NCT02271217|DRUG|dalfampridine-ER 10mg|
224152515|NCT02218762|DRUG|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
224152516|NCT02218762|DRUG|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
224152517|NCT02218762|DRUG|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
224152518|NCT04410081|DRUG|14C-lazertinib|A single oral dose of 14C-lazertinib will be administered.
224152519|NCT04409990|DIAGNOSTIC_TEST|Shear Wave Elastography|SWE value of rectal lesions
224152520|NCT05460572|DIETARY_SUPPLEMENT|Peripheral Parental Nutrition|Peripheral parenteral nutrition (PPN) through an intravenous (iv) line
224152521|NCT02923310|BIOLOGICAL|Platelets Rich Plasma|
224152522|NCT02923310|BIOLOGICAL|Leucocyte - Platelets Rich Plasma|
224152523|NCT02923310|DRUG|Hialuronic Acid|
223455966|NCT01680809|DEVICE|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
223455967|NCT01680809|DEVICE|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
223455968|NCT04854005|PROCEDURE|Breast surgery|Patients will undergo SLNB with single or dual-tracer lymphatic with technetium-99m sulfur colloid either lymphazurin or methylene blue dye, per institution standard, in accordance with routine clinical practice.
223455969|NCT01441869|DRUG|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
223455970|NCT01441869|DRUG|Diabex|Extended release oral tablets, 1000 mg, single dose
223455971|NCT01441869|DRUG|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
223455972|NCT01441869|DRUG|Diabex|Extended release oral tablets, 500 mg, single dose
224152524|NCT02005783|DRUG|DBD|DBD:one dose of medicine twice per day, orally
223455973|NCT01441869|DRUG|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
223455974|NCT04609423|DIETARY_SUPPLEMENT|Cod liver oil|5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.
223455975|NCT04609423|DIETARY_SUPPLEMENT|Corn oil (placebo)|5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
223455976|NCT02423811|DIETARY_SUPPLEMENT|Fursultiamine|Use of Fursultiamine in addition to CCRT
224152525|NCT02005783|DRUG|Epirubicin|Epirubicin:90mg/m2, d1, q3w\*4
224152526|NCT02005783|DRUG|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w\*4
224152527|NCT02005783|DRUG|Docetaxel|Docetaxel:75mg/m2, d1, q3w\*4
224152528|NCT03857607|GENETIC|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
224152529|NCT01527110|DRUG|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
224152530|NCT01709708|DRUG|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
224152531|NCT01709708|DRUG|Saline|Saline
224152532|NCT02480803|DRUG|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
224302069|NCT00932139|PROCEDURE|Electro-acupuncture control|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
224152533|NCT02480803|DEVICE|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
224152534|NCT02546310|DRUG|HTL0009936|
224152535|NCT02546310|DRUG|HTL0009936 matching placebo|
224152536|NCT04279652|OTHER|Combined exercise|Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
224152537|NCT01858597|DIAGNOSTIC_TEST|biachemical detection|"Serum FGF19 and FGF21 levels were determined by enzyme-linked immunosorbent assay (ELISA) and were correlated with anthropometric, metabolic, and endocrine parameters. Homeostasis model assessment (HOMA-IR) index was calculated and analysed.~Second, samples for measurement were obtained from 30 women with GDM and 35 healthy pregnant controls undergoing caesarean sections at term. mRNA and protein expression levels of FGF19/FGF21 and their co-receptor βKlotho（KLB）in placenta, rectus muscle and subcutaneous fat tissues were investigated with real-time quantitative polymerase chain reaction (qRT-PCR), western-blot and immunohistochemistry (IHC), respectively. Clinical data were collected and analysed."
224152538|NCT04494529|DRUG|12 mg betamethasone + placebo|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo."
224152539|NCT04494529|DRUG|24 mg betamethasone|"After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone."
224152540|NCT06133985|OTHER|Costovertebral mobilizations + Conventional PT|"Costovertebral mobilizations along conventional treatment patient would receive costovertebral mobilization in side lying position for 10th to 6th ribs, in sitting position for 10th to 2nd rib and in supine position for 1 rib.~Frequency: 5 times/week for 3 weeks. Intensity: moderate intensity (pain free) Time: 10 mins Type: costovertebral joint mobilization to improve respiratory function and chest tightness.~Conventional treatment diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness."
224152541|NCT06133985|OTHER|Conventional treatment|diaphragmatic breathing exercises pursed-lip expiration exercises. Patient will receive diaphragmatic breathing and pursed lip breathing exercise in sitting position Frequency: 5 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 mins Type: breathing exercises to improve respiratory function and chest tightness.
224152542|NCT03218189|OTHER|Country characteristics|Observational study of country characteristics
224152543|NCT03780985|PROCEDURE|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
224152544|NCT03780985|PROCEDURE|Cesarean section|to delivery of the fetus
224152545|NCT03780985|PROCEDURE|Suture|to fix the intrauterine device
223455977|NCT03654729|DRUG|Calmangafodipir (2 µmol/kg)|Solution in 20 mL single dose glass vials
223455978|NCT03654729|DRUG|Calmangafodipir (5 µmol/kg)|Solution in 20 mL single dose glass vials
223455979|NCT03654729|DRUG|Placebo|Solution in 20 mL single dose glass vials
223455980|NCT06101186|OTHER|NPECP based on NSM|A comprehensive training booklet which integrated NPECP and NSM principles was sent to five experts for their evaluation and feedback. Among these experts, one was a physician who specialized in obstetrics and gynecology while the remaining individuals were nurses. Group training sessions were conducted online, with each group comprising 4-6 participants. These sessions spanned four weeks, with each session being held weekly and lasting for approximately 60-90 minutes. The training covered various topics - including pregnancy, pregnancy-related changes, pregnancy danger signs, premature birth, stress, stress symptoms, stress coping strategies, childbirth, the postpartum period and the challenges of parenting (particularly when dealing with a pre-term baby)
223455981|NCT00519467|DRUG|Chlorproguanil-dapsone-artesunate (CDA)|
224152546|NCT01155791|DRUG|Docetaxel|IV 75 mg/m2
224152547|NCT01155791|DRUG|Biosyn|IV dosage varies
224152548|NCT01155791|DRUG|Prednisone|5mg, orally
224152549|NCT02579902|DIETARY_SUPPLEMENT|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
224152550|NCT02579902|DIETARY_SUPPLEMENT|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
224152551|NCT02260674|DRUG|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
224302070|NCT00932139|PROCEDURE|Electro-acupuncture test|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA. At end of 8-week treatment, 24 hours blood pressure and heart rate will be measured.
224302071|NCT00342836|PROCEDURE|Akt levels|
224302072|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8\_TCID50
224302073|NCT00686582|BIOLOGICAL|IMVAMUNE|1x 10E8\_TCID50
224152552|NCT02260674|DRUG|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
224152553|NCT02260674|DRUG|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
224152554|NCT01998958|DRUG|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
224152555|NCT01998958|DRUG|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
224302074|NCT00686582|PROCEDURE|Blood Draw Only|
224152556|NCT01998958|DRUG|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
224152557|NCT01998958|DRUG|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
224152558|NCT01998958|DRUG|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
224152559|NCT03443895|DRUG|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
224152560|NCT03443895|DRUG|Placebo oral capsule|Matching placebo capsule
224152561|NCT00297128|DRUG|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
224152562|NCT00297128|DRUG|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
224302075|NCT03480126|OTHER|Herbal Teas|Steeped tea ingested 3 times a day for 3 mos
224302076|NCT02009748|DIETARY_SUPPLEMENT|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
224302077|NCT02009748|DIETARY_SUPPLEMENT|Placebo|oral administration of placebo (vehicle) once daily
224302078|NCT05566548|DIAGNOSTIC_TEST|Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species|It will determine the concentration of the different molecular species of bilirubin and examine the pattern of increase present in patients with liver cirrhosis who develop hepatic encephalopathy and acute-on-chronic liver failure (ACLF) compared to other groups like patients with liver cirrhosis and healthy people.
224152563|NCT01473303|BIOLOGICAL|ganitumab|Given IV
224152564|NCT01473303|DRUG|fluorouracil|Given IV
224152565|NCT01473303|DRUG|irinotecan hydrochloride|Given IV
224152566|NCT01473303|DRUG|leucovorin calcium|Given IV
224152567|NCT01473303|DRUG|oxaliplatin|Given IV
224152568|NCT01473303|OTHER|placebo|Given IV
224152569|NCT01473303|OTHER|questionnaire administration|Completed on paper
224152570|NCT01128881|BIOLOGICAL|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
224152571|NCT05892263|OTHER|early feeding|Enteral force feeding with 5% dextrose injection within 24 hours after operation
224152572|NCT03808428|DEVICE|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
224152573|NCT05098418|DRUG|Poison|standard of care and propre antidotes will be provided for each poisoned patients in addition to gastric lavage and activated charcoal administration when it is applicable
224152574|NCT03320889|OTHER|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
224152575|NCT03950960|DRUG|BMS-986256|Specified dose on specified days
224302079|NCT03335579|COMBINATION_PRODUCT|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
224302080|NCT05192759|DEVICE|Transcranial Magnetic Stimulation|The stimulations were performed by MagStim Rapid2.
224302081|NCT02167542|DEVICE|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2\>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
224302082|NCT02167542|DEVICE|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2\>92%."
224152576|NCT03950960|DRUG|Itraconazole|Specified dose on specified days
224152577|NCT06145217|DRUG|SPRYCEL® (dasatinib) 100 mg Film-Coated Tablets in combination with Omeprazole Delayed-Release Capsules USP, 40 mg|To evaluate the drug-drug interaction between SPRYCEL® 100 mg and Omeprazole under fasted conditions in healthy, adult, human subjects.
224152578|NCT01628393|DRUG|Ozanimod|Oral capsule taken once a day
224152579|NCT01628393|DRUG|Placebo|Oral capsule taken once a day
224152580|NCT02137304|DEVICE|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
224152581|NCT00445341|DRUG|Flavopiridol|Flavopiridol 30 mg/m\^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
224152582|NCT05330624|BIOLOGICAL|plague vaccine(F1+rV)|plague vaccine(F1+rV) (Lanzhou Institute of Biological Products Co.,Ltd) of 1.0ml, three doses
224152583|NCT02733471|DRUG|Lidocaine|
224152584|NCT02733471|DRUG|Placebo|Placebo
224152585|NCT06402968|DRUG|Clevidipine Injection|Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
224152586|NCT06402968|DRUG|Alternate IV Antihypertensive Regimen|"The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour."
224152587|NCT04880772|OTHER|Prehabilitation|exercise \& multivitamin (nutritional/dietary advice)
224152588|NCT00251017|PROCEDURE|Vancomycin|Two hour creatinine clearance before and after vancomycin
224152589|NCT00251017|PROCEDURE|DNA are extracted from the whole blood of subjects|
224152590|NCT01220505|PROCEDURE|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
224152591|NCT02251678|DIETARY_SUPPLEMENT|Elimune Capsules|2 capsules BID for 28 days
224152592|NCT00201981|DRUG|Rebamipide|"1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
224152593|NCT01618526|DIETARY_SUPPLEMENT|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
224152594|NCT01618526|DIETARY_SUPPLEMENT|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
224152595|NCT01110226|DRUG|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
224152596|NCT01110226|DRUG|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
224152597|NCT02379312|DIETARY_SUPPLEMENT|Very low energy aerated beverage|
224152598|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 1|
224152599|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 2|
224152600|NCT02379312|DIETARY_SUPPLEMENT|Normal energy aerated beverage 3|
223455982|NCT04947410|DEVICE|CPAP or nasal dilators|CPAP = active comparator nasal dilators = placebo comparator
224152601|NCT01286701|DRUG|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
224152602|NCT01789658|OTHER|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
224152603|NCT01498588|DRUG|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
224152604|NCT01498588|DRUG|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
224152605|NCT01498588|DRUG|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
224152606|NCT01498588|DRUG|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
224152607|NCT05703139|PROCEDURE|TRIANGLE procedure|The Triangle procedure aims to develop a novel method for patients with locally advanced pancreatic cancer after neoadjuvant therapy and was described in 2017. The basis of this operation is the notice that after neoadjuvant therapy conventional imaging fails to differentiate between actual tumor encasement and only fibrotic residual tissue mainly to the arterial structures
223572567|NCT05235958|OTHER|Exercise counselling|Standard recommendations for exercise and physical activity, that are individualized according to a medical health and fitness profile
223572568|NCT05341895|OTHER|Kinesiotape|Taping
224152608|NCT05388955|OTHER|None, transplantation recipients|None, observational
224152609|NCT02186457|DRUG|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
224152610|NCT02186457|OTHER|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
224152611|NCT00480207|DIETARY_SUPPLEMENT|folic acid|
224152612|NCT00480207|DIETARY_SUPPLEMENT|omega-3|
224152613|NCT00480207|DIETARY_SUPPLEMENT|vit B12|
223455983|NCT04530838|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|20-valent pneumococcal conjugate vaccine
223455984|NCT04530838|BIOLOGICAL|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
224152614|NCT00480207|OTHER|folic acid placebo|
224152615|NCT00480207|OTHER|omega-3 placebo|
224152616|NCT05554718|BEHAVIORAL|Self-help Smartphone App|The app provides a 12-week adaptation of scientifically proven cognitive behavioral therapy techniques for the treatment of SAD and is intended for use as a mobile intervention. The app includes modules such as learning (e.g., creating a model, learning about the maintaining factors), changing the maintaining factors (e.g., safety behaviors), or behavioral experiments.
224152617|NCT05554718|BEHAVIORAL|Therapist-guided App Use|In addition to using the app, patients receive a total of 8 video-based therapy sessions over the course of 12 weeks. The sessions include topics such as video feedback and behavioral experiments.
224152618|NCT01369225|DRUG|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
224152619|NCT01369225|DRUG|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
224152620|NCT01369225|DRUG|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
224152621|NCT01369225|DRUG|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
223572569|NCT03454269|DIAGNOSTIC_TEST|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
224152622|NCT01369225|DRUG|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
224152623|NCT03975712|OTHER|Not applicable, no intervention|Not applicable, no intervention
224152624|NCT04354441|DRUG|hydroxychloroquine sulfate 200 MG|Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.
224152625|NCT04354441|DRUG|Placebo oral tablet|Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
224152626|NCT01988597|OTHER|Dry eyes|
224152627|NCT01999023|DIETARY_SUPPLEMENT|Low protein formula group|Low protein formula formula (28.5 g) twice a day
224152628|NCT04390997|PROCEDURE|Non-surgical Periodontal Treatment|Non-surgical periodontal treatment includes scaling and root planning by using curettes and ultrasonic devices only in the periodontitis group.
224152629|NCT04623463|BEHAVIORAL|Physical activity intervention|Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
224152630|NCT05008133|BEHAVIORAL|Bicycle exercise|Stepwise increased exercise for 5 minutes at 0, 50, 100 and 150 Watts. One series lying flat in prone position, after 15 minutes of rest, series repeated at 70 degrees head up tilt.
224152631|NCT06374524|PROCEDURE|greater occipital nerve block|Patients will receive an ultrasound-guided bilateral GONB (distal approach) of 5 mLs of injectate of bupivacaine 0.25% (5 mLs) + depomedrol 40 mg in 1 mL (3 mLs to each side).
224152632|NCT04198519|OTHER|Weight Loss|The total energy value (TEV) of the diet prescribed for each study participant will be determined by subtracting 800 kcal / day from the total daily energy expenditure, which will be based on Dietary Reference Intake (DRI) recommendations. The distribution of macronutrients will be as follows: protein 15 to 20% of TEV, lipids 25 to 30% of TEV and carbohydrates 50 to 60% of TEV.
224152633|NCT02980692|DRUG|SUNPG1623 I|injection
224152634|NCT02980692|DRUG|SUNPG1623 II|injection
224152635|NCT02980692|DRUG|SUNPG1623 III|injection
224152636|NCT02980692|DRUG|SUNPG1623 IV|injection
224152637|NCT02980692|DRUG|PLACEBO|injection
224152638|NCT01743885|DRUG|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
224152639|NCT01743885|DRUG|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
224152640|NCT02972112|BEHAVIORAL|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
224152641|NCT02972112|OTHER|Sham|standard birth preparation sessions.
224152642|NCT01478295|BEHAVIORAL|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
224152643|NCT01478295|OTHER|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
224152644|NCT02923908|OTHER|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
224152645|NCT02923908|OTHER|Voice Recording|A voice recording will be made for the duration of the tasting period.
224152646|NCT02923908|OTHER|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
224152647|NCT02923908|OTHER|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
224152648|NCT01535768|DRUG|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
224152649|NCT00000324|DRUG|Tryptophan|
224302083|NCT03045237|OTHER|physical exercises classes|3 physical exercises classes, one of them in the pool.
224302084|NCT00741936|DRUG|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
224302085|NCT00741936|DRUG|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
224152650|NCT03177785|BEHAVIORAL|EverydayMatters|
224152651|NCT01998438|DRUG|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
224152652|NCT06211127|DEVICE|Cold laser plaque ablation|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
224152653|NCT06211127|DEVICE|The excimer laser|Patients were randomly divided into two groups. After being included in the two groups, different laser equipment was used to revascularize the lower limbs. The patients' revascularization status was evaluated through regular follow-up after surgery.
224302086|NCT01427842|DRUG|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
224302087|NCT03347136|DEVICE|CPAP|
224302088|NCT03347136|DEVICE|NIPPV|
224152654|NCT04701749|DEVICE|Percutaneous left atrial closure|Percutaneous left atrial closure was performed under general anesthesia with angiographic control and transesophageal echocardiography. The procedure takes between 15 and 20 minutes. This begins with a right femoral venipuncture, progression of the guide in the right atrium allowing atrial trans-septal puncture to catheterize the left atrium. A nitinol prosthesis is implanted (Boston Watchman) at the ostium of the left auricle between the left superior pulmonary vein and the circumflex artery. After a tensile test verifying the stability of the prosthesis, the absence of peri-prosthetic leakage is verified by ETO and angiographic control. The patient is monitored 48 hours before discharge to eliminate the appearance of pericardial effusion and prosthetic embolization. Aspirin 75 mg monotherapy is started the same day with stopping anticoagulation.
224152655|NCT04701749|OTHER|No Percutaneous left atrial closure|No Percutaneous left atrial closure
224152656|NCT04328012|DRUG|Losartan|administered 14 days
224152657|NCT04328012|DRUG|Placebo|administered 14 days
224152658|NCT02048267|PROCEDURE|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
224152659|NCT02409147|PROCEDURE|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
224152660|NCT04955496|PROCEDURE|Enhanced recovery after surgery|ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
224152661|NCT01661946|DRUG|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
224152662|NCT01661946|DRUG|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
224152663|NCT01902004|DRUG|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
224152664|NCT01902004|DRUG|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
224152665|NCT01902004|DRUG|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
223455985|NCT05575739|DIAGNOSTIC_TEST|Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )|Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.
223455986|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 16 weeks
223455987|NCT00920777|BEHAVIORAL|CBT|Individual Cognitive Behavior Therapy during 8 weeks
223455988|NCT00920777|BEHAVIORAL|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
223455989|NCT05581823|DRUG|Tavapadon|Oral tablets
223572570|NCT02649374|BEHAVIORAL|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
223572571|NCT05797532|OTHER|breastfeeding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
223742995|NCT02192918|BEHAVIORAL|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
224152666|NCT01494415|DRUG|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
224152667|NCT01494415|DRUG|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
224152668|NCT01494415|RADIATION|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
223455990|NCT05581823|DRUG|Carbamazepine|Extended-release oral tablets
223455991|NCT00803712|DRUG|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
223455992|NCT00803712|DRUG|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
223455993|NCT05819372|PROCEDURE|Zygomaticomaxillary fracture repair|"A cone beam CT (CBCT) scan of the patient will be used to create a 3D scanned image of zygomaticomaxillary complex fracture (ZMC)~* 3D images will be introduced to finite element (FA) software to evaluate Stresses (MPa), Micromotion (microns), and Life time (cycle) For each model and determine which point of fixation is the best~* After application this point of fixation on the patient~* Finite element analysis will be done again to verify the previous results"
223455994|NCT01834170|DRUG|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
223455995|NCT00052078|DRUG|Sertraline (SRT)|Participants were treated with sertraline.
223455996|NCT00052078|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
223455997|NCT00052078|DRUG|Placebo|Participants were treated with a placebo pill.
223455998|NCT04380376|DRUG|Melphalan|Inhalations with low doses of Melphalan for 7-10 consequent days
224152669|NCT01767012|DEVICE|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
223455999|NCT04380376|OTHER|Standard of care|the patients will receive only SOC (standard of care) treatment
223456000|NCT02672176|BEHAVIORAL|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
223456001|NCT02672176|BEHAVIORAL|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
223456002|NCT03018275|BIOLOGICAL|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
224152670|NCT01767012|DEVICE|Polylens EC-Y10-PAL (uncoated)|
224152671|NCT04205695|PROCEDURE|CEMP (closed-ended multiport catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® FX Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. the Non-Stimulating Needle and the closed-tip multiport catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
224152672|NCT04205695|PROCEDURE|OESP (open-ended single port catheter) group|The linear probe will be placed parasagittally at the junction between the clavicle and the choroidal process. After medial to lateral scanning, the branches of the brachial plexus will be seen as posterior, lateral and medial truncus around the axillary artery. Contiplex® Non-Stimulating Tuohy Set, 17Ga. x 3½ inches. hhe Non-Stimulating Needle and the Non-Stimulating open-ended catheter will be delivered through the needle and placed at the 6 o'clock position relative to the axillary artery and then secured by forming a tunnel under the skin. After negative aspiration, the location of the catheter will be confirmed by injecting 1-2 ml of local anesthetic under ultrasonic guidance.
224152673|NCT04205695|PROCEDURE|Patient-controlled analgesia|A patient-controlled analgesic device will be attached to the catheter for postoperative analgesia. continuous peripheral nerve patient-controlled analgesia is as follows: 0.125% bupivacaine; hourly infusion: 4 ml / hour, pca dose (bolus): 5 ml / hour, lock-up time: 30 min, 4-hours limit: 30 ml.
224152674|NCT05872256|DRUG|0.045% Tazarotene/0.01% Halobetasol Lotion|FDA approved drug for psoriasis treatment
224152675|NCT01600001|DRUG|KWA-0711|
224152676|NCT01600001|DRUG|Placebo|
224152677|NCT05752240|DEVICE|Transcranial direct current stimulation|Ten sessions of transcranial direct current stimulation over primary motor cortex to treat levodopa-induced dyskinesia
224152678|NCT04898127|DIAGNOSTIC_TEST|SARS-CoV-2 antigen rapid test|Rapid test before access to mass gathering event (concert), provided the test result is negative.
224152679|NCT02062242|OTHER|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
224152680|NCT02062242|OTHER|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
224152681|NCT02062242|OTHER|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
224152682|NCT02062242|OTHER|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
224152683|NCT03954990|DRUG|Metronidazole Oral|4 tablets (2 g of metronidazole)
224152684|NCT03954990|DRUG|Placebo Oral Tablet|4 tablets
224152685|NCT00055848|GENETIC|cytogenetic analysis|
224152686|NCT00055848|GENETIC|gene mapping|
224152687|NCT00055848|GENETIC|microarray analysis|
224152688|NCT03024385|BEHAVIORAL|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
224152689|NCT00826488|DEVICE|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
224152690|NCT04344704|OTHER|Single chamber DAI device with floating atrial dipole|DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
224152691|NCT00603850|DEVICE|ForeseeHome|human factor
224152692|NCT02608372|OTHER|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
224152693|NCT02608372|OTHER|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
223456003|NCT02876796|DRUG|GS-0976|Capsule(s) administered orally
223456004|NCT02876796|DRUG|Placebo|Capsule(s) administered orally
223456005|NCT02876796|OTHER|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
224152694|NCT02608372|OTHER|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
224152695|NCT01706991|DEVICE|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
224152696|NCT04655768|DEVICE|Palmar Plate Fixation|Patients are treated by surgery (palmar plate)
224152697|NCT00834925|DRUG|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
224152698|NCT03015623|BIOLOGICAL|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
224152699|NCT03015623|DEVICE|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
224152700|NCT03274245|BEHAVIORAL|Intervention Package|"* Community Level:~  * Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~ * Transect Walk: village walk to identify and mark feces in community;~ * Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~ * Wall painting: village map noting households that use latrines always.~* Sub-Community level:~  * Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~* Household Level:~  * Household visits: to those with latrines to motivate use;~ * Latrine repairs: for households with non-functional latrines to make functional."
224152701|NCT03274245|OTHER|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
224152702|NCT01819506|BEHAVIORAL|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
224152703|NCT06269588|DEVICE|Nexpowder|Endoscopic hemostasis
224152704|NCT02019017|DRUG|Botulinum Toxin Type A 25 IU|
224152705|NCT02019017|DRUG|Botulinum Toxin Type A 50 IU|
224152706|NCT00216268|DRUG|Ribavirin|
223456006|NCT02876796|OTHER|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
224152707|NCT01771367|BIOLOGICAL|Fluad|
224152708|NCT01771367|BIOLOGICAL|Agrippal|
224152709|NCT01771367|BIOLOGICAL|Placebo|
224152710|NCT05897060|DEVICE|Venus Jugular O2 Saturation optical fiber|A continuous measurement of VjO2S, the usual reference measurement of the marketed devices, will be performed by implanting an optical fiber (CEVOX, PULSION Medical Systems) through an internal jugular catheter in addition to the classical catheter of the external electro-systolic drive probe. The following parameters will be recorded every 2 seconds: invasive blood pressure (systolic, mean and diastolic), heart rate, SaO2 on the pulse wave. VjO2S will be recorded continuously during the entire implantation procedure. The time of the beginning of the surgical incision, of the beginning of sinus tachycardia (overdriving) induced by external electro-systolic stimulation, of the beginning of inflation of the intravalvular aortic balloon, of the maximum occlusion of the balloon, of the end of complete deflation of the balloon, of the end of stimulation and of the end of skin closure will be recorded.
224152711|NCT05097157|DEVICE|Potenza|Subjects are treated with the Potenza™ device if they present with conditions such as, but not limited to: wrinkles, fine lines, crepey skin, acne scars, active acne, enlarged pores, stretch marks, or loose skin on the face, neck and/or body.
224152712|NCT05813613|OTHER|Squatting with the aid of Kynapsis Virtual Training apparatus.|Squatting exercise was performed using a virtual reality (VR) machine (kynapsis) for guidance in both groups. Squats were performed while the hands were kept in front of the bodies and the knees flexed to 90 degrees following a rhythm of two seconds for descent, two second ascent mimicking the movement done on the VR machine.
224152713|NCT02695576|PROCEDURE|Lumbar Fusion Surgery|Interbody fusion with fixation
224152714|NCT02695576|OTHER|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
224152715|NCT02695576|OTHER|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
224152716|NCT00178698|OTHER|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
224152717|NCT00178698|DRUG|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
224152718|NCT00178698|OTHER|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
223456007|NCT03117634|DRUG|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
223456008|NCT03117634|DRUG|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
223456009|NCT02245815|DIETARY_SUPPLEMENT|use probiotics boucardii|group A was administered the lactobacillus acidophilus boucardii probiotic (1x10⁹ colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
224152719|NCT01763983|BEHAVIORAL|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
224152720|NCT01763983|BEHAVIORAL|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
224152721|NCT02532569|BIOLOGICAL|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
224152722|NCT05729269|DIAGNOSTIC_TEST|Sarcopenia_CT|measurement of skeletal muscle through abdominal computed tomography
224152723|NCT00968708|DRUG|Alogliptin|Alogliptin tablets
224152724|NCT00968708|DRUG|Placebo|Alogliptin placebo matching tablets
224152725|NCT03429764|PROCEDURE|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
224152726|NCT03429764|PROCEDURE|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
224152727|NCT04373707|DRUG|Enoxaparin|"For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg"
224152728|NCT04373707|DRUG|Enoxaparin|For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.
224152729|NCT01539213|DRUG|secukinumab (AIN457)|anti-IL-17 antibody
224152730|NCT00422890|DRUG|5-Azacytidin|in case of decreasing CD34 chimerism
224152731|NCT00971230|DRUG|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
224152732|NCT00971230|DRUG|Placebo|Placebo
224152733|NCT01998113|DRUG|Glyburide vs Insulin trials|Affecting groups 1 and 2
224152734|NCT01998113|DRUG|Metformin vs Insulin trials|Affecting groups 3 and 4
224302089|NCT01408628|BEHAVIORAL|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm."
224302090|NCT04160845|PROCEDURE|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
224302091|NCT02015689|BEHAVIORAL|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
224302092|NCT02015689|BEHAVIORAL|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
224302093|NCT02015689|BEHAVIORAL|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
224302094|NCT02015689|BEHAVIORAL|CDC VIS|CDC Vaccine Information Statement (VIS)
224302095|NCT05768126|DRUG|Rivastigmine Transdermal Product|The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).
224302096|NCT05768126|OTHER|Sham|The sham patches will be administered during the same period of time as the rivastigmine.
224302097|NCT01941940|DRUG|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
224302098|NCT01941940|DRUG|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
224152735|NCT01998113|DRUG|Metformin vs Glyburide trials|Affecting groups 5 and 6
224152736|NCT03407170|BIOLOGICAL|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
224152737|NCT04144049|DRUG|MT921|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
224152738|NCT04144049|DRUG|Placebo|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
224152739|NCT00218361|DRUG|Hydromorphone|
224152740|NCT01153672|DRUG|vorinostat|Given PO
224152741|NCT01153672|OTHER|laboratory biomarker analysis|Correlative studies
224152742|NCT01153672|PROCEDURE|biopsy|Optional correlative studies
224152743|NCT01153672|RADIATION|F-18 16 alpha-fluoroestradiol|Correlative studies
224152744|NCT01153672|PROCEDURE|positron emission tomography|Correlative studies
224152745|NCT01153672|DRUG|anastrozole|Given PO
224152746|NCT01153672|DRUG|letrozole|Given PO
224152747|NCT01153672|DRUG|exemestane|Given PO
224152748|NCT01153672|GENETIC|gene expression analysis|Correlative studies
224152749|NCT04913571|DRUG|Eribulin|Eribulin
224152750|NCT04913571|DRUG|Tislelizumab|Tislelizumab
224152751|NCT04530968|OTHER|No intervention|No intervention
224152752|NCT05825313|BEHAVIORAL|Podcast Using|Students in the experimental group listened to podcast episodes any time they desired following the course every week during the semester from February 2021 to June 2021.
224152753|NCT01591811|RADIATION|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
224152754|NCT01591811|RADIATION|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
224152755|NCT03466671|DRUG|TTA-121|A nove intranasal spray of oxytocin and placebo
224302099|NCT01846117|DIETARY_SUPPLEMENT|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
224302100|NCT00750308|DRUG|Ramipril|Ramipril 10 mg per day for three weeks
224302101|NCT00750308|DRUG|Tadalafil|tadalafil 10 mg every other day for three weeks
224302102|NCT00750308|DRUG|placebo|placebo matching ramipril
224152756|NCT06054438|OTHER|Chinese medicine nutritional supplement Cs4|Cs4 will be provided by Chinese Pharm, produced by GMP standard manufacturing. The intervention will be given according to the product instruction. Each capsule is 0.4g. According to the product sheet, adults should take 3-4 capsules daily as a way to nourish and strengthen the lungs and kidneys. In our study, the participants are people with long-COVID symptoms. Therefore, in order to achieve maximum efficacy, we will follow the directions and let participants take the maximum amount allowed by the product which is 4 capsules daily. Participants will take one capsule (each 400mg) 4 times a day, for a total of 1.6g. Treatment will last 12 weeks.
224152757|NCT03561168|DIAGNOSTIC_TEST|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
224152758|NCT01666860|PROCEDURE|Anterior Lumbar Interbody Fusion procedure|
224152759|NCT05210972|RADIATION|Cardiac catheterization|All the study population will be exposed to diagnostic coronary angiography and invasive coronary intervention as per standard guidelines.
224152760|NCT04523467|DRUG|Anti-angiogenic Targeted Drugs|A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
224152761|NCT04523467|DRUG|Ginsenoside Rg3|An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
224152762|NCT04523467|PROCEDURE|TACE|A specific type of chemoembolization that blocks the hepatic artery to treat liver cancer
224152763|NCT03373344|BEHAVIORAL|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
224152764|NCT03373344|BEHAVIORAL|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
224152765|NCT01522768|DRUG|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m\^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
224152766|NCT02731976|OTHER|Dietary intervention|
224152767|NCT01408134|OTHER|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
224152768|NCT01150760|DRUG|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
224152769|NCT00051090|DRUG|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
224152770|NCT00051090|DRUG|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
224152771|NCT00051090|DRUG|Efavirenz|Administered orally at a daily dose of 600 mg
224152772|NCT00051090|DRUG|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
224152773|NCT00051090|DRUG|Abacavir|Administered orally twice daily in doses of 300 mg
224152774|NCT03242304|OTHER|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
224152775|NCT01126502|DRUG|alvespimycin hydrochloride|Given IV
224152776|NCT01126502|OTHER|diagnostic laboratory biomarker analysis|
224152777|NCT01126502|OTHER|pharmacogenomic studies|
224152778|NCT01126502|OTHER|pharmacological study|
224152779|NCT01851863|DRUG|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
224152780|NCT01851863|DRUG|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
224152781|NCT01851863|DRUG|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
224152782|NCT01851863|DRUG|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
224152783|NCT02347852|DRUG|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
224152784|NCT03198104|DEVICE|MRI|
224152785|NCT01761994|DRUG|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
224152786|NCT04513405|DIAGNOSTIC_TEST|Blood sampling|"a peripheral venous blood sample will be analyzed to measure the levels of estrone and estradiol.~The sample of the blood sample will be deposited in the red cap tube with a polymeric gel."
224302103|NCT00750308|DRUG|placebo|placebo matching tadalafil
224152787|NCT04513405|PROCEDURE|Shave Biopsy|in the tissues, of the related estrogenic receptors, estrogen α receptors, estrogen β receptors (ER- α, ER-β) and G protein-coupled estrogen receptor 1 (GPER) correlates with the functional status of these receptors
223456010|NCT02245815|DIETARY_SUPPLEMENT|use probiotics Multi-species|Group B was administered multi-species probiotic (1x10⁹colonies forming units (UFC) per day for 3 weeks). The diagnosis of (NEC) was made using the Bell criteria by the attending physician. Gastric tolerance was measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) was measured at the beginning and at the end of treatment.
223456011|NCT01919164|DRUG|Sprifermin|Participants received Sprifermin as intra-articular injection.
223456012|NCT01919164|DRUG|Placebo|Participants received Placebo matched to sprifermin as intra-articular injection.
223456013|NCT00458315|DRUG|Cisplatin|
223456014|NCT00458315|DRUG|Paclitaxel|
223456015|NCT00458315|DRUG|Gemcitabine|
223456016|NCT00458315|DRUG|Avastin (Bevacizumab)|
223456017|NCT01736735|DRUG|CLP|
223456018|NCT01736735|DRUG|placebo|
223456019|NCT01398852|DRUG|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
223456020|NCT01398852|DEVICE|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
224152788|NCT03183960|BEHAVIORAL|Mentor|Traditional rehabilitation.
224152789|NCT00558740|OTHER|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
224152790|NCT05059847|OTHER|Training|Training routine assigned by randomized chart
224152791|NCT02713945|DRUG|Simvastatin|Experimental drug administrated orally
224152792|NCT02713945|DRUG|Placebo|Treatment for the control group
224152793|NCT04546867|DIAGNOSTIC_TEST|Sonographic based visualization of a pancreatic stent|As described above. All patients start with an ultasound-based approach to visualize pancreatic stents position. Depending on the findings, x-ray will be performed if no stent is visualized in the pancreatic duct or an esophagogastroduodenoscopy will be performed to remove the pancreatic stent and confirm sonographic findings if the pancreatic stent is displayed in situ.
224152794|NCT04992377|DRUG|R-EPOCH in Combination With Ibrutinib|"Induction:~(21-day per cycle) Ibrutinib:420mg given orally , once daily.~Details of R-DA-EPOCH are as follows:~Rituximab: 375 mg/m2 given intravenously (IV) on day 0 Etoposide: 50 mg/m2 given CIV from day 1-4 Doxorubicin: 10 mg/m2 given CIV from day 1-4 Vincristine: 0.4 mg/m2 given CIV from day 1-4 Cyclophosphamide: 750 mg/m2/day IV on day 5 Prednisone: 60 mg/m2 given orally bid on days 1-5. Patients who achieve CR after 4 cycles enter the consolidation treatment ; Patients with PR after 4 cycles would receive another 2 cycles of R-EPOCH + ibrutinib induction therapy, they could enter the consolidation treatment if they achieve CR ,withdrawn from the study if they achieve ≤ PR; Patients with SD/PD after 4 cycles of treatment are withdrawn from the study.~Consolidation:~2 cycles of R-EPOCH + Ibrutinib (dose as before) treatment~Maintenance:~Ibrutinib 420 mg/day for 24 months or until disease progression or intolerable toxicity"
224152795|NCT04738604|OTHER|Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany|The prepared cavities will be restored with Ceram•X (Dentsply De Trey GmbH, Konstanz, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 20 seconds according to manufacturer's instructions.
224152796|NCT04738604|OTHER|Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany)|The prepared cavities will be restored with Zenit Nano Ceramic Composite (PRESIDENT DENTAL, GmbH, Munich, Germany) with incremental placement technique (maximum: 2-mm layer). Increments will be light curing for 40 seconds according to manufacturer's instructions.
224152797|NCT04259060|DRUG|Hydroxocobalamin with Butyrate|"In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2."
224152798|NCT04259060|DRUG|Placebo with Butyrate|"In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day."
224302104|NCT05120102|DEVICE|Diode laser|K2 diode laser of 980nm wavelength
223456021|NCT04074434|DEVICE|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
223456022|NCT01010737|BIOLOGICAL|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
223456023|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
223456024|NCT01010737|BIOLOGICAL|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
223456025|NCT01010737|BIOLOGICAL|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
223456026|NCT01010737|BIOLOGICAL|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
223456027|NCT01010737|BIOLOGICAL|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
223456028|NCT01010737|BIOLOGICAL|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
223456029|NCT00435110|PROCEDURE|standard ventilatory settings|
223456030|NCT00435110|PROCEDURE|PEEP and FiO2|
223456031|NCT03531723|OTHER|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
223456032|NCT04052607|DRUG|LH Suppression|Stimulation protocols
224152799|NCT05381675|OTHER|Tele-rehabillitation|"Tele-rehabilitation program will be performed by physiotherapist two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
224152800|NCT05381675|OTHER|Prescribed Exercise Program|"The prescribed exercise program will be performed two times a week for six consecutive weeks. Program including the following exercises:~Breathing exercises Aerobic exercises Flexibility Strengthening exercises"
224152801|NCT02158455|PROCEDURE|NT SVG grafts|
224152802|NCT03121456|OTHER|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
224152803|NCT03121456|OTHER|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
224152804|NCT03238352|DEVICE|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
224152805|NCT03238352|DRUG|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
224152806|NCT03238352|OTHER|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
224152807|NCT02805062|PROCEDURE|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
224152808|NCT02805062|PROCEDURE|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
224152809|NCT03713424|DRUG|Clavulanic Acid|Beta lactamase inhibitor for smoking cessation
224152810|NCT03713424|DRUG|Placebo oral capsule|placebo
224152811|NCT05839639|DRUG|NrtIs|Subjects will receive NrtIs therapy for 24 weeks.
224152812|NCT05839639|DRUG|HH-003|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks.
224152813|NCT05839639|DRUG|HH-003+NrtIs|Subjects will receive HH-003 20 mg/kg intravenously Q2W for 24 weeks. Subjects will receive NrtIs therapy for 24 weeks.
224152814|NCT00928512|DRUG|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
224152815|NCT00928512|DRUG|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
224152816|NCT04153929|DRUG|BI 456906|Solution for Injection
224152817|NCT04153929|DRUG|Placebo|Solution for Injection
224152818|NCT04153929|DRUG|Semaglutide|Solution for Injection
224152819|NCT01963780|DEVICE|OCS Lung Preservation|
224152820|NCT00493480|DRUG|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
224152821|NCT00493480|DRUG|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
224152822|NCT00086294|DRUG|Intravenous Levodopa|
224152823|NCT00086294|DRUG|ACP-103|
224152824|NCT06238011|DRUG|Dexmedetomidine|Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
224152825|NCT06238011|DRUG|Normal saline|Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
224152826|NCT02732223|DIETARY_SUPPLEMENT|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
224152827|NCT02732223|DIETARY_SUPPLEMENT|Control treatment|placebo supplements
224152828|NCT06122753|PROCEDURE|preemptive TIPS|The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
224152829|NCT06122753|PROCEDURE|standard second prophylaxis|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
224152830|NCT01060683|BIOLOGICAL|Hemoglobin determination + NaCl 0.9% bolus|
224152831|NCT01060683|BIOLOGICAL|hemoglobin determination + Venofundin bolus|
224152832|NCT04083794|OTHER|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
224152833|NCT01894867|DIETARY_SUPPLEMENT|magnesium|supply magnesium oxide for 6 weeks
224152834|NCT01894867|DIETARY_SUPPLEMENT|Placebo|
224152835|NCT03383614|DRUG|LSF emodepside (BAY 44-4400) or matching placebo|Emodepside administered as an LSF oral solution (1mg/mL)
224152836|NCT01170949|DRUG|Miltefosine|50 or 100 or 150mg per day
224152837|NCT01170949|DRUG|Placebo|Placebo
224152838|NCT05621018|DEVICE|Maze Out|Play for 15 weeks, at list once a week the serious game: Maze Out
224152839|NCT02801006|DEVICE|stenfilcon A|contact lens
224152840|NCT02801006|DEVICE|etafilcon A|contact lens
224152841|NCT01997697|OTHER|behavior change program|behavior change program among patients with obesity
224152842|NCT02971293|DRUG|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
224152843|NCT02971293|DRUG|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
223456033|NCT00532909|DRUG|Vandetanib|100mg or 300mg By mouth every day continuous
224152844|NCT02971293|DRUG|Placebo|The subject will receive Placebo single dose DPI.
224152845|NCT03104985|DEVICE|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
224152846|NCT03104985|OTHER|Conventional therapy|"* An elastic compression of lower extremities,~* Pharmacotherapy,~* Topical treatment"
224152847|NCT00729326|DRUG|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
224152848|NCT00729326|DRUG|sitagliptin|oral administration (100mg), once a day in the morning
224152849|NCT00729326|DRUG|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
224152850|NCT00729326|DRUG|placebo|oral administration (100mg), once a day in the morning
224152851|NCT00567957|DRUG|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
224152852|NCT00567957|DRUG|Saline|same volume iv bolus before induction followed by same volume infusion
224152853|NCT05189704|DRUG|NSAID|NSAID based patient-controlled analgesia will connected to intravenous line for pain control.
224152854|NCT05189704|DRUG|Opioid|Opioid based patient-controlled analgesia will connected to intravenous line for pain control.
224152855|NCT02793089|OTHER|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
224152856|NCT03538275|OTHER|Monitoring test|Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
224152857|NCT01876394|OTHER|Coconut Oil|Shake with 50 g Coconut oil
224152858|NCT01876394|OTHER|Canola Oil|Shake with 50 g Canola oil
224152859|NCT01876394|OTHER|Grapeseed Oil|Shake with 50 g Grapeseed oil
224152860|NCT01876394|OTHER|Chia Oil|Shake with 50 g Chia oil
224152861|NCT01876394|OTHER|Butter|Shake with 50 g Butter
224152862|NCT04101760|DRUG|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
224152863|NCT04101760|DRUG|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
224152864|NCT05124340|BIOLOGICAL|BCG vial vaccine|Intradermal injection
224152865|NCT05124340|BIOLOGICAL|BCG ampoule vaccine|Intradermal injection
224152866|NCT03520725|OTHER|No Intervention|This gruop did not have an intervention
224152867|NCT03520725|DIETARY_SUPPLEMENT|Pineapple snack bar|30 g daily of pineapple snack bar
224152868|NCT03520725|DIETARY_SUPPLEMENT|Mango snack bar|30 g daily of mango snack bar
224152869|NCT03340311|DEVICE|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
224152870|NCT01202760|DRUG|LY2127399|
224152871|NCT01202760|DRUG|Placebo|
224152872|NCT04227392|DEVICE|vaginal radiofrequency|2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
224152873|NCT00549510|DRUG|COREG CR and lisinopril (FDC)|
224152874|NCT06067282|OTHER|Microteaching|"This program selects five kinds of core teaching skills for training, and the training program is extracted in Microteaching ."
224152875|NCT02483689|DRUG|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
223456034|NCT00532909|DRUG|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
223456035|NCT00532909|DRUG|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
223456036|NCT00532909|DRUG|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
224152876|NCT02483689|OTHER|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
224152877|NCT02483689|DRUG|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
224152878|NCT02483689|OTHER|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
224152879|NCT03018457|DEVICE|ISQ|Measured by Osstell.
224152880|NCT03043729|DRUG|Oxaliplatin|Oxaliplatin 85 mg/m\^2, as 2h infusion on Day 1 (Arm A + Arm B)
223456037|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
223456038|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
223456039|NCT01686945|DRUG|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
223456040|NCT01686945|DRUG|placebo|Placebo semaglutide. For oral administration.
224152881|NCT03043729|DRUG|5-FU|5-FU 400 mg/m\^2 i.v. as bolus on Day 1 and 2400 mg/m\^2 as 46 h infusion q2w (Arm A + Arm B)
224152882|NCT03043729|DRUG|Leucovorin|Leucovorin 350 mg/m\^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
224152883|NCT03043729|BIOLOGICAL|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
224152884|NCT00871572|DRUG|LY2409021|4 capsules by mouth taken once daily for 12 weeks
224152885|NCT00871572|DRUG|Placebo|4 capsules by mouth once daily for 12 weeks
224152886|NCT03788187|OTHER|Blood test sample|
224152887|NCT03788187|OTHER|Peritumoral adipose tissue sample|
224152888|NCT01577199|DRUG|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
224152889|NCT01577199|DRUG|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
224152890|NCT02026206|DEVICE|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
224152891|NCT02026206|DEVICE|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
224152892|NCT00830570|OTHER|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
224152893|NCT04783285|BEHAVIORAL|Individual cognitive stimulation therapy (iCST)|The intervention group will receive 32 individual CS sessions per participant. Each session will last approximately 45 minutes and will have the following structure: session introduction (5 minutes); reality orientation (10 minutes); stimulation of cognitive domain (25 minutes); session closure (5 minutes). The sessions will be led by a previously trained therapist. The intervention program will include several activities based on the principles of CS and adjusted for participants with psychotic disorders.
224152894|NCT00735670|DRUG|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
224152895|NCT00735670|OTHER|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
224152896|NCT05713578|DRUG|apantamide+docetaxel+ADT|Apantamide, 240 mg (4 × 60 mg tablets), once a day, orally; ADT regimen was treated with gonadotropin releasing hormone analog (GnRHa), including GnRHa agonist or GnRHa antagonist. The type, frequency and dose of ADT to be used in each research center are determined by the investigator; The treatment of docetaxel was started within 6 weeks after the treatment of apantamide and ADT. The single dose of docetaxel was 75 mg/m2, intravenous drip for 1 hour, repeated every 3 weeks, and docetaxel lasted for 6 cycles.
224152897|NCT05713578|DRUG|apantamide+ADT treatment|apantamide+ADT treatment
224152898|NCT02828007|DEVICE|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
224152899|NCT04354155|DRUG|Enoxaparin Prefilled Syringe [Lovenox]|Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
224152900|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 alone
224152901|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
224152902|NCT05608148|BIOLOGICAL|Biological|Intravenous injection of GAIA-102 with nivolumab combination
224152903|NCT03679429|DEVICE|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
224152904|NCT00187889|DRUG|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
224152905|NCT00187889|DRUG|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
224152906|NCT06299813|DRUG|Bentelan|The experimental treatment group will be administered betamethasone 0.1 mg per kg.
224152907|NCT06299813|DRUG|Placebo|The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
224152908|NCT00036543|DRUG|Atrasentan|
224152909|NCT04572581|OTHER|Donor Breast Milk|Donor breast milk will be given to the newborn if supplementation is required
224152910|NCT04197986|DRUG|Infigratinib|Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
224152911|NCT04197986|DRUG|Placebo|Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.
224152912|NCT05693038|DIAGNOSTIC_TEST|Electromyography|Electromyography (EMG) monitoring will be performed, using the instrumentation available (Nemus 2, EB Neuro, Italy), to evaluate the occurrence of brachial plexus injury (BPI). EMG will be performed at the end of each pronation cycle. To rule out BPI at ICU admission, an EMG will be performed within two hours from the first pronation maneuver. Particularly, somatosensory evoked potential (SSEP) and sensory action potential (SAP) will be obtained from radial, ulnar, median and sural nerves. In case patients are awake, compound muscle action potential (CMAP) will be obtained as well.
224152913|NCT05693038|DIAGNOSTIC_TEST|Muscle strength measurement|Muscle strength measure willl be assessed at ICU discharge using hand-held dynamometer.
224152914|NCT00979680|RADIATION|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
224152915|NCT00979680|RADIATION|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
224152916|NCT04248062|OTHER|Survey|Survey: 38 preselected patient and parent reported outcomes; rating scale: 9 point likert scale (1=not at all important - 9=very important)
224152917|NCT06303492|PROCEDURE|GUS|Aspiration risk assessment by GUS
224152918|NCT03380624|DRUG|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
224152919|NCT03380624|DRUG|Refresh Optive MEGA-3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
224302105|NCT03035552|BEHAVIORAL|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
224302106|NCT01679587|DRUG|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
224302107|NCT01679587|DRUG|Placebo|Single oral dose of matching placebo will be given in each treatment arm
224152920|NCT02576015|PROCEDURE|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
224152921|NCT02576015|PROCEDURE|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G\*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher \&Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
224152922|NCT02576015|DRUG|lidocaine|
224152923|NCT02576015|DEVICE|ultrasound|
224152924|NCT02576015|DEVICE|insulated needle (Contiplex B Braun, Melsungen, Germany)|
224152925|NCT02576015|DRUG|ropivacaine|
224152926|NCT02576015|DRUG|saline|
224152927|NCT00108797|DRUG|eptacog alfa (activated)|
224152928|NCT00108797|DRUG|Feiba VH|
224152929|NCT02650297|OTHER|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
224152930|NCT02650297|DEVICE|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
224152931|NCT05750420|OTHER|There was no intervention, the study was a cross-sectional observational study|Questionnaires for measuring self-care, anxiety, depression, emotinal distress and quality of live were administered to patients with chronic cardiovascular disease
224152932|NCT04953065|OTHER|COVID-19 vaccine hesitancy and acceptance survey|Participants will be provided with a COVID-19 vaccine hesitancy and acceptance survey developed by the study team.
224152933|NCT02557854|DRUG|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
224152934|NCT02557854|DEVICE|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
224152935|NCT04994080|DRUG|Paricalcitol|Paricalcitol QD Treatment
224302108|NCT02169349|OTHER|laboratory biomarker analysis|
223572572|NCT05797532|OTHER|skin to skin contact|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
223742996|NCT02192918|BEHAVIORAL|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
224152936|NCT04994080|DRUG|Placebo|Placebo QD or TIW
224152937|NCT03891394|DIAGNOSTIC_TEST|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
224152938|NCT02027922|OTHER|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
224152939|NCT01207817|OTHER|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
224152940|NCT05983835|PROCEDURE|Patients receive subsegmentectomy|Patients receive lobectomy
224152941|NCT02389686|DEVICE|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
224152942|NCT03134924|BEHAVIORAL|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
224152943|NCT03134924|BEHAVIORAL|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
224152944|NCT02374034|OTHER|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
224152945|NCT03199638|DRUG|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
224302109|NCT02169349|OTHER|Next Generation Sequencing|
224302110|NCT02169349|GENETIC|DNA Analysis|
224152946|NCT03199638|BEHAVIORAL|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
224152947|NCT02584413|DEVICE|Magnetic resonance imaging|-Standard of care
224152948|NCT02584413|DRUG|Gadolinium contrast|-Standard of care
224152949|NCT02543502|PROCEDURE|periodontal treatment|treatment of periodontal cleaning
224152950|NCT06100549|OTHER|No intervention|No intervention will be provided.
224152951|NCT01597011|PROCEDURE|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
224152952|NCT01597011|PROCEDURE|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
224152953|NCT03226561|PROCEDURE|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
224152954|NCT01042951|BIOLOGICAL|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
224152955|NCT01042951|OTHER|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
224152956|NCT01237028|DRUG|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
224152957|NCT06187311|DRUG|Rivaroxaban 20 MG|Subjects should take clinical trial drugs (20 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
224152958|NCT06187311|DRUG|Rivaroxaban 15 MG|Subjects should take clinical trial drugs (15 mg of rivaroxaban) for each group of administration once a day for 12 months, according to random assignments.
224152959|NCT04480931|BEHAVIORAL|mHealth Intervention Group|Access to the mobile health application with exercise plans and education
224152960|NCT04480931|BEHAVIORAL|Educational Brochure|An evidence-based educational brochure with general information about the benefits of physical activity during pregnancy
224152961|NCT06580860|DRUG|Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids|Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
224152962|NCT03097029|DRUG|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
224152963|NCT04278482|DIETARY_SUPPLEMENT|Dietary supplement, DHA or Placebo|Consumption of 2 capsules per day of the dietary supplement, DHA or Placebo
224152964|NCT02166229|DRUG|Divalproex sodium|
224152965|NCT02807844|DRUG|MCS110|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
224152966|NCT02807844|DRUG|PDR001|MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
224152967|NCT06236230|DRUG|levodopa/carbidopa/entacapone|"On Day 1, subjects will be treated with levodopa/carbidopa/entacapone. Based on previous regimen. The dosage of levodopa/carbidopa/entacapone will be equal to the previous total daily dose of LD, and the frequency of administration of levodopa/carbidopa/entacapone is three or four times a day.~Levodopa/carbidopa/entacapone could be titrated in next 2 weeks according to the investigator's judgment, based on individual clinical response and tolerability.~After 2-week titration, the dose of levodopa/carbidopa/entacapone will remain as constant as possible to the end of study."
224152968|NCT02238548|BIOLOGICAL|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
224152969|NCT02238548|OTHER|Raw milk|
224152970|NCT00411086|BIOLOGICAL|Rituximab|375 mg/m\^2 By Vein Weekly on Days 1, 8, 15, and 22.
224152971|NCT00411086|BIOLOGICAL|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
224152972|NCT05752786|BEHAVIORAL|"Eat Less Meat Challenge"|Participants will be able to choose their goal for the challenge for one month: (i) no meat, (ii) meat 3 times a week, (iii) meat 6 times a week (which will need to be lower than current consumption). The first day of the challenge, the participants will receive by email a cookbook and a starter kit with advices and motivational tips, then they will receive an email each week with more advices and motivational tips. Participants will be also asked to follow the Instagram account of the challenge during one month where (i) one post will be posted each day, (ii) engaging stories requiring interactions will be posted regularly, (iii) participants can ask their questions to the research team, (iv) participants can interact with each other's. The Instagram posts will cover three main topics: (i) knowledge about meat and its impact on health and environment, (ii) tips for meat-free cooking, (iii) social/contextual pressure to eat meat and how to avoid it.
224152973|NCT03323996|OTHER|Semi-Structured interviews|individual semi-structured interviews
224152974|NCT00709124|DEVICE|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
224152975|NCT00709124|DEVICE|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
224152976|NCT02758223|BIOLOGICAL|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
224152977|NCT03490435|DIAGNOSTIC_TEST|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~1. fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~2. A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
224152978|NCT00373490|DRUG|Vorinostat|600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
224152979|NCT00373490|DRUG|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
224152980|NCT01669642|DRUG|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
224152981|NCT02437552|DEVICE|ergometer cycle exercise|
224152982|NCT02437552|OTHER|routine physiotherapy|routine physiotherapy
224152983|NCT00108953|DRUG|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
224152984|NCT00108953|DRUG|Doxorubicin/Placebo|Chemotherapy plus Placebo
224152985|NCT03443609|DIAGNOSTIC_TEST|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
224152986|NCT05149612|OTHER|Heat Therapy|Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
224152987|NCT05793216|BEHAVIORAL|VestibulOTherapy|"For this study, the following activity-orientated interventions will occur within the natural learning environments so that generous opportunities exist for neural plasticity and growth.~Each student will be engaged in 20-30 minutes/day of intermittent classroom activities, plus 20-30- minutes of daily stability work embedded into classroom routines including stabilizing self on a Hokki stool or t-stool or standing on a balance board during sedentary work, such as circle time or read-a-loud."
224152988|NCT05035095|DRUG|Oral semaglutide|Participants will receive a daily dose of oral semaglutide.
224152989|NCT05035095|DRUG|Placebo (semaglutide)|Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
224302111|NCT03143478|DEVICE|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
224302112|NCT02274207|DEVICE|NPWT application|NPWT mode is cyclic mode : -125\~-50 mmHg
224302113|NCT00399971|PROCEDURE|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
224302114|NCT00399971|DRUG|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
224302115|NCT03875937|DRUG|Tranexamic 1 gram|To be administered intramuscularly (2 injections)
224302116|NCT02218112|PROCEDURE|bariatric surgery (gastric bypass)|
224302117|NCT01921491|PROCEDURE|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
224302118|NCT01921491|DEVICE|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
224302119|NCT04882319|DRUG|HP-5000 Topical Patch|HP-5000, placebo and saline will be administered simultaneously
224302120|NCT04882319|DRUG|HP-5000 Placebo Patch|HP-5000, placebo and saline will be administered simultaneously
224302121|NCT04882319|DRUG|Saline Patch|HP-5000, placebo and saline will be administered simultaneously
224302122|NCT00281476|DRUG|Simvastatine|
224302123|NCT02196740|DRUG|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
224302124|NCT02196740|DRUG|creosote|Pulp removal,Root canal irrigation and disinfection
224152990|NCT03934424|BEHAVIORAL|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
224152991|NCT03934424|BEHAVIORAL|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
224152992|NCT04503941|DEVICE|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
224302125|NCT03797820|OTHER|Our study type is observational|Our study type is observational
224302126|NCT00513682|DRUG|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
224302127|NCT02941276|DEVICE|Active Electrostimulator device|Patients who will receive a fully functioning device
224302128|NCT02941276|DEVICE|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
224302129|NCT03316326|DRUG|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
224302130|NCT03316326|DRUG|Oxaliplatin|85 mg/m2, D1
224302131|NCT03316326|DRUG|Irinotecan|150 mg/m2, D8
223456041|NCT01686945|DRUG|placebo|Placebo semaglutide with carrier. For oral administration.
224302132|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
224302133|NCT02450526|BIOLOGICAL|Botulinum toxin type A|
224302134|NCT02450526|DRUG|Placebo|50 Units
224302135|NCT02450526|DRUG|Placebo|20 Units
224302136|NCT01468376|DIETARY_SUPPLEMENT|GLU-01|14 day dosing
224302137|NCT01468376|DIETARY_SUPPLEMENT|GLU-02|14 day dosing
224302138|NCT01468376|DIETARY_SUPPLEMENT|GLU-03|14 day dosing
224152993|NCT04503941|DEVICE|False Needle treatment|False Needle treatment treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
224152994|NCT01860963|PROCEDURE|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
224152995|NCT02986919|DRUG|CPI-0610|"* Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
224152996|NCT00702910|DRUG|Placebo|comparator
224152997|NCT00702910|DRUG|GW642444|investigational drug or placebo
223742997|NCT02192918|BEHAVIORAL|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
224152998|NCT00702910|DRUG|Magnesium Stearate|Magnesium Stearate
224152999|NCT00306241|BIOLOGICAL|HPV-16/18 L1 VLP AS04|
224153000|NCT03775590|PROCEDURE|Water|To evaluate using water in the treatment of atopic dermatitis
224153001|NCT03775590|PROCEDURE|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
224153002|NCT03775590|PROCEDURE|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
224153003|NCT00516984|PROCEDURE|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
224153004|NCT00516984|PROCEDURE|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
224153005|NCT00516984|PROCEDURE|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
224153006|NCT01154881|DRUG|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
224153007|NCT04818541|DEVICE|PPCI|Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
224153008|NCT04818541|DEVICE|Cardiogenic shock|Closure of the femoral access site with PerQseal device after removal of the Impella pump.
224153009|NCT01027013|DRUG|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
224153010|NCT01027013|DRUG|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
224153011|NCT00992602|DRUG|methotrexate|Given IV
224153012|NCT00992602|DRUG|liposomal cytarabine|Given IT or via LP
224153013|NCT00992602|OTHER|quality-of-life assessment|Ancillary studies
224153014|NCT00992602|OTHER|laboratory biomarker analysis|Correlative studies
224153015|NCT00003203|BIOLOGICAL|filgrastim|Given IV
224153016|NCT00003203|DRUG|carboplatin|Given IV
224153017|NCT00003203|DRUG|cisplatin|Given IV
224153018|NCT00003203|DRUG|cyclophosphamide|Given IV
224153019|NCT00003203|DRUG|vincristine sulfate|Given IV
224153020|NCT00003203|PROCEDURE|adjuvant therapy|
224153021|NCT00003203|RADIATION|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT\*
224153022|NCT00210379|DRUG|rituximab|
224153023|NCT00210379|DRUG|CHOP|
224153024|NCT00210379|DRUG|intrathecal methotrexate|
224153025|NCT00210379|PROCEDURE|radiotherapy|
224153026|NCT05400356|PROCEDURE|On-pump valve surgery or CABG|On-pump valve surgery or coronary arterial bypass grafting
224153027|NCT00004685|DRUG|albuterol|
224153028|NCT01854593|DRUG|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
224153029|NCT01854593|PROCEDURE|Vitrectomy|vitrectomy of 25 gauge system.
224153030|NCT01854593|DEVICE|Sham injection|Sham injection one day before vitrectomy
224153031|NCT03694054|OTHER|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
224153032|NCT00347893|PROCEDURE|Selective laser trabeculoplasty|
224153033|NCT00476177|BIOLOGICAL|Infusion of donor dendritic cells|Given in the outpatient setting
224153034|NCT00476177|BIOLOGICAL|Infusion of donor lymphocytes|Given in outpatient setting
224153035|NCT02629614|DEVICE|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
224153036|NCT03256071|DRUG|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
224153037|NCT03256071|DRUG|Modified BUCY|"1. Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~2. Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~3. Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
224153038|NCT01331720|DRUG|hMG-HP|
224153039|NCT05445882|DRUG|Bintrafusp alfa|Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
224153040|NCT05445882|DRUG|N-803|N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
224302139|NCT01468376|DIETARY_SUPPLEMENT|GLU-04|14 day dosing
224302140|NCT01468376|DIETARY_SUPPLEMENT|GLU-05|14 day dosing
224302141|NCT01468376|DIETARY_SUPPLEMENT|GLU-06|14 day dosing
224153041|NCT05445882|BIOLOGICAL|BN-Brachyury|BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
224153042|NCT04695548|OTHER|Concentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder against the resistance of the elastic band, slowly and for 5 seconds
224153043|NCT04695548|OTHER|Isometric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of raising the shoulder and maintaining the tension of the elastic band for 5 seconds
224153044|NCT04695548|OTHER|Eccentric contraction exercise|The participant will be placed in a standing position, with the shoulders positioned in the scapular plane. A medium stiffness Theraband elastic band will be placed between the participant's ipsilateral foot on the side on which the dry needling technique was applied and the acromio-clavicular joint on the same side.The exercise will consist of asking the participant to lower their shoulder, against the resistance of the elastic band, in a slow and controlled manner for 5 seconds.
224153045|NCT04695548|OTHER|Analytic passive stretching|The patient remains supine position. The analytical passive stretch of the upper trapezius will be performed only once, bringing the muscle to the limit of elastic tension perceived by the subject. The passive stretching technique will be held for 30 seconds.
224153046|NCT04132648|DRUG|Curcumin|Oral supplement one time at 2,000 mg
224153047|NCT04132648|OTHER|Placebo|Oral supplement one time at 2,000 mg
224153048|NCT02522572|DRUG|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
224153049|NCT02522572|DRUG|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
224153050|NCT02522572|OTHER|plasmapheresis|Plasmapheresis will be administered based on group assignment.
224153051|NCT01948869|DEVICE|Phoenix II (BAY81-2996)|
224302142|NCT03992794|DIAGNOSTIC_TEST|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
224302143|NCT05010044|BEHAVIORAL|mindfulness-based cognitive therapy (MBCT)|Mindfulness- Based Cognitive Therapy (MBCT) It involves practicing to be present 'in the moment' and an attitude of non- judgmental acceptance with the aim to maintain awareness, disengaging oneself from strong attachment and thereby developing a greater sense of emotional balance and well-being.
224302144|NCT05010044|OTHER|Antipsoriatic treatment|The routine drug therapy for psoriasis.
224302145|NCT05303376|BIOLOGICAL|IBIO123|5 or 10 mg
224302146|NCT05303376|OTHER|Placebo|matching placebo
224302147|NCT04298060|DRUG|DAS181|SD (4.5mg/day), HD (9mg/day)
224302148|NCT04298060|DRUG|Placebo|Placebo 0mg/day
224302149|NCT02024373|DRUG|Atorvastatin|20 mg (every evening orally) for 8 weeks
224302150|NCT02024373|DRUG|placebo|20 mg (every evening orally) for 8 weeks
224302151|NCT00429520|DRUG|Hyaluronic acid filler/IMD1 basic|
224302152|NCT05282979|DEVICE|Tixel 2|Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
224302153|NCT00539357|DEVICE|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
224302154|NCT01197430|OTHER|exercise training|
224302155|NCT00093002|DRUG|Fulvestrant|250 mg \& 500 mg intramuscular injection
224302156|NCT00502801|DRUG|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
224302157|NCT00561314|OTHER|questionnaire administration|
224302158|NCT00561314|PROCEDURE|biopsy|
224302159|NCT00561314|PROCEDURE|high-intensity focused ultrasound ablation|
224302160|NCT00561314|PROCEDURE|magnetic resonance imaging|
224302161|NCT00561314|PROCEDURE|quality-of-life assessment|
223456042|NCT00588146|DRUG|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
223456043|NCT00588146|OTHER|Standard care|Standard care
224302162|NCT03095573|DEVICE|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
223456044|NCT00302536|DRUG|Tacrolimus|Tacrolimus
223456045|NCT03902093|DIAGNOSTIC_TEST|Morphology changes with extended wear hearing aid|Possible changes in morphology due to wearing an extended wear hearing aid device will be assessed with imaging
224302163|NCT03095573|DEVICE|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
224302164|NCT02516904|DRUG|CD101 IV|antifungal
224302165|NCT02516904|DRUG|Placebo|normal saline
224302166|NCT01565616|DRUG|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
224153052|NCT01948869|DEVICE|Phoenix I (BAY81-2996)|
224153053|NCT00574444|PROCEDURE|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
224153054|NCT04237818|DIETARY_SUPPLEMENT|Placebo drink|consume 2 bottle (30 mL) per day for 56 days
224153055|NCT04237818|DIETARY_SUPPLEMENT|Chenopodium Formosanum and Fagopyrum Esculentum Extract drink|consume 2 bottle (30 mL) per day for 56 days
224153056|NCT05706649|BEHAVIORAL|Plant-based diet|21 day diet that excludes any form of meat and other animal products, including dairy products.
224153057|NCT02999100|DRUG|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
224153058|NCT02999100|DRUG|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
224153059|NCT02999100|DRUG|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
224153060|NCT02999100|DEVICE|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
224153061|NCT00373100|DRUG|Zinc acetate|
224153062|NCT00373100|DRUG|Placebo|Placebo
224153063|NCT02818127|PROCEDURE|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
224153064|NCT05666882|OTHER|Non-interventional|Non-interventional
224153065|NCT00265967|DRUG|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
224153066|NCT01385267|PROCEDURE|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
224153067|NCT03697486|BEHAVIORAL|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
224153068|NCT01095341|OTHER|No intervention performed|
224153069|NCT04829266|BEHAVIORAL|mental simulation|Audio recordings with a mental simulation. The women listened to the text using headphones about 10-15 min before verticalization (5 h after arrival in the postoperative room, about 6 h after anesthesia). In each group, the mental training lasted for about 10 min.
224302167|NCT04705870|DEVICE|cerebral MRI|"MRI of routine care in the context of MS includes at least the following sequences:~* 3D T1 TFE (2 minutes)~* T2 TSE (2 minutes)~* 3D FLAIR (3 minutes)~* SWI EPI 0.6 iso (7 minutes)~The sequences added by the search are:~* SWI non EPI QSM 6 echo (10 minutes)~* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)~* SWI EPI to TR equivalent to SWI non EPI (6 minutes)"
224302168|NCT03149458|OTHER|dance|dance program
224302169|NCT03149458|OTHER|control|upper limb rehabilitation
224302170|NCT02452996|DRUG|GNbAC1|Single dose of IMP, IV infusion
224302171|NCT05241717|BEHAVIORAL|Web-based Management of Adolescent Pain (WebMAP)|Participants will be asked to complete one module per week, which are approximately 20 minutes in length. Survivors and parents will be asked to spend approximately 4.5 hours each over the course of the intervention on WebMAP including 4 hours to complete the modules and 30 minutes total corresponding with a coach. Each week, patients log into WebMAP to learn a new skill and practice that skill for 1 week to allow time for skills acquisition. WebMAP consists of two separate, password-protected programs including one for adolescents and one for parents (http://webmap2.com).
224302172|NCT02031016|DRUG|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
224302173|NCT02031016|DRUG|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
224302174|NCT02031016|DRUG|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
224302175|NCT02116699|OTHER|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
223456046|NCT02343367|BEHAVIORAL|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
224153070|NCT04709718|PROCEDURE|hepatectomy|liver resection taking over the liver hemangioma
224153071|NCT05883085|DRUG|Anlotinib hydrochloride|Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
224153072|NCT00457470|DRUG|AG-014699|
224153073|NCT01585493|OTHER|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
224153074|NCT01585493|BEHAVIORAL|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
224153075|NCT01585493|BEHAVIORAL|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
224153076|NCT01125293|DRUG|Everolimus|
224153077|NCT01125293|DRUG|Rituximab|
224153078|NCT01125293|DRUG|Bortezomib|
224153079|NCT03411668|OTHER|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
224153080|NCT03496727|PROCEDURE|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
224153081|NCT03496727|PROCEDURE|Patient controlled analgesia|Patient-controlled analgesia
224153082|NCT00703859|DRUG|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
224153083|NCT06196918|DRUG|Rivaroxaban 10 MG|Patients with postoperative lower extremity dyskinesia are treated with rivaroxaban (10 mg/day) and compression stockings until 1 month after surgery.
224153084|NCT06196918|DRUG|Placebo|Patients with postoperative lower extremity dyskinesia are treated with placebo (10 mg/day) and compression stockings until 1 month after surgery.
224153085|NCT02224638|DEVICE|TheraHoney HD|Honey
224153086|NCT02224638|DEVICE|SkinTegrity|Hydrogel
224153087|NCT04864678|OTHER|Referral to the Young People's Health Service immunisation nurse|Young people who have been referred to an immunisation nurse at the Young People's Health Service.
224153088|NCT00314080|DRUG|Botulinum AntiToxin|
224153089|NCT00314080|PROCEDURE|neuro-electrophysiologic study, repetitive nerve stimulation|
224153090|NCT00314080|PROCEDURE|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
224153091|NCT03928860|OTHER|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
224153092|NCT01367860|PROCEDURE|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
224153093|NCT01367860|PROCEDURE|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
224153094|NCT02436044|PROCEDURE|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
224153095|NCT02436044|DRUG|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
224153096|NCT02436044|DRUG|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
224153097|NCT02436044|DRUG|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
224153098|NCT03734562|PROCEDURE|Ablation|Substrate-based radiofrequency catheter ablation
224153099|NCT03734562|DRUG|Antiarrhythmic drug|Amiodarone or sotalol therapy
224153100|NCT02016222|PROCEDURE|tears sampling|
224153101|NCT02176304|DRUG|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
224153102|NCT02176304|DRUG|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
224153103|NCT00037544|DRUG|ReFacto AF|
224153104|NCT01270958|DRUG|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
224153105|NCT02467855|OTHER|No Intervention|No intervention was administered in this study.
224153106|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.
224153107|NCT03926338|DRUG|Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.
224153108|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.
224153109|NCT03926338|DRUG|Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
224153110|NCT03095404|DRUG|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
224153111|NCT03095404|DRUG|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
224153112|NCT05608330|OTHER|PETRUSHKA tool|In the experimental arm, the PETRUSHKA tool will automatically select the antidepressants that have the best profile in terms of efficacy and acceptability for each individual participant (based on their baseline demographic and clinical characteristics) and then ask the participant to provide their preferences about common (and non-serious) adverse events. Based on patient's preferences and their individual characteristics, the PETRUSHKA tool will then identify the three best antidepressants for the participant. The clinician and the participant will be presented with an overall recommendation (in the format of a pictogram) showing how strongly each antidepressant is recommended for that individual patient. Via a shared decision-making process, the participant and the clinician will then agree on which antidepressant to choose from the shortlist.
224153113|NCT05608330|OTHER|Usual Care|Any antidepressant prescribed by clinician based upon their clinical judgement.
224153114|NCT05129787|PROCEDURE|Surgical resection|Resection of metastasis
224153115|NCT05129787|PROCEDURE|Thermal ablation|Ablation of metastasis
224153116|NCT02348424|DRUG|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
224153117|NCT01477138|PROCEDURE|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
224153118|NCT04142515|OTHER|no intervention|no intervention
224153119|NCT04800471|DEVICE|Smart insulin pens and CGM|Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
224153120|NCT04800471|OTHER|Point of Care Glucose Group|Participants in this group will be monitored by POC glucose values.
224153121|NCT01369407|OTHER|No Intervention|Not an interventional study
224153122|NCT05419271|PROCEDURE|home hemodialysis session with 9L internal convection|home hemodialysis session with 9L internal convection
224153123|NCT06138028|DRUG|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）|TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
224153124|NCT03289871|DEVICE|Excilor|
224153125|NCT03289871|DRUG|Loceryl 5%|
224153126|NCT03482128|DEVICE|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
224153127|NCT03482128|DEVICE|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
223456047|NCT02343367|OTHER|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
224153128|NCT02481596|BEHAVIORAL|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
224153129|NCT02481596|BEHAVIORAL|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
223456048|NCT02343367|BEHAVIORAL|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
223456049|NCT02343367|BEHAVIORAL|Text messages|regularly scheduled cell phone text messages for 12 months
223456050|NCT02343367|BEHAVIORAL|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
224153130|NCT02481596|BEHAVIORAL|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
224153131|NCT01241955|BEHAVIORAL|video decision aid|video of CPR
224153132|NCT02722629|PROCEDURE|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
223456051|NCT02343367|BEHAVIORAL|Newsletters|12 monthly newsletters mailed to participant homes
223456052|NCT04756622|DRUG|N acetyl cysteine|N acetyl cysteine dissolved in water at a dose of 600 mg three times daily from day of transplant until neutrophil engraftment, or upon resolution of OM, whichever appears later.
223456053|NCT02100839|DRUG|AEM-28|Solution for injection
223456054|NCT02100839|DRUG|Normal Saline|0.9% saline for injection
224153133|NCT01779596|DRUG|Bosentan|
224153134|NCT01779596|DRUG|Placebo|
224153135|NCT00089102|DRUG|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
224153136|NCT00089102|DRUG|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
224153137|NCT04879784|OTHER|No intervention|No intervention
224153138|NCT04774614|PROCEDURE|anterior laminate veneers|VITA ENAMIC multiColor
224153139|NCT00003085|PROCEDURE|laparoscopy|
224153140|NCT00003085|PROCEDURE|ultrasound imaging|
223456055|NCT00018824|DRUG|NALTREXONE|
223456056|NCT00018824|DRUG|Placebo|
223456057|NCT06034197|DRUG|VGT-309|0.32mg/kg IV of VGT-309 given 12-36 hours before surgery
224153141|NCT04957680|BEHAVIORAL|CCBT|computer-based treatment program for depressed adolescents
224153142|NCT02140892|PROCEDURE|respiratory physical therapy manual technique- Autogenic Drainage|
224153143|NCT02140892|DEVICE|respiratory physical therapy technique- IPV|
224302176|NCT02116699|OTHER|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
224153144|NCT01462916|DIETARY_SUPPLEMENT|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control \[I/C\] and control to intervention \[C/I\] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
224153145|NCT06183736|DRUG|CVL237 tablets|CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
224153146|NCT04254055|OTHER|exercises|Those subjects included in the experimental group will receive an intervention through a program with plyometric, proprioceptive and strength exercises. The subjects included in the control group will not receive any intervention.
224153147|NCT00002908|DRUG|bryostatin 1|
224153148|NCT00002908|DRUG|vincristine sulfate|
224153149|NCT02790294|DEVICE|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
224153150|NCT01972594|PROCEDURE|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
224153151|NCT01972594|DEVICE|Accelerometer(ActivPAL)|
224153152|NCT05165550|DRUG|Elsulfavirine|Elsulfavirine (Elpida®) 20 mg capsules for oral administration
224153153|NCT03810521|BIOLOGICAL|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
224302177|NCT01733147|DRUG|Omega-3 polyunsaturated fatty acids|3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
224302178|NCT01733147|DRUG|Placebo|3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
224302179|NCT02055443|OTHER|12-lead holter monitor application|"\-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~* The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~* After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
224302180|NCT04921124|DRUG|Teriparatide|PTH(1-34) cartridge and pen device
224302181|NCT05221424|OTHER|Patient Education|"The training program about hypertension prepared according to the Roy Adaptation Model was performed in a room in the cardiology outpatient clinic of a state hospital. The training content was shaped according to 4 (four) basic areas of the Roy Adaptation Model (physiological field, self-concept field, role function field and interdependence field). The training taught to each patient individually and interactively with the support of powerpoint presentation lasted for averagely 45-50 minutes. A Hypertension Training Booklet was prepared according to the Roy Adaptation Model in order to be used during the training and to strengthen the training."
224302182|NCT04899817|DRUG|Granisetron|The drug is given after induction of general anesthesia
224302183|NCT02505490|OTHER|Television|The purpose is to determine whether television impacts liking of food.
224302184|NCT02505490|OTHER|No Television|The purpose is to determine whether the lack of television impacts liking of food.
224302185|NCT03212521|DRUG|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
224153154|NCT03375138|DRUG|belatacept|Specified dose on specified days
224153155|NCT02855138|DRUG|oral isotretinoin|
224153156|NCT00006299|DRUG|Celebrex|
224153157|NCT02096042|DRUG|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
224153158|NCT02096042|DRUG|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
224153159|NCT05881512|DEVICE|Transcutaneous Upper Airway Stimulation Device|Multiple frequency stimulation of the hypoglossal nerve
224153160|NCT04009460|DRUG|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
224153161|NCT02783209|PROCEDURE|Cataract surgery|
224153162|NCT04516733|OTHER|supportive care|visit with supportiv unit and neuropsychologue every 3 months
224153163|NCT03380507|DRUG|Triple therapy group|Refer to arms description
224302186|NCT05790421|OTHER|Foot Muscle Energy Technique|Starting from the preparation position, at the restriction barrier, the patient is asked to exert a small effort (no more than 20% of available strength) towards plantarflexion, against unyielding resistance, with appropriate breathing. The patient produces isometric effort contracts either gastrocnemius or soleus (depending on whether the knee is unflexed or flexed). This contraction is held for 7-10 seconds together with a held breath. The exercise was repeated until the full range of movement was obtained.
224302187|NCT05790421|OTHER|Conventional Physical Therapy Program|Graduated active resisted range of motion exercises for both UL and LL and graduated gait training
224302188|NCT04320979|RADIATION|internal mammary nodal irradiation|chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
224302189|NCT04320979|RADIATION|no internal mammary nodal irradiation|chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
224153164|NCT05750888|BEHAVIORAL|integrated exercise therapy with 3D printing exerciser for training intrinsic foot muscles|The therapeutic exercise program with a custom-made 3-D printing foot core exerciser, consisting of warm-up exercise, active range of motion in the foot and ankle joints, foot core system strengthening program using the 3D printing device, and stretching exercises for foot and ankle.
224153165|NCT05750888|BEHAVIORAL|regular exercises for the elderly|The regular exercise provided for the elderly in the dwelling community, including walking, simple aerobic exercises, stretching exercises
224153166|NCT02195609|DIETARY_SUPPLEMENT|Omega-3|600 mg oral twice a day
224153167|NCT02195609|DIETARY_SUPPLEMENT|Soy Isoflavones|54.4 mg oral twice a day
224153168|NCT04644484|BIOLOGICAL|SYN023|The finished product of SYN023 is a mixture of 3.0 mg/mL CTB011 and 3.0 mg/mL CTB012 at a ratio of 1:1. SYN023 is a sterile and preservative-free injection, and the excipient contains 25 mM histidine (3.879 mg/mL), 150 mM sodium chloride (8.766 mg/mL) and 0.02% polysorbate 80 (0.2 mg/mL) and pH of 6.0. Each vial contains 2.15 mL of SYN023, or 6.45 mg of monoclonal antibody. The glass bottle was closed with a 13 mm bromobutyl rubber stopper, a 13 mm aluminum crimping cap and a polypropylene flip-open lid.
223456058|NCT05702580|PROCEDURE|Agitated Pleural Fluid Thoracentesis|Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
223456059|NCT02823470|DRUG|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
223456060|NCT02823470|DEVICE|activated smart device|
223456061|NCT02823470|DEVICE|de-activated smart device|
224153169|NCT04644484|BIOLOGICAL|Human Rabies Immune Globulin (HRIG)|The HRIG is a Chinese licensed Human Rabies Immunoglobulin, which are derived from human plasma, and then purified and filled in the injectable vial form. The HRIG is indicated for the Post-exposure Prophylactic (PEP) of Rabies
224153170|NCT04644484|BIOLOGICAL|Rabies Vaccine|Interventions: The Chinese licensed rabies vaccine should be administered in deltoid muscle Dosage form: \>=2.5 IU, freeze-dried vaccine, reconstitute into 0.5 milliliters (mL) before use Dosage: 0.5 mL after reconstitution Frequency/duration: at Day 1, 4, 8, 15, 29
224153171|NCT05225480|BEHAVIORAL|Illness perception conversation|A conversation based on the indvidual's knee pain related illness perceptions
224153172|NCT05225480|BEHAVIORAL|research motivation conversation|A conversation based on the indvidual's motivation for participating in research
224153173|NCT02152449|DIETARY_SUPPLEMENT|Oral nutritional supplementation|
224153174|NCT00156013|DRUG|CLOFARABINE|4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
224153175|NCT03182153|DEVICE|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
224153176|NCT03767998|OTHER|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
224153177|NCT03767998|OTHER|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
224153178|NCT03767998|OTHER|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
224153179|NCT03001310|BIOLOGICAL|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
224153180|NCT03744130|DIAGNOSTIC_TEST|Contrast-enhanced Ultrasound|"1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station"
224153181|NCT04637191|DEVICE|MentalPlus®|A digital game named MentalPlus will be used to evaluate the possibility of this game becoming a neuropsychological test.
224153182|NCT03532984|DIAGNOSTIC_TEST|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
224153183|NCT00631540|DEVICE|Formula Balloon-Expandable Stent|renal artery stenting
224153184|NCT05726448|BEHAVIORAL|Telehealth solution|Mobile-friendly nutrition education platform
224153185|NCT05353868|OTHER|No intervention|No intervention
224153186|NCT00800930|BIOLOGICAL|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
224153187|NCT00800930|BIOLOGICAL|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
224153188|NCT00222248|BEHAVIORAL|Pelvic floor muscle training and bladder training|
224153189|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
224153190|NCT00970268|DRUG|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
224153191|NCT04249167|DRUG|Atezolizumab|Given IV
224153192|NCT04249167|PROCEDURE|Cryosurgery|Undergo cryoablation of the primary tumor
224153193|NCT04249167|DRUG|Nab-paclitaxel|Given IV
224153194|NCT03967275|OTHER|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
224153195|NCT00909818|RADIATION|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
224153196|NCT00909818|RADIATION|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
224153197|NCT03419910|DRUG|BMS-986165|Specified dose on specified days
224153198|NCT03419910|DRUG|Cyclosporine|Specified dose on specified days
224153199|NCT03437213|DRUG|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
224153200|NCT03437213|DRUG|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
224153201|NCT03984838|DRUG|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
224153202|NCT03136367|OTHER|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
224153203|NCT03136367|OTHER|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
224153204|NCT00034151|DRUG|S-8184 Paclitaxel Injectable Emulsion|
224153205|NCT05380960|DEVICE|cbc coaglation profile|The Demographic, clinical, and laboratory data for the enrolled subjects will be collected. To assess the coagulability state in the participants, we will measure the levels of certain markers in the blood that are thought to be associated with an increased coagulability. A comparison will be made between the different included groups regarding the level of these markers. These markers included complete blood count (CBC) indices (hematocrit, red cell distribution width, platelets count, mean platelet volume and platelet distribution width), C - reactive protein, d dimer, and blood coagulation tests (prothrombin time, international normalized ratio and partial thromboplastin time).
224153206|NCT03854812|DRUG|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
224153207|NCT03854812|DRUG|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
224153208|NCT03854812|DRUG|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
224153209|NCT00935337|BEHAVIORAL|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
224153210|NCT00935337|BEHAVIORAL|Sleep Hygiene|treatment as usual
224153211|NCT00771173|DRUG|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
224153212|NCT00771173|OTHER|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
224153213|NCT05200455|DEVICE|Microelectrodes|Microelectrode implantation
224153214|NCT04026763|PROCEDURE|prostate biopsy|standard of care
224153215|NCT04026763|PROCEDURE|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
224153216|NCT04026763|DEVICE|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
224153217|NCT01602549|DRUG|GSK962040 (25 mg tablet)|25 mg tablet
224153218|NCT01602549|DRUG|Placebo|matching placebo tablet
224153219|NCT02937532|BEHAVIORAL|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
223456062|NCT01087164|BEHAVIORAL|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
224153220|NCT02937532|BEHAVIORAL|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
224153221|NCT02823080|DRUG|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
224153222|NCT00522574|DRUG|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
224153223|NCT05340491|DRUG|Toripalimab|240mg, D1, every 3 weeks per cycle, three cycles with chemotherapy and eight cycles after IMRT
224153224|NCT05340491|DRUG|Chemotherapy|Gemcitabine: 1.0g/m2, D1 and D8, Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
224153225|NCT05340491|RADIATION|Intensity modulated radiotherapy|total 60-66Gy, 1.8-2.0Gy/f/day
224153226|NCT01966653|DRUG|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
224153227|NCT01966653|DRUG|fosfomycin|fosfomycin 3g po single dose
224153228|NCT00111436|DRUG|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
224153229|NCT04597515|PROCEDURE|Robot Breast reduction surgery|Breast reduction surgery, using a robot by removing a breast disc at the base
224153230|NCT01352767|DEVICE|InsuPad|Heating pad
224153231|NCT06263725|OTHER|Restricted dietary protein|Participants will be allocated to 5 week isocaloric restricted protein intake
224153232|NCT06263725|OTHER|Habitual diet|Participants will be follow their habitual, high protein intake
224153233|NCT04409496|BEHAVIORAL|Chat-based instant messaging support|"Subjects will receive personalised instant messaging support for 12 weeks after baseline, address the five problems that contributed to smoking relapse:~(1) lack of support for cessation, (2) negative mood or depression, (3) strong or prolonged withdrawal symptoms, (4) weight gain, and (5) smoking lapses. Updated information about the negative effect of smoking on risk of COVID-19 infection and prognosis will also be delivered."
224153234|NCT04409496|BEHAVIORAL|SMS message support|Subjects will receive regular SMS on generic smoking cessation for 3 months.
224153235|NCT04409496|BEHAVIORAL|Self-help booklet|Subjects will receive a standard self-help booklet on smoking relapse prevention.
224153236|NCT05759390|DIAGNOSTIC_TEST|Ultrasound elastography|Using an ultrasound scanner for chest ultrasound examinations. If patients has multiple sub pleural lung lesions, the largest and most approachable lesion to perform 2 Dimensions- shear wave elastography (2D-SWE) will be chosen.
224153237|NCT04116619|OTHER|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
224153238|NCT05616624|DRUG|ADI-PEG 20|-Given 60 minutes (+/- 15 minutes) prior to docetaxel
224153239|NCT05616624|DRUG|Gemcitabine|-Given over the course of 90 minutes (+/- 10 minutes)
224153240|NCT05616624|DRUG|Docetaxel|-Given over the course of 60 minutes (+/- 10 minutes)
224153241|NCT05316818|DRUG|FOLFOXIRI Protocol|Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
224153242|NCT04011319|BEHAVIORAL|group culture|Four embryos were cultured in the same droplet by a special dish.
224153243|NCT02401113|DIETARY_SUPPLEMENT|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
224153244|NCT05478057|DEVICE|"MAGSTIM Repetitive transcranial magnetic stimulator (rTMS) system"|we plan to recruit 60 patients with Parkinson disease, comprising 30 patients with speech disturbance and 30 age- and sex-match patients without speech disturbance. Each group of patients will be randomly divided into sham stimulation or rTMS. A total of 10 rTMS sessions will be applied in 2 weeks. The effect of rTMS will be evaluated via the changes of speech performance and functional connectivity which was analyzed from resting-state functional magnetic resonance imaging.
224153245|NCT00005675|DRUG|Oral bovine type I collagen|500 mcg of CI daily for 15 months
224153246|NCT00005675|DRUG|Placebo|CI placebo daily for 15 months
224153247|NCT01600391|BEHAVIORAL|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
224153248|NCT01600391|BEHAVIORAL|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
224153249|NCT01600391|BEHAVIORAL|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
223456063|NCT01087164|BEHAVIORAL|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
224153250|NCT00511108|DRUG|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
224153251|NCT00511108|DRUG|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
224153252|NCT00511108|DRUG|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
224153253|NCT00511108|DRUG|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
224153254|NCT01234311|DRUG|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
224153255|NCT01234311|DRUG|Placebo|
224153256|NCT03186040|DRUG|Lacosamide|Sodium channel blocker
224153257|NCT02698566|DRUG|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
224153258|NCT05560919|DRUG|Dihydroxycholecalciferols|Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
224153259|NCT05560919|OTHER|dimethyl sulfoxide|Injection of dimethyl sulfoxide in the periodontal ligament for lower anterior segment teeth.
224153260|NCT05560919|OTHER|serum|Injection of serum in the periodontal ligament for lower anterior segment teeth.
224153261|NCT00163163|PROCEDURE|Echographic measurements|
224153262|NCT00163163|PROCEDURE|Blood samples|
224153263|NCT02528799|BIOLOGICAL|Nexvax2|Nexvax2 intra-dermal injections twice weekly
224153264|NCT02528799|BIOLOGICAL|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
224153265|NCT02147691|DRUG|Azelaic acid 15%|Applied to the face each AM and PM
224153266|NCT02147691|DRUG|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
224153267|NCT02404584|GENETIC|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
224153268|NCT02404584|BIOLOGICAL|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\*~\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
224153269|NCT06186492|DRUG|WVE-006|RNA editing oligonucleotide
224153270|NCT02708472|DEVICE|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
224153271|NCT02382770|PROCEDURE|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
224153272|NCT02954952|DEVICE|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
224153273|NCT02954952|DEVICE|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
224153274|NCT04866823|BEHAVIORAL|Medically Tailored Meals|Participants will receive weekly meals (20 per week) prepared by a local community kitchen and catering group. Each week, 10 dinners and 10 lunches will be delivered to the participant's home with instructions for storage, re-heating, recipes, and nutritional information.
224153275|NCT04971993|DEVICE|Wearable Cardiac Monitor|Participants will be fitted with a wearable cardiac monitor placed on their skin that measures physiological signals.
224153276|NCT04179032|COMBINATION_PRODUCT|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
224153277|NCT06183242|DRUG|Remaxa, enteric-coated tablets|enteric-coated tablets
224153278|NCT06183242|DRUG|Remaxol|solution for infusions
224153279|NCT06183242|DRUG|Placebo|enteric-coated tablets
224153280|NCT06667674|BEHAVIORAL|iCBT for prolonged grief|Participants will undergo a 10-week internet-delivered, therapist-led cognitive behavioral therapy treatment (iCBT) for prolonged grief, which includes psychoeducation about grief and common grief reactions, exposure, cognitive restructuring and behavioral activation.
224153281|NCT06667674|BEHAVIORAL|Active control|Participants will undergo a 10-week internet-delivered, therapist-led treatment, which includes psychoeducation about grief and common grief reactions.
223456064|NCT04356157|BEHAVIORAL|Behavioural change interventions|"The study evaluates three different interventions aimed at improving adherence and retention to Anti Retroviral therapy among HIV positive women through engagement with their life partner. The interventions are 1) opening the facility once a month, only for men, special day; 2) testing peer-to-peer counselling among men, male champions; 3) providing incentive to all women accompanied by their partners at the facility, nudge or incentive."
224153282|NCT04703244|PROCEDURE|chemotherapy or endocrine therapy for breast cancer|Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
224153283|NCT05767658|BEHAVIORAL|Safe Sleep|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for infant safe sleep and b) an online community and social network of other pregnant WIC clients and new parents.
224153284|NCT05767658|BEHAVIORAL|Breastfeeding|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for breastfeeding and b) an online community and social network of other pregnant WIC clients and new parents.
224153285|NCT05767658|BEHAVIORAL|Early Brain Development and Parent-Child Relationships|Participants will be part of a private Facebook group from approximately 32 weeks gestation to 6 months postpartum. The Facebook group will provide a) evidence-based education through videos and other multi-media supporting best practices for early brain development and parent-child interactions (control intervention) and b) an online community and social network of other pregnant WIC clients and new parents.
224153286|NCT02983279|DIETARY_SUPPLEMENT|Dietary Intervention|Undergo caloric restriction diet
224153287|NCT02983279|OTHER|Counseling|Undergo counselor-led dietary counseling
224153288|NCT02983279|PROCEDURE|Therapeutic|Undergo standard of care surgery
224153289|NCT02432703|DRUG|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
224153290|NCT02432703|DRUG|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
224153291|NCT06307444|PROCEDURE|Ultrasound-Guided Stellate Ganglion Block|high frequency (6 to 13 MHz) linear transducer will be placed perpendicular to the tracheal axis at the cricoid cartilage and will be moved inferiorly until the superior aspect of the thyroid gland is visualized. Later, the transducer should be relocated laterally to visualize the anterior aspect of the Chassaignac's tubercle on \[\]the C6 transverse process. The carotid artery, internal jugular vein, thyroid gland, trachea, Longus colli, and Longus capitis muscle, prevertebral fascia, the root of C6 spinal nerve, and transverse process of C6 can be identified. Color Doppler will be used to detect the position of the vessels. With an in-plane approach, 22 to 25 gauge echo-enhanced needle is placed beside the trachea with a lateral to medial direction.
224153292|NCT06307444|PROCEDURE|T2 T3 (High Thorathic) ESP Block|We will count the laminae in the cephaled-to-caudal direction, starting from the C7 using the US to determine the exact vertebral level where the needle will be inserted. A linear high-frequency ultrasound probe will be used to perform the blocks. After the determination of the needle insertion site, the US probe was placed over the spinous processes of the vertebrae at the midline in the longitudinal plane. The US probe will then slid laterally from the spinous processes to visualize the transverse process. The needle will be advanced posterior-to-anteriorly, in the caudal to cephalic direction using the in-plane orientation within paraspinal muscles, targeting the transverse process. When the tip of the needle reaches and contact the transverse process, the local anesthetic drugs(0.2-0.3ml/kg(11) of bupivacaine 0.25% 8mg Dexamethazone) will be administered
224153293|NCT04929678|DEVICE|Braive™ Growth Modulation System (Braive™ GMS)|"The Braive™ GMS is designed as a growth-modulation, non-fusion technique, which utilizes patients' remaining growth potential to limit further progression of the curve, to provide correction of the thoracic spine, and allow continued growth while maintaining mobility.~The system consists of the following components: Braid, Fixed Angle Screws (FAS), Plate, and Break-Off Set Screw."
224153294|NCT02170350|PROCEDURE|Meditation therapy|Use brief mindful meditation practice
224153295|NCT02170350|OTHER|Quality-of-life assessment|Ancillary studies
224153296|NCT02170350|OTHER|Questionnaire administration|Ancillary studies
224153297|NCT02281981|DIETARY_SUPPLEMENT|Curcumin|333mg CurcuWin OAHTCUR002-2014
224153298|NCT02281981|DIETARY_SUPPLEMENT|Placebo|OAHTCUR005-2014
224153299|NCT04045574|PROCEDURE|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
224153300|NCT04430946|DIAGNOSTIC_TEST|Standardized test meal|A test meal of \~700 kcal consisting of protein and fat will be consumed within 10 minutes
224153301|NCT00484276|DRUG|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
224153302|NCT05474755|DRUG|GP681 40mg|2X20mg tablets taken orally
224153303|NCT05474755|DRUG|Placebo|Placebo tablets matching GP681 40mg
224153304|NCT01901978|BEHAVIORAL|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
224153305|NCT05428553|PROCEDURE|Endoscopic resection: CSP/p-CSP|Patients in the experimental arm will be assigned to receive CSP/p-CSP.
224153306|NCT05428553|PROCEDURE|Endoscopic resection: EMR/EPMR|Patients in the historical control arm have already finished EMR/EPMR
224153307|NCT00724815|DRUG|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
224153308|NCT00724815|DRUG|Placebo|NP101 Placebo iontophoretic transdermal patch
223456065|NCT03442725|DRUG|Telotristat etiprate|Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
223456066|NCT01543568|DRUG|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
223456067|NCT03025113|DRUG|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
223456068|NCT03025113|DRUG|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
223456069|NCT03446092|BEHAVIORAL|Mindfulness for health|A course of mindfulness using the mindfulness for health programme.
223456070|NCT02653365|DEVICE|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
223456071|NCT04515836|DRUG|Olaparib|Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
223456072|NCT05181098|PROCEDURE|Robotic-guided spine surgery|The Mazor X Stealth Edition robotic platform will be used to guide posterior instrumentation during spine fusion surgery.
224153309|NCT00810043|DEVICE|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
224153310|NCT04285710|DEVICE|Phototherapy|The key intervention aspect of this study is the application of 15 J/cm2 of 410 nm pulsed light directly onto the infected diabetic wounds of subjects every week over the course of 3 months, allowing for the cumulative exposure of around 180 J/cm2 for the entire study. This 15 J/cm2 weekly dosage of blue light will split up into two sessions every week, with each session applying 7.5 J/cm2 of light treatment. Phototherapy will be applied twice per week, with one phototherapy session occurring directly following the debridement surgery during the first visit of the week and the other session occurring after the study clinician removes the subjects wound dressings at the second visit.
224153311|NCT04285710|PROCEDURE|Debridement Surgery and Wound Dressing|All patients enrolled in the study will undergo standard care and treatment for infected diabetic wounds, which includes the weekly surgical removal of infected necrotic tissue from the diabetic wounds. In addition to debridement, both groups will utilize an antimicrobial wound dressing to cover and treat the infected diabetic wound. The subject's wounds will be dressed with Aquacel Ag Advantage Wound Dressings to protect and treat their diabetic wounds. These dressings will be changed twice a week by clinicians.
224153312|NCT02582931|DEVICE|MRI-guided SBRT|
224153313|NCT02582931|BEHAVIORAL|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
223456073|NCT00241007|DRUG|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
223456074|NCT00678847|DEVICE|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
223456075|NCT00678847|DEVICE|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
224153314|NCT02582931|BEHAVIORAL|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
224153315|NCT04677023|OTHER|GrandioSO x-tra® bulk|The prepared cavities will be restored with GrandioSO X-tra (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using using Elipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
224302190|NCT03022058|DEVICE|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
224153316|NCT04677023|OTHER|Admira fusion X--tra® bulk|he prepared cavities will be restored with Admira fusion X-tra®️ bulk (VOCO, Cuxhaven, Germany) in layers that are a maximum of 4 mm thick then cured for 20 seconds using usingElipar™️ S10 LED curing light (3M ESPE, St Paul, MN, USA) with light intensity of 1200 mW/cm2.
224153317|NCT04913480|DRUG|Durvalumab|Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
224153318|NCT04913480|RADIATION|Stereotactic body radiation therapy|Stereotactic body radiation therapy of 27.5Gy to 50Gy in 5 fractions to the liver tumors delivered over 5 to 14 days.
224153319|NCT05307341|DRUG|sufentanil|One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
224153320|NCT03230721|PROCEDURE|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
224153321|NCT03230721|PROCEDURE|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
224153322|NCT03230721|PROCEDURE|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
224153323|NCT01359046|DEVICE|silver SPC|subject randomized to receive silver alloy impregnated catheter
224153324|NCT01359046|DEVICE|standard SPC|subject randomized to receive standard catheter
224153325|NCT04252248|DRUG|Dacogen|Intravenous (i.v.) infusion of 20 mg/m2 over 1 hour repeated daily for 5 days starting on day 1. Single repetition of cycle on day 29.
224153326|NCT04397692|DEVICE|Nitric Oxide delivered via LungFit™ system|Patients will receive inhalations of 80 ppm for 40 min 4 times a day
223456076|NCT03565874|DEVICE|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
223456077|NCT06017401|PROCEDURE|Oblique Subcostal Transversus Abdominis Plane Block|The investigator will perform oblique subcostal transversus abdominis plane block to that patient group for postoperative analgesia
223456078|NCT06017401|PROCEDURE|Transmuscular Quadratus Lumborum Block|The investigator will perform transmuscular quadratus lumborum block to that patient group for postoperative analgesia
223456079|NCT03440619|DEVICE|INVSENSOR00013|Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
223456080|NCT03281746|PROCEDURE|Dental Procedure|Undergo dental examination
223456081|NCT03281746|OTHER|Educational Intervention (prevention education)|Receive prevention education
223456082|NCT03281746|OTHER|Interview|Ancillary studies
223572573|NCT05797532|OTHER|swaddling and holding|"The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance."
223572574|NCT01824329|PROCEDURE|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
223572575|NCT01824329|PROCEDURE|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
224153327|NCT03168841|DRUG|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
224153328|NCT03364491|DRUG|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
224153329|NCT03364491|DRUG|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
224153330|NCT05127291|OTHER|Dual-task|In the study, both groups are going to evaluate with and without dual-task. The dual-task will be counting back down 3 by 3 from a three-digit number.
224153331|NCT02198989|BEHAVIORAL|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
224153332|NCT00723268|DRUG|Prednisolone|5MG Prednisolone per day for 3 months
224153333|NCT00723268|DRUG|Colchicine|0.5 MG Colchicine per day for 3 months
223456083|NCT03281746|OTHER|Survey Administration|Ancillary studies
223456084|NCT03281746|OTHER|Educational Intervention (one-on one education)|Receive one-on-one education
223456085|NCT03967860|DIAGNOSTIC_TEST|CT scan|Post surgical standard CT Scan as predictor of complication
223456086|NCT03241576|BEHAVIORAL|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
223572576|NCT05451173|RADIATION|Stereotactic body radiotherapy|An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.
224153334|NCT04240912|DEVICE|CompuFlo Epidural Computer Controlled System|"The CompuFlo Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the physician to perform epidural anesthesia and epidural injections using standard methods. However, for the purpose of this study the instrument will be used only as a monitor to detect the occurrence of EPW.~The CompuFlo Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
224302191|NCT00210236|PROCEDURE|Conventional surgery|
224153335|NCT06167772|DIETARY_SUPPLEMENT|BCAA|"branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days"
224153336|NCT06167772|OTHER|Standard nutrition|Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
224153337|NCT06167772|OTHER|Standard physiotherapy|A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
224153338|NCT01455506|DRUG|Decitabine plus Fludarabine and Busulfan|"* Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient \>20% above ideal body weight~* Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~* Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
224153339|NCT04539262|DRUG|Remdesivir (RDV)|Administered as an aerosolized solution
224153340|NCT04539262|DRUG|Placebo|Administered as an aerosolized solution
224153341|NCT05590104|PROCEDURE|Hysteroscopic CS scar defect repair|Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
224153342|NCT05169736|BEHAVIORAL|Cognitive Behavioural Therapy|Intervention based on cognitive behavioural therapy principles and adapted to mental health problems related to the climate crisis. Intervention's main purpose is to increase management of mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
224153343|NCT04831268|OTHER|Glucose as reference food|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
224153344|NCT04831268|OTHER|Lentils and lupins mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from lentils and lupins mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
224153345|NCT04831268|OTHER|Trahanas with tomato sauce mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from trahanas with tomato sauce mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
224153346|NCT04831268|OTHER|Halva with currants mixed meal|Twelve healthy, normal weight subjects (male: 7, female:7) after 10-14 hr fast, consumed 25g available carbohydrates from halva with currants mixed meal along with 250ml water, tested once, in different weeks, within 10-15min. Fingertip capillary blood glucose samples were takenat baseline, 15, 30, 45, 60, 90 and 120min.
224153347|NCT02270489|BIOLOGICAL|AFFITOPE® PD01A + Adjuvant|s.c. injection
224153348|NCT02270489|BIOLOGICAL|AFFITOPE® PD03A + Adjuvant|s.c. injection
224153349|NCT02270489|BIOLOGICAL|Adjuvant without active component|s.c. injection
224153350|NCT03157336|OTHER|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be \< 10 ppm as per the recommendations of the World Health Organization.
224153351|NCT03174561|DIETARY_SUPPLEMENT|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
224153352|NCT03174561|OTHER|diet restriction|diet restriction for 28 days
224153353|NCT04207008|OTHER|iBDecide Decision Support Application|The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
224153354|NCT04400227|OTHER|Family Talk|"Family Talk is an evidence-based, parent-youth dyadic approach that uses psychoeducation and skills building to help families make meaning of a parent's adversity, increase resilience, and improve family functioning.~The Family Talk model comprises two components: the first involves a series of cognitive-behavioral techniques to bolster problem solving and communication skills among family members; the second involves a facilitated family meeting to develop a shared narrative for discussing each family member's experience of the parent's illness."
224153355|NCT02351739|DRUG|pembrolizumab|
224153356|NCT02351739|DRUG|ACP-196 in combination with pembrolizumab|
224302192|NCT05496335|DRUG|AGN-151586|Intramuscular Injection
224302193|NCT05496335|DRUG|BOTOX|Intramuscular Injection
224302194|NCT05496335|DRUG|Placebo|Intramuscular Injection
223456087|NCT03241576|BEHAVIORAL|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
223456088|NCT00463801|DRUG|Daptomycin|
223572577|NCT05451173|RADIATION|Hypofractionated radiotherapy|Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.
224153357|NCT02482740|DRUG|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
224153358|NCT02482740|DRUG|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
224153359|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration with laser irradiation|Patients will receive inferior alveolar nerve block local anesthesia followed by laser irradiation after completion of the operative procedure.
224153360|NCT05648981|OTHER|Inferior Alveolar Nerve Block administration|Patients will not receive any laser irradiation after administration of inferior alveolar nerve block local anesthesia.
224153361|NCT02773056|DEVICE|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
224153362|NCT02773056|DEVICE|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
224153363|NCT02773056|DEVICE|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
224153364|NCT05471206|OTHER|Milk and SmartPill intakes|During visit V2, the subject will ingest the SmartPill capsule. Then, subjects will drink milk.
224153365|NCT02260895|DIETARY_SUPPLEMENT|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
224153366|NCT03184116|BEHAVIORAL|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning \& Rehabilitation
224153367|NCT02954302|PROCEDURE|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
224153368|NCT02954302|PROCEDURE|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
224153369|NCT03914534|DRUG|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
224153370|NCT03914534|DRUG|Valcote 500 mg|Administration of 500 mg of Valproic Acid
224153371|NCT00292578|PROCEDURE|NAET Testing Modalities|
224153372|NCT05499598|PROCEDURE|Experimental: Modified minimally invasive surgical technique with PRF and vitamins A and C|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. Ascorbic Acid will be added to the fresh blood to achieve a concentration of 250 μg/ml, Retinol will also be added to achieve a concentration of 20 μmol/L. The resultant PRF clot will be placed into the intra-osseous defect.
224153373|NCT05499598|PROCEDURE|Modified minimally invasive surgical technique with PRF|Surgical technique (M-MIST) with the same procedures will be performed. Approximately 10 mm of fresh blood will be drawn by venipuncture of the antecubital vein and collected into a blood collection tube without anticoagulant. The resultant PRF clot will be placed into the intra-osseous defect.
224153374|NCT00555282|DEVICE|central venous catheter|coated central venous catheter
224153375|NCT00555282|DEVICE|central venous catheter|standard central venous catheter
224153376|NCT00511121|DRUG|STI571 and PEG INTRON|
224153377|NCT02665468|BEHAVIORAL|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
224153378|NCT02665468|BEHAVIORAL|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
224153379|NCT04045691|DRUG|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
224153380|NCT04045691|DRUG|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
224153381|NCT03370198|BIOLOGICAL|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
224153382|NCT04612803|DRUG|Antihistamine|Cetirizine 10 mg and famotidine 20 mg will be dispensed to each patient, to be taken twice a day at 6-9AM one hour before eating breakfast and again at evening 12 hours after the morning dose for 30 days
224153383|NCT02021071|RADIATION|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
224153384|NCT02021071|RADIATION|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
224153385|NCT03487406|DRUG|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
224153386|NCT03487406|DRUG|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
224153387|NCT03487406|DRUG|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
224153388|NCT03487406|DRUG|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
224153389|NCT01472991|DRUG|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
224153390|NCT01472991|DRUG|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
224153391|NCT01472991|DRUG|Placebo|Placebo capsules will be taken once daily for 4 weeks
224153392|NCT01977248|BEHAVIORAL|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
224302195|NCT02435836|DRUG|Aripiprazole|
224153393|NCT03720301|PROCEDURE|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~1. Soft tissue massage to the posterior cervical musculature for approximately 1 minute~2. Muscle energy to the muscles of neck extension approximately 1 minute~3. Muscle energy to the Occipital Atlanto (OA) joint 1 minute~4. Muscle energy to the jaw. Approximately 1 minute~5. Occipital decompression approximately 1 minute~6. With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~1. Myofascial Steering wheel Technique~2. Sibson's Fascia Release~3. Occipital decompression"
224153394|NCT03720301|PROCEDURE|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
224153395|NCT01442701|OTHER|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
224153396|NCT05286996|DEVICE|Iovera - Cryoneurolysis|Iovera system delivers precise, controlled doses of cold temperature only to the targeted nerve through a handheld device.
224153397|NCT05286996|DRUG|Local anesthetic|Placebo - local anaesthesia
224153398|NCT04946162|DRUG|Tadalafil Pill|Each patient will be given tadalafil 40 mg one time
224153399|NCT01831804|DRUG|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
224153400|NCT01831804|DRUG|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
224153401|NCT04019457|OTHER|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
224153402|NCT05214404|OTHER|Patients diagnosed with ulcerative colitis|Patients with ulcerative colitis diagnosed by endoscopy and histopathology
224153403|NCT05289856|DRUG|combination of Avelumab and Cabozantinib|Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
224153404|NCT03496441|OTHER|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
224153405|NCT06009068|OTHER|Surgimap soft ware|20 healthy subjects will be recruited in the study, the q angle will be measured using goniometer and surgimap soft ware, 3 examiners will measure the q angles for the same individuals to check the inter rater reliability, and the test will be repeated after 2 days by the same examiners to check the intra rater reliability
224153406|NCT04399057|DIAGNOSTIC_TEST|shear Wave Elastosonography|both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
224153407|NCT00133185|DRUG|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
223456089|NCT03194178|OTHER|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :~* Kidscreen 52 (generic quality of life questionnaire)~* Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~* Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~* MDI-C (composite depression scale for minors)"
223456090|NCT00826098|BIOLOGICAL|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
224153408|NCT00133185|DRUG|losartan 50 mg/hydrochlorothiazide 12.5 mg|
224153409|NCT01744457|DEVICE|Measurement of tear film osmolarity with the TearLab® instrument|
224153410|NCT01744457|OTHER|Schirmer I test|
224153411|NCT01744457|OTHER|Tear break up time|
224153412|NCT01744457|DEVICE|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
224153413|NCT01744457|OTHER|Ocular Surface Disease Index|
224302196|NCT00002321|DRUG|Aldesleukin|
223456091|NCT00669318|BIOLOGICAL|alemtuzumab|
223456092|NCT00669318|BIOLOGICAL|rituximab|
223456093|NCT00669318|DRUG|pentostatin|
223456094|NCT00669318|DRUG|sargramostim|
223572578|NCT05451173|DRUG|Durvalumab|an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
223572579|NCT03233763|PROCEDURE|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
223572580|NCT05480436|BIOLOGICAL|coadministration|the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and IIV4 on Day 0, and the coadministration of BBIBP-CorV and PPV23 on Day 28
223572581|NCT05480436|BIOLOGICAL|COVID-19 vaccine|received two doses of inactivated COVID-19 vaccine (BBIBP-CorV)
223572582|NCT05480436|BIOLOGICAL|IIV4+PPV23|received one dose of IIV4 on Day 0, and one dose of PPV23 on Day 28
223572583|NCT00624819|BIOLOGICAL|GSK1024805A|No vaccination in this trial
224153414|NCT03293186|COMBINATION_PRODUCT|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
224302197|NCT02963870|OTHER|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
224302198|NCT05372133|DRUG|Morphine|Children will be provided with morphine for at-home pain management following supracondylar fracture repair
224302199|NCT05372874|DRUG|Direct Acting Antivirals|hepatitis C patients will be treated by direct acting antiviral drugs (DAAs)for 12 weeks.
224302200|NCT00000651|DRUG|Zidovudine|
224302201|NCT00000651|DRUG|Zalcitabine|
224302202|NCT01970865|DRUG|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
224153415|NCT05148169|DRUG|SSRIs|One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
224153416|NCT05148169|DIETARY_SUPPLEMENT|SSRI plus Sulforaphane|"One SSRI(No-specified) is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN (ZHIYINGUOSU, Shenzhen Fushan Biotech Co. Ltd.) is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
224153417|NCT01937481|BEHAVIORAL|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
224153418|NCT02052141|BIOLOGICAL|CINRYZE 500|500 Units of CINRYZE administered by IV injection
224153419|NCT02052141|BIOLOGICAL|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
224153420|NCT00396305|DRUG|Placebo|Sterile phosphate buffered saline solution.
224153421|NCT00396305|BIOLOGICAL|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
224153422|NCT03945201|OTHER|Virtual walking trails|During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
224153423|NCT03945201|OTHER|Standard of care|"Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes."
224153424|NCT02976545|DEVICE|fMRI (functional Magnetic Resonance Imaging)|fMRI examination
224153425|NCT02976545|BEHAVIORAL|psychiatric evaluation|psychiatric evaluation
224153426|NCT00268463|DRUG|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
224153427|NCT00268463|DRUG|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
224153428|NCT00268463|DRUG|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
224153429|NCT02920450|DRUG|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
224153430|NCT02920450|DRUG|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
224302203|NCT01970865|DRUG|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
223572584|NCT00624819|BIOLOGICAL|Prevenar|No vaccination in this trial
223572585|NCT00624819|BIOLOGICAL|Infanrix hexa|No vaccination in this trial
224153431|NCT02920450|DRUG|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
224153432|NCT02435862|DRUG|1.0mg Luminate®|
224153433|NCT02435862|DRUG|2.0mg Luminate®|
224153434|NCT02435862|DRUG|3.0mg Luminate®|
224153435|NCT02435862|OTHER|Balanced Salt Solution for intravitreal injection in 0.10cc|
224153436|NCT03199742|BEHAVIORAL|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress \& use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
224153437|NCT03199742|BEHAVIORAL|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
224153438|NCT00290524|BEHAVIORAL|Oral alimentation started 12 hours after colorectal surgery|
224153439|NCT02668172|DRUG|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
224153440|NCT02668172|DRUG|Pegvisomant|only in combination with pasireotide LAR
224153441|NCT00228410|DRUG|Tigecycline|
224153442|NCT00228410|DRUG|vancomycin with aztreonam|
224153443|NCT00291187|DRUG|20 mg VEC-162|20 mg VEC-162
224302204|NCT01576874|DRUG|Oxytocin|40 IUs of oxytocin administered intranasally one time
223572586|NCT00624819|BIOLOGICAL|Havrix|No vaccination in this trial
223572587|NCT00624819|BIOLOGICAL|Varilrix|No vaccination in this trial
224153444|NCT00291187|DRUG|50 mg VEC-162|50 mg VEC-162
224153445|NCT00291187|DRUG|100 mg VEC-162|100 mg VEC-162
224153446|NCT00291187|DRUG|Placebo|Placebo
224153447|NCT00047853|DEVICE|Shock device|A participant could receive a shock or not receive as shock
224153448|NCT00047853|DEVICE|Acoustic startle|Acoustic startle for MEG only
224153449|NCT01927887|DRUG|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
224153450|NCT01927887|DEVICE|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
224153451|NCT00383877|DRUG|insulin detemir|
224153452|NCT00383877|DRUG|insulin NPH|
224153453|NCT02654470|DEVICE|Watchman FLX|Patients who are receiving the Watchman FLX device
224153454|NCT04206670|DEVICE|In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes after enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
224153455|NCT04206670|DEVICE|Waiting Control In-Home Technology System and Questionnaires|Participants self-install the in-home technology system in their homes six months after their enrollment in the study (i.e., consent procedures and initial questionnaire). Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using caregiver resources and a trusted circle of friends and family who are encouraged to stay in contact with the caregiver and person with dementia or mild cognitive impairment.
224153456|NCT02443805|BIOLOGICAL|300 IR|300 IR tablet of HDM Allergen Extracts
224153457|NCT02443805|BIOLOGICAL|Placebo|Placebo tablet
224153458|NCT02090465|DRUG|Ingenol Mebutate|No intervention: observation of routine use of Picato®
224153459|NCT03656666|DRUG|Apremilast|Apremilast oral tablets
224153460|NCT03656666|DRUG|Placebo|Placebo oral tablets
224153461|NCT00400556|DRUG|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
224153462|NCT02319408|RADIATION|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
224153463|NCT02645461|DRUG|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
224153464|NCT02645461|DRUG|Riluzole|Riluzole 50 mg twice daily
223456095|NCT04955795|BEHAVIORAL|Alcohol Brief Intervention (BI)|The BI we will use was based on CETA's substance use module and was designed for one-on-one delivery. It is comprised of 6 elements (i.e. assessment, understanding impacts, exploring change, goal setting, identifying the reasons, and skill building) including a 2-week alcohol timeline follow back assessment, which is completed by the therapist. BI will be provided by a trained research assistant who has completed consent, enrollment, and randomized procedures with the client.
223572588|NCT02880514|DEVICE|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
224153465|NCT00419458|PROCEDURE|inspiratory muscle strength training|
224153466|NCT04595409|DRUG|FYB202 (Proposed ustekinumab biosimilar)|Patients will receive 1 subcutaneous (SC) injection of FYB202 at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
224153467|NCT04595409|DRUG|Stelara® (Ustekinumab)|Patients will receive 1 subcutaneous (SC) injection of Stelara® at week 0 and week 4, followed by 1 SC injection every 12 weeks thereafter for the next 3 consecutive doses.
223572589|NCT02880514|PROCEDURE|Balloon Sinus Dilation Alone|
223572590|NCT00622089|DRUG|DIO-902|150mg DIO-902 + 10mg atorvastatin
224153468|NCT04362813|DRUG|Canakinumab|Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
224153469|NCT04362813|DRUG|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
224153470|NCT04824222|DRUG|Human fecal microbiota, MBiotix HBI|The FMT will be administered orally in double cover, gastro-resistant, enteric release capsules in 60g dose (about 30-50 frozen capsules).
224153471|NCT04824222|DRUG|Placebo|Double cover, gastro-resistant, enteric release capsules with lactose (about 30-50 frozen capsules)
224153472|NCT04824222|DRUG|SOC|The standard COVID 19 pharmacological treatment
224153473|NCT01787955|PROCEDURE|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
224153474|NCT01787955|PROCEDURE|conventional PPPD|
224153475|NCT05570799|OTHER|Augmented Reality and Kahoot game learning|"* An augmented reality (AR) mobile application with image based will be used by the participants in the experimental group.~* Also, students will participate in Kahoot game. Students will participate in the game using their own devices by going to https://kahoot on their phones and entering their password and password."
223572591|NCT00622089|DRUG|DIO-902|300mg dose once per day for 24 weeks
223572592|NCT00622089|DRUG|DIO-902|450mg dose once per day for 24 weeks
224153476|NCT00961116|DRUG|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
224153477|NCT00961116|DRUG|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
224153478|NCT01543113|OTHER|sequencing|sequencing
224153479|NCT00354952|DRUG|Macrolides (azithromycin or clarithromycin)|
224302205|NCT01576874|DRUG|placebo|placebo administered intranasally one time
224153480|NCT02708966|DRUG|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
224153481|NCT02708966|DRUG|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
224153482|NCT03632304|PROCEDURE|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
224153483|NCT01515488|OTHER|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
224153484|NCT01515488|OTHER|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
224153485|NCT01082003|DRUG|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
224153486|NCT00704431|DRUG|SB-480848 (darapladib)|160 mg darapladib
224153487|NCT00007982|BIOLOGICAL|filgrastim|
224153488|NCT00007982|DRUG|carmustine|
224153489|NCT00007982|DRUG|cisplatin|
224153490|NCT00007982|DRUG|cyclophosphamide|
224153491|NCT00007982|DRUG|etoposide|
224153492|NCT00007982|DRUG|thiotepa|
224153493|NCT00007982|PROCEDURE|adjuvant therapy|
224153494|NCT00007982|PROCEDURE|autologous bone marrow transplantation|
224153495|NCT00007982|PROCEDURE|bone marrow ablation with stem cell support|
224153496|NCT00007982|PROCEDURE|peripheral blood stem cell transplantation|
224153497|NCT03789968|DRUG|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
224153498|NCT04571476|PROCEDURE|Ultrathin bronchoscope|Ultrathin bronchoscope (UTB) with an outer diameter no more than 3.0-mm and a 1.7-mm working channel.
224153499|NCT04571476|PROCEDURE|Thin bronchoscope|Thin bronchoscope with a 4.0-mm outer diameter and a 2.0-mm working channel.
224153500|NCT04571476|PROCEDURE|Virtual bronchoscopic navigation combined with endobronchial ultrasound|VBN can create a path to the target lesion automatically when the lesion is depicted in this software.VBN combined with EBUS can improve the diagnostic yield of PPL and shorten the examination time, which has become the standard method for the diagnosis of PPL.
224153501|NCT04571476|PROCEDURE|Guide sheath|GS is a cannula with the thinnest outer diameter of 1.95 mm.
224153502|NCT00056836|DRUG|rhuFab V2 (ranibizumab)|
224153503|NCT05191849|DIAGNOSTIC_TEST|Blood sample collection|Baseline blood samples are collected before chemotherapy. Dynamic blood samples are also prospectively collected after 2\~4 cycles of chemotherapy, or at the time of disease progression.
224153504|NCT01732107|DRUG|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
223572593|NCT05499338|PROCEDURE|Stretching program|The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
224153505|NCT02763241|DRUG|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
224153506|NCT02763241|DRUG|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
224153507|NCT03891615|DRUG|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage."
224153508|NCT03891615|DRUG|Osimertinib|Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
224153509|NCT04746209|DEVICE|Alpha/Beta T-cell and B-cell depleted HCT|Device: Alpha/Beta T-cell and B-cell depletion
224153510|NCT04746209|DRUG|Blinatumomab|28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
224153511|NCT02023268|DEVICE|T2762|1 drop in each eye 3 to 6 times daily during 84 days
224153512|NCT02023268|DEVICE|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
224153513|NCT06452368|DEVICE|facemask|Fixation of miniplates by four screws in the maxilla and protraction by using facemask
224153514|NCT00871936|DRUG|SLx-4090|SLx-4090
224153515|NCT00871936|OTHER|Placebo|matching tablets
224153516|NCT00871936|DRUG|Metformin|
224153517|NCT00374270|BEHAVIORAL|Lifestyle Counselling; Opinion Leader Influence Statements|
224153518|NCT05812768|DEVICE|Suture-Tight Suture Delivery System|Implantation of the Suture-Tight Suture in the deployment of multiple nitinol sutures to provide augmented fixation and sealing between endovascular aortic graft and the native artery.
224153519|NCT03791268|PROCEDURE|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
224153520|NCT02899624|BIOLOGICAL|Extra blood draw samples|
224153521|NCT02899624|BIOLOGICAL|additional tissue samples|
224153522|NCT00615459|DRUG|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
224153523|NCT00615459|DRUG|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
224153524|NCT00615459|DRUG|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
224302206|NCT03642782|DEVICE|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
224302207|NCT02041091|DRUG|Tabalumab Auto-Injector|Administered SC
224153525|NCT02866929|PROCEDURE|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
224153526|NCT02866929|DEVICE|Orthodontics|Self-ligation brackets in upper and lower teeth
224153527|NCT02866929|DRUG|Mucograft|Porcine naturally cross-linked collagen matrix
224153528|NCT01661504|BEHAVIORAL|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
224153529|NCT04615780|OTHER|mouthwash with green tea|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.
224153530|NCT04615780|OTHER|mouthwash with tap water group|All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
224153531|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
224153532|NCT00427167|BIOLOGICAL|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
224153533|NCT00427167|DRUG|AMA1-C1/Alhydrogel + CPG 7909|
224153534|NCT02621645|PROCEDURE|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
223572594|NCT03521713|DRUG|EPORON|"* Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS"
224153535|NCT02621645|PROCEDURE|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
224153536|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
224153537|NCT02621645|DEVICE|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
224153538|NCT02621645|DEVICE|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
224153539|NCT05300893|OTHER|No night splint|Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
224153540|NCT06449846|DIAGNOSTIC_TEST|circulating tumor cell DNA detection|circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma
224153541|NCT03701204|BEHAVIORAL|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule."
224153542|NCT04433156|DRUG|Bortezomib|1.3 mg/m2, hypodermic injection on day 1 and day 4 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
224153543|NCT04433156|DRUG|Rituximab|375 mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
224153544|NCT04433156|DRUG|Epirubicin|70 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
224153545|NCT04433156|DRUG|Cyclophosphamide|750 mg/m2, Intravenous administration on day 1 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.
224153546|NCT04433156|DRUG|Prednisone|100mg, oral administration on day 1 to 5 of each 3-week cycle until disease progression/stable disease after 2/4 cycles treatment or unacceptable toxicity develops, up to 6 cycles
224153547|NCT02494219|PROCEDURE|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
223572595|NCT03521713|DRUG|EPREX|"* Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS"
223572596|NCT02436668|DRUG|Ibrutinib|
223572597|NCT02436668|DRUG|Gemcitabine|
223572598|NCT02436668|DRUG|Nab-paclitaxel|
223572599|NCT02105493|DRUG|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
224153548|NCT01878240|PROCEDURE|EVAR without coils embolization/ Coils embolization during EVAR|
224302208|NCT02041091|DRUG|Tabalumab Prefilled Syringe|Administered SC
224302209|NCT02520752|DRUG|INC280|
224302210|NCT02520752|DRUG|Midazolam|
224302211|NCT02520752|DRUG|Caffeine|
224302212|NCT01855074|DRUG|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
224153549|NCT04119401|PROCEDURE|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
223572600|NCT02105493|DRUG|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
223572601|NCT04171596|BEHAVIORAL|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
224153550|NCT04119401|PROCEDURE|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
224153551|NCT03358498|OTHER|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
224153552|NCT02987244|DRUG|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
224153553|NCT02987244|DRUG|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
224153554|NCT02987244|DRUG|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
224153555|NCT02987244|DRUG|Vindesine|vindesine (4mg)was administered intravenously on d1;
224153556|NCT02987244|DRUG|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
224153557|NCT02987244|DRUG|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
224153558|NCT00251186|DRUG|Capecitabine and Cetuximab|
224153559|NCT01975675|DRUG|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
224153560|NCT01975675|DRUG|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
224153561|NCT00224003|DRUG|Sodium Ferric Gluconate Complex in Sucrose.|
224153562|NCT03225937|DRUG|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
224153563|NCT03225937|DRUG|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
224153564|NCT02611700|DRUG|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
224153565|NCT02611700|DRUG|Paclitaxel|175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
224153566|NCT02611700|DRUG|Cisplatin|60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
223572602|NCT00460759|DRUG|Moxifloxacin|
223572603|NCT00460759|DRUG|Rifapentine|
223572604|NCT01371253|OTHER|Nintendo wii balance training|
223572605|NCT01371253|OTHER|EVA-soles|
223572606|NCT06086860|OTHER|Mulligan mobilization with dry needling.|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
224153567|NCT02611700|DRUG|Placebo|400mg,day1,weekly,until disease progression or toxicity
224153568|NCT04197141|RADIATION|Conventionally-fractionated WPRT|Total dose: 45 Gy in 25 fractions WPRT
224153569|NCT04197141|RADIATION|Hypofractionated WPRT|Total dose: 25 Gy in 5 fractions WPRT
224153570|NCT00753688|DRUG|PAZOPANIB|800 mg once daily orally
224153571|NCT00753688|DRUG|Placebo|matching placebo 800 mg once daily orally
224153572|NCT05738772|DIAGNOSTIC_TEST|serum sample for ELIZA|Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
223572607|NCT06086860|OTHER|Mulligan mobilization without dry needling|The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
224153573|NCT02043184|BEHAVIORAL|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
224302213|NCT01747720|DIETARY_SUPPLEMENT|Vitamin D3|Given orally
224302214|NCT01747720|DIETARY_SUPPLEMENT|Placebo|
224302215|NCT03880773|DEVICE|Stapler|for transection of the pancreas and pancreatic stump treatment
224153574|NCT00855387|OTHER|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
224153575|NCT04063072|PROCEDURE|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
224153576|NCT01893684|BEHAVIORAL|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
224153577|NCT01893684|BEHAVIORAL|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
224153578|NCT01893684|BEHAVIORAL|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein \> 3.5 and dietary lipids at \~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
224153579|NCT03803202|BIOLOGICAL|ASP3772|Participants received a single dose of ASP3772 (ASP3772 low dose, ASP3772 medium dose and ASP3772 high dose) intramuscularly
224302216|NCT03880773|DEVICE|ultrasonic shears|for transection of the pancreas and pancreatic stump treatment
224153580|NCT03803202|BIOLOGICAL|PCV13|Participants received a single dose of PCV13 intramuscularly.
224302217|NCT02349620|BIOLOGICAL|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
224302218|NCT05258331|GENETIC|CT303|"1. Cohort 1 : Single-dose administration, intravenous injection~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg~2. Cohort 2 : Multiple-dose administration, intravenous injections (Week 0, Week 4)~   * Dose 1(Starting dose) : 1.0\*10\^6 cells/kg~  * Dose 2 : 2.0\*10\^6 cells/kg~  * Dose 3 : 3.0\*10\^6 cells/kg"
224302219|NCT00601666|DRUG|Zolpidem|
224302220|NCT02724865|DEVICE|Somnodent® (Oral appliance therapy)|
224302221|NCT02724865|DEVICE|Herbst® (Oral appliance therapy)|
224302222|NCT05560789|BEHAVIORAL|Physical activity (cycling on a stationary bicycle ergometer or walking on a treadmill)|At time 0, exercise will be initiated and intensity will be increased at 2 minute intervals to achieve low intensity for 30 minutes (as defined by heart rate target 50-55% of maximum heart rate determined as 220-age). Next, intensity will be increased at 2 minute intervals until the heart rate target for moderate intensity exercise is achieved (55-65% of max heart rate), or the total duration of exercise of up to 60 minutes is achieved.
224302223|NCT00002040|DRUG|Fluconazole|
224302224|NCT04610463|DIAGNOSTIC_TEST|Cardiac flow measurement|Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
224302225|NCT01298401|BIOLOGICAL|ganitumab|
224302226|NCT01298401|DRUG|capecitabine|
224302227|NCT01298401|DRUG|gemcitabine hydrochloride|
224302228|NCT01298401|RADIATION|3-dimensional conformal radiation therapy|
223572608|NCT04804657|DIETARY_SUPPLEMENT|Sage extracts Cognivia|Cognivia is composed of 400 mg of aqueous extract from Salvia officinalis and the remaining 200 mg contained 50 µL of Salvia lavandulaefolia essential oil and encapsulated with gum acacia. It will be administrated the the morning before the endurance test (oral administration).
224302229|NCT00026286|DRUG|conjugated estrogens|
224302230|NCT00026286|DRUG|medroxyprogesterone|
224302231|NCT02643017|DRUG|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
224302232|NCT02643017|DRUG|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
224302233|NCT02299817|DRUG|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
224302234|NCT02299817|DRUG|Placebo|Placebo
224302235|NCT01150890|BIOLOGICAL|Brodalumab|Administered as as an intravenous (IV) infusion over at least 30 minutes.
224153581|NCT03803202|BIOLOGICAL|PPSV23|Participants received a single dose of PPSV23 intramuscularly.
224153582|NCT00293241|DEVICE|Managed Ventricular Pacing programmed ON/OFF|Device programming
224153583|NCT03595384|BEHAVIORAL|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
224153584|NCT02181985|DRUG|Full dose TNK-tPA|
224153585|NCT02181985|DRUG|Half dose TNK-tPA|
224153586|NCT02181985|DRUG|Heparin|
224153587|NCT02181985|DRUG|Enoxaparin|
224153588|NCT02181985|DRUG|Abciximab|
224153589|NCT03162393|PROCEDURE|nerve transfer|
224153590|NCT02715583|DRUG|11C-Acetate|
224153591|NCT03368040|DEVICE|Tcore|Monitoring system to measure body temperature based on heat-flux technology
224153592|NCT02111512|DRUG|Administration of Live attenuated influenza vaccine (LAIV)|
224153593|NCT02080286|BEHAVIORAL|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
224153594|NCT02080286|DEVICE|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
224153595|NCT02080286|DEVICE|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
224153596|NCT03073343|DIETARY_SUPPLEMENT|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
224153597|NCT01256203|DRUG|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
224153598|NCT01256203|PROCEDURE|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
224153599|NCT03618602|DRUG|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
224302236|NCT01150890|DRUG|Placebo|Administered as as an intravenous (IV) infusion over at least 30 minutes.
224153600|NCT01319279|DRUG|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
224153601|NCT00927264|BEHAVIORAL|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits \& 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
224153602|NCT00927264|BEHAVIORAL|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
224153603|NCT00936299|DRUG|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
224153604|NCT00936299|OTHER|Placebo|
224153605|NCT01730287|DRUG|Control|The teeth in this group restored only by filling material,without liner application.
223456096|NCT04955795|BEHAVIORAL|Common Elements Treatment Approach (CETA) via Telemedicine|CETA consists of nine key elements (i.e. engagement and education; safety assessment and planning; psychoeducation/introduction; substance use reduction; behavioral activation; cognitive coping/restructuring; relaxation; exposure; and problem solving) that address common mental health problems such as trauma, PTSD, depression, and anxiety. Participants randomized to CETA will be assigned to a CETA provider (clinical psychology or social work graduate student or master's degree substance abuse counselor). Enrolled participants will be discussed at weekly supervision meetings. An individualized treatment plan will be designed for each participant including type and order of CETA modules. The counselor will contact the participant by phone to schedule CETA sessions and follow up any missed appointments. Counselors, who will also be given a unique ID# for documentation and analysis, will carry 3-10 active CETA cases at a time depending on their experience level.
224153606|NCT01730287|DRUG|Calcium Hydroxide|Calcium Hydroxide paste applied.
224153607|NCT01730287|DRUG|Mineral Trioxide Aggregate(MTA)|MTA applied .
224153608|NCT01730287|DRUG|CEM cement|CEM cement applied .
224153609|NCT04359342|DIETARY_SUPPLEMENT|HIIT + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
224302237|NCT02715206|BEHAVIORAL|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
224302238|NCT02715206|BEHAVIORAL|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
224302239|NCT02715206|BEHAVIORAL|control|control group continues to teach whatever prevention curriculum they were using prior to study
224153610|NCT04359342|DIETARY_SUPPLEMENT|HIIT + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT).~HIIT: 10x1 min at 85-95% HRmax divided by low intensity recovery periods. Three exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
224153611|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + protein|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available protein supplement administered as a shake after every exercise session."
224153612|NCT04359342|DIETARY_SUPPLEMENT|HIIT and resistance training + placebo|"8-week supervised exercise program consisting of high-intensity interval training (HIIT) and resistance training (RST).~HIIT: 5x1 min at 85-95% HRmax divided by low intensity recovery periods. RST: 3-set resistance training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum. Two exercise sessions per week. Participants receive 40 g of a commercially available iso-caloric placebo (Maltodextrin) administered as a shake after every exercise session."
224153613|NCT04896307|OTHER|Survey|Survey
224153614|NCT03260907|PROCEDURE|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).
224153615|NCT03260907|PROCEDURE|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
224153616|NCT05797688|DEVICE|The Celution System|The Celution System will isolate regenerative cells, including stem cells, from fat harvested from the treatment patients.
224153617|NCT04355494|BIOLOGICAL|eculizumab|Eculizumab at doses of 900-1200 mg will be administered intravenously (up to 7 doses)
224153618|NCT04977973|BEHAVIORAL|Self-guided programme on body image|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
224153619|NCT04977973|BEHAVIORAL|Self-guided programme on cooperation|"Participants will download the application from the App store or Google Play store for free. In both programs, participants engage in content learning and short activities daily on the phone application. The anticipated time participants will spend on each program is comparable, of about less than five minutes per day.~Participants complete the same set of questionnaires immediately after completing the program (post-intervention measure), and again at 4 weeks after completing the program (follow-up measure).~At the end of the six weeks data collection period, all participants will be debriefed about the purpose of the study. Participants in the active wait-list control condition will be given access to the body image program."
224153620|NCT06278129|DIAGNOSTIC_TEST|Vestibular myogenic potentials|observational study
224302240|NCT00922987|DRUG|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
223742998|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
224302241|NCT06213870|DIAGNOSTIC_TEST|Surgical criteria|"In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.~In the perfusion group, patients who meet the criteria of DEFUSE3 will receive EVT surgery, otherwise receive medication."
224302242|NCT01547364|DRUG|Saline|Injection of 10 ml of normal saline into the caudal epidural space
224302243|NCT01547364|DRUG|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
224302244|NCT00446199|DRUG|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
224302245|NCT00446199|DRUG|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 3 cycles (28 days per cycle).
223456097|NCT01701544|DEVICE|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
223456098|NCT00844779|PROCEDURE|Bariatric surgery|Gastric bypass.
223456099|NCT00844779|PROCEDURE|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
223456100|NCT02667314|BEHAVIORAL|Jigsaw puzzles|"Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up."
224153621|NCT04496557|DEVICE|PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)|"Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax."
224153622|NCT04530396|BIOLOGICAL|Gam-COVID-Vac|vaccine for intramuscular injection
224153623|NCT04530396|OTHER|placebo|placebo comparator
224153624|NCT04505150|BEHAVIORAL|Lifestyle changes, e.g., take part in regular exercise, quitting smoking, and reduce salt consumption|Intervention participants will receive ongoing counselling with evidence-based information with pictures, fact sheets, published literature about the harmful effect of smoking on hypertension and other cardiovascular diseases for the cessation of smoking and to take part in regular exercise.
224153625|NCT05957588|OTHER|Proning group|"Patients were educated about self-proning, and instructed to self-prone every 2 hours. The patient documented their position on the checklists every 2 hours.~Upon initiation of the initial proning, the patient was monitored by the research team RN for adverse effects for 15 minutes (such as inability to tolerate position or signs of respiratory distress).~If the patient tolerated the proning well, the RN entered the patient's oxygen saturation into the EMR, and documented the initial position (prone or supine) on the checklist. O2 saturation was documented at least every 4 hours per unit protocol.~The checklists were placed in a binder at the nurses' station at the end of each shift and collected daily by a member of the research team.~This intervention for each proned patient continued until either of the following occurred: ei the patient was discharged to a lower level of care or 14 days had passed."
224153626|NCT05957588|OTHER|Control group|A retrospective chart review was completed by the research team to ascertain length of stay, oxygenation, and pressure injuries for the control group on the acute care, telemetry monitored unit.
224153627|NCT05690971|BEHAVIORAL|App|"HORIZONS is self-administered with several features to promote engagement and health behavior change including gamification strategies, videos of chronic GVHD survivors, and optional content.~HORIZONS includes five interactive modules to be completed during an eight week period. HORIZONS also includes a sixth optional helpful resources section with a review of the domains and skills covered in the first five modules"
224153628|NCT05690971|BEHAVIORAL|Usual Care|Patients in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.
224153629|NCT03779061|DRUG|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
224302246|NCT00446199|DRUG|Estradiol (E2 0.3mg)|One tablet \[17β-estradiol (E2 0.3mg)\] per day taken orally for 3 cycles (28 days per cycle).
223572609|NCT04804657|DIETARY_SUPPLEMENT|Placebo|Made with maltodextrin. It will be administrated the the morning before the endurance test (oral administration).
224153630|NCT03779061|DRUG|Propofol|Initial dose plus supplemental doses as necessary
224153631|NCT03944083|OTHER|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
224153632|NCT05065307|DIAGNOSTIC_TEST|Venipuncture|Diagnostic venipuncture
224153633|NCT01100645|DRUG|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
224153634|NCT01100645|DRUG|Placebo|Excipient
224153635|NCT02894528|DRUG|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
224153636|NCT02894528|DRUG|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
224153637|NCT06422429|DRUG|Traditional deep-fried Youtiao|45g 4 times a week for 4 months
224153638|NCT06422429|DRUG|PI Youtiao|45g 4 times a week for 4 months
224153639|NCT03962712|OTHER|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
224153640|NCT03962712|OTHER|No Increase in Minimum Wage|No increase in minimum wage
224302247|NCT00446199|DRUG|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
224153641|NCT05859360|OTHER|Physical performance and cardiovascular health measures|"* Retinal vessel analysis~* Muscle ultrasound~* Knee extension~* Voluntary activation~* spiroergometry"
224153642|NCT00383227|BIOLOGICAL|Hepatitis B adjuvanted vaccine|
224153643|NCT00659126|PROCEDURE|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
224153644|NCT00659126|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
224153645|NCT00659126|PROCEDURE|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
224153646|NCT00659126|DRUG|Ferumoxytol|Given IV
224153647|NCT00659126|DRUG|Gadolinium|Given IV
224153648|NCT00659126|PROCEDURE|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
224153649|NCT00659126|PROCEDURE|Susceptibility Weighted Imaging|Undergo SWI
224153650|NCT06185894|PROCEDURE|Uterovesical tourniquet before uterine devascularization steps|Insertion of a Foley catheter tourniquet through broad ligament apertures \& tightening it immediately before hysterotomy in cases of conservative management of placenta accreta spectrum
224153651|NCT06185894|PROCEDURE|Conventional conservative surgery|Conventional conservative surgery
224153652|NCT01837017|BEHAVIORAL|Home-based Exercise|This is a control group with no intervention
224153653|NCT00222417|PROCEDURE|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
224302248|NCT02381951|DEVICE|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
224302249|NCT03120533|DRUG|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
224153654|NCT00222417|PROCEDURE|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
224153655|NCT04961086|OTHER|energy drink|An easily available 250 ml branded energy drink will be randomized to the partcipants after informed consent. Before and thirty minutes after drinking the given energy drink the participant cognition, heart rate, blood pressure and blood glucose will be measured.
224153656|NCT01742533|BIOLOGICAL|human umbilical cord mesenchymal stem cells|
224153657|NCT01742533|BIOLOGICAL|hUCMSCs and hCBMNCs|
224153658|NCT01742533|BIOLOGICAL|human cord blood mononuclear cells|
224153659|NCT01742533|DRUG|Hormone Replacement Therapy|
224153660|NCT00870038|DEVICE|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
224153661|NCT00870038|DEVICE|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
224153662|NCT00870038|DEVICE|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
224153663|NCT01265342|DRUG|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
224153664|NCT01265342|DRUG|Placebo|Placebo nebulised suspension twice a day for 10 days
224153665|NCT01216397|DRUG|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
224153666|NCT01216397|DRUG|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
224153667|NCT05385627|PROCEDURE|Ankle block|Injection of local anaesthetics at the level of the ankle blindly (local infiltration analgesia). The dose, volume, and type of local anaesthetic will be registered.
224153668|NCT06059092|BEHAVIORAL|Adapt Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to coping strategies, locus of control, coping metacognition, positive psychology strategies. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
224153669|NCT06059092|BEHAVIORAL|Engage Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to goal setting, planning, strengths identification, motivation; goal pursuit metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
224153670|NCT06059092|BEHAVIORAL|Interact Module|In each intervention, participants will be trained selected psychological skills using cognitive-behavioral-inspired techniques related to social cognition, assertive communication and conflict resolution, proactive prosocial behaviors, interactional metacognition. Activities will involve brainstorming and exercises based on fictional situations, allowing active participation and reflection as well as feedback from animators and peers. Activities and aids have been designed to meet adolescents' developmental level, concerns and capacities and to support effective learning. Participants will be asked to carry out home tasks to practice learned skills. They will also be provided additional resources related to their module's thematic, accessible through a workbook and a website.
224153671|NCT06059092|BEHAVIORAL|Control Group|Sessions will be devoted to serious game training cognitive and executive functions through individual and group activities based on board games.
224153672|NCT03091699|DRUG|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
224302250|NCT03120533|DRUG|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
224302251|NCT01822574|PROCEDURE|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
224302252|NCT01822574|PROCEDURE|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
224153673|NCT03091699|BEHAVIORAL|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
224153674|NCT00648570|DRUG|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
224153675|NCT00648570|DRUG|Lexapro® Tablets (20 mg|20mg, single dose fasting
224153676|NCT02633046|DRUG|Acthar Gel|Acthar Gel 80 U/mL solution for subcutaneous injection
224153677|NCT04153643|PROCEDURE|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
224153678|NCT00869219|DRUG|Nevanac|1 drop of NEVANAC at random eye
224153679|NCT00869219|DRUG|Acular LS|One drop of Acular LS
224153680|NCT03449121|BEHAVIORAL|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
224153681|NCT00927719|BIOLOGICAL|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
224153682|NCT02352103|PROCEDURE|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
224153683|NCT02352103|PROCEDURE|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
224066143|NCT04687579|PROCEDURE|Umbilical hernia repair|A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
224066144|NCT06293612|OTHER|No intervention was administrated to the two cohorts.|
224066145|NCT01003496|BEHAVIORAL|Treatment as Usual (TAU)|Outpatient substance abuse treatment
224066146|NCT01003496|BEHAVIORAL|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
224066147|NCT03134872|BIOLOGICAL|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
224066148|NCT03134872|DRUG|Carboplatin|Carboplatin
224066149|NCT03134872|DRUG|Pemetrexed|Pemetrexed
224066150|NCT02765568|BEHAVIORAL|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
224066151|NCT02765568|BEHAVIORAL|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
224066152|NCT02765568|BEHAVIORAL|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
224066153|NCT00865826|OTHER|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
224066154|NCT01310894|DRUG|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
224153684|NCT02352103|DEVICE|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
224153685|NCT00592670|DRUG|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
224153686|NCT00592670|DRUG|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
224153687|NCT00971633|DRUG|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
224153688|NCT00971633|DRUG|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
224153689|NCT00971633|DRUG|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
224153690|NCT03124901|DEVICE|DCI pulse oximeter sensor|
224153691|NCT02843919|OTHER|Electroencephalography and Electrocardiography|
224153692|NCT03366818|DEVICE|thrombectomy|mechanical thrombectomy
223572610|NCT01213186|DRUG|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
224066155|NCT04038788|DEVICE|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
224066156|NCT03061981|DRUG|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
224066157|NCT03061981|DRUG|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
224066158|NCT03061981|DRUG|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
224066159|NCT04356560|DIAGNOSTIC_TEST|COVID-19 test, polymerase chain reaction for SARS-CoV-2|surveillance
224066160|NCT02821702|DEVICE|Vaginal ultrasound|
224066161|NCT02821702|BIOLOGICAL|Blood sample|
224066162|NCT02171585|DRUG|Dabigatran etexilate|
224066163|NCT02171585|DRUG|Clarithromycin|
224066164|NCT01902290|BIOLOGICAL|Placebo|Placebo administered subcutaneously
224066165|NCT01902290|BIOLOGICAL|Brodalumab|Brodalumab administered subcutaneously
224066166|NCT02626897|DEVICE|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
224066167|NCT02626897|DEVICE|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
224153693|NCT03094819|BEHAVIORAL|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
224153694|NCT03094819|BEHAVIORAL|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
224153695|NCT00686010|DRUG|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
224153696|NCT00686010|DRUG|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
224153697|NCT00686010|DRUG|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
224153698|NCT00686010|DRUG|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
224153699|NCT04420910|OTHER|Non-Motor Symptoms|NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
224153700|NCT04420910|OTHER|Balance|To measure balance, the Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) was used. The participants were asked to position themselves in a comfortable position on the platform, and their foot position coordinates were recorded. The participants focused on a characteristic dot on the monitor screen. Their task was to balance the body in such a way that the dot was in the center of a circle displayed on the monitor at the point of intersection of the coordinate axes. The test consisted of three 20 s trials, each separated by 10 s breaks. Measurements were conducted while their eyes were open and close, and the results were analyzed by calculating the average value of the measurements.
224153701|NCT04420910|OTHER|Lower Limb Strength|A Biodex® System 4 Dynamometer device was used to evaluate muscle strength. The participants' dominant extremity was determined by asking them the foot with which they most often hit the ball.The dynamometer arm of the device was placed at the lateral condyle level of the knee, and the belt at the distal end of the dynamometer was attached to the lower leg on the malleolus. Knee flexion and extension movements were evaluated in sitting position between 90ᵒ flexion and 0ᵒ extension angles. The individual was asked to perform it with the maximum strength, while the therapist motivated the individual with verbal stimulation.
224153702|NCT04420910|OTHER|Functional mobility|The Timed Up and Go test (TUG) was used in the evaluation of functional mobility. . For this test, participants were seated on a standard armless chair and a cone was placed 3 meters away from the chair. Participants were instructed to stand up and (1) walk towards the cone, (2) turn around the cone, (3) walk back to the chair, and (4) sit back on the chair. It was stated that patients should walk without running but as fast as possible. Dual task performance was performed by adding cognitive and motor tasks into the TUG.
224153703|NCT02681718|BEHAVIORAL|Community health worker education|Diabetes self-management education by community health workers
224153704|NCT02681718|BEHAVIORAL|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
224153705|NCT02876679|DRUG|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
224153706|NCT02876679|DRUG|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
224153707|NCT02876679|DRUG|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
224153708|NCT03310736|DIAGNOSTIC_TEST|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
224153709|NCT01549457|OTHER|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
224153710|NCT02281344|DRUG|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
224153711|NCT02738762|OTHER|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
224153712|NCT04006080|BIOLOGICAL|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
224153713|NCT03222440|DRUG|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
224302253|NCT01822574|PROCEDURE|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
224302254|NCT03071094|BIOLOGICAL|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10\^9 pfu at day 1 and weeks 2 and 4
224302255|NCT03071094|DRUG|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
224153714|NCT02024841|DRUG|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
224302256|NCT02074592|BEHAVIORAL|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
224153715|NCT00562016|DEVICE|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
224153716|NCT00562016|DEVICE|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
224302257|NCT02074592|BEHAVIORAL|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
224302258|NCT02312063|DRUG|Sitagliptin|
224302259|NCT02312063|DRUG|Glimepiride|
224302260|NCT00239655|DRUG|MK0812|
224302261|NCT05137470|OTHER|This is an observational study|This is an observational study
224302262|NCT01079832|RADIATION|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
224302263|NCT01079832|PROCEDURE|quality-of-life assessment|Ancillary studies
224066168|NCT02905474|OTHER|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
224066169|NCT02905474|DEVICE|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
224066170|NCT02905474|DEVICE|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
224066171|NCT02883751|RADIATION|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
224066172|NCT02883751|PROCEDURE|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
224066173|NCT05211479|BEHAVIORAL|educational intervention|"In the light of up-to-date information, Type I Diabetes Education Guide was created. With this guide, both face-to-face and tele-nursing training will be provided. Both working groups will receive training before starting research. The intervention group will continue their weekly training throughout the study."
224066174|NCT03043248|DRUG|TRK-700|repeated oral administration
224066175|NCT03043248|DRUG|Digoxin|single oral administration with/without TRK-700
224066176|NCT03043248|DRUG|Midazolam|single oral administration with/without TRK-700
224066177|NCT04996121|DRUG|XZP-5955 tablets|"Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle"
224066178|NCT02666573|DEVICE|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
224066179|NCT02666573|OTHER|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
224066180|NCT00223028|DRUG|sirolimus, mycophenolat mofetil, fluvastatin|
224066181|NCT02194127|DRUG|Anthocyan capsules|
224066182|NCT02194127|DRUG|Placebo|
224066183|NCT01514227|DRUG|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
224066184|NCT01514227|DRUG|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
224066185|NCT05595083|DRUG|intranasal dexmedetomidine group|patients will receive 1.5 ug/kg intranasal dexmedetomidine diluted with saline + infusion saline
224066186|NCT05595083|DRUG|intravouns dexmedetomidine group|patients will receive 0.1- 0.4 ug/kg intravenous infusion dexmedetomidine + intranasal saline.
224153717|NCT00259038|DRUG|Carperitide|
224153718|NCT00259038|DRUG|Placebo|
224153719|NCT06165523|OTHER|Water|340 mL plain tap water consumed immediately following glycogen depleting exercise
224153720|NCT06165523|OTHER|Flavored Kefir|320 mL kefir consumed immediately following glycogen depleting exercise
224153721|NCT06165523|OTHER|Flavored Milk|240 mL flavored milk consumed immediately following glycogen depleting exercise
224153722|NCT04228887|DIAGNOSTIC_TEST|Respiratory Muscle Strength|Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.
224153723|NCT04228887|DEVICE|Balance Training|Balance training will provide with Biodex® Balance Training System
224153724|NCT04228887|DEVICE|Inspiratory Muscle Training|15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
224153725|NCT01856842|PROCEDURE|Angiography and embolotherapy|
224153726|NCT04271670|OTHER|Ginger powder footbaths|20-minute footbath with 12 liters of 40°C warm water and an additive of 80g dried ginger powder (reaching up to mid-calf level)
224153727|NCT04271670|OTHER|Mustard powder footbaths|20-minute footbath with 12 liters of 40° C warm water and an additive of 80g dried mustard powder (reaching up to mid-calf level)
224066187|NCT00517829|DRUG|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
224066188|NCT00517829|DRUG|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
224066189|NCT00517829|DRUG|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
224066190|NCT00251940|DRUG|Tesaglitazar 0.5 or 1 mg|
224066191|NCT00251940|DRUG|Glibenclamide 2.5, 5, 10 or 15 mg|
224066192|NCT02486055|DRUG|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
224066193|NCT00805831|DEVICE|HDH|sutureless vascular anastomosis
224153728|NCT04271670|OTHER|Warm water only footbaths|20-minute footbath with 12 liters of 40° C warm water without any additive (reaching up to mid-calf level)
224153729|NCT01455415|DRUG|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
224153730|NCT01455415|DRUG|placebo|matching placebo 3 time a day
224153731|NCT03998761|DRUG|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
224153732|NCT03998761|DRUG|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
224153733|NCT04374578|DRUG|Dulaglutide 1.5 MG/ML|Dulaglutide 1.5Mg qw sc injection for 4 weeks
224153734|NCT00891761|DRUG|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
224153735|NCT00891761|DRUG|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
224153736|NCT00891761|DRUG|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
224153737|NCT00891761|DRUG|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
224153738|NCT00891761|DRUG|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
224153739|NCT02334553|DRUG|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
224153740|NCT02334553|DRUG|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
223456101|NCT02667314|BEHAVIORAL|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
224153741|NCT01601951|OTHER|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
223456102|NCT05349019|OTHER|Observational|This is an observational study to investigate the natural history of G2019S LRRK2 PD using traditional and digital methodology (digital phenotyping). Study conduct will be decentralized (at home as much as possible) consisting of two parts: Part A with Healthy Volunteers (HV) participants and Part B in patients with G2019S LRRK2 PD.
223456103|NCT04241913|BEHAVIORAL|Mom Power Intervention|Mom Power is a 10-week therapeutic intervention for at-risk families that incorporates elements of several evidence based practices. It combines didactic material with mindbody self-care skills and in vivo practice to improve the quality of attachment between parent and child, and to reduce the psychopathology of at-risk parents. The child team component provides each child with one-on-one care focusing on meeting the child's social-emotional needs and providing attachment-related experiences within a developmental framework.
224153742|NCT00014547|DRUG|BBR 3464|
224153743|NCT00818311|DEVICE|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
223456104|NCT00935077|OTHER|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
223456105|NCT00935077|OTHER|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
224153744|NCT01328197|DEVICE|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
224153745|NCT01699646|DEVICE|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
224153746|NCT01699646|PROCEDURE|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
224153747|NCT00587301|DEVICE|Lap-Band|Obesity and adolescents
224153748|NCT03670901|BIOLOGICAL|JHL1101|JHL1101, 100mg/10mL
224153749|NCT03670901|BIOLOGICAL|MabThera|Rituximab, 100mg/10mL
224153750|NCT03620604|DEVICE|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
224153751|NCT02758613|DRUG|Baricitinib|Administered orally.
224153752|NCT02758613|DRUG|Placebo|Administered orally.
224153753|NCT04128527|DEVICE|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
224153754|NCT02358564|PROCEDURE|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
224153755|NCT02358564|PROCEDURE|Upper Endoscopy|
224153756|NCT02358564|PROCEDURE|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
224153757|NCT01496274|BIOLOGICAL|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
223572611|NCT01213186|DRUG|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
223572612|NCT03369899|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
223572613|NCT01498627|BIOLOGICAL|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
223572614|NCT01498627|OTHER|Data collection|PGRx information system
223572615|NCT04352985|DEVICE|Toraymyxin PMX-20R (PMX Cartridge)|The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.
223572616|NCT05660902|OTHER|ROM Exercises|The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
223572617|NCT02664051|DRUG|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
223572618|NCT02664051|DRUG|placebo|100mg 4x2 daily mannitol
223572619|NCT02998905|DRUG|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
223572620|NCT02998905|DRUG|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
223572621|NCT01410669|BEHAVIORAL|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
223572622|NCT04304794|PROCEDURE|Administration of iodinated contrast media|Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
223572623|NCT04304794|DRUG|Prophylactic administration of antithyroid drugs before iodinated contrast media exposure|13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
223572624|NCT03334279|OTHER|Cigarette smokers|frequent cigarette smoking for not less than 5 years
223572625|NCT03334279|OTHER|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
223572626|NCT05938920|DRUG|INS018_055|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
223572627|NCT05938920|DRUG|Placebo|"Pharmaceutical formulation: Capsules~Mode of Administration: Oral"
223572628|NCT03473964|DRUG|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
224153758|NCT03364634|DIAGNOSTIC_TEST|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
224153759|NCT04587596|OTHER|Pain education|70 minute lecture about chronic pain and one focus group afterwards
224153760|NCT00721617|OTHER|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
224153761|NCT00721617|OTHER|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
224153762|NCT00721617|OTHER|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
224153763|NCT00351819|DRUG|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
224153764|NCT00351819|OTHER|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
224153765|NCT01213914|DEVICE|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~* double lumen dialysis catheter should be placed in the internal jugular or femoral vein~* Anticoagulation will be determined by prescribing physician~* Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~* Blood flow rate will be set to ensure a filtration fraction of no more than 25%~* Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~* Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~* All antibiotics will be dose adjusted for renal replacement therapy"
223456106|NCT00935077|OTHER|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
224153766|NCT01213914|OTHER|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
224153767|NCT01804114|PROCEDURE|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
224153768|NCT01804114|PROCEDURE|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
224153769|NCT04714723|BEHAVIORAL|Programmed smartphone intervention|Interactive programmed lifestyle education based on smartphone for six month
224153770|NCT04714723|BEHAVIORAL|Programmed smartphone plus dietitian intervention|Interactive programmed lifestyle education based on smartphone plus dietitians support for six month
224153771|NCT05236959|BEHAVIORAL|Mindfulness-Based Cognitive Therapy|Following an initial interview session, patients are offered eight weekly group-based session, delivered via videoconferencing, and asked to engage in regular daily home practice of mindfulness meditation
224153772|NCT05236959|OTHER|Treatment as Usual|Following an initial interview session, patients continue with their usual care
224153773|NCT01018693|DRUG|VAK694; Alutard Avanz SQ|
224153774|NCT01018693|DRUG|VAK694 placebo infusion; Alutard Avanz SQ|
224153775|NCT01018693|DRUG|VAK694 placebo infusion; Saline|
224153776|NCT01605383|BIOLOGICAL|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
224153777|NCT01605383|PROCEDURE|Standard treatment|Isolated core decompression
224153778|NCT06508853|OTHER|Qualitative research (no intervention)|Interviews are being conducted with support workers and managers.
224153779|NCT02182297|DRUG|BI 201335 NA in single rising doses|
224153780|NCT02182297|DRUG|Placebo|
224153781|NCT06174883|DIETARY_SUPPLEMENT|Folic acid fortified iodized salt|addition of folic acid to iodized salt to be consumed daily and assess rise in serum folate levels.
224153782|NCT03447119|BEHAVIORAL|Living Well with a Disability|Implementation of an adapted health promotion program.
224153783|NCT02910219|DRUG|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
224153784|NCT05106218|DEVICE|SurroundScope|The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
223456107|NCT05077553|DIETARY_SUPPLEMENT|TCI999 probiotic sachet|Testing product
223456108|NCT05077553|DIETARY_SUPPLEMENT|Placebo sachet|Blank
223456109|NCT02315664|BEHAVIORAL|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
223456110|NCT02315664|BEHAVIORAL|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
223456111|NCT02575378|DRUG|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
224153785|NCT05106218|DEVICE|Standard Laparoscope|The procedure will be performed according to the institution's standard of care, using the Standard laparoscope for visualization.
224153786|NCT02055170|DRUG|finasteride 5mg oral daily|
224153787|NCT01719679|BEHAVIORAL|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
224153788|NCT02659475|DRUG|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
224302264|NCT06910696|DRUG|Regional Anesthetic Injection|The probe will be placed in the parasagittal plane at the level of the L3 vertebrae. The spinous process will be visualized, and the probe was moved 3 cm laterally from the midline. The erector spinae musclewill be visualized above the transverse process. The needle will be punctured in the craniocaudal direction using the in-plane technique. The needle will be directed superior to the transverse process . Then, 2 mL normal saline solution will be injected into the deep fascia of the erector spinae muscle to confirm the proper injection site. After ensuring the location of the needle, 20 mL of 0.25% bupivacaine will be administered. The same ESPB procedure will be performed on the other side. In total, 40 mL of 0.25% bupivacaine was administered
224153789|NCT00706615|BIOLOGICAL|Ad-sig-hMUC-1/ecdCD40L vaccine|
224153790|NCT02382653|DRUG|oral perixicam|Oral adminstration of buccal perixicam
223456112|NCT02575378|DRUG|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
224153791|NCT01015820|PROCEDURE|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
224153792|NCT01015820|DEVICE|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
224153793|NCT06052189|PROCEDURE|Ultrasound|Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
224153794|NCT06378060|DRUG|Modified transplantation system|Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
224153795|NCT03578380|PROCEDURE|Surgery|Lymphovenous anastomosis
224153796|NCT03578380|OTHER|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
224153797|NCT03271957|PROCEDURE|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
224153798|NCT00578604|DEVICE|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
224153799|NCT04163055|DEVICE|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
224153800|NCT02690168|BEHAVIORAL|Fasting|72 hour fasting
224153801|NCT02219217|DRUG|Dolutegravir, Elvitegravir and Cobicistat|
224153802|NCT03835013|DRUG|Saline 0.9%|Intravenous infusion of 0.9% saline
224153803|NCT03835013|DRUG|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
224153804|NCT03835013|DRUG|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
224153805|NCT03835013|DRUG|Exenatide|Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes
224153806|NCT01998152|PROCEDURE|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
224153807|NCT03906175|DEVICE|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
224153808|NCT00243685|OTHER|Laboratory Assay|Chemotherapy
223456113|NCT01451099|BIOLOGICAL|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
223456114|NCT02922465|DRUG|K-877|
223456115|NCT02922465|DRUG|Clopidogrel|
223456116|NCT04288882|DEVICE|Enteroscopy|Role of Balloon-Assisted Enteroscopy (BAE) in management of Small Intestinal Disorders
223456117|NCT02501161|DRUG|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
224066194|NCT00505999|BEHAVIORAL|Questionnaire|Questionnaire taking 30-40 minutes to complete.
224066195|NCT03410888|PROCEDURE|Popliteal approach|"Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
224066196|NCT03410888|PROCEDURE|Infragluteal approach|Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
224066197|NCT03042715|BEHAVIORAL|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
224066198|NCT04793425|BEHAVIORAL|Mobile application (afterAMI)|"The rehabilitation process of the patients in the intervention group will be supported by the mobile application (afterAMI) with synchronized, dedicated web page.~Patients in the intervention group will be given an access to educational data regarding their individualized diseases. Additionally every patient will receive regularly messages with notifications regarding lifestyle and adherence to the therapy. All reported vital signs (blood pressure, heart rate, weight and many more) will be analyzed every day and in case of need a short message will be sent to the patient with indication to go to the primary healthcare clinic/hospital.~Additionally, application will send notifications with reminders to take drugs."
223456118|NCT02501161|DRUG|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
223456119|NCT03159299|BEHAVIORAL|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
224066199|NCT02184078|DRUG|Nevirapine|
224066200|NCT02184078|DRUG|Rifabutin|
224066201|NCT01825707|DRUG|[14C]-YH4808 200 mg|\[14C\]-YH4808 200 mg (oral) on day1
224066202|NCT02672670|BEHAVIORAL|Experimental: Intervention group---coping-oriented supportive programme|
224066203|NCT02672670|BEHAVIORAL|Active Comparator: Comparison group---a didactic talk (usual care)|
224066204|NCT02688595|DEVICE|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
224066205|NCT02688595|OTHER|General anesthesia|Scheduled operation under general anesthesia
224066206|NCT02267694|DRUG|Freeze-dried black raspberry powder|
223456120|NCT00253006|PROCEDURE|Tissue examination for protein- and mRNA-expression of NO|
223456121|NCT05249387|DRUG|A-967079 and BAM8-22 application|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
223456122|NCT05249387|DRUG|A-967079 and BAM8-22 application after 5 minutes.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
223456123|NCT05249387|DRUG|A-967079 application.|A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
224066207|NCT04538794|DRUG|CDX-0159|Administered intravenously
224066208|NCT04538794|DRUG|Normal Saline|Administered intravenously
224066209|NCT04160130|PROCEDURE|Transcatheter aortic valve replacement|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
224066210|NCT00062335|RADIATION|radiation therapy|
224066211|NCT04609852|DRUG|E8001|Intravenous infusion.
224066212|NCT04609852|DRUG|Placebo|Intravenous infusion.
224153809|NCT00243685|OTHER|Mick Assay|Chemotherapy doctor determined from results
224163556|NCT05240781|DEVICE|Sirolimus eluting stent|"Size (diameter and length) will be chosen at operator's discretion aided by simple angiography, QCA, or intravascular image; so that the lesion previously prepared and 2 mm at each end are covered by DES with an stent to artery ratio of 1.1. Post-dilatation will be performed when indicated. Device will be used in accordance with the CE mark instructions.~All patients will receive DAPT as follows: After a loading dose (if necessary) of aspirin and a P2Y12 inhibitor, aspirin 100 mg and a P2Y12 inhibitor daily will be indicated for 1 month in both ACS and CCS. Patients with high ischemic risk could be extended to 3 months. After DAPT, SAPT will be continued with the drug of choice, preferably P2Y12 inhibitor. Patients requiring chronic anticoagulation will receive triple therapy only during hospitalization. At release, an oral anticoagulant (NOAC preferred over VKA) will be indicated along with 6 months of SAPT with a P2Y12 inhibitor."
224153810|NCT02313415|PROCEDURE|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
224153811|NCT03558971|DRUG|Cortisol|Participants determine when to administer 5-day regimens of cortisol
224153812|NCT01313078|DRUG|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m\^2 intramuscular or intravenously every 2 weeks
224153813|NCT01757587|DRUG|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
224153814|NCT01757587|DRUG|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
224153815|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
224153816|NCT01227720|DRUG|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
224153817|NCT01227720|DRUG|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
224153818|NCT01227720|DRUG|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
224153819|NCT01565811|PROCEDURE|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
224153820|NCT04628611|DEVICE|Video laryngoscopy|Endotracheal intubation using video laryngoscopy
224153821|NCT04628611|DEVICE|Flexible intubating laryngoscopy|Endotracheal intubation using flexible intubating laryngoscope
224153822|NCT05666661|OTHER|Sound and light therapy (BBT and FL group)|During intervention, the participants close their eyes and wear an eye mask and stereo earphones. They then listen to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phone. The intervention music was first embedded in the participant's mobile phone and the BBT music application was purchased from the mobile phone app (Brainwave Studio software, Dalcoms Inc). When listening to music, 10 Hz light stimulation was added to the BBT and FL group (using a mobile phone). Table 1 shows the intervention status. The rhythmical photic stimulation program was a commercially available mobile phone app (Strobe Therapy software released by FuwhatSoft).
224153823|NCT05666661|OTHER|Sound therapy group (BBT)|Participants in the sound therapy group (BBT) listened to 30 minutes of 10 Hz BBT music (intercalated with relaxing music) through their mobile phones. Except for rhythmical photic stimulation, the other steps were the same as the BBT and FL group.
224153824|NCT05666661|OTHER|Relaxing music group|Participants listened to 30 minutes of relaxing music (the same as that of the experimental groups) through their mobile phone. Except for rhythmical photic stimulation and 10 Hz BBT, the other steps were the same as the experimental groups.
224153825|NCT00501462|DRUG|GSK189075|single 250 mg dose of drug
224153826|NCT01961089|DEVICE|Galilei Lens Professional|Measurement device
224153827|NCT01961089|DEVICE|IOLMaster|Measurement device
224153828|NCT01961089|DEVICE|Lenstar|Measurement device
224153829|NCT01155960|DRUG|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
224153830|NCT04745468|DEVICE|CRP apheresis|Selective CRP apheresis by use of the PentraSorb-CRP adsorber
224153831|NCT04938089|OTHER|Maintenance|Regular compliant individual is defined in the study as a subject attending 100% of his/her recall visits with a maximum interval of 6 months. Irregular compliant individual is defined as a subject who missed at least one of the recall visits but continued to appear on an irregular basis with a maximum interval of 18 months, non-smoker individual is defined as a subject who never smoked, and lastly, smoker individual is defined as a subject who is smoking \> 9 cigarettes per day.
224153832|NCT01268904|DRUG|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
224153833|NCT01559701|DRUG|PF-00345439|5-80 mg twice-a-day for 12 months
224153834|NCT05955430|OTHER|Therapeutic exercise|It consists of strengthening exercises and gradual walking. The lower limb strengthening exercises are individualized and progressive for each patient for twelve weeks. There will be eight face-to-face sessions over four weeks. And then the patient will continue with those exercises for eight more weeks. In addition, they must perform twelve weeks of progressive walking until they are walking at least 30 minutes, 5 days a week at a moderate intensity (defined as moderate shortness of breath while walking).
224153835|NCT05955430|OTHER|Pain education|A therapeutic pain education program for patients will be implemented. There will be four 30-minute face-to-face sessions (one session per week). The objective is to change the participants' conceptualization of pain. From seeing pain as a marker of tissue damage to a marker of the body's perceived need for protection. Contents include basic structure of the nervous system, distinction between nociception and pain, peripheral and central sensitization, neuroplasticity and benefits of exercise.
224153836|NCT05955430|OTHER|Percutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four needles located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
224163557|NCT01938391|DEVICE|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
224153837|NCT05955430|OTHER|Transcutaneous electrical stimulation|A TENS (100 Hz 100 ms) current will be applied through four patches located in the knee for 30 minutes. Eight sessions will be held during a month (two per week). The distribution of the channels will be for the first channel anode in lateral anterior zone and cathode in medial anterior zone and for the second channel anode in Hoffa's fat and cathode in goose foot. Participants will be able to adjust the amplitude to a strong and manageable sensory stimulation intensity that was not strong enough to cause muscle contraction.
224153838|NCT05955430|OTHER|Placebo stimulation|To perform the dry needling placebo, modified needles will be used according to the validation performed by Mitchell et al. 2018, since they generate more puncture sensation than normal needles, which has been shown to generate more analgesia and to be more effective as a placebo. To perform placebo TENS, the protocol established by Rakel et al. 2010 will be used, which consists of applying a TENS of 100 Hz and 100 ms for 30 seconds and then lowering the intensity during the following 15 seconds. Eight sessions will be held during a month (two per week).
224153839|NCT02476344|OTHER|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
224153840|NCT00014001|DRUG|perphenazine|
224153841|NCT00014001|DRUG|olanzapine|
224153842|NCT00014001|DRUG|quetiapine|
224153843|NCT00014001|DRUG|risperidone|
224153844|NCT00014001|DRUG|ziprasidone|
224153845|NCT00014001|DRUG|clozapine|
224153846|NCT00014001|DRUG|fluphenazine decanoate|
224153847|NCT03990701|COMBINATION_PRODUCT|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
224153848|NCT05739240|PROCEDURE|Osteosynthesis|Osteosynthesis of distal radius fractures
224153849|NCT01225172|DRUG|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
224153850|NCT01225172|DRUG|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
224153851|NCT01729104|DRUG|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
224153852|NCT01729104|DRUG|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
224153853|NCT01729104|DRUG|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
224153854|NCT05163834|BIOLOGICAL|Efgartigimod|intravenous infusion of efgartigimod
224153855|NCT05163834|OTHER|Placebo|intravenous infusion of placebo
224153856|NCT05163834|BIOLOGICAL|PNEUMOVAX 23|PNEUMOVAX 23 vaccine
224153857|NCT01414517|DIETARY_SUPPLEMENT|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
224153858|NCT01414517|DIETARY_SUPPLEMENT|Maltodextrin|a non-prebiotic carbohydrate
224153859|NCT03410134|DEVICE|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
224153860|NCT01692834|DRUG|Sandimmune® Injection|
223572629|NCT01125969|BEHAVIORAL|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
224153861|NCT01692834|DRUG|NeuroSTAT®|
224153862|NCT05581355|BEHAVIORAL|Abdominal breathing training|In the sleep center, it is carried out in a one-on-one manner by the trainer. At home, self-training through abdominal breathing training videos (10 minutes per day, you can accumulate up to 10 minutes in divided doses)
224153863|NCT02679781|DRUG|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
224153864|NCT02679781|DRUG|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
224153865|NCT03490019|DRUG|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
224153866|NCT04209400|BIOLOGICAL|Sci-B-Vac®|Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml
224153867|NCT04209400|BIOLOGICAL|Engerix-B®|Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
223572630|NCT01125969|BEHAVIORAL|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
224153868|NCT03638115|DEVICE|VaSecure™|Drug Coated PTA Balloon Catheter
224153869|NCT02529670|PROCEDURE|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
224153870|NCT02529670|PROCEDURE|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
224153871|NCT02529670|PROCEDURE|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
224153872|NCT01754285|DRUG|LF-PB and Placebo|
224153873|NCT01754285|DRUG|Placebo|
224153874|NCT01754285|DRUG|LF-PB|
224153875|NCT05191732|COMBINATION_PRODUCT|Platelet-Rich Plasma; Bone marrow concentrate|Platelet-rich plasma (PRP) (Dosage form: APA-15) Bone marrow concentrate (BMC) (Dosage form: APA-15Q)
224153876|NCT00317876|DRUG|cyclophosphamide|
224153877|NCT00317876|DRUG|cyclosporine|
224153878|NCT00317876|DRUG|methotrexate|
224153879|NCT00317876|PROCEDURE|allogeneic bone marrow transplantation|
224153880|NCT00317876|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
224153881|NCT02560480|DEVICE|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
224153882|NCT04128618|DEVICE|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
224153883|NCT00209833|DRUG|Cytarabine|
223572631|NCT01125969|BEHAVIORAL|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
223572632|NCT02157792|DRUG|M6620|
223572633|NCT02157792|DRUG|Gemcitabine|
223572634|NCT02157792|DRUG|Cisplatin|
223572635|NCT02157792|DRUG|Etoposide|
223572636|NCT02157792|DRUG|Carboplatin|
223572637|NCT02157792|DRUG|Irinotecan|
223572638|NCT02815436|OTHER|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
223572639|NCT02815436|OTHER|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
223572640|NCT00545220|BEHAVIORAL|problem-solving training|
224066213|NCT00725400|OTHER|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
224066214|NCT00725400|PROCEDURE|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
224066215|NCT03245931|OTHER|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
224066216|NCT02875639|DRUG|Yiqi prescription|
224066217|NCT02875639|DRUG|Huoxue prescription|
224066218|NCT02875639|DRUG|Buyang huanwu decoction|
224066219|NCT02875639|DRUG|QISHEN YIQI DRIPPING PILLS|
224066220|NCT02875639|DRUG|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
224066221|NCT02875639|DRUG|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
224066222|NCT00796276|DRUG|IR OROS paliperidone and ER OROS paliperidone|
224066223|NCT05979298|DRUG|Gemcitabine|Chemotherapeutics
224066224|NCT05979298|BIOLOGICAL|ELENAGEN|DNA plasmid
224066225|NCT00736346|BEHAVIORAL|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
224066226|NCT00736346|BEHAVIORAL|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
224066227|NCT00736346|DRUG|paroxetine|40 mg die, for 6 months
224066228|NCT00004420|DRUG|gamma-Linolenic acid|
224066229|NCT03579355|BEHAVIORAL|DFND Program|The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
224066230|NCT01178450|PROCEDURE|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
224066231|NCT01178450|DRUG|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
224066232|NCT04683965|DRUG|Pemetrexed|Pemetrexed 500 mg/m2 d1
223572641|NCT00545220|BEHAVIORAL|sham intervention|
223572642|NCT00257595|DRUG|Cetirizine Dry Syrup|
223572643|NCT04486482|OTHER|KB109 + Self Supportive Care (SSC)|KB109 is a novel glycan
223572644|NCT04486482|OTHER|Self Supportive Care (SSC) Alone|Self Supportive Care (SSC) Alone
223572645|NCT04341987|BEHAVIORAL|brief Imagery Rehearsal Therapy|Two-sessions of behaviorally-based imagery rehearsal therapy.
223572646|NCT04341987|OTHER|Treatment As Usual|may include medication treatment or behavioral treatment for nightmares other than imagery rehearsal therapy
223742999|NCT01227941|DRUG|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m\^2 will be administered intravenously on Day 3 of the cycle.
224066233|NCT04683965|DRUG|TAS-102|TAS-102, capsule, 35mg/m2, bid,p.o, d1\~5,d8\~12
224066234|NCT04683965|DRUG|Bevacizumab|Bevacizumab 5 mg/kg d1,d14
224066235|NCT03436862|DRUG|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
224066236|NCT01508728|DEVICE|ORTHOSENS orthosis|with active vibration
224066237|NCT01508728|DEVICE|ORTHOSENS orthosis|with placebo vibration
224066238|NCT01329393|BEHAVIORAL|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
224066239|NCT01329393|BEHAVIORAL|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
224066240|NCT00285727|DRUG|Ropinirole CR|
224066241|NCT02204696|PROCEDURE|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
224066242|NCT03393767|DRUG|Ranibizumab|Intravitreal injection
224066243|NCT00793481|DEVICE|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
224153884|NCT00209833|DRUG|Idarubicin|
224153885|NCT00209833|DRUG|Etoposide|
224153886|NCT00209833|DRUG|Fludarabine|
224153887|NCT00209833|DRUG|G-CSF|
224153888|NCT00209833|DRUG|Daunorubicine|
224153889|NCT04066530|DRUG|AD-203|AD-203 administered two times daily for two weeks
224153890|NCT04066530|DRUG|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
224153891|NCT01445964|DRUG|Atenolol|Atenolol oral administration
223456124|NCT05249387|DRUG|Vehicle and BAM8-22 application.|Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
223456125|NCT03450408|PROCEDURE|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
223456126|NCT03843320|DEVICE|SAPIEN 3|Transcatheter aortic valve replacement
223456127|NCT03843320|DEVICE|SAPIEN XT|Transcatheter aortic valve replacement
223456128|NCT03843320|DEVICE|INSPIRIS RESILIA|Surgical aortic valve replacement
224066244|NCT00674050|DRUG|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
223456129|NCT03843320|DEVICE|EDWARDS INTUITY|Surgical aortic valve replacement
223456130|NCT03843320|DEVICE|Carpentier-Edwards PERIMOUNT Magna-Ease|Surgical aortic valve replacement
224066245|NCT00674050|DRUG|Albuterol (Salbutamol)|2 puff= 200ug total dose
224066246|NCT00674050|DRUG|Fluticasone|2 puffs= 500ug total dose
224066247|NCT00006456|RADIATION|stereotactic radiosurgery|
224066248|NCT02970890|DEVICE|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
224066249|NCT06288620|PROCEDURE|Microwave Ablation|Preoperative US-guided microwave ablation of breast cancer
224066250|NCT00978315|DIETARY_SUPPLEMENT|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
224066251|NCT00978315|DIETARY_SUPPLEMENT|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
224066252|NCT05455112|BIOLOGICAL|RUTI® Vaccine|One subcutaneous injection of RUTI 25µg FCMtb
224066253|NCT05455112|BIOLOGICAL|Placebo|One subcutaneous injection of saline
224066254|NCT01501305|DIETARY_SUPPLEMENT|Mineral solution|Rehydration mineral solution
224066255|NCT01501305|DIETARY_SUPPLEMENT|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
224066256|NCT05940779|OTHER|Therapeutic exercise program|The intervention is a therapeutic program composed of self-resisted strength exercises, balance training and exercises to improve posture.
224066257|NCT02961335|PROCEDURE|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
224066258|NCT02961335|PROCEDURE|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
224066259|NCT02961335|PROCEDURE|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
224066260|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF)|Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
224066261|NCT05285293|BIOLOGICAL|Platelet Rich Fibrin (PRF) and Retinol|Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
224066262|NCT03658382|OTHER|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
224066263|NCT03743870|DRUG|Levobupivacaine|Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
224066264|NCT03743870|DRUG|Bupivacaine|Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
224066265|NCT05915572|OTHER|Mulligan Mobilization Technique|The therapist applied passive accessory glide to increase shoulder flexion, abduction, external rotation
224066266|NCT05915572|OTHER|Traditional Physical Therapy Program|Myofascial release and ROM ex. 3 sessions per week for 6 weeks.
224066267|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Test product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
224066268|NCT06233071|DRUG|Drospirenone+ Ethinyl Estradiol Tablets-Reference product|Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
224066269|NCT01606111|DRUG|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
224066270|NCT01606111|DRUG|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
224153892|NCT01445964|DRUG|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
224153893|NCT01445964|DRUG|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
224153894|NCT00795509|DRUG|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
224153895|NCT05474989|DRUG|LSD|Moderate to high dose LSD
224153896|NCT05474989|DRUG|Active placebo|Low dose LSD
224153897|NCT03305601|OTHER|application on smarthphone|application on smarthphone
224153898|NCT03907787|DIETARY_SUPPLEMENT|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
224153899|NCT06170281|BEHAVIORAL|Migraine Behavioral Treatment|Migraine Behavioral Treatment involving daily activities
224153900|NCT02288039|OTHER|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
224153901|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
224153902|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
224153903|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
224153904|NCT00638755|DRUG|Nasal Carbon Dioxide|Nasal Carbon Dioxide
224153905|NCT03966495|OTHER|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
224153906|NCT03006081|DRUG|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
224153907|NCT04905823|DIAGNOSTIC_TEST|blood test|assessment of humoral, immune cell response and glycemia
224153908|NCT00053638|DRUG|efavirenz|
224153909|NCT00053638|DRUG|tenofovir|
224153910|NCT00053638|DRUG|abacavir/lamivudine|
224153911|NCT05609851|OTHER|Short Physical Performance Batary|"The SPPB includes usual walking speed over 4 m, five chair-stands test, and balance test. A score (scale: 0-4) was assigned to performance on time to rise five times from a seated position, standing balance, and 4-m walking velocity. Individuals received a score of 0 for each task they were unable to complete. Participants coded in the unable to perform category included (a) those who tried but were unable and (b) the interviewer or participant felt it was unsafe. Summing the three individual categorical scores, a summary performance score was created for each participant (range: 0-12), with higher scores indicating better lower body function."
224153912|NCT05609851|OTHER|Occupational Balance Self-Assessment|"The Occupational Self-Assessment (OSA) is a self-reported assessment tool consisting of 21 items in which the patient rates their occupational competence (i.e., how well they do) and value (i.e., how important it is to them). The first 11 items are related to skills and occupational performance, the next five items concern habitation (including habits and roles), and the last five items correspond to volition (including personal causation, values, and interests). In the OSA, each item is scored on two separate 4-point scales, one for occupational competence (1 = I have a lot of problems doing this; 4 = I do this extremely well) and the other for value (1 = This is not important to me; 4 = This is most important to me).~The individual item scores are summed to obtain separate total scores for competence and value. Higher total scores indicate higher occupational competence and value."
224153913|NCT01871272|PROCEDURE|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
224153914|NCT03066297|PROCEDURE|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
224153915|NCT00644124|DRUG|aflibercept|in combination with standard treatment R-CHOP
224153916|NCT02468960|DEVICE|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
224153917|NCT02468960|DEVICE|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
224153918|NCT02468960|DEVICE|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
224153919|NCT02468960|PROCEDURE|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
224153920|NCT02468960|OTHER|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
224153921|NCT02151968|PROCEDURE|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
224153922|NCT02151968|PROCEDURE|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
224153923|NCT01090869|BEHAVIORAL|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
224153924|NCT00083629|PROCEDURE|PET|
224153925|NCT00279032|DRUG|GW406381|
224153926|NCT02045056|DRUG|Gemfibrozil|
224153927|NCT02045056|DRUG|Placebo|
224153928|NCT00033982|DRUG|Posaconazole|
224153929|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
224153930|NCT00613717|DIETARY_SUPPLEMENT|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
224153931|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
224153932|NCT00613717|DIETARY_SUPPLEMENT|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
224153933|NCT01522560|OTHER|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
224066271|NCT04450121|DEVICE|Patients will be intubated using Air-Q airway|"Both groups:~Grade 1: Split airway provides an unobstructed path for bronchoscope from mouth to glottis.~Grade 2: Tongue rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 3: Epiglottis rests against posterior pharyngeal wall causing partial obstruction to bronchoscope.~Grade 4: Tongue and epiglottis rest against posterior pharyngeal wall, both causing partial obstruction to bronchoscope.~Grade 5: Tongue rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure).~Grade 6: Epiglottis rests against posterior pharyngeal wall causing total obstruction to bronchoscope (failure)"
224066272|NCT00606086|DRUG|GI-5005|40YU, subcutaneous
224066273|NCT00606086|DRUG|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
224066274|NCT03460782|BIOLOGICAL|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
224066275|NCT02881632|DEVICE|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
224066276|NCT00887393|OTHER|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (\< 15% of total kcaloric intake)
224066277|NCT00887393|OTHER|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
224066278|NCT02432768|DRUG|Triheptanoin|Anaplerotic dietary oil
224066279|NCT02432768|OTHER|Placebo oil|Safflower oil
224066280|NCT02620696|DRUG|netazepide|
224066281|NCT00436371|DRUG|Amisulpride|Oral tablets
224066282|NCT00548496|DRUG|SB-751689|SB-751689
224066283|NCT00548496|OTHER|Placebo|Placebo to match
224066284|NCT02500628|DRUG|Metformin|500 mg orally after baseline testing of heart rate
224066285|NCT04212676|OTHER|Body Awareness Therapy|The BAT for the participants was based on the works of Roxendal and Dropsy. Activities include relaxation exercises, breathing exercises, floor exercises for trunk and pelvic movements, weight transfer using extremities and proprioceptive movements. Movements will be made in various positions to determine the centerline of the body. All exercises will be started in the supine position to maximize proprioceptive motion feedback and minimize energy requirements during tasks. Movements will be taught in a series of lessons over a period of 8 weeks with advance advancement of selected movements depending on participant comfort.
224066286|NCT04212676|OTHER|Pulmonary Rehabilitation|Diaphragmatic breathing exercise Thoracic expansion exercises (Chest breathing and bilateral segmental breathing exercises) Inductive spirometry (Triflo®) exercise Cough development techniques
224066287|NCT03934983|DIAGNOSTIC_TEST|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
224066288|NCT04640883|BEHAVIORAL|Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)|Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (\>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of \~50% in load compared to habitual training.
224066289|NCT04640883|BEHAVIORAL|Low-intensity cycling during a 14-day training camp (high training load)|Five low-intensity cycling sessions (\>four hours per session), distance-matched to sprint group.
224066290|NCT04640883|BEHAVIORAL|Recovery for 10 days (low training load)|Habitual low-intensity cycling (\>0.5-2 hours per session)
224066291|NCT02381665|DEVICE|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
224066292|NCT02381665|DEVICE|Flexstim IF faked|Patient enrolled will receive a sham device.
224066293|NCT05190003|OTHER|Experimental Study|On the basis of neurosurgical examination and MRI imaging, 40 patients aged 20-65 years with pains in the lumbar spine will be referred for the first-time single-level microdiscectomy procedure. Microdiscectomy patients will begin a rehabilitation program that will be includes exercises to reduce pain and strengthen the stabilizing muscles of the lumbar spine. From week to week, exercises will be difficult, among others due to the change of initial positions, the number of repetitions of exercises, or a longer duration of isometric exercises.
224066294|NCT00391222|DRUG|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
224066295|NCT00391222|DRUG|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
224066296|NCT00391222|DRUG|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
224066297|NCT02702037|DIETARY_SUPPLEMENT|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
224153934|NCT01522560|OTHER|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
224153935|NCT00201760|DRUG|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
224302265|NCT06910696|DRUG|Regional Anesthetic Injection|The probe will be placed vertically at the L3 vertebrae level. The spinous process and the interspinous muscles (i.e., multifidus, longissimus, and iliocostalis) will be visualized as the anatomic guide points. The probewill be moved laterally to identify the longissimus and iliocostalis muscles . The needlewill be inserted between the longissimus and iliocostalis in the medial-to-lateral direction using the in-plane technique. After confirming the location of the needle, 20 mL of 0.25% bupivacaine will be administered. The same mTLIP procedure will be performed on the opposite side. In total, 40 mL of 0.25% bupivacaine will be administered
224302266|NCT06926816|GENETIC|Natera® Empower™ hereditary cancer panel test|The test will be the Natera® Empower™ hereditary cancer panel test and will be collected by saliva.
224153936|NCT00201760|DRUG|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
224153937|NCT00201760|DRUG|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
224153938|NCT05160662|PROCEDURE|New guidlines|New guidelines for this group are being developed using NICE guidelines (evidence-based recommendations for health and care in England) as a model and will be tested in clinical practice
224153939|NCT01999348|DRUG|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
224153940|NCT05308667|OTHER|Rehabilitation (modified constraint-induced movement therapy)|Modified constraint-induced movement therapy (mCIMT): It is an intervention used to improve functionality and mobility in the more affected upper extremity post-stroke.
224153941|NCT05308667|OTHER|non-invasive brain stimulation (intermittent theta-burst stimulation)|Intermittent theta-burst stimulation (iTBS): It is a form of repetitive transcranial magnetic stimulation and it increases the facilitation of the motor cortex.
224153942|NCT01574937|DRUG|Cabozantinib|28 day cycle
224153943|NCT01574937|DRUG|Abiraterone|28 day cycle
224153944|NCT00273299|DRUG|valsartan plus hydrochlorothiazide|
224153945|NCT00383708|DRUG|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
224153946|NCT00383708|DRUG|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
224153947|NCT03191812|OTHER|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
224153948|NCT02945306|PROCEDURE|Adenotonsillectomy|
224153949|NCT02945306|DRUG|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
224153950|NCT06266871|DRUG|SOX+Tislelizumab+LDRT|"All patients will start with one cycle of neoadjuvant therapy of SOX plus tislelizumab regimen: S-1: 40-60 mg Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; tislelizumab: 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another two cycles of SOX plus tislelizumab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of SOX plus tislelizumab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with SOX regimen for up to 5 cycles."
224153951|NCT00054184|DRUG|docetaxel|
224153952|NCT00054184|DRUG|paclitaxel poliglumex|
224153953|NCT03908580|DRUG|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
224153954|NCT06156904|DEVICE|Bone grafting for the treatment of surgically created bone defects or bone defects/voids resulting from traumatic injury to promote healing in the pelvis, upper and lower extremities.|"All patients enrolled in this clinical investigation will undergo a reconstruction of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone as per the standard of care at the investigational sites. Patients will be treated with b.Bone which will be used as a bone substitute in isolation or as a graft expander to promote healing in the pelvis, upper and lower extremities.~b.Bone is a bone substitute without initial mechanical properties, therefore it is to be used in conjunction with internal/external fixation devices suitable for primary stabilization."
224153955|NCT01841294|DRUG|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
224153956|NCT01841294|DRUG|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
224153957|NCT02077491|OTHER|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
224153958|NCT00121680|DRUG|E7080|Oral.
224153959|NCT05460689|OTHER|M-HEALTH APP|The intervention group will have in use a mHealth App for education and support of caregivers of children undergoing tonsillectomy and/or adenoidectomy in the perioperative process. An out-patient nurse will be in charge of instructing intervention group participants to mHealth App use and content options. The mHealth App will be available for intervention group families from the day of pre-admission visits to the 7th day post surgery or follow up visit.
224302267|NCT06926816|OTHER|Specialist Referral|Participants with actionable pathogenic variants will be referred to the appropriate specialists (e.g., medical oncologist, gynecologic oncologist, breast surgeon) to discuss risk-reduction strategies and offered genetic counseling
224302268|NCT06927258|DRUG|changyanning granules|From one day before the procedure to five days postoperatively, patients in the experimental group will be administered Chanyanning granules.
224302269|NCT06927258|DRUG|Placebo|control
224302270|NCT02053675|DRUG|Vasopressin infusion|
224302271|NCT06485960|OTHER|ESDAM validation|"* 3\* 24-Hour Dietary Recalls~* Experience Sampling Dietary Assessment Method (mobile application)~* Continuous Blood Glucose Monitoring~* Doubly-labeled water administration~* Blood drawings (Erythrocyte Membrane Fatty Acid composition, Carotenoids)~* Urine sampling (Doubly-labeled water, urinary nitrogen)"
224302272|NCT02205762|DRUG|Prednisone|Stratum I
224302273|NCT02205762|DRUG|Vinblastine|Stratum I
224153960|NCT05460689|OTHER|Standard Care|The control group will receive information and education provided by nurses and physician in the preoperative visits and during hospitalization. Information and education will be provided orally or through printed booklets.
224153961|NCT00936793|DRUG|Darunavir|
223572647|NCT05290454|OTHER|mNGS-guided treatment|mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
223572648|NCT05999110|OTHER|Physical Exercise|The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
224153962|NCT00936793|DRUG|Ritonavir|
224153963|NCT00936793|DRUG|Beclomethasone Dipropionate HFA|
224153964|NCT03125993|BEHAVIORAL|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: \> 10000 steps, \> five days, per week brisk walking.
224153965|NCT04535505|DIAGNOSTIC_TEST|Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology|This is an observational study and there are no interventions. The purpose of the study is to compare the accuracy （including sensitivity and specificity）of the new CPA platform based on CRISPR technology detection method and the gold standard in detecting pertussis patients.
224153966|NCT02880462|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
224153967|NCT02880462|OTHER|placebo|Placebo is made of starch
224153968|NCT03152396|OTHER|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
224153969|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (1 application)|1 application of LET topical anesthetic gel
224153970|NCT04536493|DRUG|LET (lidocaine 4%; epinephrine 0.1%; tetracaine 0.5%) gel (3 applications)|3 applications of LET topical anesthetic gel
224153971|NCT02320214|DEVICE|Miami w/ frag Personal lubricant|
224153972|NCT06045143|DEVICE|Patients undergoing DDD pacemaker implantation|compare the effect right ventricular apical versus septal pacing on left ventricular function by deformation imaging using 2D speckle tracking echocardiography.
224153973|NCT02398981|OTHER|Clinical decision support tool|
224153974|NCT03550742|OTHER|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
224153975|NCT01684891|DRUG|RG1662|multiple doses of RG1662
224153976|NCT01957852|OTHER|FloSeal|
224302274|NCT02205762|DRUG|mercaptopurine|Stratum I
224302275|NCT02205762|DRUG|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
223572649|NCT00405964|DRUG|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
223572650|NCT00405964|DRUG|Placebo tablet|Placebo tablet, once daily for 12 weeks
224153977|NCT01014949|OTHER|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine \[140 ug/kg/min\] to induce steady state maximal hyperemia."
224153978|NCT00231855|DRUG|Topotecan and Taxotere|
224153979|NCT03717363|PROCEDURE|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
224153980|NCT03717363|BEHAVIORAL|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
224153981|NCT00663598|DRUG|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
224302276|NCT02205762|DRUG|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
223572651|NCT00003787|BEHAVIORAL|educational/counseling intervention|
223572652|NCT00003787|BEHAVIORAL|therapeutic dietary intervention|
224153982|NCT01094990|DRUG|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
224153983|NCT06528054|OTHER|Development of a model for predicting 90-day mortality and to compare various treatment strategies for anastomotic leakage|The prediction model and comparison of various treatment strategies will be studies when the data is available for analysis.
224153984|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
224153985|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
224153986|NCT01576406|DRUG|crizotinib|crizotinib 250 mg twice a day
224153987|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
224153988|NCT01576406|DRUG|crizotinib|crizotinib 250 mg once a day
224153989|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-NA)|Root canal treatment procedures explained in arm descriptions.
224153990|NCT06403293|PROCEDURE|Root canal treatment (AH Plus-EA)|Root canal treatment procedures explained in arm descriptions.
224153991|NCT06403293|PROCEDURE|Root canal treatment (BC-NA)|Root canal treatment procedures explained in arm descriptions.
224153992|NCT06403293|PROCEDURE|Root canal treatment (BC-EA)|Root canal treatment procedures explained in arm descriptions.
224153993|NCT00141856|BEHAVIORAL|Telephone care|
224302277|NCT02205762|DRUG|Cytosine Arabinoside|
224302278|NCT02205762|DRUG|2-chlorodeoxyadenosine|
224302279|NCT02205762|PROCEDURE|hematopoietic stem cell transplantation (RIC-HSCT)|
224302280|NCT02205762|BIOLOGICAL|Intravenous immunoglobulin|
224302281|NCT06210399|PROCEDURE|Extracorporeal Shockwave Therapy|3 to 6 shock wave treatment sessions will be performed (PiezoWave 2 Control Unit Generator, classification 93/42/EEC class IIb), with a frequency of two sessions per week.
223572653|NCT02168738|DRUG|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
223572654|NCT02168738|DRUG|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
223572655|NCT02168738|DRUG|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
223572656|NCT02272751|BEHAVIORAL|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
224066298|NCT02702037|OTHER|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
224066299|NCT01656863|OTHER|Questionnaire|
224066300|NCT03428165|OTHER|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
224066301|NCT05195697|OTHER|Observational study of different treatments and time to treatment|Different treatment based on the clinical decision
224066302|NCT06452966|OTHER|traditional Chinese medicine|"patients in the group will receive one of or a combination of the following interventions:~Oral Chinese medicine decoction:~The Chinese medicine practitioner will personally examine the patient and judge the patient's condition through the four diagnostic methods of traditional Chinese medicine(TCM): sight, smell, inquiry, and incision. Based on the syndrome differentiation and treatment of the patient's condition, he or she will prescribe an oral Chinese herbal decoction, two to three times a day, for two weeks.~Acupuncture or low level laser acupuncture treatment:~Chinese medicine practitioners select acupuncture points for treatment based on the patient's condition and treat them twice a week for 20 minutes each time for a total of two weeks.~the intervantion depents on the TCM doctor decision based on the patient's diagnosis and needs.~in addition, the patients will recive ICU care and medication based on patient's needs."
224066303|NCT06452966|OTHER|Routine ICU care|Patients will receive ICU care
224066304|NCT06452966|OTHER|historical Routine ICU care|Patients had received ICU care
224066305|NCT03672279|DIAGNOSTIC_TEST|CogCheck|Novel self-administered cognitive assessment tool
224066306|NCT03705585|DRUG|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
224066307|NCT03705585|DRUG|Vaxchora|One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
224066308|NCT02524574|PROCEDURE|cardiac Rehabilitation|
224066309|NCT02524574|OTHER|Tomography Positron Emission|
224066310|NCT03215771|DEVICE|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
224066311|NCT03215771|OTHER|Motor Learning-Based Therapy|Motor learning-based (MLB) therapy included movement practice as close to normal as possible, high repetition, progression of challenge, part versus whole task practice, and knowledge of results. Treatment was customized to abilities of each subject and consisted of both MyoPro training and MLB therapy without device. Training with device was progressed using a hierarchy of challenge to increase complexity of movement. MLB therapy without device followed the same hierarchy, incorporating training of movements that could not be accomplished with the device and those that were trained with device. Movement quality was monitored and training practice was incrementally progressed as subject demonstrated improved ability to perform a given task/movement component. Subjects performed a custom home exercise program (HEP) on non-clinic days, increasing repetition as tolerated. At conclusion of in-clinic phase, individuals transitioned to a home phase where they continued to use the HEP.
224066312|NCT02039375|OTHER|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
224066313|NCT02462668|PROCEDURE|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
224066314|NCT02462668|PROCEDURE|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
224066315|NCT02462668|PROCEDURE|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
224066316|NCT04770389|DRUG|Obicetrapib 5mg|tablet
224066317|NCT04770389|DRUG|Ezetimibe 10mg|tablet
224153994|NCT06068296|DIAGNOSTIC_TEST|short term memory assessment|"Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered."
224153995|NCT06068296|DIAGNOSTIC_TEST|Oxford cognitive screen|Evaluation of the cognitive abilities of the patients with aphasia.
224153996|NCT06068296|DIAGNOSTIC_TEST|Token Test|Evaluation of the severity of the aphasia in patients with aphasia.
224153997|NCT06068296|DIAGNOSTIC_TEST|Montreal cognitive assessment|Evaluation of cognitive dysfunction in the group of healthy volunteers.
223572657|NCT02272751|BEHAVIORAL|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
223743000|NCT01888146|BEHAVIORAL|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
223743001|NCT02337907|DRUG|Placebo|for blinding purposes
223743002|NCT02337907|DRUG|Placebo|
223743003|NCT02337907|DRUG|BI 409306|
224066318|NCT04770389|OTHER|Placebo|tablet
224066319|NCT00870402|DRUG|Spironolactone|25 mg per day for 9 months
224153998|NCT01109550|PROCEDURE|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
224153999|NCT01626053|BEHAVIORAL|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
224154000|NCT01626053|OTHER|Control Group|no intervention
224154001|NCT02401243|DRUG|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
224154002|NCT04201938|COMBINATION_PRODUCT|Symbiter-Omega|Symbiter-Omega contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera.
224154003|NCT04201938|DIETARY_SUPPLEMENT|Placebo|Placebo
224154004|NCT03256838|DRUG|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
224154005|NCT01612442|BEHAVIORAL|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
224154006|NCT01612442|BEHAVIORAL|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
224154007|NCT05151367|BEHAVIORAL|Text message reminder|Receipt of text messages notifying when the next HPV vaccine dose is due (either first or second)
224154008|NCT06291467|BIOLOGICAL|Blood samples|Blood samples will be collected at both visit between 8:30 a.m. and 9:30 a.m. and fasting from midnight.
224154009|NCT06291467|OTHER|questionnaires|"Questionnaires will be administrated at both visits to assess the suicide spectrum, the depression level and some personality traits.~Hetero-questionnaires will be administrated during a clinical interview conducted by a psychiatrist or psychologist at the inclusion.~* MINI 7.0 Mini-International Neuropsychiatric Interview :~* MADRS (Montgomery Asberg Depression Scale)~* C-SSRS (Columbia-Suicide Severity Rating Scale)~* FAST (Functioning Assessment Short Test)~Self-administered questionnaire will be completed by the participant at the inclusion and at the end of hospitalisation (D7+/- 2 days) :~* STAI-Y (State-Trait Anxiety Inventory )~* PPP-VAS (Visual Analog Scale to measure Psychological and Physical Pain)~* SHAPS (Snaith-Hamilton-Pleasure Scale )~* CTQ (Childhood Trauma Questionnaire)~* ESUL : Echelle de solitude de l'université de Laval~* BIS-11 : (Barratt Impulsiveness Scale)~* QIDS (Quick Inventory of Depressive Symptomatology)"
224154010|NCT00436267|DRUG|fluorouracil|
224154011|NCT00436267|RADIATION|selective external radiation therapy|
224154012|NCT00436267|RADIATION|tomotherapy|
224154013|NCT00436267|RADIATION|yttrium Y 90 glass microspheres|
224154014|NCT00436267|RADIATION|yttrium Y 90 resin microspheres|
224154015|NCT02905903|DRUG|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
224154016|NCT00106821|DRUG|Tiotropium Bromide Inhalation Powder|
224154017|NCT03661372|OTHER|Robot|Use of a telesimulation robot using contextual interview format.
224154018|NCT03661372|OTHER|Face-to-face|Use of face-to-face patient interview using contextual interview format.
224154019|NCT03655587|DEVICE|Solid ankle foot orthotic|
224154020|NCT03655587|DEVICE|Resting night splint|
224154021|NCT03990259|OTHER|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
224154022|NCT04939870|DIAGNOSTIC_TEST|Biochemical parameters evaluation|selected biochemical parameters
224154023|NCT04212052|RADIATION|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-intensity-modulated radiotherapy (IMRT). The dose of 30Gy with a fraction dose of 5Gy was delivered to PTV-GTV as the hypo-RT course. Patients were eligible to receive the hypo-boost when there was no disease progression and no persistent ≥G2 treatment-related toxicities. For patients with persistent ≥G2 toxicities, a re-evaluation was planned every 2 weeks to determine whether they were qualified to receive the hypoboost. All eligible patients underwent a repeat 4DCT simulation scan to reformulate the adaptive radiation therapy plan. The adaptive plan of the hypo-boost was delivered to the residual tumor (PTV-GTV-residual) at a dose of 30Gy in 6 fractions (5 Gy per fraction).
224154024|NCT04212052|DRUG|concurrent chemotherapy|Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy. Intended chemotherapy included 4 cycles throughout the course of treatment.
224154025|NCT04212052|DRUG|consolidation immunotherapy|Patients without disease progression or persistent grade2+ toxicities after thoracic radiotherapy were recommended to receive consolidation immunotherapy
224154026|NCT04193670|OTHER|Clinical examination|This is a classic dermatological clinical examination during a classic consultation
224154027|NCT04193670|PROCEDURE|Biopsies|"2 skin biopsies on a lesion area selected according to the inclusion criteria (2 punchs of 4 mm) for each experimental group.~The first half of whole cutaneous biopsies (n = 25) will be studied using biphotonic microscopy. This will be performed on whole biopsies in 3-D according to the protocol developed in the laboratory.~The second half of whole skin biopsies (n = 25) will be studied using the technique of single-cell RNA seq.~The skin controls skin-free subjects will be obtained from skin reduction surgery (abdominoplasty) to subjects who have agreed to the use of their skin sample."
224154028|NCT04193670|OTHER|Blood test|A blood test on a tube (2 tubes of 10 mL).An assay of specific IgE and the serum level of IL-4, IL-13 and IL-5 will be carried out by ELISA (Enzyme Linked ImmunoSorbent Assay) from the blood samples.The blood samples will be obtained through the French blood establishment from different donors who have given their consent.
224154029|NCT00122304|DRUG|eculizumab|
224154030|NCT02186756|OTHER|EMG-Biofeedback and Usual care|Please refer to arm description
224154031|NCT01962688|DEVICE|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
224154032|NCT01962688|DEVICE|Sham ultrasound|sham ultrasound to facilitate blinding
223743004|NCT02337907|DRUG|Donepezil|
224302282|NCT04523610|BEHAVIORAL|Telehealth phone calls|The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
223743005|NCT02876900|DRUG|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
224066320|NCT00870402|DRUG|Placebo|Placebo 1 tablet per day for nine months
224066321|NCT03949933|RADIATION|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
224066322|NCT04170322|DEVICE|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
224066323|NCT04170322|DEVICE|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
224066324|NCT01734577|PROCEDURE|Dry needling|Sterile monofilament needles
224066325|NCT01734577|PROCEDURE|Sham needling|Applicator tubes from the sterile monofilament needles
224066326|NCT01890642|DEVICE|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
224066327|NCT01890642|OTHER|Pain Ease Spray|Cold Spray used to anesthetize the skin
224066328|NCT01890642|DRUG|1% buffered lidocaine|Lidocaine placed using Jet Injection
224066329|NCT01890642|OTHER|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
224066330|NCT01890642|OTHER|Sucrose|Oral Sucrose used for children \< 1 year
224066331|NCT00533442|DRUG|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
224066332|NCT00533442|DRUG|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
224066333|NCT00533442|DRUG|Tacrolimus|Part of standard maintenance.
224066334|NCT00533442|DRUG|Steroids|Part of standard maintenance
224066335|NCT00579852|PROCEDURE|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
224066336|NCT03808727|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
224066337|NCT02745275|BEHAVIORAL|Peer-led Health Education|Peer-led health education
224066338|NCT01251107|DRUG|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
224066339|NCT01251107|DRUG|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
224066340|NCT01251107|DRUG|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
224066341|NCT01251107|DRUG|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
224302283|NCT04523610|OTHER|Volunteer of TIP-OA Program|Participant is a volunteer of the TIP-OA Program
224066342|NCT01251107|DRUG|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
224066343|NCT01251107|DRUG|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
224066344|NCT01251107|DRUG|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
224066345|NCT01251107|DRUG|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
224066346|NCT01251107|DRUG|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
224066347|NCT01251107|DRUG|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
224066348|NCT01251107|DRUG|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
224066349|NCT03115567|DRUG|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
224066350|NCT03362424|BIOLOGICAL|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
224066351|NCT03362424|PROCEDURE|Rotator cuff repair|Rotator cuff repair
224066352|NCT02090322|PROCEDURE|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
224066353|NCT00606203|DRUG|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
224066354|NCT00606203|DRUG|placebo|placebo
224066355|NCT03371446|GENETIC|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
224066356|NCT05690529|PROCEDURE|Ablation|Radiofrequency AF ablatoon
224066357|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5421|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
224066358|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5424|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
224066359|NCT06361875|BIOLOGICAL|Quadrivalent Influenza mRNA Vaccine MRT5429|Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection
224066360|NCT06361875|BIOLOGICAL|Quadrivalent Influenza Standard Dose Vaccine|Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection
224066361|NCT06361875|BIOLOGICAL|Quadrivalent Influenza High-Dose Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection
224066362|NCT06361875|BIOLOGICAL|Quadrivalent Recombinant Influenza Vaccine|Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
224066363|NCT01422122|DRUG|Vitamin D3|4000 mg per day, one tablespoon syrup per day
224066364|NCT01422122|DRUG|Placebo|one table spoon Syrup per day
224066365|NCT01849471|OTHER|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
224066366|NCT03319875|DEVICE|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
224302284|NCT04523610|OTHER|Stakeholder of TIP-OA Program|Participant is a stakeholder of the TIP-OA Program
224154033|NCT04437173|DEVICE|Virtual Reality Headset Distraction|Patient wears a virtual reality headset during interventional pain procedure
224302285|NCT05102292|DRUG|HLX208|HLX208 450mg bid po
224066367|NCT02544685|DIETARY_SUPPLEMENT|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
224066368|NCT02544685|DIETARY_SUPPLEMENT|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
224066369|NCT02544685|OTHER|Placebo|Same dosage regimen as active drugs
224066370|NCT00947336|DRUG|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
224066371|NCT00947336|DRUG|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
224066372|NCT04156880|OTHER|mammography|standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
224066373|NCT02060682|DEVICE|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
224066374|NCT02757183|DEVICE|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
224066375|NCT01981642|OTHER|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
224066376|NCT01981642|OTHER|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
224066377|NCT00456352|PROCEDURE|duodenal exclusion|
224066378|NCT06002399|DEVICE|cataract surgery|cataract surgery
224066379|NCT01315860|OTHER|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
224066380|NCT04462094|DRUG|Ketamine 0.3 mg/kg at end-of-surgery|Ketamine 0.3 mg/kg at end-of-surgery (intravenously)
224066381|NCT04462094|DRUG|Ketamine 0.3 mg/kg at anesthesia induction|Ketamine 0.3 mg/kg at anesthesia induction (intravenously)
224066382|NCT03693625|DRUG|GDC-0853|Participants were administered GDC-0853 200mg orally, as per the dosing schedules described above.
224066383|NCT01508702|DRUG|lesinurad|Tablets, 400 mg QD
224066384|NCT01508702|DRUG|Placebo|Tablets, Placebo QD
224066385|NCT04632758|DRUG|WX-0593 Tablets|tablets, 60 mg→180mg, QD
224066386|NCT04632758|DRUG|crizotinib|Capsules, 250mg, BID
224066387|NCT01464502|PROCEDURE|Standard CRT Implant|
224066388|NCT01464502|PROCEDURE|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
224066389|NCT05482685|BEHAVIORAL|Questionnaire|Conduct a 10-minute survey
224066390|NCT00684255|PROCEDURE|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
224066391|NCT00684255|DRUG|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
224066392|NCT00684255|DRUG|Busulfan|Busulfan 3.2 mg/kg Days \_8, -7, -6, -5
224066393|NCT00684255|DRUG|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
224066394|NCT03847129|OTHER|Biofeedback training|Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.
224066395|NCT03847129|OTHER|Home-based tendon gliding and resistance training|The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
224066396|NCT03402529|DIAGNOSTIC_TEST|Contrast Enhanced Spectral Mammography|Pilot study
224066397|NCT02072811|DRUG|DAC|"* DNR 60 mg/m2 0,5h infusion iv on 1-3 days~* 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~* Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
224066398|NCT02072811|DRUG|CLAG|"* G-CSF 30MU sc, on 0-5 days~* Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~* Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~* Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
224066399|NCT02072811|DRUG|Consolidation, I HAM cycle|"* Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~* Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
224066400|NCT02072811|DRUG|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
224066401|NCT02072811|DRUG|Consolidation, III HiDAraC cycle|"* Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~* 2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
224066402|NCT00250835|OTHER|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
224302286|NCT02756026|DIETARY_SUPPLEMENT|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
224302287|NCT01002014|PROCEDURE|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
224302288|NCT03576183|BIOLOGICAL|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
223456131|NCT05695729|OTHER|PLYOMETRIC EXERCISE PROGRAM|"This group will perform following exercises in first four weeks. Reverse overhead throw Rotational wall throws Overhead medicine ball Chest passes Resistance tubing 90-90 external rotation~Frequency~* Rest between Exercises-: 60-120 Seconds~* Rest between Set of Exercise-: 45-60 Seconds after four weeks rest between exercise and rest between set of exercise will be reduced:~* Rest between Exercises-: 45-60 Seconds~* Rest between Set of Exercise-: 20-30 Seconds~Tools used:~Medicine Ball, Resistance band"
223743006|NCT02876900|DRUG|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
223743007|NCT02876900|DRUG|Placebo|The study will evaluate placebo transdermal patch.
224066403|NCT04967937|OTHER|Strengthening, resistance exercise, plyometric and dynamic movement training|(1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training.
224066404|NCT01187953|DRUG|Prograf (tacrolimus)|Administered per current product labeling
224066405|NCT01187953|DRUG|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
224066406|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
224066407|NCT00827021|DRUG|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
224066408|NCT03536988|PROCEDURE|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
224066409|NCT03536988|PROCEDURE|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
224066410|NCT02572752|DRUG|Nintedanib|1 soft gelatine capsule, single dose, oral
224066411|NCT02572752|DRUG|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
224066412|NCT02572752|DRUG|Nintedanib|
224066413|NCT02105402|BEHAVIORAL|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
224066414|NCT01505842|PROCEDURE|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
224066415|NCT01505842|PROCEDURE|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
224066416|NCT01464307|DRUG|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
224066417|NCT01464307|DRUG|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
224066418|NCT05537597|PROCEDURE|active M1-rTMS|"Magnetic stimulation will be carried out using a MagPro X100 machine with a MCF-B70 figure-of-eight coil (Magventure, Farum). All rTMS sessions will be assisted by a neuronavigation system (TMS Navigator，Localite GmbH), maintaining the M1 target and the orientation of coil stable during stimulation sessions. The M1 target was defined as the hand knob region, which corresponds to the motor cortical representation of the hand, regardless of the location of pain.~Stimulation paradigm consists of 20 trains of pulses with an intra-train frequency of 20 Hz, resulting in 2000 pulses for a total duration of 20 minutes.~The stimulation intensity will be 80% of RMT, defined as the lowest stimulation intensity necessary to induce a visible muscle twitch of the hand contralateral to the stimulated hemisphere.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
224066419|NCT05537597|PROCEDURE|sham rTMS|"The sham protocol was similar to the rTMS protocol. Sham stimulations will be performed with a MCF-P-B65 figure-of-eight coil (Magventure) to M1, assisted by a neuronavigation system.~The following stimulation parameters will be used: stimulus frequency 20 Hz; stimulus intensity 80 % of RMT; total stimulation pulses 2,000; total stimulation time 20 min.~Participants will receive 7 sessions of treatment once a day in the same time continuously for 7 days, and keep antiparkinsonism drugs unchanged throughout the whole study."
224066420|NCT00964327|DRUG|TMC114|
224066421|NCT02714920|OTHER|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
224066422|NCT01648127|DRUG|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
224066423|NCT01335763|DRUG|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of \<=5.5mmol/L
224066424|NCT02911922|DEVICE|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
224066425|NCT02911922|DEVICE|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
224302289|NCT03576183|BIOLOGICAL|Placebo|buffer component of VLA1701
224302290|NCT03576183|OTHER|Challenge Strain|LSN03-016011/A
224302291|NCT00069511|DRUG|UT-231B|
224302292|NCT02711683|DRUG|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
224302293|NCT02711683|DRUG|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
224302294|NCT00042458|DRUG|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
223456132|NCT05695729|OTHER|CONVENTIONAL EXERCISE PROGRAM|"This group will perform following exercise through out the session with different frequencies after 4 weeks Bench presses Triceps kickbacks bicep curls Overhead presses Push-ups~Frequency:~Rest between Exercises-: 60-120 Seconds Rest between Set of Exercise-: 45-60 Seconds~After 4 weeks the frequency will be:~Rest between Exercises-: 45-60 Seconds Rest between Set of Exercise-: 20-30 Seconds"
223456133|NCT00451113|DRUG|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
223456134|NCT00667992|DRUG|Budesonide HFA|standard daily inhaled dose
223456135|NCT00667992|DRUG|Budesonide CFC|standard daily inhaled dose
223456136|NCT00399698|DRUG|Risperdal|
223456137|NCT05691777|DEVICE|Hand and shoulder task|"Hand task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform flexion / extension movements of the fingers of the right hand at 0.5 Hz.~Shoulder task: the participant is seated on a chair facing a table, both hands resting on the table. The participant is asked, for each block of 10 seconds, to perform alternating movement of abduction and adduction of the right shoulder at 0.5 Hz with the elbow flexed."
223456138|NCT01236625|PROCEDURE|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
223456139|NCT04023214|DIAGNOSTIC_TEST|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
223456140|NCT04076852|OTHER|Administration of questionnaires|"According to clinical practice, the following questionnaires are administered:~* Y-GTSS~* Y-BOCS or cY-BOCS"
223456141|NCT00000311|DRUG|Buprenorphine|Medication and Behavioral
223456142|NCT00000311|DRUG|methadone|medication and behavioral
223456143|NCT00696319|OTHER|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
223456144|NCT00696319|OTHER|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
223456145|NCT01718587|PROCEDURE|stem cell transplantation through interventional procedure|interventional procedure once
223456146|NCT01718587|DRUG|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
223456147|NCT01973517|DRUG|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
223456148|NCT01973517|DRUG|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
223456149|NCT03750877|PROCEDURE|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
223456150|NCT03750877|PROCEDURE|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
223456151|NCT00361608|DEVICE|EarlySense ES 16|
224066426|NCT02911922|RADIATION|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
224066427|NCT01217021|DRUG|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]MNI-558, followed by PET imaging.
224066428|NCT00338871|PROCEDURE|home exercise|
224066429|NCT00256737|DRUG|Omeprazole|
224066430|NCT06123065|BEHAVIORAL|Yoga|8 week Yoga for chronic pain and PTSD group intervention, conducted virtually
224066431|NCT06537713|DIAGNOSTIC_TEST|Testican-1|Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.
224066432|NCT00916266|PROCEDURE|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
224066433|NCT02457637|OTHER|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
224066434|NCT05185271|BEHAVIORAL|Dyad-focused strategy training|"Rehabilitation therapists will be hired to deliver the intervention to the stroke survivors-caregiver dyads on a one-to-two base. The therapist will ask the dyad to identify their shared goals and provide them the global strategy Goal-Plan-Do-Check (also called guided discovery strategy), which involves (1) setting a goal to address the barriers, (2) developing a plan to address the goal, (3) doing the plan, and (4) checking if the plan worked or required revising. This procedure will be repeated iteratively until the dyad's goal is met, and the next goal can be moved on to."
224066435|NCT05182151|DRUG|Istradefylline 40 mg|adenosine A2A receptor antagonist
224066436|NCT00042861|DRUG|7-hydroxystaurosporine|
224066437|NCT00042861|DRUG|fluorouracil|
224066438|NCT00042861|DRUG|leucovorin calcium|
224066439|NCT04916509|DRUG|Palbociclib plus an aromatase inhibitor|Palbociclib plus an aromatase inhibitor therapy
224066440|NCT04916509|DRUG|Palbociclib plus fulvestrant|Palbociclib plus fulvestrant
224066441|NCT01588717|DRUG|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
224066442|NCT04011280|DRUG|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
224066443|NCT05558280|DRUG|Dinutuximab beta|The study treatment will be administered with a continuous intravenous infusion at a dose of 14 mg/mq/day, days 1-5, a total of 60 hours (cumulative dose/cycle: 70 mg/mq). Each cycle lasts 28 days.The treatment phase foresees 5 cycles of Dinutuximab Beta.
223456152|NCT05418439|DIETARY_SUPPLEMENT|Drink Poppi Soda|Drink Poppi Vinager Soda
224154034|NCT06403748|DIETARY_SUPPLEMENT|Dietary supplement formulated with components of natural origin: artichoke, danshen, bergamot, folic acid, chromium and excipients.|The study will be conducted in male and female subjects, at least 18 and less than 70 years of age, with suboptimal level of LDL-Cholesterol (LDL 115-190 mg/dL) randomized into two groups to receive a preconstituted food supplement (NUT) combination containing (Red yeast rice 160 mg + Berberis aristate 449,7 mg + Folic acid 200 μg and others) in combination with a standard Mediterranean diet at low cholesterol content (\<200 mg/day) (Standard of Care - SOC) \[group 1\], or a PLACEBO in combination with hypo-cholesterol diet (healthy Mediterranean diet following the indication of the European Atherosclerosis Society guidelines) \[group 2\].
224154035|NCT06403748|OTHER|Placebo|Placebo
224154036|NCT04416945|OTHER|Household Reactive Case Detection|Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
224154037|NCT04416945|OTHER|RACD of cases' co-workers/co-travelers|"Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~1. Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~2. Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days."
224154038|NCT04416945|OTHER|Case Management and Follow-up|"All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions."
224154039|NCT05194787|DIAGNOSTIC_TEST|Cognitive test scores, clinical diagnosis and blood biomarkers|"Clinical diagnosis of Alzheimer's disease, mild cognitive impairment or normal ageing.~Cognitive test score on CANTAB Blood biomarker (p-tau 181) level"
224154040|NCT03900741|PROCEDURE|Submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol
224154041|NCT03900741|PROCEDURE|Non-submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
224154042|NCT00141557|DRUG|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
224154043|NCT00141557|DRUG|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
224154044|NCT00669032|DEVICE|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
224154045|NCT00669032|OTHER|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
224154046|NCT00602511|DRUG|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
224154047|NCT00602511|DRUG|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
224154048|NCT05595603|PROCEDURE|4mg ZOL loaded gentamicin PMMA|During surgery, 4mg ZOL will be mixed with gentamicin (1000mg) PMMA cement (40g) by surgeon under sterile conditions to prepare ZOL loaded bone cement, and then it will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
224154049|NCT05595603|PROCEDURE|gentamicin PMMA|During surgery, gentamicin (1000mg) PMMA (40g) was prepared by surgeon under sterile conditions and will be filled into the bony defects of the patient where the lesion has been removed after intralesional curettage.
224154050|NCT01607073|DRUG|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
223456153|NCT04820296|OTHER|Solution-Oriented Approach|First Session: Sharing thoughts about perception of childbirth, Creating positive goals, Informing about Birth, Birth Process, Basic Breathing Exercises and Deep Relaxation Exercises, Homework Second Session: Evaluating homework, Sharing thoughts about fear of childbirth, Miracle Question Technique, Evaluating with the Rating Questions Technique, Reframing the problem, Briefing on 'Body-Mind Connection at Birth, Fear-Tension-Pain Cycle, Hormones of Birth' and Breathing exercises, Homework Third session: Evaluating homework, Sharing thoughts about positive birth story, Information on symptoms indicating that the childbirth is approaching, pushing techniques, delivery positions, endorphin massage and breathing exercises (4/8 breaths, full breath when baby moves), Homework Fourth Session: Evaluating homework, Mother Baby Friendly Caesarean and Breathing exercises (3 candles a feather breath), Sharing feelings about the counseling process
224302295|NCT00042458|DRUG|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
223456154|NCT03814902|DEVICE|Electronic Tracking Device|This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
223456155|NCT01222312|DRUG|Cisplatin|75 mg/m2, d1 every 3 weeks
223456156|NCT01222312|DRUG|Oxaliplatin|85 mg/m², d1 every 2 weeks
223456157|NCT01222312|DRUG|Docetaxel|75 mg/m2, d1 every 3 weeks
223456158|NCT01222312|DRUG|Docetaxel|50mg/m2, d1 every 2 weeks
223456159|NCT01431313|DRUG|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
223456160|NCT00301912|BIOLOGICAL|filgrastim|
223456161|NCT00301912|DRUG|busulfan|
223456162|NCT00301912|DRUG|fludarabine phosphate|
224066444|NCT01966133|DRUG|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
224066445|NCT00934986|OTHER|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~* Stage A patient who does not require a treatment: one sample the day of enrollment.~* Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
224066446|NCT03027700|DEVICE|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
224066447|NCT04845828|PROCEDURE|Sentinel lymph node mapping|"Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy 2. Inject 1.25 mg/ml of ICG and a total of 6ml into the cornual area (0.5-1 cm deep) of the uterus. And then inject 1 ml of mucous membrane (1-3 mm deep) and 1 ml of substrate (1-2 cm deep) into the cervix, and a total of 4 ml in each direction of 3 and 9 o'clock.~3\. Sentinel lymph node is excised"
224066448|NCT04845828|PROCEDURE|Routine lymph node dissection|"1. Laparoscopic or robotic hysterectomy with/without bilateral salpingo-oophorectomy~2. Lymph node detection is performed."
224066449|NCT06168838|DRUG|Anticoagulant|Know the casuistry of spontaneous intracranial hemorrhages and secondary to the use of both oral and parenteral anticoagulants
224066450|NCT06584929|DRUG|Nicoderm CQ nicotine patch|Two week supply provided to participants on study.
224066451|NCT06584929|DRUG|Nicorette Nicotine Lozenges|Two week supply provided to participants on study.
224066452|NCT04942925|DEVICE|Verofilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
224066453|NCT04942925|DEVICE|Kalifilcon A contact lenses|Commercially available silicone hydrogel contact lenses for daily disposable wear
224066454|NCT01273883|DIETARY_SUPPLEMENT|Magnesium|Magnesium 532 mg a day
224066455|NCT01273883|OTHER|Placebo|matching form/dosage
224066456|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
224066457|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
224066458|NCT01052298|DRUG|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
224066459|NCT01052298|DRUG|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
224066460|NCT01803243|OTHER|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
224066461|NCT01803243|OTHER|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
224066462|NCT01803243|OTHER|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
224154051|NCT06150989|BEHAVIORAL|Observational Group|"All participants will go through a series of lab-based assessments to evaluate their vascular health. These assessments include: heart rhythm/rate, blood pressure, large blood vessel flow, central aortic blood pressure and pulse wave velocity, brain blood flow, carbon dioxide concentration, flow mediated dilation/blood vessel responsiveness, breathing rate, and cerebral vasomotor reactivity. In addition, venous blood sample will be taken to identify biomarkers that are associated with elevating blood pressure and decreasing blood flow.~The 10-day monitoring period includes a wrist-worn activity tracker and a blood pressure monitor bracelet; a smartphone app that will prompt surveys up to 6 times a day to assess behaviors, social/physical context, mood/stress, and experience of racial discrimination/microaggression. Participants will also collect saliva samples on three consecutive days during the 10-day monitoring period."
224154052|NCT06011603|DEVICE|Prineo dressing|Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
224154053|NCT05300971|OTHER|Heat therapy|36 sessions (\~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.
224302296|NCT02860221|DRUG|Tranexamic acid (TXA)|IV and topical administration
224302297|NCT02860221|DRUG|Epinephrine|
224066463|NCT02215720|DRUG|Cetuximab|
224066464|NCT02215720|DRUG|Temsirolimus|
224066465|NCT00005870|DRUG|fluorouracil|
224066466|NCT00005870|DRUG|gemcitabine hydrochloride|
224066467|NCT00005870|DRUG|mitomycin C|
224066468|NCT00005870|DRUG|rubitecan|
224302298|NCT01951885|DRUG|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1 or tacrolimus 0.03mg/kg/dose BID orally beginning on day -3. If Tac is administered intravenously, it will be given over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and/or can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
224302299|NCT01951885|DRUG|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient \< 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
224302300|NCT01951885|DRUG|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients \>40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients \< 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
224302301|NCT01951885|DRUG|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient\<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
224302302|NCT01674153|PROCEDURE|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
224302303|NCT05192694|PROCEDURE|Computed tomography|Positron Emission Tomography
224302304|NCT01546376|RADIATION|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
224302305|NCT01546376|OTHER|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
224302306|NCT06400134|OTHER|Cognitive Function|The Standardized Mini Mental Test (SMMT) was used to evaluate the cognitive status of the geriatric individuals'. In the test, which has a total score of 30, those with a score of 24 or less are recommended to be evaluated for dementia.
224302307|NCT06400134|OTHER|Physical Performance|The Brief Physical Performance Battery (BPPB) was used to assess the physical performance of geriatric individuals. All three physical performance measures (balance, walking speed, getting up from the chair) were scored between 0-4 according to the duration of the activity, these scores were summed and the total score was determined between 0 (poor) and 12 (very good).
224302308|NCT06400134|OTHER|Grip Strength|Muscle strength was assessed with a hand grip dynamometer. In the geriatric individuals, less than 30 kg for men and less than 20 kg for women was considered as low hand grip strength.
224302309|NCT06400134|OTHER|Walking speed|Walking speed was assessed with the 6-metre walk test. Speed was calculated by dividing each known distance by the time it took for each individual, on each trial, to walk from the start to the end points marked on the floor and then converting to m/s.
224302310|NCT06400134|OTHER|Mobility|The Time up Go test (TUG) was used for mobility. The risk of falling increases with increasing duration.
223456163|NCT00301912|DRUG|methotrexate|
223456164|NCT00301912|DRUG|tacrolimus|
223743008|NCT00497172|DEVICE|CYPHER Sirolimus-eluting stent|drug-eluting stent
224066469|NCT05021783|DIAGNOSTIC_TEST|Pressure pain threshold|The sacroiliac PPT scores will be obtained bilaterally from four measurement points; the first point is located 1 cm medially and caudally from spina iliaca posterior superior (SIPS) and 3 more laterally, medially and cranially.The left trapezius muscle will be used to evaluate distant control point .The 1 cm2 algometer probe will be placed vertically in the each selected point and pressure will be increased with 0.1 kg/sc until the participant reporting pressure became painful. The pressure value at which the pain is first felt will be accepted as the PPT of that point.
224066470|NCT05021783|DIAGNOSTIC_TEST|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization
224066471|NCT05021783|OTHER|Spondyloarthritis Research Consortium of Canada scoring system|SPARCC scoring consists of two subcomponents to detect sacroiliitis activation and structural damage. In the short tau inversion recovery (STIR) sequence, 6 consecutive coronal sections will be examined and the signal increase will be scored as 0 = normal signal and 1 = increased signal. In this way, the maximum score can be 12 in a single coronal section. Evaluations Total maximum score of 72 in 6 consecutive coronal sections. In structural scoring, similar to sacroiliitis scoring, the SI joint is divided into four quadrants to evaluate whether there is fatty change, erosion, backfill and ankylosis. Each lesion is scored as 0=absent or 1=present. In this way, fatty change and erosion can be scored between 0-40 and backfill and ankylosis can be scored between 0-20 in 5 consecutive sections in total scoring.
224066472|NCT05021783|DIAGNOSTIC_TEST|Temporal Summation|TS will be evaluated over the trapezius muscle and sacroiliac joints with manuel algometer. In the evaluation of TS, a pressure as much the PPT value of each point will be applied with pain pressure algometer ten times with a 1-second interstimulus interval. Patients will be asked to rate their pain using on a 0 to 10 visual analogue scale (VAS) at 0, 5, and 10 seconds. TS will be calculated by subtracting the rating at 0 seconds from the rating at 10 seconds. The point that is located 1 cm medially and caudally from SIPS was used for SI joint TS measurement on both sides.
224066473|NCT05021783|DIAGNOSTIC_TEST|Conditioned pain modulation|First stimulus will be applied to trapezius with the pressure that induced a pain intensity of 4 point on a 10 point VAS as called a test stimulus. After that the right hand of the patient will be immersed in 7 Celsius water for 20 seconds to create a conditioning stimulus. Second test stimulus with the same intensity of first one will be applied to trapezius after the conditioning stimulus and patients will be asked to rate their pain. If the patients cannot hold their hand in the water for 20 seconds, the test stimulus will be applied immediately after the patients removed their hands out of water. The ratio between the first and second VAS values multiplied by 100 will be defined as CPM score
223456165|NCT00301912|PROCEDURE|allogeneic bone marrow transplantation|
223456166|NCT00301912|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223456167|NCT00301912|PROCEDURE|peripheral blood stem cell transplantation|
223743009|NCT00497172|DEVICE|Bx SONIC bare metal stent|bare-metal stent
224066474|NCT04978207|BEHAVIORAL|A Faithful Response to COVID-19|See previous description
224066475|NCT03794921|OTHER|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
224066476|NCT03441178|DEVICE|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
224066477|NCT01988610|DRUG|28 days treatment with Mifepristone.|
224154054|NCT05300971|OTHER|Thermoneutral water immersion|36 sessions (\~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature \>0.2°C, and 12 weeks of follow-up.
224154055|NCT01375647|BIOLOGICAL|IPV (inactivated polio vaccine)|Administered per protocol
224154056|NCT01375647|BIOLOGICAL|Rotarix|Administered per protocol
224154057|NCT06195852|BEHAVIORAL|Usual Safe Touches|The in-person Safe Touches workshop is delivered in the classroom by 2 facilitators with live puppet skits, as designed.
224154058|NCT06195852|BEHAVIORAL|Modified Safe Touches|The modified Safe Touches workshop will be delivered by 1 facilitator in the classroom by utilizing prerecorded workshop skit videos.
224302311|NCT06400134|OTHER|Fraility|Frailty assessment was performed using the FRAIL scale.The scale was scored by giving 0 or 1 point according to the answer given. The higher the score, the greater the fraility.
223572658|NCT01932151|DRUG|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
224154059|NCT03366844|DRUG|Pembrolizumab|checkpoint inhibitor
224154060|NCT03366844|RADIATION|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
224154061|NCT06844396|OTHER|Music Therapy|"Music Therapy consisting of four types of protocol:~* Music combined with skin to skin~* Developmental multimodal technique~* Infant directed singing~* Parent/caregiver therapeutic support"
224154062|NCT03322397|BEHAVIORAL|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
224154063|NCT03322397|BEHAVIORAL|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
224154064|NCT03322397|BEHAVIORAL|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
224154065|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
224302312|NCT05903014|DRUG|n-acetylcysteine|we give 3600 mg n-acetylcysteine divided twice a day, for 12 weeks
224302313|NCT05903014|BEHAVIORAL|Motivational Enhancement Therapy|Motivational enhancement therapy with individual and/or group session to maintain and increase subject's motivation to quit smoking
224154066|NCT01138397|BIOLOGICAL|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
224154067|NCT02244658|DRUG|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7\~14 consecutive days
224302314|NCT01685450|DEVICE|Echodia® hand-held equipment|
224302315|NCT05362734|BEHAVIORAL|obstetric outcomes after fresh versus cryopreserved embryo transfer|measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
223572659|NCT03466619|DEVICE|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
223572660|NCT01582737|DRUG|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner
224154068|NCT06398951|DEVICE|Two nare high flow nasal cannula|Recently a new mode of high flow oxygen therapy has presented on the market where the prongs of high flow have different diameters .These two-nare size high flow nasal cannula are capable of delivering gases at a flow rate of 15-50 L/min, similar to the conventional HFNP but the difference in the diameters provide different levels of positive pressure as compared to conventional HFNP.
224154069|NCT00789724|DRUG|Anakinra|100 mg daily subcutaneous injection for 14 days
224154070|NCT00789724|DRUG|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
224154071|NCT00914719|BEHAVIORAL|Information only|
224154072|NCT00914719|BEHAVIORAL|Sexual risk reduction intervention|
224154073|NCT00914719|BEHAVIORAL|sexual risk reduction + alcohol risk reduction component|
224154074|NCT01786434|DRUG|Routine medication arm|50 micrograms of fentanyl given before the procedure
224154075|NCT01786434|DRUG|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
224154076|NCT02481791|DRUG|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
224154077|NCT02481791|DRUG|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
224154078|NCT02481791|DRUG|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
224154079|NCT03505957|DEVICE|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
224302316|NCT05191017|DRUG|NUV-422|NUV-422 is an investigational drug for oral dosing.
224302317|NCT05191017|DRUG|Enzalutamide|Enzalutamide
224302318|NCT00081536|DRUG|Aroplatin (Liposomal NDDP) in combination with capecitabine|
224302319|NCT06273839|DRUG|Tafamidis 61 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
224302320|NCT06273839|DRUG|Tafamidis 70 mg free acid tablet (Test 1)|Tafamidis 61 mg free acid tablet (Test 1)
224302321|NCT06273839|DRUG|Tafamidis 61 mg free acid capsule (Reference)|Tafamidis 61 mg free acid capsule (Reference)
224154080|NCT04624529|OTHER|Self evaluation tool|This self-evaluation tool to evaluate cognitive function, developed by the occupational therapy department, is a paperwork task with guidelines for semi-structured interpretation.
224154081|NCT00554528|DEVICE|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
224154082|NCT00554528|PROCEDURE|arthrodesis - cervical disk surgery|discectomy and arthrodesis
224154083|NCT03914651|DRUG|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
224154084|NCT03914651|DRUG|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
224154085|NCT04202796|PROCEDURE|Catheter ablation|Catheter ablation of arrhythmia
224154086|NCT04312789|DRUG|Avatrombopag|Given PO
224154087|NCT03386006|BEHAVIORAL|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
224154088|NCT03397550|OTHER|salt restriction education|Salt intake target：\<5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
224154089|NCT01979328|DEVICE|geko|
224154090|NCT01979328|DEVICE|Plaster cast|
224154091|NCT02193854|DEVICE|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
224154092|NCT01788111|OTHER|Low back exercises 1|Excentric / concentric extension type exercises
224154093|NCT01788111|OTHER|Low back exercise 2|Traditional low back training
224154094|NCT00150514|DRUG|Oralgen|
224154095|NCT00150514|PROCEDURE|Nasal biopsy|
224154096|NCT00150514|PROCEDURE|Nasal washing|
224154097|NCT00150514|PROCEDURE|Peak nasal inspiratory flow|
223743010|NCT03533192|BEHAVIORAL|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
223743011|NCT04811170|OTHER|Counselling|Participants with mild to moderate mood symptoms will receive a maximum of 6 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W8), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention. Participants with severe mood symptoms will receive a maximum of 10 counselling sessions and will be assessed at baseline (T0, W1), at post-treatment for counselling group (T1, W12), and after 2 booster sessions. Participants in the waiting list control group will receive the same counselling service after the counselling group completed the intervention.
224066478|NCT04358835|DIETARY_SUPPLEMENT|Ketogenic diet|4:1 ratio enteral ketogenic formula within 48 hours of intubation
224066479|NCT04358835|OTHER|standard of care|standard of care/supportive therapy
224066480|NCT02931058|OTHER|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
224066481|NCT02931058|OTHER|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
224066482|NCT02931058|OTHER|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
224066483|NCT01665183|DRUG|ADI-PEG 20|
224066484|NCT06241040|OTHER|Aerobic Exercises with core Muscle strengthening|Participants assigned to this group will undergo a combination of aerobic exercise and core muscle strengthening interventions. The aerobic exercise component will be similar to the first group, while additional exercises targeting the core muscles (abdomen, back, and pelvis) will be included.
223572661|NCT00717587|DRUG|motexafin gadolinium|
223572662|NCT00717587|DRUG|sunitinib malate|
223572663|NCT00717587|GENETIC|comparative genomic hybridization|
223572664|NCT00717587|GENETIC|gene expression analysis|
223572665|NCT00717587|GENETIC|mutation analysis|
224066485|NCT06241040|OTHER|Aerobic Exercise without Core Muscle Strengthening|Aerobic Exercise without Core Muscle Strengthening
224066486|NCT01452399|PROCEDURE|Shave margins|Partial mastectomy with shave margins.
224066487|NCT01452399|PROCEDURE|No Shave Margins|Partial mastectomy without shave margins.
224066488|NCT03070847|DRUG|Tranexamic Acid|Dose: 5mg/kg
224066489|NCT03070847|DRUG|Tranexamic Acid|Dose: 10mg/kg
224066490|NCT03070847|DRUG|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
223572666|NCT00717587|GENETIC|polymorphism analysis|
223572667|NCT00717587|OTHER|immunohistochemistry staining method|
223572668|NCT00717587|OTHER|iodine I-124 girentuximab|
223572669|NCT00717587|OTHER|laboratory biomarker analysis|
223572670|NCT00717587|OTHER|pharmacological study|
223743012|NCT00629499|DRUG|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
223743013|NCT00629499|DRUG|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
223743014|NCT00629499|DRUG|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
223744861|NCT05215301|DIAGNOSTIC_TEST|Multidimensional Voice Program|"MDVP (Multidimensional Voice Program) is a computerized acoustic analysis used to analyze sound quality using various parameters. Multidimensional Voice Program (MDVP) 4500 produced by Kay Elemetric Corp was used for voice evaluation.~Research subjects were asked to make a vowel sound /a/ using the same tone and intensity as the subject's daily speech. The researcher will give an example before letting the research subject tries. Voice recording was done using a microphone connected to a computer with the MDVP program. Voice recording was done in a quiet room for at least 3 seconds with a microphone distance of 10 cm from the mouth of the research subject. The recorded sound will be directly analyzed with the MDVP program. Sound recording was done 3 - 5 times, and the best sound acoustic analysis results were used for the study."
224066491|NCT06086132|COMBINATION_PRODUCT|Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy|Follow-up visits at baseline, 3-months, and 1-year
224066492|NCT05942300|DRUG|CPI-0209|A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
224066493|NCT05942300|DRUG|carboplatin|Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
224066494|NCT05388461|OTHER|electroconvulsive therapy|electroconvulsive therapy
224066495|NCT04756505|DRUG|Bintrafusp Alfa|Given IV
224066496|NCT04756505|BIOLOGICAL|Immunocytokine NHS-IL12|Given SC
224066497|NCT04756505|RADIATION|Radiation Therapy|Undergo radiation therapy
224066498|NCT03615677|DRUG|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
224066499|NCT03615677|DRUG|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
224066500|NCT05817877|OTHER|phone use|There is no intervention.
224066501|NCT05673551|OTHER|VR-PAT|Smartphone-based Virtual Reality Pain Alleviation Tool (VR-PAT) via a lightweight, mobile VR headset
224066502|NCT01698164|DRUG|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
224066503|NCT01698164|DRUG|Ximingting Tablet|Participants are given phytoestrogen.
224066504|NCT01698164|DRUG|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
224066505|NCT01430455|DRUG|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
224066506|NCT01195727|DRUG|Apixaban|
224154098|NCT04994275|OTHER|no intervention, but presence of ID or not|This is an observational study regarding patients admitted to undergo a major elective surgery supposed to last more than an hour. Investigators will analyzed the incidence of postoperative infections up to 90 days after surgery according to the preoperative iron status: iron deficiency (defined as a ferritin of less than 100 µg/L or \<300 µg/L And TSAT\<20%) or no iron deficiency
224154099|NCT03140722|DRUG|vadadustat|vadadustat
223572671|NCT00717587|PROCEDURE|adjuvant therapy|
223572672|NCT00717587|PROCEDURE|neoadjuvant therapy|
223572673|NCT00717587|PROCEDURE|therapeutic conventional surgery|
223572674|NCT01397682|OTHER|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
223572675|NCT06434129|DIAGNOSTIC_TEST|DTI|Diffusion MRI imaging
223572676|NCT01680692|DRUG|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
224066507|NCT05468268|DEVICE|20 Hz rTMS|rTMS stimulation
224066508|NCT05468268|DEVICE|Sham rTMS|Sham stimulation
224066509|NCT01996475|DRUG|Escitalopram Oxalate Tablets|
224066510|NCT05075811|DRUG|Ossium vBM-MSC|Vertebral bone marrow derived mesenchymal stem cells
224066511|NCT05075811|OTHER|Placebo|Normal Saline
224066512|NCT01696526|OTHER|vitamin D fortified fish|fish containing vitamin D3
224066513|NCT01696526|OTHER|conventional fish|fish containing low concentrations of vitamin D3
224066514|NCT00362011|BEHAVIORAL|Salba diet|
224066515|NCT02549209|DRUG|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
224066516|NCT02549209|DRUG|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
224154100|NCT03140722|DRUG|epoetin alfa|epoetin alfa
224154101|NCT04244773|OTHER|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224302322|NCT05900128|BEHAVIORAL|workshop|Patients will receive workshops and they will encourage to practice physical activity
224154102|NCT04244773|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224154103|NCT05988086|PROCEDURE|platelet rich fibrin|12 children in whom nasal layer of alveolar cleft will be repaired using autologous platelet rich fibrin with autogenous chin bone.
224154104|NCT05988086|PROCEDURE|collagen membrane|12 children in whom nasal layer of alveolar cleft will be repaired using collagen membrane with autogenous chin bone.
224154105|NCT03117699|DEVICE|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair"
224154106|NCT02564562|DRUG|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + \[14C\] PF-06463922
224154107|NCT05516615|OTHER|4 minute breathing maneuver|The 4-minute breathing maneuver comprised of 2 minutes of normal breathing and 1-min hyperventilation (rate of 30 breaths or more per minute) followed by a maximal breath-hold.
224154108|NCT03185169|COMBINATION_PRODUCT|Replens and coconut oil|
224154109|NCT01208389|BIOLOGICAL|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
224154110|NCT03190317|OTHER|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
224154111|NCT03190317|OTHER|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
224154112|NCT03190317|OTHER|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
224154113|NCT04233957|DIETARY_SUPPLEMENT|High Sodium|10 days of 3900 mg of sodium/day in excess of normal dietary intake delivered via enteric capsules filled with table salt.
224154114|NCT04233957|OTHER|Placebo|10 days of enteric capsules filled with dextrose.
224154115|NCT06410924|DRUG|DD01|Dual GLP-1 and glucagon receptor agonist
224154116|NCT06410924|DRUG|Placebo|Placebo matching DD01
224154117|NCT02559752|OTHER|NIH Toolbox Cognitive Battery|"* For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~* For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
224154118|NCT00848445|DEVICE|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
224302323|NCT05900128|OTHER|no workshop|patients won't receive educative workshops
224154119|NCT00848445|DEVICE|Atrial pacing preference turned on or off|programing changes in the device
224154120|NCT03636308|DRUG|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
224154121|NCT03636308|DRUG|S1|S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
224154122|NCT03636308|DRUG|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
224154123|NCT05685719|DRUG|STI-1558|An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
224154124|NCT05685719|DRUG|Itraconazole|A strong CYP3A4 inhibitor
224154125|NCT05685719|DRUG|Rifampin|A strong CYP3A4 inducer
224154126|NCT02088541|DRUG|Selinexor|Selinexor oral tablet.
224154127|NCT02088541|DRUG|Hydroxyurea|
224154128|NCT02088541|DRUG|Ara-C|Ara-C Subcutaneous Injection.
224302324|NCT01878461|DRUG|Vehicle|
224302325|NCT01878461|DRUG|M518101|
224302326|NCT06020287|PROCEDURE|the robot-assisted laparoscopic radical prostatectomy|We collect medical data of 233 patients with clinically localized prostate cancer who underwent AP-RARP, RS-RARP or anterior-RARP. Perioperative outcomes, including operation time, intraoperative blood loss, intraoperative and postoperative transfusion, postoperative infection, and anastomotic leakage, were compared among the three groups. The postoperative continence rates and PSM rates were also compared.
224302327|NCT00418301|OTHER|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
224302328|NCT00142233|DIETARY_SUPPLEMENT|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
224302329|NCT00142233|DRUG|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
224302330|NCT00142233|OTHER|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
224302331|NCT00142233|OTHER|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
224154129|NCT00612339|DRUG|Avastin and Temozolomide|This is Phase II study with the combination of Avastin \& Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin \& Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI \& repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy \& requests discontinuation, patients will receive up to 4 cycles of Avastin \& Temozolomide, then proceed with standard XRT therapy, \& future therapy after 4 cycles will be at discretion of patient \& treating physicians.
224154130|NCT03705260|OTHER|Usual Care|Usual care from Primary Care Physician and dietitian.
224154131|NCT03705260|BEHAVIORAL|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
224154132|NCT03705260|OTHER|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
224154133|NCT03499613|OTHER|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
224154134|NCT00516958|DRUG|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
224154135|NCT00516958|DRUG|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
224154136|NCT00516958|DRUG|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
224154137|NCT03892525|DRUG|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
224154138|NCT03892525|DRUG|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
224154139|NCT05523804|PROCEDURE|interval cytoreductive surgery|cytoreductive surgery after 3-4 cycles of chemotherapy
224154140|NCT05523804|PROCEDURE|delayed cytoreductive surgery|surgery after \>5 cycles of chemotherapy
224154141|NCT05523804|OTHER|no surgery|no cytoreductive surgery (\>5 cycles of chemotherapy alone)
224154142|NCT00323310|DRUG|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
224154143|NCT06257134|OTHER|No systematic monitoring of symptoms|No systematic monitoring of symptoms will be carried out, and patients will receive the usual care. Data collection will be carried out with the assistance of a clinical research nurse up to 12 months, then under the direction of local healthcare teams at 18 months.
224302332|NCT00004553|PROCEDURE|Electromyography|
223456168|NCT03604848|DRUG|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
223456169|NCT03604848|DRUG|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
223572677|NCT01680692|DEVICE|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
223572678|NCT01680692|DEVICE|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
224066517|NCT02549209|DRUG|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
224066518|NCT05686200|BEHAVIORAL|Forearm isometric exercise intervention program|Experimental group using the intelligent gripper for forearm isometric exercise in the 3rd to 8th participants after operation, and using the smart mobile phone to install the forearm isometric exercise training game program software to provides an interactive and real- time exercise grip strength feedback mechanism, which are uses the interest of the participant to complete the forearm isometric exercise every day, and can implement the isometric exercise training for fistulization. Study nurses will track exercise adherence with telephone interviews 2, 4 and 8 participants after participant exercise intervention.
224066519|NCT00333359|DRUG|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
224066520|NCT00322283|DRUG|Oglemilast|Oglemilast, 15mg once per day, oral administration
224066521|NCT00322283|DRUG|Placebo|Dose-marched placebo, once per day, oral administration
224066522|NCT02282644|BIOLOGICAL|Bone marrow sampling|
224066523|NCT00584155|DRUG|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
224066524|NCT00584155|DRUG|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
224154144|NCT06257134|OTHER|Systematic monitoring of symptoms|"once a month, individual patient scores will be sent to dialysis staff. Any score of 3 (severe symptoms) or 4 (overwhelming) on a scale of 0 to 4, on the IPOS-Renal instrument, will be permanently reported to the referrer to trigger the patient's usual symptom management.~Patients will complete 3 further HRQoL questionnaires at baseline, M6, M12 and M18: EQ-5D-5L, KDQoL-36, SONG Fatigue.~A clinical research nurse will be present in half of the participating dialysis units to help patients and dialysis teams to include and follow up patients, up to 12 months. Between 12 and 18 months, data will be collected in real life, under the guidance of local healthcare teams.~In the other half of the dialysis units, data will be collected under the direction of the local healthcare teams, who will have to organize themselves to ensure data collection. These units will also be asked to conduct semi-structured interviews as part of the qualitative phase."
224154145|NCT03984812|DRUG|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
224154146|NCT03984812|DRUG|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
224154147|NCT01954810|BIOLOGICAL|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
224154148|NCT04216706|DRUG|tailored pharmaceutical treatment|Tailored medication is advised in women with inadequate hemodynamic adaptation to pregnancy. Type of medication depends on total peripheral vascular resistance and heart rate. In short, women with a low peripheral vascular resistance in parallel with a high heart rate are advised a betablocker (labetalol), while a vasodilating agent (calcium channel blocker, nifedipine) was advised in women with a high total peripheral vascular resistance in combination with a low heart rate. Women with suboptimal adaptation to pregnancy without an extreme pronounced vascular profile are advised a centrally acting sympatholytic agent (methyldopa).
224154149|NCT00446641|DRUG|Cilostazol|cilostazol 100mg twice a day for 4 weeks
224154150|NCT00446641|DRUG|placebo|placebo 1 tablet twice a day matching for cilostazol
224154151|NCT04251741|DIAGNOSTIC_TEST|Adalimumab trough concentration|In the 'drug concentration guided' group, switching to subsequent biological is based on adalimumab trough concentration
224154152|NCT04251741|OTHER|Usual care|In the usual care group, switch to subsequent biological is based on secondary randomisation
224154153|NCT03961295|DRUG|Vedolizumab SC|Vedolizumab SC liquid.
224154154|NCT04942522|BIOLOGICAL|probiotics PS128|6×10\^10 CFU/capsule
224154155|NCT04942522|DRUG|placebo (Microcrystalline cellulose )|450 mg/capsule
224154156|NCT05726955|OTHER|Exercise training program|an exercise training program applied with conservative treatment and a stretching platform (ETSP) 3 days a week for 6 weeks
224154157|NCT00951119|DEVICE|Resperate|device-guided breathing exercises
224154158|NCT00951119|DEVICE|Resperate|breathing device without slowing of breathing frequency
224154159|NCT02941042|DRUG|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
224154160|NCT02941042|DRUG|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
224154161|NCT02455843|OTHER|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
224154162|NCT02479386|OTHER|No intervention|No intervention was administered in this study.
224154163|NCT01511692|DRUG|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
224154164|NCT01511692|DRUG|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
224154165|NCT01511692|DRUG|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
224154166|NCT01511692|DRUG|glimepiride|Dose individually adjusted, administered orally for 4 weeks
224154167|NCT02929862|DRUG|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
224154168|NCT05948319|DIAGNOSTIC_TEST|Doppler ultrasonography|Doppler study was performed in all cases. perinatal outcomes were evaluated.
224154169|NCT04834050|PROCEDURE|Quadriceps femoris isometric home-based exercise|All 3 groups of participants were given 4-week (5 days/week) quadriceps-hamstring isometric home-based exercise training for their both knees. Exercises were performed (with maximal effort for 10 seconds) at a rate of 20 repetitions per day. Training was performed at outpatient clinic for 30 minutes.
224154170|NCT05211245|DEVICE|therapeutic ultrasound|Therapeutic ultrasound ranges from 750,000 to 3,300,000 Hz (0.75 to 3.3 MHz). Depending upon the output parameters it may produce effects like increase tissue extensibility, reduction of calcium deposits, reduction of pain \& muscle spasm by altering nerve conduction velocity \& changes in cell membrane permeability along with increased rate of tissue repair \& wound healing.There are two main types of ultrasound therapy: thermal and mechanical. Thermal effect which is a result of continuous mode of US therapy causes transient increase in the flexibility of collagenous structures including ligaments, tendons \& joint capsules, thus leading to decrease in the pain \& muscle spasm, stiffness of the joint \& temporary increase in the blood flow. Pulsed mode of US results in nonthermal effect i.e., micro massage like which lead to segmental analgesia due to decreased central \& peripheral sensitization.
224154171|NCT05833568|DEVICE|Active Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition."
223456170|NCT03604848|DRUG|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
223456171|NCT03604848|DRUG|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, \>70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, \>70kg 1200 mg daily;"
223456172|NCT02748057|DRUG|Ezetimibe|
223456173|NCT02748057|DRUG|Rosuvastatin|
223456174|NCT03957486|OTHER|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
223456175|NCT03957486|OTHER|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
223456176|NCT01990573|DRUG|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
223744862|NCT01830439|DRUG|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
224066525|NCT06285591|DRUG|Lactobacillus reuteri Tablets|Lactobacillus reuteri lozenges (NOW Foods, Sweden) contained 2×10\^8 CFU viable cells of Lactobacillus reuteri as the active ingredient.
223744863|NCT01830439|DRUG|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
223744864|NCT00367952|DRUG|apricitabine|800mg apricitabine twice daily orally for 96 weeks
224066526|NCT06285591|DRUG|Placebo-containing tablets|Starch preparations that look and taste like Lactobacillus reuteri.
224066527|NCT06285591|RADIATION|Radiotherapy|One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy.
224066528|NCT00941265|DRUG|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
224066529|NCT00941265|DRUG|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
224066530|NCT02148965|BEHAVIORAL|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
224066531|NCT04793178|DEVICE|Oxygen Reserve Index, Masimo Corporation, USA.|The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
224066532|NCT01217671|BIOLOGICAL|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
224066533|NCT01217671|OTHER|Placebo|Placebo
224066534|NCT02030743|OTHER|Visual training|6 training sessions with computerised visual attention paradigm
224066535|NCT06363214|PROCEDURE|Patient blood management|Perioperative optimization of hemoglobin level, perioperative minimization of blood loss, increase of anemia tolerance
224066536|NCT01770132|DRUG|porfimer sodium|Given IV
224066537|NCT01770132|PROCEDURE|endoscopic ultrasonography|Undergo EUS-PDT
224066538|NCT01770132|PROCEDURE|photodynamic therapy|Undergo EUS-PDT
224066539|NCT01770132|DRUG|gemcitabine hydrochloride|Given IV
224066540|NCT06841913|BIOLOGICAL|LAIV nasal vaccine is chosen as a model viral infection|Inoculation with LAIV
223456177|NCT01990573|DRUG|0.4mg/kg IV methadon HCl|Group II will receive 0.4mg/kg IV methadone HCl.
223456178|NCT01990573|OTHER|control no methadone|The control group will not receive methadone.
223456179|NCT00144560|DRUG|MRA(Tocilizumab)|
223456180|NCT06106880|DRUG|Wintergreen Throat Spray and Aspirin Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet"
224066541|NCT06841913|OTHER|Wood smoke|Wood smoke exposure concentrations at 500 ug/m3 for two hours.
224066542|NCT06841913|BIOLOGICAL|Placebo for LAIV nasal vaccine is chosen as a model viral infection|Placebo for LAIV inoculation. Nasal administration of normal saline.
224066543|NCT06841913|OTHER|Placebo for Wood Smoke (clean Air Exposure)|Clean Air Exposure for 2 hours
224066544|NCT06568692|DRUG|PCS6422 and capecitabine|PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
224066545|NCT06568692|DRUG|Capecitabine|Commercially available capecitabine is a commonly used oral fluoropyrimidine.
224066546|NCT04061421|DRUG|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
224066547|NCT04061421|DRUG|Itacitinib|Taken by mouth daily during each 28-day cycle
224066548|NCT02956603|OTHER|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
224066549|NCT00612638|DRUG|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 \& 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
224154172|NCT05833568|DEVICE|SHAM Transcranial alternative current stimulation|"GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions."
224154173|NCT02707601|DRUG|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
223456181|NCT06106880|DRUG|Aspirin Throat Spray and Placebo Tablet|"The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
223456182|NCT06106880|DIETARY_SUPPLEMENT|Wintergreen Throat Spray and Placebo Tablet|"The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
223456183|NCT06106880|OTHER|Placebo Throat Spray and Placebo Tablet|"The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients."
223456184|NCT05182801|DIETARY_SUPPLEMENT|Placebo sachet|Blank
223456185|NCT05182801|DIETARY_SUPPLEMENT|Banana flower extract sachet|Happy Angel Banana Flower Extract sachet
223572679|NCT03255538|OTHER|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
223572680|NCT03255538|OTHER|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
224066550|NCT05571514|DIETARY_SUPPLEMENT|Mother-of-pearl|"The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation."
224066551|NCT05571514|DIETARY_SUPPLEMENT|Calcium Carbonate|Calcium carbonate is a source of calcium.
224066552|NCT06816017|DRUG|Eciskafusp Alfa|Participants will receive eciskafusp alfa via intravesical instillation.
224066553|NCT06816017|DRUG|BCG Medac Strain|Participants will receive BCG via intravesical instillation.
224066554|NCT02072408|DRUG|aflibercept|"1. Three monthly intravitreal aflibercept (2mg) injections~2. Five bimonthly intravitreal aflibercept (2mg) injections~3. Rescue treatment: Verteporfin photodynamic therapy~   * Loss of five ETDRS letters or one Snellen line of vision from baseline~  * Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~  * Presence of active polyp on indocyanine green angiography"
224066555|NCT02380716|DEVICE|GORE® Ascending Stent Graft|
224066556|NCT02867995|DEVICE|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
224066557|NCT02548104|OTHER|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
224066558|NCT02548104|OTHER|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
224066559|NCT00502762|DRUG|topotecan|
224066560|NCT05618327|DRUG|JS203 for Injection|"2-steps:JS203 for Injection is administered on the first and eighth day of the first cycle and every 3 weeks thereafter.~3-steps:JS203 for Injection is administered on the first, eighth and fifteenth day of the first cycle and every 3 weeks thereafter.~4-steps:JS203 for Injection is administered on the first, eighth, fifteenth and twenty-second day of the first cycle and every 3 weeks thereafter."
224066561|NCT07001540|DRUG|Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)|Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx)
224066562|NCT07008170|PROCEDURE|Laparoendoscopic rendezvous|"The main principles of LERV technique consists of~1. An antegrade trans cystic cannulation of the bile duct during laparoscopic cholecystectomy, with a guidewire that can be retrieved with a duodenoscope, thus facilitating retrograde bile duct cannulation.~2. An over-the-wire sphincterotome is then inserted and standard maneuvers of endoscopic common bile duct stones clearance are performed.~3. The procedure is then completed by cholecystectomy in one procedure"
224066563|NCT06868446|DEVICE|Digital Therapeutic (Version 1)|Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD
224066564|NCT06868446|DEVICE|Digital Therapeutic (Version 2)|Prescription digital therapeutic (increased dose) designed to overcome existing barriers and deliver evidence-based treatment for PTSD
224066565|NCT06868446|BEHAVIORAL|Treatment as Usual (TAU)|Treatment as usual may include psychotherapy and/or pharmacological interventions.
224066566|NCT07014176|OTHER|Amnion-Intermediate-Chorion|Dehydrated human placental multilayer allograft from derived donated human tissue. AIC contains amnion and chorion layers as well as basement membrane and trophoblast.
224066567|NCT07014176|PROCEDURE|Standard of Care (SOC)|Standard of care is to establish a clean, healthy wound bed and optimize the wound environment to have the best chance of healing the wound. This is achieved through wound cleansing, debridement, offloading and moisture balance.
224066568|NCT06871462|BEHAVIORAL|BP monitor use training and app training|Patients will be taught how to use a BP monitor, along with the accompanying mobile app to view their readings.
224066569|NCT06871462|BEHAVIORAL|Online patient portal enrollment and training|Patients will receive training on how to use an online patient portal. If they are not yet enrolled in an online patient portal and would like to be, they will also be enrolled into one.
224302333|NCT04819048|DEVICE|Low-Level Laser Therapy+acupuncture|"The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.~The needles using are disposable, sterile, individually packed, and made of stainless steel (Hua Tuo; Suzhou Medical Supplies Factory Co, Ltd,Suzhou, China), in sizes 0.25 mm ×40 mm.Asepsis of the skin will be performed with cotton wool and 75% alcohol."
223456186|NCT02121548|BEHAVIORAL|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
223456187|NCT02121548|BEHAVIORAL|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
223456188|NCT04854759|DRUG|Amantadine Hydrochloride|100 mg, capsule
223456189|NCT04854759|DRUG|Placebo|100 mg, capsule
223456190|NCT02307149|BIOLOGICAL|CAVATAK|CAVATAK is a preparation of CVA21
223456191|NCT02307149|DRUG|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
223456192|NCT04945564|PROCEDURE|Oxygen therapy and physical therapy|Patients receive oxygen therapy and physical therapy
223456193|NCT04945564|DEVICE|Oxygen therapy|Patients receive oxygen therapy
223456194|NCT01768065|DEVICE|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
223456195|NCT01768065|DEVICE|placebo sham|
223456196|NCT03112226|OTHER|GnRHant + E2|GnRH antagonist with estradiol add-back
223456197|NCT03112226|OTHER|GnRHant + Placebo|GnRH antagonist with placebo add-back
223456198|NCT00447096|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
224066570|NCT06871462|BEHAVIORAL|SMS reminders to take blood pressure|Patients will receive reminders via SMS to take their blood pressure.
224066571|NCT06871462|BEHAVIORAL|Education about self-management of hypertension|One-time training with action planning, access to website with language concordant patient education, and educational text messages
224066572|NCT06871462|BEHAVIORAL|Educational text messages that encourage seeking support from a support person|Educational text messages about behavioral changes that explicitly encourage seeking support from a support person
224066573|NCT06871462|BEHAVIORAL|Involvement of caregiver or support person|Patients will be asked to involve a caregiver or support person for all activities above, including patient portal proxy access.
224066574|NCT06871462|BEHAVIORAL|Group classes|Patients will be asked to attend in-person or online group education classes on hypertension management
224066575|NCT03894670|OTHER|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
224066576|NCT03894670|OTHER|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
224066577|NCT06691672|DIAGNOSTIC_TEST|Robotic Tomographic ultrasound imaging of the arm vasculature.|Semi-autonomous robotic tomographic ultrasound imaging of the arm vasculature for vascular access creation mapping in CKD patients.
224066578|NCT07019636|PROCEDURE|Weaning strategy with direct extubation (no spontaneous breathing trial)|Patients will be extubated within the 60 minutes following randomization
224066579|NCT07019636|PROCEDURE|Weaning strategy with extubation only after a successful spontaneous breathing|Patients will undergo a spontaneous breathing trial and will be extubated only in case of successful spontaneous breathing
224066580|NCT05132101|DRUG|Patients who received Palbociclib as first line therapy in MBC setting|Patients who received Palbociclib as first line therapy in MBC setting
224066581|NCT07029594|OTHER|balneotherapy|"Specific procedures performed during the 3-week spa therapy~Thermal Treatments (Number of sessions)~Individual nasal irrigation (18) Sonic aerosol therapy (18) Simple aerosol therapy (18) Individual inhalation therapy (18)~Administered by a licensed physiotherapist~Individual respiratory rehabilitation and bronchial drainage (18)~Administered by a spa physician Tubo-tympanic insufflation (9) Sinus lavage using the Proëtz displacement method 9"
224066582|NCT07028567|DRUG|Calcium hydroxylapatite filler|Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
224066583|NCT07028567|DRUG|Painting chemical reconstruction of skin scars trichloroacetic acid technique|Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.
224066584|NCT07029802|OTHER|No intervention|This is an observational study
224066585|NCT07027787|BEHAVIORAL|Standard Physical Therapy for Hand Dexterity in Stroke Patients|Standard physical therapy program for stroke patients targeting hand dexterity. Conducted 3 times/week for 8 weeks (60 min/session), exercises included wrist and forearm movements, object manipulation, ball gripping, and putty-based hand strengthening.
224066586|NCT07027787|BEHAVIORAL|Rehacom Attention Training + Physical Therapy|Combined intervention: 30 minutes of computerized attention training using the Rehacom system, followed by 30 minutes of standard hand dexterity physical therapy. Conducted 3 times/week for 8 weeks. Rehacom provided task-based cognitive training with visual, auditory, and performance feedback in a controlled lab setting.
224066587|NCT07028333|BEHAVIORAL|Motor-Motor Dual Task Exercise Group|Participants in this group will perform motor tasks (such as ball handling, throwing, holding) accompanied by physiotherapist. Exercises will last about 40 minutes, 2 days a week, 6 weeks.
223456199|NCT02408731|DRUG|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
223456200|NCT03958188|OTHER|Standardized computerized tomography (CT) reading grid for preoperative planning|"Using the standardized reading grid, the following data will be collected:~* Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~* Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~* Mesentery: moniliform venous dilatations, combed appearance.~* Duodenal invasion.~* Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital."
223456201|NCT00886366|DRUG|AZD6714|Oral single doses a-h suspension
223456202|NCT00886366|DRUG|Placebo|Oral single doses suspension
223456203|NCT00886366|DRUG|AZD6714|Oral single doses a-d suspension
223456204|NCT00886366|DRUG|AZD6714|Oral single doses d and g suspension
223456205|NCT04655729|DRUG|Infliximab|Blood collection
223456206|NCT02136459|OTHER|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
223456207|NCT02136459|OTHER|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
224066588|NCT07028333|BEHAVIORAL|Motor-Cognitive Dual Task Exercise Group|This group will also do walking and balance exercises with the physiotherapist, while simultaneously doing cognitive tasks (rhythmic counting, saying color names, finding words, etc.). The exercises will last approximately 40 minutes, 2 days a week, for 6 weeks.
224066589|NCT07028333|BEHAVIORAL|Control Group|Standard walking and balance exercises will be given to the control group at home and followed by parents. Exercises will last about 40 minutes, 2 days a week, 6 weeks.
224066590|NCT07029100|OTHER|Ex-vivo organoid culture|ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection
224066591|NCT07028242|PROCEDURE|Hysteroscopic fertility-sparing surgery and hormonal treatment|"Patients undergo hysteroscopic endometrial resection using the Mazzon three-step technique or tissue removal device (TRD), depending on the lesion type. Following surgery, hormonal treatment is administered either via intrauterine device (IUD) or oral progestin. Monitoring includes serial endometrial biopsies and transvaginal ultrasounds at 3, 6, and 12 months."
224066592|NCT07029906|DRUG|Bisoprolol 2.5 mg|Active bisoprolol 2.5mg tablets
224066593|NCT07029906|DRUG|Placebo|Blinded placebo for a total of 3 weeks
224066594|NCT07028970|OTHER|No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )|This study is observational study and all participants will be obsreved with no intervention.
224066595|NCT07029997|DEVICE|Solo+ Tympanostomy Tube Device (Solo+ TTD)|insertion of eartubes
224066596|NCT07029061|DEVICE|Air splints|Application of CPPS (Urias splints) + physiotherapy
224066597|NCT07029659|DIAGNOSTIC_TEST|Ovarian Cancer Score|Preoperatively, 5 ml blood samples were collected for OCS testing to determine the benign or malignant nature of ovarian endometriotic tissues. The OCS results were statistically analyzed against the gold standard of histopathological diagnosis.
224066598|NCT07027917|DEVICE|Virtual Reality Goggles|VR
224066599|NCT07028736|OTHER|Dry eye assessment|Dry eye assessment was performed using the Mediworks Dry Eye Diagnostic System.
224066600|NCT07028918|RADIATION|Low dose radiotherapy regimen|On the first and second day of chemotherapy and immunotherapy, low-dose radiotherapy of 1 Gy/1f was administered to the primary tumor lesion and metastatic lymph nodes, respectively, for a total of 4 Gy/4f.
224066601|NCT07028918|DRUG|New adjuvant immunotherapy regimen|Terriptylimab: fixed dose 240 mg, q30000, intravenous infusion, each infusion lasting 30 minutes (not less than 20 minutes, not more than 60 minutes); Chemotherapy regimen: Albumin bound paclitaxel: 175-260 mg/m2, d1, q3w; Platinum class: Cisplatin: 75mg/m2, d1-3, q3w; Carboplatin: AUC=5, d1, q3w (for patients with cisplatin allergy, intolerance, hearing impairment, creatinine clearance rate\<50ml/min, or grade 1 neuropathy that are not suitable for cisplatin use).
224066602|NCT07028918|PROCEDURE|Surgical treatment|Surgery begins around 4 weeks after the first day of the second cycle of neoadjuvant therapy. The surgical plan is developed and evaluated by oral surgeons with years of clinical surgical experience. The determination of surgical margins is mainly based on baseline standards before neoadjuvant therapy for tumors, and can be appropriately reduced by oral surgeons depending on the situation.
224066603|NCT07028918|DRUG|Postoperative adjuvant therapy plan|"* Patients with postoperative pathological progression of pCR were given maintenance treatment with Triprolizumab Q3W for 1 year.~  * Patients with postoperative pathology not reaching pCR should receive adjuvant radiotherapy (60-66Gy/30-33f) ③ Patients with high-risk recurrence factors in postoperative pathology (positive tumor margin or insufficient safe margin, presence of lymph node extracellular invasion) are given adjuvant radiotherapy and chemotherapy."
224066604|NCT07028918|RADIATION|Radical radiotherapy plan|"① Radical radiotherapy for the primary lesion and cervical lymphatic drainage area.~② Synchronous cisplatin during radiotherapy: 75mg/m2, d1-3, q3w."
224066605|NCT07028593|DRUG|Propofol|Using as sedative agents in the total intravenous anesthesia in video-assisted thoracoscopic aurgery in propofol group.
224066606|NCT07028593|DRUG|ciprofol|Using as sedative agents in the total intravenous anesthesia in video-assisted thoracoscopic aurgery in ciprofol group.
224154174|NCT02707601|DRUG|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
223456208|NCT02403050|DEVICE|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
223456209|NCT03161730|OTHER|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
224154175|NCT02707601|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
224154176|NCT03551184|BIOLOGICAL|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
224154177|NCT03551184|BIOLOGICAL|Placebo|Saline administered intravenously
223456210|NCT03161730|OTHER|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
223572681|NCT03255538|OTHER|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
224154178|NCT01769612|OTHER|No Intervention|
224154179|NCT00704392|DRUG|XL647|Tablets supplied at 50-mg strength administered orally daily
223456211|NCT03161730|OTHER|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
223456212|NCT02588586|DRUG|3BNC117|3BNC117 infusions
223456213|NCT02588586|OTHER|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
223456214|NCT05554640|DEVICE|Acuvue® Oasys MAX 1-Day|TEST Lens
223572682|NCT01001546|BEHAVIORAL|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
223572683|NCT01001546|BEHAVIORAL|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
224066607|NCT07029815|PROCEDURE|irradiation with Er:YAG laser|An Er:YAG laser (LightTouch, LightInstruments, Yokneam, Israel) was used with the following parameters: 400mJ (millijoules), 6W (Watt), 15Hz (Hertz), 5/8 water cooling, laser tip with a diameter of 800 microns. Tissue debridement continued until hard, healthy, lively bleeding bone was exposed, indicative of normal bone.
224066608|NCT07029815|PROCEDURE|Tissue preparation|Rose-shaped rotary drills (8 mm diameter) were used with water cooling at a speed not exceeding 40.000 rpm. Tissue preparation limits were consistent with those used for the Er:YAG laser group.
224066609|NCT07027878|DEVICE|JETi lower extremity venous thrombosis|The JETi System is a hydro-mechanical aspiration system, intended for the removal of intravascular thrombus. The system comprises of the JETi Catheter (6F or 8F), JETi Pump Set, JETi Saline Drive Unit (SDU), JETi Accessory Cart, JETi Suction tubing and JETi Non-Sterile Canister Set. The JETi System is designed to continuously aspirate thrombotic material into the catheter, where a high-pressure stream of saline within the catheter tip macerates the thrombus as it is aspirated.
224066610|NCT07028138|OTHER|electrical stimulation with mime therapy|"A total of 38 Bell's palsy patients will be randomly selected and divided into two equal groups at Shalamar Hospital.~Group A will receive mime therapy with electrical stimulation, including facial massage, relaxation, stretching, and facial movement exercises.~Group B will undergo electrical stimulation followed by proprioceptive neuromuscular facilitation (PNF) with resisted facial and tongue exercises.~Each group will receive 30-minute sessions, three times per week, for six weeks.~Outcomes will be assessed using the Facial Disability Index (FDI), Sunnybrook Facial Grading System, and SF-12 quality of life scale.~Evaluations will be conducted at baseline, after one month, and at a 2-3 month follow-up."
224066611|NCT07028229|BEHAVIORAL|Training Group|A structured educational and practical training program in gynecologic oncology ultrasound designed for residents. The intervention includes lectures, clinical case discussions, supervised and independent ultrasound examinations, and performance assessments to evaluate learning progression and diagnostic concordance with experts.
224066612|NCT07028047|BIOLOGICAL|WGc-043 Injection|WGc-043 Injection, intramuscular injection
224066613|NCT07029854|OTHER|Medical treatment|They will receive oral chemotherapy, based on the cancer stage, and will also undergo radiotherapy.
224066614|NCT07029854|OTHER|LASER acupoints therapy|LASER acupoints therapy will use the Pointer Pulse device (GMT2000 s.r.l., Italy), emitting 650 nm red light with an audio trimmer for acupoint detection. Treatment parameters include 5 mW power, 120 s irradiation per point over a 3.14 mm² area (fluence: 19.2 J/cm², power density: 0.16 W/cm², total dose: 0.6 J). Continuous red laser will be applied for effective stimulation. Sessions will occur once weekly for five weeks. Bilateral stimulation will follow this order: left hand, left face, trunk, right face, and right hand. Targeted acupoints: LI 2 Erjian, ST 5 Daying, ST 6 Jiache, ST 7 Xiaguan, SI 19 Tinggong, and BL 13 Feishu.
224066615|NCT07029854|OTHER|Pseudo-LASER acupoints therapy|For the pseudo-LASER acupoints therapy, the same procedures and sequence of acupoint application will be followed as in the active treatment. However, the Pointer Pulse device (GMT2000 s.r.l., Italy) will be deactivated to emit no therapeutic laser light while maintaining visual and audio cues to mimic real stimulation. The device will appear active to ensure blinding. Sessions will be conducted once weekly for five weeks, applying the probe to the same bilateral acupoints in the following order: left hand, left face, trunk, right face, and right hand. The targeted points will be LI 2 Erjian, ST 5 Daying, ST 6 Jiache, ST 7 Xiaguan, SI 19 Tinggong, and BL 13 Feishu.
224066616|NCT07028827|DRUG|0.05% atropine eye drops|One drop of 0.05% atropine in each eye once a day before bedtime
224066617|NCT07028827|DRUG|0.025% atropine eye drops|One drop of 0.025% atropine in each eye once a day before bedtime
224066618|NCT07028827|DRUG|placebo eye drops|One drop of placebo in each eye once a day before bedtime
224154180|NCT00704392|DRUG|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
224154181|NCT01255189|DEVICE|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
223456215|NCT05554640|DEVICE|Dailies Total 1|CONTROL Lens
223456216|NCT03089645|BIOLOGICAL|MEDI5083 monotherapy|Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab
223456217|NCT03089645|BIOLOGICAL|MEID5083 with Durvalumab or Tremelimumab|Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab
223572684|NCT00167180|PROCEDURE|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
223572685|NCT00167180|DRUG|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
223572686|NCT05330858|DRUG|ESK-001|Oral tablet or liquid
223572687|NCT05330858|DRUG|Rabeprazole|Oral Tablet
224154182|NCT01255189|DEVICE|invos 5100|near infrared spectroscopy: invos 5100
224154183|NCT03907969|DRUG|AZD7648|Core: AZD7648 will be administered orally
224154184|NCT03907969|DRUG|PLD|The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
224154185|NCT02821988|DEVICE|External fetal monitor for Nonstress test|
224302334|NCT04819048|DEVICE|Low-Level Laser Therapy|The experimental group will be firstly irradiated by the GaAlAs infrared laser (CDHC,Denlase 980/7 Diode Laser Therapy System,China), with an output of 500 mW, emitting radiation wavelength of 980 nm, spot size 0.2cm2 ,15J/point, in a continuous mode .The therapeutic LLLT application is achieved through direct contact of the probe on the skin.
224302335|NCT03748030|RADIATION|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
224302336|NCT01948466|BEHAVIORAL|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
224302337|NCT04105426|DIETARY_SUPPLEMENT|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
224302338|NCT04105426|DIETARY_SUPPLEMENT|Placebo|one placebo tablet three times per day for 3 months.
224302339|NCT05445661|DEVICE|injectable poly-L-lactic acid|Injectable biostimulant for volume loss
224302340|NCT05445661|OTHER|Normal Saline|Sham Comparator
223456218|NCT03089645|BIOLOGICAL|Medi5083 with Durvalumab and Docetaxel|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
223456219|NCT04587141|DRUG|Sucrosomial iron|This is an oral iron formulation commercially available as an integrator
223456220|NCT04587141|DRUG|Ferric Gluconate|This is a commercially available iron formulation for parenteral administration
224066619|NCT06877845|OTHER|Activity Tracker & Postural Corrector|"Use of Activity Tracker \& Postural Corrector along with following baseline treatment.~* HOT PACKS:for 15 minutes~* TENS (transcutaneous electric nerve stimulator): for 10 minutes~* ROMs(range of motions): at knee joint Passive and Active-Assisted Knee Flexion and Extension Quadriceps Sets Straight Leg Raises (SLR) Ankle Pumps~* Strengthening Exercises:~Quadriceps Strengthening Hamstring Curls Gluteal Strengthening Calf Raises~Total Duration of Exercise Session: 25 minutes"
224066620|NCT06877845|OTHER|Conventional Therapy|"* HOT PACKS:for 15 minutes~* TENS (transcutaneous electric nerve stimulator): for 10 minutes~* ROMs(range of motions): at knee joint Passive and Active-Assisted Knee Flexion and Extension Quadriceps Sets Straight Leg Raises (SLR) Ankle Pumps~* Strengthening Exercises:~Quadriceps Strengthening Hamstring Curls Gluteal Strengthening Calf Raises~Total Duration of Exercise Session: 25 minutes"
224066621|NCT06203561|BEHAVIORAL|Basic treatment|including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control
224066622|NCT06203561|BEHAVIORAL|comprehensive rehabilitation therapy|including respiratory tract management, care for tracheotomy tube, comprehensive training for hemiplegic limbs, swallowing function training, pulmonary function training, and acupuncture.
224066623|NCT06203561|DEVICE|Intermittent Oro-esophageal Tube Feeding|The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
224154186|NCT02821988|DEVICE|Ultrasonography for Biophysical profile|
224154187|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
224154188|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
224154189|NCT00862394|DRUG|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
224154190|NCT00862394|DRUG|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
224154191|NCT00666536|DRUG|valsartan and amlodipine|
224154192|NCT00666536|DRUG|valsartan and amlodipine|
224154193|NCT02122055|DRUG|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
224154194|NCT02122055|PROCEDURE|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
223456221|NCT04587141|DRUG|Ferric carboxymaltose|This is a commercially available iron formulation for parenteral administration
223456222|NCT00568217|DRUG|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
223456223|NCT04541329|BIOLOGICAL|Tildrakizumab|IL-23 inhibitor
223456224|NCT00878579|DEVICE|PDS System|Percutaneous Dynamic Stabilization System
224154195|NCT02122055|PROCEDURE|Screen of weaning|1\. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
224302341|NCT03929276|DEVICE|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
224302342|NCT03929276|DEVICE|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
224302343|NCT03929276|OTHER|exercise|Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
224154196|NCT02122055|DRUG|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
224154197|NCT02122055|DRUG|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
224154198|NCT02122055|DRUG|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
224154199|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
224154200|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
224154201|NCT01061840|BIOLOGICAL|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
224154202|NCT02779530|DRUG|Diclofenac|50 mg po, b.i.d for 6 days
224154203|NCT02779530|OTHER|Placebo|Placebo po, b.i.d. for 6 days
224154204|NCT01055470|DRUG|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
224154205|NCT01055470|DRUG|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
224154206|NCT01333098|DRUG|Mifepristone|300mg per day, by mouth, for 21-28 days
224154207|NCT01761136|BIOLOGICAL|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
224154208|NCT01761136|BIOLOGICAL|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
224154209|NCT00116194|BEHAVIORAL|Physical Activity|
224154210|NCT01391468|DIETARY_SUPPLEMENT|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
224154211|NCT01391468|DIETARY_SUPPLEMENT|Cornstarch|placebo will be given in 6 months
224154212|NCT01674985|BIOLOGICAL|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
224154213|NCT00063986|PROCEDURE|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
224154214|NCT02977039|OTHER|NDPR diet|nutrient rich plant based diert
224154215|NCT02977039|OTHER|USDA healthy eating diet|DASH diet
224154216|NCT01844791|DRUG|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
224154217|NCT01844791|DRUG|Platinum|Platinum is given as standard chemotherapy each cycle
224302344|NCT02910674|DEVICE|Dario Blood Glucose Monitoring System|Accuracy with usability assessment
224302345|NCT01216618|DEVICE|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
224154218|NCT01844791|DRUG|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
224154219|NCT05989295|DIETARY_SUPPLEMENT|probiotic LRa05|treatment about 12 weeks
224302346|NCT00244478|DIETARY_SUPPLEMENT|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
224302347|NCT00244478|DIETARY_SUPPLEMENT|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
224302348|NCT01879930|DRUG|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
224302349|NCT01879930|DRUG|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
224154220|NCT00798473|DRUG|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
223456225|NCT00878579|DEVICE|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
223456226|NCT02705378|DRUG|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
224154221|NCT00798473|OTHER|IV saline infusion|
224154222|NCT01591993|PROCEDURE|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
224154223|NCT01591993|PROCEDURE|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
224154224|NCT03515239|PROCEDURE|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
223456227|NCT02705378|DRUG|naloxegol|Intervention would be given by OG or NG tube
224154225|NCT03556332|DRUG|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
224154226|NCT03556332|DRUG|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
224154227|NCT03556332|DRUG|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
224154228|NCT03556332|DRUG|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
224154229|NCT03556332|PROCEDURE|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine \>2mg/dL, they will receive 140 mg/m2.
224154230|NCT00054158|DRUG|dexamethasone|
224154231|NCT00054158|DRUG|doxorubicin hydrochloride|
224154232|NCT00054158|DRUG|thalidomide|
224154233|NCT00054158|DRUG|vincristine sulfate|
224154234|NCT04839393|DRUG|PF-06882961 followed by PF-06882961/PF-06865571|Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
224154235|NCT04839393|DRUG|PF-06882961/PF-06865571 followed by PF-06882961|Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
224154236|NCT04839393|DRUG|PF-06882961 + PF-06865571|Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
224154237|NCT00715013|DRUG|Patupilone|Patupilone
223456228|NCT00638469|RADIATION|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
224154238|NCT04483297|DRUG|AK1320 MS|AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.
224154239|NCT04483297|OTHER|Control|Local Autologous Bone + Posterior Fixation
224154240|NCT00608881|DRUG|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
224154241|NCT00608881|OTHER|placebo|an inactive substance
224154242|NCT01197092|DIETARY_SUPPLEMENT|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
224154243|NCT01197092|DIETARY_SUPPLEMENT|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
224154244|NCT01197092|DEVICE|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
224154245|NCT01197092|BEHAVIORAL|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
224154246|NCT00336661|DEVICE|PerioWave|
224154247|NCT04890561|DRUG|Lemborexant|Lemborexant oral tablets.
224154248|NCT03381625|DRUG|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
224154249|NCT03381625|DRUG|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
224154250|NCT01063218|OTHER|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
224154251|NCT05272657|OTHER|low-carbohydrate diet|subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet.
224154252|NCT05272657|OTHER|Mediterranean diet|subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
224154253|NCT02125630|PROCEDURE|Surgery|Surgery to primary tumor
224154254|NCT02125630|DRUG|Systemic therapy|Systemic therapy based on tumor phenotype
224154255|NCT03638336|DEVICE|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
224154256|NCT04254445|OTHER|Personalized training video|Using a few demographic and medical details of the patients, provided by the medical staff, the video generator will create a 2-minute personalized custom video, suitable to the age, gender, language, and medical condition of the patients. No identifying information will be used, to protect patient's privacy.
223456229|NCT00638469|OTHER|No treatment|no UV exposure
223572688|NCT06426368|DIAGNOSTIC_TEST|ST2|ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
223572689|NCT01289223|DRUG|Bendamustine IV|
223572690|NCT01289223|OTHER|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
223572691|NCT00871546|DRUG|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
223572692|NCT00871546|DRUG|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
223572693|NCT00871546|BIOLOGICAL|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
223572694|NCT01221025|DRUG|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
224302350|NCT03361930|DEVICE|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
224154257|NCT05263726|BEHAVIORAL|DSMP through a Mobile Applications|This interventional divided the disease self-management program manual for patients with hypertension into 4 units, including: Unit 1: hypertension brief introduction and complications. Unit 2: dietary precautions for patients with hypertension. Unit 3: medication treatments for patients with hypertension. Unit 4: the content included stress management (emotional control, spiritual support) of patients with hypertension. The experimental group received the mobile apps educational program for at least 30 minutes each session and at least once every two days. After two weeks and six weeks, a follow-up telephone interview helped to strengthen the health self-management self-confidence. The researcher used the back office administration at the computer end to observe how the experimental group operated and used the mobile devices. The effect of interventions was then evaluated after three months when the patients returned.
223572695|NCT01124227|DRUG|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
224066624|NCT06203561|DEVICE|Nasogastric Tube Feeding|The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224066625|NCT00481650|DRUG|Leios/Alesse|
224066626|NCT01307215|DRUG|Ropivacaine|20mLs of 0.5%
224066627|NCT01307215|DRUG|Ropivacaine|30mLs of 0.33%
224066628|NCT01307215|DRUG|Ropivacaine|40mLs of 0.25%
224066629|NCT06758362|BEHAVIORAL|Eye Movement Desensitization and Reprocessing (EMDR)|A structured psychotherapy approach focused on reducing PTSD symptoms through guided eye movements and trauma processing.
224066630|NCT06758362|BEHAVIORAL|Cognitive Behavioral Therapy (CBT)|A psychotherapy approach focused on identifying and modifying maladaptive thought patterns and behaviors to reduce PTSD symptoms.
224066631|NCT06673277|DEVICE|Prolonged (2-hour) cryocompression therapy|The cuff of the device will be attached around the knee randomised to receive the treatment as per the manufacturer's instruction. Then the device will be set to apply a standard 30-minute treatment with a temperature of 8 ℃ and intermittent compression of 25-50 mmHg. Following this, and depending on the randomised condition, the treatment will continue for a further 90-minutes with a temperature of either 10 ℃ or 12 ℃ being applied by the device. The level of compression will remain the same (25-50 mmHg) throughout all tests.
224066632|NCT03177772|BEHAVIORAL|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
224066633|NCT00006121|DRUG|oxaliplatin|
224066634|NCT01456676|DRUG|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
224066635|NCT01950351|OTHER|Laboratory Biomarker Analysis|Correlative studies
224066636|NCT01950351|RADIATION|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
224066637|NCT01950351|OTHER|Quality-of-Life Assessment|Ancillary studies
224066638|NCT04674592|OTHER|Blood samples and biopsies|Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
224066639|NCT04889300|BEHAVIORAL|Best Possible Self|Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
224066640|NCT04889300|BEHAVIORAL|Typical Day|Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
224066641|NCT04429178|OTHER|ultrasound|portal vein pulsatility fraction (percent) measured with ultrasound
224066642|NCT00662103|BEHAVIORAL|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
224066643|NCT00662103|OTHER|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health \& Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
224066644|NCT00662103|OTHER|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
224066645|NCT00662103|OTHER|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
224066646|NCT00662103|PROCEDURE|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
224066647|NCT00662103|PROCEDURE|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
224154258|NCT00000768|DRUG|Glutamic acid hydrochloride|
224154259|NCT00000768|DRUG|Ganciclovir|
224154260|NCT05528328|DEVICE|CACIPLIQ20®|CACIPLIQ20®
224154261|NCT05528328|DRUG|Placebo (saline solution)|Placebo (saline solution) administered in identic al vials
224154262|NCT00633893|DRUG|Apixaban|Tablets, Oral, twice daily, 12 months
224154263|NCT00633893|DRUG|Placebo|Tablets, Oral, twice daily, 12 months
224154264|NCT03408288|OTHER|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
224154265|NCT03408288|OTHER|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
224154266|NCT03408288|OTHER|Color description|Describe color of reference sample
224154267|NCT00911222|OTHER|non-interventional|non-interventional
224154268|NCT02756741|DRUG|ALBUMIN|Albumin in two different doses
224154269|NCT06367335|DRUG|Ribociclib, palbociclib, abemaciclib|evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI
224154270|NCT05091918|DEVICE|MotionSense|MotionSense Wearable: Remote patient monitoring
223456230|NCT06501807|DRUG|Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).|Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
223456231|NCT03335813|DEVICE|Endoesophageal Brachytherapy|Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
223456232|NCT04497532|OTHER|Diet as suited for gestational diabetes mellitus|Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
223456233|NCT02315144|DRUG|TV48108|TV48108 15, 60, 120 μg
223456234|NCT02315144|DRUG|Placebo|Placebo Comparator
223456235|NCT03476057|DIAGNOSTIC_TEST|Device： NGS sequencing cfDNA|NGS sequencing cfDNA and Tumor Burden
223456236|NCT00961779|DRUG|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
223456237|NCT00961779|DRUG|Placebo|Normal saline infusion
223456238|NCT00752336|BEHAVIORAL|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
224154271|NCT01921699|PROCEDURE|taking blood samples from healthy people|
224154272|NCT04618549|PROCEDURE|Direct Anterior Approach Hemiarthroplasty|Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach
224154273|NCT04618549|PROCEDURE|Mini Posterior Approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach
223456239|NCT01557478|DRUG|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
223456240|NCT01557478|DRUG|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
223456241|NCT02210520|DEVICE|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
223456242|NCT02210520|DEVICE|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
223456243|NCT02210520|DEVICE|laser|1 W/cm², 2 minutes in 6 points around the back spine
223456244|NCT06053632|BEHAVIORAL|Low-load and high-velocity - lying prone - eccentric hamstring exercise|Low-load and high-velocity - lying prone - eccentric hamstring exercise 3 times per week for 4 weeks.
223456245|NCT01747096|DRUG|68-Ga-DOTANOC|
223456246|NCT00494546|PROCEDURE|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
223456247|NCT02562586|DEVICE|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
223456248|NCT02063594|DRUG|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
223456249|NCT02063594|DRUG|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
223456250|NCT04323384|DEVICE|Biotene® Oralbalance Moisturizing Gel|Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
224154274|NCT04618549|PROCEDURE|Lateral approach|Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
224154275|NCT00994760|DRUG|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
224154276|NCT06169891|DRUG|Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg|one s.c. injection of SSGJ-613 once, on Day 1.
224154277|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching Compound Betamethasone Injection to maintain the blinding of the Investigational Medicinal Products.
224154278|NCT06169891|DRUG|Compound Betamethasone Injection|1 mL i.m. once on Day 1
224154279|NCT06169891|OTHER|Placebo|Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
224154280|NCT02936336|OTHER|exercise|circuit exercise, aerobic dance and Tai Chi exercise
224163558|NCT05574478|BEHAVIORAL|Patients and Caregivers Qualitative Interview|Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
224163559|NCT00071604|BEHAVIORAL|Medication Adherence Therapy|
224163560|NCT00071604|BEHAVIORAL|Friendly Support Group|
224163561|NCT04514705|OTHER|Exercise|Exercise with treadmil and weight training station
224163562|NCT02460120|DEVICE|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
224163563|NCT02603380|OTHER|No intervention|This is an observational study. No intervention will be given.
224154281|NCT01196312|BEHAVIORAL|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
224154282|NCT06171815|BEHAVIORAL|Scenario-based simulation|Scenario-based simulation prepared for Respiratory Activity and Diabetes Management topics in the course curriculum
224154283|NCT03177746|DRUG|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
224154284|NCT00716989|BIOLOGICAL|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
224154285|NCT05857007|DEVICE|Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids|Ten patients with hyperglycemia or/and diabetes in the neuro ICU requires subcutaneous insulin with concomitant high dose glucocorticoids will wear Libre 2.0 CGM for either 14 days or their stay in the neuro ICU
224154286|NCT04909294|RADIATION|Stereotactic Radiotherapy with Linac MRI|"38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI."
224154287|NCT06110104|OTHER|routine physiotherapy program for knee osteoarthritis|The Routine physiotherapy program comprises a combination of closed kinetic chain and open kinetic chain exercises, including straight leg raising, isometric quadriceps, isometric hip adduction, terminal knee extension, semi-squat, and leg press for 6 weeks.
224154288|NCT06110104|OTHER|Retro-walking program|Retro-walking program is about 10 min of supervised retro walking training 3 days a week for 6 weeks at their comfortable walking speed . The participants will be instructed to gradually increase their walking time up to 30 min over the 6-week period.
224154289|NCT06110104|OTHER|whole body vibration training|whole body vibration is 3 days per week for 6 weeks. During the training, the participants will perform static squat training barefoot on the platform with bent knees (30° and 60°). The distance between the feet was consistent with the shoulders. the duration time, sets and total time will be increased progressively over the 6-week.
224154290|NCT00074542|DRUG|Epanova™ (Omega-3 Free Fatty Acids)|
224154291|NCT03512119|DRUG|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
224154292|NCT01823757|OTHER|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
224154293|NCT03422016|DIAGNOSTIC_TEST|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
224154294|NCT05843617|DIETARY_SUPPLEMENT|Liposomal Vitamin C|1000 mg of ascorbic acid in liposomal formulation
224154295|NCT05843617|DIETARY_SUPPLEMENT|Traditional Vitamin C|1000 mg of ascorbic acid in traditional formulation
224154296|NCT02596425|PROCEDURE|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
224154297|NCT02596425|PROCEDURE|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
224154298|NCT02596425|PROCEDURE|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
224154299|NCT04601181|BIOLOGICAL|ThisCART22 cells injection|"Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight.~Intervention study"
224154300|NCT05207709|DRUG|Ribociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
224154301|NCT05207709|DRUG|Palbociclib + Letrozole OR Fulvestrant|Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
224154302|NCT05207709|DRUG|Paclitaxel +/- Tislelizumab|Patients in this arm could receive as the first line of therapy
224154303|NCT04437316|DEVICE|Use of Low level Laser after wisdom tooth removal|Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
224154304|NCT05078307|PROCEDURE|OHR VS OHV|"Control group : use of the OHR system to perform an Operative Hysteroscopy by Resection of the fibroid.~Experimental group : use of the OHV system to perform an Operative Hysteroscopy by Vaporization of the fibroid."
224154305|NCT01877811|DRUG|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
224154306|NCT03210220|PROCEDURE|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
224163564|NCT05857215|DRUG|amilo-5MER|amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
224163565|NCT05684315|PROCEDURE|soft tissue flossing therapy|BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
224154307|NCT03470857|DIAGNOSTIC_TEST|Patients|The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
224154308|NCT02268448|DRUG|Clonidine|
224154309|NCT02268448|DRUG|Naltrexone|
224154310|NCT06109077|OTHER|Levator ani release|Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).
224154311|NCT06109077|OTHER|Post isometric relaxion|Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks
224154312|NCT00178061|BEHAVIORAL|Interpersonal Social Rhythm Therapy (IPSRT)|
224154313|NCT02911519|OTHER|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
224154314|NCT02911519|OTHER|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
224154315|NCT00653328|DRUG|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
224154316|NCT00653328|DRUG|doxil|50 mg/m2 intravenously every 28 days
224154317|NCT00220857|DRUG|Rabeprazole|
224154318|NCT06094114|DEVICE|pacemaker follow-up|Performance of an exercise test in patients previously implanted with Micra AV
224154319|NCT02667522|BEHAVIORAL|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
224154320|NCT06021847|OTHER|Ozonated water|ozonated water was prepared with a concentration of (2-4 mg/l) ozone for 1 min. in a 25 mg of double distilled water 37o C employing an Ozone generator (Ozone generator type N 1888A, China.)
224154321|NCT06021847|OTHER|Chlorhexidine mouthwash|Commercial available chlorhexidine mouthwash in the market was used.
224154322|NCT00722098|BIOLOGICAL|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
224154323|NCT00722098|BIOLOGICAL|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
224154324|NCT01707095|OTHER|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
224154325|NCT01707095|OTHER|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
224154326|NCT04261283|OTHER|Experimental|"The Circuit Training will be consisting of:~1. Habituation Exercises~2. Exercises for the gaze stability (The two exercises are specifically for the patients who reported a high score on oscillopsia severity questionnaire~3. Exercises to improve Saccade Latency.~4. Adaptation Exercises~5. Substitution Exercises~6. Postural Control Exercises~7. General Conditioning Activities~8. Cawthorne-Cooksey Exercises~9. Ocular Motor Exercises~10. Gait Exercises~11. Treatment to Decrease Sensitivity to Motion in the Environment"
224154327|NCT04261283|OTHER|Active Comparator|Medicines as prescribed by the ear, nose, and throat (ENT) specialist and Home-based exercise Programme (Simple and general vestibular rehabilitation exercises) will be recommended to the patients to perform. ( Not under the supervision of neuro-therapist)
224154328|NCT01222936|DRUG|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
224154329|NCT00839436|DRUG|CYT107|
223456251|NCT03014271|BEHAVIORAL|Sources of Strength (SOS) Prevention Program|Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
223456252|NCT03697941|PROCEDURE|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
223456253|NCT03697941|PROCEDURE|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
223456254|NCT06458907|DEVICE|TricValve® Transcatheter Bicaval Valve System|TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.
224154330|NCT01578590|DIETARY_SUPPLEMENT|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
224154331|NCT00005061|BIOLOGICAL|bevacizumab|
224154332|NCT05854797|OTHER|Normal Walking|"Adhering to FITT method, normal walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 3.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
224154333|NCT05854797|OTHER|Brisk Walking|"Adhering to FITT method, brisk walking will be performed 5 days a week (frequency) to ensure optimal results. Speed (intensity) for normal will be 4.5 mph. The pulse rate of participants will be monitored through treadmill monitor. The duration (time) of walk each day will be 30 minutes.~Measurement of body fat percentage, hypertension, diabetes, and level of happiness (at the beginning and ending of twelve weeks)"
224154334|NCT05466981|BEHAVIORAL|Cognitive Behavioral Counseling|The intervention consisted of 12 weeks of HCV treatment combined with smoking cessation pharmacotherapy and brief behavioral counseling conducted by a LMSW. The brief behavioral counseling consisted of cognitive behaioral components and was provided by phone and in-person. The intervention followed these 5 phases: increase motivation to quit smoking, quit attempt, maintain short-term abstinence, and lapse and relapse prevention.
224154335|NCT02592668|DEVICE|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
224154336|NCT01521572|DRUG|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
224154337|NCT04969367|OTHER|Medical Device Usage and Evaluation|Wear activity monitor (Fitbit)
224154338|NCT04969367|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224154339|NCT04969367|OTHER|Questionnaire Administration|Complete questionnaires
224154340|NCT04969367|OTHER|Quality-of-Life Assessment|Complete questionnaires
224154341|NCT03402282|PROCEDURE|embolization|upper rectal artery embolization with coils
224154342|NCT03402282|PROCEDURE|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
224154343|NCT00407550|DRUG|gemcitabine HCL|1250 mg/m\^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 \& 8 of each cycle (21 days) x6 cycles.
224154344|NCT00407550|DRUG|pemetrexed disodium|500 mg/m\^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
224154345|NCT00407550|DRUG|gemcitabine HCL|1500 mg/m\^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
224154346|NCT03460288|BEHAVIORAL|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
224154347|NCT04202978|DRUG|Camrelizumab|Camrelizumab ：200mg intravenous injection d1 q3w
224154348|NCT04202978|DRUG|Apatinib Mesylate|Apatinib：250mg/d P.O ,qd ,3weeks
224154349|NCT04202978|DRUG|Capecitabine|capecitabine:850mg/m2 P.O ,bid ,d1-d14
224066648|NCT00662103|PROCEDURE|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
224154350|NCT04202978|DRUG|Oxaliplatin|oxaliplatin:130mg/m2 intravenous injection d1 q3w
224154351|NCT04202978|RADIATION|radiofrequency ablation|radiofrequency ablation:between first cycle and second cycle percutaneous
224154352|NCT00885885|DRUG|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~* Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~* 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
224154353|NCT00885885|DRUG|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~* Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~* Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~* A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~* 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
224154354|NCT02521389|DRUG|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
224154355|NCT00364819|DRUG|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
224066649|NCT00662103|PROCEDURE|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
224154356|NCT04874844|BIOLOGICAL|Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)|"The ratio of subjects in the experimental drug group to the placebo control group is 1:1, and you will have a 50% probability of receiving JY025 combined with gefitinib or erlotinib, and a 50% probability of receiving placebo combined with gefitinib Or erlotinib.~Blind people, researchers, nurses, research assistants, inspectors, applicants and blind statisticians involved in clinical trials."
224154357|NCT04227067|DEVICE|TENS|An electrical impulse is delivered to the skin around the painful area using pads attached to an electric generator.
224154358|NCT04227067|DEVICE|SHAM TENS|A TENS generator without batteries is used. The pads are attached to the generator and to the skin around the painful area.
224154359|NCT00086216|DRUG|Atiprimod|Oral, once a day, 14 days on 14 days off
224154360|NCT01444898|DRUG|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
224154361|NCT03273504|OTHER|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
224154362|NCT03273504|OTHER|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
224154363|NCT02928666|OTHER|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
224154364|NCT02077842|DEVICE|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
224154365|NCT02077842|DEVICE|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
224154366|NCT02183610|DRUG|[14C] BI 1356 as oral (p.o.) solution|
224154367|NCT02183610|DRUG|[14C] BI 1356 solution for i.v. infusion|
224154368|NCT02361619|DRUG|Caffeine|probe
224154369|NCT02361619|DRUG|Diclofenac|probe
224154370|NCT02361619|DRUG|Esomeprazole|probe
224154371|NCT02361619|DRUG|Metoprolol|probe
224154372|NCT02361619|DRUG|Midazolam|probe
224154373|NCT02361619|DRUG|Dabigatran|probe
224154374|NCT02361619|DRUG|Clarithromycin|perpetrator
224154375|NCT03528590|DEVICE|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
224154376|NCT03528590|DEVICE|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
224154377|NCT02238782|DRUG|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
224154378|NCT02238782|OTHER|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
224154379|NCT03498118|DRUG|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient's abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
224154380|NCT06370949|DRUG|Bupivacain|Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
224154381|NCT06370949|DRUG|bupivacain+dexmedetomidine|Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
224154382|NCT00066508|DRUG|bortezomib|
224154383|NCT01567423|DRUG|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
224154384|NCT01567423|DRUG|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~1. tab/dose for children 5 to 14.9 kg (total 6 tabs)~2. tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
224154385|NCT03029897|OTHER|My eReport France|"patients are educated to the use of My eReport France application"
224302351|NCT04029753|BEHAVIORAL|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
224302352|NCT01034254|BIOLOGICAL|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
224302353|NCT01034254|BIOLOGICAL|saline placebo|Vaccination of pregnant women with saline placebo.
224302354|NCT00002865|BIOLOGICAL|filgrastim|
224302355|NCT00002865|DRUG|cyclophosphamide|
224302356|NCT00002865|DRUG|cytarabine|
224302357|NCT00002865|DRUG|dexamethasone|
224302358|NCT00002865|DRUG|doxorubicin hydrochloride|
224302359|NCT00002865|DRUG|etoposide|
224302360|NCT00002865|DRUG|ifosfamide|
224302361|NCT00002865|DRUG|leucovorin calcium|
224302362|NCT00002865|DRUG|mesna|
224302363|NCT00002865|DRUG|methotrexate|
224302364|NCT00002865|DRUG|therapeutic hydrocortisone|
224302365|NCT00002865|DRUG|vincristine sulfate|
224302366|NCT00002865|RADIATION|low-LET cobalt-60 gamma ray therapy|
224302367|NCT00002865|RADIATION|low-LET photon therapy|
224302368|NCT03771248|DEVICE|peek telescopic partial denture|removable partial denture
224302369|NCT03544710|OTHER|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
224302370|NCT01242995|PROCEDURE|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
224066650|NCT05667714|DRUG|SA58 Nasal Spray|SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
223456255|NCT06458907|DRUG|Optimal medical therapy|Optimal medical therapy
223456256|NCT00308516|DRUG|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
223456257|NCT00308516|DRUG|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
223456258|NCT00308516|PROCEDURE|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
223456259|NCT00308516|DRUG|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
224066651|NCT05667714|DRUG|Placebo|Placebo was provided by Sinovac Life Sciences Co. , Ltd.
223456260|NCT00308516|DRUG|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
223456261|NCT02982889|DRUG|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
223456262|NCT02982889|DRUG|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
223456263|NCT02982889|DRUG|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
223456264|NCT02982889|DRUG|0.5% bupivacaine hydrochoride|single subcutaneous injection
223456265|NCT06082310|OTHER|Exercise|Two HIIT modalities
223456266|NCT03787602|DRUG|KRT-232|KRT-232 is an experimental MDM2 anticancer drug taken by mouth.
224066652|NCT06333509|BIOLOGICAL|CT071|a single CAR-T infusion of CT071
224066653|NCT02567890|BEHAVIORAL|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
224066654|NCT02567890|BEHAVIORAL|Expressive writing|Participants will be asked to reflect upon issues related to body image.
224066655|NCT05269758|BEHAVIORAL|activity-based resistance training of ingestive skills (ACT-ING-program)|The ACT-ING program is based on a task-oriented approach within motor behavior theories and combines resistance training principles with goal-directed and task-specific swallowing exercises in eating and drinking activities through a client-centered procedure informed by self-determination theory.
224066656|NCT05865236|PROCEDURE|Infra-red lamp therapy + Kegal Exercises|The infrared the infrared lamp will be placed at distance of 45 cm away from the perineum with the heat emitted with 220 volts used for 10-15 minutes IRR is beneficial for promoting wound healing, tissue repair, and skin rejuvenation.
224066657|NCT05865236|PROCEDURE|Dry air heat group + Kegal Exercises|Woman should lie on the bed without panties or the sanitary Pad. Place towels under buttocks to absorb any vaginal discharge. She should lie on her back with the knees bent and feet flat. Let the vagina dry by holding a hair dryer 10 to 12 inches away from episiotomy. The dry heat will gives a soothing effect on the wound
224066658|NCT00015977|BIOLOGICAL|PSA prostate cancer vaccine|
224066659|NCT00015977|BIOLOGICAL|recombinant interleukin-12|
224066660|NCT01751308|DRUG|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
224066661|NCT00813423|DRUG|Hydroxychloroquine|Given PO
224066662|NCT00813423|OTHER|Laboratory Biomarker Analysis|Correlative studies
224066663|NCT00813423|OTHER|Pharmacological Study|Correlative studies
224066664|NCT00813423|DRUG|Sunitinib Malate|Given PO
224066665|NCT03938805|BEHAVIORAL|Internet-based cognitive behavioral therapy for insomnia|Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.
224066666|NCT03938805|OTHER|Control group|Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
224066667|NCT06239987|BEHAVIORAL|Care-oriented Practical Training|The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
224066668|NCT04418700|DEVICE|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
224066669|NCT01960621|DRUG|cyclodextrin|intravenous
224066670|NCT02918773|DEVICE|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
224154386|NCT03261141|COMBINATION_PRODUCT|(PV-RQOL),(APA) ,Acoustic analysis|"1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
224154387|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
224154388|NCT01171014|DIETARY_SUPPLEMENT|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
224154389|NCT01171014|DIETARY_SUPPLEMENT|Placebo|Placebo, once a day for 14 days
224154390|NCT02267369|BEHAVIORAL|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
224066671|NCT02918773|DEVICE|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
224154391|NCT02267369|BEHAVIORAL|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
224154392|NCT02267369|BEHAVIORAL|Basic fitness program|Participants can register workshops online and track program participation.
224154393|NCT02580591|DRUG|Empagliflozin|
224154394|NCT02580591|DRUG|Placebo|For blinding purposes
224154395|NCT03336060|DIAGNOSTIC_TEST|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
224154396|NCT00696098|OTHER|sodium butyrate|1 enema (60 ml) once daily containing 100mM
224154397|NCT00696098|OTHER|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
224154398|NCT03304262|DEVICE|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
224154399|NCT03802240|DRUG|Sintilimab|200mg IV Q3W
224154400|NCT03802240|DRUG|IBI305|15mg/kg IV Q3W
224154401|NCT03802240|DRUG|Pemetrexed|500mg/m2 IV Q3W
224154402|NCT03802240|DRUG|Cisplatin|75mg/m2 IV Q3W
224154403|NCT03802240|DRUG|Placebo1|Placebo1 IV Q3W
224154404|NCT03802240|DRUG|Placebo2|Placebo2 IV Q3W
224154405|NCT03736668|DIAGNOSTIC_TEST|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
224154406|NCT04127461|DEVICE|Medtronic endoscope|The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
224302371|NCT00914953|DRUG|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
224302372|NCT00471289|DEVICE|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
224302373|NCT00471289|DEVICE|PTA|PTA
224302374|NCT00411957|DRUG|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
224302375|NCT06186934|DRUG|the standard-dose group (4 g/day)|Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
224154407|NCT02152072|OTHER|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
224154408|NCT00493610|DRUG|N-acetylcysteine(Mucomyst)|
224066672|NCT01803360|DRUG|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
224066673|NCT03934450|DRUG|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
224066674|NCT03934450|DRUG|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
224154409|NCT01937013|DRUG|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
224154410|NCT01937013|DRUG|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
224154411|NCT02477306|DRUG|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
224154412|NCT02477306|DRUG|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
224154413|NCT03842501|DIETARY_SUPPLEMENT|Release Supplement|Calorie reduced diet plus Release supplement
224154414|NCT03842501|DIETARY_SUPPLEMENT|Placebo|Calorie reduced diet plus Placebo
224302376|NCT03828916|OTHER|NuShield|SOC surgery with the addition of NuShield
224302377|NCT03888781|DEVICE|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
224302378|NCT00577395|DRUG|placebo|oral tablet once a month for 12 months
224302379|NCT00577395|DRUG|risedronate|tablet, 150 mg once a month for 12 months
224154415|NCT01402024|DRUG|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
224154416|NCT01402024|DRUG|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
224154417|NCT00655304|DEVICE|Prometheus (R) liver support dialysis|6-8 hours of dialysis
224154418|NCT00655304|DEVICE|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
224066675|NCT03934450|DRUG|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
224066676|NCT03934450|DRUG|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
224154419|NCT04572698|DRUG|LY09004|LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
224154420|NCT04572698|DRUG|Eylea|EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.
224154421|NCT00561340|DIETARY_SUPPLEMENT|Pediasure|50% will be randomized to pediasure with nutritional counseling
224154422|NCT00561340|BEHAVIORAL|Nutritional counseling|50% randomized to nutritional counseling only
224154423|NCT02812108|DEVICE|intracranial stent, flow diverter and coils|
224154424|NCT04567953|OTHER|Saliva collection|Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
224154425|NCT05326074|OTHER|Animal assisted therapy cohort|A therapy dog will be present in the room during the routine outpatient psychiatric visit.
224154426|NCT03051217|OTHER|Placebo|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use Q2W"
224154427|NCT03051217|DRUG|Certolizumab Pegol|"* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
224154428|NCT00380406|DRUG|Leuprolide acetate|
224154429|NCT00641706|DRUG|vorinostat|Given orally
224154430|NCT00641706|PROCEDURE|therapeutic conventional surgery|Patient undergoes surgery
224302380|NCT05202730|PROCEDURE|New local anesthesia injection site and new local anesthetic drug formulation.|The traditional injection site is the posterior joint capsule and the popliteal artery space (iPACK) plus multiple layers of tissues around the knee joint (posterior joint capsule, ligaments and subcutaneous tissue). The traditional local anesthetic formulation is 1% ropivacaine 10ml+ normal saline 40ml+10mg Morphine + 5mg dexamethasone. The new local anesthesia injection site is iPACK+Knee Cutaneous Nerve Block. The new local anesthetic formula is 1% ropivacaine 10ml+ normal saline 40ml+10mg morphine+1ml triamcinolone acetonide.
224302381|NCT03364166|PROCEDURE|surgical excision|"* Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~* A neck dissection will be done in all cases of negative or positive neck lymph node.~* Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
224154431|NCT00641706|DRUG|bortezomib|Given IV
224154432|NCT04880993|DRUG|Dapagliflozin 10 mg tablets|Manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd
224154433|NCT04880993|DRUG|Farxiga® 10 mg tablets|Manufactured by AstraZeneca Pharmaceuticals LP
224154434|NCT03879954|DEVICE|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
224154435|NCT04746989|DRUG|Probenecid|Probenecid claim is used as the exposure group.
224154436|NCT04746989|DRUG|Allopurinol|Allopurinol claim is used as the reference group.
224154437|NCT00591396|DRUG|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
223456267|NCT03787602|DRUG|Avelumab|Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
224066677|NCT05797324|OTHER|Luminette|Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
224066678|NCT05797324|OTHER|Sham|Sham protocol (white light \<100 lux equivalent).
224154438|NCT00109772|DRUG|lenalidomide|Two 5 mg capsules taken one time per day
224154439|NCT00109772|DRUG|Placebo|Two placebo capsules taken one time per day
224154440|NCT01517828|DRUG|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
224154441|NCT01517828|DRUG|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
224154442|NCT04861311|BEHAVIORAL|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention|The intervention is based on the principles of Acceptance and Commitment Therapy (ACT). Therefore, the intervention is an ACT-based smartphone app delivered for 6 weeks in which participants will be applying the mindfulness and acceptance exercises embedded in the app. The mindfulness and acceptance exercises are audio-guided mindfulness meditations and video lessons about ACT.
224154443|NCT03437044|DRUG|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
224154444|NCT03437044|DRUG|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
224154445|NCT00345501|DRUG|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
224154446|NCT00345501|DRUG|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
224154447|NCT05690672|DIAGNOSTIC_TEST|Delirium Screening|Either 3D-CAM or 4AT
224154448|NCT02574819|DRUG|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
224154449|NCT02574819|DRUG|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
224154450|NCT04018157|DRUG|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
224154451|NCT00035568|DRUG|Glucovance (metformin HCl/glyburide)|
224154452|NCT00035568|DRUG|or Metformin HCl alone|
224154453|NCT00035568|DRUG|or Glyburide alone.|
224154454|NCT00134407|PROCEDURE|Normal diet|
224154455|NCT00134407|PROCEDURE|Nutrition via jejunal needle-catheter|
224154456|NCT06353360|DEVICE|Tumor Treating Fields|Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day, starting on the Day 1 of cycle 1 (C1D1), throughout the entire course of treatment.
224154457|NCT06353360|DRUG|Tislelizumab|Tislelizumab will be given 300 mg intravenously every 4 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. The Tislelizumab treatment should be continued until confirmed PD, unacceptable toxicity, or finished Tislelizumab treatment for other reasons.
224154458|NCT06353360|DRUG|Temozolomide (TMZ)|The patients will carry out 6 cycles of TMZ adjuvant chemotherapy according to the instructions. The dosage of TMZ is 150-200 mg/(m2·d), daily for 5 days followed by 23 days without treatment, the treatment cycle is 28 days. The initial dose of cycle 1 is 150 mg/(m2·d), if patients do not experience TMZ chemotherapy toxicity, the dose should be increased to 200 mg/(m2·d) in subsequent treatment cycles. After 6 cycles of TMZ adjuvant chemotherapy, if the patients do not experience disease progression, it is recommended to continue TMZ adjuvant chemotherapy, or treated according to investigators' recommendations. The TMZ treatment should be continued until confirmed progressive disease (PD), unacceptable toxicity, or finished TMZ treatment for other reasons.
224154459|NCT01213290|DEVICE|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
224154460|NCT01213290|DEVICE|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
224154461|NCT03436147|OTHER|POP-Q|Pelvic Organ Prolapse Quantification
224154462|NCT06212388|BIOLOGICAL|Ex-vivo expanded allogeneic γδ T cells|Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
224154463|NCT06212388|DRUG|Recombinant human interferon α1b|Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
224154464|NCT06212388|DRUG|Pembrolizumab|Pembrolizumab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
224154465|NCT04642378|DRUG|iNCDSS based insulin regime|Patients of this group will receive the insulin regime set by the AI assisted insulin titration system (iNCDSS).
224154466|NCT04642378|DRUG|routine insulin treatment regime|Patients of this group will receive the insulin regime recommended by professional endocrinologists.
224154467|NCT01365013|BEHAVIORAL|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
224154468|NCT01365013|BEHAVIORAL|Control group|Standard advice for lifestyle change
224154469|NCT02169960|BEHAVIORAL|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
224154470|NCT02169960|BEHAVIORAL|Breaking Free|Online based intervention for Drug and Alcohol Use
224154471|NCT02169960|BEHAVIORAL|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
224154472|NCT02169960|BEHAVIORAL|Resiliency Training|Op Volle Kracht (OVK)
224154473|NCT00703430|DRUG|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
224154474|NCT00282568|DRUG|Tacrolimus Modified Release (MR)|Oral
224154475|NCT00282568|DRUG|tacrolimus|Oral
224154476|NCT03800433|DRUG|Trental 400 MG Extended Release Oral Tablet|oral tablets
224154477|NCT00135408|DRUG|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
224154478|NCT00135408|DRUG|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
224154479|NCT02721446|BEHAVIORAL|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
224154480|NCT02721446|BEHAVIORAL|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
224154481|NCT02721446|BEHAVIORAL|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
224154482|NCT02721446|BEHAVIORAL|Incentive + Salience|Combined message of incentive plus salience.
224154483|NCT03006926|DRUG|lenvatinib|4 mg capsules
224154484|NCT03006926|DRUG|pembrolizumab (200 mg)|30-minute intravenous infusion
224154485|NCT00332046|DRUG|GW679769|
224154486|NCT00423241|DEVICE|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
224154487|NCT00423241|DEVICE|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
224154488|NCT03554785|BEHAVIORAL|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
224154489|NCT01400074|DRUG|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
224154490|NCT00175071|BEHAVIORAL|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
224154491|NCT03547349|DEVICE|Digital Incentive Spirometer|This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
224154492|NCT03547349|DEVICE|Jamboxx Respiratory Therapy Device|THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
224154493|NCT05137210|OTHER|Male Counseling and Facility Navigation|At enrollment, study staff distribute pamphlet with male-specific messaging and contact information for nearest facility. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling. Meeting at location of participants choice. Follow-up male-specific counseling is offered every 14 days thereafter until 90 days is reached OR 4-week follow-up ART refill visit is completed. Participants who choose to initiate ART are escorted to nearest health facility and provided facility navigation assistance.
224154494|NCT05137210|OTHER|Home-Based ART Initiation and Facility Navigation|"At enrollment, study staff distribute two pamphlets on: 1) male-specific messaging and 2) details about home-based ART initiation. Low-level cadre traces participants and provides one-on-one, in person male-specific counseling, and a detailed description of home-based ART initiation with a nurse. Meeting at the location of participants choice. Follow-up male-specific counseling and information about home-based initiation is offered every 14 days thereafter until 90 days OR 4-week ART follow-up refill visit is complete. Participants who choose to initiate ART at home or in the community will meet with a nurse at a place of the participants choosing. Those who choose to initiate at the facility will receive facility navigation and initiation. All clients will receive a warm handover for their 4-week ART follow-up visit."
223572696|NCT01361074|BEHAVIORAL|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
224154495|NCT05137210|OTHER|Stepped Intervention|"Day 0-14 Arm 1 (Male-specific counseling and facility navigation arm) implemented. Day 14-30, if not yet initiated, a psychosocial counsellor will trace the participant to provide advanced counselling and motivational interviewing. Psychosocial counsellors will act as 'Male Mentors' and meet with men as frequently as needed. Day 30-89 if not yet initiated, nurse-led home-based ART initiation will be offered, following the same steps as listed in the Home-Based ART Initiation Arm."
223572697|NCT01361074|BEHAVIORAL|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
223572698|NCT00137696|BIOLOGICAL|Vaccination with inactivated polio vaccine|
223572699|NCT00137696|PROCEDURE|Collection of serum|
223572700|NCT04702906|OTHER|standard treatment|Standard treatment if indicated.
224154496|NCT00324272|DRUG|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
224154497|NCT01541501|DEVICE|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
224154498|NCT03498547|PROCEDURE|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
224154499|NCT03498547|PROCEDURE|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
224154500|NCT05200884|DRUG|Lidocaine 2%|The child will be injected with lidocaine 2% and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker FACES pain rating scale
224154501|NCT05200884|DRUG|Articaine 4%|The child will be injected with 4% Articaine and After 10 minutes the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and face scale
224154502|NCT06527859|DRUG|Levothyroxin|The disease group were divided into two groups ,25ugLT4 (HA group, n=17) and 50ugLT4 (HB group, n=17) respectively.
224154503|NCT02465255|DRUG|Ketorolac|
224154504|NCT02465255|DRUG|Tramadol|
224154505|NCT02465255|DRUG|Acetaminophen|
224154506|NCT00789295|OTHER|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
224154507|NCT01181310|DRUG|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
224154508|NCT01181310|DRUG|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
224154509|NCT01181310|DRUG|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
224154510|NCT01181310|DRUG|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
224154511|NCT01181310|DRUG|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
224154512|NCT05477017|DRUG|SGLT2 inhibitor|Selective inhibitors of the sodium and glucose co-transporter 2 (SGLT2) originated as antidiabetic drugs thanks to their hypoglycemic and glycosuric effect.
223572701|NCT04702906|DRUG|"trimetazidine hydrochloride metacardia ® 20 mg tablet"|"trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)"
223572702|NCT04832906|DRUG|Ulipristal Oral Tablet|A selective progesterone receptor modulator (SPRM), as a medical line of treatment for uterine fibroids. Due to its selective anti-proliferative and pro-apoptotic action, Ulipristal Acetate (UA) is assumed to be effective in reducing abnormal uterine bleeding (AUB) and fibroid size.
224154513|NCT03725293|DEVICE|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
224154514|NCT03725293|DEVICE|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
224154515|NCT00241449|DRUG|Fulvestrant|intramuscular injection 250 mg
224154516|NCT00241449|DRUG|Tamoxifen|20 mg oral tablet
224154517|NCT00602771|DRUG|tipifarnib|Given orally
224154518|NCT00602771|DRUG|etoposide|Given orally
224154519|NCT00179569|BEHAVIORAL|Relaxation response|8 weeks of relaxation response training
224154520|NCT00791804|DRUG|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
224154521|NCT00914238|BEHAVIORAL|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
224154522|NCT00914238|BEHAVIORAL|OPUS 5 years|
224154523|NCT06508970|BEHAVIORAL|Experimental RAM-based virtual reality glasses|"RAM-based virtual reality glasses were applied to the experimental group for 4 weeks.~Video contents:~1. week; 1st sub-dimension (physiological domain)~2. weeks; 2nd sub-dimension (self-space) Three weeks; 3rd sub-dimension (Role function/function area) week 4; 4th sub-dimension (Independence and interdependence/autonomy)"
224154524|NCT06508970|OTHER|pre-post test|Adaptation Difficulty Assessment Scale in the Elderly, Life Satisfaction Scale in the Elderly , and Psychological Well-Being Scale in the Elderly
224154525|NCT06097325|DIAGNOSTIC_TEST|Clance impostor phenomenon scale|"The CIPS will be used as diagnostic test in the online survey."
224154526|NCT06097325|DIAGNOSTIC_TEST|Maslach Burnout Inventory for Medical Professional|"The MBI-HSS-MP will be used as diagnostic test in the online survey."
224154527|NCT00137670|DEVICE|Video-based HIV/STD prevention intervention|
224154528|NCT00383006|BEHAVIORAL|Skills for affect regulation (behavior)|
224154529|NCT05829395|OTHER|metaverse- based education|"The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test."
224154530|NCT02705443|OTHER|No Intervention|Standard of Care Only
224154531|NCT02562976|OTHER|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
224154532|NCT00289393|BEHAVIORAL|Perceived outcome by both patient and physician|
224154533|NCT04418219|DRUG|Cyclophosphamide|alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
224154534|NCT04418219|BIOLOGICAL|Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
224154535|NCT04418219|BIOLOGICAL|Pembrolizumab|1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
224154536|NCT04418219|BIOLOGICAL|Recombinant Interferon Alpha 2b-like Protein|Novaferon, Recombinant IFN Alfa-2b-like Protein
224154537|NCT04418219|OTHER|Questionnaire Administration|Ancillary studies
224154538|NCT04418219|OTHER|Quality of Life Assessment|Ancillary studies
223456268|NCT03412292|DRUG|MAX-40279|"MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses."
223456269|NCT05118620|DRUG|Active bupivacaine 0.375% PENG block|A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance
223456270|NCT05118620|DRUG|Placebo normal saline PENG block|A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
223456271|NCT04478565|OTHER|Indirect Calorimetry|"RMR was calculated by breath oxygen consumption (O2 in mL·min-1), minute by minute, using a portable device (Breezing®, Arizona, USA), and the Weir equation (1949), while participants remained in a sitting position for ≈15 to 20 minutes.~The anthropometric measurements were performed by certified level 3 anthropometrists following the guidelines of the International Society for the Advancement of Kinanthropometry, ISAK"
223456272|NCT02168023|DEVICE|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
223456273|NCT02168023|DEVICE|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
224154539|NCT06238115|DRUG|Tirofiban|Initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
224154540|NCT06238115|DRUG|aspirin, clopidogrel|aspirin 100 mg/day, clopidogrel 75 mg/day
224154541|NCT00330239|DRUG|Paroxetine CR|
224154542|NCT01057862|DRUG|Naltrexone|Targeted dosage of 50mg PO daily
224154543|NCT01057862|OTHER|Placebo|Sugar pills daily PO
224154544|NCT00415584|DRUG|Cinacalcet HCl|
224154545|NCT05377827|BIOLOGICAL|WU-CART-007|Provided by Miltenyi Biotec
224154546|NCT01757977|DEVICE|double lumen endotracheal tube placement and use|
224154547|NCT03067844|DRUG|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
224154548|NCT00802867|BIOLOGICAL|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
224154549|NCT03434041|DRUG|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
224154550|NCT03434041|DRUG|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
224154551|NCT03434041|DRUG|Placebo|Participants will self-administer matching placebo as intranasal spray.
224154552|NCT03434041|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
224154553|NCT03434041|DRUG|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
224154554|NCT03434041|DRUG|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
224154555|NCT03434041|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
224154556|NCT04075396|DRUG|Lazertinib|Participants will receive Lazertinib tablets once daily.
224154557|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
224154558|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
224154559|NCT01215669|BIOLOGICAL|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
224154560|NCT01215669|BIOLOGICAL|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
224154561|NCT00654212|PROCEDURE|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
224154562|NCT00654212|PROCEDURE|open approach|emergency open surgery
224154563|NCT01362699|DRUG|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
224154564|NCT01362699|DRUG|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
224154565|NCT04189991|DEVICE|Free 02|"With the manual oxygen titration, the physiotherapist adjust manually the oxygen flow using the FreeO2 device during a titration 6 minutes walk test.~With the automated adjustment oxygen titration, the flow will be self adjusted by the FreeO2 device during a titration 6 minutes walk test. In that hase, the median flow rate and the 95th flow rate will be evaluated during the validation 6 minutes walk test."
224154566|NCT01765946|DRUG|Metformin|Metformin tablets 500 mg tris in die (tid)
224154567|NCT01765946|DRUG|placebo|
224154568|NCT00444080|PROCEDURE|Trabeculectomy|"Standard trabeculectomy procedure~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of a limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Creation of fistula 1mm x 2mm in size~5. Iridectomy~6. Suturing the scleral flap~7. Repositioning of conjunctiva with sutures After procedure, antibiotics \& steroids are administered topically; eye is covered with a pad - patient is discharged."
224154569|NCT00444080|DEVICE|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~1. Creation of a fornix or limbal based conjunctival flap in upper quadrants~2. Creation of limbal-based scleral flap extending into clear cornea~3. Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~4. Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~5. Prior to implantation, a thorough mobility check should be performed~6. Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~7. Withdrawal of introducer~8. Tucking plate under the scleral flap, and verification of its position~9. Suturing scleral flap After implantation procedure, antibiotics \& steroids administered topically; eye is covered with a pad - patient is discharged."
224154570|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
224154571|NCT04865445|DRUG|AT-527 550 mg + midazolam|"Day 1: 2 mg midazolam Day 3: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Days 4 to 6: 550 mg AT-527 administered twice daily (BID) Day 7: 550 mg AT-527 and 2 mg midazolam (with dosing offset by 2 hrs) in the morning and a second 550 mg AT-527 dose in the evening.~Other Names: AT-527 is also know as R07496998"
224154572|NCT03979872|DIAGNOSTIC_TEST|MC1R Genetic Testing|\[See arm/group descriptions\]
224154573|NCT03979872|OTHER|Skin Cancer Education|\[See arm/group descriptions\]
224154574|NCT03979872|DEVICE|UV Photo|\[See arm/group descriptions\]
224154575|NCT03684070|BEHAVIORAL|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
224154576|NCT03684070|BEHAVIORAL|Self-monitoring|Self-monitoring of data from wearable step count tracker
224154577|NCT03363165|DRUG|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
224154578|NCT03363165|OTHER|Placebo|"Participants randomized to placebo will receive calf muscle injections of placebo (the excipient buffer formulation minus the VM202) to each leg with evidence of PAD. Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD."
224066679|NCT01829256|BEHAVIORAL|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
224066680|NCT00290433|DRUG|Cyclophosphamide|Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
224066681|NCT00290433|DRUG|Mesna|Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.
224066682|NCT00290433|DRUG|Vincristine|Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.
224066683|NCT00290433|DRUG|Methotrexate|Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.
224066684|NCT00290433|DRUG|Ara-C|Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.
224066685|NCT00290433|DRUG|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
224066686|NCT00290433|DRUG|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
224066687|NCT00290433|DRUG|Doxil|Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.
224154579|NCT03855241|BEHAVIORAL|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
224154580|NCT03855241|BEHAVIORAL|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
224154581|NCT01287598|DRUG|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
224154582|NCT01287598|DRUG|Warfarin|CYP 2C9 (warfarin) at Cycle 1
224154583|NCT01287598|DRUG|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
224154584|NCT01287598|DRUG|Midazolam|CYP 3A4 (midazolam) at Cycle 1
224154585|NCT01287598|DRUG|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
224154586|NCT02255760|DRUG|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
224154587|NCT02255760|DRUG|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
224154588|NCT02255760|DRUG|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
224154589|NCT02255760|DRUG|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
224154590|NCT02255760|OTHER|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
224154591|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution high dose|Topical treatment for 24 weeks
224154592|NCT05636904|DRUG|prostaglandin F2a analogue in vehicle solution low dose|Topical treatment for 24 weeks
224154593|NCT05636904|DRUG|active ingredient-free vehicle solution to DLQ01|Topical treatment for 24 weeks
224154594|NCT05636904|DRUG|Minoxidil 5% Topical Solution|Topical treatment for 24 weeks
224154595|NCT00003838|PROCEDURE|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver \>5x10\^6 CD34+ cells/kg.
224154596|NCT00003838|DRUG|Methotrexate|IV MTX on days +1, +3, and +6 will be given
224154597|NCT00003838|DRUG|Cyclosporine|CSA will be given beginning on day -4 for graft versus host disease prophylaxis. Participants with mixed T-cell chimerism on day 30 will begin a CSA taper. Participants with 100% donor T-cell chimerism by day 30 will be tapered off CSA from days 60 through 100 (25% reduction in dose every 10 days-off by day 100). CSA will not be tapered in any subjects with grade \> II acute GVHD regardless of chimerism results. In addition, participants with evidence of disease progression without grade \> II GVHD will have CSA discontinued regardless of chimerism results.
224154598|NCT00003838|DRUG|G-CSF|G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.
224154599|NCT00618813|OTHER|radiation therapy|Undergo radiation therapy
224154600|NCT00618813|OTHER|therapeutic conventional surgery|Undergo surgery
224154601|NCT00618813|DRUG|etoposide|Given IV
224154602|NCT00618813|DRUG|ifosfamide|Given IV
224154603|NCT00618813|DRUG|doxorubicin hydrochloride|Given IV
224154604|NCT00618813|DRUG|cyclophosphamide|Given IV
224302382|NCT00676325|PROCEDURE|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
224302383|NCT00676325|DEVICE|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
224154605|NCT00618813|DRUG|vincristine sulfate|Given IV
224154606|NCT00618813|DRUG|topotecan hydrochloride|Given IV
224154607|NCT00618813|BIOLOGICAL|filgrastim|Given SC
224154608|NCT00022893|DRUG|Iodine-131 Anti-B1 Antibody|
224154609|NCT01150604|BEHAVIORAL|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
224154610|NCT04960462|PROCEDURE|nerve root sleeve reinforcement|treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
224154611|NCT02208505|DRUG|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
224154612|NCT02208505|DRUG|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
224154613|NCT01336595|DEVICE|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
224154614|NCT01336595|DEVICE|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
224154615|NCT03454724|DEVICE|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
224154616|NCT03454724|DEVICE|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
224154617|NCT00262327|DRUG|Antangiogenesis|
224154618|NCT00262327|GENETIC|endostatin gene|
224154619|NCT03115125|OTHER|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
224302384|NCT00676325|PROCEDURE|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
223743015|NCT06362434|DEVICE|Audiovisual stimulation|The MOT IVR audiovisual stimulation task involves the 3D multiple-object-tracking paradigm composed of 6-8 high-contrast spheres which features are adapted to the visual ability of individuals with low-vision (luminosity = 80 nits, size = 1° to 3° visual angle). The spheres move for 20s. following random linear paths, bouncing on one another and on the walls of a virtual 3D cube when collisions occur. The participant, comfortably seated, is asked to track the moving cued target among moving distractors for 20s. A spatial sound is correlated to the movement of the cued target. After 20s., the movement stops and the participant is asked to select, using a laser pointer, the cued sphere among the distractors (mark-all procedure). Speed of the spheres is regulated by a staircase 1:1 procedure. The stimulation can here be stopped by the participant if required. After 3 blocks of 15x20s., the system stops and goes on stand-by mode until the next session. Data are collected in real time.
224154620|NCT03151538|BEHAVIORAL|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
224154621|NCT03151538|OTHER|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
224154622|NCT06470620|DIAGNOSTIC_TEST|pelvic floor muscle assessment|no intervention will be performed - several diagnostic assessments tools
224154623|NCT06643260|DRUG|piclidenoson|Piclidenoson is a selective A3AR agonist, supplied as tablets.
224154624|NCT06643260|DRUG|Placebo|Inactive control
224154625|NCT01809197|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
223743016|NCT01393808|DRUG|Paricalcitol|1-month Paricalcitol 2mcg/day
224154626|NCT01809197|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
224154627|NCT01809197|DEVICE|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
224154628|NCT01809197|DEVICE|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
224154629|NCT01016808|DRUG|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
224154630|NCT01016808|DRUG|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
224154631|NCT01016808|DRUG|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
224154632|NCT01892241|DRUG|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
224154633|NCT01892241|DRUG|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
224154634|NCT04282876|DRUG|Degarelix|Patients receiving Degarelix
224154635|NCT01715272|DEVICE|TF037|
224154636|NCT01715272|DRUG|Fleet enema|
224154637|NCT03432117|OTHER|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
224154638|NCT03432117|OTHER|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
224154639|NCT00344760|DRUG|Enfuvirtide|subcutaneously twice a day
223743017|NCT01393808|OTHER|placebo|1-month Placebo Treatment
223743018|NCT01770483|DRUG|nitazoxanide|nitazoxanide 500mg twice daily
223743019|NCT01770483|DRUG|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
223743020|NCT01770483|DRUG|Ribavirin|ribazole
224154640|NCT00344760|DRUG|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
224154641|NCT04414527|BEHAVIORAL|Standard counselling|"The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
224154642|NCT04414527|BEHAVIORAL|Health-Video|"The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis."
224154643|NCT00405717|DRUG|atorvastatin,pravastatin|
224154644|NCT00000608|BEHAVIORAL|diet, fat-restricted|
224154645|NCT00000608|BEHAVIORAL|diet, sodium-restricted|
224154646|NCT02638272|PROCEDURE|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
224154647|NCT05385926|RADIATION|Radiotherapy|Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
224302385|NCT06632392|OTHER|Simulation training|Theory and simulation training
224302386|NCT06632392|OTHER|Theory training|Theory training
224154648|NCT03882853|OTHER|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
224154649|NCT03882853|OTHER|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
224154650|NCT05793424|OTHER|Cerebrospinal fluid (CSF) sample and additional blood samples|Lumbar puncture (Spinal Tap) and additional blood samples
224154651|NCT00430391|OTHER|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
224154652|NCT00430391|OTHER|Routine Control|Participants are assigned to the routine, standard consent.
224154653|NCT04749160|DEVICE|Connected device|Connected device is a smart watch (with accelerometer without location data).
224154654|NCT06423170|DRUG|Camrelizumab plus GEMOX|"1. Camrelizumab：200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~2. GEMOX chemotherapy : oxaliplatin 100mg/m2，D1, gemcitabine1000mg/m2，D1，intravenous infusion.~3. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses."
224154655|NCT00157170|BEHAVIORAL|supervised exercise|
224154656|NCT02746770|OTHER|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
224154657|NCT02645071|BEHAVIORAL|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
224154658|NCT02260388|DRUG|Nortriptyline|
224154659|NCT02260388|DRUG|Duloxetine|
224154660|NCT02260388|DRUG|Pregabalin|
224154661|NCT02260388|DRUG|Mexiletine|
224154662|NCT02687607|DEVICE|WEB Aneurysm Embolization System|
224154663|NCT01869803|DRUG|gemtuzumab ozogamicin|Given IV
224154664|NCT01869803|OTHER|laboratory biomarker analysis|Correlative studies
224154665|NCT02959190|DRUG|Galcanezumab|Administered SC
224154666|NCT04735809|DIETARY_SUPPLEMENT|Whole Cell Algae Fermentate|Contains at minimum 50% Beta Glucan
224154667|NCT04735809|DIETARY_SUPPLEMENT|Placebo|microcrystalline cellulose
224154668|NCT05117593|DRUG|FBL-MTX|FBL-MTX is available as sterile liposomal dispersion for injection at nominal dose strength of 1 mg/mL of methotrexate free base. The dose of 0.1 mg was selected as starting dose in the present study. Three subsequent FBL-MTX dose levels are pre-planned: 0.33 mg, 1 mg and 2.5 mg.
224154669|NCT05117593|DRUG|Placebo|Placebo will consist of sterile saline 0.9% NaCl solution.
224154670|NCT05768542|DRUG|Metoprolol Injection|If heart rate below 60, give 5 mg IV. If heart rate above 60, give 5 mg IV and repeat until heart rate below 65 or 20 mg given in total or systolic blood pressure below 110 mmHg.
224154671|NCT05768542|DRUG|Saline|5 ml given IV
224154672|NCT01045928|DRUG|lenalidomide|Given orally
224154673|NCT01045928|BIOLOGICAL|rituximab|Given IV
224154674|NCT01045928|GENETIC|polymerase chain reaction|Correlative study
224154675|NCT01045928|GENETIC|nucleic acid sequencing|Correlative study
224154676|NCT01045928|GENETIC|polymorphism analysis|Correlative study
224154677|NCT01045928|OTHER|flow cytometry|Correlative study
224154678|NCT01045928|OTHER|laboratory biomarker analysis|Correlative study
224154679|NCT05141734|DIAGNOSTIC_TEST|The relationship between the vestibulo-ocular reflex (VOR) gains and the slow phase velocity (SPV)|The vestibulo-ocular reflex (VOR) gains were measured by video Head Impulse Test (vHIT) in both the study group and the control group. The slow phase velocity (SPV) values of the nystagmus observed during the Dix-Hallpike maneuver in the study group were recorded by Videonystagmography (VNG) and compared with the VOR gains.
224154680|NCT06227806|PROCEDURE|Tibial Tubercle Transfer|Patients will receive the TTT surgery followed by a home exercise program.
224302387|NCT02562339|BEHAVIORAL|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
224302388|NCT06082895|BEHAVIORAL|Birth self-efficacy enhancement training based on motivational interviewing method|Birth self-efficacy enhancement training based on motivational interviewing method
224302389|NCT02527538|DEVICE|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
224302390|NCT01404078|DRUG|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
224302391|NCT01404078|DRUG|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
224302392|NCT05394311|OTHER|sports based mental health promotion program|sports related programs
224154681|NCT06227806|PROCEDURE|Home Exercise Program|Patients will receive an extensive home exercise program.
224154682|NCT02032186|DRUG|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
224302393|NCT04775849|DEVICE|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed uni- or bilateral
224154683|NCT01066169|BIOLOGICAL|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
224154684|NCT03152188|DRUG|FMT|Fifteen FMT Openbiome capsules administered at the same time
224154685|NCT03152188|OTHER|Placebo|Fifteen placebo capsules administered at the same time
224154686|NCT00856817|DRUG|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
224154687|NCT00856817|DRUG|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
224154688|NCT04500067|DRUG|IVIG|Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
224154689|NCT00137293|DRUG|GAP-486 (ZP-123)|
224154690|NCT00137293|DRUG|0.9% Sodium Chloride, USP|
224154691|NCT01980225|PROCEDURE|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
224154692|NCT05221255|OTHER|spinal magnetic stimulation|"* Biofeedback pelvic floor muscle training sessions will be performed for both groups for a total of 12 sessions. Menstruating women will be temporarily withdrawn from BF sessions till end of the menses. The session will last for 30 minutes of transrectal pressure biofeedback relaxation technique. Auditory and visual feedback will be provided in addition to positive verbal reinforcement.~* Sham SMS will be used in the Sham group using the placebo program in the magnetic stimulation machine.~* Spinal magnetic stimulation using the Neuro-MS/D machine. It will be used in spinal magnetic stimulation group, circular coil will be used to stimulate S2,3 and 4 sacral roots. Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 20 Hz, burst length = 5 seconds, inter-burst interval = 25 seconds."
224154693|NCT01363258|BEHAVIORAL|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
224154694|NCT01363258|PROCEDURE|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
224154695|NCT05833555|BEHAVIORAL|MH task-sharing training|Providers will be trained to screen for MH, provide education, refer, and coordinate to range of social services. MH training typically consists of education and resources, such as one-time workshops and toolkits, provided with limited technical assistance.
224154696|NCT05833555|BEHAVIORAL|Supervision|Additionally, Community Health Workers (CHWs) will receive bi-weekly group supervision for the first 6-months, and monthly supervision for the remaining year on Zoom from a supervisor at Center for Innovation in Mental Health.
224154697|NCT05833555|BEHAVIORAL|Learning Collaborative|A learning collaborative with multidisciplinary teams from various healthcare organizations will support continuous quality improvement and develop develop structured approach to improve provision of care.
224154698|NCT05833555|OTHER|Technology Intervention|To be determined by community crowdsourcing after the first phase of implementation of the multisector collaborative care for MH task-sharing.
224154699|NCT02428673|OTHER|Assisted Standing Treatment Program|
224154700|NCT00045812|DRUG|SCH-58235|
224154701|NCT02678728|DRUG|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
224154702|NCT02678728|DRUG|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
224154703|NCT00158223|DRUG|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
224154704|NCT00158223|DRUG|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
224154705|NCT03171311|PROCEDURE|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
224154706|NCT03171311|PROCEDURE|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
223743021|NCT04052048|DIAGNOSTIC_TEST|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
223743022|NCT05521256|DRUG|NNC0113-6856|Participants will receive NN0113-6856 orally or intravenously.
223743023|NCT05521256|DRUG|Placebo|Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
223743024|NCT05986292|DRUG|LY3016859 ISA|Administered intravenously (IV)
224154707|NCT00583661|DEVICE|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
224154708|NCT02879370|PROCEDURE|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
223743025|NCT05986292|DRUG|LY3556050 ISA|Administered orally
223743026|NCT05986292|DRUG|LY3526318 ISA|Administered orally
223743027|NCT05986292|DRUG|LY3857210 ISA|Administered orally
223743028|NCT05986292|DRUG|Placebo Oral|Placebo administered orally
223743029|NCT05986292|DRUG|Placebo|Placebo administered IV
223743030|NCT02488681|DEVICE|Micra Pacemaker Implant|
224302394|NCT05282225|BEHAVIORAL|MI- Safety Plan|"The MI-enhanced safety plan (MI-SP) component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy"
223456274|NCT00975546|OTHER|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
223456275|NCT00975546|PROCEDURE|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
223456276|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
223456277|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
223456278|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
223456279|NCT02492165|BIOLOGICAL|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
224302395|NCT05282225|BEHAVIORAL|Texts messages|For participants randomized to receive supportive text messages (Texts), text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
224302396|NCT05282225|BEHAVIORAL|Monitoring|Adolescent participants will complete daily surveys for 4 weeks (including assessment of suicidal ideation, behavior, and other relevant risk and protective factors) and these will be monitored daily to identify presence of heightened suicidal ideation and presence of suicidal behavior. In addition, daily surveys will be used to determine if adolescents are sufficient responders to Phase 1 intervention.
224302397|NCT05282225|BEHAVIORAL|Portal follow-up|This will be part of Phase 2. The portal follow-up will similarly address content offered in the booster call. For the adolescent, the focus will be on revisiting and adjusting the safety plan, addressing barriers to safety plan adherence, as well as enhancing motivation and self-efficacy to use healthy coping. For the parent, portal communication will focus on revisiting safety recommendations provided as part of MI-SP, addressing barriers in implementing safety recommendations and in supporting the adolescent's safety plan use, as well as enhancing parents' motivation and self-efficacy in these areas. The portal will enable additional asynchronous contacts up to 3 weeks to provide added support and problem solving, based on identified barriers and concerns, to promote post-discharge behavior change. Counselors will initiate approximately 6 contacts with adolescents and, separately, with parents over 3 weeks as soon as non-response is detected.
224302398|NCT05282225|BEHAVIORAL|Booster call|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, is to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
224302399|NCT05189886|PROCEDURE|Double Balloon Valvuloplasty in TAVR|The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
224302400|NCT06251492|RADIATION|Stereotactic body radiotherapy|8 Gray x 3 for 2 cycles
224302401|NCT06251492|DRUG|Adebrelimab|Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression
224302402|NCT01206101|DRUG|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
224302403|NCT01206101|DRUG|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
224302404|NCT00569530|DRUG|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
224302405|NCT00569530|DRUG|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
224302406|NCT04653272|OTHER|Questionnaire|Patients will be evaluated identically to routine care with reference tests (Lysholm-Tegner, and Knee injury and Osteoarthritis Outcome Score (KOSS) and, IKDC (Evaluation of knee ligament injuries). This is filled in without any external help. The questionnaire includes the Lysholm-Tegner (young adult group), IKDC and KOOS scores (young and senior adult groups).
224302407|NCT04709835|DRUG|AT-527|Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.
224302408|NCT04709835|DRUG|Placebo|The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
224154709|NCT03514004|BEHAVIORAL|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
224154710|NCT04432740|PROCEDURE|Conservative Treatment of Distal Radius Fracture|The purpose of this prospective randomized study was to compare a new reverse sugar tong splint technique that does not immobilize the elbow with a below-arm cast, in terms of patient radiological and clinical outcomes and the ability to maintain fracture reduction.
224154711|NCT03182842|DEVICE|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
224154712|NCT03182842|DEVICE|SMBG - Blinded Sensor|Insulin dosing based on SMBG
224154713|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
224154714|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
224154715|NCT03234400|COMBINATION_PRODUCT|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
224154716|NCT00588887|DEVICE|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
224154717|NCT00588887|DEVICE|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
224154718|NCT04294654|DRUG|Vortioxetine|Vortioxetine 5, 10 and 20 mg/day, tablets, orally Patients will receive 5 mg vortioxetine once daily for one week. At visit 3, the dose will be increased to 10 mg/day for all patients. Thereafter the dose may be adjusted to 5, 10 or 20 mg/day.
224154719|NCT04219488|OTHER|Radial nerve mobilization|
224154720|NCT04219488|OTHER|Supervised home program|
224154721|NCT03760276|DRUG|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
224154722|NCT02339857|PROCEDURE|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
224154723|NCT02532426|PROCEDURE|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
224154724|NCT05401591|DIETARY_SUPPLEMENT|Protein shake|Participant will drink a protein shake made using each of the four protein types.
224154725|NCT00819104|DRUG|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
224154726|NCT00819104|DRUG|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
224154727|NCT00819104|DRUG|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
224154728|NCT00819104|DRUG|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
224154729|NCT00819104|DRUG|Amlodipine 5mg|tablet,oral,OD,8 weeks
224154730|NCT06202339|DEVICE|DaRT seeds|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
224154731|NCT05114148|DEVICE|Holmium-166 radioembolization|Individualized 166Ho-RE will be performed via a catheter during angiography. Dosimetry-based treatment planning will be individualized based on Q-Suite™ software.
224154732|NCT00038272|DRUG|Mycophenolate mofetil|
224154733|NCT00038272|DRUG|Amdoxovir|
223456280|NCT00176657|DRUG|HEMOBAG Assessment|
223456281|NCT03162042|PROCEDURE|Tumor removal|Surgery
224154734|NCT02925312|OTHER|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication facilitated by near, real-time blood glucose monitoring
224154735|NCT02142504|BIOLOGICAL|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
224154736|NCT02142504|DRUG|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
224154737|NCT00463879|DRUG|Galantamine|
224154738|NCT00482300|PROCEDURE|Systematic pelvic lymphadenectomy|
223456282|NCT05136235|DIAGNOSTIC_TEST|Echocardiography|There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period
223456283|NCT05136235|DIAGNOSTIC_TEST|NT-proBNP|At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample
224154739|NCT01778270|DEVICE|Body Bioimpedance Sensor|
224154740|NCT01998399|DRUG|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
224154741|NCT01998399|DRUG|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
224154742|NCT03235375|DRUG|MEDI0382|MEDI0382 administered subcutaneously
223456284|NCT04403555|DRUG|Ivermectin|Ivermectin treatment
224154743|NCT03126578|DRUG|LEO 32731|LEO 32731 is being developed by LEO Pharma.
224154744|NCT03126578|DRUG|Midazolam|Benzodiazepine
224154745|NCT06192667|DEVICE|GC Geanial Injectable (Tokyo,Japan)|Highly filled composite resin
224154746|NCT06192667|DEVICE|3M Filtek Z250 Universal Restorative (Germany)|Conventional composite resin
224154747|NCT00376246|DRUG|Ezetimibe|
224154748|NCT01875510|DIETARY_SUPPLEMENT|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
224154749|NCT01875510|DIETARY_SUPPLEMENT|soybean-oil emulsion|soybean-oil emulsion
224154750|NCT00987090|BIOLOGICAL|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
224154751|NCT00987090|RADIATION|MRI|intervention at the inclusion and 18 months after
224154752|NCT00987090|PROCEDURE|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
224154753|NCT00987090|BIOLOGICAL|Apolipoprotein E genotyping|genotyping at the inclusion
224154754|NCT00987090|BIOLOGICAL|Study of cerebrospinal fluid|intervention at the inclusion
224154755|NCT05276427|OTHER|Non Clinical procedure|Non clinical procedure- Informed consent completion and interview session
223456285|NCT01075997|DEVICE|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
224154756|NCT00877604|DRUG|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
224154757|NCT00877604|DRUG|Placebo|identical placebo by oral route at the same dosing schedule
224154758|NCT01463020|BEHAVIORAL|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
224154759|NCT01463020|OTHER|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
224154760|NCT03483376|PROCEDURE|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
224154761|NCT03483376|DEVICE|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
224154762|NCT00418717|DRUG|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
224154763|NCT05941663|OTHER|Dental implant surface|Implants provided were Bone Level Tapered (Bone Level Tapered) Roxolid® implants with a SLActive® or SLActive® surface
224154764|NCT02867163|DRUG|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
224154765|NCT01763112|DEVICE|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
224154766|NCT02294669|DEVICE|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
224154767|NCT00561587|DRUG|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
224154768|NCT05772442|DIAGNOSTIC_TEST|Extra blood samples (5-10 mL) drawn|Extra blood samples will be sent for metabolomics analysis.
224154769|NCT00241878|BEHAVIORAL|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
224154770|NCT00241878|BEHAVIORAL|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
224154771|NCT00719537|DRUG|Aspirin|Aspirin 81 mg once a day
224154772|NCT00719537|DRUG|Placebo Oral Tablet|Placebo 1 tab Daily
224154773|NCT00719537|DRUG|Progesterone|Oral Progesterone 200 mg Twice Daily
224154774|NCT00795171|DRUG|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
224154775|NCT00795171|DRUG|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
223456286|NCT01075997|DEVICE|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
223456287|NCT06376708|OTHER|platelet rich fibrin|platelet rich fibrin
224154776|NCT00795171|DRUG|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
223456288|NCT06376708|OTHER|Polyether ether ketone|Polyether ether ketone
223456289|NCT02749227|DRUG|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
223456290|NCT02660437|OTHER|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
223456291|NCT03630159|BIOLOGICAL|Tisagenlecleucel|Gene modified autologous T cells
223456292|NCT03630159|DRUG|Pembrolizumab|anti PD-1
223456293|NCT03836157|DRUG|Mirvetuximab Soravtansine|The dose will not be recalculated unless the patient has ±10% weight change.
223456294|NCT03836157|DRUG|Bevacizumab|Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
223456295|NCT02364583|DRUG|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
224154777|NCT05462405|PROCEDURE|Experimental group|In the setting phase subjects will be in recumbent position. A microneurography needle (0.2mm diameter isolated Tungsten micro-electrode) will be placed under the skin. An identical (not isolated) reference needle tip will be inserted within 2 cm of the first electrode. These are connected to a recording system (ADInstruments PowerLab). Once sympathetic activity can be measured using the needles, a sympathetic specific test will be used to calibrate the measurement and recording system. In the testing phase sequential pacing and CNT delivery will be programmed for a few minutes, the whole procedure expected to last less than 2 hours.
224154778|NCT02301754|BIOLOGICAL|INVAC-1|intradermal injection combined with electroporation
224154779|NCT00158405|PROCEDURE|Structured Treatment Interruption|
224154780|NCT00158405|DRUG|Zidovudine (ZDV)|
224154781|NCT00158405|DRUG|Lamivudine (3TC)|
224154782|NCT00158405|DRUG|Efavirenz (EFV)|
224154783|NCT00158405|DRUG|Ritonavir (NRV)|
224302409|NCT06634017|BIOLOGICAL|Platelet rich fibrin|Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
223456296|NCT05495308|PROCEDURE|neoadjuvant treatment|We study the number of patients who achive a complete pathological response after neoadjuvant treatment with radiochemotherapy.
223456297|NCT04398810|PROCEDURE|robotic single port cholecystectomy|"1. Local anesthetic administration during wound incision In the experimental group and the control group, a local anesthetic was administered to the wound surface when a glove port was installed on the navel at the start of surgery. (bupivacaine 0.5% 14ml subcutaneous injection)~2. Residual gas aspiration~3. Pulmonary recruitment maneuver In both the experimental group and the control group, before the operation was completed and the wound was closed, the patient was taken to the Trenedelenburg position, and then the pressure of 60 cm H2o in the abdomen was applied, and manual inflation was performed twice, 5 seconds at a time, and pulmonary recruitment was performed.~4. Warming of the washing solution in the abdominal cavity"
223456298|NCT00006329|PROCEDURE|Minimally invasive radioguided parathyroidectomy|
223456299|NCT01463943|OTHER|Probiotic|
223456300|NCT01463943|OTHER|Probiotic|
223456301|NCT01463943|OTHER|Probiotic|
223456302|NCT04070248|OTHER|No intervention|No intervention
223456303|NCT02962232|DEVICE|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
223456304|NCT02962232|DEVICE|PTA catheter|control group
223456305|NCT02136901|DEVICE|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
223456306|NCT02136901|DRUG|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
223456307|NCT02136901|DRUG|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
223456308|NCT02136901|DRUG|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
223456309|NCT00091468|DRUG|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
223456310|NCT00091468|DRUG|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
224154784|NCT00158405|DRUG|Indinavir (IDV)|
224154785|NCT01142193|DRUG|USL255|
224154786|NCT01142193|DRUG|Placebo|
224302410|NCT03328195|DEVICE|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
223456311|NCT05978219|DRUG|Mirtazapine Tablets|Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
223456312|NCT00079651|BEHAVIORAL|Montessori-based dementia programming|
223456313|NCT03380871|BIOLOGICAL|NEO-PV-01|Personal Cancer Vaccine
223456314|NCT03380871|BIOLOGICAL|Pembrolizumab|monoclonal antibody against PDL1
223456315|NCT03380871|OTHER|Adjuvant|immune adjuvant
223456316|NCT03380871|DRUG|Carboplatin|chemotherapy
223456317|NCT03380871|DRUG|Pemetrexed|chemotherapy
223456318|NCT02637310|DRUG|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
223456319|NCT02637310|DRUG|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
223456320|NCT00780780|DRUG|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
223456321|NCT00780780|DRUG|triamcinolone intravitreal injection|triamcinolone intravitreal injection
224154787|NCT04397029|DEVICE|SureTouch|"The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch."
224154788|NCT05982639|PROCEDURE|two lung ventilation|The intervention do not involve a drug or device. It will be compared two different approaches to ventilate the lungs during the procedure . In this arm both lungs will be ventilated inserting a disposable trocar into the pleural cavity, and insufflating CO2 into the thoracic cavity via an insufflator. The insufflation pressure and the flow rate will be set as 8 mmHg and 10 l.min-1, of the cavity with CO2. The insufflator will be adjusted for cavity pressure in 8mmHg and flow of 10L/min.
224154789|NCT05982639|PROCEDURE|one lung ventilation|In this arm only one lung (the contralateral lung) will be ventilated using a Carlens type orotracheal tube
224154790|NCT02381548|DRUG|Adavosertib|Given PO
224154791|NCT02381548|DRUG|Belinostat|Given IV
224154792|NCT02381548|OTHER|Laboratory Biomarker Analysis|Correlative studies
224154793|NCT02381548|OTHER|Pharmacological Study|Correlative studies
224154794|NCT02077504|OTHER|MEG and MRI|CONDUCTOME
224154795|NCT00708903|DRUG|neratinib|HKI-272
224154796|NCT00708903|OTHER|Placebo|Placebo
224154797|NCT00708903|DRUG|Moxifloxacin|
224154798|NCT01513863|DRUG|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
224154799|NCT01513863|DRUG|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
224154800|NCT01513863|DRUG|Placebo|Placebo applied to affected area once a day for 70 days
224154801|NCT02840513|OTHER|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
224154802|NCT03255304|BEHAVIORAL|health mindest|groups be confronted with health aspects of food items
223456322|NCT01443741|OTHER|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
223456323|NCT01691417|DEVICE|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
223456324|NCT00124891|DRUG|Double-blind investigational anti-arrhythmic|
223456325|NCT00124891|DRUG|GAP-486|
223456326|NCT02892617|OTHER|Bacteriological analysis of disc|
223456327|NCT01957579|DRUG|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
223456328|NCT01000974|BIOLOGICAL|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
223456329|NCT01000974|BIOLOGICAL|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
223456330|NCT01000974|BIOLOGICAL|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
223456331|NCT01000974|BIOLOGICAL|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
223456332|NCT01000974|BIOLOGICAL|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
223456333|NCT01000974|BIOLOGICAL|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
224154803|NCT03255304|BEHAVIORAL|palatability mindset|groups be confronted with palatability aspects of food items
224154804|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients \> 45 kg/99 lbs: idebenone 900 mg/day
224154805|NCT00537680|DRUG|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
224154806|NCT00537680|DRUG|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
224154807|NCT01774292|PROCEDURE|Endotracheal intubation with injection of liquid in the cuff|
224154808|NCT02191280|DRUG|Antistax®, low dose|
224154809|NCT02191280|DRUG|Antistax®, high dose|
224154810|NCT02191280|DRUG|Placebo|
224154811|NCT01752972|DIETARY_SUPPLEMENT|Spirulina|10 g/day orally for 12 weeks
224154812|NCT04409301|OTHER|My Special Aflac Duck (MSAD)|The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.
224154813|NCT04409301|BEHAVIORAL|Standard of care control|Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
224154814|NCT02409758|BEHAVIORAL|Voice therapy|Voice therapy applied during 6 weeks.
224154815|NCT01203787|DRUG|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
224154816|NCT01203787|DRUG|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
224154817|NCT05759546|DRUG|Fluzoparib|Parp inhibitor
223456334|NCT01000974|BIOLOGICAL|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
223456335|NCT01000974|BIOLOGICAL|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
224154818|NCT05759546|DRUG|Dalpiciclib|CDK4/6 inhibitor
224154819|NCT05759546|DRUG|Fulvestrant/AI|Endocrine therapy
224154820|NCT03404518|DRUG|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
224154821|NCT03404518|DRUG|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
224154822|NCT04907318|DEVICE|Cataract surgery|
224154823|NCT05911412|BEHAVIORAL|Mindfulness-based cognitive therapy using neuroscience (NMBCT)|Mindfulness-based cognitive therapy using neuroscience (NMBCT) is a standardized 8-week course taught by trained instructors. The NMBCT is a group therapy that takes place once a week for about 90 minutes per session. The program consists of mental education for each session, 2-3 mindfulness meditation practice, mindfulness practice in daily life, and about 30 minutes of daily home mindfulness meditation task. While participating in the program, the subjects will receive psychoeducation and various mindfulness meditation techniques (eating meditation, breathing meditation, sedentary meditation, viewing meditation, and listening meditation, etc.).
224154824|NCT04213118|DRUG|Anlotinib Hydrochloride|Anlotinib 12mg QD PO d1-14, 21 days per cycle.
224154825|NCT04213118|PROCEDURE|TACE|TACE first, followed by anlotinib within day4（+/-1days）
224154826|NCT00825149|DRUG|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
224154827|NCT00825149|DRUG|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
224154828|NCT00825149|DRUG|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
224154829|NCT00825149|DRUG|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
224154830|NCT00825149|DRUG|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
224154831|NCT00825149|DRUG|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
224154832|NCT00825149|DRUG|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
224154833|NCT05674604|PROCEDURE|Cryoneurolysis|This is on observational study. All participants are already candidate for cryoneurolysis. Cryoneurolysis uses a cold probe to generate an ice ball, which initiates Wallerian Degeneration, a process where axon is destroyed but the epineurium and perineurium remain intact. The treated nerve is able to regenerate over time due to this preserved tube.
224154834|NCT05830526|OTHER|Escape Room|"The next day, 56 students, who agreed to participate in the study, were divided into groups of 5, and they had to fill out a 10-question test, which includes the stages of the ERAS Protocol preoperative period, within the scope of the pre-test. A simulation room for students has been set up as an escape room. At the briefing on the theme of the escape room, it was explained that they would have 10 minutes to complete six missions using the clues given to them.~The 6 stations created in the room were numerically numbered from 1 to 6. There were question/answer cards at each station and a clue on the back of the correct answer card to reach the next station. The first clue was given by the observer who made the information in the information room.The student who could not get out of the room within 10 minutes was considered as unable to leave the escape room."
224154835|NCT04454138|DEVICE|XEN-45 gelatin microstent|Placement either in the subconjunctival space or supratenon's area
224154836|NCT03693404|DRUG|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
224154837|NCT03693404|DRUG|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
224154838|NCT03693404|DRUG|General Anesthetics|Placebo group will only receive standard of care general anesthesia
224154839|NCT04821960|BEHAVIORAL|Tailored Mindfulness Program for Fear of Memory Loss|The tailored mindfulness program has been specifically created to focus on fear of memory loss compared to general mindfulness lessons and activities.
224154840|NCT04821960|BEHAVIORAL|Conventional Mindfulness Program|Routine non-tailored mindfulness lessons and activities.
224154841|NCT05820646|OTHER|Boswellia Sacra|"1. Boswellia Sacra used as an intracanal medicament for 3 days~2. Boswellia Sacra used as an intracanal medicament for 7 days"
224154842|NCT04155125|DRUG|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
224154843|NCT04155125|DRUG|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
224154844|NCT02524067|BEHAVIORAL|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
224154845|NCT01041404|DRUG|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
224154846|NCT01041404|DRUG|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
224154847|NCT01041404|DRUG|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
224154848|NCT01041404|DRUG|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
224302411|NCT03328195|DEVICE|Sham|Twenty minutes, six days per week for 12 weeks with sham device
224302412|NCT03328195|DEVICE|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
224154849|NCT01157455|PROCEDURE|Everolimus Drug Eluting Stent|Implantation
224154850|NCT01157455|DRUG|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
224302413|NCT00169481|BIOLOGICAL|Pneumococcal (vaccine)|
224302414|NCT01832207|DEVICE|Transcutaneous electrical nerve stimulation|
224302415|NCT01832207|DEVICE|Placebo transcutaneous electrical nerve stimulation|
224302416|NCT05834530|OTHER|3D Printed Complete Dentures|Denture bases printed from a pre-polymerized block via additive technique, using photon S desktop 3D printer\* that relies on SLA technology and post cured by post curing unit.
224302417|NCT02468622|OTHER|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
223456336|NCT01589419|DRUG|veliparib|see arm description
223456337|NCT01589419|DRUG|capecitabine|see arm description
223456338|NCT01589419|RADIATION|radiation|see arm description
223456339|NCT00635934|DEVICE|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
223456340|NCT00652145|DRUG|mesalamine|Increase dose by 2.4gm per day over baseline dose
223456341|NCT00014612|PROCEDURE|axillary lymph node dissection|
223456342|NCT00014612|PROCEDURE|lymphoscintigraphy|
223456343|NCT00014612|PROCEDURE|therapeutic conventional surgery|
223456344|NCT00014612|RADIATION|radiation therapy|
223456345|NCT01639144|BIOLOGICAL|PRP and PPP|Autogenous PRP and PPP
223456346|NCT02554045|DRUG|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
224302418|NCT03996629|OTHER|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
224302419|NCT03545230|PROCEDURE|":Four Not Techniques"|":Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft."
224302420|NCT00000326|DRUG|Heroin Dependence|
224302421|NCT06336395|DRUG|Prednisolone|Oral
223572703|NCT04832906|PROCEDURE|Uterine artery embolization|Selective embolization of uterine arteries bilaterally, using polyvinyl alcohol (PVA) particles administered via a catheter followed by capping with a plug of gelatin sponge. The end point for embolization is to have a static column of contrast in the uterine artery, with only a stump filling when the internal iliac artery was injected.
224154851|NCT01157455|DRUG|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
224154852|NCT01157455|DRUG|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
224154853|NCT05060198|DRUG|Artemether-lumefantrine (AL)|AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
224154854|NCT05060198|DRUG|Dihydroartemisinin-piperaquine (DP)|DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
224154855|NCT04559412|DEVICE|Sofusa DoseConnect|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
224154856|NCT04559412|DRUG|Enbrel|25 to 50 mg Enbrel® administered by the Sofusa® DoseConnect™ delivery system once weekly for 12 weeks
224154857|NCT04555408|DEVICE|blue light|Patients receive exposure to 100lux blue light, which dominant wave-length is 468nm for 30 minutes in the morning.
224302422|NCT06336395|DRUG|Dexamethasone|Oral
224302423|NCT06336395|DRUG|Vincristine|Intravenous
224302424|NCT06336395|DRUG|Methotrexate|Oral/ intrathecal/intravenous/subcutaneous
224302425|NCT06336395|DRUG|L-Asparaginase|Intramuscular
223572704|NCT04038892|OTHER|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
223572705|NCT04038892|OTHER|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
224154858|NCT04555408|DEVICE|bright light|Patients receive exposure to 1000lux bright light, which dominant wave-length is 490nm for 30 minutes in the morning.
224154859|NCT04555408|DEVICE|dim light|Patients receive exposure to 100lux dim light, which dominant wave-length is 490nm for 30 minutes in the morning.
224154860|NCT01810549|DRUG|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
224154861|NCT01810549|DRUG|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
224154862|NCT05663242|DRUG|Propofol|The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
224154863|NCT05663242|DRUG|Sevoflurane|The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC)
224154864|NCT05410899|OTHER|exercise|Women with urinary incontinence will done exercise including pelvic floor muscle and will taught pelvic floor muscle anatomy, physiology, disorders, treatment of disease
224154865|NCT03655574|BEHAVIORAL|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
224154866|NCT03655574|OTHER|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
224154867|NCT02292498|DEVICE|FLIR ONE|
224154868|NCT03143868|BEHAVIORAL|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
224154869|NCT03404271|DIETARY_SUPPLEMENT|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
224154870|NCT03404271|OTHER|Resistance Training|Performing supervised resistance training three times per week.
224154871|NCT03404271|DIETARY_SUPPLEMENT|Protein Supplementation|Consuming a protein supplement daily.
224302426|NCT06336395|DRUG|Pegylated asparaginase|Intravenous
224302427|NCT06336395|DRUG|Erwinase|Optional for those allergic to E.coli/PEG L-asparaginase (intravenous)
224302428|NCT06336395|DRUG|Dasatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
224302429|NCT06336395|DRUG|Imatinib|Indicated only for ALL with BCR::ABL1 /BCR::ABL1-like/ tyrosine kinase fusion positive (oral)
224302430|NCT06336395|DRUG|Cyclophosphamide|Intravenous
224302431|NCT06336395|DRUG|Cytarabine|Subcutaneous/ Intravenous
224302432|NCT06336395|DRUG|Mercaptopurine|Oral
224302433|NCT06336395|DRUG|Thioguanine|Oral
224302434|NCT06336395|DRUG|Rituximab|Intravenous
224302435|NCT06336395|DRUG|Doxorubicin|Intravenous
224154872|NCT03404271|BEHAVIORAL|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
224154873|NCT00439153|DEVICE|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
224154874|NCT04913415|OTHER|Low Suction Strategy of Chest Tube Management|A digital chest tube will be set to a low pressure mode (-8mmHg) during recovery after minimally invasive lung resection.
224154875|NCT04913415|OTHER|Standard Suction Strategy of Chest Tube Management|A digital chest tube will be to the standard suction mode (-20mmHg) during recovery after minimally invasive lung resection.
224154876|NCT03536650|DEVICE|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
224154877|NCT03587818|OTHER|person-centred communication|The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
224154878|NCT06131229|BEHAVIORAL|Structured emotional education program (PEE)|The principal investigator, together with the class-tutor of the experimental groups, conducts the 20 activities of which the program is composed during the hour dedicated to tutorial action. The sessions are held at Lauro School on Monday mornings in the respective classrooms, with the possibility of using the courtyard and other multipurpose rooms if the activities so require. Each session lasts one hour and is held throughout the school year 23-24.
224154879|NCT06131229|BEHAVIORAL|Incidental tutorial action based on the school's regular curriculum (PCO)|One hour tutorial action per week according to the regular school curriculum. This curriculum contemplates the incidental approach to the problems that arise in daily life and the work with the KIVA program.
224154880|NCT00284349|DEVICE|Use of a rehabilitation brace instead of a plaster|
224154881|NCT03627494|DRUG|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
224154882|NCT03627494|DRUG|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
224154883|NCT06783244|OTHER|Low intraabdominal pressure (8 mmHg)|Only difference in treatment is the lower level of intraabdominal pressure by which the procedure is performed. The intervention does not change the treatment. The surgical procedure is performed due to Danish national guidelines and remains the same in the two arms.
224154884|NCT05717166|RADIATION|Palliative Radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
224154885|NCT05717166|DRUG|Chemotherapy|Pre-specified based on the standard of care approach for that patient.
224154886|NCT05717166|DRUG|Hormone therapy|Pre-specified based on the standard of care approach for that patient.
224154887|NCT05717166|DRUG|Immunotherapy|Pre-specified based on the standard of care approach for that patient.
224302436|NCT06336395|DRUG|Fludarabine|Intravenous
223456347|NCT02554045|DRUG|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
223456348|NCT04346407|DRUG|Dronabinol 2.5mg Cap|2.5mg of oral Dronabinol daily starting with pre-op cocktail and continued twice daily for three days after surgery
224154888|NCT05717166|DRUG|Targeted Systemic Therapy|Pre-specified based on the standard of care approach for that patient.
224154889|NCT05717166|OTHER|Observation|Pre-specified based on the standard of care approach for that patient.
224154890|NCT05717166|RADIATION|Stereotactic Ablative Radiotherapy|"The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board.~Preferred doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every second day), and 35 Gy in 5 fractions (daily)."
224154891|NCT05717166|PROCEDURE|Surgery|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~The primary tumor may be treated with SABR or with other local modalities at the discretion of the treating team and/or the local multidisciplinary tumor board. Because of the convenience in using SABR for all lesions, non-SABR modalities should only be used if they are likely to provide a benefit over SABR."
224154892|NCT05717166|OTHER|Radiofrequency Therapy (RFA)|Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.
224302437|NCT04325204|BEHAVIORAL|Faith-based Home Activity Toolbox (Faith-HAT)|"They will select activities from Faith-HAT at least 3 times a week. Possible examples of these activities include devotional readings, prayer, music, religious images, and video and audio recorded sermons.~Faith-HAT will be placed on online, which requires little technical know-how by users. The PI will provide training to participants on how to use the Faith-HAT and online diary on the tablet computer provided by the project."
224302438|NCT03745157|DRUG|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
223456349|NCT04346407|DRUG|Placebo|Placebo capsule daily starting with pre-op cocktail and continued twice daily for three days after surgery
223456350|NCT03717779|DIAGNOSTIC_TEST|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
223456351|NCT04608916|PROCEDURE|Using surgical diathermy to make skin incision|Using surgical diathermy to make skin incision during shoulder arthroplasty
224154893|NCT05717166|RADIATION|Fractionated Radiation|"Treatment to the primary tumor and metastases, with SABR preferred, but other options all allowable if those are deemed to be preferable by the treating oncologists.~Tumors in the esophagus, stomach, small intestine or colon should be treated with either fractionated radiation or a lower SABR dose (e.g. 25 Gy in 5 fractions) to minimize the risk of perforation."
224154894|NCT03368352|DIETARY_SUPPLEMENT|Melatonin|Dietary supplement melatonin
224154895|NCT03368352|OTHER|Hypoxia|Sleep in a hypoxic tent simulating high altitude
224154896|NCT03565991|DRUG|Avelumab|IV treatment
224154897|NCT03565991|DRUG|Talazoparib|Oral treatment
224154898|NCT03073382|OTHER|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
224154899|NCT04263493|OTHER|Rehabilitation (physiotheraphy)|Time of loading, range of motion exercises, strength training
224154900|NCT00784459|DRUG|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
224154901|NCT00784459|DRUG|Placebo|Treatment with Placebo, IV
224154902|NCT05421091|OTHER|Asciminib|Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
224302439|NCT03557879|GENETIC|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
224302440|NCT00820443|DEVICE|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
224302441|NCT05643053|OTHER|thomas fixation|Use of the thomas tube holder for endotracheal tube fixation in patients operated in the prone position
224302442|NCT05643053|OTHER|elastic band|Use of the elastic band for endotracheal tube fixation in patients operated in the prone position
224302443|NCT05643053|OTHER|normal fixation adhesive tape|Use of the adhesive tape for endotracheal tube fixation in patients operated in the prone position
224302444|NCT05643053|OTHER|reinforced adhesive tape fixation|Use of the reinforced adhesive tape fixation for endotracheal tube fixation in patients operated in the prone position
224302445|NCT06632249|OTHER|Practice with the virtual reality game|4 weeks of practice with the virtual reality game, totalling 20 sessions, 5 supervised in the laboratory and 15 at home with remote monitoring.
224302446|NCT04556851|DRUG|HSK7653 10 mg Q2W|HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
223456352|NCT04608916|PROCEDURE|Using scalpel blade to make skin incision|Using scaple blade to make skin incision during shoulder arthroplasty
223456353|NCT00064103|BIOLOGICAL|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
223456354|NCT00064103|OTHER|laboratory biomarker analysis|Correlative studies
223456355|NCT02750332|DRUG|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
223456356|NCT01757860|DRUG|CARD-024|Comparison of different dosages of drug
223456357|NCT01757860|OTHER|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
223456358|NCT00160056|PROCEDURE|Hypoglycemia|
223456359|NCT02608996|DRUG|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
224154903|NCT01332695|DRUG|ST101|tablets for oral administration
224154904|NCT01332695|DRUG|Placebo|placebo to match
224154905|NCT04134377|OTHER|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
224154906|NCT03669146|DEVICE|Glasses|Partial refractive correction in a pair of glasses.
224154907|NCT01114698|DRUG|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
224154908|NCT01114698|DRUG|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
224154909|NCT01114698|DRUG|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
224154910|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
224154911|NCT01488188|BIOLOGICAL|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
224154912|NCT06103591|DEVICE|The EmStop Embolic Protection System (EmStop System)|The EmStop Embolic Protection System (EmStop System) is a catheter-based filter system that captures and removes debris dislodged during transcatheter aortic valve replacement (TAVR) procedures.
224154913|NCT02925208|OTHER|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
224154914|NCT00794859|DRUG|Sorafenib|400mg twice daily
224154915|NCT00221663|DEVICE|surgery techniques (sternotomy for aortic valve replacement)|
224154916|NCT02172846|RADIATION|Proton beam radiation therapy (PBT)|
224154917|NCT02172846|DRUG|Paclitaxel|
224154918|NCT02172846|DRUG|Carboplatin|
224154919|NCT02389530|DRUG|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
224154920|NCT02933372|DRUG|Varenicline|Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
224302447|NCT04556851|DRUG|HSK7653 25 mg Q2W|HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
224302448|NCT04556851|DRUG|Placebo|Placebo 25 mg (1 tablet) and placebo 5 mg (2 tablets), Q2W, oral, week 1 to week 24; HSK7653 25 mg (1 tablet), Q2W, oral, week 25 to week 52.
224154921|NCT01489228|DRUG|E1224|100 mg tablets
224154922|NCT01489228|DRUG|Benznidazole|100mg tablets
224154923|NCT01489228|DRUG|Placebo|tablets
224154924|NCT03820557|OTHER|Educational Intervention|Undergo Decision Counseling Program
224154925|NCT05092399|PROCEDURE|Bariatric Surgery|No study interventions
224154926|NCT03613818|BEHAVIORAL|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
224154927|NCT04882358|DEVICE|ALFAPUMP DSR (DIRECT SODIUM REMOVAL) SYSTEM|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis; sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
224154928|NCT04882358|DRUG|SGLT2 inhibitor|treatment with a standard dose of SGLT-2 inhibitor
224154929|NCT04039763|DEVICE|Dexcom G6|Realtime Continous Glucose Monitoring
224154930|NCT04039763|DEVICE|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
224154931|NCT03379441|DRUG|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
224154932|NCT04194515|DRUG|YH1|YH1 treatment for one month
224154933|NCT04194515|DRUG|metformin|metformin treatment for one month
224154934|NCT00956462|DRUG|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
224154935|NCT04424004|OTHER|COVID-19 PCR and serology testing|"1. PCR testing: participate will conduct at-home collection and return of self-administered nasal swabs for COVID-19 polymerase chain reaction (PCR) viral testing. Saliva specimens may replace the nasal swab specimen. Specimens will be collected at baseline and every 2 weeks in conjunction with questionnaire administration.~2. Serology testing: The same randomized participants will also provide a blood sample for serologic testing for SARS-CoV-2 IgG antibodies. Specimens will be collected by routine venipuncture at the MURDOCK Study office in Kannapolis, NC.Specimens for serology will be collected at baseline approximately 1 month after the first questionnaire and 2 weeks after the first nasal swab collection and COVID-19 PCR testing. Specimens for serology will be collected at least bi-monthly and up to monthly thereafter through a total study duration of 6, and up to 12, months."
224154936|NCT00676156|DRUG|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
224154937|NCT00676156|DRUG|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
224154938|NCT00676156|DRUG|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
224154939|NCT04105322|OTHER|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
224154940|NCT00470678|DRUG|ranibizumab|
224154941|NCT06156449|OTHER|Thyme oil|The composition of NV-2016 Coded Thyme Essential oil (Origanum vulgare) (GC-201900528) was obtained with Nature\&Nurture (10 µL) macra (Barcode No: 8697742121135, Registration No: 381751). Content of origanum vulgare oil used: 1.3% y-Terpinene, 2.7% p-Cymene, 5.6% linalool, 1.2% terpinen-4-ol, 1.2 borneol, 1.2% β-Bisabolene Contains 3.2% tymol and 75.7% carvacrol.
223572706|NCT04038892|OTHER|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
224154942|NCT00671970|DRUG|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs \& 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
224154943|NCT00468611|DRUG|MBP8298|500mg MBP8298 IV every six months for a period of two years
224154944|NCT02741310|DRUG|Placebo|Administered by intravenous infusion
224154945|NCT02741310|DRUG|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
224154946|NCT02741310|DRUG|Erenumab|Administered by intravenous infusion
224154947|NCT06393413|DRUG|Jiedu Yizhi Formula|Observation after 24 weeks of drug treatment
224154948|NCT06393413|DRUG|Donepezil Hydrochloride Tablets|Donepezil Hydrochloride Tablets
224154949|NCT00872781|DRUG|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
224154950|NCT00239356|DRUG|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
224154951|NCT02312011|DRUG|IONIS-DMPKRx|Drug
224154952|NCT02312011|DRUG|Placebo|Placebo
224154953|NCT04616092|DRUG|FEFINJECT|FEFINJECT injection
224154954|NCT03309904|OTHER|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
224154955|NCT02176980|BEHAVIORAL|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
224154956|NCT02176980|BEHAVIORAL|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
224154957|NCT05457400|DRUG|ENSO 16|30 g ENSO 16 dissolved in Water
224154958|NCT05457400|DRUG|Glucose Powder|30 g Glucose Powder dissolved in Water
224154959|NCT03998891|OTHER|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
224154960|NCT01378091|DRUG|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
224154961|NCT01378091|DRUG|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
224154962|NCT01378091|DRUG|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
224154963|NCT02044822|DRUG|Idelalisib|150 mg tablets administered orally twice daily
224154964|NCT02044822|DRUG|Rituximab|375 mg/m\^2 administered intravenously once weekly x 8 weeks
224154965|NCT04218513|DRUG|Compound Edaravone Injection|30 min intravenous infusion
224154966|NCT04218513|DRUG|Edaravone Injection|30 min intravenous infusion
224154967|NCT04218513|DRUG|2-Aminoethanesulfonic Acid Injection|30 min intravenous infusion
224154968|NCT00164099|DRUG|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
224154969|NCT02967172|DRUG|Ropivacaine|
224154970|NCT02967172|DRUG|Epinephrine|
224154971|NCT02967172|DRUG|Morphine|
224154972|NCT02967172|DRUG|0.9% sodium chloride solution|
224154973|NCT03417505|DEVICE|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
224154974|NCT03417505|DEVICE|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
224154975|NCT06950073|RADIATION|Radiotherapy|Radiotherapy is offered in the same dose to all patients eligible to reirradiation no matter if they are enrolled in the study or not. Meaning no intervention is done. This is a registration study.
224154976|NCT01650441|DRUG|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
224154977|NCT01650441|RADIATION|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
224154978|NCT06948331|DEVICE|PuraStat|Sterile gel composed of synthetic peptide and sterile water; provided as a prefilled syringe. The will be applied to the inside of the prostate to help stop bleeding following Aquablation.
224154979|NCT02100410|DEVICE|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
224154980|NCT02100410|DEVICE|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
224154981|NCT02100410|DEVICE|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
224154982|NCT02100410|DEVICE|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
224154983|NCT02100410|DEVICE|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
224154984|NCT02100410|DEVICE|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
224154985|NCT05423704|OTHER|Proton radiotherapy|Proton radiotherapy according to the guidelines defined by the Danish Head-Neck Cancer Group (DAHANCA). Treatment: 66-68 Gy/ 33-34 fx/ 6/W, with cisplatin 40 mg/m2/W and nimorazole to suitable patients
224154986|NCT01237223|DRUG|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
224154987|NCT01237223|DRUG|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
224154988|NCT01237223|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet
224154989|NCT01237223|DRUG|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
224154990|NCT01237223|DRUG|Placebo of Aliskiren|Aliskiren placebo tablet
224154991|NCT01237223|DRUG|Placebo of Amlodipine|Amlodipine placebo capsule
224154992|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
224154993|NCT01237223|DRUG|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
224154994|NCT04570228|DEVICE|Pulmonary artery denervation|The TIVUS system will be used for pulmonary artery denervation using non focused ultrasound
224154995|NCT04570228|DEVICE|Sham procedure|A sham procedure would be performed using the TIVUS system without delivering the non focused ultrasound
224154996|NCT02488356|DIETARY_SUPPLEMENT|Litramine|
224154997|NCT03288818|DRUG|Mechlorethamine Hydrochloride Gel|Given topically
224154998|NCT03288818|PROCEDURE|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
224154999|NCT05179343|DEVICE|Active AffeX-CT device|(Trans-cutaneous Autonomic Neurostimulation) tAN treatment will be administered using AffeX-CT device (a device based on a totally TENS unit). AffeX device comprises of a battery-operated control unit, two electrode pairs arranged on ear clips and connected to the control unit with electrical leads. The AffeX device generates an electrical signal that is used to stimulate the nerves that naturally control the output from the sympathetic nervous system.
224155000|NCT05179343|DEVICE|Sham AffeX-CT device|Sham Totally TENS device. The device is identical to the active device used in the study, but its only purpose is to act as a placebo. The ear-clip electrodes have been modified so that the electric current is not transmitted to the participant.
224155001|NCT05686044|DRUG|Buntanetap/Posiphen|HPMC (vegetarian source) capsule shells
224155002|NCT05686044|DRUG|Placebo|HPMC (vegetarian source) capsule shells
224155003|NCT02403713|DRUG|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
224155004|NCT02403713|DRUG|Formoterol|Formoterol
224155005|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
224155006|NCT02403713|DRUG|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
224155007|NCT02403713|DRUG|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
224155008|NCT00443846|BIOLOGICAL|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
224155009|NCT00443846|BIOLOGICAL|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
224155010|NCT04280484|OTHER|Intermittent Hypoxia|1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
224155011|NCT04280484|OTHER|Sham Hypoxia|1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
224155012|NCT06272357|OTHER|Antiarrhythmic drugs|Antiarrhythmic drugs in pediatrics
224155013|NCT05539924|DRUG|Pregabalin 150mg gabapentin 400mg|oral administration
224155014|NCT03612947|DRUG|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
224155015|NCT03612947|DRUG|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
224155016|NCT03395067|BEHAVIORAL|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
224155017|NCT04419662|DRUG|Phenylephrine|"Three time points: before, during and 20-30 minutes after infusion of phenylephrine.~Patients will receive an infusion of up to 1 mcg/kg/min phenylephrine intravenously to raise mean arterial pressure with 20 mmHg for 10 minutes. Infusion of phenylephrine will start at 0.1 mcg/kg/min with subsequent titration to effect."
224155018|NCT04419662|OTHER|Combination of PEEP and positioning|"Six time points based on combinations of the following:~Three different levels of PEEP (as set on the ventilator): 0, 6 and 12 mmHg. Two different positions: 1) torso elevated 30 degrees, legs horizontal and 2) torso horizontal, legs elevated 30 degrees."
224155019|NCT04314609|DEVICE|Ultrasonography, fluoroscopy|success rate of Ultrasound guided SIJ steroid injection confirmed by contrast spread in fluoroscopy
224155020|NCT05287204|DIAGNOSTIC_TEST|Musculoskeletal ultrasound|Ultrasound of rectus femoris to determine cross-sectional area, muscle thickness, echo intensity.
224155021|NCT05287204|DIAGNOSTIC_TEST|Assessments of muscle strength and physical function|A battery of tests of physical function and muscle strength (see outcomes section for details).
224155022|NCT05287204|DIAGNOSTIC_TEST|Metabolomics|Using metabolomic analysis, concentrations of amino acids and other important analytes will be measured in patient plasma and CRRT effluent
224155023|NCT00432211|DRUG|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
224155024|NCT04624217|DRUG|SHR-1701|PDL1/TGFβ
224155025|NCT00990249|DRUG|Busulfan|Test Dose 32 mg/m\^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
224155026|NCT00990249|DRUG|Clofarabine|40 mg/m\^2 by vein over 1 hour daily Day -6 through Day -3
224155027|NCT00990249|DRUG|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
224155028|NCT00990249|PROCEDURE|Stem Cell Transplant|Stem cell infusion on Day 0.
224302449|NCT01959854|DEVICE|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
224302450|NCT01959854|DEVICE|xanthan gum|0.2% xanthan gum preservative free
224302451|NCT02033057|PROCEDURE|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
224302452|NCT05063435|DIAGNOSTIC_TEST|Carotid ultrasonography|"1. Study takes 10 - 15 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The ultrasound probe will be placed on one side of the neck to capture images of the carotid artery. When images from one side have been captured, the probe will be moved to the other side of the neck to capture images from the other carotid artery.~4. Blood pressure and heart rate will be obtained during the study~5. Results will be anonymized, digitized and stored on CD with unique identifier"
224155029|NCT04716478|OTHER|Clinical and radiological data collection|No specific intervention. Data of the usual care will be collected as the demographic data, the medical history, imaging report, etc.
224155030|NCT02714608|DRUG|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
224155031|NCT02714608|DRUG|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
224155032|NCT02714608|DRUG|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
224155033|NCT00543868|DRUG|MK0782|
224302453|NCT05063435|DIAGNOSTIC_TEST|Echocardiography, transthoracic|"1. Study takes 15 - 20 minutes to complete~2. Subject will be asked to lay still and quietly during procedure~3. The technician will apply an ultrasound probe to the chest. Images and movies will be acquired.~4. Results will be digitized and stored on CD"
223456360|NCT02608996|DRUG|Placebo|For comparison to elucidate the true effect of nesiritide
223456361|NCT01751321|DRUG|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
223456362|NCT03975504|DEVICE|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
223456363|NCT03975504|DEVICE|artificial intelligence (AI)|AI was performed in high-risk individuals recruitment and lung nodules management
224155034|NCT04583969|BIOLOGICAL|Lenzilumab|Lenzilumab is a first-in-class recombinant monoclonal antibody targeting soluble human GM-CSF, with potential immunomodulating activity, high binding affinity in the pM range, and 94% specificity to the human germline, which reduces immunogenicity.
224155035|NCT04583969|OTHER|Placebo|Placebo for lenzilumab is commercially sourced 0.9% sodium chloride.
224155036|NCT04583969|DRUG|Remdesivir|Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
224155037|NCT05430204|DEVICE|Group 1: one-hour GCT|Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be diagnosed with GDM and treated according to the standard of care. This group will also receive the CGM.CGM data will not be observed until completion of study and will not be available to provider. Participants will return transmitter at follow up visit after completion of 7 days.Group I will receive routine prenatal care follow-up depending upon one-hour glucose results as written above.
224155038|NCT05430204|DEVICE|Group 2: CGM placement|"CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after placement.The device will be reviewed by the Diabetes team 48 hours after CGM is removed. The recommended range for glucose during pregnancy is defined as 63-140 mg/dL .The time above range has been defined as ≥ 140 mg/dL, greater than 10% of total CGM placement time. The following criteria will currently be used to diagnose gestational diabetes in the CGM group:~* Time above range (≥140 mg/dL) ≥ 10% of the time while using CGM or~* Average glucose≥130 mg/dL or~* Any glucose value ≥200 mg/dL"
224155039|NCT05658419|PROCEDURE|socket sheild|the socket shield technique, in which a partial root fragment was retained around an immediately placed implant with the aim of avoiding tissue alterations after tooth extraction. Histologic evaluation in a beagle dog showed no resorption of the root fragment and new cementum formed on the implant surface.
224155040|NCT04485468|OTHER|Questionnaire|The patient answers the questionnaire directly following his consultation or teleconsultation or may arrange a telephone appointment with the clinical research associate a little later.
224155041|NCT03086148|DRUG|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
224155042|NCT03086148|DRUG|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
224155043|NCT02697058|BIOLOGICAL|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
224155044|NCT02697058|DRUG|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
224155045|NCT00718250|BIOLOGICAL|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
224155046|NCT00718250|BIOLOGICAL|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
224155047|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
224155048|NCT00718250|BIOLOGICAL|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
224155049|NCT04249284|DRUG|BMS-986165|Specified dose on specified days
224155050|NCT04249284|DRUG|BMS-986165 prototype 1|Specified dose on specified days
224155051|NCT04249284|DRUG|BMS-986165 prototype 2|Specified dose on specified days
224302454|NCT05063435|PROCEDURE|Venipuncture|"1. 10 mL of blood total will be drawn (5 mL in a blue top citrate tube, 5 mL in a purple top EDTA tube). Measurements of cytokines, clusterin, lipidomics, cathepsin S protease, and elastin (previously identified potential biomarker candidates) will be performed.~2. Blood will preferably be drawn via venipuncture, but if patient has a port-a-cath already implanted and is having blood drawn via port-a-cath for clinically required reasons, then study-related blood draw via port-a-cath can take place concurrently with clinically required blood draws."
223456364|NCT03975504|DIAGNOSTIC_TEST|autofluorescence imaging (AFI)|AFI applied in screening of centrally located SCC.
224302455|NCT05530343|DIAGNOSTIC_TEST|Seattle protocol|Participants undergo 4-quadrant biopsies with standard biopsy forceps taken at 2 cm intervals. For participants undergoing a confirmatory endoscopy for cases in which discordant results are noted (WATS3D positive for dysplasia/cancer and Seattle biopsy negative for dysplasia/cancer), repeat biopsies will be taken at 1 cm intervals along with target biopsies from any visible lesions.
223456365|NCT01060189|DRUG|Ulinastatin|
224155052|NCT05228756|OTHER|Accelerometer|Participants will complete 16 exercise sessions at home wearing an accelerometer
224302456|NCT05530343|DIAGNOSTIC_TEST|WATS3D brushings|Participants undergo 2 WATS3D biopsies of every 5 cm segment of Barrett's esophagus, starting from the gastroesophageal junction and moving proximally through the entire segment of Barrett's.
224302457|NCT02077218|PROCEDURE|computed tomography|Undergo cardiac CT
224302458|NCT02077218|OTHER|cytology specimen collection procedure|Undergo collection of blood samples
224302459|NCT02077218|OTHER|laboratory biomarker analysis|Correlative studies
224302460|NCT02077218|OTHER|questionnaire administration|Ancillary studies
223456366|NCT01060189|DRUG|Tranexamic Acid|
223456367|NCT01060189|DRUG|Saline Solution|
223456368|NCT00983645|DRUG|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
223456369|NCT00983645|DRUG|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
223456370|NCT02397941|OTHER|Ultrasound|ultrasound measures
223456371|NCT01304134|DRUG|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
223456372|NCT01304134|DRUG|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
223572707|NCT03546504|BEHAVIORAL|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
224155053|NCT01228188|PROCEDURE|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
224155054|NCT04397796|BIOLOGICAL|BM-Allo.MSC|BM-Allo.MSC for Infusion, is manufactured from normal donor derived bone marrow product and are phenotypically CD73+, CD90+, CD105+, and negative for CD14-, CD34-, CD45-, HLA-DR-.
224155055|NCT04397796|BIOLOGICAL|Placebo|plasmalyte and human albumin
224155056|NCT04255966|DEVICE|Plasmafit® Revision Structan®|Plasmafit® Revision Structan® Hip Endoprosthesis Cup
224155057|NCT05582551|OTHER|Highlighting Patients at Risk for Sensory Screening (HPARSS)|Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
224155058|NCT05885048|DIAGNOSTIC_TEST|Blood samples for analysis|Test hormone levels in blood
224155059|NCT05885048|DIAGNOSTIC_TEST|Sperm samples for analysis|Spermiogram
224155060|NCT05885048|OTHER|Satisfaction evaluation|Participant satisfaction assessment
224155061|NCT05885048|OTHER|Quality of Life questionnaire|The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)
224155062|NCT03000634|DRUG|Elotuzumab|Administered through a small tube that goes directly into the vein
224155063|NCT03000634|DRUG|Bortezomib|Administered as a subcutaneous injection under the skin
224155064|NCT03000634|DRUG|Lenalidomide|Capsule taken by mouth
224155065|NCT03000634|DRUG|Dexamethasone|Taken by mouth
224155066|NCT02808013|DRUG|NDS-446|
224155067|NCT02808013|DRUG|Placebo|
224155068|NCT02640755|DRUG|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
224155069|NCT02640755|DRUG|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
224155070|NCT02640755|DRUG|Fulvestrant|Hormonal Agent
224155071|NCT02640755|DRUG|Paclitaxel|Taxane
224155072|NCT00442182|DRUG|ITF2357|
224155073|NCT03023241|PROCEDURE|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
224155074|NCT03869671|BEHAVIORAL|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
223456373|NCT02019342|OTHER|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
223456374|NCT02019342|OTHER|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
224155075|NCT03869671|BEHAVIORAL|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
224155076|NCT05851794|PROCEDURE|endomanometric guided LNF|use of endomanometry during LNF
224155077|NCT05851794|PROCEDURE|laparoscopic Nissen fundoplication alone|laparoscopic Nissen fundoplication alone
224155078|NCT03819270|DRUG|LY3372689|Administered orally
224155079|NCT03819270|DRUG|Placebo|Administered orally
224155080|NCT03942146|BEHAVIORAL|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
224155081|NCT01391455|PROCEDURE|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
224155082|NCT00001669|DRUG|rhIGF-1 (CEP-151)|
224155083|NCT02062372|DEVICE|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
224155084|NCT02062372|PROCEDURE|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
224155085|NCT00397553|DRUG|Insulin glulisine|
224155086|NCT03722992|OTHER|MBSR|Guided yoga and meditation practices
223456375|NCT06517498|OTHER|No Intervention|No Intervention will be conducted
223456376|NCT01520207|DRUG|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
223456377|NCT01520207|DRUG|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
224155087|NCT05024890|OTHER|Splash WASH in Schools programme (Project WISE)|"The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide"
224155088|NCT01994278|DEVICE|Peri Clean|
224155089|NCT06651645|OTHER|COVID-19 Surge|Impact of COVID-19 pandemic on hospital care delivery
224155090|NCT03509623|DIAGNOSTIC_TEST|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
224155091|NCT05438706|DRUG|chidamide|Chidamide, an HDAC inhibitor
224155092|NCT05438706|DRUG|camrelizumab|Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer.
224155093|NCT05438706|DRUG|carboplatin|Carboplatin \[diammine(1,1-cyclobutanedicarboxylato)platinum(II)\] is one of the most promising second generation platinum compounds. Its greater chemical stability in comparison with cisplatin accounts for its lower reactivity with nucleophilic sites of DNA.
224155094|NCT05438706|DRUG|capecitabine|Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or pharmacodynamics and account for differences in treatment response and adverse events among patients.
224155095|NCT06221436|BEHAVIORAL|Mental Imagery|"Olfactory mental imagery is the ability to detect an odor in the absence of any odor stimulus.~Participants will be asked to choose their 4 favorite fragrances from 20 different scents (such as rose, lavender scent) determined by the researcher and proven to have positive effects on mind-body therapy. The determined odors will be visualized by the researcher and picture cards measuring 15X12 cm (for example, a card with a rose picture for the rose smell, etc.) will be created. Participants will visualize the smell by looking at the picture cards, so they will be expected to make their breathing exercises more effective. Vagus breathing technique will be combined with olfactory mental imagery."
224155096|NCT05952999|OTHER|Digital Care Solution as supportive personalized care|Patients will need to meet screening and inclusion criteria at time of enrollment. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
224155097|NCT05952999|OTHER|Traditional Hospital Level Care|Patients will be cared for in the inpatient setting for management of diseases that meet screening and inclusion criteria at time of enrollment for hospital at home. As a pragmatic study, researchers will not determine criteria or management of care aspects for patients.
224155098|NCT04883697|OTHER|vitrectomy with ILM peeling and ILM flap technique|outcomes after vitrectomy with ILM peeling and ILM flap technique for macukar hole repair are assessed
224155099|NCT00141206|DRUG|varenicline (CP-526,555)|
224155100|NCT02256345|DRUG|KNO3|Active Comparator
224155101|NCT02256345|DRUG|KCl|Placebo Comparator
224155102|NCT04516941|DRUG|Edoxaban Tablets|Treatment
224155103|NCT04516941|DRUG|Colchicine Tablets|Treatment
224155104|NCT04931550|DEVICE|Pacemaker implantation|Different pacing sites will be chosen according to the patients condition.
224155105|NCT03481504|BEHAVIORAL|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
224155106|NCT04903704|DIAGNOSTIC_TEST|1 Minute Sit to Stand Test|Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
224155107|NCT02262338|DRUG|AGT-182|Recombinant HIRMAb-IDS
224155108|NCT02552667|DRUG|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
223456378|NCT00423280|DRUG|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
223456379|NCT04203212|DRUG|Goserelin Acetate|Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
223456380|NCT01706835|DRUG|aldoxorubicin|
223456381|NCT00473057|OTHER|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
223456382|NCT01882296|DRUG|AGSPT_10|AGSPT 10mg for 7days administration
223456383|NCT01882296|DRUG|AGSPT_20|AGSPT 20mg for 7days administration
224155109|NCT02552667|DRUG|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
223456384|NCT01882296|DRUG|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
223456385|NCT01882296|DRUG|Pantoprazole_20|Pantoprazole 20mg for 7days administration
223456386|NCT01882296|DRUG|Pantoprazole_40|Pantoprazole 40mg for 7days administration
223456387|NCT01795794|DRUG|omeprazole|
223456388|NCT04819789|OTHER|Fermotein™ dry powder porridge|At one out of four test days: Fermotein™ dry powder mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
223456389|NCT04819789|OTHER|Fermotein™ wet porridge|At one out of four test days: Fermotein™ wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
223456390|NCT04819789|OTHER|Fermotein™ modified wet porridge|At one out of four test days: Fermotein™ modified wet mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
223456391|NCT04819789|OTHER|Mycoprotein porridge (matching control)|At one out of four test days: Mycoprotein (Quorn) mixed with water and a few drops of food grade flavor concentrates, to obtain a porridge representing a 20g protein load.
224155110|NCT01599572|OTHER|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
224155111|NCT00878891|DEVICE|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
224155112|NCT03275415|DRUG|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
224155113|NCT03275415|DRUG|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
224155114|NCT00758407|DRUG|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
224155115|NCT00758407|DRUG|Placebo|dosage according to an individual titration schedule
224155116|NCT01402388|BEHAVIORAL|Group lifestyle programme|
224155117|NCT01154907|DRUG|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
224155118|NCT02420990|BEHAVIORAL|Medication Integration Protocol (MIP)|
224155119|NCT02420990|BEHAVIORAL|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
224155120|NCT04602819|DEVICE|PicoSure 755nm picosecond alexandrite laser with diffractive lens|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
224155121|NCT04602819|DEVICE|ApolloVue® S100 Image System|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
224155122|NCT04602819|DEVICE|Cutometer® dual MPA 580|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
224155123|NCT04602819|DEVICE|VISIA®|Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
224155124|NCT02788851|DRUG|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
224155125|NCT02788851|BEHAVIORAL|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
224155126|NCT04803890|PROCEDURE|"No-Touch Radiofrequency Ablation"|"No-Touch Radiofrequency Ablation Using Octopus Electrodes and Combined RF Energy Delivery Mode"
224155127|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
224155128|NCT02955771|COMBINATION_PRODUCT|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
224155129|NCT02955771|DEVICE|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
224155130|NCT03385408|DEVICE|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
224155131|NCT03385408|DEVICE|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
224155132|NCT02680392|PROCEDURE|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
224155133|NCT02680392|DRUG|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
224155134|NCT03792802|PROCEDURE|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
224155135|NCT04159922|OTHER|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
224155136|NCT04740333|OTHER|No intervention- observational study|No intervention- observational study
224155137|NCT01592006|DRUG|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
223743031|NCT03560050|BEHAVIORAL|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
224066688|NCT03046875|OTHER|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
224066689|NCT03046875|OTHER|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
224066690|NCT01554137|OTHER|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
224066691|NCT01554137|OTHER|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
224066692|NCT02559687|BIOLOGICAL|pembrolizumab|IV Q3W
224066693|NCT05679635|DEVICE|Evone|The conventional tube adapter (CTA) from the Evone ventilator (Ventinova Medical B.V., Eindhoven, The Netherlands), equipped with an tracheal pressure measurement catheter will be connected to the tracheal tube of intubated intensive care unit patients. Subsequently tracheal pressure values will be displayed and recorded from the ventilator.
224066694|NCT05679635|DEVICE|Evita Infinity V500|Displayed airway pressure values will be directly recorded from the Evita Infinity V500 ventilator (Dräger Medical, Lübeck, Germany)
224066695|NCT03245073|OTHER|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
224066696|NCT03245073|OTHER|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
224066697|NCT03001674|DEVICE|Conductance catheterization|CD Leycom Conductance Catheter
224066698|NCT03224273|OTHER|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
224066699|NCT05204966|DIAGNOSTIC_TEST|AI analysis|"1. Bottle feeding filming~   \- With a camera that can measure depth, take a video of feeding milk from a bottle for 5-10 minutes.~2. NOMAS (Neonatal Oral-Motor Assessment Scale) evaluation~   * Evaluate NOMAS with bottle feeding video by certified evaluators.~  * NOMAS, developed by Marjorie Meyer Palmer in 1983, is an evaluation method for dysphagia applicable to infants under 48 weeks of PMA.~3. Implementation of video analysis using deep learning (A) Analysis method - Implement a deep learning network that sets keypoints of faces and environments related to swallowing and detects specified keypoints in units of frames.~(B) Analyze the movement of key points, and figure out the correlation between swallowing states.~(C) Create an input/output process that can automatically classify swallowing states with video as input."
224066700|NCT01702610|RADIATION|IMRT Technique|
224066701|NCT01702610|RADIATION|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
224066702|NCT01702610|RADIATION|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
224066703|NCT01702610|DRUG|Temozolomide and Accelerated Hypofractionation RT|
224066704|NCT04344587|OTHER|Self-prone position recommendation|"The Qualtrics self-prone position recommendation intervention website will include the following sections:~1. Welcome message~2. Educational review of the potential benefits of prone positioning~3. How-To guide to safely prone in a hospital bed~4. A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~5. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
224066705|NCT04344587|OTHER|Usual care|"The Qualtrics usual care website will include the following sections:~1. Welcome message~2. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking"
224066706|NCT03285737|DIETARY_SUPPLEMENT|Whey|Supplement provided twice daily in 30g doses
224066707|NCT03285737|DIETARY_SUPPLEMENT|Collagen|Supplement provided twice daily in 30g doses
224066708|NCT05324046|DIAGNOSTIC_TEST|contrast-enhanced abdomen CT|"contrast-enhanced abdomen CT using dual-source CT scanner using A-tube (67% radiation) and B-tube (33% radiation).~* full dose CT data (A +B tubes, 100%) are reconstructed with iterative reconstruction (conventional)~* low dose CT data (A-tube only, B-tube only) are reconstructed with deep learning commercially available software.~* images are reconstructed using full dose (A- \& B- tubes) and smaller dose (A-tube only, B-tube only)"
224066709|NCT03971201|PROCEDURE|hepatic resection|removal of portion of liver containing cancer
224066710|NCT03971201|DRUG|Sorafenib|sorafenib either as adjuvant therapy after resection or as only treatment
224066711|NCT00620412|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10\^10 LGG organisms.
224066712|NCT00620412|DIETARY_SUPPLEMENT|placebo control|2 capsules by mouth twice a day for 28 days
224066713|NCT00620412|BIOLOGICAL|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
224155138|NCT01592006|DRUG|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
223456392|NCT01684514|DEVICE|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
224066714|NCT03919708|DEVICE|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
223456393|NCT04330144|DRUG|Hydroxychloroquine as post exposure prophylaxis|1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
224066715|NCT00940407|DEVICE|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
224066716|NCT00881400|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
224066717|NCT00881400|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
224066718|NCT05051774|BEHAVIORAL|1. Education|Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
224066719|NCT05051774|BEHAVIORAL|2. Exercise|"The exercise intervention comprised of two elements as follows:~1. Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~2. Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week."
224066720|NCT05051774|BEHAVIORAL|3. Telephone follow-up|A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
224066721|NCT03760900|COMBINATION_PRODUCT|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth
224066722|NCT05006469|DRUG|Bendamustine|Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
224066723|NCT02742285|DRUG|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
224066724|NCT04472585|DRUG|Ivermectin Injectable Solution|Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
224066725|NCT04472585|OTHER|Injectable Placebo|0.9% normal saline
224066726|NCT04472585|DRUG|Zinc|Zinc Sulphate 20mg 3 times a day
224066727|NCT04472585|DRUG|Placebo empty capsule|Placebo empty capsule
224066728|NCT04472585|DRUG|Oral Ivermectin|0.2mg/kg/day
224066729|NCT03668483|OTHER|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
224066730|NCT04025827|OTHER|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
224066731|NCT00222183|DRUG|Elidel (pimecrolimus)|
224066732|NCT03072056|DRUG|MIN-101|
224066733|NCT00001287|DRUG|intravenous immunoglobulin (IVIg)|
224066734|NCT01968135|DRUG|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
224066735|NCT01968135|DRUG|Placebo Sugar Pill|Placebo Sugar Pill
224066736|NCT01780831|DRUG|Raltegravir|RAL was given as oral granules for suspension.
224066737|NCT04481529|OTHER|Health Questionnaire|Completion of a short questionnaire noting the result of the serology and looking for elements in favor of exposure to the virus, whether professional or extra-professional.
224066738|NCT05101603|DEVICE|Air Abrasive|Applied with Nd:YAG Laser on periodontal pockets
224066739|NCT05101603|DEVICE|Nd:YAG Laser|Applied with Air Abrasive on periodontal pockets
224066740|NCT05101603|PROCEDURE|Non surgical periodontal therapy|The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
224066741|NCT04612010|DEVICE|WAVES (Wobble-oscillator Auditory/Visual Excitatory Stimulation)|An app-based stimulation program administered that provides desynchronizing visual and auditory stimulation. The frequency of the stimulation oscillates around the baseline frequency determined by EEG.
223456394|NCT04330144|OTHER|Others(No intervention)|No treatment. Close monitoring and quarantine.
224066742|NCT04993365|BIOLOGICAL|Experimental Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
224066743|NCT04993365|BIOLOGICAL|Control Group|The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
224066744|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
223456395|NCT01289327|DRUG|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
223456396|NCT04474808|OTHER|L-Arginin containing foot cream|The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
224066745|NCT03690765|DRUG|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
224066746|NCT00723970|DRUG|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
224066747|NCT03330886|DRUG|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
224066748|NCT04057274|OTHER|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
224066749|NCT02559466|DEVICE|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
224066750|NCT02559466|DEVICE|Positon Emission Tomography (PET) - Discovery 710®|Class IB
224066751|NCT02585011|DRUG|Ropivacaine|
224066752|NCT02585011|DRUG|Epinephrine|
224066753|NCT02585011|DRUG|Saline|
224066754|NCT06409312|DEVICE|Akina Cloud|Akina Cloud is a digital health application that supports the therapeutic training of people with musculoskeletal conditions. It provides two therapeutic training programs for patients, one for each specific indication. Patients have continuous access to these programs through Akina Cloud, allowing them to independently complete nine training sessions without supervision. A minimum of three sessions per week is recommended, but patients have the option to engage in daily sessions if preferred. These therapy programs are based on current treatment guidelines and supported by relevant scientific research. They include customizable physical exercises tailored to individual needs and difficulty levels. Patients receive audio-visual guidance during these exercise sessions to ensure proper execution. Exercise therapy has demonstrated its ability to reduce pain, improve physical function, and enhance the overall quality of life for patients suffering from back pain and hip osteoarthritis.
224066755|NCT04995393|PROCEDURE|Heating with a disposable glove containing water|Heating of the infants heel with a glove before blood sampling.
224066756|NCT04995393|PROCEDURE|Heating with a blanket|Heating of the infants heel with a blanket before blood sampling.
224066757|NCT04995393|PROCEDURE|Heating with a gel pack|Heating of the infants heel with a gel pack before blood sampling.
224066758|NCT02281695|OTHER|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
224066759|NCT02128230|DEVICE|myPRS|Genome expression profiling used to identify high-risk and low-risk multiple myeloma
224066760|NCT02128230|DRUG|Induction 1 - MEL-10+CFZ-TD-PACE|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days 1, 5, \& 6; MEL 10mg/m2 on day 3; T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 400 mg/m2/d, and E 40 mg/m2/d on days 5-8; G-CSF 10 mcg/kg/day from day 11 through end of Peripheral Blood Stem Cell (PBSC) collection.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 1st transplant."
224066761|NCT02128230|DRUG|First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until inter-therapy."
224066762|NCT02128230|DRUG|Inter-Therapy - MEL-20+CFZ-TD-PACE (75%)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 27 mg/m2 on days 1-2; MEL 5 mg/m2/d, T 200 mg/d, D 20 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 75 mg/m2/d, and E 60 mg/m2/d on days 1-4.~Optional Bridging with T 50 mg/d and D 20 mg on day 1-4 every 21 days until 2nd transplant."
224155139|NCT01592006|DRUG|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
223456397|NCT04474808|OTHER|Urea-containing foot cream|The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
224155140|NCT00747539|DRUG|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
224155141|NCT04355026|DRUG|Bromhexine Oral Tablet and/or hydroxychloroquine tablet|bromhexine 16 mg TID hydroxychloroquine 200 mg BID
224155142|NCT03107598|DRUG|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
224155143|NCT01277471|BEHAVIORAL|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
224155144|NCT01277471|BEHAVIORAL|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
224155145|NCT02783417|OTHER|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
224155146|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - single-session
224155147|NCT00682240|PROCEDURE|laser treatment with PASCAL®|panretinal laser treatment - multi-session
224155148|NCT00682240|PROCEDURE|laser treatment with PASCAL®|grid / focal laser treatment
224155149|NCT00682240|PROCEDURE|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
224155150|NCT02938221|DEVICE|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
224155151|NCT02157103|DRUG|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
224155152|NCT02858284|DEVICE|TUG|Therapeutic Ultrasound for Glaucoma
224155153|NCT02858284|DEVICE|Sham|
224155154|NCT02648243|BEHAVIORAL|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
224155155|NCT03625089|DRUG|Atorvastatin|"Group 1 patients will be prescribed statin when FRS \> 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS\>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
224155156|NCT03518489|DRUG|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
224155157|NCT03518489|DRUG|standard care|Standard care will include mouth wash with antibiotics.
224155158|NCT05480241|DRUG|Pancreatic Enzyme Replacement Therapy|Pancreatic Enzyme Replacement Therapy (PERT) 50000 Ph.U./meal + 25000 Ph.U./snack + Omeprazole 20mg once daily on fasting
224155159|NCT05480241|DRUG|Placebo|Placebo + Omeprazole 20mg once daily on fasting
224155160|NCT05704842|BEHAVIORAL|Exercise|Home-based exercise program including core exercises as follows: Core Stabilization, core extension, leg extensions, squats with and without weights, shoulder and arm exercises.
224155161|NCT06037512|DIAGNOSTIC_TEST|subject|blood glucose measurement by subject
224155162|NCT06037512|DIAGNOSTIC_TEST|reference|blood glucose measurement with reference
224155163|NCT02522078|DRUG|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
224155164|NCT02522078|DRUG|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
224155165|NCT01921452|DEVICE|Quantitative POC TSH Kit|A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
224155166|NCT01921452|DEVICE|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
224155167|NCT01921452|DEVICE|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
224155168|NCT02019745|BIOLOGICAL|LAIV|Standard dose of LAIV administered by a licensed health care providers.
224155169|NCT00493155|DRUG|RG1530|Administered po at escalating doses (10 cohorts)
224155170|NCT06431412|OTHER|no intervention|no intervention
224155171|NCT04815733|PROCEDURE|Mandatory ventilation|Use PCV-VG
224155172|NCT04815733|PROCEDURE|pressure support ventilation|Use PSVpro
224155173|NCT01525667|BIOLOGICAL|150M PLX-PAD|Single course, multiple IM injections
224155174|NCT01525667|BIOLOGICAL|300M PLX-PAD|Single course, multiple IM injections
224155175|NCT01525667|BIOLOGICAL|Placebo|Single course, multiple IM injections
224155176|NCT04971369|DIAGNOSTIC_TEST|89Zr-NY001|89Zr-NY001 injection followed by 89Zr-NY001 PET scan
224155177|NCT00426933|DRUG|Daptomycin|
224302461|NCT05501990|BEHAVIORAL|Health intervention based on intelligent applet|Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
224155178|NCT00426933|DRUG|Vancomycin|
224155179|NCT03809247|OTHER||have no any intervention
224155180|NCT03226548|OTHER|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
224155181|NCT03301233|DRUG|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
224155182|NCT00770224|BIOLOGICAL|rituximab|
224155183|NCT00770224|BIOLOGICAL|tositumomab|
224155184|NCT00770224|DRUG|cyclophosphamide|
224302462|NCT05177302|OTHER|HAGOS-C|The subjects will be instructed to complete HAGOS-C at the initial contact and again after 1 week and 4 month for reliability and responsiveness test, respectively
224155185|NCT00770224|DRUG|doxorubicin|
224155186|NCT00770224|DRUG|prednisone|
224155187|NCT00770224|DRUG|vincristine|
224155188|NCT00770224|RADIATION|tositumomab|
224155189|NCT03954379|DRUG|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~IV propofol for sedation~INTERVENTION AFTER SURGERY~Injection of salty water through the tube in the thigh x 2"
224155190|NCT03954379|DRUG|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~1. Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~2. iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~1. IV dexmedetomidine~2. IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~1. injection of freezing medication through the tube in the thigh x 2~2. IV dexamethasone 8 mg 1 day after surgery"
224155191|NCT03954379|PROCEDURE|Periarticular Local Anesthetic Infiltration|INTERVENTION DURING SURGERY
224155192|NCT03954379|DRUG|IV Dexamethasone 8mg at the end of surgery as standard of care|INTERVENTION DURING SURGERY
224155193|NCT00517218|DRUG|Genasense® (, oblimersen sodium G3139)|
224155194|NCT00395213|DRUG|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
224155195|NCT01484561|DRUG|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
224155196|NCT01484561|DRUG|Placebo|Placebo BID orally, approximately 72 days
224155197|NCT03854851|DRUG|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
224155198|NCT03854851|DRUG|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
224155199|NCT01712503|DEVICE|Phacoemulsfication cataract surgery and intra-ocular lens implant|
224302463|NCT05177302|OTHER|SF-36v2|The subjects will be instructed to complete SF-36v2 at the initial contact to determine the validity of HAGOS-C
224302464|NCT05349643|BIOLOGICAL|AMB-05X|A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
224155200|NCT01784614|DRUG|LY2624803 - Solution|Administered orally as reconstituted solution
224155201|NCT01784614|DRUG|LY2624803 - Capsule|Administered orally as a capsule
224155202|NCT01784614|DRUG|Placebo - Solution|Administered orally as solution
224155203|NCT01784614|DRUG|Placebo - Capsule|Administered orally as a capsule
224155204|NCT05569616|OTHER|Hand massage|Hand massage is a simple comfort intervention that involves touch and conveys care that can easily be incorporated independently into routine nursing care activities. Hand massage is a western technique that includes five basic classical massage manipulations, including eufluorage, petrissage, friction, tapotman and vibration. Kolcaba et al. (2006) hand massage procedure will be applied with baby oil for 20 minutes, three times a week (12 times in total) for 4 weeks.
224155205|NCT05569616|OTHER|Play activity|The number of people for the Jenga game was determined as two people in order to strengthen the social relationship among the elderly and to strengthen their psychomotor skills. Each game will be played with two people. For this reason, the elderly will be divided into five separate groups, two people each.These groups will be played the Jenga game for one hour a week on a certain day of the week, accompanied by the researcher, during the activity hours determined by the nursing home. After the game activity (Jenga) application is completed at the end of the fourth week, the post-test scales will be re-administered to the elderly by the researcher.
224155206|NCT05929638|BEHAVIORAL|lavender oil|The patients participating in the study were provided with the steps of applying lavender oil by inhalation, the points to be considered during the application, and the application was done in the same way by all patients.
224155207|NCT00162513|BIOLOGICAL|Allogeneic tumor cell vaccine|
224155208|NCT00220454|DRUG|Climara|
224155209|NCT00220454|DRUG|Hydrocortone|
224155210|NCT03371251|DRUG|BOS161721|SC administration
224155211|NCT03371251|DRUG|Placebo|SC administration
224155212|NCT01476761|DEVICE|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
224155213|NCT01233570|DRUG|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
224155214|NCT02915640|OTHER|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
224155215|NCT04125875|DIAGNOSTIC_TEST|Electrogastrogram(EGG)|Heart Rate Variability
224155216|NCT04125875|DIAGNOSTIC_TEST|Heart Rate Variability(HRV)|Heart Rate Variability
224155217|NCT00114218|DRUG|Gemcitabine Hydrochloride|Given IV
224155218|NCT00114218|DRUG|Docetaxel|Given IV
224066763|NCT02128230|DRUG|Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)|"Melphalan (MEL) and Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and Dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), Adriamycin (A), Cyclophosphamide (C) and Etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter. After completion of the continuous chemotherapy, Granulocyte colony-stimulating factor (G-CSF), a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy, will be given.~Regimen: CFZ 20 mg/m2 on days -5 \& -4; MEL 20 mg/m2/d, T 200 mg/d, D 40 mg/d, P 10 mg/m2/d, A 10 mg/m2/d, C 100 mg/m2/d, and E 80 mg/m2/d on days -5 \& -2; PBSC transplant on day 0.~Optional Bridging with T 50mg/d and D 20 mg on day 1-4 every 21 days until consolidation."
224066764|NCT02128230|DRUG|Consolidation - CFZ-TD-PACE|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) is a capsule and dexamethasone (D) is a pill; both will be taken by mouth. Cisplatin (P), adriamycin (A), cyclophosphamide (C) and etoposide (E) are all given into the vein (IV) by a continuous infusion through a central catheter.~Regimen: CFZ 27 mg/m2 on days 1-2; T 200 mg/d, D 40 mg/d, P 7.5 mg/m2/d, A 7.5 mg/m2/d, C 300 mg/m2/d, and E 30 mg/m2/d on days 1-4."
224066765|NCT02128230|DRUG|Maintenance - CFZ-R(T)-D|"Carfilzomib (CFZ) will be given into a central venous catheter. Thalidomide (T) and lenalidomide (R) are capsules and dexamethasone (D) is a pill; all will be taken by mouth.~Regimen: For Cycles 1-12 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22; lenalidomide (R) 15 mg/d on days 1-21. For Cycles 13-24 CFZ 27 mg/m2/wk and D 12 mg/wk on days 1, 8, 15, \& 22. T may be substituted for R at 100 mg/day at the treating physician's discretion."
224066766|NCT01200901|DRUG|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
224066767|NCT04749459|DRUG|ChapStick Moisturizer, Strawberry Flavor|A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.
224066768|NCT04749459|DRUG|ChapStick Moisturizer, Classic Flavor|A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
224066769|NCT04749459|DRUG|ISO 24444:2010 P2 Standard Reference Sunscreen|A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
224066770|NCT00097760|DRUG|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
224066771|NCT00097760|DRUG|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
224066772|NCT00097760|DRUG|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
224066773|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|iPACK block + Adductor Canal Block
224066774|NCT06302218|DRUG|Ropivacaine 0.2% Injectable Solution|Erector Spinae Plane Block
224066775|NCT06302218|DRUG|control group|only spinal anesthesia
224066776|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
224066777|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
224066778|NCT01356914|DRUG|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
224155219|NCT01068613|DRUG|QAX028|QAX028 60 mcg via inhalation device
224155220|NCT01068613|DRUG|QAX028|QAX028 20 mcg via inhalation device
224066779|NCT01356914|DRUG|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
224066780|NCT02991092|PROCEDURE|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
224066781|NCT06437678|DRUG|Liposomal Irinotecan Hydrochloride|Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
224066782|NCT04901299|DRUG|NERATINIB|Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol
224066783|NCT04901299|DRUG|FULVESTRANT|Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
224066784|NCT06339879|OTHER|High Whole Grain, Low Sugar|6 servings of whole grain and \<13% energy from added sugars.
224066785|NCT06339879|OTHER|Low Whole Grain, Low Sugar|3 servings of whole grain and \<13% energy from added sugars.
224066786|NCT06339879|OTHER|High Whole Grain, High Sugar|6 servings of whole grain and \>13% energy from added sugars.
224066787|NCT06339879|OTHER|Low Whole Grain, High Sugar|3 servings of whole grain and \>13% energy from added sugars.
224066788|NCT03534700|PROCEDURE|parasacral flap reconstruction|parasacral flap reconstruction
224066789|NCT03534700|PROCEDURE|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
224066790|NCT06023979|OTHER|Full weight bearing|Full weight bearing monitored with a bio-feedback insole
224066791|NCT06023979|OTHER|Partial weight bearing|Partial weight bearing monitored with a bio-feedback insole
224155221|NCT01068613|DRUG|Tiotropium|Tiotropium via inhalation device
224155222|NCT01068613|DRUG|Placebo|Placebo to QAX028 via inhalation device
224155223|NCT04672902|PROCEDURE|Single-operator cholangioscopy guided electrohydraulic lithotripsy|Single-operator cholangioscopy guided electrohydraulic lithotripsy has the advantage of providing direct visualization of the bile ducts, enabling a single physician to diagnose and perform the therapeutic intervention in a single procedure.
224155224|NCT02361489|DEVICE|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
224155225|NCT01505114|DRUG|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
224155226|NCT01505114|DRUG|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
224155227|NCT01505114|DRUG|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
223743032|NCT03560050|BEHAVIORAL|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
223743033|NCT05144984|DRUG|NNC0480-0389|A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
223743034|NCT05144984|DRUG|Semaglutide|A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
224155228|NCT01505114|OTHER|Maraviroc placebo|Once daily from Week 0 through Week 48
224155229|NCT01505114|OTHER|Emtricitabine placebo|Once daily from Week 0 through Week 48
224155230|NCT01505114|OTHER|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
224155231|NCT03168555|DRUG|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
224155232|NCT05666570|DEVICE|Avelle NPWT|wound management therapy
224155233|NCT02229253|DRUG|degarelix|
224155234|NCT01020032|OTHER|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
224155235|NCT04116216|COMBINATION_PRODUCT|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
224302465|NCT04710979|BEHAVIORAL|Yoga Intervention|This group will have in-person, 60 minute yoga sessions three times per week for 12 weeks. These sessions will also include a sharing circle to provide group feedback as to how the practice felt and integration into ones' daily life. There will be biweekly themes established for these sessions (i.e. common yoga poses, importance of breath) and biweekly in-person workshops will be offered. These will be specialty classes for participants to experience additional exposure to meditation and breathing. They will be a longer format so participants can delve deeper into yogic philosophy and practice. There will also be a private Facebook group for participants to connect with each other and for the research staff to maintain contact and share information with the participants (eg. weekly reminder for yoga sessions and workshops).
224155236|NCT04116216|COMBINATION_PRODUCT|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
224155237|NCT04116216|COMBINATION_PRODUCT|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
224155238|NCT01782924|DRUG|KHK4827|
224155239|NCT06274268|DIAGNOSTIC_TEST|Sarcopenia diagnostic test|the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.
224155240|NCT01040845|DRUG|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
224155241|NCT01040845|DRUG|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
224155242|NCT01040845|DRUG|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
224155243|NCT01852916|DEVICE|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
224155244|NCT01852916|DEVICE|NHFOV|Nasal High Frequency Oscillatory Ventilation
224155245|NCT00460681|DRUG|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
224155246|NCT00454480|BIOLOGICAL|alemtuzumab|
224155247|NCT00454480|DRUG|arsenic trioxide|
224155248|NCT00454480|DRUG|azacitidine|
224155249|NCT00454480|DRUG|busulfan|
224155250|NCT00454480|DRUG|clofarabine|
224155251|NCT00454480|DRUG|cytarabine|
224155252|NCT00454480|DRUG|daunorubicin hydrochloride|
224155253|NCT00454480|DRUG|fludarabine phosphate|
224155254|NCT00454480|DRUG|gemtuzumab ozogamicin|
224302466|NCT03019159|DEVICE|Teleconsulting|
223743035|NCT05144984|DRUG|Placebo (NNC080-0389)|A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
223743036|NCT05144984|DRUG|Placebo (semaglutide)|A weekly dose of placebo (semaglutide). The study will last for about 41weeks.
224155255|NCT00454480|DRUG|melphalan|
224155256|NCT00454480|DRUG|tipifarnib|
224155257|NCT00454480|GENETIC|DNA methylation analysis|
224155258|NCT00454480|GENETIC|cytogenetic analysis|
224155259|NCT00454480|GENETIC|gene expression analysis|
224155260|NCT00454480|GENETIC|mutation analysis|
224155261|NCT00454480|OTHER|diagnostic laboratory biomarker analysis|
224155262|NCT00454480|OTHER|immunologic technique|
223456398|NCT02853526|PROCEDURE|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
223456399|NCT02853526|DRUG|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
223456400|NCT02853526|PROCEDURE|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
223456401|NCT02853526|DRUG|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
223456402|NCT03320265|DRUG|PC-mAb|Monthly treatment for 3 months (4 administrations)
223456403|NCT03320265|DRUG|Placebo|Monthly treatment for 3 months (4 administrations)
223456404|NCT00144443|BEHAVIORAL|Basic home repair|
223456405|NCT00144443|BEHAVIORAL|Asthma Trigger Education|
223456406|NCT03615261|BEHAVIORAL|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy \& attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing \& strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
224066792|NCT06221163|OTHER|collection of biographical and sociological data|collection of biographical and sociological data. Conducting non-directive interviews (life stories) with transgender patients consulting the Reproductive Medicine Department and their volunteer relatives. Patients are given a 'flyer' at the time of their consultation on which the interviewer's contact details are given. They are free to contact the interviewer to find out when and where an interview might take place (outside hospital).
223456407|NCT05183334|DRUG|Sildenafil 50 mg|PD5I
224066793|NCT05152550|OTHER|Non-severe pre-eclampsia|Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
224066794|NCT03031301|DEVICE|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
224066795|NCT03031301|DEVICE|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
224066796|NCT01936545|DRUG|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
224066797|NCT01936545|DRUG|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
224066798|NCT04687696|OTHER|Post Isometric Relaxation Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
224066799|NCT04687696|OTHER|Isolytic Stretching Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
224066800|NCT04687696|OTHER|Static Stretching Group Group|Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
224066801|NCT02549768|DRUG|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
224066802|NCT02549768|DRUG|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
224066803|NCT05532410|DEVICE|Fundus Camera|The fundus camera is suitable for photographing, displaying and storing data relating to the retina and surrounding parts of the eye. These photographs assist with the diagnosis and follow-up of eye diseases, which can be visually monitored and photographically documented.
223456408|NCT05183334|DRUG|Placebo|placebo
223456409|NCT05183334|DRUG|Tramadol Hydrochloride 100 MG|opiod
223456410|NCT03100656|OTHER|A breakfast sandwich|A meat-based breakfast sandwich
223743037|NCT06545370|OTHER|Intervention 1 / Nurse-led patients' education|nurse-led education through oral sessions, educational materials, and regular phone calls
224066804|NCT00209378|OTHER|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
224066805|NCT00209378|OTHER|HfCitPre|regional anticoagulation with citrate containing replacement solution
224066806|NCT06020456|DRUG|Desmopressin|For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
224066807|NCT05337332|DRUG|Triamcinolone Acetonide|Suprachoroidal injection of triamcinolone acetonide
224066808|NCT02429414|DEVICE|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
224066809|NCT02429414|PROCEDURE|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
224066810|NCT02429414|DEVICE|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
224302467|NCT04637932|PROCEDURE|Percutaneous Dilatation Tracheostomy|pro-seal laryngeal mask or intubation tube in bronchoscopy-guided percutaneous dilation tracheostomy procedure.
223456411|NCT04583007|DRUG|Lanadelumab 150 mg|TAK-743-6001: Participants will receive subcutaneous (SC) injection of lanadelumab at a dose of 150 milligrams (mg) at the same frequency (for every 2 weeks \[Q2W\] or for every 4 weeks \[Q4W\]) given at the completion of SPRING study until benefit-risk no longer favors the individual participant or an appropriate alternative therapy becomes available or lanadelumab 150 mg/ 1 milliliter (mL) becomes commercially available or the participants turns 12 years of age or participant chooses to discontinue treatment. For participants aged 6-12 years, a dose frequency may be modified based on a benefit-risk assessment and medical decision from the treating physician.
223456412|NCT04583007|DRUG|Lanadelumab 300 mg|TAK-743-5012: Participants will receive SC injection of lanadelumab in prefilled syringe at a dose of 300 mg, Q2W or Q4W if well controlled for 26 weeks across Study TAK-743-3001 and this (TAK-743-5012) program.
223456413|NCT02154932|DRUG|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
223456414|NCT02154932|DRUG|single dose misoprostol|1 dose, 1 hours, prior surgery
224066811|NCT03245450|DRUG|Eribulin mesilate|IV infusion
224066812|NCT03245450|DRUG|Irinotecan hydrochloride|IV infusion
224066813|NCT01859442|PROCEDURE|Structured responsive interval exercise training programme|
224066814|NCT01859442|OTHER|Sham group|NO intervention in this group, only standard care (no exercise programme)
224066815|NCT02326558|PROCEDURE|laparoscopic microwave ablation-assisted enucleation|
224066816|NCT02326558|PROCEDURE|conventional laparoscopic partial nephrectomy|
224066817|NCT05477290|PROCEDURE|Trigger Finger Release through Transverse Incision|At the level of the A1 pulley, a transverse incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
224066818|NCT05477290|PROCEDURE|Trigger Finger Release through Oblique Incision|At the level of the A1 pulley, a oblique incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
224066819|NCT05477290|PROCEDURE|Trigger Finger Release through Vertical Incision|At the level of the A1 pulley, a vertical incision will be made and the flexor pulley will be exposed with blunt dissection. The pulley will be transected and the wound will subsequently be closed with 4.0 Monocryl after ensuring complete release.
224066820|NCT03959280|OTHER|Tailored intervention|"* The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~* The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~* Behavioural changes techniques will be included in diet and exercise interventions."
224066821|NCT03959280|OTHER|Control|This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
224066822|NCT03130088|OTHER|no intervention planed|no intervention planed
224066823|NCT03155594|DEVICE|Freestyle Libre|Continuous glucose monitoring patch
224066824|NCT06033820|DRUG|ZR2-ICE|"* Drug: zanubrutinib Oral Capsule~* Drug: lenalidomide Oral Capsule~* Drug: R-ICE chemotherapy"
224066825|NCT01731652|DRUG|TMX-101|
224066826|NCT00969449|DRUG|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
224066827|NCT00969449|DRUG|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
224066828|NCT06260280|DIAGNOSTIC_TEST|Cerebral Nuclear Magnetic Resonance|Cerebral Nuclear Magnetic Resonance before the start of the shifts and a control 2 months after the start of the residency to evaluate if there is an association between chronic sleep deprivation and changes in cortical and hippocampal volume.
224066829|NCT04381910|DRUG|LY01610( Irinotecan hydrochloride liposome injection )|LY01610 will be administered via intravenous infusion every 2 weeks on Day 1
224066830|NCT03729492|DIAGNOSTIC_TEST|CTEPH/CTED work-up|Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
224066831|NCT00000511|DIETARY_SUPPLEMENT|mineral supplements|
224066832|NCT00000511|DIETARY_SUPPLEMENT|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
224066833|NCT00000511|BEHAVIORAL|dietary supplements|
224066834|NCT03283176|DIAGNOSTIC_TEST|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
224066835|NCT00983983|DIETARY_SUPPLEMENT|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
224066836|NCT00983983|DIETARY_SUPPLEMENT|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
224066837|NCT00983983|DIETARY_SUPPLEMENT|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
224066838|NCT03961087|DRUG|Coenzyme Q10|Coenzyme Q10 will be given twice
224066839|NCT03961087|DRUG|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
224155263|NCT00454480|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223456415|NCT03446378|DEVICE|Anodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
224155264|NCT00454480|PROCEDURE|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
223456416|NCT03446378|BEHAVIORAL|Physical therapy|all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
223456417|NCT03446378|DEVICE|Cathodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
223456418|NCT03446378|DEVICE|Sham tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
223456419|NCT03289247|DEVICE|tissue adhesive (Leukosan®)|Tissue ahaesive
223456420|NCT00447525|BIOLOGICAL|REVAXIS®|
223456421|NCT00447525|BIOLOGICAL|DT-Polio®|
223456422|NCT01772927|DIETARY_SUPPLEMENT|Parenteral Nutrition|Protein and energy intakes
223456423|NCT05074134|DRUG|[14C]-TNP-2092|Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
223456424|NCT02453880|BEHAVIORAL|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
223456425|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
223456426|NCT02702843|PROCEDURE|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
223456427|NCT01495052|DIETARY_SUPPLEMENT|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
223456428|NCT00892463|DRUG|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
223572708|NCT05800028|BEHAVIORAL|Learning new information|The purpose of this study is to test the effects of different social contexts when learning new information. Participants in the AD, SPPA, and HC experimental groups will be given tests to learn verbal information (location of drawings in a grid). The learning phases of these tests are presented in the form of a memory game in which participants are asked to make pairs of drawings by finding the second copy of the proposed pair by trial and error in a grid. After learning, a task of recognizing the position of the drawings in the grid is performed. Each participant will carry out this learning in three different conditions: 1) learning alone, 2) learning by observation of the reconstruction of the pairs of images by a partner, and 3) collaborative learning in which the two game partners discover and reconstruct the pairs together.
223572709|NCT00517439|DRUG|Copegus|1000/1200mg po daily for 24 weeks
223572710|NCT00517439|DRUG|Pegasys|180 micrograms sc weekly for 24 weeks
223572711|NCT00517439|DRUG|Pegasys|90 micrograms sc weekly for 24 weeks
223572712|NCT00517439|DRUG|RO4588161|1000mg po bid for 24 weeks
223572713|NCT00517439|DRUG|RO4588161|500mg po bid for 24 weeks
223572714|NCT00517439|DRUG|RO4588161|1500mg po bid for 24 weeks
223572715|NCT01161550|DRUG|Granulocyte colony-stimulating factor (G-CSF)|
223572716|NCT01161550|DRUG|Cladribine|
223572717|NCT01161550|DRUG|Cytarabine|
223572718|NCT01161550|DRUG|All-Trans Retinoic Acid (ATRA)|
223572719|NCT01161550|DRUG|Midostaurin|
224155265|NCT01053403|DRUG|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
224155266|NCT00288041|DRUG|carboplatin|Given IV
224155267|NCT00288041|DRUG|paclitaxel|Given IV
224155268|NCT00288041|DRUG|bortezomib|Given IV
224155269|NCT04965116|DRUG|Progestin Only Contraceptive Pills|Daily pill (placebo or active tablet)
224155270|NCT02441192|OTHER|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
224155271|NCT02441192|OTHER|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
224155272|NCT02441192|OTHER|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
224155273|NCT05351190|DEVICE|Dexcom G6 CGM|rtCGM to be worn by user continuously for the duration of the 12 month study
224155274|NCT04709913|DRUG|HU6|HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
224155275|NCT03645915|OTHER|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
223456429|NCT06203535|OTHER|Aerobic training|In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
223456430|NCT03291951|BEHAVIORAL|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
224155276|NCT05625815|DEVICE|Prototypes (816-v1 001) to (816-v1 050)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224155277|NCT05625815|DEVICE|Prototype (816-v1 051) to (816-v1 100)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
223456431|NCT06251141|PROCEDURE|Gum Health gel|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket with normal saline, and filling the socket with the Gum Health gel
223456432|NCT06251141|PROCEDURE|Gel foam|Extraction of impacted mandibular third molars under local anaesthesia and irrigating the socket
223456433|NCT05411835|DIETARY_SUPPLEMENT|Nutritional Ketone Supplement|Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
223456434|NCT05411835|DIETARY_SUPPLEMENT|Isocaloric Placebo Supplement|Maltodextrin with flavors and stevia sweetener
223572720|NCT02981407|BIOLOGICAL|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
223572721|NCT00325676|DRUG|Pantoprazole|
224066840|NCT02491255|DEVICE|Lotus Valve System|Device: Lotus Valve System
224066841|NCT00014183|DRUG|gefitinib|
224066842|NCT04769011|DIAGNOSTIC_TEST|Clinical evaluation|Clinical evaluation of participants by means of Autism Diagnostic Observation Schedule, Social Responsiveness Scale, Children Behavior Check List, Conners' Scale
224066843|NCT04769011|DIAGNOSTIC_TEST|Neuropsychological evaluation|The participants' motor skills are measured using the Movement Assessment Battery for Children 2 (MABC2) (Henderson et al., 2007), the Developmental Coordination Disorder Questionnaire (DCDQ) (Wilson et al., 2007), and the kinematic analysis of a reach-to-drop task (Forti et al., 2011; Crippa et al., 2015).Sensorimotor domain will be also further investigated with NEPSY-II (Korkman et al., 2007) (Fingertip Tapping, Imitating Hand Positions, Manual Motor Sequences, and Visuomotor Precision).
224066844|NCT04769011|DIAGNOSTIC_TEST|Neurophysiological evaluation|Magnetic Resonance Imaging (structural MRI and DTI)
224066845|NCT04769011|DIAGNOSTIC_TEST|Genetic evaluation|Either blood or saliva will be obtained for participants for DNA collection. DNA will be extracted in the Molecular Biology Laboratory at the Scientific Institute IRCCS Medea. Captured exome libraries will be sequenced using the Illumina NextSeq 500 in 100 bp paired end reads. Postsequencing reads will be aligned using BWA Enrichment application on BaseSpace. VCF file will be then marked using wANNOVAR (Wang Genomics Lab). The analysis will be focused on non-synonymous variants enrichment in Gene Ontology and Human Phenotype.
224066846|NCT02041377|DEVICE|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
224066847|NCT04499261|PROCEDURE|laparoscopic surgery|Patients were supine in a reverse Trendelenburg position and received intravenous inhalation combined with anesthesia. The patients' legs were spread apart. A carbon dioxide pneumoperitoneum was established. The intermittent Pringle's maneuver was carried out when necessary. Five trocars were placed in a fan shape around the lesion. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
224155278|NCT05625815|DEVICE|Prototypes (816-v1 101) to (816-v1 150)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224155279|NCT05625815|DEVICE|Prototypes (816-v1 151) to (816-v1 200)|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying supine, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224155280|NCT05810298|OTHER|Asana Practice|Yogasana training will be comprised of active movements when standing. Spine and limbs stretches eccentrically respecting the movement patterns of body without pushing limits. Transition in between poses will be synchronized with breathing pattern in zero resistance flow. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of standing poses training will last for 4 weeks.
224155281|NCT05810298|OTHER|Pranayam Practice (Rhythmic regulated breathing)|Breathing exercises will be comprised of diaphragmatic breathing, holding the breath after inhaling deeply and exhaling passively or exhaling actively by contracting abdominal muscles and inhaling passively. The exercises will be done 2 days a week online under the supervision of physiotherapist. Total duration of breathing exercises will last for 4 weeks.
224155282|NCT05810298|BEHAVIORAL|Smoking Education Program|The aim of the education is to increase awareness of subjects who are chronical smokers. The subject education will be performed at least once via face to face interview. Education topics will be covered basic information about harmful effects of habitual smoking and how to reduce the side effects of nicotine withdrawal.
224066848|NCT04499261|PROCEDURE|Open surgery|Patients were placed in the supine position and received intravenous inhalation combined with anesthesia. The intermittent Pringle's maneuver was carried out when necessary. Routinely, a reversed L-shape incision was performed. Cholecystectomy was performed routinely. First, the liver was mobilized. Then, the liver parenchyma was transected and the branches of the hepatic veins and pedicles encountered were clipped and divided. The lesion was meticulously separated from the vascular structures and liver parenchyma and completely resected. The raw surface was treated with bipolar coagulation to achieve hemostasis and repeatedly washed until no bleeding or bile leakage was confirmed. Finally, the specimens were packed in a specimen bag and removed. The raw surface was packed with biological hemostatic materials, and drainage tubes were routinely placed.
224155283|NCT03377569|OTHER|Sleep, PD and DBS|Sleep, PD and DBS
224155284|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm A)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
224155285|NCT03739736|OTHER|Combination of TB/HIV prevention activities (arm B)|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In this arm B ART was initiated according to national guidelines. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
224155286|NCT03739736|OTHER|Standard of care (arm C)|"The standard of care arm C communities have access to HIV testing services (usually at the health facility), HIV care and ART provision according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility. TB diagnostics are as per national guidelines including Xpert®TB/RIF for those who are HIV positive. All diagnosed cases of TB are treated as in the intervention arm. TB screening and prevention at HIV care clinics are as is in the intervention arm."
224155287|NCT04420208|PROCEDURE|Modified Pap test|Adding a non-painful step after the most uncomfortable phase of Pap smear
224155288|NCT02714023|PROCEDURE|Normal Saline|Intra-operative irrigation with normal saline
224155289|NCT02714023|PROCEDURE|Sterile Water|Intra-operative irrigation with sterile water
223456435|NCT03762577|OTHER|Ground-based walking training|Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
223456436|NCT02632370|DRUG|Gliolan®|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
223456437|NCT02632370|PROCEDURE|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
223456438|NCT00777166|DRUG|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
224066849|NCT01826682|OTHER|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
224066850|NCT01826682|OTHER|Medical treatment|Standard medical treatment without physiotherapy.
224066851|NCT01784861|DRUG|X-82|
224066852|NCT01784861|DRUG|Everolimus|
224066853|NCT05376826|BEHAVIORAL|Nurse Led Physical Therapy|Nurse Led Physical Therapy in Form of Range of Motion Exercises
223456439|NCT00777166|DRUG|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
224066854|NCT06349395|OTHER|MBSR surgical nursing care|This study delivered an eight-session mindfulness-based stress reduction (MBSR) program online to its intervention group, each lasting about two hours, incorporating daily exercises monitored via phone. The evaluation of MBSR's effectiveness focused on postoperative pain at 6, 12, 18, and 24 hours after surgery and assessed fear of movement before starting arm exercises on the 5th day post-mastectomy. This approach provided a detailed examination of MBSR's role in pain and movement fear management, highlighting its potential as a preoperative care component for breast cancer patients.
224066855|NCT02122237|DEVICE|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
224066856|NCT04901143|DEVICE|Advanced hybrid closed loop system|Phase 1: meals in open loop- 3 weeks Phase 2: closed loop conventional meal announcement- 3 weeks Phase 3: closed loop, pre define universal bolus- 3 weeks
224066857|NCT00673166|PROCEDURE|Staff incentive & supervision|Control \& management of funds for incentive of staff; supervision
224066858|NCT00673166|BEHAVIORAL|Staff motivation|Supervision, control of funds
224066859|NCT01120496|DRUG|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
224066860|NCT01120496|DRUG|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
224066861|NCT05009719|BIOLOGICAL|Prophylactic Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes arel freezed for next using. DLI is transfused to patients IV using central venous access.~Donor lymphocytes infusion start from D+60 - D+100 and continue with escalating doses every 1.5-3 months during first year after HSCT up to appearance of GVHD or signs of disease. First dose is 1\*10\*6 CD3+/kg. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
224066862|NCT05009719|BIOLOGICAL|Preventive Donor lymphocytes infusions|"Donor lymphocytes is taken by apheresis or dose of blood from allogeneic donor. After apheresis lymphocytes freeze for next using. DLI are transfused to patients IV using central venous access.~Donor lymphocytes infusion continue with escalating doses every 1.5-3 months up to achieving MRD negative status or appearance of GVHD or signs of active disease.~First dose is 1\*10\*6 CD3+/kg for patients without previous GVHD and 1\*10\*5 CD3+/kg for patients with previous GVHD. Subsequent doses increases by 0.5 log for haploidentical and unrelated donor and 1 log for sibling donor up to 1\*10\*8 CD3+/kg."
224066863|NCT03504410|DRUG|CPI-613 + High Dose Cytarabine and Mitoxantrone|CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
224066864|NCT03504410|DRUG|High Dose Cytarabine and Mitoxantrone|Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
224066865|NCT03504410|DRUG|Mitoxantrone, Etoposide and Cytarabine|"Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6"
224066866|NCT03504410|DRUG|Fludarabine, Cytarabine, Filgrastim|"Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5"
224066867|NCT00003683|DRUG|doxorubicin hydrochloride|
224066868|NCT00003683|DRUG|ifosfamide|
224066869|NCT01275482|PROCEDURE|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
223456440|NCT02651870|DRUG|Candesartan 16mg|
223456441|NCT02651870|DRUG|Amlodipine 5mg|
223456442|NCT02651870|DRUG|Amlodipine 10mg|
223456443|NCT03454087|OTHER|Enteral Dextrose Infusion|A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
223456444|NCT03454087|OTHER|Free Water Infusion|An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
223456445|NCT01965002|DEVICE|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
223456446|NCT01965002|DRUG|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
223456447|NCT01965002|DRUG|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
223456448|NCT01105104|DEVICE|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
223456449|NCT01105104|DEVICE|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
223456450|NCT01724177|DRUG|Lenalidomide|25 mg of Lenalidomide administered orally once daily
223456451|NCT01773018|DRUG|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
224155290|NCT04393909|BEHAVIORAL|Diagnostic Uncertainty Educational Curriculum|"A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial."
224155291|NCT04393909|BEHAVIORAL|Diagnostic Timeout|"A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training."
223456452|NCT00700375|DRUG|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
223456453|NCT00700375|DRUG|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
223456454|NCT04226300|PROCEDURE|Laparoscopic|A transversus abdominis nerve block will be placed laparoscopically.
223456455|NCT04226300|PROCEDURE|Ultrasound|A transversus abdominis nerve block will be place by ultrasound
223456456|NCT00581061|DRUG|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
223456457|NCT03592836|DRUG|Loop Diuretics|intravenous administration of diuretics
223456458|NCT00370591|DRUG|Salmeterol/fluticasone propionate and fluticasone propionate|
223456459|NCT05063084|PROCEDURE|Optiflow - HFNO|Pre-oxygenation: HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2 Oxygenation: during the tracheal intubation, HFNO with a 2 L/Kg/min flow during 2 min with 100% FiO2
223456460|NCT05063084|PROCEDURE|Classic|Pre-oxygenation: with facemask during 2 min with 100% FiO2, flow 6 to 8L/min. No oxygenation during the tracheal intubation
223456461|NCT02214940|DRUG|BI 11634|
223456462|NCT02214940|DRUG|Placebo|
223456463|NCT02999334|BEHAVIORAL|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
223572722|NCT03790800|DRUG|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
223572723|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
224066870|NCT01275482|PROCEDURE|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
224066871|NCT05800249|DRUG|PE0116|This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
224066872|NCT03375450|OTHER|Standard of Care|Participants will be followed as per local routine primary healthcare practice
224066873|NCT04213612|DRUG|pegylated liposomal doxorubicin, cyclophosphamide, vincristine,|PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity
224066874|NCT03784066|DRUG|Durvalumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
224066875|NCT03784066|COMBINATION_PRODUCT|Durvalumab + Tremelimumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
224066876|NCT02661425|OTHER|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
224066877|NCT00645983|DIETARY_SUPPLEMENT|Chamomile Extract|220 mg - 1100 mg daily
224066878|NCT00645983|OTHER|Placebo|1 to 5 capsules daily
223456464|NCT04984122|PROCEDURE|LEEP|According to the size of the cervix, a loop electrode size was selected. The electrical power for the loop electrode was set to 50 W cut and 45 W coagulation in blended mode. LEEP was performed by carefully passing the loop around the transformation zone from 12 o'clock to 6 o'clock. An additional top-hat excision was performed in patients with a lesion deep in the cervical canal. After completion of the excision, hemostasis was exclusively obtained using the ball electrode in spray coagulation mode. No suturing or other methods were used for hemostasis.
223456465|NCT00816127|DRUG|Desmopressin|intranasal desmopressin (300μg)
223456466|NCT00816127|BIOLOGICAL|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
223456467|NCT03868839|DRUG|Telmisartan Pill|telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
223456468|NCT05915273|OTHER|Computer Aided Design/ Computer Aided Manufacturing Retainers|Custom-bent fixed retainer wires from an in-office CAD/CAM system with FixR software and the BenderI machine (YOAT Corporation, Lynwood, WA). Dentaflex wires- round, 0.5mm in diameter, three-stranded Stainless Steel (Dentaurum GmbH \& Co., Ispringen, Germany)- were used for the CAD/CAM group
223572724|NCT01258153|DRUG|Nepadutant oral solution|Oral administration once daily for 7 days
223572725|NCT01258153|DRUG|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
223572726|NCT02227953|DEVICE|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
223572727|NCT02227953|DEVICE|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
224066879|NCT00525395|GENETIC|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
224066880|NCT00525395|PROCEDURE|Continuous phototherapy|Group B: 6 months non-stop treatment.
223456469|NCT05915273|OTHER|Lab-based Retainers|The lab group used the same type of wire as the CAD/CAM group but was manually bent by a lab technician
223456470|NCT05915273|OTHER|Chairside Retainers|The chairside group used three-stranded Stainless Steel, 0.974mm x 0.402 mm, flexible Ortho-FlexTech wires (Reliance, Itasca, IL)
223456471|NCT00192972|PROCEDURE|Catheter ablation (pulmonary vein isolation)|
224066881|NCT02114580|OTHER|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
224066882|NCT03413020|DRUG|esomeprazole|proton pump inhibitor
224066883|NCT03413020|DRUG|bismuth Potassium Citrate|gastric mucosal protective drug with anti-H. pylori effect
224066884|NCT03413020|DRUG|amoxicillin|antibiotic for H. pylori eradication
224066885|NCT03413020|DRUG|clarithromycin|antibiotic for H. pylori eradication
224066886|NCT03413020|DRUG|metronidazole|antibiotic for H. pylori eradication
224066887|NCT03413020|DRUG|levofloxacin|antibiotic for H. pylori eradication
224066888|NCT03729388|OTHER|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
224066889|NCT03665402|DRUG|Isoniazid|One of the first line anti-tubercolosis drug
224066890|NCT01797900|DRUG|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
224066891|NCT01797900|DRUG|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
224066892|NCT01797900|RADIATION|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
224066893|NCT04064775|BEHAVIORAL|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
224066894|NCT03098329|OTHER|Ct/GC screening|Men aged 15-26 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
224066895|NCT02973737|DRUG|pyrotinib|400 mg once daily
224066896|NCT02973737|DRUG|placebo|400 mg once daily
224066897|NCT02973737|DRUG|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
223456472|NCT02457195|DRUG|granisetron|Application granisetron transdermal patch preoperatively
223456473|NCT03163641|DEVICE|Acuvue Oasys|Bandage Contact Lens
223572728|NCT00624780|DRUG|Pregabalin|Pregabalin 150-300 mg given twice a day
223572729|NCT00624780|DRUG|Lorazepam|Lorazepam 3-4 mg given twice a day
223572730|NCT00624780|DRUG|Pregabalin|Pregabalin 450-600 mg given twice a day
223572731|NCT00624780|DRUG|Placebo|Placebo
223572732|NCT00922155|DEVICE|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
223572733|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
223572734|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
223572735|NCT00743028|DRUG|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
223572736|NCT01376375|PROCEDURE|Acupuncture|
223572737|NCT02045693|DRUG|Methadone|
224066898|NCT00018265|BEHAVIORAL|Task specific endurance training|
224066899|NCT00018265|BEHAVIORAL|Tai Chi|
224066900|NCT03089073|DRUG|Desmopressin|60μg or 120μg once daily at bedtime
224155292|NCT04393909|BEHAVIORAL|Patient Diagnostic (Dx) Questionnaire|"We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse)."
224155293|NCT04393909|BEHAVIORAL|Enhancements to Epic-integrated Quality & Safety Dashboard|"Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation."
224155294|NCT02548741|DRUG|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy \& David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
224155295|NCT02548741|DRUG|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy \& David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
224155296|NCT02548741|OTHER|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
224155297|NCT02548741|OTHER|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
224155298|NCT03460613|OTHER|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
223456474|NCT03163641|DEVICE|Ocular Bandage Gel|0.75% crosslinked HA
223456475|NCT00666107|BIOLOGICAL|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
223456476|NCT00738647|PROCEDURE|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
223456477|NCT05598359|DIETARY_SUPPLEMENT|TA-65|TA-65 is a purified small molecule extracted from Astragalus root
223456478|NCT05598359|OTHER|Placebo|Inactive formulation
223456479|NCT03987308|DRUG|Beinaglutide|Beinaglutide (continuous subcutaneous infusion)
223456480|NCT03987308|DRUG|Insulin aspart|Insulin aspart (CSII)
223456481|NCT01977768|BIOLOGICAL|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
223456482|NCT01977768|BIOLOGICAL|Placebo|
223456483|NCT03045497|DRUG|Perflutren Lipid Microspheres|Given IV
223456484|NCT03045497|DEVICE|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
223456485|NCT03045497|DEVICE|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
223456486|NCT02498977|GENETIC|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
224071353|NCT06106464|OTHER|Aerobic exercise+8 minutes of walking breaks every 2-h|Volunteers, whose fasting blood samples are drawn and who eat a standard breakfast, will perform a 30-minute walking exercise on a treadmill at 40-45% of their heart rate reserve. They will then interrupt sitting with 8-minute walks at 35-40% of their heart rate reserve every 2 hour for 6.5 hours after moderate-intensity aerobic exercise. They will make six interruptions throughout 6.5 hours period and will have a total of 24 minutes of interruption throughout the intervention. While seated, volunteers will be asked not to leave their seats except to use the toilet. Volunteers will be able to read and use computers and phones while sitting. Venous and capillary blood samples will be drawn at regular intervals and their blood pressures will be measured.
223456487|NCT02498977|DRUG|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
223456488|NCT05919550|DRUG|search for a clozapine intake|search for a clozapine intake
223456489|NCT05384470|DRUG|Marihuana|Two doses of marijuana given.
223572738|NCT02045693|DRUG|DCV 3DAA FDC|
223572739|NCT02045693|DRUG|BMS-791325|
223572740|NCT02045693|DRUG|Buprenorphine|
223572741|NCT02045693|DRUG|Naloxone|
223572742|NCT03911752|OTHER|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
223572743|NCT03911752|OTHER|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
224155299|NCT01136213|RADIATION|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
224155300|NCT01136213|OTHER|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
224155301|NCT01136213|DRUG|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
224155302|NCT04445688|DRUG|AD036|Oral administration before bed
224155303|NCT04445688|DRUG|Atomoxetine|Oral administration before bed
224155304|NCT04445688|DRUG|Placebo|Oral administration before bed
224155305|NCT00299416|DRUG|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
224155306|NCT00299416|PROCEDURE|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
224155307|NCT01759355|PROCEDURE|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
224155308|NCT02331641|PROCEDURE|Hepatectomy|Removal of a part of the liver
224155309|NCT06082375|DIETARY_SUPPLEMENT|Vitamin D|Vitamin D3 in the form of cholecalciferol.
224155310|NCT06082375|DIETARY_SUPPLEMENT|Placebo|Vegetable oil.
224155311|NCT04732572|BEHAVIORAL|Sleep and healthy lifestyle education|Participants in both groups will receive age-appropriate standardized educational material for both Optimal Sleep Hygiene and Healthy Habits. Educational play will also be encouraged by providing take-home materials. Participant and parent/legal guardian (s) will be given verbal and written directions on the use of these materials at the time of the visit. Research Coordinators will encourage and track utilization of the sleep hygiene educational tools during the trial.
224155312|NCT04732572|OTHER|Other supportive care|Throughout the course of the trial participants identified by the principal investigator as having suboptimal asthma or rhinitis will be referred to their primary care physician for management and further treatment of these problems. All participants will receive a generic brand of an over-the-counter saline nasal spray to use as needed for nasal dryness and crusting. Proper use of the spray will be reviewed and demonstrated by the research coordinator at the baseline visit.
224155313|NCT04732572|PROCEDURE|Adenotonsillectomy|Surgery will be performed by board-certified otolaryngologists with or without the assistance of resident physicians in accredited otolaryngology training programs. Prior to the surgical procedure, tonsillar size will be graded using a standardized scale of 0-4. Extent of adenoid tissue will also be graded as mild (0-33%), moderate (34-66%) or severely (67-100%) obstructing the posterior choanae. Complete bilateral tonsillectomy and removal of obstructing adenoid tissue will be performed by cold dissection, monopolar electrocautery or plasma knife-assisted surgical technique under general anesthesia. All procedures will be performed using inpatient facility for 3-4 days.
224155314|NCT02792283|BIOLOGICAL|whole blood collection|
224155315|NCT00005883|DRUG|phenethyl isothiocyanate|
223572744|NCT00869245|OTHER|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
224155316|NCT05615155|OTHER|Platelets Rich Fibrin (i-PRF / C-PRF)|one site of the mouth will be injected with i-PRF and the other site will be injected with C-PRF
224155317|NCT02114398|OTHER|usual treatment|usual treatment
224155318|NCT02114398|OTHER|usual treatment + sophrology|usual treatment + sophrology
224155319|NCT03919006|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
224155320|NCT03919006|OTHER|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
224155321|NCT05118568|DEVICE|Histolog Scanner|imaging of fresh lumpectomy specimens with the Histolog Scanner, confocal microscopy scanning medical imaging device
224155322|NCT01023373|DRUG|Medical treatment|hypotensive drugs, statins and anti-platelets
224155323|NCT01023373|PROCEDURE|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
224155324|NCT01023373|DEVICE|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
224155325|NCT01023373|DEVICE|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
224155326|NCT01235507|DRUG|methotrexate|stable dose as prescribed
224155327|NCT01235507|DRUG|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
224155328|NCT05915117|DIETARY_SUPPLEMENT|Polyphenols of pomegranate fruit peel extract (PoPex)|PoPex in form of capsule will be orally administered in total daily dose of 500/mg in subjects with metabolic syndrome and obesity over 8 weeks.
224155329|NCT05915117|DRUG|Placebo|Placebo in form of capsule will be orally administered in subjects with metabolic syndrome and obesity over 8 weeks.
224155330|NCT00202345|DRUG|Iron sucrose|
224155331|NCT01962389|DEVICE|Winsor Laser Catheter|
224155332|NCT05226767|DIETARY_SUPPLEMENT|NLC-V|NLC-V
224155333|NCT04761952|DRUG|azathioprine|daily orally
224155334|NCT04761952|DRUG|infliximab|intravenously, at 0, 2,6 weeks with every 8-week-interval later
224155335|NCT04761952|DRUG|N-3 Polyunsaturated Fatty Acids|Ethyl polyenoate capsule is given as drug intervention. The main components are ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoate (DHA-E), both of which will transform into ethyl eicosapentaenoate (EPA) and ethyl docosahexaenoate (DHA). Drug dose is 0.25 g EPA-E\&DHA-E; per capsule one at a time, Three times a day.
224155336|NCT02397967|OTHER|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
224155337|NCT04725201|DRUG|Intravenous unfractionated heparin|See experimental arm description for intervention description.
224155338|NCT04725201|DRUG|Sham|See sham comparator arm description for intervention description.
224155339|NCT00442260|DRUG|DOXIL|
224155340|NCT00442260|DRUG|Abraxane|
224066901|NCT05304507|BEHAVIORAL|I-PROTECT model|The I-PROTECT model is based on existing research and knowledge of experts in sport medicine, sport psychology and implementation science, with the involvement of end-users throughout the process. The interdisciplinary intervention includes exercises based on physical and psychological principles of effective injury prevention training, specifically tailored for youth handball players, and support for developing a continuous implementation strategy. The intervention is delivered through a mobile application specifically developed for the I-PROTECT project (the I-PROTECT GO), including coach, player, club administrator, and caregiver modules. Coaches are introduced to the intervention in a workshop, and they will conduct the exercises with their teams during handball practice. Players will have support for conducting exercises on their own, and club administrators for developing an implementation strategy. Caregivers will have tailored information about injury prevention training.
224066902|NCT05304507|BEHAVIORAL|Control group|"Youth coaches in the control group club will be asked to use injury prevention training available in the coach education material (Ready for handball), i.e., current practice in Sweden."
224066903|NCT04283695|DRUG|GX-I7 or [14C] GX-I7|IM GX-I7 or IV/IM microdose of GX-I7
224066904|NCT01598038|OTHER|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
224066905|NCT04699487|DEVICE|Photobiomodulation|"Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session."
224066906|NCT04592783|DRUG|Antihypertensive Agents|Antihypertensive medications will be initialed once BP is at predetermined threshold
224066907|NCT00909311|DRUG|ABT-450|capsules, QD, 1 dose in each cross-over period
224066908|NCT00909311|DRUG|ritonavir|capsule, QD, 1 dose in each cross-over period
224066909|NCT03006510|OTHER|Hypoglycemia prediction alert|"In real time, for a patient with a glucose \<90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is \>35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
224066910|NCT06106854|BEHAVIORAL|Behavioral: SystemCHANGE|six-month SystemCHANGE™ intervention
224066911|NCT06106854|OTHER|Education|Six patient education booklets
224066912|NCT05102955|OTHER|Observational questionnaires|All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters (physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
224066913|NCT03948178|DRUG|Levosimendan|Levosimendan 1 mg capsule for oral administration
224066914|NCT05099861|OTHER|No intervention|this is an observational study
224066915|NCT00138736|DRUG|Mannan Binding Lectin (MBL)|
224066916|NCT00138736|DRUG|Mannan Binding Lectin|"MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"
224066917|NCT04606459|DEVICE|Coronary sinus reducer|The Reducer System comprises the Reducer device (Reducer) pre-mounted on the Reducer Balloon Catheter. The Reducer System is available in one model size. The Reducer is a sterile, single-use, implantable device designed to establish a narrowing in the coronary sinus (CS) and is intended to improve perfusion to ischemic myocardium in the presence of reversible ischemic heart disease to alleviate the symptoms of refractory angina. The device is implanted percutaneously through the right internal jugular vein into the CS. The Reducer is pre-mounted (crimped) on the Reducer Balloon Catheter which, after inflation, causes device expansion and apposition with the vessel wall. The balloon catheter is then deflated and removed from the CS, leaving the device permanently implanted.
224066918|NCT04606459|OTHER|Optimal medical therapy|Guideline-directed medical therapy
224066919|NCT02357498|PROCEDURE|transsphenoidal surgery|
224155341|NCT01674738|DRUG|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
224155342|NCT01674738|DRUG|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
223572745|NCT00869245|OTHER|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
223743038|NCT06545370|OTHER|Intervention 2 / Nurse-led patients' & caregivers' education|nurse-led education while caregivers also undergo training through oral sessions, phone calls, and appropriately designed educational materials
224066920|NCT02009527|DRUG|N-hydroxy-nor-arginine|
224066921|NCT02009527|DRUG|NaCl|
224066922|NCT05771298|DEVICE|532nm KTP|one to three treatment sessions
224066923|NCT05771298|DEVICE|585nm PDL|one to three treatment sessions
224155343|NCT01674738|DRUG|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
224155344|NCT00004852|DRUG|Efavirenz|
224155345|NCT00004852|DRUG|Lamivudine|
224155346|NCT00004852|DRUG|Zidovudine|
224155347|NCT03828500|BEHAVIORAL|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
224155348|NCT06212206|DEVICE|PillBot|The PillBot System uses active, motorized propulsion technology to facilitate the navigation and positioning of the capsule within the stomach anatomy for imaging of the gastric mucosa by an operator.
224155349|NCT02423460|OTHER|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
224155350|NCT01896661|DRUG|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
224155351|NCT01896661|DRUG|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
224066924|NCT03190200|DEVICE|MRI|No intervention - observational trial using MRI
224066925|NCT03783390|BEHAVIORAL|Exercise Intervention|Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
224066926|NCT03783390|BEHAVIORAL|Newsletter|"Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies."
224066927|NCT05178732|DIETARY_SUPPLEMENT|Dose of protein|One of three protein doses provided
224066928|NCT05178732|OTHER|Menstrual cycle phase|Different phase of the menstrual cycle
224066929|NCT04234711|PROCEDURE|Surgical strategy|To compare the efficacy between conventional repair and sutureless technique for total anomalous pulmonary venous connection
224066930|NCT02432235|DRUG|Camidanlumab tesirine|Intravenous (IV) infusion.
224066931|NCT01399580|DRUG|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
224066932|NCT01399580|DRUG|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
224066933|NCT03535259|RADIATION|concurrent sorafenib and IMRT, followed sorafenib maintenance|IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
224066934|NCT00282503|DRUG|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~* Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~* Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be \> 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
224066935|NCT00282503|PROCEDURE|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
224066936|NCT03597932|DEVICE|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
224066937|NCT03178227|BEHAVIORAL|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
224066938|NCT02148237|BEHAVIORAL|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
224066939|NCT05628714|OTHER|Patient decision aid for patients with superficial basal cell carcinoma|An online WebApp
224066940|NCT00382993|DRUG|Placebo|Matching placebo tablet
224066941|NCT00382993|DRUG|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
224066942|NCT03177083|DRUG|peginterferon beta-1a|SC every 2 weeks
224155352|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG|Participants will take 2 capsules per day of either LGG or placebo.
224155353|NCT04399252|DIETARY_SUPPLEMENT|Lactobacillus rhamnosus GG Placebo|Participants will take 2 capsules per day of LGG placebo
224155354|NCT04566757|BIOLOGICAL|Umbilical Cord Blood Plasma|Intravenous Infusion of Umbilical Cord Blood Plasma
224155355|NCT05218304|BIOLOGICAL|Blood sample|A questionnaire, physical measurements (height, weight, perimeter abdominal and blood pressure) for all arm will be done, approximately 5400 people carried out by investigators. Only 1800 will undergo blood samples carried out by nurses
224155356|NCT00466661|DRUG|Acamprosate|666 mg po TID
224066943|NCT03177083|DRUG|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
224066944|NCT03177083|DRUG|interferon beta-1b|Per SMPC
224066945|NCT03865693|DEVICE|scarmbler therapy|Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
224066946|NCT05872776|DEVICE|Neuromodulation with RR2 device|non-invasive neuromodulation with RR2 device
224066947|NCT05872776|DEVICE|Mock sham neuromodulation with sham RR2 device|Mock sham stimulation with RR2 device
224066948|NCT01052311|DRUG|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
224066949|NCT01052311|DRUG|Placebo|Placebo tablets once daily
224066950|NCT01052311|DRUG|Tredaptive|Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
224066951|NCT06131879|DEVICE|Laser acupuncture|Biostimulation of temporalis and masseter muscles
224066952|NCT06131879|BEHAVIORAL|Modified physical therapy|Progressive muscle relaxation of temporalis and masseter muscles
224066953|NCT02826109|DEVICE|PeriAcryl®90 HV|
224155357|NCT00466661|DRUG|Placebo|2 tabs po TID
224155358|NCT00663104|BEHAVIORAL|exercise|exercise: 3 joint sessions/week for 12 months
224155359|NCT00663104|BEHAVIORAL|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
224155360|NCT00663104|BEHAVIORAL|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
224155361|NCT05031104|OTHER|Physical Exercise|The control group received a standard exercise program for 40 minutes, three times a week for three successive months. The program encompassed aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises.
224155362|NCT05031104|OTHER|Physical Exercise plus Low-energy Laser Therapy|The LLT group received the same program in addition to the application of LLT on both knees, each session before exercises.
224155363|NCT02907281|OTHER|Observational|Observational
224155364|NCT05170672|BIOLOGICAL|Abatacept|
223456490|NCT05384470|DEVICE|BID2 Instrument - breathalyzer|The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
223456491|NCT04791332|DRUG|JNJ-67953964|JNJ-67953964 capsule will be administered orally.
223456492|NCT04791332|DRUG|Placebo|Matching placebo will be administered orally.
223456493|NCT00902759|OTHER|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
224155365|NCT04582604|DRUG|modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine|Day -15 to -14 ： Decitabine 20 mg/m2/day, Ruxolitinib 70mg bid; Day-10： Cytarabine 1.6 g/m2/day CI (only for Haploidentical and unrelated donor), Ruxolitinib 60mg bid; Day- 9： Cytarabine 4g/m2/day CI, Ruxolitinib 60mg bid; Day- 8 to -7： Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 50mg bid; Day-6: Busulfan 0.8mg/kg Q6h iv, Ruxolitinib 40mg bid; Day-5： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 30mg bid; Day-4： Cyclophosphamide 1.8 g/m2/day CI, Ruxolitinib 20mg bid; Day-3： Carmustine 250mg/m2/day iv, Ruxolitinib 10mg bid; Day-2： Ruxolitinib 5mg bid; Day-1： Ruxolitinib 5mg qd;
224155366|NCT02017704|RADIATION|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
224155367|NCT02017704|DRUG|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
224155368|NCT02017704|RADIATION|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
224155369|NCT02017704|DRUG|FOLFOX6|"* Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~* Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~* 5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
224302468|NCT06633107|BEHAVIORAL|Cardiac、rehabilitation、exercise|"Routine cardiac rehabilitation treatment + corresponding rehabilitation exercise therapy prescription according to the condition: (1) slow walking + stairs climbing + standing aerobic exercise for patients with cardiac function level I; Grade II patients should take slow walking + standing aerobics; Grade III patients undergo bedside chair aerobics; Class IV aerobic exercises on bed.~After discharge aerobic exercise with the help of community exercise equipment. The duration is gradually increased from 10-20min to 30-40min each time; Gradually increase the intensity from 55% to 60% of the maximum heart rate and not exceed 85% (maximum heart rate (times / min) = 220 - age (years)); The frequency gradually increased from 3 days/week to 5 days/week"
223456494|NCT05359614|DEVICE|CoolSculpting Elite combined with CoolTone Treatments|Coolsculpting treatment combined with Cooltone treatments for the banana roll region of the buttocks.
223456495|NCT05359614|DEVICE|CoolSculpting Elite|Coolsculpting treatment alone for the banana roll region of the buttocks
223456496|NCT02811991|DRUG|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
224155370|NCT02017704|PROCEDURE|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
224155371|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 20 ml|Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.
224155372|NCT05255536|PROCEDURE|Serratus Anterior Plan Block with 30 ml|Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
224155373|NCT01864317|DEVICE|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
224155374|NCT01864317|OTHER|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
224155375|NCT01864317|OTHER|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
224155376|NCT01864317|OTHER|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
224155377|NCT01864317|OTHER|Humphrey Perimetry|Visual Field Testing
224155378|NCT01864317|OTHER|Applanation Tonometry|Measurement of Intraocular Pressure
223456497|NCT02811991|DRUG|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
224155379|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
224155380|NCT00859807|DRUG|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
224155381|NCT04584931|PROCEDURE|coronally advanced flap|flap surgery to achieve root coverage at gingival recession defect
223456498|NCT02811991|DRUG|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose\<25mg/4h.
223456499|NCT02021110|DRUG|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
223456500|NCT03445403|OTHER|Offset analgesia|Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
223743039|NCT02809677|OTHER|Non-Interventional|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
224066954|NCT05134961|PROCEDURE|Pancreaduodenectomy and possible adjuvant therapy|Adjuvant therapy was generally offered to patients with T4 or lymph node positive disease. As no national Danish guidelines exist, patients were treated based on the oncologists' preference.
224066955|NCT05437003|OTHER|NeuraLight software-based platform|NeuraLight is an investigational software-based platform that is used for assessment and evaluation of neurological conditions including PD patients
224066956|NCT06277895|DIAGNOSTIC_TEST|VOCs|test the end-expiratory gas
224066957|NCT00181194|DEVICE|Asthma Control and Communication Instrument|
224066958|NCT05515250|DEVICE|Use of neurostimulation device|In humans, abdominal pain is modulated by the vagus nerve. Stimulation of the vagus nerve has been suggested to reduce visceral sensitivity and abdominal pain. IB-stim is the Percutaneous Electrical Nerve Field Stimulation (PENS) device. It is a non-invasive, outpatient therapy. PENFS has been shown to be efficacious in pediatric patients with abdominal pain.
224066959|NCT03527563|BEHAVIORAL|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
224066960|NCT01305538|DRUG|BMS-954561|
224066961|NCT01305538|DRUG|BMS-954561|
224066962|NCT01305538|DRUG|Placebo|
224066963|NCT03015259|DRUG|Budesonide/Formoterol fumarate dihydrate|Experimental: Treatment 1
224066964|NCT03015259|DRUG|Symbicort|Active Comparator: Treatment 2
224066965|NCT03015259|DRUG|Placebo|Placebo Comparator: Treatment 3
224066966|NCT02296398|DRUG|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
224066967|NCT04149067|DRUG|Dapagliflozin|Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
224066968|NCT04149067|DRUG|Sitagliptin|Evaluation of the effectiveness and safety of the Sitagliptin treatment.
224066969|NCT00385645|DRUG|Combivir+Kaletra|
224066970|NCT00385645|DRUG|Combivir+Reyataz|
224066971|NCT03232086|OTHER|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
224066972|NCT03232086|OTHER|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
224155382|NCT04584931|PROCEDURE|restorative intervention|colored composite restoration to camouflage the gingival recession defect
224155383|NCT02858102|BEHAVIORAL|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
224155384|NCT03381911|OTHER|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
224155385|NCT00821899|BIOLOGICAL|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
223456501|NCT01995344|DRUG|Cyclophosphamide|
223456502|NCT01995344|DRUG|Fludarabine|
223456503|NCT01995344|GENETIC|Tumour Infiltrating Lymphocytes|
223456504|NCT01995344|DRUG|Interleukin-2|
223456505|NCT02237989|DRUG|paracetamol|1500 mg
223456506|NCT02237989|DRUG|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
223743040|NCT03165110|DEVICE|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
223743041|NCT05533632|DRUG|Semaglutide|Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.
223743042|NCT06520865|OTHER|Acoustic paradigms|Acoustic oddball Gap detection
223743043|NCT03968315|PROCEDURE|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
224155386|NCT01587274|DRUG|Naproxen|Naproxen 500mg twice/ day x 10 days
224155387|NCT01587274|DRUG|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
224155388|NCT01587274|DRUG|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
224155389|NCT00918346|DRUG|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
224155390|NCT06291545|DEVICE|Coronary artery scoring balloon dilation catheter（JW Medical Systems Ltd）|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the Coronary artery scoring balloon dilation catheter treatment group.
224155391|NCT06291545|DEVICE|ScoreFlex NC Coronary Dilatation Catheter|One hundred subjects who met the inclusion and exclusion criteria were enrolled and assigned to the ScoreFlex NC Coronary Dilatation Catheter treatment group.
224155392|NCT03676205|BIOLOGICAL|PRP|Platelet-Rich Plasma
224155393|NCT03676205|OTHER|Traumeel|Homeophatic Treatment
224155394|NCT01339208|OTHER|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
224155395|NCT02854670|DRUG|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
224155396|NCT00168909|DRUG|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
224155397|NCT00168909|DRUG|placebo|placebo once daily, oral, for 3 years
224155398|NCT02012881|BEHAVIORAL|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
224155399|NCT02012881|BEHAVIORAL|Usual practice|Normal curriculum
223456507|NCT02371902|DEVICE|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
223743044|NCT03968315|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224155400|NCT05533073|DRUG|A1: Etoricoxib / Tramadol Fixed dose combination|Sachet with granules (Laboratorios Silanes S.A. de C.V.). Formula : 90 mg/ 50 mg Pharmaceutical Form: Sachet with granules Dosage: 100 mL (90 mg/ 50mg) Administration way: oral
224155401|NCT05533073|DRUG|A2: Etoricoxib|Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
224155402|NCT05533073|DRUG|A3: Tramadol|Tradol®, from Grünenthal GMBH. Pharmaceutical Form: Capsule Formula: Each capsule contains 50 mg Dosage: 1 capsule of 50 mg Administration way: oral
224155403|NCT03175874|PROCEDURE|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
224155404|NCT00000240|DRUG|Buprenorphine|
224155405|NCT02362542|DEVICE|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
224155406|NCT02565615|OTHER|No intervention|Because this is a non-interventional study, there is no intervention here.
224155407|NCT04655053|BEHAVIORAL|Goal intention|Researcher instructs participants to adopt and learn the goal intention requesting them to write it three times and verbally repeat once.
224155408|NCT04655053|BEHAVIORAL|Implementation intention to initiate the behavior|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
224155409|NCT04655053|BEHAVIORAL|Implementation intention to manage the goal preference (avoiding behavior or not)|Researcher instructs participants to adopt and learn the goal intention and the plan requesting them to write it three times and verbally repeat once.
224155410|NCT01852929|OTHER|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
224155411|NCT00592917|DIETARY_SUPPLEMENT|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
224155412|NCT01932658|BIOLOGICAL|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
224155413|NCT03686696|DRUG|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
224155414|NCT03686696|DRUG|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
224155415|NCT03686696|DRUG|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
224155416|NCT01250756|BIOLOGICAL|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
224155417|NCT01250756|BIOLOGICAL|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
224155418|NCT01250756|BIOLOGICAL|DTaP|0.5 mL per dose, 4 doses
224155419|NCT01688440|OTHER|#1 Respiratory Care Solution|Respiratory care solution.
224155420|NCT02229110|OTHER|Signal|Automatic signal in the electronic medical record
224155421|NCT00889395|BEHAVIORAL|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
224302469|NCT03426137|DRUG|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
224302470|NCT03426137|DRUG|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
224302471|NCT03426137|OTHER|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
224066973|NCT02371447|DRUG|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
224066974|NCT06364085|DEVICE|Neuromodulation programming|"Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.~Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up."
224066975|NCT04400474|DRUG|Cabozantinib 40 mg|All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
224066976|NCT01965262|DEVICE|Hema-copolymer Lens|contact lens
224066977|NCT01965262|DEVICE|etafilcon A Lens|contact lens
224066978|NCT04499872|OTHER|Advance Care Plan with Trajectory Touchpoint Technique|Advance Care Plan with Trajectory Touchpoint Technique
224066979|NCT03173794|OTHER|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
224066980|NCT00362089|DIETARY_SUPPLEMENT|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
224066981|NCT02150590|DRUG|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
224066982|NCT02150590|DRUG|sham oxygen (room air)|
224066983|NCT00252707|DRUG|Gefitinib or Docetaxel|
224066984|NCT01785212|DEVICE|Stapler|stapler hepatectomy
224066985|NCT01785212|DEVICE|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
224066986|NCT04283136|DRUG|Padsevonil type 1 Tablet 200 mg|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 1 tablet in a pre-specified sequence during the Treatment Period."
224066987|NCT04283136|DRUG|Padsevonil type 2 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 2 tablet in a pre-specified sequence during the Treatment Period"
224066988|NCT04283136|DRUG|Padsevonil type 3 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 3 tablet in a pre-specified sequence during the Treatment Period."
224066989|NCT04283136|DRUG|Padsevonil type 4 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 4 tablet in a pre-specified sequence during the Treatment Period."
224066990|NCT04283136|DRUG|Padsevonil type 5 Tablet|"* Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~Subjects will receive a padsevonil type 5 tablet in a pre-specified sequence during the Treatment Period."
224066991|NCT00491348|DRUG|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
224066992|NCT05601375|OTHER|Echocardiography|Fetal echocardiography (ultrasound)
224066993|NCT03238820|PROCEDURE|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
224066994|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
224066995|NCT00967551|DIETARY_SUPPLEMENT|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
224066996|NCT01827670|DRUG|Stannous fluoride|Test dentifrice containing 0.454% SnF
224066997|NCT01827670|DRUG|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate \[1000 parts per million (ppm) fluoride\]
224066998|NCT04307992|DEVICE|Prophylactic sac filling with AneuFix|ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.
224066999|NCT06470269|BEHAVIORAL|Eye tracking|Recording the eye movement of participants while they read medical cases.
224067000|NCT06320769|DEVICE|Plate Technique|Using Plates, non-absorbable sutures or cerclage wires to guide the distal femoral physis towards rotational growth to correct deformity
224067001|NCT03428971|PROCEDURE|cardioversion|Direct current (DC) cardioversion for sinus rhythm restoration
224067002|NCT03711500|DRUG|D-serine|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
224067003|NCT03711500|DRUG|Placebo|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
224067004|NCT00368511|PROCEDURE|Music Listening|Listen to music and posture measurements
224302472|NCT00501098|DRUG|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
224155422|NCT05576610|PROCEDURE|Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
224155423|NCT05576610|PROCEDURE|Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )|"The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures."
224155424|NCT04146337|BIOLOGICAL|FMT|Fecal microbiota in frozen capsules
224155425|NCT02205398|DRUG|INC280|
224155426|NCT02205398|DRUG|cetuximab|
224155427|NCT01787799|DEVICE|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
224155428|NCT05568056|BEHAVIORAL|Visualizing and Verbalizing for Language comprehension and Thinking|The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
224155429|NCT03511820|DRUG|Lipo-AB® (amphotericin B) liposome|"1. Name: Lipo-AB® (amphotericin B) liposome for injection~2. Dosage form: Lyophilized powder 50 mg/vial~3. Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~4. Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
224155430|NCT00006063|DRUG|pancrelipase with bicarbonate|
224155431|NCT03890393|DEVICE|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
224155432|NCT02533193|PROCEDURE|ERAS perioperative cares|"1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~7. Intravenous patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. No nasogastric tube~10. No drain insertion~11. Patients will be discharged at POD#4 if there's no problem"
224155433|NCT02533193|PROCEDURE|Conventional perioperative cares|"1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Drainage tube insertion if needed"
224155434|NCT00106288|DRUG|Micafungin|IV
224155435|NCT00106288|DRUG|Liposomal Amphotericin B|IV
224155436|NCT00460837|DRUG|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
224155437|NCT00248378|DRUG|Smoked Cannabis|
224155438|NCT03129633|OTHER|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
224155439|NCT04077411|OTHER|Observational|This is an observational study with no interventions.
224155440|NCT00339118|DRUG|doxorubicin, cytoxan|
224155441|NCT01815580|DRUG|Atripla or Stribild|Antiretroviral therapy
224155442|NCT05584904|OTHER|volunteer anesthesiologists and nurses|18 not expert in electroencephalography digestive endoscopy and operating room nurses, and 8 anesthesiologists interpreting EEGs obtained with a single electrode EEG
224155443|NCT04480541|BEHAVIORAL|Roadmap 2.0 information system|Caregivers and patients download the Roadmap 2.0 app on their own mobile phones/tablet
224155444|NCT04480541|OTHER|Wearable activity sensor|Caregivers and patients will receive a Fitbit wearable activity sensor
224155445|NCT04480541|OTHER|Survey administration|Caregivers and patients will be asked to complete health-related quality of life surveys
224155446|NCT02228564|PROCEDURE|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
224155447|NCT02228564|DEVICE|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
224155448|NCT03481387|DEVICE|Aortic Valve Replacement with Perceval S sutureless heart valve|Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
224155449|NCT01262599|DEVICE|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
224155450|NCT01262599|DEVICE|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
224155451|NCT00018629|OTHER||
224155452|NCT03141892|DEVICE|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
224155453|NCT04562532|DEVICE|Microport Firehawk stent|MicroPort Firehawk biodegradable polymer rapamycin target eluting stent
224155454|NCT04562532|DEVICE|2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)|"* Everolimus eluting stents (Xience family - Abbott Vascular, Promus family- Boston Scientific, Synergy - Boston Scientific)~* Zotarolimus eluting stents (Resolute/Onyx family and Endeavor- Medtronic)~* Sirolimus eluting stents (Orsiro- Biotronik)"
224155455|NCT03802656|DEVICE|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
224155456|NCT05793957|OTHER|Questionnaire Administration|Ancillary studies
224155457|NCT05793957|BEHAVIORAL|Telephone-Based Intervention|Use smartphone
224155458|NCT05793957|OTHER|Virtual Technology Intervention|Use VR headset
224155459|NCT06090448|DEVICE|EarSwitch device|The Earswitch™ device consists of an earpiece made from silicon or similar bio-compatible material and incorporates a miniature camera. The earpiece sits within the ear canal and is not in direct contact with the eardrum and the camera is not in contact with the ear-canal. The camera detects voluntary movement from the tensor tympani muscle as presented at the eardrum and the Earswitch system translates this movement to an external virtual keypad or similar to allow the patient to communicate nonverbally.
224155460|NCT04539925|OTHER|Acute coronary syndrome|The effect of air pollution on acute coronary syndrome
224155461|NCT04768530|PROCEDURE|Scaling and Root Planing|Supra- and sub-gingival calculus and debris were removed
224155462|NCT04768530|DRUG|Nitazoxanide hydrogel|Scaling and root planing was performed in combination with the subgingivally delivered thermosensitive Nitazoxanide hydrogel as adjunct antimicrobial therapy.
224155463|NCT03446989|BEHAVIORAL|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
224155464|NCT05291572|BEHAVIORAL|speech therapy only|fluency shaping technique
224155465|NCT05291572|DEVICE|hyperbaric oxygen therapy|chamber system using oxygen with pressure
224155466|NCT05291572|DRUG|medical treatment|brain stimulant
224155467|NCT04975672|OTHER|Myofuncional Therapy|Group 1, with myofunctional therapy and SN1 functional orthopedic appliances The participant underwent a myofunctional therapy session every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system. The myofunctional therapy performed will be by an expert speech therapist
224155468|NCT01939964|OTHER|Activation Mist|Activation Mist topical spray
224155469|NCT04319406|PROCEDURE|Prolotherapy|Test group will be administered 12.5% Dextrose mainly into superior joint space according to symptoms of patient at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
224155470|NCT04319406|PROCEDURE|Dry needling|Only dry needling will be performed at baseline (0 week) and at biweekly intervals at 2 and 4 weeks i.e. a total of 3 injections. A 4th injection will be given at 6 weeks if required.
224155471|NCT05218577|OTHER|high selenium functional food|HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
224155472|NCT05218577|DIETARY_SUPPLEMENT|selenium supplement|20 microgram/day selenium suppplement powder.
224155473|NCT05218577|OTHER|Placebo|the placebo mocaf powder
224155474|NCT01269047|DRUG|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
224155475|NCT01269047|DRUG|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
224155476|NCT01269047|DRUG|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
224155477|NCT04114539|DRUG|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
224155478|NCT00617591|DRUG|Lenalidomide|25 mg orally on days 1-21
224155479|NCT00617591|DRUG|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m\^2 intravenously on day 1 (reduced to 30 mg/m\^2 after the initial 29 patients were treated)
224155480|NCT00617591|DRUG|Dexamethasone|40 mg orally on days on 1-4
224155481|NCT00599235|DRUG|sildenafil|50mg 3 times daily for 7 days
224155482|NCT00599235|DRUG|hydralazine|25mg 3 times daily for 7 days
224155483|NCT00599235|DRUG|placebo|3 times daily for 7 days
224155484|NCT04948814|BIOLOGICAL|Fecal microbiota transplantation|FMT utilizing stool from healthy children
224155485|NCT04948814|DRUG|Vancomycin|40mg/kg/day
224155486|NCT03224910|OTHER|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
224155487|NCT05630560|OTHER|Psychotherapy treatment|The psychotherapist will conduct psychotherapy as normally done by them in their practice. The treatment will thus be un-manualized and consist of a broad range of therapeutic orientations and treatment lengths.
224155488|NCT04911829|BEHAVIORAL|Psychotherapy|
224155489|NCT04841694|DIETARY_SUPPLEMENT|Probiotic|Bacillus indicus
224155490|NCT03391076|DIAGNOSTIC_TEST|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
224155491|NCT01711658|RADIATION|IMRT|Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy
224155492|NCT01711658|DRUG|Cisplatin|100 mg/m\^2 administered intravenously on days 8 and 29
224155493|NCT01711658|DRUG|placebo|1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
224155494|NCT01711658|DRUG|Lapatinib|1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
224155495|NCT04155658|OTHER|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
224155496|NCT04155658|OTHER|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
224155497|NCT04155658|OTHER|Toothpaste with no fluoride|Toothpaste with no fluoride
224155498|NCT03078959|OTHER|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
224155499|NCT00044642|DRUG|Lorazepam|
223456508|NCT02371902|DEVICE|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
223743045|NCT05562167|DRUG|KNO3|10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
224067005|NCT00790907|DRUG|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
224067006|NCT00790907|DRUG|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
224067007|NCT00790907|DRUG|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
224067008|NCT00907101|DRUG|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
224067009|NCT00109707|DRUG|Nilotinib|
224067010|NCT00037180|DRUG|Celecoxib|
224067011|NCT00037180|DRUG|Irinotecan|
224067012|NCT00037180|DRUG|5-fluorouracil|
224067013|NCT00037180|DRUG|Leucovorin|
224067014|NCT00001288|DRUG|15 O Water|
224067015|NCT00001288|DRUG|FDG|
224067016|NCT04807348|DRUG|Chiglitazar 32mg|Administrated once daily
224067017|NCT04807348|DRUG|Chiglitazar 48mg|Administrated once daily
224067018|NCT04807348|DRUG|Placebo|Placebo of Chiglitazar
224067019|NCT04807348|DRUG|Metformin Hydrochloride|most tolerable dose
224067020|NCT04707898|DEVICE|Single Bond Universal|Adhesive system
224067021|NCT04707898|DEVICE|G-Premio Bond|Adhesive system
224067022|NCT02250274|BIOLOGICAL|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
224067023|NCT02250274|BIOLOGICAL|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~\[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.\]"
224067024|NCT02018627|DRUG|Xeris glucagon|The subject is given an injection of xeris glucagon
224067025|NCT02018627|DRUG|Lilly glucagon|The subject is given an injection of lilly glucagon
224067026|NCT04395911|DEVICE|SCD|cytopheretic device
224155500|NCT02918656|OTHER|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
224155501|NCT02918656|OTHER|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
224155502|NCT02918656|OTHER|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
224155503|NCT04671615|DRUG|palbociclib|As provided in real world practice
224155504|NCT00248105|BEHAVIORAL|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
224302473|NCT03507647|BEHAVIORAL|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams \& Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
224302474|NCT03507647|OTHER|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
224302475|NCT02677181|DRUG|ATG|rabbit ATG（Sanofi）
224302476|NCT02677181|DRUG|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
224302477|NCT02677181|DRUG|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
224067027|NCT03166293|BEHAVIORAL|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
223572746|NCT01206283|PROCEDURE|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~* Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~* Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~* Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~* Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~* Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
223572747|NCT01206283|PROCEDURE|Cerebral perfusion pressure-targeted therapy|"* ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~* Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~* No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~* Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes \[Na, Cl and K\]);"
223572748|NCT03194191|DEVICE|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
223572749|NCT03417817|DEVICE|Bravo|wireless pH monitoring over 96 hours
223572750|NCT01037049|OTHER|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
223572751|NCT00881764|PROCEDURE|Inguinal hernia surgery|Non-experimental procedure
223572752|NCT00881764|PROCEDURE|General anesthesia|Non-experimental procedure/treatment
223572753|NCT01759563|DEVICE|nasopharyngeal targeted brain cooling|
224067028|NCT00446511|DRUG|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
224067029|NCT00446511|DRUG|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
224067030|NCT00446511|DRUG|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
224067031|NCT00446511|DRUG|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
224067032|NCT00514956|BEHAVIORAL|Emotional Freedom Techniques (EFT)|
224067033|NCT03030430|BIOLOGICAL|BAT1706 injection|1mg/kg, IV on day 1
224067034|NCT03030430|BIOLOGICAL|EU-sourced Avastin|1mg/kg, IV on day 1
224067035|NCT03030430|BIOLOGICAL|US-sourced Avastin|1mg/kg, IV on day 1
224067036|NCT05785143|PROCEDURE|Utilizing dry lab database to analyze the prognostic factors of multi-trauma patients and determine the optimal timing of definitive orthopedic operation|to analyze if serum lactate a predictive factor of optimal surgical timing in multi-trauma patients. In order to obtain more accurate data, we choose to utilize ili database and trauma database instead of National Health Insurance Research Database.
224067037|NCT04394533|DRUG|Prilocaine (Hyperbaric 2%)|2 ml hyperbaric prilocaine
224067038|NCT04394533|DRUG|Bupivacaine (Hyperbaric 0.5%)|2 ml hyperbaric bupivacaine
224067039|NCT01618214|DRUG|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
224067040|NCT01312935|DRUG|PMX-60056|investigational drug
224067041|NCT01758250|OTHER|Acoustic Radiation Force Impulse (ARFI)|
224067042|NCT01758250|OTHER|Laser Doppler Flowmetry (LDF)|
224067043|NCT01758250|OTHER|Laser Doppler Perfusion Imaging (LDI)|
224067044|NCT01758250|OTHER|Optical Coherence Tomography (OCT)|
224067045|NCT01758250|OTHER|Orthogonal Polarization Spectral Imaging (OPSI)|
224067046|NCT01758250|OTHER|Nail fold video capillaroscopy (NVC)|
223572754|NCT03497091|OTHER|Enteral Formula|Enteral Feeding with an amino acid-based formula
223572755|NCT00496197|DRUG|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
224155505|NCT01072448|DRUG|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
223572756|NCT00496197|DRUG|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
223743046|NCT05562167|DRUG|Placebo|10 mmol of placebo via a single gel capsule to be consumed orally once per day for 6 weeks.
223743047|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
223743048|NCT03903016|DRUG|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
224067047|NCT01617980|OTHER|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
224067048|NCT03472157|OTHER|Lifestyle therapy|Lifestyle habits (caloric intake and exercise) + pedometer
224067049|NCT03472157|PROCEDURE|Bariatric surgery|Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
224067050|NCT03256500|DEVICE|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
224067051|NCT02563847|DIETARY_SUPPLEMENT|0.52 g L-Tryptophan|
224067052|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Tryptophan|
224067053|NCT02563847|DIETARY_SUPPLEMENT|1.56 g L-Leucine|
224067054|NCT02563847|DIETARY_SUPPLEMENT|50 g Xylitol|
224067055|NCT02563847|DIETARY_SUPPLEMENT|75 g Erythritol|
224067056|NCT02563847|DIETARY_SUPPLEMENT|75 g Glucose|
224067057|NCT02563847|DIETARY_SUPPLEMENT|300 mL tap water|
224067058|NCT02563847|OTHER|50 mg 13C-sodium acetate|
224067059|NCT02756507|BEHAVIORAL|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
224067060|NCT02756507|BEHAVIORAL|Wait list|Delayed intervention
224067061|NCT02971579|PROCEDURE|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
224067062|NCT02398591|DRUG|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
224067063|NCT02398591|DRUG|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
224067064|NCT01948843|DRUG|ADI-PEG 20|
224067065|NCT01839864|BEHAVIORAL|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
224302478|NCT02677181|DRUG|Methotrexate|short-term methotrexate
224067066|NCT04352439|DRUG|Aspirin|81 mg aspirin daily
224067067|NCT02228590|DRUG|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
224067068|NCT02997579|PROCEDURE|patellar resurfacing|patellar component insert with cement
224067069|NCT05700162|BEHAVIORAL|Photograph|As soon as she starts to express her milk from the mother, on whatsapp will be asked to look at the photo of the baby sent to her for 5 minutes. She will be asked to express both breasts for 15 minutes every 3 hours.
224067070|NCT05700162|BEHAVIORAL|Video|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
224067071|NCT05700162|BEHAVIORAL|Live Broadcast|As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
224067072|NCT05700162|BEHAVIORAL|Control Group|She will be asked to express both breasts for 15 minutes every 3 hours. No additional action will be taken.
224067073|NCT03106038|DRUG|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
224067074|NCT04744337|PROCEDURE|orthodontic treatment|fixed orthodontic treatment in adolescent females initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
224067075|NCT05603715|DRUG|Pyridostigmine Bromide|Dose escalation trial of Pyridostigmine bromide oral tablets 60-180 mg TID for four weeks
224067076|NCT00259883|DRUG|paroxetine|1 or 2 tablets once a day
224067077|NCT01588795|PROCEDURE|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
224071354|NCT04829851|DEVICE|PROTEIN Mobile App|All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.
224071355|NCT04829851|DEVICE|Expert Dashboard|Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
224071356|NCT04354714|DRUG|Ruxolitinib|For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube
224071357|NCT04354714|PROCEDURE|Peripheral blood draw|-Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
224071358|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
224071359|NCT02611388|DEVICE|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
224071360|NCT02611388|DEVICE|fake stimulation|Patients were only attached electrodes without electric current
224071361|NCT03140137|DRUG|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
224067078|NCT01588795|DRUG|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
224155506|NCT01072448|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
224155507|NCT03846973|DRUG|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
224155508|NCT03846973|OTHER|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
224155509|NCT02585076|OTHER|Standard of care|As prescribed by treated physician
224155510|NCT00003882|DRUG|anhydrovinblastine|
224155511|NCT05484427|OTHER|Telemedicine|Replacement of the regullar meeting with diabetologist by remote communication only
224155512|NCT01799304|PROCEDURE|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
224155513|NCT01799304|PROCEDURE|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
223456509|NCT03256357|BEHAVIORAL|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
223456510|NCT03256357|BEHAVIORAL|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
223456511|NCT03256357|BEHAVIORAL|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
223456512|NCT00158262|DRUG|Propranolol|Propranolol short-acting or long-acting capsule
223456513|NCT00158262|DRUG|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
223456514|NCT00156026|PROCEDURE|loop electrosurgical excision procedure (LEEP)|1\. loop electrosurgical excision procedure
223456515|NCT04785898|DIAGNOSTIC_TEST|ID Now™ COVID-19 Screening Test|"Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol."
223456516|NCT05463497|DRUG|Treatment A|JW0201: single administration, Tablet, Oral, BID for 5 days
223456517|NCT05463497|DRUG|Treatment B|C2103: single administration, Tablet, Oral, BID for 5 days
223456518|NCT05463497|DRUG|Treatment C|JW0201 and C2103 : combination administration, Tablet, Oral, BID for 5 days
223456519|NCT05463497|DRUG|Treatment D|C2104 : single administration, Tablet, Oral, QD for 5 days
223456520|NCT05463497|DRUG|Treatment E|JW0201 and C2104 : combination administration, JW0201 twice a day and C2104 once a day for 5days
224067079|NCT03134170|OTHER|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
224067080|NCT03383484|OTHER|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
224067081|NCT03383484|OTHER|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
223572757|NCT00496197|DRUG|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
223572758|NCT02172495|DRUG|Tiotropium bromide|Tiotropium bromide 18 micrograms
224067082|NCT03873714|DEVICE|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
224067083|NCT02599701|DRUG|Gabapentin|A single dose Gabapentin 300mg at bedtime.
224067084|NCT02599701|DRUG|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
224067085|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
224067086|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
224067087|NCT03061032|DRUG|Sofosbuvir/Ledipasvir 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
224067088|NCT03061032|DRUG|Sofosbuvir/Ledipasvir plus Ribavirin 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
224067089|NCT03028870|DRUG|V120083|Capsules
224067090|NCT03028870|DRUG|Naproxen|Capsules
224067091|NCT03028870|DRUG|Placebo|Capsules to match V120083 and/or naproxen
224067092|NCT00012779|BEHAVIORAL|Health Education Program|
224067093|NCT01411436|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
224155514|NCT01799304|PROCEDURE|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
224155515|NCT01799304|PROCEDURE|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
224155516|NCT05848076|OTHER|TNE|McGill exercise focuses on the ability of the spine to stabilize in different positions 3 sets of 3 repletion with of each of muscle and briefly explains the patient about their pain
224155517|NCT05848076|OTHER|core stability|McGill exercises for the low back.
224155518|NCT02445703|BIOLOGICAL|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
224155519|NCT02445703|BIOLOGICAL|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
224155520|NCT01400139|DRUG|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
224155521|NCT02251158|DRUG|Tipranavir oral solution|
224155522|NCT02251158|DRUG|Tipranavir capsules|
223743049|NCT04410965|DRUG|TERIFLUNOMIDE|Pharmaceutical form:tablet Route of administration: oral
223743050|NCT02930551|DRUG|Lidocaine|
224155523|NCT02251158|DRUG|Ritonavir oral solution|
224155524|NCT02251158|DRUG|Ritonavir soft gel capsules|
224155525|NCT02251158|OTHER|High fat breakfast|
224155526|NCT00249795|DRUG|Irbesartan|oral administration (tablets) once daily
224155527|NCT00249795|DRUG|placebo|oral administration (tablets) once daily
224155528|NCT03134612|DRUG|Ondansetron 8 mg|
224155529|NCT03134612|DRUG|Lidocain 40 mg|
224155530|NCT06204289|BEHAVIORAL|Nurse-led Supportive Care Programme|Nurse-led supportive care programme was applied to family caregivers for eight weeks in the form of face-to-face clinic interviews. It took an average of 40 minutes to interview with family caregivers at the clinic.
224155531|NCT02285517|PROCEDURE|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
223456521|NCT01727817|DEVICE|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
223456522|NCT05289388|DIAGNOSTIC_TEST|Lactate/CRT index|index will be calculated as the product of multiplying the CRT and serum lactate
223456523|NCT02959918|DRUG|SEL-212|SEL-212, biologic
223456524|NCT02959918|DRUG|SEL-037|SEL-037, biologic
223456525|NCT02959918|DRUG|SVP-rapamycin (SEL-110)|SVP-rapamycin, biologic
224067094|NCT02175732|BEHAVIORAL|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
224155532|NCT02285517|PROCEDURE|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
224155533|NCT01535612|DEVICE|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
224067095|NCT02175732|BEHAVIORAL|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
224155534|NCT03179410|DRUG|Avelumab|10 mg/kg intravenously every 2 weeks
224155535|NCT05117749|DRUG|Saffron 100|to Mild and Moderate UC patients
224155536|NCT05117749|DRUG|Saffron 50|to Mild and Moderate UC patients
224155537|NCT05117749|DRUG|Placebo|to Mild and Moderate UC patients
224155538|NCT05369546|DIAGNOSTIC_TEST|q3CB|The q3CB/ncCEM/DBT acquisition protocol consists of a combination of DBT volume reconstructions and projection dual-energy mammograms acquired with a clinical contrast enhanced mammography (CEM) protocol, without contrast administration agent.
224155539|NCT02015806|BEHAVIORAL|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
224155540|NCT02015806|BEHAVIORAL|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
224155541|NCT02015806|BEHAVIORAL|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
224155542|NCT01191632|RADIATION|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
224155543|NCT01191632|RADIATION|No Radiation|Control group with 0Gy
224155544|NCT04661852|DRUG|Cabozantinib|PO (dose and schedule based upon dose level and nomogram)
224155545|NCT04661852|DRUG|Topotecan|IV, over 30 minutes (schedule based upon dose level)
224155546|NCT04661852|DRUG|Cyclophosphamide|IV, over 30 minutes (schedule based upon dose level)
224155547|NCT04661852|DRUG|Myeloid growth factor|subcutaneous filgrastim (daily until ANC ≥ 1,500/mm3 after nadir) or pegfilgrastim (once) must be given, with choice of agent per institutional standard or treating physician preference, starting on day 5, 6, 7 or 8 (depending upon chemotherapy timing)
224155548|NCT04239170|DRUG|Camrelizumab(SHR-1210)|Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin
224155549|NCT06345599|RADIATION|Radiotherapy|This study is a phase I clinical study. The study is divided into phases Ia and Ib. Phase Ia is a dose-escalation experiment, divided into two cohorts based on radiotherapy dose, with 3+3 patients per cohort for a total of 12 patients. The first group undergoes two cycles of radiotherapy: 24Gy:8Gy3f d4-d6. The second group undergoes one cycle of radiotherapy: 40Gy:8Gy5f d3-d7. Phase II consists of 40 patients who choose the radiotherapy dose based on the results of phase I.
224155550|NCT06345599|DRUG|Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab|GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
224155551|NCT06345599|DRUG|Chemotherapy:Albumin-bound paclitaxel、Gemcitabine|Albumin-bound paclitaxel 125mg/m2 d1, d8 Gemcitabine 1000mg/m2 d1, d8 After 3 cycles of neoadjuvant combination treatment with cadumilimab, the patient's surgical status will be evaluated. If surgery is possible, the patient will continue with another 3 cycles of treatment post-operation.
224155552|NCT02460978|DRUG|Dapagliflozin|Tablets
224155553|NCT02460978|OTHER|Placebo for dapagliflozin|Tablets
224155554|NCT02573337|DEVICE|Emervel Classic Lidocaine|Treatment of wrinkles and folds
224155555|NCT02573337|DEVICE|Emervel Deep Lidocaine|Treatment of wrinkles and folds
224155556|NCT04347278|DRUG|Patients with the treatment agains COVID19|"Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise."
224155557|NCT01800851|OTHER|Energy expenditure evaluation in calorimetric chamber|
224155558|NCT01360853|DRUG|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
224302479|NCT00209105|DRUG|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
224302480|NCT00209105|BEHAVIORAL|Psychosocial stress induction|Laboratory stress induction, no drug administration
224302481|NCT00209105|PROCEDURE|Brain imaging of sad mood , self-reference, reward|Brain imaging
224302482|NCT00209105|BEHAVIORAL|Acoustic startle|No drugs involved
224302483|NCT01446328|DRUG|Amisulpride|Tablets, dose range 50-1200 mg/ day
224302484|NCT01446328|DRUG|Aripiprazole|Tablets, dose range 5-30 mg/ day
224302485|NCT01446328|DRUG|Olanzapine|Tablets, dose range 2.5-20 mg/ day
224302486|NCT03954314|DRUG|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
224302487|NCT01914055|DEVICE|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
223456526|NCT03894709|BEHAVIORAL|family-centered care model|Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
223456527|NCT03541148|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
223456528|NCT04758195|PROCEDURE|Transanal irrigation|Transanal irrigation (TAI) is performed using the irrigation bag, electronic irrigation system, or balloon catheter with syringe. TAI is performed with up to 2000 ml tap water every 24-48 hours (3-7 times per week) over the course of 6 months.
223743051|NCT02930551|DRUG|Isotonic Saline|
224155559|NCT01360853|DRUG|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
224155560|NCT01360853|DRUG|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
224155561|NCT02091947|DEVICE|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
224155562|NCT04724512|DEVICE|suture|a type of suture used in entropion surgery
224155563|NCT03380000|DRUG|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
224155564|NCT03380000|DRUG|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
224155565|NCT05434104|OTHER|Vaginal lactoferrin|Lactoferrin vaginal pessaries to insert nightly for seven nights
224155566|NCT05434104|DRUG|Usual care|Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
224155567|NCT03549429|DEVICE|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
224155568|NCT04263194|DEVICE|rTMS|25 min of high frequency (20 Hz) repetitive TMS applied at 100% of resting motor threshold (rMT).
224155569|NCT04263194|DEVICE|Sham rTMS|Placebo intervention will consist in the same procedure but using a sham rTMS coil.
224302488|NCT01914055|DEVICE|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
224067096|NCT05193110|OTHER|Polyetheretherketone (PEEK) Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis|Sub-periosteal Implant Retaining Maxillary Fixed Prosthesis fabricated by digital \& milling technology
224067097|NCT05949775|BIOLOGICAL|Neoantigen mRNA Personalised Cancer vaccine|Drug: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab Injection Subcutaneous Injection
224067098|NCT03574870|DEVICE|wearable sensor|A commercially-available wearable fitness sensor
224067099|NCT00708123|DRUG|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
224067100|NCT00708123|DRUG|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
224302489|NCT00166036|DRUG|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
224067101|NCT00407524|DRUG|AKL 1|
224302490|NCT00166036|DRUG|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
224302491|NCT01462318|DRUG|Midazolam|5 mg
224302492|NCT01462318|OTHER|Caffeine|200 mg
224302493|NCT01462318|DRUG|S-warfarin|10 mg
224302494|NCT01462318|OTHER|Vitamin K|10 mg
224302495|NCT01462318|DRUG|Omeprazole|40 mg
224302496|NCT01462318|DRUG|Dextromethorphan|30 mg
224067102|NCT02813278|DIETARY_SUPPLEMENT|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
224067103|NCT02813278|OTHER|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
224067104|NCT05630248|DIAGNOSTIC_TEST|Recurrent Neural Network|it is to classify pulse types by using specialized pulse measuring instruments.
223456529|NCT04758195|OTHER|Best supportive therapy|Best supportive therapy consists of dietary modification, pelvic floor muscle training, biofeedback, and necessary medication.
224067105|NCT04879043|DRUG|HDP-101|HDP-101 is available as lyophilized white powder for preparation of infusion.
224067106|NCT00776607|DRUG|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
224067107|NCT00776607|DRUG|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
224302497|NCT01462318|BIOLOGICAL|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
223456530|NCT04538469|OTHER|COVID visitation restrictions|Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
223456531|NCT04953143|BEHAVIORAL|LiverPal Intervention|"Inpatient longitudinal palliative care intervention~\- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period~LiverPal intervention domains include the following:~* Therapeutic relationship~* Symptom management~* Coping with illness~* Prognostic awareness and illness understanding~* Treatment decision-making~* End-of-life care"
223456532|NCT05505695|OTHER|Brace and Exercise Treatment|Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.
223456533|NCT05505695|OTHER|Brace Treatment|Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
223456534|NCT05141318|OTHER|FROM-16 Questionnaire|A 16-item questionnaire to provide information about the impact of a patient's disease/condition the participants (family member of patient) quality of life
223456535|NCT05141318|OTHER|Semi-structured two-part interview|A telephone/video interview to provide additional context to the FROM-16 responses
223456536|NCT04268758|DEVICE|tulipon|Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.
223456537|NCT05141929|BEHAVIORAL|web based education|In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
223456538|NCT02585713|DRUG|Apixaban|Given PO
223456539|NCT02585713|DRUG|Dalteparin|Given SC
223456540|NCT02585713|OTHER|Questionnaire Administration|Ancillary studies
223456541|NCT02264210|DRUG|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
224155570|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
224155571|NCT02155894|BEHAVIORAL|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
224155572|NCT02021851|DRUG|Dexamethasone and aprepitant|
224155573|NCT02021851|DRUG|Dexamethasone and ondansetron|
224155574|NCT02562989|DRUG|[18F]MK-6240, ~185 MBq|IV dose of \~185 MBq \[18F\]MK-6240
224155575|NCT02562989|DRUG|[18F]MK-6240, ~160 MBq|IV dose of \~160 MBq \[18F\]MK-6240
224155576|NCT00531492|BEHAVIORAL|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
224155577|NCT00531492|OTHER|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
224155578|NCT00498225|DRUG|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
224155579|NCT00498225|DRUG|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
224155580|NCT00498225|DRUG|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
224155581|NCT04737980|DRUG|Liposomal bupivacaine|Injection of 10 ml of liposomal bupivacaine 1.3% (133 mg) for ultrasound guided interscalene block
224155582|NCT04737980|DRUG|Bupivacaine Hcl 0.5% Inj|Injection of 10 ml of 0.5% bupivacaine hydrochloride as admixture for ultrasound guided interscalene block
224155583|NCT04737980|DRUG|Ropivacaine 0.5% Injectable Solution|Injection of 30 ml of ropivacaine 0.5% injectable solution for ultrasound guided interscalene block
224155584|NCT04737980|DRUG|Dexamethasone|Injection of 8mg (2ml) dexamethasone injectable as admixture
224155585|NCT00588523|DRUG|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
224155586|NCT01641718|DRUG|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
224155587|NCT01641718|DEVICE|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
224155588|NCT00518843|BEHAVIORAL|FBT-BN|Mobilizing parents to curtail binge eating and purging
223456542|NCT03160495|OTHER|All patients|All patients are scanned with PET/MR prior to surgery.
223456543|NCT00820287|PROCEDURE|Biopsy of testicular tumor|testicular biopsies performed through open surgery
223456544|NCT02783313|DEVICE|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
223456545|NCT02783313|OTHER|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
223456546|NCT03956030|OTHER|Contraception Handout|Handout covering contraception options
223456547|NCT03956030|OTHER|Nutritional Handout|Handout covering nutrition
223456548|NCT04682379|DIAGNOSTIC_TEST|Proprioceptive assessment|"1. Trunk flexion-extension repositioning test~2. Trunk lateral-flexion repositioning test~3. Trunk axial-rotation repositioning test~4. Neck rotation repositioning test~5. Elbow flexion repositioning test~6. Knee extension repositioning test"
223456549|NCT01409187|DRUG|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
223456550|NCT01409187|DRUG|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
223456551|NCT01409187|DRUG|Interleukin-2 (Aldesleukin)|9 million IU/m\^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
223456552|NCT02933398|PROCEDURE|Robotic Assisted Nephrectomy|Robotic (Davinci)
224155589|NCT00518843|BEHAVIORAL|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
224155590|NCT03420313|DRUG|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
224155591|NCT01233180|OTHER|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
224155592|NCT01233180|DEVICE|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
224155593|NCT03879993|OTHER|Exercise group|Resistance training 3 times per week (45-60 minutes of resistance training)
224155594|NCT02711605|DEVICE|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
224155595|NCT02020291|DRUG|Foxy-5|
224155596|NCT03958994|OTHER|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
224155597|NCT01709968|DRUG|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
224155598|NCT01709968|DRUG|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
224155599|NCT00841269|DRUG|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
224155600|NCT01459068|BEHAVIORAL|Common Elements Treatment Approach|"CETA components include:~1. Engagement (encouraging participation)~2. Psychoeducation (introduction)~3. Anxiety Management Strategies (relaxation)~4. Behavioral Activation (getting active)~5. Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~6. Imaginal Gradual Exposure (talking about difficult memories)~7. In Vivo Exposure (Live exposure)~8. Suicide/Homicide/Danger Assessment and Planning (safety)~9. Screening and Brief Intervention for Alcohol (alcohol intervention)"
224155601|NCT04742972|RADIATION|SABR|SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.
224155602|NCT04742972|OTHER|SOC|"Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment"
224155603|NCT00196196|DEVICE|Codman VPV System|Valve Positioning Verification (VPV) System
224155604|NCT01154595|DIETARY_SUPPLEMENT|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
224155605|NCT01154595|BEHAVIORAL|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
224155606|NCT00126854|PROCEDURE|Magnetic Resonance Spectroscopy Imaging|
224155607|NCT00313755|PROCEDURE|Narrow Band Imaging|
224155608|NCT02226978|DRUG|Tipranavir|
224155609|NCT02226978|DRUG|Ritonavir|
224155610|NCT02226978|DRUG|Valaciclovir|
224155611|NCT03949998|DEVICE|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
224155612|NCT03949998|OTHER|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
224155613|NCT03347812|PROCEDURE|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
224155614|NCT03347812|PROCEDURE|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
224155615|NCT04368104|DIAGNOSTIC_TEST|Darwish test (office hysteroscopic bubble suction and tubal peristalsis)|Testing Darwish test (office hysteroscopic bubble suction test and proximal tubal peristalsis) in women using minipills versus other cases not using hormones..
223456553|NCT02933398|PROCEDURE|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
223456554|NCT04844008|DIETARY_SUPPLEMENT|Nanobubble drink|Commercially available sports drink
223456555|NCT02204345|DRUG|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
223456556|NCT02204345|DRUG|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
223456557|NCT02204345|DRUG|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
223572759|NCT03283969|OTHER|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
223572760|NCT03283969|OTHER|Isocaloric powder|Isocaloric powder
223572761|NCT01332838|PROCEDURE|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
223572762|NCT01332838|DEVICE|compression stockings (Sigvaris )|Specialized monoleg compression
224067108|NCT02550184|OTHER|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
224067109|NCT00153686|PROCEDURE|capsule endoscopy|capsule endoscopy of small intestine
224067110|NCT00153686|PROCEDURE|Mesenteric Angiogram|Mesenteric Angiogram
224067111|NCT05277545|BEHAVIORAL|Technology addiction education|Technology addiction personal development training was applied by the researcher to the students in the experimental group for 10 weeks.
224155616|NCT03032510|DRUG|Eravacycline|
224155617|NCT03032510|DRUG|Ertapenem|
224155618|NCT03032510|DRUG|Placebo|
224155619|NCT03032510|DRUG|Levofloxacin|
224155620|NCT01601470|DRUG|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
224155621|NCT01601470|DRUG|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
224155622|NCT05285436|DEVICE|CloudCath System|The CloudCath System enables drainage and measures turbidity, reported as a numeric score, in peritoneal dialysate effluent.
224155623|NCT00259467|BEHAVIORAL|Home-Based Behavorial Intervention|
224155624|NCT01291849|DRUG|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
224155625|NCT01821404|DRUG|Atorvastatin|Capsules including 80 mg of atorvastatin
224155626|NCT01821404|DRUG|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
224155627|NCT01052181|DRUG|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
224155628|NCT01052181|DRUG|placebo|2 sachets monthly for an year
224155629|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
224155630|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
224155631|NCT00496613|BEHAVIORAL|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
224155632|NCT03765710|OTHER|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
224155633|NCT03765710|OTHER|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
224155634|NCT04641910|OTHER|No intervention|No intervention
223456558|NCT00441870|DRUG|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
223743052|NCT05191212|PROCEDURE|indocyanine green|Cervical indocyanine green injection for the detection of sentinel lymph node
223743053|NCT01584687|BIOLOGICAL|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
224155635|NCT03494023|DIAGNOSTIC_TEST|Endoscopic ultrasound|Measurement of the common bile duct diameter
224155636|NCT03822338|PROCEDURE|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
224155637|NCT03822338|PROCEDURE|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
224155638|NCT05895695|PROCEDURE|levator muscle resection|resection of levator muscle in congenital unilateral ptosis
224155639|NCT05895695|PROCEDURE|levator muscle plication|plication of levator muscle in congenital unilateral ptosis
224155640|NCT00301470|DEVICE|MR urography|undergoing both renal scintigraphy and MR within a month
223456559|NCT00441870|DRUG|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
223456560|NCT00597389|DRUG|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
223456561|NCT03173456|DRUG|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
223743054|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
223743055|NCT01998698|PROCEDURE|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
223743056|NCT05644249|DRUG|Combined Doxorubicin and Cisplatin Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic FOLFOX chemotherapy|Each course of combined treatment will start with PIPAC (a pressurized aerosol containing cisplatin 10.5 mg/m2 and doxorubicin 2.1 mg/m2 diluted in NaCl 0.9% applied through the nebulizer inside the abdominal cavity during laparoscopy). Fourteen days afterward 2 cycles of systemic FOLFOX chemotherapy will be applied within 28 days. The interval between combined treatment courses will be 14 days.
223743057|NCT01185938|DRUG|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
224155641|NCT01909219|DRUG|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
224155642|NCT01745913|DEVICE|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
224155643|NCT01745913|DRUG|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
224155644|NCT01745913|DRUG|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
223456562|NCT03173456|DRUG|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
223456563|NCT03173456|DRUG|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
223456564|NCT03173456|DRUG|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
223456565|NCT03173456|DRUG|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
223743058|NCT03632655|PROCEDURE|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
223743059|NCT04327388|DRUG|Sarilumab SAR153191|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
223743060|NCT04327388|DRUG|Placebo|Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
223743061|NCT06639087|DRUG|AZD5462|Participants will receive AZD5462 on top of dapagliflozin once daily.
223743062|NCT06639087|DRUG|Dapagliflozin|Participants will receive dapagliflozin once daily with AZD5462 or placebo.
223743063|NCT06639087|OTHER|Placebo|Participants will receive placebo on top of dapagliflozin once daily.
223743064|NCT02429518|DRUG|Miltefosine|
223743065|NCT04120974|BEHAVIORAL|Optimal insulin injection|subjects receive training in optimal injection technique.
224067112|NCT03456921|OTHER|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
224067113|NCT02350972|BIOLOGICAL|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
224067114|NCT03413501|BEHAVIORAL|MUD-PI|
224067115|NCT01731379|PROCEDURE|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
224067116|NCT00090194|BIOLOGICAL|Immune Globulin Intravenous (Human), 10%|
224067117|NCT05339295|DRUG|Levofloxacin 500mg|A single dose consisting of one tablet of either test drug (Levomerc 500 mg) or reference drug (Tavanic 500mg) administered to each of the subjects in both Period.
224067118|NCT01541475|DRUG|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
224067119|NCT01541475|DRUG|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
224067120|NCT04486950|DRUG|TAK-951|TAK-951 intravenous infusion.
224067121|NCT04486950|DRUG|TAK-951 Placebo|TAK-951 placebo-matching intravenous infusion.
224067122|NCT00710476|PROCEDURE|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
224067123|NCT05220826|PROCEDURE|Post surgical embolization of middle meningeal artery with liquid embolic agents (ethylene vinyl alcohol copolymers as Onix, Squid, Phil or Libro)|The endovascular procedure will be performed until 72 hours after surgical evacuation of chronic subdural hematoma. Embolization will be performed with non-adhesive embolizing fluids such as Onix®, Phil®, Squid® or Libro®.
224067124|NCT01914874|BEHAVIORAL|Mindfulness Meditation|
224067125|NCT03651284|BEHAVIORAL|Aim2Be app with Live Coach + Fitbit + BMI tracking tools|Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
224067126|NCT03651284|BEHAVIORAL|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools|Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
224067127|NCT04235556|BEHAVIORAL|Care pathway unit|Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
224067128|NCT05607875|BEHAVIORAL|The Grow to Recovery Train-the-Trainer program|"Mental health professionals will receive an online training, a trainer manual, a recovery manual (for people with mental illness), and Pathways to Recovery: A Strengths Recovery Self-help Workbook. The online training includes the concept of recovery, the implementation of recovery-oriented services, and the introduction of the Grow to recovery group. After the training, these professionals will conduct a 5-month Grow to recovery group in their own organization.~People with mental illness will attend the Grow to recovery group delivered by mental health professionals who has received the online training."
224067129|NCT05607875|OTHER|Control group|Mental health professionals will not receive any training. People with mental illness will receive a spiritual book and read by themselves.
224067130|NCT02559440|DRUG|mometasone furoate|50μg, 1 puff in each nostril every evening
224067131|NCT02559440|DRUG|Placebo|1 puff in each nostril every evening
224067132|NCT02559440|DRUG|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
224067133|NCT02559440|DRUG|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
224067134|NCT02559440|DRUG|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
223572766|NCT00683917|DRUG|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
223743066|NCT05941897|DRUG|Ceralasertib|Participants will receive ceralasertib oral tablets.
223743067|NCT05941897|DRUG|Durvalumab|Participants will receive durvalumab as an intravenous infusion
223743068|NCT00257842|PROCEDURE|Standard treatment, sham feedback and biofeedback therapy|
223743069|NCT05769790|DIAGNOSTIC_TEST|ddPCR|The search for cfDNA will be performed using assays available in the literature for the search for E. granulosus cfDNA developed for PCR analysis in biological samples, targeting EgG1 Hae III repeat region, cox1 and nad1 (Zhao et al 2021). Appropriate controls (synthetic sequences and Parasitic reference DNA, provided by the Echinococcosis Reference Center of the Istituto Superiore di Sanità, Rome) will be included in each experiment.
224067135|NCT02559440|DRUG|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
223572767|NCT00683917|DRUG|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
223572768|NCT00683917|DRUG|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
223572769|NCT00123097|COMBINATION_PRODUCT|Chlorinated polyethylene elastomer|Chlorinated polyethylene
224067136|NCT03268044|OTHER|Hospital admission and surgery|Hospital admission and noncardiac surgery
224067137|NCT03186170|OTHER|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
224155645|NCT01745913|DRUG|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
224302498|NCT04604743|BEHAVIORAL|Intervention, TBN|The intervention will target adolescents aged 15-17 years who have not received at least one dose of the HPV vaccine. The intervention has yet to be named; this will occur through the conduct of Aim 1. Our intervention, when developed, will improve knowledge of HPV, COVID-19, the HPV vaccine, and the COVID-19 vaccine (Information), reduce stigma and distrust improving motivation (Motivation), leading to improved vaccine confidence and higher vaccination rates and lower vaccine hesitancy (Behavioral Skills). Each one of these three change objectives will be encapsulated in its own Zoom-based session with the near peer interventionist. We anticipate that each modular session will be no longer than seven minutes; thus, the entire three module intervention will be no longer than twenty-one minutes long.
223456566|NCT02764476|OTHER|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
223456567|NCT02764476|OTHER|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
223456568|NCT04910581|PROCEDURE|rTMS|Single 30-minutes session of 1Hz rTMS applied over the left laryngeal motor cortex
223456569|NCT04910581|PROCEDURE|Sham stimulation|Single 30-minutes session of sham stimulation applied over the left laryngeal motor cortex
223456570|NCT02450838|BIOLOGICAL|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
223456571|NCT02450838|BIOLOGICAL|Alhydrogel™|Aluminum hydroxide gel adjuvant
223456572|NCT02450838|BIOLOGICAL|Placebo|
223456573|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
223456574|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
223456575|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
223572770|NCT04465318|OTHER|E-cigarette (EC)|NJOY Daily E-cigarettes are self-contained and non-refillable. Each DAILY provides approximately 300 puffs, comparable to a full pack of cigarettes.
224067138|NCT06095661|OTHER|REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.|The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
224067139|NCT04403581|OTHER|Questionnaire|Questionnaire for assessing stresses, knowledge and attitudes of doctors in COVID-19 pandemic
224067140|NCT01083303|BEHAVIORAL|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
224155646|NCT01745913|PROCEDURE|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of \> 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
224302499|NCT03827564|DEVICE|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
223572771|NCT04465318|OTHER|Nicotine Replacement Therapy (NRT)|Participants in the NRT arm will receive 21 mg nicotine patch (for those with CPD \>= 20) or 14 mg nicotine patch (for those with CPD \< 20) + 4 mg nicotine gum. CPD stands for Cigarettes Per Day.
224155647|NCT01745913|PROCEDURE|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
224155648|NCT03682406|BEHAVIORAL|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
224302500|NCT00326287|DRUG|Ceftobiprole medocaril|
223456576|NCT01028404|DRUG|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
223456577|NCT01028404|DRUG|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
223456578|NCT01028404|DRUG|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
223456579|NCT03264612|BEHAVIORAL|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
223456580|NCT01050322|DRUG|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
223456581|NCT01050322|DRUG|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
223456582|NCT01050322|DRUG|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
223456583|NCT01651975|DIETARY_SUPPLEMENT|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
223456584|NCT01651975|DIETARY_SUPPLEMENT|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
223456585|NCT01733121|DRUG|NBI-98854|25 mg capsule
223572772|NCT04465318|BEHAVIORAL|Smoking Harm Reduction Counseling Sessions|Counseling will cover health education, social support issues, and motivational enhancement to improve self-efficacy while addressing other aspects know to contribute to smoking among people with COPD (e.g., tips on dealing with depression)
223572773|NCT00592540|PROCEDURE|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
223572774|NCT06180330|OTHER|Aquatic baby class|The intervention will consist of exercises for infants. They will be in the water together with parents
223572775|NCT00819377|DRUG|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
223572776|NCT00819377|DRUG|Normal saline|5 ml normal saline by inhalation over 15 min
223572777|NCT02813642|BIOLOGICAL|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
223456586|NCT01733121|DRUG|NBI-98854|50 mg capsule
223456587|NCT01733121|DRUG|Placebo|
223456588|NCT05903638|BEHAVIORAL|Mindfulness-Based Stress Reduction course|8-week, 26-hour, virtual mindfulness course
223456589|NCT03340038|OTHER|Non-ICU Specialty ward|
223456590|NCT03698539|BEHAVIORAL|hand gestures|We observe the use of spontaneous hand gestures in all the groups.
223572778|NCT02813642|BIOLOGICAL|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
223456591|NCT04736069|OTHER|Physical therapy program|In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
223572779|NCT02813642|PROCEDURE|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
223572780|NCT02638207|DRUG|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
224155649|NCT03127579|BEHAVIORAL|Longer meal duration|Participants have 50% more time to eat than usual
224155650|NCT04961879|PROCEDURE|Reversed Cross Finger Flap|"distal dorsal finger defect will be reconstructed by reversed cross finger flap~\- reversed cross finger flap is a modified cross finger flap harvested from an adjacent finger ."
224155651|NCT04961879|PROCEDURE|reversed island homo-digital flap|"distal dorsal finger defect will be reconstructed by reversed island homo-digital flap~\- this flap is harvested from the same finger ."
224302501|NCT00326287|DRUG|Ceftriaxone with or without Linezolid|
224155652|NCT02569021|DEVICE|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)"
224155653|NCT02569021|OTHER|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
224155654|NCT02569021|OTHER|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
224155655|NCT02569021|DEVICE|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
224155656|NCT02569021|DEVICE|Trigno wireless system|The Trigno system measure muscle contractions.
224155657|NCT02569021|OTHER|GaitRite walking assessment.|GaitRite records a patients gait pattern.
224155658|NCT02089503|OTHER|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
224155659|NCT04916756|DRUG|Baricitinib 2 MG|baricitinib 2mg per day for 24 weeks
224155660|NCT02603406|DRUG|erythropoietin|
224155661|NCT01728727|OTHER|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
224155662|NCT01728727|OTHER|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
224155663|NCT01700881|OTHER|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
224155664|NCT01700881|OTHER|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
224155665|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #1)|Single dose administered intranasally on Day 1
224155666|NCT04227210|BIOLOGICAL|RSV vaccine MV-012-968 (dosage #2)|Single dose administered intranasally on Day 1
224155667|NCT04848012|DEVICE|Auto-titrating non-invasive ventilation|A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
224155668|NCT00223912|DEVICE|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
224155669|NCT05073913|DIAGNOSTIC_TEST|Vascular remodeling characterization|Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with decrease in plasma of Iohexol
224155670|NCT02079519|DRUG|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
224155671|NCT01900756|BEHAVIORAL|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
224155672|NCT03769337|DIAGNOSTIC_TEST|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
224302502|NCT02799030|DRUG|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
223456592|NCT02670421|BEHAVIORAL|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
223456593|NCT02670421|BEHAVIORAL|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
223456594|NCT02670421|BEHAVIORAL|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
223456595|NCT05399147|OTHER|fiberoptic intubation classic technique|classic fiberoptic intubation
224155673|NCT00127088|DRUG|docetaxel|
224155674|NCT00127088|PROCEDURE|laparoscopic radical prostatectomy|
224155675|NCT00829660|DRUG|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
224155676|NCT00829660|DRUG|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
224155677|NCT02580838|DRUG|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
224155678|NCT04511936|DEVICE|i-Lumen AMD|Microcurrent stimulator
224155679|NCT04511936|DEVICE|i-Lumen AMD Sham|Sham microcurrent stimulator
224155680|NCT02171949|BIOLOGICAL|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
224302503|NCT02799030|DRUG|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
224302504|NCT02799030|DRUG|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
224302505|NCT01775449|BEHAVIORAL|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
224155681|NCT04541732|OTHER|Thoracic epidural block|Patients who will be subjected to epidural block will be placed in the lateral position then, after sterilization of the skin, 21 G spinal needle will be inserted at T9-T11 intervertebral spaces. The epidural space will be located using the loss of resistance to air technique and a mixture of bupivacaine 0.25% + 50 μ fentanyl targeting T6 level will be injected following induction of general anaesthesia.
224155682|NCT04541732|OTHER|Ultrasound-guided bilateral quadratus lumborum block|Patients who will be subjected to major abdominal surgeries will be placed in a supine position with a pillow under their side to obtain an appropriate view of quadratus lumborum muscle. After sterilization of the skin and ultrasound-guided identification of the quadratus lumborum muscle, 20 ml bupivacaine 0.25% + 25μ fentanyl will be injected on each side following induction of general anaesthesia
224155683|NCT04541732|DRUG|Induction of general anaesthesia with propofol|propofol: 1.5-2.5mg/Kg
224155684|NCT04541732|DRUG|Muscle Relaxant|Atracurium : 0.5mg/Kg.
224155685|NCT04541732|DRUG|Maintenance of general anaesthesia|Sevoflurane 0.7-1.5 MAC in 40% oxygen
224155686|NCT00509652|PROCEDURE|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
224155687|NCT00509652|PROCEDURE|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
224155688|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
224155689|NCT01225276|DRUG|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
224155690|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
224155691|NCT01225276|DRUG|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
224155692|NCT06022172|DIAGNOSTIC_TEST|MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.|"Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used."
223456596|NCT05399147|OTHER|fiberoptic intubation tube 1st technique|tube 1st technique
223456597|NCT04671394|PROCEDURE|FMUD + DLIG|Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution
223456598|NCT04671394|PROCEDURE|FMUD + ST|Full-Mouth Ultrasonic Debridement + Sham Treatment
223456599|NCT02247739|BIOLOGICAL|Recombinant human C1 inhibitor|
223456600|NCT02247739|OTHER|Placebo|
223456601|NCT04501952|DRUG|RDV|Administered as an intravenous infusion
223456602|NCT04501952|DRUG|Placebo to Match RDV|Administered as an intravenous infusion
223456603|NCT00941304|DRUG|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
223456604|NCT00941304|DRUG|Buprenorphine|Single-dose of buprenorphine HCl buccal film
223456605|NCT00941304|DRUG|Placebo Film|Single-dose of placebo buccal film
223572781|NCT05144880|OTHER|electroacupuncture|A total of 12 treatment sessions will be administered to each participant. The acupoints of needles inserted for each participant in each session are DU20, EX-HN1, DU29, HT17, PC6, RN6, RN4, LR3 and SP6. The needles will be manually stimulated by rotating, thrusting, stirring, etc. to produce ''De Qi'' sensation. Then we will use electroacupuncture for acupoint stimulation lasting 30min. The frequency will be set as 2Hz for the electroacupuncture with 2Hz group and the frequency will be set as 100Hz for the electroacupuncture with 100Hz group.
223572782|NCT00731965|BIOLOGICAL|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
223572783|NCT01170598|OTHER|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
223572784|NCT00575432|RADIATION|diffusion MRI|diffusion MRI
223572785|NCT00575432|RADIATION|BOLD MRI|BOLD MRI
223456606|NCT00941304|DRUG|Placebo Capsule|Single-dose of oral placebo capsule
223456607|NCT00835835|OTHER|Body-weight supported treadmill training +/- Lokomat assistance|walking
223456608|NCT00835835|OTHER|Usual Care - no active intervention|No treatment used for comparison
223456609|NCT04262063|BEHAVIORAL|Tell play do technique|it apply the concept of learning by doing .children will enjoy playing with customized dental models
223456610|NCT04262063|BEHAVIORAL|tell show do|Tell: your dentist explaining to you what they'd like to do Show: showing you what is involved (e. g. showing the equipment and demonstrating it on a finger) Do: performing the procedure
223456611|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
223572786|NCT00575432|OTHER|Clinical Outcome|Clinical outcome
224155693|NCT00399867|DRUG|Simvastatin|
224155694|NCT04787926|DEVICE|Locking Solution|The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
224155695|NCT02720250|DIETARY_SUPPLEMENT|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
224155696|NCT02720250|DIETARY_SUPPLEMENT|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
224155697|NCT00092404|BIOLOGICAL|measles, mumps, and rubella virus vaccine live|
224155698|NCT00092404|BIOLOGICAL|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
223456612|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
223456613|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
223572787|NCT02728414|DIETARY_SUPPLEMENT|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
223572788|NCT02728414|DIETARY_SUPPLEMENT|placebo|the patients in this arm will receive placebo intervention
223572789|NCT01768104|PROCEDURE|ESTD|"1. A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~2. Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~3. Dissection was done along the margin of the tumor.~4. After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~5. Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
223572790|NCT01768104|PROCEDURE|VATS|"1. General anesthesia with double lumen intubation.~2. Three to four cameras or working ports are placed over the chest wall.~3. After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~4. The mass is exposed after the overlying muscle is split longitudinally.~5. The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~6. The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
223572791|NCT04297189|BEHAVIORAL|Coaching and health information intervention|8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
223572792|NCT05023616|OTHER|Real-time home CPR training|The participants in the intervention group will have Little Anne QCPR mannequins (Laerdal, Stavanger, Norway) delivered to their homes. The participants will use an online platform specifically developed for CPR training (HEROS Remote app). The training program will provide video-based self-instruction training followed by hands-on chest compression training with the instructor. The hands-on chest compression training session provides real-time chest compression quality measurement followed by real-time feedback from the instructor. Chest compression quality will be measured by Little Anne QCPR mannequins.
223572793|NCT05023616|OTHER|Conventional CPR training|"Participants in the conventional CPR training program group will be provided CPR education with the Home Education and Resuscitation Outcome Study (HEROS) program that is currently provided in Seoul, Korea. The HEROS program is a 1-hour training course, consisting of a 30-minute video-based self-instruction training with a mannequin. The program also includes a bystander CPR simulation with a simulated dispatcher using the participants own cell phone. Little Anne QCPR mannequins will be provided to measure and give feedback on the participants chest compression performance."
223572794|NCT00826358|DRUG|ABT-143|Once, please see Arm Description for more details.
223572795|NCT00826358|DRUG|ABT-335|Once, see Arm Description for more detail
223572796|NCT00826358|DRUG|rosuvastatin|once, see Arm Description for more detail
223572797|NCT01823783|OTHER|Muscle biopsy|Muscle biopsy
223572798|NCT05777122|DRUG|lignocaine gel|pharmacological ,topical anesthetic gel
223572799|NCT05777122|OTHER|sugar free chewing gum|non pharmacological
223572800|NCT04344496|OTHER|PAM50|PAM50 results is as one of the references for the physicians and the participants to choose adjuvant treatments.
224067143|NCT05061173|OTHER|Aerobic exercise training Group|Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 30 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 30 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 30 minutes
224067144|NCT05061173|OTHER|Resistance Exercise Training Group|"Resistive Exercises includes (a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction.~At Week 1-2, 10 repetitions 1 set, 3 days/week, for 30 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 30 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 30 minutes"
224071362|NCT04737655|DRUG|TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation|Evaluate Trimbow associated with the standard of care in comparison with the standard of care alone.
224071363|NCT05130463|DRUG|Empagliflozin/Linagliptin|Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food.
223456614|NCT00784719|DRUG|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
224071364|NCT03461757|DRUG|Rimegepant|75 mg ODT QD
223456615|NCT00784719|DRUG|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
223456616|NCT00784719|DRUG|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
223572801|NCT03014310|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
223572802|NCT03014310|DRUG|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
223572803|NCT03014310|BIOLOGICAL|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
223572804|NCT05008731|DRUG|Botulinum toxin|100 units (0.5ml) in 1 injection
223572805|NCT05008731|OTHER|Placebo|Placebo 0.5 ml in 1 injection
223572806|NCT05868863|OTHER|datas of medical record.|"Analysis datas of medical record:~* Feasibility of the technique~* Safety of the technique with evaluation by Cardiovascular and Interventional Radiological Society of Europe (CIRSE) scale~* Analgesic intake before and after the procedure~* Functional criteria: early rising, walking"
223572807|NCT05706233|PROCEDURE|Erector Spina Plane Group|ESPB had been applied postoperatively: from T8 level, 20mL bupivacaine %0,5 + 5ml %2 lidocaine was applied.
224071365|NCT03461757|DRUG|Placebo|Placebo ODT to match rimegepant dose QD
224071366|NCT02142777|DRUG|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
224071367|NCT02142777|DRUG|Placebo|The placebo has no active ingredients but is made to look like the study drug.
224071368|NCT01258764|DRUG|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
224071369|NCT01258764|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
223572808|NCT05706233|PROCEDURE|IV analgesic intervention|IV analgesics had been applied: All meperidine boluses are dosed in line with the pain intensity as follows: 10 mg if NRS \> 3, 20 mg if NRS \> 5, 30 mg if NRS \> 8. If NRS score is not reduced at least 20% when compared to prior one, additional meperidine bolus is applied.
223456617|NCT01408901|BEHAVIORAL|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
223456618|NCT01408901|OTHER|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
223456619|NCT01408901|DRUG|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.
223456620|NCT06155474|DIETARY_SUPPLEMENT|Prebiotic galacto-oligosaccharide (GOS) Powder|"Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product"
223456621|NCT06155474|DIETARY_SUPPLEMENT|Starch Only|The Starch Solution is a low-fat diet.
223456622|NCT06155474|DIETARY_SUPPLEMENT|RUTF + Starch|ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
223743070|NCT01320462|DRUG|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
223572809|NCT02853812|OTHER|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
223572810|NCT01011491|OTHER|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 \& 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
223572811|NCT01011491|OTHER|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 \& 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
223572812|NCT01779869|DRUG|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
223572813|NCT00222430|PROCEDURE|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
223572814|NCT00222430|PROCEDURE|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
223572815|NCT01996267|DRUG|PTC+Pertuzumab|Cycle repeated every 21 days
223572816|NCT01996267|DRUG|FEC-T+Pertuzumab|Cycle is repeated every 21 days
224067145|NCT05061173|OTHER|Combined Exercise Training Group|"Combined Exercise training includes \[Aerobic: Treadmill walking + Resistive Training: a) Leg press b) Quadriceps extension c) Bicep curl d) Hip abduction\] Time will be reduced to 15 minutes for both trainings in respective weeks. Aerobic Exercise includes Treadmill walking At Week 1-2, intensity of 40-45% Heart rate maximum (HR max), 3 days/week, for 15 minutes At Week 3-4, intensity of 45-50% HR max, 3 days /week, for 15 minutes At Week 5-6, intensity of 50-60% HR max 3 days per week, for 15 minutes~Resistive Exercises At Week 1-2, 10 repetitions 1 set, 3 days/week, for 15 minutes At Week 3-4, 2 sets of 10 repetitions, 3 times /week for 15 minutes At week 5-6, 2 sets of 10 repetitions with 5 sec hold 3 times per week for 15 minutes"
224067146|NCT02312635|DRUG|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
223572817|NCT06605365|DEVICE|CX-HA and CS|Sterile Isotonic ophthalmic solution
223572818|NCT06661317|OTHER|no intervention|no intervention
223572819|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (reproducibility)|The experienced examiner performed tests on 20 healthy subjects
223572820|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (availability)|Two examiners performed the test on one healthy subject with both devices for ten consecutive days.
223572821|NCT04956315|DIAGNOSTIC_TEST|Side-to-side difference (Accuracy)|200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
223743071|NCT01320462|OTHER|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
223743072|NCT00148889|DEVICE|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
223743073|NCT00893750|BEHAVIORAL|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
223743074|NCT00893750|BEHAVIORAL|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
224067147|NCT02312635|BEHAVIORAL|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
224067148|NCT03054376|OTHER|Immobilization|Full length cast of one leg R/L randomized
224071370|NCT03514628|OTHER|Standard Care|The Valsalva strain will be produced using Standard Care techniques
223572822|NCT00027378|DRUG|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
223456623|NCT01504672|OTHER|Medication review|"In the intervention, the pharmacist will evaluate:~* Is there an indication for the drug?~* Has the drug desired effect?~* Is the dose correct and dosing scheme correct?~* Side effects, contraindications, inappropriate drugs~* Interactions~* Treatment time~* Cost effectiveness~* Adherence to recommendation list~* Problems with handling the drugs (for example crushing of the tablets)~* Untreated indication~* Double medications~* Administration of drugs"
223456624|NCT00606749|DRUG|KC706|300 mg once daily (QD) for 12 weeks.
223456625|NCT03509181|BEHAVIORAL|I-Change|smartphone delivered word-sentence association task that encourages a healthier interpretive style
223456626|NCT03509181|BEHAVIORAL|Symptom Tracking|smartphone delivered self-monitoring of anxiety and depression symptoms
223456627|NCT06039137|DRUG|Cetirizine|Subjects were treated with a paclitaxel premedication regimen which contained oral cetirizine instead of intravenous clemastine
223456628|NCT06039137|DRUG|Clemastine IV|Subjects were treated with paclitaxel premedication containing clemastine 2 mg IV
223456629|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (Before Positioning)|Before Reverse Trendelenburg Position
223456630|NCT04224532|PROCEDURE|Pneumoperitoneum Timing (After Positioning)|After Reverse Trendelenburg Position
223456631|NCT01860716|DRUG|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
223456632|NCT01860716|DRUG|Placebo|
223456633|NCT06117254|BEHAVIORAL|Communication Counseling|Individuals randomized to this group will receive information on how to improve their ability to hear and communicate including general tips on environmental modification and communication repair strategies and personalized tips to help with patient-specific listening difficulties. This is consistent with current audiological standard of care.
223572823|NCT00027378|DRUG|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
223456634|NCT06117254|DEVICE|Hearing Aids|Hearing aids will be provided with amplification settings programmed specific to each participant's pure-tone hearing thresholds with subsequent adjustments based upon participant preferences. Standard noise cancelation and signal-to-noise ratio improvement strategies will be activated.
223456635|NCT06117254|DEVICE|Remote Microphones|Remote microphone systems will be provided for use with hearing aids.
223456636|NCT05190666|BEHAVIORAL|PACE Weight Loss program|12 month phone-based behavioral weight loss program
223456637|NCT05190666|BEHAVIORAL|Chronic Disease Self-Management|12 month phone-based chronic disease self-management program
223456638|NCT03648918|OTHER|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
223456639|NCT04225013|DIAGNOSTIC_TEST|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured
223456640|NCT04225013|DIAGNOSTIC_TEST|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured
223456641|NCT06822101|BEHAVIORAL|Visual Training|Participants are asked to detect or discriminate visual stimuli.
223456642|NCT04396899|BIOLOGICAL|EHM implantation|Implantation of EHM on dysfunctional left or right ventricular myocardium in patients with HFrEF (EF \<35%).
223572824|NCT05605691|DEVICE|Renuvion APR System|"The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures.~Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System."
223572825|NCT05764473|OTHER|The impact of MedDiet on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
223572826|NCT05764473|OTHER|The impact of UCLP on cardiometabolic risk factors and menopause symptoms|12-week randomised parallel cross-over study with 32 participants. Impact of diet on CMR factors and menopause symptoms will be explored with diet quality and adherence to diet determined via diet quality indices for MedDiet and Portfolio diet.
223572827|NCT06229665|DEVICE|Valeda Light Delivery System|The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
223572828|NCT04883710|OTHER|Gene therapy|This is a prospective patient registry.
223572829|NCT05985876|BEHAVIORAL|KULEA-NET application|African American/Black (AA/B) women recruited at 3 distinct stages of pregnancy - i.e. 1) 29 to 34 weeks gestational age, 2) 35 to 40 weeks gestational age, and 3)immediately post-partum, will be assigned to the intervention group and start using the KULEA-NET platform. Women in the intervention arm #1 will use KULEA-NET for a total duration of approximately 9 months (3 months prenatal and 6 months post-partum; women in the intervention arm #2 will use KULEA-NET for a total duration of approximately 7 months (1 month prenatal and 6 months post-partum); and women in the intervention arm #3 will use KULEA-NET for a total duration of approximately 6 months (only post-partum). Each woman will have access to all components of the KULEA-NET platform: the text messages, knowledge base, 3 different types of videos, and breastfeeding-friendly spaces and breastfeeding classes near them.
223572830|NCT05985876|BEHAVIORAL|Control Group: Usual Care|Control participants will receive usual care i.e. standard obstetrical care at MWHC and Mamatoto Village and will receive standard Babyscripts app only without the KULEA-NET tile. Information from the ACOG about the maternal and infant health benefits of breastfeeding will also be provided (e.g., they will get pamphlets on the importance of breastfeeding as well as lactation consultation).
223572831|NCT04347473|DRUG|Ilumya Injectable Product|IL-23 injection
223572832|NCT06036160|OTHER|Integrated care|Psychiatric follow-up, cognitive behavioral therapy, physical exercise, psychoeducation
224071371|NCT03514628|DEVICE|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
223572833|NCT02098369|BEHAVIORAL|Written education material (basic)|Education material on COPD distributed to all participants.
223456643|NCT05658172|DIAGNOSTIC_TEST|Determination of tumormarkers (CA27.29, CEA, CA125)|CA27.29, CEA and CA125 will be measured with the AIA®-CL1200 by TOSOH BIOSCIENCE (TOSOH CORPORATION, Tokyo, Japan). The CL AIA-PACK assays are two-step chemiluminescence enzyme immunoassay kits. CA27.29/CEA/CA125 present in a test sample is bound to the anti- CA27.29/CEA/CA125 mouse monoclonal antibody immobilized on the magnetic microparticles in one cell (Cell-I). After first incubation, the magnetic microparticles are washed and the enzyme-labeled anti- CA27.29/CEA/CA125 mouse monoclonal antibody that has been reconstituted in another cell (Cell-II) is dispensed into Cell-I. After second incubation, the magnetic microparticles are washed again and are incubated with a chemiluminescent substrate, DIFURAT®. The amount of enzyme-labeled antibodies that bind to the magnetic microparticles is directly proportional to the CA27.29/CEA/CA125 concentration in the test sample. A standard curve is constructed, unknown sample concentrations are calculated by using this curve.
223572834|NCT02098369|BEHAVIORAL|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
223572835|NCT02098369|BEHAVIORAL|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
223572836|NCT02098369|BEHAVIORAL|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
223572837|NCT00420615|DRUG|Patupilone and Omeprazole|
223572838|NCT00420615|DRUG|Patupilone + Midalzolam|
223572839|NCT04951271|BEHAVIORAL|Solution focused approach|The SFA intervention consists of seven sessions, one preparation and six solution-oriented sessions. Each session lasted 55 minutes. Filling in the applied scales was excluded from this period. Sessions were held once a week in two groups (Grade 10 and Grade 11 students).
223572840|NCT04994730|BEHAVIORAL|Quality of life according to the reconstruction technique|"For this retrospective analysis, 118 patients could be included, 17 of whom had undergone ante-brachial free flap reconstruction, 16 of whom had undergone this reconstruction within the last 2 years.~The primary endpoint: Analysis of the quality of life score according to the reconstruction technique (free ante-brachial flap versus others) will be performed by a Wilcoxon-Mann-Whitney test."
223572841|NCT03134365|OTHER|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
223572842|NCT03134365|OTHER|Combined meal|Combined meal.
223743075|NCT00893750|BEHAVIORAL|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
223743076|NCT02340598|OTHER|cold vest|The lowering of body temperature increases basal metabolic rate
223743077|NCT04135833|DRUG|BPI-7711|BPI-7711 60 mg
223743078|NCT04135833|DRUG|BPI-7711|BPI-7711 180 mg
223743079|NCT04135833|DRUG|Itraconazole|Itraconazole 200 mg
223743080|NCT04135833|DRUG|Rifampicin|Rifampicin 600 mg
224302506|NCT05562908|PROCEDURE|Pedicled|Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.
224302507|NCT05562908|PROCEDURE|Surgical skeletonised|Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
224302508|NCT05562908|PROCEDURE|Thunderbeat skeletonised|Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.
224302509|NCT00709436|DRUG|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
224302510|NCT00709436|DRUG|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
224302511|NCT01841775|DRUG|interferon α 2b + ribavirin|"1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
223572843|NCT05879770|OTHER|suture material|Some patients have had a shouldice repair with wire in the past and others with Prolene.
223572844|NCT02196116|OTHER|PET|PET Scan with \[18F\]-Flutemetamol
223743081|NCT06040554|OTHER|Elastic Band Resistance Exercises|8 Warm-Up Exercises followed by 10 Elastic Band Exercises followed by 8 Post-Workout Exercises.
223743082|NCT03559257|DRUG|Galcanezumab|Administered SC.
223743083|NCT03559257|DRUG|Placebo|Administered SC.
223743084|NCT05576740|PROCEDURE|Determination of hormone level concentrations|Determination of concentration of 17β-oestradiol (pg/mL), progesterone (ng/mL), LH (mUI/mL), FSH (mUI/mL), prolactin (ng/mL), total testosterone (ng/mL), free testosterone (pmol/L) sex hormone binding globulin (SHBG) (nmol/L), cortisol (μg/dL), T3 (ng/dL), T4 (mcg/dL), TSH (mcU/mL), basal insulin (mcUI/mL) during the early follicular phase, late follicular phase, and mid-luteal phase.
224067149|NCT03054376|OTHER|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
224302512|NCT02631018|BEHAVIORAL|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
224302513|NCT02631018|BEHAVIORAL|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
224302514|NCT00891371|DRUG|lanreotide (Autogel formulation)|Autogel 120mg
224302515|NCT02622113|DRUG|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
224302516|NCT02622113|DRUG|Insulin|
223456644|NCT05658172|DIAGNOSTIC_TEST|Determination of CTC levels|CTCs will be analyzed using the CellSearch® System (Menarini Silicon Biosystems). The CellSearch® system is designed to enumerate CTCs of epithelial origin (CD45-, EpCAM+, cytokeratin 8+ / 18+ and/or 19+). The basic principle is linking a magnetic ferrofluid reagent that contains i. a. antibodies targeting the EpCAM antigen to CTCs. After steps of immunomagnetic capture and enrichment as well as addition of fluorescent reagents (that contain anti-CK-PE, DAPI and anti-CD45-APC), the automatic dispersion to a magnetic cartridge holder takes place. Via strong magnetic field, the magnetically labeled epithelial cells are attracted to the surface of the cartridge where they can be scanned automatically. Images of events where CK-PE and DAPI fluorescence are co-located are presented to the user for final classification. An event is classified as a tumor cell when its morphological features are consistent with that of a tumor cell and it exhibits the phenotype EpCAM+, CK+, DAPI+ and CD45-.
223572845|NCT02196116|OTHER|MRI|
223572846|NCT02196116|OTHER|neuropsychological tests|
223572847|NCT00823745|DRUG|[14C]-PF-00868554|solution, single dose
223572848|NCT05967546|OTHER|Observational|No interventions will be given to patients.
224302517|NCT02239341|OTHER|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
223572849|NCT06162546|OTHER|Registry|Registry Participation, providing data and clinical specimen
223572850|NCT04841759|OTHER|Exercise|8 week exercise program, nutritional \& psychological consultation
224302518|NCT02239341|OTHER|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
224302519|NCT03525158|BEHAVIORAL|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
224302520|NCT02969941|OTHER|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
224302521|NCT00221611|DRUG|Administration of intrathecal baclofen|
224302522|NCT01562340|OTHER|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
224302523|NCT01562340|OTHER|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
224302524|NCT00672165|BIOLOGICAL|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
224302525|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
224302526|NCT03961048|DRUG|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
224302527|NCT00774696|DRUG|clarithromycin 500mg tablets|
224302528|NCT05619055|OTHER|Routine treatment|Antibiotics, intravenous fluids and symptomatic supportive treatment.
224302529|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
224302530|NCT00667810|DRUG|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
224302531|NCT00667810|DRUG|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
224302532|NCT05034341|OTHER|Multimodal Prehabilitation|"In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free."
224302533|NCT05034341|OTHER|Standard Pre-Surgical Clinical Care|"* Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment."
224302534|NCT03265613|BIOLOGICAL|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
224302535|NCT05921513|PROCEDURE|Free Gingival Graft Procedure|This procedure is done to increase the width of keratinized gingiva around teeth or dental implant. The healing of the palatal wound at the donor site will be recorded.
224302536|NCT01946360|DEVICE|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
224302537|NCT02244918|DRUG|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
224302538|NCT02244918|BEHAVIORAL|Smoking Cessation Counseling|
223572851|NCT00711347|DEVICE|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
223572852|NCT00711347|DEVICE|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
223456645|NCT05658172|DIAGNOSTIC_TEST|Determination of ctDNA levels|Presence of ctDNA will be analyzed centrally at Inivata Inc. using the RaDaRTM assay. Therefore, primary tumor tissue and peripheral blood specimens will be shipped for centralized analysis to Inivata Inc. RaDaRTM is a tumor-informed approach, beginning with whole exome sequencing of a tumor specimen from a patient's biopsy or surgical resection. SNVs and indels identified from the exome sequencing are prioritized to build a patient specific primer panel of up to 48 tumor-specific somatic variants. Patient specific primers are combined with common SNP primers for NGS for quality control purposes. To detect patient specific ctDNA, NGS testing is performed with the RaDaRTM assay using a multiplex PCR based on the InVision® platform.
223456646|NCT05658172|OTHER|Biobanking of blood samples|To ensure the possibility of retrospective studies during and after the ongoing study, a biobank will be implemented.
223456647|NCT04892199|DRUG|Semaglutide, 1.34 mg/mL|Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.
223456648|NCT04892199|DRUG|Semaglutide-placebo|"The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study."
223572853|NCT01070563|OTHER|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
223572854|NCT05639101|OTHER|Clinical Decission support system management & mobile App Intervention Group|"The clinicians treating the patients will use a clinical decision support system that includes predictive models associated with the level of risk of exacerbation. This models have been obtained in asthmatic patients by applying data mining techniques and multilevel analysis in the study of the influence of clinical characteristics and the environment of each subject.~The patients will use a mobile app to help manage their symptoms."
223572855|NCT03000777|DIETARY_SUPPLEMENT|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
223572856|NCT03000777|OTHER|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
223572857|NCT00701298|BIOLOGICAL|peginterferon alfa-2b|Given SC
223572858|NCT00701298|DRUG|decitabine|Given IV
223572859|NCT00701298|OTHER|laboratory biomarker analysis|Correlative studies
223572860|NCT02539498|DEVICE|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
223572861|NCT02802241|DRUG|placebo|
223572862|NCT02802241|DIETARY_SUPPLEMENT|peppermint oil|
223572863|NCT02865889|PROCEDURE|Laparoscopy in Gynecologic Oncologic Indications|
223572864|NCT02865889|PROCEDURE|Conventional surgery (abdominal radical surgery)|
223572865|NCT01453738|BIOLOGICAL|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
223572866|NCT01453738|BIOLOGICAL|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
223572867|NCT00075387|DRUG|Carboplatin|Given IA
223572868|NCT00075387|DRUG|Cyclophosphamide|Given IV
223572869|NCT00075387|DRUG|Etoposide Phosphate|Given IV
223572870|NCT00075387|OTHER|Quality-of-Life Assessment|Ancillary studies
223743085|NCT05576740|PROCEDURE|Jump height determination|by Chronojump contact mat, determine five types of jump in centimeters: Squat jump without additional weight, Squat jump with 50% of body weight, Countermovement jump, Abalakov jump, and Drop jump, during the early follicular phase, late follicular phase, and mid-luteal phase.
223743086|NCT05576740|PROCEDURE|Grip strength determination|measuring of changes in muscle strength by handgrip dynamometer in the hand to be tested (handgrip test) during the early follicular phase, late follicular phase, and mid-luteal phase. Three attempts on each hand.
224071372|NCT04754880|DIAGNOSTIC_TEST|Comparison of oxidative and antioxidative markers between groups|Oxidant and anti-oxidant markers
223572871|NCT00075387|DRUG|Sodium Thiosulfate|Given IV
223572872|NCT01655043|DRUG|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
223572873|NCT01655043|DRUG|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
223572874|NCT03150069|OTHER|Interview|In-person or telephone in-depth interview
223572875|NCT01245881|DEVICE|Non-ablative fractional photothermolysis laser|"* Wavelength: 1,550 nm;~* Energy: 15 mJ/MTZ;~* Total coverage: 20%;~* Total density: 1,048 MTZs/cm2;~* Density per pass: 131 MTZ/cm2;~* Number of passes: 8."
223572876|NCT01245881|OTHER|broad-spectrum sunblock (SPF 50+)|
223572877|NCT05293444|DIETARY_SUPPLEMENT|Maltodextrine|400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.
223572878|NCT05293444|OTHER|overnight fasting|no intervention
223572879|NCT05133869|DEVICE|Metacognitive training + direct training|"The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules."
223572880|NCT01212211|OTHER|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
223572881|NCT02927925|DRUG|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
223456649|NCT04060797|DEVICE|endovascular denervation|Treating with endovascular denervation (EDN) at the site of the iliac artery distal to the superficial femoral artery proximal before balloon dilation or stent implantation
223456650|NCT04060797|DEVICE|PTA|Treating with balloon dilation or stent implantation which were Percutaneous transluminal angioplasty (PTA)
223572882|NCT01263392|DEVICE|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria \& leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
223456651|NCT02797509|BEHAVIORAL|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
223572883|NCT01057225|DRUG|carfilzomib|Given IV
223572884|NCT01057225|DRUG|cyclophosphamide|Given orally
223572885|NCT01057225|DRUG|thalidomide|Given orally
223572886|NCT01057225|DRUG|dexamethasone|Given orally
223572887|NCT02229214|DRUG|Qsymia|
223572888|NCT02229214|DRUG|Placebo|
223572889|NCT03262025|PROCEDURE|Operated|Patients were either managed conservatively or underwent emergency laparotomy
223572890|NCT01252550|DIETARY_SUPPLEMENT|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
223572891|NCT01252550|DIETARY_SUPPLEMENT|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
223572892|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
223572893|NCT00246025|DRUG|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
224302539|NCT04650503|OTHER|No intervention|No intervention
223456652|NCT04504565|DIAGNOSTIC_TEST|99mTc-3PRGD2|intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
223572894|NCT00246025|DRUG|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
224067150|NCT03054376|OTHER|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
224302540|NCT03142906|DIAGNOSTIC_TEST|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
223572895|NCT00246025|DRUG|placebo|matching placebo capsule, once a day, oral administration
223572896|NCT05540769|PROCEDURE|catheter guided ASD closure|transcatheter secundum ASD device closure
223572897|NCT05528367|DRUG|Nab-PTX,S-1,Tirelizumab|"S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w."
223572898|NCT05528367|RADIATION|Chemoradiation|45-50Gy/25F
223572899|NCT00559468|DRUG|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
223572900|NCT00559468|DRUG|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
224067151|NCT04423497|OTHER|Balance Evaluation Systems Test|Balance Evaluation Systems Test application
224302541|NCT05154435|DRUG|mostcare hemodynamic monitor|mostcare hemodynamic monitoring integrated into the radial artery catheter. According to the data obtained, intraoperative fluid management was arranged with certain algorithms.
224302542|NCT06394349|COMBINATION_PRODUCT|PRP+308nm|PRP+308nm
224302543|NCT06394349|COMBINATION_PRODUCT|NS+308nm|NS+308nm
224302544|NCT03296436|BIOLOGICAL|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
224302545|NCT00505375|DRUG|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
223456653|NCT04004260|BEHAVIORAL|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
223456654|NCT02594917|PROCEDURE|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
223572901|NCT00559468|DRUG|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
223572902|NCT00559468|DRUG|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
223572903|NCT03172806|DIAGNOSTIC_TEST|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
224067152|NCT00236808|DRUG|levofloxacin|
224067153|NCT00050609|DRUG|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
224067154|NCT00050609|DRUG|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
224067155|NCT00050609|DRUG|placebo|Placebo tablet taken by mouth once a day for 8 weeks
224067156|NCT01545856|DRUG|levodopa|levodopa use
223456655|NCT02594917|OTHER|Blood draw|Test and control group will be asked to give 20 ml of blood samples
223456656|NCT01698944|DRUG|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
224302546|NCT00505375|OTHER|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
224302547|NCT02000661|DEVICE|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
224302548|NCT05631353|DEVICE|Carriere Motion Appliance|"Patient will be randomly allocated into two groups:~Group I: conventional mandibular anchorage using passive lingual arch. Group II: anchorage by direct mini-screws. In the group I, Class II elastics will be attached from the maxillary canine to the mandibular first molar bilaterally with passive lingual arch in the lower arch as anchorage means.~In the group I, Class II elastics will be attached from the maxillary canine to mandiular miniscrews bilaterally.~For each patient, two CBCT radiographs will be obtained: one preoperatively and another after completion of distalization."
224302549|NCT04821531|OTHER|PT Pal|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength balance and mobility
224302550|NCT04821531|OTHER|Exercise Manual|Patients will be guided through individualized exercises that will be selected by their primary physical therapists. The exercises aim to improve lung function, maintain joint flexibility, muscle strength, balance and mobility
223456657|NCT05826340|BEHAVIORAL|Tailored progressive loading and return to sport|Participants will undergo a 5-stage progressive return to sport tool.
223456658|NCT05826340|BEHAVIORAL|Pain guided activity|Participants will be provided on information on how to guide activity based on pain response.
223456659|NCT03608813|OTHER|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
223456660|NCT05464420|BIOLOGICAL|V116|Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
223456661|NCT05464420|BIOLOGICAL|PPSV23|Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
223456662|NCT01643447|DRUG|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
223456663|NCT01643447|DRUG|Diammonium glycyrrhizinate|
223456664|NCT03383224|OTHER|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
223572904|NCT01953549|PROCEDURE|physical fitness training|
223572905|NCT01953549|PROCEDURE|relaxation|
223572906|NCT04872933|OTHER|Kidney Beam Online Platform|Kidney Beam is a wellbeing digital health intervention platform that offers patients living with kidney disease a way to improve their physical activity and boost their mental health through live and on demand movement classes and expert educational videos, while remaining in their own home. Kidney Beam is led by specialist kidney professionals, including renal physiotherapists and renal counsellors, from a number of different NHS Trusts and backgrounds, as well as people living with kidney disease.
223572907|NCT02351687|DIETARY_SUPPLEMENT|Lipid Nutrient Supplement|
223456665|NCT03383224|DRUG|Nicotine patch|
223456666|NCT03383224|BEHAVIORAL|Smoking cessation counseling|
223456667|NCT00558987|BEHAVIORAL|Discipline Video|"1. The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~2. A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
223456668|NCT00558987|BEHAVIORAL|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
223456669|NCT05460858|DRUG|N-acetyl cysteine|One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
223456670|NCT05460858|DRUG|placebo|placebo
223456671|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
223456672|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
223456673|NCT00971490|DEVICE|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
223572908|NCT02351687|DRUG|Sulfadoxine-pyrimethamine|
223572909|NCT02351687|DRUG|Albendazole|
223572910|NCT02351687|DRUG|Zinc|
223572911|NCT02351687|OTHER|Insecticide-treated bednet|
223572912|NCT02478840|DRUG|Lamazym|recombinant human alpha-mannosidase
223572913|NCT02753621|BEHAVIORAL|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
224302551|NCT00324766|DRUG|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
224302552|NCT00324766|DRUG|placebo,|24 h, infusion
223572914|NCT02753621|BEHAVIORAL|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
223572915|NCT01414101|DRUG|ISIS CRP Rx or Placebo|
223572916|NCT02654392|DIETARY_SUPPLEMENT|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
223572917|NCT02654392|DIETARY_SUPPLEMENT|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, \& Pumpkin oils) every day for 5 weeks
223572918|NCT01238835|DEVICE|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
224302553|NCT05430126|DRUG|Protein Kinase Inhibitor|This retrospective pharmacovigilance study will include protein kinase inhibitor and exclude those drugs known to cause hepatotoxicities
223456674|NCT04226014|PROCEDURE|Endoscopic ultrasound|Echo-endoscopy ultrasound is an examination that presents little risk. However, any medical act, exploration, intervention even conducted under conditions of competence and safety in accordance with current data of medicine and the regulations in force, conceals a risk of complications. In particular, esophageal perforations can occur. They are often favored by underlying lesions (tumor, diverticulum, anatomical variants ...). Other complications are possible such as cardiovascular, respiratory or infectious disorders, as with any anesthesia.
223456675|NCT00650338|DRUG|DE-104 ophthalmic solution, low concentration|Topical ocular application
223456676|NCT00650338|DRUG|DE-104 ophthalmic solution, medium concentration|Topical ocular application
223456677|NCT00650338|DRUG|DE-104 ophthalmic solution, high concentration|Topical ocular application
223456678|NCT00650338|DRUG|Placebo|placebo
223456679|NCT00650338|DRUG|0.005% latanoprost|Topical ocular application
223456680|NCT03460873|PROCEDURE|holmium laser enucleation of the prostate|undergo holmium laser enucleation of the prostate
223456681|NCT03414229|DRUG|Epacadostat|100mg bid days 1-21
223456682|NCT03414229|DRUG|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
223456683|NCT04533438|DEVICE|RhinAer Stylus|The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior turbinate) in both nostrils treated during a single study procedure session.
223456684|NCT04533438|DEVICE|Sham|The control treatment will be performed in the study clinic using the RhinAer Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
223572919|NCT00992381|DRUG|PN400|500mg Naproxen and 20mg esomeprazole
223572920|NCT00992381|DRUG|Naprosyn|500mg Naproxen
223743087|NCT05576740|PROCEDURE|Flexibility determination|measurement of changes in the range of motion of the hamstring musculature, by sit and reach test (cm), during the early follicular phase, late follicular phase, and mid-luteal phase. Three tries.
223456685|NCT03459508|DIAGNOSTIC_TEST|Ophthalmological examination|Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
223456686|NCT05138055|OTHER|No intervention|No intervention
223456687|NCT00271219|DRUG|Methadone|daily oral dosing 20-140 mg
223456688|NCT00271219|DRUG|Buprenorphine|sl daily 2-32 mg
223456689|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅰb|6 subjects in GR1603 low dose，2 subjects in placebo
223456690|NCT06015230|BIOLOGICAL|high dose GR1603 in phaseⅠb|6 subjects in GR1603 high dose，2 subjects in placebo
223456691|NCT06015230|BIOLOGICAL|low dose GR1603 in phase Ⅱ|low dose GR1603 monthly
223456692|NCT06015230|BIOLOGICAL|high dose GR1603 in phase Ⅱ|high dose GR1603 monthly
223572921|NCT02250807|DRUG|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
223572922|NCT02250807|DRUG|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
223572923|NCT02116114|OTHER|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
223572924|NCT00907803|DRUG|ST-246 400 mg|Capsules, 400 mg daily for 14 days
223572925|NCT00907803|DRUG|ST-246 600 mg|Capsules, 600 mg daily for 14 days
223456693|NCT06015230|BIOLOGICAL|Placebo in phase Ⅱ|Placebo
223456694|NCT06329687|DRUG|Tyrvaya Nasal Pump|Tyrvaya Nasal Pump with Silicone Lubricant
223572926|NCT00907803|DRUG|Placebo|Capsules, once daily for 14 days
223743088|NCT05576740|PROCEDURE|Indirect maximum oxygen consumption determination|by the Course Navette test, the indirect oxygen consumption is calculated using the formula: VO2max = (6xFA) - 27,4 (FA = Speed of the last stage of the test completed. It takes place during the early follicular phase, late follicular phase, and mid-luteal phase.
223456695|NCT05781087|DIAGNOSTIC_TEST|Optical coherence tomography and pressure wire assessment|Non-culprit coronary arteries
223456696|NCT05781087|DIAGNOSTIC_TEST|Cardiac magnetic resonance angiogram|1.5T
223456697|NCT04667715|DEVICE|Exablate BBBD|Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
223456698|NCT03143270|DRUG|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
223743089|NCT05576740|DEVICE|Sensory and pain threshold determination|by electrical muscle stimulator (Digitimer DS7A), during the early follicular phase, late follicular phase, and mid-luteal phase.
223743090|NCT05576740|OTHER|Physical and mental symptoms associated with the menstrual cycle|By The Daily Record of Severity of Problems (DRSP) questionnaire, during a full menstrual cycle.
223743091|NCT05576740|DEVICE|Daily activity|by accelerometer (GENEActiv) during a full menstrual cylcle: Wrist-worn device measuring accelerations as a measure of daily activity, in cpm, counts per minute.
223743092|NCT05576740|PROCEDURE|Biochemical parameters determination|Determination of concentration of iron (μg/dL), ferritin (ng/mL), and transferrin (mg/dL), during the early follicular phase, late follicular phase, and mid-luteal phase.
224071373|NCT02984527|DEVICE|wet wipes|intimate hygiene with disposable wet wipes
223456699|NCT03143270|DRUG|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
223456700|NCT06620185|BIOLOGICAL|FLUENZ|LAIV (Intranasal Influenza Vaccine)
223572927|NCT06140381|PROCEDURE|Eccentric training|The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase
223572928|NCT06140381|PROCEDURE|Conventional therapy|3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation
223456701|NCT06620185|BIOLOGICAL|Influenza challenge virus|Influenza challenge virus (H3N2 strain)
223456702|NCT05443997|BEHAVIORAL|MIYCN capacity building|"* MIYCN knowledge, skills, and motivation of FLWs~* Supportive supervision~* Decentralized programmatic decision-making using data~* PRI member involvement~* Availability of THR~* IYCF knowledge and practices"
223456703|NCT05680142|DRUG|superficial cervical plexus block|The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
223572929|NCT06463704|OTHER|There is no intervention|There is no intervention
223572930|NCT06279104|DRUG|physician's choice of chemotherapy|physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
223572931|NCT06279104|DRUG|immune checkpoint inhibitor based therapy|immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
223572932|NCT03142555|BEHAVIORAL|Health talk plus intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
223572933|NCT03142555|BEHAVIORAL|Health talk plus less intensive social media intervention|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
223572934|NCT01212497|BEHAVIORAL|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
223572935|NCT03510468|DRUG|Tenofovir alafenamide|Each tablet contains 25 mg of tenofovir alafenamide.
223572936|NCT03510468|DRUG|Rifapentine|Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
223572937|NCT03510468|DRUG|Isoniazid (INH)|Each tablet is formulated as 100 or 300 mg of isoniazid.
223572938|NCT03510468|DIETARY_SUPPLEMENT|Pyridoxine|Each tablet contains 50 mg of pyridoxine
223572939|NCT01719029|OTHER|Low-Carbohydrate/Higher Fat Diet|
223572940|NCT01719029|OTHER|High Carbohydrate/Low fat diet|
223572941|NCT05179083|OTHER|High-Impact Aerobic Exercise|Participants will be submitted to a 12-week high-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (80% of maximum) is reached, followed by 10 minutes of cool down.
223456704|NCT05680142|DRUG|cervical erector spinae plane block|The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
223456705|NCT04178616|DIAGNOSTIC_TEST|olfactory testing with specific odorants (localisation and identification)|Olfactory testing : ETOC (European Test of Olfactory capabilities)
223456706|NCT00679224|DRUG|ambrisentan|ambrisentan
223572942|NCT05179083|OTHER|Low-Impact Aerobic Exercise|Participants will be submitted to a 12-week low-impact aerobic exercise program using a recliner bike with three sessions per week. The exercise protocol takes 45 minutes per session and consists of five minutes of warm-up, 30 minutes of cycling with progressive increase in intensity until the target heart rate (40% of maximum) is reached, followed by 10 minutes of cool down.
223572943|NCT04612842|BEHAVIORAL|Motivational Interviewing|The PI and two study staff members (interventionists) will conduct study visits and phone calls. The same person will complete participant follow-ups to establish rapport and consistency. All of the study encounters will be audio recorded with participants' permission and study encounter notes will be completed by the interventionist. Interventionists will facilitate MI sessions using the MI guide and a participant handout. The goal of each MI session is to identify a specific fall prevention behavior, the participant's goal with this behavior, readiness to change, specific plan to move toward the goal, barriers and facilitators, and the participant's commitment level to change.
223572944|NCT01654159|PROCEDURE|Monofocal IOL|Monofocal Intraocular lens will be implanted
223572945|NCT01654159|PROCEDURE|Multifocal IOL|Multifocal IOL will be implanted
223572946|NCT01654159|PROCEDURE|Toric IOL|Toric IOLS will be implanted
223743093|NCT05576740|PROCEDURE|Blood count determination|Determination of concentration of hemoglobin (g/dL), red blood cells (10\^6/μL), hematocrit (%), white blood cells (10\^3/μl), platelets (10\^3/μl), during the early follicular phase, late follicular phase, and mid-luteal phase.
224071374|NCT02984527|DEVICE|water and soap|Intimate hygiene with water and soap
223456707|NCT05284903|OTHER|Beamformer Benefit: Speech intelligibility and Listening effort|Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.
223456708|NCT05284903|OTHER|Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility|"Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment."
223456709|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
223456710|NCT05284903|OTHER|Hearing aid benefit: Speech intelligibility in noise (aided condition)|Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
223456711|NCT06308900|OTHER|Clinical simulation|Carrying out a total of 9 clinical simulation in three days, one day a week, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.
223456712|NCT00157001|PROCEDURE|Photopheresis Post Angioplasty|
223456713|NCT00544908|DRUG|dasatinib|
223456714|NCT00544908|OTHER|immunoenzyme technique|
223456715|NCT00544908|OTHER|immunohistochemistry staining method|
223572947|NCT02419131|BEHAVIORAL|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
223572948|NCT02419131|BEHAVIORAL|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
224155699|NCT00768768|OTHER|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
224155700|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
224155701|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
224302554|NCT01289665|PROCEDURE|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
224302555|NCT01289665|PROCEDURE|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
223572949|NCT02419131|BEHAVIORAL|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
223572950|NCT04382625|DRUG|Hydroxychloroquine|Hydroxychloroquine is currently widely used for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis, and it has been used to prevent and treat malaria.
223572951|NCT05426031|DRUG|Protamine fixed dose|250 mg of protamine intravenously (IV), one time use
224302556|NCT03972267|PROCEDURE|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
224302557|NCT03972267|DEVICE|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
223456716|NCT00544908|OTHER|laboratory biomarker analysis|
223456717|NCT00544908|PROCEDURE|quality-of-life assessment|
223456718|NCT00704977|PROCEDURE|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
223572952|NCT05426031|DRUG|Protamine ratio dose|1mg of protamine per 100 units of heparin given intravenously (IV), one time use
223572953|NCT02076269|OTHER|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
223572954|NCT04419740|BEHAVIORAL|Mindfulness based psychological intervention|Women in the intervention group will have to use an application during 1 month. They will do meditation during 15 minutes each day.
223572955|NCT02372552|DEVICE|CROMA|Microwave coagulation of small blood vessels
223572956|NCT05923294|PROCEDURE|Coronally advanced flap with connective tissue graft|In both groups, connective tissue graft with a trapezoidal flap design will be applied to the recession area.
223572957|NCT05801757|DRUG|Remimazolam|Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
223456719|NCT02716584|BEHAVIORAL|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
223456720|NCT02716584|BEHAVIORAL|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
223456721|NCT01423929|DRUG|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
223456722|NCT01423929|DEVICE|Room air|Fitting of Oxymask TM
223456723|NCT03466723|GENETIC|biomarker identification in Parkinson disease|circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants
223456724|NCT06253910|OTHER|Patients selection|Patient selection were selected according to selected criteria.
223456725|NCT06253910|OTHER|Recall visits|Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.
223456726|NCT01504373|DEVICE|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
223456727|NCT04858867|RADIATION|rhTSH-stimulated I-124 dosimetry|"Preparation:~* Low iodine diet 7 days prior to I-124 ingestion until 24 hours post-ingestion~* Thyrogen injections 24 and 48h prior to I-124 ingestion~Procedures following Jentzen et al:~* Ingestion of capsule with 37±10% MBq I-124~* I-124 PET/CT at 24 and 96h post-ingestion~* Blood draws at 2, 24 and 96h post-ingestion~* Whole body counting at 2, 24 and 96h post-ingestion"
223456728|NCT04858867|RADIATION|Intra-therapeutic I-131 dosimetry|"Procedures following EANM guidelines:~* I-131 SPECT/CT at 2, 6, 24, 96 and 144h post-ingestion~* Blood draws at 2, 6, 24, 96 and 144h post-ingestion~* Whole body counting at 2, 6, 24, 96 and 144h post-ingestion"
223456729|NCT03163537|DEVICE|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
223456730|NCT02088892|DRUG|BCG SSI|Intradermal injection
223456731|NCT02088892|DRUG|BCG Tice|Intradermal injection
223572958|NCT05801757|DRUG|Propofol|propofol 2-3mg/kg/h
223572959|NCT04677660|BIOLOGICAL|TAK-919|TAK-919 intramuscular injection
224155702|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
224155703|NCT00768768|OTHER|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
224302558|NCT01561430|DRUG|LY2886721|
224302559|NCT01561430|DRUG|Placebo|
224302560|NCT00070057|DRUG|celecoxib|Given orally
224302561|NCT00070057|PROCEDURE|therapeutic conventional surgery|Undergo surgery
224302562|NCT00070057|OTHER|pharmacological study|Correlative studies
223456732|NCT01903993|DRUG|Docetaxel|Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
223456733|NCT01903993|DRUG|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
223456734|NCT01588405|DRUG|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
223456735|NCT00897871|DRUG|carboplatin|
223456736|NCT00897871|DRUG|cyclophosphamide|
223456737|NCT00897871|DRUG|etoposide phosphate|
223456738|NCT00897871|GENETIC|gene expression analysis|
223456739|NCT00897871|GENETIC|polymorphism analysis|
223572960|NCT04677660|BIOLOGICAL|Placebo|Placebo intramuscular injection
223572961|NCT00002211|DRUG|Nelfinavir mesylate|
223456740|NCT00897871|OTHER|pharmacological study|
223456741|NCT02853045|DRUG|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
223456742|NCT02853045|DRUG|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
223572962|NCT00002211|DRUG|Delavirdine mesylate|
223572963|NCT00002211|DRUG|Stavudine|
223572964|NCT00002211|DRUG|Didanosine|
223572965|NCT00278902|DRUG|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
223572966|NCT01648296|DRUG|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
223572967|NCT00017589|BIOLOGICAL|oblimersen sodium|
223572968|NCT00017589|DRUG|gemtuzumab ozogamicin|
223572969|NCT02093429|DRUG|INCB047986|INCB047986 will be supplied as tablets.
223572970|NCT03416920|OTHER|Wellframe|Wellframe mobile phone app
224302563|NCT00070057|OTHER|laboratory biomarker analysis|Correlative studies
224302564|NCT00111423|DRUG|Pegsunercept (PEG sTNF-RI)|
224155704|NCT01240304|DRUG|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
224155705|NCT01240304|RADIATION|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
224155706|NCT01240304|PROCEDURE|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
224155707|NCT00195481|DRUG|Rapamune|
224155708|NCT02795611|BEHAVIORAL|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
224155709|NCT02795611|BEHAVIORAL|regular occupational therapy|regular occupational therapy
223456743|NCT05730855|DIAGNOSTIC_TEST|Real-time Polymerase Chain Reaction technique|Real-time Polymerase Chain Reaction technique
224155710|NCT02795611|OTHER|intervention done outside our hospital|intervention done outside our hospital
224155711|NCT00005945|DRUG|cyclophosphamide|Given IV
224155712|NCT00005945|DRUG|cytarabine|Given IT
224302565|NCT03709823|DRUG|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
224302566|NCT03709823|DRUG|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
224302567|NCT03709823|BEHAVIORAL|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
224302568|NCT05998941|DRUG|TQB2868 injection|TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
224302569|NCT05998941|DRUG|Paclitaxel injection|Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
224302570|NCT05998941|DRUG|Cisplatin injection|Cisplatin injection can inhibit the DNA replication process of cancer cells
223456744|NCT02547896|DRUG|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
223456745|NCT02547896|DRUG|Diclofenac|The patients will receive only diclofenac
223456746|NCT05859282|BEHAVIORAL|Survey|A short 25-item tool was developed and can be applied in clinics to assess the awareness of pregnancy hypertension.
224155713|NCT00005945|DRUG|daunorubicin hydrochloride|Given IV
224302571|NCT05998941|DRUG|Carboplatin injection|Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
224302572|NCT05998941|DRUG|Bevacizumab injection|Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
224155714|NCT00005945|DRUG|dexamethasone|Given PO
224155715|NCT00005945|DRUG|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
224155716|NCT00005945|DRUG|mercaptopurine|Given PO
224155717|NCT00005945|DRUG|methotrexate|Given PO and IT
224155718|NCT00005945|DRUG|pegaspargase|Given IM
224155719|NCT00005945|DRUG|thioguanine|Given PO
224155720|NCT00005945|DRUG|vincristine sulfate|Given IV
224155721|NCT00005945|RADIATION|radiation therapy|Undergo radiation therapy
224302573|NCT02716935|DIETARY_SUPPLEMENT|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
224302574|NCT02716935|DIETARY_SUPPLEMENT|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
224302575|NCT02960919|DRUG|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
224302576|NCT02960919|DRUG|parenteral ampicillin/ penicillin|
224302577|NCT02960919|DRUG|gentamicin|
224302578|NCT00094003|DRUG|NS-9 [Poly I: Poly C]|
223456747|NCT03027076|PROCEDURE|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
223456748|NCT03027076|PROCEDURE|Collect midstream urine samples|Collect midstream urine samples
223456749|NCT02735473|DRUG|Choline bitartrate|
223456750|NCT02735473|DRUG|Placebo|
223456751|NCT07022847|OTHER|Non-invasive Monitoring|All participants will undergo non-invasive measurement of Pleth Variability Index (PVI) and routine blood pressure monitoring before and during hemodialysis sessions. No treatment or experimental intervention will be applied.
223456752|NCT02544958|DEVICE|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
223456753|NCT03545269|DRUG|CartiLife®|CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
223456754|NCT03545269|PROCEDURE|Microfracture|The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
224302579|NCT00334100|BEHAVIORAL|Exercise|Treadmill exercise
224302580|NCT06410170|DEVICE|MIRA Device|At home diagnostic testing
224302581|NCT03976583|DRUG|Cpp-Acp|Remineralising agent
224302582|NCT03976583|OTHER|Pearl powder|Natural product
224302583|NCT02746471|DEVICE|Reveal LINQ|
224302584|NCT03868462|DEVICE|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
223456755|NCT02992184|DEVICE|HCV RNA detection with Genedrive assay|
223572971|NCT05477173|BEHAVIORAL|The Strengths and Difficulties Questionnaire (SDQ) Parent Version Parent : It consists of 25 questionnaires used to screen for behavioral problems in children aged 4-17 years.|screen by using psychometric scales
223456756|NCT02992184|DEVICE|HCV RNA detection with RealTime HCV|
223456757|NCT00000356|DRUG|LAAM|
223456758|NCT04274309|DEVICE|EndoSWIR|Exposition of the respected tissues to the camera
223456759|NCT03009253|OTHER|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
223456760|NCT00401427|DRUG|trastuzumab|
223456761|NCT00401427|DRUG|vinorelbine|
223572972|NCT01753219|PROCEDURE|Onstep|
223572973|NCT01753219|PROCEDURE|Lichtenstein|
223572974|NCT03327376|DEVICE|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
223572975|NCT03886337|DEVICE|Germicidal lighting|Germicidal ambient lighting
224302585|NCT03868462|DEVICE|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
224302586|NCT00784186|DRUG|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
224302587|NCT00784186|DRUG|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
224302588|NCT00784186|DRUG|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
224302589|NCT04701515|OTHER|Chart review|Chart review
223456762|NCT04651166|DRUG|Tranexamic acid|1g tranexamic acid mixed in 100mL saline or lactated ringer
223456763|NCT04651166|DRUG|Placebo|100mL saline or lactated ringers
223456764|NCT04437446|DIAGNOSTIC_TEST|Case Group|The additional examination corresponds to an OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.
223456765|NCT04437446|DIAGNOSTIC_TEST|Control Group|"The additional examinations correspond to:~* OCTA which is a non-invasive examination, without potential risks, without radiation, using infrared light.~* OCT: non-invasive examination, without potential risks, without radiation, using infrared light. The patient must sit in front of a screen and a contact is taken without contact in about ten seconds.~* Visual field"
223456766|NCT02859519|DRUG|MOB015B|MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
223456767|NCT02859519|DRUG|MOB015B Vehicle|MOB015B Vehicle without the active ingredient Terbinafine
223456768|NCT00792714|DRUG|Mannitol|400mg twice daily for 7 days
223456769|NCT02007655|DRUG|Eliquis|
223456770|NCT05392777|DIAGNOSTIC_TEST|Residual syntax score|residual syntax score will be calculated as the conventional syntax score from the web based tool, but subtract the score of the culprit lesion(s) that are fixed (stented) in the index procedure.
223456771|NCT01243177|DRUG|Lacosamide|"Lacosamide:~* Strengths: 50 mg / 100 mg~* Form: tablets~* Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~* Duration: up to 118 weeks"
223456772|NCT01243177|DRUG|Carbamazepine-Controlled Release|"Carbamazepine-CR:~* Strengths: 200 mg~* Form: tablets~* Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~* Duration: up to 118 weeks"
223456773|NCT00830583|PROCEDURE|blood test|There is only a blood test at the beginning.
223456774|NCT02801981|DRUG|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
223456775|NCT02801981|DRUG|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
223456776|NCT06795100|OTHER|Pre-inclusion|Information and presentation of the proposed study to participants during the anesthesia consultation scheduled prior to surgery, including provision of the information document and consent form. Trial participants will have at least 2 days to decide whether or not to take part in the trial.
223456777|NCT06795100|OTHER|Inclusion|"Participants will be welcomed according to the usual process in the digestive, hepatic, urological, or gynecological surgery service. The inclusion visit will coincide with the pre-anesthesia visit during which the absence of contraindications for starting the study will be verified, particularly the occurrence of any health changes since the anesthesia visit that would contraindicate anesthesia or lidocaine administration. During this visit, participant consent will be obtained. The informed consent form must be signed no later than the morning of the intervention.~For women of childbearing age, the absence of current pregnancy will be verified orally for each participant included. A pregnancy test may be performed if the participant so wishes, but a systematic test is not justified."
223456778|NCT06795100|DRUG|Lidocaine|Induction of anesthesia will be at the discretion of the attending anesthesiologist, with a lidocaine bolus of 2 mg/kg administered over 1 minute, followed by a continuous IV infusion of 2 mg/kg/h.
223572976|NCT02178813|DRUG|Administration of minocycline|"Administration of minocycline with the following schedule:~* Day prior to procedure: 800mg p.o., 700mg p.o.~* Day of procedure: 600mg i.v., 500mg p.o.~* Day after procedure: 400mg p.o., 400mg p.o."
223743094|NCT05576740|PROCEDURE|Body composition parameters determination|Determination of weight (kg), total body water (L), proteins (kg), minerals (kg), body fat mass (kg), body mass index (BMI) (kg/m2), basal metabolic rate (kcal) by Bioelectrical Impedance Analysis, during the early follicular phase, late follicular phase, and mid-luteal phase.
223743095|NCT05576740|PROCEDURE|Vital signs|Determination of blood pressure (mmHg) and heart rate (bpm) at baseline, one minute and three minutes after the Course Navette test
223743096|NCT05576740|OTHER|Checking for correct use of contraceptive methods|Pre-test questions about possible forgetfulness or mishandling of the method
224302590|NCT04596228|DEVICE|BTL-899|Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.
224302591|NCT04781101|OTHER|conventional therapy|Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.
223456779|NCT06795100|OTHER|Pharmacokinetic study of intravenous lidocaine|Blood samples of 3 mL will be collected in heparinized tubes without gel of 4 ml at 30, 60 and 120 minutes after the start of lidocaine infusion, then every two hours during surgery, and two finals samples at 15 and 60 minutes after the infusion stops.
223456780|NCT06795100|OTHER|Pain|. Maximal pain reported in the post-anesthesia care unit (PACU) and maximal pain at rest and with movement at 24 hours post-extubation will be recorded.
223456781|NCT06795100|OTHER|adverse effects/events|Any adverse effects/events will be documented from the start of lidocaine administration until 24 hours post-extubation,
223456782|NCT06795100|BIOLOGICAL|biological blood test|A biological blood test, not performed in routine practice, will be carried out to measure the following parameters: albumin, ASAT, ALAT, PAL, GammaGT, total and conjugated bilirubin, creatinine, with calculation of GFR.
223456783|NCT03663933|DRUG|Immunosuppression Only Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
223456784|NCT03663933|DRUG|Reduced Intensity Conditioning|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
223456785|NCT03663933|DRUG|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25
223456786|NCT03663933|PROCEDURE|Allogeneic HSC|Stem cell transplant
223456787|NCT03191825|OTHER|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
223456788|NCT03191825|OTHER|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
223456789|NCT03191825|OTHER|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
223456790|NCT06926738|OTHER|Upper Thoracic Manipulation|"Segmental mobility will be assessed using posteroanterior central vertebral pressure and posteroanterior unilateral vertebral pressure. It will be done while the patient lies in a prone position and the examiner stands at the level of the patient's head.~Afterwards, the subjects in the thoracic manipulation group will be asked to lie in a prone position on a standard examination table and they were marked on both sides of the zygapophyseal joint of the selected segments including levels from T1- T4. Subjects will then be instructed to perform deep inhalation and exhalation and at the end of exhalation, the Clinician will perform thoracic manipulation (screw thrust technique) at the selected segmental level/s. This maneuver will be repeated for a maximum of two attempts in case of no hearing of a pop sound. It will be performed by an experienced physiotherapist with more than 10-year experience."
223456791|NCT06926738|OTHER|Sham Comparison|"Segmental mobility will be assessed using posteroanterior central vertebral pressure and posteroanterior unilateral vertebral pressure. It will be done while the patient lies in a prone position and the examiner stands at the level of the patient's head.~Afterwards, the subjects in the thoracic manipulation group will be asked to lie in a prone position on a standard examination table and they were marked on both sides of the zygapophyseal joint of the selected segments including levels from T1- T4. Subjects will then be instructed to perform deep inhalation and exhalation and at the end of exhalation, the Clinician will just the place the hands on the selected levels in the same hand placement of Thoracic manipulation group (screw thrust technique) without applying the manipulation. It will be performed by an experienced physiotherapist with more than 10-year experience."
223456792|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
223456793|NCT02417857|PROCEDURE|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
223743097|NCT05576740|PROCEDURE|Urinary LH determination|Urine LH test strips are performed from day 8 of the cycle until positive.
223743098|NCT00176007|PROCEDURE|Hypoxia|
224067157|NCT00550680|DRUG|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
224067158|NCT06066827|DRUG|Minoxidil Topical|20 subjects received minoxidil only for the treatment of AGA
224067159|NCT06066827|OTHER|Secretome from adipose-derived stem cells|20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA
224067160|NCT06066827|COMBINATION_PRODUCT|Combination of minoxidil and secretome from adipose-derived stem cells|20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA
224067161|NCT03397407|OTHER|No intervention|
223456794|NCT05058846|PROCEDURE|Biospecimen Collection|Undergo blood, tissue, and saliva collection
223456795|NCT05058846|PROCEDURE|Magnetic Resonance Cholangiopancreatography|Undergo MRCP
223456796|NCT05058846|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223456797|NCT05058846|PROCEDURE|Endoscopic ultrasound|Undergo endoscopic ultrasound
223456798|NCT05058846|OTHER|Questionnaires|Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire
223456799|NCT06949709|BEHAVIORAL|Fasted-exercise|Breakfast intake before 30 min brisk walking on a treadmill
223456800|NCT06949709|BEHAVIORAL|Fed-exercise|30 min brisk walking on a treadmill before breakfast intake
223456801|NCT06955572|DIAGNOSTIC_TEST|Patients with colorectal cancer|Analysis of the lower fecal gene count (fGC) compared with the control group
223456802|NCT06955572|DIAGNOSTIC_TEST|Patients with Parkinson's disease|Analysis of the lower fecal gene count (fGC) compared with the control group
223456803|NCT06955572|DIAGNOSTIC_TEST|Patients with non-alcoholic steatohepatitis|Analysis of the lower fecal gene count (fGC) compared with the control group
223456804|NCT06955572|DIAGNOSTIC_TEST|Patients with obesity|Analysis of the lower fecal gene count (fGC) compared with the control group
223456805|NCT06955572|DIAGNOSTIC_TEST|Healthy volunteers|Determination of the number of bacterial faecal genes (fGC, fecal Gene Count) inferior reference
223456806|NCT06955273|DEVICE|Corsano CardioWatch 287-2|Patients receive monitoring of their heart rhythm by the CardioWatch 287-2 next to monitoring of their heart rhythm by either a 24-48 holter or a short in-clinic 12-lead ECG monitoring.
223456807|NCT06955663|BEHAVIORAL|Exercise training|12 week exercise intervention + cardiopulmonary exercise test (CPET) + wearable activity monitor
223456808|NCT06955026|OTHER|Hockey slideboard combined with BFR training|Hockey slideboard combined with BFR training
223456809|NCT06955026|OTHER|Hockey slideboard|Hockey slideboard
223456810|NCT06956131|DIETARY_SUPPLEMENT|Casein Protein Isolate Drink|30 g protein equivalent of casein protein isolate dissolved in \~250 mL of water
223572977|NCT05726565|OTHER|multidisciplinary cardiac rehabilitation|A heart failure disease management program was delivered to all patients before discharge, including an HF specialist nurse education program, dietitian consultation, physiatrist consultation, and psychologist consultation and assessment. Participants were advised to receive phase II CR after the CPET within one month. Moderate continuous aerobic exercise training was prescribed individually according to the CPET result.4 The training intensity was within 10 beats of the anaerobic threshold or 40-60% of peak VO2. The training intensity was gradually increased fortnightly as tolerated (Borg's scale of 12-14). Phase II CR consisted of 12 weeks of 36 sessions in the entire course. Patients who received at least one exercise session were considered as receiving CR. Other patients were considered non-receiving CR.
223572978|NCT04219319|DRUG|Efficacy of LCAR-T2C CAR-T cells|CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
224155722|NCT02143960|DEVICE|VelaShape III|Subjects will receive one treatment to their entire waist / love-handle/ flanks area in a split-waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
224155723|NCT02143960|DEVICE|CoolSculpt|Noninvasive Cryolipolysis
224155724|NCT05239884|OTHER|ENDS Product A with 1.5% nicotine|P1211216, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
223456811|NCT06956131|DIETARY_SUPPLEMENT|Whey Protein Isolate Drink|30 g protein equivalent of whey protein isolate dissolved in \~250 mL of water
223456812|NCT06956131|DIETARY_SUPPLEMENT|Soy Protein Isolate Drink|30 g protein equivalent of soy protein isolate dissolved in \~250 mL of water
223456813|NCT06956131|DIETARY_SUPPLEMENT|Maltodextrin Drink|30 g carbohydrate equivalent of maltodextrin powder dissolved in \~250 mL of water
223456814|NCT06954844|DEVICE|Transcutaneous non-invasive vagus nerve stimulation (tVNS)|To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established conventional stimulation protocol (30 s ON, 30s OFF, 25 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany). Stimulation intensity will be pre-set for each participant for the following stimulation period to correspond to a mild pricking sensation determined with a staircase procedure in the lab session.
223456815|NCT06954844|DEVICE|Low intensity stimulation|The electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA, 1s ON, 30s OFF, 1 Hz frequency, 250 µs pulse widths; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
223456816|NCT02843815|DEVICE|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
223572979|NCT02887053|DEVICE|MRI|
223572980|NCT05082220|PROCEDURE|Erector spinae plane block|fascial plane injection using ultrasound and fluoroscopic guidance
223572981|NCT06413420|DRUG|Sunosi (solriamfetol)|Exposure to at least 1 dose of solriamfetol at any time during pregnancy.
223456817|NCT02843815|BIOLOGICAL|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
223456818|NCT05022459|DRUG|Emicizumab|Patients in this group will be on standard of care Emicizumab prophylaxis for Hemophilia A
223456819|NCT05022459|DRUG|FVIII|Patients in this group will be on standard of care FVIII prophylaxis for Hemophilia A
223456820|NCT06359262|OTHER|Hope@School|A digital platform aimed at promoting student mental health in schools
223456821|NCT06359262|OTHER|Treatment as usual|Regular student health care in schools
224155725|NCT05239884|OTHER|ENDS Product B with 1.5% nicotine|P1213516, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224155726|NCT05239884|OTHER|ENDS Product C with 1.5% nicotine|P1213416, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224155727|NCT05239884|OTHER|ENDS Product D with 1.5% nicotine|P1212716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224067162|NCT03098784|OTHER|Exposure to aircraft exhaust|The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.
224067163|NCT03098784|OTHER|Non exposure to aircraft exhaust|The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
224067164|NCT03000907|OTHER|Intervention|Diet and physical exercises
224067165|NCT01119248|OTHER|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
224155728|NCT05239884|OTHER|ENDS Product E with 1.5% nicotine|P1213716, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224155729|NCT05239884|OTHER|ENDS Product F with 1.5% nicotine|P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224155730|NCT05239884|OTHER|ENDS Product G with 1.5% nicotine|P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224067166|NCT00138788|PROCEDURE|Radiotherapy, dose fractionation|
224155731|NCT05239884|OTHER|ENDS Product H with 1.5% nicotine|P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
224155732|NCT01685203|DRUG|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
224155733|NCT01685203|DRUG|ABT-267|Tablet
224155734|NCT01685203|DRUG|Ribavirin (RBV)|Tablet
224155735|NCT03212599|DRUG|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
224155736|NCT00318370|DRUG|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
223456822|NCT05178823|DRUG|Chlorhexidine mouthwash|Comparison of oral rinses
223456823|NCT01073163|DRUG|Bendamustine|Bendamustine at 90 mg/m\^2 IV on Days 1 and 2 of a 28-day cycle.
223456824|NCT01073163|DRUG|Rituximab|Rituximab at 375 mg/m\^2 IV on Day 1 of a 28-day cycle.
223456825|NCT05914818|DEVICE|EXPLORER V2|4 sessions of use of the exoskeleton, 1 in a laboratory of gait analysis and 3 in the home and the community of the participants
223456826|NCT05358899|DEVICE|accelerated theta burst stimulation|cTBS was administered at 80% of each participant's M1 area in a burst-firing pattern (3 pulses at 50 Hz) with a repetition frequency of 5 Hz (200 ms intervals). During each session, participants received 1800 pulses (120 s).
223456827|NCT05358899|DEVICE|Sham stimulation|Similar process with the accelerated theta burst stimulation with the coil 90 degrees tilted to the surface of the scalp, which could produce identical sound and vibration while avoiding real magnetic stimulation.
223456828|NCT01058291|DRUG|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
223456829|NCT01058291|DRUG|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
223456830|NCT01935986|DIETARY_SUPPLEMENT|probiotic|
223456831|NCT01935986|DIETARY_SUPPLEMENT|placebo|
223456832|NCT00703677|DRUG|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
223456833|NCT03103256|DRUG|YHP1701|PO, Once daily (QD), 8 weeks
223456834|NCT03103256|DRUG|YHR1703|PO, Once daily (QD), 8 weeks
223456835|NCT03103256|DRUG|YHR1704|PO, Once daily (QD), 8 weeks
224155737|NCT00318370|DRUG|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
224155738|NCT05428540|DIETARY_SUPPLEMENT|Polyphenol-rich supplement|Polyphenol-rich capsules containing 1,200 mg of a combination of plant extracts rich in polyphenols. Frequency: 3 capsules a day. Duration: 12 weeks.
224155739|NCT05428540|OTHER|Placebo|Placebo
224155740|NCT01750840|DEVICE|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
224155741|NCT01750840|DEVICE|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
224155742|NCT01750840|DEVICE|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
224155743|NCT00530491|PROCEDURE|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
224155744|NCT03641794|DRUG|DN1406131|IDO1 and TDO2 inhibitor
224155745|NCT03641794|DRUG|Placebo|Placebo
224155746|NCT00067626|DIETARY_SUPPLEMENT|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
224155747|NCT04613271|DRUG|Favipiravir|"Assignment of Administration Group 1:~Favipiravir 1600 mg twice a day at day 1 and 600 mg twice a day at day 7-14 + Azithromycin 500 mg once a day for 5 days."
224155748|NCT04613271|DRUG|Azithromycin|Azithromycin 500 mg once a day for 5 days.
224155749|NCT02225925|RADIATION|Brachytherapy|
224155750|NCT05302804|DRUG|Menthol Gel|5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
224155751|NCT05302804|DRUG|Control Gel|Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
224155752|NCT01720693|PROCEDURE|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
224155753|NCT02220530|DRUG|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
224155754|NCT03016039|DIETARY_SUPPLEMENT|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
223572982|NCT06413420|DRUG|Other prescription wake-promoting medications or stimulants|Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
223456836|NCT05201326|DRUG|Bevacizumab，Irinotecan and Re-radiotherapy|All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
223572983|NCT06413420|OTHER|No treatment|No treatment
223572984|NCT01949025|OTHER|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
223572985|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
223572986|NCT02437305|BEHAVIORAL|ABCDEs of Melanoma|Conventional melanoma educational intervention.
223456837|NCT02383069|OTHER|Intervention Group|Aerobic training
223456838|NCT02383069|OTHER|Control Group|Chest physiotherapy: Flutter and muscle stretching
223456839|NCT04389528|OTHER|Neuromodulation by tDCS|The tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.
223743099|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
223572987|NCT04174989|OTHER|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
224155755|NCT01921283|DEVICE|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
223456840|NCT02809352|BIOLOGICAL|Human papillomavirus genotyping|
223456841|NCT05930171|PROCEDURE|Ultrasound guided L-ESPB and PENG block using Bupivacaine|Combined Lumbar Erector Spinae Plane Block and Pericapsular Nerve Group Block in Patients Undergoing Hip Surgeries
223456842|NCT05930171|DRUG|Postoperative conventional analgesia in form of Acetaminophen|Postoperative conventional analgesia in form of acetaminophen 15 mg/kg/6hrs
223456843|NCT01085422|DRUG|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
223456844|NCT01085422|DRUG|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
223572988|NCT04174989|OTHER|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
223456845|NCT00940888|DEVICE|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
223456846|NCT03688347|PROCEDURE|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
223456847|NCT03688347|PROCEDURE|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
223456848|NCT03688347|OTHER|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
223572989|NCT02762955|BIOLOGICAL|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
223572990|NCT02762955|BIOLOGICAL|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
223572991|NCT04953819|OTHER|Revascularization|Percutaneous coronary intervention and/or coronary bypass grafting for coronary artery disease
223572992|NCT04953819|OTHER|Medical therapy|Optimal medical therapy for coronary artery disease
223572993|NCT06009887|BEHAVIORAL|Motivational Interview|Motivational interviewing is a collaborative speaking style to strengthen one's own motivation and commitment to change. Motivational interviewing is not a technique but a fundamental therapeutic style that does not try to make people change their behavior against their will. Proven to be effective in many areas of healthcare, motivational interviewing is widely used to help people resolve their indecision about change, explore their concerns, and set their own goals. The purpose of the motivational interviews conducted in the study is to increase the belief in normal and natural birth by enabling pregnant women to understand the factors that affect their low belief in normal birth, to take action for change and to believe in change, and to minimize the practices that cause medicalization of birth such as cesarean section by reducing medical birth beliefs.
223572994|NCT03466138|DEVICE|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
223743100|NCT01109251|PROCEDURE|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
223743101|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
223456849|NCT03688347|GENETIC|Microbiome analysis|Study of microbial communities found in and on the human body.
223456850|NCT03688347|GENETIC|DNA Banking|Secure, long term storage of an individual's genetic material.
223456851|NCT03688347|PROCEDURE|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
223456852|NCT05497297|DRUG|HSK7653 tablets|HSK7653, tablet, oral
224067167|NCT05446545|OTHER|ND-EOC or platinum-sensitive rEOC|platinum-based combined chemotherapy or bevacizumab will be used for adjuvant treatment, followed by maintenance therapy with poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, or bevacizumab, or other anti-tumor angiogenesis drugs or immune checkpoint inhibitors
224067168|NCT00505440|BEHAVIORAL|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
223572995|NCT01279629|DRUG|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
223572996|NCT04312360|DRUG|therapeutic endoscopy with metronidazole and fosfomycin disodium|therapeutic endoscopy where the two drugs: metronidazole and fosfomycin disodium are sprayed through out the right colon section (from caecum to right colon flexure). This intervention is going to be performed on patients in both track 1 and track 2a.
223572997|NCT03088631|DRUG|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
223456853|NCT00578279|DRUG|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
223456854|NCT01535469|DRUG|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
223572998|NCT03088631|OTHER|Placebo|will receive corn-flour placebo tablets (three tablets daily).
223572999|NCT03403231|BEHAVIORAL|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
223573000|NCT06118541|BEHAVIORAL|Vestibular Rehabilitation therapy|"Vestibular rehabilitation exercises of 30 to 60 minutes twice a week for eight weeks~Vestibular rehabilitation exercise program:~1. Eye-Head Coordination exercise~2. Sitting balance exercises~3. Standing Static balance exercises~4. Standing Dynamic balance exercises~5. Ambulation exercises"
223573001|NCT01560637|DRUG|UT-15C (treprostinil diolamine)|UT-15C extended release oral tablet three times daily
224067169|NCT00505440|BEHAVIORAL|Usual care|Usual care with mailed screening results
224067170|NCT03456752|DRUG|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia
224067171|NCT03456752|DRUG|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia
224067172|NCT05047757|DIETARY_SUPPLEMENT|Test meal with 15N labeled favabean|Ingestion of a 15N labeled test meal. Subjects are equipped with a nasoileal tube. 15N is followed in biological fluids (plasma, effluents, urines).
224067173|NCT02247323|OTHER|Risk of malignancy index|Calculation of RMI before sugery.
224067174|NCT05017207|PROCEDURE|Pancreaticoduodenectomy|Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
224067175|NCT00562354|BIOLOGICAL|13vPnC|13vPnC for both stratum
224067176|NCT04257825|DEVICE|Chili Sleep System|A mattress pad that cools or warms bed to maintain a constant temperature.
224067177|NCT00317109|BIOLOGICAL|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
224067178|NCT00317109|BIOLOGICAL|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
224067179|NCT00317109|BIOLOGICAL|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
224067180|NCT04687800|DRUG|Dextenza 0.4mg intracanalicular Insert|intracanalicular insert delivery system
224067181|NCT04687800|DRUG|Durezol 0.05% Ophthalmic Emulsion|Standard therapy, topical steroid drop
224067182|NCT03124771|DEVICE|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
224067183|NCT01883635|BEHAVIORAL|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
224067184|NCT01883635|BEHAVIORAL|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
224067185|NCT05480748|DEVICE|monitoring|ORI warning time, SpO2 warning time, added time were recorded.
224067186|NCT00761514|DRUG|Humira (adalimumab)|40 mg eow
224155756|NCT01921283|DRUG|no- BIS sensor attachment|
223456855|NCT03923777|OTHER|Active Surveillance|Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is \>3 cm in size or the VDT decreases to \<400 days.
223456856|NCT03215875|DRUG|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
223456857|NCT03215875|DRUG|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
223456858|NCT01963559|DRUG|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
223456859|NCT03003702|DEVICE|Nonin|
223456860|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
223456861|NCT04441788|DRUG|Placebo|Placebo administered by oral inhalation
223456862|NCT04441788|DRUG|ION-827359|ION-827359 administered by oral inhalation
223456863|NCT02415192|DRUG|Levacalm|
223456864|NCT02415192|DRUG|Valsartan/amlodipine|
223456865|NCT03161041|PROCEDURE|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
223456866|NCT03161041|DRUG|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
223456867|NCT01196377|DRUG|Albuterol|Nebulized albuterol
223456868|NCT03859648|DEVICE|BONEBRIDGE|Bone Conduction Implant
223456869|NCT03758768|OTHER|Blue light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
223456870|NCT03758768|OTHER|Full spectrum light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
223456871|NCT05013502|DRUG|Empagliflozin 10 MG|empagliflozin 10mg PO once daily
223456872|NCT03313531|DIAGNOSTIC_TEST|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
224155757|NCT01807611|RADIATION|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
224155758|NCT01807611|DRUG|Fludarabine|Given IV.
223456873|NCT03313531|DRUG|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
223456874|NCT06321120|DRUG|variability-based lenvatinib regimen|Dosages and administration times were tailored within individual predefined ranges to accommodate personalized therapeutic regimens. As per protocol, the daily dose was limited to match or remain below the patients' pre-enrollment dosage level. In the initial 4 weeks of the follow-up, participants followed a fixed standard regimen with the app serving as a reminder, allowing for an adaptation period. Subsequently, the algorithm-driven treatment plan was implemented for an additional 10 weeks.
223456875|NCT03977987|DRUG|nucleos(t)ide analogue|Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
223456876|NCT00405015|DRUG|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
223456877|NCT01018745|DRUG|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
223456878|NCT01677182|DRUG|Ramelteon|Ramelteon tablets for sublingual administration
223456879|NCT01677182|DRUG|Placebo|Ramelteon placebo-matching tablets for sublingual administration
223456880|NCT06321185|PROCEDURE|Subcostal TAP block|"Subcostal TAP block will be applied after intubation and before surgery. A local anesthetic solution of 20 ml 0.25% bupivacaine for each side will be injected bilaterally between the rectus abdominis and transversus abdominis muscles along the oblique subcostal line. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
223456881|NCT06321185|OTHER|Port site local anesthetic infiltration|"After intubation and before port placements, a solution of 20 ml 0.25% bupivacaine will be infiltrated into the laparoscopic port sites. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
223456882|NCT06321185|OTHER|No intervention or local anesthetic administration|"There will not be an intervention or local anesthetic administration. A multimodal routine IV analgesic regimen will be administered intraoperatively (1 gr paracetamol, 8 mg lornoxicam and 1mg/kg tramadol).~Patients will receive a standard postoperative multimodal analgesia protocol comprising paracetamol and lornoxicam at the ward. Pain severity will be assessed with a Numeric Rating Scale (NRS) rated between 0 and 10; a rescue analgesic IV 50 mg tramadol will be applied when it is four or higher."
224155759|NCT01807611|DRUG|Cyclophosphamide|Given IV.
224155760|NCT01807611|DRUG|Thiotepa|Given IV.
224155761|NCT01807611|DRUG|Melphalan|Given IV.
223456883|NCT02706769|DRUG|Placebo|Study medication contains blinded placebo
223456884|NCT02706769|DRUG|Paracetamol|Study medication contains blinded paracetamol
223456885|NCT00995722|DRUG|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
223456886|NCT00995722|DRUG|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
223456887|NCT03206840|BEHAVIORAL|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
223456888|NCT03627078|OTHER|motor interference therapy|
223456889|NCT03627078|OTHER|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
223456890|NCT02945735|BEHAVIORAL|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
224155762|NCT01807611|BIOLOGICAL|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
224155763|NCT01807611|BIOLOGICAL|TC-NK Infusion|Participants receive infusions of TC-NK.
223456891|NCT01288651|DRUG|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
223456892|NCT05784376|BEHAVIORAL|Education-based|Nutrition education delivered via text messages through mobile applications (e.g. WhatsApp).
223456893|NCT05733845|OTHER|Samples|The intervention is to collect blood; urine; saliva and stool samples but also mucosal biopsies at each protocol visits (baseline and follow up visits).
223743102|NCT01519960|DRUG|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
224155764|NCT01807611|BIOLOGICAL|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
223456894|NCT05376761|DRUG|Dexmedetomidine|The loading dose of DEX (0.5 µg/kg) is transfused intravenously within 15min.The maintaining concentration of DEX, which is started at 0.3 µg/kg/h in the first patient, is determined by the NRMS in the MER signal of the previous patient according to the up and down sequence. If the NRMS is higher than 2.0, a positive response is defined and the concentration of DEX will be added by 0.05µg/kg/h in the next patient. A negative response is defined as NRMS lower than 2.0, and in such cases the concentration of DEX is reduced by 0.3 µg/kg/h.
223456895|NCT01952418|DEVICE|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
223456896|NCT00762762|DRUG|Triclosan/copolymer/fluoride|Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
224155765|NCT01807611|DRUG|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
224155766|NCT01807611|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
224155767|NCT01807611|DRUG|Mycophenolate mofetil|Given intravenously or orally.
224155768|NCT04672317|DRUG|Immunotherapy combined with chemotherapy|"Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy"
224155769|NCT02935595|DRUG|Ketamine|Ketamine Hydrochloride Injection
224155770|NCT01680146|DIETARY_SUPPLEMENT|PRO+FAT|
224155771|NCT01680146|DIETARY_SUPPLEMENT|PRO|
224155772|NCT06380036|PROCEDURE|video assisted fistula tract surgery|in one group pt recieved VAAFTS
223456897|NCT00762762|DRUG|Fluoride|Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
223456898|NCT04034212|OTHER|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
223456899|NCT06312384|PROCEDURE|3D Surgical Template on the Contour of Bone Augmentation, in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|a two-piece tooth-supported surgical template will fabricated through 3D printing technology before surgery base on the digital simulation of bone graft contour.Sticky bone will placed into the defect under the guidance of the template to form customized sticky bone and will be covered with collagen membrane.
223456900|NCT06312384|PROCEDURE|conventional guided bone regeneration,in Patient With Labial Alveolar Ridge Defect and Simultaneous Implantation|The defected site will be grafted with sticky bone (particulate bone substitute mixed with injectable platelet-rich fibrin (i-PRF)) and will be covered with collagen membrane.
223456901|NCT02489448|DRUG|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
223456902|NCT01418911|OTHER|questionnaire|questionnaire only
223573002|NCT03876015|DRUG|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
223573003|NCT00888524|PROCEDURE|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
223573004|NCT00888524|PROCEDURE|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
223743103|NCT01387347|DRUG|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
224067187|NCT02328430|DEVICE|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
224067188|NCT03649061|DRUG|Etanercept 50 MG/ML|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
224067189|NCT03649061|DRUG|Leflunomide 10 milligram (MG)|Leflunomide 10mg PO daily added to the COBRA-Slim scheme
224067190|NCT03885089|DRUG|Infliximab [infliximab biosimilar 3]|\<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
224067191|NCT00802204|RADIATION|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
224067192|NCT00802204|PROCEDURE|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
224067193|NCT00802204|PROCEDURE|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
224155773|NCT01287988|DRUG|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
224155774|NCT01287988|DRUG|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
224155775|NCT00442611|DRUG|Abatacept|
224155776|NCT00442611|DRUG|Placebo|
224302592|NCT04781101|OTHER|RoboGait®|The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
223743104|NCT01387347|DRUG|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
224302593|NCT00244530|DRUG|Nifedipine|
224302594|NCT02218125|BIOLOGICAL|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
223456903|NCT03198429|BEHAVIORAL|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
223456904|NCT03198429|BEHAVIORAL|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
223456905|NCT04063735|DIETARY_SUPPLEMENT|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia supplement for 3 months
223456906|NCT04063735|DIETARY_SUPPLEMENT|Placebo|Placebo was given to participants.
223456907|NCT00765739|OTHER|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
223456908|NCT00765739|OTHER|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
224067194|NCT00802204|BEHAVIORAL|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
224067195|NCT00802204|OTHER|Caloric Restriction|Obese participants only complete a short-term (\~10days) very low calorie diet
224067196|NCT06975891|DRUG|Systane PRO|Lubricating Eyedrops
224067197|NCT06975891|DRUG|Refresh Optive MEGA-3|Lubricating Eyedrops
224067198|NCT01383577|PROCEDURE|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
224067199|NCT01383577|PROCEDURE|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
224155777|NCT02726607|BEHAVIORAL|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
224155778|NCT02726607|BEHAVIORAL|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
224155779|NCT04778644|DRUG|CBD|Oral gel capsule CBD
224155780|NCT04778644|DRUG|Placebo|Oral gel capsule placebo
224155781|NCT02431702|DRUG|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
224302595|NCT02218125|BIOLOGICAL|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
224302596|NCT00595686|DRUG|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
224302597|NCT04870138|DRUG|Azithromycin|Alternative antibiotic treatment failure therapy: Azithromycin 2 g orally in a single dose after treatment failure with both cephalosporin and quinolone antibiotics.
224302598|NCT04870138|DRUG|Ceftriaxone|Mandatory antibiotic treatment failure therapy: Ceftriaxone 250 mg intramuscular in a single dose on patient request, at the onset of symptoms, or on the 5th study day after inoculation.
224302599|NCT04870138|DRUG|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose on patient request, at the onset of symptoms or on the 5th study day after inoculation.
224302600|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of wild-type (WT) Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
223456909|NCT00929487|DEVICE|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
223456910|NCT00929487|OTHER|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
223456911|NCT00929487|DEVICE|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
223456912|NCT03308604|DRUG|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg."
223456913|NCT03308604|RADIATION|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
223456914|NCT03308604|RADIATION|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
223456915|NCT03308604|DRUG|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
223456916|NCT05275465|DRUG|HH-006|Different dose levels of HH-006
223456917|NCT05275465|DRUG|Placebo|Different dose levels of placebo
224067200|NCT05062863|DEVICE|T3 dental implant system|This clinical study will evaluate patients being treated with the T3 dental implant to confirm its safety and performance (effect of treatment of edentulism). The patients treated will experience a benefit from treatment of edentulism with the T3 dental implant system. The patients will be followed prospectively from the time of exposure (dental implant placement surgery) to outcome (implant survival at 2 years).
224067201|NCT01518218|BEHAVIORAL|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
224067202|NCT03834415|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10\>8 CFU
224067203|NCT03834415|OTHER|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
224067204|NCT02385630|OTHER|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
224067205|NCT06539910|PROCEDURE|General Anesthesia|All blocks will be performed after induction of general anaesthesia (GA). Upon arrival to the operating room (OR), a multichannel monitor will be attached to patients, followed by the administration of 2 mg midazolam IV after securing an IV cannula. Controlled GA via a laryngeal mask airway (LMA) will be done to all patients
224067206|NCT06539910|PROCEDURE|TIPS block|Patients will receive distal FTB through conventional lateral to medial approach, in addition to a supra-sartorial plane injection. Distal adductor canal block via another needle puncture.Ten mL of a mixture of 0.25 % bupivacaine and 8 mg dexamethasone will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane lateral to medial approach just lateral to the superficial femoral artery
224067207|NCT06539910|PROCEDURE|Modified TIPS block|Patients will receive ultrasound guided single puncture triple injections through medial to lateral approach. LA will be injected at the distal FT lateral to the superficial femoral artery (FA), deep to adductor longus muscle (ALM), and at the supra-sartorial plane.Both groups will receive a mixture of 0.25 % bupivacaine and 8 mg dexamethasone. Ten mL will be injected in the suprasartorial plane and 20 mL will be injected at the distal adductor canal.Ten mL of the LA anaesthetic mixture will be injected 2 cm above the FT apex via ultrasound guided in-plane medial to lateral approach just lateral to the superficial femoral artery. Then, the needle will be redirected just underneath the ALM and 10 mL of the LA mixture will be injected in the plane between the ALM and the adductor magnus muscle (AMM).Total volume of LA will be 50 mL.
224067208|NCT06539910|PROCEDURE|Mutimodal analgesia|Postoperatively, multimodal analgesia regimen will be continued in the form of paracetamol 1 g /8 hours and ketorolac 30 mg /8 hours intravenously for 24 hours. Intravenous morphine patient controlled analgesia will be started at the end of surgery at a concentration of 0.5 mg/ml without a background infusion on a demand dose of 1 mg with a lockout interval of 10 minutes
224067209|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
224067210|NCT03277976|DEVICE|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
224067211|NCT02701387|DEVICE|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
224067212|NCT02701387|DEVICE|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
224067213|NCT05699265|DIAGNOSTIC_TEST|Measures of arterial stiffness and endothelial function|baseline cMRI, vascular reactivity studies, and CPET
224067214|NCT05699265|DIAGNOSTIC_TEST|Ambulatory blood pressure monitoring|A manual blood pressure with a mercury sphygmomanometer will be performed in order to have an accurate baseline measurement. The SphygmoCor SCOR-PVx System (Atcor Medical, Syndey, Australia), previously validated in the young, will be used for the assessment of PWV (pulse wave velocity) and the Heart Rate Variability (HRV).
223456918|NCT03834025|BEHAVIORAL|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation.
223456919|NCT03834025|BEHAVIORAL|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
223456920|NCT03834025|BEHAVIORAL|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3).
223573005|NCT06896123|BEHAVIORAL|Dance Well: an artistic, multisensory dance intervention based on art and music|DW is specifically designed for people with early to mild severe PD and aims to de-liver multiple stimuli, including rhythmical auditory cues, proprioceptive and sensorimo-tor stimulation, balance training, and aerobic exercise, using carefully selected music to cue movement and promote relaxation. The components of DW are relatively simple and easy to be learned and performed for people with compromised mobility. The intervention is also enjoyable and engaging, as reported for other genres of dance
224067215|NCT05699265|DIAGNOSTIC_TEST|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing will be performed, and the patients will have a baseline oxygen uptake at rest to determine the rates for testing. A 12 lead ECG, heart rate, a 12 lead rhythm strip, and a 6 lead rhythm strip will be recorded. Oxygen consumption and carbon dioxide production will be measured. Blood pressure will be measured. Perceived exertion will be obtained during each workload using the Borg Scale. The results for submaximal effort testing will be derived from completed maximal testing. The outcome measures will be obtained once the subject reaches anaerobic threshold.
224067216|NCT05699265|DIAGNOSTIC_TEST|Serum and urine biomarkers|Clinical labs drawn will include plasma and urine globotriaosylsphingosine (lyso-Gb3), globotriaosylceramide (GL3), blood urea nitrogen, creatinine, cystatin C, urinalysis, urine protein, urine microalbumin and urine creatinine. Labs specific for this study will include N-acetyl-β-glucosaminidase, urine neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1 (KIM-1). All data will be obtained at three different time intervals: enrollment, 1 year and 2 years.
224067217|NCT04703673|DRUG|Cineole|self administration according to directions for use
224067218|NCT04703673|DRUG|Nasal Decongestant|self administration according to directions for use
224067219|NCT04571216|DRUG|NFL-101 dose 1|Subcutaneous injections
224067220|NCT04571216|DRUG|NFL-101 dose 2|Subcutaneous injections
224067221|NCT04571216|DRUG|Placebo|Subcutaneous injections
224067222|NCT03050242|DRUG|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
224067223|NCT04986397|DEVICE|Cold Therapy|A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.
224067224|NCT04986397|OTHER|Standard of Care|Standard post-operative analgesia without the use of cryotherapy.
224067225|NCT04132791|OTHER|placebo after awakening + aspirin before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
224067226|NCT04132791|OTHER|aspirin after awakening + placebo before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
224067227|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D and K2 supplementation|if supplementation of vitamin D and K2 changes the time to fracture healing
224067228|NCT03871322|DIETARY_SUPPLEMENT|Vitamin D supplementation|if supplementation of vitamin D alone changes the time to fracture healing
224067229|NCT03871322|DIETARY_SUPPLEMENT|Placebo|Placebo control group
224067230|NCT00254462|DRUG|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
224067231|NCT00254462|DRUG|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
224067232|NCT00254462|BEHAVIORAL|Parent Training|All children will receive parent training for the duration of the study.
224067233|NCT01952561|DRUG|dapivirine ring|
224067234|NCT02346032|DRUG|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
224067235|NCT00631748|DRUG|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
224067236|NCT00631748|DRUG|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
224067237|NCT00631748|BEHAVIORAL|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
224067238|NCT05685875|OTHER|diabetes|Diabetes and metabolic syndrome defined using criteria by IDF. Obesity defined as BMI\>=30
224067239|NCT02136030|DRUG|Liposomal amphotericin B|4mg/kg/day, IV infusion
224067240|NCT02136030|DRUG|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
224067241|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
224067242|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
224067243|NCT01141842|PROCEDURE|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
224067244|NCT02532894|DEVICE|Electronic cigarette|Inhaling e-cigarette vapor
224067245|NCT00863200|BEHAVIORAL|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
223456921|NCT03834025|BEHAVIORAL|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4).
223456922|NCT03834025|BEHAVIORAL|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. Other than the opportunity to participate in a learning collaborative, participants receive no compensation.
223456923|NCT03834025|BEHAVIORAL|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 30% of the NC Medicaid rate for a patient visit.
223456924|NCT03834025|BEHAVIORAL|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. In addition to the opportunity to participate in the learning collaborative, participants receive a reimbursement at 100 percent of the NC Medicaid rate for a patient visit for their time participating in the learning collaborative.
223456925|NCT04835961|OTHER|Maintenace and As needed|This study will record the use of budesonide / formoterol either as maintenance treatment or / or as needed according to standard clinical practice and at the discretion of the treating physician.
223456926|NCT04423133|BEHAVIORAL|Online Family Literacy Program|Parent-child dyads will participate in 8 weekly online health-themed workshops that introduce language and literacy skills. Participants will also receive 2-3 text messages per week for the duration of the program and children's books.
223573006|NCT06896123|BEHAVIORAL|Conventional motor therapy group|Conventional Motor Therapy consisted on 60-minute conventional physiotherapy, twice a week, for four weeks
223573007|NCT04211987|PROCEDURE|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
223573008|NCT04211987|PROCEDURE|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
223573009|NCT00427531|OTHER|physiologic testing|
223573010|NCT02943824|OTHER|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
224155782|NCT02431702|DRUG|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
224155783|NCT02431702|DRUG|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
224155784|NCT02431702|DRUG|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
224155785|NCT02431702|DRUG|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
224155786|NCT02431702|DRUG|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
224155787|NCT02431702|DRUG|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
224155788|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
224155789|NCT02431702|DRUG|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
224302601|NCT04870138|BIOLOGICAL|Neisseria gonorrhoeae strain FA7527|0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of isogenic LptA mutant Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
224155790|NCT05364658|DEVICE|Juvene IOL|Indicated for Implantation in the human eye after removal of a cataractous crystalline lens
224155791|NCT01496989|BIOLOGICAL|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
224155792|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
224155793|NCT01496989|BIOLOGICAL|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
224155794|NCT01496989|BIOLOGICAL|Ad35-GRIN/ENV|(2x10\^10vp) Delivered intramuscularly by standard needle injection
224302602|NCT06445634|OTHER|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis|Gonioscopy-Assisted Transluminal Trabeculotomy Combined with Goniosynechiolysis in Glaucoma Patients with Secondary Synechial Angle Closure
224302603|NCT02564419|DEVICE|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
223573011|NCT02943824|OTHER|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
223456927|NCT00030966|DRUG|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
223456928|NCT00030966|DRUG|Placebo|Placebo monthly infusion for up to 116 weeks.
223573012|NCT03921619|DEVICE|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
223573013|NCT02817113|DRUG|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
223573014|NCT02817113|DRUG|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
223456929|NCT04235426|DRUG|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.|30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
223456930|NCT04235426|PROCEDURE|30 patients went to surgical procedure|30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.
223456931|NCT04235426|OTHER|Injection|Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
223456932|NCT01084057|DRUG|vorinostat|Given orally
223456933|NCT01084057|DRUG|ixabepilone|Given IV
223456934|NCT01084057|OTHER|laboratory biomarker analysis|Correlative studies
223456935|NCT01084057|OTHER|pharmacological study|Correlative studies
223743105|NCT04232072|OTHER|Group ESPB|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period.
224067246|NCT00863200|BEHAVIORAL|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
224067247|NCT02292030|DRUG|HTEA|usually high thoracic epidural anesthesia
224067248|NCT05506176|DRUG|SIM0417|dose of 750 mg SIM0417 with 100 mg ritonavir.
224302604|NCT03559621|BEHAVIORAL|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
224302605|NCT00798187|BEHAVIORAL|Group Meetings|10 weekly group meetings lasting 2 hours.
224302606|NCT00798187|BEHAVIORAL|Questionnaire|Surveys
224302607|NCT03009916|DRUG|"cholestagel® (Colesevelam)"|3750mg
224302608|NCT03009916|DRUG|Placebos|3750mg
223456936|NCT02010905|DRUG|Losartan|
224302609|NCT03327636|DEVICE|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
224302610|NCT02633488|DRUG|Placebos|A 12 week single blind placebos
224302611|NCT02633488|DRUG|metformin|A 12 week single blind metformin
223456937|NCT02010905|DRUG|Placebo|
223456938|NCT03065686|GENETIC|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
223456939|NCT03516162|OTHER|There is no study-specific intervention|There is no study-specific intervention
223456940|NCT04407039|DEVICE|PET/CT, H-MRS and MRI|Use imaging methods to get metabolic parameters.
223456941|NCT02484092|BIOLOGICAL|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
223456942|NCT02411279|OTHER|Equiped group with telemedicine systems|
223456943|NCT02335879|BIOLOGICAL|Gonal-F|
223456944|NCT02871622|DEVICE|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
223456945|NCT05332041|OTHER|Predicta Bioactive bulk fil composite restoration|Predicta Bioactive bulk fil resin composite restoration material
223456946|NCT00242411|DRUG|Budesonide/Formoterol Turbuhaler|
223456947|NCT00242411|DRUG|Conventional Best Asthma Therapy|
223456948|NCT02966132|BEHAVIORAL|iMD|Interactive video education delivered on a tablet computer
223456949|NCT02966132|BEHAVIORAL|NPA|
223456950|NCT01672268|OTHER|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
223456951|NCT01766531|DEVICE|body bioelectrical impedance|
223456952|NCT02752438|DEVICE|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
224302612|NCT03178565|OTHER|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
224302613|NCT03178565|OTHER|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
224302614|NCT03201250|DRUG|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
224302615|NCT01439750|DRUG|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
224302616|NCT01439750|DRUG|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
223456953|NCT00356161|DEVICE|interventionally implanted hepatic arterial port catheter|
223456954|NCT01239394|DRUG|ofatumumab|Weekly infusion for 8 weeks
223456955|NCT04256564|PROCEDURE|Central venous catheterization|A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
223456956|NCT02861664|OTHER|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
223456957|NCT02861664|OTHER|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
223456958|NCT00997347|DRUG|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
223456959|NCT04998214|DIAGNOSTIC_TEST|liver function , prothrombin time , INR , US .|analytic
224302617|NCT01439750|DRUG|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
224302618|NCT04859621|DRUG|Vitamin D3 4000 IU|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
223456960|NCT06153615|OTHER|EEG (64 electrodes)|EEG recording while awake, at rest then during an attentional cognitive test
224067249|NCT05506176|DRUG|Placebo|Placebo (tablet)
224302619|NCT04859621|DRUG|Vitamin D3 2000 IU|Oral administration, 1 tablet of each per time, qd, oral administration with the first meal, continuous use for 48 weeks
223456961|NCT06153615|OTHER|Cognitive task (SART)|Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)
223456962|NCT06153615|OTHER|Pupillometry and eye tracking|Study of pupil size and gaze path during the cognitive test (correlated with alertness)
223456963|NCT06153615|OTHER|Thoracoabdominal belts|Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)
223456964|NCT06105814|DEVICE|Rapid diagnostics|Sputum sampes will in addition to standard diagnostics be investigated using a rapid diagnostic plattform (FilmArray)
223456965|NCT00540397|DRUG|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
223456966|NCT01563198|BEHAVIORAL|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
223456967|NCT04306497|DRUG|TCM prescriptions|TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
223456968|NCT04626609|OTHER|Biopsy samples|Esophageal mucosal biopsies are collected during gastroscopy
223456969|NCT04626609|OTHER|Blood samples|Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
223456970|NCT03959046|BEHAVIORAL|GIST|The GIST intervention will train physicians in an alternative way of communicating with their patients.
223456971|NCT05118035|OTHER|AI-enabled ECG-based Screening Tool|Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
223456972|NCT03290118|OTHER|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
223456973|NCT03290118|OTHER|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
223456974|NCT03290118|OTHER|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
223456975|NCT03290118|DEVICE|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
223456976|NCT00610272|RADIATION|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
224067250|NCT01481051|DRUG|Latanoprost-PPDS|Sustained delivery for 12 weeks
224067251|NCT01222455|DRUG|Fostamatinib|Oral tablets, single dose
224067252|NCT05437120|DRUG|VX-121/TEZ/D-IVA|Fixed-dose combination tablets for oral administration.
224067253|NCT03319485|DEVICE|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
224067254|NCT03319485|DEVICE|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
224067255|NCT00858858|DRUG|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
224067256|NCT06329037|DRUG|Vasopressin|Administration of Vasopressin (20 IU) (oral spray)
224067257|NCT06329037|DRUG|Placebo|Administration of Placebo (oral spray)
224067258|NCT04314856|DRUG|18F-FTC-146|18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
224067259|NCT02097914|BEHAVIORAL|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
224067260|NCT01425008|DRUG|MLN2480|Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
224071375|NCT06374823|DRUG|Multiple Electrolyte|Patients who are randomized to multiple electrolyte group will be receiving Multiple Electrolytes injection II for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
224071376|NCT06374823|DRUG|Normal Saline|Patients who are randomized to normal saline group will be receiving Sodium Chloride injection for 72 hours continously after inrollment as maintence and rescutation fluids. Infusion speed and volume will be determained by physicians.
223456977|NCT00610272|RADIATION|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), \>4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after \> 4 weeks
223456978|NCT00610272|RADIATION|Radiotherapy|8 Gy in a single fraction; retreatments \> 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
223456979|NCT00610272|RADIATION|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments \> 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
223456980|NCT03060226|DIAGNOSTIC_TEST|blood sample|Search of blood predictive marker (s)
223456981|NCT02781818|DRUG|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
223456982|NCT02781818|DRUG|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
223456983|NCT02781818|DRUG|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
223456984|NCT01439646|OTHER|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
223456985|NCT04127877|DEVICE|NICAS|Electric regional bio impedance device
223456986|NCT01947842|DEVICE|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
223456987|NCT00683488|BEHAVIORAL|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
223456988|NCT00683488|BEHAVIORAL|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~* Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~* Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~* Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
223456989|NCT00683488|BEHAVIORAL|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
223456990|NCT00799084|BEHAVIORAL|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
223456991|NCT00799084|BEHAVIORAL|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
223456992|NCT03464032|DRUG|BCD-135|Monoclonal anti-PD-L1 antibody
223456993|NCT01594918|DRUG|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
223456994|NCT01594918|DRUG|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
223456995|NCT01594918|DRUG|Prednisone|5 mg PO BID
223456996|NCT01594918|DRUG|Pegfilgrastim|6 mg, SC, once every 21 days
223456997|NCT01223404|DRUG|Placebo|Participants are administered a placebo patch and a placebo capsule
223456998|NCT01223404|DRUG|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
223456999|NCT01223404|DRUG|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
223457000|NCT04461548|BEHAVIORAL|Thinking, writing and imagining|All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
223457001|NCT00707057|DRUG|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
223457002|NCT00707057|DRUG|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
224302620|NCT04859621|DRUG|Placebo|Oral administration, 2 tablet per time, qd, oral administration with the first meal, continuous use for 48 weeks
223457003|NCT04560556|DIAGNOSTIC_TEST|Point-of-Care (POC) Rapid HIV Test|Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
223457004|NCT04560556|DIAGNOSTIC_TEST|Fourth Generation Antigen/antibody (Ag/Ab) HIV Test|Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
223457005|NCT04041596|DEVICE|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
224302621|NCT04859621|OTHER|standard antibiotic therapy|standard antibiotic therapy
224302622|NCT03167723|DEVICE|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
224302623|NCT06157203|DEVICE|Uterine electromyography|electromyographic and fetal electrocardiographic recordings will be obtained during threatened labor
223457006|NCT01646840|DRUG|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
223457007|NCT01646840|DRUG|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
223457008|NCT05535374|DEVICE|Feetme Connected Soles|Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
223457009|NCT05186584|OTHER|MAITLAND'S ANTEROPOSTERIOR(AP) MOBILIZATION|"Group A will receive the 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set (total 75 oscillations) for AP mobilizations at most symptomatic segment, with 10 seconds rest between sets. Most symptomatic segment is that segment of cervical spine at which patient will feel greatest pain by palpation.~For AP mobilizations, patient will lye supine and therapist will stand by his head. Therapist will make broad contact with the thumb, at the costal process of the vertebrae to be mobilized and spread fingers around adjacent neck for stability. Shoulder will be positioned above the joint being treated. Gentle oscillatory Anteroposterior pressure will be performed by the therapist's arm and trunk."
223457010|NCT05186584|OTHER|MAITLAND'S LATERAL MOBILIZATION|Group B will receive the same sets (i.e. 5 sets of 10 seconds Grade 1 mobilizations with a rate of 15 oscillations each set) for lateral mobilizations at most symptomatic segment, with 10 sec rest between each set. For lateral mobilization, patient will lye supine and therapist will stand by his head. Therapist will place the anterolateral aspect 2nd metacarpophalangeal joint over the lateral aspect of transverse process of most symptomatic segment. Gentle lateral oscillations towards the asymptomatic side will be provided by the therapist.
223573015|NCT02817113|DRUG|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
223573016|NCT03783741|BEHAVIORAL|Questionnaire|Interview
223573017|NCT00716430|BEHAVIORAL|Quality Improvement Programme|Quality Improvement training programme
223573018|NCT00567671|PROCEDURE|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
223573019|NCT00567671|PROCEDURE|Sham comparator|Sham treatment
223573020|NCT01071200|DRUG|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
223573021|NCT01071200|DRUG|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
223573022|NCT00413920|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
223573023|NCT00413920|DRUG|Prednisone|Oral tablets
223573024|NCT00675818|DEVICE|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
224155795|NCT04297345|DEVICE|Hemodialysis|"Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances."
224155796|NCT02398721|OTHER|Fine Needle Aspiration Cytology|
223573025|NCT00675818|DEVICE|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
223573026|NCT06453330|BIOLOGICAL|Horizontal platelet-rich fibrin (H-PRF)|Most commercially available centrifuges used for PRF production are fixed-angle systems designed primarily for pelleting samples to the bottom of tubes and are not particularly efficient at separating the cell layers effectively. Research has demonstrated that PRF produced using horizontal centrifugation (H-PRF) can lead to a higher concentration of platelets and leukocytes compared to PRF produced from fixed-angle centrifugation (LPRF). The resulting PRF from horizontal centrifugation is termed 'horizontal platelet-rich fibrin' (H-PRF). The H-PRF clot will be produced using a Bio-PRF horizontal centrifuge machine. This machine is CE marked and regularly used in the Dublin Dental University Hospital.
223573027|NCT00144768|DRUG|laronidase|dose of 0.58mg/kg body weight IV every week
223573028|NCT06301828|DRUG|Envafolimab Injection|Endostar+SBRT+Envafolimab Injection
223573029|NCT06301828|DRUG|Endostar|Endostar+SBRT+Envafolimab Injection
224067261|NCT04770051|PROCEDURE|Percutaneous inferior cervical sympathetic block|The procedure will be performed while the patient was awake and under fluoroscopic guidance. A total of 3 ml of 1% lidocaine will be infiltrated to anesthetize the skin and subcutaneous tissues down to the left common carotid artery. A 22 gauge × 3.5 inch BD™ Quincke spinal needle will be introduced at the level of the body of the sixth cervical vertebra, medial to the left common carotid artery. The needle will be advanced until it reached the junction between the body and transverse process of the sixth cervical vertebra. Contrast injection will be used to demonstrate the position of the needle anterior to the paravertebral muscles, with spread along the axis of the interfascial compartment (Figure 1). A total of 20 ml of 0.25% bupivacaine (Marcaine, Hospira, Lake Forest, IL) will be injected over 10 min through the needle. The effectiveness of sympathetic blockade will be confirmed by postprocedure development of ptosis and miosis in the left eye.
224067262|NCT03216473|DRUG|Neuronox|Clostridium Botulinum Toxin A 100 U
224067263|NCT03216473|DRUG|Botox|Clostridium Botulinum Toxin A 100 U
224067264|NCT05269485|RADIATION|High-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
224067265|NCT05269485|RADIATION|Low-dose fractionated radiotherapy|Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
223457011|NCT01688622|BEHAVIORAL|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
223457012|NCT03570775|DEVICE|Sleeping bag phototherapy|This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
223457013|NCT03570775|DEVICE|Conventional phototherapy|This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
223457014|NCT06407219|DEVICE|Robot Assisted Gait Training|The Trexo robotic gait trainer will be used to facilitate physical activity in people who cannot walk independently, either at all or without the use of assistive gait aids (ie. walkers or canes). Session length will be determined by the participant's perceived fatigue level (ie. the session will run until the participant feels they want to or need to stop), and will not exceed 1 hour of training time.
223457015|NCT03880136|DRUG|CTP-543|Once daily dosing
223573030|NCT01824199|DRUG|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
223573031|NCT02152059|DRUG|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
223573032|NCT06346366|DEVICE|Bihormonal artificial pancreas (BIHAP) / closed loop|"The investigational device is a dual-hormonal fully closed loop system (BIHAP; industrial name AP® 5, Inreda Diabetic B.V.) which aims at optimally controlling plasma glucose levels. This BIHAP contains of two pumps for subcutaneous infusion of either insulin (Humalog, 3 ml pre-fill cartridge, Eli Lilly) or glucagon (GlucaGen, Novo Nordisk; 3.15 ml cartridge Accu-Chek Spirit, Roche) via an infusion set (Accu-Chek Insight Flex or AccuChek Flex Link, Roche), two subcutaneously placed glucose-sensors (Guardian, Medtronic) and an algorithm driving pump infusion rates based on the sensor input. Daily self-measurements of blood glucose (SMBGs; Accu-Chek Instant, Roche) are needed for calibration of the glucose sensors.~The BIHAP-system has to be worn continuously, except while showering."
223573033|NCT02088619|BEHAVIORAL|Quality of Life Therapy (QOLT)|
223573034|NCT02088619|BEHAVIORAL|Heart Healthy Education (HHE)|
223573035|NCT05027490|OTHER|CANUT support|CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
223573036|NCT05027490|OTHER|Anthropometric measures|These measures include weight, waist size, hip size and brachial circumference
223573037|NCT05027490|OTHER|Prehension strength measurement|Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
223573038|NCT05027490|BEHAVIORAL|QVA Questionnaire|Food quality of life questionnaire
223573039|NCT05027490|BEHAVIORAL|QLQ C30 Questionnaire|Quality of Life questionnaire Core 30
223573040|NCT05027490|BEHAVIORAL|Scratch & Snif Test|The Scratch \& Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
223573041|NCT05027490|BEHAVIORAL|Taste Strip Test|The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
223573042|NCT05027490|BEHAVIORAL|24 H feed back questionnaire|This questionnaire describes patient's food and drink intakes during the last 24 ours
223573043|NCT05027490|BEHAVIORAL|Condiment questionnaire|This questionnaire used to assess condiments consumption
223573044|NCT05027490|BEHAVIORAL|Tobacco questionnaire|This questionnaire used to assess tobacco consumption
223457016|NCT00121706|BEHAVIORAL|Condition A (see detailed summary)|
223457017|NCT00121706|BEHAVIORAL|Condition B (see detailed summary)|
223457018|NCT00121706|BEHAVIORAL|Condition C (see detailed summary)|
223457019|NCT03613714|OTHER|At-home Blood Pressure Monitoring|Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
223573045|NCT05027490|OTHER|Nutrition interview|This interview will be conducted by a dietician
223573046|NCT02138474|OTHER|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
223573047|NCT02138474|OTHER|Placebo|Unmedicated sucrose pillules
223573048|NCT03730961|DRUG|BMS-986231|Intravenous administration
223573049|NCT03730961|DRUG|Furosemide|Intravenous administration
223573050|NCT03730961|DRUG|Placebo|Intravenous administration
223573051|NCT02728960|PROCEDURE|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
224067266|NCT03718286|DRUG|Alirocumab|150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
224067267|NCT03718286|OTHER|Sham Control|Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
224067268|NCT00312988|DRUG|Hycamtin|
223457020|NCT02089802|DRUG|Pazopanib|
223457021|NCT02380365|DEVICE|Electrocardiography|"Duration of intervention per patient/subject:~5 min, observation 6 months"
223457022|NCT01613261|DRUG|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
223457023|NCT01773083|DRUG|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
223457024|NCT01773083|DRUG|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
223457025|NCT00001577|PROCEDURE|double isolated limb perfusion with melphalan alone|
223457026|NCT04611542|BEHAVIORAL|Fathering In Recovery|Fathering In Recovery (FIR) will be designed to address the unique needs of fathers in treatment for opioid misuse. FIR integrates evidence-based parenting interventions that have well-documented positive outcomes on children, parents, and families, with innovative web-based mobile technology to maximize accessibility, fidelity, and consistency of intervention and support.
223573052|NCT03411200|BEHAVIORAL|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~1. Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~2. Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~3. Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~4. A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
223573053|NCT01244581|DRUG|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
223573054|NCT01244581|DRUG|Placebo|Placebo mixture in two daily doses for 7 days
223573055|NCT02306863|DEVICE|vibrating chair|vibration provided via physioacoustic method
223573056|NCT02306863|DEVICE|sham treatment|simulated whole-body vibration
223573057|NCT02071420|BEHAVIORAL|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
223573058|NCT02071420|BEHAVIORAL|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
223573059|NCT02071420|BEHAVIORAL|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
223573060|NCT02071420|DEVICE|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
223573061|NCT03410797|DEVICE|Inclusion of semi-occluded mask in voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use during in person voice therapy and for use at home therapy practice.
223457027|NCT02813928|GENETIC|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
223457028|NCT03094884|RADIATION|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
223457029|NCT03094884|DRUG|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
223457030|NCT03094884|DRUG|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
223743106|NCT04232072|OTHER|Group Ibuprofen|A dose of 100 mg tramadol intravenously will be performed to all patients 30 min before the end of the surgery for postoperative analgesia. At the end of the surgery, local anesthetic infiltration will be perfomed around the port entrance sites by the surgical team to the all patients. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit at the postoperative period. In Group Ibuprofen, patients will be administered ibuprofen 800 mgr IV every 8 hours in the postoperative period.
223743107|NCT02658357|DRUG|Risperidone Implant|
223743108|NCT01096121|DRUG|Enalapril|"* during 1 month : 0,2 mg/kg/day~* then during 2 months (if no adverse event): 0,35 mg/kg/day~* and then during 6 months (if no adverse event): 0,5 mg/kg/day"
223743109|NCT01096121|DRUG|Placebo|Glucose
224067269|NCT00312988|DRUG|Gemcitabine|
224067270|NCT01808300|DRUG|Pregabalin 300mg, Thioctic acid 600mg|"* A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
224067271|NCT02706808|DIETARY_SUPPLEMENT|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
223457031|NCT04424147|COMBINATION_PRODUCT|HVA Regimens as Salvage Treatment|venetoclax with a dose of 400mg per day for 14 days, combined with azacitidine (AZA) with a dose of 75mg/m2 per day for 7 days, and HHT 1mg/m2 per day for 7 days
223457032|NCT00320242|DEVICE|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
223457033|NCT02548377|PROCEDURE|Remote ischemic preconditioning|
223457034|NCT02548377|PROCEDURE|Sham|
223457035|NCT04217460|BEHAVIORAL|Intervention for fluency difficulty|Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
223573062|NCT02615860|OTHER|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
223573063|NCT02615860|PROCEDURE|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
223573064|NCT05718752|DIAGNOSTIC_TEST|Maximal incremental exercise test|Gas exchange are measured during all the test on ergocycle until oxygen consumption reach its maximum value
223573065|NCT05718752|DIAGNOSTIC_TEST|30-min submaximal exercise test|A 30-min submaximal test on ergocycle. Gas exchange are measured during all the test. Blood samples are collected before, at the end of exercise and after 3 hours of recovery
223573066|NCT00274560|DRUG|Tiotropium|
223573067|NCT00274560|DRUG|Salmeterol|
223573068|NCT05709067|DIETARY_SUPPLEMENT|Probiotic|6 Billion CFU per day
223573069|NCT05709067|DIETARY_SUPPLEMENT|Placebo|0 CFU per day
223573070|NCT01854892|OTHER|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
223573071|NCT01854892|OTHER|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
223573072|NCT01854892|OTHER|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
223457036|NCT03202290|BEHAVIORAL|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
223457037|NCT02076386|DRUG|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
223457038|NCT05468216|OTHER|MovIn-Lessons group|The MovIn-Lessons intervention will consist of infusing PA in math, English and natural sciences lessons in primary education. The movement will be integrated in the learning activities for at least 20 minutes per session, at different physical intensities.
223457039|NCT01668056|DRUG|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
223457040|NCT01668056|PROCEDURE|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
223573073|NCT03606447|DRUG|Uproleselan|\[14C\]-Uproleselan
223573074|NCT05211804|DRUG|Ophthalmic Drugs|Patients will receive the same treatment as if not a part of the project
223573075|NCT03084913|OTHER|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
223573076|NCT03084913|OTHER|Prostate Cancer Foundation diet|followed for 8 weeks
223573077|NCT03241771|BEHAVIORAL|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
223573078|NCT04083313|DEVICE|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
223573079|NCT00537667|DRUG|anakinra|anakinra
223573080|NCT00537667|DRUG|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
223573081|NCT02441140|PROCEDURE|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
223573082|NCT02441140|PROCEDURE|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
224067272|NCT02706808|DIETARY_SUPPLEMENT|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
224067273|NCT06061549|BIOLOGICAL|AAV1/SERCA2a|3E13 viral genomes fixed dose
224071377|NCT03260959|BEHAVIORAL|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
224071378|NCT02864368|DRUG|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m\^2/day on days 1-5 of each 28 day cycle
224071379|NCT02864368|DRUG|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
224155797|NCT01498770|DRUG|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
223573083|NCT02441140|PROCEDURE|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
223573084|NCT02441140|PROCEDURE|Blood collection|Intravenous blood collection will be drawn from an IV
223457041|NCT01668056|OTHER|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
223457042|NCT05409950|PROCEDURE|Immediate implant placement using socket shield technique|Evaluation of socket shield technique with immediate implant placement at the esthetic zone in comparison with the conventional immediate implant placement
223457043|NCT01131559|DRUG|Lisdexamfetamine|Oral; 20-70mg/day
223457044|NCT01131559|DRUG|Placebo control|Oral; 20-70mg/day
223457045|NCT05856253|PROCEDURE|Enhanced recovery program|Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.
223457046|NCT03477292|DRUG|Duration of antibiotic|Duration of antibiotic for treatment of VAP
223457047|NCT06148103|DRUG|Patients who received Dexmedetomodine|1 microgram/kg over a period of 10 minutes, and then a maintenance infusion was titrated in a range from 0.2-1 μg/kg/h).
223457048|NCT06148103|DRUG|patients who received propofol-fentanyl|Continued infusions of both fentanyl and propofol were 0.01-0.05 μg kg/ min 25-150 mg/h respectively.
223457049|NCT03145753|OTHER|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
223457050|NCT03145753|OTHER|HIV/HCV Education|Only education and support will be provided in this arm
223457051|NCT00102843|PROCEDURE|supplementation with folic acid and betaine|
223457052|NCT05102071|DRUG|empagliflozin|empagliflozin
223457053|NCT05102071|DRUG|metformin|metformin
223457054|NCT05102071|DRUG|sulfonylurea|sulfonylurea
223457055|NCT00577772|DRUG|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
223457056|NCT00577772|DEVICE|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
223457057|NCT00577772|PROCEDURE|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
223457058|NCT02843464|OTHER|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
223573085|NCT02441140|PROCEDURE|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
223573086|NCT02913001|OTHER|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
223573087|NCT02913001|OTHER|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
223573088|NCT03355560|DRUG|Nivolumab|Nivolumab 480 mg IV infusion
223573089|NCT05764304|DRUG|Sinomenine|Participants will receive one intra-articular injection every 4 months
223573090|NCT05764304|DRUG|Glucocorticoid|Participants will receive one intra-articular injection every 4 months
223573091|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
224067274|NCT05314205|PROCEDURE|ligation of inter-sphincteric fistula tract|"The surgical treatment was achieved through identification of the fistula by injecting hydrogen peroxide (H2O2) through the external opening. Probing of the fistulous tract by a metallic probe for proper identification of the fistula in the inter-sphincteric plane.~Perpendicular skin incision (about 1 cm) was done at inter-sphinctric zone, perpendicular to the fistulous tract. Dissection between the internal and external sphincters and identification of the fistula.~Finally, Ligation and transection of the tract in inter-sphinctric space followed by excision of a segment and transferred for histopathology examination. Trans-fixation suture was applied near to the internal mucosal opening of the divided tract to confirm closure using polyglactin suture 2/0. Insertion of a probe to check the closure of the tract segments.~The remaining part of the tract was curetted till external opening and left for spontaneous healing."
224067275|NCT04069065|DRUG|Conversion to Once-daily Tacrolimus|"* Orally, once-daily in the morning~* The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~10ng/ml."
224067276|NCT03294031|OTHER|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
224071380|NCT02864368|BIOLOGICAL|PEP-CMV: Component A|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered
224155798|NCT01498770|DRUG|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
223457059|NCT02012400|OTHER|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
223457060|NCT01510964|BEHAVIORAL|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
223457061|NCT01510964|BEHAVIORAL|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
223457062|NCT00572455|DRUG|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
223457063|NCT00572455|DRUG|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
223457064|NCT00572455|DRUG|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
223457065|NCT00572455|DRUG|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
223457066|NCT00572455|DRUG|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
223457067|NCT00572455|DRUG|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
223457068|NCT00572455|DRUG|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
223457069|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
223457070|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
223457071|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
223457072|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
223457073|NCT00572455|DRUG|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
223457074|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
223457075|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
223457076|NCT00572455|DRUG|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
223457077|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
224067277|NCT03294031|OTHER|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
223457078|NCT00572455|DRUG|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
223457079|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
223457080|NCT00572455|DRUG|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
223457081|NCT00572455|DRUG|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
223457082|NCT00572455|DRUG|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
223457083|NCT06484296|OTHER|Education|"Before the training, students in all groups will be provided to take the Pretest.~The students included in the training group will be trained on good and green health practices in the conference hall of the Faculty by expert researchers and the green transformation coordinator of the university who have a certificate of Conscious Awareness training. Three weeks after the training, all students will be given the Green Culture Scale Post-Test."
223457084|NCT06105606|DEVICE|AveCure Flexible Microwave Ablation Probe|Consists of a handheld, surgical device which delivers microwave energy from its microwave antenna. The flexible probe has a 3cm active microwave field that radiates from the tip.
223457085|NCT03627793|OTHER|resistance training|Moving muscles against loads with the purpose of increasing strength.
223457086|NCT00334412|DRUG|Ambisome|
223457087|NCT00334412|DRUG|caspofungin|
223457088|NCT03446209|DRUG|Tocilizumab Infusion RoAcemtra (EU)|Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
223457089|NCT03446209|DRUG|0.9% physiological saline|"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."
223457090|NCT00484471|DRUG|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
224067278|NCT00939900|DRUG|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
224067279|NCT04468165|DRUG|Dimethyl Fumarate (DMF)|Gastro-resistant Hard Capsules. Each capsule contains 240mg or 120mg Dimethyl Fumarate
224067280|NCT04368728|BIOLOGICAL|BNT162b1|Intramuscular injection
224067281|NCT04368728|BIOLOGICAL|BNT162b2|Intramuscular injection
224067282|NCT04368728|OTHER|Placebo|Intramuscular injection
224067283|NCT04368728|BIOLOGICAL|BNT162b2SA|Intramuscular injection
224067284|NCT05711290|DIETARY_SUPPLEMENT|Oxygen Nanobubble|This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
224067285|NCT05711290|OTHER|Placebo|The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
223573092|NCT02480400|DRUG|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS \> 30 receive a fixed dose 20mg until the end of treatment.
223573093|NCT03952117|DEVICE|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
223573094|NCT01527513|DRUG|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
223457091|NCT00484471|DRUG|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
223457092|NCT00484471|DRUG|placebo|placebo to aripiprazole, 22 weeks
223457093|NCT04302207|BEHAVIORAL|De-implementation Strategy for Bronchiolitis|De-implementation strategy to reduce over-use of treatments for patients with bronchiolitis
223573095|NCT01527513|DRUG|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
223573096|NCT02200419|OTHER|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
223457094|NCT06274502|OTHER|YOLOv8|After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model.
223457095|NCT02955953|DRUG|LY2963016|Administered SC
223457096|NCT02453464|DRUG|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
223457097|NCT02453464|DRUG|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
223457098|NCT02453464|DRUG|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
223573097|NCT03489967|OTHER|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
223573098|NCT05058105|DRUG|FL058 500mg and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223573099|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
224067286|NCT00805480|DRUG|AIN457|AIN457 was administered intravenously.
224067287|NCT00805480|DRUG|Placebo|Matching placebo to AIN457 was administered intravenously.
224067288|NCT01234272|DRUG|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
224067289|NCT01234272|DRUG|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
224071381|NCT02864368|DRUG|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
223457099|NCT02453464|DRUG|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
223457100|NCT03671876|DEVICE|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
223457101|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus plantarum strain 299v|Given PO
223457102|NCT01644097|DIETARY_SUPPLEMENT|Lactobacillus acidophilus probiotic|Given PO
223457103|NCT01644097|DIETARY_SUPPLEMENT|placebo|Given PO
223457104|NCT01644097|OTHER|laboratory biomarker analysis|Correlative studies
223457105|NCT01644097|OTHER|questionnaire administration|Ancillary studies
223457106|NCT01644097|PROCEDURE|quality-of-life assessment|Ancillary studies
223457107|NCT01644097|DIETARY_SUPPLEMENT|Bifidobacterium lactis probiotic supplement|Given PO
223457108|NCT00117169|PROCEDURE|multi-detector helical computed tomography|
223457109|NCT03310242|BEHAVIORAL|Sunlight Exposure|"* Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~* Completing a Sun Diary after sunlight exposure"
223457110|NCT03310242|DIETARY_SUPPLEMENT|Vitamin D Supplementation|\- Supplementation of vitamin D3 500 IU/day for 8 weeks
223457111|NCT03310242|OTHER|Placebo|\- Intake of placebo for 8 weeks
223457112|NCT06958874|PROCEDURE|Non-surgical periodontal therapy + sub-gingival air polishing|Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments, combined with sub-gingival air polishing using erythritol powder. The treatment is applied to periodontal pockets with probing depth ≥ 4 mm in non-adjacent teeth.
223457113|NCT06958874|PROCEDURE|Non-surgical periodontal therapy alone|Participants receive a single session of non-surgical periodontal therapy (NSPT) using ultrasonic and manual instruments.
223457114|NCT00245024|DRUG|sulindac|
223457115|NCT00245024|OTHER|laboratory biomarker analysis|
223457116|NCT03695146|BEHAVIORAL|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
223573100|NCT05058105|DRUG|FL058 1000mg（ IV 120min）|D1 qd;
223573101|NCT05058105|DRUG|FL058 Placebo （ IV 120min）|D1 qd;
223573102|NCT05058105|DRUG|Meropenem 1000 mg （ IV 120min）|D4 qd;
223573103|NCT05058105|DRUG|Meropenem Placebo （ IV 120min）|D4 qd;
223573104|NCT05058105|DRUG|FL058 1000mg and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
223573105|NCT05058105|DRUG|FL058 Placebo and Meropenem 1000mg （ IV 120min）|"D7 qd;~D8\~ D14 q8h;~D15 qd;"
223573106|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223457117|NCT03695146|BEHAVIORAL|Active relaxation|Individuals will be provided with headphones while resting quietly listening to relaxing tones/music.
224155799|NCT01498770|DRUG|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
224155800|NCT01498770|DRUG|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
224155801|NCT01498770|DRUG|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
224302624|NCT05134506|BEHAVIORAL|Dance for PD® classes|The intervention consisted of 16 60-min classes, performed twice weekly over a period of 8 weeks and instructed by a single researcher who had the approval to use it for research reasons.
224302625|NCT00250796|DRUG|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
224302626|NCT00250796|DRUG|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
224302627|NCT01175811|DRUG|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
224302628|NCT01175811|DRUG|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
224302629|NCT01175811|DRUG|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
224302630|NCT05291065|BEHAVIORAL|Fasted exercise|Participants will remain fast (Fasted) 2 h prior to 45 min exercise at 65% VO2max.
224302631|NCT05291065|BEHAVIORAL|High protein breakfast exercise|Participants will consume a high protein breakfast (Protein) 2 h prior to 45 min exercise at 65% VO2max.
224302632|NCT05291065|BEHAVIORAL|High carbohydrate breakfast exercise|Participants will consume a high carbohydrate breakfast (Carbohydrate) 2 h prior to 45 min exercise at 65% VO2max.
224302633|NCT03579966|DRUG|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
223457118|NCT06958991|DEVICE|Histolog Scanner|The clinical performance study is collecting data from the use of a CE mark product used within the scope of its intended purpose to intraoperatively visualize tissue specimen. The subjects are not submitted to invasive and burdensome procedures compared to the standard of care surgical practices and regular use of the CE mark product.
223457119|NCT06959667|OTHER|Observational study, no intervention|Observational study, no intervention
223457120|NCT02990403|DRUG|Aspirin|
223457121|NCT02990403|DRUG|Heparin|
224302634|NCT01150318|DRUG|Administration of 131 iodine|100 mCi 131 iodine irradiation
224302635|NCT00476554|DRUG|Sapacitabine|Sapacitabine
224302636|NCT01166906|DEVICE|pain blocking|pain blocking
224302637|NCT01239875|BIOLOGICAL|dendritic cell vaccine therapy|Given intratumorally
224302638|NCT01239875|PROCEDURE|cryotherapy|Undergo cryoablation
224302639|NCT01239875|BIOLOGICAL|pneumococcal polyvalent vaccine|Given intramuscularly
224302640|NCT01239875|OTHER|laboratory biomarker analysis|Correlative studies
224302641|NCT01239875|OTHER|immunoenzyme technique|Correlative studies
224302642|NCT01239875|OTHER|immunohistochemistry staining method|Correlative studies
224302643|NCT01239875|BIOLOGICAL|autologous dendritic cell-tumor fusion vaccine|Given intradermally
224302644|NCT02377518|RADIATION|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
224302645|NCT00437632|DRUG|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
224302646|NCT00437632|DRUG|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
223457122|NCT02990403|DRUG|Prednisone|
223457123|NCT02990403|DRUG|Immunoglobulin|
223457124|NCT02990403|DRUG|Dydrogesterone|
223457125|NCT05314829|OTHER|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
224155802|NCT01498770|DRUG|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
224155803|NCT01498770|DRUG|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
224155804|NCT01498770|DRUG|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
224155805|NCT01498770|DRUG|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
224155806|NCT01498770|DRUG|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
224155807|NCT01498770|DRUG|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
224155808|NCT01498770|DRUG|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
224155809|NCT01498770|DRUG|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
224155810|NCT04248686|BEHAVIORAL|CoED Online Intervention|Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity
224155811|NCT00002146|DRUG|Magnesium sulfate|
224155812|NCT00002146|DRUG|Foscarnet sodium|
224155813|NCT00001036|DRUG|Thymalfasin|
224155814|NCT00001036|DRUG|Interleukin-2, Polyethylene Glycolated|
224302647|NCT00437632|DRUG|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
224302648|NCT03121287|OTHER|Imaging Biomarkers|Whole lung volumetric CT scans
224302649|NCT03121287|OTHER|Pulmonary|Pulmonary Function Tests \& 6 minute hall walk
224302650|NCT03121287|OTHER|Imaging|Cardiac MRI
224302651|NCT03121287|OTHER|Specimen Collection|Blood draw
224302652|NCT05016193|DEVICE|Axem Home Prototype Device|The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.
223573107|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 120min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223573108|NCT05058105|DRUG|FL058 1000mg and Meropenem 2000mg （ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223573109|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000m（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223573110|NCT05058105|DRUG|FL058 2000mg and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223573111|NCT05058105|DRUG|FL058 Placebo and Meropenem 2000mg（ IV 180min）|"D1 qd;~D2\~ D8 q8h;~D9 qd"
223573112|NCT04005560|OTHER|no interventional study|no interventional study
223573113|NCT04104919|DRUG|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
223573114|NCT04104919|DRUG|Placebo 6 mL|Single preoperative intrathecal injection
223573115|NCT01810848|DEVICE|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
223573116|NCT01810848|OTHER|Control|Control is puncture of the skin at the site of the knee.
223573117|NCT03663374|DRUG|Odelepan|Tablets, 125 mg
223457126|NCT01912859|BEHAVIORAL|Nutrition/physical activity intervention|Nutrition/physical activity intervention
223457127|NCT01761643|DEVICE|SoC + iTab|Text messaging reminders to improve adherence to PrEP
223457128|NCT01839071|PROCEDURE|biopsy|
223457129|NCT02821416|BIOLOGICAL|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
223457130|NCT02821416|OTHER|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
223457131|NCT01296854|OTHER|Spa therapy|3 weeks of spa therapy
223457132|NCT04059289|OTHER|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
223457133|NCT02047435|BEHAVIORAL|Information, event and workshops at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~   * A guided tour at the museum~  * A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~  * The museum serves a refreshment and offer participants a season pass to the museum.~   And~2. Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
223457134|NCT02047435|BEHAVIORAL|Information and event at a cartoon museum|"1\. An event at the Storm P. Museum consisting of:~* A guided tour at the museum~* A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~* The museum serves a refreshment and offer participants a season pass to the museum."
224067290|NCT05536765|PROCEDURE|Surgical exposure of impacted tooth|"The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment."
224155815|NCT00001036|DRUG|Zidovudine|
224155816|NCT05826041|BEHAVIORAL|(INSPIRE) INtervention Support groups: Peers Inspiring Resilience and Empowerment.|The support group contains both structured components, which are psychoeducational and focused on skill-building, and an unstructured component where discussion is open and determined by the needs and interests of the clients present (e.g., support and process-oriented.)
223457135|NCT00629031|DRUG|Paromomycin|11 mg/kg for 14 days
223457136|NCT00629031|DRUG|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
223573118|NCT03663374|DRUG|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
223573119|NCT02280902|BIOLOGICAL|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
223573120|NCT05293613|DEVICE|extracorporeal shock wave lithotripsy|shock wave transmited from the device through patient body towards the stone to disintegrate it
223573121|NCT04442256|DRUG|Dupilumab|All patients will be administered subcutaneous doses of dupilumab in a biweekly fashion.
223573122|NCT00975819|DRUG|sirolimus|liquid dosing based on trough levels
223573123|NCT01185964|BIOLOGICAL|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
223573124|NCT01185964|DRUG|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
223573125|NCT04782245|DRUG|Dapagliflozin 10mg|The intervention group will receive, during 6 months, dapagliflozin per oral route at a dose of 10 mg once daily in addition to the optimal medical management based on current heart failure practice guidelines.
223573126|NCT04782245|DRUG|Placebo|Patients randomized in the control group will receive during 6 months, placebo once daily per oral route, in addition to the optimal medical management based on current heart failure practice guidelines.
223573127|NCT02793596|OTHER|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
224155817|NCT05826041|BEHAVIORAL|Traditional Domestic Violence Support Group|The activities of the group are determined by agency staff from week to week and may be open group discussion, psychoeducation, or a combination of both.
224155818|NCT00763607|GENETIC|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
224155819|NCT04269941|OTHER|total or subtotal gastrectomy|resection of the gastric tumor
224155820|NCT02947490|OTHER|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
223457137|NCT03187184|DEVICE|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
223573128|NCT06027333|BEHAVIORAL|inpatient rehabilitation|This is an uncontrolled observational study on patients undergoing usual care in pulmonary rehabilitation and care
223573129|NCT04290468|DEVICE|Dynamic ultrasound|"The ultrasound examination will be carried out blinded to the results of MRI using the Affiniti 70 ultrasound machine by Philips (USA) via a 5-12MHz linear transducer.~MRI was performed on a high field system (1.5 Tesla) magnet units (Philips Acheiva)."
223573130|NCT01920893|DRUG|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
223573131|NCT01920893|DRUG|Dupilumab|Solution for injection; Subcutaneous injection.
223573132|NCT01920893|DRUG|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
223743110|NCT06478537|DRUG|Hetrombopag Olamine|"Treatment period: 24-week Hetrombopag (2.5mg/d\~7.5mg/d) treatment.~* Two consecutive visits with PLT\>600 × 10\^9/L: daily dose reduction of 2.5mg; If the lowest dose has been used, extend the dosing interval.~* Two consecutive visits with PLT\<300 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached.~* Two consecutive visits with PLT\<50 × 10\^9/L: increase the daily dose by 2.5mg until the maximum dose is reached; If PLT is still\<50 × 10\^9/L with7.5mg/d × 28d, the patient will be withdrawn.~Drug discontinuation period：8-week Hetrombopag (2.5mg/d\~7.5mg/d) reduction. Hetrombopag reduces by 2.5mg every 2 weeks, and after reducing to the minimum dose of 2.5mg/d x 2 weeks, it is changed to 2.5mg once every other day (Qod) treatment, with a maximum reduction time of 8 weeks. If the PLT during two consecutive visits is less than 30 × 10\^9/L, the patient will be withdrawn."
223457138|NCT02533583|DEVICE|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
223457139|NCT02403583|BEHAVIORAL|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
223743111|NCT06478537|DRUG|Aspirin|Aspirin 100mg, qd
223457140|NCT00137787|DRUG|ciprofloxacin|
223457141|NCT00137787|DRUG|cefepime|
223457142|NCT03001947|OTHER|No intervention|Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
223457143|NCT03352492|PROCEDURE|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
223457144|NCT03352492|PROCEDURE|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
223457145|NCT06959654|DIAGNOSTIC_TEST|ELISA test|ELISA test to evaulate serum oncostatin M and galactin 3 in two group of patientsL
223457146|NCT00287456|DEVICE|Insulin Pump|
223457147|NCT00287456|DRUG|Insulin|0
223457148|NCT00287456|PROCEDURE|Oral Glucose Tolerance Test|0
223457149|NCT00287456|PROCEDURE|Whole body Protein Turnover|0
223573133|NCT03279913|DEVICE|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
223573134|NCT01079013|DRUG|treosulfan|12 g/m2 x 3 days
223573135|NCT04897919|DRUG|Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet|Dihydroartemisinin-piperaquine is given as recommended by manufacturer and compared to the Artemether-lumefantrine group.
223573136|NCT04897919|DRUG|Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet|Artemether-Lumefantrine is given as recommended by manufacturer
223573137|NCT01933126|DRUG|HCG injection|
223457150|NCT04037514|DRUG|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
223457151|NCT04037514|DRUG|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
223573138|NCT01933126|DRUG|Placebo|
223573139|NCT00236418|DRUG|topiramate|
223573140|NCT01068782|DRUG|XL184|given orally as capsules
223573141|NCT04963530|PROCEDURE|Treatment with monolithic zirconia restorations|Treatment with monolithic zirconia restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
223573142|NCT04963530|PROCEDURE|Treatment with lithium disilicate restorations|Treatment with lithium disilicate restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
223573143|NCT04963530|PROCEDURE|Treatment with metal ceramic restorations|Treatment with metal ceramic restorations on teeth (single crowns). The sample (75 patients) will be divided into three groups according to the ceramic material used: monolithic zirconia, lithium disilicate and metal ceramic.
223573144|NCT04963530|PROCEDURE|No intervention|No intervention.
223573145|NCT03919513|DEVICE|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
223573146|NCT00661024|PROCEDURE|intraoperative RLN visualization|intraoperative RLN visualization
223573147|NCT00661024|PROCEDURE|intraoperative neuromonitoring of the RLN|IONM
223573148|NCT00244348|DRUG|Oxaliplatin (via HAI)|
223743112|NCT04599894|DRUG|37.5mg Pregabalin + 75mg Pregabalin|37.5mg pregabalin preoperatively + 75mg pregabalin postoperatively
223743113|NCT04599894|DRUG|75mg Pregabalin|75mg pregabalin postoperatively
223743114|NCT00198757|BEHAVIORAL|Medifast Plus for Diabetics Meal Replacement Supplements|
223743115|NCT00198757|BEHAVIORAL|Standard ADA recommended diet for type 2 diabetics|
223743116|NCT01721642|DEVICE|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
223457152|NCT01773629|OTHER|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
223457153|NCT01773629|OTHER|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
223457154|NCT06492447|DRUG|Against HER 2-ADC Drug|Breast cancer subjects receiving anti-HER2-ADC drugs were treated with a 3-week treatment cycle lasting 6 cycles. Serum of patients before and after treatment was collected, and the changes of serum HER2 level before chemotherapy and after 2, 4 and 6 cycles of chemotherapy were dynamically monitored, and the relationship between HER2 level and the therapeutic effect of different targeted drugs was analyzed.
223457155|NCT00202020|DRUG|Cilostazol 200mg/day Oral|
223457156|NCT00202020|DRUG|Aspirin 100mg/day Oral|
223457157|NCT01005017|PROCEDURE|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
223457158|NCT01401946|DRUG|soy isoflavones|
223457159|NCT01401946|DRUG|Placebo|
223457160|NCT03579121|OTHER|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
223457161|NCT03579121|OTHER|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
223457162|NCT04152083|DRUG|Eptinezumab|Injection for IV administration
223457163|NCT04152083|DRUG|Placebo|Injection for IV administration
223457164|NCT06165198|DEVICE|Closed-loop tACS stimulation based on addiction-induced states|We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
223573149|NCT00244348|DRUG|5 Fluorouracil (systemic)|
223573150|NCT03855813|OTHER|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
223573151|NCT03855813|OTHER|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
223573152|NCT01015235|DRUG|Placebo|Subcutaneous infusion-once over 4 hours
223457165|NCT06059937|OTHER|Patient with pre-eclampsia|Cardiovascular risk assessment by the general practitioner in the year following pre-eclampsia
223573153|NCT01015235|DRUG|KAI-1678|Subcutaneous infusion-once over 4 hours
223573154|NCT01015235|DRUG|Ketorolac Tromethamine|Active comparator, IV infusion, once
223457166|NCT05084183|DEVICE|PermeaDerm®|Wound Management Device
223457167|NCT05084183|DEVICE|Mepilex Ag|Wound Dressing
223457168|NCT06391359|PROCEDURE|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
223457169|NCT06391359|OTHER|Watchful waiting|Watchful waiting
223573155|NCT01470690|DRUG|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
223573156|NCT01470690|DRUG|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
223573157|NCT00159731|DRUG|Pregabalin|
223573158|NCT00505037|DRUG|ASP1585|Oral
223573159|NCT00505037|DRUG|Placebo|Oral
223743117|NCT01190709|PROCEDURE|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
223457170|NCT04366154|OTHER|Questionnaire|delivery of questionnaires on perceived stress, post-traumatic stress, sleep disorders, quality of life, cognitive complaint
223457171|NCT00856999|DRUG|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
223457172|NCT05010213|OTHER|Educational intervention|Educational intervention
223573160|NCT00505037|DRUG|Sevelamer hydrochloride|Oral
223573161|NCT01563120|DRUG|metformin|metformin up to 2550mg per day.
223573162|NCT01563120|DRUG|glybenclamide|glybenclamide up to 20mg per day.
223573163|NCT05827562|DIAGNOSTIC_TEST|flow cytometry|"Levels of circulating and synovial fluid CD4+ and CD4- T cells expressing CD8αα and CD8αβ will be assessed by flow cytometry using fluorochrome-labelled monoclonal antibodies against CD3, CD4, CD8α and CD8β surface markers. Levels of the following cells will be assessed:~1. CD3+CD4-CD8αα+~2. CD3+CD4-CD8α+CD8βlow~3. CD3+CD4-CD8α+CD8βhigh~4. CD3+CD4+CD8αβhigh~5. CD3+CD4+CD8αα+"
223573164|NCT03042377|OTHER|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
223573165|NCT03042377|DRUG|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
224067291|NCT00865072|DRUG|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
223457173|NCT06959433|DRUG|Lu-177 PSMA-617|Included patients will receive 4 cycles of 7.4GBq Lu-177 PSMa therapy every 6 weeks. If any toxicity develops after the first cycle, dose reduction will be performed for the other cycles. At 1. And 4. Cycles of therapy, whole body planar and SPECT/CT imaging will be performed at 4. And 24. Hours and any time at 4-7.days of injection. On these images , kindey, liver and salivary gland doses will be calculated. Mean tumor dose will also be calculated by measurinf the tumoral uptake. In the follow up, patients will be controlled at 9. And 24. Weeks and every 12 months then after.
223573166|NCT03042377|DRUG|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid \& antibiotic paste and the cavity was filled with temporary restorative material.
223573167|NCT03042377|DRUG|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
223573168|NCT04873167|BEHAVIORAL|low fat|subjects subjected to a low-fat dietary regime
223573169|NCT04873167|BEHAVIORAL|mediterranean diet|subjects subjected to a mediterranean dietary regime
223573170|NCT03762616|DIAGNOSTIC_TEST|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
223573171|NCT03762616|DIAGNOSTIC_TEST|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
223573172|NCT04465877|DRUG|JTT-662|Active drug tablets containing JTT-662
223573173|NCT04465877|DRUG|Placebo|Placebo tablets matching in appearance to the active drug tablets
223573174|NCT05425654|DRUG|Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide|The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
223573175|NCT01384331|DRUG|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~* 21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~* 21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~* 21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
223573176|NCT00926731|DRUG|AZD1152|Variable dose via a 7-day continuous infusion
223573177|NCT00926731|DRUG|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
223573178|NCT05894538|DRUG|Ivermectin|"Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use."
223573179|NCT05894538|OTHER|Placebo|Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
223573180|NCT06420362|OTHER|Blood Flow Restriction|"Before BFR training, a repetition maximal (1-RM) test will be determined by selecting a weight with which athletes can perform a maximum of 10 repetitions. The number of repetitions obtained here and the weight lifted will be written into the Brzycki formula, whose validity and reliability has been proven, and 1-TM will be calculated.~Brzycki formula; 1-TM = \[100 x (Weight Lifted) / \[(102.78 - 2.78 x (Number of Reps)\] The arterial occlusion pressure of the participants will be measured with a Doppler Ultrasound device by increasing the cuff to the point where the auscultatory pulse of the brachial artery ceases until occlusion occurs in the brachial artery. Then, 60% of this value will be calculated and BFR will be performed during the exercises."
223573181|NCT02794844|DRUG|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
224155821|NCT02947490|OTHER|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
223457174|NCT04164368|DRUG|Lenalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 \[capped at 2.0 mg\], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
223457175|NCT06959147|DRUG|High-Voltage Long-Duration Pulsed Radiofrequency plus Liposomal Bupivacaine group|High-Voltage Long-Duration Pulsed Radiofrequency Combined with Liposomal Bupivacaine Subcutaneous Block
223457176|NCT06959147|OTHER|High-Voltage Long-Duration Pulsed Radiofrequency|High-Voltage Long-Duration Pulsed Radiofrequency
224155822|NCT02947490|OTHER|Standard BP management|GP to measure BP and manage BP control
223457177|NCT06958705|DRUG|Venetoclax combined with Ibrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using ibrutinib. After the completion of combination therapy, patients will stop both the ibrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and ibrutinib will continue for an additional 12 cycles. Venetoclax and ibrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Ibrutinib is intended to be admistratered orally 420mg once daily."
223457178|NCT06958705|DRUG|Venetoclax combined with Zanubrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using zanubrutinib. After the completion of combination therapy, patients will stop both the zanubrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and zanubrutinib will continue for an additional 12 cycles. Venetoclax and zanubrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Zanubrutinib is intended to be admistratered orally 160mg twice daily."
223457179|NCT06958705|DRUG|Venetoclax combined with Acalabrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using acalabrutinib. After the completion of combination therapy, patients will stop both the acalabrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and acalabrutinib will continue for an additional 12 cycles. Venetoclax and acalabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Acalabrutinib is intended to be admistratered orally 100mg twice daily."
223457180|NCT06958705|DRUG|Venetoclax combined with Orelabrutinib|"All Patients will be treated with venetoclax for 12 cycles after a standard 5-week dose ramp-up, as an add-on to the primary using orelabrutinib. After the completion of combination therapy, patients will stop both the orelabrutinib and venetoclax then be followed.~Each cycle is 28 days. At the start of cycle 0, patients will start venetoclax by 20mg-50mg-100mg-200mg daily in a weekly dose escalation way. The combination of full dose venetoclax (400mg) and orelabrutinib will continue for an additional 12 cycles. Venetoclax and orelabrutinib will be continued until the completion of cycle 12, start of new CLL-directed therapies, disease progression or unacceptable toxicities, depending on which comes first.~Orelabrutinib is intended to be admistratered orally 150mg once daily."
223457181|NCT03784313|PROCEDURE|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
223457182|NCT03784313|PROCEDURE|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
223457183|NCT03350490|DEVICE|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
223457184|NCT03350490|DRUG|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
223457185|NCT06958185|DEVICE|deep peripheral sensory stimulation|The proprioceptive stimulus will consist of intermittent mechanical pressure on the skin, localized at the neuromuscular motor points of the rectus femoris, vastus lateralis, and vastus medialis of the quadriceps. The tissue subjected to this precise pressure in areas of high neuromuscular innervation facilitates the stimulation of kinesthetic cortical sensitivity. The experimental group (EG) will be randomly and crosswise subdivided into two groups, so that both receive the intervention in two different modalities at two different times.
223457186|NCT06958965|OTHER|Resistance exercise training|The total duration of the training was 12 weeks, with a frequency of two sessions per week. Each session lasted approximately 90 to 120 minutes. The exercise intensity was set at 40-70% of the participants' one-repetition maximum (1RM), or adjusted based on the Modified Borg Rating of Perceived Exertion (RPE), targeting a moderate intensity level (approximately a score of 3).
223573182|NCT02323204|BEHAVIORAL|Link for Injured Kids|Psychological First Aid
224155823|NCT02947490|OTHER|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
224155824|NCT01063504|DRUG|teriparatide|
224155825|NCT02959970|DRUG|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
223457187|NCT06959485|BIOLOGICAL|Oxygen Therapy|"1. To evaluate the effect of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask) and early morning air on proteinuria in patients with diabetic kidney disease.~2. To evaluate the effect of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask) and early morning air on glycated haemoglobin in patients with diabetic kidney disease.~3. Comparing the effects of oxygen therapy (hyperbaric oxygen and oxygen by non- rebreather mask), early morning air exposure, and standard care on kidney function"
223573183|NCT02323204|OTHER|So you've been in an accident|Educational materials
223573184|NCT03032653|OTHER|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
223573185|NCT03032653|OTHER|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
224155826|NCT04695418|DIETARY_SUPPLEMENT|Rice Germ|The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
224155827|NCT04695418|COMBINATION_PRODUCT|Placebo|An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
224155828|NCT03486561|DRUG|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
224302653|NCT05016193|BEHAVIORAL|Rehabilitation Exercise Program|Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.
224302654|NCT01874067|DEVICE|Arthritis glove|Isotoner three-quarter finger arthritis glove
223457188|NCT00872521|DRUG|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)"
223457189|NCT01918501|PROCEDURE|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
223457190|NCT02533700|DRUG|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
223457191|NCT02533700|DRUG|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses"
223457192|NCT03765060|PROCEDURE|Monomax® 2/0 HR26|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
223457193|NCT03765060|PROCEDURE|Monomax® 1 HR48|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
223457194|NCT05886114|BEHAVIORAL|Structured Multi-domain Intervention|Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
223457195|NCT05886114|BEHAVIORAL|Self-Guided Intervention|In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
223573186|NCT03535662|DRUG|Orvepitant|Single oral dose
223573187|NCT03535662|DRUG|Itraconazole|Once daily dosing for 10 days
223573188|NCT04806490|DIAGNOSTIC_TEST|the diagnosis for Yin Deficiency Syndrome|The measurement of the standard scale for syndrome differentiation of Yin Deficiency Syndrome
223573189|NCT00395135|DRUG|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
223573190|NCT00395135|DRUG|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
223573191|NCT04060381|DRUG|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
223573192|NCT02695823|DEVICE|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
223573193|NCT04332939|OTHER|transcranial direct current stimulation|real tDCS sessions
223573194|NCT04332939|OTHER|Physical exercise|Aerobic exercise and physical training combined with sham tDCS
223573195|NCT03440918|OTHER|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
223573196|NCT03440918|OTHER|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
223573197|NCT00597363|DEVICE|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH \& Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
223573198|NCT00597363|OTHER|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
223573199|NCT00001155|DRUG|cyclophosphamide|
223573200|NCT02257177|DRUG|Inhaled TD139|DPI Galectin-3 inhibitor
223573201|NCT02257177|DRUG|Placebo|DPI placebo
223573202|NCT03054597|DEVICE|Circular light motion|Exercise with circular light motion
223573203|NCT03054597|DEVICE|Diagonal light motion|Exercise with diagonal light motion
223573204|NCT03054597|DEVICE|Peripheral light motion|Exercise with peripheral light motion
223573205|NCT03054597|PROCEDURE|Exercise|
223457196|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, high Positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 5 cmH2O
223457197|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Low support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with low pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
223573206|NCT05553964|DIAGNOSTIC_TEST|In Vitro|In vitro diagnostic test for COVID-19 using anterior nasal swabs.
223573207|NCT03332719|BIOLOGICAL|Etanercept|
223573208|NCT03332719|DRUG|Methotrexate|
223573209|NCT03576755|DRUG|Spironolactone 100mg|Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
223573210|NCT03576755|DRUG|Placebo oral capsule|Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
223457198|NCT05726513|DIAGNOSTIC_TEST|Weaning trial - Zero support, zero positive end-expiratory pressure|The researcher will evaluate the readiness to be weaned of the patient using a weaning trial with 0 pressure support ventilation and a positive end expiratory pressure of 0 cmH2O
223457199|NCT00126919|DEVICE|SonoPrep|
223457200|NCT04682899|DRUG|procalcitonin-guided antibiotic therapy|In procalcitonin group, clinican make a decision of antibiotic precription based on the results of procalcitonin.
223457201|NCT04682899|DRUG|guideline-guided antibiotic therapy|In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
223457202|NCT01558219|DRUG|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
223573211|NCT05244460|DRUG|Droperidol Injectable Product|Treatment
223573212|NCT05244460|DRUG|Diphenhydramine|Treatment
223573213|NCT04962230|DRUG|PF-07321332/ritonavir|PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
223573214|NCT04962230|DRUG|Carbamazepine|In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
223573215|NCT04962230|DRUG|PF 07321332/ritonavir|In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
223573216|NCT01396265|DRUG|Afatinib|single dose
223573217|NCT01396265|DRUG|Afatinib|single dose
223573218|NCT01396265|DRUG|Rifampicin|multiple doses
223573219|NCT02529748|OTHER|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
223573220|NCT02529748|OTHER|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
223573221|NCT02529748|OTHER|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
223573222|NCT03895398|OTHER|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
223573223|NCT01683513|DRUG|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
223573224|NCT01530841|DEVICE|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
223573225|NCT00791401|DRUG|ER OROS Paliperidone|
224305133|NCT01633736|OTHER|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
223573226|NCT05976503|DRUG|Tunodafil Hydrochloride Tablets|100mg Tunodafil Hydrochloride Tablets
223573227|NCT05976503|DRUG|Placebo|Placebo
223457203|NCT02859350|BIOLOGICAL|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
223457204|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
223457205|NCT02859350|OTHER|Normal Saline|0.9% Sodium chloride
223457206|NCT02859350|BIOLOGICAL|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
223457207|NCT00984269|PROCEDURE|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
223573228|NCT05976503|OTHER|Alcohol|0.5 g/kg alcohol
223573229|NCT06300918|OTHER|Time|Time point of injecting anti-VEGF drugs
223573230|NCT01672658|DEVICE|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
223573231|NCT01672658|OTHER|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
223573232|NCT03958656|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
223573233|NCT03958656|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
223573234|NCT03958656|DRUG|Rimiducid|0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
223573235|NCT03958656|BIOLOGICAL|Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells|0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
223573236|NCT03831880|DRUG|Genotropin|Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
223573237|NCT03831880|DRUG|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
223573238|NCT02789670|OTHER|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
223573239|NCT05946291|OTHER|Pressure injury training|Pressure injury training with mulage application on a standardized patient
223573240|NCT05946291|OTHER|Simulated Manneqquin training|Pressure injury training with mulage application on a simulated manneqquin
223573241|NCT02885870|PROCEDURE|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
223573242|NCT00334360|DRUG|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
223457208|NCT06235580|OTHER|Biological Samples|"For patients, different types of banked frozen or fresh biological samples will be used in this research:~* Blood~* Skin biopsy or other tissues (liver, muscle, brain, lung...)~* Urine~* Saliva~* Cerebrospinal fluid~* Occasionally: operative leftovers (e.g. muscle, brain, lung tissue)~In control patients, we would like to collect operative remnants of cell types involved in the inflammatory and/or neurological diseases studied in the laboratory, if these patients require surgery as part of their management, and if any biological material remains after surgery. Under the same conditions, a sample of cerebrospinal fluid could be recovered.~For unaffected relatives, a single blood sample of maximum 10 ml is taken at inclusion, and samples already taken during routine care are used."
223457209|NCT04544098|DRUG|177Lu-DOTATATE|The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
223457210|NCT05196425|GENETIC|Blood sampling|Blood sample for detection of PARP-1 gene and correlate to changes of the optic disc, RNFL and GCC layers of the retina of MS patients
223457211|NCT04819438|DRUG|Riluzole 50 mg orodispersible film|Before each administration, the subjects will drink 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy will take the orodispersible film (32.0x22.0 mm) out of the provided pouch and place the product directly on the top surface (dorsal aspect) of the subjects' tongue.
223573243|NCT00334360|DRUG|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
223573244|NCT00334360|DRUG|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
223573245|NCT00334360|DRUG|Control|No drugs given during controlled hypothermia
223573246|NCT01804712|DRUG|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
223573247|NCT01151735|DRUG|C-1-esterase|1000 units of C-1-esterase inhibitor
223573248|NCT01151735|DRUG|C-1-esterase|1500 units of C-1-esterase inhibitor
223573249|NCT01151735|DRUG|placebo|placebo
223573250|NCT02081638|DRUG|Aspirin|Daily Asprin daily
224067292|NCT00865072|DRUG|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
223457212|NCT04819438|DRUG|Rilutek® 50 mg riluzole tablets|One film-coated tablet will be swallowed (without chewing) with 150 mL of still mineral water.
223457213|NCT06154226|DRUG|Pantoprazole|Subjects will receive pantoprazole (40 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on post operative day 1 (POD 1) for a total of 4 doses over 2 days.
223457214|NCT06154226|DRUG|Famotidine|Subjects will receive famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days.
223457215|NCT05463861|DRUG|Lemborexant|Lemborexant tablet administered orally once daily.
223457216|NCT05463861|DRUG|Placebo|Placebo to match Lemborexant tablet administered orally once daily.
223457217|NCT03465709|DRUG|Pegcetacoplan|Study Drug
223457218|NCT00243971|DRUG|SPM 962|
223457219|NCT04298606|OTHER|Quality-of-Life Assessment|Ancillary studies
223457220|NCT04298606|OTHER|Questionnaire Administration|Ancillary studies
223573251|NCT02081638|DRUG|Atorvastatin|Daily Atorvastatin Daily
223573252|NCT00129870|DRUG|oxaliplatin|
223573253|NCT00599404|DRUG|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
223573254|NCT04698135|OTHER|Biological samples collection|Collection of faeces, coproculture examination, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening. Analysis for the identification, quantification and characterization of health-promoting bacteria
223457221|NCT04298606|BIOLOGICAL|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given IM
223573255|NCT04698135|OTHER|Questionnaire|Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
223573256|NCT04698135|OTHER|Medical/laboratory examinations|Blood pressure measurement, abdominal and thoracic physical examination, body composition through bioimpedance analysis and metabolic, cardiovascular and respiratory variables; OGTT 75gr for blood glucose and insulin at times 0, 30, 60, 90 and 120', and a nocturnal oximetry and subsequently, if necessary, overnight polysomnography for the diagnosis of obstructive sleep
223573257|NCT04811105|PROCEDURE|steam ablation|32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
223573258|NCT06289088|OTHER|First Intervention|Firstly, For individuals with low back pain, all measurements will be evaluated without wearing any orthosis. The waist circumference of individuals with low back pain will be measured and the orthosis was adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the measurements will be repeated. Then, the person will be asked to wear the orthosis without any intervention.
223743118|NCT01190709|PROCEDURE|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
224067293|NCT05580133|PROCEDURE|anterior cruciate ligament reconstruction|Arthroscopic reconstruction of the anterior cruciate ligament is a surgical tissue graft replacement of the anterior cruciate ligament, located in the knee, to restore function after injury.
224067294|NCT05026398|DRUG|Fenfluramine|Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
224305134|NCT06049836|OTHER|Holograms|Clinical decision making based on visualising liver 3D holographic augmented reality liver models
223457222|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
223457223|NCT03060291|BEHAVIORAL|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
223573259|NCT06289088|OTHER|Second Intervention|Firstly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be repeated. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis.
223457224|NCT05653947|PROCEDURE|Root canal instrumentation, 2.5% NaOCl irrigation|Root canal instrumentation, 2.5% NaOCl irrigation
223457225|NCT01543802|DRUG|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
223573260|NCT06289088|OTHER|Third Intervention|Firstly, the person will be asked to wear the orthosis without any intervention and the outcome measurements will be done. The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotist. After waiting with the orthosis for half an hour, all measurements will be evaluated without wearing any orthosis. Lastly, The waist circumference of individuals with low back pain will be measured and the orthosis will be adapted to the appropriate orthosis size by the prosthetist orthotis. After waiting with the orthosis for half an hour, all measurements will be evaluated.
223457226|NCT03243253|OTHER|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
223573261|NCT04346108|BIOLOGICAL|Immune Globulin Intravenous (IGIV)|Participants will receive IGIV infusion.
223573262|NCT04346108|BIOLOGICAL|Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)|Participants will receive IGSC, 20% SC infusion.
223573263|NCT03158012|BIOLOGICAL|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
223573264|NCT01162174|DIETARY_SUPPLEMENT|Oligonol|
223573265|NCT00031746|DIETARY_SUPPLEMENT|soy protein isolate|25 mg daily
223573266|NCT00031746|DIETARY_SUPPLEMENT|casein proteins|25 mg daily
223573267|NCT01598753|DRUG|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
223573268|NCT01598753|DRUG|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
223573269|NCT01598753|BEHAVIORAL|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
223573270|NCT01598753|BEHAVIORAL|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
223573271|NCT04397913|DRUG|Paracetamol|15 mg/kg, q6h
223573272|NCT04397913|DRUG|Ibuprofen|10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
223573273|NCT05126264|DRUG|Ibuprofen 400 mg|morning and afternoon
223573274|NCT05126264|DRUG|Ibuprofen 400 mg|morning, afternoon and night
223573275|NCT03984149|OTHER|Observational study|Observational study: There is no intervention.
224067295|NCT05026398|OTHER|Placebo|The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
223573276|NCT00196586|DRUG|Interleukin 2|
223573277|NCT00196586|DRUG|pegylated interferon alpha 2a|
223573278|NCT00196586|DRUG|ribavirin|
223573279|NCT02788201|DRUG|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocin, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
223457227|NCT03029455|DRUG|VX-659|
223457228|NCT03029455|DRUG|Tezacaftor|
223573280|NCT02788201|OTHER|COXEN|The CO eXpression ExtrapolatioN (COXEN) algorithm will be used to determine the next best therapy from among 75 Food and Drug Administration (FDA) approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
224067296|NCT03544827|DRUG|Atropine|Atropine 0.01% then atropine 0.1%
223457229|NCT03029455|DRUG|Ivacaftor|
223457230|NCT03029455|DRUG|VX-659 Matching Placebo|
223457231|NCT03029455|DRUG|Triple Combination (TC) Matching Placebos|
223457232|NCT05777837|PROCEDURE|laparoscopic repair of cesarean scar niche|Intentional perforation of the niche will be done using uterine sound and excision of the fibrotic edges then suturing the uterine incision using 2-0 absorbable suture.
223457233|NCT05777837|PROCEDURE|Combined hysteroscopic and laparoscopic repair of cesarean scar niche|Hysteroscopic resection of the niche under laparoscopic guide will be done to avoid perforation of the niche. After completion of the hysteroscopic approach, laparoscopic plication of the niche without opening it will be done using multiple interrupted 2-0 absorbable suture.
223457234|NCT06251921|PROCEDURE|Restoration|with resin-based composite
223457235|NCT01720524|DRUG|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
223457236|NCT01720524|DRUG|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
223457237|NCT02493452|DRUG|Plecanatide|
223457238|NCT02493452|DRUG|Placebo|
223457239|NCT02332941|DRUG|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
223457240|NCT03628378|DEVICE|Verasense|Ligamentous balancing device
223457241|NCT00182741|DIETARY_SUPPLEMENT|calcitriol|
223457242|NCT00182741|DRUG|mitoxantrone hydrochloride|
223457243|NCT00182741|DRUG|prednisone|
223457244|NCT04769232|DEVICE|EG-760Z endoscope by Fujifilm|"Within a single endoscopic procedure under propofol sedation, images of the esophageal wall will be acquired and biopsies will be taken. All patients will be examined using the EG-760Z endoscope by Fujifilm.~In all patients as part of the clinical routine 4 biopsies of the proximal and 4 biopsies of the distal esophagus will be taken."
223457245|NCT02105285|DRUG|OPC-1085EL ophthalmic solution|
223457246|NCT02105285|DRUG|Carteolol long-acting ophthalmic solution|
223457247|NCT02383901|DRUG|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
223457248|NCT06152380|OTHER|Knee Care @Home Programme|Over 24 weeks after undergoing surgical reconstruction of the anterior cruciate ligament, patients in the intervention group will receive supervised guidance on therapeutic exercises to be performed at home. This guidance will be provided through individualised synchronous internet-based remote sessions using conferencing software.
223457249|NCT01779063|BEHAVIORAL|web based multimedia intervention|cognitive therapy based web intervention
223457250|NCT01779063|OTHER|educational booklet|patient education booklet
223457251|NCT04716374|OTHER|Tumor molecular profiling|Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H\&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content \[(former tumor cell content (TCC%)\] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
223457252|NCT01421641|DRUG|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
223573281|NCT04768959|BEHAVIORAL|FelizMente|The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
223573282|NCT05807776|DRUG|Tislelizumab|Tislelizumab 200mg, iv, d1, Q3W
223457253|NCT01421641|DRUG|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
223457254|NCT00883415|DRUG|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
223573283|NCT05807776|DRUG|Tislelizumab, Lenvatinib|"Tislelizumab combined with lenvatinib:~Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd."
224305135|NCT06049836|OTHER|PDF|Clinical decision making based on visualisation of 3D liver rendering on computer monitors on a PDF file
223457255|NCT05221697|DEVICE|PRESAGE CARE|Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
223457256|NCT01881607|BEHAVIORAL|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
223457257|NCT04002726|OTHER|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
223457258|NCT04530929|DIETARY_SUPPLEMENT|SANPROBI BARRIER|Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
223457259|NCT04530929|DIETARY_SUPPLEMENT|PLACEBO|Competitors used placebo for three months at a dose of 2x2 capsules daily.
223457260|NCT05691413|OTHER|Other: Product X facial cleanser|Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid
223573284|NCT02737644|OTHER|observation|This is an observational study
223573285|NCT06086444|DRUG|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.
223573286|NCT06086444|DRUG|Tranexamic acid|Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
223573287|NCT01022372|PROCEDURE|Endometrial biopsy|For all the groups
223573288|NCT00776464|DEVICE|Noveon laser|Two wavelenghts of light
223573289|NCT00174681|DRUG|Insulin Glargine|
223573290|NCT01701479|DRUG|ch14.18/CHO|
224305136|NCT02902536|OTHER|No interventions|
224305137|NCT02286596|DEVICE|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
223457261|NCT04691219|DIETARY_SUPPLEMENT|Mulberry leaves powder|Dried powder of mulberry leaves crude extract containing 12 mg of DNJ will be packed in a sealed packet with light and moisture protection. Participants will be instructed to mix 1 packet of the powder with a half glass (approximately 120 mL) of plain water and ingest thrice daily before meals. Additionally, they will be informed to rinse the glass with more water and drink to ensure that all of the powder will be taken.
223457262|NCT04691219|BEHAVIORAL|Diet control|Participants will be requested for diet control. They will be asked for attending the diet control program, maintaining diet pattern throughout the study period, and recording a 3-day food record. Individual counseling and assessment of compliance will be performed by licensed dietitians every 4 weeks. Diet control is principally based on carbohydrate counting.
223457263|NCT01945346|DRUG|PRX167700|Oral capsule
223457264|NCT01945346|DRUG|Placebo|Oral capsule
223573291|NCT01701479|DRUG|Aldesleukin|
224067297|NCT03544827|DRUG|Atropine|Atropine 0.1% then atropine 0.01%
224067298|NCT02295527|OTHER|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
223457265|NCT01057667|DRUG|RO5024048|1000mg bid po, 24 weeks
223457266|NCT01057667|DRUG|Ribavirin [Copegus]|1000mg or 1200mg po daily
224067299|NCT02295527|OTHER|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
223457267|NCT01057667|DRUG|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
223457268|NCT03860298|DEVICE|NaviFUS System|Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
223457269|NCT01048853|PROCEDURE|Lymph Node Mapping|Undergo lymphatic mapping with sentinel lymph node biopsy
223457270|NCT01048853|OTHER|Quality-of-Life Assessment|Ancillary studies
223457271|NCT01048853|PROCEDURE|Salpingo-Oophorectomy|Undergo hysterectomy with or without salpingo-oophorectomy
223457272|NCT01048853|PROCEDURE|Sentinel Lymph Node Biopsy|Undergo lymphatic mapping with sentinel lymph node biopsy
223573292|NCT01701479|DRUG|Isotretinoin|
223573293|NCT00612014|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
223573294|NCT00612014|DRUG|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
223573295|NCT00612014|DRUG|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
223573296|NCT00612014|DRUG|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
224067300|NCT01430039|PROCEDURE|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
224067301|NCT01430039|PROCEDURE|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
224067302|NCT04091997|DIAGNOSTIC_TEST|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
224067303|NCT03156088|DEVICE|"Sacral Neuromodulator InterStim"|
224067304|NCT00105651|BEHAVIORAL|Combined nursing invention|
224067305|NCT06682468|BEHAVIORAL|Population level patient portal based substance involvement screening|Participants 18 years or older, with an active patient portal account, who have attended an HIV care clinic visit in the HIV clinic in the last two years and have not completed the validated National Institute for Drug Abuse (NIDA) Quick Screen V1.0 in the previous year will be eligible for intervention randomization. Those randomized into the intervention group will receive the validated NIDA Quick Screen V1.0 over their patient portal account. Participants randomized to this group can complete the screener over the patient portal without a scheduled appointment with their HIV clinician.
223457273|NCT01048853|PROCEDURE|Therapeutic Conventional Surgery|Undergo hysterectomy with or without salpingo-oophorectomy
223457274|NCT00672607|DRUG|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
223457275|NCT00672607|DRUG|Placebo|Placebo
223457276|NCT04294199|OTHER|Early Range of MOtion|Groups will be compared to see if immobilization or early range of motion is better at returning to their sport after patellar dislocation.
223573297|NCT00612014|DRUG|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
223573298|NCT00612014|DRUG|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
223573299|NCT04862949|DRUG|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab
223573300|NCT01283906|DEVICE|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
223573301|NCT01283906|DEVICE|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
223573302|NCT04739618|DRUG|Keytruda Injectable Product|PD-1 inhibitor antibody
223573303|NCT04739618|DRUG|Yervoy Injectable Product|Anti-CTLA-4 antibody
223573304|NCT04739618|DRUG|GM-CSF|1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
224305138|NCT02286596|DEVICE|dextran sulfate adsorption|Lipid apheresis for 3 hours
223457277|NCT00178217|BEHAVIORAL|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
223457278|NCT02297425|DRUG|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
223457279|NCT05075863|DRUG|Letrozole|Letrozole as 5mg from day 3 to 7 of menstrual cycle
223457280|NCT06549738|DEVICE|Intermittent pneumatic compression therapy|Lympha Press Optimal Plus is an advanced intermittent pneumatic compression therapy device. It is FDA cleared (K170658) for the indication of lipedema as well as for other indications for use.
223457281|NCT04351880|OTHER|Medically Tailored Meals|Compare 2 and 4 weeks of meal delivery
223457282|NCT01400724|DIETARY_SUPPLEMENT|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
223457283|NCT03061188|OTHER|Laboratory Biomarker Analysis|Correlative studies
223457284|NCT03061188|BIOLOGICAL|Nivolumab|Given IV
223457285|NCT03061188|OTHER|Pharmacological Study|Correlative studies
223457286|NCT03061188|DRUG|Veliparib|Given PO
223457287|NCT03025269|DRUG|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
223457288|NCT01439984|DRUG|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
223457289|NCT04649086|OTHER|Rehabilitation by Eccentric exercises|Participants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.
223457290|NCT04649086|OTHER|Rehabilitation by Concentric exercises|The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.
223457291|NCT04442087|BIOLOGICAL|Serology SARS-CoV2|Collect serum for Serology SARS-CoV2 at inclusion
223457292|NCT04442087|BEHAVIORAL|Data collection|Collect clinical and demographic data, habitus, Lifestyle Counseling at inclusion
223573305|NCT04739618|PROCEDURE|Non-ablative Cryosurgical freezing|To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
223573306|NCT01304368|PROCEDURE|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
223573307|NCT01852825|BIOLOGICAL|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
223573308|NCT01852825|OTHER|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
223573309|NCT01852825|BIOLOGICAL|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
223573310|NCT02059759|DRUG|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
223573311|NCT02059759|DRUG|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
224067306|NCT06682468|BEHAVIORAL|Usual Care Substance Use Involvement Screening|Participants randomized to the usual care group will receive the validated NIDA Quick Screen V1.0 during routine in-clinic visits if they attend their scheduled visit. The medical assistant will ask participants to complete the NIDA Quick Screen V1.0. Participants who endorse the use of illegal drugs or prescription drugs for non-medical reasons, tobacco use, or heavy drinking will be referred to SUD treatment.
224067307|NCT06654414|BEHAVIORAL|PRIDE QUIT|"This is an adapted behavioral intervention based on the integrated treatment for smoking cessation, anxiety, and depressed mood, known as QUIT, for persons with HIV. Through our treatment adaption process of QUIT (guided by Aim 1 and 2 data), PRIDE QUIT will be a Cognitive-Behavioral therapy-based intervention tailored for transgender and gender diverse (TGD) individuals, aimed at to helping participants quit smoking and address gender minority stressors, anxiety, depression, and improve distress tolerance.~There will be three major assessments: baseline (T1), at the end of the intervention (T2), and a three-month follow-up visit (T3). This intervention group will likely receive 6-10 weekly sessions, with the quit day set around session 4-6. They will also receive transdermal nicotine patches (TNP) for a period of 8 weeks prior to the quit session."
224067308|NCT06654414|BEHAVIORAL|Enhanced Treatment As Usual (ETAU)|Brief counseling, the option of nicotine replacement therapy, and referral to the Quit Line.
224067309|NCT00562588|DRUG|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
224067310|NCT00562588|DRUG|ASA 100 mg qd|
224067311|NCT03798158|OTHER|Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization
224071382|NCT02864368|DRUG|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
224071383|NCT02864368|BIOLOGICAL|PEP-CMV: Component B|500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered
223457293|NCT04444765|OTHER|Collection of clinical and biological data during renal replacement therapy sessions|Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
223573312|NCT02059759|DRUG|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
223457294|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract, mixed power of pueraria, schisandra and salvia miltiorrhiza|Take 4 tablets with warm water twice a day
223457295|NCT05497765|DIETARY_SUPPLEMENT|Silibinin extract|Take 4 tablets with warm water twice a day
223457296|NCT05497765|DIETARY_SUPPLEMENT|Placebo|Take 4 tablets with warm water twice a day
223457297|NCT00537186|DRUG|Iron oligosaccharide|
223457298|NCT01139346|DRUG|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
223457299|NCT02609984|BIOLOGICAL|CMB305|A combination of LV305 administered intradermally (ID) and G305 administered intramuscularly (IM)
223573313|NCT00000627|DRUG|Fluconazole|
223573314|NCT02764723|DRUG|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
223743119|NCT05775315|OTHER|Action Observation Therapy|"Exercises of AO protocol MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
224302655|NCT02431182|BEHAVIORAL|Memory Training Workshop|"1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop"
224302656|NCT03590392|BIOLOGICAL|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
224302657|NCT00415194|DRUG|pemetrexed|500 mg/m\^2, IV, every 21 days, six 21 day cycles
224302658|NCT00415194|DRUG|cisplatin|75 mg/m\^2, administered IV, every 21 days, six 21 day cycles
224302659|NCT00415194|DRUG|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
224302660|NCT03205891|DRUG|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
224302661|NCT03205891|DRUG|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
223573315|NCT02764723|DRUG|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
223573316|NCT02944227|DRUG|Lucentis|Lucentis fixed-treatment arm
223573317|NCT02492360|PROCEDURE|Blood sample collection|Six tubes of blood will be collected during one blood draw.
223457300|NCT02609984|BIOLOGICAL|atezolizumab|IV Infusion
223457301|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
223457302|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
223457303|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
223457304|NCT02504320|DRUG|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
223457305|NCT03404388|BEHAVIORAL|Balance Training|4 days of a challenging balance training task
223457306|NCT00712894|DRUG|Diltiazem|Intracoronary Infusion 400-2000ug
223457307|NCT00712894|DRUG|Verapamil|Intracoronary Infusion 200-1000ug
223457308|NCT00712894|DRUG|Nitroglycerin|Intracoronary Infusion 200-1000ug
223573318|NCT02492360|BEHAVIORAL|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
223573319|NCT01219036|DRUG|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
223573320|NCT03132103|DIETARY_SUPPLEMENT|Oral Vitamin D3|
223573321|NCT03132103|DIETARY_SUPPLEMENT|Placebo Oral Vitamin D3|
223573322|NCT03132103|RADIATION|Solar simulated radiation (SSR)|
223573323|NCT03132103|RADIATION|Placebo SSR|
224071384|NCT03652662|DEVICE|RESP-FIT|Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
224071385|NCT03652662|BEHAVIORAL|RESP-FIT Comparator|Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
224071386|NCT01725009|DRUG|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
224071387|NCT03195907|OTHER|Pulmonary physiotherapy|
224071388|NCT00861952|OTHER|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
224071389|NCT00861952|OTHER|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
224071390|NCT03841929|OTHER|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
223457309|NCT04240561|DEVICE|High level of signal manipulation|Hearing aid will be programmed to a high level of signal manipulation.
223457310|NCT04240561|DEVICE|Low level of signal manipulation|Hearing aid will be programmed to a low level of signal manipulation.
223457311|NCT05974228|DEVICE|Bioactive glass wound dressing|Bioactive glass wound dressing is a dressing covered on the wound bed
223457312|NCT05945121|OTHER|Cardio-oncology program|Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
223457313|NCT05762640|DRUG|Ruxolitinib|"Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT."
223457314|NCT04979533|DEVICE|Insufflator oxygen tubing|high flow, low pressure oxygen with pressure relief valve and luer Lock connections delivered at 15 L/min through surgeon's laryngoscope.
223457315|NCT03141515|DEVICE|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
223457316|NCT01758614|PROCEDURE|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
223457317|NCT01758614|DRUG|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
223457318|NCT01758614|DRUG|Clopidogrel|
223457319|NCT00986323|DEVICE|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
223457320|NCT00986323|DEVICE|Placebo TLA|Placebo TLA (without filtration and TLA function)
223457321|NCT00833404|DRUG|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
223457322|NCT01210222|BIOLOGICAL|Trebananib|Given IV
223573324|NCT01630551|DIETARY_SUPPLEMENT|Fishoil supplement|1 capsule per day
223457323|NCT02797860|DRUG|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
223573325|NCT01630551|DIETARY_SUPPLEMENT|Olive Oil|1 capsule per day
223573326|NCT05961176|DEVICE|Skiin pediatric band and Skiin biometric pod|Infants that meet the inclusion criteria will be equipped with a Skiin pediatric band appropriate for their chest size. Heart rate, respiratory rate, temperature, and electrocardiogram will be monitored from 2 to 12 hours through the Skiin pediatric band and a standard of care device (Phillips Intellivue MX750) commonly used in the CCCU at SickKids.
223573327|NCT02159118|DEVICE|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
223573328|NCT02159118|DEVICE|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
223573329|NCT03679637|BEHAVIORAL|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
223573330|NCT01045941|DRUG|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
223573331|NCT01045941|PROCEDURE|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
224067312|NCT02191943|DEVICE|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
224067313|NCT02191943|DEVICE|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
224067314|NCT06594354|OTHER|ICE|"The patients in the intervention group will have ice applied to their mouths for three cycles (the first cycle they met with the researcher and the second and third cycles/an average of two months) when they come for treatment at the hospital with the researcher and at home on the days they do not come for treatment, within the scope of the oral cryotherapy application protocol, they will be monitored by phone and a reminder message will be sent. During chemotherapy, ice cubes will be applied to the patients in the first hour they start receiving chemotherapy and in the same time period, three consecutive ice cubes (each ice cube melts for an average of 1.5-2 minutes/total average of 4.5-6 minutes) and the same application will be repeated three hours later. The patients will be asked to apply ice cubes at home six times (an average of 27-36 minutes/day) at two or three hour intervals for seven days, including the day they receive chemotherapy, and to record their applications on the "
223457324|NCT01770808|DIETARY_SUPPLEMENT|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
223457325|NCT01770808|DIETARY_SUPPLEMENT|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
223457326|NCT01770808|DIETARY_SUPPLEMENT|Placebo|Subjects swallowed 4 capsules/day for six weeks.
223457327|NCT00973284|BIOLOGICAL|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
223573332|NCT01327274|DEVICE|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI \> 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (\< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
223573333|NCT04369118|PROCEDURE|Conventional follow-up|Patients in this group benefit from conventional post-operative follow-up
223457328|NCT00973284|BIOLOGICAL|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
223573334|NCT04369118|DEVICE|Conventional follow-up+chest wall restriction belt|Patients in this group benefit from conventional post-operative follow-up. The patient wear the selective chest wall restriction belt from Day 2 (after surgery) until he ceases to need it.
223573335|NCT03419273|PROCEDURE|bariatric surgery|We are recruiting only those going through bariatric surgery
223457329|NCT00973284|BIOLOGICAL|Norwalk virus|Norwalk virus solution
223573336|NCT00911092|PROCEDURE|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
224155829|NCT04846972|BEHAVIORAL|FASTRACS intervention|"Intervention (4 steps) :~* Penultimate to last chemotherapy : patient will receive tools of the intervention~* 1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~* 2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~* 5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP."
224155830|NCT01060722|DRUG|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
223573337|NCT00911092|RADIATION|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
223573338|NCT00911092|DRUG|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~* Day 1 to day 4: Fluorouracil 1 gr/m²/day~* Day 1 or 2: Cisplatin 75 mg/m²"
223573339|NCT02240823|OTHER|adipose derived stem cells|
223573340|NCT05536492|PROCEDURE|A-PRF|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF
223573341|NCT05536492|PROCEDURE|ALLOGRAFT|EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
223573342|NCT01389401|DRUG|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
224155831|NCT01060722|DRUG|Placebo|Single subcutaneous dose of placebo material
224155832|NCT05031806|DRUG|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.randomized 7:3 for each active concentration to Vehicle.
224155833|NCT05031806|DRUG|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
224155834|NCT05031806|DRUG|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.
224155835|NCT05031806|DRUG|Vehicle (eye drop formulation without aCT1)|"36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle.~During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2)."
224155836|NCT02628704|DRUG|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
223457330|NCT04957784|OTHER|questionnaire survey|Understand the current situation of hypertension management in a poor county in Shanxi Province through questionnaire surveys, and explore the factors that affect patients' blood pressure control based on local conditions
223457331|NCT05963932|DRUG|BMS-986419 DR Capsule|Specified dose on specified days
223457332|NCT05963932|DRUG|BMS-986419 IR Tablet|Specified dose on specified days
223457333|NCT03569826|OTHER|Observational; no intervention|Observational; no intervention
223457334|NCT04832451|BEHAVIORAL|Interpersonal Relational Role Analysis|"Interpersonal Relational Role Analysis (IRRA) is a psychosocial group intervention that allows individuals to see the problems they experience in interpersonal relationships and interactions in the group environment and to be handled together with group members.~Similar to Yalom's interactional group therapy model, IRRA sessions comprise warm up, the stages of setting the agenda, working, evaluating, and getting feedback from observers, which are based on the 'here and now' principle. IRRA helps to safely examine the roles in which group members are stuck, in a group environment which is a small example of social life, and these roles are addressed in six steps."
223573343|NCT00799045|DRUG|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
223573344|NCT03356418|OTHER|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
223573345|NCT03356418|OTHER|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
223573346|NCT00198861|OTHER|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
223573347|NCT03760757|DIETARY_SUPPLEMENT|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
224155837|NCT02628704|DRUG|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
223457335|NCT01322087|DIETARY_SUPPLEMENT|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
223457336|NCT02959333|BIOLOGICAL|hAEC|hAEC: human amniotic epithelial cells
223573348|NCT03760757|DIETARY_SUPPLEMENT|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
224155838|NCT02628704|DRUG|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
224155839|NCT02628704|DRUG|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
224155840|NCT00693420|DRUG|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
224155841|NCT00693420|DRUG|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
224155842|NCT03300427|DRUG|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
224155843|NCT03300427|DRUG|valsartan|Valsartan 80 or 160 mg BID
224155844|NCT03300427|DRUG|placebo to valsartan|placebo to valsartan 80 or 160 BID
224155845|NCT03300427|DRUG|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
224155846|NCT03932890|DEVICE|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
224302662|NCT03205891|DEVICE|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
224302663|NCT01297465|DRUG|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
223457337|NCT06109350|OTHER|Supporting play exploration and early developmental intervention(SPEEDI)|SPEEDI will be performed by the parents
223457338|NCT06109350|OTHER|Standard care|Standard care will be performed by the parents
224302664|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
223457339|NCT03293394|DEVICE|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223457340|NCT03293394|DEVICE|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
223573349|NCT04401306|OTHER|Home-based self-regulated simulation training (SRST)|Participants allocated to the SRST arm train basic laparoscopic skills at home. Participants train by themselves using a portable box training model (BT). Training is conducted and structured through an online application-based training platform. Training is instructed by online instructional videos and texts. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
223573350|NCT04401306|OTHER|Centralized instructor-regulated simulation training (IRST)|Participants allocated to the IRST arm train basic laparoscopic skills at the simulation centre. Participants train on a portable box training model (BT). Training is structured through an online application-based training platform and facilitated and instructed by surgical specialists. The BT is connected to a laptop and the participants can submit videos of their training exercises for assessment through the online training platform.
223573351|NCT04381637|DEVICE|NIPE monitor|NIPE monitor connected to the anesthetic station. No part of the device in contact with the patient. No action on patient or anesthesia. Automatic recording of Heart rate and NIPE index during the study period.
223573352|NCT04381637|PROCEDURE|Tetanic stimulations|"Three tetanic stimulations will be performed (10-30 and 60 milliamps) under general anesthesia, before surgical incision.~Stims performed via the muscle relaxation monitor (used in standard practice in this population) Each stim lasts for 5 seconds. Interval between two stims : 3-5 minutes Order on intensities randomized by a latin square of order 3."
223573353|NCT04829474|OTHER|Survey|It is a survey that the patient and doctor must complete.
223573354|NCT01716338|DRUG|Glyburide|
223573355|NCT01716338|DRUG|Placebo|
223573356|NCT04508751|OTHER|"3T Free-Breathing Fetal Magnetic Resonance Imaging"|Subject will have a one time MRI scan.
223573357|NCT02911740|OTHER|Urine LAM Ag test|TB diagnostic assay
224155847|NCT03932890|DEVICE|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
224155848|NCT04246268|DEVICE|INVOcell|Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
224155849|NCT03250624|DRUG|CD5024 0.3% cream|Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
224155850|NCT03250624|DRUG|Placebo|Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
224155851|NCT01894555|DRUG|Aspirin|81 mg daily for 4 weeks
223457341|NCT00086450|PROCEDURE|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
223457342|NCT00086450|DEVICE|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
223457343|NCT00436826|DRUG|Cladribine|Participants were administered with cladribine tablets orally as cumulative dose.
223457344|NCT00436826|DRUG|Placebo|Participants were administered with placebo orally.
223457345|NCT00436826|DRUG|Interferon-beta (IFN-beta)|Participants received IFN-beta therapy (Rebif® new formulation \[RNF\] 44 microgram \[mcg\] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
223573358|NCT03826836|BEHAVIORAL|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
223573359|NCT04384380|DRUG|Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
223573360|NCT01758224|OTHER|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
223573361|NCT01758224|OTHER|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
223573362|NCT04364607|DRUG|Neostigmine|Participants will receive 0.5 mg IM neostigmine
223457346|NCT05689567|DEVICE|DEFOG glasses(peripheral focus-out glasses)|Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.
223457347|NCT04978337|DRUG|Rilematovir|Rilematovir 250 mg will be administered orally.
223457348|NCT04978337|DRUG|Placebo|Placebo matching to rilematovir will be administered orally.
223457349|NCT00222638|DRUG|Influenza vaccination|
223457350|NCT00725907|BIOLOGICAL|PGRF|injection of 6cc into injured area
223457351|NCT00725907|BIOLOGICAL|placebo saline|injection of 6cc into injured area
223573363|NCT04364607|DRUG|NaCl 0.9%|Participants will receive IM NaCl 0.9% as a placebo
223573364|NCT03836326|OTHER|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
224067315|NCT00337870|BEHAVIORAL|PAT|Cognitive-Behavioral/Relaxation Intervention
224067316|NCT00698243|DRUG|OSI-027|Administered orally
224067317|NCT06126237|BIOLOGICAL|CM313 injection|CM313, subcutaneous injection
223457352|NCT01436227|OTHER|Laboratory Biomarker Analysis|Correlative studies
223457353|NCT01436227|DRUG|Pazopanib Hydrochloride|Given PO
224067318|NCT00893321|PROCEDURE|Inferior Oblique Muscle Recession and Myectomy|
223457354|NCT03465761|DEVICE|ExAblate|Bilateral side treatment of Essential Tremor
223457355|NCT03971591|BEHAVIORAL|Immediate Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
223457356|NCT06039319|OTHER|Physical activity|30 minute bout of moderate intensity physical activity performed on a treadmill
223457357|NCT06234098|DRUG|AT-1965 Liposome Injection|AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
223457358|NCT06462898|DIETARY_SUPPLEMENT|Omega-3 Fortified Protein Smoothie|Omega-3 powder and protein supplementation.
223457359|NCT06462898|DIETARY_SUPPLEMENT|Non-Fortified Protein Smoothie|Protein without omega-3 powder supplementation.
223457360|NCT00438204|BIOLOGICAL|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
223457361|NCT00438204|DRUG|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
224067319|NCT00313209|DRUG|Roflumilast|500 µg, once daily, oral administration in the morning
224067320|NCT00313209|DRUG|Placebo|once daily
224067321|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
224067322|NCT01332357|DRUG|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
224067323|NCT00484653|PROCEDURE|cervical smear|biological analysis
224067324|NCT04434391|OTHER|QF-PCR for GBS screening|QF-PCR for GBS screening in pregnant women,compared with GBS culture test.
223457362|NCT00438204|DRUG|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
223457363|NCT02077309|DRUG|Linagliptin|
223457364|NCT02077309|DRUG|Placebo|
223457365|NCT01158742|OTHER|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
223457366|NCT01158742|OTHER|Glomerular Filtration Rate with Iohexol|used to determine kidney function
223457367|NCT03184129|DEVICE|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
223457368|NCT03184129|DEVICE|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
223457369|NCT03428399|OTHER|Psychosocial variables|The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
223457370|NCT03881202|DEVICE|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
223573365|NCT03836326|OTHER|Control|Routine care provided by health professionals in the NICU
223573366|NCT03836326|OTHER|Story telling attention refocusing intervention|A contact-free intervention where parents share stories with their infant for 10 minutes 3 times per week.
223573367|NCT00724854|BIOLOGICAL|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
223573368|NCT00724854|DRUG|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
223573369|NCT01865812|DRUG|Obeticholic Acid|All participants were treated with OCA (oral administration, 10 mg, once daily \[QD\]) for 8 weeks and continued their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8-week Primary Treatment Phase of the study and the 4-week follow-up period, during which time participants did not take OCA, all eligible participants were offered the opportunity to enter an open-label, long-term safety extension phase, during which they could receive 10 mg OCA QD for up to 2 years.
223573370|NCT01338610|BIOLOGICAL|ESBA105 ophthalmic solution|
223573371|NCT01338610|OTHER|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
223573372|NCT05839340|DEVICE|Neurally Adjusted Ventilatory Assist|NAVA uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen, to which proportion is set by the clinician as the NAVA level.
223573373|NCT05839340|DEVICE|Assist Control Ventilation|ACV delivers fixed oxygen pressure set by the clinician at the start of each inspiratory breath.
223573374|NCT01420172|OTHER|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
223573375|NCT00188851|DRUG|therapeutic management strategy|
223573376|NCT00633230|DRUG|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
223573377|NCT00633230|OTHER|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
223573378|NCT05249881|DRUG|Semaglutide Pen Injector|All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
223573379|NCT00753805|DIETARY_SUPPLEMENT|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
223573380|NCT05910125|DRUG|Aspirin|See arm/group descriptions.
223573381|NCT05910125|DRUG|Clopidogrel|See arm/group descriptions.
223573382|NCT05910125|DRUG|Alteplase|See arm/group descriptions.
224067325|NCT03828591|PROCEDURE|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
224067326|NCT03828591|PROCEDURE|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
224067327|NCT00163787|BEHAVIORAL|outcome measures and self report|
224067328|NCT06539923|OTHER|retrieving data|Data will be retrieved retrospectively
224067329|NCT01819051|DEVICE|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
224067330|NCT02997761|BIOLOGICAL|Blinatumomab|Given IV
224067331|NCT02997761|DRUG|Ibrutinib|Given PO
224067332|NCT02011659|DRUG|Ramosetron|
224067333|NCT04451356|DEVICE|Bioimpedance Spectroscopy|This analysis will be performed at baseline using the portable whole-body multifrequency bioimpedance analysis device (BCM®Body Composition Monitor - Fresenius Medical Care D GmbH). The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid overload. All calculations are automatically performed by the software of the BCM® device. In addition, this analysis will provide the LTI and FTI for the included patients.
223573383|NCT02954419|OTHER|No intervention|No intervention
223573384|NCT05026372|BEHAVIORAL|Mindfulness Compassion (MC)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
223573385|NCT05026372|BEHAVIORAL|Mindfulness Gratitude (MG)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
223573386|NCT05026372|BEHAVIORAL|Mindfulness Value-Based Living (MV)|The interventionist will review the tools the couples had learned over the course of this program and help them proactively identify strategies to continue to implement them into their lives. Couples will receive instructions on how to continue with this program when no longer meeting with the interventionist.
224067334|NCT04451356|DEVICE|Arterial Stiffness|Arterial stiffness assessment will be performed by applanation tonometry (SphygmoCorTM; PWV Inc., Westmead, Sydney, Australia) with the patient being recumbent, 10 minutes before the measures were done. The carotid and femoral pulse will be acquired by applanation tonometry sequentially, allowing a single operator to acquire the measurement. The transit time from the R-wave of the simultaneously acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference acquired electrocardiogram to the foot of the carotid and femoral pulse is measured. The difference between these 2 transit times is divided by distances measured from the body surface to estimate the arterial path length in order to calculate carotid-femoral PWV.
224067335|NCT04451356|DIAGNOSTIC_TEST|Echocardiography|Echocardiographic evaluations will be made in each patient at baseline. All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
224071391|NCT01988064|OTHER|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
224302665|NCT01297465|DRUG|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles \>= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
224302666|NCT01297465|DRUG|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles \>= 18 mm).
224302667|NCT00270348|DRUG|ciclesonide|
224302668|NCT03669939|OTHER|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
224302669|NCT03669939|OTHER|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
224302670|NCT05816057|BIOLOGICAL|semaglutide injection|The subject will receive either a dose semaglutide once weekly (subcutaneous (s.c.) injection). The initial dose of 0.25 mg is s.c. once weekly, and the dose is increased to 0.5 mg after 4 weeks of administration, and the dose is increased to 1 mg after 4 weeks of 0.5 mg administration, and the dose is continued at a stable dose of 1 mg for 24 weeks.Treatment duration 32 weeks.
224302671|NCT05304286|BEHAVIORAL|Acceptance and Commitment Therapy|The aim of ACT is to address avoidance behaviors by increasing openness to difficult experiences, such as pain, and to develop an awareness of behavioral options that will aid to facilitate behavior change processes that are in accord with living a values-based life.
224302672|NCT03956810|OTHER|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
224302673|NCT03956810|OTHER|Usual transportation|Usual transportation scheduling via call-center.
224302674|NCT00986063|GENETIC|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
224302675|NCT00986063|OTHER|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
224302676|NCT02714517|OTHER|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
224302677|NCT02714517|OTHER|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
224302678|NCT05621408|BEHAVIORAL|Attention Training Technique|Attention Training Technique is a six weeks psychological intervention provided by trained professionals
224302679|NCT00369655|BIOLOGICAL|ziv-aflibercept|
223573387|NCT04155346|BEHAVIORAL|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
223573388|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
223573389|NCT01095653|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
223573390|NCT01095653|DRUG|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
223573391|NCT01095653|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
223573392|NCT03103672|PROCEDURE|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
223573393|NCT02046226|DEVICE|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
224071392|NCT01988064|OTHER|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
224302680|NCT04662138|DRUG|directly acting antivirals|Different regimens given for genotype 4 relapse: Sofosbuvir/velpatasvir/voxilaprevir ±ribavirin; sofosbuvir/velpatasvir ±ribavirin; ombitasvir/paritaprevir/ritonavir+ ribavirin
224302681|NCT00256438|DEVICE|Transcranial Direct Current Stimulation|
224302682|NCT04049617|DRUG|Evixapodlin|Tablets administered orally.
224155852|NCT03756870|PROCEDURE|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
224155853|NCT01644019|PROCEDURE|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
224155854|NCT01597440|DRUG|N-carbamylglutamate|"Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
224155855|NCT01597440|OTHER|Standard of Care|Standard of Care
224155856|NCT02359136|PROCEDURE|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
224155857|NCT02359136|PROCEDURE|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
224155858|NCT02359136|PROCEDURE|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
224155859|NCT05505539|DRUG|5-fluorouracil|Given intralesionally by injection
224155860|NCT00509028|DRUG|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
224155861|NCT00509028|DRUG|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
223457371|NCT05628857|DRUG|RC108|RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
223457372|NCT02716922|PROCEDURE|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
223457373|NCT05443074|OTHER|Face to face intervention group|"Participants of this group will participate in a one 15 minutes face to face session where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge urinary incontinence (UI)."
223573394|NCT00171925|DRUG|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance \> 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg\*hr/l).
223573395|NCT00171925|DIETARY_SUPPLEMENT|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
223573396|NCT04720274|DEVICE|Electromyopathy (EMG) Shorts|Participants will be asked to complete physical activities while wearing EMG shorts
223573397|NCT03865667|DEVICE|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
223573398|NCT02692040|DRUG|G3215|Gut hormone analogue
223573399|NCT02692040|DRUG|Placebo|0.9% saline
223573400|NCT05482178|BEHAVIORAL|Resistance exercise training plus hypocaloric diet|"The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day)."
223573401|NCT05482178|BEHAVIORAL|Hypocaloric diet|The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (\>25g per day).
224155862|NCT00948428|DRUG|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
224155863|NCT00948428|DRUG|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
224155864|NCT00948428|DRUG|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
224302683|NCT05157958|BIOLOGICAL|ALLO-ASC-SHEET|Weekly administration
224302684|NCT05157958|OTHER|Vehicle Control|Weekly administration
224302685|NCT03551496|COMBINATION_PRODUCT|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
223573402|NCT03905369|OTHER|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
223573403|NCT03905369|OTHER|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
224155865|NCT05668806|DEVICE|Cerviron|Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.
224155866|NCT00904111|DRUG|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
224302686|NCT03551496|DEVICE|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
223573404|NCT02470754|DEVICE|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
223573405|NCT02470754|DEVICE|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
223573406|NCT04679857|OTHER|TKA|Total Knee Arthroplasty
223573407|NCT03592719|BEHAVIORAL|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
223573408|NCT03592719|BEHAVIORAL|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
223573409|NCT02265419|DEVICE|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
223573410|NCT01103154|DRUG|carvedilol|6.25mg per day, increase to 6.25mg bid
223573411|NCT01103154|DRUG|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
223573412|NCT01890395|OTHER|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
223743120|NCT05775315|OTHER|Action Observation Therapy along with visual feedback|"Exercises of AO protocol in front of a mirror MOVEMENT TOTAL VIDEO TIME PATIENT TIME Upright the pelvis 1 minute 5 minutes Move weight forward 1 minute 5 minutes Move weight to the left and right 1 minute 5 minutes Rotate right and left 1 minute 5 minutes Upright the pelvis in sitting position 1 minute 5 minutes Move weight forward from a sitting position 1 minute 5 minutes Stand up from a sitting position 1 minute 5 minutes Move weight right and left 1 minute 5 minutes Forward weight shift with right foot and left foot 1 minute 5 minutes Walking sideways to left 1 minute 5 minutes Walking sideways to right 1 minute 5 minutes~Rest time between watching and performing each video will be 1 minute. the exercises will be done 3 times a week."
223743121|NCT00561080|BIOLOGICAL|Zostavax|
224302687|NCT03967535|DEVICE|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
224302688|NCT03967535|BEHAVIORAL|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
224302689|NCT02430779|PROCEDURE|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
224302690|NCT02430779|DEVICE|NanoKnife|
224302691|NCT02789553|OTHER|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
224302692|NCT02789553|OTHER|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
224305139|NCT02296021|DRUG|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
223573413|NCT02274272|OTHER|ADR-1|two ADR-1 capsules, once daily, QD
223573414|NCT02274272|OTHER|GMNL-263|two GMNL-263 capsules, once daily, QD
223573415|NCT02274272|OTHER|placebo|two placebo capsules, once daily, QD
223743122|NCT00300950|BIOLOGICAL|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
223743123|NCT00300950|DRUG|Gemcitabine|Chemotherapy
223743124|NCT04460547|DRUG|Convalescent Plasma Transfusion|Convalescent Plasma Transfusion to COVID-19 infected patients.
223743125|NCT04460547|DRUG|Hydroxychloroquine|Hydroxychloroquine administration to COVID-19 infected patients.
223573416|NCT02779907|OTHER|No Intervention|No interventions planned for this observational study
223457374|NCT05443074|OTHER|Remote intervention group|"Participants of this group will be referred to a room with a computer (inside the rehabilitation center) to participate in a one 15 minutes real time remote session, where they will receive information about anatomy, functions and dysfunctions of the pelvic floor. During the session, some teaching materials will be used (an anatomical model, prototype simulator of the functions of the PFM, posters, videos and images), in order to facilitate the learning of women about how to contract their PFM and how to avoid urinary loss by contracting their muscles.~At the end of the session, the participants will have time to ask their questions and will receive a home booklet reinforcing the information given during the session including instructions for them to perform a PFM contraction during daily live situations that generate an increased intra-abdominal pressure, such as coughing, sneezing, weight lifting and other activities, as well as strategies to inhibit urge UI."
223457375|NCT05443074|OTHER|Control group|Participants of this group will be assessed in the same time points of the participants of the two other groups. They will not receive any intervention or information about pelvic floor anatomy, functions and dysfunctions of the pelvic floor, however after the last assessment (20 days after) for ethical reasons they will receive the same intervention.
223457376|NCT05341791|OTHER|Cartoon video describing study information notice|The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
223457377|NCT05521113|BEHAVIORAL|Home Rehabilitation Monitoring System|The system consists of a small activity monitor worn on the wrist and a pulse oximeter worn on the finger while exercising. Simple exercises will be completed daily and the monitors will send information to a rehabilitation coach during a 12-week period.
223457378|NCT05521113|BEHAVIORAL|Health coaching calls|12 telephone-based health coaching calls over a 12-week period
223457379|NCT00285766|DRUG|Selegiline Transdermal System|
223457380|NCT01135043|BEHAVIORAL|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
223457381|NCT01135043|BEHAVIORAL|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
223573417|NCT01409083|DEVICE|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
223573418|NCT05105282|PROCEDURE|Two different blocks with same local anesthetic volume|Deep serratus anterior block and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
223573419|NCT02281487|PROCEDURE|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
223573420|NCT02281487|PROCEDURE|Hysterectomy|standard hysterectomy
223573421|NCT02281487|DEVICE|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
223573422|NCT03749096|DRUG|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
223573423|NCT03749096|DRUG|Placebos|Normal Saline
223573424|NCT01310179|GENETIC|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
223573425|NCT04175522|DRUG|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
223573426|NCT02540330|DRUG|Fulvestrant|
223743126|NCT04460547|DRUG|DAS181|DAS181 administration to COVID-19 infected patients.
223743127|NCT04460547|DRUG|Ivermectin|Ivermectin administration to COVID-19 infected patients.
223743128|NCT04460547|DRUG|Interferon Beta-1A|Interferon Beta-1A administration to COVID-19 infected patients.
223743129|NCT04389424|DRUG|Tamoxifen|Use of tamoxifen for breast cancer recurrence prevention
223573427|NCT02937298|DIETARY_SUPPLEMENT|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
223573428|NCT02937298|DIETARY_SUPPLEMENT|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
223573429|NCT02937298|DIETARY_SUPPLEMENT|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
223573430|NCT02937298|DIETARY_SUPPLEMENT|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
223573431|NCT06241001|OTHER|eccentric streching|The player will lift up one leg from starting position so he stands on his to-be-trained leg. For performing eccentric exercises of the gastrocnemius muscles, the player will lower his heel until he will feel a slight stretch, while keeping his knee extended
223573432|NCT06241001|OTHER|IASTM|Specially designed tools are used to apply longitudinal pressure along muscle fibers, and treatment usually includes applying to more than the tissues in the isolated location of the pain
223573433|NCT03373890|BEHAVIORAL|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
223743130|NCT04389424|DRUG|Exemestane|Use of exemestane for breast cancer recurrence prevention
223743131|NCT04389424|DRUG|Anastrozole|Use of anastrozole for breast cancer recurrence prevention
223743132|NCT04389424|DIAGNOSTIC_TEST|Basal|Initial diagnosis of breast cacner by biopsy or mastectomy
223743133|NCT04389424|DIAGNOSTIC_TEST|Recurrence|Breast cancer recurrence under endocrine therapy
223743134|NCT02953327|BIOLOGICAL|Bacille Calmette-Guerin|Vaccine against tuberculosis
223743135|NCT02953327|BIOLOGICAL|BCG solvent|Simple solvent
224155867|NCT00904111|DRUG|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
224155868|NCT01557127|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
224155869|NCT02936362|OTHER|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
223457382|NCT03338504|DIAGNOSTIC_TEST|Invasive coronary angiography|Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
223457383|NCT03338504|RADIATION|CT coronary angiography|CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
223573434|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
223573435|NCT02330302|DRUG|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
223573436|NCT03158623|BIOLOGICAL|Platelet Rich Plasma|
223573437|NCT03158623|BIOLOGICAL|Cellerate|
223573438|NCT04159272|BEHAVIORAL|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision."
223573439|NCT00346489|DRUG|5-fluorouracil|
223573440|NCT00346489|DRUG|Mitomycin C|
223573441|NCT02193035|OTHER|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
223573442|NCT02826421|DEVICE|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
223573443|NCT02826421|DEVICE|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
223743136|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 140μg/kg, s.c., once a week, for 52 weeks
224155870|NCT02936362|OTHER|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
224155871|NCT03667794|DIAGNOSTIC_TEST|body plethysmography|measurement of conventional lung function parameters
224155872|NCT03667794|DIAGNOSTIC_TEST|impulse oscillometry|measurement of central and peripheral airway resistance
223573444|NCT02826421|DEVICE|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
223743137|NCT05838885|DRUG|YPEG-rhGH|YPEG-rhGH, 280μg/kg, s.c., once a week, for 52 weeks
223743138|NCT05838885|DRUG|rhGH|rhGH, 245μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
223743139|NCT05838885|DRUG|rhGH|rhGH, 470μg/kg/week, divided into 7 subcutaneous injections, once daily, for 52 weeks
224155873|NCT03667794|DIAGNOSTIC_TEST|multiple breath washout|measurement of ventilation heterogeneity
224155874|NCT01656018|DRUG|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
224155875|NCT01069809|BIOLOGICAL|AGS-004|HIV-1 Immune Therapy
224155876|NCT01069809|BIOLOGICAL|Placebo|Inactive Placebo Injection
224155877|NCT04395989|DRUG|A1: Pyrotinib with nab-paclitaxel|A1: pyrotinib(EGFR-TKI) 400mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
224155878|NCT04395989|DRUG|A2: nab-paclitaxel|A2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
224155879|NCT04395989|DRUG|B1: everolimus with nab-paclitaxel|B1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
224155880|NCT04395989|DRUG|B2: nab-paclitaxel|B2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
224155881|NCT04395989|DRUG|C1: PD-1 with nab-paclitaxel and famitinib|C1: PD-1 antibody SHR1210 200mg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt + famitinib 20mg po qd, 4 weeks as a cycle
224155882|NCT04395989|DRUG|C2: nab-paclitaxel|C2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
223457384|NCT03338504|DIAGNOSTIC_TEST|Cardiac MRI|Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
223457385|NCT00000267|DRUG|Risperidone|
223457386|NCT00826150|BIOLOGICAL|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
223457387|NCT04962035|OTHER|Neurocognitive Follow-up|Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
223457388|NCT02651337|DEVICE|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
223457389|NCT01085240|OTHER|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
223457390|NCT03381859|DRUG|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Hepatitis C Virus direct-acting antiviral
223457391|NCT03188783|DRUG|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
223457392|NCT03188783|DRUG|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
223457393|NCT00869128|DRUG|Circadin|2 mg prolonged-release melatonin
223457394|NCT00869128|DRUG|Placebo|
223457395|NCT05137002|DRUG|CIN-107|CIN-107 tablets by mouth once daily
223457396|NCT05137002|DRUG|Placebo|Placebo tablets by mouth once daily
223457397|NCT05340296|BEHAVIORAL|Acute Youth Connect|This intervention is being piloted will be revised with feedback from the first 5-10 patients who complete it. At the time of registration, the protocol is as follows: Roughly one week prior to discharge, the patient and a parent/caregiver will together nominate 3-4 trusted adults in the patient's life to serve as their post-discharge support team. Consenting nominees will then attend a 45-90 minute training on how to provide social support to the patient. Each adult support will also receive weekly (3-15 minute) check in calls from study staff to monitor progress and concerns. Each patient will also attend 3 interactive sessions with a study interventionist, and will be encouraged to bring an adult from their support team. These sessions will be evenly spaced throughout the post-discharge intervention period. Adolescents will receive weekly reflection-prompting text messages to practice skills taught in the interactive sessions.
223457398|NCT00700128|DRUG|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
223457399|NCT00700128|DRUG|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
223457400|NCT00700128|DRUG|placebo|placebo
223457401|NCT01136564|DRUG|Zemplar|2 capsules of 1 microgram daily
223457402|NCT01136564|DRUG|Placebo|2 capsules daily
223457403|NCT03338283|OTHER|Electromassage|Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
223457404|NCT03338283|OTHER|Conservatory treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
223457405|NCT01566422|DRUG|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
223457406|NCT05039125|RADIATION|ultrasonic cavitation|"* From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months"
223457407|NCT04594109|BEHAVIORAL|Tailored behavioral counseling|Participants in the intervention arm were provided a one-time tailored cognitive-behavioral therapy in-person cessation counseling intervention lasting approximately one hour, a 30-day supply of nicotine replacement therapy (consisting of nicotine patches and nicotine gum; dosage according to current smoking intensity according to manufacturers instructions), and a tailored bi-directional text messaging program delivering two messages per day for four weeks. The TI session was adapted from the clinical practice guidelines to include behavioral elements rooted in the minority stress model. The intervention used addressed issues of stress related to HIV stigma, minority status and socioeconomic condition.
223573445|NCT02826421|DEVICE|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
223573446|NCT02526082|OTHER|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
223573447|NCT01325090|DRUG|BOTOX|A syringe of 1 ml contain 25 Allergan units.
223573448|NCT01325090|OTHER|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
223573449|NCT04821674|BIOLOGICAL|DS-5670a|DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
223573450|NCT04821674|BIOLOGICAL|Placebo|Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total
223573451|NCT02273635|DRUG|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
223573452|NCT02273635|DRUG|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
223573453|NCT04899440|DEVICE|Water Flosser|A pressurized stream of water to reduce gingivitis and remove adherent plaque
223573454|NCT04899440|OTHER|Control|No Oral Irrigator Control
223573455|NCT05617053|DEVICE|DAART|
223573456|NCT05617053|DEVICE|ATP/Supera stenting|
223573457|NCT02230761|DRUG|XOPH5 Ointment|
223573458|NCT02230761|DRUG|Placebo|
223573459|NCT02076360|BEHAVIORAL|Preoperative Video|Patients will watch preoperative instructional video
223573460|NCT03078790|DEVICE|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
223573461|NCT05326581|DEVICE|mri|The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
223573462|NCT04257175|BIOLOGICAL|CAR-T CD19|The CAR-T infusion will be given in IV infusion. The target dose is 1 X 106 positive CAR / kg T cells (range: 0.5-1.5X 106 CAR / kg positive T cells).
223573463|NCT02291757|DIETARY_SUPPLEMENT|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
223573464|NCT02291757|DIETARY_SUPPLEMENT|Placebo|Placebo, 500 mg, once daily, p.o.
223573465|NCT01551290|DRUG|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
223573466|NCT01551290|DRUG|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
223573467|NCT02141490|DRUG|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
223573468|NCT02141490|DIAGNOSTIC_TEST|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
223743140|NCT06404606|COMBINATION_PRODUCT|Black cumin and turmeric with Quantum Acoustic Waves (QAW)|Black cumin and turmeric are known to be helpful in reduction of inflammation of human body so it will be used in combination with Quantum Acoustic Waves (QAW) to determine effects on initial degenerative changes in osteoarthritis.
224071393|NCT02505880|OTHER|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
224071394|NCT02505880|DRUG|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
223457408|NCT04594109|BEHAVIORAL|Standard of Care|One-time standard of care in-person behavioral counseling lasting approximately one hour, plus a 30-day supply of nicotine replacement therapy consisting of nicotine patches and nicotine gum (dosage according to current smoking intensity according to manufacturers instructions). The standard of care behavioral counseling was adapted from the current U.S. clinical practice guidelines.
223457409|NCT01321632|DRUG|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
223457410|NCT02555917|PROCEDURE|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
223457411|NCT02787122|BEHAVIORAL|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
223457412|NCT02787122|BEHAVIORAL|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
223457413|NCT04130152|DRUG|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
223457414|NCT04130152|DRUG|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
223457415|NCT06144203|BEHAVIORAL|Exercise|Participants will complete either a 30-minute bout of light-, moderate-, or high-intensity aerobic exercise at one of the visits.
223573469|NCT06305936|OTHER|Intervention with 100% plant-based diet|The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
223573470|NCT04656041|DRUG|FOLFOX/ nal-IRI|"A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1\) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2\) Oxaliplatin via IV, predetermined dosage per protocol~* 3\) Leucovorin via IV, predetermined dosage per protocol~* 4\) 5-Fluorouracil via IV, predetermined dosage per protocol"
223573471|NCT04656041|DRUG|Paclitaxel|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
223573472|NCT04656041|DRUG|Carboplatin|Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
223457416|NCT01744158|OTHER|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~* differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~* measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~* measurement of severity of spasticity using the modified Ashworth score~* description of presence of chorea or athetosis~* classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~* classification of fine motor abilities using the manual ability classification system (MACS)~* collection of demographic data and associated medical history"
223457417|NCT05320419|OTHER|Amniotic membrane preparation and injection (AM group)|The dehydrated AM product used in this study is derived from donated human placental tissue following healthy, live, caesarian section, full-term births which are then cleaned of blood under aseptic conditions. The product comes as a 20mg dry powder in a small vial stored at room temperature and mixed with 2 mL 0.9% sterile normal saline. Then the suspended AM will be injected to the injured tendon and the surrounding area with ultrasound-guidance via a 7cm, 23-gauge needle.
223573473|NCT04656041|RADIATION|Proton Radiation Therapy|Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
223573474|NCT05966428|OTHER|Conventional Exercises|"This conventional exercises included stretching and strengthening, balance-coordination, mobility and range of motion exercises.~The control group received conventional therapy 3 days a week for 8 weeks. Each therapy session a day lasted 45 minutes in control group."
224067336|NCT04451356|DIAGNOSTIC_TEST|Lung ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts. The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
224067337|NCT03701828|PROCEDURE|Weight loss surgery|All surgery types will be included. However, only participants scheduled for surgery with collaborating surgeons will be included. Surgery is not provided by study team.
224067338|NCT04505098|DRUG|Icosapent ethyl|2 g by mouth twice daily for at least 6 months
224067339|NCT06459154|OTHER|Mixed Reality|The experimental group MR will use the mixed reality project involving activities in a supermarket. MR HoloLens2 glasses will be used to conduct the program. The technological equipment that will be used will allow the provision of visual and auditory stimuli. The program presents 5-10 different objects found in a supermarket, where you need, as you walk, to collect them within a mixed environment. This program offers coordination activities, posture, cognitive activities and balance exercises. The mixed reality program lasts 30 minutes, with a frequency of 3 times a week for 12 weeks.
224067340|NCT06459154|OTHER|Traditional Physiotherapy|The group of traditional physiotherapy follows the guidelines of EPDA. Specifically, the program will be 35-40 minutes long, 3 times a week for 12 weeks. The program includes 5 minutes warm up, 10 minutes resistance exercises, 10 minutes of balance exercises and stretching.
224067341|NCT07009964|OTHER|ContextWell Educational Programme|ContextWell Educational Programme
224067342|NCT07016022|OTHER|CardioPulmonary Variability Assessment|The Preoperative CardioPulmonary Variability Assessment (CPVA) will assess baseline HRV \& RRV and the ability to tolerate mild physiologic stress. The assessment will involve a a Philips MP50 monitor that will collect continuous ECG (Lead II) and CO2-based respiratory waveform data with intermittent blood pressure (BP) measurements over a test of less than 60 minutes. We will measure the response to mild physiological stress which reflects adaptability, autonomic function and functional mobility by having the participant perform certain tasks such as sitting, standing, deep breathing, valsalva manoeuvres, and marching.
224067343|NCT04994951|DRUG|Triamcinolone Acetonide Acetate and Urea Cream.|10g/tube and CalcipotriolOintment,10g/tube are used alternately.
224067344|NCT04994951|DRUG|Qing-Re-Liang-Xue Decoction.|One dose of granules is mixed, poured into 500ml of boiling water, and taken twice in the morning and afternoon. Women stop taking Chinese medicine during the first 3 days of menstruation.The period of treatment will be 10 weeks.
224067345|NCT07021079|DEVICE|Focal muscle vibration|focal muscle vibration sessions, using small and portable vibrator devices.
224067346|NCT07021079|DEVICE|NO Focal muscle vibration|The control group will not receive any intervention.
224067347|NCT07028944|OTHER|Gravity assisted stress|Patients have a post 7-10 day ankle fracture x-ray taken under gravity assisted stress
224067348|NCT07028944|OTHER|Manual external rotation stress|Patients have a post 7-10 day ankle fracture x-ray taken under manual external rotation stress
224067349|NCT07028944|OTHER|Weight-bearing stress|Patients have a post 7-10 day ankle fracture x-ray taken under manual weigh-bearing stress
224067350|NCT07030101|DRUG|TCA108|TCA108
224067351|NCT07030101|DRUG|Bramicar HCT|Bramicar HCT
224067352|NCT07029984|OTHER|Baylor Continence Scale|This study may be one of the first to test the Turkish adaptation and validity of the scale in Turkish children with anorectal malformations.
224067353|NCT07029087|PROCEDURE|Pudendal Nerve Block|Pudendal nerve blocks are often preferred as an initial diagnostic and therapeutic method for chronic pelvic pain caused by pudendal neuralgia due to nerve entrapment. Additionally, the pudendal nerve block is a widely used regional anesthesia technique in gynecologic, obstetric, and anorectal procedures . It is particularly applied to provide perineal anesthesia during the second stage of vaginal delivery, vaginal repairs, and obstetric procedures including anorectal surgeries such as hemorrhoidectomy . Pudendal nerve blocks can effectively anesthetize the posterior perineum, anus, lower vagina, vulva/scrotum, and penis.
224071395|NCT00487539|BIOLOGICAL|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
224071396|NCT00487539|BIOLOGICAL|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -\> 50 mg arm group and at Week 2 for Golimumab 200 mg -\> 100 mg arm group.
223573475|NCT05966428|OTHER|Sensory Integration Therapy|"The Sensory Integration Therapy was applied to the intervention group in addition to the conventional exercise program. Sensory Integration Therapy included tactile, proprioceptive, and vestibular activities. The tactile sensory activities consisted of materials such as stepping stones, tactile box, brushing, fabric walking path. The vestibular sensory activities consisted of materials such as hammock swings, trampolines, rope nets, rock walls, river stones. Proprioceptive sensory activities consisted of materials such as weight bearing activities, heavy lifting, deep pressure, big ball activities, tug of war and ball pits.~The intervention group underwent each session 45 minute conventional therapy and 15 minutes SIT. The therapy program continued 3 days a week for 8 weeks in intervention group."
223573476|NCT03234855|DEVICE|LMD|Physician uses LMD to measure defect during procedure.
223573477|NCT03457506|DIAGNOSTIC_TEST|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
224155883|NCT04395989|DRUG|D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine|D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
224155884|NCT04395989|DRUG|D2: nab-paclitaxel, with maintenance of capecitabine|D2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
224155885|NCT04395989|DRUG|E1: everolimus with nab-paclitaxel|E1: everolimus 10mg po qd + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
224155886|NCT04395989|DRUG|E2: nab-paclitaxel|E2: nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle
224155887|NCT02471586|PROCEDURE|Coronary PCI guided by IVUS|Imaging type
224155888|NCT02471586|PROCEDURE|Coronary PCI guided by OCT|Imaging type
224155889|NCT02471586|PROCEDURE|Coronary PCI guided by Angiography|Imaging type
224155890|NCT03793894|BEHAVIORAL|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
224155891|NCT03793894|BEHAVIORAL|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
224155892|NCT03793894|BEHAVIORAL|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
224155893|NCT03793894|BEHAVIORAL|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
224155894|NCT02668952|DRUG|0.9% Normal Saline (0.9% Sodium Chloride) injection|
224155895|NCT02668952|DRUG|Isolyte S injection|
223457418|NCT05320419|OTHER|Physiotherapy (PT group)|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretching, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, and scapular stabilization exercise, 3 times a week, and will be continued for 12 weeks.
223457419|NCT04855331|PROCEDURE|Laparoscopic pancreatoduodenectomy|Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
223457420|NCT04855331|PROCEDURE|Open pancreatoduodenectomy|Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
223457421|NCT06110598|DRUG|Capecitabine|Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
223457422|NCT02980406|DIETARY_SUPPLEMENT|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
223573478|NCT02938078|DEVICE|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
223573479|NCT00127283|DRUG|eptacog alfa (activated)|
224155896|NCT02970396|BEHAVIORAL|self-management|
224155897|NCT03809156|DRUG|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
224155898|NCT02231489|DRUG|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
224155899|NCT02231489|DRUG|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
224155900|NCT02231489|DRUG|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
223457423|NCT02980406|DIETARY_SUPPLEMENT|Glucose (control)|Glucose is not a FODMAP.
223457424|NCT01616160|DRUG|mometasone furoate|2 sprays/nostril BID
223457425|NCT03034837|DRUG|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
223457426|NCT03034837|DRUG|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
223457427|NCT03109626|DIETARY_SUPPLEMENT|DHA|
223743141|NCT03330522|OTHER|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
223743142|NCT03330522|OTHER|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. …. If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
224155901|NCT00441727|DRUG|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
224155902|NCT00441727|DRUG|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
224155903|NCT00441727|DRUG|Placebo|Placebo once daily
224155904|NCT03042195|OTHER|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
223457428|NCT03327857|BIOLOGICAL|Neihulizumab (ALTB-168)|"Single dose phase: Patients will receive single dose of Neihulizumab based on the protocol escalation criteria.~Multiple dose phase: Parients will receive weekly doses of Neihulizumab for 4 weeks."
223457429|NCT01564992|OTHER|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
223457430|NCT01492192|DRUG|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
223457431|NCT03789097|DRUG|Pembrolizumab|200 mg administered as an IV infusion over 30 minutes Q3W
223457432|NCT03789097|DRUG|Flt3L|an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
223457433|NCT03789097|RADIATION|Radiation|The target site will get 2 small treatments of radiation.
223457434|NCT03789097|DRUG|Poly ICLC|an immune cell activating factor. vials containing 1 ml of 2 mg/mL
223457435|NCT02309957|DEVICE|BioMatrix CRD|
223457436|NCT02497508|DRUG|nivolumab|
223457437|NCT00401518|DEVICE|Non-randomized ACADIA® Facet Replacement System|Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
223457438|NCT00401518|DEVICE|Randomized ACADIA® Facet Replacement System|Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
223457439|NCT00401518|DEVICE|Randomized Instrumented posterolateral fusion (PLF)|Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
223457440|NCT02601222|DRUG|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
223457441|NCT02601222|DRUG|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
223457442|NCT02601222|DRUG|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
223457443|NCT02858232|BIOLOGICAL|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
223457444|NCT06319729|DRUG|CDD-2105|A Chinese herbal medicine formula containing four granular herbs.
223457445|NCT06319729|DRUG|Placebo|Placebo
223457446|NCT01242241|DRUG|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
223457447|NCT01242241|DRUG|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
223573480|NCT02363374|DRUG|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
223573481|NCT02363374|RADIATION|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
223573482|NCT02363374|RADIATION|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
223573483|NCT02363374|DRUG|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
223457448|NCT03358381|PROCEDURE|the gap balance type of total knee arthroplasty|A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
223457449|NCT03358381|PROCEDURE|the measured resection type of total knee arthroplasty|A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
223573484|NCT02363374|PROCEDURE|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
223573485|NCT02496845|DRUG|VL#FIA3-30|Vasoactive dual treatment (MH30-01 \& IS045-01)
223573486|NCT01236092|OTHER|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
223573487|NCT00263640|BIOLOGICAL|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
223457450|NCT03507985|OTHER|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
223573488|NCT00263640|DRUG|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
223573489|NCT03417362|OTHER|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
223573490|NCT06225947|DRUG|Lemborexant 5 MG|The recommended dosage of Lemborexant(LEM) is 5 mg taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to the maximum recommended dose of 10 mg based on clinical response and tolerability.
223573491|NCT00287937|DRUG|vorinostat|Given orally
223743143|NCT02692599|BIOLOGICAL|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
223573492|NCT00287937|DRUG|paclitaxel|Given IV
223573493|NCT00287937|DRUG|carboplatin|Given IV
223743144|NCT02692599|BIOLOGICAL|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
223743145|NCT02154191|PROCEDURE|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
223743146|NCT04392297|DIAGNOSTIC_TEST|Bood leukocyte subsets|Determination of blood leukocyte subpopulations: myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells; circulating endothelial cells
223743147|NCT04392297|DIAGNOSTIC_TEST|CMV specific T-cells|CMV specific T-cells detected by flow cytometry
224067354|NCT07028606|PROCEDURE|Sandwich technique with xenograft, collagen membrane and simultaneous implant placement.|"All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft.~Osteotomy for implant will be carried out with advanced kit of roott\_system Switzerland brand, sandwich osteotomy technique will be carried out with three full thickness cuts using the tungsten carbide disc were performed in the form of two vertical cuts away from the neighboring teeth by 3 mm and one horizontal bony cut on the labial surface of alveolar ridge. Bone splitting chisels were used in sequential width (2 mm, 3 mm) and lightweight mallet to complete splitting of the bony segment, the surgical sites will be irrigated with sterile saline. Surgical flaps will be sutured to the pre-surgical level."
224067355|NCT07028606|BIOLOGICAL|Sandwich technique with (RGD), xenograft, collagen membrane and simultaneous implant placement.|"All surgery will be in upper arch, for sandwich osteotomy technique, after local anesthesia, crestal incision with buccal intrasulcular incisions will be done extending at least one tooth mesial and distal to the implant associated site. Full thickness mucoperiosteal flaps will be reflected to allow access for implant, distraction osteogenesis, xenograft with and with RGD.~Injectable RGD-bioconjugate Mussel Adhesive Proteins (RGD-MAPs) composite hydroxypropyl methylcellulose (HPMC) hydrogels . Previously we developed a novel type of injectable self-supported hydrogel (2 mg/ml of RGD-MAPs/HPMC) based porcine nano hydroxyapatite (MPH) for dental graft, which could good handling property, biodegradation or biocompatibility with the hydrogel disassembly and provided efficient cell adhesion activity and no inflammatory responses. Surgical flaps will be sutured to the pre-surgical level with 4-0 polyproline non resorbable suture utilizing a single interrupted suturing technique."
224067356|NCT07029126|DRUG|Fremanezumab|subcutaneous injection 225 mg monthly or 675 mg quarterly
224067357|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: PROSTVAC-V|Recombinant vaccinia virus vector antigen direct immunotherapy of the genus Orthopoxvirus. Administered by subcutaneous injection.
223573494|NCT00287937|OTHER|laboratory biomarker analysis|Correlative studies
223573495|NCT00287937|OTHER|pharmacological study|Correlative studies
223573496|NCT06235762|BEHAVIORAL|Nutritional Intervention|This clinical trial evaluate the effects of nutritional intervention (individualized and personalized for each patient) on anthropometric, biochemical and cardiovascular parameters in participants with type 2 diabetes mellitus
223573497|NCT00000630|BIOLOGICAL|HIVAC-1e|
223573498|NCT00000630|BIOLOGICAL|gp160 Vaccine (MicroGeneSys)|
223573499|NCT04024215|DEVICE|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
223573500|NCT05789186|DRUG|CAVO aromatherapy patch at 3% concentration+Fluoxetine hydrochloride mimetic|CAVO aromatherapy patch at 3% concentration enhances neuroelectrical activity in the brain (especially in the prefrontal cortex), exerting an antidepressant effect.Fluoxetine hydrochloride mimetic without drug treatment effect.
223573501|NCT05789186|DRUG|Fluoxetine hydrochloride tablet+CAVO aromatherapy patch at 0.1% concentration|Fluoxetine hydrochloride tablet was widely used selective 5-HT reuptake inhibitor (SSRI) that selectively inhibits the 5-HT transporter, blocks the reuptake of 5-HT by the presynaptic membrane, and prolongs and increases the effects of 5-HT, resulting in antidepressant effects.CAVO aromatherapy patch at 0.1% concentration without drug treatment effect.
223573502|NCT05789186|DRUG|Fluoxetine hydrochloride mimetic+CAVO aromatherapy patch at 0.1% concentration|Placebo without drug treatment effect
224155905|NCT03058848|DIETARY_SUPPLEMENT|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
223457451|NCT05552053|DEVICE|MWSH plus Candlelit Care|Candlelit Care is a virtual perinatal mental health application that builds on cognitive behavioral therapy (CBT) to provide Black, Indigenous and POC women and birthing parents access to culturally affirming mental health support during pregnancy. Driven by an integrated care team, women have access to self-guided therapeutic tools, peer coaching and education about perinatal mood disorders as a primary resource. This convenient and trauma informed app allows parents to see if their mental health symptoms warrant further treatment in a secure setting. The app also provides education of role transitions, discussion of types of interpersonal conflicts common around childbirth (including racial discrimination) and techniques for resolving them, and role-playing with feedback from other parents during groups. The goals are to improve self-advocacy skills; patient communication with medical providers and provide a support network with other Black pregnant women.
223457452|NCT05552053|DEVICE|MWSH|The Maternal Wellness Self Help (MWSH) app was created to help individuals to manage perinatal depression and anxiety. The app is designed is to meet the emotional needs of those who are pregnant, want to become pregnant or have given birth. This psycho-educational app informs and normalizes the range of emotional responses throughout the reproductive journey. By learning about perinatal mental health, this app hopes to empower patients to understand and name their experiences.
223457453|NCT02282163|DRUG|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
223457454|NCT04231240|DEVICE|Measure of ACT with IStat|Measure of ACT with a point of care device named IStat
223457455|NCT04748952|DEVICE|Densah burs|Osseodensification is a non-excavating implant site preparation technique. It creates a densified layer of surrounding bone through compaction autografting while simultaneously plastically expanding the bony ridge at the same time facilitating for placement of large diameter implants and also avoiding fenestration and dehiscence defects. The autografting occurs along the entire length of the osteotomy through a hydrodynamic process with the use of irrigation. The result is a consistently cylindrical and densified osteotomy.
223457456|NCT03895450|BEHAVIORAL|Aerobic Exercise Protocol|Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
223573503|NCT02156544|DRUG|CKD-519|
223573504|NCT02156544|DRUG|placebo|
223573505|NCT02333981|DEVICE|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
223573506|NCT02374658|BEHAVIORAL|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
223573507|NCT00003825|DRUG|pentosan polysulfate sodium|
223743148|NCT04392297|DIAGNOSTIC_TEST|serum CMV IgM / IgG antibodies|serum CMV IgM / IgG antibodies detected by ELISA
224305140|NCT02296021|DRUG|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
223573508|NCT00003825|PROCEDURE|quality-of-life assessment|
223573509|NCT02342379|DRUG|Bevacizumab|10mg/kg
223573510|NCT02342379|DRUG|TH-302|670mg/m2
223573511|NCT00769717|BEHAVIORAL|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
224067358|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: PROSTVAC-F|Recombinant fowlpox virus vector Antigen direct immunotherapy of the genus Avipoxvirus. Administered by subcutaneous injection.
224067359|NCT03315871|DRUG|MSB0011359C (M7824)|Fully human bifunctional fusion protein that combines immunoglobulin G1 (IgG1) anti-programmed death-ligand 1 (PD-L1) and Transforming growth factor, beta receptor II (TGFbetaRII) as a monoclonal antibody. Administered via intravenous (IV) infusion over 1 hour.
224067360|NCT03315871|BIOLOGICAL|Antigen direct immunotherapy: CV301|Recombinant vaccinia virus Antigen direct immunotherapy of the genus Avipoxvirus. Administered subcutaneously.
224155906|NCT02315105|PROCEDURE|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
224155907|NCT04751058|GENETIC|genetic analysis|"Intervention details: sampling in peripheral blood for the Methodology:~1. Automatic DNA extraction (ChemagicTM 360)~2. Mass sequencing using SeqCap EZ Choice Library capture technology (NimbleGen) and NextSeq sequencer (Illumina).~3. Bioinformatic analysis:.~   * Identification of point mutations and small deletions or insertions~  * Analysis of CNVs using the BEDtools program package~  * Search of the identified variants in the following public databases: 1000G, dbSNP, ExAC, EVS, GenomADm CSVS and DGV. Those with a MAF\> 1% have been considered benign, in public or private databases of our population.~The analysis process has focused exclusively on the genes described to date as associated with the pathology under study and included in the panel used. The reference sequences used for these genes are: determination of possible mutations, nucleotics, etc."
224155908|NCT04067115|DRUG|Trabectedin 1 MG [Yondelis]|Patients with Ewing sarcoma will be administered trabectedin intravenously. Cycles are 21 days.
224155909|NCT04067115|DRUG|Irinotecan|Patients with Ewing sarcoma will be administered inirotecan intravenously. Cycles are 21 days.
224302693|NCT05497193|DRUG|perampanel|China's state food and drug administration approved indications for adults and children aged 4 or more focal epileptic hair company or not with secondary comprehensive seizures of epilepsy, adding treatment, in July 2020 to monotherapy without clinical approval, the current domestic perampanel monotherapy clinical effectiveness and safety of focal epilepsy in children have not been reported.
224302694|NCT00140426|DRUG|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
224302695|NCT00140426|DRUG|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
224302696|NCT01760525|DRUG|CGM097|Patients treated with CGM097
224302697|NCT02651779|PROCEDURE|Open reduction and internal plate fixation|
224302698|NCT02651779|OTHER|Closed reduction and plasterimmobilisation|
224302699|NCT02149108|DRUG|Nintedanib (BIBF 1120)|
224302700|NCT02149108|DRUG|Placebo|
224302701|NCT02149108|DRUG|BSC|
224302702|NCT02149108|DRUG|BSC|
224302703|NCT03281863|DIAGNOSTIC_TEST|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
224302704|NCT06483139|PROCEDURE|Plasma exchange|Patients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
224302705|NCT06483139|DRUG|Daratumumab|Patients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
224302706|NCT04047914|DEVICE|Antimicrobial Photodynamic therapy|"Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2"
223457457|NCT03895450|BEHAVIORAL|Stretching Protocol|Participants will follow a stretching protocol for 30 minutes a day, 5 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
223743149|NCT05884047|DEVICE|Virtual Glasses|"In the research, Samsung Gear VR SM-R323 brand and model SG glasses provided by the researcher were used. Patients were offered four different options to watch as Forest of Serenity, Calm Place, Happy Place, Gala 360 Travel \& Relax. Forest of Serenity is a nature video consisting of bird sounds, colorful trees and flowers, and a clear lake where fish can be seen swimming in it. Calm Place is a relaxing video where cycles are shown 24 hours a day, where a person finds himself by the lake in the forest in snowy, rainy sunny weather. In Happy Place, one finds himself in a virtual camp environment where natural events such as dynamically changing weather, day-night cycles, and falling stars are experienced. Gala 360 Travel \& Relax is a Paris-Notre Dame museum tour video."
224302707|NCT04047914|DRUG|Mupirocin ointment|Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
224302708|NCT03716414|PROCEDURE|SLN mapping|"Intra-operative SLN mapping with indocyanine green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
224302709|NCT02775708|DEVICE|Pillcam endoscopy system|
224302710|NCT00627315|PROCEDURE|Gastric bypass|NOTE: Surgery will not be paid by the study
224302711|NCT00627315|PROCEDURE|Gastric banding|NOTE: Surgery will not be paid by the study
224302712|NCT03508505|DEVICE|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
224302713|NCT01776697|DRUG|pelubiprofen (30mg) tablet IR|
224302714|NCT01776697|DRUG|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
224302715|NCT04765384|BIOLOGICAL|Ad26.COV2.S|Participants will receive intramuscular (IM) injection of Ad26.COV2.S.
224302716|NCT03202524|BIOLOGICAL|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
223457458|NCT04203251|DEVICE|Caption Health Guidance Technology|
223457459|NCT01603407|DRUG|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
223457460|NCT01603407|DRUG|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
223743150|NCT04506476|DEVICE|"Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C"|"Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy."
224155910|NCT04067115|DIAGNOSTIC_TEST|tumor biopsy|Tumor tissue samples will be collected collected at two timepoints. The first biopsy will be prior to treatment. If a biopsy is not possible archival tissue may be submitted. A second tumor biopsy will be taken fro consenting patients when possible after the first administration of Trabectedin to evaluate the effect on the tumor cells.
224155911|NCT04067115|OTHER|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|Some patients will receive PET scans with the use of 18F-FLT, a radioactive tracer, performed at the National Institute of Health.
224155912|NCT06105853|BEHAVIORAL|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors, representing the judging panel, and a faked exam situation (15 minutes duration).
223457461|NCT01603407|DRUG|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
224155913|NCT06105853|BEHAVIORAL|Barlab Cue-Exposure|Participants are exposed to a bar situation with their individual favorite alcohol presented. They handle their favorite alcoholic drink and water (9 minutes duration).
224155914|NCT06105853|BEHAVIORAL|Functional magnetic resonance imaging|Participants undergo a fMRI screening including three different behavioral tasks assessing alcohol cue reactivity, response inhibition, and emotion processing
224155915|NCT01290055|BIOLOGICAL|Yellow fever vaccine|The yellow fever vaccine (YFV-17D) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug Service (IDS) between 2 to 8 degrees Celsius as per the manufacturer's instructions. It will be transported to the Hope Clinic per the Standard Operating Procedures.
224155916|NCT01290055|OTHER|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1 Liter containers. An Emory Investigational Drug Service (IDS) pharmacist will prepare sterile 50 milliliter aliquots with a tamper seal which will be transported to the Hope Clinic at room temperature.
224155917|NCT06225284|DRUG|Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg|After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.
224155918|NCT01700647|OTHER|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
224155919|NCT01700647|OTHER|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
224302717|NCT03202524|BIOLOGICAL|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
224302718|NCT02554136|DRUG|HGP0918|
224302719|NCT02554136|DRUG|HGP0816|
224302720|NCT02554136|DRUG|HGP0918 + HGP0816|
223457462|NCT05867225|PROCEDURE|Laparoscopic hiatal hernia repair|laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
223457463|NCT05615142|RADIATION|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.
223457464|NCT05615142|RADIATION|stereotactic body radiation therapy|Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.
223457465|NCT05615142|DRUG|PD-1 Inhibitors|Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.
223457466|NCT00574093|DRUG|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
223457467|NCT03648138|BEHAVIORAL|Sugary drink warning labels|This information appears in the description of the study arms.
223457468|NCT02500719|DEVICE|Computational Model - Real-time Support Vector Machine|A support vector machine algorithm will be applied in real-time to fMRI data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory (note, this is equivalent to predictions of fitted Q-iteration in which the all actions are specified as zero, reward is equal to the support vector machine predicted arousal, and the discount factor of 0). The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
223457469|NCT03127709|BEHAVIORAL|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
223457470|NCT03127709|BEHAVIORAL|Brief Test of Attention|Assesses auditory working memory
223457471|NCT03127709|BEHAVIORAL|Symbol Span|Assesses visual working memory
223457472|NCT03127709|BEHAVIORAL|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
223457473|NCT03127709|BEHAVIORAL|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
223457474|NCT03127709|BEHAVIORAL|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
223457475|NCT03127709|BEHAVIORAL|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
223457476|NCT03127709|BEHAVIORAL|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
223743151|NCT05543876|PROCEDURE|suturing procedure|Children presenting to the emergency department for suturing
223457477|NCT03127709|DIAGNOSTIC_TEST|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
223457478|NCT03127709|DIAGNOSTIC_TEST|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
223743152|NCT03582020|DIETARY_SUPPLEMENT|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
223743153|NCT03925740|DRUG|MI Varnish|Application of MI varnish material versus the standard 1.23% APF.
223743154|NCT03925740|DRUG|PreviDent Varnish|Application of PreviDent Varnish material versus the standard 1.23% APF.
224067361|NCT03315871|DIAGNOSTIC_TEST|CT scan of chest|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
224067362|NCT03315871|DIAGNOSTIC_TEST|CT scan of abdomen/pelvis|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
224067363|NCT03315871|DIAGNOSTIC_TEST|MRI|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
224067364|NCT03315871|DIAGNOSTIC_TEST|PSMA|Biochemical recurrence group only. Screening, prior to Antigen direct immunotherapy therapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
224067365|NCT03315871|DIAGNOSTIC_TEST|Bone scan|Screening, prior to Antigen direct immunotherapy, end of study therapy, then every 6 months as long as participants remain in follow-up. And as clinically indicated after one year.
224067366|NCT06067555|DEVICE|MicronJet|MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
223457479|NCT03127709|BEHAVIORAL|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
223457480|NCT03074461|PROCEDURE|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
223457481|NCT03074461|PROCEDURE|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
223457482|NCT03125850|OTHER|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
223457483|NCT03125850|OTHER|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
223457484|NCT03746639|OTHER|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
223457485|NCT05178693|DRUG|ASTX727|Cedazuridine 100mg + 35mg decitabine
224067367|NCT06067555|BIOLOGICAL|Fluzone® Quadrivalent|Intradermal injections of 0.3mL
224067368|NCT06067555|BIOLOGICAL|Fluzone® Quadrivalent|Intramuscular injection of 0.3mL
223457486|NCT05178693|RADIATION|Lutathera|Peptide receptor radionuclide therapy (PRRT)
223743155|NCT03925740|DRUG|1.23% APF|Standard 1.23% APF application
223743156|NCT02144441|DRUG|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
223743157|NCT02295033|RADIATION|Boost irradiation|
223743158|NCT03594279|BEHAVIORAL|Community Mobilization|Community Mobilization
224067369|NCT06067555|OTHER|Bacteriostatic Saline|Intradermal injection of 0.3mL (control)
224067370|NCT05952557|DRUG|Camizestrant|Camizestrant. Experimental. Administered orally
224067371|NCT05952557|DRUG|Tamoxifen|Tamoxifen. Comparator. Administered orally
224067372|NCT05952557|DRUG|Anastrozole|Anastrozole. Comparator. Administered orally
224067373|NCT05952557|DRUG|Letrozole|Letrozole. Comparator. Administered orally
224067374|NCT05952557|DRUG|Exemestane|Exemestane. Comparator. Administered orally
224067375|NCT05952557|DRUG|Abemaciclib|Abemaciclib adjuvant treatment Administered orally
224067376|NCT06781814|DIETARY_SUPPLEMENT|Probiotic|Probiotic strips with different strain formulas, specification: 3g/bag. Storage method: Keep away from light, seal tightly, and store in a cool, dry place.
224071397|NCT00487539|BIOLOGICAL|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -\> 100 mg arm group and at Week 2 for Golimumab 400 mg -\> 200 mg arm group.
223457487|NCT04420117|OTHER|Perioperative assessment of physical capacity|Evaluation of physical capacity with the Short Physical Performance Battery (SPPB) questionaire
223743159|NCT03594279|BEHAVIORAL|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
223457488|NCT01245153|OTHER|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
223457489|NCT01245153|OTHER|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
223457490|NCT01473706|OTHER|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
223743160|NCT06241079|OTHER|non-intervention|non-intervention
224071398|NCT00487539|BIOLOGICAL|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -\> 200 mg arm group.
224071399|NCT00487539|BIOLOGICAL|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -\> 50 mg arm group.
224071400|NCT01659008|DRUG|Estradiol|
224071401|NCT01659008|DRUG|Lysteda|
224071402|NCT01926288|DRUG|Entecavir maleate tablets|
224071403|NCT01926288|DRUG|blank Baraclude tablets|
224071404|NCT01926288|DRUG|Blank maleate entecavir tablets|
224071405|NCT01926288|DRUG|Baraclude tablets|
224071406|NCT01394588|DEVICE|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
224071407|NCT03440814|DRUG|DCCR|Once daily oral administration
224071408|NCT03440814|DRUG|Placebo for DCCR|Once daily oral administration
224071409|NCT03477760|BIOLOGICAL|rectal swab for Multi-Drug resistant bacteria|A rectal swab will be performed at admission of patients to look for intestinal carriage of Multi-Drug resistant bacteria
224071410|NCT06421558|DEVICE|Neubie Direct Current Electrical Stimulation Device|Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.
224071411|NCT06421558|DEVICE|Transcutaneous Electrical Stimulation|Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
224071412|NCT05706389|DIETARY_SUPPLEMENT|Ca-AKG|Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
224071413|NCT00879697|BEHAVIORAL|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
224071414|NCT00879697|BEHAVIORAL|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
224071415|NCT02195388|OTHER|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
224071416|NCT04885725|DEVICE|All group|All the participants performed the isokinetic proprioception and strength tests and the functional tests, on the same visit.
224071417|NCT02774837|DRUG|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
224071418|NCT02774837|DRUG|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
224071419|NCT06241846|DRUG|YL201 for Injection|Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.
224071420|NCT00847483|DRUG|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
224071421|NCT00847483|DRUG|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
224071422|NCT00847483|DRUG|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
224071423|NCT04627272|DEVICE|AutoDX-DR|AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.
224071424|NCT01201161|DRUG|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
224071425|NCT01201161|OTHER|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
224071426|NCT01565733|DRUG|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
224071427|NCT05448911|PROCEDURE|Intraoperative navigation combined with Catheter screw technique|It uses minimally invasive small incisions, physiological access to the pelvis, and hollow screws for Pelvic and Acetabular fractures
224071428|NCT05448911|PROCEDURE|Open reduction and internal fixation with steel plate|Open reduction and plate internal fixation is the most commonly used method to treat pelvic fracture, which can achieve anatomical reduction and rigid fixation. However, this method requires extensive dissection of the surrounding soft-tissue fracture and is invasive
224071429|NCT03593252|DRUG|Senna|Laxative,used for bowel preparation
224071430|NCT03593252|DRUG|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
224071431|NCT03593252|DRUG|Metronidazole Oral|Oral antibiotic
224071432|NCT03593252|DRUG|Neomycin|Oral non-absorbable antibiotic
224071433|NCT03593252|DRUG|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
224071434|NCT03593252|DRUG|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
224071435|NCT03593252|OTHER|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for \>=8 hours, no formula milk/full liquids \>= 4hours; no breast milk or clear fluids \>=2hours.
223457491|NCT01990768|DRUG|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
223457492|NCT01990768|DRUG|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
223457493|NCT01990768|DRUG|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
223457494|NCT03418597|PROCEDURE|Deep local anesthesia + Virtual reality|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.
223573512|NCT00769717|BEHAVIORAL|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
223573513|NCT02863523|BEHAVIORAL|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
223743161|NCT05505357|PROCEDURE|Breast surgery omission|For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
223743162|NCT01092182|DRUG|EPOCH-R|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
223743163|NCT01092182|DRUG|EPOCH-RR|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
223457495|NCT03418597|PROCEDURE|Deep local anesthesia alone|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
223457496|NCT05393297|DIAGNOSTIC_TEST|Imaging: Intra-treatment FDG-PET-CT and MRI|FDG-PET-CT and MRI scan will be used during radiotherapy to assess early treatment response and identify tumours eligible for dose-escalation.
223457497|NCT05393297|RADIATION|Intra-treatment Image-Guided Adaptive Radiotherapy Dose-escalation|Tumours eligible for dose-escalation (boost), as seen on intra-treatment FDG-PET-CT and MRI scan, will receive 76.9 Gy to the residual gross primary tumour. The radiotherapy plan will be replanned to incorporate the simultaneous-integrated-boost to the GTVp which will be delivered over the last 3 weeks of treatment
223743164|NCT03194555|DRUG|Low-Dose Naltrexone and Acetaminophen Combination|Twice daily
223743165|NCT03194555|DRUG|Placebo|Twice daily
223743166|NCT01423487|DRUG|Metformin|0.5g bid 26 weeks
223743167|NCT01423487|OTHER|Starch tablets|0.5g bid 26 weeks
224071436|NCT03593252|OTHER|Clear fluids the day before surgery|As part of bowel preparation, participants will be asked to stick to clear fluids following breakfast the day before surgery. Breast milk is allowed if applicable.
224071437|NCT00756873|DRUG|Administration of placebo|Placebo qd orally day 0-14
224071438|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
224071439|NCT00756873|DRUG|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
224071440|NCT05235035|BEHAVIORAL|Night shift work|Subjects are exposed to irregular sleep and sleep misalignment due to hospital night shifts.
223457498|NCT00966732|BEHAVIORAL|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
223457499|NCT05500014|OTHER|Biofortified potato, not genetically modified|Cooked potato, not genetically modified, with the addition of an acqueous solution of 57FeSO4 (3 mg in total).
223457500|NCT00415324|DRUG|eribulin mesylate|Given IV
223457501|NCT00415324|DRUG|cisplatin|Given IV
223457502|NCT00415324|OTHER|laboratory biomarker analysis|correlative study
223457503|NCT00415324|OTHER|pharmacological study|correlative study
224071441|NCT01386359|DRUG|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
224071442|NCT03506555|PROCEDURE|Laparoscopic peritoneal entry technique: Veress needle versus Hasson|According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
224071443|NCT00301951|BIOLOGICAL|anti-thymocyte globulin|
224071444|NCT00301951|BIOLOGICAL|sargramostim|
224071445|NCT00301951|DRUG|busulfan|
224071446|NCT00301951|DRUG|fludarabine phosphate|
224071447|NCT00301951|DRUG|mycophenolate mofetil|
224071448|NCT00301951|DRUG|tacrolimus|
224071449|NCT00301951|PROCEDURE|umbilical cord blood transplantation|
224071450|NCT05566756|OTHER|Ofatumumab|There is no treatment allocation. Patients administered Ofatumumab by prescription will be enrolled.
224071451|NCT04647500|DRUG|Concerta|Evaluation of a treatment of Concerta over a period of 13 days.
224071452|NCT00088374|DRUG|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
224071453|NCT00088374|DRUG|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
223457504|NCT04029259|DIAGNOSTIC_TEST|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
224155920|NCT03235726|DRUG|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
224155921|NCT03235726|DRUG|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
224155922|NCT04813302|PROCEDURE|Coronally advanced flap and connective tissue graft|CAF+CTG treatment will be performed by starting with two vertical releasing incisions lateral to the teeth to be treated and split-full-split thickness flap will be raised beyond the MGJ. The periosteum will be cut, and a blunt dissection into the vestibular lining mucosa will be carried out to eliminate muscle tension so that the mucosal flap can be passively positioned above the level of CEJ on the tooth. The papillae adjacent to the involved teeth will be de-epithelialized. CTG of 1mm in thickness will be harvested from the posterior palate by means of disepithelization of a free gingival graft, cut to the exact size of the defect, and placed over the dehisced defect, sutured to the interdental papillae and subsequently covered with CAF. Sling sutures will be placed to stabilize the flap in a coronal position about 1-2 mm above the CEJ , followed by interrupted sutures to close the releasing incisions.
224155923|NCT01709214|DRUG|Cebranopadol (GRT6005) Low-Dose Range|Capsules
224155924|NCT01709214|DRUG|Cebranopadol (GRT6005) High-Dose Range|Capsules
224155925|NCT01709214|DRUG|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
224155926|NCT01709214|DRUG|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
224155927|NCT04436783|DEVICE|Virtual Reality Epley Maneuver System (VREMS)|The VREMS system includes a smartphone placed inside virtual reality goggles worn by the participant. On the smartphone there is a virtual reality application. When viewed through the VR goggles the participants see a three-dimensional environment. Audio and text cues are presented in a 3D environment to help guide the patient through the Epley maneuver.
224155928|NCT04436783|OTHER|Instructional Handout (IH)|Patients randomized to the IH group will be given an instructional handout with image and text-based instructions on the steps involved in performing the Epley maneuver. They will then be given the chance to perform the Epley maneuver.
224155929|NCT02003118|DRUG|AKR 202|
224155930|NCT02003118|DRUG|Placebo|
224155931|NCT05975372|DEVICE|Blossom tissue expander|Mentor spectrum adjustable saline breast implant for expansion is placed with the Blossom tissue expander above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
224155932|NCT05975372|DEVICE|Standard tissue expansion|Mentor spectrum adjustable saline breast implant for expansion is placed with (without the Blossom tissue expander) above pectoralis major during first stage surgery of an implant-based breast reconstruction/ augmentation.
224155933|NCT02864706|DRUG|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
224155934|NCT02864706|DRUG|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
224155935|NCT02864706|DRUG|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
224155936|NCT02864706|DRUG|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
224155937|NCT03135262|DRUG|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams \[mg\], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
224155938|NCT03135262|DRUG|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
224155939|NCT03135262|DRUG|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
224155940|NCT03135262|DRUG|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment.
224155941|NCT04415190|OTHER|early palliative care|early palliative care
224155942|NCT05442125|OTHER|Using DNA methylome to select embryos|DNA methylation level Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
224155943|NCT05442125|OTHER|Using morphologic score to select embryos|blastocyst will transferred according to morphologic score or blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
224302721|NCT01971970|BIOLOGICAL|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
224302722|NCT01971970|BIOLOGICAL|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
223457505|NCT03538691|DRUG|Brexpiprazole|Administered as tablets.
223457506|NCT03538691|DRUG|Antidepressant therapy|"Protocol-specified oral ADTs included:~citalopram hydrobromide (Celexa®) tablets, escitalopram (Lexapro®) tablets, fluoxetine (Prozac®) capsules, paroxetine (Paxil CR®) controlled-release tablets, sertraline (Zoloft®) tablets, duloxetine (Cymbalta®) delayed-release capsules, venlafaxine XR (Effexor XR®) extended-release (XR) capsules."
223457507|NCT03915483|DEVICE|transcranial direct current stimulation (tDCS)|sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
223457508|NCT05424354|DEVICE|Altrazeal (R) Transforming Powder Dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.
224155944|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold spreaded with photoinduced-imine-crosslink hydrogel|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
224155945|NCT06508151|PROCEDURE|neovaginoplasty and vaginal mold|Under general anesthesia and catheterized bladder, the patient was in the lithotomy position. In the connective tissue plane between the bladder and rectum, the vestiges of the müllerian ducts were identified. With the index finger in the rectum as a direction and protection, Hegar's dilators of increasing size (4.5-10) were pushed through the dimples gently. After that, a double-barreled canal appeared. Then, the raphe between the canals was incised. The neovagina was created. According to the randomization, a vaginal mold spreaded with hydrogel or not was placed in the neovagina for 6 months. The patients were suggested to wear the vaginal mold continuously over the following 6 months. After that, they were allowed to have the first sexual intercourse. Otherwise, the mold wearing time was 1 h daily, until they had sexual activity at least twice a week.
224155946|NCT04002258|DRUG|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
224155947|NCT01675141|DRUG|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
224155948|NCT02057276|DEVICE|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
224155949|NCT02057276|DEVICE|Sham Repetitive Transcranial Magnetic Stimulation|
224155950|NCT02057276|OTHER|Occupational Therapy|
224155951|NCT00810095|DEVICE|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
224155952|NCT02030665|BEHAVIORAL|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
224155953|NCT02030665|BEHAVIORAL|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
224155954|NCT02030665|BEHAVIORAL|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
224155955|NCT04535206|DIAGNOSTIC_TEST|Venous blood collecting and test and ultrasound screening|To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
224155956|NCT01770093|OTHER|Questionnaire|
224155957|NCT03046160|OTHER|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
224155958|NCT03046160|OTHER|neck and scapular exercises.|A program of 12 neck and scapular exercises.
224155959|NCT03046160|OTHER|corrective tape|elastic tape used to correct the anterior tilt of the scapula
224155960|NCT01599806|DRUG|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
224155961|NCT01599806|DRUG|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
224155962|NCT01599806|DRUG|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
224155963|NCT01599806|DRUG|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
224155964|NCT05325944|BEHAVIORAL|Self-guided digital intervention for NSSI|"Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies."
224155965|NCT05325944|BEHAVIORAL|Digital intervention for NSSI with coaching|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.
224155966|NCT05325944|BEHAVIORAL|Active control|Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
224155967|NCT01407848|DRUG|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
224155968|NCT01407848|DRUG|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
224155969|NCT00489034|BEHAVIORAL|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
224302723|NCT02728570|OTHER|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
223457509|NCT05424354|OTHER|Standard of Care burn dressing|After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.
224302724|NCT02728570|OTHER|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
223457510|NCT06597084|DRUG|ESL 800 mg|800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
223457511|NCT06597084|DRUG|Placebo|Placebo tablets for oral administration, matching the test product. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
223457512|NCT04450914|BEHAVIORAL|CV Prevention Choice Tool|The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.
223457513|NCT04450914|BEHAVIORAL|Implementation Facilitation Strategies|During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
223457514|NCT01583283|DRUG|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
223457515|NCT01583283|DRUG|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
223457516|NCT01583283|DRUG|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
223457517|NCT05907187|BEHAVIORAL|Cervical Cancer Prevention Education|Participants will receive in-person, one-time health education on the importance of cervical cancer screening using a short intervention/educational script; and motivation to encourage women to have human papillomavirus (HPV) screening. Participants will also be informed of the nature and risks of HPV infection, and the importance of seeing a doctor including having a gynecologic exam.
223457518|NCT05542251|BEHAVIORAL|Parent Educational Program|The intervention is a series of 9 educational modules delivered via social media that will teach participants: 1) principles of infant learning, 2) principles of infant motor learning, and 3) principles of positive parenting.
223457519|NCT00696007|DRUG|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
223457520|NCT00696007|OTHER|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
223457521|NCT04930614|OTHER|Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour|Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
223457522|NCT00431145|DRUG|Niacin|
223573514|NCT02972541|DEVICE|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
223573515|NCT02972541|DEVICE|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
223573516|NCT02822131|DIETARY_SUPPLEMENT|sodium phosphate|
223457523|NCT00431145|DRUG|Niacin+Statin|
223457524|NCT01403259|DRUG|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
223457525|NCT04329325|BIOLOGICAL|Blinatumomab|Please see detailed summary.
223457526|NCT04329325|DRUG|dasatinib|Please see detailed summary.
223457527|NCT04329325|DRUG|dexamethasone|Please see detailed summary.
223457528|NCT04329325|DRUG|methotrexate|Please see detailed summary.
223457529|NCT02185807|PROCEDURE|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
223457530|NCT02185807|PROCEDURE|control group|The control patients receive verbal information and discussion from their physicians.
223457531|NCT03762005|OTHER|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
223457532|NCT03762005|OTHER|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
223457533|NCT00768885|DEVICE|PureVision 1|Currently marketed PureVision soft contact lens.
223457534|NCT00768885|DEVICE|PureVision 2|Alternate design soft contact lens.
223457535|NCT00370097|DRUG|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
223457536|NCT00370097|DRUG|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
223457537|NCT01027377|DRUG|rFVIIIFc|Single dose
223457538|NCT01027377|DRUG|rFVIIIFc|Single dose
223573517|NCT02822131|DRUG|sevelamer, sodium bicarbonate, sodium chloride|
223573518|NCT04176120|BIOLOGICAL|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
223573519|NCT04176120|OTHER|Standard Care|"Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics."
223573520|NCT01110798|OTHER|intraoperative complication management/prevention|
223573521|NCT01110798|PROCEDURE|assessment of therapy complications|
223573522|NCT01110798|PROCEDURE|gastrointestinal complications management/prevention|
223573523|NCT01110798|PROCEDURE|quality-of-life assessment|
223573524|NCT01110798|PROCEDURE|therapeutic conventional surgery|
224071454|NCT00088374|DRUG|[15-O] H2O|\[15-0\] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
223457539|NCT04551560|OTHER|Mental Stress|Patients will undergo a lab mental stress protocol, and a field protocol using ecological momentary assessment (EMA) to test the effects of psychological stress and negative emotion on PAP in HF patients.
223457540|NCT06481124|DEVICE|electrical impedance tomography|Measurement of ventilation and perfusion during mechanical ventilation with different positive end-expiratory pressure by electrical impedance tomography
223457541|NCT04215692|DIAGNOSTIC_TEST|Pulmonary ultrasound|Pulmonary ultrasound is a basic application of critical ultrasound, defined as a loop associating urgent diagnoses with immediate therapeutic decisions.
223457542|NCT06612580|DRUG|68Ga-AAZTA-NI-093|Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.
223457543|NCT06612749|OTHER|Integrative medicine including manual and/or mind-body treatments|Referred HCPs are recommended a multi-modal IM program, include at least one of the following: acupuncture; manual-movement therapies (e.g., acupressure, Anthroposophic medicine touch therapies, reflexology, Qi Gong, and Feldenkrais method); and mind-body medicine (e.g., relaxation and breathing techniques).
223457544|NCT06612684|DEVICE|Piezoelectric syndesmotomy|Syndesmotomy, the first phase of tooth extraction, will be provided by a piezoelectric device instead of manual instruments.
223457545|NCT06867926|OTHER|Cardiac rehabilitation|Individuals diagnosed with coronary artery disease will engage in a programme of cardiac rehabilitation.
223457546|NCT07022964|DRUG|CD5 CAR-T cells infusion|Approximately 3-5 days prior to CD5 CAR-T cell infusion, subjects are treated with FC regimen (fludarabine and cyclophosphamide) for lymphodepletion. CAR-T cell infusion are performed 48 h after completion of chemotherapy.
223457547|NCT03479944|PROCEDURE|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
223457548|NCT03479944|PROCEDURE|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
223457549|NCT03479944|DEVICE|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
223457550|NCT03479944|DEVICE|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
223457551|NCT00729300|DRUG|placebo|0mg daily
223457552|NCT00729300|DRUG|disulfiram|250mg daily
223457553|NCT06087705|DEVICE|Intra-articular injection of hyaluronic acid|"The injection must necessarily be performed by a practitioner in compliance with the rules of asepsis.~Procedure of use:~* Before the injection, a rigorous prior disinfection of the area to be treated will be carried out.~* Check the integrity of the sterility protector.~* Take the syringe and remove the protective tip.~* Hold the syringe body and insert a sterile intra-articular injection needle into the Luer-Lock system.~* Gently turn the needle clockwise to secure the needle in the Luer-Lock system.~* A visual check of the attachment of the needle will be carried out.~* Remove the needle cap.~* Inject slowly."
223573525|NCT02702531|DEVICE|FloShield Defogging and Cleaning System|
224155970|NCT00489034|BEHAVIORAL|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
223457554|NCT00819481|DEVICE|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
223457555|NCT05834127|OTHER|Aerobic exercise|"Group A will receive aerobic exercise in the form of warm up and cool down (both for 5 min)~* Treadmill (30 min) based on Target Heart Rate (calculated using Karvina formula at 60%-70% of heart rate reserve).~* Treatment will be given 3 times a week for 1 month"
223457556|NCT05834127|OTHER|Yoga Exercises|"Group B will receive yoga movements for 40 min, 3 times a week for 1 month.~* They will be given yoga movements, including 10 min of Kapalbharti Pranayama which includes automatic inhalation with short and forceful exhalations.~* 20 min of yoga movements (Cat-cow pose, Child's pose, Plank pose, Cobra pose - each for 5 min).~* 10 min of meditation/relaxation in Savasana pose"
223457557|NCT02870556|DEVICE|cervical epidural analgesia|
223457558|NCT02963636|OTHER|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
223457559|NCT06239181|BEHAVIORAL|Breathing Exercises|The patients in the intervention group scheduled for angiography were administered the Beck Anxiety Scale, and then they underwent conscious, deep breathing exercises along with synchronized breathing training. The face-to-face teaching and application of the breathing exercises took an average of 15-20 minutes. Additionally, routine treatment was applied. For both the intervention and control groups, the Beck Anxiety Scale was administered again after the completion of the coronary angiography procedure, once stabilization was achieved.
223457560|NCT06239181|OTHER|no intervention/routine procedure|Beck Anxiety Scale was administered to the control group before coronary angiography. No intervention was performed in between. The routine procedure of the hospital continued. Beck Anxiety Scale was administered again after leaving the procedure.
223457561|NCT04823390|DRUG|Midazolam-Fentanyl combination|Sedation is given to patients undergoing cataract surgery under local anesthesia
223457562|NCT04760535|DEVICE|Invisalign® First Phase I treatment (Align Technology, Inc., Santa Clara, CA, USA)|Subjects in this arm will be instructed to wear aligners 24h/day for entire duration of the therapy. They will be asked to remove their retainers only while eating, drinking (except water), or cleaning. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
223457563|NCT04760535|DEVICE|Tooth-borne Hyrax-type maxillary expander|The expansion protocol was one quarter-turn twice a day (0.45 mm activation per day) until overcorrection with the maxillary lingual cusps contacting the mandibular buccal cusps. The expander was left passively for retention for a minimum of 6 months. At the time of appliance delivery, both written and verbal oral hygiene instructions were given, including methods for cleaning appliances themselves. Also, written informed consent were obtained for each patient or the parents.
223457564|NCT01440634|OTHER|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
223457565|NCT02029274|DRUG|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
223457566|NCT02029274|DRUG|Placebo|Matching placebo to BAF312 as tablets for oral administration.
223457567|NCT06877949|DIAGNOSTIC_TEST|FDG-PET/CT|FDG-PET/CT is used regulary for a continuous, long term monitoring
223457568|NCT06877949|DIAGNOSTIC_TEST|CE-CT|CE-CT is used regulary for a continuous, long-term monitoring
223457569|NCT06880809|BEHAVIORAL|Bridge the Gap (BTG) - Black Youth Group|Participants will complete a group intervention, rooted in the Collaborative Assessment \& Management of Suicidality (CAMS) evidence-based model, driven by their own unique identification of suicide drivers.
223457570|NCT06892990|DIAGNOSTIC_TEST|TXI mode vs. WLE mode|Experimental use of TXI mode compared to standard use of WLE to assess inflammatory activity in patients with IBD during ileocolonoscopy. Both endoscopy modes are used during the same ileocolonoscopy on the same patient.
223457571|NCT04758247|DEVICE|TheraNova Neuromodulation System|The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
223457572|NCT05803759|DIETARY_SUPPLEMENT|Allicor|Each capsule contains 150 mg dried garlic powder
223457573|NCT05803759|DRUG|Placebo|Capsules manufactured to mimic Allicor 150 mg capsules
223573526|NCT00915655|DRUG|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
223573527|NCT00915655|DRUG|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
223573528|NCT00915655|DRUG|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
224155971|NCT00489034|BEHAVIORAL|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
224155972|NCT03149926|OTHER|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
223743168|NCT04559815|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
224302725|NCT06351475|OTHER|Intra-operative albumin administration|Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.
224302726|NCT06351475|OTHER|Control|Ringer lactate
224302727|NCT05107388|DEVICE|FreeStyle Libre Pro|Measurements of interstitial glucose variations with FreeStyle Libre Pro
223457574|NCT03678415|BEHAVIORAL|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
223573529|NCT00915655|DRUG|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
223573530|NCT00915655|DRUG|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
223743169|NCT01831154|DRUG|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
223743170|NCT01831154|DRUG|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
223743171|NCT01831154|DRUG|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
223743172|NCT03831347|BEHAVIORAL|Hatha Yoga|12 weeks of Hatha Yoga
223743173|NCT01254526|DRUG|GDC-0980|Oral repeating dose
224067377|NCT06900777|DRUG|Tacrolimus|Participants receive oral tacrolimus capsules at a dosage of 0.1 ± 0.05 mg/kg per day, divided into two administrations. The treatment duration is 24 weeks. Blood drug concentration is monitored to maintain trough levels between 7-15 ng/mL. Safety assessments include regular blood tests (hematology, liver/kidney function, blood glucose) and adverse event tracking.
224067378|NCT06900777|DRUG|Dexamethasone|Participants receive oral dexamethasone tablets at a dosage of 0.05 ± 0.025 mg/kg per day, administered as a single dose on weekends (Saturday and Sunday). The treatment duration is 24 weeks. Safety evaluations include monitoring of blood parameters (hematology, liver/kidney function, blood glucose), weight, and adrenal function (cortisol, ACTH levels).
224067379|NCT02907398|DEVICE|Inspire therapy|
224067380|NCT02907398|OTHER|No intervention|
224067381|NCT04305795|BIOLOGICAL|200 mg Pembrolizumab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
224067382|NCT04305795|BIOLOGICAL|350 mg Cemiplimab|every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
224067383|NCT04305795|COMBINATION_PRODUCT|ASP-1929 PIT|"ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months."
224067384|NCT06298474|BEHAVIORAL|The BRAIN App|The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.
224067385|NCT06789601|OTHER|Informatics system for eligibility monitoring|A daily automated data query of eligible subjects will collect EHR data, and our informatics system will be run on these data behind our institution's secure firewall. The daily list of subjects identified by the informatics system as having a new irAE will be accessed by the Alliance irAE biorespository study team at Dana-Farber/Brigham Cancer Center for review.
224067386|NCT06789601|OTHER|Standard eligibility monitoring|Reporting of an eligible event to the biorepository study staff by the treating clinician and EHR review by the study staff.
224067387|NCT04068376|OTHER|Control excercise|Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of balance-stretching exercise; and 5) 5 minutes of cool-down stretching (this times does not count as activity).
224067388|NCT04068376|OTHER|"Mind and Movement for Cognitive Health in the Older Adult"|The T1-GR will consist of 60-minute training sessions delivered three days a week during a 24-week period. Each session will be guided by a health profesional certified to coach SSE. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).
224071455|NCT00088374|DRUG|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
224302728|NCT00848107|DRUG|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
223743174|NCT01254526|DRUG|bevacizumab|Intravenous repeating dose
223457575|NCT05988346|PROCEDURE|abdominal plastic intervention|According to international guidelines, authors will remove the superficial abdominal fat from the patients enrolled in the study.
223457576|NCT03682029|DIETARY_SUPPLEMENT|Vitamin C (ascorbic acid)|Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
223457577|NCT03682029|OTHER|Placebo|Placebo
223457578|NCT00821197|PROCEDURE|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
223457579|NCT00821197|PROCEDURE|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
223457580|NCT06955676|OTHER|treadmill exercise|Intervention consists of exercises only. Participants in this group will walk on a treadmill. The heart rates of the participants will be monitored with a heart rate monitor while exercising in order to maintain moderate-intensity.
223457581|NCT06955676|OTHER|cycle ergometer exercise|Intervention consists of exercises only. Participants in this group will cycle on an ergometer. The heart rates of the participants will be monitored with a heart rate monitor while exercising in order to maintain moderate-intensity.
223457582|NCT01940640|DIETARY_SUPPLEMENT|DHA|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
223457583|NCT01940640|DIETARY_SUPPLEMENT|control|We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
223457584|NCT02250456|PROCEDURE|Echo doppler|vascular ultrasound explorations
223457585|NCT00159770|DRUG|ziprasidone versus olanzapine , risperidone or quetiapine|
223457586|NCT00159770|BEHAVIORAL|Panss , CGI-C, UKU-SERS-Pa|
223457587|NCT00159770|PROCEDURE|Blood tests|
223457588|NCT00331539|DEVICE|Cochlear Implant|
223457589|NCT06298955|DRUG|OMS906 study drug|OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals
223457590|NCT05251233|DRUG|Placebo|Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
223457591|NCT05251233|DRUG|Pantoprazole|The study will use commercial supply.
223457592|NCT06294535|DEVICE|reconstruction of orbital walls|under GA, incision to access to orbital walls. Then insertion of prebent titanium mesh or customized titanium implant and fixation with miniscrews, examination of ocular motility using forced duction test followed by closure of flap.
223457593|NCT04047732|BIOLOGICAL|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
223457594|NCT02546869|DRUG|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
223457595|NCT02546869|DEVICE|Prefilled Syringes|
223573531|NCT05258084|BEHAVIORAL|sexual minority awareness training|sexual minority awareness training is planned as 4 interviews (1 interview per week) for a total of 4 hours. Gender and sexuality-related terminologies and concepts will be discussed in the 1st meeting. Expression of sexual identity and gender transition processes will be examined in the 2nd meeting. In the 3rd meeting, the determining factors in the inadequate utilization of health services by LGBT individuals will be discussed. In the 4th meeting, what can be done to create a safe and health-friendly environment for LGBT individuals and healthcare professionals will be discussed.
223573532|NCT00002522|DRUG|cisplatin|
223573533|NCT00002522|DRUG|cyclophosphamide|
223573534|NCT00002522|DRUG|etoposide|
224071456|NCT00720109|DRUG|Asparaginase|Given IT
224071457|NCT00720109|DRUG|Cyclophosphamide|Given IV
224071458|NCT00720109|DRUG|Cytarabine|Given IT or IV
224071459|NCT00720109|DRUG|Dasatinib|Given PO
224071460|NCT00720109|DRUG|Daunorubicin Hydrochloride|Given IV
224071461|NCT00720109|DRUG|Dexamethasone|Given IV or PO
223457596|NCT06247839|DRUG|Psilocybin|COMP360 (Brand name of psilocybin to be used)
223457597|NCT06958393|DRUG|Dexmedetomidine|Continuous infusion at 0.5-1.0 μg/kg/h during surgery
223457598|NCT06958393|DRUG|Esketamine|Induction dose 0.3-0.5 mg/kg; maintenance 0.2-0.5 mg/kg/h; 0.02 mg/kg at closure; PCIA: 1.5 mg/kg in 100 mL saline
223457599|NCT06958393|DRUG|Esmolol|Maintenance 20-100 μg/kg/min during surgery
223457600|NCT06958393|DRUG|Sufentanil|0.3-0.5 μg/kg induction; 0.15 μg/kg at closure; 2 μg/kg in 100 mL for PCIA
223457601|NCT06958393|DRUG|Remifentanil|0.2-1.0 μg/kg/min maintenance
223457602|NCT04780815|OTHER|myBluTM Formulation 1|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 1, with inhalation of the vapour into the lungs
223457603|NCT04780815|OTHER|myBluTM Formulation 2|1-2 puffs of each 3-5 seconds duration taken from myBluTM with Formulation 2, with inhalation of the vapour into the lungs
223457604|NCT05236907|DRUG|Melatonin|The patients were assessed using the Memorial Delirium Assessment Scale (MDAS) after the operation at 30, 60, and 90 min. Melatonin was shown to reduce delirium from 41.6% to 16.6% at 60 minutes, and the significant reduction was at 90 minutes (0%) when compared to both groups. Thus, melatonin was found to be successful in decreasing postoperative delirium when administered preoperatively.
223457605|NCT05236907|OTHER|No intervention|No intervention was used.
223457606|NCT05236907|DRUG|Midazolam|7.5 mg of Midazolam orally.
223457607|NCT01427010|RADIATION|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography (\[18F\]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
223457608|NCT03272347|DRUG|Islatravir|Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
223457609|NCT03272347|DRUG|Placebo to Islatravir|Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
224071462|NCT00720109|DRUG|Etoposide|Given IV
223457610|NCT03272347|DRUG|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
223457611|NCT03272347|DRUG|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
223457612|NCT03272347|DRUG|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
223457613|NCT03272347|DRUG|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
223457614|NCT03272347|DRUG|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
223457615|NCT03272347|DRUG|Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate|Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
223573535|NCT00002522|PROCEDURE|autologous bone marrow transplantation|
223573536|NCT00002522|PROCEDURE|bone marrow ablation with stem cell support|
223573537|NCT00002522|PROCEDURE|peripheral blood stem cell transplantation|
223573538|NCT00002522|PROCEDURE|syngeneic bone marrow transplantation|
223573539|NCT00002522|RADIATION|radiation therapy|
223573540|NCT03808363|OTHER|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the Borg rating of perceived exertion (RPE) scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
223573541|NCT04531358|DEVICE|nasal spray|application of nasal spray
223573542|NCT04531358|OTHER|no treatment|no treatment
223573543|NCT01050374|DRUG|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
223573544|NCT01050374|DRUG|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
223573545|NCT04370990|DEVICE|O2matic|O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
223573546|NCT01884558|DRUG|isavuconazole|oral
223573547|NCT01884558|DRUG|metformin|oral
223573548|NCT03647111|DRUG|Crizotinib|Crizotinib 250mg po bid
223573549|NCT00866346|BIOLOGICAL|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
223573550|NCT04094142|DRUG|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
223743175|NCT01254526|DRUG|paclitaxel|Intravenous repeating dose
223457616|NCT03272347|DRUG|Doravirine/Islatravir|Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
223457617|NCT01450514|DRUG|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
223457618|NCT01450514|DRUG|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
223457619|NCT03885323|DEVICE|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
223573551|NCT02654288|OTHER|gemcitabine-based chemotherapy|
223573552|NCT01421316|RADIATION|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
223573553|NCT00034229|DRUG|Felbamate|
223743176|NCT05348161|PROCEDURE|Samples including blood and tissue collection|Tissue and peripheral blood sample of 100 gastric cancer patients will be collected at the baseline and time point response of therapy.
223743177|NCT05348161|PROCEDURE|CTC detection|Peripheral blood collected from patients will be administrated to CTC detection.
224155973|NCT04521920|DRUG|Suboxone|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
224155974|NCT04521920|DRUG|PrEP|Enrolled participants will be prescribed PrEP and/or Suboxone. Follow up visits will be conducted by telemedicine. We are testing whether telemedicine is a feasible method for follow up.
224155975|NCT00391807|DRUG|Norethindrone acetate/ethinyl estradiol|one tablet per day
223457620|NCT03885323|DEVICE|Control placebo with no RF|Placebo control, with no RF
223457621|NCT05133583|OTHER|Laughter yoga|"The experimental group was interviewed in an online meeting prepared by a certified LY trainer.~She received LY exercises once a week (40 minutes per session) for 6 weeks (6 sessions). Each The meeting was organized with a maximum of 12 people."
223457622|NCT01082679|DRUG|Methadone|daily for 12 months
223457623|NCT01082679|DRUG|buprenorphine (Suboxone)|daily for 12 months
223457624|NCT00753298|DEVICE|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
223573554|NCT00355342|DRUG|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
223573555|NCT00355342|DRUG|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
223573556|NCT00355342|DEVICE|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
223743178|NCT05348161|PROCEDURE|ctDNA detection|DNA extraction from patients' peripheral blood will be measured by 741 panel DNA sequence.
223743179|NCT05348161|PROCEDURE|10×genomics single cell RNA sequence|Tissue collected from patients will be digested into single cell suspension and administrated to 10×genomics single cell RNA sequence.
224155976|NCT04843969|BEHAVIORAL|Stress induction|Exposure to a psychosocial stressor
223457625|NCT00753298|DEVICE|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
223457626|NCT00921258|PROCEDURE|prostate biopsy|"patient of control group will have :~* 1 prostate biopsy 3 months after diagnostic biopsy~* 1 prostate biopsy each year during 2 years~* 1 prostate biopsy each 2 years during 8 years"
223457627|NCT06079996|OTHER|CAFFEINE GUM|Observing the effect of chewing gum on the performance of female softball players.
223457628|NCT01344694|OTHER|patient with liver fat|30 patient with liver fat
223457629|NCT01344694|OTHER|pts. with excess of visceral fat|pts. with excess of visceral fat
223457630|NCT01344694|OTHER|control|30 control subjects
223457631|NCT03547258|GENETIC|Clinical and Molecular data collection|Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
223457632|NCT01228656|DRUG|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
223457633|NCT01228656|DRUG|Mometasone furoate|Dermatologic ointment applied once a day
223457634|NCT04739592|DRUG|alendronate sodium vitamin D3 tablets|once per week for one year
223457635|NCT04739592|DRUG|Placebo|once per week for one year
223457636|NCT03088228|DIAGNOSTIC_TEST|gingival crevicular fluid collection|
223457637|NCT04416919|OTHER|Assembled mask|Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
223573557|NCT04304885|DIAGNOSTIC_TEST|Sonication method|Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
223457638|NCT06172738|PROCEDURE|the left atrial appendage closure through surgery.|Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
223573558|NCT00434759|BEHAVIORAL|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
223573559|NCT00434759|BEHAVIORAL|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
224067389|NCT04068376|OTHER|Double-task exercise by older adults and their caregivers|"In the case of T2-GR, older adults and their caregivers will participate in the same SSE program led by a coach for 12 weeks; older adults will then be asked to continue SSE at home under the supervision and with the active participation of their caregivers for another 12 weeks. They will be asked to practice SSE for 60 minutes, three times a week, and to reach a ≥65% heart rate increase. In the field of sports, the people who perform the above-mentioned activities are called pacers, and they supervise physical activity through active accompaniment of older adults."
223457639|NCT03868189|OTHER|Electroneuromyography with ultrasound|Patients whose electroneuromyography examination will be performed using an ultrasound
223457640|NCT03868189|OTHER|Electroneuromyography without ultrasound|Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
223457641|NCT06260917|DIAGNOSTIC_TEST|position of urination|effect of position on uroflowmetry parameters
223457642|NCT03559283|DIAGNOSTIC_TEST|Walking and Record Cortical Activity|"The cortical activity of each patient is recorded by NIRS under the following conditions:~* Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~* Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~* Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer."
223743180|NCT05348161|PROCEDURE|Whole exon sequence|DNA will be extracted from patients' tissue and administrated to whole exon sequence.
223457643|NCT02097511|DRUG|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
223457644|NCT02097511|DRUG|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
223457645|NCT02097511|DRUG|Metoprolol|Metoprolol Tartrate 100 mg once a day
223457646|NCT00075452|DRUG|gemcitabine hydrochloride|
223457647|NCT00075452|DRUG|oxaliplatin|
223457648|NCT00391872|DRUG|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
223743181|NCT05348161|PROCEDURE|Proteomics detection|Peripheral blood collected from patients will be administrated to proximity extension assay .
223743182|NCT03068247|DRUG|Duloxetine|10 week treatment
224071463|NCT00720109|BIOLOGICAL|Filgrastim|Given IV or SC
223457649|NCT00391872|DRUG|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
224071464|NCT00720109|DRUG|Hydrocortisone Sodium Succinate|Given IT
223457650|NCT01476267|DRUG|dalcetrapib|Single oral radiolabeled dose
223457651|NCT01137487|PROCEDURE|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
223457652|NCT01137487|PROCEDURE|not monitoring of residual gastric volume|no measurements of residual gastric volume
223457653|NCT00002125|DRUG|Foscarnet sodium|
223457654|NCT02229799|DRUG|Actilyse|
223457655|NCT00901615|DRUG|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
223457656|NCT01268657|BEHAVIORAL|Education|Learning about anxiety
223457657|NCT01268657|BEHAVIORAL|Relaxation Training|Learning skills to reduce tension
223457658|NCT01268657|BEHAVIORAL|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
223743183|NCT03068247|DRUG|Placebo|10 week treatment
224071465|NCT00720109|DRUG|Ifosfamide|Given IV
224071466|NCT00720109|OTHER|Laboratory Biomarker Analysis|Correlative studies
224071467|NCT00720109|DRUG|Leucovorin Calcium|Given IV or PO
224071468|NCT00720109|DRUG|Mercaptopurine|Given PO
223457659|NCT01268657|BEHAVIORAL|Behavioral Activation|Learning to initiate healthy activity
223573560|NCT04298866|OTHER|Experimental Arm|"* 3T MRI, maximum 1H30 long duration, including diffusion tensor imaging, susceptibility weighted imaging, multiparametric acquisitions, without contrast perfusion acquisitions.~* 7T MRI, maximum 1H30 long duration, including contrast enhanced acquisitions~* Neuropsychological battery including chronometric measures obtained through a computer interface"
223573561|NCT00712621|BEHAVIORAL|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
224155977|NCT04843969|BEHAVIORAL|Control stress exposure|Exposure to a control task (no stress)
224155978|NCT04843969|BEHAVIORAL|Cue induction|Exposure to a smoking-related task
224155979|NCT04843969|BEHAVIORAL|Neutral cue exposure|Exposure to neutral cues
224155980|NCT00310349|BIOLOGICAL|23 valent pneumococcal polysaccharide vaccine|
224155981|NCT02712281|BEHAVIORAL|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
223457660|NCT01268657|BEHAVIORAL|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
223457661|NCT00905632|DRUG|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
223457662|NCT00905632|DRUG|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
223457663|NCT00905632|DRUG|Placebo + SOC|Placebo tid +SOC
223457664|NCT00905632|DRUG|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
223457665|NCT03832270|BEHAVIORAL|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
223457666|NCT03832270|BEHAVIORAL|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
223457667|NCT01278602|DRUG|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
223457668|NCT06420037|DEVICE|Hearing aid feature adjustment (frequency compression) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely frequency compression turned off, to the basic setting.
223457669|NCT06420037|DEVICE|Hearing aid feature adjustment (noise reduction) of the following hearing aids: Phonak Audéo Paradise/Lumity 70|Upon enrollment, each participant will be allocated to one of three research groups and participants will remain unaware of their group assignment. This groups will undergo a slight modification, namely noise reduction turned off, to the basic setting.
223457670|NCT06420037|BEHAVIORAL|Cognitive screening and vision screening|The Dutch Montreal Cognitive Assessment will be assessed. The Snellen Eye Test will be used to screen for normal or corrected-to-normal vision.
223573562|NCT00712621|BEHAVIORAL|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
223743184|NCT03106155|DRUG|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
223743185|NCT02515045|DRUG|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
223743186|NCT02515045|DRUG|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
223743187|NCT02515045|DRUG|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
224305141|NCT02296021|DRUG|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
224305142|NCT02296021|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
223457671|NCT06420037|BEHAVIORAL|Audiological Assessment|Three audiological tests are included: 1) Tympanometry to assess the middle ear status, 2) Pure-tone audiometry with headphone to evaluate the hearing thresholds, 3) Speech audiometry in free field to assess the ability to understand spoken sentences in quiet and in the presence of background noise.
223573563|NCT03697499|COMBINATION_PRODUCT|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
223573564|NCT03697499|COMBINATION_PRODUCT|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
223743188|NCT02515045|DRUG|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
223743189|NCT02865993|OTHER|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
223743190|NCT02865993|OTHER|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
223743191|NCT03214159|DRUG|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
223457672|NCT06420037|BEHAVIORAL|Questionnaires|"Three questionnaires are included:~1. The HAVICOP questionnaire to assess the hearing-related quality of life (Ceuleers, D., Baudonck, N., Keppler, H., Kestens, K., Dhooge, I., \& Degeest, S. (2023). Development of the hearing-related quality of life questionnaire for auditory-visual, cognitive and psychosocial functioning (hAVICOP). Journal of communication disorders, 101, 106291.)~2. the FAS (fatigue assessment scale) to assess how you usually feel~3. the EEAS (extended effort assessment scale) to assess how you experience listening in everyday life."
223457673|NCT06420037|BEHAVIORAL|Cognition|Four cognitive functions, important for speech understanding, will be assessed both audibly and visually: divided attention, working memory, processing speed, and cognitive flexibility and inhibition.
223457674|NCT06420037|OTHER|Real ear measurement|This test will give an objective assessment of the hearing aids' configuration.
223457675|NCT00148044|PROCEDURE|Blood sampling for determination of uremic toxins|
223457676|NCT00938665|DEVICE|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
223457677|NCT02793219|BIOLOGICAL|Sipuleucel-T|
223457678|NCT02793219|DRUG|Docetaxel|
223457679|NCT02778035|DEVICE|Dorsomedial prefrontal rTMS|Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
223457680|NCT06326086|DRUG|Chemotherapy drug|Chemotherapy drug as prescribed by primary treating physician
223457681|NCT06326086|DRUG|Targeted Agent|Targeted agents as prescribed by primary treating physician
223457682|NCT06326086|DRUG|Immunotherapy|Immunotherapy as prescribed by primary treating physician
223457683|NCT01557673|DIETARY_SUPPLEMENT|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
223457684|NCT01557673|DIETARY_SUPPLEMENT|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
223457685|NCT05630443|PROCEDURE|prone position|Ordinary ERAS treatment postoperatvely adding the prone position and voicetraining
223457686|NCT02762435|OTHER|sham|light touch at established points on hand and wrist
223457687|NCT02762435|OTHER|control|no contact with the subject
223457688|NCT02762435|OTHER|acupressure|moderate pressure at established points on hand and wrist
223457689|NCT01405495|PROCEDURE|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
223457690|NCT04617119|DEVICE|Threshold IMT device|10 breaths X 3 sets, two times a day for 2 weeks. starting intensity 10 % of pre-measured maximal inspiratory pressure.
223457691|NCT04617119|OTHER|Conventional physical therapy|daily
224071469|NCT00720109|DRUG|Methotrexate|Given IT, PO, or IV
224305143|NCT02296021|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
223457692|NCT02603211|DEVICE|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
223457693|NCT04349540|OTHER|no intervention|no intervention
223457694|NCT01229969|OTHER|Wii Fit Balance Games|Ski Slaloms and Table Tilt
223457695|NCT01229969|OTHER|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
223457696|NCT03822156|OTHER|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
223457697|NCT06158217|PROCEDURE|ultrasound combined with microbubbles|IBC tumors were treated with microbubbles (MBs) stimulated by ultrasound
224071470|NCT00720109|DRUG|Methylprednisolone|Given IV
223457698|NCT03166501|DRUG|Lanicemine|Three 60 min parenteral infusions over a 5 day period
223457699|NCT03166501|DRUG|Placebo|Three 60 min parenteral infusions over a 5 day period
223457700|NCT05171114|DIAGNOSTIC_TEST|Measurement of joint amplitudes|Measurement of joint amplitudes by goniometry of the MCP, IPP, IPD for 2, 3, 4 and 5th radii, 1st commissure spacing and Kapandji score for the thumb
223457701|NCT05225025|BEHAVIORAL|ROSE|"The ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) program is an evidence-based intervention that has been proven to reduce cases of post-partum depression among low-income and racially and ethnically diverse women.~ROSE is administered to pregnant women in small group settings, typically in the same location that prenatal care is being provided (in this study, a hospital setting). It is divided into four 90-minute group sessions and teaches interpersonal psychotherapy-based skills that mitigate identified risk factors for PPD such as social support, stress management skills and communication.~ROSE curriculum will be implemented using groups in a continuous cycle, with patients entering into the intervention curriculum at the time of their enrollment and continuing through until all 4 total sessions have been accomplished."
223457702|NCT05225025|OTHER|Standard of Care|Usual hospital care with no behavioral intervention
223457703|NCT06336317|BIOLOGICAL|Influenza vaccine|VaxigripTetra Suspension for injection, 0,5ml prefilled syringe ATC code: J07BB02
223457704|NCT06336317|BIOLOGICAL|Placebo|Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01
223457705|NCT04284683|OTHER|DRINK - Water, Protein, Fat, Carbohydrate|Following exercise participants will consume a drink (with different composition in each visit) and than RMR will be evaluated.
223457706|NCT01307891|DRUG|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
223573565|NCT03697499|COMBINATION_PRODUCT|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
224071471|NCT00720109|DRUG|Pegaspargase|Given IM
224071472|NCT00720109|DRUG|Prednisone|Given PO or IV
224071473|NCT00720109|RADIATION|Radiation Therapy|Some patients undergo cranial RT
224071474|NCT00720109|DRUG|Vincristine Sulfate|Given IV
224305144|NCT02134743|PROCEDURE|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
224302729|NCT06437483|PROCEDURE|Sustained Natural Apophyseal Glides|"SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions."
223457707|NCT01307891|DRUG|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
223457708|NCT00527137|DRUG|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
223457709|NCT00527137|DRUG|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
223457710|NCT03128450|BIOLOGICAL|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
223457711|NCT02937740|DRUG|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 \[Day 90\] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
223457712|NCT04683796|DRUG|100% Autologous platelet rich plasma|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
223457713|NCT04683796|DRUG|100% Autologous serum|Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
223457714|NCT01737307|DRUG|Fluoride varnish|Fluoride Varnish (NaF 5%)
223457715|NCT01737307|OTHER|Oral Hygiene|Oral hygiene followed.
223457716|NCT01737307|DRUG|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
223457717|NCT03018314|OTHER|Blood sample|Serum analysis
223457718|NCT02288702|DEVICE|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
223457719|NCT00214617|DRUG|Rosuvastatin at 5 mg/day and 40 mg/day|
223457720|NCT05704855|BEHAVIORAL|Combined Exercise + Behavioural Counselling|The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
223743192|NCT03214159|DRUG|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
224302730|NCT06437483|PROCEDURE|Kinesiotaping|"Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension."
223457721|NCT05704855|BEHAVIORAL|Active Control|The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
223457722|NCT03062215|BEHAVIORAL|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
223457723|NCT01546051|DRUG|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
223457724|NCT01546051|DRUG|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
223743193|NCT04626635|DRUG|REGN7075|Intravenous (IV) infusion or subcutaneous (SC) injection will be administered every week (QW) or every 3 weeks (Q3W)
223573566|NCT03697499|COMBINATION_PRODUCT|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
223573567|NCT01357135|DRUG|Metformin|
223573568|NCT01357135|DRUG|Sitagliptin|
223573569|NCT01357135|DRUG|Sulfonylurea|
223573570|NCT01357135|DRUG|Antihyperglycemic Medication|
223573571|NCT00969761|DRUG|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
223573572|NCT00969761|DRUG|BI 6727|low to high dose
223573573|NCT02017392|DRUG|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
223573574|NCT02062892|DRUG|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
223573575|NCT02062892|DRUG|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
223573576|NCT01579825|OTHER|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
223573577|NCT03005301|DEVICE|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25\~40mm in length and 0.30\~0,38mm in diameter.Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
223573578|NCT03005301|DEVICE|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120\~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
223457725|NCT01546051|DRUG|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
223457726|NCT01546051|DRUG|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
223457727|NCT02812641|DRUG|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If \> 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
223573579|NCT01500369|OTHER|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
223573580|NCT01500369|OTHER|standard of care|Placebo Comparator
223743194|NCT04626635|DRUG|Cemiplimab|Administered concomitantly Q3W by IV infusion or SC injection
224155982|NCT02712281|BEHAVIORAL|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
223457728|NCT02812641|DRUG|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
223457729|NCT02812641|DRUG|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
223573581|NCT03507959|OTHER|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
223573582|NCT03507959|OTHER|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
224155983|NCT02919410|DEVICE|iodophor-impregnated adhesive drapes|
224155984|NCT02919410|OTHER|No adhesive drapes|
224155985|NCT04430686|OTHER|Questionaires|Any validated functional rating scale, such as the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) or the ALSFRS-Revised (if available)
224302731|NCT06437483|PROCEDURE|Conventional Treatment|Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
223573583|NCT03507959|OTHER|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
223573584|NCT03507959|OTHER|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
223573585|NCT00219037|DRUG|aliskiren|
223743195|NCT04626635|DRUG|Platinum-based doublet chemotherapy|Administered IV Q3W
223743196|NCT04626635|DRUG|Bevacizumab|Administered per protocol
223743197|NCT04626635|DRUG|Trifluridine-tipiracil|Administered per protocol
223743198|NCT00014209|DRUG|cisplatin|
223743199|NCT00014209|DRUG|dexamethasone|
223743200|NCT00014209|DRUG|gemcitabine hydrochloride|
223457730|NCT03952572|DRUG|Cyclophosphamide|750mg/m² ivgtt on day 1
223573586|NCT00806923|DRUG|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
223457731|NCT03952572|DRUG|pegylated liposomal doxorubicin|40mg/m² ivgtt on day 1
223457732|NCT03952572|DRUG|Vincristine|1.4mg/m²(Maximum 2 mg) ivgtt on day 1
223573587|NCT00806923|DRUG|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
224155986|NCT03683043|DRUG|Long GnRH agonist protocol|"8\. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9\. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
223457733|NCT03952572|DRUG|Prednisone|Prednisone100mg/m² po on day1-5
223457734|NCT03952572|DRUG|Doxorubicin|50mg/m² ivgtt on day 1
223457735|NCT03296969|PROCEDURE|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
223457736|NCT03296969|PROCEDURE|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
223457737|NCT04745741|RADIATION|IB-positive group|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
223457738|NCT03397121|DRUG|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
224155987|NCT03683043|PROCEDURE|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
224155988|NCT02314871|OTHER|Epidural analgesia|see Arm/group description
224155989|NCT02314871|DRUG|Piritramide|see Arm/group description
223457739|NCT03397121|DRUG|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
223457740|NCT00230789|DRUG|Tolterodine ER 4 mg QD|
223457741|NCT00230789|BEHAVIORAL|OAB Patient Behavioral Training Material|
223457742|NCT02801825|PROCEDURE|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
223457743|NCT02801825|PROCEDURE|Real-time ultrasound-guided out-of-plane femoral artery cannulation.|Real-time ultrasound-guided out-of-plane femoral artery cannulation.
223457744|NCT03939442|PROCEDURE|Sleeve gastrectomy with jejunoileal anastomosis|The sleeve gastrectomy was performed first, after using a sealer and divider device to dissect the omentum away from the greater gastric curvature from approximately 5 cm proximal to the pylorus up to the angle of His. Excision of the fundus and the body of the stomach was then performed with a laparoscopic linear stapler upon a 36 French orogastric tube (bougie). An isoperistaltic side-to-side anastomosis between the jejunum (at 50 cm distal to the Treitz ligament) and the distal ileum ( at 200 cm proximal to the ileocecal valve) was then created using the same linear stapler with a blue cartridge (3.5 mm). A soft Penrose drain was left at the subdiaphragmatic space, and the abdominal wound was closed.
223457745|NCT05761418|DRUG|Dinoprostone|prostaglandin (PG) E2 analog
223457746|NCT05761418|DRUG|Misoprostol|prostaglandin (PG) E1 analog
224155990|NCT02314871|DRUG|Morphine|see Arm/group description
224155991|NCT00816283|DRUG|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
224155992|NCT00816283|DRUG|vorinostat|100 mg orally 2 times per day
224155993|NCT00816283|GENETIC|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
224155994|NCT00816283|GENETIC|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
224155995|NCT00816283|GENETIC|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
224155996|NCT00816283|GENETIC|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
224155997|NCT00816283|OTHER|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
223573588|NCT00806923|DRUG|Placebo|iv on day 1 of each 3 week cycle until disease progression
223573589|NCT00806923|DRUG|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
223573590|NCT00806923|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
223743201|NCT01237535|DRUG|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
223457747|NCT05237115|DRUG|Clostridium butyricum capsule|Clostridium butyricum group: given for 14 days at a dose of Clostridium butyricum capsule 420mg 3 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
223457748|NCT05237115|DRUG|esomeprazole|Esmeprazole 40mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
223457749|NCT05237115|DRUG|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 40mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
223457750|NCT05237115|DRUG|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
223457751|NCT05237115|DRUG|Bacillus clotting|given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
223573591|NCT05110313|BIOLOGICAL|TILDRAKIZUMAB|"ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses.~ILUMYA injection for subcutaneous use is a sterile, clear to slightly opalescent, colorless to slightly yellow solution supplied in 1mL single-dose prefilled syringe which contains 100 mg of tildrakizumab-asmn formulated in: L-histidine (0.495 mg), L-histidine hydrochloride monohydrate (1.42 mg), polysorbate 80 (0.5 mg), sucrose (70.0 mg), and Water for Injection, USP with a pH of 5.7-6.3. ILUMYA is supplied in a single-dose prefilled syringe with a glass barrel and 29-gauge fixed, 1/2-inch needle."
223573592|NCT01779505|BIOLOGICAL|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
223573593|NCT04030247|DRUG|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
223573594|NCT03223623|DEVICE|TMS|Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
223573595|NCT03223623|DEVICE|MRI|High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
223743202|NCT01237535|DRUG|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone \[(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg\].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
224302732|NCT02335983|DRUG|Carfilzomib|Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
224067390|NCT05625516|DEVICE|Bilateral external torque device|"The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent."
224067393|NCT00085761|DRUG|Capsaicin Dermal Patch|
224067394|NCT03317938|DEVICE|Fecobionics|Fecobionics is a new device for studying defecation
224067395|NCT05388773|PROCEDURE|therapeutic conventional surgery|Transoral surgical resection of tumor(s).
224067396|NCT05388773|OTHER|laboratory biomarker analysis|Correlative studies
224067397|NCT05388773|OTHER|quality-of-life assessment|Ancillary studies.
224067398|NCT05388773|RADIATION|intensity-modulated radiation therapy|Low-dose IMRT
224067399|NCT05388773|DRUG|Cisplatin|Given IV.
224067400|NCT05388773|DRUG|Carboplatin|Given IV
224067401|NCT03424707|DRUG|DW340(pelubiprofen/eperisone)|DW340
224067402|NCT03424707|DRUG|Pelubi(pelubiprofen)|pelubiprofen
224067403|NCT03424707|DRUG|Placebo Oral Tablet|Placebo Oral Tablet
224067404|NCT05692037|COMBINATION_PRODUCT|Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres|Yttrium-90 carbon microspheres SIRT
224071475|NCT01596998|DRUG|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
224302733|NCT02335983|DRUG|Lenalidomide|Administered orally once daily on days 1-21 of each 28-day cycle.
224302734|NCT02335983|DRUG|Dexamethasone|Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
224302735|NCT03528083|OTHER|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
224302736|NCT00237783|DRUG|dialysate sodium (140 mmol/L)|
223457752|NCT05237115|DRUG|Bismuth|given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
223457753|NCT01605864|DRUG|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
224155998|NCT00816283|OTHER|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
223457754|NCT00305227|DRUG|Lactin-V|
223457755|NCT00305227|DRUG|Placebo|
223457756|NCT03069235|BEHAVIORAL|Family member / peer support|supplemental individualized counselling
223457757|NCT03069235|BEHAVIORAL|Enhanced intervention with counselor support|"hands on EBF demonstrations"
223457758|NCT03069235|BEHAVIORAL|standard of care|one on one and in-group counselling
223457759|NCT05447143|OTHER|Fatigue Severity Scale|Evaluation for severity of fatigue
223457760|NCT05447143|OTHER|Berg Balance Test|Evaluation of balance
223457761|NCT05447143|OTHER|Time up and go- 25 steps walking test|Evaluation for walking
223457762|NCT05447143|OTHER|Multiple Sclerosis Quality of Life|Evaluation of quality of life
223457763|NCT05447143|OTHER|Brief International Cognitive Assessment for MS (BICAMS)|Evaluation of cognitive functions
223457764|NCT05447143|OTHER|Beck Depression and Anxiety Scale|Evaluation of depression and anxiety
223743203|NCT01237535|PROCEDURE|Insemination without luteal support|Routine insemination procedure without luteal support
224155999|NCT03957746|OTHER|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
224156000|NCT01263314|DRUG|MK-8266|Oral capsules, 0.1 mg potency
224156001|NCT01263314|DRUG|Placebo|Oral placebo capsules to match MK-8266 capsules
224156002|NCT05911737|BEHAVIORAL|Short video and Questionnaire|A 10-minute video in a foreign language (not English or Greek) with greek subtitles will be presented and a questionnaire will follow to assess the level of concentration during the video
224156003|NCT04331925|BEHAVIORAL|Anxiety and depression screening|At the time of consent, the participant parent will be randomized into either the control or intervention groups. The control group will complete the Hospital Anxiety and Depression Scale (HADS) questionnaire at the start of the study. After two weeks or at the time of discharge, the control group will complete the HADS questionnaire again.
224156004|NCT04331925|BEHAVIORAL|Journaling|Parents randomized into the intervention group be given verbal instructions to use a journal how/when they choose for the duration of the intervention period
223457765|NCT03407001|PROCEDURE|Contrast-Enhanced Ultrasound|Undergo CEUS
223457766|NCT03407001|DRUG|Sulfur Hexafluoride Lipid Microspheres|Given IV
223457767|NCT03407001|PROCEDURE|Ultrasound|Undergo non-contrast US
223457768|NCT02632006|BIOLOGICAL|PIK-PD-1 cells|"DC cell suspension (1×10\*7 DC+ physiological saline~\+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10\*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
223457769|NCT02632006|BIOLOGICAL|DC-PMAT|"DC cell suspension (1×10\*7 DC+ physiological saline~\+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10\*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
223457770|NCT03395626|DIETARY_SUPPLEMENT|ID-JPL934|probiotics
223457771|NCT03395626|DIETARY_SUPPLEMENT|Placebo|corn starch
223457772|NCT02851459|BEHAVIORAL|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
223457773|NCT02851459|BEHAVIORAL|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
223457774|NCT02851459|BEHAVIORAL|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
223457775|NCT02851459|BEHAVIORAL|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
223457776|NCT02851459|BEHAVIORAL|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
223457777|NCT02851459|BEHAVIORAL|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
223457778|NCT01852123|DEVICE|High-sensitivity troponin I assay|
223457779|NCT04085601|DRUG|APL-2|Complement (C3) Inhibitor
223743204|NCT03929861|DRUG|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
223743205|NCT03929861|DRUG|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
223743206|NCT01750099|PROCEDURE|Combined Spinal-epidural|See arm description
224156005|NCT04071171|DRUG|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
223457780|NCT06293274|PROCEDURE|Discharge training|What is motherhood blues? Why does it occur? What are its symptoms? How to deal with it? What is postpartum depression? What causes postpartum depression? Information is provided on this topic.
223573596|NCT03223623|DEVICE|VASO Imaging|The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
223457781|NCT00429832|DRUG|Ondansetron|
223457782|NCT00429832|DRUG|promethazine|
223573597|NCT05017818|OTHER|Observational retrospective data|Non-intervention
223573598|NCT04150952|OTHER|HRV-based training|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
223573599|NCT04150952|OTHER|TRAD training|Traditional endurance training
223573600|NCT03645304|DRUG|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
223573601|NCT03645304|DRUG|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
224156006|NCT04071171|DRUG|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
224156007|NCT04071171|DRUG|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
224156008|NCT04071171|DRUG|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
224302737|NCT00237783|DRUG|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
224302738|NCT02190474|BEHAVIORAL|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
224302739|NCT03806374|DRUG|Ketamine|ketamine
224302740|NCT03806374|DRUG|Propofol|propofol
223457783|NCT03492437|DRUG|Dabigatran Etexilate|Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.
223457784|NCT03492437|DRUG|Tepotinib|Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.
223457785|NCT04559477|OTHER|Static extension endurance exercise|"Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
223457786|NCT04559477|OTHER|Dynamic extension endurance exercise|"Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks"
223457787|NCT02418234|OTHER|mutation detection|
223457788|NCT02418234|OTHER|ARMS and ddPCR|
223457789|NCT02418234|GENETIC|ctDNA analysis|
223457790|NCT02915159|BIOLOGICAL|Abatacept|
223457791|NCT02915159|OTHER|Placebo|
223457792|NCT04534517|DEVICE|JJV Investigational Multifocal Contact Lens|TEST Lens
223457793|NCT04534517|DEVICE|ACUVUE OASYS® with HYDRACLEAR® PLUS|The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
223457794|NCT00612911|OTHER|Cell therapy|bone marrow mononuclear cell
223573602|NCT03645304|DEVICE|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
223573603|NCT03299543|DEVICE|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
223573604|NCT00509093|DRUG|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
223573605|NCT00509093|GENETIC|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
223743207|NCT01750099|PROCEDURE|Continuous Lumbar epidural|See arm description
224302741|NCT03806374|DRUG|Fentanyl|fentanyl
224302742|NCT03806374|DRUG|Cisatracurium|cisatracurium
224302743|NCT03806374|DRUG|Lidocaine|lidocaine
224302744|NCT02757365|DRUG|aspirin|
223457795|NCT01299350|OTHER|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops \>30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
223457796|NCT04407676|OTHER|Summary PIS and Online Video Modules|Complex trial information presented in alternative and more accessible formats
223457797|NCT03363607|PROCEDURE|Digital indirect bonding|Indirect bonding of orthodontic attachments using digital 3D printed transfer tray
223457798|NCT03363607|PROCEDURE|Conventional indirect bonding|Indirect bonding of orthodontic attachments using thermoformed transfer tray
223457799|NCT03363607|PROCEDURE|Intraoral scanning|Intraoral Scanning of the bonded brackets
223457800|NCT03363607|PROCEDURE|Superimposition and evaluation|superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
223457801|NCT05515133|OTHER|stressors|Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
223457802|NCT03872843|DRUG|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
223457803|NCT03872843|DRUG|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
223573606|NCT00509093|GENETIC|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
223573607|NCT00509093|GENETIC|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
224156009|NCT00995267|BEHAVIORAL|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories \& pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
224156010|NCT00623285|DRUG|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
224156011|NCT00623285|DRUG|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
224156012|NCT02068950|BEHAVIORAL|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
224156013|NCT04250025|PROCEDURE|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation|60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
223457804|NCT00938353|DRUG|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
223573608|NCT00509093|OTHER|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
223573609|NCT00509093|PROCEDURE|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
223573610|NCT05240521|OTHER|ARM A|30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days
223573611|NCT05240521|OTHER|ARM B|30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days
223573612|NCT02408809|BEHAVIORAL|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
223573613|NCT02408809|BEHAVIORAL|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
223743208|NCT00790881|DRUG|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
223457805|NCT00938353|DRUG|Placebo solution for nebulisation 2 ml|single dose: 4 ml
223457806|NCT04828031|DRUG|Vitamin D|Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
223573614|NCT03497364|DRUG|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173\~174cm, 1.65 ml for 170\~172cm, 1.6 ml for 168\~169cm, 1.55 ml for 165\~167cm, 1.5 ml for 163\~164cm, 1.45 ml for 160\~162cm, 1.4 ml for 158\~159cm, 1.35 ml for 155\~157cm, 1.3 ml for 153\~154cm, 1.25 ml for 150\~152cm, 1.2 ml for 148\~149cm)，1.15 ml for 145\~147cm).
223457807|NCT03100409|OTHER|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~1. No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~2. Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~3. Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
223573615|NCT03497364|DRUG|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173\~174cm, 2.225 ml for 170\~172cm, 2.15 0ml for 168\~169cm, 2.075 ml for 165\~167cm, 2.000 ml for 163\~164cm, 1.925 ml for 160\~162cm, 1.850 ml for 158\~159cm, 1.775 ml for 155\~157cm, 1.700 ml for 153\~154cm, 1.625 ml for 150\~152cm, 1.55 0ml for 148\~149cm, 1.475 ml for 145\~147cm)
223573616|NCT06006624|DRUG|Exparel 30 mL|30 mL Liposomal bupivacaine (Exparel) evenly distributed and administered in adductor canal block
223573617|NCT06006624|DRUG|0.5% bupivacaine|5 cc's of 0.5% bupivacaine evenly distributed and administered in adductor canal
223573618|NCT06006624|DRUG|Dexamethasone|10 mg preservative free Dexamethasone evenly distributed and administered in adductor canal
223573619|NCT06006624|DRUG|iPACK block|iPACK (Infiltration between the Popliteal artery and Capsule of the Knee) block
223573620|NCT01106508|DRUG|LEQ506|
223573621|NCT06331468|DRUG|Cisplatin|A total of two IV infusions of cisplatin will be administered on Day 1 and again on Day 8 +/- 1 day. Cisplatin starting dose is 40 mg/m2. Dose reduction is allowed (30 mg/m2) as needed for management of toxicities.
223573622|NCT06331468|RADIATION|intensity modulated radiation therapy (IMRT)|given once daily Monday-Thursday, four fractions per week for 2 weeks. The radiation dose is 4.56 Gy x 8 fractions.
223573623|NCT06331468|RADIATION|high-dose-rate (HDR) brachytherapy|administered 2x weekly (allow at least 72-hours window between sessions); weekdays only for 2 weeks. The radiation dose is 7 Gy x 4 fractions.
223573624|NCT01179061|DRUG|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
223573625|NCT01179061|DRUG|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
223573626|NCT03187834|DRUG|Azithromycin|Children in this arm will receive Azithromycin once a day.
223573627|NCT03187834|DRUG|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
223573628|NCT03187834|DRUG|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
223573629|NCT03187834|DRUG|Placebo|Children in this arm will receive Placebo once a day.
223573630|NCT02857192|BIOLOGICAL|Blood samples|
223573631|NCT01731834|OTHER|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
224156014|NCT04460040|BEHAVIORAL|Exercise training|"The first phase of the study will comprise two weeks of control phase when participants will not engage in any exercise training but will be monitored for total daily energy expenditure and its components (REE, SMR, and DIT) and assessed volume of metabolic organs and skeletal muscle efficiency.~Next, participants will start the active phase. In the first two weeks, participants will perform 150 - 200 min/week of a moderate intensity exercise so that they can adapt to the new regime and avoid injury. All exercise training will be monitored using heart rate sensor (HR) to track exercise adherence and HR range goals. Changes in daily non-exercise physical activity and sedentary behavior will be assessed for 10 days pre- and post-intervention by a tri-axial accelerometer. All study participants will be instructed to consume their habitual diet and to maintain the same caloric intake."
223457808|NCT04088162|DEVICE|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
223457809|NCT02155192|DRUG|No Intervention|
223457810|NCT00823264|DRUG|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
223573632|NCT03008135|OTHER|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
223573633|NCT03008135|OTHER|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
223573634|NCT03209648|DRUG|Debio 1450|Debio 1450, 40 mg capsule.
223573635|NCT03209648|DRUG|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
223573636|NCT05595018|OTHER|End user|Participants will provide their opinions in two rounds to reach consensus
223573637|NCT05595018|OTHER|Demand side- management|Participants will provide their opinions in two rounds to reach consensus
223573638|NCT05595018|OTHER|Supply side|Participants will provide their opinions in two rounds to reach consensus
223573639|NCT05595018|OTHER|Funder|Participants will provide their opinions in two rounds to reach consensus
223457811|NCT05133323|DRUG|Lu AG09222|Lu AG09222 will be administered per schedule specified in the arm.
223457812|NCT05133323|DRUG|Placebo|Placebo matching to Lu AG09222 will be administered per schedule specified in the arm.
223457813|NCT05407285|DRUG|cannabis 0 mg, placebo|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
223457814|NCT05407285|DRUG|Cannabis 20 mg,|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
223457815|NCT05407285|DRUG|Cannabis 50 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
223457816|NCT05407285|DRUG|Cannabis 100 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
223457817|NCT05407285|DRUG|Cannabis 200 mg|Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
223457818|NCT00113295|DRUG|Continued Paroxetine CR|
223457819|NCT00113295|DRUG|Quetiapine|
223457820|NCT00113295|DRUG|Placebo|
223457821|NCT01714544|DRUG|Cloderm Cream|
223457822|NCT06474156|BEHAVIORAL|Multidimensional Family Therapy|Multidimensional family therapy is a manualized,evidence-based, intensive intervention program with assessment and treatment modules focusing on four areas: (a) the individual adolescents' issues regarding substance use disorder, delinquency, and comorbid psychopathology, (b) the parents' child-rearing skills and personal functioning, (c) communication and relationship between adolescent and parent(s), and (d) interactions between family members and key social systems (Liddle, 2002).
223457823|NCT02697214|DEVICE|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
223457824|NCT02697214|DEVICE|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
223457825|NCT02697214|DEVICE|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
223573640|NCT05595018|OTHER|Academia|Participants will provide their opinions in two rounds to reach consensus
223457826|NCT02697214|DEVICE|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
223457827|NCT01179607|DRUG|M0002|
223457828|NCT01179607|DRUG|Placebo|
223457829|NCT04891666|DIETARY_SUPPLEMENT|Lactobacillus plantarum DSM 33464|1 sachet SmartGuard® per day for 12 weeks
223457830|NCT04891666|DIETARY_SUPPLEMENT|Placebo|1 sachet of placebo per day for 12 weeks
223457831|NCT02459197|BEHAVIORAL|Heat Pain Stimuli A|
223457832|NCT02459197|BEHAVIORAL|Heat Pain Stimuli B|
223457833|NCT02459197|BEHAVIORAL|Positive Video|
223457834|NCT02459197|BEHAVIORAL|Neutral Video|
223457835|NCT02459197|DRUG|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
223457836|NCT02459197|DRUG|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
223457837|NCT06076031|BEHAVIORAL|Streaming Media|The aim of this study is to conduct a cross-over randomized clinical trial to compare the effects of with using streaming media (video and audio) on reducing pain medication use, anxiety, pain intensity, and factors related to pain during dressing changes for second-degree burn patients.
223457838|NCT05030116|DRUG|Shenqu Xiaoshi oral liquid|Shenqu Xiaoshi oral liquid
224067405|NCT06923761|DRUG|Module 1 (GRWD5769 on its own as monotherapy)|"Module 1 will initially be conducted in 4 study parts:~Part A: Monotherapy dose escalation (where the safety of increasing doses of GRWD5769 will initially be assessed in a small group of patients, overseen by a safety review committee)~Part B: (Optional) Monotherapy dose expansion part (to look at the effect of GRWD5769 on the body, and of the body on GRWD5769, at particular dose levels to include evaluation of biopsies of tumour tissue)~Part C: (Optional) Intra-patient dose escalation (where a patient may receive three different GRWD5769 doses so that blood levels at each dose can be measured in an individual)~Part D: Monotherapy dose expansion group(s) (where a dose of GRWD5769 may be chosen to be evaluated in specific types of cancer)"
224067406|NCT06923761|DRUG|Module 2 (GRWD5769 in combination with cemiplimab, administered IV)|"Module 2 will initially be conducted as 3 study parts, similar to those above, but looking at GRWD5769 when given in combination with cemiplimab:~Part A: Combination therapy dose escalation (like Module 1 Part A)~Part B: (Optional) Combination therapy dose expansion part (like Module 1 Part B)~Part C: Combination therapy dose expansion group(s) (where a dose of GRWD5769 given with cemiplimab will be evaluated in specific types of cancer)"
224156015|NCT00519883|OTHER|Exercise|
223457839|NCT05030116|DRUG|Domperidone suspension|Domperidone suspension
223457840|NCT00041197|DRUG|imatinib mesylate|Given orally (PO)
223457841|NCT00041197|OTHER|placebo|Given PO
223457842|NCT00041197|OTHER|laboratory biomarker analysis|Correlative studies
223457843|NCT00004244|BIOLOGICAL|recombinant interferon alfa|
223457844|NCT00004244|BIOLOGICAL|recombinant interleukin-12|
223457845|NCT02824224|DRUG|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
223457846|NCT02824224|DRUG|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
223457847|NCT03005639|DRUG|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
223573641|NCT00612742|DRUG|testosterone gel|once daily transdermal testosterone gel, 300 mcg
223573642|NCT00612742|DRUG|placebo gel|once daily transdermal placebo gel
223743209|NCT00790881|DRUG|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
223743210|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection|Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
223743211|NCT05663307|DRUG|Ginkgo diterpene lactone meglumine injection simulation|Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
223743212|NCT05663307|DRUG|Aspirin|plus aspirin at a dose of 100 mg per day for 90 days.
223743213|NCT02355119|DRUG|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
223457848|NCT04494269|DRUG|Tegoprazan 50mg|Oral administration once daily
223457849|NCT03903250|DIETARY_SUPPLEMENT|A-GPC|Taken orally in liquid form
223457850|NCT03903250|DIETARY_SUPPLEMENT|Sugar|Taken orally in liquid form
223743214|NCT02355119|DRUG|Gemcitabine|
224156016|NCT00519883|OTHER|Supportive Care|
224302745|NCT02757365|DRUG|Levofloxacin|
224302746|NCT03043976|DEVICE|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
224305145|NCT02916043|PROCEDURE|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
223457851|NCT03180957|DRUG|Adalimumab|
223457852|NCT03180957|DRUG|Saline|
223457853|NCT06959589|DRUG|IBI351, cetuximab β combined with FOLFIRI|"Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for metastatic colorectal cancer with KRAS G12C mutations; Twenty untreated patients with advanced colorectal cancer with KRAS G12C mutation are proposed to be enrolled and treated with the first-line IBI351+ cetuximab β injection +FOLFIRI regimen. The historical reference is expected to be around 40-50%, and it is expected to increase to around 75%. Therefore, among the 20 patients, if ≥15 patients achieve remission, it is considered that the efficacy of the trial protocol is statistically significant.~Cohort B - To evaluate the efficacy and safety of BI351 and cetuximab β as second-line treatment for metastatic colorectal cancer with KRAS G12C mutations.~It is proposed to enrolled 30 patients with advanced colorectal cancer with KRAS G12C mutation who have progressed after first-line treatment, and evaluate IBI351+ cetuximab β injection for second-line treatment. The hi"
223457854|NCT04257396|DEVICE|Carbon-Fibre Adjustable Reuseable Accessory (CARA)|Breast support device having a carbon-fibre breast cradle for supine patient positioning.
223457855|NCT03792542|DRUG|Anlotinib|Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
223457856|NCT06958510|DEVICE|3D-Modified Anatomical-Mesh.|3D-Modified Anatomical-Mesh.
223457857|NCT06958510|DEVICE|conventional orbital rim miniplates and orbital mesh configuration|conventional orbital rim miniplates and orbital mesh configuration
223457858|NCT06054945|PROCEDURE|SIFIB (suprainguinal fascia iliaca block)|Ultrasound guided Suprainguinal Fascia Iliaca Block for Knee Arthroplasty Patients
223457859|NCT06054945|OTHER|IPACK (Interspace between the popliteal artery and capsule of the posterior knee )|Ultrasound guided IPACK (Interspace between the popliteal artery and capsule of the posterior knee ) Block for Knee Arthroplasty Patients
223457860|NCT06054945|DEVICE|Patient controlled anagesia device|Those who were administered opioids with PCA as rescue analgesic in the postoperative analgesia plan on the selected dates will be included in the study.
223457861|NCT00215891|DRUG|PEG-Interferon a-2b + Ribavirin|
223457862|NCT04512963|DRUG|Progerinin|100 mg/g nano-suspension for oral use
223457863|NCT04512963|DRUG|Placebo|A substance that has no therapeutic effect, used as a control in testing Progerinin
223457864|NCT01953042|BEHAVIORAL|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
223457865|NCT04870632|OTHER|Education|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.
223457866|NCT04870632|OTHER|Video-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by watching Youtube videos which were made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
223457867|NCT04870632|OTHER|Booklet-based pulmonary rehabilitation|COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
223457868|NCT01427543|BEHAVIORAL|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
223457869|NCT00626652|DRUG|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
223457870|NCT03557918|DRUG|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
224156017|NCT00366418|DRUG|Rituximab|
224156018|NCT01142544|OTHER|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
224156019|NCT01590667|DEVICE|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
224156020|NCT01590667|DEVICE|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
224156021|NCT04645004|DRUG|Aspirin 81Mg Non-enteric coated Tab|one tab daily
224156022|NCT04260529|DRUG|CyPep-1|Intratumoral injection
224156023|NCT04260529|DRUG|Pembrolizumab 25 MG/ML [KEYTRUDA®]|IV infusion
223457871|NCT06958133|OTHER|Standard Postoperative Rehabilitation|Standard rehabilitation protocol after surgical fixation of Weber type B ankle fractures without Kinesio taping.
223457872|NCT06958133|OTHER|Kinesio Taping|Kinesio taping applied over the surgical ankle to assist in reducing postoperative pain, swelling, and improving range of motion.
223457873|NCT01341015|OTHER|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
223457874|NCT04575090|DRUG|Simvastatin|Simvastatin 40 mg daily.
223457875|NCT01695382|BEHAVIORAL|Navigation|As per Arm description
223457876|NCT02702362|DEVICE|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
224067407|NCT06931600|PROCEDURE|Sham adjustment|Two manual high velocity, low amplitude (HVLA) simulated/sham chiropractic interventions in the cervical, thoracic, and/or lumbopelvic regions
224067408|NCT06931600|PROCEDURE|Chiropractic adjustment|Two manual high velocity, low amplitude (HVLA) genuine/real chiropractic interventions in the cervical, thoracic, and/or lumbopelvic regions
224067409|NCT06945653|OTHER|Survey using a questionnaire.|The survey questions are aimed to assess the current state of diversity training in anesthesiology education. This survey serves as a needs assessment and will help gather information on the current state of DEI education within the specialty.
224067410|NCT06945900|OTHER|Telehealth|Paramedics will utilize Telehealth for STEMI patients during transport to determine appropriate care steps.
224067411|NCT00729456|OTHER|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
224067412|NCT00001498|DRUG|methotrexate|
224067413|NCT00001498|DRUG|leucovorin|
224067414|NCT00001498|DRUG|5-fluorouracil|
224067415|NCT00001498|DRUG|cyclophosphamide|
224067416|NCT00001498|PROCEDURE|peripheral blood progenitor cell|
224067417|NCT00001498|DRUG|paclitaxel|
224067418|NCT00001498|DRUG|doxorubicin|
224067419|NCT06213155|DEVICE|Cryoneurolysis|Cryoneurolysis
224067420|NCT06213155|DEVICE|Stimulation|Stimulation
224067421|NCT03713164|DIETARY_SUPPLEMENT|Pomegranate Juice|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
224067422|NCT03713164|DIETARY_SUPPLEMENT|Ellagic Acid|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
224067423|NCT04421248|DRUG|Methylphenidate|In ADHD participants only: blinded, randomized, placebo-controlled single dose, crossover on separate days separated by at least one week.
224067424|NCT04421248|DRUG|Placebo|In ADHD participants only: blinded, randomized, placebo-controlled, single dose, crossover on separate days separated by at least one week.
224067425|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort|For the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae with reference vessel diameters of 4 to 12 mm.
224067426|NCT04543539|COMBINATION_PRODUCT|IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort|For treatment of stenosis in the AV circuit
224067427|NCT02023333|DRUG|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
224067428|NCT04274998|DRUG|[18F]NOS|Main Study: PET/CT imaging will be used to evaluate neuroinflammation in the brain using the investigational radiotracer \[18F\]NOS.
224067429|NCT04274998|DRUG|[11C]PBR28|Sub-Study: Additional PET/CT imaging will be used to evaluate neuroinflammation in the brain for subjects with specific genetic polymorphism using the investigational radiotracer \[11C\]PBR28 in comparison to \[18F\]NOS.
224067430|NCT06568601|GENETIC|Pharmacogenetic and polygenic risk testing|The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.
224067431|NCT06568601|OTHER|Active control|The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test
224067432|NCT04099251|BIOLOGICAL|Nivolumab|Specified dose on specified days
224067433|NCT04099251|OTHER|Placebo|Specified dose on specified days
224067434|NCT03094026|BEHAVIORAL|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
224067435|NCT03094026|BEHAVIORAL|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
224067436|NCT03727971|DRUG|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
224067437|NCT03727971|DRUG|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
224067438|NCT06957405|BEHAVIORAL|MPPG (Mental and Physical Practice Group)|Participants in this group will undergo 10 remote sessions over 6 weeks, each session lasting 45-60 minutes. Each session consists of: (1) two blocks of first-person kinesthetic MP, conducted while seated with eyes closed and guided using DNI principles; and (2) two blocks of corresponding PP, involving simulated gait components such as ankle mobility, postural weight shifts, and short-distance walking under real-time supervision. Each block lasts approximately 10 minutes. The MP emphasizes attentional focus, sensory detail, and task-specific goals. Sessions are conducted synchronously via video call by trained physiotherapists.
223457877|NCT02465437|DRUG|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
223457878|NCT02465437|DRUG|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
223457879|NCT02465437|DRUG|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
223457880|NCT05999591|PROCEDURE|Intrauterine insemination|Transfer of sperm into the fallopian tube through a specialised cannula
223457881|NCT05680662|COMBINATION_PRODUCT|quercetin, EGCG, metformin , zinc|this intervention target many mechanisms at tumorigenesis, metastasis autophagy, apoptosis, interleukin 6, cathepsin L, and also epigenetic DNA methylation
223457882|NCT03128853|DEVICE|Rad-67 and DCI Mini Sensor|
223457883|NCT02104245|DRUG|Ciprofloxacin dispersion for inhalation|
223457884|NCT02104245|DRUG|Placebo|
223457885|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
223457886|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
223457887|NCT02987699|DRUG|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
223457888|NCT03403881|BEHAVIORAL|Physical activity promotion + TAU|"Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual"
223457889|NCT03403881|BEHAVIORAL|Control|Weekly call on general health aspects + treatment as usual
223457890|NCT01533402|BEHAVIORAL|therapist support|Weekly therapist support without CBT-interventions
223457891|NCT01533402|BEHAVIORAL|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
223457892|NCT01874626|DRUG|Placebo|Placebo cream
223457893|NCT01874626|DRUG|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
223457894|NCT01666561|OTHER|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
223573643|NCT03693339|DRUG|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
223573644|NCT05027685|DEVICE|The Paradise Ultrasound Renal Denervation System|The CE-marked and commercially available ReCor Medical Paradise Ultrasound Renal Denervation System (Paradise System) is a catheter-based device designed to use ultrasound energy to thermally ablate the nerves surrounding the renal artery and serving the kidney.
223573645|NCT04592900|OTHER|balance exercising|selected physical therapy program strengthening the muscles of upper and lower limbs, balancing exercise, gait training in open environment,stretching for elbow flexors and forearms pronators,lower limb hip flexors and knee extensor and ankle dorsiflexors
224067439|NCT06957405|BEHAVIORAL|PPG (Physical Practice Group)|Participants in the control group will receive 10 remote sessions over 6 weeks, each session lasting 45-60 minutes. Each session consists of the same PP as the experimental group but replaces motor imagery with two 10-minute seated stretching block, focusing on the upper limbs and trunk. The PP follows the same structure and duration as in the experimental group. All sessions are delivered remotely via live video by physiotherapists trained in both protocols. Volume, frequency, and interaction levels are matched between groups to ensure equivalence.
224067440|NCT05032157|DRUG|LOU064 (blinded)|LOU064 (blinded) active treatment
224067441|NCT05032157|DRUG|Placebo|Placebo
224067442|NCT05032157|DRUG|LOU064 (open-label)|LOU064 (open-label) active treatment
224067443|NCT04392518|OTHER|exercise|Breathing, posture, dynamic core stabilization, upper and lower extremity strengthening exercises.
224067444|NCT04495738|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
224067445|NCT04495738|OTHER|Control Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
224067446|NCT04495738|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
224067447|NCT04495738|OTHER|Experimental Toddler Drink|16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
224067448|NCT04495738|OTHER|Supplemental Formula for HM Group|Ad libitum formula given up to 12 months of age if HM is supplemented
224067449|NCT04495738|OTHER|Toddler Drink for HM group|16 fl oz per day if weaned from HM feedings
224067450|NCT00480610|DRUG|tacrolimus ointment|Topical application
224067451|NCT00480610|DRUG|Placebo ointment|Topical application
224067452|NCT03047980|DRUG|Sirolimus|Low dose oral sirolimus
224067453|NCT05686174|DIETARY_SUPPLEMENT|MBS217|Soybean Fermented Extract (MBS217)
224067454|NCT05686174|DIETARY_SUPPLEMENT|Placebo|Without active ingredient
224067455|NCT00880893|BIOLOGICAL|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
224067456|NCT00880893|BIOLOGICAL|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
224067457|NCT04411550|DRUG|HLX11|healthy volunteers receive HLX11 (420mg) once
224067458|NCT04411550|DRUG|CN-Perjeta(Pertuzumab)|healthy volunteers receive CN-Perjeta (420mg) once
224067459|NCT04411550|DRUG|EU-Perjeta(Pertuzumab)|healthy volunteers receive EU-Perjeta (420mg) once
224067460|NCT04411550|DRUG|US-Perjeta(Pertuzumab)|healthy volunteers receive US-Perjeta (420mg) once
224067461|NCT05299437|DRUG|Radioiodine optimized therapy|"124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal.~Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status."
224067462|NCT06246760|OTHER|Exercise|Incremental exercise test until volitional exhaustion
224067463|NCT00006565|DEVICE|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
224067464|NCT00006565|DEVICE|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
223457895|NCT01666561|OTHER|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
223457896|NCT01666561|OTHER|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
223457897|NCT00001919|DRUG|Hypericum (LI-160)|
223457898|NCT00003483|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
223573646|NCT05097300|OTHER|Suboccipital inhibition|The therapist will place his hands under the patient's head, making contact with the suboccipital muscles in the region of the posterior arch of the atlas, applying progressive and deep pressure. This pressure will be maintained for 10 minutes
223573647|NCT05097300|OTHER|Ischemic pressure|"Pressures will be made on the temporal, superior trapezius, masseter and sternocleidomastoid muscles. Physical therapist will apply gradual sustained finger pressure to the muscle's active trigger points for 5-15 seconds. The therapist will begin with light firm pressure and gradually increase the pressure until the patient feels a moderate but bearable level of pain (corresponding to a level 7 on a pain scale of 1 to 10 levels where 1 indicates no pain and 10 is excruciating pain). Pressure will remain at this level until pain levels decrease to level 3. The therapist will repeat this procedure approximately 3-4 times over a 90 second period."
223573648|NCT05097300|OTHER|Passive stretching|Passive stretches will be applied to each muscle 2 times for 30 seconds, they will be performed slowly at the rate of the patient's normal breathing and checking that no compensations appear.
223573649|NCT05097300|OTHER|Diaphragmatic breathing exercice|To perform diaphragmatic breaths, there will first be an education on how to do them. The patient will lie supine, with the hips and knees semi-flexed. The therapist will ask you to place one hand on your chest and one on your abdomen. Successively, it will ask you to take a few deep breaths, inhaling through your nose for 2 seconds and exhaling through your mouth, with your lips pursed (almost closed) for 4 seconds, helping you to maintain the rhythm of your breath by counting out loud. The patient should note that during inspiration his hand on top of the chest does not rise (the chest remains still) and during expiration that his hand on top of the abdomen goes down (the abdomen sinks).
223457899|NCT02363387|BEHAVIORAL|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
223573650|NCT06301750|BEHAVIORAL|Conventional Care|"Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training."
223573651|NCT06301750|DEVICE|Intermittent Oral-esophageal Tube Feeding|Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
223743215|NCT03724409|DRUG|[90]Y-DOTATOC|Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
223457900|NCT02363387|BEHAVIORAL|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
223457901|NCT02609386|BIOLOGICAL|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
223743216|NCT00238121|DRUG|sorafenib tosylate|Given orally
223743217|NCT02448654|DRUG|Tolcapone|Tolcapone will be compared to sugar pill
224067465|NCT03331809|PROCEDURE|Two-handed jaw thrust|The assistant applied two-handed jaw thrust when intubating with double-lumen tube endotracheal tube.
223457902|NCT02609386|DRUG|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
223457903|NCT02609386|DRUG|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
223457904|NCT02609386|DIETARY_SUPPLEMENT|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
223457905|NCT02609386|DRUG|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
224067466|NCT03331809|PROCEDURE|Conventional intubation|The attending anesthesiologist provided intubation with double-lumen tube endotracheal tube without two-handed jaw thrust.
224067467|NCT05185609|OTHER|Exposure 1: Visceral hypersensitivity or phenotype suggestive of IBS|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
223457906|NCT04142671|OTHER|Individualised gait modification intervention|An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
223457907|NCT03967067|PROCEDURE|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
223457908|NCT04567004|OTHER|Control|Participants will be shown images of juice, bread, yogurt, cookies, and cereal without any added front-of-package labels.
223457909|NCT04567004|OTHER|Nutriscore Label|A front-of-package Nutriscore label will be applied to images of juice, bread, yogurt, cookies, and cereal. This label applies a score of A, B, C, D, or E based on the product's nutrition profile.
223457910|NCT04567004|OTHER|Adapted Peruvian Nutrient Label|A front-of-package octagonal nutrient label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label text informs consumers if a product is high in sugar, saturated fat, or salt/sodium. These labels were developed by the Peruvian government and adapted by investigators.
223457911|NCT04567004|OTHER|Guideline Daily Amount Label|A front-of-package Guideline Daily Amount label will be applied to images of juice, bread, yogurt, cookies, and cereal. The label shows the amount and percent of daily value of calories, total fat, saturated fat, sugar, and sodium in one serving of a product.
223457912|NCT04630782|DIAGNOSTIC_TEST|PET-MRI scan|Participants will be scanned centrally at Clinical Imaging Research Centre (CIRC, Singapore), on a Biograph mMR PET-MR scanner. Combined FDG-PET-MRI scan is critical for co-registration of peristaltic bowel for optimal image quality. The oesophagus to anorectum will be imaged. The PET-MRI scan starts 60 minutes post-FDG injection of 6mCi and immediately after injecting 10mg hyoscine butylbromide to reduce peristalsis. MRI sequences are non-contrast.
223457913|NCT01065571|DIETARY_SUPPLEMENT|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
223457914|NCT01065571|OTHER|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
223457915|NCT01784276|BEHAVIORAL|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
223457916|NCT05498597|DRUG|AMT-151|Administered intravenously
223457917|NCT05409716|PROCEDURE|Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.
223457918|NCT05409716|PROCEDURE|Wristband TR band for hemostasis in cardiac procedure using radial approach|Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
223457919|NCT00198263|COMBINATION_PRODUCT|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
223457920|NCT00196703|DRUG|memantine|
223457921|NCT00196703|PROCEDURE|constraint-induced language therapy|
223457922|NCT04330417|DEVICE|Robot-Assisted Hand Training|Perform activities of daily living, e.g., write sentences, turn cards, move small and big objects, simulated feeding, stack checkers, pour water, squeeze handles
223457923|NCT04330417|OTHER|Standard Hand Therapy|Stretching, Strengthening, Hand Functional Training
223457924|NCT02454348|DRUG|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
223457925|NCT02454348|DRUG|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
223457926|NCT00459771|DRUG|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
223457927|NCT00459771|DRUG|Placebo|Placebo, 32 mg, oral QD
223457928|NCT02244047|DRUG|Bifidobacterium breve|
223457929|NCT02244047|DRUG|Placebo (for Bifidobacterium breve)|
223457930|NCT00815997|PROCEDURE|PCI (percutaneous coronary intervention)|PCI will be performed via the radial artery.
223457931|NCT03464084|DRUG|placebo|Capsules containing microcrystalline cellulose
224067468|NCT05185609|OTHER|Exposure 2: Changes in anorectal motor function or compliance.|Assess the relation between the exposure and the outcome which is persistent symptoms in the patients with quiescent disease.
223457932|NCT03464084|DIETARY_SUPPLEMENT|melatonin|5 mg of melatonin per os.
223457933|NCT03464084|OTHER|bright light|room light will be bright
223457934|NCT03464084|OTHER|dim light|room light will be dim
223457935|NCT06199427|DRUG|Cyclophosphamide|Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
223457936|NCT06199427|DRUG|Ruxolitinib|Ruxolitinib 7 mg/m2 from day +5 after HSCT
223457937|NCT03446976|BIOLOGICAL|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
223457938|NCT03446976|BIOLOGICAL|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
223457939|NCT02429102|DRUG|MT-8554|
223457940|NCT02429102|DRUG|Placebo|
223457941|NCT03925129|DEVICE|high frequency TENS treatment|Treatment with high frequency for minimum of 1 hour after misoprostol administration
223457942|NCT03925129|DEVICE|Sham TENS treatment|Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
223457943|NCT00054223|PROCEDURE|psychosocial assessment and care|
223457944|NCT01562652|DEVICE|AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)|
223457945|NCT01348685|OTHER|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
223457946|NCT01348685|OTHER|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
224067469|NCT05230186|PROCEDURE|Tumor Biopsy|Research biopsy of solid tumor or sharing of excess tumor tissue during a planned surgical or biopsy procedure and a companion blood sample.
224067470|NCT02164981|DRUG|sodium nitroprusside|intravenous
223573652|NCT06301750|DEVICE|Nasogastric tube|Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
224156024|NCT02201667|DRUG|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
224156025|NCT02201667|DRUG|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
223573653|NCT03584191|OTHER|No treatment given|Completion of a survey
223457947|NCT01348685|OTHER|The effect of solid vs. liquid forms of whey protein on food intake|
223457948|NCT03019029|OTHER|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
223457949|NCT04579432|OTHER|Education|With the training module prepared according to the ADDIE model, the intervention group will be trained on reproductive health and sexual health.
223457950|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
223457951|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
223457952|NCT00716807|DRUG|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
223457953|NCT00716807|DRUG|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
223573654|NCT06508268|BEHAVIORAL|GAITRite walkway system OR 4-meter walking speed test|Gait will be assessed by the GAITRite walkway system OR the 4-meter walking speed test
223573655|NCT06508268|BEHAVIORAL|Jamar hand dynamometer|Hand grip strength will be assessed by a Jamar hand dynamometer
223743218|NCT02448654|DRUG|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
223743219|NCT03255382|DRUG|Fumaderm|Fumaderm tablet administered orally
224156026|NCT02201667|DRUG|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
223457954|NCT00216528|DRUG|risperidone|
223457955|NCT04033406|DRUG|VIR-2482|VIR-2482 given by intramuscular injection
223457956|NCT04033406|DRUG|Placebo|Sterile normal saline (0.9% NaCl) given by intramuscular injection
223457957|NCT00570336|DRUG|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
223457958|NCT00570336|OTHER|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
223743220|NCT03255382|DRUG|risankizumab|Risankizumab administered by subcutaneous (SC) injection
223743221|NCT03816059|DIAGNOSTIC_TEST|Respiratory virus testing|All patients will be tested for respiratory viruses
223457959|NCT01957423|DIETARY_SUPPLEMENT|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
223457960|NCT01957423|DIETARY_SUPPLEMENT|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
223457961|NCT01773603|DEVICE|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
223457962|NCT00652704|DRUG|Doxycycline monohydrate|Capsules, 100 mg, fed
223457963|NCT00652704|DRUG|Monodox|Capsules, 100 mg, fed
223457964|NCT00652704|DRUG|Doxycycline Monohydrate|Capsules, 100 mg, fasting
223573656|NCT06508268|BEHAVIORAL|Picture description task|Characteristics Dutch/Frisian language Language and speech will be assessed by the Cookie Theft Picture-task (a picture description task from Berube et al., 2019)
223743222|NCT02155647|DRUG|Avelumab|Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
223743223|NCT02221284|DRUG|Alogliptin|Alogliptin tablets
223743224|NCT05190731|OTHER|Osteopathic cranial manipulative medicine|Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
223743225|NCT05190731|OTHER|Sham|Touch only, no osteopathic cranial manipulation
223743226|NCT00140647|DRUG|Ramipril|
223743227|NCT00140647|DRUG|Rosiglitazone|
223743228|NCT02450110|DEVICE|Spinal cord stimulation|
224067471|NCT02164981|OTHER|Placebo|Placebo
224067472|NCT04395261|DIAGNOSTIC_TEST|Wideband Tympanometry|
224067473|NCT01072370|BIOLOGICAL|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
224067474|NCT01072370|BIOLOGICAL|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
224067475|NCT01489514|OTHER|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~1. Histamine control purchased from Greer.~2. Saline control purchased from Greer.~3. Standard Peanut Extract purchased from Greer.~4. Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A \& T.~5. Sterile extract prepared from roasted \& blanched but untreated peanuts. This is prepared by North Carolina A \& T.~6. Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A \& T. This is not classified as a drug and is~7. Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~8. Sterile extracts containing peanuts that have been treated with alcalase"
224067476|NCT05738850|DRUG|ABBV-932|Oral Capsule
224067477|NCT05738850|DRUG|Placebo|Oral Capsule
223743229|NCT03706794|BEHAVIORAL|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
223457965|NCT01001520|DRUG|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
223457966|NCT01001520|DRUG|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
223457967|NCT02541422|DIETARY_SUPPLEMENT|N Acetyl Cysteine|
223457968|NCT02541422|OTHER|placebo|
223457969|NCT03146338|OTHER|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
223457970|NCT03944213|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
223457971|NCT02033044|OTHER|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
223457972|NCT02033044|OTHER|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
223457973|NCT02710019|OTHER|Back to Reality Series Video Games|Back to Reality Series are a psycho-educational video games that provide information about psychosis and marijuana use from the perspective of 'Harry': a character who experiences problems with both issues. The aim is for players to learn how to detect some signs of psychosis and where to seek help for mental health and addictions problems.
223457974|NCT02710019|OTHER|Control Video Game|The control video game consists of digital puzzles and spelling game about pop culture. The control games does not have any content related to mental health and addictions problems
223457975|NCT00789620|DRUG|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
223457976|NCT00789620|DRUG|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
223457977|NCT05929742|BEHAVIORAL|virtual reality training|The experimental group received five additional days of supervised VR training using a wireless sensor in a private room in the neurological care ward.
223457978|NCT05929742|BEHAVIORAL|early rehabilitation|Five 60-minute sessions per week, was prescribed by a rehabilitation physician and performed by physical, occupational, and speech therapists from 3 to 6 days after admission.
223457979|NCT05004792|OTHER|DermLoop Learn|DermLoop Learn is our AI-augmented digital educational platform with case training on a library of 18,000+ benign and malignant skin lesions, educational videos on the correlation between dermoscopy and histology, as well as written learning modules for the most common skin lesion diagnosis. The education platform will give the user feedback on the image-based case training in dermoscopic diagnostic accuracy and adjust the cases depending on the user's progression.
223457980|NCT04272463|OTHER|No intervention|Patients currently in treatment with benralizumab as per approved indication and clinical practice
223457981|NCT00968955|DRUG|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
223457982|NCT06164938|DIAGNOSTIC_TEST|Diagnostic accuracy|The aim is to obtain a regional measure of brain glucose metabolism in each normal subject because this is a functional measure of brain activity.
223457983|NCT00209950|DRUG|Gaboxadol|
223457984|NCT01967004|DEVICE|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
223457985|NCT03335319|OTHER|Periodized Exercise Training Regime|MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or \> 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
223573657|NCT06508268|BEHAVIORAL|Autobiographical semi-structured conversation|Characteristics Dutch/Frisian language and speech will be assessed by an autobiographical semi-structured conversation
223573658|NCT06508268|BEHAVIORAL|Verbal fluency|The mental lexicon of Dutch/Frisian language will be assessed by a two verbal fluency tests, including letter fluency and categorical fluency
223573659|NCT05720364|DRUG|TP-05 (lotilaner oral), fasted group|TP-05 (lotilaner oral), fasted group
223573660|NCT05720364|DRUG|TP-05 (lotilaner oral), high-fat group|TP-05 (lotilaner oral), high-fat group
223573661|NCT05720364|DRUG|TP-05 (lotilaner oral), low-fat group|TP-05 (lotilaner oral), low-fat group
223743230|NCT03706794|BEHAVIORAL|Headache Education|Non-tailored education provided via a smartphone application.
223743231|NCT04102592|OTHER|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
223743232|NCT04102592|OTHER|Untreated Lesu (baby wrap)|Matching untreated lesu
223457986|NCT03335319|OTHER|Non Periodized Exercise Training Regime|To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
223457987|NCT00209391|DRUG|Gadodiamide Injection|
223457988|NCT01351090|DRUG|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
223457989|NCT01351090|DRUG|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
223457990|NCT01351090|DRUG|Placebo|Intranasal
223457991|NCT06542367|PROCEDURE|"Tympanoplasty performed under local anesthesia using fat graft and Tachosil."|"Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane to fill the ear canal. follow-up will be held at 2, 4-6 and 12 months following the procedure, with audiometric and otological evaluation"
223457992|NCT04199377|PROCEDURE|HIP KNEE REPLACEMENT|HIP KNEE REPLACEMENT
223457993|NCT06039072|DRUG|Patients with cardiac function recovered for more than one year and discontinued were in the discontinuation group.|Among the patients with perinatal cardiomyopathy who were included in the study, their heart function returned to normal in 1 year after receiving standardized treatment, and then after another 1 year of standardized treatment to respect the patients' individual wishes, fully inform the patients of the relevant information and potential risks, including the possibility of deterioration of heart function after discontinuation of the medication, and only after obtaining the patients' informed consent and signing the informed consent form could they be included in the discontinuation group, and the rest were in the non-discontinuation group.
223457994|NCT04165356|PROCEDURE|Mouth-rinse with 0.12% clorhexidine|mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
223457995|NCT04165356|PROCEDURE|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate|mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
223457996|NCT00202501|DEVICE|Nasal CPAP (Continuous Positive Airway Pressure)|
223457997|NCT05136079|PROCEDURE|Prophylactic lymphaticonvenous anastomosis|Prophylactic lymphaticovenous anastomosis is an immediate prophylactic approach whereby the lymphaticovenous anastomosis is performed at the time of nodal dissection utilizing fluorescing indocynanine green (ICG) and an operating microscope.
223457998|NCT02197585|PROCEDURE|Inguinal mesh hernioplasty|
223457999|NCT03824717|DRUG|Dose of ropivacaine|Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
223458000|NCT06316596|PROCEDURE|Spinal Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
223458001|NCT06316596|PROCEDURE|Epidural Anesthesia|Near infrared spectroscopy , neonatal peripheral oxygen saturation measurements and hemodynamic data will be compared between groups
223458002|NCT03591601|OTHER|Manual Therapy protocol|Treatment based on manual therapy with proven evidence.
223458003|NCT03591601|OTHER|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
223458004|NCT03591601|OTHER|Placebo control|Placebo treatment based on the placement of the hands on the head without intention to treat.
223458005|NCT02807831|BEHAVIORAL|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
223458006|NCT02807831|BEHAVIORAL|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
224156027|NCT02201667|PROCEDURE|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
223458007|NCT02807831|OTHER|Regular school curriculum|Ministry of Education national school curriculum.
223458008|NCT03000985|BEHAVIORAL|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
223458009|NCT00002182|DRUG|Megestrol acetate|
223458010|NCT04254081|DRUG|Buprenorphine 0.15 MG|Buprenorphine 0.15mg solution will be added to a 20mL 1% buffered lidocaine solution (paracervical block) which will be administered in the paracervical space prior to osmotic dilator insertion.
223458011|NCT04254081|DRUG|Lidocaine 1% Injectable Solution|20mL of 1% buffered lidocaine solution (paracervical block) will be administered in the paracervical space prior to osmotic dilator insertion.
223458012|NCT00254059|PROCEDURE|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
223458013|NCT02210507|OTHER|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
223458014|NCT02210507|OTHER|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
223743233|NCT04178187|DRUG|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
223743234|NCT04178187|DRUG|Caps Placebo|Caps Placebo
223458015|NCT02210507|OTHER|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
224156028|NCT01464814|DIETARY_SUPPLEMENT|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
224156029|NCT01464814|DIETARY_SUPPLEMENT|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
224302747|NCT01819974|OTHER|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
223573662|NCT03644914|BEHAVIORAL|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
223573663|NCT02830607|DEVICE|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
223573664|NCT00823212|DEVICE|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
223573665|NCT00823212|DEVICE|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS \[XIENCE V\] stent).
223573666|NCT00823212|DRUG|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
223573667|NCT00823212|DRUG|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
223573668|NCT03141463|BIOLOGICAL|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
223573669|NCT01551277|OTHER|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
223743235|NCT02711046|PROCEDURE|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
223743236|NCT02071888|DRUG|CB-839|Glutaminase inhibitor
223743237|NCT02071888|DRUG|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
223458016|NCT06433843|BEHAVIORAL|Dialectical behavioral therapy for the treatment of posttraumatic stress disorder (DBT-PTSD)|12 weeks inpatient disorder specific psychotherapy
223458017|NCT06480136|DRUG|SHR-A1921 injection and adebrelimab injection|The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
223458018|NCT06392152|DRUG|Focal Mass Drug Administration with Primaquine|"A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year."
223458019|NCT05115539|OTHER|doppler US of portal vein, hepatic veins, intrarenal veins|"Hepatic Vein Doppler : To obtain the HV PW, a phased array transducer is used with cardiac pre-sets. ECG leads are placed to assist in the interpretation of HVD in sinus rhythm as well as atrial fibrillation. The middle hepatic vein is identified from mid-subcostal or lateral views during the end-expiratory phase of the patients respiratory cycle.~Portal vein Doppler: From a lateral costal or subcostal window, the portal vein is identified in the coronal plane using a phased-array transducer. The PV were considered abnormal if the pulsatilty index was greater than 30%. The portal pulsatility index was defined as: (VMax - VMin/VMax) \* 100%. Here, VMax is the maximal velocity and VMin is the minimal velocity during the cardiac cycle.~Intra-renal venous Doppler: From lateral costal window, the kidney is located in the coronal plane and a color flow box placed over the distal renal calyceal junction to cortex."
223458020|NCT05174156|DRUG|Combination therapy|SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin
223458021|NCT04020536|DRUG|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
223458022|NCT04694976|BIOLOGICAL|25-OH Vitamin D measure|As a complement to the off-study prescription, the investigator are taking two 1 mL tubes of extra blood to measure vitamin D, calcium, phosphorus, parathyroid hormone (PTH) and creatinine.
223458023|NCT04420169|OTHER|Questionnaire|A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
223458024|NCT06064058|DIETARY_SUPPLEMENT|Ghazwan program|6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
223458025|NCT06064058|DRUG|Standard management|Standard care with NSAIDs and acetaminophen for pain management
223458026|NCT01176786|OTHER|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
223458027|NCT03028675|OTHER|MRI Scan|MRI scans will consist of a 1-hour brain scan for both patients and controls.
224156030|NCT05154357|OTHER|Elastic Sac|Half an hour before the feeding time, the infant will be placed in the elastic sac, be laid in the right lateral position within the nest with an angle of 45 degrees and will be allowed to take a rest within the elastic sac for half an hour. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
224156031|NCT05154357|OTHER|Control|Half an hour before the feeding time, the infant will be laid in the right lateral position within the nest with an angle of 45 degrees without performing any different application and will be allowed to take a rest. At the feeding time, he/she will be fed by the researcher with a bottle in the right lateral position within the elastic sac with an angle of 45 degrees without making any change in his/her position.
224156032|NCT05723874|DRUG|BI 425809|BI 425809
224156033|NCT05723874|DRUG|bosentan|bosentan
224156034|NCT00130468|DRUG|Hyalgan (sodium hyaluronate)|
224156035|NCT02945839|DRUG|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
224156036|NCT02945839|BEHAVIORAL|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
223573670|NCT01551277|OTHER|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
223573671|NCT03730077|DRUG|18F-FMISO|18F-FMISO PET/CT
224302748|NCT02195089|DRUG|BLS_ILS_E710c 500mg|\- 2 capsules per day for 20 days (week 1,2,4 \& 8)
224302749|NCT02195089|DRUG|BLS_ILB_710c 1000mg|\- 4 capsules per day for 20 days (week 1,2,4 \& 8)
223573672|NCT05232968|OTHER|Long-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
223573673|NCT05232968|OTHER|Short-term exercise program|Training intervention (aerobic-strength training) will combine a 1-hour aerobics training, which requires movement coordination, and two 1-hour lessons, combining strength load (25 minutes, 50-60% 1RM, which gradually increases in proportion to increasing strength, 8-12 repetitions, training all major muscle groups) and aerobic exercise (25 minutes of Nordic walking or stationary bike), with a short warm-up at the beginning and stretching at the end. The individualized training program will be based on the determination of physical fitness (Rockport gait test) and muscle strength (dynamometry).
224156037|NCT02945839|BEHAVIORAL|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
224156038|NCT01083225|BEHAVIORAL|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
224156039|NCT01083225|BEHAVIORAL|Treatment as usual|Treatment as usual, consultations
224156040|NCT03224104|DRUG|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
224156041|NCT03224104|RADIATION|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
224156042|NCT03224104|DRUG|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
224156043|NCT04211844|DRUG|sofosbuvir plus daclatasvir|50 patients in the first group will receive 400 mg sofosbuvir plus daclatasvir 60 mg once daily for 12 weeks.
224156044|NCT04211844|DRUG|Sofosbuvir plus Ledipasvir|50 patients in the second group will receive 400 mg sofosbuvir plus ledipasvir 90 mg (Harvoni) once daily for 12 weeks.
224156045|NCT02011672|OTHER|nutrient-enriched milk|
224302750|NCT02195089|DRUG|BLS_ILS_E710c 1500mg|\- 6 capsules per day for 8 weeks (week 1,2,4 \& 8)
224302751|NCT04048044|DEVICE|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
224302752|NCT00987389|PROCEDURE|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
224302753|NCT00987389|OTHER|No Plasma Exchange|No plasma exchange.
224302754|NCT00987389|DRUG|Glucocorticoids [Standard Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a standard regimen.
224302755|NCT00987389|DRUG|Glucocorticoids [Reduced Dose]|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following a reduced regimen.
224156046|NCT02011672|OTHER|regular milk|
224302756|NCT04514068|PROCEDURE|Acupuncture|In each session, acupuncture are applied unilaterally or bilaterally on P6 acupoint. Each acupuncture needle will be stimulated by transcutaneous electric device.
224302757|NCT04514068|PROCEDURE|Sham acupuncture|Sham acupuncture
223573674|NCT03179111|PROCEDURE|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
223573675|NCT01344538|DRUG|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
223573676|NCT01344538|DIETARY_SUPPLEMENT|Placebo Capsule|2.0 g per day
223573677|NCT02763475|DRUG|cyclophosphamide|60mg/kg by vein on day -6
223573678|NCT02763475|DRUG|Fludarabine|25mg/m2 iv daily on day -5 to -1
223573679|NCT02763475|PROCEDURE|NK cell infusion|"* First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~* Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
223573680|NCT02763475|DRUG|IL-2|1x10\^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
223573681|NCT02854124|PROCEDURE|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
223573682|NCT05801393|RADIATION|CT, MRI|"HRCT with no IV contrast administration and bone algorithm. Intra thecal injection of contrast, then CT in prone position to obtain direct coronal cuts.~MR cisternography using a three dimensional constructive interference in steady state (3D-CISS) sequence."
223743238|NCT02071888|DRUG|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
223743239|NCT01675128|DRUG|ISIS 183750|
224156047|NCT00678236|OTHER|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
224156048|NCT00678236|OTHER|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
223458028|NCT02820870|BEHAVIORAL|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
223458029|NCT01653145|OTHER|Diet A|Dietary
223458030|NCT01653145|OTHER|Diet B|Dietary
223458031|NCT01653145|OTHER|Diet C|Dietary
223573683|NCT05452369|DRUG|Rhomboid intercostal plane block|\- 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
223573684|NCT01655381|DRUG|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
223573685|NCT01574898|DRUG|V0474 - A mg|Single oral administration
223573686|NCT01574898|DRUG|V0474 - B mg|Single oral administration
223458032|NCT03285035|DEVICE|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
223458033|NCT04491981|PROCEDURE|Encapsulated Glass Ionomer Cement|Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).
223458034|NCT04491981|PROCEDURE|Composite resin|Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
223458035|NCT00006114|DRUG|mitoxantrone hydrochloride|
223458036|NCT00006114|DRUG|vinorelbine tartrate|
223573687|NCT01574898|DRUG|V0474 - C mg|Single oral administration
223573688|NCT01574898|DRUG|V0018 - B mg|Single oral administration
223573689|NCT01574898|DRUG|Niquitin® Fresh Mint 4 mg|Single oral administration
223573690|NCT00973544|OTHER|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
223573691|NCT00320255|DRUG|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
223573692|NCT00320255|DRUG|Placebo|Oral tablets administered once daily
223743240|NCT01675128|DRUG|Irinotecan|
223743241|NCT02749812|DEVICE|Constant Continuous Positive Airway Pressure|
223743242|NCT02749812|DEVICE|Automatic continuous Positive Airway Pressure|
223743243|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
223743244|NCT02225756|DRUG|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
223743245|NCT02225756|DRUG|Placebo|Oral administration for a short time of placebo
224156049|NCT00534924|DRUG|Vit C|
224156050|NCT00534924|PROCEDURE|Postconditioning|
224156051|NCT00534924|OTHER|no intervention|
224156052|NCT02645136|OTHER|Pilates|Pilates exercises
224156053|NCT02645136|OTHER|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
224156054|NCT02645136|OTHER|Control|
224156055|NCT03782844|DEVICE|Simple CPAP+Conventional fixed CPAP|Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.
224156056|NCT03782844|DEVICE|Simple CPAP + Auto CPAP|Patients used simple CPAP and Auto CPAP during overnight polysomnography.
224156057|NCT01266070|DRUG|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
224156058|NCT00032006|RADIATION|brachytherapy|
224156059|NCT00032006|RADIATION|radiation therapy|
223458037|NCT02565602|OTHER|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
223458038|NCT02565602|OTHER|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
223458039|NCT02565602|DIETARY_SUPPLEMENT|Vitamin D|One tablet daily (400IU per tablet)
223573693|NCT04201366|OTHER|No intervention|No intervention
223458040|NCT01369745|DRUG|Prednisolone|Prednisolone 2.7 mg daily
223458041|NCT01369745|DRUG|dipyridamole|dipyridamole 360 mg daily
223458042|NCT01369745|DRUG|Prednisone|Prednisone 5 mg daily
223458043|NCT01369745|DRUG|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
223458044|NCT01369745|OTHER|placebo|
223458045|NCT03953521|DEVICE|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
223458046|NCT02861963|PROCEDURE|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
223743246|NCT02162342|OTHER|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
224156060|NCT05375786|BIOLOGICAL|Vaccination completion status|the relation between vaccination completion status and the target population
224156061|NCT02131389|DEVICE|Iconacy Hip System|
223458047|NCT02861963|PROCEDURE|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
223458048|NCT03042351|DEVICE|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
223458049|NCT02754518|DRUG|Entresto|
223458050|NCT00878800|DRUG|PXD101|Administered in combination with doxorubicin (BelDox)
223458051|NCT00878800|DRUG|Doxorubicin|Administered in combination with PXD101 (BelDox)
223458052|NCT01080092|BEHAVIORAL|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
223743247|NCT01396460|OTHER|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
224067478|NCT05650983|BEHAVIORAL|Aerobic exercise; Resistance exercise|To investigate affect/effect of dissimilar modes of exercise, Aerobic exercise versus Resistance exercise, on execution function and psychological symptoms in heroin addicts, 1 hour of characteristic exercise protocols aiming to (a) maximize the strain on the cardiovascular system with Aerobic exercise(60-70% of heart rate recovery) and (b) promote the greatest hypertrophy response with Resistance exercise(65% of 1 repetition maximum \& repeated up to 15 time) were used. Both exercise programs were designed to match the male heroin addicts, with medium-intensity Strength-Trained for Resistance exercise and playing balloon volleyball for Aerobic exercise. Two exercise groups performed at 65% of their pre-determine peak oxygen uptake.
224156062|NCT04231513|DRUG|E2814|E2814, intravenous infusion.
224156063|NCT04231513|DRUG|E2814-matched placebo|E2814-matched placebo, intravenous infusion.
224156064|NCT03234972|DRUG|Daratumumab|Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
223458053|NCT01080092|BEHAVIORAL|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
223458054|NCT00613821|DRUG|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
223458055|NCT00613821|DRUG|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
223458056|NCT00459719|DRUG|Tacrolimus modified-release|oral
223458057|NCT00459719|DRUG|Prograf|oral
223458058|NCT01252407|OTHER|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
223458059|NCT00292708|DRUG|Cefmetazole (drug)|
223458060|NCT00002034|DRUG|Zidovudine|
223458061|NCT00002034|DRUG|Ganciclovir|
223458062|NCT03318003|DEVICE|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
223458063|NCT04286620|DEVICE|LASIK|Correcting errors of refraction
223573694|NCT04748068|DEVICE|7-Fr Glidesheath Slender|The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market
223573695|NCT04748068|DEVICE|Cordis 7-Fr radial sheath|Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm
223573696|NCT05569057|DRUG|SIM1811-03|SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors
223573697|NCT00552630|DEVICE|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
223573698|NCT00552630|DRUG|placebo|placebo with same characteristics as drug
223573699|NCT00043108|DRUG|carboplatin|
223573700|NCT00043108|DRUG|paclitaxel|
223573701|NCT00043108|PROCEDURE|conventional surgery|
223573702|NCT00043108|RADIATION|radiation therapy|
223573703|NCT02443493|DEVICE|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
223743248|NCT00967993|DRUG|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
224156065|NCT03234972|DRUG|Velcade|Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
224156066|NCT03234972|DRUG|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
224156067|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg IV infusion.
224156068|NCT03689972|DRUG|Natalizumab|Natalizumab 300 mg SC injection or IV infusion.
224156069|NCT00611611|BIOLOGICAL|fluzone|once
224156070|NCT00611611|BIOLOGICAL|pneumovax|once
224156071|NCT00096551|DRUG|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
224156072|NCT00096551|DRUG|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
224156073|NCT00096551|DRUG|Recombinant Fowlpox-GM-CSF|
223458064|NCT03943914|COMBINATION_PRODUCT|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio \< 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate \< 25/min and SpO2 \> 92% under FiO2 \< 30% for at least 6 hours.
223458065|NCT03943914|COMBINATION_PRODUCT|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 \> 92%. NIV is initiated only in patients having PaO2/FiO2 ratio \< 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
223458066|NCT02051790|DRUG|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
223458067|NCT04091737|BIOLOGICAL|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"* Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~* Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~* Single dose melphalan before administration of CSL200"
223458068|NCT03363867|DRUG|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
223458069|NCT03363867|DRUG|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
223458070|NCT03363867|DRUG|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
223458071|NCT02302846|DRUG|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
223458072|NCT05555277|OTHER|No interventions - retrospective data collection|The differences between the two diagnoses were investigated by using the scale results and EEG data in the patient files.
223458073|NCT04135482|OTHER|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
223458074|NCT04994561|DRUG|Study Drugs and Nutritional Supplements|"Step 1: 500 mg of metformin and increase their dose 500 mg every 2 weeks up to 2000 mg or until tolerable.~Step 2: Once at tolerable daily metformin dose, subjects will take 140 mg of dasatinib along with 58 mg to 174 mg (based on body weight) bio-quercetin and 44.5 mg bio-fisetin. Subjects will take dasatinib, bio-quercetin and bio-fisetin for 2 consecutive days as described 4 times over one year (every 3 months) while participating on this study.~Step 3: Two weeks after the first dasatinib dose is complete, subjects will start taking daily nutritional supplements of 1,500 mg glucosamine, 600 mg nicotinamide riboside and 500 mg trans-resveratrol.~Step 4: Two weeks after starting daily supplements in Step 3, subjects will take a once weekly 6 mg dose of rapamycin.~Once subject is taking rapamycin, they will continue on this intervention for 12 months."
223458075|NCT01468454|DRUG|18 F-DOPA|1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
223458076|NCT00003494|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223458077|NCT00242697|PROCEDURE|spinal analgesia and anesthesia for coronary artery surgery|
223458078|NCT00317746|DRUG|Citalopram|
223573704|NCT02443493|DEVICE|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
224156074|NCT02417064|DRUG|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
223573705|NCT02443493|RADIATION|radiotherapy|
223743249|NCT01487590|OTHER|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
223743250|NCT01487590|OTHER|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
224156075|NCT02417064|DRUG|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
224156076|NCT02417064|DRUG|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
224156077|NCT02417064|DRUG|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
224156078|NCT02417064|DRUG|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
224156079|NCT02417064|DRUG|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
223458079|NCT00317746|DRUG|Placebos|
223458080|NCT04435808|DRUG|Hydroxychloroquine|"Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily"
223458081|NCT02620787|DRUG|Tedizolid|
223458082|NCT02620787|PROCEDURE|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
223458083|NCT05821387|DRUG|Lucid-21-302|A small molecule inhibitor of hypercitrullination
223458084|NCT05821387|DRUG|Placebo|Product containing excipients with no active ingredients
223458085|NCT01333423|DRUG|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
223458086|NCT01333423|DRUG|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
223458087|NCT00164138|PROCEDURE|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
223573706|NCT06185634|OTHER|Dietary intervention - Pasta at dinner|"The pasta at dinner nutritional intervention will consist, as the name suggests, in eating pasta at dinner for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
223743251|NCT00606476|DRUG|Bapineuzumab (AAB-001)|IV q13w
224156080|NCT02628951|DRUG|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
224156081|NCT02628951|DRUG|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
224156082|NCT00371540|OTHER|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
224156083|NCT05452317|OTHER|Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
224156084|NCT05452317|OTHER|Non-Chronic active AMR group|Past kidney transplant. This is a retrospective, non-interventional, observational study. No study treatment will be administered in this study.
224156085|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenate
224156086|NCT00212212|DIETARY_SUPPLEMENT|selenium|400 µg selenium as selenate
224156087|NCT00212212|DIETARY_SUPPLEMENT|selenium|200 µg selenium as selenomethionine
224156088|NCT00212212|DIETARY_SUPPLEMENT|placebo|placebo tablet
224156089|NCT00139841|DRUG|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
223458088|NCT03744897|BEHAVIORAL|Hypnotic analgesia|Subjects will receive hypnotic analgesia during 20 minutes
223458089|NCT03744897|DEVICE|a-tDCS|Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
223458090|NCT03744897|OTHER|Hypnotic analgesia + a-tDCS|Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
223458091|NCT03744897|DEVICE|s-tDCS|Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
223458092|NCT01735318|DRUG|Lisinopril Tablets 40 mg|40 mg tablet once a day
223458093|NCT01735318|DRUG|Lisinopril|40 mg tablet once a day
223458094|NCT00967577|DRUG|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
223458095|NCT03929263|BEHAVIORAL|Real-time fMRI neurofeedback|Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
223458096|NCT01200706|DRUG|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
223458097|NCT06231134|DEVICE|Conventional surgery|an implant will be exposed using the conventional surgical exposure techniques with a tissue punch, the cover screw will be removed, and the healing abutment placed
223458098|NCT06231134|DEVICE|Diode laser 940 nm|implant will be uncovered using a diode laser (940nm) in contact type with a continuous mode at a power of 1.5 watts, the laser tip will be used in a circular motion to create a small opening which will be increased till large enough to expose and remove the cover screw and place the healing abutments.
223458099|NCT06231134|DEVICE|Electrosurgical|the monopolar electrosurgical device will be used in the same way as the laser tip with additional care avoiding contacting the implants during exposure.
223458100|NCT05549583|DRUG|Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet|The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
224156090|NCT01548417|DRUG|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
224156091|NCT01548417|DRUG|Sugar Pill|600 mg/day, oral pill, 7 days
224156092|NCT03933124|DEVICE|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
224156093|NCT04752917|DEVICE|Noise Cancelling headphones|Use of headphones playing patients choice of music
224156094|NCT02212080|DRUG|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
224156095|NCT02212080|DRUG|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
223573707|NCT06185634|OTHER|Dietary intervention - Pasta at lunch|"The pasta at lunch nutritional intervention will consist, as the name suggests, in eating pasta at lunch for 3 months. The dietary intervention will consist of a normo-caloric diet, defined on the basis of the individual basal metabolic rate measured by indirect calorimetry and on the calculation of the participant's calorie intake extrapolated from a 3-day food diary. The diet will be of the Mediterranean type with 30% of energy coming from fats, 15-20% from proteins and the remaining 50-55% from carbohydrates (mainly complexes). Calorie intake will be distributed as follows: 20% calories at breakfast, 5% calories in the mid-morning snack, 40% calories at lunch, 5% calories in the mid-afternoon snack, 30% calories at dinner."
223573708|NCT03405935|DRUG|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
223573709|NCT03839992|DIAGNOSTIC_TEST|spirometry|measure spirometry and lung CT
223458101|NCT04486508|DRUG|intermediate dose Enoxaparin/ unfractionated heparin|Intermediate dose anticoagulation according to creatinine clearance and weight
223458102|NCT04486508|DRUG|standard prophylactic dose Enoxaparin/ unfractionated heparin|Standard prophylaxis anticoagulation according to creatinine clearance and weight
223458103|NCT04486508|DRUG|Atorvastatin 20mg|Statin
223458104|NCT04486508|DRUG|Matched placebo|Matched placebo to atorvastatin 20 mg
223458105|NCT06444334|RADIATION|low level Diode Laser|Group 2 was exposed to laser irradiation following implant insertion for 3 sessions: Immediately after implant insertion, 2 days after implant insertion and 1 week after insertion , using a red Diode(gallium-aluminun-arsenide) LLLT using calibrated diode laser device
223458106|NCT06444334|PROCEDURE|PRF platelet rich fibrin|The preparation method of PRF was performed in accordance with the protocol developed by Choukroun et al 2001. PRF was withdrawn and processed from the same operated-on patient's blood; 6ml IV blood withdrawn from the antecubital vein in to two sterile 3ml red vacutainer tubes without anticoagulant, followed by a 12 minute centrifuge with 3000 RPM producing a platelet rich fibrin clot, which is then incised \& separated with 2mm basal layer of RBCs rich in growth factors
223458107|NCT05201846|DEVICE|DIA:CONN G8 insulin pump|Subjects on continuous subcutaneous insulin infusion system with CGM
223458108|NCT05201846|OTHER|Multiple daily insulin injection|Subjects on multiple daily insulin injection with CGM
223458109|NCT06538987|PROCEDURE|percutaneous epicardial ablation|Epicardial catheter ablation is often necessary for the successful treatment of scar-induced ventricular tachycardia (VT), especially in patients with nonischemic cardiomyopathy (NICMP) where scarring is more extensive on the mid-myocardial or epicardial surface. Because epicardial mapping can be painful and patient movement can limit mapping and safe epicardial access, a common strategy for these patients is general anesthesia.
223458110|NCT01625871|DRUG|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
223458111|NCT03549598|DRUG|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
223458112|NCT03549598|DRUG|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
223458113|NCT03549598|DRUG|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
223458114|NCT05969990|OTHER|tryptophan metabolites in plasma|we will investigate the tryptophan metabolites in plasma of children with migraine
223458115|NCT01885832|BIOLOGICAL|Autologous adipose tissue stromal vascular fraction|
223458116|NCT03869762|DRUG|Xgeva|Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
224067479|NCT04710095|BEHAVIORAL|Brief Alcohol Intervention|Brief alcohol intervention uses a motivational interviewing approach and covers the following components: giving information about the possible health risks associated with alcohol use, placing the responsibility for change on the individual, discussing the reasons for drinking and downsides of drinking, and setting a goal and change plan if the participant is receptive.
224067480|NCT04710095|BEHAVIORAL|Control Condition|The attention-matched control condition consisting of a 30-min video about astronomy.
224067481|NCT02930993|BIOLOGICAL|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
224067482|NCT00809770|BEHAVIORAL|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
224067483|NCT00809770|BEHAVIORAL|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
224067484|NCT04590092|DEVICE|Cooper Surgical Ring Pessary with Incontinence Knob|A pessary is a silicone ring with a knob that in inserted into the vagina to treat urinary incontinence by providing urethral support.
224067485|NCT01465906|DRUG|tulobuterol|patch, 2mg, qN, 3 months
223458117|NCT03869762|DRUG|Xtandi|"Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression."
223743252|NCT03526458|DEVICE|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
224156096|NCT01585168|DRUG|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
223458118|NCT01416077|OTHER|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~1. Crystalloid infusion (2,5 ml/kg/t) throughout surgery~2. 3 ml/kg Volulyte (synthetic colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase \> 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~3. If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI \> 2,5.~4. If despite CI \> 2,5 Mean Arterial Pressure \<65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
224156097|NCT01585168|DRUG|Placebo|Identically appearing sugar pill, given orally
223458119|NCT02862938|DRUG|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
223458120|NCT02862938|OTHER|Sham|Sham surgery
223458121|NCT04094779|OTHER|Usual relation care|When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
223458122|NCT04094779|OTHER|"Flash activity breath of fresh air"|When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
223458123|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
223458124|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
223458125|NCT00807612|DRUG|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
223458126|NCT00807612|BIOLOGICAL|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
223458127|NCT00807612|DRUG|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
223458128|NCT05817188|OTHER|No intervention|No intervention was applied
223458129|NCT05819879|PROCEDURE|peri capsular nerve group block|The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
223573710|NCT04979897|OTHER|Intensive care unit stay during the COVID-19 pandemic|Patients will be screened daily for a potential ICU discharge. Each site coordinator, which is a clinician physiotherapist responsible for the site, will check that the patient is delirium-free (CAM-ICU negative) and cooperative (i.e. using 5 standardised questions: open \[close\] your eyes; look at me; open your mouth and stick out your tongue; nod your head; raise your eyebrows when I have counted up to five) within 72 hours from ICU discharge. Every patient deemed eligible will be invited to participate through a face-to-face visit by the assigned evaluator, receiving verbal and written information about the study
224067486|NCT01465906|DRUG|Tiotropium Bromide|18ug, inhale, qD, 3 months
224067487|NCT01465906|DRUG|tiotropium bromide|18ug, inhale, qD, 3 months
224067488|NCT00913029|DEVICE|iStent|iStent
224067489|NCT00913029|DRUG|latanoprost/timolol|Combination latanoprost/timolol
224067490|NCT04886687|PROCEDURE|mechanical thrombectomy|mechanical thrombectomy
224067491|NCT00651092|PROCEDURE|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
224156098|NCT01194414|DRUG|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
224156099|NCT01194414|DRUG|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
224067492|NCT00651092|PROCEDURE|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
224067493|NCT02469766|PROCEDURE|SWL|Patients in this arm will undergo SWL
224067494|NCT02469766|PROCEDURE|Semirigid URS|Patients in this arm will undergo semirigid URS
224067495|NCT02469766|PROCEDURE|Flexible URS|Patients in this arm will undergo Flexible URS
224067496|NCT02404103|DRUG|Flunisolide HFA|
224067497|NCT01039337|OTHER|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
224067498|NCT01039337|OTHER|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
224156100|NCT01194414|DRUG|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
224156101|NCT01194414|DRUG|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
223458130|NCT05819879|PROCEDURE|scaitico femoral block|. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
223458131|NCT00080015|DRUG|Diflomotecan (BN80915)|
223458132|NCT01878695|DRUG|IV/oral n-acetylcysteine|
223458133|NCT05612217|OTHER|to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD|to estimate Sensitivity and Specificity of the AI-based AIVARIX app in detecting C1 and C2 classes of CVD in patients who are seeking for professional advice from a phlebologist regarding symptoms and signs suggestive to CVD.
223458134|NCT04293705|DEVICE|Teen On-line Problem Solving|The TOPS program is a web-based platform delivered on computers and tablets, which is composed of different self-guided, online sessions on different contents: executive functions, social skills, behavioral strategies, injury-related issues and health and wellness. The TOPS program has been designed to be performed by patients and their families at home. Biweekly Google Meet videoconferences between a coach with expertise in cognitive-behavioral psychotherapy and patients are scheduled along the entire duration of the program.
223458135|NCT06517745|PROCEDURE|Prone positioning|Prone positioning sessions: at least one session per day proning duration: 2 hours at least per session
223458136|NCT00225186|DRUG|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
223458137|NCT02912221|OTHER|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
223458138|NCT00334087|BEHAVIORAL|feeding habits|
223458139|NCT03050177|DRUG|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
223458140|NCT03050177|DRUG|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
223458141|NCT04227418|DEVICE|12 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
223458142|NCT04227418|DEVICE|6 lead ECG monitoring|Rate, Rhythm, QTc and PR interval will be assessed
223458143|NCT04227418|DEVICE|Hand held ECG monitoring|Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
223458144|NCT04213391|DIETARY_SUPPLEMENT|sulforaphane|Sulforaphane take 2550mg once a day.
223458145|NCT04213391|DIETARY_SUPPLEMENT|Placebo|Placebo take 2550mg once a day.
223458146|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte count|Automatically calculated immature granulocyte count in white blood cell count
223458147|NCT05033249|DIAGNOSTIC_TEST|Immature granulocyte percentage|Automatically calculated immature granulocyte percentage in white blood cell count
223458148|NCT02028507|DRUG|Palbociclib|
223458149|NCT02028507|DRUG|Capecitabine|
224156102|NCT01194414|DRUG|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
224156103|NCT03540641|DEVICE|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
224156104|NCT02031510|DRUG|placebo|transversus abdominis plane block with saline 0.9%
223458150|NCT02028507|DRUG|Exemestane|
223458151|NCT02028507|DRUG|Fulvestrant|
223458152|NCT06957990|OTHER|Music|Music of the participant's selected genre will be played through headphones according to the arm assigned.
223458153|NCT06308393|DRUG|RSS0393 ointment；Placebo|RSS0393 ointment；RSS0393 ointment placebo
223458154|NCT02258659|DRUG|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
223458155|NCT02258659|DRUG|carboplatin|Given IV
223458156|NCT02258659|RADIATION|radiation therapy|Undergo radiation therapy
223458157|NCT02258659|DRUG|paclitaxel|Given IV
223458158|NCT02258659|DRUG|fluorouracil|Given IV
223458159|NCT02258659|DRUG|hydroxyurea|Given PO
224156105|NCT02031510|DRUG|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
224156106|NCT02031510|DRUG|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
224156107|NCT04493593|BEHAVIORAL|SilverCloud|"'Space for Sleep' is a seven-module online CBT-based intervention for sleep. The structure and content of the programme modules follow evidence-based CBT principles for insomnia. Each module is structured to incorporate introductory quizzes. videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.~As per normal service provision, each participant will be assigned a clinician (PWP) who will monitor participants' progress through the program. Every one to two weeks, the PWP will login and review participants' progress, leaving feedback for them and responding to the work they have completed."
224156108|NCT04611061|DRUG|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
224156109|NCT04611061|DRUG|No one|Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
223458160|NCT02258659|DRUG|cisplatin|Given IV
223458161|NCT02258659|OTHER|laboratory biomarker analysis|Correlative studies
223458162|NCT02258659|PROCEDURE|quality-of-life assessment|Ancillary studies
223458163|NCT04854070|DEVICE|IVUS|IVUS-guided approach in patients with complex coronary lesions undergoing PCI
223458164|NCT04854070|DEVICE|Angio|Angio-guided approach in patients with complex coronary lesions undergoing PCI
223458165|NCT04437914|DIAGNOSTIC_TEST|Electrocardiogram diagnosis|Electrocardiographic diagnosis will be made in a double-blind manner by two specialists in cardiology and cardiac arrhythmias and the results will be compared between the groups studied.
223458166|NCT04892446|DRUG|Magrolimab|Administered IV
223458167|NCT04892446|DRUG|Daratumumab|Administered either SC or IV
223458168|NCT04892446|DRUG|Pomalidomide|Administered orally
223458169|NCT04892446|DRUG|Dexamethasone|Administered orally
223458170|NCT04892446|DRUG|Bortezomib|Administered either SC or IV
223458171|NCT04892446|DRUG|Carfilzomib|Administered IV
223458172|NCT00272844|DRUG|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
223458173|NCT05709912|BEHAVIORAL|CARE Application|Self-administered, psychosocial mobile application comprised of 5 learning modules.
223458174|NCT05709912|BEHAVIORAL|Usual Care|Meeting with transplant social worker prior to HCT, consistent with standard-of-care.
223458175|NCT01116752|OTHER|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children \<1 year old and 25% of those \>1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
223458176|NCT05463588|OTHER|Exercising with virtual reality glasses|"GIVE PATIENTS EXERCISE WITH A 360 DEGREE EXERCISE VIDEO INSIDE VIRTUAL REALITY EYES.~Exercising with the training material taught at the beginning of the training"
223458177|NCT00096187|DRUG|pemetrexed disodium|
223458178|NCT05495386|DEVICE|Hyposafe hypoglycaemia notification device (H02)|"The H02 device consists of two parts:~1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~2. The external device receiving signals and storing data from the implant."
223458179|NCT04783233|BIOLOGICAL|Chitosan succinamide|Chitogel will be tested for suitability as a packing material in tympanoplasty surgery.
223458180|NCT04783233|BIOLOGICAL|Gelfoam|Gelfoam is the current packing material for tympanoplasty surgery.
223458181|NCT00247520|DRUG|topical nasal rEV131|
223458182|NCT00005032|BIOLOGICAL|oblimersen sodium|
223458183|NCT00005032|DRUG|paclitaxel|
223458184|NCT00718094|DRUG|Polyphenon E®|Oral capsules
224156110|NCT04337723|BEHAVIORAL|ABI/WIFI scoring|The initial ABI training workshop will be coordinated by the non-physician clinic staff champion, and all non-provider clinic staff will be asked to participate. The PI and a research assistant will conduct a 1.5-hour telemedicine training session instructing clinical staff in ABI measurement and WIfI and scoring, using the clinical scoring sheet. Following didactic teaching, participants will perform ABI tests under the guidance of the PI/research assistant and with the support of other participants. During each part of the workshop, specific attention will be directed to pitfalls and technical errors of the test. A pre-post assessment will be used to ensure comprehension of key concepts and performance of the ABI and WIfI tools.
224156111|NCT01913197|OTHER|An MRI-based technique to identify prostate cancer|
224156112|NCT01495364|BIOLOGICAL|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
223458185|NCT00718094|DRUG|Placebo Oral Tablet|Oral tablet: placebo
224156113|NCT01495364|OTHER|placebo|matching placebo
223458186|NCT06218771|DRUG|TQB3454 Tablets|TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
223458187|NCT02983175|OTHER|ultrasound assessment of gastric content|"Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~* First, a qualitative assessment of antral contents in 3 grades according to the Perlas method \[24\].~* Second, performing a quantitative analysis of antral contents calculating the CSA.~* Then, volume of gastric contents calculation as from the CSA."
223458188|NCT04701450|OTHER|digital consent|the patient's medical history is taken in a digital survey, information about the anaesthetic procedure is aided by video material
223458189|NCT02954328|DEVICE|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
223458190|NCT01664702|DIETARY_SUPPLEMENT|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
223458191|NCT01664702|DIETARY_SUPPLEMENT|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
223458192|NCT06382116|DRUG|BL-B01D1|Administration by intravenous infusion for a cycle of 3 weeks.
223458193|NCT06382116|DRUG|Pemetrexed+Cisplatin or Carboplatin|Administration by intravenous infusion for a cycle of 3 weeks.
223458194|NCT05398796|BIOLOGICAL|mRNA -1215|mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
223458195|NCT05171270|OTHER|Questionnaire|PsAID questionnaire
223573711|NCT01761591|DEVICE|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
223573712|NCT01761591|DEVICE|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
223743253|NCT01695694|BEHAVIORAL|supporting positive and healthy relationships|
223743254|NCT01695694|BEHAVIORAL|community support group|
223743255|NCT01824407|DEVICE|Electrohydraulic-generated shock wave|
224156114|NCT03326583|DRUG|Patiromer|Patiromer will be orally self-administered by participants.
224156115|NCT01317693|DEVICE|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
224156116|NCT00228943|DIETARY_SUPPLEMENT|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
224156117|NCT00228943|DIETARY_SUPPLEMENT|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
224156118|NCT05267483|OTHER|No intervention|No intervention
223458196|NCT04953741|DRUG|Fluticasone propionate inhaled aerosol|The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
223458197|NCT02090387|OTHER|ONS without AN777|2 servings a day
223458198|NCT02090387|OTHER|ONS containing AN777|2 servings a day
223458199|NCT03139136|DRUG|MBS2320|As described in the arm descriptions
223458200|NCT03139136|DRUG|Placebo|As described in the arm descriptions
224156119|NCT00116987|DEVICE|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
223458201|NCT00232206|DRUG|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
223458202|NCT00579332|DIETARY_SUPPLEMENT|brassica intervention|diet and phyto-chemical intervention
223458203|NCT03925181|BEHAVIORAL|Counselling Group|All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
223458204|NCT02033278|DRUG|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
223458205|NCT02033278|DRUG|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
223458206|NCT00871364|DRUG|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
223458207|NCT00871364|DRUG|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
223458208|NCT06066255|DRUG|Thymoglobulin Injectable Product|single intravenous injection of thymoglobulin
223458209|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with radiofrequency|The QDOT (Biosense Webster, Inc.) or TactiFlex (Abbott S.E.) catheters will be used. The ablation will be controlled by temperature, with a limit of 42ºC and a power target of 30-40W. A high-power strategy (90 W/4 seconds) can be used on the posterior wall when the QDOT catheter is used.
223458210|NCT06351553|PROCEDURE|Pulmonary vein isolation exclusively with pulsed field ablation|The Sphere-9 catheter will be used (with biphasic and unipolar wave), with a duration per application of 5 seconds and a separation between lesions of 5-6mm. The target temperature increase will be at least 1.5ºC above the patient's basal temperature to mark the ablation as effective.
223458211|NCT06351553|PROCEDURE|Combined pulmonary vein isolation|"The Sphere-9 catheter will be used for both radiofrequency and pulsed field ablation. When using radiofrequency, the ablation will be temperature controlled, with a target temperature of 73ºC. The duration per application will be 5 seconds. Catheter irrigation during ablation will be 30ml/min, with a maximum current intensity of 3700mA, and a maximum current density of 13.6mA/mm2. The separation between lesions will be 7-8mm. Regarding pulsed field ablation, the characteristics will be those indicated in Pulmonary vein isolation exclusively with pulsed field ablation group."
223458212|NCT06002659|BIOLOGICAL|CAR20(NAP)-T|Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP
223458213|NCT06002659|DRUG|Cyclophosphamide|pre-conditioning chemotherapy
223458214|NCT06002659|DRUG|Fludarabine|pre-conditioning chemotherapy
223458215|NCT04525209|OTHER|No intervention|No intervention
223458216|NCT05376072|OTHER|Electromyographic Biofeedback|"The players performed 10 work sessions with EMG-BF. Each session was divided into three phases: (a) three trials without receiving feedback, (b) between six and ten trials with feedback of electromyographic activity, (c) three trials without feedback. In each trial, isometric contractions of the vastus lateralis were performed.~During maximum effort isometric contraction, the software associated with the ProComp Infiniti biofeedback unit collects the amplitude, the mean and maximum electromyographic signal, and also the contraction and tightening times. The contrac-tion time comprises the interval between the start of the contraction and achievement of the desired muscle tension. The tightening time is the period in which the tension voluntarily reached is maintained. For this study, the maximum and mean elec-tromyographic activity values were considered, calculated during the muscle tension time and maintained during each trial."
223458217|NCT03613792|DRUG|Remifentanil|Opioid analgesic
223458218|NCT03613792|DRUG|Fentanyl|Opioid analgesic
223458219|NCT03613792|DRUG|Midazolam|Benzodiazepine
223458220|NCT03613792|DRUG|Ketamine|Analgesic
223458221|NCT02036684|BEHAVIORAL|Prehabilitation (PREHAB)|
223458222|NCT00560482|DRUG|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
223458223|NCT00560482|DRUG|Placebo|Identical appearing gelatin capsules containing placebo
223458224|NCT05265832|PROCEDURE|Phacoemulsification|Endocapsular technique (Divide-and-conquer) and supracapsular technique (Subluxation) will be used equally.
223743256|NCT01824407|DEVICE|Sham device plus standard of care|
223573713|NCT03200639|OTHER|Combined training|The CT and CTc protocol (total length time \~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
223573714|NCT03200639|OTHER|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time \~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (\<60% of HRmax or Borg Scale at \<5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
223458225|NCT06265909|DEVICE|AmDTx|AmDTx (Mobio Interactive Pte Ltd, Singapore), is an advanced mobile health platform equipped with computer vision and AI to objectively quantify psychological stress and benchmarked ecological momentary assessments to subjectively measure stress, valence, and arousal. Asynchronous and on-demand psychotherapy available as audio files within AmDTx has been clinically validated across the mental illness severity spectrum. Psychotherapy within AmDTx primarily leverages meditation/mindfulness techniques to enhance relaxation, build stress resilience, improve focus and decision making, and influence behaviour and affect bias.
223458226|NCT02044562|DIETARY_SUPPLEMENT|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
223458227|NCT02044562|DIETARY_SUPPLEMENT|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
223458228|NCT00705341|DRUG|fluticasone|Inhaled corticosteroid approved for treatment of asthma
223573715|NCT02198599|PROCEDURE|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
223458229|NCT03942887|DRUG|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
223458230|NCT03942887|DRUG|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
223458231|NCT03942887|DRUG|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
223458232|NCT03942887|DRUG|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
223458233|NCT04569604|DIAGNOSTIC_TEST|MRI scans|Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain
223458234|NCT04569604|DIAGNOSTIC_TEST|Neuro cognitive tests|Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.
223458235|NCT04569604|DIAGNOSTIC_TEST|Questionnaires on Quality of Life|SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.
223573716|NCT05036382|BEHAVIORAL|Steps data observation|Sending more step data from the experimental group that received the incentive message
223573717|NCT05097508|DRUG|Atracurium Besylate|Anesthesia will be induced by atracurium (dose 0.5 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Atracurium (dose 0.005-0.01 mg/kg/min) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given
224302758|NCT00767169|DEVICE|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
224302759|NCT00326963|DRUG|Background ARVs|As prescribed
224302760|NCT00326963|DRUG|PI|As prescribed
224302761|NCT00326963|DRUG|enfuvirtide [Fuzeon]|90mg sc bid
224302762|NCT02524730|DEVICE|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
224302763|NCT00507130|BIOLOGICAL|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
223458236|NCT04569604|DIAGNOSTIC_TEST|Blood samples|Markers of calcium homeostasis, inflammatory markers and hematology.
223458237|NCT04569604|DIAGNOSTIC_TEST|24 hr urine samples|24 hr urine content of calcium, phosphate, magnesium, and creatinine.
223458238|NCT01384747|DRUG|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
224302764|NCT00507130|BIOLOGICAL|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
224156120|NCT00116987|DEVICE|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
223458239|NCT01384747|DRUG|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
223458240|NCT03070275|BIOLOGICAL|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
223458241|NCT03070275|PROCEDURE|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
223458242|NCT00005083|PROCEDURE|conventional surgery|
223458243|NCT00005083|PROCEDURE|magnetic resonance imaging|
223458244|NCT00005083|PROCEDURE|magnetic resonance spectroscopic imaging|
224156121|NCT02565277|BIOLOGICAL|Influenza Vaccine|
224156122|NCT02565277|DRUG|Placebo|
224156123|NCT00152945|DRUG|Intravenous Intralipid|intravenous infusion
224156124|NCT00152945|DRUG|Intravenous leucine, glycerol|intravenous infusion
224156125|NCT02944734|DRUG|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
224156126|NCT02944734|DRUG|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
223458245|NCT00845273|DRUG|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
223458246|NCT02412397|PROCEDURE|Total Shoulder Arthroplasty|
223458247|NCT05783947|DIAGNOSTIC_TEST|Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera|Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
224156127|NCT02944734|DRUG|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
224302765|NCT00507130|BIOLOGICAL|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
223458248|NCT00791700|DRUG|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
223458249|NCT06494592|BEHAVIORAL|Aerobic Exercise|Participants in the aerobic exercise intervention group will engage in a virtual aerobic exercise intervention three times a week for 12 weeks for a 30-minute session (5 minute warm up, 20 minutes of aerobic exercise, 5 minutes cooldown) and will receive information about the session prior to their appointment. Sessions have a goal of reaching at least 20 minutes of supervised exercise performed at 80% of the heart rate at symptom threshold.
223458250|NCT06494592|BEHAVIORAL|Balance Exercise|Participants in the balance exercise intervention group will participate in a staff-led virtual session three times a week for 12 weeks for a 30-minute session and will receive information about the session prior to their appointment. This group will focus on improving balance, with some additional work on flexibility and strength.
223458251|NCT05024656|OTHER|AmnioExcel Plus Amniotic Membrane|AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
223458252|NCT05024656|OTHER|Standard of Care|The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
223458253|NCT05007626|OTHER|axial length and refractive error|Comparing the correlation between heterophoria and refraction, even after age adjustment.
223743257|NCT04287777|DRUG|Mupirocin gel|Topical administration of Mupirocin gel 20 mg/g BID for 7 days
223743258|NCT04287777|DRUG|Mupirocin ointment|Topical treatment of Mupirocin ointment 20 mg/g TID for 7 days
223743259|NCT04287777|DRUG|Placebo|Topical administration of Placebo (ointment) TID during 7 days
224156128|NCT02944734|DRUG|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
224156129|NCT04737759|BEHAVIORAL|Taking Care of Us|A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.
224156130|NCT04737759|OTHER|SUPPORT|SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
224302766|NCT00507130|OTHER|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
223458254|NCT01472822|DIETARY_SUPPLEMENT|Omija extract.|Omija extract 1.2g/day for 12weeks
223458255|NCT01472822|DIETARY_SUPPLEMENT|Placebo|Placebo 1.2g/day for 12weeks
223458256|NCT05767346|DRUG|Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)|Aficamten (CK-3773274) tablets administered orally
224156131|NCT00633048|DRUG|NSA-789|
224156132|NCT00633048|DRUG|placebo|
224156133|NCT00322751|DRUG|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
224156134|NCT01046968|DIETARY_SUPPLEMENT|Lepticore|300 mg twice daily
224302767|NCT01597466|DEVICE|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
224302768|NCT01597466|PROCEDURE|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
224302769|NCT00006055|DRUG|anti-thymocyte globulin|
223458257|NCT05767346|DRUG|Placebo to match aficamten|Placebo for aficamten (CK-3773274) administered orally
224302770|NCT00006055|DRUG|cyclophosphamide|
224302771|NCT00006055|DRUG|cyclosporine|
224302772|NCT00006055|DRUG|filgrastim|
224302773|NCT00006055|DRUG|methylprednisolone|
224302774|NCT00006055|DRUG|prednisone|
223458258|NCT05767346|DRUG|Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)|Metoprolol succinate tablets administered orally
223458259|NCT05767346|DRUG|Placebo to match metoprolol succinate|Placebo for metoprolol succinate administered orally
223458260|NCT04873635|OTHER|Implant support prostheses|Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
223458261|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
223458262|NCT00527826|DRUG|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
223458263|NCT01466413|DEVICE|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
223458264|NCT05203601|BIOLOGICAL|SIBP-03|"Stage 1:~Six dose groups of 2, 5, 10, 15, 20 and 40 mg/kg were planned. Dose increments began at 2 mg/kg using accelerated titration. In the first dose group, after the first patient was injected with Sibp-03, if the subject developed toxicity grade ≥2（CTCAE v5.0 standard）within 21 days of initial administration，then the subject increased to 3 and the study design method in this dose level convert to 3+3. If the subject didn't develop toxicity grade ≥2, then the study of the second and next dose group can be carried out using 3+3 incremental design.~Stage 2:~Cohort 1 included patients with advanced head and neck squamous cell carcinoma and cohort 2 included patients with breast cancer. According to the results of dose escalation stage and similar drug trials, 5mg/kg and 10mg/kg dose levels were selected to enter this phase. Each cohort will be extended to include 6-8 subjects to receive this product in combination with the standard treatment study."
223458265|NCT02738359|PROCEDURE|optical colonoscopy|optical colonoscopy
223458266|NCT02738359|PROCEDURE|colon capsule endoscopy|colon capsule endoscopy
223458267|NCT02738359|DIAGNOSTIC_TEST|fecal immunological test (FIT)|fecal immunological test (FIT)
223573718|NCT05097508|DRUG|Rocuronium Bromide|Anesthesia will be induced by rocuronium (dose 0.6 mg/kg).After equilibrium for 30 minutes SE, RE and the difference between them will be recorded at MAC 0.8 and MAC 1 at two levels of muscle relaxation assessed by TOF value of 50% and 100%. Rocuronium (dose 0.01-0.012 mg/kg/min ) will be administered as a continuous IV infusion adjusted until 50% and 100% depression of T1 ( first twitch by acceleromyography) will be observed. The entire experiment ended before the start of surgery. In case of hypotension (drop of blood pressure ˃20% of baseline reading), 10-30 mg of ephedrine diluted over 10 ml normal saline 0.9% will be given intravenously by titration according to the blood pressure. In case of bradycardia (heart rate less than 60 beat per minute), when it is associated with hypotension or any signs of impaired perfusion, 0.01 - 0.02 mg/kg of atropine will be given.
223573719|NCT05097508|DEVICE|Entropy|No premedication will be given. After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system , starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
223573720|NCT05097508|DEVICE|train of four|After the patients enter the operating room, a venous cannula will be inserted into a large peripheral vein. Data from routine monitoring, including non-invasive arterial blood pressure, oxygen saturation, and end-tidal oxygen concentration (ETO2) and end-tidal carbon dioxide concentration (ETCO2) will be collected. Neuromuscular blockade will be continuously assessed by acceleromyography using the Train-of-Four-watch SX system, starting when the patients will be unconscious. RE and SE will be monitored using a Datex Ohmeda Entropy Module (M-Entropy) and the Entropy Sensor system.
223573721|NCT00868218|BIOLOGICAL|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
224156135|NCT03882723|DEVICE|Evaluated 4 masks used for NIV with mechanical ventilators|Order of the masks (BiTrac MaxShield™ with standard elbow, BiTrac™ Full Face with standard elbow, Respironics PerforMax with standard elbow, and Respironics AF531 with standard elbow) were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, \& 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
224156136|NCT01007513|PROCEDURE|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
224156137|NCT01007513|PROCEDURE|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
224156138|NCT04758741|BEHAVIORAL|Acceptance and Commitment Therapy|Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
224156139|NCT04758741|OTHER|placebo|This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
223458268|NCT00516100|DRUG|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
223458269|NCT05475899|DEVICE|Instrument assisted soft tissue mobilization|Application of IASTM on the plantar fascia with 10-15 strokes followed by stretching
223458270|NCT02834858|BIOLOGICAL|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
223458271|NCT02834858|BIOLOGICAL|saline|
223458272|NCT02122315|OTHER|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
223573722|NCT00929773|DEVICE|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
223458273|NCT02122315|OTHER|Physical therapy|Best-evidence physical therapy intervention
223458274|NCT01266005|DRUG|Clevudine|30mg,QD
223458275|NCT01266005|DRUG|Entecavir|0.5mg QD
223458276|NCT03213392|DRUG|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
224302775|NCT00006055|PROCEDURE|Autologous Peripheral Blood Stem Cell Transplantation|
223458277|NCT01808261|DRUG|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
223458278|NCT01808261|DRUG|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
223458279|NCT00939614|DRUG|Lamotrigine|
224067499|NCT01039337|OTHER|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
223458280|NCT00573872|RADIATION|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
223458281|NCT03128619|PROCEDURE|Biopsy of Breast|Undergo biopsy
223458282|NCT03128619|DRUG|Copanlisib|Given IV
223458283|NCT03128619|OTHER|Laboratory Biomarker Analysis|Correlative studies
223458284|NCT03128619|DRUG|Letrozole|Given PO
223458285|NCT03128619|DRUG|Palbociclib|Given PO
223458286|NCT03128619|OTHER|Pharmacological Study|Correlative studies
224067500|NCT01783678|DRUG|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
224067501|NCT01783678|DRUG|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
224067502|NCT00006388|DRUG|tamoxifen citrate|
224067503|NCT00006388|RADIATION|radiation therapy|
224067504|NCT01995071|DRUG|ABT-493|Tablet
224067505|NCT01995071|DRUG|ABT-530|Tablet
224067506|NCT01995071|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
224067507|NCT01995071|DRUG|Ribavirin (RBV)|Tablet
224067508|NCT05546892|PROCEDURE|Full bowel preparation prior to colon resection for cancer|Mechanical bowel preparation and oral antibiotics
224067509|NCT05546892|PROCEDURE|No bowel preparation|Omission of any bowel preparation
224067510|NCT05328037|DIAGNOSTIC_TEST|Blood sample collection|Blood sample collection for dosage of vitamin C
224067511|NCT04275622|BEHAVIORAL|Lifestyle including optimal exercise and diet modification.|The intervention group will receive diet education and be given exercise suggestion.
224067512|NCT01277094|DRUG|Placebo|Oral daily doses for 12 weeks
224067513|NCT01277094|DRUG|RO5093151|Oral daily doses for 12 weeks
224067514|NCT05903287|DEVICE|Chang Gung Pleural Effusion Detection Software|"The Chang Gung Pleural Effusion Detection Software is an independent software as a medical device, which inputs digital Chest X-Ray to automatically detect whether there is a pleural effusion. The inferred results output by this software can assist clinicians or professional medical personnel to identify whether a patient has pleural effusion.~This product is only used to analyze the digitized Chest X-Ray DICOM of patients over 20 years old and under 100 years old."
224067515|NCT00328627|DRUG|Alogliptin|Alogliptin tablets.
224067516|NCT00328627|DRUG|Alogliptin placebo|Alogliptin placebo-matching tablets.
224067517|NCT00328627|DRUG|Pioglitazone|Pioglitazone tablets.
224067518|NCT00328627|DRUG|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
224067519|NCT02652897|PROCEDURE|Exposure to glioma resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
224302776|NCT02140723|RADIATION|preoperative short course radiation|
224302777|NCT01772758|DRUG|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
223458287|NCT05358990|OTHER|Plain Language Recommendation (PLR)|New easy to read COVID-19 recommendations available on the COVID19 Living Map of Recommendations and Gateway to Contextualization (RecMap).
223458288|NCT05358990|OTHER|Standard Language Version (SLV)|Original recommendation as initially published by the guideline organization.
223458289|NCT00812032|DRUG|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
223458290|NCT00812032|DRUG|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
223458291|NCT03965520|BEHAVIORAL|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
223458292|NCT00613379|DRUG|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
223458293|NCT00613379|DRUG|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
224067520|NCT02652897|PROCEDURE|Exposure to colon resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
224067521|NCT00112905|DRUG|sorafenib tosylate|Given PO
224067522|NCT00112905|OTHER|laboratory biomarker analysis|Optional correlative studies
224067523|NCT03999424|BIOLOGICAL|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
224067524|NCT02600507|DRUG|Lumateperone (ITI-007)|
223458294|NCT00613379|DRUG|Placebo|PBO, one IV dose (N=10)
223573723|NCT00929773|DEVICE|Placebo laser|Inactive laser light.
223573724|NCT02781792|DRUG|Temozolomide|-Given standard of care
223573725|NCT02781792|OTHER|Functional Assessment of Cancer Therapy - Brain|"* 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
223573726|NCT02781792|OTHER|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
223573727|NCT03593135|DIETARY_SUPPLEMENT|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
223573728|NCT03593135|OTHER|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
223573729|NCT02699008|DRUG|Clopidogrel|Antiplatelet agent
223573730|NCT02699008|DRUG|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
223573731|NCT01703117|DRUG|Riluzole|20-22 subjects between the ages of 60-85 will receive study drug.
223573732|NCT01703117|DRUG|Placebo|20-22 subjects between the ages of 60-85 will receive placebo
223573733|NCT05768204|DRUG|Prednisolone Acetate|The experimental group took prednisolone acetate which is a kind of oral glucocorticoid.
223573734|NCT05768204|OTHER|placebo|A placebo consistent in appearance with the prednisolone acetate.
223458295|NCT03791762|PROCEDURE|WaveOne Gold|"WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting."
223458296|NCT03791762|PROCEDURE|Reciproc Blue|"Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting."
223573735|NCT02583230|BEHAVIORAL|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
223573736|NCT01871155|DIETARY_SUPPLEMENT|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
223458297|NCT03791762|PROCEDURE|ProTaper Next|ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
223458298|NCT00635544|OTHER|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
223458299|NCT00635544|OTHER|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
223458300|NCT01840592|DRUG|Sorafenib|
223458301|NCT01840592|DRUG|Doxorubicin|
223573737|NCT03661905|OTHER|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
223573738|NCT03661905|BEHAVIORAL|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
224067525|NCT02600507|DRUG|Placebo|
224067526|NCT06473909|DRUG|CD25 antibody combined glucocorticoid as first-line treatment|CD25 antibody combined glucocorticoid as first-line treatment
224067527|NCT03678480|DRUG|HTD1801|HTD1801 capsules, 250mg
224067528|NCT03678480|DRUG|Ursodeoxycholic Acid|UDCA capsules, 125mg
224067529|NCT04771533|PROCEDURE|hand motor coordination in a sitting position|The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
224067530|NCT04771533|PROCEDURE|hand motor coordination in a supine position|In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
224067531|NCT02643004|DEVICE|Senofilcon A|contact lens
224067532|NCT02643004|DEVICE|Stenfilcon A|contact lens
224067533|NCT01975922|BEHAVIORAL|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
224067534|NCT01932957|PROCEDURE|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
223573739|NCT04789161|PROCEDURE|double kissing crush stenting|Patients with true bifurcation lesion treating with double kissing crsuh stenting technique
223573740|NCT04789161|PROCEDURE|double kissing culotte stenting|Patients with true bifurcation lesion treating with double kissing culotte stenting technique
223573741|NCT05860491|OTHER|dietary fiber|Retrospective analysis of the relationship between patient dietary fiber intake and hyperkalemia
223573742|NCT04251780|PROCEDURE|Surgical Treatment of Hyperaldosteronism|Surgery of an Aldosterone-producing adenoma
223573743|NCT04251780|DRUG|Drug treatment of Hyperaldosteronism|Treatment of Hyperaldosteronism with Spironolactone or Eplerenone.
224067535|NCT01932957|PROCEDURE|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
224067536|NCT01082185|DEVICE|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
224067537|NCT06326242|OTHER|Solid Tumor|The study focuses on defining the problem of geographical accessibility of patients to the Phase 1 facility of the European Institute of Oncology, based on anonymized data extraction from the enrolled patient database, to evaluate national territorial disparities in access to innovative experimental therapies, in relation to various socioeconomic determinants. Finally, relevant information on psychological factors for participation in clinical trials will also be collected.
224067538|NCT04632355|OTHER|Interview|This interview will be conducted to collecting all outcomes about musculoskeletal pain in COVID-19 survivors
223458302|NCT04997876|OTHER|Biomarker analysis|Biomarkers from presurgical OCTs are assessed
224067539|NCT04970004|OTHER|No intervention|No study intervention will be administered as part of this study.
223458303|NCT05754671|OTHER|perceptual assessment of the recorded voice sample|perceptual assessment of the recorded voice samples
223458304|NCT05754671|OTHER|voice recording|voice recording
223458305|NCT05038449|DRUG|Colchicine Tablets|Colchicine Tablets (Each tablet contains colchicine 0.5mg)
223458306|NCT05038449|DRUG|Standard therapy|Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
223458307|NCT05034380|BEHAVIORAL|Acute exercise|All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
223458308|NCT01737879|DRUG|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
223458309|NCT01737879|DRUG|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
223458310|NCT00421083|DRUG|tadalafil|
223458311|NCT05201677|PROCEDURE|Supplement of perfusion fluid through the subiris suspensory ligament space from the lateral incision|After the capsule is filled with viscoelastic material, if the IOP is less than 10 mmHg, the investigators will supply the perfusion fluid through the subiris suspensory ligament space from the lateral incision.
223458312|NCT06324643|PROCEDURE|sensory motor integration training|one group treated by strengthening exercises , stretching ,and occupational therapy and other group treated by strengthening exercises , stretching ,and occupational therapy and sensory motor integration training
223458313|NCT03997097|DRUG|Sildenafil|Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
223458314|NCT03997097|DRUG|Placebos|Patients randomised in the group placebo in 3 oral doses of per day
223458315|NCT00063804|DRUG|Ritonavir|
223458316|NCT00063804|DRUG|AMD070|
223458317|NCT02497404|DRUG|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
223458318|NCT02497404|DRUG|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
223458319|NCT02497404|DRUG|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
223458320|NCT02497404|DRUG|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
223458321|NCT02497404|RADIATION|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
223458322|NCT05264909|DEVICE|Multi-channel Transcranial direct current stimulation|A medical grade tDCS device will be use in this study (Star Stim TES, Neuroelectrics, Spain). The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
223458323|NCT05854485|COMBINATION_PRODUCT|REACH robotic training and multi-muscle Functional Electrical Stimulation (FES) group|Participants in this group will receive multi-muscle FES during arm robotic training
223458324|NCT05854485|COMBINATION_PRODUCT|Robot only group|Participants in this group will receive arm robotic training only
223458325|NCT04387409|BIOLOGICAL|VPM1002|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
223458326|NCT04387409|BIOLOGICAL|Placebo|The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
223458327|NCT04964167|COMBINATION_PRODUCT|Plant extract|Natural plant extract
223458328|NCT02084017|DEVICE|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
224302778|NCT01772758|DRUG|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
223458329|NCT02084017|DEVICE|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
223458330|NCT03774888|PROCEDURE|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
223458331|NCT03774888|PROCEDURE|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
223458332|NCT03774888|PROCEDURE|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
223458333|NCT03576924|BEHAVIORAL|MICT|Individuals randomized to MICT will be asked to engage in only MICT 5 times/week for 30 min/session at 60-70% of heart rate max, consistent with physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in only MICT exercise during the 4-week supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the heart rate (HR) monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
223458334|NCT03576924|BEHAVIORAL|HIIT|Individuals randomized to HIIT will be asked to engage in only HIIT 5 times/week for 4 weeks. HIIT consists of 5 repeated vigorous intervals of 1-min duration at 80-90% of heart rate max interspersed with 1-min recovery periods. A 3-min warm-up and 2-min cool-down are also included, for a total session duration of 15 minutes. This matches the guidelines of 75 min of vigorous exercise per week. During the supervised exercise sessions, intensity will be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
223458335|NCT03576924|BEHAVIORAL|CHOICE|Participants will first be familiarized with HIIT and MICT in a randomized, counter-balanced order during supervised sessions 1 and 2, and will subsequently self-select the exercise type for the supervised and unsupervised exercise sessions. The HIIT and MICT protocols will match to the parallel imposed conditions. During the supervised exercise, intensity will also be based on HR monitors and psychophysiological responses of perceived exertion. The exercise training is paired with 30-50 minutes of behavioral counselling that is identical for all three interventions.
223458336|NCT04963725|DRUG|Ustekinumab|No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
223458337|NCT06585280|OTHER|No intervention|No intervention
223573744|NCT04301180|DEVICE|Education food|The intervention consisted of the presentation of food education content while conducting an orchard with seasonal vegetables
223573745|NCT00681980|DRUG|Valproic acid|15 mg/kg/day
224067540|NCT04917211|PROCEDURE|Virtual reality mask|"The virtual reality mask is a mask with a screen that is put on the patient's face in the theatre before the surgery. It offers 3D scenarios of about 20 to 40 minutes on five different themes (the Zen garden, the mountain, the forest, the beach, the scuba diving) with music. The video-headset, equipped with head movement sensors, allows the 3D vision of a natural virtual world and the audio-headset emits sounds adapted to the virtual world and music therapy. The RV mask, via multi-sensorial immersion, focuses on two therapeutic targets which are pain and anxiety. It is a non-drug approach cousin to hypnosis. Its therapeutic effects are based on a distractive effect: attentive capture, an emotional effect: playfulness and positive suggestion, and a behavioral effect: the patient participates and is an actor in his care.~"
224067541|NCT03536351|BEHAVIORAL|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
223458338|NCT06342401|DIAGNOSTIC_TEST|ENCODE|A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.
223458339|NCT04704609|OTHER|Standard of Care Imaging|We are collecting imaging that is standard of care for uveitis patients
223458340|NCT04061746|BIOLOGICAL|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
223573746|NCT00681980|DRUG|costicosteroids|metypredsolone 1 g/day
224067542|NCT04484532|BIOLOGICAL|Trivalent Influenza Vaccine|Given IM
224067543|NCT01013987|DRUG|maraviroc|maraviroc: one 150 mg pill twice daily
223573747|NCT00681980|DRUG|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
223573748|NCT05960305|OTHER|P1213416|Tobacco Flavor
223573749|NCT05960305|OTHER|P1213422|Tobacco Flavor
224067544|NCT01013987|DRUG|Raltegravir|raltegravir : one 400 mg pill twice daily
224067545|NCT01013987|DRUG|Darunavir/ritonavir|"* darunavir : two 300 mg pills twice daily with meal~* ritonavir: one 100 mg pill twice daily with meal"
224067546|NCT00141765|PROCEDURE|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
224067547|NCT00141765|PROCEDURE|Stem Cell Rescue|autologous stem cell transplantation
224067548|NCT00190593|DRUG|raloxifene|
224067549|NCT00190593|DRUG|placebo|
224067550|NCT05054452|DEVICE|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
224302779|NCT01772758|DIETARY_SUPPLEMENT|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
223573750|NCT05960305|OTHER|P1213716|Tobacco Flavor
223573751|NCT05960305|OTHER|P1213722|Tobacco Flavor
223573752|NCT05960305|OTHER|P1211216|Menthol Flavor
223573753|NCT05960305|OTHER|P1211222|Menthol Flavor
223573754|NCT05960305|OTHER|P1213616|Menthol Flavor
223573755|NCT05960305|OTHER|P1213622|Menthol Flavor
223573756|NCT05960305|OTHER|P1213816|NTNM Flavor
223573757|NCT05960305|OTHER|P1213822|NTNM Flavor
223573758|NCT05960305|OTHER|P1211916|NTNM Flavor
223573759|NCT05960305|OTHER|P1211922|NTNM Flavor
223573760|NCT01985490|PROCEDURE|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
223573761|NCT02124512|DRUG|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
223573762|NCT02124512|OTHER|Placebo|80 mg placebo once daily
223573763|NCT05020964|DRUG|Trastuzumab and Pyrotinib|"Trastuzumab: 3-week dosing regimen, The initial load dose was 8 mg/kg. Pyrotinib: 400 mg orally once daily, take it continuously, every 21 days as a cycle.~Use until intolerable toxicity or disease progression occurs."
223573764|NCT01735669|DRUG|Remifentanil|
223573765|NCT01735669|DRUG|Nitrous Oxide|
224067551|NCT00605085|BIOLOGICAL|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
224067552|NCT00605085|BIOLOGICAL|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
224067553|NCT05396274|DEVICE|High Flow Nasal Cannula|high flow nasale cannula
224067554|NCT00621504|DRUG|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
223458341|NCT04061746|OTHER|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
223458342|NCT05568797|BIOLOGICAL|RSVPreF3 OA vaccine|One dose of RSVPreF3 OA vaccine administered intramuscularly.
223458343|NCT05568797|BIOLOGICAL|FLU vaccine|One dose of FLU vaccine administered intramuscularly.
223458344|NCT03315494|DRUG|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
223458345|NCT03315494|DRUG|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
223458346|NCT03538704|DRUG|Metformin|Metformin is given to patients 1-1.5g/d.
223458347|NCT00778349|DRUG|Metformin solution 100 mg/mL|
223573766|NCT05732636|OTHER|Validation study|"The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved.~1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1)~2. Second Version: Three experts compared the original FADI with urdu version of FADI.~3. Backward translation: Version 2 was translated Back in English by an independent translator.~4. Third Version: was finalized after tracking differences in forward and backward translation.~5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients.~Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability."
223573767|NCT00792662|DRUG|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
223573768|NCT00792662|DRUG|Placebo|Standard inactive pill.
223573769|NCT02572232|DEVICE|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
223573770|NCT05926349|DRUG|Andexanet alfa|Andexanet is a recombinant version of human FXa
223573771|NCT05926349|DRUG|Usual Care|As per the label of the chosen usual care product(s) and/or usual care standards.
223573772|NCT05352698|DIAGNOSTIC_TEST|NT ProBNP (Roche)|This NT ProBNP assay is a point-of-care (POC) test that will be conducted on a 2 mL sample of whole blood collected in a non-heparinized tube. NT ProBNP results are used in this setting to predict perioperative cardiovascular risk.
223573773|NCT00097162|PROCEDURE|Anodal stimulation|
223573774|NCT02361424|DRUG|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
223573775|NCT02361424|DRUG|placebo|
223573776|NCT05616819|OTHER|Active light exposure|Active light at the wave length of 470nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a method to regulated circadian rhythm.
223573777|NCT05616819|OTHER|Placebo light exposure|Placebo light at the wave length of 578nm will be emitted for 30 minutes over a 2 week time frame, from commercially available ayo glasses, as a control to investigate the regulation of circadian rhythm.
223573778|NCT00464061|DRUG|Volinanserin|oral administration
223573779|NCT00464061|DRUG|Placebo|oral administration
223573780|NCT00152711|DEVICE|nCPAP|
223573781|NCT01431014|DRUG|"Dexamethasonelow-dose"|5mg
223573782|NCT01431014|DRUG|"Dexamethasonehigh-dose"|15 mg
223573783|NCT04202224|DRUG|Ibuprofen 400 mg and Acetaminophen 500 mg|Analgesia.
223573784|NCT04202224|DRUG|Glucose|Placebo.
223573785|NCT04202224|OTHER|No drug|Standard surgical procedure without any preoperative medication.
223573786|NCT05190354|DEVICE|Xtremity Polymer Prosthetic Socket|Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
224067555|NCT00621504|DRUG|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
224067556|NCT00621504|DRUG|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
224067557|NCT00621504|DRUG|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
224067558|NCT01952587|BIOLOGICAL|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
224156140|NCT03556865|OTHER|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
224156141|NCT01496404|PROCEDURE|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
223458348|NCT04875780|BEHAVIORAL|Digital diabetes prevention app intervention|"16-week core program consisting of 16 online weekly interactive lessons on diet and physical activity for weight loss. After the completion of the core program, participant can proceed to the 36-week post-core phase. The post-core program provides 8 monthly lessons focusing on maintaining lifestyle habits and weight loss.~Participants will be guided to use the smartphone app for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 persons. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
223458349|NCT04875780|BEHAVIORAL|Digital weight loss tracking app intervention|"All participants will be provided the same smartphone app as the intervention group for goal setting and self-monitoring of diet, physical activity and weight loss.~Participants will be demographically matched into online groups of 10-12 person. Online group discussion board will be set up for participants to discuss goals, share progress and provide supports to each other."
223458350|NCT04875780|BEHAVIORAL|Wait-list control (usual care)|Participants in the control group will be invited to have an annual review and blood test at baseline, 4 and 12 months and received general lifestyle advices from a registered nurse at a community clinic.
223458351|NCT03131687|DRUG|tirzepatide|Administered SC
223458352|NCT03131687|DRUG|Dulaglutide|Administered SC
223458353|NCT03131687|DRUG|Placebo|Administered SC
223573787|NCT02705014|DRUG|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
223573788|NCT04015037|COMBINATION_PRODUCT|placebo or drug|Group A and B (medicated or placebo)
223573789|NCT02362516|DRUG|BI 425809|
223573790|NCT03660228|OTHER|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
223573791|NCT04811443|DRUG|Empegfilgrastim|Extimia®
223573792|NCT01810068|PROCEDURE|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
223573793|NCT01810068|PROCEDURE|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
223573794|NCT01810068|PROCEDURE|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
224156142|NCT01496404|PROCEDURE|Scalpel|Incising skin (epidermis and dermis) with scalpel.
224156143|NCT05003141|DRUG|PSB202|PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
223458354|NCT04555707|DRUG|Apremilast 30mg|30mg PO BID started within 10 days of baseline
223458355|NCT04555707|DRUG|calcipotriene and betamethasone dipropionate|1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
223458356|NCT02400619|DEVICE|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
223458357|NCT02400619|DRUG|Botulinum Toxin Type A|Botulinum toxin type A Botox
223458358|NCT02998996|BIOLOGICAL|15 µg HA/strain and 1% Endocine™|intranasal administration
223573795|NCT01810068|PROCEDURE|Diagnostic cystoscopy|Cysto-urethroscopy
223573796|NCT00279097|DEVICE|High Frequency Chest Wall Oscillation|
223573797|NCT03379987|DRUG|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
223573798|NCT03379987|DRUG|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
224156144|NCT04163913|OTHER|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
224156145|NCT04163913|OTHER|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
224156146|NCT04182906|BEHAVIORAL|Care Coordination|Screening and referral for basic needs and adult mental health
224156147|NCT04182906|BEHAVIORAL|Resiliency Clinic|Mindfulness-based caregiver-child group medical care
224156148|NCT04182906|BEHAVIORAL|Usual Care|Usual Primary Pediatric Care
224156149|NCT00959881|DRUG|Donepezil plus placebo|5- and 10-mg tablets, single dose
224156150|NCT00959881|DRUG|Donepezil|5- and 10-mg tablets, single dose
224156151|NCT00959881|DRUG|Begacestat|6 x 50-mg capsules, single dose
224156152|NCT00617838|OTHER|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
224156153|NCT03591913|DRUG|Misoprostol|Oral tablets
223458359|NCT02998996|BIOLOGICAL|15 µg HA/strain and 2% Endocine™|intranasal administration
223458360|NCT02998996|BIOLOGICAL|15 µg HA/strain|intranasal administration
223458361|NCT02998996|BIOLOGICAL|intramuscular comparator|intramuscular administration
223458362|NCT02998996|BIOLOGICAL|intranasal comparator|intranasal administration
223458363|NCT02998996|BIOLOGICAL|Placebo, Saline|intranasal administration
223458364|NCT00848029|BIOLOGICAL|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
223458365|NCT02447913|BEHAVIORAL|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
223458366|NCT01118663|DRUG|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
223458367|NCT01118663|DRUG|Acetadote|Acetadote \[old formulation\] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
223458368|NCT02419391|BIOLOGICAL|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
223458369|NCT02419391|OTHER|Placebo|Tris Buffered Saline, sterile
223458370|NCT04663243|BEHAVIORAL|Thinking healthy Program sessions designed for antenatal period|Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
223458371|NCT01468571|DRUG|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
223458372|NCT01468571|DRUG|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
223458373|NCT06076122|DIETARY_SUPPLEMENT|Food supplement based on Salicornia extracts|Freshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain \[https://evesa.com/\]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain \[https://www.bio-dis.com/\]), experts in food supplements and certified for such procedures.
223458374|NCT06076122|DIETARY_SUPPLEMENT|Placebo|Placebo capsules physically equal to the Salicornia extracts capsules
223458375|NCT04291118|PROCEDURE|Private system endoscopic sinus surgery|Patients that will undergo endoscopic sinus surgery though the private system. Beforehand they could of used medical management including, budesonide for their symptoms.
223458376|NCT04291118|PROCEDURE|Public system endoscopic sinus surgery|Patients that undergo endoscopic sinus surgery though the public system after waiting for at least 1 year. Beforehand they could of used medical management, including budesonide for their symptoms.
223458377|NCT04291118|DRUG|Budesonide|Patients will receive medical management for their symptoms that will consist of topical nasal steroid, budesonide and any other required medication for their disease.
223458378|NCT03578133|DIAGNOSTIC_TEST|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
223458379|NCT05642104|DRUG|Neoadjuvant therapy|all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
224067559|NCT02132104|PROCEDURE|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
224067560|NCT02132104|DEVICE|Foley balloon|Uterine application of Foley balloon
223458380|NCT04356287|BIOLOGICAL|UCMSC|Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.
223458381|NCT04356287|OTHER|Placebo|Each infusion will consist of 50 mL of PlasmaLyte A.
224067561|NCT02132104|DRUG|Femoston|Hormones treatment after surgery.
224067562|NCT05836298|OTHER|Non-surgical periodontal treatment|Each selected patient underwent randomly, without anaesthesia, after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional Quadrant Scaling and Root Planing (SRP) or MINST
223458382|NCT03635762|BEHAVIORAL|Be In Charge|comparison of pre and post-program weight and calorie intake
223458383|NCT05279131|DRUG|Tirbanibulin ointment 1%|Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
223458384|NCT04350047|PROCEDURE|Radical nephrectomy with inferior vena cava thrombectomy without thoracotomy|The abdomen was accessed through a Makuuchi incision. After mobilization of the liver and assessment of the inferior vena cava infiltration (IVC), IVC was clamped below the level of the renal veins. In order to get access to the intrapericardial IVC, an incision was made through the tendon of the diaphragm and a clamp was placed first in the hepatoduodenal ligament (Pringle maneuver) and then in the endopericardial portion of the IVC, in that order. A longitudinal 3-4 cm incision was made incorporating the junction of IVC and right renal vein. After tumor removal thrombus was removed and a fine clamp was placed at the IVC just below the hepatocaval junction and immediate release of the clamping of the hepatoduodenal ligament. Total endopericardial clamp time was 4 minutes. Patients then underwent radical nephrectomy in a standard fashion with en bloc resection of the IVC thrombus.
223458385|NCT03142776|PROCEDURE|periodontal debridement|
223458386|NCT03142776|PROCEDURE|photodynamic therapy|
223458387|NCT03142776|DRUG|systemic clarithromycin|
223458388|NCT00990509|DRUG|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
223458389|NCT00990509|DRUG|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
223458390|NCT00990509|PROCEDURE|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)"
224067563|NCT02844387|DIETARY_SUPPLEMENT|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
224067564|NCT02844387|OTHER|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
224156154|NCT02074904|DRUG|Topiramate|
223458391|NCT00716768|PROCEDURE|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
223458392|NCT00716768|PROCEDURE|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
223458393|NCT03454451|DRUG|CPI-006|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
223458394|NCT03454451|DRUG|CPI-006 + ciforadenant|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
224067565|NCT02514967|DRUG|Blisibimod|Administered via subcutaneous injection once per week
224067566|NCT02514967|DRUG|Placebo|Administered via subcutaneous injection once per week
223458395|NCT03454451|DRUG|CPI-006 + pembrolizumab|Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
223458396|NCT03454451|DRUG|CPI-006|Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
223458397|NCT03454451|DRUG|CPI-006 + ciforadenant|Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
223458398|NCT03454451|DRUG|CPI-006 + pembrolizumab|Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
223458399|NCT04965337|DRUG|ASC42|ASC42 tablet administered orally
224067567|NCT00600015|DRUG|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
224067568|NCT00600015|DRUG|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
224067569|NCT03980366|DEVICE|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
224067570|NCT05662267|OTHER|Pancreatic islet transplantation after kidney transplantation|Pancreatic islet transplantation consists in the intrahepatic transplantation of pancreatic islets, as a result of enzymatic digestion of a deceased-donor pancreas.
223458400|NCT04965337|DRUG|Placebo|Matching placebo administered orally
223458401|NCT04269824|BEHAVIORAL|Behavioral intervention package|"Community mobilization and commitment events~* Update factual beliefs~* Establish public commitment~* Update empirical expectations about toilet use~Audio announcements - Disseminate norms-related messages regarding toilet use and ownership~Group level~\- Facilitated sex-segregated group meetings to share information and action knowledge through increased social connections~Network-level social media messages - Transmit norms-related messages, and testimonials of adopters through influential social network members~Household-level Counseling visits~* Update empirical expectations of improved sanitation behaviors in their community~* Motivate improved sanitation practices~* Build capacity to achieve exclusive toilet use~Stickers/decals~\- Signal adoption of promoted behaviors to community members~Individual-level~* Update empirical expectations of improved behaviors among similar others~* Set goals, track progress and maintain improved behavior"
223458402|NCT05329350|DEVICE|muscular ventricular septal defects|intervention cardiology and structural heart disease, including transseptal puncture.
223458403|NCT02927574|DEVICE|DCB|
224067571|NCT00731874|DRUG|Tacrolimus|Dosed to achieve target trough concentrations.
224067572|NCT04999189|OTHER|Mobile app forDiabetes (Tessera Multimedia, 2020)|Patients will use a mobile app forDiabetes (Tessera Multimedia, 2020) to manage their disease.
224067573|NCT00936624|DRUG|SOTB07|SOTB07 100mg
224067574|NCT00936624|DRUG|SOTB07|SOTB07 200mg
224067575|NCT00936624|DRUG|placebo|placebo
224067576|NCT00936624|DRUG|montelukast|montelukast 10mg po, bid, 12week
224067577|NCT02934009|DEVICE|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
224067578|NCT05130307|BEHAVIORAL|virtual reality game|participants interact with a computer generated world
224067579|NCT03110055|DRUG|Grazoprevir/Elbasvir|anti-viral treatment for HCV
224067580|NCT03110055|OTHER|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
224067581|NCT03110055|PROCEDURE|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
224067582|NCT02258360|OTHER|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
224156155|NCT02074904|DRUG|Placebo|
224156156|NCT02533076|OTHER|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
224156157|NCT02533076|OTHER|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
223458404|NCT02927574|DEVICE|POBA|
223458405|NCT06612359|BEHAVIORAL|BOOST GAIT Program|In addition to usual care, participants will undergo additional therapy over a four-week period, with sessions occurring five times per week for one hour. The BOOST GAIT sessions will be conducted as group-based therapy with four patients and two physiotherapists present to oversee the performance of mobility-specific exercises, including sit-to-stand transfers, standing and stepping, and eventually walking.
223458406|NCT00865657|DRUG|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
223458407|NCT00865657|DRUG|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia \& Upjohn Company formulated products under non-fasting conditions
223458408|NCT01066871|DRUG|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
223458409|NCT01066871|DRUG|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
223458410|NCT01066871|DRUG|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
223458411|NCT01066871|OTHER|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
223458412|NCT05702099|DIAGNOSTIC_TEST|ultrasonography|By performing transvaginal or transabdominal ultrasonography on women, ovarian volume will be calculated and antral follicle will be counted.
223573799|NCT02724735|DRUG|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
223573800|NCT04283942|BEHAVIORAL|Intermittent calorie restriction (ICR)|"Participants in ICR group were instructed to ensure 2 successive days of fasting-mimicking and 5 days of recovery per week. On fasting-mimicking days, the participants were instructed to consume approximately 500 kcal/day and they were provided with plant-based meal replacement to improve adherence and ensured adequate intake of micronutrients. In the rest 5 days of recovery per week, participants were allowed to consume their usual diet.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
223573801|NCT04283942|BEHAVIORAL|Continuous calorie restriction (CCR)|"Participants in CCR group were instructed to consume the prescribed calories (25 kcal / kg × \[height (cm) - 100\] kg) every day by eating conventional food without time restriction.~Participants will receive dietary counseling from experienced nutritionists and eat a balanced diet (macronutrient distribution of approximately 10-15% protein, 55-65% carbohydrate and 20-30% fat).They are required to write daily dietary log. Besides, they are required to maintain their exercise routines and record their daily steps using a unified pedometer (Redmi Smart Band, Xiaomi Corporation, China). The use of drugs affecting blood glucose and LFC will be avoided."
223458413|NCT06751719|OTHER|core stabilization exercises|"The core exercises would be held for 7 to 8 seconds, repeated 10 times, and rest for 3 seconds between repetitions and 1 minute rest between each exercise. These exercises will include:~1. Abdominal hollowing~2. Supine extension bridge~3. Partial Curls"
224156158|NCT02533076|DEVICE|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
224156159|NCT02533076|DEVICE|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
224156160|NCT05106439|BEHAVIORAL|Intern Health Study competition-related mobile notification|Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).
224156161|NCT05106439|BEHAVIORAL|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
223458414|NCT06751719|OTHER|heat therapy|The heat therapy would be applied to the lumbar region for 10 minutes.
223458415|NCT06751719|OTHER|proprioceptive exercises|"The proprioceptive exercises will include rest for 3 seconds between repetitions and 1-minute rest between each exercise. These exercises will include:~1. One leg balance - 10 seconds hold time with 3 repetitions~2. Forward leg swings - 15 swings~3. Sideways leg swings - 15 swings"
223458416|NCT06751719|OTHER|calisthenic exercises|"The calisthenic exercises will include:~1. Abductor's leg raise for 10 repetitions~2. Prone leg extension for 10 repetitions~3. Alternate toe touch for 10 repetitions"
223458417|NCT06751719|OTHER|kinesthetic exercises|"The kinesthetic exercises will have 1 minute rest in between exercises. These exercises will include:~1. Toe walking for 20 meters distance~2. Heel walking for 20 meters distance"
223458418|NCT04611776|DRUG|Atezolizumab|Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
223458419|NCT04611776|DRUG|Placebo|Placebo will be administered intravenously during the induction phase and the maintenance phase.
223458420|NCT04611776|DRUG|Carboplatin|Carboplatin will be administered intravenously during the induction phase.
224071476|NCT01596998|DRUG|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
223458421|NCT04611776|DRUG|Cisplatin|Cisplatin will be administered intravenously during the induction phase.
223458422|NCT04611776|DRUG|Pemetrexed|Pemetrexed will be administered intravenously during the induction phase.
223458423|NCT04611776|DRUG|Gemcitabine|Gemcitabine will be administered intravenously during the induction phase.
223458424|NCT04611776|DRUG|Paclitaxel|Paclitaxel will be administered intravenously during the induction phase.
223458425|NCT04551365|BEHAVIORAL|Lifestyle changes|Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks
223458426|NCT04551365|DIETARY_SUPPLEMENT|Chitosan|Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks
223458427|NCT04551365|OTHER|Placebo|Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
223458428|NCT05373563|PROCEDURE|cesarean section women|The test will be applied to women who have had a cesarean section and the Turkish validity and reliability of the scale will be determined according to the answers given.
223458429|NCT03229317|OTHER|Plethysmography|Lung plethysmography
223458430|NCT06948617|DEVICE|digital intraoral scanner|Alginate impressions were obtained with an irreversible hydrocolloid impression material (Cavex Impressional; Cavex Holland, Haarlem, The Netherlands) and standard plastic trays. For each impression, the time required to mix the material and complete a full-mouth (maxillary and mandibular arches) impression was recorded.
223458431|NCT06948617|DEVICE|Alginate Impression|Alginate impressions were obtained with an irreversible hydrocolloid impression material (Cavex Impressional; Cavex Holland, Haarlem, The Netherlands) and standard plastic trays. For each impression, the time required to mix the material and complete a full-mouth (maxillary and mandibular arches) impression was recorded.
223458432|NCT06956118|DEVICE|Intervention (VeNS Stimulation) Device|The Modius Sleep device is a non-invasive, battery-powered headset that delivers low-level electrical stimulation (up to 1.0 mA at 0.25 Hz) to the skin behind the ears over the mastoid processes. It is worn like headphones and used for 30 minutes per session, five times per week for four weeks, under clinical supervision. Participants are assisted by a staff member to position the electrodes and adjust stimulation intensity in 0.1 mA steps, up to a maximum of 1.0 mA. The headset is turned on manually, and participants are encouraged to set it up independently after initial guidance. Sessions take place while seated, and participants remain supervised throughout to ensure correct use and safety.
223458433|NCT06956118|DEVICE|Control (Sham Stimulation) Device|The sham version of the Modius Sleep device is visually and operationally identical to the active device to preserve blinding. It delivers a brief initial stimulation (30 seconds, with a 20-second taper) at 0.8 Hz to mimic the sensation of the active device without providing ongoing vestibular modulation. The appearance, placement, and user experience are the same, and participants are informed that the sensation may fade during use. Like the intervention device, the sham is used under supervision in the clinic for 30-minute sessions, ensuring identical procedures across both groups. This design maintains blinding while minimizing any physiological effects from the sham stimulation.
223458434|NCT04027088|DIETARY_SUPPLEMENT|Immunonutrition|It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
223458435|NCT04027088|DIETARY_SUPPLEMENT|Standard|It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
223458436|NCT05502627|DRUG|0.25% lemon grass oil mouthwash|0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
223458437|NCT05753592|DRUG|Part 1; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
223458438|NCT05753592|DRUG|Part 2; LOU064 (Remibrutinib)|25 mg remibrutinib (5.5 days)
223458439|NCT05095194|PROCEDURE|Cataract surgery with IOL implantation and with/without capsular tension ring implatation|Patients in this study will receive cataract surgery with IOL implantation and capsular tension ring implantation or cataract surgery with IOL implantation
223458440|NCT04398602|BEHAVIORAL|behavior of the leader|A study investigator, expert in both PPH and simulation debriefing, not involved in the simulation, observed each scenario to record and check the team's technical skills according to the established 23 PPH key tasks. The behavioral scores were assigned by two independent observers, experts in communication and evaluation in simulation, who reviewed the videos of each simulation each simulation all participants were asked to complete a survey related to the leader and the team behaviors. Questions required a yes/no answer or an answer based on an ordinal scale (1=poor, 5=excellent).
223458441|NCT05438342|BIOLOGICAL|Autologous Adoptive immune cells|Immunotherapy Mononuclear cells were collected from 50ml peripheral blood , and cultured adoptive immune cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion.
223458442|NCT05438342|DEVICE|Thermotron RF-8EX|Hyperthermia for 40-50 minutes
223458443|NCT05438342|DRUG|Chemotherapy，checkpoint immunotherapy, targeted therapy|The doctor chooses the appropriate systemic treatment for the patient based on NCCN guidelines
223573802|NCT06115486|OTHER|Control Arm ACSM Guidelines|The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.
223743260|NCT01611181|DRUG|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
223458444|NCT04090385|DEVICE|Transcranial Direct Current Stimulation|Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
224156162|NCT05106439|BEHAVIORAL|Intern Health Study mobile app competition scoreboard and history|Participant can view their current competition scoreboard and competition history at any time via the study app.
224156163|NCT06405685|DRUG|Nimotuzumab|Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
223458445|NCT03493438|OTHER|exercise|A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
224067583|NCT03206723|DEVICE|Bandage contact lens|"Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.~Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time."
224156164|NCT06405685|DRUG|AG|Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
223458446|NCT02524834|PROCEDURE|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
223458447|NCT02524834|DEVICE|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
223458448|NCT01550510|DRUG|Ascorbic Acid|3x a week for 9 weeks
223458449|NCT01550510|DRUG|Irinotecan|350mg/m2 once a week every 3 weeks
223458450|NCT06952517|DRUG|Clascoterone Cream 1%|Clascoterone 1% cream
223458451|NCT04991792|OTHER|Intervention Group 1: Infant Formula with synbiotics|Infants will receive infant formula during the first 6 months of life
223458452|NCT04991792|OTHER|Intervention Group 2: Infant Formula with prebiotics|Infants will receive infant formula during the first 6 months of life
223458453|NCT04991792|OTHER|Control Group 1 and 2: Infant Formula without synbiotics|Infants will receive infant formula during the first 6 months of life
224067584|NCT03206723|DRUG|Eyedrop|Fluoroquinolone eyedrops 4x/day
224067585|NCT03206723|DRUG|Hydrocodone|Hydrocone 1-2 tabs 4x/day if needed
224067586|NCT05443841|OTHER|pleural lavage|pleural lavages before tumor resection and after tumor resecion, respectively
224067587|NCT02544308|DRUG|Lenalidomide|Experimental Arm
224067588|NCT02544308|DRUG|Dexamethasone|Experimental Arm
224067589|NCT02544308|OTHER|No further treatment|Comparator Arm
224067590|NCT03311711|BEHAVIORAL|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
224067591|NCT03311711|BEHAVIORAL|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
224067592|NCT03311711|BEHAVIORAL|Usual care|Participants will receive the usual care that is provided through the clinic they receive care through. This may include completing advanced directives, referral to a support group, or referral to a social worker for further discussion about end of life issues.
224067593|NCT01946607|DRUG|Citalopram|
224067594|NCT01946607|DRUG|Placebo|
224067595|NCT04509778|OTHER|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
224067596|NCT05896982|OTHER|Care as usual with information support|Comprises of additional visual information in the form of two videos that show details about the procedure on both days of the MPI diagnostic procedure. Each of these two videos are approximately 5 minutes long and are made available to the patients before the first day (video 1), and in between the first and second day (video 2).
224067597|NCT05896982|OTHER|Care as usual with supportive coaching|Patients receive coaching from one person who is present throughout the complete diagnostic process. The coach is available for answering questions as well as comforting the patients when necessary (e.g., to reassure patients if they are anxious or stressed).
224067598|NCT05896982|OTHER|Care as usual with information support and supportive coaching|This intervention comprises additional visual information in the form of two videos and coaching throughout the diagnostic process as described above.
223458454|NCT02404402|OTHER|LED|Low Level Light Therapy
223458455|NCT02404402|OTHER|sham LED|Inactive (sham) LED treatment
223458456|NCT03187743|OTHER|Blood samples|"Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
223458457|NCT00954122|DRUG|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
223458458|NCT00689962|DEVICE|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
223458459|NCT00689962|DEVICE|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
223458460|NCT02726789|DRUG|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
223458461|NCT02726789|DRUG|pegylated interferon|immunotherapy
223458462|NCT02726789|DRUG|entecavir|local generic entecavir
223458463|NCT03365934|DEVICE|ADHESIVE BANDAGE #1|Bandage applied daily to wounded site for 14 days
223458464|NCT03365934|DEVICE|ADHESIVE BANDAGE #2|Bandage applied daily to wounded site for 14 days
223458465|NCT03365934|DEVICE|ADHESIVE BANDAGE #3|Bandage applied daily to wounded site for 14 days
223573803|NCT06115486|OTHER|Experimental Arm 6-12-25 repetitions per set|The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
223573804|NCT00328653|DRUG|Cyclosporine NOVA22007 0.05%|
223573805|NCT00328653|DRUG|Cyclosporine NOVA22007 0.1%|
224067599|NCT02457871|BEHAVIORAL|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
223458466|NCT03365934|DEVICE|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
223458467|NCT03365934|OTHER|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
224067600|NCT01451710|DRUG|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
224067601|NCT03657368|PROCEDURE|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
223458468|NCT03365934|OTHER|Wounded and No Bandage|This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
223458469|NCT03106883|BEHAVIORAL|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
223458470|NCT03106883|BEHAVIORAL|Sham training|3 sessions of sham attention training using non-affective stimuli
223458471|NCT00351585|DRUG|Vildagliptin|
224067602|NCT03657368|PROCEDURE|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
224067603|NCT03657368|PROCEDURE|Low PEEP|PEEP = 5 cm H2O
223458472|NCT05118347|OTHER|Buteyko Breathing Technique|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. This helps prevent lung problems, such as pneumonia. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
223458473|NCT01289548|DEVICE|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
223458474|NCT05242302|PROCEDURE|nerve transfer|the anterior interosseous nerve will be used as a donor to reinnervation the injured ulnar nerve.
223458475|NCT00490347|DEVICE|VentrAssist Left Ventricular Assist Device|
223458476|NCT05191719|PROCEDURE|Botox injection|Comparator, current gold standard
223458477|NCT05191719|PROCEDURE|Neurotomy|Surgical procedure
223458478|NCT00002168|DRUG|Indinavir sulfate|
223458479|NCT00002168|DRUG|Lamivudine|
223458480|NCT00002168|DRUG|Stavudine|
223458481|NCT00002168|DRUG|Zidovudine|
223458482|NCT00002168|DRUG|Didanosine|
223573806|NCT00328653|DRUG|Vehicle|
223573807|NCT00937404|BIOLOGICAL|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
223573808|NCT02510651|PROCEDURE|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
223573809|NCT04571307|PROCEDURE|cryotherapy|comparison between cryotherapy and surgery
223573810|NCT04886544|DEVICE|YVOIRE Y-Solution 720|Hyaluronic acid dermal filler
223573811|NCT01054937|DRUG|4SC-203|i.v. administration
223573812|NCT01054937|DRUG|Placebo|i.v. administration
223743261|NCT01611181|DRUG|Kräuterblut|40 mg iron, 20 ml twice daily.
223743262|NCT01611181|DRUG|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
224067604|NCT03657368|PROCEDURE|High PEEP|PEEP = 8 cm H2O
224067605|NCT01623271|DRUG|Gabapentin|
224067606|NCT04188184|DRUG|Tranexamic Acid|received topical 1 gram of TXA diluted in 200 ml of normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
224067607|NCT04188184|DRUG|Epinephrine|received Epinephrine 1 mg diluted in 200 ml normal saline (0.9%) for topical use to rinse the bleeding sites and soak the used gauze for local compression.
224067608|NCT01614132|DRUG|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
224067609|NCT01614132|RADIATION|Radiotherapy|Radiotherapy of the partial brain
223458483|NCT04474561|OTHER|Reduced sulfur diet|A reduced sulfur diet includes reducing foods, food additives (e.g., carrageenan) and beverages high in sulfate/sulfur, limiting sulfur containing supplements, and consuming omega-3 fatty acid supplements to potentially help control overgrowth of sulfur-reducing bacteria in the colon. Omega-3 fatty acid intake for cardiovascular disease prevention should be around 500 mg/d23. After dietary assessment if patients are not meeting their required daily intake of 500 mg/d of Omega-3, the RD will recommend increased fish consumption to 200 g per week or 1 g/d of an Omega-3 supplement. This will ensure the daily recommended intake of 500 mg/d is being met to reduce the chances of a deficiency; however, a therapeutic dose for UC will not be recommended (i.e., \> 4 g/d18).
223458484|NCT01726062|BEHAVIORAL|Motivational Interviewing plus Incentives|"1. Two hospital-based, face-to-face MI+ sessions~2. Two home-based MI+ sessions~3. Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
223458485|NCT01726062|BEHAVIORAL|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
223458486|NCT04300712|BEHAVIORAL|Questionnaires at the start and end of the school year|Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
223458487|NCT05127564|DRUG|Diroximel fumarate|Administered as specified in the treatment arm
223458488|NCT01000987|DRUG|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
223458489|NCT01000987|DRUG|placebo|placebo
223458490|NCT01991964|OTHER|laryngeal ultrasound|
223458491|NCT02598739|OTHER|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
223458492|NCT02598739|OTHER|Waiting list for the exercises|
223458493|NCT01570140|BEHAVIORAL|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
223458494|NCT03642535|DRUG|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
223458495|NCT03752476|PROCEDURE|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
223458496|NCT03590171|DRUG|Bortezomib|Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
223458497|NCT04853823|DRUG|PDC-APB|PDC-APB Intra-muscular Injection
223458498|NCT04853823|OTHER|Placebo|Vehicle
223458499|NCT06394583|PROCEDURE|Lung ultrasound|We will perform a LU at birth to all infants, before the first dose of surfactant.
223743263|NCT02304263|DRUG|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
224067610|NCT03715283|OTHER|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
224067611|NCT03715283|OTHER|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
224067612|NCT02738658|DEVICE|Bioresorbable vascular scaffold|
224067613|NCT02738658|DEVICE|Everolimus-eluting stent|
224067614|NCT06375109|DRUG|Tislelizumab|administered via Intravenous (IV) injection
224067615|NCT06375109|DRUG|Carboplatin injection|administered via IV injection
224067616|NCT06375109|DRUG|Cisplatin injection|administered via IV injection
224067617|NCT06375109|DRUG|Etoposide injection|administered via IV injection
224067618|NCT01632514|DRUG|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
224067619|NCT04349423|BEHAVIORAL|Social Media Usage Manipulation|Behavioral Intervention of social media usage.
224067620|NCT01372904|DRUG|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
224067621|NCT02730884|DRUG|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
224067622|NCT02730884|BEHAVIORAL|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
223458500|NCT05377112|DRUG|SYNB8802v1|"SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites."
223458501|NCT05377112|OTHER|Placebo|placebo powder will be aliquoted into high density polyethylene (HDPE) bottles and diluted in the same formulation buffer as SYNB8802v1 lyophilized powder. The placebo consists of corn starch and dyes to color match the placebo to the SYNB8802v1 powder for oral suspension
223458502|NCT01571141|DEVICE|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
223458503|NCT05995834|OTHER|Research questions|"Stage 1: Secondary analysis of a previous international survey to identify items~Stage 2: Cognitive debriefing interviews with about 10 people living with iMCD to assess the content validity of the items~Stage 3: Completion of questionnaire to finalise scale~Stage 4a: Re-administering of follow-up questionnaire to Stage 3 patients to assess minimally important clinical difference. Test-retest will be calculated only in patients exhibiting no change.~Stage 4b: Qualitative interviews with a subset of participants from Stages and 4 to help with interpretation of meaningful difference from their perspective"
223458504|NCT02114619|DRUG|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
223458505|NCT02114619|DRUG|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
223458506|NCT02114619|DRUG|High dose|We will administer 200 micro currie of iodine per thyroid gram
223573813|NCT05019612|PROCEDURE|Laparoscopy: A minimal invasive surgery|A low-risk minimal invasive surgery performed in the pelvis using small incisions. With the aid of a laparoscope, the operator views the affected area in real-time. Beyond that, the camera sends images to a video monitor. The operator obtains endometriosis and biopsy samples with small surgical instruments. Before laparoscopy, individuals are provided with a general anaesthetic to relax muscles and prevent pain during surgery.
223573814|NCT04615975|DIETARY_SUPPLEMENT|Ketogenic diet with phytoextracts|Patients were provided with an individualized nutritional ketogenic plan during hospitalization
223573815|NCT02898961|DRUG|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
223743264|NCT03515772|DRUG|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
224067623|NCT05787262|PROCEDURE|upper endoscopy|Upper endoscopy , biopsy and histopathological examination of taken biopsies.
224067624|NCT01339559|DRUG|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
224067625|NCT03405623|PROCEDURE|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
224067626|NCT03405623|PROCEDURE|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
224067627|NCT05017740|PROCEDURE|ICSI|In ICSI, the sperm is chosen based on motility and gross morphology to be inseminated directly into the cytoplasm of the oocyte.
223458507|NCT00260013|PROCEDURE|program of care delivery|
223458508|NCT01851655|BEHAVIORAL|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
223458509|NCT02262650|DRUG|Telmisartan|
223458510|NCT02262650|DRUG|Clopidogrel|
223458511|NCT04576650|DEVICE|Summit System|Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
223458512|NCT00186342|PROCEDURE|ablative allogeneic hematopoietic cell transplantation|
223573816|NCT05117619|BEHAVIORAL|HOME for Us|HOME is an in-home, family inclusive, rehabilitation intervention in 8 sessions. Six of the sessions will be in-home and 2 will be over the phone. The in-home sessions will be about 1 ½ hrs. each, and the phone sessions will be about 15 minutes each. The sessions are delivered by an occupational therapist (OT).
223573817|NCT05117619|BEHAVIORAL|Attention-control condition|The Attention-control condition consists of educational materials presented over 8 contacts. Two of the contacts are by video conferences or phone calls and last 1 to 2 hours each. Two of the contacts are mailings of educational materials for discussion during the longer sessions. Three of the contacts are phone calls lasting about 10-15 minutes each to check for general updates, health care utilization/access, and study reminders.
223573818|NCT03201692|DEVICE|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
223573819|NCT03201692|DEVICE|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
223743265|NCT03604042|COMBINATION_PRODUCT|Protein fortifier|Protein Fortifier to be added to Fortified human milk according to feeding regimen
223458513|NCT03151447|RADIATION|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
223458514|NCT04378686|OTHER|dialysis|treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
223458515|NCT01815658|DEVICE|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
223458516|NCT00416819|BIOLOGICAL|filgrastim|
224156165|NCT02819349|BEHAVIORAL|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
224156166|NCT01914783|OTHER|ultrafine particles|exposure to ultrafine particles
224156167|NCT01914783|OTHER|ultrafine particles and ozone|exposure to ultrafine particles and ozone
223458517|NCT00416819|BIOLOGICAL|rituximab|
223458518|NCT00416819|DRUG|cytarabine|
223458519|NCT00416819|DRUG|etoposide phosphate|
223458520|NCT00416819|DRUG|leucovorin calcium|
223458521|NCT00416819|DRUG|methotrexate|
223458522|NCT00416819|DRUG|temozolomide|
223458523|NCT02508376|OTHER|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
223458524|NCT02508376|BIOLOGICAL|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
223458525|NCT02508376|BIOLOGICAL|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
223458526|NCT01285661|DRUG|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
223458527|NCT02104076|DEVICE|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
223458528|NCT05119127|DEVICE|Alcon Vivity toric intra ocular lens|implanting vivity toric IOL to asses rotational stability. IOL is already FDA approved for implantation at time of cataract surger. Intervention is to assess rotational stability and visual outcome.
223458529|NCT01703390|DRUG|FOLFIRI + Cetuximab|
223458530|NCT01703390|DRUG|modifiedFOLFOX6 + Cetuximab|
223458531|NCT05200377|DIAGNOSTIC_TEST|Magnetic resonance imaging|Patients recruited will receive Magnetic resonance imaging.
223458532|NCT00218478|BEHAVIORAL|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
223458533|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
223458534|NCT02030262|PROCEDURE|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
223458535|NCT04361799|DEVICE|CamAPS|Fully automated closed-loop subcutaneous insulin delivery system. A model predictive controller modulates insulin delivery every 10-12 minutes based on interstitial glucose measurements.
223458536|NCT04361799|DRUG|Standard insulin therapy|Standard insulin therapy according to local clinical practice.
223458537|NCT04956471|OTHER|interview|A sample method: convenience sampling, selecting A 3 armour hospital between September 2019 and January 2020 neurology hospital patients with swallowing disorder after stroke, about 15 cases.
223458538|NCT02077686|BEHAVIORAL|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
223458539|NCT00141414|DRUG|Pregabalin|
223458540|NCT01781104|DRUG|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
223458541|NCT01781104|DRUG|Placebo|Placebo delivered subcutaneously once daily for 14 days.
223458542|NCT04360460|OTHER|Immersive virtual reality + related functional translation into real-life|The experimental group will perform tasks in an immersive virtual reality setting designed to encourage functional task performance for 30 minutes. The patient will then be brought to a real-life setting and evaluated on similar task performances for an additional 30 minutes for a total of 60 minutes per day, 3 times a week for 2 weeks.
224156168|NCT01914783|OTHER|clean air|Exposure to clean air.
224156169|NCT04176536|DRUG|BI 764198|Capsules
224156170|NCT01635036|DEVICE|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
223458543|NCT04360460|OTHER|Immersive virtual reality + non-related translation into real-life|The control group will also be asked to perform tasks in an immersive VR setting for 30 minutes, however tasks will be unrelated to the tasks performed in the real-life setting in the following 30 minutes. The control group will also receive 60 minutes of therapy a day, 3 times a week, for 2 weeks.
223458544|NCT00338546|DRUG|Cocaine hydrochloride|
223458545|NCT00338546|DRUG|Dexmedetomidine|
223458546|NCT00338546|PROCEDURE|Microneurography|
223458547|NCT00338546|PROCEDURE|Laser doppler velocimetry|
223458548|NCT02635919|DEVICE|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
223458549|NCT05089578|OTHER|focus interview|"The Information Form including descriptive characteristics of the individuals undergoing Covid-19, the semi-structured Interview Form, and the Complementary Therapy Use Form were used as the data collection tools. The Information Form consisted of 13 questions including socio-demographic and disease-related characteristics of individuals. In-depth interview method was used to collect data. Interviews were held by organizing video calls and online meeting programs on mobile phones both due to pandemic measures and in order to enable individuals to communicate comfortably. The time period in which the individuals felt most ready for the interview was determined and the data were collected during that time. During the interview, effective communication techniques were used, active listening was carried out and individuals were guided using question forms in accordance with the aim of the study. The interviews lasted for an average of 25-30 minutes."
223458550|NCT05722262|DRUG|K-001|K-877-ER and CSG452 combination tablet
223458551|NCT05722262|DRUG|K-877-ER|K-877-ER tablet
223458552|NCT05722262|DRUG|CSG452|CSG452 tablet
223458553|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
223458554|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 472 mg QD|SFC 118 mg capsules will be given to the patients as 472 mg QD
223458555|NCT04020653|DRUG|Artemisinin-based combination (ACT)|Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
223458556|NCT04020653|DRUG|Placebo|Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
223458557|NCT04020653|DRUG|5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
223458558|NCT04020653|DRUG|Sodium ferrous citrate (SFC) 236 mg BID|SFC 118 mg capsules will be given to the patients as 236 mg BID
223458559|NCT01945879|DRUG|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
223458560|NCT01151306|DRUG|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
223458561|NCT01151306|DRUG|Lactose tablet|One tablet taken each evening for 6 weeks
223458562|NCT04861844|BEHAVIORAL|mindfulness training|phone based mindfulness training on 4 consecutive days
223458563|NCT04861844|BEHAVIORAL|active listening|The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
223458564|NCT02121795|DRUG|FTC/TDF|200/300 mg FDC tablets administered orally once daily
223458565|NCT02121795|DRUG|F/TAF|Tablets administered orally once daily
223458566|NCT02121795|DRUG|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
223458567|NCT02121795|DRUG|FTC/TDF Placebo|Tablets administered orally once daily
223458568|NCT02121795|DRUG|F/TAF Placebo|Tablets administered orally once daily
223458569|NCT00849069|BIOLOGICAL|GSK2231395A|3 doses intramuscular injections
223458570|NCT00849069|BIOLOGICAL|TwinrixTM|3 doses intramuscular injections
223458571|NCT05544591|DRUG|611 Q2W|subcutaneous injection, 600mg (loading dose, week 0) + 300mg Q2W (maintenance dose, from Week 2 to Week 14, 7 cycles)
223458572|NCT05544591|DRUG|611 Q4W|subcutaneous injection, 600mg (loading dose, Day1) + 300mg Q4W (maintenance dose, on week 4, 8, 12) + placebo Q4W (on week 2, 6, 10, 14)
223458573|NCT05544591|DRUG|Matching placebo|subcutaneous injection, Q2W, from Week 2 to Week 14, 7 cycles
223458574|NCT02379013|PROCEDURE|Volunteer with MRI|functional MRI
223458575|NCT00346749|DRUG|Salmeterol|
223458576|NCT00346749|DRUG|Fluticasone Propionate/Salmeterol Combination Product|
223458577|NCT06084702|OTHER|Rehydration with plain water|Plain water without calories, sweetener, or electolytes
223458578|NCT06084702|OTHER|Rehydration Drink|Roaring Water. An electrolyte drink with low Carbohydrate content
223458579|NCT03523195|BEHAVIORAL|Exercise Intervention|Complete exercise program
223458580|NCT03523195|OTHER|Informational Intervention|Receive written information on healthy exercise and diet recommendations
223458581|NCT03523195|OTHER|Laboratory Biomarker Analysis|Blood tests
223458582|NCT03523195|DEVICE|Monitoring Device|Wear Fitbit
223458583|NCT03523195|OTHER|Questionnaire Administration|Ancillary studies
223458584|NCT03523195|OTHER|Physical Performance Testing|Performance of physical tests
223458585|NCT06029881|DEVICE|Movesense MD|This device can be attached to the skin (on the chest and center of mass) during sleep using a belt and adhesive electrodes.
223458586|NCT00666211|OTHER|educational intervention|Participants will be educated on pain management.
223458587|NCT00666211|OTHER|Titrated pain management|Pain will be Monitored and Medication Titrated
223458588|NCT00666211|OTHER|questionnaire administration|Participants will be given questionnaires to complete.
223458589|NCT02299440|OTHER|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
223458590|NCT02299440|DRUG|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
223458591|NCT02299440|DRUG|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
223458592|NCT02299440|OTHER|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
223573820|NCT01811602|OTHER|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
223458593|NCT02299440|DRUG|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
223458594|NCT02299440|DRUG|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
223458595|NCT05882929|OTHER|Watching Cartoons|The cartoon will be watched after the child comes to the service after the operation and the postoperative period is prepared (taking the vital signs, putting on the clothes, controlling the bleeding, telling the feeding time, etc.).
223458596|NCT05882929|OTHER|ball spin|ball squeezing will be applied after the child comes to the service after the operation and after the postoperative period preparation is made (taking the vital signs, dressing the clothes, controlling the bleeding, telling the feeding time, etc.).
223458597|NCT05094414|DRUG|Valacyclovir|oral valacyclovir 500 mg twice per day for 4 weeks
223458598|NCT04054817|DEVICE|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
223458599|NCT00346762|BEHAVIORAL|Education|HIV prevention education and risk reduction counselig
223458600|NCT03015298|DEVICE|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
223458601|NCT03015298|DEVICE|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
223458602|NCT04124380|BEHAVIORAL|Imaginal Exposure|Six 50 min, twice weekly video telehealth sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
223458603|NCT04124380|BEHAVIORAL|Alcohol Skills Training|Six 50 min, twice weekly video telehealth sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
223458604|NCT04124380|BEHAVIORAL|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
223458605|NCT02299388|DRUG|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
223458606|NCT02741648|DEVICE|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
223573821|NCT01811602|OTHER|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
223573822|NCT02557113|PROCEDURE|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
223573823|NCT02557113|PROCEDURE|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
223458607|NCT04391179|DRUG|Dipyridamole 100 Milligram(mg)|Drug will be given for 14 days while in the hospital.
223573824|NCT02703870|DEVICE|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
223573825|NCT02703870|DEVICE|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
223573826|NCT02703870|BEHAVIORAL|VRT|Vision restoration training, 10 sessions, 20 minutes
223573827|NCT06363318|PROCEDURE|Laparoscopic appendicectomy|In group A laparoscopic appendicectomy was done while in group B Open appendicectomy was done
223573828|NCT03445910|DRUG|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
223573829|NCT00902993|DRUG|AZD1446|Solution, oral single and multiple dose
223573830|NCT00902993|DRUG|Placebo|Placebo
224067628|NCT05017740|PROCEDURE|PICSI|In PICSI, the sperm is selected via hyaluronic binding before insemination into the cytoplasm of the oocyte.
223458608|NCT04391179|DRUG|Placebo oral tablet|Placebo will be given for 14 days while in the hospital.
223458609|NCT03334188|BEHAVIORAL|Patient engagement materials|The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.
223458610|NCT03334188|BEHAVIORAL|No Intervention--Usual Care|Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
223458611|NCT01146015|BIOLOGICAL|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
223458612|NCT03373760|BIOLOGICAL|Durvalumab|Given IV
223458613|NCT03373760|OTHER|Laboratory Biomarker Analysis|Correlative studies
223458614|NCT03373760|BIOLOGICAL|Tremelimumab|Given IV
223458615|NCT04218279|OTHER|Sleep Health Education|Intervention materials include 10 brief education modules that the target population will review/view on a secure study-specific website.
223458616|NCT04407702|OTHER|Hygiene Instructions|Two weeks prior to the onset of the study, the volunteers will undergo a wash-out period, in which they will only use oral hygiene products donated by the researchers. These products will be used through to the end of the study. The oral hygiene kit will contain a soft-bristle toothbrush (Professional Lab Series, Colgate Palmolive), fluoride toothpaste with no desensitizing agent (Elmex) and dental floss (Colgate). The participants will be extensively trained with regards to all procedures involved in the experiment.
223458617|NCT04407702|PROCEDURE|Sealant application|The teeth to be sealed will be isolated and 35% phosphoric acid will be applied for 20 seconds, followed by rinsing and drying the dental surfaces. A thin layer of PermaSeal will be applied to the tooth surface for 5 seconds and photopolymerized for 20 seconds. The occlusion will then be evaluated.
223458618|NCT04407702|RADIATION|Low-level Laser|Irradiation with AsGaAl laser at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP, Brazil) with relative isolation. The power will be set to 100 mW; energy density will be 35 J/cm2 (considering a spot size of 0.028 cm2 of the equipment) and the dose will be 1 J per point. Irradiation will be performed on a cervical point, an apical point and a point precisely over the lesion, totaling a dose of 3 J. Treatment will be performed in three sessions with a 72-hour interval between sessions.
223458619|NCT05950880|OTHER|High intensity shoulder exercise|Exercises that target the rotator cuff muscles using 90% of one repetition maximum only for 5 repetitions
223458620|NCT05950880|OTHER|Conventional physical therapy|Conventional physical therapy consisting of scapular stabilization exercises, posterior capsule stretch, and rotator cuff activation exercises
223458621|NCT02616198|OTHER|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
223458622|NCT02616198|OTHER|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
223458623|NCT02616198|OTHER|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
223458624|NCT02616198|OTHER|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
223458625|NCT01710397|OTHER|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
223458626|NCT02419599|OTHER|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
223458627|NCT02419599|OTHER|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
223458628|NCT05827692|BEHAVIORAL|Intervention group A|The forest bath sessions will be led by a specialized guide and will be conceived as a silent walk of about 3 km along a path and forest track with an average gradient of 3%, with three 10-minute stops (at the beginning, in the middle and at the end) to practice deep breathing and awareness of the 5 senses.
223458629|NCT01093586|PROCEDURE|double-unit umbilical cord blood transplantation|Undergo transplantation
223458630|NCT01093586|OTHER|cytogenetic analysis|Correlative studies
223573831|NCT05550038|DIAGNOSTIC_TEST|Compression ultrasound|Patients receive a 3-point compression ultrasound performed by the general practitioner to look for proximal deep vein thrombosis.
223458631|NCT01093586|PROCEDURE|bone marrow aspiration|Correlative studies
223458632|NCT01093586|OTHER|fluorescence in situ hybridization|Correlative studies
223458633|NCT01093586|DRUG|busulfan|Given orally
223458634|NCT01093586|DRUG|cyclophosphamide|Given IV
223458635|NCT01093586|DRUG|anti-thymocyte globulin|Given IV
223458636|NCT01093586|DRUG|methylprednisolone|Given IV
223458637|NCT01093586|DRUG|cyclosporine|Given IV
223458638|NCT01093586|DRUG|mycophenolate mofetil|Given orally or IV
223458639|NCT01093586|OTHER|flow cytometry|Correlative studies
223458640|NCT01093586|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
223458641|NCT01867320|DRUG|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
223458642|NCT02949882|DIETARY_SUPPLEMENT|Yakult|Containing at least 6,5\*10\^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
223458643|NCT02949882|DIETARY_SUPPLEMENT|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
223458644|NCT05873270|OTHER|Wrist and ankle acupuncture|Patients in the intervention arm started the wrist and ankle acupuncture treatment 1 day before the surgery. Take up and down 1,2 area as a needle point, use hua tuo brand sterile acupuncture needle (specification: 0.25mm 25mm), into the skin disinfection into the needle, keep 30 subcutaneous needle and skin, when the operator under the needle, patients without acid swelling, pain, close to the skin dermis, to about 1.5 inches, give tape fixed 24h, left under the skin, until postoperative 3 day.
224156171|NCT05260606|DIAGNOSTIC_TEST|F-18 FDG PET/CT|"1. 1st scan: pre-Tx, ICI Tx must be started within 35 days after 1st scan.~2. 2nd scan: interim~   * Pembrolizumab or atezolizumab: after the 2nd Tx cycle to before the start of the 3rd Tx cycle~  * Nivolumab: after the 3rd Tx cycle to before the start of the 4th Tx cycle~3. 3rd scan: optional (3rd scan can be performed when disease progression is suspected)~4. Imaging~   * Fasting: at least 6 hours~  * Blood glucose level: \< 200 mg/dL~  * F-18 FDG 0.14 mCi/kg (IV)~  * Image acquisition: 1 hr after FDG injection, CT images are acquired. After CT scan, PET images are acquired and attenuation-corrected PET images are reconstructed based on the CT image data.~  * PET/CT: Discovery MIDR or MI (GE Healthcare, Chicago, Illinois, USA)~  * First and second scans have to be performed with same scan."
223458645|NCT06117722|OTHER|Eplerenone torasemide in chronic heart failure|Heart Failure patients treated with eplerenone and torasemide
224156172|NCT00083876|DRUG|Thalidomide|
224156173|NCT01121952|OTHER|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
223458646|NCT01560026|PROCEDURE|surgery|endometrial cancer with or without oophorectomy
223458647|NCT05926141|BEHAVIORAL|ACE intervention|Participants attend the ACE Program for 12 weeks after school. On one assigned day of the week, participants attend ACE in person after school. The session begins with mindfulness exercises (15 minutes), professional development session (50 minutes), nutrition education lesson (20 minutes), and reflection period to talk about their experience in cooking lessons (25 minutes). On any day during the week, the students will make a dish using groceries they received (1 hour).
223458648|NCT00105989|DRUG|Duloxetine|
224156174|NCT04055025|OTHER|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
223458649|NCT00105989|DRUG|placebo|
223458650|NCT03442088|DRUG|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
223458651|NCT00817388|OTHER|No intervention|No intervention
223458652|NCT00357877|DRUG|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
223458653|NCT00357877|OTHER|Placebo|
223458654|NCT05678439|DIETARY_SUPPLEMENT|sesame extract|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
224156175|NCT04055025|OTHER|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
224156176|NCT00232414|DRUG|Quetiapine|
224156177|NCT01553760|PROCEDURE|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
223458655|NCT05678439|OTHER|placebo|At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
223458656|NCT00738855|OTHER|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
223458657|NCT00738855|OTHER|Nothing per os|A nasogastric tube
223458658|NCT01687634|BEHAVIORAL|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
223458659|NCT01687634|BEHAVIORAL|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
223458660|NCT04668209|DRUG|Silmitasertib|Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
223458661|NCT03147950|PROCEDURE|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
223458662|NCT03147950|PROCEDURE|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
223458663|NCT03301077|OTHER|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
223458664|NCT03327285|BIOLOGICAL|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
223458665|NCT01863290|OTHER|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
223458666|NCT00534872|DRUG|SB-649868|10 mg
224156178|NCT01553760|PROCEDURE|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
224156179|NCT04289194|DRUG|HCR040 (Phase 1)|(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)
224156180|NCT04289194|DRUG|Placebo (Phase 2)|(Phase 2) Intravenous administration of vehicle solution
223458667|NCT05618288|BEHAVIORAL|mobile Health Breastfeeding Counseling|a phone-based breastfeeding counseling intervention, delivered by labor and delivery nurses, nutritionists, and maternal and child health nurses.
223458668|NCT05618288|BEHAVIORAL|Standard of care breastfeeding counseling|The ongoing antenatal, delivery and postnatal breastfeeding and lactation counseling that is provided by the Naivasha sub-County Referral Hospital.
223458669|NCT00767221|DRUG|Budesonide|8 mg PL-56 once daily for six months
223458670|NCT05834218|OTHER|split body resistance training|"Split-group training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust) 3x12 repetitions for each exercise Day 2 ( Lat pulldown, Bench press, Cabled seated row)3x12 reps (Triceps press and biceps curls in cable (superset) Day 3 (Day 1 exercise repeated) Day 4 (Day 2 exercise repeated)"
223458671|NCT05834218|OTHER|full body resistance training|"Full body training regime:~Day 1 (Leg press, Stiffed-legged deadlift, Leg extension, Hip thrust, Lat pulldown, Bench press, Cabled seated) 3x12 reps for each exercise, (Triceps press and biceps curls in cable (superset) Day 2 (Repeat first day exercise)"
223458672|NCT05128266|PROCEDURE|Endodontical Retreatment|"1. Linear canal Removal of the coronal dentine in order to create the space useful to an extractor to catch and remove the instrument. The preferred instrument to reach this aim is a .15 or .20 ultrasonic tip.~2. Curve canal When the instrument is broken inside a curve canal, it is not possible to create a circumferential space around the separated instrument without the risk of root perforation. Thus, the first step is the removal of the dentine of the external wall of the root canal. The second step is the removal of the dentine of the internal wall of the root canal. This selective removal of dentinal tissue unlocks thee separated instrument and determines its mobilization. Thus, the irrigation itself makes the instrument available for the removal.~After the removal of the broken instrument, root canal preparation was completed Canal filling was performed based on Schilder's technique."
223458673|NCT05323877|DEVICE|Test Device (PerQseal+)|Percutaneous arterial closure device
223458674|NCT02959216|OTHER|Aerobic Exercise|Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
223458675|NCT02959216|OTHER|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
223458676|NCT05258253|OTHER|High intensity aerobics|"London bridges (8mins) Jumping lunges(8mins) Mountain climbers(8mins) Quadruped bent knee hip extension (8mins)"
223458677|NCT05258253|OTHER|Pelvic clock exercises|Lie with your back on the floor in a neutral position with your legs bent and toes facing forward. Subject begin with gentle movements from 12 to 6 o'clock, as instructed to move from 3 o'clock to 9 o'clock. Then move in a clockwise manner from 12 to 3 to 6 to 9 and then back to 12 o' clock.
223573832|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10\^5 cells/kg~Dose Level 2: 1×10\^6 cells/kg~Dose Level 3: 5×10\^6 cells/kg"
224156181|NCT04289194|DRUG|HCR040 (Phase 2)|(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
224156182|NCT05369780|DIETARY_SUPPLEMENT|Hydrolyzed Collagen Peptide|Dietary Hydrolized Collagen Peptide sourced from bovine
224156183|NCT01301417|DEVICE|ColonRing™|Creation of a circular Compression Anastomosis
224302780|NCT04525235|COMBINATION_PRODUCT|phenotyping cocktail|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
224302781|NCT04525235|DRUG|rifampicin|A single dose of a cocktail of phenotyping probe drugs (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam and digoxin) will be administered together with standard dose rifampicin and 40 mg/kg rifampicin, respectively. Blood samples will be taken to assess phenotyping metrics of the cocktail agents and rifampicin pharmacokinetic parameters. The effect of high and standard dose rifampicin on the phenotyping metrics of the cocktail agents will be compared by using the bioequivalence approach
223458678|NCT00608751|RADIATION|IMRT|
223458679|NCT03559543|DIETARY_SUPPLEMENT|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
223458680|NCT02311608|DRUG|Terlipressin|administered as a first-line medicine or as salvage
223458681|NCT02311608|DRUG|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
223458682|NCT02311608|DRUG|High Dose Somatostatin/Octreotide|administered as salvage
223458683|NCT03735082|DRUG|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
223458684|NCT03735082|DRUG|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
223458685|NCT03735082|DRUG|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
223573833|NCT02050347|GENETIC|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10\^5 cells/kg~Dose Level 2: 5x10\^5 cells/kg~Dose Level 3: 1x10\^6 cells/kg"
224156184|NCT03896906|DEVICE|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher \& Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
224156185|NCT03896906|DEVICE|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
224156186|NCT04753723|COMBINATION_PRODUCT|Gentamycin with Platform Wound Device|Treatment of wounds with gentamycin and covered with platform wound device.
224156187|NCT00646438|DRUG|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
224156188|NCT03907813|DRUG|Exparel|liposomal bupivacaine wound infiltration
223458686|NCT04883151|BEHAVIORAL|SOFUS pilot program|"The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is \<10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered."
223458687|NCT03620149|DRUG|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
223458688|NCT01718392|BEHAVIORAL|Training|
223458689|NCT05964985|DRUG|Normal saline|After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
223458690|NCT05964985|DRUG|Ropivacaine|After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
223458691|NCT05964985|DRUG|Compound lidocaine|After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
223458692|NCT05964985|DRUG|Esketamine|After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
223458693|NCT02988739|BIOLOGICAL|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
223458694|NCT02988739|DEVICE|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
224156189|NCT03907813|OTHER|Saline infiltration|saline wound infiltration
223458695|NCT03341845|DRUG|Axitinib|axitinib in combination with avelumab
223458696|NCT03341845|DRUG|Avelumab|axitinib in combination with avelumab
223458697|NCT05454995|OTHER|Vessel Restoration System (VRS)|Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
223458698|NCT03610074|OTHER|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
223458699|NCT03610074|PROCEDURE|Blood test|Additional blood test 5 min after mint ice cubes application
223458700|NCT03610074|OTHER|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
223458701|NCT02884739|OTHER|Data collection|
223573834|NCT05540561|OTHER|blood collection|Biological analyses in the framework of care with conservation of blood samples
223458702|NCT00028262|DRUG|Cystagon|
223458703|NCT05748574|DIETARY_SUPPLEMENT|Sleep Well Sachet|Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment
223458704|NCT01869777|PROCEDURE|bioelectric impedance analysis|Undergo bioelectric impedance analysis
223458705|NCT03866421|DIAGNOSTIC_TEST|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
223458706|NCT03866421|DIAGNOSTIC_TEST|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
224156190|NCT02475629|BIOLOGICAL|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
223458707|NCT03866421|DEVICE|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
223458708|NCT03866421|DIAGNOSTIC_TEST|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
223458709|NCT03866421|DIAGNOSTIC_TEST|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
223458710|NCT03866421|RADIATION|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
223458711|NCT03866421|BIOLOGICAL|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
223458712|NCT03866421|OTHER|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
223573835|NCT04646161|DRUG|Misoprostol|misoprostol 200 mcg will be given sublingual 2 hrs before mirena iud insertion
223573836|NCT03387995|DEVICE|LVIS stent|The paitents treated by LVIS stent implantation.
223573837|NCT03387995|DEVICE|Solitaire stent|The paitents treated by Solitaire stent implantation.
223573838|NCT03387995|DEVICE|Enterprise stent|The paitents treated by Enterprise stent implantation.
223458713|NCT00018564|DRUG|treatments for essential tremor|
223458714|NCT01588158|DRUG|Acetaminophen|325 mg
223458715|NCT01588158|DRUG|Vicodin|Vicodin 5/325 mg
223458716|NCT05293522|COMBINATION_PRODUCT|NTX-001|2 solutions plus a delivery device; one time use surgical product
223458717|NCT04644120|DRUG|ABBV-47D11|Intravenous (IV) infusion.
223458718|NCT04644120|DRUG|Placebo for ABBV-47D11|Intravenous (IV) infusion.
223458719|NCT04644120|DRUG|ABBV-2B04|Intervenous (IV) Infusion
223458720|NCT04644120|DRUG|Placebo for ABBV-2B04|Intervenous (IV) Infusion
223458721|NCT00613366|DRUG|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
224156191|NCT02475629|DRUG|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
224156192|NCT01089218|DRUG|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
224156193|NCT01089218|DRUG|control|no intervention with the same procedure of FB
224156194|NCT01964729|DEVICE|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
224302782|NCT03024658|OTHER|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
223458722|NCT00613366|DIETARY_SUPPLEMENT|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
223458723|NCT02966847|PROCEDURE|CBCT acquisition|Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device
223458724|NCT02966847|PROCEDURE|Anesthesia and surgery|The anesthesia and surgery will take place according clinical routine practice
223458725|NCT05208827|DRUG|Vitamin D3|Participants began to take medication at 12 weeks of gestation, and participants in the second trimester began to take medication at the time point of enrollment.The dosage is 2 tablets per day, taken orally for 12 weeks.The drug in the intervention group was fat-soluble vitamin D3, which was produced by Sinopril Holding Starfish Pharmaceutical (Xiamen) Co., LTD. Each tablet contained 800 units of vitamin D3, vegetable oil and starch as auxiliary material.
223458726|NCT05208827|DRUG|The placebo(not contain vitamin D)|Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
223458727|NCT02392026|DRUG|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
223458728|NCT03583879|OTHER|Exoskeleton exercise|Functional exercise with a robotic exoskeleton
223458729|NCT03583879|OTHER|Standard exercise|Functional exercise without a robotic exoskeleton
223458730|NCT03583879|OTHER|No treatment|Wait-list control
223458731|NCT02235181|DEVICE|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
223458732|NCT01146535|DRUG|Interferon-alpha|150 IU lozenges bid for 5 days
223458733|NCT01146535|DRUG|Oseltamivir|75 mg capsules bid for 5 days
223458734|NCT01146535|OTHER|maltose|200 mg maltose lozenges bid for 5 days
223458735|NCT00766597|DRUG|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
223573839|NCT03387995|DEVICE|Neuroform stent|The paitents treated by Neuroform stent implantation.
224156195|NCT01964729|DEVICE|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
224156196|NCT04257604|DRUG|Perampanel|Perampanel tablets.
224156197|NCT02403960|DIETARY_SUPPLEMENT|probiotic|the patients used probiotic tablets in addition to scaling and root planning
224156198|NCT02403960|DIETARY_SUPPLEMENT|placebo|the patients used placebo tablets in addition to scaling and root planning
224156199|NCT04115345|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Autologous selected renal cells (SRC)
224156200|NCT02257125|BEHAVIORAL|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
224156201|NCT02257125|BEHAVIORAL|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
223458736|NCT01992250|DEVICE|Visica 2 Treatment System|Cryoablation
223458737|NCT00003205|DRUG|bryostatin 1|
223458738|NCT00874315|OTHER|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
223458739|NCT00874315|DRUG|busulfan|0.8 mg/kg/dose for total of 8 doses.
223458740|NCT00874315|DRUG|cyclosporine|1.5 mg/kg/dose every 12 hours.
223458741|NCT00874315|DRUG|fludarabine phosphate|30 mg/m2/day for 5 days.
223458742|NCT00874315|DRUG|mycophenolate mofetil|15 mg/kg/dose every 8 hours
223458743|NCT00874315|DRUG|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
223458744|NCT00874315|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
223458745|NCT03564769|BEHAVIORAL|Intervention Arm|Individuals randomized to the intervention group will receive skin cancer screening educational materials.
223458746|NCT03564769|OTHER|AAD SPOTmeⓇ skin cancer screening|All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
223458747|NCT02651844|DRUG|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
223458748|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
223458749|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
224156202|NCT03520205|PROCEDURE|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
223458750|NCT01135524|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
223458751|NCT03317717|DRUG|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
223458752|NCT03317717|DRUG|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
223458753|NCT02044003|DEVICE|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
223458754|NCT00311688|DRUG|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
223458755|NCT04178408|OTHER|No intervention|No intervention
223458756|NCT01865721|DRUG|Entonox|Entonox will be used according to the allocated method
223458757|NCT06400901|OTHER|No interventions|No interventions were given to patients except for the deep brain stimulation surgery they originally planned to take
223458758|NCT04019717|DRUG|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
223458759|NCT04019717|DRUG|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
223458760|NCT05036941|DEVICE|Acteev™ Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 1 will be supplied adequate number of Acteev™ N95 masks YQD8008 during 8-hour shift and Acteev™ fabric masks for community use.
223458761|NCT05036941|DEVICE|Comparison Masks|Participants will wear the mask on every shift for 8 consecutive weeks. Participants in Arm 2 will be supplied with adequate number of standard N95 masks during 8-hour shift and fabric mask for community use.
224067629|NCT00963001|DRUG|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
223458762|NCT04089254|BEHAVIORAL|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
223458763|NCT04089254|BEHAVIORAL|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
223458764|NCT03761485|OTHER|Use of Dentifrice Fluoride|Use of few of dentifrice on brushing during a year
223458765|NCT03444805|PROCEDURE|Autologous HSCT|1st AHSCT
223458766|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
223458767|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
223458768|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
223458769|NCT00827515|DRUG|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
223458770|NCT06355375|BEHAVIORAL|exercise in pregnancy|aerobic exercise
223458771|NCT05258734|OTHER|COVOS app|In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.
223458772|NCT05258734|OTHER|Standard Care|In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
223458773|NCT03972384|BEHAVIORAL|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
223458774|NCT02575196|DEVICE|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
223458775|NCT01266824|DRUG|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
223573840|NCT03387995|DEVICE|Flow diverter (FD) stent|The paitents treated by Enterprise FD implantation.
223743266|NCT05158868|DIAGNOSTIC_TEST|HiF-1 alpha measurement|HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
223743267|NCT03319355|BEHAVIORAL|cognitive behavioral therapy|exercise therapy
224067630|NCT00963001|OTHER|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
224156203|NCT03520205|PROCEDURE|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
224156204|NCT01813968|PROCEDURE|Ischemic postconditioning|
224156205|NCT02593461|DEVICE|Daifert|
224156206|NCT02593461|OTHER|Control Group|
224067631|NCT03922009|DEVICE|Virtual Reality|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
224156207|NCT01428440|RADIATION|18FML10|apoptosis imaging radio ligand
224156208|NCT03616847|OTHER|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
224156209|NCT03616847|OTHER|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
224156210|NCT02242760|DRUG|SB204 2%|Applied topically twice daily
224156211|NCT02242760|DRUG|SB204 4%|Applied topically daily
223458776|NCT02285075|DRUG|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T \> MIC of 8 and 16 mg/L).
223458777|NCT01678118|BEHAVIORAL|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder \& to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs \& barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
223458778|NCT05156996|DEVICE|Supersaturated O2 Therapy of the Therox Downstream System®|SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient's left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.
223458779|NCT05156996|PROCEDURE|PCI alone|Percutaneous Coronary Intervention for treatment of acute MI
223458780|NCT06312397|OTHER|Acupressure|"For the acupressure group, a total of three points will be applied: the heart meridian 7th point (HT7), the large intestine meridian 4th point (LI4), and the stomach meridian 36th point (ST36), which is deemed appropriate in the lower extremity The symmetry of the three selected different points will also be applied to the other extremity.~After coronary angiography, acupressure will be applied for a total of 15 minutes."
223743268|NCT00529542|DRUG|Lipitor|40mg caplets per day for six weeks
223743269|NCT00529542|DRUG|Placebo|1 placebo caplet per day for six weeks.
223743270|NCT02587065|DRUG|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
224156212|NCT02242760|DRUG|Vehicle Gel|Applied topically twice and once daily
224156213|NCT00643097|BIOLOGICAL|PEP-3 vaccine|Given intradermally
224156214|NCT00643097|BIOLOGICAL|sargramostim|Given intradermally
224156215|NCT00643097|DRUG|Temozolomide|Standard of care chemotherapy
224156216|NCT05210621|DRUG|Ocrelizumab|ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
224156217|NCT05778929|DIAGNOSTIC_TEST|Radiomics Model|"A total of 694 consecutive eligible patients with first episode of acute pancreatitis that recommended for iopromide 370 mgI/ml enhanced pancreatic CT scan within 14 days after onset of symptoms (the sample size ratio of training set: test set: validation set is 5:2:3) will be sequentially enrolled at 10 sites (This study is observational in nature. The routine enhanced pancreatic CT protocol at all selected sites is similar or equivalent to that used in the PI site in the study).~Relevant clinical information of the enrolled subjects is collected. Radiomics features are extracted from the selected regions of interest on pancreatic CT images and classified. The subjects are followed up for 12 months and divided into recurrent group and non-recurrent group according to the first recurrence status."
224156218|NCT05720962|PROCEDURE|uninterrupted accompanying support|"When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm."
224156219|NCT03555071|BIOLOGICAL|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
224156220|NCT03555071|BIOLOGICAL|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
224156221|NCT04000022|DEVICE|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
224156222|NCT00353990|DRUG|Insulin Aspart|
224156223|NCT01749800|DEVICE|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
223458781|NCT06312397|OTHER|Sham acupressure|In the acupressure application applied to the sham group, parallel pressure will be applied to the bone area and points where the HT7, LI4, ST36 meridians do not pass.
224156224|NCT01749800|DEVICE|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
224156225|NCT01749800|DEVICE|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
224156226|NCT02180490|DRUG|UHAC 62 XX tablet|
224156227|NCT02180490|DRUG|UHAC 62 XX capsule|
224156228|NCT04214041|OTHER|Autologous fat grafting|A fat graft will be aspirated from the abdomen under local anaesthesia and processed using the Microfat grafting technique. Afterwards the fat graft will be injected in the previously created pouch at the recipient site. Then the pouch will be closed using interrupted sutures 5-0 vicryl.
224156229|NCT04214041|OTHER|Sub-epithelial connective tissue graft|A subepithelial connective tissue graft of a size that corresponds to that of the defect will be harvested from the palate using the trap door technique. The donor site will be closed using cross horizontal sling sutures and interrupted sutures 4-0 vicryl. Subsequently, the graft will be inserted in the previously created pouch at the recipient site and secured to the flap using vicryl sutures 5-0. Then the pouch will be closed using interrupted sutures.
224156230|NCT04046276|BEHAVIORAL|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
223458782|NCT02790918|OTHER|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
223573841|NCT04698785|DRUG|Treatment by regorafenib and best supportive care|"Treatment for 13 cycles (12 months) maximum.~During each cycle :~* patients ≥ 16 years old and patients \<16 old with Body Surface Area (BSA) ≥ 1,70 m2 will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.~* patients \< 16 years old with a 1,30 m2 ≤ BSA ≥ 1,70 m2 will take 2 tablets, once a day, corresponding to a total of 80 mg Regorafenib, during 21 days, followed by 7 days without treatment"
223458783|NCT02790918|OTHER|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
223458784|NCT06180434|RADIATION|proton therapy|Radiotherapy delivered with protons
223458785|NCT06180434|RADIATION|photon therapy|Radiotherapy delivered with photons
223458786|NCT00171626|DRUG|Diclofenac Topical Sodium Gel 1%|
223458787|NCT00417144|DRUG|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
223458788|NCT00417144|DRUG|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
223458789|NCT02274597|DEVICE|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
223458790|NCT03235466|BEHAVIORAL|Voice Therapy|See Arm 1 \& 2
223458791|NCT03235466|BEHAVIORAL|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 \& 3
223458792|NCT03235466|BEHAVIORAL|Heart Rate Variability Biofeedback|See Arm 2 \& 3
223573842|NCT04644237|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan 100 mg will be provided as a sterile lyophilized powder and reconstituted with 5 mL water for injection (final concentration 20 mg/mL \[ie, 100 mg/5 mL\]). The study drug will be administered as an intravenous (IV) infusion over 30 to 90 min Q3W ± 2 days. The initial dose of study drug will be infused for 90 ± 10 min.
224067632|NCT04821427|BEHAVIORAL|Brief mhealth intervention + mobile messaging to reduce sexual risk behavior and heavy drinking|The intervention is a brief, motivational video-conferencing intervention followed by four weeks of app-based, interactive mobile messages to reduce heavy episodic drinking and sexual risk behavior (condomless anal intercourse) among Black/African American and Hispanic/Latino men who have sex with men
223458793|NCT03038529|PROCEDURE|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
223458794|NCT03038529|PROCEDURE|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
223458795|NCT02004938|DEVICE|Sonosite Titan Ultrasound Machine|
223458796|NCT00411450|BIOLOGICAL|Panitumumab|Administered by intravenous infusion
224067633|NCT04728685|PROCEDURE|Mechanical Traction|Mechanical Traction will be applied to the lumbar region using a traction unit.
223458797|NCT00411450|DRUG|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
223458798|NCT05503459|OTHER|Bicycle learning|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.
223458799|NCT05503459|OTHER|Stationary cycling|The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
223458800|NCT02300623|DRUG|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
223458801|NCT02300623|DRUG|Antiretroviral therapy alone|Standard antiretroviral therapy
223458802|NCT01617239|BIOLOGICAL|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~* 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~* 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~* 15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
223458803|NCT00760721|BEHAVIORAL|Educational Small Group Session|1 hour small group health-related discussion
223458804|NCT01716663|DEVICE|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
223458805|NCT01936363|DRUG|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
223458806|NCT01936363|DRUG|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
224067634|NCT06552169|DRUG|Arm 1: SOC (mTOR + CNI)|Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.
224071477|NCT01596998|OTHER|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
223458807|NCT01936363|DRUG|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
223458808|NCT01936363|DRUG|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
223458809|NCT01936363|DRUG|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
223573843|NCT06556238|OTHER|Nicotine Metabolite Ratio|Blood specimens will be drawn, in clinic, by clinical staff trained in blood collection (e.g., certified medical assistant, nurse). Through regular clinic procedures, lab staff will ship for processing to Quest. Quest uses liquid chromatography tandem mass spectrometry with a limit of detection of 2ng/ml for all analytes and will quantify NMR within 3-6 days of sample arrival. Samples will be consumed during testing. Results of NMR will be returned to primary care providers, and NMR-informed medication recommendations will be made to participants.
223573844|NCT06223789|DEVICE|Pulsed Field Ablation|Pulsed field ablation using the Volt PFA System
223743271|NCT03369054|BEHAVIORAL|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
223743272|NCT03369054|BEHAVIORAL|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
224302783|NCT03967496|PROCEDURE|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
224302784|NCT03967496|PROCEDURE|Access of Surgery|Type of surgical access
224302785|NCT03967496|OTHER|Comorbidities|A patient may have more than one comorbidity
223458810|NCT05807971|DRUG|ATH-063|12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
223458811|NCT05807971|DRUG|Placebo|Identical capsule to the drug without the active ingredient.
223458812|NCT02661230|DEVICE|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
224302786|NCT03967496|DRUG|Preoperative Medication|Preoperative medications
224302787|NCT03967496|DIAGNOSTIC_TEST|Routine blood test|Preoperative and Intraoperative Investigations
224302788|NCT00080938|DRUG|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
224302789|NCT00080938|RADIATION|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
224302790|NCT00977379|RADIATION|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
223458813|NCT01342575|PROCEDURE|Intra-operative exposure maneuvers|"* Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~* Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~* Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~* Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~* Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
223458814|NCT01018758|DRUG|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
223458815|NCT03049228|DIAGNOSTIC_TEST|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
223573845|NCT05705973|DEVICE|Ultimaster Nagomi™|The Ultimaster NagomiTM Sirolimus eluting coronary stent system with Rapid Exchange Balloon Delivery System consists of a balloon expandable intra-coronary L605 cobalt chromium (CoCr) stent with abluminal drug eluting coating, that consists of a blend of Sirolimus and Poly(D,L-lactide-co-caprolactone), pre-mounted onto a high pressure, semi-compliant balloon delivery catheter
223573846|NCT00090233|BIOLOGICAL|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
224156231|NCT04046276|OTHER|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
224156232|NCT04046276|BEHAVIORAL|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
224156233|NCT03111589|BIOLOGICAL|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
224156234|NCT03111589|DIAGNOSTIC_TEST|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
224156235|NCT04733872|DIETARY_SUPPLEMENT|placebo|subjects drank 50 ml , 1 bottle a day for 8 week
224302791|NCT00977379|DRUG|Capecitabine|825 mg/m\^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
224302792|NCT00977379|DRUG|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
224302793|NCT00556400|DRUG|Lo-Ovral Oral Contraceptive Pills|
224302794|NCT00556400|DRUG|Placebo - sugar pill|
223458816|NCT03049228|DIAGNOSTIC_TEST|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
223458817|NCT03049228|DIAGNOSTIC_TEST|Blood analysis|To determine blood glucose metabolism and renal function.
223458818|NCT03049228|DIAGNOSTIC_TEST|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
224156236|NCT04733872|DIETARY_SUPPLEMENT|Vegetable and Berry Drink|subjects drank 50 ml , 1 bottle a day for 8 week
224156237|NCT01040754|OTHER|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
224156238|NCT03077789|PROCEDURE|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
224156239|NCT02489851|PROCEDURE|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
223458819|NCT03049228|DIAGNOSTIC_TEST|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
223458820|NCT01301261|DRUG|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
224156240|NCT02489851|PROCEDURE|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
224156241|NCT01511640|DRUG|Pregabalin|pregabalin 2x daily for duration of study
223458821|NCT01301261|DRUG|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
223458822|NCT01301261|DRUG|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
223458823|NCT04328025|OTHER|Peer-delivered HIV self-testing, STI self-sampling and PrEP|Peer delivery of combination HIV prevention interventions to transgender women.
223458824|NCT06169306|PROCEDURE|throat pack|Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
224156242|NCT01511640|DRUG|Placebo|placebo 2x daily for duration of study
224156243|NCT00000281|BEHAVIORAL|Amantadine|
224156244|NCT04418739|DRUG|Human albumin|Intravenous human albumin given at a maximum dose of 1g/kg at skin incision which is infused at 100ml/hour
224156245|NCT03297944|DRUG|Alprazolam 2mg (2ALP/PLC)|2mg alprazolam administered at night, placebo administered in the morning.
224156246|NCT03297944|DRUG|Alprazolam 1mg (1ALP/PLC)|1mg alprazolam administered at night, placebo administered in the morning.
224156247|NCT03297944|DRUG|Alprazolam 0.5mg (0.5ALP/PLC)|0.5mg alprazolam administered at night, placebo administered in the morning.
224156248|NCT03297944|DRUG|Zolpidem 10mg (ZOL/PLC)|10mg alprazolam administered at night, placebo administered in the morning.
224156249|NCT03297944|DRUG|Placebo (PLC/PLC)|Placebo administered at night, placebo administered in the morning.
224156250|NCT03297944|DRUG|Alprazolam 1mg (PLC/ALC)|Placebo administered at night, 1mg alprazolam administered in the morning.
224156251|NCT04063644|DEVICE|Vis Glyc Neo|1 drop in each eye, three times a day.
224156252|NCT04063644|DEVICE|Physiological saline solution|1 drop in each eye, three times a day.
224156253|NCT03049085|DRUG|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
224156254|NCT03049085|DRUG|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
224156255|NCT00357786|DRUG|Replagal agalsidase alfa|
224302795|NCT06279559|BEHAVIORAL|Music-therapy|10 sessions of online music therapy held by expert music therapists
224302796|NCT04561375|DRUG|Sufentanil|30 µg tablet of sublingual sufentanil
224302797|NCT04561375|DRUG|Fentanyl|50 µg fentanyl
224302798|NCT04173832|DRUG|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
224302799|NCT04173832|DRUG|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
224302800|NCT05036356|OTHER|Headspace App|"A mobile-application (app) focusing on teaching and sustaining mental well-being."
224302801|NCT02861742|OTHER|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
223573847|NCT00090233|BIOLOGICAL|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
223573848|NCT02978963|BEHAVIORAL|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
223573849|NCT02349607|DRUG|PF-05089771 300mg|PF-05089771 300 mg
223573850|NCT02349607|DRUG|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
223573851|NCT02349607|DRUG|Placebo|Placeco
223573852|NCT02349607|DRUG|pregabalin 300 mg|pregabalin 300 mg
223573853|NCT02349607|DRUG|ibuprofen 600 mg|ibuprofen 600 mg
223573854|NCT02349191|PROCEDURE|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
223573855|NCT02924714|OTHER|Discontinuation of imatinib|
223573856|NCT04863248|DRUG|Trilaciclib|Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
224156256|NCT00357786|DRUG|Replagal|
223458825|NCT02923583|BIOLOGICAL|M834|
223458826|NCT02923583|BIOLOGICAL|US-Sourced Orencia®|
223458827|NCT02923583|BIOLOGICAL|EU-Sourced Orencia®|
223458828|NCT05618015|PROCEDURE|Supervised progressive resistance training|Exercises were performed with cable resistance training machine
223458829|NCT05618015|PROCEDURE|Home-based progressive resistance training|In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
223458830|NCT01252771|OTHER|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
223458831|NCT02770638|DEVICE|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
223458832|NCT02770638|DEVICE|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
223458833|NCT01142934|DEVICE|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
223458834|NCT03556969|OTHER|Observation|no intervention
223458835|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10\^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
223458836|NCT01161576|BIOLOGICAL|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10\^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
223458837|NCT02415153|OTHER|Laboratory Biomarker Analysis|Optional correlative studies
223458838|NCT02415153|OTHER|Pharmacological Study|Correlative studies
223458839|NCT02415153|DRUG|Pomalidomide|Given PO
223458840|NCT01726075|DRUG|COLIRIOBCN070660|One drop per eye twice a day during 24 months
223458841|NCT01726075|DRUG|Placebo|One drop per eye twice a day during 24 months
223458842|NCT01726075|DRUG|Brimonidine|One drop per eye twice a day during 24 months
223458843|NCT04102293|PROCEDURE|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
223458844|NCT04102293|PROCEDURE|manual K-files|manual instrumentation used in pulp therapy
223458845|NCT03816553|DRUG|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
223458846|NCT03816553|DRUG|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
223573857|NCT04863248|DRUG|Placebo|Placebo administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
223573858|NCT04863248|DRUG|Docetaxel|Docetaxel administered IV on Day 1 of each 21-day cycle.
223573859|NCT05756114|BEHAVIORAL|Support Group|Support Group condition, meetings will be held online via HIPAA-compliant Zoom and run by a trained SMART Recovery meeting facilitator
223573860|NCT05756114|OTHER|Psychoeducational Email|Participants receive a weekly email with a Qualtrics survey link containing psychoeducational content.
223458847|NCT03561896|RADIATION|IGRT|Image-Guided Radiation Therapy
223573861|NCT04348019|BEHAVIORAL|Fasting|Fasting was defined as no foods or caloric beverages.
223573862|NCT02536300|DRUG|Idelalisib|Idelalisib tablet administered orally
223458848|NCT03561896|RADIATION|SRS|stereotactic radiation therapy
223458849|NCT04007965|PROCEDURE|Pneumatic Posterior Capsulorhexis|Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
223458850|NCT04870021|BIOLOGICAL|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm),|recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs
223458851|NCT04870021|BEHAVIORAL|Short text messages and calls to parents for compliance to routine immunization schedule|After the discharge of mothers from hospital, preformed, short text messages (SMS) were sent to parents, reminding them of the due date for as per the vaccination schedule. One day after the due date of the vaccine shot, a phone call was made to confirm the child was vaccinated or not
223743273|NCT05045976|OTHER|Web-based interactive self-management support program|The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
224156257|NCT00616291|BIOLOGICAL|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
224156258|NCT02703142|PROCEDURE|Patients after esophagectomy|postoperative endoscopic evaluation
224156259|NCT05983042|GENETIC|Ibuprofen|Ibuprofen 400mg three times a day for three days
224156260|NCT04390789|PROCEDURE|Non surgical Single visit Retreatment|Non-surgical endodontic retreatment will be carried out in single visit.
224156261|NCT04390789|PROCEDURE|Multi visit Retreatment with calcium hydroxide dressing|In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
224156262|NCT01451398|DRUG|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
224302802|NCT02861742|BEHAVIORAL|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
223458852|NCT04043429|BEHAVIORAL|Vision Restoration Training (VRT)|
223458853|NCT04043429|BEHAVIORAL|Vision Exploration Training (VET)|
223458854|NCT04531748|DRUG|Toremifene|Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
223458855|NCT04531748|DRUG|Melatonin|Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
223573863|NCT03758313|OTHER|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
223573864|NCT03050515|BIOLOGICAL|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
223743274|NCT01467947|BIOLOGICAL|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
223743275|NCT05466747|BIOLOGICAL|RYMPHYSIA|RYMPHYSIA administered through an IV injection.
223743276|NCT05466747|BIOLOGICAL|Another Available A1PI|Another available A1PI administered through an IV injection.
224156263|NCT01451398|DRUG|Technosphere Powder|Placebo Comparator
224156264|NCT04016987|BEHAVIORAL|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
223458856|NCT04531748|OTHER|Placebo|Oral placebo will be used with the same number and appearance to the pills as the interventions.
223458857|NCT02254772|BIOLOGICAL|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
223458858|NCT02254772|DRUG|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
223458859|NCT02254772|RADIATION|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
223458860|NCT04552600|DRUG|Nuvastatic|Phase 1b Interventional, multi-centered, double-masked, randomized
223458861|NCT04552600|OTHER|Placebo|Phase 1b Interventional, multi-centered, double-masked, randomized
223458862|NCT04288947|OTHER|Disrespect and Abuse in Maternity Care|Changing the culture of disrespect and abuse in maternity care
223573865|NCT04754230|DRUG|Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)|Medication administered 15 minutes prior to end of surgery.
223573866|NCT00532571|DRUG|CoQ10|
223573867|NCT01318278|DRUG|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
223573868|NCT01318278|DRUG|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
223573869|NCT05009641|DIETARY_SUPPLEMENT|L-carnitine|
224156265|NCT01564602|DEVICE|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
224302803|NCT02861742|BEHAVIORAL|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
224302804|NCT02861742|BEHAVIORAL|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
224302805|NCT02861742|BEHAVIORAL|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
224302806|NCT02861742|BEHAVIORAL|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
224302807|NCT01025271|DRUG|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
224302808|NCT00231647|DRUG|topiramate|
223458863|NCT05225558|DRUG|Delpazolid|BID, PO
223458864|NCT05225558|DRUG|Vancomycin|IV infusion per 2020 IDSA guideline
223458865|NCT05225558|DRUG|Placebo of Delpazolid|BID, PO
223458866|NCT00584584|DRUG|QAX576|
223458867|NCT00584584|DRUG|Placebo|
223458868|NCT01001910|DRUG|Carboplatin|Given IV
223458869|NCT01001910|OTHER|Laboratory Biomarker Analysis|Correlative studies
223458870|NCT01001910|DRUG|Pemetrexed Disodium|Given IV
223458871|NCT00614874|DRUG|rosiglitazone|2mg, 4mg, 8mg
223458872|NCT03006562|DRUG|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
223458873|NCT05453110|BEHAVIORAL|Deadlift Form Education|The education will include information about the lumbar spine as it relates to a deadlift. The researchers will administer this education shortly prior to participants taking a strength test.
223458874|NCT04071782|DEVICE|Drug Coated Balloon|SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
223458875|NCT03583658|DRUG|ambroxol BIH1526|Pharmaceutical form: lozenges Route of administration: oromucosal
223458876|NCT03583658|DRUG|placebo|Pharmaceutical form: lozenges Route of administration: oromucosal
223458877|NCT00078013|DRUG|MCC-135|
223458878|NCT05793749|BEHAVIORAL|Prophylactic lymphedema treatment|1\. perform manual lymphatic drainage twice a week after the start of radiotherapy for a total of 10 times, and wear lymphedema compression stockings after each manual lymphatic drainage, 2. teach patients how to care for their skin. 3. perform functional exercises for lymphedema of the lower extremities twice a day for 15 \~ 20 minutes each time. 4. follow up observation: before the start of radiotherapy, every Friday during radiotherapy, and every 3 months after the end of radiotherapy, the occurrence of lymphedema and related symptoms and quality of life were evaluated.
223458879|NCT03514719|DIAGNOSTIC_TEST|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
223458880|NCT03514719|DRUG|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
223573870|NCT01691105|OTHER|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
223573871|NCT01341808|BIOLOGICAL|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
223573872|NCT02202213|DRUG|Placebo|
224156266|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"* 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
224156267|NCT02562027|BEHAVIORAL|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"* 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
224302809|NCT04509882|DRUG|bear bile pill|Bear bile pill (15 pills) taken orally three times a day after meals with water.
223458881|NCT03044847|OTHER|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
223573873|NCT02202213|DRUG|Lu AF11167|
223573874|NCT01244594|OTHER|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
223573875|NCT02367001|OTHER|Normal invitation|No modification and signed by the coordinating doctor as usual
223573876|NCT02367001|OTHER|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
223573877|NCT02367001|OTHER|Revised invitation signed by the attending physician|signature typed or typed + handwritten
223573878|NCT04017923|DIAGNOSTIC_TEST|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
223573879|NCT03965884|OTHER|Physical therapy and rehabilitation|Physical therapy and rehabilitation
223573880|NCT05195957|PROCEDURE|Robotic tranversus abdominis release operation|Mini-invasive robotic-assisted TAR using either DaVinci Xi or Si systems and 6 laparoscopic ports.
224302810|NCT04509882|DRUG|placebo|Placebo(15 pills) taken orally three times a day after meals with water.
224302811|NCT00440960|DRUG|propofol|
224302812|NCT00440960|DRUG|midazolam|
224302813|NCT00440960|DRUG|alfentanil|
224302814|NCT00440960|DRUG|lidocaine|
223458882|NCT00553488|DRUG|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
223458883|NCT00553488|DRUG|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
223573881|NCT05195957|PROCEDURE|Open transversus abdominis release operation|Original open TAR using midline incision.
223743277|NCT03809520|RADIATION|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
223743278|NCT01528956|GENETIC|DNA methylation analysis|
223743279|NCT01528956|GENETIC|RNA analysis|
223743280|NCT01528956|GENETIC|gene expression analysis|
223743281|NCT01528956|GENETIC|nucleic acid sequencing|
223458884|NCT04488913|OTHER|RACE-IT Pathway|This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score
223458885|NCT04488913|OTHER|Standard of Care|Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
223458886|NCT03019900|PROCEDURE|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
223458887|NCT04584515|DRUG|IMP4297 40 mg|IMP4297 40 mg: IMP4297 alone, Itraconazole + IMP4297
223458888|NCT04584515|DRUG|IMP4297 100 mg|IMP4297 100 mg: IMP4297 alone, Rifampin + IMP4297
223458889|NCT00026247|PROCEDURE|pain therapy|
223458890|NCT00026247|PROCEDURE|radiofrequency ablation|
223458891|NCT04996966|BIOLOGICAL|human umbilical cord-derived mesenchymal stem cells|In the MSCs injection group, 1×10\^6/kg human umbilical cord-derived mesenchymal stem cells were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
223458892|NCT04996966|OTHER|saline|In the control group, saline containing 2% albumin (2ml/kg) were intravenously injected to the patient immediately after the surgery and at day 3 after the surgery.
223458893|NCT05861830|DRUG|The combination of Dalpiciclib with physician-selected endocrine therapy|"* Dalpiciclib: 150 mg, orally, once daily, on days 1-21, every 28 days (3 weeks on, 1 week off)~* Letrozole: 2.5 mg, orally, once daily (continuous), every 28 days OR Anastrozole: 1.0 mg, orally, once daily (continuous), every 28 days OR Exemestane: 25 mg, orally, once daily (continuous), every 28 days OR Fulvestrant: 500 mg, intramuscular injection on day 1/15 of the first cycle, then on day 1 of each subsequent cycle, every 28 days OR Tamoxifen: 10-20 mg, orally, twice daily (continuous), every 28 days~* Pre/perimenopausal women also require ovarian function suppression (OFS), which can be achieved through bilateral oophorectomy or the use of gonadotropin-releasing hormone (GnRH) analog drugs"
223458894|NCT05861830|DRUG|Chemotherapy selected by the physician|The chemotherapy regimen is chosen by the clinical physician and may include, but is not limited to, the following options: the combination of paclitaxel and capecitabine, the combination of paclitaxel and carboplatin, single-agent capecitabine, single-agent platinum drugs, and the combination of gemcitabine and platinum-based chemotherapy. Each treatment cycle consists of a 21-day duration.
223458895|NCT03545945|PROCEDURE|Additional office hysteroscopy|Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
223458896|NCT03545945|PROCEDURE|Endometrial biopsy|Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
223458897|NCT02993835|OTHER|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
223458898|NCT02993835|OTHER|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
223458899|NCT02993835|OTHER|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
223458900|NCT02137941|BEHAVIORAL|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
223458901|NCT02137941|BEHAVIORAL|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
223458902|NCT06011694|OTHER|MERCURY test, health questionnaires and annual routine physical exams|Each participant will undergo peripheral blood collection for MERCURY test, health questionnaires and annual routine physical exams once a year for three consecutive years, then followed up two additional years.
223573882|NCT02233738|BEHAVIORAL|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
223573883|NCT02233738|BEHAVIORAL|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
223573884|NCT00648674|DEVICE|Apligraf|Applied at Day 0, possible re-application at Week 6
223573885|NCT00096174|BIOLOGICAL|cetuximab C225|400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
223458903|NCT05090202|DIAGNOSTIC_TEST|hbA1C|hbA1C will be measured for all patients and results will be analysed into Non diabetic, Prediabetic and Diabetic
223458904|NCT04691128|DRUG|Desflurane|After induction, anesthesia will be maintained with 0.8-1.3 MAC desflurane and 0.05-0.2 μg/kg/min remifentanil.
223458905|NCT04691128|DRUG|Propofol|After induction, anesthesia will be maintained with 6-8 mg/kg/h propofol and 0.05- 0.2 μg/kg/min remifentanil
223458906|NCT05610488|DRUG|FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]|Intravitreal injection of faricimab 6 mg at baseline (week 0), at week 4, 8, 12 (=4x loading) and each of the following treat and extend visits
223743282|NCT01528956|GENETIC|polymorphism analysis|
223458907|NCT01971814|DRUG|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
223458908|NCT05947604|DRUG|Acoziborole|Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
223458909|NCT05947604|DRUG|Midazolam|• Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
223458910|NCT05947604|DRUG|Dextromethorphan|• Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
223458911|NCT06069739|BEHAVIORAL|Guided physical activity|To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.
223458912|NCT06069739|BEHAVIORAL|Standard physical activity|"Participants randomised to the SPAG performed their usual daily activities and continued with their daily routine.~Both conditions were matched for duration of physical activity. Participants in both conditions were required to attend three on-site sessions by week over 12 weeks that served as checkpoints. Moreover, both conditions were provided with brief healthy lifestyle counseling at baseline."
223458913|NCT00710255|PROCEDURE|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
223458914|NCT00572260|DRUG|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
223458915|NCT02233699|DRUG|XEN-D0501|
224156268|NCT02562027|BEHAVIORAL|Modified Medical Research Council|"* Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
224156269|NCT02562027|BEHAVIORAL|EQ-5D|"* 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
224302815|NCT00654966|DRUG|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
224302816|NCT00654966|DRUG|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
223458916|NCT02233699|DRUG|Placebo|
223458917|NCT00372632|DRUG|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
223458918|NCT00372632|DRUG|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
223458919|NCT06369558|OTHER|PLYOMETRIC TRAINING|A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT
223458920|NCT06369558|OTHER|CLASSIC PHYSIOTHERAPY PROGRAM|HOT PACKED ENTEFERANTIAL CURRENT THERAPY AND US THERAPY
223458921|NCT02643641|BIOLOGICAL|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
223458922|NCT02643641|BIOLOGICAL|Placebo|Placebo contains aluminum hydroxide only
223573886|NCT00096174|DRUG|cisplatin|75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
223573887|NCT00096174|RADIATION|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
223573888|NCT03315104|BIOLOGICAL|FLU-IGIV|Single dose, sterile liquid formulation for IV administration.
223573889|NCT03315104|OTHER|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration.
223573890|NCT01945645|BEHAVIORAL|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
223458923|NCT02597309|DRUG|Canagliflozin|
223458924|NCT02427841|DRUG|Fluorouracil|Given IV
223458925|NCT02427841|DRUG|Gemcitabine|Given IV
223458926|NCT02427841|RADIATION|Image Guided Radiation Therapy|Undergo IG-IMRT
223458927|NCT02427841|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
223458928|NCT02427841|OTHER|Laboratory Biomarker Analysis|Correlative studies
223458929|NCT02427841|DRUG|Nab-paclitaxel|Given IV
224302817|NCT01342107|DEVICE|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
224302818|NCT01342107|DEVICE|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
224302819|NCT01342107|DEVICE|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
224302820|NCT02538848|DRUG|HTD4010|injectable solution
223458930|NCT02427841|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
223458931|NCT00511810|DRUG|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
223458932|NCT00511810|DRUG|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
223573891|NCT00445848|BIOLOGICAL|bevacizumab|
223573892|NCT00445848|DRUG|erlotinib hydrochloride|
223573893|NCT03224871|DRUG|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
223573894|NCT03224871|DRUG|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
223743283|NCT00089349|BIOLOGICAL|alemtuzumab|Given IV
223458933|NCT01551966|DEVICE|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
223458934|NCT05699512|BEHAVIORAL|Multiprofessional, tailored rehabilitation|Patients receive individual, tailored, multiprofessional rehabilitation
223458935|NCT05604365|BEHAVIORAL|FearLess Intervention|8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
223458936|NCT02945826|DRUG|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
223458937|NCT02945826|DEVICE|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
223458938|NCT02909790|DEVICE|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
223458939|NCT03165773|OTHER|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
223458940|NCT03165773|OTHER|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
223458941|NCT03582384|DRUG|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
223458942|NCT05758896|DRUG|Isuzinaxib (APX-115)|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
223458943|NCT05758896|DRUG|Placebo|Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
223458944|NCT03722082|BEHAVIORAL|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
223458945|NCT03722082|BEHAVIORAL|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
223458946|NCT06171854|DRUG|Cabozantinib|cabozantinib in patients with refractory mCRC
223458947|NCT04583605|DEVICE|PREVENA|A negative pressure wound closure therapy is used after lymph node dissection
223458948|NCT05648903|OTHER|Total diet replacement|The TDR intervention involves a low-calorie, nutritionally complete diet for 12 weeks consuming four meal replacement products exclusively per day, followed by a 4-week food-based reintroduction period; and then weight loss maintenance support monthly to 12 months. The TDR products will be provided to participants free of charge. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a TDR for an additional 4 weeks but participants would have to self-fund these products.
223573895|NCT03224871|DRUG|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
223573896|NCT03224871|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
223743284|NCT00089349|DRUG|methotrexate|Given IV
223743285|NCT00089349|DRUG|mercaptopurine|Given PO
223458949|NCT05648903|OTHER|Low-carbohydrate diet|Participants who choose this intervention will be supported to undertake a low-carbohydrate diet. During the first 12 weeks of the programme patients will be supported to consume below 100g carbohydrate per day, whilst being encouraged to increase protein, choose predominantly unsaturated fats alongside a high intake of non-starchy vegetables and low-carbohydrate fruits. After 12 weeks patients will be able to increase their carbohydrate intake up to 130g per day. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 100g carbohydrate for an additional 4 weeks.
223458950|NCT05648903|OTHER|Intermittent fasting 5:2|"Participants will have the option to follow a 5:2 dietary approach whereby calories are significantly reduced on two days of the week to 500 calories per day for women and 600 calories per day for men. The placement of the fasting days can vary each week, but there must be two fasting days in each seven-day period. After 12 weeks, patients will have the option of continuing with the 5:2 approach for further weight loss or adopting a 6:1 approach whereby patients would only fast on 1 day in each seven-day cycle for weight maintenance. If a patient gains more than 2kg in the maintenance phase, they have the option to follow a 5:2 approach for an additional 4 weeks."
223573897|NCT00723866|OTHER|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
223743286|NCT05132959|DIAGNOSTIC_TEST|magnetic resonance imaging|The MRI images of patients who had undergone to shoulder magnetic resonance imaging because of shoulder pain or another pathology were studied
223743287|NCT00458523|BIOLOGICAL|alemtuzumab|
223743288|NCT00458523|GENETIC|fluorescence in situ hybridization|
223743289|NCT00458523|GENETIC|mutation analysis|
223743290|NCT00458523|OTHER|flow cytometry|
223743291|NCT00419198|PROCEDURE|Postconditioning|Postconditioning during angioplasty
223743292|NCT00419198|PROCEDURE|standard angioplasty|standard angioplasty without postconditioning
223458951|NCT04868669|BEHAVIORAL|In-home, intensive nutrition counseling|"* Individualized sessions will be conducted by trained health workers following a standard document (counseling booklet)~* The messages to be provided through the counseling will be contextualized~* Sessions will start from the early second trimester and repeat monthly until 36 weeks of gestation~* Counseling sessions will be conducted at the participant's place~* Sessions will involve influential family members such as the husband, mother-in-law, mother, and the household head along with the pregnant women~* Women will receive personalized feedback on their dietary intake pattern (dietary diversity) and the rate of weight gain in each session~* Sessions will be tailored according to each participant's need and progress"
223458952|NCT02050334|DRUG|CC100|CC100 reconstituted in diluent
223458953|NCT02050334|DRUG|Placebo|Diluent. Amount to match CC100 dose.
223458954|NCT06386380|OTHER|Rheumatic diseases Mistreatment Scale (RDMS)|In 2012, Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS); translation, cultural adaptation, and validation were performed prior to its application.
224156270|NCT02562027|BEHAVIORAL|Center for Epidemiological Studies Depression Scale|"* 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
224156271|NCT02562027|BEHAVIORAL|Medical Outcomes Study Social Support Survey|"* 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
224156272|NCT00661570|DEVICE|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
223458955|NCT06386380|OTHER|Routine assessment of patient index data 3 (RAPID-3)|RAPID- 3 measures: function, pain, and patient global status estimate. Each of the three individual measures is scored 0 to 10, for a total of 30
223458956|NCT06386380|OTHER|Health Assessment Questionnaire (HAQ)|The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality.
223458957|NCT06386380|OTHER|WHOQOL-BREF|WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
223458958|NCT06386380|OTHER|Depression, Anxiety and Stress Scale (DASS-21)|DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains seven items, divided into subscales with similar content.
223573898|NCT00723866|OTHER|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
223573899|NCT01844102|DEVICE|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
223573900|NCT06390540|OTHER|Exercise|During the training, verbal information will be given about the importance of exercise, exercise barriers, and the potential benefits of exercise on the mother and baby in the postpartum period. In the training, the points that the mother should pay attention to before exercise will also be discussed. In the following process, videos containing deep breathing and relaxation exercises will be sent to women. The videos will be recorded by the researchers at Ankara University Physiotherapy application laboratory. Recording videos will be delivered to women through social networks. Women will be allowed to do these exercises for a total of 8 weeks.
224156273|NCT02754661|DEVICE|COLON Capsule endoscopy|
224156274|NCT02754661|DEVICE|Computed Tomographic Colonography|
224156275|NCT00784082|DRUG|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
224156276|NCT04107428|DRUG|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
224156277|NCT04107428|DRUG|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
224156278|NCT04049812|DEVICE|PEMF|
224156279|NCT04049812|DEVICE|Hot pack|
224156280|NCT04049812|DEVICE|TENS|
224156281|NCT04049812|DEVICE|Sham PEMF|
224156282|NCT02134041|OTHER|traumatic brain injury|mild TBI, GCS \>/=13 after traumatic brain injury
224156283|NCT00002204|BIOLOGICAL|HIV p24/MF59 Vaccine|
224156284|NCT05011331|DEVICE|MedCline Shoulder Relief System|Patients will receive a customized pillow to aid with sleep
223458959|NCT06386380|OTHER|Brief Resilient Coping Scale|The Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner.
223458960|NCT06386380|GENETIC|Expression of CDKN2A /p16INK4a|CDKN2A/p16INK4a expression will be measured using the Taqman qPCR assay (TaqMan Universal Master Mix II, with UNG, Applied Biosystems, Foster City, USA) according to the manufacturer's specifications.
223458961|NCT06386380|OTHER|Immunophenotype of leukocyte subpopulations|CD4+ and CD8+ subpopulations will be analyzed. Blood samples will be analyzed by 8-color flow cytometry (Becton Dickinson Canto II cytometer) using fluorescently labeled antibodies from Biolegend Inc. (San Diego, USA).
223458962|NCT06386380|GENETIC|Telomere length|The rLTL will be estimated by quantitative monochromatic multiplex PCR (MM-qPCR). Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) will synthesize the primers used for telomere measurements.
223458963|NCT06386380|OTHER|Cellular senescence|Expression of co-stimulatory molecules and surface receptors CD27- and CD28-
223458964|NCT04789525|OTHER|High-intensity aerobic training with high protein diet|High-intensity aerobic training was given with 50 to 70 % of the maximum heart rate. the intervention started with 10 mins of warm-up exercise through stretching of upper and lower limb muscles. Subsequent to stretching, the subjects were asked to do 30 mins of exercises; consisting of 20 mins on the treadmill and 10 mins of cycle ergometer at 50 to 70 % of MHR, then with 10 mins of cool down.
223573901|NCT06605742|OTHER|Consultancy|In the single-blind method, subjects do not know which of the experimental or control groups they were selected and therefore which method was applied to them.The researcher knows the subjects selected for the experimental and control groups, and therefore which method was applied to which subjects
223573902|NCT06069141|DRUG|Benzathine Penicillin G|Benzathine Penicillin G (2.4 MU intramuscularly once)
224156285|NCT06283225|DEVICE|Pia-App|The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
223458965|NCT05748964|PROCEDURE|Laparoscopic pyeloplasty|Twenty patients presented with ureteropelvic junction obstruction \[UPJO\] will be divided into two equal groups. The first was subjected to trans-peritoneal pyeloplasty while the second was subjected to retroperitoneal pyeloplasty.
223458966|NCT01583413|PROCEDURE|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
223458967|NCT00532545|DRUG|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
223458968|NCT04868019|DRUG|Fenofibrate Capsules|Solutions will be prepared in the required strengths and labeled accordingly. Group A will receive Solution A i.e. Fenofibrate suspension is prepared by dissolving 200 mg capsule in 10 ml distilled water and given as a single dose of 10mg/kg (0.5 ml/kg) and Group B will receive solution B i.e. 0.5ml/ kg normal saline as a placebo. Both groups will receive LED phototherapy under standard conditions. The serum bilirubin level will be noted at the time of admission and then at 12hr, 24hr, and 48 hours of treatment
223458969|NCT05565170|BEHAVIORAL|Structured ICT-assisted multimodal lifestyle intervention|The structured lifestyle intervention programme, partly tailored and personalised to individual needs, covers the following domains: physical activity, nutrition, cognitive activity, cardiovascular risk management, social interaction, sleep, and relaxation / stress management. The programme includes regular scheduled in-person sessions (group-based + individual) which are supported with independent digital activities in the LETHE App. The App has features such as e.g., a cognitive training programme, on-demand exercise videos, calendar to schedule activities, advice and educational material, group chat, and possibility to set and monitor goals and self-monitor risk factors such as e.g., blood pressure.
223458970|NCT05565170|BEHAVIORAL|Self-guided multimodal lifestyle intervention|Participants are advised to build their own healthy lifestyle programme based on standard healthy lifestyle advice that they will receive at individual consultations with the study physician/nurse as part of the study visits and through the simplified version of the LETHE app. The control group app does not include any structured / scheduled activities or personalised content.
223458971|NCT05684289|DRUG|BMS-986278|Specified dose on specified days
223458972|NCT05684289|DRUG|Sildenafil|Specified dose on specified days
223573903|NCT06069141|DRUG|Doxycycline Capsule|doxycycline (100 mg orally twice daily for 7 days)
223573904|NCT06599983|OTHER|Educational program, Educational Storytelling, an Educational Program Against Child Abuse and Neglect.|One day educational program, aiming at increase dental personnels attitude, knowledge and behaviour in regard to detect and report child abuse and neglect, and to treat patients with known and unknown history of child abuse and neglect.
223573905|NCT06605313|DEVICE|SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System|Transcathether Edge-to-Edge repair for tricuspid regurgitation with SQ-Kyrin-T Transcatheter Tricuspid Valve Repair System.
223573906|NCT06605261|OTHER|Yoga (intervention) group|The yoga (intervention) group comprises 64 women with breast cancer who have been randomly assigned and are undergoing endocrine therapy. To alleviate arthralgia and vasomotor symptoms (hot flashes, night sweats), a structured yoga program will be administered during the initial months of endocrine therapy, consisting of 60-minute sessions, 4 days per week, for a duration of one month.
223573907|NCT05209451|BEHAVIORAL|Digital, evidence-based behavioral health program for smoking cessation|Remotely delivered, 12-week smoking cessation program delivered through the patient portal. The program will deliver a smoking cessation intervention that links study participants to tailored, interactive and effective evidence-based smoking cessation resources.
224156286|NCT04083118|DIAGNOSTIC_TEST|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
224156287|NCT04083118|DIAGNOSTIC_TEST|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
223458973|NCT05684289|DRUG|Placebo|Specified dose on specified days
223458974|NCT05805683|DRUG|Calcitonin|patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.
223458975|NCT05805683|DRUG|Placebo|patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
223458976|NCT04917354|DEVICE|Superb-Microvascular imaging|Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
224156288|NCT01000025|DRUG|PF-00299804|PF-804 45 mg PO, daily
224156289|NCT01000025|DRUG|Placebo|Placebo 45 mg PO, daily
224156290|NCT01632072|DIETARY_SUPPLEMENT|Nutritional support|Nutritional support and counseling
223458977|NCT00525473|DRUG|Azathioprine|azathioprine usual dosage 100mg per day
223458978|NCT04663165|PROCEDURE|Periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing. Elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device. Flap closure with non-resorbable sutures.
223458979|NCT04663165|PROCEDURE|Regenerative periodontal surgery|Flap surgery at teeth with periodontal pocket depth 5 mm or more with additional bleeding or pus on probing combined with vertical bone defect of 4mm or more. After elimination of dental calculus and granulation tissue as well as scaling of the root surface with scalers and ultrasonic device, adjunctive treatment with EDTA gel applied to root surface for two minutes, followed by rinsing with saline solution. Finally, application of enamel matrix derivative on a blood free root surface, followed by flap closure with non-resorbable sutures.
223458980|NCT06073509|DIAGNOSTIC_TEST|Screening for atrial fibrillation and other cardiac arrhythmias and diseases|"In addition to retrospective data collection based on a medical questionnaire, a 5-year post-RT cardiovascular screening will include:~* connected smartwatches for atrial fibrillation screening~* complete ECG for other cardiac arrhythmias~* echocardiography for other cardiac diseases (including cardiac dysfunction, cardiomyopathy, valvulopathy, ...)"
223458981|NCT01514110|DRUG|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
223458982|NCT00868478|DRUG|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
223458983|NCT03063736|DRUG|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
223458984|NCT03063736|BIOLOGICAL|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
223458985|NCT03961763|DIETARY_SUPPLEMENT|EPA+DHA|4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
223458986|NCT03961763|OTHER|Placebo|4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
223458987|NCT02412202|OTHER|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
223458988|NCT01502033|DEVICE|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
223458989|NCT02018432|DRUG|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
223458990|NCT02018432|DRUG|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
223573908|NCT05209451|OTHER|Bluetooth enabled iPad|Bluetooth enabled iPad with data plan coverage that provides a personal Wi-Fi (Internet) hot spot for all home devices and allows for up to 64 GB of cellular data.
223573909|NCT05209451|BEHAVIORAL|Coaching Support|Six coaching calls, 15-20 minutes each in duration. The research coach will use motivational interviewing and goal setting to enhance the participant's technology access and use and digital literacy.
223573910|NCT06661148|DRUG|EPI-003|Intravenous (IV) infusion.
223573911|NCT06661486|BEHAVIORAL|Uniformed intervention group|The investigators provide lifestyle intervention through a health education programme which is in a group setting. The sessions consisted of short talks on a health-related topic targeting lifestyle factors associated with dementia risk, followed by group activities that required interactions, cognitive engagement, and the acquisition of certain skills (for example, how to read food labels, how to measure blood pressure, how to recognize signs of depression, et al).
223573912|NCT06661486|BEHAVIORAL|Individualised intervention group|On top of the uniformed intervention group, the individualised intervention group receives also 1:1 sessions every 3 months within 2 years. Participants will review the knowledge taught in the group sessions individually and the investigator will address the participant's concerns and provide advice to the participant for a better lifestyle accordingly.
223573913|NCT06662175|DRUG|Hyperbaric bupivacaine|Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
223573914|NCT06662175|DRUG|hyperbaric bupivacaine and dexmedetomidine|Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
223573915|NCT06607250|RADIATION|MRI|All enrolled patients underwent multiparametric magnetic resonance imaging, encompassing T2-weighted imaging (T2WI) and magnetic resonance diffusion-weighted imaging (DWI), in the coronal, sagittal, and axial planes.
223743293|NCT05719012|BIOLOGICAL|UC-MSCs|Intravenous injection three times with one-month interval
223743294|NCT02099097|OTHER|web-based video game (Quit IT)|
223743295|NCT02099097|BEHAVIORAL|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
223458991|NCT03709147|DRUG|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
223458992|NCT03709147|DRUG|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
223458993|NCT03709147|DRUG|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
223458994|NCT03709147|DRUG|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
224156291|NCT04123171|DIAGNOSTIC_TEST|Neuroimaging studies|Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
223458995|NCT03709147|DIETARY_SUPPLEMENT|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
223458996|NCT03709147|DRUG|Pembrolizumab|Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
223458997|NCT02548663|OTHER|Sport therapy|"Frequency: 60 min three times/week~1. 20 min: aerobic training on bicycle ergometer.~2. 20 min: strength training at 60% of maximal load.~3. 20 min: proprioception and stretching exercises."
223458998|NCT02548663|OTHER|Osteopathic treatment|Frequency: 60 min weekly
223458999|NCT00921206|BIOLOGICAL|VAX102|1 ug i.m. compared to 2 ug s.c.
223573916|NCT06608056|DRUG|Pain management after surgery|Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
223573917|NCT05469243|DRUG|Psychedelic|retrospective survey of previous use
223573918|NCT06658626|DRUG|[¹⁴C]Enlicitide chloride|IV Injection
223573919|NCT05985278|DRUG|[ Lu-177]-Catalase|\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor
223573920|NCT06606132|OTHER|Exercise|The virtual reality program consisted of twelve sessions (2 per week for six weeks) of 10 min warm-up plus 15 minutes of exercise with the FitXR game (developed by FITAR LIMITED) on the Oculus Quest 2™ device. The warm-up consisted of moderate-intensity aerobic exercise on a cycle ergometer. The BORG CR-10 perceived exertion scale was used to determine this intensity. Subsequently, they continued with the FitXR game, starting with a 5-minute phase of muscular activation and global movements of their limbs. They performed eye-hand coordination exercises, hitting balls that came to the person at different speeds, and ended with muscle stretching and slow breathing. These exercises presented different difficulty levels and were adjusted to the person\&#39;s condition. In the same way, as the game developed, it was possible to increase the level and thus increase its complexity.
224067635|NCT06552169|BIOLOGICAL|Arm 2A: TRACT/MONO mTOR|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
223573921|NCT06605729|OTHER|e-learning|The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
223573922|NCT00659217|BIOLOGICAL|mesenchymal stem cell|Autologous MSC transplantation
223573923|NCT04435639|OTHER|Manual lymph drainage.|"Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period."
224071478|NCT01596998|OTHER|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
224156292|NCT00422669|DEVICE|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
224156293|NCT00422669|DEVICE|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
223459000|NCT02102347|OTHER|exercise|
223459001|NCT02102347|OTHER|Phototherapy|
223459002|NCT04476498|PROCEDURE|Pull-PEG with Gastropexy|Additionally to a conventional pull-PEG a gastropexy will be performed.
223459003|NCT05980897|BEHAVIORAL|Naming treatment|"In this alternating treatment single-subject experimental design study, the investigators will alternate between two treatment conditions, i.e., two different types of stimulus items: those that are consistently reported as successful IS prior to treatment (sIS items) and those that are consistently reported as unsuccessful IS prior to treatment (uIS items). The treatment will be computerized to ensure consistency of presentation, timing, and cues across participants.~For each stimulus presentation, the treatment hierarchy will proceed as follows:~1. Name the picture independently~2. Name the picture with a written cue~3. Repeat the name of the picture~4. Name the picture after a 5 second delay Each participant will be trained on a set of 40 items chosen specifically for them based on initial/baseline testing."
223573924|NCT04435639|PROCEDURE|Coban compression bandage..|Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
224071479|NCT02590380|DEVICE|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
224071480|NCT02590380|DEVICE|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
224071481|NCT01594021|DRUG|Gelatin 500 mL|intravenous administration
224071482|NCT01594021|DRUG|Gelatin 50 mL|intravenous administration
224071483|NCT02678858|BEHAVIORAL|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
223573925|NCT04435639|DEVICE|Adjustable Compression Sleeve|Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
223573926|NCT06598228|OTHER|No Intervention: Observational Cohort|no intervention
223573927|NCT06607211|DIAGNOSTIC_TEST|Transcranial Color-Coded Doppler (TCCD)|As part of the clinical practice, the examination will be performed with ultrasound machines that have presets for TCCD, using a low-frequency sector probe (2-25 MHz) with a transtemporal approach to obtain a scan through the midbrain plane. Through the use of Color Doppler and Pulsed-Wave Doppler, a spectral doppler waveform of the M1 segment of the middle cerebral artery velocity is obtained bilaterally. If hypoperfusion signs are discovered, TCCD will be repeated to assess the effects of each intervention.
223459004|NCT01861002|DRUG|Azacytidine|Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
223459005|NCT01861002|DRUG|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
223459006|NCT01861002|DRUG|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
223459007|NCT01861002|DRUG|Intrathecal (IT) Cytarabine|"Intrathecally to AML patients on day 1 of course 1 and 2.~* Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. \- 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~2. \- 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~   * 3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg"
223459008|NCT01861002|DRUG|Intrathecal Methotrexate (IT MTX)|"* Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. \- 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. \- 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. \- 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg"
223459009|NCT05816668|DRUG|Tranexamic acid|Patients with prostate cancer and radical video laparoscopy prostatectomy indication will receive 1,0g of Tranexamic Acid solution IV in bolus 20 minutes before of anesthetic induction, followed by a maintenance hose of 1,0mg/kg/h of surgery.
223459010|NCT05816668|OTHER|Placebo|Patients randomized to placebo group will receive physiological saline and will undergo to the radical video laparoscopu prostatectomy normally
223459011|NCT02742363|OTHER|Collecting data|Collecting data from patient records
223459012|NCT05101759|PROCEDURE|Comprehensive Geriatric Assessment|A systematic reassessment of geriatric parameters will be performed at 3 and 6 months post-inclusion.
223459013|NCT00064415|DRUG|arformoterol|Arformoterol inhalation solution, 50 mcg QD
223573928|NCT06606652|DIETARY_SUPPLEMENT|Caffeine|Acute caffeine intake (3 mg/kg)
223573929|NCT06606652|DIETARY_SUPPLEMENT|Placebo|Acute placebo intake (3 mg/kg of maltodextrin)
223573930|NCT06606015|DRUG|I.V Paracetamol.|Pharmacological thereby for hsPDA closure in the preterm neonates.
223573931|NCT06606015|DEVICE|Echocardiography.|It is routinely performed in neonates for PDA screening and detection of any other cardiac anomalies.
223573932|NCT06606015|DEVICE|Electrical Cardiometry|Non invasive hemodynamics monitoring
223573933|NCT06607081|COMBINATION_PRODUCT|Multidisciplinary Preoperative Risk Evaluation and the Corresponded Pre ERAS intervention|The operative risk factors are multidisciplinary evaluated and the corresponded multimodal measures are used to optimize the whole condition of the elderly patient undergo spinal fusion surgery for his/her safty, early and fully recovery.
224067636|NCT06552169|BIOLOGICAL|Arm 2B: TRACT/MONO CNI|"All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either:~* Arm 2A: mTOR monotherapy or~* Arm 2B: CNI monotherapy.~These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant.~Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product."
223459014|NCT00064415|DRUG|Salmeterol|Salmeterol MDI, 42 mcg BID
223459015|NCT05285787|DRUG|EPN-701 (Oral)|MK-7
223459016|NCT01509612|DRUG|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
223459017|NCT01509612|DRUG|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
223459018|NCT04827758|PROCEDURE|Screening and diagnostic tests for sarcopenia|"All of the following tests and questionnaires will be performed :~* SARC-F questionnaire,~* measurement of muscle strengh by a grip test,~* measurement of muscle mass by impedancemetry (ASM/size2),~* 4-meter walking speed test,~* Timed-Up and Go (TUG) test,~* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires."
223573934|NCT04906720|DRUG|Colchicine|colchicine 0.6mg oral twice daily for 7 days
223573935|NCT01513603|DRUG|CLAG-M|IV times 5 days
223573936|NCT01513603|DRUG|CLAG-M|Chemotherapy
223573937|NCT04706273|DEVICE|GORE® VIABAHN® Endoprosthesis|Participants receiving the GORE® VIABAHN® Endoprosthesis
223573938|NCT06607393|DRUG|Pembrolizumab|
223573939|NCT06607393|DRUG|Pemetrexed|
223459019|NCT02195973|DRUG|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
223459020|NCT03278366|BEHAVIORAL|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
223459021|NCT02360280|DRUG|ketamine|sedative
223459022|NCT02360280|DRUG|midazolam|sedative
223459023|NCT02472886|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223459024|NCT02472886|DRUG|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
223459025|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
223459026|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
223459027|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
223459028|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
223459029|NCT00320788|BIOLOGICAL|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
223459030|NCT00921583|DEVICE|Long-term examination|Follow-up dental implants 20 year in function
223459031|NCT04058197|DRUG|Deferoxamine Product|Deferoxamine Intradermal Delivery Patch
223459032|NCT04058197|OTHER|Placebo|Placebo Patch
223459033|NCT06101147|DRUG|Vitamin D3|These patients will receive Vitamin D3 1000 I.U daily and the Metformin as prescribed by the physician for 8 weeks.
223459034|NCT06101147|DRUG|Placebo Oral Tablet|These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
223459035|NCT03343743|OTHER|Oligomineral water|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
223459036|NCT03662035|DRUG|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
223459037|NCT03662035|DRUG|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA\<1.25m2, 80mg/d for 1.25\<BSA\<1.5m2, and 100mg for BSA \>1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
223459038|NCT01539746|PROCEDURE|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
223459039|NCT01539746|PROCEDURE|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
223459040|NCT06289439|DIETARY_SUPPLEMENT|Green tea (Camellia sinensis) 1000 mg as extract|Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))
224067637|NCT04584580|DRUG|low-molecular-weight heparin|low-molecular-weight heparin administered via subcutaneous injection
223459041|NCT06289439|OTHER|Placebo|Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
223459042|NCT00056303|BEHAVIORAL|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
223459043|NCT00056303|BEHAVIORAL|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
223459044|NCT05180019|DEVICE|SMD ( Self Monitoring Device)|Automated 3D ultrasound based follicullometry with SMD self-performed by the patient.
223459045|NCT01408719|DIETARY_SUPPLEMENT|Control|Minimal beta-glucan
223459046|NCT01408719|DIETARY_SUPPLEMENT|3g LMW beta-glucan|3grams beta-glucan
223459047|NCT01408719|DIETARY_SUPPLEMENT|5g LMW beta-glucan|5 grams beta-glucan
223459048|NCT01408719|DIETARY_SUPPLEMENT|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
223459049|NCT01675388|OTHER|Hypothermia|Hypothermia to 33.5 deg C
223459050|NCT02797678|DEVICE|Powersleep|Participants will receive 5 nights of stimulation
223459051|NCT02797678|DEVICE|Sham Powersleep|Participants will receive 5 nights of no stimulation
223459052|NCT02401035|DRUG|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
223459053|NCT05307679|DRUG|Basmisanil|Participants will receive oral basmisanil at age-appropriate dosages
223459054|NCT05307679|DRUG|Placebo|Participants will receive oral placebo
223459055|NCT00028626|DRUG|embolization therapy|
223459056|NCT04693078|DEVICE|AI polyp detection system based on deep learning|A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
223459057|NCT00168155|DRUG|perioperative chemotherapy|
223459058|NCT02567175|DRUG|Domperidone|
223459059|NCT03046953|DRUG|Avelumab|anti-PDL1 antibody
224067638|NCT03483480|PROCEDURE|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
224067639|NCT03483480|PROCEDURE|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
223573940|NCT06607393|DRUG|Cisplatin|
223573941|NCT06607393|DRUG|Carboplatin|
224067640|NCT03354754|DRUG|LYS228|LYS228 IV infusion every 6 hours
223459060|NCT04039204|DRUG|Elagolix|This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
223459061|NCT04039204|DRUG|Ortho Cyclen|Oral contraceptive prescribed by physician.
223573942|NCT06604910|DIETARY_SUPPLEMENT|branched chained amino acid|patients undergoing branched chained amino acid
223573943|NCT03539289|BEHAVIORAL|MUFA Diet|Control of patient MUFA Diet
223573944|NCT03539289|BEHAVIORAL|SFA Diet|Control of patient SFA Diet
223459062|NCT00281723|DRUG|Pro-Pe adhesive tablet|
223573945|NCT02637427|BIOLOGICAL|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
223459063|NCT02766036|DRUG|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
223459064|NCT02766036|DRUG|Placebo|Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
223459065|NCT01199887|DRUG|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
223459066|NCT01363284|DRUG|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
223459067|NCT01189461|DRUG|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
223459068|NCT05745545|BIOLOGICAL|SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine|One dose was administered by intramuscular injection, 100μg，1.0ml/dose
223459069|NCT05745545|DRUG|Saline solution|One dose was administered by intramuscular injection, 0.5ml/vial
223459070|NCT06058273|BEHAVIORAL|Bruni® training|10 sessions (7 individual and 3 group) based on the Bruni method, which was born as a method for the artistic voice (rock, pop, gospel, R\&B, grunge, metal), acting and dubbing. It is a method based on the didactic desire to lead any artist to the ability to produce various types of noise, specifically generically supraglottic, predominantly arytenoid and falsechordal emissions, providing the perceptive, proprioceptive and praxis tools to safely emit and manage the many sounds generated from a supraglottic source
223459071|NCT05184387|OTHER|Blood samples|Collection of blood samples and completion of an electronic Diary (eDiary)
223459072|NCT02924233|DRUG|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
223459073|NCT02924233|DRUG|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
223459074|NCT02938338|PROCEDURE|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
223459075|NCT00023738|BIOLOGICAL|filgrastim|
223459076|NCT00023738|DRUG|dacarbazine|
223459077|NCT00023738|DRUG|doxorubicin hydrochloride|
223459078|NCT00023738|DRUG|ifosfamide|
223459079|NCT00023738|DRUG|semaxanib|
223459080|NCT00023738|PROCEDURE|conventional surgery|
223459081|NCT00023738|RADIATION|radiation therapy|
223573946|NCT06454890|BIOLOGICAL|Anti-Trop2 CAR-NK cell|chemotherapy followed by Trop2 CAR-NK infusion
223573947|NCT03199053|DRUG|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
223459082|NCT00585338|DEVICE|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
223459083|NCT00006390|BIOLOGICAL|alemtuzumab|
223573948|NCT03199053|DRUG|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
223743296|NCT02099097|OTHER|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
224067641|NCT03354754|DRUG|Standard of care therapy|IV infusion of standard of care antibiotics
223459084|NCT00006390|BIOLOGICAL|filgrastim|
223459085|NCT00006390|DRUG|cyclophosphamide|
223459086|NCT00006390|PROCEDURE|peripheral blood stem cell transplantation|
223459087|NCT00006390|RADIATION|radiation therapy|
223459088|NCT02566499|DEVICE|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
223459089|NCT05355077|DRUG|JT001 200mg Bid|JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
223459090|NCT05355077|DRUG|JT001 400mg Bid|JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
223459091|NCT05355077|DRUG|JT001 600mg Bid|JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
223459092|NCT00229749|DRUG|AVI-4065 Injection|
223459093|NCT03938363|OTHER|Treadmill|Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
223459094|NCT03938363|DRUG|Botulinum Toxin injection|injection of Botulinum Toxin in the two groups of CD and BS
223459095|NCT03938363|DIAGNOSTIC_TEST|Severity scale of the disease|JRS for BS TWSTRS for CD
223573949|NCT03199053|DRUG|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
223573950|NCT02769338|OTHER|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
223573951|NCT05131776|DEVICE|EUS-guided oncosil injection|All patients will receive OncoSilTM during the 4th week of the first chemotherapy cycle.
223573952|NCT05974657|OTHER|Probiotic Lactobacillus acidophilus LA85|Through a randomized double-blind placebo-controlled method, the patients were randomly divided into placebo group and probiotic intervention group, and took probiotics once a day for 14 consecutive days.
223573953|NCT00728247|PROCEDURE|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
224067642|NCT05791656|DEVICE|Mectascrew-C|reconstruction of ACL or PCL rupture
223573954|NCT05731076|BEHAVIORAL|Self-management support nutrition and exercise intervention|Provide information about different home exercise type(walking, strength training, flexibility training), nutrition knowledge to maintain or improve cancer cachexia syndrome.
224156294|NCT02969967|DEVICE|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
223459096|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using the Arthrex NanoScope|"A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment."
223459097|NCT04457362|DIAGNOSTIC_TEST|Diagnostic Arthroscopy using standard arthroscopic instruments|"A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment."
223459098|NCT00048633|DRUG|Chemotherapy|
223459099|NCT01712139|DRUG|Irbesartan and Hydrochlorothiazide|
223459100|NCT01712139|DRUG|Avalide|
224067643|NCT01137773|DRUG|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
224067644|NCT01137773|DRUG|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
223459101|NCT06361186|DRUG|Proximod|Single and multiple-dose to establish the safety and PK profile
224067645|NCT03981237|DEVICE|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
224156295|NCT04423757|DRUG|BI 1358894|125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.
223459102|NCT06361186|DRUG|Placebo|Placebo controlled
223459103|NCT03112486|PROCEDURE|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
223459104|NCT00758381|DRUG|Sorafenib 400 mg po bid, continuously|"NEXAVAR\*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
223459105|NCT00758381|DRUG|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
223459106|NCT01204086|DRUG|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
223459107|NCT01204086|DRUG|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
223459108|NCT01706432|RADIATION|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
223459109|NCT01706432|OTHER|laboratory biomarker analysis|Correlative studies
223743297|NCT06485063|OTHER|Myofascial Reorganization|It is a manual technique in which the therapist applies a manual sustained oblique load of 45° with subsequent shear load. In general, the technique is divided into two stages, the first when the oblique load is accompanied by a passive shear load (applied by the therapist) during 1minute, and the second stage, when the shear oblique manual load is maintained but the shear load provoked by the participants' active movement (active shear load) during 1minute.
224067646|NCT03981237|DEVICE|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3\*20s).
224067647|NCT03981237|PROCEDURE|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
224067648|NCT01525004|DRUG|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
224067649|NCT01525004|DRUG|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
224067650|NCT06273332|OTHER|AI-assisted registration|We will use artificial intelligence to register 3d model on intra-oral scan
224067651|NCT06273332|OTHER|Point-based registration|We will use five references points or more to perform model registration
224156296|NCT04423757|DRUG|Placebo|Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
224156297|NCT04307173|DRUG|KBL693|"Part 1: 680 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
223459110|NCT01706432|RADIATION|stereotactic radiosurgery|Undergo stereotactic radiosurgery
223459111|NCT05941624|DEVICE|Ha-330 Hemoperfusion Filter Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
223459112|NCT05941624|DEVICE|Conventional Hemodialysis|a total of 4 hours therapy, 3 times a week. Each therapy should be two days apart
223459113|NCT00656175|DRUG|raltegravir|raltegravir
223573955|NCT02516293|BEHAVIORAL|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
223573956|NCT02213848|DRUG|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
223573957|NCT02213848|DRUG|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
223573958|NCT00349323|BEHAVIORAL|Community directed treatment|
223573959|NCT02509052|OTHER|Laboratory Biomarker Analysis|Correlative studies
224156298|NCT04307173|DRUG|KBL693|"Part 2: 6800 mg/day of KBL693 or Placebo;~Route of Administration: Oral"
223573960|NCT02509052|DRUG|Leflunomide|Given PO
223573961|NCT02509052|OTHER|Pharmacological Study|Correlative studies
223573962|NCT02472418|DRUG|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
223573963|NCT02472418|DRUG|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
224156299|NCT00810589|DRUG|Levemir|0,4 IE per kg bodyweight
224302821|NCT05473962|DIAGNOSTIC_TEST|assessment and quantification of symptoms related to post-traumatic stress.|Semi-structured interview based on the Clinician-Administered PTSD scale for DSM-5 Child/Adolescent -CAPS-CA-5. This instrument allows for the This instrument is validated in English, and a French translation was carried out by the investigators (translation/back-translation method). The instrument uses the DSM-5 diagnostic criteria for post-traumatic stress disorder (PTSD).
223459114|NCT00994227|PROCEDURE|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
223573964|NCT02472418|OTHER|Placebo (treatment C)|Placebo administered
223573965|NCT03836430|BEHAVIORAL|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
223459115|NCT00939926|DRUG|Risperidone|
223459116|NCT04821843|DRUG|Platinum based chemotherapy|q1-3W according to physician's preference
223459117|NCT04821843|DRUG|Paclitaxel based chemotherapy|q1-3W according to physician's preference
223459118|NCT04821843|RADIATION|Radiotherpay|40-50Gy/1.8-2.2Gy/20-25f
223573966|NCT05326191|DIAGNOSTIC_TEST|Ultrasound|All study interventions/procedures will happen during the participants routine clinic visit in which they will receive their routine Ultrasound scan, followed by an additional research scan, which will take approximately 2-3 minutes. A blood sample will also be taken from participants as part of their routine pregnancy care. Residual blood from the same sample will be used to conduct an additional test to quantify Placental Growth Factor (PlGF). Participants will also be asked questions about their relevant medical history and demographic data which is also routinely collected as part of their pregnancy record.
223573967|NCT05884112|DEVICE|"MAGSTIM reprtitive Transcranial Magnetic Stimulator (rTMS) System"|iTBS is a new treatment method for depression. It uses the principle of magnetoelectricity to intermittently stimulate local brain nerves. In recent years, domestic and foreign studies have confirmed its efficacy and safety for depression. In addition, research has also It shows that iTBS has better therapeutic effect and efficiency than the previous regular rTMS.
223573968|NCT05884112|DEVICE|sham control|sham control
223573969|NCT01524003|PROCEDURE|cryotherapy|cryotherapy treatment of the uterine cervix
223573970|NCT01524003|PROCEDURE|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
224156300|NCT00810589|DRUG|Humalog NPL Insulin|0,4 IE per kg bodyweight
224156301|NCT05681897|PROCEDURE|Platelet-Rich Plasma Injections (PRP) on the Scalp|each subject will be treated with 3x PRP injections on the scalp with 2 weeks interval in addition to daily minoxidil administration.
224156302|NCT02709109|DRUG|VX-371 + HS|
224156303|NCT02709109|DRUG|Hypertonic saline|
223459119|NCT04821843|PROCEDURE|Surgery|Radical esophagectomy
223459120|NCT04821843|DRUG|Immunotherapy|Anti-PD-1/PD-L1 Antibody
223459121|NCT04821843|DRUG|5-FU Analog based chemotherpay|W1-5 qW or d1-14, q3W according to physician's preference
223459122|NCT04821843|DRUG|Nimotuzumab|200-400mg, d1,qW
223459123|NCT05003284|DEVICE|acupressure wristband|acupressure after surgery
223459124|NCT05003284|DEVICE|placebo wristband|acupressure after surgery
223459125|NCT01818973|DRUG|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
223459126|NCT01818973|DRUG|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
223459127|NCT01818973|DRUG|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
223459128|NCT01818973|RADIATION|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
224156304|NCT02709109|DRUG|Placebo|
224156305|NCT02709109|DRUG|Orkambi|
224156306|NCT02709109|DRUG|VX-371|
223573971|NCT03861572|OTHER|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
224302822|NCT04935424|DEVICE|ApolloVue® S100 Image System (Apollo Medical Optics)|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
223573972|NCT03861572|OTHER|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
223573973|NCT01476319|OTHER|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
223573974|NCT02295215|OTHER|Exercise|Exercise Training for 4 months
223573975|NCT04720040|DEVICE|Mind STIM|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
223573976|NCT01824823|DRUG|afatinib|Given PO
224067652|NCT03548051|PROCEDURE|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
224067653|NCT03548051|DRUG|Saline|250 ml of saline delivered by retention enema
224067654|NCT05581914|OTHER|MY LIFE treatment|"The MY LIFE is a group treatment consisting of 5 workshops, for adolescents with a low motivation for mental health treatment. It aims to increase self- worth, hope for the future and seeking social support through exercises by using music and lyrics and other creative exercises to engage adolescents. The MY LIFE treatment also uses methods that stem from psychodynamic, cognitive behavioral, and solution focused theories. The therapeutic attitude is based on client-centered therapy of Rogers, which includes a genuine, positive regard and empathic understanding, focusing on the inner strength and growth potential of a person. Adolescents are never forced to participate during the workshops, merely encouraged.~The core of the treatment is: the adolescent decides"
224067655|NCT05581914|OTHER|Care as Usual|The care as usual the adolescents receives
224067656|NCT05941598|DEVICE|Electroacupuncture|Participants in the electroacupuncture group will receive electroacupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
224067657|NCT05941598|DEVICE|Sham acupuncture|Participants in the sham acupuncture group will receive minimal acupuncture twice a week, with each session lasting 30 minutes. The treatment will start one week before chemotherapy and continue throughout the chemotherapy period.
224067658|NCT01378312|BIOLOGICAL|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
224067659|NCT01378312|BIOLOGICAL|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
224067660|NCT00317798|BIOLOGICAL|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
224302823|NCT01123135|DRUG|Vaginal ERT|1gm of estrogen vaginal cream \[EVC\] at bed time 3 times a week
224302824|NCT01123135|DRUG|Placebo|Placebo
223459129|NCT01818973|PROCEDURE|surgery|Total Mesorectal Excision (TME)
223459130|NCT05955144|DEVICE|Picterus JP|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is placed.
223459131|NCT02951624|BEHAVIORAL|Control|Control intervention
223459132|NCT02951624|BEHAVIORAL|Breaker|Short breaks of physical activity
223459133|NCT02951624|BEHAVIORAL|Prolonger|longer breaks of physical activity
223459134|NCT02951624|BEHAVIORAL|Intermediate|Intermediate breaks of physical activity
223459135|NCT01403571|DIETARY_SUPPLEMENT|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
223459136|NCT01403571|DIETARY_SUPPLEMENT|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
223459137|NCT05223816|DRUG|VG161|"Name: VG161 (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) Concentration/Content: ≥1×107 PFU/mL; 1.0 mL/vial. Actual titer will be recorded on Certificate of Analysis.~Composition: VG161,50 mM Tris-HCl, 150mM NaCl, \<5% glycerol Route of Administration: Intratumoral injection or image guided intratumoral injections."
223459138|NCT05223816|DRUG|Nivolumab Injection [Opdivo]|immunotherapy treatment
223459139|NCT04900649|OTHER|chest resistance exercise|lung function.
223459140|NCT04900649|OTHER|chest expansion exercises|thoracic excursion
223459141|NCT04967105|DEVICE|Near-infrared spectroscopy|Before the induction of anesthesia, NIRS sensors were placed on both sides of the flank area that overlies the kidney to monitor renal SO2, whose alteration trends over time during operation will be recorded and evaluated in later analysis.
223459142|NCT04839666|DRUG|Propofol|Perioperatively propofol administration
223459143|NCT00204061|BEHAVIORAL|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
223459144|NCT00204061|DRUG|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
223459145|NCT03086005|DRUG|Metformin|
223459146|NCT06043648|DEVICE|Endotracheal tube cuff pressure monitoring|The endotracheal tube cuff pressure was continuously monitored using a transducer from a standard invasive pressure monitoring device that is routinely used to measure arterial or central venous pressure.
223459147|NCT02344511|DRUG|Dalbavancin|Drug
223459148|NCT02344511|DRUG|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
223459149|NCT04693299|DIAGNOSTIC_TEST|colonoscopy|A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
223459150|NCT01014195|OTHER|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
223459151|NCT02723448|DRUG|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
223459152|NCT04949282|DRUG|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
223459153|NCT04949282|DEVICE|Lutetium [177Lu] oxodotreotide/dotatate|Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)
223459154|NCT03017196|OTHER|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
223573977|NCT01824823|OTHER|placebo|Given PO
223573978|NCT00324428|PROCEDURE|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
224067661|NCT00317798|DRUG|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
224067662|NCT01768455|DRUG|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1\~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
224067663|NCT01768455|DRUG|Glimepiride|Glimepiride 4mg (qd) on Day1
224067664|NCT02716610|DRUG|INH 69 U (low)|inhaled human insulin
224067665|NCT02716610|DRUG|INH 69 U (high)|inhaled human insulin
224067666|NCT02716610|DRUG|INH 139 U|inhaled human insulin
224067667|NCT02716610|DRUG|INH 208 U|inhaled human insulin
224067668|NCT02716610|DRUG|LIS 18 U|subcutaneous insulin lispro
224067669|NCT00976066|DRUG|Part A Assessing GSK1521498|"Each participant will receive up to three \[11C\]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
224067670|NCT00976066|DRUG|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three \[11C\]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
224067671|NCT00976066|DRUG|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three \[11C\]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline \[11C\]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
224067672|NCT06100341|OTHER|Virtual reality|A role-playing game set in a spaceship in outer space where a user will need to accomplish three activities to complete the game. These activities were designed based on typical therapy goals for children with cerebral palsy of improving balance, gross motor performance, walking speed, and functional mobility.
224067673|NCT04623476|PROCEDURE|Pathophysiological Excision for Crohn's disease|Pathophysiological excision for Crohn's (PEC) requires a medio-lateral approach and a high vascular tie, which enables excision of lymph nodes draining the disease bowel. This procedure should not alter length of bowel resection and no additional risks are foreseen. A latero-lateral anastomosis will be fashioned following current guidelines.
224067674|NCT01745146|BEHAVIORAL|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
223459155|NCT04088539|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
223459156|NCT04088539|BEHAVIORAL|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. The videos aim to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
223459157|NCT06553963|OTHER|Control group|The control group maintained their regular diet and training without additional nutritional support.
223459158|NCT06553963|OTHER|Experimental group|Biochemical Monitoring and Nutritional Support
223459159|NCT02497937|DRUG|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
223573979|NCT06511557|DEVICE|Non immersive virtual reality ( xbox kinetic)|"Treatment starts with a gentle warm-up i.e. hot pack for 10 minutes and gentle stretching of Quadriceps, hamstrings and calves. Each game was performed for 10 minutes with 1 minute rest between games. 3 sessions Per Weeks for 8 weeks (45 Min per Session) were given. All the exergames target muscles like Hamstring, Quadriceps and calves to improve function of knee joint and reduce pain.~Baseline assessment was done at the start of the session and proper cool down and stretching will be performed at the end of each session to promote flexibility and reduce muscle soreness"
223573980|NCT06511557|OTHER|Kinetic chain exercises|Session starts with a gentle warm-up i.e. Hot pack for 10 minutes and gentle stretching. Each exercise is performed in 2 sets, each set of 10 repetitions with 1min rest between sets. 3 sessions Per Weeks for 8 weeks (45 Min Per Session) were given .Kinetic chain exercises involve integrated movements that engage multiple joints and muscle groups \& focus on strengthening muscles like quadriceps, hamstrings, glutes, and calf muscles, improving joint stability, function, and reducing pain. Baseline assessment was done at the start of the session and proper cool down and stretching was performed at the end of each session to promote flexibility and reduce muscle soreness
223573981|NCT01044212|DRUG|Docusate|Docusate 100mg BID
223573982|NCT01044212|DRUG|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
223459160|NCT02497937|DRUG|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
223459161|NCT00179803|PROCEDURE|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor~* Cytoxan treatment~* Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~* Carboplatin and Etoposide treatment~* Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to \>1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
223459162|NCT05297890|DRUG|Lorlatinib|Dosage Form: Lorlatinib tablet, Dosage: 25mg/tablet, Dosing Regimens: 100mg, oral, Quaque Die (QD), continuous administration in 21 days as a cycle
223573983|NCT03649373|PROCEDURE|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
223573984|NCT00218582|BEHAVIORAL|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
223573985|NCT00218582|BEHAVIORAL|Standard psychiatric day treatment|Individual counseling, groups, medication
223573986|NCT02495246|BIOLOGICAL|ChAd3-EBO-Z|
223573987|NCT02495246|BIOLOGICAL|Ad26.ZEBOV|
223573988|NCT00431886|PROCEDURE|64 multi-detector computed tomography|
223459163|NCT04712864|BIOLOGICAL|LB1901|LB1901 - an autologous CD4-targeted CAR-T immunotherapy
223459164|NCT00735514|BEHAVIORAL|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
223573989|NCT03975127|OTHER|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
223573990|NCT03362931|DEVICE|XEN45|XEN45 unilaterally implanted in the study eye
223573991|NCT03076086|OTHER|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
223573992|NCT04710407|DRUG|TBPM-PI-HBr|TBPM-PI-HBr (2 x 300mg tablets) a total of five doses
223573993|NCT00993109|DRUG|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
223573994|NCT00993109|DRUG|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
223573995|NCT05266183|OTHER|Simultaneous Variety|3 different foods served
223573996|NCT05266183|OTHER|Single-Food|1 food served
223573997|NCT05266183|OTHER|Small Portion|Small meal portion size
223573998|NCT05266183|OTHER|Large Portion|Large meal portion size
223573999|NCT05370963|DRUG|Hylase versus dexmedtemodine|fluroscopic guided lumber epidural injection
223574000|NCT05517369|PROCEDURE|Hybrid ESD+|Injection of the Lift Up solution, followed by circumcision of the lesion using a snare tip or ESD knife. Using an additional working channel (AWC), the lesion is resected using a grasper and snare.
224067675|NCT01745146|BEHAVIORAL|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
224067676|NCT00699517|DRUG|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
224067677|NCT00699517|DRUG|Placebo|I.V. infusion followed by administration of cisplatin
224067678|NCT01667471|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
224067679|NCT00753870|BIOLOGICAL|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
224067680|NCT01863511|DRUG|loop diuretic|
224067681|NCT01863511|DRUG|tolvaptan|
224067682|NCT01863511|PROCEDURE|ultrafiltration|
224067683|NCT03605680|DRUG|Centanafadine SR|100 mg, BID, oral tablets
224067684|NCT03605680|OTHER|Placebo|BID, oral tablet.
224067685|NCT03605680|DRUG|Centanafadine SR|200 mg, BID, oral tablets
224067686|NCT02346760|DRUG|UB-621|100 mg/ml, subcutaneous injection
224067687|NCT00369187|DRUG|large protein molecule|
224067688|NCT05319392|DIAGNOSTIC_TEST|Observational study|Exploration of transcriptomic signatures related to tumor microenvironment having a significant role in prognosis of gastric adenocarcinoma patients
224067689|NCT05403983|BEHAVIORAL|Yoga movement intervention|Mixture of yoga, tai chi, pilates. Will be delivered in person (experimental) and online (active comparator)
224067690|NCT05403983|OTHER|Education booklet|Recently published postpartum physical activity guidebook through the Sport Information Resource Center of Canada
224302825|NCT02992418|BIOLOGICAL|CYD Dengue Vaccine|0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively
223459165|NCT00735514|OTHER|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
223459166|NCT00735514|PROCEDURE|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
223459167|NCT00735514|PROCEDURE|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
223574001|NCT03745365|PROCEDURE|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
223574002|NCT01323270|BIOLOGICAL|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
223459168|NCT00735514|PROCEDURE|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
223459169|NCT00671801|DRUG|Irinotecan|200 mg/m\^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
223459170|NCT00671801|DRUG|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
223459171|NCT02145208|DEVICE|TIND System|An implant
223459172|NCT06302049|DRUG|Esomeprazole|esomeprazole 20 mg once daily
223459173|NCT06302049|DRUG|Placebo|Placebo once daily
223459174|NCT06050096|PROCEDURE|PCI|CTO patients treated by DCB
223574003|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
223574004|NCT01323270|BIOLOGICAL|Saline|0.5 mL dose, given at 0, 2 and 6 months.
223459175|NCT02677597|DRUG|Cisplatin Combined With S-1|
223459176|NCT02677597|DRUG|Cisplatin Combined With Paclitaxel|
223459177|NCT05680077|DIAGNOSTIC_TEST|KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)|Blood samples from participants in both groups were collected and methylation tests were performed according to the kit instructions.
223459178|NCT02045186|OTHER|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~1. Polymerase chain reaction (PCR) for HPV DNA.~2. Fluorescent in-situ hybridization (FISH).~3. Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
223574005|NCT01323270|BIOLOGICAL|Repevax|0.5 mL dose, given at 0 months.
223574006|NCT04361604|BIOLOGICAL|Biological collection (patients co infected HIV Sras-CoV-2)|Biological sampling (blood,saliva, tear urine, stool, respiratory tract, semen only for 20 patients, or other samples if indicated.)
223574007|NCT04361604|OTHER|Auto-questionnaires (patients co infected HIV Sras-CoV-2)|4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV
223574008|NCT04361604|OTHER|Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)|Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
223574009|NCT03404804|DRUG|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
223574010|NCT01269359|PROCEDURE|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
223574011|NCT03409211|DIETARY_SUPPLEMENT|PEVCO|All subjects will receive PEVCO for 6 more weeks.
223574012|NCT03409211|DIETARY_SUPPLEMENT|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
223574013|NCT01061047|DRUG|Ertapeneme|
223574014|NCT02360644|DIETARY_SUPPLEMENT|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
224067691|NCT04834531|DRUG|Zhuli capsule|This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
224067692|NCT04834531|DRUG|Placebo|The placebo capsule is filled with amylodextrin made with food colour and flavor，with the similar appearance, smell and flavor with Zhuli Capsule. It is oral used, 2 capsules for once, three times a day, for 7 days.
224067693|NCT04834531|OTHER|Standard medical treatment|"Standard medical treatment will be given according to the recent guidelines with the evaluation of the clinicians, include:~1. if the patient with AECOPD, he or she will be given with oxygen therapy, bronchodilators, glucocorticoid or antibacterial drugs;~2. if the patient with AECB, he or she will be given with antibacterial drugs or anti-asthmatic drugs for asthma attacks."
224067694|NCT01480297|DRUG|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
224302826|NCT02992418|BIOLOGICAL|Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed|0.5 mL, intramuscularly (IM) at Month 1.
224302827|NCT02992418|BIOLOGICAL|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0.
224302828|NCT06213935|DRUG|Norepinephrine|after spinal anesthesia, norepinephrine will be injected intravenous as bolus at 0.05 μg/kg, followed by norepinephrine infusion at a rate of 0.05 μg/kg.min to prevent post spinal hypotension
223459179|NCT00256009|DRUG|Cytotec|
223459180|NCT01388712|DIETARY_SUPPLEMENT|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10\^8CFU).
223459181|NCT01388712|DIETARY_SUPPLEMENT|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
223459182|NCT03790865|DRUG|Livoletide|Daily subcutaneous injection
223459183|NCT03790865|DRUG|Placebo|Daily subcutaneous injection
223459184|NCT06047223|DIAGNOSTIC_TEST|Magnetic resonanace imaging|Magnetic resonance imaging for measurement of diffustion tensor imaging
223459185|NCT00443157|BIOLOGICAL|Meningococcal B Vaccine NZ|
223459186|NCT02118779|BEHAVIORAL|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
223459187|NCT05892250|BEHAVIORAL|Conventional physical therapy|Manual techniques and therapeutic exercise
223459188|NCT05892250|BEHAVIORAL|Conventional physical therapy + Dynamic Humeral Centering exercises|Manual techniques and therapeutic exercise and active dynamic humeral centering exercises
223459189|NCT02273362|DRUG|Erlotinib|Given PO
223459190|NCT02273362|DRUG|Erlotinib Hydrochloride|Given PO
223459191|NCT02273362|OTHER|Laboratory Biomarker Analysis|Correlative studies
223459192|NCT02273362|OTHER|Quality-of-Life Assessment|Ancillary studies
223459193|NCT01719991|OTHER|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
223459194|NCT04540328|OTHER|Non-surgical periodontal treatment|
223459195|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
223459196|NCT06428032|BEHAVIORAL|Hand-Arm Bimanual Intensive Therapy Including Lower Extremities|Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
223459197|NCT01973426|DEVICE|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
223459198|NCT05210439|DRUG|Short-treatment of any active antibiotic regimen|7 days of any active antibiotic treatment for BSI-PA
223459199|NCT05210439|DRUG|Long-treatment of any active antibiotic regimen|14 days of any active antibiotic treatment for BSI-PA
224067695|NCT06550154|OTHER|Data collection|Participants were identified by reviewing electronic medical records. Medical history information of thyroid disease and associated medication were collected in both groups, as well as a history of other comorbidities such as diabetes mellitus type 2, arterial hypertension, dyslipidemia, anxiety, and depression. Cases and controls were matched by age and sex.
224067696|NCT05297968|DRUG|Oseltamivir Phosphate For Oral Suspension/Tamiflu|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)
224067697|NCT05297968|DRUG|Oseltamivir Phosphate For Oral Suspension|the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
224302829|NCT06213935|DRUG|Midodrine|10 mg tablets of midodrine 1 hour before spinal anesthesia to prevent post spinal anesthesia hypotension
223459200|NCT02741375|DEVICE|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
223459201|NCT02954549|DIETARY_SUPPLEMENT|Vitamin D3|As in Arms
223459202|NCT02377232|BEHAVIORAL|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
223459203|NCT02377232|BEHAVIORAL|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
223459204|NCT01421992|DRUG|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
223459205|NCT01421992|DRUG|Placebo|one tablet placebo per day during 3 weeks
223459206|NCT02966821|DRUG|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
223459207|NCT03340467|DEVICE|CGM patch|Patient receives four CGM patches.
223459208|NCT00534638|BIOLOGICAL|Cervarix|Intramuscular injection, 3 doses
223459209|NCT00534638|BIOLOGICAL|Engerix-B|Intramuscular injection, 3 doses
223459210|NCT04918472|PROCEDURE|MCCE|Mangetically controlled capsule endoscopy will be performed
223459211|NCT05382013|DRUG|Avatrombopag|Patients will receive treatment of oral avatrombopag 20mg per day for the first 5 days
223574015|NCT03720665|COMBINATION_PRODUCT|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order \[transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)\]
223574016|NCT03112746|BEHAVIORAL|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
223574017|NCT06299982|DRUG|608 Q2W|608 160 mg at week 0 + 80 mg Q2W (5 cycles)
223574018|NCT06299982|DRUG|608 Q4W|608 160 mg Q4W (3 cycles)
223574019|NCT03556098|DRUG|glucose-dependent insulinotropic peptide|Infusion of GIP
224156307|NCT04360772|DIAGNOSTIC_TEST|mHLA-DR|"* Before treatment/ At inclusion/Day 0 : Collection of gender, date of birth, comorbidities, pathology implicating treatment by corticosteroids and other treatment administered at the time of inclusion.~* At Day 0, Month 1, Month 3, Month 6 : Blood sampling (3mL) to proceed to mHLA-DR measurement. At those time-points, results from lymphocytes immunophenotyping, C-reactive protein and numeration will be collected.~* At Month 24 : Collection from medical report of~* any infectious events that would have occured during the follow-up~* course of the disease with corticosteroids~* survival or death at 24 months of follow-up."
223743298|NCT06485063|OTHER|PLACEBO Myofascial Reorganization|it is light touch to the skin applied by the therapist, without provoking compression, or any constant or shear load during the fist minute. In the second minute, the participant adds active movements to the light touch. This two stage (each one during 1minute) is constructed to mimic the passive and the active stages of the real myofascial reorganization technique.
223743299|NCT05678829|OTHER|Education|The trainings for the Virtual Reality group will continue in accordance with the training titles according to the weeks, using virtual reality glasses.
224067698|NCT01334034|DRUG|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
224156308|NCT02791360|OTHER|Brain MRI|
223459212|NCT05382013|OTHER|Artificial Liver Support System|Patients will receive treatment of double plasma molecular adsorption system (DPMAS) and low volume plasma exchange (LPE) for three times. The volume of plasma adsorption in DPMAS is 5000\~6000 millilitre. The volume of fresh frozen plasma used in LPE is 1000 millilitre.
224067699|NCT01334034|DRUG|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
224067700|NCT01334034|DRUG|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
224067701|NCT05744999|PROCEDURE|Coconut technique|We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
224067702|NCT03640923|OTHER|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
224067703|NCT05321017|BEHAVIORAL|MEP Operant Up-conditioning of the Wrist Extensor|This is a training intervention in which the brain-spinal cord-muscle pathways are strengthened in individuals with incomplete spinal cord injury. Transcranial magnetic stimulation (TMS), a type of brain stimulation, will be used to elicit a muscle response from the wrist extensor (extensor carpi radialis), the muscle the bends the wrist back.
224067704|NCT03714945|OTHER|No intervention|No intervention is required as this study is observational.
224067705|NCT00488982|DRUG|Docetaxel|Docetaxel 75mg/m2 every 21 days
224156309|NCT04657354|PROCEDURE|Assessment|Early surgical assessment
224156310|NCT02666690|DEVICE|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
224156311|NCT02491827|OTHER|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
224156312|NCT03295591|DIAGNOSTIC_TEST|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
223459213|NCT05382013|OTHER|Comprehensive internal medical treatment.|Patients will receive comprehensive internal medical treatment.
223459214|NCT01672905|OTHER|laboratory biomarker analysis|
223459215|NCT02522793|OTHER|No intervention; this is an observational study|
223459216|NCT04993703|OTHER|Kinesiotaping|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, kinesiotaping and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.times per day 3sets of ten repetitions) will be applied.
223459217|NCT04993703|OTHER|Night Splinting|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound, night splinting and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
223459218|NCT04993703|OTHER|Control Group|A total of 20 sessions physiotherapy sessions including hot pack, ultrasound and exercise program (tendon and nerve gliding exercises=2 times per day 3 sets of ten repetitions) will be applied.
223459219|NCT04609449|PROCEDURE|Long biliopancreatic limb Roux-en-Y gastric bypass.|Long biliopancreatic limb Roux-en-Y gastric bypass.
223459220|NCT04609449|PROCEDURE|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass
223459221|NCT03067259|OTHER|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
223459222|NCT02898636|OTHER|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
224156313|NCT02738580|DRUG|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
224156314|NCT02738580|DRUG|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
224156315|NCT00708747|DRUG|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
223459223|NCT05198856|DRUG|Thalidomide Combined With Chemotherapy and Monotherapy|"Combined period：chemotherapy + T ：Thalidomide tablets: 100mg/d~Maintenance period: 100 mg/d, qn, orally. Sustained to disease progression or intolerable adverse reactions."
223459224|NCT06842576|BEHAVIORAL|Health Education Videos|Participants will be prompted to explore the 7 health education videos for up to 20 minutes.
223459225|NCT06842576|BEHAVIORAL|GotTransition.org Website|Participants will be prompted to explore the Gottransition.org website for up to 20 minutes
224156316|NCT00708747|DRUG|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
224156317|NCT00996593|BIOLOGICAL|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
224156318|NCT05663476|OTHER|Non Surgical Periodontal Therapy|Scaling and root planing using scalers and periodontal curettes will be done
224156319|NCT03736811|DEVICE|Polyglactin 910 or polydioxanone|Vicryl or PDS II
224156320|NCT03736811|DEVICE|Polyester or polypropylene|Ethibond Excel or prolene
224156321|NCT03044080|DRUG|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
224302830|NCT05979649|BEHAVIORAL|behavioral corrective tasks|"After each personalized conversation, the interveners will, based on a clear understanding of the participants' completion status and personal experiences with the previous behavioral corrective tasks, assist in formulating future behavioral corrective tasks for the next two weeks. These tasks will be selected from our designated To Do List, requiring at least one task from each category: social support, coping strategies, and emotional intelligence."
223459226|NCT06613308|DRUG|Neoadjuvant immunotherapy combined with chemotherapy|The treatment regimen consisted of a PD-1/PD-L1 monoclonal antibody in combination with a platinum-containing two-agent standard chemotherapy regimen administered every three weeks. Following two to four cycles of therapy, patients who demonstrated no evidence of disease progression were eligible for surgical resection, which was performed within three to four weeks after the conclusion of the last neoadjuvant therapy. Consolidation with a PD-1/PD-L1 monoclonal antibody was initiated within three to eight weeks after surgery and continued every three weeks. The efficacy of the treatment was evaluated according to the irRECIST criteria. Chemotherapy regimens were selected based on tumour histology and investigator judgement. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments.
223574020|NCT03556098|DRUG|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP\[3-30\]
223574021|NCT03556098|DRUG|Saline Solution|Infusion of Saline
224067706|NCT00488982|DRUG|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
224067707|NCT02823977|DRUG|Ketamine|Blinded study drug administered to experimental arm
224067708|NCT02823977|DRUG|Dexmedetomidine|Open-label study drug administered to both arms
224067709|NCT02823977|DRUG|Normal saline|Blinded comparator administered to control arm
224067710|NCT06786520|DRUG|CAB LA|CAB LA injection will be administered
224067711|NCT06786520|DRUG|CAB ULA|CAB ULA injection will be administered
224067712|NCT00999414|DRUG|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
224156322|NCT03044080|DRUG|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
224156323|NCT04907162|DIAGNOSTIC_TEST|Beck depression inventory fast screen|Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.
224302831|NCT05979649|OTHER|Counselling on psychological knowledge|Counselling on psychological knowledge includes weekly personalized feeds, as well as the methods and techniques for coping with challenges provided by the interveners.during personalized conversations with the participants.
224302832|NCT05979649|OTHER|placebo-controlled study|"feel-good articles without professional psychological knowledge will be sent to the control group participants weekly."
224302833|NCT05979649|OTHER|Peer Interventionist Training|The training is a one-day course, encompassing a broad range of topics, including but not limited to counseling techniques and specialized medical psychology knowledge.
224302834|NCT02376543|DEVICE|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
224302835|NCT02376543|DEVICE|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
223459227|NCT06613308|DRUG|Neoadjuvant chemotherapy|"A platinum-containing two-agent standard chemotherapy regimen was administered every three weeks. Following a two-to-four-cycle therapy, if the patients were evaluated without progressive disease, patients undergo surgical resection within three to four weeks of the final neoadjuvant treatment. Postoperative adjuvant chemotherapy is then conducted in accordance with the recommended regimen outlined in the 2022 edition of the CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer. The efficacy of the treatment was evaluated in accordance with the RECIST 1.1 criteria.~The chemotherapy regimens were selected based on the tumor histology and the judgement of the investigators, in accordance with the standard clinical practice. In the event of poor tolerability, patients may switch between cisplatin or carboplatin treatments."
223459228|NCT01888952|DRUG|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
223574022|NCT01369082|DRUG|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
223574023|NCT04326244|DIAGNOSTIC_TEST|blood test|High-density lipoprotein- cholesterol, Low-density lipoprotein- cholesterol, Total cholesterol, Triglyceride, Leptin, Glucose AC, Hemoglobin A1C, Insulin
223574024|NCT04326244|DIAGNOSTIC_TEST|genetic test|FTO、MC4R、BDNF、PPARG、ADRB3、UCP1
223574025|NCT04326244|DIAGNOSTIC_TEST|Constitution in Chinese Medicine Questionnaire|Constitution in Chinese Medicine Questionnaire
224156324|NCT04907162|DIAGNOSTIC_TEST|German Pain Inventory|German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.
223459229|NCT01888952|DRUG|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
223459230|NCT07016100|BEHAVIORAL|Contingency management|See arm description
223459231|NCT07016100|BEHAVIORAL|Cognitive behavioral therapy/ treatment as usual|See arm description
223459232|NCT07016919|OTHER|early enteral nutrition|Oral nutrition started within 6hours after paediatric open appendectomy
223459233|NCT07016919|OTHER|Conventional enteral nutrition|Oral nutrition started within 24hours after paediatric open appendectomy
223459234|NCT04162795|DRUG|Loratadine (Claritin, BAY76-2211)|Chewable tablet, oral, single dose
223459235|NCT00552214|DEVICE|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
223459236|NCT04171362|OTHER|Connective Tissue Massage|Connective tissue massage (CTM) is a manipulative technique that facilitates the diagnosis and treatment of a wide range of pathologies. Observation and subsequent manipulation of the skin and subcutaneous tissues can have a beneficial effect upon tissues remote from the area of treatment.
223459237|NCT04171362|OTHER|Education|Education patients were informed about migraine triggers, migraine prevention and coping strategies and exercise options. The exercises were demonstrated by the physiotherapist
223574026|NCT04326244|DIAGNOSTIC_TEST|Epworth Sleepiness Scale|Epworth Sleepiness Scale
223574027|NCT04326244|DIAGNOSTIC_TEST|cephalometry|Evaluation of craniofacial morphology in OSA patients
224156325|NCT04907162|DIAGNOSTIC_TEST|Brief Pain Inventory|Validated questionnaire for pain.
224156326|NCT04907162|DIAGNOSTIC_TEST|Fatigue Severity and Disability Scale (FSS)|Validated questionnaire for perceived fatigue
224156327|NCT04907162|DIAGNOSTIC_TEST|Quick Motor Function Test|An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.
223459238|NCT01406184|OTHER|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
223459239|NCT03519113|BIOLOGICAL|GC1102 80,000 IU|recombinant human hepatitis B immunoglobulin
223459240|NCT03519113|BIOLOGICAL|GC1102 100,000 IU|recombinant human hepatitis B immunoglobulin
223574028|NCT04326244|DIAGNOSTIC_TEST|polysomnography|to evaluate Apnea-Hypopnea Index (AHI) for the severity of sleep apnea
223574029|NCT03761394|DEVICE|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
223574030|NCT03761394|DEVICE|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
223574031|NCT03761394|DEVICE|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
223574032|NCT04069377|DEVICE|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
223574033|NCT04069377|OTHER|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
223574034|NCT02636244|DRUG|SHAPE Gel|
223574035|NCT00174174|DRUG|Modafinil|
223574036|NCT00823992|DRUG|placebo|sc once weekly
223574037|NCT00823992|DRUG|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
223574038|NCT02567682|DRUG|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
223574039|NCT02147223|DIETARY_SUPPLEMENT|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
223574040|NCT02147223|DIETARY_SUPPLEMENT|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
223574041|NCT00005764|DRUG|Lamivudine/Zidovudine|
223574042|NCT00005764|DRUG|Abacavir sulfate|
223574043|NCT00005764|DRUG|Lamivudine|
223459241|NCT03519113|BIOLOGICAL|I.V HBIG|human anti-hepatitis B Immunoglobulin
223459242|NCT05962827|DIAGNOSTIC_TEST|lipoprotein (a)|dosage of lipoprotein (a)
223459243|NCT05080725|OTHER|TelePEPP intervention|TelePEPP sessions will be conducted twice per week by a Speech Language Pathologist and/or graduate student clinician, on the study team. This clinician will deliver the intervention from the NYU Voice Center using the web conferencing software Webex (institutional license) on a Dell desktop computer with a 3.1 GHz intel core processor and high definition camera. Each exercise set will include 40 repetitions (10 reps of effortful swallows, tongue hold swallows, effortful pitch glides and maximal posterior tongue presses). All exercises are widely-adopted by clinicians as standard of care exercises. The number of sets will be gradually increased as tolerance builds \[2 sets in week 1, 3 sets in week 2, 4 sets in weeks 3+\].
223459244|NCT02870764|DRUG|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
223459245|NCT02870764|DRUG|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
223459246|NCT02870764|OTHER|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
223574044|NCT05357664|DEVICE|Total Hip Arthroplasty|Pinnacle acetabular shells used with PINNACLE DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
223574045|NCT05357664|DEVICE|Revision Total Hip Arthroplasty|Pinnacle acetabular shells used with Pinnacle DM Metal liner and BIMENTUM ALTRX PE liner with DePuy metal or ceramic heads and DePuy femoral prostheses
224156328|NCT04907162|DIAGNOSTIC_TEST|Handheld Dynamometry (HHD)|To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.
223574046|NCT01724567|OTHER|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
223574047|NCT01724567|OTHER|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
223574048|NCT03000504|DEVICE|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
223574049|NCT03328169|BEHAVIORAL|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
223574050|NCT03328169|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
223574051|NCT04517786|DEVICE|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
223574052|NCT03424369|PROCEDURE|Tympanoplasty|Tympanoplasty
223574053|NCT00793429|DRUG|Prucalopride|
223574054|NCT00793429|OTHER|Placebo|
224156329|NCT04907162|DIAGNOSTIC_TEST|Six-minute walk test (6MWT)|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
224156330|NCT04907162|DIAGNOSTIC_TEST|Pressure pain threshold|"For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of burning, stinging, drilling or aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles."
224302836|NCT01454908|DEVICE|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
224302837|NCT01830205|DRUG|Daclatasvir|
224302838|NCT03915353|OTHER|No Intervention|No Intervention
223574055|NCT00975104|DRUG|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
223574056|NCT00975104|DRUG|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
223574057|NCT00975104|DRUG|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
223574058|NCT00975104|DRUG|Placebo|Placebo IV QW
223459247|NCT01899105|DRUG|lumacaftor|
223459248|NCT01899105|DRUG|ivacaftor|
223459249|NCT02107950|BIOLOGICAL|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
223459250|NCT02107950|DRUG|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
223459251|NCT06023862|DRUG|Dostarlimab|Intravenous (IV) infusion
223459252|NCT06023862|DRUG|Bevacizumab|Intravenous (IV) infusion
223459253|NCT06023862|DRUG|Doxorubicin|Intravenous (IV) infusion
223459254|NCT06023862|DRUG|Gemcitabine|Intravenous (IV) infusion
223459255|NCT06023862|DRUG|Paclitaxel|Intravenous (IV) infusion
223459256|NCT06023862|DRUG|Pegylated liposomal doxorubicin|Intravenous (IV) infusion
223459257|NCT06956001|DRUG|Firmonertinib Mesilate Tablets|Usage and dosage: oral, 240mg, QD。 Medication duration: 21 days as a cycle, until intolerable toxicity, loss of clinical benefit, disease progression (confirmed by BICR), death or other anti-tumor treatment (whichever occurs first).
223574059|NCT01080768|DRUG|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
223574060|NCT01080768|DRUG|Amlodipine|Amlodipine 5 mg/day.
223459258|NCT06956001|DRUG|Pemetrexed Disodium for Injection|Usage and dosage: 500mg/m2, intravenous infusion. Medication duration: 21 days as a cycle, D1 administration, until the occurrence of intolerable toxicity, loss of clinical benefit, disease progression (confirmed by BICR), death or other anti-tumor treatment (whichever occurs first).
223459259|NCT06956001|DRUG|Cisplatin for injection|Usage and dosage: 75 mg/m2, i.v. Medication duration: 21 days as a cycle, D1 administration, up to 4 cycles.
223459260|NCT06956001|DRUG|Carboplatin Injection|"Usage and dosage: give the drug according to AUC 5 mg/ml, intravenous drip.~Medication duration: 21 days as a cycle, D1 administration, up to 4 cycles."
223459261|NCT01060423|DRUG|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
223574061|NCT01080768|DRUG|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
223574062|NCT01080768|DRUG|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
223574063|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-active|Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
223574064|NCT05774223|DEVICE|Transcranial magnetic stimulation (TMS)-sham|Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
223574065|NCT03832114|DRUG|LNP023|Increasing doses of LNP023 up to 200 mg.
223574066|NCT02984150|DIETARY_SUPPLEMENT|dodecanoic acid|
223574067|NCT02984150|DIETARY_SUPPLEMENT|saline|
224156331|NCT04907162|DIAGNOSTIC_TEST|Myotonometer Assessment|Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.
224156332|NCT04907162|DIAGNOSTIC_TEST|Vital signs|Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).
223459262|NCT01060423|DRUG|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
223459263|NCT01060423|DEVICE|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
223459264|NCT05750563|DIETARY_SUPPLEMENT|diosmin and micronized flavonoids|the symptomatic treatment of haemorrhoids
223459265|NCT05750563|OTHER|Placebo|Use as comparator
223459266|NCT05259163|DEVICE|LFR-260 portable phoropter|Portable unit to evaluate visual refractive state of the patient
223459267|NCT05259163|DEVICE|Traditional phoropter (SOC)|Standard unit for evaluating visual refractive state of the patient
223459268|NCT06134661|DEVICE|cTBS (continuous Theta Burst Stimulation)|"Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 1500 pulses per session."
223574068|NCT04911244|DIAGNOSTIC_TEST|bronchoalveolar lavage|endobronchial sampling through bronchoscopy
223574069|NCT00338273|DRUG|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
223574070|NCT00338273|DRUG|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
223574071|NCT05628506|DRUG|Potassium iodide|Patients will receive a single oral administration of a pharmacological dose (97.5 mg) of potassium iodide 20±4 hours before surgery.
223574072|NCT00521391|OTHER|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
224067713|NCT04711707|OTHER|Community navigator|All patients who consent to participate in the study will complete a pediatric social history tool to identify social needs. The intervention group will receive support through a community navigator to guide and understand appropriate services for their specific needs. This arm will receive guidance and bimonthly check-ins.
224067714|NCT04711707|OTHER|Self-Navigation|The control group will receive an electronic or paper copy of community resources that address the identified social needs.
224067715|NCT04141709|RADIATION|local ablative radiotherapy|"Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~* Scheme A 3\*10 Gy (once a day, 2-3 days a week)~* Scheme B 25\*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3\*10 Gy or 25\*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons."
224067716|NCT04788355|DRUG|Control group (standard hospital treatment)|Medications defined by the hospital involved in the study
224067717|NCT04788355|DRUG|Group Hydroxychloroquine|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.
223459269|NCT05998759|BIOLOGICAL|Telitacicept|subcutaneous telitacicept 160 mg weekly for 24 weeks.
223459270|NCT05998759|DRUG|Placebo|subcutaneous placebo weekly for 24 weeks.
223574073|NCT05804513|DRUG|Placebo|s/c injection
223574074|NCT05804513|DRUG|Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector|s/c injection
223574075|NCT04199273|PROCEDURE|Magnetic stimulation|Cervical bilateral phrenic nerve stimulation with the MagStim 200 tool.
223459271|NCT03031340|DRUG|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
223459272|NCT03031340|OTHER|placebo|placebo
223459273|NCT05133115|BEHAVIORAL|Fostering Resilience in Adolescents at Risk|"The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual \& Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support."
223459274|NCT04956211|PROCEDURE|Periodontal therapy|Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
223574076|NCT04199273|PROCEDURE|Electric stimulation|Cervical bilateral phrenic nerve stimulation after ultrasonography nerve tracking and targeted electric stimulation with a nerve stimulator usually used for neuromuscular transmission monitoring (TOFScan, Drager)
223574077|NCT03473106|DEVICE|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
223574078|NCT03394599|DEVICE|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
223574079|NCT03394599|DEVICE|TheraTrainer Only|TheraTrainer will be used.
223574080|NCT00165750|DRUG|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
223574081|NCT01218451|BIOLOGICAL|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
223574082|NCT01218451|BIOLOGICAL|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
223574083|NCT01218451|BIOLOGICAL|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
223574084|NCT00931723|DRUG|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
223574085|NCT00931723|DRUG|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
223574086|NCT00931723|DRUG|Placebo|Oral treatment twice daily.
223574087|NCT04274153|BIOLOGICAL|Gardasil9|Two doses of the HPV vaccine across a 12 month period (two doses of 0.5mL).
223574088|NCT02115750|DRUG|Etanercept|Head-to-head comparison
224302839|NCT03246126|DEVICE|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
223574089|NCT02115750|DRUG|CHS-0214|
223574090|NCT01643850|DRUG|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
223574091|NCT01643850|DRUG|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
223574092|NCT00881153|DRUG|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
223574093|NCT00881153|DRUG|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
223574094|NCT03054350|DRUG|Vadadustat|Daily oral dose
223574095|NCT03054350|DRUG|Placebo|Daily oral dose
223574096|NCT04627623|DIAGNOSTIC_TEST|IgM and IgG antibodies assay|5 ml venous blood sample collection to assay IgM and IgM against COVID19
223574097|NCT05391425|OTHER|no intervention|no intervention planned, since it is an observational study
223574098|NCT05850910|OTHER|Supine practice group|The practitioner's arm was placed in the mid-thoracic region from the opposite side of the individual's torso in the form of a half fist. In this position, the SPs coincide with the space in the middle of the half fist, while the TPs coincide with the fingertips and the thenar region. With the practitioner's other hand supporting the patient's elbows, a high-speed-low-amplitude thrust is applied from front to back.
223574099|NCT05850910|OTHER|Prone application group|the practitioner positions the hypothenar part of his hands above the TPs in the mid-thoracic segment. From this point, a high-velocity-low-amplitude thrust is applied from the back to the front.
223574100|NCT01858805|PROCEDURE|esophagectomy|
223574101|NCT00769925|BEHAVIORAL|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
223574102|NCT00769925|BEHAVIORAL|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
223574103|NCT06178536|PROCEDURE|Bone Consumption|The surgery will be done using a bone consumption protocol
223574104|NCT06178536|PROCEDURE|Bone expansion|implants will be placed after a bone expansion protocol
223574105|NCT01133405|DRUG|LY2886721|Oral capsules
223574106|NCT01133405|DRUG|Placebo|Oral capsules
223574107|NCT03351816|PROCEDURE|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
223574108|NCT03351816|PROCEDURE|Cardioversion|External electric shock delivery under general anesthesia.
223574109|NCT04960878|DIETARY_SUPPLEMENT|Synbiotic|Synbiotics sachet mainly contained Lactobacillus rhamnosus HN001, Bifidobacterium lactis HN019, and fructooligosaccharides.
223574110|NCT04960878|DIETARY_SUPPLEMENT|Placebo|Maltodextrin
223574111|NCT05675267|OTHER|data collection|HEART score calculation
223574112|NCT02673567|DRUG|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
223574113|NCT02673567|DRUG|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
224156333|NCT04907162|DIAGNOSTIC_TEST|Borg Scale|the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).
224156334|NCT02995473|DRUG|NP000888|270 µg/g topical (BID) for 24 weeks
224156335|NCT02995473|DRUG|Vehicle|Topical (BID) for 24 weeks
224156336|NCT03483831|BEHAVIORAL|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
224156337|NCT05362331|OTHER|Web Application|Internet based application
224156338|NCT03195504|DEVICE|HFNC|High flow nasal oxygen (60 l) under GA
224156339|NCT03195504|DEVICE|CON (control)|Standard oxygen (10-15 l) under GA
224156340|NCT03039933|BEHAVIORAL|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
224156341|NCT03039933|OTHER|Treatment As Usual|Treatment As Usual
224156342|NCT01125878|DIETARY_SUPPLEMENT|Placebo|placebo
224156343|NCT01125878|DIETARY_SUPPLEMENT|Starch composite B|fiber mixture
223459275|NCT04808583|PROCEDURE|TLH with uterine artery ligation at its origin at the beginning of the operation|After insertion of the ports and surveying the abdomen as in the conventional method a window will be created in the broad ligament to enter the retroperitoneal space with exposure of the iliac vessel and identification of the internal iliac artery and its anterior branch which give rise to the uterine artery. Blunt dissection continues with identification of the paravesical and the pararectal spaces. The ureter is identified medially and the uterine artery laterally and dissection of the ureter away from the uterine artery will be done, followed by sealing the uterine artery 2 mm from its origin from the anterior branch of internal iliac artery
223459276|NCT04808583|PROCEDURE|conventional TLH with uterine artery ligation after the cornual pedicles|"Coagulation and section of round ligaments will be performed about 2 to 3 cm from the pelvic wall using blunt tip laparoscopic sealer LigaSure COVIDIEN (5mm-37cm) with average of sealing cycle of 2 to 4 seconds and 40 watts , followed by opening the anterior leaflet of the broad ligament to the vesico-uterine peritoneal reflection, coagulation and section of the infundibulo-pelvic ligament (total hysterectomy with bilateral adnexectomy) or of the uteroovarian ligament and the fallopian tubes (total hysterectomy). Then opening the posterior leaflet of the broad ligament to the cervix, opening of the vesico-vaginal space and dissecting the bladder downwards will be done (Poojari et al., 2014).~Coagulation and section of the uterine pedicles: performed on the ascending segment of the uterine artery, will be carried out in a progressive manner on both sides."
223459277|NCT02944175|DRUG|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
223574114|NCT02673567|DRUG|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
223574115|NCT02673567|DRUG|Placebo|Matching Placebo
223574116|NCT03109808|OTHER|e-health strategy|"* First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~* Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
223574117|NCT03109808|OTHER|Traditional Oral Hygiene Education|traditional oral hygiene education
224156344|NCT01125878|DIETARY_SUPPLEMENT|Starch composite C|fiber mixture
224156345|NCT01125878|DIETARY_SUPPLEMENT|Starch composite D|fiber mixture
224156346|NCT02950012|DIETARY_SUPPLEMENT|OPTI-BIOME™ Bacillus subtilis MB40|
224156347|NCT02950012|OTHER|Placebo|
224156348|NCT03920865|DRUG|Risdiplam|5 milligram (mg) oral dose administered in fasted state
224156349|NCT02810951|GENETIC|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.
224156350|NCT02878629|DEVICE|Mandibular Advancement Devices|
224156351|NCT05550896|DIAGNOSTIC_TEST|Echocardiogaphy|Assessment of high velocity low amplitude signals on Doppler echocardiography
224156352|NCT00030355|DRUG|homoharringtonine|
224156353|NCT00030355|PROCEDURE|chemotherapy|
224156354|NCT03240718|PROCEDURE|Laser treatment|CORE fractional CO2 laser treatment
224156355|NCT05438810|DRUG|FCN-437c,Fulvestrant,Goserelin acetate|FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
224156356|NCT05438810|DRUG|Placebo,Fulvestrant,Goserelin acetate|Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
224156357|NCT01928082|DRUG|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
224156358|NCT05560178|OTHER|SEXUAL HEALTH EDUCATION|Women in the intervention group will be given sexual health education once a week for 4 weeks
224156359|NCT05226897|DRUG|YYC405-T|Subjects take the investigational products once a day for 24 weeks.
224156360|NCT05226897|DRUG|Metformin≥1000mg|Subjects take the investigational products once a day for 24 weeks.
223574118|NCT05768438|OTHER|Mulligan with upper limb movement|Group A subjects will receive mulligan mobilizations with upper limb movement of the involved side. The patient will be in a sitting position and the therapist will stand beside the patient. The therapist will place one thumb overlapped by the other on one of the selected cervical and then the therapist will push down the spinous process of that specific vertebrae, the pressure will be sustained and the patient will actively abduct his/her arm, assistance will be provided if needed. Initially it will start from 10 repetitions and 1 set which will further progress up to 2 or 3 sets as per patient's tolerance with 60 seconds rest in between each set.
224302840|NCT01996618|DRUG|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
223574119|NCT05768438|OTHER|McKenzie exercises with neural mobilizations|The subjects of Group B will receive McKenzie exercises. Initially, it will start with retraction exercises. The frequency of exercises will be 10 to 15 repetitions followed by three to four sets with one second hold. On the second or third day, the cervical extension will be added. While in the second week the same set of exercises will be administered with the patient in a sitting position combined with application of over pressure at the end range by therapist. In the third week, extension and retraction exercises will be performed along with traction which will be applied by the therapist. Finally, in the fourth week all retraction and lateral flexion then neck rotation and the last one retraction with neck flexion will be added. Neural mobilizations will be given to patients in group B in supine lying. From proximal to distal, 20 oscillations (1 oscillation/ 1 second)
223574120|NCT04971538|DIAGNOSTIC_TEST|OraQuick® HCV Self-Test|The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
223574121|NCT02995083|DRUG|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
223574122|NCT02995083|DRUG|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
223574123|NCT02995083|DRUG|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
223574124|NCT04911400|OTHER|Upper-lower clear plastic retainers + Class III elastics|Addition of Class III elastics to clear plastic retainers
223574125|NCT04911400|OTHER|Upper-lower clear plastic retainers|Upper-lower clear plastic retainers
224302841|NCT05943808|OTHER|Book reading|subjects are given an acupuncture textbook to read for 30 minutes
223574126|NCT03242772|DRUG|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward and may be decreased or stopped at any time.
223574127|NCT03242772|BEHAVIORAL|ESDM informed parent coaching|All participants will receive 8 weekly parent child therapy sessions will be delivered by a therapist trained in parent coaching and ESDM principles and strategies and utilizing a therapy manual,(includes coaching for behavior management and handouts).
223574128|NCT03242772|DRUG|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 11 weeks . The tablets will be titrated in the same way as the active drug and may be stopped at any time.
224067718|NCT04788355|DRUG|Group Hydroxychloroquine and apixaban|Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
224067719|NCT04788355|DRUG|Group Apixaban|Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.
224067720|NCT04457427|DEVICE|NeuRx Diaphragm Pacing System (DPS)|4 electrodes are implanted into the diaphragm, 2 on each side, during the tracheostomy procedure. The electrodes are connected to the NeuRx external stimulator which will be used to stimulate and monitor diaphragm activity.
224067721|NCT05291494|BEHAVIORAL|follow the WeChat public platform to watch the education videos|In addition to the regular preoperative visits, the WeChat education group will watch science videos through WeChat before the surgical procedures.
224067722|NCT05291494|BEHAVIORAL|regular preoperative visits and education by ward nurses.|received oral instruction from the ward nurse covering the same contents as above instead of the education video.
224067723|NCT03232476|DEVICE|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
224067724|NCT04682080|BEHAVIORAL|Needle-free injection|"This study was performed among children aged 4-10 years who required dental treatment and were treated at the Department of Pedodontics, Faculty of Dentistry, Gaziosmanpasa University. A total of 120 patients were evaluated in accordance with the exclusion criteria and 94 children (39 girls and 55 boys) were included in this study. Children who needed dental treatment were randomly divided into two groups. All dental injections were administered by the same operator (MB), a pediatric dentist with two years of experience in using the Comfort-In system.~In both groups, the children were asked to rate their pain intensity by choosing the closest statement on the colorful Wong-Baker Pain Scale at four time points: immediately after injection (Pain 1), during treatment (Pain 2), at the end of the treatment (Pain 3) and postoperative first day.Anxiety levels were recorded using the Modified Children's Dental Anxiety Scale face version"
224067725|NCT00003338|PROCEDURE|immunoscintigraphy|
224067726|NCT00003338|RADIATION|technetium Tc 99m epratuzumab|
224067727|NCT06187376|DRUG|Chinese Herbal Medicine (CHM) supplement|Dropper of tincture by mouth for 12 weeks.
223459278|NCT02944175|DRUG|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
223459279|NCT03526042|DRUG|Losartan|Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
223459280|NCT03526042|DRUG|Enalapril|Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
223459281|NCT03574623|DEVICE|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
223459282|NCT03574623|BEHAVIORAL|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
223459283|NCT06725277|DRUG|Spravato|Intranasal esketamine
223459284|NCT06725277|DRUG|IV Ketamine|IV ketamine
223574129|NCT02053207|BEHAVIORAL|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
223574130|NCT06357091|PROCEDURE|ACL reconstruction with Shark Screw ACL®|ACL reconstruction with the Shark Screw ACL®, Investigation of tunnel widening
223574131|NCT06357091|PROCEDURE|ACL reconstruction with biocomposite screw (Mecta)|ACL reconstruction with biocomposite screw (Mecta), Investigation of tunnel widening
223574132|NCT01638208|DRUG|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
224156361|NCT05226897|DRUG|Dapagliflozin 10mg|Subjects take the investigational products once a day for 24 weeks.
223459285|NCT01517308|DRUG|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
223459286|NCT06259214|OTHER|15% HCl gel|Icon , DMG, Hamburg, Germany
223459287|NCT06259214|OTHER|H3PO4 gel|Scotchbond Etchant, 3M ESPE, St. Paul, MN, USA
223459288|NCT06259214|OTHER|Er:YAG laser|Fotona AT Fidelis III, Ljubljana, Slovenia
223459289|NCT01381926|DRUG|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
223459290|NCT01381926|DRUG|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
224156362|NCT05226897|DRUG|YYC405-T placebo|Microcrystalline cellulose, Subjects take the investigational products once a day for 24 weeks.
224156363|NCT04893928|OTHER|QUECOMIICAT survey|IBD-related knowledge. It will be assessed using the recently validated QUECOMIICAT (Qüestionari Coneixements Malaltia Inflamatòria Intestinal Catalunya) questionnaire (27) originally developed in Spanish. Compared with the most well-known CCKNOW (Eaden JA et al in 1999)(28), it incorporates IBD updated data (29).
224156364|NCT04893928|OTHER|Self-Efficacy for Appropriate Medication Use Scale|Treatment adherence and compliance. It will be assessed using the Self-Efficacy for Appropriate Medication Use Scale (SEAMS), a 13-item self-administered scale previously translated into Spanish and validated by Bozada-Gutiérrez K et al on a Mexican population (3). According to 13 situations asked by the items, patients stratify the level of confidence about correctly taking their medications: 1, not at all confident; 2, somewhat confident; 3, very confident. The sum of results ranges from 13 to 39 points, where higher scores indicate optimal self-efficacy for taking the pharmacological treatment.
224156365|NCT04893928|OTHER|ICTs preferences and barriers survey|"Information and communication technologies (ICTs) preferences and barriers. It will be assessed using an ad-hoc inventory designed by the authorship. It has 45 questions mainly answered through a 5-points Likert scale. This inventory was inspired by the surveys used by Mauer M et al on an international population with urticaria (11), and those used by Reich J et al (30) and Chowdhary TS et al (31) on American patients with IBD. Survey approaches aspects related to:~* Frequency of use of ten different ICTs for personal purposes;~* Frequency of use of ten different ICTs for IBD-related purposes;~* A free question about others ICTs that the patient uses for IBD-related purposes;~* Eight specific IBD-related purposes ICTs are used to;~* Assessment of ICTs for eight IBD-related purposes;~* Eight Features an IBD-related App must comprehend."
224302842|NCT05943808|OTHER|VR pre-recorded video watching|subjects are given an pre-recorded VR video to watch for 30 minutes
224302843|NCT05073952|PROCEDURE|Connective tissue graft|Implants will be placed with a flap and a connective tissue graft.
224302844|NCT05073952|PROCEDURE|Flapless|Implants will be placed with a flapless approach
223459291|NCT02437994|BEHAVIORAL|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
223459292|NCT04585490|DRUG|Durvalumab|Cohort 1 (1500 mg IV every 21 days, for 1 year), •Cohort 2 (10mg/kg every 2 weeks for 1 year)
223459293|NCT04585490|DRUG|Carboplatin|Target area under the curve (AUC) not to exceed 750mg on Day 1 of every 21-day cycle
223574133|NCT00043017|PROCEDURE|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
223574134|NCT00043017|RADIATION|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
223459294|NCT04585490|DRUG|Pemetrexed|500mg/m2 on Day 1 of every 21-day cycle
223459295|NCT04585490|DRUG|Paclitaxel|175mg/m2 on Day 1 of every 21-day cycle
223459296|NCT04585490|DRUG|Cisplatin|Cisplatin (75mg/m2 per institution guidelines) may be substituted for Carboplatin
224302845|NCT06189547|OTHER|different prior cancer history type|different types of prior cancer history
223459297|NCT04585490|DEVICE|AVENIO ctDNA Surveillance Kit|Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)
223459298|NCT04585490|DRUG|Tremelimumab|not to exceed 75mg IV on Day 1 of every 21-day cycle
223459299|NCT06262633|DEVICE|Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation|Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.
223459300|NCT03060369|DEVICE|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
223459301|NCT03734523|COMBINATION_PRODUCT|Flourish Vaginal Care System|This is not technically an intervention. All women who enroll in the study will be those who have opted to use the Flourish Vaginal Care System. This system is comprised of a vaginal wash (Balance), an intravaginal moisturizing gel (Restore), and a vaginal probiotic supplement (BiopHresh). Balance will be used daily. Restore will be used every other day. BiopHresh will be used twice a week with Restore. All products will be started after the first visit and continue throughout the 6-month study.
223459302|NCT00826410|DEVICE|Redon drain|subcutaneous suction drain after laparotomy for two days
223459303|NCT05820243|OTHER|Moderate Intensity Aerobic Exercise|Participants will complete 1 hour of exercise on a cycle ergometer at the power output that elicits 60% of their peak rate of oxygen consumption (V02peak).
223459304|NCT01932749|DEVICE|Transcranial Magnetic stimulation|
223459305|NCT02953015|BEHAVIORAL|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
223459306|NCT02953015|DEVICE|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
223459307|NCT02953015|DRUG|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
223459308|NCT02090686|DEVICE|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
223459309|NCT02090686|DEVICE|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
223574135|NCT01375868|BIOLOGICAL|Silgard|vaccination with tetravalent antiviral vaccine
223574136|NCT00089986|DRUG|Intravenous GR270773- Phospholipid Emulsion|
223574137|NCT00089986|OTHER|Placebo|
223574138|NCT00522314|DEVICE|NIV and ACBT|
223574139|NCT00522314|OTHER|Active Cycle of Breathing Techniques|
223574140|NCT01613989|PROCEDURE|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
224067728|NCT06187376|DRUG|Placebo|Matching placebo tincture.
224067729|NCT03393273|DRUG|Elotuzumab|"* Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~* melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~* Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
224067730|NCT00923390|GENETIC|2G-1 TCR Retroviral Vector-Transduced lyn|
224302846|NCT03982979|DEVICE|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
224067731|NCT00923390|DRUG|Aldesleukin|
224067732|NCT00923390|DRUG|Cyclophosphamide|
224067733|NCT00923390|DRUG|Fludarabine|
224067734|NCT00923390|DRUG|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
224067735|NCT01068171|OTHER|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
224067736|NCT01068171|OTHER|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
224067737|NCT00006130|PROCEDURE|Core decompression|
224067738|NCT05972811|OTHER|Cold application|In the experimental group, cold application will be made until the skin temperature of the drain exit area reaches 13.6 °C. And before drain removal, immediately after drain removal and 15 minutes later, pain levels will be measured with VAS and analgesic needs will be questioned
224067739|NCT05362409|DRUG|5 Aminolevulinic Acid|5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks
224067740|NCT05362409|DEVICE|CV01-delivered ultrasound|CV01-delivered ultrasound every 4 weeks
224067741|NCT03102905|OTHER|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
223459310|NCT02800005|DEVICE|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
223459311|NCT02800005|OTHER|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
223459312|NCT03726073|DEVICE|Transcutaneous acupoint electrical acupoint stimulation(TEAS) and auricular acupressure|Bilaterally Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) will be used as the TEAS acupoints. Six acupoints (Shenmen, Point Zero, subcortex, heart, liver, and endocrine) located on ears will be used as the auricular acupressure points.
223459313|NCT03726073|OTHER|Usual care|Patients in this group only receive usual care developed by the study hospital
223459314|NCT06380205|DRUG|Povorcitinib|Povorcitinib will be administered at protocol defined dose.
223459315|NCT06380205|DRUG|Levonorgestrel/Ethinyl estradiol|Levonorgestrel/Ethinyl estradiol will be administered at protocol defined dose.
223459316|NCT00058071|DRUG|amifostine trihydrate|
223459317|NCT00417157|DRUG|recombinant FSH (Puregon, Organon, The Netherlands)|
223574141|NCT01613989|PROCEDURE|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
223574142|NCT02088593|DEVICE|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
223574143|NCT02088593|BEHAVIORAL|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
223574144|NCT03207178|BIOLOGICAL|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
223574145|NCT02199951|DRUG|Dihydroartemisinin and piperaquine|Antimalarial
223574146|NCT03683654|OTHER|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
223574147|NCT01151111|BEHAVIORAL|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
223574148|NCT04695054|DEVICE|Buzzy device plus EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure; the Buzzy device will be used during the procedure
224156366|NCT04893928|OTHER|Focus group and IBD mobile App for health support (MAHS) development and validation|In stage II, a qualitative study will be performed using focus group discussion to explore the experiences and perceptions of patients with IBD using ICTs for health support in different contexts. Focus groups will be established following the Krueger and Casey guidelines (32). Collected data will address the development of an IBD MASH. The developed IBD MASH will be validated on a randomised pilot study along stage III. Methodology and ethical aspects of stage II and III will be defined in another proposal, after stage I preliminary findings.
224156367|NCT01679561|DRUG|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
224302847|NCT02468570|OTHER|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
224302848|NCT00005399|OTHER|No interventions|No interventions
224302849|NCT05644015|OTHER|escape room game|Escape room game is a live action team based game where players discover clues, solve puzzles and complete tasks in one or more rooms to accomplish a specific goal (usually by escaping the room) in limited time.
224302850|NCT00045188|DRUG|imatinib mesylate|Given PO
224302851|NCT00045188|OTHER|laboratory biomarker analysis|Optional correlative studies
223459318|NCT00417157|DRUG|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
223459319|NCT00417157|DRUG|hCG (Pregnyl, Organon, The Netherlands)|
223459320|NCT00610181|PROCEDURE|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
223574149|NCT04695054|DRUG|Only EMLA cream|EMLA cream will be applied 60 minutes before the needle procedure
223574150|NCT00529126|DRUG|SKY0402|SKY0402
223574151|NCT00529126|DRUG|Bupivacaine HCl|Bupivacaine HCl
223574152|NCT03995680|DRUG|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
223574153|NCT01906723|DEVICE|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
223574154|NCT01468610|DRUG|desvenlafaxine|50-100 mg daily for 8 weeks
223574155|NCT02281474|DRUG|Nilotinib|
223574156|NCT02334683|DEVICE|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
223574157|NCT02334683|DEVICE|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
223459321|NCT04334525|BEHAVIORAL|Choice architecture + repeated exposure|Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period.
223459328|NCT02624947|BIOLOGICAL|RSV F vaccine with adjuvant|
223459329|NCT02624947|BIOLOGICAL|Formulation buffer|
223459330|NCT02604537|DRUG|betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone
223459331|NCT02604537|DRUG|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
223459332|NCT03107182|DRUG|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
223459333|NCT03107182|DRUG|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
223459334|NCT03107182|DRUG|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
223459335|NCT03107182|DRUG|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
223459336|NCT03107182|DRUG|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
223459337|NCT03107182|DRUG|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
223459338|NCT03107182|DRUG|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
223459339|NCT03107182|DRUG|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
223459340|NCT03107182|DRUG|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
224067742|NCT01641614|PROCEDURE|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
224067743|NCT01641614|PROCEDURE|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
224067744|NCT03548558|BEHAVIORAL|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 8 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send a short message service (SMS) mobile phone reminder of the session's topic, time and location to all participants.
224067745|NCT03548558|BEHAVIORAL|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV.
224067746|NCT03548558|BEHAVIORAL|Booster sessions|After the end of the 16 biweekly sessions (phase 1), we will re-randomize across the 40 intervention villages, stratified by Arms 1 and 2, and half of each of Arm 1 and Arm 2 villages will receive group booster visits every other month for the period between end-line and follow-up surveys. This will constitute Phase 2 of the study.
224156368|NCT04208646|BIOLOGICAL|Mesenchymal progenitor cells|Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use
224156369|NCT04208646|BIOLOGICAL|No mesenchymal progenitor cells|No mesenchymal progenitor cells for intra- articular use
224156370|NCT02882737|DRUG|Glucagon before exercise|
224156371|NCT02882737|DRUG|Glucagon after exercise|
224156372|NCT02882737|DRUG|Glucagon after resting|
224156373|NCT03557515|BEHAVIORAL|Stress Management and CBT|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Cognitive Behavioral Therapy will focus on:~1. Intro to CBT-Tracking Automatic Thoughts~2. Identifying Distorted Thoughts~3. Challenging Distorted Thoughts~4. Core Beliefs/Relapse Prevention"
223459341|NCT03107182|DRUG|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
223459342|NCT03107182|PROCEDURE|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
223459343|NCT03107182|RADIATION|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
223574158|NCT06061289|DIETARY_SUPPLEMENT|SP Detox Program|The production use and disposal of toxic chemicals and synthetic materials have increased the risk of exposure to health-threatening toxins. Causal relationships between toxic chemicals and diseases have been well established. However, many patients endure chronic symptoms that are associated with exposure to toxins before advanced stages of specific diseases are realized. Thus, there is a great demand for noninvasive laboratory tests that can provide timely assessment of chemical exposure and the capability of hepatic detoxification
223574159|NCT03241823|DIAGNOSTIC_TEST|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
223574160|NCT03241823|DIAGNOSTIC_TEST|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
223574161|NCT03241823|DIAGNOSTIC_TEST|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
223574162|NCT03241823|DIAGNOSTIC_TEST|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
223574163|NCT01069263|OTHER|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
223574164|NCT01069263|DRUG|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
223574165|NCT01598337|DRUG|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
223574166|NCT01598337|DRUG|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
224302852|NCT00918840|BIOLOGICAL|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
223459344|NCT03107182|RADIATION|Chemoradiotherapy|"Patients who have low risk disease with \<50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and \<30% reduction of tumor, patients who have high risk disease and \<50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
223574167|NCT01598337|DRUG|Clopidogrel|75 mg orally started 6-8hours before surgery
223574168|NCT01598337|DRUG|Prasugrel|10 mg daily as per instructions of investigators
223574169|NCT00364572|DRUG|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
223574170|NCT00364572|DRUG|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
223574171|NCT01062841|BEHAVIORAL|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
223574172|NCT01023087|DRUG|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
223574173|NCT01023087|DRUG|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
223743300|NCT05384067|BEHAVIORAL|Mindfulness-based intervention|Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
223743301|NCT03280290|BIOLOGICAL|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
223743302|NCT06477614|BIOLOGICAL|DC cell Vaccine|Deliver DC cell vaccine into patients for anti-ancer therapy.
223743303|NCT05762146|DRUG|Riociguat|Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.
223743304|NCT05762146|DRUG|Propylthiouracil|Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors
223743305|NCT05762146|DRUG|Perphenazine|Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.
223459345|NCT05787860|DRUG|Ruxolitinib 1.5% Cream|topical ruxolitinib 1.5% cream twice daily for 4 weeks
223459346|NCT06785090|DRUG|Bromfenac|Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.
223459347|NCT06785090|DRUG|Moxifloxacin 0.5% ophthalmic solution|antibiotic, standard postoperative care regimen
223459348|NCT06785090|DRUG|Dexamethasone phosphate 0.1%|steroid, standard postoperative care regimen
223743306|NCT00827983|DRUG|Progesterone|25 mg, s.c., once à day
223459349|NCT04143659|BIOLOGICAL|levonorgestrel butanoate (LB) injection|"The initial formulation of the investigational product (IP) is LB Injectable Suspension at a concentration of 40 mg/2 mL (20 mg/mL). Each vial contains 2 mL at 20mg/mL for a total of 40 mg. This formulation will only be used for dosing groups A and B with the injections completed as 40 mg IM (2 mL) or 40 mg SQ (2 mL).~The second formulation of the investigational product (IP) is LB Injectable Suspension is a concentration of 140 mg/2 mL (70 mg/mL). Each vial contains 2 mL at 70 mg/mL for a total of 140 mg. This formulation will only be used for dosing groups B2, C, and D with the injections completed as 40 mg SQ (0.57 mL), 50 mg SQ (0.71 mL), and 60 mg SQ (0.86 mL)."
223459350|NCT02201589|DEVICE|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
223459351|NCT04416997|PROCEDURE|Blood and serum samples|The blood and serum samples will taken from RA patients
223459352|NCT01065558|DRUG|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
223459353|NCT01237288|DRUG|Z-521|
223459354|NCT06957977|PROCEDURE|Endoscopic Cryoballoon Ablation Treatment|ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice. PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions.
223459355|NCT06957977|DRUG|PD1 Inhibitor|The first administration of the PD-1 monoclonal antibody is initiated when patients achieve a partial response (PR) following standard treatment. Subsequent administrations are given every three weeks according to the prescribing information.
223459356|NCT00832988|OTHER|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
223459357|NCT06099730|DEVICE|Pulsed Field Ablation (PFA)|PFA using Irreversible Electroporation (IRE) Ablation System
223459358|NCT00203658|DRUG|Tinzaparin sodium|
223459359|NCT00858806|DRUG|Imatinib|"Intermittent Imatinib administration.~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
223459360|NCT01923675|OTHER|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
223459361|NCT01923675|OTHER|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
223459362|NCT01923675|OTHER|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
223459363|NCT01923675|OTHER|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
223459364|NCT01695005|DRUG|LY3039478|Administered orally
223459365|NCT01695005|DRUG|Prednisone|Administered orally
223459366|NCT03284034|DEVICE|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
223459367|NCT03284034|DRUG|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
223459368|NCT03612466|DRUG|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
223459369|NCT03612466|RADIATION|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
224067747|NCT03548558|BEHAVIORAL|Fathers invited|During phase 1's 16 biweekly sessions, in half of Arm 1 and Arm 2 villages (20 total), fathers will additionally be invited to attend the 16 sessions. Separate father-only sessions will be held for 4 of the 16 sessions. This randomization will end after phase 1.
224067748|NCT03431571|PROCEDURE|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
224067749|NCT04491656|OTHER|WALANT Technique|A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
224067750|NCT00413361|DRUG|versus hydroxychloroquine|versus hydroxychloroquine
224067751|NCT03868683|OTHER|Glucose Reference 1|30 g of glucose dissolved in 250 ml of water
224067752|NCT03868683|OTHER|Glucose Reference 2|30 g of glucose dissolved in 250 ml of water
224067753|NCT03868683|OTHER|Glucose reference 3|30 g of glucose dissolved in 250 ml of water
224067754|NCT03868683|OTHER|Sucrose|30 g of Sucrose dissolved in 250 ml of water
224067755|NCT03868683|OTHER|Regular Bake beans in tomato sauce|Bake beans in tomato sauce containing 14 g of sugar
224067756|NCT03868683|OTHER|Bake beans in tomato sauce, reduced sugar|Bake beans in tomato sauce containing 12.2 g of sugar
224067757|NCT03868683|OTHER|Bake beans in tomato sauce, low GI|Bake beans in tomato sauce containing 7.2 g of sugar
224067758|NCT05449678|BEHAVIORAL|Low-carb diet|A close nutritional follow-up will take place with a qualified nutritionist to adapt the participants' usual diet to their assignment diet. This is not a strict diet to follow or a ketogenic diet. Nutritional modifications will be based on the participants' usual diet to improve adherence (personalized follow-up).
224067759|NCT01789814|DRUG|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
224067760|NCT01789814|DRUG|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
224067761|NCT05526833|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
224067762|NCT01090401|DEVICE|Linox smart S DX|ICD lead
224067763|NCT03273166|DEVICE|INVSENSOR00001|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
223459370|NCT03612466|DRUG|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
223459371|NCT03612466|DRUG|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
223459372|NCT03612466|DRUG|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
223459373|NCT04206345|OTHER|exercise with blood flow restriction|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
223459374|NCT04206345|OTHER|exercise|Elbow bending exercises
223459375|NCT03783117|DEVICE|Magnetic field treatment|The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
223459376|NCT02675764|OTHER|Vibration|peripheral vibration at the wrist skin at an imperceptible level
223459377|NCT02675764|OTHER|Placebo (for vibration)|No peripheral vibration at the wrist skin
223459378|NCT02675764|BEHAVIORAL|therapy|standardized hand therapy program
223459379|NCT03539276|BEHAVIORAL|Knowledge exchange|OptimaMed
223459380|NCT00335517|DRUG|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
223459381|NCT01162044|OTHER|Computer game|Playing with specially designed computer game while in emergency room
223459382|NCT03720925|PROCEDURE|TDI treatment|The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
223459383|NCT06428266|DEVICE|Bicanalicular intubation|Placement of the bicanalicular intubation set at each lacrimal point and fixed by means of its flaps at the level of the opening of the lacrimal sac.
223459384|NCT06428266|PROCEDURE|Closed dacryointubation|Placement of dacryointubation tube through the canaliculus until it reaches the medial wall of the lacrimal sac and then passed the nasolacrimal duct until it empties out at the level of the inferior meatus.
223459385|NCT05630482|BEHAVIORAL|Healthy Family Foundations|Healthy Family Foundations Curriculum
223459386|NCT05630482|OTHER|Standard of Care|Standard of Care
223459387|NCT04248946|OTHER|Transcranial direct current stimulation|tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
223459388|NCT05527795|OTHER|Frequency and duration of response to adjuvant immunotherapy according to clinical features|"* Frequency of relapse to adjuvant immunotherapy according to clinical features~* Duration of relapse as defined by the time (days) between adjuvant immunotherapy onset and relapse date according to clinical features"
223459389|NCT05527795|OTHER|Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features|Percentages of each type of relapse (i. e. local, distant, unique or multiple) according to clinical features
223459390|NCT05527795|OTHER|Duration of relapse-free survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and relapse date.
223459391|NCT05527795|OTHER|Duration of overall survival according to clinical features|Duration of relapse-free survival as defined by the time (days) between adjuvant immunotherapy onset and the date of death (irrespectively of the cause) 10 years after inclusion in the study. Alive or lost to follow-up patients will be censored at the date of the last follow-up visit.
223459392|NCT05527795|OTHER|Overall response rate|Response rate to adjuvant immunotherapy and to treatment lines subsequent to relapse. Response rate to adjuvant immunotherapy is defined by the absence of relapse as assessed by the physician following the first year of adjuvant therapy. Response to treatment after relapse is defined as partial or complete response as assessed by the physician following the first year of adjuvant therapy.
223459393|NCT05527795|OTHER|Frequency of adverse events according to clinical features|Rate of adverse events according to their nature and grade (as defined by CTCAE V 5.0) and according to clinical features
223459394|NCT04643327|DRUG|Levetiracetam|Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
223459395|NCT04643327|DRUG|Placebo|Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
224302853|NCT00918840|BIOLOGICAL|Placebo|Dextrose/glucose solution
224302854|NCT00918840|DRUG|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
223574174|NCT01218100|DRUG|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
223459396|NCT05524766|DEVICE|BTL-785-7 Treatment|Treatment with BTL-785F device (BTL-785-7 applicator) for improvement of overall facial appearance and muscle tone in patients injected with botulinum toxin.
223459397|NCT05227443|PROCEDURE|Exercise aerobic training|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide only lower limbs training exercises.
223459398|NCT05227443|PROCEDURE|Upper, lower and breathing (ULB) exercise|It is a procedure that is in the form of exercise training as a part of rehabilitation. The patients were subjected to 3 supervised sessions of exercise training / week for a total duration of 6 weeks. The form of training was aerobic intensity exercise that lasts for 15 minutes of continuous exercise. In this intervention, the investigators provide lower and upper limbs training exercises as well as breathing exercises.
223459399|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
223459400|NCT00921635|PROCEDURE|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
223459401|NCT03289013|OTHER|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
223459402|NCT03289013|OTHER|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
223459403|NCT03289013|OTHER|LT-2|Newly developed adhesive
223459404|NCT03289013|OTHER|LT-21|Newly developed adhesive
223459405|NCT03289013|OTHER|LT-25|Newly developed adhesive
223459406|NCT03289013|OTHER|33-20|Newly developed adhesive
223459407|NCT04076436|OTHER|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
223459408|NCT04076436|OTHER|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
223574175|NCT01218100|DRUG|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
223743307|NCT00827983|DRUG|Progesterone|90 mg, vaginally, once à day
223743308|NCT02124863|DEVICE|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
224067764|NCT03273166|DEVICE|Control SpHb sensor|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
224067765|NCT03273166|PROCEDURE|Hemodilution|This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.
224302855|NCT00894101|DRUG|[F-18] FLT|10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
223459409|NCT05771454|PROCEDURE|Histopathological confirmation|After mastectomy, each specimen will be assessed histopathologically for the presence or absence of invasive focus of breast cancer.
223459410|NCT03082027|DIAGNOSTIC_TEST|ultrasonography|ultrasonography of median nerve
223459411|NCT01563731|DRUG|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
223459412|NCT00492700|DRUG|rosiglitazone|
223459413|NCT02758288|OTHER|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
223459414|NCT02758288|OTHER|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
223459415|NCT01700257|RADIATION|CT scan & Early CDT Lung test|
223459416|NCT01700257|OTHER|CT scan & Early CDT Lung test|
223459417|NCT05339815|DEVICE|SMR shoulder arthroplasty|Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
223459418|NCT02052427|DEVICE|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
223459419|NCT02052427|DEVICE|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (\<1mL) of autologous blood
223459420|NCT05505383|OTHER|Exercise training|People with multiple sclerosis will be received a supervised physiotherapy and rehabilitation program.
223459421|NCT04099238|DRUG|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
223459422|NCT04553614|BEHAVIORAL|Home-based HIIT|Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.
224302856|NCT01059266|DRUG|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
223459423|NCT04553614|OTHER|Control|Usual exercise referral scheme procedure.
223459424|NCT03336814|DRUG|Terlipressin|Administration of terlipressine
223459425|NCT03336814|OTHER|Placebo|Administration of placebo
223574176|NCT01218100|DRUG|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
223574177|NCT01218100|DRUG|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
223459426|NCT00351689|BEHAVIORAL|dietary supplement|
223459427|NCT01275989|OTHER|Ear acupuncture|
223459428|NCT02806856|DEVICE|tDCS neuroConn|Cathodal on M1
223459429|NCT02806856|DEVICE|Sham stimulation|Sham
223459430|NCT03701542|DIAGNOSTIC_TEST|Microperymetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
223459431|NCT03701542|DIAGNOSTIC_TEST|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
224156374|NCT03557515|BEHAVIORAL|Stress Management and Metta-Meditation|"Stress Management will focus on:~1. Mind-Body Connection~2. Coping Skills~3. Communication~4. Social Support~Metta-Meditation will focus on:~1. Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~2. Intro to Brief Loving-Kindness Meditation and Self-Care~3. Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~4. Review/Plan for Future"
223459432|NCT00640939|DRUG|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
223459433|NCT00640939|DRUG|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
223574178|NCT00502723|PROCEDURE|Radical retropubic prostatectomy|Radical retropubic prostatectomy
224156375|NCT05563714|BEHAVIORAL|Clinician Notification with Nurse Facilitation (CNNF)|An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.
224156376|NCT05563714|BEHAVIORAL|Wait list control|The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
223459434|NCT02212925|DRUG|BI 14332 CL|
223459435|NCT02212925|DRUG|Placebo|
223459436|NCT00027547|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223459437|NCT00027547|DRUG|cyclosporine|
223459438|NCT00027547|DRUG|cytarabine|
223459439|NCT00027547|DRUG|fludarabine phosphate|
223459440|NCT00027547|DRUG|methotrexate|
223459441|NCT00027547|DRUG|mycophenolate mofetil|
223459442|NCT00027547|PROCEDURE|allogeneic bone marrow transplantation|
223459443|NCT00027547|PROCEDURE|peripheral blood stem cell transplantation|
223459444|NCT00027547|RADIATION|radiation therapy|
223459445|NCT00256932|DRUG|alvimopan|0.5 mg
223459446|NCT00256932|DRUG|Placebo|
223459447|NCT04362202|OTHER|Water-based Sequential Preparatory Approach|"The experimental training consists of a sequential and a preparatory approach aimed at enhancing dynamic postural stability. The exercises followed a specific sequence starting from a kneeling position, proceeding to a sitting position and ending with a supine position. Step exercises preparatory for gait were performed using a step and two floating aids. Gait exercises were performed first with the upper limbs placed on two floating aids and then during a dual motor task (i.e., catching a ball thrown by the therapist).~The control aquatic therapy consists of water-based exercises, in line with suggestions of the Hydrotherapy Association of Chartered Physiotherapists Guidance on Good Practice in Hydrotherapy.~These consisted of warm-up exercises, stretching exercises for the lower limbs, recruitment exercises and walking exercises during each phase of gait (single stance, swing and double stance)."
223459448|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50
223459449|NCT00366782|BIOLOGICAL|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50
223459450|NCT00366782|BIOLOGICAL|Placebo|Placebo for rB/HPIV3 vaccine
223459451|NCT03628859|BIOLOGICAL|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib \[in France only\], as per product SmPC or 1st line treatment with sunitinib or pazopanib or receiving 2nd or 3rd line of treatment with nivolumab)
223459452|NCT02586311|DRUG|CKD-330 16/5mg|Once a day, 8 weeks
223459453|NCT02586311|DRUG|Amlodipine 5mg Placebo|Once a day, 8 weeks
223459454|NCT02586311|DRUG|CKD-330 16/5mg Placebo|Once a day, 8 weeks
223459455|NCT02586311|DRUG|Amlodipine 5mg|Once a day, 8 weeks
223459456|NCT00678015|DRUG|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
223459457|NCT02377492|DRUG|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
223459458|NCT05681364|OTHER|metabonomics|profiles of metabolites in serum and exhale breath condensate (EBC) at baseline and after pulmonary rehabilitation
223574179|NCT00502723|PROCEDURE|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
223574180|NCT06180681|BEHAVIORAL|Team-Enhanced Collaborative Life Skills Program|We will integrate three team-based implementation strategies to enhance team effectiveness in CLS, including Team Charters, Team Communication Training via Student Handoff Protocols, and Team Performance Monitoring. These interventions have been shown to improve cognitive (e.g., shared mental models) and affective ((e.g., trust, collective efficacy) team-based emergent states and enhance team-based processes, such as communication and coordination.
223459459|NCT05017805|BIOLOGICAL|COVID-19 Vaccines|One dose (0.5 mL) of coronavirus vaccine was inoculated on day 0 and day 25±3, respectively.
223459460|NCT02128659|BEHAVIORAL|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
223459461|NCT02358265|DRUG|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
223459462|NCT02358265|DRUG|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
223459463|NCT02358265|DRUG|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
223574181|NCT06180681|BEHAVIORAL|Standard Collaborative Life Skills Program|CLS is a school-delivered intervention coordinating three empirically-supported approaches: teacher consultation and a daily behavior report card, behavioral parent training and child skills training. The three components are integrated over a 10-12 week period to improve symptoms and functional impairment among youth with ADHD.
223574182|NCT05121220|DEVICE|fixed retainer|bonded lingual mandibular fixed retainer on frontal teeth 33-43
223574183|NCT05121220|DEVICE|removable retainer|thermoplastic vacuum-formed removable mandibular retainer
223574184|NCT03964246|BEHAVIORAL|Compassion Meditation (CM) intervention|"10 weekly 90-minute sessions. Sessions 1-3 assist participants in basic mindfulness breathing practices; sessions 4-8 focus on personal analysis of factors underlying difficulties with compassion for self or others; sessions 9 and 10 review content and assist with relapse prevention.~\[These were planned as in-person groups but due to the COVID-19 social distancing requirements that started after initiation of cohort 1, the investigators had to retool the intervention for telehealth delivery.\]"
223574185|NCT03964246|OTHER|Healthy Aging Psychoeducation|"The investigators planned to administer a 10-week psychoeducational in-person group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent randomized controlled trial. This would include use of an existing library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity.~\[Unfortunately, with the switch to telehealth format necessitated by the COVID-19 social distancing requirements, the consensus of the investigators and staff was that these proved too be too dry/dull/academic to be a credible attention control in a telehealth format for the target population.\]"
223574186|NCT01185418|DRUG|risperidone|
223574187|NCT01185418|DRUG|aripiprazole|
224302857|NCT04755257|DEVICE|Isokinetic test|Using IsoMed 2000 device (D. \& R. Ferstl GmbH, Hemau, Germany) we conducted the isokinetic test of concentric (CON) and eccentric (ECC) shoulder internal (IR) and external (ER) strength at the angular velocity of 60˚/s in both Method I (scapular position) and Method II (25⁰ Abd and 20⁰ ER). There were seven days between the testing sessions, and both tests were conducted at the same time of day. The same examiner with experience in performing isokinetic testing with IsoMed 2000 tested all subjects in both testing sessions.
223459464|NCT02358265|DRUG|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
223459465|NCT01297543|BIOLOGICAL|human myeloid progenitor cells|Single intravenous injection/infusion
223459466|NCT01297543|DRUG|G-CSF|Background therapy
223459467|NCT01971567|DEVICE|HIRREM|
223459468|NCT03499106|DRUG|IW-1973|Oral Tablet
223459469|NCT03499106|DRUG|Itraconazole|Oral Capsule
223459470|NCT02761590|OTHER|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
223574188|NCT01185418|DRUG|haloperidol|
223574189|NCT01185418|DRUG|amisulpride|
223574190|NCT01185418|DRUG|lactose|
223574191|NCT06896942|OTHER|Autism Doula|The Autism Doula provides caregiver support, navigation with next steps for their child, connects families to resources and the Black autism community, and coordinates services to help alleviate caregiver stress (e.g., cleaning, cooking, respite care).
223574192|NCT06896942|OTHER|DDBP Family Navigation|A one-time consult with a DDBP family navigator via telehealth to come up with an action plan for next steps for the patient's care.
223574193|NCT00637637|DRUG|indinavir sulfate|
223574194|NCT00637637|DRUG|ritonavir|
224067766|NCT01317589|DRUG|fentanyl|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
224067767|NCT01317589|DRUG|methadone|"T = 0~* start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~* breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~* if necessary increase dose strong opioid with 50%~T=2 3 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T=3 5 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~* if necessary increase dose strong opioid with 50%~* if necessary decrease dose strong opioid with 30%"
224067768|NCT04329195|DRUG|1: discontinuation of RAS blocker therapy|discontinuation of RAS blocker therapy
224067769|NCT04329195|DRUG|2: continuation of RAS blocker therapy|continuation of RAS blocker therapy
223459471|NCT04472546|OTHER|in-vivo mesure|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
223459472|NCT04472546|OTHER|Scotch|"* for acne of the face subgroup and its associated control : face and inner side of the forearm~* for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm~* for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm"
223459473|NCT04472546|OTHER|Lipid index|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face"
223459474|NCT04472546|OTHER|Absorbant paper|"* for acne of the face subgroup and its associated control : face~* for seborrheic dermatitis of scalp subgroup and its associated control: scalp~* for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead"
223459475|NCT04472546|OTHER|Hydratation Index|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
223459476|NCT04472546|OTHER|TransEpidermal Water Loss|-for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
223459477|NCT00115206|DRUG|Neulasta® (pegfilgrastim)|
223459478|NCT06473116|DRUG|Isoprenaline Only Product|Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
223459479|NCT01562717|DRUG|Ibuprofen|3 times a day
223574195|NCT00637637|RADIATION|radiation therapy|
223459480|NCT01562717|DRUG|Placebo|3 times a day
223574196|NCT04217967|DRUG|Ixazomib|the ixazomib group uses ixazomib as the comparator group, the combination group receives both lenalidomide and ixazomib as the experimental group
223574197|NCT04217967|DRUG|Lenalidomide|the lenalidomide group uses lenalidomide as comparitor group and the combination group receives both lenalidomide and ixazomib
223574198|NCT03094650|DEVICE|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
223574199|NCT04644796|DRUG|saline 0.9%|Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
223574200|NCT04644796|DRUG|Liposomal bupivacaine|Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
223574201|NCT00379782|OTHER|Navigation|Navigation and escourt
223574202|NCT01949623|OTHER|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
223459481|NCT00118989|DIETARY_SUPPLEMENT|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
223459482|NCT01580826|OTHER|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
223459483|NCT01409915|DRUG|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
223459484|NCT01409915|DRUG|Saline -- placebo comparator|subcutaneous injection
223459485|NCT02137148|DEVICE|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
223459486|NCT04826484|DRUG|Exparel 133 miligrams per 10 milliliter injection|Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection
223574203|NCT01459640|DRUG|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
223459487|NCT04826484|DRUG|Bupivacaine Hydrochloride|Local wound infiltration with 0.25% bupivacaine.
223459488|NCT00511173|GENETIC|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
223459489|NCT05122624|OTHER|PredicTB score|"This is an easy-to-use clinical risk score designed to improve early management of tuberculosis in highly resource-constrained settings where same-day microbiological testing is unavailable. It consists of readily accessible demographic and clinical data and is scored from 1-10.~We will train clinic staff in eight clinics (four study clinics and four comparison clinics) on the Ugandan standard of care for the diagnosis and treatment of TB. In addition, in the four study clinics, we will provide training on the PredicTB score."
223574204|NCT01459640|BIOLOGICAL|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
223574205|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
223574206|NCT04092881|DEVICE|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
224067770|NCT01898182|OTHER|Kinetin, N6-furfuryladenine, 0.1%|
224067771|NCT05677074|DIETARY_SUPPLEMENT|Fish oil|The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
223574207|NCT02434354|DRUG|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
223459490|NCT02250300|DRUG|MLN9708 (2.3 mg)|2.3 mg
223459491|NCT02250300|DRUG|MLN9708 (4.0 mg)|4.0 mg
223574208|NCT00591968|DEVICE|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
223574209|NCT00110630|BEHAVIORAL|10-week smoking cessation group therapy combined with NicoDerm CQ|
223574210|NCT00549029|GENETIC|DNA|withdraw 5\~10mL blood from vein only once during the whole design
223574211|NCT01259076|PROCEDURE|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
223574212|NCT01259076|PROCEDURE|digital mammography|Undergo digital mammography at baseline and 1 year later.
223574213|NCT01259076|PROCEDURE|conventional surgery|Undergo gastric bypass surgery
224156377|NCT05750316|OTHER|Cowpea leaves mixed with Jam|6g of freeze-dried cowpea leaves, equivalent to 80g(a portion) of vegetables mixed with Jam and spread on bread
224156378|NCT05750316|OTHER|Jam mixed with green food colour|Jam with green food colouring spread on bread
223459492|NCT02250300|DRUG|MLN9708 (3.0 mg)|3.0 mg
223459493|NCT00215644|DRUG|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
223459494|NCT00215644|DRUG|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
223459495|NCT00215644|DRUG|Cisplatin|Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
223459496|NCT00215644|DRUG|Capecitabine|Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
223574214|NCT02446418|DRUG|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
223574215|NCT02446418|DRUG|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
223574216|NCT02446418|DRUG|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
223574217|NCT02446418|DRUG|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
223574218|NCT02446418|DRUG|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
223574219|NCT02446418|DRUG|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
223574220|NCT05851872|PROCEDURE|Coronary angiogram|Being done per standard of care
223459497|NCT01745562|DRUG|Alprazolam 0.5 mg|Reference product
223459498|NCT01745562|DRUG|Alprazolam 0.5 mg|Test product
223459499|NCT03981146|DRUG|Nivolumab|60 Minute IV Infusion
223459500|NCT03170817|DIAGNOSTIC_TEST|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~1. One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of \~20 minute duration.~2. A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~3. One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of \~20 minute duration~Total patient time will take approximately up to 120 minutes."
223459501|NCT03170817|DRUG|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
223459502|NCT03170817|DRUG|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
223459503|NCT00270101|DRUG|epoetin alfa|
223574221|NCT05851872|PROCEDURE|Right heart catheterization|Being done per standard of care
223574222|NCT03114124|DEVICE|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
223574223|NCT03114124|DEVICE|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
223574224|NCT02014480|DEVICE|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
223574225|NCT02014480|DEVICE|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
223574226|NCT02014480|DEVICE|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
223574227|NCT02905617|DEVICE|Sientra 207 Silicone Gel Breast Implant|The Sientra 207 Silicone Gel Breast Implant is a textured, round device with high-strength cohesive plus (HSC+) silicone gel fill.
223743309|NCT02113956|BEHAVIORAL|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
224156379|NCT02473835|OTHER|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
223459504|NCT03569098|BIOLOGICAL|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
223459505|NCT03569098|DRUG|Placebo|Investigators will inject the reconstituted solution into foot muscles.
223459506|NCT04232644|DRUG|ADAIR 10mg IR capsules|manipulated ADAIR IR 3x10 mg capsules
223459507|NCT04232644|DRUG|Crushed d-amphetamine sulfate IR tablets|crushed d-amphetamine sulfate IR 6 x 5 mg tablets
223459508|NCT01467193|DIETARY_SUPPLEMENT|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
223459509|NCT01467193|OTHER|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
223459510|NCT00758498|DRUG|armodafinil|50 mg/day orally, once daily in the morning for 3 days
223459511|NCT00758498|DRUG|armodafinil|150 mg/day orally, once daily in the morning for 3 days
223459512|NCT00758498|DRUG|placebo|placebo tablets, once daily in the morning for 3 days
223459513|NCT03939923|DRUG|Rocuronium|Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
223459514|NCT03939923|DRUG|Neostigmine|Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
223459515|NCT03939923|DRUG|Glycopyrrolate|Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
223574228|NCT01575938|BEHAVIORAL|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
223574229|NCT01575938|BEHAVIORAL|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
223574230|NCT01854632|BIOLOGICAL|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
223574231|NCT01854632|BIOLOGICAL|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
223574232|NCT05238012|DRUG|Xuezhikang Capsule|Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
223459516|NCT03939923|DRUG|Sugammadex|Reversal with Sugammadex (2mg/kg)
223459517|NCT01288365|BEHAVIORAL|Exercise training|Exercise training program for 3 months (two times a week).
223459518|NCT01666912|DRUG|Contraceptive implant|
223459519|NCT01516736|DRUG|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
223459520|NCT01516736|DRUG|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
223459521|NCT05720195|DIAGNOSTIC_TEST|ALBI|Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC
223459522|NCT00125060|DRUG|Simvastatin (20mg versus 80mg/day)|
223459523|NCT03671655|DEVICE|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
223459524|NCT03671655|DEVICE|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
223459525|NCT03450759|DRUG|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
223459526|NCT03450759|DRUG|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
223459527|NCT03450759|DRUG|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
223459528|NCT03450759|DRUG|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
223459529|NCT04508686|DRUG|Capecitabine, camrelizumab|This is a single-arm study with all patients receiving these two drugs.
223459530|NCT01967680|PROCEDURE|Non-sedation for intubated, mechanically ventilated patients|
223459531|NCT01967680|PROCEDURE|Controlgroup, sedation with daily wake-up trial|
223459532|NCT01697800|DRUG|Tadalafil|
223459533|NCT01697800|DRUG|Placebo|
223459534|NCT00526448|DRUG|ribavirin|2000 mg/day
223459535|NCT00526448|DRUG|ribavirin|1000-1200 mg/day
223459536|NCT00526448|DRUG|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
223459537|NCT00526448|DRUG|epoetin beta|epoetin beta 450 UI/week
223459538|NCT05911126|DRUG|Celecoxib 200 mg, Hyoscine-N-butyl bromide (HBB), placebo tablet|Tablet form received prior to the procedure
223574233|NCT05238012|DRUG|Atorvastatin Calcium Tablets|Atorvastatin Calcium Tablets, 20mg/day, once a day, one tablet each time, before bedtime;
223574234|NCT01414205|DRUG|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
223574235|NCT01414205|DRUG|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
223574236|NCT04123912|BEHAVIORAL|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
223743310|NCT00939913|DRUG|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
223743311|NCT00939913|DRUG|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
223743312|NCT00575055|DRUG|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
223459541|NCT02981199|PROCEDURE|stem cell transplantation|conditioning with chemotherapy \[VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)\], then stem cell transfusion
223459542|NCT01810562|OTHER|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
223459543|NCT03782181|DEVICE|Whole body vibration platform|A neuromuscular treatment using a rotational whole body vibration platform.
223459544|NCT01030016|DRUG|atenolol|25 mg/day, twice a day for 6 weeks
223459545|NCT04878068|DEVICE|Theram COVID-19 Rapid Antigen Test|The Therma COVID-19 Rapid Antigen Test is an in vitro rapid, lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens in human saliva specimens. This test is intended for near-patient use at the point-of-care or lay person, self-use in a non-laboratory or home setting using saliva samples from individuals with or without symptoms of COVID-19.
223459546|NCT06067867|OTHER|Data extraction from medical files|Data extraction from medical files
223459547|NCT03289988|OTHER|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
223574237|NCT04123912|BEHAVIORAL|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
223459548|NCT03438084|DIETARY_SUPPLEMENT|Interesterified fat|50 g fat provided as commercially available interesterified fat.
223459549|NCT03438084|DIETARY_SUPPLEMENT|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
223574238|NCT04189653|OTHER|Continuous Monitoring|Wireless continuous vital sign monitoring (HR, RR, SBP/DBP, SAT)
223574239|NCT01119833|DRUG|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
224067772|NCT05677074|DIETARY_SUPPLEMENT|Cod oil|The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
224067773|NCT05677074|DIETARY_SUPPLEMENT|Krill oil|The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
224067774|NCT02669017|DRUG|ADCT-402|intravenous infusion
224067775|NCT06639984|DRUG|Psyllium (0.7 g/year of age per day)|Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
224067776|NCT06639984|DRUG|Psyllium (0.5 g/year of age per day)|Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
224067777|NCT06639984|DRUG|Placebo|Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \&amp; Lyle, Staley, London, UK)
224067778|NCT06639984|OTHER|fructans|Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
224067779|NCT03113643|DRUG|Azacitidine|Chemotherapy
224067780|NCT03113643|DRUG|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
223743313|NCT00575055|DRUG|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
224067781|NCT03113643|DRUG|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
224067782|NCT03621280|DRUG|Levoketoconazole|Levoketoconazole up to 1200 mg daily
224067783|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days
224067784|NCT05627037|DEVICE|Dental implant produced by additive manufacture|In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days
224067785|NCT03382795|DRUG|EGFR|Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
224067786|NCT03940859|DEVICE|intracranial stent, flow diverter and coils|Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
224067787|NCT01714427|DRUG|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
224067788|NCT01714427|DRUG|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
224067789|NCT01217632|DRUG|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
224067790|NCT01217632|DRUG|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
223459550|NCT03438084|DIETARY_SUPPLEMENT|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
223459551|NCT03438084|DIETARY_SUPPLEMENT|Butter|50g fat provided as commercially available spreadable butter
223574240|NCT01119833|DRUG|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
223574241|NCT03089879|BIOLOGICAL|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
224067791|NCT01217632|DRUG|Entecavir|
223459552|NCT01587105|BEHAVIORAL|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
223459553|NCT01416545|BEHAVIORAL|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
223459554|NCT01416545|BEHAVIORAL|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
223459555|NCT01563328|DRUG|DTG|50 mg q24h
223459556|NCT01563328|DRUG|BCV|800 mg q8h
223459557|NCT01563328|DRUG|TVR|750 mg q8h
223459558|NCT01569945|DRUG|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
223459559|NCT01569945|DRUG|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
223459560|NCT00848900|BEHAVIORAL|Outdoor activity|Adding 1 hour outdoor time into school curricula
223459561|NCT02049736|DRUG|Telbivudine|
223459562|NCT03559504|DRUG|Sevoflurane Inhal Soln|Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
223574242|NCT02523131|DEVICE|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
223459563|NCT02511041|DRUG|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
223459564|NCT02511041|DRUG|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
223459565|NCT00005916|DRUG|rV-PSA|
223459566|NCT00005916|DRUG|rF-PSA|
223459567|NCT00005916|DRUG|rV-B7.1|
223459568|NCT01684852|OTHER|Medical device, drug-like|
223574243|NCT02523131|DEVICE|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
223574244|NCT04362371|DEVICE|Ainara|1 g at each administration
224067792|NCT04089007|DEVICE|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
224067793|NCT04089007|OTHER|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
224067794|NCT01857661|DEVICE|sound generator|hearing aid with an integrated sound generator
224067795|NCT01857661|DEVICE|hearing aids with only amplification|
223459569|NCT01510821|OTHER|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
223574245|NCT06217523|OTHER|Pharmacogenomics-directed Hyperlipidaemia Management|Pharmacogenomics-directed Hyperlipidaemia Management
223574246|NCT00022685|BIOLOGICAL|epratuzumab|
223574247|NCT03690492|OTHER|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
223743314|NCT00575055|DRUG|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
223743315|NCT00000806|DRUG|Telinavir|
224067796|NCT01423799|DIETARY_SUPPLEMENT|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
224067797|NCT01423799|DIETARY_SUPPLEMENT|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
224067798|NCT04469413|DRUG|Paracetamol Infusion|Continuous and Standard Intermittent Boluses Paracetamol Infusion
224067799|NCT00123006|BEHAVIORAL|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
224067800|NCT00123006|BEHAVIORAL|Control Diet|4 week feeding intervention
224067801|NCT00003022|RADIATION|iodine I 131 monoclonal antibody 3F8|
224067802|NCT02329769|DRUG|PRO044 SC 6 mg/kg|
224067803|NCT02329769|DRUG|PRO044 IV 6 mg/kg|
224067804|NCT02329769|DRUG|PRO044 IV 9 mg/kg|
224156380|NCT02473835|OTHER|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
223459570|NCT01510821|OTHER|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
223459571|NCT01781208|DEVICE|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
223459572|NCT04194489|OTHER|FMF Connect|The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
223459573|NCT03455712|BEHAVIORAL|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
223459574|NCT00798941|BEHAVIORAL|mouth care|mouth spray, mouth swab, moisturizer
223459575|NCT00798941|BEHAVIORAL|pain intervention|music and massage
223459576|NCT03897569|OTHER|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
223459577|NCT01808274|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
223459578|NCT04552561|BEHAVIORAL|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
223459579|NCT04192721|BEHAVIORAL|Cognitive Behavioral Therapy-Based Group Counseling|"* Relaxation techniques~* Providing personal development books~* Sharing the factors affecting the situation defined as depression (brainstorming)~* Explaining the link between depressive symptoms, thoughts, feelings, and behaviors~* Explaining automatic thoughts~* Application of relaxation techniques; deep-breathing exercises~* Identifying alternative thoughts~* Explaining the correlation between alternative thoughts and mood~* Introduction of the Automatic-Thought Registration Form and distribution to students~* Describing the effects of depression on social interaction~* Explaining activities that could be done individually and with the group~* Distribution of the activity list to students~* Description of ways of coping with stress~* Determination of individual stressors and their effects~* Planning for the future: preventing depression~* Discussion of assumptions/expectations about life~* Homeworks related to session contents"
223459580|NCT00370773|DEVICE|Precision Spinal Cord Stimulation System|
223459581|NCT01649882|PROCEDURE|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (\< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
223459582|NCT02478515|DRUG|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
223459583|NCT00379561|DRUG|PSA-Activated PSA-PAH1|
223574248|NCT04072679|DRUG|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
223574249|NCT03386786|BEHAVIORAL|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
223574250|NCT03386786|BEHAVIORAL|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
223574251|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
223574252|NCT01860157|DEVICE|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
223574253|NCT04773561|DEVICE|Corneal tomography, optical coherence tomography and optical coherence tomography angiography|Ocular investigations were performed in one time during 30-36 weeks of gestational age. Due to avoidance of diurnal variation, all examinations were done between 10 am - 12 pm.
223574254|NCT00003772|PROCEDURE|quality-of-life assessment|
223574255|NCT02139735|OTHER|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
223743316|NCT02270827|DRUG|Aminophylline|intravenous medication
223743317|NCT02270827|DRUG|Hydrocortisone|Intravenous medication
223743318|NCT05772936|BEHAVIORAL|Balance training|perturbation induce step training to improve reactive stepping with paretic leg.
223459584|NCT03175614|OTHER|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
223459585|NCT03175614|OTHER|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
223459586|NCT04081675|DEVICE|Ankle Foot Orthosis (AFO)|Thermoplastic orthotic device spanning the calf, ankle and foot.
223459587|NCT05390008|OTHER|Pelvic Floor Muscle Training|"In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased."
223574256|NCT02139735|OTHER|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
223459588|NCT05390008|OTHER|Modified Pilates Exercise|"Before starting the 12-week practice protocol, the concept of stabilization was explained to the participants. Participants were taught how to control the core region by using the stabilizer device and the basic principles of pilates. The exercise program was planned that would last 50 minutes. This program was carried out as three-stage and these stages were warm-up phase, main exercise program and cool down phase. The allocated times for the warm-up phase was 10 minutes. The allocated time for the main exercise program was 30 minutes and active resting was done by performing breathing exercises in the 15th minute of the main exercise program. The allocated time for the cool down phase was 10 minutes. Each exercise was done as 10 repetitions then the next exercise was started.~The exercises of the second 6 weeks were performed by adding a red elastic exercise band at the beginner-intermediate level, which released 1.7 kg force with 100% stretching."
223574257|NCT02139735|OTHER|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
223459589|NCT03934008|OTHER|MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)|The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
224156381|NCT02473835|OTHER|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
223459590|NCT02076204|BEHAVIORAL|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
223459591|NCT00409981|DEVICE|paclitaxel coated balloon catheter (device with drug)|
223459592|NCT02458560|DEVICE|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
223459593|NCT05121610|PROCEDURE|The procedures include PCI, CABG and HCR|The procedures include PCI, CABG and HCR
223459594|NCT00498680|DRUG|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
223459595|NCT00498680|DRUG|Sildenafil|100mg
223459596|NCT00498680|DRUG|Vardenafil|20mg
223459597|NCT00498680|DRUG|Sildenafil & Vardenafil|50mg \& 10 mg
223459598|NCT01667445|DRUG|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
223459599|NCT01667445|DRUG|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
223459600|NCT03793569|BEHAVIORAL|Peer discussion group|Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
223459601|NCT01999647|PROCEDURE|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
223574258|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Immediately|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
223459602|NCT01999647|PROCEDURE|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
223459603|NCT01999647|PROCEDURE|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
223743319|NCT00620438|DRUG|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
224156382|NCT04087603|BEHAVIORAL|Weekend Morning Bright Light & Early Bedtime|
224156383|NCT02016729|DRUG|AMG 232|Given an an oral tablet in escalating doses.
223459604|NCT01999647|PROCEDURE|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
223459605|NCT01999647|DRUG|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
223459606|NCT00522548|DRUG|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
223459607|NCT00522548|DRUG|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
223459608|NCT03959007|OTHER|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
223459609|NCT03959007|OTHER|Questionnaire|Both arm at 3 times during hospitalization
223459610|NCT00977912|DIETARY_SUPPLEMENT|Probiotic supplementation|one capsule containing probiotics per day added to milk
223459611|NCT00977912|DIETARY_SUPPLEMENT|Milk containing placebo|one capsule containing placebo per day added to milk
223459612|NCT03272243|PROCEDURE|short segment posterior spine fixation|
223459613|NCT03272243|PROCEDURE|long segment posterior spine fixation|
223459614|NCT02380404|PROCEDURE|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
223459615|NCT05704400|DRUG|Rituximab Biosimilar ABP 798|Rituximab IV: the dose is standard for pediatric nephrotic syndrome; for dosage between 100 and 250 mg rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
223459616|NCT05704400|DRUG|Daratumumab|Daratumumab vials 20 mg 1 ml will be collected to reach the desired dose of 16 mg /Kg, the dose is standard recommend to treat myeloma; diluted in 1000 ml of normal saline and infused at the constant speed of 50 ml/h. This will be reduced in case of cutaneous allergic reactions
223459617|NCT00478270|DRUG|ibandronate [Bondronat]|6mg iv on days 1-3
223459618|NCT04147247|DRUG|BI 905681|Infusion
223459619|NCT03788161|OTHER|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
223459620|NCT03788161|OTHER|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
223459621|NCT06086938|DEVICE|active cTBS combined with iTBS|"Daily TBS treatment consists of the following combination: active 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + active 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + active 600-pulse cTBS applied to the SFG in the unaffected hemisphere + active 600-pulses iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
223459622|NCT06086938|DEVICE|sham cTBS combined with iTBS|"Daily sham TBS treatment consists of the following combination: sham 600-pulse cTBS applied to the superior frontal gyrus (SFG) in the unaffected hemisphere + sham 600-pulse iTBS applied to the SFG in the affected hemisphere + 15 minutes of rest + sham 600-pulse cTBS applied to the SFG in the unaffected hemisphere + 600-pulse sham iTBS applied to the SFG in the affected hemisphere, totaling 2400 pulses of sham TBS intervention.~The intervention mentioned above will be administered once per day with five consecutive days per week, continuously for three weeks."
223459623|NCT01255072|PROCEDURE|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
223459624|NCT01255072|PROCEDURE|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
223459625|NCT02738112|DEVICE|Encore System|Hyo-mandibular suspension
223459626|NCT01089842|BEHAVIORAL|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
223459627|NCT01089842|OTHER|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
223459628|NCT03851770|OTHER|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
223459629|NCT05978518|DEVICE|CPM Device + Monitoring|Daily device use \& data monitoring leading to symptomology assessment and notification to provider.
223459630|NCT05978518|DRUG|CPM Device|Daily device use
223459631|NCT01751750|OTHER|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
223459632|NCT04328909|DEVICE|E-Care|Parent-centered care software application (e-Care) to ensure parents of febrile infants are optimally informed and participate in shared decision making in the ED
224156384|NCT02016729|DRUG|Trametinib|Trametinib is an oral tablet given in a fixed dose.
224156385|NCT05610722|DEVICE|DreaMed Endo Digital|The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
224156386|NCT00184158|PROCEDURE|decompression|Conservative, simple decompression and nerve transfer
223459633|NCT04328909|OTHER|Control Group|Usual care - No E-Care app will be provided
224156387|NCT03867110|DRUG|Placebo|
224156388|NCT03867110|DRUG|Ezetimibe 10 mg|
224156389|NCT03867110|DRUG|Atorvastatin 10 mg|
224156390|NCT03867110|DRUG|Atorvastatin 20 mg|
224156391|NCT03867110|DRUG|Atorvastatin 40 mg|
224156392|NCT03867110|DRUG|Atorvastatin 80 mg|
224156393|NCT02219997|DEVICE|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
224156394|NCT02219997|DEVICE|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
224156395|NCT02219997|DEVICE|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
224302858|NCT01992523|DRUG|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
223459634|NCT03113669|BEHAVIORAL|CBT-GSH|
223459635|NCT01986803|DEVICE|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
223459636|NCT04244617|BEHAVIORAL|iCBT with addition of peer-support|Peer-supporters and participants, as well as psychologists and participants, interact in the treatment program via asynchronous secure messages. Peer-supporters are able to give support and feedback on exercises. A reconciliation call via telephone is entered into the middle of the treatment and a follow-up call after completion of treatment conducted by the peer-support. The interaction between peer-supporters and participants is tracked by the psychologist.
223459637|NCT06132334|OTHER|Upper extremity aerobic exercise training|"Aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of aerobic exercise training will be applied at 50-80% of peak oxygen consumption or 60-80% of peak heart rate, dyspnea 3-4 points according to the Modified Borg Scale (MBS) or fatigue 4-6 points.~Blood sugar measurement will be performed before exercise training. Individuals with a blood sugar result of \>300 mg/dL will not be allowed to exercise that day."
223459638|NCT06132334|OTHER|Control Group|The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
223459639|NCT03877146|BEHAVIORAL|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
223459640|NCT04214574|DEVICE|Parasagittal oblique technique (Ultrasound)|the probe will be placed in a parasagittal plane to identify the articular processes then the sacrum will be identified. The probe will be moved cephalad in the parasagittal axis until the identification of the target lumbar interspaces L2-L3, L3-L4 or L4-L5. Once the appropriate lumbar interspace is identified, the probe will be tilted 45 degree towards the midline into a parasagittal oblique view. The needle will be inserted in plane from the caudal end of the ultrasound transducer with its tip directed towards the interlaminar space under real-time in-plane US guidance.
223459641|NCT04214574|DEVICE|Paramedian tranverse technique (Ultrasound)|the transducer will be applied in the parasagittal plane, and after identification of the intervertebral level, the probe will be rotated 90 degrees into a transverse orientation and centered on the neuraxial midline in a way to align the beam with the interspinous and interlaminar space and thus to get a paramedian transverse interlaminar view. The needle will be inserted in plane from the lateral end of the ultrasound transducer with its tip directed towards the medial border of the articular process.
223459642|NCT01328639|OTHER|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
224156396|NCT02219997|DEVICE|Clear IOL|Clear IOL, previously implanted
224156397|NCT00907972|DIETARY_SUPPLEMENT|Vitamin D3|Vitamin D3
224156398|NCT00907972|OTHER|Placebo|Placebo
224156399|NCT02894489|DEVICE|corneal lenses|wear corneal lenses on daily basis
224156400|NCT02894489|DEVICE|large diameter lenses|
224156401|NCT01037972|BEHAVIORAL|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
224156402|NCT01037972|BEHAVIORAL|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
224156403|NCT05163067|BEHAVIORAL|Combined aerobic exercise and cognitive training program|Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.
224156404|NCT02600494|DRUG|ITI-007 (Lumateperone)|
223459643|NCT01328639|OTHER|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
223459644|NCT05707416|DEVICE|gallium aluminum arsenide (Ga-Al-As) semiconductor diode laser (SMARTTM PRO, LASOTRONIX, Poland)|The laser will be applied to 4 points of application for each tooth two labial and two palatal started immediately after first intrusive wire then at days 3,7,14 and then every 15 day until achievement of the study objectives
223459645|NCT05707416|OTHER|group B|Will includes 9 patients who will receive intrusive arches after leveling and alignment without laser application
223459646|NCT01553565|PROCEDURE|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
223459647|NCT00541567|DRUG|ibipinabant|oral, tablet, once daily
223459648|NCT03457389|DRUG|Cabergoline|Cabergoline tablet
223459649|NCT00163566|DRUG|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
223459650|NCT06436079|BEHAVIORAL|Intervention group|Patients who begin the first session in the hyperbaric chamber will receive a nursing educational intervention, with audiovisual support, about the operation of the chamber and aspects that must be taken into account once inside.
223459651|NCT06100796|COMBINATION_PRODUCT|Pembrolizumab|Immune check inhibitor with OHA
223459652|NCT01193946|DIETARY_SUPPLEMENT|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
223459653|NCT02068638|PROCEDURE|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
223459654|NCT02068638|PROCEDURE|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
223459655|NCT02068638|PROCEDURE|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
223459656|NCT02068638|PROCEDURE|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
223459657|NCT04088669|OTHER|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
223459658|NCT04088669|OTHER|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
223459659|NCT03791801|DRUG|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
223459660|NCT03791801|DRUG|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
223459661|NCT03791801|DRUG|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
223459662|NCT03791801|DRUG|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
223459663|NCT03049423|DEVICE|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
223459664|NCT03049423|DIAGNOSTIC_TEST|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
223459665|NCT01111565|DRUG|Escitalopram|Escitalopram capsule administered orally, once daily without regard to meals.
223459666|NCT01111565|DRUG|Aripiprazole|Aripiprazole capsule administered orally, once daily without regard to meals.
223459667|NCT05026944|OTHER|Percussive massage and static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
223459668|NCT05026944|OTHER|static stretching exercises|All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
223459669|NCT02581683|DRUG|Magnesium Sulfate|Given via adductor canal block
223574259|NCT05287529|BEHAVIORAL|Yoga Via Telehealth - Waitlisted|The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
223574260|NCT03482284|OTHER|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
223574261|NCT05455008|BEHAVIORAL|Remotely-delivered health coaching intervention|Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
223574262|NCT04154319|BEHAVIORAL|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
223459670|NCT02581683|DRUG|Ropivacaine|Given via adductor canal block
223459671|NCT02581683|OTHER|Sham|Sham adductor canal block
223459672|NCT03205293|BEHAVIORAL|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
223459673|NCT02683239|DRUG|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
223459674|NCT02683239|DRUG|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
223459675|NCT03846544|DRUG|Corifollitoropin alfa (CFA)-double pick up|In the study group, 225 IU of recombinant FSH (rFSH) will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with human chorionic gonadotropin (hCG) 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
223459676|NCT00320060|DRUG|Pyridorin (pyridoxamine dihydrochloride)|
223459677|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 800 mg/day|FADA is given twice a day (total dose of 800 per day per patient)
223574263|NCT04154319|BEHAVIORAL|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
223574264|NCT02305849|DRUG|Peficitinib|oral tablet
223743320|NCT00620438|DRUG|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
223743321|NCT00620438|DRUG|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
224156405|NCT02600494|DRUG|Placebo|
223459678|NCT05033925|DIETARY_SUPPLEMENT|FADA (active fraction of Ficus septica leaf) 2000 mg/day|FADA is given twice a day (total dose of 2000 per day per patient)
223459679|NCT05033925|OTHER|Placebo capsule|Placebo capsule is given twice a day
223459680|NCT04797507|DRUG|SHR-1210 plus Anlotinib|SHR-1210: a novel anti-PD-1 antibody Anlotinib: a multi-kinase inhibitor
223459681|NCT05948137|DIAGNOSTIC_TEST|F-18 FDOPA PET/CT|Nuclear medicine imaging modalities
223459682|NCT01610856|DRUG|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
223459683|NCT01610856|DRUG|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
223743322|NCT03004066|DRUG|Daptomycin|standard care
223743323|NCT01602380|DRUG|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
223743324|NCT01602380|DRUG|arimidex 1mg|oral tablet 1 daily
223459684|NCT00629759|GENETIC|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
223459685|NCT01967771|DRUG|DTG|DTG will be supplied as 50 mg tablet to be administered orally
223459686|NCT01967771|DRUG|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
223459687|NCT06958952|DIETARY_SUPPLEMENT|Digestive Aid|one tablet daily for one month
223459688|NCT06958952|DIETARY_SUPPLEMENT|Placebo|Placebo
223459689|NCT06194162|DEVICE|Weighted blanket|"The intervention group will receive a weighted blanket classified as a medical device class 1 as an add on to usual treatment. Participants will be asked to choose one out of at least three different weighted blankets, each with different weight classes. The choice of weighted blanket is solely taken by the participant after having tried all five blankets.~Adherence to the weighted blanket intervention is defined as reported use 60 % of the intervention period.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
223574265|NCT02305849|DRUG|Placebo|oral tablet
223574266|NCT02305849|DRUG|Methotrexate|Oral tablet/capsule
223574267|NCT03698175|BEHAVIORAL|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
223574268|NCT03698175|BEHAVIORAL|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
223574269|NCT00110071|DRUG|fludarabine phosphate|Given IV
224156406|NCT01195194|DRUG|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
224156407|NCT03509844|BEHAVIORAL|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
223459690|NCT06194162|DEVICE|Non-weighted blanket|"The control comparator will receive a sham intervention in the form of a non-weighted blanket as an add on to usual care. Participants will be asked to choose one out of two different sham blankets.~Usual treatment as part of standard care for children with ADHD, which can consist of sleep hygiene, psychoeducation, cognitive behavioral theory, medications such as melatonin or ADHD medication."
223574270|NCT00110071|PROCEDURE|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
223574271|NCT00110071|RADIATION|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
224156408|NCT03402269|OTHER|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
224156409|NCT00346138|PROCEDURE|Corneal transplantation|
223459691|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery -\> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
223574272|NCT00110071|OTHER|laboratory biomarker analysis|Correlative studies
224156410|NCT04003181|DRUG|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
224156411|NCT04003181|DRUG|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
224156412|NCT03032289|BEHAVIORAL|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
224156413|NCT01433120|DIETARY_SUPPLEMENT|Lactobacillus paracasei ssp paracasei F19|10\^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
224156414|NCT01433120|DIETARY_SUPPLEMENT|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
224156415|NCT01433120|DIETARY_SUPPLEMENT|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
224156416|NCT00351091|DRUG|RISEDRONATE|
224156417|NCT02483455|DRUG|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
224156418|NCT02483455|DRUG|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
224156419|NCT05007223|DRUG|Doxycycline|200mg/day for 28 days(Given doxycycline to patients with Hailey-Hailey disease)
224156420|NCT01351064|OTHER|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
223459692|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -\> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
223459693|NCT00798811|PROCEDURE|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
223574273|NCT00110071|OTHER|flow cytometry|Correlative studies
223574274|NCT00110071|GENETIC|polymerase chain reaction|Correlative studies
223574275|NCT01241344|DRUG|Brincidofovir|"* Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
223574276|NCT01241344|OTHER|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
223574277|NCT00640640|DEVICE|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
223574278|NCT00640640|DRUG|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
223574279|NCT00640640|DRUG|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
223574280|NCT04225091|DIETARY_SUPPLEMENT|Testing product|consume 1 bottle (50 mL) per day for 28 days
223574281|NCT04225091|DIETARY_SUPPLEMENT|Blank|consume 1 bottle (50 mL) per day for 28 days
223574282|NCT00839865|DRUG|herb ointment|a kind of ointment made from herb
223743325|NCT01602380|DRUG|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
224156421|NCT01629979|PROCEDURE|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
223574283|NCT00456066|DEVICE|Export Aspiration System|Patients scheduled for emergency angioplasty
224156422|NCT01629979|RADIATION|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
224156423|NCT01610206|DRUG|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
224156424|NCT01610206|DRUG|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
224156425|NCT01670136|DRUG|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
223459694|NCT05276206|DRUG|NSAID , NALUFIN , local anesthetic andTAP Block|"The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.~In all groups non steroidal anti-inflammatory drugs will be given as a rescue analgesic and the total dose will be calculated and compared"
223574284|NCT01831440|BEHAVIORAL|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
223459695|NCT04131712|OTHER|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
223459696|NCT02858635|OTHER|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
223459697|NCT01240499|OTHER|Health-At-Every-Size (HAES)|"1. HAES group: 14 weekly sessions.~   Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~2. SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian \& psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study."
223459698|NCT00809536|DRUG|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
223459699|NCT00809536|DRUG|Metformin|Single, oral, 500 mg of metformin immediate release
223459700|NCT00809536|DRUG|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
223459701|NCT00809536|DRUG|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
223574285|NCT01831440|DRUG|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
224067805|NCT05093738|OTHER|Cognitive Rehabilitation|In the content of the person-centered intervention program, attention, memory, orientation, praxis (motor planning) training; metacognition (metacognition) training; visual perception; There will be cognitive training for executive functions. The intervention will consist of play activities (games, computer-assisted games) for cognitive skills; The games will be applied in a way that suits the child from simple to complex. Visual perception applications (designing blocks, recognizing and sorting the shapes in the picture, matching opposite shapes etc.); attention practices, memory practices, strategy development, space-time orientation, motor planning, games and metacognitive strategies aimed at developing skills such as planning, organization, working memory, impulse control, time management and awareness, abstract thinking, cognitive flexibility will form our intervention program.
223459702|NCT01965314|OTHER|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
223459703|NCT01965314|OTHER|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
223459704|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
223459705|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
223459706|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
223459707|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
223743326|NCT01602380|DRUG|arimidex dummy|oral tablet 1 daily
223743327|NCT05478447|PROCEDURE|Vibration|whole-body vibration, and tendon vibrations will be applied to the human body
223743328|NCT00496756|DRUG|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
224067806|NCT01175109|DRUG|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
224156426|NCT05186987|PROCEDURE|15 minutes eccentric cycling|The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
224156427|NCT05186987|PROCEDURE|15 minutes concentric (normal) cycling|The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
224156428|NCT00055575|DRUG|Scopolamine Nasal Spray|
223459708|NCT01951599|DRUG|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
223459709|NCT06314360|OTHER|No intervention.|There is no intervention in this study.
223574286|NCT00997425|DEVICE|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
223574287|NCT00302016|DRUG|AMN107|
223574288|NCT06072716|DRUG|Chitosan|chitosan loaded with miconazole nanoparticles gel
223574289|NCT03871452|PROCEDURE|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
223574290|NCT05970094|OTHER|Low PRAL|Two weeks on a low PRAL diet compared to 2 week free living
223574291|NCT00002824|BIOLOGICAL|gene therapy|
223574292|NCT00002824|DRUG|chemotherapy|
223574293|NCT00002824|DRUG|ganciclovir|
223574294|NCT00002824|PROCEDURE|conventional surgery|
223574295|NCT02327936|DRUG|Fesoterodine|Administer medication to patients with overactive bladder
223574296|NCT02327936|DRUG|Oxybutynin XL|Administer medication to patients with overactive bladder
223574297|NCT02751034|DEVICE|Neuramis® Deep Lidocaine|HA filler
223459710|NCT02820077|DEVICE|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
223574298|NCT02751034|DEVICE|Restylane® PERLANE-L|HA filler
224156429|NCT03895970|DRUG|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
224156430|NCT01046656|DIETARY_SUPPLEMENT|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
223459711|NCT00873730|DRUG|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
223459712|NCT00873730|DRUG|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
223459713|NCT03413163|DRUG|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
223459714|NCT03413163|OTHER|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
223459715|NCT00002692|DRUG|fluorouracil|
223574299|NCT00495521|DRUG|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
223574300|NCT04254016|DIETARY_SUPPLEMENT|HIBISTEVER1|During 8 weeks, administration of a Hibiscus-Stevia drink for 8 weeks at a dose of 4 mg / kg / day for Stevia and 4 g / day for Hibiscus. Evaluation will take place the 30th and 60th days.
223574301|NCT04927767|DEVICE|denture adhesive|Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
223574302|NCT05259761|OTHER|Unmanned ariel vehicle|Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
223574303|NCT02178046|DEVICE|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
223574304|NCT01300819|OTHER|Placebo|"Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
223574305|NCT01300819|DRUG|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
223574306|NCT05215015|BIOLOGICAL|Anti-CD33/CLL1 CAR-NK Cells|The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
224156431|NCT00216515|DRUG|galantamine hydrobromide|
223459716|NCT00002692|DRUG|isolated perfusion|
223459717|NCT00002692|DRUG|leucovorin calcium|
223459718|NCT03112070|OTHER|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
223459719|NCT03633253|OTHER|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
223459720|NCT00017641|DRUG|anti-thymocyte globulin|
223459721|NCT00017641|DRUG|cyclophosphamide|
223459722|NCT00017641|DRUG|filgrastim|
223459723|NCT00017641|PROCEDURE|CD34+ Peripheral Blood Stem Cell Reinfusion|
223459724|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
223459725|NCT00103662|DRUG|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
223459726|NCT00664118|PROCEDURE|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
223459727|NCT00664118|PROCEDURE|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
223459728|NCT00006029|DRUG|gemcitabine hydrochloride|
223459729|NCT00006029|DRUG|pegylated liposomal doxorubicin hydrochloride|
223459730|NCT00006029|DRUG|vinorelbine tartrate|
223459731|NCT04612985|DEVICE|XACT Robotic System|CT-guided Minimally Invasive Procedures e.g., Biopsies
223459732|NCT03826537|OTHER|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin
223459733|NCT00884260|DRUG|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
223459734|NCT02070510|DRUG|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
223459735|NCT02070510|DRUG|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
223459736|NCT02070510|DRUG|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
223459737|NCT02070510|DRUG|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
223459738|NCT02535650|DRUG|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
223459739|NCT01749046|DRUG|Remegal|Remegal 1500 mg for 12 weeks
223459740|NCT04263246|DIETARY_SUPPLEMENT|PhytoDyNAmic|PhytoDyNAmic (6 capsules per day)
223459741|NCT04263246|DIETARY_SUPPLEMENT|Inulin|Inulin (6 capsules per day)
223459742|NCT04591756|OTHER|Qualitative Fit Testing|Qualitative fit testing with denatonium benzoate
223459743|NCT01942876|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
223459744|NCT01942876|BEHAVIORAL|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
223459745|NCT00010751|PROCEDURE|Reiki|
224302859|NCT01992523|DRUG|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
223459746|NCT01901042|DIETARY_SUPPLEMENT|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
223459747|NCT01901042|DIETARY_SUPPLEMENT|Maltodextrin|Control patients will receive sachets containing maltodextrin
223459748|NCT03560011|DRUG|immunoglobulin IV|5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
223459749|NCT00503347|DRUG|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
223459750|NCT02809950|OTHER|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
223459751|NCT02809950|OTHER|control group|NPO from midnight of the day before surgery
223459752|NCT00528749|OTHER|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
223459753|NCT02487537|DIETARY_SUPPLEMENT|custom-made soft drink|
223459754|NCT02403011|OTHER|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
223459755|NCT02403011|OTHER|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
223459756|NCT00943397|DRUG|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
223459757|NCT00943397|DRUG|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
223459758|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia (TEA) group|Under full aseptic conditions while the patient is in setting position, skin infiltration will be done with 2 ml of 1% lidocaine an 18-G Tuohy needle with a 20-G catheter (Perifix, B.Braun, Germany) will be inserted through the T6-T7 interspace, and the epidural space located using the loss of resistance technique. The catheter then advanced approximately 3 cm cephalic. A test dose of 3 ml of 1% lidocaine containing epinephrine in a ratio of 1:200,000 administered to detect unintentional intrathecal . After negative response, 15 ml of 0.25% epidural bupivacine will be injected and the patient will be turned to the supine position.
223574307|NCT05318612|PROCEDURE|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive neurosurgical procedure in which a laser catheter is placed into the tumor and warms the tumor to such an extent that tumor tissue is destroyed. LITT is performed under MR-guidance.
223574308|NCT05318612|PROCEDURE|Biopsy|A sample of tissue from the tumor is obtained to confirm the diagnosis.
223574309|NCT03796143|BEHAVIORAL|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
223574310|NCT03796143|BEHAVIORAL|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
223574311|NCT00938977|DEVICE|CPAP|Before and after effect of treatment with CPAP
223574312|NCT00938977|DEVICE|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
223574313|NCT00364052|DRUG|oral Valganciclovir vs oral Ganciclovir|
224156432|NCT01324427|BEHAVIORAL|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
224156433|NCT03274180|OTHER|Nursing consultation|travel preventive consultation was performed by nurse
224156434|NCT01454024|DEVICE|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
224156435|NCT01454024|DEVICE|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
224156436|NCT02549963|DEVICE|WATCHMAN Left Atrial Appendage Occlusion Device|
224156437|NCT02549963|DRUG|Rivaroxaban|
224156438|NCT02581124|DRUG|JTZ-951|
224156439|NCT02581124|DRUG|Lapatinib|
224156440|NCT04108819|DIETARY_SUPPLEMENT|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
224156441|NCT00004910|PROCEDURE|bowel obstruction management|
224156442|NCT00004910|PROCEDURE|quality-of-life assessment|
224156443|NCT06530121|BEHAVIORAL|Toolbox trainings|Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
224156444|NCT02796612|OTHER|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
224302860|NCT00730223|DRUG|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
223459759|NCT05238688|PROCEDURE|Thoracic Epidural Analgesia and Erector Spinae Plane Block (ESPB) group|Thoracic Epidural Analgesia will be done at first. Then, the ultrasound probe will be placed longitudinally 2-3 cm lateral to the T2 spinous process in the sagittal line. The T2 spinous process will be identified by counting down anatomically from the vertebral prominens (C7), and the T2 transverse process will be visualized by counting down from the first rib via real-time ultrasound guidance. The erector spinae muscle will be visualized above the T2 transverse process. The needle will be inserted in a caudal cranial direction using the in-plane technique. A dose of 5 mL normal saline will be injected into the inter-fascial area between the erector spinae muscle and the transverse process for the correction of the injection site (hydro-dissection). After hydro-dissection, 15 mL of 0.25% bupivacaine will be injected here, and the linear spread of the solution will be visualized in the inter-fascial plane.
223459760|NCT06262971|DEVICE|Percutaneous coronary intervention|balloon angioplasty, stent implantation, atherectomy, intravascular ultrasound.
223459761|NCT01608464|DRUG|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
223459762|NCT01608464|DRUG|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
223574314|NCT03118999|DIETARY_SUPPLEMENT|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
223574315|NCT03118999|DIETARY_SUPPLEMENT|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
223574316|NCT03118999|DIETARY_SUPPLEMENT|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
223574317|NCT01156168|GENETIC|DNA analysis|
223574318|NCT01156168|GENETIC|gene expression analysis|
223574319|NCT01156168|GENETIC|polymorphism analysis|
223574320|NCT01156168|GENETIC|protein expression analysis|
223574321|NCT01156168|OTHER|immunohistochemistry staining method|
223574322|NCT01156168|OTHER|laboratory biomarker analysis|
223574323|NCT02181101|DRUG|FEC-DocGemzar adjuvant chemotherapy|
223574324|NCT02181101|DRUG|FEC-Doc adjuvant chemotherapy|
223574325|NCT02181101|DRUG|Zoledronic acid i.v. 2 years|
223574326|NCT02181101|DRUG|Zoledronic acid i.v. 5 years|
223574327|NCT03467984|BIOLOGICAL|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
223574328|NCT03467984|BIOLOGICAL|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
223574329|NCT02491034|BEHAVIORAL|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
223574330|NCT00792532|PROCEDURE|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
223574331|NCT00792532|DEVICE|DBS electrodes|Deep brain stimulation (DBS) electrodes
223574332|NCT04367597|DEVICE|Home-based Neuromuscular Electrical Stimulation (NMES) therapy|A home-based NMES treatment applied by the subjects daily
223743329|NCT06448910|DRUG|Cadonilimab (AK104)|Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.
224156445|NCT02796612|BEHAVIORAL|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
224156446|NCT02796612|BEHAVIORAL|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
223459763|NCT01499693|DRUG|Magnesium Pantoprazole 20 mg|oral dose, twice a day
223459764|NCT01499693|DRUG|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
223574333|NCT01406496|DRUG|insulin|Three different timings of insulin delivered by a pump
223574334|NCT03568955|DIAGNOSTIC_TEST|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
223574335|NCT04103463|OTHER|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
223574336|NCT04103463|OTHER|Home exercise|Home exercise
223574337|NCT04184128|DIAGNOSTIC_TEST|Urodynamic study|The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
223743330|NCT06573086|OTHER|Resistance Training|12-week resistance training
223743331|NCT06632054|BEHAVIORAL|Text Message Reminders|Text message reminders (instead of usual care - phone call reminders) to complete FIT for colon cancer screening.
223743332|NCT04596631|DRUG|Oral semaglutide|Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
224156447|NCT04550936|DRUG|Isavuconazole|antifungal agent
224156448|NCT05843591|BEHAVIORAL|aerobic exercise or Tai Chi Chuan interventions|8-week aerobic exercise (AE group), 8-week Tai Chi Chuan training (TCC group)
224156449|NCT00868335|DEVICE|Activ C disc prosthesis|cervical disc prosthesis
223743333|NCT04596631|DRUG|Placebo (semaglutide)|Placebo treatment for 52 weeks.
223743334|NCT05615233|BEHAVIORAL|TACAD|"Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of PLAD (TACAD). It includes four components in three languages (English, MandarinChinese, and Korean):~1. 2 sub-ethnic specific social media sites;~2. interactive online educational modules;~3. online resources; and~4. a VR component based on A Walk Through Dementia (WTD)"
223743335|NCT05615233|BEHAVIORAL|Alzheimer's Association website|The webpage on caregiving includes information on caregiving, care option, financial/legal planning, caregiver health, daily care, stages and behaviors, and safety. The content will be available in the three languages at the project website.
223459765|NCT01499693|DRUG|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
223743336|NCT06975618|DRUG|CYH33|CYH33: Participants will receive oral CYH33 once daily. The starting dose for adults in Phase I is 10 mg QD; adolescents begin at 5 mg QD. In Phase II, patients will receive RP2D determined in the Phase I study.
223743337|NCT06975618|DRUG|Placebo|Placebo: Matching placebo tablets will be administered once daily during the double-blind period of the Phase II PRVM cohort. Patients randomized to placebo will switch to CYH33 at the end of the blinded phase.
223743338|NCT06574789|DRUG|Standard dosing of IV ganciclovir|IV ganciclovir at standard dosing
223743339|NCT06574789|DRUG|Personalised dosing of IV ganciclovir|IV ganciclovir at a personalised dosing calculated using a ganciclovir dosing web app
224156450|NCT00868335|PROCEDURE|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
224156451|NCT04976296|DIAGNOSTIC_TEST|MRD detection|The Geneplus OncoMRD lung assay is used to detect the MRD status.
224156452|NCT03527316|DRUG|MDMA|125 mg MDMA per os, single dose
224156453|NCT03527316|DRUG|Placebo|Capsules containing mannitol looking identical to the other drugs.
224156454|NCT00991224|BIOLOGICAL|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
224156455|NCT00991224|BIOLOGICAL|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
224156456|NCT00991224|OTHER|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
224156457|NCT00897741|GENETIC|microarray analysis|
224156458|NCT00897741|OTHER|laboratory biomarker analysis|
224156459|NCT03082417|OTHER|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:~1. Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~2. Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~3. Inform the patients and their family about how to better manage the pain after a fracture"
224156460|NCT00166517|BIOLOGICAL|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
224156461|NCT00166517|BIOLOGICAL|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
224156462|NCT01578538|PROCEDURE|inguinal hernia repair|strangulated hernias will be repaired surgically
223459766|NCT01966887|GENETIC|MYDICAR-single intracoronary infusion|AAV1/Serca2a
223459767|NCT01966887|GENETIC|Placebo; single intracoronary infusion|single intracoronary infusion
223459768|NCT04878055|DRUG|Reparixin|2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).
223459769|NCT04878055|OTHER|Placebo|Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
223459770|NCT02407873|OTHER|Non|
223459771|NCT01827735|DRUG|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
223459772|NCT03844425|DEVICE|Conventional VFR|Conventional retainers
223459773|NCT03844425|DEVICE|VFR from SLA|SLA has better finishing compared to FDM but it is more expensive.
223459774|NCT03844425|DEVICE|VFR from FDM|FDM has poorer finishing compared to SLA but it is cheaper.
223459775|NCT01968811|DEVICE|Avance Foam dressing kit|
223459776|NCT04658264|DIETARY_SUPPLEMENT|Wheat-Barley Composite flour|A combination of wheat and barley flour with 0.5% food grade xanthan gum as replacement for lost gluten, tested for sensory properties, nutrient profile, and rheology
223459777|NCT06358833|PROCEDURE|endodontic needle (EN)|the irrigation of root canals will be done with 2.5 % sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The tip of the needle will be pre-measured and positioned within 1 millimeter of the working length. No activation of the irrigant will be performed.
223459778|NCT06358833|PROCEDURE|Endodontic activation (EA)|the irrigation of root canals will be done with 2.5% sodium hypochlorite. The delivery of the irrigant will be done using 27G side-vented endodontic irrigation needles (Omega, Inc). The irrigant will be activated with ultrasonic energy using the Endo-1 Ultrasonic Endo Activator (Guilin Woodpecker, Guilin, China). The tip of the Endo-1 Ultrasonic Endo Activator device will be pre-measured and kept within 1 mm from the working length. The manufacturer's instructions regarding irrigant activation will be followed.
223459779|NCT02591641|DEVICE|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
223459780|NCT02591641|OTHER|Standard of Care|Standard ambulance stretcher mattress
223459781|NCT04574453|DEVICE|Iracross|Administration of max 2ml of Iracross at first visit
223459782|NCT04574453|DEVICE|Iraline|Administration of maximum 2 ml of Iraline at visit 1 to visit 3, 4 and 5 depending of suject's need
223459783|NCT00463918|DRUG|varenicline|
223459784|NCT00055445|DRUG|IdB 1016|
223459785|NCT01014247|DRUG|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
223459786|NCT01014247|DRUG|Placebo|Single dose of matching tablet
223459787|NCT00137345|DRUG|sirolimus|
223459788|NCT04993079|DEVICE|Clotild®|Use of Clotild® as neurovascular guidewire
223459789|NCT00116948|DEVICE|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
224156463|NCT03091595|DRUG|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
224156464|NCT03091595|DRUG|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
224156465|NCT03014921|OTHER|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
224156466|NCT03014921|OTHER|saline solution injection|Injection of a 250mL saline solution
223459790|NCT05765357|DRUG|Trastuzumab for injection|Trastuzumab for injection manufactured by Chia Tai Tianqing. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
223459791|NCT05765357|DRUG|Herceptin|Herceptin is the brand name of Trastuzumab for injection manufactured by Roche. Trastuzumab is a humanized IGG1-class monoclonal antibody produced by CHO cells. Its mechanism of action is to prevent the attachment of human epidermal growth factor to Her2 by attaching itself to Her2, thus blocking the growth of cancer cells. In addition, Trastuzumab can also stimulate the body's own immune cells to destroy cancer cells.
223459792|NCT01433419|DRUG|TAK-875|
223459793|NCT01433419|DRUG|TAK-875|
223459794|NCT02372344|DRUG|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
223459795|NCT02309970|DRUG|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
223459796|NCT02309970|DRUG|alteplase|subject in this group will receive intravenous tPA
223459797|NCT02309970|PROCEDURE|endovascular|
223459798|NCT00973583|DIETARY_SUPPLEMENT|vitamin D|vitamin D3 400 IU daily
223459799|NCT00973583|DIETARY_SUPPLEMENT|placebo|placebo
223459800|NCT02258217|DRUG|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
223459801|NCT03904420|OTHER|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
223459802|NCT03904420|OTHER|Traditional Model|Standard clinical practice and education
223459803|NCT02644278|DRUG|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
223459804|NCT02644278|DRUG|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
223459805|NCT02644278|DRUG|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
223459806|NCT02644278|DRUG|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.
223459807|NCT01089127|DRUG|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
223459808|NCT01089127|DRUG|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
223459809|NCT01089127|DRUG|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
223459810|NCT01089127|DRUG|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
223574338|NCT03700619|OTHER|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
223574339|NCT02262104|BEHAVIORAL|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
223574340|NCT02262104|BEHAVIORAL|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
223459811|NCT02702089|PROCEDURE|Rectal cancer surgery|Rectal cancer resection
223574341|NCT03345719|DIAGNOSTIC_TEST|3D Cone-Beam Imaging|
223459812|NCT01042834|OTHER|Air pollution study on healthy volunteers.|"The subjects are examined three times:~* First the volunteers get used to equipments.~* Second and third the volunteers sleep in a pollution or purified air."
224156467|NCT02209038|BEHAVIORAL|Expanded AD Choice|
224156468|NCT02209038|BEHAVIORAL|Expanded Life-sustaining Therapy Choice|
224156469|NCT04783870|DRUG|Dapagliflozin|Dapagliflozin 10 mg PO QD
223459813|NCT02025192|DRUG|Tucatinib|Administered twice per day, orally.
223459814|NCT02025192|DRUG|Capecitabine|1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
224156470|NCT04783870|DRUG|Placebo|Placebo
224156471|NCT01854671|OTHER|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
224156472|NCT04310878|OTHER|Survey among perioperative nurses and surgeons|Online survey
224156473|NCT06527209|OTHER|Coffee and agave inulin-based beverage (A)|"Intervention beverage:~134 mL of cold-brew coffee 18 g of agave inulin Total beverage weight: 350 g"
224156474|NCT06527209|OTHER|Control beverage (B)|"Control beverage:~40 mL of cold brew coffee 5.4 g of agave inulin Total beverage weight: 350 g."
224156475|NCT01758211|PROCEDURE|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
224156476|NCT01758211|PROCEDURE|conventional resection|conventional resection in AVM patients
224302861|NCT03425695|DEVICE|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
224302862|NCT03425695|OTHER|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
224302863|NCT05509738|BEHAVIORAL|SMS Text Messaging|"The text message-based healthcare assistance includes 1) message reminders and 2) a daily achievement reflection. The delivery schedule is as below.~1. Message reminders:~   The investigators will send participants two text reminders per day, one in the morning and one in the afternoon, from Monday to Friday, with the information on helping their child achieve healthy bladder goals.~2. Daily achievement reflection:~The investigators will send participants a text message with a survey link to reflect their and their children's daily goal achievement Monday to Friday evenings. Timely feedback (e.g., inspirational and compliment messages) will be provided based on participants' responses."
224302864|NCT06289803|DEVICE|probe confocal laser endomicroscopy|probe confocal laser endomicroscopy will be used to identify the tumor behavior
224156477|NCT02186561|DEVICE|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
224156478|NCT03275428|DEVICE|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
224302865|NCT03557424|DRUG|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
224302866|NCT03557424|DRUG|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
224302867|NCT03557424|DRUG|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
224302868|NCT00467935|DRUG|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
224302869|NCT01051219|DRUG|Losartan|50 milligrams to be taken orally, daily
224302870|NCT03641521|BEHAVIORAL|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
224302871|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 1|Free mobile mental health application that focuses on meditation
224302872|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 2|Free mobile mental health application that assists with coping with COVID-19
224302873|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 3|Free mobile mental health application that focuses on positive psychology.
224302874|NCT04536935|BEHAVIORAL|Mobile Mental Health App - 4|Free mobile application that addresses mental health issues through mood tracking
224302875|NCT00423475|DRUG|goserelin acetate|
224302876|NCT00423475|PROCEDURE|adjuvant therapy|
224302877|NCT00423475|RADIATION|radiation therapy|
224302878|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
224302879|NCT02217787|DRUG|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
224156479|NCT00149383|DRUG|Rosiglitazone|
224156480|NCT00149383|DRUG|Placebo|
224156481|NCT02197598|DRUG|nalmefene|
224156482|NCT00934011|OTHER|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
224156483|NCT00934011|OTHER|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
223459815|NCT02025192|DRUG|Trastuzumab|Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
223459816|NCT03576339|PROCEDURE|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
223459817|NCT03576339|DEVICE|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
223459818|NCT03576339|DEVICE|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
223459819|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
223459820|NCT01734447|DRUG|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
223459821|NCT01734447|DRUG|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
223459822|NCT03280485|OTHER|no intervention|no intervention validation of guidelines via database
223459823|NCT02622152|PROCEDURE|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
223459824|NCT02622152|PROCEDURE|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
223574342|NCT03625232|DEVICE|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
223574343|NCT02877654|PROCEDURE|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
223574344|NCT00671372|DRUG|FOLFIRI regimen|Intravenous repeating dose
223574345|NCT00671372|DRUG|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
224302880|NCT02758522|DRUG|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
223574346|NCT00671372|DRUG|cetuximab|Intravenous repeating dose
223574347|NCT00671372|DRUG|dulanermin|Intravenous repeating dose
223574348|NCT00671372|DRUG|irinotecan|Intravenous repeating dose
223574349|NCT04885322|DEVICE|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.
223574350|NCT04423458|DEVICE|3D imaging|"The study will focus on the accuracy of ultrasound technology in assessing renal transplants.~The entire assessment should not take more than 25 minutes."
223574351|NCT04194918|BEHAVIORAL|Computer-Assisted Smoking Cessation Intervention|Use the Flexiquit+ program
223574352|NCT04194918|OTHER|Text Message|Receive text messages
224156484|NCT04030897|BEHAVIORAL|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
224156485|NCT04030897|BEHAVIORAL|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
224156486|NCT04030897|BEHAVIORAL|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
223459825|NCT02622152|PROCEDURE|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
223459826|NCT02622152|PROCEDURE|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
223459827|NCT02622152|PROCEDURE|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
223459828|NCT04110431|PROCEDURE|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold\<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
223459829|NCT04110431|PROCEDURE|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
223459830|NCT01429467|DEVICE|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
223459831|NCT01963702|DRUG|Docetaxol|
223459832|NCT01963702|DRUG|Oxaliplatin|
223459833|NCT01963702|DRUG|Capecitabine|
223459834|NCT03826017|DIETARY_SUPPLEMENT|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
223459835|NCT03826017|DIETARY_SUPPLEMENT|Placebo|Placebo for 12 weeks.
223459836|NCT00627562|DEVICE|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
223459837|NCT02975401|PROCEDURE|rTAPP technique|robot-assisted rTAPP technique
223574353|NCT04194918|OTHER|Handout|Receive handouts via email
223574354|NCT04194918|OTHER|Questionnaire Administration|Ancillary studies
223574355|NCT04194918|OTHER|Quality-of-Life Assessment|Ancillary studies
224156487|NCT04285853|DRUG|Oxycodone|5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
224156488|NCT04285853|DRUG|Placebo oral tablet|"Placebo tablets (both trial and rescue) will be matched to size, shape, color, and texture of oxycodone tablets."
223459838|NCT01178905|PROCEDURE|ultrashort heat inactivation|
223459839|NCT00147706|PROCEDURE|Tailored Healthmedia programs on EHR Patient Portal|
223459840|NCT02816294|BEHAVIORAL|Housing Prescription|
223459841|NCT05743153|BEHAVIORAL|Multimodal intervention program|"Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support."
223459842|NCT06249581|DRUG|AUX-001 40mg once-daily|AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
223459843|NCT01339871|DRUG|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
223459844|NCT01339871|DRUG|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
223459845|NCT05881655|DEVICE|Airdoc Red Lighting Device|A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
223459846|NCT05881655|DEVICE|Special Spectacles to Control Myopia|Customer designed power and fitting to each subject for all the study periods.
223459847|NCT00827710|BEHAVIORAL|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
223459848|NCT00827710|BEHAVIORAL|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
223459849|NCT06363643|DEVICE|ELECTROSTIMULATION (ES)|ES will receive the electrostimulator directly at home and will do three weekly Tele supervised sessions of 30 minutes of indirect electrostimulation. The treatment will last 4 weeks.
223459850|NCT06363643|OTHER|EXERCISE (C)|C will perform three weekly Tele supervised sessions of exercise. The treatment will last 4 weeks.
223459851|NCT00130507|DRUG|Vinorelbine|
223459852|NCT00130507|DRUG|Capecitabine|
223459853|NCT00130507|DRUG|Trastuzumab|
223459854|NCT03936088|DEVICE|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
223459855|NCT03936088|DEVICE|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
223459856|NCT02266446|BEHAVIORAL|Attention & Interpretation Modification|
223459857|NCT03236597|OTHER|Treadmill desk|A standing height desk with a treadmill attached.
223459858|NCT05438277|DRUG|Methylprednisolone (MPA)|injection into subacromial or glenohumeral space with MPA
223459859|NCT05438277|DRUG|Triamcinolone Acetonide (TA)|injection into subacromial or glenohumeral space with TA
223459860|NCT01217996|BEHAVIORAL|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
223459861|NCT01217996|BEHAVIORAL|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
223574356|NCT04194918|OTHER|Survey Administration|Ancillary studies
223574357|NCT02416700|PROCEDURE|immediate implant surgery|Surgery of dental implants in one side of the mouth.
224156489|NCT00790127|DRUG|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
224156490|NCT00790127|DRUG|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
224156491|NCT00002004|DRUG|CD4 Antigens|
224156492|NCT01718964|DRUG|Cortisol 20 mg|
224156493|NCT01718964|DRUG|Mannitol|Mannitol used as placebo
224156494|NCT00119236|DRUG|tanespimycin|
224156495|NCT00119236|DRUG|irinotecan hydrochloride|
224156496|NCT01009021|DRUG|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
224156497|NCT05565014|DRUG|Virus Activated Killer immune Cells|The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
224156498|NCT05565014|DRUG|Saline|The use of saline was the same as VAK group.
224156499|NCT02895412|BIOLOGICAL|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
224156500|NCT03543670|DIETARY_SUPPLEMENT|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
223574358|NCT02416700|DEVICE|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
223574359|NCT01960127|BEHAVIORAL|Aerobic Exercise|Aerobic exercise
223574360|NCT01960127|BEHAVIORAL|No Intervention|No Intervention
223574361|NCT00432744|DRUG|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
223574362|NCT00432744|DRUG|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
223574363|NCT03121170|OTHER|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25), Guilai(ST29) and Zigong(EX-CA1) at the right and left sides of the lower abdomen. All acupuncture points should be placed according to participants' feedback during treatment.
223574364|NCT03121170|OTHER|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
223574365|NCT03198364|BEHAVIORAL|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
223574366|NCT03198364|BEHAVIORAL|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
223574367|NCT06155734|DRUG|Fluorescence guided identification using indocyanine green|During minimally invasive surgery using intravenous administration of indocyanine green (ICG) near-infrared fluorescence imaging will be applied to identify and treat paragangliomas
223574368|NCT05577364|DRUG|Selinexor|"Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen."
223574369|NCT05577364|DRUG|R-CHOP Protocol|"Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;"
223574370|NCT04941937|DRUG|Selinexor|Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs. Selinexor 60mg/d QW
224156501|NCT02455778|DIETARY_SUPPLEMENT|Cinnamon|
224156502|NCT02455778|DIETARY_SUPPLEMENT|Placebo|
224156503|NCT04714489|OTHER|NO.|NO.
224156504|NCT05245994|DRUG|Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib|Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy. Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator. The initial dose of olaparib is 300mg twice daily. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food.
223459862|NCT02068937|DRUG|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
223459863|NCT02068937|DRUG|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
223459864|NCT01841970|DEVICE|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
223574371|NCT04941937|DRUG|Thalidomide|100mg/d, Po. on day1-28
223574372|NCT04941937|DRUG|Lenalidomide|PO,Lenalidomide 25mg once daily from D1-21
223574373|NCT04941937|DRUG|Pomalidomide|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle, PO.
223574374|NCT04941937|DRUG|Dexamethasone|Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
223574375|NCT01319721|PROCEDURE|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
223574376|NCT01319721|PROCEDURE|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
223574377|NCT01319721|PROCEDURE|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
223574378|NCT00824551|PROCEDURE|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
223574379|NCT00824551|OTHER|Standard care|Patient will undergo standard care
223574380|NCT00438854|DRUG|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
223574381|NCT01672099|DIETARY_SUPPLEMENT|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
224156505|NCT03061812|DRUG|Rovalpituzumab tesirine|Powder for solution for infusion in vials.
224156506|NCT03061812|DRUG|Topotecan|Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
224156507|NCT03061812|DRUG|Dexamethasone|Oral tablet.
224156508|NCT05506696|DIETARY_SUPPLEMENT|Fultium|3200IU Fultium
224156509|NCT00259350|DRUG|Skin disinfection|
224156510|NCT01753700|DIETARY_SUPPLEMENT|UHT treated milk|
223459865|NCT02592447|OTHER|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
223459866|NCT02592447|OTHER|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
223459867|NCT01425736|DRUG|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
223459868|NCT01425736|DRUG|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
223459869|NCT00750113|DRUG|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
223574382|NCT01672099|DIETARY_SUPPLEMENT|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
223574383|NCT04575818|DRUG|GLPG4059 oral suspension|GLPG4059 for oral administration
223574384|NCT04575818|DRUG|Placebo|Placebo oral suspension
223574385|NCT04575818|DRUG|GLPG4059 tablet|GLPG4059 for oral administration
223574386|NCT00644618|DRUG|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
223574387|NCT00644618|OTHER|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
223574388|NCT04688918|PROCEDURE|Retrolaminar block|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The spinous process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vertebral lamina. A 50 mm 22-gauge needle will be inserted in an in-plane technique from cranial to caudal direction and will be advanced till hitting the laminae of fourth thoracic vertebrae and then we will try to inject the local anesthetic, if the resistance to injection is very high, hence we will withdraw the needle slowly and its tip will be kept in its position immediately after disappearance this high resistance. Bupivacaine 0.25%, 0.4mL/kg will be injected.
223574389|NCT04688918|PROCEDURE|paravertebral group|A high-resolution 5-12 MHz linear probe with a sterile cover will be used to perform the block. The patient will be placed in a prone position with a pillow under the chest. The transverse process of the fourth thoracic vertebrae will be identified and marked. Under complete sterilization, the ultrasound high frequency linear probe will be placed in a para-sagittal position, just lateral to the spinous processes of thoracic vertebra, to identify the vcostotransverse ligament, 0.4mL/kg will be injected
223574390|NCT05901805|OTHER|questionnaire application|"Participants will be asked to fill in the Occupational Sitting and Physical Activity Questionnaire adapted into Turkish. Correlation of the scale with the International Physical Activity Questionnaire-Short Form, VAS and YİBT-SF, Buss-Perry Aggression Scale will be tested. The questionnaire will be repeated every 7-14 days in order to perform the test-retest analysis of the questionnaire."
223574391|NCT03783611|BEHAVIORAL|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
223574392|NCT01668641|DRUG|GLPG0634|
223574393|NCT01668641|DRUG|Placebo|
223574394|NCT04076345|DIAGNOSTIC_TEST|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
223574395|NCT05615194|DRUG|Dexmedetomidine|0.6 mcg/kg in infusion over 10 minutes
223574396|NCT05615194|DRUG|Placebo|Volume equivalent in infusion over 10 minutes
223574397|NCT00002650|DIETARY_SUPPLEMENT|folic acid|
223459870|NCT00750113|DRUG|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
223574398|NCT00461305|DRUG|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
223574399|NCT00461305|DRUG|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
223574400|NCT02652416|DRUG|BI 1026706|oral administration
223574401|NCT02652416|DRUG|Placebo|placebo
223574402|NCT01609335|DRUG|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
223459871|NCT00750113|DRUG|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
224156511|NCT03774368|OTHER|Emergency contraception website|Existing website with factual information about emergency contraception
224156512|NCT03774368|OTHER|Emergency contraception video|Existing video with factual information about emergency contraception
224156513|NCT02945995|PROCEDURE|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
224156514|NCT00235664|PROCEDURE|Collection of stool and endotracheal aspirate samples|collection of samples
224156515|NCT05067712|PROCEDURE|Open Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances."
224302881|NCT02758522|DRUG|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
223459872|NCT03692429|DRUG|CYAD-101|Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
223459873|NCT03692429|DRUG|FOLFOX|5-FU, leucovorin and oxaliplatin
223459874|NCT03692429|DRUG|FOLFIRI|5-FU, leucovorin and irinotecan
223459875|NCT02652169|DRUG|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
223459876|NCT02652169|DRUG|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
223459877|NCT02652169|DRUG|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
223459878|NCT02652169|OTHER|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
223459879|NCT03861780|DRUG|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
223459880|NCT03861780|DRUG|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
223459881|NCT03861780|DRUG|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
223459882|NCT00902655|DRUG|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
223459883|NCT05410678|DRUG|Renal stent|renal stent implantation in ectatic/aneurysmatic coronary arteries
223459884|NCT05926648|DEVICE|INVSENSOR00061|Noninvasive pulse oximetry and pulse rate device
223459885|NCT05855434|DIAGNOSTIC_TEST|Magnetic Resonance Imaging|Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy
223459886|NCT04936503|DIAGNOSTIC_TEST|Resting electrocardiogram|An ECG at rest is performed for all participants at Day 0. A centralized reading is performed by one of the 6 expert cardiologists participating in the research.
223459887|NCT04936503|DIAGNOSTIC_TEST|Stress test|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a stress test is performed.
223459888|NCT04936503|DIAGNOSTIC_TEST|Cardiac echocardiography|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac echocardiography is performed.
223459889|NCT04936503|DIAGNOSTIC_TEST|Cardiac rhythm monitoring|In case of positive COVID-19 serology and/or positive COVID-19 RT-PCR and/or new ECG abnormality and/or positive questionnaire, a Cardiac rhythm monitoring is performed.
223459890|NCT04936503|OTHER|Questionnaire|To determine the rhythmic risk of athletes
223459891|NCT04936503|DEVICE|Injected Cardiac MRI|"High resolution MRIs is performed on 200 athletes :~* 100 athletes without rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)~* 100 athletes with rhythmic abnormalities (50 individuals with positive COVID-19 status and 50 individuals with negative COVID-19 status)"
223459892|NCT04936503|BIOLOGICAL|Blood sampling for biobank|"For all athletes included at the D0 inclusion visit, a centralized COVID-19 serology is performed to search for biomarkers associated with the occurrence of myocardial fibrosis: analysis of genetic determinants in relation to cardiac damage.~For athletes who have performed MRI: Search for biomarkers associated with the occurrence of myocardial fibrosis: analyses of low-grade inflammation markers (cytokine assay and fibrosis markers)."
223459893|NCT03407417|OTHER|virtual technology|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
223459894|NCT02635308|BEHAVIORAL|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
223459895|NCT02605759|DEVICE|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
223459896|NCT01983215|DEVICE|Prevena vac|
223459897|NCT00844090|DRUG|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
223459898|NCT04518618|DRUG|Fentanyl|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and 25 ugs fentanyl (0.5 ml)
223459899|NCT04518618|DRUG|Naloxone|Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
223459900|NCT01290510|DEVICE|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
223459901|NCT03509168|DRUG|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
223459902|NCT03509168|OTHER|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
223459903|NCT02902835|BEHAVIORAL|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
223459904|NCT02902835|BEHAVIORAL|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
223459905|NCT06107647|DEVICE|COVIDIEN WarmTouch|"COVIDIEN WarmTouch will be used as an active air blowing heater. Patients will be warmed starting from the beginning of anesthesia.~The INDITHERM Medical Alpha, which is a resistive heater, will be applied to patients starting at the beginning of anesthesia."
223459906|NCT01048541|DEVICE|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
223459907|NCT01048541|DEVICE|SpeediCath|Catheter for intermittent catheterisation
223459908|NCT00627497|PROCEDURE|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
223459909|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
223459910|NCT00627497|DEVICE|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
223459911|NCT00627497|DEVICE|Fusion|Posterolateral Interbody Fusion
223459912|NCT03768778|PROCEDURE|Debridement and dural repair|
223459913|NCT01372046|BEHAVIORAL|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
223459914|NCT01372046|BEHAVIORAL|Training|memorandums, staff meetings
223459915|NCT00236691|DRUG|topiramate|
223459916|NCT03578627|BEHAVIORAL|BioBehavioral Intervention|Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints-recurrence, disease free interval) might be affected.
223459917|NCT02770911|PROCEDURE|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
223459918|NCT02770911|PROCEDURE|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
223459919|NCT01848171|DRUG|L-thyroxine|
223459920|NCT03647306|BEHAVIORAL|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
223459921|NCT03647306|BEHAVIORAL|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
223459922|NCT03647306|BEHAVIORAL|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
223459923|NCT03743766|DRUG|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
223459924|NCT03743766|DRUG|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
223459925|NCT03743766|DRUG|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
223459926|NCT04195724|OTHER|mNGS for pathogen detection|mNGS for pathogen detection and metabonomics (ascites, fecal,venous blood from superior mesenteric vein, hepatic vein and peripheral vein, respectively)
223459927|NCT02410408|DEVICE|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
223459928|NCT02410408|OTHER|information package|Information on PSC and RCA
223459929|NCT05268341|BEHAVIORAL|My Sentence Builder|computer-assisted treatment program for expressive grammar
223459930|NCT06843486|OTHER|Multicomponent Exercise|Training sessions will include aerobic, resistance, balance and flexibility exercises, following the American College of Sports Medicine (ACSM) guidelines for osteoporosis prevention.
223459931|NCT03153241|OTHER|No intervention|No intervention
223459932|NCT00913211|DEVICE|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
223459933|NCT00913211|PROCEDURE|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
223459934|NCT00913211|PROCEDURE|rTMS and Tracking|Combination of rTMS and finger tracking
223459935|NCT00913211|DEVICE|Sham rTMS|Sham treatment of rTMS
223459936|NCT01340729|DRUG|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
223459937|NCT01015716|BEHAVIORAL|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
223459938|NCT01015716|BEHAVIORAL|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
223459939|NCT00622102|BEHAVIORAL|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
223459940|NCT00622102|BEHAVIORAL|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
223459941|NCT00062348|DRUG|boronophenylalanine-fructose complex|
223459942|NCT00062348|DRUG|sodium borocaptate|
223459943|NCT00062348|PROCEDURE|conventional surgery|
223459944|NCT03521869|DEVICE|Compression bandage|Compression bandage placed after total knee replacement
223459945|NCT03521869|DEVICE|Gauze dressing|standard of care gauze dressing placed after total knee replacement
223574403|NCT01609335|DRUG|C-11 PiB|One time intravenous administration of 10-20 mCi
224156516|NCT05067712|PROCEDURE|Closed Surgical Exposure Technique|"* A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch."
223459946|NCT00327717|DRUG|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
223574404|NCT06289816|PROCEDURE|Minimally Invasive Surgery|Minimally Invasive Surgery : Laparoscopic partial splenectomy, cystectomy, and cyst deroofing.
223459947|NCT00327717|DRUG|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
223459948|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
223459949|NCT00402792|DRUG|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
223459950|NCT00402792|DRUG|Placebo|2 tablets q 12 hours
223459951|NCT02734134|PROCEDURE|One-stage exchange joint replacement surgery|
223459952|NCT02734134|PROCEDURE|Two-stage exchange joint replacement surgery|
223459953|NCT01664507|DRUG|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
223459954|NCT01664507|DRUG|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
223574405|NCT00787930|DRUG|Valproic Acid|Tablets, 250mg-3000mg
223574406|NCT01896271|DRUG|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
223574407|NCT01896271|RADIATION|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
223574408|NCT00758121|DEVICE|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
223574409|NCT04790812|DRUG|Celecoxib|Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
224156517|NCT01613508|PROCEDURE|Direct Anterior Approach|
224156518|NCT01613508|PROCEDURE|Mini-Posterior Approach|
223459955|NCT03647566|DIAGNOSTIC_TEST|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
223459956|NCT03647566|DIAGNOSTIC_TEST|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
223459957|NCT03647566|DIAGNOSTIC_TEST|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
223459958|NCT02308449|DRUG|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
223459959|NCT02308449|DRUG|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
223459960|NCT00239473|DEVICE|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
223459961|NCT00239473|DEVICE|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
223459962|NCT02080364|DRUG|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
223459963|NCT02080364|DRUG|Placebo|Placebo administered orally, once daily for 18 months
223459964|NCT05476354|DRUG|Irbesartan/Amlodipine low|Irbesartan/Amlodipine low once daily for 8 weeks
223459965|NCT05476354|DRUG|Irbesartan/Amlodipine high|Irbesartan/Amlodipine high once daily for 8 weeks
223459966|NCT05476354|DRUG|Irbesartan|Irbesartan once daily for 8 weeks
223459967|NCT03126461|RADIATION|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
223459968|NCT03126461|DRUG|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
223459969|NCT03126461|DRUG|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
223459970|NCT05065294|DRUG|Psilocybin therapy|\- Psilocybin administration session 10mg-25mg delivered orally with psychological support and monitoring
223574410|NCT04790812|DRUG|Acetaminophen|Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
223574411|NCT04790812|DRUG|Placebo|A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
223574412|NCT02091284|DEVICE|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
223574413|NCT01454349|DRUG|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
223574414|NCT01454349|DRUG|Placebo|Single intraprostatic injection of matching placebo
223574415|NCT04299919|PROCEDURE|Minimally invasive treatment|All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
223574416|NCT04299919|PROCEDURE|Hepatectomy|All hepatocellular carcinoma (HCC) patients received hepatectomy.
223574417|NCT02855957|OTHER|Free α-Hb pool analysis|
223574418|NCT05854576|PROCEDURE|vascular acess|AVF
224156519|NCT00594087|DRUG|eszopiclone|eszopiclone 2mg or 3mg at bedtime
224156520|NCT00594087|OTHER|placebo|2 mg or 3 mg at bedtime
223459971|NCT01635374|PROCEDURE|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
223459972|NCT00202098|PROCEDURE|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
223574419|NCT03383783|DRUG|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
223574420|NCT03383783|DRUG|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
223574421|NCT03383783|DRUG|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
223574422|NCT03383783|DRUG|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
223574423|NCT00348907|DRUG|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
223574424|NCT00348907|DRUG|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
223574425|NCT00403780|DRUG|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
223574426|NCT00403780|DRUG|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
223574427|NCT00049608|DIETARY_SUPPLEMENT|mistletoe extract|
223574428|NCT00049608|DRUG|gemcitabine hydrochloride|
223574429|NCT03282110|DEVICE|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
223574430|NCT03282110|OTHER|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
223574431|NCT03282110|DRUG|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
223574432|NCT00665756|PROCEDURE|second Trabeculectomy|second trabeculectomy with mitomycin-c
223574433|NCT00665756|PROCEDURE|Ahmed Implant|Ahmed silicone drainage device
224156521|NCT05376956|DIAGNOSTIC_TEST|Muscle Energy Technique|Using Muscle Energy Technique in Individuals With Hamstring Shortness
223574434|NCT01847105|OTHER|RevitaLens|Multi-purpose disinfecting solution
223574435|NCT01847105|OTHER|OptiFree PureMoist|Multi-purpose disinfecting solution
223574436|NCT05976022|DEVICE|active rTMS|2 sessions with 1800 pulses per session and 50min inter-session interval of active rTMS will deliver to the assigned target
223574437|NCT02159222|PROCEDURE|Additional physical therapy|
223574438|NCT03082573|DRUG|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
223574439|NCT03234348|DEVICE|Percutaneous coronary intervention|PCI + stent implantation
224156522|NCT05376956|DIAGNOSTIC_TEST|Proprioception neuromuscular facilitation (PNF)|Using proprioception neuromuscular facilitation (PNF) in Individuals With Hamstring Shortness
224156523|NCT06047106|RADIATION|multiparametric MRI|"For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.~For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment."
224156524|NCT06047106|PROCEDURE|kidney graft biopsy|Biopsy of the graft itself prior to transplantation in the recipient.
223459973|NCT02574364|RADIATION|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
223574440|NCT01340937|BIOLOGICAL|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate \[Meningococcal Outer Membrane Protein Complex\], and Hepatitis B \[Recombinant\] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
223574441|NCT01340937|BIOLOGICAL|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
223574442|NCT01340937|BIOLOGICAL|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
223574443|NCT01340937|BIOLOGICAL|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
223574444|NCT01340937|BIOLOGICAL|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
223574445|NCT03741803|PROCEDURE|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
223574446|NCT03741803|PROCEDURE|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
223574447|NCT04475484|OTHER|Online questionnaire|"Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress."
223574448|NCT02119156|DRUG|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
223574449|NCT02469415|DRUG|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
223574450|NCT02469415|DRUG|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
223574451|NCT02469415|DRUG|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
223574452|NCT03384823|DRUG|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
223574453|NCT03384823|DRUG|Placebo|placebo to match EDP-938
223459974|NCT02574364|OTHER|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
223459975|NCT06067997|DIAGNOSTIC_TEST|pulmonary embolism diagnosis|"The diagnosis of pulmonary embolism will be made using the diagnostic algorithm suggested by the 2019 European guidelines . The pre-test clinical probability of pulmonary embolism will be defined based on the simplified Wells score. In patients with a low pre-test clinical probability and a D-dimer level below the threshold value the diagnosis of pulmonary embolism will be excluded. The D-dimer level will be measured using the quantitative assay routinely used in each participating center; the threshold value for a positive result compared to a negative result is 500 μg per milliliter for patients under 50 years of age. For each additional decade of age, the exclusion cutoff will increase by 100 μg per milliliter.~The criterion for the presence of pulmonary embolism is the detection of an intraluminal filling defect on CT."
223459976|NCT04686422|DEVICE|Tetric PowerFill|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
223459977|NCT03875196|DEVICE|Pelvic Floor Muscle Training With Biofeedback|Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.
223459978|NCT03875196|DEVICE|Extracorporeal Magnetic Innervation|Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
223459979|NCT00696735|PROCEDURE|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
223459980|NCT00696735|PROCEDURE|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
223574454|NCT04108715|PROCEDURE|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
224067807|NCT04807907|BEHAVIORAL|Infant Directed Speech (IDS) Video + IDS Wall Calendar|"IDS Video: The IDS video was developed by the research team. It is a simple animation with a voiceover describing the value of IDS and encouraging the viewer to speak to her babies and to tell family members to do so as well. The video has been translated into Dagbani and English (viewers select the language). They may choose to watch it twice.~Breastfeeding women are told by the surveyor following the video, For instance, you could talk to your baby in full sentences when your baby is breastfeeding.~Wall Calendar: The calendar contains images from the video of parents practicing IDS, and key facts about IDS in bullet points. The 12-month calendar contains an empty star next to each week that the respondent can fill in if they perform IDS at least once a day in that week. The calendar also provides a link to a Facebook page where the respondents can re-watch the video or show it to others (https://www.facebook.com/ghanababytalk/videos)."
223459981|NCT02810275|DRUG|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
223459982|NCT02810275|DRUG|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
223459983|NCT04036591|DIAGNOSTIC_TEST|Acute Bronchiolitis Severity Scale (ABSS)|All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
224156525|NCT06047106|BIOLOGICAL|blood samples|"For donors who are not selected to donate their kidney, a total of 2 mL of blood will be collected at inclusion.~For donors eligible to donate, a total of 4 mL of blood will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 26 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant)."
224156526|NCT06047106|BIOLOGICAL|urine specimens|"For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.~For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).~For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant)."
223743340|NCT03681054|OTHER|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
223743341|NCT03681054|OTHER|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: \<10 E%; fatty acids: saturated fatty acids \< 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
223459984|NCT04639362|DRUG|ibrutinib, venetoclax, obinutuzumab|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are not in CR or who have detectable MRD after 15 cycles (3 cycles lead-in and 12 cycles induction) will continue with 6 intensification cycles ibrutinib in combination with obinutuzumab day 1, 2, 8, 15 for the first cycle and with obinutuzumab day 1 for the following 5 cycles.
223459985|NCT04639362|DRUG|ibrutinib, venetoclax|Patients will receive 3 cycles lead-in with ibrutinib 420 mg/day. Here-after, patients will continue with 13 induction cycles (including one bridging cycle) combining ibrutinib 420 mg/day and venetoclax 400 mg/day (including a ramp up of 5 weeks). Patients who are in CR or have no detectable MRD will be observed.
223459986|NCT00100347|DRUG|PPI-2458|
224067808|NCT06279156|DEVICE|Bioelectrical Impedance Analysis (BIA)|"Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition."
223459987|NCT00571662|DRUG|Pentostatin|4 mg/m\^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
223459988|NCT00571662|RADIATION|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
223459989|NCT00571662|DRUG|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
223743342|NCT03695796|DIAGNOSTIC_TEST|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
224067809|NCT03509350|DRUG|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
224067810|NCT03509350|DRUG|Thiamine|Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
224067811|NCT03509350|DRUG|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
224067812|NCT03509350|DRUG|Vitamin C Placebo|A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
224067813|NCT03509350|DRUG|Thiamine Placebo|A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
224067814|NCT03509350|DRUG|Hydrocortisone Placebo|A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
224067815|NCT02277509|BEHAVIORAL|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
224067816|NCT02277509|BEHAVIORAL|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
224067817|NCT01425203|DRUG|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
224067818|NCT01425203|DRUG|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
224067819|NCT01425203|BIOLOGICAL|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
224067820|NCT01425203|DRUG|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
224067821|NCT04338815|OTHER|Exoskeleton Optimization|Participants will walk 10-minute trials while an optimization algorithm changes the assistance profile of the exoskeleton.
224156527|NCT03358615|PROCEDURE|cesarean section|assessment of the indications of cesarean section according to Robson criteria
224156528|NCT04864600|OTHER|Candle C|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
224156529|NCT04864600|OTHER|Candle 1|Burning candles will produce particulate air pollution being passed on an exposure chamber where the participants will be sitting for 5 hours.
224156530|NCT01347632|DRUG|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
224156531|NCT01090674|OTHER|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
223459990|NCT00571662|DRUG|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
224067822|NCT04338815|OTHER|Endurance Evaluation|Participants will walk 2 trials at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes, which ever comes first.
223459991|NCT00571662|DRUG|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
224067823|NCT05773196|OTHER|Biospecimen Collection|"Cohort 1-Huntington's Disease:~The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).~Sample Collection:~* 10 mL EDTA Vial (Box 1; Frozen)~  o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1.~* 10 mL EDTA Vial (Box 2; Ambient)~  * Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2."
224067824|NCT00535132|DRUG|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
224067825|NCT00535132|DRUG|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
224067826|NCT02878954|OTHER|No intervention (Observational study)|"160 patients will be recruited to:~* Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~* Perform a six-minute walk test Comparison between men and women will be performed."
224067827|NCT02878954|OTHER|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
223459992|NCT01948921|DRUG|placebo|
223459993|NCT01948921|DRUG|Meperidine|
223459994|NCT03883763|DRUG|bupivacaine S75:R25 plus 8% glucose|Spinal anesthesia, 20 mg
223459995|NCT03883763|DRUG|bupivacaine S50:R50 plus 8% glucose|Spinal anesthesia, 20 mg
224067828|NCT02878954|OTHER|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
224067829|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Control Protocol|To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
224067830|NCT04094571|DEVICE|Functional Electrical Stimulation (FES) Angle Protocol|To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
224067831|NCT00261430|BEHAVIORAL|GAIN Acceptance Approach|
224067832|NCT03700307|PROCEDURE|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
224067833|NCT02764827|BIOLOGICAL|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
224067834|NCT00871312|DEVICE|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
224067835|NCT00871312|DEVICE|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
224067836|NCT05133635|DRUG|Methylprednisolone|Patients with the clinical and laboratory diagnosis of cytokine storm will receive methylprednisolone 250 mg for 3 days.
224067837|NCT05133635|DRUG|Tocilizumab|Patients with the clinical and laboratory diagnosis of cytokine storm will receive tocilizumab 400-800 mg for one time.
224156532|NCT05054231|OTHER|Blood sample collection|Blood samples collection: at Day (D)-6 and D0 before CAR-T cells injection, post injection at Day (D)3, D5,D7, D9, D11, D14, D18, D 21, Month 2 and Month 12 post injection.
224156533|NCT02865265|PROCEDURE|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
224156534|NCT00689169|DRUG|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
224156535|NCT00689169|PROCEDURE|ASCT|ASCT : D0
224156536|NCT00689169|DRUG|Rituximab|Rituximab 250 mg/m² :D-21 D-14
224156537|NCT04447118|DRUG|Pyrotinib|400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.
224156538|NCT04447118|DRUG|Docetaxel|75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.
224156539|NCT00492414|DRUG|Paroxetine CR|
223459996|NCT02629744|DRUG|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
223459997|NCT02629744|DEVICE|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
223459998|NCT06024707|DRUG|Biological Drug|This intervention is part of regular treatment, subjects will be included if they get this treatment.
224156540|NCT01577355|RADIATION|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
224156541|NCT04957303|DEVICE|sublingual microcirculation video recording|The sublingual microcirculation videos were recorded by video microscope
224156542|NCT04742036|DRUG|Capivasertib|Part A Cycle 0: Single dose 480 mg(3 x 160 mg tablets) on Day 1 of Cycle 0 Cycle 1 (monotherapy): 480 mg(3 x 160 mg tablets) twice daily given on an intermittent weekly dosing schedule (4 days on, 3 days off for 7 days) Part B Cycle 2 (in combination therapy with paclitaxel): 400 mg (2 x 200 mg tablets) twice daily given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Capivasertib treatment will continue until disease progression, unacceptable toxicity or the participant requests to stop treatment.
224156543|NCT04742036|DRUG|Paclitaxel|"Part B Cycle 2: Patients will receive 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle.~Paclitaxel treatment will continue for at least 6 cycles, unless the participant experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel, or disease progression."
224156544|NCT00846469|PROCEDURE|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
224156545|NCT00846469|OTHER|Control section|Normal emergency room treatment for symptoms of chest pain.
224156546|NCT06239324|DRUG|Latanoprost|Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.
224302882|NCT02758522|DRUG|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
224302883|NCT01684436|DEVICE|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
224302884|NCT00476983|DRUG|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
224302885|NCT05297578|BIOLOGICAL|24-Valent Pneumococcal Conjugate Vaccine|0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1
224302886|NCT05297578|BIOLOGICAL|Pneumococcal 20-valent Conjugate Vaccine|0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1
224302887|NCT06552065|OTHER|collagen with silk fibroin membrane|"A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.~An immediate implant with collagen membrane ( comparative group) will be placed according to the standard protocol .~The surgical wound closure will be coapted with mattress and single interrupted sutures"
224302888|NCT06552065|OTHER|cross linked collagen membrane|A mucoperiosteal flap will be raised and atraumatic extraction will be done. An immediate implant with collagen with silk fibroin membrane (experimental group) will be placed according to the standard protocol.
224302889|NCT02770885|DRUG|Dulaglutide|Treatment with dulaglutide for 3 weeks.
224302890|NCT02770885|DRUG|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
224302891|NCT04040023|DRUG|Iron and vitamin Deficiencies Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation"
224302892|NCT04040023|OTHER|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
224302893|NCT00889369|DRUG|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
224302894|NCT02266134|BEHAVIORAL|Tailored Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire; the implementation of measurement-based care will be tailored based on clinic specific barriers and facilitators.
223459999|NCT02985112|DEVICE|FFR and IVUS-NIRS|
224067838|NCT04377451|DRUG|Metformin|"The trial will be conducted in two phases, with a dose escalation of metformin. Metformin dosing will begin at 500mg (children) and 850mg (adults) once daily for 5 days in cohort 1.~Cohort 2 will be received weight-based doses; 5 days of 1000mg (500mg twice daily) for those weighing \<60kg and 5 days of 1500mg (1000mg mane, 500mg nocte) for those weighing ≥60kg"
224067839|NCT00793650|DRUG|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
224067840|NCT00793650|DRUG|Melphalan|"All patients received melphalan (100 mg/m\^2/day × 2; days~-3 and -2), for a total dose of 200 mg/m\^2."
224067841|NCT00793650|PROCEDURE|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
224067842|NCT02645175|DIETARY_SUPPLEMENT|TW1025|20ml, 3 times per day (daily dose: 60 ml)
224067843|NCT02645175|DIETARY_SUPPLEMENT|Placebo|20ml, 3 times per day (daily dose: 60 ml)
224067844|NCT04864665|DIETARY_SUPPLEMENT|a formula with prebiotics and milk fat|Provided in a formula added with prebiotics and milk fat for 1 month
224067845|NCT00267748|DRUG|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
224067846|NCT00267748|DRUG|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
224067847|NCT03992937|DRUG|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
224067848|NCT03992937|DEVICE|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
223460000|NCT06305975|PROCEDURE|Blunt fascial abdominal entry|Blunt fascial entry technique description: a 5 mm incision is made in the umbilicus. Next, a curved Kelly forceps is used to open the fascia, and, if possible, the peritoneum. The Kelly forceps are then used to expand the opening to a 10 mm diameter. A 5 mm trocar is placed into the fascial hole and used to quickly insufflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
224156547|NCT00671619|DRUG|ESBA105|eye drops
223460001|NCT06305975|PROCEDURE|Veress needle abdominal entry|Veress needle abdominal entry technique description: a 5 mm incision is made in the umbilicus. Next, a Veress needle is used to enter the peritoneal cavity and inflate the abdomen to 15 mm Hg. Once the abdomen is fully insufflated, a 10 mm trocar is placed using optical guidance.
223574455|NCT04108715|PROCEDURE|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
223574456|NCT05396729|DEVICE|transcutaneous electrical acupoint stimulation|Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given for 30 minutes, twice a day for 3 days.
223574457|NCT00499655|DRUG|erlotinib hydrochloride|Given orally
223574458|NCT00499655|DRUG|celecoxib|Given orally
223743343|NCT03398057|OTHER|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
224067849|NCT04833283|DEVICE|ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)|Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
224067850|NCT04833283|DEVICE|ReOxy Cardio device|Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
224067851|NCT01294800|DRUG|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
224067852|NCT01294800|DRUG|Placebo tablet to match Preladenant|tablets taken orally BID
223743344|NCT03398057|OTHER|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
224067853|NCT00958204|PROCEDURE|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
224067854|NCT00958204|PROCEDURE|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
224067855|NCT00958204|DRUG|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
224067856|NCT00958204|DRUG|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
224067857|NCT00381771|BEHAVIORAL|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
224067858|NCT00225472|DEVICE|Modified Viaspan|
224067859|NCT02499068|DEVICE|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
224067860|NCT00864955|RADIATION|UVA and UVB irradiation|"* 4 cutaneous biopsies for Ex-vivo irradiation~* Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
224067861|NCT00000559|DRUG|estrogen replacement therapy|
224067862|NCT00000559|DRUG|hormone replacement therapy|
224067863|NCT00000559|DRUG|estradiol|
224067864|NCT00000559|DRUG|medroxyprogesterone|
224067865|NCT01409720|OTHER|exercise|tailored isometric physical exercise
224067866|NCT01857713|DEVICE|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
224067867|NCT03236558|PROCEDURE|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
224067868|NCT01531114|DRUG|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
224067869|NCT01531114|DRUG|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
224067870|NCT00938756|OTHER|diagnostic laboratory biomarker analysis|
224156548|NCT03032250|OTHER|Communication Intervention|Attend interventionist sessions
224156549|NCT03032250|OTHER|Watch video|Watch video on a DVD
224156550|NCT03032250|OTHER|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
224156551|NCT03032250|OTHER|Quality-of-Life Assessment|Ancillary studies
224156552|NCT03032250|OTHER|Survey Administration|Ancillary studies
224156553|NCT03032250|OTHER|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
224156554|NCT04287439|BEHAVIORAL|Progressive muscle relaxation|Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
223460002|NCT03729791|DEVICE|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
223460003|NCT00964028|BIOLOGICAL|Infanrix™-IPV/Hib|Intramuscular, three doses
223460004|NCT03666949|DRUG|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
223460005|NCT03666949|DRUG|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
223460006|NCT03577314|OTHER|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
223460007|NCT00183508|BEHAVIORAL|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
223460008|NCT00183508|BEHAVIORAL|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
223460009|NCT03472521|DRUG|Gabapentin|Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
223460010|NCT03472521|DRUG|Placebo|Placebo to match gabapentin
223460011|NCT02385110|DRUG|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
223460012|NCT02385110|DRUG|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
223460013|NCT02385110|DRUG|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
223460014|NCT02385110|DRUG|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
223460015|NCT02385110|BEHAVIORAL|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
223460016|NCT02385110|DRUG|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
223460017|NCT00343629|DRUG|sulindac|
223460018|NCT00343629|OTHER|pharmacological study|
223460019|NCT03934840|DRUG|Cabazitaxel|20 mg/m2 Q 21 days
223460020|NCT03934840|DRUG|Carboplatin|AUC 4 Q21 Days x 6 cycles with ADT
223460021|NCT03934840|DRUG|Abiraterone|1000 mg PO daily
223460022|NCT03934840|DRUG|Prednisone|5 mg PO daily on chemotherapy completion
223460023|NCT04054726|DEVICE|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
223460024|NCT04054726|DEVICE|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
223460025|NCT04956939|DRUG|Low dose levodopa|Low frequency is defined as ≤ 3 LD doses a day
223460026|NCT04956939|DRUG|High dose levodopa|High frequency dosage is defined as ≥ 5 LD doses per day
223460027|NCT03634202|COMBINATION_PRODUCT|IMRT + oral chemotherapy|"It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)"
223460028|NCT03051347|OTHER|Itch Questionnaire and Interview|
223460029|NCT03051347|OTHER|Stigma Questionnaire and Interview|
223460030|NCT03051347|OTHER|Cognitive Interview and PROMIS Itch Questionnaire|
223460031|NCT05085470|BIOLOGICAL|Schistosoma mansoni infection|20 viable male Schistosoma mansoni cercariae of the Puerto Rican strain
223460032|NCT05085470|BIOLOGICAL|Placebo mock infection|Placebo mock infection with water
223460033|NCT01122459|OTHER|fluid administration|1.5mls/kg/hr fasting
223460034|NCT01002248|DRUG|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
223460035|NCT01002248|DRUG|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
223460036|NCT01002248|DRUG|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
223460037|NCT01002248|DRUG|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
223460038|NCT02076815|DRUG|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
223460039|NCT02076815|DRUG|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
223460040|NCT01768923|PROCEDURE|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score \[SDAI\] \<3.3)
223574459|NCT00499655|OTHER|placebo|Given orally
224156555|NCT04287439|BEHAVIORAL|Mindfulness meditation|Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.
223460041|NCT01768923|PROCEDURE|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28\<2.6) (minimal disease activity group)
223460042|NCT03705286|DEVICE|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
223460043|NCT03705286|DEVICE|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
223460044|NCT01815502|DIAGNOSTIC_TEST|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
223460045|NCT01476800|DRUG|YM178 OCAS|oral
223460046|NCT01476800|DRUG|Ketoconazole|oral
223460047|NCT01060917|DEVICE|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
223460048|NCT01060917|PROCEDURE|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
223460049|NCT01060917|DEVICE|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
223460050|NCT05395156|DEVICE|Transcutaneous electrical nerve stimulation (TENS)|Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
223460051|NCT03193229|BEHAVIORAL|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
223460052|NCT03193229|DEVICE|Fitbit|Fitbit
223460053|NCT00613392|DIETARY_SUPPLEMENT|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
223460054|NCT00613392|DIETARY_SUPPLEMENT|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
223460055|NCT02338401|DIETARY_SUPPLEMENT|Omega-3 Complete|Fish Oil Capsules
223460056|NCT02338401|DIETARY_SUPPLEMENT|Placebo Pill|Olive Oil Capsules
223460057|NCT01330550|DIETARY_SUPPLEMENT|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
223460058|NCT05297461|OTHER|Medication review|Community pharmacy benchmarking guideline Pharmaceutical Services Division provides guidelines for medication review in community pharmacy settings in Malaysia
223460059|NCT02587195|DRUG|Teriflunomide|
223460060|NCT04544059|DRUG|Lenalidomide|Lenalidomide orally 25 mg per day was administered on days 1 through 10 of each cycle and delivered concomitantly with standard dose R-CHOP-21 regimen (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2 or Liposome doxorubicin 30mg/m2, vincristine 1.4 mg/m2 \[capped at 2.0 mg\], all on day 1; prednisone 100 mg per day on days 1 through 5). All patients received aspirin 100mg per day prophylaxis throughout, unless they were on therapeutic dose warfarin or low molecular weight heparin for intercurrent conditions. The treatment continued for a maximum of six to eight cycles or until disease progression. Tumor lysis prophylaxis, antiemetics, and supportive care were standard of care.
223460061|NCT00001013|DRUG|Trimetrexate glucuronate|
223460062|NCT00001013|DRUG|Pentamidine isethionate|
224156556|NCT04287439|OTHER|Attention matched control|Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
224156557|NCT06221072|DRUG|JMT103|120 mg by subcutaneous injection every 4 weeks
224156558|NCT06221072|DRUG|zoledronic acid|4 mg by intravenous drip (100mL:4mg) every 4 weeks
223460063|NCT00001013|DRUG|Sulfamethoxazole-Trimethoprim|
223460064|NCT00001013|DRUG|Leucovorin calcium|
223460065|NCT02494895|DRUG|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
223460066|NCT02494895|DRUG|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
224156559|NCT01176240|DRUG|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
224156560|NCT01176240|OTHER|Placebo|Placebo
223460067|NCT02709837|OTHER|Nutritional|
223574460|NCT00499655|OTHER|laboratory biomarker analysis|Correlative studies
223574461|NCT00499655|OTHER|immunohistochemistry staining method|Correlative studies
223574462|NCT00499655|GENETIC|fluorescence in situ hybridization|Correlative studies
223574463|NCT00499655|GENETIC|mutation analysis|Correlative studies
223574464|NCT00499655|GENETIC|protein expression analysis|Correlative studies
223574465|NCT00499655|GENETIC|gene expression analysis|Correlative studies
224156561|NCT01115517|DRUG|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
223574466|NCT02017145|DRUG|Chloraprep|
223574467|NCT06506799|OTHER|Training Given to Intensive Care Nurses on the Use of Physical Fixation|"Data will be collected with the 'Participant Information Form' and the 'Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale', prepared by the researcher in line with the literature and containing the demographic characteristics of the participants.~Intensive care nurses who will participate in the research will be asked to fill out the survey forms with individual consent.~Participant Information Form and Nurses' Knowledge, Attitude and Practice Levels Regarding Physical Restraint Scale will be used as pre-tests. After the pre-test, nurses will be given physical restraint training. The training content was created using the ADDIE model as reference. After the training, the Nurses' Knowledge Level, Attitudes and Practices Regarding Physical Restraint Scale will be used as the final test."
223574468|NCT02986932|DEVICE|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
223574469|NCT04393272|DEVICE|Three dimensional sensor system designed for fall detection (Fearless)|Detection of falls in nursing home residents and acute geriatric hospital patiients
223574470|NCT04392921|DRUG|Amiodarone|"Patients will undergo one of the two regimens of amiodarone, based on their ability to tolerate po (per os) intake in the post-operative period:~• All patient will receive 1050mg of amiodarone in 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~* If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* If unable to tolerate po intake: daily infusion of 1050mg in 100mL of 5% dextrose for postoperative days 1 to 5 or until the day of discharge (whichever occurs first)."
223574471|NCT04392921|DRUG|Placebo|"Patients will undergo one of the two schedules or intravenous infusion, based on their ability to tolerate po intake in the post-operative period:~* All patients will receive 100mL of 5% dextrose administered intravenously initiated at the time of anesthesia induction at a rate of 0.73mg/min or 43.75mg/h and continued over 24 hours followed by:~  o If able to tolerate po intake: 400mg po BID for post-operative days 1 to 5 or until the day of discharge (whichever occurs first).~* Esophagectomy patient will receive 100mL of 5% dextrose at the time of anesthesia induction at a rate of what would be 0.73mg/min or 43.75mg/h if it contained 1050mg of amiodarone, followed by daily infusion of 100mL of 5% dextrose for 4 days or until the day of discharge (whichever occurs first)."
223574472|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
223574473|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10\^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
223574474|NCT00350623|BIOLOGICAL|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10\^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
224302895|NCT02266134|BEHAVIORAL|Standard Implementation of Measurement Based Care|Measurement-based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9); the implementation of measurement-based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session.
224302896|NCT04035915|PROCEDURE|Limited driving pressure|Keep driving pressure \<15 cmH2O
224302897|NCT04035915|PROCEDURE|Conventional mechanical ventilation strategies|Keep tidalvolume \</= 8
224302898|NCT06593639|OTHER|Prehabilitation before surgery|Prehabilitation multimodal program will start about 4 weeks before the surgery and will be continued until 2 weeks after the surgical intervention. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
224302899|NCT06593639|OTHER|Prehabilitation before and during CRT|Prehabilitation multimodal program will start about 4 weeks CRT and will be continued in parallel until 2 weeks after the end. Multimodal program comprises physical exercise, nutritional intervention, and psychological support provided before and during curative treatment for HNC patients.
224302900|NCT00019786|DRUG|isolated perfusion|
224302901|NCT00019786|DRUG|melphalan|
224302902|NCT00019786|PROCEDURE|conventional surgery|
223574475|NCT00554658|DRUG|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
223574476|NCT02372708|DRUG|dinitrophenyl(DNP)|
223574477|NCT02372708|RADIATION|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
223574478|NCT04767178|DRUG|Ibuprofen (Sanofi, Istanbul, Turkey)|Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
223574479|NCT04767178|DRUG|Paracetamol (GlaxoSmithKline, Istanbul, Turkey)|Each enrolled infant received oral paracetamol at a dose of 10 mg/kg 60 min before the onset of the eye examination.
224302903|NCT01920607|DEVICE|magnetic anal sphincter|
224302904|NCT01920607|DEVICE|sacral nerve stimulation|
224302905|NCT00751907|DRUG|atorvastatin|40mg daily for 4 months
224302906|NCT00751907|DRUG|Placebo|Matching placebo daily for 4 months
224302907|NCT01437943|DRUG|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
224302908|NCT01437943|DRUG|Placebo|Take 1 tablet (0 mg) daily for 180 days.
224302909|NCT00006243|BIOLOGICAL|tyrosinase peptide|Given SC
224302910|NCT00006243|BIOLOGICAL|MART-1:27-35 peptide vaccine|Given SC
224302911|NCT00006243|BIOLOGICAL|gp100 antigen|Given SC
224302912|NCT00006243|BIOLOGICAL|incomplete Freund's adjuvant|Given SC
224302913|NCT00006243|BIOLOGICAL|sargramostim|Given SC
224302914|NCT00006243|OTHER|laboratory biomarker analysis|Correlative studies
223574480|NCT05043519|DRUG|FAM-NP41|The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
223574481|NCT01292564|DEVICE|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
223574482|NCT01292564|DEVICE|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
223574483|NCT01060436|DEVICE|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
223460068|NCT06503978|COMBINATION_PRODUCT|MTP-101P|MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.
223460069|NCT06503978|COMBINATION_PRODUCT|Vancomycin|"Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 14 Days"
223460070|NCT06503978|COMBINATION_PRODUCT|Miralax|Miralax is a common over-the-counter laxative and bowel cleanse
223460071|NCT06503978|COMBINATION_PRODUCT|Antacid|"The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12 weeks"
223460072|NCT06503978|COMBINATION_PRODUCT|Placebo MTP-101P|"The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12 weeks"
223460073|NCT06503978|COMBINATION_PRODUCT|Placebo Vancomycin|"Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 14 days"
223460074|NCT06180161|BEHAVIORAL|multidomain intervention|"Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community."
223460075|NCT04715282|PROCEDURE|Epley maneuver|Epley maneuver
223574484|NCT00580580|DRUG|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
223574485|NCT00580580|DRUG|Definity|intravenous injection at 0.05-0.20 mL
223574486|NCT00580580|DRUG|PESDA|intravenous injections dosage 0.05-0.20 mL
223574487|NCT05641428|DRUG|ARI-0001|Infusion with a single target dose of 2.0 x 10\^6 Point of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
223574488|NCT05641428|DRUG|Axi-cel|Infusion with a single target dose of 2.0 x 10\^6 Standard of Care CAR T-cells/kg BW (range 1 -2.0x 10\^6 CAR T-cells /kg BW).
223574489|NCT05491070|DEVICE|Vascular closure device (Angio-Seal, Progilde)|In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
223574490|NCT02685748|DRUG|Aspirin|1000 mg pd in two doses
223574491|NCT02685748|DRUG|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
223574492|NCT02685748|DRUG|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
223574493|NCT04126564|BEHAVIORAL|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations \& yoga.
223574494|NCT04126564|BEHAVIORAL|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
223574495|NCT02928302|OTHER|TVU CL screening|Transvaginal ultrasound cervical length screening
223574496|NCT03500172|BEHAVIORAL|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
224067871|NCT00938756|OTHER|immunoenzyme technique|
224067872|NCT00938756|PROCEDURE|magnetic resonance imaging|
224067873|NCT02925130|DRUG|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
224067874|NCT02925130|DRUG|Placebo|Acute oral intake of a placebo drug
224067875|NCT03099889|BEHAVIORAL|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
224067876|NCT04819152|BEHAVIORAL|Tobacco cessation intervention|Already implemented in-person (including online meetings) tobacco cessation interventions in Sweden
224067877|NCT04162574|OTHER|Recovery Record|Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
223574497|NCT03500172|BEHAVIORAL|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
223574498|NCT03769818|DRUG|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
223574499|NCT03769818|DRUG|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
223574500|NCT03769818|DRUG|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
223574501|NCT03769818|DRUG|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
224067878|NCT02941627|DEVICE|Neuro Zti|Cochlear implant
224067879|NCT02941627|DEVICE|Neuro One|Sound processor
224067880|NCT01419912|DIETARY_SUPPLEMENT|soy milk|
224067881|NCT01419912|DIETARY_SUPPLEMENT|cow's milk|
224067882|NCT02237300|BEHAVIORAL|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
223574502|NCT00907530|DRUG|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
223574503|NCT00907530|DRUG|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
223574504|NCT03009708|OTHER|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
223574505|NCT00136968|DRUG|Voriconazole|
223574506|NCT05825144|DEVICE|Robotic exoskeleton-assisted gait rehabilitation|Use a robotic exoskeleton for gait rehabilitation in addition to conventional rehabilitation
224156562|NCT01115517|DRUG|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
223574507|NCT05825144|OTHER|Conventional rehabilitation|Regular post-stroke rehabilitation
223574508|NCT02956759|PROCEDURE|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
223574509|NCT03518268|DRUG|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
223574510|NCT03518268|DRUG|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
223574511|NCT00915668|DRUG|JNJ-31001074|
223574512|NCT00003847|DRUG|biricodar dicitrate|
223574513|NCT00003847|DRUG|doxorubicin hydrochloride|
223574514|NCT00003847|DRUG|vincristine sulfate|
223574515|NCT05131399|DEVICE|Phase A1|Plastic standard ankle foot orthosis
224156563|NCT01917240|OTHER|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
224156564|NCT01053572|PROCEDURE|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
223574516|NCT05131399|DEVICE|Phase B1|carbon medical device ankle foot orthosis
223574517|NCT05131399|DEVICE|Phase A2|Plastic standard ankle foot orthosis
223574518|NCT05131399|DEVICE|Phase B2|carbon medical device ankle foot orthosis
223574519|NCT00562276|PROCEDURE|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
223574520|NCT04815122|RADIATION|SPECT TRODAT-1|The Single-photon Emission Tomography (SPECT) TRODAT-1 will be performed after the voluntary rest in a dark and silent room for 30 minutes, to eliminate possible influences from external stimuli; the radiopharmaceutical \[99mTC\] -TRODAT-1 will be injected through the venous access previously established, 4 hours after the injection of the radiopharmaceutical, the acquisition of cerebral SPECT will be performed in the two groups of obese women, with and without COMT Val158Met polymorphism. The images will be acquired on Philips BrightView XCT equipment, equipped with a double detector.
223574521|NCT01035346|DRUG|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
223574522|NCT01035346|DRUG|Placebo|Single dose of a placebo
223574523|NCT01974752|DRUG|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
223574524|NCT01974752|DRUG|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
223574525|NCT01974752|DRUG|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
223574526|NCT00690807|DRUG|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
223574527|NCT01752790|DRUG|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
223574528|NCT01752790|DRUG|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
223574529|NCT04502264|DEVICE|Hand of Hope|A virtual reality (VR)-based, electromyography (EMG)-driven, and task-oriented hand robot.
223574530|NCT04502264|DRUG|Botulinum toxin type A injection|A safe agent representing the gold standard treatment for focal spasticity.
223574531|NCT02654431|PROCEDURE|Breast Cancer patient|Samples
223574532|NCT02654431|PROCEDURE|Cancer patients|Samples
223574533|NCT02281786|DRUG|Placebo|Matching placebo to RO6926496
223574534|NCT02281786|DRUG|RO6926496|single, ascending dose, intravenous administration
223574535|NCT03524690|DIETARY_SUPPLEMENT|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
223574536|NCT03524690|DIETARY_SUPPLEMENT|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
224156565|NCT02480504|OTHER|dietary intervention intermittent energy restriction|Randomized clinical trial
224156566|NCT02480504|OTHER|continuous energy restriction|
224156567|NCT00615212|DRUG|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
224156568|NCT00615212|DRUG|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
224156569|NCT00615212|DRUG|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
223574537|NCT04744389|DEVICE|Hypothermic Machine Perfusion|The perfusion system was primed with 4 L of Belzer machine perfusion solution University of Wisconsin Machine Perfusion Solution (Bridge for Life, Ltd., Columbia, SC). The arterial and portal pressures were set at 25 mm Hg with a flow and at 3-4 mm Hg with a continuous flow, respectively. The oxygen flow was set at 0.25 L/minute. The target liver temperature was between 4°C and 10°C.
223574538|NCT04744389|DEVICE|Normothermic Machine Perfusion|Grafts were perfused at 37°C in an OR next to the transplant OR and under medical supervision using a blood-based perfusate. Initial perfusate temperature was set at 20°C and raised by 1°C every 2 minutes. Oxygenation was provided by an anesthesia ventilator initially set at 4 L/minute with 30% fraction of inspired oxygen, and later adjusted based on perfusate pH, partial pressure of oxygen, and partial pressure of carbon dioxide. Blood gas analyses were drawn every 20 minutes during the first hour and every 30 minutes thereafter with the aim to maintain a physiological pH and ionogram result, and a partial pressure of oxygen between 200 and 250 mm Hg. Perfusate glucose, transaminases, and lactate were measured during NMP as were bile production and quality (pH, sodium, glycemia, lactate, and HCO3)
224067883|NCT02237300|BEHAVIORAL|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
224067884|NCT00599482|RADIATION|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
224067885|NCT02286700|DRUG|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
224067886|NCT02286700|OTHER|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
224067887|NCT03132337|OTHER|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
224067888|NCT03058042|OTHER|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
224067889|NCT03058042|OTHER|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
224067890|NCT04888273|BEHAVIORAL|Transition Intervention|Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
224067891|NCT02777671|DRUG|BIA 2-093|
224067892|NCT02777671|DRUG|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
224067893|NCT02763202|OTHER|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
224067894|NCT04319328|DRUG|Cefazolin|Non-interventional pharmacokinetic evaluation
224067895|NCT04319328|DRUG|Ceftazidime|Non-interventional pharmacokinetic evaluation
224067896|NCT04640467|DIAGNOSTIC_TEST|Biophsical profile|There are five components measured during the biophysical examination. A score of 2 points is given for each component that meets criteria. The test is continued until all criteria are met or 30 minutes have elapsed. The points are then added for a possible maximum score of 10. A total score of 10 out of 10 or 8 out of 10 with normal fluid is considered normal. A score of 6 is considered equivocal, and a score of 4 or less is abnormal.
224156570|NCT00615212|DRUG|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
224156571|NCT04016103|DEVICE|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
224156572|NCT02655406|OTHER|Class 2 compression stockings|
224156573|NCT05793684|DRUG|Period A|Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo
224156574|NCT05793684|DRUG|Period B|Week 1: AD816 low dose; Week 2: AD816 high dose
224156575|NCT05793684|DRUG|Period C|Week 1: Placebo + Placebo; Week 2: Placebo + Placebo
224156576|NCT00220259|DRUG|Fluticasone or placebo|
224156577|NCT03561246|OTHER|Incline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
224156578|NCT03561246|OTHER|Decline treadmill walking|Those with a Pp \<0.47 or \>0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
224156579|NCT03561246|OTHER|Level Treadmill (Control)|Those with a Pp \<0.47 or \>0.53 will undergo LEVEL training during which individuals will walk for 15 minutes at a 0-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
224156580|NCT03945448|DRUG|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
224156581|NCT03945448|DRUG|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
224156582|NCT00292812|DRUG|Nutritional supplementation (nucleotides)|
224156583|NCT00544804|DRUG|lapatinib ditosylate|
224156584|NCT00544804|GENETIC|gene expression analysis|
224156585|NCT00544804|OTHER|diagnostic laboratory biomarker analysis|
224156586|NCT00410904|DRUG|cediranib maleate|
224156587|NCT00410904|DRUG|pemetrexed disodium|
224156588|NCT04570969|PROCEDURE|Erector spinae plane block|Insertion of bilateral catheters in the intersfacia space of erector spinae muscle
224156589|NCT00535444|OTHER|Parish nurse visit|One visit with the parish nurse in 2 weeks
223460076|NCT03168451|BEHAVIORAL|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
223460077|NCT05365815|BEHAVIORAL|Melanated Group Midwifery Care|Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
223460078|NCT03460626|DRUG|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
223460079|NCT03460626|OTHER|Placebo|an odorless oil without any therapeutic effect
223574539|NCT03837665|BIOLOGICAL|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
223574540|NCT05108025|DRUG|Topical Powder|Topical Powder mixed with diluent
223574541|NCT05108025|DRUG|Placebo Topical Powder|Placebo Topical Powder mixed with diluent
223460080|NCT00181883|DRUG|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
223574542|NCT01636388|BIOLOGICAL|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
223574543|NCT02435680|DRUG|MCS110|taken by I.V
223574544|NCT02435680|DRUG|carboplatin|taken by I.V
223574545|NCT02435680|DRUG|gemcitabine|taken by I.V
223574546|NCT00631150|DRUG|Levetiracetam (Keppra)|
223574547|NCT05139199|BEHAVIORAL|Auricular Point Acupressure group|A 1-month regimen of auricular point acupressure, comprising usual-care of approximately 15-20 point pressing each time,3 times a day, seven times peer week.
223574548|NCT02794987|DEVICE|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
224067897|NCT04640467|DIAGNOSTIC_TEST|Cerebroplacental ratio|CPR is the ratio of the Middle Cerebral Artery Pulsatility Index (MCA PI) to the Umbilical Artery Pulsatility Index (UA PI). The pulsatility indices will be measured from an automated trace of at least three consecutive waveforms of the relevant vessel in the absence of fetal breathing movements or uterine contractions. The angle of insonation will be as close to zero degrees as possible. The UA PI will be recorded from a free-floating section of cord, and the MCA PI will be obtained from the proximal third of the vessel (10, 14).
224067898|NCT04925609|DRUG|Brigatinib|Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
223460081|NCT02405767|OTHER|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
223460082|NCT06483906|DRUG|Venetoclax, Azacitidine and Homoharringtonine|Patients will receive the VAH regimen for the treatment of AML
223574549|NCT01688947|DRUG|V116517 50-mg tablets|Taken orally twice daily
223574550|NCT01688947|DRUG|V116517 30-mg tablets|Taken orally twice daily
223574551|NCT01688947|DRUG|Pregabalin capsules|1-2 capsules taken orally twice daily
223574552|NCT01688947|DRUG|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
223574553|NCT00330928|DEVICE|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
223574554|NCT00330928|DEVICE|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
223574555|NCT06464744|PROCEDURE|Repetitive transcranial magnetic stimulation (rTMS)|Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation. The stimulation intensity will be set to 90% of the motor threshold
223574556|NCT06464744|PROCEDURE|Placebo stimulation using a placebo coil|The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
223574557|NCT01309906|DEVICE|Investigational lens|Bausch \& Lomb investigational silicone hydrogel contact lens worn on a daily wear basis for 1 week.
223574558|NCT01309906|DEVICE|Air Optix Aqua lens|Ciba Visions Air Optix Aqua contact lens, worn on a daily wear basis for 1 week.
223574559|NCT02729610|DEVICE|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
223574560|NCT02729610|DEVICE|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
223574561|NCT03028480|DRUG|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
223574562|NCT06980961|PROCEDURE|short-pulse ND: YAG 1064 laser|Nd: YAG 1064 nm short pulse laser (5 nanoseconds), 4 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Smart, a Q-Switch Laser produced by Medical San (Lajeado, RS, Brazil).
223743345|NCT06261554|DIETARY_SUPPLEMENT|Dietary Supplement: Low dose OIT|Following the building-up phase (up to 14 months), patients will receive a daily low dose of sesame paste (300 mg sesame protein) mixed with well-tolerated fruit mousse or bread for 3 months (12 +/- 3 weeks).
224067899|NCT01708642|DRUG|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
224067900|NCT01708642|DRUG|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
224302915|NCT06406218|BEHAVIORAL|Phase I Cardiac Rehabilitation Exercise Training|"A) In the morning, take a supine position and perform straight leg raises with each leg individually, lifting to a height of 30° and holding for 3-5 seconds. Raise both arms to the side of the head to a 90° angle and hold for 5-10 seconds. Inhale deeply when exerting force and exhale slowly when lowering. Alternate between leg lifts and arm raises, performing 5 sets per session. Adjust intensity based on individual condition and may be repeated. In the afternoon, sit beside the bed for 5 minutes. B) After transitioning to secondary care according to the patient's condition, stand beside the bed for 5 minutes in the morning; in the afternoon, march in place beside the bed for 5 minutes. C) Walk beside the bed for 10 minutes per session, twice a day. D) Move around and doing activities under supervision inside the ward, 10 minutes per session, twice a day.~Spend approximately one day at each level, gradually progressing the exercise to the patient's tolerance level."
224302916|NCT01265810|OTHER|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
224302917|NCT01265810|OTHER|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
224302918|NCT04117360|OTHER|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
224302919|NCT06260332|BEHAVIORAL|Supportive Care (Fitbit)|Wear Fitbit, Use Fitbit application, Receive educational materials, attend coaching calls, Ancillary studies
224302920|NCT05855486|DEVICE|Saline eye drops|Ocular drops used to facilitate the removal of ocular secretions in pediatric subjects
224302921|NCT06483542|OTHER|bioenergetic balance|Bioenergetic balance is calculated for all patients who had a resting energy expenditure measurement with indirect calorimetry.
224302922|NCT02125253|DRUG|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
224302923|NCT02125253|DRUG|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
224302924|NCT02125253|DRUG|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
224302925|NCT06968182|DIETARY_SUPPLEMENT|Sodium Chloride|During the examination day after a baseline period, from 11.00 AM to 11.30 AM, a sustained infusion of 1 L isotonic NaCl, was administered.
224302926|NCT05294419|DEVICE|CVD Integrated Risk Test|CVD IRT (IVD regulations with a software device)
224302927|NCT04727437|OTHER|No treatment|Withholding anticoagulation for at least 3 months.
224302928|NCT04727437|DRUG|Warfarin|anticoagulation drug given for at least 3 months.
224302929|NCT04727437|DRUG|direct oral anticoagulants|anticoagulation drug given for at least 3 months.
224302930|NCT04727437|DRUG|Low molecular weight heparin|anticoagulation drug, subcutaneous injection given for at least 3 months.
224302931|NCT05456711|DIAGNOSTIC_TEST|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality|ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
224302932|NCT03297528|DRUG|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
224302933|NCT03003273|OTHER|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
224302934|NCT03003273|OTHER|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
224302935|NCT03003273|OTHER|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
224302936|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
224302937|NCT00714129|OTHER|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
224302938|NCT01066689|DRUG|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
223574563|NCT06980961|PROCEDURE|ultra-short-pulse ND: YAG 1064 laser|Nd: YAG1064 nm ultra-short pulse laser (400 picoseconds), 2 to 10 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for 6 visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Premium, a picolaser produced by Medical San (Lajeado, RS, Brazil).
223574564|NCT06980961|DRUG|cold cream|The control vehicle is a cold cream, supplied by HERVA'S manipulation pharmacy. The composition of cold cream will be beeswax, acetyl palmitate, BHA, cetearyl alcohol, propylparaben, and water. This topical agent will be applied to patients daily throughout the treatment period. It is scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days.
224302939|NCT01066689|DRUG|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
224302940|NCT03535779|BIOLOGICAL|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
224302941|NCT03535779|BIOLOGICAL|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
224302942|NCT06227156|DRUG|Disitamab Vedotin Injection|2.0 mg/kg, intravenous infusion，D1, every 2 weeks is a treatment cycle
224302943|NCT04315870|OTHER|pregnant women with laboratory-confirmed 2019-n-CoV|Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database
224302944|NCT00516009|DRUG|DEXAMETHASONE|
224302945|NCT00516009|OTHER|PLACEBO|
224302946|NCT01923623|DRUG|Ropivacaine block|
224302947|NCT05863143|BEHAVIORAL|Nutritional and Exercise|Provide Nutritional Education Program and Falls Module Exercise (FME) to the intervention group
223574565|NCT02677636|DRUG|MSRD-100|MSRD-100 is a topical gel.
223574566|NCT02677636|DRUG|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
223460083|NCT04710069|BEHAVIORAL|POINT|Patients randomized to the POINT program will be given preoperative counseling on adverse effects of opioids and expectations will be set that most patients do not require opioids for pain control after endocrine surgery, they will receive the info in writing afterwards as well. These patients will also be shown a short instructional video reiterating the counseling provided in the preoperative clinic visit. Information in the video will pertain to the expected pain after surgery, the over-the-counter options for pain control, the risks and side effects of using opioids, and reassurances that opioids may be prescribed at any time after discharge if pain is unmanageable. After the video, the patient will be provided with paperwork, requiring patient consent/signature to receive opioids if they opt into narcotic treatment. They will not be provided with a narcotic prescription if consent is not explicitly provided.
223460084|NCT06241885|BEHAVIORAL|Intervention group I|Women in Intervention Group II will wear gynaecological shorts specially developed by the researchers before vaginal examination. These shorts will be made of disposable fabric and will be sewn by the researchers in four different sizes (S-M-L-XL) according to the weight of the women. The middle part of the shorts will be closed with a snap button, and the opening will be provided when the snap button is opened during vaginal examination. In addition, these shorts will be approximately knee-cap length for women.
223460085|NCT06283407|OTHER|ICF-based cross-country comparative analysis|ICF-based cross-country comparative analysis
223460086|NCT00765817|DRUG|placebo|subcutaneous injection, twice a day
223460087|NCT00765817|DRUG|exenatide|subcutaneous injection, twice a day, 10mcg
223460088|NCT05798481|DRUG|Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.|Exactly 2.5 mg or 5 mg sodium nitrite and 50 mg N-acetylcysteine are weighed and mixed together just before use. The mixture is placed under the participant's tongue. The powder slowly dissolves in saliva and generate S-nitrosoacetylcysteine. Investigators will ask the subjects not to swallow the drug at least for 30 min. Administration of nitrite and N-acetylcysteine individually at these concentrations is not expected to change any blood NO chemistry or the systemic blood pressure. Hence, investigators will not investigate the effects of nitrite and N-acetylcysteine individually in this study. Placebo control is not needed for this study because the baseline parameters will serve as control. Investigators will assess the drug effect based on the difference between pre-treatment and post-treatment values.
223460089|NCT03433300|DEVICE|Ottobock Kenevo/C-Leg|Microprocessor-controlled prosthetic knee
223460090|NCT03433300|DEVICE|Ottobock 3R60/3R62|Nonmicroprocessor-controlled knee
223460091|NCT04911491|DEVICE|IMST|Inspiratory muscle strength training (IMST) is a form of physical training that utilizes the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device.
223460092|NCT04911491|DEVICE|Sham Training|Repeated inhalations against a low resistance will be performed using a handheld device.
223460093|NCT06955858|DRUG|Recombinant Human Thrombopoietin（rhTPO）|"G-CSF will be administered at a dose of 10 μg/kg/day subcutaneously for 7-10 days post-chemotherapy.~rhTPO is started on the same day as G-CSF at 300 U/kg/d and injected subcutaneously until the stem cell collection was completed."
223574567|NCT03313284|PROCEDURE|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
224156590|NCT05878691|DRUG|GRC 54276|"Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm."
224156591|NCT05878691|DRUG|GRC 54276 + Pembrolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of pembrolizumab IV every 21 days.~Part 2: GRC 54276 in combination with pembrolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
224156592|NCT05878691|DRUG|GRC 54276 + Atezolizumab|"Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm."
224302948|NCT03386565|DRUG|sodium chloride solution|intraoperative IV infusion
223460094|NCT06432478|DEVICE|3D-printed custom applicator|3D-printed custom applicator
223460095|NCT04776928|BEHAVIORAL|Push reports|"Surgeons in the experimental arm will receive provider-level push report notifications through an email displaying their personal prescribing performance compared to Michigan Opioid Prescribing Engagement Network (OPEN) prescribing guidelines and their de-identified peers.~The push report will also include a link to the secure MSQC data platform that displays more information about the case so the surgeon can further investigate prescribing information. The email will also contain contact information for the study team so as to help any surgeons troubleshoot, learn more, request to stop receiving reports, etc."
223574568|NCT03313284|PROCEDURE|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
223574569|NCT03313284|PROCEDURE|Control|No intervention
223574570|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Placebo Product (PP)|1 spray (0 mg melatonin)
223574571|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Active Control (AC)|1 spray (1 mg melatonin)
223574572|NCT06600633|DIETARY_SUPPLEMENT|14 days of intervention with Test Product (TP)|1 spray (0.3 mg melatonin)
223574573|NCT02337283|DRUG|BI 425809|Tablets
223574574|NCT02337283|DRUG|Placebo|Tablets
224067901|NCT06057779|OTHER|Slow and heavy exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
224067902|NCT06057779|OTHER|Slow and light exercise therapy|6 sets of 10 single leg isolated eccentric heel drops into neutral ankle position at an exercise speed of 0.33 Hz, with 1-min rest period between each set.
224067903|NCT06057779|OTHER|Fast and heavy exercise therapy|6 sets of 30 single leg isolated eccentric heel drops into maximal dorsiflexion at an exercise speed of 1 Hz, with 1-min rest period between each set.
224067904|NCT02832973|DRUG|Spironolactone|Spironolactone 25 mg
224067905|NCT02832973|DRUG|Furosemide,|Furosemide 20-40 mg
224067906|NCT02832973|DRUG|Amiloride|Amiloride 5 mg
224067907|NCT02832973|DRUG|Ramipril|Ramipril 5-10 mg
224067908|NCT02832973|DRUG|Bisoprolol|Bisoprolol 5-10 mg
223460096|NCT04722107|DRUG|rAAV2/8-hCYP4V2|rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
223460097|NCT05521048|DRUG|Doxycycline Injection [Doxy]|Injections between 0.1 ml to 4 ml of 10mg/ml doxycycline hyclate will be administered to a maximum of three tumors per patient. The dose administered will be calculated based on tumor size, not to exceed the estimated volume of the tumor or a maximum of 4 ml. Injection of 1% lidocaine may be given pre-doxycycline to reduce injection pain.
223460098|NCT06777329|BEHAVIORAL|10 days of dry immersion|The volunteers in this arm will be immersed up to the neck for 10 days in a specially designed bath filled with tap water.
223574575|NCT06604780|BEHAVIORAL|Transitional discharge program|"For patients classified in the low-risk group, general measures would be applied. For patients in the medium-risk group, reinforced measures would be implemented. Lastly, for patients considered to be in the high-risk group, intensive case management measures would be applied, and if they meet the inclusion criteria, they would be included in the Post-Discharge Group Psychotherapeutic Intervention.~1. General measures~2. Reinforcement measures~3. Intensive measures~   * Intensive case management measures~  * Post-Discharge Psychotherapeutic Recovery Support Program: For application to patients at high risk of early readmission who meet the inclusion criteria. It consists of a multicomponent group psychotherapeutic intervention from a rehabilitative and recovery-oriented perspective. This intervention will be structured into 20 sessions, each lasting 90 minutes, held weekly in an open format."
223574576|NCT06605755|PROCEDURE|Different immunization regiments with DTaP-IPV/Hib Pentavalent Vaccine|"The test vaccine in this study was Pentaxim®, a pentavalent vaccine produced by Sanofi Pasteur, France.This vaccine is a combination vaccine consisting of adsorbed acellular DTP and inactivated polio vaccine (DTaP-IPV) and Haemophilus influenzae type b conjugate vaccine (Hib).~1. Intervention group: 1 dose of experimental vaccine at 2, 4 and 6 months of age, and 1 dose of enhanced vaccine at 18 months of age.~2. Control group: 1 dose of experimental vaccine at 2, 3 and 4 months of age, and 1 dose of enhanced vaccine at 18 months of age."
223574577|NCT03610139|DIETARY_SUPPLEMENT|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
223574578|NCT03824275|DRUG|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
223574579|NCT06658717|DIETARY_SUPPLEMENT|Investigational product (IP): Natural orange extract|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
223574580|NCT06658717|DIETARY_SUPPLEMENT|Group II: Placebo: Microcrystalline cellulose (MCC)|Strength: 500 mg Dose regimen: One capsule to be taken with breakfast orally once a day
223574581|NCT05074888|DRUG|Prospekta|Oral administration.
223574582|NCT05074888|DRUG|Placebo|Oral administration.
223574583|NCT06604286|DRUG|In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
223574584|NCT06604286|DRUG|8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.|8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.
224067909|NCT00997100|DRUG|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
224156593|NCT01769482|DRUG|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
224156594|NCT01769482|DRUG|placebo|
224156595|NCT00807014|DRUG|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
224067910|NCT05070767|DEVICE|Neurolens spectacle lens|spectacle lens
224156596|NCT00807014|DRUG|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
224156597|NCT01792297|DIETARY_SUPPLEMENT|Bovine colostrum|
224156598|NCT01792297|DIETARY_SUPPLEMENT|Whey protein|
224156599|NCT00651313|DRUG|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
224067911|NCT05070767|DEVICE|Placebo spectacle lens|spectacle lens for refractive error correction
224156600|NCT00651313|DRUG|Placebo|Placebo vaginal gel administered once daily for 4 days
224156601|NCT02650895|BIOLOGICAL|Efprezimod alfa|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
224156602|NCT02650895|DRUG|Saline|0.9% sodium chloride
224156603|NCT06365372|DIAGNOSTIC_TEST|Western blot|Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.
224156604|NCT05243719|BIOLOGICAL|ADP101|Active dry powder formulation at various volumes.
224156605|NCT02890732|DEVICE|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
224156606|NCT04871685|DIAGNOSTIC_TEST|lung ultrasound|the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
224156607|NCT03148587|BEHAVIORAL|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
224156608|NCT03148587|BEHAVIORAL|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
224156609|NCT04239547|PROCEDURE|Alveolar Recruitment maneuver (ARM) +PEEP|Following anesthesia induction and intubation, alveolar recruitment maneuver followed by 5 mmHg PEEP
224156610|NCT04239547|PROCEDURE|PEEP|Following anesthesia induction and intubation, only 5 mmHg PEEP
224156611|NCT04006535|GENETIC|genetic analysis|Saliva sample collection for genetic analysis
223574585|NCT06605794|DEVICE|FreeFlow percutaneous atrial septal shunt|The trial devices included a percutaneous atrial septal shunt and an atrial septal shunt delivery system. The specifications of the atrial septal shunt device were -φ5, φ7, φ9, φ11, and the specifications of the atrial septal shunt delivery system-FFISS-B were 9F and 10F.
223574586|NCT06607367|DRUG|Ruxolitinib (JAKAVI®)|Initial starting dose will be 10mg BD
224156612|NCT03468049|BIOLOGICAL|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
223460099|NCT06777329|BEHAVIORAL|10 days of Head Down Bed Rest|The volunteers in this arm will spend 10 days in -6° head down bed rest.
223460100|NCT00103285|RADIATION|3-Dimensional Conformal Radiation Therapy|Some patients undergo cranial radiotherapy
223574587|NCT06607367|DRUG|Eltrombopag (Revolade®)|Initial starting dose will be 50mg daily
223574588|NCT06606912|OTHER|Skeletal muscle, subcutaneous fat and visceral fat area|CT-based measurement of skeletal muscle, subcutaneous fat and visceral fat areas at L1, L2, L3, L4 and L5 levels.
223574589|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 5|(Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
223574590|NCT06606704|DIETARY_SUPPLEMENT|Creatine Bolus 3|(Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).
223574591|NCT06606704|DIETARY_SUPPLEMENT|Creatine Intermittent 5|(Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).
223574592|NCT06606704|DIETARY_SUPPLEMENT|Placebo|(Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
223574593|NCT06606457|BEHAVIORAL|Pain Acknowledgment Coping and Empowerment in CF (PACE CF)|The Pain Acknowledgment Coping and Empowerment in CF (PACE CF) program is a newly developed 3-session mind-body pain management intervention for adults with cystic fibrosis (CF), developed with CF community input. The sessions are delivered by the the CF care team psychologist. Each session will teach mind-body strategies to increase comfort and reduce the impact of pain on the participant\&#39;s life. These strategies include understanding pain in CF from a mind-body perspective, learning relaxation and mindfulness-based skills, identifying and practicing individualized cognitive and behavioral strategies that improve comfort and well-being, and discussing communication skills that empower people living with CF and pain. Participants will receive a workbook that will provide related education and resources and reinforce skill practice.
223574594|NCT06607159|OTHER|Implementation of healthy habits teaching protocol|Protocol for teaching healthy lifestyle habits, aimed at school-age children (initially between 1st and 4th grade of primary school), to be implemented transversally in schools. This protocol takes into account three levels of action: school, family and pupils. It includes materials in paper format and digital materials, that can be used both at school and at home.
224156613|NCT03468049|BIOLOGICAL|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
224156614|NCT03468049|BIOLOGICAL|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
224156615|NCT03468049|OTHER|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
224156616|NCT05034458|DIETARY_SUPPLEMENT|Crohn's disease exclusion diet|Patients will receive, in addition to their normal treatment, polymeric formula + diet
224156617|NCT02881879|BIOLOGICAL|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
223460101|NCT00103285|DRUG|Cyclophosphamide|Given IV
223460102|NCT00103285|DRUG|Cytarabine|Given IV or SC
224156618|NCT00981682|DRUG|SER120|once a day treatment of nocturia
224156619|NCT03517657|BEHAVIORAL|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
224156620|NCT03517657|BEHAVIORAL|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
224156621|NCT03906136|BIOLOGICAL|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab biosimilar 40 mg, s.c.
223460103|NCT00103285|DRUG|Dexamethasone|Given IV or PO
223460104|NCT00103285|DRUG|Doxorubicin Hydrochloride|Given IV or IT
224156622|NCT03906136|OTHER|Standard-of-care|Treatment according to local practice standards by the rheumatologist following latest treatment recommendations with NSAIDs as the first-choice drug treatment and DMARDs for patients with active disease despite the use (or intolerance/contraindication) of NSAIDs.
224156623|NCT06183229|DRUG|Cycloferon|Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
224156624|NCT06183229|DRUG|Placebo|Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
224156625|NCT04057716|BEHAVIORAL|Sleep restriction|Participants will be asked to restrict their time in bed to 8 hours each night for one week.
224156626|NCT04057716|BEHAVIORAL|Sleep extension|Participants will be asked to extend their time in bed to 11 hours each night for one week.
224302949|NCT03386565|DRUG|Lidocaine|intraoperative IV infusion
223460105|NCT00103285|DRUG|Leucovorin Calcium|Given PO
223460106|NCT00103285|DRUG|Mercaptopurine|Given PO
223460107|NCT00103285|DRUG|Methotrexate|Given IM or IT
223460108|NCT00103285|DRUG|Pegaspargase|Given IM
223460109|NCT00103285|DRUG|Thioguanine|Given PO
223460110|NCT00103285|DRUG|Vincristine Sulfate|Given IV
223460111|NCT00913081|DIETARY_SUPPLEMENT|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
223460112|NCT00913081|DIETARY_SUPPLEMENT|Placebo|Placebo PO one time
223460113|NCT02150941|DEVICE|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
223460114|NCT02150941|DEVICE|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
223460115|NCT00103558|DRUG|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
223460116|NCT00452439|DRUG|Actonel (Risedronate)|35 mg (pill) by mouth weekly
223460117|NCT00452439|DIETARY_SUPPLEMENT|Calcium|500 mg by mouth twice a day for a total of 24 months.
223460118|NCT00452439|DIETARY_SUPPLEMENT|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
223460119|NCT02847325|DRUG|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
223460120|NCT02847325|DRUG|Placebo capsules|Placebo capsules
223460121|NCT01407016|DRUG|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
223460122|NCT03052205|DRUG|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
223460123|NCT06337734|BEHAVIORAL|AI-Driven Lifestyle Coaching Program|The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
223460124|NCT03974802|DEVICE|somofilcon A contact lens|Contact Lens
223460125|NCT03974802|DEVICE|fanfilcon A contact lens|Contact Lens
223460126|NCT01302418|DEVICE|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
223460127|NCT06212986|DEVICE|Promotion of mental training through mobile application Perform-UP Tennis|"Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises."
223574595|NCT06608706|OTHER|Eye Movement Desensitization and Reprocessing (EMDR) for psychosis|EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
223574596|NCT03078933|DEVICE|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
223574597|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
223574598|NCT03078933|DEVICE|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
223460128|NCT03424798|DEVICE|Inspiwave|patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
223460129|NCT03685097|DIAGNOSTIC_TEST|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
223574599|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
223460130|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
223460131|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
223460132|NCT04050462|DRUG|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
223460133|NCT01828970|DRUG|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
223460134|NCT06046677|OTHER|No intervention|No intervention
223460135|NCT04572776|DRUG|Resiniferatoxin|Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.
223460136|NCT04572776|OTHER|Standard of Care|Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.
223460137|NCT04708158|BIOLOGICAL|Novaferon|a novel recombinant antiviral protein drug
223460138|NCT04708158|BIOLOGICAL|Placebo|Saline
223460139|NCT01842269|DRUG|Mycophenolate Mofetil 500mg|
223574600|NCT03078933|DEVICE|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
223574601|NCT02279719|DRUG|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
223460140|NCT01842269|DRUG|Mycophenolate Mofetil 250mg|
223460141|NCT00377637|DRUG|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
223574602|NCT02279719|DRUG|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
223460142|NCT00377637|DRUG|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m\^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m\^2. The target dose was 1.0 g/m\^2, but doses were titrated by 0.25 g/m\^2 increments to maintain nadir leukocyte count between 2500-4000/mm\^3."
223460143|NCT00377637|DRUG|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
223460144|NCT00377637|DRUG|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
223460145|NCT00377637|DRUG|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
223574603|NCT02279719|DRUG|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
223574604|NCT03099941|OTHER|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
223574605|NCT01155921|DRUG|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
223574606|NCT03065101|DEVICE|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
223574607|NCT03065101|OTHER|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
223574608|NCT03065101|DEVICE|Sliding Hip Screw|Sliding Hip Screw
223574609|NCT03541187|BIOLOGICAL|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
223574610|NCT03541187|BIOLOGICAL|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
223574611|NCT06605911|DRUG|topical triamcinolone acetonide|ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks
223574612|NCT06605911|DRUG|Topical Curcumin|Ten patients with OLP received topical curcumin four times per day for six weeks.
224156627|NCT06088303|BEHAVIORAL|Adjunctive writing to amplify response and engagement (AWARE)|AWARE includes two components: 1) patients complete brief writing prompts asking about their experiences in treatment, and 2) therapists review patients' responses and facilitate guided discussion related to patients' experiences during check-ins at the beginning of each session.
224156628|NCT06088303|BEHAVIORAL|Cognitive processing therapy (CPT)|CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.
224156629|NCT06088303|BEHAVIORAL|Prolonged exposure (PE)|PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.
224156630|NCT05443061|DRUG|Nitroglycerin|Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
224156631|NCT05443061|DRUG|Normal saline|Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
224156632|NCT06010472|DRUG|anti-CD19 CAR NK cells (KN5501)|"Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5501) will infused in each group using the 3 + 3 dose-escalation strategy."
223460146|NCT00377637|DRUG|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
223460147|NCT00657800|BEHAVIORAL|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
223460148|NCT00735345|DRUG|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
223460149|NCT00735345|DRUG|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
223460150|NCT00735345|DRUG|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
223460151|NCT00735345|BIOLOGICAL|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
223460152|NCT00735345|RADIATION|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
223460153|NCT04113291|OTHER|DASH Diet|12 Weeks of isocaloric DASH diet \<2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
223574613|NCT06605911|DRUG|topical triamcinolone acetonide combiend with topical curcumin|Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.
223574614|NCT05173428|BEHAVIORAL|Smoking Cessation Program Based on Transtheoretic Model|Conducting motivational interviews based on the transtheoretic model according to the stages of change that individuals are in.
223460154|NCT04113291|OTHER|Usual diet|12 weeks usual diet \<2300 mg Na/day
223574615|NCT01671501|BEHAVIORAL|Motivational Interviewing|
223460155|NCT04179877|BEHAVIORAL|IPS|Occupational rehabilitation and support Integrated with clinical treatment
223460156|NCT01507116|OTHER|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
223460157|NCT01914237|DEVICE|Castor Stent Graft|Endovascular Repair of Aortic Dissection
223460158|NCT02029131|BEHAVIORAL|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
223574616|NCT01671501|BEHAVIORAL|Email Feedback|
223574617|NCT01671501|OTHER|Usual Care|
223574618|NCT02448979|PROCEDURE|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
223574619|NCT02448979|PROCEDURE|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
223574620|NCT00206882|DRUG|corticosteroids|
223574621|NCT01369680|DRUG|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
223574622|NCT02399280|BEHAVIORAL|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
223574623|NCT02399280|BEHAVIORAL|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
223574624|NCT05433038|DEVICE|skeletally anchored maxillary expander|used from day one and activated two times per day for two weeks
223574625|NCT01426919|OTHER|Head CT scan and blood draw within 12 hours of injury|
223574626|NCT06439888|DRUG|all-trans retinoic acid|per os treatment, started from the same day as SBRT, during 3 successive days, every 3 weeks, for a maximum of 4 cycles
224156633|NCT05644639|DEVICE|StimRouter Neuromodulation System|The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.
224156634|NCT01140464|OTHER|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
223460159|NCT03319433|DEVICE|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
223460160|NCT03045653|DRUG|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
223574627|NCT06439888|RADIATION|Stereotactic Body Radiation Therapy|Standard of Care, planned over 1 or 2 weeks, every lesions must be irradiated
223574628|NCT01817673|DIETARY_SUPPLEMENT|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
223574629|NCT01817673|DIETARY_SUPPLEMENT|placebo|
223574630|NCT00380991|DRUG|lactoserum|
223574631|NCT02736266|DRUG|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
223574632|NCT00970814|BEHAVIORAL|BBCET|11 BBCET sessions
223574633|NCT00970814|BEHAVIORAL|BBCET|11 BBCET Sessions
223574634|NCT00970814|DRUG|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
223574635|NCT00970814|DRUG|Sugar Pill|500mg - 2000mg Once per day 16 weeks
224156635|NCT01140464|OTHER|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
223460161|NCT02799563|OTHER|Coach, Preselected number of cases|
224156636|NCT00878644|PROCEDURE|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
224156637|NCT00878644|OTHER|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
223460162|NCT02799563|OTHER|Coach, Self-selected number of cases|
223460163|NCT02799563|OTHER|No coach, Preselected number of cases|
224156638|NCT00823186|DRUG|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
223460164|NCT02799563|OTHER|No coach, Self-selected number of cases|
223460165|NCT03243825|RADIATION|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
223460166|NCT03243825|DRUG|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
223460167|NCT03141190|BEHAVIORAL|Mindfulness Based Stress Reduction - modified|already described
223574636|NCT00393302|PROCEDURE|HIV screening in pregnancy|
223574637|NCT05530044|BEHAVIORAL|Social diffusion intervention|training in communication skills
223574638|NCT05199376|DEVICE|Cryotherapy|The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.
223574639|NCT05176002|DRUG|Camrelizumab|Neoadjuvant Camrelizumab combined with radiotherapy
223574640|NCT00003234|DRUG|vinorelbine tartrate|
223574641|NCT00585221|DRUG|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
223574642|NCT00585221|DRUG|Imatinib|Continue imatinib until progression.
223574643|NCT02027818|DRUG|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
223574644|NCT02494089|OTHER|distress analysis|
223574645|NCT01968291|BEHAVIORAL|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
223574646|NCT00010387|DRUG|cyclophosphamide|
223574647|NCT00010387|DRUG|filgrastim|
224156639|NCT01833793|DRUG|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
224156640|NCT00806533|DRUG|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
224156641|NCT01549028|BEHAVIORAL|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
223460168|NCT03141190|BEHAVIORAL|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
223460169|NCT04487808|DRUG|Pecan|Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern
223460170|NCT04487808|OTHER|Average American Diet devoid of nuts|Diet mimicking usual American intake
223460171|NCT00388648|DRUG|mixture of amino and keto acids|
223460172|NCT01601769|DEVICE|Vitom|Patients treated and diagnosed by vitom
223460173|NCT01601769|DEVICE|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
223460174|NCT04571047|OTHER|Time to treatment|Treatment before or after 4 weeks after diagnosis
223460175|NCT06234540|PROCEDURE|PRP|a-PRP intrauterine instillation before frozen-thawed embryo transfer cycle
223460176|NCT06234540|OTHER|Standard treatment|Standard treatment
223460177|NCT04954521|DRUG|Anlotinib|This is an observational study
223460178|NCT03239678|DRUG|100% Oxygen|Conventional preoxygenation with 100% oxygen
223460179|NCT03239678|DRUG|30% Oxygen|preoxygenation with 30% oxygen
223460180|NCT03239678|DRUG|21% Oxygen|preoxygenation with 21% oxygen
223460181|NCT03239678|DRUG|40% Oxygen|preoxygenation with 40% oxygen
223460182|NCT03239678|DRUG|60% Oxygen|preoxygenation with 60% oxygen
224156642|NCT01389076|DRUG|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
224156643|NCT01389076|DRUG|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
223460183|NCT03239678|DRUG|80% Oxygen|preoxygenation with 80% oxygen
223460184|NCT00994110|DRUG|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
223460185|NCT00994110|OTHER|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
223460186|NCT04363060|COMBINATION_PRODUCT|Azithromycin with amoxicillin/clavulanate|Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
223460187|NCT04363060|DRUG|amoxicillin/clavulanate|Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
224156644|NCT06016595|DIAGNOSTIC_TEST|Chronic prostatitis/chronic pelvic pain syndrome|Chronic prostatitis/chronic pelvic pain syndrome UPOINT
224156645|NCT04089228|OTHER|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
224156646|NCT04089228|OTHER|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
223460188|NCT03983538|OTHER|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
223460189|NCT06959316|DEVICE|Hybrid closed loop insulin delivery system|Hybrid closed loop insulin delivery system is a system that uses a continuous glucose monitor (CGM) to send blood glucose values to an insulin pump that automatically provides insulin based on the blood glucose value and anticipated future level.
224156647|NCT02638753|OTHER|education|Patients will be educated about pain neurophysiology.
223460190|NCT00368108|DRUG|2 mg perampanel|2 mg perampanel
223460191|NCT00368108|DRUG|4 mg perampanel|4 mg perampanel
223460192|NCT00368108|DRUG|placebo comparator|placebo comparator
223460193|NCT00635921|DRUG|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
223460194|NCT00635921|DRUG|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
223460195|NCT00534027|DRUG|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
223460196|NCT00534027|OTHER|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
223460197|NCT05208333|DRUG|Albenza 200Mg Tablet|"Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection"
223574648|NCT02156557|BIOLOGICAL|Colon KCC Heptapeptide|"* Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~* The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~* The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~* We will obtain copies of your endoscopy report and any pathology reports."
223574649|NCT00760461|DRUG|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
223574650|NCT06552481|DEVICE|NP-PWD|Application of NP-PWD device.
223574651|NCT06552481|DEVICE|Wound Vac|Application of wound vac device.
223574652|NCT01641146|BEHAVIORAL|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
223574653|NCT01641146|BEHAVIORAL|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
224156648|NCT02638753|OTHER|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
224156649|NCT03374852|DRUG|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
224156650|NCT03374852|DRUG|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
224156651|NCT02371980|DRUG|Vortioxetine|Vortioxetine capsules
224156652|NCT02371980|DRUG|Placebo|Vortioxetine placebo-matching capsules
224156653|NCT05815004|DRUG|Gene therapy|AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase)
224156654|NCT05815004|DRUG|Enzyme Replacement Agent|A hydrolytic lysosomal glucocerebrosidase-specific enzyme
224156655|NCT03162731|BIOLOGICAL|Nivolumab|Given IV
224156656|NCT03162731|BIOLOGICAL|Ipilimumab|Given IV
224156657|NCT03162731|RADIATION|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
224156658|NCT03162731|RADIATION|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
224156659|NCT04410835|DIAGNOSTIC_TEST|Online Survey|Psychological questionnaires
224156660|NCT06494501|DRUG|Inclisiran|Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
224156661|NCT01352312|DRUG|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
224156662|NCT01352312|DRUG|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
223460198|NCT03679559|OTHER|Best Practice|Continue usual physical activity
223460199|NCT03679559|BEHAVIORAL|Exercise Intervention (home walking program and resistance training)|Complete home-based walking program and resistance training
223460200|NCT03679559|BEHAVIORAL|Exercise Intervention (home-based Zumba program and resistance training)|Complete home-based Zumba program and resistance training
223460201|NCT03679559|BEHAVIORAL|Exercise Intervention (HIIT program and resistance training)|Complete HIIT program and resistance training
223460202|NCT03679559|OTHER|Informational Intervention|Watch video
224156663|NCT01352312|DRUG|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
224156664|NCT00692159|DRUG|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
224156665|NCT01731990|DRUG|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
224156666|NCT01731990|DRUG|Placebo|Matching placebo of Canakinumab
224156667|NCT05305053|OTHER|preoperative MDT discussion|high-risk patients are subjected to an MDT discussion among care providers
224156668|NCT04683133|DIAGNOSTIC_TEST|Optical coherence tomography assessment|Optical coherence tomography assessment of coronary arteries with intermediate to severe stenosis
224156669|NCT03731975|PROCEDURE|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
223460203|NCT03679559|OTHER|Laboratory Biomarker Analysis|Correlative studies
223460204|NCT03679559|DEVICE|Monitoring Device|Wear Fitbit
223460205|NCT03679559|OTHER|Quality-of-Life Assessment|Ancillary studies
223460206|NCT03679559|OTHER|Questionnaire Administration|Ancillary studies
223460207|NCT03221998|DRUG|IV paracetamol|100 gram paracetamol infusion for moderate pain management
223460208|NCT03221998|DRUG|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
223460209|NCT03131115|PROCEDURE|Lateral Crural Strut Graft|surgical technique as described
223460210|NCT03131115|PROCEDURE|Bone Anchored Suspension|Surgical technique as described
223460211|NCT00036088|DRUG|Olanzapine|
223460212|NCT05662748|DEVICE|Transfemoral aortic valve replacement|aortic valve replacement
223460213|NCT04533113|PROCEDURE|Carious tissue selective removal|Carious tissue selective removal in deep carious lesions in posterior teeth, using one of three materials as a liner under the final composite restoration
223460214|NCT00130689|DRUG|Cetuximab|
223460215|NCT03602716|DEVICE|HD-tDCS|HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
223460216|NCT03602716|DEVICE|Sham HD-tDCS|HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
223460217|NCT04632277|OTHER|Water|Participants will receive a tab water
223460218|NCT04632277|DIETARY_SUPPLEMENT|Water with low Mg|Participants will receive Low Mg bottle water (50mg/l)
223460219|NCT04632277|DIETARY_SUPPLEMENT|Water with high Mg|Participants will receive High Mg bottle water (100mg/l)
223460220|NCT05763810|OTHER|Erector Spinae Plane Block|Erector Spinae Plane Block
223460221|NCT05763810|OTHER|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block|Superficial Parasternal Intercostal Plane Block combined with Rectus Sheath Block
223460222|NCT01254656|DRUG|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
223460223|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
223574654|NCT03171246|DIETARY_SUPPLEMENT|Solid food-based intervention|Individually tailored energy content according to age/activity
223574655|NCT03282773|DEVICE|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
223574656|NCT03282773|DEVICE|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
224156670|NCT03731975|PROCEDURE|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
224156671|NCT03083964|BEHAVIORAL|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
223460224|NCT01254656|DRUG|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
223460225|NCT01254656|DRUG|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
223460226|NCT01254656|DRUG|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
223460227|NCT01254656|DRUG|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
223460228|NCT06418113|RADIATION|hypofractionated stereotactic radiotherapy|conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period
223460229|NCT06418113|PROCEDURE|Stereotactic biopsy|Stereotactic biopsy
223460230|NCT06418113|PROCEDURE|resection|supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
223460231|NCT06418113|DRUG|Chemotherapy|4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
223460232|NCT06418113|RADIATION|radiotherapy Stupp protocol|radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.
223460233|NCT06418113|DRUG|Chemotherapy Stupp Protocol|temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
224156672|NCT03083964|BEHAVIORAL|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
224156673|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
223460234|NCT01659840|RADIATION|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
223574657|NCT03729193|BEHAVIORAL|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
223574658|NCT00673023|OTHER|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
223574659|NCT02238431|DRUG|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
223574660|NCT02238431|DRUG|OCP|to schedule the start of the artificial cycle
224156674|NCT01949792|DRUG|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
224302950|NCT03206580|OTHER|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
224302951|NCT03206580|OTHER|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
224302952|NCT06077331|DRUG|HS-10374 tablets 1mg|Administered orally QD for 12 weeks
224302953|NCT06077331|DRUG|HS-10374 tablets 5mg|Administered orally QD for 12 weeks
224302954|NCT06077331|DRUG|HS-10374-matched placebo tablets|Administered orally QD for 12 weeks
224302955|NCT02043665|BIOLOGICAL|CVA21/pembrolizumab|
224302956|NCT06007131|DEVICE|CardioPumlonary Management System|The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
224302957|NCT04761874|OTHER|Telestroke|In the telestroke cohort, acute ischemic stroke patients at a single comprehensive stroke center received their stroke care and management exclusively via telestroke.
224302958|NCT00512382|DEVICE|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
224302959|NCT04740814|DRUG|Certolizumab pegol|"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."
224302960|NCT02187510|PROCEDURE|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
223574661|NCT02238431|OTHER|Natural|to use the normal menstrual period to schedule treatment start
224156675|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
224156676|NCT02871518|DRUG|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
224156677|NCT03903536|PROCEDURE|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
224156678|NCT03903536|PROCEDURE|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
224156679|NCT06206707|PROCEDURE|Faecal Microbiota Transplantation (FMT)|Capsule FMT
224156680|NCT06206707|PROCEDURE|Placebo|Placebo capsules
224156681|NCT00471783|PROCEDURE|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
224156682|NCT02929628|DEVICE|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
224156683|NCT00405236|DRUG|tiotropium|
224156684|NCT06102863|DRUG|statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);|Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
224156685|NCT00040950|BIOLOGICAL|rituximab|
224156686|NCT00040950|DRUG|agatolimod sodium|
224156687|NCT02283346|RADIATION|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~\+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
224156688|NCT02094729|DRUG|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
224156689|NCT02094729|DRUG|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
224156690|NCT02094729|DRUG|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
224156691|NCT02094729|DRUG|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
224156692|NCT04143425|DIAGNOSTIC_TEST|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
224156693|NCT04143425|DIAGNOSTIC_TEST|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
224156694|NCT04143425|DIAGNOSTIC_TEST|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
224156695|NCT01689324|BIOLOGICAL|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
224156696|NCT04236219|DRUG|ALLN-346|ALLN-346 is novel urate oxidase provided as capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
224302961|NCT02187510|PROCEDURE|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
224156697|NCT04236219|DRUG|Placebo|Matching placebo capsules for oral administration. Single ascending doses within 3 sequential cohorts: Cohort A - 3 capsules administered once, Cohort B - 6 capsules administered once and Cohort C - 12 capsules administered as 6 capsules twice on 1 day.
224156698|NCT02736396|OTHER|fMRI|Functional MRI scan to be performed
224156699|NCT02736396|OTHER|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
224156700|NCT00004300|DRUG|bromocriptine|
224156701|NCT00004300|DRUG|sertraline hydrochloride|
224156702|NCT02049229|DEVICE|percutaneous coronary intervention|Optimax-stent implantation
224302962|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule
224302963|NCT00952536|DIETARY_SUPPLEMENT|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
224302964|NCT00952536|DIETARY_SUPPLEMENT|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
224302965|NCT02309775|OTHER|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
224302966|NCT00188487|DEVICE|magnetic resonance imaging (MRI) of the thorax|
224302967|NCT03933436|OTHER|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
224302968|NCT03933436|OTHER|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
224302969|NCT05435716|DEVICE|C-wave™ peripheral seismic waveguide system|In the experimental group, if the target lesions did not show flow-limiting dissection or severe elastic retraction, drug-coated balloon was subsequently performed after lumen preparation by peripheral seismic catheterization system (IVL). If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
224302970|NCT05435716|DEVICE|Peripheral vascular balloon dilatation catheter (PTA)|Subjects in the control group received balloon dilatation catheter in peripheral blood for lumen preparation, and if the target lesions did not show flow-limiting interlayer or severe elastic retraction, drug-coated balloon therapy was subsequently performed. If there is limited flow dissection or severe elastic retraction, stent therapy is followed.
224302971|NCT00545207|DRUG|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
224302972|NCT00545207|DRUG|Placebo|po monthly for 2 years
224302973|NCT05238818|BIOLOGICAL|Autologous Tumor Infiltrating Lymphocyte Injection (GT202)|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. T cells then are manufactured to express mbIL-12. After lymphodepletion, patients are infused with GT202 followed by IL-2.
224302974|NCT05466006|PROCEDURE|Soft tissue augmentation with subepithelial connective tissue graft (SCTG)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), SCTG will be harvested from the palate and sutured to the flap. Simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
224302975|NCT05466006|PROCEDURE|Soft tissue augmentation with xenogenic volume stable collagen matrix (VCXM)|After the assessment of the vestibular bone dehiscence at implant site from the most apical extension of the trans-mucosal implant collar (≤3 mm evaluated in a vertical direction), VCMX will be sutured to the flap and simple interdental sutures will be performed in order to stabilize the flap in close contact with the healing screw.
224302976|NCT03982472|OTHER|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
224156703|NCT02049229|DEVICE|percutaneous coronary intervention|Synergy stent implantation
224156704|NCT01364857|GENETIC|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
224302977|NCT05367726|OTHER|patients having had skin coverage of the knee|the cutaneous cover is not always optimal to protect the prosthesis, an act of reconstructive plastic surgery is then necessary
224302978|NCT05167604|DRUG|Adjuvants, Pharmaceutic|Patients with stage IB-IIA NSCLC after curative surgery were treated with adjuvant chemotherapy. The blood samples of the patients before and after adjuvant chemotherapy will be collected to examine the MRD status
224302979|NCT01844739|DRUG|NVN1000 4% Gel|Applied topically twice daily
224302980|NCT01844739|DRUG|Vehicle Gel|Applied topically twice daily
224302981|NCT03891186|BEHAVIORAL|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
224302982|NCT03891186|OTHER|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
224302983|NCT01222286|DRUG|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
224302984|NCT04093635|DEVICE|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
224302985|NCT04489758|DIAGNOSTIC_TEST|X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis|Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
223460235|NCT01659840|RADIATION|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
223460236|NCT03158961|PROCEDURE|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
223460237|NCT04279080|OTHER|low anterior resection syndrome evaluation|evaluation of postoperative functional bowel outcome
223460238|NCT01164202|DRUG|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
223460239|NCT01164202|DRUG|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
223460240|NCT01164202|PROCEDURE|transarterial chemoembolization|Chimioembolisation
223460241|NCT03980262|BEHAVIORAL|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
223460242|NCT03980262|BEHAVIORAL|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
223460243|NCT03248869|OTHER|Current Daily Survey|need description
224156705|NCT05914740|PROCEDURE|Ultrasound guided functional remodeling of lower extremity superficial vein valve|Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
224156706|NCT04127240|OTHER|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
224156707|NCT01826448|DRUG|PLX3397|
224156708|NCT01826448|DRUG|vemurafenib|
224156709|NCT02833818|DIETARY_SUPPLEMENT|CAKE-intervention|Increased protein and energy supplementation and conversations
224156710|NCT02833818|DIETARY_SUPPLEMENT|CAKE-control|nutrition according to established procedures
224156711|NCT05769907|BEHAVIORAL|Intervention Group|The study will consist of one session per week for 8 weeks, during which the participant will receive MI for 30-45 minutes. All participants will receive the MI intervention according to their readiness to lose weight measured by means the P-weight and S-weight at the beginning of each session.
224156712|NCT03981185|DEVICE|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
224156713|NCT02130752|DEVICE|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
224156714|NCT02130752|DEVICE|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
224156715|NCT02314598|OTHER|No treatment|
223460244|NCT03248869|OTHER|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
223460245|NCT03416270|DRUG|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
223460246|NCT03416270|DRUG|Placebo|Placebo once daily for 12 weeks
223460247|NCT00958854|DRUG|cyclophosphamide|
223460248|NCT00958854|DRUG|fludarabine phosphate|
223460249|NCT00958854|DRUG|thalidomide|
223460250|NCT00958854|OTHER|laboratory biomarker analysis|
223460251|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
223574662|NCT05990699|BEHAVIORAL|Mindfulness-Based Relapse Prevention program|"This program consists of eight sessions spanning across four weeks, each focusing on specific techniques and skills to aid in substance use disorder treatment. The first session emphasizes the correlation between the unconscious pilot and substance use, incorporating a corporeal examination technique to promote intentional concentration. The second session focuses on mindfulness to identify stimuli and observe accompanying sentiments, thoughts, and feelings. The third session introduces the ABSTEMIOUS space technique, urging patients to pause, observe their experiences, concentrate on breathing, broaden cognizance, and choose judicious responses in trying or hazardous situations. The remaining sessions address coping mechanisms for relapse risks, taking pragmatic action in high-risk situations, integrating healthy activities into life, and sustaining mindfulness practice through the development of a support network."
224156716|NCT02818270|DRUG|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
224156717|NCT02818270|DRUG|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
224156718|NCT05135429|OTHER|Bathing|The data of the study were obtained from premature newborns born at 34 weeks and above, who were hospitalized.
224156719|NCT00381589|DRUG|ipratropium bromide 0.03% spray|
224156720|NCT01038089|DIETARY_SUPPLEMENT|Resveratrol|Resveratrol
224156721|NCT02617329|OTHER|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
224156722|NCT02617329|OTHER|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
223460252|NCT03747393|BEHAVIORAL|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
224156723|NCT02690389|DRUG|Flumazenil|used alone or with acupuncture
224156724|NCT02690389|PROCEDURE|Acupuncture|used alone or with flumazenil
223460253|NCT03200548|BEHAVIORAL|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
223460254|NCT03200548|BEHAVIORAL|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
223460255|NCT03200548|BEHAVIORAL|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
223460256|NCT03200548|BEHAVIORAL|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
223460257|NCT06238024|DRUG|Tocilizumab|Single dose intravenous application
223460258|NCT06238024|DRUG|NaCl 0.9% 100ml|Single dose intravenous application
223460259|NCT03035565|BEHAVIORAL|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
223460260|NCT03035565|BEHAVIORAL|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
223460261|NCT03555487|DRUG|18F-choline PET|5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
223460262|NCT05704868|BEHAVIORAL|UniVRse + TAU|"UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~1. Attending a lecture;~2. Group work in a seminar;~3. Delivering a presentation;~4. Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company."
223460263|NCT04577989|OTHER|data collection|data collection for treatment strategies (cefepime vs. piperacillin/tazobactam vs. carbapenems) of infections caused by AmpC beta-lactamase producing Enterobacterales for the period January 1st , 2015 until July 31st , 2020.
223460264|NCT03098680|DRUG|Albuterol Sulfate|see arm/group descriptions
223460265|NCT03098680|DRUG|Nicardipine Hydrochloride|see arm/group descriptions
223460266|NCT03098680|DRUG|Dobutamine Hydrochloride|see arm/group descriptions
223460267|NCT03098680|DRUG|Phenylephrine Hydrochloride|see arm/group descriptions
223460268|NCT03098680|DRUG|Verapamil Hydrochloride|see arm/group descriptions
223460269|NCT03098680|DRUG|Phentolamine Mesylate|see arm/group descriptions
223460270|NCT03098680|DRUG|Placebo|see arm/group descriptions
223574663|NCT04326725|DRUG|Plaquenil 200Mg Tablet|health workers under risk who took this medications
223574664|NCT03109028|BEHAVIORAL|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
224156725|NCT04800094|DEVICE|Investigational Liver Fat Quantification Software|All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.
224156726|NCT02490839|DRUG|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
224156727|NCT02490839|DRUG|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
224156728|NCT05153863|DEVICE|C Scope Visualization System|The C Scope Visualization System is indicated to be used by a trained physician to provide illumination and visualization in arthroscopic procedures of an interior cavity of the body through a surgical opening.
224156729|NCT05339204|PROCEDURE|allo-HSCT|allo-HSCT from any type of donor
224302986|NCT02500641|DRUG|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration \> 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
224156730|NCT05370846|OTHER|Clinical pharmacy antimicrobial stewardship intervention|"A new AMS group will be introduced in Tauernklinikum in Zell am See, based on the S3-AWMF-guideline Strategien zur Sicherung rationale Antibiotika-Anwendung im Krankenhaus on antibiotic use in hospitals. As part of this, a new formulary will be developed and gradually introduced where we determined which AMS guidelines need to be incorporated. Antimicrobial use will be audited after set-up of the local formulary against the data from before implementation (using defined daily dose, DDD, as suggested by the WHO). Data on antimicrobial use will be obtained from a recently purchased and installed AMS programme called HyBase® by epiNET AG. AMS group will be provided with implementation material and toolkits, baseline data for antimicrobial use within hospital will be obtained."
223460271|NCT00716456|DRUG|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
223460272|NCT00447772|BIOLOGICAL|Botulinum toxin type A|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
223460273|NCT02177929|OTHER|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
223460274|NCT04651998|DIAGNOSTIC_TEST|MMSE, MoCA, functional near-infrared spectroscopy|MMSE and MoCA are used for cognitive test before carotid artery stent implant and 6 months later. Cerebral blood oxygenation is evaluated by functional near-infrared spectroscopy under the mental task before and after revascularization within one week, 6 months later respectively.
223460275|NCT04046068|PROCEDURE|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
223460276|NCT04010409|OTHER|no intervention|no intervention
223460277|NCT02862080|DEVICE|cathode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
223460278|NCT02862080|DEVICE|Ekso|Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.
223460279|NCT02862080|DEVICE|anode tsDCS|Non-invasive electrical stimulation, transcutaneous spinal direct current stimulation (tsDCS) is the application of electrical current to the spinal cord via surface electrodes placed on the skin.
223460280|NCT00875563|DEVICE|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H\&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
223460281|NCT03404986|PROCEDURE|ureteroscopy|The patients will be subjected to rigid ureteroscopy
223460282|NCT03404986|RADIATION|Ultrasonography|The patients will be subjected to Ultrasonography
223460283|NCT00920153|BIOLOGICAL|bleomycin sulfate|Given IV
223460284|NCT00920153|DRUG|ABVD regimen|Given IV
223460285|NCT00920153|DRUG|carmustine|Given IV
223460286|NCT00920153|DRUG|cisplatin|Given IV
223460287|NCT00920153|DRUG|cytarabine|Given IV
223460288|NCT00920153|DRUG|dacarbazine|Given IV
223460289|NCT00920153|DRUG|dexamethasone|Given orally
223460290|NCT00920153|DRUG|doxorubicin hydrochloride|Given IV
224156731|NCT05402904|DIAGNOSTIC_TEST|nerve conduction study|Routine nerve conduction study on both lower limbs as well as F- wave , Hoffman reflex and somatosensory evoked potential.
224156732|NCT00790218|DRUG|CF102|CF102 capsules twice daily by mouth
223460291|NCT00920153|DRUG|etoposide|Given IV
223460292|NCT00920153|DRUG|gemcitabine hydrochloride|Given IV
223460293|NCT00920153|DRUG|ifosfamide|Given IV
223460294|NCT00920153|DRUG|melphalan|Given IV
223460295|NCT00920153|DRUG|methylprednisolone|Given IV
223574665|NCT03109028|BEHAVIORAL|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
224156733|NCT00059319|PROCEDURE|single aorta clamp with retrograde cardioplegia|
223460296|NCT00920153|DRUG|mitoguazone|Given IV
223460297|NCT00920153|DRUG|vincristine sulfate|Given IV
223460298|NCT00920153|DRUG|vindesine|Given IV
223460299|NCT00920153|DRUG|vinorelbine tartrate|Given IV
223460300|NCT00920153|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
223460301|NCT00920153|PROCEDURE|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
223460302|NCT00059228|DRUG|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
223574666|NCT03109028|BEHAVIORAL|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
223574667|NCT03109028|BEHAVIORAL|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
223460303|NCT00059228|DRUG|Placebos|Placebo skin patch for 6 weeks
223460304|NCT00060970|PROCEDURE|Physical Therapy|
223460305|NCT06405178|DRUG|Metformin|Insulin Sensitizer
223460306|NCT06405178|DRUG|Dapagliflozin|Sodium-Glucose Co-transporter-2
223460307|NCT06405178|DRUG|Dapagliflozin/Metformin|Anti diabetic drug
223460308|NCT06405178|DRUG|Letrozole|Aromataze inhibitor
223460309|NCT01730807|DEVICE|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
223460310|NCT02896569|OTHER|Topical combination therapy|
223460311|NCT03151382|DRUG|Tandospirone Citrate|Tandospirone, 30-60 mg/d
223460312|NCT03151382|DRUG|Donepezil Hydrochloride|Donepezil, 10 mg/d
223460313|NCT06273761|BEHAVIORAL|Medication Management Service (MMS)|Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
223460314|NCT03398694|PROCEDURE|Radiosurgery|"Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife or linear accelerator based techniques as per RTOG-9005 dosing criteria (Section 11 Table 1) based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time.~Radiosurgery will be performed 1-4 days prior to surgical resection. Vital signs and MRI Brain planning scan will be performed on the day of radiosurgery prior to the procedure."
223460315|NCT03943628|BEHAVIORAL|Familias Unidas|
223460316|NCT02938364|OTHER|Earplugs|Plastic earplugs on both ears
223460317|NCT02938364|OTHER|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
223460318|NCT02938364|OTHER|Placebo|Non pressure bands put on the wrists of the participant
223460319|NCT01462630|DRUG|pazopanib hydrochloride|Given PO
224156734|NCT00059319|PROCEDURE|multiple aorta clamps with antegrade cardioplegia|
224156735|NCT00899600|DRUG|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
224156736|NCT00899600|OTHER|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
224156737|NCT05299645|BEHAVIORAL|Interview|Pilot study with digital browsers
224156738|NCT03869164|DEVICE|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
223460320|NCT01462630|OTHER|laboratory biomarker analysis|Correlative studies
224156739|NCT01245231|GENETIC|protein expression analysis|
223460321|NCT01462630|PROCEDURE|positron emission tomography|Correlative studies
223460322|NCT01462630|PROCEDURE|computed tomography|Correlative studies
223460323|NCT01462630|RADIATION|fludeoxyglucose F 18|Correlative studies
223460324|NCT01033500|DRUG|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
223460325|NCT01102712|DEVICE|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
223460326|NCT05554029|DIAGNOSTIC_TEST|Coronaphobia|Coronophobia will be assessed with COVID-19-phobia scale.
223460327|NCT01302405|DRUG|PRI-724|Dose escalation
223460328|NCT03745053|DEVICE|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
223460329|NCT03745053|DEVICE|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
223460330|NCT03257436|DEVICE|CRT-D|Left Ventricular MultiSite Pacing
223460331|NCT01464190|DRUG|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
223460332|NCT01464190|DRUG|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
223460333|NCT03787823|PROCEDURE|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
223460334|NCT01268852|DEVICE|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
223460335|NCT01268852|DEVICE|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
223460336|NCT04985045|OTHER|Evaluation|Individuals' menstrual status, pain, menstrual symptoms and genital hygiene behaviors will be evaluated.
223460337|NCT00394186|DRUG|GW427353|
223460338|NCT00394186|DRUG|Placebo|
223460339|NCT00970489|DRUG|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
223460340|NCT00970489|DRUG|Placebo|Olive Oil capsules
223574668|NCT03109028|BEHAVIORAL|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
223574669|NCT03109028|OTHER|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
223574670|NCT02099162|DEVICE|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
224156740|NCT01245231|GENETIC|western blotting|
224156741|NCT01245231|OTHER|flow cytometry|
224156742|NCT01245231|OTHER|laboratory biomarker analysis|
223460341|NCT02277327|BEHAVIORAL|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
223460342|NCT02277327|BEHAVIORAL|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
223460343|NCT00002610|BIOLOGICAL|dactinomycin|
223460344|NCT00002610|BIOLOGICAL|filgrastim|
223460345|NCT00002610|DRUG|carboplatin|
223460346|NCT00002610|DRUG|cyclophosphamide|
223460347|NCT00002610|DRUG|doxorubicin hydrochloride|
223460348|NCT00002610|DRUG|etoposide|
223460349|NCT00002610|DRUG|vincristine sulfate|IV
223460350|NCT00002610|PROCEDURE|conventional surgery|
223460351|NCT00002610|RADIATION|radiation therapy|
223460352|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
223460353|NCT03583008|BEHAVIORAL|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
223460354|NCT06304571|DRUG|HC006|Specified dose on specified days
223460355|NCT05417412|BEHAVIORAL|Brief Behavioral Therapy|8-12 sessions of brief behavioral therapy administered by behavioral health / mental health staff at participating community health centers (CHCs)
224156743|NCT01245231|OTHER|medical chart review|
224156744|NCT06198894|PROCEDURE|steroid-eluting sinus stent implant|In-office bilateral placement of the steroid-eluting sinus stent in the ethmoid sinuses under local anesthesia
224302987|NCT02500641|DRUG|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration \>6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
224302988|NCT02500641|DRUG|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
223460356|NCT02704312|RADIATION|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
223460357|NCT02227277|DRUG|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
223460358|NCT03415516|DEVICE|Gluma Universal|Adhesive systems
223460359|NCT03415516|DEVICE|All Bond Universal|Adhesive systems
223460360|NCT03415516|DRUG|Single Bond2|Adhesive systems
223460361|NCT01305811|DEVICE|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
223460362|NCT02339103|OTHER|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
223460363|NCT02339103|OTHER|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
223460364|NCT03301662|DIAGNOSTIC_TEST|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
223460365|NCT03107910|BEHAVIORAL|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
223460366|NCT03107910|BEHAVIORAL|Health Information Seeking|Seeking and evaluating online health information will be assessed.
223460367|NCT06376487|DEVICE|Flow rate evaluation|Four different randomized flow rates will be used for evaluation: 2.0 liter.Kg-1.min-1, 1.5 liter.Kg-1.min-1, 1.0 liter.Kg-1.min-1, 0.5 liter.Kg-1.min-1. At the end of the randomized order evaluation the infant will remain in the flow of 0.5 liter.Kg-1.min-1 for 5 minutes and then return to the flow of 2.0 liter.Kg-1.min-1. The EIT parameters, ultrasound assessment, and clinical variables will be collected at the end of the 5-minute stay in each lane.
223460368|NCT00132080|DRUG|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
223460369|NCT03478371|DEVICE|tampon D|regular absorbency tampon
223460370|NCT03478371|DEVICE|tampon M|regular absorbency tampon
223460371|NCT03478371|DEVICE|tampon T|regular absorbency tampon
224156745|NCT06198894|DRUG|Systemic glucocorticoids|Groups were given oral methylprednisolone (32 mg/d on days 1-5; 16 mg/d on days 6-10; and 8 mg/d on days 11-20),
224156746|NCT06198894|DRUG|saline irrigations|Patients were routinely treated with saline irrigations (250ml) twice daily
224156747|NCT06198894|DRUG|Placebo|Groups were given systemic glucocorticoid placebo
224156748|NCT06198894|PROCEDURE|sham procedure|The sham procedure was performed in-office under local anesthesia
224302989|NCT02500641|DRUG|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
223460372|NCT03478371|DEVICE|tampon V|regular absorbency tampon
223460373|NCT03943498|DRUG|Fingolimod|Given PO daily for 4 weeks
223460374|NCT03943498|DRUG|Fingolimod Hydrochloride|Given PO
223460375|NCT03943498|OTHER|Questionnaire Administration|Ancillary studies
223460376|NCT03308240|BEHAVIORAL|Magic Therapy|As described in the arm description
223574671|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
223574672|NCT01310400|BIOLOGICAL|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~* 15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
223574673|NCT01310400|BIOLOGICAL|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
223574674|NCT02345668|BEHAVIORAL|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
223574675|NCT02345668|DRUG|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
223574676|NCT02345668|BEHAVIORAL|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
224156749|NCT05698004|OTHER|prone positioning|The target duration of prone positioning is 8 h/d to 10 h/d with 2 to 3 breaks (1-2 hours each), if needed. Daily prone positioning sessions will be protocolized to continue until 1 of the following stopping criteria is met: a relative improvement in the FIO2 requirement by 40% from the baseline value that sustained for 24 hours; endotracheal intubation; or discharge from the ICU.
224156750|NCT04533516|OTHER|Manual therapy technics|Manual therapy technics
224156751|NCT04533516|OTHER|Inspiratory Muscle Training|Inspiratory Muscle Training
224156752|NCT00626834|DRUG|Vigabatrin|Dose 1 BID
224156753|NCT00626834|DRUG|Vigabatrin|Dose 2 BID
223460377|NCT03994978|PROCEDURE|elective sigmoidectomy|elective sigmoidectomy
223460378|NCT00261755|PROCEDURE|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
223460379|NCT00261755|OTHER|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
223460380|NCT00261755|OTHER|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
223574677|NCT04694521|PROCEDURE|openSide to end colorectal anastomosis .|open Side to end colorectal anastomosis
223574678|NCT04694521|PROCEDURE|open end end to end stapler anastomosis|open end to end stapler anastomosis
223574679|NCT02426775|DRUG|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
223574680|NCT06105216|OTHER|Crossword and word search puzzles|Students in the intervention group received hard copies of the puzzles at the end of the laboratory practice.
223574681|NCT05186831|BEHAVIORAL|Texting|Patients will be asked to text their BP. They will receive an automated response to their texts.
224156754|NCT00626834|DRUG|Vigabatrin|Dose 3 BID
224156755|NCT00626834|DRUG|Matching placebo|Matching placebo BID
224302990|NCT02500641|DRUG|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
223460381|NCT02667925|DRUG|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
223460382|NCT02849743|DRUG|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
223460383|NCT02849743|DRUG|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
223574682|NCT05186831|BEHAVIORAL|Online patient portal|Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
223574683|NCT06349187|DIAGNOSTIC_TEST|Interview|Interviewing with using the Hall Emotional Intelligence test, the Maslach emotional burnout test, and the test for determining general and specialized digital competencies
224302991|NCT04694183|DRUG|Camrelizumab|200mg, intravenous drip administration, d1, every 3 weeks.
224302992|NCT04694183|DRUG|S-1|Oral, d1-14, every 3 weeks.
224302993|NCT04694183|DRUG|Oxaliplatin|130mg/m² intravenous drip administration, d1, every 3 weeks(For patients with liver and/or para-aortic lymph node metastasis).
224156756|NCT03424044|DEVICE|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
223574684|NCT03112967|OTHER|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
223574685|NCT03112967|OTHER|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
224156757|NCT03424044|DEVICE|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
224156758|NCT03424044|DEVICE|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
224156759|NCT03424044|DRUG|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
224156760|NCT03498989|OTHER|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
224156761|NCT03498989|OTHER|exclusive breast milk|exclusive breast milk
224156762|NCT04336007|DEVICE|Resistive Diathermy (INDIBA® Activ Ct9)|Intervention is conducted using a 65-mm diameter Resistive (RES) electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity is administered in the following manner: cream was applied to the upper limbs existent area, and the electrical output is marked at 75% by moving the movable electrode and if not tolerated by the patient lowered until 35%, Therapy is conducted for 20 minutes, prior swimming time trials.
223460384|NCT00594776|DEVICE|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
223460385|NCT03064113|DRUG|Placebo|
223460386|NCT03064113|DRUG|TD-4208 700 μg|
223460387|NCT03064113|DRUG|TD-4208 350 μg|
223460388|NCT03064113|DRUG|Ipratropium 500 μg|
223460389|NCT05682417|DEVICE|Body Map Assessment Tool: MOVE Tool|"In VR, a spherical object approaches with linear trajectory the body of patients, it can be sent to 4 parts of the body (mid-arm/waist/hip/mid-thigh) both left and right side. Several conditions are presented, either the trajectory leads the object to touch the body, or it passes at ≠ distances from it. Patient is instructed to move only if he thinks the object will touch his body.~Procedure begins with a measurement taken on 3 body locations via the Move tool (shoulders/hips/thighs) to create an avatar allowing the tool to determine whether or not movement was necessary. Then, the movement of the patient is recorded. For each object/body distance, the software determines if dodging was necessary. The overestimation of the body schema corresponds to the average distance from which the patient considers that the object would have touched her body and performs a dodging movement, compared to her real morphological dimensions. This generates a body limit distortion % for each body area."
223460390|NCT05682417|OTHER|PAQ questionnaire|This questionnaire has been translated and validated (French version, Luminet et al., 2021). This is a self-reported measure of alexithymia in 24 items. It is designed to measure all the components of alexithymia for both negative and positive emotions. Five subscale scores and six composite scores can be obtained from the questionnaire, with high scores indicating higher levels of alexithymia.
223574686|NCT05491941|OTHER|Sepsis Bundle|Intervention initiated within 1 hour or 3 hours of presentation depending on the Arm: 1. Measure lactate level. 2. Obtain blood cultures before administering antibiotics. 3. Administer broad-spectrum antibiotics. 4. Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate greater than or equal to 4mmol/L. 5. Apply vasopressor if hypotensive during or after fluid resuscitation to maintain a mean arterial pressure greater than or equal to 65 mm Hg.
223574687|NCT04086537|DIAGNOSTIC_TEST|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
223574688|NCT01118520|DRUG|perindopril arginine|10mgs orally daily for the duration of the trial
223574689|NCT01118520|DRUG|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
224302994|NCT04694183|DRUG|Paclitaxel|Intraperitoneal paclitaxel 20 mg/m² and intravenous paclitaxel 50 mg/m² on days 1 and 8, every 3 weeks(For patients with peritoneal metastasis ).
223574690|NCT01118520|DRUG|placebo|one daily
223460391|NCT05682417|OTHER|F-DFlex questionnaire|This questionnaire (Detail and Flexibility Questionnaire, French version of Maria et al, 2020) assesses cognitive rigidity. This questionnaire assesses two frequently impaired cognitive dimensions in people with anorexia nervosa, central coherence and cognitive flexibility in daily functioning using 20 self-completed items.
223460392|NCT05682417|OTHER|BSQ questionnaire|"The Body Shape Questionnaire (BSQ, translated and validated in French by Rousseau et al., 2005) is a one-dimensional Anglo-Saxon self-questionnaire of 34 items that assesses concerns about body shape over the past four weeks. Responses are scored on a 6-point Likert scale. A score of 1 (never) means the problem is not present, up to a score of 6 (always) which means the problem is always present. The higher the score, the more the concern/dissatisfaction with one's body tends to be pathological."
223460393|NCT05682417|OTHER|Silhouette testing|Body overestimation is assessed by the computerized silhouette test (adapted from Gardner \& Brown, 2010, Van der Linder et al., 2017). Twenty-seven Body Mass Index silhouettes ranging from 11 to 40 are presented to participants in random order. For each silhouette presented, the participant answers whether or not the silhouette presented corresponds to her current silhouette. A body underestimation index is calculated as follows: Estimated figure average BMI - actual BMI.
223574691|NCT05234424|OTHER|THRIVE|During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.
223574692|NCT05671575|OTHER|Questionnaire about Epilepsy|After obtaining informed consent, a structured questionnaire will be administered to the accompanying relative. The questionnaire consists of 5 sections: participants socio-demographic characteristics, patient demographic and clinical characteristics, participants knowledge about epilepsy including sources of knowledge and management of an acute seizure, general attitudes, and behaviors towards the People with epilepsy, Stigma scale of epilepsy.\[14\], and Quality of life in epilepsy-10 inventory (QOLIE-10) as the main data collection tool as regard quality of life of patients with epilepsy.
223574693|NCT05016167|PROCEDURE|Replacement every 24 hours|"Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded."
224156763|NCT04336007|DEVICE|Resistive Diathermy OFF (INDIBA® Activ Ct9)|Placebo is conducted using a 65-mm diameter RES electrode (movable), and a planar electrode was used as a return electrode on the abdomen. The electricity IS NOT administered, the cream was applied to the upper limbs existent area and moving the movable electrode, intervention is conducted for 20 minutes, prior to swimming time trials.
224156764|NCT04336007|OTHER|Control|This group will warm-up as they usually do in competitions, for later time trial measuring.
224156765|NCT02971007|DRUG|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
224156766|NCT02971007|DRUG|Fluconazole|
223460394|NCT05682417|OTHER|Eating Disorder Inventory - 2|"Allows self-assessment of symptoms of eating disorders. It is composed of 91 questions grouped into 11 subscales that assess specific cognitive and behavioral dimensions: desire for thinness, bulimia, body dissatisfaction, feeling of inefficiency, perfectionism, interpersonal distrust, interoceptive sensitivity, fears relating to maturity, asceticism. , impulsiveness and social insecurity. For each item, participants can answer always, usually, often, sometimes, rarely or never. The score for each item is between 0 and 3. The subscale scores are calculated by simply adding all the item scores for each specific subscale. This questionnaire has demonstrated good internal consistency, test-retest reliability, and validity (Garner, 1991)"
223460395|NCT05682417|OTHER|EDEQ questionnaire|"Or Eating Disorders Examination - Questionnaire (Fairburn \& Beglin, 2008). This questionnaire assesses eating behaviors and concerns about weight and body shape, using 28 items focusing on these aspects over the past 28 days."
223460396|NCT05682417|OTHER|STAI questionnaire|The Spielberger Anxiety Scale (STAI) State and Trait. This questionnaire includes two distinct scales: one evaluating the current state of anxiety (STAI form Y-A: feelings of apprehension, tension, nervousness and worry that the subject feels at a precise precise moment) and the second evaluating the anxious personality trait (STAI form Y-B: feelings of apprehension, tension, nervousness, and worry that the subject usually feels). The Y version was developed in order to eliminate the items having appeal to depression compared to the initial form. Each scale has 20 items. This questionnaire has good psychometric qualities regarding validity, reproducibility and inter-individual sensitivity. It correlates well with other anxiety questionnaires in a literature review of anxiety questionnaires (Elwood, 2012).
223460397|NCT05682417|OTHER|BECK questionnaire|Beck Depression Inventory (Beck, 1987). The inventory is composed of items related to depressive symptoms as well as physical symptoms. This is a questionnaire that gives a quantitative estimate of the intensity of depression. Investigators will use the abbreviated version consisting of 13 items, each item comprising 4 sentences corresponding to 4 degrees of increasing intensity of a symptom on a scale of 0 to 3. The total score corresponds to the sum of the different items and makes it possible to judge the presence of depression and its intensity.
223460398|NCT00002293|DRUG|Nystatin|
223460399|NCT05865223|OTHER|Mckenzie exercise program|MacKenzie extension exercise program for cervical spine
223460400|NCT05865223|OTHER|Conventional Physical therapy|hot pack for 15 minutes will be given followed by joint mobilization,and home exercise program.
223460401|NCT02167438|DEVICE|Hem-Avert Perianal Stabilizer|
223460402|NCT02026765|DEVICE|traditional lens|A random eyes with traditional lens
223460403|NCT02026765|DEVICE|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
223460404|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation A|Biological
223460405|NCT05831124|OTHER|Low dose multivalent pneumococcal conjugate vaccine formulation B|Biological
223460406|NCT05831124|BIOLOGICAL|Low dose of multivalent pneumococcal conjugate vaccine control|low dose multivalent pneumococcal conjugate vaccine
223460407|NCT05831124|BIOLOGICAL|Standard dose multivalent pneumococcal conjugate vaccine control|multivalent pneumococcal conjugate vaccine
224156767|NCT00486512|DRUG|0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
223460408|NCT05438979|DIETARY_SUPPLEMENT|Placebo|Placebo for comparison to CFB
223574694|NCT05016167|PROCEDURE|Replacement every 12 hours|"Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded."
223574695|NCT00000419|DRUG|Premarin and Provera|
223574696|NCT01070693|PROCEDURE|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
223574697|NCT01070693|DEVICE|Prolene Hernia System|Prolene Hernia System
223574698|NCT01070693|PROCEDURE|Lichtenstein technique|Lichtenstein technique
223574699|NCT01089023|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
223574700|NCT02203383|DEVICE|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
223460409|NCT05438979|DIETARY_SUPPLEMENT|Calcium Fructoborate|216mg CFB
223460410|NCT03874013|DRUG|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
223460411|NCT03874013|DRUG|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
223460412|NCT04331691|DRUG|Spironolactone|After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
223574701|NCT03130660|DEVICE|Ultrasonography|Ultrasound guidance for central line
223574702|NCT01169688|OTHER|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
223574703|NCT02008513|BIOLOGICAL|AFFITOPE® AD02|
223574704|NCT02008513|BIOLOGICAL|Placebo|
223460413|NCT04331691|DRUG|Amiloride|After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
223460414|NCT05814315|BEHAVIORAL|HOPE Intervention|Participants used the Health Checkins Platform for 12 weeks for emotional support and to obtain pain management tools
223460415|NCT05747859|OTHER|teletherapy|speech therapy remotely delivered
223460416|NCT06333730|PROCEDURE|inferior alveolar nerve block|After informed consent, the needle will be inserted into the muco-buccal fold adjacent to the mandibular molars and advanced it towards the mandibular foramen, aiming slightly anteriorly and superiorly. Aspirating to check for blood or resistance, the needle will be repositioned if either was present. Once the needle will be correctly positioned, the dental practitioner will slowly inject 1.8-1.9 mL of the anesthetic solution.
223574705|NCT05551013|DRUG|APG-157|"APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)"
223574706|NCT03421743|DRUG|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
223574707|NCT03421743|DRUG|Antimycobacterial regimen|Multidrug NTM guideline-based antimycobacterial regimen
223574708|NCT01166373|BEHAVIORAL|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
223574709|NCT01166373|PROCEDURE|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
223574710|NCT01166373|PROCEDURE|ULS|uterosacral ligament suspension to suspend the vaginal apex
223574711|NCT01166373|BEHAVIORAL|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
223574712|NCT01166373|OTHER|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
223574713|NCT02969096|PROCEDURE|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
223574714|NCT01819129|DRUG|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
223574715|NCT01819129|DRUG|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
223574716|NCT01819129|DRUG|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
223574717|NCT02684812|DRUG|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
224156768|NCT00486512|DRUG|75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
223574718|NCT00001250|DRUG|preoperative dose intense chemotherapy (FLAC/G-CSF)|
224156769|NCT00486512|DRUG|placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)|
224156770|NCT00486512|DRUG|placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)|
224156771|NCT00486512|PROCEDURE|Colonoscopy|
224156772|NCT00706758|BEHAVIORAL|IBS school|Structured patient group education
224156773|NCT00706758|BEHAVIORAL|IBS-guidebook|Written information - IBS-guidebook
223460417|NCT06333730|PROCEDURE|mental nerve block|After informed consent, the needle will be inserted into the buccal fold between the lower premolars. Aspirating to check for blood or resistance. Once needle is correctly positioned, 0.6-0.9 ml of the anesthetic solution will be deposited.
223460418|NCT05469126|DRUG|LY3502970|Administered orally.
223460419|NCT05469126|DRUG|Clarithromycin|Administered orally.
223460420|NCT00943657|BIOLOGICAL|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
223460421|NCT04753294|DEVICE|Avance Solo NPWT System|Wound treatment with Avance Solo NPWT System for up to 28 days.
223460422|NCT04753294|DEVICE|Avance Solo Adapt NPWT System|Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
223460423|NCT03628651|OTHER|Blood Sample Collection|HCC subjects will have one blood sample collected.
224156774|NCT05265936|PROCEDURE|Passing a guidewire through a double j stent|The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.
224156775|NCT05265936|PROCEDURE|Double J stent removal and guidewire insertion|The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.
224156776|NCT03174769|OTHER|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
224156777|NCT03174769|OTHER|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
224156778|NCT04450004|BIOLOGICAL|Intramuscular Vaccine|Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with their assigned vaccine.
224156779|NCT01086904|BIOLOGICAL|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
223460424|NCT03628651|OTHER|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
223460425|NCT04976439|OTHER|co-occuring mutation|APC, TP53, PIK3CA, KRAS APC, TP53, PIK3CA, MLH1 APC, TP53, PIK3CA, KRAS, and MLH1 APC, TP53, PIK3CA
223460426|NCT06040814|BEHAVIORAL|Rehabilitation Training|12 week Rehabilitation Training course
223574719|NCT02985892|OTHER|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
223574720|NCT02985892|OTHER|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
223574721|NCT05041595|DIAGNOSTIC_TEST|Lyme diagnostic assay|Serological and immunoresponse assay
223574722|NCT03073018|DRUG|Fosinopril|oral administration, capsules
223574723|NCT03073018|DRUG|Pravastatin|oral administration, capsules
223574724|NCT03073018|DRUG|Fosinopril Placebo|oral administration, capsules
223574725|NCT03073018|DRUG|Pravastatin Placebo|oral administration, capsules
224156780|NCT00797810|DRUG|Rituximab|
224156781|NCT04352881|OTHER|Questionary patient|Assessing pain reduction using a 4-step questionary
224156782|NCT06120192|BEHAVIORAL|Piano|Receives the piano training
224156783|NCT02764086|RADIATION|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
223460427|NCT05594147|DRUG|Non-TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
223460428|NCT05594147|DRUG|Other TKIs|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
223460429|NCT05594147|DRUG|Regorafenib (Stivarga, BAY73- 4506)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
223460430|NCT05594147|DRUG|Sorafenib (Nexavar, BAY43-9006)|Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.
223460431|NCT02481076|DEVICE|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
223460432|NCT02481076|OTHER|Braun frame|The leg is elevated on a Braun frame
223460433|NCT02481076|DEVICE|compression bandage|application of flowtron hydroven boot and compression bandage
223460434|NCT06324877|DRUG|Nicotinamide riboside|Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses
223460435|NCT04705012|OTHER|Submucosal supportive therapy|Increased frequency of submucosal cleaning using a rotating chitosan brush
223460436|NCT02909010|DEVICE|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
223574726|NCT00391469|OTHER|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
223574727|NCT00391469|DRUG|Rapid infusion of cold normal saline|
223460437|NCT02909010|OTHER|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
223460438|NCT01204203|DRUG|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
223460439|NCT03507855|OTHER|Reduced noise|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
223460440|NCT03507855|OTHER|Normal|No change in the normal operating room environment.
223574728|NCT01084980|DRUG|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
224302995|NCT03424512|BEHAVIORAL|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
223460441|NCT01096160|DRUG|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
223460442|NCT01096160|DRUG|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
223460443|NCT01096160|DRUG|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
223460444|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
223460445|NCT01096160|DRUG|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
223460446|NCT01096160|DRUG|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
223460447|NCT01096160|DRUG|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
223460448|NCT01096160|DRUG|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
223460449|NCT01096160|DRUG|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
223574729|NCT04284124|OTHER|Erector Spinae block|Patient in the prone position 20 min before induction of general anesthesia. Skin is sterilized by 10% povidone iodine. An US multifrequency convex probe (1-8 MHz) will be used for block. A 22G, 50-mm in length needle will be used and block will be performed at the T4 level of the spine using in-plane approach where a convex probe is placed 2-3 cm lateral to the spine using sagittal approach. Erector spinae muscle and the transverse processes are located and the needle will be inserted deep into the muscle. The needle is directed craniotomy-caudally. Correct position of the needle tip is confirmed with administration of 0.5-1 ml of local anesthetic to monitor spread then 20 ml of 0.25% bupivacaine will be administered for block performance. Distribution of local anesthetic is monitored in both cranial and caudal directions
223574730|NCT02825966|DEVICE|AUDICOR then LifeVest then AUDICOR|Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
223574731|NCT01725230|DRUG|Fostamatinib|100-mg tablet
223574732|NCT01725230|DRUG|Rosuvastatin|20-mg tablet
223574733|NCT01725230|DRUG|Simvastatin|40-mg tablet
223574734|NCT05124509|BIOLOGICAL|Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)|Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
223460450|NCT01096160|DRUG|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
223460451|NCT06164457|OTHER|ePROM Survey|The APPROACH ePROM survey consists of several well validated PROM instruments, including the Seattle Angina Questionnaire 7-item version,\[4\] the EuroQol EQ5D-5L,\[5\] the Medical Outcomes Study Social Support Scale (8 item version),\[6\] the Patient Health Questionnaire 2-item and 9-item (PHQ2/9) depression screening tools\[7\], and the Self-Care of Coronary Heart Disease Inventory (SC-CHDI-V3).\[8\]
223460452|NCT01536210|DRUG|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
223460453|NCT01536210|DRUG|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
223574735|NCT05124509|BIOLOGICAL|Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)|Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
223574736|NCT05670548|OTHER|Questionnaire survey and specimen collection|A questionnaire survey was conducted when pregnant women were enrolled, and blood were collected at 24-28 gestational weeks. Placenta and umbilical cord blood are collected during delivery.
223460454|NCT05931536|OTHER|Dietary fibre|Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
223460455|NCT05660382|DRUG|Miconazole (2%) oil and mineral oil|Twice daily application, for 14 days.
223460456|NCT05660382|OTHER|Placebo|Twice daily application, for 14 days
223460457|NCT01837251|DRUG|Carboplatin|
223460458|NCT01837251|DRUG|PLD|
223460459|NCT01837251|BIOLOGICAL|Bevacizumab|
223460460|NCT01460732|DEVICE|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
223460461|NCT00715234|OTHER|Reminder/recall notices for vaccines|"1. Receive a generic letter reminding them to make an appointment to get vaccines.~2. Receive a computer-generated telephone message at 1 week post initial letter.~3. Receive a computer-generated telephone message at 2 months post initial letter.~4. Receive a letter at 3 months post initial letter."
223460462|NCT05375500|DEVICE|telemedicine digital therapeutic|digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
223460463|NCT03796312|BEHAVIORAL|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
223460464|NCT03796312|BEHAVIORAL|Sponge Bathing|Sponge bathing is routine care of the clinic
223460465|NCT06312865|DEVICE|Ophthalmic exam|include best corrected visual acuity and cycloplegic refraction data
223460466|NCT00325910|DRUG|Metformin|
223460467|NCT00922116|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
223460468|NCT00741312|BEHAVIORAL|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
223460469|NCT00741312|BEHAVIORAL|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
223460470|NCT05015036|PROCEDURE|ERAS|Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
223460471|NCT05015036|PROCEDURE|Minimally invasive surgery|Classic Minimally invasive surgery of the lumbar spine
223574737|NCT03812926|DEVICE|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
223574738|NCT00491660|BEHAVIORAL|supine positioning|
223574739|NCT00491660|BEHAVIORAL|lateral positioning|
223574740|NCT04740840|DRUG|Levamlodipine|According to the inclusion criteria of the trial, those who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was treated with 2.5mg levamlodipine to lower blood pressure. Abdominal blood was emptying before the start of the trial and at the first and third month of medication.Data on CRP, TNF-α, IL-6, Lp-PLA2 and ATP were collected.
223460472|NCT05179824|OTHER|Observation|No Intervention
223574741|NCT04740840|DRUG|Amlodipine|According to the inclusion criteria, patients who met the diagnosis of hypertension were randomly divided into the experimental group and the control group. The experimental group was given 5mg amlodipine to lower blood pressure. Fasting blood was collected before the trial and during the first and third months of treatment. CRP, TNF-α, IL-6, Lp-PLA2 and ATP data were collected.
223574742|NCT04835909|BEHAVIORAL|Modern board and card games group|Modern board and card games group
223574743|NCT04835909|BEHAVIORAL|Paper and pencil tasks group|Paper and pencil tasks group
223460473|NCT04607135|DEVICE|Acoustic radiation force impulse (ARFI)|"Sound waves are sent in a series and are expected to push on the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system"
223460474|NCT04607135|DEVICE|Ultrasound|Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen
223460475|NCT05288114|DEVICE|Signal Relief Patch|Eligible subjects will be provided a Signal Relief patch, the instructions for use, and patch placement materials (adhesive, athletic tape, or wrap as applicable for the location of the pain). Subjects will be instructed to use the patch daily for seven days. The patch must be worn constantly except when showing or swimming.
223460476|NCT05490355|PROCEDURE|Radiofrequency Ablation (RFA)|RFA involves heating of periarticular nerves using continuous RFA (80-90C for 60-90 seconds) that results in electromodulation and denervation reducing pain. It can be done under fluoroscopy or CT guidance. CT guidance has additional benefit of better localization of the nerves, as opposed to simple bony landmarks used in fluoroscopy, since nerve branching variations are common and will be used in this study.
223574744|NCT01564095|DRUG|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
223574745|NCT01564095|DRUG|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
223574746|NCT03651518|DRUG|Kineret|100 mg, once/day sc 6 months
223574747|NCT03651518|DRUG|Humira|40 mg/15 days sc 6 months
223574748|NCT03651518|DRUG|Stelara|45 mg/12 weeks sc, 6 months
223574749|NCT03651518|DRUG|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
223574750|NCT03651518|DRUG|Roactemra|480 mg/perf/4 weeks 6 months
223574751|NCT03651518|DRUG|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
223574752|NCT06154941|PROCEDURE|Giomer Varnish|A light-cured Giomer varnish for prolonged hypersensitivity relief. Seals and protects exposed dentinal tubules to prevent pain. Ideal for patients experiencing loss of enamel, gingival recession
223574753|NCT06154941|PROCEDURE|CPP-ACP varnish|CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. CPP-ACP Varnish delivers bioavailable calcium and phosphate ions to occlude dentinal tubules treating dentin hypersensitivity
224302996|NCT03989622|OTHER|evaluation of the visual field on the ground|evaluation of the visual field on the ground
223460477|NCT05490355|PROCEDURE|Perineural Steroid Injection|Perineural Steroid Injections involve CT guided injection of Local Anesthetic and Steroid into a nerve root of the spine to provide ongoing pain relief.
223460478|NCT06060496|DEVICE|Active cTBS|Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
223460479|NCT06060496|DEVICE|Sham cTBS|Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
223460480|NCT05465369|OTHER|giomer|injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
223460481|NCT05465369|OTHER|high viscosity glass ionomer|High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
223460482|NCT06958549|PROCEDURE|Nerve block with Lidocain|Injection of Lidocaine (7mg/kg) with Epinephrine 1:100000 under Ultrasonographical guidance
223460483|NCT06958549|DRUG|pharmacological analgesics|Oral Paracetamol (500mg/6hr), IV Ketolac (15mg/6hr) and IV perfelgan (1gm/6hr)
223460484|NCT06958445|DRUG|Alginos Oral Suspension|containing: Sodium alginate 50mg/mL Sodium bicarbonate 26.7mg/mL Calcium carbonate 16mg/mL
223460485|NCT05722821|OTHER|Hypopressive intervention|"Hypopressive abdominal gymnastics is based on a basic level hypopressive exercise program that will be:~* A duration of 12 weeks with a frequency of 2 sessions a week and lasting 45 minutes each. Hypopressive abdominal exercises will be performed individually adapted to the capacity of the participant.~* There will be an initial anatomical training of the muscles involved in carrying out the exercise and practice in the respiratory technique for a duration of 15 minutes. Afterwards, hypopressive exercises will begin for 20-30 minutes, changing positions if possible."
223460486|NCT03990051|DRUG|Pro-ocular™ topical gel|Topical gel for forehead dermal application
223460487|NCT03990051|DRUG|Placebo topical gel|Topical gel for forehead dermal application
223460488|NCT06444503|OTHER|Biological samples|Blood and urine will be taken in larger quantity
223460489|NCT06444503|OTHER|Biological|Surgical residues may be preserved in the event of surgery carried out as part of the treatment.
223460490|NCT00921661|DRUG|AVE0005 (aflibercept)|IV infusion
223460491|NCT00618826|DRUG|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
223574754|NCT04802239|OTHER|Medical hypnosis group|"Hypnotic induction is performed according to a standard protocol and identical for all.~A script will be written to give all the important steps. .Only the pleasant place and the characteristics of the analgesic glove will be different between the subjects .the procedure will follow the following protocol:~* State of calm at rest of 3 minutes.~* Hypnotic induction by catalepsy of the eyes guided by breathing.~* The hypnosis session takes place in safety place , with glove protect by dissociation and confusion techniques."
223574755|NCT04802239|OTHER|calm wake group|healthy volunteers will observe 3 minutes calm waking state before standardized thermal harmful stimulation
223460492|NCT00618826|DRUG|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
223460493|NCT00618826|DRUG|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
223574756|NCT01819558|BIOLOGICAL|recwt1-A10+AS01B|
223460494|NCT04167189|DRUG|Lidocaine gel|Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg
223460495|NCT03193047|DRUG|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
223460496|NCT03193047|OTHER|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
223460497|NCT03193047|DRUG|evolocumab|Monthly PCSK9i (evolocumab) background therapy
223460498|NCT03861091|DRUG|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
223460499|NCT03861091|DRUG|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
223574757|NCT03436641|OTHER|No intervention|No intervention
223574758|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Physical Activity|Self-Monitoring of Behavior for Physical Activity: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring the number of steps taken on the prior day relative to their baseline average number of steps.
224302997|NCT00543946|DRUG|GAP-134|24-Hour IV infusion, SAD
223574759|NCT05941000|BEHAVIORAL|Action Planning for Physical Activity|Action Planning for Physical Activity: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to walk an extra 1,000 steps relative to their baseline average step count.
223574760|NCT05941000|BEHAVIORAL|Self-Monitoring of Behavior for Mood|Self-Monitoring of Behavior for Mood: Individuals will receive daily text messages that include the Self-Monitoring behavior change technique message with the goal of self-monitoring their mood on the prior day.
224302998|NCT03508414|BEHAVIORAL|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
223574761|NCT05941000|BEHAVIORAL|Action Planning for Mood|Action Planning for Mood: Individuals will receive daily text messages that include the Action Planning behavior change technique with the goal of planning to take action to improve their mood.
223460500|NCT01161810|OTHER|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
223460501|NCT05042752|PROCEDURE|CLINICAL ULTRASOUND|The intervention group will receive the standard care of treatment in AHF and the performance of CU.
223460502|NCT04006470|DRUG|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
223460503|NCT04006470|DRUG|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
223460504|NCT04006470|DRUG|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
223460505|NCT01509664|BEHAVIORAL|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
223460506|NCT02855567|DEVICE|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
223460507|NCT05519956|RADIATION|level Ib-covering IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
223460508|NCT05519956|RADIATION|level Ib-sparing IMRT|Patients who had level II involvement with extracapsular extension (ECE), and/or had a maximum nodal axial diameter (MAD) of greater than 2cm in level II.
223460509|NCT01942811|BEHAVIORAL|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
223460510|NCT01025102|DRUG|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
223460511|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.
223460512|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove lipids in peripheral blood.
224156784|NCT03588104|DEVICE|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
223460513|NCT06224296|DEVICE|DFPP|One session of blood purification using DFPP to remove toxic metal ions.
223460514|NCT02431104|DEVICE|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
223574762|NCT02770976|DEVICE|Increasing and decreasing NAVA levels with 10-min intervals|
223574763|NCT03741946|PROCEDURE|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
224156785|NCT03588104|OTHER|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
224156786|NCT03582839|BEHAVIORAL|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
224156787|NCT00402285|DIETARY_SUPPLEMENT|lycopene supplement|
224156788|NCT00402285|DIETARY_SUPPLEMENT|fish oil supplement|
224156789|NCT00402285|OTHER|Placebo|placebos for lycopene and fish oil.
224156790|NCT01017666|DRUG|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
224156791|NCT01017666|DRUG|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
223460515|NCT01960465|DEVICE|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
223460516|NCT02213315|DRUG|100mg Mavrilimumab|100mg Mavrilimumab
223460517|NCT02213315|DRUG|150mg mavrilimumab|150mg mavrilmumab
223460518|NCT02213315|OTHER|Placebo|Placebo
223460519|NCT05262335|DRUG|Anlotinib + Oxaliplatin + Capecitabine|"1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
223460520|NCT05262335|DRUG|Anlotinib + Cisplatin + Paclitaxel/ Docetaxel|"1. Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
223460521|NCT05262335|DRUG|Anlotinib + Standard first-line chemotherapy|"1. Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity."
223460522|NCT05582629|DRUG|JT001|JT001 administered orally in tablet form every 12 hours for 5 days
223574764|NCT01296074|DRUG|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
223574765|NCT03009838|DRUG|Letrozole|oral tablets 2.5 mg
223574766|NCT03009838|PROCEDURE|ovarian drilling|laparoscopic electrocauterization
224156792|NCT03309241|DRUG|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
223460523|NCT05582629|DRUG|Placebo|Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days
223460524|NCT04753502|PROCEDURE|Laparoscopy|laparoscopic removal of pathologic appendix
223460525|NCT02413957|OTHER|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
223460526|NCT02413957|OTHER|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
223460527|NCT03626701|DEVICE|RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
223574767|NCT02266277|OTHER|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
224156793|NCT03309241|OTHER|Placebo|Placebo Single Dose
224156794|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
224156795|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
224156796|NCT02640989|BIOLOGICAL|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
224156797|NCT04479007|DEVICE|Probe based optical techniques|During the intervention of inspecting the airways, different segments of the alveolar compartment will be imaged by two different probe based (CLE and OCT).
224156798|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
224156799|NCT03464890|OTHER|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
223460528|NCT03626701|COMBINATION_PRODUCT|Mepilex® Ag Wound Dressing|Application of Mepilex® Ag Wound Dressing
223460529|NCT03626701|PROCEDURE|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
223460530|NCT03701880|DRUG|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
223460531|NCT03701880|DRUG|Bisoprolol|Bisoprolol is beta-blocker
223460532|NCT03093441|OTHER|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
224156800|NCT03464890|OTHER|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
224156801|NCT03464890|OTHER|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
224156802|NCT04012333|DRUG|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
224156803|NCT02108223|DRUG|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
223460533|NCT00149396|DRUG|NV1020|NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
223460534|NCT02690012|OTHER|Magnesium Oxide|Magnesium Oxide
223460535|NCT02690012|OTHER|Magnesium Citrate|Magnesium Citrate
224156804|NCT02108223|DRUG|r-LH supplementation|recombinant luteinizing hormone
224156805|NCT02108223|DRUG|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
224156806|NCT05905770|DRUG|Alemtuzumab Injection [Campath]|Alemtuzumab 1mg/kg
223460536|NCT06355661|DIETARY_SUPPLEMENT|ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
223460537|NCT06355661|DIETARY_SUPPLEMENT|MCC: 400 mg (± 10%) per Capsule|Two capsules/day (One capsule to be taken 30 minutes before breakfast \& one capsule to be taken 30 minutes before dinner)
223460538|NCT04001192|BEHAVIORAL|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
223460539|NCT01095627|OTHER|Metacholine challenge|Exhaled breath analysis following metacholine challenge
223460540|NCT05756881|OTHER|Cosmetic product|Apply on the face twice a day
223574768|NCT02266277|OTHER|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
224156807|NCT00877760|DRUG|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
224156808|NCT00877760|DRUG|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
224156809|NCT04563572|DEVICE|PPG Smartwatch|Participants will then receive a PPG sensor in form of a smartwatch) model and will be instructed to wear them continuously for 48 hours. Simultaneously, a 48-hour Holter ECG will be performed. Start time on the PPG-sensor and the Holter ECG will be matched and continuous heart rhythm and -rate monitoring will be initiated. Patients will wear the devices over a 48-hour period of time.
223574769|NCT02266277|OTHER|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
223460541|NCT03069534|DRUG|RhIL-2|RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
223460542|NCT02364388|DEVICE|Imagio IUS|Imagio diagnostic gray-scale ultrasound
223460543|NCT02364388|DEVICE|Imagio OA/US|Diagnostic opto-acoustic +gray-scale ultrasound
223460544|NCT04884347|DIETARY_SUPPLEMENT|Alline proMEN|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
223460545|NCT04884347|DIETARY_SUPPLEMENT|Placebo|1 tablet per day intake during the meal with a glass of water. Treatment duration: 3 months
223460546|NCT05682833|PROCEDURE|Non surgical periodontal therapy|Subgingival ultrasonic debridement + manual root planning
224156810|NCT02468804|DEVICE|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
223460547|NCT05437809|OTHER|Intake of nutritionally diverse ultra-processed foods|All participants will attend four food consumption assessment visits where, at each visit, they will be asked to consume a standardized snack portion of: 1) ultra-processed foods (UPFs) high in both fat and refined carbohydrates (UPF+FRC), 2) UPF high in fat (UPF+F), 3) UPF high in refined carbohydrates (white flour, sugar) (UPF+RC), or 4) minimally processed foods. The order of the four food consumption assessment visits will be randomized and counterbalanced across participants, who will each consume all the test snacks across the four appointments.
223460548|NCT01308892|DIETARY_SUPPLEMENT|High flavanol chocolate|chocolate high in flavanols
223460549|NCT01308892|DIETARY_SUPPLEMENT|Low flavanol chocolate|chocolate low in flavanols
223574770|NCT02266277|OTHER|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
223574771|NCT02836873|DRUG|Bexagliflozin|Bexagliflozin tablet, 20 mg
223574772|NCT02836873|DRUG|Placebo|Placebo (inactive) tablet to match the active comparator
224156811|NCT02468804|DEVICE|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
223460550|NCT01308892|DIETARY_SUPPLEMENT|High fat challenge|Milkshake with 95g fat
223460551|NCT02681458|OTHER|Direct Examination|It was an observational study and subjects received their routine treatment.
223460552|NCT00287521|DRUG|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
223460553|NCT00287521|DRUG|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
223460554|NCT00287521|OTHER|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
223574773|NCT01059253|OTHER|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
223574774|NCT03143673|DEVICE|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
223574775|NCT00694096|DRUG|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
223460555|NCT00287521|DRUG|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
223460556|NCT00186485|DEVICE|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
223460557|NCT00905424|DRUG|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
223460558|NCT00905424|DRUG|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
223460559|NCT00037063|DRUG|Thiamine hydrochloride|
223460560|NCT00037063|DRUG|Riboflavin|
223460561|NCT00037063|DRUG|Ascorbic acid|
223460562|NCT00037063|DRUG|Vitamin E|
223460563|NCT00379899|DRUG|cinacalcet|Low dose vitamin D with cinacalcet
223460564|NCT05225389|DRUG|300 mg [C14] CT1812|Single dose of 300 mg CT1812 with microtracer dose of \[C14\]
223460565|NCT04069676|OTHER|EEG|EEG, ECG and EDR record during a behavioral task
223460566|NCT02235025|OTHER|Cardio-pulmonary exercise testing|
223460567|NCT02666001|DRUG|BMS-663068|BMS-663068
223460568|NCT02666001|DRUG|Methadone|Methadone
223574776|NCT02011620|OTHER|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
223574777|NCT02430896|DRUG|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
223574778|NCT02430896|DRUG|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
223574779|NCT04923646|OTHER|Primer|Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
223574780|NCT03190265|DRUG|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
224156812|NCT02561676|OTHER|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
224156813|NCT02561676|OTHER|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
223460569|NCT02666001|DRUG|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
223460570|NCT03311841|DRUG|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
223460571|NCT03311841|DRUG|Dabigatran and pitavastatin oral solution|375/10 μg dabigatran etexilate and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
223460572|NCT03311841|DRUG|Atorvastatin and rosuvastatin oral solution|100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
223460573|NCT03311841|DRUG|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
223574781|NCT03190265|DRUG|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
223574782|NCT03190265|DRUG|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
223574783|NCT03190265|DRUG|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
223574784|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
223574785|NCT03190265|DRUG|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
223574786|NCT02914548|DRUG|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
223574787|NCT02914548|DRUG|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
224156814|NCT02667028|PROCEDURE|PCI|percutaneous coronary intervention
224156815|NCT00092391|BIOLOGICAL|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
224156816|NCT00092391|BIOLOGICAL|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
224156817|NCT06316934|DRUG|Lavandula angustifolia, Aura Cacia|Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
223574788|NCT01071005|DRUG|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
223460574|NCT05332314|DRUG|NSAIDs|The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
223574789|NCT01071005|DRUG|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
223574790|NCT00024661|DRUG|LErafAON|
223574791|NCT00532740|RADIATION|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
223574792|NCT01900106|DRUG|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
223574793|NCT01900106|DRUG|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
223574794|NCT00580125|DRUG|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
223574795|NCT00580125|OTHER|Placebo|Placebo, oral capsule, once daily for 21 days
223574796|NCT00580125|DRUG|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
223574797|NCT00580125|DRUG|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
223574798|NCT00580125|DRUG|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
223574799|NCT02345356|GENETIC|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
223574800|NCT02345356|OTHER|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
223574801|NCT02214225|BIOLOGICAL|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
223574802|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
223574803|NCT02214225|BIOLOGICAL|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
223574804|NCT03754582|DRUG|Perampanel|Oral tablets.
223574805|NCT03754582|DRUG|Perampanel|Intravenous infusion.
224156818|NCT06316934|OTHER|Placebo|Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
224156819|NCT04944927|OTHER|Recording of clinical parameters and electrocardiogram parameters|Retrospective recording of demographic information (age, sex, age at diagnosis), genetic information, cardiological information, pharmacological treatments, electrocardiogram data. All above data will be deidentified.
224156820|NCT02252068|BEHAVIORAL|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
224156821|NCT02252068|BEHAVIORAL|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
224156822|NCT02352649|DRUG|Neovasculgen|
224156823|NCT02568852|PROCEDURE|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
224156824|NCT02568852|PROCEDURE|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
224302999|NCT03508414|BEHAVIORAL|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
223460575|NCT01972412|BEHAVIORAL|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
223460576|NCT05939245|PROCEDURE|Furosemide Injection|Continuous infusion of furosemide is administered starting at 2 mg/hour and can be titrated until the target urine output of 1-2 cc/kg/hour is achieved for 48 hours. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
223460577|NCT05939245|PROCEDURE|Placebo Injection|Continuous infusion of placebo fluid is administered at a rate of 2 mL/hour. In case of hypotension (MAP \<65 mmHg), norepinephrine is administered with titration starting at a dose of 0.05 mcg/kg/minute, along with a fluid loading of 4 cc/kg body weight or 300 cc within 5-10 minutes, until the target MAP of ≥65 mmHg is reached for 48 hours.
223460578|NCT05719298|DEVICE|Respiratory interface|Application of the new interface and accessories and provision of non-invasive respiratory support through the device.
223460579|NCT06253533|BIOLOGICAL|ICVAX|ICVAX is a HIV therapeutic DNA drug developed by Immuno Cure Group based on the PD-1-Enhanced DNA Vaccine Technology platform. The unit dose strength is 2 mg in 1 mL. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
223460580|NCT06253533|OTHER|Placebo|Phosphate buffered saline of the same volume will be administered. The dose volume is 0.5 mL/dose for the Low-dose Group, 1.0 mL/dose for the Medium-dose Group, and 2.0 mL/dose for the High-dose Group.
223460581|NCT01324635|DRUG|Panobinostat|Given PO
223460582|NCT01324635|RADIATION|Stereotactic body radiation therapy|Undergo SBRT
223460583|NCT01324635|PROCEDURE|Quality-of-life assessment|Ancillary studies
223574806|NCT04619446|DEVICE|Removable Twin Block|Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
223574807|NCT04619446|DEVICE|Fixed Functional , AdvanSync Appliance|AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
223460584|NCT01324635|RADIATION|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
224156825|NCT01951911|DRUG|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
223460585|NCT01674465|BIOLOGICAL|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m\^2 two-three hours prior to their standard of care biopsy
223460586|NCT04110899|OTHER|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
223460587|NCT05728333|DRUG|Tirofiban|Intravenous tirofiban before endovascular thrombectomy.
223574808|NCT03608137|OTHER|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
223460588|NCT05728333|DRUG|Alteplase|Intravenous alteplase before endovascular thrombectomy.
223574809|NCT03321903|DEVICE|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
223574810|NCT03321903|OTHER|EPR Oximetry Measurement|An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
223574811|NCT02889679|PROCEDURE|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
224156826|NCT01951911|DRUG|Placebo|
224156827|NCT02027064|DRUG|Interferon-alpha|
224156828|NCT04371185|DRUG|BAT2206|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
224156829|NCT04371185|DRUG|Stelara(US-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
224156830|NCT04371185|DRUG|Stelara(EU-licensed)|45mg/0.5 ml; single dose；prefilled syringe; subcutaneous injection
224156831|NCT05509491|BEHAVIORAL|A postural awareness program with exercises|A program about postural awareness, bad posture, good posture and their effects on daily life
224303000|NCT03508414|BEHAVIORAL|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
223460589|NCT00826059|DEVICE|Active Sphenopalatine Ganglion (SPG) Stimulation|SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
224156832|NCT02408484|BIOLOGICAL|Octafibrin|Plasma-derived Fibrinogen concentrate
224156833|NCT03247218|DRUG|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
224156834|NCT01951976|OTHER|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
223460590|NCT00826059|DEVICE|Sham Sphenopalatine Ganglion (SPG) Stimulation|Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
223460591|NCT01026948|DRUG|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
223460592|NCT01026948|DEVICE|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
223460593|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
223460594|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
223460595|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
223460596|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
223460597|NCT01706367|BIOLOGICAL|C. difficile vaccine|0.5 mL IM injection
223574812|NCT02889679|PROCEDURE|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
223574813|NCT02889679|PROCEDURE|Standard polypectomy|Standard polypectomy will be performed for diminutive (\<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
223574814|NCT05400902|DRUG|HAIC Combined with Tislelizumab and Apatinib|"Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W"
223574815|NCT02680574|DRUG|Vadadustat|Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
224156835|NCT01951976|OTHER|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
223460598|NCT01706367|BIOLOGICAL|C. difficile vaccine +adjuvant|0.5 mL IM injection
223460599|NCT05205200|DRUG|SHR-1316|PD-L1 antibody
223460600|NCT05205200|DRUG|SHR6390|CDK4/6 inhibitor
223460601|NCT05205200|DRUG|Nab paclitaxel|Albumin bound paclitaxel
223574816|NCT02680574|DRUG|Darbepoetin alfa|Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.
223574817|NCT01806025|OTHER|no intervention|
223574818|NCT02504112|OTHER|there is no intervention|
223574819|NCT02847858|BEHAVIORAL|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
224156836|NCT05822388|PROCEDURE|Deep Brain Stimulation Surgical Procedures as Part of Routine Clinical Care|Participants in this study will already be undergoing a DBS intervention, however, this is part of their standard clinical care. Pre-surgical DBS candidates that enroll in this study will consent to participate in 1) pre-operative neuroimaging including a high-resolution MRI scan, 2) collection of pre-operative neurocognitive data via chart review and 3) a 1-year postoperative neurocognitive assessment.
224156837|NCT05794880|DEVICE|Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)|Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.
223460602|NCT05205200|DRUG|SERD|Fulvestrant
223460603|NCT05205200|DRUG|AI|aromatase inhibitor
223460604|NCT05857800|OTHER|Observation|Analysis of dynamic changes of lung cancer microenvironment in neoadjuvant therapy using bio-omics information collected in clinical trials.
224303001|NCT05066763|OTHER|Non-interventional|non-interventional
224303002|NCT05555563|OTHER|MTAD irrigation|Final irrigation protocol was performed using 5 ml MTAD (n=50).
224303003|NCT05335733|DIAGNOSTIC_TEST|Intraoral examination, saliva, dental plaque and serum collection.|"Probing pocket depth will be defined as the distance in millimeters from the gingival margin to the base of the gingival sulcus measured using a manual probe (Michigan 0 probe with Williams Markings) in all the teeth present except for third molars. Similarly, clinical attachment level (CAL) will be measured as distance from cementoenamel junction to the base of pocket and will be recorded manually to the nearest millimeter marking on probe.~1 mililiter of saliva will be obtained by each participant. Subgingival dental plaque will be collected with sterile endodontic paperpoints from mesial sides of each natural teeth without a prostethic restoration. Serum samples will be also collected at the time of visit."
224156838|NCT04639635|OTHER|No intervention, this is a natural history progression study|The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.
224156839|NCT03036930|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
224156840|NCT03036930|PROCEDURE|HPV Self-Collection|Undergo self-collection of vaginal/cervical samples
224156841|NCT03036930|OTHER|Questionnaire Administration|Ancillary studies
224156842|NCT03036930|BIOLOGICAL|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
224303004|NCT01604590|RADIATION|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
224303005|NCT06967714|BEHAVIORAL|Exercise|25 min cycling exercise at 75% of hear rate reserve. Physical use of one upper-limb will be restricted with a sling.
224303006|NCT04300010|DRUG|5% Topical Benzoyl Peroxide Gel|Gel treatment used to treat acne
224303007|NCT04300010|DEVICE|Blue Light Therapy|Blue light therapy treatment for acne
223460605|NCT00701792|PROCEDURE|liver transplantation|liver transplantation
223460606|NCT00701792|OTHER|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
223460607|NCT00098007|DRUG|Everolimus (Certican)|
223460608|NCT00704951|DRUG|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
223460609|NCT00627926|BIOLOGICAL|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
223460610|NCT00627926|DRUG|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
223460611|NCT00627926|DRUG|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
223460612|NCT00627926|OTHER|Placebo|Telaprevir matching placebo
223460613|NCT02017093|DEVICE|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
223460614|NCT02017093|DEVICE|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
223574820|NCT02700789|PROCEDURE|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
224156843|NCT01978392|BEHAVIORAL|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
224156844|NCT02515188|DRUG|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
224156845|NCT02515188|DRUG|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
224156846|NCT05737667|BEHAVIORAL|Youth Readiness Intervention (YRI)|The YRI is a culturally adapted group intervention that integrates common practice elements of cognitive behavioral and interpersonal therapies. The YRI's core treatment elements target improving emotion regulation skills, interpersonal functioning, and problem-solving skills. The YRI has 12 session that last about 90 minutes. The YRI will be delivered in schools by teachers receiving either mobile-based supervision or standard, in-person supervision.
224156847|NCT06441227|DRUG|HRS-5346 tablets|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
224303008|NCT02331368|PROCEDURE|Autologous Stem Cell Transplant|
224303009|NCT02331368|DRUG|Melphalan|140-200 mg/m\^2
224303010|NCT02331368|DRUG|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
224303011|NCT02331368|DRUG|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
224303012|NCT02838810|DRUG|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
224303013|NCT02838810|DRUG|Nucleoside analogues|Nucleoside analogues
224303014|NCT05873010|DIAGNOSTIC_TEST|Manual Compression and Stretching|Manual Compression and Stretching for The Myofascial Trigger Points
224303015|NCT03123510|DIETARY_SUPPLEMENT|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
224303016|NCT03123510|DIETARY_SUPPLEMENT|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
223460615|NCT01951118|DRUG|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
224156848|NCT06441227|DRUG|placebo|Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
224156849|NCT05194397|DIETARY_SUPPLEMENT|Nicotinamide Riboside|"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
224156850|NCT05194397|DIETARY_SUPPLEMENT|Placebo|The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
224156851|NCT05194397|OTHER|Exercise Intervention|The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
224156852|NCT05201404|DRUG|Namodenoson|Adenosine A3 Receptor (A3AR) agonist
224156853|NCT05201404|DRUG|Placebo|Control arm
224156854|NCT01823016|DRUG|Placebo|Placebo tablet, taken once daily
224156855|NCT01823016|DRUG|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
224156856|NCT04349800|DRUG|KVD900|Active
224156857|NCT04349800|DRUG|Placebo to KVD900|Placebo
224156858|NCT02708992|DRUG|Azithromycin|
224156859|NCT02708992|DRUG|Cefixime|
224156860|NCT06092086|DRUG|Loratinib|Continuous daily PO dosing of lorlatinib 100mg QD.
224303017|NCT01031953|DRUG|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
223460616|NCT04657263|OTHER|Vaccine coverage assessment|Vaccine coverage assessment
223460617|NCT06336057|BEHAVIORAL|Mentalization|complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization
223460618|NCT03037346|OTHER|Questionnaire Administration|Complete questionnaires about MPOAD
223460619|NCT03037346|OTHER|Questionnaire Administration|Ancillary studies
223460620|NCT03037346|OTHER|Video|Watch educational video
223460621|NCT05798156|DRUG|Glofitamab|Glofitamab is a fully humanized, engineered monoclonal bivalent antibody of the IgG1 isotype.
223460622|NCT05798156|DRUG|Rituximab|Rituximab is a genetically engineered chimeric mouse/human anti-CD20 monoclonal antibody
223460623|NCT05798156|DRUG|Obinutuzumab|Obinutuzumab is a fully humanized, glycoengineered type II monoclonal antibody of the IgG1 isotype that binds to an epitope on CD20
223460624|NCT05798156|DRUG|Polatuzumab vedotin|Polatuzumab vedotin is an antibody-drug-conjugate that contains a humanized IgG1 anti-CD79b monoclonal antibody (MCDS4409A) and a potent anti-mitotic agent (MMAE) linked through a protease-cleavable linker.
223460625|NCT01678664|DRUG|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
223460626|NCT01678664|DEVICE|embolization|2 sessions embolization with spheric particles
224156861|NCT05229640|DEVICE|Fibroscan|Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.
224156862|NCT04484506|DRUG|pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone|Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
224156863|NCT02969694|OTHER|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
224156864|NCT01116310|DRUG|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
224303018|NCT01031953|DRUG|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
224156865|NCT01116310|DRUG|Placebo|Bottles containing 60 capsules.
224156866|NCT02744560|DIETARY_SUPPLEMENT|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
224156867|NCT00185536|BEHAVIORAL|Packaging and identification of source|
224156868|NCT06148649|DRUG|HEC88473, Placebo, Dulaglutide|T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
224156869|NCT01461798|DIETARY_SUPPLEMENT|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
224156870|NCT01461798|DIETARY_SUPPLEMENT|Placebo Yogurt|Yogurt without the active principle
224156871|NCT01461798|DIETARY_SUPPLEMENT|yogurt|yogurt without plant stanols
224303019|NCT01031953|OTHER|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
224303020|NCT01031953|PROCEDURE|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
223574821|NCT00681564|PROCEDURE|One-Stage Full-Mouth Disinfection|"* Scaling and root planing, four quadrants in one session~* Tongue brushing with a 1% chlorhexidine gel (1 minute)~* Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~* Subgingival chlorhexidine (1%) irrigation in all pockets~* Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~* Basic oral hygiene instructions~* Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
223460627|NCT01678664|DRUG|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
223460628|NCT05312970|DRUG|Varithena®|Varithena® (polidocanol injectable foam) 1%
223460629|NCT05312970|DEVICE|FDA-approved Endothermal Ablation (ETA) systems|FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
223460630|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
223460631|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
223460632|NCT00124722|DRUG|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
223460633|NCT02981914|DRUG|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
223574822|NCT00681564|PROCEDURE|Periodontal care|"* Basic oral hygiene instructions~* Supragingival plaque removal"
223574823|NCT04151628|DEVICE|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
223574824|NCT02615405|DIETARY_SUPPLEMENT|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.
223574825|NCT02615405|DIETARY_SUPPLEMENT|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.
224156872|NCT05145673|OTHER|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
224156873|NCT05145673|OTHER|Cinnamon (OGTT plus aqueous cinnamon extract)|The intervention group was given an glucose solution to OGTT followed by a cinnamon aqueous extract. The glucose solution consist in a glucose drink with 75g of anhydrous D-Glucose dissolved in 200 mL of water at room temperature, as prescribed by ADA. The blood glucose levels were measured before intervention at fasting (t0) and after 30 (t30), 60 (t60, 90 (t90) and 120 (t120) minutes after intervention from both groups.
223460634|NCT03913871|BEHAVIORAL|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
223460635|NCT03913871|BEHAVIORAL|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
223460636|NCT04322669|DRUG|Pidotimod|Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
223460637|NCT04322669|DRUG|Placebo|Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
223574826|NCT02615405|DIETARY_SUPPLEMENT|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
223574827|NCT01698450|DEVICE|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
223574828|NCT05788588|DRUG|HR19006|An emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume, administered via a central venous line over a time period of approximately 15 hours per day.
223574829|NCT05788588|DRUG|All-in-one parenteral nutrition|Trial participants are prescribed TPN by the attending physician, which will be administered via a central venous line over a time period of approximately 15 hours per day. The formulation is an emulsion containing the full supply of carbohydrates, amino acids and lipids with a total energy content of 1265kcal in a 1250 ml volume (nitrogen content, heat and liquid quantity as equal as HR19006).
223574830|NCT03468816|DEVICE|Sensor activation (on DryMax Extra Soft)|Study profile of sensor activation
223574831|NCT00167596|DEVICE|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
223574832|NCT00167596|DEVICE|conventional|resuscitation will be based according to Surviving Sepsis Campaign
223574833|NCT03738995|BIOLOGICAL|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
223574834|NCT00044681|DRUG|risperidone|
223574835|NCT03661788|DRUG|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
224156874|NCT03008187|DRUG|MEN1703|MEN1703 given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
224156875|NCT00500838|DEVICE|Transthoracic Impedance|Impedance measures will be automatically collected via the device
223574836|NCT03661788|DRUG|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
223574837|NCT05011214|DRUG|Sevoflurane|All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
223460638|NCT01852513|DRUG|QNASL|
223460639|NCT01852513|DRUG|Placebo nasal spray|
223460640|NCT05886088|DRUG|LID104|Experimental
223460641|NCT05886088|DRUG|Dapagliflozin|Active comparator
223460642|NCT05886088|DRUG|Linagliptin|Active comparator
223460643|NCT02169843|DRUG|Sevoflurane|inhale Sevoflurane
223460644|NCT02169843|DRUG|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
223574838|NCT05011214|DRUG|Esketamine|All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
223574839|NCT01663428|OTHER|Sup-ER Splint|
223574840|NCT01663428|OTHER|Currently accepted treatment|
223574841|NCT01009346|DRUG|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001"
223574842|NCT01009346|DRUG|Cetuximab|250mg/m2/week
223574843|NCT01009346|DRUG|Cisplatin|40mg/m2 Day 1, 8 every 28 days
223574844|NCT01009346|DRUG|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
223574845|NCT00301548|DRUG|perioperative chemotherapy|
223574846|NCT04171180|DRUG|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
223574847|NCT03419949|DRUG|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
223574848|NCT03419949|DRUG|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
223574849|NCT06008769|BEHAVIORAL|12 Week Manualized Cognitive-Behavioral Therapy Intervention|The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
223574850|NCT00310284|BEHAVIORAL|Computerized delivery of cognitive-behavioral treatment of insomnia|
223574851|NCT00310284|BEHAVIORAL|Self-help manual to improve insomnia symptoms|
223574852|NCT00267605|BEHAVIORAL|FHPADHD|Evidence-based psychological and behavioural distance intervention
223574853|NCT00267605|BEHAVIORAL|ADHD Standard Care|
223574854|NCT05923736|OTHER|Intima media thickness ultrasound|EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.
223574855|NCT05923736|OTHER|hand ultrasound|Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.
224163566|NCT01077193|PROCEDURE|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
223460645|NCT02169843|DRUG|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
223460646|NCT00884078|OTHER|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
223460647|NCT00164632|BEHAVIORAL|counselling, exercise, referrals (behavior)|
223574856|NCT05923736|OTHER|EndoPAT™ 2000 system|It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.
223574857|NCT05923736|OTHER|X-ray absorptiometry (DXA)|This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators
223460648|NCT00666159|DRUG|tacrolimus ointment|topical
223460649|NCT00666159|DRUG|pimecrolimus cream|topical
223574858|NCT06031142|DEVICE|use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.
223574859|NCT03067285|DRUG|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
223574860|NCT03067285|DRUG|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
223460650|NCT01463800|BEHAVIORAL|Structured exercise training|12 weeks low level ambulatory structured exercise training
223460651|NCT01681238|PROCEDURE|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR \<100 bpm, Hb\> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
223574861|NCT04429581|OTHER|Anthropometry|
223574862|NCT02928003|PROCEDURE|Lung surgery|Genetic analysis and questionnaires
223574863|NCT05785260|BEHAVIORAL|ACT MINDFULNESS|"Mindfulness (MCBT) practices were offered to patients with the aim of fostering the elderly's pro-active role in health prevention by making them~aware of the relationship between thoughts, emotions and symptomatology of the disorder. The exercises will also be used as a motivational work tool within a protocol of Acceptance and Commitment Therapy (ACT), a new generation cognitive behavioral approach, in which commitment components are added to mindfulness, suitable for lifestyle modification."
223574864|NCT03302455|BEHAVIORAL|eCBTI|The brief eCBTI contains a one-week core course: sleep hygiene education, sleep restriction, stimulus control, relaxation audios, cognitive components, information about sleeping pills, and a brief overview. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
223574865|NCT01316952|DRUG|Carvedilol immediate release only|All dosages of carvedilol immediate release
223574866|NCT01316952|DRUG|Carvedilol extended release only|All dosages of carvedilol extended release
223574867|NCT01316952|DRUG|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
223574868|NCT01316952|DRUG|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
223574869|NCT01316952|DRUG|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
223574870|NCT01316952|OTHER|No β-blocker|No β-blocker within the month prior to the index date
223574871|NCT05491746|DEVICE|Eye4|Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
223574872|NCT05491746|OTHER|Placebo|This is the patient's best corrected vision with or without glasses/contact lenses
223574873|NCT04054492|BIOLOGICAL|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
223574874|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
223574875|NCT04054492|BIOLOGICAL|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
223574876|NCT06228638|OTHER|CognivAID (Sailuotong)|CognivAiD is 27.27 mg of panax ginseng standard extract, 27.27 mg of gingo biloba standard extract and 5.46 mg of crocus sativus standard extract which is equal to 60mg /capsule .CognivAiD is available at 60 mg /cap 2 caps twice a day.
223574877|NCT02044666|DEVICE|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
223574878|NCT01537055|DRUG|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
223574879|NCT01537055|DRUG|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
223574880|NCT02593812|BEHAVIORAL|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
223574881|NCT04317326|PROCEDURE|"Lifestyle modifications group (Control)"|It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
223574882|NCT04317326|PROCEDURE|Automatic NIV|In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
224163567|NCT01468389|DRUG|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
224163568|NCT01468389|DRUG|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
224163569|NCT03671434|BEHAVIORAL|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
223574883|NCT04317326|PROCEDURE|CPAP treatment group|In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
223574884|NCT04317326|PROCEDURE|NIV treatment groups|In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
223574885|NCT04922931|PROCEDURE|scheduled surgery|Patients undergoing scheduled surgery with lung ultrasound before surgery and determination of lung compliance during general anesthesia
223460652|NCT01681238|PROCEDURE|Protocol group 1|The goal of this protocol is to ensure MAP\> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP \<8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
223460653|NCT03360019|DEVICE|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
223460654|NCT03360019|OTHER|Activlink Phone Application|Smartphone tool used for monitoring location
223460655|NCT00200577|DRUG|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
223460656|NCT00736294|DRUG|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
223460657|NCT00736294|DRUG|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
223460658|NCT03253536|OTHER|observational|none (observational study)
223574886|NCT01812356|DEVICE|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
223460659|NCT02496364|OTHER|Observational|
223460660|NCT02132143|RADIATION|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
223460661|NCT02132143|RADIATION|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
223460662|NCT04337021|BEHAVIORAL|Caregiver SOS|SOS care is brief, telephonic care (6 one-hour sessions over 3-4 months) tailored to the CG's needs, preferences, and priorities. SOS care addresses both work and caregiving stress. The five pillars of behavior change in SOS care are: 1) knowledge of work and CG stress; 2) stress management skills and abilities; 3) supports and resources; 4) confidence and motivation to modify stress; and 5) work and CG-focused problem-solving skills. The pillars are addressed through seven modules. In six sessions, the CM will cover each module at least once. SOS care involves an ongoing process of formulating self-management goals and action plans and preparing CGs to succeed in implementing them. Addressing both work and caregiving contexts, CMs will educate CGs about stress. CMs introduce strategies for self-managing stress and collaboratively design experiments to test these strategies. The CG's progress is monitored to identify strategies that effectively achieve self management goals.
223460663|NCT01462110|DEVICE|19416-154-1|0.15% ethyl lauroyl arginate HCl-containing mouthrinse
223460664|NCT01462110|DEVICE|W002194-0221P|5% hydroalcohol mouthrinse
223460665|NCT05207527|OTHER|cardiovascular exercise|Exercise that mainly stimulates the cardiovascular and respiratory systems.
223460666|NCT05207527|OTHER|Muscle strength|Exercise that primarily stimulates the musculoskeletal system.
223460667|NCT05207527|OTHER|Mixed|Exercise that stimulates the musculoskeletal, cardiovascular and respiratory systems.
223460668|NCT00753675|DRUG|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
223460669|NCT00753675|DRUG|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
223460670|NCT00753675|DRUG|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
223460671|NCT00753675|DRUG|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
223460672|NCT02454751|DRUG|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
223460673|NCT03009227|PROCEDURE|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
223460674|NCT03009227|PROCEDURE|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
223460675|NCT00203697|DRUG|minocycline|
223460676|NCT06415019|DRUG|Naproxen (BAYH006689)|BAYH006689 gel will be dispensed directly on the patch
223574887|NCT01812356|DEVICE|Cryomaze procedure using Argon|Cryomaze procedure using Argon
223574888|NCT01134926|DRUG|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
223574889|NCT06120595|DRUG|REBECCA-assisted intervention 1|The intervention will include changes in medication (e.g. change from Letrozol to Tamoxifen, treatment for polyneuropathy, osteoporosis).
223574890|NCT06120595|BEHAVIORAL|REBECCA-assisted intervention 2|The intervention will include dietary advice, to a psychologist/psychiatrist and/or personal training with a physiotherapist at 'Pusterommet' (SUH).
223574891|NCT06120595|OTHER|Standard follow-up|Standard follow-up
223574892|NCT02031081|DRUG|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
223574893|NCT02031081|DRUG|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
223574894|NCT02189499|DEVICE|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
223460677|NCT06415019|DRUG|Placebo Gel|Placebo gel will be dispensed directly on the patch
223460678|NCT06415019|DRUG|A solution of 0.9% Saline|0.9% Saline will be dispensed directly on the patch.
223460679|NCT01789788|DRUG|Placebo|Matching placebo, multiple doses
223460680|NCT01789788|DRUG|RO6811135|multiple ascending doses
223460681|NCT00594230|DRUG|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
223460682|NCT04847583|DRUG|Telacebec|Telacebec 100 mg tablet
223460683|NCT04847583|DRUG|COVID-19 Standard of care|The Standard of Care treatment and administration thereof will be determined by the Investigator
223460684|NCT05501392|BEHAVIORAL|STEPS-PreK|Intervention group received the BN CHSP, a Texas Education Agency (TEA)-approved CSHP. This health program was first piloted in schools located in low-income neighborhoods where enrollment was predominantly Black and Latino children. The Social-Ecological Model guided the BN CSHP design. This theory postulates that health behaviors are molded by individual, interpersonal, and environmental interactions. Thus, BN CSHP encompasses curricula from preschool to eighth grade and is designed to target the four environments that influence children's health behaviors: 1) Healthy Lifestyles Healthy Minds (Health), 2) Moving For Life (Physical Education), 3) Eat to Live (Child Nutrition/School Food Service), and 4) MyFamily/MiFamilia (Home).
223574895|NCT03990103|DRUG|S1|80-120 mg/day, PO, D1-14, every 21 days
223574896|NCT03990103|DRUG|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
224163570|NCT03671434|BEHAVIORAL|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
224163571|NCT00911326|DRUG|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
223460685|NCT02017275|DEVICE|BuMA|This group will contain 1175 subjects.
223460686|NCT02017275|DEVICE|EXCEL|This group will contain 1175 subjects.
223460687|NCT03320174|DRUG|Tafenoquine|Tafenoquine 200mg
223460688|NCT03320174|OTHER|Placebo|Placebo
223460689|NCT06198998|DEVICE|CorVad Percutaneous Ventricular Assist System|The CorVad Percutaneous Ventricular Assist System provides hemodynamics support for intraoperative protection during high-risk percutaneous coronary intervention.
223460690|NCT01091870|DRUG|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
223460691|NCT01091870|DRUG|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
223574897|NCT03990103|DRUG|Bevacizumab|200 mg, IP, D1, every 21 days
223574898|NCT03990103|DRUG|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
223574899|NCT01878110|BEHAVIORAL|COMB|
223460692|NCT01091870|DRUG|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
223460693|NCT02805946|DRUG|posaconazole|iv versus oral
223460694|NCT04478162|OTHER|Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.|At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
223460695|NCT03135509|DRUG|CC-220|CC-220 gelatin capsules
223460696|NCT01441128|DRUG|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
223574900|NCT01329614|BEHAVIORAL|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
223574901|NCT01329614|DRUG|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
223574902|NCT01329614|BEHAVIORAL|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
223574903|NCT01329614|BEHAVIORAL|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
223460697|NCT01441128|DRUG|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
223460698|NCT00333710|BEHAVIORAL|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
223460699|NCT00333710|BEHAVIORAL|Telehealth Intervention|Individual telephone contact with educational and goal setting components
223460700|NCT01096381|OTHER|laboratory biomarker analysis|Blood collection
223460701|NCT01096381|OTHER|questionnaire administration|Survey regarding baseline health and activity level.
223460702|NCT06392464|DEVICE|Clinical decision support system (software)|"Use of a clinical decision support system. Naevia Medical is clinical decision support software (CDSS) that, based on clinical input data (patient history, symptoms, complementary test data, etc.) from adult patients with heart disease, provides healthcare professionals with prioritized, justified, and referenced recommendations and knowledge-related suggestions related to diagnosis, prognosis, and/or treatment (recommended tests, medications, alerts, etc.)"
223574904|NCT01688843|DEVICE|INGEVITY lead|
223574905|NCT00453947|DEVICE|CPAP and Non Invasive Ventilation|
224163572|NCT02579525|OTHER|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
224163573|NCT02579525|OTHER|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
223460703|NCT00866112|OTHER|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
223460704|NCT00866112|OTHER|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
223574906|NCT00248430|BIOLOGICAL|aldesleukin|
223574907|NCT00248430|BIOLOGICAL|therapeutic allogeneic lymphocytes|
223460705|NCT03914274|DEVICE|Technical sock|Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
223574908|NCT00248430|DRUG|melphalan|
223574909|NCT00248430|PROCEDURE|bone marrow ablation with stem cell support|
223460706|NCT06467747|OTHER|Music|Music group: wear earphones to listen to music and receive standardized anesthesia protocol
223574910|NCT00248430|PROCEDURE|peripheral blood stem cell transplantation|
223574911|NCT01253265|DRUG|LY2439821|Administered subcutaneously
223574912|NCT01253265|DRUG|Placebo|Administered subcutaneously
223574913|NCT02483130|DIETARY_SUPPLEMENT|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
223574914|NCT02483130|OTHER|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
223574915|NCT00469963|PROCEDURE|quality-of-life assessment|quality-of-life assessment
223574916|NCT00469963|RADIATION|yttrium Y 90 resin microspheres|radiation therapy
223574917|NCT02267330|PROCEDURE|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
223574918|NCT00541099|BIOLOGICAL|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
223574919|NCT00541099|DRUG|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
223574920|NCT04026269|DRUG|MOAP|the new chemotherapy regimen for r/r cHL
223574921|NCT05326360|DRUG|Ramosetron Hydrochloride|we injected two additional remosetron doses in different way in experimental groups. In group B, patients received additional ramosetron at 12 hour interval, in group M, patients received additional ramosetron in mixed with the patient controlled analgesia regimen.
223574922|NCT02321891|DEVICE|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
223574923|NCT04913701|OTHER|Observation group 1|Subjects will be followed with 3 swabs and serological test
223574924|NCT01788579|BEHAVIORAL|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
223574925|NCT01788579|BEHAVIORAL|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
223574926|NCT06298981|DEVICE|noninvasive and investigational NuraLogix AMC-SDK|The NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.
223574927|NCT00384982|PROCEDURE|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
223460707|NCT06467747|OTHER|Mute|Mute group: wear earphones without music and receive standardized anesthesia protocol
223460708|NCT02529254|BEHAVIORAL|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
223460709|NCT04525040|DIETARY_SUPPLEMENT|ProbioKid®|Probiokid formulation includes three probiotic strains and fructooligosaccharides.
223460710|NCT04525040|OTHER|Pragmatic comparator|Standard of care as usual without a preventive intervention
223460711|NCT02928523|DRUG|Autologous Fecal Microbiota Transplantation|
223574928|NCT03935555|DRUG|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
223574929|NCT02159378|OTHER|Fructosamines|
223574930|NCT05149131|DRUG|ADT (Eligard®*) with or without treatment intensification|"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"
224303021|NCT03670264|BEHAVIORAL|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
223460712|NCT01100632|DIETARY_SUPPLEMENT|Ginseng, vitamins, minerals|2 capsules per day
223460713|NCT01100632|OTHER|Placebo - Gelatin capsule|2 capsules per day
223460714|NCT03156257|BIOLOGICAL|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
223460715|NCT03902470|PROCEDURE|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3-4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3-T4 and T4-T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
223574931|NCT06344910|OTHER|Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies|"An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert."
223460716|NCT03162185|DRUG|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
223460717|NCT03162185|DRUG|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
223460718|NCT02149264|DRUG|Testosterone gel (FE 999303)|
223460719|NCT06071117|DEVICE|Virtual Reality Glasses (VR)|Children allocated to this group will be distracted using VR glasses during dental treatment which is an individual headset that has earphones incorporated. Age-appropriate cartoons and movies will be shown to the children. The VR glasses will be then introduced to the children. The children will be given time to accommodate with the device before starting the procedure. The VR glasses will be applied during the dental examination and treatment.
223460720|NCT06071117|OTHER|White noise|"Wireless kids' headphones will be introduced to the children allocated to this group. They will be given some time to accommodate with the headphones. Then, the white noise will be played and children will be asked to concentrate on the music during the procedure.~White noise stimulus will be set at 70 decibels, within the normal conversation volume range and below what is considered harmful to hearing. The white noise of rain sound, managed with an iPhone application called Muse. The decibel level of white noise will be calibrated using a portable digital sound level meter"
223460721|NCT06071117|BEHAVIORAL|Basic behavior management techniques|Children allocated to this group will be managed by the basic behavior guidance techniques: (Tell-Show-Do). No adjunctive distraction tool will be used.
223574932|NCT02525991|DEVICE|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
223574933|NCT03490604|DEVICE|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
223574934|NCT03490604|OTHER|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
223574935|NCT04167072|PROCEDURE|Stent removal|This is a procedural intervention in which the stent will be removed via endoscopy.
223574936|NCT01584635|PROCEDURE|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
223574937|NCT05956808|DEVICE|Phonak Naida BTE hearing aid|Newest generation of ultra-power Phonak BTE hearing aids
223574938|NCT05956808|DEVICE|Phonak Naida legacy BTE hearing aid|Previous model/generation of the Naida BTE hearing aid
223574939|NCT01710735|PROCEDURE|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
223574940|NCT02532712|DRUG|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
223574941|NCT02532712|DRUG|Placebo|Placebo with same shape and size
223574942|NCT03517995|DRUG|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
223460722|NCT02729480|DEVICE|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
223460723|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
223460724|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
223460725|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
223460726|NCT01236040|BIOLOGICAL|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
223574943|NCT03517995|OTHER|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
223574944|NCT03517995|PROCEDURE|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
223574945|NCT01862835|DRUG|Degarelix|
223460727|NCT01236040|OTHER|Placebo|Intramuscular injection, two doses
223460728|NCT04329845|PROCEDURE|open splenectomy|open splenectomy for treatment of splenic injury
223460729|NCT04329845|PROCEDURE|laparoscopic splenectomy for splenic injury in trauma|laparoscopy as a technique for removal of the spleen in injury
223460730|NCT00697853|BIOLOGICAL|Engerix™-B|3-dose intramuscular injection
223460731|NCT00697853|BIOLOGICAL|HBV-MPL vaccine 208129|2-dose intramuscular injection
223574946|NCT01862835|DRUG|Testosterone|
223574947|NCT01862835|DRUG|Anastrozole|
223574948|NCT01862835|DRUG|Estrogen patch|
223574949|NCT03785587|DRUG|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
223574950|NCT02699151|DRUG|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
223460732|NCT03283930|BEHAVIORAL|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
223460733|NCT03283930|BEHAVIORAL|Placebo Attention Bias Modification Training|
223460734|NCT01243515|DEVICE|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
223460735|NCT01243515|PROCEDURE|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
223460736|NCT00805129|DRUG|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
223460737|NCT01610869|DRUG|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
223460738|NCT00753129|PROCEDURE|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
223460739|NCT00778791|DRUG|metformin HC1 750 mg extended-release tablets|
223460740|NCT02590237|DEVICE|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
223460741|NCT02590237|DEVICE|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
223460742|NCT02797977|DRUG|SRA737, gemcitabine, cisplatin|
223460743|NCT02797977|DRUG|SRA737, gemcitabine|
223574951|NCT02699151|PROCEDURE|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
223460744|NCT03293017|DRUG|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
223460745|NCT03293017|DRUG|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
223460746|NCT03293017|DRUG|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
223460747|NCT02775097|DEVICE|OCT|OCT for all Arms
223460748|NCT00929344|DRUG|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
223574952|NCT02699151|OTHER|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
223574953|NCT02867774|BEHAVIORAL|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
223460749|NCT00929344|DRUG|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
223460750|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
223460751|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
223460752|NCT00929344|DRUG|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
223460753|NCT00929344|BEHAVIORAL|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
223460754|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
223460755|NCT01007370|PROCEDURE|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
223574954|NCT02844283|DRUG|Ad-HGF|
223574955|NCT02844283|OTHER|0.9% NaCl|
223574956|NCT04526470|DRUG|Alpelisib|Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily
223574957|NCT04526470|DRUG|Paclitaxel|Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
223574958|NCT00066469|BIOLOGICAL|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
223574959|NCT00066469|DRUG|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
223574960|NCT00066469|DRUG|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
223460756|NCT02714010|DRUG|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
223460757|NCT02714010|RADIATION|whole brain radiotherapy|30Gy/10F
223460758|NCT04293497|DIAGNOSTIC_TEST|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained using endoscopic ultrasound-guided fine needle aspiration. Three types of slides (direct smear, thinprep, surepath) are prepared for staining.~1. conventional cytology staining method~2. new cytology staining method using antibody of methionyl-tRNA synthetase 1"
223460759|NCT04213092|PROCEDURE|ERCP+LC|Patients in this group underwent a single setting ERCP and Laparoscopic cholecystectomy.
223460760|NCT04213092|PROCEDURE|OC+CBD|Patients in this group underwent a single setting open cholecystectomy and open CBD exploration.
223460761|NCT03452956|OTHER|None-Observation Only|No intervention-this is an observational study
223460762|NCT04258124|OTHER|Control motor intervention|The intervention through motor control will consist in the application of the protocol described by Hidalgo-Peréz et al. The objective of the application of the technique is to produce an increase in the strength of the deep cervical musculature. The exercises will be performed with the subject in different positions: supine, quadrupedic and standing position. The physiotherapist will be placed in standing position in front of the subject. The intervention will be carried out in 3 sessions with 3 exercises of 15 repetitions, and with breaks of 40 seconds between each series and exercise.
223460763|NCT03973541|BEHAVIORAL|Cognitive Behavioral Therapy with Exposure therapy|Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
223460764|NCT03973541|BEHAVIORAL|Relaxation Therapy|Relaxation Therapy
224156876|NCT05516134|BEHAVIORAL|SAFE at Home|The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
224156877|NCT03805971|DEVICE|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
223460765|NCT03821077|BIOLOGICAL|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
223460766|NCT03967041|DIAGNOSTIC_TEST|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
223460767|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-anodal group|2mA/20mins/session; 2sessions/day,5days
223460768|NCT06538259|DEVICE|Transcranial direct current stimulation (tDCS)-sham group|0mA/20mins/session; 2sessions/day,5days
223460769|NCT02499120|DRUG|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
223460770|NCT02499120|DRUG|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
223460771|NCT02499120|DRUG|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
223460772|NCT06442722|PROCEDURE|DDH with capsulorrhaphy|group will undergo capsulorrhaphy, a surgical procedure to tighten the hip capsule ,
223460773|NCT06442722|PROCEDURE|DDH without capsulorrhaphy|group will not undergo capsulorrhaphy, a surgical procedure without tightness the hip capsule
223574961|NCT00066469|DRUG|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
223574962|NCT03287570|DEVICE|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
224156878|NCT03354572|DRUG|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
224156879|NCT03354572|DRUG|Placebos|saline 0.9% prior to surgery
223460774|NCT06111898|OTHER|No Intervention|No intervention
223460775|NCT02477358|PROCEDURE|Left Tooth Platelet Rich Fibrin; Right Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy will be applied to the left tooth socket only. The right tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
223460776|NCT02477358|PROCEDURE|Right Tooth Platelet Rich Fibrin; Left Tooth Implant Alone|All study participants will have two teeth extracted and 2 mm of root removed. Half of the subjects will have platelet rich fibrin endodontic revascularization therapy to the right tooth socket only. The left tooth is implanted alone. Each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
223460777|NCT01689441|DRUG|Calcitriol|
223460778|NCT01689441|DRUG|Placebo|
223460779|NCT01833585|BIOLOGICAL|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
223460780|NCT03134729|DRUG|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
223460781|NCT00970645|PROCEDURE|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
223460782|NCT00970645|PROCEDURE|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
223460783|NCT00065702|DRUG|Active liquid remedy|
223460784|NCT03653845|PROCEDURE|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
223460785|NCT03653845|DRUG|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
223460786|NCT03571724|OTHER|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
223460787|NCT03571724|OTHER|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
223460788|NCT03571724|OTHER|Subject's UB non-mentholated filtered cigarettes|King size non-menthol cigarettes
223460789|NCT03571724|OTHER|Subject's UB mentholated filtered cigarettes|King size menthol cigarettes
223460790|NCT01839916|BIOLOGICAL|therapeutic allogeneic lymphocytes|Given IV
223460791|NCT01839916|OTHER|laboratory biomarker analysis|Correlative studies
223574963|NCT03287570|PROCEDURE|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
223574964|NCT03287570|OTHER|Usual care|The patients in this group maintain the usual treatment and self-care.
223574965|NCT03271047|DRUG|binimetinib|Orally, twice daily.
223574966|NCT03271047|DRUG|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
223574967|NCT03271047|DRUG|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
223574968|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
223574969|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
223743346|NCT06359691|BEHAVIORAL|Patient-focused strategies|"Patient-focused strategies to increase HTN management practices:~1. Hypertension registry: notify patients of their status, target education and resources to patients~2. Home BP monitoring: provide BP monitors, encourage reporting of home BP readings~3. Enhance standardization of home and office BP readings: patients trained by care staff, posters in clinics on how to measure BP correctly~4. Nurse-directed BP medication titration with CHW/Health Educator reinforcement: self-directed referrals to nurse-directed clinics and CHW/health educators~5. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: tailored educational materials offered to patients in clinic, via text and the patient portal.~6. Social needs screening and linkage to community resources: awareness of and self-referrals to community resources~7. Behavioral science intervention messaging: posters in clinic waiting rooms, scripts for RN/PCP, texts to patients"
224156880|NCT05392049|OTHER|Bowen's therapy|Bowens technique will be apply on patients of TMJ for 2 repetitions in 1 set, 4 sets in each session for 4 weeks.
224156881|NCT05392049|OTHER|Post isometric relaxation|post isometric relaxation technique and jaw exercises (strengthen the weakened muscles, stretch the shortened muscles) with dosage 5 times/session, 5 sec rest and 2times/week for 4 weeks will apply on patients.
224156882|NCT06086236|DEVICE|Transcutaneous Auricular Vagus Nerve Stimulation|Through a special Ear set, bilateral Transcutaneous Auricular Vagus Nerve Stimulation was applied to all participants for 20 minutes.
224156883|NCT03622541|DRUG|Sorafenib 200mg|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
223460792|NCT03471832|DEVICE|stenfilcon A lens|contact lens
223460793|NCT03471832|DEVICE|narafilcon A lens|contact lens
223460794|NCT02371876|DEVICE|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
223460795|NCT02284386|DRUG|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
223460796|NCT02284386|DRUG|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
223460797|NCT02741232|DRUG|Lidocaine 1% with epinephrine 1/400000|
223460798|NCT02741232|OTHER|sham block|
223460799|NCT00843011|DRUG|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
223460800|NCT03694223|OTHER|Health education delivery methods|
223460801|NCT00999622|OTHER|laboratory biomarker analysis|
223460802|NCT00999622|OTHER|questionnaire administration|
223460803|NCT04235504|OTHER|MDI|Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
223460804|NCT04235504|DEVICE|AHCL|"Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment."
223574970|NCT02817347|DRUG|piperacillin 2% + tazobactam 0.25%|
223574971|NCT02817347|DRUG|piperacillin 4% + tazobactam 0.5%|
223574972|NCT02817347|DRUG|piperacillin 8% + tazobactam 1.0%|
223574973|NCT03105648|OTHER|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
223574974|NCT01452295|DRUG|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
223574975|NCT04014621|DEVICE|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
224156884|NCT04128605|PROCEDURE|Suprascapular nerve block (SSNB)|"SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve."
224156885|NCT04128605|PROCEDURE|Intraarticular shoulder steroid injection (IAS)|"IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space"
223460805|NCT05454020|DRUG|XG004|XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
223460806|NCT05454020|DRUG|Placebo|Placebo gel will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
223460807|NCT05627050|DEVICE|An Online Augmented Reality (AR) Training Platform|The hardware system is based on camera depth sensor and combined with 3D human tracking technology and intelligent technology, to monitor, correct and record the user's whole body movements in real-time, and the users can follow the training program.
223460808|NCT00870467|BIOLOGICAL|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
223460809|NCT00870467|DRUG|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
223460810|NCT00870467|BIOLOGICAL|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
223460811|NCT00870467|BIOLOGICAL|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
223460812|NCT02340143|OTHER|Control|Marketed partially hydrolyzed cow's milk protein infant formula
223460813|NCT02340143|OTHER|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
223460814|NCT00003925|DRUG|gemcitabine hydrochloride|
223460815|NCT00003925|DRUG|leucovorin calcium|
223460816|NCT00003925|DRUG|tegafur-uracil|
223460817|NCT00167518|DRUG|Triamcinolone acetate|
223460818|NCT03155555|OTHER|Measurement of aortic and carotid Doppler peak systolic velocity variation|Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
223460819|NCT02106351|BIOLOGICAL|Botulinum toxin type A|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
223460820|NCT00992641|OTHER|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
223460821|NCT00992641|OTHER|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
223460822|NCT00101868|DEVICE|Discharge communication software|Computerized physician order entry software used by discharging physician
223574976|NCT00711802|DRUG|Daptomycin|
223574977|NCT00711802|DRUG|Standard of Care (SOC)|
223574978|NCT02425800|OTHER|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
223460823|NCT00101868|OTHER|Usual care discharge process|Handwritten
223460824|NCT00524706|DRUG|S-1, oral Leucovorin, Oxaliplatin|
223460825|NCT03924388|DEVICE|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
223460826|NCT03924388|DEVICE|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and \~ 70° upright adjusted by the tilt-up table.
223460827|NCT02188524|OTHER|Exercise|Tai Chi and Compensatory Stepping
223460828|NCT02214030|DEVICE|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
223460829|NCT00094523|DRUG|Fosamprenavir|Fosamprenavir
223460830|NCT05405764|DIETARY_SUPPLEMENT|Porcine protein supplement|Porcine protein supplementation
223460831|NCT05405764|DIETARY_SUPPLEMENT|Control product maltodextrin supplement|Maltodextrin supplementation
223460832|NCT00000256|DRUG|20% N2O|
223460833|NCT00000256|DRUG|40% N2O|
223460834|NCT00000256|DRUG|60% N2O|
223460835|NCT00000256|DRUG|80% N2O|
223460836|NCT00287209|DRUG|Amiodarone|
223460837|NCT02005237|BEHAVIORAL|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
223460838|NCT06376617|DEVICE|fibroptic bronchoscopy|take bal through fibrooptic bronchoscopy and send for stain and culcure
223574979|NCT02425800|OTHER|Laboratory Biomarker Analysis|Correlative studies
223574980|NCT00334906|DRUG|memantine HCl|
223574981|NCT02753686|DRUG|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
223574982|NCT02753686|DRUG|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
223574983|NCT06200974|RADIATION|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
223574984|NCT02351830|OTHER|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
223574985|NCT02351830|PROCEDURE|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
223574986|NCT00716378|BEHAVIORAL|Teen Passenger Presence|
223574987|NCT02750865|BEHAVIORAL|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
223574988|NCT05593276|BEHAVIORAL|Empower@Home|Participants will be provided with access to a 9-session online program and will receive supportive remote assistance throughout regarding technical and programmatic issues.
223574989|NCT00051467|GENETIC|TNFerade|
223574990|NCT01913665|OTHER|B.lactis|
223574991|NCT01913665|OTHER|Inulin|
223574992|NCT01913665|OTHER|B.Lactis +Inulin|
223574993|NCT01913665|OTHER|Placebo|
223574994|NCT05497258|DEVICE|Artificial intelligence assistant system|The AI-assisted diagnosis system can provide the direction of disease diagnosis in real time and assist the doctor to give the final diagnosis
223574995|NCT00002652|DRUG|suramin|
223574996|NCT05493189|OTHER|Additional autonomous training sessions|The duration of the autonomous training will be 30 minutes, using a feedback CPR training simulator (eg Laerdal Little Anne QCPR).
223574997|NCT02410824|DEVICE|stenfilcon A toric lens|toric contact lens
223574998|NCT02410824|DEVICE|etafilcon A toric lens|toric contact lens
224156886|NCT05543824|DRUG|Levobupivacaine|Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
224156887|NCT00254163|DRUG|Fludarabine|
224156888|NCT00254163|DRUG|Cyclophosphamide|
224156889|NCT00254163|DRUG|Rituximab|
224156890|NCT00254163|DRUG|Pentostatin|
224156891|NCT02557334|DIETARY_SUPPLEMENT|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
224156892|NCT02557334|DIETARY_SUPPLEMENT|High Dose Strawberry Powder|40 g freeze dried strawberry powder
223574999|NCT00619346|DRUG|Placebo|Placebo tablets, BID X 14 days
223575000|NCT00619346|DRUG|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
223575001|NCT01030185|DEVICE|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
223575002|NCT05622266|PROCEDURE|Pulpotomy|The patients who are randomly assigned to the experimental group receive pulpotomy.
223575003|NCT05622266|PROCEDURE|Root Canal Therapy|The patients who are randomly assigned to the Active Comparator group receive root canal therapy.
223575004|NCT00084019|DRUG|Atazanavir|
223575005|NCT00084019|DRUG|Ritonavir|
223575006|NCT05008757|OTHER|no drug|no intervention
223575007|NCT02436408|DRUG|Vismodegib|
223575008|NCT00392808|BIOLOGICAL|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
223575009|NCT04424030|DIAGNOSTIC_TEST|Echocardiography|Standard echocardiography exam performed as part of clinical management.
223575010|NCT04424030|DIAGNOSTIC_TEST|Magnetic resonance imaging (MRI)|Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.
223575011|NCT04424030|DIAGNOSTIC_TEST|Computed tomography (CT)|ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
223575012|NCT02649855|BIOLOGICAL|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
223575013|NCT02649855|BIOLOGICAL|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules (cluster of differentiation 80 (B7.1), intercellular adhesion molecule 1 (ICAM-1), and lymphocyte function-associated antigen 3 (LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
223575014|NCT02649855|DRUG|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
223575015|NCT03177811|DRUG|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
223575016|NCT03177811|DRUG|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
223575017|NCT01333995|BEHAVIORAL|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
224156893|NCT02557334|DIETARY_SUPPLEMENT|Placebo Powder|40 g color and taste matched placebo powder
224156894|NCT03507881|DEVICE|fusion|Internal fixation
224156895|NCT03012594|DRUG|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
224156896|NCT00519168|PROCEDURE|Urine sample|Standard of care
224156897|NCT00519168|DEVICE|Electrode sleep recorder|Standard of care
224156898|NCT00519168|PROCEDURE|phlebotomy|Standard of care
224156899|NCT01952288|DRUG|simvastatin|simvastatin 40 mg/day for 12 months
224156900|NCT01952288|DRUG|Placebo Oral Tablet|placebo comparator
224156901|NCT05068388|DRUG|Z-Endoxifen|Z-Endoxifen
223460839|NCT03876483|BEHAVIORAL|Virtual peer support group|Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
223460840|NCT02986347|PROCEDURE|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
223460841|NCT02986347|PROCEDURE|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
223460842|NCT01394341|DRUG|Liraglutide|Daily sc. injection, individual dosage
223575018|NCT01476280|DRUG|palonosetron|0.075mg immediately before induction of anesthesia
223460843|NCT02708797|OTHER|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
223460844|NCT02708797|OTHER|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
223460845|NCT06477705|OTHER|FAM|Participants will perform a recreational Football Training session for 60 minutes. The training will include the warm-up, soccer technical exercises and a small-side game
223460846|NCT00069823|DRUG|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
223460847|NCT00069823|DRUG|Placebo proton pump inhibitor|Placebo proton pump inhibitor
223460848|NCT01941199|DRUG|DA-1229|
223460849|NCT01941199|DRUG|metformin|
223460850|NCT01941199|DRUG|DA-1229 + metformin|
223460851|NCT05495529|PROCEDURE|Thermal Ablation|Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
223460852|NCT04261647|OTHER|kinesio-taping techniques.|
223460853|NCT04261647|OTHER|Pelvic floor exercise|
223460854|NCT04261647|OTHER|traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.|
223460855|NCT01034228|OTHER|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
223460856|NCT01034228|OTHER|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
224156902|NCT05068388|DRUG|Placebo|Placebo
224156903|NCT03962634|DRUG|Kovanaze Nasal Spray|Intra-nasal local anesthetic
224156904|NCT03962634|DRUG|Articaine Injection|Local anesthetic
223460857|NCT00683761|DRUG|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
223460858|NCT04296578|DRUG|Abiraterone Acetate|Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
223460859|NCT04296578|DRUG|Sodium Selenite|11 mg tablets
223460860|NCT04296578|DRUG|Prednisone|SOC prednisone 5 mg PO twice daily
223460861|NCT04506723|PROCEDURE|Percutaneous Nephrolithotomy|PCNL will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
223460862|NCT04506723|PROCEDURE|Partial nephrectomy|Partial nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
223460863|NCT04506723|PROCEDURE|Radical nephrectomy|Nephrectomy will be carried out in accordance with the standards and capabilities of the medical center. After the procedure pathomorphological data of the renal parenchyma will be assessed
223460864|NCT01544647|OTHER|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
223460865|NCT01544647|OTHER|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
223460866|NCT00520039|PROCEDURE|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
223575019|NCT01476280|DRUG|Ramosetron|0.3mg immediately before induction of anesthesia
223575020|NCT01592019|DRUG|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
223575021|NCT01592019|DEVICE|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
223575022|NCT01592019|DRUG|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
223575023|NCT01592019|DEVICE|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
223575024|NCT03509493|DIAGNOSTIC_TEST|FibriCheck|Digital health application
224156905|NCT06005038|BEHAVIORAL|pSOPT|computerized cognitive training practicing speed of processing, the difficulty will be adjusted based on real-time monitored RMSSD (parasympathetic nervous system signals)
224156906|NCT06005038|BEHAVIORAL|MLA|computerized mental leisure activities on cross-word puzzle, Sudoku, and solitaire; ECG will also be applied.
224156907|NCT02264015|DRUG|Cilobradine, low, film-coated tablets|
224156908|NCT02264015|DRUG|Cilobradine, high, film-coated tablets|
224156909|NCT02264015|DRUG|Placebo, film-coated tablets|
224156910|NCT02264015|DRUG|Moxifloxacin, film-coated tablets|
223460867|NCT05679245|DIAGNOSTIC_TEST|Assessment for exposure to psychological trauma and related symptoms|To be assessed for exposure to traumatic life events, post-traumatic stress disorder, trauma-related symptoms, dissociative symptoms, affective symptoms, and psychosocial functioning.
223460868|NCT02329327|BIOLOGICAL|Andexanet|There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
223460869|NCT03905941|DRUG|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
223460870|NCT03905941|DRUG|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
223460871|NCT03562858|PROCEDURE|Immediate dentin sealing protocol|Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation
223460872|NCT03562858|PROCEDURE|Delayed dentin sealing protocol|Sealing the dentin just prior to cementation
223460873|NCT03560869|OTHER|Normal hydration|see description in 'arms'
223460874|NCT03560869|OTHER|Dehydration|see description in 'arms'
223460875|NCT01137097|PROCEDURE|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
223460876|NCT01184612|BEHAVIORAL|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
223460877|NCT01801111|DRUG|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
223575025|NCT04347980|DRUG|Dexamethasone and Hydroxychloroquine|"Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before."
223575026|NCT04347980|DRUG|Hydroxychloroquine|Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
223575027|NCT00136825|DRUG|N-Acetylcysteine|
224303022|NCT03670264|BEHAVIORAL|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
224303023|NCT03670264|BEHAVIORAL|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
223460878|NCT01801111|DRUG|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
223460879|NCT05533489|OTHER|No intervention|No intervention This study is a retrospective descriptive study.
223460880|NCT00244153|DRUG|intraarticular morphine|
223460881|NCT00244153|DRUG|intraarticular dexamethasone|
223575028|NCT00136825|DRUG|Placebo|
223575029|NCT00319475|PROCEDURE|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
223575030|NCT02782325|BIOLOGICAL|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
223575031|NCT02782325|BIOLOGICAL|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
223460882|NCT04072250|PROCEDURE|hepatectomy|Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
223460883|NCT04870957|BEHAVIORAL|PainGuide|A 4-week, online, self-management program for pain known as PainGuide (online or smart phone). Participants will use this during the run-in period as well as after the run-in period.
223460884|NCT04870957|BEHAVIORAL|MBSR|"In this group (mindfulness-based stress reduction) participants will take part in 9 group sessions.~The groups sessions will be divided into 8 weekly 2-hour groups sessions and one 6-hour retreat. During the sessions participants will practice mindfulness exercises directed by the a MBSR therapist. Additionally, participants will also be asked to practice daily formal mindfulness at home using audio recordings of 30-45 minute guided meditation exercises. These audio recordings can be accessed online. The sessions may take place in-person or virtually."
223575032|NCT01115335|PROCEDURE|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
223575033|NCT05675761|DRUG|Azorubine|Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)
223460885|NCT04870957|BEHAVIORAL|PT and exercise|"Participants will take part in 10 physical therapy visits over the course of 8 weeks. Participants will meet with the physical therapist twice a week for a 1-hour session for weeks 1 and 2 and then weekly for the remaining 6 weeks. The physical therapist will tailor a program to the participant's needs according to recommended PT practice guidelines that will include in-person treatment, home exercise prescription, and encouragement of progressive, low-intensity, submaximal fitness and endurance activities, such as walking.~Participants will be given a home program of exercises to be done daily and asked to engage in daily walking with a set goal based on the individual's capacity and current fitness level. Walking was selected as the aerobic exercise of focus for this treatment because it is recommended for patients with all levels of pain severity, is highly feasible to complete, and has shown effects on outcomes such as pain and disability."
223460886|NCT04870957|DEVICE|Self -administered acupressure|"A device called the AcuWand will be used to administer the self-acupressure intervention for approximately 30 minutes daily for 8 weeks. Participants will use a mobile application (app) called MeTime that will have daily instructions on how to use the AcuWand. Research staff will show participants how to use the AcuWand and MeTime app. In addition, participants will keep a daily log to track at-home acupressure sessions."
223460887|NCT04870957|DRUG|Duloxetine|For days 1-7, patients will take 30mg of duloxetine once a day, in the morning. Starting day 8, participants tolerating the medication will be escalated to 60mg once a day. They will also have the option of staying at 30mg, once a day or stopping the medication. At the end of the 8-week intervention period, participants will have the option to continue the medication commercially (non-study medication) under the care of their physician or taper off the medication. During the entire 8-week intervention, patients will be asked to keep a daily log of medication dosage, any missed doses, and any side-effects they may have experienced.
223460888|NCT04870957|DEVICE|Pro-Diary monitor|"Participants will wear during 5 separate 7-day home monitoring periods to assess physical activity (objectively measured via accelerometry), and ecological momentary assessment (EMA) of mental and physical symptoms. EMA will be collected during Weeks 1, 6, 15, 24 and 36."
223460889|NCT01210482|DRUG|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
223575034|NCT00407004|DEVICE|MARS (Molecular Adsorbents Recirculating System)|
223575035|NCT00407004|DEVICE|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
223575036|NCT05434013|BEHAVIORAL|Cigarillo warnings-Surgeon General Text-Only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Surgeon General Text-Only format.
223575037|NCT05434013|BEHAVIORAL|Cigarillo warnings-FDA proposed text-only|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the FDA Proposed Text-Only format.
223575038|NCT05434013|BEHAVIORAL|Cigarillo warnings-Pictorial|Participants will complete 6 mock shopping trips in the Experimental Tobacco Marketplace, and be asked to spend their weekly tobacco budget. Cigarillos in the Marketplace will have one of three cigarillo warnings in the Pictorial format.
223575039|NCT02818036|DRUG|Naltrexone|
223575040|NCT02818036|DRUG|Placebo|
224156911|NCT04965285|BEHAVIORAL|quality assesment|"For each time-out procedure observed, the investigators will record compliance for each element of the time-out. Elements that are clearly verbalized by the member of the operating room team performing the time-out were considered compliant.~As each step of the time-out is verbalized by a team member, the operating room team members are expected to respond. The observations will be conducted by trained study staff using a standardized Checklist/ Proforma to assess surgical team compliance with the time-out protocol and to record general observations of the operating room environment. Any non-routine events that occurred during the time-out process will be recorded.~In each phase, the Checklist coordinator must be permitted to confirm that the team has completed its tasks before it proceeds onward."
224156912|NCT02542670|GENETIC|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
223575041|NCT02953236|PROCEDURE|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
224156913|NCT02478918|OTHER|Phone call|Automated phone call reminder
224156914|NCT04262908|OTHER|Telephone call|Patients who did not return to work after the SL prescribed initially and had an extension of the SL will be called at 4 months postoperatively to collect infomation
224156915|NCT03193450|BEHAVIORAL|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
224156916|NCT03193450|BEHAVIORAL|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
224156917|NCT02792660|DEVICE|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
224156918|NCT00517413|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
224156919|NCT00632996|OTHER|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
224156920|NCT01230918|RADIATION|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
224156921|NCT01917552|DRUG|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
223460890|NCT05492513|BEHAVIORAL|Grade 1 CI Therapy +Sensory Components|All participants will receive Grade 1 CI Therapy + Sensory Components over a two-week period of time. The treatment intervention will include all CI Therapy treatment strategies including: 1) supervised motor training in the form of shaping with repeated trials and task practice for 1.5 hours per day for 5 weekdays for 2 weeks 2) a behavioral Transfer Package (TP) will be employed to aid carry-over of skills gained by the participant in the laboratory to the life situation 3) each participant will wear a mitt on the less-affected hand for most of their waking hours to encourage use of the more-affected hand 4) participants will be given home assignments to be carried out for at least 30 minutes each day. Sensory component strategies will be added to stimulate sensory input through the more-affected arm and hand as well as to train sensory discrimination skills.
223460891|NCT06822387|BEHAVIORAL|Mindfulness-Based Intervention|Learning to BREATHE (L2B) is an evidence-based mindfulness curriculum for adolescents. L2B in this program consists of 6 sessions of approximately 1 hour per session. In between sessions, participants are asked to practice brief mindfulness skills individually.
223460892|NCT06822387|BEHAVIORAL|Parent Education|The parent education curriculum includes 3 modules: 1) family support/parenting, 2) nutrition education and 3) physical activity education. Parents set weekly goals to implement what they learned in each session at home with their family.
223460893|NCT06822387|BEHAVIORAL|Physical Activity|Focuses on using cardio and resistance training to improve cardiorespiratory health in youth.
223575042|NCT02953236|PROCEDURE|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
223460894|NCT06822387|BEHAVIORAL|Brief Mindfulness Intervention for Parents|Parent-based mindfulness education is based on the Learning to BREATHE curriculum.
223460895|NCT06822387|BEHAVIORAL|Preschool Curriculum|Preschool age children learn about and try new foods.
223460896|NCT06822387|BEHAVIORAL|Nutrition and Cooking Education|Nutrition education and hands-on cooking lessons for the whole family.
223460897|NCT06180148|DEVICE|Mechanical insufflator-exsufflator|"In the active comparator group a mechanical insufflator-exsufflator will be used in the postoperative period 6 and 24 hours after extubation as follows (coughing maneuver): application of inspiratory pressure of 40-70 cm of water (the minimum value to achieve a peak cough flow of 300 l/min) for 2 seconds with the subsequent creation of an expiratory vacuum of -40 cm of water within 2 seconds. During inhalation and exhalation, the patient will apply oscillations with a frequency of 10 Hz and an amplitude of 10 cm of water. A series of 10 such maneuvers will be used, with a pause of a few seconds to ensure patient comfort. The coughing maneuver will be performed through an oronasal mask tightly pressed to the face."
223460898|NCT04140214|DRUG|Hypertonic saline|Nebulized hypertonic saline solution (6%)
223460899|NCT04140214|DRUG|Carbocysteine 750 MG|Carbocisteine tablet
223460900|NCT01223937|DRUG|Desmopressin|
223460901|NCT01223937|DRUG|Placebo|
223460902|NCT00223665|DRUG|Flutamide|Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
223460903|NCT00223665|DRUG|Leuprolide Acetate|Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
223460904|NCT03871985|PROCEDURE|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
223460905|NCT03871985|PROCEDURE|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
223460906|NCT04482088|BEHAVIORAL|Occupational Therapy in an Equine Environment|10 weeks of occupational therapy in an equine environment aimed at improving individual goals related to self-regulation, social communication, and play
223460907|NCT04482088|BEHAVIORAL|Occupational Therapy in a Clinic (OTC)|10 weeks of occupational therapy in a clinic aimed at improving individual goals related to self-regulation, social communication, and play
223575043|NCT01038713|DEVICE|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
223575044|NCT03058666|DRUG|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
223575045|NCT03058666|DEVICE|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
223575046|NCT03033563|PROCEDURE|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
223575047|NCT03638869|DRUG|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
224156922|NCT01122888|DRUG|Cilengitide|Given IV
223575048|NCT03638869|DRUG|Placebo|
224156923|NCT01122888|OTHER|Clinical Observation|Patients undergo a 2-week rest period
224156924|NCT01122888|OTHER|Laboratory Biomarker Analysis|Correlative studies
224156925|NCT00442949|PROCEDURE|Catheterization immediate PCI|Catheterization immediate PCI
224156926|NCT00442949|PROCEDURE|delayed PCI|delayed PCI
224156927|NCT01519349|BIOLOGICAL|rAAV1.CMV.huFollistatin344|"* First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~* Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~* Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
223460908|NCT03284853|DRUG|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
223460909|NCT03284853|DRUG|GANFORT®|Topical sterile ophthalmic solution
223460910|NCT05176717|DRUG|QR-421a|RNA antisense oligonucleotide for intravitreal injection
223460911|NCT05176717|OTHER|Sham-procedure|Sham-procedure (no experimental drug administered)
223460912|NCT05263518|PROCEDURE|Cataract surgery with AcrySof IQ IOL implantation.|Patients in this study will receive cataract surgery with AcrySof IQ IOL implantation.
223460913|NCT05263518|PROCEDURE|Cataract surgery with TECNIS toric IOL implantation.|Patients in this study will receive cataract surgery with TECNIS toric IOL implantation.
223460914|NCT03208608|DIAGNOSTIC_TEST|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
223460915|NCT00534417|DRUG|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight \< 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
223460916|NCT00534417|DRUG|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
223460917|NCT04753333|BEHAVIORAL|Electromyography biofeedback (EMG-BF)|Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training with patellar taping
223460918|NCT04753333|BEHAVIORAL|Sham electromyography biofeedback (EMG-BF)|Participants in this group will receive Sham electromyography biofeedback (EMG-BF) guided strength training without patellar taping
223460919|NCT04239352|DIAGNOSTIC_TEST|Pentraxin 3 ; new biomarker|"Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component."
223460920|NCT04239352|DIAGNOSTIC_TEST|Lipoprotein-associated phospholipase A2 ; new biomarker|Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
223460921|NCT03905304|BIOLOGICAL|Medytoxin|Intramuscular injection up to 300U.
223460922|NCT03905304|BIOLOGICAL|Botox|Intramuscular injection up to 300U.
223460923|NCT02308228|BEHAVIORAL|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
223460924|NCT02308228|DRUG|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
223460925|NCT04360369|DEVICE|IOP with Goldmann Applanation Tonometer|Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (\>23 mmHg).
223460926|NCT04360369|DEVICE|IOP with comparator ORA G3 and ic100 tonometers|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.
223460927|NCT04360369|DEVICE|IOP with Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer
223460928|NCT02429570|DRUG|Meclofenamate|
223460929|NCT01043133|BEHAVIORAL|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
223460930|NCT06607796|DRUG|Toluenesulfonamide (PTS) Intratumoral Injection|intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
223460931|NCT06608017|DRUG|Chinese Herbal Medicine granules|Treatment group
223460932|NCT06608017|OTHER|Placebo|Placebo-controlled group
223460933|NCT05732558|PROCEDURE|8 Patients who were prescribed a CT-guided percutaneous bone biopsy, performed with the aid of endosight navigation system|The study is based on a comparison of the number of CT scans required for needle placement in bone biopsies (trunk area) performed with augmented reality navigation system (endosight) and without.
223460934|NCT06611566|BEHAVIORAL|VR-guided aerobic exercise|The intervention was 5 minutes of VR-guided aerobic exercise
223460935|NCT06611566|BEHAVIORAL|VR-guided mindfulness exercise|The intervention was 5 minutes of VR-guided mindfulness exercise
223460936|NCT06611566|BEHAVIORAL|TV-guided aerobic exercises|The intervention was 5 minutes of TV-guided aerobic exercises
223460937|NCT06611566|BEHAVIORAL|TV-guided mindfulness exercises|The intervention was 5 minutes of VR-guided mindfulness exercises
223460938|NCT06480786|DEVICE|Spinal cord stimulation|active spinal cord stimulation
223460939|NCT06480786|DEVICE|Sham stimulation|Sham stimulation
223460940|NCT04460248|DRUG|Zanubrutinib, Lenalidomide and Rituximab (ZR2)|"Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~1. Zanubrutinib, 160 mg bid, po, day 1-21;~2. Lenalidomide, 25 mg qd, po, day 2-11;~3. Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years."
223460941|NCT00298883|DRUG|Myfortic|Myfortic 360mg PO BID for six weeks
223460942|NCT06730152|BEHAVIORAL|WeChat Intervention Based on the IMB Model|The intervention group would undergo a six-week intervention program. Researchers promoted a public WeChat account to the intervention group, and participants received the intervention by following the account. They automatically received pushed articles or videos, providing them with relevant knowledge about overcoming smartphone addiction. Furthermore, they would be motivated to quit their addiction through real-life cases of smartphone addiction etc., in addition to some practical skills of overcoming.
223575049|NCT03777917|DEVICE|Belotero Balance®|Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
223575050|NCT01154283|DEVICE|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
223575051|NCT02196415|DEVICE|Biplanar Radiography|standard biplanar radiography of the foot
223575052|NCT00031018|DRUG|Aricept|
223575053|NCT00031018|DRUG|IFN-alpha2A|
223575054|NCT05302856|DIAGNOSTIC_TEST|Blood test (CMV IGG, Anti sperm antibody, Testosterone levels)|Peripheric blood extraction
223575055|NCT00042432|DRUG|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
223575056|NCT03000491|OTHER|No intervention|Variations in clinical practice as assessed by data relating to asthma extracted from patient electronic health records.
224156928|NCT02463318|DRUG|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
223460943|NCT03999749|DRUG|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
223460944|NCT03999749|DRUG|Nivolumab|Nivolumab (3 mg/kg) will be administered IV on Days 1 and 22 of each 42-day induction treatment cycle. Nivolumab will continue to be administered IV at 240 mg flat dose every 2 weeks; i.e., at Days 1, 15, 29, 43, 57, and 71 of the 84-day treatment cycle for the first maintenance cycle until week 24, then nivolumab will be administered at 480 mg flat dose every 4 weeks to a maximum of 2 years
223460945|NCT03999749|DRUG|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle. After 12 weeks of therapy, starting at Week 13, subjects enter the maintenance phase. Tocilizumab will be administered intravenously every 6 weeks during the first 84 day maintenance treatment cycle only at 4 mg/kg
223460946|NCT03852823|DRUG|SG001|Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
223460947|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
223460948|NCT00255164|DRUG|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
223460949|NCT00255164|DRUG|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
223460950|NCT02017626|BIOLOGICAL|mCyp c 1|2 patient groups with different doses of allergen.
223460951|NCT03369873|OTHER|Guidance Manual|The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
223460952|NCT03378245|BEHAVIORAL|Behavioral modification and education on pharmacologic treatments.|Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
223575057|NCT02223416|DRUG|RGB-10|
223575058|NCT02223416|DRUG|Teriparatide|
223575059|NCT00657150|DRUG|Enoxaparin|40 mg once daily
224156929|NCT02463318|OTHER|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
223460953|NCT06671977|DRUG|DMT-Medium Dose|14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.
223460954|NCT06671977|DRUG|DMT-Low Dose|10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes
223460955|NCT06671977|DRUG|THC-Medium Dose|0.5 mg over 5 minutes and then 2 mg over and 55 minutes
223460956|NCT06671977|DRUG|THC-Low Dose|0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes
223460957|NCT05219968|DRUG|LYR-210|LYR-210 drug matrix (mometasone furoate)
223460958|NCT05219968|DRUG|Sham procedure control|Sham procedure control
223460959|NCT05219968|OTHER|Background Therapy|Daily Saline Irrigation
223460960|NCT04157205|DIAGNOSTIC_TEST|Non-invasive ECG imaging - CardioInsight test|"1. Consent session~2. Fitting of ECGi vest and CT scan of the chest~3. Supervised exercise test and Valsalva maneuvre~4. Programmed stimulation via ICD (selected participants)~5. Blood tests - genetics"
223460961|NCT06445582|DIAGNOSTIC_TEST|[18F]SDM-8|synaptic vesicle glycoprotein 2 A（SV2A）PET tracer \[18F\]SDM-8
223460962|NCT03888326|DEVICE|1x1 anodal tDCS|20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
223460963|NCT03888326|DEVICE|Sham tDCS|Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
223575060|NCT00657150|DRUG|Dabigatran etexilate|220 mg once daily
223575061|NCT03807297|DRUG|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
223575062|NCT03807297|DRUG|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
223575063|NCT03807297|OTHER|sevoflurane|inhalational anaesthetic agent
223575064|NCT03807297|OTHER|nitrous oxide|inhalational anaesthetic agent
223575065|NCT02966795|DRUG|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
223575066|NCT00151034|DRUG|Trastuzumab|
223575067|NCT00151034|DRUG|Paclitaxel|
223575068|NCT00151034|DRUG|Carboplatin|
223575069|NCT00151034|DRUG|Gemcitabine|
223575070|NCT03622437|BEHAVIORAL|Patient-led follow-up|"1. Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~2. The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~\- access to stoma care by specialist nurses"
224156930|NCT01152411|OTHER|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
224156931|NCT02866461|OTHER|No treatment|Observation
224156932|NCT05194605|OTHER|Prediction model|We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
224156933|NCT06180733|DRUG|Pembrolizumab Injection [Keytruda]|Pembrolizumab (Keytruda), 200mg IV Q3W for a total of 9 administrations per patient, prior to standard-of-care surgery. Patients will be monitored for response and possible progression using MRI and pipelle biopsies.
224156934|NCT02939313|DEVICE|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
224303024|NCT03670264|BEHAVIORAL|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
223460964|NCT03888326|BEHAVIORAL|Robotic Rehabilitation|10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
223460965|NCT03782805|DIETARY_SUPPLEMENT|cholecalciferol (Euro-Pharm International, Canada)|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
223460966|NCT03782805|DIETARY_SUPPLEMENT|Placebo tablet|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
223460967|NCT02066597|DEVICE|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
223460968|NCT04587336|BEHAVIORAL|Cognitive Interview|Examine the understanding and interpretation of diabetes distress and the Diabetes Distress Scale in Veterans with T2D.
223460969|NCT04587336|BEHAVIORAL|Baseline Survey|Examine the association of psychosocial factors (depression, PTSD), environmental factors (finances, support), self-management behaviors, and HbA1c with DD.
223460970|NCT04587336|BEHAVIORAL|Qualitative Interviews|Describe self-management challenges and preferred learning strategies to inform intervention components and delivery approach for Veterans with T2D.
223460971|NCT06950047|PROCEDURE|distal femoral osteotomies using the PediLoc® Locking Cannulated Blade Plate System|distal femoral osteotomies using the PediLoc® Locking Cannulated Blade Plate System
223460972|NCT06950047|PROCEDURE|distal femoral osteotomies using the 90°LCP-PCP|distal femoral osteotomies using the 90°LCP-PCP
223460973|NCT06949007|BEHAVIORAL|Yoga|Duration: 12 weeks; Class length: Three ∼75-minute classes per week. Two in-person/virtual (hybrid), one virtual only (MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
223460974|NCT06949007|BEHAVIORAL|Chronic Pain Health Education|Duration: 12 weeks (short videos and PowerPoint presentations); Class length: Interactive 15-30 minute education sessions delivered via video conference (i.e., MGB Zoom); Frequency: Three classes per week; Group size: 8-9 PPSP patients.
223460975|NCT06955156|DRUG|Trilaciclib|trilaciclib 240mg/m2 ivgtt d1 Q3w; anti-PD-1 antibody 200mg ivgtt d1 Q3w; Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w; carboplatin AUC=5 ivgtt d1 Q3w; Review every 2 cycles until the best efficacy or intolerable toxicity, usually 6-8 cycles;
223460976|NCT00049725|DRUG|Daclizumab|
223460977|NCT05707390|DRUG|Mezigdomide|Specified dose on specified days
223575071|NCT03622437|OTHER|Standard follow-up|"Patients with sphincter-preserving resection:~\- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~* outpatient visits at 3, 12 and 36 months~* access to stoma care by specialist nurses~All patients:~* CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~* perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
224303025|NCT03720379|DEVICE|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
224303026|NCT03720379|DEVICE|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
223460978|NCT00437996|DRUG|Clonidine|
223460979|NCT00437996|DRUG|Levobupivacaine|
223460980|NCT00437996|DRUG|Sufentanil|
223460981|NCT04232020|DIAGNOSTIC_TEST|Mismatch repair|MSI testing using Biocartis Idylla and MMR immunohistochemistry
223460982|NCT06147258|BEHAVIORAL|expressive writing|A typical session will begin with the teaching artist (i.e., writing coach) introducing a new writing theme. Participants will have at least 20 minutes to write, and each session will include post-writing reflections and sharing, an undirected supportive interaction among participants.
224156935|NCT02939313|DEVICE|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
223460983|NCT05076877|DRUG|Lazertinib|Lazertinib tablets will be administered orally, alone or in combination with probe substrates.
223460984|NCT05076877|DRUG|Midazolam|Midazolam (cytochrome P450 3A4 \[CYP3A4\] substrate) will be administered orally as a syrup as a part of probe substrates.
224156936|NCT02939313|DEVICE|sham|sham stimulation
224156937|NCT05573568|DRUG|N,N-Dimethyltryptamine|DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
224156938|NCT02768389|DRUG|Bevacizumab|Subjects receive Bevacizumab as standard of care
224156939|NCT02768389|BEHAVIORAL|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).
224156940|NCT00784706|OTHER|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
223460985|NCT05076877|DRUG|Rosuvastatin|Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
223460986|NCT05076877|DRUG|Metformin|Metformin (organic cation transporter 1 \[OCT1\] substrate) will be administered orally as a syrup as a part of probe substrates.
223460987|NCT03263715|DRUG|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
223460988|NCT03263715|DRUG|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
223460989|NCT03263715|DRUG|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
223460990|NCT00378885|BEHAVIORAL|Cognitive-behavioral tailored intervention|
223460991|NCT05869071|DEVICE|Sensor analyzing software (own development)|A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
223575072|NCT01046227|BIOLOGICAL|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
223575073|NCT05581095|BEHAVIORAL|Mindful Eating Self-Help Program|10-week exposure to mindful eating principles and practices outlined in the Eat What You Love, Love What You Eat for Binge Eating book
223575074|NCT05581095|BEHAVIORAL|Mindful Eating Smartphone Application (Am I Hungry? Virtual Coach)|10-week exposure to using a mindful eating mobile phone application daily.
223575075|NCT02649192|BIOLOGICAL|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
223575076|NCT02649192|DIETARY_SUPPLEMENT|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
223575077|NCT02649192|OTHER|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
223575078|NCT05212844|PROCEDURE|Musculoskeletal Physical Therapy|Therapeutic exercise and manual physical therapy based on the individual response to end range repeated movements.
223575079|NCT03849690|DRUG|TAK-906|TAK-906 capsules.
223575080|NCT03849690|DRUG|Esomeprazole|Esomeprazole capsules.
223575081|NCT00836459|BEHAVIORAL|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
223575082|NCT00836459|BEHAVIORAL|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
223575083|NCT03164083|BIOLOGICAL|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
223460992|NCT05869071|DEVICE|Body plethysmograph|Body plethysmograph measures specific airway resistance
223460993|NCT03515863|GENETIC|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
223460994|NCT03515863|DEVICE|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
223575084|NCT03164083|BIOLOGICAL|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
223575085|NCT01665989|BEHAVIORAL|Group Lifestyle Program|
223575086|NCT01665989|BEHAVIORAL|Usual Care|Visits with a dietitian at nutrition services at MGH
223575087|NCT03561701|DRUG|Oteseconazole (VT-1161)|Oteseconazole (VT-1161) 150mg capsule
223460995|NCT03515863|OTHER|Collection of life style data|Collection of life style data using quality of life questionnaire
223575088|NCT03561701|DRUG|Placebo|matching placebo capsule
223575089|NCT04353219|DEVICE|compression stocking|participants will continue their training program as prepared by their coach with compression stocking
223575090|NCT04353219|OTHER|control|participants will continue their training program as prepared by their coach without compression stocking
223575091|NCT01470833|PROCEDURE|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
223460996|NCT00898430|GENETIC|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
223460997|NCT00898430|GENETIC|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
223460998|NCT00898430|GENETIC|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
223460999|NCT01046864|DRUG|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
223461000|NCT01046864|DRUG|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
223461001|NCT01046864|DRUG|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
223461002|NCT01046864|DRUG|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
223461003|NCT01046864|DRUG|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
223461004|NCT01046864|DRUG|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
223461005|NCT01046864|DRUG|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
223461006|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Tea|Chamomile tea bags consumed by subjects as described in study arms section.
223461007|NCT05006378|DIETARY_SUPPLEMENT|Chamomile Extract Capsule|"Chamomile extract capsules consumed by subjects as described in Experimental: Chamomile Extract Capsule study arms section."
223461008|NCT05006378|DIETARY_SUPPLEMENT|Placebo Capsule|"Placebo capsules consumed by subjects as described in Placebo Comparator study arms section."
223461009|NCT03541291|DEVICE|SMART-SYNC LM03|Doppler ultrasound cardiac gating device for fetal MRI application
223461010|NCT05570552|BEHAVIORAL|mHealth based behavioral change communication intervention|We will implement a mHealth based communication system. The number of text messages and push notifications that a participant receives, will be variable and will occur at least weekly (based upon their responses) or the participant opts out of receiving messages. Participant change of behavior and use of improved stoves will be monitored by tracking clicks/views of educational materials and video vignettes.
223461011|NCT02259205|OTHER|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
223461012|NCT02259205|OTHER|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
223461013|NCT05801861|DEVICE|Active 10-Hz TMS to the parietal cortex|The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
223461014|NCT05801861|DEVICE|Active single pulse TMS to the parietal cortex|The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.
223461015|NCT05801861|DEVICE|Sham 10-Hz TMS to the right parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223461016|NCT05801861|DEVICE|Sham single-pulse rTMS the rigt parietal cortex|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223461017|NCT02809924|OTHER|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
223461018|NCT02809924|OTHER|Video training|Video describing endotracheal intubation
223461019|NCT02915172|DRUG|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
223461020|NCT02915172|DRUG|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
223461021|NCT02202798|DEVICE|Syringe device|
223461022|NCT03763201|DIAGNOSTIC_TEST|measurement of GITR|serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
223461023|NCT00535431|DRUG|AER 001|60 mg (in nebuliser), twice daily for 28 days
223461024|NCT00535431|DRUG|placebo|Sterile saline nebulised, twice daily for 28 days
223461025|NCT05556460|DEVICE|DragonFly-T Transcatheter Tricuspid Valve Repair System|To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.
223461026|NCT05556460|DRUG|Medical therapy|Subjects will continue to be managed on medical therapy, per physician discretion
223461027|NCT02855775|OTHER|additional blood sample|blood sample every 3 weeks
223461028|NCT00186407|PROCEDURE|high dose chemo then auto hematopoietic cell transplant|
223461029|NCT03512353|DRUG|Dexamethasone|Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.
223461030|NCT03512353|DRUG|Carfilzomib|Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
223461031|NCT00630799|DRUG|leuprolide acetate|17 mg i.m.
223461032|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to children preference|The parent who will accompany the child during the perioperative period will be determined by children preference
223461033|NCT05646927|PROCEDURE|Selection of parent(mother or father) according to randomization|The parent who will accompany the child during the perioperative period will be determined by randomization.
223461034|NCT01845597|PROCEDURE|MAKOplasty® medial UKA|A robot guided medial Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
223461035|NCT01229215|DRUG|FCFD4514S|Repeating intravitreal injection
223461036|NCT01229215|DRUG|sham|Repeating sham injection
223461037|NCT03782987|DRUG|BI 730357|0 mg BI 730357 tablet orally on Day 1
223461038|NCT03782987|DRUG|Itraconazole|20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
223461039|NCT05927077|PROCEDURE|planned surgery for weight reduction|planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
223461040|NCT04403113|OTHER|Structured neck and trunk stabilization exercises|Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
223575092|NCT01243567|DRUG|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
223575093|NCT01243567|DRUG|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
223461041|NCT04403113|OTHER|Feeding and oral motor intervention strategies|Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
223461042|NCT04403113|OTHER|Caregiver training related to feeding|In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
223461043|NCT04214496|DEVICE|Sedline|Intraoperative EEG monitorization
223461044|NCT02581488|BIOLOGICAL|Santyl|
223461045|NCT02581488|OTHER|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
223461046|NCT01877668|DRUG|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
223461047|NCT01877668|DRUG|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
223461048|NCT01877668|DRUG|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
223461049|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
223461050|NCT01877668|DRUG|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
223461051|NCT03251157|OTHER|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
223461052|NCT00319709|DRUG|SR58611A|
223461053|NCT05681013|BEHAVIORAL|Laughter Therapy|The effect of the Laughter Therapy on nursing students
223461054|NCT02174107|RADIATION|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1\*8 Gy; 5\*4 Gy and 10\*3 Gy
223461055|NCT02174107|PROCEDURE|Percutaneous vertebroplasty|
223575094|NCT05896787|DRUG|AK104, nab-paclitaxel, carboplatin|AK104 plus nab-paclitaxel and carboplatin as neoadjuvant therapy，and AK104 as adjuvant therapy for those who do not achieve pCR;
223461056|NCT00230334|DRUG|Gleevec|
223461057|NCT03157674|OTHER|Non-Interventional|Non-Interventional
223461058|NCT04754646|DEVICE|Split-face injection of RHA® 4 with a cannula into a single NLF.|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).~The brand of cannula used for injection is up to the discretion of the Treating Investigator (TI), providing the cannula is registered for use by the US FDA."
223461059|NCT04754646|DEVICE|"Split-face injection of RHA® 4 with a needle (TSK 27G x ½) into the contralateral NLF."|"RHA® 4 is a sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer.~Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF)."
223461060|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
223461061|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
223575095|NCT05693051|OTHER|Prone position ventilation|Turning the patient prone for 16 hours
223575096|NCT00202033|BEHAVIORAL|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
223461062|NCT01535677|DRUG|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
223461063|NCT01535677|DRUG|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
223461064|NCT05909020|OTHER|No intervention.|No intervention.
223461065|NCT01019161|DRUG|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
223461066|NCT01019161|DRUG|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
223461067|NCT01214889|BIOLOGICAL|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
223461068|NCT01214889|BIOLOGICAL|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
223461069|NCT06435975|OTHER|Physical Activity|Participants will perform a baseline +4000 steps/day for the duration of the study. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
223575097|NCT01034618|DIETARY_SUPPLEMENT|Protein hydrolyzation|
223575098|NCT02852941|DEVICE|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
223575099|NCT02852941|DEVICE|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
223575100|NCT00974285|DRUG|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
223461070|NCT06435975|OTHER|Survey|Participants will complete a series of survey at multiple points throughout this study to assess quality of life issues. Questionnaires may be completed via paper forms with prepaid postage envelopes or using a REDCap online survey.
223461071|NCT06435975|BEHAVIORAL|Telehealth Lifestyle Coaching|Participants will meet with a health coach, the Principal Investigator, to review baseline bowel habits and symptoms as well as discuss physical activity and potential strategies to achieve this goal, on a weekly basis for 12 weeks.
223461072|NCT01759953|OTHER|Game|InsuOnline game, on the web, in the player´s own time and rhythm
223461073|NCT01759953|OTHER|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
223461074|NCT06465472|DRUG|Stiripentol Oral Capsule|The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.
223461075|NCT06465472|DRUG|Placebo Oral Capsule|Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
223461076|NCT06465472|BIOLOGICAL|Urine samples collect|Collections of urine over 24 hours and the first urine in the morning (spot urines) will be carried out. Urine collections will be performed either during hospitalizations, or at home if appropriate conditions are met.
223461077|NCT06465472|BIOLOGICAL|Blood samples collect|Series of blood samples will be taken (serum pregnancy test, Primary Hyperoxaluria genetic characterization, clinical laboratory assessments, vitamin B6 dosage, plasma oxalate dosage, stiripentol pharmacokinetics)
223461078|NCT06465472|OTHER|Kidney imaging|Kidney imaging will be obtained. Renal ultrasounds will be compulsory for all patients.
223461079|NCT06465472|OTHER|Quality of Life questionnaires|"Kidney Disease Quality of Life Questionnaire : KDQOL-36 for patients ≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL) including the generic and KF modules (parent and/or self-report versions) for patients \<18 years of age at screening.~EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions. Scoring of the questionnaire is based on degrees of disability. Scoring of the visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Higher scores indicate better health status. The EQ-5D-5L questionnaire (will be utilized in patients ≥18 years of age at screening, and the EQ-5D-Y questionnaire will be utilized in patients \<18 years of age at screening, where available."
223461080|NCT03414333|PROCEDURE|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
223461081|NCT03414333|DRUG|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
223461082|NCT04561648|DRUG|Unfractionated Heparin|Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
223461083|NCT00563121|PROCEDURE|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
223461084|NCT03043742|DRUG|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
223461085|NCT01693679|DRUG|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
223461086|NCT06244732|PROCEDURE|Postoperative pain control|Postoperative analgesia after OR-AAA
223461087|NCT03539107|PROCEDURE|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
224303027|NCT01763684|DEVICE|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
223461088|NCT03539107|OTHER|spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
223461089|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 60 mg iron sulfate|control agent
223575101|NCT00974285|DRUG|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
223461090|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (60 mg iron)|contains 60 mg of iron
223461091|NCT02037724|DIETARY_SUPPLEMENT|iron rich food supplement (10 mg iron)|contains 10 mg iron
223461092|NCT02037724|DIETARY_SUPPLEMENT|supplement containing 10 mg iron sulfate|control agent
223461093|NCT03407313|DEVICE|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
223575102|NCT02322294|DIETARY_SUPPLEMENT|Glucodia™|
223575103|NCT02322294|OTHER|Placebo|
223575104|NCT03251040|DEVICE|Autologous activated fibrin sealant|Application of fibrin sealant
223575105|NCT03308045|BIOLOGICAL|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
223575106|NCT03288194|BEHAVIORAL|Problem-Solving Treatment|
224303028|NCT01763684|PROCEDURE|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
223575107|NCT03288194|BEHAVIORAL|Time Management|
223575108|NCT04149860|DRUG|Lu AF87908|Lu AF87908 concentrate for solution for intravenous (IV) infusion
223575109|NCT04149860|DRUG|Placebo|Concentrate for solution for IV infusion
223575110|NCT03510351|DRUG|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
223575111|NCT00468845|DRUG|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
223575112|NCT00468845|DRUG|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
223575113|NCT00468845|DRUG|matched placebo|matched placebo
223575114|NCT02960646|DRUG|Cyclophosphamide|Given IV
223575115|NCT02960646|BIOLOGICAL|Filgrastim|Given SC
223575116|NCT02960646|DRUG|Fludarabine Phosphate|Given IV
223575117|NCT02960646|OTHER|Laboratory Biomarker Analysis|Correlative studies
223575118|NCT02960646|DRUG|Melphalan|Given IV
223575119|NCT02960646|PROCEDURE|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
223575120|NCT02960646|BIOLOGICAL|Rituximab|Given IV
223575121|NCT02960646|DRUG|Tacrolimus|Given IV or PO
223575122|NCT02960646|RADIATION|Total-Body Irradiation|Undergo TBI
223575123|NCT02757794|OTHER|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
223461094|NCT06077539|DRUG|Dexmedetomidine|a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.
223461095|NCT06077539|DRUG|Ketamine|NMDA (N-methyl-D-aspartate) receptor antagonist
223575124|NCT02757794|OTHER|standard remediation|A speech therapy and / or academic support is realized.
224156941|NCT00784706|OTHER|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
224156942|NCT00784706|OTHER|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
223461096|NCT06077539|DRUG|Magnesium|NMDA (N-methyl-D-aspartate) receptor antagonist
223575125|NCT02388594|DRUG|ZFN Modified CD4+ T Cells|
223575126|NCT02388594|DRUG|Cyclophosphamide|
223575127|NCT01183819|BEHAVIORAL|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
223575128|NCT01183819|BEHAVIORAL|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
223575129|NCT01183819|BEHAVIORAL|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
223575130|NCT01183819|BEHAVIORAL|Control Games|Control games session 3 times a week for 12 weeks
223575131|NCT05202665|PROCEDURE|ICON DMG Resin Infiltration (micro-invasive approach)|A plastic wedge located below the contact point to apart from the surface from adjacent tooth. A 15% HCl etching gel (Icon, DMG, Hamburg, Germany) was applied by syringe below the contact point for 120 s. After, the gel was washed off with air-water-spray for 30 s. The lesion was desiccated by air-blowing for 10 s, application of ethanol for 30 s and air-blowing again for 30 s. A resin infiltrant (Icon, DMG, Hamburg, Germany) was applied with another plastic holder during 3 min. Following the penetration, excess of material was removed by air blowing and flossing. The resin was light-cured for 40 s total from the buccal, occlusal, and lingual/palatal aspects. It was needed to reapplicate the resin infiltration for once because of infiltrating remaining porosities during 1 minute. Excess material removing process was again repeated and light cured for 40 s.
223575132|NCT05202665|PROCEDURE|ClinproTM White Varnish, 3M ESPE Fluoride Varnish (non-invasive approach)|Tooth surfaces were cleaned thoroughly and isolated with cotton rolls. According to the manufacturer's instructions, the unit dose packages were opened, and the contents were dispensed onto the application guide and mixed to avoid the separation of sodium fluoride components. A thin coat of varnish (ClinproTM White Varnish, 3M ESPE, USA) with 22600 ppm fluoride was applied to the tooth interface with a brush tip applicator and waited for 5 minutes. Aproximal areas were coated with dental floss. The patient was instructed not to rinse or apply suction immediately after application. Patients were advised to avoid eating hard and sticky foods or drinking hot beverages for the next 2 hours, to consume a soft diet immediately after 30 minutes and to avoid brushing and flossing for the rest of the day.
223575133|NCT04218162|DRUG|Lasmiditan 50mg|Lasmiditan 50mg
223575134|NCT04218162|DRUG|Lasmiditan 100mg|Lasmiditan 100mg
223575135|NCT04218162|DRUG|Placebo|Placebo
223575136|NCT05566457|DRUG|Huangqi Guizhi Wuwu decoction (HGWD) infusion packs|Patients in the HGWD group (n = 46) soaked and washed Immersion and Washing limbs with HGWD infusion packs, followed by smearing limbs with vitamin E and vitamin B12. The composition of HGWD infusion pack was: 60g Radix Astragali (Huangqi), 15g Ramulus Cinnamomi (Guizhi), 15g Paeonia lactiflora (Baishao), 15g Gentiana (Qinjiao), 6g Scorpio (Quan-Xie), 20g Rhizoma Zingiberis Recens (Shengjiang), 20 Jujubes (Dazao), 30g Geranium wilfordii (Laoguancao), 12g radix sileris (Fangfeng), 30g Spatholobus suberectus (Jixueteng), 15g Ligusticum (Chuanxiong), 15g Poria (Fuling), and 15g Radixcyathulae (Chuanniuxi). HGWD infusion pack was boiled in water and extraction was performed twice to obtain a total of 500 ml drug-containing water. The drug-containing water was maintained at 39 to 40℃ for soaking and washing limbs for 20min twice a day for consecutive 14 days
223575137|NCT02547493|BIOLOGICAL|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
223575138|NCT02547493|BIOLOGICAL|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
223575139|NCT02547493|DRUG|Abatacept|Abatacept started on frst day
223575140|NCT05864131|BEHAVIORAL|Lying|After the urethral catheter is inserted, the participant lies on an examination table lined with paper towels and diapers.
223575141|NCT05864131|BEHAVIORAL|Holding|Holding is performed as a non-pharmacological intervention to relieve pain in children during cystometry. After the urethral catheter is inserted, the participant's parent sits in the chair, placing a paper towel and diaper on their lap. The researcher lifts the participant by the shoulder and puts them on their parent's lap, and the parent holds the participant in their arms.
223575142|NCT03198195|PROCEDURE|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
223461097|NCT06077539|OTHER|normal saline 0.9% NaCL|saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
223461098|NCT02589080|BEHAVIORAL|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
223461099|NCT06010797|DEVICE|Showing Pre-treatment photographs of the patient|Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
223461100|NCT05352932|DIAGNOSTIC_TEST|pancreatic duct biopsy|"Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination."
223461101|NCT05502952|DRUG|Pentoxifylline|Combined microneedling and topicalpentoxifylline vesrus intalesional pentoxifylline in Alopecia Areata patches in the same patient
223461102|NCT03795337|RADIATION|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
223461103|NCT00814138|DRUG|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
223461104|NCT00814138|OTHER|Placebo|Weekly
223575143|NCT04432493|DEVICE|Active repetitive transcranial magnetic stimulation (rTMS)|rTMS will be used to stimulate neuronal activity of the dorsolateral prefrontal cortex (DLPFC). Participants will receive no more than 2000 pulses of rTMS at 110% of participants' resting motor threshold at 10 Hz continuously for the duration of the t-maze task.
223575144|NCT04432493|DEVICE|Sham repetitive transcranial magnetic stimulation (rTMS)|Sham TMS will be used to mimic the auditory sensation of the Active rTMS condition. Protocols for the sham condition will be the same as the active condition, however the TMS coil will be flipped 180 degrees so that participants in this condition will not receive any active stimulation.
223575145|NCT03764917|OTHER|Time|Different detecting time
223575146|NCT03635034|DEVICE|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
223575147|NCT03635034|DEVICE|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
223575148|NCT00288457|DEVICE|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
223575149|NCT02438956|DIETARY_SUPPLEMENT|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
223575150|NCT02438956|DIETARY_SUPPLEMENT|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
223575151|NCT02668861|DRUG|Vitamin D|Vitamin D 4000IU/day for 8 weeks
223575152|NCT02668861|DRUG|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
223575153|NCT02668861|OTHER|placebo|placebo for 8 weeks
223575154|NCT03655327|OTHER|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
223575155|NCT00568113|DRUG|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
223461105|NCT05364476|BEHAVIORAL|16 weeks digital intervention|"Participants will be enrolled into a 16-week program which consist of an online and offline support from health coaches and dietitian. Participants will be given diet and exercise recommendations and lesson plans on a weekly basis by the health coaches, and supported by the dietitian.~Participants will be required to log in their blood sugar levels, weight and steps daily using connected device, including glucometer, smart band and body fat weighing scale provided into the daily report card. They will also be required to manually record their meals and exercise daily in the daily report card provided upon enrollment into study. Reviews of log will be done on a weekly/biweekly interval by the health coaches."
223575156|NCT02761694|DRUG|Vevorisertib|Administered as an oral dose every day or every other day.
223461106|NCT02381678|DEVICE|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
223575157|NCT02761694|DRUG|Fulvestrant|Administered as an intramuscular (IM) injection.
223575158|NCT02761694|DRUG|Paclitaxel|Administered as an intravenous (IV) infusion.
223575159|NCT03973463|BEHAVIORAL|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
223575160|NCT03815994|DEVICE|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
223575161|NCT03071991|PROCEDURE|study group|local anesthetic drug will be used
223575162|NCT03071991|PROCEDURE|control group|no local anesthetic drug will be used
223575163|NCT01669018|PROCEDURE|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
224156943|NCT01510028|BIOLOGICAL|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
224156944|NCT00837239|DRUG|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
223461107|NCT01407991|OTHER|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
223461108|NCT01407991|OTHER|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
223461109|NCT02196857|DRUG|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
223461110|NCT02196857|DRUG|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
223461111|NCT00712257|DEVICE|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
223461112|NCT05636813|OTHER|Training|Patients are trained to use AT (2 sessions of 4 hours). Written langage skills, autonomy, the use are evaluated before and after training.
223461113|NCT02336867|DEVICE|Closure clip (OTSC® Proctology)|
223461114|NCT00583908|DEVICE|senofilcon A|toric contact lens
223461115|NCT00583908|DEVICE|balafilcon A toric|toric contact lens
223461116|NCT00583908|DEVICE|lotrafilcon B toric|toric contact lens
223461117|NCT00583908|DEVICE|omafilcon A|toric contact lens
223461118|NCT00346957|DRUG|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
223461119|NCT00346957|DRUG|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
223461120|NCT00346957|DRUG|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
223461121|NCT00346957|OTHER|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
223461122|NCT02534597|BEHAVIORAL|Promotores Training|
223461123|NCT02534597|BEHAVIORAL|Delayed Promotores training|
223461124|NCT02534597|BEHAVIORAL|Caregiver training|
223461125|NCT02534597|BEHAVIORAL|Delayed caregiver training|
223461126|NCT02534597|BEHAVIORAL|Materials support|
223461127|NCT02534597|BEHAVIORAL|Delayed materials support|
223461128|NCT02534597|BEHAVIORAL|Technical assistance|
223461129|NCT02534597|BEHAVIORAL|Delayed technical assistance|
223461130|NCT01749410|BIOLOGICAL|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
223461131|NCT02037815|DRUG|20% mannitol solution, 125 ml, IV infusion in 15 min|
223461132|NCT02037815|DRUG|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
223461133|NCT05591157|DEVICE|CSF-3 watch, designed to monitor a user's heart rate based on ECG (electrocardiogram) and PPG (Photoplethysmograph) readings|The subjects will be connected to an ECG Holter, and an investigational Device will be placed simultaneously on the subject's wrist. All subjects in this phase will be asked to participate in a single continuous data recording measurement for seven (7) minutes
223461134|NCT04678843|BEHAVIORAL|Virtual Family-Based Treatment|Treatment involving the youth/adolescent who has been diagnosed with anorexia nervosa and their family, delivered virtually via videoconferencing.
223461135|NCT00027885|BIOLOGICAL|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
223461136|NCT00027885|DRUG|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
223461137|NCT00027885|DRUG|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
223461138|NCT00027885|DRUG|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
223461139|NCT00027885|PROCEDURE|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
223461140|NCT00027885|PROCEDURE|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
223461141|NCT00027885|PROCEDURE|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
223461142|NCT00027885|RADIATION|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
223461143|NCT01253096|DRUG|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
224156945|NCT00837239|DRUG|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
224156946|NCT00837239|DRUG|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
223461144|NCT05713357|PROCEDURE|Catheter ablation|Endocardial catheter ablation
223461145|NCT02664012|OTHER|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
223461146|NCT02664012|OTHER|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
223461147|NCT02664012|OTHER|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
223461148|NCT02664012|OTHER|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
223461149|NCT02664012|OTHER|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
223461150|NCT06049446|DEVICE|Pintuition|Magnetic seed localization
224156947|NCT01355497|DRUG|GTx-024|subjects will be randomized to receive GTx-024 3mg softgel for the duration of the trial.
223575164|NCT01669018|PROCEDURE|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
223575165|NCT04008511|DRUG|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
223575166|NCT04008511|DRUG|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
223575167|NCT04008511|DRUG|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
223575168|NCT04008511|DRUG|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
223575169|NCT02590822|DIETARY_SUPPLEMENT|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
223575170|NCT02590822|OTHER|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
223575171|NCT03297489|PROCEDURE|Diagnostic Microscopy|Undergo observation via intravital microscopy
223575172|NCT03297489|DRUG|Fluorescein Sodium Injection|Given IV
223575173|NCT03297489|OTHER|Laboratory Biomarker Analysis|Correlative studies
223575174|NCT03825250|DRUG|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
223575175|NCT00886249|DEVICE|Acrysof IQ|Intraocular lens
223575176|NCT00886249|DEVICE|Acrysof Natural IOL|Intraocular Lens
223575177|NCT01869361|DRUG|Indomethacin|Study drug
224156948|NCT01355497|DRUG|placebo|subject will receive matching placebo for the duration of the trial
224156949|NCT02321397|DRUG|Oxycodone|
224156950|NCT02321397|DRUG|Naloxone|Prolonged Release Tablets
224156951|NCT01502761|DRUG|Magnesium Sulfate|Intra-arterial
224156952|NCT04889690|DRUG|Danicopan|
224156953|NCT04889690|DRUG|Placebo|
224156954|NCT01384188|DRUG|ONO-5334|150 mg for 5 days administered in the morning or in the evening
223575178|NCT01869361|DRUG|Placebo|Control drug
223575179|NCT05773261|DEVICE|MobilLINK TrabecuLINK cup|THA with MobilLINK TrabecuLINK cup and LCU stem
223575180|NCT05773261|DEVICE|Pinnacle Gription cup|THA with Pinnacle Gription cup and Coral stem
224156955|NCT01384188|DRUG|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
224156956|NCT01787045|OTHER|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
224156957|NCT01787045|OTHER|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
224156958|NCT05055037|OTHER|Neurofeedback|In neurofeedback (NF), the brainwave activity is measured by an electro-encephalography and fed back to the person as an auditory or visual signal, rewarding the person each time progress is made toward normalizing dysregulated neural activity. The learning mechanism is at its base considered to be operant conditioning, where the behavior of the participant-in this case, neurological activity-is gradually changed through repeated reinforcement. In neurofeedback, this simple learning mechanism is accelerated by continuous and instant feedback, with rewards occurring as often as every second. The NF intervention included 12 NF training sessions, one session per week, off approximately 12-20 min. The protocol was a replicate of the setup of recent NF studies investigating NF as a treatment for chronic PTSD. The feedback was based on a single channel recording, rewarding brainwave frequencies associated with a calm and relaxed state and inhibiting drowsiness and hyperarousal.
224303029|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
224303030|NCT01401621|BEHAVIORAL|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
223575181|NCT02395055|DRUG|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
223575182|NCT02395055|DRUG|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
223575183|NCT01403545|DRUG|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
224303031|NCT01401621|BEHAVIORAL|Control|No scratch-off element
223575184|NCT01403545|OTHER|Placebo|5% glucose infusion over 120 minutes
223575185|NCT02698904|BEHAVIORAL|Guided Relaxation Technique|
223575186|NCT02698904|OTHER|Documentary Movie|
224303032|NCT03744702|DRUG|Ascorbic Acid|Patients will receive IV ascorbic acid.
224303033|NCT03113513|PROCEDURE|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
223461151|NCT05270980|OTHER|Cohorting|"The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure."
224303034|NCT04340609|BIOLOGICAL|Mesenchymal Stem Cells|The UC-MSCs from a donor will be cultured in a clinical grade laboratory with xeno-free medium. Maximum passage of expanded-UC MSCs was VI and doubling population is less than 30. To assure the quality of our expanded-UC MSCs at ProSTEM the following tests are done: cell adherence, cell surface marker, in vitro differentiation, cell viability, sterility, Mycoplasma, endotoxin, and karyotyping.
224303035|NCT03453671|BEHAVIORAL|Mindfulness|Participants will use mindfulness techniques while exercising
223461152|NCT03131284|BEHAVIORAL|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
223461153|NCT03072667|DRUG|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
223461154|NCT05946200|PROCEDURE|Low flow technique in general anesthesia|It will be used a low flow technique by giving airflow as 0.75 l/min after the intubation and will keep going on until the end of the laparoscopic cholecystectomy.
223461155|NCT05897866|PROCEDURE|Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management|Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.
223461156|NCT05722717|GENETIC|Saliva collection at home|Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
223575187|NCT05732883|DRUG|Dexamethasone|Dexamethasone injection
224071484|NCT02678858|BEHAVIORAL|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
224303036|NCT03453671|BEHAVIORAL|Distraction|Participants will distract themselves while exercising
224303037|NCT03453671|BEHAVIORAL|Self-monitoring|Participants will use associative attentional focus while exercising
223575188|NCT05732883|DRUG|Normal saline|Placebo
223575189|NCT05202821|DRUG|PRG Barrier Coat|3 arm randomized single blind clinical trial comparing 3 groups. first group will be receiving fluoride varnish, second group will be receiving PRG Barrier Coat and the third group will be receiving MI paste
223575190|NCT05202821|DRUG|Fluoride varnish|First group will be receiving Fluoride varnish every 3 months
223575191|NCT05202821|DRUG|MI paste|Third group will be receiving MI paste
223575192|NCT04979403|OTHER|Physiotherapy|Participants from each group will receive 8 intervention sessions (45 min) over 11 weeks by a physiotherapist. For both groups, each intervention will be tailored to the patient's profile and the choice of interventions and parameters will be at the judgment of the physiotherapist.
223575193|NCT03303898|PROCEDURE|Blood sampling|sampling of 7 blood tubes
223575194|NCT06093178|BEHAVIORAL|Human coach-led digital health platform|This is an existing commercial digital platform developed by our technology partners (Empeal). The platform comes in the form of a smartphone app available via Android and Apple devices. Participants will communicate with their coach through the app via video, audio or text. Surveys are conducted on the app. Support content is also available through this app.
223575195|NCT01955434|DRUG|Cyclophosphamide|Given PO
223575196|NCT01955434|OTHER|Laboratory Biomarker Analysis|Correlative studies
223575197|NCT01955434|OTHER|Pharmacological Study|Correlative studies
223575198|NCT01955434|OTHER|Quality-of-Life Assessment|Ancillary studies
224303038|NCT04312529|OTHER|Isokinetic test + EMG|Isokinetic test:The isokinetic device is used to evaluate the strength of a subject. The test will be performed in two positions. This will determine the best position to activate shoulder muscles EMG (electromyography):it's a device that measures the electrical activity of muscles. This will allow us to record the maximum activity of the shoulder muscles during force tests.
223575199|NCT01955434|DRUG|Smac Mimetic LCL161|Given PO
223575200|NCT01480609|DRUG|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
224303039|NCT01339481|DRUG|abatacept|Intravenous Infusion
224303040|NCT00000723|DRUG|Methotrexate|
224303041|NCT00000723|DRUG|Leucovorin calcium|
224303042|NCT00000723|DRUG|Zidovudine|
224303043|NCT00000723|DRUG|Dexamethasone|
224303044|NCT00090181|DRUG|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
224303045|NCT00090181|DRUG|Comparator: diclofenac / Duration of Treatment: 4 weeks|
224303046|NCT03341819|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
224303047|NCT03341819|PROCEDURE|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
223461157|NCT02248064|DEVICE|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
223461158|NCT04354415|PROCEDURE|Carpal tunnel or trigger finger release|Carpal tunnel or trigger finger release with and without the use of tourniquet
223461159|NCT02879955|OTHER|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
223461160|NCT02879955|OTHER|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
223461161|NCT02879955|OTHER|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
223461162|NCT02879955|OTHER|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
223461163|NCT02942069|BEHAVIORAL|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
223461164|NCT01116037|DEVICE|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
223461165|NCT00890448|OTHER|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
223461166|NCT03452462|DEVICE|Pacing|Programming of either Direct His Bundle pacing or biventricular pacing
223743347|NCT06359691|BEHAVIORAL|Provider-focused strategies|"Provider-focused strategies to increase HTN management practices:~1. Hypertension registry: identify patients with uncontrolled BP, notify care team~2. Home BP monitoring: provide home BP monitors, encourage reporting of BP readings~3. Enhance standardization of home/office BP readings: staff training, posters in clinic~4. Simplify treatment protocols using fixed-dose combo meds: education on fixed-dose combo meds~5. Nurse-directed BP med titration w/ CHW/Health Educator support: system for team-based care, referral to nurse-directed clinics \& CHWs/health educators~6. Enhance patient understanding of BP using culturally- and linguistically- tailored materials: Increased availability of tailored materials~7. Social needs screening and linkage to community resources: referral system to resources~8. CHW assigned to patients with complex medical and social needs: referral of complex patients to CHWs~9. Behavioral science messaging: posters in charting rooms, scripts for RNs"
223743348|NCT06359691|BEHAVIORAL|Patient- and provider-focused strategies|A combination of the 7 patient-focused strategies (see patient-focused strategies outlined above) and 9 provider-focused strategies (see provider-focused strategies outlined above) implemented simultaneously.
223743349|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) with a goal inventory|Goal Attainment Scaling (GAS) with a goal inventory (list of common goals) as a behavioral interventional tool
223461167|NCT05952921|OTHER|Mouthwash|Concentration rinse with 0.05% HOCl
223461168|NCT05952921|OTHER|Chlorhexidine|A high concentration of 0.2% CHX (7 days), followed by 0.012% CHX (14 days).
223461169|NCT02351401|BEHAVIORAL|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
223461170|NCT03297229|BEHAVIORAL|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
223461171|NCT03297229|BEHAVIORAL|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
223743350|NCT06019143|BEHAVIORAL|Goal Attainment Scaling (GAS) without inventory|Goal Attainment Scaling (GAS) without a goal inventory (list of common goals) as a behavioral interventional tool
224071485|NCT00710528|DRUG|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
224071486|NCT03881150|OTHER|Comprehensive assessment|Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
224071487|NCT03881150|OTHER|Counseling|Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.
224071488|NCT03881150|OTHER|Group education|Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.
224071489|NCT03881150|OTHER|Exercise sessions in hybrid program|"10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate."
224071490|NCT03881150|OTHER|Exercise sessions in standard program|"18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate."
224071491|NCT03881150|OTHER|Transition to unsupervised phase|After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
224071492|NCT04865068|DIAGNOSTIC_TEST|Echocardiography measures on SSA participants|"Upon SSA Subject is admitted to the hospital for an echocardiography,~* Information about this study process,~* Participants will receive an information note ;~* Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~* Performing and recording the echocardiographic examination according to routine protocol~* delivery of the results according to the usual management;~* deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards"
223461172|NCT05194345|BEHAVIORAL|Autism Eats nutrition intervention|The Autism Eats intervention group will spend about 8.5 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, and a 60-minute exit interview). The Autism Eats intervention group EI provider will spend about 12 hours over 5 months (two 90-minutes training sessions, 25-30 minutes weekly sessions for up to 10 weeks, two 25-30 minutes monthly booster sessions, 10-minute fidelity checklist completion after each session, and a 60-minute exit interview).
223461173|NCT05194345|BEHAVIORAL|We Can! enhanced usual care|We Can! EUC control group will spend about 3 hours over 5 months (baseline, post intervention, and 5-month follow-up assessments are 30 minutes each, one 25-30 minute nutrition session, and a 60-minute exit interview). We Can! EUC control group EI provider will spend about 4.5 hours over 5 months (two 90-minutes training sessions, one 25-30 minutes session, 1-2-minute written material distribution at their 9 weekly EI sessions, and a 60-minute exit interview).
223575201|NCT04042272|DIAGNOSTIC_TEST|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
223575202|NCT05282576|OTHER|NPF Group|Participants allocated to the experimental group completed until discharged, neurophysiological facilitation(NPF) techniques in addition to conventional physiotherapy.
223575203|NCT05282576|OTHER|Control Group|Critical ill patients was applied their conventional physiotherapy which includes chest physiotherapy and mobilization until discharged
223575204|NCT02659553|PROCEDURE|steatosis|Liver Transplantation with graft steatosis
223575205|NCT06107439|BIOLOGICAL|Bood and urine sampling|Bood and urine sampling
223575206|NCT05363761|COMBINATION_PRODUCT|Neurotronic Infusion Catheter|Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter
223575207|NCT03594916|DEVICE|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
223575208|NCT03594916|DEVICE|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
224156959|NCT05679440|BEHAVIORAL|Postural interventions based on pulmonary imaging|The main difference between the intervention group and the control group was the position during oxygen therapy. Patients in the intervention group were placed in the appropriate position for oxygen therapy according to pulmonary imaging, while patients in the control group were placed in the appropriate position for oxygen therapy according to conventional treatment principles and the patient's wishes.
224303048|NCT03043859|BEHAVIORAL|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
223575209|NCT05785507|OTHER|PriskA tool|PriskA tool is an algorithm that generates a risk score of having PCOS.
223575210|NCT01049802|DEVICE|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
223575211|NCT04070326|DRUG|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
223575212|NCT00958464|PROCEDURE|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
223575213|NCT01287377|BEHAVIORAL|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
223575214|NCT01287377|DRUG|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
223575215|NCT04006990|BEHAVIORAL|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
224156960|NCT01838655|DRUG|Nitisinone|Oral dose of 2mg daily for 12 months.
224303049|NCT04906083|DRUG|Avatrombopag|"Avatrombopag:~PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d."
224303050|NCT04906083|DRUG|Standard medical treatment|Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.
223575216|NCT01656343|DRUG|Calcineurin inhibitors (CNI)|No Intervention
224156961|NCT01285414|DRUG|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide \& Radiation Therapy
223575217|NCT01656343|DRUG|Belatacept|No Intervention
223575218|NCT00526110|DRUG|5-Fluorouracil|2.2 Gm/m\^2 IV over 48 hours on Day 1.
223575219|NCT00526110|DRUG|Docetaxel|20 mg/m\^2 IV over 60 minutes
223575220|NCT00526110|DRUG|Oxaliplatin|85 mg/m\^2 IV over 120 minutes on Day 1.
223461174|NCT02266823|BEHAVIORAL|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
224156962|NCT01285414|DRUG|Temozolomide & Radiation Therapy|Temozolomide \& Radiation Therapy
224156963|NCT00650364|DRUG|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
224156964|NCT00650364|DRUG|ProAmatine® Tablets 5 mg|5mg, single dose fasting
224156965|NCT04230590|OTHER|Observational|"Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected."
224156966|NCT02948504|PROCEDURE|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
223575221|NCT04289077|OTHER|Questionnaires|\- Baseline questionnaire, version 1.0, October 29 2019, (Dutch) - Health care utilization, version 1.0, October 29 2019, (Dutch) - Decision-making, version 1.0, October 29 2019, (Dutch) - EORTC QLQ-C30, version 3.0, (Dutch) - DTF-QoL, version 1.0, October
224156967|NCT03463213|BEHAVIORAL|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
224156968|NCT02916199|DEVICE|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
224156969|NCT03038516|DRUG|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
224156970|NCT03038516|DEVICE|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
224156971|NCT04371549|PROCEDURE|Glue (Dermabond®; Ethicon, Somerville, NJ).|Arm 1: Skin after cesarean section will be closed by glue
223461175|NCT04987463|DRUG|Vigabatrin|Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
224156972|NCT04371549|PROCEDURE|Monocryl|Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
224156973|NCT00927576|BEHAVIORAL|Digit span testing|Testing of short-term verbal memory with digit span
224156974|NCT00927576|BEHAVIORAL|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
224156975|NCT00927576|BEHAVIORAL|Finger tapping|Testing motor speed with a finger tapping test.
224156976|NCT00927576|BEHAVIORAL|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
224156977|NCT00927576|BEHAVIORAL|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
224156978|NCT00927576|BEHAVIORAL|Verbal fluency|Evaluating how many words are produced in 90s.
224156979|NCT00927576|BEHAVIORAL|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
224156980|NCT00927576|BEHAVIORAL|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
224156981|NCT00927576|BEHAVIORAL|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
224156982|NCT00927576|BEHAVIORAL|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
224156983|NCT05915104|DRUG|Budesonide MMX®|9 mg delayed and extended-release tablet once daily
223461176|NCT04987463|DRUG|Rapamycin|Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
223575222|NCT00001399|DRUG|Transduced CD34+ Cells|
223575223|NCT05062304|DRUG|Fluticasone Furoate-Vilanterol Trifenatate|Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.
224156984|NCT05915104|DRUG|Budesonide controlled ileal release (CR) capsules|three 3 mg capsules daily oral administration for 8 weeks
224156985|NCT01495260|DRUG|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
224156986|NCT01495260|DRUG|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
224156987|NCT01495260|DRUG|vitamin E|vitamin E, 150-300 mg daily for 2 months
224156988|NCT00840385|DRUG|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
224156989|NCT03551704|BEHAVIORAL|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
224156990|NCT03551704|BEHAVIORAL|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
223461177|NCT04987463|DRUG|Placebo|Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
223461178|NCT04987463|DRUG|Placebo|Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
223461179|NCT03870334|DRUG|BT-11 880 mg|Oral once daily tablet
223461180|NCT03870334|DRUG|Placebo|Oral once daily tablet
223461181|NCT04388410|BIOLOGICAL|convalescent plasma|Plasma obtained from volunteers who have recovered from SARS-Cov-2 infection. Two 200 ml infusions will be administered with 24-72 hours in between.
223461182|NCT03967288|DRUG|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
223461183|NCT03967288|DRUG|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
223461184|NCT00887614|BEHAVIORAL|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
223743351|NCT04768465|DRUG|Pyridostigmine, Prednisone, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
224067912|NCT04755361|BEHAVIORAL|Housing Outreach Project Collaboration (HOP-C)|HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
223461185|NCT05775601|DRUG|18F-LY3950321|3 millicuries (±1 mCi)
223461186|NCT05775601|PROCEDURE|PET Scan|positron emission tomography (PET) scan
223461187|NCT00488423|PROCEDURE|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.
223461188|NCT01361750|PROCEDURE|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
223461189|NCT02447445|PROCEDURE|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men \< 27 kg and women \<16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
223461190|NCT00848757|BEHAVIORAL|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
223461191|NCT02479659|OTHER|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
223461192|NCT02479659|OTHER|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
224156991|NCT03022604|DIETARY_SUPPLEMENT|C4/Generation 4|12 grams of C4/Generation 4
224156992|NCT03022604|DIETARY_SUPPLEMENT|C450X|12 grams of C450X
224156993|NCT03022604|DIETARY_SUPPLEMENT|Placebo|12 grams of flavored dextrose
224156994|NCT02935907|DRUG|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
224156995|NCT01784211|DRUG|LY2605541|
224156996|NCT01784211|DRUG|Insulin Glargine|
224156997|NCT02453828|PROCEDURE|Non-cardiac surgery|patients having non-cardiac surgery
224156998|NCT06171711|BEHAVIORAL|Exposure Therapy|The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
224156999|NCT04313101|OTHER|withdrawl of blood samples for thyroid function testing|"Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels."
223461193|NCT02479659|OTHER|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~* If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~* If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
224157000|NCT03713827|DEVICE|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
223461194|NCT02479659|OTHER|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
223461195|NCT02479659|OTHER|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
223461196|NCT03718390|DRUG|Formulation A|Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
223461197|NCT03718390|DRUG|Formulation B|Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
223461198|NCT03718390|DRUG|Formulation C|Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
223461199|NCT03718390|DRUG|Formulation D|Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
223575224|NCT05062304|DRUG|Furoate-umeclidinium-vilanterol|Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.
223575225|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
223575226|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
223575227|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
223575228|NCT01261130|BIOLOGICAL|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
223575229|NCT01261130|BIOLOGICAL|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
223575230|NCT01261130|BIOLOGICAL|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
223575231|NCT01261130|BIOLOGICAL|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
223575232|NCT04895293|DRUG|RBM-007 Injectable Solution|Sterile solution
223575233|NCT01913028|DRUG|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
223461200|NCT03718390|DRUG|Formulation E|Placebo Capsule containing microcrystalline cellulose
223461201|NCT03718390|PROCEDURE|Endoscopy|Endoscopy at 2 hours post dosing
223461202|NCT03718390|PROCEDURE|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
223461203|NCT03472638|DEVICE|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
223461204|NCT03534661|DRUG|Teduglutide + Normal Saline|Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
223575234|NCT01913028|DRUG|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
223575235|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.
223575236|NCT05997667|DEVICE|Rechargeable implantable deep brain stimulation system|The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.
223461205|NCT03534661|DRUG|Teduglutide + L-NMMA|Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
223461206|NCT03534661|DRUG|Placebo + L-NMMA|Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
223461207|NCT05022277|BEHAVIORAL|Low tech health SMS messages|Weekly health-related SMS messages are provided to adolescents.
223461208|NCT05022277|BEHAVIORAL|Low tech health Phone + SMS messages|Weekly health-related phone calls plus SMS messages are provided to adolescents.
223461209|NCT01769677|DRUG|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
223743352|NCT04768465|DRUG|Pyridostigmine, Tacrolimus|Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
223461210|NCT04986241|DRUG|Statin|Chronic use of statin prescribed previously by the assistant physician.
223461211|NCT04986241|OTHER|Physical activity|Physically active participants
223461212|NCT04986241|OTHER|Sedentary|Physically inactive or sedentary participants.
223461213|NCT05837273|DEVICE|Fully-immersive VR|For fully-immersive VR sets the highest level of immersion of VR technologies, presenting improvement in cognitive function in cognitive decline seniors. Fully immersive VR-based cognitive training also has a positive effect on psychological performance.
223461214|NCT05837273|BEHAVIORAL|Cognitive training|For the cognitive training, the therapy is a non-pharmacological approach, used for a series of standardized tasks to maintain or even increase person's cognitive function. The therapy can effectively improve multiple cognitive performance, such as: attention, reaction time (processing speed), working memory, and visual-spatial ability.
223461215|NCT04064112|PROCEDURE|S-BLR|Surgery of slanted bilateral LR recession for CI-IXT patients
223461216|NCT04064112|PROCEDURE|C-BLR|Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
223461217|NCT04616716|DRUG|FMTN|Single dose of FMTN after high-fat meal,low-fat meal and fast
223461218|NCT04521556|PROCEDURE|Epidural anesthesia with light general anesthesia|"Epidural anaesthesia: mixture of ropivacaine 6.5 mg/ml and fentanyl 8.3 μg/ml.~Light general anesthesia: isoflurane in mixture of 50/50 of nitrous oxide and oxygen to achieve Minimum alveolar concentration between 0.6 and 0.8."
223461219|NCT04521556|PROCEDURE|Postoperative epidural analgesia|Before the end of operation was given 4 ml of the mixture of ropivacaine 4.4 mg/ml and morphine 0.8mg/ml. Epidural analgesia was continued for next 24 hours with a mixture of ropivacaine 2.2 mg/ml and morphine 0.4 mg/ml.
223461220|NCT04521556|PROCEDURE|General anesthesia|"Maintaining general anesthesia: nitrous oxide and oxygen in mixture 50/50 and isoflurane to achieve minimum alveolar concentration between 0.8 and 1.~Fentanyl loading dose: 6-8 μg/kg. Additional fentanyl doses were given incrementally."
223461221|NCT04521556|DRUG|Continuous intravenous analgesia|Tramadol 100 mg in the first hour followed by tramadol 300 mg continuously for the next 24 hours.
223461222|NCT04406922|PROCEDURE|Personalized cooling protocol|As an intervention, a personalized cooling protocol will be used in order to activate BAT and induce non-shivering thermogenesis. During the cooling procedure, subjects will be exposed to mild cold (approx. 14°C) for 150 min. Since the onset temperature of shivering shows a high interindividual variation, we will use a personal cooling protocol to ensure maximum non-shivering EE (and thus an equal maximum activation of BAT). The right temperature will be determined via a subjective method, e.g. to ask the subject if he or she experiences shivering. The time needed to achieve the right temperature is approximately 30-60 minutes. Then, the stable cooling period of 90 min is started. During this time the subject will be asked every 15 minutes whether he is experiencing shivering. If so, temperature will be increased with 2-3°C so that shivering just stops.
223461223|NCT01518803|DIETARY_SUPPLEMENT|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
223461224|NCT01518803|DIETARY_SUPPLEMENT|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
223461225|NCT03865030|DEVICE|audiovestibular function|"Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~\- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness."
223575237|NCT01310959|OTHER|Database|Database
223575238|NCT04886947|PROCEDURE|stem cell transplantation|After surgical repair of alveolar cleft using gingivoperiosteoplasty, processed and stored autologous stem cells will be added at the repair site. After which the patient will be followed up for bone regeneration and this will be compared to control where no stem cell is added.
223575239|NCT00165542|OTHER|A PROTEIN level|
223575240|NCT00029757|DRUG|Estrogen|
223575241|NCT04789694|OTHER|Physiological intervention|"* Rehabilitation specialist consultation (3x)~* Individualized home-based exercise plan~* Functional capacity measuring"
223575242|NCT04789694|BEHAVIORAL|Psychological intervention|"* Clinical psychologist consultation (3x)~* Anxiety and depression scoring~* Psychological support"
223575243|NCT04789694|DIETARY_SUPPLEMENT|Nutritional intervention|"* Nutritional specialist consultation (3x)~* Malnutrition scoring~* Dietary supplementation"
223743353|NCT06799364|OTHER|28-days consumption of Product A in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Product A twice per day during 28 consecutive days.
223461226|NCT01129401|BEHAVIORAL|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
223575244|NCT03463395|DEVICE|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
223575245|NCT04911179|OTHER|Vivfrail-Cog combined multicomponent physical exercise and cognitive stimulation.|"The areas to be worked on are: Attentional system: selective attention and concentration; alternating attention / dual attention; Processing speed; perceptual organization; working memory and cognitive flexibility; comprehension, abstraction and verbal reasoning, planning, execution, and problem solving.~Four programs have been developed stimulation different difficulty levels to adapt to the capabilities of each participant."
223575246|NCT03959982|DEVICE|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
224303051|NCT04582461|DEVICE|multislice computed tomography|All patients will undergo a preoperative multiphasic multidetector CT scan before surgery.The unenhanced scan will be used to generate a CT reconstruction of the upper abdomen (from the diaphragm to the kidneys) with a 5mm thickness. Two different radiologists (D.F. and D.I.), blinded to patient information, measured total fat volume (TFV), visceral fat volume (VFV), and analyzed pixels with densities in the - 190 hounsfield units (HU) to - 20 HU range. the ratio between the density of the pancreas over the density of the spleen will be calculated and the maximum diameter of the pancreatic duct will be measured using the arterial phase in order to better identify the entire length of the duct.
223461227|NCT05688865|OTHER|urinary markers|urinary marker testing
223461228|NCT01517633|DEVICE|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
223461229|NCT04988204|BEHAVIORAL|Diabetes Prevention Program|The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
223461230|NCT00533819|OTHER|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
223461231|NCT02727738|DIETARY_SUPPLEMENT|Selenium|Selenium 80 mg bid for 90 days
223461232|NCT02727738|DRUG|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
223461233|NCT03286218|DRUG|Lasmiditan|Administered orally
223461234|NCT03286218|DRUG|Alprazolam|Administered orally
223461235|NCT03286218|DRUG|Placebo|Administered orally
223461236|NCT04553666|DRUG|Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)|800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
223461237|NCT02532374|OTHER|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
223575247|NCT03959982|DIAGNOSTIC_TEST|Spirometry|Pre and post spirometry using albuterol.
223575248|NCT03959982|DIAGNOSTIC_TEST|6-minute walk|6-minute walk
223575249|NCT03959982|DIAGNOSTIC_TEST|CT scan|CT scan
223575250|NCT03959982|OTHER|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
223575251|NCT03959982|OTHER|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
223575252|NCT03959982|OTHER|COPD Assessment Test (CAT)|CAT questionnaire
223743354|NCT06799364|OTHER|28-days consumption of Product B in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Product B twice per day during 28 consecutive days.
223743355|NCT06799364|OTHER|28-days consumption of Control product in 45 to 60-year-old healthy subjects.|48 healthy volunteers will consume Control product twice per day during 28 consecutive days.
223743356|NCT02606565|BIOLOGICAL|Intervention arm: 4% chlorhexidine|See previous description
223743357|NCT04007094|OTHER|ViviGen Cellular Bone Matrix|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10
224303052|NCT00643565|DRUG|Standard chemotherapy|As prescribed
223461238|NCT02532374|OTHER|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
223461239|NCT02068911|DEVICE|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
223461240|NCT03155711|PROCEDURE|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
223461241|NCT03155711|PROCEDURE|Standard group|Supplemental oxygen through venturi mask
223461242|NCT03164447|BIOLOGICAL|UB-421|Monoclonal antibody by IV infusion
223461243|NCT03164447|DRUG|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
223461244|NCT06102720|DRUG|Colchicine|Oral colchicine will be initiated with a dose of 0.5 mg per day during 14 days. Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).
223461245|NCT06102720|DRUG|Clopidogrel|Dual antiplatelet therapy includes ASA (300 mg on days 1 and continuing with 100 mg/day) and clopidogrel (300 mg on days 1 and continuing with 75 mg/day).
223575253|NCT03959982|OTHER|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
223575254|NCT03959982|OTHER|CASA-Q|CASA-Q questionnaire
223575255|NCT03959982|OTHER|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
223575256|NCT00758589|DRUG|AZD1981|Oral tablet, 50 mg twice daily
223575257|NCT00758589|DRUG|AZD1981|Oral tablet, 400 mg twice daily
223575258|NCT00758589|DRUG|AZD1981|Oral tablet, 1000 mg twice daily
223575259|NCT00758589|DRUG|Placebo|
223461246|NCT01979874|DIETARY_SUPPLEMENT|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
223461247|NCT01979874|OTHER|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
223461248|NCT02044757|BEHAVIORAL|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
223461249|NCT04184557|BEHAVIORAL|Staying Calm in the OR|"Staying Calm in the OR is a mindfulness-based stress-reduction smartphone tailored for people who are waiting for surgery. It consists of a free, accessible, on-demand, short training through a series of guided meditation practices. They are based on widely studied mindfulness-based programs, such as Mindfulness-Based Stress Reduction (MBSR) ir Mindfulness Self Compassion (MSC)."
223461250|NCT02931760|DEVICE|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
223575260|NCT01054521|PROCEDURE|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
223575261|NCT01054521|DEVICE|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
223575262|NCT00005048|DRUG|estramustine phosphate sodium|
223575263|NCT00005048|DRUG|paclitaxel|
223575264|NCT01422668|OTHER|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
223575265|NCT06547060|OTHER|Exercise leggings|The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
223575266|NCT02088567|PROCEDURE|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
223575267|NCT02088567|OTHER|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
223575268|NCT00238368|BIOLOGICAL|filgrastim|
223575269|NCT00238368|BIOLOGICAL|rituximab|
224303053|NCT00643565|DRUG|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
223461251|NCT02931760|DEVICE|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
223461252|NCT01493050|DRUG|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
223461253|NCT01493050|DRUG|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
224067913|NCT01696240|DRUG|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
224303054|NCT05739344|BEHAVIORAL|Cognitive behavioral approach based resilience development program for schizophrenic individuals|The intervention will be administered as sessions of 2 hours once a week.
223461254|NCT02896764|DEVICE|Cone-beam CT|
223461255|NCT02990013|DEVICE|Avenova|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
223461256|NCT02990013|DRUG|Povidone-iodine 5% solution|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
223461257|NCT02990013|DRUG|4% chlorhexidine|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
223461258|NCT02990013|DRUG|Isopropyl alcohol|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
223461259|NCT02762084|DRUG|Patidegib|
223461260|NCT02762084|DRUG|Vehicle gel|
223461261|NCT01348139|DRUG|AZD3199|Inhaled via single inhaler device (SID)
223461262|NCT01348139|DRUG|AZD3199|Inhaled via Turbuhaler inhaler
223461263|NCT01348139|OTHER|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
223461264|NCT04008225|PROCEDURE|Bronchoalveolar lavage|
223461265|NCT03190824|DRUG|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
223461266|NCT03141112|PROCEDURE|renal replacement therapy|
223461267|NCT01015326|OTHER|Questionnaire|Administered questionnaire
223575270|NCT00238368|DRUG|busulfan|
223575271|NCT00238368|DRUG|cisplatin|
223575272|NCT00238368|DRUG|cyclophosphamide|
223575273|NCT00238368|DRUG|cytarabine|
223575274|NCT00238368|DRUG|doxorubicin hydrochloride|
223575275|NCT00238368|DRUG|etoposide|
223575276|NCT00238368|DRUG|methylprednisolone|
223575277|NCT00238368|DRUG|prednisone|
223575278|NCT00238368|DRUG|vincristine sulfate|
223575279|NCT00238368|PROCEDURE|autologous bone marrow transplantation|
223575280|NCT00238368|PROCEDURE|peripheral blood stem cell transplantation|
223575281|NCT00238368|PROCEDURE|positron emission tomography|
223575282|NCT00238368|RADIATION|fludeoxyglucose F 18|
223575283|NCT00238368|RADIATION|radiation therapy|
223575284|NCT06264297|PROCEDURE|Radiofrequency|Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.
223461268|NCT01015326|OTHER|Questionnaire|Administered questionnaire
223461269|NCT02862145|DRUG|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
223461270|NCT02862145|DRUG|Dexamethasone|Premedication during the week of treatment
223461271|NCT01961414|DRUG|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
223461272|NCT01428843|DRUG|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
223461273|NCT01428843|DRUG|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
223461274|NCT00037050|DRUG|Linezolid|
223461275|NCT00037050|DRUG|Vancomycin|
223461276|NCT00037050|DRUG|Oxacillin|
223461277|NCT00037050|DRUG|Dicloxacillin|
223461278|NCT03262077|DRUG|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
223461279|NCT03262077|DRUG|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
223461280|NCT00857662|DEVICE|Onyx|Embolization
223461281|NCT00857662|DEVICE|TRUFILL|Embolization
223461282|NCT02869763|DIETARY_SUPPLEMENT|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
223575285|NCT04759469|BEHAVIORAL|High-intensity interval training|High-intensity interval training is a form of intermittent training using relatively high exercise intensity
223575286|NCT04759469|BEHAVIORAL|Moderate intensity interval training|Moderate intensity interval training is a form of intermittent training using moderate exercise intensity
223461283|NCT02869763|DIETARY_SUPPLEMENT|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
223461284|NCT02869763|DIETARY_SUPPLEMENT|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
223461285|NCT00090727|DRUG|AQ4N|
223461286|NCT04702152|BEHAVIORAL|Targeted memory reactivation (sounds)|I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
223461287|NCT02576262|PROCEDURE|TCT，HPV，colposcopic inspection|
223461288|NCT01781962|OTHER|No Treatment|No Treatment was given in this study.
223575287|NCT06013189|OTHER|Gas Flow Adjustment|Decreased gas flow causes PaCO2 to elevate and prevents alkalosis
223575288|NCT01243827|DRUG|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
223461289|NCT03984344|DEVICE|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
223461290|NCT03984344|DEVICE|Continuous Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
223575289|NCT01243827|DRUG|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
223575290|NCT03913195|DRUG|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
223575291|NCT05901324|RADIATION|intensity-modulated radiotherapy (IMRT)|1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.
224067914|NCT01696240|DRUG|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
223461291|NCT03984344|DEVICE|Sham Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
223461292|NCT05380245|DRUG|Voriconazole 200 mg x 2 Tablets|Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).
223461293|NCT05380245|DRUG|Clarithromycin 500 mg x 1Tablets|Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
223461294|NCT04806022|OTHER|Fatigability assessment|Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
223461295|NCT02525016|BIOLOGICAL|Blood sampling|
223461296|NCT02525016|DRUG|Lidocaine|
223461297|NCT03049826|OTHER|Nutritional status|Body composition and nutrient status
223461298|NCT01809756|OTHER|Caphosol|Caphosol 4 times a day
223461299|NCT03565354|DRUG|iron isomaltoside(Monofer®)|intravenous iron isomaltoside
223461300|NCT01765296|DRUG|CG100649|2 mg capsule
223461301|NCT01765296|DRUG|Celecoxib|200 mg capsule
223461302|NCT01765296|DRUG|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
223461303|NCT06314386|OTHER|Systems Analysis and Improvement Approach for TB (SAIA-TB)|The Systems Analysis and Improvement Approach for TB (SAIA-TB) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by clinic staff with support from study personnel in intervention clinics. Components of the intervention include TB cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally optimize TB screening, evaluation, diagnosis, TB preventive therapy and TB disease treatment initiation, successful treatment, and TB-free survival among the population at the intervention clinics.
223461304|NCT01619852|DRUG|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
223461305|NCT01619852|DRUG|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
223461306|NCT00707044|PROCEDURE|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
223461307|NCT00707044|PROCEDURE|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
223461308|NCT05934006|BIOLOGICAL|spot urine samples|No intervention, but measurement of urinary iodine concentration by 6 repeated spot urine samples
223461309|NCT04358016|DRUG|Terlipressin|Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
223461310|NCT04358016|DRUG|Somatostatin|Somatostatin
223461311|NCT02541344|DEVICE|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
223461312|NCT02541344|DEVICE|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
223461313|NCT02541344|DEVICE|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
223575292|NCT01113034|DRUG|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
223575293|NCT01113034|DRUG|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
223575294|NCT00053807|BIOLOGICAL|aldesleukin|
223575295|NCT00053807|BIOLOGICAL|recombinant interferon alfa|
223575296|NCT00053807|DRUG|fluorouracil|
223575297|NCT00053807|PROCEDURE|adjuvant therapy|
223575298|NCT04631965|BEHAVIORAL|Transition support service|The hospital-wide transition support service provides systematic care coordination for young patients prior to the transfer of care
223575299|NCT06530888|OTHER|Process-based Cognitive Behavioral Therapy (PBT)|Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
223575300|NCT06530888|OTHER|Routine practice (r-PT)|Intervention planning as usual.
223575301|NCT06764771|DRUG|BMS-986488|Specified dose on specified days
223575302|NCT06764771|DRUG|Adagrasib|Specified dose on specified days
223461314|NCT05370898|DRUG|Caltrate D|Caltrate D is allowed for basic treatment when the patient is diagnosed with primary osteoporosis (Kidney Yang Deficiency Syndrome).Take it continuously for 3 months.
223461315|NCT05370898|DRUG|Chinese medicine prescription|The Chinese medicine application prescription is composed of Rhizoma Drynariae 12g, psoralen 10g, dog ridge 10g, medlar 10g, raw oyster 10g, ginseng 6g, Panax notoginseng 3g, Amomum villosum 6g.Patients take 200ml each time, twice a day. Treatment duration are 3 months.
223461316|NCT05370898|DRUG|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 3 months.
223461317|NCT05122689|DIETARY_SUPPLEMENT|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
223461318|NCT05122689|DIETARY_SUPPLEMENT|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
223461319|NCT02376686|OTHER|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
223461320|NCT03933449|BIOLOGICAL|pembrolizumab|IV infusion
223461321|NCT03933449|DRUG|paclitaxel|IV infusion
223461322|NCT03933449|DRUG|docetaxel|IV infusion
223461323|NCT03933449|DRUG|irinotecan|IV infusion
223461324|NCT06519916|BEHAVIORAL|Assessment of mental performance|There was no intervention, the mental performance was assessed
223461325|NCT02659943|BIOLOGICAL|Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|Dose-escalation trial starting dose: 0.66x10\^6 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
223461326|NCT02659943|DRUG|Cyclophosphamide|300 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
223575303|NCT06764771|DRUG|Cetuximab|Specified dose on specified days
223575304|NCT06764771|DRUG|Nivolumab|Specified dose on specified days
223575305|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 40 units
223575306|NCT05320393|DRUG|OnabotulinumtoxinA|One treatment of 20 units
223575307|NCT05320393|DRUG|PrabotulinumtoxinA-Xvfs|One treatment of 20 units
223575308|NCT01488292|BEHAVIORAL|RECAP social skills and reading program|weekly individual and group sessions
223575309|NCT02517632|BEHAVIORAL|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
223575310|NCT02517632|BEHAVIORAL|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
223575311|NCT06503380|OTHER|No intervenrion.|This study will respect the medication choices of researchers in the study, without specifying which medication to choose for treatment, dosage, mode of administration (including single drug, combination therapy, or sequential therapy), and duration of administration.
223575312|NCT04379115|DEVICE|Active Comparator: Active tDCS + Active TUS|"Device: Active comparator device: Active transcranial Direct Current Stimulation (tDCS). Subjects will receive 20 minutes of active tDCS. During each Active stimulation session, stimulation will be applied for the full 20 minutes.~Device: Active comparator device: Active Transcranial Ultrasound (TUS). Subjects will receive 20 minutes of active Transcranial Ultrasound (TUS). During active stimulation the (TUS) will be active for the full 20 minutes."
223461327|NCT02659943|DRUG|Fludarabine|30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
223461328|NCT00345124|BEHAVIORAL|high sodium diet|250-350 mmol
223575313|NCT04379115|DEVICE|Sham Comparator: Sham tDCS + Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of sham tDCS. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of sham TUS. During sham stimulation the ultrasound will not be active for the full 20 minutes."
223575314|NCT05951959|DRUG|Acalabrutinib|Investigational Product
223575315|NCT05951959|DRUG|Venetoclax|Investigator Product
223575316|NCT05951959|DRUG|Rituximab|Investigator Product
223461329|NCT00345124|BEHAVIORAL|Low Sodium Diet|25-35 mmol
223461330|NCT01359930|OTHER|placebo|matching placebo
223461331|NCT01359930|DRUG|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
223461332|NCT03705702|OTHER|Education Program|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.
223461333|NCT03705702|BEHAVIORAL|Behavioral intervention|The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
223461334|NCT02463669|DEVICE|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
223575317|NCT02525614|DEVICE|Triathlon Standard Keel|Implantation of Knee Prosthesis
223461335|NCT02198196|BEHAVIORAL|Weight Talk-Mindfulness|
223575318|NCT02525614|DEVICE|Triathlon Short Keel|Implantation of Knee Prosthesis
223575319|NCT05964335|DRUG|NAL ER|Oral tablets
223575320|NCT05964335|DRUG|Placebo|Oral tablets
223461336|NCT01474850|PROCEDURE|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
223461337|NCT01576575|DRUG|Buprenorphine Control|Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
223461338|NCT01576575|DRUG|Buprenorphine + Rifampin|Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
223575321|NCT05964335|DRUG|NAL ER|Oral Tablets
223461339|NCT01576575|DRUG|Buprenorphine + Grapefruit juice|Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
223575322|NCT05964335|DRUG|NAL ER|Oral tablets
223461340|NCT01576575|DRUG|Buprenorphine + Ketoconazole|Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
223461341|NCT01321034|DRUG|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
223575323|NCT05693922|DEVICE|Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Delta-beta stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
223575324|NCT05693922|BEHAVIORAL|Single-session behavioral activation|"Participants will take part in a single-session behavioral activation (BA) intervention. This intervention was adapted from standard BA protocols for the treatment of depression to be completed in a single, 90-minute session. This intervention will have 4 main components based on prior protocols:~* Treatment overview and rationale~* Tracking of daily activities~* Exploration of values~* Planning/scheduling activities"
223575325|NCT05693922|DEVICE|Active sham cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC|Active sham stimulation will be delivered via the NeuroConn DC-STIMULATOR MC, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
223575326|NCT03383757|DEVICE|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
223575327|NCT02248207|DRUG|Pramipexole|
223575328|NCT00650026|BIOLOGICAL|adalimumab|40 mg adalimumab every other week
223575329|NCT03559699|DRUG|AG-348|"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
223461342|NCT03971331|DEVICE|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
223461343|NCT05649670|OTHER|Mobile Stroke Unit deployment|Deployment of an MSU + conventional ambulance, allowing prehospital CT-scan imaging with intracranial CT angiography. This will allow prehospital intravenous thrombolysis and optimal triage (i.e. accurate identification of patients with large vessel occlusion, who are eligible for mechanical thrombectomy).
223575330|NCT00238784|DRUG|Budesonide/formoterol Turbuhaler|
223575331|NCT02571660|DRUG|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
223575332|NCT02571660|DRUG|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
223575333|NCT01502150|OTHER|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
223575334|NCT01502150|OTHER|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
223461344|NCT05562245|OTHER|Motivational Interviewing-Based Breastfeeding Education|"Motivational interviewing is basically a directive and client-centered psychosocial intervention used to help individuals discover and analyze ambivalent emotions related to their health behaviors, to learn new skills and to improve their existing skills. One of the main guiding principles in motivational interviewing is self-support and empowerment. The interviews consist of one to four sessions lasting between 7.5-60 minutes.~A total of four motivational interviews will be held with the mothers in the experimental group."
223461345|NCT03400527|OTHER|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
223461346|NCT01670864|BEHAVIORAL|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week \& 1-month will be made to the participants in this group.
223461347|NCT01670864|BEHAVIORAL|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
223461348|NCT04270812|BEHAVIORAL|Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)|"TranS-C adopts a modular approach to reversing the psychosocial, behavioral, and cognitive processes maintaining sleep problems via 4 cross-cutting modules (introduced in the first session and included in every session thereafter), 4 core modules and 7 optional modules. TranS-C typically involves 6-8 individual, weekly 50-minute sessions."
223461349|NCT05122611|OTHER|no intervention, imaging study only|Imaging study only
223461350|NCT06551896|DRUG|Pemigatinib|Pemigatinib and immune checkpoint inhibitors
223461351|NCT01723072|BIOLOGICAL|Omalizumab|Humanized monoclonal antibody against human IgE
223461352|NCT01723072|DRUG|Placebo|Placebo to omalizumab
223461353|NCT02785211|BEHAVIORAL|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
223461354|NCT01418469|DIETARY_SUPPLEMENT|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
223461355|NCT01418469|DIETARY_SUPPLEMENT|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
223461356|NCT01418469|DIETARY_SUPPLEMENT|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
223461357|NCT01418469|DIETARY_SUPPLEMENT|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
223461358|NCT03511703|DRUG|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
223461359|NCT03511703|DRUG|Chemotherapy drugs+Iodized oil|Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
223461360|NCT03362762|OTHER|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
223461361|NCT04001088|DIETARY_SUPPLEMENT|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
223575335|NCT03502304|BEHAVIORAL|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
223461362|NCT04001088|OTHER|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
223461363|NCT02671253|PROCEDURE|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
223461364|NCT01753882|DRUG|Lexapro|Agent + training vs Placebo + training
223461365|NCT01753882|DRUG|Placebo|Agent + training vs Placebo + training
223461366|NCT03428100|DRUG|Baricitinib|Administered orally.
223461367|NCT03428100|DRUG|Placebo|Administered orally.
223461368|NCT03428100|DRUG|Topical corticosteroid|Administered as standard-of-care.
223461369|NCT04664257|BEHAVIORAL|e-CBT|e-CBT will be administered with weekly modules. See arm/group descriptions for more information.
223461370|NCT03854721|DRUG|VAX014|Solution for intravesical infusion, 3.33x10\^10 rBMCs per vial
223461371|NCT04556760|DRUG|AZD9567|Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
223461372|NCT04556760|DRUG|Prednisolone|Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
223461373|NCT04556760|OTHER|Placebo|Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
223461374|NCT05673356|PROCEDURE|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)|Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
223461375|NCT05116436|PROCEDURE|Blood sample|It will test the presence or absence of genetic mutations found in other cohorts in previous studies.
223461376|NCT05116436|PROCEDURE|Spine X-ray|To determine the scoliosis
223461377|NCT03286920|DIETARY_SUPPLEMENT|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
223461378|NCT03286920|DIETARY_SUPPLEMENT|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
223461379|NCT05399199|PROCEDURE|virtual reality distraction|study group patients will view VR scene for 6 minutes before puncture .It involves a soothing nature experience and calming background music. Patients in intervention group will not able to see the puncture procedure due to the VR glasses.
223461380|NCT03278496|BEHAVIORAL|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
223461381|NCT03278496|BEHAVIORAL|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
223461382|NCT03278496|BEHAVIORAL|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
223461383|NCT02873767|DRUG|PR1|"* Active substance: UCB4019~* Route of Administration: subcutaneously"
223461384|NCT02873767|OTHER|PL1|"* Active substance: Placebo~* Concentration: 0.9 % saline~* Route of Administration: subcutaneously"
223461385|NCT03089463|DIAGNOSTIC_TEST|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
223575336|NCT01932255|PROCEDURE|prophylactic spinal tap|
223575337|NCT01932255|PROCEDURE|no prophylactic spinal tap|
223575338|NCT03353103|DRUG|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
223461386|NCT04564911|COMBINATION_PRODUCT|Flash Glucose Monitoring and Education|Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
223461387|NCT04564911|COMBINATION_PRODUCT|Capillary glucose monitoring and Education|Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
223461388|NCT06213987|DRUG|0.025% Tretinoin|Total duration of 8 weeks.
223461389|NCT06136468|BEHAVIORAL|Virtual coach|The virtual coch will be displayed to the participants using an optical see-through head-mounted display
223461390|NCT02979821|DRUG|Poziotinib|A cycle of study treatment is defined as 28 days.
223461391|NCT05340335|DRUG|Remimazolam|A beginning dose of remimazolam is 1mg/kg/hr. When sedation is not achieved in 10 minutes, the dose will be increased by 0.1mg/kg/hr in the next patient. When sedation is successful, the same dose will be used with the probability of 0.89, or the dose will be decreased by 0.1mg/kg/hr with the probability of 0.11 in the next patient. (maximal dose: 2mg/kg/hr)
223461392|NCT00400075|DRUG|azathioprine|
223461393|NCT00400075|DRUG|cyclophosphamide|
223461394|NCT04633746|DIAGNOSTIC_TEST|measuring plasma Endostatin level|measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
223461395|NCT04604834|OTHER|PFAT first|Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
223461396|NCT04604834|OTHER|APRP first|Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
223461397|NCT06391424|DIAGNOSTIC_TEST|Spontaneous Breathing Trial|Patients will undergo an SBT to determine whether they are ready for extubation.
223461398|NCT01047280|DIETARY_SUPPLEMENT|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
223461399|NCT01047280|DIETARY_SUPPLEMENT|Safflower oil|3.5 g/d of safflower oil
223461400|NCT01047280|DIETARY_SUPPLEMENT|G-c9, t11|3.5 g/day of c9, t11 CLA
223461401|NCT00954681|DRUG|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
223575339|NCT04627181|DRUG|Ferric carboxymaltose|Single dose of ferric carboxymaltose (Encicarb, Emcure Pharmaceuticals Ltd., Pune, India) 500 mg administered intravenously in 100 ml normal saline over 1 hour via the dialysis blood line immediately following HD
224303055|NCT02317614|BEHAVIORAL|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
223461402|NCT01954589|DRUG|ACT-462206 5 mg|
223575340|NCT04627181|DRUG|Hydroxycobalamin|Single dose of hydroxycobalamine (Trineurosol Hp, Tridoss Laboratories, Mumbai, India) 1000 mcg administered intramuscularly in the deltoid of the non-fistula arm immediately following HD
223461403|NCT01954589|DRUG|ACT-462206 25 mg|
223461404|NCT01954589|DRUG|ACT-462206 100mg|
223461405|NCT01954589|DRUG|ACT-462206 200mg|
223461406|NCT01954589|DRUG|ACT-462206 400mg|
223461407|NCT01954589|DRUG|ACT-462206 1000 mg|
223461408|NCT01954589|DRUG|ACT-462206 1500mg|
223461409|NCT01954589|DRUG|Almorexant 400mg|
223461410|NCT01954589|DRUG|Placebo|
223461411|NCT01759706|BEHAVIORAL|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
223461412|NCT01759706|PROCEDURE|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
223461413|NCT01759706|DRUG|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
223461414|NCT01759706|OTHER|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
223575341|NCT04627181|DRUG|Placebo|Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
223575342|NCT04627181|DRUG|Placebo|Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
223575343|NCT04699812|DEVICE|ELECTROCARDIOGRAM (ECG) PATCH WEAR|ALL PARTICIPANTS WILL WEAR AN ECG PATCH ON THEIR UPPER LEFT CHEST THROUGHOUT THE STUDY PARTICIPATION
223461415|NCT01759706|DRUG|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
223575344|NCT05393414|DRUG|Opioid based protocol|Use of combination of drug dosage frequency and duration of morphine injection with percocet oral as standard postoperative pain control for up to 72 hours as requested by each patient
223575345|NCT05393414|DRUG|Opioid sparing protocol|Use of combination of drug dosage frequency and duration of ketorolac injection with acetaminophen oral as standard postoperative pain control for up to 72 hours as requested by each patient
223575346|NCT05438602|DRUG|Nirmatrelvir|Participants will receive 2 tablets of nirmatrelvir every 12 hours
223575347|NCT05438602|DRUG|Ritonavir|Participants will receive 1 capsule of ritonavir every 12 hours
223575348|NCT05438602|DRUG|Placebo for nirmatrelvir|Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
223575349|NCT05438602|DRUG|Placebo for ritonavir|Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
223575350|NCT03406416|DEVICE|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
223575351|NCT02036736|DRUG|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~* Sufentanil (0.15 mg / kg intravenously (IV))~* Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
223575352|NCT02036736|DRUG|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~* Sufentanil (0.15 mg / kg IV)~* Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 \<BIS \<60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
223575353|NCT05932264|DRUG|Apatinib + Fluzoparib|Cohort 1: Apatinib 375 mg po qd; Fluzoparib 100mg po bid
223575354|NCT05932264|DRUG|Apatinib + Fluzoparib + Adebrelimab|Cohort 2: Apatinib 375 mg po qd; Fluzoparib 100mg po bid; Adebrelimab 1200mg, iv, d1, q3w\]
223575355|NCT00348114|PROCEDURE|Transplantation of cultivated limbal epithelium|
223575356|NCT02462408|PROCEDURE|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
223575357|NCT02462408|PROCEDURE|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
223575358|NCT01012752|BIOLOGICAL|modified allergen extract|subcutaneous injections
223575359|NCT01012752|BIOLOGICAL|Placebo|subcutaneous injections
223575360|NCT01930890|BIOLOGICAL|BIIB023|
223575361|NCT01930890|DRUG|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
224157001|NCT06070636|PROCEDURE|bTAE-HAIC|bTAE procedure was a 2.8-F microcatheter was superselectively inserted into the tumor feeding artery using the coaxial technique. Then blank microspheres were used according to the tumor blood supply vessels (40-120um, 100-300um, 300-500um, 500-700um). The microcatheter was reserved at the proper/left/right hepatic artery according tumor location. After the patient returned to the ward, the following FOLFOX-based regime was intra-arterially administered through the microcatheter. The FOLFOX regimen was administered via the hepatic artery as follows: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1, and 400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
224157002|NCT06070636|DRUG|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
224157003|NCT06070636|DRUG|Sintilimab|200mg intravenously every 32 weeks
224157004|NCT04694820|OTHER|Text Message-Based Navigation Intervention|Receive txt4TKI
224157005|NCT04694820|OTHER|Survey Administration|Ancillary studies
224157006|NCT01001572|DRUG|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
223461416|NCT01759706|DRUG|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
223461417|NCT01759706|BEHAVIORAL|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
223461418|NCT01759706|DRUG|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
223461419|NCT01877200|OTHER|No treatment given|Patients will fill out a questionnaire by interview.
223461420|NCT05528172|DRUG|Ripasudil|K-321 ophthalmic solution
223575362|NCT01930890|DRUG|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
223575363|NCT01278407|DRUG|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
223575364|NCT01278407|DRUG|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
223575365|NCT01278407|DRUG|Donepezil matched placebo|
223575366|NCT05216003|BEHAVIORAL|PATH4YOU|PATH4YOU offers patient-center, comprehensive, contraceptive counseling; pregnancy planning; and same to next day access to birth control. This clinical care program will reduce obstacles to contraception in Indiana and enables access to healthy pregnancy planning conversations.
223575367|NCT05883943|DEVICE|Cook® Venous Valve System|The Cook® Venous Valve is a permanent prosthetic, bicuspid, one-way flow valve designed to be percutaneously implanted into the peripheral deep venous system. The Cook® Venous Valve Delivery System is used to percutaneously deliver the Cook® Venous Valve into the deep venous system.
223575368|NCT04427995|DEVICE|OMNI surgical system|GATT + viscodilation
223575369|NCT06258486|DRUG|ICG injection|Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
223461421|NCT05528172|DRUG|Placebo|Placebo ophthalmic solution
223461422|NCT04307862|DRUG|ZEP-3Na 0.1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
223461423|NCT04307862|DRUG|ZEP-3Na 1%|The Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase, with optional 2 weeks of open label with ZEP-3Na 1%.
223461424|NCT04307862|DRUG|Placebo Vehicle only|he Investigational Product will be applied topically twice daily for up to 4 weeks in the double blind phase
223461425|NCT02168491|DRUG|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
223461426|NCT02168491|DRUG|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
223575370|NCT06258486|OTHER|Non-Injection/Control|No ICG injection
223575371|NCT06258486|PROCEDURE|Prostatectomy with pelvic lymph node dissection|Robotic assisted prostatectomy with pelvic lymph node dissection
223575372|NCT04735198|PROCEDURE|Primary tumor surgery|Large bowel resection.
223575373|NCT04735198|PROCEDURE|Primary tumor surgery (bowel resection) combined with prophylactic cholecystectomy|Large bowel resection combined and cholecystectomy.
223575374|NCT02241876|DRUG|N-acetylcysteine|
223575375|NCT00693641|OTHER|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
223575376|NCT00693641|OTHER|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
223575377|NCT02534935|BIOLOGICAL|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
223575378|NCT02534935|BIOLOGICAL|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
223575379|NCT04666831|BEHAVIORAL|Adapted Motivational Interviewing (AMI) and Cognitive Behavioural Therapy (CBT)|The intervention combines AMI techniques as described by Miller and Rollnick (2013) in the third edition of their Motivational Interviewing book, as well as CBT techniques from the Tele-CBT protocol for bariatric surgery patients by Cassin et al. (2013).
223575380|NCT01460719|BIOLOGICAL|V212|V212 viral antigen for HZ
223461427|NCT02303639|PROCEDURE|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
223461428|NCT02303639|DRUG|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
223743358|NCT02921776|OTHER|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~* Tell me you are tired~* Tell me you are having pain~* Rate this pain~* Tell me there is pain in your back~* Tell me your pain is sharp~* Ask to see the doctor~* Write your favorite color by drawing with your finger~* Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
223461430|NCT03624491|OTHER|Esophageal pressure measurement guided ventilation|Use of esophageal pressure measurements to guide mechanical ventilation
223461431|NCT02996721|BIOLOGICAL|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
223575381|NCT06100094|OTHER|semi-structured qualitative interviews|"During the interview, a list of semi-open questions will be asked :~* What were your expectations/state of mind before the group?~* How would you describe your experience overall?~* If you had to describe the group how would you do it?~* Between two group sessions, how did it go for you?~* What do you think of the group ultimately?~Interviews will be carried out until data saturation.~Collection of socio-demographic data (age), medical history and criminal history in the patient's file"
223743359|NCT02921776|OTHER|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
223461432|NCT05772676|DRUG|Aprepitant|80 or 125 mg tablet + standard antiemetic regimen, once two hours before surgery
223461433|NCT05772676|OTHER|Placebo|Placebo + standard antiemetic regimen, once two hours before surgery
223461434|NCT05728736|DRUG|Lemborexant 25 mg|Lemborexant 25mg will be taken nightly for two consecutive nights.
223461435|NCT05728736|DRUG|Placebo|Placebo will be taken nightly for two consecutive nights
223461436|NCT04592016|DRUG|Voltaren - Diclofenac sodium gel 1% (GSK, USA)|Topical application in dermal-sampling visit
223575382|NCT02253823|DRUG|EFV|
223575383|NCT02253823|DRUG|TPV/RTV - low dose|
223575384|NCT02253823|DRUG|TPV/RTV - high dose|
223461437|NCT04592016|DRUG|Pennsaid 2 % Topical Solution (Horizon Therapeutics, USA)|Topical application in dermal-sampling visit
223461438|NCT04592016|DRUG|Diclofenac sodium gel 1% (Perrigo, USA)|Topical application in dermal-sampling visit
223461439|NCT04592016|DEVICE|Dermal open flow microperfusion - Pilot|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 24 hours post-dose.
223461440|NCT04592016|DEVICE|Dermal open flow microperfusion - Pivotal|Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess diclofenac concentration in the dermis. Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose.
223461441|NCT04592016|PROCEDURE|Blood sampling - Pilot|1 sample is taken pre-dose and 24 samples are taken post-dose.
223461442|NCT04592016|PROCEDURE|Blood sampling - Pivotal|1 sample is taken pre-dose and 12 samples are taken post-dose.
223461443|NCT03335800|DEVICE|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
223461444|NCT05143684|PROCEDURE|Left Lateral Uterine Displacement|a wooden wedge wrapped with cotton, to make it comfortable, and medical sheets with a measured angle of 15° under the right flank of the laying down patient
223575385|NCT06081413|PROCEDURE|bariatric surgery|bariatric surgeries - sleeve gastrectomy, roux-en-Y gastric bypass, one anastomosis gastric bypass, adjustable gastric band
223743360|NCT02921776|DEVICE|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
224157007|NCT01001572|DRUG|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
224157008|NCT01001572|DRUG|Placebo|1 capsule or tablet taken orally once daily
224157009|NCT02772224|DEVICE|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
223461445|NCT00180089|DRUG|Budesonide|
223461446|NCT00380536|BEHAVIORAL|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
223461447|NCT02691546|OTHER|blood sample collection|
223461448|NCT01610037|DRUG|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
223461449|NCT01610037|DRUG|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
223461450|NCT01610037|DRUG|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
223461451|NCT02824835|PROCEDURE|biopsy during colonoscopy|sampling the lesion with forcept biopter
223461452|NCT03573596|DRUG|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
223461453|NCT00705757|DRUG|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
223461454|NCT00705757|DRUG|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
223461455|NCT00705757|DRUG|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
223461456|NCT01644721|BIOLOGICAL|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
223461457|NCT03217292|PROCEDURE|Serratus Anterior Plane Block|
223575386|NCT03542916|DRUG|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
223575387|NCT03542916|DRUG|NESP 60ug|NESP 60ug SC, IV injection
223575388|NCT05512702|DRUG|Tissue Plasminogen Activator, Alteplase|Reduced dose (50 mg) Alteplase is used for the patients in the thrombolytic treatment group.
223575389|NCT05512702|DRUG|Low-molecular weight heparin|Patients in the anticoagulation treatment group receive this treatment and do not receive thrombolytic treatment.
223575390|NCT00549185|DRUG|SAR3419|Intravenous infusion
223743361|NCT02921776|OTHER|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
224157010|NCT02772224|DEVICE|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
224157011|NCT05265793|DRUG|Camrelizumab Combined With Apatinib|After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
224157012|NCT06104891|DIETARY_SUPPLEMENT|Recharge Placebo Control 1|Participants will use their Radicle Recharge Placebo Control 1 as directed for a period of 5 hours.
224157013|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 1|Participants will use their Radicle Recharge Active Study Product 1 as directed for a period of 5 hours.
224157014|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 2|Participants will use their Radicle Recharge Active Study Product 2 as directed for a period of 5 hours.
223461458|NCT03217292|DRUG|IV patient-controlled analgesia (PCA) tramadol|
223461459|NCT04113941|DRUG|Neuronox|intradetrusor injection
223461460|NCT04113941|DRUG|Placebo|intradetrusor injection
223461461|NCT06336421|OTHER|Virtual Reality|"VR Box brand virtual reality glasses were used in primiparous pregnant women undergoing cesarean section.~During the cesarean section, the researcher showed the pregnant woman in the experimental group a video accompanied by music and baby pictures using virtual reality glasses for an average of 10 minutes."
223461462|NCT05321420|DRUG|Placebo|placebo
223461463|NCT05321420|DRUG|Pirfenidone|pirfenidone 801 mg TID
223461464|NCT05321420|DRUG|Deupirfenidone|Deupirfenidone
223461465|NCT02202304|DRUG|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
223461466|NCT00971477|OTHER|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
223461467|NCT00971477|OTHER|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
223461468|NCT01484080|DRUG|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
223461469|NCT01484080|DRUG|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
223461470|NCT00413543|OTHER|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
223461471|NCT05532423|DRUG|Beetroot Juice - Active|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This juice will be the active juice, meaning it has the high nitrate content that is of interest. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
224157015|NCT06104891|DIETARY_SUPPLEMENT|Recharge Active Study Product 3|Participants will use their Radicle Recharge Active Study Product 3 as directed for a period of 5 hours.
224157016|NCT01958554|BEHAVIORAL|Intervention Group|
224157017|NCT03652545|BIOLOGICAL|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
224157018|NCT02597192|OTHER|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
224157019|NCT02597192|OTHER|oral hygiene products without Bacillus|products without Bacillus
224157020|NCT00964600|PROCEDURE|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
224157021|NCT00643799|DRUG|Celecoxib|200 mg oral capsule once daily for 6 months
224157022|NCT00643799|DRUG|Naproxen|500 mg oral capsule twice daily for 6 months
224157023|NCT00643799|DRUG|Placebo|Matched oral placebo for 6 months
224157024|NCT01094808|DRUG|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
224157025|NCT01094808|DRUG|Placebo|Placebo capsules
223461472|NCT05532423|DRUG|beetroot juice - Placebo|Participants with Metabolic syndrome will drink 140mL of organic nitrate rich beetroot juice from the James White Beet It Company. This drink will be the placebo drink, which means all of the nitrate has been extracted, however it tastes and smells the same as the active drink. This drink will be given two 70 mL bottles of the juice that will be blinded to them and investigators.
223461473|NCT03817944|OTHER|Warm Water|300 mL Warm Water per day for 8 weeks
223461474|NCT03817944|OTHER|Caffeinated Coffee|300 mL Caffeinated Coffee per day for 8 weeks
223461475|NCT03817944|OTHER|Decaffeinated Coffee|300 mL Decaffeinated Coffee per day for 8 weeks
223461476|NCT04758351|OTHER|Usual clinical practice|Based on European Respiratory Society guidelines on management for chronic cough.
223461477|NCT05377372|BEHAVIORAL|Breastfeeding support group|community-based breastfeeding support group aimed to increase exclusive breastfeeding success rates among Black women
223461478|NCT05377372|OTHER|Observation|Observe prospectively for breastfeeding initiation, duration and longitudinal health of child with sickle cell disease
223461479|NCT01411852|DRUG|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
224157026|NCT01094808|OTHER|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
224157027|NCT02474914|DRUG|Octreotide|Octreotide will be given after PD
224157028|NCT02474914|DRUG|Placebo|Octreotide will NOT be given after PD
224157029|NCT03127436|DRUG|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
224157030|NCT01481506|PROCEDURE|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
223461480|NCT01411852|DRUG|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
223461481|NCT06010602|PROCEDURE|Quadratus lumborum block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
223461482|NCT06010602|PROCEDURE|İlioinguinal-İliohipogastric nerve block|For all patients, postoperative analgesia was planned as paracetamol 1g four times a day for the first 24 hours after surgery. Patients with Numeric Rating Scale (NRS) scores greater than 3 at 2, 4, 8, 12, and 24 hours postoperatively were administered rescue analgesia with tramadol hydrochloride at a dose of 1mg/kg.
223461483|NCT06047756|OTHER|Hippotherapy|Patient will perform different movement of the trunk while sitting on a horse.
223461484|NCT06047756|OTHER|Swiss Ball therapy|Patient will perform movements of trunk on swiss ball
223461485|NCT01698970|OTHER|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
223461486|NCT01698970|OTHER|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
223461487|NCT03887182|DIAGNOSTIC_TEST|functional MRI|Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
223461488|NCT03887182|DIAGNOSTIC_TEST|Automated Cortical Brainstem Auditory Evoked Potential|Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
223461489|NCT03887182|GENETIC|whole exome sequencing|A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
223461490|NCT03887182|DIAGNOSTIC_TEST|Standard Cortical Brainstem Auditory Evoked Potential|Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
223461491|NCT03887182|DIAGNOSTIC_TEST|multidisciplinary consultation|"multidisciplinary consultation is composed of:~* an ENT consultation and audiometry~* a speech therapy assessment~* a psychometric evaluation"
223461492|NCT00467428|DRUG|NS2359|
223575391|NCT06507514|COMBINATION_PRODUCT|"blinatumomab and auto-HSCT sandwich  strategy"|The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
223575392|NCT01151761|PROCEDURE|Stereotactic Body Radiotherapy|Standard of care
223461493|NCT00467428|DRUG|Placebo|
223461494|NCT05643391|RADIATION|Radioembolization using Holmium-166|This technic consists of the intra-arterial infusion of smaller beads that are loaded with a radioactive isotope (yttrium-90), and it relies on the beta radiation emitted by the isotope to induce tumor necrosis, with a minor contribution from microembolization and without risk of ischemia of the remaining liver.
223461495|NCT01328938|BIOLOGICAL|GCPGC 3.6mg|Stage I:Single blinded
223461496|NCT01328938|BIOLOGICAL|GCPGC 6mg|Stage I: Single blinded;
223461497|NCT01328938|BIOLOGICAL|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
223461498|NCT01328938|BIOLOGICAL|GCPGC 6mg|Experimental: Stage II
223461499|NCT02372994|OTHER|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
223461500|NCT06438887|DIETARY_SUPPLEMENT|Placebo|Corn-Starch Maltodextrin
223461501|NCT06438887|DIETARY_SUPPLEMENT|Creatine monohydrate|Creatine
223575393|NCT01151761|DRUG|Gemcitabine|100 mg/m2, IV
223575394|NCT01151761|DRUG|Cisplatin|25 mg/m2, IV
223575395|NCT01151761|DRUG|Carboplatin|AUC 2, based on Calvert formula, IV
223575396|NCT01151761|DRUG|Capecitabine|1000 mg/m2, PO
223575397|NCT01151761|DRUG|5FU|200 mg/m2
223575398|NCT01151761|PROCEDURE|Liver transplantation|
223575399|NCT03093636|DEVICE|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
223575400|NCT03093636|OTHER|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
223575401|NCT01113346|DRUG|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
223461502|NCT04642482|DIETARY_SUPPLEMENT|Synbiotic (Rillus)|Participants in this group will be given a fine powder of synbiotic formula and should be taken orally without diluted with water.
224157031|NCT00646750|DRUG|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
224157032|NCT02020928|DEVICE|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
223461503|NCT04642482|DRUG|Placebo|Participants in this group will be given a fine powder of maltodextrin formula and should be taken orally without diluted with water.
223461504|NCT05489107|OTHER|Ziverel|Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.
223461505|NCT04724785|OTHER|only monitoring|monitoring the viraemia only
223461506|NCT04724785|OTHER|monitoring and regimen change if necessary|if those patients agree, the regimen will be changed.
223461507|NCT04724785|DRUG|regimen change|Based on ongoing one, regimen will be changed . The principle for adjusting anti-viral regimen is as follows: 1. The patients were treated with second-line drugs: changing ADV to ETV/TAF/TDF , changing LAM to TAF/TDF and changing LdT to TAF/TDF; 2. The patients were treated with ETV: adding or switching to TAF/TDF;3. TAF or ETV is recommended for patients with one or more TDF risk factors, such as \> 40 years old, patients with abnormal bone/kidney related indicators or patients with high risk of bone/kidney injuries.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
223461508|NCT03743025|DRUG|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
223461509|NCT03743025|OTHER|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
223461510|NCT05306847|DRUG|Sintilimab|Sintilimab will be given intravenously at a dose of 200mg every 21 days.
223461511|NCT05306847|DRUG|Anlotinib|Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
223461512|NCT00374348|DRUG|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
223461513|NCT02144038|DRUG|LGH447|pan-PIM inhibitor
223461514|NCT02144038|DRUG|BYL719|PI3K-alpha inhibitor
223461515|NCT05876884|DEVICE|Celsi Warmer Mattress|The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time
223461516|NCT04832256|DEVICE|Radical-7 Pulse CO-Oximeter|COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
223461517|NCT03289767|OTHER|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
223461518|NCT05061147|DRUG|MAX-40279-01|"Drug: AZA AZA will be administered at 75 mg/m\^2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.~Other Name: Azacitidine~Drug: Max-40279-01 Max-40279-01 will be administered as a combination of multiple oral capsules containing 5 and 25 mg. An alternate combination of 35 mg, 50 mg and 60 mg Max-40279-01 twice a day may be utilized.~Other Name: NA"
223461519|NCT02420119|OTHER|non interventional|
223461520|NCT00807885|DRUG|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
223461521|NCT00503893|BEHAVIORAL|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
223461522|NCT00503893|OTHER|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
223461523|NCT02236312|DRUG|Botulinum Toxin Type A|
223461524|NCT02236312|DRUG|Placebo|
223461525|NCT04797988|DEVICE|eon® FR 1064 nm device|The subject will be treatment area - flanks, will be treated with the eon device.
223461526|NCT04909515|DRUG|Naxitamab|3.0 mg/kg/day = 9.0 mg/kg/cycle
223461527|NCT04909515|DRUG|GM-CSF|250 - 500 microgram/m2/day
223461528|NCT04909515|DRUG|Isotretinoin|160 mg/m2/day
223461529|NCT01366313|DRUG|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
223461530|NCT01366313|DRUG|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
223575402|NCT01113346|DRUG|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
223461531|NCT01366313|DRUG|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
223461532|NCT00524251|DRUG|esomeprazole|
223461533|NCT05625724|DRUG|Aspirin|Experimental drug administrated orally
223461534|NCT05625724|DRUG|Placebo|Treatment for the control group
223461535|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
223461536|NCT03704831|OTHER|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
224157033|NCT00565357|DEVICE|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
224157034|NCT00565357|OTHER|Control|Standard care in the neonatal intensive care unit
224303056|NCT06162130|DIAGNOSTIC_TEST|Eccentric quadriceps exercises|The activation of the vastus medialis, vastus lateralis, and rectus femoris muscles will be measured using surface electromyography (sEMG) during four distinct quadriceps eccentric exercises: Reverse Nordic, Pistol squat, Suspension-based Bulgarian split squat, and Bulgarian split squat. Participants will be instructed to perform three successful repetitions for each exercise. A 30-second break will be provided between each repetition, and there will be a minimum of 10 minutes of rest between each of the four exercises. Due to the belief that fatigue could impact exercise performance, the modified Borg scale will be used to ensure that fatigue does not occur before each exercise. Exercise recording will commence when scores reported using the modified Borg scale are 1 or lower.
224303057|NCT06405217|DRUG|Recombinant Human Thyroid Stimulating Hormone|Recombinant human thyroid stimulating hormone injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days
224303058|NCT04763694|DEVICE|Multifocal soft contact lenses|Myopic subjects wore multifocal soft contact lenses for 12 months
224303059|NCT00673244|DRUG|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
224303060|NCT01011179|BEHAVIORAL|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
224303061|NCT01011179|BEHAVIORAL|Self-Management|"Adolescents' own best efforts at managing their JIA"
224303062|NCT02667015|BEHAVIORAL|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
224303063|NCT00669071|DRUG|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
224303064|NCT00669071|DRUG|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
224303065|NCT00556023|DRUG|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
224303066|NCT00360737|BIOLOGICAL|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from pooled plasma obtained from horses that have been immunized against one of seven botulinum antitoxins (A-G). .
224303067|NCT04178161|DEVICE|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
224303068|NCT04059224|DRUG|Trametinib|Trametinib 2 mg once a day by mouth.
224303069|NCT04059224|DRUG|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
224303070|NCT03809988|DRUG|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
224303071|NCT03809988|DRUG|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
224303072|NCT03659097|PROCEDURE|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
224303073|NCT03966482|BEHAVIORAL|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
223461537|NCT02356952|BEHAVIORAL|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
223461538|NCT02356952|BEHAVIORAL|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
223461539|NCT02356952|BEHAVIORAL|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
223461540|NCT04710875|DRUG|Na-lactate|intravenous
224157035|NCT05104788|DRUG|Icotinib|Oral
223461541|NCT04710875|DRUG|Sodium chloride|Intravenous
223461542|NCT00306046|DRUG|Bisphosphonate treatment|
223743362|NCT04343950|BEHAVIORAL|SMS reminders to enhance colorectal cancer screening|Individual randomization will be used. Individuals assigned to the experimental arm with a wrong phone number will get a reminder letter (protocol analysis).
224157036|NCT05104788|DRUG|Cisplatin|Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.
224157037|NCT05104788|DRUG|Carboplatin|Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles
224157038|NCT05104788|DRUG|Pemetrexed|Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles
224157039|NCT03358004|DRUG|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
224303074|NCT04339920|DIAGNOSTIC_TEST|Spermine Measuring Device|The Spermine Measuring Device (SMD) is a simple device, with automatic urine aspiration and also spermine level assessment. First about 30 cc urine will be freshly collected by a prepared collection device. Then the cap of the SMD will be removed and the aspiration tip of the device will be immersed into the urine specimen. After firmly pressed on the device, a small sample of urine will be aspirated into the SMD. The device will then automatically assess the urine spermine level. The result will then be read at a indicator window after about 5 minutes. If the level was below a pre-set cutoff, i.e. suggestive of having increase risk of prostate cancer, the indicator window will turn into red colour. However, if the spermine level is higher than the cutoff value, i.e. low risk of having cancer, the indicator window will turn blue.
224303075|NCT01720199|OTHER|Diario della Salute (DDS)|"DDS is composed by~1. tools for children and their parents on health and social and emotional well-being issues:~   1. a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~  2. a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~2. five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
224303076|NCT02773199|OTHER|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
224157040|NCT03358004|DRUG|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
224157041|NCT03534791|OTHER|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
224157042|NCT05778357|OTHER|Group1|75 healthy infants were included. Neuromotor development was evaluated with the Denver II Developmental Screening Test and Alberta Infant motor scale.
224303077|NCT02773199|OTHER|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
224303078|NCT02773199|DRUG|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
224157043|NCT06263790|DEVICE|Intubating laryngeal mask|Intubation through a laryngeal mask
224157044|NCT06263790|DEVICE|Direct laryngoscopy|Intubation by using a direct laryngoscope
224157045|NCT00369278|DRUG|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
224303079|NCT00663832|DRUG|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
224303080|NCT02876926|BEHAVIORAL|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
224303081|NCT02876926|BEHAVIORAL|Home-based testing only|A standard home-based HIV test kit.
224157046|NCT01224106|DRUG|Gantenerumab|Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.
224157047|NCT01224106|DRUG|Placebo|Participants received Placebo SC injection Q4W.
224157048|NCT02019758|DRUG|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
224157049|NCT02019758|DRUG|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
224303082|NCT02876926|BEHAVIORAL|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
224303083|NCT00939120|DRUG|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
224303084|NCT00939120|DRUG|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
224303085|NCT00939120|DRUG|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
224303086|NCT01674413|DRUG|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
223743363|NCT04343950|BEHAVIORAL|SMS reminders to return the fecal immunochemical test at the pharmacy in CRC screening:|Individual randomization will be used. Individuals with a wrong phone number assigned to the experimental arm will not get any reminder (protocol analysis).
224157050|NCT02019758|DRUG|Placebo slurry|Slurry of sucralose - 4 mL twice daily
224157051|NCT02019758|DRUG|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
224157052|NCT00446797|DRUG|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
224157053|NCT00446797|DRUG|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
224157054|NCT00943410|RADIATION|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
224157055|NCT00943410|DRUG|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
224157056|NCT05994495|DIAGNOSTIC_TEST|nuclear acid amplification tests|The NAAT test will be performed with Bosch Vivalytic STI test. It is a qualitative Polymerase Chain Reaction-based assay for simultaneous detection of 10 common sexually transmitted pathogens: Herpes simplex virus 1 (HSV 1)- Herpes simplex virus 2 (HSV 2)- Chlamydia trachomatis (CT) - Haemophilus ducreyi (HD)- Mycoplasma genitalium (MG) - Mycoplasma hominis (MH) - Neisseria gonorrhoeae (NG) - Treponema pallidum (TP)- Ureaplasma urealyticum (UU) - Trichomonas vaginalis (TV)
224157057|NCT05994495|OTHER|Clinical Syndromic Approach|Physical examination
224157058|NCT04171167|DRUG|Fluticasone Propionate|three visits: 0, after washout, after FP usage
224303087|NCT01674413|DRUG|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool."
223461543|NCT04919148|BEHAVIORAL|Heat risk and pro-environment behavior message|Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
223461544|NCT01158937|DRUG|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
223461545|NCT04773821|OTHER|Targeted biopsies|Prostate MpMRI at 12 month (after PCa focal treatment in standard care) and targeted biopsies in the presence of lesion(s) suggestive(s) of recurrence
223461546|NCT04714645|DEVICE|VR neglect training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. The training consists of 5 different VR tasks specifically designed for neglect training.
223743364|NCT04343950|BEHAVIORAL|Invitation by SMS to previous participants in breast cancer screening:|Individual randomization. Women assigned to the experimental arm and with a wrong phone number will get an invitation letter (protocol analysis).
223743365|NCT03975829|DRUG|dabrafenib|dabrafenib oral, twice daily
223743366|NCT03975829|DRUG|trametinib|trametinib oral, once daily
224157059|NCT03138291|DEVICE|Somnodent|Each pregnant women will be treat with a Somnodent
224157060|NCT02703649|DRUG|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
224157061|NCT06392178|DEVICE|SugarVita|Serious digital game (application) that can be played on mobile phone, tablet or personal computer. Self-developed game.
224157062|NCT05865756|OTHER|Acoustic cough features analysis|Acoustic cough features analysis
224157063|NCT05983679|DIAGNOSTIC_TEST|Blood sample|Blood sample
224303088|NCT01674413|DRUG|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
224303089|NCT00916136|PROCEDURE|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
224303090|NCT02593513|DEVICE|Daifert|
224303091|NCT02593513|PROCEDURE|Control Group|Control - Morphological Assessment
224303092|NCT05393505|DRUG|Meropenem Injection|Given if patient has no known allergies at 1 g IV bolus within 1 hour of ED registration, then every 8 hours
223461547|NCT04714645|DEVICE|VR control training|Patients will undergo 1 session a day for 30 minutes for 5 consecutive days. This is a placebo training, where patients will also wear the HMD. Patients will be immersed in a virtual environment without a specific task.
223461548|NCT00889655|DRUG|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
223743367|NCT06824506|OTHER|No-intervention|No interventions will be performed by the research team.
224157064|NCT03948594|DIETARY_SUPPLEMENT|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
224157065|NCT03948594|OTHER|plain water|250ml plain water
224157066|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners are blinded to each other and to the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
224157067|NCT06000215|DIAGNOSTIC_TEST|Perineal/introital ultrasound examination, two different examiners. The examiners is now being informed of the previous prolapse surgery.|"Each examiner to answer:~1. Is there a mesh or not: Yes or No~2. If Yes:~   * Which type of mesh? Uphold, Pinnacle Posterior or Artisyn® Y-Shaped Mesh~  * What is the length of the mesh in a single midsagittal view image~3. Examination record time is to be registered."
224157068|NCT01548209|DRUG|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
224157069|NCT01548209|DRUG|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
224157070|NCT00748111|OTHER|Blood sample|Blood sample and thrombus sample
224157071|NCT01829867|DRUG|sNN0031|
224157072|NCT03455634|DEVICE|Twin Block|functional appliances for the stimulation of the mandibular growth
224157073|NCT03455634|DEVICE|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
224157074|NCT02314169|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224157075|NCT02314169|PROCEDURE|Computed Tomography|Undergo CT scan
224157076|NCT02314169|BIOLOGICAL|Ipilimumab|Given IV
224157077|NCT02314169|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224157078|NCT02314169|BIOLOGICAL|Nivolumab|Given IV
224303093|NCT05393505|DRUG|Levofloxacin|Given if patient is allergic to beta lactam at 500 g IV in 100 mL 0.9% sodium chloride solution, infused over 1 hour started within 1 hour of ED registration, then every 24 hours. If the patient can tolerate oral drugs, 500 mg daily after the first IV dose.
224303094|NCT05393505|DRUG|Amoxicillin Clavulanate|Given if patient has no known allergies at 1.2 g IV bolus within 1 hour of ED registration, then every 8 hours. If the patient can tolerate oral drugs, 1 g twice daily after the first IV bolus.
224303095|NCT05393505|DRUG|Antibiotic|"Any antibiotic for empirical therapy of common infections as recommended by the fifth version of Hospital Authority Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) guideline, with reference to previous bacterial sensitivity pattern"
224303096|NCT02972177|PROCEDURE|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
224303097|NCT02972177|PROCEDURE|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
224303098|NCT03255512|DRUG|Vericiguat (BAY1021189)|2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
224303099|NCT03255512|DRUG|Placebo|Matching placebo
224303100|NCT03255512|DRUG|Isosorbide mononitrate (ISMN)|30 mg/tablet or 60 mg/tablet
224303101|NCT00110162|DRUG|antiandrogen therapy|
224303102|NCT00110162|DRUG|releasing hormone agonist therapy|
223461549|NCT00889655|DRUG|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
223461550|NCT03126786|DRUG|IVT aflibercept|IVT aflibercept \[2 mg/0.05 mL\]
223461551|NCT03126786|DRUG|Sham SC|sham SC
224157079|NCT04464798|DRUG|CC-220|Oral
224157080|NCT04464798|DRUG|Rituximab|SC and IV infusion
224157081|NCT04464798|DRUG|Obinutuzumab|IV Infusion
224157082|NCT05746533|PROCEDURE|Hip Arthroscopy|Hip Preservation surgeries
223461552|NCT03126786|DRUG|SC CLS-TA|CLS-TA \[4 mg/100 μL\] SC injection
223461553|NCT00228839|DRUG|Infliximab|
223461554|NCT03234803|OTHER|poly-amide|new denture base material
223461555|NCT03234803|OTHER|poly-methyl methacrylate|gold standard for denture base materials
223461556|NCT04428840|DEVICE|Self-measurement kiosk|Use of the self-measurement kiosk, with results forwarded to the triage nurse screens
223461557|NCT05030532|BEHAVIORAL|EVERYbody Project|Brief behavioral group intervention (4 hours across two meetings)
223461558|NCT05030532|OTHER|Video + Expressive Writing|Brief video-based group intervention (4 hours across two meetings)
223575403|NCT06410521|BEHAVIORAL|Exercise|Patients randomised to the intervention arm will undergo non-consecutive training sessions three times a week for a period of 12 weeks. The training session is divided into an aerobic and a resistance training component, with a 5-min warm-up (stretching exercises) and a 5-min cool-down (stretching and relaxing exercises). The cardiovascular component will comprise a progressive exercise duration from 30 to 40 minutes, an exercise intensity promoting moderate to severe claudication pain between 8-12 minutes, with rest time until the pain disappears, and a personalised load progression manipulated based on the claudication pain level, reaching a total of 60 minutes of walking per session. The resistance training component will comprise dynamic muscle contraction exercises (Leg extension, unilateral hip extension, and standing calf raise), with a load progression from 50% of 1-estimated one repetition maximum (e-RM) to 80% of 1-eRM.
223575404|NCT06410521|BEHAVIORAL|Usual care|Patients randomised to the active comparator arm will be advised about the importance of lifestyle modification (including general advice to increase walking but without specific recommendations about the exercise program) for a period of 12 weeks.
224157083|NCT05364437|DIETARY_SUPPLEMENT|Dietary Fibres Supplement|The dietary fibres supplement, which comprises of a mix of dietary fibres (inulin, pectin and oat beta-glucan) will need to be taken by participants twice daily for 2 weeks with their usual food.
224157084|NCT05364437|DIETARY_SUPPLEMENT|Cellulose Control|The control, which comprises of cellulose will need to be taken by participants twice daily for 2 weeks with their usual food.
224157085|NCT05947318|DEVICE|transcranial alternating current stimulation 70 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 70 Hz"
224157086|NCT05947318|BEHAVIORAL|Training|Training of the upper limb with specific kinematic and kinetic tasks plus functional training
224303103|NCT00110162|PROCEDURE|orchiectomy|
224303104|NCT04962984|PROCEDURE|blood sampling|additional blood sampling for coagulation tests
223461559|NCT02602314|DRUG|Imatinib|
223461560|NCT02602314|DRUG|Nilotinib|
223461561|NCT00227539|DRUG|cisplatin|
223461562|NCT00227539|DRUG|pemetrexed disodium|
223461563|NCT00227539|PROCEDURE|adjuvant therapy|
223461564|NCT00227539|PROCEDURE|therapeutic conventional surgery|
223461565|NCT00227539|RADIATION|fludeoxyglucose F 18|
223461566|NCT01954238|DRUG|GCC-4401C|"* Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
223461567|NCT01954238|DRUG|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
223461568|NCT01954238|DRUG|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
223461569|NCT00991289|DRUG|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
223461570|NCT00991289|DRUG|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
223461571|NCT00991289|DRUG|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
223461572|NCT02250339|OTHER|LAKU family program|Multi-systemic and multicomponent family-based intervention program
223461573|NCT02250339|OTHER|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
223461574|NCT02250339|OTHER|Family therapy|Treatment as usual (TAU)
223461575|NCT00426764|DRUG|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
223461576|NCT02412176|PROCEDURE|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
223461577|NCT02412176|PROCEDURE|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
224303105|NCT02251691|DRUG|Advagraf|Compare the drug compliance between once daily or twice daily regimen
224303106|NCT02251691|DRUG|Prograf|Compare the drug compliance between once daily or twice daily regimen
224303107|NCT03712982|BEHAVIORAL|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
223461578|NCT04780672|DRUG|Molixan|The investigational drug in this study is Molixan in the dosage form of 30 mg/ml solution for intravenous and intramuscular injection. Against the background of standard therapy: Molixan® at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
223461579|NCT04780672|DRUG|Placebo|Placebo will be used as a comparator drug and will be an analogue of the investigational drug without active substance. Against the background of standard therapy: Placebo at a dose of 3.0 mg/kg per day is administered once intravenously (stream injection) with 0.9% sodium chloride solution at a volume ratio of 1:1 for 10 days.
223461580|NCT03307941|DRUG|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
223461581|NCT03307941|DRUG|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
223461582|NCT03307941|DRUG|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
223461583|NCT03307941|RADIATION|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
223461584|NCT03307941|OTHER|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
223575405|NCT01478841|DRUG|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
223575406|NCT01478841|DRUG|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
223575407|NCT00076336|DRUG|Telbivudine|600mg/day oral tablet for 104 weeks
223575408|NCT00076336|DRUG|Lamivudine|100mg/day oral tablet for 104 weeks
223575409|NCT00076336|DRUG|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
223575410|NCT02838901|DRUG|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
223461585|NCT03307941|PROCEDURE|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
223461586|NCT02404610|PROCEDURE|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
223461587|NCT02404610|PROCEDURE|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
223575411|NCT02838901|DRUG|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
223575412|NCT02849782|DRUG|Fampridine|Oral intake of 10 mg twice daily
223575413|NCT02110329|GENETIC|evaluation of the recurrence rate according to molecular analysis|
223575414|NCT05642143|DIAGNOSTIC_TEST|Dual Energy X-ray Absorbtiometry scan|Evaluation of body composition and bone mass density
223575415|NCT05642143|DIAGNOSTIC_TEST|High-resolution peripheral quantitative computed tomography|High-resolution peripheral quantitative computed tomography (HR-pQCT) assesses both volumetric bone mineral density (vBMD) and trabecular and cortical microarchitecture.
223575416|NCT05642143|DIAGNOSTIC_TEST|Microindentation|Measures Bone Material Strength Index (BMSi) of cortical bone.
223575417|NCT05642143|DIAGNOSTIC_TEST|Thermal perception thresholds|Heat and cold perception thresholds
223575418|NCT05642143|DIAGNOSTIC_TEST|Nerve conduction studies|Nerve conduction and amplitude of sural nerve
223575419|NCT05642143|DIAGNOSTIC_TEST|Composite Autonomic Symptom Score 31|A validated self-assessment questionnaire quantifying the severity and distribution of autonomic symptoms across six domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder and pupillomotor functions) by scoring 31 clinically selected questions
223575420|NCT05642143|DIAGNOSTIC_TEST|Skin biopsies with quantification of intra-epidermal nerve fibre density|Skin biopsy
223575421|NCT05642143|DIAGNOSTIC_TEST|Perception Threshold Tracking|Transcutaneous stimulation of large and small nerve fibres using weak electrical currents
223575422|NCT05642143|DIAGNOSTIC_TEST|Assessment of cardiovascular autonomic neuropathy|Electrocardiographic recordings at rest and during cardiovascular autonomic reflex tests.
223575423|NCT05642143|DIAGNOSTIC_TEST|Handgrip strength|Evaluation of muscle strength
223575424|NCT05642143|DIAGNOSTIC_TEST|Force plate platform|Evaluation of balance while standing still
223461588|NCT02404610|DRUG|propofol|
223461589|NCT06149572|PROCEDURE|lateral position procedure|Lateral positioning will be used as an intervention for spinal hypotension.
223461590|NCT06149572|PROCEDURE|sitting position porocedure|parturients will get spinal punctures in the sitting position
223575425|NCT05642143|DIAGNOSTIC_TEST|Biospecimen collection|Biochemistry including bone turnover markers, glycemic status, inflammation markers i.e
223575426|NCT05642143|DIAGNOSTIC_TEST|Isometric leg extension strength|Evaluation of muscle strength
223575427|NCT05642143|DIAGNOSTIC_TEST|Michigan Neuropathy Screening Instrument|MNSI is used to assess status of peripheral neuropathy. It includes two separate assessments: a 15-item self-administered questionnaire and a lower extremity examination that includes inspection and assessment of vibratory sensation and ankle reflexes.
223575428|NCT02441348|BEHAVIORAL|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
223575429|NCT03287674|DRUG|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
223575430|NCT03287674|DRUG|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
223461591|NCT05360407|OTHER|Using mobile information application about before and after surgery|"The mobile application had three sections: Information forum (I), Personal forum (notebook and reminder) (II) and Ask the Researcher (messaging) (III). The information forum (Figure 2) is a section that enables patients to access related articles, pictures, and videos. The personal forum is a section that allows patients to create their notes and use the necessary reminders. Ask the researcher section allows patients to communicate with the researcher via messages.~The participants could download the mobile application with the name Breast Cancer Surgery Information Guide from the Google Play Store and install it on their phones. Users who were authenticated by the researcher were able to access the content with an e-mail and password."
223461592|NCT06523049|DRUG|Vorolanib Tablets|Multi-targeted receptor tyrosine kinase inhibitor with potent inhibition of VEGFR2, KIT, PDGFR, FLT3 and RET, exerting anti-tumor effects mainly through inhibition of neovascularization.
223461593|NCT06523049|DRUG|Sintilimab Injection|Recombinant human-derived immunoglobulin G (IgG4)-type anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, by binding to PD-1 and blocking PD-1 binding to PD-L1 and PD-L2, disarms the immunosuppressive effect, activates T-cell function, and enhances T-cell immunosurveillance and killing ability against tumors to generate tumor immune response.
223461594|NCT01701804|DRUG|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
223461595|NCT01701804|PROCEDURE|Chuna manual therapy|A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
223461596|NCT01701804|PROCEDURE|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.
223461597|NCT01701804|PROCEDURE|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
223461598|NCT00013871|BIOLOGICAL|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
223461599|NCT00013871|BIOLOGICAL|Measles-Mumps-Rubella Vaccine (Live)|
223461600|NCT00013871|BIOLOGICAL|Pneumococcal Vaccine, Polyvalent (23-valent)|
223575431|NCT03287674|BIOLOGICAL|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
223575432|NCT03287674|DRUG|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
223575433|NCT03287674|DRUG|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
224157087|NCT05947318|DEVICE|transcranial alternating current stimulation 7 Hz|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The frequency stimulation will be 7 Hz"
224303108|NCT03712982|BEHAVIORAL|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
223461601|NCT00013871|BIOLOGICAL|Pneumococcal Conjugate Vaccine, Heptavalent|
223461602|NCT00013871|BIOLOGICAL|Hepatitis B Vaccine (Recombinant)|
223461603|NCT03695263|BEHAVIORAL|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
223461604|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
223461605|NCT02074293|DRUG|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
223461606|NCT02074293|DRUG|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
223461607|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223575434|NCT03287674|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
223575435|NCT01538940|BIOLOGICAL|Intradermal vaccine|15ug
223575436|NCT01538940|BIOLOGICAL|Intramuscular vaccine|15ug
223575437|NCT03630744|OTHER|Fluid therapy|"* Analyze the type of fluid administered:~  * crystalloids:~    * Saline serum 0.9% ....... ml~   * Ringer Lactate ........ ml~   * Isofundin ® ........ ml~   * Plasmalyte® ... ... ml~   * Glucose Serum 5% ....... ml~   * Glucose serum 10% ........ ml~ * Glucosaline serum ........ ml~ * colloids:~    * Hydroxyethyl starch 130 / 0.4 ... ... ml~   * Hydroxyethyl alimdon 130 / 0.42 ... .... ml~   * Gelatins ... ....... ml~   * Albumin 5% .......... ml~ * Albumin 20% .......... ml.~* Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~* Analyze the form of administration:~  * Standard~ * Standard with dosimeters~ * on pump"
223743368|NCT05230615|DRUG|Oral semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223743369|NCT06982599|DIETARY_SUPPLEMENT|postbiotics|3 capsules/day postbiotics (20 × 10\^9 CFU/day) for 8 weeks
223461608|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
223461609|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
223461610|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461611|NCT02074293|DRUG|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461612|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461613|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461614|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461615|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461616|NCT02074293|DRUG|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
223461617|NCT02074293|DRUG|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
223461618|NCT02074293|DRUG|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
223461619|NCT00532532|DRUG|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
223461620|NCT00532532|DRUG|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
223461621|NCT00532532|DRUG|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
223461622|NCT01340755|PROCEDURE|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
223461623|NCT05923918|DRUG|PBK_M2101 2-Day|Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
223461624|NCT05923918|DRUG|PBK_M2101 1-Day|Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
223461625|NCT05923918|DRUG|Oral Sulfate Tablet 2-Day|Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
223461626|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Experimental|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.2% ropivacaine), intermittent boluses of 10 mL 0.2% ropivacaine per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
223575438|NCT04677816|DRUG|Standard of Care Neoadjuvant Chemotherapy (NAC)|"Participants will receive standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles. Doxorubicin and cyclophosphamide (AC) may be administered on a classical every 3 week or dose dense every 2-week (with growth factor support) schedule at the treating physician's discretion. Routine incorporation of carboplatin is not required, however use of carboplatin (AUC 1.5 to 2 weekly or AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the treating investigator's discretion.~Upon completion of neoadjuvant chemotherapy, all patients will undergo definitive surgery with either breast conservation or mastectomy with axillary lymph node staging. Type of surgery will be determined by the treating physician."
223575439|NCT04677816|DIETARY_SUPPLEMENT|Vitamin D3|Participants with deficient levels of vitamin D will receive vitamin D supplementation at the initiation of chemotherapy with 50,000 IU of oral vitamin D3 (cholecalciferol) once a week to be continued for 20 weeks during neoadjuvant chemotherapy.
223575440|NCT04677816|OTHER|Drug Diary|Participants that will receive Vitamin D will be asked to fill out a drug diary on a daily basis. Compliance and feasibility will be assessed through a drug diary and pill counts at set time points.
223575441|NCT00118352|BIOLOGICAL|alemtuzumab|Given IV
223743370|NCT06982599|DIETARY_SUPPLEMENT|placebo|3 capsules/day placebo for 8 weeks
223743371|NCT06606899|DRUG|Melatonin 3 MG|Oral syrup melatonin 3 mg
223461627|NCT06028126|PROCEDURE|Intermittent Superficial Parasternal Intercostal Plane Block - Sham|"Catheter insertion will be performed by an anesthesiologist with regional block training immediately following skin closure in the operating room. Catheters will be inserted under ultrasound guidance, in a sterile fashion, with a high-frequency linear transducer which will be placed 1 cm lateral to the sternal border in the longitudinal plane in order to view the T4-T5 intercostal space. A Tuohy needle will be used to enter the superficial parasternal intercostal plane, with saline being injected to help visualize the plane between the pectoralis major and intercostal muscles. Subsequently, the catheters will be advanced into the plane, and secured on the skin.~Following initial bolus dosing at the time of catheter placement (20 mL 0.9% Saline), intermittent boluses of 10 mL 0.9% Saline per side will be delivered via catheters q6-8 hours for 48 hours post-catheter insertion."
223461628|NCT05329857|DRUG|Metformin and Vildagliptin 1000/50 mg|50 mg Vildagliptin + 1000 mg Metformin as single-dose per study period
223461629|NCT03037515|DRUG|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
223461630|NCT03804268|OTHER|Vehicle|Vehicle, one drop in each eye, once daily, for up to 30 days.
224157088|NCT05947318|DEVICE|transcranial alternating current stimulation Sham|"Transcranial alternating current stimulation in the head above the motor cortex area of one side of the brain, according to the hemiparesis side.~Electrodes with 3.14 cm2 of stimulation area will be used, therefore, the initial current intensity will be 0.21 mA, with a current density of 0.07 mA / cm2. The current intensity will be adjusted to the tactile sensory threshold and phosphenes of each patient, with in order to reduce such sensory effects, but considering that the decrease in current will not be greater than 10% of the initial intensity, in order to obtain a comparable configuration between subjects.~The stimulation will be turn on for 30 seconds (at 70 Hz)"
223461631|NCT03804268|DRUG|Pilocarpine HCl Ophthalmic Solution|Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
223461632|NCT04915560|DEVICE|Connected T-shirt|Ware of a connected T-shirt
223461633|NCT03585972|BEHAVIORAL|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
223461634|NCT06156605|PROCEDURE|Sidelying lumbar manipulation|R sided lumbar manipulation
223461635|NCT03158610|DRUG|Capecitabine|Oral fluorouracil
223461636|NCT02362893|OTHER|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
223461637|NCT05315648|PROCEDURE|anesthesia approach (general anesthesia or non-general anesthesia)|patients in group GA received general anesthesia followed with FNB. patients in group NGA received CSEA followed with FNB
223575442|NCT00118352|RADIATION|total-body irradiation|Undergo low-dose TBI
223575443|NCT00118352|DRUG|fludarabine phosphate|Given IV
223575444|NCT00118352|DRUG|cyclosporine|Given PO or IV
223575445|NCT00118352|DRUG|mycophenolate mofetil|Given PO
223575446|NCT00118352|PROCEDURE|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
223461638|NCT02716779|DRUG|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton \[KD\]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
223575447|NCT00118352|PROCEDURE|peripheral blood stem cell transplantation|Undergo PBSCT
223575448|NCT00118352|BIOLOGICAL|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
223575449|NCT00118352|OTHER|laboratory biomarker analysis|Correlative studies
223575450|NCT05600816|DEVICE|Pounce Venous Thrombectomy System|The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.
223575451|NCT01224821|BIOLOGICAL|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
223575452|NCT04337736|OTHER|Physical exercise|
224157089|NCT04236479|BIOLOGICAL|BM-MSC|Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.
223575453|NCT00136240|BEHAVIORAL|Computer Assisted Education for Behavior Change|
224157090|NCT03551626|DRUG|Dabrafenib|Supplied as dabrafenib 50 mg and 75 mg capsules for oral administration
223575454|NCT04133896|DIAGNOSTIC_TEST|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
224157091|NCT03551626|DRUG|Trametinib|Supplied as trametinib 0.5mg, and 2.0mg tablets for oral administration
223575455|NCT00623545|DRUG|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
223575456|NCT06585904|DIETARY_SUPPLEMENT|1 dose of Beetroot juice intake|The volunteer will ingest 1 dose of beetroot juice containing 400mg of inorganic nitrate for 10 days.
223575457|NCT06585904|OTHER|Exercise|The volunteer will perform moderate aerobic exercise for 10 consultative days on a cyclergometer.
223575458|NCT06592495|DRUG|Period 1|DWJ1589 or DWC202315
223575459|NCT06592495|DRUG|Period 2|DWJ1589 or DWC202315
223461639|NCT02716779|DRUG|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
223461640|NCT02716779|DRUG|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning \[=2 tablets\] and 600 mg in the evening \[=3 tablets\]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
223461641|NCT00658892|BIOLOGICAL|B7-DC cross-linking antibody rHIgM12B7|
223461642|NCT00658892|OTHER|flow cytometry|
223461643|NCT00658892|OTHER|immunologic technique|
223461644|NCT00658892|OTHER|laboratory biomarker analysis|
223461645|NCT05524454|DEVICE|Novel CBCT Imaging|One or two CBCT images are acquired on the novel CBCT imaging system.
223461646|NCT01156805|OTHER|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
223461647|NCT02931786|DRUG|propofol|propofol, midazolam and atropine administration via intravenous cannula.
223461648|NCT02931786|DRUG|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
223461649|NCT00601315|DRUG|Clarithromycin|
223461650|NCT01843803|OTHER|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
223461651|NCT01843803|OTHER|attention control|Patients will view a brief healthy living video on an iPad
223461652|NCT04917614|DEVICE|Transcutaneous Electrical Acupoint Stimulation|Transcutaneous Electrical Acupoint Stimulation
223461653|NCT05205304|DRUG|D'Oxyva|The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
223461654|NCT00107757|DRUG|GW685698X|
223575460|NCT06592495|DRUG|Period 3|DWJ1589 or DWC202315
223575461|NCT06592495|DRUG|Period 4|DWJ1589 or DWC202315
223575462|NCT06607510|OTHER|Experimental HIIT|Subjects belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. This program is designed in a standardized warm-up: joint mobility exercises and neuromuscular activation (5 minutes). Main part os the training is design in treadmill walking exercise (28 minutes). Participants must complete four four-minute blocks at an intensity of 85-95% of peak heart rate.The initial starting speed is 5 km/h and adjust the intensity with incline increments of 2%. Between sets, a prescribed active rest period lasts three minutes, during which patients walk on the treadmill at an intensity of 60-70% of peak heart. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
223743372|NCT06606899|DRUG|Chloral Hydrate|Oral chloral hydrate (50 mg/kg, maximum 2 g)
223461655|NCT03790852|DRUG|KSI-301|Intravitreal injection
223461656|NCT00985972|BEHAVIORAL|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
223461657|NCT04734808|DIAGNOSTIC_TEST|Electroencephalography|Electroencephalography is an electrophysiological monitoring method to record electrical activity of the brain.
223461658|NCT04734808|DIAGNOSTIC_TEST|Electromyography|Electromyography is an electrodiagnostic medicine technique for evaluating and recording the electrical activity produced by skeletal muscles. We will use the hdEMG version.
223461659|NCT03048669|OTHER|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
223461660|NCT04387461|BIOLOGICAL|CG0070|Engineered Oncolytic Adenovirus
223461661|NCT04387461|BIOLOGICAL|Pembrolizumab Injection|Immune checkpoint inhibitor, Monoclonal antibody
223461662|NCT04387461|OTHER|n-dodecyl-B-D-maltoside|Transduction-enhancing agent.
223461663|NCT05598749|DIETARY_SUPPLEMENT|Placebo|Arabic gum, sucrose and silicon dioxide mix
223461664|NCT05598749|DIETARY_SUPPLEMENT|Verum|Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
223461665|NCT04713930|DRUG|JNJ-61393215|JNJ-61393215 will be administered orally.
223743373|NCT06606899|DRUG|Sevoflurane|Inhalational Sevoflurane
223743374|NCT06987058|DRUG|RVU120|RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
223743375|NCT06409767|OTHER|Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7.|The calculation of NEWS requires vital signs such as respiratory rate, peripheral oxygen saturation, need for oxygen therapy, body temperature, arterial pressure, heart rate, and level of consciousness. Each parameter used to calculate the NEWS will be collected least three times a day by the attending nurse.
223461666|NCT04713930|DRUG|Placebo|Placebo will be administered orally.
223461667|NCT03339414|OTHER|collect blood|collect blood at different time point
223461668|NCT06058611|OTHER|Cognitive stimulation|Cognitive stimulation through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
223743376|NCT06589804|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223743377|NCT06589804|BIOLOGICAL|Cetuximab|Given IV
223461669|NCT06058611|OTHER|Stimulating leisure activities|"Intervention group 2 (IG2) will perform between 2 and 5 cognitively stimulating leisure activities for 8 weeks. These leisure activities will be selected from the adapted version of the Karp et al. 2006 questionnaire (Karp et al., 2006) taking into account the three components of leisure activities (mental, physical and social). The questionnaire contains 29 activities.~In addition to indicating which cognitively stimulating leisure activities they perform on a weekly basis, participants in IG2 will indicate their daily frequency (\< 30 min, 30min-1 hour, 1-2 hours, \> 2 hours), commenting on whether they have carried them out individually or in a group. It will also be taken into account whether these activities were previously carried out according to their stage of life."
223461670|NCT04028063|DRUG|Balstilimab|Balstilimab (AGEN2034) is a human monoclonal antibody that targets programmed cell death 1 (PD-1). Engagement of PD-1 by its ligands, programmed death ligand (PD-L1) and PD-L2, leads to signal transduction that inhibits important aspects of T cell function including proliferation, cytokine production and cytolytic activity. Balstilimab (AGEN2034) potently inhibits PD-1 binding to PD- L1 and PD- L2 and is intended to reverse the immunosuppressive effects of this signaling pathway in the context of tumor immuno-surveillance by T cells. Balstilimab (AGEN2034) is intended for development as a treatment for advanced malignancies as a single agent or in combinations.
223461671|NCT04028063|DRUG|Zalifrelimab|Zalifrelimab (AGEN1884) is a fully human monoclonal immunoglobulin G1 κ subclass (IgG1κ) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152). Zalifrelimab (AGEN1884) is being developed as a monotherapy for cancer indications with potential for future development in combination with other immunotherapies.
223461672|NCT04028063|DRUG|Doxorubicin|Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
223461673|NCT04028063|DRUG|Botensilimab|Botensilimab (AGEN1181) is a novel, human, fragment-crystallizable (Fc)-engineered immunoglobulin G1 (IgG1) anti-CTLA-4 antibody designed to exploit a novel mechanism by which increased Fc engagement enhances antigen-specific effector T cell responses.
223461674|NCT04677530|DRUG|JNJ-40411813|JNJ-40411813 will be administered orally.
223461675|NCT04677530|DRUG|Matching Placebo|Matching placebo will be administered orally.
223461676|NCT01693770|PROCEDURE|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
223461677|NCT06188325|DRUG|Eliglustat|Pharmaceutical form:Capsule-Route of administration:Oral
223461678|NCT04631237|OTHER|Observational, no intervention|No intervention involved
223461679|NCT06387446|PROCEDURE|Valve transplant|Heart valves from an organ donor will be transplanted into recipient
223461680|NCT03955159|DIETARY_SUPPLEMENT|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
223461681|NCT03138577|DIAGNOSTIC_TEST|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
223461682|NCT03138577|DRUG|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
223461683|NCT03138577|OTHER|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
223461684|NCT03140163|RADIATION|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
223461685|NCT03140163|RADIATION|CXR|Conventional chest radiograph
223461686|NCT01051817|DRUG|AIN457|infusion 10 mg/Kg
223461687|NCT01051817|DRUG|Placebo|infusion
223461688|NCT04132037|OTHER|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
223461689|NCT03805737|OTHER|Amulez and sunlight|Amulez and sun exposure for 2 hours
223461690|NCT03805737|OTHER|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
223461691|NCT04009265|COMBINATION_PRODUCT|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
223461692|NCT01162616|DIETARY_SUPPLEMENT|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
223461693|NCT03999502|DEVICE|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
223743378|NCT06589804|PROCEDURE|Computed Tomography|Undergo CT or PET/CT
223743379|NCT06589804|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223743380|NCT06589804|BIOLOGICAL|Pembrolizumab|Given IV
223743381|NCT06589804|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224157092|NCT02133001|DRUG|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
224157093|NCT02133001|DRUG|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
223461694|NCT03159598|DEVICE|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
223461695|NCT03159598|DEVICE|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
223461696|NCT03159598|OTHER|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
224157094|NCT03702920|BIOLOGICAL|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
223461697|NCT03573635|DEVICE|Supratube|Aspiration of orotracheal secretions with supratube device
223461698|NCT03573635|OTHER|Reference|Usual aspiration with any other device
223461699|NCT02156440|DIETARY_SUPPLEMENT|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
224157095|NCT03702920|OTHER|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
224157096|NCT05038553|OTHER|No intervention|No intervention
223461700|NCT02156440|DIETARY_SUPPLEMENT|Placebo|
223461701|NCT06158035|DRUG|Norepinephrine|An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
223461702|NCT06158035|DRUG|Phenylephrine|An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
223461703|NCT03155347|DRUG|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
223461704|NCT03155347|DRUG|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
223461705|NCT03155347|DRUG|Placebo Matched to MTX|Placebo matched to MTX.
223461706|NCT03155347|DRUG|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
223461707|NCT02989402|DRUG|Rivastigmine|15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day
223461708|NCT03310632|DRUG|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
223743382|NCT06591533|OTHER|Music therapy + standard care|In the pre-extubation and extubation phase, the musical characteristics will be based on a slow to medium tempo, simple harmonic structures (e.g., tonic-subdominant movements), fluid melodies, and avoiding large intervals or abrupt changes of tonalities. The musical instruments used will be a classical guitar with nylon strings (Yamaha C-40) and the voice of the music therapist without lyrics or words. In the post-extubation phase, the musical characteristics will be based on a moderate tempo, introducing chord progressions aiming at tension-resolution (e.g., dominant-tonic), and a more rhythmic application of melodic or harmonic material.
223743383|NCT06591533|OTHER|Standard Care (in control arm)|Standard care during the extubation process involves providing usual the medical care provided for patients according to each hospital's guidelines.
224157097|NCT05509933|DRUG|Budesonide|budesonide starting day 5 after transplant
224157098|NCT04211961|OTHER|Placebo / Saline|The placebo group will receive a 100ml infusion of saline at 4 visits during the study
223461709|NCT04891302|DRUG|Clevudine|Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
223461710|NCT04891302|DRUG|Placebo|Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
223461711|NCT06201039|DRUG|0.5% Lidocaine Hydrochloride|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 24 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI block will start immediately at a speed of 4ml/h containing 0.5% lidocaine hydrochloride + 1:400000 adrenaline.
223461712|NCT06201039|DRUG|0.9% Normal Saline|Prior to the end of neck dissection and any additional procedures, the bilateral catheter will be placed adjacent to the cervical plexus underneath the internal jugular vein, left in place for 72 hours and removed in a similar way to the Redon drainage by the surgeon. The CWI placebo will start immediately at a speed of 4ml/h containing 0.9% normal saline + 1:400000 adrenaline.
223461713|NCT03714464|OTHER|Whole apples|350 of whole apples containing 49g of available carbohydrate with 173ml water
224157099|NCT04211961|DRUG|Scopolamine|The treatment group will receive a 100ml infusion of Scopolamine ( dose 4μg/kg) at 4 visits during the study
224157100|NCT05168566|DRUG|Sutetinib Maleate Capsule|Study drug to be taken orally with or without food (with food preferred) for up to13 cycles
224157101|NCT05935982|BEHAVIORAL|Virtual reality exercise|During school special physical education, participants will be asked to exercise using a virtual reality exercise headset, that will be adapted for arm use. Participants will asked to be seated during gameplay. Heart rate will be monitored and recorded during exercise.
224157102|NCT04906863|GENETIC|Blood draw|Blood draw for identification of genetic variants associated with the development of memory problems
224157103|NCT04906863|OTHER|Neurocognitive testing|Brief memory test
224157104|NCT04906863|OTHER|Medical questionnaire|Collection of medical history
224157105|NCT03238365|BIOLOGICAL|Nivolumab|Given IV
224157106|NCT03238365|DRUG|Tadalafil|Given orally
224157107|NCT03238365|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgery
224157108|NCT04578119|PROCEDURE|Sliding Intubating Technique|Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
223461714|NCT03714464|OTHER|Apple puree|384g of apple puree containing 44g of available carbohydrates with 224 ml water
223461715|NCT03714464|OTHER|Apple Juice|338g apple juice containing 46g of available carbohydrate with 260 ml water
223461716|NCT02288819|DEVICE|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
224157109|NCT01349985|OTHER|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
224157110|NCT01349985|OTHER|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
223461717|NCT02288819|DRUG|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved."
223461718|NCT03708263|DEVICE|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
223461719|NCT03708263|DEVICE|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
223461720|NCT05324553|PROCEDURE|Tissue Collection|Research tissue specimen will be obtained during the patient's clinical biopsy or clinical tumor resection, if feasible.
223461721|NCT05324553|DIAGNOSTIC_TEST|Blood Collection|Up to 50 mL of research blood will be drawn around the time of the procedure. Additional blood may be collected in selected cases, as warranted, to monitor disease recurrence/remission or perform additional
223461722|NCT05324553|DIAGNOSTIC_TEST|Buccal Swab|Buccal swab may be requested, if necessary, to generate germline data.
223461723|NCT05604404|OTHER|Supine|The patient will be positioned supine with head-of-bed at zero degrees.
223461724|NCT05604404|OTHER|Semi-Recumbent|The patient will be placed in a semi-recumbent position with head-of-bed at thirty degrees.
223461725|NCT05604404|OTHER|Semi-Recumbent with Legs Flexed|The patient will be placed in a semi- recumbent position with head-of-bed at thirty degrees and legs flexed.
223461726|NCT06378203|OTHER|tele-rehabilitation system with virtual reality Home Kit - Virtual Reality Rehabilitation System (VRRS KHYMEIA)|"A personalized exercise plan following macro-areas of objectives:~* maintenance of muscle lengths with selective and/or prolonged static stretching exercises;~* maintenance/improvement of muscle trophism with selective and/or postural and/or functional muscle recruitment exercises at moderate intensity (approximately 65%-70% of the maximum);~* maintenance of respiratory muscle weakness with thoracic and/or diaphragmatic breathing exercises combined with muscle exercise;~* endurance training with walking, cycle ergometer (to be used with both the upper and lower limbs) and treadmill at moderate intensity (approximately 65%-70% of the maximum).~Home treatment will mostly take place with the KHYMEIA tele-rehabilitation system."
223461727|NCT01972737|BIOLOGICAL|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
223461728|NCT05168995|DRUG|BDP/FF NEXThaler® 100/6 micrograms|"BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)"
223461729|NCT02837302|DRUG|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
223461730|NCT01537848|PROCEDURE|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
223461731|NCT02732288|DIETARY_SUPPLEMENT|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
223461732|NCT02686164|DRUG|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
223461733|NCT02686164|DRUG|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
223461734|NCT02487797|DRUG|Oxytocin|
223461735|NCT02487797|OTHER|Sodium Chloride 0.9%|
223743384|NCT05938361|OTHER|Psoriasis clinical assessments|Global evaluation of psoriasis and specific evaluation by areas
223743385|NCT05938361|OTHER|Quality of life evaluation|DLQI questionnaire at each visit
223743386|NCT05938361|OTHER|Satisfaction assessment|Visual analogic scale at W16, W28, W52
223743387|NCT05938361|OTHER|Pruritus evaluation|Visual analogic scale at each visit
223743388|NCT06609343|DRUG|Bupropion Hydrochloride 150 MG|Bupropion Hydrochloride Extended Release is administered orally three times a week during routine dialysis sessions for 8 consecutive weeks
224157111|NCT00161811|BIOLOGICAL|Vero Cell-derived Influenza Vaccine|
224157112|NCT00161811|BIOLOGICAL|Egg cell-derived Influenza Vaccine|
224157113|NCT04770298|OTHER|Halliwick Concept|Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
224157114|NCT02061904|RADIATION|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
224157115|NCT02061904|OTHER|Short Form Health Survey 12|questionnaire for general health monitoring
224157116|NCT02061904|OTHER|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
224157117|NCT02061904|OTHER|VAS-pain|questionnaire for pain monitoring
224157118|NCT02061904|OTHER|Harris Hip Score|questionnaire for hip function monitoring
223461736|NCT01829698|DRUG|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
223461737|NCT01829698|DRUG|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
223461738|NCT02824627|DRUG|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
223461739|NCT02824627|DRUG|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
223461740|NCT01822210|DRUG|Botox|injection by gastroscopy (100 Allergen units)
223461741|NCT06521190|DRUG|ACOU085 (bimokalner)|Transtympanic injection
223461742|NCT06521190|DRUG|Placebo|Transtympanic injection
223461743|NCT04819139|OTHER|Active Excersises|Active thumb exercises
223461744|NCT04819139|OTHER|Reeducation ADL|Reeducation in the activities daily life
223461745|NCT04819139|OTHER|Joint protection|Used of a thumb orthosis
223461746|NCT04819139|OTHER|Proprioception exercises|Specific proprioception exercises
223461747|NCT00672633|DRUG|Lovaza|Lovaza , 4 grams/day orally for 6 months
223461748|NCT00672633|DRUG|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
223461749|NCT05661695|DEVICE|RT Assistant|RRT's will be given the RT Assistant to use during a regular ICU shift to make patient care decisions.
223461750|NCT00443222|DRUG|Infliximab|
223461751|NCT02235129|OTHER|breath-holding|
223461752|NCT05716685|OTHER|Health coaching|The intervention consisted of transferring the knowledge acquired on health coaching by the nurses of the cardiology unit to their care activity with CHF patients. To this end, all the nurses in the cardiology unit received two training packages: 1) five theoretical and practical sessions on health coaching competencies, emotional intelligence, communication and support for CHF patients in the hospital setting; and 2) training sessions 7 months after the first training package to reinforce the theoretical and practical knowledge acquired in health coaching. During this period, debriefing was carried out to provide feedback on the health coaching process with patients.
223461753|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
224157119|NCT04307953|DRUG|AZD0530 Difumarate|AZD0530 for the duration of the trial
224157120|NCT04307953|DRUG|Matching placebo|Matching placebo during 6 month RCT, AZD0530 thereafter
224157121|NCT03967847|DRUG|Ketorolac|Oral Ketorolac
224157122|NCT05661175|PROCEDURE|one-handed technique|Traditional percutaneous nephrolithotripsy usually requires the left hand to hold the nephroscope and the right hand to control the fiber for lithotripsy.Our intervention is to control the depth and direction of the sheath with the left hand, the nephroscope in the right hand and control the fiber optic lithotripsy
224157123|NCT02949687|PROCEDURE|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
224157124|NCT04112745|OTHER|Static magnet|Static magnet with 2,000 Gauss
224157125|NCT04112745|OTHER|Placebo|Polyvinyl chloride resin material black jewelry
223461754|NCT01938846|DRUG|exemestane|exemestane once daily
223461755|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
223461756|NCT01938846|DRUG|BI 860585|BI 860585 multiple dose escalation, once daily
223461757|NCT01938846|DRUG|paclitaxel|paclitaxel once weekly
224157126|NCT00549354|DEVICE|Endoluminal Graft|
224157127|NCT04647695|DRUG|Interferon beta-1b|a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
224157128|NCT04647695|DRUG|Remdesivir|a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
223461758|NCT04568798|DEVICE|Sana Sham Device|Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
223461759|NCT02465164|DEVICE|Cook catheter|
223461760|NCT02465164|DRUG|Oxytocin|
223461761|NCT01115777|OTHER|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
223461762|NCT01853293|DRUG|Kudzu extract|
223461763|NCT01853293|DRUG|Placebo|
223461764|NCT01853293|BEHAVIORAL|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
223461765|NCT02324361|OTHER|Physical Activity|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
223461766|NCT02324361|BEHAVIORAL|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
223461767|NCT04575441|OTHER|Exercise with pilates ball|Pilates ball exercises are used to give various sensory stimulation and increase motor skills. Children usually enjoy these kind of exercises as there is ball in every movement.
223461768|NCT01481558|DEVICE|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
223461769|NCT00353223|BEHAVIORAL|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
224157129|NCT05616845|DEVICE|Picterus Jaundice Pro|Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
224157130|NCT03382197|DEVICE|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
224157131|NCT03382197|DEVICE|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
224157132|NCT03382197|DEVICE|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
224157133|NCT04586673|BIOLOGICAL|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10\^9 vp
224157134|NCT04586673|BIOLOGICAL|ChAdOx1.tHIVconsv1 (C1)|ChAdOx1.tHIVconsv1 5 x 10\^10 vp
224157135|NCT04586673|BIOLOGICAL|MVA.tHIVconsv3 (M3)|MVA.tHIVconsv3 1 x 10\^8 pfu
224157136|NCT04586673|BIOLOGICAL|MVA.tHIVconsv4 (M4)|MVA.tHIVconsv4 09. x 10\^8 pfu
224303109|NCT03712982|BEHAVIORAL|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
223461770|NCT00353223|BEHAVIORAL|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
223743389|NCT06013176|OTHER|Encounter-based PRO monitoring|This arm consists of usual practice plus the addition of patient reminders to complete PRO questionnaires and triage nurse alerts for severe symptoms. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
223743390|NCT06013176|OTHER|Remote PRO monitoring|This arm will consist of weekly PRO questionnaires administered via the patient portal, de-linked from clinical encounters. Patient reminders will be operationalized through the Epic patient portal. Triage nurse alerts will be routed to Epic symptom management pools in response to a patient reporting moderate or severe symptoms. Patients will have the opportunity to decline or opt-out of triage nurse support. Clinical interventions stemming from triage nurse alerts will be up to the discretion of clinical teams - i.e., clinical responses will be neither prescriptive nor mandatory. Notably, the entry point for triage nurse alerts (i.e., Epic symptom management pools), as well as resultant clinical responses, are existing standard operating procedures/practices for patients reporting symptoms by phone.
223743391|NCT04960722|DEVICE|OIF/β-TCP|bone graft implantation
223743392|NCT06326021|DRUG|autologous FL-33 CAR T therapy|Autologous FL-33 CAR T cells are infused intravenously.
223743393|NCT06326021|DRUG|prior-HSCT donor-derived FL-33 CAR T therapy|Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.
223743394|NCT06326021|DRUG|Newly matched donor-derived FL-33 CAR T therapy|Newly matched donor-derived FL-33 CAR T cells are infused intravenously
224303110|NCT03712982|OTHER|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
223461771|NCT02568462|DEVICE|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
223461772|NCT01655095|DRUG|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
223461773|NCT01655095|DRUG|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
223461774|NCT01655095|DRUG|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
223461775|NCT01655095|DRUG|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
223743395|NCT06992297|OTHER|Questionnaire|a standardised, structured questionnaire, validated by the department's clinicians, to assess the physical, cognitive and psychological after-effects.
223743396|NCT06854042|DRUG|E1018|Specified dose on specified days.
223743397|NCT06854042|DRUG|Placebo|E1018 matching placebo on specified days.
223743398|NCT06672250|PROCEDURE|CTCs/CTMs culture|Collect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture
223743399|NCT06671613|DIETARY_SUPPLEMENT|FMD|Plant-based diet program
223743400|NCT06671613|COMBINATION_PRODUCT|Regular Diet Plus FMD|Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6
224303111|NCT00677079|DRUG|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
223461776|NCT01655095|PROCEDURE|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
223461777|NCT01655095|PROCEDURE|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
223461778|NCT03097432|DRUG|ORALVAC COMPACT BÄUME|
223461779|NCT00291564|DEVICE|Cardiac Resynchronization Therapy Device|
223461780|NCT02592941|DRUG|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
223461781|NCT00246584|DRUG|SPP100|
223461782|NCT06469450|DRUG|Atorvastatin|one 40 mg atorvastatin tablet once daily for 28 days
223461783|NCT03819413|DIAGNOSTIC_TEST|serum aquaporin 4 antibody (AQP-4-Ab)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)
223461784|NCT03819413|DIAGNOSTIC_TEST|serum MOG antibody (anti-MOG)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)
223461785|NCT03819413|DIAGNOSTIC_TEST|MRI brain, spine and orbit|All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium
223461786|NCT00559143|OTHER|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
223461787|NCT00043277|DRUG|Angiomax (bivalirudin)|
223461788|NCT02150252|DRUG|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
223461789|NCT04633993|BEHAVIORAL|PCSMP|This study divided the patient-centered self-management manual for patients with hypertensive nephropathy into 4 units, including: Unit 1: hypertensive nephropathy brief introduction and complications. Unit 2: dietary precautions for patients with hypertensive nephropathy. Unit 3: medication treatments for patients with hypertensive nephropathy. Unit 4: the content included stress management (emotional control, spiritual support). This program was implemented in small groups with 5-10 patients. This study used patient-centered self-management group activity manual as the tool. The group activities with 4 units lasting for 400 minutes were expected to be designed. The group activities were expected to last for 4 weeks and be implemented once per week and 100 minutes per time (including: 90 minutes of group discussion and 5-10 minutes of video-waring).
223461790|NCT01727830|OTHER|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
223461791|NCT00684164|DRUG|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
223461792|NCT00684164|OTHER|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
223461793|NCT03448523|BEHAVIORAL|Right To Play's Positive Child and Youth Development program|"1. Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~2. Training of junior leaders~3. Related play-based activities such as sports days~4. Quarterly awareness sessions with community groups and parents~5. Summer camps for children~6. training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection"
223461794|NCT05003869|PROCEDURE|Scar tissue is removed|The patients were divided into two groups according to whether the scar tissue was removed during TCRA operation: study group: resection of uterine scar tissue during TCRA operation;In the control group, the scar tissue covering the anterior, posterior and lateral walls of the uterine cavity was ploughed longitudinally into several narrow strips using needle-like electrodes, and the scar tissue was not excised.
223461795|NCT04468724|BEHAVIORAL|MAKASI|"The Makasi intervention consists in a unique Empowerment interview, based on motivational interviewing techniques. Is is made of three components:~* Listening and building trust~* Active referral to structures that answers sanitary and social needs~* Sexual Health Prevention~Materials used are: referral letters, bilingual health guides, adapted maps of the the neighborhoods with useful addresses.~The Makasi intervention is proposed and delivered in an outreach setting: health mediators propose information on general health and rapid HIV and HCV testing. They screen the people attending and propose Makasi to eligible persons."
223461796|NCT03192124|DEVICE|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
223461797|NCT04560959|DEVICE|tACS|tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
223461798|NCT05947162|BEHAVIORAL|extinction training (nicotine cues)|extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.
223461799|NCT05947162|BEHAVIORAL|extinction training (neutral cues)|extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.
223461800|NCT05947162|BEHAVIORAL|Time-restricted smoking cessation|Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.
223461801|NCT05947162|BEHAVIORAL|Time-restricted fasting|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.
223743401|NCT06037785|BEHAVIORAL|Self-Paced Self-Management (SPSM)|(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
224157137|NCT04741295|DRUG|Low molecular weight heparin|Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.
223461802|NCT05947162|BEHAVIORAL|Time-restricted fasting with food supplemnet|Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
223575463|NCT06607510|OTHER|Experimental HIFT|Subject belonging to this group perform a 12-week supervised exercise (3 sessions weekly spaced at least 48 hours apart with a maximum duration of 40 minutes), followed by 12 weeks of detraining follow-up. Before starting the intervention, two familiarization sessions for assessing strength and functional capacity will be conducted. AMRAP will consist of a circuit of six global, functional exercises with external loads \[i) squat; ii) rowing; iii) dead weight; iv) chest press; v) step up; vi) farmer walk\]. Patients will perform 10 repetitions of each exercise and complete as many rounds as possible within the specified time. Between blocks, there will be a prescribed active rest period lasting three minutes, during which patients will walk on the treadmill at an intensity of 60-70% of peak heart rate. The last part of the training is a cool-down (5 minutes treadmill walking at an intensity of 50-60% of peak heart rate).
223575464|NCT06607887|DRUG|IV antibiotic|Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.
223575465|NCT06607887|DRUG|Oral antibiotic|Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
223575466|NCT06607562|DIETARY_SUPPLEMENT|Probiotic group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
223575467|NCT06607562|DIETARY_SUPPLEMENT|Placebo group|The experimental phase of this study lasted for 56 days, during which we will measure participants' liver function, such as alanine aminotransferase (ALT) at baseline and end.
223575468|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
223575469|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin and Sunlight exposure
223575470|NCT04371822|DRUG|SnPP Protoporphyrin plus Sunlight exposure|SnPP Protoporphyrin plus Sunlight exposure
223575471|NCT04371822|DRUG|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.|Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
223575472|NCT04371822|OTHER|placebo|No Intervention
223575473|NCT02270255|PROCEDURE|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
223575474|NCT02270255|DRUG|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
223575475|NCT02270255|PROCEDURE|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
223575476|NCT02270255|DRUG|1% Xylocaine|5ml of 1% Xylocaine
223575477|NCT06607926|DRUG|Thymosin Alpha 1|4.8 mg subcutaneous injection twice weekly over 12 weeks
223575478|NCT06607926|DRUG|Tislelizumab|200mg, IV, d1 of each 21-d cycle, four cycles
223743402|NCT06994442|DRUG|Acetaminophen|"Intravenous (IV) dose, 15 mg/kg\* (maximum 600 mg) every 6 h for 5 days.~\*Note: For children \<28 days old, dose will be 12.5 mg/kg every 6 hours, as per U.S. Food and Drug Administration (FDA) recommendations. The dosing of acetaminophen for intravenous infusion will follow the current Acetaminophen for injection labeling based on the participant's age and weight."
223575479|NCT06607926|DRUG|Platinum-doublet chemotherapy|Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
224157138|NCT02498392|DRUG|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
223575480|NCT06994013|OTHER|High-frequency vibration foam rolling|Athletes will be performed three sets of HFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during HFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During HFVFR, the vibrator booster will be set to a frequency of 67 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
223575481|NCT06994013|OTHER|Low-frequency vibration foam rolling|Athletes will be performed three sets of LFVFR for 30 s, with a 30 s break between each set and exercise. The rolling frequency will be standardized using a metronome set at 60 beats per minute. Athletes will be instructed to roll at a velocity of two metronome beats for each rolling direction. Intensity of pressure will be controlled with a target rating of 7 of 10 on a Numerical Rating Scale (0 = no discomfort and 10 = maximum discomfort) during LFVFR intervention. The target muscle groups and/or body sides will be anterior thigh, posterior thigh, posterior calf, iliotibial-band, and gluteals (buttocks).During LFVFR, the vibrator booster will be set to a frequency of 35 hz, which is within the optimal frequency range (12 to 90 hz) to influence musculoskeletal system, and an amplitude of 1.95 mm.
223575482|NCT06605183|BEHAVIORAL|Community walking program using Nordic walking poles|This is a group, community walking program at local parks using Nordic walking poles. Participants will be encouraged to walk briskly but safely for 60 minutes one time per week with the ultimate goal of using this community walking program to build up their step count to 10,000 steps per day. We do not anticipate that the weekly walk will get them to 10,000 steps but we will use that as a weekly event to drive behavioral change throughout the week.
223575483|NCT04333056|OTHER|Biometric measurement agreement|Patients scheduled for cataract surgery were measured with both ss-OCT devices. The following biometry parameters were compared: anterior keratometry, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT) and axial length (AL).
223461803|NCT00292253|DEVICE|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
223461804|NCT00292253|DEVICE|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
223461805|NCT04284826|PROCEDURE|Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture|
223461806|NCT04804176|DEVICE|Ultra-low frequency repetitive transcranial magnetic stimulation|Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.
223461807|NCT02950038|DRUG|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
223743403|NCT06994442|DRUG|Ketorolac|IV dose; 0.5mg/kg (maximum 30 mg) every 6 h for 5 days 4.1.d. \*Note: Ketorolac for intravenous bolus administration is currently labeled for multiple-dose treatment in adults. For patients under 65 years of age, the recommended dose is 30 mg every 6 hours, with a maximum daily dose of 120 mg. For patients 65 years or older, renally impaired patients, and those weighting less than 50 kg, the recommended dose is 15 mg every 6 hours, with a maximum daily dose of 60 mg. In this study, we will be limiting ketorolac to \<15 mg per dose, with a maximum of 60 mg per day.
223461808|NCT02950038|DRUG|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
223461809|NCT02595112|OTHER|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
224157139|NCT02498392|OTHER|Placebo|Matching Placebo will be administered orally.
223461810|NCT05276102|OTHER|Emollient cream|Commercially available emollient cream
223461811|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
223461812|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
223461813|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
223461814|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
223461815|NCT01290419|BIOLOGICAL|Placebo|Placebo; Day 0 and Day 30
223461816|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
223461817|NCT01290419|BIOLOGICAL|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
223461818|NCT05204914|DEVICE|Supra glottic airway devices|Using the device in save air way in patients under general anesthesia and the change in the tempromandibular joint will be evaluated
223461819|NCT02152215|PROCEDURE|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
223461820|NCT02152215|PROCEDURE|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
223461821|NCT00831402|DIETARY_SUPPLEMENT|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
223461822|NCT00831402|DIETARY_SUPPLEMENT|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
223461823|NCT05308849|OTHER|Dosage of serum and peritoneal of the betalactam used for antibiotic treatment|"All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method"
223461824|NCT00379405|DRUG|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
223461825|NCT04056949|DRUG|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
223461826|NCT04056949|DRUG|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
223461827|NCT00889629|DRUG|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
223461828|NCT00889629|DRUG|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
223461829|NCT00889629|DRUG|25-OH Vitamin D3|All groups received cholecalciferol
223461830|NCT03618901|OTHER|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
223461831|NCT03618901|OTHER|PD SAFEx|Progressive proprioception training.
223461832|NCT03885414|BEHAVIORAL|In-session Virtual Reality exposure therapy|A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
223461833|NCT03885414|BEHAVIORAL|Internet-administered transition program|Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
223743404|NCT06994442|DRUG|Placebo|Placebos will be normal saline solution, i.e., 0.9% NaCl. In order to maintain blinding, the investigational pharmacy will dispense placebo in a volume to match the corresponding study drug.
224157140|NCT05784129|DRUG|Guselkumab|Guselkumab will be administered subcutaneously.
224157141|NCT05784129|DRUG|Placebo|Placebo will be administered subcutaneously.
223461834|NCT02359110|DRUG|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
223461835|NCT02359110|OTHER|Placebo|Patient will receive placebo tab less than 1 hour before surgery
224157142|NCT00230295|PROCEDURE|IMR LAG|
224157143|NCT04675788|DRUG|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
224157144|NCT04675788|DRUG|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval
224157145|NCT04675788|DRUG|Testosterone|Subjects will apply transdermal testosterone gel once daily every morning for 3 days
224157146|NCT04675788|DRUG|Placebo|Lactose capsules
224157147|NCT01349075|RADIATION|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
223461836|NCT02762448|DRUG|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
223461837|NCT06520527|DIETARY_SUPPLEMENT|Andrographis paniculata|Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days.
223461838|NCT06520527|BEHAVIORAL|Brisk Walking Exercise|Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.
223461839|NCT06520527|OTHER|Combination|"Moderate activity that uses brisk walking techniques for 30 minutes at an average speed of up to 5 km/h or 100 steps per minute.~Jamu Sambiloto is herbal medicine obtained through products that already have a distribution permit and have a distribution permit registration number, with a consumption dose of 1 capul / day or 350 grams for 7 consecutive days."
223461840|NCT05897749|OTHER|Brucea javanica oil emulsion injection|Drug: Brucea javanica oil emulsion injection Brucea javanica oil emulsion injection: intravenous drip, 30ml each time (add 250ml sterile physiological saline),once a day, 14 consecutive days as a cycle, at least 2 cycles completed. The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
223461841|NCT05897749|OTHER|The best supportive treatment|The best supportive treatment:According to the NCCN Best Palliative Treatment Guidelines (2022. V1), provide the best supportive treatment
223461842|NCT02976610|DEVICE|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
223461843|NCT01061697|DRUG|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
223461844|NCT03423212|BEHAVIORAL|Just Do You|Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services \& how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
223461845|NCT03423212|BEHAVIORAL|Active Control|The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
223461846|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + resveravine|
223461847|NCT00303238|DRUG|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
223575484|NCT01012206|BEHAVIORAL|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
223575485|NCT02630368|DRUG|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
223575486|NCT02630368|DRUG|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
223575487|NCT02630368|DRUG|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
223575488|NCT02630368|DRUG|Avelumab and JX-594 and Cyclophosphamide|"Avelumab will be administered by intravenous infusion (10 mg/kg) every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered bi-daily (50 mg x 2), starting 7 days prior to cycle 1 day 1 (impregnation phase) and given on a week on/week off schedule.~JX-594 will be administered by intratumoral injection (1 x109 p.f.u) on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections ."
223575489|NCT07041944|OTHER|HEMImprove APP|"Experimental Group:~Use HEMImprove 1.0 mobile app at home for 30 minutes/session, 5 days/week, for 4 weeks. Exercises tailored progressively with avatar guidance.~Control Group:~Perform conventional home exercises guided by printed manual with instructions and images, matching frequency and duration of intervention group."
223575490|NCT07041944|OTHER|exercises to upper limb|The patients will do the same exercises than the experimental group, without APP and using the same dosage
223575491|NCT07040540|PROCEDURE|Intradermal methylene blue injection|All eligible patients will receive an intradermal injection of 5 mL of 1% methylene blue into the quadrant of the breast where the tumor is located or into the subareolar region prior to skin incision, as part of the standard sentinel lymph node mapping procedure during elective breast surgery. After injection, the site will be massaged for 10 minutes to facilitate lymphatic uptake. The procedure will be performed under general anesthesia, and all other aspects of perioperative care will follow standard clinical practice.
223575492|NCT03142399|DIETARY_SUPPLEMENT|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
223575493|NCT05791695|OTHER|Non Applicable|No study-specific interventions for this observational study.
223575494|NCT04315688|DRUG|insulin degludec|Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
223575495|NCT03078283|OTHER|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
223461848|NCT00303238|DRUG|Rose hips extract + resveravine + Aframomum melegueta extract|
223461849|NCT00193414|DRUG|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
223461850|NCT00193414|DRUG|Gemcitabine|1500mg/m2, 30min IV
223461851|NCT01116947|OTHER|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
223461852|NCT05934916|DEVICE|CPAP ( Continuous positive airway pressure)|The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.
223575496|NCT05846425|OTHER|Nose-breathing training|13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day
223575497|NCT05846425|OTHER|Mouth-breathing training|13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
223575498|NCT00560534|PROCEDURE|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
223575499|NCT02089113|DRUG|Dexamethasone|
223575500|NCT02089113|PROCEDURE|Placebo Vehicle|
223575501|NCT00015860|DRUG|daunorubicin hydrochloride|
223575502|NCT00015860|DRUG|imatinib mesylate|
223575503|NCT00015860|DRUG|prednisone|
223575504|NCT00015860|DRUG|vincristine sulfate|
223575505|NCT03217084|DRUG|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
223575506|NCT03217084|DRUG|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
223575507|NCT05042765|OTHER|self-reported entheogen use|self-reported participation in therapy or a retreat in a naturalistic setting that incorporated the use of entheogens in the past five (5) years
223575508|NCT01975519|DRUG|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
223575509|NCT01478230|DRUG|Nicotine|Nicotine 5 mg Inhaler
223461853|NCT05934916|DEVICE|oxygen therapy|both groups will receive oxygen
223575510|NCT01478230|DRUG|Nicotine|Nicotine 10 mg Inhaler
223575511|NCT05063188|OTHER|Connective Tissue Massage|Connective tissue massage was started from lumbosacral region and continued lower thoracic, scapular, interscapular, and cervical regions, respectively.
223575512|NCT05063188|OTHER|clinical pilates exercises|Exercises were applied 3 times for 6 weeks, a total of 18 sessions. One session consisted of 10 minutes of warm-up, 40 minutes of Clinical Pilates exercises and 10 minutes of cooling down (60 minutes in total).
223575513|NCT06301724|PROCEDURE|Injection|The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223575514|NCT06301724|DRUG|Lidocaine hydrochloride|the patients were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223575515|NCT00003103|BIOLOGICAL|oblimersen sodium|
223575516|NCT00003103|DRUG|docetaxel|
223743405|NCT06359171|OTHER|Application ARTH-e|"The ARTH-e application must be downloaded via the PlayStore or Applestore platform on phone and/or tablet. Once the application has been downloaded, the patient must scan a QRcode sent by the CHU to anonymize the data.~Participants will have 6 months to use the application at their convenience."
223575517|NCT06276582|DEVICE|Screening for neonatal jaundice with a mobile health device|Picterus Jaundice Pro will be used to screen for neonatal jaundice by taking 6 photos of the newborns skin, where the Picterus calibration card is place.
223575518|NCT04848714|DRUG|ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL|Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
223575519|NCT01389154|PROCEDURE|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
223461854|NCT05435469|OTHER|Questionnaires|Participants will be asked to respond to the demographic information sheet, Adolescent Self-Rating Life Events Check List, Coping Inventory For Stressful Situations, Social Skills Rating System, brief-symptom-inventory, and Wong and Law EI Scale.
223461855|NCT01519817|BIOLOGICAL|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
223743406|NCT03860584|DIETARY_SUPPLEMENT|MFGM-enriched full-fat dairy milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at \~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.
223743407|NCT03860584|DIETARY_SUPPLEMENT|Soy phospholipid/lecithin milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
223461856|NCT02194972|DRUG|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
223461857|NCT02922153|DEVICE|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
223461858|NCT02922153|DRUG|Standard of Care|Institutional SOC for pain management will be followed.
223575520|NCT04930549|DRUG|Dapagliflozin 10Mg Tab|Patients receive dapagliflozin 10mg tablets once a day during 12 weeks
223575521|NCT04930549|DRUG|Placebo|Patients receive placebo tablets once a day during 12 weeks
223575522|NCT04930549|PROCEDURE|impedance cardiography|impedance cardiography (PhysioFlow® PF-05 Lab1TM, Manatec Biomedical) is done for evaluation of cardiac function
223575523|NCT04930549|PROCEDURE|Applanation tonometry|Applanation tonometry will be done using SphygmoCor®, Hogimed) is done for evaluation of arterial stiffness
223575524|NCT04930549|PROCEDURE|post-ischemic hyperemia of forearm|An arterial occlusion cuff will be placed on the forearm, and will be deflated to allow post-ischemic hyperemia with the continuous measurements of brachial artery diameter and blood flow velocity by high-resolution echotracking coupled to a Doppler system (ArtLab system®)
223575525|NCT04930549|PROCEDURE|haemodynamics parameters|haemodynamics parameters will be evaluated using automatic oscillometric recorder
223575526|NCT00620425|DRUG|Sumatriptan|injection
223575527|NCT04942665|DRUG|Indocyanine green|Low dose or standard dose ICG will be administered by the anesthesiologist as guided by the study coordinator at the beginning of the case, at two points during the operation (1- prior to the dissection of the biliary tract and 2- upon completion of the dissection and establishment of the critical view of safety).
223743408|NCT07001462|BEHAVIORAL|Inspiratory Muscle Training / Positive Expiratory Pressure (IMT/PEP) Therapy|IMT/PEP therapy was administered using a dual-function device (BİO Breathe, Korea) designed to provide both inspiratory muscle resistance and positive expiratory pressure. Patients performed the therapy for 15 minutes, twice daily, over a 12-week period, in addition to standard pharmacological treatment. Pressure levels were individually adjusted between 5-40 cmH₂O based on patient capacity.
224157148|NCT05256992|OTHER|Standard Servies + Ray of Hope Curriculum|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula. Optional services available to both study groups by selecting 1-3 hours of coursework from menu of courses that address a variety of needs.
224157149|NCT05256992|OTHER|Standard Services|Standard services delivered as primary services to participants in both study groups under a shared condition are: 20 hours of TYRO Dads curricula and 6 hours of Core Communication curricula.
224157150|NCT06851910|DRUG|Lacosamide|Patients will be included if they are prescribed intravenous lacosamide for their trigeminal neuralgia exacerbation
224157151|NCT00854438|OTHER|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
224157152|NCT00049140|DRUG|EF5|
224157153|NCT00049140|OTHER|bioluminescence|
224157154|NCT00049140|OTHER|flow cytometry|
223461859|NCT04228484|OTHER|Placebo|Placebo infusion
223461860|NCT04228484|OTHER|GIP receptor antagonization|GIP(3-30)NH2 infusion
223461861|NCT03429348|OTHER|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
223575528|NCT04942665|DEVICE|PINPOINT Endoscopic Fluorescence|The PINPOINT Endoscopic Fluorescence Imaging System (Stryker Corporation, Kalamazoo, Michigan) will be used. This device enables the surgeon to simultaneously see real-time, high-definition visible-range and NIR fluorescence videos and to superimpose them. It is currently approved by the FDA for intraoperative near-infrared fluorescence imaging.
224157155|NCT00049140|OTHER|immunohistochemistry staining method|
224157156|NCT00049140|PROCEDURE|biopsy|
224157157|NCT00305734|DRUG|bortezomib|Given IV
224157158|NCT00305734|DRUG|gemcitabine hydrochloride|Given IV
224157159|NCT00305734|OTHER|laboratory biomarker analysis|Correlative studies
224157160|NCT06280053|DEVICE|HealiAid Collagen Wound Dressing|HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
224303112|NCT04274023|DRUG|TSR-042|TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
223461862|NCT05439746|DEVICE|Microlyte® Matrix|Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.
223461863|NCT01461642|OTHER|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
223461864|NCT04545450|DRUG|dutasteride 5 mg/day|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
223461865|NCT04545450|DRUG|Testosterone Undecanoate|Administration of a placebo pill or dutasteride 5 mg pill daily in addition to intramuscolar testosterone undecanoate
223461866|NCT05179304|PROCEDURE|Oncoplastic technique with a droplet-shaped glandular flap|"A droplet-shaped glandular flap (DSG) is in a shape of a water drop, with the pedicle at the top of the defect and the base underlying nipple-areolar complex (NAC). It runs from the outer upper quadrant to the center along a line parallel to the radial line. We harvest a DSG flap by dissociating the supplement mammary gland from the lateral of the defect after resection, developing deep to the pectoralis fascia, from the cusp at the defect and the round pore underlying nipple-areolar complex (NAC). The DSG flap was rotated inwards around the cusp, reaching the top of the defect. This tailored redistribution allowed the defects to be plugged with the lateral glandular flaps."
223461867|NCT02585453|DEVICE|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
223461868|NCT02585453|DEVICE|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
223461869|NCT02585453|DEVICE|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
223461870|NCT02962427|DRUG|Sphenopalatine ganglion Block|
223461871|NCT02962427|PROCEDURE|Epidural blood patch|
223461872|NCT05945238|OTHER|Thrower's Ten Exercise Program|T10 group were given thrower's ten exercises 3 times per week for 10 weeks, each exercise being 2x10 repetitions.
223461873|NCT01086670|OTHER|Physical Exercise|Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
223461874|NCT06080516|OTHER|Kettlebell exercise|Both arms include an exercise intervention consisted of 7 different exercises with kettlebell: (1) plank with kettlebell pass, (2) swings, (3) overhead squat-thrusters, (4) lunges with motion hands, (5) single leg deadlift, (6) wood chop και (7) snatch
223461875|NCT02692586|DEVICE|FlowTriever System|
223461876|NCT02752815|DRUG|Rituximab|
223461877|NCT02752815|DRUG|Cyclophosphamide|
223461878|NCT02752815|DRUG|Epirubicin|
223461879|NCT02752815|DRUG|Vincristine|
223461880|NCT02752815|DRUG|Prednisone|
223461881|NCT04421040|DEVICE|Biotronik Biomonitor 3 implant of device|The Biotronik Biomonitor 3 device will be implanted by the research team physician.
223461882|NCT04421040|DEVICE|Biotronik Biomonitor 3 explant of device|The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.
223461883|NCT00742794|OTHER|Observation|Observation of sting frequency
223461884|NCT02667340|DIETARY_SUPPLEMENT|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game \& at halftime)
223461885|NCT02667340|OTHER|Placebo|0.7 g glucose per kg body mass in two ingestions (before game \& at halftime)
223461886|NCT03234036|DRUG|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
223461887|NCT03234036|DRUG|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
223461888|NCT03234036|DRUG|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
223461889|NCT03234036|DRUG|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
223461890|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
223575529|NCT02010736|OTHER|Single treadmill gait training with additional loading|
223461891|NCT01506856|DRUG|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
223461892|NCT05857722|BEHAVIORAL|Jóvenes Capibara|Jóvenes Capibara is a 10-session group intervention that was culturally adapted from the Youth Readiness Intervention, which was originally developed in Sierra Leone for conflict-affected youth. Jóvenes Capibara was adapted to the Colombian context using the ADAPT-ITT framework, which ensured that the intervention was relevant to the needs of Colombian and Venezuelan youth.
223461893|NCT01913301|DRUG|Alagebrium|
223461894|NCT02999789|DEVICE|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
223461895|NCT02999789|DEVICE|SmartInhaler|The SmartInhaler is a medication monitoring system manufactured by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
223461896|NCT00975377|PROCEDURE|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
223575530|NCT06415981|DEVICE|Hypoglossal nerve and/or Ansa Cervicalis stimulation|Device stimulation of the hypoglossal nerve and/or Ansa Cervicalis
223575531|NCT00387738|BIOLOGICAL|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
223575532|NCT00387738|BIOLOGICAL|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
223575533|NCT06012279|DRUG|Dapagliflozin 10mg Tab|Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
223575534|NCT00361699|DRUG|Statin|
223461897|NCT03221114|BEHAVIORAL|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
223461898|NCT06959082|DRUG|VS-101|VS-101
223461899|NCT06959082|DRUG|Cisplatin|Cisplatin
223461900|NCT06959082|RADIATION|Radiation|Radiation
223461901|NCT06225973|DRUG|TL-925|TL-925 is an eye drop.
223461902|NCT06225973|OTHER|Placebo|The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.
223461903|NCT00552695|DEVICE|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
223461904|NCT00552695|DEVICE|Placebo|Placebo patch identical in appearance to Synera
223461905|NCT00191243|DRUG|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
223461906|NCT00191243|DRUG|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
223461907|NCT06959069|OTHER|Intermittent Fasting - Late feeding window|Intermittent fasting is an eating pattern that consists of alternating periods of fasting of varying duration with periods of eating. In the present study, all participants will follow a time-restricted feeding/eating (TRF/E) that restricts all dietary intake to an 8- hour daily eating window. There will be two different feeding periods. The first window will allow a feeding period from12 p.m. to 8 p.m. (late feeding window).
223575535|NCT05652231|DIAGNOSTIC_TEST|caries assessment|the child will examined for dental caries, caries prevalence, caries indices (def and DMF, or DMF)
224157161|NCT03590093|PROCEDURE|Periodontal surgery|After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
223575536|NCT03276052|DRUG|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
223575537|NCT03148145|BEHAVIORAL|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
223575538|NCT03148145|BEHAVIORAL|Message Delivery by Smartphone|Message Delivery by Smartphone
223575539|NCT06216782|OTHER|Non-intervention|Non-intervention
223575540|NCT01519050|BEHAVIORAL|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
224157162|NCT03590093|PROCEDURE|EMD application|Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
224157163|NCT05071443|OTHER|Negative pressure wound therapy (NPWT)|"The therapeutic intervention being tested is the use of a negative pressure wound therapy (NPWT) device. Several medical devices are currently being used and are based on the same principle. They involve applying negative pressure, generally between -100 and -150 mmHg, to a wound using a dressing (mostly a polyurethane foam dressing with hydrophobic pores), which hermetically covers the wound's surface and is connected to a container for collecting the fluids drained off. These devices are widely available and used to treat post-operative wounds.~Duration of treatment: the use of NPWT will be maintained until the recovery of the skin has been achieved by the skin graft. An average duration of 3 weeks' treatment is expected in the intervention group."
224157164|NCT05071443|OTHER|Conventional dressing|"Conventional dressings will be performed from randomization to skin grafting and applied every day based on the methods normally used in the participating centres, and also until the recovery of the skin has been achieved by the skin graft.~This generally involves local care provided on a daily basis, ensuring gentle mechanical and chemical debridement by covering the wound with alginate type or other dressings, according to the condition of the wound. The methods used to apply these conventional dressings will be recorded."
224157165|NCT02637648|DRUG|Sodium Oxybate|parallel Group administration
224157166|NCT02637648|DRUG|Placebo|parallel Group administration
223461908|NCT06959069|OTHER|Intermittent Fasting - Early feeding window|Intermittent fasting is an eating pattern that consists of alternating periods of fasting of varying duration with periods of eating. In the present study, all participants will follow a time-restricted feeding/eating (TRF/E) that restricts all dietary intake to an 8- hour daily eating window. There will be two different feeding periods. The second window will allow a feeding period from 8 a.m. to 4 p.m (early feeding window).
223461909|NCT00917826|DRUG|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
223461910|NCT00917826|DRUG|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
223461911|NCT00917826|DRUG|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
223461912|NCT00994942|DRUG|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
223575541|NCT01982006|PROCEDURE|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
223575542|NCT01982006|DEVICE|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
223575543|NCT04510883|BEHAVIORAL|PACO|The intervention is a fully-automated web-based eHealth application in which two embodied conversational agents engage in dialogue with older adults in order to motivate them towards dietary behavior change and decrease loneliness. The application consists of five different modules, each one applying different behavior change techniques.
223461913|NCT03600831|DRUG|Docetaxel plus cisplatin|cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
224157167|NCT04293042|BIOLOGICAL|BK-virus specific CTLs|"HLA Matched Related Donors: BK-virus specific CTLs (2.5 x 104 CD3/kg) infused intravenously on day 0 and may be additionally reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 12.5 x 104 CD3/kg).~HLA Mismatched Related Donors: BK-virus specific CTLs (0.5x104 CD3/kg) infused intravenously on day 0 and may additionally be reinfused at a minimum of every two weeks (depending on safety and efficacy) for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg)."
223461914|NCT03600831|RADIATION|radiotherapy|radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
223461915|NCT00197093|DRUG|SB773812|
223461916|NCT04102618|BIOLOGICAL|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
223461917|NCT04102618|DRUG|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
223461918|NCT04102618|DRUG|Atezolizumab|1200 mg administered intravenously on Day 3
223461919|NCT04102618|DRUG|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
223461920|NCT06034093|DEVICE|Real-time AI-assisted muscle ultrasound|RAIMUS software provides automatic segmentation and size measurement for the RFCSA
223461921|NCT05621447|DRUG|TAS-303, [14C]TAS-303|oral administration on day 1
223461922|NCT06958497|DEVICE|Sphinkeeper™|The procedure was performed under spinal anesthesia, with the patients in lithotomy position. Ten 2-mm perianal skin incisions were made 1-2 cm from the anal margin (i.e., 0.5-1 cm from the intersphinteral sulcus), equidistant one each other, around the entire anal circumference, to allow implantation of 10 prostheses using a specifically designed delivery system (THD Sphinkeeeper Delivery System, THD Sp, Correggio, Italy). The introducer was placed through each skin incision in the intersphincteric space where the prostheses were delivered at a level below the puborectalis muscle. All of the steps were verified by palpation and direct vision using the Eisenhammer anal speculum. Patients were discharged on the same day and recommended to avoid any trauma or sexual practice during the first 48 hours after implantation. A 5-day course of antibiotics was also prescribed.
223461923|NCT02196298|DEVICE|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
223461924|NCT02196298|OTHER|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
223461925|NCT04613739|BEHAVIORAL|insurance navigation|Intervention subjects will be offered access to AAFA's chat bot and navigation services. The chat bot is an artificial intelligence-enabled interactive online tool that can answer clinical and insurance-related questions and provide information on coverage options and how to find lower-cost alternatives for asthma care. Intervention participants will be given a link to access the chat bot. They will also be provided with information about AAFA's insurance navigation program, how it can help with finding coverage and managing asthma costs, and how to access it within AAFA's asthma community platform. Subjects can access AAFA's community platform and join the private group where they can ask questions and share resources, with moderation by AAFA staff. They will be able to send private messages to an AAFA navigator who can provide support about insurance issues, access to asthma care, and assistance with asthma costs. The navigator will offer telephonic follow-up as needed.
223461926|NCT00517608|DEVICE|Laparoscopic colectomy|
223461927|NCT00093483|BIOLOGICAL|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
223575544|NCT04510883|BEHAVIORAL|Waiting list + PACO|Waiting list + PACO
224157168|NCT01301755|PROCEDURE|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
224157169|NCT05932394|BEHAVIORAL|Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery|"Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered."
224157170|NCT05932394|BEHAVIORAL|the usual unit treatment|CAM-ICU scale is administered to the Control group. No visual material is used.
224303113|NCT03195036|BEHAVIORAL|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
223461928|NCT00093483|DRUG|arsenic trioxide|IV over 1 hour on day 1
223461929|NCT00093483|DRUG|cytarabine|IV over 1 hour every 12 hours on days 1-6
223461930|NCT00093483|DRUG|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
223461931|NCT04658979|OTHER|Pulmonary tele-rehabilitation|All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
223461932|NCT03019991|DRUG|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
223461933|NCT03019991|DRUG|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
223461934|NCT03019991|DRUG|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
223461935|NCT03175926|DEVICE|placebo Diskus®|device will be given daily for one week, two puffs per day
223575545|NCT04882644|BEHAVIORAL|Aerobic Exercise|The subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption three times per week for 60 min/session (including 5 min warm-up and 5 min cool down) with treadmills, ellipticals, and rowing machine. The subjects attend health education sessions (eg, general health knowledge of NAFLD and metabolic diseases, and elements of a healthy lifestyle) monthly in the 12 months.
223461936|NCT03175926|DEVICE|placebo Ellipta®|device will be given daily for one week, one puff per day
223461937|NCT03175926|DEVICE|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
223461938|NCT04559646|PROCEDURE|Pacemaker implantation|Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.
223461939|NCT04559646|DRUG|"Haemostatic solution Haemoblock application"|"Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation."
223461940|NCT04559646|DRUG|Saline solution application|Saline solution will be used after pocket formation during pacemaker implantation.
223461941|NCT04559646|DIAGNOSTIC_TEST|Ultrasound of pacemaker pocket|Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.
223461942|NCT04559646|DIAGNOSTIC_TEST|Blood sampling|Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.
223461943|NCT04559646|DIAGNOSTIC_TEST|Echocardiography|Heart ultrasound examination for left ventricular ejection fraction measurement.
223461944|NCT02972983|DRUG|Daptomycin|Adjuvant therapy for up to five days
223461945|NCT02972983|OTHER|Placebo|Placebo
223461946|NCT02090504|DRUG|Sodium Oxybate (SMO)|
223461947|NCT02090504|DRUG|Oxazepam|
223461948|NCT05448378|DIETARY_SUPPLEMENT|D-chiro-inositol|D-chiro-inositol 600 mg twice per day on an empty stomach for one month
223461949|NCT04685252|OTHER|(BL) NCC3001|Probiotic strain (BL) NCC3001 packed in stickpack, to be consumed daily.
223461950|NCT04685252|OTHER|Placebo|Matching placebo containing maltodextrin packed in stickpack, to be consumed daily.
223461951|NCT01447407|BIOLOGICAL|NDV-3 vaccine with alum IM|One dose administered IM
223461952|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum IM|One dose administered IM
223575546|NCT01539343|DRUG|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
223575547|NCT02728544|OTHER|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
224157171|NCT01456728|DIETARY_SUPPLEMENT|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
223575548|NCT05980364|OTHER|Technology-based training structured according to the Health Promotion Model|Experimental group: A video recording was created with a total of 6 zoom applications to be shared with the patients. The content of the video recordings consists of a presentation accompanied by a slide show with open-ended questions prepared by considering the basic concepts of the trainings and the Health Promotion Model. Video recordings, each of which lasted approximately 15-25 minutes, were shared with patients once a week for a total of 6 weeks via WhatsApp. After each video, patients were given three days to watch the video recordings and create their own responses. After this three-day period, the researcher called the patients with whom he shared the content and gave counseling for 10-15 minutes and received feedback. Follow-up was done in the second 6-week period. During the monitoring process, two reminder interviews were made over the phone, with an interval of 2 weeks, for reminder and counseling, and the post-test data were collected at the end of the monitoring period.
224157172|NCT01456728|DIETARY_SUPPLEMENT|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
223461953|NCT01447407|BIOLOGICAL|Placebo with alum IM|One dose administered ID
223461954|NCT01447407|BIOLOGICAL|NDV-3 vaccine without alum ID|One dose administered ID
223461955|NCT02671851|DRUG|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
223461956|NCT02671851|DRUG|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
223461957|NCT02571140|DRUG|Teriparatide|subcutaneous standard injection
223461958|NCT02571140|DRUG|Oral PTH (1-34)|Different optimization of API
223461959|NCT02548624|DEVICE|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
223461960|NCT02962310|DRUG|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
223461961|NCT02962310|DRUG|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
223461962|NCT05991011|OTHER|Immersive and Interactive Wall Exergames|This intervention will be performed using the Neo One device. It was chosen because of the variety and quality of the games offered which are accessible to older people. The target intensity of core workout will be moderate. Five to 7 five-minutes games will be selected from 19 games. A variety of materials will be used (e.g., basketball, rugby, handball ball, balloon, chair, hoop, rhythm ladder, tennis racket). The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity. Interventions will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Neo One device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants.
223461963|NCT05991011|OTHER|Complex Cognitive and Motor Activities program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving cooperation and opposition exercises inspired by team sports (basketball, volleyball, rugby) and individual sports (boxing, weight training), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants. The target intensity of body workout will be moderate. The first part will be focused on endurance and the second on muscle strengthening and coordination work in the form of circuit training. A variety of equipment will be used (e.g., tennis balls, basketballs, volleyballs, rugby balls, balloons, elastics, chairs, blocks). The number of partners and/or opponents will be changed regularly.
223461964|NCT05991011|OTHER|exergames program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, physically active (standing). The sessions will consist in 10 minutes of warmup, 45 minutes of the main session using the Nintendo Switch device and 5 minutes of cooldown with full body stretching exercises, in groups of 4 participants. The games (Fitness Boxing 2, Switch Sport, Just Dance 2020, 2021, 2023, Let's Get Fit, Mario and Sonic at the Olympic Games Tokyo 2020, Instant Sport, Ring Fit, Zumba Burn It Up!) will be carried out in the form of circuit training, in pairs or groups of 4. The games will be made more complex by selecting difficulty settings (easy, normal, hard) and by adding extra exercises to add cooperative and/or oppositional situations to the games where they are not initially implemented and to increase the physical and/or motor complexity.
223461965|NCT05991011|OTHER|video games program|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). The sessions will be performed using the Nintendo Switch device, while being inactive (sitting). The sessions will consist in one-hour single and multi-players games, using the Nintendo Switch device, in groups of 6 participants.
223461966|NCT05991011|OTHER|Bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this active comparator intervention, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike at about 50% of Heart Rate Reserve, and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
223461967|NCT05991011|OTHER|Video games + bike|The intervention will last 12 weeks, with 2 sessions of 1-h per week (24 h in total). In this experimental arm, the sessions will consist in 10 minutes of warmup, 45 minutes of the main sessions involving riding a stationary bike (like BIKE program at about 50% of Heart Rate Reserve) and at the same time playing on a Nintendo Switch (like VG program), and 5 minutes of cooldown with full body stretching exercises, in groups of 6 participants.
223461968|NCT00777868|DRUG|Low Strength IDP-108|Topical application once a day for 9 months
223461969|NCT00777868|DRUG|High Strength IDP-108|Topical application once a day for 9 months
223461970|NCT00777868|DRUG|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
223461971|NCT00777868|DRUG|Vehicle|Topical application once a day for 9 months
223461972|NCT02842047|BEHAVIORAL|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
224157173|NCT04223206|DIETARY_SUPPLEMENT|NATURLENS|Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
224157174|NCT03531606|DRUG|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
224157175|NCT03531606|DRUG|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
224157176|NCT01156363|PROCEDURE|Dialysis|regular haemodialysis or peritoneal dialysis
224157177|NCT01156363|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
224157178|NCT03484689|BEHAVIORAL|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
223461973|NCT02842047|BEHAVIORAL|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
223575549|NCT00145418|DRUG|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
223575550|NCT02667223|BIOLOGICAL|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
223575551|NCT02667223|BIOLOGICAL|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
223575552|NCT02667223|BIOLOGICAL|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
223575553|NCT02667223|BIOLOGICAL|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
223575554|NCT02667223|BIOLOGICAL|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
223575555|NCT04582435|DRUG|Insulin Icodec|Participants will receive 1 dose from a prefilled pen, administered subcutaneously (under the skin), once a week by designated study staff, for a total of at least 8 and a maximum of 16 doses which equals 8-16 weeks of treatment.
223575556|NCT03220581|BEHAVIORAL|Referral for care|referral for addictions support
223575557|NCT03220581|BEHAVIORAL|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
223575558|NCT03286946|PROCEDURE|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
223575559|NCT03286946|PROCEDURE|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
223461974|NCT02842047|BEHAVIORAL|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
223461975|NCT00455169|BIOLOGICAL|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
223461976|NCT02874612|OTHER|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
223461977|NCT02311829|OTHER|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
223461978|NCT04601727|DIAGNOSTIC_TEST|16srRNA pyrosequencing analysis of microbiota of saliva and faeces|No intervention in this study
223461979|NCT02479555|DRUG|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
223461980|NCT01064414|DRUG|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
223461981|NCT01064414|DRUG|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
223461982|NCT02708550|BEHAVIORAL|Participatory Organizational Intervention|
223461983|NCT02603198|DRUG|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
223461984|NCT02603198|DRUG|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
223461985|NCT00107562|BEHAVIORAL|Adolescent Safer Sex Social Network Intervention|
223461986|NCT03065491|DIETARY_SUPPLEMENT|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
223461987|NCT03065491|OTHER|Placebo|Oral administration: 1 tablet per day
223461988|NCT00995839|DRUG|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
223461989|NCT00995839|DRUG|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
223461990|NCT00995839|DRUG|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
223461991|NCT00354965|DRUG|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
223461992|NCT04795063|PROCEDURE|Total Robotic Distal Gastrectomy|All the surgical procedures are performed using the robot system.
223461993|NCT04795063|PROCEDURE|Robotic-Assisted Distal Gastrectomy|After finishing the lymphadenectomy, the digestive tract reconstruction is performed extracorporal.
223461994|NCT04381780|DIETARY_SUPPLEMENT|Recovery Factors|A unique porcine serum based polypeptide nutritional support
223461995|NCT01582113|DRUG|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
223461996|NCT01582113|OTHER|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
223461997|NCT00249873|DRUG|clopidogrel (SR25990C)|oral administration (tablets)
223461998|NCT00249873|DRUG|placebo|oral administration (tablets)
223461999|NCT03315845|OTHER|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
223462000|NCT03860740|OTHER|Exercise|Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum
223462001|NCT03860740|OTHER|Stretching|Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
223462002|NCT04348708|GENETIC|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
223462003|NCT03131167|DRUG|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
223462004|NCT03131167|DRUG|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
223462005|NCT01699048|PROCEDURE|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
223462006|NCT01699048|PROCEDURE|PCI|Multi-vessel PCI with DES
223462007|NCT01699048|PROCEDURE|CABG|Coronary artery bypass graft (CABG) treatment
223462008|NCT00643201|DRUG|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
223462009|NCT00643201|DRUG|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
223462010|NCT00643201|DRUG|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
223462011|NCT00643201|DRUG|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
223462012|NCT00643201|DRUG|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
223462013|NCT00643201|DRUG|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
223462014|NCT00165503|DRUG|Cisplatin|
223462015|NCT00165503|DRUG|Sodium Thiosulfate|
223462016|NCT00165503|DRUG|ALIMTA|
223462017|NCT04716972|OTHER|survey|Online survey
223462018|NCT04716972|OTHER|Interview|Interview
224157179|NCT00004690|DRUG|monolaurin cream|
223575560|NCT02488213|OTHER|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
223462019|NCT02085200|OTHER|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
223575561|NCT02488213|OTHER|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
223462020|NCT02085200|OTHER|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
223462021|NCT02976519|DRUG|BI 443651|twice daily
223462022|NCT02976519|DRUG|Placebo|twice daily
223462023|NCT02346708|DEVICE|Real TMS|real treatment
223462024|NCT02346708|DEVICE|Sham TMS|placebo treatment
223462025|NCT04215562|COMBINATION_PRODUCT|rehabilitation|electro-therapy, heat therapy, massage and exercise therapy
223462026|NCT03069872|DIAGNOSTIC_TEST|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
223462027|NCT03728439|DEVICE|LED before|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
223575562|NCT00919867|DRUG|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
223575563|NCT00919867|DRUG|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
223575564|NCT00919867|DRUG|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
223575565|NCT04336371|DIAGNOSTIC_TEST|Self-administered questionnaires|Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
223575566|NCT00435162|DRUG|Valsartan 0.25 mg/kg|once daily
223575567|NCT00435162|DRUG|Valsartan 1.0 mg/kg|once daily
223575568|NCT00435162|DRUG|Valsartan 4.0 mg/kg|once daily
223575569|NCT00533065|DRUG|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
223575570|NCT05525754|PROCEDURE|computed tomography-guided nasotracheal intubation|Before intubation, the lower part of the nasal valve region, aka the narrowest area of the nasal passage, was measured by calculating the distance between the anterior border of the inferior concha and the septal cartilage
223575571|NCT02963987|OTHER|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
223575572|NCT03204799|OTHER|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
223575573|NCT03204799|DRUG|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
223575574|NCT03204799|DRUG|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
223575575|NCT04018976|DEVICE|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
224157180|NCT03363568|BEHAVIORAL|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
224157181|NCT03363568|BEHAVIORAL|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
224157182|NCT00877734|DRUG|baclofen|10 mg Baclofen administered tid for 11 weeks
224157183|NCT00877734|DRUG|placebo|Placebo administered tid for 11 weeks
223462028|NCT03728439|DEVICE|LED interval|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
223462029|NCT03728439|DEVICE|LED after|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
223462030|NCT05419297|DRUG|Buprenorphine Buccal Film [Belbuca]|buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
223462031|NCT05419297|OTHER|Urine Drug Screening|Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
224157184|NCT00877734|BEHAVIORAL|BRENDA counseling|
224157185|NCT04383106|OTHER|no intervention|no intervention
223462032|NCT05419297|DEVICE|actigraph|Subjects will wear this device to monitor sleep and activity
223462033|NCT05419297|BEHAVIORAL|PROMIS 29|questionnaire will be administered once a week via e-dairy to monitor mood and sleep
223462034|NCT05419297|OTHER|sit to stand test|Subjects will complete this daily with specific instructions through the e-diary
223462035|NCT05419297|OTHER|numerical rating scale pain score|subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
223462036|NCT05419297|BEHAVIORAL|patient global impression of function|subjects will be asked three questions once a day to assess their personal impression of functional status
223462037|NCT05419297|BEHAVIORAL|PROMIS - sleep|Subjects will answer 5 questions about sleep every morning via e-diary
223575576|NCT04018976|DEVICE|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
223462038|NCT01908868|OTHER|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
223462039|NCT01908868|OTHER|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
223462040|NCT01908868|OTHER|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
223575577|NCT04018976|DEVICE|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
223575578|NCT05135858|DRUG|Glucarpidase|Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)
223575579|NCT05135858|DRUG|Methotrexate (MTX)|MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration
223575580|NCT00715364|DRUG|NTx™-265: rhCG, then rEPO|"* rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
223575581|NCT00715364|DRUG|Saline Placebo|"* Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation"
223462041|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
223575582|NCT00058149|DRUG|gemcitabine hydrochloride|
223575583|NCT00058149|DRUG|oxaliplatin|
223575584|NCT01983722|DRUG|Stiripentol|
223575585|NCT00481312|DRUG|Dexmedetomidine|Continuous Infusion
223575586|NCT00481312|DRUG|Midazolam|Continuous Infusion
223575587|NCT01765426|BIOLOGICAL|TDV|TDV suspension for intradermal administration
223575588|NCT01765426|DRUG|Placebo|Phosphate buffered saline (PBS)
223575589|NCT02307292|DEVICE|POLARIS Peripheral Vascular Self Expanding Stent System|
223462042|NCT00928434|DRUG|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
223462043|NCT00928434|DRUG|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
223462044|NCT03928054|OTHER|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
223462045|NCT04758013|PROCEDURE|Epidural injection through thoracic epidural catheter|The investigators inject drugs through a catheter inserted into the thoracic epidural space to control pain after surgery in patients undergoing gastric surgery by laparoscopy.
223462046|NCT04758013|PROCEDURE|Without epidural injection|The investigators don't epidural injection to find out the effect of only inter-abdominal pressure on intracranial pressure.
223462047|NCT06410664|OTHER|72-hour HME exchange interval group|All patients in the experimental arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 72 hours. At the exchange point, both outlets of the HME filter will be swabbed.
223575590|NCT01510184|DRUG|Zevalin|Zevalin administered intravenous infusion.
223575591|NCT01510184|DRUG|Y-90-Zevalin|Y-90-Zevalin administered by intravenous infusion.
223575592|NCT01510184|DRUG|Rituximab|Rituximab administered by intravenous infusion.
223575593|NCT01510184|DRUG|In-111 Zevalin|In-111-Zevalin administered by intravenously.
223575594|NCT03671707|BEHAVIORAL|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
223575595|NCT03671707|DRUG|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
223575596|NCT03671707|BEHAVIORAL|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
223575597|NCT03671707|BEHAVIORAL|Very brief advice|Subjects will receive general advice to quit
223575598|NCT03671707|BEHAVIORAL|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
224157186|NCT02569333|OTHER|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
224157187|NCT04989504|OTHER|Best Practice|Receive standard of care
223575599|NCT05379062|BEHAVIORAL|Active Singing Group|The participants of the Active Singing Group take part in a weekly 45-minute singing activity in a group over a period of 3 months. In total the investigators expect 12 choir rehearsals. The rehearsals will take place between 2pm and 3.30pm in the church of the Wehrle-Diakonissen Private Clinic in Salzburg. The group will be led by a professional and experienced choir director.
223575600|NCT05379062|BEHAVIORAL|Receptive Music Group|The participants of the Receptive Music Group will individually listen to the already researched CD for Parkinson's patients (Bernatzky, Wendtner, Volc, 2012) at home at the same time on one weekday.
223575601|NCT05256784|COMBINATION_PRODUCT|Natural probiotics|Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
223575602|NCT00002368|DRUG|Nevirapine|
223575603|NCT00002368|DRUG|Lamivudine|
223575604|NCT03068416|BIOLOGICAL|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
223575605|NCT04061954|BEHAVIORAL|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~1. Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~2. Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~3. Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~4. Parents receive training regarding agriculture and micro credit projects, and financial assistance~5. One child per family receives a social skill training group preparing them for returning to school~6. Access to schools and school material~7. If needed medical assistance is provided~8. If needed legal assistance is provided"
223575606|NCT04075968|OTHER|Cognitive exercise|Cognitive exercise will be applied
223575607|NCT04075968|OTHER|Home exercise|Home exercise will be applied
223575608|NCT01863134|DRUG|Eptifibatide|
223575609|NCT01863134|DRUG|Placebo|
223575610|NCT02069730|DRUG|Selinexor|"If no druggable aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE)."
223575611|NCT02069730|DRUG|EGFR or HER2 Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor"
223575612|NCT02069730|DRUG|FGFR Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor"
223575613|NCT02069730|DRUG|C-KIT Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor"
223575614|NCT02069730|DRUG|Anti-androgen|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens"
224157188|NCT04989504|DEVICE|Wound Dressing Material|Apply Mepitel Film
224157189|NCT04989504|OTHER|Quality-of-Life Assessment|Ancillary studies
224157190|NCT04989504|OTHER|Questionnaire Administration|Ancillary studies
224157191|NCT01880879|DEVICE|helios stent|the group with helios stent implanted
224157192|NCT03167827|OTHER|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
223575615|NCT02069730|DRUG|NOTCH Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor"
223575616|NCT02069730|DRUG|MEK or PI3K Inhibitor|"If specific druggable aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor"
223575617|NCT01074333|DRUG|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
223575618|NCT03097575|DRUG|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
223575619|NCT03097575|DEVICE|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
223575620|NCT04842474|OTHER|Gaze stability exercises and balance exercises|Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
223575621|NCT02024022|DRUG|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
224157193|NCT03167827|OTHER|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
224157194|NCT03167827|OTHER|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
224157195|NCT04176562|DEVICE|RTI Spine products|"* Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~* Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~* Bone graft substitute - is intended to aid in fusion."
224157196|NCT06317415|BEHAVIORAL|WeChat-based health education on antibiotic use|Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
224157197|NCT06317415|BEHAVIORAL|Regular public health education|Health education information on the prevention and control of common chronic diseases
223462048|NCT06410664|OTHER|24-hour HME exchange interval group|All patients in the control arm will receive the usual best medical and nursing care with respect to VAP prevention. A dual-limb ventilator circuit with a closed suction system will be used. Bronchodilation or inhalational antibiotics, when ordered, will be delivered by a meshed nebuliser, a part of the ventilatory support circuit and will not be removed between treatments. A closed-circuit suction device will be used, and the frequency of suctioning will be monitored, including the sputum consistency and blood on suctioning. HME filter resistance by estimating the pressure drop over HME using the ventilatory circuit's auxiliary force (Paux) and flow. Temperature and humidity in the ventilator circuit will be measured. HME filters will be exchanged every 24 hours. At the exchange point, both outlets of the HME filter will be swabbed.
223462049|NCT02607501|DEVICE|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
223462050|NCT05767853|OTHER|Immune-phenotyping of tissue and peripheral blood myeloid compartment|"Peripheral blood sampling and bronchoalveolar lavage fluid collection based on the clinical indication at baseline (T0) and peripheral blood sample at the time of clinical worsening/improvement during the follow-up (T1). Moreover, after complete recovery and discharge from the hospital peripheral blood sampling in the outpatient clinical assessment will be performed (T2).~BALF and peripheral blood will be processed for immune-phenotyping of the myeloid compartment using single-cell RAN sequencing analysis."
223575622|NCT02024022|DRUG|Individualized approach|
223575623|NCT01943838|DRUG|SAR245408|Pharmaceutical form: tablet Route of administration: oral
223575624|NCT00058526|BIOLOGICAL|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
223575625|NCT03900923|DRUG|98% pure CBD|A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
223575626|NCT01790282|DRUG|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
223575627|NCT01790282|DRUG|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
223575628|NCT01065948|DEVICE|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
223575629|NCT03236012|DRUG|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
223575630|NCT04540458|OTHER|3D printed model|Mother or Mother/Father is given 3D printed model of fetus' face
223575631|NCT04540458|OTHER|Placebo|Mother or Mother/Father is given a picture of 3D ultrasound of fetus
223575632|NCT00182767|DRUG|ixabepilone|Given IV
223575633|NCT00182767|DRUG|pegylated liposomal doxorubicin hydrochloride|Given IV
223575634|NCT01463930|BEHAVIORAL|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
223575635|NCT01463930|BEHAVIORAL|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
223575636|NCT03135444|BEHAVIORAL|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
223575637|NCT03135444|BEHAVIORAL|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
224067915|NCT00689715|PROCEDURE|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
224067916|NCT03594227|DRUG|ATI-501 400mg BID (Low dose)|ATI-501 400mg BID oral low dose for oral administration
224067917|NCT03594227|DRUG|ATI-501 600mg BID (Mid dose)|ATI-501 600mg BID oral mid dose for oral administration
224067918|NCT03594227|DRUG|ATI-501 800mg BID (High dose)|ATI-501 800mg BID high dose for oral administration
224157198|NCT00821054|DRUG|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
224157199|NCT05035823|DEVICE|Motor Neuroprosthesis (MNP)|Type of implantable brain computer interface
224157200|NCT01949298|PROCEDURE|dental implant placement|
224067919|NCT03594227|DRUG|Placebo|Placebo - oral administration
224157201|NCT05301803|DEVICE|Electrophysiology procedure|Electrophysiology testing and cardiac ablation of arrhythmia
224157202|NCT05599854|PROCEDURE|vitrectomy and silicone oil injection|Parsplana vitrectomy and silicone oil injection
224067920|NCT05555537|DIAGNOSTIC_TEST|MiRNA223 and High mobility group box1(HMGB1)|Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
224067921|NCT01801956|BEHAVIORAL|physical activity|free membership of a sport club
224067922|NCT01801956|OTHER|Motivational interview|Four motivational interviews by instructors of the local sport club
224067923|NCT01801956|OTHER|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
223462051|NCT03263455|OTHER|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
223462052|NCT03263455|OTHER|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
223462053|NCT04702464|DRUG|Fedratinib|Fedratinib
223462054|NCT04702464|DRUG|Fluconazole|Fluconazole
223462055|NCT04549662|DIETARY_SUPPLEMENT|Active A|Powdered formula containing whey protein and arginine
223462056|NCT04549662|DIETARY_SUPPLEMENT|Active B|Powdered formula containing whey protein
223462057|NCT04549662|DIETARY_SUPPLEMENT|Lipid bolus|Omega-3 fatty acids
223462058|NCT04549662|DIETARY_SUPPLEMENT|Placebo oil|Control placebo oil that does not contain omega-3 fatty acids
223462059|NCT06331507|DEVICE|CMR patch|The Cardiac Magnetic Resonance (MR) patch is a sequence modification for enhancing the images in patients with devices (CIED) for assessing heart muscle scar. The Philips tested patch supports multiple cardiac MR imaging enhancements compiled from several individual patches generated by multiple Philips MR research collaborators for use on 1.5 Tesla Philips scanners.
223462060|NCT01687114|OTHER|cranberry juice|27% cranberry juice
223462061|NCT05224700|BEHAVIORAL|JAPI|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. All the activities are games with the following structure: an introduction with instructions and protagonist selection, followed by a practice exercise to ensure that the children understand what they have to do (the exercise is repeated until the child performs it correctly), and, finally, the activity itself (4 different activities with 5 tries each). The first 10 sessions jointly stimulate working memory and emotion knowledge (4 activities focused on each skill per session), while the 10 remaining sessions stimulate inhibitory control and the selection of prosocial behaviours. In the inhibitory control activities, they must suppress automatic stimuli and processes; in the emotion recognition activities, they must identify basic emotions; and in the selection of prosocial behaviours, they must choose an option to deal with a social problem.
223462062|NCT05224700|BEHAVIORAL|Painting group|Each child will play on a tablet with headphones during 20 sessions lasting 30 minutes each, 2 times per week. They will play a tablet-based painting game that involves no cognitive, emotional, or social competence stimulation
223462063|NCT02281617|BEHAVIORAL|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
223575638|NCT03135444|BEHAVIORAL|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
223462064|NCT03276598|DRUG|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
223462065|NCT03276598|DRUG|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
223462066|NCT03276598|DRUG|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
223462067|NCT03276598|DRUG|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
223462068|NCT03276598|DRUG|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
223462069|NCT06410716|DEVICE|Valve-regulated pleural drainage system|Patients using valve-regulated pleural drainage system (Ningbo Xinyue Medical Technology Co., Ltd., model AFG31-1) postoperatively.
223462070|NCT02138565|PROCEDURE|Gastric by-pass surgery|
223462071|NCT02016768|PROCEDURE|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
224067924|NCT01888640|DEVICE|TENS|"TENS Parameters: Active TENS and Placebo TENS~* TENS Frequency - 2-125 Hz~* TENS Pulse Width - 200 µs~* TENS Intensity - Maximal tolerable intensity~* Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~* Administration - Daily~* TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
223462072|NCT01278342|DRUG|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
223462073|NCT01278342|DRUG|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
224067925|NCT04434495|BIOLOGICAL|PRP|PRP injection into uterine cavity
224157203|NCT02023918|DRUG|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
224157204|NCT02779881|DIETARY_SUPPLEMENT|Extensively hydrolyzed casein formula plus LGG|
223575639|NCT04677426|DRUG|Hyperpolarized Xe129|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to assess patients with cHP and IPF.
223575640|NCT06524557|DIAGNOSTIC_TEST|with chronic liver disease|patients with hepatitis B virus，hepatitis C virus, or other chronic liver disease
223575641|NCT03723174|BEHAVIORAL|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
223575642|NCT04175457|OTHER|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
223575643|NCT01636505|DRUG|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
224067926|NCT06199388|OTHER|Survival state|We recorded clinically relevant information and survival status of pediatric glioma patients
224067927|NCT06518577|BIOLOGICAL|Flucelvax (ccIIV4)|Participants will receive Flucelvax (ccIIV4)
224067928|NCT06518577|BIOLOGICAL|Flublok (RIV) or Fluzone (IIV)|Participants will receive Flublok (RIV) or Fluzone (IIV)
224067929|NCT03389854|DEVICE|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
223462074|NCT01278342|DRUG|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
223575644|NCT01636505|DRUG|gnrh agonist (suprefact)|suprefact 5.5 ml
223575645|NCT04382521|BEHAVIORAL|Text Message Intervention|Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
223575646|NCT01329796|DRUG|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
223575647|NCT01329796|DRUG|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
223575648|NCT01484834|BEHAVIORAL|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
223575649|NCT01484834|BEHAVIORAL|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
223575650|NCT01484834|BEHAVIORAL|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
223575651|NCT01484834|OTHER|Control Company|No intervention was applied for the participants of this group
223575652|NCT00747344|DRUG|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
223575653|NCT00747344|DRUG|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
223575654|NCT00747344|DRUG|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
223575655|NCT00747344|DRUG|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
223575656|NCT03326557|PROCEDURE|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
224157205|NCT03423563|DEVICE|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
224157206|NCT03423563|DEVICE|Fexible intubation video endoscopy|Fexible intubation video endoscopy
223575657|NCT01117506|DIAGNOSTIC_TEST|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
224157207|NCT04694716|OTHER|No intervention|No intervention will be applied.
224157208|NCT01307553|DEVICE|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
224157209|NCT03895918|OTHER|Educational Activity|Undergo parenting skills intervention
223575658|NCT00765882|DRUG|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
223575659|NCT00765882|DRUG|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
223575660|NCT00765882|DRUG|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
223575661|NCT02231762|DRUG|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
223575662|NCT02231762|DRUG|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
224157210|NCT03895918|PROCEDURE|Patient Monitoring|Undergo medication adherence monitoring
224303114|NCT04219683|PROCEDURE|Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap|Using Free Fibula Flap for reconstruction of mandibular segemental defect
223462075|NCT05862493|DIAGNOSTIC_TEST|FOCUS echocardiography|Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
223575663|NCT01404013|DRUG|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
223575664|NCT01404013|DRUG|Montelukast|Montelukast 10mg ,every night, for 8 weeks
224157211|NCT03895918|OTHER|Questionnaire Administration|Ancillary studies
224157212|NCT05062551|PROCEDURE|three steps hysteroscopic resection of an isthmocele|removing the distal edge of the niche then the proximal edge and lastly ball cauterization of the floor of the pouch of the isthmocele. Post-operative trans vaginal ultrasound and follow up for 2 menstrual cycles.
224157213|NCT02556411|DRUG|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
224157214|NCT02556411|DRUG|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
224303115|NCT03722355|RADIATION|Conventional RT|Radiation therapy
224303116|NCT03722355|RADIATION|Hyperfractionated RT|Radiation therapy
223462076|NCT03210493|DRUG|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
223462077|NCT04869592|BIOLOGICAL|low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
223462078|NCT04869592|BIOLOGICAL|high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)|Intramuscular injection of high-dose Recombinant SARS-CoV-2 Vaccine (CHO cell) in the deltoid muscle of the upper arm
223462079|NCT04869592|BIOLOGICAL|placebo|Intramuscular injection of placebo in the deltoid muscle of the upper arm
223462080|NCT05946226|BIOLOGICAL|IMC002 injection|"three different IMC002 Doses will be escalated in 3+3 design"
223462081|NCT00171990|DRUG|Famciclovir|
223575665|NCT01404013|DRUG|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
223575666|NCT06306690|DIAGNOSTIC_TEST|OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence.|"the best visual acuity will be evaluated using decimal tables and then converted to logMar.~Ocular fundus examination will be evaluated following pharmacological mydriasis with Tropicamide 1%.~OCT will be essential to quantify the central macular thickness and the thickness of the RPE.~OCT angiography is a non-invasive method to assess the presence or absence of neovascular membrane and macular flow density.~Color and ultra wide field autofluorescence images of the retina will be performed with Zeiss Clarus retinography to search for signs that identify different types of RP and predict their activity and evolution.~Electroretinogram flicker (ERG) is a common measure of cone pathway function that is used to study the normal visual system and that of patients with inherited and acquired retinal dysfunction Measurements will be performed using an electrophysiological recording system (CSO). Intermittent stimuli are presented using a Ganzfeld dome (CSO)."
223462082|NCT00224302|DRUG|Duloxetine|
223575667|NCT05384535|DIAGNOSTIC_TEST|Bi-parametric MRI|When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
223575668|NCT00212199|DRUG|orlistat|
223575669|NCT00212199|BEHAVIORAL|Brief cognitive behavioral counseling|
223575670|NCT02973542|DRUG|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
223575671|NCT02973542|OTHER|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
223575672|NCT01844011|OTHER|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
223575673|NCT04547114|DIAGNOSTIC_TEST|Multicapillary column coupled ion mobility spectrometry|sampling of nasal air via a foam cuffed oxygen catheter
224067930|NCT03389854|DEVICE|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
224303117|NCT03722355|DRUG|Carmustine|Chemotherapy
223462083|NCT04968678|DIAGNOSTIC_TEST|P-wave duration measurement on 12 lead ECG with standard parameters|Hospital records will be used in order to obtain baseline characteristics and the most recent 12-lead ECG in sinus rhythm prior to ablation will be used to calculate PWD. Measurement of the PWD will be obtained at standard surface ECG recording settings of 25mm/s and 10mm/mV and measured accordingly to our previous protocol. In brief, all ECGs obtained will subsequently be anonymised and randomised by an Independent Clinical Investigator (ICI) before measured by the main clinical investigators blinded to initial results. If a dispute of the measurements arouse, consensus will be used to resolve it after consulting the Chief Investigator (CI) blinded to the results. Bland-Altman plots to minimise bias will be used
223462084|NCT05439421|BEHAVIORAL|Package/Advertisement With Claim|Waterpipe tobacco packages and digital marketing advertisement images with claim of interest as part of design
223462085|NCT05439421|BEHAVIORAL|Package/Advertisement Without Claim|Waterpipe tobacco packages and digital marketing advertisements shown without claim of interest as part of design
223462086|NCT01848574|OTHER|standardized multifaceted information procedure to improve patients' comprehension|
223462087|NCT06195436|BEHAVIORAL|Acceptance and Commitment Therapy for people with and without depression|Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.
223575674|NCT03445728|DRUG|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
223575675|NCT03445728|OTHER|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
223575676|NCT00069524|DRUG|oyster mushroom|
223575677|NCT00741494|DEVICE|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
223575678|NCT01799239|DEVICE|Test product|The test product consists of an adhesive with a new top film
224067931|NCT00576043|PROCEDURE|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
224067932|NCT00586209|DRUG|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)
224067933|NCT00586209|DRUG|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
224067934|NCT02199080|OTHER|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
224303118|NCT00204165|PROCEDURE|MRI of the small bowel|
223462088|NCT02654639|DRUG|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
223462089|NCT02654639|DRUG|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
223462090|NCT06223230|OTHER|Nutritional psychological interventions and vomit-free management|Nutritional psychological interventions and vomit-free management
223462091|NCT04253340|DIAGNOSTIC_TEST|Bone mineral analyser|high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12
223575679|NCT01799239|DEVICE|SenSura|SenSura is the CE-marked and commercially available comparator product
223575680|NCT02917213|OTHER|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
223575681|NCT02917213|OTHER|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
223575682|NCT02917213|OTHER|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
223462092|NCT03606811|PROCEDURE|fluroscopic guided block|SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
223462093|NCT03606811|PROCEDURE|double modality (ultrasound and fluroscopic) guided block|SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A \& dead lateral)
223462094|NCT03154580|DRUG|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
223575683|NCT02917213|OTHER|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of\> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
223743409|NCT03204721|OTHER|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
223743410|NCT07128615|BIOLOGICAL|AZD4117|Intramuscular (IM) injection
223743411|NCT07128615|BIOLOGICAL|AZD5315|IM injection
224157215|NCT04897646|OTHER|SFRMS/SPLF CPAP-telemonitoring diagnosis/therapeutic algorithm.|"In 2020, a working group from the Société Française de Recherche et de Médecine du Sommeil (SFRMS) and the Société de Pneumologie de Langue Française (SPLF) have proposed a CPAP-telemonitoring diagnosis/therapeutic algorithm for newly treated patients with obstructive sleep apnea.~The algorithm is exhasutively described in the following published article: Prigent, A., Gentina, T., Launois, S., et al. \[Telemonitoring in continuous positive airway pressure-treated patients with obstructive sleep apnoea syndrome: An algorithm proposal\]. Rev. Mal. Respir., 2020, 37: 550-560."
224157216|NCT02680119|DRUG|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
224303119|NCT05697926|OTHER|No intervention|This is a preclinical study. No intervention will be performed.
223462095|NCT02348229|PROCEDURE|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
223462096|NCT02348229|PROCEDURE|ERAS protocols|No bowel preparation
223462097|NCT02348229|PROCEDURE|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
223462098|NCT02348229|PROCEDURE|ERAS protocols|Vasoactive drugs used if need be
223462099|NCT02348229|PROCEDURE|ERAS protocols|Temperature management
223462100|NCT02348229|PROCEDURE|ERAS protocols|Intra-abdominal drains not to be used
223462101|NCT02348229|PROCEDURE|ERAS protocols|Intraperitoneal Ropivicaine infusion
223462102|NCT02348229|PROCEDURE|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non-opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
223743412|NCT07128615|OTHER|Placebo|IM injection
223743413|NCT05356741|DRUG|VIR-5818|Administered as IV infusion
223743414|NCT05356741|DRUG|pembrolizumab|Administered as IV infusion
224157217|NCT02680119|DRUG|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
224157218|NCT03628495|DEVICE|compression|compression will be delivered using compression garment
224157219|NCT03628495|DEVICE|occlusion|occlusion will be delivered using silicone gel sheeting
224157220|NCT01721148|DRUG|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
223462103|NCT02348229|PROCEDURE|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
223462104|NCT02348229|PROCEDURE|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
223462105|NCT02348229|PROCEDURE|ERAS protocols|On the5-6th postoperative day Check discharge criteria
223462106|NCT02348229|PROCEDURE|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
223462107|NCT02348229|PROCEDURE|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
223462108|NCT02348229|PROCEDURE|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
223462109|NCT02348229|PROCEDURE|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
223462110|NCT02348229|PROCEDURE|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
223462111|NCT02348229|PROCEDURE|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
223462112|NCT03011866|DRUG|Wound topically irrigated with 500mg TXA|
223575684|NCT02917213|PROCEDURE|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
223575685|NCT02917213|OTHER|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
223575686|NCT02917213|OTHER|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
223575687|NCT02740543|DRUG|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
223575688|NCT01620502|DIETARY_SUPPLEMENT|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
223575689|NCT01817101|DIETARY_SUPPLEMENT|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
223575690|NCT04380103|DRUG|XELOXIRI/Bevacizumab|bevacizumab 5mg/kg on day1, irinotecan 150mg/m2 or 165mg/m2 on day1, oxaliplatin 85mg/m2 on day1 and capecitabine 1000mg/m2 twice a day on day1-7 repeated every 2 week for 12 cycles, after 12 cycles, bevacizumab 5mg/kg on day 1 and capecitabine 1000mg/m2 twice a day on day1-7 as maintenance therapy repeated every 2 week
223462113|NCT03011866|DRUG|1mg/kg/hr TXA intravenous infusion till the last suture|
223462114|NCT02996071|PROCEDURE|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
223462115|NCT05481801|BIOLOGICAL|Covid-19 vaccination|"Correct Covid19 vaccination status was considered in the following situation:~Received at least two Covid-19 vaccine doses being the last in the last 6 months."
223462116|NCT05481801|BIOLOGICAL|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~\- Received at least one Influenza vaccine dose in the last year."
223462117|NCT05481801|BIOLOGICAL|Pneumococal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year. One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years. One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
223462118|NCT05481801|BIOLOGICAL|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
223462119|NCT04214522|BEHAVIORAL|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
223462120|NCT00987168|DRUG|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
223462121|NCT03760224|OTHER|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
223462122|NCT03760224|OTHER|SMS group|SMS group for 8 weeks
223462123|NCT05459909|DIETARY_SUPPLEMENT|Synbiotic supplementation|Daily supplementation of synbiotic
223462124|NCT05459909|BEHAVIORAL|Dietary intervention|Increased fruits and vegetables consumption
223462125|NCT02256098|DEVICE|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
223575691|NCT03627312|COMBINATION_PRODUCT|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
223462126|NCT02256098|DEVICE|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
223462127|NCT00021723|BIOLOGICAL|AN-1792 also known as AIP-001|
223462128|NCT02988011|PROCEDURE|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
223462129|NCT02988011|DIETARY_SUPPLEMENT|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
223462130|NCT02773498|PROCEDURE|conventional TESE|usual procedure for sperm extraction
223575692|NCT03627312|COMBINATION_PRODUCT|Placebo|Fruit juice drink only
223575693|NCT03627312|OTHER|Treatment as Usual|Young Offenders Intervention Programme
223575694|NCT03454867|DEVICE|Hemofiltration|
223575695|NCT03454867|PROCEDURE|Standard acute ischemic stroke treatment|
223575696|NCT02804698|BEHAVIORAL|Education intervention|13-week educational and physical activity intervention
223575697|NCT04790513|BIOLOGICAL|lerodalcibep|anti-PCSK9 small binding protein
223575698|NCT04790513|BIOLOGICAL|evolocumab|monoclonal antibody to PCSK9
223575699|NCT04790513|BIOLOGICAL|alirocumab|monoclonal antibody to PCSK9
223743415|NCT02070744|DRUG|VX-661|Tablet, oral use
223743416|NCT02070744|DRUG|Ivacaftor|Film coated tablet, oral use
223743417|NCT02070744|DRUG|Placebo matched to VX-661|Tablet, oral use
223462131|NCT02773498|PROCEDURE|Micro TESE|procedure of extraction is performed under the operating microscope
223462132|NCT00313846|DRUG|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
223462133|NCT00313846|DRUG|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
223462134|NCT02276963|DRUG|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
223462135|NCT06446934|DEVICE|CPAP|Initial CPAP titration and subsequent CPAP therapy for 12 weeks
223462136|NCT03531866|BEHAVIORAL|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
223462137|NCT00222703|BEHAVIORAL|Smoking relapse prevention|
223462138|NCT04564001|DRUG|Infliximab|Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
223462139|NCT04564001|DRUG|Tocilizumab|Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
223462140|NCT03172728|BEHAVIORAL|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
223462141|NCT05401994|PROCEDURE|screw retained arch bar|maxillomandibular fixation with bone screwed arch bar
223575700|NCT03368716|BEHAVIORAL|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
223743418|NCT02070744|DRUG|Placebo matched to Ivacaftor|Film coated tablet, oral use
223743419|NCT05220137|BEHAVIORAL|Modified A-B-C: Working with Events, Thoughts, and Feelings|The Modified A-B-C session teaches the Veteran how to draw connections between events, thoughts, and feelings and incorporates preliminary cognitive restructuring to help challenge stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
223462142|NCT05401994|PROCEDURE|conventional Erich's Arch Bar|maxillomandibular fixation with conventional arch bar fixed to the teeth
223462143|NCT02307227|DRUG|Trastuzumab|
223462144|NCT02307227|DRUG|Paclitaxel|
223462145|NCT02307227|DRUG|Epirubicin|
223462146|NCT02307227|DRUG|Docetaxel|
223462147|NCT03490617|DRUG|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
223462148|NCT03786107|DIAGNOSTIC_TEST|Almac HER-Seq Assay|whole blood sample analysis
224067935|NCT02556398|BEHAVIORAL|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
223462149|NCT01666483|PROCEDURE|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
223462150|NCT01666483|PROCEDURE|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
223462151|NCT04283812|DEVICE|DBS Electrode Implantation using D1 Sterotactic System|Treatment intervention will consist of subjects undergoing Mayo Clinic standard deep brain stimulation surgery specific to their diagnosed neurological disorder consisting of implantation of stimulating electrodes using the D1 stereotactic system.
223462152|NCT03949595|OTHER|Data collection|
223462153|NCT04572828|PROCEDURE|Paracervical Block|Two-point (at 4 and 8 o'clock only) technique will be used for paracervical block for Group 1: Waiting 1 Minute After Paracervical Block and Group 2: Waiting 3 Minute After Paracervical Block. For these groups 10 ml 2% Prilocaine (VEM İlac, Tekirdag, Turkey) will be injected for each side approximately 10 mm into the cervical stroma at the cervico-vaginal junction with a 22- gauge hypodermic needle.
223462154|NCT04572828|DRUG|550 mg Naproxen Sodium 60 minutes before the procedure|550 mg Naproxen Sodium (Abdi Ibrahim, Turkey) will be given to participants in the Group 4, 60 minutes before the procedure.
223462155|NCT04572828|PROCEDURE|The capped needle|The capped needle model will be employed for Group 3: Control Group. After cervical and vaginal preparation with povidone iodine a capped needle will be touched the cervico-vaginal junction at 4 and 8 o'clock.
223462156|NCT02590666|PROCEDURE|Bipolar Polypectomy|Polyps resection with bipolar electrode
223462157|NCT02590666|PROCEDURE|Mechanical Polypectomy|Polyps resection with microscissors or graspers
223462158|NCT02590666|DEVICE|Bipolar electrode|Bipolar electrode used to performs polypectomy
223462159|NCT02590666|DEVICE|Microscissors or graspers|Mechanical instruments used to performs polypectomy
223462160|NCT03920085|DEVICE|OneTouch Verio|OneTouch Verio Blood Glucose Monitoring System.
223462161|NCT03920085|DEVICE|OneTouch Select Plus|OneTouch Select Plus Blood Glucose Monitoring System.
223462162|NCT03920085|DEVICE|OneTouch Ultra|OneTouch Ultra Blood Glucose Monitoring System.
223575701|NCT01673815|OTHER|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
223575702|NCT00387413|DRUG|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
223575703|NCT00387413|DRUG|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
223575704|NCT00387413|DRUG|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
223575705|NCT00387413|DRUG|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
223462163|NCT00178737|BEHAVIORAL|Electronic reminder message|
223462164|NCT06254794|DEVICE|Blood flow restriction with Delfi Personalized Tourniquet System (PTS)|Standard of care physical therapy exercises with the use of the Delfi PTS cuff
223462165|NCT06254794|OTHER|Physical therapy|Standard of care physical therapy exercises
223462166|NCT02895269|BEHAVIORAL|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
223462167|NCT03461198|DEVICE|Restylane® Silk|Restylane® Silk to a defined area of mid to low cheeks
223462168|NCT02432339|DRUG|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
223462169|NCT02432339|DRUG|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
223462170|NCT03921736|DRUG|Perindopril|4 mg/day p.o. for 12 months
223462171|NCT03921736|DRUG|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
223462172|NCT03921736|DRUG|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
223575706|NCT06051747|PROCEDURE|Three-dimensional patient-specific bioprinting trachea implantation|The intervention entails the creation of a 3D cell-printed tracheal organ, achieved through the fusion of biopolymer materials and the bioprinting (3D cell printing) technique. This process involves distribution of nasal cavity stem cells (hNTSCs) and nasal septum cartilage cells (hNCs) within hydrogel matrices, culminating in the formation of a personalized tracheal structure.
223575707|NCT02085096|BEHAVIORAL|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
223575708|NCT02129478|DRUG|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
223575709|NCT01286987|DRUG|Talazoparib|Oral capsule with multiple dosage forms given once daily
223462173|NCT06057168|DRUG|Elucirem|Intravenous administration
223462174|NCT06057168|DRUG|Dotarem|Intravenous administration
223462175|NCT06169735|DRUG|Indocyanine green|ICG Administration: All enrolled patients with scheduled thyroidectomy or parathyroidectomy will receive a standard cervical incision that afford access to either side of neck. Following sufficient exposure of thyroid, 25 mg of indocyanine green (ICG), reconstituted in 10 ml of sterile water, will be administered intravenously. A dosage of 1 ml of this solution will be injected into a peripheral IV line, followed by a 5 ml flush of normal saline to ensure the propagation of the dye within the vascular compartment.
223462176|NCT06169735|DEVICE|SPY Portable Handheld Imaging|Fluorescent Imaging: Approximately 30 seconds post-administration, the parathyroid glands are expected to exhibit fluorescence under near-infrared imaging. The emitted fluorescence is anticipated to persist for approximately 20 minutes, allowing ample time for intraoperative evaluation of parathyroid viability and perfusion
223462177|NCT02990130|OTHER|Observational|
223462178|NCT06957951|OTHER|Conventional Physiotherapy|Application of hot packs, TENS (transcutaneous electrical nerve stimulation), therapeutic ultrasound, and posture/activity education for low back pain management.
223462179|NCT06957951|BEHAVIORAL|Core Stabilization Exercises|Supervised core stabilization exercises including planks, bird-dog, and pelvic bridging, targeting trunk muscle strength and stability.
223462180|NCT06957951|BEHAVIORAL|WBV-Supported Core Exercises|Core stabilization exercises performed on a whole-body vibration platform (30 Hz frequency, low amplitude \~2 mm) during exercise execution to enhance neuromuscular stimulation.
223462181|NCT06474039|DRUG|Trelegy or Anoro|Both drugs delivered via Ellipta device and blinded package appearance
223462182|NCT06198920|PROCEDURE|Stenting of the superficial femoral artery|Submitted to stenting of the superficial femoral artery for stenosis or occlusion causing intermittent claudication or critical limb ischemia
223575710|NCT03657563|OTHER|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
223462183|NCT06483932|OTHER|Dried barberry|Subjects will ingest 10 grams of powdered seedless barberry on a daily basis, in conjunction with the low-calorie diet.
223462184|NCT06483932|OTHER|Low-calorie diet|Diet with 500 kcal subtracted from the daily energy requirement
223462185|NCT03607799|BEHAVIORAL|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
223575711|NCT03043495|PROCEDURE|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
223575712|NCT03043495|DRUG|Dexamethasone|Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs
223575713|NCT02594098|DRUG|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
223575714|NCT02594098|DRUG|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
223462186|NCT03607799|BEHAVIORAL|Control|Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
223462187|NCT02633969|DRUG|Indomethacin Capsules low dose|
223462188|NCT02633969|DRUG|Indomethacin Capsules high dose|
223462189|NCT04715464|OTHER|review of surveillance cultures within the past year|"ASC results are reported as positive or negative based on the culture source. Antimicrobial susceptibility testing is performed but not reported; however, physicians may obtain susceptibility information for MDR GNB only if clinically indicated through the microbiology department.~1. Nasal swab for MRSA~2. Respiratory specimens~i. Sputum for MRSA, VRE, and Multi Drug Resistant gram-negative Bacteria (MDR GNB) (if not intubated but with productive cough) ii. Endotracheal aspirate for MRSA, VRE, and MDR GNB (if intubated) c. Drainage from any wounds for MRSA, VRE, and MDR GNB d. Rectal/ perianal swab for VRE, and MDR GNB e. Urine for MRSA, VRE, and MDR GNB (from patients catheterized prior to admission only)"
223462190|NCT05237726|DRUG|Enoxaparin 40 mg q24 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
223462191|NCT05237726|DRUG|Enoxaparin 30 mg q12 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
223462192|NCT05237726|DRUG|Unfractionated heparin 5000 U q8 hours|Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
223462193|NCT02038179|DRUG|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.
223462194|NCT02038179|DRUG|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
223462195|NCT02899975|OTHER|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
223462196|NCT02927054|OTHER|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
223462197|NCT02426008|OTHER|Growth Factors and Cytokine adding to embryo culture media|
223462198|NCT02426008|OTHER|No Intervention|Nothing to Add
223462199|NCT00181675|DRUG|galantamine HBr|
223462200|NCT01820247|DRUG|enteral nutrition|
223462201|NCT01820247|DRUG|Tripterygium glycosides|
223462202|NCT02221648|DRUG|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
223462203|NCT02221648|DRUG|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
223462204|NCT00184938|DRUG|morphine|
223462205|NCT00184938|DRUG|naloxone|
223462206|NCT00184938|DRUG|Technetium-TC99m-labeled Annexin A5|
223462207|NCT00184938|PROCEDURE|forearm ischemic exercise|
223575715|NCT04796688|DRUG|Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells|fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
223575716|NCT03752268|BEHAVIORAL|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
223462208|NCT00184938|PROCEDURE|ten minute forearm ischemia|
223462209|NCT00953888|DRUG|AZD5069|Single dose of oral solution.
223462210|NCT00953888|DRUG|Placebo|Single dose of oral solution.
223462211|NCT06397430|DIETARY_SUPPLEMENT|parenteral nutrition supplements|parenteral nutrition
223462212|NCT06397430|DIETARY_SUPPLEMENT|enteral nutrition supplements|enteral nutrition
223462213|NCT06397430|DIETARY_SUPPLEMENT|mixed nutrition supplements|mixed nutrition
223462214|NCT03975257|DEVICE|Medical Device: Ectoin Lozenge|Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
223575717|NCT05910034|DRUG|Trilaciclib+Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
223575718|NCT05910034|DRUG|Envafolimab+Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
223462215|NCT03639246|DRUG|AVB-S6-500|AVB-S6-500 is experimental drug
223462216|NCT03639246|DRUG|Paclitaxel (Pac)|Paclitaxel is active comparator
223462217|NCT03639246|DRUG|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
223462218|NCT03639246|OTHER|Placebo|Placebo comparator
223462219|NCT05430802|DRUG|Furmonertinib+cisplating/pemetrexed|Furmonertinib 80mg/d for 9 weeks and cisplating75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv in 21-day cycles for 3 cycles
223462220|NCT05074641|OTHER|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
223462221|NCT05074641|OTHER|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
223462222|NCT02438189|DEVICE|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
223462223|NCT01168921|DRUG|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
223462224|NCT02937623|DEVICE|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight\[w/w\] calcium sodium phosphosilicate).
224157221|NCT05539872|DRUG|I004|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
224157222|NCT05539872|DRUG|NovoLog|Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
224157223|NCT03432767|DEVICE|Non-invasive hemoglobin monitor|
224157224|NCT00510107|DRUG|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
224157225|NCT00510107|DRUG|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
224157226|NCT01952093|BEHAVIORAL|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
224157227|NCT01952093|BEHAVIORAL|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
223462225|NCT00324974|DRUG|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
223462226|NCT00324974|DRUG|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
224157228|NCT02877316|OTHER|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
223743420|NCT05220137|BEHAVIORAL|Challenging Questions|The Challenging Questions session teaches the Veteran to question and confront maladaptive self-statements and stuck points. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
224157229|NCT02877316|OTHER|safety plan on paper|Standard treatment with safety plan on paper
224157230|NCT01544686|DEVICE|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
224157231|NCT02856906|OTHER|occlusal adjustment|
224157232|NCT05968872|BEHAVIORAL|no intervation|it is observational, no intervention was taken
224157233|NCT04746560|DEVICE|TEG®6S device with its Platelet mapping® cartridge|Platelet function monitoring using the TEG®6S device with its Platelet mapping® cartridge
224157234|NCT04673188|PROCEDURE|Reconstruction of MPFL with or without tibial tuberositas osteotomy|Reconstruction of the medial patellofemoral ligament with autologous grafts with or without osteotomy and transfer of tibial tuberosities.
224157235|NCT04771546|DEVICE|Colpofix|Intravaginal gel with carboxymtheyl beta-glucan and polycabophil. Posology: 1 application / day x 20 days, rest 10. Repeat 20 x 3 cycles
224157236|NCT02551913|BEHAVIORAL|Control|the adolescents will not receive any specific intervention
223462227|NCT06522815|DEVICE|CART-I plus|"CART-I PLUS collects signals in two ways:~ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle.~PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin.~In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method."
223462228|NCT06522815|DEVICE|Polysomnography|"In polysomnography, the following data are collected:~Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring"
224157237|NCT02551913|BEHAVIORAL|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
224157238|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
224157239|NCT01425320|DRUG|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
224157240|NCT01425320|DRUG|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
224157241|NCT01425320|DRUG|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
224157242|NCT05967208|BEHAVIORAL|CONSORT referrals|"Participants will be offered SMS-based confidential social network referrals for HIV testing (CONSORT referrals) to extend to any of their social and sexual network contacts."
224157243|NCT05967208|BEHAVIORAL|Card referrals|"Participants will be offered physical invitation cards (card referrals) to extend to any of their social and sexual network contacts."
224157244|NCT00026585|DRUG|Tamoxifen|
224157245|NCT02868099|DRUG|Romiplostim|
224157246|NCT02868099|DRUG|Placebo|
224157247|NCT05703113|BEHAVIORAL|Web 2.0 tools|Education with Web 2.0 tools
224157248|NCT04776915|DIAGNOSTIC_TEST|Ultrasound and Hysterosalpingography|Ultrasound and Hysterosalpingography
224157249|NCT02068586|DRUG|Sunitinib|Given PO
224157250|NCT02068586|DRUG|Valproic Acid|Given PO
223743421|NCT05220137|BEHAVIORAL|Patterns of Problematic Thinking|The Patterns of Problematic Thinking session teaches the Veteran to identify counterproductive thinking patterns. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
224157251|NCT02068586|DRUG|Sunitinib Malate|Given PO
224157252|NCT02068586|DRUG|Sunitinib Malate + Valproic Acid|Given PO
224157253|NCT01691053|DRUG|Spironolactone|50mg once daily
224157254|NCT01691053|DRUG|Placebo|Placebo
224157255|NCT04451317|OTHER|Questionnaire, phone call|phone call and 3 questionnaires on a digital platform
224157256|NCT04727645|OTHER|Philips interventional MRI suite (Philips Healthcare, Best, the Netherlands)|iSuite is an an electroanatomical mapping system (EAM) designed to support real-time MRI guided interventional procedures.
223462229|NCT05060575|OTHER|Education and Telephone Counceling|"Drug use and rational drug use training will be given to hypertension patients in the experimental group.~The patients in the experimental group twice in the 1st month (2nd and 4th weeks), once in the 2nd month (8th week) and once in the 3rd month (12th week) phone call counseling will be providedved an average of 10-15 minutes."
223462230|NCT03207191|DRUG|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
223462231|NCT03207191|DRUG|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
223575719|NCT05910034|DRUG|Docetaxel|This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
223575720|NCT03029078|DRUG|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
223743422|NCT05220137|BEHAVIORAL|Challenging Beliefs|The Challenging Beliefs session teaches the Veteran to generate alternative thoughts based on the outcome of cognitive restructuring. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
224157257|NCT05263687|DIAGNOSTIC_TEST|Maximal exercise test|Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
223462232|NCT04687904|BEHAVIORAL|Mindfulness meditation training|Patients will be able to benefit from mindfulness meditation training at the rate of 1h30 in the morning and 1h30 in the afternoon. During this training, patients will be invited to share with the psychologist their vision of mindfulness meditation and their expectations of this practice. The psychologist will then introduce what mindfulness is and how the sessions will take place. Several sessions guided by the psychologist will then be offered to the patient (body scan, focused attention, mindfulness movements...).
223462233|NCT04687904|BEHAVIORAL|Therapeutic education|"Patients will benefit from a 2-hour interview which will be conducted by the psychologist associated with the project.~The aim of this interview is to help patients better understand their disease in order to adopt the right behaviors on a daily basis. This session will inform patients about their disease, its origins, its treatment, the difficulties it causes and the means to remedy it. The objective of this session is to better understand and manage epilepsy and to enable patients to take an active part in the process of care and management of the disease.~No specific instructions will be given at the end of this interview."
223462234|NCT02533934|DRUG|Harvoni|Treatment of Hepatitis C with sofosbuvir based HCC therapy
223462235|NCT03198858|PROCEDURE|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
223462236|NCT03198858|PROCEDURE|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
223743423|NCT05220137|BEHAVIORAL|Veteran's choice of Module (Safety/Trust/Power and Control/Esteem/Intimacy)|The therapist will present the Module options to the Veteran and the Veteran will select one Module to work on. As in standard CPT, each session will begin with a review of homework from the previous session, and then provide the listed component.
223743424|NCT06876077|OTHER|Auricular acupuncture|Auricular acupuncture is administered in each side of the ear for 4 weeks using patches, each possessing a square shape with a side length of 10 mm, coupled with a sterilized needle measuring 0.25 x 1.3 mm. Five acupoints are selected on one ear, including the will be performed at Shenmen (TF4), Mu 1 (TG2b), Mu 2 (AT1b), Kidney (CO10), and Liver (CO12). These acupoints are believed to be effective in relieving dry eye symptoms. The patch will be kept on the auricle for 5 days and be replaced 5 times during the experimental period.
224067936|NCT01277549|DEVICE|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
224067937|NCT01437020|DRUG|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
224067938|NCT01437020|DRUG|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
224067939|NCT05084911|DRUG|Pyramax|Pyronaridine-Artesunate(180/60mg) tablet for 3days.
224067940|NCT05084911|DRUG|Placebo|Placebo tablet for 3days.
224067941|NCT03344302|DRUG|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
224067942|NCT01365559|DRUG|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
224067943|NCT01365559|DRUG|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m\^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
224157258|NCT02873208|DRUG|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
223462237|NCT03215537|BEHAVIORAL|comprehensive intervention|preoperative and postoperative exercise program
223575721|NCT02606435|PROCEDURE|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
223575722|NCT02606435|DEVICE|thrombus aspiration|thrombus aspiration with export catheter
223575723|NCT01618383|OTHER|colonoscopy or rectosigmoidoscopy|Usual procedure
223575724|NCT03289221|DIAGNOSTIC_TEST|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
223575725|NCT02032693|DIETARY_SUPPLEMENT|Everycell™|
223575726|NCT02032693|OTHER|Placebo|
223575727|NCT06078111|BEHAVIORAL|Prism 10 + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with 10 degrees of visual field deviation
223575728|NCT06078111|BEHAVIORAL|Neutral Prism + visuo-motor activities|Visuo-motor activities of exploration in the left and right space, adapting activities of daily living, while wearing prisms with no visual field deviation
223462238|NCT04693780|OTHER|Structured guide|Structured guide
223462239|NCT04693780|OTHER|List|List
223462240|NCT02900248|OTHER|Provider determined|Provider will treat patient as he/she feels best
223462241|NCT06367946|PROCEDURE|mechanical ventilation|Mechanical ventilation is machine-delivered flow of gases to both oxygenate and ventilate a patient who is unable to maintain physiological gas exchange.
223462242|NCT01922258|DRUG|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
223462243|NCT00673257|OTHER|pharmacological study|pharmacological studies
223462244|NCT00673257|PROCEDURE|dual x-ray absorptimetry|
223462245|NCT05855837|OTHER|Ready to Eat Cereal|Cereal products available in retail stores
223462246|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
223462247|NCT00299819|BIOLOGICAL|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
223462248|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
223462249|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
223462250|NCT00299819|BIOLOGICAL|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
223575729|NCT00940095|DRUG|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
223575730|NCT00940095|DRUG|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
223575731|NCT00940095|DRUG|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
223462251|NCT04956510|OTHER|Evaluation|health status and quality of life were evaluated
223575732|NCT00723346|BIOLOGICAL|GRASPA|50 UI/Kg
223462252|NCT02183012|DRUG|Ibuprofen extrudate|
223462253|NCT02183012|DRUG|Ibuprofen lysinate|
223575733|NCT00723346|BIOLOGICAL|GRASPA|100 UI/Kg
223462254|NCT02183012|DRUG|Ibuprofen|
223462255|NCT04397874|DIAGNOSTIC_TEST|; Computerized cardiotocography (cCTG)|To estimate the correlation between the maternal perception of fetal movement and antepartum computerised cardiotocography parameters.
223462256|NCT02638779|BIOLOGICAL|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
223462257|NCT04979091|DIAGNOSTIC_TEST|Sex Hormones|A panel of 13 hormones was measured in plasma samples of COVID-19 patients (total testosterone, free testosterone, dihydrotestosterone, androstenedione, 17-β-estradiol, estrone, sex hormone-binding globulin, thyroid-stimulating hormone, free triiodothyronine (T3), free thyroxine (T4), luteinizing hormone, follicle-stimulating hormone and cortisol).
223462258|NCT03722706|OTHER|Educational handbook|The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
223462259|NCT04552132|DEVICE|Multisonic vs Sonic activation of irrigants|Energy is input into the intracanal irrigants for activation in the hopes of increasing irrigant efficacy.
223462260|NCT04846192|OTHER|Nutritional evaluation|Collecting existing data on pre operative nutritional status and outcomes after surgery
223462261|NCT00920959|DRUG|FP 100mcg|Once-daily dosing
223462262|NCT00920959|DRUG|FSC 100/50mcg|Once-daily dosing
223462263|NCT00920959|DRUG|Placebo|Once-daily dosing
223462264|NCT03365661|BIOLOGICAL|ALT-803|A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains \> 2 x 105 α/β T cells/kg recipient weight.
223462265|NCT02996916|DRUG|Olmesartan|10-40mg daily
223575734|NCT00723346|BIOLOGICAL|GRASPA|150 UI/Kg
223575735|NCT00723346|DRUG|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
223462266|NCT02996916|DRUG|Amlodipine|2.5-10mg daily
223462267|NCT05679453|DRUG|Lornoxicam 8 Mg Oral Tablet|Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
223462268|NCT05023538|OTHER|Cycling|Exercise on bicycle ergometer
223575736|NCT00061074|DRUG|Nicotrol|
223575737|NCT01740479|PROCEDURE|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
223575738|NCT05325216|PROCEDURE|POPRC+OIN|Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder
223575739|NCT05325216|PROCEDURE|SRC+OIN|Standard radical cystectomy with orthotopic ileal neobladder
223575740|NCT03114436|OTHER|Observational Data Collection|All aspects of deceased donor care in the ICU.
223575741|NCT00701142|BIOLOGICAL|Haemocomplettan® P|Single intravenous infusion
223575742|NCT00701142|BIOLOGICAL|Saline solution|Single intravenous infusion
223575743|NCT00033540|DRUG|capecitabine|650 mg/m\^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
223575744|NCT00033540|DRUG|gemcitabine hydrochloride|1000 mg/m\^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
223575745|NCT03366103|BIOLOGICAL|Navitoclax|Given PO
223575746|NCT03366103|DRUG|Vistusertib|Given PO
223575747|NCT03897946|BIOLOGICAL|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
223462269|NCT06121440|OTHER|Listening to audiobook|Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.
223462270|NCT06121440|OTHER|Playing musical-moving toy|Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
223462271|NCT06478329|OTHER|Progressive Core Stabilization Exercise Training|The effects of 6 weeks progressive core stabilization exercise training on adolescent volleyball players' balance, strength and endurance
223575748|NCT03670329|DEVICE|URGO2875|Dressing
223575749|NCT01036529|DEVICE|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
223462272|NCT03540732|OTHER|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
223462273|NCT03540732|PROCEDURE|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
223462274|NCT00595543|DRUG|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
223462275|NCT00595543|DRUG|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
223462276|NCT00595543|DRUG|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
223462277|NCT00512499|BEHAVIORAL|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
223462278|NCT00512499|BEHAVIORAL|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
223462279|NCT00512499|BEHAVIORAL|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
223462280|NCT02256839|DEVICE|CST_001|
223462281|NCT01918917|DRUG|Levobupivacaine|intraarticular
223575750|NCT01036529|PROCEDURE|Back Surgery|Different types of back surgery may be performed
223575751|NCT01497821|DRUG|AMG 172|AMG 172 is an antibody drug conjugate
223462282|NCT01918917|DRUG|Dexmedetomidine|intraarticular 1 ml (100 mcg)
223575752|NCT01340781|PROCEDURE|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
223575753|NCT00456976|DRUG|Selegiline|
223575754|NCT05295823|DEVICE|Butterfly portable ultrasound device with bladder ultrasound images|Point-of-care PVR measurement using existing ultrasound technology (3 consecutive measurements during the same encounter) the Butterfly portable ultrasound device with bladder ultrasound images
223462283|NCT01918917|DRUG|Morphine|intravenously, patient-controlled analgesia
223462284|NCT03930095|BEHAVIORAL|Acceptance-based Behavior Therapy|The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
223575755|NCT05295823|DEVICE|Butterfly portable ultrasound device with abstract bladder images|Point-of-care PVR measurement using the Butterfly portable ultrasound device with abstract bladder images
223575756|NCT03696082|BEHAVIORAL|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
223575757|NCT03696082|BEHAVIORAL|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
223575758|NCT03696082|BEHAVIORAL|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
224067944|NCT00599040|BEHAVIORAL|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
223462285|NCT03930095|BEHAVIORAL|Non-directive Supportive Therapy|NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
223462286|NCT03119948|DRUG|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
223462287|NCT03119948|DRUG|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
223462288|NCT03119948|DRUG|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
223462289|NCT04928144|DRUG|SHJ - Low concentration|Topical ophthalmic
223462290|NCT04928144|DRUG|SHJ - Mid concentration|Topical ophthalmic
223462291|NCT04928144|DRUG|SHJ - High concentration|Topical ophthalmic
223462292|NCT04928144|DRUG|SHJ - Maximum tolerated|SHJ - Maximum tolerated
223462293|NCT01834456|OTHER|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
223462294|NCT04964661|OTHER|Medical Imaging|MRI imaging
223462295|NCT00121719|DRUG|Lenvatinib|Lenvatinib tablets taken orally, once daily.
223462296|NCT01748019|DRUG|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
223462297|NCT01951417|DRUG|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
223462298|NCT01951417|OTHER|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
223462299|NCT01951417|OTHER|Foam Wash|Foam Wash (twice daily)
223462300|NCT06420817|BEHAVIORAL|Indian version of a 'Portfolio' diet|The participants will be required to follow the prescribed diet plan for 4 weeks
223462301|NCT06420817|BEHAVIORAL|Physical Activity|"The participants will be required to join for an hour of group online exercise program 3 days a week for 4 weeks~• (Exercise Duration = 180 minutes per week including cardio, strength training and flexibility)"
223575759|NCT03696082|BEHAVIORAL|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
223575760|NCT00052312|DRUG|cisplatin|
223575761|NCT00052312|DRUG|doxorubicin hydrochloride|
223575762|NCT00052312|DRUG|paclitaxel|
223462302|NCT06420817|BEHAVIORAL|Intermittent fasting|The participants will be required to do intermittent fasting for 12 hours daily for 4 weeks
223462303|NCT06420817|BEHAVIORAL|Monitoring of sleep and stress levels|The participants will be required to monitor their sleep and stress levels
223462304|NCT02664077|DRUG|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
223575763|NCT04287088|DIAGNOSTIC_TEST|A shared decision making|Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
223575764|NCT02995226|OTHER|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
223575765|NCT02995226|OTHER|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
223462305|NCT02664077|DRUG|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
223462306|NCT03644420|DIAGNOSTIC_TEST|Clinical evaluation|Functional scores for the pathological joint will be determined
223462307|NCT03644420|DIAGNOSTIC_TEST|Radiology|
223462308|NCT03644420|DIAGNOSTIC_TEST|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
223462309|NCT03644420|DIAGNOSTIC_TEST|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
223575766|NCT05472077|DIAGNOSTIC_TEST|Lollipop Swab|"The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop."
223575767|NCT03983772|DIETARY_SUPPLEMENT|RS blend|The intervention is a proprietary resistant starch blend.
223575768|NCT03983772|OTHER|Placebo|The placebo is starch.
223575769|NCT00819494|PROCEDURE|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
224067945|NCT00599040|BEHAVIORAL|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
223575770|NCT01386268|BIOLOGICAL|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
223575771|NCT03129594|DIAGNOSTIC_TEST|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
223575772|NCT01853072|DRUG|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
223575773|NCT01853072|OTHER|Nepafenac vehicle|Inactive ingredients used as placebo comparator
223575774|NCT01853072|DRUG|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
223575775|NCT05908526|BEHAVIORAL|Baseline surveys, Cognitive testing and EMAs|Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
223575776|NCT05908526|DEVICE|Actiwatch|Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
223575777|NCT05908526|DRUG|suvorexant (or placebo)|FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
223575778|NCT05908526|OTHER|Placebo|An inactive substance that looks like the drug or treatment being tested.
223575779|NCT00440856|BEHAVIORAL|Presentation of excised intervertebral disc fragments|
223575780|NCT02585648|DEVICE|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
223575781|NCT02585648|DEVICE|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
223575782|NCT01816906|DEVICE|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
223575783|NCT01816906|DEVICE|Footwear: MCP|One group of patients will receive footwear with MCP insoles
223575784|NCT01304810|BIOLOGICAL|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
223575785|NCT01304810|BIOLOGICAL|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
223575786|NCT05828472|DRUG|MY008211A tablets|MY008211A tablets, low/moderate/high dose orally, for 7 days
223575787|NCT05828472|DRUG|MY008211A tablets matched placebo|MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
223575788|NCT04199364|DRUG|Poractant Alfa 80 mg/mL Intratracheal Suspension|Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.
223575789|NCT03283397|DRUG|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
223575790|NCT03283397|DRUG|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
223575791|NCT01628861|DEVICE|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
223575792|NCT01628861|BEHAVIORAL|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
224157259|NCT04411706|DRUG|Sintilimab Combined With Apatinib and Capecitabine|"Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;"
224157260|NCT05126134|DIAGNOSTIC_TEST|KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)|completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h
223575793|NCT02544334|PROCEDURE|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
223575794|NCT02544334|OTHER|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
223575795|NCT02544334|OTHER|Saliva Collection|All participants will have a saliva collection.
223575796|NCT00690170|DRUG|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
223575797|NCT00690170|DRUG|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
223575798|NCT00690170|DRUG|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
223575799|NCT00690170|DRUG|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
223575800|NCT05995197|OTHER|action observation|cartoon observation
224067946|NCT00599040|BEHAVIORAL|Dairy diet|participants are given a high dairy, reduced calorie diet
224067947|NCT05468632|DRUG|Semaglutide|Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
224067948|NCT04051437|PROCEDURE|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
224067949|NCT04051437|DRUG|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
223575801|NCT03950713|BEHAVIORAL|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
223575802|NCT00746733|DRUG|Lisdexamfetamine Dimesylate|50mg capsule
223462310|NCT04577417|DRUG|ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate|Both ADHD and control groups of subjects will participate in 2 sessions (on-med and off-med conditions) conducted on the same day. ADHD group will be asked to come to the laboratory in the morning before taking their morning ADHD stimulant medication. They will be tested before and after taking their ADHD medication (off-med and on-med conditions). The investigators will observe changes between the two conditions.
223575803|NCT00746733|DRUG|Adderall XR (mixed salts amphetamine)|20mg capsule
223575804|NCT01527383|BIOLOGICAL|V212|V212 viral antigen for HZ
223575805|NCT01527383|BIOLOGICAL|Placebo|Placebo comparator to V212 vaccine
223575806|NCT00206284|DRUG|AZD0865|
223575807|NCT04041427|DRUG|Albendazole Pill|Albendazole 400mg po
223575808|NCT04041427|OTHER|High fat content diet|High fat content diet
223575809|NCT04041427|OTHER|Moderate fat content die|Moderate fat content die
223575810|NCT03854292|PROCEDURE|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
223575811|NCT05221775|DRUG|Lenvatinib|XELOX regimen combined with GLS-010 and different doses of Lenvatinib
224157261|NCT04401410|BIOLOGICAL|Dose Finding Phase (MTD)|Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
223462311|NCT01816178|BEHAVIORAL|communication training|Participants were instructed in the use of a voices output communication aid.
223462312|NCT01497067|DEVICE|ACRYSOF CACHET Phakic Lens (L-series)|Intraocular lens for the treatment of moderate to high myopia
223462313|NCT01472445|DRUG|Vitamin D|
223575812|NCT02984059|GENETIC|Genomic DNA|blood draw
223575813|NCT02984059|GENETIC|RNA analysis|Mucosal Biopsy via colonoscopy
223575814|NCT02984059|GENETIC|Microbiome|Stool microbiome
223575815|NCT02984059|OTHER|Calprotectin|stool or blood analysis for calprotectin
223575816|NCT02984059|OTHER|Pain questionnaires|PSDS PCS-C/P PBI APPT
223575817|NCT02984059|OTHER|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
223575818|NCT03412604|DEVICE|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
223575819|NCT05300841|DRUG|dydrogesterone 20 mg /d (Duphaston, Abott Healthcare , Egypt)|Pretreatment with dydrogestrone (Duphaston, Abott Healthcare, Egypt) will be administered during the cycle preceding the ICSI cycle in a daily dose of 20 mg/ day starting 10 days before the presumed onset of menses
224067950|NCT01595776|OTHER|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
224067951|NCT04467307|DEVICE|Rigit bronchoscopy|After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
224067952|NCT06542055|OTHER|Preoperative and postoperative pulmonary rehabilitation exercise|Besides receiving preoperative thoracic surgery health education manuals and postoperative regular pulmonary rehabilitation exercises, they also receive exercises originally tailored for pulmonary rehabilitation, including upper-body resistance exercise, lower-body resistance exercise, aerobic exercise, and respiratory muscle training for 4-7 days before surgery. In addition, a communication app group will be set up and an exercise diary will be provided.
224067953|NCT06542055|OTHER|Preoperative education and postoperative exercise|Receiving preoperative thoracic surgery health education manual and postoperative regular pulmonary rehabilitation exercises
224067954|NCT03339921|DRUG|Botulinum toxin injections for chronic compartment syndrome|Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
224067955|NCT03339921|PROCEDURE|surgical fasciotomy for chronic compartment syndrome|linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
224067956|NCT01438580|DRUG|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
224067957|NCT01438580|DRUG|aspirin|100mg aspirin was administrated every day
224067958|NCT02109900|OTHER|Serum Progesterone Levels|
224067959|NCT05934500|DRUG|Cannabidiol Oil|Subjects will self administer CBD sublingually
224067960|NCT00571350|PROCEDURE|tvt-o operation|transvaginal tention free obturator tape
224067961|NCT00571350|PROCEDURE|tvt o operation|transobturator vaginal tape insertion
224157262|NCT04401410|BIOLOGICAL|Partially HLA-matched SARS-CoVSTs|Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
223462314|NCT03130933|PROCEDURE|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures."
223462315|NCT03130933|DRUG|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
223462316|NCT03130933|OTHER|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
223462317|NCT00382785|BEHAVIORAL|moderated support|one 12-week online support group led by a professional healthcare provider
223462318|NCT00382785|BEHAVIORAL|peer-led|12-week online support in a peer-led format
223462319|NCT01649115|OTHER|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
223462320|NCT00649077|DRUG|Meloxicam Tablets 15 mg|15mg, single dose fasting
223462321|NCT00649077|DRUG|Mobic® Tablets 15 mg|15mg, single dose fasting
223462322|NCT01167348|PROCEDURE|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
223462323|NCT03919123|OTHER|Evaluation of laparoscopic promontofixation|Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
223462324|NCT01535313|DEVICE|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
223462325|NCT01598610|DEVICE|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
223462326|NCT05826210|PROCEDURE|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was performed in all patients with or without SO.
223462327|NCT04346199|DRUG|Acalabrutinib|Acalabrutinib- administered orally
223462328|NCT00228228|BIOLOGICAL|T cell vaccination|
223462329|NCT00653367|PROCEDURE|Nerve section|Intercostal nerve is divided during surgery
223462330|NCT02921945|BIOLOGICAL|SCT800|recombinant human coagulation factor VIII
223462331|NCT02925858|DRUG|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
223462332|NCT02925858|DRUG|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
223462333|NCT05449171|OTHER|high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D|Patients will take an association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, from the first visit at the experimental center (within the 12th week of gestation) for 3 months.
223462334|NCT06140433|DEVICE|VSC-MEDlib|VSC-MEDlib will be used for post-processing
223462335|NCT01043978|BEHAVIORAL|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
223462336|NCT05397197|OTHER|Electroencephalography|experimental task, neuropsychological evaluation, clinical exam
223462337|NCT01705977|BIOLOGICAL|Placebo plus standard therapy|Placebo plus standard therapy
223575820|NCT05300841|DRUG|estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Shering, Germany)|will receive dydrogestrone 10mg /day plus estradiol valerate 2 mg /d (white tablets of cycloprognova, Bayer Schering, Germany) for 10 days.
223462338|NCT01705977|BIOLOGICAL|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
223462339|NCT01705977|OTHER|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
223462340|NCT03764514|DEVICE|Spinal Cord Stimulator|Permanent Implantation
223462341|NCT03227718|BEHAVIORAL|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
223462342|NCT06560684|DRUG|Oral F/TDF Pills|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated RAI.
223462343|NCT06560684|DRUG|TFV rectal douche|For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
223462344|NCT05341973|BEHAVIORAL|Education|Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
223575821|NCT05476432|PROCEDURE|HAIC|The microcatheter was advanced into the hepatic artery, and patients were transferred to the inpatient ward for drug infusion via the hepatic artery
223575822|NCT05476432|DRUG|FOLFOX 2d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 46 hours
223575823|NCT05476432|DRUG|FOLFOX 1d|Oxaliplatin, leucovorin, bolus fluorouracil, and infusional fluorouracil 2400 mg/m² over 23 hours
224067962|NCT01109914|BIOLOGICAL|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~* Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria\*~* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria\*~* Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
224067963|NCT02733666|PROCEDURE|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
224067964|NCT04580381|DRUG|Natalizumab Injection [Tysabri]|Natalizumab infusion interval according to local practice defining the patient's group
223462345|NCT05288322|PROCEDURE|Mostafa Maged maneuver|"The Mostafa Maged maneuveur has been applied to those all female patients to prevent or control post-partum bleeding in normal delivery . The Mostafa Maged technique is applied by :- (Description of the new Mostafa Maged technique) :-~1. First , placing our right hand to the posterior fornix of vaginal canal trying to cuddle the lower part of uterus compressing the anterior and posterior walls of the uterus .~2. Second , placing our left hand over the fundus of the uterus and the posterior wall of uterus from the abdominal part.~3. Third , by our two hands , trying to grasp the whole uterus by our two hands abdominally and vaginally against the symphysis pubis as if the uterus is cuddling the symphysis pubis bone and in this way , we try to get the anterior and posterior walls against each other and reducing the intra-cavitary space so we prevent the expansion of the uterus ."
223462346|NCT03066830|DRUG|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
223462347|NCT03066830|DRUG|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
223462348|NCT03066830|DRUG|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
223462349|NCT03066830|DRUG|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
223462350|NCT00045799|DRUG|Omeprazole sodium bicarbonate immediate release PWD/FS|
223462351|NCT00045799|DRUG|Cimetidine IV|
223462352|NCT02039778|RADIATION|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin \& the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
223462353|NCT00765856|DRUG|Oxymorphone ER|"Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications"
223462354|NCT02198846|DEVICE|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
223462355|NCT02198846|DRUG|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
223462356|NCT06309667|DRUG|PG-102(MG12)|GLP-1 and GLP-2 fusion protein
223462357|NCT06309667|OTHER|Placebo|Placebo drug of PG-102(MG12)
223462358|NCT04786691|OTHER|Addition of half and half to coffee|1 oz of half and half is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
223462359|NCT04786691|OTHER|Addition of non-dairy creamer to coffee|1 oz of non-dairy creamer is added to 12 oz of black coffee and given to participants assigned to this arm after the baseline gastric ultrasound
223462360|NCT04786691|OTHER|Black|No Creamer
223462361|NCT03801642|DRUG|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
223462362|NCT03801642|OTHER|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
223462363|NCT05782803|BEHAVIORAL|Exercises Group|A Pressure Biofeedback Device will be used in CCF training to increase awareness and focus on the desired muscle. After the person is brought to the hook position, the pressurized biofeedback device will be placed in the middle position between the craniocervical and cervical vertebrae or horizontally so that the protrusion between the earlobe and the chin is removed. It is inflated to a standard 20 mmHg to ensure surface-to-longitudinal contact. Participants are taught the correct craniocervical flexion movement without first working the superficial muscles. The patient is then asked to look with their eyes slightly toward the chest cavity. During the exercises, starting from 20 mmHg and increasing by 2 mmHg, the desired level of 30 mmHg will be reached. At each level, the movement is continued for 10 seconds, resting for 3-5 seconds, 10 repetitions are required. If the same level is maintained for 10 seconds and 10 repetitions, the next level is passed.
223462364|NCT05943470|DRUG|Icodextrin Peritoneal Dialysis Solution|alternative day use of icodextrin comparing with daily use of icodextrin
223462365|NCT03513679|PROCEDURE|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
223462366|NCT04346160|DIAGNOSTIC_TEST|Schirmer Test I|Collection of tear fluid
223462367|NCT05222165|DRUG|Infigratinib|Hard gelatin capsules for oral use
223575824|NCT06126367|DIAGNOSTIC_TEST|Thrombotic assessment|"The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
223575825|NCT06126367|DIAGNOSTIC_TEST|Measurement of Lp(a)|"Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification."
223575826|NCT00027586|DRUG|Imatinib mesylate (STI571)|400 mg twice a day orally
223575827|NCT02989844|DRUG|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
223462368|NCT02571556|DRUG|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
223462369|NCT05959967|BEHAVIORAL|Vestibular Rehabilitation Exercises|The VRE group will receive exercises aimed at improving gaze stability, postural control, and balance. This includes activities like gaze stabilization exercises, balance training on different surfaces, and walking with head movements.
223462370|NCT05959967|BEHAVIORAL|General Fitness Training|The GFT group will undertake exercises to enhance cardiovascular fitness, strength, and flexibility, such as light aerobic exercises, resistance training, and stretching. The exercise sessions will be 60 minutes in duration, consisting of a warm-up phase, the main exercise phase, and a cool-down phase.
223462371|NCT01131390|DEVICE|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
223462372|NCT02298426|BEHAVIORAL|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
223462373|NCT02298426|BEHAVIORAL|General Management|We provide general information about health. Information is provided through telephones and materials.
223462374|NCT02298426|OTHER|Placebo|We use placebo to replace the health product.
223462375|NCT02298426|DIETARY_SUPPLEMENT|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
223462376|NCT01185470|DEVICE|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
223462377|NCT00096538|DRUG|valganciclovir|
223462378|NCT04522557|DRUG|IFNα-2a|After mastectomy, it is used in the cavity of breast before conducting implantation.
223462379|NCT01211756|DRUG|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
223462380|NCT01211756|DRUG|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
223462381|NCT01877161|DEVICE|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
223462382|NCT01877161|DEVICE|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
223462383|NCT01877161|DEVICE|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
223462384|NCT00473447|BEHAVIORAL|Modified Constraint-induced movement therapy|
223575828|NCT05449275|OTHER|Faradic current|The most common Electrical stimulation applied for foot drop is faradic current. Faradic current provides the strength and improvement to volitational muscles and increase the coordination and reduce spasticity.
223575829|NCT05449275|OTHER|Ankle foot orthosis|AFO is most commonly used technique but it also has some disadvantage mainly is the movement in limited direction and also in development of contractures and may have the problem in standing from chair
224157263|NCT04401410|OTHER|Routine care (no SARS-CoVSTs)|Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
223462385|NCT03603119|DRUG|Normal saline, Midazolam|2 cc normal saline i.v. after anaesthesia induction.2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery
223462386|NCT03603119|DRUG|Dexamethasone, ondansetron|8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
224157264|NCT01240967|DRUG|TC-5214|Oral tablets, single dose
224157265|NCT04080752|DRUG|JNJ-61393215|JNJ-61393215 will be administrated orally.
224157266|NCT04080752|DRUG|Placebo|Matching placebo will be administered orally.
224157267|NCT06265467|PROCEDURE|Closed Sinus Elevation|using a unique design of osteotomes to crestally elevate the Schneiderian membrane of the maxillary sinus floor
224157268|NCT06265467|PROCEDURE|Open Sinus Elevation|using a unique design of sinus elevators to laterally elevate the Schneiderian membrane of the maxillary sinus floor
224157269|NCT00379886|DRUG|Propofol Thiopental|
223462387|NCT04338477|DRUG|Nephrosolid tablets|Adminstration of drug
224157270|NCT01192100|BEHAVIORAL|Breakfast Skipping|Participants will continue to skip breakfast each morning.
223462388|NCT04551664|DRUG|Best medical management|All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate.
223462389|NCT04551664|PROCEDURE|Endovascular therapy|In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy (recommended with Solitaire、EMBOTRAP、Trevo or Reco revascularization device) or aspiration thrombectomy (recommended with Penumbra) will be recommended as the primary treatment.
223462390|NCT02171117|PROCEDURE|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
224157271|NCT01192100|BEHAVIORAL|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
224157272|NCT01192100|BEHAVIORAL|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
224303120|NCT05134896|DEVICE|Spatial light modulator|This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
223462391|NCT02171117|BIOLOGICAL|HLA-mismatched donor peripheral stem cell infusion|
223462392|NCT04423640|OTHER|Active COVID-19 disease|Adult patients admitted to the UMAE Specialty Hospital of CMN SXXI with a diagnosis of COVID-19. The diagnosis must be corroborated by the RT-PCR test.
223462393|NCT01827592|DRUG|Elobixibat 10 mg|Elobixibat 10 mg/day
223462394|NCT01827592|DRUG|Elobixibat 5 mg|Elobixibat 5 mg/day
223462395|NCT01827592|DRUG|Placebo|Placebo
223462396|NCT00178516|OTHER|behavior, procedure|
223462397|NCT00331565|PROCEDURE|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
223462398|NCT05651386|OTHER|Diet|No blinded, no controlled intervention.
223462399|NCT02057263|DRUG|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
223462400|NCT02057263|DRUG|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
223462401|NCT02057263|DRUG|Placebo|Participants will receive 4 doses of placebo during the course of the study.
223462402|NCT04030741|DRUG|Meronem and flagyl|meronem and flagy
224157273|NCT04409730|OTHER|Photographic Posture Analysis|Postural evaluation was done using the photographic method. All measurements were made by two researchers experienced in postural analysis evaluation. Canon camera and national geographic tripod with double spirit level were used for evaluation. The camera was placed on a 115 cm high tripod, 1.5 m away from the subjects. Spirit levels have been adjusted so that the tripod is completely flat on the ground. The tripod was taped to the floor to maintain the same distance between the camera and the participants. Six photographs of each child whose feet on the ground, in a free-sitting position, 3 from the front and 3 sides were taken by the researchers.
224157274|NCT00921427|BEHAVIORAL|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
223462403|NCT04030741|PROCEDURE|Appendectomy|Appendectomy as treatment for acute appendicitis
223462404|NCT03334357|OTHER|PAR|
223462405|NCT03334357|OTHER|HIIT|
223462406|NCT03334357|OTHER|WB-EMS|
223462407|NCT02390089|DRUG|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
223462408|NCT02390089|OTHER|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
223462409|NCT02390089|RADIATION|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
223462410|NCT02390089|DEVICE|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
223462411|NCT03995888|DRUG|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
223462412|NCT01345656|DRUG|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
223462413|NCT01345656|DRUG|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
223462414|NCT01345656|DRUG|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
223462415|NCT01345656|DRUG|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
223462416|NCT01345656|DRUG|Placebo|Placebo tablets for duration of 4 weeks
223462417|NCT01345656|DRUG|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
223462418|NCT01377636|DRUG|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
223462419|NCT03030625|RADIATION|IGRT/VMAT focal therapy boost to DIL|Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
223462420|NCT04988334|OTHER|Wait Control|usual activities
223462421|NCT05293782|OTHER|Kinesitaping|Kinesiotaping - muscle facilitation technique
223462422|NCT01388933|DRUG|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
223462423|NCT01388933|DRUG|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
223462424|NCT03669601|DRUG|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
223462425|NCT03669601|DRUG|Gemcitabine|Nucleoside metabolic inhibitor.
223462426|NCT02590055|DRUG|gemcitabine/docetaxel combination|
223462427|NCT02459522|OTHER|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
223462428|NCT00168571|BIOLOGICAL|Measles vaccine|
223462429|NCT05031377|BEHAVIORAL|HE programme|Participants will receive a 12-week integrated exercise and cardiovascular health education programme (HE programme) which is constructed based on self-efficacy theory. A booster intervention in the form of SMS messaging will be given from Week 1 to Week 12.
223462430|NCT05031377|BEHAVIORAL|Usual care|Participants will receive usual care which primarily includes an education talk on basic health issues. Governmental health education leaflets will be provided for reference.
223462431|NCT04102384|OTHER|e-PRO App|The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
223462432|NCT04087837|DEVICE|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
223462433|NCT04087837|DEVICE|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
223462434|NCT00309023|DRUG|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
223462435|NCT05291923|OTHER|no intervention|no intervention
223462436|NCT04969588|DIAGNOSTIC_TEST|Microsoft Azure Kinect Developer Kit|3D images and 3D joint coordinates are obtained.
224157275|NCT00921427|DEVICE|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
224157276|NCT01784003|DEVICE|Powered ankle-foot prosthesis|
224157277|NCT01009736|DIETARY_SUPPLEMENT|tomato-soy juice|
224157278|NCT01009736|OTHER|laboratory biomarker analysis|
223575830|NCT02916225|BEHAVIORAL|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
223575831|NCT02916225|BEHAVIORAL|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
223575832|NCT02242175|DEVICE|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
223575833|NCT04217161|DEVICE|Dexcom G6 Continuous Glucose Monitor|Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement
223575834|NCT01711229|DRUG|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
223575835|NCT01711229|DRUG|oral acetaminophen|oral acetaminophen will be given preoperatively
223575836|NCT02183129|DRUG|Diclofenac|
223575837|NCT02183129|DRUG|Meloxicam|
223575838|NCT04630717|OTHER|Medical hypnosis session|"the therapist will use a standard and identical protocol in all patients: the International characteristics of the hypnosis protocol are the following hypnotic induction through conversational hypnosis and interviewing about leisure activity.~A catalepsy of the hand or the finger will be done, also to stabilize hypnosis if it is accepted by the patient"
223462437|NCT04969588|DIAGNOSTIC_TEST|Bioelectrical impedance analyzer|Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
223462438|NCT04969588|DIAGNOSTIC_TEST|Dual Energy X-ray Absorptiometry|Skeletal length and body composition are estimated.
223462439|NCT03259256|PROCEDURE|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
223462440|NCT02320448|DRUG|PIPAC|
223462441|NCT03833232|DEVICE|omentopexy with cyanoacrilate glue|apposition of omentum with cyanoacrilate glue on gastric section
223462442|NCT05905432|DRUG|Vaccine AnAPN1|AnAPN1 is a recombinant protein expressed in Escherichia coli. It consists of the UF6b construct, derived from the sequence of the Anopheles gambiae alanyl aminopeptidase N (XM\_318000.4) and will be formulated with or without Synthetic Glucopyranosyl Lipid A (GLA)- LSQ adjuvant. Route of administration is intramuscular.
223462443|NCT04499833|PROCEDURE|liver transplant|liver transplant
223575839|NCT04630717|OTHER|control groupe|the therapist will use usual voice,loud and strong voice,. clear, high position of the doctor, medical speech focused,no question about the patient's privacy will be made.
223462444|NCT03492879|DEVICE|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
223462445|NCT01901016|BEHAVIORAL|Jacobson progressive muscular relaxation|PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth
223462446|NCT01901016|BEHAVIORAL|Schultz's autogenic training|AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas \[28\]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
223462447|NCT02357056|OTHER|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
223462448|NCT02357056|OTHER|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
223462449|NCT02357056|OTHER|Virtual Reality|daVinci Surgical Skills simulation
223575840|NCT03302117|OTHER|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
223575841|NCT01107119|OTHER|integrated care pathway|communication and follow-up program for integrated care
223575842|NCT01107119|OTHER|usual care|
223575843|NCT00930969|DEVICE|ICD|Subjects implanted with an ICD.
223575844|NCT01287221|DRUG|Rifampicin|300 mg, 2 times daily
224067965|NCT04931004|DRUG|Mouthwash Product|Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples.
224067966|NCT04931004|OTHER|Water rinse|30-second water rinse will occur in the control group. Viral load will be measured prior to and after water rinse using serial face mask and saliva samples.
224067967|NCT03386175|DEVICE|therapy with negative pression and instillation|therapy with negative pression and instillation
224067968|NCT04393922|BEHAVIORAL|Acoustic stimuli (Startle)|A startle stimulus (120 dB, 500 Hz, 50 ms) will be delivered through headphones
224067969|NCT00278278|DRUG|cisplatin|Given IV
224067970|NCT00278278|DRUG|etoposide|Given IV
224067971|NCT00278278|DRUG|ifosfamide|Given IV
224067972|NCT00278278|DRUG|lomustine|Given IV
224067973|NCT00278278|DRUG|methotrexate|Given IV
224067974|NCT00278278|DRUG|prednisone|Given IV
224067975|NCT00278278|DRUG|vincristine sulfate|Given IV
224067976|NCT04732182|DEVICE|BrightGo cognitive training|Training on the BrightGo experimental device in the home
224067977|NCT04732182|DRUG|Standard of Care medication for early Alzheimer's Disease|Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
224067978|NCT00634829|DRUG|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
223462450|NCT05681832|BEHAVIORAL|Intervention group|"The children in this group will participate in a 15-minute HIIT (High-intensity interval training) program twice a week for eight weeks. Motivational interviewing through presentations and Kahoot for the children and their parents will be done at the program's beginning, middle, and end.~The HIIT program will consist of 2.5 minutes of warm-up 12.5 exercises then a cool-down period of 5 minutes. The intensity of the exercise was increased based on each kid's performance and monitored during the sessions using a smartwatch."
223462451|NCT04929977|DEVICE|Wearable device with smart mobile phone|The wearable device will act as a sensor designed to identify critical parameters such as Kangaroo Mother Care adherence and temperature of the infant 24/7 and of the mother-infant pairs during these sessions.
223462452|NCT04825756|BEHAVIORAL|Manualized equine assisted therapy|This equine assisted therapy (EAT), which is delivered in a group setting, combines therapeutic horseback riding with cognitive behavioral strategies for anxiety. Each 45 minute session is delivered in a group format with up to four children between 6 and 17 years of age. Each session follows the same structure: (1) weekly review; (2) groom and connect; (3) warm-up period; (4) session activity; (5) cool down; (6) parent/caregiver psychoeducation, during which the instructor facilitates psychoeducation; and (7) homework instruction.
223462453|NCT05929989|DIAGNOSTIC_TEST|ELISA TEST|ELISA TEST for cystatin D and fibrinogen like protein
223462454|NCT03389880|PROCEDURE|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
223575845|NCT01287221|DRUG|placebo|placebo
223575846|NCT04041206|DEVICE|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~1. Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~2. Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated \[Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)\]. The acupoint microcirculation will be recorded for 5 minutes.~3. Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
223575847|NCT01533467|DEVICE|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
223575848|NCT02595697|BEHAVIORAL|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
223575849|NCT00000916|DRUG|Indinavir sulfate|
223575850|NCT00000916|DRUG|Lamivudine/Zidovudine|
223462455|NCT03389880|PROCEDURE|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
223462456|NCT03228940|DRUG|RVX000222|oral, BID
223462457|NCT02666833|DEVICE|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
223462458|NCT05314777|PROCEDURE|Low dose ESWT application|Patients trained for low dose ESWT application.
223462459|NCT05314777|PROCEDURE|High dose ESWT application|Patients trained for high dose ESWT application.
223743425|NCT06876077|OTHER|Sham auricular acupuncture|Sham auricular acupuncture is administered in each side of the ear for 4 weeks using patches, each possessing a square shape with a side length of 10 mm, without a needle. Five acupoints are selected on one ear, including the will be performed at Shenmen (TF4), Mu 1 (TG2b), Mu 2 (AT1b), Kidney (CO10), and Liver (CO12). These acupoints are believed to be effective in relieving dry eye symptoms. The patch will be kept on the auricle for 5 days and be replaced 5 times during the experimental period.
223462460|NCT05314777|PROCEDURE|Sham ESWT|Patients trained for sham ESWT.
223575851|NCT00000916|DRUG|Hydroxyurea|
223575852|NCT00000916|DRUG|Lamivudine|
223575853|NCT00000916|DRUG|Stavudine|
223575854|NCT00000916|DRUG|Zidovudine|
223575855|NCT00000916|DRUG|Didanosine|
223575856|NCT05482581|OTHER|Questionnaires set|Participants will be asked to respond to the demographic information sheet,e-cigarette using characteristics sheet,awareness of e-cigarettes sheet;,willingness to use e-cigarettes sheet, knowledge, attitudes and cognitions related to e-cigarettes sheet, awareness of new regulations on e-cigarette control sheet.
223575857|NCT05837949|BEHAVIORAL|MS FIT: Falls Insight Track|Participants will respond to a set of surveys every two weeks to increase communication on falls with their clinician.
223575858|NCT05315375|DEVICE|corpectomy|vertebral corpectomy using expandable cage
223575859|NCT02066506|OTHER|asymptomatic group|2 visits with MRI
223743426|NCT06876077|OTHER|Artificial Tears (AT)|Artificial tear drops were applied 5-6 times per day over the 4-week period
223462461|NCT05314777|PROCEDURE|Exercise Training|Patients trained for exercise training.
223462462|NCT03798548|BEHAVIORAL|Brief Bedside CBT|4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
223575860|NCT02066506|OTHER|symptomatic group|2 visits with MRI
223575861|NCT04411537|DRUG|PD-1 antibody|Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
223575862|NCT04411537|DRUG|Capecitabine|During neo-CRT: 625mg/m2 bid Monday-Friday per week
223575863|NCT04411537|DRUG|Irinotecan|During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
223575864|NCT04411537|RADIATION|Neoadjuvant Radiotherapy|IMRT DT: 50Gy/25Fx
223575865|NCT01922375|DRUG|Naftopidil|
223575866|NCT03908827|BIOLOGICAL|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
223743427|NCT03745235|OTHER|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
223743428|NCT03745235|BIOLOGICAL|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
224067979|NCT00634829|DRUG|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
224067980|NCT00634829|DRUG|Placebo-HFA|Placebo containing HFA propellant without active drug substance
224303121|NCT01859806|PROCEDURE|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
224303122|NCT01859806|PROCEDURE|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
224303123|NCT02647736|OTHER|Hypertonic saline infusion|
224303124|NCT05726760|BEHAVIORAL|Seeking informed consent for participation in the study.|The parturients will undergo an informed consent process including an explanation of the methods and risks of the study. The Anaesthetist or researcher will conduct this process. A patient information leaflet will be provided for the parturients.
224303125|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
223462463|NCT00928850|PROCEDURE|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
223462464|NCT00928850|PROCEDURE|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
223462465|NCT00928850|PROCEDURE|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
223462466|NCT00928850|PROCEDURE|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
223462467|NCT04028791|OTHER|Exercise on ergocycle|The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
223462468|NCT03701412|RADIATION|MRI|MRI brain
223462469|NCT04069143|DIAGNOSTIC_TEST|18F-BMS-986327|Imaging Agent
223462470|NCT05680428|OTHER|early feeding|oral feeding within 12hours after stoma reversal
223462471|NCT05680428|PROCEDURE|conventional feeding|oral feeding after 48hours of NBM after stoma reversal
223462472|NCT02423083|DRUG|Guanabenz|
223462473|NCT00691288|DRUG|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
223743429|NCT03745235|OTHER|psychometric questionnaires|"* Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire"
223743430|NCT07007273|DRUG|Pembrolizumab|Outpatient infusion
224067981|NCT05113836|BIOLOGICAL|Deep nasopharyngeal swab|On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
224067982|NCT05113836|BIOLOGICAL|Blood sample at D1, D3 and D7|"Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total)."
224067983|NCT00450476|DEVICE|Hi-Lo Evac Endotracheal Tube|
224067984|NCT00337064|PROCEDURE|Radiation Therapy|
223462474|NCT00691288|DRUG|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
223462475|NCT01074177|DRUG|BIBW 2992|Taken orally once a day
223462476|NCT00069849|DRUG|ABT-089|
223462477|NCT05429671|PROCEDURE|total knee arthroplasty|Participants will have total knee arthroplasty
223462478|NCT05429671|DRUG|Tobramycin|Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
223462479|NCT05429671|DRUG|Gentamicin|Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
224067985|NCT05279846|DRUG|MOB015B|Applied topically for 48 weeks
224067986|NCT05279846|DRUG|Vehicle (Placebo Comparator)|Applied topically for 48 weeks
224067987|NCT04576598|OTHER|Self-management program to increase physical activity levels|Information and Communication Technologies will be used to carry out various remote sessions. The sessions will address important issues to promote self-management of sedentary lifestyle by stroke survivors. Additionally, a peer support group will be created in order to improve adherence to the program.
224067988|NCT04576598|OTHER|Education information|Education on the importance of active lifestyle habits post-stroke.
224067989|NCT03144466|COMBINATION_PRODUCT|Pembrolizumab|antiPD1 monoclonal antibody
224067990|NCT02447315|DRUG|Pilocarpine|oral
224067991|NCT02447315|DRUG|Placebo|oral
223462480|NCT05429671|DEVICE|Antibiotic cement spacer|participants getting an antibiotic-loaded cement spacer during surgery comprised of vancomycin and tobramycin.
223462481|NCT06092528|OTHER|Inspiratory muscle training|Inspiratory muscle training will be performed with Power Breathe®. Inspiratory muscle training will be given to the training group, starting from 50% of the MIP, and 2 sessions/day, 15 minutes/session. Patients will be asked to check breathing for 4-5 breaths after 8-10 consecutive breathing cycles. The patient will continue this cycle for 15 minutes.
223462482|NCT06092528|OTHER|Upper extremity aerobic exercise training|Upper extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 min/session using arm ergometer device accompanied by a physiotherapist. Aerobic exercise training workload will be 60-80% of maximal heart rate. In this study, the perception of dyspnea will be between 3-4, arm fatigue and general fatigue perception will be between 5-6, warm-up and cool-down periods will be 5 minutes, and pedaling speed will be 40-50 rev/min, according to MBS.
223462483|NCT06092528|OTHER|Lower extremity aerobic exercise training|Lower extremity aerobic exercise training will be performed 3 days/week, 1 session/day, 15 minutes/session using the treadmill device, accompanied by a physiotherapist. Aerobic exercise training workload was set at 60-80% of maximal heart rate, dyspnea perception according to MBS was between 3-4, arm fatigue and general fatigue perception was between 5-6, and warm-up and cool-down periods were 5 minutes.
223462484|NCT06092528|OTHER|Resistant exercise training|Upper and lower additional limb strengthening training will be performed 3 days/week, 1 session/day, 10 repetitions/sessions from the first day by using bullion weights in the presence of a physiotherapist. The upper extremity strengthening program will consist of a progressive exercise program to strengthen the shoulder flexors and abductors, and the lower extremity strengthening program to strengthen the knee extensors. The training workload will be increased progressively. For strength training, the workload will be adjusted so that the perception of fatigue is between 4 and 6 according to MBS.
223575867|NCT01697150|DEVICE|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
223575868|NCT00298493|PROCEDURE|Sedation management strategy|
223575869|NCT02726191|BEHAVIORAL|Spatial Match Exercise|
223575870|NCT02726191|BEHAVIORAL|Temporal Sequence Reconstruction Exercise|
223462485|NCT06092528|OTHER|Thoracic expansion exercises|The control group will be asked to do thoracic expansion exercises seven days/week and 120 pieces/day for six weeks.
223462486|NCT05455151|PROCEDURE|Conservative therapy|Conservative therapy to which the patients were subjected was the effect of an electrical impulse
223575871|NCT02726191|BEHAVIORAL|Token Task Exercise|
223575872|NCT02726191|BEHAVIORAL|Story Recall Exercise|
223575873|NCT02726191|BEHAVIORAL|Sample-Match (Within Modality) Exercise|
223575874|NCT02726191|BEHAVIORAL|Pair-Match (Across-Modality) Exercise|
223575875|NCT02726191|BEHAVIORAL|Triad-FiguresExercise|
223575876|NCT02726191|BEHAVIORAL|Monster Garden Exercise|
223575877|NCT02726191|BEHAVIORAL|Memory Match Exercise|
223575878|NCT02726191|BEHAVIORAL|Memory Matrix Exercise|
223575879|NCT02726191|BEHAVIORAL|Familiar Faces Exercises|
223575880|NCT02726191|BEHAVIORAL|Lost in Migration Exercise|
223575881|NCT02726191|BEHAVIORAL|Playing Koi Exercise|
223575882|NCT02358655|OTHER|Retrospective review of OAC prescription|
223575883|NCT02358655|OTHER|Prescription of OAC in ED|
223575884|NCT02358655|OTHER|Community AF clinic|
223575885|NCT04956055|OTHER|Reflexology|The patient will be kept in a lying position. First, the patient will be given four minutes of hand reflexology on each hand with warming and stimulation techniques.Reflexology will be applied to the left hand with the thumb of the right hand, the thumb of the left hand and the special points in the right hand. It will be applied to the fingers, palm, back of the hand, and finally the wrists, respectively, starting with the fingertips and using special reflexology techniques (a total of six minutes for each hand separately). By sending a moderate stimulus, a total of 20 minutes of reflexology session will continue.Since the patient reveals and uses his own internal energy at the end of the session, nobody should talk to the patient until five minutes after the procedure. Survey questions and vital signs would be examined five minutes after the session and the research with the participant would end.
223743431|NCT03935685|DRUG|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
223743432|NCT07023289|DRUG|Telisotuzumab Adizutecan|Intravenous (IV) Infusion
223743433|NCT07023289|DRUG|Standard of Care|Standard of care treatment based on investigator's judgement to the active surveillance.
223462487|NCT05455151|BIOLOGICAL|PRP injection|This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium
223462488|NCT05455151|BIOLOGICAL|Injection of PRP after conservative therapy|This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium
223575886|NCT01256281|PROCEDURE|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
223575887|NCT00100295|DRUG|Hypericum perforatum|300 mg capsule taken three times a day
223575888|NCT00100295|OTHER|Placebo|300 mg given three times a day, containing rice protein powder
223575889|NCT02579694|DEVICE|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
224067992|NCT00847366|DRUG|Perifosine|All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
224067993|NCT00847366|DRUG|Trastuzumab|Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
223462489|NCT05455151|BIOLOGICAL|Injection of PRP with endometrial cells|This intervention consisted of injecting endometrial cells suspended in prp
223462490|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days),administered orally combination with one background chemotherapy in 21-day cycles.
223462491|NCT02584478|DRUG|Paclitaxel|"Weekly single agent Paclitaxel will be administered on Day 1, 8, and 15 of each 21-day cycle. Suggested dose: 80 mg/m\^2 intravenously or local standard.~Paclitaxel may also be administered once weekly with a 1-week break every 3 weeks in lieu of every week"
223462492|NCT02584478|DRUG|Pegylated Liposomal Doxorubicin (PLD)|"Single agent Pegylated Liposomal Doxorubicin (PLD) administered every 4 weeks on the following cycle days corresponding with AL3818 cycles until maximum cumulative dose per local standard reached.~Suggested dose: 40 mg/m\^2 intravenously or local standard"
223462493|NCT02584478|DRUG|Topotecan|Daily Topotecan on Days 1-5 of each 21-day cycle Suggested dose: 1.25 mg/m2 intravenously or local standard OR Weekly Topotecan with a 1 week break every 3 weeks. Suggested dose: 4 mg/m2 intravenously or local standard
223462494|NCT02584478|DRUG|Topotecan|Weekly Topotecan with a 1 week break every 3 weeks Suggested dose: 4 mg/m2 intravenously or local standard
223462495|NCT02584478|DRUG|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
223462496|NCT02584478|DRUG|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
223462497|NCT02584478|DRUG|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
223462498|NCT01514383|DEVICE|Cyanoacrylate (Octylseal )|surgical adhesive
223462499|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
223462500|NCT01999439|PROCEDURE|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
223462501|NCT02581033|DRUG|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
223462502|NCT01401543|DRUG|LY2452473|Administered orally
223575890|NCT04976218|BIOLOGICAL|TGFβR-KO CAR-EGFR T Cells|Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
223575891|NCT03350139|DEVICE|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
223575892|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy|The experimenter gives the subject psychoeducation about emotional regulation and distraction strategy with the help of a conversation and a presentation.
223575893|NCT06197464|DEVICE|Using the FLOAT app on a virtual reality device|The subject should wear the VR device, and use the FLOAT application.
223462503|NCT01401543|DRUG|Tadalafil|Administered orally
223575894|NCT06197464|BEHAVIORAL|psychoeducation on emotional regulation and distraction strategy + Application|psychoeducation on emotional regulation and distraction strategy + Application
223575895|NCT00002465|DRUG|megestrol acetate|
223575896|NCT05616884|PROCEDURE|Cementless fixation|Three dimensional printed porous metal, a biomaterial with morphological and mechanical properties that resemble those of native trabecular bone, is now being used for fixation of the tibial component in unicondylar knee arthroplasty. This can reliably achieve osseointegration into the tibia and could lead to a lower risk of aseptic loosening which is the leading cause of revision in partial knee replacements.
223575897|NCT02126566|DEVICE|Administration of light therapy - measurement of results before and after therapy|
223575898|NCT05703451|OTHER|laparoscopic surgery|"during laparoscopy Any adhesions will be noticed, the prevalence of adhesions will be calculated regarding the age, parity, previous history of miscarriage and past medical history.~The prevalence of adhesions will be calculated according to the indication of laparoscopy.~The prevalence of adhesions will be compared according to different items. Comparison between patients with no past surgical history and those who have past surgical history.~Comparison between patients who have history of ectopic pregnancy and those who have no history of ectopic pregnancy.~Comparison between patients with previous caesarean section and patients with previous other abdominopelvic surgery."
223743434|NCT04199117|DRUG|Varenicline|Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
224067994|NCT00847366|DRUG|Tamoxifen|Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
224067995|NCT01097863|DEVICE|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
224067996|NCT01097863|DEVICE|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
224157279|NCT01009736|OTHER|pharmacological study|
224157280|NCT01009736|PROCEDURE|therapeutic conventional surgery|
223462504|NCT01401543|DRUG|LY900010|Administered orally
223462505|NCT05643729|DRUG|Zofin|Intravenous Infusion (IV) of Zofin
223462506|NCT05643729|OTHER|Placebo|Intravenous Infusion of sterile saline
223462507|NCT01739504|PROCEDURE|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
223462508|NCT01739504|BIOLOGICAL|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~* AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~* Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
223462509|NCT00086606|DRUG|Xolair (omalizumab)|
223462510|NCT01494012|RADIATION|stereotactic body radiation therapy|Undergo SBRT
223462511|NCT01494012|PROCEDURE|positron emission tomography|Undergo FDG-PET/CT
223462512|NCT01494012|PROCEDURE|computed tomography|Undergo FDG-PET/CT
223462513|NCT01494012|OTHER|questionnaire administration|Ancillary studies
223462514|NCT01494012|DRUG|fludeoxyglucose F 18|Undergo FDG-PET/CT
223462515|NCT02541409|DRUG|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
223462516|NCT02541409|DRUG|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
223462517|NCT02541409|DRUG|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
223462518|NCT00160264|DRUG|Lactulose, Vitamin D, Calcium|
223462519|NCT02574936|PROCEDURE|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
223575899|NCT01556776|DRUG|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
224067997|NCT01097863|DEVICE|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
223462520|NCT02085746|OTHER|Defining Sexual Activity Questionnaire|
223462521|NCT03285945|DRUG|PET3|Prednisolone 60 mg daily for 3 days
223462522|NCT03285945|DRUG|PET10|Prednisolone 60 mg daily for 10 days
223462523|NCT04350645|DRUG|Tranexamic acid injection|1g slow bolus of tranexamic acid over 2 minutes
224067998|NCT02996188|PROCEDURE|routine therapeutic paracentesis|
224067999|NCT03993366|COMBINATION_PRODUCT|Fiasp+Pramlintide Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin and pramlintide
224068000|NCT03993366|DEVICE|Fiasp Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin alone
224068001|NCT01908660|DRUG|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
224068002|NCT05458388|PROCEDURE|Kimura-Takemoto classification|All patients were given two risk scores, the order of which was randomly determined.
224068003|NCT05458388|PROCEDURE|EGGIM|All patients were given two risk scores, the order of which was randomly determined.
224068004|NCT01214785|BEHAVIORAL|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
224068005|NCT03915873|DIAGNOSTIC_TEST|The von Willebrand Antigen level|blood sample
224068006|NCT01871584|DEVICE|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
224157281|NCT04368689|OTHER|Floatation-based reduced environmental stimulation therapy|Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
224157282|NCT04685538|DRUG|Chloroprocaine 3%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
224157283|NCT04685538|DRUG|Tetracaine 0.5%|"Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery."
223462524|NCT04350645|DRUG|Normal Saline 0.9%|10mls normal saline 0.9% over 2 minutes
223462525|NCT02841384|OTHER|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
223462526|NCT02841384|OTHER|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
223462527|NCT02731170|BEHAVIORAL|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
223462528|NCT03500926|DEVICE|total hip replacement - standard femoral stem|total hip replacement with standard femoral stem
223462529|NCT03500926|DEVICE|total hip replacement - short femoral stem|total hip replacement with short femoral stem
223462530|NCT00142272|DRUG|Ciprofloxacin|
223462531|NCT05130645|DIAGNOSTIC_TEST|Mental Angle|In order to standardize and measure the mental angle, the projection of the mental will be accepted as the midline, the jaw structure will be transferred to the paper using the profile contour meter, and the angle between the angulus mandible and the mental will be measured and recorded with a digital protractor.
223462532|NCT00420719|DEVICE|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
223462533|NCT06272149|DRUG|VGN-R08b|VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.
223462534|NCT01383408|OTHER|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
223462535|NCT03104608|OTHER|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
223462536|NCT03104608|OTHER|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
223462537|NCT00812942|PROCEDURE|colonoscopy|colonoscopy screening
223462538|NCT00812942|PROCEDURE|faecal test|faecal occult blood test for screening
223462539|NCT00765947|DRUG|Aliskiren|Aliskiren 150 or 300 mg
223462540|NCT00765947|DRUG|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
223462541|NCT00765947|DRUG|Amlodipine|Amlodipine 5 or 10 mg
223462542|NCT02058589|BIOLOGICAL|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
223462543|NCT02058589|DRUG|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
223462544|NCT04516239|DEVICE|THA|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. For the THA, the standard techniques proposed by the manufacturer for insertion of the stem were followed. Neck sleeve adapters and three different prosthetic neck-shaft angles (125, 135, and 145) were available to adjust leg length and femoral offset with the large-diameter head THA system.
223462545|NCT04516239|DEVICE|HR|Three surgeons performed the surgeries through a posterior surgical approach in both groups. The fascia lata was opened and the gluteus maximus was split in line with its muscle fibers. The short external rotators were released from the greater trochanter. A posterior capsulotomy was performed and the hip dislocated. In the HR group, the capsulotomy was completed circumferentially, and the gluteus tendinous insertion on the femur was released in all men, but only when needed in women, to improve femur mobilization.
223462546|NCT06542900|DEVICE|Deep Brain Stimulation (DBS)|The DBS lead is stereotactically introduced into the target in the brain (SCC, VC/VS, ALIC, ITP, NAc, LHb, MFB, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
223462547|NCT02638987|PROCEDURE|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
223462548|NCT02894814|BEHAVIORAL|One-Stop Dispensing|Use of own medication, review of the patient's medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
223462549|NCT02894814|BEHAVIORAL|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
223462550|NCT01792102|DRUG|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m\^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m\^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
224157284|NCT03121482|DEVICE|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
224157285|NCT03121482|DEVICE|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
224157286|NCT01655745|PROCEDURE|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
224157287|NCT02225236|BEHAVIORAL|Classroom Intervention|
224157288|NCT06004193|BEHAVIORAL|Exercise|At least 150 minutes of exercise in a week
224157289|NCT01421069|DRUG|etanercept|"Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or \>62 kg will receive etanercept SC at a dose of 50 mg QW."
224157290|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
224157291|NCT01641081|DRUG|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
224157292|NCT01641081|DRUG|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
224157293|NCT01641081|DRUG|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
224157294|NCT01641081|DRUG|Placebo|Placebo in the Pressair for 14 days
223462551|NCT02143024|BEHAVIORAL|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
223462552|NCT02143024|BEHAVIORAL|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
223462553|NCT01945944|DRUG|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
223462554|NCT01945944|DRUG|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
223462555|NCT01167400|BEHAVIORAL|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
223462556|NCT01167400|BEHAVIORAL|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
223462557|NCT00526318|BIOLOGICAL|filgrastim|
223462558|NCT00526318|DRUG|carboplatin|
223462559|NCT00526318|DRUG|cisplatin|
223462560|NCT00526318|DRUG|cyclophosphamide|
223462561|NCT00526318|DRUG|dacarbazine|
223462562|NCT00526318|DRUG|doxorubicin hydrochloride|
223462563|NCT00526318|DRUG|etoposide phosphate|
223462564|NCT00526318|DRUG|ifosfamide|
223462565|NCT00526318|DRUG|isotretinoin|
223462566|NCT00526318|DRUG|melphalan|
223462567|NCT00526318|DRUG|topotecan hydrochloride|
223462568|NCT00526318|DRUG|vincristine sulfate|
223462569|NCT00526318|DRUG|vindesine|
223462570|NCT00526318|PROCEDURE|autologous hematopoietic stem cell transplantation|
223462571|NCT00526318|RADIATION|iobenguane I 131|
223462572|NCT00526318|RADIATION|radiation therapy|
223462573|NCT06813339|DRUG|UDP-003|The UDP-003 finished product is clear, colourless to yellow liquid that is intended to be a sterile solution for IV bolus push administration in sterile water at a concentration of 300 mg/mL.
223462574|NCT06813339|OTHER|Placebo|Placebo will be provided as a sterile clear, colourless solution formulated to match viscosity of the UDP-003 solution.
223462575|NCT06373120|DEVICE|Microaxial flow pump|The microaxial flow pump (The CorVad percutaneous ventricular assist system device) is a microaxial rotary blood pump that expels blood from the left ventricle into the ascending aorta, thus unloading the left ventricle. The CorVad system device can be introduced through a femoral percutaneous approach (14Fr) and can deliver an output of up to 4-6 L/min.
223462576|NCT06373120|DEVICE|VA-ECMO|Veno-arterial extracorporeal Membrane Oxygenation (VA-ECMO) is a device originally created to replace heart and lung function. Venous deoxygenated blood is mechanically suctioned from a large central vein through a venous cannula by a centrifugal pump. It is then oxygenated, warmed, and restored into systemic circulation through an arterial cannula.
223462577|NCT03973398|PROCEDURE|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
223462578|NCT06600919|OTHER|Preoperative Music Therapy Session|"Upon admission to the operating room:~Patients in the music therapy group will undergo a 20-minute music therapy session while lying on a stretcher in a designated room. This session will be conducted using the Music Care® application (https://www.music.care).~The sessions are standardized and divided into several phases, following a U-shaped sequence. The effect of this U-sequence is first achieved by a phase of reduced tempo, instrumental density, frequency, and sound volume , followed by a phase of reactivation .~Patients will be allowed to choose the musical style based on their preferences (influenced by their musical tastes and ethnicity). Given the ethnically diverse population of Réunion Island, a wide range of musical preferences is expected."
223462579|NCT02850549|OTHER|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
223462580|NCT01908309|DRUG|Iobitridol 350|
223462581|NCT01908309|DRUG|Iodixanol 320|
223462582|NCT02578849|DRUG|L-DOPA|Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.
223462583|NCT05754541|DEVICE|WeFlow-Tribranch Aortic Arch Stent Graft System|Endovascular treament in patients with aortic arch dissection and aneurysm by WeFlow-Tribranch Aortic Arch Stent Graft System
224157295|NCT02491216|OTHER|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
224157296|NCT00781404|DRUG|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
224157297|NCT06224868|OTHER|insufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg (Normal values are 5-7 mmHg) it is aimed to monitor optic sheat nerve diameter and lung ultrasound score changes with different intraabdominal pressures.
223462584|NCT01545141|DRUG|Chemokin Modulatory Regimen (5 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
223462585|NCT01545141|DRUG|Chemokin Modulatory Regimen (10 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
223462586|NCT01545141|DRUG|Chemokin Modulatory Regimen (20 MU/m2)|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
223462587|NCT02385565|OTHER|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
223462588|NCT02385565|OTHER|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
223462589|NCT04442477|DIETARY_SUPPLEMENT|Enriched Protein Fractions|Enriched protein fractions
223462590|NCT04442477|DIETARY_SUPPLEMENT|Protein Fraction|Protein fractions
223462591|NCT02837393|PROCEDURE|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
223575900|NCT01556776|DRUG|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
223575901|NCT02714270|PROCEDURE|modified partograph|
224157298|NCT06224868|OTHER|desufflation|Laparoscopic surgery begins with intraabdominal placement of the insufflation needle or trochar, followed by carbon dioxide (CO2) insufflation of the abdominal cavity to an intraabdominal pressure (IAP) of 12 to 15 mm Hg. When the surgery is completed, the trochars are removed and intra-abdominal pressure is returned to normal which is 5-7 mmHg.
223462592|NCT04501055|BEHAVIORAL|perineal nerve block|An anesthesia method to block perineal nerve
223462593|NCT04501055|BEHAVIORAL|periprostatic block|An anesthesia method to block periprostate
223462594|NCT04794517|DRUG|Dapagliflozin 10Mg Tab|Dapagliflozin 10 mg/die will be administered orally for six-weeks.
223462595|NCT04794517|OTHER|Placebo|Placebo one tablet/die will be administered orally for six-weeks.
223462596|NCT02711358|DRUG|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
223462597|NCT02711358|DRUG|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
223462598|NCT06657274|DEVICE|RICORDO-DTx|"Tele@cognitive treatment group will receive a total of 5 weeks (3 sessions/week, 45 minutes/session) of home-based cognitive rehabilitation activities with an innovative digital solution for remote rehabilitation of cognitive difficulties according to digital therapeutics delivery model. Subjects assigned to the tele@cognitive group can access the app RICORDO-DTx through a tablet showing the prescribed rehabilitation activities to be performed.~Each cognitive exercise is structured into five levels of difficulty that adaptively increase (algorithm on both subject's performance and perceived difficulty). All data about patient progress and adherence will be collected with this digital solution and will be available to evaluate and monitor the results of rehabilitation."
223462599|NCT06657274|BEHAVIORAL|Home-based unstructured cognitive stimulation|Subjects assigned to the home-based unstructured cognitive stimulation will be requested to work on detailed activities for the same duration of the tele@cognitive intervention (3 sessions/week, 45 minutes/session). They will receive, from the therapist, an instructions booklet and a participant diary.
223462600|NCT02213588|DIETARY_SUPPLEMENT|AOX blend|Antioxidant supplement
223462601|NCT02213588|DIETARY_SUPPLEMENT|Placebo|
223462602|NCT04972799|OTHER|injection of autologous fat at Day 0 and injection of saline at 6 months|injection into the intersphincter space
223462603|NCT04972799|OTHER|injection of saline at Day 0 and injection of autologous fat at 6 months|injection into the intersphincter space
223462604|NCT04435938|RADIATION|Stereotactic Body Radiotherapy (SBRT)|45 Gy in 5 fractions delivered once every 3-4 days
223462605|NCT04041921|PROCEDURE|Percutaneous coronary intervention|
223575902|NCT02714270|PROCEDURE|paperless partograph|
223575903|NCT00787137|DRUG|PG102|A single intravenous infusion
224157299|NCT00565006|DRUG|MK0859|
223462606|NCT04041921|PROCEDURE|Coronary Artery Bypass Grafting|
223462607|NCT04041921|DRUG|Medical treatment|
223462608|NCT03932461|PROCEDURE|Vacuum assisted closure|The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
223462609|NCT03932461|PROCEDURE|"Relaparotomy on demand"|Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
223462610|NCT04917705|OTHER|Collection of biological samples|Skin, muscle fiber and blood sampling
223462611|NCT04262193|DRUG|Suvorexant|In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.
223462612|NCT04262193|DRUG|Suvorexant Placebo|Suvorexant Placebo
223462613|NCT03809234|DRUG|Ondansetron 8mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
223462614|NCT03809234|DRUG|Ondansetron 16mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
223462615|NCT06342856|DRUG|co enzyme Q10 , L- Carnitine|Patient fulfilling inclusion criteria after obtaining consent will be randomized into four equal groups randomization will be computer based
223462616|NCT01575756|BIOLOGICAL|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
223462617|NCT01575756|BIOLOGICAL|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
223462618|NCT05011578|RADIATION|Radiographic assessment|Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
223462619|NCT02049983|DEVICE|Use of Levita Magnetics Grasper|
223462620|NCT00959283|OTHER|Diagnostic Laboratory Biomarker Analysis|Correlative studies
223575904|NCT00787137|DRUG|Placebo comparator|Phosphate-buffered saline
223575905|NCT02102152|DRUG|Tobramycin|
223575906|NCT04181580|DEVICE|Made-to-measure compression garment|Made-to-measure compression garment
224157300|NCT03850171|OTHER|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
223462621|NCT00959283|OTHER|Pharmacological Study|Correlative studies
223462622|NCT06587633|DEVICE|Endoscopic procedure|tSVFem injection + 3D scaffold placement
223462623|NCT03927859|OTHER|a mail letter, a phone call and a phone call plus mailed letter|"All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention."
223462624|NCT04177433|DRUG|Depo-Medrol Injectable Product|Corticosteroid
223462625|NCT04177433|DRUG|Saline|Placebo
223462626|NCT06609291|BEHAVIORAL|Telematic Prenatal Psychological Intervention for Preventing Anxious Symptomatology|The psychological intervention will consist of 7 group sessions, conducted weekly, with a duration of approximately 60 minutes each, with the exception of the first and last ones, which will last an hour and a half, since they will carry out the presentation and evaluation of the intervention, respectively. In turn, the program will be divided into 3 modules. Module 1. Psychoeducation and awareness about perinatal mental health, which provides information on the prevalence of anxious symptoms in the perinatal stage and the consequences for mothers and babies. Module 2. Management of emotions and thoughts. It covers 3 sessions and aims to provide strategies to identify and restructure those thoughts that harm us, as well as recognize the behaviors and emotions that they generate. Module 3. Aimed at teaching how to solve problems effec-tively and communicate in the best possible way.
223462627|NCT06859983|BEHAVIORAL|progressive relaxation exercise|he researcher will provide approximately 45 minutes of information about relaxation exercises to the nurses. During the application of progressive relaxation exercises, the necessary precautions to be taken during and after the exercise will be explained to the nurses. In the study, a sound recording that includes the PRE will be uploaded to each nurse's phone. The relaxation exercises CD created by the Turkish Psychologists Association will be used for the sound recording. The first section of the CD, which is 10 minutes long, defines deep relaxation, its purpose, and the precautions to be taken during the exercise. The second 30-minute section explains the relaxation exercises with the sound of a stream and verbal instructions. The third 30-minute section contains only relaxation music without any verbal instructions. After the training, nurses will be given the sound recording in CD form. Nurses will be asked to perform the PRE according to the instructions. They will be instructed
223462628|NCT03552601|OTHER|traditional speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
223462629|NCT03552601|OTHER|faster speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
224303126|NCT05726760|DEVICE|Covidien Mon-a-Therm skin temperature probes will be applied to the dorsum of the right and left feet above space between the 2nd and 3rd metatarsal bones.|The Anaesthetist or researcher will conduct the intervention in theatre. The probes will be removed in the recovery ward.
224303127|NCT05726760|DEVICE|Temperature measurement by Braun Welch Allyn tympanic membrane thermometer device to the ear.|The Anaesthetist or researcher and recovery nurse will conduct the intervention in theatre and in the recovery ward.
224303128|NCT02811263|DRUG|Normal saline placebo|Equal volume of normal saline to be used as placebo
224303129|NCT02811263|DRUG|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
224303130|NCT05163197|PROCEDURE|Transperineal Laser Ablation of Prostate Cancer|Minimal invasive transperineal laser ablation treatment for prostate cancer
224303131|NCT00000660|DRUG|Etoposide|
224303132|NCT02289859|PROCEDURE|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
223462630|NCT06612138|OTHER|pilates exercises|the patients will receive pilates exercises in the form of breathing exercises, chest lift, bridging, mermaid, swan, quadruped exercises
224303133|NCT02289859|PROCEDURE|Wound Closure without Undermining|One side of the wound will remain un-undermined.
224303134|NCT06928129|DIAGNOSTIC_TEST|BinaxNOW™ COVID-19/Flu A&B Combo Self-Test|"Diagnostic Test: BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test~The BinaxNOW™ COVID-19/Flu A\&B Combo Self-Test is a visually read lateral flow in vitro immunoassay for the qualitative detection and differentiation of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B directly in anterior nasal swab specimens from individuals with signs and symptoms of respiratory infection."
224303135|NCT06077487|DRUG|Ketamine|Given orally (PO)
224303136|NCT06077487|DRUG|Ketamine Injectable Product|Given intramuscularly (IM)
224303137|NCT06077487|BEHAVIORAL|Meaning and Purpose therapy|In-person sessions
224303138|NCT06077487|OTHER|Placebo|Given PO or IM
224303139|NCT06077487|OTHER|Questionnaires|Questionnaires will be given over the course of the study
224303140|NCT06214988|PROCEDURE|selective approach defunctioning stoma|With randomisation to this experimental arm (selective approach), no defunctioning stoma is constructed.
224157301|NCT01283893|PROCEDURE|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
224157302|NCT05181241|DRUG|Dimolegin|"Dimolegin (DD217) - enteric coated tablets 10 mg developed by PharmaDiall Ltd (Moscow), manufactured by Federal State Unitary Enterprise Research and Practical Center Pharmaceutical Protection at The Federal Medical Biological Agency (FMBA) of Russia"
223462631|NCT06612138|OTHER|yoga exercises|"the patients will receive yoga in the form of Bhastrikā: rapid and powerful inhalations and exhalations by means of the force of the diaphragm, letting the air sound when exhaling, Nāḏī Śoḏhana: from Sanskrit, nadi means \&#39;to channel\&#39; and shodhana means \&#39;purify, cleanse\&#39;, o Hand position Mrigi mudra: It consists of flexing the index and ring fingers of the hand, o Breathing: Gently close the right nostril with the thumb, inhale fingers and exhale slowly through the right. Keeping your right nostril open, inhale, close it, and slowly open and exhale through the left. This is a cycle. Repeat 3-5 times and then release the hand mudra and return to normal breathing."
223462632|NCT06612138|OTHER|tai chi exercises|the patients will receive tai chi in the form of Commencing form, Repulse Monkey,Grasp Peacock's Tail,Move Hands like Moving Clouds (left side only), Fair Lady Works at Shuttles, Golden Cock Stands on One Leg (left and right),Brush Knees and Twist Steps, Closing form.
223462633|NCT06612138|OTHER|tradional physical therapy|Patients will receive traditional physiotherapy breathing, massage and relaxation exercises
223462634|NCT06404359|OTHER|Exercise|"There will be 2 weekly sessions of 50 minutes, always guided by a physiotherapist, with the following distribution:~1.- Warm-up: 15 minutes of global exercises of strength and resistance, focusing on the areas that are going to be worked as a priority in that session.~Strength training: 6 to 8 strength exercises of large muscle groups. The approximate duration will be 25 minutes.~3.- Cool down / cool down: Combination of breathing exercises and stretching, 10 minutes.~Monitoring with activity bracelets."
223462635|NCT06404359|OTHER|Physical activity recommendations|They will be provided with a physical activity plan to be followed on a weekly basis.
223462636|NCT00610779|DIETARY_SUPPLEMENT|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
223462637|NCT00610779|DIETARY_SUPPLEMENT|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
223462638|NCT06613295|RADIATION|SABR|SABR
223462639|NCT06613295|PROCEDURE|Separation surgery|Separation surgery
223462640|NCT06613191|DRUG|Aspirin|Participant will be on aspirin alone or P2Y12 inhibitor alone
223462641|NCT06613191|DRUG|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|Participant will be taking either P2Y12 inhibitor at time of colonoscopy
223462642|NCT06613373|DRUG|Dalpiciclib|Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.
223462643|NCT06612450|DEVICE|turbinate surgery|Turbinoplasty to decrease the turbinate size in cases with turbinate hypertrophy with mainly soft tissue component without sacrificing the mucosal function
223462644|NCT06612398|BEHAVIORAL|Preoperative preparation video|An animated video illustrating the story of a child's journey through the hospital facilities, including the anaesthesia induction, and the postoperative return home.
223462645|NCT06612411|DRUG|B. subtilis|2 capsules, 3 times a day, orally taken for one month
223462646|NCT06612411|DRUG|Dead B. subtilis|2 capsules, 3 times a day, orally taken for one month
223462647|NCT04495751|DIETARY_SUPPLEMENT|Muscadine grape extract|Four pills twice daily
223462648|NCT04495751|DRUG|Placebo|Four pills twice daily.
223462649|NCT04495751|OTHER|Quality of Life Assessment|Ancillary studies
223462650|NCT04495751|OTHER|Questionnaires|Ancillary studies
224157303|NCT00112567|DRUG|fludarabine phosphate|
223462651|NCT04495751|OTHER|Participant Feedback|Ancillary studies
223462652|NCT05430685|DIETARY_SUPPLEMENT|Ashwagandha|Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.
223462653|NCT05430685|OTHER|Placebo|The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
223462654|NCT02643433|BIOLOGICAL|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
223462655|NCT02643433|BIOLOGICAL|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
223462656|NCT04862260|DRUG|Cholesterol metabolism disruption|Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
223462657|NCT06392035|OTHER|health education, web-based education|Data collection tools will be filled in by two study groups (experimental group, control group) and based on the pre-test results of both groups, Pender\&#39;s SGM-based breakfast training will be given only to the experimental group. No intervention will be made to the control group. In this study, a total of 6 sessions will be held for the experimental group for 6 weeks (one session per week), each lasting 40 minutes. In these sessions, web-based training will be given every week according to the components of the model and will be supported with written and visual brochures.
223462658|NCT00395993|DRUG|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
223462659|NCT00395993|DRUG|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
223462660|NCT00971217|OTHER|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
224157304|NCT00112567|DRUG|thiotepa|
223462661|NCT00971217|BEHAVIORAL|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
223575907|NCT05792306|DEVICE|The novel electrolyzed water spray|The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
223575908|NCT05792306|DEVICE|The saline spray|The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
223462662|NCT00293553|PROCEDURE|Electronic Barostat|
223462663|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
223462664|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
223462665|NCT01571388|DRUG|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
223462666|NCT06525519|DRUG|ATLG|5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
223462667|NCT06525519|DRUG|ATLG|7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
223462668|NCT01984710|DEVICE|Medtronic Activa PC+S System|
223462669|NCT06473558|DEVICE|Biometrics (or AI Biomaker)|Patients will be asked to read a story and their facial expressions and audio cues will be recorded.
223462670|NCT05449444|DRUG|Masitinib 4.5 mg/kg/day|Masitinib 4.5 mg/kg/day
223462671|NCT05449444|DRUG|Placebo|Matching placebo
223462672|NCT05449444|OTHER|Best supportive care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.
223462673|NCT05449444|DRUG|Masitinib 6.0 mg/kg/day|Masitinib 6.0 mg/kg/day
223462674|NCT03082469|DEVICE|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
223462675|NCT01470703|DEVICE|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure \<25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level \<25 cm H2O and low pressure level ≥10 cm H2O
223462676|NCT01470703|OTHER|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 \<80% for \>6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
223462677|NCT01212094|DRUG|Rituximab|
223462678|NCT01212094|OTHER|normal saline|normal saline
223462679|NCT01490892|DRUG|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
223462680|NCT00913601|DEVICE|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
223462681|NCT05094375|DRUG|Vaginal Misoprostol 600 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 600 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home.~* Two doses of misoprostol 600 mcg each (3 tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
223575909|NCT06146868|OTHER|Doing questionnaire|Participants will provide their opinions in a questionnaire
223575910|NCT06239090|DEVICE|Rehacor-T|During each session of bio/neurofeedback IG patients will view their recorded brain waves and physiological responses in a computer screen, while a professional will explain to them what they need to do to intervene and make corrective changes to their brain waves.
223575911|NCT06239090|BEHAVIORAL|Sham Intervention|SG patients will be given irrelevant information (recorded data of other patients) and thus, they cannot modulate their cortical activation and see only the scenarios
223575912|NCT02869412|OTHER|Computer-Assisted Intervention|Use BCG website
223575913|NCT02869412|OTHER|Computer-Assisted Intervention|Use passive website
223575914|NCT02869412|OTHER|Quality-of-Life Assessment|Ancillary studies
223575915|NCT02869412|OTHER|Questionnaire Administration|Ancillary studies
223575916|NCT03726515|BIOLOGICAL|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
224157305|NCT00112567|PROCEDURE|peripheral blood stem cell transplantation|
224157306|NCT00112567|RADIATION|radiation therapy|
223462682|NCT05094375|DRUG|Vaginal Misoprostol 800 mcg|"All patients will receive three doses of vaginal misoprostol every four hours. The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourlies, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
223462683|NCT00092924|DRUG|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
223462684|NCT04042584|PROCEDURE|Visio conference device evaluation (DVCM)|Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
223462685|NCT05985863|DRUG|standard medical treatment|standard medical treatment for ACLF
223575917|NCT03726515|BIOLOGICAL|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
223575918|NCT00134732|BIOLOGICAL|Live attenuated human rotavirus vaccine|
223575919|NCT02823132|BIOLOGICAL|blood sample|
223575920|NCT01361932|OTHER|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
223575921|NCT05841199|DIAGNOSTIC_TEST|Pressure and flow measurement during simulated VT|Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
223575922|NCT02263456|BIOLOGICAL|Replenine®-VF (High Purity Factor IX)|
223575923|NCT05828420|OTHER|White noise|Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.
224157307|NCT01335594|PROCEDURE|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
224157308|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
224157309|NCT01095666|DRUG|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
223462686|NCT05985863|DRUG|Placebo|5% human serum albumin in 0.9% saline (at week0, week1 and week2)
223462687|NCT05985863|DRUG|hUC-MSC|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)
224157310|NCT01095666|DRUG|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
224157311|NCT01095666|DRUG|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
224157312|NCT01095666|DRUG|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
223462688|NCT05985863|DRUG|hUC-MSC_Prolonged|hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
223462689|NCT02112695|OTHER|[11C]diprenorphine|3 micrograms \[11C\]diprenorphine - intravenous use - 1 time
223462690|NCT02728232|PROCEDURE|internal iliac artery ligation|
223462691|NCT02728232|PROCEDURE|Cesarean Hysterectomy|
223575924|NCT05828420|OTHER|Heart sound|Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.
223575925|NCT05828420|OTHER|Music|Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
223575926|NCT04401956|OTHER|bread|Different types of bread
223575927|NCT01628614|OTHER|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
224157313|NCT00853619|OTHER|Service based decision support intervention|Delivering CDS via services
224157314|NCT04677049|DRUG|Niacin CRT|A controlled release technology (CRT) tablet of Niacin
224157315|NCT05152667|DEVICE|levonorgestrel-releasing intrauterine device (LNG-IUS)|Intervention is administered proceeding the ICSI
223462692|NCT05004090|DIAGNOSTIC_TEST|DNA methylation analysis|Genomic DNA will be extracted from 0.4 ml aliquots of each saliva sample using the kit manufacturer's suggested protocol, quantified with Qubit 2.0 (Invitrogen), and stored at -20°C. Aliquots of 250 ng of each DNA will be edited for methylation analysis with the EZ DNA Methylation Lightning kit (Zymo Research). Amplification of samples and their preparation for NGS sequencing will be performed as described. Samples will be sequenced on NextSeq 500 (Illumina). Individual processed sequences (PE reads) will be independently aligned to reference sequences using a parallel Smith-Waterman algorithm. Only reads that consistently align to the same reference sequence will be retained. At each CpG site in each analyzed sequence, the frequencies of the four bases will be evaluated and tabulated.
223575928|NCT02252809|DRUG|adalimumab|
223575929|NCT02252809|DRUG|methylprednisolone|
223575930|NCT04766385|DRUG|KHK7791|oral administration
223575931|NCT01376479|BIOLOGICAL|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
223575932|NCT01376479|BIOLOGICAL|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
223575933|NCT01376479|BIOLOGICAL|Placebo|Phosphate Buffered Saline (PBS)
223575934|NCT02513823|DIETARY_SUPPLEMENT|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
224157316|NCT01042054|OTHER|Standard optimised recovery protocol.|"* Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
224303141|NCT05382221|OTHER|Comprehensive Chronic Care|Those randomized to CCC will receive smoking treatment offers via the following routes: 1) Four Outreach Calls from a Health Counselor at 4, 8, 12, and 14 months post-study enrollment; 2) Four texts and/or mailings (depending on healthcare system preferences) over 14 months. These outreach contacts will offer cessation treatment or reduction treatment.
224157317|NCT01042054|OTHER|Wound catheter plus patient-controlled analgesia.|"* Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~* Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~* Sham epidural catheter applied to the patient's back for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout."
223462693|NCT05004090|DIAGNOSTIC_TEST|Proteomics analysis|Urine samples are collected using non-invasive methods and are prepared according to a procedure preparatory to quantitative recovery of exosomes: once thawed and centrifuged at 17,000 x g for 10 min at 4°C, the recovered supernatants are separated and centrifuged at 200,000 x g for 1 hr at 4°C. Exosome pellets are separated, washed repeatedly and resuspended in buffer (NH4HCO3, 0.1 mM ph=7.8). Protein concentration is estimated with the SPNTM Protein Assay kit and each sample (50 ± 0.5 μg protein) is digested with trypsin using a 1:50 (w/w) enzyme/substrate ratio at 37 °C over night (o/w). A second tryptic digestion is performed with an enzyme:substrate ratio of 1:100 (w/w) for 4h. Digested samples, centrifuged at 13,000 × g for 10 min, are purified and concentrated using PepClean C-18 columns. The samples obtained are analyzed by reversed-phase liquid chromatography coupled to high-resolution mass spectrometry.
223462694|NCT05004090|DIAGNOSTIC_TEST|Still Face Paradigm|During an observational session, a short video recording of the mother-child interaction of approximately 10 minutes will be made in a semi-structured setting to assess the child's emotional regulation and social behavior. The interaction will be structured in 5 different phases according to the Still Face paradigm (Tronick et al., 1978): Play, Still#1, Reunion#1, Still#2, Reunion#2. Play: Mothers will be invited to interact with their babies for 10 minutes; Still: mothers will be asked to remain still while maintaining an unresponsive expressionless face and not to smile, touch, or talk to the child for 2 minutes (Still#1: 2 minutes; Still#2: 2 minutes); Reunion: mothers will be asked to resume the play activity with their own for an additional 2 minutes (Reunion#1: 2 minutes; Reunion#2: 2 minutes).
223462695|NCT00863915|DRUG|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
223462696|NCT00863915|DRUG|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
223462697|NCT02772666|DEVICE|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
223462698|NCT02772666|OTHER|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
223462699|NCT05190874|DEVICE|Grappler Interference Screw System|Foot and/or ankle procedure involving soft tissue attachment to bone using the Grappler® Interference Screw System
223462700|NCT04789382|DEVICE|LID018869+RepleniSH|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
223462701|NCT04789382|DEVICE|LID018869+Biotrue|Lehfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
223462702|NCT04789382|DEVICE|Biofinity+RepleniSH|Comfilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with OPTI-FREE® RepleniSH® multi-purpose disinfecting solution (RepleniSH)
223462703|NCT04789382|DEVICE|PV+Biotrue|Balafilcon A silicone hydrogel spherical contact lens pre-cycled (pre-soaked prior to dispense) with Biotrue® multi-purpose solution (Biotrue)
223575935|NCT04942340|DRUG|Atipamezole & Caffeine|In this arm, subjects will be infused with Atipamezole (2 g/kg) and caffeine (15 mg/kg) across 5 minutes
223575936|NCT04942340|DRUG|Dexmedetomidine Hydrochloride & Saline|In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
224157318|NCT03011775|DRUG|Pioglitazone 15 mg Tablet|Pioglar (Ranbaxy India):1 tablet per day in the morning for 6 months
224157319|NCT03011775|DRUG|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
224157320|NCT03011775|DRUG|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
224157321|NCT03011775|DRUG|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
223575937|NCT06158230|DRUG|Pizotifen|Pizotifen will be given only at night time to avoid daytime somnolence. Starting dose will be 0.5mg then gradually increased to 1.5 mg
223575938|NCT06158230|DRUG|Amitriptyline-propranolol|"Amitriptyline will be given at bedtime only, starting at 10 mg daily and gradually increasing to 25 mg daily.~Propranolol will be started in 40 mg daily in divided doses, which gradually increases to 80 mg daily in divided doses"
224157322|NCT03011775|DRUG|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
224157323|NCT03011775|DRUG|Ramipril 5 MG|1 tablet per a day
224157324|NCT00674375|OTHER|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
224157325|NCT00588380|DRUG|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
223575939|NCT04671082|DRUG|Tolperisone Hydrochloride|TID
223575940|NCT04671082|DRUG|Placebo|TID
223575941|NCT00183963|DRUG|Tamoxifen|20mg
224157326|NCT00369044|DRUG|prednisone|
224157327|NCT01502670|DRUG|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
224157328|NCT01505244|BEHAVIORAL|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
224157329|NCT04556448|OTHER|Aligners|Clear aligners
224157330|NCT04556448|OTHER|Clear braces|Clear braces
224157331|NCT00742040|DRUG|Captopril|A rapid 3-day up-titration protocol
224157332|NCT00742040|DRUG|Captopril|A slower 9-day up-titration protocol
224157333|NCT01781624|OTHER|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
224303142|NCT05382221|OTHER|Standard Care|one offer of cessation treatment annually
223575942|NCT00183963|DRUG|Fulvestrant|250mg
223575943|NCT00183963|DRUG|Fulvestrant|500 mg IM
223575944|NCT02666456|OTHER|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
223575945|NCT02998047|DRUG|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.
223575946|NCT00176176|DEVICE|EEG|
223575947|NCT02743780|DRUG|MGV354 ophthalmic suspension|
223575948|NCT02743780|DRUG|MGV354 placebo|Inactive ingredients used as placebo comparator
224157334|NCT05355181|OTHER|Scar mobilization techniques|"Scar mobilization techniques include the gentle stroking and lifting of the scar as well as moving the scar tissue in different directions. It also includes rolling, C- grip, S-grip, and ram horn mobilization of the scar tissue.~Core stabilization exercises administered after cesarean section include the posture corrective exercises, abdominal draw-in, squatting, pelvis tilting, knee to chest, flexibility and stretching exercises, and bridges."
223575949|NCT01294462|DRUG|Ticagrelor|90 mg, oral dose twice daily
224157335|NCT05355181|OTHER|Core stabilization exercises|Core stabilization exercises
224157336|NCT02447640|DRUG|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
224157337|NCT02447640|RADIATION|[18F]FPEB|radiotracer used for PET scanning
224157338|NCT03758872|DIAGNOSTIC_TEST|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
224157339|NCT01459887|DRUG|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
224157340|NCT01459887|DRUG|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
224157341|NCT02997774|OTHER|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
224157342|NCT02997774|OTHER|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
224157343|NCT02293590|DRUG|Certolizumab Pegol|
224157344|NCT03419845|DEVICE|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
224157345|NCT00295737|PROCEDURE|bronchoscopy, allergen/endotoxin instillation|
224157346|NCT05706961|OTHER|Power Walking|"For 1- 2 Week 60% of the target heart rate with 5,000 to 7,500 steps/day Total 30 min Session The exercise intensity was set at 60% of the target heart rate during the first 2 weeks.~For 3- 4 week 70 % of the target heart rate with 7,500 to 10,000 steps/day Total 30 min Session B) Progressive increase walk according to 6MWD as improved Low intensity"
224157347|NCT05706961|OTHER|Standardized Outpatient Cardiac Rehabilitation|"For 1- 2 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 60 % of of target heart rate, resistive ex with 1- 3 kg of weight for 20 min and 10 min of cool down)~For 3 - 4 week Standardized Outpatient Cardiac Rehabilitation (includes warm up of 5 min, aerobic 70 % of target heart rate, resistive ex with 2- 3 kg of weight for 20 min and 10 min of cool down)"
224157348|NCT02620709|BEHAVIORAL|Hula intervention|Hula and heart health education
224157349|NCT04751968|OTHER|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. Adolescents are taught skills for coping and relating more effectively with others. Caregivers learn about adolescent development, effective parenting and the importance of connection. The groups consist of 6 stand-alone modules permitting rolling entry and prompt access. Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, homework from that week's intervention group and crisis resources.
223575950|NCT01294462|DRUG|Clopidogrel|75 mg, oral dose once daily
223575951|NCT01294462|DRUG|Acetylsalicylic acid ASA|Low Dose ASA
223575952|NCT06480175|PROCEDURE|cervical plexus block|patients will receive cervical radiofrequency ablation on both sides then after 2 weeks they will be readmitted and will receive superficial cervical plexus block on one side only
223575953|NCT01367223|DIETARY_SUPPLEMENT|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
223575954|NCT01367223|DIETARY_SUPPLEMENT|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
223575955|NCT06157320|DRUG|Shen-Fu|Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
223575956|NCT06157320|DRUG|Norepinephrine (NE)，antibiotics，fluid resuscitation|empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
223575957|NCT04253990|PROCEDURE|Precut EMR|"For treating of 10\~20mm colon polyp, patient will be randomly divided into two groups, a Precut-EMR group and a EMR group.~In Precut-EMR, endoscopist submucosally inject with saline around a polyp. Subsequently, circumferential incision/precutting was made with the tip of the snare around 2 mm outside the tumor. After that, the snare was positioned in the cut groove and tightend, and the tumor was resected using electrical current."
223575958|NCT04253990|PROCEDURE|Conventional MER|EMR had been widely used technique. Endoscopist submucosally inject with saline around a polyp. After that, snare is positioned around a polyp, and polyp was resected using electrical current.
223575959|NCT03002688|OTHER|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
223575960|NCT05513664|DRUG|Osimertinib|80 or 160 mg/qd
223462704|NCT03650153|PROCEDURE|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
223462705|NCT03650153|PROCEDURE|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
223462706|NCT02126280|OTHER|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
223462707|NCT01042340|OTHER|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
223462708|NCT03180203|DEVICE|INTELLiVENT-ASV|"After ICU admission:~* The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~* After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if \>10minutes PEEP:\<9cmH2O,FiO2:\<41%,VT/IBW\<5ml/kg and RSB:\<106l/l\*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate \>35b/min or increases \>100% since start of SBT, FiO2 \>50%, PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
223462709|NCT03180203|DEVICE|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if \>10min PS\<11cmH2O,PEEP\<9cmH2O,FiO2\<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate \>35b/min or increases \>100% since the start of SBT, saturation \<92% or the PeTCO2 increases \>8mmHg.~Extubation criteria: Leakage \<50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT \>10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
223575961|NCT06375642|DRUG|Adebrelimab|Adebrelimab, Surufatinib and HAIC
223575962|NCT04900948|DRUG|Pimecrolimus cream 1%|Patients received pimecrolimus cream 1% 2 times a day for 3 months. Then use in a double application mode (morning / evening) 3 times a week for up to 1 year of age. Also, patients used emollients 1-2 times a day.
223575963|NCT04900948|DRUG|cream 0.1% methylprednisolone aceponate|Patients received 0.1% methylprednisolone aceponate cream 2 times a week for 3 months, and then used for exacerbation of atopic dermatitis. Also, patients used emollients 1-2 times a day.
223575964|NCT03820453|DIETARY_SUPPLEMENT|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
223575965|NCT03820453|OTHER|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
223575966|NCT01041300|DEVICE|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
223575967|NCT01041300|DEVICE|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
223575968|NCT02076399|DRUG|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
223462710|NCT02065401|DRUG|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
223462711|NCT02065401|DRUG|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
223462712|NCT02065401|DRUG|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
223575969|NCT02076399|DRUG|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
223575970|NCT00976378|DRUG|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
223575971|NCT00976378|DRUG|NOX-A12|single IV dose, at efficacious dose level
223575972|NCT01811576|DRUG|TV-1106|
223575973|NCT01811576|DRUG|Recombinant human growth hormone|Subcutaneous once daily
223575974|NCT00085254|DRUG|cilengitide|Given IV
223575975|NCT00085254|DRUG|temozolomide|Given orally
223575976|NCT00085254|RADIATION|radiation therapy|Undergo radiotherapy
223575977|NCT00085254|OTHER|laboratory biomarker analysis|Correlative studies
223575978|NCT00085254|OTHER|pharmacological study|Correlative studies
223575979|NCT03177447|BEHAVIORAL|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
223575980|NCT03594149|DRUG|Levofloxacin|Levofloxacin 500 mg/d p.o.
223575981|NCT05750810|OTHER|Severe exacerbation frequency|A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms.
223575982|NCT01983280|OTHER|Healing Touch|
223575983|NCT01540409|DRUG|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
223462713|NCT01301300|DEVICE|Disinfecting Cap|Replace standard practice with using the disinfecting cap
223462714|NCT02467361|DRUG|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
223462715|NCT02467361|DRUG|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
223462716|NCT02467361|DRUG|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
223462717|NCT02467361|DRUG|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
223462718|NCT02019550|DEVICE|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
223462719|NCT02019550|DEVICE|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
223462720|NCT04161235|DEVICE|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
223462721|NCT06109389|DRUG|Lidocaine IV|LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
224157350|NCT04751968|BEHAVIORAL|Enhanced Treatment as Usual|Youth and Caregivers will receive a weekly text message reminder of their exit assessment date/time, a mental health tip and crisis resources.
223462722|NCT00687986|RADIATION|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
223462723|NCT00687986|PROCEDURE|primary surgery|an anatomical surgical resection with lymph node dissection
223575984|NCT06349135|PROCEDURE|Open Reduction & Internal Fixation|Open Reduction \& Internal Fixation of Mandibular fracture either through intraoral or extraoral approaches.
223743435|NCT04199117|DRUG|Combination nicotine patch and nicotine mini-lozenge treatment|Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
223462724|NCT04264780|OTHER|Neuropsychological examination|Neuropsychological follow-up examination, including questionaires
223743436|NCT04199117|BEHAVIORAL|Monetary incentives for initiating treatment|Participants randomized to this intervention will earn an incentive each time they complete a first counseling session in an available treatment, up to 2 rounds of counseling per year, and up to 4 rounds of counseling over 2 years of enrollment.
223743437|NCT04199117|BEHAVIORAL|Automated tailored outreach|Participants randomized to this intervention will receive 5 tailored letters delivered every 4-6 months. Letter content will be tailored to participant demographics and use of study treatment, and personalized with references to their primary care teams and tobacco care manager. Letters offer encouragement to quit and information about how to access available treatments.
224157351|NCT02657187|DEVICE|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
224157352|NCT02657187|DRUG|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
224157353|NCT01324687|OTHER|Telemedicine care|Availability of telemedicine
224157354|NCT04969432|OTHER|Client-centered|Rehabilitation
224157355|NCT03383627|DEVICE|Continuous Glucose Monitoring|"* The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~* CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~* Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
224157356|NCT03972826|OTHER|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
223462725|NCT00675987|DRUG|losartan|losartan 100 mg tablets 1 tab po QD
223575985|NCT00004437|DEVICE|Multichannel Auditory Brain Stem Implant|
223575986|NCT04342689|DRUG|Dietary Supplement containing resistant starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
223575987|NCT04342689|DIETARY_SUPPLEMENT|Placebo Starch|Two tablespoons (\~ 20 grams) to be taken twice daily for 14 days (start with 2 tablespoons once daily for three days, followed by twice daily on days 4 through 14)
223462726|NCT00675987|DRUG|Placebo control|Placebo 1 po QD
223462727|NCT03714763|DRUG|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
223462728|NCT03714763|OTHER|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
223462729|NCT01429662|BEHAVIORAL|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
223462730|NCT01429662|BEHAVIORAL|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
223462731|NCT02133391|OTHER|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
223462732|NCT02133391|OTHER|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
223575988|NCT03503292|DRUG|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
223462733|NCT04394598|DRUG|Dendrobium Huoshanense Granules|3g tid per day for 5weeks
223462734|NCT04394598|RADIATION|Pelvic Radiation|50Gy/25Fx
223462735|NCT04394598|DRUG|Capecitabine|625mg/m2 bid Monday-Friday per week
223462736|NCT04394598|DRUG|Irinotecan|80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
223462737|NCT04394598|OTHER|Placebo|3g tid per day for 5weeks
223575989|NCT03503292|DRUG|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
223575990|NCT01460407|DRUG|LY2216684|Administered orally
223575991|NCT01460407|DRUG|Clarithromycin|Administered orally
223575992|NCT00702455|BEHAVIORAL|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
223575993|NCT00702455|BEHAVIORAL|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
223575994|NCT02046850|DRUG|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
224157357|NCT02673723|DRUG|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
224157358|NCT02673723|DRUG|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
224157359|NCT04853589|DEVICE|Hyaluronic acid gel|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.
224157360|NCT04853589|DEVICE|Hyaluronic acid gel + carrier|After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
224157361|NCT03525626|BEHAVIORAL|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
224303143|NCT06262191|DEVICE|Differential and adjustable stiffness AFO (DAS-AFO)|Walking with a differential and adjustable stiffness AFO (DAS-AFO)
224303144|NCT06299956|OTHER|Supervised exercise therapy|Walking on a treadmill at increasing elevation and pace.
223575995|NCT02046850|DRUG|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
224157362|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)|Oral administration
224303145|NCT04267302|OTHER|Baby Bouncer|Fischer Price baby bouncer.
223462738|NCT01450319|DRUG|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m\^2) every 2 weeks until disease progression, death, or consent withdrawal.
223462739|NCT04771013|BIOLOGICAL|Thymic peptides|250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
223462740|NCT00823134|DEVICE|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
223462741|NCT02192671|PROCEDURE|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
223462742|NCT02192671|PROCEDURE|Radiofrequency Ablation|
223462743|NCT01561937|DRUG|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
223575996|NCT02046850|DRUG|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
223575997|NCT02046850|DRUG|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
223575998|NCT02720601|DRUG|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
224157363|NCT04939779|DRUG|LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)|Oral administration
224157364|NCT06413368|DRUG|Maralixibat 9.5 MG/ML [Livmarli]|Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.
224157365|NCT00631618|DRUG|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
224303146|NCT04267302|OTHER|Infant t-shirts with Language Environment Analysis (LENA) audio recorders|Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.
224303147|NCT04267302|OTHER|Baby Carrier|Ergobaby Baby carrier.
224303148|NCT00759902|DRUG|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
224303149|NCT00759902|DRUG|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
224303150|NCT02609412|OTHER|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
223575999|NCT00146185|DRUG|ALGRX 3268|
223462744|NCT01561937|DRUG|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
223462745|NCT01561937|DRUG|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
223462746|NCT03941340|DRUG|[14]-AST2818|Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1
223576000|NCT01367704|BEHAVIORAL|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
223576001|NCT01216943|DRUG|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
223576002|NCT01400243|DRUG|Nicotine|Nicotine patch 7mg
223576003|NCT01400243|DRUG|Placebo Patch|Placebo patch
223576004|NCT04304911|BEHAVIORAL|Blended intervention (UP-APP)|Unified Protocol (UP) for transdiagnostic treatment of EDs in the blended intervention (UP-APP)
223576005|NCT04304911|BEHAVIORAL|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
223576006|NCT00043823|DRUG|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
223576007|NCT00043823|DRUG|Tarceva|100 mg By Mouth Daily for 3 Weeks
223576008|NCT04365543|BEHAVIORAL|Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents (UP-C/A) for youth with misophonia|Please see arm/group descriptions
223576009|NCT04365543|BEHAVIORAL|Psychoeducation and Relaxation Therapy (PRT)|Please see arm/group descriptions
223576010|NCT02193087|DRUG|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
223576011|NCT02193087|DRUG|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
223576012|NCT02193087|DRUG|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
223576013|NCT02193087|DRUG|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
223576014|NCT04096820|BIOLOGICAL|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
223576015|NCT04172961|DRUG|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
223743438|NCT04199117|BEHAVIORAL|Care management|Participants randomized to this intervention will receive 5 live, proactive phone calls lasting 10-15 minutes from as assigned Tobacco Care Manager who will provide manualized support and motivational encouragement, discuss available treatment options, and inform the participant how to initiate treatment when ready to quit.
224157366|NCT02685787|BEHAVIORAL|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
224157367|NCT02685787|BEHAVIORAL|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
224157368|NCT03180242|BIOLOGICAL|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
224157369|NCT03180242|BIOLOGICAL|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
223576016|NCT04172961|DRUG|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
223576017|NCT01336530|DRUG|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
223576018|NCT01336530|DRUG|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
223576019|NCT01336530|DRUG|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
223576020|NCT01336530|OTHER|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
223576021|NCT04563234|BEHAVIORAL|COFLEX neurocognitive training|The COFLEX training group will then be provided with the cognitive training module and participants will be required to complete a targeted 30-minute daily training until the day of surgery, and then after the surgery, for a total of 6 weeks.
223576022|NCT04563234|BEHAVIORAL|Crossword puzzles|The control (crossword puzzles) group will be given a training module, where they can access crossword puzzles on the same platform, and can do puzzles whenever they desire over the 6-week time period.
223576023|NCT03395730|DRUG|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
223576024|NCT03395730|PROCEDURE|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
224071493|NCT03770585|PROCEDURE|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
224157370|NCT03180242|BIOLOGICAL|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
223462747|NCT03463629|OTHER|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
223462748|NCT03463629|OTHER|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
223462749|NCT04787367|PROCEDURE|TAP block|"An 18-gauge needle will be introduced externally at the center of the mid axillary line between the lower costal margin and the iliac crest until the surgeon feels a pop, after which the surgeon will inject the first 2 mL of 0.25% bupivicaine to verify the correct position. Doyle's internal bulge sign (the bulge seen when the transversus abdominis muscle and peritoneum is pushed internally) will be visualized and the remainder of the 60 mL of 0.25% bupivacaine will be injected. The contralateral block will be performed according to the same technique but with only 30 ml of bupivicaine."
223462750|NCT00078403|DRUG|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
223462751|NCT00078403|DRUG|Ribavirin|One tablet or capsule containing ribavirin 200 mg
223462752|NCT02291029|DRUG|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
224157371|NCT01716026|DRUG|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
224157372|NCT02917629|OTHER|Laboratory Biomarker Analysis|Correlative studies
224157373|NCT02917629|DRUG|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
224157374|NCT02917629|OTHER|Pharmacological Study|Correlative studies
224157375|NCT02917629|OTHER|Placebo|Given PO
224157376|NCT00718523|DRUG|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
224157377|NCT00718523|DRUG|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
224157378|NCT03636880|BEHAVIORAL|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
224157379|NCT03636880|BEHAVIORAL|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
223462753|NCT02291029|DRUG|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
224157380|NCT05070325|OTHER|Cold application group|Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
224157381|NCT05070325|OTHER|Shotblocker group|Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
224157382|NCT05070325|OTHER|Control Group|Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
224157383|NCT03465384|BEHAVIORAL|Comet|The intervention is a behaviorally based and manualized parent training program.
224157384|NCT03136484|DRUG|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
223462754|NCT02291029|DRUG|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
223462755|NCT02291029|DRUG|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
223462756|NCT02291029|DRUG|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
223462757|NCT02291029|DRUG|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
223462758|NCT06129383|PROCEDURE|serratus anterior plane block and pectointercostal plane block in breast surgery|Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
223462759|NCT02558842|OTHER|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
223462760|NCT05002166|OTHER|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.|labortatory such as fecal calprotectin ,CRP,CBC,ESR. Endoscopic examination of the gastrointestinal tract Histological examination of the biopsies retrieved during gastrointestinal endoscope.
223462761|NCT06344715|BIOLOGICAL|SL-T10|A therapeutic DNA vaccine containing three prostate cancer-specific antigen genes and genetic adjuvants
223462762|NCT06344715|BIOLOGICAL|GX-I7|A T-cell growth factor
223462763|NCT06344715|BIOLOGICAL|Pembrolizumab|An immune check point inhibitor
223462764|NCT01403558|BEHAVIORAL|Cognitive behavioral therapy|Cognitive behavioral therapy
223462765|NCT02410863|DRUG|Dabrafenib|150 mg twice daily
223462766|NCT02410863|DRUG|Trametinib|2 mg daily
223462767|NCT06491355|DRUG|mfolfox6 and hlx04 regimen and Serplulimab|mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
223462768|NCT06491355|DRUG|mfolfox6 and hlx04 regimen|In the active comparator. only with mfolfox6 and hlx04 regimen treatment.
223462769|NCT04575220|OTHER|12 weeks of bicycle exercise|Subjects will conduct monitored exercise, three sessions per week for 12 weeks.
223462770|NCT00419757|DRUG|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
223462771|NCT00419757|DRUG|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
223576025|NCT03395730|PROCEDURE|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
224157385|NCT03136484|DRUG|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
224157386|NCT03136484|DRUG|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
224157387|NCT03136484|DRUG|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
224157388|NCT05400538|OTHER|Biorepair Toothpaste + Mousse|Domiciliary application of the products twice a day.
224157389|NCT05400538|OTHER|Biorepair Toothpaste|Domiciliary application of the product twice a day.
223462772|NCT04265222|DEVICE|Hipcheck Software|Software
223462773|NCT04265222|OTHER|Conventional Fluoroscopy|Conventional Fluoroscopy
223462774|NCT03983408|DIETARY_SUPPLEMENT|Korean Red Ginseng|Participants are provided with 2 Korean Red Ginseng extract tablets twice a day for total 24 weeks.
223462775|NCT03983408|DIETARY_SUPPLEMENT|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets. Participants are parovided with 2 placebo tablets twice a day for first 12 weeks, following Korean Red Ginseng extract tablets twice a day for another 12 weeks.
223576026|NCT00168077|DRUG|Prothrombin Complex Concentrate|
223576027|NCT05027334|OTHER|DiaMon - Mobile Application for Type 2 Diabetes mellitus and pre-diabetes|Each participant will be provided with a mobile application aimed at monitoring their clinical markers such as FBG and HbA1c. The mobile application consists of medical details and demographics as well as a section dedicated to daily glucose levels and record of physical activity.
223576028|NCT00475865|DRUG|Teriflunomide|"Film-coated tablet~Oral administration"
223576029|NCT00475865|DRUG|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
223462776|NCT05235932|PROCEDURE|Robotic radical total gastrectomy with D2 lymphadenectomy|Most surgical procedures are performed using the robot system.
223462777|NCT05235932|PROCEDURE|Laparoscopic radical total gastrectomy with D2 lymphadenectomy|Without the robot system, Most surgical procedures are performed using laparoscopic equipment.
223462778|NCT04750018|OTHER|surgery|Patients were divided into surgery and no disease.
223462779|NCT01906242|OTHER|water|
223462780|NCT01906242|OTHER|sodium hypochlorite|
223462781|NCT01906242|OTHER|sodium bicarbonate|
223462782|NCT01906242|OTHER|chlorhexidine|
223462783|NCT00493012|DIETARY_SUPPLEMENT|vitamin D|6 drops of a vitamin D containing oil
223462784|NCT00732927|DRUG|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
223462785|NCT00732927|DRUG|aspirin|tablets, 100 mg for 3 months
223462786|NCT00368303|DRUG|Paroxetine CR|
223462787|NCT00368303|DRUG|Paroxetine IR|
223462788|NCT03709251|BEHAVIORAL|High Intensity Walking|Intense walking activity at an intensity of 70-80% of the maximum heart rate
223462789|NCT03709251|BEHAVIORAL|Casual Speed Walking|Moderate intensity (50-60% of Heart Rate maximum)
223462790|NCT01128296|DRUG|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
223462791|NCT01128296|DRUG|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
223576030|NCT00475865|DRUG|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
224157390|NCT00360685|DRUG|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
224157391|NCT00360685|DRUG|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
224303151|NCT02609412|OTHER|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
223576031|NCT01568372|OTHER|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
223576032|NCT00572611|DRUG|[14C]-bilastine|Single oral dose of 20 mg \[14C\]-bilastine. 1 capsule. 1 day dosing only
223576033|NCT05044104|DEVICE|Consumer-facing wearable smart watch|Wearable watch technology that has the ability to measure heart rate, respiratory rate, single-lead electrocardiography, and blood oxygen saturation.
223576034|NCT03918226|PROCEDURE|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
223576035|NCT03189654|DEVICE|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
223576036|NCT01048294|DEVICE|Original Energy Light,|9000 lux, 30 minutes in the morning
223576037|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 20 minutes in the morning
223576038|NCT01048294|DEVICE|Original Energy Light prototype|9000 lux 30 minutes in the morning
223576039|NCT04194723|PROCEDURE|Antireflux Mucosectomy|ARMS aimed at resection of mucosa at gastric cardia to induce fibrosis and tighten the gastroesophageal junction and reduce acid reflux
223576040|NCT00057434|DRUG|multivitamin|
223576041|NCT02445937|BEHAVIORAL|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
223576042|NCT04852510|DRUG|Metformin Versus a combination of Metformin and Thymoquinone (TQ)|Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
223576043|NCT05995041|BIOLOGICAL|CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells|Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
223576044|NCT00946322|BEHAVIORAL|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
223576045|NCT02032641|DEVICE|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
223576046|NCT01271257|DRUG|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
223576047|NCT02110888|DEVICE|Subcutaneous peripheral nerve stimulation|
224157392|NCT02239367|BEHAVIORAL|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
223576048|NCT02110888|OTHER|SCS Only|
223576049|NCT03387943|DRUG|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
224157393|NCT05131529|OTHER|Taste-focused labels|"We will implement taste-focused labels on plant-based dishes in each of the 3 treatment dining halls to re-brand dishes with attributes focused on the taste of the dish (e.g., renaming a Squash with Ginger side to Aromatic Thai Curry Kabocha Squash With Zesty Ginger)."
223462792|NCT04155463|OTHER|Organic Diet|Participants receive one week of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
223462793|NCT04155463|OTHER|Conventional Diet|Participants receive one week of conventionally grown (non-organic) food.
223462794|NCT00032448|PROCEDURE|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
223462795|NCT02597517|DEVICE|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
223462796|NCT02092753|OTHER|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
223462797|NCT02092753|OTHER|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
223462798|NCT02092753|OTHER|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
223462799|NCT01914393|DRUG|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
223462800|NCT06251271|DEVICE|Point-of-Care Ultrasound|Patients will undergo routine point-of-care ultrasound scans as part of the diagnostic process. The collected sonographic data and PFT results will assess point-of-care ultrasound's accuracy in diagnosing OLDs within the natural clinical setting.
223462801|NCT02881658|DIETARY_SUPPLEMENT|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
223462802|NCT02881658|DIETARY_SUPPLEMENT|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
223462803|NCT00356447|DRUG|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
223462804|NCT00356447|DRUG|Placebo|Same administration.
223462805|NCT05667662|DRUG|Itraconazole Powder|Capsules with 20 mg total powder (10 mg itraconazole plus 10 mg excipients)
223462806|NCT05667662|DRUG|Placebo|Capsules with 11.8 mg total powder (excipients only)
223462807|NCT01055015|DRUG|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
224303152|NCT02609412|DEVICE|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
223462808|NCT01055015|DRUG|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
223462809|NCT05625685|OTHER|Quitbuddy|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD EMA/GPS smoking data collection. GPS guided NRT usage prompts, via hotspot algorithms, will be provided to participants in the Quitbuddy Arm. Participants will contribute four weeks of post-TQD EMA/GPS data to capture lapses and NRT use in real-time. Carbon Monoxide (CO) levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
223462810|NCT05625685|OTHER|Control|"Participants will be mailed a one week supply of nicotine lozenges as nicotine replacement therapy (NRT) for their upcoming quit attempt, with the ability to order more as needed. Participants will have a set Target Quit Date (TQD) set on Day 8 after enrollment, following one week of ad-lib smoking that comprises the pre-TQD smoking data collection. Participants will contribute four weeks of post-TQD data to capture lapses and NRT use. CO levels will be tested at each of the six post-TQD remote assessments to provide objective verification of smoking status (i.e., 1 day, 1 week, 1 month, 2 month, 3 month, and 6 month abstinence rates). Computerized data collection methods (RedCap) will be used throughout the study to optimize quality assurance."
223462811|NCT05625685|OTHER|SDoH Augmentation|The SDoH intervention is based on the findhelp.org online platform, with customization to meet the specific needs of the study and communities being served: includes validated SDoH assessments, personalized social needs searching based on priorities, access to the most comprehensive social service database, and a streamlined closed loop referral system that integrates with workflows.
223462812|NCT05625685|OTHER|SDoH Control|No SDoH intervention
223462813|NCT01116336|DRUG|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
223462814|NCT01116336|DIETARY_SUPPLEMENT|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
223462815|NCT02396225|DRUG|Voriconazole|
223462816|NCT03328481|PROCEDURE|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety."
223462817|NCT03328481|PROCEDURE|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
223462818|NCT03328481|PROCEDURE|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
223462819|NCT06958692|DRUG|Dextromethorphan and Bupropion Sustained-Release Tablets|Oral dextromethorphan and bupropion sustained-release tablets, taken daily for 6 weeks.
223462820|NCT06958692|DRUG|Placebo|Oral placebo tablets, taken daily for 6 weeks.
223462821|NCT06958757|OTHER|Standard Exercise Therapy + Ankle Dorsiflexion Training|"The experimental group receives:~Standard Exercise Therapy (30 min/session, 3x/week for 8 weeks): Quadriceps eccentric exercises (e.g., slow step-downs), Hip abductor strengthening (e.g., side-lying leg lifts), and Neuromuscular control drills (e.g., single-leg balance on unstable surfaces).~Ankle Dorsiflexion Training (15 min/session, 3x/week for 8 weeks): Mobilization techniques (posterior glides of the talus), Resistance band exercises (dorsiflexion against elastic bands), Progressive Achilles tendon stretching (weight-bearing calf stretches).~Exercise progression (resistance/intensity) is adjusted biweekly based on functional assessments."
223576050|NCT03387943|DRUG|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
223576051|NCT04366557|OTHER|Manual therapy, exercises and education program|a six week body posture therapy consisted of manual therapy (once per week) and home exercises; education about pelvic floor
223576052|NCT04366557|OTHER|Education program|education about pelvic floor
223576053|NCT00174538|DRUG|Codeine (30 mg)|
223576054|NCT01223898|DRUG|Tasigna|
224303153|NCT03722095|DEVICE|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
224303154|NCT03722095|DEVICE|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
224303155|NCT03722095|DEVICE|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
223576055|NCT03400657|PROCEDURE|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
223462822|NCT06958757|OTHER|Standard Exercise Therapy Only|"Standard Exercise Therapy (30 min/session, 3x/week for 8 weeks): Quadriceps eccentric exercises (e.g., slow step-downs), Hip abductor strengthening (e.g., side-lying leg lifts), and Neuromuscular control drills (e.g., single-leg balance on unstable surfaces).~Exercise progression (resistance/intensity) is adjusted biweekly based on functional assessments."
223462823|NCT00408551|DRUG|floxuridine|Given IV
223462824|NCT00408551|DRUG|fluorouracil|Given IV
223462825|NCT00408551|DRUG|irinotecan hydrochloride|Given IV
223462826|NCT00408551|DRUG|leucovorin calcium|Given IV
223462827|NCT00408551|DRUG|oxaliplatin|Given IV
223462828|NCT06959134|BEHAVIORAL|The intervention will be mainly focused on the lifestyle modification and medication adherence, and self monitoring at home|In the intervention arm, study participants will received health education mainly based on lifemodification changes which will include; eating healthy diet, adopting healthy physical exercise, smoking cessation , moderate alcohol consumption and stress amanagement), and will be taugh on medication adherence, but also on self monitoring of blood pressure for detecting the variation and react accordingly.
223462829|NCT04831034|DRUG|68Ga-FAPI-04|Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
223462830|NCT01569282|PROCEDURE|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
223462831|NCT01569282|PROCEDURE|Stent strategy|Biliary and/or enteral stents on demand
223462832|NCT00600093|DRUG|Amantadine|IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery
223462833|NCT04214587|DIAGNOSTIC_TEST|tissue and blood sampling|only diagnostics will be peformed
223576056|NCT06242639|OTHER|Clinical examination|clinic and radiographic evaluation
223576057|NCT05615857|DEVICE|Use of Endocuff during colonoscopy|We will be adding the Endocuff device to the proximal end of the colonoscope, adding an additional tool to facilitate the visualization of the difficult-to-see mucosal areas as well as the rectum. There will be no need for retroflexion to evaluate the colon
223576058|NCT01747200|PROCEDURE|Sham rTMS|
223576059|NCT01747200|PROCEDURE|Bilateral rTMS at same frequency and in phase|
223576060|NCT01747200|PROCEDURE|Bilateral rTMS at different frequencies|
223576061|NCT01747200|PROCEDURE|Bilateral rTMSat same frequency and out of phase|
223576062|NCT01747200|PROCEDURE|rTMS over TP8|
223576063|NCT01747200|PROCEDURE|rTMS over TP7|
223576064|NCT01453946|DRUG|Entocort|Entocort capsules, taken orally, 6 mg daily.
223576065|NCT00363727|DRUG|ropinirole controlled-release (REQUIP CR) for RLS|
223576066|NCT00846040|OTHER|Reduced fat diet|RF (selective reduction of 85% of baseline fat calories per day)
223576067|NCT00846040|OTHER|Reduced carbohydrate diet|RC (selective reduction of 60% of baseline carbohydrate calories per day)
223576068|NCT00846040|DRUG|Drug: f-18 fallypride|Dopamine D2 receptor availability is measured by positron emission tomography (PET) using the positron emitting compound \[18F\] fallypride which binds competitively with dopamine to the D2 receptor.
223576069|NCT00846040|DEVICE|fMRI|Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
223576070|NCT00846040|DEVICE|PET|Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
223462834|NCT01417468|BEHAVIORAL|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
223462835|NCT01417468|BEHAVIORAL|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
223462836|NCT02408848|OTHER|Observational|This is an observational study. There is no intervention.
223462837|NCT05827276|OTHER|Life story questionnaire|Participant will receive physical therapy treatment as usual using information from Life Story Questionnaire.
223462838|NCT00018317|BEHAVIORAL|low protein diet|
223462839|NCT00018317|BEHAVIORAL|resistance training|
223462840|NCT00018317|BEHAVIORAL|combination of diet control and exercise|
223462841|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
223576071|NCT01912157|BEHAVIORAL|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
223576072|NCT03155334|OTHER|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~* individual reading of the text;~* individual questionnaire for a quantitative and qualitative evaluation;~* a brief semi-structured interview to each participant;~* a text revision to address any problems identified from participant feedback."
223576073|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
223576074|NCT00621829|DIETARY_SUPPLEMENT|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
223576075|NCT00858897|OTHER|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-\[3,3-2H2\]cysteine
223462842|NCT00904475|DRUG|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
223462843|NCT04547140|BIOLOGICAL|Liquid Alpha1-Proteinase Inhibitor (Human)|Intravenous infusion 120 mg/kg
223462844|NCT04547140|DRUG|Placebo|Intravenous infusion
223462845|NCT04547140|DRUG|Standard Medical Treatment|SMT
223576076|NCT00858897|DRUG|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
223576077|NCT03208114|OTHER|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
223576078|NCT04947631|DRUG|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg once daily for 48 weeks
223462846|NCT01819714|OTHER|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
223462847|NCT05369143|OTHER|Chiropractic care|The mechanical properties of chiropractic adjustment have been investigated; and although the actual force applied to the patient's spine depends on the chiropractor, the patient, and the spinal location of the subluxation, the general shape of the force-time history of spinal adjustments is very consistent68 and the duration of the thrust is always less than 200 milliseconds.
223462848|NCT05369143|OTHER|Control Group|The participants head and/or spine will be moved in ways that include passive and active movements, similar to what is done when assessing the spine by a chiropractor. The sham intervention will also include the participants moving into adjustment setup positions similar to how the chiropractor would typically set up a patient with no joint pre-loading or adjustive thrust
223462849|NCT05083663|DRUG|Hyaluronidase|using hyaluronidase as an additive to bupivacaine
223462850|NCT01344239|PROCEDURE|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
223462851|NCT03535363|DRUG|Osimertinib|Drug: Osimertinib 80mg or 40mg
223462852|NCT06300502|DRUG|Kybella|Injection into the cutaneous Neurofibromas lesion.
223462853|NCT06300502|DRUG|Asclera|Injection into the cutaneous Neurofibromas lesion.
223462854|NCT06300502|DEVICE|755nm Alexandrite Laser|Pulse laser at a wavelength of 755nm to the cutaneous Neurofibromas lesion.
223462855|NCT06300502|DEVICE|1064nm Nd:YAG Laser|Pulse laser at a wavelength of 1064nm to the cutaneous Neurofibromas lesion
223462856|NCT05116553|BEHAVIORAL|SDT|Standard 2 SDT (Self Determination Theory) psychological interviews.
223462857|NCT05116553|DEVICE|APP + CA|An APP with a CA (Conversational Agent).
223462858|NCT05382546|DRUG|Ketorolac Tromethamine|Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, polyolefin bag filled with 125 mL of NTM-001.
223462859|NCT03458377|OTHER|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
223462860|NCT02347709|PROCEDURE|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
223462861|NCT02347709|OTHER|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
223462862|NCT02347709|OTHER|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
223462863|NCT02347709|OTHER|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
223462864|NCT05853029|COMBINATION_PRODUCT|Combined shockwave therapy & conventional therapy , focused shockwave therapy& conventional therapy , conventional therapy|"The device used for management is from Storz-Medical company; Duolith-SD1 with focused and radial module.~\- Conventional therapy in the form of eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007)."
223462865|NCT00003537|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
223462866|NCT03893760|DIAGNOSTIC_TEST|Ventriculo-arterial coupling assessment (R-V/A)|R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
223462867|NCT05433610|DEVICE|Non-invasive Ventilation|Exercise capacity testing using the device
223462868|NCT01554124|DRUG|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: \< 32 weeks GA and \< 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
223462869|NCT03209193|DRUG|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
223462870|NCT03209193|DRUG|Desflurane|Desflurane use as main anesthetic drug during the surgery
223462871|NCT02318888|PROCEDURE|Surgery|
223462872|NCT02318888|DRUG|Icodextrin|
223462873|NCT01051557|OTHER|Laboratory Biomarker Analysis|Correlative studies
223462874|NCT01051557|DRUG|Perifosine|Given PO
223462875|NCT01051557|DRUG|Temsirolimus|Given IV
223462876|NCT01051557|PROCEDURE|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
223462877|NCT04221360|DRUG|CKD-375|Test drug, QD, PO
223462878|NCT04221360|DRUG|D390|Reference drug, QD, PO
223576079|NCT04947631|DRUG|Dutasteride|Dutasteride 0.5 mg once daily for 48 weeks
223462879|NCT04858308|DRUG|YYC506|YYC506
223462880|NCT04858308|DRUG|Control|Active control
223462881|NCT04858308|DRUG|YYC506 Placebo|Placebo
223462882|NCT04858308|DRUG|Control Placebo|Placebo
223462883|NCT00293852|PROCEDURE|Outpatient clinic follow-up|
223462884|NCT04724551|PROCEDURE|pancreatoduodenectomy (PD)|A pancreaticogastrostomy or -jejunostomy duct-to-mucosa was achieved according to the surgeon's preference and pancreatic texture.
223462885|NCT02953496|DRUG|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
223462886|NCT05532384|BEHAVIORAL|Early resumption of oral intake|as above
223462887|NCT05532384|BEHAVIORAL|Late resumption of oral intake|as above
223462888|NCT02958787|RADIATION|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
224157394|NCT05131529|OTHER|Carbon impact labels|We will add labels next to all dishes served in treatment dining halls that indicate whether production of the ingredients in the dish contribute a high, moderate or low amount of carbon emissions. These labels will be absent from the same dishes served in control dining halls. Labels will be added to point-of-service signs, digital menu boards, and menu information on a mobile app.
224157395|NCT05131529|OTHER|Changing default menu options|We will make red meat items an opt-in (as opposed to opt-out) item across all meal stations in treatment dining halls. All menu stations will exclude red meat by default, and dining hall patrons will have to request the addition of red meat to meals. At control dining halls, red meat items will be provided by default at meal stations as normal.
224303156|NCT01754116|DRUG|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
223462889|NCT03202420|OTHER|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
223462890|NCT01033630|DRUG|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
223462891|NCT01033630|DRUG|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
223462892|NCT01033630|DRUG|Placebo|Image-matched placebo, made with starch.
223462893|NCT03808233|OTHER|ACTIVE mini|the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
223462894|NCT04124770|OTHER|Movement|Re-positioning of neck
223462895|NCT03723863|BEHAVIORAL|Occupational Therapy|Receive in-person occupational therapist-led work consultation
223462896|NCT04020029|OTHER|Mindset|Mindset Intervention will include watching three brief \~10-25 minute films
223462897|NCT04020029|OTHER|Reflection activities|Reflection activity include exercises to internalize the message
223462898|NCT03476421|PROCEDURE|Hepatic resection|Surgery of the liver; removal of a part of the liver
223462899|NCT05865470|DRUG|Cannabis|smoked cannabis
223462900|NCT05865470|DRUG|Dronabinol|Oral delta-9-THC
223462901|NCT05865470|DRUG|Smoked Placebo|Placebo Cannabis
223462902|NCT05865470|DRUG|Oral Placebo|Oral Placebo
223576080|NCT04947631|DRUG|Tadalafil|Tadalafil 5 mg once daily for 48 weeks
223576081|NCT04947631|DRUG|DKF-313 placebo|Once daily for 48 weeks
223462903|NCT04742504|BIOLOGICAL|BENRALIZUMAB|The decision of the patients treatment with benralizumab (Fasenra®, Astra Zeneca) included in the study will not come in any case influenced by their participation in the study but will be made in accordance with the clinical criteria established by the Asthma Multidisciplinary Unit (UMA).
223462904|NCT03878823|DRUG|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
223462905|NCT00609544|DRUG|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
223462906|NCT02760719|DRUG|nebulized 3% hypertonic solution|already described
223462907|NCT00360425|DRUG|ferumoxytol|
223462908|NCT00360425|DRUG|moxifloxacin|
223462909|NCT00360425|DRUG|placebo|
223462910|NCT04754815|DRUG|Pembrolizumab|PD-L1 inhibitor administered as an intravenous (IV) infusion.
223576082|NCT04947631|DRUG|Dutasteride placebo|Once daily for 48 weeks
223462911|NCT04754815|DRUG|Pemetrexed|Folate analog metabolic inhibitor administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
223462912|NCT04754815|DRUG|Paclitaxel|A novel antimicrotubular agent administered as an intravenous (IV) infusion single agent chemotherapy for advanced NSCLC
223462913|NCT04754815|DRUG|Nab-paclitaxel|Microtubule inhibitor administered as an intravenous (IV) infusion indicated for the treatment of locally advanced or metastatic NSCLC
223462914|NCT04754815|OTHER|Laboratory Biomarker Analysis|Correlative studies
223462915|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Gain-framed|Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
223462916|NCT04110314|BEHAVIORAL|Portal Reminders for Influenza Vaccination: Loss-framed|Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
223462917|NCT04110314|BEHAVIORAL|Pre-commitment prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
223462918|NCT03052881|DEVICE|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of \<10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
223576083|NCT04947631|DRUG|Tadalafil placebo|Once daily for 48 weeks
223576084|NCT01822535|DRUG|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
223576085|NCT02278614|DRUG|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
224303157|NCT01754116|DRUG|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
224303158|NCT01754116|DRUG|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
224303159|NCT01754116|DRUG|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
224303160|NCT01754116|DRUG|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
224303161|NCT05989724|DRUG|SON-DP|Solution for IV administration
224303162|NCT02327117|DRUG|Tranexamic Acid|
223576086|NCT02278614|DRUG|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
223462919|NCT00510341|BEHAVIORAL|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
223462920|NCT01099358|DRUG|Cetuximab|Administered Intravenously
223462921|NCT01099358|DRUG|Cisplatin|Administered Intravenously
223462922|NCT01099358|DRUG|5 - Fluorouracil|Administered Intravenously
223462923|NCT03072290|DRUG|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
223462924|NCT03072290|DRUG|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
223462925|NCT03746834|DEVICE|NASHA/Dx (Solesta®)|Perianal submucosal injection of 3-4 ml of NASHA/Dx
223462926|NCT04241770|OTHER|no intervention|no intervention
223576087|NCT03453866|PROCEDURE|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
223576088|NCT03453866|PROCEDURE|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
223576089|NCT04919460|OTHER|clinical observation combined with pathological biopsy|Inspecting and palpating the oral cavity and neck of the screened object. If positive lesions are found, then further pathological biopsy will be performed.
223462927|NCT05018702|DRUG|ARX788|1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
223576090|NCT04919460|OTHER|Clinical observation, in vivo staining (reagent: toluidine blue) combined with pathological biopsy|(2) Inspecting and palpating the oral cavity and neck of the screened object. At the same time, in vivo staining is performed on each participant. The reagent used for staining is toluidine blue. As long as the screening subjects found positive lesions or abnormal living body staining, pathological biopsy was performed.
223462928|NCT00099164|DRUG|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
223462929|NCT03459716|OTHER|No intervention|No intervention
223462930|NCT04658797|DEVICE|somofilcon A Daily Disposable Contact Lens|Daily Disposable Contact Lens
223462931|NCT04658797|DEVICE|Single Vision Spectacle for Vision Correction|Single Vision Spectacle
223576091|NCT06508606|DRUG|AK117|AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
223462932|NCT04658797|OTHER|Personal Facemask|Personal Facemask
223462933|NCT02946892|DRUG|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
223462934|NCT02946892|DRUG|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
223462935|NCT01178125|DRUG|DR-102|
223462936|NCT00122291|DRUG|Capecitabine|
223462937|NCT00122291|PROCEDURE|Pelvic radiation|
223462938|NCT02948829|BIOLOGICAL|TDV|TDV SC injection.
223462939|NCT05088499|GENETIC|DNA analysis|GWAS
223462940|NCT01004978|DRUG|Cisplatin|Undergo TACE
223576092|NCT06508606|DRUG|anti-EGFR|anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
223576093|NCT03190694|DRUG|Dapagliflozin 10mg|Tablet
223576094|NCT04596865|PROCEDURE|Pancreaticoduodenectomy|Date of surgery 01/06/2010 - 31/05/2015
223576095|NCT02279498|DRUG|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
223576096|NCT02279498|DRUG|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
223576097|NCT01048866|DRUG|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
224068007|NCT04568226|OTHER|ConquerFear Intervention|ConquerFear is a manualized intervention, consists of six individual sessions over 10 weeks. The key goals of this intervention are the following: (1) teach strategies for controlling worry and excessive threat monitoring, (2) modify underlying unhelpful beliefs about worry, (3) develop appropriate monitoring and screening behaviours, (4) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (5) clarify values and encourage engagement in values-based goal setting (19). Each session will last 60-90 minutes and be delivered by a trained therapist. After each session, participants will be given home-based exercises to practice the skills learned in the sessions. With the uncertainty surrounding the COVID-19 pandemic, instead of face-to-face sessions only, a hybrid mode of intervention delivery will be used by offering participants the choice of face-to-face or online sessions.
224071494|NCT03770585|PROCEDURE|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
223462941|NCT01004978|PROCEDURE|Computed Tomography|Undergo CT scan
223462942|NCT01004978|DRUG|Doxorubicin Hydrochloride|Undergo TACE
223462943|NCT01004978|DRUG|Doxorubicin-Eluting Beads|Undergo TACE
223462944|NCT01004978|OTHER|Laboratory Biomarker Analysis|Correlative studies
223462945|NCT01004978|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223462946|NCT01004978|DRUG|Mitomycin|Undergo TACE
223462947|NCT01004978|OTHER|Pharmacological Study|Correlative studies
223462948|NCT01004978|OTHER|Placebo Administration|Given PO
223462949|NCT01004978|DRUG|Sorafenib Tosylate|Given PO
223462950|NCT04126044|DRUG|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
223462951|NCT04126044|DRUG|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
223462952|NCT05441228|DEVICE|Oculus Quest 2|Oculus Quest 2 is virtual reality headset with 2 hand control remotes. Beat Saber application will be used on Oculus Quest 2.
223462953|NCT05441228|DEVICE|Mirror therapy box|Mirror therapy is provided by mirror therapy box by placing it in sagittal plane of patient.
223462954|NCT00369915|DRUG|Scopolamine|
224303163|NCT02327117|DRUG|Normal saline|
224303164|NCT02128217|DRUG|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
224303165|NCT02128217|DRUG|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
224303166|NCT02128217|DRUG|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
224303167|NCT05071313|BIOLOGICAL|Ad26.RSV.preF-based vaccine|Ad26.RSV.preF-based vaccine will be administered as single IM injection.
224303168|NCT05071313|BIOLOGICAL|Quadrivalent High-dose Influenza Vaccine|Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.
224303169|NCT05071313|BIOLOGICAL|Placebo|Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
224303170|NCT03911050|DIETARY_SUPPLEMENT|Apple consumption|Apple blends (600 g) One single dose
224303171|NCT03911050|DIETARY_SUPPLEMENT|Control group|Breakfast without any apple-related products
224303172|NCT02733081|PROCEDURE|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
224303173|NCT06074081|OTHER|motor relearning program|MRP is a therapy to regain particular motor function and neglecting accessory movements by engaging cognitive behavior .
224303174|NCT06074081|OTHER|mirror therapy|Mirror therapy enhance functional activities in patient with hemiplegic stroke. For betterment of result high quality methodological studies and larger sample size is required.
224303175|NCT01211418|BEHAVIORAL|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB \& IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
224303176|NCT01211418|BEHAVIORAL|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
224303177|NCT00057993|BIOLOGICAL|trastuzumab|
224303178|NCT00057993|DRUG|exemestane|
224303179|NCT00304226|DRUG|valsartan|
224303180|NCT00304226|DRUG|amlodipine|
224303181|NCT04438226|PROCEDURE|Surgical approach|The surgical approach of hemiarthroplasty after femoral neck fracture
224303182|NCT03107026|DRUG|dasotraline 4mg|dasotraline 4mg tablet once daily
224303183|NCT03107026|DRUG|dasotraline 6mg|dasotraline 6mg tablet once daily
223462955|NCT00369915|DRUG|Scopolamine|
223462956|NCT00061841|BEHAVIORAL|exercise|
223462957|NCT01711983|DEVICE|GORE® CARDIOFORM Septal Occluder|Percutaneous Atrial Septal Defect Closure
223462958|NCT02575417|BEHAVIORAL|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
223462959|NCT04473872|OTHER|respiratory rehabilitation|intervention includes respiratory muscle strengthening with diaphragmatic respiration and IMT device, in addition to neurodevelopmental rehabilitation.
223462960|NCT04350268|DEVICE|Wearable sensor|Wireless sensor
224303184|NCT03107026|DRUG|Placebo|Placebo tablet once daily
224303185|NCT02267668|BEHAVIORAL|STEP|Physical therapists guide participants through novel set of assigned exercises
223462961|NCT02907567|DRUG|CT1812|Active study drug
223462962|NCT02907567|DRUG|Placebo|non-active study drug
223462963|NCT02326272|BIOLOGICAL|Certolizumab Pegol|"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"
224303186|NCT02267668|BEHAVIORAL|Control|Participants self-guide through standard exercises
224303187|NCT05748106|DEVICE|Ultrasound-based imaging|Ultrasound-based imaging
224303188|NCT04885153|DRUG|Fenofibrate|Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.
224303189|NCT04885153|DRUG|Placebo|Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
224303190|NCT04365218|DRUG|MEDI8367|Subjects will receive subcutaneous (SC) single dose of MEDI8367, depending upon dose escalation strategy and Safety Review Committee results. The maximum dose will not exceed 600 mg. The dose will be administered as a single injection or multiple injections in the abdomen region.
224303191|NCT04365218|DRUG|Placebo|Saline solution for injection and the placebo volume to be administered will be equivalent to the MEDI8367 volume administered for each dosing cohort.
224303192|NCT05522985|DRUG|Triprilimab combined with TP|Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
224303193|NCT04331938|DRUG|Regional anesthetic SPG block-bilateral|Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
224303194|NCT02049450|DRUG|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
223462964|NCT02326272|OTHER|Placebo|"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"
223462965|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
223462966|NCT04175132|DRUG|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
223462967|NCT01276912|DRUG|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
223462968|NCT01276912|BEHAVIORAL|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
223462969|NCT01497548|DRUG|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
223462970|NCT01497548|DRUG|Placebo|Placebo given on morning (0800) and noon (1200)daily
223462971|NCT04420728|COMBINATION_PRODUCT|Early auto-mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
223462972|NCT04420728|COMBINATION_PRODUCT|Delayed auto mode|Participant will be switched to or continue to use the MiniMed 670G insulin pump in manual mode during pregnancy. After the birth of their child, each participant will be randomized to either early auto-mode enabled MiniMed 670G or delayed auto-mode.
223462973|NCT00944346|DRUG|Metformin HCl|
223576098|NCT01048866|DRUG|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
223576099|NCT01048866|DRUG|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
223576100|NCT03582813|BEHAVIORAL|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
223576101|NCT03582813|BEHAVIORAL|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
223576102|NCT03048591|DEVICE|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
223576103|NCT03745183|OTHER|Senna alata leaf decoction|"Preparation of the akapulko decoction~1. Remove the leaflets from the rachis of a mature leaf.~2. Wash the mature leaflets thoroughly to remove dust, dirt and debris.~3. In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~4. Cook the leaves and bring to a rolling boil.~5. When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~6. Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~7. Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
223576104|NCT04859244|DRUG|GS-441524|750 mg administered as a solution
223576105|NCT04765644|DRUG|Celecoxib|Two 200 mg capsules per day (400 mg/day) for 7 days
224157396|NCT03284021|DEVICE|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
223462974|NCT00945412|DEVICE|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
223462975|NCT00945412|DEVICE|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
223576106|NCT04765644|OTHER|Placebo|2 capsules/day for 7 days
223576107|NCT04765644|OTHER|L-arginine + placebo|L-arginine = Five capsules of 2 mg per day (10 mg/day) for 7 days Placebo = 2 capsules/day for 7 days
224071495|NCT00722150|DRUG|Artesunate|2 mg/kg/day x 7 days
224071496|NCT00722150|DRUG|Artesunate|4 mg/kg/day x 7 days
224071497|NCT00722150|DRUG|Artesunate|6 mg/kg/day x 7 days
224071498|NCT05334186|BEHAVIORAL|Telehealth Reasoning Training|The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
224157397|NCT03747536|DRUG|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
224157398|NCT03747536|OTHER|Placebo|normal saline delivered via metered dose spray
224157399|NCT03983213|PROCEDURE|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
224157400|NCT01854489|DRUG|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
224303195|NCT04736043|OTHER|Organoid|The investigators create organoid from the pancreatic cancer tissue obtained via EUS-FNA and EUS-FNB within the pancreatic cancer diagnostic process. And also the investigators create organoid from the pancreatic cancer tissue obtained after surgery as part of the pancreatic cancer treatment process. Check for the reactivity to anti-cancer drugs through cell viability assay after treating with various anti-cancer drugs, such as anti-cancer drugs used as adjuvant chemotherapy for pancreatic cancer to the organoid. Also, perform genomic analysis on each organoid, and then check if there are any unique genomic mutations for each organoid. By recognizing the relationship between the unique genomic mutations and reactivity to the anti-cancer drug within pancreatic cancer patients eligible for surgery, the investigators aim to strategize appropriate adjuvant chemotherapy after surgery, thus developing a platform to predict the outcomes of each patient.
224157401|NCT01854489|DRUG|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
224157402|NCT01854489|DRUG|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
223576108|NCT04765644|OTHER|L-arginine + celecoxib|L-arginine = Five capsules of 2 mg per day (10 mg/day) Celecoxib = Two 200 mg capsules per day (400 mg/day) for 7 days
224157403|NCT03345368|DEVICE|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
224157404|NCT03345368|DEVICE|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
224157405|NCT03345368|OTHER|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
224157406|NCT01077869|PROCEDURE|endoscopic examination|on a weekly basis during 7 weeks
224157407|NCT01077869|PROCEDURE|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
224157408|NCT05041062|DRUG|Nivolumab|Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
224157409|NCT05041062|DRUG|Ipilimumab|Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
224157410|NCT02206321|PROCEDURE|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
224157411|NCT02206321|PROCEDURE|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
224157412|NCT00136838|BEHAVIORAL|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
224157413|NCT03418064|DEVICE|Fanfilcon A toric lens|Contact lens
224157414|NCT03418064|DEVICE|Lotrafilcon B toric lens|Contact lens
224157415|NCT02279979|DEVICE|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
224157416|NCT03865238|BIOLOGICAL|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
224157417|NCT03865238|BIOLOGICAL|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to \< 2 years of age will receive a booster vaccination on Day 366.
224157418|NCT01802515|DRUG|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
224157419|NCT01802515|DRUG|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
224157420|NCT01802515|DRUG|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
224157421|NCT00568204|DEVICE|Mexyn-A|Atomised topical self-chilled pressurised spray
224157422|NCT04307901|DEVICE|Colon capsule endoscopy|Endoscopy performed using PillCam2 camera capsule for oral ingestion
224157423|NCT01628042|DRUG|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
224157424|NCT00316654|BIOLOGICAL|Meningococcal C conjugate vaccine|
224157425|NCT05386849|DEVICE|FUSION closed loop glucose control system|The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
224157426|NCT04465461|PROCEDURE|Video-assisted thoracoscopic surgery (VATS) fissure completion|Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.
224157427|NCT04465461|DEVICE|Zephyr Valve insertion|Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
224157428|NCT06217562|DRUG|Vasopressin|Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
223576109|NCT04454593|OTHER|no intervention|This is an observation study,with no intervention
224157429|NCT06217562|OTHER|Recommendation to use a lower initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
224157430|NCT06217562|OTHER|Recommendation to use a higher initiation threshold for vasopressin|Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
224157431|NCT04586166|DEVICE|RP Sling|Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.
224157432|NCT04586166|DEVICE|SIS|Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.
224157433|NCT06096259|DRUG|Metformin|Metformin is an oral anti-hyperglycemic agent widely used as first-line treatment for type II diabetes to improve glycemic control. It is the fourth most commonly prescribed drug in the United States. Participants will receive commercially available extended-release metformin 500mg tablets manufactured by Granules India Limited, Hyderabad, India and then sourced, packaged, and labeled for the study by Sharp Labs. The study will follow standard dosing procedures for extended-release metformin. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
224157434|NCT06096259|DRUG|Placebo|The study will use matching placebo tablets that are almost indistinguishable from the 500 mg metformin ER tablets. Participants will begin by taking 1x500 mg pill once a day, and then the dose will be increased in 500 mg/day increments every 5 days as tolerated, up to a maximum dose of 1500 mg daily.
223462976|NCT01050946|BIOLOGICAL|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
223462977|NCT04024605|DIETARY_SUPPLEMENT|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
223462978|NCT04024605|DIETARY_SUPPLEMENT|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
223462979|NCT04024605|DIETARY_SUPPLEMENT|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
223462980|NCT04024605|DIETARY_SUPPLEMENT|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
223462981|NCT04978324|BIOLOGICAL|leukocyte platelet rich fibrin (L-PRF)|Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
223462982|NCT04978324|PROCEDURE|Scaling and Root Planing|Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
223462983|NCT02757729|DRUG|PAC-14028 cream 0.1%|Topical application
223462984|NCT02757729|DRUG|PAC-14028 cream 0.3%|Topical application
223462985|NCT02757729|DRUG|PAC-14028 cream 1.0%|Topical application
223462986|NCT02757729|DRUG|PAC-14028 cream vehicle|Topical application
223462987|NCT03409536|DEVICE|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
223462988|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and dairy fat|12-weeks, 3x per day
223462989|NCT04194983|DIETARY_SUPPLEMENT|Fish oils and plant fat|12-weeks, 3x per day
223462990|NCT05235360|BEHAVIORAL|Episodic future thinking|Participants will listen to a guided thinking task directing them to think about themselves at a future, positive event and to imagine the event in vivid and specific detail.
223462991|NCT05235360|BEHAVIORAL|Positive affect imagery|Participants will listen to a guided thinking task directing them to think about positive feelings and associations about physical activity in specific, personal, and positive detail.
223576110|NCT03199521|OTHER|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
223576111|NCT00377546|DRUG|Nepafenac|
224068008|NCT04568226|OTHER|Active control: Basic Cancer Care|Basic Cancer Care intervention for the control arm was developed to help cancer survivors with health maintenance in long-term through providing comprehensive lifestyle guidance. The intervention incorporates relaxation training, dietary and physical fitness consultations with the key goals to (1) teach relaxation techniques, (2) offer personalized diet and physical activity advice, and (3) enhance survivors' perceived control over illness, thereby leading to better adjustment to cancer. Similar to the ConquerFear intervention, Basic Cancer Care intervention consists of 6 individual sessions over 10 weeks. Each session will last 60-90 minutes and be delivered by a trained therapist, a registered dietitian, and an exercise physiologist, respectively. A hybrid mode of intervention delivery will be also used by offering participants the choice of face-to-face or online sessions.
224068009|NCT04307290|DRUG|Dexmedetomidine Hydrochloride, or Saline|drug infusion from 10 min before the start of surgery to the end of surgery
224068010|NCT00005070|DRUG|irofulven|
224068011|NCT05088278|PROCEDURE|Anatomical single bundle ACL reconstruction with hamstrings|Anatomical ACL reconstruction with quadruple-bundle hamstrings graft
224068012|NCT05088278|PROCEDURE|Anatomical single bundle ACL reconstruction with patellar tendon|Anatomical single bundle ACL reconstruction with patellar tendon
223462992|NCT05235360|BEHAVIORAL|Action planning|Participants will listen to a guided thinking task directing them to think about the remainder of their week and when, where, and how they plan to attain their remaining activity for the week.
223462993|NCT05235360|BEHAVIORAL|High dose|Participants will listen to the audio-recording with the guided thinking tasks 5 times/week.
223462994|NCT05235360|BEHAVIORAL|Recent thinking|Participants will listen to a guided thinking task directing them to think about a regular habit or activity they completed in the past week and to imagine that activity in specific and vivid detail.
223462995|NCT05235360|BEHAVIORAL|Neutral imagery|Participants will listen to a guided thinking task directing them to imagine physical sensations (i.e., movements, muscles used) of a routine, daily activity (non-physical activity).
223462996|NCT05235360|BEHAVIORAL|Low dose|Participants will listen to the audio-recording with the guided thinking tasks 1 time/week.
223462997|NCT00270296|DRUG|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
223576112|NCT00377546|DRUG|Ketorolac LS, Bromfenac|
223576113|NCT03464357|RADIATION|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
224157435|NCT04772469|BEHAVIORAL|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
224157436|NCT04772469|OTHER|Small monetary incentives|Use of small incentive voucher (\~$5) to encourage linkage to confirmatory testing.
224157437|NCT04772469|BEHAVIORAL|Use of SMS/text reminders to motivate adherence to ART or PrEP|"Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support."
224157438|NCT06382207|DEVICE|Eko Duo electronic stethoscope|A digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time.
224157439|NCT06382207|DEVICE|CORE 500 electronic stethoscope|The CORE 500 has 3 electrodes that produce a 3 lead ECG, which can be viewed through the Eko app. The CORE 500 also has a user interface screen which provides a number of functions including confirming when all three electrodes have good skin contact, showing a single lead ECG wave, providing heart rate, allowing the user to switch between audio modes, allowing the user to take recordings, and providing AI analysis results for recordings.
224157440|NCT03038672|BIOLOGICAL|Nivolumab|Given IV
224157441|NCT03038672|DRUG|Varlilumab|Given IV
224157442|NCT04694911|BEHAVIORAL|Focus Group|Participate in focus group
224157443|NCT04694911|OTHER|Interview|Complete cognitive interview
224157444|NCT04694911|OTHER|Research or Clinical Assessment Tool|Receive OOCAT
223462998|NCT00270296|DRUG|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
223462999|NCT00270296|DRUG|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
223463000|NCT00270296|DRUG|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
223463001|NCT05337176|OTHER|app-coo application|"The Montreal Cognitive Assessment (MoCA) is a measure designed specifically for detecting mental cognitive impairment(MCI) APP-Coo-Balance-Test can assess the oscillation of the trunk in different static positions: Feet Together, On a Broad Base (medial malleoli 30 cm apart) , and during the gait Dynamic(Arcuria et al., 2020)."
223463002|NCT05983796|DIAGNOSTIC_TEST|18F-HER2 PET|18F-HER2 PET
223463003|NCT05922644|DEVICE|SCS|21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
223463004|NCT05922644|OTHER|Conventional|Routine brain resuscitation and rehabilitation awakening treatment.
223463005|NCT02432885|DRUG|Enalapril|up to 20mg bid
223463006|NCT06347367|OTHER|Group 1 (exercise and self-manual approaches targeting only the diaphragm muscles)|Both groups will receive the patient education before treatment. Diaphragmatic stretching technique, pectoral muscle relaxation, diaphragmatic mobilisation, thoracic mobilisation and diaphragmatic breathing. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
223576114|NCT02230683|DRUG|IDN-6556|25 mg BID
223576115|NCT00260065|DRUG|Decitabine|20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
223576116|NCT05123404|DIAGNOSTIC_TEST|multi parametric MRI|In our study we aim to evaluate role of Multiparametric MRI in differentiation between invasive and non-invasive bladder cancer and accuracy of vesical imaging reporting and data system (VI-RADS) score.
223576117|NCT05123404|PROCEDURE|transurethral resection of bladder tumor|detection of degree of invasion to test accuracy of ViRADS score
223576118|NCT04068519|DRUG|Tislelizumab|Administered intravenously
223576119|NCT00025168|DRUG|gemcitabine hydrochloride|
223576120|NCT00025168|DRUG|irinotecan hydrochloride|
223576121|NCT00025168|RADIATION|radiation therapy|
223576122|NCT04559022|PROCEDURE|Fat Grafting|This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with acne scars on the face.
223463007|NCT06347367|OTHER|Group 2 (exercise and self-manual approaches targeting both diaphragm and core muscles)|İn addition to Group 1, patients in group 2 will receive, abdominal massage, abdominal mobilisation, stabilisation exercises and pelvic floor muscle training. Exercise and self-manual approaches will be performed at home 3 times a day for 8 repetitions for 4 weeks and approximately 45-60 minutes.
223463008|NCT06470490|BEHAVIORAL|psychoeducational|educational program
223463009|NCT00737100|DRUG|Placebo Respimat|patient to receive placebo matching active drug once daily
223463010|NCT00737100|DRUG|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
223463011|NCT00737100|DRUG|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
223463012|NCT02420535|BEHAVIORAL|Immediately Receive Tool|
223463013|NCT02420535|BEHAVIORAL|One Month Delay|
224157445|NCT06136494|BEHAVIORAL|Internet-delivered cognitive behavioural therapy|Psychoeducation aims at teaching patients about chest pain and anxiety and their impact on daily life. Mindfulness is used to raise awareness of what is going on in the body and emotions and to learn how to relate to chest pain. Physical activity consists of psychoeducation and recommendations regarding physical activity with the goal to get patients to learn that their heart tolerates physical activity and to reduce cardiac anxiety and avoidance of physical activity. Avoidance/exposure is to teach patients how avoidance and safety behaviours can maintain/exacerbate chest pain and negatively impact daily life. Acceptance is about learning to accept having the chest pain without letting it take over one's life. The participants will have weekly assignments with weekly feedback and advice. Reminders and encouraging messages will be sent to motivate participants to complete the intervention. The treatment will be carried out through our own web platform.
224157446|NCT06136494|BEHAVIORAL|Attention control|General support via weekly email contact to check how participants are feeling and how they are dealing with their situation. iCBT will be offered after 3 months.
223463014|NCT04240223|DRUG|Brilacidin|Brilacidin
224157447|NCT02994576|DRUG|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
224157448|NCT03443180|OTHER|Gluten and Amylase Trypsin Inhibitors (ATI)-free diet|Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
224157449|NCT05155345|DRUG|Mosunetuzumab|Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
223463015|NCT04240223|DRUG|Placebo|Placebo
223463016|NCT04240223|RADIATION|4Mq 99mTc-DTPA|4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
223463017|NCT00580957|DRUG|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
223463018|NCT00580957|DRUG|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
223463019|NCT00631059|OTHER|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
223463020|NCT00427141|DRUG|GSK580416|
223463021|NCT03249428|DEVICE|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
223463022|NCT04245592|DIETARY_SUPPLEMENT|Extra Virgin Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of organic EVOO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
223463023|NCT04245592|DIETARY_SUPPLEMENT|Refined Olive Oil|Before beginning the 3-week dietary trial, participants will conduct a 2-week washout period during which they consumed ROO (50 ml daily for 2 weeks) because they are part of a population that consumes olive oil regularly. After thar, patients of this groups will consume 50 ml/day of ROO for 3 weeks. Biochemical markers and clinical parameters in each participant will be determine before and after the 3-week treatment period.
223463024|NCT05423457|BEHAVIORAL|Vegan diet|The participants were advised to eat foods in their original type.
223463025|NCT00735943|OTHER|No intervention|No intervention
223463026|NCT01265394|DRUG|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
223463027|NCT00434772|DRUG|glucagon|
223463028|NCT02464124|DRUG|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
223463029|NCT02464124|DRUG|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
223463030|NCT01629550|PROCEDURE|skin disinfection prior catheter insertion|
223463031|NCT04033146|DEVICE|Ankle Exoskeleton Assistance|The investigators will use ankle-exoskeletons to modulate the amount of mechanical power generated by the user's ankle joint. That is, participants will walk in a robotic device that either (a) adds a spring or (b) a motor in parallel with their calf muscles to help them generate a stronger propulsive push-off that could reduce the effort of walking.
223463032|NCT00746226|BIOLOGICAL|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10\^9 CFU of a combination of L. acidophilus and B. lactis
223463033|NCT00746226|BIOLOGICAL|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
223463034|NCT00275171|DRUG|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
223463035|NCT00275171|DRUG|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
223463036|NCT00275171|OTHER|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
223463037|NCT00500578|DRUG|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
223463038|NCT00500578|DRUG|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
223463039|NCT02739217|DRUG|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
223463040|NCT00268983|BIOLOGICAL|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
223463041|NCT00268983|BIOLOGICAL|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
223463042|NCT06203470|DRUG|Botulinum Toxin-A|Botulinum Toxin-A (BoNT-A) is an injectable neuromodulator produced by Clostridium Botulinum, a Gram-positive bacillus that causes Botulism.
223463043|NCT06203470|DRUG|Tacrolimus|topical Calcineurin inhibitor
223463044|NCT01908712|DRUG|Lamazym|ERT, i.v. infusions weekly
223463045|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
223576123|NCT06320509|BIOLOGICAL|Continuous measurement of uPO2 (both groups)|uPO2 is collected continuously for the first 5 days of admission or until discharge from intensive care or removal of the urinary catheter.
223576124|NCT05775146|RADIATION|stereotactic body radiation treatment (SBRT)|SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
223576125|NCT02418312|DRUG|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
223576126|NCT02418312|DRUG|Placebo|placebo plus thienopyridine
223576127|NCT00803413|BEHAVIORAL|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
223576128|NCT00803413|BEHAVIORAL|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
223576129|NCT00803413|BEHAVIORAL|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
223576130|NCT00803413|BEHAVIORAL|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
223576131|NCT04907526|BIOLOGICAL|Autologous mononuclear cells|Autologous mononuclear cells delivered into right ventricle at time of Stage III Fontan surgery.
223576132|NCT02127034|DRUG|Mirabegron|oral
223576133|NCT02127034|DRUG|Solifenacin|oral
223576134|NCT02127034|DRUG|Digoxin|oral
223576135|NCT05394532|OTHER|Education|Common Education
223576136|NCT01164332|OTHER|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
223576137|NCT04102553|DRUG|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
223576138|NCT04102553|DRUG|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
223576139|NCT03852979|DRUG|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
223576140|NCT03852979|DRUG|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
224157450|NCT05155345|DRUG|Tocilizumab|Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
224157451|NCT02518568|DRUG|V0355|Oral administration (2 tablets)
224157452|NCT00352170|DIETARY_SUPPLEMENT|calcium supplementation|calcium carbonate 1500 mg/day
224157453|NCT00352170|DIETARY_SUPPLEMENT|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
223463046|NCT00475137|DRUG|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
223463047|NCT01719380|DRUG|LGX818|
223463048|NCT01719380|DRUG|Cetuximab|
223463049|NCT01719380|DRUG|BYL719|
223576141|NCT03852979|PROCEDURE|conisation|if tumor is reduced to \<2 cm, patients will be treated with a conisation
223576142|NCT06198088|OTHER|PNF techniques|The patient in the experiment group will PNF techniques (hold relax) the participants who were assigned for post traumatic stiffness of the elbow with baseline treatment (heating pad), stretching applied for 30 sec then relaxation time 10 sec, 5 repetition were given in a session for 5 days a week for 4 weeks.
223576143|NCT06198088|OTHER|Exercise therapy|exercise therapy range of motion, stretching and strengthening were applied with heating pad as baseline treatment. 5 repetition were given in a session for 5 days a week for 4 week.
223576144|NCT03573700|DRUG|Cyclophosphamide|Given IV
223576145|NCT03573700|DRUG|Fludarabine|Given IV
223576146|NCT03573700|DRUG|Mesna|Given IV
223576147|NCT03573700|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
223576148|NCT03573700|BIOLOGICAL|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
224157454|NCT00352170|DIETARY_SUPPLEMENT|Placebo|calcium and vitamin D3 placebo
224157455|NCT01696396|DRUG|Abrilumab|Administered by subcutaneous injection.
223463050|NCT05366595|DRUG|oral zinc sulfate|Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
224157456|NCT01696396|DRUG|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
224157457|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
224068013|NCT05088278|PROCEDURE|ACL reconstruction with over the top plus lateral plasty technique|Non-anatomical ACL reconstruction, the hamstrings' tibial insertion is preserved; a double-bundle hamstring graft is passed intra-articularly, fixed in over the top position on the lateral femoral condyle, and then passed extra-articularly deeply to ileo-tibial band up to the tibia, where it is fixed at the level of Gerdy's tubercle.
224303196|NCT03363399|DIAGNOSTIC_TEST|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
223463051|NCT02147613|OTHER|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
223463052|NCT02147613|OTHER|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
223463053|NCT03533231|COMBINATION_PRODUCT|Canal Disinfection Triple Antibiotic Paste (TAP)|"Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity."
223463054|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Propolis Paste|
223463055|NCT03533231|COMBINATION_PRODUCT|Ciprofloxacin + Metronidazole Paste|
223463056|NCT03533231|COMBINATION_PRODUCT|Propolis + Metronidazole paste|
223463057|NCT01756989|DRUG|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
223463058|NCT05618314|DRUG|AT-527|single dose AT-527
223463059|NCT05618314|DRUG|AT-527|Single dose of AT-527 pre- and post-dialysis
223463060|NCT05618314|DRUG|AT-527 and Probenecid|Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
224303197|NCT00273039|DRUG|paroxetine|
224303198|NCT04242914|DRUG|Ketamine|Intravenous Ketamine, dose 0.5mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
224303199|NCT04242914|DRUG|Midazolam|Intravenous Midazolam, dose 0.03mg/kg in 100ml Sodium Chloride 0.9% over 40 minutes.
224303200|NCT00429195|BEHAVIORAL|Dietary Fatty Acid Modification|
224303201|NCT05078164|BEHAVIORAL|Bridging the Gap (BTG)|"Bridging the Gap: Bridging the Gap is a hybrid model for violence prevention which integrates a hospital-based brief violence intervention (BVI) delivered to the patient while in hospital with a wrap-around community case management prevention strategy.~Firearm Counseling Program: The firearm counseling program was developed to be administered in the hospital alongside the 6-step intervention program, as well as in the patient's home after hospital discharge. The firearm safety counseling program includes 3 components aimed at understanding patient risk, reducing firearm-related violence risk-factors, and helping patients increase firearm safety practices."
224303202|NCT05479656|OTHER|Training program|8-week rehabilitation program aimed at increasing trunk and lower limb motor control on balance and walking abilities, and accomplishment of activities of daily living.
224303203|NCT03788304|DEVICE|non-invasive ventilation|conventional NIV
224303204|NCT03788304|DEVICE|high flow nasal cannula|HFNC ventilation
224303205|NCT03781401|DEVICE|Ambulatory blood pressure monitoring|
224303206|NCT00853463|BEHAVIORAL|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
224303207|NCT00933348|DRUG|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
223463061|NCT00412841|DRUG|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
223463062|NCT00412841|PROCEDURE|MRI, Venipuncture|MRIs done baseline, four and nine months
223463063|NCT00412841|DRUG|Placebo|Tablets identical to atorvastatin 40mg
224068014|NCT00772486|BIOLOGICAL|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10\^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
224068015|NCT02023645|DIETARY_SUPPLEMENT|active supplement|tablet
224068016|NCT02023645|OTHER|placebo|tablet
224068017|NCT00745563|DEVICE|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
224071499|NCT02058680|BIOLOGICAL|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
223576149|NCT06350747|BEHAVIORAL|Face-to-Face Laughter Yoga Group|"In this study, each laughter yoga session lasted approximately 30-40 minutes and consisted of four parts: hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. According to Kataria (2011), the first three parts remained consistent across all sessions, while the laughter exercises in the fourth part varied (Kataria 2011). In the first session of each new group, participants were introduced to laughter yoga, its purpose, and objectives, with 10 minutes allocated to this introductory section. As a result, the first session for each group lasted 40 minutes, while the remaining sessions were 30 minutes each. The structure and duration of each session were as follows:~* Section 1: Hand Clapping and Warm-up Exercises - 5 minutes~* Section 2: Deep Breathing Exercises - 10 minutes~* Section 3: Playful Games - 5 minutes~* Section 4: Laughter Exercises - 10 minutes"
223463064|NCT05074875|OTHER|Questionnaires and Patient Reported Outcomes (PROs)|"* EuroQol 5 Dimensional Quality of Life Questionnaire (EQ-5D).~* St. George's Respiratory Questionnaire (SGRQ)~* Impact of Events Scale Revised (IES-R)~* Generalized Anxiety Disorder 7-Item (GAD-7)~* Patient Health Questionnaire (PHQ-9)"
223463065|NCT05074875|DIAGNOSTIC_TEST|Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)|If required by the local site's COVID-19 guidelines, subjects should have the COVID-19 RT-PCR Nasal Swab collected at the beginning of the visit or within 5 days prior to the scheduled visit.
223463066|NCT05074875|GENETIC|Blood Samples for Biomarkers|Venous blood will be collected using pre-labeled tubes.
223463067|NCT05074875|DIAGNOSTIC_TEST|High Resolution Computed Tomography|Subjects will have HRCTs at Visits 1, 2, 3, and 4. Inpatient HRCT scans will be collected during the baseline visit (V0 or V1)
223463068|NCT05074875|DIAGNOSTIC_TEST|Physical Exam and Vital Signs|"A complete physical exam, including height, weight, general appearance, neck, lungs, cardiovascular system, abdomen, extremities, and skin will be performed at Visit 1.A brief physical exam will be completed at subsequent visits, including weight, general appearance, lungs, cardiovascular symptoms, extremities, and other body systems pertinent to the participants health status, at the discretion of the investigator.~Blood pressure, heart rate, and oxygen saturation will be collected at all visits, prior to blood draws and after subjects have rested."
223576150|NCT06350747|BEHAVIORAL|Online Laughter Yoga Group|"In this study, each laughter yoga session lasted approximately 30-40 minutes and consisted of four parts: hand clapping and warm-up exercises, deep breathing exercises, playful games, and laughter exercises. According to Kataria (2011), the first three parts remained consistent across all sessions, while the laughter exercises in the fourth part varied (Kataria 2011). In the first session of each new group, participants were introduced to laughter yoga, its purpose, and objectives, with 10 minutes allocated to this introductory section. As a result, the first session for each group lasted 40 minutes, while the remaining sessions were 30 minutes each. The structure and duration of each session were as follows:~* Section 1: Hand Clapping and Warm-up Exercises - 5 minutes~* Section 2: Deep Breathing Exercises - 10 minutes~* Section 3: Playful Games - 5 minutes~* Section 4: Laughter Exercises - 10 minutes"
223576151|NCT06350747|OTHER|control group|Participants in the control group will not receive the laughter yoga intervention. They will continue with their usual daily routines and will only complete pre- and post-test assessments.
223576152|NCT00801476|PROCEDURE|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
223576153|NCT06076291|DRUG|SG1827|PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.
223576154|NCT03633279|DRUG|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
224303208|NCT00933348|DRUG|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
223576155|NCT03633279|DRUG|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
223576156|NCT00413829|DRUG|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
223463069|NCT05074875|DIAGNOSTIC_TEST|Medical Research Council Sum Score|The Medical Research Council Sum Score (MRC-SS) is used globally to detect peripheral muscle strength and to help diagnose ICU-acquired muscle weakness. The MRC-SS ranging from 0 (complete paralysis) to 60 (normal).
223576157|NCT02922842|DEVICE|Transcutaneous Electrical Nerve Stimulation|
224068018|NCT04966377|BEHAVIORAL|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS)|Nurse Navigation Program Based On Health Belief Model In Breast Cancer Screening (NaHeB-CaS), increasing awareness of Syrian women under temporary protection against breast cancer, decreasing their perception of barriers to screening tests, developing early diagnosis behaviors (such as BSE, CBE and mammography), increasing their self-efficacy and breast cancer fears are expected to be reduced.
224303209|NCT05373121|BEHAVIORAL|Online Peer Support|Signposting to online peer support groups and forums
223463070|NCT05074875|DIAGNOSTIC_TEST|Hand Grip Strength|Each subject will have hand grip strength measured at each visit. This is being done in order to assess the maximum isometric strength of hand and forearm muscles.
224071500|NCT00066079|PROCEDURE|massage|
224303210|NCT01630577|OTHER|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
224303211|NCT06355102|OTHER|Conventional treatment and care|Conventional treatment and care
223463071|NCT05074875|DIAGNOSTIC_TEST|Spirometry|Spirometry will be assessed at Visits 1, 2, 3 and 4. Each site will use its own spirometry machine. Each subject should use the same machine at each visit and conduct measurements at approximately the same time. Before any testing, the maneuver should be demonstrated to the subject. The spirometry should be reviewed by the investigator.
223463072|NCT05074875|DIAGNOSTIC_TEST|Diffusing Capacity of Carbon Monoxide|The site will use its own DLCO equipment for measurements at Visits, 1, 2, 3, and 4. The Single-breath DLCO maneuver will be carried out in accordance with the 2017 American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Subjects should use the same device at approximately that same time at each visit. The maneuver should be demonstrated to the subject prior to the test.
223463073|NCT05074875|DIAGNOSTIC_TEST|6 Minute Walk Test|"The 6 Minute Walk Test (6MWT) will assess exercise capacity and tolerance. 6MWTs will be conducted at Visits 1, 2, 3, and 4.~The procedure of the 6MWT should be explained and demonstrated to the subject prior to the start of the test."
223463074|NCT05074875|DIAGNOSTIC_TEST|Sit to Stand (STS) Measurement|The STS will be conducted at Visits 1, 2, 3, and 4 to assess the physical functioning of the adult participants.
223576158|NCT03705780|OTHER|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
223576159|NCT03705780|DIAGNOSTIC_TEST|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
223576160|NCT04431713|DRUG|Exenatide Pen Injector [Bydureon]|Exenatide is a treatment licensed for use in Type 2 diabetes.
223576161|NCT01963013|DEVICE|Non-returning catheter valve|
224068019|NCT00574275|DRUG|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
224068020|NCT00574275|DRUG|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
224068021|NCT00574275|DRUG|Gemcitabine|1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
224068022|NCT06350838|DRUG|BCG for Therapeutic Use|Take 120 mg BCG for treatment, dissolved in 40 \~ 50 mL normal saline, bladder perfusion through catheter. The injection was performed once a week for 6 consecutive times.
224071501|NCT00066079|BEHAVIORAL|relaxation|
223463075|NCT00003740|BIOLOGICAL|trastuzumab|
223463076|NCT01081782|DRUG|ONO-4641|0.15 mg once per day for 26 weeks
223463077|NCT01081782|DRUG|ONO-4641|0.1 mg once per day for 26 weeks
223463078|NCT01081782|DRUG|ONO-4641|0.05 mg once per day for 26 weeks
223463079|NCT01081782|DRUG|ONO-4641 placebo|Placebo once per day for 26 weeks
223463080|NCT03136718|OTHER|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
223463081|NCT00002223|DRUG|Indinavir sulfate|
223463082|NCT00002223|DRUG|Ritonavir|
223463083|NCT05262816|OTHER|electroacupuncture|electroacupuncture at Sanyinjiao (SP6)
223463084|NCT05695742|OTHER|Active Smoking|Being active smoker
223463085|NCT05695742|OTHER|Passive smoker|Being exposed to secondhand smoke
223463086|NCT05695742|OTHER|Non-smoker|Not being an active or passive smoker.
223463087|NCT01139996|DRUG|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
223463088|NCT01139996|DRUG|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
223463089|NCT01586234|PROCEDURE|DSAEK with graft shaping and smoothing|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
223463090|NCT01586234|PROCEDURE|Standard DSAEK|"1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
223463091|NCT02766348|DRUG|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
223463092|NCT02766348|BIOLOGICAL|DC-CTL|8×10\^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
223463093|NCT02766348|DRUG|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
223576162|NCT01963013|DEVICE|Conventional urine bag|
223576163|NCT02238314|DRUG|Tipranavir low dose|
223576164|NCT02238314|DRUG|Tipranavir high dose|
223576165|NCT02238314|DRUG|Ritonavir|
223576166|NCT02238314|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
223576167|NCT02238314|DRUG|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
223576168|NCT00266929|PROCEDURE|surgical|surgical treatment of odontoid fractures
223576169|NCT00266929|PROCEDURE|conservative treatment|conservative stabilization of fractures
223576170|NCT01981200|OTHER|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
223576171|NCT02285114|DRUG|F/TAF|F/TAF tablets administered orally once daily
223576172|NCT02285114|DRUG|3rd ARV agent|A 3rd antiretroviral (ARV) agent may include one of the following: allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV); Allowed unboosted 3rd ARV agents: efavirenz (EFV), raltegravir (RAL), dolutegravir (DTG), or nevirapine (NVP)
223576173|NCT02285114|DRUG|Boosted PIs|Allowed boosted PIs: LPV, ATV, DRV.
223463094|NCT03540862|DEVICE|maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)|hospital-based NPV once every week as the maintenance program
223576174|NCT03397134|DRUG|Placebo Oral Tablet|Placebo administered as a single dose once daily
223463095|NCT03212716|DRUG|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
223576175|NCT03397134|DRUG|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
224068023|NCT00763750|DRUG|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
224157458|NCT00983242|DRUG|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
224303212|NCT04711902|DRUG|AIN457|Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
223463096|NCT03212716|DRUG|Diltiazem|60 mgx3 per day during 10 days.
223463097|NCT03212716|DRUG|Placebos|Placebo of diltiazem
224157459|NCT00983242|DRUG|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
224303213|NCT04711902|OTHER|Secukinumab Placebo|Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
223463098|NCT04746469|BEHAVIORAL|Delayed automated phone call|Cipher provides automated phone calls to patients; in this case the script for Cipher was modified to provide patients a reminder to return FIT kits, allow patients to request a new kit in case they need a replacement, and to allow patients to provide information if they already completed CRC screening
223463099|NCT01854749|DRUG|S1 combined with cisplatin|
223463100|NCT03618446|OTHER|The presence of a pelvic fracture|
223463101|NCT04924634|DIAGNOSTIC_TEST|Stress Levels and Mental Well-Being assessment|At the beginning of the summer semester of the 2020/2021 academic year, stress levels as well as symptoms of anxiety and depression were assessed in students at four universities.
223463102|NCT01061541|BIOLOGICAL|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
223463103|NCT01061541|BIOLOGICAL|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
223576176|NCT03397134|DRUG|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
223576177|NCT05904522|DIAGNOSTIC_TEST|biopsy|biopsy for histopathological examination
223576178|NCT01156389|DRUG|Ritonavir and Pyramax|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
223576179|NCT01156389|DRUG|Pyramax|Pyramax (pyronaridine/artesunate) 180:60 mg (3 to 4 tablets once per day according to weight for 3 days).
223576180|NCT02371200|DEVICE|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
224068024|NCT00644774|DRUG|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
223463104|NCT01061541|BIOLOGICAL|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
223576181|NCT06008899|PROCEDURE|US assisted caudal epidural pulsed radiofrequency|patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
223576182|NCT00241098|DRUG|valsartan|
223576183|NCT05320159|DRUG|Secukinumab|Included all the patients treated with secukinumab
223576184|NCT01121445|DEVICE|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
223576185|NCT02682589|PROCEDURE|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
224068025|NCT00644774|DRUG|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
224068026|NCT02734836|DEVICE|Balloon Angioplasty|
224068027|NCT02734836|OTHER|Optical Coherence Tomography|
224068028|NCT02703311|DEVICE|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
224068029|NCT01959711|PROCEDURE|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
224068030|NCT01959711|PROCEDURE|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
224071502|NCT00371865|BEHAVIORAL|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
224071503|NCT00371865|BEHAVIORAL|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
224071504|NCT00245362|BIOLOGICAL|CG 8020 and CG 2505|
224071505|NCT02508194|BIOLOGICAL|MEDI7510|RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
223463105|NCT01061541|BIOLOGICAL|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
223463106|NCT01061541|BIOLOGICAL|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
223463107|NCT00155714|DRUG|type-5 phosphodiesterase Inhibitor (Sildenafil)|
223463108|NCT00972959|DRUG|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
223463109|NCT00972959|DRUG|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
223463110|NCT00972959|DRUG|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
223463111|NCT02365935|PROCEDURE|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
224071506|NCT02508194|BIOLOGICAL|IIV|Marketed Inactivated Influenza Vaccine
224071507|NCT02508194|OTHER|Placebo|Sterile Saline
224071508|NCT02415738|PROCEDURE|Prone positioning|
224157460|NCT02774863|OTHER|Home passages|Three home passages between the 2nd and 3rd months of follow up.
224157461|NCT02992912|DRUG|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
224157462|NCT02992912|PROCEDURE|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
223576186|NCT02682589|PROCEDURE|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
223463112|NCT02365935|PROCEDURE|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
223463113|NCT02365935|DRUG|Cisplatin|
223463114|NCT02365935|DRUG|Paclitaxel|
223463115|NCT06175286|OTHER|POWERBreath Plus Medium Resistance training device|30 inspirations with the POWERBreath Plus Medium Resistance training device, twice per day for 5 weeks
223463116|NCT03135314|DIETARY_SUPPLEMENT|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
223463117|NCT03135314|DIETARY_SUPPLEMENT|placebo|7 days of placebo intake
223463118|NCT03022591|OTHER|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
223463119|NCT02917174|BEHAVIORAL|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
223463120|NCT02917174|BEHAVIORAL|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
223463121|NCT01098084|DRUG|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
223463122|NCT04511897|DRUG|An'ningpai|An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
223463123|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
223463124|NCT01133548|DRUG|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
223463125|NCT04590118|DRUG|it-hMSC|Single intravenous infusion of it-hMSC for ischemic stroke patients
223463126|NCT04590118|DRUG|Placebo|Single intravenous infusion of 1 ml/kg placebo
223463127|NCT02733718|DEVICE|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
223463128|NCT04159467|OTHER|Pelvic Floor Muscle Training|4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
223463129|NCT02884102|GENETIC|genetic sequencing|
223463130|NCT04398940|DRUG|TQ-B3139|TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
223463131|NCT04760301|DRUG|local tranexamic acid injection|local tranexamic acid injection to cervix- 1 g tranexamic acid diluted in 10 ml saline
223576187|NCT04081961|DEVICE|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
223576188|NCT01646619|DRUG|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
223576189|NCT01646619|DRUG|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
224303214|NCT00138554|DRUG|vildagliptin|
224303215|NCT00138554|DRUG|pioglitazone|pioglitazone 45 mg qd
223463132|NCT04760301|OTHER|local normal saline injection to cervix|local normal saline injection to the cervix- 20 ml saline
223463133|NCT02570386|PROCEDURE|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
223463134|NCT02570386|PROCEDURE|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
223463135|NCT01870986|BIOLOGICAL|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
223463136|NCT01870986|BIOLOGICAL|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
223463137|NCT01870986|BIOLOGICAL|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
223463138|NCT00405405|DRUG|Cisplatin|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
223463139|NCT00405405|DRUG|Docetaxel|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
223463140|NCT00405405|DRUG|Bevacizumab|"* Two cycles during neoadjuvant therapy~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
223463141|NCT00405405|DRUG|Erlotinib|"* Two cycles during neoadjuvant therapy (dose escalation)~* Response assessment at approximately day 36~* Concurrent biochemoradiotherapy"
223463142|NCT00405405|RADIATION|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
223463143|NCT01021397|DRUG|rHPIV3cp45|10\^5 TCID50 nasal drops
223463144|NCT01021397|DRUG|rHPIV3cp45 placebo|1X-L15 nasal drops
223463145|NCT05870306|PROCEDURE|pulmonary vein isolation and targeted radiofrequency ablation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins. Extra radiofrequency ablation will be performed on the targeted areas
223463146|NCT05870306|PROCEDURE|pulmonary vein isolation|Radiofrequency will be delivered around the left atrial ostia to isolate the veins.
223463147|NCT05766579|DEVICE|Elastic-compressive stockings|Use of Elastic-compressive stockings at 21 mmHg and 32 mmHg.
223463148|NCT05564598|BIOLOGICAL|CMV Cytotoxic T-Lymphocytes|Patients will receive maternal CMV CTLs on day 0. Additional doses of CMV CTLs may be re-infused at a minimum of every two weeks for a maximum of five total infusions (maximum 2.5 x 104 CD3/kg) only in patients not achieving a CR and no prior dose limiting toxicity of any prior dose.
224157463|NCT03714451|DIETARY_SUPPLEMENT|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
224157464|NCT03714451|DIETARY_SUPPLEMENT|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
224157465|NCT04297176|DRUG|Vancomycin-traditional dosing|The dose is calculated based on 2 vancomycin serum levels
224157466|NCT04297176|DRUG|Vancomycin- Trough-only based dosing|The dose is calculated based on 1 vancomycin serum level (i.e. trough)
224157467|NCT00394277|DRUG|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
224157468|NCT00394277|DRUG|Ribavirin|1200 mg po daily for 48 weeks
224157469|NCT00394277|DRUG|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
224157470|NCT00394277|DRUG|Ribavirin|1400-1600 mg po daily for 48 weeks
224157471|NCT01609361|OTHER|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
224157472|NCT01719042|DRUG|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
224157473|NCT01719042|DIETARY_SUPPLEMENT|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
224157474|NCT00547729|DEVICE|HeartPOD™ System|HeartPOD™ device with DynamicRx® automatically measures left heart pressures throughout the day.
224157475|NCT04122118|OTHER|Medical Chart Review|Review of medical chart
224157476|NCT04122118|OTHER|Educational Intervention|Receive pharmacist-led education
224157477|NCT04122118|OTHER|Survey Administration|Ancillary studies
223463149|NCT05564598|DRUG|Anti-viral Therapy|"All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months"
223463150|NCT03191851|DEVICE|standard device|paracentesis using standard
223463151|NCT03191851|DEVICE|Melody Device|paracentesis using Melody Device
223463152|NCT03191851|DEVICE|Melody Device with Pump|paracentesis using Melody Device with Pump
223463153|NCT00248469|BEHAVIORAL|In-school Sexual Health Education|
223463154|NCT00248469|BEHAVIORAL|Youth-friendly health services|
224157478|NCT00026195|DRUG|irinotecan hydrochloride|
224157479|NCT05225740|BEHAVIORAL|Standard Exposure|The standard intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a post-exposure exercise. The post-exposure exercise will involve completing a set of questions regarding the exercises and the group experience.
224157480|NCT05225740|BEHAVIORAL|Stress Management Training|Stress management training (SMT) is designed to help people better cope with feelings of anxiety that accompany high levels of anxiety sensitivity. SMT will involve group instruction in healthy ways to experience and cope with stress whenever difficult situations arise. Participants will teach participants ways to maintain a healthy lifestyle, targeting things like nutrition, exercise, and sleep hygiene. This intervention will also involve progressive muscle relaxation training.
224157481|NCT05225740|BEHAVIORAL|Enhanced Exposure|The enhanced intervention will include an orientation and psychoeducation phase, an exposure practice phase consisting five repeated trials per each of the three exposure exercises, and a processing exercise. The post-processing exercise will involve completing a set of questions that will highlight harm expectancy violations.
224157482|NCT04090827|OTHER|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
224157483|NCT04139629|DIAGNOSTIC_TEST|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
224157484|NCT04139629|DRUG|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
223463155|NCT00248469|BEHAVIORAL|Youth condom promotion & distribution|
223463156|NCT00248469|BEHAVIORAL|Community activities related to adolescent sexual health|
223463157|NCT03079167|DRUG|Epoetin Alfa|
223463158|NCT03079167|DRUG|Normal saline|
223463159|NCT00321906|DRUG|azathioprine|azathioprine 2mg/kg
223463160|NCT00321906|DRUG|sirolimus|sirolimus 2-4mg daily
224157485|NCT06354075|OTHER|Questionary|Questionary will be administrated to evaluated the information for patients on interventional radiology (explanatory video, information form, etc.).
224157486|NCT02998931|DRUG|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
224157487|NCT02998931|OTHER|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
224157488|NCT05135507|BEHAVIORAL|An integrated parenting intervention for families of children with developmental disabilities|Deliver three training modules to parent and track program usage, psychological flexibility, parents' stress, parents mindfulness, and child behavior
224157489|NCT02712008|DRUG|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
224157490|NCT02712008|DRUG|Intravitreal Aflibercept Injection (IAI)|
223463161|NCT00516685|BIOLOGICAL|Recombinant Human rEGF-P64K/Montanide Vaccine|
223463162|NCT01018914|DRUG|Prograf|oral
223463163|NCT01018914|DRUG|Advagraf|oral
223463164|NCT01018914|DRUG|Myfortic|oral
223463165|NCT01449292|DEVICE|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
223463166|NCT01449292|OTHER|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
223463167|NCT05833126|DRUG|Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab|Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
223463168|NCT00132288|BEHAVIORAL|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
223463169|NCT00132288|BEHAVIORAL|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
223463170|NCT02056418|DIETARY_SUPPLEMENT|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
223463171|NCT02056418|DRUG|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
223463172|NCT05986981|DRUG|Vaccine|"Dose-escalation trial, according to the classic 3+3 model, divided into three dose levels of 0.5 mg, 1.0 mg, 2.0 mg for enrollment, is expected to enroll a total of 9-18 subjects (0.5 mg dose group to be enrolled in 3-6 subjects, 1.0 mg dose group is proposed to be enrolled in 3-6 subjects, 2.0 mg dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects, and the dose group is proposed to be enrolled in 3-6 subjects. dose group is proposed to include 3-6 subjects)."
223463173|NCT02773095|OTHER|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
223463174|NCT04977141|OTHER|Decisional Conflict Scale|Decisional Conflict Scale
223463175|NCT00289094|DEVICE|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
223463176|NCT00289094|DEVICE|Total knee replacement|Fixed Cruciate Retaining Knee System
223463177|NCT02835859|OTHER|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
223463178|NCT02835859|OTHER|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
223463179|NCT03733366|OTHER|Desk surface|The participants will test all 10 desk surfaces and will be randomly allocated to one of the desks each time.
223463180|NCT04361422|DRUG|Isotretinoin Only Product in Oral Dose Form|assess antiviral efficacy, tolerability and safety of oral isotretinoin in the treatment of COVID-19 versus combined oral isotretinoin with standard therapy for COVID-19 versus the standard therapy alone.
223576190|NCT03796754|BEHAVIORAL|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
223576191|NCT03037541|DRUG|Carac Cream|Carac Cream will be used once daily for seven consecutive days
223576192|NCT03037541|DRUG|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
223576193|NCT01752400|DRUG|AUY922|
223576194|NCT06333522|DRUG|Losartan|Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
223576195|NCT06419179|DRUG|Durvalumab|1500 mg i.v. Q4W
223576196|NCT06419179|DRUG|Olaparib|300 mg BID orally
223576197|NCT05740332|DRUG|Alcohol hand sanitizer foam|"1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)"
223463181|NCT01209403|DRUG|Glucose-infusion|Continuous iv infusion of glucose
223463182|NCT01209403|DRUG|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
223463183|NCT04001010|DRUG|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
223463184|NCT04001010|DRUG|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
223463185|NCT00871234|DRUG|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
223463186|NCT02288104|DEVICE|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
223463187|NCT00970905|DRUG|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
223463188|NCT00970905|DRUG|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
223463189|NCT00687908|DRUG|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
223463190|NCT00687908|DRUG|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
223463191|NCT03380377|DRUG|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
223463192|NCT00910845|BIOLOGICAL|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
223463193|NCT00910845|DRUG|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
223463194|NCT02600923|DRUG|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
223576198|NCT06026995|DRUG|PEG-rhG-CSF|Subcutaneous injection with a fixed dose of 12 mg
223576199|NCT06026995|DRUG|RhG-CSF|Inject rhG-CSF 5-10 μg/kg subcutaneously every day
223576200|NCT05883254|DIAGNOSTIC_TEST|RNA Binding Protein Pumilio1 (PUM1) Expression by reverse transcriptase quantatative PCR|"Quantatative Real -Time PCR for quantification of PUM1;~* The type of the recruited samples: Ethylenediamine tetra-acetic acid (EDTA) peripheral blood samples.~* The method of total RNA extraction: TRIzol and TRIzol LS.~* The purity and concentration of the RNA were measured using a Nano Drop 2000 instrument.~* cDNA was amplified with primers using the GoScript Reverse Transcription system.~Western Blotting Assay of PUM1 protein levels"
223576201|NCT03287024|DEVICE|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
223576202|NCT04599166|BEHAVIORAL|Who Would You Choose: Serious Fun|"Who Would You Choose: Serious Fun is a conversation activity that prompts players (using scenarios and metaphors) to choose a spokesperson whose qualities are best suited to the role. At the end of the activity, players identify a real-life spokesperson based on the qualities considered during gameplay."
223576203|NCT01437644|DRUG|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
223576204|NCT05669586|DRUG|Antitumor therapy guided by organoid drug sensitivity test|Antitumor therapy guided by organoid will be given to Multi-line Drug-resistant Non-small Cell Lung Cancer patients.
223576205|NCT03289169|DRUG|MEDITOXIN®|20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
223576206|NCT05371080|BIOLOGICAL|HZ/su vaccine|No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)
223576207|NCT03523793|BEHAVIORAL|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
223576208|NCT03523793|OTHER|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
223576209|NCT06394752|DEVICE|Visual Saline Infusion|Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).
223576210|NCT06394752|DEVICE|Hydrosonography|Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.
223576211|NCT00272324|DRUG|Aspirin|
223576212|NCT00272324|DRUG|Folate|
223576213|NCT05304143|OTHER|Virtual Immersive Reality Glasses|"The day of the examination, the patient will go to the MRI room and he will be fitted with virtual reality glasses compatible with the MRI equipment. The patient will visualize relaxing contents in open spaces with music and verbal instructions during all the procedure. The contents will be previously validated by the clinical psychologist of the center with experience in this regard.~During the test, the patient's heart rate will be monitored."
223576214|NCT05304143|OTHER|Conventional nurse support|Patients will be treated using the usual support technique to reduce anxiety in the Diagnostic Imaging service
224068031|NCT03692728|OTHER|Psychological and Behavioral Problems|Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
223463195|NCT02600923|DRUG|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
223463196|NCT01590901|DRUG|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
223576215|NCT06980922|DRUG|Guilu Erxian Jiao|A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.
224303216|NCT01966588|OTHER|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
223463197|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
223463198|NCT00792909|BIOLOGICAL|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
223463199|NCT03948152|OTHER|Standard of Care|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
223463200|NCT03948152|OTHER|Mask Advice Tool|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
223463201|NCT04865029|OTHER|Placebo injection and placebo pill|Standard of Care consistent with the National Institutes of Health (NIH) COVID-19 Treatment Guidelines
223463202|NCT04865029|DRUG|Estradiol Cypionate 5 mg/ml|Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
223463203|NCT04865029|DRUG|Progesterone 200 mg Oral Capsule|Standard of Care along with Progesterone 200mg by mouth daily for 5 days starting at admission.
223463204|NCT03281941|OTHER|Inhaled capsaicin cough challenge|
223576216|NCT06979726|DRUG|Lasix ONYU|Providing subcutaneous furosemide to eligible patients
223576217|NCT06981481|DEVICE|Breast tissue expander|Silimed brand breast tissue expander
223576218|NCT06980402|PROCEDURE|Early post-surgical discharge with post-surgical home based monitoring|The SKH@home program, is a post-discharge monitoring program, which allows stable post-surgical patients to be discharged earlier from hospital while providing regular post-discharge monitoring at the patient's own home, either through home visits and patient assessment, or telemonitoring of patients.
223576219|NCT06980402|PROCEDURE|Standard inpatient care until deemed suitable for discharge|Patients will receive standard postoperative management in the acute hospital until they are deemed fit for discharge by their primary surgeon
223576220|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
224068032|NCT05595824|DRUG|Molnupiravir (Esperavir)|Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days
224068033|NCT05595824|DRUG|Standard of care|The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study
224068034|NCT03278600|GENETIC|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
224068035|NCT01620242|DRUG|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
224068036|NCT00960843|DEVICE|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
224303217|NCT01966588|OTHER|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
224303218|NCT02238626|DRUG|Placebo (for MN-166)|
223463205|NCT04990115|OTHER|root canal shaping|root canal treatment
223463206|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair|Only arthroscopic primary anterior cruciate ligament repair was performed in patients with proximal anterior cruciate ligament tear.
223463207|NCT05923710|PROCEDURE|Primary anterior cruciate ligament repair and lateral extraarticular tenodesis (LET) with iliotibial band|In addition to primary anterior cruciate ligament repair, lateral extraarticular tenodesis was performed using the iliotibial band.
223463208|NCT03502499|DRUG|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
223463209|NCT03502499|DRUG|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
223463210|NCT04504110|DIAGNOSTIC_TEST|68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT|Patients with epithelial ovarian cancer who are scheduled for surgical intervention will undergo a comparative 68Ga-FAPI-04 and 18F-FDG PET/CT study before the surgery.
223463211|NCT02590991|OTHER|Prebiotics|To study the long term effect of supplementation in early life
223463212|NCT02590991|OTHER|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
223463213|NCT00128661|BIOLOGICAL|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
223463214|NCT00128661|BIOLOGICAL|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
223463215|NCT01836562|BIOLOGICAL|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
223463216|NCT03200353|DEVICE|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
223463217|NCT02211378|OTHER|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
223463218|NCT02211378|OTHER|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
223463219|NCT02126215|PROCEDURE|MRI CO2 and O2 stress testing|Pre and post operatively
223576221|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223576222|NCT06979882|OTHER|Multi-gene methylation testing|Undergo multi-gene methylation testing in blood during follow-up
223576223|NCT06980792|PROCEDURE|Pancreatectomy and liver resection|Surgery for synchronous liver metastasis from PDAC with or without previous neoadjuvant chemotherapy
223576224|NCT06980792|DRUG|Chemotherapy|Chemotherapy alone in potentially resectable patients with PDAC and synchronous liver metastasis
224068037|NCT00960843|OTHER|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
224303219|NCT02238626|DRUG|MN-166|
224303220|NCT02238626|DRUG|riluzole|Patient is given 50 mg riluzole twice daily.
223463220|NCT01614015|BEHAVIORAL|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
223463221|NCT01614015|BEHAVIORAL|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
224068038|NCT03957564|DRUG|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
224068039|NCT03957564|OTHER|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
224068040|NCT03957564|OTHER|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
224303221|NCT00197392|DEVICE|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
224303222|NCT00197392|DEVICE|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
223463222|NCT01518569|DRUG|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
223463223|NCT01518569|DRUG|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
223463224|NCT00954265|DRUG|10000 IU urinary HCG|ovulation triggering
223463225|NCT00954265|DRUG|250 mcg recombinant HCG|ovulation triggering
223463226|NCT03758157|DIAGNOSTIC_TEST|welloStationX|welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
223463227|NCT03758157|DIAGNOSTIC_TEST|SureTemp|SureTemp is an oral thermometer to measure human body skin temperature.
223463228|NCT03292185|DRUG|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
223463229|NCT03292185|DRUG|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
223463230|NCT03292185|DRUG|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
223463231|NCT01488552|DRUG|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
223463232|NCT01488552|DRUG|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
223463233|NCT01488552|DRUG|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
223463234|NCT01488552|GENETIC|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
223463235|NCT01488552|DRUG|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
223463236|NCT01488552|DRUG|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
223463237|NCT00642226|PROCEDURE|Grid Laser|ETDRS Grid Laser
223463238|NCT00642226|PROCEDURE|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
223463239|NCT01148264|DRUG|olanzapine|1x10mg per day for three days
223463240|NCT01148264|DRUG|metoclopramide|3x10mg per day for three days
223576225|NCT06981026|OTHER|Telemedicine-based prehabilitation and postoperative rehabilitation protocol, including physical activity monitoring, respiratory and postural training, and guidance via telehealth tools.|A combination of wearable technology, activity guidelines, educational support, remote monitoring with notifications and consultations with physiotherapists.
223576226|NCT06985381|OTHER|Carotenoid-rich juice|The intervention is based on the additional consumption of 200 ml natural carotneoid-rich juice a day for a period of six weeks. The participants are asked to drink the natural and commercially available juice in addition to their regular diet. Further, they are asked not to change their diets and lifestyle behaviour during the intervention.
223576227|NCT06985381|OTHER|Control|Participants assigned to the control group are asked to drink additional 200ml of water a day to control liquid intake.
223576228|NCT04839471|DRUG|BI-754091 plus afatinib|Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
223576229|NCT01986309|DRUG|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
223576230|NCT01986309|DRUG|Normal saline|Sodium Chloride 0.9% infusion
223463241|NCT01261390|BEHAVIORAL|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
223576231|NCT00371969|BEHAVIORAL|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
223576232|NCT00371969|BEHAVIORAL|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
223576233|NCT06979817|OTHER|TLS-Informed Machine Learning Prognostic Model|This intervention involves the development and application of a machine learning-based prognostic model that integrates features derived from tertiary lymphoid structures (TLSs) identified in tumor pathology slides, along with clinical and immunological data, to predict overall survival and immune landscape in patients with locally advanced gastric cancer. The model utilizes digital pathology, image analysis, and advanced computational algorithms to quantify TLS-related characteristics and correlate them with patient outcomes. It is designed to stratify patients into risk groups and provide insight into the tumor immune microenvironment, aiming to support personalized treatment planning.
223576234|NCT06984692|OTHER|iRise curriculum|"Intervention group: The intervention group would download the iRise mHealth app (iRise app) via Canvas on the participant's respective smart phones, and based on the participant's own schedules and preferences, would complete different modules of iRise. The iRise app would include emergency management elements as received by the control group, but presented via smart phone-based content delivery (i.e., rather than rather than via the in-person modality utilized for the control group)."
223576235|NCT06984692|OTHER|Control Curriculum|The control group will receive standard training in crisis response and management, which is offered as a course on Emergency Management and Response at AKU, for which study participants from JPMC will also readily access. The course involves introduction to disaster terminology, emergency management cycle and hospital-based patient treatment guidelines. The control curriculum will offer a comprehensive focus on disaster preparedness, addressing important subjects such as emergency management techniques, disasters, and triage. The eight-hour training will be split into two parts, aiming to improve academic and practical understanding. The first part will be a didactic session, where participants will learn fundamental information through lectures and discussions. The second part will consist of hands-on training, allowing attendees to practice and apply learned concepts in simulated emergency scenarios.
223576236|NCT06605573|DIAGNOSTIC_TEST|Panbio™ HCV Self Test|Rapid diagnostic test (self-test and professional) plus laboratory reference tests
223576237|NCT06606431|BEHAVIORAL|Multileveled-community approach|One-to-one delivered interaction at relational level (Interpersonal Relations, Volunteers) Socio-health interaction at personalized level (Social Work) Group delivered interaction for volunteers (Group Dynamics) Community-level interactions (Social Cohesion, Community Networks)
223576238|NCT06607848|DEVICE|Low-Add EDOF IOL|Acunex Vario AN6V
223576239|NCT06607848|DEVICE|EDOF IOL|PureSee EDOF IOL
223576240|NCT06607094|DEVICE|Rezum|The Rezum System is designed to treat patients with urinary symptoms associated with BPH. The Rezum System utilizes radiofrequency current to generate thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate in controlled 9-second doses. The vapor injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue, and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
223576241|NCT06606418|OTHER|Acupuncture group|The patients in this group received acupuncture treatment 3 times a week for 4 weeks. Acupuncture points selection: bilateral Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), Shangqiu (SP5), Yin Bai (SP5), foot Qioyin (GB44), Li Dui (ST45). Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to skew 0.5\~0.8 inches at the back acupoint, 0.5\~0.8 inches at Shangqiu (SP5), 0.1 inches at Yin Bai (SP5), foot Qiaoyin (GB44) and Li Dui (ST45), and left the needle for 30 minutes to wait for qi.
223576242|NCT06606418|OTHER|Sham acupuncture group|The patients in this group received sham acupuncture treatment 3 times a week for 4 weeks. Sham acupuncture points are selected at sham points close to the acupoints of the acupuncture group: 3 inches beside Fei Shu (BL13), Xin Shu (BL15), Ji Shu (BL17), Gan Shu (BL18), PI Shu (BL20), Shen Shu (BL23), 1 inches below Shangqiu (SP5), 0.1 inches behind the middle edge of the great toe, second toe and fourth toenail of the foot. Acupuncture operation method: The patient took the lateral position and used Huacheng acupuncture needle (body length 40mm, diameter 0.30mm) to pierce the skin shallowly, and left the needle for 30 minutes.
223576243|NCT06608836|OTHER|an ice massage|an ice massage
223576244|NCT06608836|OTHER|the cold spray|the cold spray
223576245|NCT01777542|DRUG|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
223576246|NCT01777542|DRUG|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
223576247|NCT00304018|BIOLOGICAL|anti-thymocyte globulin|
223576248|NCT00304018|BIOLOGICAL|sargramostim|
223576249|NCT00304018|DRUG|busulfan|
223576250|NCT00304018|DRUG|etoposide|
223576251|NCT00304018|DRUG|fludarabine phosphate|
223576252|NCT00304018|DRUG|prednisone|
223576253|NCT00304018|DRUG|tacrolimus|
223576254|NCT00304018|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223576255|NCT00304018|PROCEDURE|umbilical cord blood transplantation|
223463242|NCT01261390|DEVICE|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
223463243|NCT01261390|DEVICE|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
223463244|NCT01261390|DEVICE|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
223463245|NCT04906226|BEHAVIORAL|Self-foot massage|The individuals in the foot massage group will be given foot massage training by the researcher. Later, people with diabetes will be enabled to continue self-massage at home. To encourage the continuation of the intervention, the researcher will be called once a week by phone and her questions will be answered. At the end of the four weeks, the patient will be interviewed again and data collection forms will be filled.
223576256|NCT04926090|BEHAVIORAL|Emotional Support Plan - Clinician Guided (ESP-C)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-C is delivered by a clinician in 2 sessions.
223576257|NCT04926090|BEHAVIORAL|Emotional Support Plan - Self Guided (ESP-S)|The Emotional Support Plan (ESP) is designed to help prepare students to cope with stress experienced during postsecondary education. The ESP-S is created by the participant on their own, with the support of self-guided materials.
223576258|NCT03761069|DRUG|PTC299|PTC299 will be administered per the treatment arm description
223576259|NCT01248754|PROCEDURE|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
223463246|NCT00873717|OTHER|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
223463247|NCT00873717|OTHER|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
223463248|NCT00873717|OTHER|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
223463249|NCT00643019|BEHAVIORAL|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
223463250|NCT00643019|OTHER|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
223463251|NCT01715948|DEVICE|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
223463252|NCT01715948|DEVICE|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
223463253|NCT00625456|DRUG|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
223463254|NCT05609396|BEHAVIORAL|Behaviorally enhanced reminder letter|Behavioral interventions to increase FIT-based colorectal cancer screening uptake
223576260|NCT02867618|DRUG|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
223576261|NCT02867618|DRUG|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
223576262|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
223576263|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
223576264|NCT00953524|BIOLOGICAL|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
223576265|NCT00953524|BIOLOGICAL|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
224157491|NCT05144542|PROCEDURE|Participants smoke their usual brand of cigarettes for 26 weeks.|Participants smoke their usual brand of cigarettes for 26 weeks.
224157492|NCT05144542|PROCEDURE|Participants will vape electronic cigarettes for 26 weeks.|Participants will vape electronic cigarettes for 26 weeks.
224157493|NCT05144542|DRUG|Nicotine Replacement|Smoke usual brand of cigarettes
224157494|NCT05144542|DRUG|Nicotine Replacement|Vape e-cigarettes
224157495|NCT05144542|OTHER|Questionnaire Administration|Use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day.
224157496|NCT06275698|DIETARY_SUPPLEMENT|Manuka honey MGO 1000|Natural Manuka honey, produced in New Zealand. With MGO content ≥ 1000.
223463255|NCT03153046|DIETARY_SUPPLEMENT|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
223463256|NCT03153046|DIETARY_SUPPLEMENT|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
223463257|NCT04928456|OTHER|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) involves a number of hands-on techniques that are meant to address somatic dysfunction in the body as a part of the osteopathic approach to treating patients. There will be five techniques in total used in the study treatment plan.
223463258|NCT01693913|BEHAVIORAL|cognitive behavioral exercise and nutrition over|
223463259|NCT01693913|BEHAVIORAL|nutrition and exercise education|
223463260|NCT00614172|RADIATION|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
223463261|NCT05861414|BEHAVIORAL|EWM-T|"This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials."
223463262|NCT02411240|DEVICE|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
223463263|NCT00646373|OTHER|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
223576266|NCT02356094|PROCEDURE|Pentacam|Corneal topography using Scheimpflug Pentacam examination
223576267|NCT06330103|OTHER|Easy EF|AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
223576268|NCT06608381|PROCEDURE|Arm I (Total omentectomy),|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
223576269|NCT06608381|PROCEDURE|Arm II (Partial omentectomy)|The surgery is performed with minimal invasive surgery, and the range of the surgery is radical gastrectomy and D2 lymph node dissection. Depending on the random assignment, total omentectomy and partial omentectomy (omentum preservation) will be performed for the control group and the experimental group, respectively. Total omentectomy removes whole greater omentum, while partial omentectomy preserves the omentum more than 3cm away from the gastro-epiploic vessels. Other surgical procedures are the same as usual in both groups.
223576270|NCT05257148|DRUG|Zofenopril 30 mg|Film-Coated tablets administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
223576271|NCT05257148|DRUG|Nebivolol 5 mg|Tablet administered as one single dose to be taken in the morning (from 6 am to 10 am) with no restriction on food intake
223576272|NCT05257148|DRUG|Zofenopril 30 mg + Nebivolol 5 mg|Both Film coated tablets of Zofenopril 30 mg and Nebivolol 5 mg Tablets will be taken in the morning (from 6 am to 10 am) with no restriction on food intake
223463264|NCT00624000|DRUG|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
223463265|NCT01005576|DRUG|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
223463266|NCT05231343|PROCEDURE|Dual Mini-fragment Plating|Patients randomized to dual mini-fragment plating will undergo clavicle fixation using any configuration of 2.0-mm, 2.4-mm and 2.7-mm limited contact dynamic compression (LC-DCP), locking compression (LCP) or reconstruction plates (i.e., 2.4-mm superior and 2.7-mm anteroinferior). One of the two plates used must be a LC-DCP or LCP plate. Surgeons will contour the mini-fragment plate intraoperatively to fit each patient's anatomy.
224068041|NCT03957564|OTHER|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
224068042|NCT04276428|DRUG|LY3209590|Administered SC.
224068043|NCT04276428|DRUG|Insulin Degludec|Administered SC.
224068044|NCT03009266|DRUG|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
224068045|NCT00652366|DRUG|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
224068046|NCT00652366|DRUG|Erlotinib, standard dose|100mg, PO, once daily
224068047|NCT00652366|DRUG|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
223463267|NCT05231343|PROCEDURE|Single Precontoured Plating|Patients randomized to a single plate construct will undergo fixation using an anatomically precontoured (superior or anterior-inferior) clavicle plate.
223463268|NCT00089518|DRUG|Valsartan|
223463269|NCT00055120|DRUG|Emtricitabine/tenofovir disoproxil fumarate|
223463270|NCT00055120|DRUG|Lopinavir/ritonavir|
223463271|NCT00055120|DRUG|Stavudine|
223463272|NCT03468725|DRUG|XPF-008|Capsule filled with XEN1101
223463273|NCT03468725|DRUG|Microcrystalline Cellulose|Placebo capsule
223463274|NCT06072118|DRUG|Adrenomedullin|Dosing at 15 ng/kg/min for 8 hours is continued for 14 days.
223463275|NCT04749095|DRUG|Erector spinae plane block|bilateral ESP block will be injected with 20 ml of 0.25% bupivacaine
224068048|NCT03377530|DIAGNOSTIC_TEST|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
223463276|NCT04749095|DRUG|sham subcutaneous infiltration|bilateral ESP block will be injected with 20 ml of normal saline
223463277|NCT02721056|RADIATION|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be 45 or 50 Gy, delivered as three fractions of 15 Gy or 5 fractions of 10 Gy each, over 5 to 15 days (45 or 50Gy, 15GyX3 or 10GyX5).
223463278|NCT00469222|PROCEDURE|hypofractionated external beam|
223463279|NCT02492893|OTHER|Hatha yoga|
223463280|NCT05398406|OTHER|TAP Block group|TAP Block: the US probe was placed on the imaginary line connecting the anterior superior iliac spine and the umbilicus. The ilioinguinal and iliohypogastric nerves in the fascia of the internal obliq and transverse abdominis muscles were visualized by US. A total of 40 ml of local anesthetic was infiltrated ESP Blok : a 100 mm 21G peripheral nerve block needle was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. 40 ml of the prepared solutions were injected PVB: In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made
223463281|NCT05398406|OTHER|Paravertebral block group|In the lateral decubitus position, the cranial to caudal transverse processes and the superior costotransverse ligament and the pleura were visualized from the T7-8 level in the in-plane section under US guidance. A 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®, USA) was advanced until it passed through the superior costotransverse ligament. A total of 40 ml of injections were made bilaterally in the form of 20+20 ml.
223463282|NCT05398406|OTHER|Erector spinae block group|In the lateral decubitus position, a 100 mm 21G peripheral nerve block needle (SonoPlex Stim Cannula, PAJUNK®,USA) was inserted between the erector spinae muscle and the transverse process structures in an in-plane section guided by US from the T7-8 level. A total of 40 ml of the prepared solutions were injected bilaterally as 20+20 ml.
223463283|NCT04432883|DEVICE|Active Comparator: Experimental: Active cathodal tDCS + language training|"Cathodal tDCS raises neuronal membrane potentials, leading to decreased probability of depolarization from incoming stimuli.~Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment."
223463284|NCT04432883|BEHAVIORAL|Sham Comparator: Placebo cathodal tDCS + Speech and language|Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment. .
223463285|NCT00407342|DRUG|Alefacept (drug)|alefaceptgiven iv
223463286|NCT00407342|PROCEDURE|Narrowband UVB phototherapy|
223463287|NCT01129245|DRUG|Celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
223463288|NCT01129245|DRUG|Placebo|Placebo identical to celecoxib
223463289|NCT06015971|DIETARY_SUPPLEMENT|omega-3|Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
223463290|NCT06015971|DIETARY_SUPPLEMENT|Standard|Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
223463291|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 100μg/kg, subcutaneous injection, Once weekly.
223463292|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 120μg/kg, subcutaneous injection, Once weekly.
224068049|NCT04905121|DRUG|Psilocybin|Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
223463293|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
223463294|NCT04513171|DRUG|Norditropin®|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
223463295|NCT04513171|DRUG|Y-shape pegylated somatropin|Y-shape pegylated somatropin 140μg/kg, subcutaneous injection, Once weekly.
224068050|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Tablet-Route of administration:Oral
224068051|NCT06418607|DRUG|Venglustat|Pharmaceutical form:Hard Capsule-Route of administration:Oral
224068052|NCT01618942|DEVICE|pressure algometer|
224068053|NCT04896554|BEHAVIORAL|Health literacy scale|"The Turkish version of The European Health Literacy Survey (HLS-EU) Health Literacy Questionnaire scale (ASOY-TR) was used to measure health literacy. This scale consists of 47 questions. Each item has 4 degrees such that 1 = Very difficult, 2 = Difficult, 3 = Easy, 4 = Very easy. Code 5 is used for the expression I don't know. The total score that can be obtained from the scale is between 47-188. For the sake of ease of calculation, the total score is standardized with the following formula to take a value between 0-50.~Formula = Index = (arithmetic mean-1) x \[50/3\] High score means better health literacy."
224068054|NCT03664999|DIAGNOSTIC_TEST|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
223463296|NCT04513171|DRUG|Norditropin|Norditropin 245μg/kg/week, subcutaneous injection, Once daily.
223463297|NCT00977613|BEHAVIORAL|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
223576273|NCT06601933|OTHER|Cognitive Training|"Participants (n=240) will be randomized to high dose crosswords, low dose crosswords, and health education at 1:1:1 ratio, stratified by site, age (\< 70 and 70 years), and MCI status (early MCI and late MCI). In the two crossword puzzles conditions, after initial training to use the web-based platform, the participant will be assigned to do 12 weeks of crossword puzzles four times per week or 12 weeks of crossword puzzles once per week at home. After these 12 weeks, booster sessions will be either four or one 30-minute session(s) completed over 1 week. These booster sessions will occur at weeks 20, 32, 42, 52, 64, and 78. In-person assessments will occur at 0, 12, 32, 52, 78 weeks with one crossword puzzle session, which will count toward the booster session.~Health education will involve reading chapters in a book on common illnesses and lifestyle, and a research staff member will review these chapters at the same assessment intervals as the crossword puzzles conditions."
223576274|NCT04145674|DRUG|D-methadone|Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
223576275|NCT04145674|OTHER|Placebo|Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
224068055|NCT01788254|DRUG|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
223463298|NCT01406314|DRUG|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
223463299|NCT03574077|BEHAVIORAL|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
223463300|NCT03574077|BEHAVIORAL|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
223463301|NCT03574077|BEHAVIORAL|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
223463302|NCT03574077|BEHAVIORAL|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
223576276|NCT04957992|OTHER|Control Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
223576277|NCT04957992|OTHER|Control Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
223576278|NCT04957992|OTHER|Experimental Infant Formula|Ad libitum or as instructed by HCP, feeding period from enrollment to 12 months of age
223576279|NCT04957992|OTHER|Experimental Toddler Drink|\~ 16 fl oz per day as primary milk beverage; feeding period from 12 to 24 months of age
223576280|NCT04957992|OTHER|Human Milk|Ad libitum or as instructed by HCP
223576281|NCT04957992|OTHER|Human Milk Supplemental Formula|Ad libitum if consuming supplemented formula; feeding period up to 12 months of age
223576282|NCT04957992|OTHER|Human Milk Toddler Drink|\~16 fl oz per day if providing supplemental nutrition other than HM; feeding period from 12 to 24 months of age
224068056|NCT01788254|DRUG|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
224068057|NCT01788254|DRUG|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
224157497|NCT06275698|DIETARY_SUPPLEMENT|Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring|"Sugar-based syrup, thickened with sodium alginate and flavoured with honey flavouring, 15ml, three times a day, for 14 days.~To be kept on the tongue for at least 10 seconds prior to swallowing."
224157498|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
224157499|NCT01640080|DRUG|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
224157500|NCT01640080|DRUG|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
224157501|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
223463303|NCT03574077|BEHAVIORAL|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
223463304|NCT03742986|DRUG|Nivolumab 360mg|Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)
223463305|NCT03742986|DRUG|Paclitaxel 80mg/m^2|Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)
223463306|NCT03742986|DRUG|Doxorubicin 60mg/m^2|Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)
223463307|NCT03742986|DRUG|Cyclophosphamide 600mg/m^2|Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)
223463308|NCT03742986|DRUG|Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)
223463309|NCT03742986|DRUG|Trastuzumab 8mg/kg and 6 mg/kg|Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4
223463310|NCT03742986|DRUG|Pertuzumab 840mg and 420mg|Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
223463311|NCT05105191|DIAGNOSTIC_TEST|Roche Cobas® Liat Influenza A/B & RSV assay|Performance of a rapid molecular assay to diagnose influenza and RSV infections
223576283|NCT06684977|BEHAVIORAL|360 Video|360° Video consists of video recordings, made with a camera to simultaneously capture and combine scenes in a 360 degrees perspective such as Instant Google Street View Instant Google Street View (instantstreetview.com). When uploaded to a VR headset, 360° videos may provide a more cost-effective method for rapidly creating virtual environments in which users can experience a sense of immersion and the viewer can control and change the viewing angle at any stage through head movement. While photorealism may be superior, this option is known to be less interactive as the viewer can't move or walk around within the virtual space. In addition, the landscape and imagery may have been changed or developed meaning the recordings captured do not match the traumatic memory. Despite these limitations, the use of 360° video has been trialled in clinical mental health settings showing positive outcomes for both user and clinician.
223576284|NCT06684977|BEHAVIORAL|VR Photoscan|VR Photoscan creates immersive virtual environments by transforming real-world imagery into detailed 3D models. Using high-resolution images captured from a smartphone, these images are processed in 3D graphics software to sculpt realistic virtual scenes. The resulting 3D models are imported into a game engine, adding VR functionality, allowing users to navigate freely with six degrees of freedom. Interactive content, such as animated cars and people, can be added in real-time, while menu systems guide users through the experience. Environmental factors like lighting, weather, and time of day can be adjusted to simulate real conditions. Spatial 360° audio enhances immersion, providing sounds from various directions. This VR environment creation process is efficient and cost-effective, requiring no specialised equipment, and ensuring high-quality immersive experiences at minimal production time and cost.
223576285|NCT06684977|BEHAVIORAL|Standard TF-CBT|Ehlers and Clark's model follows the general style of reliving (recommended by NICE) suggested by Foa and Rothbaum with some fluidity and in vivo exposure (i.e., trauma site visit). During the treatment process of reliving, clients are asked to close their eyes and intentionally recall the traumatic memories, i.e., relive the trauma in their mind in detail and narrate their experience in present tense, including recalling images, sensory experiences, thoughts, and feelings. VR-based PTSD treatments can promote emotional engagement and the process of trauma via providing visual, auditory, and haptic sensory cues.
223576286|NCT06689735|OTHER|schroth exercises|Exercises will be given in lying, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the type of scoliosis. Exercises will be given progressively in supine, prone, side sitting, sitting and standing positions. In each exercise, elongation of the spine will be ensured and the person will be positioned according to the upper and lower extremities. Progress in the exercises will be made positionally by increasing the number of repetitions and the number of rotational breathing during the exercise.
223576287|NCT06689735|OTHER|pilates exercises|The average application time of the exercises is 30-40 minutes (with the first 10 minutes of warming up and the last 5 minutes of stretching). The first four exercises were used for the warm-up period and the last four exercises were used for the stretching period. The exercises will be done as 1 set of 8 repetitions. The Hundred exercise will be increased to 10 sets of 10 reps every two weeks to 10 reps, 12 reps, and 14 reps, respectively.
223576288|NCT01442506|OTHER|biopsies|taking biopsies
223463312|NCT00262652|DRUG|sodium pyruvate|
223463313|NCT05895045|BEHAVIORAL|Yoga|Restorative Vinyasa Yoga
223463314|NCT01715233|DRUG|Docetaxel|Modified Docetaxel 40mg/m2 on Day 1
223576289|NCT01442506|OTHER|biopsy|biopsy
224304954|NCT05673330|OTHER|Myofascial Release Technique|"Suboccipital Inhibition Technique: While the patient will be in the supine position, the physician sitting at the top end of the table will place the fingers of both hands on the patient's suboccipital region. Flexi-perpendicular long fingers exerting an inhibitory pressure on the muscle insertions of the neck extensors in the occiput, perpendicularly to muscle fibers, while the thumbs counterbalance the head against rotation. A deep and progressive pressure would be applied perpendicular to the fibers until a decrease in muscle tone would be detected. This deep and progressive pressure would be maintained for a total of 10 min until release of suboccipital tissues is achieved.~The patients will receive myofascial release with the frequency of 1 set and 10 repetitions once a day three times per week for four weeks. Pre and post intervention values will be taken on 1st day and after 4 weeks."
223463315|NCT01715233|DRUG|Leucovorin|Leucovorin 400mg/m2 on Day 1
223463316|NCT01715233|DRUG|Fluorouracil|Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
223463317|NCT01715233|DRUG|Cisplatin|Cisplatin (or Carboplatin) 40mg/m2 on Day 3
223463318|NCT06265337|DIETARY_SUPPLEMENT|Lactate|Lactate in an OGTT (300 mL lactate drink = 25 g D/L-lactate bound to Na) =LAC with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
223463319|NCT06265337|OTHER|Placebo|Placebo in an OGTT (300 mL salt water, NaCl) =CTR with a stable isotope glucose tracer (D2-glucose) added to measure glucose.
223576290|NCT05206071|BIOLOGICAL|CD19+22 CAR-T cells|Biological: CD19+22 CAR-T; Drug: Cyclophosphamide,Fludarabine;
223576291|NCT06239441|DRUG|IL5/IL5R Antagonists|Treatment with IL5/IL5R antagonists for one year
223463320|NCT05970965|PROCEDURE|Biological sampling|\- Saliva and blood sampling
223576292|NCT06699589|BEHAVIORAL|Old SCHOOL Hip-Hop (Dementia Education)|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
223576293|NCT06699589|BEHAVIORAL|My Plate (Nutrition Education)|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
223576294|NCT00101764|DRUG|Triamcinolone Acetonide|
223576295|NCT02299570|BIOLOGICAL|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
223576296|NCT02299570|OTHER|Placebo|A suspension of saline and cryoprotectant
223576297|NCT07033949|DEVICE|Green light glasses|Exposure to green light for 30 minutes
223576298|NCT07033949|DEVICE|Transparent light exposure|Exposure to transparent light for 30 minutes
223576299|NCT07033286|DEVICE|Ambu aScope Gastro|CE-marked single-use gastroscopes from Ambu are used in the single-use group.
223576300|NCT07033286|DEVICE|Diagnostic gastroscopes, Olympus|Reusable gastroscopes from Olympus are used in the reusable group.
223463321|NCT04736095|DIAGNOSTIC_TEST|3D Ultrasound|Doing 3D ultrasound for diagnosis of submucous myoma
223463322|NCT04736095|DIAGNOSTIC_TEST|Hysteroscopy|Doing hysteroscopy for diagnosis of submucous myoma
223463323|NCT06553404|DEVICE|Myoslow|The Myoslow spectacle lens is based on the Defocus Incorporated Multiple Segments (DIMS) mechanism of action. This lens provides the same optical image as the Defocusing Incorporated Soft Contact Lens (DISC) without the drawbacks inherent with contact lens fitting.
223463324|NCT06553404|DEVICE|Single Vision|Single vision glasses
223576301|NCT07041957|OTHER|Individualized flow-controlled ventilation strategy|"1. Compliance-guided PEEP trial: An incremental PEEP trial from 5 to 15 cmH2O in 2 cmH2O steps with a constant driving pressure (ΔP) will be performed. At the first PEEP level, the tidal volume is set to 6-8 ml/kg PBW. The best PEEP level is defined as the one with the highest dynamic compliance. Participants are ventilated with this PEEP level + 1-2 cmH2O for a reduction of lung de-recruitment and atelectrauma.~2. Compliance-guided driving pressure (ΔP) trial: In the FCV group, an additional incremental ΔP trial in 1 cmH2O steps is initiated after the PEEP trial. This trial evaluates if the tidal volume increases (over-)proportional to the dynamic compliance on the previous ΔP level when the ΔP is increased by 1 cmH2O. In the FCV group, participants are ventilated with a ΔP consistent with the highest dynamic compliance ± 1-2 cmH2O. The compliance-guided PEEP and ΔP trials are repeated every 8 hours in order to account for changes in overall lung compliance."
223576302|NCT07041957|OTHER|Pressure-controlled ventilation strategy via the application of Biphasic Positive Airway Pressure ventilation|"1. Compliance-guided PEEP trial: An incremental PEEP trial from 5 to 15 cmH2O in 2 cmH2O steps with a constant driving pressure (ΔP)will be performed. At the first PEEP level, the tidal volume is set to 6-8 ml/kg PBW. The best PEEP level is defined as the one with the highest dynamic compliance. Participants are ventilated with this PEEP level + 1-2 cmH2O for a reduction of lung de-recruitment and atelectrauma.~2. The driving pressure (ΔP) is set to achieve a tidal volume of 6-8 ml/kg predicted body weight.~The compliance-guided PEEP trial is repeated every 8 hours in order to account for changes in overall lung compliance."
223576303|NCT07041866|DIETARY_SUPPLEMENT|Fortified Biscuit with Local Iron-Rich Ingredients|Participants consumed one fortified biscuit per day, five days a week (school days), for a period of three months. The biscuit was formulated using wheat flour, millet, maize, peanut paste, sugar, and was filled with a blend of Moringa oleifera, Hibiscus sabdariffa, Adansonia digitata, and Detarium senegalense-all selected for their high iron and vitamin C content. The iron content was approximately 4 mg per 100 g.
223576304|NCT07041866|DIETARY_SUPPLEMENT|Non-Fortified Biscuit|Participants received a placebo biscuit daily for the same period and frequency as the intervention group. The placebo biscuit was visually and texturally identical to the fortified biscuit but did not contain the micronutrient-rich filling.
224068058|NCT01788254|DRUG|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
224068059|NCT01788254|DRUG|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
224068060|NCT03632733|DRUG|Tetracycline|Tetracycline cream
224068061|NCT03632733|DRUG|Clotrimazole|Clotrimazole cream
224068062|NCT03632733|DRUG|Tetracycline and Clotrimazole|Combination cream
224068063|NCT03632733|OTHER|Placebo|Placebo cream without active drug ingredients
224068064|NCT00558870|DRUG|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
224068065|NCT00558870|DRUG|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
224068066|NCT03609697|BEHAVIORAL|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
224068067|NCT03609697|BEHAVIORAL|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
224068068|NCT03728075|DEVICE|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
224068069|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
223463325|NCT02882126|DRUG|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
223463326|NCT06360965|DRUG|Improved warm meridians and relieve pain plaster|Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
223463327|NCT06360965|DRUG|Traditional warm meridians and relieve pain plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
223463328|NCT06360965|DRUG|Placebo plaster|The treatment course is the same as the improved warm meridians and relieve pain plaster group.
223463329|NCT02012725|DRUG|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
223463330|NCT00598065|OTHER|PET/CT|Synchronized PET/CT Imaging
223463331|NCT00029393|PROCEDURE|Hematopoietic Stem Cell Transplantation|
223463332|NCT00029393|DRUG|Immunosuppression|
223463333|NCT01691378|OTHER|Window to Hope|Psychotherapy - Group
223463334|NCT01691378|OTHER|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
223463335|NCT01944748|BEHAVIORAL|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
223463336|NCT00563615|DRUG|Tegaserod|
223463337|NCT00073450|DRUG|Farnesyl Protein Transferase Inhibitor|
223463338|NCT01634503|GENETIC|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
223463339|NCT02260206|DRUG|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
223463340|NCT00823238|DRUG|ceftazidime and tobramycin|
223463341|NCT00823238|DRUG|inhaled tobramycin|
223463342|NCT02975817|OTHER|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
223463343|NCT02975817|OTHER|Warm Air|Active, convective warming of patient using warm air blanket
223463344|NCT03145103|DEVICE|CT ASPHINA 409|intraocular lens
223463345|NCT01676246|DRUG|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
223463346|NCT01676246|DRUG|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
223463347|NCT01676246|DRUG|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
223463348|NCT01676246|PROCEDURE|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
223463349|NCT01676246|PROCEDURE|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
223463350|NCT00384202|DRUG|Tacrolimus|Immunosuppression
223463351|NCT03472911|OTHER|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
223463352|NCT05150457|DRUG|BNA035|Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody
223463353|NCT04750057|DRUG|Anifrolumab|Multi-centre, open-label, early access program (EAP) designed to provide access to intravenous (IV) treatment regimen of 300 mg anifrolumab (MEDI-546) every 4 weeks (Q4W) for eligible patients with moderate-to-severe active SLE while receiving standard therapy.
223463354|NCT02958371|PROCEDURE|fMRI|
223463355|NCT02958371|BEHAVIORAL|fruit-flavored drink ingestion|
223463356|NCT00039624|RADIATION|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
223463357|NCT02223351|DRUG|ASP2151|
224304955|NCT01167257|DRUG|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
223463358|NCT02223351|DRUG|ritonavir|
223463359|NCT00808067|DRUG|dabigatran dose 1|dabigatran high dose twice daily
223463360|NCT00808067|DRUG|dabigatran dose 2|dabigatran low dose twice daily
223463361|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
223463362|NCT01494805|BIOLOGICAL|rAAV.sFlt-1|1 x 10\^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
223463363|NCT01494805|OTHER|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
223463364|NCT05957185|DIETARY_SUPPLEMENT|OPTIZIOME® P³ HYDROLYZER® - WHEY|One dose of P3 - WHEY will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
223463365|NCT05957185|OTHER|Placebo|One dose of placebo maltodextrain will be combined with 31.9 grams whey protein concentrate in 300 mL water and consumed within 5 minutes at the start of each of the aminoacidemia trials.
223463366|NCT01878318|DRUG|methotrexate|stable dose
223463367|NCT01878318|DRUG|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
223463368|NCT02532283|DRUG|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
223463369|NCT02532283|DRUG|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
223576305|NCT07040852|BEHAVIORAL|Mental Health Literacy Promotion Intervention Program|10 sessions, 90 minutes each, weekly. A face-to-face group treatment for Chronic Pain that focuses on enhancing individuals' understanding of mental health issues, promoting help-seeking behaviors, and reducing stigma associated with mental illness. Intervention includes group discussions, audio-visual material and written material.
223576306|NCT07042009|OTHER|Nutritional resources|The participants will be provided with the nutritional resources only.
223576307|NCT07042009|OTHER|Milk docosahexaenoic acid levels|The participants will be provided with information on the levels of docosahexaenoic acid in their breast milk.
223576308|NCT07040124|PROCEDURE|ti mesh|prebent titamesh on a 3-d virtually augmented model
223576309|NCT07040124|PROCEDURE|3d peek mesh|milled 3d peek mesh
223576310|NCT07032675|DEVICE|Low-temperature radio-frequency reshaping of autologous cartilage nasal and/or auricular cartilage|The device settings will be set per the manufacturer's instructions: temperature = 60° C, power = 4 W, treatment time = 18 seconds, and cooldown = 12 seconds. For curved-to-straight (CTS) samples (natively curved cartilage to be remolded to be flat), the cartilage specimens will be placed on a blue towel on a flat surface with the transmission medium over top and treated. For straight-to-curved (STC) samples (natively flat cartilage to be remolded to be curved), cartilage specimens will be placed along the inner surface of various shallow, plastic, cylindrical objects with the transmission medium over top and treated. Various device settings may be tested for reshaping efficacy.
223576311|NCT07040501|DEVICE|Chat GPT|On the date of appointment, participants will be given up to 30 minutes, to interact with a pre-prompted Chat GPT (Prostate Pathology Guide) using a Cleveland clinic device.
223576312|NCT07040189|OTHER|Gustabor server|AI based web platform providing individual lifestyle tips and recipe recommendations based on the patient's individual data and taste disorder
224068070|NCT00742768|DIETARY_SUPPLEMENT|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
224068071|NCT02069899|DRUG|Emapalumab|Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
224068072|NCT04344938|OTHER|questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality|Many critical ethical questions arise in pandemic covid 19planning, preparedness and response. These include: Who will get priority access to medications, vaccines and intensive care unit beds, given the potential shortage of these essential resources? In the face of a pandemic, what obligations do health-care workers have to work notwithstanding risks to their own health and the health of their families? How can surveillance, isolation, quarantine and social-distancing measures be undertaken in a way that respects ethical norms? What obligations do countries have to one another with respect to pandemic covid 19 planning and response efforts?
224068073|NCT02511730|DEVICE|FFDM Plus DBT|FujiFilm Aspire Cristalle System
224068074|NCT02511730|DEVICE|FFDM|FujiFilm Aspire Cristalle System
224304956|NCT01167257|DRUG|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
223463370|NCT02532283|DRUG|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
223463371|NCT01150253|DIETARY_SUPPLEMENT|L. paracasei fermented milk|
223463372|NCT03205475|BEHAVIORAL|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
223463373|NCT03205475|BEHAVIORAL|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
223463374|NCT03205475|BEHAVIORAL|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
223463375|NCT03205475|BEHAVIORAL|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
223463376|NCT03205475|BEHAVIORAL|Video Feedback Only Phase 2|Receive video feedback and calls only
223463377|NCT00418028|DRUG|Capecitabine|
223463378|NCT04608331|DRUG|Dexmedetomidine|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml) and dexmedetomidine (1.25 microgram/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
223576313|NCT07041762|PROCEDURE|Rhomboid Intercostal Block with Sub-Serratus Plane Block|"Ultrasound-guided regional anesthesia combining two injections:~Rhomboid Intercostal Block (20 mL of 0.25% bupivacaine injected between rhomboid major and intercostal space)~Sub-Serratus Plane Block (20 mL of 0.25% bupivacaine injected between serratus anterior and ribs).~Both performed 30-45 minutes before Modified Radical Mastectomy under general anesthesia."
223576314|NCT07041762|PROCEDURE|Erector Spinae Plane Block|"Ultrasound-guided regional block with 30 mL of 0.25% bupivacaine injected into the paraspinal plane at the T4-T5 level, between the erector spinae muscle and the transverse processes.~Performed 30-45 minutes prior to general anesthesia for Modified Radical Mastectomy."
223576315|NCT07040241|PROCEDURE|Confocoal laser endomicroscopy-assisted ultrasound-guided pleural biopsy|Using the probe-based confocal laser endomicroscopy to detect the pleural, and ensure the biopsy location. Then, use the pleural biopsy tool to complete the pleural biopsy. The whole procession will under the ultrasound guidance.
224304957|NCT00496353|DRUG|MK2461|MK2461 treatment, bid, 28-day
223463379|NCT04608331|DRUG|Placebo|Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours. The pump is established with morphine (0.5 mg/ml), in a total volume of 160 ml normal saline, and programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate of 1 ml/h.
223463380|NCT00042055|DRUG|CP-461|
223576316|NCT07040241|PROCEDURE|Ultrasound-guided pleural biopsy|Using ultrasound to detect the biopsy site and perform pleural biopsy.
224157502|NCT01280812|BEHAVIORAL|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
224157503|NCT01280812|BEHAVIORAL|Control (pedometer only)|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
224157504|NCT03719430|DRUG|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
224157505|NCT03719430|DRUG|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
224157506|NCT04032197|DRUG|Semaglutide|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
224157507|NCT04032197|DRUG|Placebo (semaglutide)|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
224157508|NCT04483544|DRUG|pembrolizumab|PD-1 inhibitor pembrolizumab, 200mg intravenously (IV) every 3 weeks
224157509|NCT04483544|DRUG|olaparib|PARP inhibitor olaparib 300 mg orally, twice daily (BID)
224157510|NCT04291079|BIOLOGICAL|SRK-181|anti-latent TGFβ1 monoclonal antibody
224157511|NCT04291079|BIOLOGICAL|anti-PD-(L)1 antibody therapy|approved anti-PD-(L)1 antibody therapy for each tumor type
224157512|NCT05569850|OTHER|Brushing|Brushing the teeth 2x a day for 4 weeks.
224157513|NCT06846528|DRUG|AZD2389|AZD2389 is administered orally
224157514|NCT06846528|DRUG|Itraconazole|Itraconazole is administered orally
224157515|NCT06843863|OTHER|No intervention.|Participants allocated to the groups were assessed only once. No intervention was applied, and they were not followed up.
224157516|NCT01871415|DRUG|aleglitazar|150 mcg orally daily
224157517|NCT01871415|DRUG|metformin|pre-existing background regimen and dose
224157518|NCT01871415|DRUG|placebo|matching aleglitazar placebo orally daily
224157519|NCT03147573|DIAGNOSTIC_TEST|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
224157520|NCT03147573|DIAGNOSTIC_TEST|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
224157521|NCT03147573|DIAGNOSTIC_TEST|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
224157522|NCT03147573|DIAGNOSTIC_TEST|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
224157523|NCT00628316|DIETARY_SUPPLEMENT|caffeine|caffeine daily intake will be reduced form 150 ml per day
224157524|NCT03197948|OTHER|Internet-Based Intervention|Complete questionnaire via a smartphone application
223576317|NCT07041697|DEVICE|Light-emitting diode photobiomodulation therapy|For the intervention, the isolated arteries were assigned to three experimental groups. The first group (red) was exposed to light at a wavelength of 650 nm for 83 seconds. The second group (infrared) received irradiation at 940 nm for 94 seconds. The third group (mixed) was irradiated with a combination of red (650 nm) and infrared (940 nm) light for 73 seconds.
224157525|NCT03140488|DRUG|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
224157526|NCT05732493|DRUG|Serplulimab|Serplulimab 300mg, d1, q3w
224157527|NCT05732493|RADIATION|short-term radiotherapy|radiation: 25Gy/5Fx
224157528|NCT05732493|DRUG|Oxaliplatin|130mg/m2 d1 q3w
224157529|NCT05732493|DRUG|Capecitabine|1000mg/m2 d1-14 q3w
224157530|NCT05841953|DEVICE|Transcutaneous neuromuscular electrical stimulation|Transcutaneous electrical stimulation will be delivered to the anal sphincter and anal resting and squeezing pressures as a result of the stimulation will be recorded for different stimulation protocols using approved electrotherapy units
224157531|NCT01131078|DRUG|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
224157532|NCT01131078|DRUG|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m\^2 twice daily (Day 2 to 15) or as 650 mg/m\^2 twice daily on Days 1 to 21.
224157533|NCT01131078|DRUG|Irinotecan|Irinotecan was administered as a 240 mg/m\^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
224157534|NCT01751204|DIETARY_SUPPLEMENT|Calcium tablet|
224157535|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (250mg)|
224157536|NCT01751204|DIETARY_SUPPLEMENT|Calcium ion water (125mg)|
224157537|NCT04576260|BEHAVIORAL|Cognitive Behavioural Therapy for Insomnia|Weekly CBTI training
224157538|NCT01161927|DRUG|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
224157539|NCT01161927|DRUG|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
224157540|NCT03675594|DEVICE|CAD/CAM titanium denture base|metallic denture base made of titanium
224157541|NCT03675594|DEVICE|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
224157542|NCT05010863|OTHER|Blood collection|The subject will be drawn a 5ml blood sample
223576318|NCT07040670|PROCEDURE|Confocal laser endomicroscopy-assisted endobronchial ultrasound-guided transbronchial needle aspiration|First, use the EBUS needle to create a hole in the airway wall. Then, insert the CLE into the lymph node via this hole and detect the lymph node. When the specific pathological finding is detected by CLE, record the location. Finally, using the needle to perform EBUS-TBNA in the area under EBUS guidance.
223463381|NCT06661460|BEHAVIORAL|Internet-Delivered Cognitive Behavioral Therapy|The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
223463382|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer only|classical arthrocentesis with lactate ringer only (control group).
223463383|NCT06508203|PROCEDURE|arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)|classical arthrocentesis with lactate ringer followed by injection with piroxicam 2 ml (40mg)
223463384|NCT02768688|OTHER|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
223463385|NCT02768688|DRUG|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
223463386|NCT03271593|OTHER|No intervention|No intervention
223463387|NCT00263471|DRUG|7-methylxanthine|
223463388|NCT05298683|DRUG|Isatuximab|Intravenous (IV) infusion. Dose regimen: Isatuximab will be given at a dose of 10 mg/kg QW by IV infusion on Days 1, 8, 15, and 22 in Cycle 1 and Days 1 and 15 in subsequent cycles. In patients with ≥VGPR who will be randomized to receive isatuximab once monthly from Cycle 7, isatuximab will be given on day 1 of each cycle.
224304958|NCT02512653|BIOLOGICAL|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
224304959|NCT04305587|DRUG|PF-07081532|Investigational Drug once daily for up to 42 days; multiple ascending dose design.
223463389|NCT05298683|DRUG|Pomalidomide|Route of administration: Oral (PO). Dose regimen: Pomalidomide will be given at 4 mg orally (PO) will be given on Days 1-21 of each cycle.
223463390|NCT05298683|DRUG|Dexamethasone|Route of administration: PO or IV. Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) PO, or IV will be given on days 1, 8, 15, and 22 in each cycle.
223463391|NCT05298683|DRUG|Acetaminophen (paracetamol)|Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
223576319|NCT07040670|PROCEDURE|Endobronchial ultrsound-guided Mediastinal cryobiopsy|Using the cryoprobe to perform EBUS-TBMC three times per person.
223576320|NCT07040176|PROCEDURE|Upper molar distalization|This study aims to compare upper molar distalization movement achieved with a non-compliance miniscrew implant supported appliance (AMDA®) with distalization of upper molars achieved with clear aligners (Spark®) supported by Class II elastics.
223576321|NCT00869050|DRUG|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
223576322|NCT00869050|DRUG|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
223576323|NCT07040683|DEVICE|Negative Pressure Wound Therapy (NPWT)|Negative pressure wound therapy (NPWT) applied over the split-thickness skin graft on the lower leg after tumour excision. A protective silicone interface layer will be used, with continuous negative pressure of -125 mmHg applied until postoperative day 5, unless earlier change is clinically indicated.
223576324|NCT07040683|OTHER|Traditional Dressing|Traditional dressing applied over the split-thickness skin graft on the lower leg after tumour excision. The dressing consists of one or more layers of foam dressing applied on top, which may or may not be fixed with sutures according to surgeon preference, and an elastic bandage applied over the foam to provide gentle, even compression and immobilisation of the graft. The dressing will remain undisturbed until postoperative day 5 unless earlier change is clinically indicated.
224068075|NCT00490451|DRUG|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
223463392|NCT05298683|DRUG|Ranitidine (or equivalent)|Route of administration: IV. Dose regimen: Ranitidine or equivalent will be given at 50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
223463393|NCT05298683|DRUG|Diphenhydramine (or equivalent)|Route of administration: IV. Dose regimen: Diphenhydramine or equivalent will be given at 25-50 mg 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion.
224068076|NCT01181011|DRUG|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
224068077|NCT03997955|OTHER|Myofascial induction|Myofascial induction in plantar fascia
224068078|NCT03997955|OTHER|Sham myofascial induction|Sham myofascial induction in plantar fascia
224304960|NCT04305587|OTHER|Placebo|Placebo once daily for up to 42 days.
223576325|NCT00383643|DRUG|zolpidem tartrate|
223576326|NCT00383643|DRUG|sodium oxybate|
223576327|NCT00383643|DRUG|Matching Placebos|
224068079|NCT04772040|DIETARY_SUPPLEMENT|Fish oil supplementation|Fish oil capsules.
223463394|NCT05701254|PROCEDURE|Transilial bone biopsy|The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
223463395|NCT06598137|PROCEDURE|Ex vivo confocal laser microscopy|Using ex-vivo confocal laser scanning microscopy, a reliable statement can be made about the extent, histological structure and possible significance of a skin change without having to send tissue samples for demanding and lengthy histological examinations.
223463396|NCT06591793|BIOLOGICAL|AAVB-081|Single subretinal administration
223463397|NCT06609200|DEVICE|Acupuncture needles|The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
223463398|NCT00490971|DRUG|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
223463399|NCT00490971|DRUG|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
223463400|NCT00490971|DRUG|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
223463401|NCT05908253|BEHAVIORAL|sham neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop sham neurofeedback protocol.
223463402|NCT05908253|BEHAVIORAL|nonadaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop nonadaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an open-loop attention model of the corresponding human subject.
223463403|NCT05908253|BEHAVIORAL|adaptive neurofeedback|Both neural activity and accuracy of behavioral responses will be evaluated before and after a closed-loop adaptive neurofeedback protocol. In this method, the stimuli is changed using the upcoming neural activity and an adaptive algorithm.
223463404|NCT06613282|DEVICE|Low Intensity Transcranial Magnetic Stimulation|"* Magnetic stimulation frequency range: 0.1 - 700 Hz.~* Amplitude of the magnetic field at a short distance from the magnetic coil: 1-5 milliTesla.~* Emitter coil dimensions: ⌀28×26 mm.~* Number of emitter coils: 32 coils.~* Covering the entire scalp of a human head with 32 coil emitters."
223463405|NCT06613282|DEVICE|Auditory and visual stimulation|"* Frequency range of light stimulation: 0.1 - 60 Hz.~* Audio stimulation frequency range: 20 - 2000 Hz.~* Sound level: 70 Decibel.~* The wavelength range of visual stimulation: red - 620 - 760 nm; green - 510 - 550 nm; blue - 450 - 480 nm.~* Illuminance: 300 - 350 lx."
223463406|NCT00691652|BIOLOGICAL|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
223463407|NCT00691652|DRUG|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
223463408|NCT00691652|GENETIC|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
223463409|NCT00691652|GENETIC|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
223463410|NCT00691652|GENETIC|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals \<\< 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
223463411|NCT00691652|GENETIC|polymerase chain reaction|
223463412|NCT00691652|OTHER|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
223463413|NCT00691652|OTHER|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
223576328|NCT00405379|DEVICE|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
223576329|NCT05786365|DRUG|Ketalar 50 MG/ML Injectable Solution|Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
223576330|NCT06428916|PROCEDURE|tucking position during endotracheal suctioning|, the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
223576331|NCT06235359|DEVICE|intercostal tube|"A chest tube is a hollow, flexible tube placed into the chest. It acts as a drain.~Chest tubes drain blood, fluid, or air from around your lungs, heart, or esophagus.~The tube around your lung is placed between your ribs and into the space between the inner lining and the outer lining of your chest cavity. This is called the pleural space. It allows your lungs to fully expand."
223576332|NCT01689714|DRUG|Tc 99m EC20|
223463414|NCT03328442|PROCEDURE|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
223463415|NCT03328442|PROCEDURE|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
223463416|NCT02253888|DRUG|TPV - Room condition|
223576333|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with carbohydrate counting|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the total grams of carbohydrates counted. This is the same as commercial hybrid closed-loop insulin therapy (standard treatment).
223576334|NCT06021158|COMBINATION_PRODUCT|Hybrid automated Lyumjev delivery system with meal size estimation|In this system, a Lyumjev insulin bolus is initiated at mealtime based on the qualitative amount of carbohydrates estimated (e.g., low-carb meal).
223576335|NCT06021158|COMBINATION_PRODUCT|Fully automated Lyumjev delivery system with meal detection|In this system, the patient does not initiate a Lyumjev insulin bolus at mealtime. An algorithm is used to detect a meal and administer a subsequent bolus, rather than requiring a carbohydrate count.
223576336|NCT02762630|DEVICE|Carestream Health Inc. weight bearing cone beam CT scanner|
223576337|NCT00429117|BEHAVIORAL|Survey|Internet survey lasting 30 to 40 minutes.
223576338|NCT00756184|DEVICE|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
223576339|NCT00756184|DEVICE|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
223576340|NCT01989780|DRUG|Paclitaxel|
223576341|NCT01989780|DRUG|Bevacizumab|
223576342|NCT01989780|DRUG|Letrozole|
223576343|NCT01989780|DRUG|Anastrozole|
224157543|NCT01174940|DRUG|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
224157544|NCT02591251|DRUG|Povidone-iodine solution|
224157545|NCT02591251|DRUG|Normal saline solution|
224157546|NCT02030457|DRUG|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
224157547|NCT02030457|DRUG|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
223463417|NCT02253888|DRUG|TPV - Refrigerated conditions|
224157548|NCT04787276|DIETARY_SUPPLEMENT|E.coli Nissle 1917|Probiotic contains biomass of E.coli Nissle 1917, 2,5-25·109 colony forming units - CFU/g
223463418|NCT02253888|DRUG|Ritonavir (RTV)|
223463419|NCT00003832|DRUG|bromodeoxyuridine|Given IV
223463420|NCT00003832|PROCEDURE|conventional surgery|Undergo surgery
223463421|NCT00003832|OTHER|laboratory biomarker analysis|Correlative studies
223463422|NCT05280613|BEHAVIORAL|Family Check-Up|See arm/group description
223463423|NCT05280613|BEHAVIORAL|Treatment as Usual|See arm/group description
223463424|NCT04303416|DRUG|Albumin solution|plasma exchange with albumin, one per week for one month, then one per month for 5 months
224157549|NCT04787276|DRUG|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day, 1 months of treatment
224157550|NCT04787276|DRUG|Rifaximin|rifaximin, oral, 500 mg BID, 1 months of treatment
223463425|NCT06611826|DRUG|GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy|The R-GEP regimen is as follows: Gemcitabine (G; 1.0 g/m2, d1, d8) in combination with recombinant human vascular endothelial growth factor (E; 150 mg, continuous intravenous infusion for 72 hours) and Carelizumab (P; 200 mg), administered every three weeks for a total of six cycles. During the 2nd-4th cycles, low-dose radiotherapy is administered to modulate the immune microenvironment (R: one course of radiotherapy per cycle: including booster fractions of 1 Gy\*3 times for the recurrent lesions, once a day, for three cycles). Approximately three weeks after the completion of the sixth cycle of GEP regimen (or the last cycle), high-dose fractionated radiotherapy (5-8 Gy\*5 times, once a day) is given to the recurrent lesions. Immune maintenance therapy continues until one year after treatment completion or disease progression.
223576344|NCT01989780|DRUG|Exemestane|
223576345|NCT01989780|DRUG|Fulvestrant|
223576346|NCT01989780|DRUG|Goserelin|
223576347|NCT01989780|DRUG|leuprorelin|
223576348|NCT05401045|BEHAVIORAL|Met exercises|Exercise plan: Each session of the self-designed MET exercise program was divided into 8 components: stretching exercises, chest expansion exercises, kicking exercises, lateral movement exercises, body rotation exercises, whole-body exercises, jumping exercises, and a cool down. There are 4 sets and 8-repetitions per component, taking approximately 4 minutes to complete and consuming approximately 18 calories. Patients were instructed to exercise once in the morning and once in the evening. For patients with moderate fatigue and an RPFS score of 4 to 6 points, low-intensity exercise was recommended, i.e., patients could choose 1 to 4 metabolic equivalent exercises and repeat them twice; for patients with mild fatigue and an RPFS score of 1 to 3 points, moderate-intensity exercise was recommended, i.e., patients could choose to complete the entire set of metabolic equivalent exercises or 5 to 8 of the exercises and repeat them twice. The exercise frequency was 5 times per week.
223576349|NCT05333172|OTHER|Dual task exercises|Dual tasks, often also referred to as secondary tasks, present an objective-direct measurement in which two tasks are to be performed simultaneously to observe performance drops in either task.
223576350|NCT03397888|DRUG|Betrixaban|80 mg capsule
223576351|NCT06138444|DIETARY_SUPPLEMENT|Functional beverages from the submerged fermentation of Cordyceps militaris|The Cordyceps militaris submerged fermentation in fruit juice.
223576352|NCT06138444|OTHER|Fruit juice|Fruit juice is used as a placebo.
223576353|NCT02626234|DRUG|INC280|
223576354|NCT02626234|DRUG|digoxin|
224157551|NCT01636453|DEVICE|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
223463426|NCT06611852|OTHER|Aerobic exercise|"Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout.~Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes.~Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core.~Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue."
223463427|NCT06611852|OTHER|electronic cupping therapy in addition to aerobic exercise|Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).
223463428|NCT06611852|OTHER|interferential therapy in addition to aerobic exercise|interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy
223463429|NCT06611852|OTHER|interferential therapy, electronic cupping therapy in addition to aerobic exercises|interferential therapy, electronic cupping therapy in addition to aerobic exercises
223463430|NCT06612619|BEHAVIORAL|Dyad instruction|Rather than being instructed solo or one-on-one the trainees are instructed in pairs of two (dyad).
223463431|NCT06613113|DRUG|Fruquintinib|After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease progression or intolerable toxicity occurred.
223463432|NCT06611488|OTHER|No Intervention: Observational Cohort|No Intervention as the study is bservational Cohort
223463433|NCT07000682|BIOLOGICAL|UTAA91 injection|CAR-modified gamma delta T cells
223463434|NCT06504485|DRUG|Bulevirtide|dose of 2 mg/day subcutaneously
223463435|NCT06866275|DRUG|KZ101|For active treatment with KZ101, a loading dose of 454 mg/m2 (salt-free) will be followed by a treatment dose of 363 mg/m2 (salt-free).
223463436|NCT06866275|DRUG|Placebo|Dosing in the placebo group will consist of a volume of normal saline equivalent to that given during the active treatment period for each participant.
223463437|NCT06880653|BEHAVIORAL|DREAM Adaptive Intervention|6-month physical activity program (Dose Response of Exercise for Arthritis Management (DREAM)) which includes monthly phone coaching, Walk With Ease Guidebook, behavioral lessons, and a Fitbit. Participants may receive additional contact (email, text, or phone) if they struggle to meet activity goal.
223463438|NCT06888570|OTHER|To evaluate fat liver content in the cases/controls population.|The studied population includes participants aged 5-22 years old with/without T21 Down Syndrome.
223463439|NCT05275933|OTHER|TCM intervention|Lian Hua Qing Wen Capsules (LH) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
223463440|NCT05275933|OTHER|Placebo intervention|Placebo Capsules (PC) are provided in addition to Standard Care medications which include Symptomatic therapies include Paracetamol, antihistamines (eg. Cetirizine, loratadine or chlorpheniramine) and etc pro re nata (PRN) basis accordingly to the patient's condition.
223463441|NCT06544330|DRUG|SYNCAR-001|SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
223463442|NCT06544330|DRUG|STK-009|STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
223463443|NCT02338115|DRUG|Paclitaxel 80mg/m2 weekly x 12 weeks|
223463444|NCT01814215|BEHAVIORAL|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
223463445|NCT04888494|DEVICE|Transcranial Magnetic Stimulation|For the brain stimulation the investigators will use Repetitive Transcranial Magnetic stimulation (rTMS). Different stimulation conditions (hippocampal or sham) will be delivered in each round of stimulation (5 days). Repetitive TMS will be applied at 100% resting motor threshold intensity, 20 Hz pulse trains separated by 28-s inter-train intervals (\~20 minutes for the entire daily stimulation session). Stimulation parameters will be identical in both groups
223463446|NCT04888494|DEVICE|Sham rTMS|Sham rTMS
223463447|NCT02185456|DRUG|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
223463448|NCT02185456|DRUG|Standard of care|oral metronidazole 500 mg twice a day for 7 days
223463449|NCT03945071|DEVICE|Punctal plug|Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
223463450|NCT00962078|OTHER|continuous endurance training|at 60 percent of peak Watt
223463451|NCT00962078|OTHER|interval training|at 100 percent of peak Watt
223576355|NCT02626234|DRUG|rosuvastatin|
224157552|NCT00959894|DRUG|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
224157553|NCT00959894|DRUG|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
224157554|NCT02744053|PROCEDURE|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
224157555|NCT02744053|OTHER|Laboratory Biomarker Analysis|Correlative studies
224157556|NCT02744053|RADIATION|Scintimammography|Undergo MBI
224157557|NCT02744053|DRUG|Technetium Tc-99m Sestamibi|Given via injection
223463452|NCT02086955|BEHAVIORAL|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
223463453|NCT06404255|BEHAVIORAL|Stress management training|Stress management training
223463454|NCT01900847|DRUG|Ketamine|0.3mg/kg ketamine
223463455|NCT01900847|DRUG|Morphine|Dosage of morphine determined by treating physician
223576356|NCT02494843|OTHER|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
223576357|NCT02494843|OTHER|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
223576358|NCT01867957|BIOLOGICAL|Low-dose GC1109|50ug/dose
223576359|NCT01867957|BIOLOGICAL|High-dose GC1109|100ug/dose
223576360|NCT01867957|BIOLOGICAL|Low-dose Placebo|0.9% Saline 0.5 mL
223576361|NCT01867957|BIOLOGICAL|High-dose Placebo|0.9% Saline 1.0 mL
223576362|NCT05533203|BIOLOGICAL|Prodencel; an autologous dendritic cell therapeutic tumor vaccine|Subcutaneous injection, each injection point should not exceed 1ml.
223576363|NCT02187523|DRUG|Hydrochlorothiazide|
223576364|NCT02187523|DRUG|Telmisartan|
223576365|NCT02187523|DRUG|Telmisartan/HCTZ FDC|
223576366|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Oral Solution
223576367|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 125 mg|Oral Solution
223576368|NCT03554772|DRUG|DFN-15 (Celecoxib Oral Solution) 250 mg|Oral Solution
223576369|NCT03554772|DRUG|Placebo|Oral Solution
223576370|NCT00629746|DEVICE|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~1. The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~2. A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~3. The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~4. The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
223576371|NCT03846531|DEVICE|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
223576372|NCT03794869|OTHER|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
223576373|NCT03794869|OTHER|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
223576374|NCT01994863|DEVICE|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
223576375|NCT01994863|DEVICE|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
223576376|NCT05136898|DRUG|UGN-102|UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
223576377|NCT05278364|DRUG|SY-5007|a RET selective Inhibitor
223576378|NCT06184464|OTHER|ACETATE LEUPRELINE|USE ACETATE LEUPRELINE BEFORE AND AFTER PROSTATE DELIMITATION
223463456|NCT01900847|DRUG|placebo|saline of same volume as appropriate weight based dose of ketamine
223463457|NCT02002871|DEVICE|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
223576379|NCT05110469|DRUG|Magnesium sulfate|"IV Magnesium sulphate 30 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
223576380|NCT05110469|DRUG|Meperidine|"IV Meperidine 0.5 mg/kg, labeled as research drug for blinding, were given in 10 minutes while patients were monitored for side effects such as hypotension, bradycardia, nausea, vomiting, itch, allergy, drowsiness, and respiratory depression."
223576381|NCT05709522|BEHAVIORAL|Neurocognitive tools|Neurocognitve and psychological tools
223576382|NCT00390481|PROCEDURE|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
223463458|NCT04437836|DRUG|Evaluation of high dose rifampicin in children|Evaluation of severity of adverse event from grade 1 to 5
223463459|NCT00565604|DEVICE|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
223576383|NCT05883332|DRUG|Self-Administered Nitrous Oxide|Nitrous oxide administered at concentrations of mild sedation (20-50%)
223576384|NCT05883332|OTHER|Oxygen|100% oxygen at 10 Liters/minute
223576385|NCT04805203|OTHER|blood sample analyses|maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
223576386|NCT05577832|PROCEDURE|Helfer Skin Tap Technique|In a single-group design, 3 technique injections will be administered to the patients, to be randomized. The HST technique will be applied to patients in any one of 1days in a randomized fashion.
223576387|NCT05577832|PROCEDURE|ShotBlocker Technique|In a single-group design, 3 technique injections will be administered to the patients, 1 technique per week, to be randomized. The ShotBlocker technique will be applied to patients in any one of 1 weeks(3 days) in a randomized manner.
224157558|NCT05406245|DIETARY_SUPPLEMENT|Carbohydrate drinking|Administration of carbohydrate fluid
223463460|NCT03904810|BEHAVIORAL|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); \[i.e., (maximal HR - resting HR) × intensity + resting HR\]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
223463461|NCT00003522|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223463462|NCT00540670|DRUG|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
223463463|NCT00540670|DRUG|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
223463464|NCT00540670|DRUG|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
223463465|NCT00540670|DRUG|Placebo|Placebo (tablet) taken orally, once a day.
223463466|NCT04536675|DRUG|Vilanterol and Umeclidinium Bromide|Perioperative inhaler therapy with VI/UME (Vilanterol 25mcg/Umeclidinium 62.5mcg) once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
223463467|NCT04536675|DRUG|Placebo|Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
223463468|NCT06948032|DRUG|BLU-808|BLU-808 will be administered per schedule specified in the arm description.
223463469|NCT06948032|DRUG|Placebo|BLU-808 matching placebo will be administered per schedule specified in the arm description.
223463470|NCT06948032|DRUG|Midazolam|Midazolam will be administered per schedule specified in the arm description.
223463471|NCT02798107|DRUG|idarucizumab|drug
223463472|NCT06948864|DRUG|Ferric Carboxymaltose (FCM)|Patients in the intervention group underwent surgery from 2020 to end-2022 and were managed according to the surgery prehabilitation protocol. Once the surgeon has included the patient on the SWL, they were evaluated and followed up by the prehabilitation nurse (no more than 72 hours in the case of cancer patients) together with the study internist. The protocol at this preoperative stage consists of a comprehensive biopsychosocial assessment and an analysis of lab and nutritional parameters, which are optimized using targeted treatment. One of the lab parameters analyzed was Hb. Study patients with Hb \< 13 g/dL received 500 mg, 1000 mg, 1500 mg or 2000 mg FCM, depending on their levels of Hb, ferritin, transferrin saturation index, and weight. The lab test was repeated immediately before surgery or 30 days after administration of FCM in order to determine whether Hb levels had improved with FCM therapy
223463473|NCT06950229|DRUG|Povidone-Iodine|Hundred (100) ml of 5% povidone iodine was poured into a sterilized bowl (galipot). Three pieces of gauze held with sponge holding forceps was dipped into the sterilized bowl containing 100mls of 5% povidone iodine and was allowed to be well soaked with 5% povidone iodine and thereafter used to swab the vulva in 360 degrees. one gram of ceftriaxone and 500mg of metronidazole was given prior to the procedure.
223463474|NCT06950229|DRUG|Normal Saline|Hundred (100) ml of Normal saline was poured into a sterilized bowl (galipot). Three pieces of gauze held with sponge holding forceps was dipped into the sterilized bowl containing 100mls of Normal Saline and was allowed to be well soaked with Normal saline and thereafter used to swab the vulva in 360 degrees. one gram of ceftriaxone and 500 mg of metronidazole was given prior to the procedure.
223463475|NCT06954935|OTHER|periorbital massage|An electronic eye massager (irest manufacturing company, China) will be applied. The massager has a vibration function and massages with a warm air bag.
223463476|NCT06956066|BIOLOGICAL|shotblocker|SHOTBLOCKER Shotblocker is a drug-free and non-invasive plastic device for all age groups that is placed during injection to press against the site of administration. It has standardized dimensions and is designed in a small, flat, horseshoe (U) shape with several blunt points on one surface in direct contact with the skin.
223576388|NCT05577832|PROCEDURE|Standard Technique|Standard Technique In a single-group design, 3 technique injections will be administered to the patients, 1 technique per days, to be randomized. The standard technique will be applied to patients in any one of 1 weeks in a randomized fashion.
223576389|NCT03564964|DRUG|SUVN-502|Tablet
223576390|NCT06482320|DIAGNOSTIC_TEST|Recording EKG traces on the smartwatch|Upon enrollment, patients are associated with a progressive identification number (ID). They will then be instructed to record a baseline single-lead EKG (EKG 0) to be sent to a dedicated email address. The sender's email address will be recorded and associated with the ID. The main clinical and demographic data will also be collected. Within 30 days of the enlistment date, a 24-hour EKG Holter will be performed. From the date of enlistment and for the following three months, before, after and during the execution of the 24-hour EKG Holter, enrolled patients can send single-lead EKGs (recorder throug the smartwatch) in case of palpitation. The report of the single-lead EKGs will be communicated electively via e-mail (in response to the email sent by the patient and containing the trace in question) in the following days. In case of diagnostic and/or therapeutic measures to be implemented following the reporting of the trace, doctors will take care of it.
223576391|NCT03972319|DIETARY_SUPPLEMENT|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
223576392|NCT01402076|DRUG|Tasimelteon|20mg daily dosing, Days 4-20
223576393|NCT01402076|DRUG|Rosiglitazone|4mg, single dose, Days 3 and 20
223576394|NCT01402076|DRUG|Midazolam|10mg, single dose, Days 1 and 18
223576395|NCT04693104|DEVICE|PVA Hydrogel|PVA Hydrogel will be supplied in 2 mL sterile and endotoxins-free pre-filled syringes containing a biocompatible polyvinyl alcohol crosslinked (PVA CL, main component) and buffered water for injections.
223576396|NCT04693104|DEVICE|Synvisk-One®|Synvisc One® (comparator) will be supplied in a 6 mL sterile and non-pyrogenic syringe containing containing Hylan polymers (hylan A + hylan B) (main component), sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate and water for injections.
223576397|NCT04972227|DRUG|CY6463|oral tablets
223576398|NCT04972227|DRUG|Placebo|oral tablets
223463477|NCT06955650|DRUG|Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor|"13N-Oxytocin is a newly developed radiotracer designed to bind selectively to oxytocin receptors. It is labelled with nitrogen-13, a short-lived positron-emitting isotope, and is administered intranasally to facilitate direct access to the central nervous system via the nasal and trigeminal pathways. This radiotracer is investigational and is not intended to exert pharmacological effects. It is used solely for imaging purposes to assess the distribution and potential receptor binding sites of oxytocin in the human brain and the trigeminal nerve.~Following administration, PET imaging is conducted using a hybrid PET/MRI scanner. The imaging procedure enables visualisation of the biodistribution of 13N-Oxytocin in vivo. The PET scan protocol includes dynamic image acquisition to track tracer uptake over time and is used in conjunction with MRI for precise anatomical localisation."
223463478|NCT06950255|DEVICE|Cane|"Individuals will receive a single-point cane, individually adjusted to maintain each individual's elbow at approximately 30 degrees of flexion. Participants will be instructed to use the device on dominant side or the side with less impairment. The training with the cane will be carried out by a trained physiotherapist. The training protocol will include gait training with the cane on different surfaces and speeds. At the beginning of each training session, individuals will have the opportunity to address any questions they may have about using a cane in their daily life context.~Individuals will be re-evaluated after the end of the training sessions. After revaluation, the canes will be left with participants who will be instructed as follows: Feel free to use the cane at any time as needed. Another diary will be provided for the participant to record the use of the device after the end of the intervention"
223463479|NCT06950255|OTHER|static stretching and health education|"The intervention for the control group will consist of 20 minutes of global static stretching and 20 minutes of guidance on general health care. The stretches will be performed in three sets of 30 seconds each, targeting different muscle groups. If a participant is unable to perform the self-stretches, the researchers responsible for implementing the intervention will provide assistance. The health education component will cover information on Parkinson's disease (PD) and fall prevention.~The intervention will be offered by the same physiotherapist responsible for training the experimental group. Individuals will be re-evaluated after the end of the training sessions. After revaluation, the participants will be instructed as follows: Feel free to continue stretching exercises and use the health information discussed as needed. Another diary will be provided for the participant to record the stretching exercises performed after the end of the intervention."
223463480|NCT06954896|DRUG|Bupivacain|The superior hypogastric plexus block (SHPB) was performed following uterine removal and closure of the vaginal cuff, but prior to trocar removal from the abdominal cavity. The promontory was identified under laparoscopic visualization. The posterior peritoneum overlying the promontory was gently grasped and elevated with an instrument to create a peritoneal tent. A needle was then inserted at the apex of the tent and advanced approximately 1 cm. At this point, a subperitoneal space was further expanded using a surgical instrument, and 30 ml of 0.25% bupivacaine was injected into the area
223463481|NCT06954896|DRUG|Dexketoprofen (KETAVEL 50 mg/2 ml)|In cases where the VAS score exceeded 3 in the postoperative period, it was deemed that the patient's analgesia was insufficient, prompting the intravenous administration of 50 mg of dexketoprofen sodium.
223463482|NCT06954896|DRUG|Intraperitoneal Bupivacaine spray|The peritoneal cavity and abdominal wall were treated with 30 milliliters of 0.25% bupivacaine, with a focus on areas involving the peritoneum in the lower abdominal region.
223463483|NCT06955793|BIOLOGICAL|TAK-881|Participants will receive SC infusion of TAK-881.
223463484|NCT06955793|DEVICE|SC Investigational Needle Sets|The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
223463485|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，25mg|Usage and dosage: 25mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
223463486|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，50mg|Usage and dosage: 50mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
223463487|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，75mg|Usage and dosage: 75mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
223463488|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，100mg|Usage and dosage: 100mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
223463489|NCT06955988|DRUG|AST2303 Tablets(ABK3376 Tablets) ，125mg|Usage and dosage: 125mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle
223463490|NCT06955611|OTHER|Community based optometry with Virtual Review|Community based OCT imaging with optometrist and virtual review by ophthalmologist
223463491|NCT06955611|OTHER|Usual Care|Hospital eye services review conducted by an ophthalmologist
223463492|NCT06955533|DRUG|Double dose tamsulosin and solifenacin|Odd number
223463493|NCT06955533|DRUG|Single dose tamsulosin and solifenacin|Even number
223463494|NCT06955182|OTHER|Dynamic hot spring hydrotherapy intervention|Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training
223463495|NCT06955182|OTHER|Conventional rehabilitation intervention|Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training
223463496|NCT06955260|DRUG|Empagliflozin 10 mg|Participants will take 10 mg of empagliflozin once daily
224157559|NCT01654393|OTHER|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
224304961|NCT04305587|DRUG|Clopidogrel|Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
223463497|NCT06955260|OTHER|Placebo|Participants will take 10 mg of placebo once daily
223463498|NCT06402461|BEHAVIORAL|Mindfulness of the breath|A 10 minute, audio guided, mindfulness of the breath meditation of the sort used in mindfulness-based cognitive therapy
223463499|NCT06402461|BEHAVIORAL|Mindfulness of sounds|A 10 minute, audio guided, mindfulness of sounds meditation of the sort used in mindfulness-based cognitive therapy
223463500|NCT06402461|BEHAVIORAL|Audiobook control|Listening to a 10 minute extract from an audiobook
223576399|NCT04617418|BEHAVIORAL|Change in touchscreen interactions|The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions
224157560|NCT03612544|OTHER|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224157561|NCT03612544|OTHER|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
224157562|NCT01729676|DRUG|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
224157563|NCT05935813|OTHER|Study characteristics of adolescents affected by dental caries|Study and compare data from The Trøndelag Health Study (The HUNT Study) and data from Public dental service records in Trøndelag collected 2008-2020 to look for Characteristics of adolescents affected by dental caries and trends in caries experience among adolescents (12-20 yo).
224157564|NCT01017692|PROCEDURE|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
224157565|NCT03275519|OTHER|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
224157566|NCT03275519|OTHER|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
224157567|NCT00653068|RADIATION|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
224157568|NCT00653068|PROCEDURE|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
224157569|NCT00653068|DRUG|Carboplatin|Given IV
223463501|NCT04570709|OTHER|Palliative And supportive Care inTervention (PACT)|Using the Adaptive Leadership Framework for Chronic Illness as a guide. The nurse, occupational and physical therapists will meet with the patient and caregiver after the baseline assessment to discuss their Specific, Measurable, Achievable, Relevant, and Time-Bound (SMART) goals. Additionally, the occupational and physical therapists will provide the patient a PACT intervention binder. Regular phone calls or visits from a registered nurse, occupational therapists, and physical therapists for patients and caregivers in the intervention.
223463502|NCT02202369|OTHER|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
223576400|NCT02202512|DRUG|Placebo|tablets
223576401|NCT02202512|DRUG|Cimetidine|
223576402|NCT02202512|DRUG|Placebo|tablets
223463503|NCT02202369|OTHER|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
223463504|NCT01466361|DRUG|Nicotine lower dose|lower dose nicotine lozenge
223463505|NCT01466361|DRUG|Nicotine higher dose|higher dose nicotine lozenge
223576403|NCT02202512|DRUG|Placebo|tablets
223463506|NCT01466361|DRUG|Placebo|placebo
223463507|NCT05696353|COMBINATION_PRODUCT|In-vehicle Device|The Azūga™ in-vehicle driving feedback technology, which consists of a pager-sized device plugged into the vehicle's on-board diagnostic port (installed in the teen's car) and a smart phone app (downloaded on the teen's smart phone), will be installed/downloaded. Three types of feedback will be provided to intervention teens: 1) Direct audio feedback from the installed device; 2) Detailed cumulative driving data via the smart phone app and study website; and 3) A customized biweekly driving summary report via study website.
223463508|NCT05696353|BEHAVIORAL|Expert-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a traffic safety communication specialist to parents in the Feedback and Expert-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
223576404|NCT02202512|DRUG|BI 1060469 high dose|tablets
223576405|NCT02202512|DRUG|BI 1060469 low dose|tablets
223576406|NCT02202512|DRUG|Naproxen|
223576407|NCT02202512|DRUG|BI 1021958|tablets
223576408|NCT03060512|DRUG|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
223576409|NCT03060512|DRUG|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
223576410|NCT01430923|DRUG|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
223576411|NCT01430923|DRUG|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
223576412|NCT00302276|DRUG|Metobes-compound|
223463509|NCT05696353|BEHAVIORAL|Peer-Delivered Parent Communication Training|An individualized virtual training in communication strategies about teen driving safety along with a booster session will be delivered by a peer trainer who is a parent of teen with traffic citation and has participated in the Feedback and Peer-Delivered Parent Communication Intervention Group. Intervention parents in this group will also be provided with access to an online parent-teen safe driving communication guide.
223463510|NCT03740204|DRUG|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
223463511|NCT03740204|DRUG|Placebo patch and pill|Placebo patch and pill
223463512|NCT02302274|DRUG|flecainide iv|infusion over 10 min
223463513|NCT01271647|DRUG|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
223463514|NCT01271647|DRUG|placebo|granules,18g per time,two times per day,six months
223463515|NCT01805661|PROCEDURE|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
223463516|NCT01805661|PROCEDURE|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
223463517|NCT03003910|BEHAVIORAL|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
223463518|NCT03003910|BEHAVIORAL|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
223463519|NCT06253377|DEVICE|Adsorption membrane filter Oxiris™|Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™
223463520|NCT01851993|DRUG|Ondansetron|
223463521|NCT01851993|DRUG|Placebo|0.9% saline
223463522|NCT02991963|OTHER|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
223463523|NCT02991963|OTHER|Blood collection (Dried Blood Spot)|Dried Blood Spot
223463524|NCT02991963|OTHER|Blood Collection (Venous Blood collection)|Venous Blood collection
223463525|NCT02991963|OTHER|Blood Smear|Slide blood smear
224068080|NCT06402266|DEVICE|tDCS|"The STM task will be combined with respectively two times active tDCS and one sham tDCS. The 3 conditions will be randomised, and both scientific staff and participants will be blinded.~Participants will perform the STM task on a tablet for 45 min. Headsets will deliver the tDCS. Two different placements will be used for the active stimulations: 1) F3 and PZ, and 2) F4 and PZ. The current output range will be 1.6mA and the stimulation will last for 30 min. The sham stimulation will function as a control condition. During the sham stimulation, the current density will be ramped up for 15 sec until the current reaches a density of 1.6mA for 60 sec and then again ramped down for 15 sec.~After the session, participants will fill out a brief questionnaire regarding their experience.~The time interval between sessions will be 1-3 weeks."
223463526|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
223463527|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
223463528|NCT00664352|DRUG|Mannose-6-Phosphate (Juvidex)|"* 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
224068081|NCT00137111|DRUG|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
224068082|NCT00137111|DRUG|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
224068083|NCT00137111|DRUG|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
224068084|NCT00137111|DRUG|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
223463529|NCT00664352|DRUG|Mannose-6-Phophate (Juvidex)|"* 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
223576413|NCT03946124|DRUG|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
223576414|NCT02792491|DRUG|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
224068085|NCT00137111|PROCEDURE|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
224068086|NCT00137111|PROCEDURE|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
224068087|NCT01582425|DRUG|Isavuconazole|oral
224157570|NCT00653068|DRUG|Cisplatin|Given IV
224157571|NCT00653068|DRUG|Cyclophosphamide|Given IV
224303223|NCT05969379|GENETIC|Analysis of biomarkers and their correlation with clinical characteristics and outcome|"This is a non-interventional study involving clinical data, neuroimaging analysis, and biological samples. Demographics and clinical data are collected in the database of the French Reference Centre. Additional or missing data will be obtained by contacting the referral physicians. All the neuroimages available will be analysed by dedicated software. Samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids). Additional samples for genetic testing will be collected upon explicit written consent."
224303224|NCT00521417|BEHAVIORAL|short-term dynamic therapy|
224303225|NCT00521417|BEHAVIORAL|long-term dynamic therapy|
224157572|NCT00653068|DRUG|Etoposide|Given IV
224157573|NCT00653068|BIOLOGICAL|Filgrastim|Given IV or SC
224157574|NCT00653068|OTHER|Laboratory Biomarker Analysis|Correlative studies
224157575|NCT00653068|DRUG|Leucovorin Calcium|Given IV or PO
224157576|NCT00653068|DRUG|Methotrexate|Given IV
224157577|NCT00653068|DRUG|Thiotepa|Given IV
224157578|NCT00653068|DRUG|Vincristine Sulfate|Given IV
224157579|NCT06287658|BEHAVIORAL|Training on Kegel exercise and Ba Duan Jin applications online|Kegel exercises and Ba Duan Jin applications online
224157580|NCT06287658|BEHAVIORAL|training on Kegel exercises and Ba Duan Jin applications after the research is completed|Women in the control group will be given training on Kegel exercises and Ba Duan Jin applications after the research is completed.
224157581|NCT03908086|OTHER|Risk factors in RA cohort|
224157582|NCT03908086|OTHER|Risk factors in general population|
224157583|NCT01305941|DRUG|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
224157584|NCT01305941|DRUG|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
224157585|NCT01305941|DRUG|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
224157586|NCT01326676|DRUG|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
224157587|NCT01326676|DRUG|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
224157588|NCT04901390|DIETARY_SUPPLEMENT|Yogurt with B. lactis and added cane sugar|The intervention condition will utilize a commercially available yogurt (Activia) that contains Bifidobacterium animalis lactis DN-173 010/CNCM I-2494 (B. lactis). Participants will consume 170 g of yogurt with cane sugar twice daily for 14 days.
224157589|NCT03869216|BEHAVIORAL|Educational Shared Decision-Making Intervention|The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the Agency for Healthcare Research and Quality (AHRQ) SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
224157590|NCT06398665|DEVICE|Intermittent Theta-Burst Stimulation|Accelerated course of left dlPFC iTBS, consisting of 600 pulses/session, 50 minutes intersession interval, 8 session/day for 5 days) at 90% resting motor threshold (MT)
224157591|NCT01940549|DEVICE|Trauma Focused Therapy + tDCS|
224157592|NCT02659137|OTHER|HV measurement|Electrophysiology (EP) study during the TAVI procedure
224157593|NCT04093206|DIETARY_SUPPLEMENT|EpiCor and Vitamin C|One daily dose
224157594|NCT04093206|DIETARY_SUPPLEMENT|Vitamin C|One daily dose
224157595|NCT04724291|DEVICE|MAGNET|This study will test the accuracy of a single-use ingestible video capsule (NaviCamTM, AnX Robotica) which is remotely controlled to record images of the inside of your stomach. Participants in this research study will have symptoms for which an evaluation by a traditional tube-based endoscopy (EGD) is indicated.
224157596|NCT02300506|OTHER|No intervention|
224157597|NCT03185091|OTHER|rapid ventricular pacing|
224157598|NCT03185091|PROCEDURE|Surgery|
224157599|NCT03189563|DRUG|DA-9805 45mg|DA-9805 15mg tid
224157600|NCT03189563|DRUG|DA-9805 90mg|DA-9805 30mg tid
224157601|NCT03189563|OTHER|Placebo|Placebo, tid
224157602|NCT00505544|BEHAVIORAL|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
224157603|NCT00505544|DEVICE|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
224157604|NCT00608244|DRUG|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
224157605|NCT00608244|DRUG|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
224157606|NCT05223686|DRUG|Human CD19-CD22 Targeted T Cells Injection|One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
224303226|NCT00026221|BIOLOGICAL|Recombinant Interferon Alfa|Given SC
224303227|NCT00026221|BIOLOGICAL|Bevacizumab|Given IV
224303228|NCT03178526|DRUG|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
224303229|NCT03178526|DRUG|Placebo|placebo gel
224303230|NCT05623072|DEVICE|Active tDCS|20 min, 2 milliampere (mA), Anodal tDCS in vmPFC
223463530|NCT00664352|DRUG|Placebo|"* 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
223463531|NCT02277275|DIETARY_SUPPLEMENT|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
223463532|NCT02277275|DIETARY_SUPPLEMENT|Placebo|Placebo will be provided to the other two arms for six months
223463533|NCT02317991|DRUG|nab-paclitaxel|nab-paclitaxel 125 mg/m\^2 IV
223463534|NCT02317991|BIOLOGICAL|ramucirumab|Ramucirumab 8 mg/kg IV
223463535|NCT03361462|BEHAVIORAL|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
223463536|NCT02677415|OTHER|Intravenous anesthetics|
223463537|NCT02677415|OTHER|local anesthesia|
223463538|NCT02677415|OTHER|Controlled ventilation|
223463539|NCT02677415|OTHER|Spontaneous breathing|
223463540|NCT03834311|DEVICE|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w
223463541|NCT03834311|OTHER|exercise band strengthening|upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
223463542|NCT02861508|OTHER|Point-of-care ultrasound|
223463543|NCT02861508|OTHER|Usual care|
223463544|NCT05299684|OTHER|EVALUATION|The level of addiction was assessed with the Smartphone Addiction Scale Short Form (SAS-SF). The posture of participants was evaluated by New York Posture Rating Chart (NYPRC), mostly usage smartphone posture, forward head and myofascial trigger points were questioned according to Simon and Travel criteria. Mann-Whitney U test Pearson's chi-squared test were used for analyzing the data.
223463545|NCT05734820|DIAGNOSTIC_TEST|HD- colonoscopy|HD-colonoscopy performed by an expert or non-expert endoscopist. All lesions will be recorded, assessed, and removed for histological analysis.
223463546|NCT05734820|DIAGNOSTIC_TEST|HD-colonoscopy assisted by AI|HD-colonoscopy with AI-assisted polyp detector. New polyps detected by AI will be recorded, removed, and studied.
223463547|NCT03036371|BEHAVIORAL|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
223463548|NCT03112694|OTHER|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
223463549|NCT04536714|BEHAVIORAL|Pythagorean Self-Awareness Intervention program|Stress management program of Pythagorean Self-Awareness Intervention (PSAI), which included eight sessions and lasted for eight weeks. On the first week, a personal session took place for measurements and training in the relaxation technique of diaphragmatic breathing. In the second week, patients attended a group session, in which they were adviced to follow specific directions for a healthy lifestyle, such as organized physical activity, adherence to the Mediterranean diet, creating a daily routine. In the third week, participants were introduced to the cognitive restructuring technique of (PSAI).In the following four group sessions, patients were trained on PSAI and the second relaxation technique, progressive muscular relaxation. In the last week, the final measurements were made. All sessions lasted for 120 minutes, except for the final one, which lasted for 60 minutes.
223463550|NCT02630862|DRUG|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
223463551|NCT02630862|DRUG|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
223463552|NCT05932758|PROCEDURE|Vacuum-assisted excisional biopsy|at least 4g of tissue sampled (excisional biopsy)
223463553|NCT05932758|PROCEDURE|Not excisional biopsy|biopsy with less than 4 g of tissue sampled
223463554|NCT04211350|DEVICE|NightBalance Sleep Position Trainer (SPT)|NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
223463555|NCT04211350|DEVICE|Automatic Positive Airway Pressure (APAP)|Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.
223463556|NCT02178904|PROCEDURE|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
223463557|NCT05240235|OTHER|Education, compression and exercise therapy|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home.
223463558|NCT05240235|OTHER|Education, compression and exercise therapy manual lymph drainage|Education; It includes information about the disease, information about risk factors, information that one should pay attention to, and skin care. For compression, sponge-shaped pads that create compression into the bra and prepared by the lymphedema physiotherapist will be used. The exercises will include breathing and upper extremity joint movement exercises determined by Casley-Smith, and the other days to be applied by the physiotherapist when the patient comes to the session will be applied by the patient once a day at home. In addition, patients will be given manual lymph drainage for one and a half hours every day for the first two weeks. Afterwards, patients will be taken to the same therapy in the hospital for 1 day a week, and on other days they will do self manual lymph drainage at home for 10 minutes.
223463559|NCT00001057|DRUG|Zidovudine|
223463560|NCT00001057|DRUG|Didanosine|
223463561|NCT00480090|DRUG|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
224068088|NCT01582425|DRUG|Methadone|oral
224303231|NCT05623072|DEVICE|Sham tDCS|20 min, vmPFC Sham tDCS
223463562|NCT00877318|DEVICE|SCAD information system|Cardiac rehabilitation at home by telemedicine
223463563|NCT04222920|OTHER|Dose reduction to 2mg/L|Adalimumab dose reduction aiming drug concentration of 2mg/L
224303232|NCT02459496|BEHAVIORAL|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
224303233|NCT04766190|BEHAVIORAL|Group 2: The DISCO App|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.
224303234|NCT04766190|BEHAVIORAL|Group 1: Usual Care|Patients randomized to this arm will receive usual care.
224303235|NCT04766190|BEHAVIORAL|Group 3: The DISCO App + Booster|Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
224303236|NCT02075827|BEHAVIORAL|Competitive video game|1 hour playing video game
224303237|NCT02075827|BEHAVIORAL|Little Big Planet|1 hour playing video game
223463564|NCT04222920|OTHER|Dose reduction to 5mg/L|Adalimumab dose reduction aiming drug concentration of 5mg/L
223463565|NCT04222920|DRUG|Adalimumab|Adalimumab
223463566|NCT05988567|DIETARY_SUPPLEMENT|Placebo candy|consume 2 tablets per day
224303238|NCT03265366|DEVICE|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
224303239|NCT03265366|DEVICE|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
223463567|NCT05988567|DIETARY_SUPPLEMENT|melon and oil olive pressed candy|consume 2 tablets per day
223576415|NCT02163720|DRUG|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
223463568|NCT01437618|DRUG|FOLFOXIRI plus bevacizumab|"* BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~* IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
223576416|NCT05516784|DRUG|Clopidogrel|Comparison of platelet reactivity between clopidogrel and ticagrelor
223576417|NCT05516784|DRUG|Ticagrelor|Comparison of platelet reactivity between clopidogrel and ticagrelor
223576418|NCT03417596|OTHER|Control|Routine treatment
223576419|NCT03417596|BEHAVIORAL|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
223576420|NCT01882049|DEVICE|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
224068089|NCT03269045|DRUG|ORL-1B|Oral ORL-1B
224068090|NCT04081350|DRUG|LY3471851|Administered SC
224068091|NCT04081350|DRUG|Placebo|Administered SC
224068092|NCT04703075|DRUG|Rifapentine 600 mg and INH 300 mg|Participants will receive Rifapentine 600 mg and INH 300 mg
224068093|NCT04703075|DRUG|Rifapentine 900 mg and INH 900 mg|Participants will receive Rifapentine 900 mg and INH 900mg
224068094|NCT05486351|OTHER|Observation|Patients are observed for stroke or systemic embolism and haemorrhagic transformation
224068095|NCT02970448|PROCEDURE|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
224068096|NCT02970448|RADIATION|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
224068097|NCT02970448|DRUG|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
224068098|NCT05622526|DRUG|Group 1 or Experimental group|Capsules of fecal microbiota transplantation
224068099|NCT05622526|OTHER|Group 2 or Control group|capsules of placebo
224068100|NCT02054026|BEHAVIORAL|Reducing the Risk|
224068101|NCT01967550|DRUG|diclofenac diethylamine, DDEA 2.32% gel|
224068102|NCT01967550|DRUG|Placebo|
224068103|NCT05309798|BEHAVIORAL|Evening Fasting|Participants will undertake acute evening fasting (feeding between 8am-4pm) for one day. After which they will attend the laboratory, following a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
224068104|NCT05309798|BEHAVIORAL|Morning Fasting|Participants will undertake an acute morning fasting trial (feeding between 12pm-8pm). After which, participants will visit the laboratory the following day, after a 16 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
224068105|NCT05309798|BEHAVIORAL|Control|Participants will undertake an acute standard western feeding pattern (feeding between 8am-8pm). After which, participants will visit the laboratory the following day, after a 12 h fast, where baseline measures will be taken and the response to a standardised meal will take place. The participant will also have an opportunity to feed ad-libitum before they leave the laboratory.
224068106|NCT01223703|DRUG|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
224068107|NCT01223703|DRUG|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
224071509|NCT03800875|DRUG|27-hour inpatient intervention|Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
223576421|NCT02059551|PROCEDURE|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
223576422|NCT02370004|PROCEDURE|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
223576423|NCT04765423|DEVICE|[F-18] NaF PET/CT|Radiotracer F-18 NaF used on the PET/CT imaging
223576424|NCT04765423|DEVICE|[F-18] fluciclovine PET/CT|F-18 fluciclovine (Axumin ®) used on the PET/CT camera
223576425|NCT02793830|OTHER|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application-BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
223576426|NCT02793830|OTHER|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (\< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
223576427|NCT00390117|DRUG|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
223576428|NCT00390117|OTHER|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
223576429|NCT04389112|OTHER|biopsy|Skin biopsies will be performed according to standard practices in the usual aseptic conditions, the operator wearing sterile gloves. A circular knife 3 mm will be used. Procedure interventions do not involve a drug or a device.
223576430|NCT01205802|PROCEDURE|MHV reconstruction|MHV reconstruction with PTFE or homograft
223576431|NCT04059523|DRUG|S6G5T-3|once daily
223463569|NCT04810988|BEHAVIORAL|Unified Protocol|The Unified Protocol is an empirically supported, transdiagnostic treatment for emotion disorders based on principles of cognitive behavioral therapy. Treatment focuses on increasing awareness of maladaptive thoughts and behaviors and decreasing avoidance of emotions and physiological sensations. Module 1 is focused on increasing motivation, readiness and self-efficacy for change. Module 2 focuses on increasing understanding and awareness of emotions. Module 3 is focused on further expanding awareness of emotions. Module 4 focuses on the role of thoughts in emotional disorders. Module 5 is focused on the role of behaviors in emotional disorders. Module 6 focuses on the role of physical sensations in emotional disorders. Module 7 focuses on exposure to interoceptive and situational triggers for emotions. Module 8 is focused on maintenance of treatment progress and relapse prevention.
223463570|NCT04810988|BEHAVIORAL|Therapist Support|4 video calls with study therapists
223463571|NCT00327340|DRUG|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
223576432|NCT04059523|DRUG|Retin-A® 0.1% Cream|once daily
223576433|NCT00241631|DRUG|Fluticasone Propionate|500 u
223576434|NCT00241631|DRUG|placebo|
223576435|NCT00241631|DRUG|Theophylline|Theophylline placebo capcule
223576436|NCT01188148|DRUG|Memantine|5 mg per day of memantine
223576437|NCT01188148|DRUG|Placebo|
223576438|NCT04999865|OTHER|4-part educational program to build patient-engagement methodology capacity|We created four online training sessions. Our first training for patients/caregivers only (Research 101) was an exception, however, in which we produced a 25-minute asynchronous, self-directed learning seminar intended to be viewed before the subsequent interactive PCOR sessions. Of the three following synchronous interactive training sessions, two included both learner working groups (patients/caregivers and researchers/providers) together (PCOR 101 and PCOR Team Dynamics) and one session (PCOR Study Design) was for researchers/healthcare providers only.
223576439|NCT00800319|DRUG|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
223576440|NCT00800319|DRUG|Placebo|Volume matched placebo; oral solution; single dose
224071510|NCT01479712|PROCEDURE|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
224071511|NCT00291005|DRUG|ARD6562, Docetaxel|
224071512|NCT01150266|DRUG|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
223463572|NCT00327340|DRUG|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
223463573|NCT02935556|OTHER|no intervention|database and epigenetic study
224157607|NCT04350918|DEVICE|Muscle Enery Techniques|Group of patients that underwent muscle energy technique as a mean of treatment for the complaint
223463574|NCT05988762|OTHER|Supramaximal Walkout|Walkout set performed at 110% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
223463575|NCT05988762|OTHER|Submaximal Walkout|Walkout set performed at 30% 1RM. Participant will unrack the weight, step back and brace as if to perform a back squat, hold for 10 seconds, then re-rack the weight without performing the squat.
223576441|NCT03289832|DIETARY_SUPPLEMENT|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
223576442|NCT03289832|DIETARY_SUPPLEMENT|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
223576443|NCT02393846|DRUG|Ketoprofen gel|Topical ketoprofen as used in gel form.
223576444|NCT02393846|DRUG|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
223576445|NCT00004664|DRUG|megestrol|
224157608|NCT04350918|DEVICE|Static Stretching|Set of patients that had static stretching technique for the treatment for the complaint
224157609|NCT02748785|DRUG|Methotrexate|Methotrexate will be continued
224157610|NCT02748785|BIOLOGICAL|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
224157611|NCT02572089|DRUG|Naloxone|
223463576|NCT01116921|DEVICE|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
223463577|NCT01116921|DEVICE|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
223576446|NCT00004664|BEHAVIORAL|Exercise|
223576447|NCT00904618|PROCEDURE|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
223576448|NCT00904618|PROCEDURE|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
224071513|NCT02001233|BIOLOGICAL|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
223463578|NCT01116921|DRUG|Surfactants, Pulmonary|Curosurf®, Chiesi USA, Inc., Cary, NC
223463579|NCT04669431|OTHER|Xbox kinect Training|Xbox kinect 360, Tennis player, Joy riding, Rally ball. Tennis player in first 2 weeks, Joy riding in 3rd and 4th weeks, and all 3 games in 5th and 6th weeks 35 minute/3 days a week for 6 weeks with Conventional physical therapy, 25 minute
224071514|NCT04722172|DRUG|Acalabrutinib|Acalabrutinib for a minimum of 13 cycles and maximum 26 cycles.
224071515|NCT04722172|DRUG|Obinutuzumab|Obinutuzumab will be administered during Cycles 2-7.
224071516|NCT05530798|DEVICE|Definity Perflutren Lipid Microsphere Ultrasound Contrast|"1. Before the spinal decompression surgery has started, the study team will inject the ultrasound contrast to visualize the spinal cord prior to decompression of the spinal cord.~2. After the spinal cord has been decompressed, the study team will inject the ultrasound contrast to visualize the spinal cord directly after decompression of the spinal cord.~3. Prior to completion and closure of the incision, the study team will once more inject the ultrasound contrast to visualize the spinal cord.~4. A member of the research team will follow up with study participants within a week of the procedure by phone. The research staff will also review the participants' medical record for up to 360 days after your procedure to collect information on clinical outcomes and any additional treatments, tests or procedures the study participants may have had."
224071517|NCT01696734|DRUG|Domperidone|Given PO
224157612|NCT04287205|DRUG|Dydrogesterone|79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
224157613|NCT00003282|DRUG|EF5|Given IV
224071518|NCT01696734|OTHER|Questionnaire Administration|Ancillary studies
224071519|NCT04607200|DRUG|AGEN2034|Anti-PD-1 Monoclonal Antibody
224071520|NCT04607200|DRUG|AGEN1884|Anti-CTLA-4 Monoclonal Antibody
224157614|NCT00003282|PROCEDURE|therapeutic conventional surgery|Undergo resection
224157615|NCT00003282|PROCEDURE|biopsy|Undergo biopsy
224157616|NCT00003282|OTHER|pharmacological study|Correlative studies
224157617|NCT04532281|DRUG|Murine CD19 CAR-T cells|Each subject receive murine CD19 CAR T-cells by intravenous infusion
223463580|NCT04669431|OTHER|Conservative Rehabilitation|Sustained Stretching, repetitive task training, activities of daily living( eating, grooming, folding of towel, basket lifting, turn key into lock, reaching forward, sideways reach, ball grasping, picking up small blocks and lifting cane and pencil) 35 minute/3 days a week for 6 weeks
223463581|NCT00006877|DRUG|temozolomide|
223463582|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_Low Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -Low Dose : 7.0X10\^6 cells (Use 3.15X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
223463583|NCT06477744|BIOLOGICAL|Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_High Dose|"1. IP Name : Allogenic embryonic stem cell-derived A9 dopamine progenitor cell (A9-DPC)~2. Main ingredients and quantities: A9-DPC~   -High Dose : 1.4X10\^7 cells (Use 6.30X10\^6 cells of this)~3. Formulation: milky white cell suspension~4. Storage method: Refrigerated storage (5±3℃)~5. Expiration date: within 36 hours of manufacture~6. Frequency: single dosing~7. Method: The subject pierces a burr hole in the skull on the day of surgery. Then the cells are injected at a predetermined stem cell administration point of the putamen in the brain of the subject. One side is administered in three tracks per putamen (6 tracks total brain). Do the same for the other side."
223463584|NCT02477592|PROCEDURE|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
223463585|NCT02477592|PROCEDURE|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
223463586|NCT03144648|OTHER|lifestyle|Observational study
223463587|NCT05517629|OTHER|It is an observational cross-sectional study|It is an observational cross-sectional study
223463588|NCT01460303|DEVICE|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
223463589|NCT01460303|DEVICE|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
223463590|NCT00778596|DRUG|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
223463591|NCT00778596|DRUG|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
223463592|NCT00962312|DRUG|capecitabine|
223463593|NCT00962312|DRUG|lapatinib ditosylate|
223463594|NCT00241202|BEHAVIORAL|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
223463595|NCT05355467|DRUG|Tenofovir disoproxil fumarate|Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.
223463596|NCT05355467|OTHER|Historical Data|Historical Data
223463597|NCT02614989|PROCEDURE|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
223463598|NCT00105612|DEVICE|Memory and Organizational Aid|
223463599|NCT00105612|BEHAVIORAL|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
223463600|NCT03852589|DEVICE|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.
223463601|NCT03852589|DEVICE|Blind|PLMA will inserted by anesthesiologist with digital finger.
223463602|NCT01980433|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
223463603|NCT01980433|OTHER|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
223463604|NCT01980433|OTHER|WCRS|Writer's cramp rating scale
223463605|NCT01980433|OTHER|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
223576449|NCT00904618|DRUG|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
224303240|NCT05296486|PROCEDURE|phacovitrectomy surgery with silicone oil tamponade|Patients in this study will receive phacovitrectomy surgery with silicone oil tamponade.
223463606|NCT01980433|OTHER|visual analog scale of discomfort writing and parameters collected on touchpad|
223463607|NCT02601079|DEVICE|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
224071521|NCT05161377|PROCEDURE|Surgical management|Surgical clipping will be performed following randomization according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
224303241|NCT05296486|PROCEDURE|phacovitrectomy surgery with gas tamponade|Patients in this study will receive phacovitrectomy surgery with gas tamponade
223463608|NCT02601079|DEVICE|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
223463609|NCT00734292|DRUG|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"
223463610|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
223463611|NCT00734292|OTHER|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
223463612|NCT03278821|BEHAVIORAL|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
224068108|NCT04163250|DIAGNOSTIC_TEST|Urinary determination of TIMP-2/ IGFBP7|"Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units."
224157618|NCT04493489|DRUG|Propranolol Hydrochloride|Trial group: BCG + propranolol: after TURBT administered for 2 consecutive years, oral propranolol, starting dose 10mg, tid, then 20mg, tid,lastly increased to 40mg, bid. After the last BCG infusion, propranolol was gradually reduced, in the order of 20 mg, tid to 10 mg, tid.
223463613|NCT03278821|BEHAVIORAL|Expert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
223463614|NCT04958070|OTHER|MPS I|MPS I, symptoms of disease onset , ERT
223463615|NCT05677711|DEVICE|ultimaster|Subjects who received Ultimaster stent will be included.
223463616|NCT03662126|DRUG|KRT-232|KRT-232, administered by mouth
223463617|NCT03662126|DRUG|Best Available Therapy (BAT)|"Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed)."
223463618|NCT01893112|BEHAVIORAL|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training \& Education Center for health).
223463619|NCT01893112|BEHAVIORAL|Breast Cancer Screening|
224157619|NCT04493489|DRUG|BCG|Control group: BCG vaccine: After TURBT, the first year: once a week for 6 times, from the 7th week, once every 2 weeks, and 3 times. Administer once a month starting from the 13th week and continue to give 10 times. Second and third years: once a month, 12 times a year.
224157620|NCT04932694|OTHER|Core stabilization training|Exercise training will be given to the participants in the study group in the form of core training exercises for 8 weeks.
224157621|NCT02616328|OTHER|No intervention|No intervention administered in this study
224303242|NCT05296486|PROCEDURE|phacovitrectomy surgery with balanced saline solution tamponade|Patients in this study will receive phacovitrectomy surgery with balanced saline solution tamponade
223463620|NCT05660278|OTHER|Milk containing A1 and A2 beta-casein|Single dose of milk
223463621|NCT05660278|OTHER|Milk containing only A2 beta-casein|Single dose of milk
223463622|NCT01716806|DRUG|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
223463623|NCT01716806|DRUG|bendamustine|70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
223463624|NCT01716806|DRUG|dacarbazine|375 mg/m\^2 every 3 weeks by IV infusion
223463625|NCT01716806|DRUG|nivolumab|3 mg/kg every 3 weeks by IV infusion
223463626|NCT02597777|OTHER|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
223463627|NCT02597777|OTHER|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
223463628|NCT03403907|OTHER|Probiotic|twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
223463629|NCT00347750|DRUG|Lopinavir pharmacokinetic/pharmacodynamic analysis|
224068109|NCT01640509|RADIATION|treated by synchrotron radiation|treated by synchrotron radiation
224068110|NCT05139186|DEVICE|Artificial Intelligence|Artificial intelligence
224068111|NCT04249687|BIOLOGICAL|botulinum toxin|neuromodulator
224068112|NCT04249687|BIOLOGICAL|Placebo|placebo
224157622|NCT02613338|DEVICE|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
224157623|NCT01018251|OTHER|3'-deoxy-3'-[18F]fluorothymidine|Given IV
224157624|NCT01018251|PROCEDURE|Positron Emission Tomography/computed tomography|
224157625|NCT01018251|RADIATION|FLT-PET/CT|
224157626|NCT05841069|PROCEDURE|Adhesiolysis|Median laparotomy with subsequent detection of intestinal obstruction cause and adhesiolysis.
224157627|NCT05841069|RADIATION|X-ray examination|Plain X-ray of abdomen (1-4 times) with water insoluble contrast.
223576450|NCT04152330|OTHER|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
223576451|NCT05679167|BEHAVIORAL|Supervised digital training with focus on core stability|After randomization, Group 1 will be digitally supervised by experienced physiotherapist.
223463630|NCT00508950|PROCEDURE|Large volume blood draw|Large volume blood draw
223463631|NCT04230369|BEHAVIORAL|Exposure-based Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
223463632|NCT04230369|OTHER|Treatment as usual|Patients randomized to treatment as usual will receive the same medical information that participants in the Internet-CBT get, with physiological information about asthma and the importance of medical adherence to achieve well controlled asthma, but without the exposure-based treatment and no therapist support. All participants in both conditions can use any other available treatment (TAU), but psychological, from pre-assessments to 2 months after treatment completion.
223463633|NCT00831116|DEVICE|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
223463634|NCT03506438|BEHAVIORAL|Needs-focused mobile app|A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.
223463635|NCT03506438|OTHER|Usual care|Usual ICU care as per the standards of the ICU attending
223463636|NCT03894839|OTHER|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
223463637|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
223576452|NCT05679167|BEHAVIORAL|Supervised digital training with focus on aerobic exercise|After randomization Group 2 will be digitally supervised by experienced physiotherapist.
223576453|NCT05679167|BEHAVIORAL|Non-supervised daily physical activity|After randomization Group 3 will receive training instruction regarding daily physical activity.
223576454|NCT01620151|PROCEDURE|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
223576455|NCT00004174|BIOLOGICAL|filgrastim|
223463638|NCT03894839|OTHER|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
223463639|NCT03894839|OTHER|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
223463640|NCT03894839|OTHER|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
223576456|NCT00004174|DRUG|cyclophosphamide|
224068113|NCT01202929|PROCEDURE|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
224068114|NCT03963635|DIAGNOSTIC_TEST|MicroB-plex Lyme Immunoassay|Subject's blood and clinical data are collected to develop a diagnostic immunoassay
224068115|NCT03991689|BEHAVIORAL|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
224068116|NCT04845100|OTHER|Animal Assisted Activity Program|"Animal Assisted Activity Program (HayDAP)~1. st week (Pre-test, introduction-introduction)~2. nd week (Information about cats)~3. th (Cat story reading)~4. th week (Teaching songs, poems, rhymes about cat)~5. th week (Making / decorating a cat house)~6. th week (Participation in the rehabilitation program with the treatment animal)~7. th week (Evaluation and closing, last test)"
224068117|NCT03014401|PROCEDURE|Arthroscopic debridement with stem cell transplantation|Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
224068118|NCT03014401|PROCEDURE|Arthroscopic debridement only|standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
224068119|NCT04169360|DRUG|ANS-6637|White, oblong 300 mg tablet
224068120|NCT04169360|DRUG|Placebo oral tablet|White, oblong 300 mg tablet
224068121|NCT00634153|OTHER|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
223576457|NCT00004174|DRUG|paclitaxel|
223576458|NCT00004174|DRUG|thiotepa|
223576459|NCT00004174|PROCEDURE|peripheral blood stem cell transplantation|
223576460|NCT00004174|RADIATION|radiation therapy|
223576461|NCT00132795|BEHAVIORAL|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
223576462|NCT00132795|BEHAVIORAL|control group|standard care (no added treatment)
224303243|NCT05296486|PROCEDURE|phacoemulsifacation surgery without vitrectomy|Patients in this study will receive phacoemulsifacation surgery without vitrectomy.
224303244|NCT01339663|DRUG|cyclophosphamide|Given IV
224303245|NCT01339663|BIOLOGICAL|aldesleukin|Given SC
224303246|NCT01339663|BIOLOGICAL|autologous tumor cell vaccine|Receive T-APC via IV
224303247|NCT01339663|OTHER|laboratory biomarker analysis|Correlative studies
224303248|NCT01339663|OTHER|immunologic technique|Correlative studies
224303249|NCT01339663|OTHER|immunohistochemistry staining method|Correlative studies
224303250|NCT01339663|GENETIC|polymerase chain reaction|Correlative studies
224303251|NCT01339663|BIOLOGICAL|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
224303252|NCT02998970|DRUG|Empagliflozin|single oral tablet once daily.
224303253|NCT02998970|DRUG|Placebo|single oral tablet once daily.
224303254|NCT06032962|PROCEDURE|salpingectomy|surgical removal of the fallopian tubes
224303255|NCT01985074|BEHAVIORAL|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
224303256|NCT00879892|DRUG|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
224303257|NCT00879892|OTHER|Hypothermia|24 hour, target core temperature 33
224303258|NCT01145430|OTHER|Laboratory Biomarker Analysis|Correlative studies
224068122|NCT05909956|OTHER|KinesioTape|The kinesio tape technique, one of the physiotherapy techniques, is an elastic thin band, water-resistant, air-permeable framework to stimulate muscle movements, assist weak muscles (fascia and soft tissue), reduce discomfort and muscle cramps, facilitate proprioceptive input, boost lymph and blood flow, and relieve pain. Participants in the KT group will receive therapeutic tape on the sacral and suprapubic regions with the Star shape and ligament technique (From initial 4 h to 72 h of the menstruation cycle)
224068123|NCT05909956|OTHER|Sham Tape|This group will receive KT tapping without stretch on the sacral and suprapubic region.
224068124|NCT05909956|OTHER|General Physio session|General physical therapy session including Hot pack (3-5min) and General body stretching(stretching of neck \& upper trapezius, arm \& shoulder girdle, triceps brachii, teres major \& minor, quadriceps muscle iliopsoas muscle, adductors muscle, hamstrings muscle) 30-45 sec each, for 7-10 min, (0-4 week) ,45-60sec each, for 10-15 min(4-8week), 15-20 min(8-12week) will be repeated 2 times/day.
224303259|NCT01145430|DRUG|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
224303260|NCT01145430|OTHER|Pharmacological Study|Correlative studies
224303261|NCT01145430|DRUG|Veliparib|Given PO
223463641|NCT03894839|OTHER|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
223463642|NCT02277483|DRUG|LAIS®|10 X 1,000 / twice a week
223463643|NCT03527277|OTHER|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
223463644|NCT03527277|OTHER|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
223463645|NCT02527629|OTHER|Decellularized human heart valves|Decellularized human aortic heart valves
224068125|NCT05091398|OTHER|Regional analgesia of thoracic surgical patients|ultrasound-guided erector spinae block on T4 and T6 levels ,paravertebral block or intercostal nerve block after the anesthesia induction and turning the patient in the lateral position with 30 mL 0.5% bupivacaine +50 µ adrenaline will be injected by the surgeon through the thoracoscope .
224068126|NCT02425826|DRUG|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
224068127|NCT02425826|DRUG|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
224068128|NCT02425826|DRUG|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
224068129|NCT00525655|BEHAVIORAL|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
224068130|NCT00525655|BEHAVIORAL|Questionnaire|Questionnaires taking 10-15 minutes to complete.
224068131|NCT04874987|OTHER|Simulation based learning with Advocacy inquiry and ladder of influence|Simulation scenarios based on identified gender and equity gaps. We will explore experiences of male and female participants, and inter-professional simulation participants (e.g nurses and doctors, medical and nursing students) post intervention exposure on their role and experiences in simulated sessions and clinical care experiences
224068132|NCT04676997|BIOLOGICAL|Camrelizumab|200mg on days1,15 of Cycles 1-4 (Q2W); IV infusion. 200mg on day 1 of Cycles 5-8 (Q2W); IV infusion.
224068133|NCT04676997|DRUG|Nab paclitaxel|125 mg/m² on day 1, 8 and 15 of Cycles 1-4 (QW 3/4); IV infusion.
224068134|NCT04676997|DRUG|Epirubicin|90 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
224068135|NCT04676997|DRUG|Cyclophosphamide|600 mg/m² on day 1 of Cycles 5-8 (Q2W); IV infusion.
224068136|NCT05667896|DRUG|glucocorticoid + tacrolimus|Prednisone 0.4-0.5mg/kg/d; Tacrolimus 0.05-0.10mg/kg/d, oral administration in two times, with an interval of 12h. The drug valley concentration is 5-10ng/ml, which will be gradually reduced to a low dose after it becomes effective.
224068137|NCT02707783|DEVICE|Bioresorbable vascular scaffold (BVS) implantation|
224068138|NCT04554160|DEVICE|Loop recorder implantation|A loop recorder is implanted in the start of the study after informed consent is signed and enables continuous cardiac monitoring.
224068139|NCT04554160|DEVICE|A smartwatch|A subgroup of the patients will be given an apple watch after informed consent to enables continuous monitoring via this non-invasive modality.
224068140|NCT02202629|OTHER|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
224068141|NCT05184608|OTHER|Cycling exercise|20 minutes of cycling (90 rpm).
224068142|NCT05184608|OTHER|Cognitive tasks|20 minutes of cognitive tasks based on the different domains of the UPDRS scale.
224068143|NCT04253795|OTHER|Laryngeal mask|After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.
223463646|NCT05525351|DEVICE|Bispectral index (BIS) or Patient State Index (PSI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI). BIS is maintained between 40 - 60 and PSI between 25 - 50. The vital signs, BIS or PSI are recorded automatically and continuously through computerized software. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
223463647|NCT05525351|DRUG|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
223463648|NCT05525351|DRUG|Alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
223463649|NCT05525351|DRUG|Dexmedetomidine|The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
223463650|NCT06141785|OTHER|Nutritional intervention|An individually targeted nutritional intervention, and a simple home-based physical exercise program. The Nutritional intervention will be delivered by a clinical dietitian, from treatment initiation and throughout the treatment trajectory
223463651|NCT00270452|DRUG|WT1 and PR1 Peptide Vaccine|
223463652|NCT03979066|DRUG|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
223463653|NCT03979066|DRUG|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
223463654|NCT03904823|DRUG|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
223463655|NCT03904823|DRUG|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
223463656|NCT05975814|DEVICE|dental implant|dental implants are placed as usual and require a healing abutment. Abutments can be straight or concave, both are equally available on the market.
223463657|NCT03316586|DRUG|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
223463658|NCT03316586|DRUG|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
223463659|NCT05868317|DRUG|Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan)|"Induction chemotherapy with six cycles of modified 5 fluorouracil,oxaliplatin and irinotecan followed by short course radiotherapy (RT) (5x5 Gy), then two cycles of 5 fluorouracil and oxaliplatin based chemotherapy and surgery will be performed 6 to 8 weeks after completion of RT.~After surgery , continuation of chemotherapy with 4 cycles of 5 fluorouracil and oxaliplatin regardless of pathological response"
223463660|NCT05868317|RADIATION|Radiotherapy|Short Course Radiotherapy
223463661|NCT03070795|PROCEDURE|early feeding|start oral sips four hours after cesarean section
223463662|NCT03070795|PROCEDURE|delayed feeding|start oral feeding on post operation day 1 (\>12hours) after surgery
223576463|NCT04526353|DRUG|Oxybutynin 1 mg/ml Syrup|"The Investigational Medicinal Product of this study is Oxybutynin 1 mg/ml Syrup (see Annex 1 for the Monograph of PMS-Oxybutynin provided by ANSM under the ATU.). It will be administered at the dose of 0.1 mg/kg/twice a day to patients randomized to the study treatment group. The dose will be adapted to the child's weight to the nearest kilogram.~The recommended dosage for older children with neurologic bladder is 0.3 to 0.4mg/kg/day, whilst the dosage we will be using is effectively 0.2mg/kg/day. This is because we are taking into account the absence or pharmacological studies of oxybutynin use in children \<1 year of age, as well as their specific liver metabolism. Furthermore, the dose of 0.1mg/kg twice daily is the dose used in children within the same age group in the study by Casey et al, 2012"
223576464|NCT01767077|DIETARY_SUPPLEMENT|Butter oil|Daily intake of 40 g butter oil
223576465|NCT01767077|DIETARY_SUPPLEMENT|Cream|Daily intake of 100 g cream (40%)
223576466|NCT00237068|DRUG|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
224068144|NCT04253795|OTHER|double lumen tube|After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
224068145|NCT01950000|DRUG|Fentanyl|
224068146|NCT01950000|OTHER|Placebo|
224068147|NCT02337400|BEHAVIORAL|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
224068148|NCT02337400|BEHAVIORAL|15 minute counseling interview|
224068149|NCT02152852|BEHAVIORAL|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
223576467|NCT04270162|DEVICE|Respiratory muscle training 1|"For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups."
223576468|NCT04270162|OTHER|Respiratory muscle training 2|"Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups."
223576469|NCT04270162|OTHER|Respiratory muscle training 3|The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
223576470|NCT01980277|DRUG|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
223576471|NCT01909180|DEVICE|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
223576472|NCT02838615|PROCEDURE|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
223576473|NCT04947878|OTHER|Prompt list|The patients in the intervention group will review a prompt list before their visit.
223576474|NCT05357963|PROCEDURE|Sternotomy application|The chronic pain findings of the patients who underwent sternotomy will be questioned at the postoperative 3rd month.
223576475|NCT01355263|DRUG|iron and vitamin a|
223576476|NCT04119622|DRUG|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
223576477|NCT04119622|DRUG|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
223576478|NCT04119622|DRUG|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
223576479|NCT01053559|DRUG|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
223576480|NCT03622671|PROCEDURE|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
223576481|NCT03622671|PROCEDURE|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
223576482|NCT06464900|BEHAVIORAL|Routine Care|Provide patients with regular medication guidance, dietary guidance, exercise guidance and knowledge about diabetes mellitus and hypoglycaemia; test and record blood glucose regularly every day; answer patients' clinical questions and provide psychological support in a timely manner.
223576483|NCT06464900|BEHAVIORAL|Based on BCW Theory of Health Education|BCW theory was applied to analyse behaviour and develop interventions in terms of capability, motivation and opportunity. Capability: Intensive daily management of diabetes through intervention functions (education, training, persuasion, modelling) to change attitudes and habits, understand the negative consequences of fear of hypoglycaemia, improve hypoglycaemia awareness and self-regulation skills. Opportunity: Through the intervention function (education, training, realization) to improve the awareness of hypoglycemia awareness, timely detection of hypoglycemia. In the event of a hypoglycaemic event patients know how to deal with it. Motivation: Through intervention functions (environmental reconstruction, realisation) that take full account of external factors and their own opportunities. Glucose management through microsoft platforms, on-site teaching and coaching by specialist nurses to create opportunities for patients who can change excessive/avoidant behaviours.
223576484|NCT04080479|DIAGNOSTIC_TEST|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
223576485|NCT04080479|DIAGNOSTIC_TEST|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
223576486|NCT04080479|DIAGNOSTIC_TEST|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
223576487|NCT04080479|DIAGNOSTIC_TEST|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
223576488|NCT04080479|DIAGNOSTIC_TEST|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
224068150|NCT02446431|DRUG|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
224068151|NCT02446431|DRUG|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
224157628|NCT05841069|PROCEDURE|Conservative treatment|A set of measures aimed at non-operative resolution of acute intestinal obstruction - nasogastric tube, infusion therapy.
224303262|NCT03347422|DRUG|sutimlimab (BIVV009)|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
223463663|NCT06106230|COMBINATION_PRODUCT|Bee venom phonophoresis|Bee venom gel preparation with low freq ultrasound Bee venom solution (100 mg/mL) that was prepared and preserved at the correct temperature was purchased from the Egyptian Organization for Biological Products \& Vaccines (Vacsera). The solution was a mix of a crude form of BV dissolved in sterile normal saline with a concentration ratio of 1:1 vol/vol. Then, the BV gel was prepared at the laboratories of the Faculty of Pharmacy, Modern University, Cairo, Egypt, by dissolving the previous mixture in 10% propylene glycol, followed by the addition of 0.01% butylparaben. To make bee venom gel, the resulting mixture was mixed with the matrix. The BV gel had a homogeneous and translucent appearance and a pH of 7.53. There was no discoloration, phase separation, or off-putting odor. Stratification was not observed after 30 min of centrifugation at 2,500 rpm at 25◦C, used with low frequency ultrasound Device: low intensity ultrasound
223463664|NCT04232930|OTHER|Music|Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
223463665|NCT01491022|DRUG|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
223463666|NCT01491022|DRUG|placebo first, then Ampyra|placebo
223463667|NCT03934216|DRUG|BMS-986165|Specified Dose on Specified Days
223463668|NCT03934216|OTHER|Placebo|Specified Dose on Specified Days
223463669|NCT01065753|BEHAVIORAL|Lifestyle Counseling|Diet control with exercise
223463670|NCT06506201|DEVICE|Velys hip navigation|Computer assisted surgery
223463671|NCT06506201|PROCEDURE|Standard of care|surgery without navigation
223463672|NCT03729050|BEHAVIORAL|Rehabilitation Coordinator in Specialist Psychiatry|Rehabilitation Coordinator service in Specialist Psychiatry
223463673|NCT03790410|OTHER|Complex pulmonary rehabilitation|Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
223463674|NCT03790410|OTHER|Inspiratory muscle training|The training program contains strengthening exercises on the diaphragm muscle.
224157629|NCT05077280|RADIATION|stereotactic body radiotherapy|Stereotactic Body radiotherapy will be given to 1-5 target metastases in 3 doses over 8 days or less. Each dose will be 15Gy for a total dose of 45GY
224157630|NCT05077280|DRUG|Immunotherapy|Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
224303263|NCT03347422|DRUG|placebo|Pharmaceutical form: solution for injection Route of administration: intravenous (i.v.)
224303264|NCT02255825|GENETIC|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
224303265|NCT02255825|PROCEDURE|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
223463675|NCT05633433|DRUG|Azvudine|Azvudine is a novel nucleoside reverse transcriptase inhibitor.
223463676|NCT05633433|DRUG|Placebo|Placebo
223463677|NCT01095497|BIOLOGICAL|CINRYZE|C1 esterase inhibitor (human)
223463678|NCT01712828|DRUG|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
223463679|NCT01712828|DRUG|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
223463680|NCT01712828|DRUG|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
223576489|NCT04080479|DIAGNOSTIC_TEST|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
224157631|NCT03600220|OTHER|acupuncture|antihypertension drug, acupuncture twice a week for 3 months
223463681|NCT01712828|DRUG|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
223463682|NCT04021966|PROCEDURE|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
223463683|NCT00228163|DRUG|teriflunomide (HMR1726)|tablet, oral administration once daily.
223463684|NCT04135404|OTHER|health-related telephone surveys|The Behavioral Risk Factor Surveillance System (BRFSS) is a health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services (Secondary-data analysis).
223463685|NCT01317147|PROCEDURE|Roux-en-Y gastric bypass (RYGBP)|
223576490|NCT05867290|BEHAVIORAL|Mindful music-listening with sleep hygiene|5 week intervention consisting of sleep hygiene (week 1) and daily bedtime mindful music-listening for 30 minutes or until about to fall asleep, if sooner (weeks 2-5)
223576491|NCT00454753|DRUG|Dasatinib|
224157632|NCT05659004|BEHAVIORAL|Qualitative interview|No intervention
224157633|NCT02579551|PROCEDURE|Therapeutic Conventional Surgery|Undergo surgical excision
224157634|NCT03687931|DRUG|Dexamethasone|Drop
224157635|NCT05367921|DEVICE|Measurement of compartment compressibility|Application of the CPM#1 device for compartment compressibility ratio measurement - 4 measurements on both legs of each healthy volunteer will be performed
224303266|NCT02255825|OTHER|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
224303267|NCT05268263|DEVICE|Artificial Intelligence Algorithm|The enrolled population will include patients with a history of lung pathologies. Artificial intelligence-based models are developed for classification of wheezes, crackles and normal lung sounds. These AI models will be tested and assessed on local lung sounds clinical data.
224303268|NCT02905214|DEVICE|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
224303269|NCT06073210|BEHAVIORAL|Motor Imagery plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
224157636|NCT00698139|DEVICE|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
224157637|NCT02937090|OTHER|Blood Draw|Blood sample will be drawn from participants at study entry.
224157638|NCT02937090|OTHER|Stool collection|Stool will be collected from participants at study entry.
223463686|NCT01071174|OTHER|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
223463687|NCT01071174|OTHER|Placebo|Vaginal Ring containing no drug substance
223463688|NCT03645642|DRUG|Midodrine|Midodrine 5 mg thrice daily
224157639|NCT01685060|DRUG|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
224157640|NCT00547989|DRUG|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
224157641|NCT00547989|DRUG|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
224157642|NCT00547989|DRUG|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
224157643|NCT04719533|OTHER|Pre-marking of episiotomy location|A template marking the pre-determined correct location of episiotomy will be used to mark to women in the interventional group
224157644|NCT04006704|DRUG|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
224157645|NCT03132441|OTHER|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
224157646|NCT03597503|DRUG|SPN-810|Flexible dose
224157647|NCT03597503|DRUG|Placebo|Placebo
224157648|NCT04023136|PROCEDURE|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
224157649|NCT05932381|OTHER|Complete decongestive therapy|the patients will receive Complete decongestive therapy in the form of intermittent pneumatic compression, Exercising, bandaging, and manual lymphatic drainage with Pressures of 50, 80, and 120 mmHg and timing 5, 20, and 50 secs
224157650|NCT05932381|OTHER|Medical treatment|the patients will receive routine medical treatment
224157651|NCT01399255|BIOLOGICAL|Insulin lispro|Dosage form- Subcutaneous Injection
224157652|NCT01318525|DRUG|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
224157653|NCT01318525|DRUG|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
224157654|NCT01506219|PROCEDURE|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
224157655|NCT05666908|DEVICE|HFNO|After the patient's mask-assisted ventilation makes the end-expiratory oxygen concentration (EtO2) \> 90%, wear the HFNO device according to the pre-adjusted mode (temperature 34°C, oxygen concentration 100%, flow rate 50 litres per minute). The nasal cannula will remain in place until intubation is complete (including DLT intubation, direct FOB guidance, and DLT alignment with FOB). After securing the HFNO device, the glottis was exposed using a laryngoscope, and the DLT main tracheal cuff was passed through the glottis and paused under direct vision. Insert the DLT into the bronchial tube lumen of the DLT using the FOB, and then advance the DLT into the corresponding main bronchus under the guidance of the FOB. After confirming the appropriate depth of the catheter using the FOB, insert the DLT into the anesthesia machine to complete the intubation process. After the DLT was connected to the anesthesia machine and mechanical ventilation was started, the HFNO device was removed.
224157656|NCT01847690|DRUG|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
224157657|NCT05058118|DRUG|FL058|50mg、250mg、500mg、1000mg、1500mg、2000mg
224157658|NCT05058118|DRUG|Placebo|empty bottle
224157659|NCT01337518|DRUG|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
224157660|NCT04695236|DEVICE|ZOLL Intravascular Temperature Management system, Quattro catheter|ZOLL Intravascular Temperature Management system, Quattro catheter
224157661|NCT04695236|OTHER|Standard Treatment|Standard Treatment for Ischemic Strokre
224157662|NCT01013090|DRUG|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
224157663|NCT01013090|DRUG|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
224157664|NCT04921657|DRUG|Rosuvastatin 10mg|
224157665|NCT00033592|OTHER|placebo|
224157666|NCT00033592|DRUG|bupropion hydrochloride|
224157667|NCT00033592|DRUG|nicotine|
224157668|NCT01841489|DRUG|Treatment A|1600 mg GS-9973 (Formulation 1)
224157669|NCT01841489|DRUG|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
224157670|NCT01841489|DRUG|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
224157671|NCT01841489|DRUG|Treatment D|1600 mg GS-9973 (Formulation 2)
224157672|NCT01841489|DRUG|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
224157673|NCT01841489|DRUG|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
224157674|NCT01841489|DRUG|Treatment G|1600 mg GS-9973 (Reference formulation)
224157675|NCT01841489|DRUG|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
223576492|NCT02723370|BEHAVIORAL|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
223576493|NCT03213574|OTHER|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
223463689|NCT03645642|BIOLOGICAL|Albumin|Albumin 20g/l
223463690|NCT03645642|DRUG|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
223463691|NCT01396083|DRUG|Ranibizumab|
223463692|NCT01396083|DRUG|Dexamethasone implant and sham injections|
223576494|NCT03213574|OTHER|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
223576495|NCT00808535|PROCEDURE|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
223576496|NCT04612660|BEHAVIORAL|Education on cervical cancer prevetnion|Motivational group education by trained bilingual community health educators (CHEs) on cervical cancer prevention
223576497|NCT04612660|BEHAVIORAL|Dynamic group interaction|Dynamic group interaction and role play discussion sessions on the benefits of Self-Sample collection HPV testing and procedures;
223576498|NCT04612660|BEHAVIORAL|Physician engagement|Engaging community bilingual physicians in cervical cancer screening and referral;
223576499|NCT04612660|BEHAVIORAL|Patient Navigation|Patient navigation assistance will be provided to participants who tested HPV positive for further diagnostic testing and treatment.
223463693|NCT02553824|DRUG|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
223576500|NCT04612660|BEHAVIORAL|General Health Education|general health education focusing on healthy lifestyle, and prevention of disease through routine health examinations.
223576501|NCT03032614|DRUG|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
223576502|NCT03032614|DRUG|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
223576503|NCT03032614|DRUG|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
223576504|NCT02731222|OTHER|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
223576505|NCT03589391|DEVICE|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
223576506|NCT02416986|BEHAVIORAL|6 hour smoking abstinence|
224071522|NCT05161377|PROCEDURE|Endovascular management|Endovascular treatment will also be performed following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents, flow-diverters, ISFD/WEBs or other innovative devices, as well as post- treatment medical management issues, will be left up to the physician performing the endovascular treatment and initial strategies determined prior to randomization.
224071523|NCT06851312|PROCEDURE|Minimal invasive hemorrhoidectomy|We propose applying minimally invasive surgery in open excisional hemorrhoidectomy, the most effective technique for treating advanced hemorrhoidal disease. We believe this approach will reduce postoperative pain and improve recovery while maintaining the excellent outcomes of OEH. Our hypothesis is based on the reduced tissue trauma and increased precision provided by minimally invasive surgery.
224071524|NCT06504459|DRUG|Azacitidine|Given IV or SC
224071525|NCT06504459|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224071526|NCT06504459|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration and biopsy
224071527|NCT06504459|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow aspiration and biopsy
224071528|NCT06504459|DRUG|Cladribine|Given IV
224071529|NCT06504459|DRUG|Cytarabine|Given SC
224071530|NCT06504459|PROCEDURE|Echocardiography|Undergo ECHO
224071531|NCT06504459|PROCEDURE|Lumbar Puncture|Undergo LP
224071532|NCT06504459|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
224071533|NCT06504459|OTHER|Questionnaire Administration|Ancillary studies
224071534|NCT06504459|DRUG|Venetoclax|Given PO
224071535|NCT00472433|DRUG|Alemtuzumab|
224071536|NCT05176119|DRUG|Nalbuphine Injection|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
224071537|NCT05176119|DRUG|Ketamine|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
224071538|NCT05176119|DRUG|Saline|At the end of the surgery and just before discontinuation of sevoflurane and extubation the study medications will be prepared by the local pharmacy as 10 ml syringes that were handed to the anesthesiologist in charge in OR room who was blinded to the nature of the medications.
224071539|NCT06967519|DRUG|Artemether-lumefantrine (AL)|Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine
224071540|NCT06967519|DRUG|artesunate-amodiaquine (AS-AQ)|Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing
224071541|NCT01708109|OTHER|no measures taken to clear bile ductus|biliary calculus remain
224157676|NCT01841489|DRUG|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
224303270|NCT06073210|BEHAVIORAL|Action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a action observation intervention (observing movements without actually doing them).
223576507|NCT02416986|BEHAVIORAL|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
224157677|NCT01841489|DRUG|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
224157678|NCT05478538|PROCEDURE|Core Needle or Forceps Biopsy|Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
224157679|NCT03320486|DRUG|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
224303271|NCT06073210|BEHAVIORAL|Sham action observation plus therapeutic exercise|Aerobic exercise (20 minutes) and strengthening exercise (15 minutes) to which will be added a sham action observation intervention (observing space planets).
224303272|NCT03683524|DRUG|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
224303273|NCT03683524|DRUG|Current ART|To continue with their current ART
224303274|NCT06155058|PROCEDURE|SYREBO|Serial ADL training of upper extremities with robotic aid
224303275|NCT06155058|PROCEDURE|Conventional Mirror Method|Serial ADL training of upper extremities assisted by physical therapist
224303276|NCT04719520|BEHAVIORAL|wireless vibrating caller|using the wireless vibrating caller to notify the patient's family to the operating room
224303277|NCT00567866|DRUG|Quetiapine|50 or 100 mg of quetiapine orally
224303278|NCT05183217|BEHAVIORAL|Online Continence promotion program without tailoring|The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.
224303279|NCT05183217|BEHAVIORAL|Online Continence promotion program with tailoring|"The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention."
224303280|NCT04619719|DEVICE|Hyperbaric Oxygen Therapy (HBOT)|Patients assigned to the treatment arm will receive up to 5 treatments of hyperbaric oxygen therapy administered daily at 2.0 atmospheres for 90 minutes per session.
224303281|NCT03300544|DRUG|Capecitabine|Given PO
224303282|NCT03300544|DRUG|Fluorouracil|Given IV
224303283|NCT03300544|DRUG|Leucovorin|Given IV
224303284|NCT03300544|DRUG|Oxaliplatin|Given IV
223576508|NCT02416986|BEHAVIORAL|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
224303285|NCT03300544|RADIATION|Radiation Therapy|Undergo chemoradiation
224303286|NCT03300544|BIOLOGICAL|Talimogene Laherparepvec|Given intralesionally
224303287|NCT03269331|BEHAVIORAL|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
224303288|NCT06197958|OTHER|eccentric exercises|eccentric exercises like walking down stairs, lowering a weight during shoulder press, the downward motion of squatting, the downward motion of a push-up, lowering the body during a crunch, lowering the body during a pull-up 3 sets with 10 RM (repetition maximum) for six week training.
224303289|NCT06197958|OTHER|concentric exercises|concentric exercises like walking upstairs, pushing up in a bench press, the beginning portion of a deadlift when you lift the barbell off the ground, sitting up in a sit up, pushing up from a lowered push-up and standing up in a back squat 3 sets with 10 RM.
224303290|NCT05535985|DEVICE|acupuncture|treatment of pain or disease by inserting the tips of needles at specific points on the skin
224303291|NCT05535985|DEVICE|placebo acupuncture|placebo acupuncture
224303292|NCT02866045|PROCEDURE|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
223463694|NCT02553824|DRUG|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
224157680|NCT03320486|DRUG|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
224157681|NCT04894357|OTHER|Phenotypic resistance measure|SDM experiments: Reverse transcriptase mutants of HIV-1 will be obtained by site-directed mutagenesis using specific primers introducing the expected mutations into plasmids pNL4.3 and CRF02\_AG. HIV-1 stocks will be obtained by transfecting 293-T cells with the various HIV-1 molecular clones. 48 hours after transfection, the viral supernatants will be recovered, quantified for HIV-1p24gag antigen (Vidas BioMérieux) and frozen at -80°C.The single-cycle virus titers will be determined on HeLa-P4 cells in which the expression of b-galactosidase is inducible by the HIV Tat protein. Phenotypic analysis: creation of replication competent chimeric viruses through homologous recombination between patient or laboratory virus-derived PCR fragments and the corresponding NL4-3 vector where the whole Gag-PR, RT-RNaseH or IN coding regions have been deleted through inverse PCR. The susceptibility to Doravirine will be calculated through a single round infection assay in TZM-bl cells.
223463695|NCT02513004|DRUG|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
223463696|NCT02513004|DRUG|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
223463697|NCT03159936|BIOLOGICAL|Tofacitinib citrate|10 mg daily by mouth
223463698|NCT04993573|OTHER|Questionnaire|Questions about the impact of COVID-19 in their works
223463699|NCT04993573|OTHER|Individual interview|Discussion between the searcher and the participant about representations of COVID-19 and experiences about confinement.
223463700|NCT00004246|DRUG|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
223463701|NCT00004246|RADIATION|Radiation Therapy (RT)|Days 1-5 for 7 weeks
223463702|NCT00383201|DEVICE|OptiFree Multi-Purpose Disinfecting Solution|
223463703|NCT03632564|DEVICE|REVIVIEW dichoptic audio-visual stimulation|REVIVIEW dichoptic audio-visual stimulation using video goggles
223576509|NCT02477735|DEVICE|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
224157682|NCT04979962|DEVICE|EW10-EC02 (Endoscopy Support Program)|EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.
223576510|NCT03551977|BEHAVIORAL|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
223576511|NCT03551977|BEHAVIORAL|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
223576512|NCT03630198|DRUG|Corticosteroid with lidocaine|Intralesional corticosteroid injection
223576513|NCT03630198|DRUG|Corticosteroid with normal saline|Intralesional corticosteroid injection
223576514|NCT00167102|DRUG|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
223576515|NCT01107600|PROCEDURE|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
223576516|NCT04129905|BIOLOGICAL|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
223463704|NCT02806713|DRUG|Phenazopyridine|
223463705|NCT02806713|OTHER|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
223463706|NCT00735709|DRUG|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
223463707|NCT00735709|DRUG|Placebo|Vortioxetine placebo-matching capsules
223463708|NCT03485443|DRUG|%0.9 NaCl 10ml/kg|Fluid administration
223463709|NCT03485443|DRUG|%0.9 NaCl 20ml/kg|Fluid administration
223463710|NCT00524927|DRUG|Methoxyflurane|
223463711|NCT00524927|DRUG|Normal Saline|
223463712|NCT03056521|OTHER|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
223463713|NCT00345917|DEVICE|Retinal transplantation instrument|
223463714|NCT00345917|DEVICE|Fetal tissue.|
223463715|NCT05428956|PROCEDURE|Single Inhalation technique|Single maximal inhalation with breath hold technique
223463716|NCT05428956|PROCEDURE|Tidal inhalation technique|5 tidal breaths technique
224157683|NCT01207674|OTHER|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
223463717|NCT04488445|BEHAVIORAL|Strength training|3 sets of 3 to 5 repetitions with 4 minutes of rest between sets. 90% load of 1 maximum repetition of a resistance exercise
223463718|NCT04488445|BEHAVIORAL|Stretch and balance training|3 sets of 3 exercises of stretching and balance of one minute each. One minute of resting time between sets.
223463719|NCT06431464|OTHER|picosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
223463720|NCT06431464|OTHER|nanosecond laser treatment + measurement with a multiphoton tomography system|Patients with unwanted tattoos who plan a laser treatment will be recruited for measurements using a multiphoton-tomography system. These are scheduled 6 weeks and 12 weeks post-treatment.
223463721|NCT01165307|DRUG|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
223463722|NCT01165307|DRUG|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
223463723|NCT01165307|DEVICE|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
223463724|NCT03569501|DIETARY_SUPPLEMENT|DHA|500 mg DHA tablets
223463725|NCT03569501|DIETARY_SUPPLEMENT|oat grains|90 mg oat, containing 4.05 mg β-glucan
223463726|NCT05175781|DRUG|Dexmedetomidine Hydrochloride|is a sympatholytic drug that acts as an agonist of α2-adrenergic receptors in certain parts of the brain.
223463727|NCT05175781|DRUG|Ketamine Hydrochloride|Ketamine is an NMDA receptor antagoni
224157684|NCT04949425|DRUG|Adavosertib|Patients will receive Adavosertib orally.
224157685|NCT05212402|DIETARY_SUPPLEMENT|Cannabinol|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
224157686|NCT05212402|OTHER|Placebo|Prospective,1:1 randomization and stratified by birth sex, and double-blinded to the condition of subjects.
224157687|NCT01319513|OTHER|whey protein bolus|single dose of 25 g whey protein
224157688|NCT01319513|OTHER|whey protein pulses|10 2.5 g pulses of whey protein
224157689|NCT00619606|DEVICE|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
224157690|NCT00619606|DEVICE|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
224157691|NCT00619606|DEVICE|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
224157692|NCT00619606|DEVICE|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
224157693|NCT05537506|DEVICE|Bracket slot 0.018|That includes12 patients who will be treated using the bracket slot 0.018×0.025-inch system.
224157694|NCT05537506|DEVICE|Bracket slot 0.022|Includes12 patients who will be treated using the bracket slot 0.022×0.028-inch system
223463728|NCT05175781|DRUG|Placebo|Normal saline
223463729|NCT02492802|DRUG|posaconazole|collection plasma samples for measuring posaconazole drug concentration
223463730|NCT03060304|DRUG|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
223463731|NCT03060304|DRUG|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
224157695|NCT02944513|DEVICE|Quell|
224157696|NCT04203108|DRUG|ATG|In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
224157697|NCT04203108|DRUG|CsA|In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
224157698|NCT04203108|DRUG|MTX|In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).
224157699|NCT04203108|DRUG|MMF|In both groups, MMF will be administrated at a dose of 1.0g/d.
223463732|NCT02920190|DRUG|Liraglutide|1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months
223463733|NCT05466721|DEVICE|Hydrustoma C3|The participant will use the device for 14 days.
224157700|NCT04263415|DRUG|Semaglutide|semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
223463734|NCT05466721|DEVICE|Coloplast Alterna|The participant will use the device for 14 days.
223463735|NCT01126099|DRUG|Prazosin|4 mg capsules twice daily for 12 weeks
224157701|NCT04263415|OTHER|Placebo|once-weekly injection with placebo pen for 16 weeks
224157702|NCT02619006|OTHER|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
224157703|NCT03921606|BEHAVIORAL|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
223463736|NCT01126099|DRUG|Placebo|Placebo capsules twice daily for 12 weeks
223463737|NCT00311493|BIOLOGICAL|Tick-Borne Encephalitis vaccine|
223463738|NCT02355717|OTHER|Observational Study|
223463739|NCT03535961|DRUG|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
223463740|NCT00015704|DRUG|Aldesleukin|
223463741|NCT00692380|RADIATION|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
223463742|NCT05726435|DIETARY_SUPPLEMENT|Soluble dietary fiber with prebiotic properties|14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. The Nutriose group in this particular intervention contains 7 randomy selected players.
223463743|NCT05726435|DIETARY_SUPPLEMENT|Placebo|"14 adult professional baskeyball players will be divided randomly in two groups, each containing 7 players. One group shall receive Nutriose fiber, two times per day 10 grams per dose in total duration of 4 weeks. Second group shall receive same amount of Placebo in form of Maltodextrin. Each group will undergo a series of sports performance tests and questionnaires and shall donate their feces several times during the study in order to monitor gut microbiota changes. This second (Placebo) group also consists of the 7 players and receives Maltodextrin supplementation. Since the study type is double-blind, neither the participants (players) nor the person handing out the supplementation know the exact nature of fiber substance being handed during the entire duration of the trial. Independent statistician is handling the randomization of both interventions."
223463744|NCT02955875|BEHAVIORAL|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
223463745|NCT04531423|DRUG|SSRI + golimumab|Golimumab will be administered at the dose of 50mg every month during the acute phase.
223463746|NCT04531423|OTHER|SSRI + placebo|placebo
223463747|NCT04531124|OTHER|integrated management|establish an integrated management on cardio-metabolic risk factors including hypertension by updating and upgrading the daily practice of practitioners and screening patients
223463748|NCT06151808|DRUG|XTR006|All participants will receive a single intravenous dose of 8.0-10.0mCi of XTR006 followed by PET scan
223463749|NCT03646942|RADIATION|low level laser therapy|low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.
223463750|NCT03646942|DEVICE|Lingual Orthodontics|Lingual braces will be used to conduct the orthodontic treatment of patients with moderate level of crowding on the upper dental arch.
223463751|NCT03290430|BEHAVIORAL|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
223463752|NCT03290430|BEHAVIORAL|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
223463753|NCT03290430|BEHAVIORAL|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
223463754|NCT03290430|BEHAVIORAL|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
223463755|NCT03290430|BEHAVIORAL|Texting support|Texts with smoking cessation support throughout the program
223463756|NCT03290430|DRUG|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
223576517|NCT04129905|DIAGNOSTIC_TEST|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
223463757|NCT02976246|DIETARY_SUPPLEMENT|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
223463758|NCT02976246|OTHER|Placebo|One tablet of placebo given once daily.
223463759|NCT02777905|BEHAVIORAL|Mindfulness Based Cognitive Therapy|
223576518|NCT04129905|DIAGNOSTIC_TEST|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
223576519|NCT04129905|DIAGNOSTIC_TEST|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
223576520|NCT04129905|DIAGNOSTIC_TEST|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
223576521|NCT04129905|DIAGNOSTIC_TEST|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
223576522|NCT04129905|BIOLOGICAL|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
224071542|NCT01708109|PROCEDURE|clearance of bile ductus|biliary calculus removed at surgery
224071543|NCT02579070|DEVICE|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
224071544|NCT00039793|PROCEDURE|Moderate-intensity and low-intensity bodywork therapy|
224071545|NCT05656352|DEVICE|Masimo Total Hemoglobin SpHb® Continuous Non-invasive Hemoglobin Monitoring Device|Masimo Radical-67® Pulse CO-Oximeter and rainbow® sensors.
224071546|NCT05656352|DIAGNOSTIC_TEST|Complete Blood Count|The test will be done using venous blood collected in EDTA tubes. Samples will be analyzed within 6 hours of collection or stored at 2 to 8C and analyzed within 24 hours. Analysis will be done using a five-part differential hematology analyzer.
224071547|NCT06576583|BIOLOGICAL|Engineered cartilage graft (N-TEC)|Nasal chondrocytes based tissue engineered cartilage
224071548|NCT06576583|PROCEDURE|Autologous Matrix Induced Chondrogenesis (AMIC)|Autologous Matrix Induced Chondrogenesis is performed through bone drilling and covering with Chondro-Gide® to attract bone marrow stem cells
224071549|NCT06576583|PROCEDURE|Patellofemoral Arthroplasty (PFA)|Surgical implantation of a medical device, Zimmer Gender Solutions Patellofemoral Joint Prosthesis.
223463760|NCT02403804|DIETARY_SUPPLEMENT|Phosphatidylcholine|Phosphatidylcholine 3600 mg qam and 2700 mg qpm
223463761|NCT02403804|DIETARY_SUPPLEMENT|Betaine (588 mg qam and 412 mg qpm)|Betaine anhydrous 588 mg qam and 412 mg qpm
223463762|NCT02403804|DIETARY_SUPPLEMENT|Betaine (1000 mg BID)|Betaine anhydrous 1000 mg BID
223463763|NCT06122350|BEHAVIORAL|Earthquake preparedness training|Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
223463764|NCT02077998|RADIATION|carbon C 14 oxaliplatin|Given IV
223463765|NCT02077998|DRUG|oxaliplatin|Given IV
223463766|NCT02077998|OTHER|laboratory biomarker analysis|Correlative studies
223463767|NCT05534139|DIAGNOSTIC_TEST|7T MRI-scan|MRI-scanning of the brain using a 7T-MRI scanner
223463768|NCT05534139|DIAGNOSTIC_TEST|CSF collection via lumbar puncture|CSF is collected by doing a lumbar puncture
223463769|NCT05534139|DIAGNOSTIC_TEST|Blood withdrawal|Blood is collected by doing a blood withdrawal
224304962|NCT06295640|OTHER|Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray|Subjects will undergo a 75 g OGTT (180 min) combined with a double tracer dilution. The double-tracer dilution technique will be used to quantify endogenous glucose production, glucose appearance and disappearance rate. \[6,6-2H\]glucose will be infused for a total of 300 minutes,while the infusion will start 120 minutes prior the OGTT and will last until the end of the OGTT. Intranasal insulin will be administered 15 minutes prior to the start of the OGTT. The drink consumed at time point 0 min contains 75 gram glucose, enriched with \[U-13C6\]-glucose.
223463770|NCT05534139|DIAGNOSTIC_TEST|Clinical measures|UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
223463771|NCT03572673|DEVICE|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
223463772|NCT03572673|DEVICE|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
223463773|NCT02975180|DEVICE|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
223463774|NCT02975180|BEHAVIORAL|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
223463775|NCT00763997|DRUG|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
223463776|NCT00763997|DRUG|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
223463777|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
223463778|NCT00763997|DRUG|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
223463779|NCT00763997|DRUG|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
223463780|NCT00763997|OTHER|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
223463781|NCT00433550|DRUG|capecitabine|given orally
223576523|NCT04412122|OTHER|Kinesio Taping|In the study, kinesio taping method was applied immediately after the surgical operation. The tape was applied on one centimeter above and one centimeter below the incision site with a 25% tension in web cutting technique (Figure 1.). In order to facilitate gas passing and defecation, the tape was applied around the navel in the Y shape with a 25% tension (Figure 2). No tension was applied to the starting and ending points of the tape. Pain level was evaluated with VAS before and after 45 minutes of tape application. Pain level was evaluated by VAS on the 1st, 2nd and 3rd postoperative day. Kinesio tape remained on women for 72 hours.
223463782|NCT00433550|DRUG|irinotecan hydrochloride|given IV
223463783|NCT00433550|DRUG|oxaliplatin|given IV
223463784|NCT02541331|BIOLOGICAL|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
223463785|NCT02541331|BIOLOGICAL|PLACEBO|Matched tablets without any active substance.
223463786|NCT03920475|DRUG|Sertraline or venlafaxine|Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
223463787|NCT03920475|DIAGNOSTIC_TEST|Immune parameters|Serum was taken before, during an after treatment for measurement of different immune parameters.
223463788|NCT06165432|DRUG|Topical Benzocaine|Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
223463789|NCT06165432|OTHER|Topical ice|For the other half of the palate topical ice would be used before greater palatine nerve block
223463790|NCT05181150|OTHER|Meal test|Ingestion of an oral liquid meal (nutridrink), 200 mL.
223463791|NCT05181150|OTHER|GIP|Subcutaneous GIP injection.
223463792|NCT05181150|OTHER|GLP-2|Subcutaneous GLP-2 injection.
223463793|NCT05181150|OTHER|GIP + GLP-2|Subcutaneous GIP + GLP-2 injection.
223463794|NCT05181150|OTHER|Placebo|Subcutaneous saline injection.
224071550|NCT04533659|BEHAVIORAL|ADA-based nutrition education with digital self-monitoring|Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity
224071551|NCT04533659|BEHAVIORAL|Personalized Behavioral Nutrition (PBN) intervention group|Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
224071552|NCT01986543|DRUG|drug administration|
224071553|NCT02656485|DRUG|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
224157704|NCT03921606|BEHAVIORAL|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
224157705|NCT03690674|BEHAVIORAL|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
223463795|NCT05235152|OTHER|Usual individual physiotherapy care|"Usual and individual physiotherapy care guidelines were developed through a round-table discussion involving experts in musculoskeletal health. From the round-table discussion, the consensus as reflecting best-practices for the rehabilitation of musculoskeletal rehabilitation supported an active exercise rehabilitation approach which includes strengthening and neuromuscular training exercises. Furthermore, the following treatments are considered in addition to active exercises:~* Range of motion: active, active-assisted, passive, repeated movements (Mulligan or McKenzie);~* Stretching / manual therapy: mobilizations, manipulation, neural mobility, active release therapy;~* Individual proprioceptive training."
223463796|NCT05235152|OTHER|Group-supervised physiotherapy training programs|Three group-supervised physiotherapy training programs (The lumbar, the upper extremity and the lower extremity training programs) were developed for military members with musculoskeletal conditions. They are composed of stations that each include several exercises of varying levels of difficulty. Group size will vary between 5 to 20 participants for one physiotherapist, and each military member performs his/her own exercises. During a typical session, the participant and therapist will choose one exercise to perform per station according to two main criteria: severity of the condition and the ability to perform the exercises optimally. The level of supervision is adapted to the participant's needs and performance. Progression in the programs leads to the execution of exercises that simulate functional and occupational tasks.
223463797|NCT01167569|DRUG|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
223463798|NCT01167569|OTHER|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
224157706|NCT03205189|OTHER|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
224303293|NCT02866045|PROCEDURE|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
223463799|NCT06958796|DRUG|Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months|The interventional arm will receive Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months as (150 mg/kg) for 3 consecutive months (Days 0, 28 and 56 +/- 3 days). The non-interventional arm will not receive any intervention.
223463800|NCT03588130|DRUG|EscharEx (5% EX-02 formulation)|Active arm
223463801|NCT03588130|DRUG|Gel Vehicle|Control arm
223463802|NCT03588130|DRUG|Non-surgical standard of care (NSSOC)|Santyl (Enzymatic debridement) or commercially approved Hydrogel
223463803|NCT05017272|OTHER|Opioid Addiction Recovery Support Software Platform|OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
223463804|NCT06581783|DRUG|Simethicone plus NAC|Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals
223463805|NCT05711095|DIETARY_SUPPLEMENT|Fortified plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
223463806|NCT05711095|DIETARY_SUPPLEMENT|Plant-based protein blend|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
223463807|NCT05711095|DIETARY_SUPPLEMENT|Whey protein|20 grams of protein dissolved in 500 mL water from a non-transparent shaker
223463808|NCT05179746|DEVICE|Implants are decontaminated with electrolytic cleaning|Implants are decontaminated with electrolytic cleaning
223463809|NCT05179746|DEVICE|Implants are decontaminated without electrolytic cleaning|Implants are decontaminated without electrolytic cleaning
223576524|NCT04412122|OTHER|Breathing Exercise|Before the surgery, researchers informed the women about the purpose and benefits of breathing exercises and showed the how to perform them. Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
223576525|NCT04412122|OTHER|Kinesio Taping+Breathing Exercise|In the study, kinesio taping method was applied immediately after the surgical operation. . Pain level was evaluated with VAS before and after 45 minutes of tape application.Breathing exercises were performed 3 times a day for 30 minutes on the first, second and third days. 15 minutes of exercises were done while sitting and in a comfortable position and 15 minutes while mobilizing. Pain levels of women were evaluated with VAS before and after 30 minutes of breathing exercises.
224157707|NCT00937326|DRUG|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
224303294|NCT03335293|DRUG|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
224303295|NCT03335293|OTHER|normal saline|placebo comparator
223463810|NCT01635829|DRUG|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
223463811|NCT01635829|DRUG|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
223463812|NCT01635829|DRUG|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
223463813|NCT00611585|DEVICE|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
223463814|NCT04380870|DIETARY_SUPPLEMENT|Chinese Herbal Medicine|Chinese Herbal Medicine (CHM) has been used in the prevention and treatment of epidemic diseases dating back to the Han, Ming and Qing Dynasties and extending al the way through modern times. CHM formulas may contain plant elements of root, seed, back, stem or leaf in addition to minerals and other natural substances. All herbs dispensed in this trial will be from Spring Wind Herb Company.
223463815|NCT03703778|PROCEDURE|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
223463816|NCT03703778|DRUG|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
223463817|NCT03703778|DRUG|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
223463818|NCT00234026|DRUG|gemcitabine hydrochloride|
223463819|NCT03113968|PROCEDURE|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
223463820|NCT03113968|DRUG|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
223463821|NCT01660009|OTHER|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
223463822|NCT01387178|DRUG|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
223463823|NCT01387178|DRUG|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
223576526|NCT04412122|OTHER|Control Group|No intervention was performed to reduce pain in the control group.
223576527|NCT01561755|DRUG|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
224157708|NCT00937326|DRUG|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
223463824|NCT04805671|DRUG|ADG20|Single dose of ADG20
223463825|NCT04805671|DRUG|Normal saline|Single dose of normal saline
223463826|NCT03217552|DIAGNOSTIC_TEST|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
223463827|NCT00140062|DRUG|latanoprost 0.005% (Xalatan)|
223463828|NCT02111174|DEVICE|Scrambler Therapy|
223463829|NCT02111174|DEVICE|Sham Therapy|
223463830|NCT02550743|DRUG|BYL719|
223463831|NCT02550743|DRUG|Capecitabine|
223576528|NCT01561755|DRUG|Placebo|Placebo - 2gr/kg over 2 days of saline
223576529|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 70% 1RM combined with complex training|This group of subjects first performed 3 sets of 70% 1RM squats after a routine warm-up, 3 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
224157709|NCT04409626|OTHER|Plasma sodium level (continuous variables)|Observational study, so the exposures of interest (5-year mean and minimum plasma sodium) are not administered to the patients. Ultimately, our interest is in hyponatraemia.
223463832|NCT02550743|RADIATION|Radiation|
223463833|NCT02361034|DRUG|GRC 27864|
223463834|NCT02361034|DRUG|Placebo|
223463835|NCT03551847|DRUG|Antibiotic|The intervention involves giving an infected patient antibiotics.
223463836|NCT03551847|DRUG|No antibiotics|The intervention involves not giving an infected patient antibiotics.
223463837|NCT00251134|DRUG|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
223463838|NCT00251134|DRUG|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
223463839|NCT03450577|PROCEDURE|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
223463840|NCT00657423|DRUG|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
223463841|NCT00657423|DRUG|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
223463842|NCT01657162|DRUG|Alendronate|Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
223463843|NCT00901342|BIOLOGICAL|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
223463844|NCT02970955|PROCEDURE|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
223463845|NCT06314334|DRUG|Sintilimab+Pegaspargase|"1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;"
223463846|NCT06314334|DRUG|P-GemOx|"1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip"
223463847|NCT06314334|DRUG|GELAD|"1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip."
223463848|NCT06314334|RADIATION|IMRT|Intensity modulated radiotherapy (50-56Gy)
223463849|NCT02993861|OTHER|Anti-epileptics|
223463850|NCT00729716|BIOLOGICAL|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
223463851|NCT00729716|PROCEDURE|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
223463852|NCT05621044|BEHAVIORAL|FitBrothers smartphone active app|The FitBrothers smartphone active app is designed to assist African American men with adopting and maintaining PA. The app will be developed with significant input from African American men and contain self-monitoring, goal setting, reward, and educational components. The app will include additional elements including PA adoption strategies, competitions, incentives, health information, and greater compatibility with activity monitoring devices. The intervention is based on the Social Cognitive and Self-Determination theories and is culturally tailored.
223463853|NCT05621044|BEHAVIORAL|Nike Training Club|The app is designed to increase fitness in users through a variety of mechanisms. Users are able to track and monitor their physical activity level, set goals, engage in competitions, and upload activity data from a wearable. They will also be provided with preset workouts, receive guidance from an expert, and receive personalized plans that automatically adapt to user behavior.
223463854|NCT01246895|DEVICE|Microfracture with BST-CarGel|
223463855|NCT01246895|DEVICE|Microfracture without BST-CarGel|
223463856|NCT03603522|DIETARY_SUPPLEMENT|BioGaia-DSM17938|2mL per day (1x10\^9 CFU) per day taken orally for 28 days
223463857|NCT03603522|OTHER|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
223463858|NCT04838002|DEVICE|Extracorporeal shock wave|Focus and Radial types Extracorporeal shock wave therapy
223463859|NCT03560453|BEHAVIORAL|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
223463860|NCT01941784|OTHER|educational intervention|Undergo health education program
223463861|NCT01941784|OTHER|counseling intervention|Undergo health education program
223463862|NCT01941784|BEHAVIORAL|telephone-based intervention|Receive follow-up phone calls
223463863|NCT01941784|OTHER|questionnaire administration|Ancillary studies
223463864|NCT01941784|PROCEDURE|quality-of-life assessment|Ancillary studies
223463865|NCT04038112|OTHER|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
223463866|NCT01648062|BEHAVIORAL|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
223463867|NCT04374370|BIOLOGICAL|SARSCoV2 Convalescent Plasma|Provide expanded access to SARSCoV2 convalescent plasma (EAP) collected from matched donors as described to patients with severe or life-threatening illness owing to COVID-19.
224071554|NCT02656485|DRUG|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
224071555|NCT05404620|OTHER|Schroth exercises|9 participants will perform Schroth exercises with 2 mint rest between each exercise. + Hot pack (10 mint) +static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be provided.
224071556|NCT05404620|OTHER|PNF technique|9 participants will perform PNF techniques followed by a hot pack for 10 minutes and static stretching of the involved muscles with 10 to 30-sec hold and 2 to 4 repetitions as a standard treatment. A total of 45 min sessions three times a week on alternate days for three weeks will be given.
223463868|NCT04824898|DRUG|Simvastatin|Statins are first known as drugs that decrease the cholesterol level by inhibiting hydroxy-methyl-glutaryl co-enzyme-A reductase as they improve the lipid profile and help in the treatment of many cardiac diseases and has a role in osteoblasts diffrentiation
223463869|NCT04824898|OTHER|injectable plasma rich fibrin|I- PRF is obtained by taking a blood sample from patients and then is centrifuged for three minutes at 3300 rpm, the I-PRF first will be in the form of liquid and then coagulate after few minutes from the injection
223463870|NCT01051479|DRUG|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
223463871|NCT06137248|DIETARY_SUPPLEMENT|Energy drink|Participants on this arm will consume an energy drink once daily in addition to their normal diet for 4 weeks.
223463872|NCT00120705|DRUG|darbepoetin alfa|
223463873|NCT04968093|BEHAVIORAL|Mindfulness-based therapy.|"Educational. Patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. Patients will be encouraged to restrict use of acute medications to headaches and to engage in regular physical activity, avoiding skipping meals, remain well hydrated, maintain a regular sleep.~Mindfulness therapy. The intervention is delivered in small groups and consisted of 7 weekly group sessions. It was aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. Each session was conducted by a neurologist and a psychologist. To patients were asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Intervention's main topics: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts."
223463874|NCT06240481|DRUG|Test Regimen|toothpaste \& mouthwash
223463875|NCT06240481|DRUG|Control Regimen|toothpaste
223463876|NCT04871152|DRUG|OnabotulinumtoxinA|To compare the effectiveness of triptans before and after initiation of treatment with OnabotuliumtoxinA.
223463877|NCT03812900|DRUG|Echinacea purpurea alcoholic extract|Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
223463878|NCT05221970|BEHAVIORAL|Mindfulness-Based Cognitive Therapy (MBCT-Ca) - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
223463879|NCT05221970|BEHAVIORAL|Positive Psychology - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
223463880|NCT05221970|BEHAVIORAL|Autogenic Training - online|This intervention can be adapted into low-intensity structured program, suitable for eHealth mental health support applications for individual use without the need of direct involvement of a trained mental health professional.
223463881|NCT01383434|PROCEDURE|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
223463882|NCT05380154|DRUG|Botulinum Toxin A type for injection (Botulax®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects
223463883|NCT05380154|DRUG|Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)|Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
224068152|NCT02446431|DRUG|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
224068153|NCT02446431|DRUG|Temsirolimus|Temsirolimus \[an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)\] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
224068154|NCT03270735|DRUG|Snake venom thrombin (Treatment)|Snake venom thrombin
224068155|NCT03270735|DRUG|Placebo|No snake venom thrombin
223463884|NCT03505372|DEVICE|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
223463885|NCT03065647|DEVICE|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
223463886|NCT05601817|BEHAVIORAL|Vita|Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
224068156|NCT02683200|RADIATION|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
224068157|NCT02683200|RADIATION|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
224068158|NCT04289844|OTHER|Elastic-explosive and resistance strength|"The resistance exercises are: running (3 minutes), 2 farmers carrying marching, 3 side to side ankle hops, 4 plyo lunge jump, 5 lateral jump over barrier, 2 monopodalic jump with ball pass, 3 board throw with half court sprint, 4 lateral shuffle mirror, and 5 combo finisher 4x4.~Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride"
224157710|NCT03225560|OTHER|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
223576530|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 80% 1RM combined with complex training|This group of subjects first performed 3 sets of 80% 1RM squats after a routine warm-up, 2 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
224157711|NCT02578992|PROCEDURE|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
223576531|NCT06083532|BEHAVIORAL|PAP induced at an intensity of 90% 1RM combined with complex training|This group of subjects first performed 3 sets of 90% 1RM squats after a routine warm-up, 1 times per set, with an interval of 2 minutes between sets. The entire process was maintained for 30 minutes, and then after a 6-minute rest, they performed complex training consists of maximum strength training (back squats) and plyometric training (drop Jump). The Intensity \& Repetition of back squats is 80% 1RM × 4, 4 sets, interval time is 2min; rest for 3 minutes. , perform drop jump, intensity \& repetition is 50cm (height) × 10, 4 sets, and the rest time is 2 minutes. Intervention training was conducted twice weekly for 12 weeks,and the intensity is gradually increasing over the 12 weeks.
223463887|NCT05601817|BEHAVIORAL|Com|Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
223576532|NCT06083532|BEHAVIORAL|Routine warm-up combined with complex training|This group of subjects first completed a 30-minute routine warm-up, then rested for 6 minutes, and then performed complex training consisted of maximum strength training (back squats) and plyometric training (drop jump). Back squat intensity \& repetition is 80% 1RM × 4, 4 sets, with an interval of 2 minutes; after resting for 3 minutes, perform a drop jump, Intensity \& Repetition is 50cm (height) × 10, 4 sets, with an interval of 2 minutes. Intervention training was conducted twice weekly for 12 weeks, and the intensity was gradually increasing over the 12 weeks.
223576533|NCT06136286|DEVICE|Blood Flow Restriction (BFR) Cuff|The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
223576534|NCT06361602|OTHER|inapplicable|inapplicable
223576535|NCT04690803|DRUG|air cooling|intervention is adding air-cooling to treatment
223576536|NCT00278369|BIOLOGICAL|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
223576537|NCT00278369|BIOLOGICAL|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
223576538|NCT06323798|DIAGNOSTIC_TEST|MRI|Standard paranasal sinus MRI
223576539|NCT02403895|DRUG|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
224157712|NCT02578992|DEVICE|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
223463888|NCT05601817|BEHAVIORAL|Vita+Com|Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
223463889|NCT06171750|DRUG|tolododekin alfa|IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
223463890|NCT06171750|DRUG|Cemiplimab|Participants will receive four cycles of ANK-101 in combination with Cemiplimab. If there is no significant clinical deterioration as determined by the Investigator or unacceptable toxicity at Week 12, participants may receive an additional four cycles of the combination treatment. After stopping ANK-101 treatment, participants may stay on Cemiplimab monotherapy for an additional 24 weeks.
223463891|NCT06009159|DEVICE|Transcutaneous Vagus Nerve Stimulation|30 minutes stimulation, twice per day for 4 weeks
223463892|NCT05694806|OTHER|analysis of thoracic scans|analysis of thoracic scans realised in standard care
223463893|NCT05995002|OTHER|Anthocyanin-rich diet|A weekly food plan aims to increase the consumption of anthocyanin-rich sources such as berries, black grapes (or currants), cherries, strawberries, pomegranates, and red onions.
223463894|NCT01821274|DRUG|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
223463895|NCT01821274|DRUG|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
223463896|NCT01821274|DRUG|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
223463897|NCT01821274|DRUG|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
223576540|NCT02403895|DRUG|paclitaxel|Taxane
223576541|NCT02962596|OTHER|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
224068159|NCT04289844|OTHER|Elastic-explosive strength|Plyometric exercises are: ankle rotations, knee extension, squat, hip flexion-extension, knee and ankle, ankle mobilizations, squat with rise, pelvis ante / retroversion, global mobilization, stride
224068160|NCT01308970|BEHAVIORAL|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
224068161|NCT01308970|BEHAVIORAL|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
224068162|NCT01308970|BEHAVIORAL|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
224068163|NCT02997904|DEVICE|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
223463898|NCT02373423|OTHER|Advocacy|See above for description
223463899|NCT02799017|OTHER|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
224303296|NCT03335293|DRUG|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
224157713|NCT01782404|DEVICE|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
224303297|NCT00365131|DRUG|Cerezyme (imiglucerase for injection)|
224303298|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
224303299|NCT01571076|GENETIC|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
224303300|NCT01571076|OTHER|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
224303301|NCT01571076|OTHER|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
224303302|NCT04053686|BEHAVIORAL|Breaks|3-min breaks every half hour at work
223463900|NCT02799017|OTHER|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
223463901|NCT01553448|GENETIC|gene expression analysis|
223463902|NCT01553448|GENETIC|protein expression analysis|
223463903|NCT01553448|OTHER|enzyme-linked immunosorbent assay|
223576542|NCT02813668|BEHAVIORAL|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
223576543|NCT02829892|DEVICE|Light therapy|14-days exposure with an innovative ambient light
223576544|NCT03426358|DEVICE|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
224157714|NCT00681291|DEVICE|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
224157715|NCT00681291|DEVICE|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
224157716|NCT05258526|OTHER|Home based exercise training|The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.
224157717|NCT02002065|BIOLOGICAL|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
224157718|NCT02002065|BIOLOGICAL|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
224157719|NCT05193604|DRUG|TQB2858 injection|TQB2858 injection is a programmed cell death 1 ligand 1 (PD-L1)/transforming growth factor-β bispecific antibody.
224157720|NCT05193604|DRUG|Anlotinib Hydrochloride Capsule|Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
224157721|NCT05193604|DRUG|Gemcitabine hydrochloride for injection|Chemotherapy medicine for metastatic pancreatic cancer
224303303|NCT04644822|DIAGNOSTIC_TEST|[18F] PSMA-1007 Injection|a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
224303304|NCT03816514|PROCEDURE|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
224303305|NCT03816514|PROCEDURE|Conventional management|Conventional management without SpHb monitoring
224303306|NCT03355014|DRUG|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
223463904|NCT01553448|OTHER|immunohistochemistry staining method|
223463905|NCT01553448|OTHER|laboratory biomarker analysis|
223463906|NCT01553448|OTHER|medical chart review|
223463907|NCT04872387|DRUG|BAY2586116|Nasal administration
223463908|NCT04872387|DRUG|Placebo|Matching placebo
223576545|NCT01997814|DRUG|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
224157722|NCT05193604|DRUG|Paclitaxel for injection (albumin bound)|Chemotherapy medicine for metastatic pancreatic cancer
224157723|NCT04151446|DEVICE|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
224157724|NCT00040469|DRUG|Campath -1H|
224157725|NCT00040469|DRUG|Dilantin|
224157726|NCT00040469|DRUG|Busulfan|
224157727|NCT00040469|DRUG|Cyclophosphamide|
224157728|NCT06117904|DRUG|MEBO ointment|This group included twenty-five patients given Mebo ointment in combination with the symptomatic therapy 3 times daily for 7 weeks
224157729|NCT06117904|DRUG|Symptomatic treatment only|"This group included twenty-five patients given symptomatic therapy 3 times daily for 7 weeks.~These therapies included anti-fungal agents (Miconaz oral gel), topical anesthetics and anti-inflammatory drugs (BBC oral spray), topical analgesic gel (Oracure gel), sodium bicarbonate mouthwash (Alkamisr sachets)."
224303307|NCT03355014|DRUG|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
224303308|NCT00148824|BIOLOGICAL|7-valent pneumococcal conjugate vaccine (vaccine)|
224303309|NCT00148824|BIOLOGICAL|23-valent pneumococcal conjugate vaccine (vaccine)|
224303310|NCT00986713|DRUG|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
224303311|NCT00070096|DRUG|ixabepilone|
223576546|NCT01997814|DRUG|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
223463909|NCT05452915|DIAGNOSTIC_TEST|Neuropsychological (NPA)|"The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session"
223463910|NCT05452915|OTHER|Imaging|"Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR)."
223463911|NCT05452915|DIAGNOSTIC_TEST|Inflammatory biomarkers|Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
223576547|NCT05170750|OTHER|Foams|Every subject will perform 24 randomized trials on force platform.
223576548|NCT05170750|OTHER|Foam / Orthopedic insole|3/5 of the initial population will perform static and locomotion task, with randomized conditions.
223576549|NCT02425605|RADIATION|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
224068164|NCT04180293|BEHAVIORAL|Pilot psychoeducation program|Canadian Armed Forces veterans and their family members will be recruited to participate in this pilot virtual psychoeducation program and its evaluation. Two six-week sessions will be implemented over a virtual care platform (Zoom for healthcare) based out of OSI Clinic in Atlantic Canada - the first in January/February of 2021 and the second in the spring of 2021. A maximum of 10-15 participants (including both veterans and their family members) will be recruited for each group. Family members are defined as spouses/partners, siblings, parents, and adult children. Each of the weekly sessions will take place virtually and will be led by at least two trained facilitators (one from the research team, and one member of the OSI clinical staff team). Each of these sessions will focus on providing education of different topics relevant to those accessing services at the clinic (e.g., types of treatments available, tools to support families, self care, etc.).
224068165|NCT04180293|OTHER|Program evaluation|At the end of each six-week session, program outcomes will be assessed qualitatively by a member of the research team. Participants will take part in semi-structured interviews guided by questions informed by the ecological family systems theory.
223463912|NCT01963884|PROCEDURE|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
223463913|NCT01963884|RADIATION|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
223463914|NCT01963884|OTHER|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
223576550|NCT02425605|DRUG|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
223576551|NCT04662073|DRUG|Camostat|200 mg (2 x 100 mg tablet) administered orally four times daily (800 mg total daily dose).
223576552|NCT04662073|DRUG|Placebo|Placebo to match camostat administered orally four times daily
224068166|NCT04036968|DRUG|Within-subject test of blinded study medications|Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
224068167|NCT00449462|PROCEDURE|consumption of CLA enriched food|
224068168|NCT01246570|BEHAVIORAL|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
224157730|NCT04442386|OTHER|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout|Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout
224157731|NCT02758925|DRUG|Rituximab|375mg/m2 IV day 1
224157732|NCT02758925|DRUG|Bendamustine|90mg/m2 IV day 1-2
223576553|NCT06160856|DIAGNOSTIC_TEST|Abdominal ultrasound|Measurement of venous congestion in abdominal target-organs (liver, kidneys) by calculating VExUS score
223576554|NCT00681694|RADIATION|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
223576555|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
223576556|NCT00681694|RADIATION|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
223576557|NCT04657640|DIETARY_SUPPLEMENT|Iron and folic acid (IFA)|Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
223576558|NCT04657640|DIETARY_SUPPLEMENT|Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)|"Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS."
223576559|NCT04844203|DIAGNOSTIC_TEST|Polygraphy with surface electrodes|Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG
224157733|NCT02758925|DRUG|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
223576560|NCT01632228|DRUG|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
223576561|NCT01632228|DRUG|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
224157734|NCT02001922|OTHER|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
224157735|NCT03491904|DRUG|Fasinumab AI|Self-administered with auto injector
224157736|NCT03491904|DRUG|Fasinumab PFS|Prefilled syringe administered by study staff
224157737|NCT06437639|DRUG|Mexidol|Neurocytoprotector
223463915|NCT03300440|DIETARY_SUPPLEMENT|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
223463916|NCT03300440|DIETARY_SUPPLEMENT|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
223463917|NCT01916460|PROCEDURE|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
223463918|NCT01871077|DRUG|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
223463919|NCT04090346|DRUG|Fecal Microbiota Transplant|Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
223463920|NCT03183115|PROCEDURE|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.
223463921|NCT03183115|DEVICE|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
223463922|NCT03183115|DRUG|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
223463923|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
223576562|NCT01632228|DRUG|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
223576563|NCT00000224|DRUG|Buprenorphine|
223576564|NCT03407495|DRUG|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
223576565|NCT02088502|DRUG|N-acetylcysteine|
223576566|NCT02088502|DRUG|Theophylline|
223576567|NCT02088502|DRUG|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
223576568|NCT05725460|PROCEDURE|dextrose 5% median nerve hydrodissection|planned to be a good alternative to steroid hydrodissection
224157738|NCT05047016|OTHER|Virtual investigational product|The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
224157739|NCT02054936|DRUG|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
223576569|NCT06384274|OTHER|Emotional Freedom Technique|All people have an energy body. If the energy flow is interrupted, emotions such as stress and fear arise. By clicking on energy points to improve energy flow, the individual gets rid of energy blockages.
223576570|NCT06384274|OTHER|Virtual Reality Glasses|It is aimed to reduce the patient's anxiety by making her feel like she7 he is there by watching and listening to relaxing content of the beach and nature.
223576571|NCT02982317|PROCEDURE|Manual palpation identification lumbar spine|
223576572|NCT02982317|PROCEDURE|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
223576573|NCT02982317|PROCEDURE|Lumbar level identification gold standard ultrasound|
223576574|NCT00933920|DRUG|Aliskiren|
223576575|NCT00933920|DRUG|Aliskiren|
224157740|NCT02054936|DRUG|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
224157741|NCT00086385|DRUG|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
224157742|NCT02428075|BEHAVIORAL|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
224157743|NCT00767793|DRUG|Placebo|One drop in each eye every 12 hours for seven days
223576576|NCT04546295|OTHER|Brushlink application|Brushlink application + Interproximal brush
223576577|NCT04546295|OTHER|Water-flosser|Water-flosser
223576578|NCT04546295|OTHER|Interproximal brush|Interproximal brush alone
223576579|NCT01294943|DEVICE|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
223576580|NCT02185014|DRUG|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
223576581|NCT04031274|DEVICE|TAVI|Trascatheter aortic valve implantation
223576582|NCT04031274|DEVICE|TMVR/r|Transcatheter mitral valve replacement/repair
224303312|NCT04040608|OTHER|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
223576583|NCT00387179|DRUG|Melatonin|5mg, pill, once
223576584|NCT00387179|DRUG|Methylxanthine|2.9 mg/kg, pill, once
223576585|NCT00387179|PROCEDURE|Light Therapy|Bright light exposure
224303313|NCT02122406|OTHER|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
224303314|NCT05691686|OTHER|Finely milled whole wheat-legume bread|The intervention examines the effect of finely milled wheat-legume bread in subjects with normal body weight.
224303315|NCT05691686|OTHER|Less processed whole wheat-legume bread|The intervention examines the effect of less processed whole wheat-legume bread in subjects with normal body weight.
224303316|NCT05691686|OTHER|Less processed whole wheat bread|The intervention examines the effect of less processed whole wheat bread in subjects with normal body weight.
224303317|NCT05691686|OTHER|White wheat bread|The intervention examines the reference food product in subjects with normal body weight.
224303318|NCT03778658|BEHAVIORAL|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
224303319|NCT04258475|DRUG|Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.|Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.
223463924|NCT00970021|DIETARY_SUPPLEMENT|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
223463925|NCT01119521|BIOLOGICAL|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10\^5 colony forming units (CFU) BCG.
223463926|NCT01119521|DRUG|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets \[5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)\].
223463927|NCT03822260|DIAGNOSTIC_TEST|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
223463928|NCT02105194|DRUG|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
223463929|NCT01326247|OTHER|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
223576586|NCT05084560|DRUG|AWZ1066S|Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
223576587|NCT05084560|DRUG|Placebo|Placebo
223576588|NCT03873181|DEVICE|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
223576589|NCT03074266|DIAGNOSTIC_TEST|GEM Hemochron 100 ACT|Activated Clotting Time
223576590|NCT04972708|GENETIC|Cross-sectional genetics study|Cross-sectional genetics study
223576591|NCT02001415|OTHER|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
223576592|NCT02001415|OTHER|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
223576593|NCT02001415|OTHER|Orthokeratology|Orthokeratology lenses.
223576594|NCT00113646|DRUG|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
223576595|NCT00113646|PROCEDURE|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
223576596|NCT01591421|DRUG|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
223576597|NCT01591421|DRUG|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
223576598|NCT06027411|DEVICE|qER (qER EU 2.0)|Qure.ai's emergency room software solution qER (qER EU 2.0) is an AI medical device, developed by training a deep-learning algorithm using over 300,000 scans labelled by expert radiologists. qER has been shown to be accurate in identifying a range of abnormalities in NCCT head scans as well as prioritising them for urgent review and radiologist reporting. It is designated as a clinical support tool and, when used with original scans, can assist the clinician to improve efficiency, accuracy, and turnaround time in reading head CTs.
224068169|NCT01246570|OTHER|Control|The patients will receive the usual care provided by the hospitals and the community health services
224068170|NCT05637918|OTHER|Group 1 (Patients who recorded as Grade 0)|When the gastric contents were evaluated with the upper gastrointestinal endoscopy, the stomach was completely empty in Group 1 that patients who recorded as Grade 0.
224068171|NCT05637918|OTHER|Group 2 ( Patients who recorded as Grade 1)|When the gastric contents were evaluated with the endoscope, small volume of gastric clear fluid was visible and gastric content aspirated and measured in Group 2 that patients who recorded as Grade 1.
224068172|NCT04724564|DIAGNOSTIC_TEST|THE SURGICAL PLETH INDEX|CORRELATION OF DIFFERENT TIME MEASUREMENTS OF THE SURGICAL PLETH INDEX WITH POSTOPERATIVE PAIN
224157744|NCT00767793|DRUG|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
223463930|NCT02141191|DRUG|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
223463931|NCT04878120|DEVICE|Standard HCL System|Standard HCL system (USS Virginia)
223463932|NCT04878120|DEVICE|HCL System with Smart Bolus Calculator|HCL system (USS Virginia) with smart bolus calculator informed by insulin sensitivity
223463933|NCT04685928|DIAGNOSTIC_TEST|MRI and MRI-guided prostate biopsy|Multiparametric MRI prostates in the MRI arm will be performed using 1.5 or 3.0 Tesla scanner with a pelvic phased array coil and contrast injection. T2-weighted, diffusion weighted and dynamic contrast enhanced scans will be included and the reporting of MRI finding will be done according to PI-RADS (Prostate Imaging-Reporting and Data Systems) v2.1 recommendations. MRI-guided targeted biopsy will be performed by Urologists experienced in MRI-guided biopsy for men with PI-RADS score 3-5.
223463934|NCT04685928|DIAGNOSTIC_TEST|TP-arm Systematic biopsy|Transperineal 24-core biopsy using a free-hand technique under local anaesthesia will be performed under transrectal ultrasound guidance for men in this arm
223463935|NCT04633681|DIETARY_SUPPLEMENT|Sweetener and sweetness enhancer consumption|Two-week consumption of combinations of different sweetener and sweetness enhancer blends in reformulated food products compared to sucrose containing product.
223463936|NCT01542138|DRUG|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
223463937|NCT01542138|DRUG|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
223463938|NCT01542138|DRUG|Placebo|Humectant placebo cream
223463939|NCT00387322|DRUG|erlotinib hydrochloride|Given orally
223463940|NCT00387322|DRUG|pemetrexed disodium|Given IV
223463941|NCT01836068|DRUG|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
223463942|NCT02340377|DEVICE|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
223463943|NCT01664676|DRUG|Liraglutide|
223463944|NCT01664676|DRUG|Placebo-liraglutide|
223463945|NCT01189877|PROCEDURE|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
223463946|NCT01602796|BEHAVIORAL|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
223463947|NCT00751140|PROCEDURE|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
223463948|NCT00870454|DRUG|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
223463949|NCT00870454|DRUG|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
223463950|NCT00870454|DRUG|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
223463951|NCT00870454|DRUG|Placebo|Placebo capsules twice daily
223463952|NCT00308789|PROCEDURE|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
223463953|NCT00308789|PROCEDURE|CPAP|Continuous positive airway pressure
223463954|NCT05005936|PROCEDURE|Ultrasonography|Undergo ABUS
223463955|NCT05005936|PROCEDURE|Ultrasonography|Undergo WBUS
223463956|NCT02413632|OTHER|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
223463957|NCT02413632|OTHER|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
223463958|NCT02665247|BEHAVIORAL|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
224068173|NCT03171207|DEVICE|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
224068174|NCT03171207|DEVICE|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
224068175|NCT02595151|DEVICE|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
224068176|NCT02955615|DRUG|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
224068177|NCT02955615|DRUG|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
224068178|NCT03937180|BEHAVIORAL|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
223576599|NCT05401695|DEVICE|HA330 hemoadsorption technique|Hemoadsorption (HA) treatment An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in the intervention group. We will select a blood circuit for each machine according to the patient's body weight. Vascular access will be established with ultrasound-guided insertion of a double-lumen venous catheter into the right internal jugular or femoral vein. HA will be performed for a maximum of 4 hours, and the second session will be started approximately 24 hours after the end of the first session. The blood flow rate will be started low and be gradually increased while monitoring real-time blood pressure and vital signs with an arterial-line monitor. After the end of the HA session, CRRT will be continued if required.
224157745|NCT00767793|DRUG|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
223463959|NCT02665247|OTHER|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
223463960|NCT02102048|DRUG|Atazanavir|
223463961|NCT03049020|PROCEDURE|laparoscopic sacrocolpopexy|standard laparoscopic sacrocolpopexy for prolapse treatment
223463962|NCT02001701|PROCEDURE|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
223463963|NCT00002424|DRUG|L-756423|
223576600|NCT05679544|BIOLOGICAL|Characterization of early biological effects following exposure to PAHs|Biological samples collected in period of exposure and after holidays
223576601|NCT03040414|DEVICE|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
224157746|NCT00767793|DRUG|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
223576602|NCT03040414|DEVICE|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
224157747|NCT04154397|DEVICE|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
224157748|NCT03372447|DRUG|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
224157749|NCT02330445|DRUG|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
224157750|NCT01149772|BEHAVIORAL|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
224157751|NCT00880100|DRUG|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
224157752|NCT02599857|DEVICE|CONCOR smartphone application|
224157753|NCT05195424|DIAGNOSTIC_TEST|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care|Estimation of central venous pressure by echocardiography in intubated children in pediatric intensive care
224157754|NCT04673240|DRUG|Botulinum toxin type A injection|"Adult patients with spasticity due to traumatic brain injury, spinal cord injury, or MS, treated with Botulinum Toxin type A.~As this is a non-interventional study, no diagnostic, therapeutic, or experimental intervention is involved. Subjects will receive clinical assessments, medications, and treatments solely as determined by their study physician."
224157755|NCT02443155|DRUG|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
224157756|NCT02443155|DRUG|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
224157757|NCT02443155|DRUG|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
224157758|NCT03527186|DRUG|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
224303320|NCT04258475|DRUG|Calcium carbonate antacid tablet|PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.
223463964|NCT00002424|DRUG|Indinavir sulfate|
223463965|NCT00002424|DRUG|Lamivudine|
223463966|NCT00002424|DRUG|Stavudine|
223463967|NCT00374023|DRUG|Zinc, or Vitamin A or both|
223463968|NCT03880552|OTHER|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
223463969|NCT01893697|OTHER|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
223463970|NCT03629769|DRUG|Proxelan|Administration of one suppository of proxelan once a day for 30 days
224303321|NCT01904617|OTHER|Dextrose|
223463971|NCT02564276|PROCEDURE|Sentinel lymph node biopsy|
223463972|NCT00036283|DRUG|Celecoxib|
223463973|NCT05278741|PROCEDURE|Surgery for unilateral breast reconstruction|"Before the surgery, patient will be completed two questionnaire DASH and BREAST-Q. Two tests will be performed (isokinetic test and EMG).~After the surgery, at one month : 2 Questionnaires (DASH / BREAST-Q) will be performed At three months, six months and 12 months: 2 questionnaires + two tests will be perfomed"
223576603|NCT05922410|RADIATION|cone beam computed tomography|cone beam computed tomography
223743439|NCT04199117|OTHER|Wisconsin Tobacco Quit Line referral|This is recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. The Wisconsin Tobacco Quit Line (WTQL) offers a single 20-minute counseling session to all Wisconsin residents ready to set a date to stop smoking in the next month, at no charge, and offers those who meet their medical eligibility criteria a 2-week supply of either nicotine patches, lozenges, or gums, at no charge. The WTQL assumes full clinical responsibility for participants' use of cessation medications dispensed by the WTQL.
223463974|NCT04001803|DRUG|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
223463975|NCT00908271|DRUG|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
223463976|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under Lidocaine alone|In this conventional procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 10 to 20 mL, i.e. a total of 50 to 200 mg of lidocaine.
223463977|NCT05343299|COMBINATION_PRODUCT|Ambulatory surgery under a combination of Lidocaine and Ropivacaine|In this experimental procedure group, the anesthetic solution is administered subcutaneously and by infiltration into the surgical area. A maximum volume of 20 ml (dose dictated by the operation) of the solution is thus injected by the operator: Lidocaine 10mg/mL combined with adrenaline 0.005mg/mL administered at a dose of 18 mL + ropivacaine 7.5 mg/mL 2 mL or 15 mg. For a total of 20 mL: lidocaine 9mg/mL, ropivacaine 0.75 mg/mL, adrenaline 0.005 mg/mL
223463978|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
223463979|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
223576604|NCT05826691|PROCEDURE|Monopolar / Bipolar Transurethral resection of prostate (TURP), photovaporisation (PVP), Plasmakinetic (PK), Holmium laser enucleation of the prostate (HOLEP) or open prostatectomy (OP)).|Any procedure advised by the EAU guidelines to ovrecome bladder outlet obstruction
223576605|NCT01297361|OTHER|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
223576606|NCT01778374|OTHER|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
223576607|NCT01778374|OTHER|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
223576608|NCT01550341|DRUG|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
223743440|NCT04199117|OTHER|Primary care provider referral|This is a form of recommended standard care that will be offered to participants who are not medically eligible for varenicline or combination nicotine patch or who are randomized to standard treatment access. Participants who choose to use this intervention will be referred electronically to their primary care provider for counseling and/or medication if they express an interest in quitting in the next 30 days and agree to this referral.
223463980|NCT00767598|DRUG|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
223463981|NCT05002504|DIAGNOSTIC_TEST|A series of questions were asked to the children's parents in a virtual questionnaire|A series of questions were asked to the children's parents in a virtual questionnaire on physical characteristics, previous health assessments and observations of their balance and coordination in front of their children
223463982|NCT05002504|DIAGNOSTIC_TEST|"neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI)"|"the school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which evaluates five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-49%), normal (50-79%) and high (80-100%). Low and high values are considered impairments in one or more of the areas evaluated. Evaluation of the Battelle scale was carried out before and after the therapy sessions."
223463983|NCT05002504|PROCEDURE|Therapy sessions|Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
223463984|NCT01750645|DRUG|Intradetrusor Injection of Type-A Botulinum Toxin|
223576609|NCT01550341|DRUG|Placebo Oral Tablet|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
223576610|NCT02370641|DIETARY_SUPPLEMENT|PomX|1000 mg POMx daily for 4 weeks
223576611|NCT00601861|DRUG|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
223576612|NCT04124458|DEVICE|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
223576613|NCT03159689|OTHER|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
223576614|NCT03159689|OTHER|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
223576615|NCT03109262|PROCEDURE|Computed Tomography (CT)|As part of PET/CT and SPECT/CT scans.
223743441|NCT04199117|BEHAVIORAL|Untailored outreach|Participants randomized to this intervention will receive 5 untailored letters delivered every 4-6 months. Letter content will not be tailored or personalized. Letters will offer information about how to access available treatments.
224157759|NCT02389218|DEVICE|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
224303322|NCT01904617|OTHER|Normal Saline|
223463985|NCT01750645|OTHER|Other interventions analyzed according to protocol|"* Placebo~* Different dosage of Type-A Botulinum Toxin injected~* Anticholinergic drugs"
224303323|NCT01884818|OTHER|Manipulation vs. TNS thoracic pain|
223463986|NCT02447770|DIETARY_SUPPLEMENT|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
223463987|NCT05799430|BEHAVIORAL|Multidisciplinary medication review|"FP communicate to the PCP patients recently discharged. The medication review process consists in 5 steps:~1. PCP perform a structured drug review based on information from health record and e-prescribing application. The drug review comprise the appraisal of potentially inappropriate medication based on lists of explicit criteria.~2. PCP communicates and discuss the results of medication review with GP and PCN, in a brief meeting face-to-face, with possible adaptation of the recommendations.~3. FP, PCN and PCP agree on a personalized therapeutic plan for the patient that includes actions to optimize the therapy.~4. FP and PCN share plan with the patient and/or carer with possible adaptation of the recommendations and agree about actions to be implemented.~5. FP and PCN communicate to PCP final agreement with patient and/or carer~6. FP and/or PCN follow-up implantation of agreed recommendations using standard health care procedures"
223463988|NCT05799430|BEHAVIORAL|Control group|Usual care by FP an PCN
223463989|NCT00050635|DRUG|Sandostatin LAR Depot|
223463990|NCT04743089|DEVICE|ERCP using SpyGlass™ DS Direct Visualization System|Lithotripsy and stone removal will be performed using ERCP and Spyglass system to patients with IHD/EHD stone, which is difficult to remove through conventional ERCP. The SpyGlass™ DS Direct Visualization System will be applied directly into the bile duct via the working channel of the duodenoscope. Under the high-resolution digital imaging, lithotripsy such as EHL could be done.
223463991|NCT04743089|OTHER|PTCS|A historical cohort of patients who underwent PTCS to remove bile duct stones which is difficult to treat by ERCP.
223463992|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
223463993|NCT00538941|DIETARY_SUPPLEMENT|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
223463994|NCT02493517|DRUG|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
223463995|NCT02493517|DRUG|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
223463996|NCT00914225|OTHER|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
223463997|NCT03189355|PROCEDURE|Blood sampling|"* D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~* D4 zonulin"
223463998|NCT03189355|PROCEDURE|Bioelectrical impedance vector analysis|"* D1~* D4"
223463999|NCT03189355|PROCEDURE|Muscular echography|"* D1~* D4"
223464000|NCT03718429|DRUG|Rivaroxaban 2.5 mg Tablet|PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
223464001|NCT02249104|DRUG|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
223464002|NCT02249104|OTHER|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
223464003|NCT00507260|BEHAVIORAL|Food Record|A record of the amount and kind of food and drink you intake will be completed.
224157760|NCT02389218|DRUG|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
224157761|NCT00505518|DRUG|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
224157762|NCT00505518|BEHAVIORAL|Collaborative psychiatric and primary medical care|Regular care visits from health workers
224157763|NCT02972736|RADIATION|Radiation dose expressed as DAP|
224157764|NCT02668055|BIOLOGICAL|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
223464004|NCT00507260|OTHER|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
223464005|NCT05254340|DIETARY_SUPPLEMENT|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
223464006|NCT05404711|DEVICE|CGM|Participants will wear blinded Dexcom G6 Pro continuously for 10 days in their home environment. Two challenges will be completed at home: 1) glucose, using 1.75 g/kg (max 75g) glucose beverage provided by study team, and 2) mixed food, containing 50g carb as well as protein and fat content of participant's choice.
223464007|NCT04305028|DRUG|Rivaroxaban|Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
224157765|NCT03472768|DIAGNOSTIC_TEST|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
224303324|NCT05410132|OTHER|Internet-delivered Mindfulness Based Training (iMBT)|"The iMBT developed for this study will be adapted from our team's previous study and the manual of mindfulness based cognitive therapy. The program is designed to be brief in nature, for example, participants will be asked to practice meditations for 15 minutes a day instead of the original 45 minutes a day, and each module is shortened to approximately 1 hour instead of the original 2.5 hours.~This iMBT is comprised of six weekly modules on education about mindfulness, guidance on using mindfulness skills to manage symptoms, guided meditations (e.g., mindful breathing, mindful eating, mindful walking, body scan, acceptance, choiceless awareness and disengaging from thoughts exercise), and guidance on using informal mindfulness skills in day-to-day life. Readings, audio and graphics are included to explain the concept of mindfulness and overcome common difficulties associated with mindfulness practice."
224303325|NCT05001932|PROCEDURE|Cataract surgery|Randomized Clinical Trial
224157766|NCT01442519|BIOLOGICAL|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0\_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
224303326|NCT06300671|OTHER|Foot Posture Index-6|Foot Posture Index 6 (API-6) is a clinical diagnostic tool that broadly measures whether a foot is in neutral, supination or pronation posture. During the evaluation, individuals' static standing postures in a comfortable position are observed and scored. When using API-6, researchers visually evaluate the foot according to 6 criteria, each rated on a 5-point (-2 to +2) Likert scale. Each item is scored between -2 (supination) and +2 (pronation) and 0 (for neutral position), with the total score being between -12 (high degree of supination) and +12 (high degree of pronation). The grouping of reference values showing foot posture can be summarized as follows; Neutral position from 0 to +5, pronation position from +6 to +9, hyperpronation position from +10 to +12, supination position from -1 to -5, and supination position from -6. It shows a high degree of supination position up to -12. Higher scores represent a more pronated foot posture.
224303327|NCT02070874|BEHAVIORAL|telehealth enhanced pain management|
223464008|NCT04305028|DRUG|Aspirin|Aspirin 75-100 mg once daily, tablet
223464009|NCT00887705|BEHAVIORAL|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
223464010|NCT03625739|DRUG|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
223464011|NCT00325819|DRUG|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
223464012|NCT00325819|OTHER|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
223464013|NCT02983890|DRUG|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
223464014|NCT02983890|DRUG|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
223464015|NCT02047279|PROCEDURE|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
223464016|NCT02047279|PROCEDURE|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
223464017|NCT02047279|PROCEDURE|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
223576616|NCT03109262|PROCEDURE|Positron Emission Tomography (PET)|As part of PET/CT scan
223576617|NCT03109262|DEVICE|90-Yttrium (Y-90) Glass Microspheres|Radiolabel for PET/CT scan
223576618|NCT03109262|DIAGNOSTIC_TEST|Technetium 99mTc albumin aggregated (99mTc-MAA)|Radiolabel for 99mTc-MAA SPECT/CT Scan
223576619|NCT03109262|PROCEDURE|Single-photon emission computerized tomography (SPECT) scan|As part of SPECT/CT scan
223576620|NCT03398265|BEHAVIORAL|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
223464018|NCT04811807|DEVICE|Subthalamic Nucleaus Deep brain stimulation|In deep brain stimulation (DBS) therapy, a specific anatomical target in the brain is stimulated via surgically fixed electrodes. These electrodes release electrical currents of a specific voltage, wavelength, and frequency. They are connected via subcutaneous wires to a device called an implantable pulse generator (IPG) which is surgically fixed on chest wall, beneath the clavicle. After electrodes and IPG are successfully installed, a clinician will be able to adjust and modulate the stimulation via a remote device connected to the IPG to obtain a maximum potential benefit. Deep brain stimulation has been used in clinics to treat various neurologic diseases including neurodegenerative disorders, mainly movement disorders.
223464019|NCT00498953|DRUG|carboplatin|
223464020|NCT00498953|DRUG|cisplatin|
223464021|NCT00498953|DRUG|docetaxel|
223464022|NCT00498953|DRUG|fluorouracil|
223464023|NCT00498953|DRUG|lapatinib ditosylate|
223464024|NCT00498953|GENETIC|cytogenetic analysis|
223464025|NCT00498953|GENETIC|fluorescence in situ hybridization|
223464026|NCT00498953|GENETIC|in situ hybridization|
223464027|NCT00498953|GENETIC|polymerase chain reaction|
223464028|NCT00498953|GENETIC|reverse transcriptase-polymerase chain reaction|
223464029|NCT00498953|OTHER|immunohistochemistry staining method|
223464030|NCT00498953|OTHER|laboratory biomarker analysis|
223464031|NCT00498953|PROCEDURE|conventional surgery|
223464032|NCT00498953|PROCEDURE|neoadjuvant therapy|
223464033|NCT00498953|RADIATION|fludeoxyglucose F 18|
223464034|NCT00498953|RADIATION|radiation therapy|
223464035|NCT05545137|DRUG|Pivmecillinam hydrochloride tablets|400mg tablet
223464036|NCT05545137|DRUG|Fosfomycin Tromethamine Granules|3g/pack
223464037|NCT02346877|BEHAVIORAL|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
223464038|NCT03054181|BIOLOGICAL|HyQvia|
223464039|NCT06236321|OTHER|Fast Field Cycling MRI scan|Three scans to be done over the period of cancer treatment
223464040|NCT06236321|OTHER|Provision of saliva and faecal samples|Three times over the period of cancer treatment
223464041|NCT03185286|DEVICE|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
223464042|NCT02154438|DRUG|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
223464043|NCT06173479|BEHAVIORAL|HeBSaPU|HeBSaPU training content explains the definition of pesticides, their way of entry into the body, and their health effects. Personal protective equipment, personal hygiene behaviors, and safe behaviors regarding the correct and safe use of pesticides were mentioned.
223464044|NCT03889249|DRUG|Tenecteplase|Stroke Thrombolytic
223464045|NCT03889249|DRUG|Alteplase|Stroke Thrombolytic
223464046|NCT03827694|DIAGNOSTIC_TEST|Non-Invasive Testing for PIFI|galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
223464047|NCT06593834|DRUG|bacillus coagulans combined with the best treatment options for preventing aGVHD|BAT means the best treatment options for preventing aGVHD
223464048|NCT06593834|DRUG|BAT|BAT
223464049|NCT06597292|DEVICE|Vision improvement|Vision improvement for patients with refractive disorders (hyperopia and presbyopia)
223464050|NCT05773625|DEVICE|Just-In-Time Adaptive Intervention|Participants will be exposed to a new innovative app to test.
223464051|NCT01779557|DRUG|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
223464052|NCT01779557|DRUG|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
223464053|NCT04839718|BEHAVIORAL|ADAPT|The Achieving Depression and Anxiety Patient Centered Treatment (ADAPT) Program is a novel collaborative psychiatric care model that is designed to unburden PCPs and psychiatrists, increase access to quality specialty mental healthcare for Kaiser Permanente members, and improve patient depression and anxiety treatment outcomes by utilizing technology-driven appointments. This program uses principles of collaborative care, including patient-centered care, population-based care, evidence-based care, measurement-based treatment to target, and accountable care.
223464054|NCT01624285|DRUG|sorafenib tosylate|Given PO
223464055|NCT01624285|OTHER|placebo|Given PO
223464056|NCT01624285|OTHER|laboratory biomarker analysis|Correlative studies
223464057|NCT00508911|DRUG|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
223464058|NCT00508911|DRUG|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
223464059|NCT06612567|DIAGNOSTIC_TEST|PET/CT|is an imaging test that can help reveal the metabolic or biochemical function of your tissues and organs. The PET scan uses a radioactive drug called a tracer to show both typical and atypical metabolic activity. A PET scan can often detect the atypical metabolism of the tracer in diseases before the disease shows up on other imaging tests, such as computerized tomography (CT) and magnetic resonance imaging (MRI).
223464060|NCT05130034|BEHAVIORAL|Home-based pulmonary rehabilitation|Home-based tablet-assisted pulmonary rehabilitation with monitoring technology and telephonic health coach calls using motivational interviewing techniques
223464061|NCT06612983|OTHER|Instrument Assisted Soft Tissue Mobilization|Instrument assisted soft tissue mobilization is a technique that is applied using specially designed tools/instruments to provide a mobilizing effect to soft tissues including the skin, fascia, muscles, and tendons by its various direct compressive stroke techniques on the gastroc/soleus complexes and Achilles tendons in the first session.
223464062|NCT06612983|OTHER|Walking Treatment|Movement itself should promote mobility so walking steadily for the same period of time as the IASTM had taken to complete is the sham treatment in second session.
223464063|NCT06611709|DEVICE|sham taping (non-elastic medical cloth tape)|sham taping
223464064|NCT06611709|DEVICE|Kinesiotaping: A standard 5-cm wide KinesioⓇ Tex Gold|A standard 5-cm wide KinesioⓇ Tex Gold
223464065|NCT06611709|OTHER|exercises|home-based exercises
223464066|NCT06611670|DEVICE|Cataract surgery with Active Sentry|Surgical instrument that detects changes in intraocular pressure and allows rapid feedback to stabilize pressure during cataract surgery.
224303328|NCT04842773|DIAGNOSTIC_TEST|Ultrasound measurement|Ultrasound measurement of sarcopenia in an elderly population
224303329|NCT03357965|OTHER|Questionnaire|Women who had gave birth in 6 weeks
223464067|NCT06611670|PROCEDURE|Traditional cataract surgery|Cataract surgery performed with high intraocular pressures
223464068|NCT06611449|OTHER|The minimal flow anesthesia with sevoflurane group|"In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
224303330|NCT05067530|DRUG|Palbociclib|CDK4/6 inhibitor
224303331|NCT05067530|DRUG|Paclitaxel|Chemotherapy
224303332|NCT05067530|DRUG|Carboplatin|Chemotherapy
223464069|NCT06611449|OTHER|The high flow anesthesia with sevoflurane group|"Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery."
223464070|NCT06613256|OTHER|Endothelial cell biopsy|Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis
223464071|NCT06613152|DRUG|HS-IT201 Injection|Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
223464072|NCT06612593|DRUG|Cilostazol|2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks
223464073|NCT06612593|DRUG|Placebo|The patient will receive 2 tablets twice daily
223464074|NCT06612593|DRUG|Standard treatment|It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
223464075|NCT03971409|BIOLOGICAL|Anti-OX40 Antibody PF-04518600|Given IV
223464076|NCT03971409|DRUG|Avelumab|Given IV
223464077|NCT03971409|DRUG|Binimetinib|Given PO
223464078|NCT03971409|BIOLOGICAL|Utomilumab|Given IV
223464079|NCT03971409|DRUG|Liposomal Doxorubicin|Given IV
223464080|NCT03971409|DRUG|Sacituzumab Govitecan|Given IV
223743442|NCT04199117|BEHAVIORAL|Multiple smoking cessation coaching calls|Participants randomized to intensive treatment access who choose to quit will receive three 15-20-minute quit coaching calls from a trained smoking cessation health counselor. Calls will be scheduled for one week pre-quit, one day after the target quit day, and one week after the target quit day.
223743443|NCT07025551|DRUG|MK-8527|Oral administration
224303333|NCT00969540|DEVICE|Active Mattress Cover|Active Mattress Cover
223464084|NCT00593450|DRUG|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
223464085|NCT00593450|DRUG|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
223464086|NCT06865872|OTHER|Direct Sexual Communication|Participants assigned to receive direct communication about their sexual preferences from their partner.
223464087|NCT06865872|OTHER|Indirect Sexual Communication|Participants assigned to receive indirect communication about their sexual preferences from their partner.
223464088|NCT06865872|DRUG|Alcohol (Ethanol)|Participants assigned to moderate alcohol dose condition (target BrAC .10%) with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) approved alcohol administration procedures.
223464089|NCT06865872|OTHER|No-Alcohol Control|Participants assigned to a no-alcohol control beverage.
223464090|NCT04817267|DEVICE|reSET-O app|The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
223464091|NCT00816777|PROCEDURE|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
223576621|NCT03398265|OTHER|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
223576622|NCT04975737|BIOLOGICAL|GamTBvac|The subunit recombinant tuberculosis vaccine GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose)
223464092|NCT00816777|DRUG|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
224303334|NCT00969540|DEVICE|Placebo Mattress Cover|Placebo Mattress Cover
223464093|NCT05182411|OTHER|assessment|Turkish version of Leg Activity Measure Rivearmead Mobility Index Nottingham Health Profile Functional Independence Measures
223464094|NCT04376515|BEHAVIORAL|HOPE intervention|Online peer support community of peers trained in behavior change science
223464095|NCT05442697|DEVICE|PEMF treatment|Patient will receive a PEMF treatment. The involved leg will be exposed to PEMF for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of PEMF exposure in total.
224303335|NCT06162104|OTHER|No intervention|No intervention
223576623|NCT04975737|BIOLOGICAL|Placebo|Placebo for subcutaneous administration
223576624|NCT02133664|DRUG|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
223576625|NCT02133664|DRUG|Placebo|placebo lipoic acid and placebo oil
224303336|NCT04616339|DRUG|PF-06882961 100 mg|"PF-06882961 100 mg will be provided in 5 different oral formulations A, B, C, D, and E. Cohort 1 is a randomized, open-label, single dose, 4-period, 4-sequence, crossover design where the first 2 periods are cross-over (Formulations A and B) and the second 2 periods are crossover (Formulations C and D).~Cohort 2 is a randomized, open-label, single dose, 2-period, 2 sequence, crossover design (Formulations A and E)"
223464096|NCT05442697|DEVICE|Placebo treatment|Patient will receive a placebo treatment. The involved leg will be exposed to placebo treatment for 30 minutes per session, and the treatment regime will run three times a week for eight weeks, summing up 24 sessions of placebo exposure in total.
223464097|NCT06589648|OTHER|mandala painting|Mandala coloring creates a relaxing effect on individuals because it starts with a pattern that develops like a flower around a point; it allows the individual to stay in the moment, to get away from stress, anxiety and worries, and it relaxes the mind.
223464098|NCT06624787|DEVICE|Rapid Diagnostic Test|The Liverpool School of Tropical Medicine (LSTM) in collaboration with Global Access Diagnostics (GADx) have achieved the development of the first RDT to detect CCHF viral antigens with a sensitivity and specificity that exceeds the minimum recommendation in the WHO target product profile (TPP)of \>80% and \>90% for sensitivity and specificity respectively for minimal performance in pre-clinical studies. The RDT is not only faster providing a test result within 20 minutes, but is also substantially cheaper than RT-PCR, and simpler to perform. A predicted price per test of around $5, whereas the current price of the RT-PCR test ranges from $1,000 to $1,200 for 96 reactions. The RDT does not require refrigeration or require specialist personnel to undertake, and the only additional apparatus needed is a stopwatch to monitor running time.
223464099|NCT03811821|BEHAVIORAL|Biofeedback|The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.
223464100|NCT03811821|DEVICE|Injection|The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
224157767|NCT01442519|DRUG|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
223464101|NCT05223322|BEHAVIORAL|Taking Charge during Treatment (TCT) Intervention|CT is a 16-20week intervention that promotes adoption of the ACSM exercise guidelines for cancer survivors during treatment, including regular moderate to vigorous physical activity (150 minutes per week of moderate activity or 75 minutes per week of vigorous activity) and a minimum of twice weekly resistance training (RT) minutes during CTx and after. Program components include (1) a binder of information, (2) weekly coaching, (3) 2-4x weekly text messaging and (4) exercise supplies. The TCT program is grounded in Social Cognitive Theory.
223464102|NCT06332612|DRUG|Metformin Hydrochloride|Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.
223464103|NCT06332612|DRUG|betamethasone dipropionate|Group 1will recieve topical cream betamethasone thrice daily
223464104|NCT06332612|DRUG|Pentoxifylline|Group 1 will receive Pentoxifylline tablet 400 mg twice daily
223464105|NCT06450457|DEVICE|Polar H10 heart rate monitor|Heart rate will be monitored using a Polar H10 heart rate monitor, with the goal of reaching moderate to high intensity for 30 minutes during the one hour long therapy intervention.
223464106|NCT06450457|DEVICE|Therastride Treadmill System|Participants will be asked to walk on the Therastride Treadmill for 30 minutes.This treadmill can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study.
223464107|NCT06450457|DEVICE|VECTOR Bioness|Participants will be asked to walk using the VECTOR Bioness on a track outside the gym with a harness attached to an overhead sling system. This system can unweight patients so that the task of walking becomes easier. The body weight can be adjusted depending on how much assistance a patient needs from 0% of their bodyweight (completely independent) to up to 50% of their bodyweight for the purposes of this study. This system allows for overground walking on a small indoor track as opposed to walking on a treadmill.
223464108|NCT06450457|OTHER|Physical therapy|Physical therapy will be administered by a physical therapist and will include overground walking, treadmill walking, stairs, and resisted walking.
223464109|NCT04589884|OTHER|Hyperspectral Imaging|Hyperspectral images of the operative field will be collected at several time points during the surgical procedure. The device used is the TIVITA® compact Hyperspectral imaging system (Diaspective Vision GmbH, Germany). It is a CE (European Economic Area) mark approved device. The acquisition takes roughly 10 seconds, is contrast-free and contact-free.
223464110|NCT06612931|PROCEDURE|Dual-lumen catheter-guided mini-forceps biopsy is performed first|In ERCP procedures, catheter-guided mini-forceps biopsy is performed before biliary brush cytology.
223464111|NCT06612931|PROCEDURE|Biliary brush cytology with vacuum aspiration is performed first|In ERCP procedures, biliary brush cytology with vacuum aspiration is performed before dilation catheter-guided mini-forceps biopsy.
223464112|NCT01683604|OTHER|Observational study|
223464113|NCT06875843|BEHAVIORAL|Contingent responses|The adult systematically responds to more complex child vocalizations with more complex responses. When the child first vocalizes, the adult imitates that vocalization. The child's response determines the next adult response. If the child produces a vocalization within 3 seconds, the adult imitates the child, provides a linguistic map (i.e., puts the apparent meaning into words), and complies nonverbally with the child's apparent intent (e.g., giving item or action). If the child does not produce another vocalization within 3 seconds, the adult remains quiet until the child vocalizes again.
223464114|NCT06875843|BEHAVIORAL|Contingent responses plus vocal elicitation strategies|The adult follows the contingent responses condition protocol with the addition of using vocal toys (e.g., echo tubes, microphones that distort voices, and microphones that amplify voices) within exciting turn-taking activities/routines (e.g., blowing bubbles, balloons, and whoopee cushions). The vocal elicitation strategies emphasize the need to help children vocalize to initiate child-adult interactions. These strategies may be especially important for children who vocalize infrequently to benefit from other intervention aspects and enhance their spoken language skills. The vocal elicitation strategies are to be used when needed, rather than being obligatory for every adult-child interaction. If the child vocalizes without a vocal elicitation prompt, the adult still responds to the vocalization
223464115|NCT06875843|BEHAVIORAL|Non-contingent control|The adult provides non-contingent vocal responses based on audio recordings from prior contingent responses condition sessions transmitted via a wireless earpiece. Recordings from these yoked sessions control for number and type of adult vocalizations and minimize the degree of contingency between adult and child vocalizations in this condition.
223576626|NCT02330523|DEVICE|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
223576627|NCT02330523|DEVICE|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
224157768|NCT04100044|OTHER|Exercise Counseling|Meet with physical therapist
223464116|NCT06465355|PROCEDURE|pharyngo-esophageal high-resolution manometry|The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure. 3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
223576628|NCT03906656|DEVICE|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
223576629|NCT03906656|DEVICE|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
223576630|NCT05753566|DRUG|Rezvilutamide|Specifications of 80 mg; orally, once a day
223576631|NCT05753566|DRUG|Androgen deprivation therapy (ADT)|Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
223464117|NCT06612190|PROCEDURE|TMS|TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
223464118|NCT06612190|PROCEDURE|Control|The sham group will be given no real magnetic stimulation.
223464119|NCT06612671|PROCEDURE|tumor wide excision|patients received properative or post-operative radiotherapy
223464120|NCT06453733|DEVICE|Crainio|Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that will estimate ICP offline.
223464121|NCT06692296|BEHAVIORAL|Balance training over stabilometric platform|"The treatment using the stabilometric platform (a total of 20 sessions) generally includes an initial phase (approximately 5 minutes) of training and warm-up in monitor mode, during which the patient becomes familiar with the equipment. The patient then moves on to training library mode, which includes the following subcategories: (1) Stabilometric tracings in both static and dynamic phases (10 minutes); (2) Dexterity exercises in both static and dynamic phases (10 minutes); (3) Imbalance exercises in both static and dynamic phases (10 minutes).~The goal during this phase is to increase the patient's stability limits and provoke balance reactions through load shifts in all directions. The session concludes with 10 minutes of TecnoBody Exergames, which help to automate the functions learned within a more complex activity."
223464122|NCT06692296|BEHAVIORAL|Balance training by means of conventional rehabilitation|Conventional rehabilitation to improve balance includes an initial phase of tissue mobilization, particularly of the foot structures (approximately 5 minutes per foot), in order to prepare them for the subsequent activation phase. This is followed by a phase focused on activating the anti-gravity muscles and aligning the trunk within the chosen setting (10 minutes). The treatment continues with balance training, both static and dynamic, load transfers, and dual-task exercises using external references (15 minutes). The session concludes with functional exercises relevant to the patient's daily life context (10 minutes).
223576632|NCT05753566|RADIATION|SRT|SRT according to standard of care (66.6-72 grays will be delivered to the bed of prostate ,\~50.4 grays to the pelvis if needed)
223576633|NCT05246826|OTHER|Clinical Pilates Exercises|Pilates exercises; warm-up and cool-down exercises will be performed for 5 repetitions, while other exercises will be performed by the same physiotherapist as 10 repetitions depending on the patient's pain and fatigue. The exercises will be advanced at the end of the 3rd week.
223576634|NCT05246826|OTHER|Clinical Pilates Exercises and Conventional Treatment|In addition to pilates exercises, a conventional treatment program will be applied. As part of the conventional treatment program, 20 minutes of Hotpack to the cervical area, 20 minutes of conventional Transcutaneous Electrical Nerve Stimulation (TENS) to the painful area (80 Hertz (Hz), 100 microseconds (μs), until tingling is felt, asymmetrical biphasic rectangular waveform), 8 minutes to the cervical area Ultrasound (US) (4 minutes + 4 minutes, 1.5 watts/cm2, 1 MHz, continuous) will be applied.
223576635|NCT01110837|OTHER|Allergen|Allergen nasal challenge
223576636|NCT01110837|OTHER|Placebo challenge|Placebo nasal challenge
223576637|NCT04231214|DRUG|Olodaterol-Tiotropium|5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
223743444|NCT06681207|COMBINATION_PRODUCT|anodal transcranial direct current stimulation (a-tDCS)|Stroke participants will be randomly assigned into one of three groups: anodal transcranial direct current stimulation (a-tDCS), sham tDCS (s-tDCS), or control groups (i.e. no brain stimulation). Stroke participants in the first two groups will receive five sessions of the assigned brain stimulation combined with visuomotor stepping training over five consecutive days. Healthy adults will be randomly assignments into a-tDCS or s-tDCS groups.
223743445|NCT07025460|DRUG|darbepoetin alfa|Participants receive darbepoetin alfa administered subcutaneously once every 4 weeks for 12 weeks during the evaluation phase. Dose adjustments are made to maintain hemoglobin levels within 10.0-11.0 g/dL.
224068179|NCT03937180|BEHAVIORAL|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
224068180|NCT05256407|OTHER|Intervention, digital support|Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
224068181|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib; In the evening: 1 tablet of 50mg and 75mg placebo, 1 tablet of 50mg Jaktinib.
223464123|NCT02595385|DEVICE|Cell Salvage|Reinfusion of shed blood during the operation
224068182|NCT04539639|DRUG|Jaktinib|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib; In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg Jaktinib.
223464124|NCT02595385|PROCEDURE|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
223576638|NCT00825396|DRUG|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
223464125|NCT02794298|DEVICE|Transcranial direct current stimulation (tDCS)|
223464126|NCT02794298|DEVICE|sham-tDCS|
223464127|NCT06361706|BEHAVIORAL|VR-Enhanced Psychoeducational Program for Chronic Pain|Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
223464128|NCT00087100|DRUG|pemetrexed disodium|
223464129|NCT05736328|PROCEDURE|Traction|Postoperative lower extremity traction
223576639|NCT05782192|DRUG|SAL067|SAL067 6mg(2 tablet) and placebo 25mg (1 tablet)
223576640|NCT05782192|DRUG|Alogliptin|Alogliptin 25mg(1 tablet) and placebo 6mg (2 tablet)
223576641|NCT05782192|DRUG|Placebo|placebo 6mg (2 tablet) and placebo 25mg (1 tablet)
223576642|NCT01595191|OTHER|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
223464130|NCT04448275|OTHER|Neurodynamics Nerve flossing|"Neurodynamics Nerve flossing for femoral nerve that includes two techniques inform of:~slider technique and the second is the tensioner technique"
223464131|NCT04448275|OTHER|conventional selected exercise program|Ultrasound therapy The flexibility exercises for iliopsoas \& quadriceps The iliopsoas \& quadriceps muscles strength exercise
224068183|NCT04539639|DRUG|Jaktinib|In the morning: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib; In the evening: 1 tablet of 75mg placebo, 2 tablet of 50mg Jaktinib.
224068184|NCT04539639|DRUG|placebo|In the morning: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo;In the evening: 2 tablet of 50mg placebo, 1 tablet of 75mg placebo.
224068185|NCT04840043|OTHER|Osteopathic sympathic harmonization|Treatments that harmonize at the sympathetic nerves or plexus, e.g., sympathetic trunk stimulation by means of the rib-raise technique or stimulation of the prevertebral ganglia.
224068186|NCT04840043|OTHER|Sham intervention|Different location, size and time of the rib-raise technique or stimulation of the prevertebral ganglia.
224068187|NCT00853671|OTHER|Adenosine Stress Dual-source CTP|"Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; Iopamidol (IV contrast)- total dose of 150cc; Siemens SOMATOM Definition CT scanner (CT scan radiation) - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)~This is an observational trial, and all patients will undergo the Adenosine Stress Dual-source CTP procedure."
224068188|NCT02567487|DRUG|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
224068189|NCT05551832|DRUG|Arm I (Placebo),|Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months
224068190|NCT05551832|DRUG|Arm II (ESMESOL)|SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD ,
224068191|NCT04875546|BEHAVIORAL|Standard treatment|Adolescent will receive a brief smoking cessation intervention based on the '5A' and '5R' models. Then the research assistant will ask about their tobacco use and assist them to quit using the STAR method. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
224068192|NCT04875546|BEHAVIORAL|Integrated Intervention|In addition to the brief smoking cessation intervention based on the '5A' and '5R' models, the participants will receive brief advice on alcohol use based on the FRAMES model. Then the RA will invite participants to complete the Alcohol Use Disorders Identification Test and provide personalized feedback. There will be a one to one, 20-30 minutes semi-structured interviews with 30 participants. Participants with high(N=15) and low (N=15) adherence will be purposively selected. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
224068193|NCT04875546|OTHER|Control|The adolescents will receive the leaflets for smoking cessation and alcohol abstinence. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
224157769|NCT04100044|BEHAVIORAL|Exercise Intervention|Receive personalized home exercise intervention
224157770|NCT04100044|OTHER|Questionnaire administration|Ancillary studies
224157771|NCT04100044|OTHER|Quality-of-Life Assessment|Ancillary studies
224157772|NCT04347902|DRUG|Intravenous Lipid Emulsion|Various types of intravenous lipids
224157773|NCT03130504|DRUG|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
223464132|NCT05632263|DIAGNOSTIC_TEST|EHMRGscore|validation of the EHMRG score for hospitalized patients with acute heart failure in the emergency department
223464133|NCT06384742|BEHAVIORAL|Shift Worker Intervention for Sleep Health|SWISH, a multicomponent behavioral intervention based on cognitive behavioral therapy for insomnia that is individually administered via telehealth across nine approximately weekly sessions that range in length from 15-60 minutes
223576643|NCT01595191|OTHER|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
223576644|NCT04819230|BEHAVIORAL|Cognitive Bias Modification|A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)
223576645|NCT04819230|BEHAVIORAL|Cognitive Bias Control|A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
224157774|NCT05537272|DRUG|Tadalafil 5mg|Administration of Tadalafil 5mg once daily seven days before and seven days after prostate biopsy
224157775|NCT05537272|DRUG|Tamsulosin Hydrochloride 400 Microgram Prolonged-Release Oral Capsule|Administration of Tamsulosin 0.4mg once daily seven days before and seven days after prostate biopsy
223464134|NCT07023276|OTHER|Neuromuscular Training|Coaches implemented neuromuscular training at the start of all warm-ups for practices and games. The neuromuscular training program was developed by sports medicine professionals at the home institution and the National Basketball Association and incorporates established principles of motor learning and performance training and has an added emphasis of being basketball-specific.
223464135|NCT05748366|PROCEDURE|Serratus Anterior Plane Block (SAPB)|The ultrasound-guided serratus anterior plane block (SAPB) will be performed in a manner previously described in published medical literature. Patients will be consented and monitored. Bupivacaine 0.5% (5 mg/ml) diluted to 30-40 ml will be used in a dose not to exceed 2 mg/kg. The serratus anterior fascial plane will be identified in the 4th/5th intercostal space. The needle will be advanced under real-time ultrasound guidance targeting the superficial serratus anterior fascial plane. The procedure assistant will inject small volumes to hydrodissect the muscle bellies evenly under direct visualization, indicating local anesthetic spread within the fascial plane. Anesthetic will then be injected in 5 ml increments and the needle will be removed. Patient will be continuously monitored on telemetry and pulse-oximetry. Reassessment of the patient will continue for 30 minutes to monitor for signs of local anesthetic systemic toxicity.
223464136|NCT05748366|DRUG|Standard Analgesic Medications|Analgesic medications will be administered via the intravenous, intramuscular or oral route at the discretion of the medical treatment team.
223464137|NCT06692959|DRUG|PD-1 vaccine IMU-201 (PD1-Vaxx)|Investigational Medicinal Product (IMP) PD1-Vaxx is supplied as lyophilized drug substance APi2568, which is a B-cell epitope (amino acids 92-110 from PD-1) linked to a promiscuous T-cell epitope (amino acid residues 288-302 from measles virus fusion protein) via a 4-amino acid linker (G-P-S-L). IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.
223464138|NCT06083376|OTHER|Spinal Stabilization Exercise|Spinal stability exercises are commonly used isometric and isotonic exercises. A spinal stabilization exercise training program will be applied to the exercise group participants using the telerehabilitation method (simultaneous connection) 3 days a week for 8 weeks and a total of 24 sessions.
223464139|NCT06083376|OTHER|physical activity counseling|Control group participants will first be given initial evaluations and verbal physical activity recommendations will be given. Patients will be contacted by phone at the 2nd, 4th and 6th weeks and reminded about the importance of physical activity.
223464140|NCT03574974|DEVICE|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
223464141|NCT03574974|DEVICE|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
223464142|NCT06713668|DEVICE|Backup Pacing Rate Change|Patients will have backup pacing programmed to A (75 bpm) and B (100 bpm), randomizing to sequence of exposure A-B or B-A
223464143|NCT07035340|OTHER|inspiratory muscle training|inspiratory muscle traning MIP%40-60
223576646|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
223464144|NCT07035340|OTHER|standart care|standart care
223464145|NCT06729528|DIAGNOSTIC_TEST|The PePCI and ManTIS scores|The PePCI and ManTIS scores have been developed to predict the indication for whole-body CT in pediatric cases presenting to the emergency department with trauma. These scores help reduce unnecessary radiation exposure in pediatric trauma cases.
223464146|NCT04921592|OTHER|upper extremity stimulation|transcutaneous stimulation of the upper extremities
223576647|NCT01459367|DRUG|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
223576648|NCT01459367|DRUG|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
223576649|NCT05463068|DRUG|NVX-Cov2373|Intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL) on Day 1
223576650|NCT01410292|OTHER|GI and fiber meals|meals with different fiber content and glycemic index
223576651|NCT01410292|OTHER|meals|four different meal regarding GI and fiber content
223576652|NCT05489627|PROCEDURE|Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement|"Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well."
224157776|NCT05537272|OTHER|Placebo|Administration of placebo ( Vitamin C \[ascorbic acid\] 500mg tablet) once daily seven days before and seven days after prostate biopsy
224157777|NCT02279160|DRUG|APD811|
224157778|NCT02279160|DRUG|Placebo|Placebo
223464147|NCT04369833|DEVICE|continuous glucose monitoring system|wearing continuous glucose monitoring device (iPro2 professional continuous glucose monitoring, MedtronicⓇ, California, USA)
223464148|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|To identify the main common genetic determinants of severe COVID-19 by conducting a GWAS: in first phase we will compare SARS-CoV-2 positive patients with severe lung affection to healthy controls from the same geographic area, in order to provide initial data informing the research in the field in a timely fashion. This will be conducted in close collaboration with the University of Kiel COVID-19 genomic initiative. Later on, we will proceed to assess objectives 1 and 2 in the full cohort, including also infected controls who did not developed clinically significant symptoms
223576653|NCT01449773|DIETARY_SUPPLEMENT|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
223576654|NCT01449773|DIETARY_SUPPLEMENT|Placebo|5 capsules/day containing corn and soybean oil
223576655|NCT00047333|DRUG|erlotinib hydrochloride|Given PO
223464149|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|To provide extensive genetic characterization of all patients managed at the Fondazione in order to facilitate other groups working on specific projects (e.g. on candidate genes such as SERPINA1 and ACE2 by the Intensive Care and Cardiology Units and other that may emerge from upcoming projects), in a large population and in a very timely fashion, and without incurring in any additional expenses for the Fondazione research network, and coordinate research efforts.
223576656|NCT00047333|OTHER|laboratory biomarker analysis|Correlative studies
223576657|NCT00047333|OTHER|pharmacological study|Correlative studies
223576658|NCT04533542|OTHER|Measurement|Undergo sensory measurements
223576659|NCT04533542|OTHER|Questionnaire Administration|Ancillary studies
223576660|NCT06177470|DEVICE|Accelerated deep iTBS|Accelerated intermittant teta burst deep Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
223576661|NCT06177470|DEVICE|Accelerated Sham iTBS|Sham accelerated intermittant teta burst Transcranial Magnetic Stimulation on anterior cingulate cortex and medial prefrontal cortex 50 Hz
223576662|NCT03557346|DEVICE|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
223576663|NCT03653468|BEHAVIORAL|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
223576664|NCT01945775|DRUG|talazoparib|Until progression or unacceptable toxicity develops
223576665|NCT01945775|DRUG|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
223576666|NCT02876328|BIOLOGICAL|Ad26.ZEBOV|0.5 mL at a dose of 5x10\^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
223576667|NCT02876328|BIOLOGICAL|MVA-BN-Filo|0.5 mL at a dose of 1x10\^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
223576668|NCT02876328|BIOLOGICAL|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
223576669|NCT02876328|BIOLOGICAL|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
223576670|NCT02876328|BIOLOGICAL|rVSV boost|1 mL at a nominal dose of 2x10\^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
223576671|NCT06279702|OTHER|SERIOUS GAME|Students will play serious game that about first aid.
223576672|NCT06279702|OTHER|COMICS|students will learn comics that about first aid.
223576673|NCT00645905|DRUG|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
224068194|NCT01056146|BEHAVIORAL|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
224068195|NCT01056146|BEHAVIORAL|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
224157779|NCT03973749|OTHER|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
224157780|NCT02249351|DRUG|Talsaclidine|
224157781|NCT02249351|DRUG|Placebo|
224157782|NCT05728424|DRUG|Vonoprazan, Amoxicillin, Levofloxacin|No additional information
223576674|NCT00645905|DRUG|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
223576675|NCT02159677|DEVICE|EIM Measurements|
223576676|NCT02302183|DEVICE|FreeO2 v2.0 automatic adjustment|
223576677|NCT02302183|DEVICE|FreeO2 v2.0 data collecting|
223576678|NCT02876497|OTHER|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
223576679|NCT03542435|DRUG|SXC-2023|Oral capsule
223576680|NCT03542435|DRUG|Placebo|Placebo
223576681|NCT00892606|DRUG|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
223576682|NCT00892606|DRUG|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
223576683|NCT00005013|DRUG|Sertraline|
223576684|NCT00005013|DRUG|Hypericum perforatum (St. John's wort)|
223464150|NCT06549712|GENETIC|genetic determinants to develop respiratory failure|"To provide a coordination to manage the collaboration with other research consortia in the field, e.g. the An anonymized GWAS to urgently query host genetic predisposition to severe COVID-19 (SARS-CoV-2 infection) lung disease, and the COVID-19 Host Genetic Initiative (https://www.covid19hg.org). Indeed, collaboration among large networks analyzing several thousand cases will be ultimately necessary to clarify the genetic basis of COVID-19 susceptibility, and large collaborative networks are essential instruments for conducting human genetic research."
223464151|NCT03862092|DIAGNOSTIC_TEST|Salivary VZV-DNA PCR|VZV-DNA PCR of saliva samples
223464152|NCT04748965|DIAGNOSTIC_TEST|Digital Subtraction Angiography|Compare optical coherence tomography lesion sizing and characteristics compared to traditional digital subtraction angiography
223464153|NCT06524154|BEHAVIORAL|positive reinforcement|normal treatment with with praising the child with encouraging words and pleasing smiles.
223464154|NCT06524154|BEHAVIORAL|rewarding|normal treatment with giving simple gifts like stickers at the end of the procedure.
223464155|NCT06524154|BEHAVIORAL|contingent escape|normal treatment with giving some rest of the procedure while the child on the chair.
223464156|NCT02194894|DRUG|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
223464157|NCT00004533|DRUG|Adeno-associated virus-CFTR vector|
223464158|NCT06236113|DRUG|Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution|administered at rate of 0.1 mg/kg/hr
223464159|NCT02404129|OTHER|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
223464160|NCT03430856|DRUG|Insulin Tregopil|Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
223464161|NCT03430856|DRUG|Insulin Aspart|Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
223464162|NCT01949142|DRUG|OTO-201|Single, intratympanic injection
223464163|NCT01949142|DRUG|Sham|Simulated single, intratympanic injection
223576685|NCT04437719|OTHER|Obvio-19 app|"As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months."
223576686|NCT01971216|BEHAVIORAL|Relaxation|
223464164|NCT00304460|BIOLOGICAL|aldesleukin|
223464165|NCT00834847|DRUG|pravastatin|40 mg tablet
223464166|NCT00834847|DRUG|Pravachol®|40 mg Tablet
223464167|NCT04833062|DIAGNOSTIC_TEST|Ultrasound|In women presenting for a routine antenatal appointment at 20 gestational weeks an ultrasound assessment will be carried out using the 3.5 MHz abdominal probe in order to assess foetal biometry and anatomy as per the guidelines. We will assess the utility of mid- and third trimester ultrasound parameters for prediction of intrapartal events and perinatal outcomes in patients with diabetes mellitus.
223464168|NCT04833062|OTHER|Survey|"The maternal baseline characteristics are defined by maternal age at enrollment, parity, number of prenatal visits, some indicators of socioeconomic status and habits, family history of DM (first degree) and prepregnancy hypertension.~The prepregnancy body mass index (BMI; kg/m2) will be calculated using the self-reported prepregnancy maternal weight; the pregnancy weight gain (kg) will be calculated by the difference between final pregnancy weight and prepregnancy maternal weight and was classified according to the prepregnancy BMI."
223464169|NCT02506062|DEVICE|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
223464170|NCT02523404|PROCEDURE|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
223576687|NCT00382915|DEVICE|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
223576688|NCT01573637|DRUG|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
224068196|NCT04986800|BEHAVIORAL|PROACTIVE Parent|PROACTIVE Parent will educate parents about their child's mental health symptoms and treatment, how to talk to the child's therapist to support treatment goals at home and in the community. PROACTIVE Parent will teach parents the function of child behavior, the role of symptomatology in child behaviors, and strategies to promote effective behavior management and healthy coping. Parents will also learn skills to manage their own emotional dysregulation to promote calm parental responding and promote healthy parent-child interaction and communication.
224068197|NCT01107431|DIETARY_SUPPLEMENT|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
224068198|NCT01107431|DIETARY_SUPPLEMENT|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
224068199|NCT02858414|OTHER|additional blood sample|
224068200|NCT03221738|BEHAVIORAL|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
224068201|NCT05404464|OTHER|Different baseline characteristics and clinical management|Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
224157783|NCT05098808|OTHER|Acoustic features (from signals obtained during phonation)|"Acoustic features will be obtained via phonation files.~A voice recorder application provided by Apple was used, and the sampling frequency of the sound was 44,100 Hz. The digitized cough sound signals were band-pass-filtered between 20 to 16,000 Hz to use data from the whole frequency band gathered by the iPad. In each case, the smart device was positioned 20cm from the patient"
223464171|NCT00523055|DRUG|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
223464172|NCT03831919|DEVICE|SYNC III|Hoya SYNC III design spectacle lenses
224157784|NCT00405275|DRUG|Etanercept|etanercept, subcutaneous injection
224157785|NCT00405275|DRUG|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
224157786|NCT00405275|DRUG|Sulfasalazine|sulfasalazine, oral
224157787|NCT00405275|DRUG|Hydroxychloroquine|hydroxychloroquine, oral
224157788|NCT00405275|DRUG|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
224157789|NCT00405275|DRUG|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
224303337|NCT01593514|BIOLOGICAL|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
223464173|NCT03831919|DEVICE|single vision lenses|single vision spectacle lenses with no addition
223464174|NCT03442231|DEVICE|Journey UNI Unicompartmental Knee System|Lateral or medial knee compartment replacement
223464175|NCT01570842|OTHER|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
223464176|NCT01570842|PROCEDURE|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
223464177|NCT02155452|PROCEDURE|ALA|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
223464178|NCT04961697|BEHAVIORAL|Hospital diaries|Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
223464179|NCT04602156|PROCEDURE|Trocar percutaneous cholecystostomy|Percutaneous cholecystostomy using the one-step Trocar technique under US guidance. An 8Fr Trocar catheter will be inserted percutaneously within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
223464180|NCT04602156|PROCEDURE|Seldinger percutaneous cholecystostomy|Percutaneous cholecystostomy using the Seldinger technique under US guidance. Following percutaneous puncture of the gallbladder with an 18G needle under real-time US guidance, an 8Fr catheter will be inserted percutaneously over the wire within the gallbladder under real-time US guidance. The procedure will be performed using an aseptic technique, local anesthesia and intravenous opioid analgesia.
223464181|NCT01213446|BIOLOGICAL|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
223464182|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
223464183|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
223464184|NCT01395810|DRUG|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
223464185|NCT04940156|DEVICE|Confirm Rx (Implantable Cardiac Monitor)|Confirm Rx implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
223464186|NCT04940156|DEVICE|Reveal LINQ (Implantable Cardiac Monitor)|Reveal LINQ implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)
223464187|NCT02252107|DRUG|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
223464188|NCT02521597|DEVICE|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
223464189|NCT02521597|DEVICE|Traditional otoscope|Use of a regular otoscope
223464190|NCT05027815|BIOLOGICAL|Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells|cryopreserved cellular therapy product in cryostor CS5, for IV infusion
223464191|NCT00523692|DRUG|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
223464192|NCT00523692|DRUG|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
223464193|NCT01307878|DRUG|chemotherapy ± targeted therapy|Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.
223464194|NCT04784507|PROCEDURE|En Bloc Resection|En bloc transurethral resection of bladder tumor (EBR-BT) using any energy source (laser and bipolar or monopolar energy)
223464195|NCT04784507|PROCEDURE|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)|Conventional Transurethral Resection Bladder Tumor (Mono/Bipolar)
223464196|NCT03574038|DEVICE|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
223464197|NCT03574038|OTHER|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
223464198|NCT03470454|DRUG|Linagliptin Oral Tablet|Linagliptin for blood glucose control
223464199|NCT03770026|DRUG|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
224303338|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
223464200|NCT03770026|DRUG|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
223464201|NCT03770026|BIOLOGICAL|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
223464202|NCT02905045|DRUG|Ketoprofen|
223464203|NCT02905045|DRUG|placebo|
223464204|NCT04019145|DRUG|EverX Posterior|fiber reinforced bulk fill resin composite
223464205|NCT04019145|DRUG|Resins, Composite|incremental packing of Nanohybrid Resin composite
223576689|NCT01573637|DRUG|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
223464206|NCT05758818|DRUG|Placebo|Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
223464207|NCT05758818|DRUG|Moxifloxacin (positive control)|Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
223464208|NCT05758818|DRUG|Milademetan|"Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2"
223464209|NCT04655326|BIOLOGICAL|Flore|personalized blend of GRAS approved probiotic strains, prebiotics, and botanicals
223464210|NCT01438138|OTHER|diagnostic laboratory biomarker analysis|Correlative studies
223464211|NCT03677869|DEVICE|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
223464212|NCT00933504|DRUG|LACTIC ACID(ND)|Treatment duration: 6 weeks.
223464213|NCT06765954|DRUG|N-803 (IL-15 Superagonist)|Administered subcutaneously (SC) both before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
223464214|NCT06765954|DRUG|ETBX-071 (PSA-based Oncolytic Virus)|Administered subcutaneously (SC) before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.
223464215|NCT06765954|DRUG|M-CENK (Activated NK Cells)|Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.
223464216|NCT06765954|RADIATION|External Beam Radiation Therapy (EBRT)|This is a standard treatment administered to all participants. The specific dose and schedule (40 Gy in 5 fractions over 2 weeks or up to 9 weeks) are determined by the investigator based on clinical judgment.
223576690|NCT00607854|DRUG|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
223576691|NCT04094233|DIETARY_SUPPLEMENT|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
223576692|NCT04094233|OTHER|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
223576693|NCT04643119|DEVICE|Medial Congruent Insert|The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
224071557|NCT04449055|DEVICE|Transcranial Magnetic Stimulation|Participants will undergo 16 treatments consisting of intermittent theta burst stimulation targeting the dorsolateral prefrontal cortex and continuous theta burst stimulation targeting the medial prefrontal cortex, over a 4-week period that coincides with psychosocial treatment for methamphetamine use disorder.
223464217|NCT06765954|RADIATION|Androgen Deprivation Therapy (ADT)|May be used in conjunction with the other therapies. The specific type and duration of ADT are at the investigator's discretion, and it may be initiated up to 6 months after the completion of radiotherapy. This treatment is not part of the experimental treatment regimen.
223464218|NCT06765954|RADIATION|Post-radiation immunotherapy|The post-radiation immunotherapy phase in the ResQ110B-PROS study involves the continued administration of N-803, ETBX-071, and M-CENK, but with a specific schedule and after the completion of radiation therapy.
223464219|NCT07068230|DRUG|Ondansetron 8mg|Ondansetron 8 mg IV Administered 5 minutes before spinal anesthesia
223464220|NCT07068230|DRUG|Dexamethasone|Dexamethasone 8 mg IV Administered 5 minutes before spinal anesthesia
223464221|NCT07068230|DRUG|Saline|5ml normal saline Administered 5 minutes before spinal anesthesia
224071558|NCT01302951|DRUG|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
224071559|NCT01740375|PROCEDURE|esophagectomy|esophagectomy
224071560|NCT03919526|BIOLOGICAL|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
223464222|NCT07073508|OTHER|Renal Artery Duplex|Renal artery duplex will be performed to all patients in terms of renal resistivity index (RRI).
223464223|NCT07072546|PROCEDURE|free gingival graft + gelatin sponge|Free gingival graft surgery and application of gelatin sponge to the palatal wound
223464224|NCT07072546|PROCEDURE|free gingival graft + chitosan|free gingival graft surgery and application of chitosan to the palatal wound
223464225|NCT07072546|PROCEDURE|free gingival graft + chitosan and i-PRF|free gingival graft surgery and application of chitosan and i-PRF to the palatal wound
223464226|NCT07072559|OTHER|dental simulation game|At the first visit children will play on any procedure in dental simulation game, after that the child will be shown two animals, after which they virtually do a root canal procedure. Tasks include performing a dental X-ray, anesthetizing the tooth using a syringe, drilling decayed cavity and start pulp treatment, rinsing, pulp treatment and filling the tooth, applying light cure and finally polishing the teeth. The second visit for pulpotomy procedure will be scheduled two days after first visit. Children will be managed using the TSD (Tell-Show-Do) technique.
223464227|NCT07072559|OTHER|tell show do|"For the control group (group 1) TSD (Tell-Show-Do) technique group, children will be managed with a verbal explanation and a friendly, non-threatening demonstration of the upcoming dental treatment. The do phase involved carrying out the dental procedure as per the prior explanation and demonstration"
223464228|NCT07072078|BEHAVIORAL|Video-based Communication|Participants received structured video-based communication sessions with their family members using the WhatsApp platform. The intervention was delivered once daily for three consecutive days, with each session lasting between 5 and 20 minutes. Communication was guided to include emotional support, positive conversations, and future-oriented discussion. The sessions were facilitated by nurses who ensured clinical stability, technical setup, and emotional readiness of the patient. This intervention aimed to reduce emotional and social loneliness among ICU patients and was integrated into standard intensive care routines without disrupting medical care.
223464229|NCT00674206|DRUG|Gemcitabine|Gemcitabine 1000mg/m\^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
223464230|NCT00674206|DRUG|Oxaliplatin|Oxaliplatin 100mg/m\^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
223464231|NCT01719159|DRUG|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
223464232|NCT03054285|DRUG|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
223464233|NCT04265261|DRUG|Placebo|Participants will receive oral placebo matched to RG7774
223464234|NCT04265261|DRUG|RG7774|Participants will receive oral RG7774
223464235|NCT02930681|DIETARY_SUPPLEMENT|Glucosanol 500mg|
223464236|NCT02930681|DIETARY_SUPPLEMENT|Placebo|
223464237|NCT00330044|DRUG|Premetrexed (Alimta)|
223464238|NCT00330044|DRUG|Carboplatin|
223464239|NCT03877224|DRUG|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
223464240|NCT03877224|OTHER|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
223464241|NCT05837546|OTHER|Animal-assisted intervention|presence of a dog, contact between dog and participant
223464242|NCT05837546|OTHER|Factice dog intervention|presence of a factice dog, contact between factice dog and participant
223464243|NCT05837546|OTHER|Plant intervention|presence of a plant, contact between plant and participant
224071561|NCT03919526|DRUG|Fludarabine|30mg/m2/d
224071562|NCT03919526|DRUG|Cyclophosphamide|300mg/m2/d
224071563|NCT01049685|DRUG|First-line Antiretroviral Therapy|"* Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~* Efavirenz: 01 capsules day, plus NRTI background"
224071564|NCT00017342|DRUG|bryostatin 1|
224071565|NCT00017342|DRUG|cytarabine|
224071566|NCT05073107|OTHER|"Mobile Dental Application, Dental Monitoring (DM)"|"o The Test group will be required to take intra-oral videos (which will be translated into photographs) using the DM application weekly and it will be monitored by the delegated team members:~* Day 0 (To be taken at the clinic)~* Day 7 (To be taken in the evening after brushing teeth)~* Day 14 (To be taken in the evening after brushing teeth)~* Day 21(To be taken in the evening after brushing teeth)~* Day 28 (To be taken before study Visit 2) There is a window period of +1 day for the intra-oral videos."
224071567|NCT04153188|DEVICE|The Vbeam® Prima System|3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
223576694|NCT04643119|DEVICE|Cruciate-Retaining Insert|The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
223464244|NCT05438966|OTHER|No intervention|No intervention
223576695|NCT01152515|DRUG|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
223464245|NCT02814617|DIETARY_SUPPLEMENT|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
223464246|NCT02814617|DIETARY_SUPPLEMENT|Placebo|
223464247|NCT05483465|DRUG|Nicotinamide riboside|Oral NR, 1g/day per os for 8 weeks
223464248|NCT05483465|DRUG|Placebo|Visually identical pill to NR, daily per os for 8 weeks
223464249|NCT00673374|DEVICE|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
223464250|NCT00348465|PROCEDURE|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
223576696|NCT03515941|DRUG|Oxaliplatin|130 mg/m2 by IV (Arm 1)
223576697|NCT03515941|DRUG|Capecitabine|625 mg/m2 (Arm 1), 1000 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
223576698|NCT03515941|DRUG|Leucovorin|400 mg/m2 by IV (Arm 1 \& Arm 2)
223576699|NCT03515941|DRUG|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
223576700|NCT03515941|RADIATION|radiation|45 Gy in 1.8 Gy/fraction
223576701|NCT00334282|DRUG|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
223576702|NCT00334282|DRUG|placebo|matching placebo (800 mg tablet) once daily
223576703|NCT00029458|DRUG|Clozapine|
223576704|NCT06105658|BIOLOGICAL|Unrelated umbilical cord blood|The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
223576705|NCT06105658|DRUG|Venetoclax|Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
223576706|NCT06105658|DRUG|Decetabine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
223576707|NCT06105658|DRUG|Azacitidine|Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)
223576708|NCT02759315|DRUG|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
224157790|NCT00731666|DEVICE|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
223464251|NCT03152266|OTHER|No intervention. Observational study|Follow up of the function of the hip after reduction of the impacted fragment which associated with acetabular fractures
223464252|NCT00816322|DIETARY_SUPPLEMENT|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
223464253|NCT00816322|DIETARY_SUPPLEMENT|Placebo|high oleic oil
223464254|NCT03285165|DRUG|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
223464255|NCT03285165|DRUG|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
223576709|NCT02759315|DRUG|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
223576710|NCT01689350|GENETIC|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
224157791|NCT03523806|BEHAVIORAL|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
224157792|NCT00467506|DRUG|bispecific antibody and di-DTPA-131I|
223464256|NCT01494701|DRUG|nusinersen|Administered by intrathecal (IT) injection
223576711|NCT00418587|DRUG|Cholecalciferol|800 IU oral daily
223576712|NCT00418587|DRUG|Cholecalciferol|2000 IU oral daily
223576713|NCT00418587|DRUG|Cholecalciferol|4000 IU oral daily
223576714|NCT03759964|DRUG|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
223576715|NCT03759964|DRUG|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
223576716|NCT00985907|DRUG|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
223576717|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
223576718|NCT01569061|DEVICE|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
223576719|NCT03484832|DEVICE|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
223576720|NCT03484832|OTHER|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
224157793|NCT02884193|PROCEDURE|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
223464257|NCT05167916|PROCEDURE|Outpatient check cytoscopy|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
223464258|NCT05167916|DIAGNOSTIC_TEST|Urine cytology|"Four weeks after primary TURBT, study participants will provide freshly voided urine sample which will be sent for cytology assessment by uropathologist in charge according to the Paris classification system. Suspicious sample for malignancy, low- and high-grade malignant samples will be considered positive results. On the other hand, hyperplastic or negative samples for malignancy will be defined as negative results.~Thereafter, patients will be assessed by flexible white light check cystoscopy under local anesthesia using flexible instrument by single operator. Checklist will be fulfilled by the operator urologist. Check cystoscopy will be considered positive when encountering residual gross lesion at the area of previous resection or newly developed lesions or both."
223464259|NCT04059341|DEVICE|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
223464260|NCT00120341|DEVICE|Anodyne Therapy System|
223464261|NCT04019886|OTHER|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
223464262|NCT02940236|OTHER|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
223464263|NCT04551235|OTHER|there are not any interventions in this study|there are not any interventions in this study
223464264|NCT02788318|OTHER|Brain samples|Collected in patients died
223464265|NCT02788318|OTHER|Skin samples|Collected in patients died
223464266|NCT02278705|OTHER|Attention to BMI|Evidence (using electronic health record data) denoting provider attention to about high BMI.
223464267|NCT02278705|OTHER|Attention to high-BMI-related Medical Risk|Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
223576721|NCT03484832|OTHER|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
223576722|NCT03484832|DRUG|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
223576723|NCT03840525|BEHAVIORAL|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
223576724|NCT03840525|BEHAVIORAL|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
223576725|NCT00989391|DRUG|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
223576726|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
223743446|NCT06503354|DEVICE|Neural Sleeve and Zeno walkway|"A standard manual stopwatch will be used to record time. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform four, 5-minute walking bouts while wearing the Neural Sleeve without electrical stimulation. Participants will not receive any intervention or treatment. Simultaneously, the Zeno walkway will be operated according to manufacturers instructions. Condition descriptions are as follows:~Condition 1 (normal walking speed): During this condition, participants will be asked to walk at their normal, comfortable pace for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course.~Condition 2 (fast walking speed): During this condition, participants will be asked to walk, covering as much distance as possible for 5 minutes. They will walk back and forth along a 12-meter course with the gait mat in the center of the course."
223743447|NCT07004972|DRUG|Mavacamten|Specified dose on specified days
223743448|NCT05364203|DEVICE|DEEPSEN virtual reality mask|DEEPSEN virtual reality mask with 360 ° vision. The audio-visual content will be chosen by the patient.
224071568|NCT04153188|DRUG|Oxymetazoline HCL 1% Cream|Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
224157794|NCT02884193|PROCEDURE|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
223464268|NCT02278705|OTHER|No attention to high BMI or high-BMI-related medical risk|Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
223464269|NCT00933114|PROCEDURE|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
223464270|NCT02360787|BEHAVIORAL|Energy restriction|
223464271|NCT02360787|BEHAVIORAL|Almonds (15% kcal/day)|
223464272|NCT03951545|PROCEDURE|First line total knee replacement for gonarthrosis .|Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
223464273|NCT01065298|BIOLOGICAL|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of \>40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
223464274|NCT03202446|DRUG|1% Glycated Chitosan|
223464275|NCT03202446|DEVICE|Photothermal Laser|
223464276|NCT03202446|DRUG|Placebo|
223464277|NCT03202446|DRUG|Cyclophosphamide|
223576727|NCT00989391|DRUG|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
223576728|NCT00989391|DRUG|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
223576729|NCT00989391|DRUG|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
223576730|NCT00989391|DRUG|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
223576731|NCT00739180|OTHER|Control|Standard care control (no exercise)
223464278|NCT03202446|DRUG|Standard of Care|
223464279|NCT03836534|BEHAVIORAL|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
223464280|NCT03099603|DRUG|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
223464281|NCT06481943|DEVICE|Sponsor MCG device (CardiAQ)|Unshielded magnetocardiography device for measuring cardiac magnetic fields
223576732|NCT00739180|OTHER|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
223576733|NCT00739180|OTHER|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
223464282|NCT04420962|DIAGNOSTIC_TEST|Visual Acuity|Best corrected visual acuity utilizing the Snellen method
223464283|NCT05919485|PROCEDURE|tDCS|"0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC"
223464284|NCT03182790|BEHAVIORAL|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
223464285|NCT03182790|BEHAVIORAL|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
224071569|NCT03560856|DRUG|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
223464286|NCT03182790|BEHAVIORAL|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
223464287|NCT03182790|BEHAVIORAL|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
224071570|NCT00000879|BIOLOGICAL|ALVAC(2)120(B,MN)GNP (vCP1452)|
223576734|NCT03464422|BEHAVIORAL|ESTEEM conneCT|"The intervention adapts the ESTEEM (Pachankis et al, 2015) intervention to address the multiple-stigma stressors faced by MSM of color, including sexual orientation and racial stigma in a manualized, CBT-based intervention. Approximately thirty participants (divided between two cohorts) will complete ten group sessions will take place at regular times once per week over the course of three months. The groups will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
223576735|NCT06044805|DRUG|Chloroquine|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 0 and 1, 5 mg base/kg on Day 2)
223576736|NCT06044805|DRUG|Primaquine|Primaquine: 7.5 mg base tablet. Medication given as 0.25mg/kg daily for 14 days.
223576737|NCT01370837|OTHER|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
223576738|NCT01370837|OTHER|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
223576739|NCT00041171|DRUG|Hypericum perforatum|
223576740|NCT00041171|DRUG|docetaxel|
223576741|NCT00041171|OTHER|placebo|
223576742|NCT05501613|DIAGNOSTIC_TEST|Multimodal Neuromonitoring|Invasive Multimodal Neuromonitoring
223576743|NCT04240093|BEHAVIORAL|Behavioral Activation (BA) Therapy|8 sessions of behavioral activation therapy
223576744|NCT04240093|BEHAVIORAL|Substance Abuse and Health Navigation Counseling|2 standard substance abuse and health navigation counseling
223576745|NCT04240093|OTHER|Medications for Opioid Use Disorder|Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
223576746|NCT04333602|DIAGNOSTIC_TEST|Urinary culture and treatment if asymptomatic bacteriuria is detected|Urinary culture: post- bladder catheter removal, three weeks post-transplant and before double-J ureteral stent removal. Based in the assigned group If we detect asymptomatic bacteriuria specific treatment will be instituted or No treatment.
223576747|NCT01247935|OTHER|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
223576748|NCT01247935|OTHER|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
223576749|NCT01247935|OTHER|Control|Patients are monitored for pain and discomfort
223576750|NCT00670176|BEHAVIORAL|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
223576751|NCT03322501|BEHAVIORAL|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
223576752|NCT00349258|DRUG|Leuprolide acetate|
223576753|NCT01628367|PROCEDURE|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
223576754|NCT01628367|DEVICE|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
223576755|NCT01628367|BIOLOGICAL|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
223576756|NCT01628367|BIOLOGICAL|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
223576757|NCT01628367|BIOLOGICAL|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
223576758|NCT01628367|DRUG|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
223576759|NCT04317157|DIETARY_SUPPLEMENT|Caffeine|Specific dosage of caffeine for each participant (6 mg.kg-1).
223576760|NCT04317157|OTHER|Placebo|Placebo pill.
223576761|NCT02209402|BEHAVIORAL|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
223576762|NCT02839902|DRUG|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
223576763|NCT02839902|OTHER|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
223743449|NCT06878326|DEVICE|tDCS|Participant will receive three stimulation conditions: cathodal tDCS of the left DLPFC, anodal tDCS of the left DLPFC and sham-tDCS. The order of the conditions will be randomized and counterbalanced across participants, and the three stimulation conditions will be administered at least a week apart to avoid carry-over effects. The tDCS session will last for 20 minutes.
223743450|NCT06713343|DEVICE|Laryngeal Mask Airways|The 172 patients who will be admitted for elective surgery will be divided into two groups as Group L and Group R by computer-assisted randomization method. Patients in Group L will be ventilated with a classical laryngeal mask airways (cLMA) stored at 10 °C to 12 °C (low temperatures), while patients in Group R will be ventilated with a classical laryngeal mask airways (cLMA) stored at 22 °C to 25 °C (room temperatures).
223464288|NCT03182790|BEHAVIORAL|Brief advice|Very brief, minimal and general smoking cessation advice
223464289|NCT03182790|BEHAVIORAL|COSH booklet|A general smoking cessation self-help booklet
223464290|NCT03182790|BEHAVIORAL|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
223464291|NCT03182790|BEHAVIORAL|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
223464292|NCT06936319|BEHAVIORAL|Best clinical practice plus CPM-biofeedback training|The CPM-biofeedback training consists of a baseline 2-minutes active standing and the following four different physical maneuver: leg crossing and muscle tensing, heel raises (10 tiptoeing per minute), squatting, unilateral handgrip (20 times per minute). All exercises will be performed under continuous heart rate and blood pressure monitoring to enable the study participants to gain feedbacks on the effect of the maneuvers on their own biosignals.
223464293|NCT06936319|OTHER|Best clinical practice|Recommendations about life-style and behavioural measures to mitigate POTS symptoms in daily life.
223464294|NCT06931977|DIETARY_SUPPLEMENT|Supplement system + copaiba softgels|"The supplement system consists of:~* dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets~* dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels~* dōTERRA PB Restore ProBiome Complex (PBR) capsules~Which will also be taken with:~• dōTERRA Copaiba Essential Oil (CEO) softgels~VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.~EOM is a softgel containing fish oil and wild orange essential oil.~PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.~CEO is a softgel containing Copaifera (copaiba) essential oil and extra virgin olive oil.~Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day."
223464295|NCT06931977|DIETARY_SUPPLEMENT|Supplement system + placebo softgels|"The supplement system consists of:~* dōTERRA VMG+ Whole-Food Nutrient Complex (VMG) sachets~* dōTERRA EO Mega+ Essential Oil Omega Complex (EOM) softgels~* dōTERRA PB Restore ProBiome Complex (PBR) capsules~Which will also be taken with:~• Olive oil placebo softgels~VMG is a powdered nutritional drink packaged in individual sachets. The powder is a blend of food powders/extracts, vitamins and minerals, probiotics, essential oils, and sweeteners.~EOM is a softgel containing fish oil and wild orange essential oil.~PBR is a capsule containing a mix of pre-, pro-, and post-biotics and bacteriophages.~The placebo is a softgel containing extra virgin olive oil.~Participants will also be asked to implement lifestyle changes. They will be asked to try to get at least 8 hours of sleep, eat at least three servings of fruit/vegetables daily, and exercise at least 30 minutes every day."
223464296|NCT02166359|DRUG|Extraneal (Icodextrin)|
223464297|NCT02166359|DRUG|Glucose solution|
223464298|NCT00447902|DRUG|tipranavir|
223464299|NCT00447902|DRUG|ritonavir|
223464300|NCT06948019|BIOLOGICAL|BFB-101 (AAV9-CBh-AP4B1)|The AAV9-CBh-AP4B1 biological drug product is an aqueous suspension of a gene transfer vector intended for CSF injection. It consists of replication deficient adeno-associated virus (AAV) vector with the AAV serotype 9 capsid enclosing a single stranded DNA with an expression cassette of AP4B1 driven by CBh promoter.
223464301|NCT06338306|DRUG|Tacrolimus（FK506）|Prograf
223464302|NCT00379834|DRUG|Cosopt|Cosopt twice daily in both eyes
223464303|NCT05700734|DRUG|MK-8510|Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
223464304|NCT04066933|COMBINATION_PRODUCT|A2M enriched plasma|Plasma enriched for alpha2macroglobulin (A2M-PPP) was produced by a centrifugation and filtration process developed by Cytonics Corporation. Initially, 7 milliliters of Anticoagulant Citrate Dextrose Solution A, ubiquitous surface protein (USP) was drawn into a 60 cc syringe and then an additional 38 cc of autologous blood was drawn up through an antecubital vein. Two syringes were prepared in this manner and then centrifuged at 4000 rpm (1280G) for 4 minutes. The supernatant plasma fraction was then transferred to a roller pump system that circulates the fluid through a proprietary filter having a high molecular weight cutoff designed to trap larger molecules including alpha 2 macroglobulin (720 kDa).
223464305|NCT00505050|OTHER|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
223464306|NCT03337815|DRUG|Treatment of MTX and TwHF placebo|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
223743451|NCT06881862|OTHER|The immediate craniocervical flexion and correct posture training|The craniocervical flexion and correct posture training were given immediately during the assessment, with no follow-up sessions or long-term interventions. The focus was solely on providing the training at that moment, without any prolonged or repeated exercises.
223464307|NCT03337815|DRUG|Treatment of TwHF and MTX placebo|Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
223464308|NCT00811694|OTHER|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
224071571|NCT00000879|BIOLOGICAL|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
224071572|NCT00000879|BIOLOGICAL|ALVAC-HIV MN120TMG (vCP205)|
224071573|NCT00264238|DRUG|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
224071574|NCT04899232|DRUG|Antithrombin III|Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).
224071575|NCT00485212|DEVICE|compression bandage|
224071576|NCT00700271|DRUG|Amlodipine|5 mg or 10 mg tablets.
223464309|NCT00115310|DRUG|NGX-4010|
223464310|NCT02027233|OTHER|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses (VRS, SARS-CoV-2 and others).
223464311|NCT01256528|PROCEDURE|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
223464312|NCT00667329|DRUG|2CdA|1.5 mg/m\^2 subcutaneous injection three times daily x 7 days.
223464313|NCT00667329|DRUG|Cyclophosphamide|40 mg/m\^2 PO twice daily x 7 days.
223464314|NCT00667329|DRUG|Rituximab|375 mg/m\^2 IV once weekly x 4 weeks.
223464315|NCT01001429|DRUG|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
223464316|NCT01001429|DRUG|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
223464317|NCT00956839|DRUG|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
223464318|NCT03425669|DEVICE|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
223464319|NCT03425669|DEVICE|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
223464320|NCT03425669|DRUG|Active medication|Patients will be examined with and without medication.
223464321|NCT02880254|DEVICE|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
223464322|NCT02880254|DEVICE|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
223464323|NCT04643132|DRUG|Normal saline|After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
223464324|NCT04643132|DRUG|S-ketamine (low-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.
223464325|NCT04643132|DRUG|S-ketamine (high-dose)|After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
223464326|NCT02472730|DEVICE|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
223464327|NCT02484144|OTHER|modern information|information by video for coronarography
223464328|NCT02484144|OTHER|usual information|usual information for coronarography
223464329|NCT04935203|BEHAVIORAL|Priming intervention|The priming manipulation will be embedded in one computerized experiment to test the effect of three priming interventions on people's emotional reaction and their subsequent sustainable food selection. The priming conditions include priming with health benefits, environment benefits, and co-benefits of having sustainable diets, respectively. The cueing manipulation will be achieved by asking participants to complete a word-search exercise. Brief introduction will be provided to guide participants to choose words/statements that can indicate having a health and sustainable diet can have one of the three benefits: health benefits, environmental benefits or both benefits. The exercise will take \~2 min.
223464330|NCT02976311|PROCEDURE|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
223464331|NCT02976311|PROCEDURE|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
223464332|NCT02163395|DEVICE|FullCeram implant|FullCeram implantation
223464333|NCT05020041|BEHAVIORAL|Physical activity|"The schools in the intervention group will receive the online educational talk aimed at schoolchildren and a talk aimed at Physical Education teachers, given that they are fundamental for the development of habits in the school stage; besides, painted games will be implemented in the school playground.~The implementation of painted games will consist of adapting a space destined for recreation, designing a psychomotor circuit that does not require contact between peers or manipulation of objects in order to maintain COVID-19 sanitary and safety protocols. The psychomotor circuit includes a line circuit, a jumping sequence game, and a letter spiral. All the games will be implemented in a space within the educational establishment to which the students will have access during recess. The game designs involve activities to develop motor patterns such as jumping with different supports, running, and dynamic balance."
223464334|NCT01541709|DRUG|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
223464335|NCT06958029|PROCEDURE|Cardiac surgery|Patients receiving general anesthesia for cardiac surgery
223464336|NCT03080740|DRUG|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
223464337|NCT03080740|DRUG|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
223464338|NCT02666989|DRUG|placebo|2 placebo pills twice a day
223464339|NCT02537951|DEVICE|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
223464340|NCT02537951|DEVICE|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
223464341|NCT02537951|DEVICE|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
223743452|NCT07041125|DEVICE|Watchman FLX™ Pro device.|Patients eligible for the main DISRUPT-AF Registry with a planned concomitant LAAC procedure using the Watchman FLX™ Pro device.
223743453|NCT06882824|PROCEDURE|myomectomy with placebo|myomectomy after administration of placebo (control group)
224071577|NCT00700271|DRUG|Valsartan|160 mg capsules.
223464342|NCT06253936|OTHER|Magnetic Resonance Venography|Detect the anatomical variants of dural sinuses by Magnetic Resonance Venography
223464343|NCT01401595|DRUG|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
223576764|NCT03009643|DRUG|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
223576765|NCT03009643|DEVICE|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
223576766|NCT03009643|DEVICE|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
223576767|NCT04596332|OTHER|no intervention measures|Because this study was a retrospective study, no intervention measures were implemented for the patients enrolled.
223576768|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
223576769|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
223576770|NCT01992614|DRUG|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
223576771|NCT04304170|DIETARY_SUPPLEMENT|VES002|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
223576772|NCT04304170|OTHER|Placebo|The sachets were to be dissolved in 200 ml of water at room temperature to be taken before breakfast.
223576773|NCT03353922|DRUG|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
223576774|NCT03353922|DRUG|Placebo Oral Tablet|sugar pill
223464344|NCT06958601|OTHER|surgical procedure|Effectiveness of different surgical modalities in the treatment of thyroid cancer
223576775|NCT00740714|DRUG|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
223576776|NCT00740714|DRUG|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
223576777|NCT03100721|BEHAVIORAL|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
223576778|NCT03100721|PROCEDURE|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
223576779|NCT03628638|OTHER|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
223576780|NCT03688555|DRUG|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
223576781|NCT03688555|DRUG|Placebo|Matching placebo hard gelatin capsules
223576782|NCT05204056|DRUG|iced normal saline|Iced normal saline (20ml) was given intraoperative joint cavity infusion therapy
223576783|NCT05204056|DRUG|Tranexamic acid injection|20ml of tranexamic was given with iced normal saline for intraoperative joint cavity infusion.
223576784|NCT05204056|OTHER|Cocktail (composing by Ropivacaine, Morphine and Epinephrine) perfusion|Cocktail was formulated during the operation by mixing Ropivacaine 150mg, Morphine 10mg and Epinephrine 1mg, then normal saline was used to dilute the mixture to 60ml. Then the cocktail mixture was applied for the joint cavity perfusion.
223576785|NCT00208520|DRUG|Carbamazepine|
223576786|NCT00208520|DRUG|Lamotrigine|
223576787|NCT00208520|DRUG|Levetiracetam|
223576788|NCT00346840|DRUG|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
223576789|NCT00346840|DRUG|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
223576790|NCT00346840|DRUG|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
223576791|NCT00346840|DRUG|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
223576792|NCT01735071|DRUG|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
223576793|NCT01735071|DRUG|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
223576794|NCT04206475|OTHER|rehabilitation|"the rehabilitation program consisted of an intensive treatment lasting 4 weeks, and including 3 daily interventions each working day (5 working days per week, for a total of 20 days of treatment and 60 sessions). The 3 daily sessions were organized as follows:~1 physio-kinesis and/or occupational therapy, 1 speech therapy, and 1 neuro-psychology treatment.~Each session lasted 45 minutes."
223576795|NCT04206475|OTHER|Intensive Memory-Focused Training Program (IM-FTP)|During each session, the patient was engaged in a one-to-one interaction with the therapist. Overall, the treatment targeted the following memory subfunctions: verbal and visuo-spatial short-term memory, verbal and visuo-spatial long-term memory, working memory and procedural memory
223576796|NCT03426475|PROCEDURE|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
223743454|NCT06882824|PROCEDURE|myomectomy with misoprostol|myomectomiy after administration of misoprostol 400μg PO (experimental group)
223464345|NCT02148393|PROCEDURE|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
223576797|NCT01339715|PROCEDURE|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
223576798|NCT03770494|DRUG|LY3405105|Administered orally.
224303339|NCT01593514|BIOLOGICAL|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
223464346|NCT02148393|PROCEDURE|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
223464347|NCT02148393|DRUG|Pregnyl®|1500 IU
223464348|NCT02148393|DRUG|Utrogestan®|200 mg tid
223464349|NCT02148393|DRUG|Progynova®|2 mg bid
223464350|NCT02148393|DEVICE|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
223576799|NCT05445908|DRUG|SKB264|SKB264 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
223576800|NCT05445908|DRUG|KL-A167|KL-A167 will be administered as an intravenous (IV) infusion every 2 weeks on Day 1 of each 14-day cycle
223464351|NCT02697643|BEHAVIORAL|BHCDS-based recommendations|
223464352|NCT02697643|BEHAVIORAL|Non-tailored recommendations|
223464353|NCT06958224|GENETIC|Large and early multigene sequencing|"Part 1 sequential multi-gene sequencing (Simple NGS),~* Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations)~* And if no contributive:~Part 2: randomized study between two sequential approaches~\- Experimental arm: early Multi-gene DNA sequencing (638 genes panel) Multi-gene RNA sequencing (ARCHER panel)~1. MMR status in molecular biology~2. \- Tumour Mutational Burden~   * Control arm: after 1st line escape, according to Plan France Medecine Genomique 2025 In the Part 2, a new biopsy could be proposed if necessary"
223464354|NCT06959212|OTHER|Physiological recordings, Semi-structured interviews, Psychological scales|(Neuro)-physiological paradigms based on EEG, ECG, electrodermal activity, and respiratory activity recordings, and auditory and olfactive stimuli, to assess memory processes without the need to communicate ('no report' approach) in patients suffering from a Disorder of Consciousness and conscious controls. Semi-structured interviews and neuropsychological assessments (scales) in patients who have recovered from a Disorder of Consciousness and conscious controls to explore memories and subjective experience of the ICU
223464355|NCT00521365|DRUG|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
223464356|NCT00006193|BEHAVIORAL|diet|
223464357|NCT04839744|DRUG|TG103 produced by the modified manufacturing process|Drug: TG103 (a modified manufacturing process), 15mg, SC
223464358|NCT04839744|DRUG|TG103 produced by the original manufacturing process|Drug: TG103 (the original manufacturing process), 15mg, SC
223464359|NCT03627832|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
223464360|NCT03627832|BEHAVIORAL|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
223464361|NCT04391257|DEVICE|geko™|Assess if cardiac pacemakers detect geko™ electrical output pulse.
223464362|NCT00624793|OTHER|Acupuncture|Standard Acup point protocol for treating nausea
223576801|NCT00554398|DRUG|MK-0518 400mg twice a day|Raltegravir, MK-0518
223576802|NCT00886119|DEVICE|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
223576803|NCT00886119|DEVICE|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
223576804|NCT05302258|DIAGNOSTIC_TEST|Attenuation imaging in ultrasonography|Attenuation imaging in ultrasonography
223464363|NCT00624793|OTHER|Individualized Acup based on TCM diagnosis|Acup
223464364|NCT00624793|OTHER|Sham Acup|Sham Acup - Non-Active
223464365|NCT00169676|OTHER|observation|registry and database for surgery outcomes
223464366|NCT03477578|OTHER|freezers|neuropsychological evaluation
223464367|NCT03477578|OTHER|non freezers|neuropsychological evaluation
223464368|NCT05888298|PROCEDURE|Greater occipital nerve radiofrequency|Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
223576805|NCT01749592|DEVICE|cochlear implant|Surgical implantation of a cochlear implant device
223743455|NCT07038876|DRUG|Placebo|Matched Placebo
223743456|NCT07038876|DRUG|ML-007C-MA BID|ML-007C-MA dosed as 210/3 mg BID
223464369|NCT02390154|DRUG|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of \[14C\] roniciclib solution
223576806|NCT01449110|DIETARY_SUPPLEMENT|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~1. capsule/day of placebo (350 mg maltodextrin) for 6 months~2. capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
223464370|NCT02390154|DRUG|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
223464371|NCT02729337|BEHAVIORAL|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
223576807|NCT01449110|DIETARY_SUPPLEMENT|Placebo in secondary prevention|"12 months follow-up:~1. capsule/day (350 mg maltodextrin) for 6 months~2. capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
223576808|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in primary prevention (PP)|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
223576809|NCT01449110|DIETARY_SUPPLEMENT|Grape extract in SP|"12 months follow-up:~1. capsule/day (350 mg grape extract) for 6 months~2. capsules/day (350 mg + 350 mg grape extract) for 6 months"
223576810|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
223576811|NCT01449110|DIETARY_SUPPLEMENT|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~1. capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~2. capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
223576812|NCT02448888|OTHER|Adapted exercise|2 months, 3 times/week
223576813|NCT02448888|OTHER|General exercise recommendations|2 months, 3 times/week
223576814|NCT06184841|DRUG|HAIC combined with intravenous PD-1|Hepatic arterial chemoinfusion (HAIC) was used for interventional therapy with at least 2 cycles of hepatic arterial infusion. The intervention was started with sintilimab at the same time, 200mg each time, and the drug was repeated every 3 weeks.
223576815|NCT04091984|DIAGNOSTIC_TEST|Prospera|No Interventions, this is an observational study.
223576816|NCT06247228|BEHAVIORAL|Click2Move|One year multicomponent intervention including a wearable, and a mobile phone application downloaded in the own mobile phone. Participants will have activity tracking and app provision, sedentary reminders, cooperative challenges, organisational support and motivational messages, educational material, self-monitoring, feedback provision, demonstration videos and strategies.
223576817|NCT02930408|PROCEDURE|electrocardiogram|
223576818|NCT02930408|PROCEDURE|Echocardiography|
223576819|NCT06355115|DRUG|Cefazolin 1000 MG Injection|Cefazolin 1000 mg given intravenously
223576820|NCT00902421|DRUG|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
223576821|NCT00902421|DRUG|Antimuscarinics|Antimuscarinics for 3 months
223576822|NCT02801721|OTHER|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
223576823|NCT03035773|BEHAVIORAL|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
223576824|NCT03035773|BEHAVIORAL|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
223464372|NCT03150082|DRUG|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
223464373|NCT03150082|DRUG|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
223464374|NCT00999505|DRUG|Amantadine|Amantadine 200mg twice a day over 12 weeks
223464375|NCT00999505|DRUG|Placebo|Placebo capsules twice a day over 12 weeks
223464376|NCT06958770|DIAGNOSTIC_TEST|Electrical impedance tomography|"* Electrical impedance tomography (EIT)：Assessing pulmonary function in chronic lung diseases.~* Lung ultrasound：Assessing diaphragm atrophy in mechanically ventilated patients.~* Esophageal pressure：The work of breathing, or the energy required by respiratory muscles to meet ventilatory demands, can be directly evaluated by esophageal pressure~* Oxygen consumption：Indirectly evaluated by measuring oxygen consumption (V̇O2) during mechanical ventilation The oxygen cost of breathing, reflected the increase in V̇O2 when transitioning from mechanical ventilation to spontaneous breathing, has been shown to predict weaning outcomes."
223743457|NCT07038876|DRUG|ML-007C-MA QD|ML-007C-MA dosed as 330/6 mg QD
223743458|NCT06723652|DRUG|SHR-1918|six administration
223743459|NCT06723652|DRUG|SHR-1918 placebo|SHR-1918 placebo three administration+SHR-1918 three administration
224071578|NCT02004080|OTHER|Intensive Care treatment|intensive care treatment
224071579|NCT06162910|DIAGNOSTIC_TEST|Daniels Water Swallow Test|Clinical water swallow dysphagia screening
223464377|NCT06959459|DEVICE|Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.|Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.
223464378|NCT06959459|DEVICE|Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.|Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.
223464379|NCT01960101|OTHER|LactoXeros|
223464380|NCT01960101|DEVICE|Aequasyal|
223464381|NCT01718483|DRUG|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
223464382|NCT01718483|DRUG|Placebo|Administered once-daily, orally, for up to 12 weeks
223464383|NCT00275522|DRUG|Sirolimus|
223464384|NCT03049501|BEHAVIORAL|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
223464385|NCT03049501|BEHAVIORAL|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
224157795|NCT02884193|PROCEDURE|Sham Ice Bag|"Placebo application through an ice bag empty."
223464386|NCT02631005|OTHER|"Walk With Ease"|Six-week walking program
223464387|NCT05402956|BEHAVIORAL|Aerobic exercise|Moderate aerobic exercise training
223464388|NCT06958809|DIAGNOSTIC_TEST|Echography|An exhaustive echography will be performed to determine fluid responsiveness (using a passive leg raising test and cardiac output measurement by left ventricular outflow tract velocity time integral)
223464389|NCT06959615|DRUG|JAB-23E73|Administered orally
223464390|NCT06959615|DRUG|JAB-23E73|Administered orally
223464391|NCT03462810|DRUG|cabotegravir, CAB|open label investigational product
223743460|NCT06880159|DEVICE|tDCS with computerized cognitive training|Participants will complete tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. The training session will last for 20 minutes.
224157796|NCT03427762|OTHER|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
223464392|NCT06958588|DEVICE|Experimental: Hyperslim|The PEMF will be carried out using the Hyperslim® device. The Hyperslim® device is produced by Medical San (Lageado, RS, Brazil).
223464393|NCT06958588|DEVICE|Active Comparator #1|The intermittent pneumatic compression group will use the devices Covidien Kendall SCD 700® (Cardinal Health) or Doctor Life 2600® (Venosan).
223464394|NCT04275258|OTHER|Provide assistance to subject's rural PCP pertaining to subject/patient pain management goals and opioid taper plan|"PA checks in with PCP at 1,2,4,8, 12, 16, and 20 weeks post hospital discharge by secure e-mail, fax or phone to provide opioid taper and pain management guidance until patient has tapered off opioids or returned to pre-trauma doses. PCP may contact PA whenever needed.~If PCP requests assistance or reports deviation from the planned opioid taper, PA will provide individualized consultations, which may include a revised taper plan and/or adjunctive therapy recommendations.~If there is continued deviation from the planned taper, the PA will facilitate a UW TelePain multidisciplinary telemedicine consultation.~The collaborative pain care and opioid taper intervention ends at 20 weeks."
223464395|NCT06959056|DEVICE|cryo nerve block at T3-T8 intercostal nerves bilaterally|In order to obtain better analgesia at the level of the chest wall, where the chest is bilaterally opened for lung extraction and donor lung implantation, intraoperative cryo-ablation will be applied to the intercostal nerves at the bilateral intercostal spaces 3-8, 3cm lateral to the sympathetic chain, under direct visualization during surgery, as such covering 2 intercostal levels above as well as below the normal access of ICR 4 or 5. By providing analgesia to level 8, we will also cover the area of chest drains, which also tend to cause pain in the postoperative course, especially when patients start mobilizing at the ward. Each nerve bundle will be cooled to a temperature between -65 and -72 °C during 120 seconds by means of the CyroSphere v2 probe (AtriCure Inc; Mason, OH, USA) connected to the provided instrument tower (AtriCure CryoICE box) including a processor device measuring and regulating the N2O flow through the probe.
223464396|NCT04137809|DEVICE|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
223464397|NCT01851941|DRUG|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
223464398|NCT02941315|DRUG|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
224157797|NCT04503473|BEHAVIORAL|High Intensity Stepping Training|"The goals will be to maximize stepping activity at high intensities for 40 minutes per 1 hour session, with rest breaks as needed~Conventional Therapy: : Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions"
224157798|NCT04503473|BEHAVIORAL|Conventional Therapy|Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions
223464399|NCT02941315|DRUG|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
223464400|NCT02941315|DRUG|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
223464401|NCT02941315|DRUG|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
223464402|NCT04567940|BEHAVIORAL|ENRED@TE: Behavioural multicomponent intervention|Information and awareness activities; activities for the acquisition of skills; activities that help the elderly to attend spaces for leisure, participation and maintenance and/or improvement of their personal relationships.
223464403|NCT06959576|OTHER|nanoparticles|Nanoparticles improve the dimensional stability of 3D printed denture base resin, so preventing instability of the denture over time
223576825|NCT03035773|BEHAVIORAL|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
223576826|NCT02295007|BEHAVIORAL|text message|
223576827|NCT00103519|DRUG|DITPA (3,5-diiodothyropropionic acid)|
223576828|NCT00103519|DRUG|Placebo|Placebo
223576829|NCT05579873|PROCEDURE|Clavicle plating|VariAx 2.0mm + 2.4 or 2.7mm vs any other single plate
223576830|NCT00462735|DRUG|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
223576831|NCT00462735|DRUG|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
223576832|NCT00462735|DRUG|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
223576833|NCT00462735|PROCEDURE|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
223576834|NCT03423290|DEVICE|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
223576835|NCT04682990|DEVICE|Tor Vergata Electronic Nose (TV eNose)|Participants will be asked to perform a breath sampling with a nose clamp in Alveolar sampling bag. This exhaled breath in the sampling bag will be analyse with the TV eNose
223576836|NCT04682990|OTHER|Survey & Physical Exam|Perform a oriented survey for risk factors, symptoms and a complete physical exam.
223576837|NCT04682990|DIAGNOSTIC_TEST|TB LAMP test|Collection of Sputum samples and Perform TB-LAMP (temperature-independent way of amplifying DNA from TB organisms)
223576838|NCT04682990|OTHER|Sputum Samples|Sputum samples for Ziehl Neelsen smear or Culture in L-J (if required by the medical staff)
223576839|NCT04682990|OTHER|Chest X-Ray|Perform anteroposterior chest X-ray (if required by the medical staff)
223576840|NCT04682990|OTHER|Follow Up 5 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
223576841|NCT04682990|OTHER|Follow Up & 15 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
223576842|NCT04682990|OTHER|Follow Up & 30 days after beginning of Tx.|"Following the usual planning of the center for Positive TB Patients, they will be asked to come during treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, to determine progress of treatment."
223576843|NCT04911907|DRUG|utidelone injection|Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle
223576844|NCT03419390|DEVICE|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
223576845|NCT04868487|OTHER|Health Literacy Education|Health literacy education, consisting of four sessions, was given to the intervention group.
223576846|NCT03564405|DEVICE|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
223464404|NCT06957964|OTHER|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy is an intervention in which a suction is applied at applied thus creating a negative pressure which not only removes any exudate but also aids in formation of granulation tissue. NPWT is provided along with empirical prophylactic antibiotics
223464405|NCT06957964|DRUG|Standard Antibiotic Treatment|According to hospital antibiogram, empirical antibiotics are given prophylactically
223464406|NCT06954324|PROCEDURE|Erector spinae plane block|This study aims to compare the effects of erector spinae plane block (ESPB) and systemic tramadol use as postoperative analgesia methods on the systemic immune-inflammatory index (SII) in patients undergoing breast cancer surgery.
223464407|NCT06958172|OTHER|Exercise|Study Group received core stabilization, thoracic mobility and hip mobility exercises
223464408|NCT03675646|DRUG|Morphine|Intrathecal injection of 250 mcg preservative-free morphine before surgery
223464409|NCT06958614|DRUG|Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor|The experimental group received prophylactic PEG-rhG-CSF 48 hours after chemotherapy
223576847|NCT01386541|DRUG|BYK324677|capsules, administered orally
223576848|NCT00074373|OTHER|No intervention; observational|
223576849|NCT00378937|DRUG|acetaminophen|
223576850|NCT00378937|DRUG|codeine phosphate|
223576851|NCT00378937|DRUG|dextropropoxyphene hydrochloride|
223576852|NCT00378937|DRUG|morphine sulfate|
223576853|NCT00378937|DRUG|oxycodone hydrochloride|
223576854|NCT00378937|PROCEDURE|management of therapy complications|
223576855|NCT00378937|PROCEDURE|quality-of-life assessment|
223464410|NCT05731115|BIOLOGICAL|Experimental 23-valent Pneumococcal|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25μg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F,18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride mixture per injection.
223464411|NCT05588531|DRUG|Group 1:YK-1169|YK-1169 0.5g (containing cefepime 0.4g, avibactam 0.1g) single intravenous infusion for 2 hours
223464412|NCT05588531|DRUG|Group 2:YK-1169/Placebo Injection|YK-1169 1.25g (containing cefepime 1.0g, avibactam 0.25g) / placebo single intravenous infusion for 2 hours
223464413|NCT05588531|DRUG|Group 3:YK-1169/Placebo|On the first day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenously infused for 2 h. On the third day, YK-1169 2.5 g (containing cefepime 2.0 g, avibactam 0.5g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
223464414|NCT05588531|DRUG|Group 4:YK-1169/Placebo|On the first day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenously infused for 2 h. On the third day, YK-1169 3.75 g (containing cefepime 3.0 g, avibactam 0.75g) was single intravenous infusion for 2 h, three times a day at 8-h intervals, until the morning dose on the tenth day
223464415|NCT05588531|DRUG|Group 5:YK-1169/Placebo Injection|YK-1169 5.0g (containing cefepime 4.0g, avibactam 1.0g) / placebo single intravenous infusion for 2 hours
223464416|NCT05588531|DRUG|Group 6:YK-1169/Cefepime hydrochloride for injection/Avibactam for injection|YK-1169 2.5g (containing cefepime 2.0g, avibactam 0.5g)/cefepime hydrochloride for injection 2.0g/avibactam for injection 0.5g, three-cycle three-cross single intravenous infusion for 2 hours
223464417|NCT06958250|DEVICE|Novel Bite Block|Patients to utilize novel bite block during routine endoscopic procedures
223464418|NCT02731378|DRUG|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
223464419|NCT02731378|DRUG|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
223464420|NCT02731378|DRUG|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
223464421|NCT02731378|DRUG|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
223464422|NCT05043740|DRUG|Repatha or Praluent|Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
223576856|NCT04126265|DEVICE|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
223743461|NCT06888024|PROCEDURE|non-contrast enhanced abdomen and pelvis MRI|non-contrast enhanced abdomen and pelvis MRI
223464423|NCT03884010|OTHER|No intervention|Cross-sectional
223464424|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
223464425|NCT00927199|DIETARY_SUPPLEMENT|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
223464426|NCT00927199|DIETARY_SUPPLEMENT|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
223464427|NCT06958887|OTHER|Betwixt app intervention|Narrative gaming smartphone app
223464428|NCT06959498|PROCEDURE|Total hip arthroplasty|Total hip arthroplasty
223464429|NCT04880668|DEVICE|Aerosol Box (Splashguard)|The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
223576857|NCT04110470|DIAGNOSTIC_TEST|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
223743462|NCT06926634|DRUG|Zanzalintinib|Provided by Exelixis
224071580|NCT06162910|DIAGNOSTIC_TEST|Flexible Endoscopic Evaluation of Swallowing|Endoscopic evaluation of swallowing function
224071581|NCT02901288|DRUG|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
224071582|NCT02901288|DRUG|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
223576858|NCT04110470|DIAGNOSTIC_TEST|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
223576859|NCT00605553|DRUG|Placebo|"Placebo oral capsules~Placebo for 7 days"
223576860|NCT00605553|DRUG|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
223576861|NCT00537732|DRUG|omeprazole|20 mg daily
223576862|NCT00537732|DRUG|omeprazole|20 vs. 60 mg daily, genotype dependent
223576863|NCT00259298|DRUG|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
223576864|NCT00645528|OTHER|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
223576865|NCT01376063|DRUG|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
223576866|NCT03354832|OTHER|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
224071583|NCT02901288|DRUG|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
224071584|NCT02901288|DRUG|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
224071585|NCT02901288|DRUG|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
224071586|NCT00002827|BIOLOGICAL|bleomycin sulfate|Given IV
224071587|NCT00002827|BIOLOGICAL|filgrastim|Given IV
224071588|NCT00002827|DRUG|dexrazoxane hydrochloride|Given IV
224071589|NCT00002827|DRUG|doxorubicin hydrochloride|Given IV
224071590|NCT00002827|DRUG|etoposide|Given IV
224071591|NCT00002827|DRUG|vincristine sulfate|Given IV
223464430|NCT06957925|BEHAVIORAL|educational|Teachers were provided with a manual that could be implemented in a flexible way adapted to the local context of the school consisting of six sessions. The manual assisted teachers to prepare students for success in understanding what is a good mental health (session 1), how to optimize and maintain good mental health, with a particular focus on being mentally, spiritually, socially and physically active including coping with stressors via breathing exercises and progressive muscle relaxation techniques (session 2), physical activity participation (session 3) and sleep hygiene measures (session 4), the importance of belongingness and commitment (session 5), and how to seek support including peer support, community engagement and existing local services (session 6). The first 6 sessions were facilitated by the teacher, and the next 6 by peers.
223464431|NCT05203653|BEHAVIORAL|Resistance exercise only|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.
223464432|NCT05203653|BEHAVIORAL|Resistance exercise plus cool down|Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
223464433|NCT01959113|BIOLOGICAL|Autologous Microbiome Transplant|
223576867|NCT03354832|OTHER|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
223576868|NCT03354832|OTHER|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
223576869|NCT03354832|OTHER|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
223576870|NCT01140568|DRUG|nilotinib|400mg po (orally) BID (twice daily)
223576871|NCT00020462|BIOLOGICAL|aldesleukin|
223576872|NCT00020462|BIOLOGICAL|autologous tumor cell vaccine|
223576873|NCT06375785|OTHER|Otago-based (slow rhythmic) exercise group|"Slow Rhythmic Exercises (Otago based) A.Strength training~1. Knee flexion and extension~2. Ankle dorsiflexion and plantar flexion~3. Toes flexion and extension~4. Hip abduction and adduction B. Balance training~1\. Stepping backwards, walking and turning 2.Side walking 3. Octet walking 4.Tandem walking 5. Standing up from a sitting position"
223576874|NCT06375785|OTHER|LSVT BIG-based (large amplitude) exercise group|"Large Amplitude Exercises (based on LSVT-BIG)~1. Bending towards the floor and rising towards the ceiling (opening) while sitting~2. While sitting, turn to the right and left with the body and reach out~3. Sit down~4. Step forward~5. Sidestepping~6. Stepping back~7. Step forward and extend arm towards the ceiling~8. Step sideways and extend arm towards the ceiling~9. Walking with big steps~10. Turning from right to left and left to right while walking"
223576875|NCT05280327|OTHER|Virtual Reality Application|The pregnant women in the experimental group were played by the researcher during the active and transitional phases of labor with virtual reality glasses, which were designed for research and included methods used to cope with labor pain
223576876|NCT03618628|DEVICE|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
223576877|NCT04150731|RADIATION|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
223576878|NCT03299231|DEVICE|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
223576879|NCT03299231|DEVICE|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
223576880|NCT01587638|DRUG|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
223576881|NCT01587638|DRUG|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
223576882|NCT05941338|DRUG|Tirelizumab ,+Carboplatin+albumin-bound paclitaxel|Sintilimab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days. Intervention: Drug: Sintilimab , Carboplatin, albumin-bound paclitaxel
223576883|NCT03998748|OTHER|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
223576884|NCT05067920|DIAGNOSTIC_TEST|Levels of SARS-COV-2 antibodies|Study of the SARS-COV-2 antibodies of COVID-19 IgM ( day 5th and 14th) and IgG ( day 14th and 28th)
223576885|NCT05067920|DIAGNOSTIC_TEST|rRT-PCR SARS-Cov-2|Real time RT-PCR for COVID-19 diagnosis at day 5th,14th and 28th
223576886|NCT05067920|DIAGNOSTIC_TEST|Hematological and immunological biomarkers|Laboratory data measure at day 5th,14th and 28th: Hemogram, cytokine levels, ratio of CD4 + / CD8 + lymphocytes, and levels of dehydrogenase lactate, ferritin, D-dimer.
223576887|NCT05067920|DIAGNOSTIC_TEST|Mitochondrial DNA|One time quantification mitochondrial DNA haplogroup.
224071592|NCT00002827|RADIATION|low-LET cobalt-60 gamma ray therapy|
223576888|NCT05067920|DIAGNOSTIC_TEST|SARS-CoV-2 Viral Culturing|Probability of isolating SARS-Cov-2 in cell culture related to CT value above 32.
224071593|NCT00002827|RADIATION|low-LET electron therapy|
224071594|NCT00002827|RADIATION|low-LET photon therapy|
224071595|NCT06269133|DRUG|REGN2810|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
224071596|NCT06269133|OTHER|Platinum-doublet chemotherapy|No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
223464434|NCT01959113|OTHER|Placebo Arm|
223464435|NCT00477763|DRUG|Restasis, Refresh Endura|"1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
223464436|NCT03996668|OTHER|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
223464437|NCT04408664|DRUG|Sodium Cromoglycate|Sodium Cromoglicate 10 mg/mL packed in ampulla of 2 mL; Daily dosis of 4X20 mg milligram delivered by aerosol.
224071597|NCT03110224|DEVICE|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the knee(Subchondroplasty (SCP) Procedure).
224071598|NCT01564862|DRUG|vortioxetine (Lu AA21004)|Lu AA21004 capsules
223576889|NCT05067920|DIAGNOSTIC_TEST|Sequencing COVID-19|Sequencing viral protein spike (S) COVID-19 related to CT value below 15.
223464438|NCT04408664|DRUG|Placebo|Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
223464439|NCT03566277|BEHAVIORAL|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
223464440|NCT03566277|BEHAVIORAL|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
223576890|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
223576891|NCT03192033|DEVICE|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
223576892|NCT03192033|DEVICE|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
223576893|NCT03192033|OTHER|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
223576894|NCT00763906|DEVICE|norepinephrine infused at the clinician's discretion|
223576895|NCT00763906|DEVICE|norepinephrine infused under computerized fuzzy logic control|
223576896|NCT03094286|DRUG|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
223576897|NCT05750433|DIETARY_SUPPLEMENT|PreforPro+B. subtilis DE111 probiotics|PreforPro is bacteriophage-based product which was used in combination with Bacillus subtilis probiotics.
223576898|NCT05750433|DIETARY_SUPPLEMENT|Placebo|Maltodextrin is rice based powder which was used as placebo.
223576899|NCT05750433|DIETARY_SUPPLEMENT|B. subtilis DE111|Bacillus subtilis probiotics.
223576900|NCT01741532|DRUG|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
223576901|NCT01741532|DRUG|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
223576902|NCT00914563|DEVICE|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
223576903|NCT00914563|OTHER|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
223576904|NCT01488214|OTHER|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
223576905|NCT00766246|DRUG|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
223576906|NCT00766246|DRUG|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
223576907|NCT00766246|DRUG|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
223576908|NCT02953665|DRUG|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
223576909|NCT02953665|DRUG|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
223576910|NCT05976464|DRUG|Magnesium sulfate in erector spinae plane block|"Ultrasound-guided Erector spinae plane (ESP) block will be done with the patient in a sitting position depending on the surgical site (lt. or Rt.) ESP block will be given using high-frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to the thoracic third and sixth spinous process, the erector spinae muscle, is identified from the surface, we will deposit 20 ml of 0.25% levobupivacaine into interfacial plane below erector spinae muscle.~General anesthesia will be induced with l/kg fentanyl, 2mg/kg propofol, 0.5 mg/kg atracurium and inhalational anesthesia (sevoflurane) No other narcotic, analgesic or sedative will be administrated during the operative period.~BP(SystolicBP, DiastolicBP) and HR will be observed and recorded every 30 min till the end of surgery."
223576911|NCT04400578|DEVICE|Trichloroacetic acid 85% (TCA)|Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
223576912|NCT00000357|DRUG|Buprenorphine|
223576913|NCT04272008|DRUG|Segesterone Acetate and Ethinyl Estradiol|Annovera taken alone
223576914|NCT04272008|OTHER|Tampon|Annovera with tampon use
223464441|NCT03566277|BEHAVIORAL|Feedback|Participants will receive text message feedback each day about progress towards their goal
224157799|NCT02411877|PROCEDURE|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
223464442|NCT03608605|DEVICE|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
223464443|NCT01884883|DEVICE|PROTEOR Internal unicompartmental knee brace|
223576915|NCT01482897|DRUG|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
223576916|NCT01482897|DRUG|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
223576917|NCT01482897|DRUG|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
223576918|NCT00488124|DRUG|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
224071599|NCT01564862|DRUG|Duloxetine|Duloxetine capsules
224071600|NCT01564862|DRUG|Placebo|Placebo matching capsules
224071601|NCT06809179|DRUG|Fasedienol Nasal Spray - Placebo Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by one dose of Placebo Nasal Spray, separated by 10-minutes in between the two doses.
224071602|NCT06809179|DRUG|Fasedienol Nasal Spray - Fasedienol Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Fasedienol Nasal Spray followed by a second dose of Fasedienol Nasal Spray, separated by 10-minutes in between the two doses.
224071603|NCT06809179|DRUG|Placebo Nasal Spray - Placebo Nasal Spray|Twenty minutes prior to the PSC, subjects will receive one dose of Placebo Nasal Spray followed by a second dose of Placebo Nasal Spray, separated by 10-minutes between the two doses.
223464444|NCT03587233|BEHAVIORAL|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
223464445|NCT03587233|DEVICE|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
223464446|NCT03587233|BEHAVIORAL|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
223464447|NCT03943355|OTHER|Patient before cohort (2005-2010)|The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
223464448|NCT03943355|OTHER|Patient after cohort (2011-2016)|The protocol of NOM became more aggressively and strictly adhered to since 2011.
223464449|NCT06828991|DRUG|Mosunetuzumab|Mosunetuzumab consolidation therapy will consist of 6 cycles of IV mosunetuzumab at the standard ramp-up dosing (Day 1 1mg, Day 8 2mg, D15 60mg, C2D1 60mg, and 30mg on day 1 of the subsequent 21-day cycles)
223464450|NCT04105608|DIETARY_SUPPLEMENT|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
223464451|NCT04105608|DIETARY_SUPPLEMENT|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
223464452|NCT04993872|DRUG|Biktarvy Tab|Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
223464453|NCT01818089|DEVICE|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
223464454|NCT00738634|BEHAVIORAL|Self-motivated physical activity|"Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
223464455|NCT00738634|BEHAVIORAL|Nutrition|"Components:~1. Nutrition education booklet (Double-sided A4 page)~2. Nutrition motivation tips (single-sided A4 page)~3. Nutrition monitoring chart~4. Online presentation of common obstacles and ways to overcome these obstacles"
223743463|NCT06728254|DEVICE|medication management|"The test system consists of:~* Linked care platform (backend) which provides a new possibility of data exchange for IT systems of caregivers, pharmacies, and GPs~* User interfaces for caregivers as well as for the systems myneva.carecenter and mynevaTOgo~* An extension of the user interface for GPs in their IT system (in the test only for the physician software PCPO by CompoGroup Medical )~* An extension of the user interface for pharmacists in their IT system (in the test only for pharmacies with software from Apothekerverlag)~Functionally, the solution should, coordinate the medication requirements between pharmacies, GPs, and caregivers (subarea medication)."
223464456|NCT00738634|BEHAVIORAL|Physical activity researcher contact|"Behavioral: Self-motivated physical activity~Components:~1. Physical activity education in the form of a brief booklet (double sided A4 page).~2. Physical activity motivation tips (one sided A4 page).~3. Pedometer~4. Monitoring chart~5. Online presentation of common obstacles and ways to overcome these obstacles"
223743464|NCT06728254|OTHER|Usual Care Group|Usual care.
223464457|NCT04553081|DRUG|Dual versus triple therapy in treatment of HIV-1 infection.|cfr arm description
223464458|NCT01831427|DRUG|Andecaliximab|Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
223464459|NCT01831427|DRUG|Placebo to match Andecaliximab|Placebo to match andecaliximab administered by IV infusion
223464460|NCT05686655|OTHER|questionnaire about sleep quality in diabetic children|Pittsburgh sleep quality index
223464461|NCT00536510|DRUG|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
224068202|NCT02124564|DRUG|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~* 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~* The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
224068203|NCT00579371|DRUG|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
224068204|NCT00247000|DEVICE|Routine Care in a HF clinic vs Home Telehealth Care for HF|
224068205|NCT01003275|DRUG|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
224068206|NCT01003275|DRUG|Placebo|Two soft gels by mouth daily for 8 weeks
224068207|NCT02043548|DRUG|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
224068208|NCT02043548|DRUG|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
224068209|NCT00507559|DEVICE|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
224068210|NCT06068712|BEHAVIORAL|Attentional Cue Type|Positive cue (target), negative cue (distractor), or neutral cue (baseline)
223464462|NCT00536510|DRUG|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
223464463|NCT05869669|DRUG|Neflamapimod|Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
223464464|NCT05869669|DRUG|Placebo|Placebo is a capsule that looks just like neflamapimod but without the active ingredients
223464465|NCT02169505|DRUG|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
223464466|NCT03166020|OTHER|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
223464467|NCT06122389|DRUG|SHR2554; Chidamide analog tablets|SHR2554 + Chidamide analog tablets
223464468|NCT06122389|DRUG|SHR2554 analog tablets; Chidamide|SHR2554 analog tablets + Chidamide
223576919|NCT03230812|DRUG|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
223576920|NCT02119039|DEVICE|RGTA OTR 4120 (CACICOL20)|
223576921|NCT02119039|DEVICE|Genteal HA eye drops|
223576922|NCT02153346|OTHER|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
223576923|NCT02153346|OTHER|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
223576924|NCT02549222|OTHER|Standard of Care|
224157800|NCT02411877|PROCEDURE|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
223576925|NCT04864626|OTHER|semi-standardized interview|annual collection of the number of consultations and hospitalizations at the center, as well as the number of treatments
223576926|NCT04864626|OTHER|care experience questionary|questionary with 12 questions to rate the quality of the telephone reception and your feelings during the interview
224157801|NCT02411877|DEVICE|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
224157802|NCT02411877|DEVICE|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
224157803|NCT05609305|OTHER|Discharge|observational study, not intervention
223464469|NCT00048035|DRUG|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
223464470|NCT00000687|DRUG|Interferon alfa-2a|
223464471|NCT00000687|DRUG|Zidovudine|
223464472|NCT01825304|DEVICE|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
223464473|NCT02246738|OTHER|Blood Collection|
223576927|NCT04794647|OTHER|Cervical mobilization|A kind of manual therapy tecnique applied to the cervical region
223576928|NCT04794647|OTHER|Placebo mobilization|It was applied to the randomly selected cervical faset without any pushing or pulling in the same position and the same grip with cervical mobilization.
223464474|NCT01045005|OTHER|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
223464475|NCT01045005|OTHER|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non-harmful/non-toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
223464476|NCT02930057|DRUG|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
223464477|NCT02930057|PROCEDURE|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
223464478|NCT02930057|DRUG|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
223576929|NCT01776671|DRUG|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
223576930|NCT00957333|OTHER|ketamine|
223576931|NCT02485652|DRUG|HM61713|"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
223576932|NCT04519047|BIOLOGICAL|PRP|Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).
223576933|NCT00514345|GENETIC|gene expression analysis|
224157804|NCT05117268|PROCEDURE|SDF Application for caries arrest|Intervention will be performed by trained consultants following the recommended protocol for SDF application: (A) Gross debris will be removed from cavity to allow better contact with SDF; (B) Protective coating of petroleum jelly will be applied to surrounding facial skin and lips to prevent chances of temporary tattoo formation; (C) Area to be treated shall be isolated using cotton rolls and saliva ejectors to prevent gingival irritation; (D) Extra caution will be exercised when applying SDF on primary teeth adjacent to permanent teeth to avoid inadvertent black staining; (E) One drop will be used used for the whole appointment. Bent micro-brush is to be used for application time of 1 min is to be used to reduce systemic absorption; (F) Compressed air shall be applied with gentle flow for up to 3 minutes. Entire dentition will be treated with sodium fluoride varnish to prevent caries
223464479|NCT03072095|BEHAVIORAL|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
223464480|NCT03072095|BEHAVIORAL|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
223464481|NCT02043288|DRUG|NC-6004|"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
223464482|NCT02043288|DRUG|Gemcitabine|"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
223464483|NCT05137717|DRUG|Maribavir|Maribavir tablets
223464484|NCT02895685|OTHER|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
223464485|NCT02035553|DRUG|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
223464486|NCT02035553|DRUG|Placebo|Placebo, two tablets, once daily by mouth
223464487|NCT01480388|DRUG|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
223576934|NCT00514345|GENETIC|polymorphism analysis|
223576935|NCT00514345|PROCEDURE|management of therapy complications|
223576936|NCT00346502|DRUG|20% betulinic acid ointment|
223576937|NCT00346502|DRUG|BA|20% Betulinic Acid Ointment
223576938|NCT03158272|BIOLOGICAL|Cabiralizumab|Specified dose on specified days
223576939|NCT03158272|BIOLOGICAL|Nivolumab|Specified dose on specified days
223464488|NCT01480388|DRUG|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
223576940|NCT06136572|DIAGNOSTIC_TEST|Rathus Assertiveness scale|Questionnaire completion
223576941|NCT05762861|OTHER|Experimental|Patients will be every two weeks monitored by the researchers' team, taking into consideration lung function, symptoms, physical activity, pulse oximetry, body temperature, need for relief medication and Sputum characteristics. Over the 18 months, they will be the target of health education interventions, 2 individual and 2 in group.
223576942|NCT00420173|PROCEDURE|Laboratory analysis|blood withdrawal
223576943|NCT01071356|BEHAVIORAL|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
223576944|NCT01071356|BEHAVIORAL|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
223576945|NCT02220023|DRUG|INOmax Inhalation|
223576946|NCT01855152|OTHER|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
223464489|NCT01480388|DRUG|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
223464490|NCT01480388|DRUG|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
223464491|NCT01480388|DRUG|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
223464492|NCT04685993|DRUG|LPCN 1144|Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
223464493|NCT02735980|DRUG|Prexasertib|Administered IV
223464494|NCT00509899|DRUG|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
223576947|NCT01855152|OTHER|Treatment as usual|Treatment delivered as usual in the care home
223576948|NCT03430505|DEVICE|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
223576949|NCT03430505|DRUG|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
223576950|NCT04943692|DRUG|Metformin glycinate|1050 mg, tablets Administered orally, twice a day, for 12 months.
223576951|NCT04943692|DRUG|Metformin Hydrochloride|850 mg, tablets. Administered orally, twice a day, for 12 months.
223576952|NCT05749653|DRUG|Bi-annual CDTI|Bi-annual CDTI
223576953|NCT02287753|OTHER|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
223576954|NCT03399357|BIOLOGICAL|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
224068211|NCT05287945|DRUG|Orellanine|Orellanine administered intravenously
223576955|NCT03164850|DEVICE|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
223576956|NCT05737277|DRUG|Gabapral|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period."
223576957|NCT05737277|DRUG|Placebo|"This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to evaluate the efficacy and safety of Bifidobacterium adolescentis PRL2019 in pediatric patients (\> 4 years) with IBS (as assessed according to the Rome IV diagnostic criteria for IBS).~The study will include a 2-week screening period, and a 12-week placebo-controlled treatment period (Figure 1). After the screening phase, eligible patients will be randomly assigned to either 1 stick containing 20 Mld UFC of Bifidobacterium adolescentis PRL2019 (Gabapral, Pontenure, Italy), or the equivalent placebo once a day, in a 1:1 ratio, for 12 weeks. Study visits will be conducted every 4 weeks during the treatment period"
223576958|NCT05951712|DRUG|Simethicone 150mg|Impact of simethicone on the mucosal visibility of stomach and duodenum
223576959|NCT05951712|DRUG|N Acetyl cysteine 600mg|Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
223576960|NCT05951712|DRUG|Simethicone 150mg plus N Acetyl cysteine 600 mg|Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
223576961|NCT05951712|OTHER|Placebo|Impact of water on the mucosal visibility of stomach and duodenum
223576962|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
223576963|NCT00187187|DEVICE|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
223576964|NCT00225342|DRUG|Rosiglitazone|
223576965|NCT00225342|DRUG|Gliclazide (Comparison drug)|
223576966|NCT05154760|OTHER|Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises|An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
223576967|NCT05042960|OTHER|Brightness|Changing the colors or brightness on the device (computer screen) for one month
223576968|NCT02366767|DEVICE|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
223576969|NCT02366767|DEVICE|Control|Threshold suspend
223576970|NCT01806649|DRUG|BKM120|
223576971|NCT00579995|DRUG|Oral N-Acetylcysteine|600 milligrams (mg)
223576972|NCT00579995|DRUG|Sodium Bicarbonate|3 milliliters per kilogram per hour (mL/kg/hr) for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
223576973|NCT03047291|DRUG|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
223576974|NCT03047291|DEVICE|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
223576975|NCT01389349|OTHER|Acupuncture|Battlefield acupuncture protocol
223576976|NCT01389349|OTHER|Sham Control|Sham control acupuncture
223576977|NCT05623215|RADIATION|Radiographs of the knee for radiostereometric analysis (RSA)|RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
223576978|NCT02558400|DRUG|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
223576979|NCT02558400|DRUG|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
223576980|NCT02558400|DRUG|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
223576981|NCT00973882|DRUG|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
223576982|NCT00973882|DRUG|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
223576983|NCT03130426|DRUG|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
223576984|NCT03130426|DRUG|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
223576985|NCT03130426|DRUG|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
223576986|NCT03130426|BEHAVIORAL|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
223576987|NCT05126160|DIAGNOSTIC_TEST|Immune Score Based Radiomics|To establish an immune score based radiomic staging system for nasopharyngeal carcinoma
223576988|NCT04561323|DIAGNOSTIC_TEST|Dual-energy CT|"Patients suspected of acute bowel ischemia will be scanned in the dual-energy CT scanner.~The abdominal imaging protocols are predetermined by the Department of Diagnostic Radiology, Righospitalet, Denmark."
223576989|NCT02302235|OTHER|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
223576990|NCT02302235|OTHER|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
223576991|NCT01986959|PROCEDURE|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
223576992|NCT01986959|PROCEDURE|Without Periodontal dressing|The dressing was not inserted.
223576993|NCT04689971|DRUG|Standard therapy|Gabapentin, pregabalin, or amitriptyline
223464495|NCT04776408|DEVICE|Lung recruitment combined inhaled Nitric oxide|Ventilator combined inhaled Nitric oxide and Electrical Impedance Tomography monitor the V/Q mismatch
223464496|NCT04776408|DEVICE|Lung recruitment|Ventilator and Electrical Impedance Tomography monitor the V/Q mismatch
223464497|NCT05192317|DEVICE|Sollievo Fisiolax|Class IIb Medical Device
223464498|NCT05192317|OTHER|Sollievo Fisiolax Placebo|Placebo
223464499|NCT06018805|OTHER|BMI≥30; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
223464500|NCT06018805|OTHER|BMI:18,5-24,9; Combined Spinal Epidural Anesthesia|Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
223464501|NCT02501746|OTHER|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
223464502|NCT02501746|OTHER|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
223464503|NCT02501746|OTHER|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
223464504|NCT02749162|DRUG|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
223464505|NCT02749162|DRUG|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
223464506|NCT02749162|DRUG|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
223464507|NCT02749162|DRUG|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
223464508|NCT02749162|DRUG|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
223464509|NCT00002192|DRUG|Rifapentine|
223464510|NCT00002192|DRUG|Ethambutol hydrochloride|
223464511|NCT00002192|DRUG|Clarithromycin|
223464512|NCT00002192|DRUG|Azithromycin|
223464513|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(montly)|once a month
223464514|NCT01904110|DRUG|Risedronate/Cholecalciferol combination(weekly)|once a week
223464515|NCT02781987|OTHER|chronic pancreatitis|patients with chronic pancreatitis
223464516|NCT00713843|OTHER|Manual Therapy Utrecht|Manual Therapy (6 weeks).
223464517|NCT00713843|OTHER|Physical Therapy|Physical Therapy (six weeks).
223576994|NCT04689971|DRUG|Vitamin B combination|Vitamin B combination (B1 100 mg, B2 200 mg and B12 200 mcg) tablet once daily
223576995|NCT05265507|DRUG|Glycopyrronium|Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.
223576996|NCT05265507|DRUG|Ondansetron|Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
223576997|NCT05438849|BEHAVIORAL|Mobile Health Application focused on behavioral treatments to treat urinary incontinence|Mobile health application for cell phones and computers that delivers evidence-based behavioral treatment for urinary incontinence, specifically tailored to women Veterans
223464518|NCT05078203|BEHAVIORAL|Exercise|36 minutes of Exercise
223464519|NCT02824146|OTHER|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
223576998|NCT05438849|COMBINATION_PRODUCT|Practice Facilitation|The toolkit has 4 components: (1) Practice Facilitation Visits, (2) Mobile-health or mHealth Application Training (MAT) training, (3) Access and education on the Data Dashboard, and (4) Health information technology (HIT) assistance.
223576999|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
223577000|NCT01357759|DRUG|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
223577001|NCT02967939|DRUG|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
223577002|NCT02967939|DRUG|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
223577003|NCT00113750|BIOLOGICAL|TreeMATA MPL|
223464520|NCT03273920|PROCEDURE|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
223464521|NCT03273920|PROCEDURE|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
223464522|NCT00976326|DRUG|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
223464523|NCT03426410|OTHER|Survey|Electronic survey containing a questionnaire regarding knowledge and use of national guidelines of low back pain rehabilitation, type and frequency of cross sectional communication, attitudes and beliefs about back pain and two patient vignettes.
223464524|NCT02174224|BEHAVIORAL|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
223464525|NCT02174224|BEHAVIORAL|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
223464526|NCT02174224|BEHAVIORAL|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
223464527|NCT03677115|DRUG|Dexmedetomidine|combination of ropivacaine and dexmedetomidine 20 ug every time
223464528|NCT04777981|DIETARY_SUPPLEMENT|CBDRA60 supplement|CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
223464529|NCT04777981|DIETARY_SUPPLEMENT|Placebo|Placebo
223464530|NCT01162889|DRUG|Placebo SC Injection|Single injection
223464531|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
223577004|NCT03191370|OTHER|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
223577005|NCT03191370|DRUG|Local Anesthetics,Topical|Anesthetic spray
224157805|NCT05117268|PROCEDURE|Glass ionomer restoration|The lesions of control group glass ionomer restoration group will be treated according to following clinical protocol: (A) Isolation of treatment area using cotton rolls and saliva ejectors; (B) Carious lesion excavation using high speed handpiece; (C) High viscosity glass ionomer cement mixed following manufacturer's instructions; (D) Cavity will be slightly overfilled using a flat plastic instrument, the occlusal surface will be protected with Vaseline and gloved finger will be used to apply slight pressure for 30s. Postoperative instructions will be clearly explained to each patient caregiver.
223464532|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
223464533|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
223464534|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
223464535|NCT01162889|DRUG|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
223464536|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
223577006|NCT02454062|DRUG|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
223577007|NCT02454062|DRUG|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
223577008|NCT03281551|DRUG|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
223577009|NCT01309776|DRUG|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
224157806|NCT05117268|PROCEDURE|Hall technique|In Hall technique, correct size preformed metal crown will be selected and shall be placed without caries excavation. The crown will be filled with glass ionomer cement and seated with finger pressure. Local anesthesia was not used finger pressure was maintained on the crown until the glass ionomer cement was set.
223577010|NCT01309776|DRUG|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
224157807|NCT02853123|DRUG|Tiotropium|fixed dose combination once daily
223464537|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
223464538|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
223464539|NCT01162889|DRUG|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
223464540|NCT01162889|DRUG|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
223464541|NCT00114985|DEVICE|Prostate Immobilization Device|Device placed during radiation treatment
223464542|NCT05343663|BEHAVIORAL|Education|Self-Management Program Conducted with Tele-Nursing will increase Treatment/Disease Adaptation, Self-Efficacy, Self-Care Management in Hypertension Patients.
223464543|NCT04126304|DRUG|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
223464544|NCT04126304|DRUG|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
223464545|NCT04126304|DIAGNOSTIC_TEST|Mycoplasma detection|"1. common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~2. community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
223464546|NCT04126304|OTHER|Data collection|"1. Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~2. Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~3. Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
223464547|NCT04126304|OTHER|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
223464548|NCT01407809|DEVICE|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
223464549|NCT05543538|OTHER|multimedia audio-visual program|Participants in the control group will receive teaching method with multimedia audio-visual material.
223464550|NCT05543538|OTHER|experiential learning programmes|Participants in the experimental group will receive teaching method with experiential learning.
223464551|NCT05543538|OTHER|teachers' personal demonstration|Participants in the experience group will receive teachers' personal demonstration.
223464552|NCT02104661|DRUG|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
223464553|NCT02104661|DRUG|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
223464554|NCT03099460|OTHER|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
223464555|NCT03099460|OTHER|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
224157808|NCT02853123|DRUG|Olodaterol|fixed dose combination once daily
224157809|NCT02853123|DRUG|Tiotropium|
224157810|NCT00564603|DRUG|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
223464556|NCT03099460|OTHER|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
223464557|NCT03273959|OTHER|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
223464558|NCT01676493|DRUG|Codeine|
223577011|NCT00771290|PROCEDURE|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
223577012|NCT02192762|BEHAVIORAL|Withdrawal regulation training|Withdrawal coping skills
223577013|NCT02192762|BEHAVIORAL|Relaxation training|Relaxation skills instruction
223577014|NCT00738764|BIOLOGICAL|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
224157811|NCT00564603|OTHER|0.9% Saline|Saline, in same volume of 2mL
224157812|NCT03207724|DRUG|Xilonix plus Onivyde and 5FU|Xilonix by IV
224157813|NCT02054663|DRUG|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
224157814|NCT01116349|PROCEDURE|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
224157815|NCT01116349|DEVICE|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
224157816|NCT00050336|DRUG|Lonafarnib (SARASAR)|
224157817|NCT02074397|PROCEDURE|Distant extrafascial injection|
223464559|NCT04784234|DIETARY_SUPPLEMENT|GlaucoCetin|GlaucoCetin, a medical food in capsule form, is FDA regulated and includes ingredients that have been shown to support and protect mitochondrial function of retinal ganglion cells. GlaucoCetin consists of a mixture of Curcumin, N-Acetyl Cysteine, Ginkgo Biloba Extract, Alpha-lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Extract, and Coenzyme Q10. Additional ingredients include L-Taurine, Niacinamide, Biotin, Natural Astaxanthin, Fisetin, Quercetin, Luteolin, Proprietary Dragonberry Flavor Complex, Monk Fruit, Bitter Blocker Natural Flavor, Citric Acid, Silica Dioxide, Fibersol-2, L-Leucine. Many of these are known anti-inflammatory and antioxidant ingredients. A 6 month supply of capsules, made for this study, will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
223464560|NCT04784234|OTHER|Placebo|The placebo is an identical capsule to the GlaucoCetin, made for this study, with no nutritional value. A 6 month supply of capsules will be provided at randomization with the following instructions: Take 6 capsules by mouth once daily with food.
223577015|NCT01798641|DEVICE|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
223577016|NCT02479776|BIOLOGICAL|stem cell injection|Injection of autologous bone marrow derived stem cells
223577017|NCT01709201|BEHAVIORAL|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
223577018|NCT04902664|BEHAVIORAL|Patient education materials|Patients receive a text-message and email with educational materials about medical testing.
223743465|NCT06742385|DEVICE|MedicWise|"* Both arms are equipped with the application, data are collected via the application and telemonitoring with alerts to the care team are activated in the active telemonitoring arm.~* Data are collected in both arms at baseline, M3, M6, M9 and M12~* Each center defines who handles alerts internally (physicians, IBD nurses, others, etc.) according to its internal organization. The application does not impose an internal operation.~* the alert thresholds are identical and fixed for all centers during the study. Within the framework of the study, alerts are defined according to the study's modalities but cannot be modified by the centers.~* Participating sites will have no obligation to respond to alerts.~* Randomization will be stratified by centers and by diseases (Crohn and UC) with unbalanced blocks of randomization"
224157818|NCT02074397|PROCEDURE|Subfascial injection|
224157819|NCT00776191|DRUG|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
224157820|NCT00776191|DRUG|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
224157821|NCT03832816|DRUG|Placebo|Placebo vapor (distilled water)
224157822|NCT03832816|DRUG|Vaporized THC alone|Acute exposure to vaporized THC
224157823|NCT03832816|DRUG|Vaporized CBD alone|Acute exposure to vaporized CBD
224157824|NCT03832816|DRUG|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
224157825|NCT01314144|DRUG|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
224157826|NCT00106249|DEVICE|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
224157827|NCT00106249|DEVICE|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
224157828|NCT03972605|DEVICE|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
224157829|NCT01810289|BEHAVIORAL|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
224157830|NCT00926991|OTHER|No intervention|No intervention; observation only
224157831|NCT01235338|DRUG|LDX + Venlafaxine XR|"* Day 1-5 LDX 30mg~* Day 6-10 LDX 50mg~* Day 11-15 LDX 70mg~* Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~* Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~* Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~* Day 31-34 Venlafaxine XR 150mg daily~* Day 35-38 Venlafaxine XR 75mg daily."
223743466|NCT07054931|BIOLOGICAL|ChAdOx1.tHIVconsv1|solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
223464561|NCT01943487|DRUG|EC905|Oral
223464562|NCT01943487|DRUG|verapamil|Oral
223464563|NCT03713684|DRUG|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223743467|NCT07054931|BIOLOGICAL|ChAdOx1.HIVconsv62|solution for injection one dose of 2.5 x 10\^10 vp/ml Arm B and Arm C
223743468|NCT07054931|BIOLOGICAL|MVA.tHIVconsv4|suspension for injection two doses of 1 x 10\^8 vpu/ml Arm B and Arm C
223577019|NCT04902664|BEHAVIORAL|Physician peer-comparison email|Physicians receive an email with feedback on how they compare to their peers in aggregate on test ordering during annual physicals.
223577020|NCT04902664|BEHAVIORAL|Physician education materials|Physicians receive reference materials on medical test interpretation and incidental findings.
223577021|NCT04902664|BEHAVIORAL|General visit preparation materials|Patients receive a text-message and email with general visit preparation tips.
223577022|NCT01441011|BEHAVIORAL|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
223577023|NCT01441011|BEHAVIORAL|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
223577024|NCT03654885|DEVICE|XEN-45 Gel Stent|XEN-45 gel stent device implant
223464564|NCT03713684|DRUG|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223464565|NCT03713684|DRUG|Background therapy|Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
223464566|NCT05656170|PROCEDURE|Stellate ganglion block|"Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total)."
223464567|NCT05656170|DRUG|Bupivacain|The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
223464568|NCT05656170|DRUG|Saline|The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
223464569|NCT01803087|DRUG|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
223464570|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
223464571|NCT01803087|DRUG|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
223464572|NCT01803087|DRUG|CHF 1535 100/6 pMDI (Foster®) (CTR)|
223464573|NCT04637243|OTHER|Treatment of Benign or Malignant Liver and Bile Duct Diseases|Available treatment of Benign or Malignant Liver and Bile Duct Diseases
223464574|NCT04542980|DIAGNOSTIC_TEST|SARS-CoV2 Autoantibody detection|Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
223464575|NCT03564990|OTHER|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
223464576|NCT03564990|OTHER|conventional approach|conventional follow-up
223464577|NCT01611623|DRUG|SNX-5422|Tablets dose every other day; dose escalation based on safety
223464578|NCT05150431|DRUG|Parecoxib|Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
223464579|NCT05150431|DRUG|Placebo|This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
224068212|NCT00400881|OTHER|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
223464580|NCT00003713|DRUG|intoplicine|
223464581|NCT01513993|PROCEDURE|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
223464582|NCT04767113|DRUG|Heparin sodium|"For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol."
223464583|NCT04767113|DRUG|Normal saline|For infants enrolled, normal saline was infused at the corresponding speed.
223464584|NCT03660748|BIOLOGICAL|MET-2|Ingestion of a novel human microbiome preparation
223464585|NCT02185417|DRUG|Hydrochlorothiazide (HCTZ)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
223464586|NCT02185417|DRUG|Chlorthalidone (CTD)|Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
223464587|NCT04096846|DIAGNOSTIC_TEST|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
223464588|NCT04653831|DRUG|Pirfenidone|Treatment with Pirfenidone as mentioned in the experimental arm description.
223464589|NCT04653831|OTHER|Standard of care|Treatment with SoC as mentioned in the control arm description.
223464590|NCT00524524|DRUG|ARQ 501|Weekly IV Infusion; 450 mg/m2
223464591|NCT02361112|DRUG|pyrotinib combined with capecitabine|
223464592|NCT01819675|DEVICE|Low frequency rTMS|
223464593|NCT01819675|DEVICE|High frequency rTMS|
223464594|NCT01819675|DEVICE|Sham rTMS|
223464595|NCT03721224|DIAGNOSTIC_TEST|Kiddie Schedule for Affective Disorders and Schizophrenia|Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
223464596|NCT05093556|BEHAVIORAL|iCHART - Interactive CBT for Headache And Relaxation Training|IVR based cognitive behavioral therapy for headache
224068213|NCT02100436|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
224068214|NCT02431351|DRUG|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
223464597|NCT00000399|DRUG|Hormone replacement therapy|
223464598|NCT00000399|PROCEDURE|Strength training|
223464599|NCT05508373|BIOLOGICAL|JS019|Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
223464600|NCT01158560|DIETARY_SUPPLEMENT|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
223464601|NCT01158560|BEHAVIORAL|Gargling|gargling with tap water, twice daily
223464602|NCT01158560|DIETARY_SUPPLEMENT|Placebo|matched placebo for active vitamin D
223464603|NCT00974311|DRUG|Enzalutamide|MDV3100, 160 mg orally per day
223464604|NCT00974311|DRUG|Placebo|Placebo comparator
223464605|NCT02437760|OTHER|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~* at time of diagnosis~* every 3 month during treatment~* stop at the progression or after 12 months"
223464606|NCT02595502|DEVICE|JJVC Marketed Contact Lens (Test)|
223464607|NCT02595502|DEVICE|Competitor Marketed Contact Lens (Control)|
223464608|NCT00549796|OTHER|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
223464609|NCT03193632|DIAGNOSTIC_TEST|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~1. Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~2. Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~3. Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
223464610|NCT03193632|DIAGNOSTIC_TEST|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
223464611|NCT01853787|DRUG|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
223464612|NCT01853787|DRUG|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
223464613|NCT04152681|DRUG|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
223464614|NCT04121338|PROCEDURE|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
223464615|NCT04121338|DRUG|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
223464616|NCT01639612|BIOLOGICAL|ALD-451|ALD-451 iv
223464617|NCT00144677|DRUG|sirolimus|
223464618|NCT00144677|DRUG|tacrolimus|
223464619|NCT05556148|DRUG|Otrivine Congestion Relief|0.1% Nasal Spray (Xylometazoline Hydrochloride)
223464620|NCT02818855|PROCEDURE|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
223464621|NCT02818855|DRUG|Collagen Matrix|A new collagen membrane
223464622|NCT02818855|PROCEDURE|Subepithelial connective tissue graft|Connective tissue graft
223464623|NCT03566095|BEHAVIORAL|Coaching and Voices for Food Kit|Community Coaching and Voices for Food Kit
223464624|NCT03566095|BEHAVIORAL|Voices for Food Kit|Voices for Food Kit
223464625|NCT06150300|BEHAVIORAL|Pulmonary rehab program|Exercise videos, breathing exercises, and educational messages delivered virtually
223464626|NCT06150300|BEHAVIORAL|Placebo|Breathing exercises and educational messages
223464627|NCT00458003|DRUG|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
223464628|NCT00458003|DRUG|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP \> 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP \< 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
223464629|NCT02016443|DRUG|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
223464630|NCT02016443|DRUG|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
223464631|NCT02885038|OTHER|Platelet concentrate transfusion|
223464632|NCT03158207|DEVICE|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
223464633|NCT03158207|OTHER|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
223464634|NCT06344975|BIOLOGICAL|STR-V003/Placebo|IM
223464635|NCT00189163|DRUG|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
223464636|NCT00189163|DRUG|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
223464637|NCT02718872|BEHAVIORAL|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
223577025|NCT03654885|PROCEDURE|Trabeculectomy|Trabeculectomy surgery
223577026|NCT05275582|BEHAVIORAL|CARE|"Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator"
223464638|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
223464639|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
223464640|NCT01951144|DRUG|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
223464641|NCT01951144|DRUG|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
223464642|NCT03266900|PROCEDURE|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
223577027|NCT05723926|DEVICE|Vine Filter|The Vine filters are designed to be implanted in the common carotid arteries in order to capture emboli coming from the heart or great vessels, before they can enter the anterior intracranial circulation. The filter is deployed percutaneously using a 22G needle under ultrasound guidance.
224068215|NCT04375202|DRUG|Colchicine 1 MG Oral Tablet|Tablets for oral administration, containing 1 mg of the active ingredient colchicine, administered 0.5 mg po every 8 hours x 30 days.
224068216|NCT03803462|OTHER|Behçet's disease Overall Damage Index (BODI)|BODI is a tool to document any organ damage that has occurred in patients since the onset of BD. It includes a form and an associated glossary with the definition of the items.
224068217|NCT02586168|DRUG|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
224068218|NCT02586168|DRUG|Placebo|Placebo
224068219|NCT00716651|DRUG|mepolizumab|750 mg mepolizumab iv q4wk until week 32
224068220|NCT01314716|DRUG|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
224068221|NCT01314716|DRUG|Placebo|Placebo to match AZLI administered via nebulizer three times daily
224070769|NCT07132632|BEHAVIORAL|12-week multicomponent therapeutic exercise program including supervised and home-based sessions focused on strength, balance, mobility, and aerobic capacity|This intervention consists of a 12-week multicomponent therapeutic exercise program for older adults with mild to moderate frailty. Participants will complete 12 sessions (8 supervised in primary care and 4 home-based), each lasting approximately 60 minutes. Sessions include warm-up, strength exercises (using body weight or elastic bands), moderate aerobic activity (e.g., walking or pedaling), balance and coordination training (including dual tasks), and a cool-down phase. The program follows FITT-VP principles and is tailored to functional capacity. Intensity is monitored using the Borg scale (CR10 and RPE), estimated 1RM (20-80%), and 64-76% HRmax. Exercises are progressively adjusted in volume, intensity, and complexity. Home sessions are guided by an illustrated manual and reinforced by biweekly follow-up phone calls to promote adherence and safety. The intervention is aligned with international guidelines and aims to improve physical performance, reduce frailty and sarcopenia.
224070770|NCT07132632|BEHAVIORAL|Placebo Pre-Treat|The pre-intervention period (Month 0 to Month 3) will serve as the control phase, during which participants will receive no specific exercise program. From Month 3 to Month 6, the intervention phase will begin. Participants act as their own control.
224070771|NCT07028073|DRUG|Group A (FIT): Avapritinib + IA regimen|Cytarabine 100mg/m² days 1-7 Idarubicin 12mg/m² days 1-3 Avapritinib orally on days 8-21 (28-day cycle)
224070772|NCT07028073|DRUG|Group B (UNFIT): Avapritinib + VA regimen|Venetoclax 100mg day 1, 200mg day 2, 400mg days 3-28 Azacitidine 75mg/m² days 1-7 Avapritinib orally on days 8-21 (28-day cycle)
224070773|NCT02447588|OTHER|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
224070774|NCT02447588|OTHER|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
224070775|NCT06715124|DRUG|QTX3544|QTX3544 will be administered at protocol defined dose.
224070776|NCT06715124|COMBINATION_PRODUCT|Cetuximab|Cetuximab will be administered at protocol defined dose.
224070777|NCT06926621|DRUG|VX-670|Solution for intravenous administration.
224070778|NCT06740435|OTHER|Enhanced Telemedicine for Type 2 Diabetes|Telemedicine-based endocrinology specialty care for type 2 diabetes with multidisciplinary diabetes care team support including pre-visit preparation, in-visit support and self-management education, and post-visit follow-up.
223464643|NCT03266900|DRUG|6 weeks BCG instillation|standard 6 weeks of BCG induction
223464644|NCT03006536|DEVICE|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
223464645|NCT04426942|OTHER|survey|survey on sexuality during pregnancy
223464646|NCT01040949|BEHAVIORAL|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
223464647|NCT01040949|BEHAVIORAL|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
223464648|NCT04100928|OTHER|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
223464649|NCT03353324|DRUG|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
223464650|NCT03353324|RADIATION|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
223464651|NCT05934474|BIOLOGICAL|Peripheral venipuncture blood sampling, as part of standard care procedures|Collection of 36 mL of blood
223464652|NCT05934474|OTHER|Interview with a psychiatrist|Research project data collection
223464653|NCT04238936|DIAGNOSTIC_TEST|Serum amyloid A values|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
223464654|NCT04238936|DIAGNOSTIC_TEST|Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)|Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
223464655|NCT01758497|PROCEDURE|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
223464656|NCT01758497|PROCEDURE|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
223464657|NCT00809445|BEHAVIORAL|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
223577028|NCT04763512|DIETARY_SUPPLEMENT|Intact Cow's Milk Protein Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 4 months.
224068222|NCT05276960|DRUG|Cholecalciferol Pill|Dose increments according to serum levels determined every 2 months
223464658|NCT00809445|BEHAVIORAL|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
224068223|NCT04875884|DEVICE|Modified MRI|A technical modification to the standard MRI which only affects radiofrequency pulse polarization attempting to optimize the image quality. All other factors, including pulse sequence parameters, and patient and coil positioning is similar to that of the standard MRI.
224068224|NCT06450509|BEHAVIORAL|Babble Boot Camp|Caregivers are coached by a pediatric speech-language pathologist to implement activities and routines into their daily home lives with the intent to foster and boost their child's precursor and earliest speech and language skills. The intervention will be conducted entirely via telehealth.
224068225|NCT04151199|OTHER|EE Training|Participants randomized to EE training engage in three school-based or center-based (PERC) EE training sessions each week for approximately 12 weeks; each session lasting roughly 70 min with a 45-50 minutes of a stimulus phase and the remaining time being used to warm-up and cool down.
223464659|NCT00809445|BEHAVIORAL|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
223743469|NCT07054931|BIOLOGICAL|GS-5423|Solution for infusion 2550 mg Arm A, Arm B and Arm C
224068226|NCT05292781|OTHER|CHOICES|An innovative web application to provide interactive information about reproductive health options for people with SCD or SCT. CHOICES is a multimedia intervention that provides targeted and tailored information for participants to become informed ns about their reproductive health options. Targeted to their sex and tailored to their SC reproductive health knowledge, reproductive health behavior during the previous 6 mo, and parenting plan (e.g., intention to have child with SCD or not), CHOICES presents information about options to help the participant achieve their parenting plan through reproductive partner selection based on sickle cell status, prenatal testing, ovum and sperm donation, advanced reproductive technologies, and options to avoid pregnancy or adopt. The website will be housed on secure University of Florida (UF) servers and accessible via computers or mobile devices (e.g., tablets, smart phones); device capture will inform plans for long-term dissemination.
223464660|NCT04822714|BEHAVIORAL|Mobile Career Competencies Intervention|Mobile career competencies intervention aim to enhance the career competencies (career behavioral action) among the participants
223464661|NCT02048722|DRUG|regorafenib|Given PO
223464662|NCT01339039|DRUG|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
223464663|NCT01339039|DRUG|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
223464664|NCT01339039|DRUG|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
223464665|NCT01339039|DRUG|Plerixafor|Daily administration for 5-9 days prior to surgery
223577029|NCT04763512|DIETARY_SUPPLEMENT|Partially Hydrolysed Whey Formula|Study product will be provided as powder, reconstituted with water by parents/caregivers according to label instructions, and consumed orally. Study participants will continue this feeding regimen for 16 months.
223743470|NCT07054931|BIOLOGICAL|GS-2872|Solution for infusion 850 mg Arm A, Arm B and Arm C
223464666|NCT01339039|PROCEDURE|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 \& 15).
223464667|NCT02406456|OTHER|Neurofeedback|
223464668|NCT03983200|DEVICE|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
223464669|NCT03983200|DRUG|Mecobalamin|mecobalamine 0.5mg,tid
223464670|NCT01487083|DRUG|Pomaglumetad methionil|Administered orally
223577030|NCT05400993|COMBINATION_PRODUCT|Chidamide|Chidamide: take orally twice a week,4 tablets/time (20mg/ time), the interval between two doses should not be less than 3 days (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), the day before chemotherapy, 30 minutes after breakfast； Chidamide: 20mg, orally, twice a week, oral for two weeks and one week, a total of 8 cycles； Epirubicin 90mg/m2 , ivgtt, d1 Cyclophosphamide 600mg/m 2, ivgtt, d1 Q3w, 4 cycle； sequential Docetaxel 100 mg/m 2, IVGtt, D1 Q3w, 4 cycle。
223577031|NCT05057507|DIAGNOSTIC_TEST|Atrial cardiac magnetic resonance imaging|To include assessment of atrial size, shape, function, fibrosis and fat
223577032|NCT05057507|DIAGNOSTIC_TEST|Atrial electro-anatomic mapping|To include assessment of atrial voltage and local activation time
223577033|NCT05057507|OTHER|Atrial fibrillation symptom questionnaire|To include assessment of atrial fibrillation symptoms and quality of life
223577034|NCT05057507|DIAGNOSTIC_TEST|Patch-based 2 week ambulatory monitor|To assess atrial fibrillation burden post-ablation
223577035|NCT03143998|DRUG|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
223577036|NCT01442792|DRUG|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
223577037|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
223577038|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
223577039|NCT01442792|DRUG|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
223577040|NCT00607113|DRUG|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
223577041|NCT00607113|DRUG|RAD001|10 mg By Mouth Daily For 21 Days
223577042|NCT06103487|GENETIC|No Intervention|Observational study
223464671|NCT06958562|DIAGNOSTIC_TEST|No intervention administered. Standard care will be provided. Blood samples for lymphocyte count and CRP will be collected, and Syntax score will be calculated from angiography.|No intervention administered. Standard care will be provided. Blood samples for lymphocyte count and CRP will be collected, and Syntax score will be calculated from angiography.
223464672|NCT02532335|DRUG|Obeticholic acid|active drug
223577043|NCT02080325|OTHER|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
223577044|NCT02080325|OTHER|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
223577045|NCT01057485|PROCEDURE|AF ablation and AV node ablation|AF ablation and AV node ablation
223577046|NCT01057485|PROCEDURE|AV node ablation|AV node ablation
223577047|NCT02976025|OTHER|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
223577048|NCT02976025|OTHER|Collaborative Care|Standard collaborative care implementation training and support.
223577049|NCT00784485|DRUG|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
224071604|NCT01262690|DRUG|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
223464673|NCT02532335|DRUG|Obeticholic acid placebo|matching placebo
223464674|NCT04144322|DEVICE|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
223464675|NCT04144322|DEVICE|Zimmer T3 with Discrete Crystalline Deposition Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
223464676|NCT01096953|BEHAVIORAL|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
223464677|NCT01096953|BEHAVIORAL|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
223464678|NCT00507936|DRUG|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
223464679|NCT00507936|DRUG|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
223464680|NCT00507936|DRUG|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
223464681|NCT00507936|DRUG|placebo|placebo capsule BID throughout the treatment period
223464682|NCT00507936|DRUG|Duloxetine|Duloxetine 60 mg QD throughout treatment period
223464683|NCT06545903|DEVICE|LMA Supreme|The device is inserted and the manikin ventilated
223464684|NCT06545903|DEVICE|SLIPA|The device is inserted and the manikin ventilated
223464685|NCT06545903|DEVICE|I-gel|The device is inserted and the manikin ventilated
223577050|NCT02127294|DEVICE|transcatheter patent foreman ovale closure|
223577051|NCT04095130|DIAGNOSTIC_TEST|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
223577052|NCT01550393|GENETIC|proteomic profiling|
223577053|NCT01550393|OTHER|enzyme-linked immunosorbent assay|
223577054|NCT01550393|OTHER|laboratory biomarker analysis|
223577055|NCT01550393|OTHER|medical chart review|
224071605|NCT01262690|DRUG|PF-05230901|Single dose SC
223464686|NCT06545903|DEVICE|AuraGain|The device is inserted and the manikin ventilated
223464687|NCT05493761|DRUG|Denosumab|60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
223464688|NCT05493761|DRUG|Alendronate Sodium|70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.
223464689|NCT06038942|BEHAVIORAL|Formal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The formal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught formal mindfulness practices (e.g., sitting meditation, body scan, thought meditation, loving-kindness meditation) during the group sessions and will be asked to commit to practicing the strategies independently throughout the project period."
223464690|NCT06038942|BEHAVIORAL|Informal mindfulness instruction|"An equal number of university students from all groups will participate in this arm (i.e., those with ADHD, those with a history of nonsuicidal self-injury, and those with self-reported stress). The informal mindfulness instruction will consist of four weekly 1 hour-long group sessions, held on Webex (i.e., online) over four consecutive weeks. Participants will learn foundational principles around the role of mindfulness in relation to emotion regulation, stress, and self-compassion.~They will also be taught how to integrate informal mindfulness into their daily routine and will be guided through a series of demonstrations within the group sessions. Participants will be asked to commit to practicing informal mindfulness independently throughout the project period."
223464691|NCT02778152|DEVICE|Laser depilation|Laser depilation of natal cleft (pilonidal region)
223464692|NCT03107208|DRUG|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
223464693|NCT03107208|DEVICE|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
223464694|NCT04078711|DRUG|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
223464695|NCT04078711|DRUG|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
223464696|NCT04078711|DRUG|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
223464697|NCT04804761|OTHER|Electroacupuncture|Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
223464698|NCT02511925|OTHER|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
223464699|NCT02511925|OTHER|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
223464700|NCT02511925|OTHER|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
223464701|NCT01747356|DEVICE|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
223464702|NCT04835727|OTHER|Semi-vegetarian diet and increase fiber consumption|All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
223464703|NCT00437164|DRUG|Insulin|
223464704|NCT00437164|DRUG|Oral GW677954 Capsules (15 mg)|
223577056|NCT02046694|DRUG|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight \>30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
223577057|NCT05055882|OTHER|children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital|Comparison of Adult-Onset Still's disease phenotypes
223464705|NCT00183118|BEHAVIORAL|Adapted Enhanced-RESPECT (HIV prevention intervention)|
223464706|NCT01272908|DRUG|rituximab|1000 mg intravenously on Days 1 and 15
223464707|NCT03602703|DIAGNOSTIC_TEST|Flow cytometry and Western Blot analysis|Diagnostic tests
223464708|NCT02482142|DIETARY_SUPPLEMENT|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
223464709|NCT04986774|PROCEDURE|Rescue intracranial stenting|Rescue Intracranial Stenting in Acute Ischemic Stroke caused by intracranial large vessel occlusion
223577058|NCT02276118|DEVICE|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
223577059|NCT02276118|DEVICE|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
223577060|NCT00031460|DRUG|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m\^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
223464710|NCT05803694|DEVICE|ABL90 FLEX PLUS analyser running SW3.5 MR2.|The ABL90 FLEX PLUS analyzer is a portable, automated analyzer that measures pH, blood gases, electrolytes, metabolites, and oximetry in whole blood - utilizing 3 measuring modes (syringe, short probe, and capillary mode) to measure samples from a syringe, test tube or a capillary tube. The analyzer provides results for 17 parameters in 35 seconds using 65 μL heparinized whole blood.
223464711|NCT04189432|BIOLOGICAL|SCM-CGH|SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
223464712|NCT04189432|OTHER|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
223464713|NCT05739604|DIAGNOSTIC_TEST|Blood sample analysis|The concentrations of AAs and related compounds were determined by liquid chromatography/mass spectrometry (LC/MS)
223577061|NCT00031460|DRUG|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
223577062|NCT02210832|BEHAVIORAL|Best practices|
223577063|NCT02210832|BEHAVIORAL|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
223464714|NCT03565757|BEHAVIORAL|SMART intervention|All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
223464715|NCT05534568|OTHER|Parent-Child Assistance Program|Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources.
223464716|NCT05800756|DRUG|pyrotinib combined with trastuzumab, dalpiciclib and letrozole|Six 4-week cycles of dalpiciclib orally, 125mg, day 1-21, and letrozole orally, 2.5 mg, day 1-28, and pyrotinib orally, 320mg, day 1-28, and trastuzumab, injection, 8 mg/kg loading dose in cycle 1, 6mg/kg in cycles 2-6, intravenous drops, 1 cycle on day 1-21.
223464717|NCT01493895|DEVICE|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
223464718|NCT01493895|DEVICE|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
223577064|NCT01401699|DEVICE|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
223577065|NCT06337591|PROCEDURE|VI-RADS|Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
223577066|NCT01547091|BIOLOGICAL|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
223577067|NCT01547091|DRUG|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
223577068|NCT01547091|BIOLOGICAL|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10\^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
223577069|NCT01722292|DRUG|LY2940680|Administered orally
223577070|NCT01722292|DRUG|Carboplatin|Administered IV
223577071|NCT01722292|DRUG|Etoposide|Administered IV
223464719|NCT03899857|DRUG|Pembrolizumab|Pembrolizumab will be added to standard of care
223464720|NCT02131064|DRUG|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg\*min/mL q3w
223464721|NCT02131064|DRUG|Docetaxel|Docetaxel 75 mg/m\^2 IV infusion q3w
223464722|NCT02131064|DRUG|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
223577072|NCT01722292|DRUG|Placebo|Administered orally
223577073|NCT05462639|DRUG|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
223577074|NCT02080260|DRUG|regorafenib|Single agent drug therapy with regorafenib
223577075|NCT00596583|DRUG|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
223577076|NCT00596583|DRUG|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
223743471|NCT07054931|OTHER|Treatment interruption induced viraemia|Participants pause ART before receiving vaccines and/or bNAbs Arm A and Arm C
223577077|NCT02968381|BEHAVIORAL|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
223577078|NCT02968381|BEHAVIORAL|Control Condition|Telephone coaching using standard cognitive behavioral methods
223577079|NCT00697294|DIETARY_SUPPLEMENT|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
223577080|NCT06544031|BEHAVIORAL|Healthy Nutrition Education Program|The program consists of two sessions totaling 2 hours. The first session includes a traditional presentation on healthy nutrition, and the second session involves an interactive question and answer segment. The intervention aims to improve nutritional knowledge and attitudes towards healthy eating among elderly residents.
223577081|NCT04345172|DEVICE|sub-Tenon's block with a lacrimal dilator group or a Wescott scissors|"Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space."
223577082|NCT01650740|DRUG|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
224070779|NCT06740435|OTHER|Usual Telemedicine Endocrinology Care for T2D|Routine telemedicine-based endocrinology specialty care for type 2 diabetes, generally consisting of synchronous virtual visit with an endocrinologist and additional support including self-management education on an individualized basis.
224070780|NCT06763328|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224070781|NCT06763328|OTHER|Educational Intervention|Receive standard of care healthy diet and exercise handouts
224070782|NCT06763328|DRUG|Extended Release Metformin Hydrochloride|Given PO
224303340|NCT01593514|BIOLOGICAL|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
224303341|NCT01593514|BIOLOGICAL|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
224303342|NCT00378612|DEVICE|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
224303343|NCT04009512|DEVICE|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
224303344|NCT01560481|DRUG|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
223464723|NCT02131064|DRUG|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
223464724|NCT02131064|DRUG|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
223577083|NCT01650740|DRUG|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
224303345|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
224303346|NCT01560481|DRUG|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
224303347|NCT01560481|DRUG|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
224303348|NCT01560481|DRUG|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
224303349|NCT01560481|DRUG|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
224303350|NCT01560481|DRUG|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
224303351|NCT02397408|DRUG|Carbon C 11 Choline|Given intravenously (IV) prior to imaging
224303352|NCT02397408|DRUG|Fluorine F 18 Choline|Given intravenously (IV) prior to imaging
224303353|NCT02397408|PROCEDURE|Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)|Undergo whole-body PET/MR imaging
223577084|NCT01650740|OTHER|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
223577085|NCT01570049|DRUG|Bendamustine|for injection
223464725|NCT05664308|OTHER|Clinical follow-up (ECG)|Clinical follow-up with a consultation at the University Hospital at 3, 6, and 12 months, with an ECG at each visit.
223464726|NCT05664308|OTHER|Ongoing monitoring|"Once operated, patients will be monitored remotely via a computerized data transfer routine anonymized by the WITHINGS software, based on the data from the watch.~It's contractually agreed with WITHINGS that the transmissions will be scheduled and transmitted weekly to the center."
223464727|NCT01062893|OTHER|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
223464728|NCT01062893|OTHER|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
224070783|NCT06763328|OTHER|Questionnaire Administration|Ancillary studies
224070784|NCT05354505|DEVICE|Placement of the GOLDBAL2 balloon|The Fetal Endoscopic Tracheal Occlusion (FETO) procedure using the Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100) will be used to treat fetuses diagnosed with severe Congenital Diaphragmatic Hernia (CDH)
224070785|NCT07058376|PROCEDURE|Herbal Medicine Strategy|A pragmatic intervention involving tailored herbal prescriptions created by Korean medicine doctors. The specific composition, dose, and duration of herbal medicine vary per patient, and prescriptions are adjusted according to clinical response.
224070786|NCT07058376|PROCEDURE|Standard Korean Medicine Treatment|"This includes the application of Korean medical procedures widely used for chronic low back pain:~Acupuncture: Insertion of needles at 10-20 selected acupoints for 10-15 minutes.~Electroacupuncture: Electrical stimulation at 3 Hz to 4 acupoints for 10-15 minutes.~Infrared Therapy: Application of infrared rays from 30 cm for 10-15 minutes.~Cupping: Wet or dry cupping at 2-4 points on the lower back.~Moxibustion: Applied to two points near the painful area at 43±1°C for 10-15 minutes.~Physical Therapy (ICT or TENS): Applied for 10-15 minutes focusing on the quadratus lumborum.~Treatment frequency is 2 times/week for 5 weeks, but may be adjusted to 1-3 times/week depending on symptoms. Total number of sessions is limited to 10."
224070787|NCT06926972|OTHER|NOURISH|Culinary medicine demonstrations and nutritional education focused on balanced eating.
224070788|NCT07135453|BIOLOGICAL|Pneumococcal Vaccine|PCV
224070789|NCT05865301|OTHER|Questionnaire for patients receiving therapy|Questionnaires will be given (at baseline, 1, 3, 6, and 12 months post CAR infusion) including baseline demographics, individual/family and neighborhood socioeconomic data, measures of household material hardship (housing and transportation insecurity, household energy and food insecurity), barriers to care at the CAR T cell institution, as well as patient reported outcomes following Kymriah infusion.
224070790|NCT06909201|DRUG|HP 129Xe MRI|Gas delivery will be from a Tedlar bag
224070791|NCT02956551|BIOLOGICAL|DC vaccine|subcutaneous administration
223464729|NCT04086810|DRUG|DCCR|Once daily oral administration
223464730|NCT01360346|PROCEDURE|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
223464731|NCT01360346|PROCEDURE|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
223464732|NCT03162406|DIETARY_SUPPLEMENT|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
223464733|NCT03162406|DIETARY_SUPPLEMENT|Placebo|Oral supplementation once per week for 6 months
223464734|NCT03086629|OTHER|Patient Concerns Inventory|
223464735|NCT03086629|OTHER|No Patient Concerns Inventory|
223464736|NCT06175208|BEHAVIORAL|Emotional Freedom Techniques|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
224157832|NCT01235338|DRUG|Venlafaxine XR + LDX|"* Day 1-5 Venlafaxine XR 75mg~* Day 6-10 Venlafaxine XR 150mg~* Day 11-15 Venlafaxine XR 225mg~* Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~* Day 21-25 Venlafaxine XR and LDX 50mg daily~* Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~* Day 31-34 Venlafaxine XR 150mg~* Day 35-38 Venlafaxine XR 75mg."
224157833|NCT02809118|DRUG|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
224157834|NCT02809118|DRUG|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
223464737|NCT06175208|BEHAVIORAL|Mindfulness Meditation|Every participant may be randomized to either the iEFT, iMMI, or WLC group. All patients will be randomised to one of the three groups and be involved in a 6-week trajectory.
223464738|NCT05354518|BEHAVIORAL|gestational diabetes management of midwifery students|Gestational diabetes management of midwifery students with a simulator
223464739|NCT02269839|DEVICE|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
223464740|NCT06047639|DEVICE|Bone-anchored hearing implants|surgically placed hearing device
223464741|NCT01388855|DRUG|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
223464742|NCT01388855|DRUG|Placebo|Pills made to look like vitamin D but have no medication in them
223464743|NCT03489343|DRUG|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
223464744|NCT02212119|DRUG|Botulinum Toxin|
223464745|NCT02212119|DRUG|Saline|
223464746|NCT04893551|BIOLOGICAL|Tilvestamab|Tilvestamab will be administered as IV infusion.
223464747|NCT04998890|OTHER|adventure-based cognitive behavioral intervention|"The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course entailed Improving Mental Health for University Success in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues."
223464748|NCT02862964|OTHER|identify L4/L5|"* For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~* The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~* The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
223464749|NCT01158261|BIOLOGICAL|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
223464750|NCT04414852|DRUG|Apatinib Mesylate|All the subjects will be administrated with 250mg apatinib on day 1
223464751|NCT05052853|DRUG|NMDAE|Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
224068227|NCT05292781|OTHER|eBook|e-Book contains information typically shared in clinical SCD care, including stick figure representation of inheritance because the investigator considers it unethical to withhold this basic information. It does not include other information related to the SCKnowIQ knowledge items or any of the behaviors needed to implement a parenting plan. Although not as long as CHOICES, the e-Book is sufficiently long, attractive, and engaging to retain participants randomized to the usual care control group; key factors for an adequate control condition. Interestingly, during the study and in interviews after the study, many e-Book participants commented that they were pleased to be assigned to the intervention group (they had not), which indicates that the control condition is sufficient for its intent--2-yr longitudinal retention of the sample. Also, human contact is the same for both groups, and the time-on-task on the computer is unlikely to influence study knowledge and behavior endpoints.
224068228|NCT03711214|PROCEDURE|Periodontal scaling|Periodontal scaling and root planing
224068229|NCT03681561|DRUG|Ruxolitinib|"Phase I: Ruxolitinib at assigned dose\* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~* Dose Levels:~  1. (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily~Phase II: Ruxolitinib 20mg twice daily by mouth begin Day 1 and continuing daily until study treatment stop."
224068230|NCT03681561|DRUG|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
224157835|NCT02809118|OTHER|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
224157836|NCT00443625|DRUG|SK3530|
224157837|NCT06258265|DRUG|TAK-279|TAK-279 capsule.
224157838|NCT06258265|DRUG|TAK-279 Placebo|TAK-279 matching placebo capsule.
223464752|NCT05052853|DRUG|Placebo Cap|Use of placebo as a comparator
223464753|NCT03143101|BIOLOGICAL|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
223464754|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
223464755|NCT03143101|BIOLOGICAL|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
223464756|NCT02732808|DRUG|Ovulation stimulation|"Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
223464757|NCT01493245|DRUG|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
223464758|NCT00719160|DRUG|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
223464759|NCT00719160|DRUG|Placebo|Placebo 20 mg twice a day for 9 days
223577086|NCT03344627|DRUG|Meropenem standard dose|"* Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
223577087|NCT03344627|DRUG|Meropenem high dose|"* Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
223577088|NCT04113460|OTHER|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
223577089|NCT00592332|DRUG|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
223577090|NCT00592332|OTHER|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
223577091|NCT00471887|BIOLOGICAL|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
224068231|NCT06191185|BEHAVIORAL|BPB, No PIN|"Patient-level: standard communication from care team.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
223464760|NCT05430425|OTHER|respiratory safety|Which of the 3 lma selection methods is effective in ensuring respiratory safety?
223464761|NCT01912950|DEVICE|Prowave LX IPL|
223464762|NCT02373150|DRUG|Imeglimin|
223464763|NCT02373150|DRUG|Placebo|
223464764|NCT05028764|DIAGNOSTIC_TEST|Buccal Swabs, Blood Draws and Skin Punch Biopsy|Buccal Swabs - FXN and specific RNA markers; Blood Draws - Lipid panel, Protein Marker Analysis and Gene RNA Analysis; Skin Punch Biopsy - Protein Markers
223464765|NCT05357534|OTHER|Physical activity|Physical activity: 10 km run on a treadmill
223464766|NCT04708080|PROCEDURE|thoracic epidural analgesia|A thoracic epidural catheter is routinely placed in patients undergoing open heart surgery in our hospital, at least 1 hour before heparin administration during the operation. After standard monitoring (ECG, SpO2, NIBP) is applied to the patients in the operating room, sedoanalgesia is provided with 1-3mg of midazolam and 50-100mcg of fentanyl. Then, by providing sterilization conditions, an epidural catheter is inserted through the T5-T6 interval with Tuohy needle. After confirming the location of the epidural catheter, 25mg / 10ml bupivacaine is administered as a bolus and then 3ml / hour bupivacaine infusion is started from the solution prepared as 3mg / ml and continues until the 48th postoperative hour. On the postoperative 2nd day, the catheter is removed 10-12 hours after LMWH administration and 2-4 hours after UFH, as recommended by the guidelines, paying attention to the anticoagulant administration times applied to the patients.
223577092|NCT03354624|DRUG|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
223577093|NCT05934318|DIETARY_SUPPLEMENT|L-citrulline|Twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring
223577094|NCT02971241|BEHAVIORAL|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
223577095|NCT04408768|OTHER|standard protocol for stroke patients|Standard protocol for stroke patients
224070792|NCT05149573|DEVICE|Pulsed Electromagnetic Field (PEMF) Device|BEMER PEMF device consists of a B. Body (full body mat), B. Pad (targeted pelvic pad), and Control Unit which powers the device. Both B. Body and B. Pad must be plugged in simultaneously into the Control Unit and activated individually. B. Body must be placed on a flat surface (e.g. floor, bed, reclining chair, etc) for best results.
223464767|NCT00201344|DRUG|Cisplatin,5-FU,Leucovorin|
223464768|NCT01285869|OTHER|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
223464769|NCT02908152|DIETARY_SUPPLEMENT|curcumin|"1500 mg~1 capsule / day for 12 weeks"
223464770|NCT02908152|DIETARY_SUPPLEMENT|placebo|"1500 mg~1 capsule / day for 12 weeks"
223464771|NCT01518647|BEHAVIORAL|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
223464772|NCT02047370|OTHER|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
223464773|NCT02047370|OTHER|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
223464774|NCT06518733|OTHER|appliance type|different types of appliances: labial fixed appliances only, fixed retainers, palatal appliances and miniscrews
223464775|NCT04687410|DEVICE|ProControl, MediGlobe|standard 22G FNA needle
223464776|NCT04687410|DEVICE|TopGain, Medi-Globe|novel 22G crown-cut FNB needle
223464777|NCT01630135|DRUG|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
223464778|NCT01630135|DRUG|Placebo|Placebo, intranasal, 2 weeks
223464779|NCT03242941|PROCEDURE|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
223464780|NCT03031717|PROCEDURE|Transjugular intrahepatic portosystemic shunt|
223464781|NCT05535608|DIETARY_SUPPLEMENT|SRW Cel System|Dietary supplement
223464782|NCT02899065|DIAGNOSTIC_TEST|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
223464783|NCT02899065|OTHER|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
223464784|NCT00971867|DRUG|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
223464785|NCT04799925|DRUG|Febuxostat|uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
223464786|NCT02554760|DEVICE|The ZELTIQ CoolSculpting System|The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
223464787|NCT02631317|BEHAVIORAL|Advance hospital notification by EMS|Advance hospital notification by EMS
223464788|NCT02631317|BEHAVIORAL|stroke team notification|stroke team notification
224070793|NCT05149573|DEVICE|Sham Pulsed Electromagnetic Field (PEMF) Device|The sham PEMF device appears identical to the BEMER PEMF device, with all of the same components and accessories, but does not emit a pulsed electromagnetic field.
223464789|NCT02631317|BEHAVIORAL|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
223464790|NCT02631317|BEHAVIORAL|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
223464791|NCT02631317|BEHAVIORAL|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
223464792|NCT05532215|DRUG|Misoprostol|The misoprostol tablets to be used in the study will be of the same brand and batch
223464793|NCT05532215|DRUG|Oxytocin|The oxytocin ampoules to be used in the study will be of the same brand and batch
223464794|NCT06223295|PROCEDURE|Focal therapy|"Focal therapy selectively treats a specific part of the prostate while preserving the rest of the gland in men with prostate cancer.~Focal therapy with ultrasound ablation (HIFU/TULSA) or irreversible electroporation (IRE) followed by an intensive MRI follow-up scheme at 12, 24, 36, 48 and 60 months, prostate biopsy at 12 months (and also when indicated) and PSA monitoring"
223464795|NCT06223295|PROCEDURE|Usual care|standard radical treatment; prostatectomy or radiotherapy with follow-up according international guidelines (PSA monitoring and imaging when indicated).
223464796|NCT00217035|DIETARY_SUPPLEMENT|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
223577096|NCT03562234|DIAGNOSTIC_TEST|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
223577097|NCT03562234|DIAGNOSTIC_TEST|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
224071606|NCT02343354|BEHAVIORAL|Nutrition/physical activity intervention|Please see arm description
224071607|NCT01767675|PROCEDURE|Secondary Cytoreductive Surgery|
224071608|NCT01767675|DRUG|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
224071609|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|5 cycles
224071610|NCT01767675|DRUG|platinum-based systemic chemotherapy postoperatively|6 cycles
224071611|NCT01493934|DRUG|injection of 6-DIG|Unique injection dose of 92.5 MBq
224071612|NCT06538480|DRUG|PRGN-2012|PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
223577098|NCT06960031|OTHER|PET/CT technique|"Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner.~The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min."
223577099|NCT06834984|DIETARY_SUPPLEMENT|Prebiotic, probiotic, postbiotic combination|The product consists of two probiotics, Lactobacillus rhamnosus LGG and Bifidibacterium animalis subsp. lactis BB-12, supplied at a total concentration of 11B CFU's, a prebiotic consisting of 1 × 106 Plaque Forming Units (PFU) LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae bacteriophages, marketed as PreforPro, and tributyrin- a stale form of butyrate
223577100|NCT06834984|DIETARY_SUPPLEMENT|Placebo|Placebo pill containing stomach acid-resistant outer vegan capsule (hypromellose, gellan gum), hi oleic safflower oil, inner vegan capsule (hypromellose, gellan gum) microcrystalline cellulose, ascorbyl palmitate, silica
223577101|NCT03460353|DRUG|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
223577102|NCT02483260|DRUG|Ribavirin|"1. Loading dose, 33 mg/kg (maximum dose: 2.64 g)~2. Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~3. Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
223743472|NCT06892509|BEHAVIORAL|mindfulness-based stress reduction program|In this study, Mindfulness-Based Stress Reduction Programme will be applied to the women to be included in the experimental group as a nursing intervention. For this programme, the researchers participated in the Mindfulness-Based Stress Reduction Programme consisting of eight internationally validated modules consisting of eight sessions given by Tera Consultancy and completed the training. The certificates of the researchers are given in the appendices. The experimental group will receive a mindfulness-based stress reduction programme for a total of eight weeks, 2-1.5 hours per week. The mindfulness programme usually lasts eight weeks because it has been reported that this is an effective period of time to produce noticeable changes in brain structure, stress levels, emotional regulation and general well-being.
224157839|NCT06258265|DRUG|Moxifloxacin|Moxifloxacin over-encapsulated tablet.
223464797|NCT00367003|DEVICE|Deep Brain Stimulation|The deep brain stimulation system (consisting of a lead, extension wire, and implanted pulse generator) will be surgically implanted to stimulate the targeted area of the brain. Stimulation will be turned off for 4 weeks following implantation, then participants will use brain stimulation for 6 months. Participants will also take part in Behavioral Activation therapy during the 6 months of active stimulation. Participants will be followed for 10 years, or until the DBS device has been FDA approved, with adjustments made to the stimulator and medications as necessary.
223464798|NCT06303206|DEVICE|Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM)|"Home Blood Pressure Telemonitoring (HBPT) includes used of an app to collect and transmit blood pressure readings.~Case Management (CM) includes pharmacists reviewing BP data and providing counselling to participants based on their BP values."
223464799|NCT06009679|DRUG|Misoprostol 200mcg Tab|Patients in the intervention group with suspected postpartum RPOC will receive 600 micrograms of misoprostol up to 3 times following delivery and followed up by ultrasound and clinical examinations for 6-12 weeks post-partum
224157840|NCT06258265|DRUG|Moxifloxacin Placebo|Moxifloxacin matching placebo capsule.
224157841|NCT04472819|DRUG|SHR2285 tablet|single dose or multi-dose
224157842|NCT04472819|DRUG|Placebo|single dose or multi-dose
224157843|NCT01801774|DRUG|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
224157844|NCT01801774|DRUG|Placebo|
224157845|NCT05166486|OTHER|Calisthenic exercise|"Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks."
224157846|NCT04185740|DEVICE|CloudUPDRS - Tapping Task|The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
224157847|NCT03477344|DRUG|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
223464800|NCT02260219|PROCEDURE|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
223464801|NCT06129097|OTHER|Thyme honey mouthwash|"* Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse."
223464802|NCT02186977|DEVICE|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
224157848|NCT03477344|DRUG|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
223464803|NCT02186977|DRUG|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
223464804|NCT02186977|DRUG|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
223464805|NCT03099577|RADIATION|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223464806|NCT03099577|RADIATION|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223464807|NCT03099577|RADIATION|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223464808|NCT03099577|RADIATION|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223464809|NCT03099577|RADIATION|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223464810|NCT03099577|RADIATION|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223577103|NCT03858179|DEVICE|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
223577104|NCT03858179|DEVICE|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
224157849|NCT04672031|OTHER|Glycemic Targets|The intervention is glycemic targets that are lower than those currently recommended by ADA and ACOG: fasting ≤80 mg/dL, pre-prandial ≤80 mg/dL, and 1-hour postprandial ≤110 mg/dL instead of fasting ≤95 mg/dL, pre-prandial ≤95 mg/dL, and 1-hour postprandial ≤140 mg/dL.
224157850|NCT00004695|DRUG|PEG-interleukin-2|
223464811|NCT03099577|RADIATION|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
223464812|NCT05259319|DRUG|Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]|Treatment given every 21 days during 24 months or until progression
223464813|NCT05259319|DRUG|Tiragolumab|Treatment given every 21 days during 24 months or until progression
223464814|NCT05259319|RADIATION|Stereotactic body radiation therapy (SBRT)|Radiothérapy is delivered as a hypofractionated schedule of 3 doses of 8Gy (idealy on Monday, Wednesday and Friday, or 3 sessions over a week, respecting at least 24 hours between each fraction)
223464815|NCT05227118|DRUG|MK-8189|MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
223577105|NCT04642157|OTHER|ELIOS|"ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media.~This includes~* A systematic initial contact with an ELIOS web-clinician~* Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk~* The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician"
223577106|NCT04642157|OTHER|other resources contacts|"Three types of resources will be suggested via the ELIOS website:~* The General Practitioner (GP)~* The closest medico-psychologic center (CMP)~* The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation."
223577107|NCT05587244|DEVICE|Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners|Primary and/or Revision total hip arthroplasty with the G7 Freedom Constrained Vivacit-E Liners
223577108|NCT05020795|PROCEDURE|Endovascular thrombectomy|Clot retrieval for large vessel occlusion in acute ischaemic stroke
223743473|NCT06745661|DEVICE|RLRL device|Each participant in the intervention group will be provided a repeated low-level red-light therapy (RLRL) device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
224157851|NCT00949949|DRUG|everolimus|Given PO
223464816|NCT05227118|DRUG|Placebo|MK-8189 matching placebo administered orally QD
223464817|NCT00394888|DEVICE|MRI|MRI of the spine.
223464818|NCT00394888|DEVICE|MRI of head and neck|MRI of head and C-spine
223464819|NCT00394888|OTHER|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
223464820|NCT00394888|OTHER|Cardiac examination|Complete cardiac examination
223464821|NCT00394888|DEVICE|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
223577109|NCT05570435|BIOLOGICAL|Blood collection|Blood collection for glucose, insulin, GLP-1, GIP and C-peptide.
224157852|NCT00949949|DRUG|gemcitabine hydrochloride|Given IV
224157853|NCT00949949|DRUG|cisplatin|Given IV
224157854|NCT00132522|DRUG|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
223464822|NCT05921656|OTHER|Construction and evaluation of airway leakage risk model of patients with endotracheal tube|"1. Conduct statistical analysis on general information, respiratory data, tracheal catheter data, and cross-sectional area of the patient's airway to clarify the current status of airway leakage and related influencing factors.~2. Based on multivariate logistic regression, a line chart prediction model for predicting the risk of airway leakage in patients with tracheal catheters is constructed. The clinical efficacy of the prediction model is evaluated by using the area under the ROC curve, the Calibration scatter plot, and the DCA decision line, respectively, to assess its discrimination, calibration, and clinical practicality."
223464823|NCT02541864|DRUG|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
223464824|NCT02541864|DRUG|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
223577110|NCT06456268|DEVICE|VibraCool mechanical stimulation and neuromodulatory therapeutic device|"Multiple studies have shown that vibration sources applied to muscles prior to exercise reduced soreness and lactate dehydrogenase production, and increased range of motion at 48 and 72 hours. Acute pain results from fast A nerves transmitting nociceptive information to the dorsal column, where the substantia gelatinosa's interneurons prioritize competing A mechanoreceptor and C-fibers to slow pain transmission. One study observed that stimulation of A mechanoreceptors shut the gate on pain transmission, an inhibitory mechanism known as gate control. Multiple physical methodologies leverage gate control physiology for pain relief, such as vibratory massage therapy and electrical stimulation to varying degrees. However, the use of vibratory massage to improve pain control and reduce opioid use following ACLR has not been well studied, and to our knowledge there are no randomized control trials (RCTs) evaluating the use of this modality compared to standard ice or cryocompression."
223743474|NCT06745661|DEVICE|sham device|Each participant in the sham group will be provided a sham therapy device, which they are required to use twice daily for 3 minutes per session, with a minimum interval of 4 hours between sessions, 7 days a week for one month.
223464825|NCT03389100|DRUG|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
223464826|NCT01526564|DRUG|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or \>4 hours for 8 weeks
223464827|NCT01526564|DRUG|Placebo|3 t.i.d, two plates per time
223464828|NCT03727841|DRUG|Marizomib|0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
223464829|NCT00561938|PROCEDURE|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
224071613|NCT06801015|DRUG|Semaglutide|Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
224071614|NCT06801015|DRUG|Tirzepatide|Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week
224071615|NCT06801015|DRUG|Placebo|Placebo administered by subcutaneous injection once per week.
224071616|NCT07006441|OTHER|Preoperative Cardiac Rehabilitation|Structured exercise program, respiratory physiotherapy, and patient education
224157855|NCT06139939|PROCEDURE|Double layer technique|Double layer technique for alveolar ridge augmentation (first layer autograft followed by xenograft second layer).
224071617|NCT07006441|OTHER|Postoperative Cardiac Rehabilitation|Structured exercise program, respiratory physiotherapy, and patient education
224071618|NCT07127380|PROCEDURE|Midline Lumbar Interbody Fusion (MIDLIF)|Midline Lumbar Interbody Fusion (MIDLIF) is a procedure utilizes a medial approach to the spine, involving the retraction of the segmental back muscles to expose the lamine and articular processes. Screw placement is medialized, with entry to a point along the pars intercularis or joint surface. It places the screw through potentially more cortical and stronger bone. Decompression is achieved by resecting the inferior articular process and lamina marginalis, followed by a discectomy. Subsequently, a transforaminal lumbar interbody fusion (TLIF) is performed to place an interbody cage and promote fusion.
224071619|NCT07127380|PROCEDURE|Minimally Invasive Transforaminal Lumbar Interbody Fusion (mini-TLIF)|Minimally invasive Transforaminal Lumbar Interbody Fusion (mini-TLIF) is a procedure that employs a percutaneous approach for pedicle screw placement through the pedicles. Decompression is performed using a lateral approach, with 2-3 cm lateral to the ipsilateral borders. This is followed by resection of the inferior articular process and removal of the ligamentum flavum, facilitating discectomy. An interbody cage is then inserted to achieve fusion.
224071620|NCT07008989|BEHAVIORAL|Memory replay|"Within the HippoCamera application, half of all recorded events will be categorized as baseline memories, and half will be categorized as replay memories.~Baseline memories are recorded, but never viewed by the participant again until the Early HippoCamera test at the end of the 12-week intervention.~Replay memories are recorded, and then placed into a memory gallery. HippoCamera uses a research-based algorithm to select 5 memories from this gallery for participants to replay each day. Prior research has shown that this replay is associated with significant memory enhancements for replayed v. baseline memories for HippoCamera users from other populations."
224071621|NCT07029750|PROCEDURE|Lipoabdominoplasty|Combination of liposuction and abdominoplasty under general anesthesia. Klein solution used for tumescent liposuction. Muscle plication performed with 0 loop polydioxanone suture. Umbilicus preserved and repositioned. Postoperative compression corset used for 1 month.
224071622|NCT05043012|DEVICE|flexible AIR coil|mpMRI scan
224071623|NCT05043012|DEVICE|endorectal coi|mpMRI scan
223464830|NCT00561938|PROCEDURE|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
224157856|NCT03965806|BEHAVIORAL|SURVEY|SURVEY
224157857|NCT05563259|RADIATION|Cognitive assessment, functional magnetic resonance imaging|Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
224157858|NCT02186535|DIETARY_SUPPLEMENT|Vitamin D and Calcium|
224157859|NCT04241120|BEHAVIORAL|Device and app system designed for participant to self-administer Habit Reversal Training|Participants will receive an awareness bracelet and an app that work together to implement key features of Habit Reversal Training. The participant will take part in psychoeducation, awareness training, and competing response training related to trichotillomania.
224157860|NCT04241120|BEHAVIORAL|Reminder bracelet control condition|Participants will receive a bracelet programmed to vibrate randomly several times per hour during waking hours. They will be instructed this is a reminder not to pull.
224157861|NCT02617706|DEVICE|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
224157862|NCT02918721|DEVICE|Restylane Lidocaine|Intradermal injection
224157863|NCT02918721|DEVICE|Restylane|Intradermal injection
224157864|NCT03945656|DRUG|insulin icodec|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
223464831|NCT01601496|DEVICE|FUSION Vascular Graft|All subjects who received the FUSION Vascular Graft at the baseline implant procedure.
223464832|NCT02653911|OTHER|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
223464833|NCT02653911|OTHER|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
223464834|NCT02342392|DRUG|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
223464835|NCT01679392|DRUG|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
223464836|NCT04607902|BEHAVIORAL|Supportive Therapy SSI|Online, 30-minute self-administered program for youth
223464837|NCT04607902|BEHAVIORAL|Behavioral Activation SSI|Online, 30-minute self-administered program for youth
223464838|NCT04607902|BEHAVIORAL|Growth Mindset SSI|Online, 30-minute self-administered program for youth
223464839|NCT04771078|BIOLOGICAL|Nonconforming idecabtagene vicleucel|Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy
223464840|NCT03243305|DRUG|AMPHORA|non-hormonal contraceptive vaginal gel
223743475|NCT04601740|DRUG|Oral Semaglutide|Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
223743476|NCT03939897|DRUG|Abemaciclib|Given PO
223743477|NCT03939897|PROCEDURE|Biopsy Procedure|Undergo tissue biopsy
224157865|NCT03945656|DRUG|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
224157866|NCT00649610|DRUG|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
224157867|NCT00649610|DRUG|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
224157868|NCT05283499|DRUG|OPIOID|Analgesic assignment
224157869|NCT05283499|DRUG|NON-OPIOID|Analgesic assignment
224157870|NCT06118944|DEVICE|ICB00 IOL|Bilateral implantation of ICB00 IOL
224157871|NCT06118944|DEVICE|ZCB00 IOL|Bilateral implantation of ZCB00 IOL
224157872|NCT06118944|DEVICE|CNA0T0 IOL|Bilateral implantation of CNA0T0 IOL
224157873|NCT01711476|BEHAVIORAL|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
224157874|NCT01711476|OTHER|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
224157875|NCT04387591|PROCEDURE|Fu's subcutaneous needling(FSN)|In this study, the doctor will use a disposable Fu's subcutaneous needling(FSN) to penetrate the subject's skin of the middle of medial epicondyle and radial styloid process. Then the doctor will push forward the needle parallel to the skin surface (maintaining in the subcutaneous layer), towards the subject's medial epicondyle. The docotr will sway the needle 50 times in 30 seconds. After swaying the needle, the doctor will instruct the subject to do elbow flextion for 10 seconds resisting the doctor's opposite force, then the subject take a rest for 10 seconds. The above actions(elbow flexion and rest) are 3 repetitions. Then the subject do palmar flexion in the position of elbow flexion for 10 seconds resisting the doctor's opposite force, and take a rest for 10 seconds. These actions are also 3 repetitions. After the above reperfusion approach of muscles, the doctor will take out the needle to finish the treatment.
224068232|NCT06191185|BEHAVIORAL|BPB, PIN|"Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the short messaging service (SMS) text messaging platform, HealthySMS.~Clinic-level: A program of best practices will be implemented to improve team communication, optimize practice workflow, and identify and track patients with abnormal FIT results through colonoscopy completion."
223464841|NCT01155622|PROCEDURE|Endovascular Cooling|Infusion of \<8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
223464842|NCT03130374|BIOLOGICAL|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
223464843|NCT01406119|DRUG|ABT-806|ABT-806 will be administered by intravenous infusion.
223464844|NCT04781296|DEVICE|CT with a photon-counting detector|Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
223464845|NCT01523145|BEHAVIORAL|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
223464846|NCT01523145|OTHER|Control Group|usual follow-up Standard follow-up at the participating heart center
223464847|NCT02689804|DRUG|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
223464848|NCT02689804|DRUG|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
223464849|NCT05251116|DEVICE|FreeStyle Libre|FreeStyle Libre 2 continuous Glucose Monitoring System
223464850|NCT04718480|DRUG|Placebo|po placebo tablets
223464851|NCT04718480|DRUG|Fluvoxamine|po fluvoxamine tablets
223464852|NCT01519011|DRUG|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
223464853|NCT01519011|DRUG|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
223464854|NCT01655719|DRUG|Pioglitazone|
223577111|NCT06456268|DEVICE|Cryocompression (Game Ready, Bregs) device|Cryotherapy has also been used as an adjunctive post-operative therapy to reduce pain and inflammation following anterior cruciate ligament reconstruction (ACLR). It has been shown to decrease local metabolism, resulting in reduced pain and inflammation. Multiple studies have shown the benefits of using cryotherapy after ACLR, and more recently dynamic intermittent compression has been shown to improve circulation while reducing the risk of skin necrosis associated with static permanent compression. A recent meta-analysis including ten RCTs found significant reductions in post-operative VAS pain scores and breakthrough opioid consumption when using cryotherapy, such as Game Ready or Breggs ice therapy, following ACLR.
223743478|NCT03939897|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223743479|NCT03939897|DRUG|Copanlisib Hydrochloride|Given IV
224068233|NCT06191185|BEHAVIORAL|No BPB, PIN|Patient-level: The patient-facing evidence-based instructions, communication, and navigation part of the intervention will leverage the SMS text messaging platform, HealthySMS.
223464855|NCT03964077|DIAGNOSTIC_TEST|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
223464856|NCT02565316|DRUG|Nepeta menthoides Boiss & Bohse freeze dried extract|
223464857|NCT02565316|DRUG|Sertraline|
223464858|NCT03425318|DEVICE|CNAP|Application of CNAP in patients with ARDS
223464859|NCT01820897|DRUG|Fosfomycin-Trometamol|
223464860|NCT01820897|DRUG|Sulfamethoxazole trimethoprim|
223464861|NCT00757393|DIETARY_SUPPLEMENT|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
223464862|NCT00757393|DRUG|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
223464863|NCT00116961|DRUG|Velcade|
223464864|NCT00116961|DRUG|Doxil|
223464865|NCT00116961|DRUG|Dexamethasone|
223464866|NCT00861666|BEHAVIORAL|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
224068234|NCT06191185|BEHAVIORAL|No BPB, No PIN|Patient-level: standard communication from their care team.
224068235|NCT02255383|DEVICE|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
224068236|NCT06048835|DEVICE|Blood sample|For each patient, a 15 ml EDTA blood sample will be collected at different time-points
224068237|NCT06407934|DRUG|Amlitelimab|"Pharmaceutical form: Injection solution~Route of administration: Subcutaneous (SC) injection"
224068238|NCT06407934|DRUG|Placebo|"Pharmaceutical form: Injection solution~Route of administration: SC injection"
224068239|NCT05774600|BEHAVIORAL|SSW Works|SSW Works is a behavioral, culturally tailored online intervention for skin cancer prevention amongst outdoor workers in the United States.
224068240|NCT05774600|BEHAVIORAL|Minimal Information Control|Provision of online materials for skin cancer prevention.
224068241|NCT03624010|DRUG|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
223464867|NCT03351543|BIOLOGICAL|microbial inoculate|volunteers will regularly receive microbial inoculate that they do not use orally
223464868|NCT05337865|OTHER|Aerobic exercise test.|Aerobic exercise test at a treadmill.
223464869|NCT01569126|DRUG|LY110140|Administered orally as capsules
223464870|NCT01569126|DRUG|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
223464871|NCT03390595|COMBINATION_PRODUCT|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~* Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~  * Intravenously every 2 weeks for two cycles.~ * During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~ * Intravenously every 2 weeks until progressive disease or intolerance.~* Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~  * Carboplatin 5AUC day +1.~ * Gemcitabine 1000mg/m2 day +1 and +8."
223464872|NCT03390595|COMBINATION_PRODUCT|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~* Carboplatin 5AUC day +1.~* Gemcitabine 1000mg/m2 day +1 and +8."
223464873|NCT04010292|BEHAVIORAL|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
223464874|NCT01921803|RADIATION|hypofractionation|
223464875|NCT01358292|PROCEDURE|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
223464876|NCT01358292|PROCEDURE|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
223743480|NCT03939897|PROCEDURE|Diagnostic Imaging Testing|Undergo imaging
223464877|NCT01166750|BEHAVIORAL|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
223464878|NCT01166750|BEHAVIORAL|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
223464879|NCT01124318|DRUG|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
223464880|NCT01124318|DRUG|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
223464881|NCT04332068|DRUG|Oral ivermectin|Ivermectin (NT007) 3 mg tablets are round, white, and scored on one side. Ivermentin 3mg tablets will be crushed and mixed thoroughly in 10mL of water.
223464882|NCT04332068|DRUG|Permethrin Cream|permethrin cream 5% (Pioletal® Plus) is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender.
223464883|NCT04332068|OTHER|Placebo tablet|placebo tablets are round, white, scored on one side. There are no active substances in the placebo tablets.
223464884|NCT04332068|OTHER|Placebo cream|A placebo cream is a white coloured lotion with a homogenous appearance and an odour of fennel and lavender but lacking the permethrin agent.
224068242|NCT06454903|BEHAVIORAL|ACT to RECOVER|During Phase 3 (Stage 1b RCT), the treatment condition will employ ACT to RECOVER. ACT to RECOVER will be a smartphone app designed to act as a flexible, semi-structured, user-friendly adjunct to standard medication treatment for opioid use disorder. Content will include components appropriate for either self-management and/or use with providers. ACT to RECOVER will be designed to have major ACT-focused modules completable within 1 month.
224068243|NCT06454903|BEHAVIORAL|Smartphone-based Symptom-Monitoring|During Phase 3 (Stage 1b RCT), the control condition will employ a smartphone-based symptom monitoring program in an effort to provide a balanced alternative to the treatment condition with respect to attention, time using a mobile application, and nonspecific intervention effects. This condition will not, however, include any content or components from the Prototype Digital Intervention hypothesized to produce active clinical effects.
224068244|NCT06202066|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224068245|NCT06202066|PROCEDURE|Computed Tomography|Undergo CT scan
224068246|NCT06202066|BIOLOGICAL|Incomplete Freund''s Adjuvant|Given SC
224068247|NCT06202066|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224068248|NCT06202066|BIOLOGICAL|Sargramostim|Given SC
223464885|NCT06010212|DRUG|Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin|"Phase Ib: Patients with advanced ESCC will be enrolled in a 3+3 dose escalation fashion, with projected enrolment of between 9-18 patients to determine RP2D. Once the RP2D is confirmed, the study will proceed to phase II.~fruquintinib: 3 mg, 4 mg, or 5 mg qd p.o., 2 weeks and 1 week, every 3 weeks ( dose exploration phases were performed sequentially from the 4 mg group, refer to the study design section for specific protocols); Camrelizumab: 200 mg I.V D1, every 3 weeks for treatment cycles; Paclitaxel liposomes: 135 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles; Nidaplatin: 70 mg/m2 i.v d1, administered every 3 weeks, up to 6 cycles. Chemotherapy is used for up to 6 cycles, followed by maintenance therapy with fruquintinib + Camrelizumab until disease progression or intolerable toxicity.~Phase II: Up to a total of 30 patients with advanced ESCC will be enrolled."
223743481|NCT03939897|PROCEDURE|Echocardiography Test|Undergo ECHO
224068249|NCT06202066|BIOLOGICAL|SVN53-67/M57-KLH Peptide Vaccine|Given SC
224068250|NCT06202066|DRUG|Temozolomide|Given PO
224068251|NCT06327893|OTHER|Submersion or immersion in liquid|The patient must have been submersed or immersed in liquid.
224303354|NCT05886010|DEVICE|prototypes 1 everyday|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
223464886|NCT03812939|DRUG|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
223464887|NCT04576728|DRUG|Trimodulin|IMP will be administered via IV infusion on 5 consecutive days.
223464888|NCT04576728|OTHER|Placebo (human albumin 1%)|IMP will be administered via IV infusion on 5 consecutive days.
223464889|NCT05499884|PROCEDURE|Endovaginal ultrasound|"Endovaginal ultrasound will be performed in the operating room by the radiology team to:~1. to confirm the operative indication for a rectal shaving ;~2. to confirm the complete removal of the lesion"
223464890|NCT02503241|PROCEDURE|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
223464891|NCT02503241|PROCEDURE|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
223464892|NCT05897515|DIAGNOSTIC_TEST|LIAISON NES FLU A/B & COVID-19|The LIAISON® NES FLU A/B \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.
224303355|NCT05886010|DEVICE|prototypes 1 every week|Application on brown spots located on the face and/or the hand (12 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
223464893|NCT04266899|DEVICE|Foot Drop Stimulator - Neuro Orthosis|The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
223464894|NCT04266899|DEVICE|Treadmill|Gait training on a treadmill
223464895|NCT01585246|DRUG|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
223464896|NCT01585246|DRUG|soybean oil soft gel|placebo (soybean oil soft gel)
223464897|NCT01704807|DEVICE|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
223464898|NCT01704807|DEVICE|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
223464899|NCT01688323|OTHER|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
223464900|NCT00145769|DRUG|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
223464901|NCT00145769|DRUG|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
223464902|NCT00145769|RADIATION|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
223464903|NCT00145769|RADIATION|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
223464904|NCT00145769|DRUG|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
224068252|NCT05380063|DRUG|De-escalated Dual Antiplatelet Therapy|ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.
224068253|NCT05380063|DRUG|Dual Antiplatelet Therapy|Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
224068254|NCT03596905|DRUG|Plecanatide|Taken orally daily for 4 weeks
224068255|NCT03596905|DRUG|Matching placebo|Taken orally daily for 4 weeks
224068256|NCT05980169|DEVICE|SensoniQ Treatment Station|The SensoniQ® Treatment Station is a chemotherapy chair with multiple transducers that release low- frequency sound waves to different points on the body in a preset frequency, distribution and time during a chemotherapy infusion.
224068257|NCT05658796|BEHAVIORAL|+RxWell|During the SuRxgWell trial, if a participant is randomized to receive RxWell, they will be provided with an access code that is required to download the app. Once the participant has downloaded the app, they will be paired with a UPMC coach who will guide the person through the sessions using in-app texting to help give them the tools needed to actively cope with anxiety and/or depression. The UPMC coaches are supervised by a licensed UPMC mental health clinician. The participant will have access to the app and coach for six months after they have consented. The digital behavioral tool includes over 30 brief Cognitive Behavioral Therapy (CBT) and mindfulness-based techniques.
224068258|NCT05658796|BEHAVIORAL|-RxWell|Treatment as usual
223464905|NCT00145769|PROCEDURE|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
223464906|NCT00219947|OTHER|blood draw|"* T cell subset enumeration~* Serologic reactivity with HIV antigens~* Viral load assays by bDNA, PCR, or RT-PCR~* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~* HIV-1 Resistance Testing"
223464907|NCT05171010|OTHER|no study-based therapeutic interventions|no study-based therapeutic interventions
223743482|NCT03939897|DRUG|Fulvestrant|Given IM
223743483|NCT03939897|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223464908|NCT04739033|BEHAVIORAL|VIVIR MEJOR EXPERIMENTAL|"This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor.~The self-applied online program will comprise a three months behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits, supported by audiovisual instructions. This group will receive access to the web-based lifestyle intervention (exercise and nutritional education), supported by audiovisual instructions given by their hypertension specialist doctor."
223464909|NCT02417753|DRUG|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
223464910|NCT03638960|DRUG|Bupivacaine liposome|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
223464911|NCT03638960|DRUG|Bupivacaine Hydrochloride|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
223464912|NCT00002295|DRUG|Inosine pranobex|
223464913|NCT04848636|DIAGNOSTIC_TEST|Cardiac Sodium and Proton MRI|Sodium-23 MRI of the Heart Proton MRI of the Heart
223464914|NCT05447845|DIAGNOSTIC_TEST|Computerized visual acuity assessment program|Each subject underwent visual acuity assessments using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and the computerized program
223464915|NCT03771963|BIOLOGICAL|Tetravalent Dengue Vaccine (TDV)|TDV SC injection.
223464916|NCT01057836|BEHAVIORAL|Neck endurance training|
223577112|NCT06456268|DEVICE|Standard ice packs|Cold also provides peripheral gate-control relief via small, slow C-Fibers that transmit low level pain. In addition to local pain relief, intense cold can raise the A pain threshold distant to the location. The mechanism has been called descending or diffuse noxious inhibitory relief, or more recently conditioned pain modulation (CPM). Injections, aches, and infiltration of local anesthesia and dermal fillers are relieved by applying cold. For acute injury, near freezing cold relieves pain by suppressing the local metabolic production of inflammation and concomitant tissue ischemia from hypoxia due to the increased metabolic rate.
223577113|NCT00628589|DRUG|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
224157876|NCT04387591|PROCEDURE|Transcutaneous Electric Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENSor TNS) is the use of electric current produced bya device to stimulate the nerves for therapeuticpurposes. TENS, by definition, covers the completerange of transcutaneously applied currents usedfor nerve excitation although the term is often usedwith a more restrictive intent, namely to describe thekind of pulses produced by portable stimulators usedto treat pain. The unit is usually connected to theskin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width,frequency and intensity. Generally TENS is applied athigh frequency (\>50 Hz) with an intensity below motorcontraction (sensory intensity) or low frequency (\<10Hz) with an intensity that produces motor contraction
223464917|NCT01057836|BEHAVIORAL|Stretching|
223577114|NCT00628589|DRUG|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
223577115|NCT00628589|DRUG|Inhaled placebo|Inhaled placebo
223577116|NCT03918850|DRUG|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
223577117|NCT03918850|DRUG|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
223577118|NCT00828399|DIETARY_SUPPLEMENT|Glutamine|Oral glutamine 30g/day
223577119|NCT00828399|DIETARY_SUPPLEMENT|Whole protein|Oral whole protein 30 g/day
224157877|NCT01464398|BEHAVIORAL|Stress reduction|8 weekly sessions
223577120|NCT04312607|DIAGNOSTIC_TEST|BCR-ABL gene PCR|peripheral blood sampling for detection of Philadelphia chromosome and flowcytometry for detection of CD26 positive stem cells
223577121|NCT04603417|DIAGNOSTIC_TEST|Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI|This cross-sectional study will present the participants with an instrumental pain avoidance learning task, while we record continuous Magnetoencephalography (MEG) brain signals, and other autonomic measurements. All patients will complete behavioral, neuropsychological and pain assessments to rate their current pain, disability, fear, anxiety, and depression using standardized scales.
223577122|NCT01131741|DRUG|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
224157878|NCT01464398|BEHAVIORAL|Stress reduction with Health education|8 weekly sessions
224157879|NCT03021044|OTHER|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
224157880|NCT03021044|OTHER|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
223464918|NCT03747705|OTHER|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (\>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
223464919|NCT01944436|DRUG|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
223464920|NCT03552991|DRUG|Agiocur Pregranules|6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
223464921|NCT04751383|PROCEDURE|Biospecimen Collection|Undergo collection of blood samples
223464922|NCT04751383|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
223577123|NCT01131741|DRUG|Control|This group receives 3 mL of saline IV during operation.
223577124|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
223577125|NCT02757859|OTHER|Lavage|Receive EIPL-S
223577126|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
223577127|NCT02757859|OTHER|Lavage|Receive EIPL-D
223464923|NCT04751383|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223464924|NCT04751383|PROCEDURE|Computed Tomography|Undergo CT
223464925|NCT04751383|BIOLOGICAL|Dinutuximab|Given IV
224157881|NCT06139094|DEVICE|CardioFlux Magnetocardiography|The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)
224157882|NCT03671642|DEVICE|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
223464926|NCT04751383|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223464927|NCT04751383|BIOLOGICAL|Magrolimab|Given IV
223464928|NCT04751383|PROCEDURE|Resection|Undergo surgical resection
223464929|NCT03751475|OTHER|Nutritional Strategy - OptiMA|"All children with a MUAC\<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
223464930|NCT03751475|OTHER|Effective nutritional standard strategy|"Children presenting with MUAC\<115 or WHZ\<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital \& anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
223464931|NCT05468463|BEHAVIORAL|Living Donor Navigator Program|The investigators have developed a 4-session educational program that simultaneously addresses potential donor concerns with the evaluation/donation process and provides advocacy training to transplant candidates and their advocates.
223464932|NCT05234177|OTHER|Observation|No intervention
223464933|NCT06466161|DEVICE|Upper Arm Cylindrical Blood Pressure Cuff|In Group 1, the upper arm cylindrical cuff is inflated first, followed by inflation of the forearm conical cuff.
223464934|NCT06466161|DEVICE|Forearm Conical Blood Pressure Cuff|In Group 2, the forearm conical cuff is inflated first, followed by inflation of the upper arm cylindrical cuff.
224157883|NCT03671642|PROCEDURE|White light perfusion assessment|Traditional visual perfusion assessment in white light
223464935|NCT03171597|DRUG|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
223464936|NCT03171597|DRUG|Lipid Regulating Drugs|Mainly including statins
223464937|NCT03171597|DRUG|Coronary Vasodilator|Mainly including nitrates
223464938|NCT03171597|DRUG|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
223464939|NCT03171597|DRUG|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
223464940|NCT03171597|DRUG|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
223464941|NCT04262011|PROCEDURE|immediate treatment|Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.
223464942|NCT04262011|PROCEDURE|postponed treatment|Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
223464943|NCT04333212|DEVICE|DR. Chip HPV genotyping IVD kit|HPV typing by gene chip
223577128|NCT02757859|PROCEDURE|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
224157884|NCT03671642|PROCEDURE|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
223464944|NCT00201019|BEHAVIORAL|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
223464945|NCT03620188|OTHER|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
223464946|NCT01720316|DRUG|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
223464947|NCT01720316|DRUG|placebo|
223464948|NCT02721615|PROCEDURE|Insertion of intra spinal sub dural pressure monitor|
223464949|NCT02721615|PROCEDURE|Insertion of sub dural microdialysis probe|
223464950|NCT01735149|DIETARY_SUPPLEMENT|Kochujang Pills|Kochujang Pills (34.5g/day)
223464951|NCT01735149|DIETARY_SUPPLEMENT|Placebo|Placebo (34.5g/day)
223464952|NCT03923153|DEVICE|Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
223577129|NCT05746936|PROCEDURE|Roux en-Y gastric bypass|gastric bypass with jejuna-jenual anastomosis and gusto-jejunal anastomosis
223577130|NCT06367088|DRUG|Cadonilimab|Patients were assigned to receive 10 mg/kg cadonilimab intravenously Q3W in combination with chemotherapy. The chemotherapy regimen is chosen by the physician.
223577131|NCT05875883|PROCEDURE|Neck ultrasound|The investigators will scan patients' necks with an ultrasound and look for anatomical landmarks to identify the phrenic nerve
223577132|NCT06606067|DRUG|Duloxetine|30 mg daily 2 weeks before surgery and 1 week after surgery
223577133|NCT06606067|DRUG|Placebo|Placebo tablet daily
223577134|NCT05193708|DEVICE|Windowed Bonding|A 3D printed tray/guide with open window for the orthodontic brackets
223577135|NCT05193708|DEVICE|Digital Indirect bonding tray|Vacuum formed on a 3d printer cast with brackets
223577136|NCT05197582|OTHER|tele-monitoring|The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
223577137|NCT01030874|OTHER|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
223577138|NCT01030874|OTHER|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
223577139|NCT01030874|OTHER|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
223743484|NCT06738355|BEHAVIORAL|PREVENT|The proposed study will assess the feasibility of an RCT for clinic-based outreach to increase vaccination rates for HPV at community clinics in rural counties. The study is a pilot trial that will assign adult parent/caregiver participants to a timeline for receiving the vaccination messaging intervention. Auto and Auto-Plus intervention arms may use some of the same components (automated calls, live calls, text messages, emails, and mailings).
223464953|NCT03923153|DEVICE|Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
223464954|NCT03438201|DIETARY_SUPPLEMENT|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
223464955|NCT03438201|DIETARY_SUPPLEMENT|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
223464956|NCT04793984|DEVICE|Carragelose|inhalation 3 times a day
223464957|NCT04793984|DEVICE|NaCl|inhalation 3 times a day
223464958|NCT05200585|BEHAVIORAL|Healthy Liver/Hígado Sano program|The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
224068259|NCT04311502|DRUG|Rifapentine|1200 mg once daily
224068260|NCT04311502|DRUG|Rifampicin|600 mg once daily
223464959|NCT05200585|BEHAVIORAL|Usual standard of care|Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
223577140|NCT01030874|OTHER|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
223577141|NCT01030874|OTHER|Drug Recommendations|The protocol permits the study physician to recommend medications for orthostatic hypotension. The patient's clinical team can implement, ignore, or modify these recommendations and only the clinical team can write orders for them. Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily \[Mukai 2002; Grubb 2003\]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily \[Low, 1997\]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
224068261|NCT04311502|DRUG|Isoniazid|300 mg once daily
224068262|NCT04311502|DRUG|Pyrazinamide|1000mg once daily if weight is 40 to \<55kg; 1500mg once daily if weight is 55 to \<71kg; 2000mg once if weight is ≥71kg
224068263|NCT04311502|DRUG|Ethambutol|800 mg once daily if weight is 40 to \<55kg; 1200 mg once daily if weight is 55 to \<71kg; 1600mg once if weight is ≥71kg
224068264|NCT04311502|DRUG|Clofazimine loading dose|300 mg once daily for 2 weeks (loading dose), then 100 mg once daily
224068265|NCT04311502|DRUG|Clofazimine 100 MG|100 mg once daily
224068266|NCT04707274|OTHER|Survey study|Victorian Institute of Sports Assessment for Gluteal Tendinopathy (VISA-G) Questionnaire will be applied.
224068267|NCT03833700|DRUG|E7386|E7386 doses.
224068268|NCT06963346|DRUG|Romidepsin|Administered as intravesical treatment.
224068269|NCT06963346|DRUG|Durvalumab|Administered as intravenous treatment.
224068270|NCT05279755|DRUG|prosetin|oral solution
224068271|NCT05279755|DRUG|placebo|oral solution
223464960|NCT05292885|DIAGNOSTIC_TEST|Gadopentetate Dimeglumine Injection|Patients with liver fibrosis after liver transplantation receive multi-parameter magnetic resonance scanning, percutaneous liver biopsy (or FibroScan).
223464961|NCT01264809|BEHAVIORAL|Specific consultation for physical activity counseling|Specific consultation
223464962|NCT01264809|BEHAVIORAL|Consultation for physical activity counseling|Specific consultation
223464963|NCT02267915|DRUG|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
223464964|NCT06128421|DIETARY_SUPPLEMENT|Individual nutritional support|Nutritional products and route（oral, parenteral）is possible to reach goals
223464965|NCT01104883|PROCEDURE|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
224157885|NCT06257615|BEHAVIORAL|Education provided via TeleNursing|"Online Video Call Online video interviews were conducted with the patients in the intervention group once in the first week (day 1-7), once in the second week (day 8-14) and once in the third week, using mobile phone programs and/or computer programs that provide video conversation opportunities. It was conducted in the form of remote online video calls, held three times in total, once within the 15-21st day.~Voice Phone Call After audio telephone interviews and online video interviews were completed within the first three weeks after the patients in the intervention group were discharged; It was carried out using a mobile phone 3 times in total: once in the fourth week (day 22-28), once in the fifth week (day 29-35) and once in the sixth week (day 36-42)."
224157886|NCT00179998|DRUG|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
224157887|NCT00179998|DRUG|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
224157888|NCT05829564|OTHER|virtual reality|The individuals participating in the study will experience virtual reality.
224157889|NCT05829564|OTHER|cervical mobilization|The individuals participating in the study will be applied cervical mobilization techniques.
224157890|NCT05829564|OTHER|exercise|The individuals participating in the study will performed neck-specific exercises.
224157891|NCT03329664|BIOLOGICAL|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
223464966|NCT01104883|PROCEDURE|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
224157892|NCT03329664|OTHER|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
224157893|NCT03765476|BEHAVIORAL|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
224157894|NCT03765476|BEHAVIORAL|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
224157895|NCT06245824|DRUG|Trastuzumab deruxtecan (T-DXd) with pyrotinib|T-DXd, 5.4mg/kg IV day 1 of a 21-day cycle. Pyrotinib, 400mg or 320mg, orally once a day, daily of a 21-day cycle.
224157896|NCT03607292|PROCEDURE|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
223464967|NCT00446017|DRUG|adrenaline|
223464968|NCT00446017|DRUG|milrinone|
223464969|NCT03356600|COMBINATION_PRODUCT|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
224071624|NCT02028455|BIOLOGICAL|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
223464970|NCT03110133|DRUG|Full Spectrum Microbiota|Orally administered donor derived microbiota
223464971|NCT03110133|DRUG|Placebo|Placebo for CP101
223464972|NCT02998151|DRUG|Acamprosate|two 666mg pills
223464973|NCT02998151|DRUG|Lovastatin|two 20mg pills
223464974|NCT02998151|DRUG|Minocycline|two 135mg pills
223464975|NCT02998151|DRUG|Placebo|placebo pill
223464976|NCT02998151|DRUG|Baclofen|one 30mg pill
223464977|NCT02155985|DRUG|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
223464978|NCT02155985|DRUG|Placebo|Placebo for aspirin
223464979|NCT02573259|DRUG|PF-06801591|IV every 21 days (Part 1)
223464980|NCT02573259|DRUG|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
223464981|NCT05347810|OTHER|Application of repetitive forces mimicking exoskeleton use|The investigational treatment consists of applying a predefined set of continuous and repetitive forces to the participant's thigh. It is applied using a custom device that has been designed specifically for this study. The forces to be applied are based on forces measured during exoskeleton use and will not exceed pain pressure thresholds reported in literature. The participants will hold an enabling switch at all times which they can activate to release the force exerted to their thigh. Alternatively, the experimenter can activate an emergency switch if the situation seems unsafe.
223464982|NCT02864732|OTHER|Rehabilitation exercises|
224071625|NCT06902584|DEVICE|comfilcon A Sphere lens|2 hours of wear
224071626|NCT06902584|DEVICE|comfilcon A Toric lens|2 hours of wear
224071627|NCT06902584|DEVICE|comfilcon A Multifocal lens|2 hours of wear
224071628|NCT06902584|DEVICE|comfilcon A Multifocal Toric lens|2 hours of wear
224071629|NCT06902584|DEVICE|comfilcon A Energys lens|2 hours of wear
224071630|NCT07093580|DRUG|S-892216-LAI|S-892216-LAI injection will be administered per schedule specified in the arm description.
224071631|NCT07093580|DRUG|Placebo|Physiological saline will be administered per schedule specified in the arm description.
223464983|NCT02864732|DEVICE|Electrical Stimulation|
223464984|NCT02316639|OTHER|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
223464985|NCT04143191|DRUG|Sorafenib|Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
223464986|NCT04143191|PROCEDURE|Transarterial chemoembolization|TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.
223464987|NCT04273516|DRUG|Rivaroxaban 2.5 Mg Oral Tablet|Tablet Rivaroxaban 2.5 mg 2 times daily add to standard treatment ASA 80 mg daily
223464988|NCT04273516|DRUG|Rivaroxaban placebo tablets|Placebo tablets add to ASA 80 mg daily that is standard treatment
223464989|NCT03588858|OTHER|structured interview questionnaires|"* Module (1): Socio-demographic characteristics~* Module (2) :Occupational history~* Module (3): Presence of work related injuries and diseases by history and observation.~* Module (4): Food frequency questionnaires (FFQ) during the past week.~* Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
223464990|NCT04776577|DEVICE|Wirecath@ and Abbott PressureWire® (20 patients)|Simultaneous FFR measurements with Wirecath@ and Abbott PressureWire®
223464991|NCT04776577|DEVICE|Wirecath® (20 patients)|FFR measurement with Wirecath® only
223464992|NCT04776577|DEVICE|Coronary flow reserve|Pressure derived CFR with Wirecath®, Thermodilution CFR with Abbott PressureWire®, Absolut flow CFR with Abbott PressureWire® and Hexacath Rayflow catheter®, Non-invasive echo derived CFR
223464993|NCT02665819|OTHER|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
223464994|NCT05254899|DRUG|Anti-PD-1 monoclonal antibody|200mg iv on Day 1 of each 14-day cycle for 3 cycles in induction treatment; 200mg iv on Day 1,15, 29 during RT treatment
223464995|NCT05254899|DRUG|Pegaspargase|3000 U/m2 im on Day 2 of each 14-day cycle for 3 cycles in induction treatment
223464996|NCT05254899|DRUG|Gemcitabine|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
223464997|NCT05254899|DRUG|Oxaliplatin|1g/m2 iv on Day 2 of each 14-day cycle for 3 cycles in induction treatment
223464998|NCT05254899|RADIATION|Involved site radiotherapy|Involved site radiotherapy according to the ILROG guideline with primary tumor dose of 50-56Gy 14-28 days after inductive therapy
223464999|NCT02472262|DIETARY_SUPPLEMENT|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
223465000|NCT02472262|DIETARY_SUPPLEMENT|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
223465001|NCT02472262|DIETARY_SUPPLEMENT|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
223465002|NCT04621058|DRUG|Vitamin D|In case of Vitamin D levels \<30 or 40ng/ml patients will take vitamin D supplements.
223465003|NCT04621058|DRUG|PLACEBO|Placebo capsules exactly the same as the above, but without the active component.
223465004|NCT05936814|PROCEDURE|total knee arthroplasty|cemented bicondylar PCL substituting total knee replacement
223465005|NCT02571764|OTHER|Nutritional Oats Cookie|
223465006|NCT01146847|DEVICE|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
223465007|NCT05940415|BEHAVIORAL|active surveillance|active surveillance without prostate biopsy
223465008|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose|50μg/dose
223465009|NCT05547256|BIOLOGICAL|COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose|100μg/dose
223465010|NCT05547256|DRUG|Placebo|Saline solution
223465011|NCT01367249|DRUG|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
223465012|NCT01367249|DRUG|Placebo|Sterile ophthalmic solution
223465013|NCT03279809|DRUG|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
223465014|NCT03279809|DRUG|Placebo|Case with placebo medication for 6 months after stenting
223465015|NCT02852421|PROCEDURE|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
223465016|NCT02852421|PROCEDURE|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
223465017|NCT03516565|OTHER|Saliva collection|
223465018|NCT03516565|OTHER|GCF collection|
223577142|NCT07006649|DIAGNOSTIC_TEST|Opthtalmologic diagnosis tests|Volunteer will be tested with : measurement of visual acuity, slit-lamp examination, fundus examination, optical coherence tomography
224071632|NCT07097545|BEHAVIORAL|Mindfulness|15 minute daily guided meditation
224071633|NCT07097545|BEHAVIORAL|Social Media Reduction|Reduce social media use at least 30 minutes daily and exercise instead
224071634|NCT07097545|BEHAVIORAL|Exercise|Participants will exercise at least 30 minutes daily. Participants are given examples of common exercises (walking, yoga, strength training, etc.), but are allowed to choose any type, although dissuaded from activities with high potential for injury.
224071635|NCT07135427|BIOLOGICAL|20-valent pneumococcal conjugate vaccine|Administration of PCV20
224071636|NCT07102433|OTHER|Children and young people with life-limiting conditions, their parents/carers, and professionals across healthcare, education, and social care sectors.|Children and young people with life-limiting conditions, their parents/carers, and professionals across healthcare, education, and social care sectors.
224157897|NCT03607292|PROCEDURE|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
224157898|NCT00000368|BEHAVIORAL|Cognitive behavior therapy|
224157899|NCT00000368|DRUG|Paroxetine or other medication - algorithm used|
224157900|NCT01665872|BEHAVIORAL|Cognitive-Behavioral Group Therapy|CBT Group
224157901|NCT01929018|BEHAVIORAL|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
224157902|NCT01929018|BEHAVIORAL|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
224303356|NCT05886010|DEVICE|prototypes 1 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224303357|NCT05886010|DEVICE|prototypes 2 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224303358|NCT05886010|DEVICE|prototypes 3 every two weeks|Application on brown spots located on the face and/or the hand (6 treatments during the study). An operator previously trained by the dermatologist will apply the study device to the patient's face or/and hand. Subjects will be lying down, and the prototypes will be administered upside down for the applications on the face and sitting for the applications on the hands. For the application on the hands, the hands will be placed flat on the table and the prototypes will be applied upside down. During applications on the face, subjects will wear diving goggles protecting the eyes from cryogenic gas.
224303359|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
224303360|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
224157903|NCT01929018|BEHAVIORAL|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
224157904|NCT00922519|OTHER|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 6 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
224157905|NCT03349593|DIAGNOSTIC_TEST|Echocardiography|Preoperative transthoracic echocardiography
224303361|NCT03449550|OTHER|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
224303362|NCT03449550|OTHER|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
224303363|NCT00573781|DIETARY_SUPPLEMENT|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
224157906|NCT02324868|DEVICE|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
224157907|NCT02324868|DEVICE|Conventional IV catheter protection|No Shower patch will be provided during study period
224157908|NCT05987475|PROCEDURE|Breast reconstruction|Breast reconstruction and breast augmentation based on the indications as listed out in the instructions for use of the medical device under investigation
224157909|NCT04769336|DEVICE|Central Lab based CBC|lab samples will be sent to the central lab for CBC analysis
224157910|NCT04769336|DEVICE|Point of Care CBC|lab samples will be analyzed at point of care
224303364|NCT00573781|DIETARY_SUPPLEMENT|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
224303365|NCT00573781|DIETARY_SUPPLEMENT|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
224303366|NCT02881138|DRUG|RC48-ADC|
224303367|NCT01646138|BIOLOGICAL|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
224303368|NCT05029830|COMBINATION_PRODUCT|investigations like MRI..|• Multiple Sclerosis Quality of Life-54 (MSQOL-54) Can be considered as the most known disease-specific instrument for the evaluation of quality of life in patients with multiple sclerosis (MS). It was developed to combine generic quality of life aspects of the SF-36 with MS-targeted dimensions and ratings for the overall quality of life. Therefore, 18 disease-specific items were added to the original 36 items of the SF-36. The 54 items are divided into 12 multi-item and 2 single-item scales. The MSQOL-54 items are transformed linearly to 0-100 scores and final scores are obtained by averaging items within the scales
224303369|NCT05634850|DEVICE|Kinder|Participants will test at their urine with at home with in the device. Results are sent via an app back to the clinic for reporting.
224303370|NCT01683838|DRUG|Fampridine-SR|25mg bid (twice daily)
224303371|NCT01683838|DRUG|Placebo|Placebo
224157911|NCT04882072|DRUG|Ustekinumab|Participants will receive IV infusion and SC injection of ustekinumab.
224157912|NCT04882072|OTHER|Placebo|Participants will receive IV infusion and SC injection of matching placebo.
224157913|NCT04882072|DRUG|Glucorticoid Taper Regimen|Glucocorticoid will be administered orally.
223465019|NCT01305707|DEVICE|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
223465020|NCT01305707|DRUG|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
223465021|NCT03588897|DIETARY_SUPPLEMENT|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
223465022|NCT00090909|DRUG|cisplatin|
223465023|NCT00090909|DRUG|dexamethasone|
223465024|NCT00090909|DRUG|gemcitabine hydrochloride|
223465025|NCT04264845|OTHER|Provider Focus|The provider focus groups will be conducted and data from the focus group sessions will be analyzed and used to evaluate clinicians' interpretation of PROs and acceptability of PRO data in routine clinical care. A formal provider training program will be designed and implemented by a subject matter expert. The focus group session will be repeated at 12 months, with the 12month administration having an increased emphasis on barriers, facilitators, and value of PROs in clinical care.
223465026|NCT04264845|OTHER|Patient Interview|A trained professional interviewer will conduct a one-time, one-hour, semi-structured telephone interview of each subject to better understand patient experiences with HF, the treatment process and quality of life determinants. Two semistructured interviews will be conducted with the first 30 patients who have had LVAD therapy (of the 100 patients who agreed to be interviewed), before and 12 months after device implantation. The goal of these interviews will be to describe patient experiences with LVAD therapy, examine factors influencing quality of life, and determine whether currently available PRO tools are likely to capture the intended experiences in HF as they relate to LVAD therapy.
223577143|NCT05090514|BEHAVIORAL|Reading and Growth Mindset|Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
223577144|NCT05090514|BEHAVIORAL|Wait-list Control|Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
224157914|NCT03097133|DRUG|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
224157915|NCT03097133|DRUG|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
224157916|NCT03097133|OTHER|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
224157917|NCT06585202|DRUG|ATI-2138|ATI-2138 Oral Tablets BID
224157918|NCT05630898|DIAGNOSTIC_TEST|CMV PCR|Saliva CMV PCR
224157919|NCT05249712|DRUG|Darolutamide 300 mg|600 mg (300 mg × 2 tablets) twice daily with meals, equivalent to a total daily dose of 1200 mg.
224157920|NCT05249712|OTHER|Androgen deprivation therapy|The ADT regimen used by each patient will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescribing information.
224157921|NCT05444985|OTHER|Pain Management|Regional anesthetic techniques for peri-operative pain management after surgery.
224157922|NCT03634878|OTHER|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
224157923|NCT04309838|COMBINATION_PRODUCT|Treprostinil via implanted pump|Patients, diagnosed with PAH classified in stagnating intermediate-risk status after triple therapy including Selexipag for at least three months will receive the implantation of LENUS pro that enables permanent infusion of Treprostinil.
224157924|NCT00559416|DRUG|Cell Transfer|
224157925|NCT04018586|DEVICE|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
224157926|NCT04018586|DEVICE|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
224157927|NCT04018586|DEVICE|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
224157928|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With amlodipine|Enalapril Folic Acid Tablets 10.8mg Combined With amlodipine 5 or 10mg
224157929|NCT04952051|DRUG|Enalapril Folic Acid Tablets Combined With hydrochlorothiazide|Enalapril Folic Acid Tablets 10.8mg Combined With hydrochlorothiazide 12.5 or 25mg
224157930|NCT01637818|PROCEDURE|Lichtenstein's operation|
224157931|NCT01637818|PROCEDURE|Mesh Plug Repair|
224157932|NCT01637818|DRUG|Opiate|Postoperative pain therapy
224157933|NCT01637818|DRUG|Paracetamol|Postoperative pain therapy
224157934|NCT01637818|DRUG|non-steroidal anti-inflammatory drug|Postoperative pain therapy
224157935|NCT05735613|PROCEDURE|osteotome crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.
223465027|NCT04264845|OTHER|PROs/Clinical Data Integration|A plan has been developed that will integrate PRO scores into patient medical records. Information will be obtained from 2 instruments (KCCQ12 and NIH PROMIS) that are routinely administered as part standard of care. PRO and clinical data will be obtained from electronic medical records of patients seen in the heart failure clinic. All required information will be obtained from the subjects' electronic medical records over a period of 3.5 years after enrollment into the study.
223465028|NCT02021214|DRUG|Methylphenidate|
224157936|NCT05735613|PROCEDURE|osseodensification crestal sinus lifting|Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.
224157937|NCT05735613|PROCEDURE|piezoelectric crestal sinus lifting|initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
224157938|NCT02575677|OTHER|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
224157939|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
224157940|NCT02817750|DRUG|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
224157941|NCT03555968|DRUG|THC 0|THC dose = 0mg
223465029|NCT02021214|DRUG|Placebo|
224157942|NCT03555968|DRUG|THC 5|THC dose = 5mg
224157943|NCT03555968|DRUG|THC 10|THC dose = 10mg
224157944|NCT03555968|OTHER|BAC 0|Blood alcohol concentration = .000%
224157945|NCT03555968|OTHER|BAC .025|Blood alcohol concentration = .025%
224157946|NCT03555968|OTHER|BAC .049|Blood alcohol concentration = .049%
224157947|NCT03827980|OTHER|no intervention, only clinical examination|standardised interview and clinical examination
224157948|NCT06812637|DRUG|WJ-MSC- Exosomes|warton jelly derived mesenschymal stem cell derived exosomes dissolved in CMC
223465030|NCT01153607|DRUG|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
223465031|NCT01153607|DRUG|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
223465032|NCT01153607|DRUG|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
223465033|NCT01803659|DIETARY_SUPPLEMENT|b-carotene|
223465034|NCT01803659|DIETARY_SUPPLEMENT|retinyl palmitate|
223465035|NCT01803659|DIETARY_SUPPLEMENT|placebo|
223577145|NCT06037265|DEVICE|PAVmed PortIO™ Intraosseous Infusion System|The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with poor/difficult vascular access. The PortIO device may be inserted into the proximal or distal tibia or the proximal humerus in adults, and provides up to 60 days of intraosseous vascular access for delivery of fluids and medications.
224157949|NCT06812637|COMBINATION_PRODUCT|SOC (Standard of care)|Wound depridement for necrotic parts , local antibiotic , dressing , unloading
224157950|NCT06812637|OTHER|Vehicle (placebo)|Vehicle for the MSC-EXO
224157951|NCT00954824|BIOLOGICAL|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
223465036|NCT05914350|PROCEDURE|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis|ultrasound guided Ozone, platelet-rich plasma or steroid injection in the treatment of sacroiliitis
223465037|NCT05914350|DRUG|methylprednisolone acetate and lidocaine|40 mg methylprednisolone acetate and 1 mL lidocaine
223465038|NCT05914350|DRUG|PRP and lidocaine|3 mL PRP and 1 mL lidocaine
223465039|NCT05914350|DRUG|medical ozone|10 ml of medical ozone
223465040|NCT01817075|PROCEDURE|Chlorhexidine Gluconate Skin Cleanser|Given CHG cleansing
223465041|NCT01817075|OTHER|Laboratory Biomarker Analysis|Correlative studies
223465042|NCT01817075|PROCEDURE|Mild Soap Skin Cleanser|Given control cleansing
223465043|NCT01817075|OTHER|Questionnaire Administration|Ancillary studies
223465044|NCT03758599|PROCEDURE|Climbing|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
223465045|NCT03758599|PROCEDURE|Nordic Walking|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
223465046|NCT03758599|PROCEDURE|Social Contact|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
223465047|NCT06082726|DIETARY_SUPPLEMENT|SCFA|Participants will ingest the capsules during a standard no fiber breakfast. A primed continuous infusion containing SCFA will run during the whole test day. Blood sampling will continue for 12 hours.
223465048|NCT00564941|DRUG|deferasirox|
223465049|NCT01502488|PROCEDURE|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
223465050|NCT03206827|OTHER|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
223465051|NCT03206827|OTHER|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
223465052|NCT03206827|OTHER|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
223465053|NCT03013192|OTHER|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
223465054|NCT03921476|OTHER|Online survey|Online survey completion through Northwestern's REDCap
223577146|NCT04639219|DRUG|Trastuzumab deruxtecan|Trastuzumab deruxtecan (T-DXd) by intravenous infusion
223577147|NCT07042048|DEVICE|EVD placement - image-guidance assisted|During EVD placement, an image-guided noninvasive systems will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of image-guidance system occurs once during initial EVD placement in this trial.
223577148|NCT07042048|DEVICE|EVD placement - AR assisted|During EVD placement, an AR system will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of AR occurs once during initial EVD placement in this trial.
224068272|NCT06963359|DEVICE|HD-sEMG|High definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair rises, depending on the patient's functional state
224068273|NCT06963359|DEVICE|Quadriceps muscle ultrasound|Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed
224068274|NCT06963359|OTHER|IPAQ Physical Activity Questionnaire|Physical activity assessment questionnaire/adapted version for seniors
224068275|NCT03040999|BIOLOGICAL|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
224068276|NCT03040999|DRUG|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
224068277|NCT03040999|DRUG|Cisplatin|100 mg/m\^2 administered as an IV infusion Q3W
224068278|NCT03040999|RADIATION|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
224068279|NCT03040999|RADIATION|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
223465055|NCT04385979|OTHER|Gel|containing herbal Curcumin or NanoCurcumin
223465056|NCT01039779|BEHAVIORAL|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
223465057|NCT01475344|DRUG|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
223465058|NCT01475344|DRUG|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
223465059|NCT06553482|OTHER|FatMAx training intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them
223465060|NCT06553482|OTHER|FatMax and physical endurance exercise intervention|FatMax training program on a treadmill or stationary bicycle, whichever is more convenient for them, with muscular endurance exercise
223465061|NCT06553482|OTHER|Control|No intervention pf physical activity
224068280|NCT05779774|BEHAVIORAL|WayToServe Plus In-service Component|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe training only \[comparison control\] v. WayToServe training plus WayToServe Plus in-service component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe training and WayToServe Plus after baseline in Month 18, stratified by state and location. Remaining premises will receive WayToServe Training Only. All premises will be recruited to have servers complete WayToServe training. Servers in intervention group will be accepted into a Facebook private group after WayToServe training to receive in-service component with \~3 posts per week for 12 months. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
224071637|NCT06057090|BEHAVIORAL|Therapy Dog|Certified, volunteer therapy dogs and their handlers will be present in the room during procedures in the experimental arm to see if their presence reduces anxiety and improves behavior in pediatric dental patients.
224071638|NCT06916702|DRUG|BI 3031185|BI 3031185
223465062|NCT00433433|DRUG|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
223465063|NCT00433433|DRUG|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l
223465064|NCT00433433|RADIATION|IN-RT 30 Gy (+ boost 6 Gy residual)|
223465065|NCT00433433|PROCEDURE|FDG-PET scan|
223465066|NCT01599169|DIETARY_SUPPLEMENT|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
223465067|NCT01599169|DIETARY_SUPPLEMENT|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
223465068|NCT04367662|PROCEDURE|blood sampling|blood sampling in hospitalized patient for COVID-19 infection
223465069|NCT03981016|OTHER|Biological collection|"* blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
223465070|NCT00616746|DRUG|Nicotine|1.0 microg/kg/min IV x 10 minutes
223465071|NCT00616746|DRUG|Ethanol|IV
223465072|NCT07072208|DRUG|Induction therapy-Pro regimen|"Pro regimen induction(21days per cycle\*1 cycle)~* Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle~* Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle~* Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle"
224071639|NCT06916702|DRUG|Midazolam|Midazolam
224071640|NCT06916702|DRUG|Placebo|Placebo matching BI 3031185
224071641|NCT06922539|DRUG|Fenretinide|Intravenous administration
224071642|NCT06922539|DRUG|Fenretinide|Intravenous administration
224071643|NCT06931301|DEVICE|Hyperbaric Oxygen Therapy|Sechrist Monoplace Hyperbaric Chamber Model 3600, Chamber will be used to supply patients with 100% oxygen to breathe at 2-2.4 ATA (the equivalent of diving to 33 - 45 feet of sea water) for two hours, 5 treatments per week
224071644|NCT07123285|DEVICE|Photobiomodulation plus Compression Therapy|This intervention uses a low-level laser device with 8 emitters, including 4 red emitters at 660 nm and 4 infrared emitters at 808 nm. Each emitter delivers 6 Joules of energy at 100 mW power, with a total power output of 800 mW. Treatment is administered twice weekly over 16 weeks, totaling 32 sessions per participant. The device is used in combination with standard compression therapy for venous leg ulcer management.
224071645|NCT07123285|DEVICE|Compression Therapy plus Sham Photobiomodulation|This intervention uses a sham photobiomodulation therapy with the same laser device used in the active group but without emission of therapeutic laser light (inactive device). The device appears identical and the treatment sessions are conducted twice weekly over 16 weeks, totaling 32 sessions per participant. Participants also receive standard compression therapy for venous leg ulcer management. This sham procedure is designed to mimic the active treatment without delivering any laser energy, serving as a placebo control.
224071646|NCT07132060|RADIATION|MR-guided Irradiation|MR-guided Irradiation
224071647|NCT07132034|PROCEDURE|Acupuncture|8 sessions of acupuncture treatment (body and auricular acupuncture) will be given once a week after randomization.
224071648|NCT07132034|OTHER|Standard supportive care|Supportive care according to local standards will be given which may also include face-to-face psychosocial support or the participation of support groups
224071649|NCT07137273|BEHAVIORAL|Operant Conditioning Tasks with Reinforcement Manipulations|This behavioral intervention involves structured operant conditioning tasks. Reinforcement parameters (e.g., schedule arrangement, magnitude, and probability) are systematically manipulated to evaluate their effects on behavioral allocation. The primary objective is to assess how variations in reinforcement contingencies influence choice patterns. The procedures are designed to examine fundamental behavioral processes rather than to provide therapeutic benefit.
224071650|NCT07142902|OTHER|Data processing only, treatment is not part of the registry|Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment.
224071651|NCT07143058|PROCEDURE|Flaps reconstruction in head and neck in oral cance|Follow up and quality of life of reconstruction flaps in head and neck
224071652|NCT07143058|PROCEDURE|Flap of head and neck|All types of flaps in oral cancer reconstruction
224071653|NCT07142993|BEHAVIORAL|Social Media-Based Nursing Intervention|A structured nursing follow-up program delivered through a WeChat group. The program included regular sharing of educational content (articles, videos), personalized care advice, remote photo-based monitoring by medical staff, and peer support within the group. The intervention was managed by a dedicated team of dermatologists and nurses.
224071654|NCT07142993|BEHAVIORAL|Conventional Nursing Care|A standard care follow-up protocol involving verbal education at discharge, provision of printed health materials, and proactive weekly telephone calls to monitor the patient's condition, correct improper self-care actions, and encourage clinic visits if necessary.
224071655|NCT07142876|PROCEDURE|Liver resection Cavitron Ultrasonic Surgical Aspirator (CUSA)|In-group A Cavitron Ultrasonic Surgical Settings Aspirator (CUSA) with standard tip was used for parenchymal transection with the following Settings; 23 kHz, 70 Watt, and continuous irrigation at rate of 4-6 ml/min with normal saline and the vessel coagulation was performed by the bipolar sealer (Valleylab force FX electrosurgical generator, Medtronic, Minneapolis, USA), the power was used at 50 Watt coagulation.
224071656|NCT07142876|PROCEDURE|Liver resection with the harmonic scalpel|In group B the harmonic scalpel (Ethicon EndoSurgery, Johnson \& Johnson, New Jersey, USA) was set at a high power, and blood vessels or bile ducts up to 3-4 mm in diameter were coagulated for 5-6 seconds.
224071657|NCT07143539|OTHER|Exercise-based rehabilitation program|Participants in the intervention group will receive a patient-tailored early (i.e., within 4 weeks of PE diagnosis) EBR program, comprising 16-18 sessions of supervised aerobic exercise and resistance/strength training at local outpatient rehabilitation centers, along with 2 PE-related educational sessions at 2 and 6 weeks of rehabilitation. Participants will receive comprehensive information on the purpose of EBR and each of its components, reassurance on its safety, and education on self-monitoring. Furthermore, physiotherapists will tailor the training based on specific capabilities, focusing on areas of weakness.
223465073|NCT07072208|DRUG|Consolidation therapy-Pro-pola regimen|Pro-pola regimen consolidation(21days per cycle\*6 cycle) -Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle -Rituximab 100mg per vial 375mg/m2, intravenous drip, Day 1 of each cycle -Orelabrutinib 50mg per tablet 150mg orally per day from Days 1 to 21 of each cycle -Polatuzumab vedotin 30mg per vial 1.8 mg/kg, intravenous drip, Day 1 of each cycle
223465074|NCT07073300|DEVICE|Endoscopy|Upper Endoscopy and colonoscopy will be used
223465075|NCT06732180|DRUG|GT-02287|Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
223465076|NCT05732831|DRUG|TNG462|TNG462, a selective PRMT5 inhibitor, will be administered orally
224157952|NCT04334772|DEVICE|Muscle belly Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.
224157953|NCT04334772|DEVICE|Tendon Microelectrolysis|three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
224157954|NCT04334772|OTHER|Stretching exercises|5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
224157955|NCT02017457|BIOLOGICAL|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6"
224157956|NCT02017457|DRUG|Azacytidine|"* Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
224157957|NCT05591651|DRUG|Treatment of damaged nipple skin: Preparation with hyaluronic acid|The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
224157958|NCT05591651|DRUG|Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid|The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
223465077|NCT05732831|DRUG|Pembrolizumab|An anti PD-1 antibody, will be administered intravenously
223465078|NCT00496704|DRUG|capecitabine|
223465079|NCT00496704|DRUG|gemcitabine hydrochloride|
223465080|NCT00496704|DRUG|oxaliplatin|
223465081|NCT03066037|PROCEDURE|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
223465082|NCT06949683|BEHAVIORAL|Meal-Exercise|Breakfast intake before 22 minutes of brisk walking, followed by a lunch intake for another 75 minutes of observation period. The entire experiment lasted a total of 150 minutes.
223465083|NCT06949683|BEHAVIORAL|Exercise-Meal|22 minutes of brisk walking before breakfast intake, followed by 75 minutes of observational period. The entire experiment lasted a total of 150 minutes
223465084|NCT06956027|DIAGNOSTIC_TEST|Ultrasound assesment|Ultrasound image taken using MV-flow technique for measuring the distance skin-lesion and echogenicity measurement
223465085|NCT06956027|PROCEDURE|ROM measurement|Range Of Motion measurement of affected finger(s) where the ultrasound image will be taken from.
223465086|NCT06955390|DRUG|SHR-A2102+HRS-4642|A fixed dose was used for SHR-A2102,HRS-4642 can be dose adjusted.
223465087|NCT06954883|BEHAVIORAL|Augmented Reality Distraction|Participants in this group wore augmented reality (AR) goggles during local anesthesia administration and dental extraction. The AR system displayed interactive 3D animated videos (celestial bodies) to divert attention and reduce procedural pain and anxiety.
223465088|NCT06955507|BEHAVIORAL|reflexology|Foot reflexology will be applied by the researcher Neziha BAYAZIT, who will receive training on this subject, in the quietest and most comfortable position possible. Foot reflexology will be applied by the researcher to the women in the experimental group. The researcher will receive training on foot reflexology before the study. In the clinic where the study will be conducted, the hours of foot reflexology application will be determined considering the analgesic treatment protocol applied. Accordingly, analgesic treatment is routinely applied to the women who will receive foot reflexology at the 4th hour according to hospital procedure. Foot reflexology will be applied by the researcher at least 1 hour before the analgesic treatment (3rd hour - 15th hour after birth). The same foot reflexology will be repeated 12 hours later at the 15th hour after the first foot reflexology is performed at the 3rd hour after birth. Each woman will be given an explanation before the application. Foot r
223465089|NCT06955559|DRUG|Magnesium sulfate|inhaled magnesium sulfate (MgSO4)
223465090|NCT06955767|OTHER|Blood will be drawn from 2 additional tubes of 5 ml each|Blood will be drawn from 2 additional tubes of 5 ml each
223577149|NCT07042230|OTHER|Proprioceptive Neuromuscular Facilitation (PNF)|Proprioceptive Neuromuscular Facilitation (PNF) techniques were applied to the cervical region using rhythmic initiation, dynamic reversals, and contract-relax methods. Movements followed diagonal cranio-cervical patterns including flexion/extension with rotational components. Each session lasted 15-30 minutes, delivered three times per week for four weeks. Repetitions and sets were progressively increased based on patient tolerance. The goal was to enhance neuromuscular coordination, improve cervical range of motion, and reduce pain through active facilitation techniques.
223465091|NCT06955949|OTHER|Control Group|The control classes applied the drugs by doing home training with eccentric strengthening exercises with dumbbells (3 sets of 10 repetitions). They were asked to flex the wrist while the wrist was fully extended. Weights were given to strengthen the wrist extensor muscles with 0.5 kg in the first week, 1 kg in the second week and 1.5 kg in the third week. In addition, stretching exercises for the wrist extensor muscles (3 sets of 20 seconds) were performed and 20 seconds of rest were given between sets. After the exercises, we applied cold therapy for 15 minutes. All treatment types were treated by the same physiotherapist in accordance with the treatment protocols and treatment sessions were performed twice a week for 3 weeks. One session lasted between 35-45 minutes.
223465092|NCT06955949|OTHER|ESWT Group|Extracorporeal Shock Wave Therapy (ESWT) is palpated at the starting areas of the extensor carpi radialis brevis and longus muscles, at tender points, and placed at the bone-tendon junctions. This budget was set at 90 Hz, and the pulse rate was determined as 10 pulses:1500.
223465093|NCT06955949|OTHER|Mobilization movement group|Mobilization Technique (lateral glide) was recorded from the Mulligan method. Patients were placed in supine positions, height was recorded together and the application was done with a belt method. During this glide movement, the patient was asked to actively perform 3 sets of 10 repetitions of wrist extension. 15-20 seconds of rest was given between sets.
223743485|NCT07063693|DRUG|ABY-029|"ABY-029 will be administered via single intravenous injection to subjects with high-grade glioma approximately 1-3 hours prior to surgery.~All research procedures will occur during surgery. The research procedures involve image and measurement data collection and biopsy specimen sampling. Research data collection will occur at 3 or 4 time points during surgery using either standard-of-care tools and methods or non-significant risk experimental devices.~No follow-up visit will be required of participants. Participants will be monitored for possible adverse events for approximately 30 days by the operating surgeon involved in the clinical trial procedures and through review of participant medical records."
223465094|NCT06955949|OTHER|Combined MWM-ESWT|In addition to mobilization with movement and ESWT treatment, this group applied home training by doing eccentric exercises with dumbbells (3 sets of 10 repetitions). 15-20 seconds of rest was given between sets. In addition, stretching exercises (3 sets of 20 seconds) were performed to strengthen the wrist extensor muscles and 20 seconds of rest was given between sets. During the exercises, a position was given such that the elbow was in extension, the forearm was in pronation and the wrist was in ulnar deviation. We apply cold therapy for 15 minutes after the exercises.
223465095|NCT06955000|DEVICE|traidmail|Patients in this group were instructed to sit on a stationary bicycle ergometer. The patients will be given explained the aerobic interval exercise training program and the intensity will be assessed using a modified Borg scale
223465096|NCT06955000|DEVICE|laser puncture therapy|This group's patients were all exposed to LLLT utilising Phyaction CL Phyaction, Bilzen, Belgium, which had the following specs: frequency 500 Hz, output 5-20 MW, wavelength 905 nm. For five minutes, a laser probe was applied to acupuncture sites
223465097|NCT04999904|OTHER|Uneven Treadmill Intervention|Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.
223465098|NCT04999904|OTHER|Standard of Care Physical Therapy|Standard of Care Physical Therapy
223465099|NCT03466632|DRUG|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
223465100|NCT03466632|DRUG|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
223465101|NCT02430558|BIOLOGICAL|OD-PHOENIX|Decellularized, freeze-dried, irradiated osteochondral allograft
223465102|NCT06214884|BEHAVIORAL|Mindfulness for All|"Experimental:~The MFA will take place in a group setting with 10-15 participants per cluster. Due to participants' convenience, the delivery mode of each intervention session would be conducted online. At the end of session, they will be provided the task and supplementary materials (e-book, short audio, and video) to be apply after the session. The modules will be delivered by two trainees. Both trainees have received the certificates from the mindfulness-based strategic awareness training course. Participants in the intervention group will be joining the modules for 5 sessions weekly for 60-minute/session. Details on the modules can be referred in the Supplement material."
223465103|NCT06253702|DRUG|Indomethacin|to inhibit cyclooxygenase (COX)
223465104|NCT06253702|DRUG|Placebo|Placebo
223465105|NCT06253702|DRUG|Orilissa|to suppress hormones 200mg dose 2x per day (all participants)
223465106|NCT06253702|DRUG|Testosterone gel|50 mg each morning for add back phase (male participants)
223465107|NCT06253702|DRUG|Anastrozole|1mg/day in men to prevent conversion of testosterone to estradiol
223465108|NCT06253702|DRUG|Estradiol|Women will receive oral estradiol 2mg/daily
223465109|NCT06440525|DRUG|RSLV-132|Fc fusion protein comprised of catalytically active human ribonuclease (RNase) fused to human immunoglobulin G1 (IgG1)
223465110|NCT06440525|DRUG|Placebo|0.9% sodium chloride solution
223465111|NCT02358031|BIOLOGICAL|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 35 cycles (up to \~2 years).
223465112|NCT02358031|DRUG|Cisplatin|Cisplatin 100 mg/m\^2 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
223465113|NCT02358031|DRUG|Carboplatin|Carboplatin at a target AUC 5 IV on Day 1 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
223465114|NCT02358031|DRUG|5-FU|5-FU 1000 mg/m\^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum \[up to \~4 months\]).
223465115|NCT02358031|BIOLOGICAL|Cetuximab|Cetuximab on Day 1 at a dose of 400 mg/m\^2 IV, and then 250 mg/m\^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity
223465116|NCT05962398|GENETIC|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua in the study CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
223465117|NCT05048836|OTHER|Food Subsidy, 6 months|Food subsidy for 6 months
223465118|NCT05048836|OTHER|Food Subsidy, 12 months|Food subsidy for 12 months
223743486|NCT06774742|DIETARY_SUPPLEMENT|HAFS Supplementation|1 capsule of HAFS per day
223743487|NCT06774742|DIETARY_SUPPLEMENT|Placebo|1 capsule of placebo per day
223743488|NCT06774573|BEHAVIORAL|CBT-txt-A|8-week automated text-message delivered treatment for Generalized Anxiety Disorder
224157959|NCT05825586|DEVICE|Distilled waters based eye drops|Distilled Waters (DW)-based eyedrops
224157960|NCT05960136|PROCEDURE|Sinus lift in patients with positive COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
224157961|NCT05960136|PROCEDURE|Sinus lift with negative COVID-19 history|Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
224157962|NCT03109444|DIAGNOSTIC_TEST|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be \>50%.
224157963|NCT00744692|BIOLOGICAL|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
224157964|NCT00744692|DRUG|Reduced Intensity Conditioning|
224157965|NCT01870791|DRUG|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
224157966|NCT02253628|OTHER|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
224157967|NCT02253628|OTHER|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
224157968|NCT02253628|OTHER|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
224157969|NCT02253628|OTHER|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
224157970|NCT03170908|BEHAVIORAL|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
224157971|NCT04894227|BIOLOGICAL|Inactivated SARS-CoV-2 Vaccine (Vero cell）|600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
224157972|NCT03480646|DRUG|CPI-1205|Administered orally
224157973|NCT03480646|DRUG|Enzalutamide|Administered orally
224157974|NCT03480646|DRUG|Abiraterone/Prednisone|Administered orally
224157975|NCT05495191|DIAGNOSTIC_TEST|Signal intensity gradient|"In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)"
224157976|NCT03592394|DEVICE|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
224157977|NCT01787851|DRUG|Triheptanoin oil|
224157978|NCT01577628|DRUG|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
224157979|NCT03250130|BEHAVIORAL|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
224157980|NCT00215228|DRUG|duloxetine vs. escitalopram|
224157981|NCT05078671|DRUG|Olaparib|olaparib treatment
224157982|NCT05078671|DRUG|Cobicistat|Pharmacokinetic booster
224157983|NCT01058057|DRUG|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
224157984|NCT05226572|DIAGNOSTIC_TEST|endoscopic ultrasound-guided fine needle biopsy|repeated endoscopic ultrasound-guided fine needle-biopsy after a previous non diagnostic or incoclusive endoscopic ultrasound-guided tissue aquisition for pancreatic solid lesions.
224157985|NCT06093945|DRUG|SHR2554 tablet dosing|SHR2554 350mg taken on Day 1 and Day 10
223743489|NCT07067697|OTHER|Physical exercise|Progressive, supervised multicomponent physical exercise program, including aerobic resistance, strength, and balance training. Strength training for lower limbs (leg press and knee extension) and upper limbs (seated chest press) will be adapted to each individual's functional capacity.
223743490|NCT07067697|OTHER|Usual Care|"* Hospital physiotherapy for preventing nosocomial disability when necessary.~* Hospital diet modifications appropriate to each participant's clinical situation.~* Oral nutritional supplementation aimed at meeting daily nutritional requirements: 30 kcal/kg body weight, 1.5-2 g protein/kg body weight, 25 g daily fiber.~* Approximate free water intake: women 1.5 L/day, men 2 L/day (unless clinically restricted)."
224157986|NCT06093945|DRUG|Omeprazole tablet dosing|Omeprazole taken from Days 5 to Day 10
224157987|NCT00841672|DRUG|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
223743491|NCT01352962|DRUG|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
223743492|NCT01352962|DRUG|Carboplatin|AUC 5\*\* IVPB over 30 min x 1
224157988|NCT00841672|DRUG|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
224157989|NCT02932319|DEVICE|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
223465119|NCT05048836|BEHAVIORAL|Lifestyle Support, 6 months|lifestyle support intervention delivered by community health workers for 6 months
224157990|NCT02932319|OTHER|expectative|expectative until the next day befor starting the induction
224157991|NCT02755610|OTHER|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
224157992|NCT01180764|DRUG|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
224157993|NCT01180764|DRUG|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
224157994|NCT00356057|DEVICE|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
224157995|NCT00002968|BIOLOGICAL|edrecolomab|Given IV
224303372|NCT05638958|DEVICE|Immediate post-extractive Implant placement|Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
224303373|NCT04657796|DEVICE|High Flow Nasal Cannula|use of high flow nasal cannula as a weaning mode from invasive mechanical ventilation to deliver oxygen
224303374|NCT05721118|DIAGNOSTIC_TEST|CBCT and DXA exams performed in current practice in Nantes University Hospital|40 patients will be enrolled in order to study DXA/CBCT acquisitions of 16 osteoporotic women vs 34 osteopenic/healthy women (Estimated osteoporotic rate = 20%)
223465120|NCT05048836|BEHAVIORAL|Lifestyle Support, 12 months|lifestyle support intervention delivered by community health workers for 6 months
223465121|NCT05048836|OTHER|Food Delivery, 6 months|Twice monthly delivery of healthy food for 6 months
223465122|NCT05048836|OTHER|Food Delivery, 12 months|Twice monthly delivery of healthy food for 12 months
223465123|NCT05960240|DRUG|AB-101|AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
223465124|NCT05960240|DRUG|Placebo|A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
223465125|NCT05960240|DRUG|Nucleos(t)ide Analogue|Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
223465126|NCT06539988|BEHAVIORAL|Clinician Coaching Sessions|PCPs will receive interactive coaching sessions from a Clinician Coach 2 months into the intervention period and again at 4 months into the intervention period.
223465127|NCT06539988|OTHER|Personalized text messages to patients|Drawing upon a library of messages that have previously been developed and refined, Veterans will receive 6 months of optimized text messages. The frequency of text messages will be determined based on feedback from Veterans in earlier phases of the research.
223465128|NCT06243068|BEHAVIORAL|Educate and Engage|Nephrology practices implement a bundle in which they will encourage their patients to a) participate in a kidney disease education program providing a balanced presentation of all options including ATPs, b) use evidence-based patient decision aids that include ATPs, and c) engage in shared decision-making with staff who have been trained in communication skills and best practices.
223465129|NCT06243068|BEHAVIORAL|Educate and Engage Plus Kidney Supportive Care Program|"In addition to bundle described under Educate and Engage, nephrology practices offer a systematic program integrating primary palliative care to support patients and their families who choose any ATP. The program closely follows patients and their families on ATP with care coordination, symptom management, advance care planning, and psychosocial support to supplement usual care from their nephrologist."
223465130|NCT00978952|DEVICE|Large Diameter Advanta™ V12 Covered Stent|Stent placement
224303375|NCT00986518|BIOLOGICAL|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
223465131|NCT05664581|DEVICE|Rapid Acoustic Pulse|Transdermal Rapid Acoustic Pulse Treatments
223465132|NCT06189755|DEVICE|Positive Airway Pressure|Case participants will use Positive Airway Pressure (PAP) treatment as part of routine clinical care.
223465133|NCT04584814|DEVICE|No intervention|Basal analysis
223465134|NCT04584814|DEVICE|scare ventilator at 20|To set scare ventilator by 20 cycles per minute
223465135|NCT04584814|DEVICE|scare ventilator at 40|To set scare ventilator by 40 cycles per minute
223465136|NCT01023607|DRUG|Atorvastatin|Atorvastatin 20mg/day
223465137|NCT01023607|DRUG|Atorvastatin|Atorvastatin, 60mg/day
223465138|NCT01023607|DRUG|Rosuvastatin|Rosuvastatin,10mg/day
223465139|NCT06489561|BEHAVIORAL|Cedrus RB-844 response pad; Adtech Behnke-Fried micro-electrodes; Neurolynx electrophysiology system|Devices listed are components of a single intervention that includes: Record patient responses (Cedrus RB-844), record neuronal activity (Neurolynx) from electrodes (Adtech Behnke-Fried)
223465140|NCT01814410|DRUG|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
223465141|NCT01814410|DRUG|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
223465142|NCT01814410|DRUG|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
224157996|NCT00002968|OTHER|laboratory biomarker analysis|Correlative studies
224157997|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
223577150|NCT07042230|OTHER|Passive Vertebral Mobilization (PVM)|Passive Vertebral Mobilization (PVM) was administered using Maitland mobilization techniques applied to the cervical spine. Posteroanterior central and unilateral glides were performed with the participant in a prone position. Mobilizations started with Grades I-II during Weeks 1-2 and progressed to Grades III-IV in Weeks 3-4, depending on patient response. Each session lasted 15-20 minutes and was conducted three times weekly over four weeks. This passive manual therapy aimed to improve joint mobility, reduce muscle stiffness, and alleviate mechanical neck pain.
223465143|NCT05702437|OTHER|assessment of cognitive performance|evaluation of the cognitive and physical performance of the participants by two separate researchers at the same time
223465144|NCT03373214|BIOLOGICAL|Na-GST-1|Na-GST-1/Alhydrogel®
223465145|NCT03373214|BIOLOGICAL|CPG 10104|CPG 10104
223465146|NCT00616551|DRUG|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
223465147|NCT00616551|DRUG|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
223465148|NCT02898857|OTHER|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
223465149|NCT04378712|DEVICE|Hydrogen Oxygen Generator with Nebulizer|Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.
223465150|NCT04378712|OTHER|Standard-of-care|Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission
223465151|NCT02751112|BIOLOGICAL|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
223465152|NCT03643718|PROCEDURE|Emergency General Surgery|Emergency General Surgery and Trauma operative/non operative management
223465153|NCT00775762|DRUG|aspirin|Aspirin (75-100 mg)die for three months
223465154|NCT00775762|DRUG|clopidogrel|Clopidogrel (75mg) die for three months
223743493|NCT01352962|DRUG|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
224157998|NCT01031199|DRUG|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET
223465155|NCT00775762|DRUG|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
223465156|NCT00269945|DRUG|epoetin alfa|
223465157|NCT00334789|DRUG|Belinostat|Given IV
223465158|NCT00334789|DRUG|Isotretinoin|Given orally
223465159|NCT00334789|OTHER|Pharmacological Study|Correlative studies
223465160|NCT03275207|DRUG|saline|an equal volume of saline
223465161|NCT03275207|DRUG|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
223465162|NCT04727957|OTHER|Diagnostic and prognostic models for VA-LRTIs|Diagnostic and prognostic models for VA-LRTIs
223465163|NCT03903263|DIAGNOSTIC_TEST|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
223465164|NCT02787304|DRUG|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
223465165|NCT02787304|DRUG|Placebo|Matching placebo
223465166|NCT04818944|DRUG|Tirofiban Hydrochloride|Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV
223465167|NCT04818944|DRUG|Placebo|Saline will be dosed for 24 hours post MT via continuous IV
223465168|NCT03561454|DEVICE|IORT|Intra-Operative Radiation Therapy
223465169|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
223465170|NCT01786057|PROCEDURE|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
223465171|NCT02745652|DEVICE|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
223743494|NCT02858336|BEHAVIORAL|NEA|Neutral Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 45 kcal/kg LBM day.
223743495|NCT02858336|BEHAVIORAL|DEA|Deficient Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 20 kcal/kg LBM day.
223743496|NCT04929028|PROCEDURE|Anoscopy|Undergo anoscopy
223743497|NCT04929028|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224157999|NCT00750178|DRUG|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
224158000|NCT06276842|DRUG|Inferior Alveolar Nerve Block|Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.
224158001|NCT06276842|DRUG|Buccal Infiltration|Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.
224158002|NCT06276842|COMBINATION_PRODUCT|Inferior Alveolar Nerve Block and Buccal Infiltration|Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
224158003|NCT00127699|PROCEDURE|Alcohol swab of umbilical cord|
224158004|NCT00274040|DRUG|Tiotropium|
224158005|NCT00274040|DRUG|Ipratropium|
224158006|NCT02233907|DRUG|Ventilat® - metered dose inhaler|
224158007|NCT05940441|DRUG|Capecitabine 500Mg Oral Tablet|650 mg/m² body surface area twice daily for 1 year
224158008|NCT00415545|BEHAVIORAL|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
223465172|NCT02745652|DEVICE|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
223465173|NCT04938076|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation on motor cortex
223465174|NCT04938076|DEVICE|sham control|sham control
223465175|NCT01051921|DRUG|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
223465176|NCT01051921|DRUG|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
223465177|NCT01051921|DRUG|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
223465178|NCT01638715|DRUG|Remicade|\- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
223465179|NCT01638715|DRUG|Orencia|\- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: \<60 kg Body weight (BW): 500 mg; \>60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
223577151|NCT07041515|OTHER|Mobile app|"This study will be conducted in two stages, recruiting patients scheduled for low anterior resection and those scheduled for ostomy restoration after low anterior resection. The pilot stage study will recruit 20 subjects without randomization to evaluate the feasibility of the management program app, and the second stage study will be a parallel experimental-control study, recruiting approximately 300 research participants, 150 from each group.~Patients scheduled for ostomy repair after low anterior resection and low anterior resection are required to fill out a consent form the day before, and participants are randomly assigned to one of two groups in a 1:1 ratio: the experimental group and the control group. Both groups are randomly assigned to four surveys. The types are three quality of life assessment questionnaires (QOL (EORTC QLQ-C30, CR-29, EQ-5D-L)) and a questionnaire related to bowel symptoms (LARS). However, patients undergoing ostomy repair are excluded from the preoperati"
224068281|NCT05779774|BEHAVIORAL|WayToServe Training Only|Investigators will test WayToServe Plus in-service component's ability to increase refusal of service to intoxicated patrons in a randomized trial. A two-group randomized field trial (WayToServe Training Only \[comparison control\] v. WayToServe Plus In-service Component \[intervention\]) with 2 assessment rounds (Baseline, Posttest) will yield a 2 factorial design. Investigators will randomly assign premises to WayToServe Traiing Only after baseline in Month 18, stratified by state and location. In Months 30-32, all premises will be posttested with PiP assessments (blind to condition).
223465180|NCT01638715|DRUG|Ro-Actemra|\- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
223465181|NCT01638715|DRUG|Mabthera|"\- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
223465182|NCT02100280|DRUG|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
223465183|NCT03103191|DIAGNOSTIC_TEST|KL-6 levels|Measure of KL-6 in serum
223465184|NCT02233218|DRUG|Telmisartan|
223465185|NCT02233218|DRUG|Amlodipine|
223465186|NCT02233218|DRUG|Rosuvastatin|
223465187|NCT02981030|DRUG|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
223465188|NCT02981030|DRUG|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
223465189|NCT03533218|DEVICE|Point of care Ultrasound machine|"POCUS methods of assessing ETT location offer an alternative that is time saving and thereby of critical importance in the neonatal time-is-brain scenario. Recently the government of Pakistan began upgrading health facilities and ensuring placement of essential equipment required to provide competent medical care, which may include provision of ultrasound machines to areas where there is established benefits to their use. Presence of trained staff and provision of portable ultrasound machine with short start-up time can save newborn lives(12).POCUS method empowers health care providers to read and interpret images in real time thereby saving critical time and need for specialized human resources (radiologists)."
223743498|NCT04929028|DRUG|Capecitabine|Given PO
223465190|NCT01325350|DRUG|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223465191|NCT01325350|DRUG|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223465192|NCT01325350|DRUG|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223465193|NCT01325350|DRUG|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
223465194|NCT01325350|DRUG|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
223465195|NCT01150630|DRUG|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
223465196|NCT01150630|DRUG|cisplatin|30 mg/mq every 14 days for 6 months
223465197|NCT01150630|DRUG|epirubicin|30 mg/mq every 14 days for 6 months
223465198|NCT01150630|DRUG|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
223465199|NCT01838239|DIETARY_SUPPLEMENT|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
223465200|NCT01621386|DRUG|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
223465201|NCT01621386|DRUG|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
223743499|NCT04929028|PROCEDURE|Colonoscopy|Undergo colonoscopy
224303376|NCT02413216|BEHAVIORAL|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
223465202|NCT05874232|BEHAVIORAL|Self-Care Program through Heartfulness|A four-week Self-Care program through Heartfulness will be offered to participants in the Heartfulness group. This would include a daily practice of relaxation tools for 15 minutes a day using an app and once a weekly webinar for 30 minutes. Guided relaxation and meditation sessions will be offered to the participants during the intervention weeks. These virtual sessions were conducted by Heartfulness Champions and certified trainers from Heartfulness Institute.
223465203|NCT02189668|DRUG|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
223465204|NCT00104936|PROCEDURE|adjuvant therapy|
223465205|NCT00104936|RADIATION|radiation therapy|
223465206|NCT00104936|RADIATION|stereotactic radiosurgery|
223465207|NCT05468255|OTHER|removal of exercise|Subjects will stop doing their normal exercise routines for 3 or 5 days and then subjects will resume doing their normal exercise routines for 3 days.
223465208|NCT00913549|DRUG|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
223465209|NCT00913549|DRUG|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
223465210|NCT03308422|BEHAVIORAL|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
223465211|NCT01549145|DEVICE|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
223465212|NCT03984708|OTHER|Samples|Blood sample, skin biopsy
223465213|NCT03984708|OTHER|Indirect calorimetry|Measurement of energy expenditure by indirect calorimetry
223465214|NCT03984708|OTHER|Electrical bioimpedance|Measurement of electrical bioimpedance
223465215|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure GPx activity|Routine blood draw to measure levels of blood markers.
223465216|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure SOD activity|Routine blood draw to measure levels of blood markers.
223465217|NCT04268160|DIAGNOSTIC_TEST|Blood draw to measure Lp(a) levels|Routine blood draw to measure levels of blood markers.
223465218|NCT01053741|BIOLOGICAL|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
223465219|NCT01053741|BIOLOGICAL|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
223465220|NCT04881643|BEHAVIORAL|Trauma-focused cognitive behavioural therapy via a digital support|A blended treatment approach to PTSD, blending internet-based CBT with face-to-face sessions with a therapist
223465221|NCT04131920|DEVICE|handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform|Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
223465222|NCT03143257|DEVICE|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of Bone Conduction (BC) of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
224068282|NCT03802851|PROCEDURE|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
224068283|NCT06296329|OTHER|Rubber Hand Illusion|The traditional behavioural illusion of the Rubber Hand will be applied
224068284|NCT06776419|DIAGNOSTIC_TEST|Cardiac Magnetic Ressonance Imaging|CMR-protocol with gadolinium contrast
223465223|NCT00933725|OTHER|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
223465224|NCT00933725|OTHER|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San\_jiu Medical \& Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
223465225|NCT00243009|DRUG|cyclosporine|
223465226|NCT00243009|DRUG|fludarabine phosphate|
223465227|NCT00243009|DRUG|mycophenolate mofetil|
223465228|NCT00243009|PROCEDURE|allogeneic bone marrow transplantation|
223465229|NCT00243009|PROCEDURE|peripheral blood stem cell transplantation|
223465230|NCT00243009|RADIATION|radiation therapy|
223465231|NCT00843141|BEHAVIORAL|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
223743500|NCT04929028|PROCEDURE|Computed Tomography|Undergo CT or FDG PET/CT
223465232|NCT00843141|BEHAVIORAL|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
223465233|NCT02696824|BEHAVIORAL|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
223465234|NCT03301389|OTHER|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
223465235|NCT00619827|DRUG|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
223465236|NCT00619827|DRUG|Placebo tablet|Placebo tablet once daily during four months
223577152|NCT07041515|OTHER|standard|Subjects classified as control group will receive educational materials. One month and three months after surgery, a questionnaire related to bowel symptoms (LARS) will be administered by phone. The researcher will call the subjects and administer it according to the period. The results of the questionnaire related to bowel symptoms (LARS) administered by phone will be confirmed by the medical staff during outpatient treatment.
223577153|NCT07041632|OTHER|electro-acupuncture|electro-acupuncture for pain relief in egg collection in IVF
223577154|NCT07041632|OTHER|Conscious sedation|IVf egg collection using conscious sedation as the usual analgesia
223577155|NCT07041437|DRUG|SHR-A2102|ADC
223577156|NCT07041437|DRUG|Adebrelimab|PD-L1 inhibitor
223577157|NCT07041567|OTHER|Inhalational anesthesia|"In Group D, patients undergoing bariatric surgery will receive low-flow inhalational anesthesia (0.5-1 L/min) with sevoflurane. The aim is to evaluate whether the reduced fresh gas flow rate decreases the incidence of postoperative atelectasis, assessed via pulmonary ultrasonography.~In Group N, patients undergoing bariatric surgery will receive standard-flow inhalational anesthesia (2-4 L/min) with sevoflurane. This group serves as the comparator to evaluate the impact of flow rate on postoperative atelectasis incidence."
223465237|NCT00434031|DRUG|docetaxel|
223465238|NCT00434031|DRUG|cyclophosphamide|
223465239|NCT00434031|DRUG|trastuzumab|
223465240|NCT00434031|DRUG|liposomal doxorubicin|
223465241|NCT01063855|DRUG|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
223465242|NCT01063855|DRUG|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
223577158|NCT07040345|OTHER|Annurca apple oleolite|3 mg twice daily for 28 days
223577159|NCT07040345|OTHER|Placebo|3 mg twice daily for 28 days
223577160|NCT07042191|BEHAVIORAL|Disco (Discussion of Cost) Provider Companion Intervention|A communication intervention for providers to assess financial toxicity in Cancer patients
223577161|NCT07041983|DRUG|anti obesity medication|"Patients with obesity or overweight, with at least one weight-related comorbidity who are expected to start treatment with Semaglutide (Wegovy) or Terzepatide (Mounjaro) at enrolment will be eligible to enrol into the study.~Patients will be treated and observed according to normal clinical practice. Participation in this study does not limit the physicians' clinical decision making as to the most appropriate treatment for the patient during the course of the study"
223743501|NCT04929028|PROCEDURE|Digital Rectal Examination|Undergo digital rectal exam
223743502|NCT04929028|PROCEDURE|Echocardiography Test|Undergo ECHO
223743503|NCT04929028|OTHER|Fludeoxyglucose F-18|Receive FDG
223743504|NCT04929028|DRUG|Fluorouracil|Given IV
223743505|NCT04929028|RADIATION|Intensity-Modulated Radiation Therapy|Undergo IMRT
223743506|NCT04929028|PROCEDURE|Lymph Node Biopsy|Undergo lymph node biopsy
223743507|NCT04929028|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI or PET/MRI
223743508|NCT04929028|DRUG|Mitomycin|Given IV
223743509|NCT04929028|BIOLOGICAL|Nivolumab|Given IV
223743510|NCT04929028|PROCEDURE|Positron Emission Tomography|Undergo FDG PET/CT or PET/MRI
223743511|NCT04929028|PROCEDURE|Proctoscopy|Undergo proctoscopy
223743512|NCT04929028|OTHER|Questionnaire Administration|Ancillary studies
223743513|NCT04929028|PROCEDURE|Sigmoidoscopy|Undergo sigmoidoscopy
224068285|NCT06776419|DIAGNOSTIC_TEST|82Rubidium-positron emission tomography and computer-tomography|cardiac Rb-PET protocol
224068286|NCT02491164|OTHER|BAC TWO|BAC TWO administration
224068287|NCT02491164|DEVICE|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
224068288|NCT04766307|DRUG|Interleukin-2|Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
224068289|NCT05269407|DEVICE|Peripheral perfusion index|"The study aimed to generate a model relating pre-spinal perfusion index to the likelihood and severity of the reduction in blood pressure in the first 20 min after spinal injection.~A correlation between the delta PI and the delta SBP (the difference between the baseline maternal systolic blood pressure and the lowest blood pressure)will be investigated to establish a predictive model to define cut-off values at which perfusion index variation indicated a low risk (no or mild hypotension groups) or a high risk (moderate, severe groups) of reduction in blood pressure.. The incremental change of a measure PI, the ΔPI will be calculated as the absolute change in PI between supine and sitting positions, ΔPI=PIsupine-sitting. The relative change in PI the rPI, will be expressed as the percentage of change in PI, rPI=ΔPI/PIsitting× 100."
224068290|NCT01047774|DIETARY_SUPPLEMENT|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
223465243|NCT01063855|DRUG|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
223465244|NCT03087305|DIAGNOSTIC_TEST|Supraclavicular lymph node ultrasound|Patients will have supraclavicular lymph node assessed prior to EBUS-TBNA
223465245|NCT03844659|OTHER|"Song Weightless by Marconi Union"|"Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music."
223465246|NCT03844659|OTHER|No Song|No song will be played during subjects labor epidural placement.
223465247|NCT04348526|PROCEDURE|Corticision|Surgical intervention is going to be used in the interdental areas between the lower anterior teeth to accelerate tooth movement. Three incisions are going to be made
223465248|NCT04348526|PROCEDURE|Traditional orthodontic treatment|No surgical intervention will be used, just normal orthodontic sequence of procedures.
223465249|NCT01241474|DIETARY_SUPPLEMENT|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
223465250|NCT01241474|DIETARY_SUPPLEMENT|Maize (corn) oil|6 x 1g capsules per day for 9 months
223465251|NCT04078620|DIAGNOSTIC_TEST|Survey for drug drug interactions on medscape and lexicomp applications|Survey for drug drug interactions on Medscape and Lexicomp interaction checker applications
223465252|NCT02536872|OTHER|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
223465253|NCT01195649|DRUG|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
223465254|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
223465255|NCT01195779|BIOLOGICAL|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
223465256|NCT01195779|BIOLOGICAL|Fluarix™|Intramuscular injections
223465259|NCT06321822|DIAGNOSTIC_TEST|Whole exome sequencing (WES)|Patient selected for genetic study will undergo blood sample collection for DNA estraction, biobank storage and WES study
223465260|NCT05324319|DRUG|Ad26COVS1|Heterologous vaccination
223465261|NCT05324319|DRUG|ChAdOx1 SARS2 Vaccine|Heterologous vaccination
223465262|NCT05324319|DRUG|BNT162B2|Homologous vaccination
223465263|NCT05324319|DRUG|mRNA-1273|Homologous vaccination
223465264|NCT05985746|OTHER|Augmented reality group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a 20 minutes tutorial to introduce the HoloLens 2 and the TEACHANATOMY learning platform.~* Study session: The study session consists of three learning blocks of approximately 20 minutes each, plus a repetition block to assess the acquired knowledge. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
223743514|NCT06893510|OTHER|Virtual Reality Based Progressive Muscle Relaxation|Participants engage in progressive muscle relaxation exercises using a virtual reality headset that provides immersive visual and auditory relaxation content. Sessions are conducted under researcher supervision, followed by self-guided practice using an audio recording.
223465265|NCT05985746|OTHER|Traditional learning group|"* Study presentation: participants will be given a 10-minute general introduction on the study followed by a presentation to introduce the study session.~* Study session: The study session consists of the learning resources most used by students: specific sections from four different neuroanatomy books, access to two websites, two 3D videos, and two online learning programs. During the study session participants will be given no time constraints and free breaks.~* Assessment test: Participants will be assessed with a 30 minutes knowledge assessment test.~* Final questionnaire: At the end participants will be given a questionnaire to assess adverse health symptoms and user experience."
223465266|NCT02084524|PROCEDURE|Malnutrition screening and perioperative nutritional support|"* Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~* Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~* Implementation of an adapted nutritional support based on ESPEN Guidelines"
223465267|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
223465268|NCT01950299|DRUG|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
223465269|NCT01950299|DRUG|Placebo|Placebo 0.67 ml injections twice daily
223465270|NCT01389739|OTHER|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
223465271|NCT00005868|DRUG|cisplatin|
223465272|NCT00005868|DRUG|docetaxel|
223465273|NCT06550843|PROCEDURE|mesentery-guided division|In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
223743515|NCT06893510|OTHER|Face-to-Face Progressive Muscle Relaxation|Participants practice progressive muscle relaxation exercises in a traditional face-to-face setting, guided by a researcher. Initial supervised sessions are complemented by self-guided practice using an audio recording.
223743516|NCT07072988|DRUG|Efgartigimod|Administration of efgartigimod, a neonatal Fc receptor (FcRn) antagonist, given either intravenously (IV) or subcutaneously (SC) to treat patients with generalized Anti-AChR Myasthenia Gravis.
223743517|NCT06901349|DRUG|Bimagrumab|Administered SC
223465274|NCT06958575|PROCEDURE|Septal extension graft|Septal extension graft will be used. The triangle-shaped cartilage graft prepared from the septal cartilage is placed into one or bothsides of the caudal septum reciprocally according to its structure and curvature and sutured with horizontal mattress sutures. After graft stabilization, two insulin needles are passed through the medial crura and the graft to determine its level of placement. After the rotation and nasal projection are adjusted, the medial crura are sutured to the septal graft.
223465275|NCT06958575|PROCEDURE|Columellar strut|Columellar strut graft will be used. A strut graft 1012 mm long is placed into a web created between the two medial crura and stabilized by sutures placed between the graft and medial crura.
223465276|NCT03551795|BIOLOGICAL|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8\~1E10) in one course of treatment.
223465277|NCT03041441|DEVICE|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
223465278|NCT03041441|PROCEDURE|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
223465279|NCT03041441|PROCEDURE|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
223465280|NCT06958146|DRUG|oral azithromycin|we will be administering single-dose oral azithromycin to ladies who go into labor and have no risk factors for sepsis, as there is increased risk of postpartum sepsis in both mother and neonate after normal vaginal delivery in low-income and middle-income countries
224303377|NCT02413216|OTHER|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
223465281|NCT06958146|OTHER|no azithromycin|participants in this arm will be given only standard labor care and no oral azithromycin
223465282|NCT03577249|DRUG|Dialysis Solutions|Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
223465283|NCT00807066|DRUG|Gefitinib|Gefitinib 250 mg/day
223465284|NCT00807066|DRUG|Platinum|Platinum based chemotherapy with cycles every 21 days
223743518|NCT06901349|DRUG|Tirzepatide|Administered SC
223465285|NCT02505958|OTHER|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing \~ 6000 Kcal/24 h.
223465286|NCT02505958|OTHER|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (\~333 calories each) totaling \~ 1,000 calories/24 hours.
223465287|NCT00710931|DEVICE|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
223465288|NCT01591798|PROCEDURE|Robotic surgery|Robotic assisted rectal resection
223465289|NCT01591798|PROCEDURE|Laparoscopic surgery|Laparoscopic assisted rectal resection
223465290|NCT01608165|PROCEDURE|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
223465291|NCT01608165|PROCEDURE|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
223465292|NCT01608165|PROCEDURE|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
223465293|NCT02787499|PROCEDURE|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
223465294|NCT02737267|BEHAVIORAL|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
223743519|NCT06901349|DRUG|Bimagrumab Placebo|Administered SC
223743520|NCT06901349|DRUG|Tirzepatide Placebo|Administered SC
223743521|NCT06836752|OTHER|Yoghurt|250 g per day
223743522|NCT06836752|OTHER|Milk|250 g per day
224068291|NCT01047774|DIETARY_SUPPLEMENT|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
224068292|NCT00276172|DRUG|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
224068293|NCT04901910|BEHAVIORAL|Physical Activity (PA) Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
224068294|NCT04901910|BEHAVIORAL|Verdi plus PA Social Media Group|Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
224068295|NCT06461260|DEVICE|Nervio-X|An 8-channel TIS device developed by NEURODOME Corporation.
224068296|NCT03790254|OTHER|systematic review|
224068297|NCT04121442|BIOLOGICAL|Isunakinra|Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling
224068298|NCT04121442|BIOLOGICAL|PD-(L)1 Inhibitor|Monoclonal antibody targeting PD-1 or PD-L1
224068299|NCT03232515|COMBINATION_PRODUCT|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
224068300|NCT01583621|DIETARY_SUPPLEMENT|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
223465295|NCT02737267|BEHAVIORAL|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
223465296|NCT03194009|DRUG|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
223465297|NCT03194009|BEHAVIORAL|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
223465298|NCT03117504|OTHER|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
223465299|NCT00000795|BIOLOGICAL|HIV-1 Peptide Immunogen, Multivalent|
223465300|NCT05906147|OTHER|Regular follow-up|Follow-up of the population was conducted to track the incidence of fractures
223465301|NCT05597995|DRUG|Sodium Tetradecyl Sulfate|subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
223465302|NCT02292459|DRUG|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
223465303|NCT02292459|DRUG|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
223465304|NCT04601168|DEVICE|kneeSOFT100|During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
223465305|NCT05687097|DEVICE|Home-based sleep screening test or hospital-unattended sleep screening test|ApneaLink device will be used to assess the number of apnea and hypopnea events per hour of sleep.
223465306|NCT05687097|DEVICE|Cardiovascular beat-to-beat monitoring|CareTaker device will be used to continuously record the participant's arterial blood pressure and heart rate during sleep.
223465307|NCT05687097|DEVICE|ECG monitoring|Faror Bithium 180 device will be used to continuously record the participant's ECG during sleep.
223465308|NCT02619617|DRUG|SOM230|The study evaluated SOM230 vs Placebo
223465309|NCT02619617|DRUG|Placebo|The study evaluated SOM230 vs Placebo
223465310|NCT05492149|OTHER|Performance follow-up|Diary performance during rehabilitation will be collected and a CAT questionnaire will be completed by the patient.
223465311|NCT01854697|DRUG|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
223465312|NCT01854697|DRUG|Ribavirin|Tablet
223465313|NCT01854697|DRUG|Telaprevir|Film-coated tablet
224158009|NCT00415545|BEHAVIORAL|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
224158010|NCT03924648|OTHER|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
224158011|NCT05158530|OTHER|Aerobic training|Aerobic training ( with cycle ergometer, 5-minute warm-up 15 - 30 minute cycle +5 minute cooldown) 40%-60% intensity calculated through Karvonen formula 3 days/ week
223465314|NCT01854697|DRUG|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
223465315|NCT02335255|DRUG|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
223465316|NCT02335255|DRUG|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
223465317|NCT02335255|DRUG|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
223465318|NCT00179595|BEHAVIORAL|relaxation response- meditation|
223465319|NCT03186144|GENETIC|Blodd punction for genetic analysis|
223465320|NCT00166868|DRUG|Lactobacillus casei rhamnosus (Lcr35)|
223465321|NCT00166868|DRUG|Neomycin|
223465322|NCT03175796|BEHAVIORAL|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
223465323|NCT04839172|DIAGNOSTIC_TEST|Dual-energy X-ray Absorptiometry (DXA) scan|Longitudinal changes in body composition are examined over four consecutive seasons (2017-2018, 2018-2019, 2019-2020, 2020-2021), four times per season in the following stages: start-preseason, start-season, mid-season and end-season.
223465324|NCT02539992|DEVICE|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
223465325|NCT02539992|DEVICE|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
223465326|NCT02539992|DEVICE|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
223465327|NCT03900208|DIAGNOSTIC_TEST|Hystological analysis of ventricular tissue|Sections (4μm thick) will be stained with hematoxylin and eosin stain (H\&E) for diagnosis. After diagnosis, sections of the representative heart tissue will be stained with a PicroSirius Red/Fast Green for fibrosis evaluation. All stained samples will be examined under digital and light microscope. Beside the location of adipose/fibrous tissue in the right or left ventricles and in the septum, seven high magnification fields (40x) will be evaluated in five regions of the myocardium.
223465328|NCT04387123|PROCEDURE|Vaginoscopy|Vaginoscopic examination and possible operative endoscopic management
223465329|NCT01240096|DRUG|Mirtazapine|Mirtazapine 15 mg daily
223465330|NCT04861142|DRUG|Anti-osteoporotic medication( alendronate or denosumab)|Initiation of anti-osteoporotic medication (alendronate or denosumab)
223465331|NCT00115778|DRUG|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
223465332|NCT00115778|OTHER|Placebo|0.1% Albumin in an equal volume to the investigational product
223465333|NCT04428385|OTHER|Testing incentive|A small incentive will be paid to the provider each time they perform a malaria rapid diagnostic test.
223465334|NCT04428385|OTHER|Conditional artemisinin combination therapy subsidy|An additional discount on WHO-approved quality assured ACTs will be offered to individuals with a positive RDT.
223465335|NCT00528424|BIOLOGICAL|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
223465336|NCT02515630|DRUG|MMB|Momelotinib (MMB) tablet administered orally once daily
223465337|NCT06086990|DEVICE|Contigo Application|Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.
223465338|NCT00905242|DRUG|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
223465339|NCT00483652|DRUG|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
223465340|NCT00483652|DRUG|Placebo|placebo (sugar pill)
223465341|NCT02548936|DRUG|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
223465342|NCT03255369|OTHER|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
223465343|NCT03326440|OTHER|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
223465344|NCT05673447|BIOLOGICAL|anti-CD19 CAR NK cells|"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Doses of 6×10\^8, 1×10\^9, 1.5×10\^9 Anti-CD19 CAR NK cells will infused in each group using the 3 + 3 dose-escalation strategy."
223465345|NCT02089477|OTHER|Support group|"The participants in the intervention group receives the intervention and support consisting of:~1. Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~2. SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
223465346|NCT03387605|DRUG|Ivabradine|ivabradine or placebo given orally 2 times daily for 72 hours
223465347|NCT03387605|DRUG|Placebo|matching placebo given 2 times daily for 72 hours
223465348|NCT00663650|PROCEDURE|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
223465349|NCT00663650|PROCEDURE|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
223465350|NCT00926250|DIETARY_SUPPLEMENT|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
223465351|NCT00926250|DIETARY_SUPPLEMENT|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
223465352|NCT00120692|DRUG|Darbepoetin Alfa|
223465353|NCT00120692|DRUG|Recombinant Human Erythropoietin|
223465354|NCT05959265|BEHAVIORAL|exercise|Patients in the treatment group will undergo a 12-week intervention consisting of three 30-minute walking exercises per week during their standard cancer treatment. A personalized walking plan using fitness trackers will be provided to record each patient's daily average heart rate, step count, and additional steps and heart rate during the three 30-minute walking exercises per week to assess their activity levels. Weekly collaborations between the principal investigator and each participant will be conducted to assess step-related parameters.
223465355|NCT04282174|DEVICE|CliniMACS|allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
223465356|NCT04282174|PROCEDURE|Bone Marrow Transplant|Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
223465357|NCT04282174|DRUG|Hyperfractionated Total Body Irradiation|Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
223465358|NCT04282174|DRUG|Thiotepa|Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
224068301|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
224158012|NCT05158530|OTHER|Pulmonary Exercises|"4 weeks protocol~1. Deep breathing Exercises\* 10 Reps 3 sets~2. Postural drainage (10 minutes \* 2 sets /day)~3. Incentive spirometry\* 10 Reps 3 sets~4. Bed activities (Active ankle and hand pumping exercise \* 10 Reps 3 sets)"
223743523|NCT06746675|DRUG|Healthy Families PrEP Counselling Intervention|Healthy Families-PrEP intervention with HIV-uninfected women with plans for pregnancy in the next year and concerns about or exposure to HIV. Session 1 focuses on providing information about HIV prevention in the context of reproductive goals (using tools with locally developed images), increasing motivation for behavior change, and developing a safer conception plan (e.g., PrEP uptake, PrEP adherence, couples-based counselling and testing, delaying condomless sex until partner serostatus known and, if living with HIV, virally suppressed). Sessions 2 and 3 (conducted at 1 and 3 months) review the safer conception plan and revise as needed (e.g., changes in readiness to initiate PrEP, partner serostatus knowledge) and engaging in problem-solving barriers (including structural) to plan execution, communication skills training, and motivational strategies for successful plan execution. Participants receive quarterly adherence counseling using tools developed by this team.
223465359|NCT04282174|DRUG|Cyclophosphamide|Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
223465360|NCT04282174|DRUG|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
223465361|NCT04282174|DRUG|Melphalan|Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
223465362|NCT04282174|DRUG|Fludarabine|"Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory."
223465363|NCT04366245|BIOLOGICAL|Hyperimmune plasma|PLASMA OF CONVALESCENT COVID-19
223465364|NCT04366245|DRUG|Standard of care for SARS-CoV-2 infection|Standard of care for SARS-CoV-2 infection
223465365|NCT02501824|OTHER|anthroposophic therapeutic speech|anthroposophic therapeutic speech
223465366|NCT02071459|DRUG|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
224158013|NCT03886922|DRUG|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
224158014|NCT03886922|DRUG|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
224158015|NCT05869786|DEVICE|Virtual Reality Mediated Upper Extremity Rehabilitation (SensoRehab®)|In the virtual reality intervention, participants will be asked to control the games with hand, wrist and forearm movements in front of a computer screen in front of the SensoRehab® sensor that can detect hand movements through gloves.
224158016|NCT05869786|OTHER|conventional rehabilitation program|conventional rehabilitation program
224158017|NCT05869786|BEHAVIORAL|Exercise|Participants in the control group will be instructed in hand, finger, wrist and forearm therapeutic exercises by a physiotherapist.
224158018|NCT06197022|DEVICE|Mozec™ SEB Sirolimus Eluting Rx PTCA Balloon Dilatation Catheter|Combination of scoring-balloon angioplasty (SBA) plus sirolimus-eluting balloon angioplasty (SEBA) for diffuse (lesion length ≥20 mm), small vessel (diameter 1.5 mm -2.75 mm) coronary disease.
224158019|NCT01000818|DRUG|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
224158020|NCT01000818|DRUG|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
224158021|NCT01000818|DRUG|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
224158022|NCT00741260|DRUG|Neratinib|Neratinib orally once daily continually
224158023|NCT00741260|DRUG|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
224158024|NCT02606344|OTHER|Mico-finance based intervention|
224158025|NCT04115527|PROCEDURE|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
224158026|NCT04115527|PROCEDURE|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
224158027|NCT03026049|DEVICE|deep venous stenting|Deep venous stent
224158028|NCT02675179|DEVICE|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
224158029|NCT02675179|DEVICE|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
224158030|NCT05518799|DRUG|Midazolam|Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
224158031|NCT00503737|BEHAVIORAL|National Colorectal Cancer Roundtable Toolbox|
223465367|NCT02071459|DRUG|placebo|initial period (4 weeks) followed by 8 weeks
223465368|NCT02376504|BEHAVIORAL|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
223465369|NCT00468585|DRUG|Capecitabine|
223465370|NCT00468585|DRUG|Bevacizumab|
224158032|NCT01664819|DIETARY_SUPPLEMENT|Antioxidant|
224158033|NCT01664819|DIETARY_SUPPLEMENT|Placebo|
224158034|NCT04335708|DIETARY_SUPPLEMENT|Postibiotic formulation|5 mL daily of edible gel with intracellular content of Lactobacillus casei CRL-431
224158035|NCT04335708|DIETARY_SUPPLEMENT|Placebo formulation|5 mL daily of edible gel without intracellular content of Lactobacillus casei CRL-431
224158036|NCT01273987|PROCEDURE|rONB|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
224158037|NCT02170038|DRUG|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
223465371|NCT04802499|PROCEDURE|Turkish Reliability and Validity of TESS|Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
223465372|NCT01477762|DRUG|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
223465373|NCT01477762|DRUG|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
223465374|NCT04101292|OTHER|Characterization of tumor tissue by fluorescence|"* HSI Imaging of the resected specimen, from the serum and the mucous side~* FF-OCT imaging of the tumor and the healthy tissue biopsies~* Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~* Standard anti-VEGF Immunohistochemistry and pathology"
223465375|NCT02154139|DRUG|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
223465376|NCT03644771|DRUG|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
223465377|NCT04872088|BEHAVIORAL|Strengthened SBCC|Social and Behavioral Change Communication related to prenatal, postnatal, IYCF practices as well as on the care of young children at several specific ages, hygiene, and health will be delivered during monthly home visits by pairs of NASG members.
223465378|NCT04872088|DIETARY_SUPPLEMENT|Preventive nutritional supplement|"Monthly delivery by NAGS pairs of a nutritional supplement: SQ-LNS, at a dose of 28 bags of 20g per month per beneficiary child. The nutritional supplement is limited to :~\- \[6-17\]months old children diagnosed as non-wasted (MUAC\>=125mm)"
223465379|NCT04872088|BEHAVIORAL|Family MUAC|"MUAC screening of children 6 to 59 months of age by family members will be introduced. This will involve distributing Shakir MUAC tapes to all intervention households and training mothers/guardians, or any other family member expressing an interest, in the screening of wasting with the MUAC criterion.~The training will be carried out by the members of the NASGs and during each home visit, they will be able to ensure that the MUAC measurement technique is well mastered by the mother (or another member) and correct the technique if necessary. They will also explain the procedure to be followed if the child is diagnosed as wasted by a family."
223465380|NCT04872088|BEHAVIORAL|Active screening by NASGs|"Monthly screening by the NASG members of the children they follow, using the MUAC.~Referral to the health center of \[6-17\] months old children screened as malnourished (result of MUAC orange or red), and follow-up on referral to confirm child was enrolled."
223465381|NCT04872088|BEHAVIORAL|Intensified followup of children with wasting referred to and enrolled in CMAM treatment|NASG members will conduct biweekly follow-up visits in the households of children with wasting referred to and enrolled in CMAM treatment programs to ensure adherence to the outpatient treatment schedule.
223465382|NCT04872088|BEHAVIORAL|Relapse prevention|NASG members will conduct biweekly home visits to monitor the nutritional status of children aged 9 to 17 months who were discharged from CMAM treatment after recovery. NASGs members will provide additional counseling to prevent relapse and screen these children for wasting to detect possible relapse.
223465383|NCT04872088|BEHAVIORAL|Cooking demonstrations|NASGs members will also be supported by the IRAM project in the organization of cooking demonstrations with nutrient-rich foods in the community, during which passive screening of children will be carried out.
223465384|NCT02151357|DRUG|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
223465385|NCT02087774|BEHAVIORAL|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
223465386|NCT04581434|BEHAVIORAL|Prolonged Exposure Therapy|Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.
223465387|NCT04581434|BEHAVIORAL|Cognitive Processing Therapy|Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions
223465388|NCT04581434|BEHAVIORAL|Present Centered Therapy|"Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation"
223465389|NCT00255619|DEVICE|Baxter's UltraBag® and FMC Andy·Disc®|
223465390|NCT05444790|DIAGNOSTIC_TEST|Rapid Diagnostic Test|The performance of two index tests and two comparator tests will be compared to reference tests and gold standard microscopy.
223465391|NCT04595006|OTHER|Cold Stimulation (CS)|Subject wear cooling vest to stay cool
223743524|NCT06444048|BIOLOGICAL|EV68-228-N|EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.
223743525|NCT06444048|OTHER|Placebo for EV68-228-N|The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.
223743526|NCT06827613|DRUG|STAR0602|solution, intravenous infusion
223743527|NCT06827613|DRUG|Sacituzumab Govitecan (SG)|intravenous infusion, 10mg/kg
224158038|NCT02170038|DRUG|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
224158039|NCT02427100|BEHAVIORAL|Diet/Physical Activity|Diet/Physical Activity Intervention
224158040|NCT02120352|DRUG|CAB Oral Tablets|White to almost white oval shaped film coated 30 mg tablets for oral administration.
223465392|NCT04595006|OTHER|Browning Nutraceutical (BN)|Subject will consume 2000mg of curcumin a naturally-occurring polyphenol antioxidant that is found in turmeric ginger rhizome root
223465393|NCT04595006|OTHER|Cold Stimulation and Browning Nutraceutical (CSBN)|Subject wear a cooling vest and consume 2000mg of curcumin
223465394|NCT03677635|BEHAVIORAL|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
223465395|NCT03478709|OTHER|volume expansion|Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
223465396|NCT03478709|OTHER|norepinephrine|Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP \<60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
223465397|NCT03143361|PROCEDURE|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
223465398|NCT04036604|OTHER|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
223465399|NCT00496340|DRUG|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m\^2 on day -28. Patients may receive additional doses on days -21 \& -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m\^2 by intravenous infusion over 1-2 hours on days -4, -3."
223465400|NCT00496340|DRUG|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m\^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
223465401|NCT00496340|DRUG|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m\^2 according to prescribing and institutional guidelines."
223465402|NCT00496340|PROCEDURE|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
223465403|NCT00597818|DRUG|Cobiprostone|18 mcg cobiprostone capsules for oral administration
223465404|NCT00597818|DRUG|Placebo|Matching placebo capsules for oral administration
223465405|NCT00597818|DRUG|Non-steroidal anti-inflammatory drug|Any marketed non-steroidal anti-inflammatory drug used by the participants as standard care.
223465406|NCT03772808|DIETARY_SUPPLEMENT|Lycocomfort|Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
223465407|NCT02157519|OTHER|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
223465408|NCT01656395|DRUG|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
223465409|NCT01656395|DRUG|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
223465410|NCT01656395|DRUG|Placebo|Parts I-II: Participants will receive Placebo tablets QD
223465411|NCT03075267|DRUG|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
223465412|NCT03075267|DRUG|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
223743528|NCT07079111|DEVICE|Formlabs 3D printed occlusal splint|In house 3D printed occlusal splint with Formlabs printer
223465413|NCT03075267|DRUG|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
223465414|NCT06265090|OTHER|therapeutic exercises|Protocol of hemibridge with ball and balloon exercise Participants were given exercise called as hemibridge with ball and balloon exercise for 3 sessions over 3 days/week.
223743529|NCT07079111|DEVICE|Industry made occlusal splint|Industry made occlusal splint
223743530|NCT06318637|OTHER|Baby Wash/Shampoo|Marketed baby wash/shampoo to be used as needed.
223743531|NCT06318637|OTHER|Daily Activities|Participants to follow their typical daily activities with their baby.
223743532|NCT06318637|OTHER|Body Lotion|Marketed body lotion to be used as needed.
224068302|NCT03988556|DEVICE|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
224158041|NCT02120352|DRUG|CAB LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
224158042|NCT02120352|DRUG|ABC/3TC Oral tablets|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
223465415|NCT06265090|OTHER|exercises|"The second group received hemibridge with ball and balloon exercise in combination to core stability exercises.~Protocol of hemibridge with ball and balloon exercise The hemibridge with ball as well as balloon exercise was provided to the participants over the course of three sessions per week.~Instructions~1. supine-lying position, feet up against a wall, and bend your knees as well as hips to a 90° angle.~2. Insert a ball measuring between four and six inches in diameter in the space between your knees.~3. Put your left hand upon a balloon and your right arm above your head.~4. Tilt your pelvis to make sure your tailbone is just slightly elevated off the ground while you inhale with your nose and exhale using your mouth. Keep your low back as flat as possible on the mat. Dig your heels into the wall instead of pushing your feet flat.~5. drop your left knee till it is below the level of your right, without moving your feet. the activation of your left inner thigh muscle."
223577162|NCT05838053|PROCEDURE|Lobectomy with systemic lymph node dissection|Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
223577163|NCT05838053|PROCEDURE|Segmentectomy with systemic lymph node dissection|Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
223577164|NCT04528615|BEHAVIORAL|CCK In-Person Sessions|This group attended eight weeks of nutrition education-focused experiential learning.
223577165|NCT04528615|BEHAVIORAL|CCK Printed Materials|This group did not attend any in-person sessions and was only provided with select CCK written materials.
223577166|NCT05254561|BIOLOGICAL|Intralesional antigen immunotherapy|Randomized double-blinded comparative effectiveness and safety clinical trial
223577167|NCT03094858|DEVICE|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
224068303|NCT02579980|PROCEDURE|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
224068304|NCT02579980|PROCEDURE|Surgery|Standard of care procedure for sarcoma patients
223465416|NCT02314858|BEHAVIORAL|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
223465417|NCT02314858|BEHAVIORAL|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
223465418|NCT02314858|BEHAVIORAL|Treatment as Usual (TAU)|The TAU group will not watch a video.
223465419|NCT00850369|OTHER|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
223465420|NCT02490826|OTHER|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
223465421|NCT02490826|OTHER|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation."
223465422|NCT00821275|PROCEDURE|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
223577168|NCT03094858|DEVICE|Wristband|Wristband will monitor activity of all participants
223577169|NCT03094858|DEVICE|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
223577170|NCT02183337|DRUG|BI 1356|
223577171|NCT02183337|DRUG|BI 1356 + Pioglitazone|
223577172|NCT02183337|DRUG|Pioglitazone|
223577173|NCT01998893|DRUG|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
223577174|NCT03784846|BEHAVIORAL|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
224068305|NCT03143231|OTHER|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
224068306|NCT03143231|OTHER|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60\[0\]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
223465423|NCT06241911|DEVICE|transcutaneous auricular vagus nerve stimulation|Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
223465424|NCT03235037|DRUG|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
223465425|NCT00844402|DRUG|Atorvastatin|oral, 10 mg, daily, 48 weeks
223465426|NCT00676403|DRUG|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
223465427|NCT00676403|DRUG|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
223465428|NCT00676403|DRUG|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
223465429|NCT00676403|DRUG|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
223465430|NCT00676403|DRUG|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
223465431|NCT00676403|DRUG|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
223465432|NCT01831869|DRUG|L-thyroxine|
223465433|NCT03747848|BEHAVIORAL|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
223465434|NCT03506048|DRUG|Lenvatinib|Given orally once daily continuously
223465435|NCT02911649|OTHER|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
223465436|NCT02911649|OTHER|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
223465437|NCT02911649|OTHER|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
223465438|NCT02911649|OTHER|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
223465439|NCT06100536|BEHAVIORAL|Music-with-movement|The intervention group participants will receive 12 weekly music-with-movement interventions facilitated by trained staff in a community centre or a residential care home. The duration lasts 30 minutes to one hour. It can be carried out individually or with up to six persons in a group. The intervention will be supported by the standalone music-with-movement system.
223465440|NCT03648788|OTHER|NA (Observation study)|NA (Observation study)
223465441|NCT04319393|BEHAVIORAL|Cognitive Behavioral Therapy|"The CBT intervention was carried out through six two-hour sessions over a month. The intervention group was divided into three subgroups of 18 to 19 nurses each. It was required for each subgroup to attend two CBT sessions to complete the intervention.~The CB therapist followed the same structure in the delivery of each CBT session. The CBT session was delivered in five modules: generating objectives and outcomes, enhancing self-esteem and interpersonal relationships, changing beliefs regarding symbolic mortality, and changing attitudes regarding death anxiety. The first session began with highlighting the objectives of the CBT. Then, a detailed presentation of the intervention modules was provided to the nurses with integration of CBT exercises, including cognitive restructuring, graded exposure, mindfulness meditation, interpersonal skills training, and activity scheduling"
223465442|NCT04987112|DRUG|CAN1012|CAN1012 IT injection (once every 4 weeks)
223465443|NCT06160089|OTHER|Isoinertial training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (inertial). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
223465444|NCT06160089|OTHER|Gravitational training|For the front lunge and the front lunge with hand grip pull, the participant will be placed frontally on the training device (gravitational). Whereas for the side lunge the participant will be placed sideways on the device (homolateral on the scrolling limb). For front and side lunge, a weight shift belt will be used, which will be placed on the waist. For the frontal lunge with hand grip pull, the grip is performed with the upper limb homolateral to the displaced lower limb. The volume and difficulty of execution of the exercises will increase over time. Investigators will instruct the participants to perform the exercises at a given intensity according to the Borg Rating of Perceived Exertion (RPE) scale. The intensity will increase throughout the training program.
223465445|NCT02052986|OTHER|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
223465446|NCT03625726|BIOLOGICAL|Thrombin generation assay (in vitro)|One blood sample.
223577175|NCT03784846|BEHAVIORAL|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
223577176|NCT03856008|OTHER|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
223577177|NCT03856008|OTHER|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
223577178|NCT01363180|BEHAVIORAL|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
223465447|NCT04623866|DRUG|Huaiqinhuang|Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
223465448|NCT04623866|DRUG|valsartan|Valsartan granules 80mg/1.73m2 based qd 24 weeks
223465449|NCT01039467|DEVICE|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
223577179|NCT01363180|OTHER|No stress condition|
223577180|NCT05184101|DRUG|Unfractionated Heparin|Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
223577181|NCT00867087|DRUG|inotuzumab ozogamicin (CMC-544)|1.8 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
223577182|NCT00867087|DRUG|rituximab|375 mg/m\^2 two days before cycle 1 by intravenous infusion; 375 mg/m\^2 every 21 days by intravenous infusion, 3 to 6 doses
223577183|NCT01082510|DRUG|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
223577184|NCT01082510|DRUG|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
223577185|NCT03597178|DEVICE|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
223465450|NCT04823780|DIETARY_SUPPLEMENT|nutrient solution|For the patients with esophageal and gastric varices after endoscopic treatment，start taking the nutrient solution at the fourth hour.
223465451|NCT04844216|DEVICE|STYLAGE® L Lidocaine|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
223465452|NCT04844216|DEVICE|Active control|An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
223577186|NCT05462977|BEHAVIORAL|Group exercise program|Participants will be asked to join a music-based group exercise program for 24 weeks (up to 6 days/week, 30 - 45 min/day), which is designed for older adults with functional limitations to safely exercise on a chair or in a supported standing posture for the improvement of aerobic capacity, upper and lower body strength, and balance control at a gradually increasing pace in synchrony with music.
223577187|NCT04253899|PROCEDURE|Appendectomy|Interval Appendectomy
223577188|NCT04253899|OTHER|Observation|observation and follow up
223577189|NCT03883113|BIOLOGICAL|MVA-NP+M1|Trial Vaccine
223577190|NCT03883113|BIOLOGICAL|Saline|Sodium Chloride Placebo
223577191|NCT03883113|BIOLOGICAL|H3N2 (A/Belgium/2417/2015)|Challenge Agent
223577192|NCT00315770|PROCEDURE|weight loss diets for young adults|
223465453|NCT01210794|PROCEDURE||The influence of different food components on zinc absorption in young adults consuming zinc fortified porridges prepared from maize, beans and sorghum
223465454|NCT01746862|DRUG|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone \[r-hGH\]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
223465455|NCT01746862|DRUG|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
223465456|NCT04621721|BEHAVIORAL|Gait/balance & resistive exercise|Walking forward and back, walking with head motion, static standing, Standing Partial Tandem, Tandem Standing heel to toe, Standing with head turns Single leg stance and March in place. Resistance exercises include: calf raises, lunges, supine leg curls and extensions.
223577193|NCT00004480|DRUG|botulinum toxin type A|
223577194|NCT04534101|BEHAVIORAL|Virtual Reality Mindfulness|This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
223577195|NCT00668018|DRUG|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
223577196|NCT04524559|OTHER|conventional physical therapy training|"The program focused on regaining typical movement, prohibiting abnormal muscle tone, promoting postural reactions and enhancing postural mechanisms. The program was applied via certified physical therapists five days/week for 4 successive months. The intended goals of the treatment program were achieved through:~* Neurodevelopmental based training (NDT)~* Functional stretching exercises to preserve muscle and soft tissues elasticity~* Sequenced trunk co-activation (STA) exercises~* Righting and protective reactions It is worth mentioned that the exercises applied in each session was influenced by the age and the specific functional abilities within the selected activity."
223577197|NCT04524559|OTHER|oral motor training.|"Children in the experimental group received 30 minutes of oral motor training five days week. The training included oral stimulation (facilitation) conducted before the child's actual meal time.~The designed protocol comprised modified perioral and intraoral maneuvers based on Fucile's protocol. The utmost aims of the protocol were to decrease hypersensitivity of oral structures, increase jaws movement, and reinforce muscle strength, improve tongue movement and enhance oral motor organization"
223577198|NCT02102126|PROCEDURE|Renal denervation|
223577199|NCT01742572|BEHAVIORAL|Diet|Change in dietary intake
223577200|NCT00001065|DRUG|Amphotericin B|
224158043|NCT02120352|DRUG|RPV Oral Tablets|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
224158044|NCT02120352|OTHER|HAART|Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.
223465457|NCT02136537|DEVICE|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
223465458|NCT02136537|OTHER|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
223577201|NCT04695002|BEHAVIORAL|MIRA|Based on the initial assessment, the citizen and professional agree what outcomes the citizen should report in MIRA. This could be pain, mood, sleep quality, energy level, dependent on the priorities of the citizen. Similarly, different activities are reported, e.g. exercise, social activities, prolonged sitting or work-related tasks. The citizen and the professional agree how often the citizen reports the outcomes and tasks, and the citizen is notified by the MIRA-app when it's time for reporting. The data will be visualized in a graph for the professional in the back-end of the system, making it possible for the citizen and the professional to view the same, real-time reported data. This provides the base for discussing and adjusting the course of rehabilitation as symptoms change over time. At the same time, this increases the citizen's knowledge of how symptoms, mood, sleep and activities all interact, thereby giving them the tools better cope with their health condition.
223577202|NCT04695002|BEHAVIORAL|Control|Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
223577203|NCT05700292|OTHER|High-intensity Interval Training|Training is based on 5 circuits, with intervals of 1 minute (high intensity) by 2 minutes (low intensity), with a total training time of 15 minutes (plus 5 more minutes of warm-up and 5 of cool-down exercises). The high intervals will be performed with the following exercises: squat, reverse lunge \& knee-up, reverse jump and walkout pushup, while the low intervals were performed jogging. The heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate of 85% to 95%. To monitor heart rate during training, a polar brand chest sensor, model H9, will be used.
223577204|NCT05700292|OTHER|Moderate-intensity continuous training|Continuous aerobic training (jogging). Also, the heart rates of the study subjects will be calculated using the Astrand test and the progression criteria is going to be based on an increase in maximum heart rate from 60% to 75% and an increase in training time from 25 to 45 minutes (considering 5 minutes of warm-up and 5 of cool-down exercises). To monitor heart rate during training, a polar brand chest sensor, model H9, will be used as well.
223577205|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 2-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 12-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
223743533|NCT03605927|DRUG|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended dose level in the phase 1 expansion cohort.
223743534|NCT03605927|DRUG|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
224158045|NCT02120352|DRUG|RPV|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
223465459|NCT03087864|DRUG|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
223465460|NCT03087864|DRUG|Carboplatin|Chemotherapy
223465461|NCT03087864|DRUG|Paclitaxel|Chemotherapy
223465462|NCT03087864|RADIATION|Radiotherapy 23 x 1.8 Gy|Radiotherapy
223465463|NCT06076785|DEVICE|OdySight|At home measurements of visual acuity through a mobile app.
223465464|NCT04742673|DRUG|Guanfacine|Patients randomized to the IV Guanfacine arm will receive intravenous guanfacine when they exhibit ICU delirium.
223465465|NCT04742673|DRUG|Placebo|Patients randomized to the placebo arm will receive intravenous normal saline when they exhibit ICU delirium.
223465466|NCT02327234|DRUG|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
223465467|NCT02327234|DRUG|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
223465468|NCT03668106|PROCEDURE|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
223465469|NCT05799846|BEHAVIORAL|Standard Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention
223465470|NCT05799846|BEHAVIORAL|PREVENT Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on preventing future negative consequences of obesity
224158046|NCT06124885|DIAGNOSTIC_TEST|AKI risk screening using RenaFAST POCT test kits|"Based on the type and duration of drug therapy, a maximum of 5 time-point urine samples will be collected and real-time biomarker measurement will be done using the RenaFAST POCT kits. Additionally, Trefoil factor 3 (TFF3) biomarker levels will also be quantified using developed POCT kits.~Patients with all 3 biomarker (Clusterin, MCP1 and ß2MG) levels higher than the study cut-off will be identified as high-risk for AKI. The nephrology consultants within the research team will perform a medical chart and physical review (where required) of these patients, detailing potential actions to be taken in research data collection forms. No actual intervention (other than a patient review) will be performed."
224158047|NCT02322099|DRUG|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
224158048|NCT02322099|DRUG|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
224158049|NCT02322099|DIETARY_SUPPLEMENT|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
224158050|NCT02322099|DRUG|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
223465471|NCT05799846|BEHAVIORAL|PROMOTE Behavioral Weight Loss Intervention|12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
223465472|NCT03286764|OTHER|Peppermint Oil|
223465473|NCT03286764|OTHER|Distilled water|Distilled water spray as a placebo during Colonoscopy
223465474|NCT04335435|DIETARY_SUPPLEMENT|Oat Bran Consumption|Oat bran (120 g), single dose.
223465475|NCT02233530|BEHAVIORAL|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
223465476|NCT03744442|PROCEDURE|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
223465477|NCT03744442|PROCEDURE|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
223465478|NCT03744442|PROCEDURE|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
223465479|NCT00006077|DRUG|NS2330|
223465480|NCT00006077|DRUG|Levodopa and Domperidone|
223465481|NCT05714462|OTHER|meals consisting of primarily animal protein sources|an omnivorous diet
223465482|NCT05714462|OTHER|meals consisting of plant protein sources|an herbivorous diet
223465483|NCT00905996|PROCEDURE|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
223465484|NCT00905996|DRUG|Beta-blocker (propranolol)|
224158051|NCT06145087|DIETARY_SUPPLEMENT|"NOVOS Core supplement"|The supplement mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee once per day.
224158052|NCT06145087|DIETARY_SUPPLEMENT|Placebo|The placebo mix (15 g) is supplied as a powder to be mixed in water or other beverages like tea or coffee.
224158053|NCT05993000|OTHER|432 Hertz frequency music|432 Hertz frequency music was played to patients through headphones during hotpack and TENS applications.
223465485|NCT01558934|DRUG|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
223465486|NCT01207947|DRUG|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
223465487|NCT05862935|OTHER|Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2|20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
223465488|NCT05862935|OTHER|Supervised Physical Activity: Phase 1|40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
223465489|NCT06058390|DRUG|Bepirovirsen|Bepirovirsen will be administered.
223743535|NCT03605927|DRUG|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
223743536|NCT06680830|DRUG|NEU-411|NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
223577206|NCT06000631|BEHAVIORAL|Ride-On Car Training in a standing posture with a 1-hour session|A licensed, independent therapist and caregivers will provide the training program in the public space in the university for a total of 24-week intervention based on ecological and dynamic systems theories. Training will concentrate on building the concept of casual effect on the control system and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person, play hide-and-seek) in certain public spaces, including hallways, convenient stores, garden, museum and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying various motor skills for mobility and socialization in natural play session. Every week's treatment program will preplanned and adjusted by the therapist and the caregivers through discussion and clinical observation of the participant's performance in the previous session. Participants will continue their regular therapy during the whole study.
223465490|NCT02065180|DIETARY_SUPPLEMENT|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
223465491|NCT02065180|DIETARY_SUPPLEMENT|placebo|
223577207|NCT06000631|BEHAVIORAL|Conventional Therapy with a 1-hour session|The other independent OT will be responsible for providing conventional therapy in the same location as the ROC-Stand training for a total of 24-week intervention based on the developmental and motor learning theories. The goals are to improve certain motor skills or psychosocial skills based on each participant's current developmental stage. The general purpose of the training is to facilitate the developmental scales and improve mobility, socialization, and upper limb use in functional tasks.
223577208|NCT02386891|OTHER|Thermal Environment|
223577209|NCT01413620|DRUG|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
223577210|NCT04216940|DEVICE|mechanical preparation of root canal system|Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
223577211|NCT02211118|DRUG|Intranasal dexemdetomidine (IN-DEX)|
223577212|NCT02157441|PROCEDURE|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
223465492|NCT04818073|DEVICE|New FINGER|New FINGER exoskeleton is a robotic device that can provide assistance and resistance to thumb and finger movement
223465493|NCT03672864|BEHAVIORAL|Intensive exercise|Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
223465494|NCT02788721|DRUG|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
223465495|NCT02788721|DRUG|Placebo|Placebo, oral suspension, daily
223465496|NCT04569175|OTHER|3D Flair sequence|Optimized 3D FLAIR sequence before and 4 hours after the usual care MRI (with contrast product). All patients will have the same intervention as each patient is its own control
223743537|NCT06680830|OTHER|Placebo|Orally-administered matched placebo
223743538|NCT07079397|DEVICE|Restylane Injectables|Participants will receive pan-facial treatment in at least one facial area using a Restylane NASHA product and at least one different facial area using Restylane OBT product. Participants will undergo three (3) scheduled MRI scans thoughout the duration of the study post HA injections.
223743539|NCT06859073|DRUG|NNC4004-0002|NNC4004-0002 will be given as a single ascending dose via subcutaneous route.
224158054|NCT05993000|OTHER|TENS|The TENS treatment was conducted using a double-channel TENS device equipped with four electrodes. The electrodes were placed around the painful area to ensure targeted stimulation. Each session lasted for 30 minutes, during which the TENS device operated at a high frequency range of 60-120 Hz. To achieve the desired analgesic effect, a short transition time of 20-120 microseconds was employed.
224158055|NCT05993000|OTHER|Mobilization|Electrophysiological agents were administered to the affected shoulder joint area before initiating mobilization. The Cyriax mobilization techniques targeted the scapula, clavicular, and GH joints, considering their biomechanical interaction and the specific dysfunction of each patient.
223465497|NCT02509377|PROCEDURE|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
223465498|NCT04577508|BEHAVIORAL|Functional Remediation|Functional Remediation is a manualized, group-based psychosocial intervention built on a neurocognitive-behavioural approach, involving modeling techniques, role-playing tasks, self-instruction, positive reinforcement and metacognitive cues (Vieta E et al, Cambridge University Press, 2014). It consists of 21 90-min weekly sessions, in which a trained therapist and co-therapist work with 10-12 patients: the first 3 sessions are dedicated to psychoeducation on neurocognitive deficits; then 13 sessions of neurocognitive training sequentially target attention, memory and executive functions domains, comprising exercises carried out individually, in pairs or in small groups; the last 5 sessions focus on skills training (communication, interpersonal relationships, autonomy, stress management). Content of the sessions involves ecological tasks adapted to real-world situations, and to-be-performed in two contexts (clinical and daily). Homework is assigned, collected and discussed each time.
223465499|NCT04577508|OTHER|Treatment as usual|Standard care for bipolar disorders according to good clinical practice, including drug therapy and individual case management.
223465500|NCT06556173|DRUG|VTX3232|Dose A
223465501|NCT03836027|OTHER|No intervention|No intervention
223465502|NCT04334759|DRUG|Durvalumab|Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks
223465503|NCT04334759|DRUG|Standard Chemotherapy|Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation
223465504|NCT04334759|DRUG|Ipilimumab and Nivolumab|Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years
223465505|NCT03413514|DRUG|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)
223465506|NCT03413514|PROCEDURE|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
223465507|NCT03413514|PROCEDURE|Surgery|Radical surgery with D2 lymph node dissection
223465508|NCT03413514|DRUG|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)
223465509|NCT03413514|OTHER|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
223465510|NCT05714501|DEVICE|Millipede System|Mechanical thrombectomy
223465511|NCT05293860|OTHER|Connective tissue manipulation|Connective tissue manipulation will be applied to participants' back for 5-20 minutes, 3 times a week for 4 weeks in this group.
223465512|NCT05293860|OTHER|Superficial massage with the head of the therapeutic ultrasound device|Superficial massage with the head of the therapeutic ultrasound device will be applied to participants' back for 15 minutes, 3 times a week for 4 weeks in this group.
223465513|NCT05257551|OTHER|Observation|No intervention
223465514|NCT06958289|DEVICE|Cryoneurolysis|Each participant will receive cryoneurolysis which involves the application of extreme cold directly to, or near targeted nerves under ultrasound guidance. This cold causes axonotmesis to occur, thereby completely preventing the treated nerve from propagating any signal. Cryoneurolysis produces an effect called Wallerian degeneration, where the treated nerve's axon is destroyed but the epineurium and perineurium are left intact. Therefore, the axon can regenerate, following the same path as prior to treatment.
223465515|NCT06958471|BEHAVIORAL|Individualized Developmental Care Education Group|"An educational program will be implemented for the mothers in the intervention group throughout the hospitalization period of their premature infants, in line with the objectives of the study.~P1:Pretests for the mothers will be completed within the first three days of the infant's admission to the neonatal intensive care unit (NICU). Mothers will be given a brochure titled Your Premature Baby, prepared by the researcher, which includes information about the NICU and its staff, visiting hours/conditions, and breast milk expression times.~P2:Education will be provided on the characteristics, feeding, and care of premature infants.~P3:Mothers will receive training on environmental regulations (temperature, light, sound), kangaroo care,non-nutritive sucking, and parent-infant interaction. Each training session will be delivered each lasting no longer than 30-45 minutes.~P4:A final training session will be provided on home care for the premature infant."
223465516|NCT04399369|DEVICE|SDF|38% silver diamine fluoride solution
223465517|NCT04399369|DEVICE|NaF|5% sodium fluoride varnish
223465518|NCT03456817|DRUG|Treatment Arm - high dose ATG|Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 \& -2, ATG will be infused after fludarabine \& busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 \& over at least 4 hrs on days -3, -2, -1 \& 0. Dose is based on actual body wt, \& rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in \>5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 \& 10 mg/m2 on days +3, +6 \& +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
223465519|NCT03456817|DRUG|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
223465520|NCT03361306|DRUG|Elotuzumab|Experimental
223743540|NCT06859073|DRUG|Placebo|Placebo matched to NNC4004-0002 will be given via subcutaneous route.
223743541|NCT06791057|BEHAVIORAL|Dyspnea Intervention|Brief behavioral intervention for dyspnea management that includes three nurse-led sessions focused on psychoeducation, behavioral techniques for managing acute breathlessness, and relaxation training for reducing physiological stress as well as a digital health app to reinforce practice of breathing skills.
224158056|NCT05993000|OTHER|Exercises|The combined utilization of exercises targeting the glenohumeral (GH) joint, scapulothoracic (ST) region, and stretching has demonstrated significant effectiveness in ameliorating range of motion and alleviating pain during the treatment of Frozen Shoulder (FS). These exercises were closely supervised and administered by the physiotherapist in each session. Furthermore, a home exercise program was provided to the patients, consisting of exercises for posture, thera band, and finger ladder. They were instructed to perform 10-15 repetitions of these exercises twice a day independently.
224158057|NCT05993000|OTHER|Hotpack|Each group of patients received a 20-minute hot pack application to the scapula and shoulder circumference.
224158058|NCT05684588|DIAGNOSTIC_TEST|Magnetic Resonance|After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization
224158059|NCT01241656|BEHAVIORAL|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
224303378|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
223465527|NCT06962007|DRUG|Sugammadex 1 mg/kg Group|Participants receive 1 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
223465528|NCT06962007|DRUG|Sugammadex 2 mg/kg Group|Participants receive 2 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
223465529|NCT06962007|DRUG|Sugammadex 4 mg/kg Group|Participants receive 4 mg/kg of sugammadex intravenously for reversal of rocuronium-induced neuromuscular blockade.
223465530|NCT06962007|DRUG|Pyridostigmine/Glycopyrrolate Group|Participants receive pyridostigmine 0.2 mg/kg and glycopyrrolate 0.01 mg/kg intravenously for reversal of rocuronium-induced neuromuscular blockade.
223465531|NCT04073303|BIOLOGICAL|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
223465532|NCT04073303|OTHER|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
223465533|NCT05417568|DIETARY_SUPPLEMENT|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
223465534|NCT05417568|DIETARY_SUPPLEMENT|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
223465535|NCT05240014|DEVICE|Modular powered orthosis|This study will investigate modular, lower-limb, powered orthoses that fit to user-specific weakened joints and control force/torque in a manner that enhances voluntary motion in broad patient populations. The central hypothesis is that high-torque, low-inertia motor systems controlled with energetic objectives will enable modular powered orthoses to partially assist the joints. High-torque electric motors combined with minimal transmissions can be freely rotated (i.e., backdriven) by human joints, allowing the use of an emerging torque control method called energy shaping to reduce the perceived weight/inertia of the body during any motion. By mounting these modular actuators to commercial orthoses, this technology will be easily prescribed/configured by clinicians.
223465536|NCT06438744|PROCEDURE|Thread embedding acupuncture (TEA) + standard therapy|"* TEA : one-time TEA using 30 gauge TEA needle with 30 mm polydioxanone thread at CV3 through CV4, SP6 and ST36 bilaterally~* Standard therapy : 2 mg dienogest daily for 8 weeks after TEA"
223465537|NCT05542199|OTHER|Multicomponent nutrition supplement (MCNS)|Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
223465538|NCT05542199|BEHAVIORAL|Behavioral weight loss program|Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
223465539|NCT04758806|BIOLOGICAL|Fecal microbial transplantation|Procured faeces procured from unrelated donor
223465540|NCT04179279|DEVICE|Gili Biosensor System (Gili Pro Biosensor)|Non-contact monitoring of heart and respiratory rates using an optical device
223465541|NCT03437694|OTHER|Medication optimization intervention|Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
223465542|NCT05692401|BEHAVIORAL|Nutrition and Exercise Instruction|Eating and exercise patterns. Educational handouts and instructions will be provided, which are intended as a guide for subjects in intervention group. Subjects will also be given a Patient Diary to complete their daily meal intake and physical exercises. Use of and return of the diary is optional but encouraged. It has been found that use of a patient diary to record food intake keeps one from eating more than they planned and can be a useful tool in weight control.
223743542|NCT06791057|BEHAVIORAL|Enhanced Usual Care|Patients will receive educational materials on the management of symptoms of lung cancer and its treatment as well as any usual care for dyspnea deemed appropriate by the clinical team.
223465543|NCT05793281|OTHER|No Drug|Retrospective data analysis, the dataset for this study will be extracted from the C-CAT database.
223465544|NCT04987866|DEVICE|vibration device , Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China|The vibration device is a reusable, handheld device with a battery-powered motor and a vibration frequency of approximately 6000 times per minute (Beauty bar facial massaging device, T-Shape Electric Sign Face Massage Tools, Dangshan, China)
223465545|NCT00001328|DRUG|Cytovene (Ganciclovir Sodium)|
223465546|NCT00001328|DEVICE|G1TKSVNa.53 Producer Cell Line|
223465547|NCT04754997|OTHER|Traditional exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. The lower extremity range of motion exercise and strengthening exercises will be applied on the mat 10 repetition. The number of repetitions and type of exercises will be changed every 3 weeks.
223465548|NCT04754997|OTHER|Specific exercise training|The therapy program will planned for 12 weeks and the sessions will be performed in 45 minutes (min) for 2 days a week. Exercise training consists of lower extremity closed kinetic chain exercises and core exercises. The type of exercise changes every 3 weeks.
223465549|NCT03781466|PROCEDURE|Cervical cerclage|Cervical cerclage indicated by short cervix ≤25mm
223465550|NCT03781466|DRUG|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
223465551|NCT06314503|DEVICE|WEAKID|"Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment"
223465552|NCT05316142|PROCEDURE|AGV with intraoperation MMC and postoperative BSS|This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
223743543|NCT06752590|DRUG|ONO-1110|ONO-1110 tablets once a day
223743544|NCT06752590|DRUG|Placebo|Placebo tablets once daily
223743545|NCT07083076|OTHER|Short term (10 day) low residue diet restriction|Patients will have an unrestricted diet (as opposed to a low residue diet restriction) 10 days after surgery.
223743546|NCT07083076|OTHER|6 week low residue diet restriction|Patients will be restricted to a low residue diet for 6 weeks after surgery. After this period, their diet will be unrestricted.
223743547|NCT07082270|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224303379|NCT03293784|COMBINATION_PRODUCT|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
224303380|NCT04340921|BIOLOGICAL|COVID-19 exposure|Observation only
224303381|NCT06483321|DIETARY_SUPPLEMENT|Creatine Supplementation|"Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)"
224303382|NCT06483321|DIETARY_SUPPLEMENT|Placebo|Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
224303383|NCT02882243|DEVICE|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
224303384|NCT01524679|DRUG|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
224303385|NCT00045903|BEHAVIORAL|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
224303386|NCT00045903|BEHAVIORAL|Stress Management Therapy (Cognitive Behavior Therapy)|
224303387|NCT01984203|OTHER|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
224303388|NCT01984203|OTHER|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
224303389|NCT03835143|PROCEDURE|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
224303390|NCT04631952|BEHAVIORAL|Online exercise|SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
223465553|NCT05316142|PROCEDURE|AGV with intraoperation MMC and post operation 5FU|This method will use Ahmad FP7 model valve shunt (New World Medical, LA). First, 5FU at a dose of 0.04% is placed in the shunt plate for two minutes and then rinsed.
224303391|NCT04631952|BEHAVIORAL|SMS message|SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
224303392|NCT00801099|DRUG|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
224303393|NCT06348706|DRUG|Dipeptidyl peptidase 4 (DPP-4) inhibitor|Intervention group received Dipeptidyl peptidase-4 (DPP-4) inhibitors supplementation in a dose of 50 mg with main meal for 6 months.
223465554|NCT05608018|OTHER|Intervention Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with all features turned on.
223465555|NCT05608018|OTHER|Intervention non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with all features turned on.
223465556|NCT05608018|OTHER|Control Bluetooth|Participants will receive a Bluetooth device to use for the duration of the study, and will use the app with some features turned off.
223465557|NCT05608018|OTHER|Control non-Bluetooth|Participants will not receive a Bluetooth device, and will use the app with some features turned off.
223743548|NCT07082270|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224303394|NCT00152737|PROCEDURE|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
224303395|NCT00152737|PROCEDURE|Ankle and arm pressure values|one test before and one test after surgery
224303396|NCT04737070|BIOLOGICAL|Prenatal test for Trisomy 21 screening|prenatal routine test for Trisomy 21 screening (blood test + nuchal translucency test)
224303397|NCT05876988|DEVICE|Chinese acupuncture|"Disposable acupuncture needles(0.30mm in diameter and 25-40mm in length) will be inserted at a depth of 10-30mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation. Electrical stimulation was additionally delivered on the 6 pairs of the frontal acupoints. The output peak current and voltage of the machine would be 6V and 48mA, respectively, with constant wave at frequency of 2Hz and phase duration of 100µs for 30min. Electrical stimulation lasted 30min. The needles on body acupoints will be also retained for 30min.~Acupuncture intervention will be conducted for 2 sessions per week over 8 consecutive weeks. The determination of 8 weeks of the treatment duration will be based on the fact that the robust eﬀects of acupuncture in cancer patients will be generally observed within 8 weeks of treatment."
224303398|NCT01551888|DRUG|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
224303399|NCT01551888|DRUG|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
224303400|NCT05477498|DRUG|Ferric carboxymaltose|Application of FCM solution (Ferinject®, Vifor Pharma AG, Villars-sur-Glâne, Switzerland) by intravenous injection.
224303401|NCT05477498|DRUG|Placebo|Application of placebo solution administered as normal saline (0.9% weight/volume (w/v) NaCl) by intravenous injection as per the instructions for active treatment.
224303402|NCT03614897|BEHAVIORAL|Education|Education on guidelines for care of individuals at risk of falling
223465558|NCT03832361|DRUG|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
223465559|NCT03796936|BEHAVIORAL|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
223465560|NCT01898403|DRUG|Indocyanine green solution|Administered peri-tumoral and intradermally
223465561|NCT01898403|DRUG|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
223465562|NCT01898403|DIAGNOSTIC_TEST|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
223743549|NCT07082270|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
223465563|NCT06001697|BEHAVIORAL|Park prescription|The park prescription given by the patients care-provider includes information about the health benefits of spending time in nature and detailed information about the parks in the neighboring area. As well as access to a web-based platform called ParkRx which includes information and details about events in the parks in the study area. Together with information about the frequency and duration of visits to the parks.
223465564|NCT06001697|BEHAVIORAL|Regular health advice|Regular health advice relating to lifestyle factors that can decrease the risk of chronic disease and/or reducing the burden of an existing chronic disease. Areas included are diet, physical activity, sleep, stress and medications.
223465565|NCT00764569|DEVICE|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
223465566|NCT03270033|DRUG|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
223465567|NCT03270033|DRUG|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
223465568|NCT04351165|DRUG|IMP4297|IMP4297 10mg/capsule; IMP4297 20mg/capsule;
223577213|NCT05618730|DEVICE|punctum plug insertion|"EXP-TC delivers the anti-inflammatory drug tacrolimus that acts as inhibitor of T lymphocytes and may therefore lead to the inhibition of release of inflammatory cytokines.~EXP-TC has a Pangolin design and has 3 different designs: big, medium and small with drug content ranging from 194 to 348 µg.~After plug insertion preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) is taken 4 times daily."
223465569|NCT01451918|DRUG|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
223465570|NCT05854420|PROCEDURE|Modified anterior Lamellar Recession|ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
223465571|NCT06278948|OTHER|Group TP|Application full face, twice daily, in the morning and at bedtime for 4 months
223465572|NCT06278948|DRUG|Group CYS|Application short contact, of thin layer once daily at bedtime for 4 months
223465573|NCT01218542|RADIATION|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
223465574|NCT02377609|DRUG|Tacrolimus|oral
223465575|NCT01475903|PROCEDURE|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
223465576|NCT05044429|DRUG|Intravenous Lidocaine|Patient will receive intravenous lidocaine 1.0-1.5 mg/kg/hour for 48 hours post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
223465577|NCT05044429|DRUG|Transversus abdominis plane (TAP) block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through transversus abdominis plane (TAP) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
223465578|NCT05044429|DRUG|Quadratus Lumborum (QL) Block|Subject will receive 0.2% Ropivacaine at 6-10ml/hour through quadratus lumborum (QL) block for up to five days post-operatively in addition to standard of care (patient-controlled analgesia (PCA) pump)
223577214|NCT05618730|DRUG|Eye Drops, Lubricant|Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.
223577215|NCT04529369|PROCEDURE|Middle lobe only Photoselective vaporization of the prostate (PVP)|Middle lobe only Photoselective vaporization of the prostate (PVP) without vaporization of the lateral lobes
223577216|NCT04529369|PROCEDURE|Complete PVP|Traditional Photoselective vaporization of the prostate PVP
223577217|NCT03538184|PROCEDURE|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
223743550|NCT07082270|DRUG|Carfilzomib|Given IV
223743551|NCT07082270|PROCEDURE|Computed Tomography|Undergo PET/CT and/or CT
223465579|NCT05292261|OTHER|Recreational team handball|Two to three weekly sessions of recreational team handball training for 36 weeks. Each 60-min session started with a standardised warm-up (including running, coordination, strength, flexibility, and balance exercises) followed by three 15-min periods of recreational team handball matches, interspersed by 2-min breaks, played as small-sided games (4v4, 5v5 or 6v6). The training sessions were performed on an indoor team handball court (40x20 m) adjusted to result in 34-36 m2 per player. During the matches, the participants rotated positions every 3 min in a random order, including the goalkeeper and no exclusions or substitutions were applied.
223743552|NCT07082270|DRUG|Daratumumab and Recombinant Human Hyaluronidase|Given SC
223465580|NCT05046015|OTHER|10% Urea foot lotion|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves."
223465581|NCT05046015|OTHER|10% Urea foot ointment|"During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves."
223465582|NCT06431529|BIOLOGICAL|tumor neoantigen specific T cell|Isolate the patient's autologous monocytes, induce and culture them into tumor antigen presenting cells in vitro, and then phagocytose tumor tissue cells obtained from biopsy or surgery to present tumor neoantigens to autologous T cells. The final product For tumor neoantigen specific T cells (NeoT).
223577218|NCT03538184|PROCEDURE|Drill|Preparation of implant beds entirely with conventional implant drills
223743553|NCT07082270|DRUG|Dexamethasone|Given PO
223743554|NCT07082270|PROCEDURE|Echocardiography Test|Undergo ECHO
223743555|NCT07082270|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
223743556|NCT07082270|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223743557|NCT07082270|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
223743558|NCT07082270|OTHER|Questionnaire Administration|Ancillary studies
223743559|NCT07082270|DRUG|Selvigaltin|Given PO
223465583|NCT03287076|DRUG|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
223465584|NCT05157880|BEHAVIORAL|Recovering Together|In the skills-based intervention group, sessions focus on developing skills to cope and manage ANI related stressors. The intervention will be tailored consistent with AHA recommendations for ANI skills-based interventions and will include 2 general and 4 specific modules. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered, in person if possible, within the NICU, or through live video using Zoom if patients leave the hospital before sessions occur, and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom.
223465585|NCT05157880|BEHAVIORAL|Recovering Together|Those in the educational program will receive general health information that mimics the skills-based intervention, but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. There will also be 6 sessions, 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits following discharge. The educational program group will not have the opportunity to specify which modules they would like to take; the modules will be predetermined. All participants will receive medical care as determined by their medical team.
223465586|NCT04464291|OTHER|Detection of Streptococcus pneumoniae strains|There will be detection of Streptococcus pneumoniae, serotype identification, susceptibility tests for penicillin, erythromycin, azithromycin, tetracycline, ciprofloxacin, levofloxacin, moxifloxacin and vancomycin
223465587|NCT03589807|BIOLOGICAL|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
223465588|NCT03589807|DRUG|AS03|AS03 oil-in-water emulsion adjuvant.
223465589|NCT03589807|BIOLOGICAL|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
223465590|NCT03589807|OTHER|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
223465591|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
223465592|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
223465593|NCT00672568|DRUG|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
223465594|NCT00672568|DRUG|Placebo|Solution, single dose, injection
223465595|NCT02263053|PROCEDURE|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
223465596|NCT02263053|PROCEDURE|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
223465597|NCT00810069|DRUG|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
223465598|NCT00810069|DRUG|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
223465599|NCT03580161|OTHER|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223465600|NCT03580161|OTHER|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223465601|NCT03580161|OTHER|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223465602|NCT03580161|OTHER|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223743560|NCT06903338|DRUG|Tobevibart|Tobevibart administered by subcutaneous injection
223743561|NCT06903338|DRUG|Elebsiran|Elebsiran administered by subcutaneous injection
223465603|NCT03580161|OTHER|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223465604|NCT03580161|OTHER|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223465605|NCT03580161|OTHER|99mTc MDP/HDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
223465606|NCT02652637|DRUG|neomycin, metronidazole, polyethylene glycol (PEG)|
223465607|NCT03675360|BEHAVIORAL|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target \<40 g net carbohydrates per day for first 3 months; \<60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
223465608|NCT02104024|OTHER|Contrast Enhanced Ultrasound Scanning|
223465609|NCT01056393|DRUG|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
223465610|NCT01056393|DRUG|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
223465611|NCT02389660|BEHAVIORAL|Blended Cognitive Behavioural Therapy (CBT)|
223465612|NCT02389660|BEHAVIORAL|Treatment as usual|
223743562|NCT06930560|DEVICE|HEARS-NPS device|Tailored fitting and programming of a personal sound amplifier accompanied by an aural rehabilitation component.
223743563|NCT06930560|BEHAVIORAL|HEARS-NPS program|Tailored aural rehabilitation for participant and care partner.
224303403|NCT04062656|DRUG|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
223465613|NCT00785161|DEVICE|Penumbra System|Mechanical Thrombectomy in acute stroke
223465614|NCT05083910|DRUG|I.V Oxytocin administration|Group I: Oxytocin( the oxytocin infusion consisting of 20 IU dissolved in 500 mL of normal 0.9 % sodium chloride solution and infused at a rate of 125 mL/h was administered immediately after clamping the umbilical cord). Group II:oxytocin plus intrauterine misoprostol (the oxytocin infusion was administered immediately after clamping the umbilical cord and misoprostol tablet (400 mg) was placed into uterine cavity at the fundus after delivery of the placenta and swabbing the cavity. Group III:100-mg carbetocin was intravenously administered immediately after birth of the baby.
224303404|NCT04062656|DRUG|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
224303405|NCT04062656|DRUG|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
224303406|NCT04062656|DRUG|Docetaxel|Docetaxel 50mg/m² IV over 1 h
224303407|NCT04062656|DRUG|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
223465615|NCT00543114|DRUG|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
223465616|NCT00543114|DRUG|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
223465617|NCT00543114|DRUG|Rituximab|Given intravenously on Day 1 of each 28 day cycle
223465618|NCT03746925|PROCEDURE|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
223465619|NCT03746925|PROCEDURE|SuperPATH|SuperPATH approach surgery to replace the hip.
223465620|NCT04453761|DRUG|Neurobion|Intravenous Thiamine 2 mg/kg in Neurobion injection
223465621|NCT04453761|DRUG|Placebo|Intravenous NaCl0.9%
223465622|NCT03984084|OTHER|no intervention|no intervention
223465623|NCT02357225|DRUG|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
223465624|NCT06268834|DIAGNOSTIC_TEST|Blood for zonulin level was drawn from the group.|Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.
223465625|NCT02915146|RADIATION|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
223465626|NCT06524986|BEHAVIORAL|Self-efficacy promoting program using computer game|The self-efficacy promotion program, inspired by Bandura's principles (1997, 2001) and employing computer games, extends across 5 weeks with 30-minute sessions conducted 10 minutes. Activities include: 1) Enactive Mastery Experiences 2) Modeling 3) Verbal Persuasion 4) Physiological and Affective States Assessment
223465627|NCT06524986|BEHAVIORAL|Standard nursing care|The control group received standard nursing care, which included providing dietary recommendations for pediatric patients. The recommended daily intake consisted of 0.8 grams of protein per kilogram of the child's weight, low-sodium foods, and low-fat options. This personalized guidance was communicated through informational brochures.
223465628|NCT04619784|OTHER|Pilates Exercises|Patients will receive 12 sessions of pilates.
223465629|NCT04619784|OTHER|control|Their routine medical treatments were continued
223465630|NCT01244074|BEHAVIORAL|biofeedback training|
223465631|NCT05774561|DIAGNOSTIC_TEST|Arm A - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.
223465632|NCT05774561|DIAGNOSTIC_TEST|Arm B - Diagnostic test: HPV detection in liquid biopsies|Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.
223465633|NCT04767373|BIOLOGICAL|Clesrovimab|Clesrovimab solution
223465634|NCT04767373|DRUG|Placebo|Placebo (0.9% sodium chloride \[NaCL\]) solution
223743564|NCT05746650|PROCEDURE|Electrical stimulation|Experimentally induced muscly injury via. neuromuscular electrical stimulation of the hamstring muscles
224303408|NCT04062656|DRUG|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
223465635|NCT04959448|DRUG|DUPIXENT®|No investigational agents will be provided. All treatments will be prescribed at the discretion of the study physician and other healthcare providers.
223465636|NCT02983045|DRUG|Dose Escalation Doublet: Combination of NKTR-214 + nivolumab|NKTR 214 + nivolumab at 5 dosage levels.
223465637|NCT02983045|DRUG|Dose Expansion Doublet: Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
223465638|NCT02983045|DRUG|Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|1L patients with RCC, NSCLC, UCC, and melanoma received NKTR-214 0.006 mg/kg q3w in combination with nivolumab and ipilimumab according to 3 dosing schedules.
223465639|NCT02983045|DRUG|Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab was administered at RP2D dose/schedules in select tumor types
224303409|NCT00301093|BIOLOGICAL|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
224303410|NCT00301093|DRUG|imatinib mesylate|Participants will continue on current dose
224303411|NCT03208361|DRUG|Penicillin V|
224303412|NCT03208361|DRUG|Amoxicillin|
224303413|NCT01155453|DRUG|BKM120|
224303414|NCT01155453|DRUG|GSK1120212|
224303415|NCT02991677|BEHAVIORAL|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
224303416|NCT02991677|OTHER|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
224303417|NCT02991677|BEHAVIORAL|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
223465640|NCT02658669|BEHAVIORAL|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
223743565|NCT05746650|DRUG|Growth hormone (somatropin)|Daily injection of growth hormone
223465641|NCT02658669|BEHAVIORAL|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
223465642|NCT02732392|PROCEDURE|standard lymphadenectomy|
223465643|NCT02732392|PROCEDURE|lymphadenectomy radio-isotope method|
223465644|NCT02932800|PROCEDURE|"Fixation with ballerina technique and flip"|
223577219|NCT06350942|PROCEDURE|one trocar-assisted retroperitoneoscopic ureteroureterostomy (OTAU)|A 12 mm transverse incision was made just above the iliac crest, followed by careful dissection of the fascia and muscle layer to expose the Gerota's fascia. Entry into the retroperitoneal space was achieved with a 10-mm balloon trocar, allowing for pneumoretroperitoneum establishment. Using a 10-mm laparoscope equipped with a Maryland dissector, the ureters were dissected and isolated, followed by careful exteriorization of both upper and lower pole moiety ureters with a Babcock grasper. The pathological upper pole moiety ureter was transected, preserving the normal lower pole moiety ureter and shared blood supply, and closed with a Vicryl 4/0 suture. Subsequently, an end-to-side ureteroureterostomy was performed with a 6/0 Polydioxanone running suture, with antegrade insertion of a double J stent if not previously conducted. A final retroperitoneoscopic evaluation ensured proper anastomosis alignment, and the incision was closed without drainage.
223577220|NCT01457950|DRUG|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
223577221|NCT01457950|DRUG|placebo|double-blind phase: placebo subcutaneous injection, single dose
223577222|NCT01457950|DRUG|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
223577223|NCT06126952|DRUG|Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)|"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
223577224|NCT06126952|DRUG|Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray|2 sprays per nostril of Placebo twice daily.
223577225|NCT06126952|DRUG|Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray|"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
223577226|NCT01158027|OTHER|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
223743566|NCT05746650|OTHER|Control (No electrical stimulation, nor growth hormone)|No electrical stimulation, nor growth hormone
223465645|NCT02932800|PROCEDURE|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
223465646|NCT02932800|OTHER|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
223465647|NCT01396889|DRUG|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
223465648|NCT01396889|DRUG|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
223465649|NCT03132090|DIAGNOSTIC_TEST|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
223465650|NCT00419042|DRUG|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
223465651|NCT00419042|DRUG|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
223465652|NCT05391997|OTHER|Modified Cervical and Shoulder Retraction exercises|11 patients will receive cervical traction and modified cervical and shoulder retraction exercises (10 to 12 repetitions). The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days.
223465653|NCT05391997|OTHER|Cervical Extension Traction exercises|11 patients will receive cervical traction force for 10 seconds and extend the cervical spine. The total treatment session will be of 20-25 minutes with a total intervention period of 6 weeks with 3 sessions per week on alternative days
223465654|NCT03752879|PROCEDURE|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
223465655|NCT04211012|DRUG|Toripalimab plus Nab-Paclitaxel +/- cisplatin|"Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin"
223577227|NCT02605811|DRUG|temozolomide|
223577228|NCT02605811|RADIATION|prophylaxis cranial radiotherapy|2
223577229|NCT00054691|DRUG|Iressa|250 mg by mouth daily
223577230|NCT00497237|DRUG|Beclomethasone plus formoterol fixed combination|100+6 pMDI
223577231|NCT00497237|DRUG|Fluticasone plus salmeterol fixed combination|diskus 250/50
223577232|NCT03159507|DIETARY_SUPPLEMENT|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
223577233|NCT02362126|DEVICE|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
223577234|NCT04120857|BEHAVIORAL|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
223577235|NCT05256342|DRUG|Duloxetine 60mg|"Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily."
223577236|NCT05256342|DRUG|Etoricoxib 60 mg|One pill daily for 8 weeks
223577237|NCT05256342|DRUG|omeprazol|20 mg daily; will be taken with Etoricoxib from the second week of treatment
223577238|NCT03719404|PROCEDURE|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
223465656|NCT06117696|OTHER|Animated video|delivery of written and oral information, supported by animated videos.
224303418|NCT06130098|OTHER|control group|"Training by the clinical nurse before discharge. Prepare an educational brochure and give it to patients. Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale During the routine check-up in the first week, evaluates the development of complications without knowing which group the patient is in.~Within the first week and at the end of the fourth week, the wound site is evaluated by the physician for the development of complications, . Patients who cannot come for a check-up should send a photo of the wound area to the researcher via WhatsApp application, and the photo will be forwarded to the clinician who performed the surgery and the physician will record the complication situation. It is planned to receive complication development and wound site evaluation results from the physician system.~At the end of the fourth and sixth weeks after discharge, the EQ-5D-5L and OKS scale must be filled in again by the patients."
224303419|NCT06130098|OTHER|experimental group|"Providing training before discharge Prepare an educational brochure and give it to patients. You will be contacted by phone at the end of the first, second, third and fourth weeks after discharge.~Application of patient information form, EQ-5D-5L Quality of Life and OKS Scale Evaluating the wound site in terms of complications within the first week and at the end of the fourth week. It is planned to receive complication development and wound site evaluation results from the system.~After the first check-up, calling the patients in the study group at the end of the first week after discharge.~Providing training on the subjects included in the training brochure in the first phone call and recording any existing problems.~In the fourth meeting, tele-nursing service will be provided through the Telephone Counseling Protocol.~EQ-5D-5L and OKS forms must be filled out again by patients at the routine check-up at the end of the fourth and sixth weeks after discharge."
224303420|NCT03251495|DRUG|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
224303421|NCT02770677|OTHER|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
224303422|NCT03474497|DRUG|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
223465657|NCT02240017|DRUG|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
223465658|NCT02240017|DRUG|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
223465659|NCT02240017|DRUG|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
223465660|NCT06218615|OTHER|Educational Intervention (Video)|Watch video
223465661|NCT06218615|OTHER|Survey Administration|Answer survey questions
223465662|NCT02078193|DRUG|Belatacept|Patients will be converted from their MMF to Belatacept
223465663|NCT03764280|OTHER|Multiple Daily Injections: Slow acting insulin and Rapid acting insulin|Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
223465664|NCT03773289|OTHER|No intervention|This is a retrospective, observational pharmacoepidemiological study using nationally collected data. There is no intervention.
223465665|NCT02589470|OTHER|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
223465666|NCT02830412|OTHER|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
223465667|NCT01028729|DRUG|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
223465668|NCT01028729|DRUG|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
223465669|NCT02205372|DRUG|MT-3995|
223465670|NCT02205372|DRUG|Placebo|
223465671|NCT04175275|OTHER|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
223465672|NCT04238377|PROCEDURE|Stellate Ganglion Block|"Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected"
223577239|NCT03719404|PROCEDURE|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
223577240|NCT00190138|DEVICE|Bi-ventricular pacing|
223577241|NCT06086652|DIAGNOSTIC_TEST|PET/CT|detection of possible primary tumor
223577242|NCT02929901|DIETARY_SUPPLEMENT|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
223577243|NCT02929901|DIETARY_SUPPLEMENT|caffeine|caffeine plus placebo
223577244|NCT02929901|DIETARY_SUPPLEMENT|chlorogenic acid|chlorogenic acid plus placebo
223577245|NCT02929901|DIETARY_SUPPLEMENT|placebo|placebo plus placebo
223577246|NCT03885570|PROCEDURE|Mitral valve replacement|Blood transfusion
223465673|NCT04238377|DRUG|Multimodal Analgesia|Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
223465674|NCT02245165|BIOLOGICAL|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
223465675|NCT02245165|BIOLOGICAL|saline|
223577247|NCT04626089|DRUG|metformin glycinate|Participants randomized to metformin glycinate wil take 620 mg bid (PO) plus standard treatment for 14 days
223577248|NCT04626089|DRUG|Placebo oral tablet|Participants randomized to placebo will take a tablet bid (PO) plus standard treatment for 14 days
223577249|NCT02516826|DRUG|Rosuvastatin|
223465676|NCT03740269|OTHER|oral health educational program|poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
223465677|NCT05399797|OTHER|Educational training|Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
223465678|NCT05507892|DRUG|canagliflozin|Canagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a used to treat type 2 diabetes. Canagliflozin lowers blood sugars by causing the kidneys to excrete more glucose in the urine.
223465679|NCT05507892|DRUG|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure renal plasma flow (RPF) PAH (Basic Pharma, Geleen, Netherlands) has been used to measure RPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
223465680|NCT02208544|PROCEDURE|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
223465681|NCT02208544|DEVICE|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
223577250|NCT02516826|DRUG|Olmesartan|
223577251|NCT02516826|DRUG|Combination|Rosuvastatin/Olmesartan(Combination)
223577252|NCT02516826|DRUG|Placebo of Rosuvastatin|
223465682|NCT02208544|RADIATION|FDG-PET/CT|Head and Neck FDG-PET/CT
223465683|NCT01575171|BEHAVIORAL|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
223465684|NCT00300222|DRUG|NGX-4010|
223465685|NCT01442662|DRUG|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
223465686|NCT03421379|DRUG|Glucagon Nasal Powder|Administered intranasally
223465687|NCT03421379|DRUG|Glucagon Hydrochloride Solution|Administered IM
223465688|NCT02782741|DRUG|Avalglucosidase alfa (GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
223465689|NCT02782741|DRUG|Alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
224303423|NCT03474497|DRUG|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
223465690|NCT06145503|DEVICE|Dance Intervention Group|The dance sessions, tailored to participants' preferences, were accompanied by music from the 80s and 90s. A dance instructor demonstrated each dance step, and the sessions comprised a 10-minute warm-up, 40 minutes of dancing, and a 10-minute cool-down. The complexity and intensity of the dance routines were adjusted based on individual abilities, functional variations, and capacity.
223465691|NCT05113680|BEHAVIORAL|compassion focused group|Based on compassion focused therapy (CFT) principles practices : soothing breathing rythm, compassionate-self, compassion for shame and self-criticism 12 sessions of 2h each
223465692|NCT05113680|BEHAVIORAL|emotional competencies|Emotional competencies group focused on identification, comprehension, expression, regulation, utilization. practices : TCC, cognitive restructuring, and mindfulness 12 sessions of 2h each
223465693|NCT04292210|DEVICE|Perisafe|A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.
223465694|NCT04157088|DRUG|Darolutamide (Nubeqa, BAY1841788)|600mg, twice daily
223465695|NCT04157088|DRUG|Enzalutamide|160mg, once daily
223465696|NCT00035178|DRUG|Argatroban|
223577253|NCT02516826|DRUG|Placebo of Olmesartan|
223577254|NCT02516826|DRUG|Placebo of Rosuvastatin/Olmesartan(Combination)|
223577255|NCT03352583|DIETARY_SUPPLEMENT|Protein|40g calcium caseinate
223577256|NCT02408081|BEHAVIORAL|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
223577257|NCT00810485|DRUG|ADX10059|oral administration
223577258|NCT00810485|DRUG|ADX10059|oral administration
223577259|NCT00810485|DRUG|ADX10059|oral administration
223577260|NCT00810485|DRUG|ADX10059 Matching Placebo|oral administration
223577261|NCT02498067|BEHAVIORAL|rPlan dual protection waiting room app intervention|
223577262|NCT00792025|DRUG|sunitinib malate|
223577263|NCT01180816|DRUG|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
224303424|NCT03474497|RADIATION|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
223465697|NCT03663296|OTHER|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
223465698|NCT04739969|DEVICE|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Soterix Neural Navigator neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark)."
223577264|NCT01763320|PROCEDURE|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
223743567|NCT06930846|BEHAVIORAL|HOBSCOTCH-CA|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-CA is an adaptation of the HOBSCOTCH program for people who are survivors of brain cancer or a brain tumor that incorporates education about the effects from brain cancer/tumor and its treatment on cognition into the education module and gives them the option of enrolling with a Caregiver. CA Participants receive all sessions of HOBSCOTCH-CA. If they enroll with a Caregiver, the Caregiver participates in the education (introductory) session and sessions 1 and 8. The HOBSCOTCH-CA Participant may invite their Caregiver to attend all sessions.
224158060|NCT01241656|BEHAVIORAL|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
224158061|NCT01241656|BEHAVIORAL|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
224158062|NCT00943254|OTHER|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
224158063|NCT00943254|OTHER|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
224158064|NCT04766983|DIAGNOSTIC_TEST|bronchoalveolar lavage|BAL and ETA are performed as per clinical practice on clinical suspicion of VAP (Johanson score)
224158065|NCT05468762|PROCEDURE|Transfemoral tranScatheter aortic valvE implantation|Transcatheter aortic valve implantation (TAVI) is an established treatment modality in patients ≥ 75 years old with severe symptomatic aortic stenosis after Heart Team evaluation
224158066|NCT02376491|DEVICE|Transcranial magnetic stimulation|
224158067|NCT04749563|DRUG|IGC AD1|IGC AD1 oral Solution
224158068|NCT04749563|DRUG|Placebo|Placebo of IGC AD1 oral Solution
224158069|NCT01078519|DRUG|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
224158070|NCT00373412|BIOLOGICAL|VCL CT02 pDNA vaccine|
224158071|NCT00373412|BIOLOGICAL|Towne CMV vaccine|
224158072|NCT02077946|DRUG|liraglutide|No treatment given.
223465699|NCT04739969|DEVICE|Sham TBS-DLPFC|The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
223465700|NCT05566301|DRUG|Clopidogrel|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
224158073|NCT02077946|DRUG|sitagliptin|No treatment given.
224158074|NCT02596685|PROCEDURE|Bronchoscopy|Undergo bronchoscopy
224158075|NCT02596685|OTHER|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
224158076|NCT02596685|OTHER|Laboratory Biomarker Analysis|Correlative studies
224158077|NCT02596685|OTHER|Questionnaire Administration|Ancillary studies
224158078|NCT04429321|DRUG|Nivolumab|Nivolumab 3 mg/kg IV every four weeks, first in combination with capecitabine then alone
224158079|NCT04429321|DRUG|Ipilimumab|ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, in combination with Nivolumab
224158080|NCT04429321|DEVICE|bland embolization|Lipiodol:ethanol embolization of their primary or target tumor
224158081|NCT00444964|DRUG|Nutropin AQ|0.0125 mg/kg/day
224158082|NCT05201482|DEVICE|SightPlus|SightPlus is a head-mounted, augmented reality low vision aid. SightPlus enables people with a visual impairment to use their remaining vision to see more clearly up close and at a distance. SightPlus is commercially available, non-invasive, CE marked, and a MHRA approved class 1 medical device.
224303425|NCT04040322|DRUG|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
223577265|NCT01763320|DRUG|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
223577266|NCT01434329|GENETIC|DNA methylation analysis|
223577267|NCT01434329|GENETIC|gene expression analysis|
223577268|NCT01434329|GENETIC|microarray analysis|
223577269|NCT01434329|OTHER|laboratory biomarker analysis|
223577270|NCT01434329|OTHER|medical chart review|
223465701|NCT05566301|DRUG|Ticagrelor|All patients will undergo carotid stenting and dual antiplatelet therapy with ASA + clopidogrel
223465702|NCT06558422|DRUG|Insulin human|Insulin infusion rate (IIR) will be determined either to maintain fasting serum insulin levels (MH protocol) or to reduce fasting serum insulin levels by approximately 50% toward euinsulinemia (RE protocol).
223465703|NCT06558422|DRUG|Octreotide Acetate|Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
223465704|NCT06558422|DRUG|Glucagon|Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
223465705|NCT06558422|DRUG|Growth Hormone, Human|Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
223465706|NCT06558422|DRUG|20% D-glucose (aq)|20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
223465707|NCT06558422|DIAGNOSTIC_TEST|[6,6-2H2] D-glucose|Stable isotope tracer administered to calculate glucose kinetics during pancreatic clamp.
223465708|NCT06558422|DIAGNOSTIC_TEST|[1-13C1] sodium acetate|Stable isotope tracer administered to calculate de novo lipogenesis during pancreatic clamp.
223465709|NCT06558422|DIETARY_SUPPLEMENT|Nestle BOOST Plus|"Nutritional supplement will be administered to provide standardized mixed meals prior to the pancreatic clamp."
223465710|NCT06558422|DIETARY_SUPPLEMENT|KIND Bar|Energy bar snack will be administered the evening before the pancreatic clamp.
223465711|NCT06558422|DEVICE|Harvard Apparatus PHD ULTRA CP syringe pump|Syringe pump used for highly precise administration of insulin, octreotide/glucagon/rhGH, and D20W (as needed) even at low infusion rates.
223465712|NCT06558422|DEVICE|Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer|Glucose oxidase analyzer used to detect plasma glucose levels at the point of care. YSI have been the gold standard in clamp studies for many years. Two machines will run in parallel to ensure accuracy of results.
223577271|NCT04750694|BEHAVIORAL|Resistance training|A full-training programme with high intensity followed by back squat exercise with blood flow restriction. Inflatable cuffs will be placed proximally on both thighs. The cuff pressure will be 50% of individual arterial occlusion pressure and will be maintained during the rest intervals. Participants will perform 30, 15, 15 and 15 repetitions of 30% of 1 Repetition Maximum. Totally 75 repetitions will be performed. 45 seconds rest interval between sets will be given.
223577272|NCT01659281|DRUG|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
223577273|NCT01659281|DRUG|Artesunate|4 mg/kg/day for 3 days
223577274|NCT01659281|DRUG|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
223577275|NCT01659281|DRUG|Mefloquine|8 mg/kg daily for 3 days
223743568|NCT06880640|BEHAVIORAL|Stress Induction|Participants will complete the Trier Social Stress Test to induce stress, which includes a public speaking simulation and mental arithmetic.
223465713|NCT03377270|BEHAVIORAL|Respiratory Swallow Training|Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
223465714|NCT05067790|DRUG|Nusinersen|Administered as specified in the treatment arm
223465715|NCT05132504|DRUG|Pembrolizumab|Pembrolizumab will be initiated starting with the Cycle 2 Day 1 and will be administered every 6 weeks with a max amount of 9 cycles throughout the study.
223465716|NCT05132504|DRUG|Folfirinox|Once eligibility has been confirmed and the patient has been registered to the study, the patient will begin induction modified FOLFIRINOX (Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil) chemotherapy treatment. Each cycle is 14 days; a total of six cycles will be administered. Patients will receive growth factor support at the discretion of treating physician.
223465717|NCT00196105|DEVICE|6 mm Nitinol Zilver Stent|
223465718|NCT00196105|DEVICE|10 mm Nitinol Zilver Stent|
223465719|NCT00196105|DEVICE|10 mm Stainless Steel Wallstent|
223465720|NCT01328470|DRUG|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
223465721|NCT04863872|OTHER|Proactive Care Management|Participants will receive one telephone nurse outreach call with follow up by the nurse or their primary care provider as clinically indicated.
223465722|NCT04863872|BEHAVIORAL|MyHC-T2D education program|Participants will be enrolled in a structured education program designed to improve hypoglycemia awareness and reduce severe hypoglycemia. The structured program will include 2 online group education sessions, 2 nurse follow up calls and use of glucose and hypoglycemia diaries, delivered over approximately 3 months.
223465723|NCT05866393|BEHAVIORAL|Clean Hands Accessible and Manageable for Patients|Use of a patient-smart hand sanitation dispenser that provides reminders that are non-beeping reminders.
223465724|NCT04808934|DRUG|Apixaban|Adults receiving apixaban
223465725|NCT04808934|DRUG|dabigatran|Adults receiving dabigatran
223465726|NCT04808934|DRUG|rivaroxaban|Adults receiving rivaroxaban
223465727|NCT04808934|DRUG|VKAs|Adults receiving VKA
223577276|NCT02185157|OTHER|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
223577277|NCT02185157|OTHER|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
223577278|NCT05936502|OTHER|Extranodal extension|Extranodal extension presence or absence on radiology and pathology assessment
223577279|NCT03564821|DRUG|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
223577280|NCT04083261|OTHER|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
223577281|NCT03610503|OTHER|Music|Participants in this arm will listen to music during the EMG testing
223577282|NCT03887260|DRUG|Morphine PCA pump|Morphine given postoperatively.
223577283|NCT03887260|PROCEDURE|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
223577284|NCT03887260|DRUG|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
223465728|NCT04680533|DEVICE|Transcutaneous Electrical Nerve Stimulation (TENS)|Quell TENS device. The device is worn on the upper calf right below the knee and secured by an elastic band. The device is controlled by an App and alternates between treatment periods and rest periods. Participants will be asked to wear the device 7-8 hours per day alternating legs.
223577285|NCT02683486|DEVICE|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
223577286|NCT02683486|DEVICE|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
223577287|NCT02337530|DRUG|Selumetinib|
223577288|NCT02337530|DRUG|Pemetrexed|
223577289|NCT02337530|DRUG|Cisplatin|
223577290|NCT02337530|DRUG|Carboplatin|
224158083|NCT05322915|OTHER|line dancing|The intervention included 60-minute sessions, two days a week for four weeks for a total of eight sessions. All sessions were administered by the physiotherapist who has 26 years of experience in dance therapy. The dance was performed on a one to one basis with minimal support from the therapist. The line dancing sequence, which was specially created for this training program, was designed as a structured goal-oriented dance. Line dancing movements/steps are comprised of moving forward and backward, or sideways and turns and scuff. In addition, the fact that one foot is always in contact with the ground makes it ideal for patients with multiple sclerosis, who may have balance problems.
224158084|NCT04835571|OTHER|Optimization of cardiovascular risk management|"Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~* blood pressure \<140/90 mmHg~* Tot cholesterol \<5 mmol/l~* LDL \<1,8 mmol/l~* Waist circumference: men \<94 cm, women \<80 cm~* BMI \<25 kg/m2~* HbA1c without diabetes mellitus \<42 mmol/mol, HbA1c with diabetes mellitus \<52 mmol/mol~* Antithrombotic treatment (or anticoagulants, if indicated)~* Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~* Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~* Smoking cessation~* Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets."
224158085|NCT00842361|DRUG|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
224158086|NCT00842361|DRUG|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
224158087|NCT01432093|OTHER|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
224158088|NCT01432093|OTHER|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
224158089|NCT01966861|OTHER|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score \>14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required \[CPIS\>6\], hemglobin\>8g/dl triggers transfusion)
224158090|NCT03094611|BIOLOGICAL|Inotuzumab Ozogamicin|Given IV
224158091|NCT01821547|DRUG|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
224158092|NCT03704805|BEHAVIORAL|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
224158093|NCT03704805|OTHER|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
224158094|NCT02573233|DRUG|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
223465729|NCT04058028|DRUG|Rozibafusp Alfa|Rozibafusp Alfa will be presented in 5 mL glass vial
223465730|NCT04058028|DRUG|Placebo for Rozibafusp Alfa|Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
223465731|NCT00980824|BEHAVIORAL|Cognitive behavioural therapy|Six sessions brief CBT.
223465732|NCT00980824|OTHER|Standard treatment|Referral to NHS services appropriate to patient's needs
223577291|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental|40 Gy / 15 Fractions EBRT + HDR-Brachytherapy
223577292|NCT04583254|RADIATION|External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care|45 Gy / 25 Fractions EBRT + HDR-Brachytherapy
223577293|NCT04583254|DRUG|Concurrent Chemotherapy|Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
223577294|NCT03351114|DRUG|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
223577295|NCT00002454|BIOLOGICAL|autologous tumor cell vaccine|
223577296|NCT04359290|DRUG|Ruxolitinib administration|Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg or 2 x 15mg bid dose at day 1 according to the investigator's decision and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function.If the patient is discharged before day 28, the therapy will be discontinued for discharge.
223743569|NCT07085845|OTHER|Inserting a swab 5 cm into the anus during self-sampling|The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 5 cm to collect anal exfoliated cells.
224158095|NCT02573233|DRUG|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
223577297|NCT05094479|BEHAVIORAL|Health information delivered via health app|Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
223577298|NCT01663701|OTHER|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
223465733|NCT03666416|BEHAVIORAL|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
223577299|NCT01663701|OTHER|Usual care|Patients are managed according to admitting doctors' orders
223743570|NCT07085845|OTHER|Self-sampling with a swab by inserting the swab 3 cm into the anus.|The swab will be inserted into the anus by the lay individual. The individual will insert the swab to a depth of 3 cm to collect anal exfoliated cells.
223743571|NCT05069545|DRUG|Insulin degludec|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
223743572|NCT05069545|DRUG|Fast-acting insulin aspart|Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
223743573|NCT07089550|RADIATION|PSMA PET/CT scan|All Patients undergoing PSMA PET for pre-treatment disease staging with different radiotracers (\[68Ga\]Ga-PSMA-11, \[18F\]-DCFPyL, \[18F\]-PSMA-1007).
223465734|NCT05201612|DRUG|Olaparib|Olaparib 300 mg, orally (po), twice a day (BID) continuously
223465735|NCT05201612|DRUG|Pembrolizumab|Pembrolizumab 200 mg, intravenously (IV), every 21 days. Max 2 years (i.e. 35 cycles)
223465736|NCT02696395|DEVICE|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
223465737|NCT02696395|DEVICE|DePuy Corail® femoral stem + Deltamotion® acetabular component|
223465738|NCT00485069|DRUG|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
223465739|NCT00485069|DRUG|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
223465740|NCT05555238|DRUG|single arm, single group(No interventional)|(Newvast® Tab, 10 to 80 mg daily administered per the locally approved product information)
223465741|NCT02081378|DRUG|Asciminib (ABL001)|Asciminib was be administered orally in a dose escalation schedule.
223465742|NCT02081378|DRUG|Nilotinib|Asciminib and Nilotinib was administered orally in CML patients
223465743|NCT02081378|DRUG|Imatinib|Asciminib and imatinib was administered orally in CML patients
223465744|NCT02081378|DRUG|Dasatinib|Asciminib and dasatinib was administered orally in CML patients
223465745|NCT00000237|DRUG|Buprenorphine|
223577300|NCT01757561|PROCEDURE|propofol|use total intravenous anesthesia with propofol
224158096|NCT02573233|DRUG|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
224158097|NCT02573233|DRUG|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
224158098|NCT02573233|DRUG|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
224158099|NCT06178094|BEHAVIORAL|Video Training|The participants in the Training Group is to sent a total of eight episodes of the Diabetes Training Videos prepare by the researcher, twice a week, through smartphones after the first interview
224158100|NCT05073172|DRUG|Calendula Ointment|Applied topically
224158101|NCT05073172|OTHER|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied topically
224158102|NCT05073172|OTHER|Polyethylene Glycol Hydrogel|Applied topically
224158103|NCT05073172|DRUG|Silicone-based Film Forming Topical Gel|Applied topically
224158104|NCT05073172|DRUG|Silver Sulfadiazine|Applied topically
224158105|NCT05073172|DRUG|Topical Hydrocortisone|Applied topically
224158106|NCT02119468|DRUG|ixazomib citrate|Given orally
224158107|NCT02119468|DRUG|dexamethasone|Given orally
224158108|NCT02119468|DRUG|pomalidomide|Given orally
224158109|NCT03371927|OTHER|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
224158110|NCT01303458|BEHAVIORAL|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
224158111|NCT01570608|DRUG|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
224158112|NCT01570608|DRUG|Verteporfin|Verteporfin photodynamic therapy standard fluence
224158113|NCT00294827|PROCEDURE|Liver transplantation and colo-rectal cancer|Liver transplantation
224158114|NCT04369768|PROCEDURE|restoration of permanent molars affected with MIH|restore MIH affected molars using direct composite or preformed metal crowns
224158115|NCT02568163|OTHER|Non surgical periodontal treatment|
224303426|NCT04040322|DRUG|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
224303427|NCT02195453|DRUG|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
224303428|NCT02195453|DRUG|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
224303429|NCT00466453|BEHAVIORAL|knowledge-adaptive Web-based instruction|
224303430|NCT04145453|BEHAVIORAL|Intervention genotype personalized nutritional recommendations|Participants will receive personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the beginning of study
224303431|NCT04145453|BEHAVIORAL|Control Group 1 personalized nutritional recommendations|Participants will receive genotype personalized nutritional recommendations to increase fruit and vegetables consumption. Information about genotype will be given at the end of study
224303432|NCT04145453|BEHAVIORAL|Control Group 2 general nutritional recommendations|Participants will receive general nutritional recommendations to increase fruit and vegetables consumption
224303433|NCT03417193|DRUG|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
224303434|NCT06314789|DIAGNOSTIC_TEST|doing lung ultrasonography|In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
223465746|NCT02988700|DRUG|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
223465747|NCT02988700|DRUG|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
224303435|NCT06169189|BEHAVIORAL|global warming-climate change based education|The experimental group will be given 8 weeks of global warming-climate change based training. No intervention will be applied to the control group.
223465748|NCT06556719|BEHAVIORAL|Hoosier Sport Re-Social|Hoosier Sport Re-Social is a 6-week school-based intervention designed to reduce cardiovascular disease risk in rural children. It includes twice-weekly physical activity sessions during PE classes and weekly social media literacy training in health classes, promoting healthier physical and digital behaviors.
224158116|NCT01877941|DEVICE|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
224158117|NCT01877941|DEVICE|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
224303436|NCT02331329|DEVICE|NICOM cardiac output measurement|
224303437|NCT02331329|DEVICE|Cardiac MRT cardiac output measurement|
224303438|NCT05898321|DRUG|Zoladex|Patients with fibroid remained will be enrolled and divided into three groups. one group wii be administrated with Zoladex (3.60mg/28 days) for three to six months.
224303439|NCT05898321|DRUG|Mifepristone Oral Tablet|Patients with fibroid remained will be enrolled and divided into three groups. one group will be administrated with mifepristone(10.0mg/d) for three to six months.
224303440|NCT00601874|DRUG|Pilocarpine|
224303441|NCT03801265|PROCEDURE|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
223465749|NCT05750264|DRUG|Ibuprofen|800 mg of IV ibuprofen
223465750|NCT06411821|DRUG|Ulixertinib|300 mg twice daily, for every 28-day cycle.
223465751|NCT06574568|DRUG|YKST02|BCMA-CD3 bispecific antibody
223465752|NCT02943798|DRUG|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
223465753|NCT02943798|DRUG|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
223465754|NCT04443647|DRUG|Oxytocin|Syntocinon nasal spray
223465755|NCT04443647|DRUG|Placebo|Placebo nasal spray
223465756|NCT05456724|DRUG|TO-O-1001|TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye
224158118|NCT01877941|DEVICE|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
224158119|NCT04606641|OTHER|functional tasks with mirror therapy|In this group a mirror will be placed in the sagittal plane of patient. The affected or paretic arm will be placed behind the mirror and the unaffected or normal arm will be placed in front of the mirror. Then the patient will be asked to perform functional tasks
223465757|NCT05456724|OTHER|Placebo|The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
223465758|NCT02529930|BIOLOGICAL|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
223465759|NCT05857410|DRUG|Dexmetomidine|Dexmetomidine (H20183219) 0.4μg / (kg·min)；
223465760|NCT05857410|DEVICE|Lower limb heating blanket|Beijing Maikang Medical Device Co., Ltd., Model: Warm-1-1.
223465761|NCT03314883|DIAGNOSTIC_TEST|D-US ARF|Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
223465762|NCT05970380|OTHER|Erector spinae plane block|Local anesthetic solution (40 mL 0.25% bupivacaine totally) will be given bilaterally between the processus transversalis of the fractured vertebra and the erector spinae muscle under ultrasound imaging by an anesthesiologist.
223465763|NCT05970380|OTHER|Local anesthesia|Local anesthetic solution (20 mL 0.25% bupivacaine) will be given extrapedicular part of the fractured vertebra by the surgeon.
223465764|NCT02300870|DRUG|Optison|Echocardiogram with IV contrast
223465765|NCT00397605|DRUG|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
223465766|NCT00061178|DRUG|rhuMAb VEGF (Bevacizumab)|
223465767|NCT01136252|DRUG|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
223577301|NCT01757561|PROCEDURE|sevoflurane|use inhalation anesthesia with sevoflurane
223577302|NCT01939132|DRUG|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
223577303|NCT06200922|OTHER|Pelvic physiotherapy|All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
223577304|NCT01430507|DRUG|Revamilast|Tablet, Low dose, Once daily for 12 weeks
223577305|NCT01430507|DRUG|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
223577306|NCT01430507|DRUG|Revamilast|Tablet, High dose, Once daily for 12 weeks
223577307|NCT01430507|DRUG|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
223577308|NCT01371643|DRUG|Octreotide LAR|
223577309|NCT01371643|PROCEDURE|transsphenoidal surgery|
223577310|NCT02055261|DEVICE|Low frequency DBS of the pedunculopontine nucleus|
223577311|NCT05245630|PROCEDURE|Robotic arm assisted PET/CT guided biopsy|"After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done."
223465768|NCT06074783|BIOLOGICAL|Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)|50 x 106 allogeneic BM-derived MSCs formulated in 4 ml infusion solution of sodium chloride supplemented with human serum albumin to be given locally under state of the art way of application that is ultrasound guidance which will ensure precise delivery of the BM derived MSCs at the site of injury or degeneration along with or without 100 x 106 allogeneic BM-derived MSCs formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion in approximately 30 min. Systemic treatment alone is used when local injection at site of injury or degeneration is not feasible.
223465769|NCT02105233|BIOLOGICAL|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
223465770|NCT04381078|OTHER|ACE - AudioVisual Guide|Audiovisual guide to Alveolar Bone Graft Procedure, Pre-surgical orthodontics and post-operative care
223465771|NCT00888888|PROCEDURE|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
223465772|NCT01121939|DRUG|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
223577312|NCT05245630|PROCEDURE|PET fused CT-Fluoroscopy guided biopsy|CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
223577313|NCT04920721|OTHER|no intervention|no intervention descriptiv study
223577314|NCT03350893|COMBINATION_PRODUCT|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10\^9 cells/ g-cream)
224158120|NCT04606641|OTHER|functional tasks without mirror therapy|The functional tasks will be explained to patient before the start of treatment. In this group a board instead of a mirror will be placed in the sagittal plane of patient. Then the patient will be asked to perform functional tasks
224158121|NCT01205919|BEHAVIORAL|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
224158122|NCT01205919|OTHER|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
223465773|NCT01121939|DRUG|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
223465774|NCT01121939|DRUG|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
223465775|NCT00477802|BIOLOGICAL|Botulinum Toxin Type A|Injected once during the course of the study.
223465776|NCT00477802|BIOLOGICAL|Placebo|Injected once during the course of the study.
223465777|NCT05438238|DEVICE|Oncomfort|Virtual Reality
223465778|NCT00908414|DRUG|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
223465779|NCT00908414|DRUG|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
223465780|NCT00908414|DRUG|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
223465781|NCT00908414|DRUG|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
223465782|NCT00908414|DRUG|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
223465783|NCT00908414|DRUG|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
223465784|NCT00908414|DRUG|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
223465785|NCT00908414|DRUG|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
223577315|NCT03350893|OTHER|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
223577316|NCT01567202|PROCEDURE|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
223465786|NCT00908414|DRUG|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
223465787|NCT00908414|DRUG|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
223465788|NCT00908414|DRUG|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
223465789|NCT00908414|DRUG|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
223465790|NCT00908414|DRUG|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
223465791|NCT00908414|DRUG|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
223465792|NCT00908414|DRUG|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
223465793|NCT00908414|DRUG|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
223577317|NCT01567202|DRUG|Chemotherapy|Temozolomide(TMZ), 200mg·m\^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
223577318|NCT01567202|RADIATION|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
223465794|NCT00908414|DRUG|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
223465795|NCT00992017|BIOLOGICAL|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
223465796|NCT03256019|PROCEDURE|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
223465797|NCT02864407|DRUG|Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)|The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
223465798|NCT05780138|BEHAVIORAL|Parents Taking Action|Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
223465799|NCT03625596|DIETARY_SUPPLEMENT|L-Arginine|Acute intervention (3 hours)
223465800|NCT03625596|DIETARY_SUPPLEMENT|Nitrate / Nitrite|Acute intervention (3 hours)
223465801|NCT03625596|DIETARY_SUPPLEMENT|Placebo|Acute intervention (3 hours)
223465802|NCT02992119|BIOLOGICAL|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
223465803|NCT02992119|BIOLOGICAL|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
223465804|NCT02992119|BIOLOGICAL|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
223465805|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
223465806|NCT02992119|BIOLOGICAL|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
223577319|NCT01567202|BIOLOGICAL|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
223577320|NCT01567202|DRUG|blank placebo|Saline that has the same appearance with DC vaccine.
223577321|NCT00135928|DRUG|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
223577322|NCT03249935|DRUG|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
223577323|NCT02727556|BEHAVIORAL|visual images|
223577324|NCT02165956|DIETARY_SUPPLEMENT|New Infant Cereal|New Infant Cereal
223465807|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
223465808|NCT02992119|BIOLOGICAL|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
223465809|NCT02701725|DEVICE|CRI status|Measurement of CRI
223465810|NCT02811315|OTHER|Observational. Non interventional study|Observational. Non interventional study
223465811|NCT04226781|DIAGNOSTIC_TEST|Hyperspectral-Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
223465812|NCT04226781|DIAGNOSTIC_TEST|Indocyaningreen-Fluorescence imaging|Photos were taken with the Fluorescence camera after injection of the indocyaningreen-dye of the gastrointestinal anastomosis
223465813|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal brushing|Gastric mucosal brushing will be performed at body of stomach in control group and non-tumorous area of body in gastric cancer group. If gastric body area could not feasible (eg. tumor involvement), then gastric antrum and more proximal part of body will be sampling.
223465814|NCT06325891|DIAGNOSTIC_TEST|Gastric mucosal biopsy|Gastric mucosal biopsy will be performed at the area within 2 cm. from brushing site.
223465815|NCT02788643|BIOLOGICAL|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
224158123|NCT04690712|BEHAVIORAL|Health Education|"All students who attended the school were provided training by the researchers to improve oral and dental health and general hygiene. These trainings were made using slide shows and various entertaining materials. In addition, education was transformed into a drama with a theater show, and the importance of hand washing, hair and toilet hygiene was explained.~In addition to hygiene, students were given training on correct eating patterns for a day so that they could develop healthy."
223465816|NCT03002636|PROCEDURE|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
223465817|NCT04577794|DRUG|GLPG3970|GLPG3970 powder and solvent for oral solution reconstituted prior to use.
223577325|NCT02165956|DIETARY_SUPPLEMENT|Standard Infant Cereal|Standard Infant Cereal
223465818|NCT04577794|DRUG|Placebo|Placebo powder and solvent for oral solution reconstituted prior to use.
223465819|NCT05460299|COMBINATION_PRODUCT|Telko plus conventional physical therapy (CPT)|All patients underwent about 15-minute CPT sessions 3 days a week for 4 weeks. The CPT intervention program consisted of closed kinetic chain exercises (squatting, hip bridge, lunge, and toe standing), 3 sets, 10 repetitions each and gait training (walking forward, backward, sidewalk, and between obstacles). Short breaks (1-5 minutes) were provided, depending on the patient tolerance. Before treatment, the skilled physical therapist was instructed about the duration, frequency, and content of therapy. The patients in the experimental group received additional lower extremities closed kinetic chain training using the Telko device. The participants train on Telko for 15 minutes using moderate resistance, 3 days a week for 4 weeks.
223465820|NCT06484283|OTHER|Meditation|Guided meditation will be applied within the scope of the study. A guided meditation video prepared by a Yoga Alliance-certified researcher will be used for this intervention. Guided meditation aims to ensure being in the moment (here and now) with the help of breathing. Meditation practice will take participants 10 minutes.
223465821|NCT04659148|PROCEDURE|Total proctocolectomy|Total proctocolectomy: surgical removal of the colon, rectum, and anus
223465822|NCT01858038|DEVICE|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
223465823|NCT00002029|DRUG|Fat Emulsion 2%|
223465824|NCT00002029|DRUG|Fat Emulsion 20%|
223465825|NCT00109746|DIETARY_SUPPLEMENT|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
223465826|NCT05217602|BEHAVIORAL|AC+ARwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+ARwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+ARwdC group will be offered incentives for using their anchoring plan during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
224158124|NCT03608046|DRUG|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
224158125|NCT03608046|DRUG|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
224158126|NCT03608046|DRUG|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
224158127|NCT00789646|PROCEDURE|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
224158128|NCT00789646|PROCEDURE|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
224158129|NCT00204412|DIETARY_SUPPLEMENT|Flax lignan|543 mg SDG per day
224158130|NCT00204412|BEHAVIORAL|Exercise (walking)|walking 45 minutes per day 5 days per week
224158131|NCT04117412|OTHER|Exercise|Same participants will undergo different one bout of exercise protocols
224158132|NCT05534152|OTHER|sumac|1% iranian brown sumac
224158133|NCT03471104|OTHER|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
224158134|NCT01469091|BEHAVIORAL|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
223465827|NCT05217602|BEHAVIORAL|AC+RwdC|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the AC+RwdC group will watch a video with information about the study, conditional rewards, and how to create an anchoring plan for their meditation habit. Weekly text message reminders will be sent during the intervention period to reinforce use of the anchoring plan. Participants in the AC+RwdC group will be offered incentives for meditating during the intervention period and for completing the baseline, post-intervention, and follow-up surveys.
223465828|NCT05217602|BEHAVIORAL|Usual Calm Control (UC)|The Calm app is downloadable by participants onto their smartphone to access meditations and other Calm app features during the intervention period. Participants in the UC group will watch a video with information about the study and how to create an anchoring plan for their meditation habit. Participants in the UC group will be offered incentives for completing the baseline, post-intervention, and follow-up surveys.
223465829|NCT02849080|DRUG|semaglutide|Oral administration once-daily.
223465830|NCT02849080|DRUG|sitagliptin|Oral administration once-daily.
223465831|NCT00263198|DRUG|PTK787/ZK222584|
223465832|NCT00263198|DRUG|Letrozole|
223465833|NCT04288934|BIOLOGICAL|Collection and expansion of BM-MSC|MSCs collection from patients owns marrow using a volume of 20 ml of bone marrow obtained from iliac crest of SCI patients under local anesthesia. Manipulations of blood and bone marrow are to be done according to Good Laboratory Practice (GLP) using the gradient sedimentation method.
223577326|NCT04075422|DRUG|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
223577327|NCT03593681|DEVICE|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
223577328|NCT04785625|COMBINATION_PRODUCT|Bupivacaine Hydrochloride|INL-001 (bupivacaine hydrochloride) implant
223577329|NCT04785625|COMBINATION_PRODUCT|Placebo collagen-matrix implant|Placebo collagen-matrix implant
223577330|NCT05140837|DIAGNOSTIC_TEST|Psychometric hepatic encephalopathy score & Stroop test|MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.
223577331|NCT05140837|DRUG|Drug therapy|Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.
223577332|NCT01229943|BIOLOGICAL|Bevacizumab|Given IV
224158135|NCT05850013|DEVICE|Lifelight Junior|Lifelight® is an app developed by xim that measures VS including heart rate, respiratory rate and blood pressure. All you need to do to have these vital signs measured is look at your smartphone or tablet camera for 20-40 seconds. The app has used data from over 1 million heartbeats to learn how to measure these vital signs in adults. The technology is already available for doctors and nurses to use with adult patients in some specific scenarios
223465834|NCT04288934|DIAGNOSTIC_TEST|VI-SCI evaluation and patients' follow up|"* At 6, and 12 months post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline.~* The (ASIA)/(ISNCSCI) score will be repeated every 3 months to evaluate any motor or neurological changes~* The Spinal Cord Independence Measure (SCIM III) score will be repeated every 3 months to evaluate the effect on daily activities.~* Blood samples will be withdrawn from patients at 3 months interval for biomarkers detection."
223465835|NCT01819727|DRUG|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
223465836|NCT00713271|DRUG|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
223577333|NCT01229943|DRUG|Everolimus|Given PO
223465837|NCT00713271|DRUG|Placebo|
223577334|NCT01229943|DRUG|Octreotide Acetate|Given IM
223577335|NCT02170363|DEVICE|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
223577336|NCT02781025|OTHER|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
223577337|NCT04553653|OTHER|checklist|The checklist will be implemented and healthcare providers use the checklist to manage the patients.
224158136|NCT01210755|DRUG|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
223465838|NCT00713271|DRUG|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
223577338|NCT02261129|DRUG|Telmisartan film-coated tablet|
223577339|NCT02261129|DRUG|Telmisartan uncoated tablet|
223577340|NCT03987932|BEHAVIORAL|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
224158137|NCT01210755|DRUG|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
224158138|NCT00346255|DRUG|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
223465839|NCT00713271|DRUG|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
223465840|NCT06197308|DRUG|oral vancomycin and oral amoxicillin|In this study, PSC patients will receive an antibiotic preconditioning regimen of oral vancomycin (500 mg liquid twice a day) for 28 days and oral amoxicillin (1000 mg twice a day) for 7 days (during the last 7 days of the oral vancomycin). Following vancomycin and amoxicillin, encapsulated, freeze-dried microbiota preparation (MTP-101C) will be administered - dosed at ≥ 5 x 10\^11 bacteria (five capsules) daily for 3 days followed by ≥ 2 x 10\^11 bacteria (two capsules) for 11 days - for a total of 14 days of MTP-101C; total of 37 capsules.
223465841|NCT03050827|DRUG|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
223465842|NCT03050827|DRUG|Placebo|Non-active placebo for 3% oxybutynin
223465843|NCT04449289|DRUG|Intravenous lidocaine|Intraoperatively and postoperatively a standard intravenous infusion of lidocaine will be used for analgesia
223465844|NCT04449289|DRUG|Epidural ropivacaine|Intraoperatively and postoperatively an epidural infusion of ropivacaine will be used for analgesia
223465845|NCT00952315|DEVICE|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
223465846|NCT00952315|DEVICE|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
223465847|NCT00952315|DEVICE|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
223465848|NCT04224025|OTHER|exercise and respiratory therapy|three weeks in-Hospital exercise Rehabilitation program with continuation at home (total 15 weeks).
223465849|NCT03163407|DRUG|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
223465850|NCT03163407|DRUG|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
223465851|NCT05251272|DIAGNOSTIC_TEST|Hepatic venous pressure gradient|All patients underwent measurement of HVPG under local anesthesia.
223577341|NCT03987932|BEHAVIORAL|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
223465852|NCT00018642|DRUG|quetiapine|
223465853|NCT00018642|DRUG|haloperidol decanoate|
223465854|NCT04148547|DEVICE|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
223465855|NCT04148547|DEVICE|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
223465856|NCT05930314|DRUG|CNCT19 cell injection|"Leukapheresis and manufacturing of CNCT19: enrolled subjects will undergo a leukapheresis to target a yield of \> 1x 10\^9 mononuclear cells~* Lymphodepleting chemotherapy i. Fludarabine 25 to 30 mg/m2, once daily for 3 days ii. Cyclophosphamide 500 mg/m2, once daily for 3 days~* CNCT19 administration i. 0.25 to 0.5 x 10\^8 CAR-positive viable T cells"
223465857|NCT05062746|OTHER|Matrix-Rhythm Therapy|One session Matrix-Rhythm Therapy will be applied to affected body parts.
223465858|NCT05062746|OTHER|Conventional physiotherapy and rehabilitation|Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
223465859|NCT00404209|PROCEDURE|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
223465860|NCT03839394|BEHAVIORAL|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
223465861|NCT03839394|OTHER|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
223465862|NCT03248648|DRUG|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
223465863|NCT03248648|DRUG|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
223465864|NCT00338403|PROCEDURE|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
223465865|NCT01976481|DEVICE|sunbed exposure|exposure to sunbed ultraviolet radiation
223465866|NCT04039724|DRUG|HCP0605 + HGP0816|
223465867|NCT04039724|DRUG|HCP1305|
223465868|NCT04201236|OTHER|respiratory muscle strengthening exercise|These exercises strengthen locally inspiratory muscles. IMT can be done with threshold loaded devices.
223465869|NCT04201236|OTHER|oropharyngeal muscles strengthening exercise|These exercises strengthen locally oropharyngeal muscles. Oropharyngeal exercise can be done with some facial movements .
223465870|NCT02258594|OTHER|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
223577342|NCT03987932|BEHAVIORAL|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
223465871|NCT02258594|BEHAVIORAL|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
223465872|NCT02426034|DRUG|ApatinibTablets|Apatinib Tablets, recommended dose of 850mg
223465873|NCT03176719|OTHER|Venipuncture|"1. Full blood count and leukocyte differentiation.~2. Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~3. Detection of anemia, thallasemia and sickle cell anemia (XN-20)~4. Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~5. Circulating cytokines and inflammatory markers (ELIZA)~6. DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~7. pan-Salmonella PCR~8. Gametocyte PCR"
223577343|NCT04864132|DIAGNOSTIC_TEST|6-minute walk test|This test assesses submaximal exercise capacity.
223465874|NCT00060606|PROCEDURE|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
223465875|NCT00060606|PROCEDURE|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
223465876|NCT06612801|BEHAVIORAL|The REThink Game|REThink is an online therapeutic game designed to improve the emotional well-being of young people, based on the principles of Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who leads players through seven levels, each dedicated to teaching a particular emotional regulation skill. Each level consists of three sub-levels that gradually become more challenging. REThink can be utilized as a standalone intervention, as a complement to self-help psychotherapeutic methods, or for focused skills training in emotional regulation. Each level trains a specific emoion-regulation skills such as emotion recognition, relaxation, cognitive change, problem solving, compassion and self-compassion.
223465877|NCT06612775|DRUG|Test drug CB03-154 5mg group|CB03-154 tablet (5mg/tablet) once daily.
223577344|NCT04864132|DIAGNOSTIC_TEST|Incremental shuttle walk test|This test assesses maximal exercise capacity.
223577345|NCT02545114|DRUG|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
223577346|NCT01669421|DRUG|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
223577347|NCT00320749|DRUG|Capecitabine|Will be give on days 8-21
224158139|NCT05222295|OTHER|Supervised Pulmonary Telerehabilitation|For pulmonary rehabilitation to be applied in the simultaneous telerehabilitation method, digital blood pressure measurement device, digital finger pulse oximeter device will be given to severe COPD patients for safe exercise and they will be informed about confidence intervals and how to use saturation and heart rate monitors. The relevant program and points to be considered will be delivered to the patients in the form of an online PDF brochure.
223465878|NCT06612775|DRUG|Test drug CB03-154 10mg group|Two CB03-154 tablets (5mg/tablet) once daily.
223465879|NCT06612775|DRUG|Test drug CB03-154 20mg group|Four CB03-154 tablets (5mg/tablet) once daily.
223465880|NCT06612775|DRUG|Placebo group|Four Placebo tablets once daily.
223465881|NCT04853043|DRUG|Cetuximab|Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
223465882|NCT00273598|PROCEDURE|Moss Miami Spine Instrumentation System|
223465883|NCT00273598|PROCEDURE|Universal Spine Instrumentation System|
223577348|NCT00320749|DRUG|Docetaxel|Will be given on days 1 and 8,
223577349|NCT00320749|DRUG|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
224158140|NCT05222295|OTHER|Cognitive Telerehabilitation|These patients will be asked to do a standardized pulmonary telerehabilitation program three times a week for 8 weeks by watching videos consisting of commands and exercise videos transmitted to them, some of them by actively doing, imagining.
224158141|NCT01566591|DEVICE|Deep TMS Treatment|24 TMS treatments over 6 weeks .
223465884|NCT07069348|OTHER|No intervention|There is no treatment or intervention administered to the patients
223465885|NCT07073027|OTHER|2D video on smartphone|2D video with audio viewed on smartphone
223577350|NCT01384500|OTHER|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
223577351|NCT00004729|BEHAVIORAL|Ketogenic diet|
223577352|NCT04197063|BEHAVIORAL|Sweetened beverage portion size limit|
223577353|NCT03095586|OTHER|News items with spin|Interpretation of news items with spin
223577354|NCT03095586|OTHER|News items without spin|Interpretation of news items without spin
223577355|NCT00145353|DRUG|Insulin NovoRapid versus Actrapid|
223577356|NCT03198455|DIETARY_SUPPLEMENT|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
223577357|NCT03198455|OTHER|Placebo|Drinking water with food coloring and salt
223577358|NCT02009293|OTHER|Cough monitor|questionnaires about cough and quality of life
223577359|NCT05553977|DRUG|Bowel preparation for colonoscopy|one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
223577360|NCT05553977|PROCEDURE|Colonoscopy|Colonoscopy will be performed to every patient included in the study
223577361|NCT02387125|BIOLOGICAL|CMB305|
223577362|NCT02387125|BIOLOGICAL|G100|
223577363|NCT02387125|DRUG|Metronomic CPA|
223465886|NCT07073027|OTHER|360 video on smartphone|360 video with audio viewed on smartphone (not in virtual reality)
223465887|NCT07073027|OTHER|360 video on smartphone inserted into VR cardboard headset|360 video with audio in virtual reality
223465888|NCT07072507|BEHAVIORAL|Chilbirth Education|Participants divided into training groups will receive training on pregnancy, birth, breastfeeding, preparation for parenthood, and baby care in groups of 6-8 people, 2 hours a week for five weeks.
223465889|NCT03101150|DRUG|400 IU Vitamin D3|Antenatal multivitamin
223465890|NCT03101150|DRUG|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
223465891|NCT04355364|DRUG|Dornase Alfa Inhalation Solution [Pulmozyme]|Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
223465892|NCT04355364|PROCEDURE|standard procedure|Patients will receive the usual care in accordance with good practice.
223465893|NCT00059553|BEHAVIORAL|Locomotor treadmill training with body weight support|
223465894|NCT03627325|OTHER|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
223465895|NCT03323593|DRUG|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
223577364|NCT03423108|BEHAVIORAL|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
223577365|NCT03423108|BEHAVIORAL|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
224158142|NCT01566591|DEVICE|Sham Treatment|24 TMS treatments over 6 weeks
224158143|NCT02685111|DRUG|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
224158144|NCT02685111|DRUG|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
224158145|NCT03027193|BIOLOGICAL|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
224158146|NCT03027193|BIOLOGICAL|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
223465896|NCT03167203|BIOLOGICAL|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
223465897|NCT02564367|DRUG|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks"
223465898|NCT00004558|BEHAVIORAL|dietary n-3 polyunsaturated fatty acids|
223465899|NCT02365662|DRUG|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
223465900|NCT00611806|DIETARY_SUPPLEMENT|Folic Acid|Folic acid 2mg po daily
223465901|NCT00611806|DIETARY_SUPPLEMENT|B12|B12 400 micrograms po daily
223465902|NCT00611806|OTHER|Placebo|1 capsule po daily
223465903|NCT00199953|DRUG|Rabeprazole 20 mg twice a day for 90-day period treatment|
223465904|NCT01356095|OTHER|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
223465905|NCT01356095|OTHER|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
223465906|NCT04603352|OTHER|Hip Helpers home program|Home program: Infants will wear Hip Helpers 30 minutes, twice per day.
223465907|NCT06241118|DRUG|Amlitelimab|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223465908|NCT06241118|DRUG|Placebo|Pharmaceutical form: Injection solution Route of administration: Subcutaneous
223465909|NCT06241118|DRUG|Topical corticosteroids|Pharmaceutical form: Various Topical formulation Route of administration: Topical
224158147|NCT02841592|OTHER|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
223465910|NCT06241118|DRUG|Topical tacrolimus or pimecrolimus|Pharmaceutical form: Various Topical formulation Route of administration: Topical
223465911|NCT03629288|OTHER|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
223465912|NCT03629288|DRUG|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
224158148|NCT02841592|OTHER|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
224158149|NCT04322162|OTHER|ASAP Intervention Quality Improvement Protocol|The intervention program includes: (1) a systems redesign Virtual Collaborative, and; (2) data monitoring and is designed to aid each of the 6 participating VAMCs in developing, implementing, and evaluating the implementation of an acute OSA testing and treatment protocol for ischemic stroke/TIA patients. The sites will choose a diagnostic strategy (i.e., unattended polysomnography \[PSG\]/home sleep test \[HST\], in-laboratory PSG, direct to auto-titrating \[auto\]-PAP) and a therapeutic strategy (i.e., in-laboratory PAP titration, auto-PAP). The intervention will employ 3 implementation strategies: (1) local adaptation; (2) external facilitation, and; (3) audit and feedback.
224158150|NCT00088972|DRUG|celecoxib|Given orally
224158151|NCT00088972|OTHER|placebo|Given orally
223465913|NCT04802434|BEHAVIORAL|Strengthening Skills Program|The Strengthening Skills Program is a new, multi-component intervention. It includes three components: (1) Forming habits to compensate for the difficulties many adults with ASD have with thinking flexibly, planning, and time management. It will emphasize habit-forming behaviors to compensate for weaknesses in functional skills by training on practical techniques; (2) Content from the PEERS Social Skills program to target social challenges, and (3) strategies derived from Mindfulness Based Stress Reduction to target emotion regulation.
223465914|NCT04802434|BEHAVIORAL|PEERS Social Skills Program|PEERS® is a well-established social communication training program, initially developed for adolescents, and more recently extended to young adults with ASD. Program content will be adapted slightly so as to be appropriate for older adults.
223465915|NCT05509400|DRUG|Rimegepant|DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
223465916|NCT05509400|DRUG|Placebo|DB Phase: matching placebo
223465917|NCT05509400|DRUG|Rimegepant|OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
223577366|NCT01228604|DRUG|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
223577367|NCT05761678|OTHER|Questionnaire quality of life|"Quantitative - Validated online self-questionnaires scientifically to assess quality of life and support perceived social. Items created for the study concerning socio-demographic characteristics and satisfaction of health services concerning the accompaniment of the transidentity.~Qualitative - Semi-structured interviews based on a guide maintenance."
223577368|NCT03488888|DRUG|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
223577369|NCT03488888|DRUG|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
223577370|NCT01658137|OTHER|Prudent Diet|This intervention lasts 2 weeks (14 days).
223577371|NCT01658137|OTHER|Typical Western Diet|This intervention lasts 2 weeks (14 days).
223577372|NCT03818347|DEVICE|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
223577373|NCT03818347|DEVICE|analogue machine|This machine has the same apperance and gas condition
224158152|NCT04401904|DRUG|Dapagliflozin 10 mg|10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
224158153|NCT04401904|BEHAVIORAL|Nutritional counseling|10 participants randomized to receive 12 weeks of weekly counseling on nutrition
224158154|NCT04902768|OTHER|This is an observational study, there is no intervention|This is an observational study, there is no intervention. Hence, this is not applicable.
224158155|NCT04381572|BEHAVIORAL|High fidelity simulation training|At the beginning of scheduled classes in the simulation center, students were placed sitting at rest for 30 min. In each team a leader was chosen. Other team members were also assigned detailed functions. Before starting the scenario, participants were oriented for 10 -15 minutes by a physician instructor about the simulation room setup and manikin features. The simulated scenarios were performed using a high fidelity computer-based manikin simulator, with the possibility of remote control of vital signs. All medications and equipment required during the clinical scenarios were available. The scenario used was prepared and validated by experienced simulation instructors. All student groups were given the same standardized scenario.
224158156|NCT02668744|BEHAVIORAL|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
224158157|NCT02811796|OTHER|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
224158158|NCT02452710|OTHER|Placebo|Open-label placebo
224158159|NCT02023112|DRUG|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
223465918|NCT00431093|DRUG|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
223577374|NCT04333953|OTHER|No intervention|No intervention, observational study
223577375|NCT00712569|BEHAVIORAL|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
223743574|NCT07087912|BIOLOGICAL|Dengue 1,2,3,4 (attenuated) vaccine|A single 0.5 mL dose of the live attenuated tetravalent dengue vaccine (Butantan-DV), administered subcutaneously on Day 1. The vaccine contains attenuated viral strains for DENV-1, DENV-3, DENV-4, and a chimeric DENV-2 component. It is manufactured and formulated by the Instituto Butantan (São Paulo, Brazil).
224158160|NCT02023112|DRUG|Ribavirin|Capsule
224158161|NCT01989819|OTHER|skin biopsy|
224158162|NCT00193349|DRUG|Imatinib|
224158163|NCT00193349|DRUG|Irinotecan|
224158164|NCT00193349|DRUG|Carboplatin|
224158165|NCT02639403|RADIATION|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
224158166|NCT03148964|BIOLOGICAL|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
224158167|NCT00050479|DRUG|Celecoxib (Celebrex)|
224158168|NCT05371938|PROCEDURE|Volar locking plate|Volar locking plate is the intervention
223465919|NCT00431093|DRUG|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
223465920|NCT05042817|DRUG|100 mcg morphine|The effect of intrathecal morphine on vesical function and the need for bladder re-catheterization after a cesarean delivery
223465921|NCT05042817|DRUG|0.9% NaCl|NaCl 0.9%
223465922|NCT05042817|DRUG|50 mg prilocaine + 2.5 mcg sufentanil|50 mg prilocaine + 2.5 mcg sufentanil
223465923|NCT05042817|PROCEDURE|bilateral transverse abdominal plane block|20 mL of ropicavaine 0.375% on each side
223465924|NCT02490774|DRUG|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
223465925|NCT02490774|DRUG|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
223465926|NCT02490774|DRUG|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
223465927|NCT00090896|BIOLOGICAL|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
223465928|NCT00715559|DRUG|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
223465929|NCT02676557|DEVICE|Exposed to the high pressure during the surgery|
223465930|NCT00305669|BIOLOGICAL|sargramostim|
223465931|NCT00305669|OTHER|immunohistochemistry staining method|
223465932|NCT00305669|OTHER|immunological diagnostic method|
223465933|NCT00305669|OTHER|laboratory biomarker analysis|
223465934|NCT00305669|PROCEDURE|conventional surgery|
223465935|NCT00305669|PROCEDURE|neoadjuvant therapy|
223465936|NCT02402946|BEHAVIORAL|Biofeedback|
223465937|NCT02402946|DRUG|Placebo|
223465938|NCT01505777|DRUG|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
223465939|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
223465940|NCT01505777|DRUG|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
223465941|NCT01505777|DRUG|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
223465942|NCT01505777|DRUG|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
223465943|NCT05555498|DEVICE|Virtual Reality glasses|The intervention used are Virtual Reality glasses. The VR-glasses used are designed by SyncVR medical (Utrecht, the Netherlands), and are applicable specifically for medical use. By distracting the patients' cognition from the procedure, using images and sounds, the patient hopefully experiences less pain and anxiety. Women can choose between relaxation excersises and nature films
223465944|NCT03008811|PROCEDURE|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
223465945|NCT03008811|PROCEDURE|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
223465946|NCT03756948|OTHER|Usual Care|Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
223465947|NCT03756948|OTHER|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates|Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
223577376|NCT00712569|BEHAVIORAL|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
223465948|NCT04882696|OTHER|Non-slip socks|Patients will wear non-slip socks during their hospitalization
223465949|NCT03732027|PROCEDURE|Surgical Transversus Abdominis Plane Block|At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
223465950|NCT03732027|PROCEDURE|Surgical Rectus Sheath Block|At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
223743575|NCT01446133|DRUG|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
223465951|NCT03799614|DEVICE|RMBand lower dose|Light-weight portable device that delivers low dose vibration to the arm
223465952|NCT03799614|DEVICE|RMBand higher dose|Light-weight portable device that delivers higher dose vibration to the arm
223465953|NCT02063672|DEVICE|Lutonix DCB|
223465954|NCT02063672|DEVICE|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
223465955|NCT04790695|DRUG|Seribantumab|For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
223465956|NCT02112942|DRUG|IDX21459|
223465957|NCT02112942|DRUG|Matching Placebo|
223465958|NCT05971771|OTHER|Placebo|Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed
223465959|NCT05971771|DIETARY_SUPPLEMENT|Treatment|14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed
223465960|NCT02498678|PROCEDURE|Tetanus|tetanic electric stimulation
223465961|NCT03610893|DRUG|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
223465962|NCT03610893|DRUG|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
223465963|NCT02850094|BEHAVIORAL|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
223465964|NCT00122434|DRUG|BEA 2180 BR|
223465965|NCT00122434|DRUG|tiotropium|
223465966|NCT03819517|DRUG|Resveratrol|Over the counter supplementation
223465967|NCT03819517|OTHER|Placebo|Empty white colored soft vegetarian capsule
223465968|NCT02754232|OTHER|Telemedical training|Intervention will involve resistance training and anaerobic training
223465969|NCT02507570|DRUG|Enzalutamide|used concomitantly
223465970|NCT02507570|RADIATION|Radium ra 223 dichloride|
223743576|NCT01446133|DRUG|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
223743577|NCT07092514|DRUG|Lenvatinib|Lenvatinib is an oral drug which will be administered on an outpatient basis at a dose of 24 mg daily or 10 mg daily for an unlimited number of cycles.
223743578|NCT05427318|BEHAVIORAL|PATH|The intervention integrates two theoretically-grounded interventions - one with a strong peer navigator component and the other with a scalable mHealth component - into the intervention called Peers plus mobile App for Treatment in HIV (PATH)
224158169|NCT05371938|PROCEDURE|external fixation|surgery with external fixation
224158170|NCT00214487|DEVICE|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
224158171|NCT00214487|DEVICE|Placebo Control|Single vision soft contact lenses
223465971|NCT06958913|DRUG|Propofol group|In group P, 0.125 cc/kg saline infusion was administered in 10 minutes. Fentanyl was administered at a dose of 3 mcg/kg at 5 minutes of this application. Then propofol was administered until the eyelash reflex disappeared and the BIS value was 40. 0.6 mg/kg rocuronium was administered to facilitate intubation. All patients received 8 mg dexamethasone and lidocaine at a dose of 1 mg/kg.
223465972|NCT06958913|DRUG|Dexmedetomidine|In group DP, dexmedetomidine at a dose of 0.5 mck/kg was administered over 10 minutes. At the 5th minute of this infusion, fentanyl was administered at a dose of 3 mcg/kg. Propofol was added until the BIS value was 40. The patients received 0.6 mg/kg rocuronium, 8 mg dexamethasone, and 1 mg/kg lidocaine.
224158172|NCT03147599|DRUG|Coloverin|Mebeverine hydrochloride 135 mg
223465973|NCT03208816|BEHAVIORAL|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
223465974|NCT06159504|DRUG|sofosbuvir/velpatasvir (SOF/VEL)|400mg of SOF and 100mg of VEL self administered daily as a tablet.
223465975|NCT06159504|DIAGNOSTIC_TEST|Shortened read time of rapid diagnostic test for hepatitis C virus.|Administered once during hepatitis C testing. Test is read after 5 minutes rather than its usual time of 20 minutes.
223465976|NCT00215917|DRUG|D-serine 2100 mg daily|
223465977|NCT01166256|DEVICE|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 \>92% or PaO2 \>65 mmHg.
223465978|NCT01166256|DEVICE|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 \>92% or PaO2 \>65 mmHg.
223465979|NCT00453375|DRUG|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
223465980|NCT00453375|DRUG|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
223465981|NCT03414853|DIAGNOSTIC_TEST|Free text prediction algorithm for appendicitis|A free-text prediction software that predicts the probability of acute appendicitis
223465982|NCT02584283|PROCEDURE|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
223465983|NCT02584283|DEVICE|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
223465984|NCT02584283|PROCEDURE|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
223743579|NCT07095738|DIAGNOSTIC_TEST|thermal images (IT)|The IT images were recorded with an OPTRIS PI 450 IRT camera coupled to Optris PI Connect Software (Germany). The IRT camera has a Noise Equivalent Temperature Difference \<40 mK with 38º x 29º FOV, a wide range of temperature from -20°C to +100°C, spectrum range of 7.5-13 μm, focal plane array sensor size of 382 × 288 pixels, emissivity set at 0.98 and a measurement uncertainty of ± 2% of the overall temperature reading. The size of the capture frame will be 55.4 × 40.63 cm (1.5 mm/px).
224158173|NCT03147599|DRUG|Placebo|Placebo
224158174|NCT02898142|OTHER|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
224158175|NCT05188599|DIAGNOSTIC_TEST|İsokinetic assessment|Isokinetic assessments of hip flexor and extensor muscle strength and proprioception wiill be performed
224158176|NCT01646853|RADIATION|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
224158177|NCT01646853|DRUG|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
224158178|NCT00773851|PROCEDURE|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
224158179|NCT00773851|PROCEDURE|mesh fixation by staples|mesh fixation by staples
224158180|NCT00101153|DRUG|cytarabine|
224158181|NCT00101153|DRUG|daunorubicin hydrochloride|
224158182|NCT00101153|DRUG|tipifarnib|
223465985|NCT02584283|DRUG|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
223465986|NCT05648799|DRUG|GP30341 capsules 200 mg|orall take of capsules twice a day
223465987|NCT05648799|DRUG|Standard therapy|Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
223465988|NCT04073719|DIETARY_SUPPLEMENT|Apple Cider Vinegar|Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
223465989|NCT04073719|DIETARY_SUPPLEMENT|Other Beverage|To what degree do other high citrate beverages impact urinary citrate output.
223577377|NCT00712569|BEHAVIORAL|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
223577378|NCT04405544|DIAGNOSTIC_TEST|CT-scan|chest CT-scan
223577379|NCT04405544|DIAGNOSTIC_TEST|EEG|Electroencephalography
223577380|NCT04405544|DIAGNOSTIC_TEST|EP|Evoked potential
223577381|NCT04405544|DIAGNOSTIC_TEST|Pulse oximetry|Pulse oximetry
223577382|NCT04405544|DIAGNOSTIC_TEST|Blood tests|Blood tests
223577383|NCT01920763|OTHER|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
223577384|NCT00307567|BIOLOGICAL|Pneumococcal (vaccine)|
223577385|NCT00810901|BEHAVIORAL|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
223577386|NCT00810901|BEHAVIORAL|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
223577387|NCT00388284|DEVICE|Arterial Sealing|
223577388|NCT06446908|BEHAVIORAL|Telehealth coaching for liver disease|"This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor."
223577389|NCT01437176|DEVICE|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
223743580|NCT04244864|BEHAVIORAL|Cross-sectoral psychosocial intervention|The intervention seeks to integrate working with social stressors alongside treatment for trauma-related mental health problems. This is done in two ways; by a cross-sectoral collaboration with the patient's case counsellor in the municipality including three collaborative meetings and by a systematic focus on social stressors during the treatment.
223465990|NCT02130999|DRUG|tasimelteon 20 mg capsule|
223465991|NCT02130999|DRUG|tasimelteon 2 mg I.V.|
224158183|NCT00649051|DRUG|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
224158184|NCT00649051|DRUG|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
224158185|NCT03114098|OTHER|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
224158186|NCT03536923|DEVICE|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
224158187|NCT01606397|DRUG|Placebo|Administered orally (capsule)
223465992|NCT00697320|DRUG|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
223577390|NCT01437176|DEVICE|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
223577391|NCT03050762|OTHER|Data Collection|Participant information collected from either source document or direct participant response.
223577392|NCT03050762|BEHAVIORAL|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
223577393|NCT04612543|DEVICE|Genial Posterior Composite with Polyethylene Fiber|Placing restorations,Genial Posterior Composite with Polyethylene Fiber, after bonding procedures, remaining tooth composite resin walls were created and cured for 20 s. Prepared ribbond fiber pieces, 2-mm-wide approximately 12mm-long, (Ribbond Thinner, Higher, Modulus, Ribbond Inc,Seattle) were wetted with an unfilled resin for 2 minutes at a non-light environment. The inner surfaces of the prepared class I cavity were lined with flowable resin. After removing the excess resin, pre-wetted polyethylene fiber was condensed circumferentially and embedded with a hand instrument into the bed of unpolymerized flowable composite and then polymerized for 20 seconds with Light Emitting Diodes. After curing for 20 s, composite resin was applied to the rest of the cavity incrementally, each increment was cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
223577394|NCT04612543|DEVICE|Genial Posterior Composite|Placing Genial Posterior Composite, the enamel and dentin were conditioned with bonding procedure using an applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Genial Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments
223577395|NCT04352257|RADIATION|pelvic Ultrasound|pelvic and transrectal ultrasound
223577396|NCT00018382|DRUG|rosiglitazone|
223577397|NCT00300482|DRUG|ABT-335|135 mg, daily, 12 weeks
223577398|NCT00300482|DRUG|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
224158188|NCT01606397|DRUG|LY2409021|Administered orally (capsule)
223465993|NCT01895985|DRUG|Latanoprostene bunod|
223743581|NCT04244864|BEHAVIORAL|Treatment as usual (TAU)|"Medical doctor, 10 sessions: Pharmacological treatment according to standard algorithm and psychoeducation.~Psychologist 16-21 sessions: Manual-based cognitive behavioural therapy."
223743582|NCT07093528|DIAGNOSTIC_TEST|Cardiovascular Magnetic Resonance (CMR)|Patients will consent to undergo a 50-minute non-invasive stress perfusion CMR.
223743583|NCT07104799|DRUG|Momelotinib|Administered orally once per day during each 28-day cycle. This will start on day -7 (7 days before HCT) and continue for up to 13 cycles. Dose cohorts (100 mg daily, 150 mg daily, 200 mg daily) will be investigated in the peri-transplant period. Once participants have achieved hematopoietic recovery and are at least Day 21 after HCT, participants will increase the dose to 200 mg daily.
223743584|NCT07108049|BEHAVIORAL|Let us Grow Together: Economic Wellbeing for Families|Married couples in clusters assigned to the intervention receive a structured program of six community-based sessions. Each session lasts between 2.5 and 3 hours and includes participatory activities, discussions, and exercises. All six sessions would be conducted by the same two facilitators - one male and one female. The content integrates financial literacy (e.g., household budgeting, saving practices, joint financial planning) with gender-transformative training (e.g., equitable household roles, communication skills, conflict resolution, and fostering empathy between spouses). Sessions are delivered by trained facilitators in a group setting with fifteen couples, approximately every 2-4 weeks. Some sensitive content to address economic violence context would be done in a gender segregated manner separately to encourage reflections, ensure safety and reduce defensiveness. Between sessions, SMS reminders and tips are sent to participants' mobile phones to reinforce key messages and e
224158189|NCT00981747|DRUG|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
224158190|NCT00981747|DRUG|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
224158191|NCT00981747|DRUG|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
223465994|NCT04979481|BEHAVIORAL|BRAVE|The BRAVE campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The role model videos (1-3 minutes each) featured relatable characters experiencing and addressing violent behavior, alcohol misuse, and suicidality (through the eyes of a perpetrator, an intimate partner violence survivor, and a peer bystander), intended to demonstrated important coping and help-seeking skills.
223465995|NCT04979481|BEHAVIORAL|STEM|The STEM campaign included 3-5 text messages per week for 8 weeks, including 1 role model video per week and a related image. The series promoted STEM career pathways and highlighted Native professionals in Science, Technology, Engineering, Math, and Medical careers.
223465996|NCT05619328|DRUG|Vitamin B combination tablet|Once daily, with some liquid with or after a meal
223465997|NCT05619328|DRUG|Placebo Tablet|Once daily, with some liquid with or after a meal
223465998|NCT06437925|DIETARY_SUPPLEMENT|probiotic ayran drink|The test group has received probiotic ayran drink for 6 weeks
223465999|NCT06437925|DIETARY_SUPPLEMENT|Placebo ayran drink|The control group has received placebo ayran drink for 6 weeks
223466000|NCT00612820|DRUG|GSK256066|200mcg bd,
223466001|NCT00612820|DRUG|fluticasone propionate|200mcg od,100mcg bd
223466002|NCT00109863|BIOLOGICAL|hu14.18-IL2 fusion protein|
223466003|NCT05273762|DEVICE|FlowTriever|Mechanical thrombectomy for pulmonary embolism
223466004|NCT01805895|DRUG|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
223466005|NCT00254436|DRUG|Procrit (epoetin alfa)|Weekly dose
223466006|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
223466007|NCT02762032|DIETARY_SUPPLEMENT|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
223466008|NCT02762032|DRUG|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
224158192|NCT00981747|DRUG|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
224158193|NCT02228824|DRUG|Very low nicotine content cigarettes|0.07 mg nicotine delivery
224158194|NCT02228824|DRUG|Normal nicotine content cigarettes|0.8 mg nicotine delivery
224158195|NCT05317260|DRUG|Antiviral Agents|The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
224158196|NCT03034057|DRUG|Sayana Press|Sayana Press in the Uniject injection system
223466009|NCT03391752|COMBINATION_PRODUCT|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
223466010|NCT00789503|DIETARY_SUPPLEMENT|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
223466011|NCT04942262|DRUG|denture adhesive (Polident®, GlaxoSmithKline, Ireland)|cream-type denture adhesive available as an over-the-counter product in Thailand
223466012|NCT02809365|DEVICE|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
223466013|NCT02809365|DEVICE|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
223466014|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr \>80 mL/min)
223466015|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
223466016|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)
223466017|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)
223466018|NCT00637403|DRUG|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
223466019|NCT06514079|PROCEDURE|Esophageal dilatation with steroids injection|Under general anesthesia with the patient in the left lateral position. A single-channel endoscope was used. Endoscopic bougie dilatation was performed using Wire-guided Polyvinyl dilator Savary Gilliard/SG. Long-acting steroids triamcinolone acetonide was injected via 25-gauge sclerotherapy catheter. One mL solution of triamcinolone acetonide 40mg/ml was diluted with one mL of saline, in a 2 mL disposable syringe, and 0.5 mL each was injected at the proximal margin of the stricture in four quadrants, 2 mL solution in four quadrants
223466020|NCT01848106|DRUG|pegnivacogin/anivamersen|
223466021|NCT01848106|DRUG|Bivalirudin|
223466022|NCT04723459|OTHER|ivermectin impregnated mask|mask with ivermectin nano solution
223466023|NCT00818584|DRUG|Micafungin|IV Administration
223466024|NCT05848960|DIETARY_SUPPLEMENT|Hypercaloric, hyperproteic oral supplement|2 supplements per day
223466025|NCT05848960|OTHER|Mediterranean diet|Mediterranean diet
223466026|NCT01136018|PROCEDURE|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
223466027|NCT04644406|OTHER|Efficacy of the Pertuzumab-Trastuzumab combination|The efficacy of the pertuzumab in combination with one of the biosimilars of Trastuzumab will be estimated by measuring the PFS at 6 months after the beginning of the treatment.
223577399|NCT00300482|DRUG|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
223577400|NCT02593708|DRUG|Neratinib|
223577401|NCT02593708|DRUG|Paclitaxel|
223577402|NCT02593708|DRUG|Pertuzumab|
224158197|NCT01814826|DRUG|MLN4924|"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"
224158198|NCT01814826|DRUG|Azacitidine|"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~\- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"
223466028|NCT02353026|DRUG|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
223466029|NCT04856111|DRUG|Pirfenidone|Same as arm description
223466030|NCT04856111|DRUG|Nintedanib|Same as arm description
223577403|NCT02593708|DRUG|Trastuzumab|
224158199|NCT00647946|DRUG|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
224158200|NCT00647946|DRUG|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
224158201|NCT02521857|DRUG|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
223466031|NCT00230048|BEHAVIORAL|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
223466032|NCT06053385|OTHER|Melatonin sleep lotion|7 g of lotion applied to hands and arms one hour before bedtime
224158202|NCT00309257|DRUG|ACE I, ATA II and Statins|
223466033|NCT06053385|OTHER|Placebo control lotion|7 g of lotion applied to hands and arms one hour before bedtime
223466034|NCT03199352|OTHER|RYGB hand-sewn|Patients will have the RYGB anastomosis hand-sewn
223466035|NCT03199352|OTHER|RYGB linear-staple|Patients will have the RYGB anastomosis performed using a linear staple.
223466036|NCT01566604|DRUG|NVA237|Delivered via a single dose dry powder inhaler
223466037|NCT01566604|DRUG|Placebo|Delivered via a single dose dry powder inhaler
223466038|NCT00339417|DRUG|Albendazole|
223466039|NCT00339417|DRUG|Ivermectin|
223466040|NCT05067855|OTHER|Pilates exercise program group|Pilates exercise program group will do a warm-up for 10 minutes and then perform five exercises includes standing footwork, hundreds with knee straight, articulating bridge, rolling like a ball, plank for 25 minutes. For first three weeks, each player will do 8 repetitions × 3 sets of exercises and for next three weeks, each player will do 15 repetitions × 3 sets of exercises. There will be cool-down for 10 minutes after exercises. Total program will be of 45 minutes.
223466041|NCT02421692|OTHER|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
223466042|NCT02903342|OTHER|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
223466043|NCT03225170|BEHAVIORAL|Self Affirmation (SA)|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
223577404|NCT00527020|DRUG|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
223577405|NCT00527020|DRUG|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
223577406|NCT00527020|DRUG|Placebo|Placebo tablets will be given to the subjects.
223577407|NCT04753554|DEVICE|ORI group|The patient group whose oxygenation will be managed by ORI values. Hyperoxia or hypoxia will be prevented by using also blood gas analysis in critically ill patients.
223577408|NCT04753554|OTHER|Conventional group|In this patient group oxygenation will be managed as usual, using blood gas analysis.
223577409|NCT00343915|BIOLOGICAL|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, \& 6)
223577410|NCT00343915|BIOLOGICAL|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 \& 6)
223577411|NCT00343915|BIOLOGICAL|placebo|In the primary study: 1 deep intramuscular injection (month 1)
223743585|NCT06913907|DRUG|Methotrexate (MTX)|Single arm study
224158203|NCT00309257|DRUG|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
224158204|NCT01960829|DRUG|Everolimus|
223466044|NCT03225170|BEHAVIORAL|Control|Clients will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. The control group will rank the list and be asked to write about the 9th ranked item and why it might be important to someone else.
223577412|NCT01237262|DRUG|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
223577413|NCT03244319|DRUG|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).
223577414|NCT03244319|DRUG|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
223577415|NCT03244319|DRUG|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
223577416|NCT01193166|DRUG|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
223577417|NCT01193166|DRUG|risperidone|flexible dosing as prescribed by the study doctor for 12 months
223577418|NCT01193166|DRUG|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
223577419|NCT01193166|DRUG|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
223577420|NCT01193166|DRUG|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
223577421|NCT01193166|DRUG|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
223577422|NCT01193166|DRUG|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
223577423|NCT01193166|DRUG|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
223577424|NCT06288971|OTHER|Self-adaption web-based software for the rehabilitation of EF and visuo-spatial abilities|\- Self-adaption web-based software integrated with neuropsychomotor activities in small groups to strengthen EF. The training will take place bi-weekly, for 3 months, for approximately 60 minutes per meeting. For the intervention will be used the Bee-bot, a robot to be programmed to achieve objectives set in space, allows to stimulate navigation, visuospatial working memory and planning skills (the activities will be taken from those already used in our previous studies in children with typical development and BES (Di Lieto et al., 2020)).
224158205|NCT03962946|OTHER|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient's utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
223577425|NCT06288971|OTHER|Tele-rehabilitation of EF and specific cognitive processes underlying academic skills|\- Tele-rehabilitation intervention on FE (RuntheRAN and MemoRAN). The training will be conducted at home, with periodic meetings with the clinician, for 3 months, for approximately 4/5 days a week for approximately 30/40 minutes per day. An adult (e.g. a family member) will support the child in the treatment and ensure that the exercises are carried out adequately at home. One of the following tele-rehabilitation software will be used: RuntheRAN (RidiNet, Coopertiva Sociale Anastasis), a software that aims to strengthen the prerequisites of reading by requiring the timed and progressively faster naming of colour matrices or black and white figures. MemoRAN (RidiNet, Cooperativa Sociale Anastasis), which involves rapid naming exercises of stimuli (figures and colors) presented in matrices, within tasks that require inhibition, cognitive flexibility and updating in working memory.
223577426|NCT06288971|OTHER|Game-based tools for the rehabilitation of EF and motor planning|\- MondoELLI intervention (Cooperativa Sociale Anastasis) integrated with neuropsychomotor activities. The game-based app involves activities in small groups to strengthen various components of EF (interference control, inhibition, working memory, flexibility). The activities are organized with increasing difficulty, according to the self-adaptive algorithm, and within a narrative context.
223577427|NCT05006144|OTHER|sequenced trunk co-activation exercises|"* Sequenced trunk co-activation exercises were basically used for facilitation of functional activities through trunk musculature dynamic co-activation of in the lateral plane which is required for basic developmental milestones. In the frontal plane, encourage the child to actively shift his/her weight to maintain the weight-bearing side straight while keeping proper active co-activation of trunk musculature. Efficient trunk rotation is essential for acquiring of equilibrium reactions and balance. Enhancement of efficient active trunk rotation as the child could achieve active trunk musculature co-activation while maintaining the weight-bearing side straight (Arndt et al., 2008).~* Righting and protective reactions~* Functional stretching exercises."
224158206|NCT03962946|OTHER|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
224158207|NCT00377104|DRUG|alvocidib|Given IV
224158208|NCT00377104|OTHER|pharmacological study|Correlative studies
224158209|NCT00377104|OTHER|laboratory biomarker analysis|Correlative studies
224158210|NCT03339401|OTHER|Standard of Care|Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
223466045|NCT01204034|DRUG|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
223466046|NCT01668836|DRUG|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
223466047|NCT01668836|BEHAVIORAL|Caloric restriction|Diet of 1000kcal per day for 30 days
224158211|NCT03339401|DRUG|Brincidofovir|Brincidofovir (BCV) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.
224158212|NCT01320969|BEHAVIORAL|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
224158213|NCT03350867|OTHER|Personalized Insole Group|Personalized Insole Group
224158214|NCT03350867|OTHER|Placebo Group|Placebo Group
223466048|NCT05191966|PROCEDURE|Subcostal Anterior Quadratus Lumborum Block|"S-QLB3 block will be performed 30 min. before general anesthesia. For anterior QL block via subcostal approach, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the interfacial plane between the QLM and PMM.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
223466049|NCT05191966|PROCEDURE|Thoracic Paravertebral Block|"TPVB block will be performed 30 min. before general anesthesia. TPVB will be performed at T10 transverse process level, 0.4 ml/kg of 0.25% bupivacaine + 1:400.000 adrenaline will be injected into the paravertebral space.~IV-PCA: The requested dose will be 20µg/kg morphine, the lock-in time will be 6-10 minutes, the 4-hour limit will be 80% of the total calculated dose."
223466050|NCT02360514|DRUG|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
223466051|NCT05719194|OTHER|Standard SBT|Weaning strategy in accordance with the care practices of the department, regarding the assessment of weaning criteria, SBT and extubation modalities.
223466052|NCT05719194|OTHER|SBT with T-piece or PSV|"\- Risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with T-piece for an hour. Measure of protein and haemoglobin by blood sample before and after the trial.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful.~If SBT failed : no extubation and new SBT the next day. Optimization of cardiac function or fluid overload will be in charge of the investigator.~\- No risk factors of WIPO~Step 1 : Daily assessment of weaning criteria in accordance with the study protocol.~Step 2 : Spontaneous breathing trial with pressure support ventilation (pressure support from 5 to 8 cmH20 - PEEP at 0 cmH20) for an hour.~Step 3 : Reconnect the patient to the ventilator for at least 30 minutes and then extubate if SBT is successful."
223466053|NCT04936516|DEVICE|Endotracheal intubation|Endotracheal intubation using either McGrath or C-MAC video laryngoscopy
223466054|NCT05563337|PROCEDURE|Arteriography and renal denervation|Diagnostic renal Arteriography - Randomization - Renal denervation
223466055|NCT05563337|PROCEDURE|Arteriography without renal denervation|Diagnostic renal Arteriography - Randomization
223577428|NCT05006144|OTHER|Standard Orthotic Management|A custom-made articulating ankle foot orthosis with a hinge at the level of the medial malleolus of the ankle is fabricated for each child from the same copolymer thermoplastic mold after casting with the subtalar joint in neutral position. The orthosis extended distally to the tip of the toes and proximally on the posterior surface of the leg to about 5 cm below the knee and secured to the foot by three straps across the forefoot, the front of the ankle, and to the anterior upper tibial portion. It is fabricated to permit free ankle dorsiflexion and lock the plantar flexion at 0 dorsiflexion. The splinting schedule started gradually for 2 h/day in the first month, 4 h/day in the second month to the entire wake-up time of the day in the third and fourth months to accommodate children to the orthosis.
223743586|NCT06913894|BEHAVIORAL|Supervised Therapy for DRF Rehabilitation|Participants assigned to the Supervised Therapy Group (STG) will receive in-person, supervised rehabilitation sessions in an outpatient clinic. Each session lasts 30-45 minutes and is conducted by a licensed physical therapist. The therapy focuses on progressive range of motion exercises, light strengthening, proprioception training, and functional task practice. In addition, participants are prescribed a daily home exercise program (lasting 10-15 minutes) to reinforce gains made during the clinic sessions. The intervention is provided over a 6-week period following cast removal, with adherence monitored via attendance records and home exercise logs.
224158215|NCT05426018|DRUG|SY-009 capsules|3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
224158216|NCT03271307|BEHAVIORAL|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
224158217|NCT03271307|DIAGNOSTIC_TEST|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
224158218|NCT03271307|DIAGNOSTIC_TEST|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
224158219|NCT02816437|BIOLOGICAL|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
224158220|NCT03365947|DRUG|ARO-HBV|sc injection
224158221|NCT03365947|OTHER|Sterile Normal Saline (0.9% NaCl)|sc injection
224158222|NCT03365947|DRUG|JNJ-56136379|oral tablets
224158223|NCT03154177|BEHAVIORAL|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
224158224|NCT03154177|PROCEDURE|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
224158225|NCT02932644|OTHER|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
224158226|NCT02932644|OTHER|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
224158227|NCT03698422|DIAGNOSTIC_TEST|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
223466056|NCT05696964|BEHAVIORAL|Motivational interviewing training enhanced with artificial intelligence|The training in motivational interviewing that medical residents will receive will make use of an artificial intelligence measurement tool, Real-time Assessment of Dialogue in Motivational Interviewing (ReadMI), that produces a spectrum of relevant MI metrics.
223577429|NCT05006144|OTHER|selective dorsal rhizotomy|All SDRs were performed by a single neurosurgeon through an osteoplastic laminotomy from L2 to L5 that left the facet joints intact. After opening the dura, the posterior nerve roots of L2 to S1 were identified and divided into 3 to 6 rootlets. At L2, from 30% to 50% of the posterior nerve rootlets were sectioned without selective stimulation. Selective electric stimulation of each nerve rootlet was performed from L3 to S1. The percentage of rootlets sectioned at each level (table 3) was determined by the surgical team based on the electromyographic results obtained intrasurgically and knowledge of the presurgical assessment results. The laminae were replaced on the completion of the rootlet stimulation and secured with sutures in the yellow ligament and the supraspinous ligament.
223466057|NCT00967304|OTHER|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
223577430|NCT00948948|DEVICE|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~* Gel-filled device which is available in smooth surface and textured surface (Siltex®)~* Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
223466058|NCT02895035|DRUG|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
223466059|NCT02895035|DRUG|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
223577431|NCT04467476|DEVICE|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
223577432|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
223577433|NCT01289106|BIOLOGICAL|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
224158228|NCT05477225|DEVICE|NovoSorb® BTM|a biodegradable polyurethane porous matrix adhered to a transparent sealing membrane. The sealing membrane is designed to physiologically close the wound limiting evaporative moisture loss during integration of the matrix.
224158229|NCT05477225|DEVICE|Human Cadaveric Allograft|"The donated human tissue (Allograft) used in this study are from Maxxeus Medical, Kettering, OH . Tissue grafts are recovered from deceased human donors. All tissue is recovered, processed, stored and distributed for use in accordance with the standards of the American Association of Tissue Banks (AATB). Tissue is manufactured in a clean room environment, following rigorous quality assurance standards. The procedures executed to manufacture this graft including recovery, donor screening, testing, processing, packaging, labeling, storage, and distribution were performed in compliance with all applicable local, state, and federal regulations, including the U.S. Food and Drug Administration (FDA) regulations published at 21 CFR Part 1271, and the current edition of the American Association of Tissue Banks Standards for Tissue Banking.~The current sizes that are available for this study: 103 sq cm., 154 sq cm and 232 sq. cm"
224158230|NCT04140539|BIOLOGICAL|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
224303442|NCT03801265|PROCEDURE|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
224303443|NCT03801265|DRUG|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
223466060|NCT03520452|OTHER|Green coffee extract|Reconstituted in water and given to subjects
223466061|NCT03520452|OTHER|Placebo|Placebo
223466062|NCT00908765|BEHAVIORAL|Exercise|"1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
223466063|NCT00661089|DRUG|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
223466064|NCT00661089|DRUG|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
223466065|NCT02977793|DEVICE|Tomey EM-4000 Specular Microscope|
223466066|NCT02977793|DEVICE|Konan CellChek XL Specular Microscope|
223577434|NCT01289106|BIOLOGICAL|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
223577435|NCT05562180|BEHAVIORAL|Customized meal plan and grocery delivery|Participants will use an app to customize their meal plans
223577436|NCT00022724|DRUG|temsirolimus|
223577437|NCT01093781|DRUG|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
223466067|NCT00570375|DRUG|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
223466068|NCT01500798|DRUG|20 mg bardoxolone methyl|20 mg, oral, once daily
223466069|NCT01500798|DRUG|Placebo|Oral, once daily
223466070|NCT02979964|BEHAVIORAL|Audit and Feedback|
223466071|NCT01187732|DEVICE|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
224158231|NCT04042038|BEHAVIORAL|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
224158232|NCT01042938|DRUG|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
224158233|NCT01042938|DRUG|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
224158234|NCT03083275|OTHER|Resistance Training|
224158235|NCT04867200|DRUG|Lixiana(D006)|NOAC(Factor Xa inhibitor)
224158236|NCT04867200|DRUG|CKD-344|NOAC(Factor Xa inhibitor)
224303444|NCT06345365|DRUG|mitoxantrone liposome, Ara-Cytarabine and azacitidine|Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7
224303445|NCT06345365|DRUG|Daunorubicin,Ara-Cytarabine, azacitidine|Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;
224303446|NCT01727466|BEHAVIORAL|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
224303447|NCT03321630|DRUG|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
223466072|NCT04228224|DEVICE|Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)|The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
223466073|NCT04228224|BEHAVIORAL|Conventional gait rehabilitation|Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
223466074|NCT00621790|DRUG|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
223466075|NCT00621790|DRUG|placebo|placebo
223466076|NCT05916222|BEHAVIORAL|Dynamic Temporal and Tactile Cueing (DTTC)|DTTC is a motor-based intervention where the client watches, listens to and imitates the clinician (Strand, 2020). Treatment follows a temporal hierarchy where children receive multisensory cueing to establish accurate movements. First, the child imitates the clinician's production. If inaccurate, the child simultaneously produces the target with the clinician while cueing is provided. Upon achieving accuracy within simultaneous productions, the target is practiced within direct imitation while the clinician adds/fades cues based on the child's productions. When the child accurately produces the target in direct imitation, the target is practiced with varied prosody. Next, the target is practiced within delayed imitation where a child produces a word following a 2-3 second delay after the clinician's production. Upon accurately producing the target at all levels, the word is practiced within spontaneous productions.
223466077|NCT00274742|BIOLOGICAL|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
223466078|NCT03064711|DIAGNOSTIC_TEST|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
223466079|NCT04712292|PROCEDURE|Surgical procedure for confirmed or suspected colorectal cancer|"Surgical procedure for cancer may include:~* any radical surgery (right or left hemicolectomy, rectal resection, abdomino-perineal resection, total colectomy, proctocolectomy, and others depending on the tumor site and other tumor characteristics),~* surgery for radicalization of cancer polyps previously removed endoscopically~* surgery for excision of large polyps which are not removable endoscopically~* staging surgery (laparoscopy or laparotomy), in case of advanced-non operable cancer~* palliative surgery (defined as any surgery with no curative intent)"
223577438|NCT01212614|PROCEDURE|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
223577439|NCT00667654|DRUG|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
223577440|NCT03597477|DRUG|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
223577441|NCT06496438|DIETARY_SUPPLEMENT|Psychobiotics|Dietary Supplement: A four probiotic regime, containing Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Bifidobacterium breve, and Bifidobacterium longum at a concentration of 1, 000,000,000 CFU.
224303448|NCT03321630|DRUG|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
224303449|NCT05224310|PROCEDURE|PECS block, SAP block|performing either PECS block or SAP block
224303450|NCT06013839|DRUG|talfirastide|TXA127 (talfirastide) is a pharmaceutically formulated angiotensin (1-7) heptapeptide, identical to the endogenously produced, non-hypertensive derivative of angiotensin II (Ang II).
224303451|NCT03250559|PROCEDURE|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
224303452|NCT04573764|DIETARY_SUPPLEMENT|D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester|"The intervention is D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester and will be bought commercially. As an example: One bottle of KetoneAid KE4 PRO with 60 ml contains 30 g D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester. For more information please refer to: https://shop.ketoneaid.com/collections/all/products/ke4-pro. Placebo will be a taste-matched water solution provided by the company. The placebo solution and the active solution will be prepared in identic bottles and investigators will be blinded."
224303453|NCT04573764|DIETARY_SUPPLEMENT|Placebo|Taste-matched water
223466080|NCT05296707|OTHER|Inspiratory muscle training|"The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day."
223466081|NCT05296707|OTHER|Used routine medicine|After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
223466082|NCT05296707|OTHER|Control group|A healthy child compatible with the age and sex of the patient group was evaluated once.
223466083|NCT02786992|DRUG|Misoprostol|
223466084|NCT02786992|DRUG|Oxytocin|
223577442|NCT06496438|OTHER|Placebo|The placebo regime, containing powdered glucose polymer, will be identical in packaging, appearance, consistency, and solubility in drinking water, thus making it impossible to recognize which are placebo and which the therapeutic formulation. Both will be identically standardized by the same pharmaceutical company \[Uni-Pharma, Greece\].
223577443|NCT00327574|BEHAVIORAL|Home heath education +/_ GP training|
223577444|NCT01792375|PROCEDURE|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
223577445|NCT01792375|DRUG|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
223743587|NCT06913894|BEHAVIORAL|Home-Based Rehabilitation Program for DRF|Participants assigned to the Home-Based Program Group (HBG) will follow a standardized, detailed home exercise program specifically designed for distal radius fracture rehabilitation. The program includes instructions for range of motion, strengthening, and functional tasks similar to the supervised protocol. Participants receive a comprehensive written and online exercise manual, and they are instructed to perform the exercises daily. In addition, they will have weekly telephone or video check-ins (approximately 10 minutes per call) with a research assistant to review progress, address questions, and ensure proper exercise technique. The home program is implemented over a 6-week period following cast removal, with adherence documented via exercise logs submitted by participants.
224158237|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
224158238|NCT00868543|PROCEDURE|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
223466085|NCT02786992|DRUG|Carbetocin|
223577446|NCT00228046|DRUG|Divalproex Sodium|
223577447|NCT00228046|DRUG|Methylphenidate|
223577448|NCT00228046|DRUG|Dextroamphetamine|
223577449|NCT00228046|DRUG|Mixed Amphetamine Salts|
223577450|NCT00228046|BEHAVIORAL|Family Counseling|
223577451|NCT00228046|BEHAVIORAL|Behavior Management Training with Parents|
223577452|NCT01532544|DRUG|Ilomedin and Integrilin|Continuous infusion
223577453|NCT01532544|DRUG|low molecular weight heparin.|
223466086|NCT02786992|DRUG|Placebo|
223466087|NCT01575080|DEVICE|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
223466088|NCT00617552|DRUG|5% dextrose in water|60 ml IV infusion over 30 minutes
223466089|NCT00617552|DRUG|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
223466090|NCT00617552|DRUG|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
223577454|NCT00882908|DRUG|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
223577455|NCT00882908|DRUG|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
223466091|NCT00617552|DRUG|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
223466092|NCT00617552|DRUG|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
223577456|NCT00882908|DRUG|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
223577457|NCT00882908|DRUG|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
223466093|NCT00617552|DRUG|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
223466094|NCT00617552|DRUG|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
223466095|NCT00617552|DRUG|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
223577458|NCT05506839|OTHER|Intervention (videoconferencing)|1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
223577459|NCT04654871|DIETARY_SUPPLEMENT|Chondroitin Sulfate|Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day
223466096|NCT02697071|DRUG|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
223466097|NCT02697071|DRUG|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
223466098|NCT02163161|DRUG|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
223466099|NCT02163161|DRUG|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
223577460|NCT04654871|PROCEDURE|Resistance exercise training|"Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval"
223577461|NCT04654871|PROCEDURE|Manual therapy / Joint Mobilization|Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization
223577462|NCT04654871|PROCEDURE|THE therapy|Interferential and Heating for 20 min
223577463|NCT01789528|DRUG|CAZ-AVI|IV infusion
223577464|NCT01789528|DRUG|CXL|IV infusion
223577465|NCT01206686|BEHAVIORAL|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
223577466|NCT01206686|BEHAVIORAL|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
223577467|NCT01206686|BEHAVIORAL|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
223577468|NCT02907853|BEHAVIORAL|Contingency Management|as described above
223577469|NCT00002427|DRUG|Hydroxyurea|
223577470|NCT00002427|DRUG|Stavudine|
223577471|NCT00002427|DRUG|Didanosine|
223577472|NCT05291936|DEVICE|PRECISION1® for Astigmatism Contact Lenses|TEST
224158239|NCT02352532|OTHER|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
224158240|NCT02352532|OTHER|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
224303454|NCT03422367|BEHAVIORAL|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
224303455|NCT02455050|DRUG|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops \[New Eye Drop Formula\] in each eye.
224303456|NCT02455050|DRUG|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
224303457|NCT02455050|DRUG|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
223466100|NCT02163161|DRUG|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
223466101|NCT04503317|DEVICE|active acupuncture low level laser in addition to nasal laser irradiation|laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt, but it can also be adjusted. The device operates at an ambient temperature of -20 to +40 ° C and relative humidity of ≤ 85%. The laser watch can be used for a variable irradiation period of 10-60 min. applied on specific acupuncture points ( acupuncture point, Radial artery acupuncture points, and ulnar artery acupuncture points) combined with nasal laser irradiation at the same time with treadmill aerobic exercise, once per day, 3 times per week for three months
223466102|NCT04503317|OTHER|treadmill exercise|aerobic exercise once per day, 3 times per week for three months
223466103|NCT00157339|DRUG|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
223577473|NCT05291936|DEVICE|MyDay® Toric Soft Contact Lenses|CONTROL
223577474|NCT00581828|DRUG|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
223577475|NCT00201591|BEHAVIORAL|Exercise training for 10 weeks|
223577476|NCT03168243|DIETARY_SUPPLEMENT|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
223577477|NCT02798770|OTHER|No Intervention Foreseen|
223577478|NCT01627444|PROCEDURE|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
223577479|NCT02370095|DRUG|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
223577480|NCT02370095|DRUG|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
223577481|NCT01256463|BEHAVIORAL|HIV prevention intervention|
223577482|NCT01694277|DRUG|Masitinib|12 mg/kg/day
223577483|NCT01694277|DRUG|Sunitinib|50 mg/day
223577484|NCT05622435|DEVICE|T10070, Plastic tube with a roll-on applicator filled with an ointment|6 times per day on both (upper and lower) eyelids of right eye during 7 to 9 days.
223577485|NCT00205842|DRUG|alvimopan|
223577486|NCT03880448|DRUG|Metronidazole|Metronidazole 500mg/8h/7days
223577487|NCT03880448|DRUG|Placebo|Cornstarch 500mg/8h/7days
223577488|NCT03880448|PROCEDURE|periodontal surgery|periodontal surgery
223577489|NCT01667562|DRUG|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
224303458|NCT03545035|DRUG|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
224303459|NCT06299917|OTHER|WORK-ON|The intervention includes three parts: 1) a coordinating occupational therapist, 2) four group sessions and 3) Individual consultations based on the agreed upon goals.
224303460|NCT02981303|BIOLOGICAL|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
224303461|NCT02981303|DRUG|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
224303462|NCT02325518|DRUG|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
223466104|NCT00157339|DRUG|injected insulin|patient specific dose, injected, before meals, 12 months.
223466105|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including experimental nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the experimental nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
223466106|NCT05394948|DIETARY_SUPPLEMENT|Dietary recommendations including control nutraceutic.|Volunteers allocated in the control group will receive every day and during 3 consecutive weeks the control nutraceutic instead of the breakfast. Nutraceutical intake will be accompanied by nutritional advice to follow for the 3 weeks of intervention.
224303463|NCT02325518|DRUG|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
224303464|NCT02325518|DRUG|Subject's habitual PGA monotherapy|
223466107|NCT03927092|OTHER|Multiple Sclerosis Knowledge Questionnaire|A 25-item self-administered questionnaire
223466108|NCT01720641|BEHAVIORAL|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
223466109|NCT01720641|BEHAVIORAL|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
223466110|NCT01720641|BEHAVIORAL|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
223577490|NCT00048815|DRUG|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
223577491|NCT00048815|DRUG|St. John's Wort|Natural extract from the St. John's Wort plant.
223577492|NCT00048815|DRUG|Placebos|Placebo pill
223577493|NCT02130986|OTHER|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
224303465|NCT05578196|DRUG|fecal bacteria solution|The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
224303466|NCT05578196|DRUG|physiological saline solution|physiological saline solution 20ml
224303467|NCT00103818|DRUG|gaboxadol|Duration of Treatment: 3 months
224303468|NCT00103818|DRUG|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
223466111|NCT01529606|OTHER|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
223466112|NCT01529606|PROCEDURE|Plasma treatment|plasma treatment after preparation and for caries prevention
223466113|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - ULTRASOUND|At baseline, ultrasonographic evaluation of patients by following AAGL Endometriosis Classification
223577494|NCT02130986|OTHER|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (\<1 hour goal) provide clinicians the procalcitonin result.
223577495|NCT02130986|OTHER|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~\< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~\> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~\> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~1. Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~2. For outpatients, antibiotic duration based on level (\> 0.25-0.5 ug/L:3 days; \> 0.5-1.0 ug/L:5 days; \>1.0 ug/L:7 days). Physician follow-up is recommended."
223577496|NCT02130986|OTHER|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
223577497|NCT03125811|OTHER|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
223577498|NCT03125811|DRUG|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
224303469|NCT00586352|OTHER|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
224303470|NCT00631449|DRUG|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
224303471|NCT00631449|DRUG|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
224303472|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 1500 mg
224303473|NCT04505137|OTHER|GMA301 Placebo Injection|GMA301 Injection without GMA301 administered as a single intravenous dose
224303474|NCT04505137|DRUG|GMA301 Injection|GMA301 Injection administered as a single dose of 2000 mg
224158241|NCT04253808|BEHAVIORAL|Carbohydrate-restricted, high-fat diet|"Diet composition was \~45% fats, \~30% carbohydrates, and \~25% proteins. Calorie needs were provided according to what the Bioelectrical Impedance (BIA) device gave as required to maintain bodyweight.~Sources of macronutrients:~* Carbohydrates: from whole grains, dairy products, legumes, fruits, and vegetables.~* Fats: from mono- and polyunsaturated fatty acids, including medium- and long-chain fatty acids.~* Proteins: plant-based proteins and lean animal-based proteins. All meals were provided to the participants throughout the study period and the diet was provided orally unless the patient was on a feeding tube or a feeding tube is ordered by a physician during the study period. Diet texture was according to patients chewing and swallowing abilities. If the patient is on a feeding tube or intake is insufficient, a formula with similar macronutrient composition + a protein supplement was provided."
224158242|NCT04253808|BEHAVIORAL|Regular composition diet|The regular composition diet contained approximately 50-52% carbohydrates, 30% fats, and 18-20% proteins
224158243|NCT05307627|DRUG|low-dose naltrexone|LDN doses \<20 mg/day
223466114|NCT05291624|DIAGNOSTIC_TEST|AAGL Endometriosis Classification score - SURGERY|Within 1 month from enrollment, surgical evaluation of patients by following AAGL Endometriosis Classification
223466115|NCT04263259|BEHAVIORAL|Attentional Bias Modification|Mobile-Delivered Cognitive Retraining Intervention
223466116|NCT02572453|DRUG|Onalespib|Given IV
223466117|NCT02844166|OTHER|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
223466118|NCT02844166|OTHER|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
223466119|NCT05074966|DRUG|Experimental: mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
223466120|NCT05074966|DRUG|Active Comparator: FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
223466121|NCT03511677|DEVICE|Insole|Customized insole
223466122|NCT03511677|DEVICE|Placebo Insole|Placebo flat insole
223466123|NCT01341496|BIOLOGICAL|Epigenetically Modified Autologous Tumor|5x 10\^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
223466124|NCT01341496|DRUG|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
223466125|NCT01341496|DRUG|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
223466126|NCT05075278|BEHAVIORAL|Survey|A survey will be completed by the participants at the conclusion of each day.
223466127|NCT05943366|DEVICE|Keep-on-Keep-Up Nutrition (KOKU-Nut)|Keep-on-Keep-Up (KOKU) is a free, tablet-based strength and balance exercise application that was soft launched in 2020 (https://kokuhealth.com/). KOKU is approved by the National Health Service (NHS) and Organisation for the Review of Care and Health Apps (ORCHA) as a lifestyle app and has been viewed positively by older adults after 6 weeks of independent use. KOKU-Nut is the latest development of this interactive platform and includes nutritional games based on the UK dietary guidelines to nudge older adults to improve their diet with a specific focus on protein, fibre and fluid.
223466128|NCT04693793|OTHER|Education Materials and Janssen Test|"Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations."
223466129|NCT01631448|BIOLOGICAL|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
223466130|NCT02955303|OTHER|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
223466131|NCT03352076|DRUG|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
223466132|NCT03352076|DRUG|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
223466133|NCT03713099|DEVICE|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
223466134|NCT05313724|OTHER|Mind-Body Online Therapy|There are 8 different modules (e.g. relaxation, mindfulness, stress management, disease management, nutrition and exercise behavior) with a mind-body focus available for the patients to independently (time, location) work on.
223466135|NCT05485311|OTHER|visual analog scale|Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
223466136|NCT00766766|BEHAVIORAL|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
223466137|NCT00766766|BEHAVIORAL|Telephone Coaching Sessions|Telephone Coaching Sessions
223466138|NCT00766766|BEHAVIORAL|Physician Feedback Letter|Physician Feedback Letter
224158244|NCT04629638|OTHER|Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores|The results will be compared with the results of covid-negative pregnant women who gave birth in the same period.
223466139|NCT02114021|DRUG|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
223466140|NCT02114021|DRUG|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
223466141|NCT02114021|DRUG|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
223466142|NCT04552197|DRUG|JNJ-64251330|JNJ-64251330 tablet will be administered orally.
223466143|NCT04552197|DRUG|Tofacitinib|Tofacitinib tablets will be administered orally.
223577499|NCT01129882|DRUG|Aripiprazole|Aripiprazole IM depot - 300 mg or 400 mg
223577500|NCT04147975|DIAGNOSTIC_TEST|RaPID/BSI Test|RaPID/BSI Test
223577501|NCT00196859|DRUG|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
223577502|NCT00196859|DRUG|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
223577503|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
223577504|NCT02980094|DIETARY_SUPPLEMENT|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
223577505|NCT02980094|DIETARY_SUPPLEMENT|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
223577506|NCT02980094|DIETARY_SUPPLEMENT|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
223577507|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
223577508|NCT00591669|OTHER|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
223466144|NCT02151721|DRUG|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
223466145|NCT01613924|DEVICE|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
224158245|NCT02463760|OTHER|Medical imaging|
224303475|NCT04847349|DIETARY_SUPPLEMENT|OL-1, standard dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
223466146|NCT01613924|DEVICE|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
223466147|NCT04222816|DRUG|Lithium Carbonate|Lithium carbonate 800-900 mg orally daily for 12 weeks
223466148|NCT04222816|DRUG|Sodium chloride|Sodium chloride 1gm daily per orally for 12 weeks
223466149|NCT01879293|DRUG|Metformin|
223466150|NCT01879293|DRUG|placebo|
223577509|NCT04254159|OTHER|Superimposed Neuromuscular Electrical Stimulation|NMES will be applied during each strengthening exercise session. A dual channel NMES stimulation device will be used with biphasic symmetric constant current impulses with a pulse width 300ms, a frequency of 50 Hz and a duty cycle of 10s on and 20s off protocol for 3 days a week for eight weeks.
223466151|NCT05033626|PROCEDURE|Simultaneous thyroidectomy and hyoid suspension|Under endotracheal anesthesia, a horizontal skin incision up to 50 mm long is made at the level of the upper thyroid cartilage, the skin and subcutaneous fat are dissected. The sternohyoid and sternothyroid muscles are retracted. An audit of the thyroid gland is performed. Step by step, using the ultrasonic dissector, the sections of the gland necessary for resection are separated, ligated and transected. Using microsurgical techniques, neurolysis of the recurrent laryngeal nerves is performed. The quality control of the return of the laryngeal nerves is ensured to the required extent using the neuromonitoring apparatus.
223577510|NCT04254159|OTHER|Quadriceps Strengthening|Quadriceps strength training will be done with resistive elastics bands for 3 days a week for eight weeks.
224158246|NCT04399980|DRUG|Mavrilimumab|Treatment infusion
224158247|NCT04399980|DRUG|Placebos|Placebo infusion
224158248|NCT06350149|OTHER|Sugar Sweetened Beverages (SSB)|The following are considered SSBs: non-diet soft drinks/sodas, flavored juice drinks, sweetened tea, energy drinks, and electrolyte replacement drinks.
224158249|NCT06350149|OTHER|Hi GI|The Glycemic Index of the high-GI meals will be at least 75
224303476|NCT04847349|DIETARY_SUPPLEMENT|OL-1, high dose|The live microbial components have been present in the food supply, have a long history of safe use in foods, and are already marketed in the United States.
223466152|NCT05033626|PROCEDURE|Thyroidectomy|The hyoid bone is mobilized in the anterocaudal direction and is fixed to the thyroid cartilage with four permanent non-absorbable sutures. If sufficient mobilization does not occur during the operation, the tendon of the stylohyoid muscle is dissected. Surgical drainage is installed 24 hours after surgery.
223466153|NCT01900444|BIOLOGICAL|IMOJEV|0.5 mL, Subcutaneous
224158250|NCT06350149|OTHER|Lo GI|The Glycemic Index of the low- -GI meals will not be higher than 55.
224158251|NCT04334512|DRUG|Hydroxychloroquine|Treatment with hydroxychloroquine
224158252|NCT04334512|DRUG|Azithromycin|Treatment with azithromycin
223466154|NCT06232096|DRUG|MBS314 Injection|"Phase Ia: The patients confirming to the eligibility criteria will be assigned to 1 of the 7 dose groups (0.03/0.09/0.3/0.9 mg \~ 0.3/1.5/9.0/60 mg, respectively) based on the sequence of inclusion. Each patient will receive MBS314 as per the schedule specified in the respective arms.~Phase Ib/Ⅱ: Based on the results of Phase Ⅰa, 1 or 2 recommended doses will be selected for Phase Ⅰb. Recommended Phase II Dose (RP2D) will be selected for Phase Ⅱ."
223466155|NCT00096213|PROCEDURE|conventional surgery|surgery
223577511|NCT04254159|BEHAVIORAL|Patient Education Program|The aim of patient education is to increase awareness of patients about COPD and develop skills to better manage their disease. The patient education will be performed at least once via face to face interview. Education topics will be covered basic information about COPD, environmental risk factors, monitoring and managing the signs and symptoms of their disease, energy conservation techniques and relaxation positions to reduce dyspnea and usage of a specific inhaler.
223577512|NCT04254159|OTHER|Aerobic Exercise Training|Exercise training will be comprised of cardiovascular endurance training with cycle ergometer and lower extremity strength training. The exercises will be done 3 days a week at the clinic under the supervision of physiotherapist. Total duration of exercise training will last for 8 weeks
223577513|NCT05590000|DEVICE|Gemini SCS neuromodulation system|This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.
223577514|NCT01047800|BEHAVIORAL|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
223577515|NCT04907968|DRUG|XMT-1536 (Upifitamab Rilsodotin)|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
223577516|NCT04907968|DRUG|Carboplatin|"Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles."
223577517|NCT02897752|DEVICE|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
223577518|NCT02897752|OTHER|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
223577519|NCT02688582|OTHER|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
223577520|NCT03745352|DRUG|Azacitidine|Given IV or SC
223577521|NCT03745352|DRUG|Pevonedistat|Given IV
223743588|NCT06913894|BEHAVIORAL|Minimal Educational Intervention for DRF|"Participants assigned to the No Therapy Group (NTG) will receive a minimal intervention consisting solely of general educational material. At the time of cast removal, they will be provided with a simple, standardized educational brochure that contains basic instructions for wrist and hand movement (e.g., move your wrist as tolerated). No additional therapy sessions, home exercise logs, or follow-up telephone calls will be provided beyond routine care. This intervention is intended to reflect the absence of a formal rehabilitation program and serves as the control for evaluating the added benefit of supervised and home-based therapy."
223743589|NCT06949072|DRUG|Test Dentifrice|Dentifrice containing 5 percent (%) weight by weight (w/w) Potassium nitrate (KNO3) and 1150ppm fluoride as sodium fluoride.
223466156|NCT01726166|PROCEDURE|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
223466157|NCT01726166|PROCEDURE|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
223466158|NCT03423043|RADIATION|Low Dose CT Scan of the Wrist|A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
223466159|NCT03434639|DIAGNOSTIC_TEST|Spectroscopic gut permeability test|"The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol."
223466160|NCT05509361|BIOLOGICAL|AK101 injection SC|AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
223743590|NCT06949072|DRUG|Reference Dentifrice|Dentifrice containing 1100ppm fluoride as stannous fluoride.
223743591|NCT06949072|DRUG|Negative Control Dentifrice|Dentifrice containing 5% KNO3 with no fluoride.
223743592|NCT04519580|DIAGNOSTIC_TEST|PET/CT|FDG-PET/CT at baseline, week 8 and week 10.
224158253|NCT04334512|DIETARY_SUPPLEMENT|Vitamin C|Treatment with vitamin C
223577522|NCT02988999|DIETARY_SUPPLEMENT|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
223577523|NCT02988999|DIETARY_SUPPLEMENT|erythritol|non-calorie sweetener
223577524|NCT00536874|DRUG|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
223577525|NCT00536874|DRUG|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
223577526|NCT00536874|GENETIC|protein expression analysis|
223577527|NCT00536874|GENETIC|proteomic profiling|
223577528|NCT00536874|OTHER|diagnostic laboratory biomarker analysis|
223577529|NCT00536874|PROCEDURE|adjuvant therapy|
223577530|NCT00536874|PROCEDURE|neoadjuvant therapy|
224158254|NCT04334512|DIETARY_SUPPLEMENT|Vitamin D|Treatment with vitamin D
224158255|NCT04334512|DIETARY_SUPPLEMENT|Zinc|Treatment with Zinc
224158256|NCT02452749|DIETARY_SUPPLEMENT|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
224158257|NCT01525303|BEHAVIORAL|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
224158258|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations containing MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the active comparator on the randomly assigned side of split-face (the treatment side) on the same day, and sequently, will apply the active comparator to this side twice a day for 28 days.
223577531|NCT00536874|PROCEDURE|therapeutic conventional surgery|
223577532|NCT05460598|OTHER|beddings with cooling effects|beddings with cooling effects (mattress topper and bed linen)
223577533|NCT05460598|OTHER|commonly used bedding|commonly used bedding
223577534|NCT03186014|DEVICE|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
223577535|NCT00011414|DRUG|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
223577536|NCT04287803|DRUG|Methoxyflurane|Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
223743593|NCT07178366|OTHER|Standard medical therapy (SMT)|Standard medical therapy includes nutritional support (25-30 kcal/kg/day), lactulose, bowel wash, albumin, vasopressors (norepinephrine/terlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.
224158259|NCT06140628|COMBINATION_PRODUCT|Fotona4D Pro® treatment followed by daily use of formulations without MLYAAT-1002®|Each subject will receive a single treatment of the Fotona4D Pro® , followed by the first application of the placebo comparator on the randomly assigned side of split-face (the control side) on the same day, and sequently, will apply the placebo comparator to this side twice a day for 28 dayd.
224158260|NCT05444413|BIOLOGICAL|ultrasound-guided platelet rich plasma nerve block|selected persons are treated by ultrasound-guided platelet rich plasma nerve block and the regular medicine
224158261|NCT03499769|PROCEDURE|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
224158262|NCT03997760|DRUG|TAK-755|Participants will receive TAK-755 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg.
224158263|NCT03997760|OTHER|Placebo|Participants will receive placebo matched to TAK-755 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion.
224158264|NCT01674946|OTHER|saline|intraduodenal perfusion
224158265|NCT01674946|OTHER|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
223577537|NCT00762996|DEVICE|etafilcon A|contact lens
223577538|NCT00762996|DEVICE|omafilcon A|contact lens
223577539|NCT00070252|DRUG|Capecitabine|Given PO
223577540|NCT00070252|DRUG|Docetaxel|Given IV
223577541|NCT00070252|OTHER|Laboratory Biomarker Analysis|Correlative studies
223577542|NCT00070252|OTHER|Pharmacological Study|Correlative studies
223577543|NCT00070252|DRUG|Tipifarnib|Given orally (PO)
223577544|NCT04610489|DIAGNOSTIC_TEST|Quidel Sofia SARS Antigen FIA|Obtained via bilateral mid-turbinate swab.
223577545|NCT05529342|BIOLOGICAL|Gene modified therapy|No investigational cell product will be administered
223577546|NCT06356779|PROCEDURE|Local ablative therapy (LAT)|Surgical metastasectomy, stereotactic ablative radiotherapy, thermal ablation, or electroporation to all oligometastatic lesions
223577547|NCT04278937|DRUG|Azithromycin Tablets|one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks
223743594|NCT07178366|DEVICE|Double Plasma Molecular Adsorption System (DPMAS)|DPMAS therapy uses extracorporeal liver support with two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). Minimum 2 sessions (3-4 hours each) are performed within the first 7 days, with additional sessions if partial response is observed.
224158266|NCT01674946|OTHER|oleanolic acid|intraduodenal perfusion
224158267|NCT01674946|DIETARY_SUPPLEMENT|oleic acid|intraduodenal perfusion
224158268|NCT00856986|DRUG|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
224303477|NCT04847349|DIETARY_SUPPLEMENT|Placebo|Capsule containing inactive ingredients such as a product of potato starch (maltodextrin), but no probiotics.
223466161|NCT05606601|BEHAVIORAL|Minder|"There are four main components of the Minder app: The Chatbot, Services, Community, and Peer Coaching components. The Services component asks participants to complete a series of questions on various mental health, substance use, and general life issues. It then recommends community and on-campus resources based on their current needs. The Community component of the app matches individuals with groups (e.g., student clubs) and events at the university or in the broader community that they may be interested in. The Chatbot component of the app contains pre-formatted conversational scripts that users engage with via a chatbot and videos designed to teach evidence-based skills (e.g., cognitive strategies to manage anxiety) that can be applied to everyday life. To support use of the app, all users in the intervention group will be offered access to trained peer coaches to help users navigate the different app components and provide non-clinical peer support."
223577548|NCT04798742|PROCEDURE|Gluteus maximus transfer|Gait analysis study of 15 patients with gluteus medius disruption
223577549|NCT02689076|OTHER|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
223577550|NCT02689076|OTHER|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
224158269|NCT00856986|DRUG|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
224158270|NCT00856986|DRUG|metformin|Metformin tablets, at least 1500 mg/day
224158271|NCT04990375|DEVICE|tDCS|5 sessions of 20-minute tDCS at 2 mA over the dorsolateral prefrontal cortex (35cm² sponge)
224303478|NCT04086836|DEVICE|TAVR|Patient recieving a TAVR
223466162|NCT02991365|OTHER|nasal insulin|
223466163|NCT02991365|OTHER|placebo spray|
223466164|NCT04074265|DRUG|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
223466165|NCT04074265|DRUG|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
223466166|NCT03694379|OTHER|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
223466167|NCT00072384|DRUG|liposomal vincristine sulfate|Given IV
223466168|NCT00072384|PROCEDURE|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
223466169|NCT00072384|PROCEDURE|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
223466170|NCT00072384|DRUG|carboplatin|Given IV
223466171|NCT00072384|DRUG|etoposide|Given IV
223466172|NCT00072384|BIOLOGICAL|filgrastim|Given subcutaneously
223466173|NCT01825200|BIOLOGICAL|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
223466174|NCT01825200|BIOLOGICAL|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
223466175|NCT04507152|OTHER|Blood flow restriction resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The experimental group will execute the training with blood flow restriction.
223466176|NCT04507152|OTHER|Resistance training|The participants will carry weights and perform certain resistance exercises, such as step-up, sit-to-stand, and tip-toe-standing. The control group will execute the training without blood flow restriction.
223466177|NCT00405301|DRUG|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
223466178|NCT03222908|BEHAVIORAL|Intervention1: Contract Agreement|Smoking Cessation Contract
223466179|NCT03222908|BEHAVIORAL|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
223466180|NCT00065299|BEHAVIORAL|Restricted phenylalanine diet|
223577551|NCT01904643|DRUG|lenalidomide|Given PO
223577552|NCT01904643|DRUG|mitoxantrone hydrochloride|Given IV
223577553|NCT01904643|DRUG|etoposide|Given IV
223466181|NCT04216147|OTHER|PNE|Percutaneous Needle Electrolysis: the application of galvanic current through an acupuncture needle.
223466182|NCT04216147|PROCEDURE|Surgery for CTS|Median nerve release
223577554|NCT01904643|DRUG|cytarabine|Given IV
223743595|NCT07177313|PROCEDURE|Ureteroscopy|patients presenting with acute ureteral obstruction who undergo primary ureteroscopy (URS).
223743596|NCT07179978|DRUG|Lorazepam|The primary exposure of interest will be oral lorazepam at a dose range of \>1-4 mg/day.
224158272|NCT04580212|BEHAVIORAL|Poultry hygiene intervention|The intervention will consist of a series of participatory training exercises designed to accomplish three main goals: (1) increase awareness of health risks and lost livelihood benefits of current poultry management practices, (2) build practical skills for poultry management, and (3) build supportive community norms by facilitating savings group discussions on poultry management. The intervention will be delivered through three activities: (1) triggering exercise designed to raise awareness of both the health risks of the current practices and the economic potential of a more active poultry management approach, and ultimately to motivate participants for behavior change, (2) poultry management training activity based on local needs and norms, and (3) periodic follow-on coaching to reinforce messages from the initial training and emphasize action planning, monitoring of plan execution, and troubleshooting.
224158273|NCT03076242|OTHER|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
224158274|NCT00858676|DRUG|acarbose|50mg acarbose 3 times a day PO. duration: one year
224303479|NCT03393806|DRUG|GSK3772847|GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
223466183|NCT06402019|DRUG|Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)|Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
223466184|NCT06402019|DRUG|normal saline|Group went under multiple sessions of normal saline injection.
223466185|NCT02810782|DRUG|Phenobarbital|Phenobarbital per os
223577555|NCT03763344|BEHAVIORAL|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
223466186|NCT02810782|DRUG|Chlorpromazine|Chlorpromazine per os
223466187|NCT02810782|DRUG|Morphine|Morphine per os
224158275|NCT04260672|BEHAVIORAL|Child Centred Health Dialog (CCHD)|"The universal part of CCHD means a structured dialogue between the nurse and the child in presence of its parents using eight illustrations based on the most important practices associated with overweight in preschool children: fruit and vegetables consumption, intake of sweetened beverages and portion size, physical activity, sedentary behaviour tooth brushing and sleep routines. The health dialog is completed by demonstrating the BMI-growth chart to show BMI development to give parents an accurate weight perception, identify overweight and support parental readiness towards a healthy lifestyle.~When the child is identified with an overweight or obesity, the entire family is invited to participate in the targeted part of CCHD: the Family Guidance, a family consultation based on the evidence based Standardized Obesity Family Therapy (Nowicka, 2011)."
224158276|NCT01955785|DEVICE|pressure controlled ventilator|
224158277|NCT01955785|DEVICE|Pressure Regulated Volume Controlled Ventilator|
224158278|NCT02335034|BEHAVIORAL|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
224158279|NCT02335034|BEHAVIORAL|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
224158280|NCT03926780|DRUG|Rivaroxaban 20 MG|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
223466188|NCT03460041|DRUG|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
223466189|NCT03460041|DRUG|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
223466190|NCT03460041|DRUG|Bupivacaine|Caudal bupivacaine for pain management
223466191|NCT00490035|OTHER|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
223466192|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
223466193|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
223466194|NCT00490035|DRUG|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
223743597|NCT07184164|BEHAVIORAL|Educational Program by Using Behavior Change Wheel Model|"The BCW model includes three layers: the behavior system, intervention functions, and policy categories, with the last not being applied in this study. The research was structured into four phases: assessment, planning, implementation, and evaluation.~Phases of the Study Assessment Phase: Researchers introduced themselves to parents and adolescents through personal interviews, explaining the study's significance. They collected demographic data in the forensic and toxicology department, using various tools to assess adolescents' behaviors before the educational program.~Planning Phase: A tailored BCW model encompassed a wide range of educational interventions. The content"
224158281|NCT03926780|DRUG|Warfarin Sodium|38 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
224158282|NCT04576416|OTHER|AI augmented training and clinical feedback|"The educational platform has two modules:~The training module includes AI enhanced case training on a library of 10,000+ benign and malignant skin lesion cases each coupled to written learning modules. Participants will be able to track their progression through automatically generated performance statistics and discuss difficult cases with peers within the application.~Clinical feedback is defined as diagnostic feedback on all cases registered in the registration module. Feedback during the trial will be based on either histopathology or the consensus agreement of domain experts (if no biopsy is taken). Feedback on referred or dismissed skin lesions will be provided by independent experts in skin cancer diagnostics ( \>10 years of experience) through a web-based review system developed by our group."
224158283|NCT04790734|DRUG|Sedation drugs|Different sedation drugs
224158284|NCT02310724|OTHER|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
223466195|NCT04076241|OTHER|Osteopathic manipulative treatment|The investigators applied six different OMT techniques including rib raising, diaphragm release, suboccipital decompression, first rib mobilization, mediastinum mobilization and thoracic inlet myofascial release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilization of the first rib which is associated with sternum, sympathetic truncus and important vascular structures. Thoracic inlet is an important structure resisting intrathoracic pressure changes during respiration. Finally, the goal of the mediastinum mobilization is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
223466196|NCT04076241|OTHER|Yoga respiratory training|Nadishodhana pranayama (Alternate nostril breathing), Ujjayi pranayama (Psychic breath) and Bhramari pranayama (Humming bee breath) were used for the study. Nadishodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 8 breathing cycles with a resting time of 2 minutes between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 2 sets of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 2 sets of 10 breathing cycles per session with a respiration rate of 3-4/min.
223466197|NCT04310722|OTHER|None intervention. This is an observational study.|None intervention. This is an observational study.
224158285|NCT01199198|DRUG|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
224158286|NCT01199198|DRUG|Placebo|Placebo by mouth once a day for 14 days.
224158287|NCT01976585|DRUG|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
224158288|NCT01976585|DRUG|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
223466198|NCT06295432|DRUG|DZD9008+AZD4205|Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
223466199|NCT03519009|BEHAVIORAL|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
223466200|NCT00731822|DRUG|GW685698/GW642444|GW685698/GW642444
223466201|NCT06354491|DEVICE|Magnetic Resonance Imaging (MRI)|MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.
223743598|NCT07184164|BEHAVIORAL|Routine Health Education|Participants in the control group received the routine health education and advice from nurses and healthcare providers working in the study settings
223743599|NCT07183813|DEVICE|Electroacupuncture group|The needles will be inserted to 15-40mm in acupoints through adhesive pads. Needles will be lifted, thrusted and twirled gently for 3 times to achieve deqi sensation and manipulated every ten minutes during 30-minute maintenance. The electronic acupuncture apparatus will be connected to the bileteral Taiyang, Anmian and Baihui, with a continuous wave of 2 Hertz (Hz) and an electric current of 1-3 milliampere (mA). Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.
224158289|NCT01507441|GENETIC|gene mapping|
224158290|NCT01507441|GENETIC|microarray analysis|
224158291|NCT01507441|GENETIC|mutation analysis|
224158292|NCT01507441|GENETIC|nucleic acid sequencing|
224158293|NCT01507441|OTHER|laboratory biomarker analysis|
224158294|NCT04945304|PROCEDURE|magnetic bariatric surgery|Perform a roux-en-y gastric bypass, sleeve gastrectomy, nissen-sleeve or revisional bariatric procedure with magnetic assistance
224158295|NCT04945304|PROCEDURE|Magnetic gastric bypass|Using the magnetic assistance to perform a gastric bypass
224158296|NCT02892734|BIOLOGICAL|Ipilimumab|Given IV
224158297|NCT02892734|OTHER|Laboratory Biomarker Analysis|Correlative studies
224158298|NCT02892734|BIOLOGICAL|Nivolumab|Given IV
224158299|NCT02043509|BEHAVIORAL|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
224158300|NCT03672552|OTHER|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
224158301|NCT03930277|DIAGNOSTIC_TEST|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
224158302|NCT01200563|DEVICE|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
224158303|NCT01200563|DEVICE|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
224158304|NCT01200563|DEVICE|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
224158305|NCT02392676|DRUG|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
224158306|NCT02392676|DRUG|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
223466202|NCT06354491|DEVICE|Ultrasound (US)|In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.
223466203|NCT04585919|BEHAVIORAL|Paired Screening Intervention|The intervention is the implementation of a paired outreach strategy to patients in need of colorectal cancer screening to offer FIT testing and to complete screening for social determinants of health. These screening activities are part of routine practice but the intervention that is being implemented is the paired outreach for both CRC screening and SDOH screening.
223466204|NCT02432599|RADIATION|F18-choline PET examination|F18-choline PET examination will be performed before surgery
223466205|NCT05686577|OTHER|no intervention|no intervention
223466206|NCT03877744|BEHAVIORAL|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
223466207|NCT03877744|BEHAVIORAL|live technician|parents will install car seat through guidance from a live certified technician who is present
223466208|NCT02779985|DIETARY_SUPPLEMENT|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
223466209|NCT02779985|DIETARY_SUPPLEMENT|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
223466210|NCT01987856|PROCEDURE|Blastocyst morphology|microscopic examination only
223466211|NCT05294952|GENETIC|real time PCR|diagnostic test
224158307|NCT00093158|DRUG|Angiomax (bivalirudin) anticoagulant|
224158308|NCT03254849|DRUG|Empagliflozin|1 tablet
223577556|NCT05892367|OTHER|Transbrachial Access for Interventions|Adding a positioning splint in addition to compression bandage after intervention in order to guarantee immobilization of puncture site
223577557|NCT01540448|PROCEDURE|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
223743600|NCT07183813|DEVICE|Sham electroacupuncture|The needle will be inserted to 2-3mm in Bai Hui acupoint. For the remaining acupoints, needles will be inserted into the pad till reaching but without penetrating the skin. Needles will be lifted, thrusted and twirled gently for 3 times to simulate the effects of the needle tip penetrating the skin. The electronic acupuncture apparatus will be connected to the Baihui acupoint, Shang Yin Tang acupoint, and bilateral An Mian acupoints, with a continuous wave of 2 Hertz (Hz) and an electric current of 0.1-0.3 mA. In about 3-5 seconds, the electric current will be turned down. Participants receive acupuncture treatment three times a week in the first two weeks and twice a week in the last six weeks.
223743601|NCT07181655|OTHER|Modified Intermittent Fasting|Participants in Intervention group will follow a structured intermittent fasting protocol, specifically the 16:8 method, where they fast for 16 consecutive hours each day and restrict their eating to an 8-hour window. The fasting period can be personalized to suit individual schedules. During these fasting hours, participants must abstain from all foods and caloric drinks, but are encouraged to stay hydrated with non-caloric beverages and they will follow a structured, calorie-restricted diet, tailored to them, using a developed Food Frequency Questionnaire tool to select their daily calorie intake across sections to identify appropriate foods and beverages for patients with metabolic conditions. They will be prescribed to engage in at least 150 minutes per week of moderate intensity aerobic activities, such as brisk walking will be measured and evaluated using the mobile application of physical activity recommended by the Ministry of Health in Saudi Arabia.
224158309|NCT03254849|DRUG|Hydrochlorothiazide 25 mg|1 tablet
224158310|NCT04535258|DEVICE|Blend-A|Treatment for alcohol use disorders will be offered also as an internet-based option.
223466212|NCT05218187|DEVICE|G-EO End-Effector Gait Trainer|The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
224158311|NCT00492895|DRUG|Discontinuation of Azathioprin|Discontinuation of Azathioprin
224158312|NCT00307944|DRUG|Pantoprazole|
224158313|NCT00251849|DRUG|Rifalazil|
224158314|NCT03474237|OTHER|Hormone study and Imaging study|"1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging"
224158315|NCT02410746|OTHER|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
224158316|NCT02410746|OTHER|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
223466213|NCT05218187|OTHER|Conventional Physical Therapy Treatment|Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
223466214|NCT06475365|OTHER|Sodium chloride gargle|15mL salt water gargle
223466215|NCT05263934|BIOLOGICAL|Depemokimab|Depemokimab will be administered
223466216|NCT05263934|BIOLOGICAL|Mepolizumab|Mepolizumab will be administered
223466217|NCT05263934|DRUG|Placebo matching mepolizumab|Placebo matching to mepolizumab will be administered.
223466218|NCT05263934|DRUG|Placebo matching depemokimab|Placebo matching to depemokimab will be administered.
223466219|NCT06638671|DRUG|Metformin Hydrochloride|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
224303480|NCT03393806|DRUG|Placebo|Commercially sourced sterile normal saline will be provided as Placebo
223466220|NCT06638671|DRUG|Placebo|Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.
223466221|NCT05879458|DRUG|Ritlecitinib|200 mg QD for 8 weeks followed by 100 mg for 16 weeks
223466222|NCT05549622|OTHER|Low-soluble fiber diet|12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet
223466223|NCT05549622|OTHER|High-soluble fiber diet|12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
223743602|NCT07181226|DEVICE|High-frequency repetitive transcranial magnetic stimulation|High-frequency rTMS was delivered to the left dorsolateral prefrontal cortex using the 5 cm rule to localize the target site. Stimulation intensity was set at 100% of the resting motor threshold, determined by visible motor-evoked potentials in the right abductor pollicis brevis muscle. Each session consisted of 1500 pulses at 10 Hz, organized into 10 trains of 15 seconds (150 pulses per train) with 50-second inter-train intervals. Total stimulation time per session was approximately 12.5 minutes. A figure-of-eight coil (70BFX-LQC, Deymed Diagnostics) connected to a DuoMagXT-100 stimulator was used, with the coil positioned at \~45° from the midline, handle pointing posterolaterally.
223466225|NCT02511327|DRUG|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
223577558|NCT01540448|PROCEDURE|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
223466226|NCT00669188|OTHER|Information absent|Information
223466227|NCT00669188|OTHER|Information|Information
223577559|NCT01540448|PROCEDURE|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
224158317|NCT02410746|OTHER|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
223466228|NCT05720559|DRUG|Oxaliplatin|Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area
223466229|NCT05720559|DRUG|S1|Orally on d2-d15 at 20 mg three times daily
223466230|NCT05720559|DRUG|Cetuximab|Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.
223466231|NCT05720559|DRUG|Metronidazole|Metronidazole 0.4g/time, qd
224158318|NCT00726492|OTHER|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
223466232|NCT05720559|DRUG|Vitamin A|Vitamin A 25,000 units/time, qd
223466233|NCT05720559|DRUG|Folic acid|Folic acid 0.4 mg/time, qd
223466234|NCT05720559|DRUG|Capecitabine|Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.
223466235|NCT01439113|PROCEDURE|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
223466236|NCT04302402|DRUG|Rifaximin|Rifaximin has been demonstrated in multiple IBS studies, through a postulated effect on the gut microbiota, to improve the symptoms of pain and bloating, which are important symptoms in subjects with functional dyspepsia
223466237|NCT04302402|DRUG|Placebo|Similar looking placebo
223466238|NCT05209880|BEHAVIORAL|ED GOAL|The emergency department clinician-led, behavioral intervention (ED GOAL) is designed to engage seriously ill yet clinically stable older adults in the emergency department to address their values and preferences towards end-of-life care with their outpatient clinicians. The intervention consists of an interview to discuss participants' values and preferences for end-of-life care. The participants will receive coaching on how to initiate/re-introduce discussions about end-of-life wishes with their loved ones and outpatient clinicians. The participants' outpatient clinicians will also receive a summary of what participants disclosed via email or mailed letter.
223466239|NCT00432900|RADIATION|[(11)C]PBR28|PET Ligand
223466240|NCT03301402|DEVICE|Air purifier|Air purifier with filter at automatic mode on all time
223466241|NCT02889224|OTHER|Obese|
223466242|NCT02889224|PROCEDURE|Hypercortisolism|
223466243|NCT02889224|OTHER|Hydrocortisone|
223466244|NCT02889224|OTHER|Control|
223466245|NCT06044818|DEVICE|Accexible|Speech Analysis
223466246|NCT04741438|DRUG|Nivolumab and IPILIMUMAB|"The combination of Nivolumab+Ipilimumab will be given to patients as follows:~* Nivolumab: 3 mg/kg IV over 30 minutes every 2 weeks for 4 cycles.~* Ipilimumab 1 mg/kg IV over 60 minutes every 6 weeks for 4 cycles. After completion of 4 courses with ipilimumab, patients continue receiving nivolumab IV at the dose of 480 mg Q4W in the absence of disease progression or unacceptable toxicity for a maximum of 18 months.~Nota Bene: A cycle is defined as a 6-weeks period.~The planned treatment period is 24 months~Nivolumab and Ipilimumab must be injected the same day every 6 weeks (Q6W). In case of toxicity, dose will be delayed, but will not be reduced."
223466247|NCT04741438|DRUG|Pazopanib Oral Tablet [Votrient]|"Treatment by pazopanib 800 mg/day per os, continuously during a maximum 24 months.~In case of toxicity, dose will be delayed and reduced."
223466248|NCT02539069|DEVICE|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
223466249|NCT00194935|DRUG|Topotecan|
223466250|NCT04261140|OTHER|EQUIA Forte Fil|"Apply cavity conditioner (20% polyacrylic acid) 10 s on enamel and dentine, rinse Mix 10 s and apply bulk-fill Apply EQUIA coat and light cure for 20 s~unit"
223466251|NCT04261140|OTHER|Clearfil Majesty Esthetic|Apply in 2-mm increment, light cure for 20 s
224158319|NCT00726492|OTHER|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
224158320|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of multiple IVT injection
224158321|NCT05489718|BIOLOGICAL|IBI324|Dose 2 IBI324 of single IVT injection
224158322|NCT05489718|BIOLOGICAL|IBI324|Dose 1 IBI324 of single IVT injection
224303481|NCT04193306|DRUG|Alirocumab|Alirocumab 150 mg s.c. every 2 weeks
224303482|NCT04193306|OTHER|Placebo|Placebo s.c. every 2 weeks
224303483|NCT00152178|DRUG|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
224303484|NCT00152178|DRUG|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
224303485|NCT02552056|OTHER|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
224303486|NCT01259115|DRUG|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
224303487|NCT01259115|DRUG|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
224303488|NCT01259115|DRUG|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
223466252|NCT04261140|OTHER|NexComp Flow|Apply in 2-mm increment light cure for 20 s
223466253|NCT04261140|OTHER|3M Espe Bulk-fill|Apply in single increment up to 4 mm; light curing for 20 s
223466254|NCT05864950|DEVICE|MRI|Participants will undergo an MRI scan while performing exercise at two intensities (light and moderate/vigorous) using an MRI-compatible stepper device.
223466255|NCT06958627|DRUG|pyrotinib|Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.
223577560|NCT06373770|DIAGNOSTIC_TEST|Ayres sensory integration therapy|"A. Jean Ayres, is a theory and practice that targets a person's ability to process and internally integrate sensory information from their body and environment. Sensory information may be visual, auditory, tactile, proprioceptive, and/or vestibular in nature. ASI uses individually tailored activities that utilize just right challenges to an individual's existing patterns of sensory processing and motor planning and encourage movement and organization of self in time and space. ASI incorporates specialized equipment and materials in purposeful and playful activities in order to improve adaptive behavior."
224158323|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of single IVT injection
224158324|NCT05489718|BIOLOGICAL|IBI324|Dose 3 IBI324 of multiple IVT injection
224158325|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - weekly
224158326|NCT00854685|DRUG|ART621|3.0mg/kg s.c. - fortnightly
224158327|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - weekly
224303489|NCT06387485|DEVICE|3D Printed Anatomic Model|Patient-specific 3D printed anatomic model for pre-surgical planning
224158328|NCT00854685|DRUG|ART621|1.5mg/kg s.c. - fortnightly
224158329|NCT00854685|DRUG|Placebo|Placebo s.c. - weekly
224158330|NCT00854685|DRUG|Placebo|Placebo s.c. - fortnightly
224158331|NCT02089178|PROCEDURE|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
224158332|NCT02089178|PROCEDURE|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
224158333|NCT02089178|DRUG|propofol-remifentanil|
224158334|NCT02089178|DRUG|sevoflurane-remifentanil|
224158335|NCT01670825|PROCEDURE|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
224158336|NCT01670825|DRUG|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
224158337|NCT01670825|DRUG|Local anethestic injection|
224158338|NCT04697888|DRUG|Omegaven|Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.
224303490|NCT06387485|DIAGNOSTIC_TEST|CT/MRI|Standard imaging type for bony tumors
224303491|NCT04809883|DIAGNOSTIC_TEST|Endoflip measurement of gastric and pyloric function|Endoflip device to measure gastric and pyloric functions
224303492|NCT00040183|DRUG|Tarceva (erlotinib HCl, OSI-774)|
224303493|NCT00006083|DRUG|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
224303494|NCT00006083|OTHER|placebo|placebo injected subcutaneously daily
224303495|NCT01151228|OTHER|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
224303496|NCT01675661|DRUG|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
224303497|NCT01675661|DRUG|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
224303498|NCT03485183|DEVICE|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
224303499|NCT03485183|OTHER|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
224158339|NCT04513106|BEHAVIORAL|"ACP programme Have a Say"|It is a theory-driven advance care planning programme specifically designed for PWEDs or persons with MCI and their family caregivers. The intervention is underpinned by the Bandura's self-efficacy model. Each dyad of participants will receive a 3-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 1 group-based sessions and 2 dyadic discussions. One hour for each session, and once weekly. Dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. They will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participant will be given an ACP booklet documenting the ACP process.
223466256|NCT06958055|RADIATION|videofluroscopy evaluation of swallowing function|Videofluoroscopy swallowing evaluation was done using solid food bolus at three different oral conditions: Without dentures (WOD), with the conventional complete denture (CDs) and with mandibular implant retained overdenture (IODs).
223466257|NCT06958939|DRUG|Dose level 1 group|1.0 × 10e6/kg S103 CAR-T cells
223466258|NCT06958939|DRUG|Dose level 2 group|2.0 × 10e6/kg S103 CAR-T cells
223466259|NCT06958939|DRUG|Dose level 3 group|4.0 × 10e6/kg S103 CAR-T cells
223466260|NCT06958939|DRUG|Dose level 4 group|8.0 × 10e6/kg S103 CAR-T cells
223466261|NCT06958640|BEHAVIORAL|Lifestyle interventions|"Dietary intervention: 30kcal energy intake per kilogram of body weight per day, increase vegetable intake, control sugar and alcohol intake, encourage overweight and obese people to lose weight, lose 0.5-1kg per month until the weight reaches the target.~Exercise intervention: Appropriate physical activity in spare time, 30-40 minutes per day, 5 times a week."
224158340|NCT04513106|BEHAVIORAL|Attention-control health talks|Dyads of participants in the control group will receive 3-session health talks. One hour for each session, and once weekly. The contents of the health talks are neither dementia-specific nor related to ACP, and cover general health information for elderly, such as drug safety, home safety, exercise and health. This is to differentiate the effect of the intervention from the effect of the extra time and attention given to the participants
224303500|NCT02620644|DEVICE|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
223466262|NCT06959628|DEVICE|Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets|To evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System Combined with Introducer Sets for Cerebral Protection During Carotid Angioplasty
223466263|NCT06810882|DRUG|Perineural ondansetron|Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml (4 mg) ondansetron. At the same time, 15 ml saline will be injected slowly IV over 15 minutes.
223466264|NCT06810882|DRUG|Intravenous ondansetron|Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml saline. At the same time, 4 mg (2 ml) ondansetron mixed with 13 ml saline (total 15 ml) will be slowly injected IV over 15 minutes.
223466265|NCT06849466|DRUG|Dexmedetomidine|Dexmedetomidine Hydrochloride Nasal Spray Dexmedetomidine is a selective alpha-2 adrenergic agonist primarily used for its sedative, anxiolytic, and analgesic effects. It works by inhibiting the release of norepinephrine in the central nervous system, leading to sedation, decreased anxiety, and reduced pain sensitivity. When used intranasally, it can offer an effective, non-invasive method for sedating patients and improving sleep quality, particularly in perioperative settings.
223466266|NCT06849466|DRUG|Saline solution|The saline solution will be used as a placebo, and the same device will be employed for intranasal administration.
223466267|NCT06090357|OTHER|Plantar pressure|Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.
223743603|NCT07181226|DEVICE|Intermittent Theta Burst Stimulation|Intermittent theta-burst stimulation (iTBS) was delivered to the left dorsolateral prefrontal cortex using the 5 cm rule for target localization. Stimulation intensity was set at 100% of the resting motor threshold, determined by motor-evoked potentials in the right abductor pollicis brevis muscle. Each session consisted of 600 pulses delivered in bursts of three 50 Hz pulses repeated every 200 ms. Trains of 2 seconds were followed by 8-second inter-train intervals. Total stimulation time per session was approximately 3 minutes and 20 seconds. A figure-of-eight coil (70HF-LQC, Deymed Diagnostics) connected to a DuoMagXT-100 stimulator was used, with coil orientation \~45° from the midline, handle pointing posterolaterally.
224303501|NCT04428515|DEVICE|Photoacoustic Imaging System|Photoacoustic Imaging investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer
224303502|NCT00567047|DRUG|vildagliptin|
223466268|NCT06962098|DRUG|Isuzinaxib|Oral dosing regimen once daily
223466269|NCT06962098|DRUG|Placebo|Oral dosing regimen once daily
223466270|NCT05573451|DIAGNOSTIC_TEST|ultrasound - transvaginal/transrectal + transabdominal|Each patient undergoes at least ultrasound examination and PET-CT.
223466271|NCT06187337|DEVICE|Maxillary expansion device|The maxillary expansion device is a orthodontic appliance that is used to expand the maxilla in children.
223466272|NCT03327818|PROCEDURE|hysterectomy|
223466273|NCT03327818|PROCEDURE|uterine conservative study|
223466274|NCT02871609|OTHER|Stent examination, urinary analysis, USSQ questionnaire|
223466275|NCT04817332|DRUG|Brensocatib|Selective, competitive, and reversible inhibitor of DPP1
223466276|NCT04817332|DRUG|Placebo|Matched placebo
223466277|NCT00333489|DRUG|valsartan|
223466278|NCT05688215|PROCEDURE|Biospecimen Collection|Undergo collection of blood and tissue samples
223466279|NCT05688215|PROCEDURE|Computed Tomography|Undergo a CT scan
223466280|NCT05688215|PROCEDURE|Core Biopsy|Undergo core biopsy
223466281|NCT05688215|DRUG|Fluorouracil|Given IV
223466282|NCT05688215|DRUG|Irinotecan|Given IV
223466283|NCT05688215|DRUG|Leucovorin|Given IV
223466284|NCT05688215|DRUG|Leucovorin Calcium|Given IV
223466285|NCT05688215|DRUG|Oxaliplatin|Given IV
223466286|NCT05688215|DRUG|Quemliclustat|Given intravenously (IV)
224303503|NCT03512860|DRUG|E4/DRSP|Administered as specified in the treatment arm.
224303504|NCT03512860|DRUG|VAL|Administered as specified in the treatment arm.
223466287|NCT05688215|DRUG|Zimberelimab|Given IV
223466288|NCT05200273|DRUG|AK114|AK114 administered by subcutaneous injection
224158341|NCT04908969|BEHAVIORAL|Internet-delivered Cognitive Behavior Therapy for Chronic Tic Dosorder/Tourette Disorder|The treatment will be provided through a secure internet platform designed for internet-administered treatments (BASS-4). In the treatment, the patient works through modules of self-help material, each ending in a short quiz with questions about the material. The treatment is supported by a therapist through text-based communication via the platform as well as occasional phone calls when needed. The central component in the treatment is exposure and response prevention (ERP). In ERP, the patient exposes her/himself to situations that trigger premonitory urges (a type of bodily sensation that precede the tic) while practicing to resist the tic. By doing this systematically and repeatedly, the patient gradually learns how to tolerate the premonitory urges and increase the ability to control and resist doing tics. Beyond ERP the treatment consists of other components such as applied relaxation, counter-movements and interventions to decrease stressors in the patient's everyday life.
224158342|NCT03419507|DEVICE|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
224158343|NCT03419507|DEVICE|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
224158344|NCT02030093|BEHAVIORAL|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
224158345|NCT04986111|PROCEDURE|Linear skin closure with wound drain|"An oval incision is made around the ileostomy and the continuity of the intestinal tract is restored after adhesion division.~Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. A Jackson-Pratt drainage tube is placed in the subcutaneous tissue and vertical mattress suture is performed with a non-absorbable thread."
224158346|NCT04986111|PROCEDURE|Purse-string skin closure with negative pressure wound therapy|"Recover the intestinal continuity after adhesion division by making a circular incision along the ileostomy Methods of anastomosis include either side-to-side or end-to-end, hand-sewing or stapling.~Linear suture of the rectus abdominis fascia layer by layer. Negative pressure wound therapy is performed after suturing the subcutaneous tissue using absorbable thread."
224158347|NCT01759693|PROCEDURE|Blood sampling|Blood sampling
224303505|NCT02393248|DRUG|Pemigatinib|
224303506|NCT02393248|DRUG|Gemcitabine|
224303507|NCT02393248|DRUG|Pembrolizumab|
224303508|NCT02393248|DRUG|Docetaxel|
224303509|NCT02393248|DRUG|Trastuzumab|
224303510|NCT02393248|DRUG|Retifanlimab|
224303511|NCT02393248|DRUG|Cisplatin|
223466289|NCT04390646|DRUG|GnRH, gonadorelin acetate|Drug administered by a subcutaneous pump
223466290|NCT04390646|DRUG|0.9% NaCl|Drug administered by a subcutaneous pump
223466291|NCT00203515|DEVICE|Standard Latex Foley Catheter|
223466292|NCT00203515|DEVICE|Silver Coated Latex Foley Catheter|
223466293|NCT03307928|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
223466294|NCT03307928|DIAGNOSTIC_TEST|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
223466295|NCT01368263|DRUG|goserelin acetate|Given SC
223466296|NCT01368263|DRUG|letrozole|Given PO
223466297|NCT01368263|DRUG|anastrozole|Given PO
223466298|NCT01368263|DRUG|chemotherapy|Standard chemotherapy
223466299|NCT01368263|PROCEDURE|Surgery|
223466300|NCT03095807|DRUG|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
223466301|NCT03095807|DRUG|Placebo|Administered subcutaneously (s.c., under the skin)
223466302|NCT01724827|DEVICE|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
223466303|NCT01724827|DEVICE|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
223743604|NCT07184398|OTHER|Intervention with Consolidated Cysteine (Immunocal) 20 g per day|CRWPI Immunocal® (Immunotec™) was administered at a dose of 20 grams (2 sachets once daily) for 12 consecutive weeks. The research team delivered Immunocal directly to the subjects and instructed them on how to mix and self-administer it.
224303512|NCT01096030|DRUG|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
224303513|NCT02890030|BEHAVIORAL|Questionnaire|"* Neurotoxicity~* Medications of interest~* General health~* Family history"
224303514|NCT02555748|DRUG|Pazopanib|
224303515|NCT02555748|DRUG|Sunitinib|
224303516|NCT05872893|DRUG|Ondansetron|Patients will receive age-adjusted doses of ondansetron 5mg/m2
224303517|NCT05872893|DRUG|Dexamethasone|Patients will receive dexamethasone 4mg/m2
224303518|NCT05515692|PROCEDURE|Biospecimen Collection|Correlative studies
224303519|NCT05515692|PROCEDURE|Computed Tomography|Undergo radiotherapy simulation using CT
224303520|NCT05515692|COMBINATION_PRODUCT|Electron Beam Therapy|Undergo electron beam radiotherapy
224303521|NCT05515692|PROCEDURE|High Frequency Ultrasound Imaging|Undergo HFUS
224303522|NCT05515692|OTHER|Questionnaire Administration|Ancillary studies
224303523|NCT05515692|RADIATION|Radiation Therapy Treatment Planning and Simulation|Undergo radiotherapy simulation using clinical setup
223466304|NCT06215742|BEHAVIORAL|Rehabilitation therapy|"Rehabilitation therapy includes~1. Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~2. Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~3. Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux."
223466305|NCT06215742|PROCEDURE|Stellate ganglion block|Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223466306|NCT03460678|DRUG|Pemetrexed|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21-day cycle, until disease progression or unacceptable toxic effects
223466307|NCT03460678|DRUG|Erlotinib|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
223577561|NCT06373770|DIAGNOSTIC_TEST|Behaviour Therapy|The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with this diagnosis. Risperidone and aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis.
223577562|NCT03377738|DIAGNOSTIC_TEST|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
224158348|NCT05298228|DRUG|Remimazolam bolus does administration|The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
224158349|NCT00650897|DRUG|Escitalopram|10-20 mg once daily
224158350|NCT01670708|BEHAVIORAL|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
224158351|NCT01670708|BEHAVIORAL|Probation as Usual|Probation officer supervises following standard protocols.
224158352|NCT00992914|PROCEDURE|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
224158353|NCT00992914|PROCEDURE|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
224158354|NCT02000219|BIOLOGICAL|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
224158355|NCT02936115|OTHER|TruSkin®|
224158356|NCT02936115|OTHER|Wound Cover|
224158357|NCT02866318|DEVICE|Echocardiography|
224158358|NCT01605890|DRUG|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
224158359|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
223466308|NCT06148870|DEVICE|Myopia Control Lens-1 (MCL1)|The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
223466309|NCT06148870|DEVICE|Myopia Control Lens-2 (MCL2)|The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
224158360|NCT00664157|BEHAVIORAL|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
223466310|NCT01982695|DRUG|Losartan|
223466311|NCT01982695|DRUG|Lisinopril|
223466312|NCT05656300|DIAGNOSTIC_TEST|MRI scan using USPIO particles|Diagnostic imaging
223466313|NCT02614638|OTHER|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
223577563|NCT02723890|DEVICE|Tyto Device|
223577564|NCT02452853|PROCEDURE|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
224158361|NCT02117791|DRUG|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
224158362|NCT00302055|BEHAVIORAL|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
224158363|NCT00302055|BEHAVIORAL|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
224303524|NCT05515692|PROCEDURE|Skin Biopsy|Undergo biopsy
223466314|NCT02614638|OTHER|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
223466315|NCT02686853|DRUG|Liposomal amphotericin B|
223466316|NCT04795466|BIOLOGICAL|Canakinumab|Biological subcutaneous injection
223466317|NCT04795466|OTHER|Placebo|Matching placebo subcutaneous injection
223466318|NCT05635045|DRUG|I 124-Evuzamitide|Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
223466319|NCT04692493|DRUG|targeted synthetic DMARD class|Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment
223577565|NCT02452853|DRUG|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
223577566|NCT02084238|DRUG|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
223466320|NCT04692493|DRUG|non-TNFi-biologic class|Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
223577567|NCT03146780|PROCEDURE|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
223577568|NCT03146780|PROCEDURE|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
223577569|NCT03146780|PROCEDURE|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
223577570|NCT03146780|PROCEDURE|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
223577571|NCT00693004|DRUG|PRX-03140|
224303525|NCT03651258|BEHAVIORAL|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
223577572|NCT00693004|DRUG|Donepezil|
223577573|NCT00693004|DRUG|Placebo|
223577574|NCT00641342|DEVICE|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
223577575|NCT03916016|BEHAVIORAL|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
223577576|NCT03916016|BEHAVIORAL|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
223577577|NCT05466695|DRUG|Tadalafil 5mg/sildenafil 25 mg|patients will use daily tadalafil or daily sildenafil for 2 months blood sample will be obtained before and after 2 months and also IIEF-5 score for clinical response
223466321|NCT05776303|BEHAVIORAL|Good Bowls|Healthy, frozen subsidized meals are made conveniently available on worksites.
223466322|NCT05776303|BEHAVIORAL|Good Bowls + App Nudges|"Healthy, frozen subsidized meals are made conveniently available on worksites.~Additionally, Bluetooth enabled beacons will be set up at each worksite that will send location specific messages to an individual's Smartphone via an App. These messages will include nutritional information, tips, and behavioral nudges."
223466323|NCT00242047|BIOLOGICAL|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
223466324|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
223466325|NCT01222000|DRUG|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
223577578|NCT00784732|DRUG|QAV680|
223577579|NCT00784732|DRUG|QAV680|
223577580|NCT00784732|DRUG|Mometasone Furoate|
223577581|NCT00442091|DRUG|dandelion juice|10 ml bid for 20-30 days
223577582|NCT04927104|DEVICE|PEEK Knee Prosthesis|After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
223577583|NCT01304329|DRUG|BI 10773|Medium dose oral administration
223577584|NCT01304329|DRUG|simvastatin|Medium dose oral administration
223577585|NCT01304329|DRUG|simvastatin|Medium dose oral administration
223577586|NCT01304329|DRUG|BI 10773|Medium dose oral administration
224303526|NCT05626439|DRUG|Staccato alprazolam|Study participants will receive single dose of Staccato alprazolam by inhalation at pre-specified time points.
223466326|NCT02296658|RADIATION|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
224158364|NCT04958525|PROCEDURE|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal|Keyhole neuroendoscopic transfrontal ultrasound-guided hematoma removal in basal ganglia region:According to the brain CT scan and reconstruct the operation plan, choose a side by 2 cm before the coronal suture line 4 cm and 3 cm center longitudinal incision formation of 2 cm bone drilling the hole, ultrasonic measurement and the size of hematoma puncture depth, and guide the puncture direction, the transparent channel under endoscopic direct placement hematoma backend, after entering the hematoma cavity, under the neural endoscopic removal of hematoma,Wash the hematoma cavity with warm salt water.Bipolar electrocoagulation hemostasis for active bleeding.An indwelling drainage tube was placed in the hematoma cavity, and ultrasonography determined that the hematoma was cleared satisfily without active bleeding.
224158365|NCT04958525|PROCEDURE|Small bone window craniotomy for hematoma removal under microscope|Small bone window craniotomy for hematoma removal under microscope:Small bone window craniotomy in frontotemporal region, no blood vessels and non-functional areas of the hematoma nearest to the cortex was cut open, the hematoma was removed under the microscope and the cavity of the hematoma was washed with warm saline, and bipolar electrocoagulation hemostasis was performed for active bleeding.An indwelling drainage tube was placed in the hematoma cavity and the operation was completed without active bleeding.
224158366|NCT01300000|OTHER|Human Milk|ad lib
224158367|NCT01300000|OTHER|Investigational infant formula|ad lib
223466327|NCT02296658|DRUG|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
223466328|NCT02517957|DRUG|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
223466329|NCT02517957|DRUG|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
223466330|NCT02517957|DRUG|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
223466331|NCT02517957|DRUG|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
223466332|NCT03383991|PROCEDURE|Reverse Total Shoulder Arthroplasty|
223466333|NCT03383991|PROCEDURE|Hemiarthroplasty|
223466334|NCT01598805|BEHAVIORAL|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
223466335|NCT00891280|DRUG|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
223466336|NCT00398944|DEVICE|Evaluation of the impact of a guideline based computerized decision support system.|
223466337|NCT05920499|OTHER|AUDIT and Feedback|"AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to small but potentially important improvements in professional practice (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259).~Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group."
223466338|NCT02638974|OTHER|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
223466339|NCT04663685|OTHER|Exercise program|Participants received two 1-on-1 exercise sessions per week to start. Each session lasted 30 minutes. As progress was made, participants were encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises were aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift \& carry and calf raise.
223466340|NCT04663685|OTHER|Nutrition education|Participants received a nutrition education booklet and had access to five online videos that correspond to key topics in the booklet (reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day). Participants attended three 60-minute nutrition Q\&A sessions led by a dietitian, where the group reviewed content from the booklet and videos, and discussed personalized strategies to increase protein intake.
223466341|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
223466342|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
223466343|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
223466344|NCT01435759|DRUG|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
223466345|NCT01435759|DRUG|Antidepressant + Placebo|oral, once daily for 8 weeks
223577587|NCT03876600|PROCEDURE|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
223577588|NCT00247832|BEHAVIORAL|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
223577589|NCT00247832|BEHAVIORAL|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
224158368|NCT01300000|OTHER|Milk based standard infant formula|ad lib
224158369|NCT00923624|OTHER|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
223466346|NCT05661019|OTHER|Obtain Myotrace measurements|Myotrace measurement equipment, consisting of an application (i.e. non-medical software) running on a Philips laptop, Porti7 data acquisition system and software (Twente Medical Systems International (TMSi), Netherlands) (CE-approved), ECG cables, and three standard ECG (for EMG) electrodes. Also an on the shelf accelerometry sensor and respiration belt (TMSi) are used for the NRD measurement (CE-approved).
223466347|NCT02558764|DEVICE|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
223466348|NCT04346576|DIETARY_SUPPLEMENT|Probiotics prevent health problems in children|A controlled field trial was conducted with 1,036 children (3-5 years old) in Thanh Hoa province in Vietnam. The probiotic group (n=518) consumed fermented milk 65 mL/day containing 108 CFU/mL of LcS for the 12-week intervention period, whereas the control group (n=493) were not given any. The incidence of constipation, diarrhea, ARI, and anthropometry in children was determined at baseline, after 4, 8, and 12-week intervention and after the 4-week follow-up period.
223466349|NCT01793753|DRUG|Propofol|
223466350|NCT04368507|DRUG|YYB101|"1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity"
223466351|NCT01579513|DRUG|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
223466352|NCT01579513|DRUG|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
223466353|NCT03081247|DRUG|BGF 320/14.4/9.6 µg MDI|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
224158370|NCT00923624|BEHAVIORAL|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
224158371|NCT05295836|OTHER|PLACEBO|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + placebo one and half hours before the test.
224158372|NCT05295836|DIETARY_SUPPLEMENT|GLYCEROL|Athletes will perform the rectangular test at a temperature of 28°C and ingested 26 mL/kg body weight + 1.2 g of glycerol one and half hours before the test.
224158373|NCT05431036|DEVICE|transthoracic ultrasonography|"1. The lung ultrasound score (LUS) will be calculated according to the observed worst ultrasound pattern and Finally, the LUSs of all the parts will added to obtain the total LUS for each patient (maximum36 points)~2. The diaphragmatic ultrasound will performed for assessment of diaphragmatic thickness and motion."
223466354|NCT03081247|DRUG|BFF 320/9.6 µg|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
223466355|NCT05596071|DRUG|Sufentanil Citrate|Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
223466356|NCT05596071|DRUG|Ropivacaine 0.75% Injectable Solution|Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
223466357|NCT05596071|PROCEDURE|Epidural catheter|Intraoperative and postoperative analgesia
223466358|NCT04650074|DRUG|LIDOCAINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
223466359|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 20 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute."
223577590|NCT01312389|BIOLOGICAL|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
223577591|NCT01312389|BIOLOGICAL|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
223577592|NCT01312389|BIOLOGICAL|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
223743605|NCT07184398|BEHAVIORAL|Cognitive rehabilitation workshops|Neuropsychological rehabilitation consisted of in-person group sessions for 40 adults (18 years or older) to work on cognitive functions such as memory and attention. Each session lasted 45 minutes. These sessions were held three times a week for a period of 12 weeks.
224158374|NCT02525809|DEVICE|Novae E®|
224158375|NCT02525809|DEVICE|Sunfit®|
224158376|NCT02525809|DEVICE|Quartz®|
224158377|NCT05538585|DRUG|Galicaftor|Oral
224158378|NCT05538585|DRUG|Navocaftor|Oral
224158379|NCT03092622|OTHER|Exercise|Exercise training intervention as described earlier.
224303527|NCT05626439|DRUG|Oral alprazolam|Study participants will receive single dose of oral alprazolam at pre-specified time points.
223466360|NCT04650074|DRUG|LIDOCAINE 20 mg + KETAMINE 40 mg|"4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute"
223466361|NCT02849587|DRUG|Cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
223466362|NCT05460546|DRUG|Jincaopian Tablets high dose|Jincaopian Tablets 0.2g tid p.o.
223466363|NCT05460546|DRUG|Jincaopian Tablets low dose|Jincaopian Tablets 0.1g tid p.o.
223466364|NCT05460546|OTHER|Placebo|Placebo tid p.o.
223466365|NCT05694858|COMBINATION_PRODUCT|Lignocaine-loaded maltose microneedle array patch|A biodegradable maltose microneedle array patch containing 12.5 mg lignocaine that will be applied on the participant's dorsal aspect of the hand for 30 minutes prior to venepuncture.
223577593|NCT04599868|DRUG|Magnesium sulfate|"Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.~All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h\& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed."
223577594|NCT01945736|DRUG|Methadone|To determine the PK of enteral methadone in children \> or = 90 days and \<18 years treated for opiate withdrawal per routine medical care.
223577595|NCT05481424|OTHER|Biodynamic|This will be a nine-hour lighting scheme that includes three modes: morning, noon, and afternoon. It mimics natural lighting by providing blue-enriched bright lighting in the morning and yellowish dimmed lighting in the afternoon. The lighting scheme is designed to satisfy the visual lighting needs of office workers while maintaining a robust circadian clock.
223577596|NCT05481424|OTHER|Active Placebo|"We will include an active placebo condition that will be a whole-day lighting scheme with constant color and brightness during working hours. This condition is designed to serve to requirements: (1) to simulate a conventional, well-lit office lighting in compliance with the WELL standard V1 recommendations for circadian lighting design, and (2) to provide an Equivalent Melanopic Lux (EML) equal to the geometric average of EML delivered by the Biodynamic condition. Participants will receive a similar dose of lighting under both the Placebo and Biodynamic conditions; however, the time factor is ignored in the Placebo, and hence the method of delivery is different (constant versus dynamic)."
223577597|NCT05870917|BIOLOGICAL|anti-BCMA CAR-T|Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
223577598|NCT01718249|OTHER|Implantable neurostimulation system|
223577599|NCT00283816|DRUG|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
223577600|NCT00283816|DRUG|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
223577601|NCT00283816|BEHAVIORAL|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise \& behavior modification skills on a regular weekly basis over the 24 week study
223577602|NCT00283816|BEHAVIORAL|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
223466366|NCT05694858|DRUG|EMLA 5% patch|EMLA 5% cream applied on the dorsum of the participant's hand which will be subsequently covered with PVA-PET adhesive for 30 minutes prior to venepuncture
223466367|NCT04547777|DRUG|D2C7-IT|D2C7-IT intratumoral infusion
223466368|NCT04547777|DRUG|2141-V11|2141-11 intratumoral infusion
223577603|NCT00283816|PROCEDURE|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
223577604|NCT00283816|PROCEDURE|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
223577605|NCT00283816|PROCEDURE|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
223577606|NCT00283816|PROCEDURE|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
223577607|NCT00283816|DRUG|placebo|placebo capsules, two capsules BID
223577608|NCT02575118|DEVICE|Restoration of dental caries with dental composite|
223577609|NCT06252818|DEVICE|ReHub|ReHub provides support to rehabilitation professionals by offering information for the design, monitoring, and analysis of therapeutic exercise programs for respiratory functional rehabilitation.
223577610|NCT01303302|DEVICE|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
223577611|NCT01303302|DEVICE|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
223466369|NCT06319794|DRUG|Bimiralisib|Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks
223466370|NCT06319794|DRUG|Bimiralisib|Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks
223466371|NCT03429790|COMBINATION_PRODUCT|intra-operative cell salvage|intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
224158380|NCT01172561|BEHAVIORAL|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
224158381|NCT01172561|BEHAVIORAL|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
224158382|NCT02554201|DEVICE|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
224158383|NCT02554201|DEVICE|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
224158384|NCT00608894|DRUG|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
224158385|NCT00608894|DRUG|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
224158386|NCT03180294|DRUG|Bupropion 150 mg XL|By mouth
224158387|NCT03180294|DRUG|Placebo|By mouth
224158388|NCT03105869|DIAGNOSTIC_TEST|fluorocholine PET/CT|standard diagnostic PET/CT procedure
224158389|NCT01002040|BIOLOGICAL|Arepanrix|Group A receives one dose of Arepanrix
223466372|NCT03429790|COMBINATION_PRODUCT|allogeneic blood transfusion|transfuse allogeneic blood to patients if blood transfusion is needed.
223466373|NCT02691390|DEVICE|Active dTMS|dTMS to ACC
224158390|NCT01002040|BIOLOGICAL|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
224158391|NCT00562536|PROCEDURE|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
224158392|NCT01856179|DIETARY_SUPPLEMENT|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
223466374|NCT02691390|DEVICE|Sham dTMS|SHAM - no stimulation
223466375|NCT03003247|DRUG|IDP-120 Gel|IDP-120 Gel is a combination product
223466376|NCT03003247|DRUG|IDP 120 Component A Gel|Monad of Component A
223466377|NCT03003247|DRUG|IDP 120 Component B Gel|Monad of Component B
223466378|NCT03003247|DRUG|IDP 120 Vehicle Gel|Vehicle
223466379|NCT05657366|PROCEDURE|Peritoneal lavage|Continuous abdominal flushing with normal saline
223466380|NCT03166787|OTHER|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
223466381|NCT03166787|OTHER|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
223466382|NCT03166787|OTHER|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
223466383|NCT03166787|DRUG|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
223466384|NCT03166787|OTHER|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
223466385|NCT03166787|DRUG|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
223466386|NCT03166787|DRUG|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
223466387|NCT03462784|OTHER|Demographic, physical examination, data will becollected .|"Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory"
223466388|NCT04907214|DRUG|Empagliflozin 25 MG|Oral empagliflozin daily
223577612|NCT03897218|DIETARY_SUPPLEMENT|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
223577613|NCT03897218|DIETARY_SUPPLEMENT|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
223466389|NCT01205347|DRUG|Simvastatin 80mg|Simvastatin 80mg once a day
223466390|NCT01205347|DRUG|Simvastatin 10mg|Simvastatin 10mg once a day
224158393|NCT03870893|BEHAVIORAL|hippotherapy|16weeks hippotherapy program
224158394|NCT03149497|PROCEDURE|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
224158395|NCT05745506|OTHER||Not applicable, there is no intervention description in this study.
224303528|NCT03274882|DRUG|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
223466391|NCT03988153|COMBINATION_PRODUCT|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
223466392|NCT04710719|DRUG|Triamcinolone Injection|Post surgical injection at site of keloid with TAC for 3 injections
223466393|NCT04710719|DRUG|Triamcinolone Injection and 5-fluorouracil injection|Post surgical injection at site of keloid with TAC and 5FU for 3 injections
223466394|NCT03030677|PROCEDURE|Pectoralis II block & catheter without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
223466395|NCT03030677|PROCEDURE|Pectoralis II block & catheter with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
223466396|NCT03030677|OTHER|catheter insertion|catheter insertion after Lidocaine dissection
223466397|NCT03940196|DEVICE|NovoTTF-100L(O)|Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
224158396|NCT00653406|DRUG|Risperidone long acting injectable|
224303529|NCT01320748|BEHAVIORAL|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
223466398|NCT03940196|DRUG|Paclitaxel|Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
223466399|NCT01023594|PROCEDURE|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
223466400|NCT01935024|OTHER|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
223466401|NCT04912843|DRUG|NR082 injection|Intravitreal injection（IVT）
223466402|NCT04912843|DEVICE|Sham Injection|Sham Intravitreal Injection
223466403|NCT03902769|PROCEDURE|Prescribing conventional chemotherapy while with holding allo-SCT|Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
223466404|NCT01171157|OTHER|Routine sample collection|Collection of routine nasal/throat swab samples
223466405|NCT01997008|BEHAVIORAL|Intervention|Positive Affect Skills Training
223466406|NCT02100046|DRUG|Zarontin® (ethosuximide) and Stodal®|
223466407|NCT00802646|DRUG|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
223466408|NCT00802646|DRUG|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
224303530|NCT01320748|BEHAVIORAL|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
223743606|NCT07190976|OTHER|Routine EEG|The study is observational. No intervention is anticipated. Patients will be submitted to EEG recording within the first seven days of stroke
223743607|NCT07190976|OTHER|Routine EEG|The study is observational
223743608|NCT07190508|OTHER|No Intervention (Observational)|Participants undergo routine diagnostic upper gastrointestinal endoscopy with standard institutional care. No additional intervention is applied beyond usual clinical practice.
224158397|NCT04468464|OTHER|Occlusal Splint Treatment|Occlusal splint is used by a dentist during sleep or day time to protect the teeth and temporomandibular joint. Manufactured individually by the technicians according to the dentists measurement procedure.
224158398|NCT04468464|OTHER|Osteopathic Manual Treatment|Osteopathy treats the body as a whole and applied by hands over the related structures of the body. TMJ, Cervical, Thoracal, Lumbar vertebra mobilization was applied as well as the fascial and visceral mobilization. Patients also used occlusal splint for 6 weeks during the intervention.
224158399|NCT02900599|OTHER|Observationnal (no intervention)|
224158400|NCT01314456|DEVICE|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
224303531|NCT01830218|PROCEDURE|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
224303532|NCT00144664|DRUG|MRA(Tocilizumab)|
224303533|NCT00030979|DRUG|Donepezil|
224303534|NCT04023643|OTHER|Ventilation Weaning|Use of different weaning strategies
224158401|NCT05789706|BEHAVIORAL|Dayamed Arthur a novel intelligent medication adherence platform|Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
223577614|NCT05767502|DIAGNOSTIC_TEST|GCS-Pupil score|"GCS+attributed verbal score- Step 1 to obtain pupillary score:~* Patients with a motor (M) and eye-opening response (E) total score between 2 and 6 are assigned a verbal score of +1~* Patients with an M+E score of 7 are assigned a verbal score of +2~* Patients with an M+E score of 8-9 are assigned a verbal score of +4~* Patients with an M+E score of 10 are assigned a verbal score of +5~GCS+attributed verbal score- Step 2 to obtain the pupillary score:~The total score is obtained by subtracting the pupil score from the score obtained in the 1st step. Pupil score is scored as follows;~* 0 points if both pupils react to light,~* 1 point if a pupil does not react to light and has anisocoria,~* 2 points if both pupils do not react to light"
223466409|NCT03857698|OTHER|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~* Ice application for pain, edema control~* Patellar mobilization~* Three-way straight leg lifting exercises~* Isometric exercises around the hips and knees~* Active assisted, active, resistant knee range of motion exercises~* Heel shift exercises in supine and sitting~* Hip abduction on the side lying~* Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~* Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
223466410|NCT03857698|OTHER|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~* Consecutive shoulder flexion and extension in supine~* Building a bridge~* Lower body and hip flip~* Single leg extension with bilateral arm elevation~* Resilient leg stretch with bilateral arm elevation~* Hip external rotation in lateral hospitalization~* Side-lying arm opening~* Shoulder girdle retraction on ball, horizantal abduction and extension"
223466411|NCT02421419|DRUG|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
223466412|NCT02421419|DRUG|Xylocaine|a local anesthetic agent
223466413|NCT02421419|DRUG|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
223577615|NCT02775110|OTHER|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
223577616|NCT04900610|DIETARY_SUPPLEMENT|MenaQ7 ®, Nattopharma, ASA, Hovik, Norway|daily per os supplementation of 1mg MK-7
223577617|NCT05993780|OTHER|No drugs or biologial agents were used in our trial|Before the measurement, a recruitment maneuver was performed for 30-40 s at a PEEP level of 20 cmH2O. At four different PEEP levels of 15, 10, 5, and 0 cmH2O, a decreasing PEEP trial was performed, and the measurement results were recorded.The measurement time at each PEEP level was chosen as 10 minutes. At the end of the measurement, static compliance was measured by applying an end-inspiratory pause. Respiratory system elastance,static strain volume gain was calculated.The estimated lung volume recovered was calculated using the formula ∆EELV - (∆PEEP x Compliance PEEPlow) and compared with the volume gain.
223577618|NCT03950687|DRUG|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
223577619|NCT03950687|DRUG|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
223577620|NCT04689152|BIOLOGICAL|Cellgram-LC|Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.
223577621|NCT03508323|DRUG|Teneligliptin|20mg/qd
223577622|NCT03508323|DRUG|Placebo|1T/qd
223577623|NCT04739397|DEVICE|Glare Testing|Vision in Cataract patients were tested with and without the EpiGlare Tester
223577624|NCT00993499|DRUG|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
223577625|NCT00993499|DRUG|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
223743609|NCT07189793|DRUG|Toripalimab|PD-1 inhibitor administered intravenously every 3 weeks (Q3W) for up to 24 months. Starts during the first intravesical treatment cycle.
223743610|NCT07189793|DRUG|Gemcitabine (GEM)|Intravesical instillation as part of a sequential regimen with mitomycin C: weekly for 6 weeks (induction); if no recurrence at first tumour assessment (\~month 3), maintenance instillations continue monthly up to 24 months.
223743611|NCT07189793|DRUG|Mitomycin C (MMC)|Intravesical instillation immediately after intravesical gemcitabine in the same visit (sequential regimen): weekly for 6 weeks (induction); if eligible, monthly maintenance up to 24 months.
223743612|NCT07190521|OTHER|hypnobreastfeeding education|"Hypnobreastfeeding education is an antenatal training method that combines:~Hypnotherapy principles~Guided imagery~Affirmations~Breathing and deep relaxation techniques"
224158402|NCT00792857|DRUG|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
224158403|NCT00792857|DRUG|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
224158404|NCT00553904|DIETARY_SUPPLEMENT|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
224158405|NCT03245294|PROCEDURE|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
224158406|NCT00645229|DRUG|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
224158407|NCT03689699|DRUG|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
223466414|NCT00726180|DRUG|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
223466415|NCT01655225|DRUG|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
223466416|NCT01655225|DRUG|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
223466417|NCT01655225|DRUG|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
223466418|NCT01655225|DRUG|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
223466419|NCT01655225|DRUG|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
223466420|NCT01655225|DRUG|Abemaciclib|Administered orally
223466421|NCT01655225|DRUG|Letrozole|Administered orally
224158408|NCT03689699|DRUG|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
224158409|NCT03689699|DRUG|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
224158410|NCT04359121|OTHER|Questionnaires for specific phobia|Questionnaires will be used.
224158411|NCT05787366|OTHER|usual care and follow-up by a nurse|follow-up by a nurse and referral to a specialist(s) according to symptoms
223466422|NCT03615313|BIOLOGICAL|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
223466423|NCT02674139|DEVICE|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
223466424|NCT04997603|OTHER|Accelerometer|Fitbit brand
223466425|NCT01878903|OTHER|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
223466426|NCT06634147|BEHAVIORAL|Exercise|"Multicomponent individualized exercise intervention As mentioned earlier, patients in the control group (G0) will receive the usual care currently provided to other patients, which includes a referral to physical therapy if needed.~The intervention for the multicomponent physical exercise intervention group (G1) will consist of a multicomponent physical training program that includes progressive and supervised aerobic endurance, strength, and balance training lasting 4-7 days during their hospitalization. This will be supervised by the research team from the Geriatrics Unit. Additionally, after hospital discharge, they will receive individualized guidelines to engage in multicomponent physical exercise for 3 months, along with individualized recommendations from the Nutrition and Dietetics Service of HUN.~The multicomponent physical training program will consist of chair squat exercises. The main part of the training will utilize machines for strength training for the lower extremit"
223466427|NCT06401824|DRUG|Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab|Sacituzumab govitecan 10mg/kg intravenous day 1 and day 8 of a 21-day cycle, + bevacizumab 15 mg/kg iv day 1 of a 21-day cycle till unacceptable toxicity or disease progression.
223466428|NCT00097214|DRUG|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
223577626|NCT03368014|BEHAVIORAL|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
224303535|NCT00172536|BEHAVIORAL|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
223466429|NCT00097214|BIOLOGICAL|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
223577627|NCT00002239|DRUG|Enfuvirtide|
223577628|NCT00002239|DRUG|Ritonavir|
223466430|NCT03224793|DRUG|BIIB059|Administered as specified in the treatment arm
223466431|NCT03224793|DRUG|Placebo|Administered as specified in the treatment arm
223466432|NCT04549181|BEHAVIORAL|Phase II: Problem-Solving for Rural HF Dyads|Participants in the Intervention Group will be trained to use a 4-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems collaboratively over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Dyadic problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this dyadic intervention is to move HF dyads toward a positive problem orientation and use of rational problem-solving strategies that support greater patient and family caregiver-contributed HF self-care.
223466433|NCT06360523|DIAGNOSTIC_TEST|AI modal|The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.
223466434|NCT06360523|DIAGNOSTIC_TEST|Standard review|The MRI image will be reviewed by radiologist.
223577629|NCT00002239|DRUG|Abacavir sulfate|
223577630|NCT00002239|DRUG|Amprenavir|
223466435|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Patients|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
223466436|NCT04963751|OTHER|Enhanced Recovery After Surgery (ERAS) Counseling to Caregiver|In pediatric and adolescent gynecology (PAG), pre-operative counseling is typically administered to the patient's caregiver rather than directly to the patient. It is possible that direct patient involvement in ERAS pre-operative counseling could be an important factor to improve post-surgical outcomes.
223466437|NCT01829958|DRUG|rituximab|
223466438|NCT01829958|DRUG|prednisone|
223466439|NCT01829958|BEHAVIORAL|Geriatric Assessment|
223466440|NCT02197390|BEHAVIORAL|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
223466441|NCT02197390|BEHAVIORAL|Obesity chronic care model|
223466442|NCT02197390|BEHAVIORAL|Physical activity, healthy eating, water drinking, healthy sleep promotion|
223466443|NCT02197390|BEHAVIORAL|Environment, policy, systems changes in clinic setting only|
223466444|NCT02197390|BEHAVIORAL|No intervention|No intervention.
223466445|NCT02197390|BEHAVIORAL|Environment, policy, and systems changes in schools, early child care education & recreation|
223466446|NCT03439267|COMBINATION_PRODUCT|Coronary Artery Calcium Screening and Statin Treatment|Will undergo coronary artery calcium screening and will receive statin treatment based on the cardiovascular risk algorithm.
223466447|NCT03439267|OTHER|Standard Treatment|Patients will be managed following the AHA/ACC guidelines for statin initiation and follow-up.
223466448|NCT04195061|PROCEDURE|Cardiopulmonary exercise test (CPET)|CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
223466449|NCT02040753|BEHAVIORAL|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
223466450|NCT06554288|DRUG|Trihexyphenidyl|6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose
223466451|NCT04460872|DRUG|Testosterone Enanthate|Subjects receive testosterone (100 mg/week) by intramuscular injection
223466452|NCT04460872|BEHAVIORAL|Locomotor Training|Subjects receive locomotor training (4 sessions/week for 2-3 months)
223466453|NCT03635697|BEHAVIORAL|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
223466454|NCT05388981|BIOLOGICAL|SBT115301|Immunomodulatory dimeric fusion protein
223466455|NCT05388981|BIOLOGICAL|Placebo|Matched placebo
223466456|NCT03913819|DRUG|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
223466457|NCT03913819|DRUG|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
223466458|NCT03913819|DRUG|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
223466459|NCT03913819|PROCEDURE|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
223466460|NCT00965133|OTHER|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
223466461|NCT01307059|DEVICE|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
224303536|NCT00172536|OTHER|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
224303537|NCT02640092|DRUG|[18F]GTP1|Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
223466462|NCT04884646|OTHER|VR with Routine physical therapy and Virtual reality|VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
223466463|NCT04884646|OTHER|Motor Imagery with Routine physical therapy|MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
223466464|NCT04884646|OTHER|Routine physical therapy|Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
223466465|NCT05029687|BEHAVIORAL|Youth-Led Hypertension Education Digital Intervention|The intervention is a youth-led HTN education digital intervention, which will be comprised of a 6-week playlist of one module per week comprising the playlist. Youth will learn from the module and will teach the adult in their dyad about hypertension education in each week's themed module.
223466466|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
223466467|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
224303538|NCT02374489|DRUG|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
223466468|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
223466469|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
223466470|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
223466471|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
223466472|NCT04999761|DRUG|TAS-116|TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
223466473|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466474|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
223577631|NCT00002239|DRUG|Efavirenz|
223577632|NCT01948232|DRUG|Perindopril|Angiotensin converting enzyme inhibitor
223577633|NCT01281098|PROCEDURE|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
224158412|NCT05787366|OTHER|Personalized Multifactorial Intervention (IMP)|"The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~* Knowledge of the disease and specific management, (led by the nurse)~* Covid-19 and anxiety/depression, (psychologist)~* Fatigue and adapted physical activities (video capsules)~* Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~* The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential."
224158413|NCT06828302|BEHAVIORAL|Internet-delivered Parent-Child Interaction Therapy|Parent management training delivered online where Internet-modules are combined with video sessions for live coaching.
224158414|NCT03412162|BEHAVIORAL|Ethnic and Racial Identity Promotion|See arm description
224158415|NCT03412162|BEHAVIORAL|Academic Skills Promotion|See arm description
224158416|NCT05920200|PROCEDURE|open non-mesh hernia repair|A groin and femoral hernia non-mesh repair. An umbilical hernia non-mesh repair. A ventral and incisional hernia non-mesh repair.
224303539|NCT04735757|OTHER|Contrast-enhanced MRI|Contrast-enhanced MRI
223466475|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466476|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
223577634|NCT01281098|DRUG|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
223577635|NCT01113489|DRUG|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
223577636|NCT01113489|DRUG|placebo|1 ml b.i.d.
223577637|NCT02190305|DEVICE|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
223577638|NCT01735708|BEHAVIORAL|HIVPASS|
223577639|NCT01735708|OTHER|Health Education|
223577640|NCT00102713|DRUG|Divalproex Sodium (Depakote Sprinkle Capsules)|
223577641|NCT01787318|DEVICE|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
223577642|NCT01787318|DEVICE|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
223577643|NCT03833570|DIETARY_SUPPLEMENT|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
223577644|NCT03833570|DRUG|Miconaz oral gel|Antifungal agent
223577645|NCT03833570|DRUG|BBC oral spray|Topical anesthetics and anti-inflammatory agent
223577646|NCT03833570|DRUG|Oracure gel|Topical analgesic gel
223577647|NCT03833570|OTHER|Alkamisr sachets|Sodium bicarbonate mouthwash
223577648|NCT04883528|DRUG|Sacubitril / Valsartan Oral Tablet [Entresto]|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
223577649|NCT04883528|DRUG|Placebo|sacubitril/valsartan matching placebo tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
223577650|NCT00650520|DRUG|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
223577651|NCT00650520|DRUG|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
224303540|NCT04735757|OTHER|Measurement of respiratory muscle force|Measurement of the maximum inspiratory and expiratory pressure.
224303541|NCT04849065|DRUG|MNC (Mononuclear cells)|"* Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)"
224303542|NCT04849065|DRUG|Placebo / Saline|\- Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
224303543|NCT00056394|BEHAVIORAL|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
223466477|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466478|NCT04999761|DRUG|TAS-115|TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
223466479|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
223466480|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
223466481|NCT04999761|DRUG|Ramucirumab|Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
223577652|NCT00725244|DEVICE|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
224158417|NCT05920200|PROCEDURE|open mesh hernia repair|"A groin and femoral hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures for Lichtenstein. Self-fixating mesh is also possible.~An umbilical, ventral, incisional hernia repair, reinforced by synthetic mesh. The mesh is affixed with sutures."
223577653|NCT00725244|DEVICE|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
224303544|NCT00056394|BEHAVIORAL|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
224303545|NCT00056394|BEHAVIORAL|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
224303546|NCT02912169|PROCEDURE|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
223466482|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
223466483|NCT04999761|DRUG|TAS-102|TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
224303547|NCT02912169|BIOLOGICAL|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
223466484|NCT04999761|DRUG|Bevacizumab|Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
223466485|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
223466486|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466487|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
223466488|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
223466489|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
223466490|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223577654|NCT04711941|BEHAVIORAL|Rehabilitation training|Rehabilitation with behavioural stimuli
224068307|NCT02416284|OTHER|NFBDG|"Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
223466491|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
223466492|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
224068308|NCT01150539|OTHER|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
224068309|NCT01150539|OTHER|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
224068310|NCT03011346|DEVICE|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
224068311|NCT03011346|DEVICE|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
223466493|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466494|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
224068312|NCT03657043|DRUG|tisotumab vedotin|Intravenous (IV) infusion
224068313|NCT06425003|DRUG|[14C] ABBV-CLS-7262|Oral Solution
224068314|NCT06193785|OTHER|Hypnosis|hypnosis realised by expert practitioner, before and during the electromyogram procedure
223466495|NCT04999761|DRUG|Fluorouracil|Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
223466496|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
223466497|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
223466498|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466499|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
223466500|NCT04999761|DRUG|AB154|AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
223466501|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466502|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
224068315|NCT01197326|DEVICE|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
224068316|NCT01497015|BEHAVIORAL|memory training|10 1-hour sessions over 6-8 weeks
224303548|NCT00346463|DRUG|Allopurinol|
224303549|NCT05851625|DEVICE|Press needle acupuncture|Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
224303550|NCT05851625|DEVICE|Plesterin|The plaster used is a round plaster that resembles the shape of an acupuncture press needle.
224303551|NCT00117325|DRUG|GW685698X|Aqueous Nasal Spray 100mcg
223466503|NCT04999761|DRUG|Carboplatin|Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
223466504|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
223466505|NCT04999761|DRUG|AB122|AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.
223466506|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
223466507|NCT04999761|DRUG|Cisplatin|Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
223466508|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
223466509|NCT04999761|DRUG|AB122|AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.
223466510|NCT04999761|DRUG|TAS-120|TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
223466511|NCT04999761|DRUG|nab-Paclitaxel|Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
223466512|NCT04999761|DRUG|Gemcitabine|Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
223466513|NCT05053269|OTHER|good body weight growth|body weight growth after birth is consistent with the growth curve
224158418|NCT05920200|PROCEDURE|MIS hernia repair|"A groin and femoral minimal invasive hernia repair (TAPP, eTEP). The mesh is affixed with tack/no-fixation. Self-fixation mesh is also possible.~An umbilical, ventral, incisional minimal invasive hernia repair (eTEP, IPOM,). The mesh is affixed with tack and no-fixation ."
224158419|NCT03743298|DRUG|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
223466514|NCT05053269|OTHER|poor body weight growth|body weight growth after birth is inconsistent with the growth curve
223466515|NCT02787577|BEHAVIORAL|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
223466516|NCT01365130|DRUG|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
223466517|NCT03683836|DIAGNOSTIC_TEST|No intervention|No intervention
223466518|NCT04621799|DRUG|Fibrin sealant|The intra-annular delivery of non-autologous fibrin into the annulus
223466519|NCT00101244|DRUG|ispinesib|Given IV
223466520|NCT00101244|OTHER|laboratory biomarker analysis|Correlative studies
223466521|NCT00101244|OTHER|pharmacological study|Correlative studies
223466522|NCT04819165|OTHER|COVID-19|Impact of covid-19 on infections associated with health care devices.
224068317|NCT01497015|BEHAVIORAL|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
224158420|NCT05264636|OTHER|Sucrose|Sucrose Beverage
223466523|NCT00909064|DRUG|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
223466524|NCT05931874|BEHAVIORAL|Core Intervention|"All participants will receive a low-resource self-monitoring intervention consisting of the Fitbit Alta HR (or similar) and the study self-monitoring app.~Participants will be provided with the Fitbit Alta HR. They will be asked to download the Fitbit app and wear the Fitbit 24/7 throughout the study. The Fitbit measures PA intensity, steps, and heart rate, and it syncs directly with the Ftibit app on the smartphone which will ill automatically sync with the study app and provide Fitbit data to the study team in real-time.~The core study app will support BCS to increase their MVPA. The app will also contain educational information on MVPA and effective behavior change strategies for building self-efficacy, overcoming barriers, enhancing facilitators, setting realistic outcome expectations, and self-regulatory skill-building (i.e., reviewing progress, goal setting, action-planning and coping with disruptions)."
223466525|NCT05931874|BEHAVIORAL|E-Coach|Participants assigned to this condition will receive a weekly scheduled text message from their coach. Text messages will focus on building self-efficacy and self-regulation skills, setting realistic outcome expectations, overcoming barriers, and problem-solving and will directly support the participant's engagement in the intervention. The coach will provide a brief overview of the participant's recent progress and goals, ask if they are having any barriers and help them troubleshoot and set specific goals for the next week. Text message protocols will be informed by the investigators' previous experience using telephone coaching to promote MVPA in cancer survivors. In addition to the scheduled messaging, participants will also be instructed to reach out to their coach with any questions or for additional assistance.
223466526|NCT05931874|BEHAVIORAL|Buddy|"Participants assigned to this condition will select a buddy of their choice (i.e. friend, co-worker, caregiver or family member) that is ≥ 18 years of age and willing to share their Fitbit data with the study team. The buddy will be mailed a Fitbit, share their Fitbit data with the study team, and be provided with access to, and instructions for, all of the study app modules the participant has access to for their assigned condition.~The study app include a buddy module where the buddy and participant can view each other's progress. The buddy will be expected to attend a 15-30 minute group orientation call and listen to four 10-15 minute podcast (one every 3 weeks) during the first 24 weeks of the intervention. Each webinar will provide social support training and peer discussion of challenges and successes in providing BCS with MVPA support."
223466527|NCT05931874|BEHAVIORAL|General Mindfulness Training|Participants assigned to this condition will be instructed to watch 1 (1-2 mins), mindfulness education videos each week which lay the foundation for what mindfulness is and how it can be an important health behavior. Each week participants will also be asked to listen to general guided mindfulness audio files ≥5 days/ week. The length of recordings will gradually increase each week from 3-5 to 25-30 minutes. All videos and recording will be available via the study app.
224068318|NCT01497015|BEHAVIORAL|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
224068319|NCT05011188|BIOLOGICAL|FOR46|Given intravenously (IV)
224068320|NCT05011188|BIOLOGICAL|Enzalutamide|Given orally (PO)
224068321|NCT05011188|DRUG|Pegfilgrastim|Given subcutaneously (subQ)
224068322|NCT05011188|PROCEDURE|Blood Samples|Blood samples will be taken for correlative studies
224158421|NCT05264636|OTHER|Steviol Glycosides|Steviol Glycoside Beverage
224158422|NCT01376388|DRUG|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
223466528|NCT05931874|BEHAVIORAL|MVPA-Specific Mindfulness Training|Participants assigned to the MVPA-specific mindfulness training component will be instructed to watch 1-2 brief (1-2 minute), mindfulness education videos each week which lay the foundation for what mindfulness is and the importance of linking mindful awareness with MVPA. Each week participants will be provided access to MVPA-specific guided mindfulness audio files (e.g., 10-minute treadmill walking meditation, 20-minute bicycling meditation) that they will be asked to listen to during ≥3 MVPA sessions/week. The length and intensity of these audio files will correspond to their progression in the program. All videos and recordings will be accessed via the study app.
223466529|NCT06441604|DRUG|Extended-release Buprenorphine|"First 10 participants will receive XR-BUP 16mg in single-blind fashion. If at least 90% of the participants who received 16mg successfully complete induction (success defined as experiencing no BPOW),10 additional participants will receive a 24mg dose in a single blind fashion.~If at least 90% who received 24mg successfully complete induction (success defined as experiencing no BPOW), 10 additional participants will receive a 32mg dose in a single blind fashion."
223466530|NCT06355440|BEHAVIORAL|Financial Navigation|"One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month.~The financial navigation encompasses comprehensive information support:~* Strategies on patient-physician costs discussion~* Skills for inquiring and tracking treatment-related costs~* Basic knowledge about health insurance~* Guidance on accessing and applying for financial assistance~* Suggestions for returning to normal life and work~* Strategies for holding a financial-related family meeting"
223466531|NCT06355440|OTHER|Usual Care|Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.
223466532|NCT04203641|BIOLOGICAL|L-DOS47|A treatment cycle will be 28 days, with patients receiving L-DOS47 on Days 1, 8, 15, and 22.
223466533|NCT04203641|DRUG|Doxorubicin|A treatment cycle will be 28 days, with patients receiving doxorubicin on Days 2, 9, 16 and 23
223466534|NCT04503967|DRUG|Anlotinib Hydrochloride With Nivolumab|Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
223577655|NCT01544413|PROCEDURE|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
223577656|NCT01393938|OTHER|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
223577657|NCT02610933|DRUG|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
224158423|NCT03643016|OTHER|Surgical strategy based on a software|Surgical strategy décision based on a software
224158424|NCT05589012|BIOLOGICAL|Cell line and virus|C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
224158425|NCT05589012|BIOLOGICAL|Infection of human placental culture explants|"Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.~Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air."
223466535|NCT04764188|DRUG|Alectinib|Participants will receive alectinib in accordance with local clinical practice and local labeling.
223466536|NCT05276778|DIAGNOSTIC_TEST|Diabetic Retinopathy Screening|Screenings are performed in the diabetes consultation in general practice
223466537|NCT06576323|BEHAVIORAL|An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU|We will use implementation mapping to develop a suite of implementation strategies to deliver evidence-based MOUD prescription to mothers attending the bedside of their infants hospitalized in the NICU. The intervention itself is buprenorphine induction and treatment, however the model for delivery is not yet developed, consistent with the need for results from Aim 1 to inform the approach used to develop the implementation model in Aim 2.
223466538|NCT04420702|DEVICE|MRI with DBSI analysis|-The procedure will take approximately 1 hour of the participant's time
223466539|NCT00816114|OTHER|Chart Review|Investigator review of MDACC CML patient charts.
223466540|NCT02983578|DRUG|Danvatirsen|Given IV
223466541|NCT02983578|BIOLOGICAL|Durvalumab|Given IV
223466542|NCT05230797|DRUG|Zinc oxide Propolis|antibacterial and anti-inflammatory
223466543|NCT05230797|DRUG|Zinc Oxide-Eugenol Cement|Antimicrobial and antiseptic
223466544|NCT04531332|DRUG|Continuous infusion Linezolid|Linezolid 600 mg intravenous Loading dose followed by 1200 mg/ day by Continuous infusion ( 50 mg /hr )
223466545|NCT04531332|DRUG|intermittent dosing linezolid|Linezolid 600 mg intravenous twice daily
223577658|NCT02610933|DIETARY_SUPPLEMENT|Vitamin K2|Vitamin K2 supplementation
223577659|NCT03246490|OTHER|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
223577660|NCT02099305|OTHER|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
223577661|NCT00275756|DRUG|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp \& Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
223577662|NCT00275756|DRUG|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp \& Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
223577663|NCT00275756|DRUG|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
223466546|NCT04881214|OTHER|Pulmonary rehabilitation|pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
224303552|NCT02208674|OTHER|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
224303553|NCT03791710|PROCEDURE|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
224303554|NCT03791710|DRUG|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
224303555|NCT03791710|PROCEDURE|split thickness skin grafting|depridment and split thickness skin grafting
224303556|NCT05951855|DRUG|Selinexor|Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,
223466547|NCT00810199|DRUG|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
223466548|NCT00810199|DRUG|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
223466549|NCT00810199|DRUG|placebo|Placebo matching methotrexate capsule taken orally once a week.
223466550|NCT01448252|BIOLOGICAL|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
223466551|NCT01448252|BIOLOGICAL|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
223466552|NCT00000887|DRUG|Nelfinavir mesylate|
223466553|NCT00000887|DRUG|Lamivudine|
223466554|NCT00000887|DRUG|Zidovudine|
223466555|NCT06486285|BEHAVIORAL|Auditory-cognitive dual-task training (ACDT)|The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.
223466556|NCT03298997|PROCEDURE|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block."
223466557|NCT03298997|PROCEDURE|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia."
224303557|NCT05951855|DRUG|Chidamide|Chidamide 10mg/day, orally on day 1 to 28
224303558|NCT03184155|DRUG|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
224303559|NCT03184155|DRUG|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
224303560|NCT00416650|DRUG|erlotinib hydrochloride|All patients will receive 150 mg orally daily
223466558|NCT01275443|DRUG|300mg TMC278LA|300mg TMC278LA intramuscular injection
223466559|NCT01275443|DRUG|150mg TMC278LA|150mg TMC278LA intramuscular injection
223466560|NCT01275443|DRUG|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
223466561|NCT01275443|DRUG|600mg TMC278LA|600mg TMC278LA intramuscular injection
223466562|NCT03174015|BEHAVIORAL|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
223466563|NCT05199922|DRUG|M TAPA block|Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 40 ml (20 ml for each side) of %0,25 bupivacaine.
223466564|NCT03414944|RADIATION|SMART-Brain|"Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy."
223466565|NCT01309412|DRUG|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
223466566|NCT04519983|DRUG|Aumolertinib Oral Tablet|Aumolertinib 110 mg p.o. qd+ SRT(32Gy/4fx)
223466567|NCT01001312|OTHER|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
223466568|NCT01001312|OTHER|Clinical volume status assessment|Volume assessment based on history and physical examination
223577664|NCT00275756|DEVICE|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
223577665|NCT00275756|DEVICE|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
223577666|NCT00275756|PROCEDURE|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
223577667|NCT01406015|DRUG|Spironolactone|50 mg once daily for 6 weeks.
224303561|NCT05652738|DEVICE|Passive cooling application|Passive cooling application for asphyxiated neonates and their effect on myocardial function and hemodynamics
224303562|NCT05652738|DEVICE|cooling using Blanket roll III|standard care using Blanket roll III in asphyxiated neonates and their effect on myocardial function and hemodynamics
223577668|NCT01406015|DRUG|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
224303563|NCT05748249|DRUG|Vertistop® D|Vitamin D supplementation
224303564|NCT03956121|OTHER|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
224303565|NCT04664790|DEVICE|Hyperbaric Oxygen|Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
224158426|NCT05589012|BIOLOGICAL|Determination of viral load in tissues by qRT-PCR|"The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.~Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV."
223466569|NCT02899247|PROCEDURE|Surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~* The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
223466570|NCT02899247|PROCEDURE|No surface sealant|"Device:~* Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~* Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~* Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~* 7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
224158427|NCT03542149|DRUG|480 mg Piperaquine phosphate|480 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
223466571|NCT00791219|DRUG|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
223466572|NCT00791219|DRUG|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
223466573|NCT00791219|DRUG|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
224303566|NCT04664790|BEHAVIORAL|Cognitive training|Neuropsychologist guided BrainHQ training
223466574|NCT03328247|OTHER|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
223466575|NCT01628848|DRUG|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
223466576|NCT01628848|DRUG|Placebo|Placebo transdermal patch
223466577|NCT03513263|PROCEDURE|Scaling and polishing|An electronic scaler will be used to clean the gums
223466578|NCT03513263|OTHER|oral hygiene instructions|It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
223466579|NCT02819570|DRUG|I.V cefuroxime 750 mg*3/d for 2 days|
223466580|NCT02819570|DRUG|I.V ampicillin 2 gram x4/d for 2 days|
223466581|NCT02819570|DRUG|P.O cefuroxime 500 mgx2/d for 5 days|
223466582|NCT02819570|DRUG|P.O roxithromycin 150 mg*2/d for 7 days|
223466583|NCT02819570|DRUG|P.O moxypen 500 mgx3/d for 5 days|
223466584|NCT00003471|DRUG|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
223466585|NCT04611100|DEVICE|ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea)|Intraductal radiofrequency ablation using ELRA endoluminal radiofrequency ablation electrode (Taewoong, Seoul, Korea) 10W 2 minutes at the obstructed bile duct before placing uncover self-expandable biliary metal stent
223466586|NCT02915224|DRUG|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
223466587|NCT02915224|DRUG|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
223577669|NCT05025722|OTHER|Non Interventional|This is an observational study.
223577670|NCT01840358|OTHER|Observation of hypoglycemias frequency 3 days before and after pump initiation|
223577671|NCT06347250|PROCEDURE|Nerve Block|The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
223577672|NCT06347250|DRUG|Lidocaine Hydrochloride|the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g).
224158428|NCT03542149|DRUG|640 mg Piperaquine phosphate|640 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
224158429|NCT03542149|DRUG|200 mg OZ 439|200 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
223466588|NCT00170209|DRUG|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
223466589|NCT00170209|DRUG|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
223466590|NCT00325741|DRUG|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
223466591|NCT06489912|DIAGNOSTIC_TEST|WAIS IV|Psychological assessement
223466592|NCT01681758|OTHER|IV fluid according to PPV|intravenous fluids
223466593|NCT01681758|OTHER|fluids according to standard care|
223466594|NCT00463736|DRUG|Magnesium sulfate|
223466595|NCT02104895|RADIATION|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
223466596|NCT02104895|RADIATION|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
223466597|NCT04253158|BEHAVIORAL|Educational standard|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
223466598|NCT04253158|BEHAVIORAL|Educational standard and Harm prevention|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
223466599|NCT04253158|BEHAVIORAL|Educational standard and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
223466600|NCT04253158|BEHAVIORAL|Expectancies and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
223577673|NCT06347250|BEHAVIORAL|routine therapy|"All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).~Regrading swallowing function training, both groups are given swallowing function training, including 1) exercises of closure of the vocal folds, pharyngeal, and laryngeal muscles exercises, and respiratory muscle strength training, for 15 min each time and twice per day. 2) isotonic／isometric swallowing exercises, supraglottic swallowing exercises, for 20 min each time and twice per day. 3) effortful swallowing exercises, and cough reflex training, for 10 min each time and twice per day."
223577674|NCT06347250|PROCEDURE|placebo block|the patients were provided with normal saline. The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
224158430|NCT03542149|DRUG|400 mg OZ 439|400 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
224158431|NCT03542149|DRUG|800 mg OZ 439|800 mg OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension
224158432|NCT03542149|DRUG|960 mg PQP|960 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
224158433|NCT03542149|DRUG|320 mg PQP|320 mg Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
224158434|NCT04518020|PROCEDURE|40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA|40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
224158435|NCT01789892|DRUG|methylprednisolone|Given IV
224158436|NCT01789892|RADIATION|fludeoxyglucose F 18|Undergo FDG PET/CT scan
224158437|NCT01789892|PROCEDURE|positron emission tomography|Undergo FDG PET/CT scan
224158438|NCT01789892|PROCEDURE|computed tomography|Undergo FDG PET/CT scan
224158439|NCT02434913|DEVICE|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
224158440|NCT05991895|DRUG|Iruplinalkib|Iruplinalkib is administered orally with approximately fixed dosing times each day. The recommended dosage is once daily, on an empty stomach or with food, at 60 mg per dose for the first 1 to 7 days. If tolerated, the dosage is increased to 180 mg per dose starting from the 8th day.
223466601|NCT04253158|BEHAVIORAL|Educational standard and Normative perceptions|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
223466602|NCT04253158|BEHAVIORAL|Normative perceptions and Harm prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
223466603|NCT04253158|BEHAVIORAL|Educational standard, Normative Perceptions, and Expectancies|Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
223466604|NCT04253158|BEHAVIORAL|Normative perceptions, Expectancies, and Harm Prevention|Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
224158441|NCT01934868|DRUG|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
224303567|NCT04728503|BEHAVIORAL|5-Minute Mindful Movement Video|5 minute video includes a brief verbal introduction to mindfulness and then guides participants through a mindful movement exercise to facilitate grounding in the present moment and activation of the parasympathetic nervous system.
224303568|NCT04728503|BEHAVIORAL|Written Educative Materials|1 page written educative material about the benefits of mindfulness to serve as a control.
223466605|NCT01241422|DRUG|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
223466606|NCT01241422|DRUG|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
223466607|NCT01241422|DRUG|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
223466608|NCT06519838|OTHER|Local anesthesia solution at room temperature|The local anesthesia cartridge is used at room temperature (average of 21 °C)
223466609|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 37°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 37°C at 120 seconds."
223466610|NCT06519838|OTHER|Local anesthesia solution pre-warmed to 40°C|"About 150 ml of water at 21°C is added to the heating compartment of the heating device. The Local anesthesia cartridge is placed at the bottom of the heating compartment. The device is plugged in and the control gauge is set at the Express milk warming setting for contents up to 180ml/6oz mark. The contents would reach 40°C at 130 seconds."
223466611|NCT06519838|OTHER|Maxillary infiltration technique|A 30 gauge short needle is oriented so that the bevel is facing the bone. The syringe is held parallel to the long axis of the tooth and the needle is inserted into the height of the mucobuccal fold over the offending tooth. The needle is advanced to a depth of 1 millimeter into the tissues. Aspiration is done, and once it is negative then 0.6 ml (nearly one third of the cartridge) of the anesthetic solution is injected slowly without permitting the tissues to balloon.
223577675|NCT06366542|OTHER|Vestibular Rehabilitation Therapy (VRT)|The VRT exercises were composed of gaze stabilization, head motion and postural stability exercises with static and dynamic balance exercises.
223577676|NCT06366542|OTHER|Virtual reality exercises|The VR exercises included watching theraputic videos using the virtual reality goggles with static and dynamic balance exercises.
223577677|NCT06366542|OTHER|Optokinetic Stimulation exercises|Optokinetic Stimulation is a type of visual stimulation used to improve visual function and balance in patients with vestibular disorders.
223577678|NCT00050973|DRUG|bexarotene|
223577679|NCT05102617|DEVICE|PicoSure Pro Device|This device will be used for up to 4 treatments over the designated areas.
223577680|NCT05102617|DEVICE|PicoSure Device|This device will be used for up to 4 treatments over the designated areas.
223577681|NCT05102617|DRUG|Topical Cosmeceuticals|Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.
223577682|NCT02738476|PROCEDURE|Patellofemoral arthroplasty|
223577683|NCT05891028|DRUG|68Ga-EB-ss-CPT|68Ga-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
223577684|NCT05891028|DRUG|64Cu-EB-ss-CPT|64Cu-EB-ss-CPT were intravenous injected into the patients before PET/CT scans
224158442|NCT01934868|DRUG|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
223577685|NCT01467115|RADIATION|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
223577686|NCT01467115|DRUG|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
223577687|NCT01467115|BIOLOGICAL|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
224158443|NCT00982748|BEHAVIORAL|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
224158444|NCT05587608|PROCEDURE|combined thoracic segmental spinal epidural anesthesia|ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
224158445|NCT03067480|DEVICE|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
223577688|NCT01467115|DRUG|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
223577689|NCT01467115|DRUG|Erythropoetin|Subcutaneous or intravenous
223466612|NCT06519838|OTHER|Inferior alveolar nerve block technique|While the mouth is opened as wide as possible, the index finger palpates the external oblique ridge reaching the Coronoid notch. A 27-gauge long dental needle will be used for injection. The needle will be directed between the two primary molars on the opposing side of the arch, penetrating the tissues at the point halfway between coronoid notch and the pterygomandibular raphe at the occlusal plane level or slightly lower.The needle is withdrawn 2mm to aspirate. Once negative aspiration is checked, the remainder of the solution is deposited slowly. Approximately 1.0 mL of LA will be delivered near the inferior alveolar nerve. The average depth of insertion is about 15mm, which is nearly two-thirds the needle length.
223466613|NCT03825822|BEHAVIORAL|ImPaC Resource Intervention (INT)|"A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change."
223466614|NCT03825822|OTHER|Standard Practice (SP)|The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
223466615|NCT02404051|DRUG|Everolimus|10 mg daily tablets
223466616|NCT02404051|DRUG|Exemestane|25 mg daily tablets
223466617|NCT02404051|DRUG|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
223466618|NCT02755506|DEVICE|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
223466619|NCT01863615|DRUG|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
223466620|NCT01863615|DRUG|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
223466621|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|One basal rate
223466622|NCT00569452|DEVICE|Accu-Chek Spirit Insulin Pump|Multiple basal rates
223466623|NCT01107925|DRUG|prasugrel|Administered orally, daily for 12 days
223466624|NCT01107925|DRUG|clopidogrel|Administered orally, daily for 12 days
223466625|NCT03311945|DRUG|Raltegravir|Raltegravir (1200 mg QD)
223466626|NCT03311945|DRUG|Lamivudine|Lamivudine (300 mg QD)
223466627|NCT00260260|DRUG|Oxycodone|
223466628|NCT01960166|BEHAVIORAL|Active Distraction|iPad will be used as active distraction
223466629|NCT01960166|BEHAVIORAL|Passive Distraction|child will watch TV as passive distraction
223577690|NCT01467115|DRUG|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
224068323|NCT02627495|DEVICE|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm\^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
224158446|NCT02325804|BEHAVIORAL|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
224158447|NCT01432704|DRUG|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
223466630|NCT02916134|PROCEDURE|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
223466631|NCT02916134|DRUG|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
223466632|NCT01078142|DRUG|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
223466633|NCT01007604|DEVICE|Peristaltic pulse PCD|Daily use for two hours
223466634|NCT01007604|OTHER|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
224068324|NCT05256498|DEVICE|Picostim Amber|Picostim Amber temporary (24h) lead placement and extracorporeal stimulation
224068325|NCT02364128|BEHAVIORAL|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
224068326|NCT03314545|PROCEDURE|laminate veneer with coronal post|laminate veneer with coronal post
223466635|NCT02693457|PROCEDURE|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
223466636|NCT02693457|PROCEDURE|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
223466637|NCT05291130|DEVICE|Plasmafit® Vitelene® Vitamin E|Plasmafit® Acetabular Cup System with an insert Aesculap ® Vitelene ® Vitamin E Stabilized Highly Crosslinked Polyethylene and BIOLOX delta Ceramic Femoral Head or ISODUR® Metal Femoral Heads
223577691|NCT01467115|DRUG|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
223577692|NCT01467115|DRUG|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
223577693|NCT00144924|PROCEDURE|laparoscopy pyloromyotomy|laparoscopic pyloromyotomy
223577694|NCT00144924|PROCEDURE|open pyloromytomy|open pyloromyotomy
223577695|NCT05510882|OTHER|different treatment modalities for OSA|Group I: patients will be treated with CPAP. Group II: patients will be treated with digitally fabricated MAD. Group II: patients will be treated with physical therapy.
223577696|NCT04937335|OTHER|intratumoral hemorrhage|Patients who were recognized as craniopharyngioma pathologically with tumoral hemorrhage observed during the operation were enrolled in the hemorrhage group.
223577697|NCT00006799|DRUG|megestrol acetate|
223577698|NCT00006799|PROCEDURE|quality-of-life assessment|
223577699|NCT01445522|DRUG|ABT-888|
223577700|NCT01445522|DRUG|Cyclophosphamide|
223577701|NCT05561465|PROCEDURE|Pterygomaxillary disjunction with interposition Y-shape plate|All patients will be treated under general anesthesia. The pterygoid plate will be fractured, pried up, and pushed backward. A Y-shape plate will be fixed to the lateral maxillary surface with its vertical limb and the other two limbs are turned to fit into the retro maxillary space preventing the reattachment of the fractured pterygoid plate
223577702|NCT04492709|DRUG|Midazolam|The subjects will receive single doses of midazolam solution 2 mg/mL orally on Day 1 alone in Treatment Period 1 and on Day 7 co-administered with oral AZD5718 tablet in Treatment Period 3.
224158448|NCT05841641|DEVICE|Laser Bandage|The Diode Laser will create a biological bandage at a wavelength of 810 nm, set at 5W in continuous-wave mode, applied via a 400-µm optical fibre.
224158449|NCT05841641|PROCEDURE|Hemostatic agent with surgical stent|Following graft harvesting, the donor site was secured with a hemostatic agent and protected with a palatal stent
224158450|NCT03855761|BEHAVIORAL|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
224158451|NCT03855761|BEHAVIORAL|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
224158452|NCT00910936|BEHAVIORAL|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
224158453|NCT06011785|DRUG|Silica 12CH|Participants will freely elect to be in either the intervention group. Individuals in the experimental group will receive the intervention while also following the standard-care protocol. All individuals will be encouraged to continue with any concurrent conventional medical treatment for their Silicosis-related symptoms. Individuals in either group may freely leave the study at any time with no consequence. Additionally, participants may freely elect to decide opt out at any time.
224158454|NCT04146402|DRUG|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
224303569|NCT04889287|DRUG|Elinzanetant (BAY3427080)|Once daily over 12 days
223466638|NCT00894088|DRUG|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
223466639|NCT01361828|PROCEDURE|Electrophysiology|Visual Evoked Potential and Elctroretinogram
223466640|NCT03649893|DEVICE|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
223466641|NCT05816382|DRUG|TAK-861|TAK-861 tablets
223577703|NCT04492709|DRUG|AZD5718|The subjects will receive oral AZD5718 tablet once daily starting on Day 2 to Day 6 in Treatment Period 2 and on Day 7 co-administered with midazolam in Treatment Period 3.
223577704|NCT02696499|DRUG|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
223577705|NCT02696499|DRUG|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
223577706|NCT03801330|OTHER|Usual Care Pulmonary Rehabilitation Program|Participants in the Usual Care Pulmonary Rehabilitation Program group will complete an 8 week clinic based Pulmonary Rehabilitation Program (usual care).
223466642|NCT05987826|DRUG|Furmonertinib|Furmonertinib 80mg QD oral 8 weeks.
223577707|NCT03801330|OTHER|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete an 8-week home-based Pulmonary Rehabilitation Program using a software app (software)
223577708|NCT01157208|OTHER|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
223577709|NCT01157208|OTHER|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
223577710|NCT00844805|DRUG|Infliximab|
223577711|NCT00844805|DRUG|Placebo|
224303570|NCT04889287|DRUG|Rosuvastatin|Single doses on Day 1, Day 8, and Day 13
223466643|NCT01619878|DRUG|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
223466644|NCT00667485|DRUG|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
224303571|NCT00759187|DRUG|Fluoride|Brush twice daily
224303572|NCT00759187|DRUG|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
223577712|NCT00844805|DRUG|Naproxen|
223577713|NCT02662114|OTHER|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
224303573|NCT00759187|DRUG|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
223466645|NCT00667485|DRUG|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
224303574|NCT01568970|BEHAVIORAL|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
224303575|NCT01568970|BEHAVIORAL|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
224303576|NCT02674906|DRUG|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
223466646|NCT00667485|DRUG|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
223466647|NCT01137513|DEVICE|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
223466648|NCT01137513|DEVICE|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
223466649|NCT04970121|DRUG|Duloxetine|"Duloxetine, tablets, 20mg as starting dose and up to 60mg as maximum dose, once daily.~Taxanes is used according to manual instruction and patient condition."
223466650|NCT03113565|BEHAVIORAL|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
223466651|NCT06439108|PROCEDURE|single symphyseal plating in management of vertically unsable open book pelvic ring injuries|open book pelvic ring injuries can be managed via the two techniques.
223466652|NCT02264808|OTHER|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
223466653|NCT04241549|DRUG|Cusatuzumab|Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
223466654|NCT04241549|DRUG|Azacitidine|Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
223466655|NCT01219712|PROCEDURE|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~* Hb would be optimized to \> 90 g/l~* SaO2 \> 96%~* Stroke volume index (SVI) \> 30~* Heart rate should ideally be \< 80~Stroke volume index (SVI) \> 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is \< 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
223466656|NCT01733745|OTHER|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
223466657|NCT01733745|OTHER|SYSTANE® BALANCE|Lubricant Eye Drops
223466658|NCT01733745|DIETARY_SUPPLEMENT|SYSTANE® Vitamins|
223466659|NCT01733745|OTHER|Microfiber towels (as warm compresses, with or without saline eye drops)|
223466660|NCT05016375|OTHER|Interview|Interview with individuals with T2DM
223466661|NCT03635827|COMBINATION_PRODUCT|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
223466662|NCT03635827|COMBINATION_PRODUCT|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
223466663|NCT05348044|OTHER|Res-ET intervention|Remote IMST delivery on Resilience
223466664|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of three different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams, 15 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams and 15.4 grams maltodextrin was used in 0 grams HC and 15 grams HC respectively. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
223577714|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
223577715|NCT01039298|PROCEDURE|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
223577716|NCT00567918|DRUG|FK506|Ophthalmic suspension
223577717|NCT01958853|DEVICE|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
223577718|NCT01352741|DRUG|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
223577719|NCT01352741|DRUG|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
223577720|NCT01352741|DRUG|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
224068327|NCT03314545|PROCEDURE|post,core and crown|post,core and crown
224303577|NCT02674906|DRUG|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
224303578|NCT02808156|OTHER|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
224303579|NCT02808156|OTHER|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
224303580|NCT05982288|OTHER|Virtual Reality Software|Training of intensive care nurses with virtual reality software
224303581|NCT00317707|DRUG|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
224303582|NCT00317707|DRUG|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
223466665|NCT05932771|DIETARY_SUPPLEMENT|Experimental: Consumption of two different doses of hydrolyzed collagen (HC) with reistance exercise|"Each trial lasts for seven hours and while participants consumed HC, performed resistance exercise and rested, 10 x 5 mL blood samples were collected from a superficial forearm vein using a cannula.~All trials were performed at the same time of day (08:00 - 15:00).~Different doses of HC (0 grams and 30 grams) and 50 milligrams vitamin C were dissolved with 250 milliliter water in an opaque bottle. To match calories of 30 grams HC, 34.1 grams maltodextrin was used in 0 grams HC. Also to mask any potential difference in HC doses, 4 grams non-caloric sweetener was used in all HC doses.~The details of nutritoinal supplements used are as follows:~Hydrolysed collagen (Myprotein, Cheshire, UK), Vitamin C powder (Holland and Barrett Retail Limited, Warwickshire, UK), Maltodextrin (Myprotein, Cheshire, UK), and Non-caloric sweetener (Truvia®, SilverSpoon, London, UK)"
223466666|NCT03916445|OTHER|Connor Davidson Resilience Scale (CD-RISC 10)|questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
223466667|NCT02895295|BEHAVIORAL|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
223466668|NCT02895295|BEHAVIORAL|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
223466669|NCT02895295|BEHAVIORAL|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
223466670|NCT04147143|OTHER|Documentation|Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
223466671|NCT03739424|OTHER|Whole egg powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
223466672|NCT03739424|OTHER|Whole milk powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
223466673|NCT03739424|OTHER|Gelatin food product|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
223466674|NCT02103660|DRUG|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
223466675|NCT02103660|DRUG|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
223466676|NCT06610643|DRUG|combination therapy|A combination of 5-day remdesivir and 10-day Nirmatrelvir/Ritonavir
223466677|NCT06610643|DRUG|SOC|Standard of care
223466678|NCT06824415|DEVICE|TMS|Transcranial magnetic stimulation (TMS) applies magnetic pulses to stimulate nerve cells in the brain.
223466679|NCT04821830|DRUG|carbidopa/levodopa, as prescribed by treating physician|"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."
223466680|NCT06612489|DEVICE|biofeedback based dynamic-difficulty game|A biofeedback based dynamic-difficulty serious game rooted in distraction therapy.
223466681|NCT06612489|DEVICE|fixed difficulty game|A fixed difficulty serious game rooted in distraction therapy.
223466682|NCT06611865|PROCEDURE|Intraligamentary anaesthesia|Injection of anesthetic solution into the intraligamentary space along the long axis of a tooth root using a pressure syringe.
223466683|NCT06611865|PROCEDURE|Inferior alveolar nerve block|Anaesthetic injection into the pterygomandibular space to block the Inferior alveolar nerve at the mandibular foramen point.
223466684|NCT06612476|DRUG|Interleukin 6-guided antibiotic therapy|In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.
223577721|NCT03576105|COMBINATION_PRODUCT|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
223466685|NCT06612476|DRUG|GOLD-guided antibiotic therapy|In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.
223466686|NCT06611904|DRUG|Dulaglutide|Combined treatment with dulaglutide and dapagliflozin
223577722|NCT03576105|COMBINATION_PRODUCT|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
223577723|NCT03576105|COMBINATION_PRODUCT|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
223577724|NCT03576105|COMBINATION_PRODUCT|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
223577725|NCT00376805|DRUG|Fludarabine|administered intravenously 25 mg/m\^2 times 5 doses
223466687|NCT06611904|DRUG|DPP-4 Inhibitors|DPP-4i treatment as an add-on to metformin
223466688|NCT06611462|BEHAVIORAL|Prehabilitation (the STRONG programme)|Participants screened positive for one or more SNAP factors and randomised to the intervention group will receive an individualised plan for prehabilitation of their specific SNAP factors.
223577726|NCT00376805|DRUG|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
223577727|NCT00376805|RADIATION|Total body irradiation|200 cGy (gray) on day -1
223466689|NCT06612528|DEVICE|tDCS|"The tDCS is a non-invasive brain stimulation technique. In this study, we used an intensity of 2mA for 20 minutes in two different areas.~M1 group: the anode was over C5 (10-10 EEG system) and the cathode was placed over Fp2. For the Cerebellum group stimulation, the targeted anode area was 2 cm below the inion and the cathode over the deltoid muscle."
223577728|NCT00376805|OTHER|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10\^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
223466690|NCT06612528|DEVICE|Flexible tube in water|"The exercise involved producing sustained /u/ vowels in ascending and descending scales, tailored to each participants vocal range.~The flexible tube was 35 cm long, 1 cm in diameter, and 2 mm thick. One end of the tube was submerged 3 cm into a 500 ml bottle filled with water. Participants produced four sets of vocal exercises, each lasting 3 minutes, with 2-minute rests between sets, totaling 20 minutes of vocal therapy."
223466691|NCT06612385|DEVICE|platelet indices|Significance of platelet indices and ratios in different degrees of burn
223466692|NCT06999980|DRUG|Ipilimumab 3mg/kg and nivolumab 1mg/kg|Neoadjuvant for 2 doses on days 1 and 22
223466693|NCT06999980|DRUG|Nivolumab 480mg and relatlimab 160mg and ipilimumab 1mg/kg|Neoadjuvant for 2 doses at days 1 and 29
223466694|NCT06999980|DRUG|Nivolumab 480mg and relatlimab 160mg|Neoadjuvant for 2 doses on days 1 and 29
223466695|NCT07003984|BIOLOGICAL|CHIKV VLP vaccine|CHIKV VLP vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide (Alhydrogel®) adjuvant 2%
223466696|NCT07003984|BIOLOGICAL|Placebo|Placebo is comprised of formulation buffer
223466697|NCT07006896|DEVICE|Foley balloon|Foley balloon for induction of labor
223466698|NCT07006896|DRUG|Oxytocin|Pitocin for induction of labor
223577729|NCT00376805|BIOLOGICAL|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
223577730|NCT00468936|DRUG|Myfortic|enteric coated Cellcept pills in applicable dose for patient
223577731|NCT04902521|DEVICE|Transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (TMS) is a safe non-invasive technique that stimulates the brain using repetitive magnetic pulses to enhance neuroplasticity. TMS has been shown to produce lasting modulation of cortical activity and improve clinical symptoms of children with neurodevelopmental disorders including CP
223577732|NCT04902521|DEVICE|Sham Transcranial Magnetic stimulation|Sham Transcranial Magnetic stimulation will be given to the control group. During the Sham procedure patients will sit near the TMS but will not receive any magnetic pulses.
223743613|NCT07190521|OTHER|Traditional prenatal education|"Traditional prenatal education programs, often referred to as antenatal or maternity school classes, are structured group sessions provided to pregnant women, typically in clinical or community settings. These classes aim to:~Prepare expectant mothers for labor, birth, and postpartum care,~Provide evidence-based information about breastfeeding, newborn care, and maternal recovery,~Promote positive health behaviors during pregnancy,~Reduce fear and anxiety by increasing knowledge and confidence."
224303583|NCT03454178|DIAGNOSTIC_TEST|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
223577733|NCT04315636|DRUG|Surfactant nebulisation|200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
223466699|NCT00994747|OTHER|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
223466700|NCT00994747|OTHER|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
223466701|NCT06695507|DRUG|Ruxolitinib|Participants will receive ruxolitinib for 6 months.
223466702|NCT05443451|DEVICE|3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH|The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
223466703|NCT06882031|DRUG|Treatment A: Arsenic Trioxide (ATO) Intravenous|0.15 mg/kg 2-hour IV infusion of ATO administered under fasted state in single dose
223466704|NCT06882031|DRUG|Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state|0.15 mg/kg SDK001 administered orally under fasted state in single dose
223466705|NCT06882031|DRUG|Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state|0.15 mg/kg SDK001 administered orally under fed state (high fat breakfast) in single dose
223466706|NCT06882031|DRUG|Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate|0.15 mg/kg SDK001 administered orally with calcium carbonate in tablet form (1g) under fasted state in single dose
223466707|NCT06706232|DRUG|Psilocybin|Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
224068328|NCT02187952|BEHAVIORAL|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
224068329|NCT01612429|DIETARY_SUPPLEMENT|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
224068330|NCT03329235|DRUG|PRP|platelet rich plasma
224068331|NCT03329235|DRUG|HA|hyaluronic acid
223466708|NCT06706232|BEHAVIORAL|Therapeutic Support|"Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before.~Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life.~If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not."
223466709|NCT03563898|OTHER|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
223466710|NCT00960804|BIOLOGICAL|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
223466711|NCT00960804|BIOLOGICAL|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
223466712|NCT00960804|OTHER|Placebo|IV, q 8 weeks, for up to 80 weeks
223466713|NCT04491461|DIETARY_SUPPLEMENT|Herbal tea blend|1 cup of freshly brewed tea from an herbal tea blend.
223466714|NCT04491461|DIETARY_SUPPLEMENT|Warm water|1 cup of warm water
223466715|NCT04235166|OTHER|Current risk scores|Current risk scores for assessing the prognosis of acute upper gastrointestinal bleeding in cirrhosis were used.
223466716|NCT04235166|OTHER|New risk scores|New risk scores for assessing the progress of acute upper gastrointestinal bleeding in cirrhosis was used.
223466717|NCT00651300|DRUG|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
223577734|NCT01886690|DRUG|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
223466718|NCT00651300|DRUG|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
223466719|NCT02248168|DRUG|Pramipexole|
223466720|NCT03810456|BEHAVIORAL|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
223577735|NCT01886690|DRUG|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
223577736|NCT04460586|DRUG|Omadacycline Injection [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
223577737|NCT04460586|DRUG|Omadacycline Oral Tablet [Nuzyra]|Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
223577738|NCT00334997|PROCEDURE|endoscopic surgery|
224158455|NCT04146402|DRUG|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
224158456|NCT00240929|DRUG|MEDI-493|Active Comparator
224158457|NCT04268706|DRUG|CD30.CAR-T|Autologous CD30.CAR-T cells infused on Day 0 after the completion of lymphodepleting chemotherapy.
223466721|NCT03810456|BEHAVIORAL|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
223577739|NCT00334997|PROCEDURE|laser surgery|
223577740|NCT00334997|RADIATION|radiation therapy|
223577741|NCT00918268|BIOLOGICAL|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
223577742|NCT04704427|DEVICE|Non-invasive BCI training|In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.
223577743|NCT04704427|OTHER|Traditional Physiotherapy protocol|In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.
223577744|NCT00283972|DEVICE|LAP-BAND System|
223577745|NCT01921413|DEVICE|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
223577746|NCT00573560|DEVICE|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
223577747|NCT04573426|DRUG|Acetaminophen|1,000mg liquid acetaminophen
223577748|NCT04573426|DRUG|Placebo|Liquid placebo solution
223577749|NCT04573426|BEHAVIORAL|Weight stigma vignette|Short vignette meant to induce weight stigma by describing one's rejection for a promotion due to their weight
224158458|NCT04268706|DRUG|Fludarabine|Lymphodepletion chemotherapy (30 mg/m2/day) for 3 consecutive days
224158459|NCT04268706|DRUG|Bendamustine|Lymphodepletion chemotherapy (70 mg/m2/day) for 3 consecutive days
224158460|NCT02255955|DRUG|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
224158461|NCT02255955|DRUG|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
224158462|NCT02255955|DRUG|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
223466722|NCT04825951|OTHER|CS 2000|treating growing Skeletal growing Class III patients
223466723|NCT03127319|DRUG|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
223466724|NCT03127319|DRUG|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv\>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
223466725|NCT06404619|BEHAVIORAL|Education program|The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
223466726|NCT00082212|BIOLOGICAL|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
223466727|NCT00490919|DRUG|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
223466728|NCT00490919|DRUG|Placebo|transdermal system (placebo) worn for 7 days
223466729|NCT01296139|DRUG|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
223466730|NCT02717728|PROCEDURE|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
223466731|NCT02717728|PROCEDURE|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
223466732|NCT00428480|BEHAVIORAL|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
223466733|NCT00428480|BEHAVIORAL|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
223466734|NCT00005743|BEHAVIORAL|exercise|
223466735|NCT00005743|BEHAVIORAL|weight loss|
223466736|NCT02176369|DRUG|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
223466737|NCT01014598|DRUG|Cisplatin|Given intra-arterially via isolated lung suffusion
223466738|NCT01014598|OTHER|Pharmacological Study|Correlative studies
223466739|NCT02193204|BEHAVIORAL|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
223466740|NCT02193204|BEHAVIORAL|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
223466741|NCT07065643|OTHER|Phase 1 - Maintenance Diet|3d maintenance diet (MT, fixed macronutrient composition of 15% protein, 30% fat and 55% CHO), fed to energy requirements (1.3 X RMR)
223466742|NCT07065643|OTHER|Phase 2 - Weight loss diet|6 week calorie restricted high protein diet (CR, fixed macronutrient composition as 30% protein, 35% fat and 35% CHO) fed to energy requirements \[0.8 X Resting Metabolic Rate (RMR)\], with stepwise reduction of 100kcal/d at week 3 and 5
223466743|NCT07073612|DIAGNOSTIC_TEST|Cardiopulmonary Exercise Testing (CPET)|CPET will be performed on a cycle ergometer using a ramp protocol designed to achieve an exercise time of 8-12 min. The entire procedure duration is approximately 60 min. CPET will be completed 6 months to 1 day before the cardiac catheterization and will be repeated 3-6 months following cardiac catheterization.
223466744|NCT07073612|DIAGNOSTIC_TEST|Shear Wave Elastography Scan|The study lasts approximately 20 minutes. Shear Wave Elastography will be completed 6 months to 1 day before the cardiac catheterization. The Scan will be repeated 2-4 weeks following cardiac catheterization, and 3-6 months following cardiac catheterization.
223577750|NCT04573426|BEHAVIORAL|Control vignette|Short vignette meant to have no effect on emotion describing a generic promotion process
223577751|NCT02737995|DRUG|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
223466745|NCT07072572|DRUG|Lower albumin dosage|A fixed dose of 35 grams of albumin on they one and day two.
223466746|NCT07073768|DRUG|Trelagliptin 100 mg|Trelagliptin will be administered as oral tablets at a dose of 100 mg once weekly for 3 months. Participants will continue background metformin therapy as prescribed. Trelagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and differs from daily DPP-4 inhibitors due to its longer duration of action, allowing weekly dosing.
223466747|NCT07073768|DRUG|Sitagliptin 100mg OD|Sitagliptin will be administered as oral tablets at a dose of 100 mg once daily for 3 months. Participants will continue background metformin therapy as prescribed. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and requires daily dosing.
224158463|NCT04830839|BEHAVIORAL|Recovery after Stress Toolkit (ReSeT)|ReSeT involves online modules with parallel videoconferencing sessions. ReSeT integrates two evidence-based treatment methods: cognitive behavioral therapy coping skills (coping CBT) and direct exposure to trauma reminders through a trauma narrative.
224303584|NCT00888056|PROCEDURE|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
224158464|NCT05257629|COMBINATION_PRODUCT|Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)|Varenicline and nicotine e-cigarettes plus counseling
224158465|NCT05257629|OTHER|Varenicline Plus Counseling|Varenicline plus counseling
224158466|NCT06158854|DRUG|ABBV-383 (Etentamig)|Intravenous Infusion
224158467|NCT01851525|DEVICE|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
223466748|NCT07073690|DRUG|Luspatercept|According to the product label
223466749|NCT07072637|DIAGNOSTIC_TEST|Neurological function assessment|Neurological evaluations including neurological examination (NE), nerve conduction study (NCS), quantitative sensory testing (QST), autonomic function testing (AFT), and the Toronto Clinical Neuropathy Score (TCNS) questionnaire. Assessments will be conducted at baseline and every three months until six months after completion of EV treatment.
223466750|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 50 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
223466751|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 100 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
223466752|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 200 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
223466753|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 400 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly)
223577752|NCT05093920|DRUG|Doxorubicin-Eluting Beads|"* The patients will be categorized in two randomized groups; c-TACE group (A) and DEB-TACE group (B).~* After patient counseling and obtaining a written consent to participate in the study, both groups will be subjected to the interventional procedure according to patient group; Group A; Lipidol-Doxorubicin emulsion material followed by gel foam embolic material will be injected through the catheter directly into tumor feeding vessels through transarterial catheter.~Group B; Doxorubicin-Eluting Beads will be injected through the catheter directly into tumor feeding vessels through transarterial catheter."
223577753|NCT03080545|DRUG|Enstilar 0.005%-0.064% Topical Foam|Topical foam
224158468|NCT03487315|DIAGNOSTIC_TEST|immunoblot|immunoblot
223466754|NCT07073183|BIOLOGICAL|CV09070101 mRNA vaccine (CVHNLC) 400 µg|CVHNLC will be administered as in IM injection (4x in induction treatment period, than during main treatment period every 3 weeks) plus pembrolizumab (3-weekly) and carboplatin/paclitaxel (3-weekly)
223577754|NCT02428920|BEHAVIORAL|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
224158469|NCT05305625|PROCEDURE|remote ischemic postcondioning|remote ischemic postcondioning twice daily, for three consecutive days，the upper arm of the lighter paralyzed side was pressurized to 200mmHg, pressurized 5min and relaxed for 5 minutes for 4 cycles as a complete remote ischemic postcondioning
223577755|NCT03454815|PROCEDURE|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
223577756|NCT00237380|DRUG|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water.
223577757|NCT01913704|DEVICE|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
223577758|NCT06466993|BEHAVIORAL|Intervention of standardized relaxing breathing|Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
223577759|NCT05562362|DRUG|RE-021, sparsentan|RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
223577760|NCT03216486|DRUG|BPS804|IV administration of BPS804 in 5% Dextrose solution
223577761|NCT02273713|DRUG|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
223577762|NCT00002177|DRUG|Hydroxyurea|
223577763|NCT00002177|DRUG|Nelfinavir mesylate|
223577764|NCT00002177|DRUG|Stavudine|
223577765|NCT00002177|DRUG|Didanosine|
223577766|NCT01510145|DRUG|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
224158470|NCT05305625|DRUG|standard therapy|received standardized treatment
224158471|NCT05084820|COMBINATION_PRODUCT|Action observation treatment|Participants will watch 5 videos of motor tasks; each video is of 30 sec and watch for 4 times (i.e. for 2 minutes). Then patient will execute the motor act, soon after the observation with an affected limb for 2 minutes, with total rest time of 5 minutes for this treatment. Conventional treatment of muscle stretching, strengthening and ROM exercises will be given for 15 minutes including rest. Total treatment time is 40 minutes.
223466755|NCT07073014|DRUG|Vosoritide|Open-label administration of vosoritide using weight-band dosing
223466756|NCT07072676|DEVICE|Assistive gait devices combined with physiotherapy|During the intervenation week, the patient undergoes 12 hours/week of gait training, fall prevention, balance group and physiotherapy as part of their inpatient rehabilitation programme. The individual sessions last 30 minutes each.
223466757|NCT06602414|PROCEDURE|Conservative treatment|Conservative treatment instead of surgical repair
223466758|NCT06882096|DRUG|Nicotinamide Mononucleotide (NMN)|Nicotinamide Mononucleotide (NMN)
223466759|NCT06882096|DRUG|Nicotinamide (NAM)|Nicotinamide (NAM)
223466760|NCT02110251|BEHAVIORAL|Supervised Exercise Therapy|
223466761|NCT06050642|OTHER|enhanced care model provided by Timkl, a home support provider|A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
223466762|NCT06955754|DRUG|BI 764198, formulation 1|BI 764198, formulation 1
223466763|NCT06955754|DRUG|BI 764198, formulation 2|BI 764198, formulation 2
223466764|NCT06955754|DRUG|BI 764198, formulation 3|BI 764198, formulation 3
223466765|NCT05074329|DEVICE|Moventis PNS|Moventis PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin.
223466766|NCT05714553|DRUG|Fosifloxuridine Nafalbenamide|Intravenous infusion
223466767|NCT05714553|DRUG|Leucovorin|Intravenous infusion
223466768|NCT05714553|DRUG|Pembrolizumab|Intravenous infusion
223466769|NCT05714553|DRUG|Docetaxel|Intravenous infusion
223466770|NCT02114138|PROCEDURE|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
223466771|NCT02114138|DIAGNOSTIC_TEST|urine collection|urine collection will be performed on both the control group and hospitalized participants
223466772|NCT00116181|DRUG|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
223466773|NCT05943951|PROCEDURE|Right hemicolectomy|It begins with a thorough laparoscopic inspection of the abdomen for evidence of metastatic disease and to confirm the location of the tumor. Usually is performed dissection using a medial-to-lateral approach. A lateral or inferior approach can also be used depending on the anatomy. The vascular dissection may begin at the ileocolic pedicle or over the superiore mesenteric vein. After completing the medial-to-lateral dissection, the sourgeons return to the ileocolic pedicle to begin vascular dissection. Whether a D2 (until encountering the right branch of the middle colic) or D3 dissection (until the root of ileocolic artery and vein) is performed depends upon the tumor stage. For an intracorporeal anastomosis, the bowel is transected proximally and distally using a linear stapler. The terminal ileum is positioned along the transverse colon in an isoperistaltic fashion. After that a colotomy and an enterotomy are made on the antimesenteric edge of the colon and small bowel respectively
223466774|NCT05541939|DRUG|Mizagliflozin|Encapsulated or Liquid Formulation
223466775|NCT00598728|BEHAVIORAL|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
223577767|NCT03043677|BIOLOGICAL|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
223577768|NCT04871802|DIETARY_SUPPLEMENT|Taxifolin Aqua|Dietary supplement
224158472|NCT05084820|COMBINATION_PRODUCT|conventional treatment|conventional treatment of 40 minutes in total will be performed including Stretching (for 8-10 sec with set of 5 repetitions/ session on each side for 3 minutes total with rest), strengthening (weighted bicep curls, side arm raise and open arm movement exercises with set of 5 repetitions/ session for 9 minutes total with rest), Range of motion exercises active and passive with set of 5 repetitions/ session for 3 minutes total with rest and gripping,reaching, grasping exercises (on each side for total 25 minutes including rest) with assistance of physiotherapist
223466776|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
223466777|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
223466778|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
224158473|NCT03908268|BEHAVIORAL|Family Nurture Intervention (FNI)|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.
224303585|NCT04975009|BEHAVIORAL|Fear conditioning|Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
223466779|NCT03242369|PROCEDURE|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
223466780|NCT03556995|OTHER|bariatric surgery patients|
223466781|NCT04588974|DEVICE|magnetic-assisted capsule endoscope system (InsightEyes EGD System) with or without 3D images|The patient will undergo both diagnostic tests within two days, a magnetic-assisted capsule endoscope system first and then conventional EGD will be carried on at least 4 hours afterward.
223466782|NCT01738945|DRUG|Amlodipine|10 mg/day for 12 weeks
223466783|NCT01095172|DRUG|Rituximab|375mg/m\^2, single dose given 2-4 weeks prior to transplantation
223466784|NCT01095172|DRUG|Tacrolimus|dose calculated to give levels of 3-7ng/ml
223466785|NCT01095172|DRUG|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
223466786|NCT01095172|DRUG|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
223577769|NCT04833153|BEHAVIORAL|Person-First - Please (PFP)|PFP takes 10 weeks and consist of four modules: Information, Person, Autonomy and Dignity. Information module takes 1 hour contact on first week. The other modules will follow every third weeks, starting from week 2. So that on week 2, 5 and 8 researcher meet nurses in 4 hours education session. Between the modules, nurses can take contact online to the researcher.
223577770|NCT02115841|DEVICE|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
223577771|NCT00574665|OTHER|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
223577772|NCT05823844|DRUG|Suvorexant|Suvorexant (Belsomra™) is an orexin receptor antagonist that will be administered as 2 tablets (10mg each) for a starting dose of 20mg. If the dose is not well tolerated (e.g., daytime sleepiness), then the dose may be decreased to 10 mg of Suvorexant.
223577773|NCT05823844|DRUG|Placebo|The placebo pill will look identical to Suvorexant and will be taken as 2 tablets.
223577774|NCT00383734|DEVICE|Newfill|1 to 7 injections of drug
223577775|NCT00383734|DEVICE|Eutrophill|1 to 7 injections of drug
223577776|NCT03378089|BEHAVIORAL|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
223577777|NCT03378089|BEHAVIORAL|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
224158474|NCT03908268|BEHAVIORAL|Standard Children's Learning Center (CLC) Program|Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
224158475|NCT04258761|DRUG|10XB-101 Solution for Injection|Active test article
224303586|NCT05490485|DRUG|Camrelizumab|Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
223466787|NCT01095172|DRUG|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
223577778|NCT06080646|OTHER|cross-sectional MRI and EEG assessments (NO INTERVENTION)|n/a there is no intervention in this observational study
223577779|NCT03934970|DIAGNOSTIC_TEST|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
224158476|NCT00250367|DRUG|risperidone|
224158477|NCT04628338|DRUG|IFN-γ (interferon gamma-1b) injection|Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)
224158478|NCT02298075|DRUG|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
223466788|NCT01095172|DRUG|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
223466789|NCT06469957|OTHER|Questionnaires and data collection sheet|Questionnaires
223466790|NCT03163446|BIOLOGICAL|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
223466791|NCT03163446|DRUG|Placebo|Placebo, given as a single 2 hour iv infusion
223466792|NCT03594929|DEVICE|Active RIC|
223466793|NCT03594929|DEVICE|Sham Control|
223466794|NCT05900375|BEHAVIORAL|Parent Decision Aid|A paper parent decision aid in color will be provided to all patients at the time of their appointment and will aid in discussion with health care professionals.
223466795|NCT01317641|DRUG|ODM-201|ODM-201 administered orally daily
223577780|NCT00533650|DRUG|MK0429|
223577781|NCT00186212|BEHAVIORAL|workbook/journal on coping with breast cancer|
223577782|NCT00186212|BEHAVIORAL|standard educational materials on breast cancer|
223577783|NCT03488589|DIAGNOSTIC_TEST|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
223577784|NCT03419377|OTHER|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
224158479|NCT02298075|DRUG|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
224303587|NCT01996683|DRUG|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
224303588|NCT05545371|BIOLOGICAL|immunization procedures|The subjects were vaccinated with rabies vaccine according to different immunization procedures
224303589|NCT03122197|DRUG|Letrozole Oral Tablet|Administration: Letrozole will be given orally once daily.
224303590|NCT03122197|DRUG|Temozolomide|50 mg/m2 TMZ administered orally once daily
224303591|NCT04620928|BEHAVIORAL|Concepts|Images and sounds that are characteristic of various common objects.
224158480|NCT04379609|OTHER|Masticatory efficiency|"Two-color chewing gum mixing ability test was used to measure masticatory efficiency in the control group, before and after treatment in the experimental group.21 Commercial two-color chewing gum was used.The gum was left on the patient's tongue and he/she was asked to chew 20 times naturally.~After chewing, the gum was put in a transparent plastic bag and squeezed to 1 mm. Both sides of the sample were scanned at 300 dpi resolution on a desktop scanner (HP Deskjet, California, USA) in the same day to prevent the colors from deteriorating due to saliva. For each patient, two sides of scanned images were processed in ViewGum software (version 1.4, Dhal Software, Kifissia, Greece, www.dhal.com) using the method of Halozenitis et al. (2013).22 The value of VOH (variance of hue) was taken as the value of chewing activity. The highness of this value indicates low masticatory efficiency."
223577785|NCT06052111|DRUG|Group F (fentanyl group)|Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
223466796|NCT00350441|DRUG|Sildenafil Citrate|
223466797|NCT05108766|DRUG|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
223466798|NCT05108766|DRUG|Placebo|Matching placebo to tildrakizumab administered SC
223577786|NCT06052111|DRUG|Group D (dexmedetomidine group)|The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
223577787|NCT02044601|DRUG|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
223577788|NCT02044601|DRUG|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
223577789|NCT02044601|DRUG|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
223577790|NCT02044601|DRUG|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
223577791|NCT02044601|RADIATION|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
224158481|NCT00112684|DRUG|alvocidib|Given IV
224158482|NCT00112684|OTHER|pharmacological study|Correlative studies
224158483|NCT00112684|OTHER|laboratory biomarker analysis|Correlative studies
224158484|NCT00488059|DRUG|enfuvirtide [Fuzeon]|90 mg SC twice daily
224158485|NCT00488059|DRUG|Optimized background ARV|As prescribed
224158486|NCT00488059|DRUG|Integrase inhibitor|As prescribed
224158487|NCT00488059|DRUG|enfuvirtide [Fuzeon]|180 mg SC once daily
223466799|NCT01228591|DEVICE|Acuvue Advance Plus|Silicone hydrogel contact lens.
223466800|NCT01228591|DEVICE|Acuvue Advance|Silicone hydrogel contact lens
223466801|NCT03159403|DRUG|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
223577792|NCT03037099|BEHAVIORAL|Enhanced GI Concept Education|
223577793|NCT04963114|BEHAVIORAL|art therapy|guided art tour and workshop
224158488|NCT02289716|DRUG|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
224158489|NCT02289716|DRUG|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
224158490|NCT02289716|DRUG|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
224158491|NCT05732597|PROCEDURE|Coronary angiography|A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
224158492|NCT04068038|OTHER|Ventilation protocol|An evidence based ventilation protocol will be implemented at participating sites. This will include limits on peak inspiratory pressure (28cmH2O), driving pressure (16cmH2O), tidal volume (mild 8ml/kg, mod/severe 6ml/kg), positive end expiratory pressure to fraction of inspired oxygen table, permissive hypercarbia (mild allow pH 7.30, mod/severe allow pH 7.20) and permissive hypoxia (mild SpO2 92-97%, mod/severe SpO2 88-92%).
223466802|NCT01121471|DIETARY_SUPPLEMENT|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
223466803|NCT01121471|DIETARY_SUPPLEMENT|Safflower OIl|8.0g/day safflower oil
223466804|NCT00944918|DRUG|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
224158493|NCT03338881|DRUG|[14C]-TAK-659|\[14C\]-TAK-659 solution.
224158494|NCT03338881|DRUG|TAK-659|TAK-659 tablets.
223466805|NCT00944918|DRUG|anastrozole|Tablet, oral, once daily until disease progression.
223466806|NCT00944918|DRUG|exemestane|Tablet, oral, once daily until disease progression.
223466807|NCT00010140|DRUG|docetaxel|
223466808|NCT00010140|DRUG|epirubicin hydrochloride|
223466809|NCT00010140|DRUG|tamoxifen citrate|
223466810|NCT00010140|PROCEDURE|adjuvant therapy|
223466811|NCT04333004|DRUG|Pembrolizumab Combined With Chemotherapy|Pembrolizumab and chemotherapy are carried out at the same time for every 3 weeks
223577794|NCT03504813|OTHER|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
223466812|NCT01505920|PROCEDURE|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
223466813|NCT01505920|PROCEDURE|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
223466814|NCT06365905|OTHER|Non-Interventional Study|Non-Interventional Study
224303592|NCT01470911|DRUG|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
224303593|NCT01470911|DRUG|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
223466815|NCT04884100|OTHER|Validating and improving PPG-based algorithms|Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
223466816|NCT04792320|DIETARY_SUPPLEMENT|Active bamboo charcoal|4g particle
223466817|NCT04792320|DIETARY_SUPPLEMENT|probiotics|0.8g powder
223466818|NCT01921517|DEVICE|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
223466819|NCT01921517|DEVICE|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
223466820|NCT00965107|DRUG|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
223466821|NCT00965107|DRUG|Propofol|Propofol given as a bolus dose of 1 mg/kg.
223466822|NCT00500448|DEVICE|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
223466823|NCT05852314|BEHAVIORAL|Culturally Adapted Manual Assisted Therapy (CMAP-SI)|C-MAP has been adapted from a self-help guide called Life After Self-Harm based on the principles of CBT. It is a brief problem-solving therapy comprising have 4 sessions weekly and then 4 fortnightly and last about 50 minutes each. The manual has been translated to Urdu giving special consideration to cultural adaptation of phrases and concepts to reflect Pakistani culture. Additionally, culturally appropriate case scenarios were incorporated and a consensual view to addressing cultural factors such as gender role, family conflicts and financial difficulties was taken. The culturally adapted intervention consists of the following components: evaluation of self-harm attempt, crisis skills, problem-solving and CBT techniques to manage emotions, negative thinking, interpersonal relationships, and relapse prevention strategies. Participants will receive sessions according to adapted CMAP-SI manual.
223466824|NCT05748132|PROCEDURE|combined conventional and pulsed RF|"1. the classic Hartle technique is used to reach the Gasserian ganglion~2. Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~3. After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~   * Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~  * Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~4. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given"
223466825|NCT01823471|OTHER|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
223577795|NCT03504813|OTHER|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
223577796|NCT03504813|OTHER|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
223466826|NCT01973686|BEHAVIORAL|Physical activity|
223466827|NCT05447273|DIAGNOSTIC_TEST|Multi-parametric, functional magnetic resonance imaging (MRI)|Multi-parametric, functional magnetic resonance imaging (MRI) will be performed in all included patients prior to surgery.
223466828|NCT01997034|BEHAVIORAL|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
223577797|NCT03504813|BEHAVIORAL|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
224158495|NCT03912324|PROCEDURE|Unipolar voltage subtraction map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury~3. Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~4. the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~5. Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~6. Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~7. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~8. Evaluate time to complete isolation after additional ablation~9. Evaluation of Procedure and Ablation time, and perfusion saline dose~10. Rhythm follow-up after the procedure in accordance with the study design."
223466829|NCT04579809|PROCEDURE|4 strand technique|4 strand technique reapir of tendin flexor injury
223466830|NCT00991081|BEHAVIORAL|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD"
223466831|NCT00991081|BEHAVIORAL|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
223466832|NCT00991081|DRUG|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion"
223466833|NCT00991081|BEHAVIORAL|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
223466834|NCT00991081|BEHAVIORAL|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
223466835|NCT01810224|PROCEDURE|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
223466836|NCT01796028|DRUG|METFORMIN|
224158496|NCT03912324|PROCEDURE|CT myocardial thickness map guided PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~4. Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~5. Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~6. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~7. Evaluate time to complete isolation after additional ablation~8. Evaluation of Procedure time, Ablation time, and perfusion saline dose~9. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
223466837|NCT01796028|DRUG|Placebo|
223466838|NCT01796028|DRUG|TAXOTERE®|
223466839|NCT02507791|OTHER|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
223466840|NCT03937115|DEVICE|Active tDCS|2 active tDCS sessions (20 min each, 2 mA) applied to the dlPFC and right motor cortex
223466841|NCT03937115|DEVICE|Sham tDCS|1 sham tDCS session (20 min, 0 mA) applied to the dlPFC
223466842|NCT03937115|DEVICE|Active tDCS|10 tDCS sessions (2 sessions/day for 5 days, 20 mA, 20 min each) applied to the dlPFC
223466843|NCT03937115|DEVICE|Sham tDCS|10 tDCS sessions (2 sessions/day for 5 days, 0 mA, 20 min each) applied to the dlPFC
223466844|NCT06455657|OTHER|breast cancer education|Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.
224158497|NCT03912324|PROCEDURE|Empirical PV isolation group|"1. Pulmonary vein isolation will be performed using a radiofrequency catheter~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~4. Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~5. Evaluate time to complete isolation after additional ablation~6. Evaluation of Procedure time, Ablation time, and perfusion saline dose~7. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
224158498|NCT02676453|OTHER|Intervention|Dental hygienist support
224303594|NCT00296231|OTHER|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
224303595|NCT02240030|DRUG|CVT-301 Low Dose|
224303596|NCT02240030|DRUG|CVT-301 High Dose|
224303597|NCT02240030|OTHER|Placebo|
224303598|NCT04898855|BEHAVIORAL|Cognitive Behavioral Therapy for Insomnia|Treatment includes sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
223466845|NCT04454008|BEHAVIORAL|executive function family training|Intervention programs include executive function training for children with ADHD and parenting guidance for parents
223466846|NCT04454008|BEHAVIORAL|treat as usual|Outpatient routine health education, behavioral guidance and family support
223466847|NCT04265521|DEVICE|Biocool Footcare|BioCool Footcare is a footbath containing granulate of sodium percarbonate that will in this study be used for treatment of foot fungus, heel cracks, calluses and/or dry feet.
223466848|NCT02843009|BEHAVIORAL|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
223466849|NCT02843009|DIETARY_SUPPLEMENT|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
223466850|NCT03110354|DRUG|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
223466851|NCT03984396|OTHER|Educational Materials - Patient & Clinician|deprescribing information for patient \& clinician
224158499|NCT02305550|DEVICE|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
223466852|NCT05761353|DEVICE|Endermologie|"Group A will receive -18 sessions by Endermologie system used to decrease postmastectomy lymphedema for group (A), three sessions per week for six weeks.~Each session was 30 minutes at the posterior thorax, upper arm, forearm and the hand.~-In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
223466853|NCT05761353|DEVICE|Negative pressure therapy|"Group B will receive negative pressure therapy with~* Pressure: 20-250 mmHg.~* Total treatment period: 6weeks~* A number of sessions: 3sessions/ week. Time of application : 30 min~* In addition to physical therapy program (active range of motion and elevation); hygiene and skin care"
223466854|NCT04101383|DRUG|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
223466855|NCT04101383|DRUG|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
223466856|NCT05415189|OTHER|Not relevant|This is a non-intervention cohort study
223466857|NCT02408042|DRUG|Pembrolizumab|
223466858|NCT02408042|DRUG|Etoposide|
223466859|NCT02408042|DRUG|Ifosfamide|
223466860|NCT02408042|DRUG|Mesna|
223466861|NCT02408042|DRUG|Carboplatin|
223466862|NCT02408042|DRUG|Brentuximab vedotin|
223466863|NCT02408042|DRUG|Rituximab|
223466864|NCT02938572|DRUG|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
223466865|NCT02938572|DRUG|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
223466866|NCT04545801|DRUG|0.25 mg/kg of Ketamine|patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
223466867|NCT04545801|DRUG|20ml of normal saline solution|20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
223577798|NCT04220112|PROCEDURE|Real-Time Functional Magnetic Resonance Imaging (RT-fMRI)|RT-fMRI neurofeedback targeting down-regulation of the amygdala
223577799|NCT04220112|PROCEDURE|Sham Procedure|RT-fMRI with feedback non-contingently tied to their activation patterns (activation patterns from a prior participant)
224158500|NCT02221960|BIOLOGICAL|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
224158501|NCT02221960|BIOLOGICAL|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
223466868|NCT02907242|OTHER|Revealment|Cerebroplacental ratio revealment
223466869|NCT03856372|RADIATION|Hypofractionated|daily fractions, five fractions per week.
223466870|NCT03856372|RADIATION|Conventional|daily fractions, five fractions per week.
223466871|NCT04318704|DRUG|Ifenprodil|Ifenprodil 20 mg TID
223466872|NCT03041389|BEHAVIORAL|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
223466873|NCT03041389|BEHAVIORAL|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
224158502|NCT01945788|DRUG|Teriparatide (rDNA origin)|
224158503|NCT00169013|DRUG|Gabapentin|
224158504|NCT04531397|DRUG|ACEI treatment|ACEI, will be given once daily based on body weight (0.2mg/kg/d-0.6mg/kg/d，max 20mg/d), for 24 weeks
224158505|NCT04531397|DRUG|Dapagliflozin+ACEI treatment|Dapagliflozin will be given 10 mg/day (weight\>30kg) or 5mg/day (weight≤30kg), for 24 weeks ACEI, will be given based on body weight (max 20mg/d), for 24 weeks.
224158506|NCT04942769|DRUG|Selenium|selenium 100ug ，take it orally twice daily
223466874|NCT00036764|DRUG|ixabepilone|Given IV
223466875|NCT00036764|OTHER|pharmacogenomic studies|Correlative studies
223466876|NCT00036764|OTHER|laboratory biomarker analysis|Correlative studies
224158507|NCT05800613|OTHER|Survey|Questionnaire
223466877|NCT01595373|DRUG|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
223466878|NCT01595373|DRUG|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
223466879|NCT02501408|DEVICE|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
223466880|NCT04268407|DRUG|Amoxicillin Clavulanate|compare the duration of antbiotic use: 2 day versus 7 day
223466881|NCT03040167|PROCEDURE|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
223466882|NCT03040167|DRUG|Bupivacaine with epinephrine|Treatment group
223466883|NCT03040167|DRUG|Normal saline|Placebo group
223466884|NCT04577638|COMBINATION_PRODUCT|Nivolumab and Intensity Modulated Radiotherapy (IMRT)|"Every included patient will receive the experimental treatment regimen as follows:~* Combination of IMRT 66 Gray (Gy)/24 fractions of 2.75 Gy) and immunotherapy with 3 doses of nivolumab, 240 mg (1th, 3th and 5th week of IMRT) during 5 weeks~* Maintenance treatment by nivolumab 240 mg (Q2W) during 6 months, or until progression and severe toxicity leading to definitive treatment interruption."
223466885|NCT03504215|OTHER|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
223577800|NCT00072891|BEHAVIORAL|telephone counseling|
223577801|NCT06177093|RADIATION|MR Linac delivered Radiotherapy|All radiotherapy will be delivered on the MR-linac. The whole prostate will receive 30 Gy in 5 fractions and the dominant lesion plus intra-prostatic margin will receive an isotoxic 45 Gy prescription.
223577802|NCT05840692|DRUG|Escitalopram 20 mg|Antidepressant
223577803|NCT05840692|DRUG|Placebo|
223577804|NCT04199819|DRUG|entecavir|Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
223577805|NCT05105893|OTHER|Dates group|Seven dates to be provided to patients
224158508|NCT02429349|PROCEDURE|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
224158509|NCT04694157|DEVICE|cardiac shock wave therapy|Two target segments of left ventricle will be chosen for all participants. In each target segment, 9 sties will be administered with 200 shots at each site. Low-intensity SW (200 impulses/spot; energy flux 0.09 mJ/mm2), will be administered under electrocardiographic R-wave gating. The entire treatment period will last 3 months with 9 sessions. CSWT will be administered in the first week, followed by a 3-week non-treatment interval.
223577806|NCT02318290|DRUG|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
224158510|NCT05791006|BEHAVIORAL|Neuropsychological tests|"Neuropsychological assessment with:~* NADL-F~* Frontal Assessment Battery (FAB)~* functional scales assessing activities of daily living (ADL) and instrumental activities of daily living (I-ADL)~* Mini-Mental Parkinson (MMP) - For Parkinson's Disease patients~* Montreal Cognitive Assessment (MoCA) - for brain tumor and stroke patients"
224158511|NCT04829461|DEVICE|Ambu® aScope™ 4 Cysto with the aView™ 2 Advance used for stent removal|Procedure using a single-use cystoscope for stent removal
224303599|NCT05545358|OTHER|Questionnaires|Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
223466886|NCT03909048|BEHAVIORAL|Interactive - Psychoeducation|Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
223466887|NCT03909048|BEHAVIORAL|Non-interactive Psychoeducation|Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
223466888|NCT00116688|BIOLOGICAL|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
223466889|NCT02864069|BEHAVIORAL|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
223466890|NCT02864069|BEHAVIORAL|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
223466891|NCT02864069|BEHAVIORAL|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
223466892|NCT04383301|PROCEDURE|Intracorneal ring segment implantaion as the first stage|Intracorneal ring segment (ICRS)
223466893|NCT04383301|PROCEDURE|ACXL and wafe front guieded TPRK as the second stage|Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
223466894|NCT03328234|RADIATION|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
223466895|NCT03328234|DRUG|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
223466896|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
223466897|NCT03328234|DRUG|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
223466898|NCT03328234|DRUG|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
223466899|NCT03328234|OTHER|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
223466900|NCT03593200|DRUG|Pegcetacoplan|Complement (C3) Inhibitor
223466901|NCT04192149|OTHER|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
223466902|NCT01775670|DEVICE|Off-the-shelf splint|Subjects will use an off-the-shelf splint
223466903|NCT01775670|DEVICE|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
223466904|NCT02794129|OTHER|Functional Magnetic Resonance Imaging|
223577807|NCT05873036|DIAGNOSTIC_TEST|Aerobic Training|Aerobic Training to Improve Functional Ability After Breast Cancer Surgery
223577808|NCT05873036|DIAGNOSTIC_TEST|Progressive Resistance Training|Progressive Resistance Training to Improve Functional Ability After Breast Cancer Surgery
223577809|NCT00795912|DRUG|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
223577810|NCT05262686|DRUG|Belimumab|Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
223577811|NCT05262686|DRUG|Interleukin-2|Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
224303600|NCT05545358|DEVICE|Brain and Spinal Cord functional Magnetic Resonance Imaging|Brain and Spinal Cord functional Magnetic Resonance Imaging
223577812|NCT00721721|BEHAVIORAL|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
223466905|NCT01298700|DRUG|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
223466906|NCT01298700|DRUG|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
223466907|NCT01455870|DRUG|ITCA 650 60 mcg/day|exenatide in DUROS
223466908|NCT01455870|DRUG|sitagliptin|oral sitagliptin 100 mg/day
223577813|NCT00721721|BEHAVIORAL|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
223577814|NCT00721721|DIETARY_SUPPLEMENT|Potassium Supplementation|60 mmol potassium supplement
223577815|NCT04665531|PROCEDURE|Erector Spinae Catheter|Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
223577816|NCT04665531|PROCEDURE|Intercostal block|Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
223577817|NCT04665531|DRUG|Ropivacaine 0.2% Injectable Solution|Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
223577818|NCT02246608|DEVICE|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
223577819|NCT02246608|DEVICE|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
223577820|NCT02366117|BEHAVIORAL|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
223577821|NCT03081858|DRUG|TSD-001|Administered via intravesical instillation.
223577822|NCT01182974|DRUG|paracetamol|1 gr of paracetamol PO/PZ/PR
223577823|NCT01182974|DRUG|dypirone|1 gr PO/PZ/PR/IM
223577824|NCT02120703|DRUG|Pregabalin|Pregablin 75 mg per oral two times a day
223577825|NCT02120703|DRUG|Gabapentin|Gabapentin 200 mg twice daily per oral
223577826|NCT05704660|BEHAVIORAL|Adjusted Cognitive-biased modification task|The intervention of the proposed project is based on a go/no-go task in which older adults need to quickly decide whether or not they should react to the stimulus. A rectangle containing an image, or a word will be presented on a screen. In the intervention group, older adults will be instructed to restrain their actions when the rectangle is tilted to the right and to react by pressing a key on the keyboard when the rectangle is tilted to the left, irrespective of the content of the rectangle (because the training is meant to be implicit). In order to train inhibitory processes counteracting the automatic attraction to sedentary behavior, 90% of the rectangles tilted to the right (counterbalanced across participants) will contain a picture or a word related to sedentary behavior. To foster the automatic attraction toward physical activity, 90% of the rectangles tilted to the left will contain a picture or a word related to physical activity.
224158512|NCT04829461|DEVICE|Standard of care reusable cystoscope used for stent removal|Procedure using a reusable cystoscope for stent removal
224158513|NCT02037204|OTHER|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
223466909|NCT06109012|PROCEDURE|duct diversion|the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock
223466910|NCT05257317|OTHER|Osteopathic Medicine|"Where compression and traction movements will be carried out on these structures.~Technique called CV4, applied on the occipital, and Technique called asynchronous rolling of the temporal bones."
223577827|NCT05704660|BEHAVIORAL|Cognitive-biased modification task|In the comparison group, instructions will be identical, but the percentage of physical activity and sedentary stimuli will be equal in each tilt condition (i.e., 50% sedentary stimuli and 50% physical activity stimuli in both right- and left-tilted rectangles)
223577828|NCT03929926|OTHER|Best Practice|receive usual care
223466911|NCT05257317|OTHER|Placebo therapy|Circular movements will be induced in a frontal and parietal bones
223466912|NCT00129441|DRUG|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
223466913|NCT00129441|DRUG|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
223577829|NCT03929926|BEHAVIORAL|Cancer Educational Materials|Receive educational materials via mail
223577830|NCT03929926|OTHER|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
223577831|NCT03929926|OTHER|Counseling|Undergo decision counseling session
223577832|NCT00979849|DRUG|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
223577833|NCT00979849|DRUG|Placebo|Solution for nebulisation, inhaled
223577834|NCT00131456|DRUG|Venlafaxine|375mg/day
223577835|NCT00131456|DRUG|Placebo|Placebo
223577836|NCT04512508|DIAGNOSTIC_TEST|Self test sample|Self test sample, DNA analysis, Biopsy and Anoscopy
224158514|NCT02660060|DRUG|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
224158515|NCT02660060|DRUG|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
224158516|NCT06219876|DEVICE|low level laser treatment|The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
224303601|NCT05545358|OTHER|Proprioceptive training|Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
223577837|NCT00262847|BIOLOGICAL|Bevacizumab|Given IV
223577838|NCT00262847|DRUG|Carboplatin|Given IV
223577839|NCT00262847|OTHER|Laboratory Biomarker Analysis|Correlative studies
223466914|NCT01897337|DRUG|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
223466915|NCT01897337|DRUG|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
223466916|NCT00449839|DRUG|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
223466917|NCT04006145|DRUG|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
223466918|NCT04006145|DRUG|Placebo oral tablet|Placebo identical in appearance to active drug
223466919|NCT01053156|DRUG|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
223577840|NCT00262847|DRUG|Paclitaxel|Given IV
223577841|NCT00262847|OTHER|Placebo|Given IV
223577842|NCT00262847|OTHER|Quality-of-Life Assessment|Ancillary studies
224158517|NCT06219876|DEVICE|High intensity laser treatment|The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
224158518|NCT06219876|OTHER|wrist splint|wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
224158519|NCT01495689|BEHAVIORAL|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
224158520|NCT01495689|BEHAVIORAL|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
224158521|NCT00564200|DRUG|Bortezomib|"PREACONDICIONAMIENTO:~* 2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~* 1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~\- Day -2: Velcade~POSTRANSPLANTATION:~* 2 cycles of 21 days : Velcade days 1, 8 and 15~* 5 cycles of 56 days : Velcade days 1, 8 and 15"
224303602|NCT04992429|PROCEDURE|SphinkeeperTM|The SphinkeeperTM includes up to 10 self-expandable prostheses, which get inserted into the intersphincteric place. They are made of inert Hyexpan (polyacrylonitrile)
224303603|NCT00978263|DRUG|metformin-based Oral Antidiabetic Drugs|
223466920|NCT01053156|DRUG|Placebo|Placebo will be given daily for 3 months.
223466921|NCT04622917|DRUG|MethylPREDNISolone 40 Mg/mL Injectable Suspension|intramuscular injection
223466922|NCT04622917|DRUG|NaCl 9 MG/ML Injectable Solution|Intramuscular injection
224303604|NCT00978263|DRUG|Glargine|
223466923|NCT01348126|DRUG|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
223466924|NCT01348126|DRUG|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
223466925|NCT00010257|DRUG|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
223466926|NCT00010257|DRUG|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
223466927|NCT02627079|OTHER|Daily SMS text messaging|
223466928|NCT01725633|BEHAVIORAL|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
223577843|NCT03562416|DRUG|Nintedanib|Nintedanib (BIBF 1120, Ofev)
223577844|NCT03562416|DRUG|Placebo Oral Tablet|Placebo
223577845|NCT01124981|DRUG|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
223577846|NCT01124981|DRUG|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
223577847|NCT00290667|BIOLOGICAL|pegfilgrastim|
223577848|NCT00290667|BIOLOGICAL|rituximab|
223577849|NCT00290667|DRUG|cyclophosphamide|
223577850|NCT00290667|DRUG|doxorubicin hydrochloride|
223577851|NCT00290667|DRUG|prednisone|
223577852|NCT00290667|DRUG|vincristine sulfate|
223577853|NCT00290667|OTHER|pharmacological study|
223577854|NCT00290667|RADIATION|radiation therapy|
223577855|NCT03901404|PROCEDURE|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
223577856|NCT03966885|BEHAVIORAL|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
223577857|NCT03966885|BEHAVIORAL|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
223466929|NCT01725633|BEHAVIORAL|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
223466930|NCT01725633|OTHER|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
223466931|NCT01725633|OTHER|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
223466932|NCT01092013|BEHAVIORAL|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
223466933|NCT01092013|BEHAVIORAL|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
223466934|NCT01092013|BEHAVIORAL|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
223466935|NCT01690507|DRUG|Decitabine|20 mg/m²/day for 5 days
223466936|NCT01690507|DRUG|Cytarabine|
223466937|NCT01690507|DRUG|aclacinomycin|
223466938|NCT01690507|DRUG|Granulocyte colony-stimulating factor|
223466939|NCT01690507|OTHER|HLA haploidentical mononuclear cells infusion|
223466940|NCT04321928|BEHAVIORAL|Personalized health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.
223466941|NCT04321928|BEHAVIORAL|General health education|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
223466942|NCT05471011|OTHER|Blood and nasal swab sampling|Blood and nasal swab sampling
223466943|NCT02179125|DEVICE|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
223466944|NCT00643760|DRUG|Placebo|placebo
223466945|NCT00643760|DRUG|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
223466946|NCT00643760|DRUG|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
223466947|NCT00643760|DRUG|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
223466948|NCT00643760|DRUG|Pregabalin|pregabalin 300mg/day
223466949|NCT04657939|DRUG|Liraglutide|Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.
223577858|NCT02212769|DRUG|Losartan 50mg|Losartan 50mg once daily for 7 days
223577859|NCT02212769|DRUG|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
223577860|NCT06562582|DRUG|Bisoprolol Oral Tablet|Timing of drug intervention after PCI
223577861|NCT06562582|DRUG|Ramipril Oral Product|Timing of drug intervention after PCI
223577862|NCT06562582|DRUG|Dapagliflozin Oral Product|Timing of drug intervention after PCI
223466950|NCT04657939|DRUG|Pioglitazone|Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.
223466951|NCT00236002|DRUG|Alendronate|Alendronate 70mgm once a week for one year
223466952|NCT02536937|DRUG|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
223466953|NCT01996371|DEVICE|Pedicle Screw|
223466954|NCT02244983|OTHER|Patients History|History taking and drawing of a blood sample
223466955|NCT03916666|PROCEDURE|Epiduroscopy|Endoscopic intervention
223466956|NCT03795480|BEHAVIORAL|MOOD|MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
223466957|NCT06379243|PROCEDURE|PVP/PKP|PVP or PKP surgery in patients with osteoporotic vertebral compression fractures
223466958|NCT05619666|PROCEDURE|Acute rehabilitation program|Patients included in the study started the rehabilitation program when they were hemodynamic stable, when it was determined that it was safe for patients. Until discharge from the hospital, a re-evaluation of neuromuscular and respiratory function was performed.
223466959|NCT00104052|BIOLOGICAL|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
223466960|NCT00104052|DRUG|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
223466961|NCT04065490|DEVICE|Valeda PBM treatment|The Valeda Light Delivery System
223466962|NCT04065490|DEVICE|Valeda Sham treatment|The sham mode of the Valeda Light Delivery System.
223466963|NCT03850717|DEVICE|acupuncture|insert in filiform needles into skin and other soft tissue to treat the illness or disorders
223577863|NCT03880838|BEHAVIORAL|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
223577864|NCT03880838|BEHAVIORAL|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
223466964|NCT04135547|DEVICE|intra-osseous access vs. intra-venous access|EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
223466965|NCT03186313|DRUG|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
223466966|NCT03186313|DRUG|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg \& Ribavirin 800 mg for 12 weeks.
223466967|NCT03186313|DRUG|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
223466968|NCT03186313|DRUG|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg \& Daclatasvir 60 mg for 12 weeks
223466969|NCT00785083|DRUG|FTY720|
223466970|NCT00785083|DRUG|Placebo|
223466971|NCT01932489|PROCEDURE|Biopsy of a metastatic lesion.|
223466972|NCT04854239|PROCEDURE|Half-guided implant placement|The surgery was performed under local anaesthesia in both groups, half-guided implant placement was carried out based on randomization.
223466973|NCT02750631|OTHER|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
223466974|NCT04789304|DRUG|BI 1595043|BI 1595043
223466975|NCT04789304|DRUG|Placebo|Placebo
223466976|NCT04789304|DRUG|Midazolam|Midazolam
223577865|NCT03880838|BEHAVIORAL|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
223577866|NCT03880838|BEHAVIORAL|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
223577867|NCT01875042|DEVICE|TENS|Transcutaneous electrical nerve stimulation
223577868|NCT01875042|DEVICE|Sham TENS|Sham Transcutaneous electrical nerve stimulation
223577869|NCT01565395|DRUG|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
223577870|NCT01565395|DRUG|placebo|Sterile preservative free 0.9% saline
223577871|NCT04595877|DRUG|Dipyrone administration|Dipyrone 2 g (Nolotil®, Europharma, Madrid, Spain); one ampoule in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
223466977|NCT04995913|OTHER|Online cognitive behavioral therapy|The intervention includes 9 online modules, 3 face-to-face/online/telephone counseling sessions, and 2 sessions of virtual reality exposure therapy. Participants will learn and practice a variety of the cognitive behavioral skills to cope with their social anxiety. The functions of the EASE Online Program include animation briefing and debriefing, case demonstration videos, assignment and feedback, forum, internal messaging, reminder, online assessment, online booking and progress checking. The duration of the intervention is 14 weeks.
223466978|NCT03913234|DRUG|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
223577872|NCT04595877|BEHAVIORAL|Pain assessment|"Pain will be evaluated by the patient according to a 100-mm visual analogue scale (VAS) (from point 0 no pain to point 10 unbearable pain)."
223577873|NCT04595877|BIOLOGICAL|beta-endorphin immunoreactivity|Plasma beta-EPIr levels will be measured by an immunoradiometric assay (Allegro Beta-endorphin, Nichols Institute Diagnostics, SAN JUAN DE CAPISTRANO, CA) (normal values 29-40 pg/mL). It will be obtained by venous blood samples (5 mL) at the same time points at pain will be measured.
223466979|NCT03159585|DRUG|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
223466980|NCT00927875|DRUG|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
223466981|NCT00927875|DRUG|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
223466982|NCT00927875|DRUG|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, \& 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
223466983|NCT01241279|DEVICE|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
223577874|NCT04595877|OTHER|Placebo administration|Placebo in 50 mL of 0.9% saline solution as an intravenous infusion over 10 min.
223466984|NCT01241279|DEVICE|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
223466985|NCT04864743|DRUG|ADVATE|a single dose.
223466986|NCT04864743|DRUG|FRSW117|a single dose.
223466987|NCT04353726|OTHER|Weight management|During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
223466988|NCT00239720|DRUG|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
223466989|NCT00239720|DRUG|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
223577875|NCT05399004|OTHER|Survey Administration|Complete surveys
223577876|NCT00434356|DRUG|bevacizumab|Intravenous repeating dose
223577877|NCT00434356|DRUG|sunitinib|Oral repeating dose
224158522|NCT00564200|DRUG|dexamethasone|"PREACONDICIONAMIENTO:~\- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
223466990|NCT03599570|BEHAVIORAL|STOP-HPV performance feedback intervention|This intervention will be the addition of performance feedback (in the presence of communication skills).
223466991|NCT01503554|BEHAVIORAL|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
223577878|NCT00434356|DRUG|paclitaxel|Intravenous repeating dose
223577879|NCT05013424|DRUG|Formulation A: OnabotulinumtoxinA|Intramuscular Injection
223577880|NCT05013424|DRUG|Formulation B: OnabotulinumtoxinA|Intramuscular Injection
223577881|NCT05013424|DRUG|Formulation C: OnabotulinumtoxinA|Intramuscular Injection
223577882|NCT00892359|DRUG|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
223577883|NCT06166329|OTHER|chair lift test|repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute
224158523|NCT00564200|DRUG|Fludarabine|"ACONDICIONAMIENTO:~\- Days -9 al -5: Fludarabine"
224158524|NCT00564200|DRUG|Melphalan|"ACONDICIONAMIENTO:~\- Days -4 and -3: Melphalan."
224158525|NCT05743517|BEHAVIORAL|Fit4Treatment|This study will test the core intervention of an activity tracker and commercially available app (Fitbit) in addition to four components which are expected to improve physical activity. The intervention will be delivered over 12 weeks with a 12 week follow up period.
224158526|NCT02977442|BEHAVIORAL|exercise|
224158527|NCT03798678|DRUG|Carfilzomib|Given IV
224158528|NCT03798678|DRUG|Dexamethasone|Given PO
224158529|NCT03798678|DRUG|Telaglenastat Hydrochloride|Given PO
223577884|NCT03617055|DIAGNOSTIC_TEST|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
223577885|NCT00245648|DRUG|fibrinolytic therapy or combination reduced fibrinolytic therapy|
223577886|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223577887|NCT03899064|DRUG|Induction: Application of MC2-01 Cream, no irradiation|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223577888|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223577889|NCT03899064|DRUG|Induction: Applications of MC2-01 vehicle, no irradiation|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
223577890|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
224158530|NCT06185868|OTHER|No intervention measures|No intervention measures
224158531|NCT03648606|OTHER|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
224158532|NCT00524043|DRUG|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
223466992|NCT01503554|BEHAVIORAL|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
223577891|NCT03899064|DRUG|Challenge: Application of MC2-01 Cream, no irradiation|Single application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
223577892|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, irradiation|Single application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
224158533|NCT00524043|DRUG|Placebo|Once daily for 6 weeks
224158534|NCT00524043|DRUG|Paliperidone ER|6 mg tablet once daily for 6 weeks
224158535|NCT01480232|DRUG|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
224158536|NCT01480232|DRUG|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
224158537|NCT01480232|DRUG|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
224158538|NCT01480232|DRUG|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
224158539|NCT01480232|BEHAVIORAL|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
224158540|NCT01512472|DRUG|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
224158541|NCT00391248|DRUG|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
224158542|NCT01843205|DRUG|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
223466993|NCT02519725|OTHER|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
223466994|NCT04514900|BEHAVIORAL|Video Chat +Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
223466995|NCT04514900|BEHAVIORAL|Video Chat + Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
223466996|NCT04514900|BEHAVIORAL|Discussion Board for Social Support +Basic Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
224158543|NCT01843205|DRUG|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
224158544|NCT04876963|DEVICE|Holter-monitor|7-day holtermonitoring of each patient
223466997|NCT04514900|BEHAVIORAL|Discussion Board for Social Support+Personalized Feedback|Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
223466998|NCT03570216|OTHER|Cardiopulmonary exercise test|Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
223466999|NCT03570216|OTHER|Moderate-intensity continuous exercise|Participants will perform a 30-minute session of moderate-intensity continuous exercise.
223467000|NCT03570216|OTHER|High-intensity interval exercise|1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
223467001|NCT05573152|PROCEDURE|Control|All previously selected patients will be under passive warming by means of blankets
223467002|NCT05573152|PROCEDURE|Nursing|All previously selected patients will be under active air flow warming device at 43 Celsius
223467003|NCT01270035|DRUG|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
223467004|NCT01145482|DRUG|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
223467005|NCT01145482|OTHER|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
223467006|NCT00464022|DEVICE|Carbon dioxide|
223467007|NCT03496389|DRUG|Gabapentin|Gabapentin 300mg daily
223467008|NCT03496389|DRUG|Tramadol|Tramadol 50mg QID
223467009|NCT03496389|DRUG|Panadol|Panadol 500mg QID
223467010|NCT01078038|DEVICE|Cypher|Sirolimus-eluting stent implantation
223467011|NCT01078038|DEVICE|Xience V|Everolimus-eluting Stent implantation
223467012|NCT05859217|DRUG|Cabozantinib|Oral once per day, Days 1 - 21 every 21 days
223467013|NCT05859217|DRUG|Atezolizumab|Intravenous (IV) once every 21 days
223467014|NCT04773223|PROCEDURE|Open surgery and complex EVAR due to AAA|"There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)"
223467015|NCT01405560|DRUG|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
223467016|NCT01405560|BIOLOGICAL|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
224158545|NCT00836303|BEHAVIORAL|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
224158546|NCT00606177|DRUG|Aripiprazole|oral, 24mg(4 tablets)/day
224158547|NCT00606177|DRUG|placebo|oral, 0mg(4tablets)/day
224158548|NCT05722977|DRUG|Surufatinib + envafolimab|Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
224158549|NCT06396988|OTHER|Novamin application|Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
224158550|NCT06396988|OTHER|Parodontax application|Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
224158551|NCT05872698|DRUG|Carvedilol|Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable. For high blood pressure, it is generally a second-line treatment. It is taken by mouth.
223467017|NCT01405560|DRUG|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
223467018|NCT02190188|DEVICE|Wedge Insole 5mm|
223467019|NCT02190188|DEVICE|Knee Brace|
223467020|NCT04339049|DRUG|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
223467021|NCT04339049|DRUG|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
223467022|NCT04339049|DRUG|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
223467023|NCT04887363|BEHAVIORAL|Core exercise|Participants will receive12-week, 60 minutes, 36-session exercise-based core stability training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
223467024|NCT04887363|BEHAVIORAL|Tai Chi exercise|Participants will receive 12-week, 60 minutes, 36-session Tai Chi exercise training class. Participants need complete baseline assessments of muscle performance, and balance ability measures 1 week prior and 1 week and 12 weeks following the intervention. All subjects will receive two post-exercise measurements at 13th week and 25th week.
223467025|NCT03259958|DRUG|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
223467026|NCT03259958|DRUG|Aricept|Aricept Tablet
223467027|NCT03556033|DRUG|Dapagliflozin|8 weeks treatment with dapagliflozin on top of insulin treatment
223467028|NCT03556033|DRUG|Placebo oral capsule|8 weeks treatment with placebo capsules on top of insulin treatment
223467029|NCT06472947|DEVICE|ULM and MSOT|transplanted kidney will be examined non-invasively with ULM and MSOT
223467030|NCT01944657|DEVICE|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
223467031|NCT01944657|DRUG|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
223467032|NCT03658291|DRUG|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
223467033|NCT03658291|DRUG|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
223467034|NCT03658291|DRUG|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
223467035|NCT02067858|RADIATION|Stereotactic Radiosurgery|
223467036|NCT00512525|DRUG|Ghrelin and saline (as placebo)|Intravenous infusion
223467037|NCT01699750|DEVICE|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
223467038|NCT01699750|DEVICE|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
224158552|NCT05872698|DRUG|Placebo|Placebo
224158553|NCT03571113|OTHER|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
224158554|NCT00136357|BEHAVIORAL|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
224158555|NCT04878289|BEHAVIORAL|TOTAL with Motivational Telemedicine Sessions|Teaching Obesity Treatment Options to Adult Learners Educational Video with 3, 30 minute motivational sessions at 1 week, 6 months, and 12 months after viewing video
224158556|NCT03405974|DRUG|Aspirin|Aspirin (acetylsalicylic acid)
224158557|NCT03405974|DRUG|Placebo|Placebo
224158558|NCT00763178|DRUG|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
224158559|NCT01799161|BIOLOGICAL|gp96-Ig Vaccine|
224158560|NCT01799161|DRUG|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
224158561|NCT01799161|OTHER|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
223467039|NCT01699750|DEVICE|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
223467040|NCT01699750|DEVICE|BIOTRUE®|Contact lens care system, Phase 2
224158562|NCT01799161|PROCEDURE|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response \[frequency of CD4+, FoxP3 (Treg), et al\] in treated patients.
224158563|NCT00675688|DRUG|Bazedoxifene/Conjugate Estrogens (CE)|
224158564|NCT00675688|DRUG|Raloxifene|
223467041|NCT01699750|DEVICE|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
223467042|NCT01699750|DEVICE|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
223467043|NCT00664586|DRUG|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
223467044|NCT02518334|OTHER|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
223467045|NCT01484951|DRUG|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
223467046|NCT05251584|DRUG|Mupirocin|Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021
223467047|NCT05251584|DRUG|Gentamicin|Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
223467048|NCT03622762|DRUG|green tea extract|Capsules of green tea extract, 400 mg twice a day, fasting
223467049|NCT03622762|DRUG|Placebo|Placebo capsules, 400 mg twice daily fasting
223467050|NCT02043977|DRUG|propofol injectable emulsion|
224158565|NCT00675688|DRUG|Placebo|
224158566|NCT00415753|BEHAVIORAL|No antibiotics if se-procalcitonin is below stated limit|
224158567|NCT02124928|PROCEDURE|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
223467051|NCT02119299|DEVICE|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
223467052|NCT01284868|DRUG|mirabegron|oral
223467053|NCT01284868|DRUG|Bisoprolol|oral
223467054|NCT01284868|DRUG|propranolol|oral
223467055|NCT01284868|DRUG|placebo|oral
223467056|NCT04533178|DEVICE|soft spinal brace|Use of a soft spinal brace 16 hours per day during the 6 week treatment period.
223467057|NCT04533178|OTHER|Resting from all sports activities|Resting from all sports activities
223467058|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food with heat stabilized rice bran|Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
223467059|NCT05319717|DIETARY_SUPPLEMENT|Ready-to-use therapeutic food (no rice bran)|Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).
223467060|NCT03915834|DEVICE|Endovascular treatment|Mechanical thrombectomy and/or Aspiration
223467061|NCT02600117|DRUG|Tenofovir disoproxil fumarate|300 mg, oral, once a day
223467062|NCT01607164|BEHAVIORAL|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
224158568|NCT04545411|DRUG|Dapagliflozin 10 MG [Farxiga]|4-Week, double-blind, once daily oral 10mg dapagliflozin
224158569|NCT04545411|DRUG|REMD-477|4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
224158570|NCT04545411|DRUG|Placebo|4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
224158571|NCT04884997|DRUG|toripalimab|toripalimab 3mg/kg, Q2w;
224158572|NCT04884997|DRUG|Temozolomide Injection|Temozolomide 150mg/m2,d1-5,Q4w
224158573|NCT01735097|DIETARY_SUPPLEMENT|Vitamin E|Vitamin E (200 mg, soft capsule)
224158574|NCT01735097|DIETARY_SUPPLEMENT|Nigella sativa|Nigella sativa (200 mg, soft capsule)
223467063|NCT02856958|PROCEDURE|Nerve decompression|
223467064|NCT02856958|OTHER|Non-operative|Physical therapy
223467065|NCT01988207|BEHAVIORAL|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
223467066|NCT01988207|BEHAVIORAL|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
223467067|NCT02452047|DRUG|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
223467068|NCT02452047|DRUG|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (\~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (\~180 to 360 mg CMS), depending on renal function, once every 12 hours
223467069|NCT02452047|DRUG|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
223467070|NCT02452047|DRUG|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
223467071|NCT02004223|RADIATION|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
223467072|NCT02948712|BEHAVIORAL|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
223467073|NCT02948712|BEHAVIORAL|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
223467074|NCT03041662|DIAGNOSTIC_TEST|MR/MRCP|MR/MRCP
223467075|NCT05271565|DIETARY_SUPPLEMENT|Oligomeric enteral feeding|Oligomeric enteral formula
223467076|NCT05271565|DIETARY_SUPPLEMENT|Polymeric enteral feeding|Polymeric enteral feeding will be administered to the PICU patients
223577893|NCT03899064|DRUG|Challenge: Applications of MC2-01 vehicle, no irradiation|Single application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
224158575|NCT01735097|DIETARY_SUPPLEMENT|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
224158576|NCT00003761|BIOLOGICAL|rV-DF3/MUC1|"\- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~\-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~* Level 1 4.76 x 106 PFU~* Level 2 4.76 x 107 PFU~* Level 3 4.76 x 108 PFU"
223467077|NCT06120725|DRUG|Ticagrelor 90 MG|Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
223467078|NCT06120725|DRUG|Clopidogrel|Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
223467079|NCT04751617|PROCEDURE|Pulmonary rehabilitation|Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.
223467080|NCT00000732|DRUG|Sulfamethoxazole-Trimethoprim|
223467081|NCT00000732|DRUG|Zidovudine|
223467082|NCT02092454|DRUG|Benzocaine|topical otic solution
223467083|NCT02092454|DRUG|Placebo|topical otic solution
223467084|NCT06309823|DRUG|MAS825|MAS825 is a bi-specific IgG1 monoclonal antibody that simultaneously targets IL-1beta and IL-18, thereby neutralizing both cytokines that are thought to be integral to the pathogenesis of XLP-2.
223467085|NCT03976908|DEVICE|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
223467086|NCT01249417|BIOLOGICAL|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
223467087|NCT01249417|DRUG|Placebo|I.M. injection on day 1 of a single treatment cycle.
223467088|NCT03021811|DEVICE|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
223467089|NCT04797208|DEVICE|Real-Time CGM|Participants will be wearing a real-time continuous glucose sensor which will enable their glucose levels to be remotely monitored. High and Low glucose alerts will also be available.
223467090|NCT04797208|DEVICE|Capillary blood glucose testing with masked CGM|Participants will have their glucose monitored in hospital in the conventional manner using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted for data collection only.
223467091|NCT04052646|OTHER|Medical condition: Subarachnoid hemorrhage|We identify patients with the condition of interest and retrospectively collect data on them.
223467092|NCT02507492|DRUG|RM-493|
223467093|NCT02416232|DRUG|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
223467094|NCT02416232|DRUG|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
223467095|NCT00527280|PROCEDURE|Feasibility ot face transplantation|Feasibility ot face transplantation
223467096|NCT00917124|DEVICE|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
223467097|NCT05055726|DRUG|Benzydamine Hydrochloride 0.15% w/v oromucosal solution|Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.
223467098|NCT05634655|OTHER|no interventions between two groups|no interventions between two groups
223467099|NCT01768780|DEVICE|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
224158577|NCT05387135|DEVICE|Transcutaneous Vagus Nerve Stimulation|Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).
224158578|NCT05567224|OTHER|Access to primary care services|Those in the pilot group will be referred to primary care services and allowed to utilize them for at least two years. Primary care services include access to a primary care physician, medical management, and other tasks typically performed by a general practitioner. Those referred to primary care services will not have access to other VUMC outpatient services.
224158579|NCT04316286|PROCEDURE|Tele-multidisciplinary care|Scheduled televisit by sleep medicine specialists, endocrinologists, legal-medicine specialists
224158580|NCT04316286|OTHER|Standard care|Scheduled in-office visit by sleep medicine specialists, endocrinologists, legal-medicine specialists
223467100|NCT02412124|PROCEDURE|Supportive Care|Complete W2W mentoring program
223467101|NCT02412124|OTHER|Quality-of-Life Assessment|Complete the FACT-G
223467102|NCT02412124|OTHER|Questionnaire Administration|Complete the W2W Patient Survey
223467103|NCT03007303|DRUG|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
223467104|NCT03007303|OTHER|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
223467105|NCT00723827|DRUG|Temozolomide|Administration of temozolomide based on the product labeling.
223467106|NCT00723827|RADIATION|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
223467107|NCT03690713|DIAGNOSTIC_TEST|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × (\[1.35 × Pd/Pa\] - 0.32).
223467108|NCT05882500|OTHER|No intervention, observation|
223467109|NCT02168959|DRUG|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
223467110|NCT05558319|DRUG|Bortezomib|Bortezomib
223467111|NCT05558319|DRUG|Isatuximab|Isatuximab
223577894|NCT03899064|DRUG|Challenge: Control, irradiation|No application, but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema and edema
223467112|NCT05558319|DRUG|Iberdomide|Iberdomide
223467113|NCT05558319|DRUG|Lenalidomide|Lenalidomide
223467114|NCT05558319|DRUG|Dexamethasone|Dexamethasone
223467115|NCT02904746|BEHAVIORAL|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
223467116|NCT05380765|BEHAVIORAL|Native PATHS|A strengths-based, behavioral economic approach to increasing engagement and reinforcement for engaging in alternative activities.
224158581|NCT00289614|DRUG|Iopamidol 370 mgI/dL|
224158582|NCT01011595|PROCEDURE|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
223467117|NCT02938468|DRUG|Dexamethasone|
223467118|NCT02938468|PROCEDURE|Any surgical intervention aim at treating chronic subdural hematoma|
223467119|NCT00126594|DRUG|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
223467120|NCT00126594|BIOLOGICAL|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10\^6 international units twice daily
224158583|NCT01011595|PROCEDURE|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
224158584|NCT01011595|PROCEDURE|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
224158585|NCT01085773|BEHAVIORAL|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
224158586|NCT01085773|BEHAVIORAL|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
223467121|NCT00126594|OTHER|Laboratory Biomarker Analysis|Correlative studies
224158587|NCT00440141|DRUG|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
224158588|NCT00440141|DRUG|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
224158589|NCT02524535|OTHER|Therapeutic alliance|
223467122|NCT01703494|BIOLOGICAL|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
223467123|NCT01703494|BIOLOGICAL|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
223467124|NCT02306889|DRUG|Fenofibrate|130mg Capsules
223467125|NCT02306889|DRUG|ANTARA® (fenofibrate)|130mg Capsules
223577895|NCT04459975|OTHER|Non interventional study|"Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis"
223577896|NCT00469326|DRUG|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
224158590|NCT00296166|PROCEDURE|Catheter ablation|
224158591|NCT00296166|PROCEDURE|Thoracoscopic epicardial ablation|
223467126|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
223467127|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
223467128|NCT01122498|BIOLOGICAL|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
223467129|NCT04207905|OTHER|Healthy Michigan Plan (HMP) coverage with work requirements|For those who are not in the Exempt for Research Purposes group, to be eligible for HMP coverage beginning January 1, 2020, enrollees ages 19-62 must report 80 hours per calendar month of community engagement activities, such as employment, education, job training, job search activities, participation in substance use disorder (SUD) treatment, or community service.
223467130|NCT01041222|DRUG|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
223467131|NCT03769649|DEVICE|CelluTite|CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
223467132|NCT01421498|DRUG|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
223467133|NCT01421498|DRUG|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
223467134|NCT01622556|DRUG|Fludarabine|35 mg/m2 IV/day x 5 days
223467135|NCT01622556|DRUG|Busulfan|.8 mg/kg IV Q6h x 8 doses
223467136|NCT01622556|DRUG|Thymoglobulin|1.5 mg/kg/day x 3 days
223467137|NCT01622556|RADIATION|Total Body Irradiation|150 cGy for 2 days
223467138|NCT01622556|BIOLOGICAL|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
223467139|NCT05793021|DIAGNOSTIC_TEST|Blood sample|Blood sample pre and post surgery to determine the level of FKBP51s protein
223467140|NCT01290718|DRUG|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
223467141|NCT01290718|DRUG|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
223467142|NCT00473655|DRUG|rosuvastatin|10mg or 20mg
224158592|NCT05505149|OTHER|physiotherapy|Children were individually included in the physiotherapy and rehabilitation program for 2 years, with 45 minutes each session, two days a week. All children's treatment program included targeted, personalized functional exercises according to neurodevelopmental treatment principles, and they were applied by the physiotherapists of the children in the rehabilitation centers.
224158593|NCT01492738|PROCEDURE|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
223467143|NCT00371735|DRUG|chlorproguanil-dapsone-artesunate|
223467144|NCT00371735|DRUG|chlorproguanil-dapsone|
223467145|NCT04035616|DIETARY_SUPPLEMENT|microbial cell preparation [MCP]|active microbial cell preparation
223467146|NCT04035616|OTHER|placebo|inactive ingredient
223467147|NCT02617615|DRUG|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
223467148|NCT02617615|DRUG|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
223467149|NCT01635660|DEVICE|Intubation|Tracheal Intubation with the assigned video laryngoscope
224158594|NCT06213415|DRUG|Corticosteroid|Oral steroids plus intratympanic injection
224158595|NCT04480749|DIAGNOSTIC_TEST|Access to Facility based Syphilis Testing|List of facilities where syphilis testing can be accessed
224158596|NCT04480749|DIAGNOSTIC_TEST|Syphilis Self-Test|Rapid Treponemal Test kit
224158597|NCT05468580|PROCEDURE|Endoscopic Coeliac Artery Release (eCAR)|Endoscopic Coeliac Artery Release (eCAR); The Median Arcuate Ligament will be cleaved via an endoscopic retroperitoneal approach using a 4 trocar technique described in detail by van Petersen (12). To rule out learning curves and procedural variation all the procedures will be performed by two experienced eCAR surgeons in the MST-Dutch Expert Centre of Gastrointestinal Ischemia. All procedures will be videotaped. Both eCAR surgeons will not be involved in the follow up procedures.
223467150|NCT04546633|DRUG|KAF156|Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
223467151|NCT04546633|DRUG|LUM-SDF|Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
223467152|NCT04546633|DRUG|Coartem|Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
223467153|NCT04536363|DRUG|Analogs, Prostaglandin E1|"Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days"
223467154|NCT04536363|DRUG|Standard therapeutic protocol|"Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours"
223467155|NCT05937880|DRUG|Leflunomide|When patients appeared with rashes and treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. The rashes do not subside or fresh rash still appears, and it frequently repeats more than 3 times during hospitalization. Leflunomide would be administered
223467156|NCT03467074|BIOLOGICAL|influenza A/B vaccine|Regardless of the study enrollment, a two-time influenza vaccination at the start of the flu season is recommended every 4 weeks for all patients after stem cell transplantation. The vaccine is a trivalent inactivated non-adjuvanted influenza virus vaccine containing two influenza A viruses: pandemic H1N1, and H3N2, and an influenza B virus
223467157|NCT00243919|BEHAVIORAL|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
223467158|NCT00243919|BEHAVIORAL|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
223467159|NCT00243919|BEHAVIORAL|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
223467160|NCT06515756|OTHER|Post operative pain assessment after root canal treatment|the sealer was administered to the root canal using the initial paper point and then uniformly distributed using a second paper point before removing any excess sealer with a third paper point. Once the sealer was applied, a single tapered gutta-percha cone was adjusted to fit the root canal. The coronal access cavities were restored with a composite resin material
223467161|NCT00000867|DRUG|Memantine|
223467162|NCT00247468|PROCEDURE|Strict Glucose Control|
223577897|NCT03987906|BEHAVIORAL|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
224158598|NCT05468580|PROCEDURE|Sham Operation|The sham operation consists of making 4 incisions up to the fascia similar to endoscopic AC release (eCAR). After 60 to 75 minutes of general anesthesia, in accordance with the average operating time of eCAR, the sham operation is ended. This study design allows for patient and observer blinding and for the sham group the eCAR approach is still feasible if the CARoSO outcome support this without applying additional scar tissue.
224158599|NCT03642275|BEHAVIORAL|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
224158600|NCT03820206|DRUG|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
223467163|NCT02048800|DRUG|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)
223467164|NCT01268267|DEVICE|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
223467165|NCT00125918|DRUG|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
223467166|NCT00125918|DRUG|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
223467167|NCT00125918|DRUG|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
223467168|NCT00125918|DRUG|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
223467169|NCT00125918|DRUG|placebo|placebo tablet taken by mouth once a day for 16 weeks
223467170|NCT03846401|DEVICE|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate \& BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~1. Direct smear by Gram stain and ZeihlNelseen stain~2. Samples culturedinBact/alert bottle(BioMérieux, France).~3. Isolation of causative organism from positive cases by:~   Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.~4. Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~5. Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
223467171|NCT02528474|DEVICE|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
223577898|NCT01614171|BIOLOGICAL|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
223577899|NCT06491810|OTHER|Arm crank exercise|The arm ergometer exercise will be the only intervention implemented during the study.
224158601|NCT03820206|PROCEDURE|Cesarean section|Lower segement transverse cesarean section
224158602|NCT03520894|RADIATION|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
224158603|NCT00216086|DRUG|Capecitabine|"Capecitabine 1000\* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~\*For calculated creatinine clearance of 30-50 mL/min or patients \> 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
224158604|NCT00216086|DRUG|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
223577900|NCT04397458|DRUG|Saline|0.9% saline on each side
223577901|NCT04397458|DRUG|Bupivacaine|0.25% bupivacaine (50mg) on each side
223577902|NCT04397458|DRUG|Dexamethasone|3mg preservative-free dexamethasone on each side
224158605|NCT00216086|PROCEDURE|EUS|biopsy per EUS
224158606|NCT00216086|DRUG|Neoadjuvant Chemotherapy|"* Irinotecan 200 mg/m2 IV, day 1~* Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
224158607|NCT00216086|PROCEDURE|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
223467172|NCT02528474|DEVICE|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
223467173|NCT04541563|DEVICE|Fisher Wallace Cranial Electrotherapy Stimulator Device|Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
223467174|NCT00703300|DRUG|bortezomib|Given IV
223467175|NCT00703300|DRUG|decitabine|Given IV
223467176|NCT00703300|OTHER|pharmacological study|Correlative studies
223467177|NCT00703300|OTHER|laboratory biomarker analysis|Optional correlative studies
223467178|NCT04176939|BIOLOGICAL|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) revaccination doses of the HZ/su vaccine administered - first dose at Month 24 and second dose at Month 25.
223467179|NCT03250689|DRUG|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
223467180|NCT03250689|DRUG|Placebo|Placebo will be available as oval shaped, white film coated tablets.
223467181|NCT03250689|DRUG|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
224158608|NCT00216086|PROCEDURE|Surgery|Surgery within 8 weeks following chemoradiotherapy
224158609|NCT00216086|PROCEDURE|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
224158610|NCT03846622|OTHER|Calculation of scoring systems for bleeding|
224158611|NCT00269685|DRUG|vasopressin|
224158612|NCT01446991|DRUG|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
223467182|NCT03250689|DRUG|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
223467183|NCT03847740|DEVICE|Isometric Trumb Force handle|Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
223467184|NCT04361084|OTHER|traditional simulated training|traditional simulation using actors as standardised patients playing out scenarios plus pre and post questionnaires and semi structured interviews
223467185|NCT04361084|OTHER|mixed reality simulation|using immersive technologies to create a virtual reality simulated training scenario's plus pre an post questionnaires and semi structured interview's
223467186|NCT03871153|DEVICE|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
223467187|NCT03871153|DRUG|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
223467188|NCT03871153|DRUG|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
223467189|NCT03871153|RADIATION|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
224158613|NCT01446991|DRUG|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
223467190|NCT03871153|PROCEDURE|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
223467191|NCT02318849|BEHAVIORAL|Web intervention|interactive website using social media and gamification
223467192|NCT02228005|DRUG|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
223467193|NCT03175081|DRUG|Ropivacaine|Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
223467194|NCT03175081|DRUG|Normal saline|Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
223577903|NCT03075995|OTHER|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
223577904|NCT03150628|DRUG|Perioperative chemotherapy|Perioperative chemotherapy
224158614|NCT05210413|DRUG|Spartalizumab in Pediatric cohort|Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
224158615|NCT05210413|DRUG|Low-dose Pazopanib in Pediatric Cohort|Oral pazopanib treatment at a fixed dose of 225mg/m²/day
224158616|NCT05210413|DRUG|Spartalizumab in Adult cohort|Infusion of 400 mg of spartalizumab on Day1 of each cycle.
224158617|NCT05210413|DRUG|Low-dose Pazopanib in Adult Cohort|Oral pazopanib treatment with a fixed dose of 400 mg/day
223577905|NCT03150628|PROCEDURE|Cytoreduction|Cytoreductive surgery
223577906|NCT03150628|DRUG|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
223577907|NCT02442258|DRUG|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
224158618|NCT02025530|OTHER|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
224158619|NCT00728728|DRUG|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
224158620|NCT00728728|DIETARY_SUPPLEMENT|Placebo|Placebo
224158621|NCT06633198|PROCEDURE|Passive Heating|The lower limbs will be immersed in warm (42C) circulating water for 60 minutes.
224158622|NCT06633198|DRUG|L-NAME|L-NAME will be used during measurement of cutaneous microvascular function to test the dependency upon NO to elicit vasodilation.
224158623|NCT05250518|PROCEDURE|argon plasma coagulation|After hot snare polypectomy, participants will be randomized assigned to the APC group for argon plasma coagulation to prevent colorectal post-procedure bleeding.
223467195|NCT06389981|OTHER|Veterans peer connect Program|To assess outcomes of the Peer-led program, the study team will collect information from Veteran pilot test participants via surveys and data abstraction on healthcare utilization (Lung cancer screening completion, tobacco treatment) from the Veterans Affairs Corporate Data Warehouse. Survey data will be collected at 3 timepoints: baseline, post-Peer-led orientation, and 3-months post-enrollment. Healthcare utilization data will be abstracted from the corporate data warehouse to reflect the 3-month post-enrollment timepoint. Finally, interviews will be conducted with a subset of participants.
223467196|NCT03184311|OTHER|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
223467197|NCT03184311|OTHER|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
223467198|NCT02979782|PROCEDURE|Endo-CABG|minimal invasive cardiac intervention
224158624|NCT05250518|PROCEDURE|clip closure|After hot snare polypectomy, participants will be randomized assigned to the Clip group for complete closure(spacing between adjacent clips \< 1cm) to prevent colorectal post-procedure bleeding.
223467199|NCT02979782|PROCEDURE|PCI|stenting procedure
223467200|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with 3D Printed Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the 3D printed endoscopy training model. Participants will receive hands-on training on the 3D printed endoscopy training model, under the guidance of the principal investigator."
223467201|NCT05732376|BEHAVIORAL|Nasopharyngoscopic Velopharyngeal Training with Ready-Made Endoscopy Training Model|"Theoretical training: The theoretical training covers the anatomy and physiology of the velopharyngeal region and nasal cavity, nasopharyngoscope, preparation of the patient for nasopharyngoscopy, use of the endoscope during nasopharyngoscopy and the procedure for nasopharyngoscopic velopharyngeal function assessment.~Practical training: At the beginning of the hands-on training, the device will be introduced to the participants. Basic information will be given about endoscopy device. Then, the principal investigator will give information about the use of the endoscope (patient instructions, holding the endoscope, placement of the endoscope in the nose, manipulation of the endoscope, anatomical structures in the nasal cavity and velopharyngeal region, velopharyngeal function assessment) on the ready-made endoscopy training model. Participants will receive hands-on training on the ready-made endoscopy training model, under the guidance of the principal investigator."
223467202|NCT04851106|DIAGNOSTIC_TEST|Endoscopic ultrasound|Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.
223467203|NCT00370500|DRUG|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
223467204|NCT00388791|DRUG|Systane Free|
223467205|NCT03444844|DRUG|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
223577908|NCT02442258|DRUG|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
223577909|NCT04306939|OTHER|venipuncture|Research blood collection is also an option via venipuncture if the subject is not scheduled for clinical testing. This will also be limited to 21cc of blood, up to 4 time a year, and with the approval of the attending physician.
223577910|NCT04306939|BEHAVIORAL|Questionnaires|PROMIS-43 Profile, PROMIS-29 Profile, Global Health Scale and Hospital Anxiety and Depression Scale (HADS). Additional assessments can be approved and administered per specific disease sub-category.
223577911|NCT04306939|OTHER|Additional Sample Collections|We may also contact subjects to request additional blood, saliva, cheek swab, hair, urine, or stool with their permission. This will be limited to no more than 4 teaspoons of blood and will happen no more than 4 times per year.
223577912|NCT05693792|OTHER|Observational|No treatment regimen will be deployed in this follow-up study.
223577913|NCT02847559|BIOLOGICAL|Bevacizumab|Given IV
224158625|NCT01017549|RADIATION|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
224158626|NCT02649829|BIOLOGICAL|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~1. four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~2. four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
224158627|NCT02940028|BEHAVIORAL|Expressive writing|Brief expressive writing intervention
224158628|NCT02940028|BEHAVIORAL|Control writing|Brief fact-based writing exercise.
224158629|NCT05685186|DIAGNOSTIC_TEST|Spirometry|To assess lung function
223577914|NCT02847559|PROCEDURE|Electric Field Therapy|Undergo electric field therapy using Optune device
223577915|NCT02847559|DEVICE|NovoTTF-200A Device|Undergo electric field therapy using Optune device
223577916|NCT02847559|PROCEDURE|Quality-of-Life Assessment|Ancillary studies
223577917|NCT06581133|DEVICE|Alarm system|Generic alarm system programmed to sound during the night to try to induce arousals from sleep.
223577918|NCT05467371|BEHAVIORAL|Parenting Action Plan|The parenting action plan a booklet with information that focuses on sleep hygiene, soothing a crying baby, what to do when the baby's crying is overwhelming, identifying safe caregivers in case of emergency, and issues surrounding feeding and bonding with the baby.
223577919|NCT05467371|BEHAVIORAL|Safe Kids Home Safety Checklist|Safe Kids created a home safety checklist to help keep kids safe, room by room.
223467206|NCT04919317|DRUG|Dexamethasone 4mg|The experimental group received 4mg dexamethasone added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
223467207|NCT04919317|DRUG|Saline|The control group received 1mL of 0.9% saline added to their bupivacaine block preoperatively just prior to bilateral reduction mammaplasty.
223467208|NCT01975558|BIOLOGICAL|Sampling at baseline, one week after baseline, two weeks after baseline|
223467209|NCT01975558|BIOLOGICAL|Sampling at baseline, during radiotherapy and after|
223467210|NCT00299065|DRUG|Zileuton injection|
223467211|NCT02869789|DRUG|Nivolumab in combination with Ipilimumab|Specified dose on specified days
223467212|NCT02389959|DRUG|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
223467213|NCT02389959|DRUG|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
223467214|NCT06059469|DIAGNOSTIC_TEST|Ga-PSMA PET/CT|Patient undergo Ga-PSMA PET/CT prior to the start of the new drug treatment
223467215|NCT05259488|DIETARY_SUPPLEMENT|immunonutrition|nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
223467216|NCT03710330|DRUG|normal saline|110 ml normal saline IV just before skin incision
224068332|NCT05898035|PROCEDURE|Endodontic Microsurgery|Osteotomy will be done either with air motor high speed hand-piece and round bur with copious irrigation or with Piezosurgery touch. After the soft tissue curettage and uncovering the root apex , the last 3 mm of the root apex will be resected perpendicular to the long axis of the tooth at ( 0 - 10) degree bevel , using either conventional dental hand-piece or piezotome (Piezotome Cube by ACTEON ).The resected root will be rinsed , dried and and stained with 1% methylene blue dye after which , it will be inspected carefully under high magnification, to identify possible reasons for the non surgical root canal treatment failure. Subsequently, ultrasonic apical preparation will be performed. After achieving adequate haemostasis with Epinephrine pellets. Biodentine®retrograde filling material will be placed. The flap will be re-approximated and interrupted suture using non-absorbable monofilament size 5-0 suture will be applied. Finally, Post-operative parallel Digital view.
223467217|NCT03710330|DRUG|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
223467218|NCT03710330|DRUG|0.5 gm tranexamic acid|0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
223467219|NCT06087770|DRUG|SM3321|Intravenous infusion, once a week, 28 days for a dosing cycle
223467220|NCT01243060|DRUG|Almorexant|100mg
223467221|NCT01243060|DRUG|Almorexant|200mg
223467222|NCT01243060|DRUG|Zolpidem 10mg|10mg
223467223|NCT01243060|DRUG|Placebo|One-time dose of Placebo
223467224|NCT04060953|OTHER|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
223467225|NCT02634073|DRUG|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
223467226|NCT02634073|DRUG|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
223467227|NCT00132535|DRUG|sulfadoxine-pyrimethamine intermittent preventive treatment|
223467228|NCT00132535|DRUG|chloroquine|
223467229|NCT02256696|DRUG|PA-824|200 mg QD
223467230|NCT02256696|DRUG|Rifampin|600 mg QD
223467231|NCT02256696|DRUG|Rifabutin|300 mg QD
223467232|NCT02256696|DRUG|Pyrazinamide|25mg/kg QD
223467233|NCT02256696|DRUG|Ethambutol|15mg/kg QD
223467234|NCT02256696|DRUG|Isoniazid|300 mg QD
223467235|NCT03043456|DEVICE|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
223467236|NCT03043456|DEVICE|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
223467237|NCT05797025|OTHER|To assess pressure pain threshold and pinch grip strengths.|To assess pressure pain threshold and pinch grip strengths.
223467238|NCT06561633|DRUG|Sugammadex administration|After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery.
223577920|NCT01912690|OTHER|aerobic training|
223577921|NCT01912690|OTHER|aerobic and strength training|
223577922|NCT05192213|DRUG|Vitamin C|Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
223577923|NCT05192213|OTHER|Placebo|Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
223467239|NCT02577640|DIETARY_SUPPLEMENT|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (\~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
223577924|NCT03814434|PROCEDURE|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
224158630|NCT05685186|DIAGNOSTIC_TEST|Multiple Breath Washout (MBW)|To measure Lung Clearance Index (LCI)
223467240|NCT05316558|BEHAVIORAL|Body Confident Coaching|The Body Confident Coaching program is a five-module online program aimed at upskilling coaches in identifying and tackling body image concerns among girls in sport. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
223467241|NCT05562063|DRUG|Sotagliflozin|Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.
223467242|NCT05562063|DRUG|Placebo|Matching placebo for 6 months.
223467243|NCT06290089|OTHER|Enterotoxigenic E. coli (ETEC) strain|Challenge strain
223467244|NCT04089046|BEHAVIORAL|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
223467245|NCT04089046|BEHAVIORAL|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
223467246|NCT05186129|DRUG|Clopid® 75 mg Tablet|Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
223467247|NCT05186129|DRUG|Plavix® 75mg Tablet|Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.
223467248|NCT05669118|PROCEDURE|Tooth Autotransplantation|Place another tooth in the place of the newly extracted tooth in the same patient.
223467249|NCT05669118|PROCEDURE|Immediate implant|Place a dental implant immediately after tooth extraction.
223467250|NCT02127658|OTHER|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
223467251|NCT02127658|OTHER|Sodium Hypochlorite|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
223467252|NCT02127658|DRUG|Mupirocin ointment|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite \[Clorox; The Clorox Company\] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupirocin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
223467253|NCT02558049|OTHER|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
223467254|NCT02824107|BIOLOGICAL|blood sample|
223467255|NCT02824107|BEHAVIORAL|questionnaires for psychosocial factors|
223467256|NCT06200935|DIETARY_SUPPLEMENT|Probiotic blend|Administration of one stick of combined probiotics per day for 5 months
223467257|NCT02585869|DRUG|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
223467258|NCT02585869|DRUG|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
223467259|NCT02585869|DRUG|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
223467260|NCT02585869|DRUG|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
223467261|NCT02585869|DRUG|Placebo|Blinded capsule and tablets, once daily, 84 days
223467262|NCT03738930|BEHAVIORAL|AI based mHealth system|AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
223467263|NCT06582875|DRUG|Tirzepatide|Titrated to dose of 5 mg once weekly subcutaneous
223467264|NCT06582875|OTHER|Placebo|Titrated to dose of 5 mg once weekly subcutaneous
223467265|NCT04261439|DRUG|NIZ985|NIZ985 injection
223467266|NCT04261439|DRUG|Spartalizumab|Spartalizumab infusion
223467267|NCT04261439|DRUG|Tislelizumab|Tislelizumab infusion
223467268|NCT01443858|DRUG|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
223467269|NCT01443858|DRUG|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
223467270|NCT01443858|DRUG|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
223467271|NCT05538871|DIAGNOSTIC_TEST|Survey + Physical exam|"Survey:~Demographic data Pain Oswestry disability index International Physical Activity Questionnaire Scoliosis Research Society (SRS-22r) Spinal appearance questionnaire Fear Avoidance and Beliefs Questionnaire Short Orebro musculoskeletal pain questionnaire Work Ability Index~Physical exam:~Repeated movements (MDT) Posture ROM Neuro Updated treatment based classification tests Pathoanatomical classification tests"
223467272|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
223577925|NCT03814434|PROCEDURE|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
223577926|NCT03925051|DRUG|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
223467273|NCT02987296|DIETARY_SUPPLEMENT|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
223467274|NCT00445471|BEHAVIORAL|Mifne Approach to PDD|
223577927|NCT03925051|DRUG|CMAB807|human monoclonal antibody targeting RANKL.
223577928|NCT03168360|PROCEDURE|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
223577929|NCT00536952|DRUG|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
223467275|NCT00445471|BEHAVIORAL|Treatment as usual|
223467276|NCT05670743|DRUG|38% silver diamine fluoride|Topical application of 38% silver diamine fluoride to dental caries lesions
223467277|NCT01867008|DEVICE|Nucleus CI422 Cochlear Implant with N6 Sound Processor|
223467278|NCT01711112|DRUG|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
223467279|NCT01534273|DRUG|LY2886721|Administered orally.
223467280|NCT01534273|DRUG|Placebo|Administered orally.
223577930|NCT00536952|DRUG|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
223577931|NCT00536952|RADIATION|Radiation Therapy|5 days per week for 4 weeks
223577932|NCT03330184|DRUG|Berberine Hydrochloride group|
223577933|NCT03330184|DRUG|Bifidobacterium group|
223577934|NCT03330184|DRUG|Berberine Hydrochloride and Bifidobacterium group|
223577935|NCT03330184|DRUG|placebo|
223467281|NCT00745303|PROCEDURE|Tai Chi Cuan|Tai Chi Cuan training for 3 months
223467282|NCT01417975|BEHAVIORAL|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
223577936|NCT04809259|DEVICE|Isothermal pouch|The study will verify it the use of an isothermal pouch to maintain the content of an elastomeric pump at 10° to 15°C avoids unacceptable meropenem degradation over the 24 hour infusion period.
223467283|NCT01417975|BEHAVIORAL|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
223467284|NCT05493293|DRUG|NBI-921352|Tablets for oral administration
223467285|NCT02435303|DRUG|Sildenafil|
223467286|NCT02435303|DRUG|Placebo|
223577937|NCT00411190|DRUG|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
223577938|NCT00411190|DRUG|Acetaminophen|Acetaminophen will be administered orally
223577939|NCT00411190|DRUG|Ibuprofen|Ibuprofen will be administered orally
223577940|NCT00411190|DRUG|Atorvastatin|Atorvastatin will be administered orally
223577941|NCT02623504|DRUG|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
223577942|NCT02623504|DRUG|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
223577943|NCT03710876|BIOLOGICAL|rAd-IFN|Adenovirus-Delivered Interferon Alpha-2b
223577944|NCT03710876|DRUG|Celecoxib Oral Product|400 mg twice daily
223577945|NCT03710876|DRUG|Gemcitabine|1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
223577946|NCT01107613|BEHAVIORAL|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader educational letter sent to the primary care provider outlining the needs of this patient.
223577947|NCT00480389|DRUG|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
223577948|NCT00885794|DRUG|Ranibizumab|3 intravitreal injection every 5 weeks
223577949|NCT02239146|DRUG|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
223577950|NCT02239146|DRUG|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
223467287|NCT03586050|DEVICE|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
223467288|NCT06028737|DRUG|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
223467289|NCT06028737|DRUG|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
223467290|NCT06028737|DRUG|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
223467291|NCT06028737|DRUG|Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
223467292|NCT04912492|BEHAVIORAL|RealConsent1.0|A web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors.
223467293|NCT04912492|BEHAVIORAL|RealConsent2.0|A revised and updated web-based multi-media sexual violence prevention program that enhances knowledge and skills for effective consent for sex and for prosocial bystander behaviors, but also integrates new program segments into RealConsent 1.0 specific to how alcohol use can inhibit SV intervention at multiple steps of the decision-making process.
223467294|NCT04912492|BEHAVIORAL|Stress Management|A web-based multimedia program designed to help individuals recognize the symptoms and sources of stress and provide them with a wide variety of powerful tools for managing stress.
223467295|NCT04912492|BEHAVIORAL|Alcohol intoxication|Men assigned to moderate alcohol dose condition (target BrAC .08%) with NIAAA approved alcohol administration procedures
223467296|NCT04912492|BEHAVIORAL|No-Alcohol Placebo|Men assigned to an no-alcohol placebo control condition.
223467297|NCT03665662|OTHER|Music|Intra-procedure music through headphones
223467298|NCT03713671|DIAGNOSTIC_TEST|gait analysis|Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
223467299|NCT01211145|DRUG|Placebo|Placebo nasal spray
223467300|NCT01211145|DRUG|Zolmitriptan|0.5 mg nasal spray
223467301|NCT01211145|DRUG|Zolmitriptan|2.5 mg nasal spray
223467302|NCT01211145|DRUG|Zolmitriptan|5.0 mg nasal spray
223577951|NCT00465140|DRUG|creatine supplementation|
223577952|NCT00465140|BEHAVIORAL|aerobic exercise training|
223577953|NCT00175409|PROCEDURE|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
223577954|NCT00175409|PROCEDURE|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
223577955|NCT05710133|OTHER|food|alectinib-d6 will be administered with breakfast on day 1 to determine the food-effect
223467303|NCT02390271|OTHER|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
223467304|NCT00570401|DRUG|dasatinib|
223577956|NCT05710133|OTHER|fast|alectinib-d6 will be administered after an overnight fast of minimal 10 hours on day 9 to determine the food-effect
223577957|NCT05991232|DRUG|Intravenous Ketamine|Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)
223577958|NCT06962163|DIAGNOSTIC_TEST|[68Ga]Ga-PentixaFor PET/CT|\[68Ga\]Ga-PentixaFor PET-CT is performed after patient inclusion. The patient is treated as per standard of care until disease progression. Then another \[68Ga\]Ga-PentixaFor PET-CT is performed.
223577959|NCT05055518|DRUG|APL-102 Capsules|"Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102."
223577960|NCT04949542|BEHAVIORAL|Bolster|Bolster is a native mobile app that provides on-demand content to caregivers of young adults with early psychosis to support their caregiving skills and knowledge of psychosis.
223577961|NCT04949542|BEHAVIORAL|Control|Exemplar resources provided in the control arm will include a selection from the National Alliance on Mental Illness and Mental Health America designed to support caregivers helping loved ones access care.
223577962|NCT02303782|DRUG|OTX015|
223577963|NCT02303782|DRUG|Vidaza (azacitidine)|
223577964|NCT01307202|DRUG|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
223577965|NCT01307202|DRUG|Placebo|Placebo will match the the gabapentin pill and will be given orally.
223577966|NCT03483870|DRUG|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
223577967|NCT03483870|DRUG|Placebo|2 mL of normal saline 0.9% IV injection
223577968|NCT03483870|DRUG|Granisetron|2 mL of 2 mg granisetron IV injection
223577969|NCT02209948|DRUG|Temozolomide|
224068333|NCT06796309|OTHER|Trak Telerehabilitation Platform|The exercise protocol designed is carried out through TRAK, the digital rehabilitation tool.
224068334|NCT06796309|OTHER|Conventional Rehabilitation Program|Exercise protocol with the methodology of conventional clinical practice.
224158631|NCT05685186|DIAGNOSTIC_TEST|Mucociliary Clearance (MCC)|To measure lung clearance after the inhalation of radiolabeled particles
223467305|NCT05619731|OTHER|Geriatric oncology tele-consultation and pharmaceutical tele-expertise|tele consultation
223467306|NCT00023868|DRUG|FOLFIRI regimen|
223467307|NCT00023868|DRUG|cisplatin|
223467308|NCT00023868|DRUG|doxorubicin hydrochloride|
223467309|NCT00023868|DRUG|fluorouracil|
223467310|NCT00023868|DRUG|irinotecan hydrochloride|
223467311|NCT00023868|DRUG|leucovorin calcium|
223467312|NCT00023868|DRUG|mitomycin C|
223467313|NCT03976752|DRUG|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat.~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic."
223467314|NCT03312816|OTHER|cookies enriched with POP|Cookies
223467315|NCT05936151|DRUG|Retatrutide|Administered SC
223467316|NCT05936151|DRUG|Placebo|Administered SC
223467317|NCT06448949|OTHER|Flow Diverter Implantation|Patients must undergo flow diverter implantation and have DSA examinations of the parent artery and TCCD examinations of Flow Diverter Implantation performed preoperatively, three days postoperatively, and six months postoperatively.
223467318|NCT04014231|PROCEDURE|Diagnostic Imaging|Undergo placement of single wave application
223467319|NCT04014231|OTHER|Laboratory Biomarker Analysis|Correlative studies
223467320|NCT06328738|DRUG|ELVN-002|capsule
223467321|NCT06328738|DRUG|Trastuzumab|intravenous
224158632|NCT05685186|DIAGNOSTIC_TEST|CT of the chest|Low radiation to assess structural lung disease
223467322|NCT06328738|DRUG|5-Fluorouracil|intravenous
223467323|NCT06328738|DRUG|Oxaliplatin|intravenous
223467324|NCT06328738|DRUG|Capecitabine|capsule
223467325|NCT06328738|DRUG|Eribulin|intravenous
223467326|NCT06328738|DRUG|paclitaxel|intravenous
223467327|NCT06328738|DRUG|Leucovorin|intravenous
223467328|NCT04938960|DIAGNOSTIC_TEST|blood draw|blood will be drawn at pre-operation, between 2 weeks and 3 months, between 3-11 months (optional; we will collect a sample if the patient returns to Mayo Clinic for any other non-study related visit), and between 12-18 months post-operatively.
223467329|NCT04741009|DEVICE|CI632 Slim Modiolar Electrode|Cochlear Ltd CI632 cochlear implant with Slim Modiolar Electrode
223467330|NCT06247696|OTHER|Herbal Pillows|Pillows containing herbs
223467331|NCT05944185|DRUG|αPD1-MSLN-CAR T Cells|αPD1-MSLN-CAR T Cells
223467332|NCT03488797|BEHAVIORAL|Supervised web- and home-based exercise intervention|"* The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~* Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~* The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)"
223467333|NCT00472745|BEHAVIORAL|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
223467334|NCT00472745|BEHAVIORAL|Weight Maintenance|Diet for weight maintenance for 6 months
223467335|NCT04535999|DRUG|Secukinumab Auto-Injector|300 mg- Every 4 weeks after loading dose (Loading Dose-300 mg once weekly for 5 weeks)
223467336|NCT01372631|DEVICE|miniature spectral imaging system|Use of miniature spectral imaging system
223467337|NCT01372631|DEVICE|Bench-top optical spectrometer|Use of bench-top optical spectrometer
223577970|NCT01335841|DEVICE|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
223467338|NCT01372631|DEVICE|High resolution microendoscope|Use of high resolution microendoscope
223577971|NCT00447473|DRUG|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
223577972|NCT00447473|DRUG|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
223577973|NCT00447473|DRUG|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
223577974|NCT04562597|DRUG|Dose Response Curve Placebo|5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
224158633|NCT05685186|DIAGNOSTIC_TEST|MRI of the chest|To assess lung function and structural lung disease
224158634|NCT06400992|DEVICE|Cochlear implant processor Sky CITM M90 (CI-5295)|"The Sky CI available to included patients (no procedures added) offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
224158635|NCT06400992|DEVICE|Hearing Aid, including sound processor Phonak: Sky Link M90|"The device is fitting and programmed for home especially for the purpose research at inclusion. The Clinical map parameters will be verified according to clinical routine.~The Sky Link offers the AutoSense Sky OS technology with the three following programming conditions possible. This three condition are fitting and evaluated in noise 6 months after inclusion:~1. Omnidirectional mode : no sound treatment~2. AS Target : Autosense is active and no modifications are made by clinician~3. AS Clinique : Autosense is active and modified by the clinician"
224158636|NCT06400992|DIAGNOSTIC_TEST|French simplified matrix test (FraSimat)|The FraSimat speech in noise test will be tested, 6 months before inclusion in the three different fitting configurations: omni, AS clinic, AS Target. The speech will be presented from the front, noise from 180°. Noise will be presented at a fixed level of 65 dB SPL while the speech signal will be adapted to find the 50% speech reception threshold (SRT).
224158637|NCT06400992|BEHAVIORAL|Audiologist Fitting Questionnaire|After the fitting of Hearing Aid at inclusion, the audiologist will complete a questionnaire describing the fitting and justifying fitting decisions and will collect the demographic information
224158638|NCT06400992|BEHAVIORAL|Patient Satisfaction Questionnaire|The patient will be giving a Patient satisfaction Questionnaire, with questions regarding device and accessory use. The audiologist will go over the instructions for filling out the questionnaire at inclusion. Patients will be asked to complete the questionnaire and return it at the next visit, 6 months after inclusion.
224158639|NCT06400992|BEHAVIORAL|AutoSens Feedback Discussion Form|6 months after inclusion and fitting, the audiologist discusses the use of AS clinic with the subject and completes the AS questionnaire (questionnaire on the experience of using the processor in different listening situations).
224158640|NCT05856149|BEHAVIORAL|Mobile Diabetes Prevention Program|The intervention is a mobile, web-based diabetes prevention program that participants will have access to for a total of 12 weeks. The intervention is a behavioral intervention aimed at increasing the knowledge and skills of participants to reduce type 2 diabetes risk behaviors.
224158641|NCT06851871|DRUG|Deucravacitinib|Specified dose on specified days
224158642|NCT06851871|DRUG|Famotidine|Specified dose on specified days
224158643|NCT01686347|DRUG|ropivacaine|
224158644|NCT03793634|DRUG|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
223467339|NCT00781053|DRUG|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
223467340|NCT03576638|DRUG|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
223467341|NCT03576638|DRUG|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
223577975|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 50 mg/kg|5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
223577976|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 100 mg/kg|5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
223577977|NCT04562597|DRUG|Dose Response Curve N-acetylcysteine 150 mg/kg|5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
223577978|NCT04562597|DRUG|Opioid Reduction with Optimal N-acetylcysteine Dose|Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
223577979|NCT04562597|DRUG|Placebo|15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
224158645|NCT04368000|BEHAVIORAL|Intermittent prone positioning instructions|Participants will be given instructions to lie in the prone position for a duration of 1-2 hours, every 4 hours while awake.
223467342|NCT01431339|DRUG|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
223467343|NCT01431339|DRUG|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
223467344|NCT03003442|DIETARY_SUPPLEMENT|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
223467345|NCT03003442|DIETARY_SUPPLEMENT|Placebo|Placebo
223467346|NCT01234597|DRUG|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
223467347|NCT01234597|DRUG|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
223467348|NCT06387758|BEHAVIORAL|Low systemic strength training|Low systemic strength training. Youth will complete exercise training for 45 minutes. Eight specific exercises will be performed to target all major muscle groups: calf raises, handgrip, squats, seated row, chest press, plank, low bac extension, and crunches (Table 1). Each exercise involves contractions with moderate load but with an extended duration of up to five minutes.16,17 During each exercise session, youth will have a 5-minute warm up, 5-minute cool down, and be allowed to take rest breaks as needed (minimum 30 seconds). Youth will initially progress by decreasing the number of rest periods and then increasing load. Youth will be provided a 2 lb medicine ball, resistance weight bands, Thera Putty, and a Yoga mat for home exercises. Youth will keep this home exercise equipment.
223467349|NCT06387758|BEHAVIORAL|Moderate systemic exercise|Youth assigned to the moderate systemic exercise load group will perform whole-body aerobic exercise at 40-59% of heart rate reserve (HRR) for 45 minutes.76,111 Youth will complete moderate systemic aerobic exercise by walking at a brisk pace and swinging their arms as they walk. Exercise personnel will supervise a 5-minute warm up and 5-minute cool down via videoconferencing and remain on the phone with youth at all times during the walking exercise session. Youth will exercise until the prescribed duration is achieved or until fatigue at which point they will either reduce the intensity or stop until they recover. All training intensities will be based around HRR so it is individualized (not exceeding 59% of HRR). Youth unable to meet the initial training requirements will be slowly progressed over the 8 weeks.
223467350|NCT00260546|PROCEDURE|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
223467351|NCT03503110|OTHER|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
223467352|NCT03503110|OTHER|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
223467353|NCT00385918|DEVICE|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
223577980|NCT04480034|PROCEDURE|Bariatric procedures|All standard, laparoscopic bariatric procedures endorsed by SICOB (Società Italiana della Chirurgia dell'Obesità, Italian Society of Obesity Surgery) and by IFSO (International Federation of the Societies of Obesity Surgery), will be considered: sleeve gastrectomy, R-en-Y gastric bypass, one anastomosis gastric bypass, single anastomosis duodeno-ileal bypass with sleeve. The selection criteria for the surgery candidates will comply to the latest guidelines for bariatric surgery endorsed by SICOB, IFSO and EAES (European Association of Endoscopic Surgery). All the participating centers will follow the usual recruitment protocol. Restart of the bariatric elective surgery is based on the guidelines of SICOB for the bariatric surgery restart in Italy during the COVID-19 phase 2-3 of endemics.
223743614|NCT07190326|OTHER|Swedish Massage Therapy|"The therapist uses non-aromatic cream to facilitate making long strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then re-draped before moving to another part. The primary techniques used in the research protocol therapy are effleurage, petrissage, kneading, tapotement and thumb friction. These techniques are performed in a very precise, carefully elaborated manner. The session starts with the subject fully draped in a prone position on the massage table and after approximately 22 minutes the subject is instructed to turn to the supine position. Finally, the therapist moves to the head area of the subject, begins working on the shoulders, neck and head using effleurage and thumb friction, and concludes by using light tapotement on the head. The total time for the entire massage is 45 minutes. Subjects randomized to SMT will undergo two sessions per week for 6-weeks."
224068335|NCT06399276|BEHAVIORAL|Weight Loss|Participants are instructed to perform a modified fast (\~500 kcal) on 3 days/week with ad libitum intake the other 4 days/week. Group-based behavioral support sessions will be held by an experienced Registered Dietician. Participants will attend BfitBwell exercise sessions in person and virtually to receive individualized support to progress to 150 min/wk of moderate-intensity physical activity
224070794|NCT06534827|BEHAVIORAL|Great Life Mentoring|The Great Life Mentoring program (GLM) provides volunteer-based mentoring for school-age youth from low-resource families who are receiving outpatient mental health care. Each youth is paired with a mentor with whom they spend time in the community on a weekly basis for at least one year. Mentors are required to complete a 20-hour intensive training prior to being paired with a youth. Mentors also receive monthly in-person supervision from GLM staff for the first year of their meetings, which continues on an as-needed basis thereafter. Training and supervision are geared toward the unique opportunities and challenges that can occur when mentoring a youth with mental health needs. The goal is for the mentor to become an integral part of the child's mental health treatment, but the mentoring relationship is also sustained after treatment ends.
224158646|NCT04368000|BEHAVIORAL|Usual care positioning with no instructions|Participants will not be given instructions to lie in the prone position for any duration.
224158647|NCT05212376|OTHER|Foot massage|"Foot massage is applied in the form of pressure, rubbing and stimulation with special hand and finger techniques to reflex - warning points corresponding to all regions, organs and systems in the body. It is applied by applying pressure to all reflex points in the area from the toes to the ankles.~In the study, a quiet and comfortable environment will be prepared at a room temperature of approximately 23-26 0C, and techniques that reveal the relaxing and calming effect of the massage will be selected. Thumb compression, slapping, patting, rubbing and squeezing movements are planned to be applied for a total of 20 minutes, 10 minutes on each foot, at the same time every day for 7 days."
224303605|NCT04810286|PROCEDURE|3d-Printing Myofunctional Appliance|To evaluate soft- and hard-tissue changes Class II division 1 tchildren with a prefabricated myofunctional appliance versus a 3D-printed myofunctional appliance.
223467354|NCT00385918|OTHER|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
223467355|NCT03923881|DEVICE|MSOT Acuity Echo|Optoacoustic imaging with the MSOT Acuity Echo
223467356|NCT06421389|DRUG|Tranexamic Acid Powder|2g of sucralfate powder, 1g of tranexamic acid powder, and 1g of barium will be sprayed through the endoscopy precisely on the bleeding site
223467357|NCT05628246|OTHER|Telemedicine|Telemedicine
223467358|NCT05628246|OTHER|In-person|In-person
223467359|NCT02727049|OTHER|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
223467360|NCT03094585|OTHER|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
223467361|NCT03094585|OTHER|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
223467362|NCT00000962|DRUG|Nevirapine|
223467363|NCT03782714|DEVICE|Low-level laser therapy|It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
223467364|NCT04609657|OTHER|Flavored carbonated soft drink (CSD)|Beverage
223467365|NCT01900041|DRUG|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
223467366|NCT01900041|DRUG|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
223467367|NCT06328257|BEHAVIORAL|Myofascial Release Training|Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
223467368|NCT06119230|BEHAVIORAL|Activity Counselling|Participants will receive a one hour goal setting session with a physiotherapist where they will use the feedback forms to create activity goals for the upcoming week of collection.
223467369|NCT00916552|DRUG|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
223467370|NCT05545176|OTHER|termination of resuscitation rules|Use retrospective data to analyze the accuracy termination of resuscitation rules and further develope a termination of resuscitation rule.
223467371|NCT05282628|BEHAVIORAL|Building Better Brains and Behavior program (B4 Preterm)|The program couples online learning modules with video conferencing sessions with a trained therapist to review skills and practice implementing the skills with live coaching. Online modules include didactic content, video clips of parents modeling the skills, and exercises. Parents will complete intervention modules sequentially in conjunction with scheduled 1:1 videoconference sessions with a trained therapist. Videoconference sessions with the therapist will be scheduled weekly, once parents have completed their modules. During these sessions, the therapist will review the online materials and provide active coaching to the parent on how to use the skills with their child (e.g., labeled praise, reflective responses). Each session follows a manualized therapy protocol to optimize content fidelity. Parents will be instructed to practice the parenting skills for 5 minutes each day to promote mastery in the home environment.
223467372|NCT01634646|DIETARY_SUPPLEMENT|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
223467373|NCT05871840|OTHER|Repeated Low-Level Red-Light (RLRL) Therapy|This treatment device was made by Eyerising SuzhouXuanjia Optoelectronics Technology, which has been on the market and used widely for amblyopia treatment for the past decade in China. This device is certified as a class IIa device by the China National Medical Products Administration. It consists of semiconductor laser diodes, which deliver low-level red light with a wavelength of 650 ±10 nm at an illuminance level of approximately 1600 lux through the pupil to the fundus. Based on calculations completed by an independent lab, the light power going through a 4-mm pupil is 0.29 mW and is classified as class 1 under the International Electrotechnical Commission 60825-1:2014 standard, which is at a level considered safe for direct ocular exposure that would not create retinal thermal hazard.
223467374|NCT02709148|DEVICE|Activa PC+S|DBS
223467375|NCT01775007|DEVICE|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
224070795|NCT07102095|DRUG|Sevabertinib|Single oral dose of 20 mg sevabertinib administered as 2 x 10 mg film-coated tablets
224070796|NCT03448237|OTHER|Speech Therapy|Speech therapy adapted to the child, at least 25 sessions over 9 months.
224070797|NCT03448237|OTHER|Proprioceptive treatment|"Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~* Proprioceptive stimulation of oculomotor muscles (active prisms).~* Oral somatosensory stimulation (ALPH).~* Proprioceptive antigravity stimulation (proprioceptive sole).~* Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)"
224070798|NCT07110064|DRUG|QL1706+Lenvatinib+AG Regimen|Participants will receive QL1706 combination with Lenvatinib and AG regimen for 8 cycles. Subsequently, the enrolled patients will continue to receive maintenance therapy with QL1706 and Lenvatinib until disease progression (PD) is observed, intolerable adverse events occur, or the investigator deems it inappropriate for the subject to continue treatment.
223467376|NCT01676701|DRUG|Tabalumab Auto-Injector|Administered SC by auto-injector
223467377|NCT01676701|DRUG|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
223467378|NCT04957524|DEVICE|iStim TENS unit and Transvaginal Probe|"iStim TENS unit and Transvaginal Probe are both commercially available products. TENS units work by delivering small electrical impulses through electrodes either attached to the skin or through a transvaginal probe.~iStim transvaginal probe will be inserted vaginally to provide transvaginal electrical stimulation."
223467379|NCT05898841|DRUG|Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day|DTG/RPV will be administered in combination as 50/25 mg/day tablets or separately as DTG 50 mg/d tablets together with RPV 25 mg/d tablets. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART (Highly Active Antiretroviral Therapy) components are respected.
223467380|NCT05898841|DRUG|Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day|TDF 245 mg/d or TAF 25mg/d together with FTC 200 mg/d and RPV 25 mg/d. They may be administered as single tablets or in combination forms where one tablet contains TDF/TAF and FTC and another RPV tablet. There will be no problem if during the course of the study the patient is switched from the combined form to the separate form and vice versa as long as the HAART components are respected.
223467381|NCT05898841|DRUG|Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.|Patients who are randomised to this treatment arm will continue with the HAART they were receiving prior to signing the informed consent. As in arms 1 and 2, a change in the form of HAART administration (from a combined to a separate form and vice versa) will be allowed as long as the HAART components are respected.
223467382|NCT01342354|RADIATION|Stereotactic Radiation 10 Gy|10 Gy three times over 10 days
223467383|NCT01342354|RADIATION|Stereotactic Radiation 12.5 Gy|12.5 Gy three times over 10 days
223577981|NCT05883046|OTHER|Performance-Enhancing Substances|All supplements were consumed 60 min before the isometric mid-thigh pull tests, to reach peak blood concentrations at evaluation time. Immediately after consumption, both Control and intervention participants rested in a quiet laboratory environment (Eskişehir Technical University, Laboratory of Human Athletic Performance), until the strength tests. Participants were previously informed verbally and in writing that they should abstain from caffeine consumption (any caffeine-containing beverages and foods, such as coffee or tea, energy drinks, cocoa and cocoa-containing foods, chocolate and chocolate-containing foods or caffeine-containing drugs) for at least 24 hours before
223577982|NCT05883046|OTHER|Placebo|20gr of maltodextrin (European origin, Alfasol®, Kimbiotek, Turkey)
223577983|NCT05883046|OTHER|Baseline (Control)|No supplement conditions
223467384|NCT01342354|RADIATION|Stereotactic Radiation 15 Gy|15 Gy three times over 10 days
223577984|NCT04944732|DIAGNOSTIC_TEST|laboratory examination, auxiliary examination, pathological results|Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)
223577985|NCT00215215|DEVICE|Vagus Nerve Stimulation Therapy|
223467385|NCT06521047|OTHER|NA - Observational study|Observational study, data collection only.
223467386|NCT05716009|DRUG|Dose Escalation -tagraxofusp-erzs|Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
223577986|NCT00289198|DRUG|FF|fluticasone furoate 110 μg nasal spray
223467387|NCT05716009|DRUG|Dose Expansion at RP2D -tagraxofusp-erzs|Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
223467388|NCT05455710|DEVICE|VigiApp|mobile application containing a patient identification module; post-discharge surveillance questionnaire with questions related to signs and symptoms of SSI previously validated; possibility of attaching and sending a photograph of the surgical wound; field for exchanging messages between professional and patient; issuing an alert / reminder to fill in the data in the application; in addition to establishing interoperability with the system used by the hospital's SCIH, containing a login for each health professional, which allows access to the answers, images and messages sent by surgical patients, categorizing risk and issuing alerts in suspected cases of SSI.
223467389|NCT04406714|BEHAVIORAL|Trial Mailed FIT Intervention - Age Group 50-75|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
223577987|NCT00289198|DRUG|Placebo|placebo nasal spray
223577988|NCT06053957|PROCEDURE|early mobilization|early mobilization program
223577989|NCT00031980|DRUG|cyclosporine|
223577990|NCT01176565|DRUG|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
223577991|NCT03602885|BEHAVIORAL|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
223577992|NCT03602885|BEHAVIORAL|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
223577993|NCT00724412|OTHER|Systane|Dry Eye relief eye drops
223577994|NCT00724412|OTHER|Optive|Dry Eye relief eye drops
223577995|NCT05141656|OTHER|No intervention will be considered in this study.|No intervention will be considered in this study.
223577996|NCT02406443|DRUG|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
223467390|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49|"Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call."
223467391|NCT04406714|BEHAVIORAL|Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49|Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
223577997|NCT02406443|OTHER|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
223577998|NCT06323967|BEHAVIORAL|Large unconditional cash transfers plus voluntary peer support.|These participants will receive monthly cash transfers of $1,500 ($750 twice per month) via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.
223467392|NCT06452771|DRUG|ALN-ANG3|Administered subcutaneous (SC) injection
223467393|NCT06452771|DRUG|Placebo (PB)|Administered SC injection
223577999|NCT06323967|BEHAVIORAL|Nominal cash transfers|These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.
223467394|NCT06432933|OTHER|No preventive oxygen therapy (2L)|Participants will not receive preventive oxygen 2L during the first postoperative night after bariatric surgery.
223467395|NCT06432933|OTHER|Preventive oxygen therapy (2L) standard care|Participants will receive preventive oxygen 2L during the first postoperative night after bariatric surgery, standard care.
223578000|NCT06323967|BEHAVIORAL|Passive comparison group|These families will receive usual care from shelter staff. They will be followed anonymously in administrative records only.
223578001|NCT05443412|DIAGNOSTIC_TEST|Diagnostic test for prostate cancer|All recruited patients will undergo investigations including urine for spermine, blood for miRNA, TRUS, and MRI prostate. Patients with high suspicion of Clinically significant prostate cancer in any one step (urine, blood, ultrasound, OR MRI) will be offered an image-guided prostate biopsy.
223578002|NCT04839341|DRUG|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
224068336|NCT05490745|BEHAVIORAL|Skills4Parenting+|Skills4Parenting+ has 6-8 weekly individual online sessions (50 min) + 8-week follow-up. First, an assessment session of parents' positive parenting skills (PPS), based on mother/father-child interaction observation. The following sessions aim to (1) promote parental reflective functioning, enhancing parents' understanding of the child´s problems, and (2) activate PPS to solve the child's problems. Written registers of problematic situations - in which the problems of the child occur, are analyzed (i.e., child's and parents' behaviors, thoughts, and feelings) (intersession activity) - are reflected upon, to understand and solve through PPS. PPS implementations are analyzed to understand the changes in the child and parent. Future situations and activation of appropriate PPS are anticipated, to solve potential upcoming problems of the child's, related to adversity. When the therapeutic goals have not been fully achieved, two additional sessions (total of 8 instead of 6), are added.
224068337|NCT05490745|OTHER|Waiting-list (nocebo)|Participants wait to receive the psychological intervention (Skills4Parenting+) for eight weeks, after the assessment session.
224068338|NCT06630793|RADIATION|IMPT (Intensity Modulated Proton Therapy)|Proton therapy is a form of radiation treatment in which high doses can be delivered within the tumour while relatively sparing the surrounding normal tissues. This may help further reduce the side-effects of radiation treatment observed with IMRT.
224068339|NCT06630793|RADIATION|IMRT (Intensity Modulated Radiation Therapy)|The standard management of carcinoma of the anal canal is radiotherapy using the IMRT technique along with concurrent chemotherapy. The use of IMRT has reduced the treatment-related side-effects as compared to older radiation techniques. However, further reducing these side effects poses a major challenge.
224068340|NCT03257267|DRUG|Cemiplimab|Intravenous (IV) administration every 3 weeks (Q3W)
224068341|NCT03257267|DRUG|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
224068342|NCT01979523|OTHER|Laboratory Biomarker Analysis|Correlative studies
224068343|NCT01979523|OTHER|Pharmacological Study|Correlative studies
224068344|NCT01979523|DRUG|Trametinib|Given PO
224068345|NCT01979523|DRUG|Uprosertib|Given PO
224068346|NCT01508871|OTHER|Observational study, no intervention|No intervention
224068347|NCT03308656|OTHER|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
224068348|NCT01926483|OTHER|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
223578003|NCT00504790|DRUG|GSK923295|anti-mitotic compound
223578004|NCT03435562|OTHER|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
223578005|NCT03435562|OTHER|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
223578006|NCT03435562|OTHER|Own Brand cigarette|Effects of own brand cigarette use.
224068349|NCT00292825|DEVICE|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
224068350|NCT00292825|DEVICE|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
224070799|NCT07111936|BEHAVIORAL|CONNECT Intervention for multilingual populations|The program includes interactive Video Doctor visits to provide participants with information tailored to their individual responses and outreach via brief telephone calls and text messaging to follow-up and connect smokers with evidence-based resources for smoking cessation.
224070800|NCT07111936|OTHER|Saliva Sample|Undergo saliva collection
224070801|NCT07111936|OTHER|Interview|Attend a focus group
223467396|NCT04536701|BEHAVIORAL|Mood Monitoring and Behavioral Recommendation System|The purpose of this project is to develop a monitoring, modeling, and interactive recommendation solution (for caregivers) for in-home dementia patient care that focuses on caregiver-patient relationships. This includes monitoring for mood and stress and analyzing the significance of monitoring those attributes to dementia patient care and subsequent behavior dynamics between the patient and caregiver. In addition, novel and adaptive behavioral suggestions will be provided to family caregivers via text messages on project Smart phones at the right moments aimed to help improve familial interactions related to caregiving, which over time should ameliorate the stressful effects of the patient's illness and reduce strain on caregivers.
223467397|NCT04167358|DRUG|Linerixibat|All participants will receive linerixibat.
223467398|NCT06318026|BEHAVIORAL|Centralized Intervention|A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use
223467399|NCT06318026|OTHER|Primary Care Intervention|A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
223467400|NCT05918406|COMBINATION_PRODUCT|Nasal Guide|Use of Nasal Guide with administration of Tyrvaya (varenicline solution 0.03 mg) BID
223467401|NCT06572540|DEVICE|Transthoracic cryoablation|Transthoracic cryoablation will be performed under the guidance of CT.
223467402|NCT06572540|DEVICE|Transbronchial cryoablation|Transbronchial cryoablation will be performed under the guidance of navigation bronchoscopy and CBCT.
223467403|NCT03954093|DEVICE|Transcranial direct current stimulation|tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
223467404|NCT01622933|BIOLOGICAL|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
223467405|NCT01622933|BIOLOGICAL|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
223467406|NCT06958003|OTHER|Air Therapy|3-5 minutes of air therapy in addition to routine diaper care
223467407|NCT06516042|DRUG|Dihydroartemisinin-piperaquine|Participants that provide consent to participate in the TDA and are deemed eligible for treatment will receive a course of dihydroartemisinin-piperaquine (DP) if male, and artemether-lumefantrine (AL) if female. They will take the first dose of the treatment under direct observed therapy, and will receive the rest of the tablets to take on their own for days two and three.
223467408|NCT00549549|DRUG|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
223467409|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
223578007|NCT04214639|DRUG|IDP-126 Gel|IDP-126 Gel applied topically to the face once daily for 12 weeks.
224068351|NCT05173454|BEHAVIORAL|Breastfeeding Education and Support|The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
224068352|NCT06022263|DRUG|Lactic Acid|180 mg of STA363 will be slowly injected into a symptom-generating herniated lumbar disc
224068353|NCT06022263|DRUG|Placebo|1.5 mL of Omnipaque in water for injection will be slowly injected into a symptom-generating herniated lumbar disc
224068354|NCT01573715|DRUG|NIMBEX|
224068355|NCT01573715|DRUG|NIMBEX|
224068356|NCT01573715|OTHER|WITHOUT NIMBEX|
224068357|NCT00184678|DRUG|somatropin|
224068358|NCT04231383|OTHER|dental caries, growth parametres|"The comparison of growth parameters before and after 6 months of treatment of dental caries will be compared.~Children's Sleep Habits Questionnaire and Early Childhood Oral Health Impact Scale will be compared before and at the 6th month of dental treatment."
224068359|NCT02077088|OTHER|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
224068360|NCT01442883|DEVICE|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
224068361|NCT05298137|PROCEDURE|Passive Leg Raise|A passive leg raise (PLR) is defined as raising a patient's legs to a 45-degree angle at the hip while supine.
224068362|NCT00706134|DRUG|Placebo|Placebo tablet taken once daily in the morning with a light meal.
224068363|NCT00706134|DRUG|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
224068364|NCT00706134|DRUG|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
224068365|NCT00706134|DRUG|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
224068366|NCT06537843|DRUG|Venetoclax|Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
224068367|NCT06537843|DRUG|Cytarabine Injection|Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
224068368|NCT06537843|DRUG|Metformin|Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
224068369|NCT04747171|DRUG|intrathecal Magnesium|intrathecal adjuvants to bupivacaine
224068370|NCT04747171|DRUG|intrathecal dexamthasone|intrathecal adjuvants to bupivacaine
223467410|NCT00549549|DRUG|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
223467411|NCT00549549|DRUG|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
223467412|NCT04554602|DIAGNOSTIC_TEST|Fusion ultrasound|Fusion ultrasound is a technique that allows a volume acquired in MRI to be coupled to an ultrasound scan with real-time image synchronisation.
223467413|NCT02155699|BEHAVIORAL|Exercise 1|65% of VO2max and 2 sessions per week
223578008|NCT04214639|DRUG|IDP-126 Vehicle Gel|IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
223578009|NCT00265265|DRUG|Atomoxetine|
223578010|NCT02519868|DEVICE|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
224303606|NCT04856423|DIAGNOSTIC_TEST|The us-qFIT and colonoscopy with pathological examination|Detect fecal hemoglobin concentration by us-qFIT before colonoscopy, detect colon lesions using colonoscopy and pathological examination.
224303607|NCT03507023|DIETARY_SUPPLEMENT|Metabolaid®|500 mg per day, in fasting conditions.
224303608|NCT03507023|DIETARY_SUPPLEMENT|Placebo|500 mg per day, in fasting conditions.
224303609|NCT00338455|DRUG|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
223467414|NCT02155699|BEHAVIORAL|Exercise 2|85% intensity and 3 sessions per peek
223467415|NCT02227784|DRUG|Evacetrapib|Administered orally
223467416|NCT02227784|DRUG|Atorvastatin|Administered orally
223467417|NCT02227784|DRUG|Ezetimibe|Administered orally
223467418|NCT02227784|DRUG|Placebo|Administered orally
223467419|NCT00550797|BIOLOGICAL|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
223578011|NCT02519868|DEVICE|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
223467420|NCT00550797|BIOLOGICAL|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
223467421|NCT02992028|DRUG|Intravenous Nutrition (Vitamins) injection|
223467422|NCT02992028|DRUG|Intravenous Saline injection|
223467423|NCT01031303|BIOLOGICAL|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
223467424|NCT00555074|DRUG|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
223578012|NCT04759365|DRUG|ASN51|ASN51 formulation for oral capsule
223578013|NCT04759365|DRUG|Placebo|Placebo formulation for oral capsule
223578014|NCT04667897|DRUG|601 1.25mg|Solution for injection (intravitreal use)
223743615|NCT07190326|OTHER|Light Touch Control|The Light Touch Control protocol entails the same duration and sequence of procedures as the massage protocol, except that the therapist employs only light-touch hand placement on the subject's body. This condition isolates the effect of the mechanical intervention of SMT. Subjects randomized to LT will undergo two sessions per week for 6-weeks.
224068371|NCT04747171|DRUG|intrathecal dexmedetomidine|intrathecal adjuvants to bupivacaine
224068372|NCT03224897|DEVICE|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
224068373|NCT03224897|DEVICE|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
224303610|NCT00338455|DRUG|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
223467425|NCT00555074|DRUG|Placebo|Placebo, BID, oral route during 6 weeks
223467426|NCT01660867|DRUG|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo =\> nebulized epinephrine + 3% saline
223467427|NCT01660867|DRUG|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone =\> nebulized epinephrine + 0.9% saline
223467428|NCT00303030|PROCEDURE|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
223467429|NCT00303030|PROCEDURE|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
223467430|NCT05580484|PROCEDURE|Second surgery|The primary outcomes were adhesion severity and adhesion area in the lower ab-dominal cavity, as determined through direct visual observation of a laparotomy wound or laparoscopic observation from stoma closure wound.
223467431|NCT00424281|DRUG|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
223578015|NCT04667897|DRUG|Ranibizuman 0.5 mg|Solution for injection (intravitreal use)
223578016|NCT05834010|BIOLOGICAL|Fecal Microbiome Transplant|Fecal matter from healthy age/sex matched established and screened donors, recruited from the Danish Blood-donor system
223578017|NCT01983605|DEVICE|LARIAT Suture Delivery Device|LAA exclusion procedure
223578018|NCT00115999|DRUG|alfimeprase|
224303611|NCT06216223|PROCEDURE|treatment of anal diseases in inflammatory bowel patients|treatment of anal diseases in inflammatory bowel patients
224303612|NCT06216223|DEVICE|Laser|laser
224303613|NCT06216223|PROCEDURE|traditional surgery|traditional surgery
224303614|NCT04260438|DRUG|CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T|single oral administration under fed condition
224303615|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 1 Tab. 1T|single oral administration under fed condition
224303616|NCT04260438|DRUG|CKD-393 0.5/100/1000mg formulation 2 Tab. 1T|single oral administration under fed condition
224303617|NCT01715792|OTHER|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
224303618|NCT00328016|BEHAVIORAL|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
223467432|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
223467433|NCT01394536|DEVICE|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
223578019|NCT03873506|DRUG|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
224158648|NCT03684525|PROCEDURE|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~* If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~* If Canine is emerged to oral cavity: No further CBCT scan will be taken~* If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
223467434|NCT00653393|DRUG|Tranylcypromine|Tablets, 10 mg, single-dose
223467435|NCT00653393|DRUG|Parnate|Tablets, 10 mg, single-dose
223467436|NCT02890316|OTHER|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
223467437|NCT02890316|RADIATION|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
223467438|NCT05775419|COMBINATION_PRODUCT|Consolidation chemotherapy (4 courses)|Consolidation chemotherapy (4 courses): After the concurrent chemoradiotherapy is over, after 2-3 weeks of rest, the patients in the consolidation chemotherapy group will be given 4 cycles of consolidation chemotherapy, and the chemotherapy regimen is the same as the concurrent chemotherapy regimen;
223467439|NCT05775419|COMBINATION_PRODUCT|Concurrent chemotherapy (2 courses)|Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;
223467440|NCT03768713|DRUG|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
223467441|NCT03768713|DRUG|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
223467442|NCT05473299|DEVICE|Xeltis Hemodialysis Access (aXess) graft|The aXess graft is a sterile, regenerative biodegradable polymer-based vascular graft, consisting of a tubular structure with a 6mm inner diameter. It is comprised of a highly porous polymer matrix and an embedded electropolished nitinol reinforcement layer (Strain Relief System). The aXess graft is able to support both straight and loop configurations and may be implanted in the upper arm and forearm.
223467443|NCT06557135|PROCEDURE|Carotid Artery Stenting (CAS)|CAS involves inserting a catheter or tube into an artery in the brachial or the femoral, and then threading the catheter through the arteries of the body to the location of the stenosis within the carotid artery in the neck. A stent is then placed in the stenosis and holds the artery open.
223467444|NCT04974528|BIOLOGICAL|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
224068374|NCT03224897|DEVICE|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
224068375|NCT01972893|DRUG|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
224158649|NCT00135525|DRUG|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
224158650|NCT00135525|DRUG|Placebo|Placebo
223467445|NCT04974528|BIOLOGICAL|Rapid-acting Insulin Analog|"Pharmaceutical form: clear and colorless solution for injection~Route of administration: subcutaneous"
223467446|NCT04974528|BIOLOGICAL|Basal Insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
223467447|NCT06320951|DRUG|Vericiguat 10 MG|The subject will be randomized, in a double-blind manner to vericiguat 10 mg once daily for a period of 12 weeks.
223467448|NCT06320951|OTHER|Placebo|The subject will be randomized, in a double-blind manner to placebo once daily for a period of 12 weeks.
223578020|NCT00662376|DIETARY_SUPPLEMENT|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
223743616|NCT07185087|DEVICE|passive self-ligating, Damon Ultima brackets|Patients will receive Damon Ultima self-ligating brackets (Ormco Corp., Glendora, California, USA) bonded from the second molar to the second molar in each arch. Archwires will follow a standardized sequence: 0.014-inch CuNiTi, 0.018-inch CuNiTi, and 0.014 × 0.0275-inch CuNiTi (Ormco Corp., Glendora, California, USA). All bonding procedures will follow a standardized protocol, including enamel cleaning, acid etching, primer application (Ortho Solo), and adhesive curing (Green Glow).
224158651|NCT02103595|DEVICE|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
223467449|NCT06320951|OTHER|Insulin Sensitivity Test|An assessment of the insulin sensitivity will be done using the Euglycemic Hyperinsulinemic Clamp, at baseline and after 12 weeks of pharmacological interventions.
223467450|NCT06320951|OTHER|Resting Energy and Exercise Energy Expenditure Assessment|Each participant's Energy Expenditure will be determined using a metabolic cart, at baseline and after 12 weeks of pharmacological interventions.
223467451|NCT06320951|OTHER|White Adipose Tissue Biopsy|Participants who consent to participate in the exploratory aim will undergo WAT biopsy to assess UCP1 gene expression from the collected biospecimens, at baseline and after 12 weeks of pharmacological interventions.
223467452|NCT06320951|OTHER|MRI-PET Scan for Brown Adipose Tissue Volume Assessment|Participants who consent to participate in the exploratory aim will undergo PET/MR to BAT volume at baseline and after 12 weeks of pharmacological interventions.
223467453|NCT03851848|OTHER|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
223467454|NCT03851848|OTHER|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
223467455|NCT01787006|DRUG|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
223467456|NCT01787006|DRUG|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
223578021|NCT06631378|PROCEDURE|Transverse groin incision|The transverse incision is made parallel to the inguinal ligament either superiorly or inferiorly to the skin crease directly over the femoral artery. The subcutaneous tissue is dissected in the transverse direction till Scarpaes fascia after which the dissection is performed in the longitudinal direction along the line of the vessels. The lymphatic vessels are spared as much as possible. Any damaged lymph vessels are closed with surgical clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage. In case of difficulty with proper access to the femoral arteries, the incision can be extended either medially, laterally, or vertically.
223578022|NCT06631378|PROCEDURE|Longitudinal incision|The longitudinal incision is made directly over the femoral artery from the inguinal ligament. The subcutaneous tissue is dissected along the line of the vessel sparing the lymphatic vessels as much as possible. Any damaged lymph vessels are closed with clips. Damages lymph nodes are either removed or the capsule is sutured to prevent lymph leakage.
223578023|NCT00947414|DEVICE|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
223578024|NCT00947414|DEVICE|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
223578025|NCT05934708|BEHAVIORAL|Eccentric leg extension|Participants will complete a 10 x 10 eccentric leg extension on a Cybex Norm dynamometer. Upon arrival, participants will be asked their perceived readiness to perform on a 11 point numeric rating scale. Before the running protocol a baseline blood sample will be collected, as well as passive and active delayed onset muscle soreness (DOMS), a countermovement jump. Half way through each set (i.e., after the 5th repetition) participants will be asked to rank their level of difficulty on a 11 point OMNI Res scale. This will occur during each set. Participants will have follow up blood draws, measures of muscle function (i.e, jump height) and soreness measured immediately after and 24 and 48 hours post-exercise.
223578026|NCT07032090|BEHAVIORAL|Health education|Participants will receive face-to-face health education, followed by 12 sessions of laughter yoga.
223578027|NCT07032090|BEHAVIORAL|Laughter Yoga|The intervention groups will receive a total of 12 sessions of laughter yoga, delivered by the researcher over 6 weeks, twice a week, each lasting 40-45 minutes.
224158652|NCT02103595|DEVICE|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
223467457|NCT01787006|RADIATION|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
223467458|NCT00292552|OTHER|Novel endpoint determination|Novel endpoint determination
223467459|NCT01794962|OTHER|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
224158653|NCT02989480|RADIATION|PET CT|PET CT scans
224158654|NCT02989480|OTHER|Cardiac MRI|Cardiac MRI
223467460|NCT01794962|OTHER|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
223467461|NCT03461458|DRUG|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
223578028|NCT07040657|PROCEDURE|Sentinel Lymph Node Detection/Cervical Methylene Blue Injection|Sentinel Lymph Node (SLN) detection using cervical methylene blue injection is a surgical technique designed to identify the primary lymph nodes responsible for draining the uterus in patients with endometrial cancer. The procedure involves injecting methylene blue dye into specific locations within the cervical stroma to enable lymphatic uptake. The dye subsequently travels through the lymphatic channels, allowing for intraoperative visual identification of the sentinel nodes. This targeted approach facilitates selective SLN excision for pathological evaluation, providing critical information about lymphatic involvement while minimizing the extent of surgical dissection. The effectiveness of SLN mapping is contingent upon the accuracy of the injection technique and the anatomical distribution of lymphatic drainage.
223743617|NCT07185087|DEVICE|Conventional ligation, MBT brackets|Patients will receive MBT Mini Diamond brackets (Ormco Corp., Glendora, California, USA) bonded in the same manner, with the same archwire sequence.
223743618|NCT07190196|DRUG|Rilzabrutinib|Pharmaceutical form:Tablet-Route of administration:Oral
223743619|NCT07190196|DRUG|Placebo|Pharmaceutical form:Tablet-Route of administration:Oral
224158655|NCT03321890|DRUG|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
224158656|NCT03321890|DRUG|prednisone|oral, 20mg / day,after breakfast
223467462|NCT04904679|DEVICE|Pars plana Vitrectomy with internal limiting membrane peeling|"The pars plana 23-gauge (23G) vitrectomy technique will be performed with removal of the internal limiting membrane (ILM) (when adhered to the macula) and placement of either an amniotic membrane plug or an ILM flap in the macular hole. This will be followed by a fluid-air exchange and buffering gas infusion (12.5% C3F8).~The amniotic membrane plug will be prepared using a dermatological punch with a diameter of 1 to 2 mm, depending on the size of the macular hole as measured by OCT. It will be positioned inside the macular hole using 23G forceps, with its chorionic side facing the retinal pigmented epithelium (RPE).~The ILM flap will be created at the time of peeling-with an inverted flap in primary cases and a free flap in refractory cases. It will be positioned over the hole (inverted flap) or inside the macular hole (free flap) using 23G ILM forceps.~These techniques will be assisted by the use of an extra lighting sclerotomy."
223467463|NCT02108977|OTHER|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
223467464|NCT02108977|OTHER|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
223467465|NCT00000863|DRUG|Sitamaquine|
223467466|NCT02688933|DRUG|HOE901-U300 (Insulin Glargine 300 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
223467467|NCT02688933|DRUG|Lantus (Insulin Glargine 100 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
223467468|NCT02688933|DRUG|Mandated back ground therapy|Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
223467469|NCT00248651|DRUG|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
223467470|NCT00248651|DRUG|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
223467471|NCT00248651|DRUG|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
223578029|NCT07040748|BEHAVIORAL|Immersive VR-Based Multimodal Intervention (Virtual-METS)|This intervention consists of a 12-week, group-based program using immersive virtual reality technology (MK360) without head-mounted displays. Each 60-minute session combines mindfulness practices adapted from the Mindfulness-Based Stress Reduction (MBSR) program, cognitive training targeting attention, processing speed, memory, and executive function through realistic virtual environments (such as parks, markets, or home interiors), and chair-based physical exercises focused on balance, stretching, and muscle strengthening. The intervention is delivered in small groups of five participants, twice per week, for a total of 24 sessions, and is led by a trained neuropsychologist.
223578030|NCT07041424|PROCEDURE|treatment group 1: total etch bonding agent used with rebonding technique|class 1 composite restoration is done using total etch type bonding agent and rebonding technique applied
223578031|NCT07041424|PROCEDURE|treatment group 2: self etch bonding agent used with rebonding technique|class 1 composite restoration is done using self etch type bonding agent and rebonding technique applied
223578032|NCT07041996|DIAGNOSTIC_TEST|Mobile-based SARC-F screening application|SARC-F mobile application as a digital health intervention for sarcopenia risk assessment.
223578033|NCT07041411|PROCEDURE|maxillary sinus elevation through transcrestal approach using OSSIX® Bone|After a careful radiologic analysis, using a surgical guide, maxillary sinus elevation through transcrestal access to sinus mucosa was achieved. The elevation of the maxillary sinus mucosa was performed through micro-elevators and graft material was inserted.
223743620|NCT07190196|DRUG|Glucocorticoid|Pharmaceutical form:Tablet, solution, suspension formulations according to local standard practices-Route of administration:Oral
224158657|NCT03321890|DRUG|Cyclophosphamide|oral, 50mg / day,after lunch
224158658|NCT03321890|DRUG|etoposide|oral, 50mg / day,after dinner
224158659|NCT03321890|DRUG|Methotrexate|oral, 10mg / times, once a week,after breakfast
224158660|NCT01801124|DRUG|EXPAREL|single dose 266 mg of undiluted EXPAREL
224158661|NCT04383964|DEVICE|Distraction Osteogenesis for Reconstruction of Ramus-Condyle|transport distraction osteogenesis in restoring the deficient condyle/ramus unit of patients with TMJ ankylosis to correct the resultant deformity either unilaterally or bilaterally.
224158662|NCT02394262|RADIATION|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
224158663|NCT02394262|OTHER|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
224158664|NCT02728206|DRUG|SOF/VEL|400/100 mg FDC tablet administered orally once daily
223467472|NCT04664101|BEHAVIORAL|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT)|REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) The intervention consists of high intensity interval training, consisting of a 30-minute exercise session that includes 10 x 1-minute intervals of high intensity 3x/week (e.g., Monday, Wednesday, Friday) and supplemented with 2 sessions per week of strength, balance, and mobility exercises (e.g., Tuesday, Thursday). Exercise will be supported by an activity tracker, which will allow study personnel to track patient heart rates during exercise on a daily basis, allowing them to provide individualized feedback and coaching.
223467473|NCT04664101|OTHER|Comparator|Patients randomized to the control arm will receive the same technology platform and education on exercise options, including HIIT, but will return home to exercise as they see fit without personalized instruction and coaching. They will be remotely monitored, but will not receive feedback unless any adverse events are noted
223467474|NCT01275144|DRUG|LY2216684|Administered orally
223467475|NCT01275144|DRUG|Placebo|Administered orally
223467476|NCT01275144|DRUG|Lorazepam|Administered orally
223467477|NCT00828113|DRUG|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
223467478|NCT00828113|DRUG|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
223467479|NCT00828113|BEHAVIORAL|Individual smoking cessation counseling|Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
223467480|NCT01832337|PROCEDURE|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
223467481|NCT00152113|PROCEDURE|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
223467482|NCT00152113|DEVICE|CliniMACS|
223467483|NCT00152113|DRUG|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
223467484|NCT03767842|DEVICE|Visor System|Subjects are monitored one time with the Visor System.
223467485|NCT02952690|DEVICE|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
223578034|NCT07040228|DRUG|Regorafenib combined with Toripalimab and Albumin paclitaxel|Regorafenib combined with Toripalimab and Albumin paclitaxel as the third line treatment for patients with advanced pancreatic cancer
223578036|NCT03106415|DRUG|Binimetinib|Given PO
223578037|NCT03106415|OTHER|Laboratory Biomarker Analysis|Correlative studies
223578038|NCT03106415|BIOLOGICAL|Pembrolizumab|Given IV
223578039|NCT06893107|PROCEDURE|Intentional Replantation|The intervention involves intentional replantation (IR) of periodontally compromised single-rooted teeth. Patients are selected based on criteria ensuring no vertical root fractures and potential for restoration. Preoperative preparation includes radiographic evaluation (CBCT/periapical), scaling, and root planing, along with antibiotic prophylaxis. The tooth is extracted non-traumatically using periotomes to preserve the periodontal ligament (PDL). After extraction, the tooth is stored in a sterile medium and granulation tissue is excised. Optional modifications (apical resection, retrograde filling, or surface treatment) may be performed. The tooth is then replanted into the socket, secured with a non-rigid splint, and occlusal adjustment is made. Postoperative care includes analgesics, antibiotics, and chlorhexidine rinse. Follow-ups are scheduled at 1 week, 4 weeks, and 9 months for evaluation of healing, survival, and patient-reported outcomes.
223578040|NCT06892444|DIETARY_SUPPLEMENT|Yellow Sweet Corn|Participants will consume 1.5 cups daily of yellow or white canned sweet corn.
223578041|NCT06892444|DIETARY_SUPPLEMENT|White Sweet Corn|1.5 cups daily of canned yellow sweet corn
224158665|NCT02373306|PROCEDURE|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
224158666|NCT01070706|DRUG|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
224158667|NCT06343454|OTHER|Digital Interocclusal Record In Different Head Positions|Recording the position of the upper and lower teeth in the bite position in different head positions with an intraoral scanner
224158668|NCT04307589|OTHER|Observation|An observational follow-up study will be implemented over a period of 2 years, consisting of 3 test occasions with a fixed time interval of 1 year in between (T0 = baseline, T1 = 12 months, T2 = 24 months). Data will be collected in participants who provide grandchild care in a non-residential grandparent context as well as in a sample of non-caregiving grandparents and a sample of middle-aged and older adults not being a grandparent. All three samples will thus be prospectively monitored over a period of 2 years.
223467486|NCT02952690|DEVICE|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
223467487|NCT06165211|OTHER|Nature sound listening|The intervention group listened to nature sounds for 30 minutes during hemodialysis. Nature sounds consisting of bird, wind and tree sounds will be played.
223467488|NCT06165211|OTHER|Routine care|Patients will watch the program they want on the bedside TV during hemodialysis.
223467489|NCT04155866|OTHER|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
223467490|NCT05708898|DEVICE|Pharyngeal exerciser|
223467491|NCT05708898|DEVICE|sham pharyngeal exerciser|
223467492|NCT05254886|OTHER|NEMO nurse-led program|"The NEMO nurse-led program will consist of a single nursing consultation conducted on the day of the inclusion visit during which the nurse will:~* Report the presence of pre-existing comorbidities/EIMs~* Detect the presence of risk factors~* Implement recommendations for the detection and/or management of comorbidities/EIMs."
223467493|NCT05607576|OTHER|Uncovered CGM during radiologic procedures|Dexcom G6 CGM will not be covered during radiologic procedures.
223578042|NCT01158144|DRUG|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
223578043|NCT01158144|DRUG|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
223578044|NCT05709925|PROCEDURE|Instrument Assisted Soft Tissue Mobilization|The Graston Technique which is the Instrument Assisted Soft Tissue Mobilization is the use of a firm instrument to break tissue adhesions and mobilize scar tissue thus improving pain, range of motion and disability.
223578045|NCT05709925|PROCEDURE|myofascial release|myofascial release through stripping technique to the lumbar region.
223578046|NCT05544175|PROCEDURE|NEUROMOdulation pain therapy in combination with intensive physiotherapy|"Neuromodulation: Spinal cord stimulation affects nerve tissues with a defined electrical current. We will use low-voltage electrical stimulation of the posterior roots of the spinal cord in the MRI region of the localized conus medullaris. Electrodes are inserted epidurally from a laminotomy in the lumbosacral region.~Physiotherapy will be based on recommendations for spinal patients."
223467494|NCT05646030|DIAGNOSTIC_TEST|TAP-II|The TAP-II device will be compared to lancet capillary sampling and the venipuncture
223467495|NCT05646030|DIAGNOSTIC_TEST|Lancet capillary sampling|The lancet capillary sampling will be compared to TAP device and the venipuncture
223578047|NCT02546440|DRUG|Dimethyl fumarate|dose escalation from 30 mg/d to maximally 720 mg/d over 9 weeks, then continuing with the highest tolerated dose following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until either progression or unacceptable side effects occur
223578048|NCT00293709|DRUG|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
223578049|NCT04355858|DRUG|SHR7390|MEK1/2 inhibitor
223578050|NCT04355858|DRUG|Famitinib|Multi-target tyrosine kinase inhibitor
223578051|NCT04355858|DRUG|SHR3162|PARP inhibitor
224158669|NCT04481724|DIETARY_SUPPLEMENT|gamma-linolenic acid|3 capsules per day of GLA for 24 months
224158670|NCT04481724|DIETARY_SUPPLEMENT|placebo|3 capsules per day of placebo for 24 months
223578052|NCT04355858|DRUG|Pyrotinib|HER1 / HER2 receptor tyrosine kinase inhibitor
223578053|NCT04355858|DRUG|Capecitabine|In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.
224158671|NCT02773368|DRUG|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
224158672|NCT02773368|DRUG|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
224158673|NCT02776852|DRUG|Coppertone (BAY987517)|Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number: SR15-43-Y65-158)
224158674|NCT03616262|DRUG|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
224158675|NCT03616262|DRUG|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
224158676|NCT01935570|DRUG|Magnesium chloride (ChronoMag Smart Tablet®)|
224158677|NCT01935570|DRUG|Magnesium carbonate (Mag2® Tablet)|
224158678|NCT05784103|DEVICE|Clarifi Modulum|During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
223467496|NCT05646030|DIAGNOSTIC_TEST|Venipuncture|The venipuncture will be compared to TAP device and the lancet capillary sampling
223467497|NCT06152185|BEHAVIORAL|Mindfulness Training|The mindfulness intervention includes 28 daily 20-minute audio lessons plus brief daily practice prompts. The first 14 lessons train techniques for developing foundational mindfulness skills through didactics and guided practice; the second 14 lessons review these techniques through guided practice. Based on the Unified Mindfulness system, lessons train 3 mindfulness skills: concentration, sensory clarity, and equanimity. Concentration, a state of stable attention, enables participants to monitor present-moment physical and emotional body experiences. Sensory clarity, the monitoring of momentary experiences, involves detecting subtle sensations and discriminating between different experiences. Equanimity, an attitude of acceptance toward momentary experiences, is trained through 3 strategies: (a) body relaxation, (b) mental welcoming, and (c) a gentle tone of voice. Practice prompts delivered 3 times daily encourage participants to practice brief moments of mindful awareness.
223578054|NCT04355858|DRUG|SHR1210|PD-1 antibody
223578055|NCT04355858|DRUG|Everolimus|mTOR inhibitor
223578056|NCT04355858|DRUG|Nab paclitaxel|Albumin bound paclitaxel
223578057|NCT04355858|DRUG|SHR2554|EZH2 inhibitor
223578058|NCT04355858|DRUG|SHR3680|AR inhibitor
224303619|NCT00328016|DEVICE|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
223578059|NCT04355858|DRUG|SHR6390|CDK4/6 inhibitor
223578060|NCT04355858|DRUG|SHR1701|anti-PD-L1/TGF-βRII bifunctional fusion protein
223578061|NCT04355858|DRUG|SERD|Fulvestrant
223578062|NCT04355858|DRUG|AI|aromatase inhibitor
223578063|NCT04355858|DRUG|VEGFi|Bevacizumab
223578064|NCT03275688|DIAGNOSTIC_TEST|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
223578065|NCT02088073|DRUG|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
223578066|NCT02088073|DRUG|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
223578067|NCT02783378|DRUG|Gaviscon Syrup|
223578068|NCT04589351|DRUG|Ezetimibe 10mg|Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.
223578069|NCT04589351|DRUG|Placebo|Matching placebo
224303620|NCT04607330|OTHER|High protein liquid|After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
223467498|NCT06152185|BEHAVIORAL|Enhanced Usual Care|Participants in the EUC condition will have no study requirements during the 4-week intervention period, but they will receive a list of stress management resources upon randomization (websites, books, health tracking apps, and mental health services) with no additional intervention support.
223467499|NCT06139354|BEHAVIORAL|decision aid|"A digital, interactive patient-provider HIV PEP decision aid. The decision aid will incorporate five sections of content: 1) key clinical factors input by providers; 2) tailored HIV risk sharing information; 3) standardized multimedia educational messaging regarding the effectiveness, risks, and benefits of HIV PEP; 4) direct comparisons of priorities (e.g., physical well-being - I want to do everything I can to prevent HIV, privacy - I don't want others to know about the exposure, or cost - I can't afford the pills'') completed by patients; and 5) tailored feedback regarding patient priorities for use in shared clinical decision making."
224303621|NCT01716624|DRUG|Oxybutynin|standard oral therapy
223578070|NCT03197974|BEHAVIORAL|Mindfulness for Bipolar|Brief online self-management program with email coaching support
223578071|NCT03197974|BEHAVIORAL|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
223578072|NCT03730831|BEHAVIORAL|Narrative Exposure Therapy|"8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder."
223578073|NCT04993729|DRUG|T89 capsule|"T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~T89 capsules, p.o. TID."
223578074|NCT04993729|DRUG|Placebo capsule|Placebo capsules, p.o. TID.
224303622|NCT01716624|DRUG|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
224303623|NCT02229123|DRUG|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
224303624|NCT05924854|OTHER|electroacupuncture|"Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints). Equipment used in the trial included:~1. Huatuo brand copper filiform needle (diameter: 0.35×50mm), Suzhou Medical Supplies Factory, Food and Drug Administration firearms production: Suzhou Food and Drug Administration firearms production No. 20010020.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675"
223467500|NCT06327490|PROCEDURE|ICG-guided manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using ICG lymphography images of the lymphatic pathway in their affected arm as guidance once daily for 2 years post-surgery.
223467501|NCT06327490|PROCEDURE|Traditional manual lymphatic drainage|Participants will perform manual lymphatic drainage on their affected arm using traditional technique once daily for 2 years post-surgery.
223578075|NCT03467490|BEHAVIORAL|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
223578076|NCT03552211|DRUG|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
223578077|NCT03552211|OTHER|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
224068376|NCT01972893|DRUG|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
224068377|NCT01982292|DRUG|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
224068378|NCT01982292|DRUG|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
224068379|NCT00720603|DRUG|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
224068380|NCT02195752|OTHER|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
223467502|NCT06327490|DRUG|Indocyanine green|All participants will be injected with indocyanine green for lymphatic mapping of the affected upper extremity, however this mapping will only be used to guide manual lymphatic drainage for participants on the ICG-guided manual lymphatic drainage arm.
224068381|NCT00891605|DRUG|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
224068382|NCT00891605|DRUG|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
224068383|NCT04320238|DRUG|recombinant human interferon Alpha-1b|recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.
224068384|NCT04320238|DRUG|thymosin alpha 1|thymosin alpha 1 subcutaneous injection 1 time per week.
223578078|NCT01804582|OTHER|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
223578079|NCT05135195|OTHER|In-House Developed VR Platform - AMD, DR, Glaucoma|Participants will conduct experiments using commercial VR headsets and controllers. Visual impairments will be systematically simulated in VR. There are three visual impairment simulations (AMD, DR, and glaucoma) at three levels of severity (mild, moderate, or severe). Symptoms' simulation tools include a gaussian blur shader, distortion shader, and a culling mask with a gray spot in the middle.
223467503|NCT05582343|BEHAVIORAL|MINDBODYSTRONG™|"Digitalized MINDBODYSTRONG™ is designed for self-paced weekly use via an online platform.~MINDBODYSTRONG© Session Content~1. Thinking, feeling, \& behaving, The ABCs of CBT, Mindfulness Skills Building: Positive self-talk/The ABCs~2. Self-esteem \& positive self-talk, Intentional gratitude, Managing change Skills building: Self-esteem \& positive self-talk~3. Stress, Healthy coping, Abdominal breathing Skills Building: Managing stress~4. Problem solving, Setting goals, Steps to problem solving Skills building: Strategies to overcoming barriers~5. Dealing w/ emotions in healthy ways, Using guided imagery, Coping strategies, Effective communication Skills building: Dealing with emotions~6. Coping w/ stressful situations/valuable sleep Skills building: Coping w/ stressful situations~7. Distress tolerance \& added emotional regulation skills Skills bulding: RAIN practice, Self-love skill, Distracting using ACCEPTS~8. Putting it all together for a healthy YOU!"
223467504|NCT05589753|OTHER|Hyperoxia|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.
223467505|NCT05589753|DRUG|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
223467506|NCT05930678|PROCEDURE|No ventilation with face mask|During the period of apnea (in general anesthesia), the patient did not help with face mask
223467507|NCT05930678|PROCEDURE|Ventilation with face mask|During the pperiod of apnea (in general anesthesia), the patient did help with face mask
223467508|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with limited number of TEE clips|The intervention group would be limited to fewer than 20 TEE clips per case (versus the average of \~ 80-100 TEE clips per case).
223467509|NCT06089434|DIAGNOSTIC_TEST|Transesophageal Echocardiography (TEE) with number of TEE clips per attending anesthesiologist|The control group would leave the number of TEE clips to the discretion of the attending anesthesiologist.
223467510|NCT05867134|BEHAVIORAL|Removal of postoperative lifting restrictions|"Patients will be randomized into one of two groups: a control group told to practice standard of care at Eastern Colorado VA with return to activity precautions (6 weeks for open surgery, 2 weeks for minimally invasive surgery) and a treatment group told to return to activity as tolerated/comfortable and stop activity if pain present."
223467511|NCT04312243|DRUG|Inhaled nitric oxide gas|Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
223467512|NCT01091246|BIOLOGICAL|Q/LAIV (MEDI3250)|10 \^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
223467513|NCT01091246|BIOLOGICAL|FluMist/B/Yamagata|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
223578080|NCT05135195|OTHER|In-House Developed VR Platform - Glaucoma|In the second set of experiments, a multidimensional visual impairment simulation of a single pathology (glaucoma) will be used at three levels of severity (mild, moderate, or severe). The post-processing package to simulate includes glare, difficulty in light, change adaptation, ambient occlusion, visual clutter, and overall blurred effect. The shader graph package will be used to create a distortion localized on assets surfaces only.
223578081|NCT04634708|OTHER|No intervention|No intervention due to observational design
223578082|NCT00344734|DRUG|Ng-monomethyl-L-arginine (drug)|
223578083|NCT03604874|DRUG|Oxytocin|intravenous infusion
223578084|NCT02046174|BIOLOGICAL|RENCA macrobeads|
223578085|NCT05180318|DRUG|Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]|Esketamine (0.25 mg/kg) will be given intravenously 24-36 hours before surgery (infusion time: 40 min) and immediately after surgery (infusion time: 40 min).
223578086|NCT05180318|DRUG|0.9% saline|0.9% saline
224158679|NCT05784103|DEVICE|Perimed PeriFlux 5000|Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
224158680|NCT05784103|DEVICE|Apple Watch Oxygen Sensor|The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
223467514|NCT01091246|BIOLOGICAL|FluMist/B/Victoria|10 \^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
223467515|NCT04916717|OTHER|Counseling|Face-to-face and telephone counseling were applied to individuals in the intervention group.
224158681|NCT05784103|DEVICE|Innovo iP 900AP|The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
224158682|NCT04767776|DRUG|Rivaroxaban|rivaroxaban 40 mg/day (1 day).
224158683|NCT04767776|DRUG|Activated charcoal|Activated charcoal 2 hours after rivaroxaban administration (1 day).
224158684|NCT01789255|DRUG|vorinostat|Given PO
224158685|NCT01789255|DRUG|tacrolimus|Given IV or PO
224158686|NCT01789255|DRUG|cyclosporine|Given IV or PO
224158687|NCT01789255|DRUG|methotrexate|Given IV
224158688|NCT01789255|OTHER|laboratory biomarker analysis|Correlative studies
224158689|NCT01789255|OTHER|pharmacological study|Correlative studies
223467516|NCT01217827|BEHAVIORAL|Clinical Reminder|
223467517|NCT00768690|DRUG|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
224158690|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
224158691|NCT02635867|PROCEDURE|Indirect Pulp capping-Calcium hydroxide - Dycal|Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
224158692|NCT02635867|PROCEDURE|Indirect Pulp capping-Resin-based dentin bonding agent|Use of a dental restorative protocol using resin-based dentin bonding system only
224158693|NCT02635867|PROCEDURE|Direct Pulp capping-Resin-modified calcium silicate - TheraCal|Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material
224158694|NCT02635867|PROCEDURE|Direct Pulp capping-Calcium hydroxide - Dycal|\\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
224303625|NCT03713775|OTHER|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
224303626|NCT03713775|OTHER|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
223467518|NCT00768690|DRUG|ketoconazole|Tablet, see arms for intervention description
223467519|NCT00768690|DRUG|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
223467520|NCT03345381|OTHER|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.
224158695|NCT01866813|BEHAVIORAL|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
224158696|NCT04693312|DRUG|Depo medrol|local injection
223467521|NCT03345381|OTHER|Usual care|Treatment as usual
223578087|NCT00016744|DRUG|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
224158697|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
224158698|NCT00748332|DIETARY_SUPPLEMENT|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
224158699|NCT05067114|DEVICE|Screening, detection and referral for atrial fibrillation|In-pharmacy cardiovascular risk assessment plus AliveCor KardiaMobile reading
224158700|NCT06950034|BIOLOGICAL|STX-0712|STX-0712 is IV administered every 21 days until the patient discontinues treatment.
224158701|NCT05068999|DEVICE|shear wave elastography|"Shear wave elastography (SWE) is an emerging technology that provides information about the inherent elasticity of tissues by producing an acoustic radiofrequency force impulse, sometimes called an acoustic wind, which generates transversely-oriented shear waves that propagate through the surrounding tissue and provide biomechanical information about tissue quality. Although SWE has the potential to revolutionize bone and joint imaging, its clinical application has been hindered by technical and artifactual challenges. Many of the stumbling blocks encountered during musculoskeletal SWE imaging are readily recognizable and can be overcome, but progressive advances in technology and a better understanding of image acquisition are required before SWE can reliably be used in musculoskeletal imaging."
224158702|NCT00064636|DRUG|VELCADE TM (bortezomib) for Injection, or PS-341|
224158703|NCT02762136|DRUG|placebo|
224158704|NCT02762136|DRUG|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
224303627|NCT01751932|DEVICE|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
224303628|NCT00460538|DIETARY_SUPPLEMENT|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
224303629|NCT00460538|DIETARY_SUPPLEMENT|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
224303630|NCT05200897|DEVICE|Transdermal trigeminal electrical neuromodulation(Cefaly)|The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
223467522|NCT03890458|DRUG|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
223467523|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
223578088|NCT00016744|DRUG|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
223578089|NCT00016744|DRUG|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
223578090|NCT00408096|PROCEDURE|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
223578091|NCT00921414|DRUG|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
223578092|NCT00921414|OTHER|Watch and wait|No treatment patient follow-up every 2 months during 3 years
223578093|NCT06045182|PROCEDURE|Maitland mobilization|Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.
223578094|NCT06045182|PROCEDURE|Piriformis stretch|Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.
223578095|NCT06045182|PROCEDURE|Electrotherapy|Hot pack and TENS for 10 min
223578096|NCT02227823|DRUG|Pyridostigmine Bromide|
224158705|NCT02918422|OTHER|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
224158706|NCT01782885|PROCEDURE|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
224158707|NCT01782885|DRUG|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
224158708|NCT04605185|DRUG|Donafenib Tosilate Tablets|100mg Qd/150mg Qd/100mg Bid, po
224158709|NCT04605185|BIOLOGICAL|Toripalimab Injection|240 mg, iv drip,q3w
224303631|NCT03260985|OTHER|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
224303632|NCT03112785|DEVICE|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
223467524|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
223467525|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
223467526|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
223578097|NCT02252601|OTHER|HFDT test|
223578098|NCT02252601|OTHER|Pure tone Audiogram|
223578099|NCT02118597|DRUG|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
223578100|NCT02118597|DRUG|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
223578101|NCT02118597|DRUG|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
223578102|NCT02118597|DRUG|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
223578103|NCT03184363|DRUG|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
223578104|NCT05853315|PROCEDURE|Surgery|Surgical Excision
223578105|NCT04931290|PROCEDURE|Supracapsular Ahmed Glaucoma Valve plate delivery technique|incision of the perilimbal superior temporal conjunctiva with separation of the conjunctiva from the Tenon's capsule till reaching the encapsulated valve plate. Incision of the capsule in a z pattern will be done then the plate is dissected from the tissues and delivered out of the capsule through the opening to the subconjunctival space.The mobility of AGV and its tube will be evaluated and refixation of the plate will be done if needed. The plate will be covered with ologen implant sizing 12mm width and 1 mm thickness. The conjunctiva will be closed by 10/0 nylon sutures.
223578106|NCT01891344|DRUG|Oral rucaparib|600 mg BID
223578107|NCT01414764|OTHER|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
223578108|NCT01414764|DRUG|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~* First injection at approximately 10 days post-operatively~* Second Injection at approximately 21 days post-operatively"
224158710|NCT04587895|BEHAVIORAL|VITAAL Exergame|12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
224158711|NCT04587895|BEHAVIORAL|Conventional Training UI|12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
223467527|NCT03871192|DIAGNOSTIC_TEST|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
224158712|NCT04587895|BEHAVIORAL|Conventional Training MI|"12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu)."
224158713|NCT02575989|OTHER|1: control group|Classic - current management of trauma patients by French medical teams
224158714|NCT02575989|OTHER|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)"
224158715|NCT00329784|BIOLOGICAL|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
224158716|NCT06298760|COMBINATION_PRODUCT|Knee Massage With Black Cumin Oil Group:|The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.
224158717|NCT06298760|COMBINATION_PRODUCT|Foot Reflexology Group With Black Cumin Oil|The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.
224158718|NCT06298760|COMBINATION_PRODUCT|placebo group|Applications were made with vaseline
224158719|NCT00809510|DRUG|ABT-089|20 mg ABT-089 taken once-daily for 6 months
224158720|NCT04741087|DRUG|AMT-101 (oral)-Dose A|AMT-101 is an orally administered biologic therapeutic, taken once daily.
224158721|NCT04741087|DRUG|AMT-101 (oral)-Dose B|AMT-101 is an orally administered biologic therapeutic, taken once daily.
224158722|NCT02884128|DRUG|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
224158723|NCT02884128|DRUG|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
224158724|NCT02884128|DRUG|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
224158725|NCT03858569|PROCEDURE|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
224158726|NCT02353403|OTHER|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
224158727|NCT02353403|OTHER|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
224158728|NCT00838383|DRUG|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
224158729|NCT00838383|DRUG|sitaxsentan (Thelin)|Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
224158730|NCT00838383|DRUG|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
224158731|NCT03293628|PROCEDURE|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
224303633|NCT06160297|PROCEDURE|Modified Otago Exercise|"The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking"
224303634|NCT06160297|PROCEDURE|Neuromuscular Exercise|"* Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair"
223467528|NCT03871192|DIAGNOSTIC_TEST|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
223467529|NCT00120471|DRUG|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
223467530|NCT00120471|DRUG|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
223467531|NCT00120471|DRUG|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
224158732|NCT00003340|DRUG|cyclophosphamide|
223467532|NCT05447065|DIETARY_SUPPLEMENT|Vitamin D supplement|Only the experimental group (D) received the vitamin D supplement.
223467533|NCT02700048|DRUG|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
224158733|NCT00003340|DRUG|topotecan hydrochloride|
224158734|NCT02216890|DRUG|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
224158735|NCT04443296|DRUG|CCRT+TIL|Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
224158736|NCT01436695|DEVICE|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
224158737|NCT00832481|DRUG|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
224158738|NCT00832481|DRUG|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
224158739|NCT03986242|DEVICE|rolling|use non- vibration rolling and the total time is 20 minutes.
224158740|NCT03986242|DEVICE|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
224158741|NCT03986242|OTHER|static stretching|static stretching and the total time is 20 minutes.
224158742|NCT02855112|BIOLOGICAL|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
224158743|NCT03355768|DRUG|Romidepsin|Intravenous administration on a 28 day cycle
223467534|NCT02700048|DRUG|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
224158744|NCT03355768|DRUG|Pralatrexate|Intravenous administration on a 28 day cycle
224158745|NCT00924729|DRUG|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
223467535|NCT06091566|DEVICE|UCon-Bar|The participant self-administer electrical stimulation to the dorsal genital nerve (DGN) for either 4 weeks or 12 weeks using UCon with the Bar electrode
224158746|NCT00924729|DRUG|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
224158747|NCT00263315|DRUG|nebulised liposomal amphotericin B|
224158748|NCT01043783|OTHER|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
224158749|NCT00190645|DRUG|Duloxetine|
224158750|NCT04506944|OTHER|No intervention|No specific exposure is explored.
224158751|NCT01482468|DRUG|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
224158752|NCT01482468|DRUG|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
224158753|NCT02620735|DEVICE|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
224158754|NCT02620735|BEHAVIORAL|Exercise Only|12 week exercise program
224158755|NCT02620735|BEHAVIORAL|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
224158756|NCT02620735|BEHAVIORAL|Health Coaching|10 over the phone health coaching sessions.
224158757|NCT01191281|BEHAVIORAL|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
224158758|NCT01191281|OTHER|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
224158759|NCT00003551|DRUG|aminocamptothecin colloidal dispersion|
224158760|NCT00822562|OTHER|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
224158761|NCT00822562|PROCEDURE|surgery|only surgery
224158762|NCT00308243|DRUG|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
223467536|NCT02740816|OTHER|Comparative blood analysis|Collection of menstrual blood and systemic blood
224158763|NCT01674192|DRUG|prucalopride|single dose of 2 mg prucalopride
224158764|NCT01676441|DRUG|cellgram-spine|Mesenchymal stem cells transplantation
224158765|NCT04883567|DIAGNOSTIC_TEST|The use of artificial intelligence system Cerebro|The artificial intelligence system Cerebro would be used during OGD
224158766|NCT00642967|DRUG|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
224303635|NCT03576482|OTHER|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
223467537|NCT02175225|DRUG|Deferoxamine Mesylate|
223467538|NCT02175225|DRUG|Placebo (for Deferoxamine Mesylate)|
223467539|NCT04028362|DRUG|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
223467540|NCT04191889|COMBINATION_PRODUCT|Hepatic Arterial Infusion combined with Apatinib and Camrelizumab|"Drug: FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets~Procedure:~1. On the first day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX7, oxaliplatin 85 mg/m2 2 hours, folinic acid 400 mg/m2, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 6 times.~2. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on day 8 in the first HAIC cycle, once a day, for continuous medication.~3. The first dose of Camrelizumab was administered on day 4 of the second HAIC cycle, at a dose of 200 mg intravenously, every three weeks.~4. The cumulative maximum drug use period is up to 2 years. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear."
223467541|NCT00284921|DRUG|Enteric-coated Mycophenolate sodium (EC-MPS)|
223467542|NCT02668640|BIOLOGICAL|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
223467543|NCT04877990|DRUG|Deucravacitinib|Specified dose on specified days
223467544|NCT00298064|GENETIC|Tissue Repository|
223467545|NCT01707641|DIETARY_SUPPLEMENT|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
224158767|NCT03689881|DEVICE|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
224158768|NCT03815812|DRUG|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
224158769|NCT03815812|DRUG|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
224158770|NCT02899260|DEVICE|Peanut Exercise Ball|A Peanut shaped exercise ball.
224158771|NCT03626480|OTHER|No treatment|No treatment
224158772|NCT04165005|BEHAVIORAL|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
224158773|NCT04165005|BEHAVIORAL|guided imagery|relaxing guided imagery including breathing exercises.
224158774|NCT01915095|DEVICE|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
224158775|NCT01915095|DEVICE|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
223467546|NCT01707641|OTHER|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
224158776|NCT01915095|OTHER|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
223467547|NCT06749210|BEHAVIORAL|Tango|The intervention being studied is a 16 session intervention (2x4-week modules), delivered over an 8-week period by community-based individuals with expertise in dance and patient care and certified in Adapted Tango or AdapTango dance instruction. Steps available to teach, including order and cues to teach them, are detailed in Hackney's AdapTango manual. All steps are based on the Argentine Tango steps that emerged within working class community centers in Buenos Aires, Argentina (milongas) in the late 1800s and have been adapted by the investigators for use as medical exercise among people with mobility deficits. Of note, Argentine Tango is distinct from, and the precursor for, the American Tango style of competitive ballroom dance: where American Tango highlights showmanship and complicated footwork, Argentine Tango prioritizes connection between partners and musicality within a basic walk motion.
223467548|NCT03429621|DRUG|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
223467549|NCT01635621|DRUG|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~* OKZ 120 mg every 2 weeks~* OKZ 240 mg every 2 weeks~* OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
224158777|NCT01915095|OTHER|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
224158778|NCT01911208|BEHAVIORAL|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
224158779|NCT01911208|BEHAVIORAL|Control|Non-intervention control.
224158780|NCT00044655|DRUG|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
224158781|NCT00044655|DRUG|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
224158782|NCT00044655|DRUG|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
224158783|NCT00044655|DRUG|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
224158784|NCT00044655|DRUG|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
224158785|NCT04593836|DRUG|L-menthol|20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
224158786|NCT04593836|DRUG|Placebo|20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
224158787|NCT05560152|DRUG|Yiqihuayu Decotion|Per os, twice a day, for 7 days.
224158788|NCT02213549|DIETARY_SUPPLEMENT|Placebo|
224158789|NCT02213549|DIETARY_SUPPLEMENT|Ume paste and ginger powder|
223467550|NCT01635621|DRUG|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
223467551|NCT00847418|DRUG|esketamine hydrochloride|
223467552|NCT01775423|DRUG|BBI608|
223467553|NCT06333886|DEVICE|Sacral electromyography|Assessment of neuro-sacral function using point-of-care sacral surface electromyography
224158790|NCT03489070|COMBINATION_PRODUCT|Traumastem®|Intraoperative application as secondary hemostatic treatment
224158791|NCT03489070|COMBINATION_PRODUCT|Surgicel®|Intraoperative application as secondary hemostatic treatment
224158792|NCT02067533|PROCEDURE|soft tissue repair in flexion position|
224158793|NCT02067533|PROCEDURE|soft tissue repair in extension position|
224158794|NCT01983878|DRUG|Ramucirumab|Administered IV
224158795|NCT02087293|BEHAVIORAL|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
224158796|NCT04854577|PROCEDURE|Opioid Free Anesthesia|Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
224303636|NCT02395952|DRUG|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
223467554|NCT02007720|DRUG|Serelaxin|Intravenous infusion
223467555|NCT02007720|DRUG|Placebo|Intravenous infusion
223467556|NCT02007720|OTHER|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
223467557|NCT06467695|DEVICE|BIOPAC Stimsola|Transcranial Electrical Stimulator
224158797|NCT04854577|PROCEDURE|Traditional Anesthetic Regimen|Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
224158798|NCT01693497|BEHAVIORAL|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
224158799|NCT01693497|BEHAVIORAL|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
224158800|NCT01873807|DRUG|IDA|Idarubicin: 15mg/m2/d: -8-\>-6d
224158801|NCT01873807|RADIATION|TBI|TBI: 4.5 Gy/d, -5d, -4d
224158802|NCT01873807|DRUG|CTX|CY:60mg/kg/d, -3d, -2d
224303637|NCT02395952|DEVICE|Acuvue Oasys Bandage Contact Lens|
224303638|NCT02395952|DEVICE|Ambiodisk|
224303639|NCT02395952|DEVICE|Prokera|
224303640|NCT05669963|DRUG|lactoferrin|"study grop receiving lactoferrin (2 capsules/day for 5 days followed by further 10 consecutive days at the dosage of 1 capsule/day) by oral intake.(pravotin).~And another group not reciving lactoferrin.(control group) During follow-up period, all women ingested 1 capsule of lactoferrin or placebo per day, for 10 consecutive days per month."
224158803|NCT01873807|DRUG|VP-16|VP-16: 15mg/kg, -2d, -1d
224158804|NCT03454945|DRUG|Vibramycin|Antibiotic
223467558|NCT06467695|DEVICE|BIOPAC Stimsola Sham (zero amps)|Transcranial Electrical Stimulator set to 0 amps
224158805|NCT03454945|DEVICE|Phototherapy|UVA+Psoralen
224158806|NCT00004898|BIOLOGICAL|filgrastim|
224158807|NCT00004898|DRUG|cyclophosphamide|
224158808|NCT00004898|DRUG|etoposide|
224158809|NCT00004898|PROCEDURE|peripheral blood stem cell transplantation|
224158810|NCT00004898|RADIATION|radiation therapy|
223467560|NCT07064902|DRUG|Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）|Ivonescimab (AK112) is a novel PD-1/VEGF bispecific antibody designed to simultaneously block PD-1-mediated immune evasion and inhibit VEGF-driven angiogenesis. In this study, ivonescimab is administered intravenously at a dose of 10 mg/kg every 3 weeks, starting on Day 1 of induction chemotherapy (3 cycles), followed by concurrent chemoradiotherapy (no ivonescimab), and then continued as adjuvant monotherapy for 9 additional cycles.
223467561|NCT07066566|DEVICE|Asymmetric nasal cannula - DUET|DUET asymmetric nasal high flow interface that fits best to patients' nostrils (size: one nostril of the patient should be fully occluded) Patients will be crossed - over between the 2 interventions
223467562|NCT07066566|DEVICE|Conventional nasal high flow cannula|Well - established conventional nasal high flow cannula (size: medium) Patients will be cross - over between the 2 interventions
223467563|NCT07073534|DRUG|SHR-1501, Adebrelimab|the combination of SHR-1501 and Adebrelimab
223467564|NCT07073430|DEVICE|AI models with NBI|AI models for detecting intestinal adenoma in magnifying endoscopy with NBI.
223467565|NCT07072520|BEHAVIORAL|Questionnaire|Questionnaire including sociodemographic characteristics and dietary assessment
223467566|NCT07072520|OTHER|Body composition assessment|Body Composition Assessment via bioelectrical impedance analysis (BIA)
223467567|NCT07072351|RADIATION|hypofractionated radiotherapy|In Phase Ib, HFRT will be administered at one of three dose levels: 3 Gy × 5 fractions, 4 Gy × 5 fractions, or 5 Gy × 5 fractions. The recommended dose determined in Phase Ib will be used in Phase II (delivered as 5 fractions).
223467568|NCT07072351|DRUG|SOX Chemotherapy|SOX chemotherapy regimen: Oxaliplatin 130 mg/m² administered by intravenous infusion on Day 1; S-1 administered orally for 14 consecutive days followed by a 7-day rest period. The dosage of S-1 is based on body surface area (BSA): 40 mg twice daily for BSA ≤1.5 m², 50 mg twice daily for BSA between 1.5-1.6 m², and 60 mg twice daily for BSA ≥1.6 m². Each cycle is repeated every 3 weeks.
223467569|NCT07072351|DRUG|PD-1 inhibitor|Sintilimab 200 mg administered by intravenous infusion on Day 1 of each 3-week cycle.
223467570|NCT07073833|DRUG|IBR900 cell injection|NK cells
223467571|NCT07073833|DRUG|rituximab|CD20 antibody
223467572|NCT01386606|DRUG|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
223467573|NCT01386606|DRUG|Testosterone|"topical gel~1X a day 6 weeks"
223467574|NCT06516640|BEHAVIORAL|Continuous Glucose Monitoring Academy|Educational materials as well as online sessions with diabetes educators.
223467575|NCT06516640|BEHAVIORAL|Standard Education|Standard of care receives general education about diabetes.
223467576|NCT02687672|BIOLOGICAL|Stem Cell Transplantation|Transplantation of autologous stem cells
223467577|NCT02637596|PROCEDURE|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
223467578|NCT04980014|DRUG|NesinaAct® Tablet|NesinaAct® tablet is a fixed dose combination (FDC) of alogliptin benzoate with pioglitazone HCl.
223578109|NCT00902018|DRUG|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
224158811|NCT06134869|PROCEDURE|Bone augmentation|Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
224158812|NCT02024945|DRUG|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
224158813|NCT03063398|DIAGNOSTIC_TEST|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
224158814|NCT00639496|DRUG|n-acetylcysteine|600 mg x 3, for 12 months
224158815|NCT00639496|DRUG|placebo|Placebo
224158816|NCT05702398|DRUG|Vitamin A|1,000 μg retinyl palmitate twice a day for 6 months
224158817|NCT05702398|DRUG|Nicotinamide|500 mg NAM twice a day for 6 months
224158818|NCT05702398|OTHER|Other: Placebo|Identical placebo pills twice a day
224158819|NCT04657445|DIAGNOSTIC_TEST|visual analogue scale|A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
224158820|NCT01670682|PROCEDURE|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
224158821|NCT01670682|PROCEDURE|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
224158822|NCT01670682|DEVICE|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
224158823|NCT03343782|COMBINATION_PRODUCT|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
224158824|NCT01577004|DIETARY_SUPPLEMENT|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
224158825|NCT05954260|DIAGNOSTIC_TEST|Blood sampling|We will collect blood samples from the patients included in the study on ICU days 1, 3 and 5. We will measure gene expression (mRNA) and plasma levels of various elements involved in the immunological synapse.
223467579|NCT05187221|BEHAVIORAL|CVS Group|CVS-F4 will be an online survey via the SurveyMonkey Company. The participants will report their potential CVS complains and associated screen factors as screen-time, screen-size, screen-resolution and other factors. We will collect the responses and analyse the results. Informed consent will be obtained from the participants as an item within the survey itself that he/she agrees to use his/her data in this research work. This group will contain participants with CVS complains.
223578110|NCT00902018|DRUG|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
223578111|NCT00902018|OTHER|healthy controls|single blood draw for all measures included in the intervention arms
223578112|NCT05361499|BIOLOGICAL|Sp_6B|Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)
223578113|NCT05361499|DRUG|Amoxicillin 500 mg|Amoxicillin, 7 days, 2x 500 mg
223578114|NCT01903395|BEHAVIORAL|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
223578115|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
223578116|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
223578117|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
223578118|NCT01497509|DRUG|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
224158826|NCT02081560|DRUG|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
224158827|NCT05522296|DRUG|Mpox Vaccine|Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
224158828|NCT01907776|DRUG|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
224158829|NCT01907776|DRUG|ME1100 placebo inhalation solution|Vehicle placebo
224158830|NCT02333669|OTHER|no intervention|no intervention
224158831|NCT05018169|BEHAVIORAL|BA-A|Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.
223578119|NCT02588703|BEHAVIORAL|Cognitive Behavioral Therapy|Coping Skills Treatment
223578120|NCT02588703|BEHAVIORAL|Usual Care|Existing DUI program group counseling
223578121|NCT03067493|BIOLOGICAL|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
223578122|NCT00121394|PROCEDURE|Chlorhexidine vaginal and infant wash|
223578123|NCT00387374|BIOLOGICAL|bevacizumab|Given IV
223578124|NCT00387374|DRUG|paclitaxel|Given IV
223578125|NCT00387374|DRUG|carboplatin|Given IV
223578126|NCT00387374|RADIATION|radiation therapy|Undergo radiotherapy
223578127|NCT00221624|DRUG|Peginterferon alfa-2a|
224158832|NCT02999191|DRUG|BI 1467335 (Treatment A)|
223467580|NCT00093522|BIOLOGICAL|autologous tumor cell vaccine|
224158833|NCT02999191|DRUG|BI 1467335 (Treatment B)|
223467581|NCT00093522|BIOLOGICAL|keyhole limpet hemocyanin|
223467582|NCT00093522|BIOLOGICAL|therapeutic autologous dendritic cells|
223467583|NCT00093522|DRUG|fludarabine phosphate|
223467584|NCT00093522|PROCEDURE|conventional surgery|
223578128|NCT00221624|DRUG|ribavirin|
223578129|NCT00221624|DRUG|amantadine|
223467585|NCT02296489|DEVICE|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
223467586|NCT02182310|DRUG|BI 201335 low dose|
223578130|NCT04774900|PROCEDURE|Administration of oxygen|Administration of high-flow oxygen via face mask to a high fidelity mannequin.
223578131|NCT04774900|PROCEDURE|Administration of drug in a nebulizer|Administration of bronchodilator via nebulizer mask to a high fidelity mannequin.
223578132|NCT04774900|PROCEDURE|Securing intravenous line|Securing an intravenous line at the forearm of high fidelity mannequin.
223578133|NCT04774900|PROCEDURE|Administration of IV drug|Administration of bronchodilator via IV line to a high fidelity mannequin.
223578134|NCT04774900|PROCEDURE|Needle decompression of tension pneumothorax|Needle decompression of tension pneumothorax on a high fidelity mannequin.
223578135|NCT05420220|BIOLOGICAL|KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)|5 mg/kg Q3W IV
223578136|NCT05420220|COMBINATION_PRODUCT|Axitinib|5mg bid po
223578137|NCT05694910|OTHER|Reiki|Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
223578138|NCT01975337|DRUG|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
223578139|NCT00186537|DRUG|Rosiglitazone|
223578140|NCT00186537|DRUG|Fenofibrate|
223578141|NCT00186537|BEHAVIORAL|Weight Loss|
223578142|NCT03294135|BIOLOGICAL|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
223578143|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
224158834|NCT02999191|DRUG|BI 1467335 (Treatment C)|
224158835|NCT03966729|OTHER|Time (outcome)|
224158836|NCT01611480|DRUG|Imiquimod (topical use)|
224158837|NCT00200512|DRUG|apomorphine HCl injection|
224158838|NCT01280019|PROCEDURE|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
224158839|NCT03777085|DRUG|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
224158840|NCT03777085|DRUG|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
224158841|NCT03189407|DIETARY_SUPPLEMENT|Moringa oleifera tea|
224158842|NCT05525832|OTHER|Normal saline|Nasopharyngeal washes with NaCl 0.9%
224158843|NCT04269837|OTHER|Counseling|Receive sexual health counseling
224158844|NCT04269837|OTHER|Quality-of-Life Assessment|Ancillary studies
224158845|NCT04269837|OTHER|Questionnaire Administration|Ancillary studies
224158846|NCT05467488|PROCEDURE|photofunctionalization|UVA and UVC photofunctionalization of dental implants
224158847|NCT02408185|DRUG|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
224158848|NCT02408185|DRUG|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
224158849|NCT04516031|PROCEDURE|Posterior Component Separation with Transversus Abdominis Muscle Release|The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.
224158850|NCT04516031|PROCEDURE|Mesh-only repair|The prosthetic mesh only repair was done as described by Wantz in 1991.
224158851|NCT01883804|DRUG|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
224158852|NCT00475371|DRUG|MKC253 Inhalation Powder|Inhalation powder
224158853|NCT05483660|OTHER|Lactobacillus plantarum|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
224158854|NCT05483660|OTHER|Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
224158855|NCT05483660|OTHER|Lactobacillus plantarum + Bacillus coagulans|1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
224158856|NCT05483660|OTHER|Placebo|Adult milk powder 15 g pertime, three times daily and half an hour before meal.
223467587|NCT02182310|DRUG|BI 201335 placebo|
224158857|NCT05057325|OTHER|Pulpectomy using single file system ( One Shape file)|Rotary file instrument for pulpectomy of primary molars ( One shape file)
224158858|NCT05057325|OTHER|Pulpectomy using single file system ( WaveOne Gold file)|Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
224158859|NCT03037567|BEHAVIORAL|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
224158860|NCT01703104|DRUG|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
223467588|NCT02182310|DRUG|Moxifloxacin|
224158861|NCT01703104|DIETARY_SUPPLEMENT|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
224158862|NCT01482455|OTHER|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
224158863|NCT01482455|OTHER|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
224158864|NCT05024617|OTHER|conservative treatment|All patients had rehabilitation for a total of three months, including activity modification, splinting and exercises.
224158865|NCT01786850|PROCEDURE|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
224158866|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
224158867|NCT00820807|OTHER|Novel dietary fiber|oral consumption in beverage
223467589|NCT02182310|DRUG|BI 201335 high dose|
223467590|NCT05743530|DEVICE|TENS - transcutaneous electrical nerve stimulation|Pre-operative day 1 till postoperative day 14.
223467591|NCT05743530|OTHER|Placebo|Pre-operative day 1 till postoperative day 14.
223578144|NCT03342040|PROCEDURE|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
224158868|NCT00820807|OTHER|Placebo|oral consumption in beverage
224158869|NCT02954445|BIOLOGICAL|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
224303641|NCT04116762|DEVICE|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
223467592|NCT05702008|OTHER|Rabies Information Education and Communication Material|The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
223467593|NCT01336725|BEHAVIORAL|Teaching life style changes|Single group: Teaching, group sessions, physical activity
223467594|NCT01336725|OTHER|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
223467595|NCT01336725|OTHER|Teaching|Morbid obesity group attend 40 hours of group sessions
223467596|NCT02668965|PROCEDURE|Intrauterine hCG (pregnyl)|
223467597|NCT02074202|DRUG|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
223467598|NCT02074202|DRUG|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
223467599|NCT05141006|DRUG|BOTOX|Injection into the bladder
223467600|NCT05141006|DRUG|Placebo for BOTOX|Injection into the bladder
223467601|NCT00956436|DRUG|BIIB022|IV Q3W
223467602|NCT00956436|DRUG|Sorafenib|Standard dosing of Sorafenib
223467603|NCT00857506|DRUG|florbetapir F 18|370 Mega Becquerel (10 mCi)
223467604|NCT00313729|DRUG|temozolomide|Chemotherapy
223467605|NCT05871307|RADIATION|Preoperative Radiotherapy|Resection of brain mestases following
223467606|NCT05871307|RADIATION|Intraoperative Radiation|While Resection
223467607|NCT05871307|RADIATION|Postoperative Radiotherapy|After resection
223467608|NCT02601755|BEHAVIORAL|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
223578145|NCT01420874|DRUG|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, \& in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
223467609|NCT02601755|BEHAVIORAL|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
223467610|NCT01009593|DRUG|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
223467611|NCT01009593|DRUG|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
223467612|NCT05260814|DEVICE|Electric toothbrush with smart phone app|Scaling and root planing, oral hygiene instructions with use of Sonicare Diamond Clean Smart®.
223467613|NCT01537224|OTHER|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
223467614|NCT05426746|DRUG|ALT-100|intravenous infusion of drug substance diluted in 0.9% normal sterile saline
223467615|NCT05426746|OTHER|Normal Saline|intravenous infusion of placebo (0.9% normal sterile saline)
223467616|NCT04510272|OTHER|Aloud Real-time Reading of ICU Diaries|Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
223467617|NCT05570448|PROCEDURE|ARAT|For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.
223467618|NCT05570448|PROCEDURE|Sham intervention (control)|Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.
223467619|NCT01965327|DRUG|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
223467620|NCT01837836|BEHAVIORAL|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
223467621|NCT04735705|DEVICE|Cerviron|Cerviron ovules ® is a class IIb medical device indicated as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora. It is also used in cervical lesions of mechanical origin as it favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.
223467622|NCT02546648|DRUG|Tranexamic Acid|
223467623|NCT02546648|DRUG|Tranexamic Acid Placebo|
223467624|NCT02546648|DRUG|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
223467625|NCT02221752|DIETARY_SUPPLEMENT|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.
223467626|NCT02221752|DIETARY_SUPPLEMENT|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
223467627|NCT01645436|OTHER|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
223467628|NCT02130869|BIOLOGICAL|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
223578146|NCT01420874|BIOLOGICAL|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
223578147|NCT02767479|DRUG|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
224158870|NCT06275997|DEVICE|Integration of Artificial Intelligence (AI) assistance to screening gastroscopy|"Two novel deep learning systems, namely one for endoscopy and one for pathology, will be trained and validated for the diagnosis of gastric atrophy and metaplasia, including extension and severity. Both of the algorithms will be validated against the cases not used for the training phases. Approximately, the partition will be 5 to 1.~The benefit and harm of AI-assistance for early diagnosis of gastric cancer will be simulated by developing a Markov model on the natural history of gastric cancer from dysplasia to early and advanced cancer, as well as by the impact of a GS on its natural history. This will also simulate the potential effect of lead- and length-time bias. These data will be incorporated in the simulation model in order to include them in the decision-making process on whether AI-assistance for gastric cancer detection should be or not recommended to health systems."
224158871|NCT04816045|PROCEDURE|Electrochemotheraoy|Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin
224158872|NCT04816045|PROCEDURE|Electroporation with saline (placebo)|Electroporation in the control group is performed endoscopically with saline
224158873|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
224158874|NCT03127553|DIETARY_SUPPLEMENT|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
224158875|NCT05933798|OTHER|ICOPE|The ICOPE approach with locally adapted care pathways was implemented by trained integrated care managers (ICMs) advised by multi-disciplinary teams, delivered in primary care settings
224303642|NCT04116762|DEVICE|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
224303643|NCT00291980|BIOLOGICAL|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
224303644|NCT00291980|BIOLOGICAL|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
224303645|NCT03581409|DRUG|Aspirin|Aspirin protect tablet
224158876|NCT05933798|OTHER|Usual Care|Participants in the Control Group would have their care plan after assessment and seek health and care services as usual without additional advice or support on implementing the care plan
224303646|NCT03581409|DRUG|Prasugrel|Prasugrel tablet
224303647|NCT03581409|DRUG|Clopidogrel|Clopidogrel 75mg tablet
224303648|NCT03581409|DRUG|Cilostazol|Cilostazol tablet
224303649|NCT03759119|BEHAVIORAL|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
223467629|NCT02130869|BIOLOGICAL|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
223467630|NCT02130869|BIOLOGICAL|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
223467631|NCT02130869|DRUG|Busulfan|Given IV - Group A only.
223467632|NCT02130869|DRUG|Melphalan|Given IV - All groups.
223467633|NCT02130869|BIOLOGICAL|GM-CSF|Given SQ - All groups.
223467634|NCT02130869|DRUG|Bendamustine|Given IV - Group B only.
223467635|NCT02130869|DRUG|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
223467636|NCT02130869|DRUG|Cytarabine|Given IV - Group B only.
223467637|NCT02130869|DRUG|Carboplatin|Given IV - Group C only.
223467638|NCT02130869|DEVICE|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
223578148|NCT02767479|DRUG|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
223578149|NCT02763254|BIOLOGICAL|baltaleucel-T|Autologous EBV-specific T cells
224158877|NCT01022645|DEVICE|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
223578150|NCT05223062|OTHER|Disease activity in psoriatic arthritis (DAPSA)|DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).
223578151|NCT05223062|OTHER|Compliance-Questionnaire-Rheumatology (CQR)|"The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100."
223578152|NCT05223062|OTHER|The Brief Illness Perception Questionnaire (BIPQ)|The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.
224158878|NCT01022645|DEVICE|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
224158879|NCT03647176|OTHER|Cold snare polypectomy|cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
223578153|NCT05223062|OTHER|The Beliefs About Medicines Questionnaire (BMQ)|The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.
223578154|NCT05223062|OTHER|Hospital Anxiety and Depression Scale (HADS)|Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
223467639|NCT02130869|BIOLOGICAL|G-CSF|Given SQ - All Groups.
223467640|NCT02130869|DRUG|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
224158880|NCT00805012|DRUG|docetaxel+CDDP|docetaxel+CDDP
224158881|NCT00805012|DRUG|docetaxel+S-1|docetaxel+S-1
224158882|NCT05721196|BEHAVIORAL|Culturally adapted Psychoeducation (CaPE)|This intervention consisted of 12 psychoeducation sessions, one session per week, that would be administered on an individual patient basis and to be added to treatment as usual. Each session lasted for approximately 1 h, beginning with a 20-30 min presentation on the topic of the day, followed by a related exercise (e.g., drawing a life chart or compiling a list of potential triggers for relapse). The content is a reduced and modified version of the Barcelona Psychoeducation Program for bipolar disorders.
224158883|NCT05721196|DRUG|Treatment as Usual (TaU)|This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
224158884|NCT01500941|DIETARY_SUPPLEMENT|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
224158885|NCT01500941|OTHER|maltodextrin|sachets
224158886|NCT01297946|DEVICE|Conventional continuous subcutaneous insulin infusion therapy|
223467641|NCT02130869|DEVICE|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
223467642|NCT04630977|DIETARY_SUPPLEMENT|Multi-ingredient Pre-workout supplement|Every important issue has been detailed before.
223467643|NCT04630977|OTHER|Progressive Resistance Training|The information about it has been detailed in advance.
223467644|NCT04630977|BEHAVIORAL|Nutritional Patterns Guideline|This intervention has also been described in advance.
223467645|NCT00846144|DIETARY_SUPPLEMENT|copper sulfate|copper sulfate 3mg/d for a period of 6 months
224158887|NCT01297946|DEVICE|Dual-hormone closed-loop|
224158888|NCT04121689|DIETARY_SUPPLEMENT|Milk Protein Concentrate|The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-\[1-13C\]phenylalanine and L-\[1-13C\]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
224158889|NCT05826990|DRUG|cefepime and enmetazobactam combination|Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
224158890|NCT03930303|BEHAVIORAL|Multimedia- based patient education|Patients will receive a 5 minutes video education before D\&C
224158891|NCT01847079|OTHER|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
224158892|NCT05410808|OTHER|Questionnaires and physical examination|Patients will be examined and demographic data, disease characteristics will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
224158893|NCT05410808|OTHER|Questionnaire|Demographic data will be recorded. Health Survey Questionnaire Short Form 36 , coronavirus disease 2019 anxiety scale ,Obsession with coronavirus disease 2019 scale, and Resilience scale for adults will be answered
224158894|NCT02597491|BEHAVIORAL|TLC monthly|Tobacco longitudinal care monthly
224158895|NCT02597491|BEHAVIORAL|TLC quarterly|Tobacco longitudinal care quarterly
224158896|NCT02597491|BEHAVIORAL|MTM|Medication management therapy
224158897|NCT02597491|BEHAVIORAL|4 week assessment|4 week assessment
224158898|NCT02597491|BEHAVIORAL|8 week assessment|8 week assessment
224158899|NCT00215592|DRUG|Zonegran|
224158900|NCT02896192|DRUG|Setmelanotide|Once daily SC injection
224158901|NCT02896192|DRUG|Placebo|Once daily SC injection
223467646|NCT03271138|DIETARY_SUPPLEMENT|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10\^9 CFU Bifidobacterium infantis NLS super strain
223467647|NCT03271138|OTHER|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
223467648|NCT03034369|OTHER|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
223467649|NCT03034369|OTHER|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
223467650|NCT03034369|OTHER|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
223467651|NCT03034369|OTHER|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
223467652|NCT03034369|OTHER|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
223467653|NCT03034369|OTHER|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
223467654|NCT03034369|OTHER|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
223467655|NCT03034369|OTHER|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
223467656|NCT03034369|OTHER|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
223467657|NCT03034369|OTHER|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
224158902|NCT02533856|OTHER|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
224158903|NCT00464711|DRUG|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
224158904|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
224158905|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
224158906|NCT00714337|DRUG|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
224158907|NCT05537493|OTHER|Telerehabilitation|It will be followed by exercising on whatsapp
224158908|NCT05537493|OTHER|Face to face|It will be followed by face to face
224158909|NCT01308294|BIOLOGICAL|2 vaccine injections in 1 limb|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
224158910|NCT01308294|BIOLOGICAL|2 vaccine injections in distinct limbs|Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
223467658|NCT03034369|OTHER|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
223467659|NCT03034369|OTHER|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
223467660|NCT03034369|OTHER|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
223467661|NCT04449965|DRUG|Povidone-iodine|This will be performed twice daily for two weeks.
223467662|NCT04449965|DRUG|Placebo|This will be performed twice daily for two weeks.
223467663|NCT03964207|DRUG|Tiotropium Respimat® (T1)|inhalation solution
223467664|NCT03964207|DRUG|Tiotropium Handihaler® (T2)|Inhalation Powder
223467665|NCT02908139|DEVICE|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
223467666|NCT02908139|DEVICE|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
223467667|NCT05606861|OTHER|Mindfulness Based Interventions in Pediatric Nurses|This intervention are structured mindfulness program including meditation and breathing techniques .
223467668|NCT04938791|OTHER|Isometric activity|Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
224158911|NCT01308294|BIOLOGICAL|"2 vaccine injections in distinct limbs"|
224158912|NCT04703062|BEHAVIORAL|Experimental group 1|It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.
224158913|NCT04703062|BEHAVIORAL|Experimental group 2|Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
223467669|NCT03597802|OTHER|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
223467670|NCT03597802|OTHER|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
223467671|NCT04795635|DEVICE|CMM + Axon Therapy|transcutaneous magnetic stimulation (tMS)
223467672|NCT04405258|PROCEDURE|Pulmonary vein isolation|Pulmonary vein isolation, superior vena cava isolation, and cavotricuspid isthmus ablation
223467673|NCT04405258|PROCEDURE|Left posterior wall isolation|Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
223467674|NCT05158621|PROCEDURE|blood collection for research (next generation sequencing [NGS])|participants will have whole blood collected for NGS
223467675|NCT05158621|PROCEDURE|blood collection for research (HLA typing)|participants will have whole blood collected for HLA typing
223578155|NCT05223062|OTHER|The Psoriatic Arthritis Quality of Life (PsAQoL)|The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
223578156|NCT03684304|DEVICE|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
223578157|NCT01143051|DRUG|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
224158914|NCT03615989|BEHAVIORAL|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
223578158|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
223578159|NCT01143051|DRUG|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
223578160|NCT01293643|DRUG|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
223578161|NCT01293643|DRUG|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
223578162|NCT04736160|OTHER|collect data|The data for this project will be obtained directly from the IVI digital work platform (SIVIS) where the characteristics and scans performed to each patient are recorded. Furthermore, it will be recollected information from the time-lapse incubator. For the current study will be used Embryoscope and Geri time-lapse incubators
223578163|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Physics Forceps|Extraction of mandibular molars using physics forceps
224158915|NCT03615989|DIETARY_SUPPLEMENT|Carbohydrate (Maltodextrin powder mixed with water)|50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
224158916|NCT03615989|DIETARY_SUPPLEMENT|Skim Milk|500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
223467676|NCT05158621|PROCEDURE|blood collection for research (circulating tumor DNA [ctDNA])|participants will have whole blood collected for ctDNA detection
223467677|NCT00624091|PROCEDURE|Cardiac surgery|Cardiac surgery within 48 hours of randomization
223467678|NCT00624091|PROCEDURE|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
223578164|NCT04875650|PROCEDURE|Extraction of Mandibular Molar using Conventional Forceps|Extraction of mandibular molars using conventional forceps
224158917|NCT00479167|DRUG|Bortezomib and Tositumomab I-131|
224158918|NCT03064269|BIOLOGICAL|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
224158919|NCT04488757|DIAGNOSTIC_TEST|functional Magnetic Resonance Imaging (fMRI)|Participants will undergo a one hour fMRI scan with pain-induction using heat-based QST protocol.
223467679|NCT02217748|OTHER|Survey questionnaire|
223578165|NCT04381325|DRUG|MSB0254 Injection|"An intravenous infusion with concentration from 4 mg/kg to 16 mg/kg every 2 weeks (Q2W).~An intravenous infusion with concentration 20 mg/kg every 3 weeks (Q3W)."
223578166|NCT00225589|DRUG|Rosuvastatin calcium|
223578167|NCT04830904|DEVICE|personalized Lycra garments|the subjects wear lycra garments during the assessment time and for some days after the assessment
223578168|NCT03036345|DEVICE|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
223578169|NCT00492479|DRUG|Kinerase Pro+Therapy Line day repair, serum, night repair|
223578170|NCT00492479|DRUG|Kinerase Pro+Therapy Line Ultra rich day repair|
223578171|NCT00492479|DRUG|LubriDerm|
223578172|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d
223578173|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
224158920|NCT04488757|OTHER|Allostatic Load Composite|All participants will be asked to provide saliva samples to measure cortisol response over time and dehydroepiandrosterone (DHEA) in addition to physiological measurements such as blood pressure/pulse, height/weight, and waist-hip ratio. Measurements will be taken at baseline and 4-month follow-up.
224158921|NCT04919772|OTHER|Assessment|The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
224158922|NCT01264068|DRUG|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
223467680|NCT02695069|PROCEDURE|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
223467681|NCT02901223|PROCEDURE|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
224158923|NCT02650440|PROCEDURE|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
223467682|NCT02901223|PROCEDURE|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
223467683|NCT06388772|DRUG|QHRD106 Injection|250IU\~8400IU,pegylated(PEG)-tissue kallikrein-1
223467684|NCT06388772|DRUG|placebo|placebo
223467685|NCT00966576|DRUG|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
223467686|NCT05843409|BEHAVIORAL|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction may be associated with short-term effects on pain intensity and physical functioning. Patients will be randomized into 2 groups. The experimental group will receive MBSR sessions, with the frequency and duration specified in the study protocol. The sessions will be free and carried out by expert staff
223467687|NCT01064011|PROCEDURE|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
223467688|NCT01064011|PROCEDURE|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
223467689|NCT02090296|DRUG|Hydroxyurea|
223467690|NCT02090296|OTHER|Placebo|
223467691|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
223467692|NCT01294423|DRUG|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
223467693|NCT01294423|DRUG|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
223467694|NCT05869799|DIETARY_SUPPLEMENT|Vigiis 101 Lactobacillus Capsules|Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.0 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
224158924|NCT02650440|PROCEDURE|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
223467695|NCT05869799|DIETARY_SUPPLEMENT|Placebo Capsules|Maltodextrin was used as a placebo
223467696|NCT02352857|OTHER|Sugar|100g of sponge cakes made with 24g of dextrose.
223467697|NCT02352857|OTHER|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
223467698|NCT01591148|DRUG|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
223467699|NCT04933318|OTHER|TENS|Transcutaneus electrical nerve stimulation (TENS)- analgesic current therapy
223467700|NCT04933318|OTHER|shamTENS|shamTranscutaneus electrical nerve stimulation (shamTENS)- analgesic current therapy
223578174|NCT00272948|DRUG|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
223578175|NCT00450671|PROCEDURE|Collagen Plug Placement|
223578176|NCT00450671|PROCEDURE|Seton placement|
223578177|NCT00872378|DRUG|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
223578178|NCT00872378|DRUG|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
224158925|NCT03702140|DRUG|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
223467701|NCT04933318|OTHER|IFC|Interferential current therapy (IFC)- analgesic current therapy
223467702|NCT04933318|OTHER|shamIFC|shamInterferential current therapy (shamIFC)- analgesic current therapy
223467703|NCT02982707|DRUG|BMS-986177|Single oral dose
223467704|NCT03468088|BEHAVIORAL|Hand grip strengthening|Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction \& with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
223467705|NCT03468088|BEHAVIORAL|Conventional treatment|Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
223578179|NCT04024332|DRUG|ACT-541468|ACT-541468 25 mg; administered orally
223578180|NCT02125357|DRUG|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
223578181|NCT02125357|DRUG|Enzalutamide|160mg PO OD as per standard of care.
223578182|NCT00055354|PROCEDURE|Acupuncture|
224158926|NCT04125992|PROCEDURE|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
223467706|NCT06958484|DRUG|Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab|The patients with high-risk recurrence will be treated with Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment .
223467707|NCT03256617|OTHER|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
223467708|NCT03091153|OTHER|Medication Review|In depth medication review with a focus on deprescribing
223467709|NCT02354326|RADIATION|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
223467710|NCT02354326|RADIATION|computed tomography|Undergo CT without VNC
223467711|NCT03445026|DIAGNOSTIC_TEST|dental panorama|radiographic examination
223467712|NCT05252858|DEVICE|nCAP Signal Relief Patch|nCAP Signal Relief Patch post-operatively applied to the subject's surgical dressing by a trained researcher in the immediate Post Anesthesia Care Unit (PACU)
223467713|NCT05252858|OTHER|Standard of Care|Subjects will undergo surgery using the approved ERAS anesthetic and post-operative pain management protocols. At Shadyside Hospital, the ERAS Protocol for these subjects involves preoperative meloxicam 15mg PO, gabapentin 300mg PO, acetaminophen 1g PO. Intra-operative, patients receive a spinal block (bupivacaine) and propofol IV sedation. Postoperative pain medication is titrated to the individual patient's level of pain (0-10). 0.2 mg IV hydromorphone can be given for breakthrough pain, oxycodone 5mg PO for moderate pain (4-6) and oxycodone 10 mg PO for severe pain (7-10). Ketorolac 15 mg IV is given Q6H during the hospital stay. Discharge medication may be Norco 5-325mg as prescribed by the surgeon.
223467714|NCT00301834|BIOLOGICAL|alemtuzumab|
223467715|NCT00301834|DRUG|busulfan|
223467716|NCT00301834|DRUG|cyclosporine|
223467717|NCT00301834|DRUG|fludarabine phosphate|
223467718|NCT00301834|DRUG|methotrexate|
223467719|NCT00301834|DRUG|methylprednisolone|
223467720|NCT00301834|PROCEDURE|allogeneic bone marrow transplantation|
223467721|NCT00301834|PROCEDURE|allogeneic hematopoietic stem cell transplantation|
223467722|NCT00301834|PROCEDURE|peripheral blood stem cell transplantation|
223467723|NCT00301834|PROCEDURE|umbilical cord blood transplantation|
223467724|NCT03294642|DIETARY_SUPPLEMENT|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
223467725|NCT03294642|DIETARY_SUPPLEMENT|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
223578183|NCT00055354|BEHAVIORAL|Cognitive Behavioral Therapy|
223578184|NCT05636384|OTHER|Home-based care|"Home-based medical care is based on a specialized home-based medical team approach, including following:~1. Specialized Home-Based Medical Team Approach~2. Initial Assessment and Education~3. Initial Home Visits and Education~4. Multidisciplinary Team Meeting~5. Regular Assessment After the Initial Visit"
223578185|NCT04051385|OTHER|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
223578186|NCT04051385|OTHER|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
224303650|NCT03759119|BEHAVIORAL|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~* Complete educational session with primary investigator.~* Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
223467726|NCT03294642|DIETARY_SUPPLEMENT|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
223467727|NCT02786303|DEVICE|Whole-body diffusion- weighted MRI|
223467728|NCT00717145|DRUG|risedronate|one risedronate 20 mg DR tablet
223467729|NCT00717145|DRUG|risedronate|One risedronate 20 mg DR tablet
223467730|NCT00717145|DRUG|risedronate|One risedronate 35 mg DR tablet
223467731|NCT00717145|DRUG|risedronate|One risedronate 35 mg IR tablet
223467732|NCT04605900|DEVICE|Orthopedic Footwear|The orthopedic footwear used by the OF Group was manufactured by the company J. Andrade Ferreira Neves Lda. with materials suitable for the diabetic foot, as registered with INFARMED under registration ID 279515.
223578187|NCT01476189|DRUG|Experimental paracetamol formulation|experimental
223578188|NCT01476189|DRUG|Marketed paracetamol|Marketed paracetamol
223467733|NCT04605900|DEVICE|Standard Footwear|In the SF Group, it was recommended to use standard shoes more suitable for diabetic foot, with some specific characteristics, such as sports or walking shoes. The acquisition or not of a more suitable shoes by the participants was at the discretion of each individual.
223467734|NCT04605900|DEVICE|Plantar Orthoses|The plantar orthoses (PO) that both groups used for distribute of plantar loads was based on the principle of total contact. The confection material consisted in a liner of EVA shore 20º and polyurethane filling ELAX flexible (expandable) from OKM Química Ortopédica SL.
223467735|NCT04605900|BEHAVIORAL|Education on foot self-care|"An information leaflet with foot care was delivered, with the aim of ensuring that participants were informed about the care they should continually take with their feet during the study period. This leaflet was created based on the guidelines of the Associação Protetora dos Diabéticos in Portugal."
224158927|NCT04125992|PROCEDURE|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
223467736|NCT01825824|RADIATION|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by \>48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of \> 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of \> 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
223467737|NCT05573230|DRUG|Midazolam|Administered orally.
223467738|NCT05573230|DRUG|LY3502970|Administered orally.
223467739|NCT05573230|DRUG|Cyclosporine|Administered orally.
223467740|NCT06959693|DRUG|Cetuxima-β|500 mg/m², initial intravenous infusion (IV)\>120 min, subsequent IV \>60 min , D1，every 2 weeks
223467741|NCT06959693|DRUG|Envafolimab|a single fixed dose of 200 mg, subcutaneous injection(SC), every 2 weeks (Day 1 of each cycle \[D1\])
223467742|NCT06959693|DRUG|mFOLFOX6|Oxaliplatin 85 mg/m² , IV, over 120 min, Day 1; Leucovorin 400 mg/m² (or Calcium Folinate 200 mg/m²), IV, over 120 min, D1; 5-FU 400 mg/m² , bolus injection, followed by 1200 mg/(m²·d) continuous IV for 2 days (total dose 2400 mg/m² over 46 - 48 hours)
223467743|NCT00308867|PROCEDURE|Photodynamic Therapy|
223467744|NCT00308867|PROCEDURE|Cryosurgery|
223467745|NCT01740232|PROCEDURE|trephination|Artroscopic meniskal repair with trephination.
223467746|NCT01740232|PROCEDURE|Normal meniscal repair|Artroscopic meniskal repair without trephination.
224158928|NCT02175303|BIOLOGICAL|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
224158929|NCT06089655|DEVICE|CGMS|The Intervention group is to use CGMS to estimate the effect on blood glucose (HbA1C).
224158930|NCT06089655|BEHAVIORAL|AI diet application|The Intervention group is to use an AI diet application to estimate the effect on blood glucose (HbA1C).
224158931|NCT01624610|OTHER|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
224158932|NCT01997281|DIETARY_SUPPLEMENT|dietary fiber-enriched cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~* one serving of steamed egg is added for dinner and breakfast"
224158933|NCT01997281|OTHER|conventional cereal|"* provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~* amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~* one serving (40g) of steamed egg is added for dinner and breakfast"
224158934|NCT02448914|DRUG|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
224158935|NCT02448914|DRUG|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
224158936|NCT02143323|DRUG|Augmentin tablet|
224158937|NCT06450223|DRUG|Perampanel 12 MG|1 tablet of Perampanel Tablets 12 mg
224158938|NCT06450223|DRUG|Fycompa 12 mg film-coated tablets|1 tablet of Perampanel Tablets 12 mg
224158939|NCT05725200|DRUG|Alectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current Summary of Product Characteristics (SMPC) and package Insert.
224158940|NCT05725200|DRUG|Cetuximab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158941|NCT05725200|DRUG|Crizotinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158942|NCT05725200|DRUG|Dasatinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158943|NCT05725200|DRUG|Everolimus|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
223467747|NCT03657069|DEVICE|Blossom|Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology
224158944|NCT05725200|DRUG|Encorafenib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158945|NCT05725200|DRUG|Gemcitabine|Dosage form, dosage, frequency and duration are described in the current SMPC and package Insert.
223467748|NCT03657069|OTHER|Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire|Ancillary studies
223467749|NCT05300386|DRUG|Escitalopram|We use Escitalopram 5\~10 mg for two groups to observe the impact of sleep apnea on the treatment of generalized anxiety disorder
224158946|NCT05725200|DRUG|Idelalisib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
223467750|NCT04900454|BIOLOGICAL|DVX201|Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells
223467751|NCT05319548|OTHER|Purple-Red Carrot Juice|Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins
223467752|NCT05319548|OTHER|Red Carrot Juice|Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..
223467753|NCT05319548|OTHER|Purple Carrot Juice|Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
223467754|NCT01112319|DEVICE|Elf care|elfcare device
223578189|NCT01476189|DRUG|Higher dose marketed paracetamol|Higher dose marketed paracetamol
223578190|NCT01665430|DRUG|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
223578191|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
224158947|NCT05725200|DRUG|Larotrectinib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158948|NCT05725200|DRUG|Methotrexate|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158949|NCT05725200|DRUG|Palbociclib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158950|NCT05725200|DRUG|Panobinostat|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158951|NCT05725200|DRUG|Pembrolizumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158952|NCT05725200|DRUG|Petrozumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158953|NCT05725200|DRUG|Trastuzumab|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158954|NCT05725200|DRUG|Talazoparib|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158955|NCT05725200|DRUG|Venetoclax|Dosage form, dosage, frequency and duration are to be implemented by study investigators as described in the current SMPC and package Insert.
224158956|NCT03012542|DIETARY_SUPPLEMENT|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
224158957|NCT03012542|DIETARY_SUPPLEMENT|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
224158958|NCT02066545|DRUG|CLS001 Topical Gel|
224158959|NCT02066545|DRUG|CLS001 Topical Gel Vehicle|
224158960|NCT00759083|DRUG|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
223467755|NCT01112319|OTHER|control group|regular physiotherapy treatment
223467756|NCT02026141|DRUG|Dexmedetomidine|
223467757|NCT02026141|DRUG|Normal Saline Placebo|
223467758|NCT02557724|PROCEDURE|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
223467759|NCT02557724|PROCEDURE|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
224158961|NCT03326661|PROCEDURE|Aspiration|Needle aspiration of pus from the peritonsilar abscess
223467760|NCT04945785|OTHER|No intervention|no intervention
223467761|NCT01288690|BEHAVIORAL|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
223467762|NCT01105520|PROCEDURE|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
223467763|NCT06524661|DEVICE|AS-OCT after vitrectomy|AS-OCT is a light based imaging technique of the anterior segment of the eye in this study it is used to measure the anterior chamber angle changes after pars plana vitrectomy.
224158962|NCT03326661|PROCEDURE|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
224158963|NCT03326661|DRUG|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
224158964|NCT01569997|OTHER|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
224303651|NCT02664714|OTHER|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
223467764|NCT00217282|DRUG|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90\* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
223467765|NCT03388424|DIAGNOSTIC_TEST|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
223467766|NCT04126434|DEVICE|mask|facemask
223467767|NCT00145886|DRUG|rhPTH|Subjects will be treated with rhPTH for 12 months.
223467768|NCT00003012|DRUG|CMF regimen|
223467769|NCT00003012|DRUG|cyclophosphamide|
223467770|NCT00003012|DRUG|epirubicin hydrochloride|
224158965|NCT00145197|BEHAVIORAL|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
224158966|NCT00513994|DRUG|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
224158967|NCT00560794|BIOLOGICAL|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
224158968|NCT01024062|DRUG|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
224158969|NCT01010269|DEVICE|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
224158970|NCT01010269|DEVICE|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
223467771|NCT00003012|DRUG|fluorouracil|
223467772|NCT00003012|DRUG|methotrexate|
223467773|NCT01207843|BEHAVIORAL|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
223467774|NCT06580015|PROCEDURE|Computed Tomography|Undergo PET-CT
223467775|NCT06580015|OTHER|Flotufolastat F-18 Gallium|Given IV
223467776|NCT06580015|OTHER|Medical Device Usage and Evaluation|Undergo X1 RMRS PET-CT
223467777|NCT06580015|PROCEDURE|Positron Emission Tomography|Undergo PET-CT
223467778|NCT04327778|PROCEDURE|Music Therapy|Automate music therapy every two weeks
223467779|NCT01959100|DRUG|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
223467780|NCT01959100|DRUG|Placebo|250 mg x 3/week during a meal for a period of 2 years
223467781|NCT05512663|DEVICE|Irreversible Electroporation (IRE)|The area of the prostate that was positive for cancer based on the transperineal prostate biopsy will be targeted for ablation via the NanoKnife System. An MRI/TRUS fusion device probe will be placed in the rectum and the prostate will be visualized in both sagittal and axial views. The ultrasound grid which was used during the mapping biopsy will be oriented using anatomical landmarks and used to identify the location of the positive biopsy cores. The NanoKnife Single Electrode Probes will be surgically inserted into the prostate through the perineum using MRI/TRUS fusion guidance and the ultrasound grid for guidance.
223467782|NCT04804137|OTHER|Blood|Blood samples are taken at each visit to the day hospital for a programmed injection of immunotherapy.
223467783|NCT04804137|OTHER|sputum|induced by saline aerosol sputum during each visit to the day hospital for a programmed injection of immunotherapy.
223467784|NCT04804137|OTHER|saliva|spontaneous saliva during each visit to the day hospital for a programmed injection of immunotherapy.
223467785|NCT04804137|OTHER|stool|Stool analyses will be carried out on a sample taken by the patient at home and brought back at the time of a day hospital.
223467786|NCT05131763|BIOLOGICAL|NKG2D-based CAR T-cells|Autologous genetically modified anti-NKG2DLs CAR transduced T cells
223467787|NCT01727921|DEVICE|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
223467788|NCT01727921|DEVICE|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
223467789|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 125 mg|One capsule before breakfast for 84 days
224158971|NCT04857892|DRUG|GSK3640254|GSK3640254 will be administered via oral route.
224158972|NCT04857892|DRUG|DTG|DTG will be administered via oral route.
224158973|NCT04857892|DRUG|GSK3640254/DTG|GSK3640254/DTG will be administered via oral route.
224158974|NCT04853199|DRUG|Quercetin|Each patient should receive one tablet twice a day 30 minutes before the meal
224158975|NCT04853199|DRUG|Placebo|Each placebo capsule contains 150 mg of microcrystalline cellulose and 1.5 mg of magnesium stearate.
224158976|NCT05906667|BEHAVIORAL|Sharing History through Active Reminiscence and Photo-imagery (SHARP)|Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
224158977|NCT00272480|DRUG|Zidovudine/lamivudine|
224158978|NCT00272480|DRUG|Placebos|
224158979|NCT00081744|DRUG|Tigecycline|
224158980|NCT01279980|OTHER|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
224158981|NCT01279980|OTHER|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
224158982|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
223467790|NCT04733924|OTHER|Aqueous extract of roots plus leaves of Withania somnifera 250 mg|One capsule before breakfast for 84 days
223467791|NCT04733924|OTHER|Microcrystalline Cellulose|One capsule before breakfast for 84 days
223467792|NCT01531634|BEHAVIORAL|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
223467793|NCT00076388|DRUG|Gefitinib|
223467794|NCT00076388|DRUG|Docetaxel|
223467795|NCT02935569|DEVICE|Compression HeadBand|"* commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~* Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
223467796|NCT01991353|PROCEDURE|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
223467797|NCT01991353|PROCEDURE|Without PRP|Standard of care meniscal repair without augmentation.
223467798|NCT05081388|DRUG|REGN14256|Sub-cutaneous (SC) single dose
223467799|NCT05081388|DRUG|imdevimab|SC single dose
223467800|NCT05081388|DRUG|casirivimab + imdevimab|SC single dose
224158983|NCT01949857|BIOLOGICAL|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
224158984|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
224158985|NCT01949857|BIOLOGICAL|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
224158986|NCT01084330|DRUG|AUY922|70mg/m2
224158987|NCT01084330|DRUG|Docetaxel|Docetaxel 75mg/m2
224158988|NCT01084330|DRUG|Irinotecan|Iriniotecan 350mg/m2
224158989|NCT03230357|DEVICE|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
224158990|NCT00701246|DRUG|ferrous sulfate|
224158991|NCT00701246|DRUG|folic acid|
224158992|NCT00701246|DRUG|placebo (folic acid)|
224158993|NCT02813863|DRUG|SP2086|
224158994|NCT02813863|DRUG|Metformin|
224158995|NCT04541095|OTHER|EX_IMF|Infant formula with large amounts of beta-palmitate (about 60%).
223467801|NCT05081388|DRUG|Placebo|SC single dose
223467802|NCT03928457|OTHER|Parental questionnaire|Parental questionnaire on pregnancy history and environmental exposure
223467803|NCT03928457|OTHER|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator
223467804|NCT03928457|OTHER|Follow-up of daily infants environmental and clinical parameters|Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures…)
224158996|NCT04541095|OTHER|ST_IMF|Infant formula with low amounts beta-palmitate (about 10%).
224158997|NCT00187850|PROCEDURE|PP|Partial pulpotomy
224158998|NCT00187850|PROCEDURE|DPC|Direct pulp capping
224158999|NCT05549414|DEVICE|Proton Radiation|Proton beam radiotherapy, first proposed by Robert Wilson at Harvard University in 1946, utilizes an energetic beam of ionized hydrogen nuclei (protons) directed at the tumor volume to effect DNA damage of the targeted cells. Today, there are hundreds of proton treatment centers worldwide and it is considered standard treatment for certain malignancies and/or clinical scenarios
224159000|NCT01311895|DRUG|H2O|2 mg IV hydromorphone
224159001|NCT01311895|DRUG|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
224159002|NCT04631614|OTHER|Warm up|Warm up through a walk or exercise bike for 5 minutes with moderate intensity according to modified Borg scale (CR-10)
224159003|NCT04631614|OTHER|Passive calf muscle stretching|With the participant lying in the supine position, the physiotherapist will passively perform the ankle dorsiflexion movement to stretch the participant's calf to the limit tolerated by the participant. This procedure will be performed in two repetitions with 30 seconds of held in the stretching position and 30 seconds of rest between repetitions.
224159004|NCT04631614|OTHER|Ankle joint mobilization - weight-bearing mobilization with movement (WB-MWM) technique|To perform the WB-MWM technique, the participant will be instructed to take a weight-bearing position with the tibia in a vertical position. The physiotherapist will be stay in front participant's ankle and will use the hands to stabilize the participant's foot as close as possible to the anterior region of the talus. A rigid belt will be placed on the participant's tibia and around physiotherapist´s hip. Then, the physiotherapist will project his hip backwards to produce a nonpainful anterior tibia glide. The participant will be asked to perform a forward lunge as far as possible without raising heel off the table and without reproducing knee symptoms. After achieving the maximum forward lunge, the participant will be instructed to hold this position for 5 seconds and then return to the starting position. This procedure will be performed in two sets of 10 repetitions with two minutes of rest between sets.
224159005|NCT04631614|OTHER|Clam exercise|The participant will side lying with trunk straight and both hips and knees at 45º and 90º of flexion, respectively. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the abduction and lateral rotation of the hip (keeping the heels in contact) against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
223467805|NCT03928457|OTHER|Nocturnal polysomnography|Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),
223467806|NCT03928457|DIAGNOSTIC_TEST|cerebral hemodynamics|cerebral hemodynamics (near infrared spectroscopy)
223467807|NCT03928457|DIAGNOSTIC_TEST|activity of the autonomic nervous system|activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)
223467808|NCT03348605|DEVICE|Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany|"This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole."
223467809|NCT05989555|OTHER|Blood drawing|Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.
223467810|NCT04817306|DEVICE|Multi-cancer early detection test|Blood collection and multi-cancer early detection testing
223467811|NCT02182401|DRUG|BI 207127 NA|Days 3-8 and days 25-30
223467812|NCT02182401|DRUG|BI 201335 NA|Days 15-30
223467813|NCT02182401|DRUG|Midazolam|Days 1, 7, 23 and 29
223467814|NCT02182401|DRUG|Tolbutamide|Days 1, 7, 23 and 29
223467815|NCT03384589|BIOLOGICAL|PCV13|Vaccine against pneumococcal disease
223578192|NCT03248193|DEVICE|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
224159006|NCT04631614|OTHER|Hip abduction exercise in side lying|The participant will side lying with trunk straight, both hips in a neutral position and both knee in extension. An elastic band will be used as external resistance, that will be positioned above the participant's knee. The individual will be instructed to perform the hip abduction against the resistance of the elastic band and then return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
224303652|NCT06532604|DEVICE|Electroretinography (ERG)|ERG are specifically carried out for research. They are performed in Nancy with the MonPackOne device developed by Metrovision for participants at center n°1, and in Paris with the RETeval device developed by LKS Technologie for participants at center n°2. Both devices comply with ISCEV standard and are CE marked. They enable the reccord of Pattern ERG, Flash ERG and Multifocal ERG using corneal and skin electrodes, or Sensor Strip skin electrodes only, for the Nancy and Paris centers respectively.
224303653|NCT04273841|DIETARY_SUPPLEMENT|Military Energy Gum|Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
223467816|NCT05138146|DRUG|609A|"609A 200mg,IV, Day 1of each treatment cycle, up to disease progression or intolerable toxicity, death, early withdrawal from the study or loss to follow-up, withdrawal of consent, or the end of the treatment period, whichever occurs first.~Every 3 weeks a treatment cycle."
223467817|NCT05138146|DRUG|doxorubicin hydrochloride|60mg/m2 or 75mg/m2, IV, Day1of the1-6th treatment cycles only. Every 3 weeks a treatment cycle.
223467818|NCT05998681|OTHER|Breastfeeding and Basic Maternal-Neonatal Care and mobile messages|"Participants in the experimental group were provided with education on Breastfeeding and Basic Maternal-Neonatal Care at the hospital and mobile messages were sent with the same content as education program for 6 weeks after discharge."
223467819|NCT02059239|DRUG|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
223467820|NCT02059239|DRUG|Carmustine|300 mg/m2 on Day -6
223467821|NCT02059239|DRUG|Etoposide|100 mg/m2 on days -5 to -2
223467822|NCT02059239|DRUG|Melphalan|140mg/m2 on Day -1
223467823|NCT02059239|DRUG|Cytarabine|200 mg/m2 on days -5 to -2
223467824|NCT02059239|DRUG|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
223467825|NCT02059239|BIOLOGICAL|Autologous Stem Cell Transplantation|
223467826|NCT02059239|BIOLOGICAL|Allogeneic Stem Cell Transplantation|
223467827|NCT02059239|DRUG|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
223467828|NCT05567081|DRUG|Triamcinolone Acetonide 40mg/mL|Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.
223467829|NCT05567081|DRUG|PRP|Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
223467830|NCT01319565|DRUG|Aldesleukin|Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).
223467831|NCT01319565|DRUG|Cyclophosphamide|Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
223467832|NCT01319565|DRUG|Fludarabine|Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
223467833|NCT01319565|BIOLOGICAL|Young TIL|Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
223467834|NCT01319565|RADIATION|Total Body Irradiation (TBI)|Arm 2 - Days -3 to -1: Ondansetron 0.15 mg/kg IV x 1 dose pre-TBI. Patients will then receive 2 Gy TBI twice a day for 3 days (total dose 12 Gy) using a linear accelerator in Radiation Oncology.
223467835|NCT01969526|OTHER|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
224159007|NCT04631614|OTHER|Knee extension exercise in a sitting position|The participant will be seated at the treatment table with the trunk straight and both knees in 90º of flexion. The external resistance will be positioned above the participant's ankle. The individual will be instructed to perform the knee extension at a protective angle (90º-45º of flexion), progressing to full extension (90º-0º of flexion) as long as the full knee extension does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
224159008|NCT04631614|OTHER|Squat exercise|The participant will be stand with the trunk straight, knees in extension and feet hip-width apart. Dumbbells will be used as external resistance.The individual will be instructed to perform the squat movement at a protective angle (0º-45º of knee flexion), progressing to a deep squat (90º of knee flexion) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
224303654|NCT04273841|DIETARY_SUPPLEMENT|Placebo Gum|Pellet form placebo gum
224303655|NCT06337097|DIAGNOSTIC_TEST|Troponin surveillance|Troponin will be monitored prior to each immune checkpoint inhibitor infusion for the first 12 weeks of therapy.
224303656|NCT06337097|OTHER|Standard of care|Standard of care if symptoms arise then evaluation with cardiac biomarkers and/or further cardiac testing.
224303657|NCT05987917|DEVICE|BTL-785-2|Treatment with BTL-785 device (BTL-785-2 applicator) for non-invasive facial rejuvenation
223467836|NCT02447419|DRUG|Gefitinib|Gefitinib 250mg will be administered orally daily
223467837|NCT05793411|OTHER|Questionnaire risk behaviors in adolescents with chronic diseases|Questionnaire risk behaviors in adolescents with chronic diseases
223467838|NCT02359461|DEVICE|Combination pulsatile Stendo3|
223467839|NCT06306976|PROCEDURE|Elective Midline Laparotomy|"Patients with midline ventral incisional hernia with a range of hernia morphology who plan to undergo open retromuscular VHR.~Hernia repair:~All study patients will have an open retromuscular repair with/without additional lateral MFR (TAR or EOR at the discretion of the operating surgeon). All repairs beginning with retrorectus dissection to the level of the linea semilunaris.~All patients will have permanent mesh reinforcement of the abdominal wall (large-pore, midweight polypropylene). Fascia will be closed over the mesh with 0 or 2-0 polydioxanone slowly absorbable suture using a small-bite technique and a 4:1 suture length:wound length ratio."
223467840|NCT06306976|PROCEDURE|Imaging: Ultrasound|"Ultrasound procedure will involve the following steps:~1\. For control group 1 and group 2 patients, Images will be taken at two points along the bilateral RA; at the level of the umbilicus and midway between the umbilicus and xiphoid process. Bilateral external oblique (EO), internal oblique (IO), and transversus abdominis (TA) images will be performed at the level of the anterior axillary line midway between the costal margin and iliac crest."
223467841|NCT06306976|OTHER|Tensiometry|"For all study patients, an analog spring-tensiometer will be used to assess intraoperative tension required to bring the fascia to the midline for closure. The tensiometer is attached to a clamp attached to the fascia at the midpoint of the hernia defect. Tension required for medialization to the midline will be performed after adhesiolysis (baseline), retrorectus dissetion, incision of the PLIO (if performed), and after completion of TAR or EOR (if performed).~Control group 2 patients will be undergoing first time laparotomy and will have tensiometry performed."
223467842|NCT04092738|BEHAVIORAL|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
223467843|NCT03514550|DRUG|Propofol|Propofol will be used for anesthesia during surgery
223467844|NCT03514550|DRUG|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
223467845|NCT03514550|PROCEDURE|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
223467846|NCT00802711|RADIATION|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
223467847|NCT00802711|RADIATION|brachytherapy|Given twice a day for 10 fractions
223467848|NCT00523913|DRUG|rosiglitazone|
223467849|NCT02219685|DRUG|LDV/SOF|90/400 mg FDC tablet administered orally once daily
223467850|NCT02219685|DRUG|Placebo|Tablet administered orally once daily
223467851|NCT00001989|DRUG|Trichosanthin|
223467852|NCT00001989|DRUG|Zidovudine|
223467853|NCT01909700|DEVICE|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
223467854|NCT02551458|OTHER|Systematic surgery|
223467855|NCT02551458|OTHER|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
223467856|NCT06211400|OTHER|Whole body vibration exercise|6-week supervised whole body vibration exercise programme (training sessions three times per week lasting 10 min) alongside a lifestyle education programme
223467857|NCT00137553|DRUG|Sulfadoxine-pyrimethamine (Fansidar)|
223467858|NCT03602105|BEHAVIORAL|Exercise|Exercises in group and/or individually
223467859|NCT04276441|DEVICE|Heart healthy Engagement Program with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.
224303658|NCT05987917|OTHER|No Treatment|The subject who will serve as control will not be treated with the study device.
224303659|NCT02068521|DRUG|somavaratan|Subcutaneous injection
224303660|NCT00045539|DRUG|leucovorin calcium|
224303661|NCT00045539|DRUG|methotrexate|
224303662|NCT00045539|DRUG|thiotepa|
224303663|NCT06006897|OTHER|Physical Evaluations of post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis with post-COVID-19 individuals. The data to be obtained from all these evaluations will be collected from the individuals at one time and over a period of approximately 1 hour at the most. Step count tracking with pedometer will be done for each individual for 3 days.
224303664|NCT06006897|OTHER|Physical evaluations of non-post-COVID-19 individuals|In this study, scoliosis degree measurement, number of steps, pain, posture and quality of life will be evaluated in idiopathic scoliosis without post-COVID-19 individuals.
224303665|NCT06973083|PROCEDURE|FASTER-assisted ESD|The patients who are randomly assigned to the FASTER-assisted ESD group will undergo the ESD procedure with the assistance of the FASTER system.
224303666|NCT06973083|PROCEDURE|Conventional ESD|The patients who are randomly assigned to the conventional ESD group will undergo the ESD following the clinically established pattern.
224303667|NCT05957809|OTHER|Structured exercise training|"This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~* Strength training on unstable surfaces - 25-30 minutes~* High repetition muscular endurance training - 25-30 minutes~* Cool-down program - 10 minutes"
224303668|NCT05084963|DRUG|IRL201104|lyophilised powder for reconstitution for IV dosing
224303669|NCT05084963|DRUG|Placebo|Matching placebo for IRL201104
224303670|NCT05357755|DRUG|JNJ-77242113|JNJ-77242113 will be administered orally as delayed release tablets.
224303671|NCT05357755|DRUG|Placebo|Matching placebo will be administered orally as delayed release tablets.
224303672|NCT05442866|DEVICE|Virtual reality experience for 10 minutes|Each 10-minute VR session will be self-administered (by each participant) using the Facebook (Facebook Inc., Menlo Park, CA) Meta Quest 2 VR and Touch controllers. This equipment was selected because it is portable, has built in audio, and has clear graphics at a lower price than VR setups that require a computer to generate graphics. The headset has an optional eyeglass spacer to allow participants to wear corrective eyeglasses during the VR session if appropriate. The hand controllers facilitate immersive, interactive VR experiences. The VR software, Nature Treks VR application (https://naturetreksvr.com) that features ten non-violent, nature-based experiences in peaceful environments (e.g. forest, river, beach, etc.) that can be played in a seated or fixed position.
224303673|NCT06014073|BIOLOGICAL|TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|"Phase 1 dose escalation (3+3) : dose 1 (1 × 10\^6 cells/kg) , dose 2 (3 × 10\^6 cells/kg), dose 3 (1 × 10\^7 cells/kg); Phase 2 : dose of RP2D.~No more than 2 × 10\^5 per kilogram of allogenic residual CD3+T cells harbouring in grafts can only be released for recipient infusion."
224303674|NCT06014073|DRUG|Fludarabine|Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.
224303675|NCT06014073|DRUG|Cyclophosphamide|Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
224303676|NCT06700109|DEVICE|Neural Ice|This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.
224303677|NCT06700109|DRUG|Triamcinolone acetate|A single dose of Triamcinolone 40mg injected directly into the joint space.
223467860|NCT04276441|DEVICE|Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later|No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
223467861|NCT06641102|OTHER|Self-Guided Program (Tier 1)|"The study intervention is a smartphone application.~Tier 1: self-guided program, includes videos, guided meditations, and worksheets that are delivered to users in 10 different topical modules. Two modules are delivered per week, with email reminders. It will emphasize that PRT is a practice that requires users to come back to the material regularly to help retrain the brain often (just like how you need to practice and complete exercises between PT sessions)."
223467862|NCT06641102|OTHER|Coach Assisted Program (Tier 3)|"The study intervention is a smartphone application.~Tier 3: one-on-one coaching program that sets users up with trained PRT coaches who will walk them through the program individually. Users will meet with the assigned coaches once per week for an hour-long Zoom-hosted session that covers the same information as Tier 1, however in a completely personal and individualized way, focusing on the content that is most relevant for the user/patient at the time of the session. Tier 3 users will also receive materials from their coaches (e.g. videos, meditations, etc.) to support their own practice between session."
223467863|NCT06641102|OTHER|Standard of Care (SOC)|SOC is defined as a comprehensive clinical care plan, including a consultation with physiatrist and prescribed interventions, which will capture a comparison representative of all potential interventions that are recommended for an individual.
223578193|NCT02310230|DEVICE|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
223578194|NCT03625830|DEVICE|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
224303678|NCT04838522|OTHER|No Intervention|This is a non-interventional study.
224303679|NCT03819049|BIOLOGICAL|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
224303680|NCT03819049|BIOLOGICAL|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
224303681|NCT03819049|BIOLOGICAL|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
224303682|NCT03819049|BIOLOGICAL|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
224303683|NCT06572631|BIOLOGICAL|Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001|Given IV
224303684|NCT06572631|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
224303685|NCT06572631|PROCEDURE|Bone Marrow Aspiration|Undergo bone marrow aspiration
224303686|NCT06572631|PROCEDURE|Bone Marrow Biopsy|Undergo bone marrow biopsy
224303687|NCT06572631|PROCEDURE|Computed Tomography|Undergo PET/CT
224303688|NCT06572631|DRUG|Cyclophosphamide|Given IV
224303689|NCT06572631|DRUG|Decitabine|Given IV
224303690|NCT06572631|PROCEDURE|Echocardiography|Undergo ECHO
223467864|NCT03471052|PROCEDURE|Radiofrequency ablation (RFA)|"Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years."
223467865|NCT03540264|DEVICE|Clearfil Majesty TM|Tooth wear - composite resin
223467866|NCT03540264|DEVICE|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
223467867|NCT04598217|OTHER|anesthesiologist|non-interventional observational
223467868|NCT06237933|BEHAVIORAL|Enhanced intervention via social networking site (SNS)|We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks
223467869|NCT06237933|BEHAVIORAL|Standard intervention|In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
223467870|NCT01643330|GENETIC|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR
223467871|NCT01643330|GENETIC|Placebo|Single intracoronary infusion
223467872|NCT04202497|DRUG|TAK-418|TAK-418 orally.
223467873|NCT04202497|DRUG|[18F]MNI-1054 (radiotracer)|\[18F\]MNI-1054 injection.
223467874|NCT05290948|DRUG|intravitreal injection of bevacizumab with acetazolamide tablets|intravitreal injection of bevacizumab with acetazolamide tablets
223467875|NCT05290948|DRUG|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
223467876|NCT03026946|DRUG|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
223467877|NCT03026946|DRUG|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
223467878|NCT05007119|PROCEDURE|Mckenzie Extension Protocol|"Moist Heat Pack for 10 mins McKenzie Extension Protocol Sequence~Static:~1. Lying Prone~2. Lying prone in extension~3. Sustained extension~4. Posture correction~   Dynamic:~5. Extension in lying~6. Extension in lying with clinician overpressure~7. Extension mobilization~8. Extension in standing"
223578195|NCT03625830|DEVICE|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
224303691|NCT06572631|DRUG|Fludarabine|Given IV
224303692|NCT06572631|PROCEDURE|Leukapheresis|Undergo leukapheresis
224303693|NCT06572631|PROCEDURE|Magnetic Resonance Imaging|Undergo MRI
224303694|NCT06572631|PROCEDURE|Positron Emission Tomography|Undergo PET/CT
224303695|NCT05500716|OTHER|Auricular Non-Invazive Vagus Nerve Stimulation + Traditional Rehabilitation Program for TMD|"In this application, vagus nerve stimulation is applied to the patients in addition to the traditional rehabilitation program. In our research, vagal nerve stimulation will be applied with the Vagustim Device and all applications will be applied at a frequency of 10 Hz, a pulse amplitude of 300 microseconds and for 20 minutes."
224303696|NCT05500716|OTHER|Traditional Rehabilitation Program|This intervention includes: Deep Friction Massage, Myofascial Trigger Point Compression Therapy, Temporomandibular Joint Mobilization, Rocabado Exercises, Muscle-Energy Techniques.
224303697|NCT01638650|DRUG|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
223467879|NCT05007119|PROCEDURE|Cupping|Cupping with blood letting
223467880|NCT06280898|PROCEDURE|Remote ischemic conditioning|Remote ischemic condition
223578196|NCT02536066|BEHAVIORAL|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
223578197|NCT03112525|DIAGNOSTIC_TEST|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
224303698|NCT01638650|DRUG|ritonavir|100 mg bid orally, Days 1-14
223578198|NCT03112525|GENETIC|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
224303699|NCT01638650|DRUG|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
224303700|NCT01912638|DEVICE|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
224303701|NCT01912638|DRUG|Provisc|Provisc is an cohesive viscoelastic.
224303702|NCT02859948|DRUG|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
224303703|NCT01568320|DEVICE|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
223467881|NCT06467214|BEHAVIORAL|CONNECTED|CONNECTED is a manualized, peer-led, group-based social isolation intervention for diverse veteran populations in VA primary care settings. It is delivered via videoconference through individual and group sessions over 8 weeks.
223467882|NCT06467214|BEHAVIORAL|VET BEFRIENDING|VET BEFRIENDING (attention control arm) consists of weekly social interactions with a research assistant (RA) over videoconference or phone.
223578199|NCT06462534|BEHAVIORAL|Band-Frail Program|"Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information."
223467883|NCT05010278|PROCEDURE|Latarjet|Patients followed up 6 months after a Latarjet procedure
223467884|NCT01777841|OTHER|Electronic Care plan delivery|
223467885|NCT01777841|OTHER|Standard care|
223467886|NCT05934851|PROCEDURE|Frozen-Section Directed Excision|Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
223467887|NCT05934851|PROCEDURE|Wide Local Excision|Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS
223467888|NCT06483061|DRUG|Ferumoxytol|Ferumoxytol will be injected to enhance MRI images
223467889|NCT02201342|DRUG|Udenafil|Drug
223467890|NCT06018337|DRUG|DB-1303/BNT323|IV
223467891|NCT06018337|DRUG|Capecitabine|Oral
223578200|NCT05026892|OTHER|no intervention|no intervention, only collection of data
223578201|NCT05353712|OTHER|SUCROSE|50g sweet creme composed of 14.3g vegetable fat and 35.7g sucrose.
223578202|NCT05353712|OTHER|CONTROL|35.7g sweet creme composed of 14.3g vegetable fat and 21.4g sucrose.
224303704|NCT01616953|BIOLOGICAL|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
223467892|NCT06018337|DRUG|Paclitaxel|IV
223467893|NCT06018337|DRUG|Nab-paclitaxel|IV
223467894|NCT06334133|DRUG|Cadisegliatin 800 mg QD|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
223467895|NCT06334133|DRUG|Cadisegliatin 800 mg BID|Cadisegliatin is an orally bioavailable small-molecule glucokinase activator; adjunctive therapy to insulin.
223467896|NCT06334133|DRUG|Placebo|Placebo (insulin alone)
223578203|NCT05353712|OTHER|ARA20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g L-arabinose
223578204|NCT05353712|OTHER|ARA40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
223578205|NCT05353712|OTHER|TAG20|42.9g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 7.1g D-tagatose
223578206|NCT05353712|OTHER|TAG40|50g sweet creme composed of 14.3g vegetable fat, 21.4g sucrose and 14.3g L-arabinose
223578207|NCT05190601|DEVICE|uroflowmetry|Qmax(ml/s),Qav(ml/s),Volume (ml)
223578208|NCT01605227|DRUG|cabozantinib|Tablets taken orally once-daily
223467897|NCT02115607|DRUG|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
223467898|NCT03844048|DRUG|Venetoclax|oral; film-coated tablets or tablets for oral suspension
223467899|NCT05078983|DIAGNOSTIC_TEST|CGA-FI (COMPREHENSIVE GERIATRIC ASSESMENT - FRAILITY INDEX)|GERIATRIC ASSESMENT TEST
223467900|NCT04616560|PROCEDURE|Biospecimen Collection|Undergo blood sample collection
223467901|NCT04616560|PROCEDURE|Echocardiography Test|Undergo echocardiography
223467902|NCT04616560|PROCEDURE|Multigated Acquisition Scan|Undergo MUGA
223467903|NCT04616560|BIOLOGICAL|Trastuzumab Deruxtecan|Given IV
223467904|NCT04921345|DRUG|Nemolizumab|Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
223467905|NCT04921345|DRUG|Nemolizumab|Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
223467906|NCT05533060|OTHER|No intervention|patients in the groups are treated surgically and brain tissue, CSF, and blood samples, as well as clinical data, neuroimaging data are collected
223467907|NCT06843148|DRUG|Niacin (250mg)|"Niacin will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"
223467908|NCT06843148|DRUG|Placebo Oral Tablet|"Placebo will be orally taken once daily with the largest meal. There will be a 3-week escalation period from 250 mg to 750 mg:~* Week 1: 250mg~* Week 2: 500mg~* Week 3 to Week 12: 750mg (3 x 250mg caplets)"
223467909|NCT03064048|DIETARY_SUPPLEMENT|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
223467910|NCT03064048|DIETARY_SUPPLEMENT|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
223467911|NCT05117112|DIETARY_SUPPLEMENT|XS Muscle Multiplier|Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.
223467912|NCT01320241|DEVICE|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
223467913|NCT01320241|DEVICE|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
223467914|NCT05982106|DRUG|TQ05105 Tablets|TQ05105 tablet is a novel JAK2 inhibitor.
223578209|NCT01605227|DRUG|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
223578210|NCT01994772|PROCEDURE|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
223467915|NCT04998864|DEVICE|Magnetic Resonance guided Focused ultrasound (MRgFUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
223467916|NCT05911477|DRUG|RhBMP-2|1mg RhBMP-2 for one fusion-level
223467917|NCT01136577|DEVICE|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
223467918|NCT01157611|BEHAVIORAL|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
223467919|NCT00102596|DRUG|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
223467920|NCT03344835|OTHER|No intervention|
223467921|NCT03366857|DRUG|Oxygen 30 %|The oxygen concentration will be set at 30%.
223467922|NCT03366857|DRUG|Oxygen 80 %|The oxygen concentration will be set at 80%.
223467923|NCT03358550|DIAGNOSTIC_TEST|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
223467924|NCT05385198|BEHAVIORAL|VOICE care|"I phase:build a relationship with parents and where the Values of the parents and NICU staff is shared.~II phase: discuss with the parents the Opportunities the parents can have to be more involved in the care of their baby.~III phase: Integration of the involvement of the parents in the care of their baby. The experiences of parents need to be shared with the NICU staff. Any raising issue about the involvement of care by the parents can be discussed and see if improvement is needed.~IV phase:Control of the knowledge about the care of their baby before going home and if the parents have any issues which need to be arranged before discharge.~V phase:Evaluation. During this conversation the overall experiences of the parents will be discussed and if there are any further questions related to the care of their baby at home will be explored and discussed."
223578211|NCT01994772|PROCEDURE|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
223578212|NCT00164398|BEHAVIORAL|HIP: HIV Intervention for Providers|
224159009|NCT04631614|OTHER|Forward lunge exercise|The participant will be stand with one lower limb in a long stride forwards of the other limb, trunk straight and both knee in extension. Dumbbells will be used as external resistance. From this position, the participant will be instructed to bend both knees to lower your body at a protective angle (0º-45º of knee flexion), progressing to a greater knee flexion (90º) as long as the movement does not reproduce the knee pain symptoms. Then, the participant will should return to starting position. This exercise will be performed in three sets of 12 repetitions with with on minutes of rest between sets. The exercise will be carried out with a load between 60-80% of the capacity and level of effort reported by the participant, according to the specifications of the modified Borg scale (CR-10). The load will be increased by 2-10% when the patient is able to perform 12 full repetitions in the last set of the exercise with perceived effort \<60%.
224159010|NCT04379323|DIAGNOSTIC_TEST|YuWell YE900 Electronic Sphygmomanometer|Measurement blood pressure by YuWell YE900 Electronic Sphygmomanometer and Desk Mercury Sphygmomanometer.
224303705|NCT01616953|PROCEDURE|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
224303706|NCT01847820|DEVICE|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
223467925|NCT05286853|BIOLOGICAL|Renal Autologous Cell Therapy (REACT)|Participants receiving institutional standard of care will have a kidney biopsy followed by 2 REACT injections into biopsied and non-biopsied contralateral kidneys 3 months (+30 days) apart and will be followed for 5 years (60 months) since last REACT injection.
223467926|NCT05286853|PROCEDURE|Sham Comparator|Participants receiving institutional standard of care will have 2 sham procedures that simulate real biopsy and injection procedure. No tissue is taken during biopsy and nothing is injected into kidney. The second sham procedure will occur 3 months (+30 days) after the first sham procedure. Participants will be followed for 5 years (60 months) since last sham REACT injection.
223467927|NCT05246891|OTHER|rehabilitation nursing|Functional respiratory rehabilitation and motor exercise plan.
223467928|NCT03087734|DEVICE|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
223467929|NCT03087734|DEVICE|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
223467930|NCT03564470|DRUG|Chidamide|Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
223578213|NCT05563116|DIAGNOSTIC_TEST|Computed tomography coronary artery calcium (CAC) score (part of routine workup)|Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
223578214|NCT00004142|DRUG|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
223578215|NCT00004142|DRUG|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
223467931|NCT03564470|DRUG|Dasatinib|Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
223467932|NCT04536662|DRUG|Hydrocortisone|The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
223467933|NCT04536662|DRUG|Prednisone|The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
223467934|NCT04536662|DRUG|Dexamethasone|The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
223467935|NCT02900742|DRUG|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
223467936|NCT02900742|DRUG|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
223467937|NCT02900742|DRUG|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
223467938|NCT02900742|DRUG|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
223467939|NCT02900742|DRUG|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
223467940|NCT02900742|DRUG|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
224068385|NCT02915081|OTHER|Blue light|"Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
224068386|NCT00011921|BIOLOGICAL|filgrastim|
223467941|NCT02900742|DRUG|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
223467942|NCT02667652|PROCEDURE|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
223467943|NCT02667652|PROCEDURE|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
223467944|NCT03871530|OTHER|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
223467945|NCT03871530|OTHER|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
223467946|NCT03871530|OTHER|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
223467947|NCT03871530|OTHER|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
223467948|NCT03871530|OTHER|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
223578216|NCT00004142|PROCEDURE|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
224068387|NCT00011921|DRUG|carboplatin|
224068388|NCT00011921|DRUG|epirubicin hydrochloride|
224068389|NCT00011921|DRUG|etoposide|
224068390|NCT00011921|DRUG|etoposide phosphate|
224068391|NCT00011921|DRUG|ifosfamide|
224068392|NCT00011921|DRUG|paclitaxel|
224068393|NCT00011921|PROCEDURE|autologous bone marrow transplantation|
224068394|NCT00011921|PROCEDURE|bone marrow ablation with stem cell support|
224068395|NCT00011921|PROCEDURE|peripheral blood stem cell transplantation|
224068396|NCT00011921|RADIATION|radiation therapy|
224068397|NCT02700490|BEHAVIORAL|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
224068398|NCT01069822|DRUG|AZD6765|IV solution
224068399|NCT01069822|DRUG|midazolam|
224068400|NCT05459831|DEVICE|QDot Micro Catheter|Atrial fibrillation radiofrequency ablation with 90W or 50W energy setting.
224068401|NCT06471556|DRUG|IV Methylprednisolone pulses|Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /
224068402|NCT03290235|DRUG|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
224068403|NCT06265766|DEVICE|Active cTBS|10 sessions of active cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
224068404|NCT06265766|DEVICE|Sham cTBS|10 sessions of sham cTBS delivered to the contralesional primary motor cortex, started within 3 weeks after stroke.
224068405|NCT00697567|BIOLOGICAL|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
223467949|NCT03871530|OTHER|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
223467950|NCT03871530|OTHER|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
223467951|NCT03871530|OTHER|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
223467952|NCT03871530|OTHER|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
223467953|NCT03871530|OTHER|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
223467954|NCT03871530|OTHER|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
223578217|NCT00004142|PROCEDURE|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
223578218|NCT03263312|BEHAVIORAL|Exercise|Exercise training all patients enrolled.
224159011|NCT06058884|DRUG|Alteplase|Following the guidelines set forth by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.
224159012|NCT03049943|DEVICE|low level laser|
224159013|NCT03571503|PROCEDURE|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
224159014|NCT03571503|DRUG|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the 